"AU","AF","TI","PY","SO","VL","PP","TC","DI","C1","AB","DE","ID","FU","FX","CR","RP","PU","LA","JI","DT","DB","UT","J9","AU_UN","AU1_UN","AU_UN_NR","SR_FULL","SR"
"ELNAGAR G;ELSEWEIDY M;ELKOMY N;KESHAWY M;FATHY O;SOBH M;MAHMOUD Y","ELNAGAR, GEHAD M. (56613221500); ELSEWEIDY, MOHAMED M. (55600488100); ELKOMY, NESREEN M.I.M. (57200690114); KESHAWY, MOHAMMED M. (57196417071); FATHY, OLA M. (56814778600); SOBH, MOHAMMED S. (57219173780); MAHMOUD, YASMIN K. (57213589033)","POLICOSANOL AMELIORATES RENAL INFLAMMATION AND PYROPTOSIS IN HYPERCHOLESTEROLEMIC RABBITS VIA MODULATION OF HMGB1PI3KMTORNLRP3CASPASE1 PATHWAY",2022,"JOURNAL OF FUNCTIONAL FOODS","97","",1,"10.1016/j.jff.2022.105250","BIOCHEMISTRY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;BIOCHEMISTRY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;PHARMACOLOGY AND TOXICOLOGY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;INTERNAL MEDICINE DEPARTMENT, FACULTY OF MEDICINE, SUEZ CANAL UNIVERSITY, ISMAILIA, EGYPT;ZAGAZIG UNIVERSITY HOSPITALS, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;PATHOLOGY DEPARTMENT, FACULTY OF VETERINARY MEDICINE, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;BIOCHEMISTRY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT","HYPERLIPIDEMIA REPRESENTS A MAJOR RISK FACTOR FOR CARDIOVASCULAR AND RENAL DISEASES. THIS STUDY AIMED TO DEMONSTRATE THE POSSIBLE AMELIORATING EFFECTS OF POLICOSANOL (PC) ON RENAL INFLAMMATION AND PYROPTOSIS. EIGHTEEN MALE NEW ZEALAND RABBITS WERE RANDOMLY DIVIDED INTO 3 GROUPS (N = 6/GROUP), ONE RECEIVED NORMAL CHOW DIET FOR 12 WEEKS WHILE THE OTHERS RECEIVED EITHER 0.5 % W/W HIGH CHOLESTEROL DIET (HCD) OR HCD AND CONCURRENTLY TREATED WITH PC (5 MG/KG BODY WEIGHT/DAY) FOR 12 WEEKS. RABBITS FED WITH HCD SHOWED SIGNIFICANT INCREASES IN BODY AND KIDNEY WEIGHTS; RENAL DYSFUNCTION, DYSLIPIDEMIA, OXIDATIVE STRESS STATUS, ELEVATED LEVELS OF OXIDIZED LOW DENSITY LIPOPROTEIN (OX-LDL) AND RENAL HIGH-MOBILITY GROUP BOX 1 (HMGB1). THESE INCREASES WERE ACCOMPANIED WITH UP-REGULATION OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3K)/MAMMALIAN TARGET OF RAPAMYCIN (MTOR) SIGNALING IN RENAL TISSUE AND ACTIVATION OF NOD-LIKE RECEPTOR, PYRIN DOMAIN-CONTAINING-3 (NLRP3) INFLAMMASOME. ADMINISTRATION OF PC CONCURRENTLY WITH HCD SIGNIFICANTLY MODULATED THE HCD-INDUCED ACTIVATION OF OX-LDL/HMGB1/PI3K/MTOR/NLRP3/CASPASE-1 SIGNALING PATHWAY AND SUBSEQUENTLY ATTENUATED THE RESULTED RENAL INJURY. © 2022","CASPASE 1; HMGB1; NLRP3; POLICOSANOL; PYROPTOSIS; RENAL INFLAMMATION","","","","ASKARPOUR M., ET AL., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENTARY THERAPIES IN MEDICINE, 45, PP. 89-97, (2019); BROZ P., CASPASE TARGET DRIVES PYROPTOSIS, NATURE, 526, 7575, PP. 642-643, (2015); CHADE A.R., ET AL., DISTINCT RENAL INJURY IN EARLY ATHEROSCLEROSIS AND RENOVASCULAR DISEASE, CIRCULATION, 106, 9, PP. 1165-1171, (2002); CHATAURET N., ET AL., DIET-INDUCED INCREASE IN PLASMA OXIDIZED LDL PROMOTES EARLY FIBROSIS IN A RENAL PORCINE AUTO-TRANSPLANTATION MODEL, JOURNAL OF TRANSLATIONAL MEDICINE, 12, 1, PP. 1-11, (2014); CHO K.-H., ET AL., (2018); COIMBRA T.M., ET AL., EARLY EVENTS LEADING TO RENAL INJURY IN OBESE ZUCKER (FATTY) RATS WITH TYPE II DIABETES, KIDNEY INTERNATIONAL, 57, 1, PP. 167-182, (2000); DAS S., DAS N., SRIVASTAVA L.M., ROLE OF ASCORBIC ACID ON IN VITRO OXIDATION OF LOW-DENSITY LIPOPROTEIN DERIVED FROM HYPERCHOLESTEROLEMIC PATIENTS, CLINICA CHIMICA ACTA, 372, 1-2, PP. 202-205, (2006); DRURY R.A.B., WALLINGTON E.A., CARLETON H.M., CARLETON'S HISTOLOGICAL TECHNIQUE, (1980); DUARTE M.M., ET AL., ASSOCIATION BETWEEN ISCHEMIA-MODIFIED ALBUMIN, LIPIDS AND INFLAMMATION BIOMARKERS IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CLINICAL BIOCHEMISTRY, 42, 7-8, PP. 666-671, (2009); ELSEWEIDY M.M., ET AL., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXPERIMENTAL BIOLOGY AND MEDICINE, 241, 17, PP. 1943-1949, (2016); ELSEWEIDY M.M., ET AL., INHIBITION OF AORTIC CALCIFICATION BY POLICOSANOL IN DYSLIPIDEMIC RABBITS IS ENHANCED BY PENTOXIFYLLINE: POTENTIAL ROLE OF PCSK9, JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 23, 6, PP. 551-560, (2018); GAMEZ R., ET AL., EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS, DRUGS IN R & D, 6, 1, PP. 11-19, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); HANEKLAUS M., O'NEILL L.A., NLRP3 AT THE INTERFACE OF METABOLISM AND INFLAMMATION, IMMUNOLOGICAL REVIEWS, 265, 1, PP. 53-62, (2015); HONDA H., ET AL., ISOLIQUIRITIGENIN IS A POTENT INHIBITOR OF NLRP3 INFLAMMASOME ACTIVATION AND DIET-INDUCED ADIPOSE TISSUE INFLAMMATION, JOURNAL OF LEUKOCYTE BIOLOGY, 96, 6, PP. 1087-1100, (2014); HSU S.-M., RAINE L., FANGER H., USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES: A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES, JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 29, 4, PP. 577-580, (1981); JOLES J.A., ET AL., EARLY MECHANISMS OF RENAL INJURY IN HYPERCHOLESTEROLEMIC OR HYPERTRIGLYCERIDEMIC RATS, JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 11, 4, PP. 669-683, (2000); KAY C.D., ET AL., PISTACHIOS INCREASE SERUM ANTIOXIDANTS AND LOWER SERUM OXIDIZED-LDL IN HYPERCHOLESTEROLEMIC ADULTS, THE JOURNAL OF NUTRITION, 140, 6, PP. 1093-1098, (2010); KOKA S., ET AL., ENDOTHELIAL NLRP3 INFLAMMASOME ACTIVATION AND ARTERIAL NEOINTIMA FORMATION ASSOCIATED WITH ACID SPHINGOMYELINASE DURING HYPERCHOLESTEROLEMIA, REDOX BIOLOGY, 13, PP. 336-344, (2017); LAMKANFI M., DIXIT V.M., MECHANISMS AND FUNCTIONS OF INFLAMMASOMES, CELL, 157, 5, PP. 1013-1022, (2014); LI X., ET AL., SHORT-TERM HESPERIDIN PRETREATMENT ATTENUATES RAT MYOCARDIAL ISCHEMIA/REPERFUSION INJURY BY INHIBITING HIGH MOBILITY GROUP BOX 1 PROTEIN EXPRESSION VIA THE PI3K/AKT PATHWAY, CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 39, 5, PP. 1850-1862, (2016); LI R., ET AL., HMGB1/PI3K/AKT/MTOR SIGNALING PARTICIPATES IN THE PATHOLOGICAL PROCESS OF ACUTE LUNG INJURY BY REGULATING THE MATURATION AND FUNCTION OF DENDRITIC CELLS, FRONTIERS IN IMMUNOLOGY, 11, (2020); LI J., ET AL., ANDROGRAPHOLIDE ALLEVIATES BLEOMYCIN-INDUCED NLRP3 INFLAMMASOME ACTIVATION AND EPITHELIAL-MESENCHYMAL TRANSITION IN LUNG EPITHELIAL CELLS BY SUPPRESSING AKT/MTOR SIGNALING PATHWAY, ANNALS OF TRANSLATIONAL MEDICINE, 9, 9, (2021); MIAO N., ET AL., THE CLEAVAGE OF GASDERMIN D BY CASPASE-11 PROMOTES TUBULAR EPITHELIAL CELL PYROPTOSIS AND URINARY IL-18 EXCRETION IN ACUTE KIDNEY INJURY, KIDNEY INTERNATIONAL, 96, 5, PP. 1105-1120, (2019); PONS P., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, 9, PP. 1084-1092, (1994); PRYOR J.B., ET AL., LIPID-LOWERING AGENTS FOR THE TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND END-STAGE RENAL DISEASE ON DIALYSIS: A REVIEW, DRUGS & THERAPY PERSPECTIVES, 35, 9, PP. 431-441, (2019); RAJAMANNAN N.M., ET AL., ATORVASTATIN INHIBITS CALCIFICATION AND ENHANCES NITRIC OXIDE SYNTHASE PRODUCTION IN THE HYPERCHOLESTEROLAEMIC AORTIC VALVE, HEART, 91, 6, PP. 806-810, (2005); ROH D.D., KAMANNA V.S., KIRSCHENBAUM M.A., OXIDATIVE MODIFICATION OF LOW-DENSITY LIPOPROTEIN ENHANCES MESANGIAL CELL PROTEIN SYNTHESIS AND GENE EXPRESSION OF EXTRACELLULAR MATRIX PROTEINS, AMERICAN JOURNAL OF NEPHROLOGY, 18, 4, PP. 344-350, (1998); RUAN X.Z., MOORHEAD J.F., VARGHESE Z., LIPID REDISTRIBUTION IN RENAL DYSFUNCTION, KIDNEY INTERNATIONAL, 74, 4, PP. 407-409, (2008); SASTRE C., ET AL., HYPERLIPIDEMIA-ASSOCIATED RENAL DAMAGE DECREASES KLOTHO EXPRESSION IN KIDNEYS FROM APOE KNOCKOUT MICE, PLOS ONE, 8, 12, (2013); SHAHZAD K., ET AL., NLRP3-INFLAMMASOME ACTIVATION IN NON-MYELOID-DERIVED CELLS AGGRAVATES DIABETIC NEPHROPATHY, KIDNEY INTERNATIONAL, 87, 1, PP. 74-84, (2015); SHAO B.-Z., ET AL., NLRP3 INFLAMMASOME AND ITS INHIBITORS: A REVIEW, FRONTIERS IN PHARMACOLOGY, 6, (2015); SHATTAT G.F., A REVIEW ARTICLE ON HYPERLIPIDEMIA: TYPES, TREATMENTS AND NEW DRUG TARGETS, BIOMEDICAL AND PHARMACOLOGY JOURNAL, 7, 1, PP. 399-409, (2015); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, JOURNAL OF FUNCTIONAL FOODS, 57, PP. 351-360, (2019); STEVENSON F.T., SHEARER G.C., ATKINSON D.N., LIPOPROTEIN-STIMULATED MESANGIAL CELL PROLIFERATION AND GENE EXPRESSION ARE REGULATED BY LIPOPROTEIN LIPASE, KIDNEY INTERNATIONAL, 59, 6, PP. 2062-2068, (2001); SUVARNA K.S., LAYTON C., BANCROFT J.D.; THOMSON A.W., TURNQUIST H.R., RAIMONDI G., IMMUNOREGULATORY FUNCTIONS OF MTOR INHIBITION, NATURE REVIEWS IMMUNOLOGY, 9, 5, PP. 324-337, (2009); VANSTHERTEM D., ET AL., EXPRESSION OF NESTIN, VIMENTIN, AND NCAM BY RENAL INTERSTITIAL CELLS AFTER ISCHEMIC TUBULAR INJURY, JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2010, (2010); VIOLA F., ET AL., POLICOSANOL: UPDATING AND PERSPECTIVES, MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM, 1, 2, PP. 77-83, (2008); XI H., ET AL., CASPASE-1 INFLAMMASOME ACTIVATION MEDIATES HOMOCYSTEINE-INDUCED PYROP-APOPTOSIS IN ENDOTHELIAL CELLS, CIRCULATION RESEARCH, 118, 10, PP. 1525-1539, (2016); YU X., ET AL., IGF-1 ALLEVIATES OX-LDL-INDUCED INFLAMMATION VIA REDUCING HMGB1 RELEASE IN HAECS, ACTA BIOCHIM BIOPHYS SIN, 44, 9, PP. 746-751, (2012); ZHAN J., ET AL., GSPE INHIBITS HMGB1 RELEASE, ATTENUATING RENAL IR-INDUCED ACUTE RENAL INJURY AND CHRONIC RENAL FIBROSIS, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 17, 10, (2016); ZHANG Y., ET AL., CORONARY ENDOTHELIAL DYSFUNCTION INDUCED BY NUCLEOTIDE OLIGOMERIZATION DOMAIN-LIKE RECEPTOR PROTEIN WITH PYRIN DOMAIN CONTAINING 3 INFLAMMASOME ACTIVATION DURING HYPERCHOLESTEROLEMIA: BEYOND INFLAMMATION, ANTIOXIDANTS & REDOX SIGNALING, 22, 13, PP. 1084-1096, (2015); ZHANG X., ET AL., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER'S DISEASE, BMC COMPLEMENTARY MEDICINE AND THERAPIES, 21, 1, PP. 1-12, (2021); ZHENG J., ET AL., URANIUM INDUCES KIDNEY CELLS PYROPTOSIS IN CULTURE INVOLVED IN ROS/NLRP3/CASPASE-1 SIGNALING, FREE RADICAL RESEARCH, PP. 1-25, (2022)","M.M. ELSEWEIDY; BIOCHEMISTRY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT; EMAIL: MMELSEWEIDY@PHARMACY.ZU.EDU.EG","ELSEVIER LTD","ENGLISH","J. FUNCT. FOODS","ARTICLE","ISI","2-S2.0-85137645227","J FUNCT FOODS","ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;SUEZ CANAL UNIVERSITY;ZAGAZIG UNIVERSITY HOSPITALS;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY","NOTREPORTED;ZAGAZIG UNIVERSITY;NOTREPORTED",NA,"ELNAGAR GM, 2022, J FUNCT FOODS","ELNAGAR GM, 2022, J FUNCT FOODS"
"YE Q;HONG L;PAN K;WANG X;YE X","YE, QING (57220822445); HONG, L.F. (57336457400); PAN, K. (57337011400); WANG, XIN (57336591400); YE, X.M. (56037798900)","STUDY ON THE EFFICACY AND SAFETY OF POLICOSANOL IN THE TREATMENT OF SENILE AND ELDERLY PATIENTS WITH HYPERLIPIDEMIA",2021,"INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES","83","4",0,"10.36468/pharmaceutical-sciences.spl.296","REHABILITATION MEDICINE CENTER OF ZHEJIANG PROVINCIAL PEOPLE’S HOSPITAL, REHABILITATION AND SPORTS MEDICINE RESEARCH INSTITUTE OF ZHEJIANG PROVINCE, PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE, HANGZHOU, 310014, CHINA;REHABILITATION MEDICINE CENTER OF ZHEJIANG PROVINCIAL PEOPLE’S HOSPITAL, REHABILITATION AND SPORTS MEDICINE RESEARCH INSTITUTE OF ZHEJIANG PROVINCE, PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE, HANGZHOU, 310014, CHINA;REHABILITATION MEDICINE CENTER OF ZHEJIANG PROVINCIAL PEOPLE’S HOSPITAL, REHABILITATION AND SPORTS MEDICINE RESEARCH INSTITUTE OF ZHEJIANG PROVINCE, PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE, HANGZHOU, 310014, CHINA;REHABILITATION MEDICINE CENTER OF ZHEJIANG PROVINCIAL PEOPLE’S HOSPITAL, REHABILITATION AND SPORTS MEDICINE RESEARCH INSTITUTE OF ZHEJIANG PROVINCE, PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE, HANGZHOU, 310014, CHINA;REHABILITATION MEDICINE CENTER OF ZHEJIANG PROVINCIAL PEOPLE’S HOSPITAL, REHABILITATION AND SPORTS MEDICINE RESEARCH INSTITUTE OF ZHEJIANG PROVINCE, PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE, HANGZHOU, 310014, CHINA","TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERANCE OF POLICOSANOL IN THE TREATMENT OF SENILE AND ELDERLY PATIENTS (≥75 Y OLD) WITH HYPERLIPIDEMIA IS THE MAIN OBJECTIVE. 150 SENILE AND ELDERLY PATIENTS WITH HYPERLIPIDEMIA FROM JUNE 2011 TO MAY 2013 WERE RANDOMLY DIVIDED INTO TWO GROUPS (TEST GROUP AND CONTROL GROUP) ACCORDING TO THE ORDER OF ADMISSION. THE TEST GROUP WAS TREATED WITH POLICOSANOL 10 MG/D, WHILE THE CONTROL GROUP WAS TREATED WITH ATORVASTATIN 20 MG/D FOR 16 W. THE CHANGES AND ADVERSE REACTIONS OF TOTAL CHOLESTEROL, TRIGLYCERIDE, HIGH DENSITY LIPOPROTEIN CHOLESTEROL, LOW DENSITY LIPOPROTEIN CHOLESTEROL, LIVER AND KIDNEY FUNCTION, FASTING BLOOD GLUCOSE AND CREATINE KINASE WERE OBSERVED BEFORE AND AFTER TREATMENT. THERE WAS NO SIGNIFICANT DIFFERENCE BETWEEN THE TWO GROUPS IN THE INDEXES BEFORE TREATMENT (P>0.05). AFTER 16 W TREATMENT, TOTAL CHOLESTEROL, TRIGLYCERIDE, LOW DENSITY LIPOPROTEIN CHOLESTEROL AND HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN THE TEST GROUP WERE 5.51±0.77, 1.79±0.88, 3.68±0.65 AND 1.11±0.31 MMOL/L BEFORE TREATMENT AND 4.90±1.03, 1.26±0.64, 3.21±0.92 AND 1.31±0.30 MMOL/L AFTER TREATMENT, RESPECTIVELY. THE ABOVE INDEXES HAD STATISTICAL SIGNIFICANCE BEFORE AND AFTER TREATMENT (P<0.01). TOTAL CHOLESTEROL, TRIGLYCERIDE, LOW DENSITY LIPOPROTEIN CHOLESTEROL AND HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN THE CONTROL GROUP WERE 5.59±1.10, 1.90±0.76, 3.68±1.00, 1.18±0.37 MMOL/L BEFORE TREATMENT AND 4.50±1.06, 1.39±0.81, 2.69±0.89, 1.32±0.35 MMOL/L AFTER TREATMENT, THE ABOVE INDEXES WERE SIGNIFICANTLY DIFFERENT FROM THOSE BEFORE TREATMENT (P<0.01). IN TERMS OF THE MAGNITUDE OF LIPID LOWERING, THE POLICOSANOL GROUP WAS WEAKER THAN THE ATORVASTATIN GROUP, ESPECIALLY IN LOWERING LOW DENSITY LIPOPROTEIN CHOLESTEROL (P<0.01). NO SIGNIFICANT ADVERSE REACTIONS WERE OBSERVED IN EITHER GROUP. POLICOSANOL CAN EFFECTIVELY LOWER THE LEVEL OF BLOOD LIPID IN PATIENTS AND IT IS SAFE AND WELL TOLERATED FOR SENILE AND ELDERLY PATIENTS. © 2021 INDIAN PHARMACEUTICAL ASSOCIATION. ALL RIGHTS RESERVED.","ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERLIPIDEMIA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TOTAL CHOLESTEROL; TRIGLYCERIDE","ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CHOLESTEROL; CREATINE KINASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POLICOSANOL; TICAGRELOR; TRIACYLGLYCEROL; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; ENZYME ACTIVITY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MYALGIA; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL","","","TAYLOR F, WARD K, MOORE TH, BURKE M, SMITH GD, CASAS JP, ET AL., STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 1, (2013); BRUGTS JJ, YETGIN T, HOEKS SE, GOTTO AM, SHEPHERD J, WESTENDORP RG, ET AL., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS: META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 338, (2009); PREISS D, SESHASAI SR, WELSH P, MURPHY SA, HO JE, WATERS DD, ET AL., RISK OF INCIDENT DIABETES WITH INTENSIVE-DOSE COMPARED WITH MODERATE-DOSE STATIN THERAPY: A META-ANALYSIS, JAMA, 305, 24, PP. 2556-2564, (2011); SATTAR N, PREISS D, MURRAY HM, WELSH P, BUCKLEY BM, DE CRAEN AJ, ET AL., STATINS AND RISK OF INCIDENT DIABETES: A COLLABORATIVE META-ANALYSIS OF RANDOMISED STATIN TRIALS, LANCET, 375, PP. 735-742, (2010); STONE NJ, ROBINSON JG, LICHTENSTEIN AH, BAIREY MERZ CN, BLUM CB, ECKEL RH, ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, 63, PP. 2889-2934, (2014); CASTANO G, MAS R, FERNANDEZ L, ILLNAIT J, MENDOZA S, GAMEZ R, ET AL., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, PP. 31-44, (2005); FERNANDEZ S, ROSA M, GAMEZ R, DIAZ A, FERNANDEZ J, ILLNAIT J, ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, 4, PP. 219-229, (2004); CHINESE GUIDELINES FOR THE PREVENTION AND TREATMENT OF DYSLIPIDEMIAINADULTS, CHINJCARDIOVASCDIS2007, 35, 5, PP. 390-419; BANERJEE S, GHOSHAL S, PORTER TD., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, 4, PP. 311-321, (2011); OLIARO-BOSSO S, CALCIO GAUDINO E, MANTEGNA S, GIRAUDO E, MEDA C, VIOLA F, ET AL., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, 10, PP. 907-916, (2009); MCCARTY MF., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE–POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, 3, PP. 268-279, (2002); SINGH DK, LI L, PORTER TD., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, 3, PP. 1020-1026, (2006); NOA M, MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH MED RES, 36, 5, PP. 441-447, (2005); CASTANO G, FERNANDEZ L, MAS R, ILLNAIT J, MESA M, FERNANDEZ JC., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVESTIG, 23, 10, PP. 639-650, (2003); ARRUZAZABALA ML, MOLINA V, MAS R, FERNANDEZ L, CARBAJAL D, VALDES S, ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, 10, PP. 891-897, (2002); CASTANO G, MAS R, FERNANDEZ L, ILLNAIT J, MESA M, ALVAREZ E, ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); SHEN L, CUI J., COST-EFFECTIVENESS ANALYSIS OF POLICOSANOL AND ROSUVASTATIN IN TREATMENT OF SENIOR PATIENTS WITH HYPERLIPIDEMIA, CLIN MISDIAGN MISTHER, 10, PP. 87-89, (2011); WANG Y, KE YN, WANG JL, JIAO Y, ZHAO XL, SUN NL, ET AL., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, CHIN J NEW DRUGS CLIN REM, 27, 2, PP. 124-128, (2008); CASTANO G, MAS R, FERNANDEZ L, GAMEZ R, ILLNAIT J., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, 1, PP. 25-38, (2003); CHEN JT, WESLEY R, SHAMBUREK RD, PUCINO F, CSAKO G., META‐ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); JIANJIANG Z, JUN Y, JINGBO Y, ZUO L, YING C, HONGXIA W., CLINICAL OBSERVATION ON EFFICACY AND SAFETY OF POLICOSANOL COMBINED WITH LOW-DOSE ATORVASTATIN IN THE TREATMENT OF ELDERLY PATIENTS WITH DIABETES MELLITUS COMPLICATED WITH HYPERLIPIDEMIA, ZHEJIANG MED J, 20, PP. 1827-1829, (2013)","X.M. YE; REHABILITATION MEDICINE CENTER OF ZHEJIANG PROVINCIAL PEOPLE’S HOSPITAL, REHABILITATION AND SPORTS MEDICINE RESEARCH INSTITUTE OF ZHEJIANG PROVINCE, PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE, HANGZHOU, 310014, CHINA; EMAIL: YEXMDR@126.COM","INDIAN PHARMACEUTICAL ASSOCIATION","ENGLISH","INDIAN J. PHARM. SCI.","ARTICLE","ISI","2-S2.0-85119003803","INDIAN J PHARM SCI","PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE;PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE;PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE;PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE;PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE","NOTREPORTED;PEOPLE’S HOSPITAL OF HANGZHOU MEDICAL COLLEGE;NOTREPORTED",NA,"YE Q, 2021, INDIAN J PHARM SCI","YE Q, 2021, INDIAN J PHARM SCI"
"BANACH M;KATSIKI N;LATKOVSKIS G;RIZZO M;PELLA D;PENSON P;REINER Z;CICERO A","BANACH, MACIEJ (22936699500); KATSIKI, NIKI (25421628400); LATKOVSKIS, GUSTAVS (6507756746); RIZZO, MANFREDI (7202023733); PELLA, DANIEL (57216122471); PENSON, PETER E. (6506734112); REINER, ZELJKO (55411641000); CICERO, ARRIGO F.G. (7003403707)","POSTMARKETING NUTRIVIGILANCE SAFETY PROFILE A LINE OF DIETARY FOOD SUPPLEMENTS CONTAINING RED YEAST RICE FOR DYSLIPIDEMIA",2021,"ARCHIVES OF MEDICAL SCIENCE","17","7",22,"10.5114/aoms/133716","POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE (PMMHRI), LODZ, POLAND, DEPARTMENT OF HYPERTENSION, MEDICAL UNIVERSITY OF LODZ (MUL), LODZ, POLAND, CARDIOVASCULAR RESEARCH CENTRE, UNIVERSITY OF ZIELONA GORA, ZIELONA GORA, POLAND;FIRST DEPARTMENT OF INTERNAL MEDICINE, DIABETES CENTER, DIVISION OF ENDOCRINOLOGY AND METABOLISM, MEDICAL SCHOOL, ARISTOTLE UNIVERSITY OF THESSALONIKI, AHEPA HOSPITAL, THESSALONIKI, GREECE;INSTITUTE OF CARDIOLOGY AND REGENERATIVE MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF LATVIA, RIGA, LATVIA, PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL, RIGA, LATVIA;DEPARTMENT OF HEALTH PROMOTION SCIENCES MATERNAL AND INFANTILE CARE, INTERNAL MEDICINE AND MEDICAL SPECIALTIES (PROMISE), UNIVERSITY OF PALERMO, PALERMO, ITALY;2NDDEPARTMENT OF CARDIOLOGY, THE EAST SLOVAK INSTITUTE OF CARDIOVASCULAR DISEASE, FACULTY OF MEDICINE, PJ SAFARIK UNIVERSITY, KOSICE, SLOVAKIA;SCHOOL OF PHARMACY AND BIOMOLECULAR SCIENCES, LIVERPOOL JOHN MOORES UNIVERSITY, LIVERPOOL, UNITED KINGDOM, LIVERPOOL CENTRE FOR CARDIOVASCULAR SCIENCE, LIVERPOOL, UNITED KINGDOM;DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY HOSPITAL CENTER ZAGREB, ZAGREB, CROATIA;IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA, BOLOGNA, ITALY, ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY","INTRODUCTION: IN THE ABSENCE OF A EUROPEAN STANDARDIZED POSTMARKETING FOOD SUPPLEMENT SURVEILLANCE SYSTEM (NUTRIVIGILANCE), SOME MEMBER STATES AND COMPANIES HAVE DEVELOPED THEIR OWN APPROACHES TO MONITORING POTENTIAL ADVERSE REACTIONS TO SECURE A HIGH LEVEL OF PRODUCT SAFETY. THIS PAPER DESCRIBES THE USE OF A NUTRIVIGILANCE SYSTEM IN MONITORING THE INCIDENCE OF SPONTANEOUSLY REPORTED SUSPECTED ADVERSE REACTIONS ASSOCIATED WITH FOOD SUPPLEMENTS CONTAINING RED YEAST RICE (RYR). MATERIAL AND METHODS: WE REPORT THE DATA FROM A WIDELY USED PRODUCT MARKETED UNDER THE TRADEMARK ARMOLIPID/ARMOLIPID PLUS. POSTMARKETING INFORMATION WAS COLLECTED IN A VOLUNTARY NUTRIVIGILANCE SYSTEM ESTABLISHED BY THE MANUFACTURING COMPANY (MEDA PHARMA SPA, A VIATRIS COMPANY, MONZA, ITALY). FROM 1ST OCTOBER 2004 TO 31ST DECEMBER 2019, THIS SYSTEM CAPTURED CASES OF SUSPECTED ADVERSE REACTIONS SPONTANEOUSLY REPORTED BY CONSUMERS, HEALTHCARE PROFESSIONALS, HEALTH AUTHORITIES, REGARDLESS OF CAUSALITY. RESULTS: THE TOTAL NUMBER OF CASE REPORTS RECEIVED MENTIONING THE RYR FOOD SUPPLEMENT PRODUCT LINE WAS 542, IN WHICH 855 ADVERSE EVENTS (AES) WERE REPORTED. THE TOTAL REPORTING RATE OF AES WAS ESTIMATED TO BE 0.037% OF 2,287,449 EXPOSED CONSUMERS. OF THE 542 CASES, 21 (0.0009% OF EXPOSED CONSUMERS) INCLUDED SUSPECTED SERIOUS ADVERSE EVENTS (SAES). AFTER CAREFUL INVESTIGATION, 6 CASES (0.0003% OF CONSUMERS EXPOSED) AND 6 AES WERE ASSESSED BY THE MANUFACTURER AS SERIOUS AND POTENTIALLY RELATED TO EXPOSURE TO THE ABOVE-MENTIONED RYR-BASED NUTRACEUTICAL. CONCLUSIONS: THIS NUTRIVIGILANCE-DERIVED DATA ANALYSIS CLEARLY DEMONSTRATES A LOW PREVALENCE OF SUSPECTED ADVERSE EVENTS ASSOCIATED WITH THE RED YEAST RICE PRODUCT LINE. CONSUMER SAFETY OF FOOD SUPPLEMENTS COULD BE GENERALLY IMPROVED BY RAISING AWARENESS OF THE IMPORTANCE OF FOLLOWING THE INDICATIONS AND WARNINGS DETAILED IN A FOOD SUPPLEMENT'S LABELING.  COPYRIGHT © 2021 TERMEDIA & BANACH.","ADVERSE EVENT; DYSLIPIDAEMIA; NUTRIVIGILANCE; RED YEAST RICE; SUPPLEMENT","AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ARMOLIPID; ASTAXANTHIN; ATENOLOL; BERBERINE; CANRENOATE POTASSIUM; CHOLESTIN; FOLIC ACID; LEVOTHYROXINE; MEVINOLIN; POLICOSANOL; ROSUVASTATIN; SERTRALINE; SIMVASTATIN; UBIDECARENONE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUSALITY; CONSUMER; DIARRHEA; DIETARY SUPPLEMENT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEALTH CARE PERSONNEL; HEPATITIS; HUMAN; INTESTINE OBSTRUCTION; LIPEDEMA; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; RHABDOMYOLYSIS; SIDE EFFECT; VOMITING","AKCEA; ABBOTT LABORATORIES; AMGEN; ELI LILLY AND COMPANY; ASTRAZENECA; BAYER; BOEHRINGER INGELHEIM; GLAXOSMITHKLINE JAPAN, GSK; ASTRAZENECA PHARMA POLAND; BAUSCH HEALTH","DR BANACH HAS RECEIVED RESEARCH GRANT(S)/SUPPORT FROM AMGEN, MYLAN, SANOFI AND VALEANT, AND HAS SERVED AS A SPEAKER AND CONSULTANT FOR AM-GEN, DAICHII SANKYO, ESPERION, FREIA PHARMACEUTICALS, HERBAPOL, KOGEN, KRKA, MYLAN, NOVARTIS, NOVO NORDISK, POLPHARMA, POLFARMEX, REGENERON, SANOFI-AVENTIS, SERVIER, ZENTIVA; DR KATSIKI HAS GIVEN TALKS, ATTENDED CONFERENCES AND PARTICIPATED IN TRIALS SPONSORED BY ASTRA ZENECA, BAUSCH HEALTH, BOEHRINGER INGELHEIM, ELPEN, MENARINI, MYLAN, NOVO NORDISK, SANOFI, SERVIER AND VIANEX; DR. LATKOVSKIS REPORTS GRANTS, HONORARIA OR NON-FINANCIAL SUPPORT FROM ABBOTT LABORATORIES, AMGEN, ASTRA-ZENECA, BAYER, BERLIN-CHEMIE/MENARINI, BOEHRINGER INGELHEIM, GLAXOSMITHKLINE, KRKA, MYLAN, NOVARTIS, NOVO NORDISK, PFIZER, ROCHE DIAGNOSTICS, SANOFI-AVENTIS, SERVIER, SIEMENS HEALTHCARE, ZENTIVA; DR RIZZO HAS GIVEN LECTURES, RECEIVED HONORARIA AND RESEARCH SUPPORT, AND PARTICIPATED IN CONFERENCES, ADVISORY BOARDS AND CLINICAL TRIALS SPONSORED BY MANY PHARMACEUTICAL COMPANIES INCLUDING AMGEN, ASTRAZENECA, BOEHRINGER INGEL-HEIM, KOWA, ELI LILLY, MEDA, MERCK SHARP & DOHME, MYLAN, NOVO NORDISK, NOVARTIS, ROCHE DIAGNOSTICS, SANOFI AND SERVIER; HE IS CURRENTLY MEDICAL DIRECTOR, NOVO NORDISK BA LM; DR PENSON OWNS FOUR SHARES IN ASTRAZENECA PLC AND HAS RECEIVED HONORARIA AND/OR TRAVEL REIMBURSEMENT FOR EVENTS SPONSORED BY AKCEA, AMGEN, AMRYT, LINK MEDICAL, NAPP AND SANOFI; DR REINER HAS RECEIVED HONORARIA FROM SA-NOFI AND NOVARTIS. DR CICERO IS A SCIENTIFIC CONSULTANT FOR MEDA-MYLAN SPA, SHARPER SPA AND MENA-RINI IFR; DR PELLA HAS NOTHING TO DECLARE.","GRUNDY SM, STONE NJ, BAILEY AL, ET AL., AHA/ACC/ AACVPR/AAPA/ ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/ PCNA GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/ AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, J AM COLL CARDIOL, 73, PP. E285-E350, (2019); MACH F, BAIGENT C, CATAPANO AL, ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR HEART J, 41, PP. 111-188, (2020); PENSON PE, PIRRO M, BANACH M., LDL-C: LOWER IS BETTER FOR LONGER-EVEN AT LOW RISK, BMC MED, 18, (2020); GE L, SADEGHIRAD B, BALL GDC, ET AL., COMPARISON OF DIETARY MACRONUTRIENT PATTERNS OF 14 POPULAR NAMED DIETARY PROGRAMMES FOR WEIGHT AND CARDIOVASCULAR RISK FACTOR REDUCTION IN ADULTS: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMISED TRIALS, BMJ, 369, (2020); REINER Z, CATAPANO AL, ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); CICERO AFG, COLLETTI A, BAJRAKTARI G, ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 13, PP. 965-1005, (2017); BANACH M, PATTI AM, GIGLIO RV, ET AL., THE ROLE OF NUTRACEUTICALS IN STATIN INTOLERANT PATIENTS, J AM COLL CARDIOL, 72, PP. 96-118, (2018); BANACH M, BRUCKERT E, DESCAMPS OS, ET AL., THE ROLE OF RED YEAST RICE (RYR) SUPPLEMENTATION IN PLASMA CHOLESTEROL CONTROL: A REVIEW AND EXPERT OPINION, ATHEROSCLER SUPPL, 39, PP. E1-E8, (2019); BARRIOS V, ESCOBAR C, CICERO AF, ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); POLI A, BARBAGALLO CM, CICERO AFG, ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOL RES, 134, PP. 51-60, (2018); PIRRO M, MANNARINO MR, BIANCONI V, ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); MAZZA A, LENTI S, SCHIAVON L, ET AL., EFFECT OF MONACOLIN K AND COQ10 SUPPLEMENTATION IN HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS WITH METABOLIC SYNDROME, BIOMED PHARMACOTHER, 105, PP. 992-996, (2018); MAZIDI M, KENGNE AP, BANACH M, EFFECTS OF COENZYME Q10 SUPPLEMENTATION ON PLASMA C-REACTIVE PROTEIN CONCENTRATIONS: A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 128, PP. 130-136, (2018); BANACH M, SERBAN C, SAHEBKAR A, ET AL., EFFECTS OF COENZYME Q10 ON STATIN-INDUCED MYOPATHY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MAYO CLIN PROC, 90, PP. 24-34, (2015); YOUNES M, AGGETT P, ET AL., SCIENTIFIC OPINION ON THE SAFETY OF MONACOLINS IN RED YEAST RICE, EFSA J, 16, (2018); MAZZANTI G, MORO PA, RASCHI E., ADVERSE REACTIONS TO DIETARY SUPPLEMENTS CONTAINING RED YEAST RICE: ASSESSMENT OF CASES FROM THE ITALIAN SURVEILLANCE SYSTEM, BR J CLIN PHARMACOL, 83, PP. 894-908, (2017); COHEN PA, AVULA B, KHAN IA., VARIABILITY IN STRENGTH OF RED YEAST RICE SUPPLEMENTS PURCHASED FROM MAINSTREAM RETAILERS, EUR J PREV CARDIOL, 24, PP. 1431-1434, (2017); LU Z, KOU W, DU B, ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); GHEITH O, SHEASHAA H, ABDELSALAM M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH SECONDARY HYPERLIPIDEMIA, CLIN EXP NEPHROL, 12, PP. 189-194, (2008); LIN CC, LI TC, LAI MM., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); AFFUSO F, RUVOLO A, MICILLO F., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); AFFUSO F, MERCURIO V, RUVOLO A, ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); FOGACCI F, BANACH M, MIKHAILIDIS DP, ET AL., SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 143, PP. 1-16, (2019); THE USE OF THE WHO-UMC SYSTEM FOR STANDARDISED CASE CAUSALITY ASSESSMENT; CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING; PENSON PE, MANCINI GBJ, TOTH PP, ET AL., INTRODUCING THE 'DRUCEBO' EFFECT IN STATIN THERAPY: A SYSTEMATIC REVIEW OF STUDIES COMPARING REPORTED RATES OF STATIN-ASSOCIATED MUSCLE SYMPTOMS, UNDER BLINDED AND OPEN-LABEL CONDITIONS, J CACHEXIA SARCOPENIA MUSCLE, 9, PP. 1023-1033, (2018); BANACH M, PENSON PE., DRUCEBO EFFECT - THE CHALLENGE WE SHOULD ALL DEFINITELY FACE!, ARCH MED SCI, 17, PP. 542-543, (2021)","M. BANACH; DEPARTMENT OF HYPERTENSION, MEDICAL UNIVERSITY OF LODZ, LODZ, 281/289 RZGOWSKA ST, 93-338, POLAND; EMAIL: MACIEJ.BANACH@ICZMP.EDU.PL","TERMEDIA PUBLISHING HOUSE LTD.","ENGLISH","ARCH. MED. SCI.","ARTICLE","ISI","2-S2.0-85109436639","ARCH MED SCI","MEDICAL UNIVERSITY OF LODZ (MUL);ARISTOTLE UNIVERSITY OF THESSALONIKI;UNIVERSITY OF LATVIA;UNIVERSITY OF PALERMO;KOSICE;LIVERPOOL JOHN MOORES UNIVERSITY;UNIVERSITY HOSPITAL CENTER ZAGREB;IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA","NOTREPORTED;MEDICAL UNIVERSITY OF LODZ;NOTREPORTED",NA,"BANACH M, 2021, ARCH MED SCI","BANACH M, 2021, ARCH MED SCI"
"BANACH M;BURCHARDT P;CHLEBUS K;DOBROWOLSKI P;DUDEK D;DYRBUŚ K;GĄSIOR M;JANKOWSKI P;JÓŹWIAK J;KŁOSIEWICZ-LATOSZEK L;KOWALSKA I;MAŁECKI M;PREJBISZ A;RAKOWSKI M;RYSZ J;SOLNICA B;SITKIEWICZ D;SYGITOWICZ G;SYPNIEWSKA G;TOMASIK T;WINDAK A;ZOZULIŃSKA-ZIÓŁKIEWICZ D;CYBULSKA B","BANACH, MACIEJ (22936699500); BURCHARDT, PAWEŁ (9633798500); CHLEBUS, KRZYSZTOF (35614248700); DOBROWOLSKI, PIOTR (56439595700); DUDEK, DARIUSZ (7006649800); DYRBUŚ, KRZYSZTOF (6507000466); GĄSIOR, MARIUSZ (7005055488); JANKOWSKI, PIOTR (57190678466); JÓŹWIAK, JACEK (21833993700); KŁOSIEWICZ-LATOSZEK, LONGINA (7003994546); KOWALSKA, IRINA (7004840503); MAŁECKI, MACIEJ (25622252400); PREJBISZ, ALEKSANDER (6602179118); RAKOWSKI, MICHAŁ (57221240171); RYSZ, JACEK (7004232269); SOLNICA, BOGDAN (6603107418); SITKIEWICZ, DARIUSZ (7003763261); SYGITOWICZ, GRAZYNA (6507148865); SYPNIEWSKA, GRAZYNA (6701464828); TOMASIK, TOMASZ (6602445472); WINDAK, ADAM (6506589548); ZOZULIŃSKA-ZIÓŁKIEWICZ, DOROTA (23986607400); CYBULSKA, BARBARA (7005907719)","POLACFPIPPCSPSLDPSDPSH GUIDELINES ON DIAGNOSIS AND THERAPY OF LIPID DISORDERS IN POLAND 2021",2021,"ARCHIVES OF MEDICAL SCIENCE","17","100",97,"10.5114/aoms/141941","DEPARTMENT OF PREVENTIVE CARDIOLOGY AND LIPIDOLOGY, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND, CARDIOVASCULAR RESEARCH CENTER, UNIVERSITY OF ZIELONA GORA, ZIELONA GORA, POLAND, DEPARTMENT OF CARDIOLOGY AND CONGENITAL DISEASES OF ADULTS, POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE (PMMHRI) IN LODZ, LODZ, POLAND;DEPARTMENT OF HYPERTENSIOLOGY, ANGIOLOGY, AND INTERNAL MEDICINE, K. MARCINKOWSKI POZNAN UNIVERSITY OF MEDICAL SCIENCE, POZNAN, POLAND, DEPARTMENT OF CARDIOLOGY, CARDIOVASCULAR UNIT, J. STRUS HOSPITAL, POZNAN, POLAND;FIRST DEPARTMENT AND CHAIR OF CARDIOLOGY, MEDICAL UNIVERSITY OF GDANSK, GDANSK, POLAND;DEPARTMENT OF HYPERTENSION, NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND;INSTITUTE OF CARDIOLOGY, JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND;3RD DEPARTMENT OF CARDIOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND, SILESIAN CENTER FOR HEART DISEASES, ZABRZE, POLAND;3RD DEPARTMENT OF CARDIOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND, SILESIAN CENTER FOR HEART DISEASES, ZABRZE, POLAND;DEPARTMENT OF INTERNAL MEDICINE AND GERIATRIC CARDIOLOGY, CENTRE OF POSTGRADUATE MEDICAL EDUCATION, WARSAW, POLAND, DEPARTMENT OF CARDIOLOGY AND ARTERIAL HYPERTENSION, INSTITUTE OF CARDIOLOGY, JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND;DEPARTMENT OF FAMILY MEDICINE AND PUBLIC HEALTH, INSTITUTE OF MEDICAL SCIENCES, FACULTY OF MEDICINE, UNIVERSITY OF OPOLE, OPOLE, POLAND;NATIONAL INSTITUTE OF PUBLIC HEALTH NIH, NATIONAL RESEARCH INSTITUTE, WARSAW, POLAND;DEPARTMENT OF INTERNAL MEDICINE AND METABOLIC DISEASES, MEDICAL UNIVERSITY OF BIALYSTOK, BIALYSTOK, POLAND;DEPARTMENT AND CHAIR OF METABOLIC DISEASES, JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND;DEPARTMENT OF HYPERTENSION, NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND;DEPARTMENT OF MOLECULAR BIOPHYSICS, INSTITUTE OF BIOPHYSICS, FACULTY OF BIOLOGY AND ENVIRONMENTAL PROTECTION, UNIVERSITY OF LODZ, LODZ, POLAND;MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND;JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND;DEPARTMENT OF CLINICAL CHEMISTRY AND LABORATORY DIAGNOSTICS, MEDICAL UNIVERSITY OF WARSAW, WARSAW, POLAND;DEPARTMENT OF CLINICAL CHEMISTRY AND LABORATORY DIAGNOSTICS, MEDICAL UNIVERSITY OF WARSAW, WARSAW, POLAND;DEPARTMENT OF LABORATORY MEDICINE, L. RYDYGIER MEDICAL COLLEGE IN BYDGOSZCZ, NICOLAUS COPERNICUS UNIVERSITY, TORUN, POLAND;JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND;JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND;DEPARTMENT AND CHAIR OF INTERNAL MEDICINE AND DIABETOLOGY, K. MARCINKOWSKI POZNAN UNIVERSITY OF MEDICAL SCIENCES, POZNAN, POLAND;NATIONAL INSTITUTE OF PUBLIC HEALTH NIH, NATIONAL RESEARCH INSTITUTE, WARSAW, POLAND","[NO ABSTRACT AVAILABLE]","","ACARBOSE; ALANINE AMINOTRANSFERASE; ALIROCUMAB; ALPHA TOCOPHEROL; AMIODARONE; ANTHOCYANIN; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; APABETALONE; APOLIPOPROTEIN B; ARTICHOKE EXTRACT; ASPARAGINASE; ATORVASTATIN; BEMPEDOIC ACID; BERBERINE; BERGAMOT OIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA GLUCAN; BILE ACID SEQUESTRANT; CARBOXYLIC ACID; CARNITINE; CHITOSAN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLARITHROMYCIN; CLOPIDOGREL; CLOZAPINE; COLECALCIFEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CURCUMIN; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; ERYTHROMYCIN; ESTROGEN; EVINACUMAB; EVOLOCUMAB; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA ORYZANOL; GARLIC EXTRACT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCLISIRAN; INSULIN; ISPAGULA; LAROPIPRANT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; METFORMIN; MIPOMERSEN; NICOTINIC ACID; NUTRACEUTICAL; OLANZAPINE; OMEGA 3 FATTY ACID; PANTETHINE; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHYTOSTEROL; PIOGLITAZONE; PITAVASTATIN; PLANT EXTRACT; POLYCOSANOL; PRAVASTATIN; PROBIOTIC AGENT; PROPROTEIN CONVERTASE 9 INHIBITOR; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RETINOL; ROSUVASTATIN; SIMVASTATIN; SINECATECHINS; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOYBEAN PROTEIN; SPIRULINA EXTRACT; STANOZOLOL; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TAMOXIFEN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERAPAMIL; VOLANESORSEN; VUPANORSEN; XUEZHIKANG; ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE LEVEL; ALLERGIC REACTION; ALTERNATIVE MEDICINE; ANTISENSE THERAPY; ARTICHOKE; AUTOIMMUNE DISEASE; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR RISK FACTOR; CEREBROVASCULAR ACCIDENT; CHILD; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CORONAVIRUS DISEASE 2019; DIABETES MELLITUS; DIARRHEA; DIETARY FIBER; DIETARY SUPPLEMENT; DISEASE PREDISPOSITION; DISORDERS OF LIPID METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; FUNCTIONAL FOOD; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE ORGANIZATION; HEALTHY DIET; HEALTHY LIFESTYLE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE REACTION; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LIPID FINGERPRINTING; LIPOPROTEIN APHERESIS; LIVER DISEASE; LOW DRUG DOSE; LUPIN; LUPUS LIKE SYNDROME; MALE; MEDICAL SOCIETY; MONOTHERAPY; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE RIGIDITY; MUSCLE TOXICITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; PALLIATIVE THERAPY; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; POLAND; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SKIN DEFECT; SYNERGISTIC EFFECT; SYSTEMATIC REVIEW; TERMINAL DISEASE; THROMBOCYTOPENIA","","","SORAN H, ADAM S, MOHAMMAD JB, ET AL., HYPERCHOLESTEROLAEMIA - PRACTICAL INFORMATION FOR NON-SPECIALISTS, ARCH MED SCI, 14, PP. 1-21, (2018); PENSON PE, PIRRO M, BANACH M., LDL-C: LOWER IS BETTER FOR LONGER-EVEN AT LOW RISK, BMC MED, 18, (2020); LING JZJ, MONTVIDA O, KHUNTI K, ZHANG AL, XUE CC, PAUL SK., THERAPEUTIC INERTIA IN THE MANAGEMENT OF DYSLIPIDAEMIA AND HYPERTENSION IN INCIDENT TYPE 2 DIABETES AND THE RESULTING RISK FACTOR BURDEN: REAL-WORLD EVIDENCE FROM PRIMARY CARE, DIABETES OBES METAB, 23, PP. 1518-1531, (2021); ZDROJEWSKI T, SOLNICA B, CYBULSKA B, ET AL., PREVALENCE OF LIPID ABNORMALITIES IN POLAND. THE NATPOL 2011 SURVEY, KARDIOL POL, 74, PP. 213-223, (2016); BANACH M, PENSON PE., CELLULAR SENESCENCE, TELOMERES, AND CARDIOVASCULAR RISK IN FAMILIAL HYPERCHOLESTEROLAEMIA, EUR J PREV CARDIOL, (2020); CYBULSKA B, KLOSIEWICZ-LATOSZEK L, PENSON PE, NABAVI SM, LAVIE CJ, BANACH M, HOW MUCH SHOULD LDL CHOLESTEROL BE LOWERED IN SECONDARY PREVENTION? CLINICAL EFFICACY AND SAFETY IN THE ERA OF PCSK9 INHIBITORS, PROG CARDIOVASC DIS, 67, PP. 65-74, (2021); BANACH M, PENSON PE., STATINS AND LDL-C IN SECONDARY PREVENTION-SO MUCH PROGRESS, SO FAR TO GO, JAMA NETW OPEN, 3, (2020); BANACH M, JANKOWSKI P, JOZWIAK J, ET AL., POLA/CFPIP/PCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS FOR FAMILY PHYSICIANS 2016, ARCH MED SCI, 13, PP. 1-45, (2017); MACH F, BAIGENT C, CATAPANO AL, ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR HEART J, 41, PP. 111-188, (2020); JOZWIAK JJ, STUDZINSKI K, TOMASIK T, ET AL., THE PREVALENCE OF CARDIOVASCULAR RISK FACTORS AND CARDIOVASCULAR DISEASE AMONG PRIMARY CARE PATIENTS IN POLAND: RESULTS FROM THE LIPIDOGRAM2015 STUDY, ATHEROSCLER SUPPL, 42, PP. E15-E24, (2020); NATIONAL TRENDS IN TOTAL CHOLESTEROL OBSCURE HETEROGENEOUS CHANGES IN HDL AND NON-HDL CHOLESTEROL AND TOTAL-TO- HDL CHOLESTEROL RATIO: A POOLED ANALYSIS OF 458 POPULATION- BASED STUDIES IN ASIAN AND WESTERN COUNTRIES, INT J EPIDEMIOL, 49, PP. 173-192, (2020); REPOSITIONING OF THE GLOBAL EPICENTRE OF NON-OPTIMAL CHOLESTEROL, NATURE, 582, PP. 73-77, (2020); JOZWIAK J., DYSLIPIDEMIE, MEDYCYNA RODZINNA. PODRȨCZNIK DLA LEKARZY I STUDENTÓW, (2015); RYWIK S, BRODA G, PIOTROWSKI W, ET AL., EPIDEMIOLOGIA CHORÓB UKŁADU KRĄZENIA - PROGRAM POL-MONICA WARSZAWA, KARDIOL POL, 44, PP. 7-35, (1996); TENDERA M, KOZAKIEWICZ K, BARTNIK M, ET AL., WYSTȨPOWANIE GŁÓWNYCH CZYNNIKÓW RYZYKA CHOROBY NIEDOKRWIENNEJ SERCA W GRUPIE 41 927 OSÓB OBJȨTYCH AKCJĄ PREWENCJI PIERWOTNEJ W POLSCE POŁUDNIOWEJ (SOUTHEREN POLAND EPIDEMIOLOGICAL SURVEY - SPES), WIAD LEK, 54, PP. 293-303, (2001); ZDROJEWSKI T, BANDOSZ P, SZPAKOWSKI P, ET AL., ROZPOWSZECHNIENIE GŁÓWNYCH CZYNNIKÓW RYZYKA CHORÓB UKŁADU SERCOWO-NACZYNIOWEGO W POLSCE. WYNIKI BADANIA NATPOL PLUS, KARDIOL POL, 61, PP. 1-26, (2004); PAJAK A, WIERCINSKA E, POLAKOWSKA M, ET AL., ROZPOWSZECHNIENIE DYSLIPIDEMII U MȨZCZYZN I KOBIET W WIEKU 20-74 LAT W POLSCE. WYNIKI PROGRAMU WOBASZ, KARDIOL POL, 63, PP. 620-626, (2005); JOZWIAK J, MASTEJ M, LUKAS W, ET AL., LIPIDOGRAM2003 - OCENA I PORÓWNANIE PARAMETRÓW PEŁNEGO LIPIDOGRAMU I WSKAZNIKA MASY CIAŁA BMI W ZALEZNOŚCI OD PŁCI I WIEKU W POPULACJI PACJENTÓW POLSKI POŁUDNIOWEJ I ZACHODNIEJ. CZȨŚĆ II: CZȨSTOŚĆ WYSTȨPOWANIA ZABURZEŃ LIPIDOWYCH W ZALEZNOŚCI OD PŁCI I BMI, PROBL MED RODZ, 7, PP. 33-39, (2005); JOZWIAK J, MASTEJ M, LUKAS W, ET AL., CZY PROBLEM ZABURZEŃ LIPIDOWYCH W RÓWNYM STOPNIU DOTYCZY RÓZNYCH REGIONÓW POLSKI?, KARDIOL POL, 64, PP. 137-145, (2006); KONDURACKA E, JOZWIAK J, MASTEJ M, ET AL., PREVALENCE OF DISLIPIDEMIA AND GENERAL INEFFECTIVENESS OF ITS TREATMENT IN BOTH PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE WITHIN FAMILY MEDICINE FRAMEWORK - RESULTS OF LIPIDOGRAM 2005 A NATIONWIDE EPIDEMIOLOGICAL STUDY. DISLIPIDEMIA IN POLAND - INEFFECTIVE TREATMENT, PRZEGL LEK, 65, PP. 834-837, (2008); PAJAK A, SZAFRANIEC K, POLAK M, ET AL., CHANGES IN THE PREVALENCE, MANAGEMENT AND TREATMENT OF HYPERCHOLESTEROLEMIA AND OTHER DYSLIPIDEMIAS OVER 10 YEARS IN POLAND. THE WOBASZ STUDY, POL ARCH MED WEWN, 126, PP. 642-652, (2016); KAESS B, JOZWIAK J, MASTEJ M, ET AL., ASSOCIATION BETWEEN ANTHROPOMETRIC OBESITY MEASURES AND CORONARY ARTERY DISEASE: A CROSS-SECTIONAL SURVEY OF 16, 657 SUBJECTS FROM 444 POLISH CITIES, HEART, 96, PP. 131-135, (2010); TOMASIK T, JOZWIAK J, WINDAK A, ET AL., PREVENTION OF CORONARY HEART DISEASE IN PRIMARY MEDICAL CARE IN POLAND: RESULTS FROM THE LIPIDOGRAM STUDY, EUR J CARDIOVASC PREV REHABIL, 18, PP. 287-296, (2011); KAESS BM, JOZWIAK J, NELSON CP, ET AL., THE RELATION OF RAPID CHANGES IN OBESITY MEASURES TO LIPID PROFILE - INSIGHTS FROM A NATIONWIDE METABOLIC HEALTH SURVEY IN 444 POLISH CITIES, PLOS ONE, 9, (2014); JANKOWSKI P, CZARNECKA D, LUKASZEWSKA A, ET AL., FACTORS RELATED TO THE EFFECTIVENESS OF HYPERCHOLESTEROLEMIA TREATMENT FOLLOWING HOSPITALIZATION FOR CORONARY ARTERY DISEASE, POL ARCH MED WEWN, 126, PP. 388-394, (2016); JANKOWSKI, CZARNECKA, BADACZ L, ET AL., PRACTICE SETTING AND SECONDARY PREVENTION OF CORONARY ARTERY DISEASE, ARCH MED SCI, 14, PP. 979-987, (2018); JOZWIAK JJ, KASPERCZYK S, TOMASIK T, ET AL., DESIGN AND RATIONALE OF A NATIONWIDE SCREENING ANALYSIS FROM THE LIPIDOGRAM2015 AND LIPIDOGEN2015 STUDIES, ARCH MED SCI, (2020); HARRISON SL, LANE DA, BANACH M, ET AL., LIPID LEVELS, ATRIAL FIBRILLATION AND THE IMPACT OF AGE: RESULTS FROM THE LIPIDOGRAM2015 STUDY, ATHEROSCLEROSIS, 312, PP. 16-22, (2020); GANCZAK M, MIAZGOWSKI T, KOZYBSKA M, ET AL., CHANGES IN DISEASE BURDEN IN POLAND BETWEEN 1990-2017 IN COMPARISON WITH OTHER CENTRAL EUROPEAN COUNTRIES: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2017, PLOS ONE, 15, (2020); RAY KK, MOLEMANS B, SCHOONEN WM, ET AL., EU-WIDE CROSS-SECTIONAL OBSERVATIONAL STUDY OF LIPID-MODIFYING THERAPY USE IN SECONDARY AND PRIMARY CARE: THE DAVINCI STUDY, EUR J PREV CARDIOL, 28, PP. 1279-1289, (2021); VRABLIK M, SEIFERT B, PARKHOMENKO A, ET AL., ARE RISKBASED LDL-C GOALS ACHIEVED IN PRIMARY AND SECONDARY CARE IN CENTRAL AND EASTERN EUROPE? COMPARISON WITH OTHER EUROPE REGIONS FROM THE DA VINCI OBSERVATIONAL STUDY, ATHEROSCLEROSIS, (2021); PODGORSKI M, SZATKO K, STANCZYK M, ET AL., APPLE DOES NOT FALL FAR FROM THE TREE"" - SUBCLINICAL ATHEROSCLEROSIS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, LIPIDS HEALTH DIS, 19, (2020); GLOBAL PERSPECTIVE OF FAMILIAL HYPERCHOLESTEROLAEMIA: A CROSS-SECTIONAL STUDY FROM THE EAS FAMILIAL HYPERCHOLESTEROLAEMIA STUDIES COLLABORATION (FHSC), LANCET, (2021); DYRBUS K, GASIOR M, DESPERAK P, OSADNIK T, NOWAK J, BANACH M., THE PREVALENCE AND MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE POLISH TERTIARY CENTRE: RESULTS FROM THE TERCET REGISTRY WITH 19, 781 INDIVIDUALS, ATHEROSCLEROSIS, 288, PP. 33-41, (2019); LANGLOIS MR, CHAPMAN MJ, COBBAERT C, ET AL., QUANTIFYING ATHEROGENIC LIPOPROTEINS: CURRENT AND FUTURE CHALLENGES IN THE ERA OF PERSONALIZED MEDICINE AND VERY LOW CONCENTRATIONS OF LDL CHOLESTEROL. A CONSENSUS STATEMENT FROM EAS AND EFLM, CLIN CHEM, 64, PP. 1006-1033, (2018); SATHIYAKUMAR V, PALLAZOLA VA, PARK J, ET AL., MODERN PREVALENCE OF THE FREDRICKSON-LEVY-LEES DYSLIPIDEMIAS: FINDINGS FROM THE VERY LARGE DATABASE OF LIPIDS AND NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, ARCH MED SCI, 16, PP. 1279-1287, (2019); BOREN J, CHAPMAN MJ, KRAUSS RM, ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: PATHOPHYSIOLOGICAL, GENETIC, AND THERAPEUTIC INSIGHTS: A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR HEART J, 41, PP. 2313-2330, (2020); CARR SS, HOOPER AJ, SULLIVAN DR, BURNETT JR., NON- HDL-CHOLESTEROL AND APOLIPOPROTEIN B COMPARED WITH LDL-CHOLESTEROL IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK ASSESSMENT, PATHOLOGY, 51, PP. 148-154, (2019); ENGER SC, HJERMANN I, FOSS OP, ET AL., HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND MYOCARDIAL INFARCTION OR SUDDEN CORONARY DEATH: A PROSPECTIVE CASE-CONTROL STUDY IN MIDDLE-AGED MEN OF THE OSLO STUDY, ARTERY, 5, PP. 170-181, (1979); GORDON DJ, PROBSTFIELD JL, GARRISON RJ, ET AL., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR DISEASE. FOUR PROSPECTIVE AMERICAN STUDIES, CIRCULATION, 79, PP. 8-15, (1989); OTOCKA-KMIECIK A, MIKHAILIDIS DP, NICHOLLS SJ, DAVIDSON M, RYSZ J, BANACH M., DYSFUNCTIONAL HDL: A NOVEL IMPORTANT DIAGNOSTIC AND THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASE?, PROG LIPID RES, 51, PP. 314-324, (2012); BARYLSKI M, TOTH PP, NIKOLIC D, BANACH M, RIZZO M, MONTALTO G., EMERGING THERAPIES FOR RAISING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND AUGMENTING HDL PARTICLE FUNCTIONALITY, BEST PRACT RES CLIN ENDOCRINOL METAB, 28, PP. 453-461, (2014); STAHEL P, XIAO C, HEGELE RA, LEWIS GF., THE ATHEROGENIC DYSLIPIDEMIA COMPLEX AND NOVEL APPROACHES TO CARDIOVASCULAR DISEASE PREVENTION IN DIABETES, CAN J CARDIOL, 34, PP. 595-604, (2018); IQBAL J, AL QARNI A, HAWWARI A, ALGHANEM AF, AHMED G., METABOLIC SYNDROME, DYSLIPIDEMIA AND REGULATION OF LIPOPROTEIN METABOLISM, CURR DIABETES REV, 14, PP. 427-433, (2018); CYBULSKA B, KLOSIEWICZ-LATOSZEK L, PENSON PE, BANACH M., WHAT DO WE KNOW ABOUT THE ROLE OF LIPOPROTEIN( A) IN ATHEROGENESIS 57 YEARS AFTER ITS DISCOVERY?, PROG CARDIOVASC DIS, 63, PP. 219-227, (2020); KAMSTRUP PR., LIPOPROTEIN(A) AND ISCHEMIC HEART DISEASE - A CAUSAL ASSOCIATION? A REVIEW, ATHEROSCLEROSIS, 211, PP. 15-23, (2010); BANACH M., LIPOPROTEIN (A) - WE KNOW SO MUCH YET STILL HAVE MUCH TO LEARN, J AM HEART ASSOC, 5, (2016); ZDROJEWSKI T, JANKOWSKI P, BANDOSZ P, ET AL., A NEW VERSION OF CARDIOVASCULAR RISK ASSESSMENT SYSTEM AND RISK CHARTS CALIBRATED FOR POLISH POPULATION, KARDIOL POL, 73, PP. 958-961, (2015); BANACH M, PENSON PE., WHAT HAVE WE LEARNED ABOUT LIPIDS AND CARDIOVASCULAR RISK FROM PCSK9 INHIBITOR OUTCOME TRIALS: ODYSSEY AND FOURIER?, CARDIOVASC RES, 115, PP. E26-E31, (2019); SOLNICA B, SYGITOWICZ G, SITKIEWICZ D, ET AL., 2020 GUIDELINES OF THE POLISH SOCIETY OF LABORATORY DIAGNOSTICS (PSLD) AND THE POLISH LIPID ASSOCIATION (POLA) ON LABORATORY DIAGNOSTICS OF LIPID METABOLISM DISORDERS, ARCH MED SCI, 2020, 16, PP. 237-252; LAMBERT JE, PARKS EJ., POSTPRANDIAL METABOLISM OF MEAL TRIGLICERYDE IN HUMANS, BIOCHIM BIOPHYS ACTA, 1821, PP. 721-726, (2012); BOREN J, MATIKAINEN N, ADIELS M, TASKINEN MR., POSTPRANDIAL HIPERTRIGLICERYDEMIA AS A CORONARY RISK FACTOR, CLIN CHIM ACTA, 431, PP. 131-142, (2014); NORDESTGAARD BG, LANGSTED A, MORA S, ET AL., FASTING IS NOT ROUTINELY REQUIRED FOR A LIPID PROFILE: CLINICAL AND LABORATORY IMPLICATIONS INCLUDING FLAGGING AT DESIRABLE CONCENTRATION CUT-POINTS - A JOINT CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, CLIN CHEM, 62, PP. 930-946, (2016); MAIEREAN SM, MIKHAILIDIS DP, TOTH PP, ET AL., THE POTENTIAL ROLE OF STATINS IN PREECLAMPSIA AND DYSLIPIDEMIA DURING GESTATION: A NARRATIVE REVIEW, EXPERT OPIN INVESTIG DRUGS, 27, PP. 427-435, (2018); BUCOLO G, DAVID H., QUANTITATIVE DETERMINATION OF SERUM TRIGLYCERIDES BY THE USE OF ENZYMES, CLIN CHEM, 19, PP. 476-482, (1973); MYASOEDOVA E, CROWSON CS, MARADIT KREMERS H, ET AL., LIPID PARADOX IN RHEUMATOID ARTHRITIS: THE IMPACT OF SERUM LIPID MEASURES AND SYSTEMIC INFLAMMATION ON THE RISK OF CARDIOVASCULAR DISEASE, ANN RHEUM DIS, 70, PP. 482-487, (2011); COLANTONIO LD, BITTNER V, REYNOLDS K, ET AL., ASSOCIATION OF SERUM LIPIDS AND CORONARY HEART DISEASE IN CONTEMPORARY OBSERVATIONAL STUDIES, CIRCULATION, 133, PP. 256-264, (2016); GIBBONS GF, ISLAM K, PEASE RJ., MOBILISATION OF TRIACYLGLYCEROL STORES, BIOCHIM BIOPHYS ACTA, 1483, PP. 37-57, (2000); RAMIREZ M, AMATE L, GIL A., ABSORPTION AND DISTRIBUTION OF DIETARY FATTY ACIDS FROM DIFFERENT SOURCES, EARLY HUM DEV, 65, PP. S95-101, (2001); NORDESTGAARD BG., TRIGLYCERIDE-RICH LIPOPROTEINS AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE NEW INSIGHTS FROM EPIDEMIOLOGY, GENETICS, AND BIOLOGY, CIRC RES, 118, PP. 547-563, (2016); QUISPE R, HENDRANI AD, BARADARAN-NOVEIRY B, ET AL., CHARACTERIZATION OF LIPOPROTEIN PROFILES IN PATIENTS WITH HYPERTRIGLYCERIDEMIC FREDRICKSON-LEVY AND LEES DYSLIPIDEMIA PHENOTYPES: THE VERY LARGE DATABASE OF LIPIDS STUDIES 6 AND 7, ARCH MED SCI, 15, PP. 1195-1202, (2019); QUISPE R, MANALAC RJ, FARIDI KF, ET AL., RELATIONSHIP OF THE TRIGLYCERIDE TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (TG/HDL-C) RATIO TO THE REMAINDER OF THE LIPID PROFILE: THE VERY LARGE DATABASE OF LIPIDS-4 (VLDL-4) STUDY, ATHEROSCLEROSIS, 242, PP. 243-250, (2015); CATAPANO AL, TOKGOZOGLU L, SILVA AM, BRUCKERT E., ATHEROGENIC MARKERS IN PREDICTING CARDIOVASCULAR RISK AND TARGETING RESIDUAL CARDIOVASCULAR RISK, ATHEROSCLEROSIS, (2019); SIEDEL J, SCHMUCK R, STAEPELS J, ET AL., LONG TERM STABLE, LIQUID READY-TO-USE MONO REAGENT FOR THE ENZYMATIC ASSAY OF SERUM OR PLASMA TRIGLYCERIDES (GPO-PAPMETHOD). AACC MEETING ABSTRACT 34, CLIN CHEM, 39, (1993); ELSHOURBAGY NA, MEYERS HV, ABDEL-MEGULD SS., CHOLESTEROL: THE GOOD, THE BAD, AND THE UNGRY - THERAPEUTIC TARGET FOR THE TREATMENT OF DYSLIPIDEMIA, MED PRINC PRACT, 23, PP. 999-1111, (2014); RYNKIEWICZ A, CYBULSKA B, BANACH M, ET AL., MANAGEMENT OF FAMILIAL HETEROZYGOUS HYPERCHOLESTEROLEMIA: POSITION PAPER OF THE POLISH LIPID EXPERT FORUM, J CLIN LIPIDOL, 7, PP. 217-221, (2013); ALLAIN CC, POON LS, CHAN CS, ET AL., ENZYMATIC DETERMINATION OF TOTAL SERUM CHOLESTEROL, CLIN CHEM, 20, PP. 470-475, (1974); CMONT L, CHAPMAN MJ, KONTUSH A., BIOLOGICAL ACTIVITIES OF HDL SUBPOPULATIONS AND THEIR RELEVANCE TO CARDIOVASCULAR DISEASE, TRENDS MOL MED, 17, PP. 594-603, (2011); SORAN H, SCHOFELD JD, DURRINGTON PN., ANTIOXIDANT PROPERTIES OF HDL, FRONT PHARMACOL, 6, (2015); VAN LENTEN BJ, NAVAB M, SHIH D, FOGELMAN AM, LUSIS AJ., THE ROLE OF HIGH-DENSITY LIPOPROTEINS IN OXIDATION AND INFLAMMATION, TRENDS CARDIOVASC MED, 11, PP. 155-161, (2001); RYSZ-GORZYNSKA M, BANACH M., SUBFRACTIONS OF HIGH-DENSITY LIPOPROTEIN (HDL) AND DYSFUNCTIONAL HDL IN CHRONIC KIDNEY DISEASE PATIENTS, ARCH MED SCI, 12, PP. 844-849, (2016); GANJALI S, WATTS GF, BANACH M, REINER Z, NACHTIGAL P, SAHEBKAR A., THE YIN AND YANG OF HIGH-DENSITY LIPOPROTEIN AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: FOCUSING ON FUNCTIONALITY AND CHOLESTEROL EFFLUX TO REFRAME THE HDL HYPOTHESIS, CURR MED CHEM, 28, PP. 6066-6081, (2021); GANJALI S, MOMTAZI AA, BANACH M, KOVANEN PT, STEIN EA, SAHEBKAR A., HDL ABNORMALITIES IN FAMILIAL HYPERCHOLESTEROLEMIA: FOCUS ON BIOLOGICAL FUNCTIONS, PROG LIPID RES, 67, PP. 16-26, (2017); MOVVA R, RADER DJ., LABORATORY ASSESSMENT OF HDL HETEROGENEITY AND FUNCTION, CLIN CHEM, 54, PP. 788-800, (2008); HAFIANE A, GENEST J., HIGH DENSITY LIPOPROTEINS: MEASUREMENT TECHNIQUES AND POTENTIAL BIOMARKERS OF CARDIOVASCULAR RISK, BIOCHEM BIOPHYS ACTA, 3, PP. 175-188, (2015); RIZZO M, OTVOS J, NIKOLIC D, MONTALTO G, TOTH PP, BANACH M., SUBFRACTIONS AND SUBPOPULATIONS OF HDL: AN UPDATE, CURR MED CHEM, 21, PP. 2881-2891, (2014); RYSZ-GORZYNSKA M, GLUBA-BRZOZKA A, BANACH M., HIGHDENSITY LIPOPROTEIN AND LOW-DENSITY LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE, CURR VASC PHARMACOL, 15, PP. 144-151, (2017); EFFECTS OF EXTENDED- RELEASE NIACIN WITH LAROPIPRANT IN HIGH-RISK PATIENTS, N ENGL J MED, 371, PP. 203-212, (2014); MARTIN SS, BLAHA MJ, ELSHAZLY MB, ET AL., COMPARISON OF A NOVEL METHOD VS THE FRIEDEWALD EQUATION FORE STIMULATING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS FROM THE STANDARD LIPID PROFILE, JAMA, 310, PP. 2061-2068, (2013); QUISPE R, HENDRANI A, ELSHAZLY MB, ET AL., ACCURACY OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL ESTIMATION AT VERY LOW LEVELS, BMC MED, 15, (2017); CHAEN H, KINCHIKU S, MIYATA M, ET AL., VALIDITY OF A NOVEL METHOD FOR ESTIMATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN DIABETIC PATIENTS, J ATHEROSCLER THROMB, 23, PP. 1355-1364, (2016); MILLER WG, MYERS GL, SAKURABAYASHI I, ET AL., SEVEN DIRECT METHODS FOR MEASURING HDL AND LDL CHOLESTEROL COMPARED WITH ULTRACENTRIFUGATION REFERENCE MEASUREMENT PROCEDURES, CLIN CHEM, 56, PP. 977-986, (2010); SAMPSON M, LING C, SUN Q, ET AL., A NEW EQUATION FOR CALCULATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH NORMOLIPIDEMIA AND/OR HYPERTRIGLYCERIDEMIA, JAMA CARDIOL, 5, PP. 540-548, (2020); LI KM, WILCKEN DE, DUDMAN NP., EFFECT OF SERUM LIPOPROTEIN( A) ON ESTIMATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY THE FRIEDEWALD FORMULA, CLIN CHEM, 40, PP. 571-573, (1994); TABAS I, WILLIAMS KJ, BOREN J., SUBENDOTHELIAL LIPOPROTEIN RETENTION AS THE INITIATING PROCESS IN ATHEROSCLEROSIS: UPDATE AND THERAPEUTIC IMPLICATIONS, CIRCULATION, 116, PP. 1832-1844, (2007); BOREN J, WILLIAMS KJ., THE CENTRAL ROLE OF ARTERIAL RETENTION OF CHOLESTEROL-RICH APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS IN THE PATHOGENESIS OF ATHEROSCLEROSIS: A TRIUMPH OF SIMPLICITY, CURR OPIN LIPIDOL, 27, PP. 473-483, (2016); NATIONAL TRENDS IN TOTAL CHOLESTEROL OBSCURE HETEROGENEOUS CHANGES IN HDL ANDNON-HDLCHOLESTEROL AND TOTAL-TO-HDL CHOLESTEROL RATIO: A POOLED ANALYSIS OF 458 POPULATION-BASED STUDIES IN ASIAN AND WESTERN COUNTRIES. NCD RISK FACTOR COLLABORATION, INT J EPIDEMIOL, 49, PP. 173-192, (2020); SYGITOWICZ G, FILIPIAK KJ, SITKIEWICZ D., CZY NIE-HDL CHOLESTEROL LEPIEJ NIZ CHOLESTEROL FRAKCJI LDL ODZWIERCIEDLA RYZYKO SERCOWO-NACZYNIOWE?, FOLIA CARDIOL, 13, PP. 435-441, (2018); DOMINICZAK MH, CASLAKE MJ., APOLIPOPROTEINS: METABOLIC ROLE AND CLINICAL BIOCHEMISTRY APPLICATIONS, ANN CLIN BIOCHEM, 48, PP. 498-515, (2011); CONTOIS JH, MCCONNELL JP, SETHI AA, ET AL., APOLIPOPROTEIN B AND CARDIOVASCULAR DISEASE RISK: POSITION STATEMENT FROM THE AACC LIPOPROTEINS AND VASCULAR DISEASES DIVISION WORKING GROUP ON BEST PRACTICES, CLIN CHEM, 55, PP. 407-419, (2009); MARCOVINA SM, ALBERS JJ., LIPOPROTEIN (A) MEASUREMENTS FOR CLINICAL APPLICATION, J LIPID RES, 57, PP. 526-537, (2016); BLANCHARD V, CHEMELLO K, HOLLSTEIN T, ET AL., THE SIZE OF APOLIPOPROTEIN (A) IS AN INDEPENDENT DETERMINANT OF THE REDUCTION IN LIPOPROTEIN (A) INDUCED BY PCSK9 INHIBITORS, CARDIOVASC RES, (2021); FERRETTI G, BACCHETTI T, JOHNSTON TP, BANACH M, PIRRO M, SAHEBKAR A., LIPOPROTEIN(A): A MISSING CULPRIT IN THE MANAGEMENT OF ATHERO-THROMBOSIS?, J CELL PHYSIOL, 233, PP. 2966-2981, (2018); TOTH PP, JONES SR, MONSALVO ML, ELLIOTT-DAVEY M, LOPEZ JAG, BANACH M., EFFECT OF EVOLOCUMAB ON NONHIGH- DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, AND LIPOPROTEIN(A): A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES, J AM HEART ASSOC, 9, (2020); BANACH M., LIPOPROTEIN (A) - WE KNOW SO MUCH YET STILL HAVE MUCH TO LEARN, J AM HEART ASSOC, 5, (2016); CAO J, STEFFEN BT, GUAN W, ET AL., EVALUATION OF LIPOPROTEIN( A) ELECTROPHORETIC AND IMMUNOASSAY METHODS IN DISCRIMINATING RISK OF CALCIFIC AORTIC VALVE DISEASE AND INCIDENT CORONARY HEART DISEASE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS, CLIN CHEM, 63, PP. 1705-1713, (2017); NORDESTGAARD BG, CHAPMAN MJ, RAY K, ET AL., LIPOPROTEIN( A) AS A CARDIOVASCULAR RISK FACTOR: CURRENT STATUS, EUR HEART J, 31, PP. 2844-2853, (2010); TSIMIKAS S., A TEST IN CONTEXT: LIPOPROTEIN(A) DIAGNOSIS, PROGNOSIS, CONTROVERSIES, AND EMERGING THERAPIES, JACC, 69, PP. 692-711, (2017); MOULIN P, DUFOUR R, AVERNA M, ET AL., IDENTIFICATION AND DIAGNOSIS OF PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME (FCS): EXPERT PANEL RECOMMENDATIONS AND PROPOSAL OF AN ""FCS SCORE, ATHEROSCLEROSIS, 275, PP. 265-272, (2018); FAHED AC, NEMER GM., FAMILIAL HYPERCHOLESTEROLEMIA: THE LIPIDS OR THE GENES?, NUTR METAB, 8, (2011); MASSON W, LOBO M, SINIAWSKI D, ET AL., ROLE OF NON-STATIN LIPID-LOWERING THERAPY IN CORONARY ATHEROSCLEROSIS REGRESSION: A META-ANALYSIS AND META-REGRESSION, LIPIDS HEALTH DIS, 19, (2020); BANACH M, SERBAN C, SAHEBKAR A, ET AL., IMPACT OF STATIN THERAPY ON CORONARY PLAQUE COMPOSITION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF VIRTUAL HISTOLOGY INTRAVASCULAR ULTRASOUND STUDIES, BMC MED, 13, (2015); NICHOLLS SJ, PURI R, ANDERSON T, ET AL., EFFECT OF EVOLOCUMAB ON CORONARY PLAQUE COMPOSITION, J AM COLL CARDIOL, 72, PP. 2012-2021, (2018); BARRIOS V, ESCOBAR C, BANACH M., PRIMARY PREVENTION. THE CORNERSTONE TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE, REV ESP CARDIOL, (2021); WANG N, JORDAN FULCHER J, ABEYSURIYA N, ET AL., INTENSIVE LDL CHOLESTEROL-LOWERING TREATMENT BEYOND CURRENT RECOMMENDATIONS FOR THE PREVENTION OF MAJOR VASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS INCLUDING 327 037 PARTICIPANTS, LANCET DIABETES ENDOCRINOL, 8, PP. 36-49, (2020); FERENCE BA, GINSBERG HN, GRAHAM I, ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR HEART J, 38, PP. 2459-2472, (2017); MANNARINO MR, SAHEBKAR A, BIANCONI V, SERBAN MC, BANACH M, PIRRO M., PCSK9 AND NEUROCOGNITIVE FUNCTION: SHOULD IT BE STILL AN ISSUE AFTER FOURIER AND EBBINGHAUS RESULTS?, J CLIN LIPIDOL, 12, PP. 1123-1132, (2018); SILVA MARQUES J, ENNIS G, VENADE G, JOAO SOARES R, MONTEIRO N, GOMES A., ASSOCIATION OF STATINS WITH FUNCTIONAL OUTCOME AND 30-DAY MORTALITY IN PATIENTS WITH INTRACEREBRAL HEMORRHAGE, CUREUS, 13, (2021); BANACH M, PENSON PE, VRABLIK M, ET AL., OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A POSITION PAPER ENDORSED BY THE INTERNATIONAL LIPID EXPERT PANEL (ILEP), PHARMACOL RES, 166, (2021); BOHULA EA, BONACA MP, BRAUNWALD E, ET AL., ATHEROTHROMBOTIC RISK STRATIFICATION AND THE EFFICACY AND SAFETY OF VORAPAXAR IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE AND PREVIOUS MYOCARDIAL INFARCTION, CIRCULATION, 134, PP. 304-313, (2016); JELLINGER PS, HANDELSMAN Y, ROSENBLIT PD, ET AL., AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ENDOCR PRACT, 23, PP. 479-497, (2017); SABATINE MS, DE FERRARI GM, GIUGLIANO RP, ET AL., CLINICAL BENEFIT OF EVOLOCUMAB BY SEVERITY AND EXTENT OF CORONARY ARTERY DISEASE: ANALYSIS FROM FOURIER, CIRCULATION, 138, PP. 756-766, (2018); JUKEMA JW, SZAREK M, ZIJLSTRA LE, ET AL., ALIROCUMAB IN PATIENTS WITH POLYVASCULAR DISEASE AND RECENT ACUTE CORONARY SYNDROME: ODYSSEY OUTCOMES TRIAL, J AM COLL CARDIOL, 74, PP. 1167-1176, (2019); DYRBUS K, GASIOR M, DESPERAK P, ET AL., RISK-FACTORS ASSOCIATED WITH EXTREMELY HIGH CARDIOVASCULAR RISK OF MID- AND LONG-TERM MORTALITY FOLLOWING MYOCARDIAL INFARCTION: ANALYSIS OF THE HYPERLIPIDAEMIA THERAPY IN TERTIARY CARDIOLOGICAL CENTER (TERCET) REGISTRY, ATHEROSCLEROSIS, 333, PP. 16-23, (2021); KATSIKI N, NIKOLIC D, MONTALTO G, BANACH M, MIKHAILIDIS DP, RIZZO M., THE ROLE OF FIBRATE TREATMENT IN DYSLIPIDEMIA: AN OVERVIEW, CURR PHARM DES, 19, PP. 3124-3131, (2013); MENSINK RP, ZOCK PL, KESTER AD, KATAN MB., EFFECTS OF DIETARY FATTY ACIDS AND CARBOHYDRATES ON THE RATIO OF SERUM TOTAL TO HDL CHOLESTEROL AND ON SERUM LIPIDS AND APOLIPOPROTEINS: A META-ANALYSIS OF 60 CONTROLLED TRIALS, AM J CLIN NUTR, 77, PP. 1146-1155, (2003); RICCARDI G, VACCARO O, COSTABILE G, RIVELLESE AA., HOW WELL CAN WE CONTROL DYSLIPIDEMIAS THROUGH LIFESTYLE MODIFICATIONS?, CURR CARDIOL REP, 18, (2016); NORDMANN AJ, NORDMANN A, BRIEL M, ET AL., EFFECTS OF LOW-CARBOHYDRATE VS LOW-FAT DIETS ON WEIGHT LOSS AND CARDIOVASCULAR RISK FACTORS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCH INTERN MED, 166, PP. 285-293, (2006); SHAW K, GENNAT H, O'ROURKE P, DEL MAR C., EXERCISE FOR OVERWEIGHT OR OBESITY, COCHRANE DATABASE SYST REV, 4, (2006); ZHUBI-BAKIJA F, BAJRAKTARI G, BYTYCI I, ET AL., THE IMPACT OF TYPE OF DIETARY PROTEIN, ANIMAL VERSUS VEGETABLE, IN MODIFYING CARDIOMETABOLIC RISK FACTORS: A POSITION PAPER FROM THE INTERNATIONAL LIPID EXPERT PANEL (ILEP), CLIN NUTR, 40, PP. 255-276, (2021); BRIEN SE, RONKSLEY PE, TURNER BJ, MUKAMAL KJ, GHALI WA., EFFECT OF ALCOHOL CONSUMPTION ON BIOLOGICAL MARKERS ASSOCIATED WITH RISK OF CORONARY HEART DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF INTERVENTIONAL STUDIES, BMJ, 342, (2011); SAHEBKAR A, SERBAN MC, GLUBA-BRZOZKA A, ET AL., LIPIDMODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCEBASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); MAZIDI M, MIKHAILIDIS DP, SATTAR N, ET AL., ASSOCIATION OF TYPES OF DIETARY FATS AND ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY: A PROSPECTIVE COHORT STUDY AND META-ANALYSIS OF PROSPECTIVE STUDIES WITH 1, 164, 029 PARTICIPANTS, CLIN NUTR, 39, PP. 3677-3686, (2020); TASKINEN MR, SODERLUND S, BOGL LH, ET AL., ADVERSE EFFECTS OF FRUCTOSE ON CARDIOMETABOLIC RISK FACTORS AND HEPATIC LIPID METABOLISM IN SUBJECTS WITH ABDOMINAL OBESITY, J INTERN MED, 282, PP. 187-201, (2017); COSENTINO F, GRANT PJ, ABOYANS V, ET AL., THE TASK FORCE FOR DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD). 2019 ESC GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES DEVELOPED IN COLLABORATION WITH THE EASD, EUR HEART J, 41, PP. 255-323, (2020); GANJALI S, BANACH M, PIRRO M, FRAS Z, SAHEBKAR A., HDL AND CANCER - CAUSALITY STILL NEEDS TO BE CONFIRMED? UPDATE 2020, SEMIN CANCER BIOL, 73, PP. 169-177, (2021); GANJALI S, RICCIUTI B, PIRRO M, ET AL., HIGH-DENSITY LIPOPROTEIN COMPONENTS AND FUNCTIONALITY IN CANCER: STATEOF- THE-ART, TRENDS ENDOCRINOL METAB, 30, PP. 12-24, (2019); HUFFMAN KM, HAWK VH, HENES ST, ET AL., EXERCISE EFFECTS ON LIPIDS IN PERSONS WITH VARYING DIETARY PATTERNS-DOES DIET MATTER IF THEY EXERCISE? RESPONSES IN STUDIES OF A TARGETED RISK REDUCTION INTERVENTION THROUGH DEFINED EXERCISE, AM HEART J, 164, PP. 117-124, (2012); MAEDA K, NOGUCHI Y, FUKUI T., THE EFFECTS OF CESSATION FROM CIGARETTE SMOKING ON THE LIPID AND LIPOPROTEIN PROFILES: A META-ANALYSIS, PREV MED, 37, PP. 283-290, (2003); ALCOHOL USE AND BURDEN FOR 195 COUNTRIES AND TERRITORIES, 1990-2016: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2016, LANCET, 392, PP. 1015-1035, (2018); PENSON PE, BANACH M., NATURAL COMPOUNDS AS ANTI-ATHEROGENIC AGENTS: CLINICAL EVIDENCE FOR IMPROVED CARDIOVASCULAR OUTCOMES, ATHEROSCLEROSIS, 316, PP. 58-65, (2021); FOGACCI F, BANACH M, MIKHAILIDIS DP, ET AL., SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 143, PP. 1-16, (2019); BANACH M, KATSIKI N, LATKOVSKIS G, ET AL., POSTMARKETING NUTRIVIGILANCE SAFETY PROFILE: A LINE OF DIETARY FOOD SUPPLEMENTS CONTAINING RED YEAST RICE FOR DYSLIPIDEMIA, ARCH MED SCI, 17, PP. 856-863, (2021); CICERO AFG, COLLETTI A, BAJRAKTARI G, ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 13, PP. 965-1005, (2017); CICERO AFG, COLLETTI A, BAJRAKTARI G, ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR REV, 75, PP. 731-767, (2017); BANACH M, PATTI AM, GIGLIO RV, ET AL., THE ROLE OF NUTRACEUTICALS IN STATIN INTOLERANT PATIENTS, J AM COLL CARDIOL, 72, PP. 96-118, (2018); GYLLING H, PLAT J, TURLEY S, ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, PP. 346-360, (2014); POLI A, BARBAGALLO CM, CICERO AFG, ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOL RES, 134, PP. 51-60, (2018); MAZIDI M, KATSIKI N, SHEKOOHI N, BANACH M., MONOUNSATURATED FATTY ACID LEVELS MAY NOT AFFECT CARDIOVASCULAR EVENTS: RESULTS FROM A MENDELIAN RANDOMIZATION ANALYSIS, FRONT NUTR, 7, (2020); AVERNA M, BANACH M, BRUCKERT E, ET AL., PRACTICAL GUIDANCE FOR COMBINATION LIPID-MODIFYING THERAPY IN HIGH- AND VERY-HIGH-RISK PATIENTS: A STATEMENT FROM A EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE, ATHEROSCLEROSIS, 325, PP. 99-109, (2021); BANACH M, BRUCKERT E, DESCAMPS OS, ET AL., THE ROLE OF RED YEAST RICE (RYR) SUPPLEMENTATION IN PLASMA CHOLESTEROL CONTROL: A REVIEW AND EXPERT OPINION, ATHEROSCLER SUPPL, 39, PP. E1-E8, (2019); MORZE J, OSADNIK T, OSADNIK K, ET AL., A NETWORK META- ANALYSIS ON THE COMPARATIVE EFFICACY OF NUTRACEUTICALS ON LIPID PROFILE, CIRCULATION, 140, (2019); MOMTAZI AA, BANACH M, PIRRO M, KATSIKI N, SAHEBKAR A., REGULATION OF PCSK9 BY NUTRACEUTICALS, PHARMACOL RES, 120, PP. 157-169, (2017); STEPNIAK U, MICEK A, WASKIEWICZ A, ET AL., PREVALENCE OF GENERAL OF ABDOMINAL OBESITY AND OVERWEIGHT AMONG ADULTS IN POLAND. RESULTS OF THE WOBASZ II STUDY (2013-2014) AND COMPARISON WITH THE WOBASZ STUDY (2003-2005), POL ARCH MED WEWN, 126, PP. 662-671, (2016); HARTLEY L, MAY MD, LOVEMAN E, COLQUITT JL, REES K., DIETARY FIBRE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 2016, (2016); RIVELLESE AA, MAFFETTONE A, VESSBY B, ET AL., EFFECTS OF DIETARY SATURATED, MONOUNSATURATED AND N-3 FATTY ACIDS ON FASTING LIPOPROTEINS, LDL SIZE AND POST-PRANDIAL LIPID METABOLISM IN HEALTHY SUBJECTS, ATHEROSCLEROSIS, 167, PP. 149-158, (2003); BHATT DL, STEG PG, MILLER M, ET AL., CARDIOVASCULAR RISK REDUCTION WITH ICOSAPENT ETHYL FOR HYPERTRIGLYCERIDEMIA, N ENGL J MED, 380, PP. 11-22, (2019); MOHOLDT T, LAVIE CJ, NAUMAN J., SUSTAINED PHYSICAL ACTIVITY, NOT WEIGHT LOSS, ASSOCIATED WITH IMPROVED SURVIVAL IN CORONARY HEART DISEASE, J AM COLL CARDIOL, 71, PP. 1094-1101, (2018); TOTH PP, BANACH M., STATINS: THEN AND NOW, METHODIST DEBAKEY CARDIOVASC J, 15, PP. 23-31, (2019); SHEHAB A, ELNOUR AA, BHAGAVATHULA AS, ET AL., A MULTICENTER PROSPECTIVE HOSPITAL-BASED COHORT STUDY ON THE EFFICACY AND SAFETY OF PITAVASTATIN, CURR DIABETES REV, 17, (2021); JONES PH, DAVIDSON MH, STEIN EA, ET AL., COMPARISON OF THE EFFICACY AND SAFETY OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN ACROSS DOSES (STELLAR∗ TRIAL), AM J CARDIOL, 92, PP. 152-160, (2003); BANACH M, STULC T, DENT R, TOTH PP., STATIN NON-ADHERENCE AND RESIDUAL CARDIOVASCULAR RISK: THERE IS NEED FOR SUBSTANTIAL IMPROVEMENT, INT J CARDIOL, 225, PP. 184-196, (2016); BANACH M, RIZZO M, TOTH P, ET AL., STATIN INTOLERANCE - AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015); BANACH M, RIZZO M, OBRADOVIC M, ET AL., PCSK9 INHIBITION - A NOVEL MECHANISM TO TREAT LIPID DISORDERS?, CURR PHARM DES, 19, PP. 3869-3877, (2013); MIKHAILIDIS DP, LAWSON RW, MCCORMICK AL, ET AL., COMPARATIVE EFFICACY OF THE ADDITION OF EZETIMIBE TO STATIN VS STATIN TITRATION IN PATIENTS WITH HYPERCHOLESTEROLAEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS, CURR MED RES OPIN, 27, PP. 1191-1210, (2011); BANACH M, MIKHAILIDIS DP., STATIN INTOLERANCE: SOME PRACTICAL HINTS, CARDIOL CLIN, 36, PP. 225-231, (2018); BANACH M, PENSON PE, FRAS Z, ET AL., BRIEF RECOMMENDATIONS ON THE MANAGEMENT OF ADULT PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA DURING THE COVID-19 PANDEMIC, PHARMACOL RES, 158, (2020); BANACH M, MIKHAILIDIS DP., STATIN THERAPY AND NEW-ONSET DIABETES: AN ATTEMPT AT RECOMMENDATIONS, EXP REV ENDOCRINOL METAB, 8, PP. 213-216, (2013); EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170 000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); GARCIA-CALVO M, LISNOCK J, BULL HG., THE TARGET OF EZETIMIBE IS NIEMANN-PICK C1-LIKE 1 (NPC1L1), PROC NATL ACAD SCI USA, 102, PP. 8132-8137, (2005); KNOPP RH, GITTER H, TRUITT T, ET AL., EFFECTS OF EZETIMIBE, A NEW CHOLESTEROL ABSORPTION INHIBITOR ON PLASMA LIPIDS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, EUR HEART J, 24, PP. 729-741, (2003); SIMON JS, KARNOUB MC, DEVLIN DJ, ET AL., SEQUENCE VARIATION IN NPC1L1 AND ASSOCIATION WITH IMPROVED LDL-CHOLESTEROL LOWERING IN RESPONSE TO EZETIMIBE TREATMENT, GENOMIC, 86, PP. 648-656, (2005); DUJOVNE CA, ETTINGER MP, MCNEER JF, ET AL., EFFICACY AND SAFETY OF A POTENT NEW SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR, EZETIMIBE, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 90, PP. 1092-1097, (2002); AWAD K, MIKHAILIDIS DP, KATSIKI N, MUNTNER P, BANACH M, EFFECT OF EZETIMIBE MONOTHERAPY ON PLASMA LIPOPROTEIN(A) CONCENTRATIONS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, DRUGS, 78, PP. 453-462, (2018); SAHEBKAR A, SIMENTAL-MENDIA LE, PIRRO M, ET AL., IMPACT OF EZETIMIBE ON PLASMA LIPOPROTEIN(A) CONCENTRATIONS AS MONOTHERAPY OR IN COMBINATION WITH STATINS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, SCI REP, 8, (2018); TSIMIKAS S, GORDTS PLSM, NORA C, YEANG C, WITZTUM JL., STATIN THERAPY INCREASES LIPOPROTEIN(A) LEVELS, EUR HEART J, 41, PP. 2275-2284, (2020)","","TERMEDIA PUBLISHING HOUSE LTD.","ENGLISH","ARCH. MED. SCI.","REVIEW","ISI","2-S2.0-85117803043","ARCH MED SCI",NA,"NOTREPORTED",NA,"BANACH M, 2021, ARCH MED SCI","BANACH M, 2021, ARCH MED SCI-a"
"MUTHUSAMY M;KIM J;KIM S;KIM J;HEO J;LEE H;LEE K;SEO W;PARK S;KIM J;LEE S","MUTHUSAMY, MUTHUSAMY (56232701600); KIM, JONG HEE (57203326267); KIM, SUK HEE (57208881099); KIM, JOO YEOL (35074228200); HEO, JEONG WOOK (7102832052); LEE, HANGYEOL (58054795600); LEE, KWANG-SIK (57891629000); SEO, WOO DUCK (8921329600); PARK, SOYOUNG (57201732841); KIM, JIN A. (55720344800); LEE, SOO IN (56648564100)","CHANGES IN BENEFICIAL CGLYCOSYLFLAVONES AND POLICOSANOL CONTENT IN WHEAT AND BARLEY SPROUTS SUBJECTED TO DIFFERENTIAL LED LIGHT CONDITIONS",2020,"PLANTS","9","14",8,"10.3390/plants9111502","DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA, DIVISION OF HORTICULTURAL BIOTECHNOLOGY, HANKYUNG NATIONAL UNIVERSITY, ANSEONG, 17579, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL ENGINEERING, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RDA, WANJU, 55365, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RDA, WANJU, 55365, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RDA, WANJU, 55365, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA;DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA","THE SPECTRAL QUALITY AND INTENSITY OF LIGHT, PHOTOPERIODISM, AND OTHER ENVIRONMENTAL FACTORS HAVE PROFOUND IMPACTS ON THE METABOLIC COMPOSITION OF LIGHT-DEPENDENT HIGHER PLANTS. HENCE, WE INVESTIGATE THE EFFECTS OF FLUORESCENT LIGHT (96 ΜMOL M−2 S−1) AND WHITE (100 ΜMOL M−2 S−1), BLUE (100 ΜMOL M−2 S−1), AND RED (93 ΜMOL M−2 S−1) LIGHT-EMITTING DIODE (LED) LIGHT IRRADIATION ON THE C-GLYCOSYLFLAVONE AND POLICOSANOL CONTENTS IN YOUNG SEEDLINGS OF WHEAT AND BARLEY. ULTRA-HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (UHPLC) ANALYSES OF C-GLYCOSYLFLAVONE CONTENTS IN BARLEY REVEAL THAT THE SAPONARIN CONTENT IS SIGNIFICANTLY ENHANCED UNDER BLUE LED LIGHT IRRADIATION. UNDER SIMILAR CONDITIONS, ISOORIENTIN AND ISOSCHAFTOSIDE CONTENTS ARE IMPROVED IN WHEAT SEEDLINGS. THE CONTENTS OF THESE C-GLYCOSYLFLAVONES DIFFERED ALONG WITH THE LIGHT QUALITY AND GROWTH PERIOD. THE HIGHEST ACCUMULATION WAS OBSERVED IN SPROUTS AFTER THREE DAYS UNDER BLUE LED LIGHT IRRADIATION. GC/MS ANALYSES OF POLICOSANOL CONTENTS SHOWED THAT 1-HEXACOSANOL (C26:O–OH) IN BARLEY AND 1-OCTACOSANOL (C28:O–OH) IN WHEAT SEEDLINGS WERE REDUCED UNDER LED LIGHT IRRADIATION, COMPARED TO SEEDLINGS UNDER FLUORESCENT LIGHT CONDITIONS. NONETHELESS, THE POLICOSANOL CONTENTS GRADUALLY IMPROVED WITH THE EXTENSION OF GROWTH TIMES AND TREATMENTS, IRRESPECTIVE OF THE LIGHT QUALITY. ADDITIONALLY, A POSITIVE CORRELATION WAS OBSERVED BETWEEN THE EXPRESSION PATTERN OF BIOSYNTHESIS-RELATED GENES AND THE RESPECTIVE METABOLITE CONTENT IN BARLEY. THIS STUDY DEMONSTRATES THAT BLUE LED LIGHT IRRADIATION IS USEFUL IN MAXIMIZING THE C-GLYCOSYLFLAVONE CONTENT IN BARLEY AND WHEAT SPROUTS. © 2020 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","FATTY ACYL-COENZYME A REDUCTASE (FAR); HEXACOSANOL; ISOORIENTIN; OCTACOSANOL; SAPONARIN","","COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY, (PJ01421201); RURAL PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY DEVELOPMENT, (PJ01495701); RURAL DEVELOPMENT ADMINISTRATION, RDA","FUNDING: THIS RESEARCH WAS FUNDED BY THE RURAL DEVELOPMENT ADMINISTRATION (KOREA) THROUGH THE RURAL PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY DEVELOPMENT, GRANT NUMBER PJ01495701 AND COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY, GRANT NUMBER PJ01421201.","GIRALDO P., BENAVENTE E., MANZANO-AGUGLIARO F., GIMENEZ E., WORLDWIDE RESEARCH TRENDS ON WHEAT AND BARLEY: A BIBLIOMETRIC COMPARATIVE ANALYSIS, AGRONOMY, 9, (2019); SHEWRY P.R., HEY S.J., THE CONTRIBUTION OF WHEAT TO HUMAN DIET AND HEALTH, FOOD ENERGY SECUR, 4, PP. 178-202, (2015); BYUN A.R., CHUN H., LEE J., LEE S.W., LEE H.S., SHIM K.W., EFFECTS OF A DIETARY SUPPLEMENT WITH BARLEY SPROUT EXTRACT ON BLOOD CHOLESTEROL METABOLISM, EVID. BASED COMPLEMENT. ALTERN. MED, PP. 1-7, (2015); ZENG Y., PU X., YANG J., DU J., YANG X., LI X., LI L., ZHOU Y., YANG T., PREVENTIVE AND THERAPEUTIC ROLE OF FUNCTIONAL INGREDIENTS OF BARLEY GRASS FOR CHRONIC DISEASES IN HUMAN BEINGS, OXID. MED. CELL. LONGEV, 2018, (2018); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., KIM Y., SEO W.D., LEE S.J., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTR. RES, 43, PP. 89-99, (2017); LEE Y.H., KIM S.H., LEE S., KIM K.M., JUNG J.C., SON T.G., KI S.H., SEO W.D., KWAK J.H., HONG J.T., ET AL., ANTIOXIDANT EFFECT OF BARLEY SPROUT EXTRACT VIA ENHANCEMENT OF NUCLEAR FACTOR-ERYTHROID 2 RELATED FACTOR 2 ACTIVITY AND GLUTATHIONE SYNTHESIS, NUTRIENTS, 9, (2017); KIM Y.J., HWANG S.H., JIA Y., SEO W.D., LEE S.J., BARLEY SPROUT EXTRACTS REDUCE HEPATIC LIPID ACCUMULATION IN ETHANOL-FED MICE BY ACTIVATING HEPATIC AMP-ACTIVATED PROTEIN KINASE, FOOD RES. INT, 101, PP. 209-217, (2017); SEO K.H., PARK M.J., RA J.E., HAN S.I., NAM M.H., KIM J.H., LEE J.H., SEO W.D., SAPONARIN FROM BARLEY SPROUTS INHIBITS NF-ΚB AND MAPK ON LPS-INDUCED RAW 264.7 CELLS, FOOD FUNCT, 5, PP. 3005-3013, (2014); PARK M.J., SEO W.D., KANG Y.H., THE ANTIOXIDANT PROPERTIES OF FOUR KOREAN BARLEY CULTIVARS AT DIFFERENT HARVEST TIMES AND PROFILING OF MAJOR METABOLITES, J. AGRIC. SCI, 7, (2015); SEO W., HAE J., JIA Y., WU C., LEE S., SAPONARIN ACTIVATES AMPK IN A CALCIUM-DEPENDENT MANNER AND SUPPRESSES GLUCONEOGENESIS AND INCREASES GLUCOSE UPTAKE VIA PHOSPHORYLATION OF CRTC2 AND HDAC5, BIOORG. MED. CHEM. LETT, 25, PP. 5237-5242, (2015); LEE H., RA S.W.J., WOO K.L., SEO D., HWAN J., SAPONARIN CONTENT AND BIOSYNTHESIS-RELATED GENE EXPRESSION IN YOUNG BARLEY (HORDEUM VULGARE L.) SEEDLINGS, J. PLANT BIOTECHNOL, 2818, PP. 247-254, (2019); YE T., SU J., HUANG C., YU D., DAI S., HUANG X., CHEN B., ZHOU M., ISOORIENTIN INDUCES APOPTOSIS, DECREASES INVASIVENESS, AND DOWNREGULATES VEGF SECRETION BY ACTIVATING AMPK SIGNALING IN PANCREATIC CANCER CELLS, ONCOTARGETS TARGETS, 9, PP. 7481-7492, (2016); XIAO J., CAPANOGLU E., JASSBI A.R., MIRON A., ADVANCE ON THE FLAVONOID C-GLYCOSIDES AND HEALTH BENEFITS, CRIT. REV. FOOD SCI. NUTR, 56, PP. S29-S45, (2016); NAM T.G., KIM D.-O., EOM S.H., EFFECTS OF LIGHT SOURCES ON MAJOR FLAVONOIDS AND ANTIOXIDANT ACTIVITY IN COMMON BUCKWHEAT SPROUTS, FOOD SCI. BIOTECHNOL, 27, PP. 169-176, (2018); SYTAR O., BOSKO P., ZIVCAK M., BRESTIC M., SMETANSKA I., BIOACTIVE PHYTOCHEMICALS AND ANTIOXIDANT PROPERTIES OF THE GRAINS AND SPROUTS OF COLORED WHEAT GENOTYPES, MOLECULES, 23, (2018); BENINCASA P., FALCINELLI B., LUTTS S., STAGNARI F., GALIENI A., SPROUTED GRAINS: A COMPREHENSIVE REVIEW, NUTRIENTS, 11, (2019); RA J., WOO S., LEE K., JA M., YOUNG H., MI H., CHUNG I., HYUN D., HWAN J., DUCK W., POLICOSANOL PROFILES AND ADENOSINE 5<SUP>′</SUP>-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME, FOOD CHEM, 317, (2020); LEMMENS E., MORONI A.V., PAGAND J., HEIRBAUT P., RITALA A., KARLEN Y., KIM-ANNE L., VAN DEN BROECK H.C., BROUNS F.J.P.H., DE BRIER N., ET AL., IMPACT OF CEREAL SEED SPROUTING ON ITS NUTRITIONAL AND TECHNOLOGICAL PROPERTIES: A CRITICAL REVIEW, COMPR. REV. FOOD SCI. FOOD SAF, 18, PP. 305-328, (2019); RICO D., PENAS E., DEL CARMEN GARCIA M., MARTINEZ-VILLALUENGA C., RAI D.K., BIRSAN R.I., FRIAS J., MARTIN-DIANA A.B., SPROUTED BARLEY FLOUR AS A NUTRITIOUS AND FUNCTIONAL INGREDIENT, FOODS, 9, (2020); ABORUS N.E., CANADANOVI J., SAPONJAC V.T., POWDERED BARLEY SPROUTS: COMPOSITION, FUNCTIONALITY AND POLYPHENOL DIGESTIBILITY, INT. J. FOOD SCI. TECHNOL, 52, PP. 231-238, (2017); WU X., CAI K., ZHANG G., ZENG F., METABOLITE PROFILING OF BARLEY GRAINS SUBJECTED TO WATER STRESS: TO EXPLAIN THE GENOTYPIC DIFFERENCE IN DROUGHT-INDUCED IMPACTS ON MALTING QUALITY, FRONT. PLANT. SCI, 8, (2017); WANG Y., ZENG X., XU Q., MEI X., YUAN H., JIABU D., SANG Z., NYIMA T., METABOLITE PROFILING IN TWO CONTRASTING TIBETAN HULLESS BARLEY CULTIVARS REVEALED THE CORE SALT-RESPONSIVE METABOLOME AND KEY SALT-TOLERANCE BIOMARKERS, AOB PLANTS, 11, (2019); KANG C.H., YOON E.K., MUTHUSAMY M., KIM J.A., JEONG M.J., LEE S.I., BLUE LED LIGHT IRRADIATION ENHANCES L-ASCORBIC ACID CONTENT WHILE REDUCING REACTIVE OXYGEN SPECIES ACCUMULATION IN CHINESE CABBAGE SEEDLINGS, SCI. HORTIC, 261, (2020); CHENG C., LIU Y., FANG W., TAO J., YANG Z., YIN Y., ITRAQ-BASED PROTEOMIC AND PHYSIOLOGICAL ANALYSES OF MUSTARD SPROUTS IN RESPONSE TO HEAT STRESS, RSC ADV, 10, PP. 6052-6062, (2020); MUTHUSAMY M., HWANG J.E., KIM S.H., KIM J.A., JEONG M.J., PARK H.C., LEE S.I., ELEVATED CARBON DIOXIDE SIGNIFICANTLY IMPROVES ASCORBIC ACID CONTENT, ANTIOXIDATIVE PROPERTIES AND RESTRICTED BIOMASS PRODUCTION IN CRUCIFEROUS VEGETABLE SEEDLINGS, PLANT. BIOTECHNOL. REP, 13, PP. 293-304, (2019); TUAN P.A., THWE A.A., KIM Y.B., KIM J.K., KIM S.J., LEE S., CHUNG S.O., PARK S.U., EFFECTS OF WHITE, BLUE, AND RED LIGHT-EMITTING DIODES ON CAROTENOID BIOSYNTHETIC GENE EXPRESSION LEVELS AND CAROTENOID ACCUMULATION IN SPROUTS OF TARTARY BUCKWHEAT (FAGOPYRUM TATARICUM GAERTN.), J. AGRIC. FOOD CHEM, 61, PP. 12356-12361, (2013); MENG T., NAKAMURA E., IRINO N., JOSHI K.R., DEVKOTA H.P., YAHARA S., KONDO R., EFFECTS OF IRRADIATION WITH LIGHT OF DIFFERENT PHOTON DENSITIES ON THE GROWTH OF YOUNG GREEN BARLEY PLANTS, AGRIC. SCI, PP. 208-216, (2015); HASAN M.M., BASHIR T., BAE H., USE OF UTRASONICATION TCHNOLOGY FOR THE ICREASED PODUCTION OF PANT SCONDARY MTABOLITES, MOLECULES, 22, (2017); KOWALSKA I., JEDREJEK D., JONCZYK K., STOCHMAL A., UPLC-PDA-ESI-MS ANALYSIS AND TLC-DPPH ACTIVITY OF WHEAT VARIETIES, ACTA CHROMATOGR, 31, PP. 151-156, (2019); KOPSELL D.A., SAMS C.E., INCREASES IN SHOOT TISSUE PIGMENTS, GLUCOSINOLATES, AND MINERAL ELEMENTS IN SPROUTING BROCCOLI AFTER EXPOSURE TO SHORT-DURATION BLUE LIGHT FROM LIGHT EMITTING DIODES, J. AM. SOC. HORTIC. SCI, 138, PP. 31-37, (2013); GHIMIRE B.K., YU C.Y., CHUNG I.M., ASSESSMENT OF THE PHENOLIC PROFILE, ANTIMICROBIAL ACTIVITY AND OXIDATIVE STABILITY OF TRANSGENIC PERILLA FRUTESCENS L.OVEREXPRESSING TOCOPHEROL METHYLTRANSFERASE (Γ-TMT) GENE, PLANT. PHYSIOL. BIOCHEM, 118, PP. 77-87, (2017); BRAUCH D., PORZEL A., SCHUMANN E., PILLEN K., MOCK H.P., CHANGES IN ISOVITEXIN-O-GLYCOSYLATION DURING THE DEVELOPMENT OF YOUNG BARLEY PLANTS, PHYTOCHEMISTRY, 148, PP. 11-20, (2018); MARINOVA K., KLEINSCHMIDT K., WEISSENBOCK G., KLEIN M., FLAVONOID BIOSYNTHESIS IN BARLEY PRIMARY LEAVES REQUIRES THE PRESENCE OF THE VACUOLE AND CONTROLS THE ACTIVITY OF VACUOLAR FLAVONOID TRANSPORT, PLANT. PHYSIOL, 144, PP. 432-444, (2007); KAMIYAMA M., SHIBAMOTO T., FLAVONOIDS WITH POTENT ANTIOXIDANT ACTIVITY FOUND IN YOUNG GREEN BARLEY LEAVES, J. AGRIC. FOOD CHEM, 60, PP. 6260-6267, (2012); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S., KANG H.W., NAM M.H., LEE S., LEE J.H., ET AL., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5<SUP>′</SUP>-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J. AGRIC. FOOD CHEM, 61, PP. 1117-1123, (2013); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., MOTOMURA K., SHIMURA T., OKAJIMA Y., MIZUNOE Y., ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI. REP, 9, (2019); RICHARDSON A., FRANKE R., KERSTIENS G., JARVIS M., SCHREIBER L., FRICKE W., CUTICULAR WAX DEPOSITION IN GROWING BARLEY (HORDEUM VULGARE) LEAVES COMMENCES IN RELATION TO THE POINT OF EMERGENCE OF EPIDERMAL CELLS FROM THE SHEATHS OF OLDER LEAVES, PLANTA, 222, PP. 472-483, (2005); GIL K.E., PARK C.M., THERMAL ADAPTATION AND PLASTICITY OF THE PLANT CIRCADIAN CLOCK, NEW PHYTOL, 221, PP. 1215-1229, (2019); WANG Y., WANG M., SUN Y., WANG Y., LI T., CHAI G., JIANG W., SHAN L., LI C., XIAO E., ET AL., FAR5, A FATTY ACYL-COENZYME A REDUCTASE, IS INVOLVED IN PRIMARY ALCOHOL BIOSYNTHESIS OF THE LEAF BLADE CUTICULAR WAX IN WHEAT (TRITICUM AESTIVUM L.), J. EXP. BOT, 66, PP. 1165-1178, (2015); WANG Y., SUN Y., YOU Q., LUO W., WANG C., ZHAO S., CHAI G., LI T., SHI X., LI C., ET AL., THREE FATTY ACYL-COENZYME A REDUCTASES, BDFAR1, BDFAR2 AND BDFAR3, ARE INVOLVED IN CUTICULAR WAX PRIMARY ALCOHOL BIOSYNTHESIS IN BRACHYPODIUM DISTACHYON, PLANT. CELL PHYSIOL, 59, PP. 527-543, (2018); WANG M., WU H., XU J., LI C., WANG Y., WANG Z., FIVE FATTY ACYL-COENZYME A REDUCTASES ARE INVOLVED IN THE BIOSYNTHESIS OF PRIMARY ALCOHOLS IN AEGILOPS TAUSCHII LEAVES, FRONT. PLANT SCI, 8, (2017); GRAINGENES","S.I. LEE; DEPARTMENT OF AGRICULTURAL BIOTECHNOLOGY, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS), RDA, JEONJU, 54874, SOUTH KOREA; EMAIL: SILEE@KOREA.KR","MDPI AG","ENGLISH","PLANTS","ARTICLE","ISI","2-S2.0-85095596326","PLANTS","NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);ANSEONG;NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);NATIONAL INSTITUTE OF CROP SCIENCE (NICS);NATIONAL INSTITUTE OF CROP SCIENCE (NICS);NATIONAL INSTITUTE OF CROP SCIENCE (NICS);NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS)","NOTREPORTED;NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES (NAS);NOTREPORTED",NA,"MUTHUSAMY M, 2020, PLANTS","MUTHUSAMY M, 2020, PLANTS"
"SIRIPATTANAKULKAJORN C;SOMBUTSUWAN P;NAKORNSADET A;CHUMSANTEA S;LILITCHAN S;KRISNANGKURA K;ARYUSUK K","SIRIPATTANAKULKAJORN, CHATCHAI (58753310100); SOMBUTSUWAN, PIRAPORN (57204622598); NAKORNSADET, AKKARADECH (57204624748); CHUMSANTEA, SALISA (37060531200); LILITCHAN, SUPATHRA (20436041500); KRISNANGKURA, KANIT (6701651738); ARYUSUK, KORNKANOK (7801495708)","POLICOSANOL AND OTHER BIOACTIVE COMPOUNDS IN DIFFERENT THAI RICE VARIETIES",2024,"JOURNAL OF FOOD COMPOSITION AND ANALYSIS","126","",0,"10.1016/j.jfca.2023.105891","DIVISION OF BIOCHEMICAL TECHNOLOGY, SCHOOL OF BIORESOURCES AND TECHNOLOGY, KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI, BANGKHUNTIEN, BANGKOK, 10150, THAILAND;PILOT PLANT DEVELOPMENT AND TRAINING INSTITUTE (PDTI), KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT), BANGKOK, 10150, THAILAND;PILOT PLANT DEVELOPMENT AND TRAINING INSTITUTE (PDTI), KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT), BANGKOK, 10150, THAILAND;DIVISION OF BIOCHEMICAL TECHNOLOGY, SCHOOL OF BIORESOURCES AND TECHNOLOGY, KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI, BANGKHUNTIEN, BANGKOK, 10150, THAILAND;DEPARTMENT OF NUTRITION, FACULTY OF PUBLIC HEALTH, MAHIDOL UNIVERSITY, RACHATHEWI, BANGKOK, 10400, THAILAND;DIVISION OF BIOCHEMICAL TECHNOLOGY, SCHOOL OF BIORESOURCES AND TECHNOLOGY, KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI, BANGKHUNTIEN, BANGKOK, 10150, THAILAND;DIVISION OF BIOCHEMICAL TECHNOLOGY, SCHOOL OF BIORESOURCES AND TECHNOLOGY, KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI, BANGKHUNTIEN, BANGKOK, 10150, THAILAND","THIS STUDY EXAMINES THE TOTAL LIPID, POLICOSANOL (PC), TOCOLS, AND Γ-ORYZANOL CONTENTS, AND FATTY ACID COMPOSITION IN RICE BRAN (RB) OBTAINED FROM 4 MIN-POLISHED BROWN RICE OF 13 THAI RICE VARIETIES, WITH A NEW EMPHASIS ON THE PC CONTENT AND COMPOSITION. THE TOTAL PC CONTENT IN THE OIL EXTRACTED FROM RB RANGED FROM 2776 TO 7274 ΜG/G. SUNGYOD RICE HAD THE HIGHEST TOTAL PC CONTENT AT 7274 ΜG/G, FOLLOWED CLOSELY BY NIAW DUM MOR AT 6407 ΜG/G, AND RD10 AT 6308 ΜG/G. THE BRAN OF THAI RICE VARIETIES CONTAINED TRIACONTANOL, DOTRIACONTANOL, AND TETRATRIACONTANOL AS THEIR MAIN COMPONENTS. SUNGYOD RICE HAD SIGNIFICANTLY MORE OCTACOSANOL. CONSIDERING THE PC COMPOSITION, BLACK-PIGMENTED GLUTINOUS RICE VARIETIES, LEUM PUA AND NIAW DUM MOR, HAD HIGHER HEXATRIACONTANOL AND OCTATRIACONTANOL LEVELS. THE TOTAL LIPIDS IN RICE BRAN (RB) RANGED FROM 14.9 TO 22.1 G/100 G. THE KEY FATTY ACIDS FOUND IN THE THAI RICE VARIETIES INCLUDED OLEIC ACID (37.8–43.0%), LINOLEIC ACID (30.3–36.4%), AND PALMITIC ACID (14.2–21.6%). IN TERMS OF OTHER BIOACTIVE COMPOUNDS, LEUM PUA HAD THE HIGHEST TOCOLS LEVEL AT 635 ΜG/G RB, WHILE PATHUM THANI 1 SHOWED AN IMPRESSIVE Γ-ORYZANOL LEVEL OF 4011 ΜG/G RB. THESE FINDINGS SUGGEST THAT CERTAIN THAI RICE VARIETIES HAVE THE POTENTIAL TO BE RICH SOURCES OF LIPIDS, PC, AND BIOACTIVE COMPOUNDS. © 2023 ELSEVIER INC.","FATTY ACID PROFILE; LONG CHAIN FATTY ALCOHOL; POLICOSANOL; RICE BRAN OIL; RICE VARIETIES; TOCOLS; TOTAL LIPID; Γ-ORYZANOL","","THAILAND RESEARCH FUND, TRF, (PHD/0204/2561); NATIONAL RESEARCH COUNCIL OF THAILAND, NRCT; THAILAND SCIENCE RESEARCH AND INNOVATION, TSRI","THE WORK WAS SUPPORTED BY THAILAND RESEARCH FUND THROUGH THE ROYAL GOLDEN JUBILEE PH.D. PROGRAM UNDER GRANT PHD/0204/2561 , THAILAND SCIENCE RESEARCH AND INNOVATION (TSRI) AND THE NATIONAL RESEARCH COUNCIL OF THAILAND (NRCT) . BASIC RESEARCH FUND: FISCAL YEAR 2023 UNDER PROJECT NUMBER FRB660073/0164 . ","ANWAR F., ANWER T., MAHMOOD Z., METHODICAL CHARACTERIZATION OF RICE (ORYZA SATIVA) BRAN OIL FROM PAKISTAN, GRASAS Y. ACEITES, 56, 2, (2005); AOAC, OFFICIAL METHODS OF ANALYSIS, (2020); ARYUSUK K., SOMBATSUWAN P., LILITCHAN S., KRISNANGKURA K., (2010); BASTIA R., PANDIT E., SANGHAMITRA P., BARIK S.R., NAYAK D.K., SAHOO A., MOHARANA A., MEHER J., DASH P.K., RAJ R., JENA B.K., PRADHAN K.C., LENKA D., BASAK N., LENKA S., PRADHAN S.K., ASSOCIATION MAPPING FOR QUANTITATIVE TRAIT LOCI CONTROLLING SUPEROXIDE DISMUTASE, FLAVONOIDS, ANTHOCYANINS, CAROTENOIDS, & GAMMA;-ORYZANOL AND ANTIOXIDANT ACTIVITY IN RICE, AGRONOMY, 12, 12, (2022); BHATTACHARYA S., CHEMICAL AND NUTRITIONAL PROPERTIES OF BROWN RICE, BROWN RICE, PP. 93-110, (2017); BISWAS S.K., KIM D.-E., KEUM Y.-S., SAINI R.K., METABOLITE PROFILING AND ANTIOXIDANT ACTIVITIES OF WHITE, RED, AND BLACK RICE (ORYZA SATIVA L.) GRAINS, J. FOOD MEAS. CHARACT., 12, 4, PP. 2484-2492, (2018); BOONSIT P., PONGPIACHAN P., JULSRIGIVAL S., KARLADEE D., GAMMA ORYZANOL CONTENT IN GLUTINOUS PURPLE RICE LANDRACE VARIETIES, CMUJ. NAT. SCI., 9, PP. 151-158, (2010); BRITZ S.J., PRASAD P.V.V., MOREAU R.A., ALLEN L.H., KREMER D.F., BOOTE K.J., INFLUENCE OF GROWTH TEMPERATURE ON THE AMOUNTS OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL IN BROWN RICE, J. AGRIC. FOOD CHEM., 55, 18, PP. 7559-7565, (2007); CHAUDHARY N., KHURANA P., VITAMIN E BIOSYNTHESIS GENES IN RICE: MOLECULAR CHARACTERIZATION, EXPRESSION PROFILING AND COMPARATIVE PHYLOGENETIC ANALYSIS, PLANT SCI., 177, 5, PP. 479-491, (2009); CHEN D., CHEN H., ZHANG L., SHI X., CHEN X., TOCOPHEROL-DEFICIENT RICE PLANTS DISPLAY INCREASED SENSITIVITY TO PHOTOOXIDATIVE STRESS, PLANTA, 239, 6, PP. 1351-1362, (2014); CHEW S.C., NYAM K.L., CHAPTER 6 - REFINING OF EDIBLE OILS, LIPIDS AND EDIBLE OILS, PP. 213-241, (2020); CHINVONGAMORN C., SANSENYA S., THANI K., KOR K., THE Γ-ORYZANOL CONTENT OF THAI RICE CULTIVARS AND THE EFFECTS OF GAMMA IRRADIATION ON THE Γ-ORYZANOL CONTENT OF GERMINATED THAI MARKET RICE, ORIENT. J. CHEM., 36, 5, PP. 812-818, (2020); CHUMSANTEA S., JIRUTTISAKUL A., NAKORNSADET A., SOMBUTSUWAN P., ARYUSUK K., SIMULTANEOUS DETERMINATION OF VITAMIN E AND G-ORYZANOL IN RICE BRAN OIL VIA HPSEC-PDA WITHOUT SAMPLE PRETREATMENT, J. OLEO SCI., 72, 7, PP. 655-665, (2023); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR. J. LIPID SCI. TECHNOL., 106, 3, PP. 147-151, (2004); ENDO Y., NAKAGAWA K., DIFFERENCES IN THE COMPOSITIONS OF VITAMIN E TOCOCHROMANOL (TOCOPHEROL AND TOCOTRIENOL) IN RICE BRAN OILS PRODUCED IN JAPAN AND OTHER COUNTRIES, J. OLEO SCI., 70, 4, PP. 503-507, (2021); GOFFMAN F.D., PINSON S., BERGMAN C., GENETIC DIVERSITY FOR LIPID CONTENT AND FATTY ACID PROFILE IN RICE BRAN, J. AM. OIL CHEM. SOC., 80, 5, PP. 485-490, (2003); HARAKOTR B., PROMPOH K., BOONYUEN S., SURIHARN B., LERTRAT K., VARIABILITY IN NUTRACEUTICAL LIPID CONTENT OF SELECTED RICE (ORYZA SATIVA L. SPP. INDICA) GERMPLASMS, AGRONOMY, 9, 12, (2019); HASHEMPOUR-BALTORK F., TORBATI M., AZADMARD-DAMIRCHI S., SAVAGE G.P., VEGETABLE OIL BLENDING: A REVIEW OF PHYSICOCHEMICAL, NUTRITIONAL AND HEALTH EFFECTS, TRENDS FOOD SCI. TECHNOL., 57, 11, PP. 52-58, (2016); HE M., QIN C.-X., WANG X., DING N.-Z., PLANT UNSATURATED FATTY ACIDS: BIOSYNTHESIS AND REGULATION, FRONT. PLANT SCI., 11, PP. 1-13, (2020); HUANG S.-H., NG L.-T., QUANTIFICATION OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL CONTENTS AND THEIR DISTRIBUTION IN SOME COMMERCIAL RICE VARIETIES IN TAIWAN, J. AGRIC. FOOD CHEM., 59, 20, PP. 11150-11159, (2011); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, 2, PP. 312-318, (2006); ISHAKA A., IMAM M.U., ISMAIL M., NANOEMULSIFICATION OF RICE BRAN WAX POLICOSANOL ENHANCES ITS CARDIO-PROTECTIVE EFFECTS VIA MODULATION OF HEPATIC PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN HYPERLIPIDEMIC RATS, J. OLEO SCI., 69, 10, PP. 1287-1295, (2020); ITO V.C., LACERDA L.G., BLACK RICE (ORYZA SATIVA L.): A REVIEW OF ITS HISTORICAL ASPECTS, CHEMICAL COMPOSITION, NUTRITIONAL AND FUNCTIONAL PROPERTIES, AND APPLICATIONS AND PROCESSING TECHNOLOGIES, FOOD CHEM., 301, (2019); KAEWKOOL P., KRISNANGKURA K., TRANSESTERIFICATION/ACETYLATION OF LONG CHAIN ALCOHOLS WITH ALKYL ACETATE, CHEM. PHYS. LIPIDS, 163, 7, PP. 685-688, (2010); KIM H.W., KIM J.B., SHANMUGAVELAN P., KIM S.N., CHO Y.S., KIM H.R., LEE J.T., JEON W.T., LEE D.J., EVALUATION OF Γ-ORYZANOL CONTENT AND COMPOSITION FROM THE GRAINS OF PIGMENTED RICE-GERMPLASMS BY LC-DAD-ESI/MS, BMC RES. NOTES, 6, (2013); LAGEIRO M.M., CASTANHO A., PEREIRA C., CALHELHA R.C., FERREIRA I.C.F.R., BRITES C., ASSESSMENT OF GAMMA ORYZANOL VARIABILITY, AN ATTRACTIVE RICE BRAN BIOACTIVE COMPOUND, EMIR. J. FOOD AGRIC., 32, 1, PP. 38-46, (2020); LERMA-GARCIA M.J., HERRERO-MARTINEZ J.M., SIMO-ALFONSO E.F., MENDONCA C.R.B., RAMIS-RAMOS G., COMPOSITION, INDUSTRIAL PROCESSING AND APPLICATIONS OF RICE BRAN Γ-ORYZANOL, FOOD CHEM., 115, 2, PP. 389-404, (2009); LEWANDOWSKA M., KEYL A., FEUSSNER I., WAX BIOSYNTHESIS IN RESPONSE TO DANGER: ITS REGULATION UPON ABIOTIC AND BIOTIC STRESS, N. PHYTOL., 227, 3, PP. 698-713, (2020); LILITCHAN S., TANGPRAWAT C., ARYUSUK K., KRISNANGKURA S., CHOKMOH S., KRISNANGKURA K., PARTIAL EXTRACTION METHOD FOR THE RAPID ANALYSIS OF TOTAL LIPIDS AND Γ-ORYZANOL CONTENTS IN RICE BRAN, FOOD CHEM., 106, 2, PP. 752-759, (2008); LIU Y., YU J., WANG X., EXTRACTION OF POLICOSANOLS FROM HYDROLYSED RICE BRAN WAX BY HIGH‐INTENSITY ULTRASOUND, INT. J. FOOD SCI. TECHNOL., 43, 5, PP. 763-769, (2008); LUO W., HUAN Q., XU Y., QIAN W., CHONG K., ZHANG J., INTEGRATED GLOBAL ANALYSIS REVEALS A VITAMIN E-VITAMIN K1 SUB-NETWORK, DOWNSTREAM OF COLD1, UNDERLYING RICE CHILLING TOLERANCE DIVERGENCE, CELL REP., 36, 3, (2021); MA X., WANG P., ZHOU S., SUN Y., LIU N., LI X., HOU Y., DE NOVO TRANSCRIPTOME SEQUENCING AND COMPREHENSIVE ANALYSIS OF THE DROUGHT-RESPONSIVE GENES IN THE DESERT PLANT CYNANCHUM KOMAROVII, BMC GENOM., 16, (2015); MAKRIDES M., NEUMANN M.A., JEFFREY B., LIEN E.L., GIBSON R.A., A RANDOMIZED TRIAL OF DIFFERENT RATIOS OF LINOLEIC TO Α-LINOLENIC ACID IN THE DIET OF TERM INFANTS: EFFECTS ON VISUAL FUNCTION AND GROWTH123, AM. J. CLIN. NUTR., 71, 1, PP. 120-129, (2000); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, 3, PP. 255-262, (2000); NAEEM M., KHAN M.M., MOINUDDIN A.S., TRIACONTANOL: A POTENT PLANT GROWTH REGULATOR IN AGRICULTURE, J. PLANT INTERACT., 7, 2, PP. 129-142, (2012); PAL Y.P., PRATAP A.P., RICE BRAN OIL: A VERSATILE SOURCE FOR EDIBLE AND INDUSTRIAL APPLICATIONS, J. OLEO SCI., 66, 6, PP. 551-556, (2017); PANDOLSOOK S., KUPONGSAK S., POTENTIAL USE OF POLICOSANOL EXTRACT FROM THAI BLEACHED RICE BRAN WAX AS AN ORGANOGELATOR, J. FOOD MEAS. CHARACT., 14, 4, PP. 2078-2086, (2020); POJJANAPORNPUN S., ARYUSUK K., LILITCHAN S., KRISNANGKURA K., GIBBS ENERGY ADDITIVITY APPROACHES TO QSRR IN GENERATING GAS CHROMATOGRAPHIC RETENTION TIME FOR IDENTIFICATION OF FATTY ACID METHYL ESTER, ANAL. BIOANAL. CHEM., 409, 11, PP. 2777-2789, (2017); POKKANTA P., SOOKWONG P., TANANG M., SETCHAIYAN S., BOONTAKHAM P., MAHATHEERANONT S., SIMULTANEOUS DETERMINATION OF TOCOLS, Γ-ORYZANOLS, PHYTOSTEROLS, SQUALENE, CHOLECALCIFEROL AND PHYLLOQUINONE IN RICE BRAN AND VEGETABLE OIL SAMPLES, FOOD CHEM., 271, 1, PP. 630-638, (2019); PUENGTHAM J., ARYUSUK K., KITTIRATANAPIBOON K., JEYASHOKE N., KRISNANGKURA K., EXTRACTION PURIFICATION AND CHARACTERIZATION OF POLICOSANOL FROM THAI RICE BRAN WAX, KMUTT RES. DEV. J., 31, 2, PP. 305-318, (2008); PUNIA S., KUMAR M., SANDHU K.S., WHITESIDE W.S., RICE-BRAN OIL: AN EMERGING SOURCE OF FUNCTIONAL OIL, J. FOOD PROCESS. PRESERV., 45, 4, (2021); RAVINDRANATH S.V., UPPUGUNDLA N., LAY J.O., CLAUSEN E.C., WILKINS M., INGRAHAM R.G., WEST C., WU Y., CARRIER D.J., POLICOSANOL, Α-TOCOPHEROL, AND MOISTURE CONTENT AS A FUNCTION OF TIMING OF HARVEST OF SWITCHGRASS (PANICUM VIRGATUM L.), J. AGRIC. FOOD CHEM., 57, 9, PP. 3500-3505, (2009); SAOUSSEM H., FERCHICHI A., BACHALI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS., 17, 1, PP. 82-88, (2018); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., KANG H.W., NAM M.H., LEE S.J., LEE J.H., PARK K.H., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J. AGRIC. FOOD CHEM., 61, 5, PP. 1117-1123, (2013); SETYANINGSIH W., HIDAYAH N., SAPUTRO I.E., LOVILLO M.P., PP. 1-2, (2015); SHAMMUGASAMY B., RAMAKRISHNAN Y., GHAZALI H.M., MUHAMMAD K., TOCOPHEROL AND TOCOTRIENOL CONTENTS OF DIFFERENT VARIETIES OF RICE IN MALAYSIA, J. SCI. FOOD AGRIC., 95, 4, PP. 672-678, (2015); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); SINGANUSONG R., GARBA U., CHAPTER 5 - MICRONUTRIENTS IN RICE BRAN OIL, RICE BRAN AND RICE BRAN OIL, PP. 125-158, (2019); SOOKWONG P., NAKAGAWA K., MURATA K., KOJIMA Y., MIYAZAWA T., QUANTITATION OF TOCOTRIENOL AND TOCOPHEROL IN VARIOUS RICE BRANS, J. AGRIC. FOOD CHEM., 55, 2, PP. 461-466, (2007); SUDTASARN G., HOMSOMBAT W., CHOTECHUEN S., CHAMARERK V., QUANTIFICATION OF TOCOPHEROLS, TOCOTRIENOLS AND Γ-ORYZANOL CONTENTS OF LOCAL RICE VARIETIES IN NORTHEASTERN THAILAND, J. NUTR. SCI. VITAM., 65, PP. S125-S128, (2019); THIND S.K., EFFECTS OF A LONG CHAIN ALIPHATIC ALCOHOL MIXTURE ON GROWTH AND SOLUTE ACCUMULATION IN WATER STRESSED WHEAT SEEDLINGS UNDER LABORATORY CONDITIONS, PLANT GROWTH REGUL., 10, 3, PP. 223-234, (1991); TRUONG H.T., LUU P.D., IMAMURA K., MATSUBARA T., TAKAHASHI H., TAKENAKA N., BOI L.V., MAEDA Y., BINARY SOLVENT EXTRACTION OF TOCOLS, Γ-ORYZANOL, AND FERULIC ACID FROM RICE BRAN USING ALKALINE TREATMENT COMBINED WITH ULTRASONICATION, J. AGRIC. FOOD CHEM., 65, 24, PP. 4897-4904, (2017); VALI S.R., JU Y.-H., KAIMAL T.N.B., CHERN Y.-T., A PROCESS FOR THE PREPARATION OF FOOD-GRADE RICE BRAN WAX AND THE DETERMINATION OF ITS COMPOSITION, J. AM. OIL CHEM. SOC., 82, 1, PP. 57-64, (2005); WANG M.-F., LIAN H.-Z., MAO L., ZHOU J.-P., GONG H.-J., QIAN B.-Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM., 55, 14, PP. 5552-5558, (2007); WIRIKULCHAROEN S., SRITULARAK B., WERAWATGANONE P., GAMMA-ORYZANOL CONTENT AND ANTIOXIDANT ACTIVITY OF RICE BRAN OIL USING VARIOUS EXTRACTION METHODS, THAI J. PHARM. SCI. (TJPS), 41, 1, PP. 149-152, (2017); WISETKOMOLMAT J., ARJIN C., SATSOOK A., SEEL-AUDOM M., RUKSIRIWANICH W., PROM-U-THAI C., SRINGARM K., COMPARATIVE ANALYSIS OF NUTRITIONAL COMPONENTS AND PHYTOCHEMICAL ATTRIBUTES OF SELECTED THAI RICE BRAN, FRONT. NUTR., 9, (2022); WONGWAIWECH D., WEERAWATANAKORN M., BOONNOUN P., SUBCRITICAL DIMETHYL ETHER EXTRACTION AS A SIMPLE METHOD TO EXTRACT NUTRACEUTICALS FROM BYPRODUCTS FROM RICE BRAN OIL MANUFACTURE, SCI. REP., 10, 1, (2020); XU D., HAO J., WANG Z., LIANG D., WANG J., MA Y., ZHANG M., PHYSICOCHEMICAL PROPERTIES, FATTY ACID COMPOSITIONS, BIOACTIVE COMPOUNDS, ANTIOXIDANT ACTIVITY AND THERMAL BEHAVIOR OF RICE BRAN OIL OBTAINED WITH AQUEOUS ENZYMATIC EXTRACTION, LWT, 149, (2021)","K. ARYUSUK; KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT), BANGKOK, 10150, THAILAND; EMAIL: KORNKANOK.ARY@KMUTT.AC.TH","ACADEMIC PRESS INC.","ENGLISH","J. FOOD COMPOS. ANAL.","ARTICLE","ISI","2-S2.0-85179110915","J FOOD COMPOS ANAL","KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI;KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT);KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT);KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI;MAHIDOL UNIVERSITY;KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI;KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI","NOTREPORTED;KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT);NOTREPORTED",NA,"SIRIPATTANAKULKAJORN C, 2024, J FOOD COMPOS ANAL","SIRIPATTANAKULKAJORN C, 2024, J FOOD COMPOS ANAL"
"MAIDEEN N;RAJKAPOOR B;MUTHUSAMY S;RAMANATHAN S;THANGADURAI S;SUGHIR A","MAIDEEN, NAINA MOHAMED PAKKIR (55312250500); RAJKAPOOR, BALASUBRAMANIAN (6603505707); MUTHUSAMY, SUDHA (57192378892); RAMANATHAN, SAMBATHKUMAR (57190250448); THANGADURAI, SUBRAMANIAM ANANDA (57249078100); SUGHIR, ABDUSSALAM A. (16176794000)","A REVIEW ON PHARMACOKINETIC AND PHARMACODYNAMIC DRUG INTERACTIONS OF ADRENERGIC ΒBLOCKERS WITH CLINICALLY RELEVANT DRUGSAN OVERVIEW",2021,"CURRENT DRUG METABOLISM","22","10",7,"10.2174/1389200222666210614112529","DUBAI HEALTH AUTHORITY, P.O. BOX: 4545, DUBAI, UNITED ARAB EMIRATES;DEPARTMENT OF PHARMACOLOGY, J.K.K. NATTRAJA COLLEGE OF PHARMACY, KOMARAPALAYAM, 638 183, INDIA;DEPARTMENT OF PHARMACOLOGY, J.K.K. NATTRAJA COLLEGE OF PHARMACY, KOMARAPALAYAM, 638 183, INDIA;DEPARTMENT OF PHARMACOLOGY, J.K.K. NATTRAJA COLLEGE OF PHARMACY, KOMARAPALAYAM, 638 183, INDIA;DEPARTMENT OF PHARMACOLOGY, J.K.K. NATTRAJA COLLEGE OF PHARMACY, KOMARAPALAYAM, 638 183, INDIA;DEPARTMENT OF PHARMACEUTICS, FACULTY OF PHARMACY, ELMERGIB UNIVERSITY, ALKHOMS, LIBYAN ARAB JAMAHIRIYA","ADRENERGIC Β-BLOCKERS ARE USED TO TREAT MANY CONDITIONS, INCLUDING HYPERTENSION, CARDIAC ARRHYTHMIAS, HEART FAILURE, ANGINA PECTORIS, MIGRAINE, AND TREMORS. THE MAJORITY OF THE Β-BLOCKERS INCLUDING PROPRANOLOL, ME-TOPROLOL, ACEBUTOLOL, ALPRENOLOL, BETAXOLOL, CARVEDILOL, NEBIVOLOL AND OXPRENOLOL ARE METABOLISED MAJORLY BY CYP2D6, AND BISOPROLOL IS PRIMARILY METABOLISED BY CYP3A4 ENZYMES. THE DRUGS INHIBITING OR INDUCING THEM MAY ALTER THE PHARMACOKINETICS OF THOSE Β-BLOCKERS. THE PLASMA CONCENTRATIONS OF PROPRANOLOL MIGHT BE ELEVATED BY THE CONCOMITANT USE OF DRUGS, SUCH AS SSRIS (FLUOXETINE, PAROXETINE), SNRIS (DULOXETINE) AND CIMETIDINE, WHILE THE PLASMA CONCENTRATIONS OF METOPROLOL INCREASED BY THE CONCURRENT USE OF SSRIS (FLUOXETINE, PAROXETINE), AMIODAR-ONE, CELECOXIB, CIMETIDINE, TERBINAFINE, AND DIPHENHYDRAMINE. Β-BLOCKERS CAN ALSO INTERACT PHARMACODYNAMICALLY WITH DRUGS, INCLUDING FLUOROQUINOLONES, ANTIDIABETIC AGENTS AND NSAIDS. IN ADDITION, Β-BLOCKERS MAY INTERACT WITH HERBS, SUCH AS CURCUMIN, GINKGO BILOBA, SCHISANDRA CHINENSIS, GREEN TEA, GUGGUL, HAWTHORN, ST. JOHN’S WORT AND YOHIMBINE. THIS ARTICLE FOCUSES ON CLINICALLY RELEVANT DRUG INTERACTIONS OF Β-BLOCKERS WITH COMMONLY PRESCRIBED MEDICATIONS. IN ADDITION TO PHARMACOKINETICS AND PHARMACODYNAMICS OF THE DRUG INTERACTIONS, RECOMMENDATIONS FOR CLINICAL PRACTICE ARE HIGHLIGHTED. THE PRESCRIBERS AND THE PHARMACISTS ARE NEEDED TO BE AWARE OF THE DRUGS INTERACTING WITH Β-BLOCKERS TO PREVENT POSSIBLE ADVERSE DRUG INTERACTIONS. © 2021 BENTHAM SCIENCE PUBLISHERS.","ADRENERGIC Β-BLOCKERS; CYP2D6 ENZYME; CYP3A4 ENZYME; DRUG INTERACTIONS; PHARMACODYNAMIC INTERACTIONS; PHARMACOKINETIC INTERACTIONS","ADRENERGIC BETA-ANTAGONISTS; DRUG INTERACTIONS; HUMANS; MEDICATION THERAPY MANAGEMENT; PHARMACEUTICAL PREPARATIONS; ACEBUTOLOL; ADENOSINE RECEPTOR; ALPRENOLOL; AMIODARONE; AMLODIPINE; AMPICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; APIXABAN; ARIPIPRAZOLE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CEFEPIME; CELECOXIB; CELIPROLOL; CIMETIDINE; CIPROFLOXACIN; CLOZAPINE; COBICISTAT; CURCUMIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DABIGATRAN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; DRUG METABOLIZING ENZYME; DULOXETINE; ENALAPRIL; EPINEPHRINE; FLUCONAZOLE; FLUOXETINE; FLURBIPROFEN; FUSIDIC ACID; GALANTAMINE; GATIFLOXACIN; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERFORIN; HYPERICIN; INDOMETACIN; LANSOPRAZOLE; LEVOFLOXACIN; LOSARTAN; MACROLIDE; METFORMIN; METOPROLOL; MIRTAZAPINE; MOXIFLOXACIN; NADOLOL; NEBIVOLOL; NICARDIPINE; NISOLDIPINE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OXPRENOLOL; PAROXETINE; PERPHENAZINE; PHENYTOIN; POLICOSANOL; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RIFAMPICIN; RISPERIDONE; SALBUTAMOL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTALOL; TELITHROMYCIN; TERBINAFINE; TERPENOID; TIMOLOL; VERAPAMIL; VORICONAZOLE; WARFARIN; YOHIMBINE; ZIPRASIDONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG; ALLERGIC RHINITIS; ALZHEIMER DISEASE; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANKYLOSING SPONDYLITIS; ANTIDEPRESSANT ACTIVITY; ANTIDIABETIC ACTIVITY; ANXIETY; ASTERACEAE; ASTHMA; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHRONIC URTICARIA; CLINICAL PRACTICE; COGNITION; COGNITIVE DEFECT; COMMIPHORA; COMMUNITY ACQUIRED PNEUMONIA; CRATAEGUS; DEPRESSION; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; FLUID RETENTION; GINKGO BILOBA; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART RATE; HERB; HIPPOCAMPUS; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INTERMITTENT CLAUDICATION; LIPOLYSIS; MALE; MAXIMUM CONCENTRATION; MAXIMUM PLASMA CONCENTRATION; MEDICINAL PLANT; MIGRAINE; MOUSE; MUSCLE HYPOTONIA; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; NONHUMAN; ONYCHOMYCOSIS; ORAL CLEARANCE; OSTEOARTHRITIS; PASSIVE SMOKING; PHARMACIST; PHARMACODYNAMICS; PHARMACOGENOMICS; PHARMACOKINETIC PARAMETERS; PHARMACOKINETICS; QT PROLONGATION; QTC INTERVAL; RAT; REVIEW; SCHISANDRA; SCHISANDRA CHINENSIS; SINUS BRADYCARDIA; TEA; THROMBOCYTE AGGREGATION; TREMOR; UPREGULATION; URTICARIA; CLASSIFICATION; DRUG INTERACTION; MEDICATION THERAPY MANAGEMENT; METABOLISM","","","CIZMARIKOVA R., HABALA L., VALENTOVA J., MARKULIAK M., SURVEY OF PHARMACOLOGICAL ACTIVITY AND PHARMACOKINETICS OF SELECTED Β-ADRENERGIC BLOCKERS IN REGARD TO THEIR STEREOCHEMISTRY, APPL. SCI, 9, (2019); FRISHMAN W.H., CARDIOLOGY PATIENT PAGE. BETA-ADRENERGIC BLOCKERS, CIRCULATION, 107, 18, PP. E117-E119, (2003); WHELTON P.K., CAREY R.M., ARONOW W.S., CASEY D.E., COLLINS K.J., DENNISON HIMMELFARB C., DEPALMA S.M., GIDDING S., JAMERSON K.A., JONES D.W., MACLAUGHLIN E.J., MUNTNER P., OVBIAGELE B., SMITH S.C., SPENCER C.C., STAFFORD R.S., TALER S.J., THOMAS R.J., WILLIAMS K.A., WILLIAMSON J.D., WRIGHT J.T., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ ASPC/NMA/PCNA GUIDELINE FOR THE PREVENTION, DETECTION, EVALUA-TION, AND MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, J. AM. COLL. CARDIOL, 71, 19, PP. E127-E248, (2018); FISKER F.Y., GRIMM D., WEHLAND M., THIRD-GENERATION BETA-ADRENOCEPTOR ANTAGONISTS IN THE TREATMENT OF HYPERTENSION AND HEART FAILURE, BASIC CLIN. PHARMACOL. TOXICOL, 117, 1, PP. 5-14, (2015); MILLS K.T., BUNDY J.D., KELLY T.N., REED J.E., KEARNEY P.M., REYNOLDS K., CHEN J., HE J., GLOBAL DISPARITIES OF HYPERTENSION PREVALENCE AND CONTROL: A SYSTEMATIC ANALYSIS OF POPULATION-BASED STUDIES FROM 90 COUNTRIES, CIRCULATION, 134, 6, PP. 441-450, (2016); MOHAMED N., MAIDEEN P., THIAZOLIDINEDIONES AND THEIR DRUG INTERACTIONS INVOLVING CYP ENZYMES, AM. J. PHYSIOL. BIOCHEM. PHARMA-COL, 8, 2, PP. 47-54, (2018); MAIDEEN N.M., PHARMACODYNAMIC INTERACTIONS OF THIAZIDE DIURETICS, INT. J. MED. DEV. CTRIES, 4, 6, PP. 1007-1010, (2020); ZISAKI A., MISKOVIC L., HATZIMANIKATIS V., ANTIHYPERTENSIVE DRUGS METABOLISM: AN UPDATE TO PHARMACOKINETIC PROFILES AND COMPUTATIONAL APPROACHES, CURR. PHARM. DES, 21, 6, PP. 806-822, (2015); FITZGERALD K.T., BRONSTEIN A.C., SELECTIVE SEROTONIN REUPTAKE IN-HIBITOR EXPOSURE, TOP. COMPANION ANIM. MED, 28, 1, PP. 13-17, (2013); SANSONE R.A., SANSONE L.A., SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS: A PHARMACOLOGICAL COMPARISON, INNOV. CLIN. NEUROSCI, 11, 3-4, PP. 37-42, (2014); YEKEHTAZ H., FAROKHNIA M., AKHONDZADEH S., CARDIOVASCULAR CONSIDERATIONS IN ANTIDEPRESSANT THERAPY: AN EVIDENCE-BASED RE-VIEW, J. TEHRAN HEART CENT, 8, 4, PP. 169-176, (2013); LOW Y., SETIA S., LIMA G., DRUG-DRUG INTERACTIONS INVOLVING ANTI-DEPRESSANTS: FOCUS ON DESVENLAFAXINE, NEUROPSYCHIATR. DIS. TREAT, 14, PP. 567-580, (2018); KURDYAK P.A., MANNO M., GOMES T., MAMDANI M.M., JUURLINK D.N., ANTIDEPRESSANTS, METOPROLOL AND THE RISK OF BRADYCARDIA, THER. ADV. PSYCHOPHARMACOL, 2, 2, PP. 43-49, (2012); BAHAR M.A., HAK E., BOS J.H.J., BORGSTEEDE S.D., WILFFERT B., THE BURDEN AND MANAGEMENT OF CYTOCHROME P450 2D6 (CYP2D6)-MEDIATED DRUG-DRUG INTERACTION (DDI): CO-MEDICATION OF METOPROLOL AND PAROXETINE OR FLUOXETINE IN THE ELDERLY, PHARMACOEPIDEMIOL. DRUG SAF, 26, 7, PP. 752-765, (2017); HOEFT D., AN OVERVIEW OF CLINICALLY SIGNIFICANT DRUG INTERACTIONS BETWEEN MEDICATIONS USED TO TREAT PSYCHIATRIC AND MEDICAL CONDI-TIONS, MENTAL HEALTH CLINICIAN, 4, 3, PP. 118-130, (2014); SIWEK M., WORON J., GOROSTOWICZ A., WORDLICZEK J., ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIPSYCHOTICS AND MEDICATIONS USED IN THE TREATMENT OF CARDIOVASCULAR DISORDERS, PHARMACOL. REP, 72, 2, PP. 350-359, (2020); KRISHNAN-NATESAN S., TERBINAFINE: A PHARMACOLOGICAL AND CLINICAL REVIEW, EXPERT OPIN. PHARMACOTHER, 10, 16, PP. 2723-2733, (2009); PARK Y.M., PROLONGED DRUG-DRUG INTERACTION BETWEEN TERBINAFINE AND PERPHENAZINE, PSYCHIATRY INVESTIG, 9, 4, PP. 422-424, (2012); BEBAWI E., JOUNI S.S., TESSIER A.A., FRENETTE A.J., BRINDAMOUR D., DORE M., A METOPROLOL-TERBINAFINE COMBINATION INDUCED BRADY-CARDIA, EUR. J. DRUG METAB. PHARMACOKINET, 40, 3, PP. 295-299, (2015); HANSTEN P.D., HORN J.R., THE TOP 100 DRUG INTERACTIONS: A GUIDE TO PATIENT MANAGEMENT, 2006 EDITION, (2006); SHAPIRO L., KNOWLES S., SHEAR N., DRUG INTERACTIONS OF CLINICAL SIGNIFICANCE FOR THE DERMATOLOGIST: RECOGNITION AND AVOIDANCE, AM. J. CLIN. DERMATOL, 4, 9, PP. 623-639, (2003); ABDEL-RAHMAN S.M., GOTSCHALL R.R., KAUFFMAN R.E., LEEDER J.S., KEARNS G.L., INVESTIGATION OF TERBINAFINE AS A CYP2D6 INHIBI-TOR IN VIVO, CLIN. PHARMACOL. THER, 65, 5, PP. 465-472, (1999); ORAP (PIMOZIDE) PACKAGE INSERT, (2005); PEYRIERE H., EIDEN C., MACIA J.C., REYNES J., ANTIHYPERTENSIVE DRUGS IN PATIENTS TREATED WITH ANTIRETROVIRALS, ANN. PHARMACOTHER, 46, 5, PP. 703-709, (2012); VAN DER POL R., LANGENDAM M., BENNINGA M., VAN WIJK M., TABBERS M., EFFICACY AND SAFETY OF HISTAMINE-2 RECEPTOR ANTAGO-NISTS, JAMA PEDIATR, 168, 10, PP. 947-954, (2014); MADEIRA M., LEVINE M., CHANG T.K., MIRFAZAELIAN A., BELLWARD G.D., THE EFFECT OF CIMETIDINE ON DEXTROMETHORPHAN O-DEMETHYLASE ACTIVITY OF HUMAN LIVER MICROSOMES AND RECOMBINANT CYP2D6, DRUG METAB. DISPOS, 32, 4, PP. 460-467, (2004); KIRCH W., SPAHN H., KOHLER H., OHNHAUS E.E., MUTSCHLER E., INTERACTION OF METOPROLOL, PROPRANOLOL AND ATENOLOL WITH CONCURRENT ADMINISTRATION OF CIMETIDINE, KLIN. WOCHENSCHR, 60, 22, PP. 1401-1407, (1982); MUTSCHLER E., SPAHN H., KIRCH W., THE INTERACTION BETWEEN H2-RECEPTOR ANTAGONISTS AND BETA-ADRENOCEPTOR BLOCKERS, BR. J. CLIN. PHARMACOL, 17, PP. 51S-57S, (1984); BACIEWICZ A.M., BACIEWICZ F.A., EFFECT OF CIMETIDINE AND RANITIDINE ON CARDIOVASCULAR DRUGS, AM. HEART J, 118, 1, PP. 144-154, (1989); KAROL M.D., LOCKE C.S., CAVANAUGH J.H., LACK OF INTERACTION BETWEEN LANSOPRAZOLE AND PROPRANOLOL, A PHARMACOKINETIC AND SAFETY ASSESSMENT, J. CLIN. PHARMACOL, 40, 3, PP. 301-308, (2000); BARTRA J., VALERO A.L., DEL CUVILLO A., DAVILA I., JAUREGUI I., MONTORO J., MULLOL J., SASTRE J., INTERACTIONS OF THE H1 ANTIHISTA-MINES, J. INVESTIG. ALLERGOL. CLIN. IMMUNOL, 16, PP. 29-36, (2006); CHURCH M.K., CHURCH D.S., PHARMACOLOGY OF ANTIHISTAMINES, IN-DIAN J. DERMATOL, 58, 3, PP. 219-224, (2013); LESSARD E., YESSINE M.A., HAMELIN B.A., GAUVIN C., LABBE L., O'HARA G., LEBLANC J., TURGEON J., DIPHENHYDRAMINE ALTERS THE DISPOSITION OF VENLAFAXINE THROUGH INHIBITION OF CYP2D6 ACTIVITY IN HUMANS, J. CLIN. PSYCHOPHARMACOL, 21, 2, PP. 175-184, (2001); HAMELIN B.A., BOUAYAD A., METHOT J., JOBIN J., DESGAGNES P., POIRIER P., ALLAIRE J., DUMESNIL J., TURGEON J., SIGNIFICANT INTERACTION BETWEEN THE NONPRESCRIPTION ANTIHISTAMINE DIPHENHYDRAMINE AND THE CYP2D6 SUBSTRATE METOPROLOL IN HEALTHY MEN WITH HIGH OR LOW CYP2D6 ACTIVITY, CLIN. PHARMACOL. THER, 67, 5, PP. 466-477, (2000); HUSAIN Z., HUSSAIN K., NAIR R., STEINMAN R., DIPHENHYDRAMINE INDUCED QT PROLONGATION AND TORSADE DE POINTES: AN UNCOMMON EFFECT OF A COMMON DRUG, CARDIOL. J, 17, 5, PP. 509-511, (2010); HAMMAN M.A., BRUCE M.A., HAEHNER-DANIELS B.D., HALL S.D., THE EFFECT OF RIFAMPIN ADMINISTRATION ON THE DISPOSITION OF FEXOFENADINE, CLIN. PHARMACOL. THER, 69, 3, PP. 114-121, (2001); CRAIG-MCFEELY P.M., ACHARYA N.V., SHAKIR S.A., EVALUATION OF THE SAFETY OF FEXOFENADINE FROM EXPERIENCE GAINED IN GENERAL PRACTICE USE IN ENGLAND IN 1997, EUR. J. CLIN. PHARMACOL, 57, 4, PP. 313-320, (2001); PRATT C.M., MASON J., RUSSELL T., REYNOLDS R., AHLBRANDT R., CARDIOVASCULAR SAFETY OF FEXOFENADINE HCL, AM. J. CARDIOL, 83, 10, PP. 1451-1454, (1999); MCLEAN A.J., TONKIN A., MCCARTHY P., HARRISON P., DOSE-DEPENDENCE OF ATENOLOL-AMPICILLIN INTERACTION, BR. J. CLIN. PHARMA-COL, 18, 6, PP. 969-971, (1984); GIELEN W., CLEOPHAS T.J., AGRAWAL R., NEBIVOLOL: A REVIEW OF ITS CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS, INT. J. CLIN. PHARMA-COL. THER, 44, 8, PP. 344-357, (2006); FONGEMIE J., FELIX-GETZIK E., A REVIEW OF NEBIVOLOL PHARMACOLOGY AND CLINICAL EVIDENCE, DRUGS, 75, 12, PP. 1349-1371, (2015); VENKATESWARLU B., JAYAPRAKASH D., RAVINDERNATH A., NARSAIAH N., RAVINDRA M.R., EFFECT OF CEFIXIME ON PHARMACOKINETICS OF NEBIVO-LOL IN HYPERTENSIVE PATIENTS, INT. J. PHARM. SCI. RES, 4, 11, PP. 4362-4365, (2013); DEMOLIS J.L., STRABACH S., VACHERON F., FUNCK-BRENTANO C., ASSESSMENT OF THE EFFECT OF A SINGLE ORAL DOSE OF TELITHROMYCIN ON SOTALOL-INDUCED QT INTERVAL PROLONGATION IN HEALTHY WOMEN, BR. J. CLIN. PHARMACOL, 60, 2, PP. 120-127, (2005); TOX LIVER, CLINICAL AND RESEARCH INFORMATION ON DRUG INDUCED LIVER INJURY, (2012); TRUJILLO T.C., NOLAN P.E., ANTIARRHYTHMIC AGENTS: DRUG INTERACTIONS OF CLINICAL SIGNIFICANCE, DRUG SAF, 23, 6, PP. 509-532, (2000); PAKKIR MAIDEEN N.M., MANAVALAN G., BALASUBRAMANIAN K., DRUG INTERACTIONS OF MEGLITINIDE ANTIDIABETICS INVOLVING CYP ENZYMES AND OATP1B1 TRANSPORTER, THER. ADV. ENDOCRINOL. METAB, 9, 8, PP. 259-268, (2018); HERMAN R.J., NAKAMURA K., WILKINSON G.R., WOOD A.J., INDUCTION OF PROPRANOLOL METABOLISM BY RIFAMPICIN, BR. J. CLIN. PHARMA-COL, 16, 5, PP. 565-569, (1983); WESTPHAL K., WEINBRENNER A., ZSCHIESCHE M., FRANKE G., KNOKE M., OERTEL R., FRITZ P., VON RICHTER O., WARZOK R., HACHENBERG T., KAUFFMANN H.M., SCHRENK D., TERHAAG B., KROEMER H.K., SIEGMUND W., INDUCTION OF P-GLYCOPROTEIN BY RIFAMPIN INCREASES INTESTINAL SECRETION OF TALINOLOL IN HUMAN BEINGS: A NEW TYPE OF DRUG/DRUG INTERACTION, CLIN. PHARMACOL. THER, 68, 4, PP. 345-355, (2000); KIRCH W., MILFERSTADT S., HALABI A., ROCHER I., EFTHYMIOPOULOS C., JUNG L., INTERACTION OF TERTATOLOL WITH RIFAMPICIN AND RANITIDINE PHARMACOKINETICS AND ANTIHYPERTENSIVE ACTIVITY, CARDIOVASC. DRUGS THER, 4, 2, PP. 487-491, (1990); (2021); HAOUALA A., WIDMER N., DUCHOSAL M.A., MONTEMURRO M., BU-CLIN T., DECOSTERD L.A., DRUG INTERACTIONS WITH THE TYROSINE KINASE INHIBITORS IMATINIB, DASATINIB, AND NILOTINIB, BLOOD, 117, 8, PP. E75-E87, (2011); HIRSH J., DALEN J., ANDERSON D.R., POLLER L., BUSSEY H., ANSELL J., DEYKIN D., ORAL ANTICOAGULANTS: MECHANISM OF ACTION, CLINICAL EF-FECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE, CHEST, 119, 1, PP. 8S-21S, (2001); BAX N.D.S., LENNARD M.S., TUCKER G.T., WOODS H.F., PORTER N.R., MALIA R.G., PRESTON F.E., THE EFFECT OF Β-ADRENOCEPTOR ANTAGONISTS ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF WAR-FARIN AFTER A SINGLE DOSE, BR. J. CLIN. PHARMACOL, 17, 5, PP. 553-557, (1984); SPAHN H., KIRCH W., MUTSCHLER E., OHNHAUS E.E., KITTERINGHAM N.R., LOGERING H.J., PAAR D., PHARMACOKINETIC AND PHARMACODY-NAMIC INTERACTIONS BETWEEN PHENPROCOUMON AND ATENOLOL OR ME-TOPROLOL, BR. J. CLIN. PHARMACOL, 17, PP. 97S-102S, (1984); CONNOLLY S.J., EIKELBOOM J., JOYNER C., DIENER H.C., HART R., GOLITSYN S., FLAKER G., AVEZUM A., HOHNLOSER S.H., DIAZ R., TALAJIC M., ZHU J., PAIS P., BUDAJ A., PARKHOMENKO A., JANSKY P., COMMERFORD P., TAN R.S., SIM K.H., LEWIS B.S., VAN MIEGHEM W., LIP G.Y., KIM J.H., LANAS-ZANETTI F., GONZALEZ-HERMOSILLO A., DANS A.L., MUNAWAR M., O'DONNELL M., LAW-RENCE J., LEWIS G., AFZAL R., YUSUF S., AVERROES STEERING COMMITTEE AND INVESTIGATORS. APIXABAN IN PATIENTS WITH ATRIAL FIBRIL-LATION, N. ENGL. J. MED, 364, 9, PP. 806-817, (2011); COMPENDIUM OF PHARMACEUTICALS AND SPECIALTIES, 2018 EDITION, (2018); STEFFEL J., VERHAMME P., POTPARA T.S., ALBALADEJO P., ANTZ M., DESTEGHE L., HAEUSLER K.G., OLDGREN J., REINECKE H., ROLDAN-SCHILLING V., ROWELL N., SINNAEVE P., COLLINS R., CAMM A.J., HEIDBUCHEL H., ESC SCIENTIFIC DOCUMENT GROUP. THE 2018 EURO-PEAN HEART RHYTHM ASSOCIATION PRACTICAL GUIDE ON THE USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIB-RILLATION, EUR. HEART J, 39, 16, PP. 1330-1393, (2018); PAKKIR M.N., PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS OF SULFONYLUREA ANTIDIABETICS, EUR. J. MED, 6, PP. 83-96, (2018); GROSSMAN E., MESSERLI F.H., GOLDBOURT U., HIGH BLOOD PRESSURE AND DIABETES MELLITUS: ARE ALL ANTIHYPERTENSIVE DRUGS CREATED EQUAL?, ARCH. INTERN. MED, 160, 16, PP. 2447-2452, (2000); BRANCH R.A., SHAND D.G., NIES A.S., INCREASE IN HEPATIC BLOOD FLOW AND D-PROPRANOLOL CLEARANCE BY GLUCAGON IN THE MONKEY, J. PHARMACOL. EXP. THER, 187, 3, PP. 581-587, (1973); FRISHMAN W.H., SONNENBLICK EH, BETA-ADRENERGIC BLOCKING DRUGS, THE HEART, (1994); EPSTEIN A.E., OLSHANSKY B., NACCARELLI G.V., KENNEDY J.I., MURPHY E.J., GOLDSCHLAGER N., PRACTICAL MANAGEMENT GUIDE FOR CLI-NICIANS WHO TREAT PATIENTS WITH AMIODARONE, AM. J. MED, 129, 5, PP. 468-475, (2016); OHYAMA K., NAKAJIMA M., SUZUKI M., SHIMADA N., YAMAZAKI H., YOKOI T., INHIBITORY EFFECTS OF AMIODARONE AND ITS N-DEETHYLATED METABOLITE ON HUMAN CYTOCHROME P450 ACTIVITIES: PREDICTION OF IN VIVO DRUG INTERACTIONS, BR. J. CLIN. PHARMACOL, 49, 3, PP. 244-253, (2000); WERNER D., WUTTKE H., FROMM M.F., SCHAEFER S., ESCHENHAGEN T., BRUNE K., DANIEL W.G., WERNER U., EFFECT OF AMIODARONE ON THE PLASMA LEVELS OF METOPROLOL, AM. J. CARDIOL, 94, 10, PP. 1319-1321, (2004); FUKUMOTO K., KOBAYASHI T., TACHIBANA K., KATO R., TANAKA K., KOMAMURA K., KAMAKURA S., KITAKAZE M., UENO K., EFFECT OF AMIODARONE ON THE SERUM CONCENTRATION/DOSE RATIO OF METOPROLOL IN PATIENTS WITH CARDIAC ARRHYTHMIA, DRUG METAB. PHARMACOKINET, 21, 6, PP. 501-505, (2006); BACHMAKOV I., WERNER U., ENDRESS B., AUGE D., FROMM M.F., CHARACTERIZATION OF BETA-ADRENOCEPTOR ANTAGONISTS AS SUBSTRATES AND INHIBITORS OF THE DRUG TRANSPORTER P-GLYCOPROTEIN, FUNDAM. CLIN. PHARMACOL, 20, 3, PP. 273-282, (2006); HII J.T.Y., DUFF H.J., BURGESS E.D., CLINICAL PHARMACOKINETICS OF PROPAFENONE, CLIN. PHARMACOKINET, 21, 1, PP. 1-10, (1991); MAIDEEN N.M., DRUG INTERACTIONS OF NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS INVOLVING CYP3A ENZYMES AND P-GP TRANSPORTER PROTEIN, BIOINTERFACE RES. APPL. CHEM, 10, 4, PP. 6026-6032, (2020); PAKKIR M.N., DRUG INTERACTIONS OF DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS (CCBS) INVOLVING CYP3A4 ENZYMES, EUR. J. MED, 7, 2, PP. 106-113, (2019); KHAN G., CONTEMPORARY CARDIOLOGY: CARDIAC DRUG THERAPY, SEV-ENTH EDITION, (2007); FDA APPROVED DRUG PRODUCTS: ZOMIG/ZOMIG-ZMT (ZOL-MITRIPTAN) ORAL TABLETS AND NASAL SPRAY, (2018); WILD M.J., MCKILLOP D., BUTTERS C.J., DETERMINATION OF THE HUMAN CYTOCHROME P450 ISOFORMS INVOLVED IN THE METABOLISM OF ZOL-MITRIPTAN, XENOBIOTICA, 29, 8, PP. 847-857, (1999); REBOREDO M., CHANG H.C.Y., BARBERO R., RODRIGUEZ-ORTIGOSA C.M., PEREZ-VIZCAINO F., MORAN A., GARCIA M., BANALES J.M., CARRENO N., ALEGRE F., HERRERO I., QUIROGA J., PRIETO J., SANGRO B., ZOLMITRIPTAN: A NOVEL PORTAL HYPOTENSIVE AGENT WHICH SYNERGIZES WITH PROPRANOLOL IN LOWERING PORTAL PRESSURE, PLOS ONE, 8, 1, (2013); PECK R.W., SEABER E.J., DIXON R., GILLOTIN C.G., WEATHERLEY B.C., LAYTON G., POSNER J., THE INTERACTION BETWEEN PROPRANOLOL AND THE NOVEL ANTIMIGRAINE AGENT ZOLMITRIPTAN (311C90), BR. J. CLIN. PHARMACOL, 44, 6, PP. 595-599, (1997); ZOLMITRIPTAN: USES, INTERACTIONS, MECHANISM OF ACTION | DRUGBANK ONLINE, (2021); GOLDBERG M.R., SCIBERRAS D., DE SMET M., LOWRY R., TOMASKO L., LEE Y., OLAH T.V., ZHAO J., VYAS K.P., HALPIN R., KARI P.H., JAMES I., INFLUENCE OF BETA-ADRENOCEPTOR ANTAGONISTS ON THE PHARMA-COKINETICS OF RIZATRIPTAN, A 5-HT1B/1D AGONIST: DIFFERENTIAL EFFECTS OF PROPRANOLOL, NADOLOL AND METOPROLOL, BR. J. CLIN. PHARMACOL, 52, 1, PP. 69-76, (2001); MACFARLANE L.L., ORAK D.J., SIMPSON W.M., NSAIDS, ANTIHYPER-TENSIVE AGENTS AND LOSS OF BLOOD PRESSURE CONTROL, AM. FAM. PHYSI-CIAN, 51, 4, PP. 849-856, (1995); FRAMPTON J.E., KEATING G.M., CELECOXIB: A REVIEW OF ITS USE IN THE MANAGEMENT OF ARTHRITIS AND ACUTE PAIN, DRUGS, 67, 16, PP. 2433-2472, (2007); GONG L., THORN C.F., BERTAGNOLLI M.M., GROSSER T., ALTMAN R.B., KLEIN T.E., CELECOXIB PATHWAYS: PHARMACOKINETICS AND PHAR-MACODYNAMICS, PHARMACOGENET. GENOMICS, 22, 4, PP. 310-318, (2012); WERNER U., WERNER D., RAU T., FROMM M.F., HINZ B., BRUNE K., CELECOXIB INHIBITS METABOLISM OF CYTOCHROME P450 2D6 SUBSTRATE METOPROLOL IN HUMANS, CLIN. PHARMACOL. THER, 74, 2, PP. 130-137, (2003); MILLS E.H., WHITWORTH J.A., ANDREWS J., KINCAID-SMITH P., NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND BLOOD PRESSURE, AUST. N. Z. J. MED, 12, 5, PP. 478-482, (1982); WEBSTER J., INTERACTIONS OF NSAIDS WITH DIURETICS AND BETA-BLOCKERS MECHANISMS AND CLINICAL IMPLICATIONS, DRUGS, 30, 1, PP. 32-41, (1985); PEPPING J., POLICOSANOL, AM. J. HEALTH SYST. PHARM, 60, 11, PP. 1112-1115, (2003); CASTANO G., MAS R., GAMEZ R., FERNANDEZ J., ILLNAIT J., FERNANDEZ L., MENDOZA S., MESA M., GUTIERREZ J.A., LOPEZ E., CONCOMITANT USE OF POLICOSANOL AND Β-BLOCKERS IN OLDER PATIENTS, INT. J. CLIN. PHARMACOL. RES, 24, 2-3, PP. 65-77, (2004); JONKMAN J.H., UPTON R.A., PHARMACOKINETIC DRUG INTERACTIONS WITH THEOPHYLLINE, CLIN. PHARMACOKINET, 9, 4, PP. 309-334, (1984); CONRAD K.A., NYMAN D.W., EFFECTS OF METOPROLOL AND PROPRANOLOL ON THEOPHYLLINE ELIMINATION, CLIN. PHARMACOL. THER, 28, 4, PP. 463-467, (1980); MAIDEEN N.M., TOBACCO SMOKING AND ITS DRUG INTERACTIONS WITH COMEDICATIONS INVOLVING CYP AND UGT ENZYMES AND NICOTINE, WORLD J. PHARMACOL, 8, PP. 14-25, (2019); DE GERMAY S., CONTE C., RASCOL O., MONTASTRUC J.L., LAPEYRE-MESTRE M., Β-ADRENOCEPTOR DRUGS AND PARKINSON’S DISEASE: A NA-TIONWIDE NESTED CASE-CONTROL STUDY, CNS DRUGS, 34, 7, PP. 763-772, (2020); EVANS A.K., ARDESTANI P.M., YI B., PARK H.H., LAM R.K., SHAMLOO M., BETA-ADRENERGIC RECEPTOR ANTAGONISM IS PROINFLAMMA-TORY AND EXACERBATES NEUROINFLAMMATION IN A MOUSE MODEL OF ALZ-HEIMER’S DISEASE, NEUROBIOL. DIS, 146, (2020); CIPRES-FLORES F.J., SEGURA-URIBE J.J., OROZCO-SUAREZ S., GUERRA-ARAIZA C., GUEVARA-SALAZAR J.A., CASTILLO-GARCIA E.L., SORIANO-URSUA M.A., FARFAN-GARCIA E.D., BETA-BLOCKERS AND SALBUTAMOL LIMITED EMOTIONAL MEMORY DISTURBANCE AND DAMAGE INDUCED BY OR-CHIECTOMY IN THE RAT HIPPOCAMPUS, LIFE SCI, 224, PP. 128-137, (2019); SAFARUDIN F., ILOABUCHI C.O., LADANI A., SAMBAMOORTHI U., THE ASSOCIATION OF BETA-BLOCKER USE TO COGNITIVE IMPAIRMENT AMONG ADULTS WITH HYPERTENSION OR CARDIOVASCULAR DISEASES IN THE UNITED STATES, CHRONIC PAIN MANAG, 4, (2020); HATCHER H., PLANALP R., CHO J., TORTI F.M., TORTI S.V., CURCUMIN: FROMANCIENT MEDICINE TO CURRENT CLINICAL TRIALS, CELL MOL. LIFE SCI, 65, (2008); HE X., MO L., LI Z.Y., TAN Z.R., CHEN Y., OUYANG D.S., EFFECTS OF CURCUMIN ON THE PHARMACOKINETICS OF TALINOLOL IN HUMAN WITH ABCB1 POLYMORPHISM, XENOBIOTICA, 42, 12, PP. 1248-1254, (2012); ZHOU W, CHAI H, LIN PH, LUMSDEN AB, YAO Q, CHEN C., CLINICAL USE AND MOLECULAR MECHANISMS OF ACTION OF EXTRACT OF GINKGO BILOBA LEAVES IN CARDIOVASCULAR DISEASES, CARDIOVASC. DRUG REV, 22, (2004); BABU P.V., LIU D., GREEN TEA CATECHINS AND CARDIOVASCULAR HEALTH: AN UPDATE, CURR. MED. CHEM, 15, 18, PP. 1840-1850, (2008); DALVI S.S., NAYAK V.K., POHUJANI S.M., DESAI N.K., KSHIRSAGAR N.A., GUPTA K.C., EFFECT OF GUGULIPID ON BIOAVAILABILITY OF DILTI-AZEM AND PROPRANOLOL, J. ASSOC. PHYSICIANS INDIA, 42, 6, PP. 454-455, (1994); WALKER A.F., MARAKIS G., SIMPSON E., HOPE J.L., ROBINSON P.A., HASSANEIN M., SIMPSON H.C.R., HYPOTENSIVE EFFECTS OF HAWTHORN FOR PATIENTS WITH DIABETES TAKING PRESCRIPTION DRUGS: A RAN-DOMISED CONTROLLED TRIAL, BR. J. GEN. PRACT, 56, 527, PP. 437-443, (2006); ALEXANDER J.S., WANG Y., THERAPEUTIC POTENTIAL OF SCHISANDRA CHINENSIS EXTRACTS FOR TREATMENT OF HYPERTENSION. INTRODUCTION TO: ‘ANTIHYPERTENSIVE EFFECT OF GOMISIN A FROM SCHISANDRA CHINENSIS ON ANGIOTENSIN II-INDUCED HYPERTENSION VIA PRESERVATION OF NITRIC OXIDE BIOAVAILABILITY’ BY PARK ET AL, HYPERTENS. RES, 35, 9, PP. 892-893, (2012); CHUN J.N., CHO M., SO I., JEON J.H., THE PROTECTIVE EFFECTS OF SCHISANDRA CHINENSIS FRUIT EXTRACT AND ITS LIGNANS AGAINST CARDIOVASCULAR DISEASE: A REVIEW OF THE MOLECULAR MECHANISMS, FITOTERAPIA, 97, PP. 224-233, (2014); FAN L., MAO X.Q., TAO G.Y., WANG G., JIANG F., CHEN Y., LI Q., ZHANG W., LEI H.P., HU D.L., HUANG Y.F., WANG D., ZHOU H.H., EFFECT OF SCHISANDRA CHINENSIS EXTRACT AND GINKGO BILOBA EXTRACT ON THE PHARMACOKINETICS OF TALINOLOL IN HEALTHY VOLUNTEERS, XENOBIOTICA, 39, 3, PP. 249-254, (2009); BENNETT D.A., PHUN L., POLK J.F., VOGLINO S.A., ZLOTNIK V., RAFFA R.B., NEUROPHARMACOLOGY OF ST. JOHN’S WORT (HYPERICUM), ANN. PHARMACOTHER, 32, 11, PP. 1201-1208, (1998); TAM S.W., WORCEL M., WYLLIE M., YOHIMBINE: A CLINICAL REVIEW, PHARMACOL. THER, 91, 3, PP. 215-243, (2001)","N.M.P. MAIDEEN; DUBAI HEALTH AUTHORITY, DUBAI, PB NO 4545, UNITED ARAB EMIRATES; EMAIL: NMMAIDEEN@DHA.GOV.AE","BENTHAM SCIENCE PUBLISHERS","ENGLISH","CURR. DRUG METAB.","REVIEW","ISI","2-S2.0-85120832911","CURR DRUG METAB","DUBAI HEALTH AUTHORITY;J.K.K. NATTRAJA COLLEGE OF PHARMACY;J.K.K. NATTRAJA COLLEGE OF PHARMACY;J.K.K. NATTRAJA COLLEGE OF PHARMACY;J.K.K. NATTRAJA COLLEGE OF PHARMACY;ELMERGIB UNIVERSITY","NOTREPORTED;DUBAI HEALTH AUTHORITY;NOTREPORTED",NA,"MAIDEEN NMP, 2021, CURR DRUG METAB","MAIDEEN NMP, 2021, CURR DRUG METAB"
"KALONA P;SUNDARESAN U;KASINATHAN I;MUTHIAH C","KALONA, PATRICK A. (57219380261); SUNDARESAN, UMA (57219391595); KASINATHAN, I.D. (57219385161); MUTHIAH, CHELLAPPANDIAN (37090190100)","STUDIES ON RED RICE BRAN AND ITS HEALTH BENEFITS OF FOOD APPLICATIONA REVIEW",2020,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH","12","11",0,"10.31838/ijpr/2020.SP2.007","PT. PHYTOCHEMINDO RESKA, GUNUNG PUTRI, BOGOR, 16966, INDONESIA;DEPARTMENT OF FOOD PROCESS ENGINEERING, SCHOOL OF BIOENGINEERING, SRM UNIVERSITY, KATTANKULATHUR, 603203, TAMIL NADU, INDIA;TVM ACADEMY OF HEALTH SCIENCE, ENTOMOLOGIST, TIRUVALLUR, PODATURPET, 631208, TAMIL NADU, INDIA;PG AND RESEARCH DEPARTMENT OF BOTANY, V.O.CHIDAMBARAM COLLEGE, THOOTHUKODI, 628008, TAMIL NADU, INDIA","RICE MAY BE A MAIN CEREAL FOOD YIELD AND IMPORTANT NUTRITION IN DETERMINED OF THE EMERGING COUNTRIES. THOUSANDS OF RICE VARIETIES ARE CULTIVATED; HOWEVER, THEIR NUTRITIONAL AND MEDICINAL VALUES HAVEN'T BEEN THOROUGHLY INVESTIGATED. RICE BRAN IS THAT THE EXTERNAL A NEIGHBORHOOD OF GERM AND SHOULD BE A BY-PRODUCT OF RICE GRINDING WHICH CONTAINS OF WHOLE RICE GRAIN AND AN HONEST COMMON SOURCE OF SEVERAL NUTRIENTS BUT HAS AROUND LIMITS IN NUTRITION APPLICATION. IT COMPRISES SEVERAL NUTRIENTS LIKE PROTEIN, CARBOHYDRATES, FATS, DIETARY FIBER, VITAMINS AND MINERALS. RICE GRAIN IS RICH IN VARIOUS BIOACTIVE COMPOUNDS LIKE PHENOLIC COMPOUNDS, PHYTOSTEROLS, ACID, POLYCOSANOL, ORYZANOL, TOCOPHEROL, TOCOTRIENOLS AND FERULIC ACID. THE RICE BRAN CAN INDIVIDUAL BE DONE BY NEUTRALIZING THESE ANTINUTRITIONAL FACTORS PARTICULARLY LIPASE WHICH PROGRESSES RANCIDITY IN RICE BRAN. IN VARIOUS METHODS ARE STABILIZING RICE BRAN AND RECOVER ITS EXCELLENCE AND POSSIBLE PART IN TREATING LIFE INTIMIDATING AILMENTS. IT CAN PLAY AN IMPORTANT ROLE IN SERUM LOWERING CHOLESTEROL, IMPROVE INSULIN SENSITIVITY, AND REDUCE THE BIOCOMPATIBLE WITH THE HUMAN SKIN AND RELATED FIT COSMETIC PRODUCTS. RICE BRAN OIL IS THE PRODUCT IS MORE IMPORTANT OF GAMMA-ORYZANOL AND OTHER ANTIOXIDANTS. © 2020, ADVANCED SCIENTIFIC RESEARCH. ALL RIGHTS RESERVED.","ANTIOXIDANTS; FOOD APPLICATION; GAMMA ORYZANOL; HEALTH BENEFITS; MEDICINAL USES; RICE BRAN","ACETIC ACID; ALPHA TOCOTRIENOL; ANTHOCYANIN; CARBOXYLIC ACID; CHOLESTEROL; FERULIC ACID; GAMMA ORYZANOL; MAGNESIUM; PHOSPHORIC ACID; PHYTOSTEROL; PROANTHOCYANIDIN; SODIUM; SODIUM METABISULFITE; TOCOPHEROL; ANTIAGING ACTIVITY; ANTIOXIDANT ACTIVITY; ASH; DIABETES MELLITUS; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; MICROWAVE COOKING; MOISTURE; OBESITY; OXIDATIVE STRESS; RED RICE; REVIEW; RICE BRAN","","","ABDUL H. A., YU S. L., FUNCTIONAL PROPERTIES OF DIETARY FIBRE PREPARED FROM DEFATTED RICE BRAN, FOOD CHEMISTRY, 68, 1, PP. 15-19, (2000); AHUJA U., AHUJA S. C., THAKRAR R., SINGH R. K., RICE-A NUTRACEUTICAL, ASIAN AGRI-HISTORY, 12, 2, PP. 93-108, (2008); AKHTER M., INACTIVATION OF LIPASE ENZYME BY USING CHEMICALS TO MAXIMIZE RICE BRAN SHELF LIFE AND ITS EDIBLE OIL RECOVERY, JOURNAL OF NUTRITION & FOOD SCIENCES, 12, (2015); BUMRUNGPERT AKKARACH, CHONGSUWAT REWADEE, PHOSAT CHANCHIRA, BUTACNUM ARISA, RICE BRAN OIL CONTAINING GAMMA-ORYZANOL IMPROVES LIPID PROFILES AND ANTIOXIDANT STATUS IN HYPERLIPIDEMIC SUBJECTS: A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL, THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 25, 3, PP. 353-358, (2019); ALI G., MOHAMAD T., HAWA Z., JAAFAR E., RAHMAT ASMAH, PHYTOCHEMICAL CONSTITUENTS, ANTIOXIDANT ACTIVITY, AND ANTIPROLIFERATIVE PROPERTIES OF BLACK, RED, AND BROWN RICE BRAN, CHEMISTRY CENTRAL JOURNAL, 17, 1, (2018); AMARASINGHE B. M. W. P. K., KUMARASIRI M. P. M., GANGODAVILAGE N. C., EFFECT OF METHOD OF STABILIZATION ON AQUEOUS EXTRACTION OF RICE BRAN OIL, FOOD AND BIOPRODUCTS PROCESSING, 87, 2, PP. 108-114, (2009); SEA HANDBOOK, PP. 885-891, (2009); ANWUNOBI A. P., EMEJE M. O., RECENT APPLICATIONS OF NATURAL POLYMERS IN NANO DRUG DELIVERY, JOURNAL OF NANOMEDICINE AND NANOTECHNOLOGY S4, 002. AOCS, 59, PP. 561-563, (2011); BABU D. P., BHAKYARAJM R., VILDHYALAKSHMI R., A LOW-COST NUTRITIOUS FOOD “TEMPEH”-A REVIEW, WORLD JOURNAL OF DAIRY FOOD SCIENCE, 4, 1, PP. 222-227, (2009); MADHURI BAMMIDI, SALMA SHAIK, JACKSON NALABOLU, PRAVALLIKA PERAM, BHARGAV KUNDRAPU, RICE BRAN RAGI PANCAKES INSTANT MIX, INTERNATIONAL JOURNAL OF RECENT TECHNOLOGY AND ENGINEERING (IJRTE), 8, 5, (2020); BERNARDI D. S., PEREIRA T. A., MACIEL N. R., BORTOLOTO J., VIERA G.S., OLIVEIRA G.C., ROCHAFILHO P. A., FORMATION AND STABILITY OF OIL-IN-WATER NANO EMULSIONS CONTAINING RICE BRAN OIL: IN VITRO AND IN VIVO ASSESSMENTS, JOURNAL OF NANOBIOTECHNOLOGY, 9, (2011); BETT-GARBER K. L., LEA J. M., CHAMPAGNE E. T., MCCLUNG A. M., WHOLE-GRAIN RICE FLAVOR ASSOCIATED WITH ASSORTED BRAN COLORS, JOURNAL OF SENSORY STUDIES, 27, PP. 78-86, (2014); BHAT F. M., RIAR C. S., HEALTH BENEFITS OF TRADITIONAL RICE VARIETIES OF TEMPERATE REGIONS, MEDICINAL AROMATIC PLANTS, 4, (2015); BHULLAR N. K., GRUISSEM W., NUTRITIONAL ENHANCEMENT OF RICE FOR HUMAN HEALTH: THE CONTRIBUTION OF BIOTECHNOLOGY, BIOTECHNOLOGY ADVANCES, 31, PP. 50-57, (2013); BUFFA C. W., RICE BRAN WAX, A NEW WAX FOR COSMETICS, DRUGS & TOILETRIES, COSMETIC TOILETRIES, 91, PP. 14-16, (1976); CAO X., WEN H., LI C., GU Z., DIFFERENCES IN FUNCTIONAL PROPERTIES AND BIOCHEMICAL CHARACTERISTICS OF COGENETIC RICE PROTEINS, JOURNAL OF CEREAL SCIENCE, 50, PP. 184-189, (2009); CHEN M. H., CHOI S. H., KOZUKUE N., KIM H. J., FRIEDMAN M., GROWTH INHIBITORY EFFECTS OF PIGMENTED RICE BRAN EXTRACTS AND THREE RED BRAN FRACTIONS AGAINST HUMAN CANCER CELLS: RELATIONSHIPS WITH COMPOSITION AND ANTIOXIDATIVE ACTIVITIES, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 60, 36, PP. 9151-9161, (2012); CHEN M. H., MCCLUNG A. M., BERGMAN C. J., CONCENTRATIONS OF LIGOMERS AND POLYMERS OF PRO ANTHOCYANIDINS IN RED AND PURPLE RICE BRAN AND THEIR RELATIONSHIPS TO TOTAL PHENOLICS, FLAVONOIDS, ANTIOXIDANT CAPACITY AND WHOLE GRAIN COLOR, FOOD CHEMISTRY, 208, PP. 279-287, (2016); CHENG -WEI YU, QI-RUI HU. QI-RUI HU., WANG HAO-WEI, DENG ZE-YUAN, COMPARISON OF 11 RICE BRAN STABILIZATION METHODS BY ANALYZING LIPASE ACTIVITIES, JOURNAL OF FOOD PROCESSING AND PRESERVATION, 44, 4, (2020); CICERO A. F. G., GADDI A., RICE BRAN OIL AND GAMMA ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINEMIA’S AND OTHER CONDITIONS, PHYTOTHERAPY RESEARCH, 15, 4, PP. 277-289, (2001); COPPINI D., PAGANIZZI P., SANTI P., GHIRARDINI A., CAPACITÁ PROTETTIVANEIC ON FRONTIDELLERA DIAZIONISOLARI DI DERIVATI DI ORIGINE VEGETABLE, COSMETICS NEWS, 136, PP. 15-20, (2001); DAMAYANTHI E., TJING L. T., PANEBAR SWADAYA., DEPOK E., DAMAYANTHI D. I., LISTYORINI, JURNAL GIZI DAN PANGAN, 2, PP. 34-44, (2006); DANIELSKI LEANDRO, ZETZ CARSTEN, HENSE HAIKO, BRUNNE GERD, A PROCESS LINE FOR THE PRODUCTION OF RAFFINATED RICE OIL FROM RICE BRAN, THE JOURNAL OF SUPERCRITICAL FLUIDS, 34, 2, PP. 133-141, (2005); DE PAEPE K., HACHEM J. P., VANPEE E., ROSEEUW D., ROGIERS V., EFFECT OF RICE STARCH AS A BATH ADDITIVE ON THE BARRIER FUNCTION OF HEALTHY BUT SLS-DAMAGED SKIN AND SKIN OF ATOPIC PATIENTS, ACTA DERMATO VENEREOLOGICA, 82, PP. 184-186, (2002); DEVI R., ARUMUGHAN C., PHYTOCHEMICAL CHARACTERIZATION OF DEFATTED RICE BRAN AND OPTIMIZATION OF A PROCESS FOR THEIR EXTRACTION AND ENRICHMENT, BIORESOURCE TECHNOLOGY, 98, PP. 3037-3043, (2007); EL-SAYED M, ABDEL-AAL J., RABALSKI CHRISTOPHER YOUNG IWONA, ANTHOCYANIN COMPOSITION IN BLACK, BLUE, PINK, PURPLE, AND RED CEREAL GRAINS, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 54, 13, PP. 4696-4704, (2006); FABIAN C., JU Y. H., A REVIEW ON RICE BRAN PROTEIN; ITS PROPERTIES AND EXTRACTION METHODS, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 51, PP. 816-827, (2011); FACCIN G. L., MIOTTO L. A., VIEIRA L. D. N., BARRETO P. L. M., AMANTE E. R., CHEMICAL, SENSORIAL AND RHEOLOGICAL PROPERTIES OF A NEW ORGANIC RICE BRAN BEVERAGE, RICE SCIENCE, 16, PP. 226-234, (2009); FARDET A., ROCK E., REMESY C., IS THE IN VITRO ANTIOXIDANT POTENTIAL OF WHOLE-GRAIN CEREALS AND CEREAL PRODUCTS WELL REFLECTED IN VIVO?, JOURNAL OF CEREAL SCIENCE, 48, PP. 258-276, (2008); FERRARI R. A., SCHULTE E., ESTEVES W., BRUHL L., MUKHERJEE K. D., MINOR CONSTITUENTS OF VEGETABLE OILS DURING INDUSTRIAL PROCESSING, JOURNAL OF ADVANCES IN CHEMISTRY, 73, PP. 587-592, (1996); IKA FITRASYAH SITI, DWIRIANI CESILIA METI, KUSTIYAH LILIK, EFFECT OF THE ANTIOXIDANT DRINKS INTERVENTION ON IMMUNOGLOBULIN G IN ADULTS OBESITY, PAKISTAN JOURNAL OF NUTRITION, 14, PP. 274-283, (2015); FRIEDMAN M., RICE BRANS, RICE BRAN OILS, AND RICE HULLS: COMPOSITION, FOOD AND INDUSTRIAL USES, AND BIOACTIVITIES IN HUMANS, ANIMALS, AND CELLS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 61, 45, PP. 10626-10641, (2013); PEREIRA-CARO GEMA, CROS GERARD, YOKOTA TAKAO, CROZIER ALAN, PHYTOCHEMICAL PROFILES OF BLACK, RED, BROWN, AND WHITE RICE FROM THE CAMARGUE REGION OF FRANCE, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 61, 33, PP. 7976-7986, (2013); GENEVIEVE M., RAINA. F. M., KUMAR AJAY, KUMAR SUSHIL, AGARWAL RAJESH, CHEN MING-HSUAN, BAUER JOHN E., MCCLUNG M., RYAN ELIZABETH P., RICE VARIETAL DIFFERENCES IN BIOACTIVE BRAN COMPONENTS FOR INHIBITION OF COLORECTAL CANCER CELL GROWTH, FOOD CHEMISTRY, 141, 2, PP. 1545-1552, (2013); DAS GITISHREE, PATRA JAYANTA KUMAR, CHOI JAEHYUK, BAEK KWANG-HYUN, RICE GRAIN, A RICH SOURCE OF NATURAL BIOACTIVE COMPOUNDS, PAKISTAN JOURNAL AGRICULTURAL SCIENCE, 54, 3, PP. 671-682, (2017); GOPALA K., KHATOON S., SHIELA C., INDIRA T. N., MISHRA A., EFFECT OF REFINING OF CRUDE RICE BRAN OIL ON THE RETENTION OF ORYZANOL IN THE REFINED OIL, JOURNAL OF THE AM ERICAN OIL CHEMISTS’ SOCIETY, 78, PP. 127-132, (2001); HA S. J., PARK J., LEE J., SONG K. M., UM M. Y., CHO S., JUNG S. K., RICE BRAN SUPPLEMENT PREVENTS UVB-INDUCED SKIN PHOTO AGING IN VIVO, BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, PP. 1-9, (2018); HADIPERNATA M., MENGOL AHDEDAK MENJADI MINYAK (RICE BRAN OIL), ARTIKELWARTA PENELITIAN DAN PENGEMBANGAN PERTANIAN, PP. 8-10, (2007); HALDEN K., DE ALWIS A. A. P., FRYER P. J., CHANGES IN THE ELECTRICAL CONDUCTIVITY OF FOODS DURING OHMIC HEATING, INTERNATIONAL JOURNAL OF FOOD SCIENCE TECHNOLOGY, 25, 1, PP. 9-25, (1990); HAYASHI S., YANASE E., A STUDY ON THE COLOR DEEPENING IN RED RICE DURING STORAGE, FOOD CHEMISTRY, 199, PP. 457-462, (2016); HEGSTED M., WINDHAUSER M. M., REDUCING HUMAN HEART DISEASE RISK WITH RICE BRAN, LOUISIANA AGRICULTURE, 36, PP. 22-23, (1993); HERNANDEZ N., RODRIGUEZ-ALEGRIA M. E., GONZALEZ F., LOPEZ-MUNGUIA A., ENZYMATIC TREATMENT OF RICE BRAN TO IMPROVE PROCESSING, JAOCS, 77, PP. 177-180, (2000); HENK HOOGENKAMP, RICE BRAN REINVENTED, ASIA PACIFIC FOOD INDUSTRY, PP. 36-39, (2009); HU W., WELLS J. H., TAI-SUN S., GODBER J. S., COMPARISON OF ISOPROPANOL AND HEXANE FOR EXTRACTION OF VITAMIN E AND ORYZANOLS FROM STABILIZED RICE BRAN, JAOCS, 73, PP. 1653-1656, (1996); IRAKLI M., KLEISIARIS F., MYGDALIA A., KATSANTONIS D., STABILIZATION OF RICE BRAN AND ITS EFFECT ON BIOACTIVE COMPOUNDS CONTENT, ANTIOXIDANT ACTIVITY AND STORAGE STABILITY DURING INFRARED RADIATION HEATING, JOURNAL OF CEREAL SCIENCE, 80, PP. 135-142, (2018); ISSARA U., RAWDKUEN S., RICE BRAN: A POTENTIAL OF MAIN INGREDIENT IN HEALTHY BEVERAGE. 2016, INTERNATIONAL FOOD RESEARCH JOURNAL, 23, 6, PP. 2306-2318, (2016); ITO M., CHARACTERIZATION OF NATURAL WAXES & THEIR APPLICATION TO COSMETIC FOUNDATIONS, FRAGRANCE JOURNAL, 31, PP. 38-46, (2003); IWAMA F., MARUTA S., COMPOSITION OF THE HARD PORTION OF CRUDE RICE BRAN WAX, KOGYO KAGAKU ZASSHI, 72, PP. 2605-2608, (1969); JARIWALLA R. J., RICE-BRAN PRODUCTS: PHYTONUTRIENTS WITH POTENTIAL APPLICATIONS IN PREVENTIVE AND CLINICAL MEDICINE, DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 27, 1, PP. 17-26, (2001); JENKINS D. J. A., LEEDS A. R., GASSELL M. A., COCKET B., ALBERTI K. G. M., DECREASE IN POSTPRANDIAL INSULIN AND GLUCOSE CONCENTRATIONS BY GAUR AND PECTIN, ANNALS OF INTERNAL MEDICINE, 86, 1, PP. 20-23, (1977); JIANG Y., WANG T., PHYTOSTEROLS IN CEREAL BY-PRODUCTS, JAOCS, 82, PP. 439-444, (2005); YANG JUN YOUNG, KANG MI YOUNG, NAM SEOK HYUN, FRIEDMAN MENDEL, ANTIDIABETIC EFFECTS OF RICE HULL SMOKE EXTRACT IN ALLOXAN-INDUCED DIABETIC MICE, JOURNAL AGRICULTURAL FOOD CHEMISTRY, 60, 1, PP. 87-94, (2012); DAS KANGABAM RAJIV, MEDHABATI KANGABAM, NONGALLEIMA KHUMUKCHAM, DEVI HUIDROM SUNITI BALA, THE POTENTIAL OF DARK PURPLE SCENTED RICE-FROM STAPLE FOOD TO NUTRACEUTICAL, CURRENT WORLD ENVIRONMENT, 9, 3, PP. 867-876, (2014); KANLAYAVATTANAKUL M., LOURITH N., CHAIKUL P., JASMINE RICE PANICLE: A SAFE AND EFFICIENT NATURAL INGREDIENT FOR SKIN AGING TREATMENTS, JOURNAL OF ETHNOPHARMACOLOGY, 193, PP. 607-616, (2016); KIM S., CHUNG H., LIM S., EFFECT OF VARIOUS HEAT TREATMENTS ON RANCIDITY AND SOME BIOACTIVE COMPOUNDS OF RICE BRAN, JOURNAL OF CEREAL SCIENCE, 60, 1, PP. 243-248, (2014); KOZUKA C., YABIKU K., SUNAGAWA S., UEDA R., TAIRA S., OHSHIRO H., IKEMA T., YAMAKAWA K., HIGA M., TANAKA H., TAKAYAMA C., MATSUSHITA M., OYADOMARI S., SHIMABUKURO M., MASUZAKI1 H., BROWN RICE AND ITS COMPONENT, G-ORYZANOL, ATTENUATE THE PREFERENCE FOR HIGH-FAT DIET BY DECREASING HYPOTHALAMIC ENDOPLASMIC RETICULUM STRESS IN MICE, DIABETES, 61, 12, PP. 3084-3093, (2012); KRISHNAMURTHY K. S., THE WEALTH OF SUSRUTA, (1991); KUMAR T. T., HISTORY OF RICE IN INDIA, (1998); KURNIAWATI M., STABILISASI BEKATUL DAN PENERAPANNYA PADA BERAS ANALOG, (2013); LAKKAKULA R. N., LIMA M., WALKER T., RICE BRAN STABILIZATION AND RICE BRAN OIL EXTRACTION USING OHMIC HEATING, BIORESOURCE TECHNOLOGY, 92, 2, PP. 157-161, (2004); LAVANYA M. N., SAIKIRAN K. C. H. S., VENKATACHALAPATHY N., STABILIZATION OF RICE BRAN MILLING FRACTIONS USING MICROWAVE HEATING AND ITS EFFECT ON STORAGE, JOURNAL OF FOOD SCIENCE TECHNOLOGY, 56, 2, PP. 889-895, (2019); LAWAL O. S., ADEBOWALE K. O., ADEBOWALE Y. A., FUNCTIONAL PROPERTIES OF NATIVE AND CHEMICALLY MODIFIED PROTEIN CONCENTRATES FROM BAMBARRA GROUNDNUT, FOOD RESEARCH INTERNATIONAL, 40, PP. 1003-1011, (2007); LERMA-GARCIA M. J., HERRERO-MARTINEZ J. M., SIMO-ALFONSO E. F., MENDONCA C. R. B., RAMIS-RAMOS G., COMPOSITION INDUSTRIAL PROCESSING AND APPLICATIONS OF RICE BRAN GAMMA-ORYZANOL, FOOD CHEMISTRY, 115, PP. 389-404, (2009); LICHTENSTEIN A. H., AUSMAN L. M., CARRASCO W., GUALTIERI L. J., JENNER J. L, ET AL., RICE BRAN OIL CONSUMPTION & PLASMA LIPID LEVELS IN MODERATELY HYPERCHOLESTEROLEMIC HUMANS, ARTERIOSCLER THROMBOSIS, 14, PP. 549-556, (1994); LONDHE S. V., JOSHI M. S., BHOSALE A. A., KALE S. B., ISOLATION OF QUALITY SOY PROTEIN FROM SOYA FLAKES, INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL AND BIOMEDICAL SCIENCES, 2, PP. 1175-1177, (2011); MALEKIAN F., RAO R. M., PRINYAWIWATKUL W., MARSHALL W. E., WINDHAUSER M., ET AL., LIPASE AND LIPOXYGENASE ACTIVITY, FUNCTIONALITY, AND NUTRIENT LOSSES IN RICE BRAN DURING STORAGE, (2000); MANOSROI A., CHUTOPRAPAT R., ABE M., MANOSROI W., MANOSROI J., ANTIAGINGEFFICACYOFTOPICALF ORMULATIONS CONTAINING NIOSOMES ENTRAPPED WITH RICE BRAN BIOACTIVE COMPOUNDS, PHARMACEUTICAL BIOLOGY, 50, 2, PP. 208-224, (2012); MARIA N., DIMITRIS I., KATSANTONIS N., RICE BRAN: A PROMISING NATURAL ANTIOXIDANT COMPONENT IN BREADMAKING, JOURNAL OF NUTRACEUTICALS FOOD SCIENCE, 3, (2017); MARINI F., BALESTRIERI F., BUCCI R., MAGRI A. L., MARINI D., SUPERVISED PATTERN RECOGNITION TO DISCRIMINATE THE GEOGRAPHICAL ORIGIN OF RBOS: A FIRST STUDY, MICROCHEMICAL JOURNAL, 74, PP. 239-248, (2003); MESA-STONESTREET N. J. D., ALAVI S., GWIRTZ J., EXTRUSION-ENZYME LIQUEFACTION AS A METHOD FOR PRODUCING SORGHUM PROTEIN CONCENTRATES, JOURNAL OF FOOD ENGINEERING, 108, PP. 365-375, (2012); MEZOURI SAND EICHNER K., COMPARATIVE STUDY ON THE STABILITY OF CRUDE AND REFINED RICE BRAN OIL DURING LONG-TERM STORAGE AT ROOM TEMPERATURE, EUROPEAN JOURNAL OF LIPID SCIENCE TECHNOLOGY, 109, PP. 198-205, (2007); MIN B., MCCLUNG A. M., CHEN M. H., PHYTOCHEMICALS AND ANTIOXIDANT CAPACITIES IN RICE BRANS OF DIFFERENT COLOR, JOURNAL OF FOOD SCIENCE, 76, PP. 117-126, (2011); MOHAMMED A., SATTER H. A., JABIN S. A., ABEDIN N., AZAD A. K., HOSSAIN ABUL, ARA U., NUTRITIONAL COMPOSITION AND STABILIZATION OF LOCAL VARIETY RICE BRAN BRRI-28, INTERNATIONAL JOURNAL OF SCIENCE AND TECHNOLOGY, 3, 5, (2014); MOONGNGARM A., DAOMUKDA N., KHUMPIKA S., CHEMICAL COMPOSITIONS, PHYTOCHEMICALS, AND ANTIOXIDANT CAPACITY OF RICE BRAN, RICE BRAN LAYER, AND RICE GERM, APCBEE PROCEDIA, 2, PP. 73-79, (2012); JAMIL MUHAMMAD, ANWAR FAWAD, PROPERTIES, HEALTH BENEFITS AND MEDICINAL USES OF ORYZA SATIVA, EUROPEAN JOURNAL OF BIOLOGICAL SCIENCES, 8, 4, PP. 136-141, (2016); MUTHULAKSHMI C., GOMATHI D., KUMAR D. G, RAVIKUMAR G., KALAISELVI M., UMA C., PRODUCTION, PURIFICATION AND CHARACTERIZATION OF PROTEASE BY ASPERGILLUS FLAVUS UNDER SOLID STATE FERMENTATION, JORDAN JOURNAL OF BIOLOGICAL SCIENCE, 4, PP. 137-148, (2011); NOBORU K., YUSHO T., ORYZANOL CONTAINING COSMETICS, 70, (1970); NORHAIZAN MOHDESA., LING TAN BEE, PENG LOHSU, BY-PRODUCTS OF RICE PROCESSING: AN OVERVIEW OF HEALTH BENEFITS AND APPLICATIONS, JOURNAL OF RICE RESEARCH, 1, (2013); OKI T., MASUDA M., KOBAYASHI M., NISHIBA Y., FURUTA S., SUDA I., ON THE GLUCOSE METABOLISM OF MICE FED WITH A HIGH-FAT DIET, JOURNAL OF FOOD SCIENCE, L76, PP. 7-10, (2002); ORTHOEFER F. T., RICE BRAN AND OIL, PP. 1125-1129, (2001); ORTHOEFER F. T., RICE BRAN OIL: HEALTHY LIPID SOURCE, FOOD TECHNOLOGY, 50, PP. 62-64, (1996); PATEL M., NAIK S. N., GAMMA– ORYZANOL FROM RICE BRAN OIL-A REVIEW, JOURNAL OF SCIENTIFIC INDUSTRIAL RESEARCH, 63, PP. 569-578, (2004); PATIL S., SHARMILA KARA, MOHAPATRA D., STABILIZATION OF RICE BRAN USING MICROWAVE: PROCESS OPTIMIZATION AND STORAGE STUDIES, FOOD AND BIOPRODUCTS PROCESSING, 99, 5, PP. 204-211, (2016); PATTARABHORN PONGRAT., SERMPONG SIRICHAI SONG, STABILIZATION OF RICE BRAN USING A CONTINUOUS MICROWAVE OVEN, AGRICULTURAL NATURAL RESOURCES, 53, PP. 373-377, (2019); PHONGTHAI S., HOMTHAWORNCHOO W., RAWDKUEN S., PREPARATION, PROPERTIES AND APPLICATION OF RICE BRAN PROTEIN: A REVIEW, INTERNATIONAL FOOD RESEARCH JOURNAL, 24, 1, PP. 25-34, (2017); PIIRONEN V., LINDSAY D. G., MIETTINEN T. A., TOIVO J., LAMPI A. M., PLANT STEROLS: BIOSYNTHESIS, BIOLOGICAL FUNCTION AND THEIR IMPORTANCE TO HUMAN NUTRITION, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 80, PP. 939-966, (2000); PITIJA K., NAKORNRIAB M., SRISEADKA T., VANAVICHIT A., WONGPORNCHAI S., ANTHOCYANIN CONTENT AND ANTIOXIDANT CAPACITY IN BRAN EXTRACTS OF SOME THAI BLACK RICE VARIETIES, INTERNATIONAL JOURNAL OF FOOD SCIENCE TECHNOLOGY, 48, 2, PP. 300-308, (2013); PITIPANA ACHCHIGE NADINI THUSHARA., PAHAN I., GODAKUMBURA M., PRASHANTHA A. B., IMPORTANCE, HEALTH BENEFITS AND BIOACTIVITIES OF SRI LANKAN TRADITIONAL RICE (ORYZA SATIVA L.) VARIETIES: A REVIEW, INTERNATIONAL JOURNAL OF AGRICULTURE, ENVIRONMENT AND BIORESEARCH, 4, (2019); MAPOUNG SARIYA, ANTHOCYANINS AND PRO ANTHOCYANIDINS IN NATURAL PIGMENTED RICE AND THEIR BIOACTIVITIES, (2019); PRABHAKAR J. V., VENKATESH K. V. L., A SIMPLE CHEMICAL METHOD FOR STABILIZATION OF RICE BRAN, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 63, 5, PP. 644-646, (1986); PRADEEP P. M., JAYADEEP A., GUHA MANISHA, SINGH VASUDEVA, HYDROTHERMAL. AND BIOTECHNOLOGICAL TREATMENTS ON NUTRACEUTICAL CONTENT AND ANTIOXIDANT ACTIVITY OF RICE BRAN, JOURNAL OF CEREAL SCIENCE, 60, 1, PP. 187-192, (2014); PRAMOD K., RAGHAV, AGARWAL NIDHI, SHARMA ANSHU, EMERGING HEALTH BENEFITS OF RICE BRAN-A REVIEW, INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND MODERN EDUCATION, II, PP. 367-382, (2016); PUTRI I. R., HASKITO A. E. P., PERMANA D. A. O. A., EFFECT OF GOAT MILK YOGURT FORTIFIED WITH RED RICE BRAN FLOUR ON SGPT LEVELS OF RATS (RATTUS NORVEGICUS) MODEL DIABETES MELLITUS INDUCED STREPTOZOTOCIN, JOURNAL OF PHYSICS: CONFERENCE SERIES, (2020); QURESHI A. A., SAMI S. A., KHAN F. A., AFFECTS OF STABILIZED RICE BRAN, ITS SOLUBLE & FIBER FRACTIONS ON BLOOD GLUCOSE LEVELS & SERUM LIPID PARAMETERS IN HUMANS WITH DIABETES MELLITUS TYPES I & II, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 13, PP. 175-187, (2002); QURESHI A. A., SAMI S. A., SALSER W. A., KHAN F. A., DOSE DEPENDENT SUPPRESSION OF SERUM CHOLESTEROL BY TOCOTRIENOL RICH FRACTION (TRF25) OF RICE BRAN IN HYPERCHOLESTEROLEMIC HUMANS, ATHEROSCLEROSIS, 161, PP. 199-207, (2002); RAMEZANZADEH F. M., RAO R. M., WINDHAUSER M., PRINYAWIWATKUL W., TULLEY R., MARSHAL W. E., PREVENTION OF HYDROLYTIC RANCIDITY IN RICE BRAN DURING STORAGE, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 47, 8, PP. 3050-3052, (1999); RAMEZANZADEH F. M., RAO R. M., PRINYAWIWATKUL W., MARSHALL W. E., WINDHAUSER M., EFFECTS OF MICROWAVE HEAT, PACKAGING AND STORAGE TEMPERATURE ON FATTY ACID AND PROXIMATE COMPOSITIONS IN RICE BRAN, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 48, 2, PP. 464-467, (2000); RATHNA PRIYA T. S., NELSON ANN RAEBOLINE LINCY ELIAZER, RAVICHANDRAN KAVITHA, ANTONY USHA, NUTRITIONAL AND FUNCTIONAL PROPERTIES OF COLOURED RICE VARIETIES OF SOUTH INDIA: A REVIEW, JOURNAL OF ETHNIC FOODS, 6, (2019); SHARMA RENU, SRIVASTAVA TANUJA, SAXENA D. C., STUDIES ON RICE BRAN AND ITS BENEFITS-A REVIEW. RENU SHARMA ET AL, INT. JOURNAL OF ENGINEERING RESEARCH AND APPLICATIONS, 5, 5, PP. 107-112, (2015); RIGO L. A., DA SILVA C. R., DE OLIVEIRA S. M., CABREIRA T. N., DE BONA DA SILVA C., FERREIRA J., BECK R. C., NANOENCAPSULATION OF RICE BRAN OIL INCREASES ITS PROTECTIVE EFFECTS AGAINST UVB RADIATION-INDUCED SKIN INJURY IN MICE, EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 93, PP. 11-17, (2015); ROHMAN A., HELMIYATI SITI, SETYANINGRUM DWI LARASATI, RICE IN HEALTH AND NUTRITION, INTERNATIONAL FOOD RESEARCH JOURNAL, 21, 1, PP. 13-24, (2014); RUPALI D., PUBALI D., MAHUA G., DIETARY EFFECTS OF PURE AND DIACYLGLYCEROL-RICH RICE BRAN OIL ON GROWTH PATTERN AND LIPID PROFILE OF RATS, JOURNAL OF OLEO SCIENCE, 61, 7, PP. 369-375, (2012); SABA E., LEE C. H., DA JEONG H., LEE K., KIM T. H., ROH S. S., KIM S. H., RHEE M. H., FERMENTED RICE BRAN PREVENTS ATOPIC DERMATITIS IN DNCB-TREATED NC/NGA MICE, JOURNAL OF BIOMEDICAL RESEARCH, 30, PP. 334-343, (2016); SAINI A., PANWARM D., PANESAR P. S., BERA M. B., BIOACTIVE COMPOUNDS FROM CEREAL AND PULSE PROCESSING BY PRODUCTS AND THEIR POTENTIAL HEALTH BENEFITS, AUSTIN JOURNAL OF NUTRITION & METABOLISM, 6, 2, (2019); SALEHI E. A., SARDARODIYAN M., BIOACTIVE PHYTOCHEMICALS IN RICE BRAN: PROCESSING AND FUNCTIONAL PROPERTIES, BIOCHEMISTRY: AN INDIAN JOURNAL, 10, 3, (2016); SAM P. Y., KIM S. J., CHANG H. I., ISOLATION OF ANTHOCYANIN FROM BLACK RICE (HEUGJINJUBYEO) AND SCREENING OF ITS ANTIOXIDANT ACTIVITIES, KOREAN JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 36, PP. 55-60, (2008); SANGKITIKOMOL W., TENCOMNAO T., ROCE JANASAROJ A., ANTIOXIDANT EFFECTS OF ANTHOCYANINS-RICH EXTRACT FROM BLACK STICKY RICE ON HUMAN ERYTHROCYTES AND MONONUCLEAR LEUKOCYTES, AFRICAN JOURNAL OF BIOTECHNOLOGY, 9, PP. 8222-8229, (2010); SAYRE B., SAUNDERS R., RICE BRAN AND RICE BRAN OIL, LIPID TECHNOLOGY, 2, PP. 72-76, (1990); SAYRE R. N., SAUNDERS R. M., ENOCHIN R. V., SCHULTZ W. G., BEAGLE E. C., REVIEW OF RICE BRAN STABILIZATION SYSTEMS WITH EMPHASIS ON EXTRUSION COOKING, CEREAL FOODS WORLD, 27, PP. 317-322, (1982); SHAIK RAMJAN VALI S. R., JU Y., KAIMAL T. N. B., CHERN Y., A PROCESS FOR THE PREPARATION OF FOOD GRADE RICE BRAN WAX & DETERMINATION OF ITS COMPOSITION, JAOCS, 82, PP. 57-64, (2005); RAHMAN SHAKEELUR, SHARMA M. P., SAHAI SUMAN, NUTRITIONAL AND MEDICINAL VALUES F SOME INDIGENOUS RICE VARIETIES, INDIAN JOURNAL OF TRADITIONAL KNOWLEDGE, 5, 4, PP. 454-458, (2006); SHARMA H. R., CHAUHAN G. S., AGRAWAL K., PHYSICO-CHEMICAL CHARACTERISTICS OF RICE BRAN PROCESSED BY DRY HEATING AND EXTRUSION COOKING, INTERNATIONAL JOURNAL OF FOOD PROPERTIES, 7, PP. 603-614, (2004); SHUGO M., ANTI-DANDRUFF AND ANTI-ITCHING SHAMPOO, JAPANESE PATENT, 79, (1979); BHOSALE SHWETA, VIJAYALAKSHMI D., PROCESSING AND NUTRITIONAL COMPOSITION OF RICE BRAN, CURRENT RESEARCH IN NUTRITION AND FOOD SCIENCE, 3, 1, PP. 74-80, (2015); SIMONE A., ZACZUKBASSINELLO P., PENTEADO M., NUTRITIONAL COMPOSITION OF RICE BRAN SUBMITTED TO DIFFERENT STABILIZATION PROCEDURES, BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 48, 4, (2012); SIRIPAIROJ W., KAEWCHADA A., JAREE A., SYNTHESIS OF MOLECULARLY IMPRINTED POLYMERS FOR THE SEPARATION OF GAMMA ORYZANOL BY USING METHACRYLIC ACID AS FUNCTIONAL MONOMER, JOURNAL OF THE TAIWAN INSTITUTE OF CHEMICAL ENGINEERS, 45, PP. 338-346, (2014); SISWANTI R. B. K., NURHARTADI E., ISKANDAR B. D., EFFECT OF VARIOUS HEAT TREATMENT ON PHYSICAL AND CHEMICAL CHARACTERISTICS OF RED RICE BRAN (ORYZA NIVARA L.) ROJOLELE, IOP CONF. SERIES: MATERIALS SCIENCE AND ENGINEERING, 633, (2019); SOMSUVRA B., GHATAK S. S., PANCHAL, ANTI-DIABETIC ACTIVITY OF ORYZANOL AND ITS RELATIONSHIP WITH THE ANTIOXIDANT, PROPERTY. INTERNATIONAL JOURNAL OF DIABETES AND DEVELOPING COUNTRIES, 32, PP. 185-192, (2012); SON M. J., RICO C. W., NAM S. H., KANG M. Y., EFFECTS OF FERULIC ACID AND Γ-ORYZANOL ON HIGH-FAT AND HIGH-FRUCTOSE DIET-INDUCED METABOLIC SYNDROME IN RATS, JOURNAL OF FOOD SCIENCE, 76, (2011); SREENARAYANAN V.V., CHATTOPADHYAY P. K., RICE BRAN STABILIZATION BY DIELECTRIC HEATING, JOURNAL OF FOOD PROCESSING & PRESERVATION, 10, PP. 89-98, (1986); STEPHEN M., BOUE KIM W., DAIGLE MING-HSUAN CHEN, CAO HEPING, HEIMAN MARK L, ANTIDIABETIC POTENTIAL OF PURPLE AND RED RICE (ORYZA SATIVA L.) BRAN EXTRACTS, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 64, 26, PP. 5345-5353, (2019); SUMITH DE D., ABEYSIRIWARDENA Z., GUNASEKARA D. C. S., DEVELOPMENT OF A RED RICE VARIETY WITH EXCELLENT HEALTH PROPERTIES AND ATTRACTIVE GRAIN QUALITIES, INDIAN JOURNAL OF GENETICS AND PLANT BREEDING, 80, 1, (2020); SUN Q., XIONG C. S. L., FUNCTIONAL AND PASTING PROPERTIES OF PEA STARCH AND PEANUT PROTEIN ISOLATE BLENDS, CARBOHYDRATE POLYMERS, 101, PP. 1134-1139, (2014); TANG S., HETTIARACHCHY N. S., HORAX R., ESWARANANDAM S., PHYSICOCHEMICAL PROPERTIES AND FUNCTIONALITY OF RICE BRAN PROTEIN HYDROLYZATE PREPARED FROM HEAT STABILIZED DEFATTED RICE BRAN WITH THE AID OF ENZYMES, JOURNAL OF FOOD SCIENCE, 68, 1, PP. 152-157, (2003); TAO JIAXUN, (2001); LAOKULDILOK THUNNOP, CHARLES F., TULYATHAN VANNA, ANTIOXIDANTS AND ANTIOXIDANT ACTIVITY OF SEVERAL PIGMENTED RICE BRANS, JOURNAL OF AGRICULTURAL FOOD CHEMISTRY, 59, 1, PP. 193-199, (2011); TRUSWELL A. S., CEREAL GRAINS & CORONARY HEART DISEASES, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 56, (2005); WHELTON A.D., HYRE B., PEDERSEN Y., YI P. K., WHELTON, ET AL., EFFECT OF DIETARY FIBER INTAKE ON BLOOD PRESSURE: A META-ANALYSIS OF RANDOMIZED, CONTROLLED CLINICAL TRIALS, JOURNAL OF HYPERTENSION, 23, PP. 475-481; TSUDA T., HORIO F., UCHIDS K., AOKI H., OSAWA T., DIETARY CYANIDIN 3-O-BETA-DGLUCOSIDE-RICE PURPLE CORN COLOR PREVENTS OBESITY AND AMELIORATES HYPERGLYCEMIA IN MICE, JOURNAL OF NUTRITION, 33, 7, PP. 2125-2130, (2003); VALI S. R, JU Y., KAIMAL T. N. B., CHERN Y., A PROCESS FOR THE PREPARATION OF FOOD GRADE RICE BRAN WAX & DETERMINATION OF ITS COMPOSITION, JAOCS, 82, PP. 157-164, (2005); WAGLAY A., KARBOUNE S., ALLI I., POTATO PROTEIN ISOLATES: RECOVERY AND CHARACTERIZATION OF THEIR PROPERTIES, FOOD CHEMISTRY, 142, PP. 373-382, (2014); KANCHANA WALIMUNI, ABEYSEKERA SUBHASHINI MENDIS, ARACHCHIGE SIRIMAL PREMAKUMARA GALBADA, JAMES SUDHAIR, SOTHEESWARAN SUBRAMANIAM, THAVARAJAH PUSHPARAJAH, RESISTANT STARCH CONTENT OF THIRTY-EIGHT SELECTED RICE (ORYZA SATIVA L.) VARIETIES OF SRI LANKA, JOURNAL OF AGRICULTURE AND CROPS, 4, 9, PP. 93-98, (2018); WALTER M., MARCHESAN E., MASSONI P.F.S., SILVA L.P., SARTORI G.M.S., FERREIRA R.B., ANTIOXIDANT PROPERTIES OF RICE GRAINS WITH LIGHT BROWN, RED AND BLACK PERICARP COLORS AND THE EFFECT OF PROCESSING, FOOD RESEARCH INTERNATIONAL, 50, PP. 693-703, (2013); WATCHARARUJI K., GOTO M., SASAKI M., SHOTIPRUK A., VALUE-ADDED SUBCRITICAL WATER HYDROLYSATE FROM RICE BRAN AND SOYBEAN MEAL, BIORESOURCE TECHNOLOGY, 99, PP. 6207-6213, (2008); WULANDARI P., SUTER I., PUTRA N. K., DAN WIDARTA I., BEKATUL BERASMERAHSEBAGAI SALAH SATU ALTERNATIFSUMBER ANTIOKSIDAN J, (2013); XIA N., WANG J.M., GONG Q., YANG X.Q., YIN S.W., QI J.R., CHARACTERIZATION AND IN VITRO DIGESTIBILITY OF RICE PROTEIN PREPARED BY ENZYME-ASSISTED MICRO FLUIDIZATION: COMPARISON TO ALKALINE EXTRACTION, JOURNAL OF CEREAL SCIENCE, 56, PP. 482-489, (2012); YAO YANG, SANG WEI, ZHOU MENGJIE, REN GUIXING, ANTIOXIDANT AND Α-GLUCOSIDASE INHIBITORY ACTIVITY OF COLORED GRAINS IN CHINA, AGRICULTURAL FOOD CHEMISTRY, 58, 2, PP. 770-774, (2010); YAWADIO R., TANIMORI S., MORITA N., IDENTIFICATION OF PHENOLIC COMPOUNDS ISOLATED FROM PIGMENTED RICE’S AND THEIR ALDOSE REDUCTASE INHIBITORY ACTIVITIES, FOOD CHEMISTRY, 101, PP. 1616-1625, (2007); YILMAZ N., TUNCEL N., KOCABIYIK H., INFRARED STABILIZATION OF RICE BRAN AND ITS EFFECTS ONΓ-ORYZANOL CONTENT, TOCOPHEROLS AND FATTY ACID COMPOSITION, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 94, 8, PP. 1568-1576, (2013); YOON S. H., KIM S. K., OXIDATIVE STABILITY OF HIGH FATTY ACID RICE BRAN OIL AT DIFFERENT STAGES OF REFINING, JAOCS, 75, PP. 227-229, (1994); ZENG Y. W., YANG J. Z., PU X. Y., DU J., YANG T., YANG S. M., ZHU W. H., STRATEGIES OF FUNCTIONAL FOOD FOR CANCER PREVENTION IN HUMAN BEINGS, ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 14, PP. 1585-1592, (2013); ZHANG M. W., GUO B. J., ZHANG R. F., CHI J. W., WEI Z. C., XU Z. H., ET AL., SEPARATION, PURIFICATION AND IDENTIFICATION OF ANTIOXIDANT COMPOSITIONS IN BLACK RICE, AGRICULTURAL SCIENCE IN CHINA, 5, PP. 431-440, (2006)","C. MUTHIAH; PG AND RESEARCH DEPARTMENT OF BOTANY, V.O.CHIDAMBARAM COLLEGE, THOOTHUKODI, 628008, INDIA; EMAIL: NMCPANDIAN@GMAIL.COM","ADVANCED SCIENTIFIC RESEARCH","ENGLISH","INT. J. PHARM. RES.","REVIEW","ISI","2-S2.0-85092511494","INT J PHARM RES","PT. PHYTOCHEMINDO RESKA;SRM UNIVERSITY;TVM ACADEMY OF HEALTH SCIENCE;V.O.CHIDAMBARAM COLLEGE","NOTREPORTED;V.O.CHIDAMBARAM COLLEGE;NOTREPORTED",NA,"KALONA PA, 2020, INT J PHARM RES","KALONA PA, 2020, INT J PHARM RES"
"RUSSO V;NAPOLITANO N;ASCRIZZI A;LEONARDI S;PISACANE F;DI M P;IMBALZANO E;SASSO F;D'ANDREA A;CATURANO A;MAURIELLO A","RUSSO, VINCENZO (55534141202); NAPOLITANO, NICOLA (58621849600); ASCRIZZI, ANTONIA (58477090900); LEONARDI, SILVIA (57205693014); PISACANE, FILOMENA (59003949200); DI MICCO, PIERPAOLO (6604056810); IMBALZANO, EGIDIO (6507712629); SASSO, FERDINANDO CARLO (19738525200); D’ANDREA, ANTONELLO (55612687400); CATURANO, ALFREDO (57203179990); MAURIELLO, ALFREDO (57216390213)","THE LIPIDLOWERING EFFICACY OF A NUTRACEUTICAL COMBINATION INCLUDING LEUCOSELECT PHYTOSOME RED YEAST RICE POLICOSANOL AND FOLIC ACID IN DYSLIPIDAEMIA PATIENTS REALWORLD INSIGHTS",2024,"PHARMACEUTICALS","17","",0,"10.3390/ph17040447","CARDIOLOGY UNIT, DEPARTMENT OF MEDICAL TRANSLATIONAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, MONALDI HOSPITAL, NAPLES, 80131, ITALY;CARDIOLOGY UNIT, DEPARTMENT OF MEDICAL TRANSLATIONAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, MONALDI HOSPITAL, NAPLES, 80131, ITALY;CARDIOLOGY UNIT, DEPARTMENT OF MEDICAL TRANSLATIONAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, MONALDI HOSPITAL, NAPLES, 80131, ITALY;CLINICAL BIOCHEMISTRY UNIT, MONALDI HOSPITAL, NAPLES, 80131, ITALY;CLINICAL BIOCHEMISTRY UNIT, MONALDI HOSPITAL, NAPLES, 80131, ITALY;DEPARTMENT OF MEDICINE, PRESIDIO OSPEDALIERO SANTA MARIA DELLE GRAZIE, POZZUOLI, 80078, ITALY;DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF MESSINA, MESSINA, 98122, ITALY;DEPARTMENT OF ADVANCED MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, NAPLES, 80138, ITALY;DEPARTMENT OF CARDIOLOGY, UMBERTO I HOSPITAL, NOCERA INFERIORE, 84014, ITALY;DEPARTMENT OF ADVANCED MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, NAPLES, 80138, ITALY;CARDIOLOGY UNIT, DEPARTMENT OF MEDICAL TRANSLATIONAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, MONALDI HOSPITAL, NAPLES, 80131, ITALY, DEPARTMENT OF ADVANCED MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, NAPLES, 80138, ITALY","BACKGROUND: CARDIOVASCULAR DISEASE IS A GLOBAL HEALTH CONCERN AND REDUCING PLASMA LDL-C LEVELS IS A MAJOR GOAL IN CARDIOVASCULAR PREVENTION. OUR STUDY AIMED TO EVALUATE THE EFFECTIVENESS OF A NUTRACEUTICAL FORMULATION INCLUDING LEUCOSELECT® PHYTOSOME®, RED YEAST RICE, POLICOSANOL AND FOLIC ACID ON LDL-C LEVELS IN PATIENTS AT LOW CARDIOVASCULAR RISK WITH DYSLIPIDEMIA. MATERIALS AND METHODS: WE PROSPECTIVELY ENROLLED ALL CONSECUTIVE PATIENTS WITH DYSLIPIDEMIA AT LOW CARDIOVASCULAR RISK WHO WERE UNRESPONSIVE TO DIET AND PHYSICAL ACTIVITY. CLINICAL ASSESSMENTS AND LABORATORY ANALYSES, ENCOMPASSING LIPID PROFILE, HEPATIC FUNCTION, AND CPK LEVELS, WERE PERFORMED AT BASELINE PRIOR TO INITIATING TREATMENT AND REPEATED AT THE 12-WEEK MARK FOLLOWING ADMINISTRATION OF THE STUDY NUTRACEUTICAL. RESULTS: SIXTY (60) CONSECUTIVE PATIENTS (MEAN AGE 48.02 ± 10.1 YEARS; 60% MALE) WERE INCLUDED. AT THE 12-WEEK FOLLOW-UP, A STATISTICALLY SIGNIFICANT REDUCTION IN TOTAL CHOLESTEROL (13.1%) AND LDL-C SERUM LEVEL (20.4%) WAS OBSERVED. HEPATIC AND MUSCULAR FUNCTION REMAIN STABLE OVER THE TIME. THE ADHERENCE TO THERAPY WAS 99% AND THE PERSISTENCE WAS MAXIMUM. CONCLUSIONS: THE NUTRACEUTICAL FORMULATION INCLUDING LEUCOSELECT® PHYTOSOME® RED YEAST RICE, POLICOSANOL AND FOLIC ACID SIGNIFICANTLY REDUCED THE LDL-C PLASMA LEVELS, CONSISTENT WITH PREVIOUS RESEARCH SHOWING THAT THE BIOACTIVE COMPONENT IN RED YEAST RICE—LOVASTATIN—IS EFFECTIVE IN ADDRESSING PROBLEMS WITH LIPID METABOLISM. IMPORTANTLY, IT WAS SAFE AND WELL-TOLERATED AMONG PATIENTS WITH DYSLIPIDEMIA IN A REAL-WORLD SETTING. © 2024 BY THE AUTHORS.","ADHERENCE; BERBERINE; CARDIOVASCULAR RISK; CHOLESTEROL; FOLIC ACID; LEUCOSELECT PHYTOSOME; NUTRACEUTICALS; POLICOSANOL; RED YEAST RICE; SAFETY PROFILE","","","","ROTH G.A., JOHNSON C., ABAJOBIR A., ABD-ALLAH F., ABERA S.F., ABYU G., AHMED M., AKSUT B., ALAM T., ALAM K., ET AL., GLOBAL, REGIONAL, AND NATIONAL BURDEN OF CARDIOVASCULAR DISEASES FOR 10 CAUSES, 1990 TO 2015, J. AM. COLL. CARDIOL, 70, PP. 1-25, (2017); YUSUF S., REDDY S., OUNPUU S., ANAND S., GLOBAL BURDEN OF CARDIOVASCULAR DISEASES, CIRCULATION, 104, PP. 2855-2864, (2001); WANG W., JIANG B., SUN H., RU X., SUN D., WANG L., WANG L., JIANG Y., LI Y., WANG Y., ET AL., PREVALENCE, INCIDENCE, AND MORTALITY OF STROKE IN CHINA, CIRCULATION, 135, PP. 759-771, (2017); TARDIF J.C., KOUZ S., WATERS D.D., BERTRAND O.F., DIAZ R., MAGGIONI A.P., PINTO F.J., IBRAHIM R., GAMRA H., KIWAN G.S., ET AL., EFFICACY AND SAFETY OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION, N. ENGL. J. MED, 381, PP. 2497-2505, (2019); NIDORF S.M., EIKELBOOM J.W., BUDGEON C.A., THOMPSON P.L., LOW-DOSE COLCHICINE FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, J. AM. COLL. CARDIOL, 61, PP. 404-410, (2013); RIDKER P.M., EVERETT B.M., THUREN T., MACFADYEN J.G., CHANG W.H., BALLANTYNE C., FONSECA F., NICOLAU J., KOENIG W., ANKER S.D., ET AL., ANTIINFLAMMATORY THERAPY WITH CANA-KINUMAB FOR ATHEROSCLEROTIC DISEASE, N. ENGL. J. MED, 377, PP. 1119-1131, (2017); FALCO L., TESSITORE V., CICCARELLI G., MALVEZZI M., D'ANDREA A., IMBALZANO E., GOLINO P., RUSSO V., ANTIOXIDANT PROPERTIES OF ORAL ANTITHROMBOTIC THERAPIES IN ATHEROSCLEROTIC DISEASE AND ATRIAL FIBRILLATION, ANTIOXIDANTS, 12, (2023); FERENCE B.A., GINSBERG H.N., GRAHAM I., RAY K.K., PACKARD C.J., BRUCKERT E., HEGELE R.A., KRAUSS R.M., RAAL F.J., SCHUNKERT H., ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR. HEART J, 38, PP. 2459-2472, (2017); BARTER P.J., CAULFIELD M., ERIKSSON M., GRUNDY S.M., KASTELEIN J.J., KOMAJDA M., LOPEZ-SENDON J., MOSCA L., TARDIF J.C., WATERS D.D., ET AL., EFFECTS OF TORCETRAPIB IN PATIENTS AT HIGH RISK FOR CORONARY EVENTS, N. ENGL. J. MED, 357, PP. 2109-2122, (2007); BAIGENT C., KEECH A., KEARNEY P.M., BLACKWELL L., BUCK G., POLLICINO C., KIRBY A., SOURJINA T., PETO R., COLLINS R., ET AL., EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); FULCHER J., O'CONNELL R., VOYSEY M., EMBERSON J., BLACKWELL L., MIHAYLOVA B., SIMES J., COLLINS R., KIRBY A., COLHOUN H., ET AL., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN: META-ANALYSIS OF INDIVIDUAL DATA FROM 174,000 PARTICIPANTS IN 27 RANDOMISED TRIALS, LANCET, 385, PP. 1397-1405, (2015); FERENCE B.A., KASTELEIN J.J., RAY K.K., GINSBERG H.N., CHAPMAN M.J., PACKARD C.J., LAUFS U., OLIVER-WILLIAMS C., WOOD A.M., BUTTERWORTH A.S., ET AL., ASSOCIATION OF TRIGLYCERIDE-LOWERING LPL VARIANTS AND LDL-C–LOWERING LDLR VARIANTS WITH RISK OF CORONARY HEART DISEASE, JAMA, 321, (2019); RAYGOR V., KHERA A., NEW RECOMMENDATIONS AND REVISED CONCEPTS IN RECENT GUIDELINES ON THE MANAGEMENT OF DYSLIPIDEMIAS TO PREVENT CARDIOVASCULAR DISEASE: THE 2018 ACC/AHA AND 2019 ESC/EAS GUIDELINES, CURR. CARDIOL. REP, 22, (2020); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, ATHEROSCLEROSIS, 253, PP. 281-344, (2016); JACOBSON T.A., MAKI K.C., ORRINGER C.E., JONES P.H., KRIS-ETHERTON P., SIKAND G., LA FORGE R., DANIELS S.R., WILSON D.P., MORRIS P.B., ET AL., NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT-CENTERED MANAGEMENT OF DYSLIPIDEMIA: PART 2, J. CLIN. LIPIDOL, 9, (2015); ESTRUCH R., ROS E., SALAS-SALVADO J., COVAS M.I., CORELLA D., AROS F., GOMEZ-GRACIA E., RUIZ-GUTIERREZ V., FIOL M., LAPETRA J., ET AL., PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE WITH A MEDITERRANEAN DIET, N. ENGL. J. MED, 368, PP. 1279-1290, (2013); SIALVERA T.E., PAPADOPOULOU A., EFSTATHIOU S.P., TRAUTWEIN E.A., RAS R.T., KOLLIA N., FARAJIAN P., GOUMAS G., DIMAKOPOULOS I., PAPAVASILIOU K., ET AL., STRUCTURED ADVICE PROVIDED BY A DIETITIAN INCREASES ADHERENCE OF CONSUMERS TO DIET AND LIFESTYLE CHANGES AND LOWERS BLOOD LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL: THE INCREASING ADHERENCE OF CONSUMERS TO DIET & LIFESTYLE CHANGES TO LOWER (LDL) CHOLESTEROL (ACT) RANDOMISED CONTROLLED TRIAL, J. HUM. NUTR. DIET, 31, PP. 197-208, (2018); SCHOENECK M., IGGMAN D., THE EFFECTS OF FOODS ON LDL CHOLESTEROL LEVELS: A SYSTEMATIC REVIEW OF THE ACCUMULATED EVIDENCE FROM SYSTEMATIC REVIEWS AND META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS, 31, PP. 1325-1338, (2021); CICERO A.F.G., COLLETTI A., COMBINATIONS OF PHYTOMEDICINES WITH DIFFERENT LIPID LOWERING ACTIVITY FOR DYSLIPIDEMIA MANAGEMENT: THE AVAILABLE CLINICAL DATA, PHYTOMEDICINE, 23, PP. 1113-1118, (2016); CICERO A.F.G., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN. DRUG. SAF, 11, PP. 753-766, (2012); CICERO A.F.G., PARINI A., ROSTICCI M., NUTRACEUTICALS AND CHOLESTEROL-LOWERING ACTION, IJC METAB. ENDOCR, 6, PP. 1-4, (2015); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ZHANG D., COOPER R., CHANG M., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGRIC. FOOD CHEM, 48, PP. 5220-5225, (2000); CICERO A.F.G., FOGACCI F., BANACH M., RED YEAST RICE FOR HYPERCHOLESTEROLEMIA, METHODIST DEBAKEY CARDIOVASC. J, 15, (2019); CICERO A.F., FOGACCI F., STOIAN A.P., VRABLIK M., AL RASADI K., BANACH M., TOTH P.P., RIZZO M., NUTRACEUTICALS IN THE MANAGEMENT OF DYSLIPIDEMIA: WHICH, WHEN, AND FOR WHOM? COULD NUTRACEUTICALS HELP LOW-RISK INDIVIDUALS WITH NON-OPTIMAL LIPID LEVELS?, CURR. ATHEROSCLER. REP, 23, (2021); BANACH M., CATAPANO A.L., CICERO A.F.G., ESCOBAR C., FOGER B., KATSIKI N., LATKOVSKIS G., RAKOWSKI M., REINER Z., SAHEBKAR A., ET AL., RED YEAST RICE FOR DYSLIPIDAEMIAS AND CARDIOVASCULAR RISK REDUCTION: A POSITION PAPER OF THE INTERNATIONAL LIPID EXPERT PANEL, PHARMACOL. RES, 183, (2022); ALBERTS A.W., DISCOVERY, BIOCHEMISTRY AND BIOLOGY OF LOVASTATIN, AM. J. CARDIOL, 62, PP. 10J-15J, (1988); LI Y.G., ZHANG F., WANG Z.T., HU Z.B., IDENTIFICATION AND CHEMICAL PROFILING OF MONACOLINS IN RED YEAST RICE USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH PHOTODIODE ARRAY DETECTOR AND MASS SPECTROMETRY, J. PHARM. BIOMED. ANAL, 35, PP. 1101-1112, (2004); BELTRAN D., FRUTOS-LISON M.D., ESPIN J.C., GARCIAVILLALBA R., RE-EXAMINING THE ROLE OF THE GUT MICROBIOTA IN THE CONVERSION OF THE LIPID-LOWERING STATIN MONACOLIN K (LOVASTATIN) INTO ITS ACTIVE BHYDROXY ACID METABOLITE, FOOD FUNCT, 10, PP. 1787-1791, (2019); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H.W., GERDES V.E.A., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN—A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM, 53, PP. 5583-5586, (2005); NAM D.E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J. MED. FOOD, 22, PP. 1110-1117, (2019); MARINANGELI C.P.F., JONES P.J.H., KASSIS A.N., ESKIN M.N.A., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR, 50, PP. 259-267, (2010); ISHAKA A., UMAR IMAM M., MAHAMUD R., ZUKI A.B., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT. J. NANOMED, 9, PP. 2261-2269, (2014); HAIM D., VALENZUELA A., BRANES M.C., FUENZALIDA M., VIDELA L.A., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASAS ACEITES, 63, PP. 345-354, (2012); CHANG W., LI K., GUAN F., YAO F., YU Y., ZHANG M., HATCH G.M., CHEN L., BERBERINE PRETREATMENT CONFERS CARDIOPROTECTION AGAINST ISCHEMIA-REPERFUSION INJURY IN A RAT MODEL OF TYPE 2 DIABETES, J. CARDIOVASC. PHARMACOL. THER, 21, PP. 486-494, (2016); RICHTER E.A., RUDERMAN N.B., AMPK AND THE BIOCHEMISTRY OF EXERCISE: IMPLICATIONS FOR HUMAN HEALTH AND DISEASE, BIOCHEM. J, 418, PP. 261-275, (2009); SKARYDOVA L., HOFMAN J., CHLEBEK J., HAVRANKOVA J., KOSANOVA K., SKARKA A., HOSTALKOVA A., PLUCHA T., CAHLIKOVA L., WSOL V., ISOQUINOLINE ALKALOIDS AS A NOVEL TYPE OF AKR1C3 INHIBITORS, J. STEROID. BIOCHEM. MOL. BIOL, 143, PP. 250-258, (2014); CICERO A., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN. LIPIDOL, 4, PP. 553-563, (2009); WANG K., FENG X., CHAI L., CAO S., QIU F., THE METABOLISM OF BERBERINE AND ITS CONTRIBUTION TO THE PHARMACOLOGICAL EFFECTS, DRUG. METAB. REV, 49, PP. 139-157, (2017); CALICETI C., FRANCO P., SPINOZZI S., RODA A., CICERO A.F., BERBERINE: NEW INSIGHTS FROM PHARMACOLOGICAL ASPECTS TO CLINICAL EVIDENCES IN THE MANAGEMENT OF METABOLIC DISORDERS, CURR. MED. CHEM, 23, PP. 1460-1476, (2016); ZUO F., NAKAMURA N., AKAO T., HATTORI M., PHARMACOKINETICS OF BERBERINE AND ITS MAIN METABOLITES IN CONVENTIONAL AND PSEUDO GERM-FREE RATS DETERMINED BY LIQUID CHROMATOGRAPHY/ION TRAP MASS SPECTROMETRY, DRUG. METAB. DISPOS, 34, PP. 2064-2072, (2006); ZHANG Z., LI X., SANG S., MCCLEMENTS D.J., CHEN L., LONG J., JIAO A., JIN Z., QIU C., POLYPHENOLS AS PLANT-BASED NUTRACEUTICALS: HEALTH EFFECTS, ENCAPSULATION, NANO-DELIVERY, AND APPLICATION, FOODS, 11, (2022); MAXWELL S., CRUICKSHANK A., THORPE G., RED WINE AND ANTIOXIDANT ACTIVITY IN SERUM, LANCET, 344, PP. 193-194, (1994); KENDALL M.J., NUTTALL S.L., MARTIN U., ANTIOXIDANT THERAPY—A NEW THERAPEUTIC OPTION FOR REDUCING MORTALITY FROM CORONARY ARTERY DISEASE, J. CLIN. PHARM. THER, 23, PP. 323-325, (1998); FUHRMAN B., LAVY A., AVIRAM M., CONSUMPTION OF RED WINE WITH MEALS REDUCES THE SUSCEPTIBILITY OF HUMAN PLASMA AND LOW-DENSITY LIPOPROTEIN TO LIPID PEROXIDATION, AM. J. CLIN. NUTR, 61, PP. 549-554, (1995); ABU-AMSHA R., CROFT K.D., PUDDEY I.B., PROUDFOOT J.M., BEILIN L.J., PHENOLIC CONTENT OF VARIOUS BEVERAGES DETERMINES THE EXTENT OF INHIBITION OF HUMAN SERUM AND LOW-DENSITY LIPOPROTEIN OXIDATION IN VITRO: IDENTIFICATION AND MECHANISM OF ACTION OF SOME CINNAMIC ACID DERIVATIVES FROM RED WINE, CLIN. SCI, 91, PP. 449-458, (1996); FACINO R., CARINI M., ALDINI G., CALLONI M., BOMBARDELLI E., MORAZZONI P., SPARING EFFECT OF PROCYANIDINS FROM VITIS VINIFERA ON VITAMIN E: IN VITRO STUDIES, PLANTA MED, 64, PP. 343-347, (1998); NUTTALL S.L., KENDALL M.J., BOMBARDELLI E., MORAZZONI P., AN EVALUATION OF THE ANTIOXIDANT ACTIVITY OF A STANDARDIZED GRAPE SEED EXTRACT, LEUCOSELECT<SUP>®</SUP>, J. CLIN. PHARM. THER, 23, PP. 385-389, (1998); BARANI M., SANGIOVANNI E., ANGARANO M., RAJIZADEH M.A., MEHRABANI M., PIAZZA S., GANGADHARAPPA H.V., PARDAKHTY A., MEHRBANI M., DELL'AGLI M., ET AL., PHYTOSOMES AS INNOVATIVE DELIVERY SYSTEMS FOR PHYTOCHEMICALS: A COMPREHENSIVE REVIEW OF LITERATURE, INT. J. NANOMED, 16, PP. 6983-7022, (2021); MAO J.T., XUE B., FAN S., NEIS P., QUALLS C., MASSIE L., FIEHN O., LEUCOSELECT PHYTOSOME MODULATES SERUM EICOSAPENTAENOIC ACID, DOCOSAHEXAENOIC ACID, AND PROSTAGLANDIN E3 IN A PHASE I LUNG CANCER CHEMOPREVENTION STUDY, CANCER PREV. RES, 14, PP. 619-626, (2021); CICERO A.F.G., D'ADDATO S., BORGHI C., A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY OF THE EFFECTS OF A NUTRACEUTICAL COMBINATION (LEVELIP DUO<SUP>®</SUP>) ON LDL CHOLESTEROL LEVELS AND LIPID PATTERN IN SUBJECTS WITH SUB-OPTIMAL BLOOD CHOLESTEROL LEVELS (NATCOL STUDY), NUTRIENTS, 12, (2020); RUSCICA M., PAVANELLO C., GANDINI S., MACCHI C., BOTTA M., DALL'ORTO D., DEL PUPPO M., BERTOLOTTI M., BOSISIO R., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH FOR THE MANAGEMENT OF CARDIOVASCULAR RISK—A COMBINATION CONTAINING THE PROBIOTIC BIFIDOBACTERIUM LONGUM BB536 AND RED YEAST RICE EXTRACT: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. J, 18, (2019); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICO-SANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. METAB. CARDIOVASC. DIS, 20, PP. 656-661, (2010); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV. THER, 28, PP. 1105-1113, (2011); CICERO A.F.G., DE SANDO V., BENEDETTO D., CEVENINI M., GRANDI E., BORGHI C., LONG-TERM EFFICACY AND TOLERABILITY OF A MULTICOMPONENT LIPID-LOWERING NUTRACEUTICAL IN OVERWEIGHT AND NORMOWEIGHT PATIENTS, NUTRAFOODS, 11, PP. 55-61, (2012); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACE-BO-CONTROLLED STUDY, CURR. THER. RES. CLIN. EXP, 77, PP. 1-6, (2015); RUSCICA M., GOMARASCHI M., MOMBELLI G., MACCHI C., BOSISIO R., PAZZUCCONI F., PAVANELLO C., CALABRESI L., ARNOLDI A., SIRTORI C.R., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CAR-DIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J. CLIN. LIPIDOL, 8, PP. 61-68, (2014); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., MORINA D., VILLAR J., MILLAN J., ANGUERA A., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); BARRIOS V., ESCOBAR C., CICERO A.F.G., BURKE D., FASCHING P., BANACH M., BRUCKERT E., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER. SUPPL, 24, PP. 1-15, (2017); RAS R.T., FUCHS D., KOPPENOL W.P., SCHALKWIJK C.G., OTTEN-HOFMAN A., GARCZAREK U., GREYLING A., WAGNER F., TRAUTWEIN E.A., EFFECT OF A PLANT STEROL-ENRICHED SPREAD ON BIOMARKERS OF ENDOTHELIAL DYSFUNCTION AND LOW-GRADE INFLAMMATION IN HYPERCHOLESTEROLAEMIC SUBJECTS, J. NUTR. SCI, 5, (2016); ROCHA V.Z., RAS R.T., GAGLIARDI A.C., MANGILI L.C., TRAUTWEIN E.A., SANTOS R.D., EFFECTS OF PHYTOSTEROLS ON MARKERS OF INFLAMMATION: A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 248, PP. 76-83, (2016); HO X.L., LIU J.J.H., LOKE W.M., PLANT STEROL-ENRICHED SOY MILK CONSUMPTION MODULATES 5-LIPOXYGENASE, 12-LIPOXYGENASE, AND MYELOPEROXIDASE ACTIVITIES IN HEALTHY ADULTS—A RANDOMIZED-CONTROLLED TRIAL, FREE RADIC. RES, 50, PP. 1396-1407, (2016); VILAHUR G., BEN-AICHA S., DIAZ-RIERA E., BADIMON L., PADRO T., PHYTOSTEROLS AND INFLAMMATION, CURR. MED. CHEM, 26, PP. 6724-6734, (2018); DOMENECH M., CASAS R., RUIZ-LEON A.M., SOBRINO J., ROS E., ESTRUCH R., EFFECTS OF A NOVEL NUTRACEUTICAL COMBINATION (AQUILEA COLESTEROL<SUP>®</SUP>) ON THE LIPID PROFILE AND INFLAMMATORY BIOMARKERS: A RANDOMIZED CONTROL TRIAL, NUTRIENTS, 11, (2019); ALBERT M.A., DANIELSON E., RIFAI N., RIDKER P.M., EFFECT OF STATIN THERAPY ON C-REACTIVE PROTEIN LEVELS: THE PRAVASTATIN INFLAMMATION/CRP EVALUATION (PRINCE): A RANDOMIZED TRIAL AND COHORT STUDY, JAMA, 286, PP. 64-70, (2001); CICERO A.F., MORBINI M., PARINI A., URSO R., ROSTICCI M., GRANDI E., BORGHI C., EFFECT OF RED YEAST RICE COMBINED WITH ANTIOXIDANTS ON LIPID PATTERN, HS-CRP LEVEL, AND ENDOTHELIAL FUNCTION IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS, THER. CLIN. RISK MANAG, 12, PP. 281-286, (2016); BADIMON L., PENA E., ARDERIU G., PADRO T., SLEVIN M., VILAHUR G., CHIVA-BLANCH G., C-REACTIVE PROTEIN IN ATHEROTHROMBOSIS AND ANGIOGENESIS, FRONT. IMMUNOL, 9, (2018); RUSSO V., FABIANI D., LEONARDI S., ATTENA E., D'ALTERIO G., COTTICELLI C., RAGO A., SARPA S., MAIONE B., D'ONOFRIO A., ET AL., DUAL PATHWAY INHIBITION WITH RIVAROXABAN AND ASPIRIN REDUCES INFLAMMATORY BIOMARKERS IN ATHEROSCLEROSIS, J. CARDIOVASC. PHARMACOL, 81, PP. 129-133, (2023); CARDILLO G., VIGGIANO G.V., RUSSO V., MANGIACAPRA S., CAVALLI A., CASTALDO G., AGRUSTA F., BELLIZZI A., AMITRANO M., IANNUZZO M., ET AL., ANTITHROMBOTIC AND ANTI-INFLAMMATORY EFFECTS OF FONDAPARINUX AND ENOXAPARIN IN HOSPITALIZED COVID-19 PATIENTS: THE FONDENOXAVID STUDY, J. BLOOD MED, 12, PP. 69-75, (2021); CONTE M., PETRAGLIA L., CAMPANA P., GERUNDO G., CARUSO A., GRIMALDI M.G., RUSSO V., ATTENA E., LEOSCO D., PARISI V., THE ROLE OF INFLAMMATION AND METABOLIC RISK FACTORS IN THE PATHOGENESIS OF CALCIFIC AORTIC VALVE STENOSIS, AGING CLIN. EXP. RES, 33, PP. 1765-1770, (2021); CONTE M., PETRAGLIA L., POGGIO P., VALERIO V., CABARO S., CAMPANA P., COMENTALE G., ATTENA E., RUSSO V., PILATO E., ET AL., INFLAMMATION AND CARDIOVASCULAR DISEASES IN THE ELDERLY: THE ROLE OF EPICARDIAL ADIPOSE TISSUE, FRONT. MED, 9, (2022); CASO V.M., MANZO V., PECCHILLO CIMMINO T., CONTI V., CASO P., ESPOSITO G., RUSSO V., FILIPPELLI A., AMMENDOLA R., CATTANEO F., REGULATION OF INFLAMMATION AND OXIDATIVE STRESS BY FORMYL PEPTIDE RECEPTORS IN CARDIOVASCULAR DISEASE PROGRESSION, LIFE, 11, (2021); RUSSO V., FABIANI D., PUT OUT THE FIRE: THE PLEIOTROPIC ANTI-INFLAMMATORY ACTION OF NON-VITAMIN K ORAL ANTICOAGULANTS, PHARMACOL. RES, 182, (2022); RUSSO V., FALCO L., TESSITORE V., MAURIELLO A., CATAPANO D., NAPOLITANO N., TARIQ M., CATURANO A., CICCARELLI G., D'ANDREA A., ET AL., ANTI-INFLAMMATORY AND ANTICANCER EFFECTS OF ANTICOAGULANT THERAPY IN PATIENTS WITH MALIGNANCY, LIFE, 13, (2023); VIGNA G.B., COSTANTINI F., ALDINI G., CARINI M., CATAPANO A., SCHENA F., TANGERINI A., ZANCA R., BOMBARDELLI E., MORAZZONI P., ET AL., EFFECT OF A STANDARDIZED GRAPE SEED EXTRACT ON LOW-DENSITY LIPOPROTEIN SUSCEPTIBILITY TO OXIDATION IN HEAVY SMOKERS, METABOLISM, 52, PP. 1250-1257, (2003); EVANS M., WILSON D., GUTHRIE N., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PILOT STUDY TO EVALUATE THE EFFECT OF WHOLE GRAPE EXTRACT ON ANTIOXIDANT STATUS AND LIPID PROFILE, J. FUNCT. FOODS, 7, PP. 680-691, (2014); KAR P., LAIGHT D., ROOPRAI H.K., SHAW K.M., CUMMINGS M., EFFECTS OF GRAPE SEED EXTRACT IN TYPE 2 DIABETIC SUBJECTS AT HIGH CARDIOVASCULAR RISK: A DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL EXAMINING METABOLIC MARKERS, VASCULAR TONE, INFLAMMATION, OXIDATIVE STRESS AND INSULIN SENSITIVITY, DIABET. MED, 26, PP. 526-531, (2009); URSINI F., TUBARO F., RONG J., SEVANIAN A., OPTIMIZATION OF NUTRITION: POLYPHENOLS AND VASCULAR PROTECTION, NUTR. REV, 57, PP. 241-249, (1999); GABETTA B., FUZZATI N., GRIFFINI A., LOLLA E., PACE R., RUFFILLI T., PETERLONGO F., CHARACTERIZATION OF PROANTHOCYANIDINS FROM GRAPE SEEDS, FITOTERAPIA, 71, PP. 162-175, (2000); MAO J.T., SMOAKE J., PARK H.K., LU Q.Y., XUE B., GRAPE SEED PROCYANIDIN EXTRACT MEDIATES ANTINEOPLASTIC EFFECTS AGAINST LUNG CANCER VIA MODULATIONS OF PROSTACYCLIN AND 15-HETE EICOSANOID PATHWAYS, CANCER PREV. RES, 9, PP. 925-932, (2016); NIKI E., DO FREE RADICALS PLAY CAUSAL ROLE IN ATHEROSCLEROSIS? LOW DENSITY LIPOPROTEIN OXIDATION AND VITAMIN E REVISITED, J. CLIN. BIOCHEM. NUTR, 48, (2011); MACH F., BAIGENT C., CATAPANO A.L., KOSKINAS K.C., CASULA M., BADIMON L., CHAPMAN M.J., DE BACKER G.G., DELGADO V., FERENCE B.A., ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR. HEART J, 41, PP. 111-188, (2020)","V. RUSSO; CARDIOLOGY UNIT, DEPARTMENT OF MEDICAL TRANSLATIONAL SCIENCES, UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”, MONALDI HOSPITAL, NAPLES, 80131, ITALY; EMAIL: VINCENZO.RUSSO@UNICAMPANIA.IT","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","PHARMACEUTICALS","ARTICLE","ISI","2-S2.0-85191484945","PHARMACEUTICALS","UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”;UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”;UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”;MONALDI HOSPITAL;MONALDI HOSPITAL;PRESIDIO OSPEDALIERO SANTA MARIA DELLE GRAZIE;UNIVERSITY OF MESSINA;UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”;UMBERTO I HOSPITAL;UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”;UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”","NOTREPORTED;UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”;NOTREPORTED",NA,"RUSSO V, 2024, PHARMACEUTICALS","RUSSO V, 2024, PHARMACEUTICALS"
"CHO K;KIM J;BAEK S","CHO, KYUNG-HYUN (7403956966); KIM, JI-EUN (57881093800); BAEK, SEUNG HEE (58120142000)","CUBAN POLICOSANOL RAYDEL POTENTLY PROTECTS THE LIVER OVARY AND TESTIS WITH AN IMPROVEMENT IN DYSLIPIDEMIA IN HYPERLIPIDEMIC ZEBRAFISH A COMPARATIVE STUDY WITH THREE CHINESE POLICOSANOLS",2023,"MOLECULES","28","",3,"10.3390/molecules28186609","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA","MANY POLICOSANOLS FROM DIFFERENT SOURCES, SUCH AS SUGAR CANE AND RICE BRAN, HAVE BEEN MARKETED WORLDWIDE TO IMPROVE BLOOD LIPID PROFILES. BUT SO FAR, NO COMPARATIVE STUDY HAS COMMENCED ELUCIDATING THE EFFECT OF DIFFERENT POLICOSANOLS TO IMPROVE THE BLOOD LIPID PROFILE AND OTHER BENEFICIAL EFFECTS. THIS STUDY COMPARED THE EFFICACY OF FOUR DIFFERENT POLICOSANOLS, INCLUDING ONE SUGAR CANE WAX ALCOHOL FROM CUBA (RAYDEL®) AND THREE POLICOSANOLS FROM CHINA (XI’AN NATURAL SUGAR CANE, XI’AN REALIN SUGAR CANE, AND SHAANXI RICE BRAN), TO TREAT DYSLIPIDEMIA IN HYPERLIPIDEMIC ZEBRAFISH. AFTER 12 WEEKS OF CONSUMPTION OF EACH POLICOSANOL (FINAL 0.1% IN DIET, WT/WT) AND A HIGH-CHOLESTEROL DIET (HCD, FINAL 4%, WT/WT), THE RAYDEL POLICOSANOL GROUP AND THE XI’AN NATURAL POLICOSANOL GROUP SHOWED THE HIGHEST SURVIVABILITY, OF APPROXIMATELY 81%. IN CONTRAST, THE XI’AN REALIN POLICOSANOL AND THE SHAANXI POLICOSANOL GROUPS SHOWED 57% AND 67% SURVIVABILITY, RESPECTIVELY. AMONG THE FIVE HCD GROUPS, THE RAYDEL POLICOSANOL GROUP SHOWED THE LOWEST SERUM TOTAL CHOLESTEROL (TC, P < 0.001 VERSUS HCD CONTROL) AND TRIGLYCERIDE (P < 0.001 VERSUS HCD CONTROL), WITH THE HIGHEST PERCENTAGE OF HIGH-DENSITY LIPOPROTEINS-CHOLESTEROL IN TC. THE RAYDEL POLICOSANOL GROUP ALSO SHOWED THE LOWEST SERUM ASPARTATE AMINOTRANSFERASE AND ALANINE AMINOTRANSFERASE LEVELS, WITH THE LEAST INFILTRATION OF INFLAMMATORY CELLS AND INTERLEUKIN-6 PRODUCTION IN HEPATOCYTES WITH A MARKED REDUCTION IN REACTIVE OXYGEN SPECIES (ROS) PRODUCTION AND FATTY LIVER CHANGES. IN THE OVARY, THE RAYDEL POLICOSANOL GROUP ALSO SHOWED THE HIGHEST CONTENT OF MATURE VITELLOGENIC OOCYTES WITH THE LOWEST PRODUCTION OF REACTIVE OXYGEN SPECIES AND CELLULAR APOPTOSIS IN OVARIAN CELLS. IN THE TESTES, THE RAYDEL POLICOSANOL GROUP ALSO SHOWED THE HEALTHIEST MORPHOLOGY FOR SPERMATOGENESIS, WITH THE LOWEST INTERSTITIAL AREA AND REACTIVE OXYGEN SPECIES PRODUCTION IN TESTICULAR CELLS. CONCLUSIVELY, AMONG THE TESTED POLICOSANOLS, CUBA (RAYDEL®) POLICOSANOL EXHIBITED A COMPARATIVELY BETTER EFFECT IN MAINTAINING ZEBRAFISH BODY WEIGHT, SURVIVABILITY, BLOOD LIPID PROFILE, HEPATIC FUNCTION BIOMARKERS, FATTY LIVER CHANGES, ROS GENERATION, INFLAMMATION, AND RESTORATION OF THE CELL MORPHOLOGY IN OVARIES AND TESTES AFFECTED BY THE HCD CONSUMPTION. © 2023 BY THE AUTHORS.","APOA-I; HIGH-CHOLESTEROL DIET; HIGH-DENSITY LIPOPROTEINS; INFLAMMATION; INTERLEUKIN-6; LIVER; OVARY; POLICOSANOL; TESTIS","ANIMALS; CHOLESTEROL; DYSLIPIDEMIAS; FATTY ALCOHOLS; FATTY LIVER; FEMALE; MALE; OVARY; REACTIVE OXYGEN SPECIES; TESTIS; ZEBRAFISH; CHOLESTEROL; FATTY ALCOHOL; POLICOSANOL; REACTIVE OXYGEN METABOLITE; ANIMAL; DYSLIPIDEMIA; FATTY LIVER; FEMALE; MALE; OVARY; TESTIS; ZEBRA FISH","","","CHO K.-H., THE CURRENT STATUS OF RESEARCH ON HIGH-DENSITY LIPOPROTEINS (HDL): A PARADIGM SHIFT FROM HDL QUANTITY TO HDL QUALITY AND HDL FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); MILMAN S., ATZMON G., CRANDALL J., BARZILAI N., PHENOTYPES AND GENOTYPES OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN EXCEPTIONAL LONGEVITY, CURR. VASC. PHARMACOL, 12, PP. 690-697, (2014); GOTTO A.M., LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AS A RISK FACTOR IN CORONARY HEART DISEASE: A WORKING GROUP REPORT, CIRCULATION, 103, PP. 2213-2218, (2001); FRANCZYK B., GLUBA-BRZOZKA A., CIALKOWSKA-RYSZ A., LAWINSKI J., RYSZ J., THE IMPACT OF AEROBIC EXERCISE ON HDL QUANTITY AND QUALITY: A NARRATIVE REVIEW, INT. J. MOL. SCI, 24, (2023); TANGVARASITTICHAI S., OXIDATIVE STRESS, INSULIN RESISTANCE, DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, WORLD J. DIABETES, 6, PP. 456-480, (2015); CIPRIANI S., SIMON J.A., SEXUAL DYSFUNCTION AS A HARBINGER OF CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN: HOW FAR ARE WE?, J. SEX. MED, 19, PP. 1321-1332, (2022); NIKOOBAKHT M., POURKASMAEE M., NASSEH H., THE RELATIONSHIP BETWEEN LIPID PROFILE AND ERECTILE DYSFUNC-TION, UROL. J, 2, PP. 40-44, (2005); VERIT F.F., ZEYREK F.Y., ZEBITAY A.G., AKYOL H., CARDIOVASCULAR RISK MAY BE INCREASED IN WOMEN WITH UNEXPLAINED INFERTILITY, CLIN. EXP. REPROD. MED, 44, PP. 28-32, (2017); LUNA-CASTILLO K.P., LIN S., MUNOZ-VALLE J.F., VIZMANOS B., LOPEZ-QUINTERO A., MARQUEZ-SANDOVAL F., FUNCTIONAL FOOD AND BIOACTIVE COMPOUNDS ON THE MODULATION OF THE FUNCTIONALITY OF HDL-C: A NARRATIVE REVIEW, NUTRIENTS, 13, (2021); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED, 45, PP. 89-97, (2019); ARRUZAZABALA M., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES, 69, PP. 321-327, (1993); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., ALEMAN C., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES, 16, PP. 67-72, (1996); VENTURELLI A., BRIGHENTI V., MASCOLO D., PELLATI F., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL, 172, PP. 200-205, (2019); WONG W.T., ISMAIL M., TOHIT E.R., ABDULLAH R., ZHANG Y.-D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVID. -BASED COMPLEMENT. ALTERN. MED, 2016, (2016); ISHAKA A., UMAR IMAM M., MAHAMUD R., ZUKI A.B., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT. J. NANOMED, 9, PP. 2261-2269, (2014); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); CHO K.-H., KIM S.-J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED. CELL. LONGEV, 2018, (2018); LEE S., LEE G.S., MOON J.H., JUNG J., POLICOSANOL SUPPRESSES TUMOR PROGRESSION IN A GASTRIC CANCER XENOGRAFT MODEL, TOXICOL. RES, 38, PP. 567-575, (2022); KIM J.-H., LIM D.-K., SUH Y.-H., CHANG K.-A., LONG-TERM TREATMENT OF CUBAN POLICOSANOL ATTENUATES ABNORMAL OXIDATIVE STRESS AND INFLAMMATORY RESPONSE VIA AMYLOID PLAQUES REDUCTION IN 5XFAD MICE, ANTIOXIDANTS, 10, (2021); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI, 24, (2023); LI X., ZHOU L., ZHENG Y., HE T., GUO H., LI J., ZHANG J., ESTABLISHMENT OF A NON-ALCOHOLIC FATTY LIVER DISEASE MODEL BY HIGH FAT DIET IN ADULT ZEBRAFISH, ANIM. MODELS EXP. MED, (2023); FANG L., LIU C., MILLER Y.I., ZEBRAFISH MODELS OF DYSLIPIDEMIA: RELEVANCE TO ATHEROSCLEROSIS AND ANGIOGENESIS, TRANSL. RES. J. LAB. CLIN. MED, 163, PP. 99-108, (2014); STOLETOV K., FANG L., CHOI S.-H., HARTVIGSEN K., HANSEN L.F., HALL C., PATTISON J., JULIANO J., MILLER E.R., ALMAZAN F., ET AL., VASCULAR LIPID ACCUMULATION, LIPOPROTEIN OXIDATION, AND MACROPHAGE LIPID UPTAKE IN HYPERCHOLESTEROLEMIC ZEBRAFISH, CIRC. RES, 104, PP. 952-960, (2009); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); AYAD B., OMOLAOYE T.S., LOUW N., RAMSUNDER Y., SKOSANA B.T., OYEIPO P.I., DU PLESSIS S.S., OXIDATIVE STRESS AND MALE INFERTILITY: EVIDENCE FROM A RESEARCH PERSPECTIVE, FRONT. REPROD. HEALTH, 4, (2022); GAO Y., ZOU Y., WU G., ZHENG L., OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION OF GRANULOSA CELLS IN POLYCYSTIC OVARIAN SYNDROME, FRONT. MED, 10, (2023); SU Y., HE L., HU Z., LI Y., ZHANG Y., FAN Z., ZHAO K., ZHANG H., LIU C., OBESITY CAUSES ABRUPT CHANGES IN THE TESTICULAR MICROBIOTA AND SPERM MOTILITY OF ZEBRAFISH, FRONT. IMMUNOL, 12, (2021); KNAUFF E.A., WESTERVELD H.E., GOVERDE A.J., EIJKEMANS M.J., VALKENBURG O., VAN SANTBRINK E.J., FAUSER B.C., VAN DER SCHOUW Y.T., LIPID PROFILE OF WOMEN WITH PREMATURE OVARIAN FAILURE, MENOPAUSE, 15, PP. 919-923, (2008); WHITFIELD M., GUITON R., RISPAL J., ACAR N., KOCER A., DREVET J.R., SAEZ F., DYSLIPIDEMIA ALTERS SPERM MATURATION AND CAPACITATION IN LXR-NULL MICE, REPRODUCTION, 154, PP. 827-842, (2017); CHO K.-H., KIM J.-E., KOMATSU T., UEHARA Y., PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED STUDY WITH HEALTHY AND MIDDLE-AGED JAPANESE PARTICIPANTS, LIFE, 13, (2023); CHO K.-H., NAM H.-S., BAEK S.-H., KANG D.-J., NA H., KOMATSU T., UEHARA Y., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT. J. MOL. SCI, 24, (2023); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., DIAZ E., FERNANDEZ L., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES, 57, PP. 568-577, (1996); YAN F., ZHAO Q., LI Y., ZHENG Z., KONG X., SHU C., LIU Y., SHI Y., THE ROLE OF OXIDATIVE STRESS IN OVARIAN AGING: A REVIEW, J. OVARIAN RES, 15, (2022); LEE E.-Y., CHO K.-H., HIGH-DOSE CONSUMPTION OF NACL RESULTED IN SEVERE DEGRADATION OF LIPOPROTEINS ASSOCIATED WITH HYPERLIPIDEMIA, HYPERGLYCEMIA, AND INFERTILITY VIA IMPAIRMENT OF TESTICULAR SPERMATOGENESIS, TOXICOL. RES, 5, PP. 557-569, (2016); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL. LETT, 90, PP. 97-106, (1997); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG. CARCINOG. MUTAGEN, 14, PP. 107-113, (1994); LONG L., WU S., SUN J., WANG J., ZHANG H., QI G., EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON BLOOD HORMONE LEVELS AND GENE EXPRESSIONS OF GLUCOSE TRANSPORTER PROTEIN-4 AND ADENOSINE MONOPHOSPHATE PROTEIN KINASE IN WEANING PIGLETS, ANIM. NUTR, 1, PP. 293-298, (2015); KLISIC A., ISAKOVIC A., KOCIC G., KAVARIC N., JOVANOVIC M., ZVRKO E., SKEROVIC V., NINIC A., RELATIONSHIP BETWEEN OXIDATIVE STRESS, INFLAMMATION AND DYSLIPIDEMIA WITH FATTY LIVER INDEX IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, EXP. CLIN. ENDOCRINOL. DIABETES OFF. J. GER. SOC. ENDOCRINOL. GER. DIABETES ASSOC, 126, PP. 371-378, (2018); NOA M., MAS R., MENDOZA S., GAMEZ R., MENDOZA N., GONZALEZ J., POLICOSANOL PREVENTS BONE LOSS IN OVARIECTOMIZED RATS, DRUGS UNDER EXP. CLIN. RES, 30, PP. 117-123, (2004); KIM K.M., LIM Y.J., JANG W.G., POLICOSANOL STIMULATES OSTEOBLAST DIFFERENTIATION VIA ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE-MEDIATED EXPRESSION OF INSULIN-INDUCED GENES 1 AND 2, CELLS, 12, (2023); ZHAI Z., LIU J., NIU K.-M., LIN C., TU Y., LIU Y., CAI L., LIU H., OUYANG K., INTEGRATED METAGENOMICS AND METABOLOMICS TO REVEAL THE EFFECTS OF POLICOSANOL ON MODULATING THE GUT MICROBIOTA AND LIPID METABOLISM IN HYPERLIPIDEMIC C57BL/6 MICE, FRONT. ENDOCRINOL, 12, (2021); GONNELLA F., KONSTANTINIDOU F., DI BERARDINO C., CAPACCHIETTI G., PESERICO A., RUSSO V., BARBONI B., STUPPIA L., GATTA V., A SYSTEMATIC REVIEW OF THE EFFECTS OF HIGH-FAT DIET EXPOSURE ON OOCYTE AND FOLLICULAR QUALITY: A MOLECULAR POINT OF VIEW, INT. J. MOL. SCI, 23, (2022); RUEBEL M.L., COTTER M., SIMS C.R., MOUTOS D.M., BADGER T.M., CLEVES M.A., SHANKAR K., ANDRES A., OBESITY MODULATES INFLAMMATION AND LIPID METABOLISM OOCYTE GENE EXPRESSION: A SINGLE-CELL TRANSCRIPTOME PERSPECTIVE, J. CLIN. ENDOCRINOL. METAB, 102, PP. 2029-2038, (2017); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS, 17, (2018); NUSSLEIN-VOLHARD C., DAHM R., ZEBRAFISH: A PRACTICAL APPROACH, (2002); GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS, (2010); PERCIE DU SERT N., HURST V., AHLUWALIA A., ALAM S., AVEY M.T., BAKER M., BROWNE W.J., CLARK A., CUTHILL I.C., DIRNAGL U., ET AL., THE ARRIVE GUIDELINES 2.0: UPDATED GUIDELINES FOR REPORTING ANIMAL RESEARCH, PLOS BIOL, 18, (2020); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT. GENET, 40, PP. 356-361, (2008); PATEL U.N., PATEL U.D., KHADAYATA A.V., VAJA R.K., MODI C.M., PATEL H.B., LONG-TERM EXPOSURE OF THE BINARY MIXTURE OF CADMIUM AND MERCURY DAMAGES THE DEVELOPED OVARY OF ADULT ZEBRAFISH, ENVIRON. SCI. POLLUT. RES. INT, 29, PP. 44928-44938, (2022); SUTHA J., ANILA P.A., GAYATHRI M., RAMESH M., LONG TERM EXPOSURE TO TRIS (2-CHLOROETHYL) PHOSPHATE (TCEP) CAUSES ALTERATIONS IN REPRODUCTIVE HORMONES, VITELLOGENIN, ANTIOXIDANT ENZYMES, AND HISTOLOGY OF GONADS IN ZEBRAFISH (DANIO RERIO): IN VIVO AND COMPUTATIONAL ANALYSIS, COMP. BIOCHEM. PHYSIOL. TOXICOL. PHARMACOL. CBP, 254, (2022); SABALIAUSKAS N.A., FOUTZ C.A., MEST J.R., BUDGEON L.R., SIDOR A.T., GERSHENSON J.A., JOSHI S.B., CHENG K.C., HIGH-THROUGHPUT ZEBRAFISH HISTOLOGY, METHODS, 39, PP. 246-254, (2006); KOC N.D., TEKSOZ N., URAL M., AKBULUT C., HISTOLOGICAL STRUCTURE OF ZEBRAFISH (DANIO RERIO, HAM-ILTON, 1822) TESTICLES, ELIXIR AQUACULT, 46, PP. 8117-8120, (2012)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","MOLECULES","ARTICLE","ISI","2-S2.0-85172761895","MOLECULES","RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2023, MOLECULES","CHO K-H, 2023, MOLECULES"
"ROY G;BOUCHER A;COUTURE P;DROUIN-CHARTIER J","ROY, GABRIELLE (57221764031); BOUCHER, ANYKIM (59051654400); COUTURE, PATRICK (57203202356); DROUIN-CHARTIER, JEAN-PHILIPPE (56397170200)","IMPACT OF DIET ON PLASMA LIPIDS IN INDIVIDUALS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED NUTRITIONAL STUDIES",2021,"NUTRIENTS","13","14",10,"10.3390/nu13010235","CENTRE NUTRITION, SANTÉ ET SOCIÉTÉ (NUTRISS), INSTITUT SUR LA NUTRITION ET LES ALIMENTS FONCTIONNELS (INAF), UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, QC, CANADA;CENTRE NUTRITION, SANTÉ ET SOCIÉTÉ (NUTRISS), INSTITUT SUR LA NUTRITION ET LES ALIMENTS FONCTIONNELS (INAF), UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, QC, CANADA;CENTRE NUTRITION, SANTÉ ET SOCIÉTÉ (NUTRISS), INSTITUT SUR LA NUTRITION ET LES ALIMENTS FONCTIONNELS (INAF), UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, QC, CANADA, CENTRE DE RECHERCHE DU CHU DE QUÉBEC-UNIVERSITÉ LAVAL, QUÉBEC, G1V 4G2, QC, CANADA;CENTRE NUTRITION, SANTÉ ET SOCIÉTÉ (NUTRISS), INSTITUT SUR LA NUTRITION ET LES ALIMENTS FONCTIONNELS (INAF), UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, QC, CANADA, FACULTÉ DE PHARMACIE, UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, QC, CANADA","BACKGROUND: CONCLUSIVE DATA ON THE EFFECTIVENESS OF DIETARY INTERVENTIONS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) MANAGEMENT ARE UNAVAILABLE. WHETHER THIS IS DUE TO A TRUE LACK OF EFFECTS OR BIASES IN INTERVENTION DESIGNS REMAINS UNSETTLED. WE SYSTEMATICALLY ASSESSED THE IMPACT ON LDL-C OF PUBLISHED DIETARY RANDOMIZED CONTROLLED TRIALS (RCTS) CONDUCTED AMONG INDIVIDUALS WITH HEFH IN RELATION TO THEIR DESIGN AND RISK OF BIAS. METHODS: WE SYSTEMATICALLY SEARCHED PUBMED, WEB OF SCIENCE, AND EMBASE IN NOVEMBER 2020 TO IDENTIFY RCTS THAT ASSESSED THE IMPACT OF: (1) FOOD-BASED INTERVENTIONS; (2) DIETARY COUNSELING INTERVENTIONS; OR (3) DIETARY SUPPLEMENTS ON LDL-C IN INDIVIDUALS WITH HEFH. WE EVALUATED THE RISK OF BIAS OF EACH STUDY USING THE COCHRANE RISK OF BIAS 2 METHOD. RESULTS: A TOTAL OF 19 RCTS COMPRISING 837 INDIVIDUALS WITH HEFH WERE INCLUDED. OF THOSE, FIVE WERE FOOD-BASED INTERVENTIONS, THREE WERE DIETARY COUNSELING INTERVENTIONS AND 12 WERE DIETARY SUPPLEMENT-BASED INTERVENTIONS (OMEGA-3, N = 3; PHYTOSTEROLS, N = 7; GUAR GUM, N = 1; POLICOSANOL, N = 1). ONE STUDY QUALIFIED BOTH AS A FOOD-BASED INTERVENTION AND AS A DIETARY SUPPLEMENT INTERVENTION DUE TO ITS FACTORIAL DESIGN. A SIGNIFICANT REDUCTION IN LDL-C LEVELS WAS REPORTED IN 10 RCTS, INCLUDING EIGHT DIETARY SUPPLEMENT INTERVENTIONS (PHYTOSTEROLS, N = 6, OMEGA-3, N = 1; GUAR GUM, N = 1), ONE FOOD-BASED INTERVENTION AND ONE DIETARY COUNSELING INTERVENTION. A TOTAL OF 13 STUDIES WERE JUDGED TO HAVE SOME METHODOLOGICAL BIASES IN A WAY THAT SUBSTANTIALLY LOWERS CONFIDENCE IN THE RESULTS. STUDIES AT LOW RISK OF BIASES WERE MORE LIKELY TO REPORT SIGNIFICANT REDUCTIONS IN LDL-C CONCENTRATIONS, COMPARED WITH STUDIES AT RISK OF BIAS (CHI-SQUARE STATISTIC: 5.49; P = 0.02). CONCLUSION: THIS SYSTEMIC REVIEW SHOWS THAT THE APPARENT LACK OF EFFECTIVENESS OF DIET MANIPULATION IN MODULATING PLASMA LEVELS OF LDL-C AMONG INDIVIDUALS WITH HEFH IS LIKELY DUE TO BIASES IN STUDY DESIGNS, RATHER THAN A TRUE LACK OF EFFECTS. THE LIKELIHOOD OF REPORTING SIGNIFICANT REDUCTIONS IN LDL-C WAS ASSOCIATED WITH THE CONCURRENT RISK OF BIAS. © 2021 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","DIET; DIETARY SUPPLEMENT; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD; INTERVENTION; NUTRIENTS; SYSTEMATIC REVIEW","ADOLESCENT; ADULT; AGED; CHILD; CHOLESTEROL, LDL; COUNSELING; DIET; DIETARY SUPPLEMENTS; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; PUBLICATION BIAS; GUAR GUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; TRIACYLGLYCEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; CHILD; CHOLESTEROL BLOOD LEVEL; COCHRANE LIBRARY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; EMBASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HUMAN; MALE; MEDLINE; META ANALYSIS; NUTRITIONAL COUNSELING; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEB OF SCIENCE; ADOLESCENT; AGED; BLOOD; COUNSELING; DIET; FAMILIAL HYPERCHOLESTEROLEMIA; GENETICS; HETEROZYGOTE; MIDDLE AGED; PUBLISHING","","","BRUNHAM L.R., RUEL I., ALJENEDIL S., RIVIERE J.B., BAASS A., TU J.V., MANCINI G.B.J., RAGGI P., GUPTA M., COUTURE P., ET AL., CANADIAN CARDIOVASCULAR SOCIETY POSITION STATEMENT ON FAMILIAL HYPERCHOLESTEROLEMIA: UPDATE 2018, CAN. J. CARDIOL, 34, PP. 1553-1563, (2018); BOREN J., CHAPMAN M.J., KRAUSS R.M., PACKARD C.J., BENTZON J.F., BINDER C.J., DAEMEN M.J., DEMER L.L., HEGELE R.A., NICHOLLS S.J., ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: PATHOPHYSIOLOGICAL, GENETIC, AND THERAPEUTIC INSIGHTS: A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR. HEART J, 41, PP. 2313-2330, (2020); KHERA A.V., WON H.-H., PELOSO G.M., LAWSON K.S., BARTZ T.M., DENG X., VAN LEEUWEN E.M., NATARAJAN P., EMDIN C.A., BICK A.G., ET AL., DIAGNOSTIC YIELD AND CLINICAL UTILITY OF SEQUENCING FAMILIAL HYPERCHOLESTEROLEMIA GENES IN PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA, J. AM. COLL. CARDIOL, 67, PP. 2578-2589, (2016); HU P., DHARMAYAT K.I., STEVENS C.A., SHARABIANI M.T., JONES R.S., WATTS G.F., GENEST J., RAY K.K., VALLEJO-VAZ A.J., PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA AMONG THE GENERAL POPULATION AND PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, CIRCULATION, 141, PP. 1742-1759, (2020); GIDDING S.S., SPECIAL COMMENTARY: IS DIET MANAGEMENT HELPFUL IN FAMILIAL HYPERCHOLESTEROLEMIA?, CURR. OPIN. CLIN. NUTR. METAB. CARE, 22, PP. 135-140, (2019); MALHOTRA A., SHAFIQ N., ARORA A., SINGH M., KUMAR R., MALHOTRA S., DIETARY INTERVENTIONS (PLANT STEROLS, STANOLS, OMEGA-3 FATTY ACIDS, SOY PROTEIN AND DIETARY FIBERS) FOR FAMILIAL HYPERCHOLESTEROLAEMIA, COCHRANE DATABASE SYST. REV, 2014, (2014); BARKAS F., NOMIKOS T., LIBEROPOULOS E., PANAGIOTAKOS D., DIET AND CARDIOVASCULAR DISEASE RISK AMONG INDIVIDUALS WITH FAMILIAL HYPERCHOLESTEROLEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS, NUTRIENTS, 12, (2020); GARDNER C.D., CRIMARCO A., LANDRY M.J., FIELDING-SINGH P., NUTRITION STUDY DESIGN ISSUES-IMPORTANT ISSUES FOR INTERPRETATION, AM. J. HEALTH PROMOT, 34, PP. 951-954, (2020); DESROCHES S., LAPOINTE A., RATTE S., GRAVEL K., LEGARE F., TURCOTTE S., INTERVENTIONS TO ENHANCE ADHERENCE TO DIETARY ADVICE FOR PREVENTING AND MANAGING CHRONIC DISEASES IN ADULTS, COCHRANE DATABASE SYST. REV, (2013); RAUTIAINEN S., SESSO H.D., MANSON J.E., LARGE-SCALE RANDOMIZED CLINICAL TRIALS OF BIOACTIVES AND NUTRIENTS IN RELATION TO HUMAN HEALTH AND DISEASE PREVENTION—LESSONS FROM THE VITAL AND COSMOS TRIALS, MOL. ASP. MED, 61, PP. 12-17, (2018); MOZAFFARIAN D., LUDWIG D.S., DIETARY GUIDELINES IN THE 21ST CENTURY—A TIME FOR FOOD, JAMA, 304, PP. 681-682, (2010); MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES: THE PRISMA STATEMENT, BMJ, 339, (2009); STERNE J.A.C., SAVOVIC J., PAGE M.J., ELBERS R.G., BLENCOWE N.S., BOUTRON I., CATES C.J., CHENG H.Y., CORBETT M.S., ELDRIDGE S.M., ET AL., ROB 2: A REVISED TOOL FOR ASSESSING RISK OF BIAS IN RANDOMISED TRIALS, BMJ, 366, (2019); HANDE L.N., THUNHAUG H., ENEBAKK T., LUDVIKSEN J., PETTERSEN K., HOVLAND A., LAPPEGARD K.T., ADDITION OF MARINE OMEGA-3 FATTY ACIDS TO STATINS IN FAMILIAL HYPERCHOLESTEROLEMIA DOES NOT AFFECT IN VIVO OR IN VITRO ENDOTHELIAL FUNCTION, J. CLIN. LIPIDOL, 13, PP. 762-770, (2019); GUSTAFSSON I.B., BOBERG J., KARLSTROM B., LITHELL H., VESSBY B., SIMILAR SERUM LIPOPROTEIN REDUCTIONS BY LIPID-LOWERING DIETS WITH DIFFERENT POLYUNSATURATED:SATURATED FAT VALUES, BR. J. NUTR, 50, PP. 531-537, (1983); FRIDAY K.E., FAILOR R.A., CHILDS M.T., BIERMAN E.L., EFFECTS OF N-3 AND N-6 FATTY ACID-ENRICHED DIETS ON PLASMA LIPOPROTEINS AND APOLIPOPROTEINS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ARTERIOSCLER. THROMB, 11, PP. 47-54, (1991); LAURIN D., JACQUES H., MOORJANI S., STEINKE F.H., GAGNE C., BRUN D., LUPIEN P.J., EFFECTS OF A SOY-PROTEIN BEVERAGE ON PLASMA LIPOPROTEINS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, AM. J. CLIN. NUTR, 54, PP. 98-103, (1991); WOLFE B.M., GIOVANNETTI P.M., HIGH PROTEIN DIET COMPLEMENTS RESIN THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA, CLIN. INVESTIG. MED. MED. CLIN. EXP, 15, PP. 349-359, (1992); FUENTES F., LOPEZ-MIRANDA J., GARCIA A., PEREZ-MARTINEZ P., MORENO J., COFAN M., CABALLERO J., PANIAGUA J.A., ROS E., PEREZ-JIMENEZ F., BASAL PLASMA CONCENTRATIONS OF PLANT STEROLS CAN PREDICT LDL-C RESPONSE TO SITOSTEROL IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA, EUR. J. CLIN. NUTR, 62, PP. 495-501, (2008); CHISHOLM A., SUTHERLAND W., BALL M., THE EFFECT OF DIETARY FAT CONTENT ON PLASMA NONCHOLESTEROL STEROL CONCENTRATIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH SIMVASTATIN, METABOLISM, 43, PP. 310-314, (1994); BROEKHUIZEN K., VAN POPPEL M.N., KOPPES L.L., KINDT I., BRUG J., VAN MECHELEN W., NO SIGNIFICANT IMPROVEMENT OF CARDIOVASCULAR DISEASE RISK INDICATORS BY A LIFESTYLE INTERVENTION IN PEOPLE WITH FAMILIAL HYPERCHOLESTEROLEMIA COMPARED TO USUAL CARE: RESULTS OF A RANDOMISED CONTROLLED TRIAL, BMC RES. NOTES, 5, (2012); HELK O., WIDHALM K., EFFECTS OF A LOW-FAT DIETARY REGIMEN ENRICHED WITH SOY IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, CLIN. NUTR. ESPEN, 36, PP. 150-156, (2020); BALESTRIERI G.P., MAFFI V., SLEIMAN I., SPANDRIO S., DI STEFANO O., SALVI A., SCALVINI T., FISH OIL SUPPLEMENTATION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, RECENTI. PROG. MED, 87, PP. 102-105, (1996); CHAN D.C., PANG J., BARRETT P.H., SULLIVAN D.R., BURNETT J.R., VAN BOCKXMEER F.M., WATTS G.F., Ω-3 FATTY ACID ETHYL ESTERS DIMINISH POSTPRANDIAL LIPEMIA IN FAMILIAL HYPERCHOLESTEROLEMIA, J. CLIN. ENDOCRINOL. METAB, 101, PP. 3732-3739, (2016); GYLLING H., SIIMES M.A., MIETTINEN T.A., SITOSTANOL ESTER MARGARINE IN DIETARY TREATMENT OF CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, J. LIPID RES, 36, PP. 1807-1812, (1995); NEIL H.A.W., MEIJER G.W., ROE L.S., RANDOMISED CONTROLLED TRIAL OF USE BY HYPERCHOLESTEROLAEMIC PATIENTS OF A VEGETABLE OIL STEROL-ENRICHED FAT SPREAD, ATHEROSCLEROSIS, 156, PP. 329-337, (2001); AMUNDSEN A.L., OSE L., NENSETER M.S., NTANIOS F.Y., PLANT STEROL ESTER-ENRICHED SPREAD LOWERS PLASMA TOTAL AND LDL CHOLESTEROL IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, AM. J. CLIN. NUTR, 76, PP. 338-344, (2002); DE JONGH S., VISSERS M.N., ROL P., BAKKER H.D., KASTELEIN J.J., STROES E.S., PLANT STEROLS LOWER LDL CHOLESTEROL WITHOUT IMPROVING ENDOTHELIAL FUNCTION IN PREPUBERTAL CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA, J. INHERIT. METAB. DIS, 26, PP. 343-351, (2003); O'NEILL F.H., BRYNES A., MANDENO R., RENDELL N., TAYLOR G., SEED M., THOMPSON G.R., COMPARISON OF THE EFFECTS OF DIETARY PLANT STEROL AND STANOL ESTERS ON LIPID METABOLISM, NUTR. METAB. CARDIOVASC. DIS, 14, PP. 133-142, (2004); JAKULJ L., VISSERS M.N., RODENBURG J., WIEGMAN A., TRIP M.D., KASTELEIN J.J.P., PLANT STANOLS DO NOT RESTORE ENDOTHELIAL FUNCTION IN PRE-PUBERTAL CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA DESPITE REDUCTION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, J. PEDIATR, 148, PP. 495-500, (2006); WIRTH A., MIDDELHOFF G., BRAEUNING C., SCHLIERF G., TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH A COMBINATION OF BEZAFIBRATE AND GUAR, ATHEROSCLEROSIS, 45, PP. 291-297, (1982); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR. J. NUTR, 95, PP. 968-975, (2006); SHAN Z., LI Y., BADEN M.Y., BHUPATHIRAJU S.N., WANG D.D., SUN Q., REXRODE K.M., RIMM E.B., QI L., WILLETT W.C., ET AL., ASSOCIATION BETWEEN HEALTHY EATING PATTERNS AND RISK OF CARDIOVASCULAR DISEASE, JAMA INTERN. MED, 180, PP. 1090-1100, (2020); BECHTHOLD A., BOEING H., SCHWEDHELM C., HOFFMANN G., KNUPPEL S., IQBAL K., DE HENAUW S., MICHELS N., DEVLEESSCHAUWER B., SCHLESINGER S., ET AL., FOOD GROUPS AND RISK OF CORONARY HEART DISEASE, STROKE AND HEART FAILURE: A SYSTEMATIC REVIEW AND DOSE-RESPONSE META-ANALYSIS OF PROSPECTIVE STUDIES, CRIT. REV. FOOD SCI. NUTR, 59, PP. 1071-1090, (2019); HEIANZA Y., ZHOU T., SUN D., HU F.B., MANSON J.E., QI L., GENETIC SUSCEPTIBILITY, PLANT-BASED DIETARY PATTERNS, AND RISK OF CARDIOVASCULAR DISEASE, AM. J. CLIN. NUTR, (2020); YOKOYAMA Y., LEVIN S.M., BARNARD N.D., ASSOCIATION BETWEEN PLANT-BASED DIETS AND PLASMA LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR. REV, 75, PP. 683-698, (2017); MENSINK R.P., KATAN M.B., EFFECT OF DIETARY FATTY ACIDS ON SERUM LIPIDS AND LIPOPROTEINS. A META-ANALYSIS OF 27 TRIALS, ARTERIOSCLER. THROMB, 12, PP. 911-919, (1992); MENSINK R.P., ZOCK P.L., KESTER A.D., KATAN M.B., EFFECTS OF DIETARY FATTY ACIDS AND CARBOHYDRATES ON THE RATIO OF SERUM TOTAL TO HDL CHOLESTEROL AND ON SERUM LIPIDS AND APOLIPOPROTEINS: A META-ANALYSIS OF 60 CONTROLLED TRIALS, AM. J. CLIN. NUTR, 77, PP. 1146-1155, (2003); ANTONIAZZI L., ARROYO-OLIVARES R., BITTENCOURT M.S., TADA M.T., LIMA I., JANNES C.E., KRIEGER J.E., PEREIRA A.C., QUINTANA NAVARRO G., MUNIZ-GRIJALVO O., ET AL., ASSOCIATION OF DIETARY COMPONENTS WITH DYSLIPIDEMIA AND LOW-GRADE INFLAMMATION BIOMARKERS IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FROM DIFFERENT COUNTRIES, EUR. J. CLIN. NUTR, 73, PP. 1622-1625, (2019); TORVIK K., NARVERUD I., OTTESTAD I., SVILAAS A., GRAN J.M., RETTERSTOL K., ELLINGVAG A., STROM E., OSE L., VEIEROD M.B., ET AL., DIETARY COUNSELING IS ASSOCIATED WITH AN IMPROVED LIPID PROFILE IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 252, PP. 21-27, (2016); RAS R.T., GELEIJNSE J.M., TRAUTWEIN E.A., LDL-CHOLESTEROL-LOWERING EFFECT OF PLANT STEROLS AND STANOLS ACROSS DIFFERENT DOSE RANGES: A META-ANALYSIS OF RANDOMISED CONTROLLED STUDIES, BR. J. NUTR, 112, PP. 214-219, (2014); BALK E.M., LICHTENSTEIN A.H., CHUNG M., KUPELNICK B., CHEW P., LAU J., EFFECTS OF OMEGA-3 FATTY ACIDS ON SERUM MARKERS OF CARDIOVASCULAR DISEASE RISK: A SYSTEMATIC REVIEW, ATHEROSCLEROSIS, 189, PP. 19-30, (2006); HEBERT J.R., FRONGILLO E.A., ADAMS S.A., TURNER-MCGRIEVY G.M., HURLEY T.G., MILLER D.R., OCKENE I.S., PERSPECTIVE: RANDOMIZED CONTROLLED TRIALS ARE NOT A PANACEA FOR DIET-RELATED RESEARCH, ADV. NUTR, 7, PP. 423-432, (2016); HU F.B., DIETARY PATTERN ANALYSIS: A NEW DIRECTION IN NUTRITIONAL EPIDEMIOLOGY, CURR. OPIN. LIPIDOL, 13, PP. 3-9, (2002); JANSEN A.C., VAN AALST-COHEN E.S., TANCK M.W., TRIP M.D., LANSBERG P.J., LIEM A.H., VAN LENNEP H.W., SIJBRANDS E.J., KASTELEIN J.J., THE CONTRIBUTION OF CLASSICAL RISK FACTORS TO CARDIOVASCULAR DISEASE IN FAMILIAL HYPERCHOLESTEROLAEMIA: DATA IN 2400 PATIENTS, J. INTERN. MED, 256, PP. 482-490, (2004); DROUIN-CHARTIER J.-P., TREMBLAY A.J., GODBOUT D., GAGNON A., CLAVEL M.-A., CLISSON M., ARSENAULT B.J., PIBAROT P., LAROSE E., COUTURE P., CORRELATES OF CORONARY ARTERY CALCIFICATION PREVALENCE AND SEVERITY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, CJC OPEN, (2020); SCHWINGSHACKL L., HOFFMANN G., DIET QUALITY AS ASSESSED BY THE HEALTHY EATING INDEX, THE ALTERNATE HEALTHY EATING INDEX, THE DIETARY APPROACHES TO STOP HYPERTENSION SCORE, AND HEALTH OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COHORT STUDIES, J. ACAD. NUTR. DIET, 115, PP. 780-800, (2015); MINAME M.H., BITTENCOURT M.S., MORAES S.R., ALVES R.I.M., SILVA P.R.S., JANNES C.E., PEREIRA A.C., KRIEGER J.E., NASIR K., SANTOS R.D., CORONARY ARTERY CALCIUM AND CARDIOVASCULAR EVENTS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA RECEIVING STANDARD LIPID-LOWERING THERAPY, JACC. CARDIOVASC. IMAGING, 12, PP. 1797-1804, (2019); VERSMISSEN J., OOSTERVEER D.M., YAZDANPANAH M., DEFESCHE J.C., BASART D.C., LIEM A.H., HEERINGA J., WITTEMAN J.C., LANSBERG P.J., KASTELEIN J.J., ET AL., EFFICACY OF STATINS IN FAMILIAL HYPERCHOLESTEROLAEMIA: A LONG TERM COHORT STUDY, BMJ, 337, (2008); LUIRINK I.K., WIEGMAN A., KUSTERS D.M., HOF M.H., GROOTHOFF J.W., DE GROOT E., KASTELEIN J.J.P., HUTTEN B.A., 20-YEAR FOLLOW-UP OF STATINS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, N. ENGL. J. MED, 381, PP. 1547-1556, (2019); DUELL P.B., GIDDING S.S., ANDERSEN R.L., KNICKELBINE T., ANDERSON L., GIANOS E., SHRADER P., KINDT I., O'BRIEN E.C., MCCANN D., ET AL., LONGITUDINAL LOW DENSITY LIPOPROTEIN CHOLESTEROL GOAL ACHIEVEMENT AND CARDIOVASCULAR OUTCOMES AMONG ADULT PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: THE CASCADE FH REGISTRY, ATHEROSCLEROSIS, 289, PP. 85-93, (2019); GALEMA-BOERS A.M., LENZEN M.J., ENGELKES S.R., SIJBRANDS E.J., ROETERS VAN LENNEP J.E., CARDIOVASCULAR RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING OPTIMAL LIPID-LOWERING THERAPY, J. CLIN. LIPIDOL, 12, PP. 409-416, (2018); PEREZ-CALAHORRA S., LACLAUSTRA M., MARCO-BENEDI V., LAMIQUIZ-MONEO I., PEDRO-BOTET J., PLANA N., SANCHEZ-HERNANDEZ R.M., AMOR A.J., ALMAGRO F., FUENTES F., ET AL., EFFECT OF LIPID-LOWERING TREATMENT IN CARDIOVASCULAR DISEASE PREVALENCE IN FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 284, PP. 245-252, (2019); KINNEAR F.J., WAINWRIGHT E., PERRY R., LITHANDER F.E., BAYLY G., HUNTLEY A., COX J., SHIELD J.P., SEARLE A., ENABLERS AND BARRIERS TO TREATMENT ADHERENCE IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: A QUALITATIVE EVIDENCE SYNTHESIS, BMJ OPEN, 9, (2019); HEALTH EFFECTS OF DIETARY RISKS IN 195 COUNTRIES, 1990–2017: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2017, LANCET, 393, PP. 1958-1972, (2019)","J.-P. DROUIN-CHARTIER; CENTRE NUTRITION, SANTÉ ET SOCIÉTÉ (NUTRISS), INSTITUT SUR LA NUTRITION ET LES ALIMENTS FONCTIONNELS (INAF), UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, CANADA; EMAIL: JEAN-PHILIPPE.DROUIN-CHARTIER@PHA.ULAVAL.CA; J.-P. DROUIN-CHARTIER; FACULTÉ DE PHARMACIE, UNIVERSITÉ LAVAL, QUÉBEC, G1V 0A6, CANADA; EMAIL: JEAN-PHILIPPE.DROUIN-CHARTIER@PHA.ULAVAL.CA","MDPI AG","ENGLISH","NUTRIENTS","REVIEW","ISI","2-S2.0-85100098541","NUTRIENTS","UNIVERSITÉ LAVAL;UNIVERSITÉ LAVAL;UNIVERSITÉ LAVAL;UNIVERSITÉ LAVAL","NOTREPORTED;UNIVERSITÉ LAVAL;NOTREPORTED;NOTREPORTED;UNIVERSITÉ LAVAL;NOTREPORTED",NA,"ROY G, 2021, NUTRIENTS","ROY G, 2021, NUTRIENTS"
"RA J;WOO S;LEE K;LEE M;KIM H;HAM H;CHUNG I;KIM D;LEE J;SEO W","RA, JI-EUN (42962383200); WOO, SO-YEUN (57214690592); LEE, KWANG-SIK (57891629000); LEE, MI JA (25823106900); KIM, HYUN YOUNG (36013294700); HAM, HYEON MI (54791049800); CHUNG, ILL-MIN (57010545800); KIM, DU HYUN (55575376400); LEE, JIN HWAN (36062793300); SEO, WOO DUCK (8921329600)","POLICOSANOL PROFILES AND ADENOSINE 5MONOPHOSPHATEACTIVATED PROTEIN KINASE AMPK ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME",2020,"FOOD CHEMISTRY","317","",12,"10.1016/j.foodchem.2020.126388","DEPARTMENT OF CROP SCIENCE, COLLEGE OF SANGHUH LIFE SCIENCE, KONKUK UNIVERSITY, SEOUL, 05029, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JELLABUK-DO, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JELLABUK-DO, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JELLABUK-DO, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JELLABUK-DO, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JELLABUK-DO, SOUTH KOREA;DEPARTMENT OF CROP SCIENCE, COLLEGE OF SANGHUH LIFE SCIENCE, KONKUK UNIVERSITY, SEOUL, 05029, SOUTH KOREA;DEPARTMENT OF LIFE RESOURCES INDUSTRY, DONG-A UNIVERSITY, 37, NAKDONG-DAERO 550 BEON-GIL, SAHA-GU, BUSAN, 49315, SOUTH KOREA;DEPARTMENT OF LIFE RESOURCES INDUSTRY, DONG-A UNIVERSITY, 37, NAKDONG-DAERO 550 BEON-GIL, SAHA-GU, BUSAN, 49315, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JELLABUK-DO, SOUTH KOREA","POLICOSANOLS IS A HEALTH PROMOTING ALIPHATIC ALCOHOL KNOWN AS LIPID-LOWING AGENT. TO ENABLE MAXIMISING THE FUNCTIONAL PROPERTIES OF WHEAT, THIS RESEARCH INVESTIGATES THE POLICOSANOL PROFILES AND ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLINGS ACCORDING TO CULTIVARS AND GROWTH TIMES. GC-MS REVEALED SIX POLICOSANOLS THAT DIFFERED MARKEDLY IN CONTENT BETWEEN 17 CULTIVARS, ESPECIALLY, OCTACOSANOL (8) SHOWED THE MOST PREDOMINANT COMPONENT (49–83%), VARYING SIGNIFICANTLY IN AVERAGE CONCENTRATIONS WITH GROWTH TIMES AS 361.4 (3 DAYS) → 613.0 (6 DAYS) → 203.1 (9 DAYS) → 196.5 (12 DAYS) → 50.9 MG/100 G (19 DAYS). THE HIGHEST AVERAGE POLICOSANOL (738.7 MG/100 G) EXHIBITED AFTER 6 DAYS, WHILE THE LOWEST WAS 104.4 MG/100 G ON 19 DAYS. MOREOVER, THE WHEAT CULTIVARS INCLUDING SHINMICHAL 1, ANBAEK, NAMHAE, AND JOAH AT 6 DAYS MAY BE RECOMMENDED AS POTENTIAL SOURCES BECAUSE OF HIGH POLICOSANOLS (921.7–990.6 MG/100 G). WESTERN BLOT ANALYSIS REVEALED MARKEDLY HIGHER AMPK ACTIVATION IN CELLS TREATED WITH THE HEXANE EXTRACTS (150–370% AT 100 ΜG/ML) AND OCTACOSANOL (8) POSSESSED POTENT AMPK ACTIVATOR (CONTROL; 100 → 280% AT 200 ΜG/ML). IT IS CONFIRMED THAT THE AMPK ACTIVATION BY WHEAT SEEDLINGS ARE POSITIVELY RELATED TO THE HIGHEST POLICOSANOL CONTENT AT THE 6 DAYS OF GROWTH TIME, INDEPENDENT OF THE CULTIVAR. OUR RESULTS MAY BE CONTRIBUTED TO ENHANCE THE WHEAT VALUE REGARDING DEVELOPMENT OF NEW CULTIVARS AND FUNCTIONAL FOODS. © 2020 ELSEVIER LTD","AMPK; DOCOSANOL (PUBCHEM CID12620); EICOSANOL (PUBCHEM CID 12404); GC–MS; GROWTH TIMES; HENEICOSANOL (PUBCHEM CID 85014); HEPTACOSANOL (PUBCHEM CID 74822); HEXACOSANOL (PUBCHEM CID 68171); OCTACOSANOL; OCTACOSANOL (PUBCHEM CID 68406); POLICOSANOL; TETRACOSANOL (PUBCHEM CID 10472); TRIACONTANOL (PUBCHEM CID 68972); TRICOSANOL (PUBCHEM CID 18431); WHEAT SEEDLING","AMP-ACTIVATED PROTEIN KINASES; ENZYME ACTIVATION; FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEXANES; PLANT EXTRACTS; SEEDLINGS; TRITICUM; CHEMICAL ACTIVATION; ELECTROPHORESIS; ENZYMES; BEHENYL ALCOHOL; EICOSANOL; HENEICOSANOL; HEPTACOSANOL; HEXACOSANOL; HEXANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KOREAN WHEAT SEEDLING EXTRACT; OCTACOSANOL; PLANT EXTRACT; POLICOSANOL; TETRACOSANOL; TRIACONTANOL; TRICOSANOL; UNCLASSIFIED DRUG; 1-OCTACOSANOL; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PLANT EXTRACT; POLICOSANOL; AMPK; GROWTH TIME; OCTACOSANOL; POLICOSANOL; PUBCHEM; WHEAT SEEDLINGS; ARTICLE; CELL VIABILITY; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETER); CONTROLLED STUDY; CULTIVAR; ENZYME ACTIVATION; FUNCTIONAL FOOD; HUMAN; HUMAN CELL; MASS FRAGMENTOGRAPHY; PLANT GROWTH; SEEDLING; SOLVENT EXTRACTION; WHEAT; CHEMISTRY; COMPARATIVE STUDY; ENZYME ACTIVATION; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; SEEDLING; WHEAT; ACTIVATION ANALYSIS","RURAL DEVELOPMENT ADMINISTRATION, RDA","THIS WORK WAS CARRIED OUT WITH THE SUPPORT OF “COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURE SCIENCE AND TECHNOLOGY DEVELOPMENT (PROJECT NO. PJ01348301)” RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA. ","BAI Y., XU Y., WANG B., LI S., GUO F., HUA H., YU Z., COMPARISON OF PHENOLIC COMPOUNDS, ANTIOXIDANT AND ANTIDIABETIC ACTIVITIES BETWEEN SELECTED EDIBLE BEANS AND THEIR DIFFERENT GROWTH PERIODS LEAVES, JOURNAL OF FUNCTIONAL FOODS, 35, PP. 694-702, (2017); BRADFORD M.M., A RAPID AND SENSITIVE METHOD FOR THE QUANTIFICATION OF MICROGRAM QUANTITIES OF PROTEIN UTILIZING THE PRINCIPLE OF PROTEIN-DYE BINDING, ANALYTICAL BIOCHEMISTRY, 72, PP. 248-254, (1976); BRANDON E.F.A., RAAP C.D., MEIJERMAN I., BEIJNEN J.H., SCHELLENS J.H.M., AN UPDATE ON IN VITRO TEST METHODS IN HUMAN HEPATIC DRUG BIOTRANSFORMATION RESEARCH: PROS AND CONS, TOXICOLOGY AND APPLIED PHARMACOLOGY, 189, PP. 233-246, (2003); BRANDON E.F.A., BOSCH T.M., DEENEN M.J., LEVINK R., VAN DER WAL E., VAN MEERVELD J.B.M., MEIJERMAN I., VALIDATION OF IN VITRO CELL MODELS USED IN DRUG METABOLISM AND TRANSPORT STUDIES: GENOTYPING OF CYTOCHROME P450, PHASE II ENZYME AND DRUG TRANSPORTER POLYMORPHISMS IN THE HUMAN HEPATOMA (HEPG2), OVARIAN CARCINOMA (IGROV-1) AND COLON CARCINOMA (CACO-2, LS180) CELL LINES, TOXICOLOGY AND APPLIED PHARMACOLOGY, 211, PP. 1-10, (2006); CARDACI S., FILOMENI G., CIRIOLO M.R., REDOX IMPLICATIONS OF AMPK-MEDIATED SIGNAL TRANSDUCTION BEYOND ENERGETIC CLUES, JOURNAL OF CELL SCIENCE, 125, PP. 2115-2125, (2012); CHEN Y., DUNFORD N.T., EDWARDS J., CARVEN B., GOAD C., POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 89, PP. 310-314, (2009); CHEN Y., DUNFORD N.T., GOAD C., TANGENTIAL ABRASIVE DEHULLING OF WHEAT GRAIN TO OBTAIN POLICOSANOL AND PHYTOSTEROL ENRICHED FRACTIONS, JOURNAL OF CEREAL SCIENCE, 57, PP. 258-260, (2013); CHOI S.J., PARK S.Y., PARK J.S., PARK S.K., JUNG M.Y., CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA (CAMELLIA SINENSIS) LEAVES, FOOD CHEMISTRY, 204, PP. 94-101, (2016); DUNFORD N.T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOURCE TECHNOLOGY, 101, PP. 422-425, (2010); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM, AND BRAN, FOOD CHEMISTRY, 119, PP. 1246-1249, (2010); FENG S., LUO Z., ZHANG Y., ZHONG Z., LU B., PHYTOCHEMICAL CONTENTS AND ANTIOXIDANT CAPACITIES OF DIFFERENT PARTS OF TWO SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, FOOD CHEMISTRY, 151, PP. 452-458, (2014); GAWLKI-DZIKI U., DZIKI D., NOWAK R., SWIECA M., OLECH M., PIETRZAK W., INFLUENCE OF SPROUTING AND ELICITATION ON PHENOLIC ACIDS PROFILE AND ANTIOXIDANT ACTIVITY OF WHEAT SEEDLINGS, JOURNAL OF CEREAL SCIENCE, 70, PP. 221-228, (2016); GUNENC A., TAVAKOLI H., SEETHARAMAN K., MAYER P.M., FAIRBANKS D., HOSSEINIAN F., STABILITY AND ANTIOXIDANT ACTIVITY OF ALKYRESORCINOLS IN BREADS ENRICHED WITH HARD AND SOFT WHEAT BRANS, FOOD RESEARCH INTERNATIONAL, 51, PP. 571-578, (2013); HA T.J., SONG S.B., KO J., PARK C.H., KO J.M., CHOE M.E., LEE J.H., ISOLATION AND IDENTIFICATION OF Α-GLUCOSIDASE INHIBITORY CONSTITUENTS FROM THE SEEDS OF VIGNA NAKASHIMAE: ENZYME KINETIC STUDY WITH ACTIVE PHYTOCHEMICAL, FOOD CHEMISTRY, 266, PP. 483-489, (2018); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEMISTRY, 115, PP. 918-923, (2009); HERATH K.H.I.N.M., CHO J., EOM T.K., KIM J.S., KIM J.B., DOH Y.H., JEE Y., PHENOLIC ACID AND FLAVONOID-RICH FRACTION OF SARA QUELPAERTENSIS NAKAI LEAVES PREVENT ALCOHOL INDUCED FATTY LIVER THROUGH AMPK ACTIVATION, JOURNAL OF ETHNOPHARMACOLOGY, 224, PP. 335-348, (2018); HUANG Q., CHEN L., SONG H., WU X., XU M., PHENOLIC COMPOUNDS AMELIORATE THE GLUCOSE UPTAKE IN HEPG2 CELL INSULIN RESISTANCE VIA ACTIVATING AMPK, JOURNAL OF FUNCTIONAL FOODS, 19, PP. 487-494, (2015); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); IRMAK S., JONNALA R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, JOURNAL OF CEREAL SCIENCE, 48, PP. 20-26, (2008); KANG N.S., LEE J.H., CHARACTERISATION OF PHENOLIC PHYTOCHEMICALS AND QUALITY CHANGES RELATED TO THE HARVEST TIMES FROM THE LEAVES OF KOREAN PURPLE PERILLA (PERILLA FRUTESCENS), FOOD CHEMISTRY, 124, PP. 556-562, (2011); KIM Y.J., HWANG S.H., JIA Y., SEO W.D., LEE S.J., BARLEY SPROUT EXTRACTS REDUCE HEPATIC ACID ACCUMULATION IN ETHANOL-FED MICE BY ACTIVATING HEPATIC AMP-ACTIVATED PROTEIN KINASE, FOOD RESEARCH INTERNATIONAL, 101, PP. 209-217, (2017); LEE J.H., HWANG C.E., SON K.S., CHO K.M., COMPARISONS OF NUTRITIONAL CONSTITUENTS IN SOYBEANS DURING SOLID STATE FERMENTATION TIMES AND SCREENING FOR THEIR GLUCOSIDASE ENZYMES AND ANTIOXIDANT PROPERTIES, FOOD CHEMISTRY, 272, PP. 362-371, (2019); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., LEE S.J., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTRITION RESEARCH, 43, 2017, PP. 89-99, (2017); LEE J.H., LEE B.W., KIM J.H., JEONG T.S., KIM M.J., LEE W.S., PARK K.H., LDL-ANTIOXIDANT PTEROCARPANS FROM ROOTS OF GLYCINE MAX (L.) MERR, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 2057-2063, (2006); LEE J.H., LEE S.Y., KIM B., SEO W.D., JIA Y., WU C., LEE S.J., BARLEY SPROUT EXTRACT CONTAINING POLICOSANOLS AND POLYPHENOLS REGULATE AMPK, SREBR2 AND ACAT2 ACTIVITY AND CHOLESTEROL AND GLUCOSE METABOLISM IN VITRO AND IN VIVO, FOOD RESEARCH INTERNATIONAL, 72, PP. 174-183, (2015); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); PEIXOTO C.A., DE OLIVEIRA W.H., DA RACHO ARAUJO S.M., NUNES A.K.S., AMPK ACTIVATION: ROLE IN THE SIGNALING PATHWAYS OF NEUROINFLAMMATION AND NEURODEGENERATION, EXPERIMENTAL NEUROLOGY, 298, PP. 31-41, (2017); RAFFO A., MASCI M., MONETA E., NICOLI S., DEL PULGAR J.S., PAOLETTI F., CHARACTERIZATION OF VOLATILES AND IDENTIFICATION OF ODOR-ACTIVE COMPOUNDS OF ROCKET LEAVES, FOOD CHEMISTRY, 240, PP. 1161-1170, (2018); RIAZ L., MAHMOOD T., COYNE M.S., KHALID A., RASHID A., HAYAT M.T., AMJAD M., PHYSIOLOGICAL AND ANTIOXIDANT RESPONSE OF WHEAT (TRITICUM AESTIVUM) SEEDLINGS TO FLUOROQUINOLONE ANTIBIOTICS, CHEMOSPHERE, 177, PP. 250-257, (2017); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., PARK K.H., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 61, PP. 1117-1123, (2013); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); VAZIRIAN M., NABAVI S.M., JAFARI S., MANAYI A., NATURAL ACTIVATORS OF ADENOSINE 5′-MONOPHOSPHATE (AMP)-ACTIVATED PROTEIN KINASE (AMPK) AND THEIR PHARMACOLOGICAL ACTIVITIES, FOOD AND CHEMICAL TOXICOLOGY, 122, PP. 69-79, (2018); WANG N., ZHAO J., LIU Q., DIAO X., KONG B., SULFORAPHANE PROTECTS HUMAN UMBILICAL VEIN CELLS AGAINST LIPOTOXICITY BY STIMULATING AUTOPHAGY VIA AN AMPK-MEDIATED PATHWAY, JOURNAL OF FUNCTIONAL FOODS, 15, PP. 23-34, (2015); ZHANG Y.Z., YANG N., FRAY R.G., LIU C., LI H., HAN Y., CHARACTERIZATION OF VOLATILE AROMA COMPOUNDS AFTER IN-VIAL COOKING OF FOXTAIL MILLET PORRIDGE WITH GAS CHROMATOGRAPHY-MASS SPECTROMETRY, JOURNAL OF CEREAL SCIENCE, 82, PP. 8-15, (2018)","J.H. LEE; DEPARTMENT OF LIFE RESOURCES INDUSTRY, DONG-A UNIVERSITY, SAHA-GU, BUSAN, 37, NAKDONG-DAERO 550 BEON-GIL, 49315, SOUTH KOREA; EMAIL: SCHEM72@DAU.AC.KR","ELSEVIER LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-85079544524","FOOD CHEM","KONKUK UNIVERSITY;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;KONKUK UNIVERSITY;DONG-A UNIVERSITY;DONG-A UNIVERSITY;NATIONAL INSTITUTE OF CROP SCIENCE","NOTREPORTED;DONG-A UNIVERSITY;NOTDECLARED",NA,"RA J-E, 2020, FOOD CHEM","RA J-E, 2020, FOOD CHEM"
"PENSON P;BANACH M","PENSON, PETER E. (6506734112); BANACH, MACIEJ (22936699500)","NATURAL COMPOUNDS AS ANTIATHEROGENIC AGENTS CLINICAL EVIDENCE FOR IMPROVED CARDIOVASCULAR OUTCOMES",2021,"ATHEROSCLEROSIS","316","7",25,"10.1016/j.atherosclerosis.2020.11.015","SCHOOL OF PHARMACY & BIOMOLECULAR SCIENCES, LIVERPOOL JOHN MOORES UNIVERSITY, LIVERPOOL, UNITED KINGDOM, LIVERPOOL CENTRE FOR CARDIOVASCULAR SCIENCE, LIVERPOOL, UNITED KINGDOM;DEPARTMENT OF HYPERTENSION, CHAIR OF NEPHROLOGY AND HYPERTENSION, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND, POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE (PMMHRI), LODZ, POLAND, CARDIOVASCULAR RESEARCH CENTRE, UNIVERSITY OF ZIELONA GORA, ZIELONA GORA, POLAND","ATHEROSCLEROSIS, A CHRONIC PROGRESSIVE INFLAMMATORY CONDITION CHARACTERIZED BY THE FORMATION OF LIPID-LADEN LESIONS IN ARTERIAL WALLS, IS ASSOCIATED WITH SUBSTANTIAL MORBIDITY (INCLUDING ISCHAEMIC STROKE AND MYOCARDIAL INFARCTION) AND MORTALITY. RISK FACTORS FOR ATHEROSCLEROSIS ARE WELL UNDERSTOOD AND CAN BE AMELIORATED BY EVIDENCE-BASED AND GUIDELINE-DIRECTED PHARMACEUTICAL AGENTS (E.G. THE REDUCTION OF CIRCULATING CONCENTRATIONS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY STATINS). ADDITIONALLY, MANY NATURAL PRODUCTS (USUALLY FOOD DERIVATIVES) AND ‘NUTRACEUTICALS’ (PHARMACEUTICAL FORMULATIONS PREPARED FROM COMPONENTS OF FOODS) HAVE BEEN SHOWN TO HAVE FAVOURABLE EFFECTS ON RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. THIS LITERATURE REVIEW SUMMARISES THE EVIDENCE FOR ANTI-ATHEROGENIC NATURAL COMPOUNDS. THE ARTICLE FOCUSES ON AGENTS WHICH ARE DISCUSSED IN INTERNATIONAL GUIDELINES AND ARE SUPPORTED BY EXTENSIVE HIGH-QUALITY RANDOMIZED-CONTROLLED TRIAL (RCT) DATA. WE FOCUS ON MICRONUTRIENTS (COMPOUNDS PRESENT IN FOOD IN SMALL QUANTITIES) AND NUTRACEUTICALS, IN PARTICULAR, PHYTOSTEROLS, POLYUNSATURATED Ω-3 FATTY ACIDS AND RED-YEAST RICE. WE CONCLUDE THAT THE ‘NUTRACEUTICAL APPROACH’ (IDENTIFY THE ACTIVE INGREDIENTS IN NATURAL PRODUCTS; PRODUCE HIGH-QUALITY PRODUCTS ACCORDING TO GOOD MANUFACTURING PRACTICE GUIDELINES; EVALUATE THEM IN LONG-TERM OUTCOMES TRIALS) IS THE MECHANISM BY WHICH THE DOMAINS OF NATURAL PRODUCT RESEARCH AND EVIDENCE-BASED MEDICINE CAN MOVE CLOSER TOGETHER. © 2020 ELSEVIER B.V.","ATHEROSCLEROSIS; CHOLESTEROL; LIPOPROTEINS; NATURAL PRODUCTS; NUTRACEUTICALS","ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; ALLICIN; ALPHA TOCOPHEROL; ANTHOCYANIN; BERBERINE; BETA GLUCAN; CARNITINE; CHOLESTIN; CONJUGATED LINOLEIC ACID; CURCUMIN; FLAVONOID; GAMMA ORYZANOL; ISPAGULA; MANNAN; MEVINOLIN; MONACOLIN J; NATURAL PRODUCT; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PANTHENINE; PEPTIDE DERIVATIVE; PHYTOSTEROL; POLICOSANOL; POLYPHENOL DERIVATIVE; PROBIOTIC AGENT; SILYMARIN; STANOZOLOL; TRACE ELEMENT; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ARTICHOKE; ATHEROSCLEROSIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPIRULINA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIETARY SUPPLEMENT","AMGEN; SANOFI; MESO SCALE DIAGNOSTICS, MSD; MYLAN","PEP OWNS FOUR SHARES IN ASTRAZENECA PLC AND HAS RECEIVED HONORARIA AND/OR TRAVEL REIMBURSEMENT FOR EVENTS SPONSORED BY AKCEA, AMGEN, AMRYT, LINK MEDICAL, NAPP AND SANOFI. MB HAS RECEIVED RESEARCH GRANT(S)/SUPPORT FROM AMGEN, SANOFI, MYLAN AND VALEANT, AND HAS SERVED AS A CONSULTANT FOR AKCEA, AMGEN, DAIICHI-SANKYO, ESPERION, FREIA PHARMACEUTICALS, KRKA, MSD, MYLAN, NOVARTIS, POLFARMEX, POLPHARMA, RESVERLOGIX, SANOFI-AVENTIS AND SERVIER. ","LIBBY P., BURING J.E., BADIMON L., ET AL., ATHEROSCLEROSIS, NAT REV DIS PRIMERS, 5, (2019); MONITORING HEALTH FOR THE SDGS, (2018); LEVY D., BRINK S., A CHANGE OF HEART : HOW THE FRAMINGHAM HEART STUDY HELPED UNRAVEL THE MYSTERIES OF CARDIOVASCULAR DISEASE, 9, (2005); WILSON P.W., D'AGOSTINO R.B., LEVY D., ET AL., PREDICTION OF CORONARY HEART DISEASE USING RISK FACTOR CATEGORIES, CIRCULATION, 97, PP. 1837-1847, (1998); GOFMAN J.W., YOUNG W., TANDY R., ISCHEMIC HEART DISEASE, ATHEROSCLEROSIS, AND LONGEVITY, CIRCULATION, 34, PP. 679-697, (1966); SPARLING P.B., LEGACY OF NUTRITIONIST ANCEL KEYS, MAYO CLIN. PROC., 95, PP. 615-617, (2020); SOSNOWSKA B., PENSON P., BANACH M., THE ROLE OF NUTRACEUTICALS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASC. DIAGN. THER., 7, PP. S21-S31, (2017); PENSON P., BANACH M., THE ROLE OF NUTRACEUTICALS IN THE OPTIMISATION OF LIPID-LOWERING THERAPY IN HIGH-RISK PATIENTS WITH DYSLIPIDEMIA, (2020); ENKHMAA B., SURAMPUDI P., ANUURAD E., ET AL., LIFESTYLE CHANGES: EFFECT OF DIET, EXERCISE, FUNCTIONAL FOOD, AND OBESITY TREATMENT, ON LIPIDS AND LIPOPROTEINS, (2015); DEFELICE S.L., THE NUTRACEUTICAL REVOLUTION - ITS IMPACT ON FOOD-INDUSTRY R-AND-D, TRENDS FOOD SCI. TECHNOL., 6, PP. 59-61, (1995); HOOPER L., MARTIN N., JIMOH O.F., ET AL., REDUCTION IN SATURATED FAT INTAKE FOR CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV., 5, (2020); NORGAARD M., EHRENSTEIN V., VANDENBROUCKE J.P., CONFOUNDING IN OBSERVATIONAL STUDIES BASED ON LARGE HEALTH CARE DATABASES: PROBLEMS AND POTENTIAL SOLUTIONS - A PRIMER FOR THE CLINICIAN, CLIN. EPIDEMIOL., 9, PP. 185-193, (2017); BANACH M., PATTI A.M., GIGLIO R.V., ET AL., THE ROLE OF NUTRACEUTICALS IN STATIN INTOLERANT PATIENTS, J. AM. COLL. CARDIOL., 72, PP. 96-118, (2018); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR. REV., 75, PP. 731-767, (2017); CICERO A.F.G., COLLETTI A., VON HAEHLING S., ET AL., NUTRACEUTICAL SUPPORT IN HEART FAILURE: A POSITION PAPER OF THE INTERNATIONAL LIPID EXPERT PANEL (ILEP), NUTR. RES. REV., PP. 1-25, (2020); MACH F., BAIGENT C., CATAPANO A.L., ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR. HEART J., 41, PP. 111-188, (2020); PENSON P., TOTH P., MIKHAILIDIS D., ET AL., P705STEP BY STEP DIAGNOSIS AND MANAGEMENT OF STATIN INTOLERANCE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, EUR. HEART J., 40, (2019); GJULADIN-HELLON T., DAVIES I.G., PENSON P., ET AL., EFFECTS OF CARBOHYDRATE-RESTRICTED DIETS ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN OVERWEIGHT AND OBESE ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR. REV., 77, PP. 161-180, (2019); MAZIDI M., MIKHAILIDIS D.P., SATTAR N., ET AL., ASSOCIATION OF TYPES OF DIETARY FATS AND ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY: A PROSPECTIVE COHORT STUDY AND META-ANALYSIS OF PROSPECTIVE STUDIES WITH 1,164,029 PARTICIPANTS, CLIN. NUTR., (2020); MAZIDI M., MIKHAILIDIS D.P., MB, OMEGA-3 FATTY ACIDS AND RISK OF CARDIOVASCULAR DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS WITH 127,447 INDIVIDUALS AND A MENDELIAN RANDOMIZATION STUDY, CIRCULATION, (2019); MAZIDI M., KATSIKI N., MIKHAILIDIS D.P., ET AL., LOWER CARBOHYDRATE DIETS AND ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY: A POPULATION-BASED COHORT STUDY AND POOLING OF PROSPECTIVE STUDIES, EUR. HEART J., 40, PP. 2870-2879, (2019); BANACH M., PENSON P.E., WHAT HAVE WE LEARNED ABOUT LIPIDS AND CARDIOVASCULAR RISK FROM PCSK9 INHIBITOR OUTCOME TRIALS: ODYSSEY AND FOURIER?, CARDIOVASC. RES., 115, PP. E26-E31, (2019); RIDKER P.M., EVERETT B.M., THUREN T., ET AL., ANTIINFLAMMATORY THERAPY WITH CANAKINUMAB FOR ATHEROSCLEROTIC DISEASE, N. ENGL. J. MED., 377, PP. 1119-1131, (2017); ROSS R., ATHEROSCLEROSIS–AN INFLAMMATORY DISEASE, N. ENGL. J. MED., 340, PP. 115-126, (1999); RIDKER P.M., EVERETT B.M., PRADHAN A., ET AL., LOW-DOSE METHOTREXATE FOR THE PREVENTION OF ATHEROSCLEROTIC EVENTS, N. ENGL. J. MED., 380, PP. 752-762, (2019); SERBAN C., MUNTEAN D., MIKHAILIDS D.P., ET AL., DYSFUNCTIONAL HDL: THE JOURNEY FROM SAVIOR TO SLAYER, CLIN. LIPIDOL., 9, PP. 49-59, (2014); CATAPANO A.L., PIRILLO A., NORATA G.D., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, CARDIOVASCULAR DISEASE RISK, AND CANCER: A RELATION WHICH DOES NOT APPLY TO ALL?, CARDIOVASC. RES., 115, PP. 6-7, (2019); SILVERMAN M.G., FERENCE B.A., IM K., ET AL., ASSOCIATION BETWEEN LOWERING LDL-C AND CARDIOVASCULAR RISK REDUCTION AMONG DIFFERENT THERAPEUTIC INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. AM. MED. ASSOC., 316, PP. 1289-1297, (2016); PENSON P.E., PIRRO M., BANACH M., ET AL., LDL-C: LOWER IS BETTER FOR LONGER – EVEN AT LOW RISK, BMC MED., 18, (2020); KATSIKI N., MIKHAILIDIS D.P., BAJRAKTARI G., ET AL., STATIN THERAPY IN ATHLETES AND PATIENTS PERFORMING REGULAR INTENSE EXERCISE - POSITION PAPER FROM THE INTERNATIONAL LIPID EXPERT PANEL (ILEP), PHARMACOL. RES., 155, (2020); ARNETT D.K., BLUMENTHAL R.S., ALBERT M.A., ET AL., 2019 ACC/AHA GUIDELINE ON THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, CIRCULATION, 140, PP. E596-E646, (2019); GRUNDY S.M., STONE N.J., BAILEY A.L., ET AL., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, CIRCULATION, 139, PP. E1082-E1143, (2019); CARDIOVASCULAR DISEASE: RISK ASSESSMENT AND REDUCTION, INCLUDING LIPID MODIFICATION, (2014); ZALESKI A.L., COENZYME Q10 AND SAMS, STATIN-ASSOCIATED MUSCLE SYMPTOMS, PP. 129-135, (2020); BARTLOMIEJCZYK M., PENSON P.E., BANACH M., VITAMIN D AND SAMS, STATIN-ASSOCIATED MUSCLE SYMPTOMS, PP. 121-128, (2020); MASON R.P., NEW INSIGHTS INTO MECHANISMS OF ACTION FOR OMEGA-3 FATTY ACIDS IN ATHEROTHROMBOTIC CARDIOVASCULAR DISEASE, CURR. ATHEROSCLEROSIS REP., 21, (2019); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., ET AL., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE, CIRCULATION, 106, PP. 2747-2757, (2002); ASCEND STUDY COLLABORATIVE GROUP, BOWMAN L., MAFHAM M., ET AL., EFFECTS OF N-3 FATTY ACID SUPPLEMENTS IN DIABETES MELLITUS, N. ENGL. J. MED., 379, PP. 1540-1550, (2018); MANSON J.E., COOK N.R., LEE I.M., ET AL., MARINE N-3 FATTY ACIDS AND PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER, N. ENGL. J. MED., 380, PP. 23-32, (2019); NICHOLLS S.J., LINCOFF A.M., BASH D., ET AL., ASSESSMENT OF OMEGA-3 CARBOXYLIC ACIDS IN STATIN-TREATED PATIENTS WITH HIGH LEVELS OF TRIGLYCERIDES AND LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: RATIONALE AND DESIGN OF THE STRENGTH TRIAL, CLIN. CARDIOL., 41, PP. 1281-1288, (2018); ASTRAZENECA P.L.C., UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED, (2020); BHATT D.L., STEG P.G., MILLER M., ET AL., CARDIOVASCULAR RISK REDUCTION WITH ICOSAPENT ETHYL FOR HYPERTRIGLYCERIDEMIA, N. ENGL. J. MED., 380, PP. 11-22, (2019); BHATT D.L., STEG P.G., MILLER M., ET AL., EFFECTS OF ICOSAPENT ETHYL ON TOTAL ISCHEMIC EVENTS: FROM REDUCE-IT, J. AM. COLL. CARDIOL., 73, PP. 2791-2802, (2019); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); HELGADOTTIR A., THORLEIFSSON G., ALEXANDERSSON K.F., ET AL., GENETIC VARIABILITY IN THE ABSORPTION OF DIETARY STEROLS AFFECTS THE RISK OF CORONARY ARTERY DISEASE, EUR. HEART J., 41, PP. 2618-2628, (2020); GYLLING H., PLAT J., TURLEY S., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, PP. 346-360, (2014); MUSA-VELOSO K., POON T.H., ELLIOT J.A., ET AL., A COMPARISON OF THE LDL-CHOLESTEROL LOWERING EFFICACY OF PLANT STANOLS AND PLANT STEROLS OVER A CONTINUOUS DOSE RANGE: RESULTS OF A META-ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 85, PP. 9-28, (2011); LI Y., JIANG L., JIA Z., ET AL., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, (2014); DE BACKER G.G., FOOD SUPPLEMENTS WITH RED YEAST RICE: MORE REGULATIONS ARE NEEDED, EUR J PREV CARDIOL, 24, PP. 1429-1430, (2017); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM. J. CARDIOL., 101, PP. 1689-1693, (2008); CICERO A.F.G., FOGACCI F., BANACH M., RED YEAST RICE FOR HYPERCHOLESTEROLEMIA, METHODIST DEBAKEY CARDIOVASC J, 15, PP. 192-199, (2019); BANACH M., BRUCKERT E., DESCAMPS O.S., ET AL., THE ROLE OF RED YEAST RICE (RYR) SUPPLEMENTATION IN PLASMA CHOLESTEROL CONTROL: A REVIEW AND EXPERT OPINION, ATHEROSCLEROSIS SUPPL., 39, PP. E1-E8, (2019); FOGACCI F., BANACH M., MIKHAILIDIS D.P., ET AL., SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL. RES., 143, PP. 1-16, (2019); HOFFMANN T.C., DEL MAR C., PATIENTS' EXPECTATIONS OF THE BENEFITS AND HARMS OF TREATMENTS, SCREENING, AND TESTS: A SYSTEMATIC REVIEW, JAMA INTERN MED, 175, PP. 274-286, (2015); HOFFMANN T.C., DEL MAR C., CLINICIANS' EXPECTATIONS OF THE BENEFITS AND HARMS OF TREATMENTS, SCREENING, AND TESTS: A SYSTEMATIC REVIEW, JAMA INTERN MED, 177, PP. 407-419, (2017); TREADWELL J.S., WONG G., MILBURN-CURTIS C., ET AL., GPS' UNDERSTANDING OF THE BENEFITS AND HARMS OF TREATMENTS FOR LONG-TERM CONDITIONS: AN ONLINE SURVEY, BJGP OPEN, 4, (2020); NISSEN S.E., STATIN DENIAL: AN INTERNET-DRIVEN CULT WITH DEADLY CONSEQUENCES, ANN. INTERN. MED., 167, PP. 281-282, (2017); ZHANG H., PLUTZKY J., SHUBINA M., ET AL., CONTINUED STATIN PRESCRIPTIONS AFTER ADVERSE REACTIONS AND PATIENT OUTCOMES: A COHORT STUDY, ANN. INTERN. MED., 167, PP. 221-227, (2017); PENSON P.E., MANCINI G.B.J., TOTH P.P., ET AL., INTRODUCING THE 'DRUCEBO' EFFECT IN STATIN THERAPY: A SYSTEMATIC REVIEW OF STUDIES COMPARING REPORTED RATES OF STATIN-ASSOCIATED MUSCLE SYMPTOMS, UNDER BLINDED AND OPEN-LABEL CONDITIONS, J CACHEXIA SARCOPENIA MUSCLE, 9, PP. 1023-1033, (2018); BARRY A.R., PATIENTS' PERCEPTIONS AND USE OF NATURAL HEALTH PRODUCTS, CAN. PHARM. J., 151, PP. 254-262, (2018); PIEPOLI M.F., HOES A.W., AGEWALL S., ET AL., 2016 EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: THE SIXTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF 10 SOCIETIES AND BY INVITED EXPERTS): DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), EUR J PREV CARDIOL, 23, PP. NP1-NP96, (2016); MACH F., BAIGENT C., CATAPANO A.L., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR. HEART J., (2019); HIPPISLEY-COX J., COUPLAND C., BRINDLE P., DEVELOPMENT AND VALIDATION OF QRISK3 RISK PREDICTION ALGORITHMS TO ESTIMATE FUTURE RISK OF CARDIOVASCULAR DISEASE: PROSPECTIVE COHORT STUDY, BMJ, 357, (2017); CARDIOVASCULAR DISEASE: RISK ASSESSMENT AND REDUCTION, INCLUDING LIPID MODIFICATION: CLINICAL GUIDELINE CG181, (2016); GOFF D.C., LLOYD-JONES D.M., BENNETT G., ET AL., ACC/AHA GUIDELINE ON THE ASSESSMENT OF CARDIOVASCULAR RISK, J. AM. COLL. CARDIOL., 63, PP. 2935-2959, (2013); ARNETT D.K., BLUMENTHAL R.S., ALBERT M.A., ET AL., 2019 ACC/AHA GUIDELINE ON THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, J. AM. COLL. CARDIOL., 74, PP. E177-E232, (2019); FERENCE B.A., GINSBERG H.N., GRAHAM I., ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR. HEART J., 38, PP. 2459-2472, (2017); FRANCZYK B., GLUBA-BRZOZKA A., JURKIEWICZ L., ET AL., EMBRACING THE POLYPILL AS A CARDIOVASCULAR THERAPEUTIC: IS THIS THE BEST STRATEGY?, EXPET OPIN. PHARMACOTHER., 19, PP. 1857-1865, (2018); BARRIOS V., ESCOBAR C., CICERO A.F., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLEROSIS SUPPL., 24, PP. 1-15, (2017); WARD N., SAHEBKAR A., BANACH M., ET AL., RECENT PERSPECTIVES ON THE ROLE OF NUTRACEUTICALS AS CHOLESTEROL-LOWERING AGENTS, CURR. OPIN. LIPIDOL., 28, PP. 495-501, (2017); POLI A., BARBAGALLO C.M., CICERO A.F.G., ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOL. RES., 134, PP. 51-60, (2018)","M. BANACH; DEPARTMENT OF HYPERTENSION, WAM UNIVERSITY HOSPITAL IN LODZ, MEDICAL UNIVERSITY OF LODZ, LODZ, ZEROMSKIEGO 113, 90-549, POLAND; EMAIL: MACIEJBANACH77@GMAIL.COM","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","REVIEW","ISI","2-S2.0-85097680060","ATHEROSCLEROSIS","LIVERPOOL JOHN MOORES UNIVERSITY;MEDICAL UNIVERSITY OF LODZ","NOTREPORTED;WAM UNIVERSITY HOSPITAL IN LODZ;NOTREPORTED",NA,"PENSON PE, 2021, ATHEROSCLEROSIS","PENSON PE, 2021, ATHEROSCLEROSIS"
"SAAVEDRA D;AÑÉ-KOURÍ A;BARZILAI N;CARUSO C;CHO K;FONTANA L;FRANCESCHI C;FRASCA D;LEDÓN N;NIEDERNHOFER L;PEREIRA K;ROBBINS P;SILVA A;SUAREZ G;BERGHE W;VON Z T;PAWELEC G;LAGE A","SAAVEDRA, DANAY (59157830400); AÑÉ-KOURÍ, ANA LAURA (57209652019); BARZILAI, NIR (7005711408); CARUSO, CALOGERO (57782506600); CHO, KYUNG-HYUN (7403956966); FONTANA, LUIGI (57197469273); FRANCESCHI, CLAUDIO (56236886700); FRASCA, DANIELA (7005490566); LEDÓN, NURIS (6602262840); NIEDERNHOFER, LAURA J. (57203024508); PEREIRA, KARLA (57221291154); ROBBINS, PAUL D. (17339473100); SILVA, ALEXA (57771636400); SUAREZ, GISELA M. (57209365120); BERGHE, WIM VANDEN (57210628755); VON ZGLINICKI, THOMAS (7006735617); PAWELEC, GRAHAM (7103106086); LAGE, AGUSTÍN (7005254213)","AGING AND CHRONIC INFLAMMATION HIGHLIGHTS FROM A MULTIDISCIPLINARY WORKSHOP",2023,"IMMUNITY AND AGEING","20","",20,"10.1186/s12979-023-00352-w","DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA;DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA;ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, UNITED STATES;LABORATORIO DI IMMUNOPATOLOGIA E IMMUNOSENESCENZA, DIPARTIMENTO DI BIOMEDICINA, NEUROSCIENZE E DIAGNOSTICA AVANZATA, UNIVERSITÀ DI PALERMO, PALERMO, ITALY;LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, SEOUL, SOUTH KOREA;CHARLES PERKINS CENTRE, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA;INSTITUTE OF BIOLOGY AND BIOMEDICINE, LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD, NIZHNY NOVGOROD, RUSSIAN FEDERATION;DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE, MIAMI, FL, UNITED STATES;DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA;UNIVERSITY OF MINNESOTA MEDICAL SCHOOL, MINNEAPOLIS, MN, UNITED STATES;DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA;UNIVERSITY OF MINNESOTA MEDICAL SCHOOL, MINNEAPOLIS, MN, UNITED STATES;DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA;DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA;LABORATORY OF PROTEIN CHEMISTRY, PROTEOMICS AND EPIGENETIC SIGNALLING (PPES), UNIVERSITY OF ANTWERP, WILRIJK, 2610, BELGIUM, INTEGRATED PERSONALIZED & PRECISION ONCOLOGY NETWORK (IPPON), UNIVERSITY OF ANTWERP, WILRIJK, 2610, BELGIUM, DEPARTMENT OF BIOMEDICAL SCIENCES, UNIVERSITY OF ANTWERP, WILRIJK, 2610, BELGIUM;AGEING BIOLOGY LABORATORIES, NEWCASTLE UNIVERSITY BIOSCIENCES INSTITUTE, NEWCASTLE UPON TYNE, UNITED KINGDOM;DEPARTMENT OF IMMUNOLOGY, UNIVERSITY OF TÜBINGEN, TÜBINGEN, GERMANY;DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, ATABEY, CUBA","AGING IS A GRADUAL, CONTINUOUS SERIES OF NATURAL CHANGES IN BIOLOGICAL, PHYSIOLOGICAL, IMMUNOLOGICAL, ENVIRONMENTAL, PSYCHOLOGICAL, BEHAVIORAL, AND SOCIAL PROCESSES. AGING ENTAILS CHANGES IN THE IMMUNE SYSTEM CHARACTERIZED BY A DECREASE IN THYMIC OUTPUT OF NAÏVE LYMPHOCYTES, AN ACCUMULATED CHRONIC ANTIGENIC STRESS NOTABLY CAUSED BY CHRONIC INFECTIONS SUCH AS CYTOMEGALOVIRUS (CMV), AND IMMUNE CELL SENESCENCE WITH ACQUISITION OF AN INFLAMMATORY SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP). FOR THIS REASON, AND DUE TO THE SASP ORIGINATING FROM OTHER TISSUES, AGING IS COMMONLY ACCOMPANIED BY LOW-GRADE CHRONIC INFLAMMATION, TERMED “INFLAMMAGING”. AFTER DECADES OF ACCUMULATING EVIDENCE REGARDING AGE-RELATED PROCESSES AND CHRONIC INFLAMMATION, THE DOMAIN NOW APPEARS MATURE ENOUGH TO ALLOW AN INTEGRATIVE REINTERPRETATION OF OLD DATA. HERE, WE PROVIDE AN OVERVIEW OF THE TOPICS DISCUSSED IN A RECENT WORKSHOP “AGING AND CHRONIC INFLAMMATION” TO WHICH MANY OF THE MAJOR PLAYERS IN THE FIELD CONTRIBUTED. WE HIGHLIGHT ADVANCES IN SYSTEMATIC MEASUREMENT AND INTERPRETATION OF BIOLOGICAL MARKERS OF AGING, AS WELL AS THEIR IMPLICATIONS FOR HUMAN HEALTH AND LONGEVITY AND THE INTERVENTIONS THAT CAN BE ENVISAGED TO MAINTAIN OR IMPROVE IMMUNE FUNCTION IN OLDER PEOPLE. © 2023, THE AUTHOR(S).","AGING; BIOMODULINA T; CELL SENESCENCE; CHRONIC INFLAMMATION; IMMUNOSENESCENCE; INFLAMMAGING; METFORMIN; SASP; SENOLYTIC","BIOLOGICAL MARKER; METFORMIN; POLICOSANOL; AGING; ANTIAGING ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CACAO; CELL AGING; CHRONIC INFLAMMATION; DIET RESTRICTION; DIETARY INTAKE; HUMAN; IMMUNE STATUS; IMMUNE SYSTEM; IMMUNOSENESCENCE; INFLAMMAGING; INTERDISCIPLINARY RESEARCH; LONGEVITY; NONHUMAN; REVIEW; RISK FACTOR; SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE","","","LOPEZ-OTIN C., BLASCO M.A., PARTRIDGE L., SERRANO M., KROEMER G., THE HALLMARKS OF AGING, CELL, 153, PP. 217-1194, (2013); CARUSO C., LIGOTTI M.E., ACCARDI G., AIELLO A., CANDORE G., AN IMMUNOLOGIST’S GUIDE TO IMMUNOSENESCENCE AND ITS TREATMENT, EXPERT REV CLIN IMMUNOL, 2022, 18, PP. 961-981; FRANCESCHI C., SALVIOLI S., GARAGNANI P., DE EGUILEOR M., MONTI D., CAPRI M., IMMUNOBIOGRAPHY AND THE HETEROGENEITY OF IMMUNE RESPONSES IN THE ELDERLY: A FOCUS ON INFLAMMAGING AND TRAINED IMMUNITY, FRONT IMMUNOL, 8, (2017); PAWELEC G., BRONIKOWSKI A., CUNNANE S.C., FERRUCCI L., FRANCESCHI C., FULOP T., GAUDREAU P., GLADYSHEV V.N., GONOS E.S., GORBUNOVA V., KENNEDY B.K., LARBI A., LEMAITRE J.F., LIU G.H., MAIER A.B., MORAIS J.A., NOBREGA O.T., MOSKALEV A., RIKKERT M.O., SELUANOV A., SENIOR A.M., UKRAINTSEVA S., VANHAELEN Q., WITKOWSKI J., COHEN A.A., THE CONUNDRUM OF HUMAN IMMUNE SYSTEM “SENESCENCE, MECH AGEING DEV, (2020); FULOP T., LARBI A., DUPUIS G., LE PAGE A., FROST E.H., COHEN A.A., WITKOWSKI J.M., FRANCESCHI C., IMMUNOSENESCENCE AND INFLAMM-AGING AS TWO SIDES OF THE SAME COIN: FRIENDS OR FOES?, FRONTIERS IN IMMUNOLOGY, 8, (2017); FULOP T., LARBI A., PAWELEC G., KHALIL A., COHEN A.A., HIROKAWA K., WITKOWSKI J.M., FRANCESCHI C., IMMUNOLOGY OF AGING: THE BIRTH OF INFLAMMAGING, CLIN REV ALLERGY IMMUNOL, PP. 1-14, (2021); PAWELEC G., AGING AS AN INFLAMMATORY DISEASE AND POSSIBLE REVERSAL STRATEGIES, J ALLERGY CLIN IMMUNOL, 145, PP. 1355-1356, (2020); AKBAR A.N., HENSON S.M., LANNA A., SENESCENCE OF T LYMPHOCYTES: IMPLICATIONS FOR ENHANCING HUMAN IMMUNITY, TRENDS IMMUNOL, 37, PP. 866-876, (2016); FULOP T., LARBI A., HIROKAWA K., COHEN A.A., WITKOWSKI J.M., IMMUNOSENESCENCE IS BOTH FUNCTIONAL/ADAPTIVE AND DYSFUNCTIONAL/MALADAPTIVE, SEMIN IMMUNOPATHOL, 42, PP. 36-521, (2020); VERSCHOOR C.P., BELSKY D.W., ANDREW M.K., HAYNES L., LOEB M., PAWELEC G., MCELHANEY J.E., KUCHEL G.A., ADVANCED BIOLOGICAL AGE IS ASSOCIATED WITH IMPROVED ANTIBODY RESPONSES IN OLDER HIGH-DOSE INFLUENZA VACCINE RECIPIENTS OVER FOUR CONSECUTIVE SEASONS, IMMUN AGEING, 19, (2022); FULOP T., DUPUIS G., WITKOWSKI J.M., LARBI A., THE ROLE OF IMMUNOSENESCENCE IN THE DEVELOPMENT OF AGE-RELATED DISEASES. REVISTA DE INVESTIGACION CLINICA; ORGANO DEL HOSPITAL DE ENFERMEDADES DE LA NUTRICION, PP. 6884-6891, (2016); LIBRI V., AZEVEDO R.I., JACKSON S.E., DI MITRI D., LACHMANN R., FUHRMANN S., VUKMANOVIC-STEJIC M., YONG K., BATTISTINI L., KERN F., SOARES M.V., AKBAR A.N., CYTOMEGALOVIRUS INFECTION INDUCES THE ACCUMULATION OF SHORT-LIVED, MULTIFUNCTIONAL CD4 + CD45RA + CD27 + T CELLS: THE POTENTIAL INVOLVEMENT OF INTERLEUKIN-7 IN THIS PROCESS, IMMUNOLOGY, 132, PP. 39-326, (2011); APPAY V., SAUCE D., PRELOG M., THE ROLE OF THE THYMUS IN IMMUNOSENESCENCE: LESSONS FROM THE STUDY OF THYMECTOMIZED INDIVIDUALS, AGING, 2, PP. 78-81, (2010); BRUNNER S., HERNDLER-BRANDSTETTER D., GRUBECK-LOEBENSTEIN W.B.B., PERSISTENT VIRAL INFECTIONS AND IMMUNE AGING, AGEING RES REV, 10, PP. 362-369, (2011); DENKINGER M.D., LEINS H., SCHIRMBECK R., FLORIAN M.C., AGING G.H.H.S.C., SENESCENT IMMUNE REMODELING, TRENDS IMMUNOL, 36, PP. 24-815, (2015); FULOP T., MCELHANEY J., PAWELEC G., COHEN A.A., MORAIS J.A., DUPUIS G., BAEHL S., CAMOUS X., WITKOWSKI J.M., FRAILTY L.A., INFLAMMATION AND IMMUNOSENESCENCE. INTERDISCIPLINARY TOPICS IN GERONTOLOGY AND GERIATRICS, PP. 4126-4140, (2015); PAWELEC G., DERHOVANESSIAN E., LARBI A., STRINDHALL J., WIKBY A., CYTOMEGALOVIRUS AND HUMAN IMMUNOSENESCENCE, REV MED VIROL, 19, PP. 47-56, (2009); CAO Y., FAN Y., LI F., HAO Y., KONG Y., CHEN C., HAO X., HAN D., LI G., WANG Z., SONG C., HAN J., ZENG H., PHENOTYPIC AND FUNCTIONAL ALTERATIONS OF MONOCYTE SUBSETS WITH AGING, IMMUN AGEING, 19, (2022); ALAM I., GOLDECK D., LARBI A., PAWELEC G., AGING AFFECTS THE PROPORTIONS OF T AND B CELLS IN A GROUP OF ELDERLY MEN IN A DEVELOPING COUNTRY–A PILOT STUDY FROM PAKISTAN, AGE (DORDR), 35, PP. 1521-1530, (2013); GARCIA VERDECIA B., SAAVEDRA HERNANDEZ D., LORENZO-LUACES P., DE JESUS BADIA T., ALVAREZ I., LEONARD RUPALE Z., MAZORRA HERRERA T., CROMBET RAMOS A., LAGE DÁVILA, IMMUNOSENESCENCE AND GENDER: A STUDY IN HEALTHY CUBANS, (2013); SAAVEDRA D., CROMBET T., CIMAVAX-EGF: A NEW THERAPEUTIC VACCINE FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS, FRONT IMMUNOL, 8, (2017); COLONNA-ROMANO G., BULATI M., AQUINO A., PELLICANO M., VITELLO S., LIO D., CANDORE G., CARUSO C., A DOUBLE-NEGATIVE (IGD-CD27-) B CELL POPULATION IS INCREASED IN THE PERIPHERAL BLOOD OF ELDERLY PEOPLE, MECH AGEING DEV, 130, PP. 681-690, (2009); FRASCA D., DIAZ A., ROMERO M., GARCIA D., BLOMBERG B.B., B CELL IMMUNOSENESCENCE, ANNU REV CELL DEV BIOL, 36, PP. 551-574, (2020); FRASCA D., BLOMBERG B.B., ADIPOSE TISSUE, IMMUNE AGING, AND CELLULAR SENESCENCE, SEMIN IMMUNOPATHOL, PP. 42;573-87, (2020); ANDREW M.K., SHINDE V., YE L., HATCHETTE T., HAGUINET F., DOS SANTOS G., MCELHANEY J.E., AMBROSE A., BOIVIN G., BOWIE W., CHIT A., ELSHERIF M., GREEN K., HALPERIN S., IBARGUCHI B., JOHNSTONE J., KATZ K., LANGLEY J., LEBLANC J., LOEB M., MACKINNON-CAMERON D., MCCARTHY A., MCGEER A., POWIS J., RICHARDSON D., SEMRET M., STIVER G., TROTTIER S., VALIQUETTE L., WEBSTER D., MCNEIL A., (2017); MCELHANEY J.E., VERSCHOOR C.P., ANDREW M.K., HAYNES L., KUCHEL G.A., PAWELEC G., THE IMMUNE RESPONSE TO INFLUENZA IN OLDER HUMANS: BEYOND IMMUNE SENESCENCE, (2020); PAWELEC G., MCELHANEY J., UNANTICIPATED EFFICACY OF SARS-COV-2 VACCINATION IN OLDER ADULTS, (2021); FULOP T., LARBI A., PAWELEC G., COHEN A.A., PROVOST G., KHALIL A., LACOMBE G., RODRIGUES S., DESROCHES M., HIROKAWA K., WITKOWSKI F.C.J.M., IMMUNOSENESCENCE AND ALTERED VACCINE EFFICIENCY IN OLDER SUBJECTS: A MYTH DIFFICULT TO CHANGE, VACCINES, 10, (2022); PAWELEC G., IMMUNE PARAMETERS ASSOCIATED WITH MORTALITY IN THE ELDERLY ARE CONTEXT-DEPENDENT: LESSONS FROM SWEDEN, HOLLAND AND BELGIUM, BIOGERONTOLOGY, 19, PP. 537-545, (2018); LEDÓN N, RAMOS MB, GONZÁLEZ A, PEREIRA K, RODRÍGUEZ M, VIDAL A, RODRÍGUEZ Y, BICET YC, LLANEZ-GREGORICH E, LORENZO-LUACES P, SUÁREZ GM, SILVA A, CROMBET T. D. SAAVEDRA,A. LAGE, ASSOCIATION AMONG TERMINALLY DIFFERENTIATED T CELLS, FRAILTY, AND DEPENDENCY IN A GROUP OF CUBAN CENTENARIANS, GERONTOLOGY, PP. 1-10, (2022); LIGOTTI M.E., AIELLO A., ACCARDI G., APRILE S., BONURA F., BULATI M., GERVASI F., GIAMMANCO G.M., POJERO F., ZAREIAN N., CARUSO C., FARZANEH F., CANDORE G., ANALYSIS OF T AND NK CELL SUBSETS IN THE SICILIAN POPULATION FROM YOUNG TO SUPERCENTENARIAN: THE ROLE OF AGE AND GENDER, CLIN EXP IMMUNOL, 205, PP. 198-212, (2021); FRANCESCHI C., BONAFE M., VALENSIN S., OLIVIERI F., DE LUCA M., OTTAVIANI E., INFLAMM-AGING D.B.G., (2000); FRANCESCHI C., CAMPISI J., CHRONIC INFLAMMATION (INFLAMMAGING) AND ITS POTENTIAL CONTRIBUTION TO AGE-ASSOCIATED DISEASES, THE JOURNALS OF GERONTOLOGY SERIES A, BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 69, PP. S4-S9, (2014); DECLERCK K., VANDEN BERGHE W., CHARACTERIZATION OF BLOOD SURROGATE IMMUNE-METHYLATION BIOMARKERS FOR IMMUNE CELL INFILTRATION IN CHRONIC INFLAMMAGING DISORDERS, FRONT GENET, (2019); ZHU X., CHEN Z., SHEN W., HUANG G., SEDIVY J.M., WANG H., JU Z., INFLAMMATION, EPIGENETICS, AND METABOLISM CONVERGE TO CELL SENESCENCE AND AGEING: THE REGULATION AND INTERVENTION, SIGNAL TRANSDUCT TARGET THERAPY, 6, (2021); BOSCO N., NOTI M., THE AGING GUT MICROBIOME AND ITS IMPACT ON HOST IMMUNITY, GENES IMMUN, 22, PP. 289-303, (2021); BULUT O., KILIC G., DOMINGUEZ-ANDRES J., NETEA M.G., OVERCOMING IMMUNE DYSFUNCTION IN THE ELDERLY: TRAINED IMMUNITY AS A NOVEL APPROACH, INT IMMUNOL, 32, PP. 53-741, (2020); CHAPMAN J., FIELDER E., PASSOS J.F., MITOCHONDRIAL DYSFUNCTION AND CELL SENESCENCE: DECIPHERING A COMPLEX RELATIONSHIP, FEBS LETT, 593, PP. 1566-1579, (2019); SALVIOLI S., CAPRI M., VALENSIN S., TIERI P., MONTI D., OTTAVIANI E., FRANCESCHI C., INFLAMM-AGING, CYTOKINES AND AGING: STATE OF THE ART, NEW HYPOTHESES ON THE ROLE OF MITOCHONDRIA AND NEW PERSPECTIVES FROM SYSTEMS BIOLOGY, CURR PHARM DESIGN, 12, PP. 3161-3171, (2006); GORGOULIS V., ADAMS P.D., ALIMONTI A., BENNETT D.C., BISCHOF O., BISHOP C., CAMPISI J., COLLADO M., EVANGELOU K., FERBEYRE G., GIL J., HARA E., KRIZHANOVSKY V., JURK D., MAIER A.B., NARITA M., NIEDERNHOFER L., PASSOS J.F., ROBBINS P.D., SCHMITT C.A., SEDIVY J., VOUGAS K., VON ZGLINICKI T., ZHOU D., SERRANO M., DEMARIA M., CELLULAR SENESCENCE: DEFINING A PATH FORWARD, CELL, 179, PP. 27-813, (2019); HUANG W., HICKSON L.J., EIRIN A., KIRKLAND J.L., LERMAN L.O., CELLULAR SENESCENCE: THE GOOD, THE BAD AND THE UNKNOWN, NAT REV NEPHROL, 18, PP. 611-627, (2022); FRANCESCHI C., GARAGNANI P., PARINI P., GIULIANI C., SANTORO A., INFLAMMAGING: A NEW IMMUNE-METABOLIC VIEWPOINT FOR AGE-RELATED DISEASES, NAT REVIEWS ENDOCRINOL, PP. 14;576-90, (2018); DI MICCO R., KRIZHANOVSKY V., FAGAGNA B., CELLULAR SENESCENCE IN AGEING: FROM MECHANISMS TO THERAPEUTIC OPPORTUNITIES, NAT REV MOL CELL BIOL, 22, PP. 75-95, (2021); ROSSIELLO F., JURK D., FAGAGNA P., TELOMERE DYSFUNCTION IN AGEING AND AGE-RELATED DISEASES, NAT CELL BIOL, PP. 24;135-47, (2022); KOROLCHUK V.I., MIWA S., CARROLL B., VON ZGLINICKI T., MITOCHONDRIA IN CELL SENESCENCE: IS MITOPHAGY THE WEAKEST LINK?, EBIOMEDICINE, PP. 213-217, (2017); ACOSTA J.C., BANITO A., WUESTEFELD T., GEORGILIS A., JANICH P., MORTON J.P., ATHINEOS D., KANG T.W., LASITSCHKA F., ANDRULIS M., PASCUAL G., MORRIS K.J., KHAN S., JIN H., DHARMALINGAM G., SNIJDERS A.P., CARROLL T., CAPPER D., PRITCHARD C., INMAN G.J., LONGERICH T., SANSOM O.J., BENITAH S.A., ZENDER L., GIL J., A COMPLEX SECRETORY PROGRAM ORCHESTRATED BY THE INFLAMMASOME CONTROLS PARACRINE SENESCENCE, NAT CELL BIOL, PP. 15;978-90, (2013); COPPE J.P., DESPREZ P.Y., KRTOLICA A., CAMPISI J., THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE: THE DARK SIDE OF TUMOR SUPPRESSION, ANNU REV PATHOL, 5, PP. 99-118, (2010); DA SILVA P.F.L., OGRODNIK M., KUCHERYAVENKO O., GLIBERT J., MIWA S., CAMERON K., ISHAQ A., SARETZKI G., NAGARAJA-GRELLSCHEID S., NELSON G., VON ZGLINICKI T., THE BYSTANDER EFFECT CONTRIBUTES TO THE ACCUMULATION OF SENESCENT CELLS IN VIVO, AGING CELL, 18, (2019); DUGGAL N.A., POLLOCK R.D., LAZARUS N.R., HARRIDGE S., LORD J.M., MAJOR FEATURES OF IMMUNESENESCENCE, INCLUDING REDUCED THYMIC OUTPUT, ARE AMELIORATED BY HIGH LEVELS OF PHYSICAL ACTIVITY IN ADULTHOOD, AGING CELL, 17, (2018); FULOP T., LARBI A., HIROKAWA K., MOCCHEGIANI E., LESOURDS B., CASTLE S., WIKBY A., FRANCESCHI C., PAWELEC G., IMMUNOSUPPORTIVE THERAPIES IN AGING, CLIN INTERV AGING, 2, PP. 33-54, (2007); MILENKOVIC D., BERGHE W.V., MORAND C., CLAUDE S., VAN DE SANDT A., GORRESSEN S., MONFOULET L.E., CHIRUMAMILLA C.S., DECLERCK K., SZIC K.S.V., LAHTELA-KAKKONEN M., GERHAUSER C., MERX M.W., KELM M., A SYSTEMS BIOLOGY NETWORK ANALYSIS OF NUTRI(EPI)GENOMIC CHANGES IN ENDOTHELIAL CELLS EXPOSED TO EPICATECHIN METABOLITES, SCI REP, 8, (2018); MILENKOVIC D., RODRIGUEZ-MATEOS A., LUCOSZ M., ISTAS G., DECLERCK K., SANSONE R., DEENEN R., KOHRER K., CORRAL-JARA K.F., ALTSCHMIED J., HAENDELER J., KELM M., BERGHE W.V., HEISS C., FLAVANOL CONSUMPTION IN HEALTHY MEN PRESERVES INTEGRITY OF IMMUNOLOGICAL-ENDOTHELIAL BARRIER CELL FUNCTIONS: NUTRI(EPI)GENOMIC ANALYSIS, MOLECULAR NUTRITION & FOOD RESEARCH, E2100991, (2022); MILENKOVIC D., DECLERCK K., GUTTMAN Y., KEREM Z., CLAUDE S., WESELER A.R., BAST A., SCHROETER H., MORAND C., VANDEN BERGHE W., EPICATECHIN METABOLITES PROMOTE VASCULAR HEALTH THROUGH EPIGENETIC REPROGRAMMING OF ENDOTHELIAL-IMMUNE CELL SIGNALING AND REVERSING SYSTEMIC LOW-GRADE INFLAMMATION, BIOCHEM PHARMACOL, (2020); MARTIN M.A., RAMOS S., IMPACT OF DIETARY FLAVANOLS ON MICROBIOTA, IMMUNITY AND INFLAMMATION IN METABOLIC DISEASES, NUTRIENTS, 13, (2021); HOLLANDS W.J., PHILO M., PEREZ-MORAL N., NEEDS P.W., SAVVA G.M., KROON P.A., MONOMERIC FLAVANOLS ARE MORE EFFICIENT SUBSTRATES FOR GUT MICROBIOTA CONVERSION TO HYDROXYPHENYL-Γ-VALEROLACTONE METABOLITES THAN OLIGOMERIC PROCYANIDINS: A RANDOMIZED, PLACEBO-CONTROLLED HUMAN INTERVENTION TRIAL, MOLECULAR NUTRITION & FOOD RESEARCH, E1901135, (2020); BADAL V.D., VACCARIELLO E.D., MURRAY E.R., YU K.E., KNIGHT R., JESTE D.V., NGUYEN T.T., THE GUT MICROBIOME, AGING, AND LONGEVITY: A SYSTEMATIC REVIEW, NUTRIENTS, 12, (2020); GALKIN F., MAMOSHINA P., ALIPER A., PUTIN E., MOSKALEV V., GLADYSHEV V.N., ZHAVORONKOV A., HUMAN GUT MICROBIOME AGING CLOCK BASED ON TAXONOMIC PROFILING AND DEEP LEARNING, ISCIENCE, 23, (2020); CONWAY J., DUGGAL A.N., AGEING OF THE GUT MICROBIOME: POTENTIAL INFLUENCES ON IMMUNE SENESCENCE AND INFLAMMAGEING, AGEING RES REV, (2021); GREEN C.L., LAMMING D.W., FONTANA L., MOLECULAR MECHANISMS OF DIETARY RESTRICTION PROMOTING HEALTH AND LONGEVITY, NAT REV MOL CELL BIOL, 23, PP. 56-73, (2022); FONTANA L., FASANO A., CHONG Y.S., VINEIS P., WILLETT W.C., TRANSDISCIPLINARY RESEARCH AND CLINICAL PRIORITIES FOR BETTER HEALTH, PLOS MED, 18, (2021); DECLERCK K., VANDEN BERGHE W., BACK TO THE FUTURE: EPIGENETIC CLOCK PLASTICITY TOWARDS HEALTHY AGING, MECH AGEING DEV, PP. 17418-17429, (2018); VANDEN BERGHE W., EPIGENETIC IMPACT OF DIETARY POLYPHENOLS IN CANCER CHEMOPREVENTION: LIFELONG REMODELING OF OUR EPIGENOMES, PHARMACOL RES, 65, PP. 76-565, (2012); CAMELL C.D., YOUSEFZADEH M.J., ZHU Y., LGPL PRATA M.A., HUGGINS M., PIERSON L., ZHANG R.D., O'KELLY T., PIRTSKHALAVA P., XUN K., EJIMA A., XUE U., TRIPATHI J.M., ESPINDOLA-NETTO N., GIORGADZE E.J., ATKINSON C.L., INMAN K.O., JOHNSON S.H., CHOLENSKY T.W., CARLSON N.K., LEBRASSEUR S., KHOSLA M.G., O'SULLIVAN D.B., ALLISON S.C., JAMESON A., MEVES M., LI Y.S., PRAKASH S.E., CHIARELLA S.E., HAMILTON T., TCHKONIA L.J., NIEDERNHOFER J.L., KIRKLAND,P. D. ROBBINS, SENOLYTICS REDUCE CORONAVIRUS-RELATED MORTALITY IN OLD MICE, (2021); LIU L., YUE X., SUN Z., HAMBRIGHT W.S., FENG Q., CUI Y., HUARD J., ROBBINS P.D., WANG Z., MU X., SENOLYTIC ELIMINATION OF SENESCENT MACROPHAGES RESTORES MUSCLE STEM CELL FUNCTION IN SEVERELY DYSTROPHIC MUSCLE, AGING, 14, PP. 7650-7661, (2022); THOMPSON E.L., PITCHER L.E., NIEDERNHOFER L.J., ROBBINS P.D., TARGETING CELLULAR SENESCENCE WITH SENOTHERAPEUTICS: DEVELOPMENT OF NEW APPROACHES FOR SKIN CARE, PLAST RECONSTR SURG, 150, PP. 12S-19, (2022); LIU L., YUE X., SUN Z., HAMBRIGHT W.S., WEI J., LI Y., MATRE P., CUI Y., WANG Z., RODNEY G., HUARD J., ROBBINS P.D., MU X., REDUCTION OF SENESCENT FIBRO-ADIPOGENIC PROGENITORS IN PROGERIA-AGED MUSCLE BY SENOLYTICS RESCUES THE FUNCTION OF MUSCLE STEM CELLS, J CACHEXIA SARCOPENIA MUSCLE, (2022); SAUL D., KOSINSKY R.L., ATKINSON E.J., DOOLITTLE M.L., ZHANG X., LEBRASSEUR N.K., PIGNOLO R.J., ROBBINS P.D., NIEDERNHOFER L.J., IKENO Y., JURK D., PASSOS J.F., HICKSON L.J., XUE A., MONROE D.G., TCHKONIA T., KIRKLAND J.L., FARR J.N., KHOSLA S., A NEW GENE SET IDENTIFIES SENESCENT CELLS AND PREDICTS SENESCENCE-ASSOCIATED PATHWAYS ACROSS TISSUES, NAT COMMUN, 2022; NARASIMHAN A., FLORES R.R., CAMELL C.D., BERNLOHR D.A., ROBBINS P.D., NIEDERNHOFER L.J., CELLULAR SENESCENCE IN OBESITY AND ASSOCIATED COMPLICATIONS: A NEW THERAPEUTIC TARGET, CURRENT DIABETES REPORTS, PP. 22;537-48, (2022); NARASIMHAN A., FLORES R.R., ROBBINS P.D., NIEDERNHOFER L.J., ROLE OF CELLULAR SENESCENCE IN TYPE II DIABETES, ENDOCRINOLOGY, 162, (2021); ZHANG L., PITCHER L.E., YOUSEFZADEH M.J., NIEDERNHOFER L.J., ROBBINS P.D., ZHU Y., CELLULAR SENESCENCE: A KEY THERAPEUTIC TARGET IN AGING AND DISEASES, J CLIN INVESTIG, 132, (2022); JUSTICE J.N., GUBBI S., KULKARNI A.S., BARTLEY J.M., KUCHEL G.A., BARZILAI N., A GEROSCIENCE PERSPECTIVE ON IMMUNE RESILIENCE AND INFECTIOUS DISEASES: A POTENTIAL CASE FOR METFORMIN, GEROSCIENCE, PP. 43;1093-112, (2021); LE COUTEUR D.G., BARZILAI N., NEW HORIZONS IN LIFE EXTENSION, HEALTHSPAN EXTENSION AND EXCEPTIONAL LONGEVITY, AGE AGEING, 51, (2022); KULKARNI A.S., ALEKSIC S., BERGER D.M., SIERRA F., KUCHEL G.A., BARZILAI N., GEROSCIENCE-GUIDED REPURPOSING OF FDA-APPROVED DRUGS TO TARGET AGING: A PROPOSED PROCESS AND PRIORITIZATION, AGING CELL, 2022; JO A.L., HAN J.W., AN J.I., CHO K.H., JEOUNG N.H., CUBAN POLICOSANOL PREVENTS THE APOPTOSIS AND THE MITOCHONDRIAL DYSFUNCTION INDUCED BY LIPOPOLYSACCHARIDE IN C2C12 MYOBLAST VIA ACTIVATION OF AKT AND ERK PATHWAYS, J NUTRI SCI VITAMINOL, 68, PP. 79-86, (2022); KIM K.M., KIM C.H., CHO K.H., JANG W.G., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN EXP PHARMACOL PHYSIOL, 48, PP. 1336-1345, (2021); SAAVEDRA D., FUERTES S.A., SUAREZ G.M., GONZALEZ A., LORENZO-LUACES P., GARCIA B., AZNAR E., MAZORRA Z., CROMBET T., SPEISER D.E., LAGE A., BIOMODULINA T PARTIALLY RESTORES IMMUNOSENESCENT CD4 AND CD8 T CELL COMPARTMENTS IN THE ELDERLY, EXP GERONTOL, (2019); SUAREZ G.M., CATALA M., PENA Y., PORTELA S., ANE-KOURI A.L., GONZALEZ A., LORENZO-LUACES P., DIAZ M., MOLINA M.L.A., PEREIRA K., HERNANDEZ J.C., RAMOS R., REYES M.C., LEDON N., MAZORRA Z., CROMBET T., LAGE A., SAAVEDRA D., THYMIC POLYPEPTIDE FRACTION BIOMODULINA T DECREASES EXHAUSTED AND TERMINALLY DIFFERENTIATED EMRA T CELLS IN ADVANCED LUNG CANCER PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY, FRONTIERS IN ONCOLOGY, 12, (2022); SUAREZ-FORMIGO G.M., SAAVEDRA-HERNANDEZ D., BIOMODULINA T MAY RESTORE IMMUNITY IN OLDER ADULTS, MEDICC REV, PP. 22;54-6, (2020); HORVATH S., RAJ K. DNA METHYLATION-BASED BIOMARKERS AND THE EPIGENETIC CLOCK THEORY OF AGEING, NAT REV GENET, 19, PP. 84-371, (2018); LI A., MUELLER A., ENGLISH B., ARENA A., VERA D., KANE A.E., SINCLAIR D.A., NOVEL FEATURE SELECTION METHODS FOR CONSTRUCTION OF ACCURATE EPIGENETIC CLOCKS, PLOS COMPUT BIOL, 2022; GILL D., PARRY A., SANTOS F., OKKENHAUG H., TODD C.D., HERNANDO-HERRAEZ I., STUBBS T.M., MILAGRE I., REIK W., MULTI-OMIC REJUVENATION OF HUMAN CELLS BY MATURATION PHASE TRANSIENT REPROGRAMMING. ELIFE. 2022:","D. SAAVEDRA; DEPARTMENT OF CLINICAL IMMUNOLOGY, CENTER OF MOLECULAR IMMUNOLOGY, ATABEY, 216 ST, CORNER 15, HAVANA, PO BOX 16040, CUBA; EMAIL: DANAYS@CIM.SLD.CU","BIOMED CENTRAL LTD","ENGLISH","IMMUN. AGEING","REVIEW","ISI","2-S2.0-85161322567","IMMUN AGEING","CENTER OF MOLECULAR IMMUNOLOGY;CENTER OF MOLECULAR IMMUNOLOGY;ALBERT EINSTEIN COLLEGE OF MEDICINE;UNIVERSITÀ DI PALERMO;YEUNGNAM UNIVERSITY;THE UNIVERSITY OF SYDNEY;LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD;UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE;CENTER OF MOLECULAR IMMUNOLOGY;UNIVERSITY OF MINNESOTA MEDICAL SCHOOL;CENTER OF MOLECULAR IMMUNOLOGY;UNIVERSITY OF MINNESOTA MEDICAL SCHOOL;CENTER OF MOLECULAR IMMUNOLOGY;CENTER OF MOLECULAR IMMUNOLOGY;UNIVERSITY OF ANTWERP;NEWCASTLE UNIVERSITY BIOSCIENCES INSTITUTE;UNIVERSITY OF TÜBINGEN;CENTER OF MOLECULAR IMMUNOLOGY","NOTREPORTED;CENTER OF MOLECULAR IMMUNOLOGY;NOTREPORTED",NA,"SAAVEDRA D, 2023, IMMUN AGEING","SAAVEDRA D, 2023, IMMUN AGEING"
"ZHAI Z;LIU J;NIU K;LIN C;TU Y;LIU Y;CAI L;LIU H;OUYANG K","ZHAI, ZHENYA (57189509834); LIU, JIANPING (57202034035); NIU, KAI-MIN (57190128221); LIN, CHONG (57248069600); TU, YUE (57312304800); LIU, YICHUN (57247420300); CAI, LICHUANG (54407998100); LIU, HUIPING (57218118479); OUYANG, KEXIAN (57202031966)","INTEGRATED METAGENOMICS AND METABOLOMICS TO REVEAL THE EFFECTS OF POLICOSANOL ON MODULATING THE GUT MICROBIOTA AND LIPID METABOLISM IN HYPERLIPIDEMIC C57BL6 MICE",2021,"FRONTIERS IN ENDOCRINOLOGY","12","",14,"10.3389/fendo.2021.722055","JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA, KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, CHANGSHA, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA, KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, CHANGSHA, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;LTD, SHENZHEN, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA","THE AIM OF THE STUDY WAS TO INVESTIGATE THE REGULATORY EFFECTS OF POLICOSANOL ON HYPERLIPIDEMIA, GUT MICROBIOTA AND METABOLIC STATUS IN A C57BL/6 MOUSE MODEL. A TOTAL OF 35 C57BL/6 MICE WERE ASSIGNED TO 3 GROUPS, CHOW (N=12), HIGH FAT DIET (HFD, N=12) AND HFD+POLICOSANOL (N=11), THEN TREATED FOR 18 WEEKS. POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY REDUCED SERUM TRIGLYCERIDES AND TOTAL CHOLESTEROL, AS WELL AS THE WEIGHT OF BROWN ADIPOSE TISSUE (BAT) (P<0.05), WITHOUT AFFECTING BODY WEIGHT IN HFD-FED MICE (P>0.05). COMBINED 16S RRNA GENE SEQUENCING AND UNTARGETED METABOLOMIC ANALYSIS DEMONSTRATED THAT POLICOSANOL HAD REGULATORY EFFECTS ON GUT MICROBIOTA AND SERUM METABOLISM IN MICE. IN OBESE MICE, POLICOSANOL INCREASED THE PROPORTION OF BACTEROIDES, DECREASED THE PROPORTION OF FIRMICUTES, AND INCREASED THE RATIO OF BACTEROIDES TO FIRMICUTES (P<0.05). POLICOSANOL PROMOTED LIPOLYSIS AND THERMOGENESIS PROCESS, INCLUDING TRICARBOXYLIC ACID (TCA) CYCLE AND PYRUVATE CYCLE, CORRELATED WITH THE INCREASING LEVEL OF BACTEROIDES, PARASUTTERELLA, AND DECREASING LEVEL OF LACTOBACILLUS AND CANDIDATUS_SACCHARIMONAS. MOREOVER, POLICOSANOL DECREASED FATTY ACID SYNTHASE (FAS) IN THE IWAT OF OBESE MICE. POLICOSANOL ALSO INCREASED PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR-Γ (PPARΓ), UNCOUPLING PROTEIN-1 (UCP-1), PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR-1Α (PGC-1Α) AND PR DOMAIN CONTAINING 16 (PRDM16) IN BROWN ADIPOSE TISSUE (BAT) OBESE MICE (P<0.05). THIS STUDY PRESENTS THE NEW INSIGHT THAT POLICOSANOL MAY INHIBIT THE SYNTHESIS OF FATTY ACIDS, AND PROMOTE LIPOLYSIS, THERMOGENESIS RELATED GENE EXPRESSION AND REGULATE GUT MICROBIOTA CONSTITUENTS, WHICH PROVIDES POTENTIAL FOR POLICOSANOL AS AN ANTIHYPERLIPIDEMIA FUNCTIONAL FOOD ADDITIVE AND PROVIDE NEW EVIDENCE FOR WHOLE GRAIN FOOD TO REPLACE REFINED FOOD. © COPYRIGHT © 2021 ZHAI, LIU, NIU, LIN, TU, LIU, CAI, LIU AND OUYANG.","ANTIHYPERLIPIDEMIA; C57BL/6 MOUSE; GUT MICROBIOTA; METABOLOMICS; POLICOSANOL","FATTY ACID SYNTHASE; NUCLEIC ACID BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POLICOSANOL; PR DOMAIN CONTAINING 16; PYRUVIC ACID; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEROIDETES; BIOINFORMATICS; BODY FAT; BROWN ADIPOSE TISSUE; C57BL 6 MOUSE; CANDIDATUS SACCHARIMONAS; CHOLESTEROL BLOOD LEVEL; CITRIC ACID CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FECES MICROFLORA; FIRMICUTES; GENE SEQUENCE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HYPERLIPIDEMIA; INTESTINE FLORA; LACTOBACILLUS; LIPID DIET; LIPID METABOLISM; LIPOLYSIS; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; METABOLOMICS; METAGENOMICS; MOUSE; MRNA EXPRESSION LEVEL; NONHUMAN; PARASUTTERELLA; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; THERMOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL","GENERAL PROJECTS OF KEY RESEARCH AND DEVELOPMENT PLAN IN JIANGXI PROVINCE, (20203BBFL63054); GUANGDONG PROVINCE ENTERPRISE SPECIAL PERSON SPECIAL PLAN PROJECT, (GDKTP2020054600); RESEARCH AND DEVELOPMENT PROJECT OF JIANGXI ACADEMY OF SCIENCES, (2020-YYB-01); CHINA POSTDOCTORAL SCIENCE FOUNDATION, (2020M682108); JIANGXI ACADEMY OF SCIENCES, JAS, (2021YSBG22008, 2021YSBG50009)","THE PROJECT WAS FUNDED BY GENERAL PROJECTS OF KEY RESEARCH AND DEVELOPMENT PLAN IN JIANGXI PROVINCE (20203BBFL63054), PROJECT FUNDED BY CHINA POSTDOCTORAL SCIENCE FOUNDATION (2020M682108), GUANGDONG PROVINCE ENTERPRISE SPECIAL PERSON SPECIAL PLAN PROJECT (GDKTP2020054600), PILOT DEMONSTRATION PROJECT FOR OVERALL RATIONING SYSTEM OF JIANGXI ACADEMY OF SCIENCES (2021YSBG22008, 2021YSBG50009) AND RESEARCH AND DEVELOPMENT PROJECT OF JIANGXI ACADEMY OF SCIENCES - DOCTORAL FUND PROJECT (2020-YYB-01).","JAACKS L.M., VANDEVIJVERE S., PAN A., MCGOWAN C.J., WALLACE C., IMAMURA F., ET AL., THE OBESITY TRANSITION: STAGES OF THE GLOBAL EPIDEMIC, LANCET DIABETES ENDOCRINOL, 7, (2019); CARDEL M.I., JASTREBOFF A.M., KELLY A.S., TREATMENT OF ADOLESCENT OBESITY IN 2020, JAMA, 322, (2019); ZHANG X., ZHANG M., ZHAO Z., HUANG Z., DENG Q., LI Y., ET AL., GEOGRAPHIC VARIATION IN PREVALENCE OF ADULT OBESITY IN CHINA: RESULTS FROM THE 2013-2014 NATIONAL CHRONIC DISEASE AND RISK FACTOR SURVEILLANCE, ANN INTERN MED, 172, (2020); LOFFREDO L., MARTINO F., CARNEVALE R., PIGNATELLI P., CATASCA E., PERRI L., ET AL., OBESITY AND HYPERCHOLESTEROLEMIA ARE ASSOCIATED WITH NOX2 GENERATED OXIDATIVE STRESS AND ARTERIAL DYSFUNCTION, J PEDIATR, 161, (2012); MARENGO A., ROSSO C., BUGIANESI E., LIVER CANCER: CONNECTIONS WITH OBESITY, FATTY LIVER, AND CIRRHOSIS, ANNU REV MED, 67, (2016); KOMAROFF A.L., THE MICROBIOME AND RISK FOR OBESITY AND DIABETES, JAMA-J AM MED ASSOC, 317, (2017); TURNBAUGH P.J., LEY R.E., MAHOWALD M.A., MAGRINI V., MARDIS E.R., GORDON J.I., AN OBESITY-ASSOCIATED GUT MICROBIOME WITH INCREASED CAPACITY FOR ENERGY HARVEST, NATURE, 444, (2006); RIDAURA V.K., FAITH J.J., REY F.E., CHENG J., DUNCAN A.E., KAU A.L., ET AL., GUT MICROBIOTA FROM TWINS DISCORDANT FOR OBESITY MODULATE METABOLISM IN MICE, SCIENCE, 341, (2013); LIU R., HONG J., XU X., FENG Q., ZHANG D., GU Y., ET AL., GUT MICROBIOME AND SERUM METABOLOME ALTERATIONS IN OBESITY AND AFTER WEIGHT-LOSS INTERVENTION, NAT MED, 23, (2017); KINCAID H.J., NAGPAL R., YADAV H., MICROBIOME-IMMUNE-METABOLIC AXIS IN THE EPIDEMIC OF CHILDHOOD OBESITY: EVIDENCE AND OPPORTUNITIES, OBES REV, 2, PP. 1-13, (2020); ZHENG X., CHEN T., JIANG R., ZHAO A., WU Q., KUANG J., ET AL., HYOCHOLIC ACID SPECIES IMPROVE GLUCOSE HOMEOSTASIS THROUGH A DISTINCT TGR5 AND FXR SIGNALING MECHANISM, CELL METAB, 33, (2020); WANG D., LIU C.D., LI H.F., TIAN M.L., PAN J.Q., SHU G., ET AL., LSD1 MEDIATES MICROBIAL METABOLITE BUTYRATE-INDUCED THERMOGENESIS IN BROWN AND WHITE ADIPOSE TISSUE, METABOLISM, 102, (2020); CHAVEZ-TALAVERA O., HAAS J., GRZYCH G., TAILLEUX A., STAELS B., BILE ACID ALTERATIONS IN NONALCOHOLIC FATTY LIVER DISEASE, OBESITY, INSULIN RESISTANCE AND TYPE 2 DIABETES: WHAT DO THE HUMAN STUDIES TELL, CURR OPIN LIPIDOL, 30, (2019); GUO J., HAN X., TAN H., HUANG W., YOU Y., ZHAN J., BLUEBERRY EXTRACT IMPROVES OBESITY THROUGH REGULATION OF THE GUT MICROBIOTA AND BILE ACIDS VIA PATHWAYS INVOLVING FXR AND TGR5, ISCIENCE, 19, (2019); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J FUNCT FOODS, 57, (2019); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, (2006); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, (1995); MAZZA A., LENTI S., SCHIAVON L., ZUIN M., D'AVINO M., RAMAZZINA E., ET AL., NUTRACEUTICALS FOR SERUM LIPID AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS AT LOW CARDIOVASCULAR RISK, ADV THER, 32, (2015); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, (2011); NAM D.E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J MED FOOD, 22, (2019); LIU Y., XIE C., ZHAI Z., DENG Z.Y., DE JONGE H.R., WU X., ET AL., URIDINE ATTENUATES OBESITY, AMELIORATES HEPATIC LIPID ACCUMULATION AND MODIFIES THE GUT MICROBIOTA COMPOSITION IN MICE FED WITH A HIGH-FAT DIET, FOOD FUNCT, 12, (2021); ZHAI Z., ZHANG F., CAO R., NI X., XIN Z., DENG J., ET AL., CECROPIN A ALLEVIATES INFLAMMATION THROUGH MODULATING THE GUT MICROBIOTA OF C57BL/6 MICE WITH DSS-INDUCED IBD, FRONT MICROBIOL, 10, (2019); SACCENTI E., HOEFSLOOT H.C.J., SMILDE A.K., WESTERHUIS J.A., HENDRIKS M.M.W.B., REFLECTIONS ON UNIVARIATE AND MULTIVARIATE ANALYSIS OF METABOLOMICS DATA, METABOLOMICS, 10, (2014); XIN Z., ZHAI Z., LONG H., ZHANG F., NI X., DENG J., ET AL., METABOLIC PROFILING BY UPLC-ORBITRAP-MS/MS OF LIVER FROM C57BL/6 MICE WITH DSS-INDUCED INFLAMMATORY BOWEL DISEASE, MEDIATORS INFLAMM, 2020, (2020); TAN C., ZHAI Z., NI X., WANG H., JI Y., TANG T., ET AL., METABOLOMIC PROFILES REVEAL POTENTIAL FACTORS THAT CORRELATE WITH LACTATION PERFORMANCE IN SOW MILK, SCI REP, 8, (2018); GONZALEZ-MUNIESA P., MARTINEZ-GONZALEZ M.A., HU F.B., DESPRES J.P., MATSUZAWA Y., LOOS R., ET AL., OBESITY, NAT REV DIS PRIMERS, 3, (2017); NGUYEN N.T., VARELA J.E., BARIATRIC SURGERY FOR OBESITY AND METABOLIC DISORDERS: STATE OF THE ART, NAT REV GASTROENTEROL HEPATOL, 14, (2017); HEYMSFIELD S.B., WADDEN T.A., MECHANISMS, PATHOPHYSIOLOGY, AND MANAGEMENT OF OBESITY, N ENGL J MED, 376, (2017); INGE T.H., JENKINS T.M., XANTHAKOS S.A., DIXON J.B., DANIELS S.R., ZELLER M.H., ET AL., LONG-TERM OUTCOMES OF BARIATRIC SURGERY IN ADOLESCENTS WITH SEVERE OBESITY (FABS-5+): A PROSPECTIVE FOLLOW-UP ANALYSIS, LANCET DIABETES ENDOCRINOL, 5, (2017); CHO K., KIM S., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, J AM COLL CARDIOL, 72S, (2018); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI REP-UK, 9, (2019); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-65, (2001); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); OTHMAN R.A., XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., THE IMPACT OF DIETARY OCTACOSANOL ON PLASMA LIPIDS AND ATHEROSCLEROTIC LESION DEVELOPMENT IN APO E-KO MICE, FASEB J, 21, (2007); LE CHATELIER E., NIELSEN T., QIN J., PRIFTI E., HILDEBRAND F., FALONY G., ET AL., RICHNESS OF HUMAN GUT MICROBIOME CORRELATES WITH METABOLIC MARKERS, NATURE, 500, (2013); JU T., KONG J.Y., STOTHARD P., WILLING B.P., DEFINING THE ROLE OF PARASUTTERELLA, A PREVIOUSLY UNCHARACTERIZED MEMBER OF THE CORE GUT MICROBIOTA, ISME J, 13, (2019); ZHANG J., NI Y., QIAN L., FANG Q., ZHENG T., ZHANG M., ET AL., DECREASED ABUNDANCE OF AKKERMANSIA MUCINIPHILA LEADS TO THE IMPAIRMENT OF INSULIN SECRETION AND GLUCOSE HOMEOSTASIS IN LEAN TYPE 2 DIABETES, ADV SCI, (2021); WANG L., TANG L., FENG Y., ZHAO S., HAN M., ZHANG C., ET AL., A PURIFIED MEMBRANE PROTEIN FROM AKKERMANSIA MUCINIPHILA OR THE PASTEURISED BACTERIUM BLUNTS COLITIS ASSOCIATED TUMOURIGENESIS BY MODULATION OF CD8(+) T CELLS IN MICE, GUT, 69, (2020); PLOVIER H., EVERARD A., DRUART C., DEPOMMIER C., VAN HUL M., GEURTS L., ET AL., A PURIFIED MEMBRANE PROTEIN FROM AKKERMANSIA MUCINIPHILA OR THE PASTEURIZED BACTERIUM IMPROVES METABOLISM IN OBESE AND DIABETIC MICE, NAT MED, 23, (2017); HSIAO W.Y., JUNG S.M., TANG Y., HALEY J.A., LI R., LI H., ET AL., THE LIPID HANDLING CAPACITY OF SUBCUTANEOUS FAT IS PROGRAMMED BY MTORC2 DURING DEVELOPMENT, CELL REP, 33, (2020); POLLARD A.E., MARTINS L., MUCKETT P.J., KHADAYATE S., BORNOT A., CLAUSEN M., ET AL., AMPK ACTIVATION PROTECTS AGAINST DIET INDUCED OBESITY THROUGH UCP1-INDEPENDENT THERMOGENESIS IN SUBCUTANEOUS WHITE ADIPOSE TISSUE, NAT METAB, 1, (2019); SUN B., JIA Y., HONG J., SUN Q., GAO S., HU Y., ET AL., SODIUM BUTYRATE AMELIORATES HIGH-FAT-DIET-INDUCED NON-ALCOHOLIC FATTY LIVER DISEASE THROUGH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA-MEDIATED ACTIVATION OF BETA OXIDATION AND SUPPRESSION OF INFLAMMATION, J AGRIC FOOD CHEM, 66, (2018); JORDAN S., TUNG N., CASANOVA-ACEBES M., CHANG C., CANTONI C., ZHANG D., ET AL., DIETARY INTAKE REGULATES THE CIRCULATING INFLAMMATORY MONOCYTE POOL, EUR J IMMUNOL, 491, (2019)","K. OUYANG; JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA; EMAIL: ZIYUANHUAXUELAB@163.COM; H. LIU; ERA BIOTECHNOLOGY (SHENZHEN) CO., LTD, SHENZHEN, CHINA; EMAIL: 546033730@QQ.COM","FRONTIERS MEDIA S.A.","ENGLISH","FRONT. ENDOCRINOL.","ARTICLE","ISI","2-S2.0-85117922358","FRONT ENDOCRINOL","INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE","NOTREPORTED;INSTITUTE OF BIOLOGICAL RESOURCE;NOTDECLARED;NOTREPORTED;ERA BIOTECHNOLOGY (SHENZHEN) CO.;NOTREPORTED",NA,"ZHAI Z, 2021, FRONT ENDOCRINOL","ZHAI Z, 2021, FRONT ENDOCRINOL"
"SAENTHAWEESUK S;THAEOMOR A;RABINTOSSAPORN P;NAOWABOOT J;SOMPARN N","SAENTHAWEESUK, SUPHAKET (28167914300); THAEOMOR, ATCHARAPORN (26424085000); RABINTOSSAPORN, PORNRUT (28167773300); NAOWABOOT, JARINYAPORN (26536398300); SOMPARN, NUNTIYA (15754381800)","EFFECTS OF OCTACOSANOL ON HMGCOA REDUCTASE AND CYCLOOXYGENASE2 ACTIVITIES IN THE HT29 HUMAN COLORECTAL CANCER CELL LINE",2022,"SCIENCEASIA","48","4",1,"10.2306/scienceasia1513-1874.2022.007","PRECLINICAL SCIENCE, FACULTY OF MEDICINE, THAMMASAT UNIVERSITY, 12120, THAILAND;SCHOOL OF PRECLINIC, INSTITUTE OF SCIENCE, SURANAREE UNIVERSITY OF TECHNOLOGY, NAKHON RATCHASIMA, 30000, THAILAND;PRECLINICAL SCIENCE, FACULTY OF MEDICINE, THAMMASAT UNIVERSITY, 12120, THAILAND;PRECLINICAL SCIENCE, FACULTY OF MEDICINE, THAMMASAT UNIVERSITY, 12120, THAILAND;PRECLINICAL SCIENCE, FACULTY OF MEDICINE, THAMMASAT UNIVERSITY, 12120, THAILAND","OCTACOSANOL (OCT) IS A MAJOR COMPONENT OF POLICOSANOL WHICH HAS BEEN REPORTED TO POSSESS ANTI-INFLAMMATORY AND LIPID-LOWERING EFFECTS. THEREFORE, IT WAS OUR INTEREST TO EVALUATE THE EFFECTS OF OCT ON HMG-COA REDUCTASE (HMGR) AND CYCLOOXYGENASE-2 (COX-2) ACTIVITIES IN A HUMAN COLORECTAL CANCER CELL LINE (HT-29). OUR RESULTS DEMONSTRATE THAT 100 ΜM OCT DECREASED VIABILITY OF HT-29 CELLS AS ANALYZED BY SULFORHODAMINE B COLORIMETRIC ASSAY WITH MORE PRONOUNCED EFFECTS SEEN IN CELLS TREATED WITH ATORVASTATIN (AST) OR CELECOXIB (CLX), THE INHIBITORS TO HMGR AND COX-2, RESPECTIVELY. ADDITIONALLY, THE ACTIVITY OF HMGR WAS FOUND TO BE INHIBITED IN CELLS TREATED WITH OCT, WHILE COX-2 ACTIVITY WAS UNAFFECTED; THESE EFFECTS WERE ALSO MORE PRONOUNCED IN AST- AND CLX-TREATED CELLS. IN CELLS TREATED WITH OCT, A SIGNIFICANT DECREASE IN HMGR PROTEIN EXPRESSION WAS OBSERVED, BUT THERE WAS NO ALTERATION IN COX-2 PROTEIN EXPRESSION AS DETERMINED BY WESTERN BLOT. TAKEN TOGETHER, OUR RESULTS SHOW THAT OCT INHIBITED HT-29 CELL GROWTH AND THAT THIS EFFECT MIGHT BE ATTRIBUTED TO THE REDUCTION OF HMGR PROTEIN EXPRESSION AND ACTIVITY. © 2022 SCIENCE SOCIETY OF THAILAND UNDER ROYAL PATRONAGE. ALL RIGHTS RESERVED.","COLORECTAL CANCER; CYCLOOXYGENASE; HMG-COA REDUCTASE; OCTACOSANOL","","THAMMASAT UNIVERSITY, THAILAND, (TP 2-04/2018); THAMMASAT UNIVERSITY, TU, (TP 2/5/2018)","ACKNOWLEDGEMENTS: THIS WORK WAS SUPPORTED BY A GRANT FROM THAMMASAT UNIVERSITY UNDER GRANT NUMBER: TP 2/5/2018 AND FACULTY OF MEDICINE, THAMMASAT UNIVERSITY, THAILAND UNDER GRANT NUMBER: TP 2-04/2018.","IRMAK S, DUNFORD NT, POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); RAVELO Y, MOLINA V, CARBAJAL D, FERNANDEZ L, FERNANDEZ JC, ARRUZAZABALA ML, MAS R, EVALUATION OF ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECTS OF D-002 (BEESWAX ALCOHOLS), J NAT MED, 65, PP. 330-335, (2011); PAL'REZ YMR, OYARZABAL A, JIMENEZ S, MOLINA V, EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, INT J PHARM SCI REV RES, 19, PP. 18-23, (2013); ARRUZAZABALA ML, CARBAJAL D, MAS R, MOLINA V, VALDES S, LAGUNA A, CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); CASTANO G, MAS R, FERNANDEZ L, ILLNAIT J, GAMEZ R, ALVAREZ E, EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CUBEDDU LX, CUBEDDU RJ, HEIMOWITZ T, RESTREPO B, LAMAS GA, WEINBERG GB, COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); NAM DE, YUN JM, KIM D, KIM OK, POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J MED FOOD, 22, PP. 1110-1117, (2019); ZHU L, GUO G, FAN Z-Q, WANG N, ZOU D-Q, SHI X-Q, ALLEVIATION OF HIGH- FAT-DIET INDUCED OBESITY AND CHOLESTEROL ACCUMULATION IN MICE BY EXTRACTS FROM MALE ZOOID OF ANTHERAEA PERNYI, SCIENCEASIA, 47, PP. 162-169, (2021); SINGH DK, LI L, PORTER TD, POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); HASHEMI GORADEL N, NAJAFI M, SALEHI E, FARHOOD B, MORTEZAEE K, CYCLOOXYGENASE-2 IN CANCER: ĖVIEW, J CELL PHYSIOL, 234, PP. 5683-5699, (2019); KHAN Z, KHAN N, TIWARI RP, SAH NK, PRASAD GB, BISEN PS, BIOLOGY OF COX-2: AN APPLICATION IN CANCER THERAPEUTICS, CURR DRUG TARGETS, 12, PP. 1082-1093, (2011); YARLA NS, BISHAYEE A, SETHI G, REDDANNA P, KALLE AM, DHANANJAYA BL, DOWLURU KS, CHINTALA R, ET AL., TARGETING ARACHIDONIC ACID PATHWAY BY NATURAL PRODUCTS FOR CANCER PREVENTION AND THERAPY, SEMIN CANCER BIOL, 40, 41, PP. 48-81, (2016); KIM MK, MYUNG SK, TRAN BT, PARK B, STATINS AND RISK OF CANCER: A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS, INDIAN J CANCER, 54, PP. 470-477, (2017); LIU BL, VI ZB, GUAN XW, MA F, ZENG YX, THE RELATIONSHIP BETWEEN STATINS AND BREAST CANCER PROGNOSIS VARIES BY STATIN TYPE AND EXPOSURE TIME: A META-ANALYSIS, BREAST CANCER RES TREAT, 164, PP. 1-11, (2017); PAAJARVI G, ROUDIER E, CRISBY M, HOGBERG J, STENIUS U, HMG-COA REDUCTASE INHIBITORS, STATINS, INDUCE PHOSPHORYLATION OF MDM2 AND ATTENUATE THE P53 RESPONSE TO DNA DAMAGE, FASEB J, 19, PP. 476-478, (2005); RIDRUEJO E, ROMERO-CAIMI G, OBREGON MJ, KLEIMAN DE PISAREV D, ALVAREZ L, POTENTIAL MOLECULAR TARGETS OF STATINS IN THE PREVENTION OF HEPATOCARCINOGENESIS, ANN HEPATOL, 17, PP. 490-500, (2018); HEROLD G, JUNGWIRTH R, ROGLER G, GEERLING I, STANGE EF, INFLUENCE OF CHOLESTEROL SUPPLY ON CELL GROWTH AND DIFFERENTIATION IN CULTURED ENTEROCYTES (CACO-2), DIGESTION, 56, PP. 57-66, (1995); SCHOINTUCH MN, GILLIAM TP, STINE JE, HAN X, ZHOU C, GEHRIG PA, KIM K, BAE-JUMP VL, SIMVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, EXHIBITS ANTI-METASTATIC AND ANTI-TUMORIGENIC EFFECTS IN ENDOMETRIAL CANCER, GYNECOL ONCOL, 134, PP. 346-355, (2014); STINE JE, GUO H, SHENG X, HAN X, SCHOINTUCH MN, GILLIAM TP, GEHRIG PA, ZHOU C, ET AL., THE HMG-COA REDUCTASE INHIBITOR, SIMVASTATIN, EXHIBITS ANTI-METASTATIC AND ANTI-TUMORIGENIC EFFECTS IN OVARIAN CANCER, ONCOTARGET, 7, PP. 946-960, (2016); GUO TY, LIN QL, LI XH, NIE Y, WANG L, SHI LM, XU W, HU T, ET AL., OCTACOSANOL ATTENUATES INFLAMMATION IN BOTH RAW264.7 MACROPHAGES AND A MOUSE MODEL OF COLITIS, J AGR FOOD CHEM, 65, PP. 3647-3658, (2017); OLIARO-BOSSO S, CALCIO GAUDINO E, MANTEGNA S, GIRAUDO E, MEDA C, VIOLA F, CRAVOTTO G, REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); SUBBARAMAIAH K, DANNENBERG AJ, CYCLOOXYGENASE 2: A MOLECULAR TARGET FOR CANCER PREVENTION AND TREATMENT, TRENDS PHARMACOL SCI, 24, PP. 96-102, (2003); ZUO C, HONG Y, QIU X, YANG D, LIU N, SHENG X, ZHOU K, TANG B, ET AL., CELECOXIB SUPPRESSES PROLIFERATION AND METASTASIS OF PANCREATIC CANCER CELLS BY DOWN-REGULATING STAT3/NF-ΚB AND L1CAM ACTIVITIES, PANCREATOLOGY, 18, PP. 328-333, (2018); GOBEL A, BREINING D, RAUNER M, HOFBAUER LC, RACHNER TD, INDUCTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE MEDIATES STATIN RESISTANCE IN BREAST CANCER CELLS, CELL DEATH DIS, 10, (2019); RAMER R, WALTHER U, BORCHERT P, LAUFER S, LINNEBACHER M, HINZ B, INDUCTION BUT NOT INHIBITION OF COX-2 CONFERS HUMAN LUNG CANCER CELL APOPTOSIS BY CELECOXIB, J LIPID RES, 54, PP. 3116-3129, (2013)","N. SOMPARN; PRECLINICAL SCIENCE, FACULTY OF MEDICINE, THAMMASAT UNIVERSITY, 12120, THAILAND; EMAIL: NUNTIYA_TOM@HOTMAIL.COM","SCIENCE SOCIETY OF THAILAND UNDER ROYAL PATRONAGE","ENGLISH","SCIENCEASIA","ARTICLE","ISI","2-S2.0-85123089385","SCIENCEASIA","THAMMASAT UNIVERSITY;SURANAREE UNIVERSITY OF TECHNOLOGY;THAMMASAT UNIVERSITY;THAMMASAT UNIVERSITY;THAMMASAT UNIVERSITY","NOTREPORTED;THAMMASAT UNIVERSITY;NOTREPORTED",NA,"SAENTHAWEESUK S, 2022, SCIENCEASIA","SAENTHAWEESUK S, 2022, SCIENCEASIA"
"MIYAMOTO K;YASUDA T;AKAHO T;RD R;SHIMOSHIKIRYO I;NISHIMOTO D;MIYAHARA H;TOKUSHIGE K;TANOUE S;KORIYAMA C;TAKEZAKI T","MIYAMOTO, KAEDE (58031552800); YASUDA, TOMOKO (58031726500); AKAHO, TAKUMI (58030538200); RD, RIE IBUSUKI (58888710000); SHIMOSHIKIRYO, IPPEI (57194900799); NISHIMOTO, DAISAKU (57208398519); MIYAHARA, HIRONORI (55897824000); TOKUSHIGE, KOUICHI (57221719800); TANOUE, SHIROH (39863612100); KORIYAMA, CHIHAYA (6603006392); TAKEZAKI, TOSHIRO (57217791380)","ASSOCIATION BETWEEN BROWN SUGAR INTAKE AND DECREASED RISK OF CANCER IN THE AMAMI ISLANDS REGION JAPAN",2023,"ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION","32","7",0,"10.6133/apjcn.202312_32(4).0007","SCHOOL OF MEDICINE, FACULTY OF MEDICINE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN, KAMEDA MEDICAL CENTER, KAMOGAWA, JAPAN;SCHOOL OF MEDICINE, FACULTY OF MEDICINE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN, KAMEDA MEDICAL CENTER, KAMOGAWA, JAPAN;SCHOOL OF MEDICINE, FACULTY OF MEDICINE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN, ARAO MUNICIPAL HOSPITAL, ARAO, JAPAN;DEPARTMENT OF COMMUNITY-BASED MEDICINE, KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES, KAGOSHIMA, JAPAN;ENVIRONMENTAL EPIDEMIOLOGY SECTION, HEALTH AND ENVIRONMENTAL RISK DIVISION, NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES, TSUKUBA, JAPAN, DEPARTMENT OF EPIDEMIOLOGY AND PREVENTIVE MEDICINE, KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES, KAGOSHIMA, JAPAN;DEPARTMENT OF EPIDEMIOLOGY AND PREVENTIVE MEDICINE, KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES, KAGOSHIMA, JAPAN, SCHOOL OF HEALTH SCIENCES, FACULTY OF MEDICINE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN;KAGOSHIMA KOUSEIREN MEDICAL HEALTH CARE CENTER, KAGOSHIMA, JAPAN;KAGOSHIMA KOUSEIREN MEDICAL HEALTH CARE CENTER, KAGOSHIMA, JAPAN;DEPARTMENT OF EPIDEMIOLOGY AND PREVENTIVE MEDICINE, KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES, KAGOSHIMA, JAPAN;DEPARTMENT OF EPIDEMIOLOGY AND PREVENTIVE MEDICINE, KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES, KAGOSHIMA, JAPAN;COMMUNITY MEDICINE SUPPORT CENTER, KAGOSHIMA UNIVERSITY HOSPITAL, KAGOSHIMA, JAPAN","BACKGROUND AND OBJECTIVES: ALTHOUGH EXCESS WHITE SUGAR INTAKE IMPOSES VARIOUS HEALTH BURDENS, BROWN SUGAR IS HIGH IN MINERALS, POLYPHENOLS, AND POLYCOSANOL. HOWEVER, FEW EPIDEMIOLOGICAL STUDIES HAVE ASSESSED BROWN SUGAR INTAKE FOR HEALTH BENEFIT. PEOPLE IN THE AMAMI ISLANDS REGION, WITH A RELATIVELY HIGH PROPORTION OF INDIVIDUALS WITH LONGEVITY, CONSUME BROWN SUGAR AS A TYPE OF REFRESHMENT. THIS COHORT STUDY WAS CONDUCTED IN AMAMI TO CLARIFY THE ASSOCIATION OF BROWN SUGAR INTAKE WITH MORTALITY RISK AND CANCER INCIDENCE. METHODS AND STUDY DESIGN: PARTICIPANTS WERE RECRUITED FROM THE GENERAL POPULATION OF AMAMI AS PART OF THE JAPAN MULTI-INSTITUTIONAL COLLABORATIVE COHORT STUDY. THE NUMBER OF ELIGIBLE PARTICIPANTS WAS 5004 (2057 MEN AND 2947 WOMEN). DURING THE MEDIAN FOLLOW-UP PERIOD OF 13.4 YEARS, 274 DEATHS AND 338 CASES OF CANCER WERE OBSERVED. HRS AND 95% CIS WERE ESTIMATED USING THE COX PROPORTIONAL HAZARD MODEL, AFTER ADJUSTING FOR SUGAR-RELATED AND OTHER VARIABLES. RESULTS: AFTER ADJUSTING FOR THEIR RELATED CONFOUNDING FACTORS, BROWN SUGAR INTAKE WAS ASSOCIATED WITH DECREASED HRS AND A DECREASING TREND FOR ALL-SITE AND STOMACH CANCER INCIDENCE (P = 0.001 AND 0.017, RESPECTIVELY) IN WOMEN AND MEN, AND FOR BREAST CANCER INCIDENCE (P = 0.034) IN WOMEN. ADDITIONALLY, A DECREASING TREND IN THE HRS FOR LUNG CANCER INCIDENCE WAS OBSERVED AMONG NEVER AND EX-SMOKERS (P = 0.039). DECREASED HRS FOR OVERALL DEATH, CANCER, AND CARDIOVASCULAR DISEASE WERE NOT APPARENT. CONCLUSIONS: BROWN SUGAR INTAKE WAS ASSOCIATED WITH DECREASED RISK OF ALL-SITE, STOMACH, AND BREAST CANCER INCIDENCES IN THE AMAMI POPULATION. © (2023), (HEC PRESS). ALL RIGHTS RESERVED.","BROWN SUGAR; CANCER RISK; COHORT STUDY; MORTALITY","BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; JAPAN; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SUGARS; CARBOHYDRATE; BREAST TUMOR; COHORT ANALYSIS; FEMALE; HUMAN; JAPAN; MALE; PROSPECTIVE STUDY; RISK FACTOR","JAPANESE MINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE; OSHIMA MEDICAL ASSOCIATION; JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE, JSPS, (JP16H06277); JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE, JSPS","FUNDING TEXT 1: WE APPRECIATE THE STUDY PARTICIPANTS AND LOCAL STAFF. WE ACKNOWLEDGE THE COOPERATION OF KAGOSHIMA PREFECTURE, WADOMARI TOWN, CHINA TOWN, ISEN TOWN, TOKUNOSHIMA TOWN, AMAGI TOWN, YORON TOWN, AMAMI CITY, SETOUCHI TOWN, TATSUGOU TOWN, KIKAI TOWN, JA KAGOSHIMA KOUSEIREN MEDICAL HEALTH CARE CENTER, OSHIMA MEDICAL ASSOCIATION, AND THE HOSPITALS AND CLINICS IN THE AMAMI ISLAND REGIONS.; FUNDING TEXT 2: THIS WORK WAS SUPPORTED BY GRANTS-IN-AID FOR SCIENTIFIC RESEARCH ON PRIORITY AREAS OF CANCER (NO. 17015018), INNOVATIVE AREAS (NO. 221S0001), AND BY JSPS KAKENHI GRANT NUMBER JP16H06277 (COBIA) FROM THE JAPANESE MINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE, AND TECHNOLOGY","THE WORLD BANK. LIFE EXPECTANCY AT BIRTH, TOTAL (YEARS); TSUGANE S., WHY HAS JAPAN BECOME THE WORLD'S MOST LONG-LIVED COUNTRY: INSIGHTS FROM A FOOD AND NUTRITION PERSPECTIVE, EUR J CLIN NUTR, 75, PP. 921-928, (2021); TAKEZAKI T., HEALTH AND MEDICAL ISSUES AND LONGEVITY IN THE AMAMI ISLAND REGION, THE ISLANDS OF KAGOSHIMA, CULTURE, SOCIETY, INDUSTRY AND NATURE, (2013); WILLCOX DC, WILLCOX BJ, TODORIKI H, SUZUKI M., THE OKINAWAN DIET: HEALTH IMPLICATIONS OF A LOW-CALORIE, NUTRIENT-DENSE, ANTIOXIDANT-RICH DIETARY PATTERN LOW IN GLYCEMIC LOAD, J AM COLL NUTR, 28, PP. 500S-516S, (2009); TODOROKI H, WILLCOX DG, WILLCOX BJ., THE EFFECTS OF POSTWAR DIETARY CHANGE ON HEALTH AND LONGEVITY IN OKINAWA, OKI J AMER STUD, 1, PP. 52-64, (2004); WILLCOX DC, SCAPAGNINI G, WILLCOX BJ., HEALTHY AGING DIETS OTHER THAN THE MEDITERRANEAN: A FOCUS ON THE OKINAWAN DIET, MECH AGEING DEV, 136-137, PP. 148-162, (2014); HIRASADA K, NIIMURA H, KUBOZONO T, NAKAMURA A, TATEBO M, OGAWA S, ET AL., VALUES OF CARDIO-ANKLE VASCULAR INDEX (CAVI) BETWEEN AMAMI ISLANDS AND KAGOSHIMA MAINLAND AMONG HEALTH CHECKUP EXAMINEES, J ATHEROSCLER THROMB, 19, PP. 69-80, (2012); OGAWA S., DISTRIBUTION AND MORPHOLOGY OF OKINAWA SPINACH (GYNURA BICOLOR) OF TRADITIONAL VEGETABLE IN ASIA, JAPAN GEOGRAPHICAL SOCIETY AUTUMN MEETING, (2019); YASUDA T, MIYAMOTO K, AKAHO T, IBUSUKI R, SHIMOSHIKIRYO I, NISHIMOTO D, TAKEZAKI T., INTAKE OF LOCAL VEGETABLES AND DECREASED RISK OF MORTALITY AND CANCER INCIDENCE IN AMAMI ISLANDS REGION, JAPAN, ASIA PAC J CLIN NUTR, 31, PP. 780-789, (2022); A REPORT OF AMAMI LONGEVITY AND KODAKARA SURVEY; KAMIYA T, WADA K, TAKARA K, HIROSE N., ON SUGARCANE-DERIVED WAX COMPONENTS CONTAINED IN HONEY-CONTAINING SUGARS, CONFERENCE ON SOUTHERN RESOURCE UTILIZATION TECHNOLOGY RESEARCH GROUP, 33, (2014); RANILLA LG, KWON YI, GENOVESE MI, LAJOLO FM, SHETTY K., ANTIDIABETES AND ANTIHYPERTENSION POTENTIAL OF COMMONLY CONSUMED CARBOHYDRATE SWEETENERS USING IN VITRO MODELS, J MED FOOD, 11, PP. 337-348, (2008); MATSUURA Y, KIMURA Y, OKUDA H., EFFECT OF AROMATIC GLUCOSIDES ISOLATED FROM BLACK SUGAR ON INTESTINAL ABSORPTION OF GLUCOSE, J TRAD MED, 7, PP. 168-172, (1990); KIMURA Y, OKUDA H, ARICHI S., EFFECTS OF NON-SUGAR FRACTION IN BLACK SUGAR ON LIPID AND CARBOHYDRATE METABOLISM; PART I, PLANTA MED, 50, PP. 465-468, (1984); ALI SE, EL GEDAILY RAE, MOCAN A, FARAG MA, EL-SEEDI HR., PROFILING METABOLITES AND BIOLOGICAL ACTIVITIES OF SUGARCANE (SACCHARUM OFFICINARUM LINN.) JUICE AND ITS PRODUCT MOLASSES VIA A MULTIPLEX METABOLOMICS APPROACH, MOLECULES, 24, (2019); TAKARA K, USHIJIMA K, WADA K, IWASAKI H, YAMASHITA M., PHENOLIC COMPOUNDS FROM SUGARCANE MOLASSES POSSESSING ANTIBACTERIAL ACTIVITY AGAINST CARIOGENIC BACTERIA, J OLEO SCI, 56, PP. 611-614, (2007); INAFUKU M, TODA T, OKABE T, WADA K, TAKARA K, IWASAKI H, OKU H., EFFECT OF KOKUTO, A NON-CENTRIFUGAL CANE SUGAR, ON THE DEVELOPMENT OF EXPERIMENTAL ATHEROSCLEROSIS IN JAPANESE QUAIL AND APOLIPOPROTEIN E DEFICIENT MICE, FOOD SCI TECHNOL RES, 13, PP. 61-66, (2007); HAMAJIMA N, WAKAI K, NAITO M, NISHIO K, ISHIDA Y, OKADA R., THE JAPAN MULTI-INSTITUTIONAL COLLABORATIVE COHORT STUDY (J-MICC STUDY) TO DETECT GENE-ENVIRONMENT INTERACTIONS FOR CANCER, ASIAN PAC J CANCER PREV, 8, PP. 317-323, (2007); TOKUDOME S, GOTO C, IMAEDA N, TOKUDOME Y, IKEDA M, MAKI S., DEVELOPMENT OF A DATA-BASED SHORT FOOD FREQUENCY QUESTIONNAIRE FOR ASSESSING NUTRIENT INTAKE BY MIDDLE-AGED JAPANESE, ASIAN PAC J CANCER PREV, 5, PP. 40-43, (2004); NAKAHATA NT, TAKADA AN, IMAEDA N, GOTO C, KUWABARA KH, NIIMURA H, ARAI Y, YOSHITA K, TAKEZAKI T., VALIDITY OF A FOOD FREQUENCY QUESTIONNAIRE IN A POPULATION WITH HIGH ALCOHOL CONSUMPTION IN JAPAN, ASIA PAC J CLIN NUTR, 25, PP. 195-201, (2016); FRIEDEWALD WT, LEVY RI, FREDRICKSON DS., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GLASS S, DWYER GB., ACSM’S METABOLIC CALCULATIONS HANDBOOK, (2007); WILLETT WC, HOWE GR, KUSHI LH., ADJUSTMENT FOR TOTAL ENERGY INTAKE IN EPIDEMIOLOGIC STUDIES, AM J CLIN NUTR, 65, PP. 1220S-1228S, (1997); RUXTON CH, GARDNER EJ, MCNULTY HM., IS SUGAR CONSUMPTION DETRIMENTAL TO HEALTH? A REVIEW OF THE EVIDENCE 1995-2006, CRIT REV FOOD SCI NUTR, 50, PP. 1-19, (2010); TASEVSKA N, PARK Y, JIAO L, HOLLENBECK A, SUBAR AF, POTISCHMAN N., SUGARS AND RISK OF MORTALITY IN THE NIH-AARP DIET AND HEALTH STUDY, AM J CLIN NUTR, 99, PP. 1077-1088, (2014); NAGATA C, WADA K, YAMAKAWA M, KONISHI K, GOTO Y, KODA S, MIZUTA F, UJI T., INTAKE OF STARCH AND SUGARS AND TOTAL AND CAUSE-SPECIFIC MORTALITY IN A JAPANESE COMMUNITY: THE TAKAYAMA STUDY, BR J NUTR, 122, PP. 820-828, (2019); YANG Q, ZHANG Z, GREGG EW, FLANDERS WD, MERRITT R, HU FB., ADDED SUGAR INTAKE AND CARDIOVASCULAR DISEASES MORTALITY AMONG US ADULTS, JAMA INTERN MED, 174, PP. 516-524, (2014); KHAN TA, TAYYIBA M, AGARWAL A, MEJIA SB, DE SOUZA RJ, WOLEVER TMS, LEITER LA, KENDALL CWC, JENKINS DJA, SIEVENPIPER JL., RELATION OF TOTAL SUGARS, SUCROSE, FRUCTOSE, AND ADDED SUGARS WITH THE RISK OF CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND DOSE-RESPONSE META-ANALYSIS OF PROSPECTIVE COHORT STUDIES, MAYO CLIN PROC, 94, PP. 2399-2414, (2019); YANG B, GLENN AJ, LIU Q, MADSEN T, ALLISON MA, SHIKANY JM, ET AL., ADDED SUGAR, SUGAR-SWEETENED BEVERAGES, AND ARTIFICIALLY SWEETENED BEVERAGES AND RISK OF CARDIOVASCULAR DISEASE: FINDINGS FROM THE WOMEN'S HEALTH INITIATIVE AND A NETWORK META-ANALYSIS OF PROSPECTIVE STUDIES, NUTRIENTS, 14, (2022); ARROYO-QUIROZ C, BRUNAUER R, ALAVEZ S., SUGAR-SWEETENED BEVERAGES AND CANCER RISK: A NARRATIVE REVIEW, NUTR CANCER, 74, PP. 3077-3095, (2022); HUR J, OTEGBEYE E, JOH HK, NIMPTSCH K, NG K, OGINO S, ET AL., SUGAR-SWEETENED BEVERAGE INTAKE IN ADULTHOOD AND ADOLESCENCE AND RISK OF EARLY-ONSET COLORECTAL CANCER AMONG WOMEN, GUT, 70, PP. 2330-2336, (2021); NAKASONE Y, TAKARA K, WADA K, TANAKA J, YOGI S, NAKATANI N., ANTIOXIDATIVE COMPOUNDS ISOLATED FROM KOKUTO, NON-CENTRIFUGAL CANE SUGAR, BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, 60, PP. 1714-1716, (1996); DUARTE-ALMEIDA JM, NEGRI G, SALATINO A, DE CARVALHO JE, LAJOLO FM., ANTIPROLIFERATIVE AND ANTIOXIDANT ACTIVITIES OF A TRICIN ACYLATED GLYCOSIDE FROM SUGARCANE (SACCHARUM OFFICINARUM) JUICE, 68, PP. 1165-1171, (2007); ZHOU Y, ZHENG J, LI Y, XU DP, LI S, CHEN YM, LI HB., NATURAL POLYPHENOLS FOR PREVENTION AND TREATMENT OF CANCER, NUTRIENTS, 8, PP. 515-549, (2016); PARK EJ, PEZZUTO JM., FLAVONOIDS IN CANCER PREVENTION, ANTICANCER AGENTS MED CHEM, 12, PP. 836-851, (2012); AZLAN A, EBADI S, YUSOF BNM, OTHMAN NMH, KANNAR D, SULTANA S, MAHMOOD Z., SATIETY, GLYCEMIC PROFILES, TOTAL ANTIOXIDANT CAPACITY, AND POSTPRANDIAL GLYCEMIC RESPONSES TO DIFFERENT SUGARS IN HEALTHY MALAYSIAN ADULTS, NUTRITION, 97, (2022); PEARSON-STUTTARD J, PAPADIMITRIOU N, MARKOZANNES G, CIVIDINI S, KAKOUROU A, GILL D, ET AL., TYPE 2 DIABETES AND CANCER: AN UMBRELLA REVIEW OF OBSERVATIONAL AND MENDELIAN RANDOMIZATION STUDIES, CANCER EPIDEMIOL BIOMARKERS PREV, 30, PP. 1218-1228, (2021)","T. TAKEZAKI; COMMUNITY MEDICINE SUPPORT CENTER, KAGOSHIMA UNIVERSITY HOSPITAL, KAGOSHIMA, JAPAN; EMAIL: TAKEZAKI@M.KUFM.KAGOSHIMA-U.AC.JP","HEC PRESS","ENGLISH","ASIA PAC. J. CLIN. NUTR.","ARTICLE","ISI","2-S2.0-85181176477","ASIA PAC J CLIN NUTR","KAGOSHIMA UNIVERSITY;KAGOSHIMA UNIVERSITY;KAGOSHIMA UNIVERSITY;KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES;KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES;KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES;KAGOSHIMA KOUSEIREN MEDICAL HEALTH CARE CENTER;KAGOSHIMA KOUSEIREN MEDICAL HEALTH CARE CENTER;KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES;KAGOSHIMA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES;KAGOSHIMA UNIVERSITY HOSPITAL","NOTREPORTED;KAGOSHIMA UNIVERSITY HOSPITAL;NOTREPORTED",NA,"MIYAMOTO K, 2023, ASIA PAC J CLIN NUTR","MIYAMOTO K, 2023, ASIA PAC J CLIN NUTR"
"HARRABI S;FERCHICHI A;FELLAH H;FEKI M;HOSSEINIAN F","HARRABI, SAOUSSEM (23110559100); FERCHICHI, AZZA (57201646098); FELLAH, HAYET (6602366023); FEKI, MONCEF (7003484117); HOSSEINIAN, FARAH (15049543400)","CHEMICAL COMPOSITION AND IN VITRO ANTIINFLAMMATORY ACTIVITY OF WHEAT GERM OIL DEPENDING ON THE EXTRACTION PROCEDURE",2021,"JOURNAL OF OLEO SCIENCE","70","7",8,"10.5650/jos.ess20317","LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE OF TUNIS, UNIVERSITY OF TUNIS EL MANAR, TUNIS, 1007, TUNISIA;LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE OF TUNIS, UNIVERSITY OF TUNIS EL MANAR, TUNIS, 1007, TUNISIA;LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE OF TUNIS, UNIVERSITY OF TUNIS EL MANAR, TUNIS, 1007, TUNISIA;LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE OF TUNIS, UNIVERSITY OF TUNIS EL MANAR, TUNIS, 1007, TUNISIA;FOOD SCIENCE PROGRAM, CARLETON UNIVERSITY, OTTAWA, K1S 5B6, ON, CANADA, INSTITUTE OF BIOCHEMISTRY, CARLETON UNIVERSITY, OTTAWA, K1S 5B6, ON, CANADA","THIS STUDY AIMED TO EXAMINE THE CHEMICAL COMPOSITION OF WHEAT GERM OIL EXTRACTED BY THREE DIFFERENT METHODS, AND TO EVALUATE ITS INHIBITORY EFFECT ON THE CYCLOOXYGENASE AND PROTEINASE ACTIVITIES. THE RESULTS SHOWED THAT THE CONTENTS OF POLICOSANOLS, TOCOPHEROLS AND PHYTOSTEROLS WERE AFFECTED BY THE EXTRACTION PROCEDURE. HOWEVER, THE FATTY ACID COMPOSITION OF THE DIFFERENT OIL EXTRACTS WAS NEARLY THE SAME. AMONG THE TESTED OILS SAMPLES, COLD PRESSED OIL EXHIBITED THE STRONGEST INHIBITORY ACTIVITY AGAINST PROTEINASE (93.4%, IC50 =195.7 ΜG/ML) AND CYCLOOXYGENASE 1 (80.5%, IC50 =58.6 ΜG/ML). FURTHERMORE, THE COLD PRESSED OIL HAD THE HIGHEST CONTENT OF OCTACOSANOL, Β-SITOSTEROL AND Α-LINOLENIC ACID, SUGGESTING THAT THOSE BIOACTIVE COMPOUNDS COULD BE ESSENTIAL FOR THE POTENT ANI-CYCLOOXYGENASE ACTIVITY. THE PRESENT DATA REVEALED THAT WHEAT GERM OIL CONTAINED CYCLOOXYGENASE AND TRYPSIN INHIBITORS, WHICH ARE THE PROMISING THERAPEUTIC TARGET FOR THE TREATMENT OF VARIOUS INFLAMMATORY DISEASES. THUS, WHEAT GERM OIL MIGHT BE USED TO DEVELOP FUNCTIONAL FOODS AND PHARMACEUTIC PRODUCTS FOR THE HUMAN HEALTH. © 2021 BY JAPAN OIL CHEMISTS’ SOCIETY.","ANTI-INFLAMMATORY ACTIVITY; BIOACTIVE LIPIDS; EFFECT OF SOLVENT; WHEAT GERM OIL","ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE INHIBITORS; FATTY ALCOHOLS; LIQUID-LIQUID EXTRACTION; PHYTOSTEROLS; PLANT OILS; TOCOPHEROLS; TRITICUM; TRYPSIN INHIBITORS; DISEASES; EXTRACTION; FATTY ACIDS; ANTIINFLAMMATORY AGENT; FATTY ALCOHOL; PHYTOSTEROL; POLICOSANOL; PROSTAGLANDIN SYNTHASE INHIBITOR; TOCOPHEROL; TRYPSIN INHIBITOR; VEGETABLE OIL; WHEAT GERM OIL; ALPHA LINOLENIC ACIDS; ANTI-INFLAMMATORY ACTIVITY; BIOACTIVE COMPOUNDS; CHEMICAL COMPOSITIONS; CYCLOOXYGENASE ACTIVITIES; EXTRACTION PROCEDURE; FATTY ACID COMPOSITION; INFLAMMATORY DISEASE; CHEMISTRY; ISOLATION AND PURIFICATION; LIQUID LIQUID EXTRACTION; PROCEDURES; WHEAT; VEGETABLE OILS","","","ROSAS E.C., CORREA L.B., HENRIQUES M., DAS G., NEU-TROPHILS IN RHEUMATOID ARTHRITIS: A TARGET FOR DISCOVER-ING NEW THERAPIES BASED ON NATURAL PRODUCTS, ROLE OF NEUTROPHILS IN DISEASE PATHOGENESIS, PP. 89-118, (2017); MIRSHAFIEY A., MOHSENZADEGAN M., THE ROLE OF REACTIVE OXYGEN SPECIES IN IMMUNOPATHOGENESIS OF RHEUMATOID ARTHRITIS, IRAN J. ALLERGY ASTHMA IMMUNOL, 7, PP. 195-202, (2008); DAS S.N., CHATTERJEE S., LONG TERM TOXICITY STUDY OF ART-400, INDIAN INDIGENOUS MED, 16, PP. 117-123, (1995); PEREIRA D.M., VALENTAO P., ANDRADE P.B., LESSONS FROM THE SEA: DISTRIBUTION, SAR, AND MOLECULAR MECHANISMS OF ANTI-INFLAMMATORY DRUGS FROM MARINE ORGANISMS, STUD. NAT. PROD. CHEM, PP. 205-228, (2013); ANYASOR G.N., FUNMILAYO O., ODUTOLA O., OLUGBENGA A., OBOUTOR E.M., EVALUATION OF COSTUS AFER KER GAWL. IN VITRO ANTI-INFLAMMATORY ACTIVITY AND ITS CHEMICAL CONSTITUENTS IDENTIFIED USING GAS CHROMATOGRAPHY-MASS SPECTROMETRY ANALYSIS, J. COAST. LIFE MED, 3, PP. 132-138, (2015); NAZ R., AYUB H., NAWAZ S., ISLAM Z. UL, YASMIN T., BANO A., WAKEEL A., ZIA S., ROBERTS T.H., ANTIMICRO-BIAL ACTIVITY, TOXICITY AND ANTI-INFLAMMATORY POTENTIAL OF METHANOLIC EXTRACTS OF FOUR ETHNOMEDICINAL PLANT SPECIES FROM PUNJAB, PAKISTAN, B.M.C. COMPLEM. AL-TERN. MED, 17, (2017); SALEHI B., RESCIGNO A., DETTORI T., CALINA D., DOCEA A.O., SINGH L., CEBECI F., OZCELIK B., BHIA M., BEIRA-MI A.D., SHARIFI-RAD J., SHAROPOV F., CHO W.C., MAR-TINS N., AVOCADO–SOYBEAN UNSAPONIFIABLES: A PANOPLY OF POTENTIALITIES TO BE EXPLOITED, BIOMOL, 10, (2020); GHAFOOR K., OZCAN M.M., AL-JUHAIM F., BABIKER E.E., SARKER Z.I., AHMED I.A., AHMED M.A., NUTRITIONAL COMPOSITION, EXTRACTION AND UTILIZATION OF WHEAT GERM OIL: A REVIEW, EUR. J. LIPID SCI. TECHNOL, 119, (2017); LIU L., DESEO M.A., MORRIS C., WINTER K.M., LEACH D.N., INVESTIGATION OF Α-GLUCOSIDASE INHIBITORY ACTIVITY OF WHEAT BRAN AND GERM, FOOD CHEM, 126, PP. 553-561, (2011); HUSSEIN S.A., ABDEL-AAL S., ELGHWAB A., BIOCHEMICAL ROLE OF WHEAT GERM OIL ON BIOMARKERS OF OXIDATIVE STRESS AND INFLAMMATORY RESPONSE IN A RAT MODEL OF EN-DOTOXEMIA, BENHA VET. MED. J, 27, PP. 157-167, (2014); KOZLOWSKA M., GRUCZYNSKA E., SCIBISZ I., RUDZINSKA M., FATTY ACIDS AND STEROLS COMPOSITION, AND ANTIOXI-DANT ACTIVITY OF OILS EXTRACTED FROM PLANT SEEDS, FOOD CHEM, 2134, PP. 450-456, (2016); CELENK V.U., GUMUS Z.P., ARGON Z.U., BUYUKHELVACIG-IL M., KARASULU E., ANALYSIS OF CHEMICAL COMPOSITIONS OF 15 DIFFERENT COLD-PRESSED OILS PRODUCED IN TURKEY: A CASE STUDY OF TOCOPHEROL AND FATTY ACID ANALYSIS, J.O.T.C.S.A, 5, PP. 1-18, (2017); ZOU Y., GAO Y., HE H., YANG T., EFFECT OF ROASTING ON PHYSICO-CHEMICAL PROPERTIES, ANTIOXIDANT CAPACITY, AND OXIDATIVE STABILITY OF WHEAT GERM OIL, LWT-FOOD SCI. TECHNOL, 90, PP. 246-253, (2018); FOLCH J., LEES M., SGM S., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDS FROM ANIMAL TISSUES, J. BIOL. CHEM, 22, PP. 497-509, (1957); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLI-COSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE（SILYBIUM MARIANUM L.）OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS, 17, (2018); DEIANA M., ROSA A., FALQUI CAO C., PIRISI F.M., BAN-DINO G., DESS M.A., NOVEL APPROACH TO STUDY OXIDATIVE STABILITY OF EXTRA VIRGIN OLIVE OILS: IMPORTANCE OF Α-TOCOPHEROL CONCENTRATION, J. AGR. FOOD CHEM, 50, PP. 4342-4346, (2002); OYEDEPO O.O., FEMUREWA A.J., ANTI-PROTEASE AND MEMBRANE STABILIZING ACTIVITIES OF EXTRACTS OF FAGRA ZANTHOXILOIDES, OLAX SUBSCORPIOIDES AND TETRAPLEU-RA TETRAPTERA, INT. J. PHARM, 33, PP. 65-69, (1995); BOUDJOU S., OOMAH B.D., ZAIDI F., HOSSEINIAN F., PHE-NOLICS CONTENT AND ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES OF LEGUME FRACTIONS, FOOD CHEM, 135, PP. 1543-1550, (2013); KOSTIC M.D., VELICKOVIC A.V., JOKOVIC N.M., STAMENKOVIC O.S., VELJKOVIC V.B., OPTIMIZATION AND KINETIC MODELING OF ESTERIFICATION OF THE OIL OBTAINED FROM WASTE PLUM STONES AS A PRETREATMENT STEP IN BIO-DIESEL PRODUCTION, WASTE MANAG, 48, PP. 619-629, (2016); HAM H., YOON S.W., KIM I.H., KWAK J., LEE J.S., JEONG H.S., LEE J., PROTECTIVE EFFECTS OF UNSAPONIFIABLE MATTER FROM RICE BRAN ON OXIDATIVE DAMAGE BY MODU-LATING ANTIOXIDANT ENZYME ACTIVITIES IN HEPG2 CELLS, LWT-FOOD. SCI TECHNOL, 61, PP. 602-608, (2015); KUMAR G.S., KRISHNA A.G.G., STUDIES ON THE NUTRACEU-TICALS COMPOSITION OF WHEAT DERIVED OILS WHEAT BRAN OIL AND WHEAT GERM OIL, J. FOOD SCI. TECHNOL, 52, PP. 1145-1151, (2015); BARNES P.J., LIPID COMPOSITION OF WHEAT GERM AND WHEAT GERM OIL, FETTE SEIFEN ANSTRICHMITTEL, 84, PP. 256-269, (1982); AZZI A., TOCOPHEROLS, TOCOTRIENOLS AND TOCOMONOENOLS: MANY SIMILAR MOLECULES BUT ONLY ONE VITAMIN E, REDOX BIO, 26, (2019); EISENMENGER M., DUNFORD N.T., BIOACTIVE COMPONENTS OF COMMERCIAL AND SUPERCRITICAL CARBON DIOXIDE PROCESSED WHEAT GERM OIL, J. AM. OIL CHEM. SOC, 85, PP. 55-61, (2008); OZCAN M.M., ROSA A., DESSI M.A., MARONGIU B., PIRAS A., AL-JUHAI F.Y.I., QUALITY OF WHEAT GERM OIL OBTAINED BY COLD PRESSING AND SUPERCRITICAL CARBON DIOXIDE EX-TRACTION, CZECH J. FOOD SCI, 31, PP. 236-240, (2013); JAFARIAN ASL P., NIAZMAND R., YAHYAVI F., EXTRACTION OF PHYTOSTEROLS AND TOCOPHEROLS FROM RAPESEED OIL WASTE BY SUPERCRITICAL CO<SUB>2</SUB> PLUS CO-SOLVENT: A COMPARISON WITH CONVENTIONAL SOLVENT EXTRACTION, HELIYON, 6, (2020); KONOPKA I., TANSKA M., FARON A., STEPIEN A., WOJT-KOWIAK K., COMPARISON OF THE PHENOLIC COMPOUNDS, CAROTENOIDS AND TOCOCHROMANOLS CONTENT IN WHEAT GRAIN UNDER ORGANIC AND MINERAL FERTILIZATION REGIMES, MOLECULES, 17, PP. 12341-12356, (2012); WOYENGO T.A., RAMPRASATH V.R., JONES P.J.H., ANTI-CANCER EFFECTS OF PHYTOSTEROLS, EUR. J. CLIN. NUTR, 63, PP. 813-882, (2009); SCHAFFARCZYK M., OSTDAL H., KOEHLER P., LIPASES IN WHEAT BREADMAKING: ANALYSIS AND FUNCTIONAL EFFECTS OF LIPID REACTION PRODUCTS, J. AGRIC. FOOD CHEM, 62, PP. 8229-8237, (2014); AMARO H.M., FERNANDES F., VALENTAO P., ANDRADE P.B., SOUSA-PINTO I., MALCATA F.X., GUEDES A.C., EFFECT OF SOLVENT SYSTEM ON EXTRACTABILITY OF LIPIDIC COMPONENTS OF SCENEDESMUS OBLIQUUS（M2-1）AND GLOEOTHECE SP. ON ANTIOXIDANT SCAVENGING CAPACITY THEREOF, MAR. DRUGS, 13, PP. 6453-6471, (2015); MONTSERRAT-DE LA PAZ S., GARCIA-GIMENEZ M., ANGEL-MARTIN M., PEREZ-CAMINO M., ARCHE A.F., LONG-CHAIN FATTY ALCOHOLS FROM EVENING PRIMROSE OIL INHIBIT THE INFLAMMATORY RESPONSE IN MURINE PERITONEAL MACRO-PHAGES, J. ETHNOPHARMACOL, 151, PP. 131-136, (2014); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM AND BRAN, FOOD CHEM, 119, PP. 1246-1249, (2010); KIRALAN M., KAYAHAN M., KIRALAN S.S., RAMADAN M.F., EFFECT OF THERMAL AND PHOTO OXIDATION ON THE STABILITY OF COLD PRESSED PLUM AND APRICOT KERNEL OILS, EUR. FOOD RES. TECHNOL, 244, PP. 31-42, (2018); SOLTAN M.M., MAHFOUZ S.A., KARAM E.A., MOTAWE F.H., INSIGHTS ON TRADITIONAL AND MODERN OIL EXTRACTIONS OF WHEAT GERM: CHEMICAL AND ANTIMICROBIAL EVALUATION, INT. J. PHARM. TECH. RES, 13, PP. 30-34, (2020); DUNFORD N.T., ZHANG M., PRESSURIZED SOLVENT EXTRACTION OF WHEAT GERM OIL, FOOD RES. INT, 36, PP. 905-909, (2003); MALIAR T., NEMECEK P., URGEOVA E., MALIAROVA M., NESVADBA V., KROFTA K., VULGANOVA K., KROSLAK E., KRAIC J., SECONDARY METABOLITES, ANTIOXIDANT AND ANTI-PROTEINASE ACTIVITIES OF METHANOLIC EXTRACTS FROM CONES OF HOP（HUMULUS LUPULUS L.）CULTIVARS, CHEM. PAP, 71, PP. 41-48, (2017); AKINLOYE O.A., AKINLOYE D.I., ONIGBINDE S.B., METIBE-MU D.S., PHYTOSTEROLS DEMONSTRATE SELECTIVE INHIBITION OF COX-2: IN-VIVO AND IN-SILICO STUDIES OF NICOTIANA TABACUM, BIOORG. CHEM, 102, (2020); HENRY G.E., MOMIN R.A., NAIR M.G., DEWITT D.L., AN-TIOXIDANT AND CYCLOOXYGENASE ACTIVITIES OF FATTY ACIDS FOUND IN FOOD, J. AGRIC. FOOD CHEM, 50, PP. 2231-2234, (2002)","S. HARRABI; LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE OF TUNIS, UNIVERSITY OF TUNIS EL MANAR, TUNIS, 15 STREET DJEBEL LAKHDAR, RABTA, 1007, TUNISIA; EMAIL: SAOUSSEM.HARRABI@FMT.UTM.TN","JAPAN OIL CHEMISTS SOCIETY","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","2-S2.0-85112130724","J OLEO SCI","TUNIS;TUNIS;TUNIS;TUNIS;CARLETON UNIVERSITY","NOTREPORTED;UNIVERSITY OF TUNIS EL MANAR;NOTREPORTED",NA,"HARRABI S, 2021, J OLEO SCI","HARRABI S, 2021, J OLEO SCI"
"ZHU Y;LI P;MENG F;HUANG D;HUANG J;XIANG H","ZHU, YAN-JIAO (57222610392); LI, PENG (57221127719); MENG, FEI (57220071591); HUANG, DONG-TING (57217130353); HUANG, JUN-SHENG (57220066961); XIANG, HUI (57640274400)","SIMULATED GASTROINTESTINAL ABSORPTION AND METABOLITE ANALYSIS OF POLICOSANOL 多廿烷醇的模拟胃肠吸收及代谢产物分析",2020,"MODERN FOOD SCIENCE AND TECHNOLOGY","36","16253",0,"10.13982/j.mfst.1673-9078.2020.11.0465","SCHOOL OF LIFE SCIENCES, SUN YAT-SEN UNIVERSITY, GUANGZHOU, 510006, CHINA;INSTITUTE OF BIOENGINEERING, GUANGDONG ACADEMY OF SCIENCES, GUANGZHOU, 510316, CHINA, GUANGDONG PROVINCE ENGINEERING RESEARCH CENTER FOR GREEN TECHNOLOGY OF SUGAR INDUSTRY, GUANGZHOU, 510316, CHINA;INSTITUTE OF BIOENGINEERING, GUANGDONG ACADEMY OF SCIENCES, GUANGZHOU, 510316, CHINA, GUANGDONG PROVINCE ENGINEERING RESEARCH CENTER FOR GREEN TECHNOLOGY OF SUGAR INDUSTRY, GUANGZHOU, 510316, CHINA;INSTITUTE OF BIOENGINEERING, GUANGDONG ACADEMY OF SCIENCES, GUANGZHOU, 510316, CHINA, GUANGDONG PROVINCE ENGINEERING RESEARCH CENTER FOR GREEN TECHNOLOGY OF SUGAR INDUSTRY, GUANGZHOU, 510316, CHINA;INSTITUTE OF BIOENGINEERING, GUANGDONG ACADEMY OF SCIENCES, GUANGZHOU, 510316, CHINA, GUANGDONG PROVINCE ENGINEERING RESEARCH CENTER FOR GREEN TECHNOLOGY OF SUGAR INDUSTRY, GUANGZHOU, 510316, CHINA;SCHOOL OF LIFE SCIENCES, SUN YAT-SEN UNIVERSITY, GUANGZHOU, 510006, CHINA","TO INVESTIGATE THE GASTROINTESTINAL ABSORPTION AND METABOLITE ANALYSIS OF POLICOSANOL IN VITRO AND IN VIVO, SINGLE-PHASE STATIC GASTROINTESTINAL SIMULATION SYSTEM, IN SITU CIRCULATING INTESTINAL PERFUSION IN RATS AND INTEGRAL ANIMAL EXPERIMENTS WERE CONDUCTED. THE RESULTS SHOWED THAT POLICOSANOL COULD BE METABOLIZED INTO THREE SATURATED FATTY ACIDS INCLUDING C12:0, C16:0 AND C18:0 IN THE SINGLE-PHASE STATIC GASTROINTESTINAL SIMULATION SYSTEM. COMPARED WITH ARTIFICIAL GASTRIC JUICE, ARTIFICIAL INTESTINAL JUICE DEGRADED 42% MORE POLICOSANOL, WHICH WAS CONVERTED TO THE SATURATED FATTY ACID. IN INTESTINAL SYSTEM OF RAT, POLICOSANOL COULD BE ABSORBED EASILY BY THE INTESTINAL TRACT OF RATS, AND THE PAPP VALUE OF POLICOSANOL WAS 7.02×10-2 CM/MIN. MOREOVER, POLICOSANOL WERE ABLE TO BE BROKN DOWN INTO FATTY ACIDS AND UNSATURATED FATTY ACIDS IN THE INTESTINAL TRACT. IN THE INTEGRAL ANIMAL EXPERIMENTS, AT 1, 4, 12 HOURS AFTER ORAL GAVAGE OF 100 MG/KG POLICOSANOL, THE ALKANOL AND ITS METABOLITES FATTY ACID COULD BE IDENTIFIED IN THE SERUM OF MICE, WHICH MAY CONTRIBUTE TO REGULATE SERUM FATTY ACID LEVELS AND INCREASE THE SERUM LEVEL OF SOME UNSATURATED FATTY ACIDS. IN SUMMARY, OUR RESULTS REVEALED THAT POLICOSANOL CAN BE METABOLIZED AND ABSORBED BY THE GASTROINTESTINAL TRACT AND CAN ALSO BE DETECTED IN THE ANIMAL BODY IN THE FORM OF PROTOTYPES OR METABOLITES, AFFECTING THE LEVEL OF FATTY ACIDS IN THE BODY, WHICH MAY BE THE BASIS FOR ITS LIPID REGULATION FUNCTION. © 2020, EDITORIAL BOARD OF MODERN FOOD SCIENCE AND TECHNOLOGY. ALL RIGHT RESERVED.","FATTY ACID; METABOLITES; OCTACOSANOL; POLICOSANOL","","","","KIM J Y, JU H L, JEONG D Y, ET AL., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYDRATE POLYMERS, 121, PP. 140-146, (2015); WEERAWATANAKORN M, MEEROD K, WONGWAIWECH D, ET AL., POLICOSANOLS: CHEMISTRY, OCCURRENCE, AND HEALTH EFFECTS, CURRENT PHARMACOLOGY REPORTS, 5, 3, PP. 131-149, (2019); POLI A, VISIOLI F., PHARMACOLOGY OF NUTRACEUTICALS WITH LIPID LOWERING PROPERTIESJ, HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 26, 2, PP. 113-118, (2019); BIANCONI V, MANNARINO M R, SAHEBKAR A, ET AL., CHOLESTEROL-LOWERING NUTRACEUTICALS AFFECTING VASCULAR FUNCTION AND CARDIOVASCULAR DISEASE RISKJ, CURRENT CARDIOLOGY REPORTS, 20, 7, PP. 53-53, (2018); ASKARPOUR M, GHAEDI E, ROSHANRAVAN N, ET AL., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENTARY THERAPIES IN MEDICINE, 45, PP. 89-97, (2019); LEE JY, CHOI HY, KANG YR, ET AL., EFFECTS OF LONG-TERM SUPPLEMENTATION OF POLICOSANOL ON BLOOD CHOLESTEROL/GLUCOSE LEVELS AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY IN A RAT MODEL FED HIGH CHOLESTEROL DIETS, FOOD SCIENCE AND BIOTECHNOLOGY, 25, 3, PP. 899-904, (2016); SHEN JUN-JUN, LUO FEI-JUN, LIN QIN-LU, ET AL., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, JOURNAL OF FUNCTIONAL FOODS, 57, PP. 351-360, (2019); DULIN M, HATCHER L, SASSER H C, ET AL., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1543-1548, (2006); FRANCINIPESENTI F, BELTRAMOLLI D, DALLACQUA S, ET AL., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHERAPY RESEARCH, 22, 3, PP. 318-322, (2008); JONES P J, KASSIS A N, MARINANGELI C P, ET AL., POLICOSANOLS LOSE THEIR LUSTRE AS CHOLESTEROL-LOWERING AGENTS, JOURNAL OF FUNCTIONAL FOODS, 1, 2, PP. 236-239, (2009); KABIR Y, KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANNALS OF NUTRITION AND METABOLISM, 37, 1, PP. 33-38, (1993); KABIR Y, KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANNALS OF NUTRITION AND METABOLISM, 39, 5, PP. 279-284, (1995); MENENDEZ R, MARRERO D, MAS R, ET AL., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCHIVES OF MEDICAL RESEARCH, 36, 2, PP. 113-119, (2005); MARINANGELI C P, KASSIS A N, JAIN D, ET AL., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BRITISH JOURNAL OF NUTRITION, 97, 2, PP. 381-388, (2007); NG C H, LEUNG K Y, HUANG YU, ET AL., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 16, PP. 6289-6293, (2005); ZHOU CUN-SHAN, QIN XIAO-PEI, YU XIAO-JIE, ET AL., ANTIOXIDANT ACTIVITY AND CHARACTERISTICS OF SIMULATED GASTROINTESTINAL DIGESTION HYDROLYSATE FROM FILEFISH NAVODON SEPTENTRIONALIS SKIN PROTEIN, TRANSACTIONS OF THE CHINESE SOCIETY FOR AGRICULTURAL MACHINERY, 46, 8, PP. 211-216, (2015); WANG XING, HUANG ZHONG-MING, WANG LI, ET AL., THE ANTIOXIDATION ACTIVITY AND COMPOSITION OF TARTARY BUCKWHEAT PROTEIN PRODUCTS PRODUCED BY SIMULATING GASTROINTESTINAL DIGESTION, JOURNAL OF CHINESE INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, 9, 6, PP. 10-15, (2009); JIANG SHEN-HUA, CAI ZHI-PENG, LIAO LIANG, ET AL., EXTRACTION OF ANTIOXIDANTS FROM CLOVE AND EFFECT OF ARTIFICIAL GASTROINTESTINAL JUICE IMMERSION ON ITS ANTIOXIDANT PROPERTIES, TRANSACTIONS OF THE CHINESE SOCIETY FOR AGRICULTURAL MACHINERY, 43, 7, PP. 149-155, (2012); FNAG JING, JIANG DONG-MEI, OUYANG ZHEN, ET AL., STUDIES ON IN VIVO INTESTINAL ABSORPTION OF SEVERAL STEROLS IN RATS WITH IN SITU SINGLE-PASS INTESTINAL PERFU-SION MODEL, TRADITIONAL CHINESE DRUG RESEARCH & CLINICAL PHARMACOLOGY, 22, 4, PP. 437-440, (2011); PONZ F, ILUNDAIN A, LLUCH M, ET AL., METHOD FOR SUCCESSIVE ABSORPTIONS WITH INTESTINAL PERFUSION IN VIVOJ, REVISTA ESPAÑOLA DEFISIOLOGÍA, 35, 1, PP. 97-103, (1979); SIERRA R, GONZALEZ V L, MAGRANER J, ET AL., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINATION OF FATTY ALCOHOLS IN 10 MG FILM-COATED TABLETS OF POLICOSANOL, JOURNAL OF AOAC INTERNATIONAL, 85, 3, PP. 563-566, (2002); ZHAI XUE-ZHEN, HUANG LIAN-QI, LIU SONG, ET AL., STUDY ON THE RAT INTESTINAL ABSORPTION OF RAPAMYCIN FORMULATED IN SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM BY SINGLE-PASS INTESTINAL PERFUSION TECHNIQUE, CHINESE JOURNAL OF HOSPITAL PHARMACY, 31, 3, PP. 217-221, (2011); XIAO ZHI-FENG, DENG YAN-PING, LIN BAO-SHU, ET AL., ABSORPTION AND METABOLISM CHARACTERISTICS OF CURCUMIN DERIVATIVE FM0807 IN SITU SINGLE-PASS PERFUSED RAT INTESTINAL MODEL, CHINESE JOURNAL OF HOSPITAL PHARMACY, 34, 13, PP. 1049-1052, (2014); FAGERHOLM U, JOHANSSON M, LENNERNAS H, ET AL., COMPARISON BETWEEN PERMEABILITY COEFFICIENTS IN RAT AND HUMAN JEJUNUM, PHARMACEUTICAL RESEARCH, 13, 9, PP. 1336-1342, (1996); CUI YAN-LI, ZHAO XIU-LI, A NEW CHOLESTEROL-LOWING MEDICINE POLICOSANOL: PHARMACOLOGY AND CLINICAL EVALUATION, CHINESE JOURNAL OF NEW DRUGS, 15, 6, PP. 480-483, (2006); WANG XIN, CAO YU-ZHEN, GUO GUI-FANG, ET AL., ANALYSIS OF FATTY ACIDS COMPOSITION IN THE LIVER OF MICE WITH NON-ALCOHOLIC FATTY LIVER DISEASE, SCIENTIA AGRICULTURA SINICA, 44, 17, PP. 3658-3665, (2011); HUANG ZUO-JUN, LI GANG, LI YUE-LING, ET AL., DETERMINATION OF FREE FATTY ACIDS IN RAT PLASMA BY HPLC, ACADEMIC JOURNAL OF GUANGDONG COLLEGE OF PHARMACY, 20, 6, PP. 656-658, (2004); CHEN FANG, YAN HONG, CAI TONG-YI, QUANTITATIVE ANALYSIS OF OCTACOSANOL AND TRICONTANOL IN EXTRACTS OF HIGHER FATTY ALCOHOLS BY GC, FOOD SCIENCE, 24, PP. 104-106, (2003)","","SOUTH CHINA UNIVERSITY OF TECHNOLOGY","CHINESE","MOD. FOOD SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-85103460768","MOD FOOD SCI TECHNOL",NA,"NOTREPORTED",NA,"ZHU Y-J, 2020, MOD FOOD SCI TECHNOL","ZHU Y-J, 2020, MOD FOOD SCI TECHNOL"
"KIM K;KIM C;CHO K;JANG W","KIM, KYEONG-MIN (57190987288); KIM, CHANG-HYUN (57226847469); CHO, KYUNG-HYUN (7403956966); JANG, WON-GU (36948705500)","POLICOSANOL ATTENUATES PIINDUCED CALCIFICATION VIA AMPKMEDIATED INSIGS EXPRESSION IN RAT VSMCS",2021,"CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY","48","9",8,"10.1111/1440-1681.13530","DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF ENGINEERING, DAEGU UNIVERSITY, GYEONGBUK, SOUTH KOREA, RESEARCH INSTITUTE OF ANTI-AGING, DAEGU UNIVERSITY, GYEONGBUK, SOUTH KOREA;COLLEGE OF MEDICINE, DONGGUK UNIVERSITY, GOYANG, SOUTH KOREA;LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF ENGINEERING, DAEGU UNIVERSITY, GYEONGBUK, SOUTH KOREA, RESEARCH INSTITUTE OF ANTI-AGING, DAEGU UNIVERSITY, GYEONGBUK, SOUTH KOREA","POLICOSANOL IS A HYPOCHOLESTEROLEMIC DERIVED FROM SUGAR CANE AND CORN THAT DOWNREGULATES BLOOD CHOLESTEROL LEVELS. IT CAN FURTHER LOWER BLOOD PRESSURE AND REDUCE LIVER INFLAMMATION. POLICOSANOL CAN ALSO AFFECT VASCULAR CALCIFICATION, HOWEVER, ITS MOLECULAR MECHANISMS ARE NOT WELL UNDERSTOOD. THIS STUDY INVESTIGATED THE EFFECT OF POLICOSANOL ON VASCULAR CALCIFICATION AND ITS MOLECULAR MECHANISM. POLICOSANOL DECREASED THE EXPRESSION OF INORGANIC PHOSPHATE (PI)-INDUCED OSTEOGENIC GENES SUCH AS DISTAL-LESS HOMEOBOX 5 (DLX5) AND RUNT-RELATED TRANSCRIPTION FACTOR 2 (RUNX2). IN ADDITION, FOLLOWING POLICOSANOL TREATMENT, ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) PHOSPHORYLATION INCREASED IN A TIME-DEPENDENT MANNER. THE CONSTITUTIVELY ACTIVE FORM OF AMPK (CA-AMPK) DRAMATICALLY SUPPRESSED PI-INDUCED DLX5 AND RUNX2 PROTEIN LEVELS. INACTIVATION OF AMPK USING COMPOUND C (COM. C; AMPK INHIBITOR) RECOVERED POLICOSANOL-SUPPRESSED ALIZARIN RED S STAINING LEVELS. INSULIN-INDUCED GENES (INSIGS) WERE INDUCED BY CA-AMPK, THEIR OVEREXPRESSION SUPPRESSED PI-INDUCED DLX5 AND RUNX2 EXPRESSION. TAKEN TOGETHER, THE RESULTS DEMONSTRATE THAT POLICOSANOL INHIBITS PI-INDUCED VASCULAR CALCIFICATION BY REGULATING AMPK-INDUCED INSIG EXPRESSION IN VASCULAR SMOOTH MUSCLE CELLS. © 2021 JOHN WILEY & SONS AUSTRALIA, LTD","AMPK; INSIGS; POLICOSANOL; VASCULAR CALCIFICATION; VSMCS","AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; FATTY ALCOHOLS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; PHOSPHATES; PLATELET AGGREGATION INHIBITORS; RATS; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION; ALIZARIN RED S; BETA ACTIN; CALCIUM; COMPLEMENTARY DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN INDUCED GENE; INSULIN INDUCED GENE 1; INSULIN INDUCED GENE 2; PHOSPHATE; POLICOSANOL; PROTEIN; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSIG1 PROTEIN, RAT; INSIG2 PROTEIN, RAT; MEMBRANE PROTEIN; PHOSPHATE; POLICOSANOL; SIGNAL PEPTIDE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; MALE; MOLECULAR BIOLOGY; NONHUMAN; PRIMARY CULTURE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STAINING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BLOOD VESSEL CALCIFICATION; CELL CULTURE; DRUG EFFECT; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE","NATIONAL RESEARCH FOUNDATION OF KOREA, NRF; MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY, MEST, (NRF‐2019R1F1A1059315)","THIS WORK WAS SUPPORTED BY THE BASIC SCIENCE RESEARCH PROGRAM THROUGH THE NATIONAL RESEARCH FOUNDATION OF KOREA (NRF) FUNDED BY MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY (NRF‐2019R1F1A1059315). ","CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, 3-4, PP. 205-208, (1994); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, 1, PP. 61-64, (1998); CHO K.H., BAE M.A., KIM J.R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC THER, 2019, (2019); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, 2, PP. 149-158, (2016); PARK H.J., YADAV D., JEONG D.J., ET AL., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT J ENVIRON RES PUBLIC HEALTH, 16, 5, (2019); STEITZ S.A., SPEER M.Y., CURINGA G., ET AL., SMOOTH MUSCLE CELL PHENOTYPIC TRANSITION ASSOCIATED WITH CALCIFICATION: UPREGULATION OF CBFA1 AND DOWNREGULATION OF SMOOTH MUSCLE LINEAGE MARKERS, CIRC RES, 89, 12, PP. 1147-1154, (2001); DEMER L.L., TINTUT Y., VASCULAR CALCIFICATION: PATHOBIOLOGY OF A MULTIFACETED DISEASE, CIRCULATION, 117, 22, PP. 2938-2948, (2008); KARWOWSKI W., NAUMNIK B., SZCZEPANSKI M., MYSLIWIEC M., THE MECHANISM OF VASCULAR CALCIFICATION – A SYSTEMATIC REVIEW, MED SCI MONIT, 18, 1, PP. RA1-RA11, (2012); GIACHELLI C.M., THE EMERGING ROLE OF PHOSPHATE IN VASCULAR CALCIFICATION, KIDNEY INT, 75, 9, PP. 890-897, (2009); SHEEN C.R., KUSS P., NARISAWA S., ET AL., PATHOPHYSIOLOGICAL ROLE OF VASCULAR SMOOTH MUSCLE ALKALINE PHOSPHATASE IN MEDIAL ARTERY CALCIFICATION, J BONE MIN RES, 30, 5, PP. 824-836, (2015); ABEDIN M., TINTUT Y., DEMER L.L., VASCULAR CALCIFICATION: MECHANISMS AND CLINICAL RAMIFICATIONS, ARTERIOSCLER THROMB VASC BIOL, 24, 7, PP. 1161-1170, (2004); OAKHILL J.S., SCOTT J.W., KEMP B.E., STRUCTURE AND FUNCTION OF AMP-ACTIVATED PROTEIN KINASE, ACTA PHYSIOL (OXF), 196, 1, PP. 3-14, (2009); RUTTER G.A., LECLERC I., THE AMP-REGULATED KINASE FAMILY: ENIGMATIC TARGETS FOR DIABETES THERAPY, MOL CELL ENDOCRINOL, 297, 1-2, PP. 41-49, (2009); SHAH M., KOLA B., BATAVELJIC A., ET AL., AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION REGULATES IN VITRO BONE FORMATION AND BONE MASS, BONE, 47, 2, PP. 309-319, (2010); MIHAYLOVA M.M., SHAW R.J., THE AMPK SIGNALLING PATHWAY COORDINATES CELL GROWTH, AUTOPHAGY AND METABOLISM, NAT CELL BIOL, 13, 9, PP. 1016-1023, (2011); JANG W.G., KIM E.J., LEE K.N., SON H.J., KOH J.T., AMP-ACTIVATED PROTEIN KINASE (AMPK) POSITIVELY REGULATES OSTEOBLAST DIFFERENTIATION VIA INDUCTION OF DLX5-DEPENDENT RUNX2 EXPRESSION IN MC3T3E1 CELLS, BIOCHEM BIOPHYS RES COMMUN, 404, 4, PP. 1004-1009, (2011); KIM D.Y., KIM E.J., JANG W.G., PIPERINE INDUCES OSTEOBLAST DIFFERENTIATION THROUGH AMPK-DEPENDENT RUNX2 EXPRESSION, BIOCHEM BIOPHYS RES COMMUN, 495, 1, PP. 1497-1502, (2018); YABE D., KOMURO R., LIANG G., GOLDSTEIN J.L., BROWN M.S., LIVER-SPECIFIC MRNA FOR INSIG-2 DOWN-REGULATED BY INSULIN: IMPLICATIONS FOR FATTY ACID SYNTHESIS, PROC NATL ACAD SCI U S A, 100, 6, PP. 3155-3160, (2003); SUN L.P., LI L., GOLDSTEIN J.L., BROWN M.S., INSIG REQUIRED FOR STEROL-MEDIATED INHIBITION OF SCAP/SREBP BINDING TO COPII PROTEINS IN VITRO, J BIOL CHEM, 280, 28, PP. 26483-26490, (2005); YANG T., ESPENSHADE P.J., WRIGHT M.E., ET AL., CRUCIAL STEP IN CHOLESTEROL HOMEOSTASIS: STEROLS PROMOTE BINDING OF SCAP TO INSIG-1, A MEMBRANE PROTEIN THAT FACILITATES RETENTION OF SREBPS IN ER, CELL, 110, 4, PP. 489-500, (2002); KA S.O., KIM K.A., KWON K.B., PARK J.W., PARK B.H., SILIBININ ATTENUATES ADIPOGENESIS IN 3T3-L1 PREADIPOCYTES THROUGH A POTENTIAL UPREGULATION OF THE INSIG PATHWAY, INT J MOL MED, 23, 5, PP. 633-637, (2009); POUDEL B., NEPALI S., XIN M., ET AL., FLAVONOIDS FROM TRITICUM AESTIVUM INHIBIT ADIPOGENESIS IN 3T3-L1 CELLS BY UPREGULATING THE INSIG PATHWAY, MOL MED REP, 12, 2, PP. 3139-3145, (2015); NAM D.E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J MED FOOD, 22, 11, PP. 1110-1117, (2019); SEO W.D., YUK H.J., CURTIS-LONG M.J., ET AL., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5'-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J AGRIC FOOD CHEM, 61, 5, PP. 1117-1123, (2013); CHEN W.R., YANG J.Q., LIU F., SHEN X.Q., ZHOU Y.J., MELATONIN ATTENUATES VASCULAR CALCIFICATION BY ACTIVATING AUTOPHAGY VIA AN AMPK/MTOR/ULK1 SIGNALING PATHWAY, EXP CELL RES, 389, 1, (2020); CHEN W.R., ZHOU Y.J., SHA Y., WU X.P., YANG J.Q., LIU F., MELATONIN ATTENUATES VASCULAR CALCIFICATION BY INHIBITING MITOCHONDRIA FISSION VIA AN AMPK/DRP1 SIGNALLING PATHWAY, J CELL MOL MED, 24, 11, PP. 6043-6054, (2020); HAN Y., HU Z., CUI A., ET AL., POST-TRANSLATIONAL REGULATION OF LIPOGENESIS VIA AMPK-DEPENDENT PHOSPHORYLATION OF INSULIN-INDUCED GENE, NAT COMMUN, 10, 1, (2019); MIZOBUCHI M., OGATA H., HATAMURA I., ET AL., UP-REGULATION OF CBFA1 AND PIT-1 IN CALCIFIED ARTERY OF URAEMIC RATS WITH SEVERE HYPERPHOSPHATAEMIA AND SECONDARY HYPERPARATHYROIDISM, NEPHROL DIAL TRANSPLANT, 21, 4, PP. 911-916, (2006); CUI X., LU Y.W., LEE V., ET AL., VENOUS ENDOTHELIAL MARKER COUP-TFII REGULATES THE DISTINCT PATHOLOGIC POTENTIALS OF ADULT ARTERIES AND VEINS, SCI REP, 5, (2015); YOSHIDA T., YAMASHITA M., HAYASHI M., KRUPPEL-LIKE FACTOR 4 CONTRIBUTES TO HIGH PHOSPHATE-INDUCED PHENOTYPIC SWITCHING OF VASCULAR SMOOTH MUSCLE CELLS INTO OSTEOGENIC CELLS, J BIOL CHEM, 287, 31, PP. 25706-25714, (2012); LEE J.H., JIA Y., THACH T.T., ET AL., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTR RES, 43, PP. 89-99, (2017); ZHANG X., XIAO J., LI R., ET AL., METFORMIN ALLEVIATES VASCULAR CALCIFICATION INDUCED BY VITAMIN D3 PLUS NICOTINE IN RATS VIA THE AMPK PATHWAY, VASCUL PHARMACOL, 81, PP. 83-90, (2016); ZHAN J.K., WANG Y.J., WANG Y., ET AL., ADIPONECTIN ATTENUATES THE OSTEOBLASTIC DIFFERENTIATION OF VASCULAR SMOOTH MUSCLE CELLS THROUGH THE AMPK/MTOR PATHWAY, EXP CELL RES, 323, 2, PP. 352-358, (2014); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, 3, PP. 1020-1026, (2006); GENG Y., HSU J.J., LU J., ET AL., ROLE OF CELLULAR CHOLESTEROL METABOLISM IN VASCULAR CELL CALCIFICATION, J BIOL CHEM, 286, 38, PP. 33701-33706, (2011); YABE D., BROWN M.S., GOLDSTEIN J.L., INSIG-2, A SECOND ENDOPLASMIC RETICULUM PROTEIN THAT BINDS SCAP AND BLOCKS EXPORT OF STEROL REGULATORY ELEMENT-BINDING PROTEINS, PROC NATL ACAD SCI USA, 99, 20, PP. 12753-12758, (2002); SONG B.L., JAVITT N.B., DEBOSE-BOYD R.A., INSIG-MEDIATED DEGRADATION OF HMG COA REDUCTASE STIMULATED BY LANOSTEROL, AN INTERMEDIATE IN THE SYNTHESIS OF CHOLESTEROL, CELL METAB, 1, 3, PP. 179-189, (2005); LEE M., HWANG J.T., LEE H.J., ET AL., AMP-ACTIVATED PROTEIN KINASE ACTIVITY IS CRITICAL FOR HYPOXIA-INDUCIBLE FACTOR-1 TRANSCRIPTIONAL ACTIVITY AND ITS TARGET GENE EXPRESSION UNDER HYPOXIC CONDITIONS IN DU145 CELLS, J BIOL CHEM, 278, 41, PP. 39653-39661, (2003)","W.-G. JANG; DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF ENGINEERING, DAEGU UNIVERSITY, GYEONGBUK, SOUTH KOREA; EMAIL: JANGWG@DAEGU.AC.KR; K.-H. CHO; LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","JOHN WILEY AND SONS INC","ENGLISH","CLIN. EXP. PHARMACOL. PHYSIOL.","ARTICLE","ISI","2-S2.0-85109127170","CLIN EXP PHARMACOL PHYSIOL","DAEGU UNIVERSITY;DONGGUK UNIVERSITY;YEUNGNAM UNIVERSITY;DAEGU UNIVERSITY","NOTREPORTED;DAEGU UNIVERSITY;NOTREPORTED;NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"KIM K-M, 2021, CLIN EXP PHARMACOL PHYSIOL","KIM K-M, 2021, CLIN EXP PHARMACOL PHYSIOL"
"DEROSA G;D'ANGELO A;MAFFIOLI P","DEROSA, GIUSEPPE (57208158793); D'ANGELO, ANGELA (55682654470); MAFFIOLI, PAMELA (23985844600)","THE ROLE OF SELECTED NUTRACEUTICALS IN MANAGEMENT OF PREDIABETES AND DIABETES AN UPDATED REVIEW OF THE LITERATURE",2022,"PHYTOTHERAPY RESEARCH","36","56",6,"10.1002/ptr.7564","DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PAVIA, PAVIA, ITALY, CENTRE OF DIABETES, METABOLIC DISEASES, AND DYSLIPIDEMIAS, UNIVERSITY OF PAVIA, PAVIA, ITALY, REGIONAL CENTRE FOR PREVENTION, SURVEILLANCE, DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIAS AND ATHEROSCLEROSIS, FONDAZIONE IRCCS POLICLINICO SAN MATTEO, PAVIA, ITALY, ITALIAN NUTRACEUTICAL SOCIETY (SINUT), BOLOGNA, ITALY, LABORATORY OF MOLECULAR MEDICINE, UNIVERSITY OF PAVIA, PAVIA, ITALY;DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PAVIA, PAVIA, ITALY, LABORATORY OF MOLECULAR MEDICINE, UNIVERSITY OF PAVIA, PAVIA, ITALY;CENTRE OF DIABETES, METABOLIC DISEASES, AND DYSLIPIDEMIAS, UNIVERSITY OF PAVIA, PAVIA, ITALY, REGIONAL CENTRE FOR PREVENTION, SURVEILLANCE, DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIAS AND ATHEROSCLEROSIS, FONDAZIONE IRCCS POLICLINICO SAN MATTEO, PAVIA, ITALY, ITALIAN NUTRACEUTICAL SOCIETY (SINUT), BOLOGNA, ITALY","DYSGLYCEMIA IS A DISEASE STATE PRECEDING THE ONSET OF DIABETES AND INCLUDES IMPAIRED FASTING GLYCEMIA AND IMPAIRED GLUCOSE TOLERANCE. THIS REVIEW AIMED TO COLLECT AND ANALYZE THE LITERATURE REPORTING THE RESULTS OF CLINICAL TRIALS EVALUATING THE EFFECTS OF SELECTED NUTRACEUTICALS ON GLYCEMIA IN HUMANS. THE RESULTS OF THE ANALYZED TRIALS, GENERALLY, SHOWED THE POSITIVE EFFECTS OF THE NUTRACEUTICALS STUDIED ALONE OR IN ASSOCIATION WITH OTHER SUPPLEMENTS ON FASTING PLASMA GLUCOSE AND POST-PRANDIAL PLASMA GLUCOSE AS PRIMARY OUTCOMES, AND THEIR EFFICACY IN IMPROVING INSULIN RESISTANCE AS A SECONDARY OUTCOME. SOME EVIDENCES, OBTAINED FROM CLINICAL TRIALS, SUGGEST A ROLE FOR SOME NUTRACEUTICALS, AND IN PARTICULAR BERBERIS, BANABA, CURCUMIN, AND GUAR GUM, IN THE MANAGEMENT OF PREDIABETES AND DIABETES. HOWEVER, CONTRADICTORY RESULTS WERE FOUND ON THE HYPOGLYCEMIC EFFECTS OF MORUS, ILEX PARAGUARIENSIS, OMEGA-3, ALLIUM CEPA, AND TRIGONELLA FAENUM GRAECUM, WHEREBY RIGOROUS LONG-TERM CLINICAL TRIALS ARE NEEDED TO CONFIRM THESE DATA. MORE STUDIES ARE ALSO NEEDED FOR EUGENIA JAMBOLANA, AS WELL AS FOR ASCOPHYLLUM NODOSUM AND FUCUS VESICULOSUS WHICH GLUCOSE-LOWERING EFFECTS WERE OBSERVED WHEN ADMINISTERED IN COMBINATION, BUT NOT ALONE. FURTHER TRIALS ARE ALSO NEEDED FOR QUERCETIN. © 2022 THE AUTHORS. PHYTOTHERAPY RESEARCH PUBLISHED BY JOHN WILEY & SONS LTD.","DYSGLYCEMIA; IFG; IGT; NUTRACEUTICALS; PRE-DIABETES","BLOOD GLUCOSE; CURCUMIN; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; PREDIABETIC STATE; QUERCETIN; ACARBOSE; ALGAL EXTRACT; ALOE VERA EXTRACT; ANTIDIABETIC AGENT; ASCOPHYLLUM NODOSUM EXTRACT; ATORVASTATIN; AURANTIIN; BERBERINE; CHLORPROPAMIDE; CHROMIUM PICOLINATE; COROSOLIC ACID; CURCUMIN; EZETIMIBE; FENUGREEK EXTRACT; FISH OIL; FOLIC ACID; FUCUS VESICULOSUS EXTRACT; GARLIC EXTRACT; GINSENG EXTRACT; GLIBENCLAMIDE; GLUCOSE; GUAR GUM; GYMNEMA SYLVESTRE EXTRACT; GYMNEMIC ACID; ILEX PARAGUARIENSIS EXTRACT; INOSITOL; INSULIN; ISPAGULA; LAGERSTROEMIA SPECIOSA EXTRACT; METFORMIN; MEVINOLIN; MULBERRY EXTRACT; NARINGENIN; NIGELLA SATIVA EXTRACT; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PIOGLITAZONE; PIPERINE; PLANT EXTRACT; POLICOSANOL; POLYPHENOL DERIVATIVE; QUERCETIN; REBAUDIOSIDE A; SILYBUM MARIANUM EXTRACT; SILYMARIN; SOYBEAN EXTRACT; STANOL ESTER; STEVIA REBAUDIANA EXTRACT; STEVIOSIDE; SULFONYLUREA DERIVATIVE; SYZYGIUM CUMINI EXTRACT; THIOCTIC ACID; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CURCUMIN; QUERCETIN; ANTIDIABETIC ACTIVITY; APPLE JUICE; AREA UNDER THE CURVE; ASCOPHYLLUM; ASCOPHYLLUM NODOSUM; BERBERIS; BLACK CUMIN; BREAST CANCER; CITRUS; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; CURCUMA LONGA; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSGLYCEMIA; DYSLIPIDEMIA; FASTING BLOOD GLUCOSE LEVEL; FENUGREEK; FUCUS VESICULOSUS; GARLIC; GINSENG; GLUCOSE BLOOD LEVEL; GRAPEFRUIT; GUAR; GYMNEMA SYLVESTRE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ILEX PARAGUARIENSIS; IMPAIRED FASTING GLUCOSE; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; IMPAIRED PLASMA GLUCOSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LAGERSTROEMIA SPECIOSA; METABOLIC SYNDROME X; MONOTHERAPY; MORUS; MULBERRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ONION; OVARY POLYCYSTIC DISEASE; PANAX QUINQUEFOLIUS; PLANTAGO OVATA; POSTPRANDIAL STATE; PREHYPERTENSION; RED RICE; REVIEW; STEVIA REBAUDIANA; SYZYGIUM CUMINI; THERAPY EFFECT; DIABETES MELLITUS; DIETARY SUPPLEMENT; GLUCOSE INTOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS","UNIVERSITÀ DEGLI STUDI DI PAVIA","OPEN ACCESS FUNDING PROVIDED BY UNIVERSITA DEGLI STUDI DI PAVIA WITHIN THE CRUI-CARE AGREEMENT.","ABUTAIR A.S., NASER I.A., HAMED A.T., SOLUBLE FIBERS FROM PSYLLIUM IMPROVE GLYCEMIC RESPONSE AND BODY WEIGHT AMONG DIABETES TYPE 2 PATIENTS (RANDOMIZED CONTROL TRIAL), NUTRITION JOURNAL, 15, 1, (2016); ADAB Z., EGHTESADI S., VAFA M.R., HEYDARI I., SHOJAII A., HAQQANI H., EGHTESADI M., EFFECT OF TURMERIC ON GLYCEMIC STATUS, LIPID PROFILE, HS-CRP, AND TOTAL ANTIOXIDANT CAPACITY IN HYPERLIPIDEMIC TYPE 2 DIABETES MELLITUS PATIENTS, PHYTOTHERAPY RESEARCH, 33, 4, PP. 1173-1181, (2019); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., FAZIO S., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD JOURNAL OF CARDIOLOGY, 4, 3, PP. 77-83, (2012); AGGARWAL B.B., HARIKUMAR K.B., POTENTIAL THERAPEUTIC EFFECTS OF CURCUMIN, THE ANTI-INFLAMMATORY AGENT, AGAINST NEURODEGENERATIVE, CARDIOVASCULAR, PULMONARY, METABOLIC, AUTOIMMUNE AND NEOPLASTIC DISEASES, THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 41, 1, PP. 40-59, (2009); AJAMI M., SEYFI M., ABDOLLAH POURI HOSSEINI F., NASERI P., VELAYATI A., MAHMOUDNIA F., HAJIFARAJI M., EFFECTS OF STEVIA ON GLYCEMIC AND LIPID PROFILE OF TYPE 2 DIABETIC PATIENTS: A RANDOMIZED CONTROLLED TRIAL, AVICENNA JOURNAL OF PHYTOMEDICINE, 10, 2, PP. 118-127, (2020); AL-ROMAIYAN A., LIU B., ASARE-ANANE H., MAITY C.R., CHATTERJEE S.K., KOLEY N., JONES P.M., A NOVEL GYMNEMA SYLVESTRE EXTRACT STIMULATES INSULIN SECRETION FROM HUMAN ISLETS IN VIVO AND IN VITRO, PHYTOTHERAPY RESEARCH, 24, 9, PP. 1370-1376, (2010); AL-ROMAIYAN A., LIU B., DOCHERTY R., HUANG G.C., AMIEL S., PERSAUD S.J., JONES P.M., INVESTIGATION OF INTRACELLULAR SIGNALLING CASCADES MEDIATING STIMULATORY EFFECT OF A GYMNEMA SYLVESTRE EXTRACT ON INSULIN SECRETION FROM ISOLATED MOUSE AND HUMAN ISLETS OF LANGERHANS, DIABETES, OBESITY & METABOLISM, 14, 12, PP. 1104-1113, (2012); STANDARDS OF MEDICAL CARE IN DIABETES-2021, DIABETES CARE, 44, PP. S1-S222, (2021); AMIN F., ISLAM N., ANILA N., GILANI A.H., CLINICAL EFFICACY OF THE CO-ADMINISTRATION OF TURMERIC AND BLACK SEEDS (KALONGI) IN METABOLIC SYNDROME – A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL – TAK-METS TRIAL, COMPLEMENTARY THERAPIES IN MEDICINE, 23, 2, PP. 165-174, (2015); ANAND P., KUNNUMAKKARA A.B., NEWMAN R.A., AGGARWAL B.B., BIOAVAILABILITY OF CURCUMIN: PROBLEMS AND PROMISES, MOLECULAR PHARMACEUTICS, 4, 6, PP. 807-818, (2007); ANDERSON J.W., ALLGOOD L.D., TURNER J., OELTGEN P.R., DAGGY B.P., EFFECTS OF PSYLLIUM ON GLUCOSE AND SERUM LIPID RESPONSES IN MEN WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 70, 4, PP. 466-473, (1999); ANTON S.D., MARTIN C.K., HAN H., COULON S., CEFALU W.T., GEISELMAN P., WILLIAMSON D.A., EFFECTS OF STEVIA, ASPARTAME, AND SUCROSE ON FOOD INTAKE, SATIETY, AND POST-PRANDIAL GLUCOSE AND INSULIN LEVELS, APPETITE, 55, 1, PP. 37-43, (2010); APPENDINO G., BELCARO G., CORNELLI U., LUZZI R., TOGNI S., DUGALL M., GIZZI G., POTENTIAL ROLE OF CURCUMIN PHYTOSOME (MERIVA) IN CONTROLLING THE EVOLUTION OF DIABETIC MICROANGIOPATHY. A PILOT STUDY, PANMINERVA MEDICA, 53, 3, PP. 43-49, (2011); ARALELIMATH V.R., BHISE S.B., ANTI-DIABETIC EFFECTS OF GYMNEMA SYLVESTRE EXTRACT ON STREPTOZOTOCIN INDUCED DIABETIC RATS AND POSSIBLE B-CELL PROTECTIVE AND REGENERATIVE EVALUATIONS, DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES, 7, 1, PP. 135-142, (2012); ARCARI D.P., PORTO V.B., RODRIGUES E.R.V., MARTINS F., DE LIMA R.J., SAWAYA A.C.H.F., DE OLIVEIRA CARVALHO P., EFFECT OF MATE TEA (ILEX PARAGUARIENSIS) SUPPLEMENTATION ON OXIDATIVE STRESS BIOMARKERS AND LDL OXIDISABILITY IN NORMO- AND HYPERLIPIDAEMIC HUMANS, JOURNAL OF FUNCTIONAL FOODS, 3, PP. 190-197, (2011); ASAI A., NAKAGAWA K., HIGUCHI O., KIMURA T., KOJIMA Y., KARIYA J., OIKAWA S., EFFECT OF MULBERRY LEAF EXTRACT WITH ENRICHED 1-DEOXYNOJIRIMYCIN CONTENT ON POST-PRANDIAL GLYCEMIC CONTROL IN SUBJECTS WITH IMPAIRED GLUCOSE METABOLISM, JOURNAL OF DIABETES INVESTIGATION, 2, 4, PP. 318-323, (2011); AVALOS-SORIANO A., DE LA CRUZ-CORDERO R., ROSADO J.L., GARCIA-GASCA T., 4-HYDROXYISOLEUCINE FROM FENUGREEK (TRIGONELLA FOENUM-GRAECUM): EFFECTS ON INSULIN RESISTANCE ASSOCIATED WITH OBESITY, MOLECULES, 21, 11, (2016); AYYANAR M., SUBASH-BABU P., SYZYGIUM CUMINI (L.) SKEELS: A REVIEW OF ITS PHYTOCHEMICAL CONSTITUENTS AND TRADITIONAL USES, ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, 2, 3, PP. 240-246, (2012); AYYANAR M., SUBASH-BABU P., IGNACIMUTHU S., SYZYGIUM CUMINI (L.) SKEELS., A NOVEL THERAPEUTIC AGENT FOR DIABETES: FOLK MEDICINAL AND PHARMACOLOGICAL EVIDENCES, COMPLEMENTARY THERAPIES IN MEDICINE, 21, 3, PP. 232-243, (2013); BAHMANI M., SHIRZAD H., MIRHOSSEINI M., MESRIPOUR A., RAFIEIAN-KOPAEI M., A REVIEW ON ETHNOBOTANICAL AND THERAPEUTIC USES OF FENUGREEK (TRIGONELLA FOENUM-GRACEUM L), JOURNAL OF EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 21, 1, PP. 53-62, (2016); BANG H., KWAK J.H., AHN H.Y., SHIN D.Y., LEE J.H., KOREAN RED GINSENG IMPROVES GLUCOSE CONTROL IN SUBJECTS WITH IMPAIRED FASTING GLUCOSE, IMPAIRED GLUCOSE TOLERANCE, OR NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS, JOURNAL OF MEDICINAL FOOD, 17, 1, PP. 128-134, (2014); BANU S., JABIR N.R., MANJUNATHM N.C., KHAN M.S., ASHRAF G.M., KAMAL M.A., TABREZ S., REDUCTION OF POST-PRANDIAL HYPERGLYCEMIA BY MULBERRY TEA IN TYPE-2 DIABETES PATIENTS, SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 22, 1, PP. 32-36, (2015); BARRIOCANAL L.A., PALACIOS M., BENITEZ G., BENITEZ S., JIMENEZ J.T., JIMENEZ N., ROJAS V., APPARENT LACK OF PHARMACOLOGICAL EFFECT OF STEVIOL GLYCOSIDES USED AS SWEETENERS IN HUMANS. A PILOT STUDY OF REPEATED EXPOSURES IN SOME NORMOTENSIVE AND HYPOTENSIVE INDIVIDUALS AND IN TYPE 1 AND TYPE 2 DIABETICS, REGULATORY TOXICOLOGY AND PHARMACOLOGY, 51, 1, PP. 37-41, (2008); BASKARAN K., KIZAR AHAMATH B., RADHA SHANMUGASUNDARAM K., SHANMUGASUNDARAM E.R., ANTIDIABETIC EFFECT OF A LEAF EXTRACT FROM GYMNEMA SYLVESTRE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS PATIENTS, JOURNAL OF ETHNOPHARMACOLOGY, 30, 3, PP. 295-300, (1990); BHARDWAJ P.K., DASGUPTA D.J., PRASHAR B.S., KAUSHAL S.S., CONTROL OF HYPERGLYCAEMIA AND HYPERLIPIDAEMIA BY PLANT PRODUCT, THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA, 42, 1, PP. 33-35, (1994); BLACKBURN N.A., HOLGATE A.M., READ N.W., DOES GUAR GUM IMPROVE POST-PRANDIAL HYPERGLYCAEMIA IN HUMANS BY REDUCING SMALL INTESTINAL CONTACT AREA?, THE BRITISH JOURNAL OF NUTRITION, 52, PP. 197-204, (1984); BLOOMGARDEN Z.T., DODIS R., VISCOLI C.M., HOLMBOE E.S., INZUCCHI S.E., LOWER BASELINE GLYCEMIA REDUCES APPARENT ORAL AGENT GLUCOSE-LOWERING EFFICACY: A META-REGRESSION ANALYSIS, DIABETES CARE, 29, 9, PP. 2137-2139, (2006); BOAVENTURA B.C.B., DI PIETRO P.F., KLEIN G.A., STEFANUTO A., DE MORAIS E.C., DE ANDRADE F., DA SILVA E.L., ANTIOXIDANT POTENTIAL OF MATE TEA (ILEX PARAGUARIENSIS) IN TYPE 2 DIABETIC MELLITUS AND PRE-DIABETIC INDIVIDUALS, JOURNAL OF FUNCTIONAL FOODS, 5, PP. 1057-1064, (2013); BORDIA A., VERMA S.K., SRIVASTAVA K.C., EFFECT OF GINGER (ZINGIBER OFFICINALE ROSC.) AND FENUGREEK (TRIGONELLA FOENUM-GRAECUM L.) ON BLOOD LIPIDS, BLOOD SUGAR AND PLATELET AGGREGATION IN PATIENTS WITH CORONARY ARTERY DISEASE, PROSTAGLANDINS, LEUKOTRIENES, AND ESSENTIAL FATTY ACIDS, 56, 5, PP. 379-384, (1997); BORKMAN M., CHISHOLM D.J., FURLER S.M., STORLIEN L.H., KRAEGEN E.W., SIMONS L.A., CHESTERMAN C.N., EFFECTS OF FISH OIL SUPPLEMENTATION ON GLUCOSE AND LIPID METABOLISM IN NIDDM, DIABETES, 38, 10, PP. 1314-1319, (1989); BOSE S.N., SEPAHA G.C., CLINICAL OBSERVATIONS ON THE ANTIDIABETIC PROPERTIES OF PTEROCARPUS MARSUPIUM AND EUGENIA JAMBOLANA, JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, 27, 11, PP. 388-391, (1956); BRACESCO N., SANCHEZ A.G., CONTRERAS V., MENINI T., GUGLIUCCI A., RECENT ADVANCES ON ILEX PARAGUARIENSIS RESEARCH: MINIREVIEW, JOURNAL OF ETHNOPHARMACOLOGY, 136, 3, PP. 378-384, (2011); BRAHMACHARI G., MANDAL L.C., ROY R., MONDAL S., BRAHMACHARI A.K., STEVIOSIDE AND RELATED COMPOUNDS – MOLECULES OF PHARMACEUTICAL PROMISE: A CRITICAL OVERVIEW, ARCHIV DER PHARMAZIE (WEINHEIM), 344, 1, PP. 5-19, (2011); BRULL V., BURAK C., STOFFEL-WAGNER B., WOLFFRAM S., NICKENIG G., MULLER C., EGERT S., NO EFFECTS OF QUERCETIN FROM ONION SKIN EXTRACT ON SERUM LEPTIN AND ADIPONECTIN CONCENTRATIONS IN OVERWEIGHT-TO-OBESE PATIENTS WITH (PRE-)HYPERTENSION: A RANDOMIZED DOUBLE-BLINDED, PLACEBO-CONTROLLED CROSSOVER TRIAL, EUROPEAN JOURNAL OF NUTRITION, 56, 7, PP. 2265-2275, (2017); BUNDGAARD ANKER C.C., RAFIQ S., JEPPESEN P.B., EFFECT OF STEVIOL GLYCOSIDES ON HUMAN HEALTH WITH EMPHASIS ON TYPE 2 DIABETIC BIOMARKERS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTRIENTS, 11, 9, (2019); CEFFA C., SARTORI M., CARENA L., EFFECT OF DIETARY FIBER (GUAR GUM) ON POST-PRANDIAL BLOOD GLUCOSE AND BLOOD INSULIN METABOLISM IN THE MORNING, MINERVA DIETOLOGICA E GASTROENTEROLOGICA, 33, 1, PP. 83-87, (1987); CHAE H.W., KIM I.W., JIN H.E., KIM D.D., CHUNG S.J., SHIM C.K., EFFECT OF ION-PAIR FORMATION WITH BILE SALTS ON THE IN VITRO CELLULAR TRANSPORT OF BERBERINE, ARCHIVES OF PHARMACAL RESEARCH, 31, 1, PP. 103-110, (2008); CHAN P., TOMLINSON B., CHEN Y.J., LIU J.C., HSIEH M.H., CHENG J.T., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTIVENESS AND TOLERABILITY OF ORAL STEVIOSIDE IN HUMAN HYPERTENSION, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 50, 3, PP. 215-220, (2000); CHEN C., ZHOU J., JI C., QUERCETIN: A POTENTIAL DRUG TO REVERSE MULTIDRUG RESISTANCE, LIFE SCIENCES, 87, 11-12, PP. 333-338, (2010); CHEN W., BALAN P., POPOVICH D.G., REVIEW OF GINSENG ANTI-DIABETIC STUDIES, MOLECULES, 24, 24, (2019); CHEN W., MIAO Y.Q., FAN D.J., YANG S.S., LIN X., MENG L.K., TANG X., BIOAVAILABILITY STUDY OF BERBERINE AND THE ENHANCING EFFECTS OF TPGS ON INTESTINAL ABSORPTION IN RATS, AAPS PHARMSCITECH, 12, 2, PP. 705-711, (2011); CHEVASSUS H., GAILLARD J.B., FARRET A., COSTA F., GABILLAUD I., MAS E., PETIT P., A FENUGREEK SEED EXTRACT SELECTIVELY REDUCES SPONTANEOUS FAT INTAKE IN OVERWEIGHT SUBJECTS, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 66, 5, PP. 449-455, (2010); CHOI E.Y., LEE H., WOO J.S., JANG H.H., HWANG S.J., KIM H.S., KIM W., EFFECT OF ONION PEEL EXTRACT ON ENDOTHELIAL FUNCTION AND ENDOTHELIAL PROGENITOR CELLS IN OVERWEIGHT AND OBESE INDIVIDUALS, NUTRITION, 31, 9, PP. 1131-1135, (2015); CHOI H.N., JEONG S.M., HUH G.H., KIM J.I., QUERCETIN AMELIORATES INSULIN SENSITIVITY AND LIVER STEATOSIS PARTLY BY INCREASING ADIPONECTIN EXPRESSION IN OB/OB MICE, FOOD SCIENCE AND BIOTECHNOLOGY, 24, PP. 273-279, (2015); CHOI H.S., KIM S., KIM M.J., KIM M.S., KIM J., PARK C.W., OH S.W., EFFICACY AND SAFETY OF PANAX GINSENG BERRY EXTRACT ON GLYCEMIC CONTROL: A 12-WK RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED CLINICAL TRIAL, JOURNAL OF GINSENG RESEARCH, 42, 1, PP. 90-97, (2018); CHOI M.S., RYU R., SEO Y.R., JEONG T.S., SHIN D.H., PARK Y.B., JUNG U.J., THE BENEFICIAL EFFECT OF SOYBEAN (GLYCINE MAX (L.) MERR.) LEAF EXTRACTS IN ADULTS WITH PREDIABETES: A RANDOMIZED PLACEBO CONTROLLED TRIAL, FOOD & FUNCTION, 5, 7, PP. 1621-1630, (2014); CHUENGSAMARN S., RATTANAMONGKOLGUL S., LUECHAPUDIPORN R., PHISALAPHONG C., JIRAWATNOTAI S., CURCUMIN EXTRACT FOR PREVENTION OF TYPE 2 DIABETES, DIABETES CARE, 35, 11, PP. 2121-2127, (2012); CHUENGSAMARN S., RATTANAMONGKOLGUL S., PHONRAT B., TUNGTRONGCHITR R., JIRAWATNOTAI S., REDUCTION OF ATHEROGENIC RISK IN PATIENTS WITH TYPE 2 DIABETES BY CURCUMINOID EXTRACT: A RANDOMIZED CONTROLLED TRIAL, THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 25, 2, PP. 144-150, (2014); CHUNG H.I., KIM J., KIM J.Y., KWON O., ACUTE INTAKE OF MULBERRY LEAF AQUEOUS EXTRACT AFFECTS POST-PRANDIAL GLUCOSE RESPONSE AFTER MALTOSE LOADING: RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PILOT STUDY, JOURNAL OF FUNCTIONAL FOODS, 13, PP. 1502-1506, (2013); CICERO A.F.G., DEROSA G., DI GREGORI V., BOVE M., GADDI A.V., BORGHI C., OMEGA 3 POLYUNSATURATED FATTY ACIDS SUPPLEMENTATION AND BLOOD PRESSURE LEVELS IN HYPERTRIGLYCERIDEMIC PATIENTS WITH UNTREATED NORMAL-HIGH BLOOD PRESSURE AND WITH OR WITHOUT METABOLIC SYNDROME: A RETROSPECTIVE STUDY, CLINICAL AND EXPERIMENTAL HYPERTENSION, 32, 2, PP. 137-144, (2010); CICERO A.F.G., DEROSA G., MANCA M., BOVE M., BORGHI C., GADDI A.V., DIFFERENT EFFECT OF PSYLLIUM AND GUAR DIETARY SUPPLEMENTATION ON BLOOD PRESSURE CONTROL IN HYPERTENSIVE OVERWEIGHT PATIENTS: A SIX-MONTH, RANDOMIZED CLINICAL TRIAL, CLINICAL AND EXPERIMENTAL HYPERTENSION, 29, 6, PP. 383-394, (2007); CICERO A.F.G., DEROSA G., BOVE M., IMOLA F., BORGHI C., GADDI A.V., PSYLLIUM IMPROVES DYSLIPIDAEMIA, HYPERGLYCAEMIA AND HYPERTENSION, WHILE GUAR GUM REDUCES BODY WEIGHT MORE RAPIDLY IN PATIENTS AFFECTED BY METABOLIC SYNDROME FOLLOWING AN AHA STEP 2 DIET, MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM, 3, PP. 47-54, (2010); CICERO A.F.G., FOGACCI F., MORBINI M., COLLETTI A., BOVE M., VERONESI M., BORGHI C., NUTRACEUTICAL EFFECTS ON GLUCOSE AND LIPID METABOLISM IN PATIENTS WITH IMPAIRED FASTING GLUCOSE: A PILOT, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL ON A COMBINED PRODUCT, HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 24, 3, PP. 283-288, (2017); CLIFTON P.M., GALBRAITH C., COLES L., EFFECT OF A LOW DOSE WHEY/GUAR PRELOAD ON GLYCEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES – A RANDOMISED CONTROLLED TRIAL, NUTRITION JOURNAL, 13, (2014); CROCHEMORE I.C., SOUZA A.F., DE SOUZA A.C., ROSADO E.L., Ω-3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION DOES NOT INFLUENCE BODY COMPOSITION, INSULIN RESISTANCE, AND LIPEMIA IN WOMEN WITH TYPE 2 DIABETES AND OBESITY, NUTRITION IN CLINICAL PRACTICE, 27, 4, PP. 553-560, (2012); CURI R., ALVAREZ M., BAZOTTE R.B., BOTION L.M., GODOY J.L., BRACHT A., EFFECT OF STEVIA REBAUDIANA ON GLUCOSE TOLERANCE IN NORMAL ADULT HUMANS, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 19, 6, PP. 771-774, (1986); DA SILVA G.E.C., ASSEF A.H., ALBINO C.C., FERRI L.D.F., TASIN G., TAKAHASHI M.H., BAZOTTE R.B., INVESTIGATION OF THE TOLERABILITY OF ORAL STEVIOSIDE IN BRAZILIAN HYPERLIPIDEMIC PATIENTS, BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 49, 4, PP. 583-587, (2006); DALL'ALBA V., SILVA F.M., ANTONIO J.P., STEEMBURGO T., ROYER C.P., ALMEIDA J.C., AZEVEDO M.J., IMPROVEMENT OF THE METABOLIC SYNDROME PROFILE BY SOLUBLE FIBRE – GUAR GUM – IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMISED CLINICAL TRIAL, THE BRITISH JOURNAL OF NUTRITION, 110, 9, PP. 1601-1610, (2013); DALLAS C., GERBI A., ELBEZ Y., CAILLARD P., ZAMARIA N., CLOAREC M., CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF A CITRUS POLYPHENOLIC EXTRACT OF RED ORANGE, GRAPEFRUIT, AND ORANGE (SINETROL-XPUR) ON WEIGHT MANAGEMENT AND METABOLIC PARAMETERS IN HEALTHY OVERWEIGHT INDIVIDUALS, PHYTOTHERAPY RESEARCH, 28, 2, PP. 212-218, (2014); DASTJERDI M.S., SALEHIOUN M., NAJAFIAN A., AMINI M., A RANDOMIZED CONTROLLED STUDY FOR EVALUATION OF PSYLLIUM EFFECTS ON KINETICS OF CARBOHYDRATE ABSORPTION, JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 12, 3, PP. 125-130, (2007); DE CARVALHO C.M., DE PAULA T.P., VIANA L.V., MACHADO V.M., DE ALMEIDA J.C., AZEVEDO M.J., PLASMA GLUCOSE AND INSULIN RESPONSES AFTER CONSUMPTION OF BREAKFASTS WITH DIFFERENT SOURCES OF SOLUBLE FIBER IN TYPE 2 DIABETES PATIENTS: A RANDOMIZED CROSSOVER CLINICAL TRIAL, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 106, 5, PP. 1238-1245, (2017); DE MARTIN S., GABBIA D., CARRARA M., FERRI N., THE BROWN ALGAE FUCUS VESICULOSUS AND ASCOPHYLLUM NODOSUM REDUCE METABOLIC SYNDROME RISK FACTORS: A CLINICAL STUDY, NATURAL PRODUCT COMMUNICATIONS, 13, PP. 1691-1694, (2018); DEFRONZO R.A., GOODMAN A.M., EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS. THE MULTICENTER METFORMIN STUDY GROUP, THE NEW ENGLAND JOURNAL OF MEDICINE, 333, 9, PP. 541-549, (1995); DEN BESTEN G., GERDING A., VAN DIJK T.H., CIAPAITE J., BLEEKER A., VAN EUNEN K., BAKKER B.M., PROTECTION AGAINST THE METABOLIC SYNDROME BY GUAR GUM-DERIVED SHORT-CHAIN FATTY ACIDS DEPENDS ON PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Γ AND GLUCAGON-LIKE PEPTIDE-1, PLOS ONE, 10, 8, (2015); DEROSA G., BONAVENTURA A., BIANCHI L., ROMANO D., D'ANGELO A., FOGARI E., MAFFIOLI P., BERBERIS ARISTATA/SILYBUM MARIANUM FIXED COMBINATION ON LIPID PROFILE AND INSULIN SECRETION IN DYSLIPIDEMIC PATIENTS, EXPERT OPINION ON BIOLOGICAL THERAPY, 13, 11, PP. 1495-1506, (2013); DEROSA G., BONAVENTURA A., BIANCHI L., ROMANO D., D'ANGELO A., FOGARI E., MAFFIOLI P., EFFECTS OF BERBERIS ARISTATA/SILYBUM MARIANUM ASSOCIATION ON METABOLIC PARAMETERS AND ADIPOCYTOKINES IN OVERWEIGHT DYSLIPIDEMIC PATIENTS, JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 27, 3, PP. 717-728, (2013); DEROSA G., CATENA G., RADDINO R., GAUDIO G., MAGGI A., D'ANGELO A., MAFFIOLI P., EFFECTS ON ORAL FAT LOAD OF A NUTRACEUTICAL COMBINATION OF FERMENTED RED RICE, STEROL ESTERS AND STANOLS, CURCUMIN, AND OLIVE POLYPHENOLS: A RANDOMIZED, PLACEBO CONTROLLED TRIAL, PHYTOMEDICINE, 42, PP. 75-82, (2018); DEROSA G., CICERO A.F., D'ANGELO A., BORGHI C., MAFFIOLI P., EFFECTS OF N-3 PUFAS ON FASTING PLASMA GLUCOSE AND INSULIN RESISTANCE IN PATIENTS WITH IMPAIRED FASTING GLUCOSE OR IMPAIRED GLUCOSE TOLERANCE, BIOFACTORS, 42, 3, PP. 316-322, (2016); DEROSA G., CICERO A.F., FOGARI E., D'ANGELO A., BONAVENTURA A., MAFFIOLI P., EFFECTS OF N-3 PUFA ON INSULIN RESISTANCE AFTER AN ORAL FAT LOAD, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 113, PP. 950-960, (2011); DEROSA G., CICERO A.F., FOGARI E., D'ANGELO A., BONAVENTURA A., ROMANO D., MAFFIOLI P., EFFECTS OF N-3 PUFAS ON POST-PRANDIAL VARIATION OF METALLOPROTEINASES, AND INFLAMMATORY AND INSULIN RESISTANCE PARAMETERS IN DYSLIPIDEMIC PATIENTS: EVALUATION WITH EUGLYCEMIC CLAMP AND ORAL FAT LOAD, JOURNAL OF CLINICAL LIPIDOLOGY, 6, 6, PP. 553-564, (2012); DEROSA G., CICERO A.F.G., D'ANGELO A., MAFFIOLI P., ASCOPHYLLUM NODOSUM AND FUCUS VESICULOSUS ON GLYCEMIC STATUS AND ON ENDOTHELIAL DAMAGE MARKERS IN DYSGLICEMIC PATIENTS, PHYTOTHERAPY RESEARCH, 33, 3, PP. 791-797, (2019); DEROSA G., D'ANGELO A., MAFFIOLI P., ILEX PARAGUARIENSIS, WHITE MULBERRY AND CHROMIUM PICOLINATE IN PATIENTS WITH PRE-DIABETES, PHYTOTHERAPY RESEARCH, 34, 6, PP. 1377-1384, (2020); DEROSA G., D'ANGELO A., ROMANO D., MAFFIOLI P., EFFECTS OF A COMBINATION OF BERBERIS ARISTATA, SILYBUM MARIANUM AND MONACOLIN ON LIPID PROFILE IN SUBJECTS AT LOW CARDIOVASCULAR RISK; A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18, 2, (2017); DEROSA G., D'ANGELO A., MAFFIOLI P., THE ROLE OF A FIXED BERBERIS ARISTATA/SILYBUM MARIANUM COMBINATION IN THE TREATMENT OF TYPE 1 DIABETES MELLITUS, CLINICAL NUTRITION, 35, 5, PP. 1091-1095, (2016); DEROSA G., D'ANGELO A., MAFFIOLI P., METABOLIC ACTIONS OF A SUPPLEMENT OF ILEX PARAGUARIENSIS (AN EXTRACT OF THE LEAF STANDARDIZED TO 2% I-DEOXINOJIRIMCINA), WHITE MULBERRY AND CHROMIUM PICOLINATE IN NONDIABETIC SUBECTS WITH DYSGLYCEMIA: A RANDOMIZED TRIAL, LIFE (BASEL), 11, 7, (2021); DEROSA G., D'ANGELO A., VANELLI A., MAFFIOLI P., AN EVALUATION OF A NUTRACEUTICAL WITH BERBERINE, CURCUMIN, INOSITOL, BANABA AND CHROMIUM PICOLINATE IN PATIENTS WITH FASTING DYSGLYCEMIA, DIABETES, METABOLIC SYNDROME AND OBESITY, 13, PP. 653-661, (2020); DEROSA G., MAFFIOLI P., CICERO A.F., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPINION ON BIOLOGICAL THERAPY, 12, 8, PP. 1113-1124, (2012); DEROSA G., MAFFIOLI P., D'ANGELO A., SALVADEO S.A., FERRARI I., FOGARI E., CICERO A.F., EFFECTS OF LONG CHAIN OMEGA-3 FATTY ACIDS ON METALLOPROTEINASES AND THEIR INHIBITORS IN COMBINED DYSLIPIDEMIA PATIENTS, EXPERT OPINION ON PHARMACOTHERAPY, 10, 8, PP. 1239-1247, (2009); DEROSA G., PASCUZZO M.D., D'ANGELO A., MAFFIOLI P., ASCOPHYLLUM NODOSUM, FUCUS VESICULOSUS AND CHROMIUM PICOLINATE NUTRACEUTICAL COMPOSITION CAN HELP TO TREAT TYPE 2 DIABETIC PATIENTS, DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY, 12, PP. 1861-1865, (2019); DEROSA G., ROMANO D., D'ANGELO A., MAFFIOLI P., BERBERIS ARISTATA COMBINED WITH SILYBUM MARIANUM ON LIPID PROFILE IN PATIENTS NOT TOLERATING STATINS AT HIGH DOSES, ATHEROSCLEROSIS, 239, 1, PP. 87-92, (2015); DEY L., XIE J.T., WANG A., WU J., MALECKAR S.A., YUAN C.S., ANTI-HYPERGLYCEMIC EFFECTS OF GINSENG: COMPARISON BETWEEN ROOT AND BERRY, PHYTOMEDICINE, 10, PP. 600-605, (2003); DI PIERRO F., BELLONE I., RAPACIOLI G., PUTIGNANO P., CLINICAL ROLE OF A FIXED COMBINATION OF STANDARDIZED BERBERIS ARISTATA AND SILYBUM MARIANUM EXTRACTS IN DIABETIC AND HYPERCHOLESTEROLEMIC PATIENTS INTOLERANT TO STATINS, DIABETES, METABOLIC SYNDROME AND OBESITY, 8, PP. 89-96, (2015); DI PIERRO F., PUTIGNANO P., FERRARA T., RAIOLA C., RAPACIOLI G., VILLANOVA N., RETROSPECTIVE ANALYSIS OF THE EFFECTS OF A HIGHLY STANDARDIZED MIXTURE OF BERBERIS ARISTATA, SILYBUM MARIANUM, AND MONACOLINS K AND KA IN PATIENTS WITH DYSLIPIDEMIA, CLINICAL PHARMACOLOGY, 9, PP. 1-7, (2016); DI PIERRO F., PUTIGNANO P., VILLANOVA N., RETROSPECTIVE ANALYSIS OF THE EFFECTS OF A HIGHLY STANDARDIZED MIXTURE OF BERBERIS ARISTATA, SILYBUM MARIANUM, AND MONACOLINS K AND KA IN DIABETIC PATIENTS WITH DYSLIPIDEMIA, ACTA BIO-MEDICA, 88, 4, PP. 462-469, (2018); DI PIERRO F., PUTIGNANO P., VILLANOVA N., MONTESI L., MOSCATIELLO S., MARCHESINI G., PRELIMINARY STUDY ABOUT THE POSSIBLE GLYCEMIC CLINICAL ADVANTAGE IN USING A FIXED COMBINATION OF BERBERIS ARISTATA AND SILYBUM MARIANUM STANDARDIZED EXTRACTS VERSUS ONLY BERBERIS ARISTATA IN PATIENTS WITH TYPE 2 DIABETES, CLINICAL PHARMACOLOGY, 5, PP. 167-174, (2013); DI PIERRO F., VILLANOVA N., AGOSTINI F., MARZOCCHI R., SOVERINI V., MARCHESINI G., PILOT STUDY ON THE ADDITIVE EFFECTS OF BERBERINE AND ORAL TYPE 2 DIABETES AGENTS FOR PATIENTS WITH SUBOPTIMAL GLYCEMIC CONTROL, DIABETES, METABOLIC SYNDROME AND OBESITY, 5, PP. 213-217, (2012); DICKERSIN K., SCHERER R., LEFEBVRE C., IDENTIFYING RELEVANT STUDIES FOR SYSTEMATIC REVIEWS, BRITISH MEDICAL JOURNAL, 309, PP. 1286-1291, (1994); DODI G., HRITCU D., POPA M., CARBOXYMETHYLATION OF GUAR GUM: SYNTHESIS AND CHARACTERIZATION, CELLULOSE CHEMISTRY AND TECHNOLOGY, 45, PP. 171-176, (2011); DUNAIF G., SCHNEEMAN B.O., THE EFFECT OF DIETARY FIBER ON HUMAN PANCREATIC ENZYME ACTIVITY IN VITRO, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 34, 6, PP. 1034-1035, (1981); EBELING P., YKI-JARVINEN H., ARO A., HELVE E., SINISALO M., KOIVISTO V.A., GLUCOSE AND LIPID METABOLISM AND INSULIN SENSITIVITY IN TYPE 1 DIABETES: THE EFFECT OF GUAR GUM, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 48, 1, PP. 98-103, (1988); EDWARDS C.A., JOHNSON I.T., READ N.W., DO VISCOUS POLYSACCHARIDES SLOW ABSORPTION BY INHIBITING DIFFUSION OR CONVECTION?, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 42, 4, PP. 307-312, (1988); EDWARDS R.L., LYON T., LITWIN S.E., RABOVSKY A., SYMONS J.D., JALILI T., QUERCETIN REDUCES BLOOD PRESSURE IN HYPERTENSIVE SUBJECTS, THE JOURNAL OF NUTRITION, 137, 11, PP. 2405-2411, (2007); EGERT S., BOSY-WESTPHAL A., SEIBERL J., KURBITZ C., SETTLER U., PLACHTA-DANIELZIK S., MULLER M.J., QUERCETIN REDUCES SYSTOLIC BLOOD PRESSURE AND PLASMA OXIDISED LOW-DENSITY LIPOPROTEIN CONCENTRATIONS IN OVERWEIGHT SUBJECTS WITH A HIGH-CARDIOVASCULAR DISEASE RISK PHENOTYPE: A DOUBLE-BLINDED, PLACEBO-CONTROLLED CROSS-OVER STUDY, THE BRITISH JOURNAL OF NUTRITION, 102, 7, PP. 1065-1074, (2009); FAKHRZADEH H., GHADERPANAHI M., SHARIFI F., MIRAREFIN M., BADAMCHIZADE Z., KAMRANI A.A., LARIJANI B., THE EFFECTS OF LOW DOSE N-3 FATTY ACIDS ON SERUM LIPID PROFILES AND INSULIN RESISTANCE OF THE ELDERLY: A RANDOMIZED CONTROLLED CLINICAL TRIAL, INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 80, 2, PP. 107-116, (2010); FARHAT G., BERSET V., MOORE L., EFFECTS OF STEVIA EXTRACT ON POST-PRANDIAL GLUCOSE RESPONSE, SATIETY AND ENERGY INTAKE: A THREE-ARM CROSSOVER TRIAL, NUTRIENTS, 11, 12, (2019); FAROOK V.S., REDDIVARI L., CHITTOOR G., PUPPALA S., ARYA R., FOWLER S.P., VANAMALA J., METABOLITES AS NOVEL BIOMARKERS FOR CHILDHOOD OBESITY-RELATED TRAITS IN MEXICAN-AMERICAN CHILDREN, PEDIATRIC OBESITY, 10, 4, PP. 320-327, (2015); FEINGLOS M.N., GIBB R.D., RAMSEY D.L., SURWIT R.S., MCRORIE J.W., PSYLLIUM IMPROVES GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS, BIOACTIVE CARBOHYDRATES AND DIETARY FIBRE, 1, 2, PP. 156-161, (2013); FERRI L.A., ALVES-DO-PRADO W., YAMADA S.S., GAZOLA S., BATISTA M.R., BAZOTTE R.B., INVESTIGATION OF THE ANTIHYPERTENSIVE EFFECT OF ORAL CRUDE STEVIOSIDE IN PATIENTS WITH MILD ESSENTIAL HYPERTENSION, PHYTOTHERAPY RESEARCH, 20, 9, PP. 732-736, (2006); FLACHS P., ROSSMEISL M., KOPECKY J., THE EFFECT OF N-3 FATTY ACIDS ON GLUCOSE HOMEOSTASIS AND INSULIN SENSITIVITY, PHYSIOLOGICAL RESEARCH, 63, PP. S93-S118, (2014); FRENCH S.J., READ N.W., EFFECT OF GUAR GUM ON HUNGER AND SATIETY AFTER MEALS OF DIFFERING FAT CONTENT: RELATIONSHIP WITH GASTRIC EMPTYING, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 59, PP. 87-91, (1994); FRIDAY K.E., CHILDS M.T., TSUNEHARA C.H., FUJIMOTO W.Y., BIERMAN E.L., ENSINCK J.W., ELEVATED PLASMA GLUCOSE AND LOWERED TRIGLYCERIDE LEVELS FROM OMEGA-3 FATTY ACID SUPPLEMENTATION IN TYPE II DIABETES, DIABETES CARE, 12, 4, PP. 276-281, (1989); FUJIOKA K., GREENWAY F., SHEARD J., YING Y., THE EFFECTS OF GRAPEFRUIT ON WEIGHT AND INSULIN RESISTANCE: RELATIONSHIP TO THE METABOLIC SYNDROME, JOURNAL OF MEDICINAL FOOD, 9, 1, PP. 49-54, (2006); FUJIWARA H., HOSOKAWA M., ZHOU X., FUJIMOTO S., FUKUDA K., TOYODA K., INAGAKI N., CURCUMIN INHIBITS GLUCOSE PRODUCTION IN ISOLATED MICE HEPATOCYTES, DIABETES RESEARCH AND CLINICAL PRACTICE, 80, 2, PP. 185-191, (2008); FUKUSHIMA M., MATSUYAMA F., UEDA N., EGAWA K., TAKEMOTO J., KAJIMOTO Y., SEINO Y., EFFECT OF COROSOLIC ACID ON POSTCHALLENGE PLASMA GLUCOSE LEVELS, DIABETES RESEARCH AND CLINICAL PRACTICE, 73, 2, PP. 174-177, (2006); FULLER S., STEPHENS J.M., DIOSGENIN, 4-HYDROXYISOLEUCINE, AND FIBER FROM FENUGREEK: MECHANISMS OF ACTIONS AND POTENTIAL EFFECTS ON METABOLIC SYNDROME, ADVANCES IN NUTRITION, 6, 2, PP. 189-197, (2015); FUNAMOTO, M., SHIMIZU, K., SUNAGAWA, Y., KATANASAKA, Y., MIYAZAKI, Y., KAKEYA, H., … MORIMOTO, T. (2019). EFFECTS OF HIGHLY ABSORBABLE CURCUMIN IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE AND NON-INSULIN-DEPENDENT DIABETES MELLITUS. JOURNAL OF DIABETES RESEARCH, 2019, 8208237; GABBIA D., DALL'ACQUA S., DI GANGI I.M., BOGIALLI S., CAPUTI V., ALBERTONI L., DE MARTIN S., THE PHYTOCOMPLEX FROM FUCUS VESICULOSUS AND ASCOPHYLLUM NODOSUM CONTROLS POST-PRANDIAL PLASMA GLUCOSE LEVELS: AN IN VITRO AND IN VIVO STUDY IN A MOUSE MODEL OF NASH, MARINE DRUGS, 15, 2, (2017); GADDAM A., GALLA C., THUMMISETTI S., MARIKANTY R.K., PALANISAMY U.D., RAO P.V., ROLE OF FENUGREEK IN THE PREVENTION OF TYPE 2 DIABETES MELLITUS IN PREDIABETES, JOURNAL OF DIABETES AND METABOLIC DISORDERS, 14, (2015); GATENBY S.J., ELLIS P.R., MORGAN L.M., JUDD P.A., EFFECT OF PARTIALLY DEPOLYMERIZED GUAR GUM ON ACUTE METABOLIC VARIABLES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES, DIABETIC MEDICINE, 13, 4, PP. 358-364, (1996); GAYTAN MARTINEZ L.A., SANCHEZ-RUIZ L.A., ZUNIGA L.Y., GONZALEZ-ORTIZ M., MARTINEZ-ABUNDIS E., EFFECT OF GYMNEMA SYLVESTRE ADMINISTRATION ON GLYCEMIC CONTROL, INSULIN SECRETION, AND INSULIN SENSITIVITY IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE, JOURNAL OF MEDICINAL FOOD, 24, 1, PP. 28-32, (2021); GERSTEIN H.C., MORE INSIGHTS ON THE DYSGLYCAEMIA-CARDIOVASCULAR CONNECTION, LANCET, 375, 9733, PP. 2195-2196, (2010); GLAUBER H., WALLACE P., GRIVER K., BRECHTEL G., ADVERSE METABOLIC EFFECT OF OMEGA-3 FATTY ACIDS IN NON-INSULIN-DEPENDENT DIABETES MELLITUS, ANNALS OF INTERNAL MEDICINE, 108, 5, PP. 663-668, (1988); GONZALEZ-PERIZ A., HORRILLO R., FERRE N., GRONERT K., DONG B., MORAN-SALVADOR E., CLARIA J., OBESITY-INDUCED INSULIN RESISTANCE AND HEPATIC STEATOSIS ARE ALLEVIATED BY OMEGA-3 FATTY ACIDS: A ROLE FOR RESOLVINS AND PROTECTINS, THE FASEB JOURNAL, 23, 6, PP. 1946-1957, (2009); GOWRI S.S., VASANTHA K., PHYTOCHEMICAL SCREENING AND ANTIBACTERIAL ACTIVITY OF SYZYGIUM CUMINI (L.) (MYRTACEAE) LEAVES EXTRACTS, INTERNATIONAL JOURNAL OF PHARMTECH RESEARCH, 2, 2, PP. 1569-1573, (2010); GRANT S.J., CHANG D.H., LIU J., WONG V., KIAT H., BENSOUSSAN A., CHINESE HERBAL MEDICINE FOR IMPAIRED GLUCOSE TOLERANCE: A RANDOMIZED PLACEBO CONTROLLED TRIAL, BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 13, (2013); GREGERSEN S., JEPPESEN P.B., HOLST J.J., HERMANSEN K., ANTIHYPERGLYCEMIC EFFECTS OF STEVIOSIDE IN TYPE 2 DIABETIC SUBJECTS, METABOLISM, 53, 1, PP. 73-76, (2004); GROOP P.H., ARO A., STENMAN S., GROOP L., LONG-TERM EFFECTS OF GUAR GUM IN SUBJECTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 58, 4, PP. 513-518, (1993); GU Y., ZHANG Y., SHI X., LI X., HONG J., CHEN J., NING G., EFFECT OF TRADITIONAL CHINESE MEDICINE BERBERINE ON TYPE 2 DIABETES BASED ON COMPREHENSIVE METABONOMICS, TALANTA, 81, 3, PP. 766-772, (2010); GUPTA A., BIRHMAN K., RAHEJA I., SHARMA S.K., KAR H.K., QUERCETIN: A WONDER BIOFLAVONOID WITH THERAPEUTIC POTENTIAL IN DISEASE MANAGEMENT, ASIAN PACIFIC JOURNAL OF TROPICAL DISEASE, 6, PP. 248-252, (2016); GUPTA A., GUPTA R., LAL B., EFFECT OF TRIGONELLA FOENUM-GRAECUM (FENUGREEK) SEEDS ON GLYCAEMIC CONTROL AND INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS: A DOUBLE BLIND PLACEBO CONTROLLED STUDY, THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA, 49, PP. 1057-1061, (2001); GUPTA S., ABU-GHANNAM N., BIOACTIVE POTENTIAL AND POSSIBLE HEALTH EFFECTS OF EDIBLE BROWN SEAWEEDS, TRENDS IN FOOD SCIENCE AND TECHNOLOGY, 22, PP. 315-326, (2011); HADI A., ARAB A., HAJIANFAR H., TALAEI B., MIRAGHAJANI M., BABAJAFARI S., TAVAKOLY R., THE EFFECT OF FENUGREEK SEED SUPPLEMENTATION ON SERUM IRISIN LEVELS, BLOOD PRESSURE, AND LIVER AND KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PARALLEL RANDOMIZED CLINICAL TRIAL, COMPLEMENTARY THERAPIES IN MEDICINE, 49, (2020); HALL A.C., FAIRCLOUGH A.C., MAHADEVAN K., PAXMAN J.R., ASCOPHYLLUM NODOSUM ENRICHED BREAD REDUCES SUBSEQUENT ENERGY INTAKE WITH NO EFFECT ON POST-PRANDIAL GLUCOSE AND CHOLESTEROL IN HEALTHY, OVERWEIGHT MALES. A PILOT STUDY, APPETITE, 58, 1, PP. 379-386, (2012); HELMSTADTER A., SYZYGIUM CUMINI (L.) SKEELS (MYRTACEAE) AGAINST DIABETES – 125 YEARS OF RESEARCH, PHARMAZIE, 63, 2, PP. 91-101, (2008); HENDRA T.J., BRITTON M.E., ROPER D.R., WAGAINE-TWABWE D., JEREMY J.Y., DANDONA P., YUDKIN J.S., EFFECTS OF FISH OIL SUPPLEMENTS IN NIDDM SUBJECTS. CONTROLLED STUDY, DIABETES CARE, 13, 8, PP. 821-829, (1990); HODAEI H., ADIBIAN M., NIKPAYAM O., HEDAYATI M., SOHRAB G., THE EFFECT OF CURCUMIN SUPPLEMENTATION ON ANTHROPOMETRIC INDICES, INSULIN RESISTANCE AND OXIDATIVE STRESS IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL, DIABETOLOGY AND METABOLIC SYNDROME, 11, (2019); HOFFMAN R., RANJBAR G., MADDEN A.M., INHIBITION OF THE GLYCAEMIC RESPONSE BY ONION: A COMPARISON BETWEEN LACTOSE-TOLERANT AND LACTOSE-INTOLERANT ADULTS, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 70, 9, PP. 1089-1091, (2016); HOLMAN R.R., STEEMSON J., DARLING P., TURNER R.C., NO GLYCEMIC BENEFIT FROM GUAR ADMINISTRATION IN NIDDM, DIABETES CARE, 10, 1, PP. 68-71, (1987); HOLT S., HEADING R.C., CARTER D.C., PRESCOTT L.F., TOTHILL P., EFFECT OF GEL FIBRE ON GASTRIC EMPTYING AND ABSORPTION OF GLUCOSE AND PARACETAMOL, LANCET, 1, 8117, PP. 636-639, (1979); HSIEH M.H., CHAN P., SUE Y.M., LIU J.C., LIANG T.H., HUANG T.Y., CHEN Y.J., EFFICACY AND TOLERABILITY OF ORAL STEVIOSIDE IN PATIENTS WITH MILD ESSENTIAL HYPERTENSION: A TWO-YEAR, RANDOMIZED, PLACEBO-CONTROLLED STUDY, CLINICAL THERAPEUTICS, 25, 11, PP. 2797-2808, (2003); HU M., ZENG W., TOMLINSON B., EVALUATION OF A CRATAEGUS-BASED MULTIHERB FORMULA FOR DYSLIPIDEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, (2014); HUSSAIN S.A., AHMED Z.A., MAHWI T.O., AZIZ T.A., EFFECT OF QUERCETINON POST-PRANDIAL GLUCOSE EXCURSION AFTER MONO- AND DISACCHARIDES CHALLENGE IN NORMAL AND DIABETIC RATS, JOURNAL OF DIABETES MELLITUS, 2, PP. 82-87, (2012); IACOVIELLO L., ZITO F., RAGO L., DI CASTELNUOVO A., DE CURTIS A., ZAPPACOSTA B., CERLETTI C., PROLONGED ADMINISTRATION OF ASCOPHYLLUM NODOSUM TO HEALTHY HUMAN VOLUNTEERS AND CARDIOVASCULAR RISK, NUTRAFOODS, 12, PP. 137-144, (2013); IDRIS S., MISHRA A., KHUSHTAR M., RECENT THERAPEUTIC INTERVENTIONS OF FENUGREEK SEED: A MECHANISTIC APPROACH, DRUG RESEARCH (STUTTGART), 71, 4, PP. 180-192, (2021); IKEDA Y., CHEN J.T., MATSUDA T., EFFECTIVENESS AND SAFETY OF BANABAMIN TABLET CONTAINING EXTRACT FROM BANABA IN PATIENTS WITH MILD TYPE 2 DIABETES, JAPANESE PHARMACOLOGY AND THERAPEUTICS, 27, PP. 829-835, (1999); IKEDA Y., NOGUCHI M., KISHI S., MASUDA K., KUSUMOTO A., ZEIDA M., KISO Y., BLOOD GLUCOSE CONTROLLING EFFECTS AND SAFETY OF SINGLE AND LONG-TERM ADMINISTRATION ON THE EXTRACT OF BANABA LEAVES, JOURNAL OF NUTRITION & FOOD, 5, PP. 41-53, (2002)","G. DEROSA; DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PAVIA, PAVIA, ITALY; EMAIL: GIUSEPPE.DEROSA@UNIPV.IT","JOHN WILEY AND SONS LTD","ENGLISH","PHYTOTHER. RES.","REVIEW","ISI","2-S2.0-85135275693","PHYTOTHER RES","UNIVERSITY OF PAVIA;UNIVERSITY OF PAVIA;UNIVERSITY OF PAVIA","NOTREPORTED;UNIVERSITY OF PAVIA;NOTREPORTED",NA,"DEROSA G, 2022, PHYTOTHER RES","DEROSA G, 2022, PHYTOTHER RES"
"CHO K;KIM J;KOMATSU T;UEHARA Y","CHO, KYUNG-HYUN (7403956966); KIM, JI-EUN (57881093800); KOMATSU, TOMOHIRO (36113558800); UEHARA, YOSHINARI (7202555528)","PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL RAYDEL WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED PLACEBOCONTROLLED AND DOUBLEBLINDED STUDY WITH HEALTHY AND MIDDLEAGED JAPANESE PARTICIPANTS",2023,"LIFE","13","",5,"10.3390/life13061319","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN, FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN;CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN, FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN","POLICOSANOL CONSUMPTION HAS BEEN ASSOCIATED WITH TREATING BLOOD PRESSURE AND DYSLIPIDEMIA BY INCREASING THE LEVEL OF HIGH-DENSITY LIPOPROTEINS-CHOLESTEROL (HDL-C) AND HDL FUNCTIONALITY. ALTHOUGH POLICOSANOL SUPPLEMENTATION ALSO AMELIORATED LIVER FUNCTION IN ANIMAL MODELS, IT HAS NOT BEEN REPORTED IN A HUMAN CLINICAL STUDY, PARTICULARLY WITH A 20 MG DOAGE OF POLICOSANOL. IN THE CURRENT STUDY, TWELVE-WEEK CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL®) SIGNIFICANTLY ENHANCED THE HEPATIC FUNCTIONS, SHOWING REMARKABLE DECREASES IN HEPATIC ENZYMES, BLOOD UREA NITROGEN, AND GLYCATED HEMOGLOBIN. FROM THE HUMAN TRIAL WITH JAPANESE PARTICIPANTS, THE POLICOSANOL GROUP (N = 26, MALE 13/FEMALE 13) SHOWED A REMARKABLE DECREASE IN ALANINE AMINOTRANSFERASE (ALT) AND ASPARTATE AMINOTRANSFERASE (AST) FROM BASELINE UP TO 21% (P = 0.041) AND 8.7% (P = 0.017), RESPECTIVELY. IN CONTRAST, THE PLACEBO GROUP (N = 26, MALE 13/FEMALE 13) SHOWED ALMOST NO CHANGE OR SLIGHT ELEVATION. THE POLICOSANOL GROUP SHOWED A 16% DECREASE IN Γ-GLUTAMYL TRANSFERASE (Γ-GTP) AT WEEK 12 FROM THE BASELINE (P = 0.015), WHILE THE PLACEBO GROUP SHOWED A 1.2% INCREASE. THE POLICOSANOL GROUP EXHIBITED SIGNIFICANTLY LOWER SERUM ALKALINE PHOSPHATASE (ALP) LEVELS AT WEEK 8 (P = 0.012), WEEK 12 (P = 0.012), AND AFTER 4-WEEKS (P = 0.006) COMPARED TO THOSE OF THE PLACEBO GROUP. AFTER 12 WEEKS OF POLICOSANOL CONSUMPTION, THE FERRIC ION REDUCTION ABILITY AND PARAOXONASE OF SERUM WERE ELEVATED BY 37% (P < 0.001) AND 29% (P = 0.004) HIGHER THAN WEEK 0, WHILE PLACEBO CONSUMPTION SHOWED NO NOTABLE CHANGES. INTERESTINGLY, GLYCATED HEMOGLOBIN (HBA1C) IN SERUM WAS LOWERED SIGNIFICANTLY IN THE POLICOSANOL GROUP 4 WEEKS AFTER CONSUMPTION, WHICH WAS APPROXIMATELY 2.1% (P = 0.004) LOWER THAN THE PLACEBO GROUP. IN ADDITION, BLOOD UREA NITROGEN (BUN) AND URIC ACID LEVELS WERE SIGNIFICANTLY LOWER IN THE POLICOSANOL GROUP AFTER 4 WEEKS: 14% LOWER (P = 0.002) AND 4% LOWER (P = 0.048) THAN THOSE OF THE PLACEBO GROUP, RESPECTIVELY. REPEATED MEASURES OF ANOVA SHOWED THAT THE POLICOSANOL GROUP HAD REMARKABLE DECREASES IN AST (P = 0.041), ALT (P = 0.008), Γ-GTP (P = 0.016), ALP (P = 0.003), HBA1C (P = 0.010), BUN (P = 0.030), AND SBP (P = 0.011) FROM THE CHANGES IN THE PLACEBO GROUP IN POINT OF TIME AND GROUP INTERACTION. IN CONCLUSION, 12 WEEKS OF 20 MG CONSUMPTION OF POLICOSANOL SIGNIFICANTLY ENHANCED HEPATIC PROTECTION BY LOWERING THE SERUM AST, ALT, ALP, AND Γ-GTP VIA A DECREASE IN GLYCATED HEMOGLOBIN, URIC ACID, AND BUN WITH AN ELEVATION OF SERUM ANTIOXIDANT ABILITIES. THESE RESULTS SUGGEST THAT IMPROVEMENTS IN BLOOD PRESSURE BY CONSUMPTION OF 20 MG OF POLICOSANOL (RAYDEL®) WERE ACCOMPANIED BY PROTECTION OF LIVER FUNCTION AND ENHANCED KIDNEY FUNCTION. © 2023 BY THE AUTHORS.","ANTI-GLYCATION; ANTIOXIDANT; BLOOD PRESSURE; BLOOD UREA NITROGEN; GLYCATED HEMOGLOBIN; LIVER FUNCTION; POLICOSANOL","","","","ROSSELLI M., LOTERSZTAJN S., VIZZUTTI F., ARENA U., PINZANI M., MARRA F., THE METABOLIC SYNDROME AND CHRONIC LIVER DISEASE, CURR. PHARM. DES, 20, PP. 5010-5024, (2014); TALWANI R., GILLIAM B.L., HOWELL C., INFECTIOUS DISEASES AND THE LIVER, CLIN. LIVER DIS, 15, PP. 111-130, (2011); ANSTEE Q.M., CASTERA L., LOOMBA R., IMPACT OF NON-INVASIVE BIOMARKERS ON HEPATOLOGY PRACTICE: PAST, PRESENT AND FUTURE, J. HEPATOL, 76, PP. 1362-1378, (2022); LIMDI J., HYDE G., EVALUATION OF ABNORMAL LIVER FUNCTION TESTS, POSTGRAD. MED. J, 79, PP. 307-312, (2003); MCGILL M.R., THE PAST AND PRESENT OF SERUM AMINOTRANSFERASES AND THE FUTURE OF LIVER INJURY BIOMARKERS, EXCLI J, 15, (2016); BEIER J.I., ARTEEL G.E., ENVIRONMENTAL EXPOSURE AS A RISK-MODIFYING FACTOR IN LIVER DISEASES: KNOWNS AND UNKNOWNS, ACTA PHARM. SIN. B, 11, PP. 3768-3778, (2021); HARRISON S.A., DAY C.P., BENEFITS OF LIFESTYLE MODIFICATION IN NAFLD, GUT, 56, PP. 1760-1769, (2007); OSNA N.A., DONOHUE T.M., KHARBANDA K.K., ALCOHOLIC LIVER DISEASE: PATHOGENESIS AND CURRENT MANAGEMENT, ALCOHOL RES. CURR. REV, 38, (2017); IMANI F., MOTAVAF M., SAFARI S., ALAVIAN S.M., THE THERAPEUTIC USE OF ANALGESICS IN PATIENTS WITH LIVER CIRRHOSIS: A LITERATURE REVIEW AND EVIDENCE-BASED RECOMMENDATIONS, HEPAT. MON, 14, (2014); CHANG W.H., MUELLER S.H., CHUNG S.-C., FOSTER G.R., LAI A.G., INCREASED BURDEN OF CARDIOVASCULAR DISEASE IN PEOPLE WITH LIVER DISEASE: UNEQUAL GEOGRAPHICAL VARIATIONS, RISK FACTORS AND EXCESS YEARS OF LIFE LOST, J. TRANSL. MED, 20, (2022); BONORA E., TARGHER G., INCREASED RISK OF CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE IN NAFLD, NAT. REV. GASTROENTEROL. HEPATOL, 9, PP. 372-381, (2012); MEGA A., MARZI L., KOB M., PICCIN A., FLOREANI A., FOOD AND NUTRITION IN THE PATHOGENESIS OF LIVER DAMAGE, NUTRIENTS, 13, (2021); TESCHKE R., EICKHOFF A., HERBAL HEPATOTOXICITY IN TRADITIONAL AND MODERN MEDICINE: ACTUAL KEY ISSUES AND NEW ENCOURAGING STEPS, FRONT. PHARMACOL, 6, (2015); CHO J.-H., OH D.-S., HONG S.-H., KO H., LEE N.-H., PARK S.-E., HAN C.-W., KIM S.-M., KIM Y.-C., KIM K.-S., A NATIONWIDE STUDY OF THE INCIDENCE RATE OF HERB-INDUCED LIVER INJURY IN KOREA, ARCH. TOXICOL, 91, PP. 4009-4015, (2017); MARCHESINI G., FORLANI G., BUGIANESI E., IS LIVER DISEASE A THREAT TO PATIENTS WITH METABOLIC DISORDERS?, ANN. MED, 37, PP. 333-346, (2005); DING Q., OUYANG J., FAN B., CAO C., FAN Z., DING L., LI F., TU W., JIN X., WANG J., ASSOCIATION BETWEEN DYSLIPIDEMIA AND NEPHROLITHIASIS RISK IN A CHINESE POPULATION, UROL. INT, 103, PP. 156-165, (2019); KABEYA Y., KATO K., TOMITA M., KATSUKI T., OIKAWA Y., SHIMADA A., ATSUMI Y., ASSOCIATIONS OF INSULIN RESISTANCE AND GLYCEMIC CONTROL WITH THE RISK OF KIDNEY STONES, INTERN. MED, 51, PP. 699-705, (2012); PARK H.-J., YADAV D., JEONG D.-J., KIM S.-J., BAE M.-A., KIM J.-R., CHO K.-H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); CHO K.-H., KIM S.-J., YADAV D., KIM J.-Y., KIM J.-R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID. MED. CELL. LONGEV, 2018, (2018); KIM J.-Y., KIM S.-M., KIM S.-J., LEE E.-Y., KIM J.-R., CHO K.-H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED, 39, (2017); KIM S.-J., YADAV D., PARK H.-J., KIM J.-R., CHO K.-H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); LIM S.-M., YOO J.-A., LEE E.-Y., CHO K.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); CHO K.-H., BAE M., KIM J.-R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC. THER, 2019, (2019); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI, 24, (2023); CHO K.-H., NAM H.-S., BAEK S.-H., KANG D.-J., NA H., KOMATSU T., UEHARA Y., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT. J. MOL. SCI, 24, (2023); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS” VERSUS GENUINE POLICOSANOL, REV. CENIC CIENC. QUÍM, 38, PP. 207-213, (2007); BENZIE I.F., STRAIN J., 2 FERRIC REDUCING/ANTIOXIDANT POWER ASSAY: DIRECT MEASURE OF TOTAL ANTIOXIDANT ACTIVITY OF BIOLOGICAL FLUIDS AND MODIFIED VERSION FOR SIMULTANEOUS MEASUREMENT OF TOTAL ANTIOXIDANT POWER AND ASCORBIC ACID CONCENTRATION, METHODS IN ENZYMOLOGY, 299, PP. 15-27, (1999); BLATTER GARIN M.-C., MOREN X., JAMES R.W., PARAOXONASE-1 AND SERUM CONCENTRATIONS OF HDL-CHOLESTEROL AND APOA-I, J. LIPID RES, 47, PP. 515-520, (2006); SPELIOTES E.K., BALAKRISHNAN M., FRIEDMAN L.S., COREY K.E., TREATMENT OF DYSLIPIDEMIA IN COMMON LIVER DISEASES, CLIN. LIVER DIS, 14, PP. 161-162, (2019); HADIZADEH F., FAGHIHIMANI E., ADIBI P., NONALCOHOLIC FATTY LIVER DISEASE: DIAGNOSTIC BIOMARKERS, WORLD J. GASTROINTEST. PATHOPHYSIOL, 8, (2017); CICERO A.F., COLLETTI A., BELLENTANI S., NUTRACEUTICAL APPROACH TO NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): THE AVAILABLE CLINICAL EVIDENCE, NUTRIENTS, 10, (2018); ZHOU F., ZHOU J., WANG W., ZHANG X.J., JI Y.X., ZHANG P., SHE Z.G., ZHU L., CAI J., LI H., UNEXPECTED RAPID INCREASE IN THE BURDEN OF NAFLD IN CHINA FROM 2008 TO 2018: A SYSTEMATIC REVIEW AND META-ANALYSIS, HEPATOLOGY, 70, PP. 1119-1133, (2019); KUMA A., KATO A., LIFESTYLE-RELATED RISK FACTORS FOR THE INCIDENCE AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN THE HEALTHY YOUNG AND MIDDLE-AGED POPULATION, NUTRIENTS, 14, (2022); ZHANG X., TONG T., CHANG A., ANG T.F.A., TAO Q., AUERBACH S., DEVINE S., QIU W.Q., MEZ J., MASSARO J., MIDLIFE LIPID AND GLUCOSE LEVELS ARE ASSOCIATED WITH ALZHEIMER’S DISEASE, ALZHEIMER’S DEMENT, 19, PP. 181-193, (2023); CAVERO-REDONDO I., PELETEIRO B., ALVAREZ-BUENO C., RODRIGUEZ-ARTALEJO F., MARTINEZ-VIZCAINO V., GLYCATED HAEMOGLOBIN A1C AS A RISK FACTOR OF CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY IN DIABETIC AND NON-DIABETIC POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, BMJ OPEN, 7, (2017); BOWER J.K., APPEL L.J., MATSUSHITA K., YOUNG J.H., ALONSO A., BRANCATI F.L., SELVIN E., GLYCATED HEMOGLOBIN AND RISK OF HYPERTENSION IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY, DIABETES CARE, 35, PP. 1031-1037, (2012); HU J., ZHANG X., GU J., YANG M., ZHANG X., ZHAO H., LI L., SERUM ALKALINE PHOSPHATASE LEVELS AS A SIMPLE AND USEFUL TEST IN SCREENING FOR SIGNIFICANT FIBROSIS IN TREATMENT-NAIVE PATIENTS WITH HEPATITIS B E-ANTIGEN NEGATIVE CHRONIC HEPATITIS B, EUR. J. GASTROENTEROL. HEPATOL, 31, PP. 817-823, (2019); RAFIQ N., BAI C., FANG Y., SRISHORD M., MCCULLOUGH A., GRAMLICH T., YOUNOSSI Z.M., LONG-TERM FOLLOW-UP OF PATIENTS WITH NONALCOHOLIC FATTY LIVER, CLIN. GASTROENTEROL. HEPATOL, 7, PP. 234-238, (2009); LIU X., ZHANG H., LIANG J., BLOOD UREA NITROGEN IS ELEVATED IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE, HEPATO-GASTROENTEROL, 60, PP. 343-345, (2013); LAN Q., ZHENG L., ZHOU X., WU H., BUYS N., LIU Z., SUN J., FAN H., THE VALUE OF BLOOD UREA NITROGEN IN THE PREDICTION OF RISKS OF CARDIOVASCULAR DISEASE IN AN OLDER POPULATION, FRONT. CARDIOVASC. MED, 8, (2021); ZHU L., FANG Z., JIN Y., CHANG W., HUANG M., HE L., CHEN Y., YAO Y., ASSOCIATION BETWEEN SERUM ALANINE AND ASPARTATE AMINOTRANSFERASE AND BLOOD PRESSURE: A CROSS-SECTIONAL STUDY OF CHINESE FRESHMEN, BMC CARDIOVASC. DISORD, 21, (2021); PARK E.-O., BAE E.J., PARK B.-H., CHAE S.-W., THE ASSOCIATIONS BETWEEN LIVER ENZYMES AND CARDIOVASCULAR RISK FACTORS IN ADULTS WITH MILD DYSLIPIDEMIA, J. CLIN. MED, 9, (2020); NOA M., MENDOZA S., MAS R., MENDOZA N., EFFECT OF POLICOSANOL ON CARBON TETRACHLORIDE-INDUCED ACUTE LIVER DAMAGE IN SPRAGUE-DAWLEY RATS, DRUGS R&D, 4, PP. 29-35, (2003); ZEIN N., YASSIN F., MAKLED S., ALOTAIBI S.S., ALBOGAMI S.M., MOSTAFA-HEDEAB G., BATIHA G.E.-S., ELEWA Y.H.A., ORAL SUPPLEMENTATION OF POLICOSANOL ALLEVIATES CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS IN RATS, BIOMED. PHARMACOTHER, 150, (2022); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); ZHAI Z., NIU K.M., LIU H., LIN C., TU Y., LIU Y., CAI L., OUYANG K., LIU J., POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6/MICE THROUGH AMPK–FXR–TGR5 CROSS-TALK, J. FOOD SCI, 86, PP. 5466-5478, (2021); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); NAM D.-E., YUN J.-M., KIM D., KIM O.-K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J. MED. FOOD, 22, PP. 1110-1117, (2019); AMADI C.N., ORISAKWE O.E., HERB-INDUCED LIVER INJURIES IN DEVELOPING NATIONS: AN UPDATE, TOXICS, 6, (2018); SUK K.T., KIM D.J., DRUG-INDUCED LIVER INJURY: PRESENT AND FUTURE, CLIN. MOL. HEPATOL, 18, (2012); OBI E., AKUNYILI D.N., EKPO B., ORISAKWE O.E., HEAVY METAL HAZARDS OF NIGERIAN HERBAL REMEDIES, SCI. TOTAL ENVIRON, 369, PP. 35-41, (2006); ERNST E., ADULTERATION OF CHINESE HERBAL MEDICINES WITH SYNTHETIC DRUGS: A SYSTEMATIC REVIEW, J. INTERN. MED, 252, PP. 107-113, (2002)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MDPI","ENGLISH","LIFE","ARTICLE","ISI","2-S2.0-85163775133","LIFE","RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;FUKUOKA UNIVERSITY HOSPITAL;FUKUOKA UNIVERSITY HOSPITAL","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2023, LIFE","CHO K-H, 2023, LIFE"
"TU Y;LIU J;HU L;WANG R;CAI L;GUO X","TU, YUE (57312304800); LIU, JIANPING (57202034035); HU, LINFANG (58860042900); WANG, RUXIA (57189490761); CAI, LICHUANG (54407998100); GUO, XIONGCHANG (58843738200)","ADVANCES IN RESEARCH ON POLICOSANOL COMPONENTS BIOACTIVITIES AND PHYSICOCHEMICAL MODIFICATIONS 米糠脂肪烷醇的组成功能及物理化学修饰研究进展",2023,"MODERN FOOD SCIENCE AND TECHNOLOGY","39","7",0,"10.13982/j.mfst.1673-9078.2023.12.0611","INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA;INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA;INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA;INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA;INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA;INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA","RICE BRAN FATTY ALCOHOLS ARE A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS THAT EXIST IN RICE BRAN WAX. THEY HAVE UNIQUE PHYSIOLOGICAL ACTIVITIES, SUCH AS LIPID-REGULATING, ANTI-INFLAMMATORY, AND ANTI-FATIGUE EFFECTS, AND IMMUNITY ENHANCEMENT. THESE ALCOHOLS ARE CONSIDERED A NEW TYPE OF FOOD INGREDIENT OF GREAT RESEARCH VALUE AND ARE APPROVED BY THE NATIONAL HEALTH COMMISSION. IN THIS PAPER, THE MAIN COMPONENTS (BEHENYL ALCOHOL, TETRACOSANOL, HEXACOSYL ALCOHOL, TRIACONTANOL, DOTRIACONTANOL), BIOACTIVITIES, AND PHYSICOCHEMICAL MODIFICATIONS (EMULSION, MICROENCAPSULATION, NANO-PARTICLES, ESTERIFICATION) OF RICE BRAN FATTY ALCOHOLS WERE REVIEWED. THE RELATIONSHIP BETWEEN ITS FINGERPRINT AND BIOACTIVITIES IS DISCUSSED. THE COMBINED EFFECT OF HIGHER ALIPHATIC ALKANOLS RESULTED IN OPTIMAL BIOACTIVITY OF RICE BRAN FATTY ALCOHOL; EXERTING A STABILIZING EFFECT MAY BE RELATED TO THE FINGERPRINT OF THE MIXTURE OF HIGHER ALIPHATIC ALKANOLS. THIS STUDY PROVIDES A REFERENCE FOR THE DEVELOPMENT OF A NEW FOOD RAW MATERIAL, POLICOSANOL, FROM RICE BRAN WAX. THERE ARE PRACTICAL IMPLICATIONS FOR THE USE OF RICE BRAN RESOURCES IN CONJUNCTION WITH THE DEVELOPMENT OF THE HUMAN HEALTH INDUSTRY. © 2023 SOUTH CHINA UNIVERSITY OF TECHNOLOGY. ALL RIGHTS RESERVED.","BIOACTIVITY; HIGHER ALIPHATIC ALCOHOL; PHYSICOCHEMICAL MODIFICATION; POLICOSANOL; RICE BRAN FATTY ALCOHOL","","","","PEPPING J., POLICOSANOL, AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 60, 11, PP. 1112-1115, (2003); SHEN JUNJUN, LUO FEIJUN, LIN QINLU, POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, JOURNAL OF FUNCTIONAL FOODS, 57, PP. 351-360, (2019); VARADY KRISTA A, WANG YANWEN, JONES PETER J H, ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDOVASCULAR DISEASE, NUTRITON REVIEWS, 61, PP. 376-383, (2003); KATO S, KARINO K, HASEGAWA S, ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BRITISH JOURNAL OF NUTRITION, 73, 3, (1995); TAYLOR JOHANNA C, RAPPORT LISA, BRIAN LOCKWOOD G, OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); SAENTHAWEESUK SUPHAKET, THAEOMOR ATCHARAPORN, RABINTOSSAPORN PORNRUT, ET AL., EFFECTS OF OCTACOSANOL ON HMG-COA REDUCTASE AND CYCLOOXYGENASE-2 ACTIVITIES IN THE HT-29 HUMAN COLORECTAL CANCER CELL LINE J, SCIENCE ASIA, 48, PP. 32-36, (2022); XU ZUYUAN, FITZ EVELYN, RIEDIGER NATALIE, ET AL., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPRPTEIN E-KNOCKOUT MICE, NUTRITION RESEARCH, 27, 4, PP. 212-217, (2007); CIRIC MILICA ZRNIC, OSTOJIC MIODRAG, BARALIC IVANA, ET AL., SUPPLEMENTATION WITH OCTACOSANOL AFFECTS THE LEVEL OF PCSK9 AND RESTORE ITS PHYSIOLOGIC RELATION WITH LDL-C IN PATIENTS ON CHRONIC STATIN THERAPY, NUTRIENTS, 13, (2021); OHASHI KOJI, ISHIKAWA HIROAKI, OHTA YOSHIJI, OCTACOSANOL AMELIORATES HYPERLIPIDEMIA AND OXIDATIVE STRESS IN KKAY MICE WITH TYPE 2 DIABETES, JOURNAL OF ANALYTICAL BIO-SCIENCE, 34, 3, PP. 223-233, (2011); ZHOU Y P, CAO F L, WU Q, ET AL., DIETARY SUPPLEMENTATION OF OCTACOSANOL IMPROVES EXERCISE-INDUCED FATIGUE AND ITS MOLECULAR MECHANISM, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 68, 27, PP. 7603-7618, (2021); GUO TIANYI, LIN QINLU, LI XINHUA, ET AL., OCTACOSANOL ATTENUATES INFLAMMATION IN BOTH RAW264.7 MACROPHAGES AND A MOUSE MODEL OF COLITIS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 65, 18, PP. 3647-3658, (2017); DE OLIVEIRA ANDERSON MARQUES, CONSERVA LUCIA M, DE SOUZA FERRO JAMYLLE N, ET AL., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 13, PP. 1598-1611, (2012); ZHOU YAPING, CAO FULIANG, LUO FEIJUN, ET AL., OCTACOSANOL AND HEALTH BENEFITS: BIOLOGICAL FUNCTIONS AND MECHANISMS OF ACTION, FOOD BIOSCIENCE, 47, (2022); THIPPESWAMY G, SHEELA M L, SALIMATH B P, OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-B AND ITS DNA BINDING ACTIVITY J, EUROPEAN JOURNAL OF PHARMACOLOGY, 588, PP. 141-150, (2008); KAUSHIK MAHESH K, ARITAKE KOSUKE, TAKEUCHI ATSUKO, ET AL., OCTACOSANOL RESTORES STRESS-AFFECTED SLEEP IN MICE BY ALLEVIATING STRESS, SCIENTIFIC REPORTS, 7, (2017); OHTA YOSHIJI, OHASHI KOJI, YAMADA KAZUO, ET AL., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 42, 2, PP. 118-125, (2008); WANG TAO, LIU YANYONG, WANG XIN, ET AL., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING J, ACTA PHARMACOLOGICA SINICA, 31, PP. 765-774, (2010); WANG TAO, LIU YANYONG, YANG NAN, ET AL., ANTI-PARKINSONIAN EFFECTS OF OCTACOSANOL IN 1-METHYL-4-PHENYL-1, 2, 3, 6 TETRAHYDROPYRIDINE-TREATED MICE, NEURAL REGENERATION RESEARCH, 7, 14, PP. 1080-1087, (2012); HSU C Y, SHIH H Y, CHANG Y C, ET AL., THE BENEFICIAL EFFECTS OF TETRACOSANOL ON INSULIN-RESISTANCE BY INSULIN RECEPTOR KINASE SENSIBILISATION J, JOURNAL OF FUNCTIONAL FOODS, 14, PP. 174-182, (2015); VERGARA MAURICIO, OLIVARES ARACELI, ALTAMIRANO CLAUDIA, ANTIPROLIFERATIVE EVALUATION OF TALL-OIL DOCOSANOL AND TETRACOSANOL OVER CHO-K1 AND HUMAN MELANOMA CELLS, ELECTRONIC JOURNAL OF BIOTECHNOLOGY, 18, 4, PP. 291-294, (2015); AZZOUZ MIMOUN, KENNEL PHILIPPE F, WARTER JEAN MARIE, ET AL., ENHANCEMENT OF MOUSE SCIATIC NERVE REGENERATION BY THE LONG CHAIN FATTY ALCOHOL, N-HEXACOSANOL, EXPERIMENTAL NEUROLOGY, 138, 2, PP. 189-197, (1996); OKADA SHINICHI, SAITO MOTOAKI, KAZUYAMA EMI, ET AL., EFFECTS OF N-HEXACOSANOL ON NITRIC OXIDE SYNTHASE SYSTEM IN DIABETIC RAT NEPHROPATHY, MOLECULAR AND CELLULAR BIOCHEMISTRY, 315, 1, PP. 169-177, (2008); SHINBORI CHIKO, SAITO MOTOAKI, KINOSHITA YUKAKO, ET AL., N-HEXACOSANOL REVERSES DIABETIC INDUCED MUSCARINIC HYPERCONTRACTILITY OF ILEUM IN THE RAT, EUROPEAN JOURNAL OF PHARMACOLOGY, 545, 2-3, PP. 177-184, (2006); ISLAM SHAISTUL, ZAID ABBU, MOHAMMAD FIROZ, ROLE OF TRIACONTANOL IN COUNTERACTING THE ILL EFFECTS OF SALINITY IN PLANTS: A REVIEW J, JOURNAL OF PLANT GROWTH REGULATION, 40, PP. 1-10, (2021); ALHARBI BASMAH M, ABDULMAJEED AWATIF MAHFOUZ, HASSAN HEBA, BIOCHEMICAL AND MOLECULAR EFFECTS INDUCED BY TRIACONTANOL IN ACQUIRED TOLERANCE OF RICE TO DROUGHT STRESS J, GENES, 12, PP. 11191-111916, (2021); SHAJI K P, UMESHA S, BHARATHI P. BHARATHI P., SALIMATH. A NOVEL LIQUID ORAL FORMULATION FOR 1-OCTACOSANOL, AN ANTICANCER DRUG AND ITS STABILITY STUDY, INTERNATIONAL JOURNAL OF PHARMACY AND ANALYTICAL RESEARCH, 4, 3, PP. 202-209, (2015); ISHAKA AMINU, IMAM MUSTAPHA UMAR, MAHAMUD ROZI, ET AL., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INTERNATIONAL JOURNAL OF NANOMEDICINE, 9, PP. 2261-2269, (2014); KIM JONG YEA, LEE JU HUN, DU YUN JEONG, ET AL., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYDRATE POLYMERS, 121, PP. 140-146, (2015); GUPTA SURASHREE SEN, GHOSH MAHUA, OCTACOSANOL EDUCES PHYSICO-CHEMICAL ATTRIBUTES, RELEASE AND BIOAVAILABILITY AS MODIFIED NANOCRYSTALS, EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 119, PP. 201-214, (2017); LI DONGZE, WU GANGCHENG, ZHANG HUI, ET AL., THE SOY PROTEIN ISOLATE-OCTACOSANOL-POLYSACCHARIDES NANOCOMPLEX FOR ENHANCED PHYSICAL STABILITY IN NEUTRAL CONDITIONS: FABRICATION, CHARACTERIZATION, THERMAL STABILITY, FOOD CHEMISTRY, 322, PP. 1-7, (2020); ZHAO TINGTING, TAE YEOUL HA, LEE JUN SOO, ET AL., MODELING AND OPTIMIZATION OF LIPASE-CATALYZED ESTERIFICATION OF POLICOSANOLS WITH CONJUGATED LINOLEIC ACID BY RESPONSE SURFACE METHODOLOGY, BIOCATALYSIS AND BIOTRANSFORMATION, 31, 2, PP. 114-122, (2013); HAIN D, VALENZUELA A, BRANES M C, ET AL., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASAS Y ACEITES, 63, 4, PP. 345-354, (2012); HE WENSEN, LIU QIAO, YU HUAN, ET AL., EFFICIENT SYNTHESIS OF OCTACOSANOL LINOLEATE CATALYZED BY IONIC LIQUID AND ITS STRUCTURE CHARACTERIZATION, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 93, PP. 509-517, (2016); KASSIS AMIRA N, MARINANGELI CHRISTOPHER P F, JAIN DEEPAK, ET AL., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, 1, PP. 153-158, (2007); LIN YUGUANG, RUDRUM MIKE, WIELEN R P, ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); DULLENS STEFAN P J, MENSINK RONALD P, BRAGT MARJOLIJN C E, ET AL., EFFECTS OF EMULSIFIED POLICOSANOLS WITH DIFFERENT CHAIN LENGTHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTOR-DEFICIENT MICE, JOURNAL OF LIPID RESEARCH, 49, 4, PP. 790-796, (2008); PENG KAI, LONG LEI, WANG YUXI, ET AL., EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON THE LAYING PERFORMANCE, EGG QUALITY AND BLOOD METABOLITES OF LAYING HENS J, ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES, 29, PP. 1458-1463, (2016); NAM DA EUN, YUN JEONG MOON, KIM DAKYUNG, ET AL., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, JOURNAL OF MEDICINAL FOOD, 22, 11, PP. 1110-1117, (2019); LEE JUNG YUN, CHOI HWANG YONG, KANG YU RI, ET AL., EFFECTS OF LONG-TERM SUPPLEMENTATION OF POLICOSANOL ON BLOOD CHOLESTEROL/GLUCOSE LEVELS AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY IN A RAT MODEL FED HIGH CHOLESTEROL DIETS, FOOD SCIENCE AND BIOTECHNOLOGY, 25, 3, PP. 899-904, (2016); ZHAI ZHENYA, NIU KAIMIN, LIU HUIPING, ET AL., POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6/MICE THROUGH AMPK-FXR-TGR5 CROSS-TALK, JOURNAL OF FOOD SCIENCE, 86, 12, PP. 5466-5478, (2021); ZHAI ZHENYA, LIU JIANPING, NIU KAIMIN, ET AL., INTEGRATED METAGENOMICS AND METABOLOMICS TO REVEAL THE EFFECTS OF POLICOSANOL ON MODULATING THE GUT MICROBIOTA AND LIPID METABOLISM IN HYPERLIPIDEMIC C57BL/6 MICE, FRONTIERS IN ENDOCRINOLOGY, 12, PP. 1-14, (2021); SHARMA RAHUL, MATSUZAKA TAKASHI, KAUSHIK MAHESH K, ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCIENTIFIC REPORTS, 9, (2019)","X. GUO; INSTITUTE OF BIOLOGICAL RESOURCES, JIANGXI ACADEMY OF SCIENCES, JIANGXI ENGINEERING LABORATORY FOR FUNCTIONAL FEED ADDITIVES, NANCHANG, 330096, CHINA; EMAIL: 411930833@QQ.COM","SOUTH CHINA UNIVERSITY OF TECHNOLOGY","CHINESE","MOD. FOOD SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-85184062311","MOD FOOD SCI TECHNOL","INSTITUTE OF BIOLOGICAL RESOURCES;INSTITUTE OF BIOLOGICAL RESOURCES;INSTITUTE OF BIOLOGICAL RESOURCES;INSTITUTE OF BIOLOGICAL RESOURCES;INSTITUTE OF BIOLOGICAL RESOURCES;INSTITUTE OF BIOLOGICAL RESOURCES","NOTREPORTED;INSTITUTE OF BIOLOGICAL RESOURCES;NOTREPORTED",NA,"TU Y, 2023, MOD FOOD SCI TECHNOL","TU Y, 2023, MOD FOOD SCI TECHNOL"
"BRUNO E;LUPI F;MAMMOLENTI D;BALDINO N;GABRIELE D","BRUNO, E. (57215077927); LUPI, F.R. (24768180600); MAMMOLENTI, D. (57324733900); BALDINO, N. (24767432700); GABRIELE, D. (6507587673)","DEVELOPMENT AND RHEOLOGICAL MODELING OF DIETARY FIBER AND POLICOSANOL PLANTBASED BIGELS FOR POTENTIAL FOOD APPLICATIONS",2024,"FOOD HYDROCOLLOIDS","150","",1,"10.1016/j.foodhyd.2024.109733","DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, CS, RENDE, I87036, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, CS, RENDE, I87036, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, CS, RENDE, I87036, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, CS, RENDE, I87036, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, CS, RENDE, I87036, ITALY","BIGELS ARE COMPOSITE MATERIALS MADE BY TWO PHASES WITH DIFFERENT POLARITIES (I.E., AN OLEOGEL AND A HYDROGEL) MIXED BETWEEN THEM WITHOUT THE ADDITION OF EMULSIFIERS. OWING TO THEIR VERSATILE RHEOLOGICAL PROPERTIES, THEY CAN BE USED FOR DESIGNING NEW PRODUCTS FOR FOOD INDUSTRY, OR FOR COSMETICS AND PHARMACEUTICAL APPLICATIONS. IN THE PAST, DIFFERENT MODELS HAVE BEEN PROPOSED TO RELATE THEIR RHEOLOGICAL PROPERTIES TO SINGLE PHASES CHARACTERISTICS AND VOLUME FRACTION. THIS PAPER PROPOSES THE RHEOLOGICAL CHARACTERIZATION AND MODELING OF BIGELS PREPARED WITH CITRUS FIBER PARTICLE GELS (AS THE AQUEOUS PHASE) AND POLICOSANOL-BASED OLEOGELS BY INVESTIGATING THE EFFECTS OF THE RATIO BETWEEN RHEOLOGICAL PROPERTIES OF PHASES AND OF THE DISPERSED PHASE VOLUME FRACTION. BOTH COMPONENTS (I.E., CITRUS FIBER AND POLICOSANOL) EXHIBIT INTERESTING PROPERTIES FOR PREPARING PLANT-BASED HEALTHY FOODSTUFFS. RHEOLOGICAL CHARACTERIZATION WAS CARRIED OUT REVEALING THAT O/W BIGELS WERE FORMED AT LOW FRACTIONS OF OLEOGEL ADDED TO GELLED SUSPENSION WHEREAS, AT HIGHER FRACTIONS, A TRANSITION THROUGH A MATRIX-IN-MATRIX SYSTEMS AND, FINALLY, A PHASE INVERSION OCCURRED. THE TREND OF PHASE ANGLE AT 1 HZ WITH OLEOGEL VOLUME FRACTION WAS USED AS A CRITERION TO HIGHLIGHT THE PHASE TRANSITION, AS CONFIRMED BY CONFOCAL MICROSCOPY. TWO MODELS WERE PROPOSED FOR PREDICTING THE RHEOLOGICAL BEHAVIOR OF SAMPLES WITH BOTH PHASE ARRANGEMENTS. © 2024 THE AUTHORS","BIPHASIC GELS; COMPOSITE GELS; CONFOCAL MICROSCOPY; OLEOGEL; PARTICLE GELS","CONFOCAL MICROSCOPY; PRODUCT DESIGN; RHEOLOGY; VOLUME FRACTION; BIPHASIC GEL; CITRUS FIBRE; COMPOSITE GELS; DEVELOPMENT MODEL; OLEOGEL; PARTICLE GELS; POLICOSANOLS; RHEOLOGICAL CHARACTERIZATION; RHEOLOGICAL MODELS; RHEOLOGICAL PROPERTY; GELS","ITALIAN PROJECT PON","THANKS ARE DUE TO ITALIAN PROJECT PON “ RICERCA E INNOVAZIONE ” 2014–2020, AZIONE IV.5 “ DOTTORATI SU TEMATICHE GREEN ” FOR FUNDING THE PHD POSITION OF ONE OF THE AUTHORS. ","BARBER T.M., KABISCH S., PFEIFFER A.F.H., WEICKERT M.O., THE HEALTH BENEFITS OF DIETARY FIBRE, NUTRIENTS, 12, 10, (2020); BOLLOM M.A., CLARK S., ACEVEDO N.C., DEVELOPMENT AND CHARACTERIZATION OF A NOVEL SOY LECITHIN-STEARIC ACID AND WHEY PROTEIN CONCENTRATE BIGEL SYSTEM FOR POTENTIAL EDIBLE APPLICATIONS, FOOD HYDROCOLLOIDS, 101, (2020); BRUNO E., LUPI F.R., MAMMOLENTI D., MILETI O., BALDINO N., GABRIELE D., EMULGELS STRUCTURED WITH DIETARY FIBER FOR FOOD USES: A RHEOLOGICAL MODEL, FOODS, 11, 23, (2022); BRUNO E., LUPI F.R., MARTIN-PINERO M.J., GIRIMONTE R., BALDINO N., MUNOZ J., GABRIELE D., INFLUENCE OF DIFFERENT DISPERSING SYSTEMS ON RHEOLOGICAL AND MICROSTRUCTURAL PROPERTIES OF CITRUS FIBER SUSPENSIONS, LWT, 152, (2021); CHEN Z., BIAN F., CAO X., SHI Z., MENG Z., NOVEL BIGELS CONSTRUCTED FROM OLEOGELS AND HYDROGELS WITH CONTRARY THERMAL CHARACTERISTICS: PHASE INVERSION AND 3D PRINTING APPLICATIONS, FOOD HYDROCOLLOIDS, 134, (2023); FASOLIN L.H., MARTINS A.J., CERQUEIRA M.A., VICENTE A.A., MODULATING PROCESS PARAMETERS TO CHANGE PHYSICAL PROPERTIES OF BIGELS FOR FOOD APPLICATIONS, FOOD STRUCTURE, 28, (2021); FRӦHICH H., SACK R., THEORY OF THE RHEOLOGICAL PROPERTIES OF DISPERSIONS, PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON. SERIES A, MATHEMATICAL AND PHYSICAL SCIENCES, 185, PP. 415-430, (1946); GENOVESE D.B., SHEAR RHEOLOGY OF HARD-SPHERE, DISPERSED, AND AGGREGATED SUSPENSIONS, AND FILLER-MATRIX COMPOSITES, ADVANCES IN COLLOID AND INTERFACE SCIENCE, 171-172, PP. 1-16, (2012); GEREMIAS-ANDRADE I.M., SOUKI N.P.B.G., MORAES I.C.F., PINHO S.C., RHEOLOGY OF EMULSION-FILLED GELS APPLIED TO THE DEVELOPMENT OF FOOD MATERIALS, GELS, 2, 3, (2016); GHIASI F., GOLMAKANI M.-T., FABRICATION AND CHARACTERIZATION OF A NOVEL BIPHASIC SYSTEM BASED ON STARCH AND ETHYLCELLULOSE AS AN ALTERNATIVE FAT REPLACER IN A MODEL FOOD SYSTEM, INNOVATIVE FOOD SCIENCE & EMERGING TECHNOLOGIES, 78, (2022); GRAVELLE A.J., NICHOLSON R.A., BARBUT S., MARANGONI A.G., CONSIDERATIONS FOR READDRESSING THEORETICAL DESCRIPTIONS OF PARTICLE-REINFORCED COMPOSITE FOOD GELS, FOOD RESEARCH INTERNATIONAL, 122, PP. 209-221, (2019); GUO Z., CHEN Z., MENG Z., BIGELS CONSTRUCTED FROM HYBRID GELATOR SYSTEMS: BULK PHASE-INTERFACE STABILITY AND 3D PRINTING, FOOD & FUNCTION, 14, 11, PP. 5078-5089, (2023); KERNER E.H., THE ELASTIC AND THERMO-ELASTIC PROPERTIES OF COMPOSITE MEDIA, PROCEEDINGS OF THE PHYSICAL SOCIETY SECTION B, 69, 8, (1956); LAPASIN R., GRASSI M., PRICL S., RHEOLOGICAL MODELING OF FRACTAL AND DENSE SUSPENSIONS, THE CHEMICAL ENGINEERING JOURNAL AND THE BIOCHEMICAL ENGINEERING JOURNAL, 64, 1, PP. 99-106, (1996); LEWIS T.B., NIELSEN L.E., DYNAMIC MECHANICAL PROPERTIES OF PARTICULATE-FILLED COMPOSITES, JOURNAL OF APPLIED POLYMER SCIENCE, 14, 6, PP. 1449-1471, (1970); LUPI F.R., DE SANTO M.P., CIUCHI F., BALDINO N., GABRIELE D., A RHEOLOGICAL MODELLING AND MICROSCOPIC ANALYSIS OF BIGELS, RHEOLOGICA ACTA, 56, 9, PP. 753-763, (2017); LUPI F.R., GABRIELE D., BALDINO N., MIJOVIC P., PARISI O.I., PUOCI F., OLIVE OIL/POLICOSANOL ORGANOGELS FOR NUTRACEUTICAL AND DRUG DELIVERY PURPOSES, FOOD & FUNCTION, 4, 10, PP. 1512-1520, (2013); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RESEARCH INTERNATIONAL, 51, 2, PP. 510-517, (2013); LUPI F.R., GENTILE L., GABRIELE D., MAZZULLA S., BALDINO N., DE CINDIO B., OLIVE OIL AND HYPERTHERMAL WATER BIGELS FOR COSMETIC USES, JOURNAL OF COLLOID AND INTERFACE SCIENCE, 459, PP. 70-78, (2015); LUPI F.R., GRECO V., BALDINO N., DE CINDIO B., FISCHER P., GABRIELE D., THE EFFECTS OF INTERMOLECULAR INTERACTIONS ON THE PHYSICAL PROPERTIES OF ORGANOGELS IN EDIBLE OILS, JOURNAL OF COLLOID AND INTERFACE SCIENCE, 483, PP. 154-164, (2016); LUPI F.R., SHAKEEL A., BALDINO N., GABRIELE D., CHAPTER 23 - RHEOLOGY OF FOOD BIGEL SYSTEM, 706, (2023); LUPI F.R., SHAKEEL A., FAROOQ U., BALDINO N., GABRIELE D., CHAPTER 6 EDIBLE OLEOGELS PRODUCED WITH FATTY ALCOHOLS: THE USE OF POLICOSANOL AS AN OLEOGELATOR, DEVELOPMENT OF TRANS-FREE LIPID SYSTEMS AND THEIR USE IN FOOD PRODUCTS, PP. 139-156, (2022); LUPI F.R., SHAKEEL A., GRECO V., OLIVIERO ROSSI C., BALDINO N., GABRIELE D., A RHEOLOGICAL AND MICROSTRUCTURAL CHARACTERISATION OF BIGELS FOR COSMETIC AND PHARMACEUTICAL USES, MATERIALS SCIENCE AND ENGINEERING: C, 69, PP. 358-365, (2016); LYU Z., SALA G., SCHOLTEN E., WATER DISTRIBUTION IN MAIZE STARCH-PEA PROTEIN GELS AS DETERMINED BY A NOVEL CONFOCAL LASER SCANNING MICROSCOPY IMAGE ANALYSIS METHOD AND ITS EFFECT ON STRUCTURAL AND MECHANICAL PROPERTIES OF COMPOSITE GELS, FOOD HYDROCOLLOIDS, 133, (2022); MARANGONI A.G., BARBUT S., MCGAULEY S.E., MARCONE M., NARINE S.S., ON THE STRUCTURE OF PARTICULATE GELS—THE CASE OF SALT-INDUCED COLD GELATION OF HEAT-DENATURED WHEY PROTEIN ISOLATE, FOOD HYDROCOLLOIDS, 14, 1, PP. 61-74, (2000); MARTINEZ L., URIBARRI E., LAGUNA A., CHARACTERIZATION AND COMPATIBILITY STUDIES BETWEEN POLICOSANOL, A NEW HYPOCHOLESTEROLEMIC DRUG, AND TABLET EXCIPIENTS USING DIFFERENTIAL SCANNING CALORIMETRY (DSC), ARCHIV DER PHARMAZIE, 332, 12, PP. 439-441, (1999); MOONEY M., THE VISCOSITY OF A CONCENTRATED SUSPENSION OF SPHERICAL PARTICLES, JOURNAL OF COLLOID SCIENCE, 6, 2, PP. 162-170, (1951); NARINE S.S., MARANGONI A.G., RELATING STRUCTURE OF FAT CRYSTAL NETWORKS TO MECHANICAL PROPERTIES: A REVIEW, FOOD RESEARCH INTERNATIONAL, 32, 4, PP. 227-248, (1999); NAVARRO-VERDUGO A.L., GOYCOOLEA F.M., ROMERO-MELENDEZ G., HIGUERA-CIAPARA I., ARGUELLES-MONAL W., A MODIFIED BOLTZMANN SIGMOIDAL MODEL FOR THE PHASE TRANSITION OF SMART GELS, SOFT MATTER, 7, 12, PP. 5847-5853, (2011); NUTTER J., SHI X., LAMSAL B., ACEVEDO N.C., DESIGNING AND CHARACTERIZING MULTICOMPONENT, PLANT-BASED BIGELS OF RICE BRAN WAX, GUMS, AND MONOGLYCERIDES, FOOD HYDROCOLLOIDS, 138, (2023); NUTTER J., SHI X., LAMSAL B., ACEVEDO N.C., PLANT-BASED BIGELS AS A NOVEL ALTERNATIVE TO COMMERCIAL SOLID FATS IN SHORT DOUGH PRODUCTS: TEXTURAL AND STRUCTURAL PROPERTIES OF SHORT DOUGH AND SHORTBREAD, FOOD BIOSCIENCE, 54, (2023); OLATUNJI L.K., JIMOH A.O., TUKUR U.M., IMAM M.U., A REVIEW OF THE EFFECTS OF POLICOSANOL ON METABOLIC SYNDROME, CLINICAL COMPLEMENTARY MEDICINE AND PHARMACOLOGY, 2, 3, (2022); PAL R., NOVEL SHEAR MODULUS EQUATIONS FOR CONCENTRATED EMULSIONS OF TWO IMMISCIBLE ELASTIC LIQUIDS WITH INTERFACIAL TENSION, JOURNAL OF NON-NEWTONIAN FLUID MECHANICS, 105, 1, PP. 21-33, (2002); PAL R., NEW MODELS FOR EFFECTIVE YOUNG'S MODULUS OF PARTICULATE COMPOSITES, COMPOSITES PART B: ENGINEERING, 36, 6-7, PP. 513-523, (2005); PAL R., A NEW LINEAR VISCOELASTIC MODEL FOR EMULSIONS AND SUSPENSIONS, POLYMER ENGINEERING & SCIENCE, 48, 7, PP. 1250-1253, (2008); PATEL A.R., MANKOC B., BIN SINTANG M.D., LESAFFER A., DEWETTINCK K., FUMED SILICA-BASED ORGANOGELS AND ‘AQUEOUS-ORGANIC’ BIGELS, RSC ADVANCES, 5, 13, PP. 9703-9708, (2015); QIU R., WANG K., TIAN H., LIU X., LIU G., HU Z., ZHAO L., ANALYSIS ON THE PRINTABILITY AND RHEOLOGICAL CHARACTERISTICS OF BIGEL INKS: POTENTIAL IN 3D FOOD PRINTING, FOOD HYDROCOLLOIDS, 129, (2022); QUILAQUEO M., ITURRA N., CONTARDO I., MILLAO S., MORALES E., RUBILAR M., FOOD-GRADE BIGELS WITH POTENTIAL TO REPLACE SATURATED AND TRANS FATS IN COOKIES, GELS, 8, 7, (2022); SAFFOLD A.C., ACEVEDO N.C., DEVELOPMENT OF NOVEL RICE BRAN WAX/GELATIN-BASED BIPHASIC EDIBLE GELS AND CHARACTERIZATION OF THEIR MICROSTRUCTURAL, THERMAL, AND MECHANICAL PROPERTIES, FOOD AND BIOPROCESS TECHNOLOGY, 14, 12, PP. 2219-2230, (2021); SHAKEEL A., FAROOQ U., IQBAL T., YASIN S., LUPI F.R., GABRIELE D., KEY CHARACTERISTICS AND MODELLING OF BIGELS SYSTEMS: A REVIEW, MATERIALS SCIENCE AND ENGINEERING: C, 97, PP. 932-953, (2019); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., MOTOMURA K., SHIMURA T., OKAJIMA Y., MIZUNOE Y., MA Y., SABER Z.M., IWASAKI H., YATOH S., SUZUKI H., AITA Y., HAN S., TAKEUCHI Y., YAHAGI N., SHIMANO H., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCIENTIFIC REPORTS, 9, 1, (2019); SMITH J.C., SIMPLIFICATION OF VAN DER POEL/S FORMULA FOR THE SHEAR MODULUS OF A PARTICULATE COMPOSITE, JOURNAL OF RESEARCH OF THE NATIO NAL BUREAU OF STANDARDS - A. PHYSICS AND CHEMISTRY, 79A, 2, PP. 419-423, (1975); SONI M., MAURYA A., DAS S., PRASAD J., YADAV A., SINGH V.K., SINGH B.K., DUBEY N.K., DWIVEDY A.K., NANOENCAPSULATION STRATEGIES FOR IMPROVING NUTRITIONAL FUNCTIONALITY, SAFETY AND DELIVERY OF PLANT-BASED FOODS: RECENT UPDATES AND FUTURE OPPORTUNITIES, PLANT NANO BIOLOGY, 1, (2022); VAN AKEN G.A., OLIVER L., SCHOLTEN E., RHEOLOGICAL EFFECT OF PARTICLE CLUSTERING IN GELLED DISPERSIONS, FOOD HYDROCOLLOIDS, 48, PP. 102-109, (2015); VAN DER POEL C., ON THE RHEOLOGY OF CONCENTRATED DISPERSIONS, RHEOLOGICA ACTA, 1, 2, PP. 198-205, (1958); XIE D., HU H., HUANG Q., LU X., DEVELOPMENT AND CHARACTERIZATION OF FOOD-GRADE BIGEL SYSTEM FOR 3D PRINTING APPLICATIONS: ROLE OF OLEOGEL/HYDROGEL RATIOS AND EMULSIFIERS, FOOD HYDROCOLLOIDS, 139, (2023); ZEIN N., YASSIN F., MAKLED S., ALOTAIBI S.S., ALBOGAMI S.M., MOSTAFA-HEDEAB G., BATIHA G.E.-S., ELEWA Y.H.A., ORAL SUPPLEMENTATION OF POLICOSANOL ALLEVIATES CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS IN RATS, BIOMEDICINE & PHARMACOTHERAPY, 150, (2022); ZHAI X., SUN Y., CEN S., WANG X., ZHANG J., YANG Z., LI Y., WANG X., ZHOU C., ARSLAN M., LI Z., SHI J., HUANG X., ZOU X., GONG Y., HOLMES M., POVEY M., ANTHOCYANINS-ENCAPSULATED 3D-PRINTABLE BIGELS: A COLORIMETRIC AND LEACHING-RESISTANT VOLATILE AMINES SENSOR FOR INTELLIGENT FOOD PACKAGING, FOOD HYDROCOLLOIDS, 133, (2022); ZHENG R., CHEN Y., WANG Y., ROGERS M.A., CAO Y., LAN Y., MICROSTRUCTURE AND PHYSICAL PROPERTIES OF NOVEL BIGEL-BASED FOAMED EMULSIONS, FOOD HYDROCOLLOIDS, 134, (2023); ZHENG H., MAO L., CUI M., LIU J., GAO Y., DEVELOPMENT OF FOOD-GRADE BIGELS BASED ON Κ-CARRAGEENAN HYDROGEL AND MONOGLYCERIDE OLEOGELS AS CARRIERS FOR Β-CAROTENE: ROLES OF OLEOGEL FRACTION, FOOD HYDROCOLLOIDS, 105, (2020)","F.R. LUPI; DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, RENDE, VIA P. BUCCI, CUBO 39C, CS, I87036, ITALY; EMAIL: FRANCESCA.LUPI@UNICAL.IT","ELSEVIER B.V.","ENGLISH","FOOD HYDROCOLLOIDS","ARTICLE","ISI","2-S2.0-85182728799","FOOD HYDROCOLLOIDS","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA","NOTREPORTED;UNIVERSITY OF CALABRIA;NOTREPORTED",NA,"BRUNO E, 2024, FOOD HYDROCOLLOIDS","BRUNO E, 2024, FOOD HYDROCOLLOIDS"
"MA J;LI K;ZHANG W;MA L;XU J;LIU L;CHEN X;ZHANG H","MA, JINJU (56149760100); LI, KUN (57188983355); ZHANG, WENWEN (55072382600); MA, LIYI (56332101700); XU, JUAN (57189688812); LIU, LANXIANG (55565702000); CHEN, XIAOMING (55739155400); ZHANG, HONG (55070241500)","ACUTE TOXICITY AND CHROMOSOMAL ABERRATION TOXICITY OF INSECT WAX AND ITS POLICOSANOL",2022,"FOOD SCIENCE AND HUMAN WELLNESS","11","9",6,"10.1016/j.fshw.2021.11.013","PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA;PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA","AN ACUTE TOXICITY TEST IN SPRAGUE DAWLEY (SD) RATS AND A CHROMOSOMAL ABERRATION TOXICITY TEST IN CHINESE HAMSTER LUNG (CHL) FIBROBLASTS WERE CONDUCTED TO PROMOTE THE APPLICATION OF INSECT WAX AND ITS POLICOSANOL. RESULTS OF ORAL ACUTE TOXICITY TEST SHOWED THAT THE LD50 VALUES OF INSECT WAX AND ITS POLICOSANOL WERE HIGHER THAN 5000 MG/KG. THE RATS SHOWED NO OBVIOUS TOXIC SYMPTOMS AND SURVIVED, SUGGESTING THAT THESE SUBSTANCES WERE NOT TOXIC. THE CHROMOSOMAL ABERRATION RATES OF THE CHL CELLS INCUBATED WITH INSECT WAX FOR 3–6 H UNDER METABOLIC ACTIVATION CONDITIONS AND FOR 3–6 H AND 24 H UNDER NON-METABOLIC ACTIVATION CONDITIONS WERE LOWER THAN 5%. NO SIGNIFICANT DIFFERENCE WAS FOUND COMPARED WITH THE NEGATIVE CONTROL GROUP. ALSO, NO SIGNIFICANT DIFFERENCE IN CHROMOSOMAL ABERRATION RATES WAS FOUND BETWEEN EACH DOSE GROUP OF POLICOSANOL UNDER METABOLIC OR NON-METABOLIC ACTIVATION CONDITIONS AND THE NEGATIVE CONTROL GROUP. THEREFORE, THE CHROMOSOMAL ABERRATION RATES OF CHL CELLS TREATED WITH INSECT WAX AND ITS POLICOSANOL WERE NEGATIVE REGARDLESS OF METABOLIC ACTIVATION CONDITIONS. THESE RESULTS INDICATE THE ABSENCE OF ACUTE TOXICITY AND POTENTIAL CHROMOSOMAL ABERRATION IN THE TESTED DOSE RANGE OF INSECT WAX AND ITS POLICOSANOL. © 2021","ACUTE TOXICITY; CHROMOSOMAL ABERRATION; INSECT WAX; POLICOSANOL FROM INSECT WAX","","FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NON-PROFIT RESEARCH INSTITUTION OF CAF, (CAFYBB2018SY025); NATIONAL HIGH-TECH RESEARCH AND DEVELOPMENT PROGRAM, (2014AA021801); NATIONAL HIGH-TECH RESEARCH AND DEVELOPMENT PROGRAM","WE GRATEFULLY ACKNOWLEDGE THE SUPPORT OF THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NON-PROFIT RESEARCH INSTITUTION OF CAF (CAFYBB2018SY025), AND THE NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (863 PROGRAM) (2014AA021801).","SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM., 53, 14, PP. 5583-5586, (2005); MA L., ZHANG Z., WANG Y., ET AL., CAPILLARY GC DETERMINATION OF POLICOSANOLS, FOOD SCI., 30, 18, PP. 288-291, (2009); VENTURELLI A., BRIGHENTI V., MASCOLO D., ET AL., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL., 172, PP. 200-205, (2019); RAVINDRANATH S.V., UPPUGUNDLA N., LAY J.O., ET AL., POLICOSANOL, Α-TOCOPHEROL, AND MOISTURE CONTENT AS A FUNCTION OF TIMING OF HARVEST OF SWITCHGRASS (PANICUM VIRGATUM L.), J. AGRIC. FOOD CHEM., 57, 9, PP. 3500-3505, (2009); MOOSBRUGGER I., BISCHOFF P., BECK J.P., ET AL., STUDIES ON THE IMMUNOLOGICAL EFFECTS OF FATTY ALCOHOLS — I. EFFECTS OF N-HEXACOSANOL ON MURINE MACROPHAGES IN CULTURE, INT. J. IMMUNOPHARMACOL., 14, 2, PP. 293-302, (1992); KIM J.K., PARK S.Y., NA J.K., ET AL., METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA (PERILLA FRUTESCENS) CULTIVARS, J. AGRIC. FOOD CHEM., 60, 9, PP. 2257-2263, (2012); LEE E.Y., YOO J.A., LIM S.M., ET AL., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES., 19, 2, PP. 149-158, (2016); MA J., MA L., ZHANG H., ET AL., THE PREPARATION AND EVALUATION OF EFFICACY ON SKIN WOUND HEALING IN MICE OF INSECT WAX COMPOUND OINTMENT, J. ENVIRON. ENTOMOL., 40, 6, PP. 1238-1247, (2018); XIAO C., CHEMISTRY OF CHINESE MATERIA MEDICA, (1986); WANG Z., FENG Y., MA L., ET AL., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMED. PHARMACOTHER., 89, PP. 438-446, (2017); MA L., WANG Y., ZHANG Z., ET AL., PREPARATION OF POLICOSANOL FROM INSECT WAX, SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, 29, 2, PP. 179-181, (2008); MA L., WANG Y., ZHANG Z., ET AL., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, LINCHAN HUAXUE YU GONGYE, 29, 5, PP. 6-10, (2009); HOU X., CAO M., GONG J., ET AL., OVERVIEW OF PHARMACOLOGICAL RESEARCH OF INSECT WAX, J. ANHUI AGRI. SCI., 39, 5, PP. 2817-2818, (2011); ZHANG R.G., ZHENG H., ZHANG H., ET AL., THERMAL ANALYSIS OF FOUR INSECT WAXES BASED ON DIFFERENTIAL SCANNING CALORIMETRY (DSC), PROCEDIA ENGINEERING, 18, PP. 101-106, (2011); LIN L., ZHOU Y., LI H., ET AL., POLYSACCHARIDE EXTRACTED FROM CHINESE WHITE WAX SCALE AMELIORATES 2,4-DINITROCHLOROBENZENE-INDUCED ATOPIC DERMATITIS-LIKE SYMPTOMS IN BALB/C MICE, SAUDI PHARM. J., 25, 4, PP. 625-632, (2017); BLOMQUIST G.J., JACKSON L.L., CHEMISTRY AND BIOCHEMISTRY OF INSECT WAXES, PROG. LIPID RES., 17, 4, PP. 319-345, (1979); ZHANG X.N., SHEN H.G., LI X.W., ET AL., PREPARATION OF ALKANOLS MIXTURE CONTAINING OCTACOSANOL, CHINESE J. PHARM., 33, 3, (2002); LI S., COMPENDIUM OF MATERIA MEDICA, (1978); FENG Y., CHEN X., CHEN Y., ET AL., STUDIES ON THE NUTRITIVE VALUE AND FOOD SAFETY OF ERICERUS PELA EGGS, FOR. RES., 14, 3, PP. 322-327, (2001); ZENG C., HEALTH CARE FUNCTION OF THE ERICERUS PELA - A LONG-TERM TOXICITY STUDY OF PAI DU HUA ZHONG CAPSULE IN RAT, YUNNAN KEY LABORATORY OF PHARMACOLOGY FOR NATURAL DRUGS, (2006); MA J., MA L., LI K., ET AL., PREPARATION OF MICROEMULSION WITH POLICOSANOL DERIVED FROM INSECT WAX AND ITS APPLICATION IN FUNCTIONAL BEVERAGE, FOOD SCI., 40, 12, PP. 78-84, (2019); KIM J.Y., LEE J.H., JEONG D.Y., ET AL., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYDR. POLYM., 121, PP. 140-146, (2015); WANG H.Y., JIAO Q.P., CHEN S.Y., ET AL., EFFICACY AND SAFETY OF POLICOSANOL PLUS FENOFIBRATE COMBINATION THERAPY IN DLDERLY PATIENTS WITH MIXED DYSLIPIDEMIA: A RANDOMIZED, CONTROLLED CLINICAL STUDY, AM. J. MED. SCI., 356, 3, PP. 254-261, (2018); ALEMAN C.L., CARIDAD HERNANDEZ R.M., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1994); GUO Z., XU L., NATURAL POLICOSANOL BLENDS: NEW CHOLESTEROL-LOWERING DRUGS FROM CANE WAX, XIANDAI YAOWU YU LINCHUANG, 16, 6, PP. 231-236, (2001); NHFPC, COMMISSION, ANNOUNCEMENT ON 10 NEW FOOD RAW MATERIALS INCLUDING SHEA BUTTER, (2017); LONG L., PENG K., GAO M., ET AL., TOXICOLOGICAL STUDY ON SAFETY OF OCTACOSANOL AS FEED ADDITIVE, FEED RESEARCH, 21, PP. 28-31, (2014); GAO M., ZHANG L., WANG R., ET AL., TOXICOLOGICAL EVALUATION OF THE SAFETY OF HIGH CARBON FATTY ALCOHOLS, PROCEEDINGS OF THE FOURTH SCIENCE AND TECHNOLOGY FORUM FOR YOUNG AND MIDDLE-AGED SCHOLARS HELD BY THE CHINESE SOCIETY OF TOXICOLOGY, (2014); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, 6, PP. 565-575, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM. TOXICOL., (1995); OECD TEST GUIDELINE 420, ACUTE ORAL TOXICITY - FIXED DOSE PROCEDURE, (2001); NATIONAL HEALTH AND FAMILY PLANNING COMMISSION, GB 15193.3-2014 ACUTE ORAL TOXICITY TEST, NATIONAL STANDARDS FOR FOOD SAFETY, (2014); OECD, GUIDANCE DOCUMENT ON THE RECOGNITION, ASSESSMENT AND USE OF CLINICAL SIGNS AS HUMANE ENDPOINTS FOR EXPERIMENTAL ANIMALS USED IN SAFETY EVALUATION, ENVIRONMENTAL HEALTH AND SAFETY MONOGRAPH SERIES ON TESTING AND ASSESMENT NO 19, (2000); OECD TEST GUIDELINE 473, IN VITRO MAMMALIAN CHROMOSOMAL ABERRATION TEST, OECD GUIDELINE FOR THE TESTING OF CHEMICALS, (2016); NATIONAL HEALTH AND FAMILY PLANNING COMMISSION, GB 15193.23-2014 CHROMOSOME ABERRATION TEST OF MAMMALIAN CELLS IN VITRO, (2014); NATIONAL HEALTH AND FAMILY PLANNING COMMISSION, GB 15193.3-2014 ACUTE ORAL TOXICITY TEST, (2014); (2011); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J. MED. FOOD, 4, 2, PP. 57-65, (2001); KEUTZ E.V., SCHLUTER G., PRECLINICAL SAFETY EVALUATION OF CERIVASTATIN, A NOVEL HMG-COA REDUCTASE INHIBITOR, AM. J. CARDIOL., 82, 4-SUPP-S2, PP. 11-17, (1998); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CEREBROVASC. DIS., 21, 6, PP. 424-429, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, 2, PP. 356-365, (2002); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, 9, PP. 691-699, (1996); OECD TEST GUIDELINE 473, IN VITRO MAMMALIAN CHROMOSOMAL ABERRATION TEST, (1997); ABBONDANDOLO A., CHROMOSOME-ABERRATION TESTS, FOOD ADDIT. CONTAM., 1, 2, (1984)","X. CHEN; PECULIAR BIOLOGICAL RESOURCES TECHNOLOGY ENGINEERING CENTER, RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING 650224, CHINA; EMAIL: AFCXM@139.COM","ELSEVIER B.V.","ENGLISH","FOOD SCI. HUM. WELLNESS","ARTICLE","ISI","2-S2.0-85119925644","FOOD SCI HUM WELLNESS","RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS","NOTREPORTED;RESEARCH INSTITUTE OF RESOURCES INSECTS;NOTREPORTED",NA,"MA J, 2022, FOOD SCI HUM WELLNESS","MA J, 2022, FOOD SCI HUM WELLNESS"
"YEON J;LEE J;KIM Y","YEON, JEYEONG (56645998400); LEE, JUNSOO (36910863400); KIM, YOUNGHWA (57193568330)","COMPARISON OF PHYTOCHEMICAL CONTENTS AND CYTOPROTECTIVE EFFECTS OF DIFFERENT RICE BRAN EXTRACTS FROM INDICA AND JAPONICA RICE CULTIVARS",2020,"PREVENTIVE NUTRITION AND FOOD SCIENCE","25","7",2,"10.3746/PNF.2020.25.4.432","DIVISION OF FOOD AND ANIMAL SCIENCES, CHUNGBUK NATIONAL UNIVERSITY, CHUNGBUK, 28644, SOUTH KOREA;DIVISION OF FOOD AND ANIMAL SCIENCES, CHUNGBUK NATIONAL UNIVERSITY, CHUNGBUK, 28644, SOUTH KOREA;SCHOOL OF FOOD BIOTECHNOLOGY AND NUTRITION, KYUNGSUNG UNIVERSITY, BUSAN, 48434, SOUTH KOREA","THE PRESENT STUDY WAS AIMED TO EVALUATE THE PHYTOCHEMICAL CONTENTS AND HEPATOCYTE PROTECTIVE EFFECTS OF FUNCTIONAL EXTRACTS FROM RICE BRAN OF INDICA AND JAPONICA RICE CULTIVARS, DASAN 1 AND ILPUM, RESPECTIVELY. THE HIGHEST VITAMIN E (23.51 MG/G) AND PHYTOSTEROL (390.25 MG/G) CONTENT WAS OBSERVED IN THE UNSAPONIFIABLE MATTER (USM) OF DASAN 1 CULTIVAR. HOWEVER, USM OF ILPUM SHOWED THE HIGHEST CONTENT OF TOTAL POLICOSANOL AND SQUALENE (232.73 MG/G AND 99.31 MG/G, RESPECTIVELY). THE METHANOLIC EXTRACT FROM THE DEFATTED RICE BRAN (MEDR) OF DASAN 1 SHOWED THE HIGHEST TOTAL POLYPHENOL CONTENT, REDUCING POWER, AND RADICAL SCAVENGING CAPACITY, WHILE USM OF DASAN 1 SHOWED THE HIGHEST CELL VIABILITY (81.3%) AGAINST OXIDATIVE STRESS IN HEPG2 CELLS. USM SIGNIFICANTLY INCREASED GLUTATHIONE LEVELS AND SUPPRESSED THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN HEPATOCYTES COMPARED WITH METHANOLIC EXTRACTS OF THE RICE BRAN OILS AND/OR MEDR. THESE RESULTS PROVIDE USEFUL INFORMATION ON THE FUNCTIONAL EXTRACTS OF RICE BRAN FROM INDICA AND JAPONICA RICE CULTIVARS, INCLUDING THEIR ANTIOXIDANT PROPERTIES AND CYTOPROTECTION IN HEPG2 CELLS. © 2020 KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION. ALL RIGHTS RESERVED.","CYTOPROTECTIVE EFFECT; PHYTOCHEMICALS; RICE BRAN; RICE CULTIVAR; UNSAPONIFIABLE MATTER","","","","AFINISHA DEEPAM LS, ARUMUGHAN C., EFFECT OF SAPONIFICATION ON COMPOSITION OF UNSAPONIFIABLE MATTER IN RICE BRAN OIL, J OLEO SCI, 61, PP. 241-247, (2012); ASHRAF S, SAEED SMG, SAIFY ZS, HAIDER S, SAYED SA, ALI R, ET AL., POTENTIAL NUTRACEUTICAL BENEFITS OF BASMATI RICE BRAN OIL AS ANALGESIC, ANTI-INFLAMMATORY AND ANTI-ARTHRITIS, PAK J PHARM SCI, 32, PP. 2545-2551, (2019); BAKER MA, CERNIGLIA GJ, ZAMAN A., MICROTITER PLATE ASSAY FOR THE MEASUREMENT OF GLUTATHIONE AND GLUTATHIONE DISULFIDE IN LARGE NUMBERS OF BIOLOGICAL SAMPLES, ANAL BIOCHEM, 190, PP. 360-365, (1990); BASU P, MAIER C., IN VITRO ANTIOXIDANT ACTIVITIES AND POLYPHENOL CONTENTS OF SEVEN COMMERCIALLY AVAILABLE FRUITS, PHARMACOGNOSY RES, 8, PP. 258-264, (2016); BENZIE IFF, STRAIN JJ., THE FERRIC REDUCING ABILITY OF PLASMA (FRAP) AS A MEASURE OF ""ANTIOXIDANT POWER"": THE FRAP ASSAY, ANAL BIOCHEM, 239, PP. 70-76, (1996); CHO ES, LEE KW, LEE HJ., COCOA PROCYANIDINS PROTECT PC12 CELLS FROM HYDROGEN-PEROXIDE-INDUCED APOPTOSIS BY INHIBITING ACTIVATION OF P38 MAPK AND JNK, MUTAT RES, 640, PP. 123-130, (2008); CHOI Y, LEE J., ANTIOXIDANT AND ANTIPROLIFERATIVE PROPERTIES OF A TOCOTRIENOL-RICH FRACTION FROM GRAPE SEEDS, FOOD CHEM, 114, PP. 1386-1390, (2009); CHOI Y, LEE SM, KIM Y, YOON J, JEONG HS, LEE J., A TOCOTRIENOL-RICH FRACTION FROM GRAPE SEEDS INHIBITS OXIDATIVE STRESS INDUCED BY TERT-BUTYL HYDROPEROXIDE IN HEPG2 CELLS, J MED FOOD, 13, PP. 1240-1246, (2010); DEWANTO V, WU X, LIU RH., PROCESSED SWEET CORN HAS HIGHER ANTIOXIDANT ACTIVITY, J AGRIC FOOD CHEM, 50, PP. 4959-4964, (2002); HALLIWELL B, GUTTERIDGE JM, CROSS CE., FREE RADICALS, ANTIOXIDANTS, AND HUMAN DISEASE: WHERE ARE WE NOW?, J LAB CLIN MED, 119, PP. 598-620, (1992); HALLIWELL B, GUTTERIDGE JM., OXYGEN TOXICITY, OXYGEN RADICALS, TRANSITION METALS AND DISEASE, BIOCHEM J, 219, PP. 1-14, (1984); HAM H, OH SK, LEE JS, CHOI IS, JEONG HS, KIM IH, ET AL., ANTIOXIDANT ACTIVITIES AND CONTENTS OF PHYTOCHEMICALS IN METHANOLIC EXTRACTS OF SPECIALTY RICE CULTIVARS IN KOREA, FOOD SCI BIOTECHNOL, 22, PP. 631-637, (2013); HAM H, YOON SW, KIM IH, KWAK J, LEE JS, JEONG HS, ET AL., PROTECTIVE EFFECTS OF UNSAPONIFIABLE MATTER FROM RICE BRAN ON OXIDATIVE DAMAGE BY MODULATING ANTIOXIDANT ENZYME ACTIVITIES IN HEPG2 CELLS, LWT-FOOD SCI TECHNOL, 61, PP. 602-608, (2015); HAMINIUK CWI, PLATA-OVIEDO MSV, DE MATTOS G, CARPES ST, BRANCO IG., EXTRACTION AND QUANTIFICATION OF PHENOLIC ACIDS AND FLAVONOLS FROM EUGENIA PYRIFORMIS USING DIFFERENT SOLVENTS, J FOOD SCI TECHNOL, 51, PP. 2862-2866, (2014); HEINEMANN RJB, XU Z, GODBER JS, LANFER-MARQUEZ UM., TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL CONTENTS IN JAPONICA AND INDICA SUBSPECIES OF RICE (ORYZA SATIVA L.) CULTIVATED IN BRAZIL, CEREAL CHEM, 85, PP. 243-247, (2008); JOSEPH JA, SHUKITT-HALE B, DENISOVA NA, BIELINSKI D, MARTIN A, MCEWEN JJ, ET AL., REVERSALS OF AGE-RELATED DECLINES IN NEURONAL SIGNAL TRANSDUCTION, COGNITIVE, AND MOTOR BEHAVIORAL DEFICITS WITH BLUEBERRY, SPINACH, OR STRAWBERRY DIETARY SUPPLEMENTATION, J NEUROSCI, 19, PP. 8114-8121, (1999); KANG H, BAK MJ, JIN KS, KIM YH, JUN M, LIM HJ, ET AL., REGULATORY ROLES OF CHRYSANTHEMUM ZAWADSKII ROOTS IN NUCLEAR FACTOR E2-RELATED FACTOR 2/ANTIOXIDANT RESPONSE ELEMENT PATHWAY, FOOD SCI BIOTECHNOL, 17, PP. 367-372, (2008); KILICGUN H, ALTINER D., CORRELATION BETWEEN ANTIOXIDANT EFFECT MECHANISMS AND POLYPHENOL CONTENT OF ROSA CANINA, PHARMACOGN MAG, 6, PP. 238-241, (2010); KWON DH, CHA HJ, LEE H, HONG SH, PARK C, PARK SH, ET AL., PROTECTIVE EFFECT OF GLUTATHIONE AGAINST OXIDATIVE STRESS-INDUCED CYTOTOXICITY IN RAW 264.7 MACROPHAGES THROUGH ACTIVATING THE NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR-2/HEME OXYGENASE-1 PATHWAY, ANTIOXIDANTS, 8, (2019); LEE H, SUNG J, KIM Y, JEONG HS, LEE J., PROTECTIVE EFFECTS OF UNSAPONIFIABLE MATTER FROM PERILLA SEED MEAL ON UVB-INDUCED DAMAGES AND THE UNDERLYING MECHANISMS IN HUMAN SKIN FIBROBLASTS, ANTIOXIDANTS, 8, (2019); LEE SM, CHOI Y, SUNG J, KIM Y, JEONG HS, LEE J., PROTECTIVE EFFECTS OF BLACK RICE EXTRACTS ON OXIDATIVE STRESS INDUCED BY TERT-BUTYL HYDROPEROXIDE IN HEPG2 CELLS, PREV NUTR FOOD SCI, 19, PP. 348-352, (2014); LERMA-GARCIA MJ, HERRERO-MARTINEZ JM, SIMO-ALFONSO EF, MENDONCA CRB, RAMIS-RAMOS G., COMPOSITION, INDUSTRIAL PROCESSING AND APPLICATIONS OF RICE BRAN Γ-ORYZANOL, FOOD CHEM, 115, PP. 389-404, (2009); MILLER A, ENGEL KH., CONTENT OF Γ-ORYZANOL AND COMPOSITION OF STERYL FERULATES IN BROWN RICE (ORYZA SATIVA L.) OF EUROPEAN ORIGIN, J AGRIC FOOD CHEM, 54, PP. 8127-8133, (2006); MOSKAUG JO, CARLSEN H, MYHRSTAD MC, BLOMHOFF R., POLYPHENOLS AND GLUTATHIONE SYNTHESIS REGULATION, AM J CLIN NUTR, 81, PP. 277S-283S, (2005); MURAMATSU H, KOGAWA K, TANAKA M, OKUMURA K, NISHIHORI Y, KOIKE K, ET AL., SUPEROXIDE DISMUTASE IN SAS HUMAN TONGUE CARCINOMA CELL LINE IS A FACTOR DEFINING INVASIVENESS AND CELL MOTILITY, CANCER RES, 55, PP. 6210-6214, (1995); MYHRSTAD MC, CARLSEN H, NORDSTROM O, BLOMHOFF R, MOSKAUG JO., FLAVONOIDS INCREASE THE INTRACELLULAR GLUTATHIONE LEVEL BY TRANSACTIVATION OF THE Γ-GLUTAMYLCYSTEINE SYNTHETASE CATALYTICAL SUBUNIT PROMOTER, FREE RADIC BIOL MED, 32, PP. 386-393, (2002); OKARTER N, LIU RH., HEALTH BENEFITS OF WHOLE GRAIN PHYTOCHEMICALS, CRIT REV FOOD SCI NUTR, 50, PP. 193-208, (2010); PELLEGRINI N, SIMONETTI P, GARDANA C, BRENNA O, BRIGHENTI F, PIETTA P., POLYPHENOL CONTENT AND TOTAL ANTIOXIDANT ACTIVITY OF VINI NOVELLI (YOUNG RED WINES), J AGRIC FOOD CHEM, 48, PP. 732-735, (2000); RE R, PELLEGRINI N, PROTEGGENTE A, PANNALA A, YANG M, RICE-EVANS C., ANTIOXIDANT ACTIVITY APPLYING AN IMPROVED ABTS RADICAL CATION DECOLORIZATION ASSAY, FREE RADIC BIOL MED, 26, PP. 1231-1237, (1999); SHARMA RD, RUKMINI C., HYPOCHOLESTEROLEMIC ACTIVITY OF UNSAPONIFIABLE MATTER OF RICE BRAN OIL, INDIAN J MED RES, 85, PP. 278-281, (1987); STEINBERG D, PARTHASARATHY S, CAREW TE, KHOO JC, WITZTUM JL., BEYOND CHOLESTEROL. MODIFICATIONS OF LOW-DENSITY LIPOPROTEIN THAT INCREASE ITS ATHEROGENICITY, N ENGL J MED, 320, PP. 915-924, (1989); TERMINI J., HYDROPEROXIDE-INDUCED DNA DAMAGE AND MUTATIONS, MUTAT RES, 450, PP. 107-124, (2000); TRUONG HT, VAN MD, HUYNH LD, NGUYEN LT, TUAN AD, THANH TLX, ET AL., A METHOD FOR FERULIC ACID PRODUCTION FROM RICE BRAN OIL SOAPSTOCK USING A HOMOGENOUS SYSTEM, APPL SCI, 7, (2017); WANG H, JOSEPH JA., QUANTIFYING CELLULAR OXIDATIVE STRESS BY DICHLOROFLUORESCEIN ASSAY USING MICROPLATE READER, FREE RADIC BIOL MED, 27, PP. 612-616, (1999); WILSON TA, NICOLOSI RJ, WOOLFREY B, KRITCHEVSKY D., RICE BRAN OIL AND ORYZANOL REDUCE PLASMA LIPID AND LIPOPROTEIN CHOLESTEROL CONCENTRATIONS AND AORTIC CHOLESTEROL ESTER ACCUMULATION TO A GREATER EXTENT THAN FERULIC ACID IN HYPERCHOLESTEROLEMIC HAMSTERS, J NUTR BIOCHEM, 18, PP. 105-112, (2007); XU DP, LI Y, MENG X, ZHOU T, ZHOU Y, ZHENG J, ET AL., NATURAL ANTIOXIDANTS IN FOODS AND MEDICINAL PLANTS: EXTRACTION, ASSESSMENT AND RESOURCES, INT J MOL SCI, 18, (2017); ZHANG Y, SONG M, RUI X, PU S, LI Y, LI C., SUPPLEMENTAL DIETARY PHYTOSTERIN PROTECTS AGAINST 4-NITROPHENOL-INDUCED OXIDATIVE STRESS AND APOPTOSIS IN RAT TESTES, TOXICOL REP, 2, PP. 664-676, (2015); ZHU Y, SANG S., PHYTOCHEMICALS IN WHOLE GRAIN WHEAT AND THEIR HEALTH-PROMOTING EFFECTS, MOL NUTR FOOD RES, 61, (2017)","Y. KIM; SCHOOL OF FOOD BIOTECHNOLOGY AND NUTRITION, KYUNGSUNG UNIVERSITY, BUSAN, 48434, SOUTH KOREA; EMAIL: YOUNGHWAKIM@KS.AC.KR","KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION","ENGLISH","PREVENT. NUTRITION FOOD SCI.","ARTICLE","ISI","2-S2.0-85100447167","PREVENT NUTRITION FOOD SCI","CHUNGBUK NATIONAL UNIVERSITY;CHUNGBUK NATIONAL UNIVERSITY;KYUNGSUNG UNIVERSITY","NOTREPORTED;KYUNGSUNG UNIVERSITY;NOTREPORTED",NA,"YEON J, 2020, PREVENT NUTRITION FOOD SCI","YEON J, 2020, PREVENT NUTRITION FOOD SCI"
"LI X;ZHANG X;MA C;SUN L;HE Z;GAN J;DING W;CHEN X;CHEN H;FENG Y","LI, XIAN (55252109700); ZHANG, XIN (56376070800); MA, CHENJING (57217217257); SUN, LONG (37060218600); HE, ZHAO (55223278500); GAN, JIN (55234305200); DING, WEIFENG (56683747800); CHEN, XIAOMING (55739155400); CHEN, HANG (36623262500); FENG, YING (34770356600)","MODULATORY EFFECTS OF POLICOSANOL FROM INSECT WAX ON LIPID METABOLISM IN HIGHFAT DIETFED RATS",2023,"JOURNAL OF FUNCTIONAL FOODS","110","",1,"10.1016/j.jff.2023.105824","KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, YUNNAN, KUNMING, 650224, CHINA","INSECT WAX IS A TRADITIONAL CHINESE MEDICINE, WHICH CAN BE CONVERTED INTO POLICOSANOL THROUGH A REDUCTION REACTION. THE EFFICACY OF POLICOSANOL FROM INSECT WAX (PIW) DEPENDS ON ITS PURITY AND COMPOSITION RATIO. PLANT-DERIVED POLICOSANOL HAS A HYPOLIPIDEMIC EFFECT, HOWEVER, THE EFFECTS OF PIW ON SERUM LIPID LEVELS HAVE NOT YET BEEN CLARIFIED. IN THIS STUDY, WE INVESTIGATED THE EFFECTS OF ORALLY ADMINISTERED PIW ON LIPID METABOLISM IN RATS FED A HIGH-FAT DIET. WE FOUND THAT PIW ADMINISTRATION REDUCED THE SERUM LIPID LEVELS OF RATS FED A HIGH-FAT DIET, AMELIORATED BODY WEIGHT GAIN, AND ALLEVIATED LIVER FAT ACCUMULATION. THIS EFFECT COULD BE ASSOCIATED WITH THE UPREGULATION OF FATTY ACID BREAKDOWN- AND LIPID METABOLISM–RELATED GENES, PPARΑ AND PPARΒ/Δ, DOWNREGULATION OF FATTY ACID ABSORPTION AND STORAGE-RELATED GENES, SREBP1C, IL6, AND TNFΑ, AND AN ANTIOXIDANT EFFECT. THESE FINDINGS SUGGEST THE POTENTIAL UTILITY OF PIW FOR DEVELOPING FUNCTIONAL FOODS WITH LIPID-LOWERING CAPABILITIES. © 2023","HIGH-FAT DIET; INSECT WAX; LIPID METABOLISM; LIPID MODULATION; POLICOSANOL","","CHINESE ACADEMY OF FORESTRY, CAF, (CAFYBB2018ZB007, CAFYBB2019SZ005); SOUTHWEST FORESTRY UNIVERSITY, SWFU","FUNDING TEXT 1: THIS RESEARCH WAS FUNDED BY THE FUNDAMENTAL RESEARCH FUNDS OF CHINESE ACADEMY OF FORESTRY [GRANT NUMBERS CAFYBB2019SZ005 , CAFYBB2018ZB007 ]. ; FUNDING TEXT 2: THIS RESEARCH WAS FUNDED BY THE FUNDAMENTAL RESEARCH FUNDS OF CHINESE ACADEMY OF FORESTRY [GRANT NUMBERS CAFYBB2019SZ005, CAFYBB2018ZB007]. THE AUTHORS WOULD LIKE TO THANK DR. CHAO WANG FROM SOUTHWEST FORESTRY UNIVERSITY FOR PHOTOGRAPHING AND PROVIDING THE IMAGE OF INSECT WAX FOR THE GRAPHICAL ABSTRACT OF THIS ARTICLE.","ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENTARY THERAPIES IN MEDICINE, 45, PP. 89-97, (2019); BARBAGALLO C.M., CEFALU A.B., NOTO D., AVERNA M.R., ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY, FRONTIERS IN CARDIOVASCULAR MEDICINE, 2, (2015); CHEN X., NATURAL POPULATION ECOLOGY OF ERICERUS PELA, (2011); CHEN X., FENG Y., AN INTRODUCTION TO RESOURCE ENTOMOLOGY, (2009); CHENG X., LI J., GUO D., SCAP/SREBPS ARE CENTRAL PLAYERS IN LIPID METABOLISM AND NOVEL METABOLIC TARGETS IN CANCER THERAPY, CURRENT TOPICS IN MEDICINAL CHEMISTRY, 18, 6, PP. 484-493, (2018); CHINESE GUIDELINES ON THE PREVENTION AND TREATMENT OF DYSLIPIDEMIA IN ADULTS, CHINESE CIRCULATION JOURNAL, 31, 10, PP. 937-950, (2016); CHINESE PHARMACOPOEIA COMMISSION, PHARMACOPOEIA OF THE PEOPLE'S REPUBLIC OF CHINA, 1, (2020); CICERO A.F.G., FOGACCI F., STOIAN A.P., VRABLIK M., RASADI K.A., BANACH M., RIZZO M., NUTRACEUTICALS IN THE MANAGEMENT OF DYSLIPIDEMIA: WHICH, WHEN, AND FOR WHOM? COULD NUTRACEUTICALS HELP LOW-RISK INDIVIDUALS WITH NON-OPTIMAL LIPID LEVELS?, CURRENT ATHEROSCLEROSIS REPORTS, 23, 10, (2021); CORRALES P., VIDAL-PUIG A., MEDINA-GOMEZ G., PPARS AND METABOLIC DISORDERS ASSOCIATED WITH CHALLENGED ADIPOSE TISSUE PLASTICITY, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19, 7, (2018); DUAN Q., MA L., ZHENG H., CHEN X., A REVIEW ON RESEARCH PROGRESS OF SOME POLICOSANOLS, COMMUNICATIONS IN CHEMICAL PROCESSING OF FOREST PRODUCTS, 39, 2, PP. 42-47, (2005); GIANFRANCESCO M.A., PAQUOT N., PIETTE J., LEGRAND-POELS S., LIPID BILAYER STRESS IN OBESITY-LINKED INFLAMMATORY AND METABOLIC DISORDERS, BIOCHEMICAL PHARMACOLOGY, 153, PP. 168-183, (2018); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); (2023); GROSS B., PAWLAK M., LEFEBVRE P., STAELS B., PPARS IN OBESITY-INDUCED T2DM, DYSLIPIDAEMIA AND NAFLD, NATURE REVIEWS ENDOCRINOLOGY, 13, 1, PP. 36-49, (2017); HE W., SI X., WANG H., GU Y., YU H., ZHANG J., REGULATION OF LIPID METABOLISM BY OCTACOSANOL IN RATS. MODERN, FOOD SCIENCE AND TECHNOLOGY, 32, 10, PP. 28-33, (2016); HU W., LI L., ZHANG L., ZHANG L., CHEN J., LIU D., WANG Y., EFFECTS OF PQQ ON SERUM LIPID AND GLUCOSE LEVELS, LIVER FUNCTION AND LIPID PEROXIDATION IN HYPERLIPIDEMIA RATS, CHINESE JOURNAL OF PREVENTIVE MEDICINE, 17, 1, PP. 23-27, (2016); HUNTER P.M., HEGELE R.A., FUNCTIONAL FOODS AND DIETARY SUPPLEMENTS FOR THE MANAGEMENT OF DYSLIPIDAEMIA, NATURE REVIEWS ENDOCRINOLOGY, 13, 5, PP. 278-288, (2017); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 14, PP. 5583-5586, (2005); ISSARA U., PARK S., LEE S., LEE J., PARK S., HEALTH FUNCTIONALITY OF DIETARY OLEOGEL IN RATS FED HIGH-FAT DIET: A POSSIBILITY FOR FAT REPLACEMENT IN FOODS, JOURNAL OF FUNCTIONAL FOODS, 70, (2020); LEI B., APPLICATIONS AND PREPARATIONS OF POLICOSANOL, CHINA WESTERN CEREALS & OILS TECHNOLOGY, 3, PP. 41-44, (2003); LI S., COMPENDIUM OF MATERIA MEDICA (THE MING DYNASTY, 1578 C.E.), (1926); LONG L., GAO M., PENG K., SUN J., WANG S., EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON PRODUCTION PERFORMANCE AND BLOOD PARAMETERS IN WEANLING PIGLETS, JOURNAL OF THE CHINESE CEREALS AND OILS ASSOCIATION, 30, 6, PP. 94-100, (2015); LUSCHER T.F., LANDMESSER U., ECKARDSTEIN A.V., FOGELMAN A.M., HIGH-DENSITY LIPOPROTEIN: VASCULAR PROTECTIVE EFFECTS, DYSFUNCTION, AND POTENTIAL AS THERAPEUTIC TARGET, CIRCULATION RESEARCH, 114, 1, PP. 171-182, (2014); MA C., FENG Y., LI X., SUN L., HE Z., GAN J., CHEN X., POTENTIAL THERAPEUTIC EFFECTS OF POLICOSANOL FROM INSECT WAX ON CAENORHABDITIS ELEGANS MODELS OF PARKINSON'S DISEASE, JOURNAL OF NEUROIMMUNE PHARMACOLOGY, PP. 1-8, (2023); MA J., LI K., ZHANG W., MA L., XU J., LIU L., ZHANG H., ACUTE TOXICITY AND CHROMOSOMAL ABERRATION TOXICITY OF INSECT WAX AND ITS POLICOSANOL, FOOD SCIENCE AND HUMAN WELLNESS, 11, 2, PP. 356-365, (2022); MA J., MA L., LI K., ZHANG W., ZHANG Y., YANG M., ZHANG H., PREPARATION OF MICROEMULSION OF POLICOSANOL FROM INSECT WAX AND ITS APPLICATION IN FUNCTIONAL BEVERAGE, FOOD SCIENCE, 40, 12, PP. 78-84, (2019); MA L., WANG Y., ZHANG Z., GAN J., ZHENG H., GUO Y., DUAN Q., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, 29, 5, PP. 6-10, (2009); MA L., WANG Y., ZHANG Z., ZHENG H., GAN J., LI Z., DUAN Q., PREPARATION OF POLICOSANOL FROM INSECT WAX, SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, 29, 2, PP. 179-181, (2008); (2017); PATHTHINIGE C.S., SIRISENA N.D., DISSANAYAKE V., GENETIC DETERMINANTS OF INHERITED SUSCEPTIBILITY TO HYPERCHOLESTEROLEMIA - A COMPREHENSIVE LITERATURE REVIEW, LIPIDS IN HEALTH AND DISEASE, 16, 1, (2017); QI X., LIU B., LV R., ZHANG S., EFFECT OF OCTACOSANOL ON SERUM LIPID, JOURNAL OF SHANXI COLLEGE OF TRADITIONAL CHINESE MEDICINE, 18, 4, (2017); SENGSUK C., TANGVARASITTICHAI O., CHANTANASKULWONG P., PIMANPROM A., WANTANEEYAWONG S., CHOOWET A., TANGVARASITTICHAI S., ASSOCIATION OF IRON OVERLOAD WITH OXIDATIVE STRESS, HEPATIC DAMAGE AND DYSLIPIDEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA/HBE PATIENTS, INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 29, 3, PP. 298-305, (2014); STANDARDIZATION ADMINISTRATION OF CHINA, GENERAL STANDARD FOR HEALTH (FUNCTIONAL) FOODS, GB, PP. 16740-111997, (1997); SUN L., FENG Y., HE Z., LI X., MA C., ZHANG X., CHEN X., A METHOD OF PREPARING POLICOSANOLS BY REDUCING WHITE WAX WITH RED ALUMINUM UNDER NORMAL PRESSURE, CHINA PATENT, NO. CN112500263A, (2021); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, 14, (2022); SUN L., WEN S., LI Q., LAI X., CHEN R., ZHANG Z., SUN S., L-THEANINE RELIEVES ACUTE ALCOHOLIC LIVER INJURY BY REGULATING THE TNF-Α/NF-ΚB SIGNALING PATHWAY IN C57BL/6J MICE, JOURNAL OF FUNCTIONAL FOODS, 86, (2021); TAILE J., BRINGART M., PLANESSE C., PATCHE J., RONDEAU P., VEEREN B., GONTHIER M.-P., ANTIOXIDANT POLYPHENOLS OF ANTIRHEA BORBONICA MEDICINAL PLANT AND CAFFEIC ACID REDUCE CEREBROVASCULAR, INFLAMMATORY AND METABOLIC DISORDERS AGGRAVATED BY HIGH-FAT DIET-INDUCED OBESITY IN A MOUSE MODEL OF STROKE, ANTIOXIDANTS, 11, 5, (2022); THE WRITING COMMITTEE OF THE REPORT ON CARDIOVASCULAR HEALTH AND DISEASES IN CHINA, REPORT ON CARDIOVASCULAR HEALTH AND DISEASES IN CHINA 2022: AN UPDATED SUMMARY, CHINESE CIRCULATION JOURNAL, 38, 6, PP. 583-612, (2023); WAGNER N., WAGNER K.-D., THE ROLE OF PPARS IN DISEASE, CELLS, 9, 11, (2020); WANG L., FAN W., ZHANG M., ZHANG Q., LI L., WANG J., WU C., ANTIOBESITY, REGULATION OF LIPID METABOLISM, AND ATTENUATION OF LIVER OXIDATIVE STRESS EFFECTS OF HYDROXY-Α-SANSHOOL ISOLATED FROM ZANTHOXYLUM BUNGEANUM ON HIGH-FAT DIET-INDUCED HYPERLIPIDEMIC RATS, OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, (2019); WANG S., JIANG S., ZHAO Y., LIN Y., ZHANG J., DAI L., EFFECT OF ACTIVE PEPTIDES OF EUPOLYPHAGA ON INTESTINAL FLORA IN RATS WITH HYPERLIPEMIA, CHINESE PHARMACOLOGICAL BULLETIN, 36, 5, PP. 621-626, (2020); WANG Z., FENG Y., SUN L., GAN J., LI X., DING W., CHEN X., ANTI-ANDROGENETIC ALOPECIA EFFECT OF POLICOSANOL FROM CHINESE WAX BY REGULATING ABNORMAL HORMONE LEVELS TO SUPPRESS PREMATURE HAIR FOLLICLE ENTRY INTO THE REGRESSION PHASE, BIOMEDICINE & PHARMACOTHERAPY, 136, (2021); XU D., CHEN Y., FANG Z., LU Y., MECHANISM OF DANZHI JIANGTANG CAPSULES ON IMPROVING LIVER INJURY IN HYPERLIPIDEMIA RATS BASED ON MAPK PATHWAY, CHINA JOURNAL OF CHINESE MATERIA MEDICA, 44, 14, PP. 2953-2959, (2019); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER'S DISEASE, BMC COMPLEMENTARY MEDICINE AND THERAPIES, 21, 1, (2021); ZHONG L., DING W., ZENG Q., HE B., ZHANG H., WANG L., WEI A., SODIUM TANSHINONE IIA SULFONATE ATTENUATES ERECTILE DYSFUNCTION IN RATS WITH HYPERLIPIDEMIA, OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2020, (2020)","Y. FENG; KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, 650224, CHINA; EMAIL: RIRIFY@139.COM","ELSEVIER LTD","ENGLISH","J. FUNCT. FOODS","ARTICLE","ISI","2-S2.0-85173250282","J FUNCT FOODS","INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE","NOTREPORTED;INSTITUTE OF HIGHLAND FOREST SCIENCE;NOTREPORTED",NA,"LI X, 2023, J FUNCT FOODS","LI X, 2023, J FUNCT FOODS"
"JO A;HAN J;AN J;CHO K;JEOUNG N","JO, AE LIM (57223012962); HAN, JI WON (57675832700); AN, JI IN (57675832800); CHO, KYUNG-HYUN (7403956966); JEOUNG, NAM HO (6506972187)","CUBAN POLICOSANOL PREVENTS THE APOPTOSIS AND THE MITOCHONDRIAL DYSFUNCTION INDUCED BY LIPOPOLYSACCHARIDE IN C2C12 MYOBLAST VIA ACTIVATION OF AKT AND ERK PATHWAYS",2022,"JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY","68","7",4,"10.3177/jnsv.68.79","DEPARTMENT OF PHARMACEUTICAL ENGINEERING, DEAGU CATHOLIC UNIVERSITY, GYEONGSAN, 38430, SOUTH KOREA;DEPARTMENT OF PHARMACEUTICAL ENGINEERING, DEAGU CATHOLIC UNIVERSITY, GYEONGSAN, 38430, SOUTH KOREA;DEPARTMENT OF PHARMACEUTICAL ENGINEERING, DEAGU CATHOLIC UNIVERSITY, GYEONGSAN, 38430, SOUTH KOREA;LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA;DEPARTMENT OF PHARMACEUTICAL ENGINEERING, DEAGU CATHOLIC UNIVERSITY, GYEONGSAN, 38430, SOUTH KOREA","SKELETAL MUSCLE PLAYS CRUCIAL ROLES IN LOCOMOTION, PROTEIN RESERVOIR, AND MAIN-TENANCE OF METABOLIC HOMEOSTASIS. LOSS OF MUSCLE, KNOWN AS MUSCLE ATROPHY, CAUSES THE METABOLIC DISEASES SUCH AS TYPE 2 DIABETES MELLITUS, HYPERTENSION, AND SO ON. THEREFORE, GREAT EFFORTS HAVE BEEN DEVOTED TO PREVENT THE MUSCLE ATROPHY. POLICOSANOLS ARE A MIXTURE OF LONG CHAIN FATTY ALCOHOLS EXTRACTED FROM VARIOUS NATURAL SOURCES. THEY HAVE LONG BEEN USED AS FUNCTIONAL FOODS TO LOWER THE LEVEL OF SERUM LIPIDS, INCLUDING TRIACYLGLYCEROL AND CHOLES-TEROL, AND TO PROTECT AGAINST INFLAMMATORY STRESS. IN THIS STUDY, WE EXAMINE THE PROTECTIVE EFFECT AND MOLECULAR MECHANISM OF CUBAN POLICOSANOL ON SKELETAL MUSCLE CELL DEATH AND MITOCHONDRIAL DYSFUNCTION USING LIPOPOLYSACCHARIDE-TREATED C2C12 CELLS. OUR RESULTS DEMONSTRATED THAT POLICOSANOL SIGNIFICANTLY RESCUED CELL SURVIVAL (40% VS. 88%; LPS VS. LPS1POLICOSANOL) VIA ACTIVATION OF THE AKT PATHWAY, RESULTING IN INHIBITION OF APOPTOSIS (P,0.05). MOREOVER, POLICOSANOL RESTORED THE LPS-INDUCED REPRESSION OF COLLAGEN BY TWO FOLD (0.3360.04 VS. 0.6760.03 COMPARED TO THAT OF CONTROL; LPS VS. LPS1POLICOSANOL) VIA ACTIVATION OF ERK-MTOR-P70S6K PATHWAYS. IN ADDITION, POLICOSANOL INCREASED THE MITO-CHONDRIAL FUSION BY REGULATING THE ACTIVITIES OF DRP1 AND MFN2, LEADING TO AMELIORATE THE MITOCHONDRIAL DYSFUNCTION INDUCED BY LPS. IMPROVED MITOCHONDRIA FUNCTION INCREASED THE OXYGEN CONSUMPTION RATE WITH GLUCOSE AS FUEL SOURCE, INDICATING THAT POLICOSANOL COULD SHIFT THE GLUCOSE METABOLISM FROM LACTATE FERMENTATION, INDUCED BY LIPOPOLYSACCHARIDE, TO OXIDA-TIVE PHOSPHORYLATION. THUS, POLICOSANOL IS A PROMISING AGENT FOR PREVENTING THE INFLAMMA-TION-INDUCED MUSCLE CELL DEATH AND MITOCHONDRIAL DYSFUNCTION. © 2022, CENTER FOR ACADEMIC PUBLICATIONS JAPAN. ALL RIGHTS RESERVED.","ERK-MTOR SIGNALING; INFLAMMATION; MITOCHONDRIAL DYNAMICS; MUSCLE CELL DEATH; POLICOSANOL","APOPTOSIS; DIABETES MELLITUS, TYPE 2; FATTY ALCOHOLS; HUMANS; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MUSCULAR ATROPHY; MYOBLASTS; PROTO-ONCOGENE PROTEINS C-AKT; ALCOHOL DERIVATIVE; COLLAGEN; GLUCOSE; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOFUSIN 2; OLIGOMYCIN; POLICOSANOL; ROTENONE; FATTY ALCOHOL; PROTEIN KINASE B; APOPTOSIS; APOPTOSIS RATE; ARTICLE; C2C12 CELL LINE; CELL CULTURE; CELL SURVIVAL; FLUORESCENCE MICROSCOPY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOFLUORESCENCE ASSAY; LACTIC ACID FERMENTATION; LIPID BLOOD LEVEL; METABOLIC DISORDER; MITOCHONDRION; MTOR SIGNALING; MUSCLE ATROPHY; MYOBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION RATE; SKELETAL MUSCLE CELL; SPECTROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; APOPTOSIS; MAPK SIGNALING; METABOLISM; MYOBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY","NHJ, (NRF-2019R1F1A105767513); MINISTRY OF EDUCATION, MOE; NATIONAL RESEARCH FOUNDATION OF KOREA, NRF","THIS RESEARCH WAS SUPPORTED BY BASIC SCIENCE RESEARCH PROGRAM THROUGH THE NATIONAL RESEARCH FOUNDATION OF KOREA (NRF) FUNDED BY THE MINISTRY OF EDUCATION (NHJ; NRF-2019R1F1A105767513).","BASKIN KK, WINDERS BR, OLSON EN., MUSCLE AS A “MEDIATOR” OF SYSTEMIC METABOLISM, CELL METAB, 21, PP. 237-248, (2015); GLASS DJ., SIGNALING PATHWAYS PERTURBING MUSCLE MASS, CURE OPIN CLIN NUTR METAB CARE, 13, PP. 225-229, (2010); O'CONNOR PMJ, KIMBALL SR, SURYAWAN A, BUSH JA, NGUYEN HV, JEFFERSON LS, DAVIS TA., REGULATION OF TRANSLATION INITIATION BY INSULIN AND AMINO ACIDS IN SKELETAL MUSCLE OF NEONATAL PIGS, AM J PHYSIOL-ENDOCRINOL METAB, 285, PP. 40-53, (2003); VELLOSO C., REGULATION OF MUSCLE MASS BY GROWTH HORMONE AND IGF-I, BR J PHARMACOL, 154, PP. 557-568, (2008); SARTORI R, ROMANELLO V, SANDRI M., MECHANISMS OF MUSCLE ATROPHY AND HYPERTROPHY: IMPLICATIONS IN HEALTH AND DISEASE, NAT COMMUN, 12, PP. 1-12, (2021); DEDKOV EI, BORISOV AB, CARLSON BM., DYNAMICS OF POSTDENERVATION ATROPHY OF YOUNG AND OLD SKELETAL MUS-CLES: DIFFERENTIAL RESPONSES OF FIBER TYPES AND MUSCLE TYPES, J GERONTOL-SER A BIOL SCI MED SCI, 58, PP. 984-991, (2003); VANDERVOORT AA., AGING OF THE HUMAN NEURO-MUSCULAR SYSTEM, MUSCLE NERVE, 25, PP. 17-25, (2002); TIAO G, FAGAN JM, SAMUELS N, JAMES JH, HUDSON K, LIEB-ERMAN M, FISCHER JE, HASSELGREN PO., SEPSIS STIMULATES NONLYSOSOMAL, ENERGY-DEPENDENT PROTEOLYSIS AND INCREASES UBIQUITIN MRNA LEVELS IN RAT SKELETAL MUSCLE, J CLIN INVEST, 94, PP. 2255-2264, (1994); BODINE SC, LATRES E, BAUMHUETER S, LAI VKM, NUNEZ L, CLARKE BA, POUEYMIROU WT, PANARO FJ, NA E, DHARMA-RAJAN K, PAN ZQ, VALENZUELA DM, DECHIARA TM, STITT TN, YANCOPOULOS GD, GLASS DJ., IDENTIFICATION OF UBIQUITIN LIGASES REQUIRED FOR SKELETAL MUSCLE ATROPHY, SCIENCE, 294, PP. 1704-1708, (2001); STITT TN, DRUJAN D, CLARKE BA, PANARO F, TIMOFEYVA Y, KLINE WO, GONZALEZ M, YANCOPOULOS GD, GLASS DJ., THE IGF-1/PI3K/AKT PATHWAY PREVENTS EXPRESSION OF MUSCLE ATROPHY-INDUCED UBIQUITIN LIGASES BY INHIBITING FOXO TRANSCRIPTION FACTORS, MOL CELL, 14, PP. 395-403, (2004); SANDRI M, SANDRI C, GILBERT A, SKURK C, CALABRIA E, PICARD A, WALSH K, SCHIAFFINO S, LECKER SH, GOLDBERG AL., FOXO TRANSCRIPTION FACTORS INDUCE THE ATRO-PHY-RELATED UBIQUITIN LIGASE ATROGIN-1 AND CAUSE SKELETAL MUSCLE ATROPHY, CELL, 117, PP. 399-412, (2004); ROMANELLO V, SANDRI M., THE CONNECTION BETWEEN THE DYNAMIC REMODELING OF THE MITOCHONDRIAL NETWORK AND THE REGULATION OF MUSCLE MASS, CELL MOL LIFE SCI, 78, PP. 1305-1328, (2021); PARRA V, VERDEJO HE, IGLEWSKI M, DEL CAMPO A, TRONCOSO R, JONES D, ZHU Y, KUZMICIC J, PENNANEN C, LOPEZ-CRISOSTO C, JANA F, FERREIRA J, NOGUERA E, CHIONG M, BER-NLOHR DA, KLIP A, HILL JA, ROTHERMEL BA, ABEL ED, ZOR-ZANO A, LAVANDERO S., INSULIN STIMULATES MITO-CHONDRIAL FUSION AND FUNCTION IN CARDIOMYOCYTES VIA THE AKT-MTOR-NFKB-OPA-1 SIGNALING PATHWAY, DIABETES, 63, PP. 75-88, (2014); IRMAK S, DUNFORD NT, MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); SHEN J, LUO F, LIN Q., POLICOSANOL: EXTRACTION AND, (2019); BIOLOGICAL FUNCTIONS, J FUNCT FOODS, 57, PP. 351-360; LEE E-Y, YOO J-A, LIM S-M, CHO K-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, 2, PP. 149-158, (2016); CHO K-H, YADAV D, KIM SJ, KIM JR., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPA-NIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPRO-TEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPER-TENSIVE RATS, MOLECULES, 23, 5, (2018); KIM H, PARK S, HAN DS, PARK T., OCTACOSANOL SUP-PLEMENTATION INCREASES RUNNING ENDURANCE TIME AND IMPROVES BIOCHEMICAL PARAMETERS AFTER EXHAUSTION IN TRAINED RATS, J MED FOOD, 6, PP. 345-351, (2003); KIM SJ, YADAV D, PARK HJ, KIM JR, CHO KH., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT PHYSIOL, 9, PP. 1-11, (2018); GUTMANN I, WAHLEFELD AW., LACTATE DETERMINATION WITH LACTATE DEHYDROGENASE AND NAD, METHODS OF ENZYMATIC ANALYSIS, 3, PP. 1464-1468, (1974); GORDALIZA-ALAGUERO I, CANTO C, ZORZANO A., METABOLIC IMPLICATIONS OF ORGANELLE–MITOCHONDRIA COMMUNI-CATION, EMBO REP, 20, PP. 1-27, (2019); GE YX, SHANG B, CHEN WZ, LU Y, WANG J., ADULT-ONSET OF MITOCHONDRIAL MYOPATHY, ENCEPHALOPA-THY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS) SYNDROME WITH HYPOTHYROIDISM AND PSYCHIATRIC DISORDERS, ENEUROLOGICALSCI, 6, PP. 16-20, (2016); PARK H, JEOUNG NH., INFLAMMATION INCREASES PYRUVATE DEHYDROGENASE KINASE 4 (PDK4) EXPRESSION VIA THE JUN N-TERMINAL KINASE (JNK) PATHWAY IN C2C12 CELLS, BIOCHEM BIOPHYS RES COMMUN, 469, PP. 1049-1054, (2016); KOUTALIANOS D, KOUTSOULIDOU A, MASTROYIANNOPOULOS NP, FURLING D, PHYLACTOU LA., MYOD TRANSCRIPTION FACTOR INDUCES MYOGENESIS BY INHIBITING TWIST-1 THROUGH MIR-206, J CELL SCI, 128, PP. 3631-3645, (2015); SHARMA R, MATSUZAKA T, KAUSHIK MK, SUGASAWA T, OHNO H, WANG Y, MOTOMURA K, SHIMURA T, OKAJIMA Y, MIZUNOE Y, MA Y, SABER ZM, IWASAKI H, YATOH S, SUZUKI H, AITA Y, HAN S, TAKEUCHI Y, YAHAGI N, MIYAMOTO T, SEKIYA M, NAKAGAWA Y, SHIMANO H., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI REP, 9, (2019); HSU CY, SHIH HY, CHANG YC, HUANG ZL, TSAI MJ, CHIA YC, CHEN C, LAI YK, WENG CF., THE BENEFICIAL EFFECTS OF TETRACOSANOL ON INSULIN-RESISTANCE BY INSULIN RECEPTOR KINASE SENSIBILISATION, J FUNCT FOODS, 14, PP. 174-182, (2015); SEOK WP, GOODPASTER BH, JUNG SL, KULLER LH, BOUDREAU R, DE REKENEIRE N, HARRIS TB, KRITCHEVSKY S, TYLAVSKY FA, NEVITT M, CHO YW, NEWMAN AB., EXCESSIVE LOSS OF SKELETAL MUSCLE MASS IN OLDER ADULTS WITH TYPE 2, (2009); DIABETES. DIABETES CARE, 32, PP. 1993-1997; OSTLER JE, MAURYA SK, DIALS J, ROOF SR, DEVOR ST, ZIOLO MT, PERIASAMY M., EFFECTS OF INSULIN RESISTANCE ON SKELETAL MUSCLE GROWTH AND EXERCISE CAPACITY IN TYPE 2 DIABETIC MOUSE MODELS, AM J PHYSIOL-ENDOCRINOL METAB, 306, PP. E592-E605, (2014); MAHAJAN K, MAHAJAN NP., PI3K-INDEPENDENT AKT ACTIVATION IN CANCERS: A TREASURE TROVE FOR NOVEL THERA-PEUTICS, J CELL PHYSIOL, 226, PP. 3178-3184, (2012); WU S, ZHOU F, ZHANG Z, XING D., MITOCHONDRIAL OXIDATIVE STRESS CAUSES MITOCHONDRIAL FRAGMENTATION VIA DIFFERENTIAL MODULATION OF MITOCHONDRIAL FISSION-FUSION PROTEINS, FEBS J, 278, PP. 941-954, (2011); LIN HY, WENG SW, CHANG YH, SU YJ, CHANG CM, TSAI CJ, SHEN FC, CHUANG JH, LIN TK, LIOU CW, LIN CY, WANG PW., THE CAUSAL ROLE OF MITOCHONDRIAL DYNAMICS IN REGULATING INSULIN RESISTANCE IN DIABETES: LINK THROUGH MITOCHONDRIAL REACTIVE OXYGEN SPECIES, OXID MED CELL LONGEV, 2018, (2018); CHEN H, CHOMYN A, CHAN DC., DISRUPTION OF FUSION RESULTS IN MITOCHONDRIAL HETEROGENEITY AND DYS-FUNCTION, J BIOL CHEM, 280, PP. 26185-26192, (2005); LIU R, JIN P, YU L, WANG Y, HAN L, SHI T, LI X., IMPAIRED MITOCHONDRIAL DYNAMICS AND BIOENERGETICS IN DIABETIC SKELETAL MUSCLE, PLOS ONE, 9, PP. 1-8, (2014); WEI Z, LIU HT., MAPK SIGNAL PATHWAYS IN THE REGULATION OF CELL PROLIFERATION IN MAMMALIAN CELLS, CELL RES, 12, PP. 9-18, (2002); MENG A, ZHANG X, SHI Y., ROLE OF P38 MAPK AND STAT3 IN LIPOPOLYSACCHARIDE-STIMULATED MOUSE ALVEOLAR MACROPHAGES, EXP THER MED, 8, PP. 1772-1776, (2014); FANG W, CAI SX, WANG CL, SUN XX, LI K, YAN XW, SUN YB, SUN XZ, GU CK, DAI MY, WANG HM, ZHOU Z., MODULATION OF MITOGEN-ACTIVATED PROTEIN KINASE ATTENUATES SEPSIS-INDUCED ACUTE LUNG INJURY IN ACUTE RESPIRATORY DISTRESS SYNDROME RATS, MOL MED REP, 16, PP. 9652-9658, (2017); WINTER JN, JEFFERSON LS, KIMBALL SR., ERK AND AKT SIGNALING PATHWAYS FUNCTION THROUGH PARALLEL MECHANISMS TO PROMOTE MTORC1 SIGNALING, AM J PHYSIOL-CELL PHYSIOL, 300, PP. 1172-1180, (2011); IMAI K, KATO H, TAGUCHI Y, UMEDA M., BIOLOGICAL EFFECTS OF SHIKONIN IN HUMAN GINGIVAL FIBROBLASTS VIA ERK 1/2 SIGNALING PATHWAY, MOLECULES, 24, PP. 1-13, (2019); DZOBO K, LEANER VD, PARKER MI., FEEDBACK REGULATION OF THE A2(1) COLLAGEN GENE VIA THE MEK-ERK SIGNALING PATHWAY, IUBMB LIFE, 64, PP. 87-98, (2012); HSIEH CC, PAPACONSTANTINOU J., AKT/PKB AND P38 MAPK SIGNALING, TRANSLATIONAL INITIATION AND LONGEVITY IN SNELL DWARF MOUSE LIVERS, MECH AGEING DEV, 125, PP. 785-798, (2004); BORA P, GAHUROVA L, MASEK T, HAUSEROVA A, POTESIL D, JANSOVA D, SUSOR A, ZDRAHAL Z, AJDUK A, POSPISEK M, BRUCE AW., P38-MAPK-MEDIATED TRANSLATION REGULATION DURING EARLY BLASTOCYST DEVELOPMENT IS REQUIRED FOR PRIMITIVE ENDODERM DIFFERENTIATION IN MICE, COMMUN BIOL, 4, PP. 1-19, (2021)","K.-H. CHO; LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR; N.H. JEOUNG; DEPARTMENT OF PHARMACEUTICAL ENGINEERING, DEAGU CATHOLIC UNIVERSITY, GYEONGSAN, 38430, SOUTH KOREA; EMAIL: SYJEOUNG@CU.AC.KR","CENTER FOR ACADEMIC PUBLICATIONS JAPAN","ENGLISH","J. NUTR. SCI. VITAMINOL.","ARTICLE","ISI","2-S2.0-85127373803","J NUTR SCI VITAMINOL","DEAGU CATHOLIC UNIVERSITY;DEAGU CATHOLIC UNIVERSITY;DEAGU CATHOLIC UNIVERSITY;YEUNGNAM UNIVERSITY;DEAGU CATHOLIC UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED;NOTREPORTED;DEAGU CATHOLIC UNIVERSITY;NOTREPORTED",NA,"JO AL, 2022, J NUTR SCI VITAMINOL","JO AL, 2022, J NUTR SCI VITAMINOL"
"TEMPLEMAN J;HOGAN K;BLANCHARD A;MARINANGELI C;CAMARA A;VERBRUGGHE A;SHOVELLER A","TEMPLEMAN, JAMES R (57201474432); HOGAN, KYLIE (57219116727); BLANCHARD, ALEXANDRA (57207724357); MARINANGELI, CHRISTOPHER PF (12787919400); CAMARA, ALEXANDRA (57219117195); VERBRUGGHE, ADRONIE (34973646000); SHOVELLER, ANNA K (6506397729)","EFFECT OF RAW AND ENCAPSULATED POLICOSANOL ON LIPID PROFILES BLOOD BIOCHEMISTRY ACTIVITY ENERGY EXPENDITURE AND MACRONUTRIENT METABOLISM OF ADULT CATS",2022,"JOURNAL OF FELINE MEDICINE AND SURGERY","24","7",2,"10.1177/1098612X211013738","DEPARTMENT OF ANIMAL BIOSCIENCES, UNIVERSITY OF GUELPH, GUELPH, ON, CANADA;DEPARTMENT OF ANIMAL BIOSCIENCES, UNIVERSITY OF GUELPH, GUELPH, ON, CANADA;PANCOSMA, LE GRAND SACONNEX, SWITZERLAND;PULSE CANADA, WINNIPEG, MB, CANADA;CLINICAL STUDIES, ONTARIO VETERINARY COLLEGE, UNIVERSITY OF GUELPH, GUELPH, ON, CANADA;CLINICAL STUDIES, ONTARIO VETERINARY COLLEGE, UNIVERSITY OF GUELPH, GUELPH, ON, CANADA;DEPARTMENT OF ANIMAL BIOSCIENCES, UNIVERSITY OF GUELPH, GUELPH, ON, CANADA","OBJECTIVES: THE OBJECTIVE OF THIS STUDY WAS TO VERIFY THE SAFETY OF POLICOSANOL SUPPLEMENTATION FOR DOMESTIC CATS. THE EFFECTS OF RAW AND ENCAPSULATED POLICOSANOL WERE COMPARED WITH POSITIVE (L-CARNITINE) AND NEGATIVE (NO SUPPLEMENTATION) CONTROLS ON OUTCOMES OF COMPLETE BLOOD COUNT, SERUM BIOCHEMISTRY, ENERGY EXPENDITURE, RESPIRATORY QUOTIENT AND PHYSICAL ACTIVITY IN HEALTHY YOUNG ADULT CATS. METHODS: THE STUDY WAS A REPLICATED 4 × 4 COMPLETE LATIN SQUARE DESIGN. EIGHT CATS (FOUR CASTRATED MALES, FOUR SPAYED FEMALES; MEAN AGE 3.0 ± 1.0 YEARS; MEAN WEIGHT 4.36 ± 1.08 KG; MEAN BODY CONDITION SCORE 5.4 ± 1.4) WERE BLOCKED BY SEX AND BODY WEIGHT THEN RANDOMIZED TO TREATMENT GROUPS: RAW POLICOSANOL (10 MG/KG BODY WEIGHT), ENCAPSULATED POLICOSANOL (50 MG/KG BODY WEIGHT), L-CARNITINE (200 MG/KG BODY WEIGHT) OR NO SUPPLEMENTATION. TREATMENTS WERE SUPPLEMENTED TO A BASAL DIET FOR 28 DAYS WITH A 1-WEEK WASHOUT BETWEEN PERIODS. FOOD WAS DISTRIBUTED EQUALLY BETWEEN TWO OFFERINGS TO ENSURE COMPLETE SUPPLEMENT CONSUMPTION (FIRST OFFERING) AND MEASURE CONSUMPTION TIME (SECOND OFFERING). BLOOD COLLECTION (LIPID PROFILE, COMPLETE BLOOD COUNT, SERUM BIOCHEMISTRY) AND INDIRECT CALORIMETRY (ENERGY EXPENDITURE, RESPIRATORY QUOTIENT) WERE CONDUCTED AT DAYS 0, 14 AND 28 OF EACH PERIOD. ACTIVITY MONITORS WERE WORN 7 DAYS PRIOR TO INDIRECT CALORIMETRY AND BLOOD COLLECTION. DATA WERE ANALYZED USING A REPEATED MEASURES MIXED MODEL (SAS, V.9.4). RESULTS: FOOD INTAKE AND BODY WEIGHT WERE SIMILAR AMONG TREATMENTS. THERE WAS NO EFFECT OF TREATMENT ON LIPID PROFILE, SERUM BIOCHEMISTRY, ACTIVITY, ENERGY EXPENDITURE OR RESPIRATORY QUOTIENT (P >0.05); HOWEVER, TIME TO CONSUME A SECOND MEAL WAS GREATEST IN CATS FED RAW POLICOSANOL (P <0.05). CONCLUSIONS AND RELEVANCE: THESE DATA SUGGEST THAT POLICOSANOL IS SAFE FOR FELINE CONSUMPTION. FURTHER STUDIES WITH CATS DEMONSTRATING CARDIOMETABOLIC RISK FACTORS ARE WARRANTED TO CONFIRM WHETHER POLICOSANOL THERAPY IS AN EFFICACIOUS TREATMENT FOR HYPERLIPIDEMIA AND OBESITY. © THE AUTHOR(S) 2021.","ENERGY EXPENDITURE; HYPERLIPIDEMIA; OBESITY; OVERWEIGHT; RESPIRATORY QUOTIENT","ANIMALS; CATS; DIET; ENERGY METABOLISM; FATTY ALCOHOLS; FEMALE; MALE; NUTRIENTS; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CARNITINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; PHOSPHORUS; POLICOSANOL; POTASSIUM; TRIACYLGLYCEROL; UREA; FATTY ALCOHOL; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BIOCHEMISTRY; BLOOD CELL COUNT; BODY CONSTITUTION; BODY WEIGHT; BODY WEIGHT GAIN; CALORIMETRY; CAT; CONTROLLED STUDY; DIET COMPOSITION; DRUG DOSE INCREASE; DRUG SAFETY; DYSLIPIDEMIA; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; GAS CHROMATOGRAPHY; HYPERLIPIDEMIA; LIPID FINGERPRINTING; LIPID METABOLISM; MACRONUTRIENT; MALE; MASS SPECTROMETRY; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION; MEAN CORPUSCULAR VOLUME; METABOLISM; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; RED BLOOD CELL DISTRIBUTION WIDTH; RESPIRATORY QUOTIENT; RISK FACTOR; SOCIAL INTERACTION; ANIMAL; DIET; ENERGY METABOLISM; VETERINARY MEDICINE","","","WARD E., 2017 PET OBESITY SURVEY RESULTS, ASSOCIATION FOR PET OBESITY PREVENTION, (2018); KOPELMAN P.G., OBESITY AS A MEDICAL PROBLEM, NATURE, 404, PP. 635-643, (2000); BLANCHARD G., PARAGON B.M., MILLIAT F., ET AL., DIETARY L-CARNITINE SUPPLEMENTATION IN OBESE CATS ALTERS CARNITINE METABOLISM AND DECREASES KETOSIS DURING FASTING AND INDUCED HEPATIC LIPIDOSIS, J NUTR, 132, PP. 204-210, (2002); CENTER S.A., WARNER K.L., RANDOLPH J.F., ET AL., INFLUENCE OF DIETARY SUPPLEMENTATION WITH L-CARNITINE ON METABOLIC RATE, FATTY ACID OXIDATION, BODY CONDITION, AND WEIGHT LOSS IN OVERWEIGHT CATS, AM J VET RES, 73, PP. 1002-1015, (2012); SHOVELLER A.K., MINIKHIEM D.L., CARNAGEY K., ET AL., LOW LEVEL OF SUPPLEMENTAL DIETARY L-CARNITINE INCREASES ENERGY EXPENDITURE IN OVERWEIGHT, BUT NOT LEAN, CATS FED A MODERATE ENERGY DENSITY DIET TO MAINTAIN BODY WEIGHT, INTERN J APPL RES VET MED, 12, PP. 33-43, (2014); DE GODOY M.R., SHOVELLER A.K., OVERWEIGHT ADULT CATS HAVE SIGNIFICANTLY LOWER VOLUNTARY PHYSICAL ACTIVITY THAN ADULT LEAN CATS, J FELINE MED SURG, 19, PP. 1267-1273, (2017); GOODING M.A., MINIKHIEM D.L., SHOVELLER A.K., CATS IN POSITIVE ENERGY BALANCE HAVE LOWER RATES OF ADIPOSE GAIN WHEN FED DIETS CONTAINING 188 VERSUS 121 PPM L-CARNITINE, SCI WORLD J, 2016, (2016); CENTER S.A., HARTE J., WATROUS D., ET AL., THE CLINICAL AND METABOLIC EFFECTS OF RAPID WEIGHT LOSS IN OBESE PET CATS AND THE INFLUENCE OF SUPPLEMENTAL ORAL L-CARNITINE, J VET INTERN MED, 14, PP. 598-608, (2000); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMOCOL RES, 21, PP. 43-57, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CRUZ-BUSTILLO D., MEDEROS D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF ATEROMIXOL (PPG) ON FATTENING HOGS, REV CENIC CIENC BIOL, 22, PP. 62-63, (1991); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-258, (1996); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARM RES, 15, PP. 159-165, (1995); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); MARINANGELI C.P.F., JONES P.J., KASSIS A.N., ET AL., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, PP. 259-267, (2010); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGARCANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, J AM COLL NUTR, 27, PP. 476-484, (2008); KASSIS A.N., MARINANGELI C.P., JAIN D., ET AL., LACK OF EFFECT OF SUGARCANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., ET AL., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); MONTAGUE M.J., LI G., GANDOLFI B., ET AL., COMPARATIVE ANALYSIS OF THE DOMESTIC CAT GENOME REVEALS GENETIC SIGNATURES UNDERLYING FELINE BIOLOGY AND DOMESTICATION, PROC NAT ACAD SCI, 111, PP. 17230-17235, (2014); LAFLAMME D.P., DEVELOPMENT AND VALIDATION OF A BODY CONDITION SCORE SYSTEM FOR CATS: A CLINICAL TOOL, FELINE PRACT, 25, PP. 13-18, (1997); GOODING M.A., ATKINSON J.L., DUNCAN I.J., ET AL., DIETARY FAT AND CARBOHYDRATE HAVE DIFFERENT EFFECTS ON BODY WEIGHT, ENERGY EXPENDITURE, GLUCOSE HOMEOSTASIS AND BEHAVIOUR IN ADULT CATS FED TO ENERGY REQUIREMENT, J NUTR SCI, 4, (2015); WEIR J., NEW METHODS FOR CALCULATING METABOLIC RATE WITH SPECIAL REFERENCE TO PROTEIN METABOLISM, J PHYSIOL-LONDON, 109, PP. 1-9, (1949); ANDREWS C.J., POTTER M.A., THOMAS D.G., QUANTIFICATION OF ACTIVITY IN DOMESTIC CATS (FELIS CATUS) BY ACCELEROMETRY, APPL ANIM BEHAV SCI, 173, PP. 17-21, (2015); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-65, (2010); MESA A.D.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); WANG Y.W., JONES P.J.H., PISCHEL I., ET AL., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); CENTER S.A., WARNER K.L., RANDOLPH J.F., ET AL., RESTING ENERGY EXPENDITURE PER LEAN BODY MASS DETERMINED BY INDIRECT CALORIMETRY AND BIOELECTRICAL IMPEDANCE ANALYSIS IN CATS, J VET INTERN MED, 25, PP. 1341-1350, (2011)","A.K. SHOVELLER; DEPARTMENT OF ANIMAL BIOSCIENCES, UNIVERSITY OF GUELPH, GUELPH, CANADA; EMAIL: ASHOVELL@UOGUELPH.CA","SAGE PUBLICATIONS LTD","ENGLISH","J. FELINE MED. SURG.","ARTICLE","ISI","2-S2.0-85105796508","J FELINE MED SURG","UNIVERSITY OF GUELPH;UNIVERSITY OF GUELPH;UNIVERSITY OF GUELPH;UNIVERSITY OF GUELPH;UNIVERSITY OF GUELPH","NOTREPORTED;UNIVERSITY OF GUELPH;NOTREPORTED",NA,"TEMPLEMAN JR, 2022, J FELINE MED SURG","TEMPLEMAN JR, 2022, J FELINE MED SURG"
"PARK J;KIM J;LEE M;KIM S;OH E;CHO K;OH K","PARK, JAE EUN (57204881904); KIM, JUNG IN (57204539161); LEE, MYOUNG HEE (56142671500); KIM, SUNGUP (56016191300); OH, EUNYOUNG (57204882790); CHO, KWANG SOO (55722770800); OH, KI WON (57209582322)","INFLUENCE OF ROASTING TEMPERATURE ON THE FUNCTIONAL COMPONENTS OF PERILLA AND SESAME OILS",2021,"JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION","50","5",5,"10.3746/JKFN.2021.50.2.149","DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SOUTH KOREA","THIS STUDY EXAMINED THE FUNCTIONAL COMPONENTS OF PERILLA (DAYU) AND SESAME (GEONBAEK) OILS AT VARIOUS ROASTING TEMPERATURES. ROASTING WAS CONDUCTED AT 170°C, 180°C, AND 190°C FOR 15 MIN. THE OIL YIELD OF UNROASTED PERILLA AND SESAME OILS WAS HIGHER THAN ROASTED OILS. WITH INCREASING ROASTING TEMPERATURE, THE BRIGHTNESS AND YELLOWNESS IN PERILLA OILS DECREASED WHILE THE REDNESS INCREASED. WITH INCREASED ROASTING TEMPERATURE, THE BRIGHTNESS WAS DECREASED WHILE THE YELLOWNESS INCREASED IN SESAME OILS. THE MAJOR FATTY ACID OF PERILLA OIL WAS LINOLENIC ACID (62.6 TO 64.0%). BUT THE MAJOR FATTY ACIDS OF SESAME OIL WERE OLEIC ACID (42.8 TO 43.8%), LINOLEIC ACID (41.2 TO 42.4%). THE TOTAL POLICOSANOL CONTENTS OF THE PERILLA OILS WERE 16.67 TO 17.61 MG/100 G OIL. THE LIGNAN CONTENTS OF SESAME OILS WERE 901 TO 919 MG/100 G OIL. BENZOPYRENE WAS NOT DETECTED IN THE PRESSED OILS. ROASTING DID NOT AFFECT THE FUNCTIONAL COMPONENTS OF PERILLA AND SESAME OILS. THIS STUDY PROVIDES BASIC DATA FOR THE PROCESSING OF EDIBLE OILS AND THE SEED INDUSTRY. © 2021 KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION. ALL RIGHTS RESERVED.","LIGNAN; PERILLA; POLICOSANOL; ROASTING TEMPERATURE; SESAME","","","","ADHIKARI P, HWANG KT, PARK JN, KIM CK., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, PP. 5359-5362, (2006); BLONDEAU N, NGUEMENI C, DEBRUYNE DN, PIENS M, WU X, PAN H, ET AL., SUBCHRONIC ALPHA-LINOLENIC ACID TREATMENT ENHANCES BRAIN PLASTICITY AND EXERTS AN ANTIDEPRESSANT EFFECT: A VERSATILE POTENTIAL THERAPY FOR STROKE, NEUROPSYCHOPHARMACOLOGY, 34, PP. 2548-2559, (2009); CHENG W, LIU G, WANG X, LIU X, LIU B., FORMATION OF BENZO (A)PYRENE IN SESAME SEEDS DURING THE ROASTING PROCESS FOR PRODUCTION OF SESAME SEED OIL, J AM OIL CHEM SOC, 92, PP. 1725-1733, (2015); COGNAULT S, JOURDAN ML, GERMAIN E, PITAVY R, MOREL E, DURAND G, ET AL., EFFECT OF AN ALPHA-LINOLENIC ACID-RICH DIET ON RAT MAMMARY TUMOR GROWTH DEPENDS ON THE DIETARY OXIDATIVE STATUS, NUTR CANCER, 36, PP. 33-41, (2000); DE LORGERIL M, SALEN P, LAPORTE F, DE LEIRIS J., ALPHA-LINOLENIC ACID IN THE PREVENTION AND TREATMENT OF CORONARY HEART DISEASE, EUR HEART J SUPPL, 3, PP. D26-D32, (2001); GOUNI-BERTHOLD I, BERTHOLD HK., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HA JH, KIM DH., CHANGES IN THE PHYSICO-CHEMICAL PROPERTIES OF THE MEALS FROM THE DEFATTED SESAME SEEDS AT VARIOUS ROASTING TEMPERATURE AND TIME, KOREAN J FOOD SCI TECHNOL, 28, PP. 246-252, (1996); JENG KCG, HOU RCW., SESAMIN AND SESAMOLIN: NATURE S THERAPEUTIC LIGNANS, CURR ENZYME INHIB, 1, PP. 11-20, (2005); JUNG DM, LEE MJ, YOON SH, JUNG MY., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J FOOD SCI, 76, PP. C891-C899, (2011); KIM BK, LIM JH, CHO YS, PARK KJ, KIM JC, JEONG JW, ET AL., STUDY ON CHARACTERISTICS OF COLD-PRESSED SESAME OIL AND VIRGIN SESAME OIL, J EAST ASIAN SOC DIET LIFE, 18, PP. 812-821, (2008); KIM EJ, HWANG SY, SON JY., PHYSIOLOGICAL ACTIVITIES OF SESAME, BLACK SESAME, PERILLA AND OLIVE OIL EXTRACTS, J KOREAN SOC FOOD SCI NUTR, 38, PP. 280-286, (2009); KIM H, SONG DS., MINIMIZING BENZO(A)PYRENE CONTENT IN THE MANUFACTURING OF SESAME OIL AND PERILLA OIL, KOREAN J FOOD PRESERV, 15, PP. 556-561, (2008); KIM JK, PARK SY, NA JK, SEONG ES, YU CY., METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA (PERILLA FRUTESCENS) CULTIVARS, J AGRIC FOOD CHEM, 60, PP. 2257-2263, (2012); KIM SU, LEE MH, PAE SB, OH EY, KIM JI, HA TJ., A SESAME VARIETY ""GOENBAEK"" WITH PHYTOPHTHORA BLIGHT DISEASE RESISTANCE AND HIGH YIELD, KOREAN J BREED SCI, 50, PP. 256-260, (2018); KIM YE, KIM IH, JUNG SY, JO JS., CHANGES IN COMPONENTS AND SENSORY ATTRIBUTE OF THE OIL EXTRACTED FROM PERILLA SEED ROASTED AT DIFFERENT ROASTING CONDITIONS, AGRIC CHEM BIOTECH, 39, PP. 118-122, (1996); LEE J, KIM M, CHOE E., STUDY ON THE CHANGES OF TOCOPHEROLS AND LIGNANS AND THE OXIDATIVE PROPERTIES OF ROASTED SESAME OIL DURING MANUFACTURING AND STORAGE, KOREAN J FOOD SCI TECHNOL, 40, PP. 15-20, (2008); LEE MH, JUNG CS, OH KW, PARK CB, KIM DG, CHOI JK, ET AL., A NEW PERILLA CULTIVAR FOR EDIBLE SEED DAYU WITH HIGH OIL CONTENT, KOREAN J BREED SCI, 43, PP. 616-619, (2011); LEE S, LEE YJ, SUNG JS, SHIN HS., INFLUENCE OF ROASTING CONDITIONS ON THE CHEMICAL PROPERTIES AND ANTIOXIDANT ACTIVITY OF PERILLA OILS, J KOREAN SOC APPL BIOL CHEM, 58, PP. 325-334, (2015); NAM MJ, CHUNG HY., OXIDATIVE STABILITY OF SESAME OIL PREPARED FROM BLACK SESAME FLOUR, KOREAN J FOOD SCI TECHNOL, 40, PP. 141-145, (2008); PARK HJ, KIM JY, PARK SH, LEE SH, JANG JS, LEE MH., STUDIES ON THE PHYSICOCHEMICAL AND BIOCHEMICAL CHARACTERISTICS IN SESAME SEED JUICE UNDER DIFFERENT ROASTING CONDITIONS, KOREAN J FOOD SCI TECHNOL, 49, PP. 421-429, (2017); SHIN HS, KIM SW., LIPID COMPOSITION OF PERILLA SEED, J AM OIL CHEM SOC, 71, PP. 619-622, (1994); YAMAMOTO N, SAITOH M, MORIUCHI A, NOMURA M, OKUYAMA H., EFFECT OF DIETARY ALPHA-LINOLENATE/LINOLEATE BALANCE ON BRAIN LIPID COMPOSITIONS AND LEARNING ABILITY OF RATS, J LIPID RES, 28, PP. 144-151, (1987); YEN GC., INFLUENCE OF SEED ROASTING PROCESS ON THE CHANGES IN COMPOSITION AND QUALITY OF SESAME (SESAME INDICUM) OIL, J SCI FOOD AGRIC, 50, PP. 563-570, (1990)","J.I. KIM; DEPARTMENT OF SOUTHERN AREA CROP SCIENCE, NICS, RDA, MIRYANG-SI, GYEONGNAM, 20, JEOMPILJAE-RO, 50424, SOUTH KOREA; EMAIL: KJI1204@KOREA.KR","KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION","KOREAN","J. KOREAN SOC. FOOD SCI. NUTR.","ARTICLE","ISI","2-S2.0-85102681487","J KOREAN SOC FOOD SCI NUTR","NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE","NOTREPORTED;DEPARTMENT OF SOUTHERN AREA CROP SCIENCE;NOTREPORTED",NA,"PARK JE, 2021, J KOREAN SOC FOOD SCI NUTR","PARK JE, 2021, J KOREAN SOC FOOD SCI NUTR"
"LEE H;WOO S;AHN H;YANG J;LEE M;KIM H;SONG S;LEE J;SEO W","LEE, HAN-GYEOL (58054795600); WOO, SO-YEUN (59113100400); AHN, HYUNG-JAE (57218825525); YANG, JI-YEONG (57188659163); LEE, MI-JA (25823106900); KIM, HYUN-YOUNG (36013294700); SONG, SEUNG-YEOB (50263045700); LEE, JIN-HWAN (36062793300); SEO, WOO-DUCK (8921329600)","COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT AVENA SATIVA L CULTIVARS AND SCREENING FOR ADENOSINE 5MONOPHOSPHATEACTIVATED PROTEIN KINASE AMPK ACTIVATION",2022,"PLANTS","11","",5,"10.3390/plants11141844","CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA, DIVISION OF LIFE SCIENCES, COLLEGE OF NATURAL SCIENCE, JEONBUK NATIONAL UNIVERSITY, 567 BAEKJE-, DAERO, JEOLLABUK-DO, JEONJU, 54896, SOUTH KOREA;NATURAL MEDICINE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, CHUNGCHEONGBUK-DO, CHEONGJU-SI, 28116, SOUTH KOREA;CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA, DEPARTMENT OF AGBIOTECHNOLOGY AND NATURAL RESOURCES, COLLEGE OF AGRICULTURE AND LIFE SCIENCE, GYEONGSANG NATIONAL UNIVERSITY, JINJU, 52828, SOUTH KOREA;CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA;CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA;CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA;CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA;DEPARTMENT OF LIFE RESOURCES INDUSTRY, COLLEGE OF NATURAL RESOURCES AND LIFE SCIENCE, DONG-A UNIVERSITY, 37, NAKDONG-DAERO 550 BEON-GIL, BUSAN, 49315, SOUTH KOREA;CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEOLLABUK-DO, WANJU-GUN, 55365, SOUTH KOREA","THE OBJECTIVES OF THIS RESEARCH WERE TO EVALUATE THE POLICOSANOL PROFILES AND ADENOSINE-5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) PROPERTIES IN THE SEEDLINGS OF KOREAN OAT (AVENA SATIVA L.) CULTIVARS AT DIFFERENT GROWTH TIMES. NINE POLICOSANOLS IN THE SILYLATED HEXANE EXTRACTS WERE DETECTED USING GC-MS AND THEIR CONTENTS SHOWED CONSIDERABLE DIFFERENCES; SPECIFICALLY, HEXACOSANOL (6) EXHIBITED THE HIGHEST COMPOSITION, CONSTITUTING 88–91% OF THE TOTAL AVERAGE CONTENT. MOREOVER, THE AVERAGE HEXACOSANOL (6) CONTENTS SHOWED REMARKABLE VARIATIONS OF 337.8 (5 DAYS) → 416.8 (7 DAYS) → 458.9 (9 DAYS) → 490.0 (11 DAYS) → 479.2 (13 DAYS) → 427.0 MG/100 G (15 DAYS). THE SEEDLINGS COLLECTED AT 11 DAYS SHOWED THE HIGHEST AVERAGE POLICOSANOL CONTENT (541.7 MG/100 G), WITH THE LOWEST CONTENT BEING 383.4 MG/100 G AFTER 5 DAYS. INTERESTINGLY, POLICOSANOLS FROM OAT SEEDLINGS GROWN FOR 11 DAYS INDUCED THE MOST PREVALENT PHENOTYPE OF AMPK ACTIVATION IN HEPG2 CELLS, INDICATING THAT POLICOSANOLS ARE AN EXCELLENT AMPK ACTIVATOR. © 2022 BY THE AUTHORS.","AMPK; GC-MS; GROWTH TIMES; HEXACOSANOL; OAT SEEDLING; POLICOSANOL","","RURAL DEVELOPMENT ADMINISTRATION, RDA, (PJ01421201); RURAL DEVELOPMENT ADMINISTRATION, RDA","THIS RESEARCH WAS FUNDED BY RURAL DEVELOPMENT ADMINISTRATION (RDA), KOREA. PROJECT TITLE: ENHANCEMENT OF SECONDARY METABOLITES FROM CROP SPROUTS AND THEIR IMPROVED EFFECTS AGAINST ATOPY AND ALOPECIA DISEASE, PROJECT NO. PJ01421201.","ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES, 33, PP. 835-840, (2000); JANG Y., KIM D., HAN E., JUNG J., PHYSIOLOGICAL ACTIVITIES OF POLICOSANOL EXTRACTED FROM SUGARCANE WAX, NAT. PROD. SCI, 25, PP. 293-297, (2019); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., CESAR J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES. CLIN. EXP, 56, PP. 176-182, (1995); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. PHYSIOL, 29, PP. 891-897, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES, 69, PP. 321-327, (1993); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J. PHARM. PHARMACOL, 47, PP. 731-733, (1995); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J. NUTR. BIOCHEM, 20, PP. 155-162, (2009); RAVELO Y., MOLINA V., CARBAJAL D., FERNANDEZ L., FERNANDEZ J.C., ARRUZAZABALA M.L., MAS R., EVALUATION OF ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECTS OF D-002 (BEEWAX ALCOHOLS), J. NAT. MED, 65, PP. 330-335, (2011); CHEN Y., DUNFORD N.T., GOAD C., TANGENTIAL ABRASIVE DEHULLING OF WHEAT GRAIN TO OBTAIN POLICOSANOL AND PHYTOSTEROL ENRICHED FRACTIONS, J. CEREAL SCI, 57, PP. 258-260, (2013); CHOI S.J., PARK S.Y., PARK J.S., PARK S.K., JUNG M.Y., CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA (CAMELLIA SINENSIS) LEAVES, FOOD CHEM, 204, PP. 94-101, (2016); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., KANG H.W., NAM M.H., LEE S.J., LEE J.H., ET AL., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J. AGRIC. FOOD CHEM, 61, PP. 1117-1123, (2013); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., KIM Y., SEO W.D., LEE S.J., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTR. RES, 43, PP. 89-99, (2017); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, (2009); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); DARZIAN ROSTAMI Z., ASGHARI A., JAHANDIDEH A., MORTAZAVI P., AKBARZADEH A., EFFECT OF OAT (AVENA SATIVA L.) EXTRACT ON EXPERIMENTAL SCIATIC NERVE INJURY IN RATS, ARCH. RAZI INST, 75, PP. 249-256, (2020); LIU B., YANG T., LUO Y., ZENG L., SHI L., WEI C., NIE Y., CHENG Y., LIN Q., LUO F., OAT Β-GLUCAN INHIBITS ADIPOGENESIS AND HEPATIC STEATOSIS IN HIGH FAT DIETINDUCED HYPERLIPIDEMIC MICE VIA AMPK SIGNALING, J. FUNCT. FOODS, 41, PP. 72-82, (2018); AHMED S., GUL S., GUL H., BANGASH M.H., ANTI-INFLAMMATORY AND ANTI-PLATELET ACTIVITIES OF AVENA SATIVA ARE MEDIATED THROUGH THE INHIBITION OF CYCLOOXYGENASE AND LIPOXYGENASE ENZYMES, INT. J. ENDORSING HEALTH SCI. RES, 1, PP. 62-65, (2013); FENG B., MA L.J., YAO J.J., FANG Y., MEI Y.A., WEI S.M., PROTECTIVE EFFECT OF OAT BRAN EXTRACTS ON HUMAN DERMAL FIBROBLAST INJURY INDUCED BY HYDROGEN PEROXIDE, J. ZHEJIANG UNIV. SCI. B, 14, PP. 97-105, (2013); WOO S.Y., LEE K.S., SHIN H.L., KIM S.H., LEE M.J., KIM H.Y., HAM H., LEE D.J., CHOI S.W., SEO W.D., TWO NEW SECONDARY METABOLITES ISOLATED FROM AVENA SATIVA L. (OAT) SEEDLINGS AND THEIR EFFECTS ON OSTEOBLAST DIFFERENTIATION, BIOORG. MED. CHEM. LETT, 30, (2020); LEE J.H., LEE S.Y., KIM B., SEO W.D., JIA Y., WU C., JUN H.J., LEE S.J., BARLEY SPROUT EXTRACT CONTAINING POLICOSANOLS AND POLYPHENOLS REGULATE AMPK, SREBP2 AND ACAT2 ACTIVITY AND CHOLESTEROL AND GLUCOSE METABOLISM IN VITRO AND IN VIVO, FOOD RES. INT, 72, PP. 174-183, (2015); BRADFORD M.M., A RAPID AND SENSITIVE METHOD FOR THE QUANTITATION OF MICROGRAM QUANTITIES OF PROTEIN UTILIZING THE PRINCIPLE OF PROTEIN-DYE BINDING, ANAL. BIOCHEM, 72, PP. 248-254, (1976); LEE J.H., PARK M.J., RYU H.W., YUK H.J., CHOI S.-W., LEE K.-S., KIM S.-L., SEO W.D., ELUCIDATION O PHENOLIC ANTIOXIDANTS IN BARLEY SEEDLINGS (HORDEUM VULGARE L.) BY UPLC-PDA-ESI/MS AND SCREENING FOR THEIR CONTENTS AT DIFFERENT HARVEST TIMES, J. FUNCT. FOODS, 26, PP. 667-680, (2016); RA J.E., WOO S.Y., LEE K.S., LEE M.J., KIM H.Y., HAM H.M., CHUNG I.M., KIM D.H., LEE J.H., SEO W.D., POLICOSANOL PROFILES AND ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME, FOOD CHEM, 317, (2020); IRMAK S., JONNALA R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, J. CEREAL SCI, 48, PP. 20-26, (2008)","W.-D. SEO; CROP FOUNDATION RESEARCH DIVISION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, WANJU-GUN, JEOLLABUK-DO, 55365, SOUTH KOREA; EMAIL: SCHEM72@DAUM.NET; J.-H. LEE; DEPARTMENT OF LIFE RESOURCES INDUSTRY, COLLEGE OF NATURAL RESOURCES AND LIFE SCIENCE, DONG-A UNIVERSITY, BUSAN, 37, NAKDONG-DAERO 550 BEON-GIL, 49315, SOUTH KOREA; EMAIL: SWD2002@KOREA.KR","MDPI","ENGLISH","PLANTS","ARTICLE","ISI","2-S2.0-85136236052","PLANTS","DAERO;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;JINJU;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;NATIONAL INSTITUTE OF CROP SCIENCE;DONG-A UNIVERSITY;NATIONAL INSTITUTE OF CROP SCIENCE","NOTREPORTED;NATIONAL INSTITUTE OF CROP SCIENCE;NOTDECLARED;NOTREPORTED;DONG-A UNIVERSITY;NOTREPORTED",NA,"LEE H-G, 2022, PLANTS","LEE H-G, 2022, PLANTS"
"SAFARI S;MIRAZI N;AHMADI N;ASADBEGI M;NOURIAN A;RASHNO M;KOMAKI A","SAFARI, SAMANEH (57222136611); MIRAZI, NASER (8247246600); AHMADI, NESA (57222143846); ASADBEGI, MASOUMEH (56974353600); NOURIAN, ALIREZA (56005452500); RASHNO, MASOME (56550020400); KOMAKI, ALIREZA (55881461900)","POLICOSANOL PROTECTS AGAINST ALZHEIMERS DISEASEASSOCIATED SPATIAL COGNITIVE DECLINE IN MALE RATS POSSIBLE INVOLVED MECHANISMS",2023,"PSYCHOPHARMACOLOGY","240","12",2,"10.1007/s00213-023-06317-7","DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN, DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN;DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN;DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN, INSTITUTE OF EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY, UNIVERSITY OF LUEBECK, LUEBECK, GERMANY;DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN;DEPARTMENT OF PATHOBIOLOGY, FACULTY OF VETERINARY SCIENCE, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN;STUDENT RESEARCH COMMITTEE, ASADABAD SCHOOL OF MEDICAL SCIENCES, ASADABAD, IRAN;DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN","RATIONALE: ALZHEIMER’S DISEASE (AD) IS A CHRONIC NEURODEGENERATIVE DISORDER CHARACTERIZED BY COGNITIVE DECLINE AND SYNAPTIC FAILURE. OBJECTIVE: THE PRESENT STUDY WAS DESIGNED TO EXPLORE THE POSSIBLE PROTECTIVE EFFECTS OF POLICOSANOL (PCO) ON SPATIAL COGNITIVE CAPACITY, LONG-TERM POTENTIATION (LTP) INDUCTION, OXIDANT/ANTIOXIDANT STATUS, AND AΒ PLAQUES FORMATION IN AN AD RAT MODEL INDUCED BY INTRACEREBROVENTRICULAR (ICV) INJECTION OF AΒ1–40. METHODS: HEALTHY ADULT MALE WISTAR RATS WERE RANDOMLY DIVIDED INTO CONTROL, SHAM (ICV INJECTION OF 5 ΜL PHOSPHATE-BUFFERED SALINE), AG (50 MG/KG; P.O., AS PCO VEHICLE), PCO (50 MG/KG; P.O.), AD MODEL (ICV INJECTION OF 5 ΜL AΒ), AD + AG (50 MG/KG; P.O.), AND AD + PCO (50 MG/KG; P.O.). TREATMENTS WERE PERFORMED FOR EIGHT CONSECUTIVE WEEKS. AT THE END OF THE TREATMENT COURSE, SPATIAL LEARNING AND MEMORY FUNCTIONS, HIPPOCAMPAL LONG-TERM POTENTIATION (LTP) INDUCTION, MALONDIALDEHYDE (MDA), AND TOTAL THIOL GROUP (TTG) LEVELS, AS WELL AS THE FORMATION OF AΒ PLAQUES, WERE EXAMINED. RESULTS: THE RESULTS SHOWED THAT INJECTION OF AΒ REDUCED SPATIAL LEARNING AND MEMORY ABILITIES IN THE BARNES MAZE TEST, WHICH WAS ACCOMPANIED BY DECREASES IN FIELD EXCITATORY POSTSYNAPTIC POTENTIAL (FEPSP) SLOPE, POPULATION SPIKE (PS) AMPLITUDE, AND TTG LEVEL AND INCREASES IN AΒ PLAQUE ACCUMULATION AND MDA CONTENT. IN CONTRAST, PCO TREATMENT IMPROVED ALL THE ABOVE-MENTIONED CHANGES IN THE AΒ-INFUSED RATS. CONCLUSIONS: THE RESULTS SUGGEST THAT AMELIORATION OF HIPPOCAMPAL SYNAPTIC PLASTICITY IMPAIRMENT, MODULATION OF OXIDANT/ANTIOXIDANT STATUS, AND INHIBITION OF AΒ PLAQUE FORMATION BY PCO MAY BE THE MECHANISMS BEHIND ITS PROTECTIVE EFFECT AGAINST AD-ASSOCIATED SPATIAL COGNITIVE DECLINE. © 2023, THE AUTHOR(S), UNDER EXCLUSIVE LICENCE TO SPRINGER-VERLAG GMBH GERMANY, PART OF SPRINGER NATURE.","ALZHEIMER’S DISEASE; AMYLOID-BETA; BARNES MAZE TEST; LONG-TERM POTENTIATION; POLICOSANOL","ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MEMORY DISORDERS; OXIDANTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; AMYLOID BETA PROTEIN[1-40]; MALONALDEHYDE; PHOSPHATE BUFFERED SALINE; POLICOSANOL; THIOL; AMYLOID BETA PROTEIN; ANTIOXIDANT; OXIDIZING AGENT; PEPTIDE FRAGMENT; POLICOSANOL; ACTION POTENTIAL AMPLITUDE; ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; COGNITION; COGNITIVE DECLINE; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; FIELD EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; LONG TERM POTENTIATION; MALE; NEUROPROTECTION; NONHUMAN; POPULATION SPIKE AMPLITUDE; RAT; SPATIAL LEARNING; SPATIAL MEMORY; ALZHEIMER DISEASE; ANIMAL; COGNITIVE DEFECT; COMPLICATION; DISEASE MODEL; HIPPOCAMPUS; MEMORY DISORDER; WISTAR RAT","NEUROPHYSIOLOGY RESEARCH CENTER, HAMADAN UNIVERSITY OF MEDICAL SCIENCES; SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES; BU-ALI SINA UNIVERSITY","FUNDING TEXT 1: THE RESULTS PRESENTED IN THIS PAPER WERE A PART OF SAMANEH SAFARI’S MSC THESIS THAT WAS SUPPORTED FINANCIALLY (GRANT NO.: 99-371) BY BU-ALI SINA UNIVERSITY, HAMADAN, IRAN. THE AUTHORS WOULD LIKE TO DEEPLY THANK MR. SHAHAB GHADERI (PH.D. STUDENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN) FOR HIS VALUABLE ASSISTANCE IN PREPARING THIS PAPER. THE AUTHORS WOULD ALSO LIKE TO GREATLY ACKNOWLEDGE MS. NAFISEH FARAJI, MR. ALI FATHI JOUZDANI, AND MS. MASOUMEH TAHERI FOR THEIR KIND SUPPORT. THE AUTHORS ARE GRATEFUL TO THE STAFF OF THE NEUROPHYSIOLOGY RESEARCH CENTER, HAMADAN UNIVERSITY OF MEDICAL SCIENCES FOR SUPPORTING THIS STUDY.; FUNDING TEXT 2: THE CURRENT STUDY WAS FUNDED (GRANT NO.: IR.BASU.REC.1398.029) BY FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN. ","AHMADI N., SAFARI S., MIRAZI N., KARIMI S.A., KOMAKI A., EFFECTS OF VANILLIC ACID ON AΒ(1–40)-INDUCED OXIDATIVE STRESS AND LEARNING AND MEMORY DEFICIT IN MALE RATS, BRAIN RES BULL, 170, PP. 264-273, (2021); ARAKI W., KAMETANI F., PROTECTION AGAINST AMYLOID-Β OLIGOMER NEUROTOXICITY BY SMALL MOLECULES WITH ANTIOXIDATIVE PROPERTIES: POTENTIAL FOR THE PREVENTION OF ALZHEIMER’S DISEASE DEMENTIA, ANTIOXIDANTS., 11, (2022); ARBEL-ORNATH M., HUDRY E., BOIVIN J.R., HASHIMOTO T., TAKEDA S., KUCHIBHOTLA K.V., HOU S., LATTARULO C.R., BELCHER A.M., SHAKERDGE N., TRUJILLO P.B., MUZIKANSKY A., BETENSKY R.A., HYMAN B.T., BACSKAI B.J., SOLUBLE OLIGOMERIC AMYLOID-Β INDUCES CALCIUM DYSHOMEOSTASIS THAT PRECEDES SYNAPSE LOSS IN THE LIVING MOUSE BRAIN, MOL NEURODEGENER, 12, (2017); ARENDT T., SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE, ACTA NEUROPATHOL, 118, PP. 167-179, (2009); ASSOC A., ALZHEIMER’S ASSOCIATION REPORT 2015 ALZHEIMER’S DISEASE FACTS AND FIGURES, ALZHEIMERS DEMENT, 11, PP. 332-384, (2015); 2019 ALZHEIMER’S DISEASE FACTS AND FIGURES, ALZHEIMER’S DEMENT, 15, PP. 321-387, (2019); BENNY A., THOMAS J., ESSENTIAL OILS AS TREATMENT STRATEGY FOR ALZHEIMERʼS DISEASE: CURRENT AND FUTURE PERSPECTIVES, PLANTA MED, 85, PP. 239-248, (2019); BILLINGS L.M., ODDO S., GREEN K.N., MCGAUGH J.L., LAFERLA F.M., INTRANEURONAL ABETA CAUSES THE ONSET OF EARLY ALZHEIMER’S DISEASE-RELATED COGNITIVE DEFICITS IN TRANSGENIC MICE, NEURON, 45, PP. 675-688, (2005); BLISS T.V., COLLINGRIDGE G.L., A SYNAPTIC MODEL OF MEMORY: LONG-TERM POTENTIATION IN THE HIPPOCAMPUS, NATURE, 361, PP. 31-39, (1993); BOURDEL-MARCHASSON I., DELMAS-BEAUVIEUX M.C., PEUCHANT E., RICHARD-HARSTON S., DECAMPS A., REIGNIER B., EMERIAU J.P., RAINFRAY M., ANTIOXIDANT DEFENCES AND OXIDATIVE STRESS MARKERS IN ERYTHROCYTES AND PLASMA FROM NORMALLY NOURISHED ELDERLY ALZHEIMER PATIENTS, AGE AGEING, 30, PP. 235-241, (2001); BUCCELLATO F.R., D'ANCA M., FENOGLIO C., SCARPINI E., GALIMBERTI D., ROLE OF OXIDATIVE DAMAGE IN ALZHEIMER’S DISEASE AND NEURODEGENERATION: FROM PATHOGENIC MECHANISMS TO BIOMARKER DISCOVERY, ANTIOXIDANTS, 10, (2021); CALKINS M.J., MANCZAK M., MAO P., SHIRENDEB U., REDDY P.H., IMPAIRED MITOCHONDRIAL BIOGENESIS, DEFECTIVE AXONAL TRANSPORT OF MITOCHONDRIA, ABNORMAL MITOCHONDRIAL DYNAMICS AND SYNAPTIC DEGENERATION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE, HUM MOL GENET, 20, PP. 4515-4529, (2011); CALVO-RODRIGUEZ M., HOU S.S., SNYDER A.C., KHARITONOVA E.K., RUSS A.N., DAS S., FAN Z., MUZIKANSKY A., GARCIA-ALLOZA M., SERRANO-POZO A., HUDRY E., BACSKAI B.J., INCREASED MITOCHONDRIAL CALCIUM LEVELS ASSOCIATED WITH NEURONAL DEATH IN A MOUSE MODEL OF ALZHEIMER’S DISEASE, NAT COMMUN, 11, (2020); CASCELLA R., CECCHI C., CALCIUM DYSHOMEOSTASIS IN ALZHEIMER’S DISEASE PATHOGENESIS, INT J MOL SCI, 22, (2021); CHOI J.E., KIM S., LEE J., KIM K., KAANG B.K., CIRCADIAN REGULATION BY REV-ERBΑ MEDIATES HIPPOCAMPAL E-LTP IN A TIME-DEPENDENT MANNER, EXP NEUROBIOL, 27, PP. 344-349, (2018); DE FELICE F.G., VELASCO P.T., LAMBERT M.P., VIOLA K., FERNANDEZ S.J., FERREIRA S.T., KLEIN W.L., ABETA OLIGOMERS INDUCE NEURONAL OXIDATIVE STRESS THROUGH AN N-METHYL-D-ASPARTATE RECEPTOR-DEPENDENT MECHANISM THAT IS BLOCKED BY THE ALZHEIMER DRUG MEMANTINE, J BIOL CHEM, 282, PP. 11590-11601, (2007); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP BIOL MED (MAYWOOD), 241, PP. 1943-1949, (2016); ESPOSITO Z., BELLI L., TONIOLO S., SANCESARIO G., BIANCONI C., MARTORANA A., AMYLOID Β, GLUTAMATE, EXCITOTOXICITY IN ALZHEIMER’S DISEASE: ARE WE ON THE RIGHT TRACK?, CNS NEUROSCI THER, 19, PP. 549-555, (2013); FERREIRA S.T., KLEIN W.L., THE AΒ OLIGOMER HYPOTHESIS FOR SYNAPSE FAILURE AND MEMORY LOSS IN ALZHEIMER’S DISEASE, NEUROBIOL LEARN MEM, 96, PP. 529-543, (2011); GHADERI S., GHOLIPOUR P., KOMAKI A., SALEHI I., RASHIDI K., ESMAEIL KHOSHNAM S., RASHNO M., P-COUMARIC ACID AMELIORATES COGNITIVE AND NON-COGNITIVE DISTURBANCES IN A RAT MODEL OF ALZHEIMER’S DISEASE: THE ROLE OF OXIDATIVE STRESS AND INFLAMMATION, INT IMMUNOPHARMACOL, 112, (2022); GHADERI S., KOMAKI A., SALEHI I., BASIR Z., RASHNO M., POSSIBLE MECHANISMS INVOLVED IN THE PROTECTIVE EFFECTS OF CHRYSIN AGAINST LEAD-INDUCED COGNITIVE DECLINE: AN IN VIVO STUDY IN A RAT MODEL, BIOMED PHARMACOTHER, 157, (2022); GHOLIPOUR P., KOMAKI A., PARSA H., RAMEZANI M., THERAPEUTIC EFFECTS OF HIGH-INTENSITY INTERVAL TRAINING EXERCISE ALONE AND ITS COMBINATION WITH ECDYSTERONE AGAINST AMYLOID BETA-INDUCED RAT MODEL OF ALZHEIMER’S DISEASE: A BEHAVIORAL, BIOCHEMICAL, AND HISTOLOGICAL STUDY, NEUROCHEM RES, 47, PP. 2090-2108, (2022); GHOLIPOUR P., KOMAKI A., RAMEZANI M., PARSA H., EFFECTS OF THE COMBINATION OF HIGH-INTENSITY INTERVAL TRAINING AND ECDYSTERONE ON LEARNING AND MEMORY ABILITIES, ANTIOXIDANT ENZYME ACTIVITIES, AND NEURONAL POPULATION IN AN AMYLOID-BETA-INDUCED RAT MODEL OF ALZHEIMER’S DISEASE, PHYSIOL BEHAV, 251, (2022); GIORDANO C.R., TERLECKY L.J., BOLLIG-FISCHER A., WALTON P.A., TERLECKY S.R., AMYLOID-BETA NEUROPROTECTION MEDIATED BY A TARGETED ANTIOXIDANT, SCI REP, 4, (2014); GLANTZ L.A., GILMORE J.H., HAMER R.M., LIEBERMAN J.A., JARSKOG L.F., SYNAPTOPHYSIN AND POSTSYNAPTIC DENSITY PROTEIN 95 IN THE HUMAN PREFRONTAL CORTEX FROM MID-GESTATION INTO EARLY ADULTHOOD, NEUROSCIENCE, 149, PP. 582-591, (2007); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES, 62, (2018); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GUERRA Y.P., CUEVAS V.M., FERREIRO R.M., YERA A.O., DESPAIGNE S.J., EFFECTS OF POLICOSANOL PRE-TREATMENT ON BLOOD-BRAIN BARRIER DAMAGE INDUCED BY ISCHEMIA-REPERFUSION IN RATS, INT J PHARM SCI REV RES, 32, PP. 1-6, (2015); GUGLIELMOTTO M., GILIBERTO L., TAMAGNO E., TABATON M., OXIDATIVE STRESS MEDIATES THE PATHOGENIC EFFECT OF DIFFERENT ALZHEIMER’S DISEASE RISK FACTORS, FRONT AGING NEUROSCI, 2, (2010); HADIPOUR M., KAKA G., BAHRAMI F., MEFTAHI G.H., PIRZAD JAHROMI G., MOHAMMADI A., SAHRAEI H., CROCIN IMPROVED AMYLOID BETA INDUCED LONG-TERM POTENTIATION AND MEMORY DEFICITS IN THE HIPPOCAMPAL CA1 NEURONS IN FREELY MOVING RATS, SYNAPSE, 72, (2018); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED (MAYWOOD), 229, PP. 215-226, (2004); HSIEH H., BOEHM J., SATO C., IWATSUBO T., TOMITA T., SISODIA S., MALINOW R., AMPAR REMOVAL UNDERLIES ABETA-INDUCED SYNAPTIC DEPRESSION AND DENDRITIC SPINE LOSS, NEURON, 52, PP. 831-843, (2006); KAMAT P.K., KALANI A., RAI S., SWARNKAR S., TOTA S., NATH C., TYAGI N., MECHANISM OF OXIDATIVE STRESS AND SYNAPSE DYSFUNCTION IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE: UNDERSTANDING THE THERAPEUTICS STRATEGIES, MOL NEUROBIOL, 53, PP. 648-661, (2016); KAWAMOTO E.M., MUNHOZ C.D., GLEZER I., BAHIA V.S., CARAMELLI P., NITRINI R., GORJAO R., CURI R., SCAVONE C., MARCOURAKIS T., OXIDATIVE STATE IN PLATELETS AND ERYTHROCYTES IN AGING AND ALZHEIMER’S DISEASE, NEUROBIOL AGING, 26, PP. 857-864, (2005); KIM J.-H., LIM D.-K., SUH Y.-H., CHANG K.-A., LONG-TERM TREATMENT OF CUBAN POLICOSANOL ATTENUATES ABNORMAL OXIDATIVE STRESS AND INFLAMMATORY RESPONSE VIA AMYLOID PLAQUES REDUCTION IN 5XFAD MICE, ANTIOXIDANTS, 10, (2021); KNOBLOCH M., MANSUY I.M., DENDRITIC SPINE LOSS AND SYNAPTIC ALTERATIONS IN ALZHEIMER’S DISEASE, MOL NEUROBIOL, 37, PP. 73-82, (2008); KOMAKI A., ESTEKY H., EFFECTS OF NEONATAL C-FIBER DEPLETION ON NEOCORTICAL LONG-TERM POTENTIATION AND DEPRESSION, BRAIN RES, 1054, PP. 135-142, (2005); KOMAKI A., SHAHIDI S., LASHGARI R., HAGHPARAST A., MALAKOUTI S.M., NOORBAKHSH S.M., EFFECTS OF GABAERGIC INHIBITION ON NEOCORTICAL LONG-TERM POTENTIATION IN THE CHRONICALLY PREPARED RAT, NEUROSCI LETT, 422, PP. 181-186, (2007); KOMAKI H., FARAJI N., KOMAKI A., SHAHIDI S., ETAEE F., RAOUFI S., MIRZAEI F., INVESTIGATION OF PROTECTIVE EFFECTS OF COENZYME Q10 ON IMPAIRED SYNAPTIC PLASTICITY IN A MALE RAT MODEL OF ALZHEIMER’S DISEASE, BRAIN RES BULL, 147, PP. 14-21, (2019); LISMAN J., BUZSAKI G., EICHENBAUM H., NADEL L., RANGANATH C., REDISH A.D., VIEWPOINTS: HOW THE HIPPOCAMPUS CONTRIBUTES TO MEMORY, NAVIGATION AND COGNITION, NAT NEUROSCI, 20, PP. 1434-1447, (2017); MA T., HOEFFER C.A., WONG H., MASSAAD C.A., ZHOU P., IADECOLA C., MURPHY M.P., PAUTLER R.G., KLANN E., AMYLOID Β-INDUCED IMPAIRMENTS IN HIPPOCAMPAL SYNAPTIC PLASTICITY ARE RESCUED BY DECREASING MITOCHONDRIAL SUPEROXIDE, J NEUROSCI, 31, PP. 5589-5595, (2011); MA T., KLANN E., AMYLOID Β: LINKING SYNAPTIC PLASTICITY FAILURE TO MEMORY DISRUPTION IN ALZHEIMER’S DISEASE, J NEUROCHEM, 120, PP. 140-148, (2012); MANCZAK M., ANEKONDA T.S., HENSON E., PARK B.S., QUINN J., REDDY P.H., MITOCHONDRIA ARE A DIRECT SITE OF A BETA ACCUMULATION IN ALZHEIMER’S DISEASE NEURONS: IMPLICATIONS FOR FREE RADICAL GENERATION AND OXIDATIVE DAMAGE IN DISEASE PROGRESSION, HUM MOL GENET, 15, PP. 1437-1449, (2006); MARCOURAKIS T., CAMARINI R., KAWAMOTO E.M., SCORSI L.R., SCAVONE C., PERIPHERAL BIOMARKERS OF OXIDATIVE STRESS IN AGING AND ALZHEIMER’S DISEASE, DEMENT NEUROPSYCHOL, 2, PP. 2-8, (2008); MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR J NUTR, 97, PP. 381-388, (2007); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); MISRANI A., TABASSUM S., YANG L., MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS IN ALZHEIMER’S DISEASE, FRONT AGING NEUROSCI, 13, (2021); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., FRAGA V., MENENDEZ R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., MENDOZA N., VALLE M., JIMENEZ S., SANCHEZ J., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J PHARM SCI, 75, PP. 635-641, (2013); MOREIRA-SILVA D., CARRETTIERO D.C., OLIVEIRA A.S., RODRIGUES S., DOS SANTOS-LOPES J., CANAS P.M., CUNHA R.A., ALMEIDA M.C., FERREIRA T.L., ANANDAMIDE EFFECTS IN A STREPTOZOTOCIN-INDUCED ALZHEIMER’S DISEASE-LIKE SPORADIC DEMENTIA IN RATS, FRONT NEUROSCI, 12, (2018); MUSTO D., MARTORELLI L., RUSSO M., ESPOSITO G., AMATO M., ESPOSITO P., RIEGLER G., NON-ALCOHOLIC HEPATIC STEATOSIS: THE ROLE OF POLICOSANOLS IN ASSOCIATED HYPERLIPIDEMIA, MINERVA GASTROENTEROL DIETOL, 56, PP. 389-395, (2010); NASLUND J., HAROUTUNIAN V., MOHS R., DAVIS K.L., DAVIES P., GREENGARD P., BUXBAUM J.D., CORRELATION BETWEEN ELEVATED LEVELS OF AMYLOID BETA-PEPTIDE IN THE BRAIN AND COGNITIVE DECLINE, JAMA, 283, PP. 1571-1577, (2000); OLIVER D.M.A., REDDY P.H., SMALL MOLECULES AS THERAPEUTIC DRUGS FOR ALZHEIMER’S DISEASE, MOL CELL NEUROSCI, 96, PP. 47-62, (2019); PAXINOS G., WATSON C., THE RAT BRAIN IN STEREOTAXIC COORDINATES SIXTH EDITION BY, ACAD PRESS, 170, 10, (2006); RAHMAN M.M., LENDEL C., EXTRACELLULAR PROTEIN COMPONENTS OF AMYLOID PLAQUES AND THEIR ROLES IN ALZHEIMER’S DISEASE PATHOLOGY, MOL NEURODEGENER, 16, (2021); RAHMAN S.O., PANDA B.P., PARVEZ S., KAUNDAL M., HUSSAIN S., AKHTAR M., NAJMI A.K., NEUROPROTECTIVE ROLE OF ASTAXANTHIN IN HIPPOCAMPAL INSULIN RESISTANCE INDUCED BY AΒ PEPTIDES IN ANIMAL MODEL OF ALZHEIMER’S DISEASE, BIOMED PHARMACOTHER, 110, PP. 47-58, (2019); RAJASEKHAR K., SAMANTA S., BAGOBAND V., MURUGAN N.A., GOVINDARAJU T., ANTIOXIDANT BERBERINE-DERIVATIVE INHIBITS MULTIFACETED AMYLOID TOXICITY, ISCIENCE, 23, (2020); RAJMOHAN R., REDDY P.H., AMYLOID-BETA AND PHOSPHORYLATED TAU ACCUMULATIONS CAUSE ABNORMALITIES AT SYNAPSES OF ALZHEIMER’S DISEASE NEURONS, J ALZHEIMERS DIS, 57, PP. 975-999, (2017); RASHNO M., GHOLIPOUR P., SALEHI I., KOMAKI A., RASHIDI K., KHOSHNAM S.E., GHADERI S., P-COUMARIC ACID MITIGATES PASSIVE AVOIDANCE MEMORY AND HIPPOCAMPAL SYNAPTIC PLASTICITY IMPAIRMENTS IN ALUMINUM CHLORIDE-INDUCED ALZHEIMER’S DISEASE RAT MODEL, J FUNCT FOODS, 94, (2022); RUANGRITCHANKUL S., CHANTHARIT P., SRISUMA S., GRAY L.C., ADVERSE DRUG REACTIONS OF ACETYLCHOLINESTERASE INHIBITORS IN OLDER PEOPLE LIVING WITH DEMENTIA: A COMPREHENSIVE LITERATURE REVIEW, THER CLIN RISK MANAG, 17, PP. 927-949, (2021); RUSH T., MARTINEZ-HERNANDEZ J., DOLLMEYER M., FRANDEMICHE M.L., BOREL E., BOISSEAU S., JACQUIER-SARLIN M., BUISSON A., SYNAPTOTOXICITY IN ALZHEIMER’S DISEASE INVOLVED A DYSREGULATION OF ACTIN CYTOSKELETON DYNAMICS THROUGH COFILIN 1 PHOSPHORYLATION, J NEUROSCI, 38, PP. 10349-10361, (2018); SCHMIDT C.W.P., PHARMACOLOGY OF NMDA (N-METHYL-D-ASPARTATE) RECEPTOR ANTAGONISTS IN ALZHEIMER’S DISEASE, PHARMACOLOGICAL TREATMENT OF ALZHEIMER’S DISEASE: SPRINGER. P, PP. 69-79, (2022); SHANKAR G.M., BLOODGOOD B.L., TOWNSEND M., WALSH D.M., SELKOE D.J., SABATINI B.L., NATURAL OLIGOMERS OF THE ALZHEIMER AMYLOID-BETA PROTEIN INDUCE REVERSIBLE SYNAPSE LOSS BY MODULATING AN NMDA-TYPE GLUTAMATE RECEPTOR-DEPENDENT SIGNALING PATHWAY, J NEUROSCI, 27, PP. 2866-2875, (2007); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J FUNCT FOODS, 57, PP. 351-360, (2019); SIMUNKOVA M., ALWASEL S.H., ALHAZZA I.M., JOMOVA K., KOLLAR V., RUSKO M., VALKO M., MANAGEMENT OF OXIDATIVE STRESS AND OTHER PATHOLOGIES IN ALZHEIMER’S DISEASE, ARCH TOXICOL, 93, PP. 2491-2513, (2019); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ET AL., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); TAYSI S., POLAT F., GUL M., SARI R.A., BAKAN E., LIPID PEROXIDATION, SOME EXTRACELLULAR ANTIOXIDANTS, AND ANTIOXIDANT ENZYMES IN SERUM OF PATIENTS WITH RHEUMATOID ARTHRITIS, RHEUMATOL INT, 21, PP. 200-204, (2002); TONNIES E., TRUSHINA E., OXIDATIVE STRESS, SYNAPTIC DYSFUNCTION, AND ALZHEIMER’S DISEASE, J ALZHEIMERS DIS, 57, PP. 1105-1121, (2017); URIBARRI E., LAGUNA A., SIERRA R., RICARDO Y., PHYSICO-MECHANICAL CHARACTERIZATION OF POLICOSANOL, A NOVEL HYPOCHOLESTEROLEMIC DRUG, DRUG DEV IND PHARM, 28, PP. 89-93, (2002); VELASQUEZ-JIMENEZ D., CORELLA-SALAZAR D.A., ZUNIGA-MARTINEZ B.S., DOMINGUEZ-AVILA J.A., MONTIEL-HERRERA M., SALAZAR-LOPEZ N.J., RODRIGO-GARCIA J., VILLEGAS-OCHOA M.A., GONZALEZ-AGUILAR G.A., PHENOLIC COMPOUNDS THAT CROSS THE BLOOD-BRAIN BARRIER EXERT POSITIVE HEALTH EFFECTS AS CENTRAL NERVOUS SYSTEM ANTIOXIDANTS, FOOD FUNCT, 12, PP. 10356-10369, (2021); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOL SIN, 31, PP. 765-774, (2010); WU C., YANG L., LI Y., DONG Y., YANG B., TUCKER L.D., ZONG X., ZHANG Q., EFFECTS OF EXERCISE TRAINING ON ANXIOUS-DEPRESSIVE-LIKE BEHAVIOR IN ALZHEIMER RAT, MED SCI SPORTS EXERC, 52, PP. 1456-1469, (2020); YANG Q., ZHAO Q., YIN Y., MIR-133B IS A POTENTIAL DIAGNOSTIC BIOMARKER FOR ALZHEIMER’S DISEASE AND HAS A NEUROPROTECTIVE ROLE, EXP THER MED, 18, PP. 2711-2718, (2019); ZHANG H., JIANG X., MA L., WEI W., LI Z., CHANG S., WEN J., SUN J., LI H., ROLE OF AΒ IN ALZHEIMER’S-RELATED SYNAPTIC DYSFUNCTION, FRONT CELL DEV BIOL, 10, (2022); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT MED THER, 21, (2021); ZHAO X.L., WANG W.A., TAN J.X., HUANG J.K., ZHANG X., ZHANG B.Z., WANG Y.H., YANGCHENG H.Y., ZHU H.L., SUN X.J., HUANG F.D., EXPRESSION OF BETA-AMYLOID INDUCED AGE-DEPENDENT PRESYNAPTIC AND AXONAL CHANGES IN DROSOPHILA, J NEUROSCI, 30, PP. 1512-1522, (2010); ZHAO Y., BHATTACHARJEE S., JONES B.M., HILL J.M., CLEMENT C., SAMBAMURTI K., DUA P., LUKIW W.J., BETA-AMYLOID PRECURSOR PROTEIN (ΒAPP) PROCESSING IN ALZHEIMER’S DISEASE (AD) AND AGE-RELATED MACULAR DEGENERATION (AMD), MOL NEUROBIOL, 52, PP. 533-544, (2015)","N. MIRAZI; DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN; EMAIL: MIRAZI@BASU.AC.IR; A. KOMAKI; DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN; EMAIL: ALIREZAKOMAKI@GMAIL.COM","SPRINGER SCIENCE AND BUSINESS MEDIA DEUTSCHLAND GMBH","ENGLISH","PSYCHOPHARMACOLOGY","ARTICLE","ISI","2-S2.0-85147184931","PSYCHOPHARMACOLOGY","BU-ALI SINA UNIVERSITY;BU-ALI SINA UNIVERSITY;BU-ALI SINA UNIVERSITY;HAMADAN UNIVERSITY OF MEDICAL SCIENCES;BU-ALI SINA UNIVERSITY;ASADABAD SCHOOL OF MEDICAL SCIENCES;HAMADAN UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;BU-ALI SINA UNIVERSITY;NOTREPORTED;NOTREPORTED;HAMADAN UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"SAFARI S, 2023, PSYCHOPHARMACOLOGY","SAFARI S, 2023, PSYCHOPHARMACOLOGY"
"ZHANG X;MA C;SUN L;HE Z;FENG Y;LI X;GAN J;CHEN X","ZHANG, XIN (56376070800); MA, CHENJING (57217217257); SUN, LONG (37060218600); HE, ZHAO (55223278500); FENG, YING (34770356600); LI, XIAN (55252109700); GAN, JIN (55234305200); CHEN, XIAOMING (55739155400)","EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID ΒPEPTIDEINDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMERS DISEASE",2021,"BMC COMPLEMENTARY MEDICINE AND THERAPIES","21","",18,"10.1186/s12906-021-03278-2","THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA","BACKGROUND: ALZHEIMER’S DISEASE (AD), AN AGE-RELATED NEURODEGENERATIVE DISORDER AND A SERIOUS PUBLIC HEALTH CONCERN, IS MAINLY CAUSED BY Β-AMYLOID (AΒ)-INDUCED TOXICITY. CURRENTLY, A LIMITED NUMBER OF DRUGS ARE EFFECTIVE AGAINST AD, AND ONLY A FEW ARE USED FOR ITS TREATMENT. ACCORDING TO TRADITIONAL CHINESE MEDICINE, WHITE WAX IS MAINLY COMPOSED OF POLICOSANOL, HEXACOSANOL, AND OCTACOSANOL. POLICOSANOL HAS BEEN SHOWN TO REDUCE LIPID LEVELS IN BLOOD AND ALLEVIATE THE SYMPTOMS ASSOCIATED WITH DIABETIC COMPLICATIONS AND NEURODEGENERATIVE DISORDERS, SUCH AS PARKINSON’S DISEASE AND AD. HOWEVER, THE EFFICACY OF POLICOSANOL DEPENDS ON THE PURITY AND COMPOSITION OF THE PREPARATION, AND THE THERAPEUTIC EFFICACY OF POLICOSANOL DERIVED FROM INSECT WAX (PIW) IN AD IS UNKNOWN. METHODS: HERE, WE IDENTIFIED THE MAIN COMPONENTS OF PIW AND INVESTIGATED THE EFFECTS OF PIW ON AΒ-INDUCED TOXICITY AND LIFE-SPAN IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF AD, CL4176. FURTHERMORE, WE ESTIMATED THE EXPRESSION OF AMYLOID PRECURSOR-LIKE PROTEIN (APL-1) AND THE GENES INVOLVED IN VARIOUS PATHWAYS ASSOCIATED WITH LONGEVITY AND ALLEVIATION OF AD-RELATED SYMPTOMS IN PIW-FED CL4176. RESULTS: PIW MAINLY CONSISTS OF TETRACOSANOL, HEXACOSANOL, OCTACOSANOL, AND TRIACONTANOL; IT COULD DECREASE THE AΒ-INDUCED PARALYSIS RATE FROM 86.87 TO 66.97% (P < 0.01) AND EXTEND THE LIFE-SPAN FROM 6.2 D TO 7.8 D (P < 0.001) IN CL4176 WORMS. FURTHERMORE, PIW DOWNREGULATED APL-1, A GENE KNOWN TO BE ASSOCIATED WITH THE LEVELS OF AΒ DEPOSITS IN C. ELEGANS. ADDITIONALLY, OUR RESULTS SHOWED THAT PIW MODULATED THE EXPRESSION OF GENES ASSOCIATED WITH LONGEVITY-RELATED PATHWAYS SUCH AS HEAT SHOCK RESPONSE, ANTI-OXIDATIVE STRESS, AND GLUTAMINE CYSTEINE SYNTHETASE. CONCLUSION: OUR FINDINGS SUGGEST THAT PIW MAY BE A POTENTIAL THERAPEUTIC AGENT FOR THE PREVENTION AND TREATMENT OF AD. HOWEVER, ITS EFFECTS ON MURINE MODELS AND PATIENTS WITH AD NEED TO BE EXPLORED FURTHER. © 2021, THE AUTHOR(S).","ALZHEIMER’S DISEASE; C. ELEGANS; CL4176; INSECT WAX; POLICOSANOL; Β-AMYLOID","ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; FATTY ALCOHOLS; INSECTA; LONGEVITY; PARALYSIS; WAXES; ALKANOL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN; EXTRACELLULAR SUPEROXIDE DISMUTASE; HEAT SHOCK TRANSCRIPTION FACTOR 1; HEXACOSANOL; OCTACOSANOL; POLICOSANOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TETRACOSANOL; TETRAHYDROFURAN; TRIACONTANOL; UNCLASSIFIED DRUG; WAX; AMYLOID BETA PROTEIN; FATTY ALCOHOL; POLICOSANOL; WAX; ALZHEIMER DISEASE; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCAT 1 GENE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DAF 16 GENE; DOWN REGULATION; DRUG EFFICACY; ESCHERICHIA COLI; GAS CHROMATOGRAPHY; GCS 1 GENE; GENE; GENE EXPRESSION; HEAT SHOCK RESPONSE; HOMEOSTASIS; HSP 16.2 GENE; LIFESPAN; LIPID METABOLISM; LIPL 4 GENE; LIPS 17 GENE; NONHUMAN; OXIDATIVE STRESS; PARALYSIS; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKN 1 GENE; TOXICITY; ALZHEIMER DISEASE; ANIMAL; CAENORHABDITIS ELEGANS; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; INSECT; LONGEVITY; PARALYSIS; TRANSGENIC ANIMAL","CHINESE ACADEMY OF FORESTRY, CAF, (CAFYBB2018ZB007)","THIS WORK WAS SUPPORTED BY GRANTS FROM THE CHINESE ACADEMY OF FORESTRY (NO. CAFYBB2018ZB007). ","CHEN X.M., NATURAL POPULATION ECOLOGY OF ERICERUS PELA, PP. 1-8, (2011); ZOU S.W., A HISTORY OF CHINESE ENTOMOLOGY, PP. 112-114, (1982); ZHOU Y., THE HISTORY OF ENTOMOLOGY IN CHINA, PP. 41-42, (1980); YANG P., CHEN X.M., PROTEIN PROFILES OF CHINESE WHITE WAX SCALE, ERICERUS PELA, AT THE MALE PUPAL STAGE BY HIGH-THROUGHPUT PROTEOMICS, ARCH INSECT BIOCHEM PHYSIOL, 87, 4, PP. 214-233, (2014); YANG P., CHEN X.M., LIU W.W., FENG Y., SUN T., TRANSCRIPTOME ANALYSIS OF SEXUALLY DIMORPHIC CHINESE WHITE WAX SCALE INSECTS REVEALS KEY DIFFERENCES IN DEVELOPMENTAL PROGRAMS AND TRANSCRIPTION FACTOR EXPRESSION, SCI REP, 5, 1, PP. 1-8, (2015); HOU X.Y., CAO M.H., GONG J., LI N., GAO A., JIA X., NI S.F., ZHAO T., ZHENG H., OVERVIEW OF PHARMACOLOGICAL RESEARCH OF INSECT WAX, J ANHUI AGRIC SCI, 39, 5, PP. 2817-2818, (2011); WANG Z.D., FENG Y., MA L.Y., LI X., DING W.F., CHEN X.M., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMED PHARMACOTHER, 89, PP. 438-446, (2017); LI S.Z., (1926); FENG Y., CHEN X.M., MA Y., HE Z., EXPERIMENTAL STUDY ON IMMUNOMODULATION OF WHITE WAX SCALE (ERICERUS PELA CHAVANNES), FOR RES, 19, 2, PP. 221-224, (2006); FENG Y., HE Z., LI X., CHENG Z.Y., SUN L., IMMUNOMODULATORY AND ANTITUMOR ACTIVITIES OF POLYSACCHARIDE FROM CHINESE WHITE WAX SCALE, FOR RES, 27, 3, PP. 388-392, (2014); HE Z., LI X., SUN L., CHEN Z.Y., FENG Y., ANTIOXIDANT ACTIVITIES OF FIVE INSECT POLYSACCHARIDES IN VITRO, J ENVIRON ENTOMOL, 37, 1, PP. 61-67, (2015); HE Z., SUN L., FENG Y., CHENG X.M., THE EXTRACTION OF POLYSACCHARIDE FROM WHITE WAX SCALE AND ANALYSIS OF MONOSACCHARIDE COMPOSITIONS, FOR RES, 21, 6, PP. 792-796, (2008); LIN L., ZHOU Y., LI H., PANG D., ZHANG L., LU X., CHEN Z., ZHAO X., ZUO D., SUN L., POLYSACCHARIDE EXTRACTED FROM CHINESE WHITE WAX SCALE AMELIORATES 2,4-DINITROCHLOROBENZENE-INDUCED ATOPIC DERMATITIS-LIKE SYMPTOMS IN BALB/C MICE, SAUDI PHARM J, 25, 4, PP. 625-632, (2017); MA L.Y., WANG Y.Q., ZHANG Z.Q., GAN J., ZHENG H., GUO Y.H., ET AL., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, CHEM INDUSTRY FOREST PROD, 29, 5, PP. 6-10, (2009); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEM, 81, 3, PP. 345-349, (2004); HARRABIA S., BOUKHCHINAA S., MAYERB P.M., KALLELA H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, 3, PP. 918-923, (2009); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, 15, PP. 5359-5362, (2006); MARINANGELI C.P.F., JONES P.J.H., KASSIS A.N., ESKIN M.N.A., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRITI REV FOOD SCI NUTR, 50, 3, PP. 259-267, (2010); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, 1, PP. 61-64, (1998); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METABOL, 39, 5, PP. 279-284, (1995); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONGTERM THERAPY WITH OCTACOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, 9, PP. 469-473, (1998); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS, 17, 1, PP. 1-7, (2018); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, 11, PP. 376-383, (2010); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, 10, PP. 891-897, (2002); DULLENS S.P., MENSINK R.P., BRAGT M.C., KIES A.K., PLAT J., EFFECTS OF EMULSIFIED POLICOSANOLS WITH DIFFERENT CHAIN LENGTHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTOR-DEFICIENT MICE, J LIPID RES, 49, 4, PP. 790-796, (2008); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, 9, PP. 656-661, (2010); AGOSTONI C., BRESSON J.L., FAIRWEATHER-TAIT S., FLYNN A., GOLLY I., KORHONEN H., SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL-CHOLESTEROL CO, EUR FOOD SAFETY AUTHORITY, 9, 6, (2011); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP BIOL MED, 241, 17, PP. 1943-1949, (2016); LEE J.Y., CHOI H.Y., KANG Y.R., CHANG H.B., CHUN H.S., LEE M.S., KWON Y.I., EFFECTS OF LONG-TERM SUPPLEMENTATION OF POLICOSANOL ON BLOOD CHOLESTEROL/GLUCOSE LEVELS AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY IN A RAT MODEL FED HIGH CHOLESTEROL DIETS, FOOD SCI BIOTECHNOL, 25, 3, PP. 899-904, (2016); SANCHEZ-LOPEZ J., ILLNAIT-FERRER J., MAS-FERREIRO R., MENDOZA-CASTANO S., FERNANDEZ-DORTA L., MESA-ANGARICA M., ET AL., LONG-TERM EFFECT OF POLICOSANOL ON THE FUNCTIONAL RECOVERY OF NON-CARDIOEMBOLIC ISCHEMIC STROKE PATIENTS: A ONE YEAR STUDY, REV NEUROL, 64, 4, PP. 153-161, (2017); MA J.J., MA L.Y., ZHANG H., ZHANG Z.Q., WANG Y.Q., THE PREPARATION AND EVALUATION OF EFFICACY ON SKIN WOUND HEALING IN MICE OF INSECT WAX COMPOUND OINTMENT, J ENVIRON ENTOMOL, 40, 6, PP. 1238-1247, (2018); WANG Z.D., FENG Y., LI X., DING W.F., CHEN X.M., EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX TWEEN AQUEOUS SOLUTION ON HFDPCS, FOR RES, 30, 1, PP. 41-45, (2017); WANG Z.D., LI X., MECHANISM OF WHITE WAX ON TREATING SEBORRHEIC ALOPECIA, CHIN J ETHNOMED ETHNOPHARM, 28, 10, PP. 17-21, (2019); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOL SIN, 31, 7, PP. 765-774, (2010); RENOUDET V.V., COSTA-MALLEN P., HOPKINS E., A DIET LOW IN ANIMAL FAT AND RICH IN N-HEXACOSANOL AND FISETIN IS EFFECTIVE IN REDUCING SYMPTOMS OF PARKINSON’S DISEASE, J MED FOOD, 15, 8, PP. 758-761, (2012); MOOSBRUGGER I., BISCHOFF P., BECK J.P., BORG J., STUDIES ON THE IMMUNOLOGICAL EFFECTS OF FATTY ALCOHOLS: I. EFFECTS OF N-HEXACOSANOL ON MURINE MACROPHAGES IN CULTURE, INT J IMMUNOPHARMACOL, 14, 2, PP. 293-302, (1992); GOEDERT M., SPILLANTINI M.G., A CENTURY OF ALZHEIMER’S DISEASE, SCIENCE, 314, 5800, PP. 777-781, (2006); SELKOE D.J., ALZHEIMER’S DISEASE GENES, PROTEINS, AND THERAPY, PHYSIOL REV, 8, 2, PP. 741-766, (2001); SNYDER S.W., LADROR U.S., WADE W.S., WANG G.T., BARRETT L.W., MATAYOSHI E.D., HUFFAKER H.J., KRAFFT G.A., HOLZMAN T.F., AMYLOID BETA AGGREGATION SELECTIVE INHIBITION OF AGGREGATION IN MIXTURES OF AMYLOID WITH DIFFERENT CHAIN LENGTHS, BIOPHYS J, 67, 3, PP. 1216-1228, (1994); SHINAGAWA S., SHIGETA M., ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER’S DISEASE, BRAIN NERVE, 66, 5, PP. 507-516, (2014); FOLCH J., BUSQUETS O., ETTCHETO M., SANCHEZ-LOPEZ E., CASTRO-TORRESA R.D., VERDAGUER E., ET AL., MEMANTINE FOR THE TREATMENT OF DEMENTIA: A REVIEW ON ITS CURRENT AND FUTURE APPLICATIONS, J ALZHEIMERS DIS, 62, 3, PP. 1223-1240, (2018); ANAND R., GILL K.D., MAHDI A.A., THERAPEUTICS OF ALZHEIMER'S DISEASE: PAST, PRESENT AND FUTURE, NEUROPHARMACOLOGY, 76, PP. 27-50, (2014); MISRA S., MEDHI B., DRUG DEVELOPMENT STATUS FOR ALZHEIMER'S DISEASE: PRESENT SCENARIO, NEUROL SCI, 34, 6, PP. 831-839, (2013); LEMERE C.A., MASLIAH E., CAN ALZHEIMER DISEASE BE PREVENTED BY AMYLOID-Β IMMUNOTHERAPY?, NAT REV NEUROL, 6, 2, PP. 108-119, (2010); LINK C.D., EXPRESSION OF HUMAN BETA-AMYLOID PEPTIDE IN TRANSGENIC CAENORHABDITIS ELEGANS, PROC NATL ACAD SCI U S A, 92, 27, PP. 9368-9372, (1995); LINK C.D., JOHNSON C.J., FONTE V., PAUPARD M.-C., HALL D.H., STYREN S., MATHIS C.A., KLUNK W.E., VISUALIZATION OF FIBRILLAR AMYLOID DEPOSITS IN LIVING, TRANSGENIC CAENORHABDITIS ELEGANS ANIMALS USING THE SENSITIVE AMYLOID DYE, X-34, NEUROBIOL AGING, 22, 2, PP. 217-226, (2001); WU Y., WU Z., BUTKO P., CHRISTEN Y., LAMBERT M.P., KLEIN W.L., LINK C.D., LUO Y., AMYLOID-BETA-INDUCED PATHOLOGICAL BEHAVIORS ARE SUPPRESSED BY GINKGO BILOBA EXTRACT EGB 761 AND GINKGOLIDES IN TRANSGENIC CAENORHABDITIS ELEGANS, J NEUROSCI, 26, 50, PP. 13102-13113, (2006); SANGHA J.S., SUN X., WALLY O.S., ZHANG K., JI X., WANG Z., ET AL., LIUWEI DIHUANG (LWDH), A TRADITIONAL CHINESE MEDICINAL FORMULA, PROTECTS AGAINST BETA-AMYLOID TOXICITY IN TRANSGENIC CAENORHABDITIS ELEGANS, PLOS ONE, 7, 8, PP. 1-10, (2012); DIOMEDE L., CASSATA G., FIORDALISO F., SALIO M., AMI D., NATALELLO A., DOGLIA S.M., DE LUIGI A., SALMONA M., TETRACYCLINE AND ITS ANALOGUES PROTECT CAENORHABDITIS ELEGANS FROM Β AMYLOID-INDUCED TOXICITY BY TARGETING OLIGOMERS, NEUROBIOL DIS, 40, 2, PP. 424-431, (2010); LUO X.H., ZHANG Y.Y., CHEN X.Y., SUN M.L., LI S., WANG H.B., LIGNANS FROM THE ROOTS OF ACORUS TATARINOWII SCHOTT AMELIORATE BETA AMYLOID-INDUCED TOXICITY IN TRANSGENIC CAENORHABDITIS ELEGANS, FITOTERAPIA, 108, PP. 5-8, (2016); TULLET J.M.A., HERTWECK M., AN J.H., BAKER J., JI Y.H., SHU L., ET AL., DIRECT INHIBITION OF THE LONGEVITY-PROMOTING FACTOR SKN-1 BY INSULIN-LIKE SIGNALING IN C. ELEGANS, CELL, 132, 6, PP. 1025-1038, (2008); ABBAS S., WINK M., EPIGALLOCATECHIN GALLATE INHIBITS BETA AMYLOID OLIGOMERIZATION IN CAENORHABDITIS ELEGANS AND AFFECTS THE DAF-2/INSULIN-LIKE SIGNALING PATHWAY, PHYTOMEDICINE, 17, 11, PP. 902-909, (2010); ZHANG X.G., WANG X., ZHOU T.T., WU X.F., PENG Y., ZHANG W.Q., LI S., ZHAO J., SCORPION VENOM HEAT-RESISTANT PEPTIDE PROTECTS TRANSGENIC CAENORHABDITIS ELEGANS FROM Β-AMYLOID TOXICITY, FRONT PHARMACOL, 7, PP. 1-9, (2016); LI F., CUI X.D., MA X.L., LI J., WANG Z.H., GLUTAREDOXIN DELAYS THE TOXICITY INDUCED BY Β-AMYLOID IN AD TRANSGENIC C.ELEGANS IN AD TRANSGENIC C.ELEGANS, CHIN J BIOCHEM MOL BIOL, 34, 8, PP. 844-853, (2018); KENYON C.J., THE GENETICS OF AGEING, NATURE, 464, 7288, PP. 504-512, (2010); GUTIERREZ-ZEPEDA A., SANTELL R., WU Z., BROWN M., WU Y., KHAN I., LINK C.D., ZHAO B., LUO Y., SOY ISOFLAVONE GLYCITEIN PROTECTS AGAINST BETA AMYLOID-INDUCED TOXICITY AND OXIDATIVE STRESS IN TRANSGENIC CAENORHABDITIS ELEGANS, BMC NEUROSCI, 6, 54, PP. 1-9, (2005); CHEN W., LIN H.R., WEI C.M., LUO X.H., SUN M.L., YANG Z.Z., CHEN X.Y., WANG H.B., ECHINACOSIDE, A PHENYLETHANOID GLYCOSIDE FROM CISTANCHE DESERTICOLA, EXTENDS LIFESPAN OF CAENORHABDITIS ELEGANS AND PROTECTS FROM AΒ-INDUCED TOXICITY, BIOGERONTOLOGY, 19, 1, PP. 47-65, (2018); AN J.H., BLACKWELL T.K., SKN-1 LINKS C. ELEGANS MESENDODERMAL SPECIFICATION TO A CONSERVED OXIDATIVE STRESS RESPONSE, GENES DEV, 17, 15, PP. 1882-1893, (2003); WIESE M., ANTEBI A., ZHENG H., INTRACELLULAR TRAFFICKING AND SYNAPTIC FUNCTION OF APL-1 IN CAENORHABDITIS ELEGANS, PLOS ONE, 5, 9, PP. 1-12, (2010); EWALD C.Y., RAPS D.A., LI C., APL-1, THE ALZHEIMER'S AMYLOID PRECURSOR PROTEIN IN CAENORHABDITIS ELEGANS, MODULATES MULTIPLE METABOLIC PATHWAYS THROUGHOUT DEVELOPMENT, GENETICS, 191, 2, PP. 493-507, (2012); LORENZO N., ALTRUDA F., SILENGO L., DEL CARMEN DOMINGUEZ M., APL-1, AN ALTERED PEPTIDE LIGAND DERIVED FROM HEAT-SHOCK PROTEIN, ALONE OR COMBINED WITH METHOTREXATE ATTENUATES MURINE COLLAGEN-INDUCED ARTHRITIS, CLIN EXP MED, 17, 2, PP. 209-216, (2017); DOUGLAS P.M., BAIRD N.A., SIMIC M.S., UHLEIN S., MCCORMICK M.A., WOLFF S.C., ET AL., HETEROTYPIC SIGNALS FROM NEURAL HSF-1 SEPARATE THERMOTOLERANCE FROM LONGEVITY, CELL REP, 12, 7, PP. 1196-1204, (2015); LINK C.D., CYPSER J.R., JOHNSON C.J., JOHNSON T.E., DIRECT OBSERVATION OF STRESS RESPONSE IN CAENORHABDITIS ELEGANS USING A REPORTER TRANSGENE, CELL STRESS CHAPERONES, 4, 4, PP. 235-242, (1999); PRAHLAD V., CORNELIUS T., MORIMOTO R.I., REGULATION OF THE CELLULAR HEAT SHOCK RESPONSE IN CAENORHABDITIS ELEGANS BY THERMOSENSORY NEURONS, SCIENCE, 320, 5877, PP. 811-814, (2008); FONTE V., KIPP D.R., YERG J., MERIN D., LINK C.D., SUPPRESSION OF IN VIVO BETA-AMYLOID PEPTIDE TOXICITY BY OVEREXPRESSION OF THE HSP-16.2 SMALL CHAPERONE PROTEIN, J BIOL CHEM, 283, 2, PP. 784-791, (2008); GERSTBREIN B., STAMATAS G., KOLLIAS N., DRISCOLL M., IN VIVO SPECTROFLUORIMETRY REVEALS ENDOGENOUS BIOMARKERS THAT REPORT HEALTHSPAN AND DIETARY RESTRICTION IN CAENORHABDITIS ELEGANS, AGING CELL, 4, 3, PP. 127-137, (2005); ZHAO Y., ZHAO B.L., OXIDATIVE STRESS AND THE PATHOGENESIS OF ALZHEIMER'S DISEASE, OXID MED CELL LONGEV, 2013, PP. 1-10, (2013); LOVELL M.A., EHMANN W.D., BUTLER S.M., MARKESBERY W.R., ELEVATED THIOBARBITURIC ACID-REACTIVE SUBSTANCES AND ANTIOXIDANT ENZYME ACTIVITY IN THE BRAIN IN ALZHEIMER'S DISEASE, NEUROLOGY, 45, 8, PP. 1594-1601, (1995); CONWAY M.E., ALZHEIMER’S DISEASE: TARGETING THE GLUTAMATERGIC SYSTEM, BIOGERONTOLOGY, 21, 3, PP. 257-274, (2020); BUTTERFIELD D.A., POCERNICH C.B., THE GLUTAMATERGIC SYSTEM AND ALZHEIMER'S DISEASE, CNS DRUGS, 17, 9, PP. 641-652, (2003); HULL J., PATEL V., EL HINDY M., LEE C., ODELEYE E., HEZWANI M., ET AL., REGIONAL INCREASE IN THE EXPRESSION OF THE BCAT PROTEINS IN ALZHEIMER'S DISEASE BRAIN: IMPLICATIONS IN GLUTAMATE TOXICITY, J ALZHEIMERS DIS, 45, 3, PP. 891-905, (2015); MANSFELD J., URBAN N., PRIEBE S., GROTH M., FRAHM C., HARTMANN N., GEBAUER J., RAVICHANDRAN M., DOMMASCHK A., SCHMEISSER S., KUHLOW D., MONAJEMBASHI S., BREMER-STRECK S., HEMMERICH P., KIEHNTOPF M., ZAMBONI N., ENGLERT C., GUTHKE R., KALETA C., PLATZER M., SUHNEL J., WITTE O.W., ZARSE K., RISTOW M., BRANCHED-CHAIN AMINO ACID CATABOLISM IS A CONSERVED REGULATOR OF PHYSIOLOGICAL AGEING, NAT COMMUN, 6, 1, PP. 1-12, (2015); TONJES M., BARBUS S., PARK Y.J., WANG W., SCHLOTTER M., LINDROTH A.M., ET AL., BCAT1 PROMOTES CELL PROLIFERATION THROUGH AMINO ACID CATABOLISM IN GLIOMAS CARRYING WILD-TYPE IDH1, NAT MED, 19, 7, PP. 1-11, (2013); LANG C.H., LYNCH C.J., VARY T.C., BCATM DEFICIENCY AMELIORATES ENDOTOXIN-INDUCED DECREASE IN MUSCLE PROTEIN SYNTHESIS AND IMPROVES SURVIVAL IN SEPTIC MICE, AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, 299, 3, PP. 935-944, (2010); GRECO D., KOTRONEN A., WESTERBACKA J., PUIG O., ARKKILA P., KIVILUOTO T., GENE EXPRESSION IN HUMAN NAFLD, AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, 294, 5, PP. 1281-1287, (2008)","Y. FENG; THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, RESEARCH INSTITUTE OF RESOURCE INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA; EMAIL: RIRIFY@139.COM","BIOMED CENTRAL LTD","ENGLISH","BMC COMPL. MED.THERAPIES","ARTICLE","ISI","2-S2.0-85103572290","BMC COMPL MEDTHERAPIES","RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS;RESEARCH INSTITUTE OF RESOURCE INSECTS","NOTREPORTED;RESEARCH INSTITUTE OF RESOURCE INSECTS;NOTREPORTED",NA,"ZHANG X, 2021, BMC COMPL MEDTHERAPIES","ZHANG X, 2021, BMC COMPL MEDTHERAPIES"
"WONGWAIWECH D;KAMCHONEMENUKOOL S;HO C;LI S;MAJAI N;RUNGRAT T;SUJIPULI K;PAN M;WEERAWATANAKORN M","WONGWAIWECH, DONPORN (57202775373); KAMCHONEMENUKOOL, SUDTHIDA (57219992228); HO, CHI-TANG (56510763200); LI, SHIMING (55741057400); MAJAI, NUTTHAPORN (57881135000); RUNGRAT, TEPSUDA (56067998300); SUJIPULI, KAWEE (57194178928); PAN, MIN-HSIUNG (7202544934); WEERAWATANAKORN, MONTHANA (55976489600)","BIOACTIVES FROM CRUDE RICE BRAN OILS EXTRACTED USING GREEN TECHNOLOGY",2023,"MOLECULES","28","",6,"10.3390/molecules28062457","DEPARTMENT OF AGRO-INDUSTRY, RAJAMANGALA UNIVERSITY OF TECHNOLOGY LANNA TAK, 41/1 MOO 7, MAI NGAM, MUEANG, TAK, 63000, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF FOOD SCIENCE, RUTGERS UNIVERSITY, 65 DUDLEY ROAD, NEW BRUNSWICK, 08901, NJ, UNITED STATES;DEPARTMENT OF FOOD SCIENCE, COLLEGE OF LIFE SCIENCES, HUANGGANG NORMAL UNIVERSITY, HUANGGANG, 438000, CHINA;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRICULTURAL SCIENCE, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRICULTURAL SCIENCE, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND;INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, NATIONAL TAIWAN UNIVERSITY, NO.1, SECTION 4, ROOSEVELT ROAD, TAIPEI, 10617, TAIWAN;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND","CRUDE RICE BRAN OILS FROM DIFFERENT RICE CULTIVARS AND EXTRACTION METHODS BEAR DIFFERENT CONTENTS OF NUTRACEUTICALS. THE HEALTH BENEFITS OF LOWERING CHOLESTEROL ACTIVITY OF RICE BRAN OIL BEING CONFIRMED BY MANY REPORTS ARE PARTLY ATTRIBUTED TO NON-NUTRIENT NUTRACEUTICALS, ESPECIALLY Γ-ORYZANOL, PHYTOSTEROLS, AND POLICOSANOLS. AS THE WORLD HAS BEEN FACING THE GLOBAL WARMING CRISIS, GREEN EXTRACTION TECHNOLOGY IS GAINING ATTENTION FROM MANY SECTORS. THE CURRENT STUDY AIMS TO COMPARE THE NUTRACEUTICAL COMPOSITION WITH RESPECT TO Γ-ORYZANOL, PHYTOSTEROL, AND POLICOSANOL CONTENT AS WELL AS THE ANTIOXIDANT PROPERTIES OF CRUDE RICE BRAN OILS EXTRACTED FROM WHITE AND RED RICE BRAN USING THREE GREEN TECHNOLOGIES, COMPARING WITH CONVENTIONAL HEXANE EXTRACTION. THE DATA SHOW THAT THE TRADITIONAL SOLVENT EXTRACTION GAVE THE HIGHEST OIL YIELD PERCENTAGE (26%), BUT IT WAS NOT SIGNIFICANTLY DIFFERENT FROM SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION (24.6%). SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION GAVE HIGHER OIL YIELD THAN SUPERCRITICAL CO2 EXTRACTION (15.5–16.2%). THE CRUDE RICE BRAN OIL EXTRACTED USING SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION PRODUCED THE HIGHEST TOTAL PHENOLIC CONTENTS AND ANTIOXIDANT ACTIVITIES. THE HIGHEST Γ-ORYZANOL CONTENT OF THE CRUDE RICE BRAN OIL WAS FOUND IN OIL EXTRACTED BY CONVENTIONAL COLD PRESS (1370.43 MG/100 G). THE Γ-ORYZANOL CONTENT OF THE OIL OBTAINED VIA SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION WAS HIGH (1213.64 MG/100 G) COMPARED WITH SUPERCRITICAL CO2 EXTRACTION. THE RED RICE BRAN YIELDED THE CRUDE RICE BRAN OIL WITH THE HIGHEST TOTAL PHYTOSTEROL CONTENT COMPARED WITH THE WHITE BRAN, AND THE OIL FROM RED RICE BRAN EXTRACTED WITH SUBCRITICAL LIQUEFIED DIMETHYL ETHER GENERATED THE HIGHEST TOTAL PHYTOSTEROL CONTENT (1784.17 MG/100 G). THE HIGHEST POLICOSANOL CONTENT (274.40 MG/100 G) WAS ALSO FOUND IN OIL OBTAINED VIA SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION. © 2023 BY THE AUTHORS.","ORYZANOL; PHYTOSTEROL; POLICOSANOL; SUBCRITICAL EXTRACTION; SUPERCRITICAL EXTRACTION","ANTIOXIDANTS; CARBON DIOXIDE; ORYZA; PHENYLPROPIONATES; PHYTOSTEROLS; RICE BRAN OIL; ANTIOXIDANT; CARBON DIOXIDE; DIMETHYL ETHER; GAMMA-ORYZANOL; PHENYLPROPIONIC ACID DERIVATIVE; PHYTOSTEROL; POLICOSANOL; RICE BRAN OIL; ORYZA","THAILAND SCIENCE RESEARCH AND INNOVATION, TSRI","THIS RESEARCH WAS FUNDED BY THAILAND SCIENCE RESEARCH AND INNOVATION (TRSI) IN FISCAL YEAR 2022 (GRANT NUMBER FRB650022/0179) AND NARESUAN UNIVERSITY (GRANT NUMBER R2565B007).","LIU R., XU Y., CHANG M., TANG L., LU M., LIU R., JIN Q., WANG X., ANTIOXIDANT INTERACTION OF Α-TOCOPHEROL, Γ-ORYZANOL AND PHYTOSTEROL IN RICE BRAN OIL, FOOD CHEM, 343, (2021); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J. FOOD SCI, 76, PP. 891-899, (2011); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR. J. LIPID SCI. TECHNOL, 106, PP. 147-151, (2004); KRISHNA A.G.G., KHATOON S., SHIELA P.M., SARMANDAL C.V., INDIRA T.N., MISHRA A., EFFECT OF REFINING OF CRUDE RICE BRAN OIL ON THE RETENTION OF ORYZANOL IN THE REFINED OIL, J. AM. OIL CHEM. SOC, 78, PP. 127-131, (2001); ORTHOEFER F.T., RICE BRAN OIL, BAILEY’S INDUSTRIAL OIL AND FAT PRODUCTS, 2, PP. 465-489, (2005); HUANG Y.P., LAI H.M., BIOACTIVE COMPOUNDS AND ANTIOXIDATIVE ACTIVITY OF COLORED RICE BRAN, J. FOOD DRUG ANAL, 24, PP. 564-574, (2016); KIM H.W., LEE A.Y., YEO S.K., CHUNG H., LEE J.H., HOANG M.H., JIA Y., HAN S.I., OH S.K., LEE S.J., ET AL., METABOLIC PROFILING AND BIOLOGICAL MECHANISMS OF BODY FAT REDUCTION IN MICE FED THE ETHANOLIC EXTRACT OF BLACK-COLORED RICE, FOOD RES. INT, 53, PP. 373-390, (2013); LING W.H., CHENG Q.X., MA J., WANG T., RED AND BLACK RICE DECREASE ATHEROSCLEROTIC PLAQUE FORMATION AND INCREASE ANTIOXIDANT STATUS IN RABBITS, J. NUTR, 131, PP. 1421-1426, (2001); RATTANACHITTHAWAT S., SUWANNALERT P., RIENGROJPITAK S., CHAIYASUT C., PANTUWATANA S., PHENOLIC CONTENT AND ANTIOXIDANT ACTIVITIES IN RED UNPOLISHED THAI RICE PREVENTS OXIDATIVE STRESS IN RATS, J. MED. PLANTS RES, 4, PP. 796-801, (2010); WANG Q., HAN P., ZHANG M., XIA M., ZHU H., MA J., HOU M., TANG Z., LING W., SUPPLEMENTATION OF BLACK RICE PIGMENT FRACTION IMPROVES ANTIOXIDANT AND ANTI-INFLAMMATORY STATUS IN PATIENTS WITH CORONARY HEART DISEASE, ASIA PAC. J. CLIN. NUTR, 16, PP. 295-301, (2007); KERCKHOFFS D.A.J.M., BROUNS F., HORNSTRA G., MENSINK R.P., EFFECTS ON THE HUMAN SERUM LIPOPROTEIN PROFILE OF Β-GLUCAN, SOY PROTEIN AND ISOFLAVONES, PLANT STEROLS AND STANOLS, GARLIC AND TOCOTRIENOLS, J. NUTR, 132, PP. 2494-2505, (2002); MOST M.M., TULLEY R., MORALES S., LEFEVRE M., RICE BRAN OIL, NOT FIBER, LOWERS CHOLESTEROL IN HUMANS, AM. J. CLIN. NUTR, 81, PP. 64-68, (2005); HONGU N., KITTS D.D., ZAWISTOWSKI J., DOSSETT C.M., KOPEC A., POPE B.T., BUCHOWSKI M.S., PIGMENTED RICE BRAN AND PLANT STEROL COMBINATION REDUCES SERUM LIPIDS IN OVERWEIGHT AND OBESE ADULTS, J. AM. COLL. NUTR, 33, PP. 231-238, (2014); VAN HOED V., DEPAEMELAERE G., AYALA J.V.V., SANTIWATTANA P., VERHE R., GREYT W., DE INFLUENCE OF CHEMICAL REFINING ON THE MAJOR AND MINOR COMPONENTS OF RICE BRAN OIL, J. AM. OIL CHEM. SOC, 83, PP. 315-321, (2006); IQBAL J., MINHAJUDDIN M., BEG Z., SUPPRESSION OF 7,12-DIMETHYLBENZALPHAANTHRACENE-INDUCED CARCINOGENESIS AND HYPERCHOLESTEROLAEMIA IN RATS BY TOCOTRIENOL-RICH FRACTION ISOLATED FROM RICE BRAN OIL, EUR. J. CANCER PREV, 12, PP. 447-453, (2003); RONG N., AUSMAN L.M., NICOLOSI R.J., ORYZANOL DECREASES CHOLESTEROL ABSORPTION AND AORTIC FATTY STREAKS IN HAMSTERS, LIPIDS, 32, PP. 303-309, (1997); WESTER I., CHOLESTEROL-LOWERING EFFECT OF PLANT STEROLS, EUR. J. LIPID SCI. TECHNOL, 102, PP. 37-44, (2000); PINTO T.I., COELHO J.A., PIRES B.I., NENG N.R., NOGUEIRA J.M., BORDADO J.C., SARDINHA J.P., SUPERCRITICAL CARBON DIOXIDE EXTRACTION, ANTIOXIDANT ACTIVITY, AND FATTY ACID COMPOSITION OF BRAN OIL FROM RICE VARIETIES CULTIVATED IN PORTUGAL, SEPARATIONS, 8, (2021); CHAROENCHAI L., SUKSAEREE J., MONTON C., CHUSUT T., KRAISINTU K., METHOD VALIDATION AND DETERMINATION OF FATTY ACID COMPONENTS IN COLD PRESSED RBO USING GAS CHROMATOGRAPHY, RANGSIT J. ARTS SCI, 3, (2013); CAKALOGLU B., OZYURT V.H., OTLES S., COLD PRESS IN OIL EXTRACTION. A REVIEW, UKR. FOOD J, 7, PP. 640-654, (2018); RESHAD A.S., TIWARI P., GOUD V.V., EXTRACTION OF OIL FROM RUBBER SEEDS FOR BIODIESEL APPLICATION: OPTIMIZATION OF PARAMETERS, FUEL, 150, PP. 636-644, (2015); BOONNOUN P., SHOTIPRUK A., KANDA H., GOTO M., OPTIMIZATION OF RUBBER SEED OIL EXTRACTION USING LIQUEFIED DIMETHYL ETHER, CHEM. ENG. COMMUN, 206, PP. 746-753, (2018); LI J., SUN D., QIAN L., LIU Y., SUBCRITICAL BUTANE EXTRACTION OF WHEAT GERM OIL AND ITS DEACIDIFICATION BY MOLECULAR DISTILLATION, MOLECULES, 21, (2016); MUNIR M.T., KHEIRKHAH H., BAROUTIAN S., QUEK S.Y., YOUNG B.R., SUBCRITICAL WATER EXTRACTION OF BIOACTIVE COMPOUNDS FROM WASTE ONION SKIN, J. CLEAN. PROD, 183, PP. 487-494, (2018); CHEIGH C.I., YOO S.Y., KO M.J., CHANG P.S., CHUNG M.S., EXTRACTION CHARACTERISTICS OF SUBCRITICAL WATER DEPENDING ON THE NUMBER OF HYDROXYL GROUP IN FLAVONOLS, FOOD CHEM, 168, PP. 21-26, (2015); SUN D., CAO C., LI B., CHEN H., LI J., CAO P., LIU Y., ANTARCTIC KRILL LIPID EXTRACTED BY SUBCRITICAL N-BUTANE AND COMPARISON WITH SUPERCRITICAL CO<SUB>2</SUB> AND CONVENTIONAL SOLVENT EXTRACTION, LWT, 94, PP. 1-7, (2018); SANTOS K.A., BARICCATTI R.A., CARDOZO-FILHO L., SCHNEIDER R., PALU F., DA SILVA C., DA SILVA E.A., EXTRACTION OF CRAMBE SEED OIL USING SUBCRITICAL PROPANE: KINETICS, CHARACTERIZATION AND MODELING, J. SUPERCRIT. FLUIDS, 104, PP. 54-61, (2015); XU B., HAN J., ZHOU S., WU Q., DING F., QUALITY CHARACTERISTICS OF WHEAT GERM OIL OBTAINED BY INNOVATIVE SUBCRITICAL BUTANE EXPERIMENTAL EQUIPMENT, J. FOOD PROCESS ENG, 39, PP. 79-87, (2016); KO M.J., CHEIGH C.I., CHUNG M.S., RELATIONSHIP ANALYSIS BETWEEN FLAVONOIDS STRUCTURE AND SUBCRITICAL WATER EXTRACTION (SWE), FOOD CHEM, 143, PP. 147-155, (2014); HERRERO M., CASTRO-PUYANA M., MENDIOLA J.A., IBANEZ E., COMPRESSED FLUIDS FOR THE EXTRACTION OF BIOACTIVE COMPOUNDS, TRAC—TRENDS ANAL. CHEM, 43, PP. 67-83, (2013); SAPKALE G.N., PATIL S.M., SURWASE U.S., BHATBHAGE P.K., SUPERCRITICAL FLUID EXTRACTION—A REVIEW, INT. J. CHEM. SCI, 8, PP. 729-743, (2010); FANG Y., GU S., LIU S., ZHANG J., DING Y., LIU J., EXTRACTION OF OIL FROM HIGH-MOISTURE TUNA LIVER BY SUBCRITICAL DIMETHYL ETHER: FEASIBILITY AND OPTIMIZATION BY THE RESPONSE SURFACE METHOD, RSC ADV, 8, PP. 2723-2732, (2018); SUBRATTI A., LALGEE L.J., JALSA N.K., LIQUIFIED DIMETHYL ETHER (DME): A GREEN SOLVENT FOR THE EXTRACTION OF HEMP (CANNABIS SATIVA L.) SEED OIL, SUSTAIN. CHEM. PHARM, 12, (2019); KANDA H., KAMO Y., MACHMUDAH S., WAHYUDIONO S., GOTO M., EXTRACTION OF FUCOXANTHIN FROM RAW MACROALGAE EXCLUDING DRYING AND CELL WALL DISRUPTION BY LIQUEFIED DIMETHYL ETHER, MAR. DRUGS, 12, PP. 2383-2396, (2014); KANDA H., LI P., MAKINO H., PRODUCTION OF DECAFFEINATED GREEN TEA LEAVES USING LIQUEFIED DIMETHYL ETHER, FOOD BIOPROD. PROCESS, 91, PP. 376-380, (2013); GOTO M., KANDA H., WAHYUDIONO H., MACHMUDAH S., EXTRACTION OF CAROTENOIDS AND LIPIDS FROM ALGAE BY SUPERCRITICAL CO<SUB>2</SUB> AND SUBCRITICAL DIMETHYL ETHER, J. SUPERCRIT. FLUIDS, 96, PP. 245-251, (2015); KANDA H., LI P., SIMPLE EXTRACTION METHOD OF GREEN CRUDE FROM NATURAL BLUE-GREEN MICROALGAE BY DIMETHYL ETHER, FUEL, 90, PP. 1264-1266, (2011); SCIENTIFIC OPINION ON THE SAFETY OF USE OF DIMETHYL ETHER AS AN EXTRACTION SOLVENT UNDER THE INTENDED CONDITIONS OF USE AND THE PROPOSED MAXIMUM RESIDUAL LIMITS, EUR. FOOD SAF. AUTH. J, 13, (2015); APPLICATION A1056 DIMETHYL ETHER AS A PROCESSING AID FOR DAIRY INGREDIENTS & PRODUCTS ASSESSMENT REPORT, (2011); VAKILI R., POURAZADI E., SETOODEH P., ESLAMLOUEYAN R., RAHIMPOUR M.R., DIRECT DIMETHYL ETHER (DME) SYNTHESIS THROUGH A THERMALLY COUPLED HEAT EXCHANGER REACTOR, APPL. ENERGY, 88, PP. 1211-1223, (2011); PEINADO C., LIUZZI D., LADERA-GALLARDO R.M., RETUERTO M., OJEDA M., PENA M.A., ROJAS S., EFFECTS OF SUPPORT AND REACTION PRESSURE FOR THE SYNTHESIS OF DIMETHYL ETHER OVER HETEROPOLYACID CATALYSTS, SCI. REP, 10, (2020); SUN J., YANG G., YONEYAMA Y., TSUBAKI N., CATALYSIS CHEMISTRY OF DIMETHYL ETHER SYNTHESIS, ACS CATAL, 4, PP. 3346-3356, (2014); BANIVAHEB S., PITTER S., DELGADO K.H., RUBIN M., SAUER J., DITTMEYER R., RECENT PROGRESS IN DIRECT DME SYNTHESIS AND POTENTIAL OF BIFUNCTIONAL CATALYSTS, CHEM. ING. TECH, 94, PP. 240-255, (2022); DELRUE F., SETIER P.A., SAHUT C., COURNAC L., ROUBAUD A., PELTIER G., FROMENT A.K., AN ECONOMIC, SUSTAINABILITY, AND ENERGETIC MODEL OF BIODIESEL PRODUCTION FROM MICROALGAE, BIORESOUR. TECHNOL, 111, PP. 191-200, (2012); GUO T., WAN C., HUANG F., EXTRACTION OF RAPESEED CAKE OIL USING SUBCRITICAL R134A/BUTANE: PROCESS OPTIMIZATION AND QUALITY EVALUATION, FOOD SCI. NUTR, 7, PP. 3570-3580, (2019); QI Z., XIAO J., YE L., CHUYUN W., CHANG Z., SHUGANG L., FENGHONG H., THE EFFECT OF THE SUBCRITICAL FLUID EXTRACTION ON THE QUALITY OF ALMOND OILS: COMPARED TO CONVENTIONAL MECHANICAL PRESSING METHOD, FOOD SCI. NUTR, 7, PP. 2231-2241, (2019); TEIXEIRA G.L., GHAZANI S.M., CORAZZA M.L., MARANGONI A.G., RIBANI R.H., ASSESSMENT OF SUBCRITICAL PROPANE, SUPERCRITICAL CO<SUB>2</SUB> AND SOXHLET EXTRACTION OF OIL FROM SAPUCAIA (LECYTHIS PISONIS) NUTS, J. SUPERCRIT. FLUIDS, 133, PP. 122-132, (2018); GAO P., LIU R., JIN Q., WANG X., EFFECTS OF PROCESSING METHODS ON THE CHEMICAL COMPOSITION AND ANTIOXIDANT CAPACITY OF WALNUT (JUGLANS REGIA L.) OIL, LWT, 135, (2021); STEVANATO N., IWASSA I.J., CARDOZO-FILHO L., DA SILVA C., QUALITY PARAMETERS OF RADISH SEED OIL OBTAINED USING COMPRESSED PROPANE AS SOLVENT, J. SUPERCRIT. FLUIDS, 159, (2020); OLIVEIRA D.A., ANGONESE M., GOMES C., FERREIRA S.R.S., VALORIZATION OF PASSION FRUIT (PASSIFLORA EDULIS SP.) BY-PRODUCTS: SUSTAINABLE RECOVERY AND BIOLOGICAL ACTIVITIES, J. SUPERCRIT. FLUIDS, 111, PP. 55-62, (2016); ERSAN S., GUCLU USTUNDAG O., CARLE R., SCHWEIGGERT R.M., SUBCRITICAL WATER EXTRACTION OF PHENOLIC AND ANTIOXIDANT CONSTITUENTS FROM PISTACHIO (PISTACIA VERA L.) HULLS, FOOD CHEM, 253, PP. 46-54, (2018); ZANQUI A.B., DA SILVA C.M., RESSUTTE J.B., ROTTA E.M., CARDOZO-FILHO L., MATSUSHITA M., CASHEW NUT OIL EXTRACTED WITH COMPRESSED PROPANE UNDER DIFFERENT EXPERIMENTAL CONDITIONS: EVALUATION OF LIPID COMPOSITION, J. FOOD PROCESS. PRESERV, 44, (2020); WANG S., ZHANG Z.S., ZHANG T.F., WANG X., DE EXTRACTION AND CHARACTERIZATION OF FLAXSEED OIL OBTAINED WITH SUBCRITICAL N-BUTANE, J. OLEO SCI, 69, PP. 1011-1020, (2020); SOARES J.F., PRA V.D., BARRALES F.M., DOS SANTOS P., KUHN R.C., REZENDE C.A., MARTINEZ J., MAZUTTI M.A., EXTRACTION OF RICE BRAN OIL USING SUPERCRITICAL CO<SUB>2</SUB> COMBINED WITH ULTRASOUND, BRAZILIAN J. CHEM. ENG, 35, PP. 785-794, (2018); KUK M.S., DOWD M.K., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF RICE BRAN, J. AM. OIL CHEM. SOC, 75, PP. 623-628, (1998); SOARES J.F., DAL PRA V., DE SOUZA M., LUNELLI F.C., ABAIDE E., DA SILVA J.R.F., KUHN R.C., MARTINEZ J., MAZUTTI M.A., EXTRACTION OF RICE BRAN OIL USING SUPERCRITICAL CO<SUB>2</SUB> AND COMPRESSED LIQUEFIED PETROLEUM GAS, J. FOOD ENG, 170, PP. 58-63, (2016); LIU H.-M., WANG F.-Y., LI H.-Y., WANG X.-D., QIN G.-Y., SUBCRITICAL BUTANE AND PROPANE EXTRACTION OF OIL FROM RICE BRAN, BIORESOURCES, 10, PP. 4652-4662, (2015); CHEN C.-R., WANG C.-H., WANG L.-Y., HONG Z.-H., CHEN S.-H., HO W.-J., CHANG C.-M.J., SUPERCRITICAL CARBON DIOXIDE EXTRACTION AND DEACIDIFICATION OF RICE BRAN OIL, J. SUPERCRIT. FLUIDS, 45, PP. 322-331, (2008); CHIA S.L., BOO H.C., MUHAMAD K., SULAIMAN R., UMANAN F., CHONG G.H., EFFECT OF SUBCRITICAL CARBON DIOXIDE EXTRACTION AND BRAN STABILIZATION METHODS ON RICE BRAN OIL, J. AM. OIL CHEM. SOC, 92, PP. 393-402, (2015); SARMENTO C.M.P., FERREIRA S.R.S., HENSE H., SUPERCRITICAL FLUID EXTRACTION (SFE) OF RICE BRAN OIL TO OBTAIN FRACTIONS ENRICHED WITH TOCOPHEROLS AND TOCOTRIENOLS, BRAZILIAN J. CHEM. ENG, 23, PP. 243-249, (2006); PENGKUMSRI N., CHAIYASUT C., SAENJUM C., SIRILUN S., PEERAJAN S., SUWANNALERT P., SIRISATTHA S., SIVAMARUTHI B.S., PHYSICOCHEMICAL AND ANTIOXIDATIVE PROPERTIES OF BLACK, BROWN AND RED RICE VARIETIES OF NORTHERN THAILAND, FOOD SCI. TECHNOL, 35, PP. 331-338, (2015); MINGYAI S., KETTAWAN A., SRIKAEO K., SINGANUSONG R., PHYSICOCHEMICAL AND ANTIOXIDANT PROPERTIES OF RICE BRAN OILS PRODUCED FROM COLORED RICE USING DIFFERENT EXTRACTION METHODS, J. OLEO SCI, 572, PP. 565-572, (2017); DUNFORD N.T., KING J.W., SUPERCRITICAL CARBON DIOXIDE FRACTIONATION OF CRUDE RICE BRAN OIL USING A PACKED COLUMN WITH CHARACTERIZATION OF THE RESULTANT FRACTIONS, PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON SUPERCRITICAL FLUIDS; BONDIOLI P., MARIANI C., LANZANI A., FEDELI E., MOSSA A., MULLER A., LAMPANTE OLIVE OIL REFINING WITH SUPERCRITICAL CARBON DIOXIDE, J. AM. OIL CHEM. SOC, 69, PP. 477-480, (1992); BRUNETTI L., DAGHETTA A., FEDELL E., KIKIC I., ZANDERIGHI L., DEACIDIFICATION OF OLIVE OILS BY SUPERCRITICAL CARBON DIOXIDE, J. AM. OIL CHEM. SOC, 66, PP. 209-217, (1989); ARORA R., TOOR A.P., WANCHOO R.K., ESTERIFICATION OF HIGH FREE FATTY ACID RICE BRAN OIL: PARAMETRIC AND KINETIC STUDY, CHEM. BIOCHEM. ENG. Q, 29, PP. 617-623, (2015); PANDEY A., HANDBOOK OF PLANT-BASED BIOFUELS, (2008); AMIN S.K., ABDALLAH H.A.M., ENHANCEMENT OF FREE FATTY ACID IN RICE BRAN OIL FOR ACID CATALYSIS BIODIESEL PRODUCTION, AUST. J. BASIC APPL. SCI, 6, PP. 795-806, (2012); OLUREMI O.I., SOLOMON A.O., SAHEED A.A., FATTY ACIDS, METAL COMPOSITION AND PHYSICO-CHEMICAL PARAMETERS OF IGBEMO EKITI RICE BRAN OIL, ENVIRON. CHEM, 5, PP. 39-46, (2013); CODEX STANDARD FOR NAMED VEGETABLE OILS CXS 210-1999; SAWADIKIAT P., HONGSPRABHAS P., PHYTOSTEROLS AND Γ-ORYZANOL IN RICE BRAN OILS AND DISTILLATES FROM PHYSICAL REFINING PROCESS, INT. J. FOOD SCI. TECHNOL, 49, PP. 2030-2036, (2014); MALEKIAN F., RAO R.M., PRINYAWIWATKUL W., MARSHALL W.E., WINDHAUSER M., AHMEDNA M., LIPASE AND LIPOXYGENASE ACTIVITY, FUNCTIONALITY, AND NUTRIENT LOSSES IN RICE BRAN DURING STORAGE, PP. 1-70, (2000); THANONKAEW A., WONGYAI S., MCCLEMENTS D.J., DECKER E.A., EFFECT OF STABILIZATION OF RICE BRAN BY DOMESTIC HEATING ON MECHANICAL EXTRACTION YIELD, QUALITY, AND ANTIOXIDANT PROPERTIES OF COLD-PRESSED RICE BRAN OIL (ORYZA SALTIVA L.), LWT, 48, PP. 231-236, (2012); KILIC B., RICHARDS M.P., LIPID OXIDATION IN POULTRY DÖNER KEBAB: PRO-OXIDATIVE AND ANTI-OXIDATIVE FACTORS, J. FOOD SCI, 68, PP. 686-689, (2003); LEARDKAMOLKARN V., THONGTHEP W., SUTTIARPORN P., KONGKACHUICHAI R., WONGPORNCHAI S., WANAVIJITR A., CHEMOPREVENTIVE PROPERTIES OF THE BRAN EXTRACTED FROM A NEWLY-DEVELOPED THAI RICE: THE RICEBERRY, FOOD CHEM, 125, PP. 978-985, (2011); KONGTHITILERD P., SUANTAWEE T., CHENG H., THILAVECH T., MARNPAE M., ADISAKWATTANA S., ANTHOCYANIN-ENRICHED RICEBERRY RICE EXTRACT INHIBITS CELL PROLIFERATION AND ADIPOGENESIS IN 3T3-L1 PREADIPOCYTES BY DOWNREGULATING ADIPOGENIC TRANSCRIPTION FACTORS AND THEIR TARGETING GENES, NUTRIENTS, 12, (2020); SETTAPRAMOTE N., LAOKULDILOK T., BOONYAWAN D., UTAMA-ANG N., PHYSIOCHEMICAL, ANTIOXIDANT ACTIVITIES AND ANTHOCYANIN OF RICEBERRY RICE FROM DIFFERENT LOCATIONS IN THAILAND, FOOD APPL. BIOSCI. J, 6, PP. 84-94, (2018); DUTHIE G.G., DUTHIE S.J., KYLE J.A.M., PLANT POLYPHENOLS IN CANCER AND HEART DISEASE: IMPLICATIONS AS NUTRITIONAL ANTIOXIDANTS, NUTR. RES. REV, 13, PP. 79-106, (2000); KRGA I., MILENKOVIC D., ANTHOCYANINS: FROM SOURCES AND BIOAVAILABILITY TO CARDIOVASCULAR-HEALTH BENEFITS AND MOLECULAR MECHANISMS OF ACTION, J. AGRIC. FOOD CHEM, 67, PP. 1771-1783, (2019); TIAN L., TAN Y., CHEN G., WANG G., SUN J., OU S., CHEN W., BAI W., METABOLISM OF ANTHOCYANINS AND CONSEQUENT EFFECTS ON THE GUT MICROBIOTA, CRIT. REV. FOOD SCI. NUTR, 59, PP. 982-991, (2019); AKIYA T., COMPONENTS OF UNSAPONIFIABLE MATTER OF RICE BRAN BY TOSHIMI AKIYA FOOD RESEARCH INSTITUTE, MINISTRY OF AGRICULTURE AND FORESTRY, TOKYO IN SEVERAL COUNTRIES, RICE BRAN IS A POTENTIAL SOURCE OF OIL IN CONSIDERABLE QUANTITY, AGRIC. BIOL. CHEM, 26, PP. 180-186, (1962); HVOLBY A., REMOVAL OF NONHYDRATABLE PHOSPHOLIPIDS FROM SOYBEAN OIL, J. AM. OIL CHEM. SOC, 48, PP. 503-509, (1971); LILITCHAN S., ARYUSUK K., HEALTH BENEFITS AND PRODUCTION OF POLICOSANOL FROM RICE BRAN WAX, J. PUBLIC HEALTH, 38, PP. 457-464, (2008); JENNINGS B.H., AKOH C.C., TRANS-FREE PLASTIC SHORTENINGS PREPARED WITH PALM STEARIN AND RICE BRAN OIL STRUCTURED LIPID, J. AM. OIL CHEM. SOC, 87, PP. 411-417, (2010); HUSSAIN N., ISHAK I., AGUS B.A.P., SAMAH N.F.A., EFFECTS OF DIFFERENT STABILIZATION CONDITIONS AND EXTRACTION METHODS (SOXHLET AND ULTRASONIC-ASSISTED) ON QUALITY OF RICE BRAN OIL, EMIR. J. FOOD AGRIC, 33, PP. 220-227, (2021); GOPALA KRISHNA A.G., INFLUENCE OF VISCOSITY ON WAX SETTLING AND REFINING LOSS IN RICE BRAN OIL, J. AM. OIL CHEM. SOC, 70, PP. 895-898, (1993); JUN H.I., SONG G.S., YANG E.I., YOUN Y., KIM Y.S., ANTIOXIDANT ACTIVITIES AND PHENOLIC COMPOUNDS OF PIGMENTED RICE BRAN EXTRACTS, J. FOOD SCI, 77, PP. C759-C764, (2012); LAOKULDILOK T., SHOEMAKER C.F., JONGKAEWWATTANA S., TULYATHAN V., ANTIOXIDANTS AND ANTIOXIDANT ACTIVITY OF SEVERAL PIGMENTED RICE BRANS, J. AGRIC. FOOD CHEM, 59, PP. 193-199, (2011); WISETKOMOLMAT J., ARJIN C., SATSOOK A., SEEL-AUDOM M., RUKSIRIWANICH W., PROM-U-THAI C., SRINGARM K., COMPARATIVE ANALYSIS OF NUTRITIONAL COMPONENTS AND PHYTOCHEMICAL ATTRIBUTES OF SELECTED THAI RICE BRAN, FRONT. NUTR, 9, (2022); PENGKUMSRI N., CHAIYASUT C., SIVAMARUTHI B.S., SAENJUM C., SIRILUN S., PEERAJAN S., SUWANNALERT P., SIRISATTHA S., CHAIYASUT K., KESIKA P., THE INFLUENCE OF EXTRACTION METHODS ON COMPOSITION AND ANTIOXIDANT PROPERTIES OF RICE BRAN OIL, FOOD SCI. TECHNOL, 35, PP. 493-501, (2015); XU Z., GODBER J.S., COMPARISON OF SUPERCRITICAL FLUID AND SOLVENT EXTRACTION METHODS IN EXTRACTING Γ-ORYZANOL FROM RICE BRAN, J. AM. OIL CHEM. SOC, 77, PP. 547-551, (2000); RUEN-NGAM D., THAWAI C., SUKONTHAMAT S., KHUWARANYU K., EFFECT OF SUBCRITICAL SOLVENT EXTRACTION CONDITIONS ON AMOUNT OF Γ-ORYZANOL AND Γ-TOCOPHEROL IN DAWK PA-YOM RICE BRAN OIL, CURR. APPL. SCI. TECHNOL, 21, PP. 151-161, (2021); KATSRI K., NOITUP P., JUNSANGSREE P., SINGANUSONG R., THE OPTIMUM MIXING RATIO BETWEEN HYDROGENATED PALM KERNEL OIL AND COLD- PRESSED RICE BRAN OIL FOR FURTHER UTILIZATION IN LIQUID COFFEE WHITENER, PROCEEDINGS OF THE 13TH ASEAN FOOD CONFERENCE 2013: MEETING FUTURE FOOD DEMANDS: SECURITY & SUSTAINABILITY, PP. 9-11; PATEL M., NAIK S.N., GAMMA-ORYZANOL FROM RICE BRAN OIL—A REVIEW, J. SCI. IND. RES, 63, PP. 569-578, (2004); SOMSEEMEE O., MORAKOT N., SITTIWET C., ANALYSIS OF STEROL CONTENT IN JASMINE RICE (ORYZA SATIVA), PROCEEDINGS OF THE RAJABHAT MAHA SARAKHAM UNIVERSITY RESEARCH CONFERENCE, PP. 1-10; MINGYAI S., SRIKAEO K., KETTAWAN A., SINGANUSONG R., NAKAGAWA K., KIMURA F., ITO J., EFFECTS OF EXTRACTION METHODS ON PHYTOCHEMICALS OF RICE BRAN OILS PRODUCED FROM COLORED RICE, J. OLEO SCI, 67, PP. 135-142, (2018); DERAKHSHAN-HONARPARVAR M., HAMEDI M.M., PIROUZIFARD M.K., RICE BRAN PHYTOSTEROLS OF THREE WIDESPREAD IRANIAN CULTIVARS, J. AGRIC. SCI. TECHNOL, 12, PP. 167-172, (2010); GECGEL U., DAGLIOGLU O., YILMAZ I., ARICI M., GUNER K.G., APAYDIN D., DULGER G.C., ONUR A.Y., ERSOZ B., COTRA Y., ET AL., DETERMINATION OF PHYSICOCHEMICAL PROPERTIES AND OXIDATIVE STABILITY OF RICE BRAN OILS, J. TEKIRDAG AGRIC. FAC, 14, PP. 93-102, (2017); SALEHI E.A., SARDARODIYAN M., BIOACTIVE PHYTOCHEMICALS IN RICE BRAN: PROCESSING AND FUNCTIONAL PROPERTIES, BIOCHEMISTRY, 10, (2016); BALACHANDRAN C., MAYAMOL P.N., THOMAS S., SUKUMAR D., SUNDARESAN A., ARUMUGHAN C., AN ECOFRIENDLY APPROACH TO PROCESS RICE BRAN FOR HIGH QUALITY RICE BRAN OIL USING SUPERCRITICAL CARBON DIOXIDE FOR NUTRACEUTICAL APPLICATIONS, BIORESOUR. TECHNOL, 99, PP. 2905-2912, (2008); KAMCHONEMENUKOOL S., HO C.-T., BOONNOUN P., LI S., PAN M.-H., KLANGPETCH W., WEERAWATANAKORN M., HIGH LEVELS OF POLICOSANOLS AND PHYTOSTEROLS FROM SUGAR MILL WASTE BY SUBCRITICAL LIQUEFIED DIMETHYL ETHER, FOODS, 11, (2022); ZANQUI A.B., DA SILVA C.M., RESSUTTE J.B., DE MORAIS D.R., SANTOS J.M., EBERLIN M.N., CARDOZO-FILHO L., VISENTAINER J.V., GOMES S.T.M., MATSUSHITA M., BRAZIL NUT OIL EXTRACTION USING SUBCRITICAL, J. BRAZ. CHEM. SOC, 31, PP. 603-612, (2020); HAN J.H., WU Q.F., XU B., ZHOU S.L., DING F., QUALITY CHARACTERISTICS OF SOYBEAN GERM OIL OBTAINED BY INNOVATIVE SUBCRITICAL BUTANE EXPERIMENTAL EQUIPMENT, QUAL. ASSUR. SAF. CROP. FOODS, 8, PP. 369-377, (2016); WONGWAIWECH D., WEERAWATANAKORN M., THARATHA S., HO C.T., COMPARATIVE STUDY ON AMOUNT OF NUTRACEUTICALS IN BY-PRODUCTS FROM SOLVENT AND COLD PRESSING METHODS OF RICE BRAN OIL PROCESSING, J. FOOD DRUG ANAL, 27, PP. 71-82, (2019); AOCS OFFICIAL METHOD: ACID VALUE, OFFICIAL METHODS AND RECOMMENDED PRACTICES OF AMERICAN OIL CHEMIST′ S SOCIETY, (2003); AOCS OFFICIAL METHOD CD 8-53: PEROXIDE VALUE, OFFICIAL METHODS AND RECOMMENDED PRACTICES OF AMERICAN OIL CHEMIST′ S SOCIETY, (1997); GUTFINGER T., POLYPHENOLS IN OLIVE OILS, J. AM. OIL CHEM. SOC. VOL, 58, PP. 966-968, (1981); BRAND-WILLIAMS W., CUVELIER M.E., BERSET C., USE OF A FREE RADICAL METHOD TO EVALUATE ANTIOXIDANT ACTIVITY, LWT—FOOD SCI. TECHNOL, 28, PP. 25-30, (1995); BENZIE I.F.F., STRAIN J.J., THE FERRIC REDUCING ABILITY OF PLASMA (FRAP) AS A MEASURE OF “ANTIOXIDANT POWER”: THE FRAP ASSAY, ANAL. BIOCHEM, 239, PP. 70-76, (1996); THANH T.T., VERGNES M.F., KALOUSTIAN J., EL-MOSELHY T.F., AMIOT-CARLIN M.J., PORTUGAL H., EFFECT OF STORAGE AND HEATING ON PHYTOSTEROL CONCENTRATIONS IN VEGETABLE OILS DETERMINED BY GC/MS, J. SCI. FOOD AGRIC, 86, PP. 220-225, (2006)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, PHITSANULOK, 99 MOO 9, THA PHO, MUEANG, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","MDPI","ENGLISH","MOLECULES","ARTICLE","ISI","2-S2.0-85151110957","MOLECULES","RAJAMANGALA UNIVERSITY OF TECHNOLOGY LANNA TAK;NARESUAN UNIVERSITY;RUTGERS UNIVERSITY;HUANGGANG NORMAL UNIVERSITY;NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;NATIONAL TAIWAN UNIVERSITY;NARESUAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"WONGWAIWECH D, 2023, MOLECULES","WONGWAIWECH D, 2023, MOLECULES"
"UEHARA Y;KOMATSU T;SASAKI K;ABE S;NAKASHIMA S;YAMAMOTO T;KIM J;CHO K","UEHARA, YOSHINARI (7202555528); KOMATSU, TOMOHIRO (36113558800); SASAKI, KEI (58118854400); ABE, SATOMI (7403335003); NAKASHIMA, SHIHOKO (56825139100); YAMAMOTO, TAIKI (57761546400); KIM, JI-EUN (57881093800); CHO, KYUNG-HYUN (7403956966)","CUBAN POLICOSANOL IMPROVES HIGHDENSITY LIPOPROTEIN CHOLESTEROL EFFLUX CAPACITY IN HEALTHY JAPANESE SUBJECTS",2023,"FRONTIERS IN NUTRITION","10","",0,"10.3389/fnut.2023.1297008","FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN, RESEARCH INSTITUTE FOR PHYSICAL ACTIVITY, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN, CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, FUKUOKA, JAPAN;RESEARCH INSTITUTE FOR PHYSICAL ACTIVITY, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN, CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, FUKUOKA, JAPAN;CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, FUKUOKA, JAPAN;RESEARCH INSTITUTE FOR PHYSICAL ACTIVITY, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN;FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN;FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA","POLICOSANOL SUPPLEMENTATION HAS BEEN REPORTED TO INCREASE HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL (HDL-C). HOWEVER, THE ASSOCIATION BETWEEN CUBAN POLICOSANOL SUPPLEMENTATION AND HDL CHOLESTEROL EFFLUX CAPACITY (CEC), AN IMPORTANT FUNCTION OF HDL, REMAINS UNCLEAR. WE PERFORMED A LIPOPROTEIN ANALYSIS INVESTIGATING 32 JAPANESE HEALTHY PARTICIPANTS (PLACEBO, N = 17 OR POLICOSANOL SUPPLEMENTATION FOR 12 WEEKS, N = 15) FROM A RANDOMIZED CUBAN POLICOSANOL CLINICAL TRIAL. FIRST, HDL CEC AND HDL-RELATED FACTORS WERE MEASURED BEFORE AND AFTER POLICOSANOL SUPPLEMENTATION. THEN, THROUGH ELECTRON MICROSCOPY AFTER ULTRACENTRIFUGATION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, HDL MORPHOLOGY AND SUBCLASS WERE ANALYZED, RESPECTIVELY. FINALLY, THE EFFECTS OF POLICOSANOL SUPPLEMENTATION REGARDING HDL FUNCTION, HDL-RELATED FACTORS, AND HDL MORPHOLOGY/COMPONENT WERE EXAMINED. CUBAN POLICOSANOL CONSIDERABLY INCREASED THE HDL CEC AND HDL-C AND APOLIPOPROTEIN A-I (APOA-I) LEVELS. FURTHERMORE, POLICOSANOL SUPPLEMENTATION LED TO LARGER HDL PARTICLES, INCREASED CHOLESTEROL CONTENT IN LARGER HDL PARTICLES, AND REDUCED TRIGLYCERIDE CONTENT IN SMALLER HDL PARTICLES. IN PARTICIPANTS WITH HIGH BASELINE HDL-C LEVELS, THE POLICOSANOL EFFECTS FOR HDL CEC ARE OBSERVED. HDL CEC FLUCTUATION INDUCED BY POLICOSANOL WAS HIGHLY ASSOCIATED WITH HDL-C AND APOA-I CHANGES. IN CONCLUSION, FOR THE FIRST TIME, WE DEMONSTRATED THAT POLICOSANOL SUPPLEMENTATION INCREASED THE HDL CEC IN HEALTHY PARTICIPANTS. COPYRIGHT © 2024 UEHARA, KOMATSU, SASAKI, ABE, NAKASHIMA, YAMAMOTO, KIM AND CHO.","APOLIPOPROTEIN A-I; HDL CHOLESTEROL EFFLUX CAPACITY; HIGH-DENSITY LIPOPROTEIN; LIPID METABOLISM; POLICOSANOL","","FUKUOKA UNIVERSITY, (220224, K22011)","THE AUTHOR(S) DECLARE FINANCIAL SUPPORT WAS RECEIVED FOR THE RESEARCH, AUTHORSHIP, AND/OR PUBLICATION OF THIS ARTICLE. THIS RESEARCH WAS PARTLY FUNDED BY FUKUOKA UNIVERSITY (GRANT NUMBER 220224 TO YU AND K22011 TO YU). ","KO D.T., ALTER D.A., GUO H., KOH M., LAU G., AUSTIN P.C., ET AL., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CAUSE-SPECIFIC MORTALITY IN INDIVIDUALS WITHOUT PREVIOUS CARDIOVASCULAR CONDITIONS: THE CANHEART STUDY, J AM COLL CARDIOL, 68, PP. 2073-2083, (2016); DI ANGELANTONIO E., SARWAR N., PERRY P., KAPTOGE S., RAY K.K., ET AL., MAJOR LIPIDS, APOLIPOPROTEINS, AND RISK OF VASCULAR DISEASE, JAMA, 302, PP. 1993-2000, (2009); KANNEL W.B., HIGH-DENSITY LIPOPROTEINS: EPIDEMIOLOGIC PROFILE AND RISKS OF CORONARY ARTERY DISEASE, AM J CARDIOL, 52, PP. B9-B12, (1983); MATSUZAKI M., KITA T., MABUCHI H., MATSUZAWA Y., NAKAYA N., OIKAWA S., ET AL., LARGE SCALE COHORT STUDY OF THE RELATIONSHIP BETWEEN SERUM CHOLESTEROL CONCENTRATION AND CORONARY EVENTS WITH LOW-DOSE SIMVASTATIN THERAPY IN JAPANESE PATIENTS WITH HYPERCHOLESTEROLEMIA, CIRC J, 66, PP. 1087-1095, (2002); HAASE C.L., TYBJAERG-HANSEN A., QAYYUM A.A., SCHOU J., NORDESTGAARD B.G., FRIKKE-SCHMIDT R., LCAT, HDL CHOLESTEROL AND ISCHEMIC CARDIOVASCULAR DISEASE: A MENDELIAN RANDOMIZATION STUDY OF HDL CHOLESTEROL IN 54,500 INDIVIDUALS, J CLIN ENDOCRINOL METAB, 97, PP. E248-E256, (2012); VOIGHT B.F., PELOSO G.M., ORHO-MELANDER M., FRIKKE-SCHMIDT R., BARBALIC M., JENSEN M.K., ET AL., PLASMA HDL CHOLESTEROL AND RISK OF MYOCARDIAL INFARCTION: A MENDELIAN RANDOMISATION STUDY, LANCET, 380, PP. 572-580, (2012); SORIA-FLORIDO M.T., SCHRODER H., GRAU M., FITO M., LASSALE C., HIGH DENSITY LIPOPROTEIN FUNCTIONALITY AND CARDIOVASCULAR EVENTS AND MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 302, PP. 36-42, (2020); PHILLIPS M.C., MOLECULAR MECHANISMS OF CELLULAR CHOLESTEROL EFFLUX, J BIOL CHEM, 289, PP. 24020-24029, (2014); LEWIS G.F., RADER D.J., NEW INSIGHTS INTO THE REGULATION OF HDL METABOLISM AND REVERSE CHOLESTEROL TRANSPORT, CIRC RES, 96, PP. 1221-1232, (2005); ATTIE A.D., KASTELEIN J.P., HAYDEN M.R., PIVOTAL ROLE OF ABCA1 IN REVERSE CHOLESTEROL TRANSPORT INFLUENCING HDL LEVELS AND SUSCEPTIBILITY TO ATHEROSCLEROSIS, J LIPID RES, 42, PP. 1717-1726, (2001); EBTEHAJ S., GRUPPEN E.G., BAKKER S.J.L., DULLAART R.P.F., TIETGE U.J.F., HDL (HIGH-DENSITY LIPOPROTEIN) CHOLESTEROL EFFLUX CAPACITY IS ASSOCIATED WITH INCIDENT CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION, ARTERIOSCLER THROMB VASC BIOL, 39, PP. 1874-1883, (2019); HISAUCHI I., ISHIKAWA T., AYAORI M., UTO-KONDO H., KOSHIKAWA Y., UKAJI T., ET AL., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL EFFLUX CAPACITY AS A NOVEL PROGNOSTIC SURROGATE FOR CORONARY ARTERY DISEASE, J ATHEROSCLER THROMB, 28, PP. 696-702, (2021); QIU C., ZHAO X., ZHOU Q., ZHANG Z., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL EFFLUX CAPACITY IS INVERSELY ASSOCIATED WITH CARDIOVASCULAR RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS, LIPIDS HEALTH DIS, 16, (2017); CHOW S.L., BOZKURT B., BAKER W.L., BLESKE B.E., BREATHETT K., FONAROW G.C., ET AL., COMPLEMENTARY AND ALTERNATIVE MEDICINES IN THE MANAGEMENT OF HEART FAILURE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 147, PP. E4-E30, (2023); CHO K.H., NAM H.S., BAEK S.H., KANG D.J., NA H., KOMATSU T., ET AL., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT J MOL SCI, 24, (2023); PARK H.J., YADAV D., JEONG D.J., KIM S.J., BAE M.A., KIM J.R., ET AL., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT J ENVIRON RES PUBLIC HEALTH, 16, (2019); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); ZHAI Z., NIU K.M., LIU H., LIN C., TU Y., LIU Y., ET AL., POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6/MICE THROUGH AMPK-FXR-TGR5 CROSS-TALK, J FOOD SCI, 86, PP. 5466-5478, (2021); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI REP, 9, (2019); ZHAI Z., LIU J., NIU K.M., LIN C., TU Y., LIU Y., ET AL., INTEGRATED METAGENOMICS AND METABOLOMICS TO REVEAL THE EFFECTS OF POLICOSANOL ON MODULATING THE GUT MICROBIOTA AND LIPID METABOLISM IN HYPERLIPIDEMIC C57BL/6 MICE, FRONT ENDOCRINOL (LAUSANNE), 12, (2021); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., ET AL., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT THER MED, 45, PP. 89-97, (2019); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVESTIG, 23, PP. 639-650, (2003); KINOSHITA M., YOKOTE K., ARAI H., IIDA M., ISHIGAKI Y., ISHIBASHI S., ET AL., JAPAN ATHEROSCLEROSIS SOCIETY (JAS) GUIDELINES FOR PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES 2017, J ATHEROSCLER THROMB, 25, PP. 846-984, (2018); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J CLIN INVEST, 34, PP. 1345-1353, (1955); CHO K.H., KIM J.R., LEE I.C., KWON H.J., NATIVE HIGH-DENSITY LIPOPROTEINS (HDL) WITH HIGHER PARAOXONASE EXERTS A POTENT ANTIVIRAL EFFECT AGAINST SARS-COV-2 (COVID-19), WHILE GLYCATED HDL LOST THE ANTIVIRAL ACTIVITY, ANTIOXIDANTS (BASEL), 10, (2021); OKAZAKI M., YAMASHITA S., RECENT ADVANCES IN ANALYTICAL METHODS ON LIPOPROTEIN SUBCLASSES: CALCULATION OF PARTICLE NUMBERS FROM LIPID LEVELS BY GEL PERMEATION HPLC USING “SPHERICAL PARTICLE MODEL, J OLEO SCI, 65, PP. 265-282, (2016); YOKOYAMA S., REMALEY A.T., SAMPSON M., AI M., OKAZAKI M., VALIDATION BY HPLC ANALYSES OF NEW EQUATIONS FOR ESTIMATING CHOLESTEROL IN PLASMA LIPOPROTEIN SUBFRACTIONS, BIOCHIM BIOPHYS ACTA MOL CELL BIOL LIPIDS, 1866, (2021); KHERA A.V., CUCHEL M., DE LA LLERA-MOYA M., RODRIGUES A., BURKE M.F., JAFRI K., ET AL., CHOLESTEROL EFFLUX CAPACITY, HIGH-DENSITY LIPOPROTEIN FUNCTION, AND ATHEROSCLEROSIS, N ENGL J MED, 364, PP. 127-135, (2011); KOMATSU T., ABE S., NAKASHIMA S., SASAKI K., HIGAKI Y., SAKU K., ET AL., DIPEPTIDYL PEPTIDASE-4 INHIBITOR SITAGLIPTIN PHOSPHATE ACCELERATES CELLULAR CHOLESTEROL EFFLUX IN THP-1 CELLS, BIOMOLECULES, 13, (2023); UEHARA Y., ENGEL T., LI Z., GOEPFERT C., RUST S., ZHOU X., ET AL., POLYUNSATURATED FATTY ACIDS AND ACETOACETATE DOWNREGULATE THE EXPRESSION OF THE ATP-BINDING CASSETTE TRANSPORTER A1, DIABETES, 51, PP. 2922-2928, (2002); UEHARA Y., MIURA S., VON ECKARDSTEIN A., ABE S., FUJII A., MATSUO Y., ET AL., UNSATURATED FATTY ACIDS SUPPRESS THE EXPRESSION OF THE ATP-BINDING CASSETTE TRANSPORTER G1 (ABCG1) AND ABCA1 GENES VIA AN LXR/RXR RESPONSIVE ELEMENT, ATHEROSCLEROSIS, 191, PP. 11-21, (2007); VIGNA G.B., SATTA E., BERNINI F., BOARINI S., BOSI C., GIUSTO L., ET AL., FLOW-MEDIATED DILATION, CAROTID WALL THICKNESS AND HDL FUNCTION IN SUBJECTS WITH HYPERALPHALIPOPROTEINEMIA, NUTR METAB CARDIOVASC DIS, 24, PP. 777-783, (2014); ROHATGI A., KHERA A., BERRY J.D., GIVENS E.G., AYERS C.R., WEDIN K.E., ET AL., HDL CHOLESTEROL EFFLUX CAPACITY AND INCIDENT CARDIOVASCULAR EVENTS, N ENGL J MED, 371, PP. 2383-2393, (2014); ISHIKAWA T., AYAORI M., UTO-KONDO H., NAKAJIMA T., MUTOH M., IKEWAKI K., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL EFFLUX CAPACITY AS A RELEVANT PREDICTOR OF ATHEROSCLEROTIC CORONARY DISEASE, ATHEROSCLEROSIS, 242, PP. 318-322, (2015); RONSEIN G.E., VAISAR T., INFLAMMATION, REMODELING, AND OTHER FACTORS AFFECTING HDL CHOLESTEROL EFFLUX, CURR OPIN LIPIDOL, 28, PP. 52-59, (2017); HERNAEZ A., CASTANER O., ELOSUA R., PINTO X., ESTRUCH R., SALAS-SALVADO J., ET AL., MEDITERRANEAN DIET IMPROVES HIGH-DENSITY LIPOPROTEIN FUNCTION IN HIGH-CARDIOVASCULAR-RISK INDIVIDUALS: A RANDOMIZED CONTROLLED TRIAL, CIRCULATION, 135, PP. 633-643, (2017); HERNAEZ A., FERNANDEZ-CASTILLEJO S., FARRAS M., CATALAN U., SUBIRANA I., MONTES R., ET AL., OLIVE OIL POLYPHENOLS ENHANCE HIGH-DENSITY LIPOPROTEIN FUNCTION IN HUMANS: A RANDOMIZED CONTROLLED TRIAL, ARTERIOSCLER THROMB VASC BIOL, 34, PP. 2115-2119, (2014); UTO-KONDO H., AYAORI M., OGURA M., NAKAYA K., ITO M., SUZUKI A., ET AL., COFFEE CONSUMPTION ENHANCES HIGH-DENSITY LIPOPROTEIN-MEDIATED CHOLESTEROL EFFLUX IN MACROPHAGES, CIRC RES, 106, PP. 779-787, (2010); ZHU Y., HUANG X., ZHANG Y., WANG Y., LIU Y., SUN R., ET AL., ANTHOCYANIN SUPPLEMENTATION IMPROVES HDL-ASSOCIATED PARAOXONASE 1 ACTIVITY AND ENHANCES CHOLESTEROL EFFLUX CAPACITY IN SUBJECTS WITH HYPERCHOLESTEROLEMIA, J CLIN ENDOCRINOL METAB, 99, PP. 561-569, (2014); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED CELL LONGEV, 2018, PP. 4809525-15, (2018); VILLARD E.F., EI KHOURY P., FRISDAL E., BRUCKERT E., CLEMENT K., BONNEFONT-ROUSSELOT D., ET AL., GENETIC DETERMINATION OF PLASMA CHOLESTEROL EFFLUX CAPACITY IS GENDER-SPECIFIC AND INDEPENDENT OF HDL-CHOLESTEROL LEVELS, ARTERIOSCLER THROMB VASC BIOL, 33, PP. 822-828, (2013); AICHER B.O., HASER E.K., FREEMAN L.A., CARNIE A.V., STONIK J.A., WANG X., ET AL., DIET-INDUCED WEIGHT LOSS IN OVERWEIGHT OR OBESE WOMEN AND CHANGES IN HIGH-DENSITY LIPOPROTEIN LEVELS AND FUNCTION, OBESITY (SILVER SPRING), 20, PP. 2057-2062, (2012); ISHIGAMI M., YAMASHITA S., SAKAI N., HIRANO K., ARAI T., MARUYAMA T., ET AL., HIGH-DENSITY LIPOPROTEINS FROM PROBUCOL-TREATED PATIENTS HAVE INCREASED CAPACITY TO PROMOTE CHOLESTEROL EFFLUX FROM MOUSE PERITONEAL MACROPHAGES LOADED WITH ACETYLATED LOW-DENSITY LIPOPROTEINS, EUR J CLIN INVESTIG, 27, PP. 285-292, (1997); FERRARA A., BARRETT-CONNOR E., SHAN J., TOTAL, LDL, AND HDL CHOLESTEROL DECREASE WITH AGE IN OLDER MEN AND WOMEN. THE RANCHO BERNARDO STUDY 1984-1994, CIRCULATION, 96, PP. 37-43, (1997); MILMAN S., ATZMON G., CRANDALL J., BARZILAI N., PHENOTYPES AND GENOTYPES OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN EXCEPTIONAL LONGEVITY, CURR VASC PHARMACOL, 12, PP. 690-697, (2014); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); LEE J.Y., CHOI H.Y., KANG Y.R., CHANG H.B., CHUN H.S., LEE M.S., ET AL., EFFECTS OF LONG-TERM SUPPLEMENTATION OF POLICOSANOL ON BLOOD CHOLESTEROL/GLUCOSE LEVELS AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY IN A RAT MODEL FED HIGH CHOLESTEROL DIETS, FOOD SCI BIOTECHNOL, 25, PP. 899-904, (2016); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES CLIN EXP, 64, PP. 522-537, (2003); NATIONAL TRENDS IN TOTAL CHOLESTEROL OBSCURE HETEROGENEOUS CHANGES IN HDL AND NON-HDL CHOLESTEROL AND TOTAL-TO-HDL CHOLESTEROL RATIO: A POOLED ANALYSIS OF 458 POPULATION-BASED STUDIES IN ASIAN AND WESTERN COUNTRIES, INT J EPIDEMIOL, 49, PP. 173-192, (2020); YOKOYAMA S., CONTINUOUS AND MARKED INCREASE OF JAPANESE HDL ASSOCIATES PARADOXICALLY WITH THEIR NUTRITIONAL SHIFT, J ATHEROSCLER THROMB, 30, (2023); MADSEN C.M., VARBO A., NORDESTGAARD B.G., NOVEL INSIGHTS FROM HUMAN STUDIES ON THE ROLE OF HIGH-DENSITY LIPOPROTEIN IN MORTALITY AND NONCARDIOVASCULAR DISEASE, ARTERIOSCLER THROMB VASC BIOL, 41, PP. 128-140, (2021); BREWER H.B., CLINICAL REVIEW: THE EVOLVING ROLE OF HDL IN THE TREATMENT OF HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE, J CLIN ENDOCRINOL METAB, 96, PP. 1246-1257, (2011); TESLOVICH T.M., MUSUNURU K., SMITH A.V., EDMONDSON A.C., STYLIANOU I.M., KOSEKI M., ET AL., BIOLOGICAL, CLINICAL AND POPULATION RELEVANCE OF 95 LOCI FOR BLOOD LIPIDS, NATURE, 466, PP. 707-713, (2010); ARMITAGE J., HOLMES M.V., PREISS D., CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION FOR PREVENTING CARDIOVASCULAR EVENTS: JACC REVIEW TOPIC OF THE WEEK, J AM COLL CARDIOL, 73, PP. 477-487, (2019); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT J MOL MED, 39, PP. 889-899, (2017); MILLAR J.S., LASSMAN M.E., THOMAS T., RAMAKRISHNAN R., JUMES P., DUNBAR R.L., ET AL., EFFECTS OF CETP INHIBITION WITH ANACETRAPIB ON METABOLISM OF VLDL-TG AND PLASMA APOLIPOPROTEINS C-II, C-III, AND E, J LIPID RES, 58, PP. 1214-1220, (2017); MCLAREN D.G., PREVIS S.F., PHAIR R.D., STOUT S.J., XIE D., CHEN Y., ET AL., EVALUATION OF CETP ACTIVITY IN VIVO UNDER NON-STEADY-STATE CONDITIONS: INFLUENCE OF ANACETRAPIB ON HDL-TG FLUX, J LIPID RES, 57, PP. 398-409, (2016); VAN CAPELLEVEEN J.C., KASTELEIN J.J., ZWINDERMAN A.H., VAN DEVENTER S.J., COLLINS H.L., ADELMAN S.J., ET AL., EFFECTS OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, TA-8995, ON CHOLESTEROL EFFLUX CAPACITY AND HIGH-DENSITY LIPOPROTEIN PARTICLE SUBCLASSES, J CLIN LIPIDOL, 10, PP. 1137-1144.E3, (2016); SINGH S.A., ANDRASKI A.B., HIGASHI H., LEE L.H., RAMSAROOP A., SACKS F.M., ET AL., METABOLISM OF PLTP, CETP, AND LCAT ON MULTIPLE HDL SIZES USING THE ORBITRAP FUSION LUMOS, JCI INSIGHT, 6, (2021); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994)","Y. UEHARA; FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, FUKUOKA, JAPAN; EMAIL: UEHARAY@FUKUOKA-U.AC.JP","FRONTIERS MEDIA SA","ENGLISH","FRONT. NUTR.","ARTICLE","ISI","2-S2.0-85182638731","FRONT NUTR","FUKUOKA UNIVERSITY;FUKUOKA UNIVERSITY;FUKUOKA UNIVERSITY HOSPITAL;FUKUOKA UNIVERSITY;FUKUOKA UNIVERSITY;FUKUOKA UNIVERSITY;RAYDEL RESEARCH INSTITUTE;YEUNGNAM UNIVERSITY","NOTREPORTED;FUKUOKA UNIVERSITY;NOTREPORTED",NA,"UEHARA Y, 2023, FRONT NUTR","UEHARA Y, 2023, FRONT NUTR"
"BANDERALI G;CAPRA M;VIGGIANO C;BIASUCCI G;PEDERIVA C","BANDERALI, GIUSEPPE (6602000083); CAPRA, MARIA ELENA (57200591334); VIGGIANO, CLAUDIA (57195536638); BIASUCCI, GIACOMO (57202895877); PEDERIVA, CRISTINA (18134025000)","NUTRACEUTICALS IN PAEDIATRIC PATIENTS WITH DYSLIPIDAEMIA",2022,"NUTRIENTS","14","",10,"10.3390/nu14030569","PAEDIATRICS UNIT, CLINICAL SERVICE FOR DYSLIPIDAEMIAS, STUDY AND PREVENTION OF ATHEROSCLEROSIS IN CHILDHOOD, ASST‐SANTI PAOLO E CARLO, MILAN, 20142, ITALY;PAEDIATRICS AND NEONATOLOGY UNIT, CENTRE FOR PAEDIATRIC DYSLIPIDAEMIAS, GUGLIELMO DA SALICETO HOSPITAL, PIACENZA, 29121, ITALY, DEPARTMENT OF TRANSLATIONAL MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF PARMA, PARMA, 43126, ITALY;PAEDIATRICS UNIT, CLINICAL SERVICE FOR DYSLIPIDAEMIAS, STUDY AND PREVENTION OF ATHEROSCLEROSIS IN CHILDHOOD, ASST‐SANTI PAOLO E CARLO, MILAN, 20142, ITALY;PAEDIATRICS AND NEONATOLOGY UNIT, CENTRE FOR PAEDIATRIC DYSLIPIDAEMIAS, GUGLIELMO DA SALICETO HOSPITAL, PIACENZA, 29121, ITALY;PAEDIATRICS UNIT, CLINICAL SERVICE FOR DYSLIPIDAEMIAS, STUDY AND PREVENTION OF ATHEROSCLEROSIS IN CHILDHOOD, ASST‐SANTI PAOLO E CARLO, MILAN, 20142, ITALY","CORONARY HEART DISEASE (CHD) IS THE MAIN CAUSE OF DEATH AND MORBIDITY IN THE WORLD. CHILDHOOD IS A CRITICAL PERIOD DURING WHICH ATHEROSCLEROSIS MAY BEGIN TO DEVELOP; IN THE PRESENCE OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH), THE LIFELONG ELEVATION OF LDL CHOLESTEROL LEVELS GREATLY ACCELERATES ATHEROSCLEROSIS. LOWERING LDL‐C LEVELS IS ASSOCIATED WITH A WELL‐DOCUMENTED REDUCTION IN CARDIOVASCULAR DISEASE RISK. CURRENT GUIDELINES SUPPORT THE DIETARY AND LIFESTYLE APPROACH AS THE PRIMARY STRATEGY OF INTERVENTION IN CHILDREN AND ADOLESCENTS WITH FH. NUTRACEUTICALS (FUNCTIONAL FOODS OR DIETARY SUPPLEMENTS OF PLANT OR MICROBIAL ORIGIN) ARE INCLUDED IN THE EU GUIDELINES AS LIFESTYLE INTERVENTIONS AND MAY PROVIDE AN ADDITIONAL CONTRIBUTION IN REDUCING LDL LEVELS WHEN PHARMACOLOGICAL THERAPY IS NOT YET INDICATED. META‐ANALYSES OF RANDOMISED CLINICAL TRIALS HAVE DEMONSTRATED THAT THE SAME NUTRACEUTICALS IMPROVE LIPID PROFILE, INCLUDING LOWERING LDL‐C, TOTAL CHOLESTEROL AND TRIGLYCERIDE LEVELS. IN THIS NARRATIVE REVIEW, STARTING FROM CURRENT SCIENTIFIC EVIDENCE, WE ANALYSE THE BENEFITS AND LIMITATIONS OF THE NUTRACEUTICALS IN CHILDREN AND ADOLESCENTS WITH DYSLIPIDAEMIA, AND WE TRY TO EVALUATE THEIR USE AND SAFETY IN CLINICAL PRACTICE. © 2022 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","DIET; DYSLIPIDAEMIA; FAMILIAL HYPERCHOLESTEROLAEMIA; NUTRACEUTICALS; PAEDIATRIC","ADOLESCENT; ATHEROSCLEROSIS; CHILD; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; FUNCTIONAL FOOD; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; BERBERINE; CHITOSAN; CHOLESTEROL; CHOLESTIN; CURCUMIN; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PROBIOTIC AGENT; SINECATECHINS; STANOZOLOL; TRIACYLGLYCEROL; BERGAMOT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EXCRETION; FIBER INTAKE; FUNCTIONAL FOOD; GARLIC; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LIFESTYLE; LIPID FINGERPRINTING; LUPIN; NONHUMAN; PEDIATRIC PATIENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOYBEAN; TRIACYLGLYCEROL LEVEL; ADOLESCENT; ATHEROSCLEROSIS; CHILD; DIETARY SUPPLEMENT; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA","","","TOWNSEND N., WILSON L., BHATNAGAR P., WICKRAMASINGHE K., RAYNER M., NICHOLS M., CARDIOVASCULAR DISEASE IN EUROPE: EPIDEMIOLOGICAL UPDATE 2016, EUR. HEART J, 37, PP. 3232-3245, (2016); SPINELLI A., NARDONE P., BUONCRISTIANO M., LAURIA L., PIERANNUNZIO D., OKKIO ALLA SALUTE: I DATI NAZIONALI 2016, (2016); EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS: SUMMARY REPORT, PEDIATRICS, 128, PP. S213-S256, (2011); WIEGMAN A., GIDDING S.S., WATTS G.F., CHAPMAN M.J., GINSBERG H.N., CUCHEL M., OSE L., AVERNA M., BOILEAU C., BOREN J., ET AL., FAMILIAL HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS: GAINING DECADES OF LIFE BY OPTIMIZING DETECTION AND TREATMENT, EUR. HEART J, 36, PP. 2425-2437, (2015); GIOVANNINI M., DE CARLIS S., RACCOMANDAZIONI PER LA PREVENZIONE IN ETÀ PEDIATRICA DELL’ATEROSCLEROSI, RIV. ITAL. PEDIAT, 26, PP. 13-28, (2000); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, 253, PP. 281-344, (2016); THE EFFICACY AND SAFETY OF LOWERING DIETARY INTAKE OF TOTAL FAT, SATURATED FAT, AND CHOLESTEROL IN CHILDREN WITH ELEVATED LDL‐C: THE DIETARY INTERVENTION STUDY IN CHILDREN (DISC), JAMA, 273, PP. 1429-1435, (1995); SAHEBKAR A., SERBAN M.-C., GLUBA-BRZOZKA A., MIKHAILIDIS D.P., CICERO A.F., RYSZ J., BANACH M., LIPID‐MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE‐BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J. CLIN. HYPERTENS, 14, PP. 121-132, (2012); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., ET AL., STATIN INTOLERANCE—AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH. MED. SCI, 11, PP. 1-23, (2015); BANACH M., SERBAN M.C., DISCUSSION AROUND STATIN DISCONTINUATION IN OLDER ADULTS AND PATIENTS WITH WASTING DISEASES, J. CACHEXIA SARCOPENIA MUSCLE, 7, PP. 396-399, (2016); BANACH M., ARONOW W.S., SERBAN M.C., RYSZ J., VORONEANU L., COVIC A., LIPIDS, BLOOD PRESSURE AND KIDNEY UPDATE 2015, LIPIDS HEALTH DIS, 14, (2015); MASSINI G., BUGANZA R., DE SANCTIS L., GUARDAMAGNA O., LA NUTRACEUTICA NEL BAMBINO DISLIPIDEMICO, GIA, 10, PP. 32-48, (2019); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., FRAS Z., KATSIKI N., LANGLOIS M., LATKOVSKIS G., ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH. MED. SCI, 13, PP. 965-1005, (2017); MCRORIE J.W., EVIDENCE‐BASED APPROACH TO FIBER SUPPLEMENTS AND CLINICALLY MEANINGFUL HEALTH BENEFITS, PART 1, WHAT TO LOOK FOR AND HOW TO RECOMMEND AN EFFECTIVE FIBER THERAPY, NUTR. TODAY, 50, PP. 82-89, (2015); VUKSAN V., JENKINS A.L., ROGOVIK A.L., FAIRGRIEVE C.D., JOVANOVSKI E., LEITER L.A., VISCOSITY RATHER THAN QUANTITY OF DIETARY FIBRE PREDICTS CHOLESTEROL‐LOWERING EFFECT IN HEALTHY INDIVIDUALS, BR. J. NUTR, 106, PP. 1349-1352, (2011); ASSMANN G., BUONO P., DANIELE A., DELLA VALLE E., FARINARO E., FERNS G., KROGH V., KROMHOUT D., MASANA L., MERINO J., ET AL., FUNCTIONAL FOODS AND CARDIOMETABOLIC DISEASES* INTERNATIONAL TASK FORCE FOR PREVENTION OF CARDIOMETABOLIC DISEASES, NUTR. METAB. CARDIOVASC. DIS, 24, PP. 1272-1300, (2014); GIACCO R., CLEMENTE G., CIPRIANO D., LUONGO D., VISCOVO D., PATTI L., DI MARINO L., GIACCO A., NAVIGLIO D., BIANCHI M., ET AL., EFFECTS OF THE REGULAR CONSUMPTION OF WHOLEMEAL WHEAT FOODS ON CARDIOVASCULAR RISK FACTORS IN HEALTHY PEOPLE, NUTR. METAB. CARDIOVASC. DIS, 20, PP. 186-194, (2010); SCIENTIFIC OPINION ON DIETARY REFERENCE VALUES FOR CARBOHYDRATES AND DIETARY FIBER, EFSA J, 8, (2010); YANG Y., ZHAO L.-G., WU Q, MA X., XIANG Y, ASSOCIATION BETWEEN DIETARY FIBER AND LOWER RISK OF ALL‐CAUSE MORTALITY: A META‐ANALYSIS OF COHORT STUDIES, AM. J. EPIDEMIOL, 181, PP. 83-91, (2015); PEREIRA M.A., O'REILLY E., AUGUSTSSON K., FRASER G.E., GOLDBOURT U., HEITMANN B.L., HALLMANS G., KNEKT P., LIU S., PIETINEN P., ET AL., DIETARY FIBER AND RISK OF CORONARY HEART DISEASE: A POOLED ANALYSIS OF COHORT STUDIES, ARCH. INTERN. MED, 164, PP. 370-376, (2004); BAZZANO L.A., THOMPSON A.M., TEES M.T., NGUYEN C.H., WINHAM D.M., NONSOY LEGUME CONSUMPTION LOWERS CHOLESTEROL LEVELS: A META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 94-103, (2011); ESTRUCH R., MARTINEZ-GONZALEZ M., CORELLA D., BASORA-GALLISA J., RUIZ-GUTIERREZ V., COVAS M., FIOL M., GOMEZ-GRACIA E., LOPEZ-SABATER M.C., ESCODA R., ET AL., PREDIMED STUDY INVESTIGATORS. EFFECTS OF DIETARY FIBRE INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK, J. EPIDEMIOL. COMMUNITY HEALTH, 63, PP. 582-588, (2009); GROOMS K.N., OMMERBORN M.J., PHAM D.Q., DJOUSSE L., CLARK C.R., DIETARY FIBER INTAKE AND CARDIOMETABOLIC RISKS AMONG US ADULTS, NHANES 1999–2010, AM. J. MED, 126, PP. 1059-1067, (2013); SETTE S., LE DONNE C., PICCINELLI R., ARCELLA D., TURRINI A., LECLERCQ C., INRAN‐SCAI 2005‐6 STUDY GROUP. THE THIRD ITALIAN NATIONAL FOOD CONSUMPTION SURVEY, INRAN‐SCAI 2005‐06‐PART 1, NUTRIENT INTAKES IN ITALY, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 922-932, (2011); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL‐LOWERING EFFECTS OF DIETARY FIBER: A META‐ANALYSIS, AM. J. CLIN. NUTR, 69, PP. 30-42, (1999); WHITEHEAD A., BECK E.J., TOSH S., WOLEVER T.M., CHOLESTEROL‐LOWERING EFFECTS OF OAT Β‐GLUCAN: A META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR, 100, PP. 1413-1421, (2014); WEI Z, WANG H., CHEN X.-Y., WANG B.-S., RONG Z.-X., SU B.-H., CHEN H, TIME‐ AND DOSE‐DEPENDENT EFFECT OF PSYLLIUM ON SERUM LIPIDS IN MILD‐TO‐MODERATE HYPERCHOLESTEROLEMIA: A META‐ANALYSIS OF CONTROLLED CLINICAL TRIALS, EUR. J. CLIN. NUTR, 63, PP. 821-827, (2009); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META‐ANALYSIS, AM. J. CLIN. NUTR, 88, PP. 1167-1175, (2008); REPPAS C., SWIDAN S.Z., TOBEY S.W., TUROWSKI M., DRESSMAN J.B., HYDROXYPROPYLMETHYLCELLULOSE SIGNIFICANTLY LOWERS BLOOD CHOLESTEROL IN MILDLY HYPERCHOLESTEROLEMIC HUMAN SUBJECTS, EUR. J. CLIN. NUTR, 63, PP. 71-77, (2009); SINGH B., PSYLLIUM AS THERAPEUTIC AND DRUG DELIVERY AGENT, INT. J. PHARM, 334, PP. 1-14, (2007); SADIQ BUTT M., TAHIR-NADEEM M., KHAN M.K.I., SHABIR R., BUTT M.S., OAT: UNIQUE AMONG THE CEREALS, EUR. J. NUTR, 47, PP. 68-97, (2008); HO H.V.T., SIEVENPIPER J.L., ZURBAU A., BLANCO MEJIA S., JOVANOVSKI E., AU-YEUNG F., JENKINS A.L., VUKSAN V., A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF THE EFFECT OF BARLEY B‐GLUCAN ON LDL‐C, NON‐HDL‐C AND APOB FOR CARDIOVASCULAR DISEASE RISK REDUCTION (I‐IV), EUR. J. CLIN. NUTR, 70, PP. 1239-1245, (2016); KRANZ S., BRAUCHLA M., SLAVIN J.L., MILLER K.B., WHAT DO WE KNOW ABOUT DIETARY FIBER INTAKE IN CHILDREN AND HEALTH? THE EFFECTS OF FIBER INTAKE ON CONSTIPATION, OBESITY, AND DIABETES IN CHILDREN, ADV. NUTR, 3, PP. 47-53, (2012); DANIELS S.R., GREER F.R., THE COMMITTEE ON NUTRITION. LIPID SCREENING AND CARDIOVASCULAR HEALTH IN CHILDHOOD, PEDIATRICS, 122, PP. 198-208, (2008); DAVIDSON M.H., DUGAN L.D., BURNS J.H., SUGIMOTO D., STORY K., DRENNAN K., A PSYLLIUM‐ENRICHED CEREAL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CHILDREN: A CONTROLLED, DOUBLE‐BLIND, CROSSOVER STUDY, AM. J. CLIN. NUTR, 63, PP. 96-102, (1996); GLASSMAN M., SPARK A., BEREZIN S., SCHWARZ S., MEDOW M., NEWMAN L.J., TREATMENT OF TYPE IIA HYPERLIPIDEMIA IN CHILDHOOD BY A SIMPLIFIED AMERICAN HEART ASSOCIATION DIET AND FIBER SUPPLEMENTATION, AM. J. DIS. CHILD, 144, PP. 193-197, (1990); WILLIAMS C.L., BOLLELLA M., SPARK A., PUDER D., SOLUBLE FIBER ENHANCES THE HYPERCHOLESTEROLEMIC EFFECT OF THE STEP I DIET IN CHILDHOOD, J. AM. COLL. NUTR, 3, PP. 251-257, (1995); RIBAS S., CUNHA D.B., SICHIERI R., DA SILVA L.C.S., EFFECTS OF PSYLLIUM ON LDL‐CHOLESTEROL CONCENTRATIONS IN BRAZILIAN CHILDREN AND ADOLESCENTS: A RANDOMISED, PLACEBO‐CONTROLLED, PARALLEL CLINICAL TRIAL, BR. J. NUTR, 113, PP. 134-141, (2015); GUARDAMAGNA O., ABELLO F., CAGLIERO P., VISIOLI F., COULD DYSLIPIDEMIC CHILDREN BENEFIT FROM GLUCOMANNAN INTAKE?, NUTRITION, 29, PP. 1060-1065, (2013); MARTINO F., PUDDU P.E., PANNARALE G., COLANTONI C., MARTINO E., NIGLIO T., ZANONI C., BARILLA F., LOW DOSE CHROMIUM-POLYNICOTINATE OR POLICOSANOL IS EFFECTIVE IN HYPERCHOLESTEROLEMIC CHILDREN ONLY IN COMBINATION WITH GLUCOMANNAN, ATHEROSCLEROSIS, 228, PP. 198-202, (2013); HO H.V.T., JOVANOVSKI E., ZURBAU A., MEJIA S.B., SIEVENPIPER J.L., AU-YEUNG F., JENKINS A.L., DUVNJAK L., LEITER L., VUKSAN V., A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF THE EFFECT OF KONJAC GLUCOMANNAN, A VISCOUS SOLUBLE FIBER, ON LDL CHOLESTEROL AND THE NEW LIPID TARGETS NON‐HDL CHOLESTEROL AND APOLIPOPROTEIN B, AM. J. CLIN. NUTR, 105, PP. 1239-1247, (2017); JANE M., MCKAY J., PAL S., EFFECTS OF DAILY CONSUMPTION OF PSYLLIUM, OAT BRAN AND POLYGLYCOPLEX ON OBESITY‐RELATED DISEASE RISK FACTORS: A CRITICAL REVIEW, NUTRITION, 57, PP. 84-91, (2019); ZAVORAL J.H., HANNAN P., FIELDS D.J., HANSON M.N., FRANTZ I.D., KUBA K., ELMER P., JACOBS D.R., THE HYPOLIPIDEMIC EFFECT OF LOCUST BEAN GUM FOOD PRODUCTS IN FAMILIAL HYPERCHOLESTEROLEMIC ADULTS AND CHILDREN, AM. J. CLIN. NUTR, 38, PP. 285-294, (1983); DEVARAJ S., JIALAL I., THE ROLE OF DIETARY SUPPLEMENTATION WITH PLANT STEROLS AND STANOLS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, NUTR. REV, 64, PP. 348-354, (2006); RAS R.T., HIEMSTRA H., LIN Y., VERMEER M.A., DUCHATEAU G.S.M.J.E., TRAUTWEIN E.A., CONSUMPTION OF PLANT STEROL‐ENRICHED FOODS AND EFFECTS ON PLASMA PLANT STEROL CONCENTRATIONS: A META‐ANALYSIS OF RANDOMIZED CONTROLLED STUDIES, ATHEROSCLEROSIS, 230, PP. 336-346, (2013); FERGUSON J.J., STOJANOVSKI E., MACDONALD-WICKS L., GARG M.L., FAT TYPE IN PHYTOSTEROL PRODUCTS INFLUENCE THEIR CHOLESTEROL-LOWERING POTENTIAL: A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RCTS, PROG. LIPID RES, 64, PP. 16-29, (2016); ANDERSSON S.W., SKINNER J., ELLEGARD L., WELCH A.A., BINGHAM S., MULLIGAN A., ANDERSSON H., KHAW K.T., INTAKE OF DIETARY PLANT STEROLS IS INVERSELY RELATED TO SERUM CHOLESTEROL CONCENTRATION IN MEN AND WOMEN IN THE EPIC NORFOLK POPULATION: A CROSS-SECTIONAL STUDY, EUR. J. CLIN. NUTR, 58, PP. 1378-1385, (2004); KLINGBERG S., ELLEGARD L., JOHANSSON I., HALLMANS G., WEINEHALL L., ANDERSSON H., WINKVIST A., INVERSE RELATION BETWEEN DIETARY INTAKE OF NATURALLY OCCURRING PLANT STEROLS AND SERUM CHOLESTEROL IN NORTHERN SWEDEN, AM. J. CLIN. NUTR, 87, PP. 993-1001, (2008); RIBAS S., SICHIERI R., MOREIRA A., SOUZA D., CABRAL C., GIANINNI D., CUNHA D., PHYTOSTEROL‐ENRICHED MILK LOWERS LDL‐ CHOLESTEROL LEVELS IN BRAZILIAN CHILDREN AND ADOLESCENTS: DOUBLE‐BLIND, CROSS‐OVER TRIAL, NUTR. METAB. CARDIOVASC. DIS, 27, PP. 971-977, (2017); AMUNDSEN L., OSE L., NENSETER M.S., NTANIOS F.Y., PLANT STEROL ESTER‐ENRICHED SPREAD LOWERS PLASMA TOTAL AND LDL CHOLESTEROL IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, AM. J. CLIN. NUTR, 76, PP. 338-344, (2002); GAROUFI A., VORRE S., SOLDATOU A., TSENTIDIS C., KOSSIVA L., DRAKATOS A., MARMARINOS A., GOURGIOTIS D., PLANT STEROLS‐ENRICHED DIET DECREASES SMALL, DENSE LDL‐CHOLESTEROL LEVELS IN CHILDREN WITH HYPERCHOLESTEROLEMIA: A PROSPECTIVE STUDY, ITAL J PEDIATR, 40, (2014); PATTI A.M., KATSIKI N., NIKOLIC D., AL-RASADI K., RIZZO M., NUTRACEUTICALS IN LIPID‐LOWERING TREATMENT: A NARRATIVE REVIEW ON THE ROLE OF CHITOSAN, ANGIOLOGY, 66, PP. 416-421, (2015); BAKER W.L., TERCIUS A., ANGLADE M., WHITE C.M., COLEMAN C.I., A META‐ANALYSIS EVALUATING THE IMPACT OF CHITOSAN ON SERUM LIPIDS IN HYPERCHOLESTEROLEMIC PATIENTS, ANN. NUTR. METAB, 55, PP. 368-374, (2008); RIZZO M., GIGLIO R.V., NIKOLIC D., PATTI A.M., CAMPANELLA C., COCCHI M., KATSIKI N., MONTALTO G., EFFECTS OF CHITOSAN ON PLASMA LIPIDS AND LIPOPROTEINS: A 4‐MONTH PROSPECTIVE PILOT STUDY, ANGIOLOGY, 65, PP. 538-542, (2014); MHURCHU C.N., POPPITT S.D., MCGILL A.-T., LEAHY F.E., BENNETT D.A., LIN R.B., ORMROD D., WARD L., STRIK C., RODGERS A., THE EFFECT OF THE DIETARY SUPPLEMENT, CHITOSAN, ON BODY WEIGHT: A RANDOMISED CONTROLLED TRIAL IN 250 OVERWEIGHT AND OBESE ADULTS, INT. J. OBES, 28, PP. 1149-1156, (2004); GILLILAND S.E., NELSON C.R., MAXWELL C., ASSIMILATION OF CHOLESTEROL BY LACTOBACILLUS ACIDOPHILUS, APPL. ENVIRON. MICROBIOL, 49, PP. 377-381, (1985); MISTRY P., NATURAL CHOLESTEROL‐LOWERING PRODUCTS: FOCUS ON PROBIOTICS, BR. J. COMMUNITY NURS, 19, PP. S14-S18, (2014); KIM G.B., YI S.H., LEE B.H., PURIFICATION AND CHARACTERIZATION OF THREE DIFFERENT TYPES OF BILE SALT HYDROLASES FROM BIFIDOBACTERIUM STRAINS, J. DAIRY SCI, 87, PP. 258-266, (2004); LIONG M.T., DUNSHEA F.R., SHAH N.P., EFFECTS OF A SYNBIOTIC CONTAINING LACTOBACILLUS ACIDOPHILUS ATCC 4962 ON PLASMA LIPID PROFILES AND MORPHOLOGY OF ERYTHROCYTES IN HYPERCHOLESTEROLAEMIC PIGS ON HIGH‐ AND LOW‐FAT DIETS, BR. J. NUTR, 98, PP. 736-744, (2007); SHIMIZU M., HASHIGUCHI M., SHIGA T., TAMURA H.O., MOCHIZUKI M., META‐ANALYSIS: EFFECTS OF PROBIOTIC SUPPLEMENTATION ON LIPID PROFILES IN NORMAL TO MILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, PLOS ONE, 10, (2015); GUARDAMAGNA O., AMARETTI A., PUDDU P.E., RAIMONDI S., ABELLO F., CAGLIERO P., ROSSI M., BIFIDOBACTERIA SUPPLEMENTATION: EFFECTS ON PLASMA LIPID PROFILES IN DYSLIPIDEMIC CHILDREN, NUTRITION, 30, PP. 831-836, (2014); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ZHANG D., COOPER R., CHANG M., CONSTITUENTS OF READ YEAST RICE A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGIC. FOOD CHEM, 48, PP. 5220-5533, (2000); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR. ATHEROSCLER. REP, 17, (2015); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL‐LOWERING EFFECTS OF A PROPRIETARY CHINESE RED‐YEAST‐RICE DIETARY SUPPLEMENT, AM. J. CLIN. NUTR, 69, PP. 231-236, (1999); GERALDS M.C., TERLOU R.J., HU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID‐LOWEING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN‐ A SYSTEMATIC REWIEV AND META‐ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., MORGAN J.M., CAPUZZI D.M., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM. J. CARDIOL, 101, PP. 1689-1693, (2008); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONAKOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS: BUYER BAWARE!, ARCH. INTERN. MED, 170, PP. 1722-1727, (2010); SCIENTIFIC OPINION ON THE RISKS FOR PUBLIC AND ANIMAL HEALTH RELATED TO THE PRESENCE OF CITRININ IN FOOD AND FEED, EFSA J, 10, (2012); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTR. METAB. CARDIOVASC. DIS, 27, PP. 2-17, (2017); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 424-429, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID‐LOWERING AGENT, AM. HEART J, 143, PP. 268-279, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META‐ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEMIC AND HETEROZIGOUS FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS, BR. J. NUTR, 95, PP. 968-975, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IN INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR, 84, PP. 1543-1548, (2006); SCIENTIFIC OPINION ON THE SUBSTATIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL‐CHOLESTEROL CONCENTRATION (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL‐CHOLESTEROL CONCENTRATION (ID 1474, 1478, 1684, 1951, 1954, 4693) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, (2011); DI DONNA L., DE LUCA G., MAZZOTTI F., NAPOLI A., SALERNO R., TAVERNA D., SINDONA G., STATIN‐LIKE PRINCIPLES OF BERGAMOT FRUIT (CITRUS BERGAMIA): ISOLATION OF 3‐HYDROXYMETHYLGLUTARYL FLAVONOID GLYCOSIDES, J. NAT. PROD, 72, PP. 1352-1354, (2009); GIGLIO R.V., PATTI A.M., NIKOLIC D., VOLTI G.L., AL-RASADI K., KATSIKI N., MIKHAILIDIS D.P., MONTALTO G., IVANOVA E., OREKHOV A.N., ET AL., THE EFFECT OF BERGAMOT ON DYSLIPIDEMIA, PHYTOMEDICINE, 23, PP. 1175-1181, (2016); GLIOZZI M., WALKER R., MUSCOLI S., VITALE C., GRATTERI S., CARRESI C., MUSOLINO V., RUSSO V., JANDA E., RAGUSA S., ET AL., BERGAMOT POLYPHENOLIC FRACTION ENHANCES ROSUVASTATIN‐INDUCED EFFECT ON LDL‐CHOLESTEROL, LOX‐1 EXPRESSION AND PROTEIN KINASE B PHOSPHORYLATION IN PATIENTS WITH HYPERLIPIDEAMIA, INT. J. CARDIOL, 170, PP. 140-145, (2013); MOLLACE V., SACCO I., JANDA E., MALARA C., VENTRICE D., COLICA C., VISALLI V., MUSCOLI S., RAGUSA S., MUSCOLI C., ET AL., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, PP. 309-316, (2011); BORLINGHAUS J., ALBRECHT F., GRUHLKE M.C.H., NWACHUKWU I., SLUSARENKO A.J., ALLICIN: CHEMISTRY AND BIOLOGICAL PROPERTIES, MOLECULES, 19, PP. 12591-12618, (2014); RIED K., TOBEN C., FACKLER P., EFFECT OF GARLIC ON SERUM LIPIDS: AN UPDATED META‐ANALISYS, NUTR. REV, 71, PP. 282-299, (2013); RIED K., GARLIC LOWERS BLOOD PRESSURE IN HYPERTENSIVE INDIVIDUALS, REGULATES SERUM CHOLESTEROL AND STIMULATES IMMUNITY: AN UPDATED META‐ANALISYS AND REVIEW, J. NUTR, 146, PP. 3895-3965, (2016); JUNG E.-S., PARK S.-H., CHOI E.-K., RYU B.-H., PARK B.-H., KIM D.-S., KIM Y.-G., CHAE S, REDUCTION OF BLOOD LIPID PARAMETERS BY A 12‐WK SUPPLEMENTATION OF AGED BLACK GARLIC: A RANDOMIZED CONTROLLED TRIAL, NUTRITION, 30, PP. 1034-1039, (2014); MORIHARA N., HINO A., AGED GLARLIC EXTRACT SUPPRESSES PLATELET AGGREGATION BY CHANGING PROPERTY OF PLATELETS, J. NAT. MED, 71, PP. 249-256, (2017); ACKERMANN R.T., MULROW C.D., RAMIREZ G., GARDNER C.D., MORBIDONI L., LAWRENCE V.A., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCH. INTERN. MED, 161, PP. 813-824, (2001); RESEARCH PROGRESS ON BERBERINE WITH A SPECIAL FOCUS ON ITS ORAL BIOAVAILABILITY, FITOTERAPIA, 109, PP. 274-282, (2016); LEE S., LIM H.J., PARK J.H., LEE K.S., JANG Y., PARK H.Y., BERBERINE INDUCED LDLR UPREGULATION INVOLVES JNK PATHWAY, BIOCHEM. BIOPHYS. RES. COMMUN, 362, PP. 853-857, (2007); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT. MED, 10, PP. 1344-1351, (2004); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASE PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); LAN J., ZHAO Y., DONG F., YAN Z., ZHENG W., FAN J., SUN G., META‐ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J. ETHNOPHARMACOL, 161, PP. 69-81, (2015); DONG H., WANG N., ZHAO L., LU F., BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A SYSTEMIC REVIEW AND META‐ANALYSIS, EVID. BASED COMPLEMENTARY ALTERN. MED, 2012, (2012); DONG H., ZHAO Y., ZHAO L., LU F., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); VAN EE J.H., SOY CONSTITUENTS: MODES OF ACTION IN LOW‐DENSITY LIPOPROTEIN MANAGEMENT, NUTR. REV, 67, PP. 222-234, (2009); SETCHELL K.D.R., PHYTOESTROGENS: THE BIOCHEMISTRY, PHYSIOLOGY, AND IMPLICATIONS FOR HUMAN HEALTH OF SOY ISOFLAVONES, AM. J. CLIN. NUTR, 68, PP. 1333S-1346S, (1998); DESCOVICH G.C., CEREDI C., GADDI A., CATTIN L., SENIN U., CARUZZO C., FRAGIACOMO C., SIRTORI M., CEREDI C., BENASSI M., ET AL., MULTICENTRE STUDY OF SOYBEAN PROTEIN DIET FOR OUTPATIENT HYPERCHOLESTEROLAEMIC PATIENTS, LANCET, 2, PP. 709-712, (1980); MARLETT J.A., SITES AND MECHANISM FOR THE HYPOCHOLESTEROLEMIC ACTIONS OF SOLUBLE DIETARY FIBER SOURCES, ADV. EXP. MED. BIOL, 427, PP. 109-121, (1997); CHO S.J., JUILLERAT M.A., LEE C.H., CHOLESTEROL LOWERING MECHANISM OF SOYBEAN PROTEIN HYDROLYSATE, J. AGRIC. FOOD CHEM, 55, PP. 10599-10604, (2007); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J. NUTR, 125, PP. 606S-611S, (1995); LAMMI C., ZANONI C., SCIGLIUOLO G.M., DʹAMATO A., ARNOLDI A., LUPIN PEPTIDES LOWER LOW‐DENSITY LIPOPROTEIN (LDL) CHOLESTEROL THROUGH AN UP‐REGULATION OF THE LDL RECEPTOR/STEROL REGULATORY LEMENT BINDING PROTEIN 2 (SREBP2) PATHWAY AT HEPG2 CELL LINE, J. AGRIC. FOOD CHEM, 62, PP. 7151-7159, (2014); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); TOKEDE O.A., ONABANJO T.A., YANSANE A., GAZIANO J.M., DJOUSSE L., SOYA PRODUCTS AND SERUM LIPIDS: A META‐ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BR. J. NUTR, 114, PP. 831-843, (2015); BAHR M., FECHNER A., KIEHNTOPF M., JAHREIS G., CONSUMING A MIXED DIET ENRICHED WITH LUPIN PROTEIN BENEFICIALLY AFFECTS PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC SUBJECTS: A RANDOMIZED CONTROLLED TRIAL, CLIN. NUTR, 34, PP. 7-14, (2015); WEGHUBER D., WIDHALM K., EFFECT OF 3‐MONTH TREATMENT OF CHILDREN AND ADOLESCENTS WITH FAMILIAL AND POLYGENIC HYPERCHOLESTEROLAEMIA WITH A SOYA‐SUBSTITUTED DIET, BR. J. NUTR, 99, PP. 281-286, (2008); HELK O., WIDHALM K., EFFECTS OF A LOW‐FAT DIETARY REGIMEN ENRICHED WITH SOY IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, CLIN. NUTR, 36, PP. 150-156, (2020); SOSNOWSKA B., PENSON P., BANACH M., THE ROLE OF NUTRACEUTICALS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASC. DIAGN. THER, 7, PP. S21-S31, (2017); WAY T.-D., LIN H.-Y., KUO D.-H., TSAI S.-J., SHIEH J.-C., WU J.-C., LEE M.-R., LIN J, PU‐ERH TEA ATTENUATES HYPERLIPOGENESIS AND INDUCES HEPATOMA CELLS GROWTH ARREST THROUGH ACTIVATING AMP‐ACTIVATED PROTEIN KINASE (AMPK) IN HUMAN HEPG2 CELLS, J. AGRIC. FOOD CHEM, 57, PP. 5257-5264, (2009); SHISHIKURA Y., KHOKHAR S., MURRAY B.S., EFFECTS OF TEA POLYPHENOLS ON EMULSIFICATION OF OLIVE OIL IN A SMALL INTESTINE MODEL SYSTEM, J. AGRIC. FOOD CHEM, 54, PP. 1906-1913, (2006); LAVIE C.J., MILANI R.V., MEHERA M.R., VENTURA H.O., OMEGA‐3 POLYUNSATURED FATTY ACIDS AND CARDIOVACSULAR DISEASES, J. AM. COLL. CARDIOL, 54, PP. 585-594, (2009); JAMES M.J., GIBSON M.A., CLELAND L.G., DIETARY POLYUNSATURED FATTY ACIDS AND INFLAMMATORY MEDIATOR PRODUCTION, AM. J. CLIN. NUTR, 71, PP. 343S-348S, (2000); MILES E.A., WALLACE F.A., CALDER P.C., DIETARY FISH OIL REDUCES INTERCELLULAR ADHESION MOLECULE I AND SCAVANGER RECEPTOR EXPRESSION ON MURINE MACROFAGES, ATHEROSCLEROSIS, 152, PP. 43-50, (2000); EFSA J, 8, PP. 1796-1828, (2010); MILLER M., STONE N.J., BALLANTYNE C., BITTNER V., CRIQUI M.H., GINSBERG H.N., GOLDBERG A.C., HOWARD W.J., JACOBSON M.S., KRIS-ETHERTON P.M., ET AL., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 2292-2333, (2011); HOWE P., MORI T., BUCKLEY J., LONG CHAIN OMEGA‐3 FATTY ACIDS AND CARDIOVASCULAR DISEASE‐FNSAZ CONSIDERATION OF A COMMISIONED REVEW, BR. J. NUTR, 107, PP. S201-S213, (2012); HARRIS W.S., BULCHANDANI D., WHY DO OMEGA‐3 FATTY ACIDS LOWER SERUM TRIGLYCERIDES?, CURR. OPIN. LIPIDOL, 17, PP. 377-393, (2006); ESLICK G.D., HOWE C.R., SMITH C., PRIEST R., BENSOUSSAN A., BENEFITS OF FISH OIL SUPPLEMENTATION IN HYPERLIPIDEMIA: A SYSTEMATIC REVIEW AND MATA‐ANALYSIS, INT. J. CARDIOL, 136, PP. 4-16, (2009); LESLIE M.A., COHEN D.J., LIDDLE D.M., ROBINSON L.E., MA D.W., A REVIEW OF THE EFFECT OF OMEGA‐3 POLYUNSATURED FATTY ACIDS ON BLOOD TRIACYLGLYCEROL LEVELS IN NORMOLIPIDEMIC AND BORDERLINE HYPERLIPIDEMIC INDIVIDUALS, LIPIDS HEALTH DIS, 14, (2015); BURR M.L., FEHILY A.M., GILBERT J.F., ROGERS S., HOLLIDAY R.M., SWEETNAM P.M., ELWOOD P.C., DEADMAN N.M., EFFECTS OF CHANGES IN FAT, FISH AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART), LANCET, 2, PP. 757-761, (1989); DIETARY SUPPLEMENTATION WITH N‐3 POLYUNSATURED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCION: RESULTS OF THE GISSI‐ PREVENZIONE TRIAL GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL’INFARTO MIOCARDICO, LANCET, 354, PP. 447-455, (1999); YOKOYAMA M., ORIGASA H., MATSUZAKI M., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLSTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN‐LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); HOOPER L., THOMPSON R.L., HARRISON R.A., SUMMERBELL C.D., NESS A.R., MOORE H.J., WORTHINGTON H.V., DURRINGTON P.N., HIGGINS J.P., CAPPS N.E., ET AL., RISKS AND BENEFITS OF OMEGA 3 FATS FOR MORTALITY, CARDIOVASCULAR DISEASE, AND CANCER: SYSTEMATIC REVIEW, BMJ, 332, PP. 752-760, (2006); KWAK S., MYUNG S., LEE Y., SEO H.G., KOREAN META‐ANALYSIS STUDY GROUP. EFFICACY OF OMEGA‐3 FATTY ACID SUPPLEMENTS IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: A META‐ANALYSIS OF RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIALS, ARCH. INTERN. MED, 172, PP. 686-694, (2012); RIZOS E.C., NTZANI E.E., BIKA E., KOSTAPANOS M.S., ELISAF M.S., ASSOCIATION BETWEEN OMEGA‐3 FATTY ACID SUPPLEMENTATION AND RISK OF MAJOR CARDIOVASCULAR DISEASE EVENTS: A SYSTEMATIC REVIEW AND META‐ANALYSIS, JAMA, 308, PP. 1024-1033, (2012); A STUDY OF AMR101 TO EVALUATE ITS ABILITY TO REDUCE CARDIOVASCULAR EVENTS IN HIGH RISK PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ON STATIN (REDUCE‐IT), (2016); OUTCOMES STUDY TO ASSESS STATIN RESIDUAL RISK REDUCTION WITH EPANOVA IN HIGH CV RISK PATIENTS WITH HYPERTRYGLICERIDEMIA (STRENGHT), (2016); AGOSTONI C., BREAEGGER C., DECSI T., KOLACEK S., MIHATSCH W., MORENO L.A., PUNTIS J., SHAMIR R., SZAJEWSKA H., TURCK D., ET AL., SUPPLEMENTATION OF N‐3 LPUFA IN THE DIET OF CHILDREN OLDER THAN 2 YEARS: A COMMENTARY BY THE ESPGHAN COMMITEE ON NUTRITION, J. PEDIATR. GASTROENTEROL. NUTR, 53, PP. 2-10, (2011); ENGLER M.M., ENGLER M.B., MALLOY M.J., PAUL S.M., KULKARNI K.R., MIETUS-SNYDER M.L., EFFECT OF DOCOSAHEXAENOIC ACID ON LIPOPROTEIN SUBCLASSES IN HYPERLIPIDEMIC CHILDREN (THE EARLY STUDY), AM. J. CARDIOL, 95, PP. 869-871, (2005); DANGARDT F., OSIKA W., CHEN Y., NILSSON U., GAN L.M., GRONOWITZ E., STRANDVIK B., FRIBERG P., OMEGA‐3 FATTY ACID SUPPLEMENTATION IMPROVES VACULAR FUNCTION AND REDUCES INFLAMMATION IN OBESE ADOLESCENTS, ATHEROSCLEROSIS, 212, PP. 580-585, (2010); NOBILI V., BEDOGNI G., ALISI A., PIETROBATTISTA A., RISE P., GALLI C., AGOSTONI C., DOCOSAHEXAENOIC ACID SUPPLEMENTATION DECREASES LIVER FAT CONTENT IN CHILDREN WITH NON‐ALCOHOLIC FATTY LIVER DISEASE: DOUBLE BLIND RANDOMIZED CONTROLLED CLINICAL TRIAL, ARCH. DIS. CHILD, 96, PP. 350-353, (2011); GIDDING S.S., PROSPERO C., HOSSAIN J., ZAPPALLA F., BALAGOPAL P.B., FALKNER B., KWITEROVICH P., A DOUBLE‐BLIND RANDOMIZED TRIAL OF FISH OIL TO LOWER TRIGLYCERIDES AND IMPROVE CARDIOMETABOLIC RISK IN ADOLESCENTS, J. PEDIATR, 165, PP. 497-503, (2014); DEL BO C., DEON V., ABELLO F., MASSINI G., PORRINI M., RISO P., GUARDAMAGNA O., EIGHT‐WEEK HEMPSEED OIL INTERVENTION IMPROVES THE FATTY ACID COMPOSITION OF ERYTHROCYTE PHOSPHOLIPIDS AND THE OMEGA‐3 INDEX, BUT DOES NOT AFFECT THE LIPID PROFILE IN CHILDREN AND ADOLESCENTS WITH PRIMARY HYPERLIPIDEMIA, FOOD RES. INT, 119, PP. 469-476, (2019); RAHMANI S., ASGARY S., ASKARY G., KESHVARI M., HATAMIPOUR M., FEIZI A., SAHEBKAR A., TREATMENT OF NON‐ALCOHOLIC FATTY LIVER DISEASE WITH CURCUMIN: A RANDOMIZED PLACEBO‐CONTROLLED TRIAL, PHYTOTHER. RES, 30, PP. 1540-1548, (2016); KUMAR P., MALHOTRA P., MA K., SINGLA A., HEDROUG O., SAKSENA S., DUDEJA P.K., GILL R.K., ALREFAI W.A., SREBP2 MEDIATES THE MODULATION OF INTESTINAL NPC1L1 EXPRESSION BY CURCUMIN, AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL, 301, PP. G148-G155, (2011); LIU X.L., LIU M.H., HU H.J., FENG H.R., FAN X.J., ZOU W.W., PAN Y.Q., HU X.M., WANG Z., CURCUMIN ENHANCED CHOLESTEROL EFFLUX BY UPREGULATING ABCA1 EXPRESSION THROUGH AMPK‐SIRT1‐LXRALPHA SIGNALING IN THP‐1 MACROPHAGE‐DERIVED FOAM CELLS, DNA CELL BIOL, 34, PP. 561-572, (2015); TAI M.H., CHEN P.K., CHEN P.Y., WU M.J., HO C.T., YEN J.H., CURCUMIN ENHANCES CELL‐SURFACE LDLR LEVEL AND PROMOTES LDL UPTAKE THROUGH DOWNREGULATION OF PCSK9 GENE EXPRESSION IN HEPG2 CELLS, MOL. NUTR. FOOD RES, 58, PP. 2133-2145, (2014); MOMTAZI A.A., DEROSA G., MAFFIOLI P., BANACH M., SAHEBKAR A., ROLE OF MICRORNAS IN THE THERAPEUTIC EFFECTS OF CURCUMIN IN NON‐CANCER DISEASES, MOL. DIAGN. THER, 20, PP. 335-345, (2016); SAHEBKAR A., A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS INVESTIGATING THE EFFECTS OF CURCUMIN ON BLOOD LIPID LEVELS, CLIN. NUTR, 33, PP. 406-414, (2014); YANG Y.S., SU Y.F., YANG H.W., LEE Y.H., CHOU J.I., UENG K.C., LIPID‐LOWERING EFFECTS OF CURCUMIN IN PATIENTS WITH METABOLIC SYNDROME: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL, PHYTOTHER. RES, 28, PP. 1770-177, (2014); DEROSA G., LIMAS C.P., MACIAS P.C., ESTRELLA A., MAFFIOLI P., DIETARY AND NUTRACEUTICAL APPROACH TO TYPE 2 DIABETES, ARCH. MED. SCI, 10, PP. 336-344, (2014); RAHIMI H.R., NEDAEINIA R., SEPEHRI SHAMLOO A., NIKDOUST S., KAZEMI OSKUEE R., NOVEL DELIVERY SYSTEM FOR NATURAL PRODUCTS: NANO‐CURCUMIN FORMULATIONS, AVICENNA J. PHYTOMED, 6, PP. 383-398, (2016); CICERO A.F., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN. DRUG SAF, 11, PP. 753-766, (2012); SIMIC I., REINER Z., ADVERSE EFFECTS OF STATINS—MYTHS AND REALITY, CURR. PHARM. DES, 21, (2015); BANACH M., STULC T., DENT R., TOTH P.P., STATIN NON‐ADHERENCE AND RESIDUAL CARDIOVASCULAR RISK: THERE IS NEED FOR SUBSTANTIAL IMPROVEMENT, INT. J. CARDIOL, 225, PP. 184-196, (2016); ALEVIZOS A., MIHAS C., MARIOLIS A., ADVERTISING CAMPAIGNS OF STEROL‐ENRICHED FOOD. AN OFTEN NEGLECTED CAUSE OF REDUCED COMPLIANCE TO LIPID LOWERING DRUG THERAPY, CARDIOVASC. DRUGS THER, 21, PP. 133-134, (2007); KATSAROU A., TYROVOLAS S., PSALTOPOULOU T., ZEIMBEKIS A., TSAKOUNTAKIS N., BOUNTZIOUKA V., GOTSIS E., METALLINOS G., POLYCHRONOPOULOS E., LIONIS C., ET AL., SOCIO‐ECONOMIC STATUS, PLACE OF RESIDENCE AND DIETARY HABITS AMONG THE ELDERLY: THE MEDITERRANEAN ISLANDS STUDY, PUBLIC HEALTH NUTR, 13, PP. 1614-1621, (2010); CAPRA M.E., PEDERIVA C., VIGGIANO C., DE SANTIS R., BANDERALI G., BIASUCCI G., NUTRITIONAL APPROACH TO PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE IN CHILDHOOD, NUTRIENTS, 13, (2021); PEDERIVA C., CAPRA M.E., VIGGIANO C., ROVELLI V., BANDERALI G., BIASUCCI G., EARLY PREVENTION OF ATHEROSCLEROSIS: DETECTION AND MANAGEMENT OF HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS, LIFE, 11, (2021)","G. BIASUCCI; PAEDIATRICS AND NEONATOLOGY UNIT, CENTRE FOR PAEDIATRIC DYSLIPIDAEMIAS, GUGLIELMO DA SALICETO HOSPITAL, PIACENZA, 29121, ITALY; EMAIL: G.BIASUCCI@AUSL.PC.IT","MDPI","ENGLISH","NUTRIENTS","REVIEW","ISI","2-S2.0-85123589761","NUTRIENTS","CLINICAL SERVICE FOR DYSLIPIDAEMIAS;PARMA;CLINICAL SERVICE FOR DYSLIPIDAEMIAS;CENTRE FOR PAEDIATRIC DYSLIPIDAEMIAS;CLINICAL SERVICE FOR DYSLIPIDAEMIAS","NOTREPORTED;CENTRE FOR PAEDIATRIC DYSLIPIDAEMIAS;NOTREPORTED",NA,"BANDERALI G, 2022, NUTRIENTS","BANDERALI G, 2022, NUTRIENTS"
"CHO K;NAM H;KIM N;LEE M;KANG D","CHO, KYUNG-HYUN (7403956966); NAM, HYO-SEON (57301198400); KIM, NA-YOUNG (58848205500); LEE, MYEONG-SUNG (58848437800); KANG, DAE-JIN (57301198300)","COMBINATION THERAPY OF CUBAN POLICOSANOL RAYDEL 20 MG AND INTENSIVE EXERCISE FOR 12 WEEKS RESULTED IN IMPROVEMENTS IN OBESITY HYPERTENSION AND DYSLIPIDEMIA WITHOUT A DECREASE IN SERUM COENZYME Q10 ENHANCEMENT OF LIPOPROTEINS QUALITY AND ANTIOXIDANT FUNCTIONALITY IN OBESE PARTICIPANTS",2024,"PHARMACEUTICALS","17","",0,"10.3390/ph17010132","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA","OBESITY AND OVERWEIGHT, FREQUENTLY CAUSED BY A LACK OF EXERCISE, ARE ASSOCIATED WITH MANY METABOLIC DISEASES, SUCH AS HYPERTENSION, DIABETES, AND DYSLIPIDEMIA. AEROBIC EXERCISE EFFECTIVELY INCREASES THE HIGH-DENSITY LIPOPROTEINS-CHOLESTEROL (HDL-C) LEVELS AND ALLEVIATES THE TRIGLYCERIDE (TG) LEVELS. THE CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL®) IS ALSO EFFECTIVE IN ENHANCING THE HDL-C QUANTITY AND HDL FUNCTIONALITY TO TREAT DYSLIPIDEMIA AND HYPERTENSION. ON THE OTHER HAND, NO STUDY HAS EXAMINED THE EFFECTS OF A COMBINATION OF HIGH-INTENSITY EXERCISE AND POLICOSANOL CONSUMPTION IN OBESE SUBJECTS TO IMPROVE METABOLIC DISORDERS. IN THE CURRENT STUDY, 17 OBESE SUBJECTS (AVERAGE BMI 30.1 ± 1.1 KG/M2, EIGHT MALE AND NINE FEMALE) WERE RECRUITED TO PARTICIPATE IN A PROGRAM COMBINING EXERCISE AND POLICOSANOL (20 MG) CONSUMPTION FOR 12 WEEKS. AFTER COMPLETION, THEIR BMI, WAIST CIRCUMFERENCE, TOTAL FAT MASS, SYSTOLIC BLOOD PRESSURE (SBP), AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCED SIGNIFICANTLY UP TO AROUND −15%, −13%, −33%, −11%, AND −13%, RESPECTIVELY. IN THE SERUM LIPID PROFILE, AT WEEK 12, A SIGNIFICANT REDUCTION WAS OBSERVED IN THE TOTAL CHOLESTEROL (TC) AND TRIGLYCERIDE (TG) LEVELS, UP TO −17% AND −54% FROM THE BASELINE, RESPECTIVELY. THE SERUM HDL-C WAS ELEVATED BY APPROXIMATELY +12% FROM THE BASELINE, AS WELL AS THE PERCENTAGE OF HDL-C IN TC, AND HDL-C/TC (%), WAS ENHANCED BY UP TO +32% AT WEEK 12. THE SERUM COENZYME Q10 (COQ10) LEVEL WAS INCREASED 1.2-FOLD FROM THE BASELINE IN ALL PARTICIPANTS AT WEEK 12. IN PARTICULAR, THE MALE PARTICIPANTS EXHIBITED A 1.4-FOLD INCREASE FROM THE BASELINE. THE LARGER RISE IN SERUM COQ10 WAS CORRELATED WITH THE LARGER INCREASE IN THE SERUM HDL-C (R = 0.621, P = 0.018). THE HEPATIC FUNCTION PARAMETERS WERE IMPROVED; THE SERUM Γ-GLUTAMYL TRANSFERASE DECREASED AT WEEK 12 BY UP TO −55% (P < 0.007), WHILE THE ASPARTATE AMINOTRANSFERASE AND ALANINE TRANSAMINASE LEVELS DIMINISHED WITHIN THE NORMAL RANGE. IN THE LIPOPROTEIN LEVEL, THE EXTENT OF OXIDATION AND GLYCATION WERE REDUCED SIGNIFICANTLY WITH THE REDUCTION IN TG CONTENT. THE ANTIOXIDANT ABILITIES OF HDL, SUCH AS PARAOXONASE (PON) AND FERRIC ION REDUCTION ABILITY (FRA), WERE ENHANCED SIGNIFICANTLY BY UP TO 1.8-FOLD AND 1.6-FOLD AT WEEK 12. THE PARTICLE SIZE AND NUMBER OF HDL WERE ELEVATED UP TO +10% DURING THE 12 WEEKS, WITH A REMARKABLE DECLINE IN THE TG CONTENT, GLYCATION EXTENT, AND OXIDATION. THE IMPROVEMENTS IN HDL QUALITY AND FUNCTIONALITY WERE LINKED TO THE HIGHER SURVIVABILITY OF ADULT ZEBRAFISH AND THEIR EMBRYOS, UNDER THE CO-PRESENCE OF CARBOXYMETHYLLYSINE (CML), A PRO-INFLAMMATORY MOLECULE KNOWN TO CAUSE ACUTE DEATH. IN CONCLUSION, 12 WEEKS OF CUBAN POLICOSANOL (RAYDEL®, 20 MG) CONSUMPTION WITH HIGH-INTENSITY EXERCISE DISPLAYED A SIGNIFICANT IMPROVEMENT IN BLOOD PRESSURE, BODY FAT MASS, BLOOD LIPID PROFILE WITHOUT LIVER DAMAGE, COQ10 METABOLISM, AND RENAL IMPAIRMENT. © 2024 BY THE AUTHORS.","APOLIPOPROTEIN A-I; COENZYME Q<SUB>10</SUB>; EXERCISE; HIGH-DENSITY LIPOPROTEINS; LOW-DENSITY LIPOPROTEINS; PARAOXONASE; POLICOSANOL","6 N CARBOXYMETHYLLYSINE; ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AYDEL; CHOLESTEROL; FERRIC ION; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; MALONALDEHYDE; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; ADULT; AEROBIC EXERCISE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; BODY MASS; DEVELOPMENTAL STAGE; DYSLIPIDEMIA; ENERGY EXPENDITURE; EXERCISE; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPID FINGERPRINTING; LIVER FUNCTION; LIVER INJURY; MALE; METABOLIC DISORDER; METABOLIC EQUIVALENT; OBESE PATIENT; OBESITY; OCCUPATIONAL HEALTH; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICAL ACTIVITY; PROTEIN ANALYSIS; QUESTIONNAIRE; STATIC EXERCISE; WAIST CIRCUMFERENCE; ZEBRA FISH","","","CHEW N.W., NG C.H., TAN D.J.H., KONG G., LIN C., CHIN Y.H., LIM W.H., HUANG D.Q., QUEK J., FU C.E., ET AL., THE GLOBAL BURDEN OF METABOLIC DISEASE: DATA FROM 2000 TO 2019, CELL METAB, 35, PP. 414-428, (2023); NOUBIAP J.J., NANSSEU J.R., LONTCHI-YIMAGOU E., NKECK J.R., NYAGA U.F., NGOUO A.T., TOUNOUGA D.N., TIANYI F.L., FOKA A.J., NDOADOUMGUE A.L., ET AL., GEOGRAPHIC DISTRIBUTION OF METABOLIC SYNDROME AND ITS COMPONENTS IN THE GENERAL ADULT POPULATION: A META-ANALYSIS OF GLOBAL DATA FROM 28 MILLION INDIVIDUALS, DIABETES RES. CLIN. PRACT, 188, (2022); MAINOUS A.G., TANNER R.J., RAHMANIAN K.P., JO A., CAREK P.J., EFFECT OF SEDENTARY LIFESTYLE ON CARDIOVASCULAR DISEASE RISK AMONG HEALTHY ADULTS WITH BODY MASS INDEXES 18.5 TO 29.9 KG/M<SUP>2</SUP>, AM. J. CARDIOL, 123, PP. 764-768, (2019); PAFFENBARGER R.S., HYDE R.T., WING A.L., LEE I.-M., JUNG D.L., KAMPERT J.B., THE ASSOCIATION OF CHANGES IN PHYSICAL-ACTIVITY LEVEL AND OTHER LIFESTYLE CHARACTERISTICS WITH MORTALITY AMONG MEN, N. ENGL. J. MED, 328, PP. 538-545, (1993); KINOSHITA K., OZATO N., YAMAGUCHI T., SUDO M., YAMASHIRO Y., MORI K., ISHIDA M., KATSURAGI Y., SASAI H., YASUKAWA T., ET AL., ASSOCIATION OF SEDENTARY BEHAVIOUR AND PHYSICAL ACTIVITY WITH CARDIOMETABOLIC HEALTH IN JAPANESE ADULTS, SCI. REP, 12, (2022); JEPPESEN J., HEIN H.O., SUADICANI P., GYNTELBERG F., RELATION OF HIGH TG–LOW HDL CHOLESTEROL AND LDL CHOLESTEROL TO THE INCIDENCE OF ISCHEMIC HEART DISEASE: AN 8-YEAR FOLLOW-UP IN THE COPENHAGEN MALE STUDY, ARTER. THROMB. VASC. BIOL, 17, PP. 1114-1120, (1997); PAFFENBARGER R.S., HYDE R., WING A.L., HSIEH C.C., PHYSICAL ACTIVITY, ALL-CAUSE MORTALITY, AND LONGEVITY OF COLLEGE ALUMNI, N. ENGL. J. MED, 314, PP. 605-613, (1986); BLAIR S.N., KOHL H.W., PAFFENBARGER R.S., CLARK D.G., COOPER K.H., GIBBONS L.W., PHYSICAL FITNESS AND ALL-CAUSE MORTALITY. A PROSPECTIVE STUDY OF HEALTHY MEN AND WOMEN, J. AM. MED. ASSOC, 262, PP. 2395-2401, (1989); COUILLARD C., DESPRES J.-P., LAMARCHE B., BERGERON J., GAGNON J., LEON A.S., RAO D.C., SKINNER J.S., WILMORE J.H., BOUCHARD C., EFFECTS OF ENDURANCE EXERCISE TRAINING ON PLASMA HDL CHOLESTEROL LEVELS DEPEND ON LEVELS OF TRIGLYCERIDES: EVIDENCE FROM MEN OF THE HEALTH, RISK FACTORS, EXERCISE TRAINING AND GENETICS (HERITAGE) FAMILY STUDY, ARTER. THROMB. VASC. BIOL, 21, PP. 1226-1232, (2001); PALAZON-BRU A., HERNANDEZ-LOZANO D., GIL-GUILLEN V.F., WHICH PHYSICAL EXERCISE INTERVENTIONS INCREASE HDL-CHOLESTEROL LEVELS? A SYSTEMATIC REVIEW OF META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS, SPORTS MED, 51, PP. 243-253, (2021); GAO W., LV M., HUANG T., EFFECTS OF DIFFERENT TYPES OF EXERCISE ON HYPERTENSION IN MIDDLE-AGED AND OLDER ADULTS: A NETWORK META-ANALYSIS, FRONT. PUBLIC HEALTH, 11, (2023); LIN M., LIN Y., LI Y., LIN X., EFFECT OF EXERCISE TRAINING ON BLOOD PRESSURE VARIABILITY IN ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, PLOS ONE, 18, (2023); TOYAMA K., SUGIYAMA S., OKA H., IWASAKI Y., SUMIDA H., TANAKA T., TAYAMA S., JINNOUCHI H., OGAWA H., COMBINATION TREATMENT OF ROSUVASTATIN OR ATORVASTATIN, WITH REGULAR EXERCISE IMPROVES ARTERIAL WALL STIFFNESS IN PATIENTS WITH CORONARY ARTERY DISEASE, PLOS ONE, 7, (2012); JOY T.R., HEGELE R.A., NARRATIVE REVIEW: STATIN-RELATED MYOPATHY, ANN. INTERN. MED, 150, PP. 858-868, (2009); BONFIM M.R., OLIVEIRA A.S.B., AMARAL S.L.D., MONTEIRO H.L., TREATMENT OF DYSLIPIDEMIA WITH STATINS AND PHYSICAL EXERCISES: RECENT FINDINGS OF SKELETAL MUSCLE RESPONSES, ARQ. BRAS. CARDIOL, 104, PP. 324-331, (2015); MEADOR B.M., HUEY K.A., STATIN-ASSOCIATED MYOPATHY AND ITS EXACERBATION WITH EXERCISE, MUSCLE NERVE, 42, PP. 469-479, (2010); VINCI P., PANIZON E., TOSONI L.M., CERRATO C., PELLICORI F., MEARELLI F., BIASINUTTO C., FIOTTI N., DI GIROLAMO F.G., BIOLO G., STATIN-ASSOCIATED MYOPATHY: EMPHASIS ON MECHANISMS AND TARGETED THERAPY, INT. J. MOL. SCI, 22, (2021); OPIE L.H., EXERCISE-INDUCED MYALGIA MAY LIMIT THE CARDIOVASCULAR BENEFITS OF STATINS, CARDIOVASC. DRUGS THER, 27, PP. 569-572, (2013); SINGH R.B., NEKI N.S., KARTIKEY K., PELLA D., KUMAR A., NIAZ M.A., THAKUR A.S., EFFECT OF COENZYME Q10 ON RISK OF ATHEROSCLEROSIS IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION, VASCUL. PHARMACOL, 246, PP. 75-82, (2003); CHO K.-H., KIM S.-J., YADAV D., KIM J.-R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED. CELL. LONGEV, 2018, (2018); PARK H.-J., YADAV D., JEONG D.-J., KIM S.-J., BAE M.-A., KIM J.-R., CHO K.-H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); KIM S.-J., YADAV D., PARK H.-J., KIM J.-R., CHO K.-H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); KIM H.R., HAN M.A., ASSOCIATION BETWEEN SERUM LIVER ENZYMES AND METABOLIC SYNDROME IN KOREAN ADULTS, INT. J. ENVIRON. RES. PUBLIC HEALTH, 15, (2018); PETTERSSON J., HINDORF U., PERSSON P., BENGTSSON T., MALMQVIST U., WERKSTROM V., EKELUND M., MUSCULAR EXERCISE CAN CAUSE HIGHLY PATHOLOGICAL LIVER FUNCTION TESTS IN HEALTHY MEN, BR. J. CLIN. PHARMACOL, 65, PP. 253-259, (2008); TREDE N.S., ZAPATA A., I ZON L., FISHING FOR LYMPHOID GENES, TRENDS IMMUNOL, 22, PP. 302-307, (2001); NOVOA B., BOWMAN T., ZON L., FIGUERAS A., LPS RESPONSE AND TOLERANCE IN THE ZEBRAFISH (DANIO RERIO), FISH SHELLFISH IMMUNOL, 26, PP. 326-331, (2009); PARK S.-H., KIM C.-G., WHAT TYPES OF EXERCISE ARE MORE EFFECTIVE IN REDUCING OBESITY AND BLOOD PRESSURE FOR MIDDLE-AGED WOMEN? A SYSTEMATIC REVIEW WITH META-ANALYSIS, BIOL. RES. NURS, 23, PP. 658-675, (2021); CHO K.-H., NAM H.-S., BAEK S.-H., KANG D.-J., NA H., KOMATSU T., UEHARA Y., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT. J. MOL. SCI, 24, (2023); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN. MED. REV, 7, PP. 203-217, (2002); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., E SYMONDS M., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED, 45, PP. 89-97, (2019); SWIFT D.L., MCGEE J.E., EARNEST C.P., CARLISLE E., NYGARD M., JOHANNSEN N.M., THE EFFECTS OF EXERCISE AND PHYSICAL ACTIVITY ON WEIGHT LOSS AND MAINTENANCE, PROG. CARDIOVASC. DIS, 61, PP. 206-213, (2018); ZMUDA J.M., YURGALEVITCH S.M., FLYNN M.M., BAUSSERMAN L.L., SARATELLI A., SPANNAUS-MARTIN D.J., HERBERT P.N., THOMPSON P.D., EXERCISE TRAINING HAS LITTLE EFFECT ON HDL LEVELS AND METABOLISM IN MEN WITH INITIALLY LOW HDL CHOLESTEROL, ATHEROSCLEROSIS, 137, PP. 215-221, (1998); KODAMA S., TANAKA S., SAITO K., SHU M., SONE Y., ONITAKE F., SUZUKI E., SHIMANO H., YAMAMOTO S., KONDO K., ET AL., EFFECT OF AEROBIC EXERCISE TRAINING ON SERUM LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: A META-ANALYSIS, ARCH. INTERN. MED, 167, PP. 999-1008, (2007); GHIRLANDA G., ORADEI A., MANTO A., LIPPA S., UCCIOLI L., CAPUTO S., GRECO A.V., LITTARRU G.P., EVIDENCE OF PLASMA COQ10-LOWERING EFFECT BY HMG-COA REDUCTASE INHIBITORS: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, J. CLIN. PHARMACOL, 33, PP. 226-229, (1993); DEICHMANN R., LAVIE C., ANDREWS S., COENZYME Q10 AND STATIN-INDUCED MITOCHONDRIAL DYSFUNCTION, OCHSNER J, 10, PP. 16-21, (2010); PACANOWSKI M.A., FRYE R.F., ENOGIERU O., SCHOFIELD R.S., ZINEH I., PLASMA COENZYME Q10 PREDICTS LIPID-LOWERING RESPONSE TO HIGH-DOSE ATORVASTATIN, J. CLIN. LIPIDOL, 2, PP. 289-297, (2008); TOMASETTI M., ALLEVA R., SOLENGHI M.D., LITTARRU G.P., DISTRIBUTION OF ANTIOXIDANTS AMONG BLOOD COMPONENTS AND LIPOPROTEINS: SIGNIFICANCE OF LIPIDS/COQ<SUB>10</SUB> RATIO AS A POSSIBLE MARKER OF INCREASED RISK FOR ATHEROSCLEROSIS, BIOFACTORS, 9, PP. 231-240, (1999); KIM J., LEE J., KIM S., RYU H.Y., CHA K.S., SUNG D.J., EXERCISE-INDUCED RHABDOMYOLYSIS MECHANISMS AND PREVENTION: A LITERATURE REVIEW, J. SPORT HEALTH SCI, 5, PP. 324-333, (2015); DA SILVA PEREIRA E.N.G., PAULA D.P., DE ARAUJO B.P., DA FONSECA M., DINIZ M., DALIRY A., GRIEP R.H., ADVANCED GLYCATION END PRODUCT: A POTENTIAL BIOMARKER FOR RISK STRATIFICATION OF NON-ALCOHOLIC FATTY LIVER DISEASE IN ELSA-BRASIL STUDY, WORLD J. GASTROENTEROL, 27, PP. 4913-4928, (2021); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS” VERSUS GENUINE POLICOSANOL. REV, CENIC CIENC. QUÍM, 38, PP. 207-213, (2007); HASKELL W.L., LEE I.M., PATE R.R., POWELL K.E., BLAIR S.N., FRANKLIN B.A., MACERA C.A., HEATH G.W., THOMPSON P.D., BAUMAN A., PHYSICAL ACTIVITY AND PUBLIC HEALTH: UPDATED RECOMMENDATION FOR ADULTS FROM THE AMERICAN COLLEGE OF SPORTS MEDICINE AND THE AMERICAN HEART ASSOCIATION, CIRCULATIONS, 116, (2007); STRATH S.J., KAMINSKY L.A., AINSWORTH B.E., EKELUND U., FREEDSON P.S., GARY R.A., RICHARDSON C.R., SMITH D.T., SWARTZ A.M., GUIDE TO THE ASSESSMENT OF PHYSICAL ACTIVITY: CLINICAL AND RESEARCH APPLICATIONS: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATIONS, 128, PP. 2259-2279, (2013); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVESTIG, 34, PP. 1345-1353, (1955); MARKWELL M.A.K., HAAS S.M., BIEBER L., TOLBERT N., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM, 87, PP. 206-210, (1978); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); NOBLE R.P., ELECTROPHORETIC SEPARATION OF PLASMA LIPOPROTEINS IN AGAROSE GEL, J. LIPID RES, 9, PP. 693-700, (1968); MACKNESS M., MACKNESS B., EFFECT OF DILUTION ON HIGH-DENSITY LIPOPROTEIN ASSOCIATED PARAOXONASE-1 ACTIVITY, CLIN. BIOCHEM, 44, PP. 1270-1271, (2011); BENZIE I.F.F., STRAIN J.J., THE FERRIC REDUCING ABILITY OF PLASMA (FRAP) AS A MEASURE OF “ANTIOXIDANT POWER”: THE FRAP ASSAY, ANAL. BIOCHEM, 239, PP. 70-76, (1996); NUSSLEIN V., DAHM R., ZEBRAFISH: A PRACTICAL APPROACH, (2002); GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS, (2011); CHO K.-H., KIM J.-E., NAM H.-S., KANG D.-J., NA H.-J., ANTI-INFLAMMATORY ACTIVITY OF CIGB-258 AGAINST ACUTE TOXICITY OF CARBOXYMETHYLLYSINE IN PARALYZED ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS STABILITY AND FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); CHO K.-H., NAM H.-S., KIM J.-E., NA H.-J., DEL CARMEN DOMINGUEZ-HORTA M., MARTINEZ-DONATO G., CIGB-258 EXERTS POTENT ANTI-INFLAMMATORY ACTIVITY AGAINST CARBOXYMETHYLLYSINE-INDUCED ACUTE INFLAMMATION IN HYPERLIPIDEMIC ZEBRAFISH VIA THE PROTECTION OF APOLIPOPROTEIN A-I, INT. J. MOL. SCI, 24, (2023); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT. GENET, 40, PP. 356-361, (2008); HAYASHI M., SOFUNI T., ISHIDATE M., AN APPLICATION OF ACRIDINE ORANGE FLUORESCENT STAINING TO THE MICRONUCLEUS TEST, MUTAT. RES. LETT, 120, PP. 241-247, (1983)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","PHARMACEUTICALS","ARTICLE","ISI","2-S2.0-85183401532","PHARMACEUTICALS","RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2024, PHARMACEUTICALS","CHO K-H, 2024, PHARMACEUTICALS"
"DOU J;ZHANG Z;XU X;ZHANG X","DOU, JINJIN (57211623165); ZHANG, ZHIMING (57674403400); XU, XIANRONG (57673587800); ZHANG, XIWU (46062563100)","EXPLORING THE EFFECTS OF CHINESE HERBAL INGREDIENTS ON THE SIGNALING PATHWAY OF ALOPECIA AND THE SCREENING OF EFFECTIVE CHINESE HERBAL COMPOUNDS",2022,"JOURNAL OF ETHNOPHARMACOLOGY","294","",14,"10.1016/j.jep.2022.115320","THE FIRST HOSPITAL OF HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE, HEILONGJIANG, HARBIN, 150040, CHINA;THE FIRST HOSPITAL OF HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE, HEILONGJIANG, HARBIN, 150040, CHINA;THE FIRST HOSPITAL OF HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE, HEILONGJIANG, HARBIN, 150040, CHINA;INSTITUTE OF CHINESE MEDICINE, HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE, HEILONGJIANG, HARBIN, 150040, CHINA","ETHNOPHARMACOLOGICAL RELEVANCE: ALOPECIA IS A HAIR DISORDER THAT CAN ADD A SIGNIFICANT MEDICAL AND PSYCHOLOGICAL BURDEN TO PATIENTS. CURRENTLY, THE FDA-APPROVED DRUGS FOR THE TREATMENT OF ANDROGENETIC ALOPECIA (AGA) ARE MINOXIDIL AND FINASTERIDE AND IMMUNOSUPPRESSIVES ARE THERAPEUTIC OPTIONS FOR ALOPECIA AREATA (AA), BUT THE OBJECTIVE ADVERSE EFFECTS AND HIGH COST OF THESE TREATMENTS REDUCE PATIENT COMPLIANCE AND THUS THE EFFECTIVENESS OF THE DRUGS. TRADITIONAL CHINESE MEDICINE (TCM) HAS GOOD EFFICACY, A HIGH SAFETY PROFILE AND LOW TREATMENT COSTS, BUT ITS MECHANISM OF ACTION IS STILL NOT FULLY UNDERSTOOD. THE USE OF SIGNALING PATHWAYS TO MODULATE HAIR LOSS IS A MAJOR DIRECTION IN THE STUDY OF THE PATHOGENESIS AND PHARMACOLOGY OF ALOPECIA. AIM OF THE STUDY: THIS REVIEW AIMS TO COLLECT THE RESULTS OF EXPERIMENTAL STUDIES RELATED TO ALOPECIA, TO SCREEN PREVIOUSLY DOCUMENTED COMBINATIONS OF HERBS CLAIMED TO BE EFFECTIVE BASED ON THE HERBS AND THEIR CONSTITUENT COMPOUNDS USED IN THE IDENTIFIED STUDIES, AND TO UNCOVER OTHER USEFUL INFORMATION THAT WE HOPE WILL BETTER GUIDE THE CLINICAL APPLICATION AND SCIENTIFIC RESEARCH OF DRUG COMBINATIONS OR INDIVIDUAL HERBS FOR THE TREATMENT OF ALOPECIA. MATERIALS AND METHODS: WE HAVE REVIEWED EXPERIMENTAL STUDIES TO DETERMINE THE METHODS USED AND THE MECHANISMS OF ACTION OF THE HERBS AND CONSTITUENT COMPOUNDS. THE FOLLOWING KEYWORDS WERE SEARCHED IN DATABASES, INCLUDING PUBMED, EMBASE, CNKI AND CSTJ.” MEDICINAL PLANTS” “CHINESE HERBAL MEDICINE”, “HAIR LOSS”, “ ALOPECIA”, “ANDROGENETIC ALOPECIA” AND ” ALOPECIA AREATA "". WE ALSO COLLECTED COMBINATIONS OF DRUGS FROM BOOKS APPROVED BY VARIOUS SCHOOLS FOR SCREENING. RESULTS: USING KNOWN COMBINATIONS OF COMPOUNDS WITHIN HERBAL MEDICINE TO MATCH THE DOCUMENTED COMBINATIONS, 34 TOPICAL COMBINATIONS AND 74 ORAL COMBINATIONS WERE IDENTIFIED, AND AMONG THE 108 HERBAL COMBINATIONS SCREENED ANGELICA, REHMANNIA GLUTINOSALIGUSTICUM CHUANXIONG HORT, RADIX REHMANNIAE, ETC. THE NUMBER OF OCCURRENCES WAS VERY HIGH, AND THE ASSOCIATION WITH VASCULAR DRUGS WAS ALSO FOUND TO BE VERY CLOSE. CONCLUSIONS: THIS REVIEW FURTHER ELUCIDATES THE THERAPEUTIC MECHANISMS OF THE COMPOUNDS WITHIN THE HERBAL COMPONENTS ASSOCIATED WITH ALOPECIA AND SCREENS FOR OTHER COMBINATIONS THAT MAY BE DOMINATED BY THIS COMPONENT FOR THE TREATMENT OF ALOPECIA, UNCOVERING COMPOUNDS FROM OTHER DRUGS THAT MAY BE KEY FACTORS IN THE TREATMENT OF ALOPECIA. THIS IMPROVEMENT WILL PROVIDE A BETTER QUALITY OF EVIDENCE FOR THE EFFECTIVENESS OF HERBS AND COMPOUNDS USED TO TREAT ALOPECIA. © 2022 ELSEVIER B.V.","ACTIVE INGREDIENTS; ALOPECIA; HERBAL MEDICINE; REVIEW; SIGNALING PATHWAYS","ALOPECIA; ALOPECIA AREATA; CHINA; DRUGS, CHINESE HERBAL; HUMANS; MINOXIDIL; PLANTS, MEDICINAL; SIGNAL TRANSDUCTION; ANDROGEN RECEPTOR; ASTRAGALOSIDE IV; BAICALIN; BETA CATENIN; CASPASE; DICKKOPF 1 PROTEIN; FAS LIGAND; GINSENOSIDE; GINSENOSIDE F2; GINSENOSIDE RB 1; GINSENOSIDE RD; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KERATINOCYTE GROWTH FACTOR; LOUREIRIN A; MITOGEN ACTIVATED PROTEIN KINASE; OCTREOTIDE ACID; OLEANOLIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; POLICOSANOL; PROANTHOCYANIDIN; PROTEIN GLI; PROTEIN KINASE B; PROTEIN P53; PROTEIN P63; QUERCITRIN; SMOOTHENED PROTEIN; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; STEROID 5ALPHA REDUCTASE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN; HERBACEOUS AGENT; MINOXIDIL; ALOPECIA; ANGELICA; CANONICAL WNT SIGNALING; CHINESE MEDICINE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL STUDY; HAIR GROWTH; HAIR LOSS; HERBAL MEDICINE; HUMAN; LIGUSTICUM SINENSE; MEDICINAL PLANT; NONHUMAN; PRESCRIPTION; PROTEIN EXPRESSION LEVEL; REHMANNIA GLUTINOSA; REVIEW; SIGNAL TRANSDUCTION; TOPICAL TREATMENT; ALOPECIA; ALOPECIA AREATA; CHINA; MEDICINAL PLANT; PATHOLOGY; SIGNAL TRANSDUCTION","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, NSFC, (81703719); NATURAL SCIENCE FOUNDATION OF HEILONGJIANG PROVINCE, (LH2019H102); HEILONGJIANG PROVINCIAL POSTDOCTORAL SCIENCE FOUNDATION, (LBH-TZ1620)","THIS WORK WAS SUPPORTED AND FUNDED BY THE GENERAL PROGRAM OF NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (NUMBER 81703719 ), SPECIAL POSTDOCTORAL FOUNDATION OF HEILONGJIANG PROVINCE (NUMBER LBH-TZ1620 )，AND NATURAL SCIENCE FOUNDATION OF HEILONGJIANG PROVINCE PROJECT ( LH2019H102 ). ","AHMADZADEH A., NOROZI F., SHAHRABI S., SHAHJAHANI M., SAKI N., WNT/Β-CATENIN SIGNALING IN BONE MARROW NICHE, CELL TISSUE RES., 363, PP. 321-335, (2016); BAYNE E.K., FLANAGAN J., EINSTEIN M., AYALA J., CHANG B., AZZOLINA B., WHITING D.A., MUMFORD R.A., THIBOUTOT D., SINGER I.I., HARRIS G., IMMUNOHISTOCHEMICAL LOCALIZATION OF TYPES 1 AND 2 5ALPHA-REDUCTASE IN HUMAN SCALP, BR. J. DERMATOL., 141, PP. 481-491, (1999); BEGUM S., LEE M.R., GU L.J., HOSSAIN J., SUNG C.K., EXOGENOUS STIMULATION WITH ECLIPTA ALBA PROMOTES HAIR MATRIX KERATINOCYTE PROLIFERATION AND DOWNREGULATES TGF-Β1 EXPRESSION IN NUDE MICE, INT. J. MOL. MED., 35, PP. 496-502, (2015); BEN-PORATH I., WEINBERG R.A., THE SIGNALS AND PATHWAYS ACTIVATE CELLULAR SENESCENCE, INT. J. BIOCHEM. CELL BIOL., 37, PP. 961-976, (2005); BENNETT M., MACDONALD K., CHAN S.W., LUZIO J.P., SIMARI R., WEISSBERG P., CELL SURFACE TRAFFICKING OF FAS: A RAPID MECHANISM OF P53-MEDIATED APOPTOSIS, SCIENCE, 282, PP. 290-293, (1998); BOTCHKAREVA N.V., AHLUWALIA G., SHANDER D., APOPTOSIS IN THE HAIR FOLLICLE, J. INVEST. DERMATOL., 126, PP. 258-264, (2006); CHANG F., LEE J.T., NAVOLANIC P.M., STEELMAN L.S., SHELTON J.G., BLALOCK W.L., FRANKLIN R.A., MCCUBREY J.A., INVOLVEMENT OF PI3K/AKT PATHWAY IN CELL CYCLE PROGRESSION, APOPTOSIS, AND NEOPLASTIC TRANSFORMATION: A TARGET FOR CANCER CHEMOTHERAPY, LEUKEMIA, 17, PP. 590-603, (2003); CHEN M.L., SYNDROME DIFFERENTIATION AND TREATMENT OF ANDROGENIC ALOPECIA, SHANGHAI J. TRADIT. CHIN. MED. 2008, 42, 12, PP. 47-48, (2008); CHEN L., DUAN H., XIE F., GAO Z., WU X., CHEN F., WU W., TETRAHYDROXYSTILBENE GLUCOSIDE EFFECTIVELY PREVENTS APOPTOSIS INDUCED HAIR LOSS, BIOMED RES. INT., 2018, (2018); CHENG Y., THE CORRELATION BETWEEN IGF-1, FGF7 AND BIOLOGICAL CHARACTERISTICS OF DERMAL PAPILLA CELLS AND THE EFFECTS OF SNMC AND DEXAMETH ON THE ACTIVITY OF DERMAL PAPILLA CELLS, (2010); CHO E.C., KIM K., A COMPREHENSIVE REVIEW OF BIOCHEMICAL FACTORS IN HERBS AND THEIR CONSTITUENT COMPOUNDS IN EXPERIMENTAL STUDIES ON ALOPECIA, J. ETHNOPHARMACOL., 258, (2020); CHO Y.-S., BAE J.-M., CHUN Y.-S., CHUNG J.-H., JEON Y.-K., KIM I.-S., KIM M.-S., PARK J.-W., HIF-1ALPHA CONTROLS KERATINOCYTE PROLIFERATION BY UP-REGULATING P21(WAF1/CIP1), BIOCHIM. BIOPHYS. ACTA, 1783, PP. 323-333, (2008); CHOI Y.M., AN S., LEE J., LEE J.H., LEE J.N., KIM Y.S., AHN K.J., AN I.-S., BAE S., TITRATED EXTRACT OF CENTELLA ASIATICA INCREASES HAIR INDUCTIVE PROPERTY THROUGH INHIBITION OF STAT SIGNALING PATHWAY IN THREE-DIMENSIONAL SPHEROID CULTURED HUMAN DERMAL PAPILLA CELLS, BIOSCI. BIOTECHNOL. BIOCHEM., 81, PP. 2323-2329, (2017); CIANFARANI F., BERNARDINI S., LUCA N.D., DELLAMBRA E., TATANGELO L., TIVERON C., NIESSEN C.M., ZAMBRUNO G., CASTIGLIA D., ODORISIO T., IMPAIRED KERATINOCYTE PROLIFERATIVE AND CLONOGENIC POTENTIAL IN TRANSGENIC MICE OVEREXPRESSING 14-3-3Σ IN THE EPIDERMIS, J. INVEST. DERMATOL., 131, PP. 1821-1829, (2011); CLEVERS H., NUSSE R., WNT/Β-CATENIN SIGNALING AND DISEASE, CELL, 149, PP. 1192-1205, (2012); DAI X., SEGRE J.A., TRANSCRIPTIONAL CONTROL OF EPIDERMAL SPECIFICATION AND DIFFERENTIATION, CURR. OPIN. GENET. DEV., 14, PP. 485-491, (2004); DAMAK S., SU H., JAY N.P., BULLOCK D.W., IMPROVED WOOL PRODUCTION IN TRANSGENIC SHEEP EXPRESSING INSULIN-LIKE GROWTH FACTOR 1, BIOTECHNOLOGY, 14, PP. 185-188, (1996); DESLYPERE J.-P., YOUNG M., WILSON J.D., MCPHAUL M.J., TESTOSTERONE AND 5Α-DIHYDROTESTOSTERONE INTERACT DIFFERENTLY WITH THE ANDROGEN RECEPTOR TO ENHANCE TRANSCRIPTION OF THE MMTV-CAT REPORTER GENE, MOL. CELL. ENDOCRINOL., 88, PP. 15-22, (1992); DHARIWALA M.Y., RAVIKUMAR P., AN OVERVIEW OF HERBAL ALTERNATIVES IN ANDROGENETIC ALOPECIA, J. COSMET. DERMATOL., 18, PP. 966-975, (2019); ELLIS J.A., STEBBING M., HARRAP S.B., GENETIC ANALYSIS OF MALE PATTERN BALDNESS AND THE 5ALPHA-REDUCTASE GENES, J. INVEST. DERMATOL., 110, PP. 849-853, (1998); FAN R.Q., ZHONG GUO PI FU BING XING BING XUECHINESE DERMATOLOGY & VENEREOLOGY, (2010); FAWZI M.M.T., MAHMOUD S.B., SHAKER O.G., SALEH M.A., ASSESSMENT OF TISSUE LEVELS OF DICKKOPF-1 IN ANDROGENETIC ALOPECIA AND ALOPECIA, J. COSMET. DERMATOL., 15, PP. 10-15, (2016); FOITZIK K., LINDNER G., MUELLER-ROEVER S., MAURER M., BOTCHKAREVA N., BOTCHKAREV V., HANDJISKI B., METZ M., HIBINO T., SOMA T., DOTTO G.P., PAUS R., CONTROL OF MURINE HAIR FOLLICLE REGRESSION (CATAGEN) BY TGF-BETA1 IN VIVO, FASEB. J., 14, PP. 752-760, (2000); GAFTER-GVILI A., SREDNI B., GAL R., GAFTER U., KALECHMAN Y., CYCLOSPORIN A-INDUCED HAIR GROWTH IN MICE IS ASSOCIATED WITH INHIBITION OF CALCINEURIN-DEPENDENT ACTIVATION OF NFAT IN FOLLICULAR KERATINOCYTES, AM. J. PHYSIOL. CELL PHYSIOL., 284, PP. C1593-C1603, (2003); GARZA L.A., LIU Y., YANG Z., ALAGESAN B., LAWSON J.A., NORBERG S.M., LOY D.E., ZHAO T., BLATT H.B., STANTON D.C., CARRASCO L., AHLUWALIA G., FISCHER S.M., FITZGERALD G.A., COTSARELIS G., PROSTAGLANDIN D2 INHIBITS HAIR GROWTH AND IS ELEVATED IN BALD SCALP OF MEN WITH ANDROGENETIC ALOPECIA, SCI. TRANSL. MED., 4, (2012); HAN W.X., YE Q.Y., IDENTIFICATION AND TREATMENT OF 290 CASES OF SEBORRHEIC ALOPECIA, ZHEJIANG J. TRADIT. CHIN. MED. 1996, 6, (1996); HEEMERS H.V., TINDALL D.J., ANDROGEN RECEPTOR (AR) COREGULATORS: A DIVERSITY OF FUNCTIONS CONVERGING ON AND REGULATING THE AR TRANSCRIPTIONAL COMPLEX, ENDOCR. REV., 28, PP. 778-808, (2007); HERMEKING H., EICK D., MEDIATION OF C-MYC-INDUCED APOPTOSIS BY P53, SCIENCE, 265, PP. 2091-2093, (1994); HIBINO T., NISHIYAMA T., ROLE OF TGF-BETA2 IN THE HUMAN HAIR CYCLE, J. DERMATOL. SCI., 35, PP. 9-18, (2004); HU S., WANG W., ZHONG E., YU B., MA G., CLINICAL STUDY ON THE ANALYSIS OF MALE PATTERN BALDNESS SCALE AND FINASTERIDE TREATMENT IN 320 CASES, J. XI'AN JIAOTONG UNIV., MED. SCI., 30, 5, PP. 620-623, (2009); HSU Y.-C., PASOLLI H.A., FUCHS E., DYNAMICS BETWEEN STEM CELLS, NICHE, AND PROGENY IN THE HAIR FOLLICLE, CELL, 144, PP. 92-105, (2011); HU S., LI Z., LUTZ H., HUANG K., SU T., CORES J., DINH P.-U.C., CHENG K., DERMAL EXOSOMES CONTAINING MIR-218-5P PROMOTE HAIR REGENERATION BY REGULATING Β-CATENIN SIGNALING, SCI. ADV., 6, (2020); HUANG P., YAN R., ZHANG X., WANG L., KE X., QU Y., ACTIVATING WNT/Β-CATENIN SIGNALING PATHWAY FOR DISEASE THERAPY: CHALLENGES AND OPPORTUNITIES, PHARMACOL. THER., 196, PP. 79-90, (2019); HUH S., LEE J., JUNG E., KIM S.-C., KANG J.-I., LEE J., KIM Y.-W., SUNG Y.K., KANG H.-K., PARK D., A CELL-BASED SYSTEM FOR SCREENING HAIR GROWTH-PROMOTING AGENTS, ARCH. DERMATOL. RES., 301, PP. 381-385, (2009); IGATA M., MOTOSHIMA H., TSURUZOE K., KOJIMA K., MATSUMURA T., KONDO T., TAGUCHI T., NAKAMARU K., YANO M., KUKIDOME D., MATSUMOTO K., TOYONAGA T., ASANO T., NISHIKAWA T., ARAKI E., ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE SUPPRESSES VASCULAR SMOOTH MUSCLE CELL PROLIFERATION THROUGH THE INHIBITION OF CELL CYCLE PROGRESSION, CIRC. RES., 97, PP. 837-844, (2005); INUI S., ITAMI S., MOLECULAR BASIS OF ANDROGENETIC ALOPECIA: FROM ANDROGEN TO PARACRINE MEDIATORS THROUGH DERMAL PAPILLA, J. DERMATOL. SCI., 61, PP. 1-6, (2011); INUI S., FUKUZATO Y., NAKAJIMA T., YOSHIKAWA K., ITAMI S., ANDROGEN-INDUCIBLE TGF-BETA1 FROM BALDING DERMAL PAPILLA CELLS INHIBITS EPITHELIAL CELL GROWTH: A CLUE TO UNDERSTAND PARADOXICAL EFFECTS OF ANDROGEN ON HUMAN HAIR GROWTH, FASEB. J., 16, PP. 1967-1969, (2002); JAMERSON T.A., AGUH C., AN APPROACH TO PATIENTS WITH ALOPECIA, MED. CLIN., 105, PP. 599-610, (2021); JINDO T., TSUBOI R., TAKAMORI K., OGAWA H., LOCAL INJECTION OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) ALTERS CYCLIC GROWTH OF MURINE HAIR FOLLICLES, J. INVEST. DERMATOL., 110, PP. 338-342, (1998); KAI-HONG J., JUN X., KAI-MENG H., YING W., HOU-QI L., P63 EXPRESSION PATTERN DURING RAT EPIDERMIS MORPHOGENESIS AND THE ROLE OF P63 AS A MARKER FOR EPIDERMAL STEM CELLS, J. CUTAN. PATHOL., 34, PP. 154-159, (2007); KANG J.-I., KIM E.-J., KIM M.-K., JEON Y.-J., KANG S.-M., KOH Y.-S., YOO E.-S., KANG H.-K., THE PROMOTING EFFECT OF ISHIGE SINICOLA ON HAIR GROWTH, MAR. DRUGS, 11, PP. 1783-1799, (2013); KARADAG KOSE O., GULEC A.T., CLINICAL EVALUATION OF ALOPECIAS USING A HANDHELD DERMATOSCOPE, J. AM. ACAD. DERMATOL., 67, PP. 206-214, (2012); KIM E.K., CHOI E.-J., PATHOLOGICAL ROLES OF MAPK SIGNALING PATHWAYS IN HUMAN DISEASES, BIOCHIM BIOPHYS ACTA 1802, PP. 396-405, (2010); KIM S.-H., SHIN T.-Y., ANTI-INFLAMMATORY EFFECT OF LEAVES OF ERIOBOTRYA JAPONICA CORRELATING WITH ATTENUATION OF P38 MAPK, ERK, AND NF-KAPPAB ACTIVATION IN MAST CELLS, TOXICOL. VITRO, 23, PP. 1215-1219, (2009); KIM S.-C., KANG J.-I., PARK D.-B., LEE Y.-K., HYUN J.-W., KOH Y.-S., YOO E.-S., KIM J.A., KIM Y.H., KANG H.-K., PROMOTION EFFECT OF ACANKOREOSIDE J, A LUPANE-TRITERPENE IN ACANTHOPANAX KOREANUM, ON HAIR GROWTH, ARCH PHARM. RES. (SEOUL), 35, PP. 1495-1503, (2012); KIM A.-R., KIM S.-N., JUNG I.-K., KIM H.-H., PARK Y.-H., PARK W.-S., THE INHIBITORY EFFECT OF SCUTELLARIA BAICALENSIS EXTRACT AND ITS ACTIVE COMPOUND, BAICALIN, ON THE TRANSLOCATION OF THE ANDROGEN RECEPTOR WITH IMPLICATIONS FOR PREVENTING ANDROGENETIC ALOPECIA, PLANTA MED., 80, PP. 153-158, (2014); KIM M.H., KIM S.-H., YANG W.M., BENEFICIAL EFFECTS OF ASTRAGALOSIDE IV FOR HAIR LOSS VIA INHIBITION OF FAS/FAS L-MEDIATED APOPTOTIC SIGNALING, PLOS ONE, 9, (2014); KIM J., SHIN J.Y., CHOI Y.-H., JANG M., NAM Y.J., LEE S.Y., JEON J., JIN M.H., LEE S., HAIR GROWTH PROMOTING EFFECT OF HOTTUYNIA CORDATA EXTRACT IN CULTURED HUMAN HAIR FOLLICLE DERMAL PAPILLA CELLS, BIOL. PHARM. BULL., 42, PP. 1665-1673, (2019); KIM J., KIM S.R., CHOI Y.-H., SHIN J.Y., KIM C.D., KANG N.-G., PARK B.C., LEE S., QUERCITRIN STIMULATES HAIR GROWTH WITH ENHANCED EXPRESSION OF GROWTH FACTORS VIA ACTIVATION OF MAPK/CREB SIGNALING PATHWAY, MOLECULES, 25, (2020); KISCHKEL F.C., HELLBARDT S., BEHRMANN I., GERMER M., PAWLITA M., KRAMMER P.H., PETER M.E., CYTOTOXICITY-DEPENDENT APO-1 (FAS/CD95)-ASSOCIATED PROTEINS FORM A DEATH-INDUCING SIGNALING COMPLEX (DISC) WITH THE RECEPTOR, EMBO J., 14, PP. 5579-5588, (1995); KISHIMOTO J., BURGESON R.E., MORGAN B.A., WNT SIGNALING MAINTAINS THE HAIR-INDUCING ACTIVITY OF THE DERMAL PAPILLA, GENES DEV., 14, PP. 1181-1185, (2000); KUMAR A.R., ISHII L.E., HAIR TRANSPLANTATION FOR SCARRING ALOPECIA, FACIAL PLAST SURG CLIN NORTH AM, 28, PP. 177-179, (2020); KWACK M.H., SUNG Y.K., CHUNG E.J., IM S.U., AHN J.S., KIM M.K., KIM J.C., DIHYDROTESTOSTERONE-INDUCIBLE DICKKOPF 1 FROM BALDING DERMAL PAPILLA CELLS CAUSES APOPTOSIS IN FOLLICULAR KERATINOCYTES, J. INVEST. DERMATOL., 128, PP. 262-269, (2008); KWACK M.H., AHN J.S., KIM M.K., KIM J.C., SUNG Y.K., PREVENTABLE EFFECT OF L-THREONATE, AN ASCORBATE METABOLITE, ON ANDROGEN-DRIVEN BALDING VIA REPRESSION OF DIHYDROTESTOSTERONE-INDUCED DICKKOPF-1 EXPRESSION IN HUMAN HAIR DERMAL PAPILLA CELLS, BMB REP, 43, PP. 688-692, (2010); LACHGAR S., MOUKADIRI H., JONCA F., CHARVERON M., BOUHADDIOUI N., GALL Y., BONAFE J.L., PLOUET J., VASCULAR ENDOTHELIAL GROWTH FACTOR IS AN AUTOCRINE GROWTH FACTOR FOR HAIR DERMAL PAPILLA CELLS, J. INVEST. DERMATOL., 106, PP. 17-23, (1996); LAO Z., FAN Y., HUO Y., LIAO F., ZHANG R., ZHANG B., KONG Z., LONG H., XIE J., SANG C., FU L., LIN J., WU Y., YU L., LI G., PHYSCION, A NOVEL INHIBITOR OF 5Α-REDUCTASE THAT PROMOTES HAIR GROWTH IN VITRO AND IN VIVO, ARCH. DERMATOL. RES., (2021); LEE Y., KIM S.N., HONG Y.D., PARK B.C., NA Y., PANAX GINSENG EXTRACT ANTAGONIZES THE EFFECT OF DKK1-INDUCED CATAGEN-LIKE CHANGES OF HAIR FOLLICLES, INT. J. MOL. MED., 40, PP. 1194-1200, (2017); LI F., THE REGULATION OF LOUREIRIN A TO PROMOTE PROLIFERATION AND DIFFERENTIATION OF FOLLICLE STEM CELLS AND LOUREIRIN A REPAIR VIBRISSA SKIN WOUND OF RATS, (2016); LI Y.-H., ZHANG K., YE J.-X., LIAN X.-H., YANG T., WNT10B PROMOTES GROWTH OF HAIR FOLLICLES VIA A CANONICAL WNT SIGNALING PATHWAY, CLIN. EXP. DERMATOL., 36, PP. 534-540, (2011); LI Z., LI J.-J., GU L.-J., ZHANG D.-L., WANG Y.-B., SUNG C.-K., GINSENOSIDES RB₁ AND RD REGULATE PROLIFERATION OF MATURE KERATINOCYTES THROUGH INDUCTION OF P63 EXPRESSION IN HAIR FOLLICLES, PHYTOTHER RES., 27, PP. 1095-1101, (2013); LI Y., HAN M., LIN P., HE Y., YU J., ZHAO R., HAIR GROWTH PROMOTION ACTIVITY AND ITS MECHANISM OF POLYGONUM MULTIFLORUM, EVID BASED COMPLEMENT ALTERNAT MED 2015, (2015); LIM X., TAN S.H., KOH W.L.C., CHAU R.M.W., YAN K.S., KUO C.J., VAN AMERONGEN R., KLEIN A.M., NUSSE R., INTERFOLLICULAR EPIDERMAL STEM CELLS SELF-RENEW VIA AUTOCRINE WNT SIGNALING, SCIENCE, 342, PP. 1226-1230, (2013); LIU W., CHEN D.C., ADVANCES IN CHINESE AND WESTERN MEDICINE RESEARCH ON SEBORRHEIC ALOPECIA, INF. TRADIT. CHIN. MED. 2003, 6, PP. 24-26, (2003); LIU B., CHEN X., YI H., HAN L., JI B., CHEN H., DENG W., WAN M., Β-CATENIN IS INVOLVED IN OLEANOLIC ACID-DEPENDENT PROMOTION OF PROLIFERATION IN HUMAN HAIR MATRIX CELLS IN AN IN VITRO ORGAN CULTURE MODEL, FITOTERAPIA, 121, PP. 136-140, (2017); MA S.R., ZHANG B.C., LIU Y.C., PROFESSOR LIU YANCHI'S EXPERIENCE IN TREATING SEBORRHEIC ALOPECIA, J. ANHUI UNIV. CHIN. MED. 2006, 6, PP. 18-20, (2006); MALKUD S., A HOSPITAL-BASED STUDY TO DETERMINE CAUSES OF DIFFUSE HAIR LOSS IN WOMEN, J. CLIN. DIAGN. RES., 9, PP. WC01-4, (2015); MARTIN S.S., VUORI K., REGULATION OF BCL-2 PROTEINS DURING ANOIKIS AND AMORPHOSIS, BIOCHIM. BIOPHYS. ACTA, 1692, PP. 145-157, (2004); MARTIN D.A., SIEGEL R.M., ZHENG L., LENARDO M.J., MEMBRANE OLIGOMERIZATION AND CLEAVAGE ACTIVATES THE CASPASE-8 (FLICE/MACHALPHA1) DEATH SIGNAL, J. BIOL. CHEM., 273, PP. 4345-4349, (1998); MASCHARAK S., DESJARDINS-PARK H.E., DAVITT M.F., GRIFFIN M., BORRELLI M.R., MOORE A.L., CHEN K., DUOTO B., CHINTA M., FOSTER D.S., SHEN A.H., JANUSZYK M., KWON S.H., WERNIG G., WAN D.C., LORENZ H.P., GURTNER G.C., LONGAKER M.T., PREVENTING ENGRAILED-1 ACTIVATION IN FIBROBLASTS YIELDS WOUND REGENERATION WITHOUT SCARRING, SCIENCE, 372, (2021); MCCUBREY J.A., STEELMAN L.S., BLALOCK W.L., LEE J.T., MOYE P.W., CHANG F., PEARCE M., SHELTON J.G., WHITE M.K., FRANKLIN R.A., POHNERT S.C., SYNERGISTIC EFFECTS OF PI3K/AKT ON ABROGATION OF CYTOKINE-DEPENDENCY INDUCED BY ONCOGENIC RAF, ADV. ENZYM. REGUL., 41, PP. 289-323, (2001); MEIDAN V.M., TOUITOU E., TREATMENTS FOR ANDROGENETIC ALOPECIA AND ALOPECIA AREATA: CURRENT OPTIONS AND FUTURE PROSPECTS, DRUGS, 61, PP. 53-69, (2001); MULLER M., STRAND S., HUG H., HEINEMANN E.M., WALCZAK H., HOFMANN W.J., STREMMEL W., KRAMMER P.H., GALLE P.R., DRUG-INDUCED APOPTOSIS IN HEPATOMA CELLS IS MEDIATED BY THE CD95 (APO-1/FAS) RECEPTOR/LIGAND SYSTEM AND INVOLVES ACTIVATION OF WILD-TYPE P53, J. CLIN. INVEST., 99, PP. 403-413, (1997); MULLER M., WILDER S., BANNASCH D., ISRAELI D., LEHLBACH K., LI-WEBER M., FRIEDMAN S.L., GALLE P.R., STREMMEL W., OREN M., KRAMMER P.H., P53 ACTIVATES THE CD95 (APO-1/FAS) GENE IN RESPONSE TO DNA DAMAGE BY ANTICANCER DRUGS, J. EXP. MED., 188, PP. 2033-2045, (1998); MURATA K., NOGUCHI K., KONDO M., ONISHI M., WATANABE N., OKAMURA K., MATSUDA H., PROMOTION OF HAIR GROWTH BY ROSMARINUS OFFICINALIS LEAF EXTRACT, PHYTOTHER RES., 27, PP. 212-217, (2013); OUJI Y., YOSHIKAWA M., MORIYA K., ISHIZAKA S., EFFECTS OF WNT-10B ON HAIR SHAFT GROWTH IN HAIR FOLLICLE CULTURES, BIOCHEM. BIOPHYS. RES. COMMUN., 359, PP. 516-522, (2007); OUJI Y., YOSHIKAWA M., MORIYA K., NISHIOFUKU M., MATSUDA R., ISHIZAKA S., WNT-10B, UNIQUELY AMONG WNTS, PROMOTES EPITHELIAL DIFFERENTIATION AND SHAFT GROWTH, BIOCHEM. BIOPHYS. RES. COMMUN., 367, PP. 299-304, (2008); OZEKI M., TABATA Y., IN VIVO PROMOTED GROWTH OF MICE HAIR FOLLICLES BY THE CONTROLLED RELEASE OF GROWTH FACTORS, BIOMATERIALS, 24, PP. 2387-2394, (2003); PARK H.-J., ZHANG N., PARK D.K., TOPICAL APPLICATION OF POLYGONUM MULTIFLORUM EXTRACT INDUCES HAIR GROWTH OF RESTING HAIR FOLLICLES THROUGH UPREGULATING SHH AND Β-CATENIN EXPRESSION IN C57BL/6 MICE, J. ETHNOPHARMACOL., 135, PP. 369-375, (2011); PELLEGRINI G., DELLAMBRA E., GOLISANO O., MARTINELLI E., FANTOZZI I., BONDANZA S., PONZIN D., MCKEON F., LUCA M.D., P63 IDENTIFIES KERATINOCYTE STEM CELLS, PROC. NATL. ACAD. SCI. U. S. A., 98, PP. 3156-3161, (2001); PRALL O.W., SARCEVIC B., MUSGROVE E.A., WATTS C.K., SUTHERLAND R.L., ESTROGEN-INDUCED ACTIVATION OF CDK4 AND CDK2 DURING G1-S PHASE PROGRESSION IS ACCOMPANIED BY INCREASED CYCLIN D1 EXPRESSION AND DECREASED CYCLIN-DEPENDENT KINASE INHIBITOR ASSOCIATION WITH CYCLIN E-CDK2, J. BIOL. CHEM., 272, PP. 10882-10894, (1997); QIN Z., WEI Y.G., PROFESSOR WEI YUEGANG'S CLINICAL EXPERIENCE OF SYNDROME DIFFERENTIATION IN TREATING ANDROGENETIC ALOPECIA, WORLD CHIN. MED. 2014, 9, 5, (2014); RANDALL V.A., 9 ROLE OF 5Α-REDUCTASE IN HEALTH AND DISEASE, BAILLIERE. CLIN. ENDOCRINOL. METABOL., 8, PP. 405-431, (1994); ROSKOSKI R., SRC PROTEIN-TYROSINE KINASE STRUCTURE, MECHANISM, AND SMALL MOLECULE INHIBITORS, PHARMACOL. RES., 94, PP. 9-25, (2015); SAKAGUCHI I., ISHIMOTO H., MATSUO M., IKEDA N., MINAMINO M., KATO Y., THE WATER-SOLUBLE EXTRACT OF ILLICIUM ANISATUM STIMULATES MOUSE VIBRISSAE FOLLICLES IN ORGAN CULTURE, EXP. DERMATOL., 13, PP. 499-504, (2004); SATO A., TAKEDA A., EVALUATION OF EFFICACY AND SAFETY OF FINASTERIDE 1 MG IN 3177 JAPANESE MEN WITH ANDROGENETIC ALOPECIA, J. DERMATOL., 39, PP. 27-32, (2012); SATO N., LEOPOLD P.L., CRYSTAL R.G., EFFECT OF ADENOVIRUS-MEDIATED EXPRESSION OF SONIC HEDGEHOG GENE ON HAIR REGROWTH IN MICE WITH CHEMOTHERAPY-INDUCED ALOPECIA, J. NATL. CANCER INST., 93, PP. 1858-1864, (2001); SAWAYA M.E., PRICE V.H., DIFFERENT LEVELS OF 5ALPHA-REDUCTASE TYPE I AND II, AROMATASE, AND ANDROGEN RECEPTOR IN HAIR FOLLICLES OF WOMEN AND MEN WITH ANDROGENETIC ALOPECIA, J. INVEST. DERMATOL., 109, PP. 296-300, (1997); SAXENA N., YADAV P., KUMAR O., THE FAS/FAS LIGAND APOPTOTIC PATHWAY IS INVOLVED IN ABRIN-INDUCED APOPTOSIS, TOXICOL. SCI., 135, PP. 103-118, (2013); SCHULTZ D.R., HARRINGTON W.J., APOPTOSIS: PROGRAMMED CELL DEATH AT A MOLECULAR LEVEL, SEMIN. ARTHRITIS RHEUM., 32, PP. 345-369, (2003); SEITZ C.S., LIN Q., DENG H., KHAVARI P.A., ALTERATIONS IN NF-KAPPAB FUNCTION IN TRANSGENIC EPITHELIAL TISSUE DEMONSTRATE A GROWTH INHIBITORY ROLE FOR NF-KAPPAB, PROC. NATL. ACAD. SCI. U. S. A., 95, PP. 2307-2312, (1998); SELLHEYER K., BICKENBACH J.R., ROTHNAGEL J.A., BUNDMAN D., LONGLEY M.A., KRIEG T., ROCHE N.S., ROBERTS A.B., ROOP D.R., INHIBITION OF SKIN DEVELOPMENT BY OVEREXPRESSION OF TRANSFORMING GROWTH FACTOR BETA 1 IN THE EPIDERMIS OF TRANSGENIC MICE, PROC. NATL. ACAD. SCI. U. S. A., 90, PP. 5237-5241, (1993); SERRANO M., LIN A.W., MCCURRACH M.E., BEACH D., LOWE S.W., ONCOGENIC RAS PROVOKES PREMATURE CELL SENESCENCE ASSOCIATED WITH ACCUMULATION OF P53 AND P16INK4A, CELL, 88, PP. 593-602, (1997); SHIN H.-S., LEE J.-M., PARK S.-Y., YANG J.-E., KIM J.-H., YI T.-H., HAIR GROWTH ACTIVITY OF CRATAEGUS PINNATIFIDA ON C57BL/6 MOUSE MODEL, PHYTOTHER RES., 27, PP. 1352-1357, (2013); SHIN H.-S., PARK S.-Y., HWANG E.-S., LEE D.-G., MAVLONOV G.T., YI T.-H., GINSENOSIDE F2 REDUCES HAIR LOSS BY CONTROLLING APOPTOSIS THROUGH THE STEROL REGULATORY ELEMENT-BINDING PROTEIN CLEAVAGE ACTIVATING PROTEIN AND TRANSFORMING GROWTH FACTOR-Β PATHWAYS IN A DIHYDROTESTOSTERONE-INDUCED MOUSE MODEL, BIOL. PHARM. BULL., 37, PP. 755-763, (2014); SHIN H.-S., PARK S.-Y., HWANG E.-S., LEE D.-G., SONG H.-G., MAVLONOV G.T., YI T.-H., THE INDUCTIVE EFFECT OF GINSENOSIDE F2 ON HAIR GROWTH BY ALTERING THE WNT SIGNAL PATHWAY IN TELOGEN MOUSE SKIN, EUR. J. PHARMACOL., 730, PP. 82-89, (2014); SHIN H.-S., PARK S.-Y., SONG H.-G., HWANG E., LEE D.-G., YI T.-H., THE ANDROGENIC ALOPECIA PROTECTIVE EFFECTS OF FORSYTHIASIDE-A AND THE MOLECULAR REGULATION IN A MOUSE MODEL, PHYTOTHER RES., 29, PP. 870-876, (2015); ST-JACQUES B., DASSULE H.R., KARAVANOVA I., BOTCHKAREV V.A., LI J., DANIELIAN P.S., MCMAHON J.A., LEWIS P.M., PAUS R., MCMAHON A.P., SONIC HEDGEHOG SIGNALING IS ESSENTIAL FOR HAIR DEVELOPMENT, CURR. BIOL., 8, PP. 1058-1069, (1998); STRAZZULLA L.C., WANG E.H.C., AVILA L., LO SICCO K., BRINSTER N., CHRISTIANO A.M., SHAPIRO J., ALOPECIA AREATA: DISEASE CHARACTERISTICS, CLINICAL EVALUATION, AND NEW PERSPECTIVES ON PATHOGENESIS, J. AM. ACAD. DERMATOL., 78, PP. 1-12, (2018); SU Y.-S., FAN Z.-X., XIAO S.-E., LIN B.-J., MIAO Y., HU Z.-Q., LIU H., ICARIIN PROMOTES MOUSE HAIR FOLLICLE GROWTH BY INCREASING INSULIN-LIKE GROWTH FACTOR 1 EXPRESSION IN DERMAL PAPILLARY CELLS, CLIN. EXP. DERMATOL., 42, PP. 287-294, (2017); TABOLLI S., SAMPOGNA F., DI PIETRO C., MANNOORANPARAMPIL T.J., RIBUFFO M., ABENI D., HEALTH STATUS, COPING STRATEGIES, AND ALEXITHYMIA IN SUBJECTS WITH ANDROGENETIC ALOPECIA: A QUESTIONNAIRE STUDY, AM. J. CLIN. DERMATOL., 14, PP. 139-145, (2013); TAGUCHI T., BRITTLE NAILS AND HAIR LOSS IN HYPOTHYROIDISM, N. ENGL. J. MED., 379, (2018); TAKAHASHI T., ISHINO A., ARAI T., HAMADA C., NAKAZAWA Y., IWABUCHI T., TAJIMA M., IMPROVEMENT OF ANDROGENETIC ALOPECIA WITH TOPICAL SOPHORA FLAVESCENS AITON EXTRACT, AND IDENTIFICATION OF THE TWO ACTIVE COMPOUNDS IN THE EXTRACT THAT STIMULATE PROLIFERATION OF HUMAN HAIR KERATINOCYTES, CLIN. EXP. DERMATOL., 41, PP. 302-307, (2016); TAKAYASU S., ADACHI K., THE CONVERSION OF TESTOSTERONE TO 17 -HYDROXY-5 -ANDROSTAN-3-ONE (DIHYDROTESTOSTERONE) BY HUMAN HAIR FOLLICLES, J. CLIN. ENDOCRINOL. METAB., 34, PP. 1098-1101, (1972); TANG Y., PLASTRUM TESTUDINIS EXTRACTS PROMOTE HAIR FOLLICLE STEM CELL PROLIFERATION AND WOUND HEALING OF SD RAT BY ACTIVATING, (2017); TRUEB R.M., DIAS M.F.R.G., ALOPECIA AREATA: A COMPREHENSIVE REVIEW OF PATHOGENESIS AND MANAGEMENT, CLIN. REV. ALLERGY IMMUNOL., 54, PP. 68-87, (2018); TRUONG A.B., KRETZ M., RIDKY T.W., KIMMEL R., KHAVARI P.A., P63 REGULATES PROLIFERATION AND DIFFERENTIATION OF DEVELOPMENTALLY MATURE KERATINOCYTES, GENES DEV., 20, PP. 3185-3197, (2006); TRUONG V.-L., BAK M.J., LEE C., JUN M., JEONG W.-S., HAIR REGENERATIVE MECHANISMS OF RED GINSENG OIL AND ITS MAJOR COMPONENTS IN THE TESTOSTERONE-INDUCED DELAY OF ANAGEN ENTRY IN C57BL/6 MICE, MOLECULES, 22, (2017); URYSIAK-CZUBATKA I., KMIEC M.L., BRONIARCZYK-DYLA G., ASSESSMENT OF THE USEFULNESS OF DIHYDROTESTOSTERONE IN THE DIAGNOSTICS OF PATIENTS WITH ANDROGENETIC ALOPECIA, POSTEPY DERMATOL. ALERGOL., 31, PP. 207-215, (2014); VASSEROT A.P., GEYFMAN M., POLOSO N.J., ANDROGENETIC ALOPECIA: COMBING THE HAIR FOLLICLE SIGNALING PATHWAYS FOR NEW THERAPEUTIC TARGETS AND MORE EFFECTIVE TREATMENT OPTIONS, EXPERT OPIN. THER. TARGETS, 23, PP. 755-771, (2019); VINCENT M., YOGIRAJ K., A DESCRIPTIVE STUDY OF ALOPECIA PATTERNS AND THEIR RELATION TO THYROID DYSFUNCTION, INT. J. TRICHOL., 5, PP. 57-60, (2013); WANG L.F., A STUDY ON THE CORRELATION BETWEEN THE PATHOGENESIS OF 214 PATIENTS WITH SEBORRHEIC ALOPECIA AND THE IDENTIFICATION OF CHINESE MEDICINE, (2016); WANG Z.D., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL ON THE MOUSE MODEL OF TESTOSTERONE INDUCED HAIR LOSS, (2017); WANG L.C., LIU Z.Y., GAMBARDELLA L., DELACOUR A., SHAPIRO R., YANG J., SIZING I., RAYHORN P., GARBER E.A., BENJAMIN C.D., WILLIAMS K.P., TAYLOR F.R., BARRANDON Y., LING L., BURKLY L.C., REGULAR ARTICLES: CONDITIONAL DISRUPTION OF HEDGEHOG SIGNALING PATHWAY DEFINES ITS CRITICAL ROLE IN HAIR DEVELOPMENT AND REGENERATION, J. INVEST. DERMATOL., 114, PP. 901-908, (2000); WANG T.L., SHEN Y.W., ZHOU C., WANG X.Y., DING X.L., TIAN S., LIU Y., PENG G.H., XUE S.Q., ZHOU J.E., WANG R.L., MENG X.M., PEI G.D., BAI Y.H., LIU Q., LI H., CHEN J., ZHANG J.Z., A SURVEY ON THE PREVALENCE OF BALDNESS IN SIX CHINESE CITIES, CHIN. J. DERMATOL. 2009, 10, PP. 668-670, (2009); WANG T.L., ZHOU C., SHEN Y.W., WANG X.Y., DING X.L., TIAN S., LIU Y., PENG G.H., XUE S.Q., ZHOU J.E., WANG R.L., MENG X.M., PEI G.D., BAI Y.H., LIU Q., LI H., ZHANG J.Z., PREVALENCE OF ANDROGENETIC ALOPECIA IN CHINA: A COMMUNITY-BASED STUDY IN SIX CITIES, BR. J. DERMATOL., 162, PP. 843-847, (2010); WERNER S., SMOLA H., LIAO X., LONGAKER M.T., KRIEG T., HOFSCHNEIDER P.H., WILLIAMS L.T., THE FUNCTION OF KGF IN MORPHOGENESIS OF EPITHELIUM AND REEPITHELIALIZATION OF WOUNDS, SCIENCE, 266, PP. 819-822, (1994); XIE X.-S., LIU H.-C., FAN J.-M., LI H.-J., EFFECTS OF GINSENOSIDE RB1 ON TGF-BETA1 INDUCED P47PHOX EXPRESSION AND EXTRACELLULAR MATRIX ACCUMULATION IN RAT RENAL TUBULAR EPETHELIAL CELLS, SICHUAN DA XUE XUE BAO YI XUE BAN, 40, PP. 106-110, (2009); XIE X.-S., LIU H.-C., YANG M., ZUO C., DENG Y., FAN J.-M., GINSENOSIDE RB1, A PANOXADIOL SAPONIN AGAINST OXIDATIVE DAMAGE AND RENAL INTERSTITIAL FIBROSIS IN RATS WITH UNILATERAL URETERAL OBSTRUCTION, CHIN. J. INTEGR. MED., 15, PP. 133-140, (2009); XING F., THE MECHANISM OF ACTIVE INGREDIENT BAICALIN FACILITATING HAIR GROWTH, (2018); YANG Z.B., ZHONG YI PI FU XING BING XUECHINESE MEDICINE DERMATOLOGY, (2020); YANG S., ZHAO Q.L., PROFESSOR CHENG YICHUN'S EXPERIENCE IN TREATING SEBORRHEIC ALOPECIA BY TREATING BLOOD AND DISPELLING WIND, YUNNAN J. TRADIT. CHIN. MED. MATER. MED. 2014, 35, 9, PP. 11-12, (2014); YANO K., BROWN L.F., DETMAR M., CONTROL OF HAIR GROWTH AND FOLLICLE SIZE BY VEGF-MEDIATED ANGIOGENESIS, J. CLIN. INVEST., 107, PP. 409-417, (2001); YOON H.-S., KANG J.-I., KIM S.M., KO A., KOH Y.-S., HYUN J.-W., YOON S.-P., AHN M.J., KIM Y.H., KANG J.-H., YOO E.-S., KANG H.-K., NORGALANTHAMINE STIMULATES PROLIFERATION OF DERMAL PAPILLA CELLS VIA ANAGEN-ACTIVATING SIGNALING PATHWAYS, BIOL PHARM BULL, 42, PP. 139-143, (2019); ZHANG L.-J., BHATTACHARYA S., LEID M., GANGULI-INDRA G., INDRA A.K., CTIP2 IS A DYNAMIC REGULATOR OF EPIDERMAL PROLIFERATION AND DIFFERENTIATION BY INTEGRATING EGFR AND NOTCH SIGNALING, J. CELL SCI., 125, PP. 5733-5744, (2012); ZHAO Z.R., CHEN Z.Q., WANG S.L., LI C.G., LI F., ZHANG D., LI X.Q., THE PATHOGENESIS AND PROGRESS OF DRUG THERAPY ON SEBORRHEIC, NORTHWEST PHARM. J., 4, PP. 440-442, (2016); ZHOU N., FAN W., LI M., ANGIOGENIN IS EXPRESSED IN HUMAN DERMAL PAPILLA CELLS AND STIMULATES HAIR GROWTH, ARCH. DERMATOL. RES., 301, PP. 139-149, (2009); ZHOU L., WANG H., JING J., YU L., WU X., LU Z., MORRONISIDE REGULATES HAIR GROWTH AND CYCLE TRANSITION VIA ACTIVATION OF THE WNT/Β-CATENIN SIGNALING PATHWAY, SCI. REP., 8, (2018); ZHU X.J., PI FU XING BING XUEDERMATOLOGICAL VENEREOLOGY, (2002)","X. ZHANG; INSTITUTE OF CHINESE MEDICINE, HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE, HARBIN, HEILONGJIANG, 150040, CHINA; EMAIL: 149772105@QQ.COM","ELSEVIER IRELAND LTD","ENGLISH","J. ETHNOPHARMACOL.","REVIEW","ISI","2-S2.0-85129729113","J ETHNOPHARMACOL","THE FIRST HOSPITAL OF HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE;THE FIRST HOSPITAL OF HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE;THE FIRST HOSPITAL OF HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE;HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE","NOTREPORTED;HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE;NOTREPORTED",NA,"DOU J, 2022, J ETHNOPHARMACOL","DOU J, 2022, J ETHNOPHARMACOL"
"PEREIRA J;OLIVEIRA D;FAUSTINO M;VIDIGAL S;PEREIRA A;FERREIRA C;OLIVEIRA A;DURÃO J;RODRÍGUEZ-ALCALÁ L;PINTADO M;MADUREIRA A;CARVALHO A","PEREIRA, JOANA ODILA (47161503100); OLIVEIRA, DIANA (54997561500); FAUSTINO, MARGARIDA (57207875726); VIDIGAL, SUSANA S. M. P. (11739488200); PEREIRA, ANA MARGARIDA (56011089300); FERREIRA, CARLOS M. H. (56379586600); OLIVEIRA, ANA SOFIA (59056017700); DURÃO, JOANA (25936036000); RODRÍGUEZ-ALCALÁ, LUÍS M. (19337562900); PINTADO, MANUELA E. (7004483898); MADUREIRA, ANA RAQUEL (8384097900); CARVALHO, ANA P. (36855267200)","USE OF VARIOUS SUGARCANE BYPRODUCTS TO PRODUCE LIPID EXTRACTS WITH BIOACTIVE PROPERTIES PHYSICOCHEMICAL AND BIOLOGICAL CHARACTERIZATION",2024,"BIOMOLECULES","14","",0,"10.3390/biom14020233","CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL, AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL, AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL, AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL, AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL, AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL","SUGARCANE, A GLOBALLY CULTIVATED CROP CONSTITUTING NEARLY 80% OF TOTAL SUGAR PRODUCTION, YIELDS RESIDUES FROM HARVESTING AND SUGAR PRODUCTION KNOWN FOR THEIR RENEWABLE BIOACTIVE COMPOUNDS WITH HEALTH-PROMOTING PROPERTIES. DESPITE PREVIOUS STUDIES, THE INTRICATE INTERPLAY OF EXTRACTS FROM DIVERSE SUGARCANE BYPRODUCTS AND THEIR BIOLOGICAL ATTRIBUTES REMAINS UNDEREXPLORED. THIS STUDY FOCUSED ON EXTRACTING THE LIPID FRACTION FROM A BLEND OF SELECTED SUGARCANE BYPRODUCTS (STRAW, BAGASSE, AND FILTER CAKE) USING ETHANOL. THE RESULTING EXTRACT UNDERWENT COMPREHENSIVE CHARACTERIZATION, INCLUDING PHYSICOCHEMICAL ANALYSIS (FT-IR, DSC, PARTICLE SIZE DISTRIBUTION, AND COLOR) AND CHEMICAL COMPOSITION ASSESSMENT (GC-MS). THE BIOLOGICAL PROPERTIES WERE EVALUATED THROUGH ANTIHYPERTENSIVE (ACE), ANTICHOLESTEROLEMIC (HMG-COA REDUCTASE), AND ANTIDIABETIC (ALPHA-GLUCOSIDASE AND DIPEPTIDYL PEPTIDASE-IV) ASSAYS, ALONGSIDE IN VITRO BIOCOMPATIBILITY ASSESSMENTS IN CACO-2 AND HEP G2 CELLS. THE PHYTOCHEMICALS IDENTIFIED, SUCH AS Β-SITOSTEROL AND 1-OCTACOSANOL, LIKELY CONTRIBUTE TO THE EXTRACT’S ANTIDIABETIC, ANTICHOLESTEROLEMIC, AND ANTIHYPERTENSIVE POTENTIAL, GIVEN THEIR ASSOCIATION WITH VARIOUS BENEFICIAL BIOACTIVITIES. THE EXTRACT EXHIBITED SUBSTANTIAL ANTIDIABETIC EFFECTS, INHIBITING Α-GLUCOSIDASE (5–60%) AND DPP-IV ACTIVITY (25–100%), ANTICHOLESTEROLEMIC POTENTIAL WITH HMG-COA REDUCTASE INHIBITION (11.4–63.2%), AND ANTIHYPERTENSIVE PROPERTIES THROUGH ACE INHIBITION (24.0–27.3%). THESE FINDINGS LAY THE GROUNDWORK FOR INCORPORATING THESE INGREDIENTS INTO THE DEVELOPMENT OF FOOD SUPPLEMENTS OR NUTRACEUTICALS, OFFERING POTENTIAL FOR PREVENTING AND MANAGING METABOLIC SYNDROME-ASSOCIATED CONDITIONS. © 2024 BY THE AUTHORS.","ANTICHOLESTEROLEMIC; ANTIDIABETIC; ANTIHYPERTENSION; LIPID EXTRACT; SUGARCANE","ALPHA-GLUCOSIDASES; ANTIHYPERTENSIVE AGENTS; CACO-2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; PLANT EXTRACTS; SACCHARUM; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUGARS; ALOGLIPTIN; ALPHA GLUCOSIDASE; CAMPESTEROL; DIPEPTIDYL PEPTIDASE IV; GEMIGLIPTIN; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; OLEIC ACID; PALMITIC ACID; POLICOSANOL; SAXAGLIPTIN; SITAGLIPTIN; STIGMASTEROL; TENELIGLIPTIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CARBOHYDRATE; LIPID; PLANT EXTRACT; ANTIDIABETIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CACO-2 CELL LINE; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MASS FRAGMENTOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PHYSICAL CHEMISTRY; SUGARCANE; CHEMISTRY; METABOLISM","AMYRIS BIO PRODUCTS PORTUGAL; ESCOLA SUPERIOR DE BIOTECNOLOGIA; INDUSTRIAL FERMENTATION BIO PRODUCTS, (POCI-01-0247-FEDER-027578); UNIVERSIDADE CATÓLICA PORTUGUESA, UCP; EUROPEAN REGIONAL DEVELOPMENT FUND, ERDF","THIS WORK WAS CO-FINANCED BY THE EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF), THROUGH THE OPERATIONAL PROGRAM FOR COMPETITIVENESS AND INTERNATIONALIZATION (POCI) SUPPORTED BY AMYRIS BIO PRODUCTS PORTUGAL, UNIPESSOAL LDA, AND THE ESCOLA SUPERIOR DE BIOTECNOLOGIA—UNIVERSIDADE CATÓLICA PORTUGUESA THROUGH THE ALCHEMY PROJECT ‘CAPTURING HIGH VALUE FROM INDUSTRIAL FERMENTATION BIO PRODUCTS (POCI-01-0247-FEDER-027578)’.","SHENOY A., BUTTAR H.S., DICHOLKAR P., KAUR G., CHINTAMANENI M., ROLE OF NUTRACEUTICALS, FUNCTIONAL FOODS, AND SPICES IN THE MANAGEMENT OF METABOLIC SYNDROME AND RELATED DISORDERS, FUNCTIONAL FOODS AND NUTRACEUTICALS METABOLIC AND NON-COMMUNICABLE DISEASES, PP. 583-601, (2022); HAYDEN M.R., OVERVIEW AND NEW INSIGHTS INTO THE METABOLIC SYNDROME: RISK FACTORS AND EMERGING VARIABLES IN THE DEVELOPMENT OF TYPE 2 DIABETES AND CEREBROCARDIOVASCULAR DISEASE, MEDICINA, 59, (2023); WANG H.H., LEE D.K., LIU M., PORTINCASA P., WANG D.Q.H., NOVEL INSIGHTS INTO THE PATHOGENESIS AND MANAGEMENT OF THE METABOLIC SYNDROME, PEDIATR. GASTROENTEROL. HEPATOL. NUTR, 23, (2020); CHENG A.Y.Y., GOMES M.B., KALRA S., KENGNE A.P., MATHIEU C., SHAW J.E., APPLYING THE WHO GLOBAL TARGETS FOR DIABETES MELLITUS, NAT. REV. ENDOCRINOL, 19, PP. 194-200, (2023); SAEEDI P., PETERSOHN I., SALPEA P., MALANDA B., KARURANGA S., UNWIN N., COLAGIURI S., GUARIGUATA L., MOTALA A.A., OGURTSOVA K., ET AL., GLOBAL AND REGIONAL DIABETES PREVALENCE ESTIMATES FOR 2019 AND PROJECTIONS FOR 2030 AND 2045: RESULTS FROM THE INTERNATIONAL DIABETES FEDERATION DIABETES ATLAS, 9TH EDITION, DIABETES RES. CLIN. PRACT, 157, (2019); SAGBO I.J., VAN DE VENTER M., KOEKEMOER T., BRADLEY G., IN VITRO ANTIDIABETIC ACTIVITY AND MECHANISM OF ACTION OF BRACHYLAENA ELLIPTICA (THUNB.) DC, EVID.-BASED COMPLEMENT. ALTERN. MED, 2018, PP. 1-13, (2018); SALEHI B., ATA A., KUMAR N.V.A., SHAROPOV F., RAMIREZ-ALARCON K., RUIZ-ORTEGA A., AYATOLLAHI S.A., FOKOU P.V.T., KOBARFARD F., ZAKARIA Z.A., ET AL., ANTIDIABETIC POTENTIAL OF MEDICINAL PLANTS AND THEIR ACTIVE COMPONENTS, BIOMOLECULES, 9, (2019); BERTOLUCI M.C., ROCHA V.Z., CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS WITH DIABETES, DIABETOL. METAB. SYNDR, 9, (2017); KO S.H., CAO W., LIU Z., HYPERTENSION MANAGEMENT AND MICROVASCULAR INSULIN RESISTANCE IN DIABETES, CURR. HYPERTENS. REP, 12, PP. 243-251, (2010); PETRIE J.R., GUZIK T.J., TOUYZ R.M., DIABETES, HYPERTENSION, AND CARDIOVASCULAR DISEASE: CLINICAL INSIGHTS AND VASCULAR MECHANISMS, CAN. J. CARDIOL, 34, PP. 575-584, (2018); YANG S.T., KREUTZBERGER A.J.B., LEE J., KIESSLING V., TAMM L.K., THE ROLE OF CHOLESTEROL IN MEMBRANE FUSION, CHEM. PHYS. LIPIDS, 199, PP. 136-143, (2016); LINTON M.F., YANCEY P.G., DAVIES S.S., JEROME W.G., LINTON E.F., SONG W.L., DORAN A.C., VICKERS K.C., THE ROLE OF LIPIDS AND LIPOPROTEINS IN ATHEROSCLEROSIS, SCIENCE, 111, PP. 166-186, (2019); CORETA-GOMES F.M., LOPES G.R., PASSOS C.P., VAZ I.M., MACHADO F., GERALDES C.F.G.C., MORENO M.J., NYSTROM L., COIMBRA M.A., IN VITRO HYPOCHOLESTEROLEMIC EFFECT OF COFFEE COMPOUNDS, NUTRIENTS, 12, (2020); CHOPRA A.S., LORDAN R., HORBANCZUK O.K., ATANASOV A.G., CHOPRA I., HORBANCZUK J.O., JOZWIK A., HUANG L., PIRGOZLIEV V., BANACH M., ET AL., THE CURRENT USE AND EVOLVING LANDSCAPE OF NUTRACEUTICALS, PHARMACOL. RES, 175, (2022); TEIXEIRA F.S., VIDIGAL S.S.M.P., PIMENTEL L.L., COSTA P.T., PINTADO M.E., RODRIGUEZ-ALCALA L.M., BIOACTIVE SUGARCANE LIPIDS IN A CIRCULAR ECONOMY CONTEXT, FOODS, 10, (2021); SINGH A., LAL U.R., MUKHTAR H.M., SINGH P.S., SHAH G., DHAWAN R.K., PHYTOCHEMICAL PROFILE OF SUGARCANE AND ITS POTENTIAL HEALTH ASPECTS, PHARMACOGN. REV, 9, PP. 45-54, (2015); MICALLEF M.A., GARG M.L., BEYOND BLOOD LIPIDS: PHYTOSTEROLS, STATINS AND OMEGA-3 POLYUNSATURATED FATTY ACID THERAPY FOR HYPERLIPIDEMIA, J. NUTR. BIOCHEM, 20, PP. 927-939, (2009); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); FURTADO N.A.J.C., PIRSON L., EDELBERG H., MIRANDA L.M., LOIRA-PASTORIZA C., PREAT V., LARONDELLE Y., ANDRE C.M., PENTACYCLIC TRITERPENE BIOAVAILABILITY: AN OVERVIEW OF IN VITRO AND IN VIVO STUDIES, MOLECULES, 22, (2017); TEIXEIRA F.S., PIMENTEL L.L., VIDIGAL S.S.M.P., COSTA P.T., PINTADO M.E., RODRIGUEZ-ALCALA L.M., SUITABILITY OF SOLVENT-ASSISTED EXTRACTION FOR RECOVERY OF LIPOPHILIC PHYTOCHEMICALS IN SUGARCANE STRAW AND BAGASSE, FOODS, 11, (2022); KWON Y.I., APOSTOLIDIS E., SHETTY K., IN VITRO STUDIES OF EGGPLANT (SOLANUM MELONGENA) PHENOLICS AS INHIBITORS OF KEY ENZYMES RELEVANT FOR TYPE 2 DIABETES AND HYPERTENSION, BIORESOUR. TECHNOL, 99, PP. 2981-2988, (2008); AMORIM M., MARQUES C., PEREIRA J.O., GUARDAO L., MARTINS M.J., OSORIO H., MOURA D., CALHAU C., PINHEIRO H., PINTADO M., ANTIHYPERTENSIVE EFFECT OF SPENT BREWER YEAST PEPTIDE, PROCESS BIOCHEM, 76, PP. 213-218, (2019); BIOLOGICAL EVALUATION OF MEDICAL DEVICES—PART 5: TESTS FOR IN VITRO CYTOTOXICITY, ANSI/AAMI/ISO 10993-5:2009/(R)2014; BIOLOGICAL EVALUATION OF MEDICAL DEVICES—PART 5: TESTS FOR IN VITRO CYTOTOXICITY, (2009); ATTARD T.M., MCELROY C.R., REZENDE C.A., POLIKARPOV I., CLARK J.H., HUNT A.J., SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES, IND. CROPS PROD, 76, PP. 95-103, (2015); DEL RIO J.C., MARQUES G., LINO A.G., LIMA C.F., COLODETTE J.L., GUTIERREZ A., LIPOPHILIC PHYTOCHEMICALS FROM SUGARCANE BAGASSE AND STRAW, IND. CROPS PROD, 77, PP. 992-1000, (2015); GUIMARAES A., VENANCIO A., THE POTENTIAL OF FATTY ACIDS AND THEIR DERIVATIVES AS ANTIFUNGAL AGENTS: A REVIEW, TOXINS, 14, (2022); RAO M.J., TAHIR UL QAMAR M., WANG D., ALI Q., MA L., HAN S., DUAN M., HU L., WANG L., A HIGH-THROUGHPUT LIPIDOMICS AND TRANSCRIPTOMIC APPROACH REVEALS NOVEL COMPOUNDS FROM SUGARCANE LINKED WITH PROMISING THERAPEUTIC POTENTIAL AGAINST COVID-19, FRONT. NUTR, 9, (2022); LEDON N., CASACO A., REMIREZ D., GONZALEZ A., CRUZ J., GONZALEZ R., CAPOTE A., TOLON Z., ROJAS E., RODRIGUEZ V.J., ET AL., EFFECTS OF A MIXTURE OF FATTY ACIDS FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) WAX OIL IN TWO MODELS OF INFLAMMATION: ZYMOSAN-INDUCED ARTHRITIS AND MICE TAIL TEST OF PSORIASIS, PHYTOMEDICINE, 14, PP. 690-695, (2007); FENG S., LUO Z., ZENG F., LIU S., KHAN Z.U., EFFECT OF WATER, METALLIC IONS, FATTY ACID AND TEMPERATURE ON OXIDATIVE STABILITY OF 1-OCTACOSANOL FROM SUGARCANE RIND, FOOD CHEM, 182, PP. 171-177, (2015); ALVAREZ-HENAO M.V., CARDONA L., HINCAPIE S., LONDONO-LONDONO J., JIMENEZ-CARTAGENA C., SUPERCRITICAL FLUID EXTRACTION OF PHYTOSTEROLS FROM SUGARCANE BAGASSE: EVALUATION OF EXTRACTION PARAMETERS, J. SUPERCRIT. FLUIDS, 179, (2022); FENG S., LIU S., LUO Z., TANG K., DIRECT SAPONIFICATION PREPARATION AND ANALYSIS OF FREE AND CONJUGATED PHYTOSTEROLS IN SUGARCANE (SACCHARUM OFFICINARUM L.) BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, FOOD CHEM, 181, PP. 9-14, (2015); FENG S., LUO Z., ZHANG Y., ZHONG Z., LU B., PHYTOCHEMICAL CONTENTS AND ANTIOXIDANT CAPACITIES OF DIFFERENT PARTS OF TWO SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, FOOD CHEM, 151, PP. 452-458, (2014); LIN Y., KNOL D., VALK I., VAN ANDEL V., FRIEDRICHS S., LUTJOHANN D., HRNCIRIK K., TRAUTWEIN E.A., THERMAL STABILITY OF PLANT STEROLS AND FORMATION OF THEIR OXIDATION PRODUCTS IN VEGETABLE OILS AND MARGARINES UPON CONTROLLED HEATING, CHEM. PHYS. LIPIDS, 207, PP. 99-107, (2017); SOCRATES G., INFRARED AND RAMAN CHARACTERISTIC GROUP FREQUENCIES: TABLES AND CHARTS, (2004); GOH C.F., HADGRAFT J., LANE M.E., THERMAL ANALYSIS OF MAMMALIAN STRATUM CORNEUM USING DIFFERENTIAL SCANNING CALORIMETRY FOR ADVANCING SKIN RESEARCH AND DRUG DELIVERY, INT. J. PHARM, 614, (2022); CHANTRAPORNCHAI W., CLYDESDALE F.M., MCCLEMENTS D.J., UNDERSTANDING COLORS IN EMULSIONS, ACS SYMP. SER, 983, PP. 364-387, (2008); GU X., DU L., MENG Z., COMPARATIVE STUDY OF NATURAL WAX-BASED W/O EMULSION GELS: MICROSTRUCTURE AND MACROSCOPIC PROPERTIES, FOOD RES. INT, 165, (2023); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT. J. NANOMED, 9, PP. 2261-2269, (2014); HO T.M., RAZZAGHI A., RAMACHANDRAN A., MIKKONEN K.S., EMULSION CHARACTERIZATION VIA MICROFLUIDIC DEVICES: A REVIEW ON INTERFACIAL TENSION AND STABILITY TO COALESCENCE, ADV. COLLOID INTERFACE SCI, 299, (2022); ALAGESAN K., THENNARASU P., KUMAR V., SANKARNARAYANAN S., BALSAMY T., IDENTIFICATION OF Α-GLUCOSIDASE INHIBITORS FROM PSIDIUM GUAJAVA LEAVES AND SYZYGIUM CUMINI LINN. SEEDS, INT. J. PHARMA SCI. RES, 3, PP. 316-322, (2012); PAPOUTSIS K., ZHANG J., BOWYER M.C., BRUNTON N., GIBNEY E.R., LYNG J., FRUIT, VEGETABLES, AND MUSHROOMS FOR THE PREPARATION OF EXTRACTS WITH Α-AMYLASE AND Α-GLUCOSIDASE INHIBITION PROPERTIES: A REVIEW, FOOD CHEM, 338, (2021); TASLIMI P., GULCIN I., ANTIDIABETIC POTENTIAL: IN VITRO INHIBITION EFFECTS OF SOME NATURAL PHENOLIC COMPOUNDS ON Α-GLYCOSIDASE AND Α-AMYLASE ENZYMES, J. BIOCHEM. MOL. TOXICOL, 31, (2017); KSHIRSAGAR A.D., AGGARWAL A.S., HARLE U.N., DESHPANDE A.D., DPP IV INHIBITORS: SUCCESSES, FAILURES AND FUTURE PROSPECTS, DIABETES METAB. SYNDR. CLIN. RES. REV, 5, PP. 105-112, (2011); AL-MASRI I.M., MOHAMMAD M.K., TAHAA M.O., INHIBITION OF DIPEPTIDYL PEPTIDASE IV (DPP IV) IS ONE OF THE MECHANISMS EXPLAINING THE HYPOGLYCEMIC EFFECT OF BERBERINE, J. ENZYME INHIB. MED. CHEM, 24, PP. 1061-1066, (2009); DEACON C.F., DIPEPTIDYL PEPTIDASE 4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, NAT. REV. ENDOCRINOL, 16, PP. 642-653, (2020); OLIVEIRA A.L.S., CARVALHO M.J., OLIVEIRA D.L., COSTA E., PINTADO M., MADUREIRA A.R., SUGARCANE STRAW POLYPHENOLS AS POTENTIAL FOOD AND NUTRACEUTICAL INGREDIENT, FOODS, 11, (2022); BASKARAN G., SALVAMANI S., AHMAD S.A., SHAHARUDDIN N.A., PATTIRAM P.D., SHUKOR M.Y., HMG-COA REDUCTASE INHIBITORY ACTIVITY AND PHYTOCOMPONENT INVESTIGATION OF BASELLA ALBA LEAF EXTRACT AS A TREATMENT FOR HYPERCHOLESTEROLEMIA, DRUG DES. DEV. THER, 9, PP. 509-517, (2015); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL. RES, 29, PP. 253-257, (1996); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES. CLIN. EXP, 51, PP. 568-575, (1992); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., MESA M., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR. THER. RES. CLIN. EXP, 64, PP. 522-537, (2003); CHO K.H., NAM H.S., BAEK S.H., KANG D.J., NA H., KOMATSU T., UEHARA Y., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT. J. MOL. SCI, 24, (2023); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); POLESI L.F., SARMENTO S.B.S., CANNIATTI-BRAZACA S.G., STARCH DIGESTIBILITY AND FUNCTIONAL PROPERTIES OF RICE STARCH SUBJECTED TO GAMMA RADIATION, RICE SCI, 25, PP. 42-51, (2018); NUNES A.R., GONCALVES A.C., ALVES G., FALCAO A., GARCIA-VIGUERA C., MORENO D.A., SILVA L.R., VALORISATION OF PRUNUS AVIUM L. BY-PRODUCTS: PHENOLIC COMPOSITION AND EFFECT ON CACO-2 CELLS VIABILITY, FOODS, 10, (2021); TEIXEIRA F.S., PIMENTEL L.L., VIDIGAL S.S.M.P., AZEVEDO-SILVA J., PINTADO M.E., RODRIGUEZ-ALCALA L.M., DIFFERENTIAL LIPID ACCUMULATION ON HEPG2 CELLS TRIGGERED BY PALMITIC AND LINOLEIC FATTY ACIDS EXPOSURE, MOLECULES, 28, (2023)","J.O. PEREIRA; CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA, LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, PORTO, RUA DIOGO BOTELHO 1327, 4169-005, PORTUGAL; EMAIL: JOANAODILA@GMAIL.COM","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","BIOMOLECULES","ARTICLE","ISI","2-S2.0-85185898891","BIOMOLECULES","UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA","NOTREPORTED;UNIVERSIDADE CATÓLICA PORTUGUESA;NOTREPORTED",NA,"PEREIRA JO, 2024, BIOMOLECULES","PEREIRA JO, 2024, BIOMOLECULES"
"BAGHERNIYA M;JOHNSTON T;SAHEBKAR A","BAGHERNIYA, MOHAMMAD (56667719200); JOHNSTON, THOMAS P. (24753436700); SAHEBKAR, AMIRHOSSEIN (26639699900)","REGULATION OF APOLIPOPROTEIN B BY NATURAL PRODUCTS AND NUTRACEUTICALS A COMPREHENSIVE REVIEW",2021,"CURRENT MEDICINAL CHEMISTRY","28","43",12,"10.2174/0929867327666200427092114","DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, FOOD SECURITY RESEARCH CENTER, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DIVISION OF PHARMACOLOGY AND PHARMACEUTICAL SCIENCES, SCHOOL OF PHARMACY, UNIVERSITY OF MISSOURI-KANSAS CITY, KANSAS CITY, MO, UNITED STATES;HALAL RESEARCH CENTER OF IRI, FDA, TEHRAN, IRAN, BIOTECHNOLOGY RESEARCH CENTER, PHARMACEUTICAL TECHNOLOGY INSTITUTE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, P.O. BOX 9177948564, MASHHAD, IRAN, NEUROGENIC INFLAMMATION RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, P.O. BOX 9177948564, MASHHAD, IRAN","CARDIOVASCULAR DISEASE (CVD) IS THE MOST IMPORTANT AND THE NUMBER ONE CAUSE OF MORTALITY IN BOTH DEVELOPING AND INDUSTRIALIZED NATIONS. THE CO-MORBIDITIES ASSOCIATED WITH CVD ARE OBSERVED FROM INFANCY TO OLD AGE. APOLIPOPROTEIN B100 (APO B) IS THE PRIMARY APOLIPOPROTEIN AND STRUCTURAL PROTEIN OF ALL MAJOR ATHEROGENIC PARTICLES DERIVED FROM THE LIVER INCLUDING VERY-LOW-DENSITY LIPOPROTEINS (VLDL), INTERMEDIATE-DENSITY LIPOPROTEIN (IDL), AND LOW-DENSITY LIPOPRO-TEIN (LDL) PARTICLES. IT HAS BEEN SUGGESTED THAT MEASUREMENT OF THE APO B CONCENTRATION IS A SUPERIOR AND MORE RELIABLE INDEX FOR THE PREDICTION OF CVD RISK THAN IS THE MEASUREMENT OF LDL-C. NUTRACEUTICALS AND MEDICINAL PLANTS HAVE ATTRACTED SIGNIFICANT ATTENTION AS IT PERTAINS TO THE TREATMENT OF NON-COMMUNICABLE DISEASES, PARTICULARLY CVD, DIABETES MELLITUS, HYPERTENSION, AND NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). THE EFFECT OF NUTRACEUTICALS AND HERBAL PRODUCTS ON CVD, AS WELL AS SOME OF ITS RISK FACTORS SUCH AS DYSLIPIDEMIA, HAVE BEEN INVESTIGATED PREVIOUSLY. HOW-EVER, TO THE BEST OF OUR KNOWLEDGE, THE EFFECT OF THESE NATURAL PRODUCTS, INCLUDING HERBAL SUPPLEMENTS AND FUNCTIONAL FOODS (E.G. FRUITS AND VEGETABLES AS EITHER DRY MATERIALS, OR THEIR EXTRACTS) ON APO B HAS NOT YET BEEN INVESTIGATED. THEREFORE, THE PRIMARY OBJECTIVE OF THIS PAPER WAS TO REVIEW THE EFFECT OF BIOACTIVE NATURAL COMPOUNDS ON PLASMA APO B CONCENTRATIONS. IT IS CONCLUDED THAT, IN GENERAL, MEDICINAL PLANTS AND NUTRACEUTICALS CAN BE USED AS COMPLEMENTARY MEDICINE TO REDUCE PLASMA APO B LEVELS IN A SAFE, ACCESSIBLE, AND INEXPENSIVE MANNER IN AN ATTEMPT TO PREVENT AND TREAT CVD. © 2021 BENTHAM SCIENCE PUBLISHERS.","APOLIPOPROTEIN B; CARDIOVASCULAR DISEASE (CVD); CHOLES-TEROL; DYSLIPIDEMIA; LIPOPROTEIN; PHYTOCHEMICALS","APOLIPOPROTEINS B; BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; HUMANS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; TRIGLYCERIDES; ACHYROCLINE SATUREOIDES EXTRACT; ALLICIN; ALPHA CYCLODEXTRIN; ANTHOCYANIN; ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ARABINOGALACTAN; ARABINOXYLAN; ARGININE; ASTAXANTHIN; BERBERINE; BETA GLUCAN; CANOLA OIL; CHINESE DRUG; CHITOSAN; CHOLESTEROL; CHOLESTIN; COPTIS RHIZOME EXTRACT; CORN OIL; CURCUMIN; CYANOCOBALAMIN; DAIDZEIN; DIHYDROMYRICETIN; EXTRA VIRGIN OLIVE OIL; FISH OIL; FLAVONOID; FOLIC ACID; GARLIC EXTRACT; GENISTEIN; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; ISOFLAVONE DERIVATIVE; ISPAGULA; JIAO TAI WAN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MYRICETIN; NATURAL PRODUCT; NUTRACEUTICAL; OLIVE OIL; PALM OIL; PEA PROTEIN; PHYTOCHEMICAL; PHYTOESTROGEN; PHYTOSTEROL; PLANT PROTEIN; POLICOSANOL; POLYPHENOL; PROBIOTIC AGENT; PYRIDOXINE; RAPESEED OIL; RESVERATROL; SAPONIN; SESAME SEED OIL; SIMVASTATIN; SOYBEAN OIL; SOYBEAN PROTEIN; SUNFLOWER OIL; TANNIN DERIVATIVE; UBIDECARENONE; UNCLASSIFIED DRUG; VEGETABLE OIL; VERY LOW DENSITY LIPOPROTEIN; WHEY PROTEIN; XUEZHIKANG; APOLIPOPROTEIN B; BIOLOGICAL PRODUCT; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; ACHYROCLINE; ACHYROCLINE SATUREOIDES; ALMOND; ALTERNATIVE MEDICINE; ANTIOXIDANT ACTIVITY; ATHEROGENIC DIET; BRAZIL NUT; CACAO; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE MEDICINE; CHLORELLA; CINNAMON; COMORBIDITY; CORNUS; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG MECHANISM; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FRUIT; FUNCTIONAL FOOD; GARLIC; GENE EXPRESSION; GINGER; GRAPE; HAZELNUT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LINSEED; LIPID DIET; MEDICINAL PLANT; NON COMMUNICABLE DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUT; NUT MEAL; PATIENT COUNSELING; PISTACHIO; POMEGRANATE JUICE; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RYE FLOUR; SENNA TORA; SOYBEAN; TEA; TRADITIONAL MEDICINE; VEGETABLE; WALNUT; DIETARY SUPPLEMENT","","","BALAKUMAR P., MAUNG-U K., JAGADEESH G., PREVALENCE AND PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES MELLITUS, PHARMACOL. RES, 113, PP. 600-609, (2016); UPADHYAY R.K., EMERGING RISK BIOMARKERS IN CARDIOVASCULAR DISEASES AND DISORDERS, J. LIPIDS, 2015, (2015); ETEMADIFAR M., MAGHZI A.-H., SHARP INCREASE IN THE INCI-DENCE AND PREVALENCE OF MULTIPLE SCLEROSIS IN ISFAHAN, IRAN, MULT. SCLER, 17, 8, PP. 1022-1027, (2011); FROSTEGARD J., IMMUNITY, ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE, BMC MED, 11, 1, (2013); BAIRAKTARI E., ELISAF M., TZALLAS C., KARABINA S.A., TSELE-PIS A.D., SIAMOPOULOS K.C., TSOLAS O., EVALUATION OF FIVE METHODS FOR DETERMINING LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN HEMODIALYSIS PATIENTS (1), CLIN. BIOCHEM, 34, 8, PP. 593-602, (2001); HOWARD B.V., ROBBINS D.C., SIEVERS M.L., LEE E.T., RHOADES D., DEVEREUX R.B., COWAN L.D., GRAY R.S., WELTY T.K., GO O.T., HOWARD W.J., LDL CHOLESTEROL AS A STRONG PREDICTOR OF CORONARY HEART DISEASE IN DIABETIC INDIVIDUALS WITH INSULIN RESISTANCE AND LOW LDL: THE STRONG HEART STUDY, ARTERIOSCLER. THROMB. VASC. BIOL, 20, 3, PP. 830-835, (2000); HERMANS M.P., AHN S.A., ROUSSEAU M.F., LOG(TG)/HDL-C IS RELATED TO BOTH RESIDUAL CARDIOMETABOLIC RISK AND Β-CELL FUNCTION LOSS IN TYPE 2 DIABETES MALES, CARDIOVASC. DIABE-TOL, 9, (2010); LI C., FORD E.S., TSAI J., ZHAO G., BALLUZ L.S., GIDDING S.S., SERUM NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION AND RISK OF DEATH FROM CARDIOVASCULAR DISEASES AMONG U.S. ADULTS WITH DIAGNOSED DIABETES: THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY LINKED MORTALITY STUDY, CARDIOVASC. DIABETOL, 10, (2011); ROSENSON R.S., OTVOS J.D., HSIA J., EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ON LDL AND HDL PARTICLE CONCENTRATIONS IN PATIENTS WITH METABOLIC SYNDROME: A RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY, DIABETES CARE, 32, 6, PP. 1087-1091, (2009); RIZZO M., BERNEIS K., SHOULD WE MEASURE ROUTINELY THE LDL PEAK PARTICLE SIZE?, INT. J. CARDIOL, 107, 2, PP. 166-170, (2006); DAVIDSON M.H., APOLIPOPROTEIN MEASUREMENTS: IS MORE WIDESPREAD USE CLINICALLY INDICATED?, CLIN. CARDIOL, 32, 9, PP. 482-486, (2009); CHO D.-S., WOO S., KIM S., BYRNE C.D., KONG J.-H., SUNG K.-C., ESTIMATION OF PLASMA APOLIPOPROTEIN B CONCENTRATION USING ROUTINELY MEASURED LIPID BIOCHEMICAL TESTS IN APPARENTLY HEALTHY ASIAN ADULTS, CARDIOVASC. DIABETOL, 11, 1, (2012); LINTON M.F., YANCEY P.G., DAVIES S.S., JEROME W.G., LINTON E.F., SONG W.L., DORAN A.C., VICKERS K.C., THE ROLE OF LIPIDS AND LIPOPROTEINS IN ATHEROSCLEROSIS, (2019); RUTLEDGE AC., SU Q., ADELI K., APOLIPOPROTEIN B100 BIO-GENESIS: A COMPLEX ARRAY OF INTRACELLULAR MECHANISMS REGULATING FOLDING, STABILITY, AND LIPOPROTEIN ASSEMBLY, BIOCHEM. CELL. BIOL, 88, 2, PP. 251-267, (2010); SHELNESS G.S., LEDFORD A.S., EVOLUTION AND MECHANISM OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEIN ASSEMBLY, CURR. OPIN. LIPIDOL, 16, 3, PP. 325-332, (2005); FISHER E., LAKE E., MCLEOD R.S., APOLIPOPROTEIN B100 QUALITY CONTROL AND THE REGULATION OF HEPATIC VERY LOW DENSITY LIPOPROTEIN SECRETION, J. BIOMED. RES, 28, 3, PP. 178-193, (2014); HERMANS M.P., SACKS F.M., AHN S.A., ROUSSEAU M.F., NON-HDL-CHOLESTEROL AS VALID SURROGATE TO APOLIPOPROTEIN B100 MEASUREMENT IN DIABETES: DISCRIMINANT RATIO AND UNBI-ASED EQUIVALENCE, CARDIOVASC. DIABETOL, 10, (2011); DAVIDSON N.O., SHELNESS G.S., APOLIPOPROTEIN B: MRNA EDITING, LIPOPROTEIN ASSEMBLY, AND PRESECRETORY DEGRADATION, ANNU. REV. NUTR, 20, PP. 169-193, (2000); FEINGOLD KR, GRUNFELD C., INTRODUCTION TO LIPIDS AND LIPO-PROTEINS, (2021); CROMWELL W.C., BARRINGER T.A., LOW-DENSITY LIPOPROTEIN AND APOLIPOPROTEIN B: CLINICAL USE IN PATIENTS WITH CORONARY HEART DISEASE, CURR. CARDIOL. REP, 11, 6, PP. 468-475, (2009); SHAPIRO M.D., FAZIO S., APOLIPOPROTEIN B-CONTAINING LIPO-PROTEINS AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, F1000 RES, 6, (2017); TWISK J., GILLIAN-DANIEL D.L., TEBON A., WANG L., BAR-RETT P.H.R., ATTIE A.D., THE ROLE OF THE LDL RECEPTOR IN APOLIPOPROTEIN B SECRETION, J. CLIN. INVEST, 105, 4, PP. 521-532, (2000); JIANG R., SCHULZE M.B., LI T., RIFAI N., STAMPFER M.J., RIMM E.B., HU F.B., NON-HDL CHOLESTEROL AND APOLIPO-PROTEIN B PREDICT CARDIOVASCULAR DISEASE EVENTS AMONG MEN WITH TYPE 2 DIABETES, DIABETES CARE, 27, 8, PP. 1991-1997, (2004); OLOFSSON S.O., BOREN J., APOLIPOPROTEIN B: A CLINICALLY IMPORTANT APOLIPOPROTEIN WHICH ASSEMBLES ATHEROGENIC LIPO-PROTEINS AND PROMOTES THE DEVELOPMENT OF ATHEROSCLEROSIS, J. INTERN. MED, 258, 5, PP. 395-410, (2005); WALLDIUS G., JUNGNER I., APOLIPOPROTEIN B AND APOLIPOPRO-TEIN A-I: RISK INDICATORS OF CORONARY HEART DISEASE AND TARGETS FOR LIPID-MODIFYING THERAPY, J. INTERN. MED, 255, 2, PP. 188-205, (2004); CONTOIS J.H., MCCONNELL J.P., SETHI A.A., CSAKO G., DEVARAJ S., HOEFNER D.M., WARNICK G.R., APOLIPOPROTEIN B AND CARDIOVASCULAR DISEASE RISK: POSITION STATEMENT FROM THE AACC LIPOPROTEINS AND VASCULAR DISEASES DIVISION WORKING GROUP ON BEST PRACTICES. CLIN. CHEM, 55, 3, PP. 407-419, (2009); WALLDIUS G., JUNGNER I., THE APOB/APOA-I RATIO: A STRONG, NEW RISK FACTOR FOR CARDIOVASCULAR DISEASE AND A TARGET FOR LIPID-LOWERING THERAPY-A REVIEW OF THE EVIDENCE, J. INTERN. MED, 259, 5, PP. 493-519, (2006); SNIDERMAN A., TARGETS FOR LDL-LOWERING THERAPY, CURR. OPIN. LIPIDOL, 20, 4, PP. 282-287, (2009); BARTER P.J., BALLANTYNE C.M., CARMENA R., CASTRO CABEZAS M., CHAPMAN M.J., COUTURE P., DE GRAAF J., DUR-RINGTON P.N., FAERGEMAN O., FROHLICH J., FURBERG C.D., GAGNE C., HAFFNER S.M., HUMPHRIES S.E., JUNGNER I., KRAUSS R.M., KWITEROVICH P., MARCOVINA S., PACKARD C.J., PEARSON T.A., REDDY K.S., ROSENSON R., SARRAFZADE-GAN N., SNIDERMAN A.D., STALENHOEF A.F., STEIN E., TAL-MUD P.J., TONKIN A.M., WALLDIUS G., WILLIAMS K.M., APO B VERSUS CHOLESTEROL IN ESTIMATING CARDIOVASCULAR RISK AND IN GUIDING THERAPY: REPORT OF THE THIRTY-PERSON/TEN-COUNTRY PANEL, J. INTERN. MED, 259, 3, PP. 247-258, (2006); LAU J.F., SMITH D.A., ADVANCED LIPOPROTEIN TESTING: REC-OMMENDATIONS BASED ON CURRENT EVIDENCE, ENDOCRINOL. ME-TAB. CLIN. NORTH AM, 38, 1, PP. 1-31, (2009); MEISINGER C., LOEWEL H., MRAZ W., KOENIG W., PROGNOS-TIC VALUE OF APOLIPOPROTEIN B AND A-I IN THE PREDICTION OF MYOCARDIAL INFARCTION IN MIDDLE-AGED MEN AND WOMEN: RESULTS FROM THE MONICA/KORA AUGSBURG COHORT STUDY, EUR. HEART J, 26, 3, PP. 271-278, (2005); TALMUD P.J., HAWE E., MILLER G.J., HUMPHRIES S.E., NON-FASTING APOLIPOPROTEIN B AND TRIGLYCERIDE LEVELS AS A USEFUL PREDICTOR OF CORONARY HEART DISEASE RISK IN MIDDLE-AGED UK MEN, ARTERIOSCLER. THROMB. VASC. BIOL, 22, 11, PP. 1918-1923, (2002); WALLDIUS G., JUNGNER I., HOLME I., AASTVEIT A.H., KOLAR W., STEINER E., HIGH APOLIPOPROTEIN B, LOW APOLIPOPROTEIN A-I, AND IMPROVEMENT IN THE PREDICTION OF FATAL MYOCARDIAL INFARCTION (AMORIS STUDY): A PROSPECTIVE STUDY, LANCET, 358, 9298, PP. 2026-2033, (2001); MOSS A.J., GOLDSTEIN R.E., MARDER V.J., SPARKS C.E., OAKES D., GREENBERG H., WEISS H.J., ZAREBA W., BROWN M.W., LIANG C.S., LICHSTEIN E., LITTLE W.C., GILLESPIE J.A., VAN VOORHEES L., KRONE R.J., BODENHEIMER M.M., HOCHMAN J., DWYER E.M., ARORA R., MARCUS F.I., WA-TELET L.F., CASE R.B., THROMBOGENIC FACTORS AND RECURRENT CORONARY EVENTS, CIRCULATION, 99, 19, PP. 2517-2522, (1999); CHAN D.C., WATTS G.F., APOLIPOPROTEINS AS MARKERS AND MANAGERS OF CORONARY RISK, QJM, 99, 5, PP. 277-287, (2006); ROSENSON R.S., MANAGEMENT OF NON-HIGH-DENSITY LIPOPRO-TEIN ABNORMALITIES, ATHEROSCLEROSIS, 207, 2, PP. 328-335, (2009); MILLER M., GINSBERG H.N., SCHAEFER E.J., RELATIVE ATHERO-GENICITY AND PREDICTIVE VALUE OF NON-HIGH-DENSITY LIPOPRO-TEIN CHOLESTEROL FOR CORONARY HEART DISEASE, AM. J. CARDIOL, 101, 7, PP. 1003-1008, (2008); LIM Y., YOO S., LEE S.A., CHIN S.O., HEO D., MOON J.C., MOON S., BOO K., KIM S.T., SEO H.M., JWA H., KOH G., APOLIPOPROTEIN B IS RELATED TO METABOLIC SYNDROME INDEPENDENTLY OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH TYPE 2 DIABETES, ENDOCRINOL. METAB. (SEOUL), 30, 2, PP. 208-215, (2015); WILLIAMS K., SNIDERMAN A.D., SATTAR N., D'AGOSTINO R., WAGENKNECHT L.E., HAFFNER S.M., COMPARISON OF THE ASSOCIATIONS OF APOLIPOPROTEIN B AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH OTHER CARDIOVASCULAR RISK FACTORS IN THE INSULIN RESISTANCE ATHEROSCLEROSIS STUDY (IRAS), CIRCULATION, 108, 19, PP. 2312-2316, (2003); CHI X.X., ZHANG T., ZHANG D.J., YU W., WANG Q.Y., ZHEN J.L., EFFECTS OF ISOFLAVONES ON LIPID AND APOLIPOPROTEIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES IN HEILONGJIANG PROVINCE IN CHINA, J. CLIN. BIOCHEM. NUTR, 59, 2, PP. 134-138, (2016); ELLSWORTH D.L., COSTANTINO N.S., BLACKBURN H.L., ENGLER R.J., KASHANI M., VERNALIS M.N., LIFESTYLE MODIFICATION INTERVENTIONS DIFFERING IN INTENSITY AND DIETARY STRINGENCY IMPROVE INSULIN RESISTANCE THROUGH CHANGES IN LIPOPROTEIN PRO-FILES, OBES. SCI. PRACT, 2, 3, PP. 282-292, (2016); KOTANI K., KOIBUCHI H., YAMADA T., TANIGUCHI N., THE EFFECTS OF LIFESTYLE MODIFICATION ON A NEW OXIDIZED LOW-DENSITY LIPOPROTEIN MARKER, SERUM AMYLOID A-LDL, IN SUBJECTS WITH PRIMARY LIPID DISORDER, CLIN. CHIM. ACTA, 409, 1-2, PP. 67-69, (2009); CHIUVE S.E., COOK N.R., SHAY C.M., REXRODE K.M., AL-BERT C.M., MANSON J.E., WILLETT W.C., RIMM E.B., LIFE-STYLE-BASED PREDICTION MODEL FOR THE PREVENTION OF CVD: THE HEALTHY HEART SCORE, J. AM. HEART ASSOC, 3, 6, (2014); MANNU G.S., ZAMAN M.J., GUPTA A., REHMAN H.U., MY-INT P.K., EVIDENCE OF LIFESTYLE MODIFICATION IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA, CURR. CARDIOL. REV, 9, 1, PP. 2-14, (2013); ALISSA E.M., FERNS G.A., FUNCTIONAL FOODS AND NUTRACEUTI-CALS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES, J. NUTR. METAB, 2012, (2012); RAMAA C.S., SHIRODE A.R., MUNDADA A.S., KADAM V.J., NUTRACEUTICALS-AN EMERGING ERA IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES, CURR. PHARM. BIOTECHNOL, 7, 1, PP. 15-23, (2006); ZUCHI C., AMBROSIO G., LUSCHER T.F., LANDMESSER U., NUTRACEUTICALS IN CARDIOVASCULAR PREVENTION: LESSONS FROM STUDIES ON ENDOTHELIAL FUNCTION, CARDIOVASC. THER, 28, 4, PP. 187-201, (2010); BADIMON L., VILAHUR G., PADRO T., NUTRACEUTICALS AND ATHE-ROSCLEROSIS: HUMAN TRIALS, CARDIOVASC. THER, 28, 4, PP. 202-215, (2010); MCCARTY M.F., NUTRACEUTICAL RESOURCES FOR DIABETES PREVEN-TION-AN UPDATE, MED. HYPOTHESES, 64, 1, PP. 151-158, (2005); DAVI G., SANTILLI F., PATRONO C., NUTRACEUTICALS IN DIABETES AND METABOLIC SYNDROME, CARDIOVASC. THER, 28, 4, PP. 216-226, (2010); BAHADORAN Z., MIRMIRAN P., AZIZI F., DIETARY POLYPHENOLS AS POTENTIAL NUTRACEUTICALS IN MANAGEMENT OF DIABETES: A RE-VIEW, J. DIABETES METAB. DISORD, 12, 1, (2013); HOUSTON M., THE ROLE OF NUTRITION AND NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF HYPERTENSION, WORLD J. CARDIOL, 6, 2, PP. 38-66, (2014); HOUSTON M.C., NUTRACEUTICALS, VITAMINS, ANTIOXIDANTS, AND MINERALS IN THE PREVENTION AND TREATMENT OF HYPERTENSION, PROG. CARDIOVASC. DIS, 47, 6, PP. 396-449, (2005); HOUSTON M.C., NUTRITION AND NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF HYPERTENSION, EXPERT REV. CARDIOVASC. THER, 8, 6, PP. 821-833, (2010); SERBAN M.C., SAHEBKAR A., ZANCHETTI A., MIKHAILIDIS D.P., HOWARD G., ANTAL D., ANDRICA F., AHMED A., ARO-NOW W.S., MUNTNER P., LIP G.Y., GRAHAM I., WONG N., RYSZ J., BANACH M., LIPID AND BLOOD PRESSURE META-­‐ANALYSIS COLLABORATION (LBPMC) GROUP. EFFECTS OF QUERCETIN ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOM- IZED CONTROLLED TRIALS, J. AM. HEART ASSOC, 5, 7, (2016); BAGHERNIYA M., NOBILI V., BLESSO C.N., SAHEBKAR A., MEDICINAL PLANTS AND BIOACTIVE NATURAL COMPOUNDS IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A CLINICAL REVIEW, PHARMACOL. RES, 130, PP. 213-240, (2018); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., TRIMARCO B., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED DYSLIP-IDEMIA, J. HYPERTENS, 28, 7, PP. 1482-1487, (2010); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J. CLIN. HYPERTENS. (GREENWICH), 14, 2, PP. 121-132, (2012); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHE-ROSCLEROSIS, 203, 1, PP. 8-17, (2009); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR. J. INTERN. MED, 25, 7, PP. 592-599, (2014); SCICCHITANO P., CAMELI M., MAIELLO M., MODESTI P.A., MUIESAN M.L., NOVO S., NUTRACEUTICALS AND DYSLIPIDAEMIA: BEYOND THE COMMON THERAPEUTICS, J. FUNCT. FOODS, 6, PP. 11-32, (2014); IMAI S., SOYBEAN AND PROCESSED SOY FOODS INGREDIENTS, AND THEIR ROLE IN CARDIOMETABOLIC RISK PREVENTION, RECENT PAT. FOOD NUTR. AGRIC, 7, 2, PP. 75-82, (2015); YANG H.-Y., TZENG Y.-H., CHAI C.-Y., HSIEH A.-T., CHEN J.-R., CHANG L.-S., YANG S.S., SOY PROTEIN RETARDS THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS VIA IMPROVEMENT OF INSULIN RESISTANCE AND STEATOSIS, NUTRITION, 27, 9, PP. 943-948, (2011); FRIEDMAN M., BRANDON D.L., NUTRITIONAL AND HEALTH BENEFITS OF SOY PROTEINS, J. AGRIC. FOOD CHEM, 49, 3, PP. 1069-1086, (2001); LI S.S., BLANCO MEJIA S., LYTVYN L., STEWART S.E., VIGUILIOUK E., HA V., DE SOUZA R.J., LEITER L.A., KENDALL C.W.C., JENKINS D.J.A., SIEVENPIPER J.L., EFFECT OF PLANT PROTEIN ON BLOOD LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J. AM. HEART AS-SOC, 6, 12, (2017); KIM M., KIM M., LEE A., YOO H.J., HER J.S., JEE S.H., LEE J.H., IMPACT OF 8-WEEK LINOLEIC ACID INTAKE IN SOY OIL ON LP-PLA<SUB>2</SUB> ACTIVITY IN HEALTHY ADULTS, NUTR. METAB. (LOND.), 14, (2017); KWAK J.H., AHN C.W., PARK S.H., JUNG S.U., MIN B.J., KIM O.Y., LEE J.H., WEIGHT REDUCTION EFFECTS OF A BLACK SOY PEPTIDE SUPPLEMENT IN OVERWEIGHT AND OBESE SUBJECTS: DOUBLE BLIND, RANDOMIZED, CONTROLLED STUDY, FOOD FUNCT, 3, 10, PP. 1019-1024, (2012); RUSCICA M., PAVANELLO C., GANDINI S., GOMARASCHI M., VITALI C., MACCHI C., MORLOTTI B., AIELLO G., BOSISIO R., CALABRESI L., ARNOLDI A., SIRTORI C.R., MAGNI P., EFFECT OF SOY ON METABOLIC SYNDROME AND CARDIOVASCULAR RISK FACTORS: A RANDOMIZED CONTROLLED TRIAL, EUR. J. NUTR, 57, 2, PP. 499-511, (2018); MAKI K.C., BUTTEIGER D.N., RAINS T.M., LAWLESS A., REEVES M.S., SCHASTEEN C., KRUL E.S., EFFECTS OF SOY PROTEIN ON LIPOPROTEIN LIPIDS AND FECAL BILE ACID EXCRETION IN MEN AND WOMEN WITH MODERATE HYPERCHOLESTEROLEMIA, J. CLIN. LIPIDOL, 4, 6, PP. 531-542, (2010); TABIBI H, IMANI H, HEDAYATI M, ATABAK S, RAHMANI L., EFFECTS OF SOY CONSUMPTION ON SERUM LIPIDS AND APOPROTEINS IN PERITONEAL DIALYSIS PATIENTS: A RANDOMIZED CONTROLLED TRIAL, PERIT. DIAL. INT, 30, 6, PP. 611-618, (2010); ZUNG A., SHACHAR S., ZADIK Z., KEREM Z., SOY-DERIVED ISOFLAVONES TREATMENT IN CHILDREN WITH HYPERCHOLESTEROLEMIA: A PILOT STUDY, J. PEDIATR. ENDOCRINOL. METAB, 23, 1-2, PP. 133-141, (2010); CAMPBELL S.C., KHALIL D.A., PAYTON M.E., ARJMANDI B.H., ONE-YEAR SOY PROTEIN SUPPLEMENTATION DOES NOT IMPROVE LIPID PROFILE IN POSTMENOPAUSAL WOMEN, MENOPAUSE, 17, 3, PP. 587-593, (2010); PIPE E.A., GOBERT C.P., CAPES S.E., DARLINGTON G.A., LAMPE J.W., DUNCAN A.M., SOY PROTEIN REDUCES SERUM LDL CHOLESTEROL AND THE LDL CHOLESTEROL: HDL CHOLESTEROL AND APOLIPOPROTEIN B: APOLIPOPROTEIN A-I RATIOS IN ADULTS WITH TYPE 2 DIABETES, J. NUTR, 139, 9, PP. 1700-1706, (2009); WELTY F.K., LEE K.S., LEW N.S., ZHOU J.R., EFFECT OF SOY NUTS ON BLOOD PRESSURE AND LIPID LEVELS IN HYPERTENSIVE, PRE-HYPERTENSIVE, AND NORMOTENSIVE POSTMENOPAUSAL WOMEN, ARCH. INTERN. MED, 167, 10, PP. 1060-1067, (2007); LERMAN R.H., MINICH D.M., DARLAND G., LAMB J.J., CHANG J.L., HSI A., BLAND J.S., TRIPP M.L., SUBJECTS WITH ELEVATED LDL CHOLESTEROL AND METABOLIC SYNDROME BENEFIT FROM SUPPLEMENTATION WITH SOY PROTEIN, PHYTOSTEROLS, HOPS RHO ISO-ALPHA ACIDS, AND ACACIA NILOTICA PROANTHOCYANIDINS, J. CLIN. LIPIDOL, 4, 1, PP. 59-68, (2010); MATTHAN N.R., JALBERT S.M., AUSMAN L.M., KUVIN J.T., KARAS R.H., LICHTENSTEIN A.H., EFFECT OF SOY PROTEIN FROM DIFFERENTLY PROCESSED PRODUCTS ON CARDIOVASCULAR DISEASE RISK FACTORS AND VASCULAR ENDOTHELIAL FUNCTION IN HYPERCHOLES-TEROLEMIC SUBJECTS, AM. J. CLIN. NUTR, 85, 4, PP. 960-966, (2007); MCVEIGH B.L., DILLINGHAM B.L., LAMPE J.W., DUNCAN A.M., EFFECT OF SOY PROTEIN VARYING IN ISOFLAVONE CONTENT ON SERUM LIPIDS IN HEALTHY YOUNG MEN, AM. J. CLIN. NUTR, 83, 2, PP. 244-251, (2006); HOIE L.H., GRAUBAUM H.J., HARDE A., GRUENWALD J., WERNECKE K.D., LIPID-LOWERING EFFECT OF 2 DOSAGES OF A SOY PROTEIN SUPPLEMENT IN HYPERCHOLESTEROLEMIA, ADV. THER, 22, 2, PP. 175-186, (2005); HOIE L.H., MORGENSTERN E.C., GRUENWALD J., GRAUBAUM H.J., BUSCH R., LUDER W., ZUNFT H.J., A DOUBLE-BLIND PLA-CEBO-CONTROLLED CLINICAL TRIAL COMPARES THE CHOLESTEROL-LOWERING EFFECTS OF TWO DIFFERENT SOY PROTEIN PREPARATIONS IN HYPERCHOLESTEROLEMIC SUBJECTS, EUR. J. NUTR, 44, 2, PP. 65-71, (2005); JENKINS D.J., KENDALL C.W., JACKSON C.J., CONNELLY P.W., PARKER T., FAULKNER D., VIDGEN E., CUNNANE S.C., LEITER L.A., JOSSE R.G., EFFECTS OF HIGH-AND LOW-ISOFLAVONE SOY-FOODS ON BLOOD LIPIDS, OXIDIZED LDL, HOMOCYSTEINE, AND BLOOD PRESSURE IN HYPERLIPIDEMIC MEN AND WOMEN, AM. J. CLIN. NUTR, 76, 2, PP. 365-372, (2002); YILDIRIR A., TOKGOZOGLU S.L., ODUNCU T., OTO A., HAZNEDAROGLU I., AKINCI D., KOKSAL G., SADE E., KIRAZLI S., KES S., SOY PROTEIN DIET SIGNIFICANTLY IMPROVES ENDOTHELIAL FUNCTION AND LIPID PARAMETERS, CLIN. CARDIOL, 24, 11, PP. 711-716, (2001); HERMANSEN K., SONDERGAARD M., HOIE L., CARSTENSEN M., BROCK B., BENEFICIAL EFFECTS OF A SOY-BASED DIETARY SUPPLEMENT ON LIPID LEVELS AND CARDIOVASCULAR RISK MARKERS IN TYPE 2 DIABETIC SUBJECTS, DIABETES CARE, 24, 2, PP. 228-233, (2001); WANGEN K.E., DUNCAN A.M., XU X., KURZER M.S., SOY ISOFLAVONES IMPROVE PLASMA LIPIDS IN NORMOCHOLESTEROLEMIC AND MILDLY HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, AM. J. CLIN. NUTR, 73, 2, PP. 225-231, (2001); MERZ-DEMLOW B.E., DUNCAN A.M., WANGEN K.E., XU X., CARR T.P., PHIPPS W.R., KURZER M.S., SOY ISOFLAVONES IMPROVE PLASMA LIPIDS IN NORMOCHOLESTEROLEMIC, PREMENO-PAUSAL WOMEN, AM. J. CLIN. NUTR, 71, 6, PP. 1462-1469, (2000); TEIXEIRA S.R., POTTER S.M., WEIGEL R., HANNUM S., ERD-MAN J.W., HASLER C.M., EFFECTS OF FEEDING 4 LEVELS OF SOY PROTEIN FOR 3 AND 6 WK ON BLOOD LIPIDS AND APOLIPOPROTEINS IN MODERATELY HYPERCHOLESTEROLEMIC MEN, AM. J. CLIN. NUTR, 71, 5, PP. 1077-1084, (2000); MOCHIZUKI Y., MAEBUCHI M., KOHNO M., HIROTSUKA M., WADAHAMA H., MORIYAMA T., KAWADA T., URADE R., CHANGES IN LIPID METABOLISM BY SOY BETA-CONGLYCININ-DERIVED PEPTIDES IN HEPG2 CELLS, J. AGRIC. FOOD CHEM, 57, 4, PP. 1473-1480, (2009); SOFI F., ABBATE R., GENSINI G.F., CASINI A., ACCRUING EVIDENCE ON BENEFITS OF ADHERENCE TO THE MEDITERRANEAN DIET ON HEALTH: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS, AM. J. CLIN. NUTR, 92, 5, PP. 1189-1196, (2010); PRIORE P., CAVALLO A., GNONI A., DAMIANO F., GNONI G.V., SICULELLA L., MODULATION OF HEPATIC LIPID METABOLISM BY OLIVE OIL AND ITS PHENOLS IN NONALCOHOLIC FATTY LIVER DIS-EASE, IUBMB LIFE, 67, 1, PP. 9-17, (2015); LIN L., ALLEMEKINDERS H., DANSBY A., CAMPBELL L., DU-RANCE-TOD S., BERGER A., JONES P.J., EVIDENCE OF HEALTH BENEFITS OF CANOLA OIL, NUTR. REV, 71, 6, PP. 370-385, (2013); KRUSE M., VON LOEFFELHOLZ C., HOFFMANN D., POHLMANN A., SELTMANN A.C., OSTERHOFF M., HORNEMANN S., PIVOVA-ROVA O., ROHN S., JAHREIS G., PFEIFFER A.F., DIETARY RAPE-SEED/CANOLA-OIL SUPPLEMENTATION REDUCES SERUM LIPIDS AND LIVER ENZYMES AND ALTERS POSTPRANDIAL INFLAMMATORY RESPONSES IN ADIPOSE TISSUE COMPARED TO OLIVE-OIL SUPPLEMEN-TATION IN OBESE MEN, MOL. NUTR. FOOD RES, 59, 3, PP. 507-519, (2015); MAKI K.C., LAWLESS A.L., KELLEY K.M., KADEN V.N., GEIGER C.J., PALACIOS O.M., DICKLIN M.R., CORN OIL INTAKE FAVORABLY IMPACTS LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN AND LIPOPROTEIN PARTICLE LEVELS COMPARED WITH EXTRA-VIRGIN OLIVE OIL, J. NUTR, 145, 8, PP. 1692-1697, (2017); SOLA R., FITO M., ESTRUCH R., SALAS-SALVADO J., CORELLA D., DE LA TORRE R., MUNOZ M.A., LOPEZ-SABATER MDEL.C., MARTINEZ-GONZALEZ M.A., AROS F., RUIZ-GUTIERREZ V., FIOL M., CASALS E., WARNBERG J., BUIL-COSIALES P., ROS E., KONSTANTINIDOU V., LAPETRA J., SERRA-MAJEM L., COVAS M.I., EFFECT OF A TRADITIONAL MEDITERRANEAN DIET ON APOLIPO-PROTEINS B, A-I, AND THEIR RATIO: A RANDOMIZED, CONTROLLED TRIAL, ATHEROSCLEROSIS, 218, 1, PP. 174-180, (2011); BOWEN K.J., KRIS-ETHERTON P.M., WEST S.G., FLEMING J.A., CONNELLY P.W., LAMARCHE B., COUTURE P., JENKINS D.J.A., TAYLOR C.G., ZAHRADKA P., HAMMAD S.S., SIHAG J., CHEN X., GUAY V., MALTAIS-GIGUERE J., PERERA D., WILSON A., JUAN S.C.S., REMPEL J., JONES P.J.H., DIETS ENRICHED WITH CONVENTIONAL OR HIGH-OLEIC ACID CANOLA OILS LOWER ATHEROGENIC LIPIDS AND LIPOPROTEINS COMPARED TO A DIET WITH A WESTERN FATTY ACID PROFILE IN ADULTS WITH CENTRAL ADIPOSITY, J. NUTR, 149, 3, PP. 471-478, (2019); VIOLANTE B., GERBAUDO L., BORRETTA G., TASSONE F., EFFECTS OF EXTRA VIRGIN OLIVE OIL SUPPLEMENTATION AT TWO DIFFERENT LOW DOSES ON LIPID PROFILE IN MILD HYPERCHOLESTEROLEMIC SUBJECTS: A RANDOMISED CLINICAL TRIAL, J. ENDOCRINOL. INVEST, 32, 10, PP. 794-796, (2009); SUN G., XIA H., YANG Y., MA S., ZHOU H., SHU G., WANG S., YANG X., TANG H., WANG F., HE Y., DING R., YIN H., WANG Y., YANG Y., ZHU H., YANG L., EFFECTS OF PALM OLEIN AND OLIVE OIL ON SERUM LIPIDS IN A CHINESE POPU-LATION: A RANDOMIZED, DOUBLE-BLIND, CROSS-OVER TRIAL, ASIA PAC. J. CLIN. NUTR, 27, 3, PP. 572-580, (2018); PEDERSEN A., BAUMSTARK M.W., MARCKMANN P., GYLLING H., SANDSTROM B., AN OLIVE OIL-RICH DIET RESULTS IN HIGHER CONCENTRATIONS OF LDL CHOLESTEROL AND A HIGHER NUMBER OF LDL SUBFRACTION PARTICLES THAN RAPESEED OIL AND SUNFLOWER OIL DIETS, J. LIPID RES, 41, 12, PP. 1901-1911, (2000); GHOBADI S., HASSANZADEH-ROSTAMI Z., MOHAMMADIAN F., ZARE M., FAGHIH S., EFFECTS OF CANOLA OIL CONSUMPTION ON LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS, J. AM. COLL. NUTR, 38, 2, PP. 185-196, (2019); IGGMAN D., GUSTAFSSON I.B., BERGLUND L., VESSBY B., MARCKMANN P., RISERUS U., REPLACING DAIRY FAT WITH RAPE-SEED OIL CAUSES RAPID IMPROVEMENT OF HYPERLIPIDAEMIA: A RANDOMIZED CONTROLLED STUDY, J. INTERN. MED, 270, 4, PP. 356-364, (2011); VEGA-LOPEZ S., AUSMAN L.M., JALBERT S.M., ERKKILA A.T., LICHTENSTEIN A.H., PALM AND PARTIALLY HYDROGENATED SOYBEAN OILS ADVERSELY ALTER LIPOPROTEIN PROFILES COMPARED WITH SOYBEAN AND CANOLA OILS IN MODERATELY HYPERLIPIDEMIC SUBJECTS, AM. J. CLIN. NUTR, 84, 1, PP. 54-62, (2006); VEGA-LOPEZ S., MATTHAN N.R., AUSMAN L.M., AI M., OTOKOZAWA S., SCHAEFER E.J., LICHTENSTEIN A.H., SUBSTITU-TION OF VEGETABLE OIL FOR A PARTIALLY-HYDROGENATED FAT FAVORABLY ALTERS CARDIOVASCULAR DISEASE RISK FACTORS IN MODERATELY HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, ATHEROSCLE-ROSIS, 207, 1, PP. 208-212, (2009); LEMCKE-NOROJARVI M., KAMAL-ELDIN A., APPELQVIST L.A., DIMBERG L.H., OHRVALL M., VESSBY B., CORN AND SESAME OILS INCREASE SERUM GAMMA-TOCOPHEROL CONCENTRATIONS IN HEALTHY SWEDISH WOMEN, J. NUTR, 131, 4, PP. 1195-1201, (2001); GOBBO L.C.D., FALK M.C., FELDMAN R., LEWIS K., MOZAF-FARIAN D., EFFECTS OF TREE NUTS ON BLOOD LIPIDS, APOLIPOPRO-TEINS, AND BLOOD PRESSURE: SYSTEMATIC REVIEW, META-ANALYSIS, AND DOSE-RESPONSE OF 61 CONTROLLED INTERVENTION TRIALS, AM. J. CLIN. NUTR, 102, 6, PP. 1347-1356, (2015); WU L., PIOTROWSKI K., RAU T., WALDMANN E., BROEDL U.C., DEMMELMAIR H., KOLETZKO B., STARK R.G., NAGEL J.M., MANTZOROS C.S., PARHOFER K.G., WALNUT-ENRICHED DIET REDUCES FASTING NON-HDL-CHOLESTEROL AND APOLIPOPROTEIN B IN HEALTHY CAUCASIAN SUBJECTS: A RANDOMIZED CONTROLLED CROSS-OVER CLINICAL TRIAL, METABOLISM, 63, 3, PP. 382-391, (2014); IWAMOTO M., IMAIZUMI K., SATO M., HIROOKA Y., SAKAI K., TAKESHITA A., KONO M., SERUM LIPID PROFILES IN JAPANESE WOMEN AND MEN DURING CONSUMPTION OF WALNUTS, EUR. J. CLIN. NUTR, 56, 7, PP. 629-637, (2002); MUNOZ S., MERLOS M., ZAMBON D., RODRIGUEZ C., SABATE J., ROS E., LAGUNA J.C., WALNUT-ENRICHED DIET INCREASES THE ASSOCIATION OF LDL FROM HYPERCHOLESTEROLEMIC MEN WITH HUMAN HEPG2 CELLS, J. LIPID RES, 42, 12, PP. 2069-2076, (2001); CHISHOLM A., MANN J., SKEAFF M., FRAMPTON C., SUTHER-LAND W., DUNCAN A., TISZAVARI S., A DIET RICH IN WALNUTS FAVOURABLY INFLUENCES PLASMA FATTY ACID PROFILE IN MODER-ATELY HYPERLIPIDAEMIC SUBJECTS, EUR. J. CLIN. NUTR, 52, 1, PP. 12-16, (1998); BAMBERGER C., ROSSMEIER A., LECHNER K., WU L., WALD-MANN E., STARK R.G., ALTENHOFER J., HENZE K., PARHOFER K.G., A WALNUT-ENRICHED DIET REDUCES LIPIDS IN HEALTHY CAUCASIAN SUBJECTS, INDEPENDENT OF RECOMMENDED MACRONUTRIENT REPLACEMENT AND TIME POINT OF CONSUMPTION: A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL, NUTRIENTS, 9, 10, (2017); CARVALHO R.F., HUGUENIN G.V., LUIZ R.R., MOREIRA A.S., OLIVEIRA G.M., ROSA G., INTAKE OF PARTIALLY DEFATTED BRAZIL NUT FLOUR REDUCES SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS-A RANDOMIZED CONTROLLED TRIAL, NUTR. J, 14, 1, (2015); TEY S.L., BROWN R.C., CHISHOLM A.W., DELAHUNTY C.M., GRAY A.R., WILLIAMS S.M., EFFECTS OF DIFFERENT FORMS OF HAZELNUTS ON BLOOD LIPIDS AND Α-TOCOPHEROL CONCENTRATIONS IN MILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, EUR. J. CLIN. NUTR, 65, 1, PP. 117-124, (2011); GEBAUER S.K., WEST S.G., KAY C.D., ALAUPOVIC P., BAG-SHAW D., KRIS-ETHERTON P.M., EFFECTS OF PISTACHIOS ON CARDIOVASCULAR DISEASE RISK FACTORS AND POTENTIAL MECHANISMS OF ACTION: A DOSE-RESPONSE STUDY, AM. J. CLIN. NUTR, 88, 3, PP. 651-659, (2008); SHERIDAN M.J., COOPER J.N., ERARIO M., CHEIFETZ C.E., PISTACHIO NUT CONSUMPTION AND SERUM LIPID LEVELS, J. AM. COLL. NUTR, 26, 2, PP. 141-148, (2007); LI S.C., LIU Y.H., LIU J.F., CHANG W.H., CHEN C.M., CHEN C.Y., ALMOND CONSUMPTION IMPROVED GLYCEMIC CONTROL AND LIPID PROFILES IN PATIENTS WITH TYPE 2 DIABETES MELLI-TUS, METABOLISM, 60, 4, PP. 474-479, (2011); SABATE J., HADDAD E., TANZMAN J.S., JAMBAZIAN P., RA-JARAM S., SERUM LIPID RESPONSE TO THE GRADUATED ENRICHMENT OF A STEP I DIET WITH ALMONDS: A RANDOMIZED FEEDING TRIAL, AM. J. CLIN. NUTR, 77, 6, PP. 1379-1384, (2003); KACZMARCZYK M.M., MILLER M.J., FREUND G.G., THE HEALTH BENEFITS OF DIETARY FIBER: BEYOND THE USUAL SUSPECTS OF TYPE 2 DIABETES MELLITUS, CARDIOVASCULAR DISEASE AND COLON CANCER, METABOLISM, 61, 8, PP. 1058-1066, (2012); MUDGIL D., BARAK S., COMPOSITION, PROPERTIES AND HEALTH BENEFITS OF INDIGESTIBLE CARBOHYDRATE POLYMERS AS DIETARY FI-BER: A REVIEW, INT. J. BIOL. MACROMOL, 61, PP. 1-6, (2013); ANDERSON J.W., BAIRD P., DAVIS R.H., FERRERI S., KNUDTSON M., KORAYM A., WATERS V., WILLIAMS C.L., HEALTH BENEFITS OF DIETARY FIBER, NUTR. REV, 67, 4, PP. 188-205, (2009); HO H.V.T., JOVANOVSKI E., ZURBAU A., BLANCO MEJIA S., SIEVENPIPER J.L., AU-YEUNG F., JENKINS A.L., DUVNJAK L., LEITER L., VUKSAN V., A SYSTEMATIC REVIEW AND META- ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF THE EFFECT OF KON-JAC GLUCOMANNAN, A VISCOUS SOLUBLE FIBER, ON LDL CHOLESTEROL AND THE NEW LIPID TARGETS NON-HDL CHOLESTEROL AND APOLIPOPROTEIN B, AM. J. CLIN. NUTR, 105, 5, PP. 1239-1247, (2017); HO H.V., SIEVENPIPER J.L., ZURBAU A., BLANCO MEJIA S., JOVANOVSKI E., AU-YEUNG F., JENKINS A.L., VUKSAN V., A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF THE EFFECT OF BARLEY Β-GLUCAN ON LDL-C, NON-HDL-C AND APOB FOR CARDIOVASCULAR DISEASE RISK REDUCTION<SUP>I-IV</SUP>, EUR. J. CLIN. NUTR, 70, 11, PP. 1239-1245, (2016); COMERFORD K.B., ARTISS J.D., JEN K.L., KARAKAS S.E., THE BENEFICIAL EFFECTS OF Α-CYCLODEXTRIN ON BLOOD LIPIDS AND WEIGHT LOSS IN HEALTHY HUMANS, OBESITY (SILVER SPRING), 19, 6, PP. 1200-1204, (2011); GANJI V., KUO J., SERUM LIPID RESPONSES TO PSYLLIUM FIBER: DIFFERENCES BETWEEN PRE-AND POST-MENOPAUSAL, HYPERCHOLES-TEROLEMIC WOMEN, NUTR. J, 7, (2008); CHO S.H., KIM T.H., LEE N.H., SON H.S., CHO I.J., HA T.Y., EFFECTS OF CASSIA TORA FIBER SUPPLEMENT ON SERUM LIPIDS IN KOREAN DIABETIC PATIENTS, J. MED. FOOD, 8, 3, PP. 311-318, (2005); SODERHOLM P.P., ALFTHAN G., KOSKELA A.H., ADLERCREUTZ H., TIKKANEN M.J., THE EFFECT OF HIGH-FIBER RYE BREAD ENRICHED WITH NONESTERIFIED PLANT STEROLS ON MAJOR SERUM LIPIDS AND APOLIPOPROTEINS IN NORMOCHOLESTEROLEMIC INDIVIDUALS, NUTR. METAB. CARDIOVASC. DIS, 22, 7, PP. 575-582, (2012); GARCIA A.L., STEINIGER J., REICH S.C., WEICKERT M.O., HARSCH I., MACHOWETZ A., MOHLIG M., SPRANGER J., RUDO-VICH N.N., MEUSER F., DOERFER J., KATZ N., SPETH M., ZUNFT H.J., PFEIFFER A.H., KOEBNICK C., ARABINOXYLAN FIBRE CONSUMPTION IMPROVED GLUCOSE METABOLISM, BUT DID NOT AF-FECT SERUM ADIPOKINES IN SUBJECTS WITH IMPAIRED GLUCOSE TOL-ERANCE, HORM. METAB. RES, 38, 11, PP. 761-766, (2006); MOREYRA A.E., WILSON A.C., KORAYM A., EFFECT OF COMBINING PSYLLIUM FIBER WITH SIMVASTATIN IN LOWERING CHOLESTEROL, ARCH. INTERN. MED, 165, 10, PP. 1161-1166, (2005); MARETT R., SLAVIN J.L., NO LONG-TERM BENEFITS OF SUPPLEMEN-TATION WITH ARABINOGALACTAN ON SERUM LIPIDS AND GLUCOSE, J. AM. DIET. ASSOC, 104, 4, PP. 636-639, (2004); JENKINS D.J., KENDALL C.W., VUKSAN V., VIDGEN E., PARKER T., FAULKNER D., MEHLING C.C., GARSETTI M., TESTOLIN G., CUNNANE S.C., RYAN M.A., COREY P.N., SOLUBLE FIBER INTAKE AT A DOSE APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR A CLAIM OF HEALTH BENEFITS: SERUM LIPID RISK FACTORS FOR CARDIOVASCULAR DISEASE ASSESSED IN A RANDOMIZED CONTROLLED CROSSOVER TRIAL, AM. J. CLIN. NUTR, 75, 5, PP. 834-839, (2002); SOLA R., VALLS R.M., GODAS G., PEREZ-BUSQUETS G., RIBALTA J., GIRONA J., HERAS M., CABRE A., CASTRO A., DOMENECH G., TORRES F., MASANA L., ANGLES N., REGUANT J., RAMIREZ B., BARRIACH J.M., COCOA, HAZELNUTS, STEROLS AND SOLUBLE FIBER CREAM REDUCES LIPIDS AND INFLAMMATION BIO-MARKERS IN HYPERTENSIVE PATIENTS: A RANDOMIZED CONTROLLED TRIAL, PLOS ONE, 7, 2, (2012); SHAKIBAEI M., HARIKUMAR K.B., AGGARWAL B.B., RESVERA-TROL ADDICTION: TO DIE OR NOT TO DIE, MOL. NUTR. FOOD RES, 53, 1, PP. 115-128, (2009); SHANKAR S., SINGH G., SRIVASTAVA R.K., CHEMOPREVENTION BY RESVERATROL: MOLECULAR MECHANISMS AND THERAPEUTIC PO-TENTIAL, FRONT. BIOSCI, 12, 12, PP. 4839-4854, (2007); SAIKO P., SZAKMARY A., JAEGER W., SZEKERES T., RESVERA-TROL AND ITS ANALOGS: DEFENSE AGAINST CANCER, CORONARY DISEASE AND NEURODEGENERATIVE MALADIES OR JUST A FAD?, MUTAT. RES, 658, 1-2, PP. 68-94, (2008); MANSUR A.P., ROGGERIO A., GOES M.F.S., AVAKIAN S.D., LEAL D.P., MARANHAO R.C., STRUNZ C.M.C., SERUM CONCENTRATIONS AND GENE EXPRESSION OF SIRTUIN 1 IN HEALTHY AND SLIGHTLY OVERWEIGHT SUBJECTS AFTER CALORIC RESTRICTION OR RES-VERATROL SUPPLEMENTATION: A RANDOMIZED TRIAL, INT. J. CAR-DIOL, 227, PP. 788-794, (2017); TOME-CARNEIRO J., GONZALVEZ M., LARROSA M., GARCIA-ALMAGRO F.J., AVILES-PLAZA F., PARRA S., YANEZ-GASCON M.J., RUIZ-ROS J.A., GARCIA-CONESA M.T., TOMAS-BARBERAN F.A., ESPIN J.C., CONSUMPTION OF A GRAPE EXTRACT SUPPLEMENT CONTAINING RESVERATROL DECREASES OXIDIZED LDL AND APOB IN PATIENTS UNDERGOING PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A TRIPLE-BLIND, 6-MONTH FOLLOW-UP, PLA-CEBO-CONTROLLED, RANDOMIZED TRIAL, MOL. NUTR. FOOD RES, 56, 5, PP. 810-821, (2012); ZERN T.L., WOOD R.J., GREENE C., WEST K.L., LIU Y., AGGARWAL D., SHACHTER N.S., FERNANDEZ M.L., GRAPE POLY-PHENOLS EXERT A CARDIOPROTECTIVE EFFECT IN PRE-AND POST-MENOPAUSAL WOMEN BY LOWERING PLASMA LIPIDS AND REDUCING OXIDATIVE STRESS, J. NUTR, 135, 8, PP. 1911-1917, (2005); DASH S., XIAO C., MORGANTINI C., SZETO L., LEWIS G.F., HIGH-DOSE RESVERATROL TREATMENT FOR 2 WEEKS INHIBITS INTESTINAL AND HEPATIC LIPOPROTEIN PRODUCTION IN OVERWEIGHT/OBESE MEN, ARTERIOSCLER. THROMB. VASC. BIOL, 33, 12, PP. 2895-2901, (2013); FARZIN L., ASGHARI S., RAFRAF M., ASGHARI-JAFARABADI M., SHIRMOHAMMADI M., NO BENEFICIAL EFFECTS OF RESVERATROL SUPPLEMENTATION ON ATHEROGENIC RISK FACTORS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE, INT. J. VITAM. NUTR. RES, 90, 3-4, PP. 279-289, (2020); VAN DER MADE S.M., PLAT J., MENSINK R.P., RESVERATROL DOES NOT INFLUENCE METABOLIC RISK MARKERS RELATED TO CARDIOVASCULAR HEALTH IN OVERWEIGHT AND SLIGHTLY OBESE SUBJECTS: A RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER TRIAL, PLOS ONE, 10, 3, (2015); CHO I.J., AHN J.Y., KIM S., CHOI M.S., HA T.Y., RESVERA-TROL ATTENUATES THE EXPRESSION OF HMG-COA REDUCTASE MRNA IN HAMSTERS, BIOCHEM. BIOPHYS. RES. COMMUN, 367, 1, PP. 190-194, (2008); JEON S.M., LEE S.A., CHOI M.S., ANTIOBESITY AND VASOPRO-TECTIVE EFFECTS OF RESVERATROL IN APOE-DEFICIENT MICE, J. MED. FOOD, 17, 3, PP. 310-316, (2014); AUGER C., TEISSEDRE P.L., GERAIN P., LEQUEUX N., BORNET A., SERISIER S., BESANCON P., CAPORICCIO B., CRISTOL J.P., ROUANET J.M., DIETARY WINE PHENOLICS CATECHIN, QUERCETIN, AND RESVERATROL EFFICIENTLY PROTECT HYPERCHOLESTEROLEMIC HAMSTERS AGAINST AORTIC FATTY STREAK ACCUMULATION, J. AGRIC. FOOD CHEM, 53, 6, PP. 2015-2021, (2005)","A. SAHEBKAR; HALAL RESEARCH CENTER OF IRI, FDA, TEHRAN, IRAN; EMAIL: SAHEBKARA@MUMS.AC.IR; A. SAHEBKAR; BIOTECHNOLOGY RESEARCH CENTER, PHARMACEUTICAL TECHNOLOGY INSTITUTE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, P.O. BOX 9177948564, IRAN; EMAIL: SAHEBKARA@MUMS.AC.IR; A. SAHEBKAR; NEUROGENIC INFLAMMATION RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, P.O. BOX 9177948564, IRAN; EMAIL: SAHEBKARA@MUMS.AC.IR","BENTHAM SCIENCE PUBLISHERS","ENGLISH","CURR. MED. CHEM.","REVIEW","ISI","2-S2.0-85104381887","CURR MED CHEM","ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;UNIVERSITY OF MISSOURI-KANSAS CITY;MASHHAD UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;HALAL RESEARCH CENTER OF IRI;NOTREPORTED;NOTREPORTED;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED;NOTREPORTED;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"BAGHERNIYA M, 2021, CURR MED CHEM","BAGHERNIYA M, 2021, CURR MED CHEM"
"SAKOUHI F;CHÉRIF A;SAADI C;BOUKHCHINA S","SAKOUHI, FAOUZI (21743784700); CHÉRIF, AMMAR (57196523789); SAADI, CHAIMA (57800354300); BOUKHCHINA, SADOK (6507257738)","ASSESSMENT OF THE BIOACTIVE LIPID PROFILES OF OIL EXTRACTED FROM TUNISIAN TABLE OLIVE CULTIVARS BAROUNI BESBASSI AND MARSALINE CVS",2023,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","125","",1,"10.1002/ejlt.202300013","FACULTY OF SCIENCES, DEPARTMENT OF BIOLOGY, LABORATORY OF NEUROPHYSIOLOGY, CELLULAR PHYSIOPATHOLOGY AND BIOMELCULES VALORIZATION (LR18ES03), UNIVERSITY OF TUNIS EL MANAR, EL MANAR I, TUNISIA;FACULTY OF SCIENCES, DEPARTMENT OF BIOLOGY, LABORATORY OF NEUROPHYSIOLOGY, CELLULAR PHYSIOPATHOLOGY AND BIOMELCULES VALORIZATION (LR18ES03), UNIVERSITY OF TUNIS EL MANAR, EL MANAR I, TUNISIA, DEPARTEMENT OF SCIENCE LABORATORIES, COLLEGE OF SCIENCES AND ARTS, QASSIM UNIVERSITY, AR RASS, SAUDI ARABIA;FACULTY OF SCIENCES, DEPARTMENT OF BIOLOGY, LABORATORY OF NEUROPHYSIOLOGY, CELLULAR PHYSIOPATHOLOGY AND BIOMELCULES VALORIZATION (LR18ES03), UNIVERSITY OF TUNIS EL MANAR, EL MANAR I, TUNISIA;FACULTY OF SCIENCES, DEPARTMENT OF BIOLOGY, LABORATORY OF NEUROPHYSIOLOGY, CELLULAR PHYSIOPATHOLOGY AND BIOMELCULES VALORIZATION (LR18ES03), UNIVERSITY OF TUNIS EL MANAR, EL MANAR I, TUNISIA","BIOACTIVE COMPOUNDS ARE COMPONENTS EXTRACTED FROM BIOLOGICAL MATRICES THAT MAY OFFER PHYSIOLOGICAL HEALTH BENEFITS AND HAVE NUTRITIVE VALUE. THE PRESENT STUDY CHARACTERIZED BIOACTIVE LIPID COMPONENTS SUCH AS FATTY ACIDS, PHYTOSTEROLS, POLICOSANOL, AND TRITERPENES FROM TABLE OLIVES. THE TABLE OLIVES WERE PROCESSED ACCORDING TO THE GREEN SPANISH-STYLE METHOD. THE OBTAINED RESULTS INDICATE THAT PHYTOSTEROL FRACTION CONSTITUTES THE MAJOR PORTION OF THE TOTAL UNSAPONIFIABLE MATTER. THE ANALYSIS OF PHYTOSTEROLS SHOWED THE PRESENCE OF 11 COMPOUNDS, Β-SITOSTEROL THE PREDOMINANT ONE. THE POLICOSANOL COMPOSITION INDICATED THAT HEXACOSANOL, TETRACOSANOL, OCTACOSANOL, AND DOCOSANOL WERE THE MAIN COMPOUNDS, ACCOUNTING FOR OVER 85% OF TOTAL POLICOSANOLS. PENTACYCLIC TRITERPENES (CYCLOARTENOL AND 24-METHYLENE CYCLOARTENOL) WERE FOUND AT A HIGHER LEVEL (OVER 85%) COMPARED TO TETRACYCLIC TRITERPENES (Β-AMYRIN, Δ-AMYRIN). THESE FINDINGS REVEAL THAT PROCESSED TABLE OLIVES CONTAIN AN INTERESTING AMOUNT OF VARIOUS BIOACTIVE COMPOUNDS COMPARED TO MARINE AND OTHER FLORAL BIOLOGICAL MATRICES. THUS, PROCESSED TABLE OLIVES REPRESENT AN INTERESTING NATURAL FUNCTIONAL FOOD THAT PRESENTS HIGH STABILITY AND BIOAVAILABILITY OF THEIR NATURAL BIOACTIVE INGREDIENTS. PRACTICAL APPLICATIONS: NOWADAYS, WITH HEALTH FOOD GAINING POPULARITY AMONG CONSUMERS, THE DEMAND FOR NATURAL BIOACTIVE COMPOUNDS AND FUNCTIONAL FOOD IS EXPANDING CONSIDERABLY ALL OVER THE WORLD. THIS STUDY FOCUSES ON ANALYZING BIOACTIVE LIPID COMPONENTS FROM PROCESSED TABLE OLIVES. FRUITS WERE PROCESSED ACCORDING TO THE GREEN SPANISH-STYLE METHOD. THE SALT CONTENT OF THE BRINE WAS ADJUSTED TO THE MINIMUM SODIUM CHLORIDE VALUE REQUIRED BY THE CODEX ALIMENTARIUS COMISSION, WHICH IS 5%, TAKING INTO CONSIDERATION PEOPLE SUFFERING FROM HYPERTENSION. THIS CONCENTRATION IS CONSIDERED THE MINIMUM AMOUNT OF SALT NECESSARY TO EXHIBIT ANTIBACTERIAL ACTIVITIES. CONSIDERING THE RESULTS OBTAINED, PROCESSED TABLE OLIVES PRESENT ONE OF THE MOST VALUABLE POTENTIAL RESOURCES FOR BIOACTIVE LIPID COMPOUNDS AND HAVE A CONSIDERABLE ABILITY TO PRESERVE THE STABILITY OF THEIR LIPID COMPONENTS. THUS, THE FOOD INDUSTRY IN MEDITERRANEAN COUNTRIES CAN PROMOTE PROCESSED TABLE OLIVES AS CONVENTIONAL FUNCTIONAL FOOD WITH NO NEED FOR ANY ENRICHMENT OR FORTIFICATION. © 2023 WILEY-VCH GMBH.","NATURAL BIOACTIVE COMPOUNDS; PHYTOSTEROLS; POLICOSANOL; TABLE OLIVE; TRITERPENES","","MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISIA","WE THANK THE MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISIA FOR FINANCIALLY SUPPORTING THIS INVESTIGATION. ","RAMIREZ E., VIVES L.E., VALERO A., RODRIGUEZ-GOMEZ F., PROPOSAL FOR TECHNOLOGICAL ADAPTATION OF SMALL-SIZED GREEN OLIVES TO SPANISH-STYLE PROCESSING, FOOD CONTROL, 126, (2021); PERPETUINI G., PRETE R., GARCIA-GONZALEZ N., ALAM M.K., CORSETTI A., TABLE OLIVES MORE THAN A FERMENTED FOOD, FOODS, 9, PP. 178-193, (2020); SULERIA H.A.R., OSBORNE S., MASCI P., GOBE G., MARINE-BASED NUTRACEUTICALS: AN INNOVATIVE TREND IN THE FOOD AND SUPPLEMENT INDUSTRIES, MARINE DRUGS, 13, PP. 6336-6351, (2015); VAN BREDA S.G.J.V., DE KOK T.M.C.M., SMART COMBINATIONS OF BIOACTIVE COMPOUNDS IN FRUITS AND VEGETABLES MAY GUIDE NEW STRATEGIES FOR PERSONALIZED PREVENTION OF CHRONIC DISEASES, MOLECULAR NUTRITION & FOOD RESEARCH, 62, (2018); KIM N.H., JUNG S.Y., PARK Y.A., LEE Y.J., JO J.Y., LEE S.M., OH Y.H., FATTY ACID COMPOSITION AND CHARACTERISATION OF COMMERCIAL VEGETABLE OILS WITH CHEMOMETRIC APPROACHES, INTERNATIONAL FOOD RESEARCH JOURNAL, 27, PP. 270-279, (2020); KATOH A., IKEDA H., MATSUSHIMA Y., SASAKI M., OKINA N., NIIYAMA H., HARADA H., NISHIYAMA Y., KAI H., LONG-CHAIN FATTY ACIDS IN SARCOPENIA PATIENTS WITH CARDIOVASCULAR DISEASES: IMPORTANCE OF N-9 MONOUNSATURATED FATTY ACIDS, JCSM CLINICAL REPORTS, 5, PP. 121-128, (2020); LI P., SONG C., POTENTIAL TREATMENT OF PARKINSON'S DISEASE WITH OMEGA-POLYUNSATURATED FATTY ACIDS, NUTRITIONAL NEUROSCIENCE, 25, PP. 180-191, (2020); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, JOURNAL OF FOOD SCIENCE, 76, PP. C891-C899, (2011); PATROCINIO M.P., PARAGAS N., PEREZ J.A., QUE D.L.S., QUIOGUE K., REYES M.R., RIGUNAY M.C., SANCHEZ I.K., SANDOVAL P.A., SANTOS M.K., SO M.F., SOLIVERES E.J., TAN B.A., THE EFFECTS OF SUGAR CANE POLICOSANOL ON THE LDL, HDL, TRIGLYCERIDE AND TOTAL CHOLESTEROL LEVELS OF DYSLIPIDEMIC PATIENTS: A META-ANALYSIS, ANESTHESIA AND MEDICAL PRACTICE JOURNAL, (2017); LI C., DING Y., SI Q., LI K., XU K., MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY PATIENTS WITH DYSLIPIDEMIA, JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 48, PP. 1-9, (2020); LUCAS A., GARCIA A., ALVAREZ A., GRACIA I., SUPERCRITICAL EXTRACTION OF LONG CHAIN N-ALCOHOLS FROM SUGAR CANE CRUDE WAX, THE JOURNAL OF SUPERCRITICAL FLUIDS, 41, PP. 267-271, (2007); SCHLAG S., HUANG Y., VETTER W., GC/EI-MS METHOD FOR THE DETERMINATION OF PHYTOSTEROLS IN VEGETABLE OILS, ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 414, PP. 1061-1071, (2022); GUPTA V.K., TUOHY M.G., BIOLOGICAL EFFECTS AND MECHANISMS OF HYPOCHOLESTEROLEMIC ACTION, BIOTECHNOLOGY OF BIOACTIVE COMPOUNDS: SOURCES AND APPLICATIONS, (2015); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., MEIJER L., ZOCK P.L., JOHANNA J.M., GELEIJNSE M., ELKE A.T., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUROPEAN JOURNAL OF NUTRITION, 52, PP. 153-160, (2013); TEIXEIRA F.S., VIDIGAL S.S.M.P., PIMENTEL L.L., COSTA P.T., TAVARES-VALENTE D., AZEVEDO-SILVA J., PINTADO M.E., FERNANDES J.C., RODRIGUEZ-ALCALA L.M., PHYTOSTEROLS AND NOVEL TRITERPENES RECOVERED FROM INDUSTRIAL FERMENTATION COPRODUCTS EXERT IN VITRO ANTI-INFLAMMATORY ACTIVITY IN MACROPHAGES, PHARMACEUTICALS, 14, PP. 583-604, (2021); KHAN M.A., SINGH D., FATMA H., AKHTAR K., ARJMAND F., MAURYA S., SIDDIQUE H.R., ANTIANDROGEN ENZALUTAMIDE INDUCED GENETIC, CELLULAR, AND HEPATIC DAMAGES: AMELIORATION BY TRITERPENE LUPEOL, DRUG AND CHEMICAL TOXICOLOGY, PP. 380-391, (2022); HARUN N.H., SEPTAMA A.W., AHMAD W.A.N.W., SUPPIAN R., IMMUNOMODULATORY EFFECTS AND STRUCTURE-ACTIVITY RELATIONSHIP OF BOTANICAL PENTACYCLIC TRITERPENES: A REVIEW, CHINESE HERBAL MEDICINES, 12, PP. 118-124, (2020); PASQUALONE A., NASTI N., MONTEMURRO C., GOMES T., EFFECT OF NATURAL-STYLE PROCESSING ON THE OXIDATIVE AND HYDROLYTIC DEGRADATION OF THE LIPID FRACTION OF TABLE OLIVES, FOOD CONTROL, 37, PP. 99-103, (2014); CAPRIOTTI A.L., CAVALIERE C., CRESCENZI C., FOGLIA P., NESCATELLI R., SAMPERI R., LAGANA A., COMPARISON OF EXTRACTION METHODS FOR THE IDENTIFICATION AND QUANTIFICATION OF POLYPHENOLS IN VIRGIN OLIVE OIL BY ULTRA-HPLC-QTOF MASS SPECTROMETRY, FOOD CHEMISTRY, 158, PP. 786-804, (2014); VISIOLI F., BERNARDINI E., EXTRA VIRGIN OLIVE OIL'S POLYPHENOLS: BIOLOGICAL ACTIVITIES, CURRENT PHARMACEUTICAL DESIGN, 17, PP. 786-804, (2011); CHYTIRI A., MARGARI T., BLEVE G., KONTOGIANNI V.G., KALLIMANIS A., KONTOMINAS M.G., EFFECT OF DIFFERENT INOCULATION STRATEGIES OF SELECTED YEAST AND LAB CULTURES ON CONSERVOLEA AND KALAMÀTA TABLE OLIVES CONSIDERING PHENOL CONTENT, TEXTURE AND SENSORY ATTRIBUTES, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 100, PP. 926-935, (2020); LANZA B., AMORUSO F., SENSORY ANALYSIS OF NATURAL TABLE OLIVES: RELATIONSHIP BETWEEN APPEARANCE OF DEFECT AND GUSTATORY-KINAESTHETIC SENSATION CHANGES, LWT—FOOD SCIENCE AND TECHNOLOGY, 68, PP. 365-372, (2016); SALES C., PORTOLES T., JOHNSEN L.G., DANIELSEN M., BELTRAN J., OLIVE OIL QUALITY CLASSIFICATION AND MEASUREMENT OF ITS ORGANOLEPTIC ATTRIBUTES BY UNTARGETED GC–MS AND MULTIVARIATE STATISTICAL-BASED APPROACH, FOOD CHEMISTRY, 271, PP. 488-496, (2019); LOPEZ-LOPEZ A., CORTES-DELGADO A., GARRIDO-FERNANDEZ A., EVOLUTION OF THE MINOR COMPONENTS OF THE DIRECTLY BRINED ALORE˜NA DE MALAGA TABLE OLIVE FAT DURING PROCESSING AND SHELF LIFE, LWT—FOOD SCIENCE AND TECHNOLOGY, 166, (2022); SAKOUHI F., ABSALON C., SEBEI K., FOUQUET F., BOUKHCHINA S., KALLEL H., GAS CHROMATOGRAPHY-MASS SPECTROMETRIC CHARACTERIZATION OF TRITERPENE ALCOHOLS AND MONOMETHYLSTEROLS IN DEVELOPING OLEA EUROPAEA L. FRUITS, FOOD CHEMISTRY, 116, PP. 345-350, (2009); ALBARRACIN W., SANCHEZ I.C., GRAU R., BARAT J.M., SALT IN FOOD PROCESSING; USAGE AND REDUCTION: A REVIEW, INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 46, PP. 1329-1336, (2011); EUROPEAN FOOD SAFETY AUTHORITY: OUTCOME OF PUBLIC CONSULTATIONS ON THE SCIENTIFIC OPINIONS OF THE EFSA PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS (NDA) ON DIETARY REFERENCE VALUES FOR SODIUM AND CHLORIDE, EFSA SUPPORTING PUBLICATION, 16, 9, (2019); SAKOUHI F., HARRABI S., ABSALON C., SBEI K., BOUKHCHINA S., KALLEL H., Α-TOCOPHEROL AND FATTY ACIDS CONTENTS OF SOME TUNISIAN TABLE OLIVES (OLEA EUROPEA L.): CHANGES IN THEIR COMPOSITION DURING RIPENING AND PROCESSING, FOOD CHEMISTRY, 108, PP. 833-839, (2008); HARRISON S., BRASSARD D., LEMIEUX S., LAMARCHE B., DIETARY SATURATED FATS FROM DIFFERENT FOOD SOURCES SHOW VARIABLE ASSOCIATIONS WITH THE 2015 HEALTHY EATING INDEX IN THE CANADIAN POPULATION, JOURNAL OF NUTRITION, 150, PP. 3288-3295, (2020); LI X., XIN Y., MO Y., MAROZIK P., HE T., GUO H., THE BIOAVAILABILITY AND BIOLOGICAL ACTIVITIES OF PHYTOSTEROLS AS MODULATORS OF CHOLESTEROL METABOLISM, MOLECULES (BASEL, SWITZERLAND), 27, (2022); NATTAGH-ESHTIVANI E., BARGHCHI H., PAHLAVANI N., BARATI M., AMIRI Y., FADEL A., KHOSRAVI M., TALEBI S., ARZHANG P., ZIAEI R., GHAVAMI A., BIOLOGICAL AND PHARMACOLOGICAL EFFECTS AND NUTRITIONAL IMPACT OF PHYTOSTEROLS: A COMPREHENSIVE REVIEW, PHYTOTHERAPY RESEARCH, 36, PP. 299-322, (2022); BAE H., PARK S., YANG C., SONG G., LIM W., DISRUPTION OF ENDOPLASMIC RETICULUM AND ROS PRODUCTION IN HUMAN OVARIAN CANCER BY CAMPESTEROL, ANTIOXIDANTS, 10, (2021); TENGA H., YUANA B., GOTHAI S., ARULSELVAN P., SONG X., CHENA L., DIETARY TRITERPENES IN THE TREATMENT OF TYPE 2 DIABETES: TO DATE, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 72, PP. 34-44, (2018); CARVALHO K., DE MELO T., DE MELO K., QUINDERE A., DE OLIVEIRA F., VIANA A., NUNES P., QUETEZ J., VIANA D., DA SILVA A., HAVT A., FONSECA S., CHAVES M., RAO V., SANTOS F., AMYRINS FROM PROTIUM HEPTAPHYLLUM REDUCE HIGH-FAT DIET-INDUCED OBESITY IN MICE VIA MODULATION OF ENZYMATIC, HORMONAL AND INFLAMMATORY RESPONSES, PLANTA MEDICA, 83, PP. 285-291, (2016); KUMAR A., GUPTA K.B., DHIMAN M., ARORA S., JAITAK V., NEW PENTACYCLIC TRITERPENE FROM POTENTILLA ATROSANGUINEA LODD. AS ANTICANCER AGENT FOR BREAST CANCER TARGETING ESTROGEN RECEPTOR-Α, NATURAL PRODUCT RESEARCH, 36, PP. 4352-4357, (2022); ZHANG T., XIE L., LIU R., CHANG M., ZHANG H., JIN Q., WANG X., REVISITING THE 4,4-DIMETHYLSTEROLS PROFILE FROM DIFFERENT KINDS OF VEGETABLE OILS BY USING GC-MS, LWT, 124, (2020); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOASONOL IN HUMAN HEALTH, NUTRITION (BURBANK, LOS ANGELES COUNTY, CALIF.), 19, PP. 192-195, (2003); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY & PHYSIOLOGY, 29, PP. 891-897, (2002); WARREN P.R., BURGER R.A., SIDWELL R.W., CLARK L.L., EFFECT OF TRIACONTANOL ON NUMBERS AND FUNCTIONS OF CELLS INVOLVED IN INFLAMMATORY RESPONSES, PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 200, PP. 349-352, (2002); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTRITION, METABOLISM & CARDIOVASCULAR DISEASES, 21, PP. 424-429, (2011); TRIMARCO V., IZZO R., STABILE E., ROZZA F., SANTORO M.M., MANZI M.V., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE, INSULIN SENSITIVITY AND ENDOTELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS. A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND TRIAL, HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 22, PP. 149-154, (2015); MICHAEL A., JACKSON A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYSED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, J SUPERCRITICAL FLUIDS, 37, PP. 173-177, (2006); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8–14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANNALS OF NUTRITION & METABOLISM, 39, PP. 279-284, (1995); LING W.H., JONES P.J.H., DIETARY PHYTOSTEROLS: A REVIEW OF METABOLISM, BENEFITS AND SIDE EFFECTS, LIFE SCIENCES, 57, PP. 195-206, (1995); JEONG D.W., KIM Y.H., KIM H.H., JI H.Y., YOO S.D., CHOI W.R., LEE S.M., HAN C.K., LEE H.S., DOSE-LINEAR PHARMACOKINETICS OF OLEANOLIC ACID AFTER INTRAVENOUS AND ORAL ADMINISTRATION IN RATS, BIOPHARMACEUTICS & DRUG DISPOSITION, 2, PP. 51-57, (2007); KOHLER A., SARKKINEN E., TAPOLA N., NISKANEN T., BRUHEIM I., BIOAVAILABILITY OF FATTY ACIDS FROM KRILL OIL, KRILL MEAL AND FISH OIL IN HEALTHY SUBJECTS–A RANDOMIZED, SINGLE-DOSE, CROSS-OVER TRIAL, LIPIDS IN HEALTH AND DISEASE, 14, (2015)","F. SAKOUHI; FACULTÉ DES SCIENCES DE TUNIS, DÉPARTEMENT DE BIOLOGIE, LABORATOIRE DE RECHERCHE LR18ES03, UNIVERSITÉ TUNIS EL MANAR, EL MANAR I, 2092, TUNISIA; EMAIL: FAOUZI.SAKOUHI@FST.RNU.TN","JOHN WILEY AND SONS INC","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-85171776730","EUR J LIPID SCI TECHNOL","EL MANAR I;EL MANAR I;EL MANAR I;EL MANAR I","NOTREPORTED;UNIVERSITÉ TUNIS EL MANAR;NOTREPORTED",NA,"SAKOUHI F, 2023, EUR J LIPID SCI TECHNOL","SAKOUHI F, 2023, EUR J LIPID SCI TECHNOL"
"REZA A M;KAZEMINEJAD S;JALALZADEH M;SADEGHI M S;KAVYANI Z;ASKARI G;HEKMATDOOST A","REZA AMINI, MOHAMMAD (57220716294); KAZEMINEJAD, SHERVIN (59132257300); JALALZADEH, MOHARAM (58785370500); SADEGHI MAJD, SARA (59132183700); KAVYANI, ZEYNAB (57823297800); ASKARI, GHOLAMREZA (57189842487); HEKMATDOOST, AZITA (7801320384)","THE EFFECTS OF POLICOSANOL SUPPLEMENTATION ON BLOOD GLUCOSE A SYSTEMATIC REVIEW AND DOSERESPONSE METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2024,"DIABETES RESEARCH AND CLINICAL PRACTICE","212","",0,"10.1016/j.diabres.2024.111709","STUDENT RESEARCH COMMITTEE, DEPARTMENT OF CLINICAL NUTRITION AND DIETETICS, FACULTY OF NUTRITION SCIENCES AND FOOD TECHNOLOGY, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN, NUTRITION AND FOOD SECURITY RESEARCH CENTER AND DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES(TUMS), TEHRAN, IRAN;DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES(TUMS), TEHRAN, IRAN;DEPARTMENT OF CLINICAL NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES(TUMS), TEHRAN, IRAN;STUDENT RESEARCH COMMITTEE, DEPARTMENT OF CLINICAL NUTRITION AND DIETETICS, FACULTY OF NUTRITION SCIENCES AND FOOD TECHNOLOGY, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN;NUTRITION AND FOOD SECURITY RESEARCH CENTER AND DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DEPARTMENT OF CLINICAL NUTRITION & DIETETICS, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN","PREVIOUS STUDIES HAVE ASSESSED HOW SUPPLEMENTING WITH POLICOSANOL AFFECTS BLOOD SUGAR LEVELS. THE OUTCOMES, NEVERTHELESS, WERE NOT CONSTANT. MULTIPLE ELECTRONIC DATABASES WERE SEARCHED INCLUDING ISI WEB OF SCIENCE, COCHRANE LIBRARY, PUBMED, GOOGLE SCHOLAR, AND SCOPUS UNTIL FEBRUARY 9, 2023. TO ASSESS THE EFFECTS OF POLICOSANOL ON GLUCOSE, WE EMPLOYED A RANDOM-EFFECTS OR FIXED-EFFECTS META-ANALYSIS APPROACH TO EXAMINE THE WEIGHTED MEAN DIFFERENCES (WMDS) AND ASSOCIATED 95 % CONFIDENCE INTERVALS (CI) BEFORE AND AFTER POLICOSANOL AND PLACEBO ADMINISTRATION. THE FINAL ANALYSIS COMPRISED A TOTAL OF 25 TRIALS WITH 2680 PARTICIPANTS. COMPARED TO THE CONTROL GROUP, POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY REDUCED BLOOD GLUCOSE LEVELS (WMD: −2.24 MG/DL; 95 % CI: −4.05, −0.42, P = 0.01). FINDINGS FROM SUBGROUP ANALYSIS REVEALED A SIGNIFICANT REDUCTION OF POLICOSANOL SUPPLEMENTATION ON GLUCOSE LEVELS IN PERIOD OF LESS THAN 24 WEEKS, AND IN INDIVIDUALS BELOW 50 YEARS OF AGE. ADDITIONALLY, THE REDUCTION WAS STATISTICALLY SIGNIFICANT IN DOSAGE OF 10 MG/DAY. OUR DOSE–RESPONSE ANALYSIS INDICATES NO EVIDENCE OF A NON-LINEAR RELATIONSHIP BETWEEN POLICOSANOL DOSE AND DURATION AND CHANGES IN GLUCOSE LEVELS (P-NONLINEARITY = 0.52, AND P-NONLINEARITY = 0.52, RESPECTIVELY). POLICOSANOL SUPPLEMENTATION MIGHT IMPROVE BLOOD GLUCOSE. FURTHER TRIALS WITH MORE COMPLEX DESIGNS ARE REQUIRED TO CONFIRM THE FINDINGS. © 2024 ELSEVIER B.V.","BLOOD GLUCOSE; META-ANALYSIS; POLICOSANOL; SYSTEMATIC REVIEW","BLOOD GLUCOSE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; POLICOSANOL; FATTY ALCOHOL; POLICOSANOL; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; META ANALYSIS; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPPLEMENTATION; SYSTEMATIC REVIEW; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG EFFECT; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC)","SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, SBUMS","WE ALSO APPRECIATE THE \U201CSTUDENT RESEARCH COMMITTEE\U201D AND \U201CRESEARCH & TECHNOLOGY CHANCELLOR\U201D AT SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES FOR THEIR FINANCIAL SUPPORT OF THIS STUDY. ","KOOTTE R.S., VRIEZE A., HOLLEMAN F., DALLINGA-THIE G.M., ZOETENDAL E.G., DE VOS W.M., ET AL., THE THERAPEUTIC POTENTIAL OF MANIPULATING GUT MICROBIOTA IN OBESITY AND TYPE 2 DIABETES MELLITUS, DIABETES OBES METAB, 14, PP. 112-120, (2012); AMERICAN DIABETES ASSOCIATION, DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS, DIABETES CARE, 35, PP. S64-S71, (2012); CERIELLO A., POSTPRANDIAL HYPERGLYCEMIA AND DIABETES COMPLICATIONS: IS IT TIME TO TREAT?, DIABETES, 54, PP. 1-7, (2005); KIM S.-H., PARK M.-J., EFFECTS OF GROWTH HORMONE ON GLUCOSE METABOLISM AND INSULIN RESISTANCE IN HUMAN, ANN PEDIATR ENDOCRINOL METAB, 22, (2017); YARIBEYGI H., FARROKHI F.R., BUTLER A.E., SAHEBKAR A., INSULIN RESISTANCE: REVIEW OF THE UNDERLYING MOLECULAR MECHANISMS, J CELL PHYSIOL, 234, PP. 8152-8161, (2019); NISHIDA C., UAUY R., KUMANYIKA S., SHETTY P., THE JOINT WHO/FAO EXPERT CONSULTATION ON DIET, NUTRITION AND THE PREVENTION OF CHRONIC DISEASES: PROCESS, PRODUCT AND POLICY IMPLICATIONS, PUBLIC HEALTH NUTR, 7, PP. 245-250, (2004); TUOMILEHTO J., LINDSTROM J., ERIKSSON J.G., VALLE T.T., HAMALAINEN H., ILANNE-PARIKKA P., ET AL., PREVENTION OF TYPE 2 DIABETES MELLITUS BY CHANGES IN LIFESTYLE AMONG SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE, N ENGL J MED, 344, PP. 1343-1350, (2001); PAIS I., HALLSCHMID M., JAUCH-CHARA K., SCHMID S.M., OLTMANNS K.M., PETERS A., ET AL., MOOD AND COGNITIVE FUNCTIONS DURING ACUTE EUGLYCAEMIA AND MILD HYPERGLYCAEMIA IN TYPE 2 DIABETIC PATIENTS, EXP CLIN ENDOCRINOL DIABETES, 115, PP. 42-46, (2007); LAAKSO M., VOUTILAINEN E., SARLUND H., ARO A., PYORALA K., PENTTILA I., SERUM LIPIDS AND LIPOPROTEINS IN MIDDLE-AGED NON-INSULIN-DEPENDENT DIABETICS, ATHEROSCLEROSIS, 56, PP. 271-281, (1985); RIZZA R.A., PATHOGENESIS OF FASTING AND POSTPRANDIAL HYPERGLYCEMIA IN TYPE 2 DIABETES: IMPLICATIONS FOR THERAPY, DIABETES, 59, PP. 2697-2707, (2010); SCHEEN A.J., DRUG INTERACTIONS OF CLINICAL IMPORTANCE WITH ANTIHYPERGLYCAEMIC AGENTS: AN UPDATE, DRUG SAF, 28, PP. 601-631, (2005); KLEIN S., SHEARD N.F., PI-SUNYER X., DALY A., WYLIE-ROSETT J., KULKARNI K., ET AL., WEIGHT MANAGEMENT THROUGH LIFESTYLE MODIFICATION FOR THE PREVENTION AND MANAGEMENT OF TYPE 2 DIABETES: RATIONALE AND STRATEGIES: A STATEMENT OF THE AMERICAN DIABETES ASSOCIATION, THE NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY, AND THE AMERICAN SOCIETY FOR CLINICAL NUTRITION, DIABETES CARE, 27, PP. 2067-2073, (2004); BRUCE S.P., ACHEAMPONG F., KRETCHY I., ADHERENCE TO ORAL ANTI-DIABETIC DRUGS AMONG PATIENTS ATTENDING A GHANAIAN TEACHING HOSPITAL, PHARM PRACT (GRANADA), 13, (2015); O'KEEFE J.H., GHEEWALA N.M., O'KEEFE J.O., DIETARY STRATEGIES FOR IMPROVING POST-PRANDIAL GLUCOSE, LIPIDS, INFLAMMATION, AND CARDIOVASCULAR HEALTH, J AM COLL CARDIOL, 51, PP. 249-255, (2008); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS, 17, (2018); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., ET AL., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); WEERAWATANAKORN M., MEEROD K., WONGWAIWECH D., HO C.-T., POLICOSANOLS: CHEMISTRY, OCCURRENCE, AND HEALTH EFFECTS, CURRENT PHARMACOLOGY REPORTS, 5, PP. 131-149, (2019); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP BIOL MED (MAYWOOD), 241, PP. 1943-1949, (2016); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT, PHYTOTHER RES, 27, PP. 264-271, (2013); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); MADHUNAPANTULA S.V., MOSCA P.J., ROBERTSON G.P., THE AKT SIGNALING PATHWAY: AN EMERGING THERAPEUTIC TARGET IN MALIGNANT MELANOMA, CANCER BIOL THER, 12, PP. 1032-1049, (2011); XU F., NA L., LI Y., CHEN L., ROLES OF THE PI3K/AKT/MTOR SIGNALLING PATHWAYS IN NEURODEGENERATIVE DISEASES AND TUMOURS, CELL BIOSCI, 10, (2020); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID MED CELL LONGEV, 2018, (2018); LIBERATI A., ALTMAN D.G., TETZLAFF J., MULROW C., GOTZSCHE P.C., IOANNIDIS J.P., ET AL., THE PRISMA STATEMENT FOR REPORTING SYSTEMATIC REVIEWS AND META-ANALYSES OF STUDIES THAT EVALUATE HEALTH CARE INTERVENTIONS: EXPLANATION AND ELABORATION, J CLIN EPIDEMIOL, 62, PP. E1-E34, (2009); CUMPSTON M., LI T., PAGE M.J., CHANDLER J., WELCH V.A., HIGGINS J.P., THOMAS J., UPDATED GUIDANCE FOR TRUSTED SYSTEMATIC REVIEWS: A NEW EDITION OF THE COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, COCHRANE DATABASE SYST REV, 2019, 10, (2019); JONATHAN A.C.S., JELENA S., MATTHEW J.P., ROY G.E., NATALIE S.B., ISABELLE B., ET AL., ROB 2: A REVISED TOOL FOR ASSESSING RISK OF BIAS IN RANDOMISED TRIALS, BMJ, 366, (2019); DERSIMONIAN R., LAIRD N., META-ANALYSIS IN CLINICAL TRIALS, CONTROL CLIN TRIALS, 7, PP. 177-188, (1986); HIGGINS J.P., THOMPSON S.G., DEEKS J.J., ALTMAN D.G., MEASURING INCONSISTENCY IN META-ANALYSES, BMJ, 327, PP. 557-560, (2003); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); ARTECHE-HIDALGO L., FERNANDEZ-TRAVIESO J., SUAREZ-CAMEJO N., MARIN J., ALVAREZ-ACOSTA V., CHAVIANO-PEREIRA J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH METABOLIC SYNDROME: A SIX-MONTH STUDY, J ENDOCRINOL METAB, 10, PP. 36-44, (2020); CASTANO G., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., MOLINA V., ET AL., EFFECTS OF COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON PLATELET AGGREGATION: A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY, CURR THER RES CLIN EXP, 67, PP. 174-192, (2006); CASTANO G., CANETTI M., MOREIRA M., TULA L., MAS R., ILLNAIT J., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R&D, 6, PP. 207-219, (2005); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES CLIN EXP, 64, PP. 522-537, (2003); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R&D, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 154-162, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. M186-M192, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., FERNANDEZ J.C., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES, 62, PP. 194-208, (2001); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ET AL., CONCOMITANT USE OF POLICOSANOL AND BENZODIAZEPINES IN OLDER PATIENTS, REVISTA CENIC CIENCIAS BIOLÓGICAS, 38, PP. 107-113, (2007); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); CHO K.H., KIM J.E., KOMATSU T., UEHARA Y., PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL(®)) WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED STUDY WITH HEALTHY AND MIDDLE-AGED JAPANESE PARTICIPANTS, LIFE (BASEL), (2023); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON—INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT PHYSIOL, 9, (2018); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, 61, PP. 346-357, (2000); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); PARK H.J., YADAV D., JEONG D.J., KIM S.J., BAE M.A., KIM J.R., ET AL., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT J ENVIRON RES PUBLIC HEALTH, 16, (2019); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); WANG H.Y., JIAO Q.P., CHEN S.Y., SHENG J., JIANG H., LU J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL PLUS FENOFIBRATE COMBINATION THERAPY IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA: A RANDOMIZED, CONTROLLED CLINICAL STUDY, AM J MED SCI, 356, PP. 254-261, (2018); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CHAN L.S., MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID)–ADDING MEANING TO STATISTICAL INFERENCE, AM J PUBLIC HEALTH, 103, PP. E24-E25, (2013); LENTERS-WESTRA E., SCHINDHELM R.K., BILO H.J., GROENIER K.H., SLINGERLAND R.J., DIFFERENCES IN INTERPRETATION OF HAEMOGLOBIN A1C VALUES AMONG DIABETES CARE PROFESSIONALS, NETH J MED, 72, PP. 462-466, (2014); GERICH J.E., CLINICAL SIGNIFICANCE, PATHOGENESIS, AND MANAGEMENT OF POSTPRANDIAL HYPERGLYCEMIA, ARCH INTERN MED, 163, PP. 1306-1316, (2003); CHO K.H., NAM H.S., BAEK S.H., KANG D.J., NA H., KOMATSU T., ET AL., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT J MOL SCI, (2023); PARHOFER K.G., INTERACTION BETWEEN GLUCOSE AND LIPID METABOLISM: MORE THAN DIABETIC DYSLIPIDEMIA, DIABETES METAB J, 39, PP. 353-362, (2015); XIE Z., DONG Y., SCHOLZ R., NEUMANN D., ZOU M.H., PHOSPHORYLATION OF LKB1 AT SERINE 428 BY PROTEIN KINASE C-ZETA IS REQUIRED FOR METFORMIN-ENHANCED ACTIVATION OF THE AMP-ACTIVATED PROTEIN KINASE IN ENDOTHELIAL CELLS, CIRCULATION, 117, PP. 952-962, (2008); BANERJEE S., GHOSHAL S., PORTER T.D., PHOSPHORYLATION OF HEPATIC AMP-ACTIVATED PROTEIN KINASE AND LIVER KINASE B1 IS INCREASED AFTER A SINGLE ORAL DOSE OF GREEN TEA EXTRACT TO MICE, NUTR RES, 32, PP. 985-990, (2012); TOWLER M.C., HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE IN METABOLIC CONTROL AND INSULIN SIGNALING, CIRC RES, 100, PP. 328-341, (2007); SHAW R.J., LAMIA K.A., VASQUEZ D., KOO S.H., BARDEESY N., DEPINHO R.A., ET AL., THE KINASE LKB1 MEDIATES GLUCOSE HOMEOSTASIS IN LIVER AND THERAPEUTIC EFFECTS OF METFORMIN, SCIENCE, 310, PP. 1642-1646, (2005); LI C., DING Y., SI Q., LI K., XU K., MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY PATIENTS WITH DYSLIPIDEMIA, J INT MED RES., 48, (2020); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); CUADRADO A., NEBREDA A.R., MECHANISMS AND FUNCTIONS OF P38 MAPK SIGNALLING, BIOCHEM J, 429, PP. 403-417, (2010); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); FERNANDEZ S., MAS R., GAMEZ R., DIAZ A., FERNANDEZ J., DEIBIS ORTA S., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, PP. 219-229, (2004); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CICERO A.F., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN DRUG SAF, 11, PP. 753-766, (2012); XU K., LIU X., LI Y., WANG Y., ZANG H., GUO L., ET AL., SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ON-TREATMENT PLATELET REACTIVITY AFTER DRUG-ELUTING STENT IMPLANTATION: TWO-YEAR FOLLOW-UP RESULTS, CARDIOVASC THER, 34, PP. 337-342, (2016); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES, 62, (2018)","A. HEKMATDOOST; DEPARTMENT OF CLINICAL NUTRITION & DIETETICS, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN; EMAIL: AZITA.HEKMATDOOST@SBMU.AC.IR","ELSEVIER IRELAND LTD","ENGLISH","DIABETES RES. CLIN. PRACT.","REVIEW","ISI","2-S2.0-85193432704","DIABETES RES CLIN PRACT","SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES;TEHRAN UNIVERSITY OF MEDICAL SCIENCES(TUMS);TEHRAN UNIVERSITY OF MEDICAL SCIENCES(TUMS);TEHRAN UNIVERSITY OF MEDICAL SCIENCES(TUMS);SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES;ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"REZA AMINI M, 2024, DIABETES RES CLIN PRACT","REZA AMINI M, 2024, DIABETES RES CLIN PRACT"
"KIM T;PARK Y;YI T;SEO W;PARK N;KIM J","KIM, TAE JIN (57202388112); PARK, YOUNG JIN (57202422844); YI, TAE GYU (57196470089); SEO, WOO DUCK (8921329600); PARK, NAM IL (35071692900); KIM, JAE KWANG (56892616700)","A COMPREHENSIVE METABOLITE PROFILE OF GREEN AND WHITE ASPARAGUS ASPARAGUS OFFICINALIS L AND THEIR ANTIOXIDANT PROPERTIES IN DIFFERING CULTIVATION CONDITIONS",2024,"NATURAL PRODUCT COMMUNICATIONS","19","",0,"10.1177/1934578X241238922","BIO-RESOURCE INDUSTRIALIZATION CENTER, NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES, GYEONGSANGBUK-DO, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, SOUTH KOREA;DEPARTMENT OF PLANT SCIENCE, GANGNEUNG-WONJU NATIONAL UNIVERSITY, GANGNEUNG, SOUTH KOREA, DEPARTMENT OF GENETIC ENGINEERING AND GRADUATE SCHOOL OF BIOTECHNOLOGY, KYUNG HEE UNIVERSITY, YONGIN, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEONBUK, SOUTH KOREA;DEPARTMENT OF PLANT SCIENCE, GANGNEUNG-WONJU NATIONAL UNIVERSITY, GANGNEUNG, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, SOUTH KOREA","ASPARAGUS (ASPARAGUS OFFICINALIS L.) IS A FOOD CROP WITH A VARIETY OF PHARMACOLOGICAL EFFECTS THAT CAN BE CLASSIFIED AS GREEN OR WHITE, DEPENDING ON CULTIVATION METHODS. HOWEVER, NO RESEARCH HAS BEEN CONDUCTED ON THE PROFILES OF PRIMARY AND SECONDARY METABOLITES IN GREEN AND WHITE ASPARAGUS. HENCE, THE AIM OF THIS STUDY WAS TO COMPREHENSIVELY ANALYZE AND UNDERSTAND THE METABOLIC VARIATIONS ASSOCIATED WITH THE COLOR DIFFERENCES IN ASPARAGUS UNDER DIFFERENT CULTIVATION CONDITIONS. THROUGH EXTENSIVE PROFILING OF PRIMARY AND SECONDARY METABOLITES, WE IDENTIFIED 48 HYDROPHILIC COMPOUNDS, NINE POLICOSANOLS, SEVEN TERPENOIDS, SIX FLAVONOIDS, AND ONE PHENOLIC ACID. MULTIVARIATE AND METABOLIC PATHWAY ANALYSES REVEALED NOTABLE DISTINCTIONS BETWEEN GREEN AND WHITE ASPARAGUS. GREEN ASPARAGUS CONTAINED HIGH LEVELS OF FLAVONOIDS, POLICOSANOLS, AND PRIMARY METABOLITES (ORGANIC AND AMINO ACIDS). IN CONTRAST, WHITE ASPARAGUS CONTAINED HIGH LEVELS OF SUGARS, PROLINE, AND TERPENOIDS (TOCOPHEROLS, PHYTOSTEROLS, AND PROTODIOSCIN). THESE RESULTS SUGGEST THAT GREEN ASPARAGUS HAS HIGHER ENERGY AND AMINO ACID SYNTHESIS METABOLISM FOR PLANT DEVELOPMENT AND GROWTH THROUGH PHOTOSYNTHESIS UNDER LIGHT CULTIVATION CONDITIONS THAN WHITE ASPARAGUS. IN CONTRAST, WHITE ASPARAGUS ACCUMULATED STRESS-RELATED METABOLITES, SUCH AS SUCROSE, PROLINE, AND PHENYLALANINE, UNDER DARK CULTIVATION CONDITIONS. IN ADDITION, FLAVONOID METABOLISM WAS ACTIVATED UNDER LIGHT CONDITIONS, WHEREAS TERPENOID BIOSYNTHESIS WAS ACTIVATED UNDER DARK CONDITIONS. THE DPPH AND ABTS SCAVENGING ACTIVITIES OF GREEN ASPARAGUS WERE AT LEAST TWICE AS HIGH AS THOSE OF WHITE ASPARAGUS. OVERALL, GREEN ASPARAGUS IS A GOOD SOURCE OF NUTRIENTS AND CONTAINS MORE ANTIOXIDANTS THAN WHITE ASPARAGUS. THESE FINDINGS MIGHT BE THE FIRST REPORT OF COMPREHENSIVE METABOLOME IN ASPARAGUS, AND THEY WILL SIGNIFICANTLY CONTRIBUTE TO UNDERSTANDING THE EFFECTS OF DIFFERENT CULTIVATION CONDITIONS ON THE ASPARAGUS METABOLOME. © THE AUTHOR(S) 2024.","ANTIOXIDANT; ASPARAGUS; FLAVONOIDS; METABOLITES; METABOLOMICS; PROTODIOSCIN; RUTIN; TERPENOIDS","4 AMINOBUTYRIC ACID; ALANINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ARABINOSE; ASCORBIC ACID; ASPARAGINE; ASPARAGUS OFFICINALIS EXTRACT; BEHENYL ALCOHOL; BETA ALANINE; BETA TOCOPHEROL; CAMPESTEROL; CARBOXYLIC ACID; CHOLESTEROL; CITRIC ACID; CYSTEINE; DRUG METABOLITE; EICOSANOL; ETHANOLAMINE; FERULIC ACID; FLAVONOID; FRUCTOSE; FUMARIC ACID; GAMMA TOCOPHEROL; GLUCOSE; GLUTAMINE; GLYCERIC ACID; GLYCEROL; GLYCINE; GLYCOLIC ACID; HENEICOSANOL; HEPTASANOL; HEXASANOL; INOSITOL; ISOLEUCINE; ISOQUERCETIN; LACTIC ACID; LEUCINE; MALIC ACID; MANNITOL; MANNOSE; METHIONINE; NARINGENIN; NICTOFLORIN; OCTACOSANOL; OXALIC ACID; PARA COUMARIC ACID; PHENYLALANINE; PHOSPHORIC ACID; PHYTOCHEMICAL; PHYTOSTEROL; PLANT EXTRACT; POLICOSANOL; PROLINE; PROTODIOSCIN; PUTRESCINE; PYROGLUTAMIC ACID; PYRUVIC ACID; QUERCETIN; QUINIC ACID; RAFFINOSE; RUTOSIDE; SERINE; SHIKIMIC ACID; SITOSTEROL; STIGMASTEROL; SUCCINIC ACID; SUCROSE; SUGAR ALCOHOL; TERPENOID; TETRACOSANOL; THREONIC ACID; THREONINE; TRIASANOL; TRICOSANOL; TRYPTOPHAN; UNCLASSIFIED DRUG; UREA; VALINE; XYLITOL; XYLOSE; ABTS RADICAL SCAVENGING ASSAY; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARAGUS; CONTROLLED STUDY; DARKNESS; DPPH RADICAL SCAVENGING ASSAY; DRUG EFFICACY; DRUG MECHANISM; ENERGY METABOLISM; ETHNOPHARMACOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT; MASS FRAGMENTOGRAPHY; METABOLIC FINGERPRINTING; METABOLIC PATHWAY ANALYSIS; METABOLOME; MULTIVARIATE ANALYSIS; NONHUMAN; PHOTOSYNTHESIS; PHYTOCHEMISTRY; PLANT DEVELOPMENT; PLANT GROWTH; PLANT METABOLISM; PLANT NUTRIENT; PLANT STRESS; SECONDARY METABOLISM; SPECIES CULTIVATION; SPECIES DIFFERENCE; TIME OF FLIGHT MASS SPECTROMETRY; ULTRAVIOLET RADIATION","NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICALRESOURCES; RURAL DEVELOPMENT ADMINISTRATION, RDA; MINISTRY OF ENVIRONMENT, MOE, (NNIBR20243112, PJ01706903); MINISTRY OF ENVIRONMENT, MOE","THE AUTHOR(S) DISCLOSED RECEIPT OF THE FOLLOWING FINANCIAL SUPPORT FOR THE RESEARCH, AUTHORSHIP, AND/OR PUBLICATION OF THIS ARTICLE: THIS WORK WAS SUPPORTED BY A GRANT FROM THE NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICALRESOURCES (NNIBR), FUNDED BY THE MINISTRY OF ENVIRONMENT (MOE) OF THE REPUBLIC OF KOREA (NNIBR20243112), AND \U201CCOOPERATIVE RESEARCH PROGRAM FOR AGRICULTURE SCIENCE & TECHNOLOGY DEVELOPMENT (PROJECT NO. PJ01706903)\U201D FUNDED BY THE RURAL DEVELOPMENT ADMINISTRATION (RDA), REPUBLIC OF KOREA. ","PEGIOU E., MUMM R., ACHARYA P., DE VOS R.C., HALL R.D., GREEN AND WHITE ASPARAGUS (ASPARAGUS OFFICINALIS): A SOURCE OF DEVELOPMENTAL, CHEMICAL AND URINARY INTRIGUE, METABOLITES, 10, 1, (2019); CHEN H., LU Z., WANG J., ET AL., INDUCTION OF NEW TETRAPLOID GENOTYPES AND HEAT TOLERANCE ASSESSMENT IN ASPARAGUS OFFICINALIS L, SCI HORTIC, 264, (2020); ZAFIRIOU P., MAMOLOS A.P., MENEXES G.C., SIOMOS A.S., TSATSARELIS C.A., KALBURTJI K.L., ANALYSIS OF ENERGY FLOW AND GREENHOUSE GAS EMISSIONS IN ORGANIC, INTEGRATED AND CONVENTIONAL CULTIVATION OF WHITE ASPARAGUS BY PCA AND HCA: CASES IN GREECE, J CLEAN PROD, 29-30, PP. 20-27, (2012); LEE E.J., YOO K.S., PATIL B.S., DEVELOPMENT OF A RAPID HPLC-UV METHOD FOR SIMULTANEOUS QUANTIFICATION OF PROTODIOSCIN AND RUTIN IN WHITE AND GREEN ASPARAGUS SPEARS, J FOOD SCI, 75, 9, (2010); KMEL A.H., MOHAMED H.A., AMER A.S., THE POSSIBLE PROTECTIVE EFFECT OF RUTIN AGAINST HEPATOTOXICITY INDUCED BY MONO-SODIUM GLUTAMATE ON MALE RATS, WULFENIA, 26, 4, PP. 42-62, (2019); GHORBANI A., MECHANISMS OF ANTIDIABETIC EFFECTS OF FLAVONOID RUTIN, BIOMED PHARMACOTHER, 96, PP. 305-312, (2017); SELLOUM L., BOURICHE H., TIGRINE C., BOUDOUKHA C., ANTI-INFLAMMATORY EFFECT OF RUTIN ON RAT PAW OEDEMA, AND ON NEUTROPHILS CHEMOTAXIS AND DEGRANULATION, EXP TOXICOL PATHOL, 54, 4, PP. 313-318, (2003); SADEGHNIA H.R., YOUSEFSANI B.S., RASHIDFAR M., BOROUSHAKI M.T., ASADPOUR E., GHORBANI A., PROTECTIVE EFFECT OF RUTIN ON HEXACHLOROBUTADIENE-INDUCED NEPHROTOXICITY, REN FAIL, 35, 8, PP. 1151-1155, (2013); YANG J., GUO J., YUAN J., IN VITRO ANTIOXIDANT PROPERTIES OF RUTIN, LWT-FOOD SCI TECHNOL, 41, 6, PP. 1060-1066, (2008); YI T.G., YEOUNG Y.R., CHOI I.Y., PARK N.I., TRANSCRIPTOME ANALYSIS OF ASPARAGUS OFFICINALIS REVEALS GENES INVOLVED IN THE BIOSYNTHESIS OF RUTIN AND PROTODIOSCIN, PLOS ONE, 14, 7, (2019); GUO C., DONG Y., ZHU H., LIU Y., XIE G., AMELIORATIVE EFFECTS OF PROTODIOSCIN ON EXPERIMENTAL DIABETIC NEPHROPATHY, PHYTOMEDICINE, 51, PP. 77-83, (2018); SONG S., FAJOL A., CHEN Y., REN B., SHI S., ANTICONVULSIVE EFFECTS OF PROTODIOSCIN AGAINST PILOCARPINE-INDUCED EPILEPSY, EUR J PHARMACOL, 833, PP. 237-246, (2018); GAUTHAMAN K., ADAIKAN P.G., PRASAD R.N.V., APHRODISIAC PROPERTIES OF TRIBULUS TERRESTRIS EXTRACT (PROTODIOSCIN) IN NORMAL AND CASTRATED RATS, LIFE SCI, 71, 12, PP. 1385-1396, (2002); LIU J.Y., HOU Y.L., CAO R., ET AL., PROTODIOSCIN AMELIORATES OXIDATIVE STRESS, INFLAMMATION AND HISTOLOGY OUTCOME IN COMPLETE FREUND’S ADJUVANT INDUCED ARTHRITIS RATS, APOPTOSIS, 22, 11, PP. 1454-1460, (2017); WU J., ZHAO Y.M., DENG Z.K., NEUROPROTECTIVE ACTION AND MECHANISTIC EVALUATION OF PROTODIOSCIN AGAINST RAT MODEL OF PARKINSON’S DISEASE, PHARMACOL REP, 70, 1, PP. 139-145, (2018); JIMENEZ-SANCHEZ C., LOZANO-SANCHEZ J., RODRIGUEZ-PEREZ C., SEGURA-CARRETERO A., FERNANDEZ-GUTIERREZ A., COMPREHENSIVE, UNTARGETED, AND QUALITATIVE RP-HPLC-ESI-QTOF/MS2 METABOLITE PROFILING OF GREEN ASPARAGUS (ASPARAGUS OFFICINALIS), J FOOD COMPOST ANAL, 46, PP. 78-87, (2016); ZHANG H., BIOACTIVE COMPOUNDS FROM ASPARAGUS ROOTS AND THEIR BIOLOGICAL ACTIVITIES, PHD THESIS, (2018); DONG T., HAN R., YU J., ET AL., ANTHOCYANINS ACCUMULATION AND MOLECULAR ANALYSIS OF CORRELATED GENES BY METABOLOME AND TRANSCRIPTOME IN GREEN AND PURPLE ASPARAGUSES (ASPARAGUS OFFICINALIS, L.), FOOD CHEM, 271, PP. 18-28, (2019); KIM T.J., LEE K.B., BAEK S.A., ET AL., DETERMINATION OF LIPOPHILIC METABOLITES FOR SPECIES DISCRIMINATION AND QUALITY ASSESSMENT OF NINE LEAFY VEGETABLES, J KOREAN SOC APPL BIOL CHEM, 58, 6, PP. 909-918, (2015); KIM T.J., HYEON H., PARK N.I., ET AL., A HIGH-THROUGHPUT PLATFORM FOR INTERPRETATION OF METABOLITE PROFILE DATA FROM PEPPER (CAPSICUM) FRUITS OF 13 PHENOTYPES ASSOCIATED WITH DIFFERENT FRUIT MATURITY STATES, FOOD CHEM, 331, (2020); EUM H.L., YI T.G., HONG S.J., PARK N.I., VARIATIONS OF BIOACTIVE COMPOUND CONTENTS AND ANTIOXIDANT CAPACITY OF ASPARAGUS SEEDLINGS IN 23 VARIETIES, HORTIC SCI TECHNOL, 38, 2, PP. 291-302, (2020); EUM H.L., PARK Y., YI T.G., ET AL., EFFECT OF GERMINATION ENVIRONMENT ON THE BIOCHEMICAL COMPOUNDS AND ANTI-INFLAMMATORY PROPERTIES OF SOYBEAN CULTIVARS, PLOS ONE, 15, 4, (2020); KUTMON M., VAN IERSEL M.P., BOHLER A., ET AL., PATHVISIO 3: AN EXTENDABLE PATHWAY ANALYSIS TOOLBOX, PLOS COMPUT BIOL, 11, 2, (2015); EBRAHIMZADEH M.A., POURMORAD F., HAFEZI S., ANTIOXIDANT ACTIVITIES OF IRANIAN CORN SILK, TURK J BIOL, 32, 1, PP. 43-49, (2008); HANAFY R.S., SADAK M.S., FOLIAR SPRAY OF STIGMASTEROL REGULATES PHYSIOLOGICAL PROCESSES AND ANTIOXIDANT MECHANISMS TO IMPROVE YIELD AND QUALITY OF SUNFLOWER UNDER DROUGHT STRESS, J SOIL SCI PLANT NUTR, 23, 2, PP. 2433-2450, (2023); TEPE B., DEGERLI S., ARSLAN S., MALATYALI E., SARIKURKCU C., DETERMINATION OF CHEMICAL PROFILE, ANTIOXIDANT, DNA DAMAGE PROTECTION AND ANTIAMOEBIC ACTIVITIES OF TEUCRIUM POLIUM AND STACHYS IBERICA, FITOTERAPIA, 82, 2, PP. 237-246, (2011); SADAK M.S., DAWOOD M.G., BIOFERTILIZER ROLE IN ALLEVIATING THE DELETERIOUS EFFECTS OF SALINITY ON WHEAT GROWTH AND PRODUCTIVITY, GESUNDE PFLANZEN, 75, 4, PP. 1207-1219, (2023); BAKHOUM G.S., SADAK M.S., TAWFIK M.M., CHITOSAN AND CHITOSAN NANOPARTICLE EFFECT ON GROWTH, PRODUCTIVITY AND SOME BIOCHEMICAL ASPECTS OF LUPINUS TERMIS L PLANT UNDER DROUGHT CONDITIONS, EGYPT J CHEM, 65, 5, PP. 537-549, (2022); SADAK M.S., BAKHOUM G.S., SELENIUM-INDUCED MODULATIONS IN GROWTH, PRODUCTIVITY AND PHYSIOCHEMICAL RESPONSES TO WATER DEFICIENCY IN QUINOA (CHENOPODIUM QUINOA) GROWN IN SANDY SOIL, BIOCATAL AGRIC BIOTECHNOL, 44, (2022); MAEDA T., KAKUTA H., SONODA T., ET AL., ANTIOXIDATION CAPACITIES OF EXTRACTS FROM GREEN, PURPLE, AND WHITE ASPARAGUS SPEARS RELATED TO POLYPHENOL CONCENTRATION, HORTSCIENCE, 40, 5, PP. 1221-1224, (2005); MOTOKI S., KITAZAWA H., MAEDA T., ET AL., EFFECTS OF VARIOUS ASPARAGUS PRODUCTION METHODS ON RUTIN AND PROTODIOSCIN CONTENTS IN SPEARS AND CLADOPHYLLS, BIOSCI BIOTECHNOL BIOCHEM, 76, 5, PP. 1047-1050, (2012); KIM T.J., CHOI J., KIM K.W., ET AL., METABOLITE PROFILING OF PEPPERS OF VARIOUS COLORS REVEALS RELATIONSHIPS BETWEEN TOCOPHEROL, CAROTENOID, AND PHYTOSTEROL CONTENT, J FOOD SCI, 82, 12, PP. 2885-2893, (2017); KIM S., SCHLICKE H., VAN REE K., ET AL., ARABIDOPSIS CHLOROPHYLL BIOSYNTHESIS: AN ESSENTIAL BALANCE BETWEEN THE METHYLERYTHRITOL PHOSPHATE AND TETRAPYRROLE PATHWAYS, PLANT CELL, 25, 12, PP. 4984-4993, (2013); HILDEBRANDT T.M., SYNTHESIS VERSUS DEGRADATION: DIRECTIONS OF AMINO ACID METABOLISM DURING ARABIDOPSIS ABIOTIC STRESS RESPONSE, PLANT MOL BIOL, 98, 1-2, PP. 121-135, (2018); OLIVEIRA A.B., MOURA C.F., GOMES-FILHO E., MARCO C.A., URBAN L., MIRANDA M.R.A., THE IMPACT OF ORGANIC FARMING ON QUALITY OF TOMATOES IS ASSOCIATED TO INCREASED OXIDATIVE STRESS DURING FRUIT DEVELOPMENT, PLOS ONE, 8, 2, (2013); LU T., YU H., LI Q., CHAI L., JIANG W., IMPROVING PLANT GROWTH AND ALLEVIATING PHOTOSYNTHETIC INHIBITION AND OXIDATIVE STRESS FROM LOW-LIGHT STRESS WITH EXOGENOUS GR24 IN TOMATO (SOLANUM LYCOPERSICUM L.) SEEDLINGS, FRONT PLANT SCI, 10, (2019); SICCAMA J.W., PEGIOU E., ZHANG L., ET AL., MALTODEXTRIN IMPROVES PHYSICAL PROPERTIES AND VOLATILE COMPOUND RETENTION OF SPRAY-DRIED ASPARAGUS CONCENTRATE, LWT, 142, (2021); LANDAUD S., HELINCK S., BONNARME P., FORMATION OF VOLATILE SULFUR COMPOUNDS AND METABOLISM OF METHIONINE AND OTHER SULFUR COMPOUNDS IN FERMENTED FOOD, APPL MICROBIOL BIOTECHNOL, 77, 6, PP. 1191-1205, (2008)","J.K. KIM; DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, SOUTH KOREA; EMAIL: KJKPJ@INU.AC.KR; N.I. PARK; DEPARTMENT OF PLANT SCIENCE, GANGNEUNG-WONJU NATIONAL UNIVERSITY, GANGNEUNG, SOUTH KOREA; EMAIL: NIPARK@GWNU.AC.KR","SAGE PUBLICATIONS INC.","ENGLISH","NAT. PRO. COMM.","ARTICLE","ISI","2-S2.0-85189652155","NAT PRO COMM","NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES;INCHEON NATIONAL UNIVERSITY;GANGNEUNG-WONJU NATIONAL UNIVERSITY;NATIONAL INSTITUTE OF CROP SCIENCE;GANGNEUNG-WONJU NATIONAL UNIVERSITY;INCHEON NATIONAL UNIVERSITY","NOTREPORTED;INCHEON NATIONAL UNIVERSITY;NOTREPORTED;NOTREPORTED;GANGNEUNG-WONJU NATIONAL UNIVERSITY;NOTREPORTED",NA,"KIM TJ, 2024, NAT PRO COMM","KIM TJ, 2024, NAT PRO COMM"
"CHO K","CHO, KYUNG-HYUN (7403956966)","THE CURRENT STATUS OF RESEARCH ON HIGHDENSITY LIPOPROTEINS HDL A PARADIGM SHIFT FROM HDL QUANTITY TO HDL QUALITY AND HDL FUNCTIONALITY",2022,"INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES","23","",55,"10.3390/ijms23073967","LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA, RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA","THE QUANTITY OF HIGH-DENSITY LIPOPROTEINS (HDL) IS REPRESENTED AS THE SERUM HDL-C CONCENTRATION (MG/DL), WHILE THE HDL QUALITY MANIFESTS AS THE DIVERSE FEATURES OF PROTEIN AND LIPID CONTENT, EXTENT OF OXIDATION, AND EXTENT OF GLYCATION. THE HDL FUNCTIONALITY REPRESENTS SEVERAL PERFORMANCE METRICS OF HDL, SUCH AS ANTIOXIDANT, ANTI-INFLAMMATORY, AND CHOLESTEROL EFFLUX ACTIVITIES. THE QUANTITY AND QUALITY OF HDL CAN CHANGE DURING ONE’S LIFETIME, DEPENDING ON INFECTION, DISEASE, AND LIFESTYLE, SUCH AS DIETARY HABITS, EXERCISE, AND SMOKING. THE QUANTITY OF HDL CAN CHANGE ACCORDING TO AGE AND GENDER, SUCH AS PUBERTY, MIDDLE-AGED SYMPTOMS, CLIMACTERIC, AND THE MENOPAUSE. HDL-C CAN DECREASE DURING DISEASE STATES, SUCH AS ACUTE INFECTION, CHRONIC INFLAMMATION, AND AUTOIMMUNE DISEASE, WHILE IT CAN BE INCREASED BY REGULAR AEROBIC EXERCISE AND HEALTHY FOOD CONSUMPTION. GENERALLY, HIGH HDL-C AT THE NORMAL LEVEL IS ASSOCIATED WITH GOOD HDL QUALITY AND FUNCTIONALITY. NEVERTHELESS, HIGH HDL QUANTITY IS NOT ALWAYS ACCOMPANIED BY GOOD HDL QUALITY OR FUNCTIONALITY. THE HDL QUALITY CONCERNS THE MORPHOLOGY OF THE HDL, SUCH AS PARTICLE SIZE, SHAPE, AND NUMBER. THE HDL QUALITY ALSO DEPENDS ON THE COMPOSITION OF THE HDL, SUCH AS APOLIPOPROTEINS (APOA-I, APOA-II, APOC-III, SERUM AMYLOID A, AND Α-SYNUCLEIN), CHOLESTEROL, AND TRIGLYCERIDE. THE HDL QUALITY IS ALSO ASSOCIATED WITH THE EXTENT OF HDL MODIFICATION, SUCH AS GLYCATION AND OXIDATION, RESULTING IN THE MULTIMERIZATION OF APOA-I, AND THE AGGREGATION LEADS TO AMYLOIDOGENESIS. THE HDL QUALITY FREQUENTLY DETERMINES THE HDL FUNCTIONALITY, WHICH DEPENDS ON THE ATTACHED ANTIOXIDANT ENZYME ACTIVITY, SUCH AS THE PARAOXONASE AND CHOLESTEROL EFFLUX ACTIVITY. CONVENTIONAL HDL FUNCTIONALITY IS REGRESSION, THE REMOVAL OF CHOLESTEROL FROM ATHEROSCLEROTIC LESIONS, AND THE REMOVAL OF OXIDIZED SPECIES IN LOW-DENSITY LIPOPROTEINS (LDL). RECENTLY, HDL FUNCTIONALITY WAS REPORTED TO EXPAND THE REMOVAL OF Β-AMYLOID PLAQUE AND INHIBIT Α-SYNUCLEIN AGGREGATION IN THE BRAIN TO ATTENUATE ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE, RESPECTIVELY. MORE RECENTLY, HDL FUNCTIONALITY HAS BEEN ASSOCIATED WITH THE SUSCEPTIBILITY AND RECOVERY ABILITY OF CORONAVIRUS DISEASE 2019 (COVID-19) BY INHIBITING THE ACTIVITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2). THE APPEARANCE OF DYSFUNCTIONAL HDL IS FREQUENTLY ASSOCIATED WITH MANY ACUTE INFECTIOUS DISEASES AND CHRONIC AGING-RELATED DISEASES. AN HDL CAN BE A SUITABLE BIOMARKER TO DIAGNOSE MANY DISEASES AND THEIR PROGRESSION BY MONITORING THE CHANGES IN ITS QUANTITY AND QUALITY IN TERMS OF THE ANTIOXIDANT AND ANTI-INFLAMMATORY ABILITIES. AN HDL CAN BE A PROTEIN DRUG USED FOR THE REMOVAL OF PLAQUE AND AS A DELIVERY VEHICLE FOR NON-SOLUBLE DRUGS AND GENES. A DYSFUNCTIONAL HDL HAS POOR HDL QUALITY, SUCH AS A LOWER APOA-I CONTENT, LOWER ANTIOXIDANT ABILITY, SMALLER SIZE, AND AMBIGUOUS SHAPE. THE CURRENT REVIEW ANALYZES THE RECENT ADVANCES IN HDL QUANTITY, QUALITY, AND FUNCTIONALITY, DEPENDING ON THE HEALTH AND DISEASE STATE DURING ONE’S LIFETIME. © 2022 BY THE AUTHOR. LICENSEE MDPI, BASEL, SWITZERLAND.","CHOLESTEROL; HDL FUNCTIONALITY; HDL QUALITY; HDL QUAN-TITY; HIGH-DENSITY LIPOPROTEIN (HDL); LOW-DENSITY LIPOPROTEINS (LDL)","ALPHA-SYNUCLEIN; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; CHOLESTEROL; CHOLESTEROL, HDL; COVID-19; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MIDDLE AGED; SARS-COV-2; ALPHA SYNUCLEIN; AMYLOID; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLICOSANOL; SERUM AMYLOID A; ALPHA SYNUCLEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; ALZHEIMER DISEASE; ARTERIAL STIFFNESS; CHOLESTEROL TRANSPORT; DIET SUPPLEMENTATION; DYSLIPIDEMIA; EXERCISE; FEMALE; HUMAN; HYPERTENSION; LIFESPAN; LIPID COMPOSITION; MALE; MENOPAUSE; PARTICLE SIZE; PUBERTY; REVIEW; SEX DIFFERENCE; SUGARCANE; METABOLISM; MIDDLE AGED","","","CHO K.H., HIGH-DENSITY LIPOPROTEINS AS BIOMARKERS AND THERAPEUTIC TOOLS: VOLUME 1. IMPACTS OF LIFESTYLE, DISEASES, AND ENVIRONMENTAL STRESSORS ON HDL, (2019); CHO K.H., HIGH-DENSITY LIPOPROTEINS AS BIOMARKERS AND THERAPEUTIC TOOLS: VOLUME 2. IMPROVEMENT AND ENHANCEMENT OF HDL AND CLINICAL APPLICATIONS, (2019); HOLVOET P., DE KEYZER D., JACOBS D.R., OXIDIZED LDL AND THE METABOLIC SYNDROME, FUTURE LIPIDOL, 3, PP. 637-649, (2008); CHEN C., KHISMATULLIN D.B., OXIDIZED LOW-DENSITY LIPOPROTEIN CONTRIBUTES TO ATHEROGENESIS VIA CO-ACTIVATION OF MACROPHAGES AND MAST CELLS, PLOS ONE, 10, (2015); HOTTMAN D.A., CHERNICK D., CHENG S., WANG Z., LI L., HDL AND COGNITION IN NEURODEGENERATIVE DISORDERS, NEUROBIOL. DIS, 72, PP. 22-36, (2014); RYSZ J., GLUBA-BRZOZKA A., RYSZ-GORZYNSKA M., FRANCZYK B., THE ROLE AND FUNCTION OF HDL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND THE RISK OF CARDIOVASCULAR DISEASE, INT. J. MOL. SCI, 21, (2020); MASANA L., CORREIG E., IBARRETXE D., ANORO E., ARROYO J.A., JERICO C., GUERRERO C., MIRET M., NAF S., PARDO A., ET AL., HDL AND HIGH TRIGLYCERIDES PREDICT COVID-19 SEVERITY, SCI. REP, 11, (2021); WANG G., ZHANG Q., ZHAO X., DONG H., WU C., WU F., YU B., LV J., ZHANG S., WU G., ET AL., LOW HIGH-DENSITY LIPOPROTEIN LEVEL IS CORRELATED WITH THE SEVERITY OF COVID-19 PATIENTS: AN OBSERVATIONAL STUDY, LIPIDS HEALTH DIS, 19, (2020); FEINGOLD K.R., THE BIDIRECTIONAL LINK BETWEEN HDL AND COVID-19 INFECTIONS, J. LIPID RES, 62, (2021); CHO K.H., KIM J.R., LEE I.C., KWON H.J., NATIVE HIGH-DENSITY LIPOPROTEINS (HDL) WITH HIGHER PARAOXONASE EXERTS A POTENT ANTIVIRAL EFFECT AGAINST SARS-COV-2 (COVID-19), WHILE GLYCATED HDL LOST THE ANTIVIRAL ACTIVITY, ANTIOXIDANTS, 10, (2021); FEDDER D.O., KORO C.E., L'ITALIEN G.J., NEW NATIONAL CHOLESTEROL EDUCATION PROGRAM III GUIDELINES FOR PRIMARY PREVENTION LIPID-LOWERING DRUG THERAPY: PROJECTED IMPACT ON THE SIZE, SEX, AND AGE DISTRIBUTION OF THE TREATMENT-ELIGIBLE POPULATION, CIRCULATION, 105, PP. 152-156, (2002); REZAPOUR M., SHAHESMAEILI A., HOSSINZADEH A., ZAHEDI R., NAJAFIPOUR H., GOZASHTI M.H., COMPARISON OF LIPID RATIOS TO IDENTIFY METABOLIC SYNDROME, ARCH. IRAN. MED, 21, PP. 572-577, (2018); MURGUIA-ROMERO M., JIMENEZ-FLORES J.R., SIGRIST-FLORES S.C., ESPINOZA-CAMACHO M.A., JIMENEZ-MORALES M., PINA E., MENDEZ-CRUZ A.R., VILLALOBOS-MOLINA R., REAVEN G.M., PLASMA TRIGLYCERIDE/HDL-CHOLESTEROL RATIO, INSULIN RESISTANCE, AND CARDIOMETABOLIC RISK IN YOUNG ADULTS, J. LIPID RES, 54, PP. 2795-2799, (2013); CHO K.H., PARK H.J., KIM J.R., DECREASE IN SERUM HDL-C LEVEL IS ASSOCIATED WITH ELEVATION OF BLOOD PRESSURE: CORRELATION ANALYSIS FROM THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2017, INT. J. ENVIRON. RES. PUBLIC HEALTH, 17, (2020); LEMIEUX I., LAMARCHE B., COUILLARD C., PASCOT A., CANTIN B., BERGERON J., DAGENAIS G.R., DESPRES J.P., TOTAL CHOLESTEROL/HDL CHOLESTEROL RATIO VS LDL CHOLESTEROL/HDL CHOLESTEROL RATIO AS INDICES OF ISCHEMIC HEART DISEASE RISK IN MEN: THE QUEBEC CARDIOVASCULAR STUDY, ARCH. INTERN. MED, 161, PP. 2685-2692, (2001); REILLY M.P., RADER D.J., THE METABOLIC SYNDROME: MORE THAN THE SUM OF ITS PARTS?, CIRCULATION, 108, PP. 1546-1551, (2003); SVENSSON T., SAWADA N., MIMURA M., NOZAKI S., SHIKIMOTO R., TSUGANE S., THE ASSOCIATION BETWEEN MIDLIFE SERUM HIGH-DENSITY LIPOPROTEIN AND MILD COGNITIVE IMPAIRMENT AND DEMENTIA AFTER 19 YEARS OF FOLLOW-UP, TRANSL. PSYCHIATRY, 9, (2019); SINGH-MANOUX A., GIMENO D., KIVIMAKI M., BRUNNER E., MARMOT M.G., LOW HDL CHOLESTEROL IS A RISK FACTOR FOR DEFICIT AND DECLINE IN MEMORY IN MIDLIFE: THE WHITEHALL II STUDY, ARTERIOSCLER. THROMB. VASC. BIOL, 28, PP. 1556-1562, (2008); CHO K.H., PARK H.J., KIM S.J., KIM J.R., DECREASE IN HDL-C IS ASSOCIATED WITH AGE AND HOUSEHOLD INCOME IN ADULTS FROM THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2017: CORRELATION ANALYSIS OF LOW HDL-C AND POVERTY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); FERRARA A., BARRETT-CONNOR E., SHAN J., TOTAL, LDL, AND HDL CHOLESTEROL DECREASE WITH AGE IN OLDER MEN AND WOMEN. THE RANCHO BERNARDO STUDY. 1984–1994, CIRCULATION, 96, PP. 37-43, (1997); SHIMAKAWA T., SORLIE P., CARPENTER M.A., DENNIS B., TELL G.S., WATSON R., WILLIAMS O.D., DIETARY INTAKE PATTERNS AND SOCIODEMOGRAPHIC FACTORS IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. ARIC STUDY INVESTIGATORS, PREV. MED, 23, PP. 769-780, (1994); CHO K.H., KIM J.R., RAPID DECREASE IN HDL-C IN THE PUBERTY PERIOD OF BOYS ASSOCIATED WITH AN ELEVATION OF BLOOD PRESSURE AND DYSLIPIDEMIA IN KOREAN TEENAGERS: AN EXPLANATION OF WHY AND WHEN MEN HAVE LOWER HDL-C LEVELS THAN WOMEN, MED. SCI, 9, (2021); KANNEL W.B., DAWBER T.R., FRIEDMAN G.D., GLENNON W.E., MCNAMARA P.M., RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY, ANN. INTERN. MED, 61, PP. 888-899, (1964); KIM H.J., PARK H.A., CHO Y.G., KANG J.H., KIM K.W., KANG J.H., KIM N.R., CHUNG W.C., KIM C.H., WHANG D.H., ET AL., GENDER DIFFERENCE IN THE LEVEL OF HDL CHOLESTEROL IN KOREAN ADULTS, KOREAN J. FAM. MED, 32, PP. 173-181, (2011); GORMAN B.K., READ J., WHY MEN DIE YOUNGER THAN WOMEN, GERIATR. AGING, 10, PP. 179-181, (2007); FOFANA M., MABOUNDOU J.C., BOCQUET J., LE GOFF D., TRANSFER OF CHOLESTEROL BETWEEN HIGH DENSITY LIPOPROTEINS AND CULTURED RAT SERTOLI CELLS, BIOCHEM. CELL BIOL, 74, PP. 681-686, (1996); LI H., SUN R., CHEN Q., GUO Q., WANG J., LU L., ZHANG Y., ASSOCIATION BETWEEN HDL-C LEVELS AND MENOPAUSE: A META-ANALYSIS, HORMONES, 20, PP. 49-59, (2021); COLLINS P., HDL-C IN POST-MENOPAUSAL WOMEN: AN IMPORTANT THERAPEUTIC TARGET, INT. J. CARDIOL, 124, PP. 275-282, (2008); MATTHEWS K.A., MEILAHN E., KULLER L.H., KELSEY S.F., CAGGIULA A.W., WING R.R., MENOPAUSE AND RISK FACTORS FOR CORONARY HEART DISEASE, N. ENGL. J. MED, 321, PP. 641-646, (1989); PARDHE B.D., GHIMIRE S., SHAKYA J., PATHAK S., SHAKYA S., BHETWAL A., KHANAL P.R., PARAJULI N.P., ELEVATED CARDIOVASCULAR RISKS AMONG POSTMENOPAUSAL WOMEN: A COMMUNITY BASED CASE CONTROL STUDY FROM NEPAL, BIOCHEM. RES. INT, 2017, (2017); KANNEL W.B., WILSON P.W., RISK FACTORS THAT ATTENUATE THE FEMALE CORONARY DISEASE ADVANTAGE, ARCH. INTERN. MED, 155, PP. 57-61, (1995); MATTHAN N.R., JALBERT S.M., LAMON-FAVA S., DOLNIKOWSKI G.G., WELTY F.K., BARRETT H.R., SCHAEFER E.J., LICHTENSTEIN A.H., TRL, IDL, AND LDL APOLIPOPROTEIN B-100 AND HDL APOLIPOPROTEIN A-I KINETICS AS A FUNCTION OF AGE AND MENOPAUSAL STATUS, ARTERIOSCLER. THROMB. VASC. BIOL, 25, PP. 1691-1696, (2005); LI Z., MCNAMARA J.R., FRUCHART J.C., LUC G., BARD J.M., ORDOVAS J.M., WILSON P.W., SCHAEFER E.J., EFFECTS OF GENDER AND MENOPAUSAL STATUS ON PLASMA LIPOPROTEIN SUBSPECIES AND PARTICLE SIZES, J. LIPID RES, 37, PP. 1886-1896, (1996); EL KHOUDARY S.R., HUTCHINS P.M., MATTHEWS K.A., BROOKS M.M., ORCHARD T.J., RONSEIN G.E., HEINECKE J.W., CHOLESTEROL EFFLUX CAPACITY AND SUBCLASSES OF HDL PARTICLES IN HEALTHY WOMEN TRANSITIONING THROUGH MENOPAUSE, J. CLIN. ENDOCRINOL. METAB, 101, PP. 3419-3428, (2016); EL KHOUDARY S.R., CEPONIENE I., SAMARGANDY S., STEIN J.H., LI D., TATTERSALL M.C., BUDOFF M.J., HDL (HIGH-DENSITY LIPOPROTEIN) METRICS AND ATHEROSCLEROTIC RISK IN WOMEN, ARTERIOSCLER. THROMB. VASC. BIOL, 38, PP. 2236-2244, (2018); JULIAN V., BERGSTEN P., FORSLUND A., AHLSTROM H., CIBA I., DAHLBOM M., FURTHNER D., GOMAHR J., KULLBERG J., MARUSZCZAK K., ET AL., SEDENTARY TIME HAS A STRONGER IMPACT ON METABOLIC HEALTH THAN MODERATE TO VIGOROUS PHYSICAL ACTIVITY IN ADOLESCENTS WITH OBESITY: A CROSS-SECTIONAL ANALYSIS OF THE BETA-JUDO STUDY, PEDIATR. OBES, (2022); LI D., CHEN P., THE EFFECTS OF DIFFERENT EXERCISE MODALITIES IN THE TREATMENT OF CARDIOMETABOLIC RISK FACTORS IN OBESE ADOLESCENTS WITH SEDENTARY BEHAVIOR-A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHILDREN, 8, (2021); KARACABEY K., THE EFFECT OF EXERCISE ON LEPTIN, INSULIN, CORTISOL AND LIPID PROFILES IN OBESE CHILDREN, J. INT. MED. RES, 37, PP. 1472-1478, (2009); ROWLAND T.W., MATTEL L., VANDERBURGH P., MANOS T., CHARKOUDIAN N., THE INFLUENCE OF SHORT TERM AEROBIC TRAINING ON BLOOD LIPIDS IN HEALTHY 10–12 YEAR OLD CHILDREN, INT. J. SPORTS MED, 17, PP. 487-492, (1996); PRABHAKARAN B., DOWLING E.A., BRANCH J.D., SWAIN D.P., LEUTHOLTZ B.C., EFFECT OF 14 WEEKS OF RESISTANCE TRAINING ON LIPID PROFILE AND BODY FAT PERCENTAGE IN PREMENOPAUSAL WOMEN, BR. J. SPORTS MED, 33, PP. 190-195, (1999); ZHAO S., ZHONG J., SUN C., ZHANG J., EFFECTS OF AEROBIC EXERCISE ON TC, HDL-C, LDL-C AND TG IN PATIENTS WITH HYPERLIPIDEMIA: A PROTOCOL OF SYSTEMATIC REVIEW AND META-ANALYSIS, MEDICINE, 100, (2021); LEMURA L.M., VON DUVILLARD S.P., ANDREACCI J., KLEBEZ J.M., CHELLAND S.A., RUSSO J., LIPID AND LIPOPROTEIN PROFILES, CADIOVASCULAR FITNESS, BODY COMPOSITION, AND DIET DURING AND AFTER RESISTANCE, AEROBIC AND COMBINATION TRAINING IN YOUNG WOMEN, EUR. J. APPL. PHYSIOL, 82, PP. 451-458, (2000); LIANG M., PAN Y., ZHONG T., ZENG Y., CHENG A.S.K., EFFECTS OF AEROBIC, RESISTANCE, AND COMBINED EXERCISE ON METABOLIC SYNDROME PARAMETERS AND CARDIOVASCULAR RISK FACTORS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS, REV. CARDIOVASC. MED, 22, PP. 1523-1533, (2021); LEE H., PARK J.E., CHOI I., CHO K.H., ENHANCED FUNCTIONAL AND STRUCTURAL PROPERTIES OF HIGH-DENSITY LIPOPROTEINS FROM RUNNERS AND WRESTLERS COMPARED TO THROWERS AND LIFTERS, BMB REP, 42, PP. 605-610, (2009); FRANCESCHINI G., CALABRESI L., MADERNA P., GALLI C., GIANFRANCESCHI G., SIRTORI C.R., OMEGA-3 FATTY ACIDS SELECTIVELY RAISE HIGH-DENSITY LIPOPROTEIN 2 LEVELS IN HEALTHY VOLUNTEERS, METABOLISM, 40, PP. 1283-1286, (1991); KOUCHAKI E., AFARINI M., ABOLHASSANI J., MIRHOSSEINI N., BAHMANI F., MASOUD S.A., ASEMI Z., HIGH-DOSE OMEGA-3 FATTY ACID PLUS VITAMIN D3 SUPPLEMENTATION AFFECTS CLINICAL SYMPTOMS AND METABOLIC STATUS OF PATIENTS WITH MULTIPLE SCLEROSIS: A RANDOMIZED CONTROLLED CLINICAL TRIAL, J. NUTR, 148, PP. 1380-1386, (2018); MANSON J.E., COOK N.R., LEE I.M., CHRISTEN W., BASSUK S.S., MORA S., GIBSON H., ALBERT C.M., GORDON D., COPELAND T., ET AL., MARINE N-3 FATTY ACIDS AND PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER, N. ENGL. J. MED, 380, PP. 23-32, (2019); BHATT D.L., STEG P.G., MILLER M., BRINTON E.A., JACOBSON T.A., KETCHUM S.B., DOYLE R.T., JULIANO R.A., JIAO L., GRANOWITZ C., ET AL., CARDIOVASCULAR RISK REDUCTION WITH ICOSAPENT ETHYL FOR HYPERTRIGLYCERIDEMIA, N. ENGL. J. MED, 380, PP. 11-22, (2019); NICHOLLS S.J., LINCOFF A.M., GARCIA M., BASH D., BALLANTYNE C.M., BARTER P.J., DAVIDSON M.H., KASTELEIN J.J.P., KOENIG W., MCGUIRE D.K., ET AL., EFFECT OF HIGH-DOSE OMEGA-3 FATTY ACIDS VS CORN OIL ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AT HIGH CARDIOVASCULAR RISK: THE STRENGTH RANDOMIZED CLINICAL TRIAL, JAMA, 324, PP. 2268-2280, (2020); MOZAFFARIAN D., MAKI K.C., BAYS H.E., AGUILERA F., GOULD G., HEGELE R.A., MORIARTY P.M., ROBINSON J.G., SHI P., TUR J.F., ET AL., EFFECTIVENESS OF A NOVEL Ω-3 KRILL OIL AGENT IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA: A RANDOMIZED CLINICAL TRIAL, JAMA NETW. OPEN, 5, (2022); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); POTTER L.K., SPRECHER D.L., WALKER M.C., TOBIN F.L., MECHANISM OF INHIBITION DEFINES CETP ACTIVITY: A MATHEMATICAL MODEL FOR CETP IN VITRO, J. LIPID RES, 50, PP. 2222-2234, (2009); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); JO A.L., HAN J.W., AN J.I., CHO K.H., JEOUNG N.H., CUBAN POLICOSANOL PREVENTS THE APOPTOSIS AND THE MITOCHONDRIAL DYSFUNCTION INDUCED BY LIPOPOLYSACCHARIDE IN C2C12 MYOBLAST VIA ACTIVATION OF AKT AND ERK PATHWAYS, J. NUTR. SCI. VITAMINOL, 68, PP. 79-86, (2022); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE—POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); KIM K.M., KIM C.H., CHO K.H., JANG W.G., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN. EXP. PHARMACOL. PHYSIOL, 48, PP. 1336-1345, (2021); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID. MED. CELL. LONGEV, 2018, (2018); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); PARK H.J., YADAV D., JEONG D.J., KIM S.J., BAE M.A., KIM J.R., CHO K.H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); GROENEN A.G., BAZIOTI V., VAN ZEVENTER I.A., CHEN L., GROOT H.E., BALDER J.W., ZHERNAKOVA A., VAN DER HARST P., RIMBERT A., KUIVENHOVEN J.A., ET AL., LARGE HDL PARTICLES NEGATIVELY ASSOCIATE WITH LEUKOCYTE COUNTS INDEPENDENT OF CHOLESTEROL EFFLUX CAPACITY: A CROSS SECTIONAL STUDY IN THE POPULATION-BASED LIFELINES DEEP COHORT, ATHEROSCLEROSIS, 343, PP. 20-27, (2022); COLLER B.S., LEUKOCYTOSIS AND ISCHEMIC VASCULAR DISEASE MORBIDITY AND MORTALITY: IS IT TIME TO INTERVENE?, ARTERIOSCLER. THROMB. VASC. BIOL, 25, PP. 658-670, (2005); KANEKO Y., TAKEUCHI T., INTERLUEKIN-6 INHIBITORS FOR THE TREATMENT OF ADULT-ONSET STILL’S DISEASE, EXPERT OPIN. BIOL. THER, 32, PP. 12-15, (2022); KIM J.Y., LEE E.Y., PARK J.K., SONG Y.W., KIM J.R., CHO K.H., PATIENTS WITH RHEUMATOID ARTHRITIS SHOW ALTERED LIPOPROTEIN PROFILES WITH DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS THAT CAN EXACERBATE INFLAMMATORY AND ATHEROGENIC PROCESS, PLOS ONE, 11, (2016); VARGAS J.I., RIVERA K., ARRESE M., BENITEZ C., BARRERA F., HUGO M., ARAB J.P., PINO K., BARRERA A., LOPEZ-LASTRA M., ET AL., LDL PARTICLE SIZE AND ANTIOXIDANT HDL FUNCTION IMPROVE AFTER SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HCV, ANN. HEPATOL, 27, (2022); ALI E.M., SHEHATA H.H., ALI-LABIB R., ESMAIL ZAHRA L.M., OXIDANT AND ANTIOXIDANT OF ARYLESTERASE AND PARAOXONASE AS BIOMARKERS IN PATIENTS WITH HEPATITIS C VIRUS, CLIN. BIOCHEM, 42, PP. 1394-1400, (2009); LI Y., ZHAI R., LI H., MEI X., QIU G., PROGNOSTIC VALUE OF SERUM PARAOXONASE AND ARYLESTERASE ACTIVITY IN PATIENTS WITH SEPSIS, J. INT. MED. RES, 41, PP. 681-687, (2013); WEI X., ZENG W., SU J., WAN H., YU X., CAO X., TAN W., WANG H., HYPOLIPIDEMIA IS ASSOCIATED WITH THE SEVERITY OF COVID-19, J. CLIN. LIPIDOL, 14, PP. 297-304, (2020); AGOURIDIS A.P., PAGKALI A., ZINTZARAS E., RIZOS E.C., NTZANI E.E., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: A MARKER OF COVID-19 INFECTION SEVERITY?, ATHEROSCLER. PLUS, 44, PP. 1-9, (2021); KLUCK G.E.G., YOO J.A., SAKARYA E.H., TRIGATTI B.L., GOOD CHOLESTEROL GONE BAD? HDL AND COVID-19, INT. J. MOL. SCI, 22, (2021); HAFIANE A., GIANOPOULOS I., SORCI-THOMAS M.G., DASKALOPOULOU S.S., CURRENT MODELS OF APOLIPOPROTEIN A-I LIPIDATION BY ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER A1, CURR. OPIN. LIPIDOL, 33, PP. 139-145, (2022); BRITES F., MARTIN M., GUILLAS I., KONTUSH A., ANTIOXIDATIVE ACTIVITY OF HIGH-DENSITY LIPOPROTEIN (HDL): MECHANISTIC INSIGHTS INTO POTENTIAL CLINICAL BENEFIT, BBA CLIN, 8, PP. 66-77, (2017); KONTUSH A., HDL PARTICLE NUMBER AND SIZE AS PREDICTORS OF CARDIOVASCULAR DISEASE, FRONT. PHARMACOL, 6, (2015); WALLDIUS G., DE FAIRE U., ALFREDSSON L., LEANDER K., WESTERHOLM P., MALMSTROM H., IVERT T., HAMMAR N., LONG-TERM RISK OF A MAJOR CARDIOVASCULAR EVENT BY APOB, APOA-1, AND THE APOB/APOA-1 RATIO-EXPERIENCE FROM THE SWEDISH AMORIS COHORT: A COHORT STUDY, PLOS MED, 18, (2021); POWNALL H.J., MORRISETT J.D., SPARROW J.T., SMITH L.C., SHEPHERD J., JACKSON R.L., GOTTO A.M., A REVIEW OF THE UNIQUE FEATURES OF HDL APOPROTEINS, LIPIDS, 14, PP. 428-434, (1979); ALEKSANDROVICH O.V., OZEROVA I.N., OLFER'EV A.M., SERDYUK A.P., METEL'SKAYA V.A., PEROVA N.V., ASSOCIATION OF SERUM APOLIPOPROTEIN A-II CONCENTRATION WITH COMBINED HYPERLIPIDEMIA AND IMPAIRED GLUCOSE TOLERANCE, BULL. EXP. BIOL. MED, 141, PP. 678-681, (2006); RIBAS V., SANCHEZ-QUESADA J.L., ANTON R., CAMACHO M., JULVE J., ESCOLA-GIL J.C., VILA L., ORDONEZ-LLANOS J., BLANCO-VACA F., HUMAN APOLIPOPROTEIN A-II ENRICHMENT DISPLACES PARAOXONASE FROM HDL AND IMPAIRS ITS ANTIOXIDANT PROPERTIES: A NEW MECHANISM LINKING HDL PROTEIN COMPOSITION AND ANTIATHEROGENIC POTENTIAL, CIRC. RES, 95, PP. 789-797, (2004); CHO K.H., IMPORTANCE OF APOLIPOPROTEIN A-I AND A-II COMPOSITION IN HDL AND ITS POTENTIAL FOR STUDYING COVID-19 AND SARS-COV-2, MEDICINES, 8, (2021); DURBIN D.M., JONAS A., THE EFFECT OF APOLIPOPROTEIN A-II ON THE STRUCTURE AND FUNCTION OF APOLIPOPROTEIN A-I IN A HOMOGENEOUS RECONSTITUTED HIGH DENSITY LIPOPROTEIN PARTICLE, J. BIOL. CHEM, 272, PP. 31333-31339, (1997); DE BEER M.C., DURBIN D.M., CAI L., MIROCHA N., JONAS A., WEBB N.R., DE BEER F.C., VAN DER WESTHUYZEN D.R., APOLIPOPROTEIN A-II MODULATES THE BINDING AND SELECTIVE LIPID UPTAKE OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN BY SCAVENGER RECEPTOR BI, J. BIOL. CHEM, 276, PP. 15832-15839, (2001); BRANCHI A., ROVELLINI A., TOMELLA C., SCIARIADA L., TORRI A., MOLGORA M., SOMMARIVA D., ASSOCIATION OF ALCOHOL CONSUMPTION WITH HDL SUBPOPULATIONS DEFINED BY APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-II CONTENT, EUR. J. CLIN. NUTR, 51, PP. 362-365, (1997); KIDO T., KURATA H., KONDO K., ITAKURA H., OKAZAKI M., URATA T., YOKOYAMA S., BIOINFORMATIC ANALYSIS OF PLASMA APOLIPOPROTEINS A-I AND A-II REVEALED UNIQUE FEATURES OF A-I/A-II HDL PARTICLES IN HUMAN PLASMA, SCI. REP, 6, (2016); KIDO T., KONDO K., KURATA H., FUJIWARA Y., URATA T., ITAKURA H., YOKOYAMA S., APOA-I/A-II-HDL POSITIVELY ASSOCIATES WITH APOB-LIPOPROTEINS AS A POTENTIAL ATHEROGENIC INDICATOR, LIPIDS HEALTH DIS, 16, (2017); SHACHTER N.S., APOLIPOPROTEINS C-I AND C-III AS IMPORTANT MODULATORS OF LIPOPROTEIN METABOLISM, CURR. OPIN. LIPIDOL, 12, PP. 297-304, (2001); LUO M., LIU A., WANG S., WANG T., HU D., WU S., PENG D., APOCIII ENRICHMENT IN HDL IMPAIRS HDL-MEDIATED CHOLESTEROL EFFLUX CAPACITY, SCI. REP, 7, (2017); PARK K.H., SHIN D.G., KIM J.R., CHO K.H., SENESCENCE-RELATED TRUNCATION AND MULTIMERIZATION OF APOLIPOPROTEIN A-I IN HIGH-DENSITY LIPOPROTEIN WITH AN ELEVATED LEVEL OF ADVANCED GLYCATED END PRODUCTS AND CHOLESTERYL ESTER TRANSFER ACTIVITY, J. GERONTOL. A BIOL. SCI. MED. SCI, 65, PP. 600-610, (2010); CHO K.H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOL. CELLS, 27, PP. 291-297, (2009); PARK K.H., SHIN D.G., CHO K.H., DYSFUNCTIONAL LIPOPROTEINS FROM YOUNG SMOKERS EXACERBATE CELLULAR SENESCENCE AND ATHEROGENESIS WITH SMALLER PARTICLE SIZE AND SEVERE OXIDATION AND GLYCATION, TOXICOL. SCI, 140, PP. 16-25, (2014); PANIN L.E., SHALBUEVA N.I., POLYAKOV L.M., EFFECTS OF APOLIPOPROTEINS C ON OXIDATIVE PHOSPHORYLATION IN RAT LIVER MITOCHONDRIA, BULL. EXP. BIOL. MED, 130, PP. 769-771, (2000); ZEWINGER S., REISER J., JANKOWSKI V., ALANSARY D., HAHM E., TRIEM S., KLUG M., SCHUNK S.J., SCHMIT D., KRAMANN R., ET AL., APOLIPOPROTEIN C3 INDUCES INFLAMMATION AND ORGAN DAMAGE BY ALTERNATIVE INFLAMMASOME ACTIVATION, NAT. IMMUNOL, 21, PP. 30-41, (2020); CHO K.H., PARK S.H., PARK J.E., KIM Y.O., CHOI I., KIM J.J., KIM J.R., THE FUNCTION, COMPOSITION, AND PARTICLE SIZE OF HIGH-DENSITY LIPOPROTEIN WERE SEVERELY IMPAIRED IN AN OLIGURIC PHASE OF HEMORRHAGIC FEVER WITH RENAL SYNDROME PATIENTS, CLIN. BIOCHEM, 41, PP. 56-64, (2008); KIM J., PARK H.H., CHOI I., KIM Y.O., CHO K.H., SEVERELY MODIFIED LIPOPROTEIN PROPERTIES WITHOUT A CHANGE IN CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY IN PATIENTS WITH ACUTE RENAL FAILURE SECONDARY TO HANTAAN VIRUS INFECTION, BMB REP, 43, PP. 535-540, (2010); JIN U., PARK S.J., PARK S.M., CHOLESTEROL METABOLISM IN THE BRAIN AND ITS ASSOCIATION WITH PARKINSON’S DISEASE, EXP. NEUROBIOL, 28, PP. 554-567, (2019); POLYMEROPOULOS M.H., LAVEDAN C., LEROY E., IDE S.E., DEHEJIA A., DUTRA A., PIKE B., ROOT H., RUBENSTEIN J., BOYER R., ET AL., MUTATION IN THE Α-SYNUCLEIN GENE IDENTIFIED IN FAMILIES WITH PARKINSON’S DISEASE, SCIENCE, 276, PP. 2045-2047, (1997); HSIAO J.T., HALLIDAY G.M., KIM W.S., Α-SYNUCLEIN REGULATES NEURONAL CHOLESTEROL EFFLUX, MOLECULES, 22, (2017); CHO K.H., STRUCTURAL AND FUNCTIONAL CHANGES OF RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (HDL) BY INCORPORATION OF Α-SYNUCLEIN: A POTENT ANTIOXIDANT AND ANTI-GLYCATION ACTIVITY OF Α-SYNUCLEIN AND APOA-I IN HDL AT HIGH MOLAR RATIO OF Α-SYNUCLEIN, MOLECULES, 26, (2021); SHIH Y.H., TSAI K.J., LEE C.W., SHIESH S.C., CHEN W.T., PAI M.C., KUO Y.M., APOLIPOPROTEIN C-III IS AN AMYLOID-Β-BINDING PROTEIN AND AN EARLY MARKER FOR ALZHEIMER’S DISEASE, J. ALZHEIMERS DIS, 41, PP. 855-865, (2014); ROBERT J., STUKAS S., BUTTON E., CHENG W.H., LEE M., FAN J., WILKINSON A., KULIC I., WRIGHT S.D., ELLINGTON C.L., RECONSTITUTED HIGH-DENSITY LIPOPROTEINS ACUTELY REDUCE SOLUBLE BRAIN AΒ LEVELS IN SYMPTOMATIC APP/PS1 MICE, BIOCHIM. BIOPHYS. ACTA, 1862, PP. 1027-1036, (2016); CHO K.H., STRUCTURAL AND FUNCTIONAL IMPAIRMENTS OF RECONSTITUTED HIGH-DENSITY LIPOPROTEIN BY INCORPORATION OF RECOMBINANT Β-AMYLOID42, MOLECULES, 26, (2021); ZULIANI G., CAVALIERI M., GALVANI M., VOLPATO S., CHERUBINI A., BANDINELLI S., CORSI A.M., LAURETANI F., GURALNIK J.M., FELLIN R., ET AL., RELATIONSHIP BETWEEN LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND DEMENTIA IN THE ELDERLY. THE INCHIANTI STUDY, J. GERONTOL. SER. A BIOL. SCI. MED. SCI, 65, PP. 559-564, (2010); SHRIDAS P., PATRICK A.C., TANNOCK L.R., ROLE OF SERUM AMYLOID A IN ABDOMINAL AORTIC ANEURYSM AND RELATED CARDIOVASCULAR DISEASES, BIOMOLECULES, 11, (2021); MALLE E., DE BEER F.C., HUMAN SERUM AMYLOID A (SAA) PROTEIN: A PROMINENT ACUTE-PHASE REACTANT FOR CLINICAL PRACTICE, EUR. J. CLIN. INVESTIG, 26, PP. 427-435, (1996); BENDITT E.P., ERIKSEN N., AMYLOID PROTEIN SAA IS ASSOCIATED WITH HIGH DENSITY LIPOPROTEIN FROM HUMAN SERUM, PROC. NATL. ACAD. SCI. USA, 74, PP. 4025-4028, (1977); SUN L., YE R.D., SERUM AMYLOID A1: STRUCTURE, FUNCTION AND GENE POLYMORPHISM, GENE, 583, PP. 48-57, (2016); REISINGER A.C., SCHULLER M., SOURIJ H., STADLER J.T., HACKL G., ELLER P., MARSCHE G., IMPACT OF SEPSIS ON HIGH-DENSITY LIPOPROTEIN METABOLISM, FRONT. CELL. DEV. BIOL, 9, (2022); WEBB N.R., HIGH-DENSITY LIPOPROTEINS AND SERUM AMYLOID A (SAA), CURR. ATHEROSCLER. REP, 23, (2021); TOHIDI M., HATAMI M., HADAEGH F., AZIZI F., TRIGLYCERIDES AND TRIGLYCERIDES TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO ARE STRONG PREDICTORS OF INCIDENT HYPERTENSION IN MIDDLE EASTERN WOMEN, J. HUM. HYPERTENS, 26, PP. 525-532, (2012); JUSTIN B.N., TUREK M., HAKIM A.M., HEART DISEASE AS A RISK FACTOR FOR DEMENTIA, CLIN. EPIDEMIOL, 5, PP. 135-145, (2013); DECKERS K., SCHIEVINK S.H.J., RODRIQUEZ M.M.F., VAN OOSTENBRUGGE R.J., VAN BOXTEL M.P.J., VERHEY F.R.J., KOHLER S., CORONARY HEART DISEASE AND RISK FOR COGNITIVE IMPAIRMENT OR DEMENTIA: SYSTEMATIC REVIEW AND META-ANALYSIS, PLOS ONE, 12, (2017); CRAFT S., THE ROLE OF METABOLIC DISORDERS IN ALZHEIMER DISEASE AND VASCULAR DEMENTIA, ARCH. NEUROL, 66, PP. 300-305, (2009); ROHRER L., HERSBERGER M., VON ECKARDSTEIN A., HIGH DENSITY LIPOPROTEINS IN THE INTERSECTION OF DIABETES MELLITUS, INFLAMMATION AND CARDIOVASCULAR DISEASE, CURR. OPIN. LIPIDOL, 15, PP. 269-278, (2004); KOSMAS C.E., MARTINEZ I., SOURLAS A., BOUZA K.V., CAMPOS F.N., TORRES V., MONTAN P.D., GUZMAN E., HIGH-DENSITY LIPOPROTEIN (HDL) FUNCTIONALITY AND ITS RELEVANCE TO ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, DRUGS CONTEXT, 7, (2018); YANG Y., SONG W., MOLECULAR LINKS BETWEEN ALZHEIMER’S DISEASE AND DIABETES MELLITUS, NEUROSCIENCE, 250, PP. 140-150, (2013); CHOU P.S., WU M.N., YANG C.C., SHEN C.T., YANG Y.H., EFFECT OF ADVANCED GLYCATION END PRODUCTS ON THE PROGRESSION OF ALZHEIMER’S DISEASE, J. ALZHEIMERS DIS, 72, PP. 191-197, (2019); LIU D., JI L., ZHANG D., TONG X., PAN B., LIU P., ZHANG Y., HUANG Y., SU J., WILLARD B., ET AL., NONENZYMATIC GLYCATION OF HIGH-DENSITY LIPOPROTEIN IMPAIRS ITS ANTI-INFLAMMATORY EFFECTS IN INNATE IMMUNITY, DIABETES METAB. RES. REV, 28, PP. 186-195, (2012); RUIZ-RAMIE J.J., BARBER J.L., SARZYNSKI M.A., EFFECTS OF EXERCISE ON HDL FUNCTIONALITY, CURR. OPIN. LIPIDOL, 30, PP. 16-23, (2019); CUCHEL M., RADER D.J., MACROPHAGE REVERSE CHOLESTEROL TRANSPORT: KEY TO THE REGRESSION OF ATHEROSCLEROSIS?, CIRCULATION, 113, PP. 2548-2555, (2006); YANCEY P.G., BORTNICK A.E., KELLNER-WEIBEL G., DE LA LLERA-MOYA M., PHILLIPS M.C., ROTHBLAT G.H., IMPORTANCE OF DIFFERENT PATHWAYS OF CELLULAR CHOLESTEROL EFFLUX, ARTERIOSCLER. THROMB. VASC. BIOL, 23, PP. 712-719, (2003); BARTER P.J., BREWER H.B., CHAPMAN M.J., HENNEKENS C.H., RADER D.J., TALL A.R., CHOLESTERYL ESTER TRANSFER PROTEIN: A NOVEL TARGET FOR RAISING HDL AND INHIBITING ATHEROSCLEROSIS, ARTERIOSCLER. THROMB. VASC. BIOL, 23, PP. 160-167, (2003); KOUDINOV A.R., BEREZOV T.T., KUMAR A., KOUDINOVA N.V., ALZHEIMER’S AMYLOID B INTERACTION WITH NORMAL HUMAN PLASMA HIGH DENSITY LIPOPROTEIN: ASSOCIATION WITH APOLIPOPROTEIN AND LIPIDS, CLIN. CHIM. ACTA, 270, PP. 75-84, (1998); PAULA-LIMA A.C., TRICERRI M.A., BRITO-MOREIRA J., BOMFIM T.R., OLIVEIRA F.F., MAGDESIAN M.H., GRINBERG L.T., PANIZZUTTI R., FERREIRA S.T., HUMAN APOLIPOPROTEIN A-I BINDS AMYLOID-BETA AND PREVENTS AΒ-INDUCED NEUROTOXICITY, INT. J. BIOCHEM. CELL. BIOL, 41, PP. 1361-1370, (2009); MERCHED A., XIA Y., VISVIKIS S., SEROT J.M., SIEST G., DECREASED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND SERUM APOLIPOPROTEIN AI CONCENTRATIONS ARE HIGHLY CORRELATED WITH THE SEVERITY OF ALZHEIMER’S DISEASE, NEUROBIOL. AGING, 21, PP. 27-30, (2000); LV P., ZHAO M., LIU Y., JIN H., CUI W., FAN C., TENG Y., ZHENG L., HUANG Y., APOLIPOPROTEIN C-III IN THE HIGH-DENSITY LIPOPROTEIN PROTEOME OF CEREBRAL LACUNAR INFARCTION PATIENTS IMPAIRS ITS ANTI-INFLAMMATORY FUNCTION, INT. J. MOL. MED, 41, PP. 61-68, (2018); BAHRAMI A., BARRETO G.E., LOMBARDI G., PIRRO M., SAHEBKAR A., EMERGING ROLES FOR HIGH-DENSITY LIPOPROTEINS IN NEURODEGENERATIVE DISORDERS, BIOFACTORS, 45, PP. 725-739, (2019); DIETSCHY J.M., TURLEY S.D., CHOLESTEROL METABOLISM IN THE BRAIN, CURR. OPIN. LIPIDOL, 12, PP. 105-112, (2001); REYNOLDS C.A., GATZ M., PRINCE J.A., BERG S., PEDERSEN N.L., SERUM LIPID LEVELS AND COGNITIVE CHANGE IN LATE LIFE, J. AM. GERIATR SOC, 58, PP. 501-509, (2010); NELSON R.H., HYPERLIPIDEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE, PRIM. CARE, 40, PP. 195-211, (2013); MCGROWDER D., RILEY C., MORRISON E.Y.S.A., GORDON L., THE ROLE OF HIGH-DENSITY LIPOPROTEINS IN REDUCING THE RISK OF VASCULAR DISEASES, NEUROGENERATIVE DISORDERS, AND CANCER, CHOLESTEROL, 2011, (2011); REITZ C., TANG M.X., SCHUPF N., MANLY J.J., MAYEUX R., LUCHSINGER J.A., ASSOCIATION OF HIGHER LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ELDERLY INDIVIDUALS AND LOWER RISK OF LATE-ONSET ALZHEIMER DISEASE, ARCH. NEUROL, 67, PP. 1491-1497, (2010); HALPERIN R.O., SESSO H.D., MA J., BURING J.E., STAMPFER M.J., GAZIANO J.M., DYSLIPIDEMIA AND THE RISK OF INCIDENT HYPERTENSION IN MEN, HYPERTENSION, 47, PP. 45-50, (2006); ROHATGI A., KHERA A., BERRY J.D., GIVENS E.G., AYERS C.R., WEDIN K.E., NEELAND I.J., YUHANNA I.S., RADER D.R., DE LEMOS J.A., ET AL., HDL CHOLESTEROL EFFLUX CAPACITY AND INCIDENT CARDIOVASCULAR EVENTS, N. ENGL. J. MED, 371, PP. 2383-2393, (2014); GRUNDY S.M., METABOLIC SYNDROME UPDATE, TRENDS CARDIOVASC. MED, 26, PP. 364-373, (2016); TSAI Y.Y., RAINEY W.E., BOLLAG W.B., VERY LOW-DENSITY LIPOPROTEIN (VLDL)-INDUCED SIGNALS MEDIATING ALDOSTERONE PRODUCTION, J. ENDOCRINOL, 232, PP. 115-129, (2017); ANSURUDEEN I., PIETZSCH J., GRAESSLER J., EHRHART-BORNSTEIN M., SAHA S., BORNSTEIN S.R., KOPPRASCH S., MODULATION OF ADRENAL ALDOSTERONE RELEASE BY OXIDATIVE MODIFICATION OF LOW-DENSITY LIPOPROTEIN, AM. J. HYPERTENS, 23, PP. 1061-1068, (2010)","K.-H. CHO; LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","MDPI","ENGLISH","INT. J. MOL. SCI.","REVIEW","ISI","2-S2.0-85127454371","INT J MOL SCI","YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"CHO K-H, 2022, INT J MOL SCI","CHO K-H, 2022, INT J MOL SCI"
"KAMCHONEMENUKOOL S;HO C;BOONNOUN P;LI S;PAN M;KLANGPETCH W;WEERAWATANAKORN M","KAMCHONEMENUKOOL, SUDTHIDA (57219992228); HO, CHI-TANG (56510763200); BOONNOUN, PANATPONG (35742804700); LI, SHIMING (55741057400); PAN, MIN-HSIUNG (7202544934); KLANGPETCH, WANNAPORN (36600605300); WEERAWATANAKORN, MONTHANA (55976489600)","HIGH LEVELS OF POLICOSANOLS AND PHYTOSTEROLS FROM SUGAR MILL WASTE BY SUBCRITICAL LIQUEFIED DIMETHYL ETHER",2022,"FOODS","11","",6,"10.3390/foods11192937","DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF FOOD SCIENCE, RUTGERS UNIVERSITY, 65 DUDLEY ROAD, NEW BRUNSWICK, 08901, NJ, UNITED STATES;CHEMICAL ENGINEERING PROGRAM, DEPARTMENT OF INDUSTRIAL ENGINEERING, FACULTY OF ENGINEERING, NARESUAN UNIVERSITY, PHITSANULOK, 65000, THAILAND;COLLEGE OF LIFE SCIENCES, HUANGGANG NORMAL UNIVERSITY, HUANGGANG, 438000, CHINA;INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, NATIONAL TAIWAN UNIVERSITY, TAIPEI, 10617, TAIWAN;FACULTY OF AGRO-INDUSTRY, CHIANG MAI UNIVERSITY, CHIANG MAI, 50100, THAILAND, CLUSTER OF HIGH VALUE PRODUCTS FROM THAI RICE AND PLANTS FOR HEALTH, CHIANG MAI UNIVERSITY, CHIANG MAI, 50100, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, PHITSANULOK, 65000, THAILAND","EXTRACTING NUTRACEUTICALS WITH HIGH VALUE FROM BAGASSE, FILTER MUD, AND SUGARCANE LEAVES DISCARDED AS SUGAR MILL BY-PRODUCTS, IS CRUCIAL FOR THE DEVELOPMENT OF A SUSTAINABLE BIO-ECONOMY. THESE BY-PRODUCTS ARE IMPORTANT SOURCES OF POLICOSANOLS AND PHYTOSTEROLS, WHICH HAVE A CHOLESTEROL-LOWERING EFFECT. THIS RESEARCH FOCUSED ON USING A PROMISING GREEN TECHNOLOGY, SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION, WITH A LOW PRESSURE OF 0.8 MPA, TO EXTRACT POLICOSANOLS AND PHYTOSTEROLS AND ON APPLICATION OF PRETREATMENTS TO INCREASE THEIR CONTENTS. FOR DIRECT EXTRACTION BY SUBCRITICAL LIQUEFIED DIMETHYL ETHER WITHOUT SAMPLE PRETREATMENT, THE HIGHEST EXTRACTION YIELD (7.4%) AND POLICOSANOL CONTENT WERE FOUND IN SUGARCANE LEAVES AT 2888 MG/100 G, WHILE THE HIGHEST AND LOWEST PHYTOSTEROL CONTENTS WERE FOUND IN FILTER MUD AT 20,878.75 MG/100 G AND SUGARCANE LEAVES AT 10,147.75 MG/100 G, RESPECTIVELY. PRETREATMENT OF FILTER MUD BY ULTRASONICATION IN HEXANE SOLUTION TOGETHER WITH TRANSESTERIFICATION BEFORE THE SECOND SUBCRITICAL LIQUEFIED DIMETHYL ETHER EXTRACTION SUCCESSFULLY INCREASED THE POLICOSANOL CONTENT, WITH AN EXTRACT PURITY OF 60%, BUT FAILED TO INCREASE THE PHYTOSTEROL CONTENT. © 2022 BY THE AUTHORS.","BAGASSE; FILTER MUD; PRETREATMENT; SUBCRITICAL EXTRACTION; SUGARCANE LEAVES","","NARESUAN UNIVERSITY, NU, (R2565B009); THAILAND SCIENCE RESEARCH AND INNOVATION, TSRI, (FRB650022/0179)","THIS STUDY WAS SUPPORTED BY THE THAILAND SCIENCE RESEARCH AND INNOVATION (GRANT NUMBER FRB650022/0179) UNDER THE GRANT AGREEMENT OF NARESUAN UNIVERSITY (GRANT NUMBER R2565B009).","FOOD, AGRICULTURAL ORGANIZATION OF THE UNITED NATIONS STATISTICAL DATABASE, (2001); EGGLESTON G., KLICH M., ANTOINE A., BELTZ S., VIATOR R., BROWN AND GREEN SUGARCANE LEAVES AS POTENTIAL BIOMASS: HOW THEY DETERIORATE UNDER DRY AND WET STORAGE CONDITIONS, IND. CROPS PROD, 57, PP. 69-81, (2014); SINGH A., LAL U.R., MUKHTAR H.M., SINGH P.S., SHAH G., DHAWAN R.K., PHYTOCHEMICAL PROFILE OF SUGARCANE AND ITS POTENTIAL HEALTH ASPECTS, PHARMACOGN. REV, 9, PP. 45-54, (2015); GUPTA A.K., SAVOPOULOS C.G., AHUJA J., HATZITOLIOS A.I., ROLE OF PHYTOSTEROLS IN LIPID-LOWERING: CURRENT PERSPECTIVES, QJM INT. J. MED, 104, PP. 301-308, (2011); RAPPORT L., LOCKWOOD B., NUTRACEUTICALS: (3) OCTACOSANOL, PHARM. J, 265, PP. 170-171, (2000); SHIMURA S., HASEGAWA T., TAKANO S., SUZUKI T., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTR. REP. INT, 36, PP. 1029-1038, (1987); LUKASHEVICH V., DAVIDSON M.H., MOREINES J., BERLIN R.G., BEESWAX POLICOSANOL FAILED TO DEMONSTRATE LIPID-ALTERING EFFECTS IN WELL-CONTROLLED CLINICAL TRIALS, CIRCULATION, 114, (2006); BABU S., JAYARAMAN S., AN UPDATE ON Β-SITOSTEROL: A POTENTIAL HERBAL NUTRACEUTICAL FOR DIABETIC MANAGEMENT, BIOMED. PHARMACOTHER, 131, (2020); TOLVE R., CONDELLI N., CAN A., TCHUENBOU-MAGAIA F.L., DEVELOPMENT AND CHARACTERIZATION OF PHYTOSTEROL-ENRICHED OIL MICROCAPSULES FOR FOODSTUFF APPLICATION, FOOD BIOPROCESS TECHNOL, 11, PP. 152-163, (2018); MOREAU R.A., WHITAKER B.D., HICKS K.B., PHYTOSTEROLS, PHYTOSTANOLS, AND THEIR CONJUGATES IN FOODS: STRUCTURAL DIVERSITY, QUANTITATIVE ANALYSIS, AND HEALTH-PROMOTING USES, PROG. LIPID RES, 41, PP. 457-500, (2002); FENG S., LIU S., LUO Z., TANG K., DIRECT SAPONIFICATION PREPARATION AND ANALYSIS OF FREE AND CONJUGATED PHYTOSTEROLS IN SUGARCANE (SACCHARUM OFFICINARUM L.) BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, FOOD CHEM, 181, PP. 9-14, (2015); FENG S., LUO Z., ZHANG Y., ZHONG Z., LU B., PHYTOCHEMICAL CONTENTS AND ANTIOXIDANT CAPACITIES OF DIFFERENT PARTS OF TWO SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, FOOD CHEM, 151, PP. 452-458, (2014); WANG L., WELLER C.L., RECENT ADVANCES IN EXTRACTION OF NUTRACEUTICALS FROM PLANTS, TRENDS FOOD SCI. TECHNOL, 17, PP. 300-312, (2006); SAHENA F., ZAIDUL I., JINAP S., KARIM A.A., ABBAS K.A., NORULAINI N., OMAR A., APPLICATION OF SUPERCRITICAL CO<SUB>2</SUB> IN LIPID EXTRACTION—A REVIEW, J. FOOD ENG, 95, PP. 240-253, (2009); ATTARD T.M., MCELROY C.R., REZENDE C.A., POLIKARPOV I., CLARK J.H., HUNT A.J., SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES, IND. CROPS PROD, 76, PP. 95-103, (2015); FERNANDES P., CABRAL J.M.S., PHYTOSTEROLS: APPLICATIONS AND RECOVERY METHODS, BIORESOUR. TECHNOL, 98, PP. 2335-2350, (2007); ALVAREZ-VINAS M., RODRIGUEZ-SEOANE P., FLOREZ-FERNANDEZ N., TORRES M.D., DIAZ-REINOSO B., MOURE A., DOMINGUEZ H., SUBCRITICAL WATER FOR THE EXTRACTION AND HYDROLYSIS OF PROTEIN AND OTHER FRACTIONS IN BIOREFINERIES FROM AGRO-FOOD WASTES AND ALGAE: A REVIEW, FOOD BIOPROCESS TECHNOL, 14, PP. 373-387, (2021); GUO T., WAN C., HUANG F., EXTRACTION OF RAPESEED CAKE OIL USING SUBCRITICAL R134A/BUTANE: PROCESS OPTIMIZATION AND QUALITY EVALUATION, FOOD SCI. NUTR, 7, PP. 3570-3580, (2019); TEIXEIRA G.L., GHAZANI S.M., CORAZZA M.L., MARANGONI A.G., RIBANI R.H., ASSESSMENT OF SUBCRITICAL PROPANE, SUPERCRITICAL CO<SUB>2</SUB> AND SOXHLET EXTRACTION OF OIL FROM SAPUCAIA (LECYTHIS PISONIS) NUTS, J. SUPERCRIT. FLUIDS, 133, PP. 122-132, (2018); SCIENTIFIC OPINION ON THE SAFETY OF USE OF DIMETHYL ETHER AS AN EXTRACTION SOLVENT UNDER THE INTENDED CONDITIONS OF USE AND THE PROPOSED MAXIMUM RESIDUAL LIMITS. EFSA PANEL ON FOOD CONTACT MATERIALS, ENZYMES, FLAVOURINGS AND PROCESSING AIDS (CEF), EFSA J, 13, (2015); CATCHPOLE O.J., TALLON S.J., GREY J.B., FENTON K., FLETCHER K., FLETCHER A.J., EXTRACTION OF LIPIDS FROM AQUEOUS PROTEIN-RICH STREAMS USING NEAR-CRITICAL DIMETHYL ETHER, CHEM. ENG. TECHNOL, 30, PP. 501-510, (2007); SUBRATTI A., LALGEE L.J., JALSA N.K., LIQUIFIED DIMETHYL ETHER (DME): A GREEN SOLVENT FOR THE EXTRACTION OF HEMP (CANNABIS SATIVA L.) SEED OIL, SUSTAIN. CHEM. PHARM, 12, (2019); SUBRATTI A., LALGEE L.J., JALSA N.K., EFFICIENT EXTRACTION OF BLACK CUMIN (NIGELLA SATIVA L.) SEED OIL CONTAINING THYMOL, USING LIQUEFIED DIMETHYL ETHER (DME), J. FOOD PROCESS. PRESERV, 43, (2019); BOONNOUN P., KURITA Y., KAMO Y., MACHMUDAH S., OKITA Y., OHASHI E., KANDA H., GOTO M., WET EXTRACTION OF LIPIDS AND ASTAXANTHIN FROM HAEMATOCOCCUS PLUVIALIS BY LIQUEFIED DIMETHYL ETHER, NUTR. FOOD SCI, 4, (2014); BOONNOUN P., SHOTIPRUK A., KANDA H., GOTO M., OPTIMIZATION OF RUBBER SEED OIL EXTRACTION USING LIQUEFIED DIMETHYL ETHER, CHEM. ENG. COMMUN, 206, PP. 746-753, (2019); FANG Y., GU S., LIU S., ZHANG J., DING Y., LIU J., EXTRACTION OF OIL FROM HIGH-MOISTURE TUNA LIVER BY SUBCRITICAL DIMETHYL ETHER: FEASIBILITY AND OPTIMIZATION BY THE RESPONSE SURFACE METHOD, RSC ADV, 8, PP. 2723-2732, (2018); FURUKAWA H., KIKUCHI A., NORIYASU A., BOUTEAU F., NISHIHAMA S., YOSHIZUKA K., LI X., KAWANO T., USE OF LIQUEFIED DIMETHYL ETHER FOR THE EXTRACTION OF PROTEINS FROM VEGETABLE TISSUES, SOLVENT EXTR. RES. DEV, 23, PP. 127-135, (2016); HOSHINO R., MACHMUDAH S., KANDA H., GOTO M., SIMULTANEOUS EXTRACTION OF WATER AND ESSENTIAL OILS FROM CITRUS LEAVES AND PEELS USING LIQUEFIED DIMETHYL ETHER, NUTR. FOOD SCI, 4, (2014); KANDA H., KAMO Y., MACHMUDAH S., WAHYUDIONO, GOTO M., EXTRACTION OF FUCOXANTHIN FROM RAW MACROALGAE EXCLUDING DRYING AND CELL WALL DISRUPTION BY LIQUEFIED DIMETHYL ETHER, MAR. DRUGS, 12, PP. 2383-2396, (2014); WONGWAIWECH D., WEERAWATANAKORN M., BOONNOUN P., SUBCRITICAL DIMETHYL ETHER EXTRACTION AS A SIMPLE METHOD TO EXTRACT NUTRACEUTICALS FROM BYPRODUCTS FROM RICE BRAN OIL MANUFACTURE, SCI. REP, 10, (2020); ASIKIN Y., CHINEN T., TAKARA K., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI. TECHNOL. RES, 14, (2008); WONGWAIWECH D., WEERAWATANAKORN M., THARATHA S., HO C.T., COMPARATIVE STUDY ON AMOUNT OF NUTRACEUTICALS IN BY-PRODUCTS FROM SOLVENT AND COLD PRESSING METHODS OF RICE BRAN OIL PROCESSING, J. FOOD DRUG ANAL, 27, PP. 71-82, (2019); BEVERIDGE T.H.J., LI T.S.C., DROVER J.C., PHYTOSTEROL CONTENT IN AMERICAN GINSENG SEED OIL, J. AGRIC. FOOD CHEM, 50, PP. 744-750, (2002); THANH T.T., VERGNES M.F., KALOUSTIAN J., EL-MOSELHY T.F., AMIOT-CARLIN M.J., PORTUGAL H., EFFECT OF STORAGE AND HEATING ON PHYTOSTEROL CONCENTRATIONS IN VEGETABLE OILS DETERMINED BY GC/MS, J. SCI. FOOD AGRIC, 86, PP. 220-225, (2006); PRASEDYA E.S., FREDIANSYAH A., MARTYASARI N.W.R., ILHAMI B.K., ABIDIN A.S., PADMI H., SUNARWIDHI A.L., EFFECT OF PARTICLE SIZE ON PHYTOCHEMICAL COMPOSITION AND ANTIOXIDANT PROPERTIES OF SARGASSUM CRISTAEFOLIUM ETHANOL EXTRACT, SCI. REP, 11, (2021); YATMA F., FALAH S., AMBARSARI L., AISYAH S.I., NURCHOLIS W., OPTIMIZATION OF EXTRACTION OF PHENOLIC AND ANTIOXIDANT ACTIVITIES FROM CELOSIA CRISTATA SEEDS USING RESPONSE SURFACE METHODOLOGY, BIOINTERFACE RES. APPL. CHEM, 13, PP. 2069-5837, (2022); BELWAL T., DHYANI P., BHATT I.D., RAWAL R.S., PANDE V., OPTIMIZATION EXTRACTION CONDITIONS FOR IMPROVING PHENOLIC CONTENT AND ANTIOXIDANT ACTIVITY IN BERBERIS ASIATICA FRUITS USING RESPONSE SURFACE METHODOLOGY (RSM), FOOD CHEM, 207, PP. 115-124, (2016); YUNUS M., HASAN M., OTHMAN N., MOHD-SEPTAPAR S., AHMAD-ZAINI M., IDHAM Z., ZHARI S., EFFECT OF PARTICLE SIZE ON THE OIL YIELD AND CATECHIN COMPOUND USING ACCELERATED SOLVENT EXTRACTION, J. TEKNOL, 60, PP. 21-25, (2013); PUTRA N.R., RIZKIYAH D.N., ZAINI A.S., YUNUS M.A.C., MACHMUDAH S., IDHAM Z.B., HAZWAN RUSLAN M.S., EFFECT OF PARTICLE SIZE ON YIELD EXTRACT AND ANTIOXIDANT ACTIVITY OF PEANUT SKIN USING MODIFIED SUPERCRITICAL CARBON DIOXIDE AND SOXHLET EXTRACTION, J. FOOD PROCESS. PRESERV, 42, (2018); PATEL S.B., ATTAR U.A., SAKATE D.M., GHANE S.G., EFFICIENT EXTRACTION OF CUCURBITACINS FROM DIPLOCYCLOS PALMATUS (L.) C. JEFFREY: OPTIMIZATION USING RESPONSE SURFACE METHODOLOGY, EXTRACTION METHODS AND STUDY OF SOME IMPORTANT BIOACTIVITIES, SCI. REP, 10, (2020); ZHAO S., KWOK K.C., LIANG H., INVESTIGATION ON ULTRASOUND ASSISTED EXTRACTION OF SAIKOSAPONINS FROM RADIX BUPLEURI, SEP. PURIF. TECHNOL, 55, PP. 307-312, (2007); NIKODINOVIC-RUNIC J., GUZIK M., KENNY S.T., BABU R., WERKER A., CONNOR K.E., CARBON-RICH WASTES AS FEEDSTOCKS FOR BIODEGRADABLE POLYMER (POLYHYDROXYALKANOATE) PRODUCTION USING BACTERIA, ADV. APPL. MICROBIOL, 84, PP. 139-200, (2013); WANG B., JIN X., CHEN X.D., INVESTIGATION ON THE RELATIONSHIP BETWEEN THE INTEGRITY OF FOOD MATRIX AND NUTRIENT EXTRACTION YIELD OF BROCCOLI, LWT—FOOD SCI. TECHNOL, 85, PP. 170-174, (2017); CROSSLEY J.I., AGUILERA J.M., MODELING THE EFFECT OF MICROSTRUCTURE ON FOOD EXTRACTION, J. FOOD PROCESS. ENG, 24, PP. 161-177, (2001); BAO N., RASHED M.M., JIANG B., ZHAI K., LUO Z., GREEN AND EFFICIENT EXTRACTION APPROACH FOR POLYPHENOL RECOVERY FROM LOTUS SEEDPODS (RECEPTACULUM NELUMBINIS): GAS-ASSISTED COMBINED WITH GLYCEROL, ACS OMEGA, 6, PP. 26722-26731, (2021); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR. J. LIPID SCI. TECHNOL, 114, PP. 583-591, (2012); DE LUCAS A., GARCIA A., ALVAREZ A., GRACIA I., SUPERCRITICAL EXTRACTION OF LONG CHAIN N-ALCOHOLS FROM SUGAR CANE CRUDE WAX, J. SUPERCRIT. FLUIDS, 41, PP. 267-271, (2007); OU S., ZHAO J., WANG Y., TIAN Y., WANG J., PREPARATION OF OCTACOSANOL FROM FILTER MUD PRODUCED AFTER SUGARCANE JUICE CLARIFICATION, LWT—FOOD SCI. TECHNOL, 45, PP. 295-298, (2012); SUN D., CAO C., LI B., CHEN H., LI J., CAO P., LIU Y., ANTARCTIC KRILL LIPID EXTRACTED BY SUBCRITICAL N-BUTANE AND COMPARISON WITH SUPERCRITICAL CO<SUB>2</SUB> AND CONVENTIONAL SOLVENT EXTRACTION, LWT—FOOD SCI. TECHNOL, 94, PP. 1-7, (2018); FUJIMOTO K., OHNO Y., GOTO S., KAJITANI S., KONNO M., SHIKADA T., SUZUKI S., DME HANDBOOK, (2007); MOTA N., ORDONEZ E.M., PAWELEC B., FIERRO J.L.G., NAVARRO R.M., DIRECT SYNTHESIS OF DIMETHYL ETHER FROM CO<SUB>2</SUB>: RECENT ADVANCES IN BIFUNCTIONAL/HYBRID CATALYTIC SYSTEMS, CATALYSTS, 11, (2021); ROSTAGNO M.A., PRADO J.M., NATURAL PRODUCT EXTRACTION: PRINCIPLES AND APPLICATIONS, PP. 197-213, (2013); ELTRINGHAM W., TALLON S.J., CATCHPOLE O.J., FENTON K., RELATIVE PERMITTIVITY MEASUREMENTS OF DIMETHYL ETHER + CARBON DIOXIDE MIXTURES, J. CHEM. ENG. DATA, 53, PP. 826-829, (2008); CATCHPOLE O.J., GREY J.B., NOERMARK K.A., SOLUBILITY OF FISH OIL COMPONENTS IN SUPERCRITICAL CO<SUB>2</SUB> AND CO<SUB>2</SUB> + ETHANOL MIXTURES, J. CHEM. ENG. DATA, 43, PP. 1091-1095, (1998); NYAM K.L., TAN C.P., LAI O.M., LONG K., MAN Y.B.C., OPTIMIZATION OF SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF PHYTOSTEROL-ENRICHED OIL FROM KALAHARI MELON SEEDS, FOOD BIOPROCESS TECHNOL, 2, PP. 1432-1441, (2011); GEORGES P., SYLVESTRE M., RUEGGER H., BOURGEOIS P., KETOSTEROIDS AND HYDROXYKETOSTEROIDS, MINOR METABOLITES OF SUGARCANE WAX, STEROIDS, 71, PP. 647-652, (2006); JOSE C., PAULO S., LUIZ P., LUCIENE L., PAULO A., LUIZ A.M., MARCOS A.A., ANTONELLA Z., ALFESIO B., THE IMPACT OF SUGAR CANE–BURNING EMISSIONS ON THE RESPIRATORY SYSTEM OF CHILDREN AND THE ELDERLY, ENVIRON. HEALTH PERSPECT, 114, PP. 725-729, (2006); CASAS L., HERNANDEZ Y., MANTELL C., CASDELO N., MARTINEZ DE LA OSSA E., FILTER CAKE OIL-WAX AS RAW MATERIAL FOR THE PRODUCTION OF BIODIESEL: ANALYSIS OF THE EXTRACTION PROCESS AND THE TRANSESTERIFICATION REACTION, J. CHEM, 2015, (2015); DUNFORD N.T., IRMAK S., JONNALA R., EFFECT OF THE SOLVENT TYPE AND TEMPERATURE ON PHYTOSTEROL CONTENTS AND COMPOSITIONS OF WHEAT STRAW, BRAN, AND GERM EXTRACTS, J. AGRIC. FOOD CHEM, 57, PP. 10608-10611, (2009); UDDIN M.S., FERDOSH S., AKANDA M.J.H., GHAFOOR K., RUKSHANA A.H., ALI M.E., KAMARUZZAMAN B.Y., FAUZI M.B., SHAARANI S., SARKER M.Z.I., TECHNIQUES FOR THE EXTRACTION OF PHYTOSTEROLS AND THEIR BENEFITS IN HUMAN HEALTH: A REVIEW, SEP. SCI. TECHNOL, 53, PP. 2206-2223, (2018); HE W.S., ZHU H., CHEN Z.Y., PLANT STEROLS: CHEMICAL AND ENZYMATIC STRUCTURAL MODIFICATIONS AND EFFECTS ON THEIR CHOLESTEROL-LOWERING ACTIVITY, J. AGRIC. FOOD CHEM, 66, PP. 3047-3062, (2018); DENG C., ADVANCE ON THE PREPARATION TECHNOLOGY AND ANTI-HYPERLIPIDEMIA MECHANISM OF PHYTOSTEROLS, IOP CONF. SER. EARTH ENVIRON. SCI, 615, (2020)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, PHITSANULOK, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","MDPI","ENGLISH","FOODS","ARTICLE","ISI","2-S2.0-85139792611","FOODS","NARESUAN UNIVERSITY;RUTGERS UNIVERSITY;NARESUAN UNIVERSITY;HUANGGANG NORMAL UNIVERSITY;NATIONAL TAIWAN UNIVERSITY;CHIANG MAI UNIVERSITY;NARESUAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"KAMCHONEMENUKOOL S, 2022, FOODS","KAMCHONEMENUKOOL S, 2022, FOODS"
"KUMAR S;MOODITHAYA S;SHRUTHI S H;MIRAJKAR A","KUMAR, SUMIT (58510512500); MOODITHAYA, SHAILAJA S. (35782126800); SHRUTHI SUVARNA, H.I. (57195585967); MIRAJKAR, AMRIT M. (54784911700)","CAN YOU BE BIOLOGICALLY YOUNGER THAN YOUR CHRONOLOGICAL AGE AN OVERVIEW OF BIOLOGICAL AGEING",2021,"BIOMEDICINE (INDIA)","41","6",2,"10.51248/.v41i3.682","DEPARTMENT OF PHYSIOLOGY, K.S HEGDE MEDICAL ACADEMY, NITTE (DEEMED TO BE UNIVERSITY), DERALAKATTE, MANGALORE, KARNATAKA, INDIA;DEPARTMENT OF PHYSIOLOGY, K.S HEGDE MEDICAL ACADEMY, NITTE (DEEMED TO BE UNIVERSITY), DERALAKATTE, MANGALORE, KARNATAKA, INDIA;DEPARTMENT OF PHYSIOLOGY, K.S HEGDE MEDICAL ACADEMY, NITTE (DEEMED TO BE UNIVERSITY), DERALAKATTE, MANGALORE, KARNATAKA, INDIA, A J INSTITUTE OF MEDICAL SCIENCES, MANGALORE, KARNATAKA, INDIA;DEPARTMENT OF PHYSIOLOGY, K.S HEGDE MEDICAL ACADEMY, NITTE (DEEMED TO BE UNIVERSITY), DERALAKATTE, MANGALORE, KARNATAKA, INDIA","THE AGEING OF THE POPULATION IS RAPIDLY ESCALATING WORLDWIDE IRRESPECTIVE OF UNPREDICTABLE HEALTH CHALLENGES LIKE CLIMATE CHANGE, EMERGING INFECTIOUS DISEASE, A MICROBE THAT DEVELOPS DRUG RESISTANCE. INDIA IS ALSO EXPERIENCING RAPID SOCIOECONOMIC PROGRESS AND URBANIZATION AND THE RESULT OF THIS DEMOGRAPHIC TRANSITION IS POPULATION AGEING. EVEN THOUGH THERE IS AN INCREASE IN LIFE EXPECTANCY, THERE IS NO INCREASE IN HEALTH SPAN, AND THUS INCREASED LIFE EXPECTANCY LEADS TO ‘EXPANSION OF MORBIDITY'. LONGER LIFE EXPECTANCY WITH THE EXPANSION OF MORBIDITY COULD ENFORCE A CHALLENGE TO GEROSCIENCE AS WELL AS A SUBSTANTIAL HEALTH BURDEN AND A THREAT TO THE NATIONAL ECONOMY. IN NORMAL AGEING, CHRONOLOGICAL AGE EQUATES TO BIOLOGICAL AGE, BUT CERTAIN DISEASE CONDITIONS ACCELERATE BIOLOGICAL AGE. SIMILARLY, INTERVENTION WITH PHYSICAL ACTIVITY, ANTI-AGEING NUTRACEUTICALS WOULD SLOW DOWN THE RATE AGEING PROCESS AND PROVIDE POWERFUL BENEFITS FOR LONGEVITY. THE CURRENT REVIEW ARTICLE IS BASED ON MESH AND FREE-TEXT TERMS IN DATABASES SUCH AS PUBMED, THE COCHRANE LIBRARY, AND SCIENCE DIRECT. THIS ARTICLE AIMS TO PROVIDE AN OVERVIEW OF THE CONCEPT OF BIOLOGICAL AGEING WITH EMPHASIS ON THE PATHOPHYSIOLOGY OF AGEING, QUANTIFICATION OF BIOLOGICAL AGEING AND THE ANTI-AGEING STRATEGIES. © 2021, INDIAN ASSOCIATION OF BIOMEDICAL SCIENTISTS. ALL RIGHTS RESERVED.","AGEING; BIOMARKERS; HEALTH SPAN; INFLAMMATION","METFORMIN; MOLECULAR MARKER; NICOTINAMIDE ADENINE DINUCLEOTIDE; POLICOSANOL; RESVERATROL; AGING; BIOLOGICAL AGE; COCHRANE LIBRARY; DIET THERAPY; DNA MARKER; HUMAN; MEDLINE; PATHOPHYSIOLOGY; REVIEW; SCIENCEDIRECT","","","HIGHLIGHTS; MADURO A. T., LUIS C., SOARES R., AGEING, CELLULAR SENESCENCE, AND THE IMPACT OF DIET: AN OVERVIEW, PORTO BIOMEDICAL JOURNAL, 6, (2021); VAN BEEK J. H., KIRKWOOD T. B., BASSINGTHWAIGHTE J. B., UNDERSTANDING THE PHYSIOLOGY OF THE AGEING INDIVIDUAL: COMPUTATIONAL MODELLING OF CHANGES IN METABOLISM AND ENDURANCE, INTERFACE FOCUS, 6, 2, (2016); ALMEIDA A. J., DE ALMEIDA REZENDE M. S., DANTAS S. H., DE LIMA SILVA S., DE OLIVEIRA J. C., ALVES R. M., ET AL., UNVEILING THE ROLE OF INFLAMMATION AND OXIDATIVE STRESS ON AGE-RELATED CARDIOVASCULAR DISEASES, OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, (2020); BUSH A., MORGAN M. D., NORMAL LUNG FUNCTION FROM CHILDHOOD TO OLD AGE, COTES’ LUNG FUNCTION, 9, PP. 435-461, (2020); MARINI S., BARONE G., MASINI A., DALLOLIO L., BRAGONZONI L., LONGOBUCCO Y., ET AL., THE EFFECT OF PHYSICAL ACTIVITY ON BONE BIOMARKERS IN PEOPLE WITH OSTEOPOROSIS: A SYSTEMATIC REVIEW, FRONTIERS IN ENDOCRINOLOGY, 11, (2020); JIN K., MODERN BIOLOGICAL THEORIES OF AGING, AGING AND DISEASE, 1, 2, (2010); WEINERT B. T., TIMIRAS P. S., INVITED REVIEW: THEORIES OF AGING, JOURNAL OF APPLIED PHYSIOLOGY, 95, 4, PP. 1706-1716, (2003); DIGGS J., ACTIVITY THEORY OF AGING, ENCYCLOPEDIA OF AGING AND PUBLIC HEALTH, PP. 79-81, (2008); ACHENBAUM W. A., BENGTSON V. L., RE-ENGAGING THE DISENGAGEMENT THEORY OF AGING: ON THE HISTORY AND ASSESSMENT OF THEORY DEVELOPMENT IN GERONTOLOGY, THE GERONTOLOGIST, 34, 6, PP. 756-763, (1994); FINKEL D., WHITFIELD K., MCGUE M. J., GENETIC AND ENVIRONMENTAL INFLUENCES ON FUNCTIONAL AGE: A TWIN STUDY, GERONTOL B PSYCHOL SCI SOC SCI, 50, 2, PP. 104-113, (1995); POULTON R., HANCOX R., MILNE B., BAXTER J., SCOTT K., WILSON N., ET AL., THE DUNEDIN MULTIDISCIPLINARY HEALTH AND DEVELOPMENT STUDY: ARE ITS FINDINGS CONSISTENT WITH THE OVERALL NEW ZEALAND POPULATION?, N Z MED J, 119, 1235, (2006); JOHNSON T. E., RECENT RESULTS: BIOMARKERS OF AGING, EXPERIMENTAL GERONTOLOGY, 41, 12, PP. 1243-1246, (2006); CRIMMINS E., VASUNILASHORN S., KIM J. K., ALLEY DAWN, BIOMARKERS RELATED TO AGING IN HUMAN POPULATIONS, ADVANCES IN CLINICAL CHEMISTRY, 46, PP. 161-216, (2008); COOPER R., KUH D., HARDY R., OBJECTIVELY MEASURED PHYSICAL CAPABILITY LEVELS AND MORTALITY: SYSTEMATIC REVIEW AND META-ANALYSIS, BMJ, (2010); WHITLOCK G., LEWINGTON S., SHERLIKER P., CLARKE R., EMBERSON J., HALSEY J., ET AL., PROSPECTIVE STUDIES COLLABORATION BODY-MASS INDEX AND CAUSE-SPECIFIC MORTALITY IN 900 000 ADULTS: COLLABORATIVE ANALYSES OF 57 PROSPECTIVE STUDIES, LANCET, 373, 9669, PP. 1083-1096, (2009); VLACHOPOULOS C., XAPLANTERIS P., ABOYANS V., BRODMANN M., CIFKOVA R., COSENTINO F., ET AL., THE ROLE OF VASCULAR BIOMARKERS FOR PRIMARY AND SECONDARY PREVENTION. A POSITION PAPER FROM THE EUROPEAN SOCIETY OF CARDIOLOGY WORKING GROUP ON PERIPHERAL CIRCULATION: ENDORSED BY THE ASSOCIATION FOR RESEARCH INTO ARTERIAL STRUCTURE AND PHYSIOLOGY (ARTERY) SOCIETY, ATHEROSCLEROSIS, 241, 2, PP. 507-532; VISSER M., PAHOR M., TAAFFE D. R., GOODPASTER B. H., SIMONSICK E. M., NEWMAN A. B., ET AL., RELATIONSHIP OF INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR-Α WITH MUSCLE MASS AND MUSCLE STRENGTH IN ELDERLY MEN AND WOMEN: THE HEALTH ABC STUDY, THE JOURNALS OF GERONTOLOGY SERIES A: BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 57, 5, PP. 326-332, (2002); INTERNATIONAL EXPERT COMMITTEE REPORT ON THE ROLE OF THE A1C ASSAY IN THE DIAGNOSIS OF DIABETES, DIABETES CARE, 32, 7, PP. 1327-1334, (2009); PARK D. C., YEO S. G., AGING, KOREAN J. AUDIOL, (2013); HAZANE F., SAUVAIGO S., DOUKI T., FAVIER A., BEANI J. C., AGE-DEPENDENT DNA REPAIR AND CELL CYCLE DISTRIBUTION OF HUMAN SKIN FIBROBLASTS IN RESPONSE TO UVA IRRADIATION, JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, 82, 3, PP. 214-223, (2006); GOBBENS R. J., VAN ASSEN M. A., SCHALK M. J., THE PREDICTION OF DISABILITY BY SELF-REPORTED PHYSICAL FRAILTY COMPONENTS OF THE TILBURG FRAILTY INDICATOR (TFI), ARCHIVES OF GERONTOLOGY AND GERIATRICS, 59, 2, PP. 280-287, (2014); SANDERS J. L., NEWMAN A. B., TELOMERE LENGTH IN EPIDEMIOLOGY: A BIOMARKER OF AGING, AGE-RELATED DISEASE, BOTH, OR NEITHER?, EPIDEMIOLOGIC REVIEWS, 35, 1, PP. 112-131, (2013); RAZI S., COGGER V. C., KENNERSON M., BENSON V. L., MCMAHON A. C., BLYTH F. M., ET AL., SIRT1 POLYMORPHISMS AND SERUM INDUCED SIRT1 PROTEIN EXPRESSION IN AGING AND FRAILTY: THE CHAMP STUDY, THE JOURNALS OF GERONTOLOGY: SERIES A, 72, 7, PP. 870-876, (2017); SHRUTHI S H. I., SHAILAJA S. M., RAGHAVA SHARMA, METABOLIC AND CARDIOVASCULAR AGEING INDICES IN RELATION TO GLYCATED HAEMOGLOBIN IN HEALTHY AND DIABETIC SUBJECTS, CURRENT AGEING SCIENCE, 10, 3, PP. 201-210, (2017); DREESEN O., STEWART. C. L. ACCELERATED AGING SYNDROMES, ARE THEY RELEVANT TO NORMAL HUMAN AGING?, AGING (ALBANY NY), 3, 9, (2011); LONGO V. D., ANTEBI A., BARTKE A., BARZILAI N., BROWN-BORG H. M., CARUSO C., ET AL., INTERVENTIONS TO SLOW AGING IN HUMANS: ARE WE READY?, AGING CELL, 14, 4, PP. 497-510, (2015); CLAUDIO FRANCESCHI, PAOLO GARAGNANI, MORSIANI CRISTINA., CONTE MARIA, SANTORO AURELIA, GRIGNOLIO ANDREA, ET AL., THE CONTINUUM OF AGING AND AGE-RELATED DISEASES: COMMON MECHANISMS BUT DIFFERENT RATES, FRONT MED (LAUSANNE), 5, (2018); ERUKAINURE O. L., SALAU V. F., CHUKWUMA C. I., ISLAM M. S., KOLAVIRON: A BIFLAVONOID WITH NUMEROUS HEALTH BENEFITS, CURRENT PHARMACEUTICAL DESIGN, 27, 4, PP. 490-504, (2021); SIEMANN E. H., CREASY L. L., CONCENTRATION OF THE PHYTOALEXIN RESVERATROL IN WINE, AMERICAN JOURNAL OF ENOLOGY AND VITICULTURE, 43, 1, PP. 49-52, (1992); HOWITZ K. T., BITTERMAN K. J., COHEN H. Y., LAMMING D. W., LAVU S., WOOD J. G., ET AL., SMALL MOLECULE ACTIVATORS OF SIRTUINS EXTEND SACCHAROMYCES CEREVISIAE LIFESPAN, NATURE, 425, 6954, PP. 191-196, (2003); MARAMBAUD P., ZHAO H., DAVIES P., RESVERATROL PROMOTES CLEARANCE OF ALZHEIMER'S DISEASE AMYLOID-Β PEPTIDES, JOURNAL OF BIOLOGICAL CHEMISTRY, 280, 45, PP. 37377-37382, (2005); SHRUTHI S. H., SHAILAJA S. M., RAGHAVA S., AMRIT M., METABOLIC AND CARDIOVASCULAR PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS UNDERGOING DIFFERENT TREATMENT MODALITIES, J. EVOLUTION MED. DENT. SCI, 8, 24, (2019); KIM J. Y., KIM S. M., KIM S. J., LEE E. Y., KIM J. R., CHO K. H., ET AL., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 39, 4, PP. 889-899, (2017); KIM S. M., LIM S. M., YOO J. A., WOO M. J., CHO K. H., CONSUMPTION OF HIGH-DOSE VITAMIN C (1250 MG PER DAY) ENHANCES FUNCTIONAL AND STRUCTURAL PROPERTIES OF SERUM LIPOPROTEIN TO IMPROVE ANTIOXIDANT, ANTI-ATHEROSCLEROTIC, AND ANTI-AGING EFFECTS VIA REGULATION OF ANTI-INFLAMMATORY MICRORNA, FOOD & FUNCTION, 6, 11, PP. 3604-3612, (2015); LEE E. Y., YOO J. A., LIM S. M., CHO K. H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RESEARCH, 19, 2, PP. 149-158, (2016); IMAI S. I., GUARENTE L., IT TAKES TWO TO TANGO: NAD+ AND SIRTUINS IN AGING/LONGEVITY CONTROL, NPJ AGING AND MECHANISMS OF DISEASE, 2, 1, PP. 1-6, (2016); CHUNG H. Y., KIM D. H., BANG E., YU B. P., IMPACTS OF CALORIE RESTRICTION AND INTERMITTENT FASTING ON HEALTH AND DISEASES: CURRENT TRENDS, (2020); MUNHOZ A. C., VILAS-BOAS E. A., PANVELOSKI-COSTA A. C., LEITE J. S., LUCENA C. F., RIVA P., ET AL., INTERMITTENT FASTING FOR TWELVE WEEKS LEADS TO INCREASES IN FAT MASS AND HYPERINSULINEMIA IN YOUNG FEMALE WISTAR RATS, NUTRIENTS, 12, 4, (2020)","S.S. MOODITHAYA; DEPARTMENT OF PHYSIOLOGY, K.S HEGDE MEDICAL ACADEMY, NITTE (DEEMED TO BE UNIVERSITY), DERALAKATTE, MANGALORE, KARNATAKA, INDIA; EMAIL: SHAILAJA.MOODITHAYA@NITTE.EDU.IN","INDIAN ASSOCIATION OF BIOMEDICAL SCIENTISTS","ENGLISH","BIOMEDICINE","REVIEW","ISI","2-S2.0-85119596023","BIOMEDICINE","NITTE (DEEMED TO BE UNIVERSITY);NITTE (DEEMED TO BE UNIVERSITY);NITTE (DEEMED TO BE UNIVERSITY);NITTE (DEEMED TO BE UNIVERSITY)","NOTREPORTED;NITTE (DEEMED TO BE UNIVERSITY);NOTREPORTED",NA,"KUMAR S, 2021, BIOMEDICINE","KUMAR S, 2021, BIOMEDICINE"
"HAN A;CHOI E;PARK J;JO S;HONG M;KIM J;RYOO G;JIN C","HAN, AH-REUM (34769874800); CHOI, EUNA (58642372200); PARK, JISU (57013620300); JO, SANG-HEE (56640636800); HONG, MIN JEONG (25629685100); KIM, JIN-BAEK (50262349800); RYOO, GA-HEE (57208901631); JIN, CHANG HYUN (37047181500)","COMPARISON OF POLICOSANOL PROFILES OF THE SPROUTS OF WHEAT MUTANT LINES AND THE EFFECT OF DIFFERENTIAL LED LIGHTS ON SELECTED LINES",2023,"PLANTS","12","",0,"10.3390/plants12193377","ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA;ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA","POLICOSANOLS (PCS) ARE LONG-CHAIN LINEAR ALIPHATIC ALCOHOLS THAT ARE PRESENT IN THE PRIMARY LEAVES OF CEREAL CROPS, SUCH AS BARLEY AND WHEAT, SUGAR CANE WAX, AND BEESWAX. PCS HAVE BEEN USED AS A NUTRACEUTICAL FOR IMPROVING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA. HOWEVER, THE PC CONTENT IN MUTANT WHEAT LINES HAS NOT BEEN INVESTIGATED. TO SELECT HIGHLY FUNCTIONAL WHEAT SPROUTS WITH A HIGH CONTENT OF PCS IN WHEAT MUTANT LINES DEVELOPED VIA GAMMA-IRRADIATED MUTATION BREEDING, WE CULTIVATED THE SPROUTS OF WHEAT MUTANT LINES IN A GROWTH CHAMBER WITH WHITE LED LIGHT (6000 K) AND ANALYZED THE PC CONTENT IN THESE SAMPLES USING GC-MS. WE STUDIED THE PC CONTENT IN 91 WHEAT SPROUT SAMPLES: THE ORIGINAL VARIETY (WOORI-MIL × D-7; WS01), COMMERCIALLY AVAILABLE CV. GEUMGANG (WS87) AND CV. CHEONGWOO (WS91), AND MUTANT LINES (WS02–WS86 AND WS88–WS90) DEVELOPED FROM WS01 AND WS87. COMPARED TO WS01, 18 MUTANT LINES EXHIBITED A HIGH TOTAL PC CONTENT (506.08–873.24 MG/100 G DRY WEIGHT). AMONG THEM, THE TOP 10 MUTANT LINES WERE EVALUATED FOR THEIR PC PRODUCTION AFTER CULTIVATING UNDER BLUE (440 NM), GREEN (520 NM), AND RED (660 NM) LED LIGHT IRRADIATION; HOWEVER, THESE COLORED LED LIGHTS REDUCED THE TOTAL PC PRODUCTION BY 35.8–49.7%, SUGGESTING THAT THE CULTIVATION WITH WHITE LED LIGHTS WAS MORE EFFICIENT IN PROMOTING PCS’ YIELD, COMPARED TO DIFFERENT LED LIGHTS. THEREFORE, OUR FINDINGS SHOW THE POTENTIAL OF RADIATION-BRED WHEAT VARIETIES AS FUNCTIONAL FOODS AGAINST HYPERLIPIDEMIA AND OBESITY AND THE OPTIMAL LIGHT CONDITIONS FOR HIGH PC PRODUCTION. © 2023 BY THE AUTHORS.","GC-MS; LED LIGHT; POLICOSANOL; TRITICUM AESTIVUM; WHEAT","","KOREA ATOMIC ENERGY RESEARCH INSTITUTE, KAERI, (523310-23)","THIS RESEARCH WAS SUPPORTED BY A RESEARCH PROGRAM OF THE KOREA ATOMIC ENERGY RESEARCH INSTITUTE (PROJECT NO. 523310-23).","SHEWRY P.R., HEY S.J., THE CONTRIBUTION OF WHEAT TO HUMAN DIET AND HEALTH, FOOD ENERGY SECUR, 4, PP. 178-202, (2015); ZHU Y., SANG S., PHYTOCHEMICALS IN WHOLE GRAIN WHEAT AND THEIR HEALTH-PROMOTING EFFECTS, MOL. NUTR. FOOD RES, 61, (2017); GENG J., LI J., ZHU F., CHEN X., DU B., TIAN H., LI J., PLANT SPROUT FOODS: BIOLOGICAL ACTIVITIES, HEALTH BENEFITS, AND BIOAVAILABILITY, J. FOOD BIOCHEM, 46, (2022); MIYAHIRA R.F., LOPES J.O., ANTUNES A.E.C., THE USE OF SPROUTS TO IMPROVE THE NUTRITIONAL VALUE OF FOOD PRODUCTS: A BRIEF REVIEW, PLANT FOODS HUM. NUTR, 76, PP. 143-152, (2021); HAN A., HONG M.J., NAM B., KIM B., PARK H.H., BAEK I., KIL Y., NAM J., JIN C.H., KIM J., COMPARISON OF FLAVONOID PROFILES IN SPROUTS OF RADIATION BREEDING WHEAT LINES (TRITICUM AESTIVUM L.), AGRONOMY, 10, (2020); RA J.E., WOO S.Y., LEE K.S., LEE M.J., KIM H.Y., HAM H.M., CHUNG I.M., KIM D.H., LEE J.H., SEO W.D., POLICOSANOL PROFILES AND ADENOSINE 5’-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME, FOOD CHEM, 317, (2020); MUTHUSAMY M., KIM J.H., KIM S.H., KIM J.Y., HEO J.W., LEE H., LEE K.S., SEO W.D., PARK S., KIM J.A., ET AL., CHANGES IN BENEFICIAL C-GLYCOSYLFLAVONES AND POLICOSANOL CONTENT IN WHEAT AND BARLEY SPROUTS SUBJECTED TO DIFFERENTIAL LED LIGHT CONDITIONS, PLANTS, 9, (2020); YADAV A., SINGH S., EFFECT OF EXOGENOUS PHYTOHORMONE TREATMENT ON ANTIOXIDANT ACTIVITY, ENZYME ACTIVITY AND PHENOLIC CONTENT IN WHEAT SPROUTS AND IDENTIFICATION OF METABOLITES OF CONTROL AND TREATED SAMPLES BY UHPLC-MS ANALYSIS, FOOD RES. INT, 169, (2023); BONFILI L., AMICI M., CECARINI V., CUCCIOLONI M., TACCONI R., ANGELETTI M., FIORETTI E., KELLER J.N., ELEUTERI A.M., WHEAT SPROUT EXTRACT-INDUCED APOPTOSIS IN HUMAN CANCER CELLS BY PROTEASOMES MODULATION, BIOCHIMIE, 91, PP. 1131-1144, (2009); PERYT B., SZYMCZYK T., LESCA P., MECHANISM OF ANTIMUTAGENICITY OF WHEAT SPROUT EXTRACTS, MUTAT. RES, 269, PP. 201-215, (1992); HAN B.K., YOON H., KIM K.H., SHIN E.C., KO K.S., LEE H.S., KIM Y.J., INHIBITORY EFFECTS OF WHEAT SPROUTS EXTRACT ON RANKL-INDUCED OSTEOCLAST DIFFERENTIATION VIA SUPPRESSING MAPK AND NFATC1 SIGNALING PATHWAYS, J. MED. FOOD, 26, PP. 480-488, (2023); LIM J.Y., YUN D.H., LEE J.H., KWON Y.B., LEE Y.M., LEE D.H., KIM D.K., EXTRACT OF TRITICUM AESTIVUM SPROUTS SUPPRESSES ACETAMINOPHEN-INDUCED HEPATOTOXICITY IN MICE BY INHIBITING OXIDATIVE STRESS, MOLECULES, 26, (2021); BRIGHENTI V., VENTURELLI A., CAROLI C., ANCESCHI L., GJIKOLAJ M., DURANTE C., PELLATI F., AN INNOVATIVE METHOD FOR THE EXTRACTION AND HPLC ANALYSIS OF BIOACTIVE POLICOSANOLS FROM NON-PSYCHOACTIVE CANNABIS SATIVA L, J. PHARM. BIOMED. ANAL, 234, (2023); SAFARI S., MIRAZI N., AHMADI N., ASADBEGI M., NOURIAN A., RASHNO M., KOMAKI A., POLICOSANOL PROTECTS AGAINST ALZHEIMER’S DISEASE-ASSOCIATED SPATIAL COGNITIVE DECLINE IN MALE RATS: POSSIBLE INVOLVED MECHANISMS, PSYCHOPHARMACOL, 240, PP. 755-767, (2023); MA C., FENG Y., LI X., SUN L., HE Z., GAN J., HE M., ZHANG X., CHEN X., POTENTIAL THERAPEUTIC EFFECTS OF POLICOSANOL FROM INSECT WAX ON CAENORHABDITIS ELEGANS MODELS OF PARKINSON’S DISEASE, J. NEUROIMMUNE PHARMACOL, 18, PP. 127-144, (2023); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ZHAO M., GAN J., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR. REV, 61, PP. 376-383, (2003); BARBAGALLO C.M., CEFALU A.B., NOTO D., AVERNA M.R., ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY, FRONT. CARDIOVASC. MED, 2, (2015); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON ""NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA"" OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTR. METAB CARDIOVASC. DIS, 27, PP. 2-17, (2017); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, (2011); NAM D.E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J. MED. FOOD, 22, PP. 1110-1117, (2019); ZHAI Z., NIU K.M., LIU H., LIN C., TU Y., LIU Y., CAI L., OUYANG K., LIU J., POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6/MICE THROUGH AMPK-FXR-TGR5 CROSS-TALK, J. FOOD SCI, 86, PP. 5466-5478, (2021); KIM K.M., KIM C.H., CHO K.H., JANG W.G., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN. EXP. PHARMACOL. PHYSIOL, 48, PP. 1336-1345, (2021); KIM K.M., LIM Y.J., JANG W.G., POLICOSANOL STIMULATES OSTEOBLAST DIFFERENTIATION VIA ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE-MEDIATED EXPRESSION OF INSULIN-INDUCED GENES 1 AND 2, CELLS, 12, (2023); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., KANG H.W., NAM M.H., LEE S.J., LEE J.H., ET AL., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J. AGRIC. FOOD CHEM, 61, PP. 1117-1123, (2013); LEE H.G., WOO S.Y., AHN H.J., YANG J.Y., LEE M.J., KIM H.Y., SONG S.Y., LEE J.H., SEO W.D., COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT (AVENA SATIVA L.) CULTIVARS AND SCREENING FOR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION, PLANTS, 11, (2022); THOMA F., SOMBORN-SCHULZ A., SCHLEHUBER D., KEUTER V., DEERBERG G., EFFECTS OF LIGHT ON SECONDARY METABOLITES IN SELECTED LEAFY GREENS: A REVIEW, FRONT. PLANT SCI, 11, (2020); YANG L., WEN K.S., RUAN X., ZHAO Y.X., WEI F., WANG Q., RESPONSE OF PLANT SECONDARY METABOLITES TO ENVIRONMENTAL FACTORS, MOLECULES, 23, (2018); LIU K., HARRISON M.T., YAN H., LIU D.L., MEINKE H., HOOGENBOOM G., WANG B., PENG B., GUAN K., JAEGERMEYR J., ET AL., SILVER LINING TO A CLIMATE CRISIS IN MULTIPLE PROSPECTS FOR ALLEVIATING CROP WATERLOGGING UNDER FUTURE CLIMATES, NAT. COMMUN, 14, (2023); ALRIFAI O., HAO X., MARCONE M.F., TSAO R., CURRENT REVIEW OF THE MODULATORY EFFECTS OF LED LIGHTS ON PHOTOSYNTHESIS OF SECONDARY METABOLITES AND FUTURE PERSPECTIVES OF MICROGREEN VEGETABLES, J. AGRIC. FOOD CHEM, 67, PP. 6075-6090, (2019); SATHASIVA R., PARK S.U., KIM J.K., PARK Y.J., KIM M.C., NGUYEN B.V., LEE S.Y., METABOLIC PROFILING OF PRIMARY AND SECONDARY METABOLITES IN KOHLRABI (BRASSICA OLERACEA VAR. GONGYLODES) SPROUTS EXPOSED TO DIFFERENT LIGHT-EMITTING DIODES, PLANTS, 12, (2023); TUAN P.A., THWE A.A., KIM Y.B., KIM J.K., KIM S.J., LEE S., CHUNG S.O., PARK S.U., EFFECTS OF WHITE, BLUE, AND RED LIGHT-EMITTING DIODES ON CAROTENOID BIOSYNTHETIC GENE EXPRESSION LEVELS AND CAROTENOID ACCUMULATION IN SPROUTS OF TARTARY BUCKWHEAT (FAGOPYRUM TATARICUM GAERTN.), J. AGRIC. FOOD CHEM, 61, PP. 12356-12361, (2013); DOU H., NIU G., GU M., MASABNI J.G., EFFECTS OF LIGHT QUALITY ON GROWTH AND PHYTONUTRIENT ACCUMULATION OF HERBS UNDER CONTROLLED ENVIRONMENTS, HORTICULTURAE, 3, (2017); HASAN M.M., BASHIR T., GHOSH R., LEE S.K., BAE H., AN OVERVIEW OF LEDS’ EFFECTS ON THE PRODUCTION OF BIOACTIVE COMPOUNDS AND CROP QUALITY, MOLECULES, 22, (2017); LI Q., KUBOTA C., EFFECTS OF SUPPLEMENTAL LIGHT QUALITY ON GROWTH AND PHYTOCHEMICALS OF BABY LEAF LETTUCE, ENVIRON. EXP. BOT, 67, PP. 59-64, (2009); BRAZAITYTE A., SAKALAUSKIENE S., SAMUOLIENE G., JANKAUSKIENE J., VIRSILE A., NOVICKOVAS A., SIRTAUTAS R., MILIAUSKIENE J., VASTAKAITE V., DABASINSKAS L., ET AL., THE EFFECTS OF LED ILLUMINATION SPECTRA AND INTENSITY ON CAROTENOID CONTENT IN BRASSICACEAE MICROGREENS, FOOD CHEM, 173, PP. 600-606, (2015); SAMUOLIENE G., VIRSILE A., BRAZAITYTE A., JANKAUSKIENE J., SAKALAUSKIENE S., VASTAKAITE V., NOVICKOVAS A., VISKELIENE A., SASNAUSKAS A., DUCHOVSKIS P., BLUE LIGHT DOSAGE AFFECTS CAROTENOIDS AND TOCOPHEROLS IN MICROGREENS, FOOD CHEM, 228, PP. 50-56, (2017); WANG Y., WANG M., SUN Y., WANG Y., LI T., CHAI G., JIANG W., SHAN L., LI C., XIAO E., ET AL., FAR5, A FATTY ACYL-COENZYME A REDUCTASE, IS INVOLVED IN PRIMARY ALCOHOL BIOSYNTHESIS OF THE LEAF BLADE CUTICULAR WAX IN WHEAT (TRITICUM AESTIVUM L.), J. EXP. BOT, 66, PP. 1165-1178, (2015); WANG M., WU H., XU J., LI C., WANG Y., WANG Z., FIVE FATTY ACYL-COENZYME A REDUCTASES ARE INVOLVED IN THE BIOSYNTHESIS OF PRIMARY ALCOHOLS IN AEGILOPS TAUSCHII LEAVES, FRONT PLANT. SCI, 8, (2017); NAM B., SO Y., KIM H., KIM J., JIN C., HAN A., A NEW MONOTERPENE FROM THE LEAVES OF A RADIATION MUTANT CULTIVAR OF PERILLA FRUTESCENS VAR. CRISPA WITH INHIBITORY ACTIVITY ON LPS-INDUCED NO PRODUCTION, MOLECULES, 22, (2017); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); WU T.-T., CHARLES A.L., HUANG T.-C., DETERMINATION OF THE CONTENTS OF THE MAIN BIOCHEMICAL COMPOUNDS OF ADLAY (COXI LACHRYMAL-JOBI), FOOD CHEM, 104, PP. 1509-1515, (2007); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), J. AGRIC. FOOD CHEM, 58, PP. 12143-12148, (2010); YUKA H.J., RYUA H.W., KIM D.-Y., PARK M.H., SEO W.D., JEONG S.H., SEI-RYANG OH S.-R., COMPARISON OF FLAVONOID AND POLICOSANOL PROFILES IN KOREAN WINTER-SPINACH (SPINACIA OLERACEA L.) CULTIVATED IN DIFFERENT REGIONS, FOOD CHEM, 279, PP. 202-208, (2019); CHAI G., LI C., XU F., LI Y., SHI X., WANG Y., WANG Z., THREE ENDOPLASMIC RETICULUM-ASSOCIATED FATTY ACYL-COENZYME A REDUCTASES WERE INVOLVED IN THE PRODUCTION OF PRIMARY ALCOHOLS IN HEXAPLOID WHEAT (TRITICUM AESTIVUM L.), BMC PLANT. BIOL, 18, (2018); WANG Y., SUN Y., YOU Q., LUO W., WANG C., ZHAO S., CHAI G., LI T., SHI X., LI C., ET AL., THREE FATTY ACYL-COENZYME A REDUCTASES, BDFAR1, BDFAR2 AND BDFAR3, ARE INVOLVED IN CUTICULAR WAX PRIMARY ALCOHOL BIOSYNTHESIS IN BRACHYPODIUM DISTACHYON, PLANT CELL PHYSIOL, 59, PP. 527-543, (2018); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); DING Y.Y., FANG Y., PAN Y., LAN J., XU T., ZHANG W., MAO H., GU Z., CHEN X., SHEN Q., ORALLY ADMINISTERED OCTACOSANOL IMPROVES LIVER INSULIN RESISTANCE IN HIGH-FAT DIET-FED MICE THROUGH THE RECONSTRUCTION OF THE GUT MICROBIOTA STRUCTURE AND INHIBITION OF THE TLR4/NF-ΚB INFLAMMATORY PATHWAY, FOOD FUNCT, 14, PP. 769-786, (2023); BAI J., YANG T., ZHOU Y., XU W., HAN S., GUO T., ZHU L., QIN D., LUO Y., HU Z., ET AL., OCTACOSANOL MODIFIES OBESITY, EXPRESSION PROFILE AND INFLAMMATION RESPONSE OF HEPATIC TISSUES IN HIGH-FAT DIET MICE, FOODS, 11, (2022); MIAO S.T., LU Q.S., ZHOU Y.J., CHANG Y.N., XU T., ZHU M.Y., ORAL ADMINISTRATION OF OCTACOSANOL MODULATES THE GUT BACTERIA AND PROTECTS THE INTESTINAL BARRIER IN ULCERATIVE COLITIS MICE, J. FOOD BIOCHEM, 46, (2022); ZHOU Y., CAO F., WU Q., LUO Y., GUO T., HAN S., HUANG M., HU Z., BAI J., LUO F., ET AL., DIETARY SUPPLEMENTATION OF OCTACOSANOL IMPROVES EXERCISE-INDUCED FATIGUE AND ITS MOLECULAR MECHANISM, J. AGRIC. FOOD CHEM, 69, PP. 7603-7618, (2021); SU J., LIU B., LIAO J., YANG Z., LIN C., OKA Y., COORDINATION OF CRYPTOCHROME AND PHYTOCHROME SIGNALS IN THE REGULATION OF PLANT LIGHT RESPONSES, AGRONOMY, 7, (2017); WANG Q., ZUO Z., WANG X., GU L., YOSHIZUMI T., YANG Z., YANG L., LIU Q., LIU W., HAN Y.J., ET AL., PHOTOACTIVATION AND INACTIVATION OF ARABIDOPSIS CRYPTOCHROME 2, SCIENCE, 354, PP. 343-347, (2016); KOPSELL D.A., SAMS C.E., INCREASES IN SHOOT TISSUE PIGMENTS, GLUCOSINOLATES, AND MINERAL ELEMENTS IN SPROUTING BROCCOLI AFTER EXPOSURE TO SHORT-DURATION BLUE LIGHT FROM LIGHT EMITTING DIODES, J. AM. SOC. HORTIC. SCI, 138, PP. 31-37, (2013); SAMUOLIENE G., SIRTAUTAS R., BRAZAITYTE A., DUCHOVSKIS P., LED LIGHTING AND SEASONALITY EFFECTS ANTIOXIDANT PROPERTIES OF BABY LEAF LETTUCE, FOOD CHEM, 134, PP. 1494-1499, (2012); LEFSRUD M.G., KOPSELL D.A., KOPSELL D.E., CURRAN-CELENTANO J., IRRADIANCE LEVELS AFFECT GROWTH PARAMETERS AND CAROTENOID PIGMENTS IN KALE AND SPINACH GROWN IN A CONTROLLED ENVIRONMENT, PHYSIOL. PLANT, 127, PP. 624-631, (2006); CHARRON C.S., SAMS C.E., GLUCOSINOLATE CONTENT AND MYROSINASE ACTIVITY IN RAPID-CYCLING BRASSICA OLERACEA GROWN IN A CONTROLLED ENVIRONMENT, J. AMER. SOC. HORT. SCI, 129, PP. 321-330, (2004); SHIN O.H., KIM D.Y., SEO Y.W., EFFECTS OF DIFFERENT DEPTH OF GRAIN COLOUR ON ANTIOXIDANT CAPACITY DURING WATER IMBIBITION IN WHEAT (TRITICUM AESTIVUM L), J. SCI. FOOD AGRIC, 97, PP. 2750-2758, (2017); GALILI T., O'CALLAGHAN A., SIDI J., SIEVERT C., HEATMAPLY: AN R PACKAGE FOR CREATING INTERACTIVE CLUSTER HEATMAPS FOR ONLINE PUBLISHING, BIOINFORMATICS, 34, PP. 1600-1602, (2018)","A.-R. HAN; ADVANCED RADIATION TECHNOLOGY INSTITUTE, KOREA ATOMIC ENERGY RESEARCH INSTITUTE, JEONGEUP-SI, 56212, SOUTH KOREA; EMAIL: ARHAN@KAERI.RE.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","PLANTS","ARTICLE","ISI","2-S2.0-85173887004","PLANTS","ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE;ADVANCED RADIATION TECHNOLOGY INSTITUTE","NOTREPORTED;ADVANCED RADIATION TECHNOLOGY INSTITUTE;NOTREPORTED",NA,"HAN A-R, 2023, PLANTS","HAN A-R, 2023, PLANTS"
"PROTIC O;BONFIGLI A;ANTONICELLI R","PROTIC, OLGA (55619864300); BONFIGLI, ANNA RITA (7004849319); ANTONICELLI, ROBERTO (7004028326)","NUTRACEUTICAL COMBINATIONS IN HYPERCHOLESTEROLEMIA EVIDENCE FROM RANDOMIZED PLACEBOCONTROLLED CLINICAL TRIALS",2021,"NUTRIENTS","13","",3,"10.3390/nu13093128","CARDIOLOGY UNIT, IRCCS INRCA, ANCONA, 60129, ITALY;SCIENTIFIC DIRECTION, IRCCS INRCA, ANCONA, 60129, ITALY;CARDIOLOGY UNIT, IRCCS INRCA, ANCONA, 60129, ITALY","THERE IS AN INCREASING NUMBER OF NUTRACEUTICAL COMBINATIONS (NCS) ON THE MARKET FOR HYPERCHOLESTEROLEMIA, ALTHOUGH CLINICAL TRIALS TO VERIFY THEIR SAFETY AND EFFICACY ARE SCARCE. WE SELECTED FOURTEEN RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIALS (RCTS) ON DIFFERENT LIPID-LOWERING NCS IN HYPERCHOLESTEROLEMIC SUBJECTS. WE DESCRIBED EACH COMPOUND’S MECHANISM OF ACTION AND EFFICACY IN THE MIXTURES AND SUMMARIZED THE CLINICAL TRIALS SETTINGS AND NCS SAFETY AND EFFICACY RESULTS. ALMOST ALL NCS RESULTED EFFICIENT AGAINST HYPERCHOLESTEROLEMIA; ONLY ONE REPORTED NO CHANGES. INTERESTINGLY, RED YEAST RICE (RYR) WAS PRESENT IN ELEVEN MIXTURES. IT IS NOT CLEAR WHETHER THE LIPID-LOWERING EFFICACY OF THESE COMBINATIONS DERIVES MAINLY FROM THE RYR COMPONENT MONACOLIN K “NATURAL STATIN” SINGLE EFFECT. UP TO NOW, FEW RCTS HAVE VERIFIED THE EFFICACY OF EVERY SINGLE COMPOUND VS. NCS TO EVALUATE POSSIBLE ADDITIVE OR SYNERGISTIC EFFECTS, PROBABLY DUE TO THE COMPLEXITY AND THE HIGH RESOURCES REQUEST. IN CONCLUSION, TO MANAGE THE ARISING NUTRACEUTICAL TIDE AGAINST HYPERCHOLESTEROLEMIA, IT COULD BE HELPFUL TO INCREASE THE NUMBER AND ROBUSTNESS OF CLINICAL STUDIES TO VERIFY THE EFFICACY AND SAFETY OF THE NEW NCS. © 2021 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","CARDIOVASCULAR DISEASE; COENZYME Q; COMBINATIONS; DIETARY SUPPLEMENTS; HYPERCHOLESTEROLEMIA; LDL-CHOLESTEROL; NUTRACEUTICALS; PHYTOSTEROLS; POLICOSANOLS; PREVENTION; PRIMARY PREVENTION; RANDOMIZED CLINICAL TRIALS; RED YEAST RICE; VITAMINS","ADULT; AGED; BIOLOGICAL PRODUCTS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAMINS; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ASTAXANTHIN; BERBERINE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CHOLESTIN; FOLIC ACID; MEVINOLIN; MICROCRYSTALLINE CELLULOSE; NICOTINAMIDE; NICOTINIC ACID; NUTRACEUTICAL; PHYTOSTEROL; POLICOSANOL; TYROSOL; UBIDECARENONE; ANTILIPEMIC AGENT; BIOLOGICAL PRODUCT; CHOLESTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; DIETARY SUPPLEMENT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; FEMALE; GOLD STANDARD; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MEDLINE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYNERGISTIC EFFECT; SYSTEMATIC REVIEW; AGED; BLOOD; DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA; MIDDLE AGED; TREATMENT OUTCOME","MINISTERO DELLA SALUTE","FUNDING: THIS STUDY WAS SUPPORTED BY RICERCA CORRENTE FUNDING FROM THE ITALIAN MINISTRY OF HEALTH TO IRCCS INRCA.","MOZAFFARIAN D., BENJAMIN E.J., GO A.S., ARNETT D.K., BLAHA M.J., CUSHMAN M., DE FERRANTI S., DESPRES J.P., FULLERTON H.J., HOWARD V.J., ET AL., HEART DISEASE AND STROKE STATISTICS–2015 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 131, PP. E29-E322, (2015); LI X., FANG P., LI Y., KUO Y.M., ANDREWS A.J., NANAYAKKARA G., JOHNSON C., FU H., SHAN H., DU F., ET AL., MITOCHONDRIAL REACTIVE OXYGEN SPECIES MEDIATE LYSOPHOSPHATIDYLCHOLINE-INDUCED ENDOTHELIAL CELL ACTIVATION, ARTERIOSCLER. THROMB. VASC. BIOL, 36, PP. 1090-1100, (2016); KOBIYAMA K., LEY K., ATHEROSCLEROSIS, CIRC. RES, 123, PP. 1118-1120, (2018); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR. HEART J, 37, PP. 2999-3058, (2016); RAFIEIAN-KOPAEI M., SETORKI M., DOUDI M., BARADARAN A., NASRI H., ATHEROSCLEROSIS: PROCESS, INDICATORS, RISK FACTORS AND NEW HOPES, INT. J. PREV. MED, 5, PP. 927-946, (2014); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., FRAS Z., KATSIKI N., LANGLOIS M., LATKOVSKIS G., ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH. MED. SCI, 75, PP. 965-1005, (2017); 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, ATHEROSCLEROSIS, 290, PP. 140-205, (2019); SANTINI A., NOVELLINO E., NUTRACEUTICALS IN HYPERCHOLESTEROLAEMIA: AN OVERVIEW, BR. J. PHARMACOL, 174, PP. 1450-1463, (2017); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTR. METAB. CARDIOVASC. DIS, 27, PP. 2-17, (2017); RUSCICA M., PAVANELLO C., GANDINI S., MACCHI C., BOTTA M., ORTO D., DEL PUPPO M., BERTOLOTTI M., BOSISIO R., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH FOR THE MANAGEMENT OF CARDIOVASCULAR RISK—A COMBINATION CONTAINING THE PROBIOTIC BIFIDOBAC-TERIUM LONGUM BB536 AND RED YEAST RICE EXTRACT: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. J, 18, (2019); DOMENECH M., CASAS R., RUIZ-LEON A.M., SOBRINO J., ROS E., ESTRUCH R., EFFECTS OF A NOVEL NUTRACEUTICAL COMBINATION (AQUILEA COLESTEROL® ) ON THE LIPID PROFILE AND INFLAMMATORY BIOMARKERS: A RANDOMIZED CONTROL TRIAL, NUTRIENTS, 11, (2019); CICERO A.F., COLLETTI A., FOGACCI F., BOVE M., ROSTICCI M., BORGHI C., EFFECTS OF A COMBINED NUTRACEUTICAL ON LIPID PATTERN, GLUCOSE METABOLISM AND INFLAMMATORY PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS: A DOUBLE-BLIND, CROSS-OVER, RANDOMIZED CLINICAL TRIAL. HIGH BLOOD PRESS, CARDIOVASC. PREV, 24, PP. 13-18, (2017); CICERO A.F.G., FOGACCI F., BOVE M., VERONESI M., RIZZO M., GIOVANNINI M., BORGHI C., SHORT-TERM EFFECTS OF A COMBINED NUTRACEUTICAL ON LIPID LEVEL, FATTY LIVER BIOMARKERS, HEMODYNAMIC PARAMETERS, AND ESTIMATED CARDIOVASCULAR DISEASE RISK: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL, ADV. THER, 34, PP. 1966-1975, (2017); CICERO A.F., MORBINI M., ROSTICCI M., D'ADDATO S., GRANDI E., BORGHI C., MIDDLE-TERM DIETARY SUPPLEMENTATION WITH RED YEAST RICE PLUS COENZYME Q10 IMPROVES LIPID PATTERN, ENDOTHELIAL REACTIVITY AND ARTERIAL STIFFNESS IN MODERATELY HYPERCHOLES-TEROLEMIC SUBJECTS, ANN. NUTR. METAB, 68, PP. 213-219, (2016); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. METAB. CARDIOVASC. DIS, 20, PP. 656-661, (2010); FERGUSON J.J.A., STOJANOVSKI E., MACDONALD-WICKS L., GARG M.L., CURCUMIN POTENTIATES CHOLESTEROL-LOWERING EFFECTS OF PHYTOS-TEROLS IN HYPERCHOLESTEROLAEMIC INDIVIDUALS. A RANDOMISED CONTROLLED TRIAL, METABOLISM, 82, PP. 22-35, (2018); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., MORINA D., VILLAR J., MILLAN J., ANGUERA A., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); OGIER N., AMIOT M.J., GEORGE S., MAILLOT M., MALLMANN C., MARANINCHI M., MORANGE S., LESCUYER J.F., PELTIER S.L., CARDINAULT N., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR. J. NUTR, 52, PP. 547-557, (2013); TRAUTWEIN E.A., DU Y., MEYNEN E., YAN X., WEN Y., WANG H., MOLHUIZEN H.O., PURIFIED BLACK TEA THEAFLAVINS AND THEAFLAVINS/CATECHIN SUPPLEMENTS DID NOT AFFECT SERUM LIPIDS IN HEALTHY INDIVIDUALS WITH MILDLY TO MODERATELY ELEVATED CHOLESTEROL CONCENTRATIONS, EUR. J. NUTR, 49, PP. 27-35, (2010); D'ADDATO S., SCANDIANI L., MOMBELLI G., FOCANTI F., PELACCHI F., SALVATORI E., DI LORETO G., COMANDINI A., MAFFIOLI P., DEROSA G., EFFECT OF A FOOD SUPPLEMENT CONTAINING BERBERINE, MONACOLIN K, HYDROXYTYROSOL AND COENZYME Q<SUB>10</SUB> ON LIPID LEVELS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY, DRUG DES. DEV. THER, 11, PP. 1585-1592, (2017); CICERO A.F.G., ADDATO S., BORGHI C., A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY OF THE EFFECTS OF A NUTRACEUTICAL COMBINATION (LEVELIP DUO® ) ON LDL CHOLESTEROL LEVELS AND LIPID PATTERN IN SUBJECTS WITH SUB-OPTIMAL BLOOD CHOLESTEROL LEVELS (NATCOL STUDY), NUTRIENTS, 12, (2020); ISKANDAR I., HARAHAP Y., WIJAYANTI T.R., SANDRA M., PRASAJA B., CAHYANINGSIH P., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION OF RED YEAST RICE, GUGGULIPID, AND CHROMIUM PICOLINATE EVALUATED IN A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY, COMPLEMENT. THER. MED, 48, (2020); CICERO A.F.G., FOGACCI F., BOVE M., GIOVANNINI M., VERONESI M., BORGHI C., SHORT-TERM EFFECTS OF DRY EXTRACTS OF ARTICHOKEAND BERBERIS IN HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CARDIOVASCULAR DISEASE, AM. J. CARDIOL, 123, PP. 588-591, (2019); CICERO A.F.G., FOGACCI F., BANACH M., RED YEAST RICE FOR HYPERCHOLESTEROLEMIA, METHODIST DEBAKEY CARDIOVASC. J, 15, PP. 192-199, (2019); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ZHANG D., COOPER R., CHANG M., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGRIC. FOOD CHEM, 48, PP. 5220-5225, (2000); YOUNES M., AGGETT P., AGUILAR F., CREBELLI R., DUSEMUND B., FILIPIC M., FRUTOS M.J., GALTIER P., GOTT D., GUNDERT-REMY U., ET AL., SCIENTIFIC OPINION ON THE SAFETY OF MONACOLINS IN RED YEAST RICE, EFSA J, 16, (2018); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN—A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); ANTONIADES C., ANTONOPOULOS A.S., TOUSOULIS D., MARINOU K., STEFANADIS C., HOMOCYSTEINE AND CORONARY ATHEROSCLEROSIS: FROM FOLATE FORTIFICATION TO THE RECENT CLINICAL TRIALS, EUR. HEART J, 30, PP. 6-15, (2009); BROWN K.S., HUANG Y., LU Z.Y., JIAN W., BLAIR I.A., WHITEHEAD A.S., MILD FOLATE DEFICIENCY INDUCES A PROATHEROSCLEROTIC PHENOTYPE IN ENDOTHELIAL CELLS, ATHEROSCLEROSIS, 189, PP. 133-141, (2006); ADAIKALAKOTESWARI A., FINER S., VOYIAS P.D., MCCARTHY C.M., VATISH M., MOORE J., SMART-HALAJKO M., BAWAZEER N., AL-DAGHRI N.M., MCTERNAN P.G., ET AL., VITAMIN B12 INSUFFICIENCY INDUCES CHOLESTEROL BIOSYNTHESIS BY LIMITING S-ADENOSYLMETHIONINE AND MODULATING THE METHYLATION OF SREBF1 AND LDLR GENES, CLIN. EPIGENET, 7, (2015); KAMANNA V.S., KASHYAP M.L., MECHANISM OF ACTION OF NIACIN, AM. J. CARDIOL, 101, PP. 20B-26B, (2008); SORCI L., KURNASOV O., RODIONOV D., OSTERMAN A., GENOMICS AND ENZYMOLOGY OF NAD BIOSYNTHESIS, COMPR. NAT. PROD. II CHEM. BIOL, 7, PP. 213-257, (2010); ZEB SHAH T., ALI A.B., AHMAD JAFRI S., QAZI M.H., EFFECT OF NICOTINIC ACID (VITAMIN B3 OR NIACIN) ON THE LIPID PROFILE OF DIABETIC AND NON–DIABETIC RATS, PAK. J. MED. SCI, 29, PP. 1259-1264, (2013); BIAN X., GAO W., WANG Y., YAO Z., XU Q., GUO C., LI B., RIBOFLAVIN DEFICIENCY AFFECTS LIPID METABOLISM PARTLY BY REDUCING APOLIPOPROTEIN B100 SYNTHESIS IN RATS, J. NUTR. BIOCHEM, 70, PP. 75-81, (2019); WANG Q., SUN Y., MA A., LI Y., HAN X., LIANG H., EFFECTS OF VITAMIN E ON PLASMA LIPID STATUS AND OXIDATIVE STRESS IN CHINESE WOMEN WITH METABOLIC SYNDROME, INT. J. VITAM. NUTR. RES, 80, PP. 178-187, (2010); ZIEGLER M., WALLERT M., LORKOWSKI S., PETER K., CARDIOVASCULAR AND METABOLIC PROTECTION BY VITAMIN E: A MATTER OF TREATMENT STRATEGY?, ANTIOXIDANTS, 9, (2020); SATAPATHY S., BANDYOPADHYAY D., PATRO B.K., KHAN S., NAIK S., FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS: A MULTI-ARM RANDOMIZED CONTROLLED CLINICAL TRIAL, COMPLEMENT. THER. MED, 53, (2020); EL BOROLOSSY R., EL WAKEEL L.M., EL HAKIM I., SABRI N., EFFICACY AND SAFETY OF NICOTINAMIDE IN THE MANAGEMENT OF HYPERPHOS-PHATEMIA IN PEDIATRIC PATIENTS ON REGULAR HEMODIALYSIS, PEDIATR. NEPHROL, 31, PP. 289-296, (2016); AJULUCHUKWU J.N., OKUBADEJO N.U., MABAYOJE M., OJINI F.I., OKWUDIAFOR R.N., MBAKWEM A.C., FASANMADE O.A., OKE D.A., COMPARATIVE STUDY OF THE EFFECT OF TOCOTRIENOLS AND-TOCOPHEROL ON FASTING SERUM LIPID PROFILES IN PATIENTS WITH MILD HYPERCHOLESTEROLAEMIA: A PRELIMINARY REPORT, NIGER. POSTGRAD. MED. J, 14, PP. 30-33, (2007); RASOOL A.H., RAHMAN A.R., YUEN K.H., WONG A.R., ARTERIAL COMPLIANCE AND VITAMIN E BLOOD LEVELS WITH A SELF EMULSIFYING PREPARATION OF TOCOTRIENOL RICH VITAMIN E, ARCH. PHARM. RES, 31, PP. 1212-1217, (2008); KATTOOR A.J., POTHINENI N.V.K., PALAGIRI D., MEHTA J.L., OXIDATIVE STRESS IN ATHEROSCLEROSIS, CURR. ATHEROSCLER. REP, 19, (2017); GARRIDO-MARAVER J., CORDERO M.D., OROPESA-AVILA M., VEGA A.F., DE LA MATA M., PAVON A.D., ALCOCER-GOMEZ E., CALERO C.P., PAZ M.V., ALANIS M., ET AL., CLINICAL APPLICATIONS OF COENZYME Q<SUB>10</SUB>, FRONT. BIOSCI. (LANDMARK ED.), 19, PP. 619-633, (2014); KUMAR A., KAUR H., DEVI P., MOHAN V., ROLE OF COENZYME Q10 (COQ10) IN CARDIAC DISEASE, HYPERTENSION AND MENIERE-LIKE SYNDROME, PHARMACOL. THER, 124, PP. 259-268, (2009); SABBATINELLI J., ORLANDO P., GALEAZZI R., SILVESTRI S., CIRILLI I., MARCHEGGIANI F., DLUDLA P.V., GIULIANI A., BONFIGLI A.R., MAZZANTI L., ET AL., UBIQUINOL AMELIORATES ENDOTHELIAL DYSFUNCTION IN SUBJECTS WITH MILD-TO-MODERATE DYSLIPIDEMIA: A RANDOMIZED CLINICAL TRIAL, NUTRIENTS, 12, (2020); JORAT M.V., TABRIZI R., MIRHOSSEINI N., LANKARANI K.B., AKBARI M., HEYDARI S.T., MOTTAGHI R., ASEMI Z., THE EFFECTS OF COENZYME Q10 SUPPLEMENTATION ON LIPID PROFILES AMONG PATIENTS WITH CORONARY ARTERY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, LIPIDS HEALTH DIS, 17, (2018); BRUSQ J.M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINTILLAN Y., ISSANDOU M., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J. LIPID RES, 47, PP. 1281-1288, (2006); LEE S., LIM H.J., PARK J.H., LEE K.S., JANG Y., PARK H.Y., BERBERINE-INDUCED LDLR UP-REGULATION INVOLVES JNK PATHWAY, BIOCHEM. BIOPHYS. RES. COMMUN, 362, PP. 853-857, (2007); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); DONG H., ZHAO Y., ZHAO L., LU F., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES, 32, PP. 8-12, (2001); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPI-DEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); SANCHEZ-LOPEZ J., FERNANDEZ-TRAVIESO J.C., ILLNAIT-FERRER J., FERNANDEZ-DORTA L., MENDOZA-CASTANO S., MAS-FERREIRO R., MESA-ANGARICA M., REYES-SUAREZ P., EFFECTS OF POLICOSANOL IN THE FUNCTIONAL RECOVERY OF NON-CARDIOEMBOLIC ISCHEMIC STROKE HYPERTENSIVE PATIENTS, REV. NEUROL, 67, PP. 331-338, (2018); FARHANGI M.A., OSTADRAHIMI A., MAHBOOB S., SERUM CALCIUM, MAGNESIUM, PHOSPHOROUS AND LIPID PROFILE IN HEALTHY IRANIAN PREMENOPAUSAL WOMEN, BIOCHEM. MED. (ZAGREB), 21, PP. 312-320, (2011); DE SMET E., MENSINK R.P., PLAT J., EFFECTS OF PLANT STEROLS AND STANOLS ON INTESTINAL CHOLESTEROL METABOLISM: SUGGESTED MECHANISMS FROM PAST TO PRESENT, MOL. NUTR. FOOD RES, 56, PP. 1058-1072, (2012); CALANDRA S., TARUGI P., SPEEDY H.E., DEAN A.F., BERTOLINI S., SHOULDERS C.C., MECHANISMS AND GENETIC DETERMINANTS REGULATING STEROL ABSORPTION, CIRCULATING LDL LEVELS, AND STEROL ELIMINATION: IMPLICATIONS FOR CLASSIFICATION AND DISEASE RISK, J. LIPID RES, 52, PP. 1885-1926, (2011); TALATI R., SOBIERAJ D.M., MAKANJI S.S., PHUNG O.J., COLEMAN C.I., THE COMPARATIVE EFFICACY OF PLANT STEROLS AND STANOLS ON SERUM LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. AM. DIET. ASSOC, 110, PP. 719-726, (2010); RAS R.T., GELEIJNSE J.M., TRAUTWEIN E.A., LDL-CHOLESTEROL-LOWERING EFFECT OF PLANT STEROLS AND STANOLS ACROSS DIFFERENT DOSE RANGES: A META-ANALYSIS OF RANDOMISED CONTROLLED STUDIES, BR. J. NUTR, 112, PP. 214-219, (2014); KARKOVIC MARKOVIC A., TORIC J., BARBARIC M., JAKOBUSIC BRALA C., HYDROXYTYROSOL, TYROSOL AND DERIVATIVES AND THEIR POTENTIAL EFFECTS ON HUMAN HEALTH, MOLECULES, 24, (2019); RIETJENS S.J., BAST A., HAENEN G.R., NEW INSIGHTS INTO CONTROVERSIES ON THE ANTIOXIDANT POTENTIAL OF THE OLIVE OIL ANTIOXIDANT HYDROXYTYROSOL, J. AGRIC. FOOD CHEM, 55, PP. 7609-7614, (2007); VISIOLI F., POLI A., GALL C., ANTIOXIDANT AND OTHER BIOLOGICAL ACTIVITIES OF PHENOLS FROM OLIVES AND OLIVE OIL, MED. RES. REV, 22, PP. 65-75, (2002); LOCKYER S., ROWLAND I., SPENCER J.P.E., YAQOOB P., STONEHOUSE W., IMPACT OF PHENOLIC-RICH OLIVE LEAF EXTRACT ON BLOOD PRESSURE, PLASMA LIPIDS AND INFLAMMATORY MARKERS: A RANDOMISED CONTROLLED TRIAL, EUR. J. NUTR, 56, PP. 1421-1432, (2017); SANTOS H.O., BUENO A.A., MOTA J.F., THE EFFECT OF ARTICHOKE ON LIPID PROFILE: A REVIEW OF POSSIBLE MECHANISMS OF ACTION, PHARMACOL. RES, 137, PP. 170-178, (2018); LI J., INOUE J., CHOI J.M., NAKAMURA S., YAN Z., FUSHINOBU S., KAMADA H., KATO H., HASHIDUME T., SHIMIZU M., ET AL., IDENTIFICATION OF THE FLAVONOID LUTEOLIN AS A REPRESSOR OF THE TRANSCRIPTION FACTOR HEPATOCYTE NUCLEAR FACTOR 4Α, J. BIOL. CHEM, 290, PP. 24021-24035, (2015); LIN Y., SHI R., WANG X., SHEN H.M., LUTEOLIN, A FLAVONOID WITH POTENTIAL FOR CANCER PREVENTION AND THERAPY, CURR. CANCER DRUG TARGETS, 8, PP. 634-646, (2008); WONG T.Y., LIN S.M., LEUNG L.K., THE FLAVONE LUTEOLIN SUPPRESSES SREBP-2 EXPRESSION AND POST-TRANSLATIONAL ACTIVATION IN HEPATIC CELLS, PLOS ONE, 10, (2015); TAJIK N., TAJIK M., MACK I., ENCK P., THE POTENTIAL EFFECTS OF CHLOROGENIC ACID, THE MAIN PHENOLIC COMPONENTS IN COFFEE, ON HEALTH: A COMPREHENSIVE REVIEW OF THE LITERATURE, EUR. J. NUTR, 56, PP. 2215-2244, (2017); SAHEBKAR A., PIRRO M., BANACH M., MIKHAILIDIS D.P., ATKIN S.L., CICERO A.F.G., LIPID-LOWERING ACTIVITY OF ARTICHOKE EXTRACTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, CRIT. REV. FOOD SCI. NUTR, 58, PP. 2549-2556, (2018); LIU L., YEH Y.Y., S-ALK(EN)YL CYSTEINES OF GARLIC INHIBIT CHOLESTEROL SYNTHESIS BY DEACTIVATING HMG-COA REDUCTASE IN CULTURED RAT HEPATOCYTES, J. NUTR, 132, PP. 1129-1134, (2002); RAI S.K., SHARMA M., TIWARI M., INHIBITORY EFFECT OF NOVEL DIALLYLDISULFIDE ANALOGS ON HMG-COA REDUCTASE EXPRESSION IN HYPERCHOLESTEROLEMIC RATS: CREB AS A POTENTIAL UPSTREAM TARGET, LIFE SCI, 85, PP. 211-219, (2009); SOBENIN I.A., ANDRIANOVA I.V., DEMIDOVA O.N., GORCHAKOVA T., OREKHOV A.N., LIPID-LOWERING EFFECTS OF TIME-RELEASED GARLIC POWDER TABLETS IN DOUBLE-BLINDED PLACEBO-CONTROLLED RANDOMIZED STUDY, J. ATHEROSCLER. THROMB, 15, PP. 334-338, (2008); RIED K., TOBEN C., FAKLER P., EFFECT OF GARLIC ON SERUM LIPIDS: AN UPDATED META-ANALYSIS, NUTR. REV, 71, PP. 282-299, (2013); CHOI H.D., YOUN Y.K., SHIN W.G., POSITIVE EFFECTS OF ASTAXANTHIN ON LIPID PROFILES AND OXIDATIVE STRESS IN OVERWEIGHT SUBJECTS, PLANT FOODS HUM. NUTR, 66, PP. 363-369, (2011); KISHIMOTO Y., YOSHIDA H., KONDO K., POTENTIAL ANTI-ATHEROSCLEROTIC PROPERTIES OF ASTAXANTHIN, MAR. DRUGS, 14, (2016); URSONIU S., SAHEBKAR A., SERBAN M.C., BANACH M., LIPID PROFILE AND GLUCOSE CHANGES AFTER SUPPLEMENTATION WITH ASTAXANTHIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCH. MED. SCI, 11, PP. 253-266, (2015); KLEIN G., KIM J., HIMMELDIRK K., CAO Y., CHEN X., ANTIDIABETES AND ANTI-OBESITY ACTIVITY OF LAGERSTROEMIA SPECIOSA, EVID.-BASED COMPLEMENT. ALTERN. MED, 4, PP. 401-407, (2007); STOHS S.J., MILLER H., KAATS G.R., A REVIEW OF THE EFFICACY AND SAFETY OF BANABA (LAGERSTROEMIA SPECIOSA L.) AND COROSOLIC ACID, PHYTOTHER. RES, 26, PP. 317-324, (2012); SAUMYA S.M., BASHA P.M., ANTIOXIDANT EFFECT OF LAGERSTROEMIA SPECIOSA PERS (BANABA) LEAF EXTRACT IN STREPTOZOTOCIN-INDUCED DIABETIC MICE, INDIAN J. EXP. BIOL, 49, PP. 125-131, (2011); FUKUSHIMA M., MATSUYAMA F., UEDA N., EGAWA K., TAKEMOTO J., KAJIMOTO Y., YONAHA N., MIURA T., KANEKO T., NISHI Y., ET AL., EFFECT OF COROSOLIC ACID ON POSTCHALLENGE PLASMA GLUCOSE LEVELS, DIABETES RES. CLIN. PRACT, 73, PP. 174-177, (2006); SHIN S.K., HA T.Y., MCGREGOR R.A., CHOI M.S., LONG-TERM CURCUMIN ADMINISTRATION PROTECTS AGAINST ATHEROSCLEROSIS VIA HEPATIC REGULATION OF LIPOPROTEIN CHOLESTEROL METABOLISM, MOL. NUTR. FOOD RES, 55, PP. 1829-1840, (2011); SHAO W., YU Z., CHIANG Y., YANG Y., CHAI T., FOLTZ W., LU H., FANTUS I.G., JIN T., CURCUMIN PREVENTS HIGH FAT DIET INDUCED INSULIN RESISTANCE AND OBESITY VIA ATTENUATING LIPOGENESIS IN LIVER AND INFLAMMATORY PATHWAY IN ADIPOCYTES, PLOS ONE, 7, (2012); KIM M., KIM Y., HYPOCHOLESTEROLEMIC EFFECTS OF CURCUMIN VIA UP-REGULATION OF CHOLESTEROL 7A-HYDROXYLASE IN RATS FED A HIGH FAT DIET, NUTR. RES. PRACT, 4, PP. 191-195, (2010); EJAZ A., WU D., KWAN P., MEYDANI M., CURCUMIN INHIBITS ADIPOGENESIS IN 3T3-L1 ADIPOCYTES AND ANGIOGENESIS AND OBESITY IN C57/BL MICE, J. NUTR, 139, PP. 919-925, (2009); PRAKASH U.N., SRINIVASAN K., FAT DIGESTION AND ABSORPTION IN SPICE-PRETREATED RATS, J. SCI. FOOD AGRIC, 92, PP. 503-510, (2012); SAHEBKAR A., A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS INVESTIGATING THE EFFECTS OF CURCUMIN ON BLOOD LIPID LEVELS, CLIN. NUTR, 33, PP. 406-414, (2014); YANG Y.S., SU Y.F., YANG H.W., LEE Y.H., CHOU J.I., UENG K.C., LIPID-LOWERING EFFECTS OF CURCUMIN IN PATIENTS WITH METABOLIC SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, PHYTOTHER. RES, 28, PP. 1770-1777, (2014); CUI J., HUANG L., ZHAO A., LEW J.L., YU J., SAHOO S., MEINKE P.T., ROYO I., PELAEZ F., WRIGHT S.D., GUGGULSTERONE IS A FARNESOID X RECEPTOR ANTAGONIST IN COACTIVATOR ASSOCIATION ASSAYS BUT ACTS TO ENHANCE TRANSCRIPTION OF BILE SALT EXPORT PUMP, J. BIOL. CHEM, 278, PP. 10214-10220, (2003); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., CUCCHIARA A.J., DERMARDEROSIAN A.H., CIRIGLIANO M.D., RADER D.J., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); NOHR L.A., RASMUSSEN L.B., STRAAND J., RESIN FROM THE MUKUL MYRRH TREE, GUGGUL, CAN IT BE USED FOR TREATING HYPERCHOLESTEROLEMIA? A RANDOMIZED, CONTROLLED STUDY, COMPLEMENT. THER. MED, 17, PP. 16-22, (2009); SHIMIZU M., HASHIGUCHI M., SHIGA T., TAMURA H.O., MOCHIZUKI M., META-ANALYSIS: EFFECTS OF PROBIOTIC SUPPLEMENTATION ON LIPID PROFILES IN NORMAL TO MILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, PLOS ONE, 10, (2015); BEGLEY M., HILL C., GAHAN C.G., BILE SALT HYDROLASE ACTIVITY IN PROBIOTICS, APPL. ENVIRON. MICROBIOL, 72, PP. 1729-1738, (2006); ANDRADE S., BORGES N., EFFECT OF FERMENTED MILK CONTAINING LACTOBACILLUS ACIDOPHILUS AND BIFIDOBACTERIUM LONGUM ON PLASMA LIPIDS OF WOMEN WITH NORMAL OR MODERATELY ELEVATED CHOLESTEROL, J. DAIRY RES, 76, PP. 469-474, (2009); LEE J.H., SULLIVAN D.J., GENOMIC INSIGHTS INTO BIFIDOBACTERIA, MICROBIOL. MOL. BIOL. REV, 74, PP. 378-416, (2010); KUMAR M., NAGPAL R., KUMAR R., HEMALATHA R., VERMA V., KUMAR A., CHAKRABORTY C., SINGH B., MAROTTA F., JAIN S., ET AL., CHOLESTEROL-LOWERING PROBIOTICS AS POTENTIAL BIOTHERAPEUTICS FOR METABOLIC DISEASES, EXP. DIABETES RES, 2012, (2012); SUN J., BUYS N., EFFECTS OF PROBIOTICS CONSUMPTION ON LOWERING LIPIDS AND CVD RISK FACTORS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ANN. MED, 47, PP. 430-440, (2015); KHAN N., MUKHTAR H., TEA AND HEALTH: STUDIES IN HUMANS, CURR. PHARM. DES, 19, PP. 6141-6147, (2013); VERMEER M.A., MULDER T.P., MOLHUIZEN H.O., THEAFLAVINS FROM BLACK TEA, ESPECIALLY THEAFLAVIN-3-GALLATE, REDUCE THE INCORPORATION OF CHOLESTEROL INTO MIXED MICELLES, J. AGRIC. FOOD CHEM, 56, PP. 12031-12036, (2008); ERBA D., RISO P., BORDONI A., FOTI P., BIAGI P.L., TESTOLIN G., EFFECTIVENESS OF MODERATE GREEN TEA CONSUMPTION ON ANTIOXIDATIVE STATUS AND PLASMA LIPID PROFILE IN HUMANS, J. NUTR. BIOCHEM, 16, PP. 144-149, (2005); MARON D.J., LU G.P., CAI N.S., WU Z.G., LI Y.H., CHEN H., ZHU J.Q., JIN X.J., WOUTERS B.C., ZHAO J., CHOLESTEROL-LOWERING EFFECT OF A THEAFLAVIN-ENRICHED GREEN TEA EXTRACT: A RANDOMIZED CONTROLLED TRIAL, ARCH. INTERN. MED, 163, PP. 1448-1453, (2003); SAMAVAT H., NEWMAN A.R., WANG R., YUAN J.M., WU A.H., KURZER M.S., EFFECTS OF GREEN TEA CATECHIN EXTRACT ON SERUM LIPIDS IN POSTMENOPAUSAL WOMEN: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL, AM. J. CLIN. NUTR, 104, PP. 1671-1682, (2016); DEVARAJ S., VEGA-LOPEZ S., KAUL N., SCHONLAU F., ROHDEWALD P., JIALAL I., SUPPLEMENTATION WITH A PINE BARK EXTRACT RICH IN POLYPHENOLS INCREASES PLASMA ANTIOXIDANT CAPACITY AND ALTERS THE PLASMA LIPOPROTEIN PROFILE, LIPIDS, 37, PP. 931-934, (2002); VALLS R.M., LLAURADO E., FERNANDEZ-CASTILLEJO S., PUIGGROS F., SOLA R., AROLA L., PEDRET A., EFFECTS OF LOW MOLECULAR WEIGHT PROCYANIDIN RICH EXTRACT FROM FRENCH MARITIME PINE BARK ON CARDIOVASCULAR DISEASE RISK FACTORS IN STAGE-1 HYPERTENSIVE SUBJECTS: RANDOMIZED, DOUBLE-BLIND, CROSSOVER, PLACEBO-CONTROLLED INTERVENTION TRIAL, PHYTOMEDICINE, 23, PP. 1451-1461, (2016); BONFIGLI A.R., PROTIC O., OLIVIERI F., MONTESANTO A., MALATESTA G., DI PILLO R., ANTONICELLI R., EFFECTS OF A NOVEL NUTRACEUTICAL COMBINATION (BRUMECHOL™) IN SUBJECTS WITH MILD HYPERCHOLESTEROLEMIA: STUDY PROTOCOL OF A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL, TRIALS, 21, (2020); NAIR B., CLINICAL TRIAL DESIGNS, INDIAN DERMATOL. ONLINE J, 10, PP. 193-201, (2019); SANTANA-GALVEZ J., CISNEROS-ZEVALLOS L., JACOBO-VELAZQUEZ D.A., A PRACTICAL GUIDE FOR DESIGNING EFFECTIVE NUTRACEUTICAL COMBINATIONS IN THE FORM OF FOODS, BEVERAGES, AND DIETARY SUPPLEMENTS AGAINST CHRONIC DEGENERATIVE DISEASES, TRENDS FOOD SCI. TECHNOL, 88, PP. 179-193, (2019); NASRI H., BARADARAN A., SHIRZAD H., RAFIEIAN-KOPAEI M., NEW CONCEPTS IN NUTRACEUTICALS AS ALTERNATIVE FOR PHARMACEUTICALS, INT. J. PREV. MED, 5, PP. 1487-1499, (2014); SONG J., LUO J., MA Z., SUN Q., WU C., LI X., QUALITY AND AUTHENTICITY CONTROL OF FUNCTIONAL RED YEAST RICE—A REVIEW, MOLECULES, 24, (2019); HEINZ T., SCHUCHARDT J.P., MOLLER K., HADJI P., HAHN A., LOW DAILY DOSE OF 3 MG MONACOLIN K FROM RYR REDUCES THE CONCENTRATION OF LDL-C IN A RANDOMIZED, PLACEBO-CONTROLLED INTERVENTION, NUTR. RES, 36, PP. 1162-1170, (2016); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR. J. ENDOCRINOL, 153, PP. 679-686, (2005); FARKOUH A., BAUMGARTEL C., MINI-REVIEW: MEDICATION SAFETY OF RED YEAST RICE PRODUCTS, INT. J. GEN. MED, 12, PP. 167-171, (2019); PHILIBERT C., BRES V., JEAN-PASTOR M.J., GUY C., LEBRUN-VIGNES B., ROBIN P., PINZANI V., HILLAIRE-BUYS D., RED YEAST-RICE-INDUCED MUSCULAR INJURIES: ANALYSIS OF FRENCH PHARMACOVIGILANCE DATABASE AND LITERATURE REVIEW, THERAPIE, (2016); ONG Y.C., AZIZ Z., SYSTEMATIC REVIEW OF RED YEAST RICE COMPARED WITH SIMVASTATIN IN DYSLIPIDAEMIA, J. CLIN. PHARM. THER, 41, PP. 170-179, (2016)","O. PROTIC; CARDIOLOGY UNIT, IRCCS INRCA, ANCONA, 60129, ITALY; EMAIL: O.PROTIC@INRCA.IT","MDPI","ENGLISH","NUTRIENTS","ARTICLE","ISI","2-S2.0-85114484226","NUTRIENTS","SCIENTIFIC DIRECTION","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"PROTIC O, 2021, NUTRIENTS","PROTIC O, 2021, NUTRIENTS"
"CHO K;NAM H;BAEK S;KANG D;NA H;KOMATSU T;UEHARA Y","CHO, KYUNG-HYUN (7403956966); NAM, HYO-SEON (57301198400); BAEK, SEUNG-HEE (58120142000); KANG, DAE-JIN (57301198300); NA, HYEJEE (57880309200); KOMATSU, TOMOHIRO (36113558800); UEHARA, YOSHINARI (7202555528)","BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGHDENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED PLACEBOCONTROLLED AND DOUBLEBLINDED TRIAL WITH HEALTHY JAPANESE",2023,"INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES","24","",12,"10.3390/ijms24065185","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN;CENTER FOR PREVENTIVE, ANTI-AGING AND REGENERATIVE MEDICINE, FUKUOKA UNIVERSITY HOSPITAL, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN, FACULTY OF SPORTS AND HEALTH SCIENCE, FUKUOKA UNIVERSITY, 8-19-1 NANAKUMA, JOHNAN-KU, FUKUOKA, 814-0180, JAPAN","THIS STUDY EVALUATED THE EFFICACY AND SAFETY OF 20 MG OF CUBAN POLICOSANOL IN BLOOD PRESSURE (BP) AND LIPID/LIPOPROTEIN PARAMETERS OF HEALTHY JAPANESE SUBJECTS VIA A PLACEBO-CONTROLLED, RANDOMIZED, AND DOUBLE-BLINDED HUMAN TRIAL. AFTER 12 WEEKS OF CONSUMPTION, THE POLICOSANOL GROUP SHOWED SIGNIFICANTLY LOWER BP, GLYCATED HEMOGLOBIN (HBA1C), AND BLOOD UREA NITROGEN (BUN) LEVELS. THE POLICOSANOL GROUP ALSO SHOWED LOWER ASPARTATE AMINOTRANSFERASE (AST), ALANINE AMINOTRANSFERASE (ALT), AND Γ-GLUTAMYL TRANSFERASE (Γ-GTP) LEVELS AT WEEK 12 THAN THOSE AT WEEK 0: A DECREASE OF UP TO 9% (P < 0.05), 17% (P < 0.05), AND 15% (P < 0.05) WAS OBSERVED, RESPECTIVELY. THE POLICOSANOL GROUP SHOWED SIGNIFICANTLY HIGHER HDL-C LEVEL AND HDL-C/TC (%), APPROXIMATELY 9.5% (P < 0.001) AND 7.2% (P = 0.003), RESPECTIVELY, THAN THE PLACEBO GROUP AND A DIFFERENCE IN THE POINT OF TIME AND GROUP INTERACTION (P < 0.001). IN LIPOPROTEIN ANALYSIS, THE POLICOSANOL GROUP SHOWED A DECREASE IN OXIDATION AND GLYCATION EXTENT IN VLDL AND LDL WITH AN IMPROVEMENT OF PARTICLE SHAPE AND MORPHOLOGY AFTER 12 WEEKS. HDL FROM THE POLICOSANOL GROUP SHOWED IN VITRO STRONGER ANTIOXIDANT AND IN VIVO ANTI-INFLAMMATORY ABILITIES. IN CONCLUSION, 12 WEEKS OF CUBAN POLICOSANOLCONSUMPTION IN JAPANESE SUBJECTS SHOWED SIGNIFICANT IMPROVEMENT IN BLOOD PRESSURE, LIPID PROFILES, HEPATIC FUNCTIONS, AND HBA1C WITH ENHANCEMENT OF HDL FUNCTIONALITIES. © 2023 BY THE AUTHORS.","APOLIPOPROTEIN A-I; GLYCATION; HDL FUNCTIONALITY; HIGH-DENSITY LIPOPROTEINS (HDL); HUMAN TRIAL; LOW-DENSITY LIPOPROTEINS (LDL); OXIDATION; POLICOSANOL; ZEBRAFISH","ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; EAST ASIAN PEOPLE; FATTY ALCOHOLS; GLYCATED HEMOGLOBIN; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLYCATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; POLICOSANOL; RAYDEL; VERY LOW DENSITY LIPOPROTEIN; FATTY ALCOHOL; GLYCATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; POLICOSANOL; ADULT; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBRYO; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; JAPANESE (PEOPLE); LIPID FINGERPRINTING; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MALE; NONHUMAN; NORMAL HUMAN; OXIDATION; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; UREA NITROGEN BLOOD LEVEL; ZEBRA FISH; BLOOD PRESSURE","","","ARRUZAZABALA M., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES, 69, PP. 321-327, (1993); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT. J. CLIN. PHARMACOL. THER, 34, PP. 134-137, (1996); VALDES S., ARRUZAZABALA M., FERNANDEZ L., MAS R., CARBAJAL D., ALEMAN C., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES, 16, PP. 67-72, (1996); LEE H.-G., WOO S.-Y., AHN H.-J., YANG J.-Y., LEE M.-J., KIM H.-Y., SONG S.-Y., LEE J.-H., SEO W.-D., COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT (AVENA SATIVA L.) CULTIVARS AND SCREENING FOR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION, PLANTS, 11, (2022); MUTHUSAMY M., KIM J.H., KIM S.H., KIM J.Y., HEO J.W., LEE H., LEE K.-S., SEO W.D., PARK S., KIM J.A., CHANGES IN BENEFICIAL C-GLYCOSYLFLAVONES AND POLICOSANOL CONTENT IN WHEAT AND BARLEY SPROUTS SUBJECTED TO DIFFERENTIAL LED LIGHT CONDITIONS, PLANTS, 9, (2020); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ZHAO M., GAN J., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT. MED. THER, 21, (2021); VENTURELLI A., BRIGHENTI V., MASCOLO D., PELLATI F., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL, 172, PP. 200-205, (2019); WONG W.-T., ISMAIL M., TOHIT E.R.M., ABDULLAH R., ZHANG Y.-D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVID.-BASED COMPLEMENT. ALTERN. MED, 2016, (2016); LI C., DING Y., SI Q., LI K., XU K., MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY PATIENTS WITH DYSLIPIDEMIA, J. INT. MED. RES, 48, (2020); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT, PHYTOTHER. RES, 27, PP. 264-271, (2013); PARK H.-J., YADAV D., JEONG D.-J., KIM S.-J., BAE M.-A., KIM J.-R., CHO K.-H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED, 45, PP. 89-97, (2019); KIM J.-H., LIM D.-K., SUH Y.-H., CHANG K.-A., LONG-TERM TREATMENT OF CUBAN POLICOSANOL ATTENUATES ABNORMAL OXIDATIVE STRESS AND INFLAMMATORY RESPONSE VIA AMYLOID PLAQUES REDUCTION IN 5XFAD MICE, ANTIOXIDANTS, 10, (2021); SAFARI S., MIRAZI N., AHMADI N., ASADBEGI M., NOURIAN A., GHADERI S., RASHNO M., KOMAKI A., THE PROTECTIVE EFFECTS OF POLICOSANOL ON LEARNING AND MEMORY IMPAIRMENTS IN A MALE RAT MODEL OF ALZHEIMER’S DISEASE, MOL. NEUROBIOL, (2023); LIM S.-M., YOO J.-A., LEE E.-Y., CHO K.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); KIM J.-Y., KIM S.-M., KIM S.-J., LEE E.-Y., KIM J.-R., CHO K.-H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED, 39, PP. 889-899, (2017); KIM S.-J., YADAV D., PARK H.-J., KIM J.-R., CHO K.-H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); CHO K.-H., KIM S.-J., YADAV D., KIM J.-Y., KIM J.-R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED. CELL. LONGEV, 2018, (2018); HUI N., BARTER P.J., ONG K.-L., RYE K.-A., ALTERED HDL METABOLISM IN METABOLIC DISORDERS: INSIGHTS INTO THE THERAPEUTIC POTENTIAL OF HDL, CLIN. SCI, 133, PP. 2221-2235, (2019); DAVIDSON M.H., UPDATE ON CETP INHIBITION, J. CLIN. LIPIDOL, 4, PP. 394-398, (2010); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); YOKOYAMA S., UNIQUE FEATURES OF HIGH-DENSITY LIPOPROTEINS IN THE JAPANESE: IN POPULATION AND IN GENETIC FACTORS, NUTRIENTS, 7, PP. 2359-2381, (2015); CARROLL M.D., LACHER D.A., SORLIE P.D., CLEEMAN J.I., GORDON D.J., WOLZ M., GRUNDY S.M., JOHNSON C.L., TRENDS IN SERUM LIPIDS AND LIPOPROTEINS OF ADULTS, 1960–2002, J. AM. MED. ASSOC, 294, PP. 1773-1781, (2005); ARAI H., YAMAMOTO A., MATSUZAWA Y., SAITO Y., YAMADA N., OIKAWA S., MABUCHI H., TERAMOTO T., SASAKI J., NAKAYA N., SERUM LIPID SURVEY AND ITS RECENT TREND IN THE GENERAL JAPANESE POPULATION IN 2000, J. ATHEROSCLER. THROMB, 12, PP. 98-106, (2005); CHOI S.-J., PARK S.-H., PARK H.-Y., INCREASED PREVALENCE OF LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS IN KOREAN ADULTS: ANALYSIS OF THE THREE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEYS (KNHANES 1998–2005), OSONG PUBLIC HEALTH RES. PERSPECT, 2, PP. 94-103, (2011); KIM S.M., HAN J.H., PARK H.S., PREVALENCE OF LOW HDL-CHOLESTEROL LEVELS AND ASSOCIATED FACTORS AMONG KOREANS, CIRC. J, 70, PP. 820-826, (2006); WU Y., LI Y., ZHENG L., WANG P., WU Y., GONG Z., THE NEUROTOXICITY OF NΕ-(CARBOXYMETHYL) LYSINE IN FOOD PROCESSING BY A STUDY BASED ON ANIMAL AND ORGANOTYPIC CELL CULTURE, ECOTOXICOL. ENVIRON. SAF, 190, (2020); BASTA G., SCHMIDT A.M., DE CATERINA R., ADVANCED GLYCATION END PRODUCTS AND VASCULAR INFLAMMATION: IMPLICATIONS FOR ACCELERATED ATHEROSCLEROSIS IN DIABETES, CARDIOVASC. RES, 63, PP. 582-592, (2004); DEVARAJ S., DASU M.R., ROCKWOOD J., WINTER W., GRIFFEN S.C., JIALAL I., INCREASED TOLL-LIKE RECEPTOR (TLR) 2 AND TLR4 EXPRESSION IN MONOCYTES FROM PATIENTS WITH TYPE 1 DIABETES: FURTHER EVIDENCE OF A PROINFLAMMATORY STATE, J. CLIN. ENDOCRINOL. METAB, 93, PP. 578-583, (2008); DASU M.R., DEVARAJ S., PARK S., JIALAL I., INCREASED TOLL-LIKE RECEPTOR (TLR) ACTIVATION AND TLR LIGANDS IN RECENTLY DIAGNOSED TYPE 2 DIABETIC SUBJECTS, DIABETES CARE, 33, PP. 861-868, (2010); NOVOA B., BOWMAN T., ZON L., FIGUERAS A., LPS RESPONSE AND TOLERANCE IN THE ZEBRAFISH (DANIO RERIO), FISH SHELLFISH. IMMUNOL, 26, PP. 326-331, (2009); TREDE N.S., ZAPATA A., ZON L.I., FISHING FOR LYMPHOID GENES, TRENDS IMMUNOL, 22, PP. 302-307, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, J. AM. MED. ASSOC, 295, PP. 2262-2269, (2006); ILLNAIT J., CASTANO G., ALVAREZ E., FERNANDEZ L., MAS R., MENDOZA S., GAMEZ R., EFFECTS OF POLICOSANOL (10 MG/D) VERSUS ASPIRIN (100 MG/D) IN PATIENTS WITH INTERMITTENT CLAUDICATION: A 10-WEEK, RANDOMIZED, COMPARATIVE STUDY, ANGIOLOGY, 59, PP. 269-277, (2008); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN. DRUG INVESTIG, 23, PP. 639-650, (2003); GUO Y.L., XU R.X., ZHU C.G., WU N.Q., CUI Z.P., LI J.J., POLICOSANOL ATTENUATES STATIN-INDUCED INCREASES IN SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WHEN COMBINED WITH ATORVASTATIN, EVID. BASED COMPLEMENT. ALTERN. MED, 2014, (2014); XU K., LIU X., LI Y., WANG Y., ZANG H., GUO L., WANG Y., ZHAO W., WANG X., HAN Y., SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ON-TREATMENT PLATELET REACTIVITY AFTER DRUG-ELUTING STENT IMPLANTATION: TWO-YEAR FOLLOW-UP RESULTS, CARDIOVASC. THER, 34, PP. 337-342, (2016); OSADNIK T., GOLAWSKI M., LEWANDOWSKI P., MORZE J., OSADNIK K., PAWLAS N., LEJAWA M., JAKUBIAK G.K., MAZUR A., SCHWINGSCHACKL L., A NETWORK META-ANALYSIS ON THE COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE IN ADULTS, PHARMACOL. RES, 183, (2022); VASDEV S., GILL V., SINGAL P., ROLE OF ADVANCED GLYCATION END PRODUCTS IN HYPERTENSION AND ATHEROSCLEROSIS: THERAPEUTIC IMPLICATIONS, CELL BIOCHEM. BIOPHYS, 49, PP. 48-63, (2007); CHO K.-H., BAE M., KIM J.-R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC. THER, 2019, (2019); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); GAENS K.H., NIESSEN P.M., RENSEN S.S., BUURMAN W.A., GREVE J.W.M., DRIESSEN A., WOLFS M.G., HOFKER M.H., BLOEMEN J.G., DEJONG C.H., ENDOGENOUS FORMATION OF NΕ-(CARBOXYMETHYL) LYSINE IS INCREASED IN FATTY LIVERS AND INDUCES INFLAMMATORY MARKERS IN AN IN VITRO MODEL OF HEPATIC STEATOSIS, J. HEPATOL, 56, PP. 647-655, (2012); YAGMUR E., TACKE F., WEISS C., LAHME B., MANNS M.P., KIEFER P., TRAUTWEIN C., GRESSNER A.M., ELEVATION OF NΕ-(CARBOXYMETHYL) LYSINE-MODIFIED ADVANCED GLYCATION END PRODUCTS IN CHRONIC LIVER DISEASE IS AN INDICATOR OF LIVER CIRRHOSIS, CLIN. BIOCHEM, 39, PP. 39-45, (2006); CHO K.-H., KIM J.-E., NAM H.-S., KANG D.-J., NA H.-J., ANTI-INFLAMMATORY ACTIVITY OF CIGB-258 AGAINST ACUTE TOXICITY OF CARBOXYMETHYLLYSINE IN PARALYZED ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS STABILITY AND FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI, 24, (2023); CHO K.H., THE CURRENT STATUS OF RESEARCH ON HIGH-DENSITY LIPOPROTEINS (HDL): A PARADIGM SHIFT FROM HDL QUANTITY TO HDL QUALITY AND HDL FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS” VERSUS GENUINE POLICOSANOL, REV. CENIC CIENC. QUÍMICAS, 38, PP. 207-213, (2007); CHO K.-H., NAM H.-S., KANG D.-J., ZEE S., PARK M.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN (HDL) QUANTITY AND QUALITY BY REGULAR AND HABITUAL EXERCISE IN MIDDLE-AGED WOMEN WITH IMPROVEMENTS IN LIPID AND APOLIPOPROTEIN PROFILES: LARGER PARTICLE SIZE AND HIGHER ANTIOXIDANT ABILITY OF HDL, INT. J. MOL. SCI, 24, (2023); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVESTIG, 34, PP. 1345-1353, (1955); MARKWELL M.A.K., HAAS S.M., BIEBER L., TOLBERT N., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM, 87, PP. 206-210, (1978); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); NOBLE R.P., ELECTROPHORETIC SEPARATION OF PLASMA LIPOPROTEINS IN AGAROSE GEL, J. LIPID RES, 9, PP. 693-700, (1968); CHO K.-H., KIM J.-R., LEE I.-C., KWON H.-J., NATIVE HIGH-DENSITY LIPOPROTEINS (HDL) WITH HIGHER PARAOXONASE EXERTS A POTENT ANTIVIRAL EFFECT AGAINST SARS-COV-2 (COVID-19), WHILE GLYCATED HDL LOST THE ANTIVIRAL ACTIVITY, ANTIOXIDANTS, 10, (2021); BLATTER GARIN M.-C., MOREN X., JAMES R.W., PARAOXONASE-1 AND SERUM CONCENTRATIONS OF HDL-CHOLESTEROL AND APOA-I, J. LIPID RES, 47, PP. 515-520, (2006); BENZIE I.F., STRAIN J., FERRIC REDUCING/ANTIOXIDANT POWER ASSAY: DIRECT MEASURE OF TOTAL ANTIOXIDANT ACTIVITY OF BIOLOGICAL FLUIDS AND MODIFIED VERSION FOR SIMULTANEOUS MEASUREMENT OF TOTAL ANTIOXIDANT POWER AND ASCORBIC ACID CONCENTRATION, METHODS ENZYMOL, 299, PP. 15-27, (1999)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","INT. J. MOL. SCI.","ARTICLE","ISI","2-S2.0-85151109183","INT J MOL SCI","GYEONGSAN;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;FUKUOKA UNIVERSITY HOSPITAL;FUKUOKA UNIVERSITY HOSPITAL","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2023, INT J MOL SCI","CHO K-H, 2023, INT J MOL SCI"
"PRAKANSAMUT N;ADULPADUNGSAK K;SONWAI S;ARYUSUK K;LILITCHAN S","PRAKANSAMUT, NARUSORN (58857880400); ADULPADUNGSAK, KANNIKAR (58857689100); SONWAI, SOPARK (14819645000); ARYUSUK, KORNKANOK (7801495708); LILITCHAN, SUPATHRA (20436041500)","APPLICATION OF FUNCTIONAL OIL BLENDBASED OLEOGELS AS NOVEL STRUCTURED OIL ALTERNATIVES IN CHOCOLATE SPREAD",2024,"LWT","203","",0,"10.1016/j.lwt.2024.116322","DEPARTMENT OF NUTRITION, FACULTY OF PUBLIC HEALTH, MAHIDOL UNIVERSITY, BANGKOK, 10400, THAILAND;DEPARTMENT OF NUTRITION, FACULTY OF PUBLIC HEALTH, MAHIDOL UNIVERSITY, BANGKOK, 10400, THAILAND;DEPARTMENT OF FOOD TECHNOLOGY, FACULTY OF ENGINEERING AND INDUSTRIAL TECHNOLOGY, SILPAKORN UNIVERSITY, NAKHONPATHOM, 73000, THAILAND;DIVISION OF BIOCHEMICAL TECHNOLOGY, SCHOOL OF BIORESOURCES AND TECHNOLOGY, KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT), BANGKOK, 10150, THAILAND;DEPARTMENT OF NUTRITION, FACULTY OF PUBLIC HEALTH, MAHIDOL UNIVERSITY, BANGKOK, 10400, THAILAND","THE OBJECTIVE OF THIS STUDY WAS TO EVALUATE THE EFFECTIVENESS OF FUNCTIONAL BLENDED OIL-BASED OLEOGELS AS A SUBSTITUTE FOR STRUCTURED OILS IN CHOCOLATE SPREADS. THE BLENDED OIL CONSISTED OF RICE BRAN OIL, CAMELLIA OLEIFERA SEED OIL, AND PERILLA SEED OIL AT A WEIGHT RATIO OF 80 G:10 G: 10 G, WITH 2 G OF FISH OIL ADDED PER 100 G OF THE BLEND. OLEOGELS WERE THEN PREPARED FROM THE BLENDED OIL USING VARIOUS OLEOGELATORS, INCLUDING MONOGLYCERIDE, POLICOSANOL AND RICE BRAN WAX. THE PHYSICOCHEMICAL PROPERTIES AND LIPID QUALITY INDICES OF SELECTED BLENDED OIL-BASED OLEOGELS (OG) AND OLEOGEL CHOCOLATE SPREADS (OG-CS) WERE DETERMINED. THE FIRMNESS OF ALL OLEOGEL SAMPLES WAS IN THE RANGE OF 0.12–1.25 N AND THE SPREADABILITY WAS IN THE RANGE OF 0.29–4.30 N.S. MONOGLYCERIDE OLEOGEL HAD SIGNIFICANTLY HIGHER LEVELS OF FIRMNESS AND SPREADABILITY THAN POLICOSANOL AND RICE BRAN WAX OLEOGELS. THE PEROXIDE VALUE OF ALL OG-CS SAMPLES INCREASED ONLY SLIGHTLY DURING STORAGE AT 6–7 °C FOR 60 DAYS. THEREFORE, BLENDED OIL-BASED OLEOGELS CAN BE USED AS NOVEL STRUCTURED OIL ALTERNATIVES IN CHOCOLATE SPREAD. © 2024 THE AUTHORS","BLENDED OIL; FATTY ACIDS; MONOGLYCERIDE; OLEOGEL; OLEOGELATOR","PHYSICOCHEMICAL PROPERTIES; BLENDED OIL; MONOGLYCERIDES; OIL BASED; OLEOGEL; OLEOGELATOR; POLICOSANOLS; RICE BRAN OIL; RICE BRAN WAX; SEED OIL; SPREADABILITY; FATTY ACIDS","","","ADULPADUNGSAK K., LILITCHAN S., ARYUSUK K., THE PHYSICAL AND CHEMICAL PROPERTIES OF POLICOSANOL-BASED ORGANOGEL SHORTENING FOR REPLACING SATURATED AD TRANS-FAT IN COOKIES, INTERNATIONAL JOURNAL OF SCIENCE, 17, 1, PP. 1-13, (2020); OFFICIAL METHODS OF ANALYSIS OF AOAC, (2000); BASCUAS S., ESPERT M., LLORCA E., QUILES A., SALVADOR A., HERNANDO I., STRUCTURAL AND SENSORY STUDIES ON CHOCOLATE SPREADS WITH HYDROCOLLOID-BASED OLEOGELS AS A FAT ALTERNATIVE, LWT-FOOD SCIENCE & TECHNOLOGY, 135, (2021); BASU S., SHIVHARE U.S., RHEOLOGICAL, TEXTURAL, MICRO-STRUCTURAL AND SENSORY PROPERTIES OF MANGO JAM, JOURNAL OF FOOD ENGINEERING, 100, 2, PP. 357-365, (2010); BIN SINTANG M.D., DANTHINE S., BROWN A., DE WALLE D.V., PATEL A.R., TAVERNIER I., ET AL., PHYTOSTEROLS-INDUCED VISCOELASTICITY OF OLEOGELS PREPARED BY USING MONOGLYCERIDES, FOOD RESEARCH INTERNATIONAL, 100, PP. 832-840, (2017); BOATENG L., ANSONG R., OWUSU W., STEINER-ASIEDU M., COCONUT OIL AND PALM OIL'S ROLE IN NUTRITION, HEALTH AND NATIONAL DEVELOPMENT: A REVIEW, GHANA MEDICAL JOURNAL, 50, 3, PP. 189-196, (2016); CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, 23, PP. 12143-12148, (2010); CHOUDHARY M., GROVER K., KAUR G., DEVELOPMENT OF RICE BRAN OIL BLENDS FOR QUALITY IMPROVEMENT, FOOD CHEMISTRY, 173, PP. 770-777, (2015); CO E.D., MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 89, 5, PP. 749-780, (2012); DA PIEVE S., CALLIGARIS S., CO E., NICOLI M.C., MARANGONI A.G., SHEAR NANOSTRUCTURING OF MONOGLYCERIDE ORGANOGELS, FOOD BIOPHYSICS, 5, 3, PP. 211-217, (2010); DHYANI A., CHOPRA R., GARG M., A REVIEW ON BLENDING OF OILS AND THEIR FUNCTIONAL AND NUTRITIONAL BENEFITS, CHEMICAL SCIENCE REVIEW AND LETTERS, 7, 27, PP. 840-847, (2018); DOAN C.D., TAVERNIER I., OKURO P.K., DEWETTINCK K., INTERNAL AND EXTERNAL FACTORS AFFECTING THE CRYSTALLIZATION, GELATION AND APPLICABILITY OF WAX-BASED OLEOGELS IN FOOD INDUSTRY, INNOVATIVE FOOD SCIENCE AND EMERGING TECHNOLOGIES, 45, PP. 42-52, (2018); DOAN C.D., VAN DE WALLE D., DEWETTINCK K., PATEL A.R., EVALUATING THE OIL-GELLING PROPERTIES OF NATURAL WAXES IN RICE BRAN OIL: RHEOLOGICAL, THERMAL, AND MICROSTRUCTURAL STUDY, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 92, 6, PP. 801-811, (2015); FAYAZ G., GOLI S.A.H., KADIVAR M., VALOPPI F., BARBA L., CALLIGARIS S., ET AL., POTENTIAL APPLICATION OF POMEGRANATE SEED OIL OLEOGELS BASED ON MONOGLYCERIDES, BEESWAX AND PROPOLIS WAX AS PARTIAL SUBSTITUTES OF PALM OIL IN FUNCTIONAL CHOCOLATE SPREAD, LWT - FOOD SCIENCE AND TECHNOLOGY, 86, PP. 523-529, (2017); FLOTER E., STRUCTURING OILS WITHOUT HIGHLY SATURATED FATS – HOW FAR ARE WE?, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, 9, PP. 983-984, (2012); HOOPER L., MARTIN N., JIMOH O.F., KIRK C., FOSTER E., ABDELHAMID A.S., REDUCTION IN SATURATED FAT INTAKE FOR CARDIOVASCULAR DISEASE, COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 8, 8, (2020); HWANG H.S., FHANER M., WINKLER-MOSER J.K., LIU S.X., OXIDATION OF FISH OIL OLEOGELS FORMED BY NATURAL WAXES IN COMPARISON WITH BULK OIL, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 120, 5, (2018); HWANG H.S., KIM S., SINGH M., WINKLER-MOSER J.K., LIU S.X., ORGANOGEL FORMATION OF SOYBEAN OIL WITH WAXES, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 89, 4, PP. 639-647, (2012); HWANG H.S., SINGH M., WINKLER-MOSER J.K., BAKOTA E.L., LIU S.X., PREPARATION OF MARGARINES FROM ORGANOGELS OF SUNFLOWER WAX AND VEGETABLE OILS, JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 79, 10, PP. C1926-C1932, (2014); IGENBAYEV A., OSPANKULOVA G., AMIRKHANOV S., ALDIYEVA A., TEMIROVA I., AMIRKHANOV K., SUBSTITUTION OF PORK FAT WITH BEESWAX-STRUCTURED OLEOGELS IN SEMI-SMOKED SAUSAGES, APPLIED SCIENCES, 13, 9, (2023); KAEWKOOL P., KITTIRATANAPIBOON K., ARYUSUK K., KRISNANGKURA K., MICRO-REACTOR FOR TRANSESTERIFICATION OF PLANT SEED OILS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 111, 5, PP. 474-480, (2009); KANCHANAMAYOON W., KANENIL W., DETEMINATION OF SOME FATTY ACID IN LOCAL PLANT SEEDS, CHIANG MAI JOURNAL OF SCIENCE, 34, PP. 249-252, (2007); KANELAKI A., ZAMPOUNI K., MOURTZINOS I., KATSANIDIS E., HYDROGELS, OLEOGELS AND BIGELS AS EDIBLE COATINGS OF SARDINE FILLETS AND DELIVERY SYSTEMS OF ROSEMARY EXTRACT, GELS, 8, (2022); KAUSHIK I., ORGANOGELATION: IT'S FOOD APPLICATION, MOJ FOOD PROCESSING & TECHNOLOGY, 4, 2, PP. 66-72, (2017); KESSELMAN E., SHIMONI E., IMAGING OF OIL/MONOGLYCERIDE NETWORKS BY POLARIZING NEAR-FIELD SCANNING OPTICAL MICROSCOPY, FOOD BIOPHYSICS, 2, PP. 117-123, (2007); KRISNANGKURA K., TANCHAROON A., KONKAO C., JEYASHOKE N., AN ALTERNATIVE METHOD FOR THE CALCULATION OF EQUIVALENT CHAIN LENGTH OR CARBON NUMBER OF FATTY ACID METHYL ESTERS IN GAS CHROMATOGRAPHY, JOURNAL OF CHROMATOGRAPHIC SCIENCE, 35, 7, (1997); LI L., LIU G., CORN OIL-BASED OLEOGELS WITH DIFFERENT GELATION MECHANISMS AS NOVEL COCOA BUTTER ALTERNATIVES IN DARK CHOCOLATE, JOURNAL OF FOOD ENGINEERING, 263, PP. 114-122, (2019); LI Y., MA W.J., QI B.K., ROKAYYA S., LI D., WANG J., ET AL., BLENDING OF SOYBEAN OIL WITH SELECTED VEGETABLE OILS: IMPACT ON OXIDATIVE STABILITY AND RADICAL SCAVENGING ACTIVITY, ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 15, 6, PP. 2583-2589, (2014); LOPEZ-MARTINEZ A., CHARO-ALONSO M.A., MARANGONI A.G., TORO-VAZQUEZ J.F., MONOGLYCERIDE ORGANOGELS DEVELOPED IN VEGETABLE OIL WITH AND WITHOUT ETHYLCELLULOSE, FOOD RESEARCH INTERNATIONAL, 72, PP. 37-46, (2015); MALVE H., KERKAR P., MISHRA N., LOKE S., REGE N., MARWAHA-JASPAL A., ET AL., LDL-CHOLESTEROL LOWERING ACTIVITY OF A BLEND OF RICE BRAN OIL AND SAFFLOWER OIL (8:2) IN PATIENTS WITH HYPERLIPIDAEMIA: A PROOF OF CONCEPT, DOUBLE BLIND, CONTROLLED, RANDOMISED PARALLEL GROUP STUDY, JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, 108, 11, PP. 785-788, (2010); MICHA R., MOZAFFARIAN D., SATURATED FAT AND CARDIOMETABOLIC RISK FACTORS, CORONARY HEART DISEASE, STROKE, AND DIABETES: A FRESH LOOK AT THE EVIDENCE, LIPIDS, 45, 10, PP. 893-905, (2010); MOHD ROZALLI N.H., CHIN N.L., YUSOF Y.A., MAHYUDIN N., QUALITY CHANGES OF STABILIZER-FREE NATURAL PEANUT BUTTER DURING STORAGE, JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 53, 1, PP. 694-702, (2016); ORSAVOVA J., MISURCOVA L., AMBROZOVA J.V., VICHA R., MLCEK J., FATTY ACIDS COMPOSITION OF VEGETABLE OILS AND ITS CONTRIBUTION TO DIETARY ENERGY INTAKE AND DEPENDENCE OF CARDIOVASCULAR MORTALITY ON DIETARY INTAKE OF FATTY ACIDS, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 16, 6, PP. 12871-12890, (2015); PAKSERESHT S., TEHRANI M.M., FARHOOSH R., KOOCHEKI A., THE MONOGLYCERIDE OLEOGEL CHARACTERISTICS MODIFIED BY CARNAUBA WAX, LWT-FOOD SCIENCE & TECHNOLOGY, 185, (2023); PALLA C.A., DOMINGUEZ M., CARRIN M.E., AN OVERVIEW OF STRUCTURE ENGINEERING TO TAILOR THE FUNCTIONALITY OF MONOGLYCERIDE OLEOGELS, COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY, 21, 3, PP. 2587-2614, (2022); PEHLIVANOGLU H., DEMIRCI M., TOKER O.S., KONAR N., KARASU S., SAGDIC O., OLEOGELS, A PROMISING STRUCTURED OIL FOR DECREASING SATURATED FATTY ACID CONCENTRATIONS: PRODUCTION AND FOOD-BASED APPLICATIONS, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 58, 8, PP. 1330-1341, (2018); REENA M.B., LOKESH B.R., HYPOLIPIDEMIC EFFECT OF OILS WITH BALANCED AMOUNTS OF FATTY ACIDS OBTAINED BY BLENDING AND INTERESTERIFICATION OF COCONUT OIL WITH RICE BRAN OIL OR SESAME OIL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 25, PP. 10461-10469, (2007); SACKS F.M., LICHTENSTEIN A.H., WU J.H.Y., APPEL L.J., CREAGER M.A., KRIS-ETHERTON P.M., ET AL., DIETARY FATS AND CARDIOVASCULAR DISEASE: A PRESIDENTIAL ADVISORY FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 136, 3, PP. E1-E23, (2017); SHAKERARDEKANI A., KARIM R., GHAZALI H.M., CHIN N.L., THE EFFECT OF MONOGLYCERIDE ADDITION ON THE RHEOLOGICAL PROPERTIES OF PISTACHIO SPREAD, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 90, 10, PP. 1517-1521, (2013); SILVA T.J., FERNANDES G.D., BERNARDINELLI O.D., SILVA E., BARRERA-ARELLANO D., RIBEIRO A.P.B., ORGANOGELS IN LOW-FAT AND HIGH-FAT MARGARINE: A STUDY OF PHYSICAL PROPERTIES AND SHELF LIFE, FOOD RESEARCH INTERNATIONAL, 140, (2021); SUKHASEM S., LIMPHAPAYOM W., STUDY ON THE QUALITY OF TEA OIL SEED (CAMELLIA OLEIFERA) AND TEA OIL, AGRICULTURAL JOURNAL, 34, PP. 270-285, (2006); TIAN Y., ACEVEDO N.C., KINETIC STUDY ON PHOTOSTABILITY OF RETINYL PALMITATE ENTRAPPED IN POLICOSANOL OLEOGELS, FOOD CHEMISTRY, 255, PP. 252-259, (2018); ULBRICHT T.L.V., SOUTHGATE D.A.T., CORONARY HEART DISEASE: SEVEN DIETARY FACTORS, LANCET, 338, 8773, PP. 985-992, (1991); UPADYA H., DEVARAJU C.J., JOSHI S.R., ANTI-INFLAMMATORY PROPERTIES OF BLENDED EDIBLE OIL WITH SYNERGISTIC ANTIOXIDANTS, INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 19, 4, PP. 511-519, (2015); WANG H., MALEKY F., EFFECTS OF COCOA BUTTER TRIACYLGLYCERIDES AND MINOR COMPOUNDS ON OIL MIGRATION, FOOD RESEARCH INTERNATIONAL, 106, PP. 213-224, (2018); INTERIM SUMMARY OF CONCLUSIONS AND DIETARY RECOMMENDATIONS ON TOTAL FAT & FATTY ACIDS, THE JOINT FAO/WHO EXPERT CONSULTATION ON FATS AND FATTY ACIDS IN HUMAN NUTRITION, (2008); WIJARNPRECHA K., ARYUSUK K., SANTIWATTANA P., SONWAI S., ROUSSEAU D., STRUCTURE AND RHEOLOGY OF OLEOGELS MADE FROM RICE BRAN WAX AND RICE BRAN OIL, FOOD RESEARCH INTERNATIONAL, 112, PP. 199-208, (2018); YILMAZ E., OGUTCU M., PROPERTIES AND STABILITY OF HAZELNUT OIL ORGANOGELS WITH BEESWAX AND MONOGLYCERIDE, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 91, 6, PP. 1007-1017, (2014); YOUNES M., AGGETT P., AGUILAR F., CREBELLI R., DUSEMUND B., FILIPIC M., ET AL., RE-EVALUATION OF MONO- AND DI-GLYCERIDES OF FATTY ACIDS (E 471) AS FOOD ADDITIVES, EFSA JOURNAL, 15, 11, (2017); ZAMPOUNI K., SONIADIS A., DIMAKOPOULOU-PAPAZOGLOU D., MOSCHAKIS T., BILIADERIS C.G., KATSANIDIS E., MODIFIED FERMENTED SAUSAGES WITH OLIVE OIL OLEOGEL AND NACL–KCL SUBSTITUTION FOR IMPROVED NUTRITIONAL QUALITY, LWT-FOOD SCIENCE & TECHNOLOGY, 158, (2022); ZAMPOUNI K., SONIADIS A., MOSCHAKIS T., BILIADERIS C.G., LAZARIDOU A., KATSANIDIS E., CRYSTALLINE MICROSTRUCTURE AND PHYSICOCHEMICAL PROPERTIES OF OLIVE OIL OLEOGELS FORMULATED WITH MONOGLYCERIDES AND PHYTOSTEROLS, LWT-FOOD SCIENCE & TECHNOLOGY, 154, (2022); ZETZL A.K., MARANGONI A.G., BARBUT S., MECHANICAL PROPERTIES OF ETHYLCELLULOSE OLEOGELS AND THEIR POTENTIAL FOR SATURATED FAT REDUCTION IN FRANKFURTERS, FOOD & FUNCTION, 3, 3, PP. 327-337, (2012)","S. LILITCHAN; DEPARTMENT OF NUTRITION, FACULTY OF PUBLIC HEALTH, MAHIDOL UNIVERSITY, BANGKOK, 10400, THAILAND; EMAIL: SUPATHRA.LIL@MAHIDOL.AC.TH","ACADEMIC PRESS","ENGLISH","LWT","ARTICLE","ISI","2-S2.0-85195776959","LWT","MAHIDOL UNIVERSITY;MAHIDOL UNIVERSITY;SILPAKORN UNIVERSITY;KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (KMUTT);MAHIDOL UNIVERSITY","NOTREPORTED;MAHIDOL UNIVERSITY;NOTREPORTED",NA,"PRAKANSAMUT N, 2024, LWT","PRAKANSAMUT N, 2024, LWT"
"RAGHAVAN P","RAGHAVAN, PALAYAKOTAI R. (57225218132)","METADICHOL A NOVEL NANOLIPID FORMULATION THAT INHIBITS SARSCOV2 AND A MULTITUDE OF PATHOLOGICAL VIRUSES IN VITRO",2022,"BIOMED RESEARCH INTERNATIONAL","2022","",5,"10.1155/2022/1558860","NANORX INC, P.O. BOX 131, CHAPPAQUA, 10514, NY, UNITED STATES","INCREASING OUTBREAKS OF NEW PATHOGENIC VIRUSES HAVE PROMOTED THE EXPLORATION OF NOVEL ALTERNATIVES TO TIME-CONSUMING VACCINES. THUS, IT IS NECESSARY TO DEVELOP A UNIVERSAL APPROACH TO HALT THE SPREAD OF NEW AND UNKNOWN VIRUSES AS THEY ARE DISCOVERED. ONE SUCH PROMISING APPROACH IS TO TARGET LIPID MEMBRANES, WHICH ARE COMMON TO ALL VIRUSES AND BACTERIA. THE ONGOING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) PANDEMIC HAS REAFFIRMED THE IMPORTANCE OF INTERACTIONS BETWEEN THE VIRUS ENVELOPE AND THE HOST CELL PLASMA MEMBRANE AS A CRITICAL MECHANISM OF INFECTION. METADICHOL®, A NANOLIPID EMULSION OF LONG-CHAIN ALCOHOLS, HAS BEEN DEMONSTRATED AS A STRONG CANDIDATE THAT INHIBITS THE PROLIFERATION OF SARS-COV-2. NATURALLY DERIVED SUBSTANCES, SUCH AS LONG-CHAIN SATURATED LIPID ALCOHOLS, REDUCE VIRAL INFECTIVITY, INCLUDING THAT OF CORONAVIRUSES (SUCH AS SARS-COV-2) BY MODIFYING THEIR LIPID-DEPENDENT ATTACHMENT MECHANISM TO HUMAN HOST CELLS. THE RECEPTOR ACE2 MEDIATES THE ENTRY OF SARS-COV-2 INTO THE HOST CELLS, WHEREAS THE SERINE PROTEASE TMPRSS2 PRIMES THE VIRAL S PROTEIN. IN THIS STUDY, METADICHOL® WAS FOUND TO BE 270 TIMES MORE POTENT AN INHIBITOR OF TMPRSS2 (EC50=96 NG/ML) THAN CAMOSTAT MESYLATE (EC50=26000 NG/ML). ADDITIONALLY, IT INHIBITS ACE WITH AN EC50 OF 71 NG/ML, BUT IT IS A VERY WEAK INHIBITOR OF ACE2 AT AN EC50 OF 31 ΜG/ML. FURTHERMORE, THE LIVE VIRAL ASSAY PERFORMED IN CACO-2 CELLS REVEALED THAT METADICHOL® INHIBITS SARS-COV-2 REPLICATION AT AN EC90 OF 0.16 ΜG/ML. MOREOVER, METADICHOL® HAD AN EC90 OF 0.00037 ΜM, MAKING IT 2081 AND 3371 TIMES MORE POTENT THAN REMDESIVIR (EC50=0.77 ΜM) AND CHLOROQUINE (EC50=1.14 ΜM), RESPECTIVELY.  © 2022 PALAYAKOTAI R. RAGHAVAN.","","ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHLOROCEBUS AETHIOPS; COVID-19; ESTERS; FATTY ALCOHOLS; GUANIDINES; HUMANS; LIPID METABOLISM; LIPIDS; NANOPARTICLE DRUG DELIVERY SYSTEM; SARS-COV-2; SERINE ENDOPEPTIDASES; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VERO CELLS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUSES; ANGIOTENSIN CONVERTING ENZYME 2; CAMOSTAT MESILATE; CAPTOPRIL; CHLOROQUINE; LIPID NANOPARTICLE; METADICHOL; REMDESIVIR; TRANSMEMBRANE PROTEASE SERINE 2; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CAMOSTAT; CORONAVIRUS SPIKE GLYCOPROTEIN; ESTER; FATTY ALCOHOL; GUANIDINE DERIVATIVE; LIPID; POLICOSANOL; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TMPRSS2 PROTEIN, HUMAN; ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EC50; EC90; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SIGNAL TRANSDUCTION; VIRUS INFECTIVITY; VIRUS REPLICATION; ANIMAL; CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECT; DRUG THERAPY; LIPID METABOLISM; METABOLISM; PATHOGENICITY; PHARMACOLOGY; PHYSIOLOGY; VERO CELL LINE; VIRUS; VIRUS ATTACHMENT; VIRUS ENTRY","","","MORSE J.S., LALONDE T., XU S., LIU W.R., LEARNING FROM THE PAST: POSSIBLE URGENT PREVENTION AND TREATMENT OPTIONS FOR SEVERE ACUTE RESPIRATORY INFECTIONS CAUSED BY 2019-NCOV, CHEMBIOCHEM: A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, 21, 5, PP. 730-738, (2020); LI G., DE CLERCQ E., THERAPEUTIC OPTIONS FOR THE 2019 NOVEL CORONAVIRUS (2019-NCOV), NATURE REVIEWS DRUG DISCOVERY, 19, 3, PP. 149-150, (2020); JANKUN J., COVID-19 PANDEMIC; TRANSMEMBRANE PROTEASE SERINE 2 (TMPRSS2) INHIBITORS AS POTENTIAL DRUGS, TRANSLATION: THE UNIVERSITY OF TOLEDO JOURNAL OF MEDICAL SCIENCES, 7, PP. 1-5, (2020); HAMMING I., COOPER M.E., HAAGMANS B.L., HOOPER N.M., KORSTANJE R., OSTERHAUS A.D.M.E., TIMENS W., TURNER A.J., NAVIS G., VAN GOOR H., THE EMERGING ROLE OF ACE2 IN PHYSIOLOGY AND DISEASE, THE JOURNAL OF PATHOLOGY, 212, 1, PP. 1-11, (2007); RABAAN A.A., MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS: FIVE YEARS LATER, EXPERT REVIEW OF RESPIRATORY MEDICINE, 11, 11, PP. 901-912, (2017); ZHOU Y., VEDANTHAM P., LU K., AGUDELO J., CARRION R., NUNNELEY J.W., BARNARD D., POHLMANN S., MCKERROW J.H., RENSLO A.R., SIMMONS G., PROTEASE INHIBITORS TARGETING CORONAVIRUS AND FILOVIRUS ENTRY, ANTIVIRAL RESEARCH, 116, PP. 76-84, (2015); HOFFMANN M., KLEINE-WEBER H., SCHROEDER S., KRUGER N., HERRLER T., ERICHSEN S., SCHIERGENS T.S., HERRLER G., WU N.H., NITSCHE A., MULLER M.A., DROSTEN C., POHLMANN S., SARS-COV-2 CELL ENTRY DEPENDS ON ACE2 AND TMPRSS2 AND IS BLOCKED BY A CLINICALLY PROVEN PROTEASE INHIBITOR, CELL, 181, 2, PP. 271-271E8, (2020); GREATOREX J.S., PAGE R.F., CURRAN M.D., DIGARD P., ENSTONE J.E., WREGHITT T., POWELL P.P., SEXTON D.W., VIVANCOS R., NGUYEN-VAN-TAM J.S., EFFECTIVENESS OF COMMON HOUSEHOLD CLEANING AGENTS IN REDUCING THE VIABILITY OF HUMAN INFLUENZA A/H1N1, PLOS ONE, 5, 2, ARTICLE E8987, (2010); SNIPES W., PERSON S., KELLER G., TAYLOR W., KEITH A., INACTIVATION OF LIPID-CONTAINING VIRUSES BY LONG-CHAIN ALCOHOLS, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 11, 1, PP. 98-104, (1977); HILMARSSON H., KRISTMUNDSDOTTIR T., THORMAR H., VIRUCIDAL ACTIVITIES OF MEDIUM- AND LONG-CHAIN FATTY ALCOHOLS, FATTY ACIDS AND MONOGLYCERIDES AGAINST HERPES SIMPLEX VIRUS TYPES 1 AND 2: COMPARISON AT DIFFERENT PH LEVELS, APMIS, 113, 1, PP. 58-65, (2005); HILMARSSON H., LARUSSON L.V., THORMAR H., VIRUCIDAL EFFECT OF LIPIDS ON VISNA VIRUS, A LENTIVIRUS RELATED TO HIV, ARCHIVES OF VIROLOGY, 151, 6, PP. 1217-1224, (2006); HILMARSSON H., TRAUSTASON B.S., KRISTMUNDSDOTTIR T., THORMAR H., VIRUCIDAL ACTIVITIES OF MEDIUM- AND LONG-CHAIN FATTY ALCOHOLS AND LIPIDS AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA VIRUS TYPE 2: COMPARISON AT DIFFERENT PH LEVELS, ARCHIVES OF VIROLOGY, 152, 12, PP. 2225-2236, (2007); ISAACS C.E., KIMS K., THORMAR H., INACTIVATION OF ENVELOPED VIRUSES IN HUMAN BODILY FLUIDS BY PURIFIED LIPIDS, ANNALS OF THE NEW YORK ACADEMY SCIENCES, 724, 1, PP. 457-464, (1994); RAGHAVAN P.R.; RAGHAVAN P.R., IN VITRO INHIBITION OF ZIKA VIRUS BY METADI00000CHOL®, A NOVEL NANO EMULSION LIPID, JOURNAL OF IMMUNOLOGICAL TECHNIQUES IN INFECTIOUS DISEASES, 5, 4, PP. 2-6, (2016); RAGHAVAN P.R., INHIBITION OF DENGUE AND OTHER ENVELOPED VIRUSES BY METADICHOL®, A NOVEL NANOEMULSION LIPID, JOURNAL OF THE SCIENCE OF HEALING OUTCOMES, 8, PP. 19-25, (2016); RAGHAVAN P.R., INHIBITION OF VIRUSES BY METADICHOL®: A NOVEL NANO EMULSION LIPID, PEDIATRIC INFECTIOUS DISEASES, 2, 35, (2017); REED L.J., MUENCH H., A SIMPLE METHOD OF ESTIMATING FIFTY-PERCENT ENDPOINTS, AMERICAN JOURNAL OF HYGIENE, 27, PP. 493-497, (1938); WANG M., CAO R., ZHANG L., YANG X., LIU J., XU M., SHI Z., HU Z., ZHONG W., XIAO G., REMDESIVIR AND CHLOROQUINE EFFECTIVELY INHIBIT THE RECENTLY EMERGED NOVEL CORONAVIRUS (2019-NCOV) IN VITRO, CELL RESEARCH, 30, 3, PP. 269-271, (2020); ALEMAN C., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., CAPOTE A., MENENDEZ R., AMOR A., FRAGA V., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOLOGY LETTERS, 70, 1, PP. 77-87, (1994); ALEMAN C.L., FERREIRO R.M., PUIG M.N., GUERRA I.R., ORTEGA C.H., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS, 14, 5, PP. 239-249, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD AND CHEMICAL TOXICOLOGY, 33, 7, PP. 573-578, (1995); RAGHAVAN P.R., METADICHOL® A NOVEL AGONIST OF THE ANTI-AGING KLOTHO GENE IN CANCER CELL LINES, JOURNAL OF CANCER SCIENCE & THERAPY, 10, 11, PP. 351-357, (2018); RAGHAVAN P.R., MANUSCRIPT IN PREPARATION ON METADICHOL ACTIVITY IN CEM-SS CELLS AND THE IIIB STRAIN OF HIV-1; UNO Y., CAMOSTAT MESILATE THERAPY FOR COVID-19, INTERNAL AND EMERGENCY MEDICINE, 15, 8, PP. 1577-1578, (2020); GUAN W.J., NI Z.Y., HU Y., LIANG W.H., OU C.Q., HE J.X., LIU L., SHAN H., LEI C.L., HUI D.S.C., DU B., LI L.J., ZENG G., YUEN K.Y., CHEN R.C., TANG C.L., WANG T., CHEN P.Y., XIANG J., LI S.Y., WANG J.L., LIANG Z.J., PENG Y.X., WEI L., LIU Y., HU Y.H., PENG P., WANG J.M., LIU J.Y., CHEN Z., LI G., ZHENG Z.J., QIU S.Q., LUO J., YE C.J., ZHU S.Y., ZHONG N.S., MEDICAL TREATMENT EXPERT GROUP FOR COVID-19 C., CLINICAL CHARACTERISTICS OF CORONAVIRUS DISEASE 2019 IN CHINA, THE NEW ENGLAND JOURNAL OF MEDICINE, 382, 18, PP. 1708-1720, (2020); MERAD M., MARTIN J.C., PATHOLOGICAL INFLAMMATION IN PATIENTS WITH COVID-19: A KEY ROLE FOR MONOCYTES AND MACROPHAGES, NATURE REVIEWS IMMUNOLOGY, 20, 6, PP. 355-362, (2020); DANESHKHAH A., AGRAWAL V., ESHEIN A., SUBRAMANIAN H., ROY H.K., BACKMAN V., THE POSSIBLE ROLE OF VITAMIN D IN SUPPRESSING CYTOKINE STORM AND ASSOCIATED MORTALITY IN COVID-19 PATIENTS, MEDRXIV, 420, (2020); PIKE J.W., CHRISTAKOS S., BIOLOGY AND MECHANISMS OF ACTION OF THE VITAMIN D HORMONE, ENDOCRINOLOGY & METABOLISM CLINICS, 46, 4, PP. 815-843, (2017); LIU P.T., SCHENK M., WALKER V.P., DEMPSEY P.W., KANCHANAPOOMI M., WHEELWRIGHT M., VAZIRNIA A., ZHANG X., STEINMEYER A., ZUGEL U., HOLLIS B.W., CHENG G., MODLIN R.L., CONVERGENCE OF IL-1BETA AND VDR ACTIVATION PATHWAYS IN HUMAN TLR2/1-INDUCED ANTIMICROBIAL RESPONSES, PLOS ONE, 4, 6, ARTICLE E5810, (2009); WANG T.T., NESTEL F.P., BOURDEAU V., NAGAI Y., WANG Q., LIAO J., TAVERA-MENDOZA L., LIN R., HANRAHAN J.W., MADER S., WHITE J.H., CUTTING EDGE: 1,25-DIHYDROXYVITAMIN D3 IS A DIRECT INDUCER OF ANTIMICROBIAL PEPTIDE GENE EXPRESSION, THE JOURNAL OF IMMUNOLOGY, 173, 5, PP. 2909-2912, (2004); MARTINEZ-MORENO J., HERNANDEZ J.C., URCUQUI-INCHIMA S., EFFECT OF HIGH DOSES OF VITAMIN D SUPPLEMENTATION ON DENGUE VIRUS REPLICATION, TOLL-LIKE RECEPTOR EXPRESSION, AND CYTOKINE PROFILES ON DENDRITIC CELLS, MOLECULAR AND CELLU000LAR BIOCHEMISTRY, 464, 1-2, PP. 169-180, (2020); SPILIANAKIS C.G., LEE G.R., FLAVELL R.A., TWISTING THE TH1/TH2 IMMUNE RESPONSE VIA THE RETINOID X RECEPTOR: LESSONS FROM A GENETIC APPROACH, EUROPEAN JOURNAL OF IMMUNOLOGY, 35, 12, PP. 3400-3404, (2005); WEI R., CHRISTAKOS S., MECHANISMS UNDERLYING THE REGULATION OF INNATE AND ADAPTIVE IMMUNITY BY VITAMIN D, NUTRIENTS, 7, 10, PP. 8251-8260, (2015); CANTORNA M.T., SNYDER L., LIN Y.D., YANG L., VITAMIN D AND 1,25(OH) 2D REGULATION OF T CELLS, NUTRIENTS, 7, 4, PP. 3011-3021, (2015); CANTORNA M.T., MECHANISMS UNDERLYING THE EFFECT OF VITAMIN D ON THE IMMUNE SYSTEM, PROCEEDINGS OF THE NUTRITION SOCIETY, 69, 3, PP. 286-289, (2010); LEMIRE J.M., ADAMS J.S., KERMANI-ARAB V., BAKKE A.C., SAKAI R., JORDAN S.C., 1,25-DIHYDROXYVITAMIN D3 SUPPRESSES HUMAN T HELPER/INDUCER LYMPHOCYTE ACTIVITY IN VITRO, THE JOURNAL OF IMMUNOLOGY, 134, 5, PP. 3032-3035, (1985); HUANG C., WANG Y., LI X., REN L., ZHAO J., HU Y., ZHANG L., FAN G., XU J., GU X., CHENG Z., YU T., XIA J., WEI Y., WU W., XIE X., YIN W., LI H., LIU M., XIAO Y., GAO H., GUO L., XIE J., WANG G., JIANG R., GAO Z., JIN Q., WANG J., CAO B., CLINICAL FEATURES OF PATIENTS INFECTED WITH 2019 NOVEL CORONAVIRUS IN WUHAN, CHINA, THE LANCET, 395, 10223, PP. 497-506, (2020); WANG D., HU B., HU C., ZHU F., LIU X., ZHANG J., WANG B., XIANG H., CHENG Z., XIONG Y., ZHAO Y., LI Y., WANG X., PENG Z., CLINICAL CHARACTERISTICS OF 138 HOSPITALIZED PATIENTS WITH 2019 NOVEL CORONAVIRUS-INFECTED PNEUMONIA IN WUHAN, CHINA, JAMA, 323, 11, PP. 1061-1069, (2020); WENG N.P., TELOMERE AND ADAPTIVE IMMUNITY, MECHANISMS OF AGEING AND DEVELOPMENT, 129, 1-2, PP. 60-66, (2008); HODES R.J., HATHCOCK K.S., WENG N.P., TELOMERES IN T AND B CELLS, NATURE REVIEWS IMMUNOLOGY, 2, 9, PP. 699-706, (2002); RAGHAVAN P.R., THE QUEST FOR IMMORTALITY: INTRODUCING METADICHOL® A NOVEL TELOMERASE ACTIVATOR, STEM CELL RESEARCH & THERAPY, 9, (2019); POPPE M., WITTIG S., JURIDA L., BARTKUHN M., WILHELM J., MULLER H., BEUERLEIN K., KARL N., BHUJU S., ZIEBUHR J., SCHMITZ M.L., KRACHT M., THE NF- Κ B-DEPENDENT AND -INDEPENDENT TRANSCRIPTOME AND CHROMATIN LANDSCAPES OF HUMAN CORONAVIRUS 229E-INFECTED CELLS, PLOS PATHOGENS, 13, 3, ARTICLE E1006286, (2017); GIOVANNONI F., BOSCH I., POLONIO C.M., TORTI M.F., WHEELER M.A., LI Z., ROMORINI L., VARELA M.S., ROTHHAMMER V., BARROSO A., TJON E.C., AHR IS A ZIKA VIRUS HOST FACTOR AND A CANDIDATE TARGET FOR ANTIVIRAL THERAPY, NATURE NEUROSCIENCE, 23, 8, PP. 729-740, (2019); YAMADA T., HORIMOTO H., KAMEYAMA T., HAYAKAWA S., YAMATO H., DAZAI M., TAKADA A., KIDA H., BOTT D., ZHOU A.C., HUTIN D., WATTS T.H., ASAKA M., MATTHEWS J., TAKAOKA A., CONSTITUTIVE ARYL HYDROCARBON RECEPTOR SIGNALING CONSTRAINS TYPE I INTERFERON-MEDIATED ANTIVIRAL INNATE DEFENSE, NATURE IMMUNOLOGY, 17, 6, PP. 687-694, (2016); RAGHAVAN P.R., METADICHOL ®. A NOVEL INVERSE AGONIST OF ARYL HYDROCARBON RECEPTOR (AHR) AND NRF2 INHIBITOR, JOURNAL OF CANCER SCIENCE AND THERAPY, 9, 9, PP. 661-668, (2017); HEUSER G., VOJDANI A., ENHANCEMENT OF NATURAL KILLER CELL ACTIVITY AND T AND B CELL FUNCTION BY BUFFERED VITAMIN C IN PATIENTS EXPOSED TO TOXIC CHEMICALS: THE ROLE OF PROTEIN KINASE-C, IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 19, 3, PP. 291-312, (1997); FURUYA A., UOZAKI M., YAMASAKI H., ARAKAWA T., ARITA M., KOYAMA A.H., ANTIVIRAL EFFECTS OF ASCORBIC AND DEHYDROASCORBIC ACIDS IN VITRO, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 22, 4, PP. 541-545, (2008); KIM H., JANG M., KIM Y., CHOI J., JEON J., KIM J., HWANG Y.I., KANG J.S., LEE W.J., RED GINSENG AND VITAMIN C INCREASE IMMUNE CELL ACTIVITY AND DECREASE LUNG INFLAMMA000000TION INDUCED BY INFLUENZA A VIRUS/H1N1 INFECTION, JOURNAL OF PHARMACY AND PHARMACOLOGY, 68, 3, PP. 406-420, (2016); MADHUSUDANA S.N., SHAMSUNDAR R., SEETHARAMAN S., IN VITRO INACTIVATION OF THE RABIES VIRUS BY ASCORBIC ACID, INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 8, 1, PP. 21-25, (2004); ALVARES O., ALTMAN L.C., SPRINGMEYER S., ENSIGN W., JACOBSON K., THE EFFECT OF SUBCLINICAL ASCORBATE DEFICIENCY ON PERIODONTAL HEALTH IN NONHUMAN PRIMATES, JOURNAL OF PERIODONTAL RESEARCH, 16, 6, PP. 628-636, (1981); GOLDSCHMIDT M.C., MASIN W.J., BROWN L.R., WYDE P.R., THE EFFECT OF ASCORBIC ACID DEFICIENCY ON LEUKOCYTE PHAGOCYTOSIS AND KILLING OF ACTINOMYCES VISCOSUS, INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH. INTERNATIONALE ZEITSCHRIFT FUR VITAMIN- UND ERNAHRUNGSFORSCHUNG. JOURNAL INTERNATIONAL DE VITAMINOLOGIE ET DE NUTRITION, 58, 3, PP. 326-334, (1988); WINTERGERST E.S., MAGGINI S., HORNIG D.H., IMMUNE-ENHANCING ROLE OF VITAMIN C AND ZINC AND EFFECT ON CLINICAL CONDITIONS, ANNALS OF NUTRITION AND METABOLISM, 50, 2, PP. 85-94, (2006); WOO A., KIM J.H., JEONG Y.J., MAENG H.G., LEE Y.T., KANG J.S., LEE W.J., HWANG Y.I., VITAMIN C ACTS INDIRECTLY TO MODULATE ISOTYPE SWITCHING IN MOUSE B CELLS, ANATOMY & CELL BIOLOGY, 43, 1, PP. 25-35, (2010); CARR A.C., MAGGINI S., VITAMIN C AND IMMUNE FUNCTION, NUTRIENTS, 9, 11, (2017); WASHKO P., ROTROSEN D., LEVINE M., ASCORBIC ACID IN HUMAN NEUTROPHILS, THE AMERICAN JOURNAL OF CLINAL NUTRITION, 54, 6, PP. 1221S-1227S, (1991); KUIPER C., VISSERS M., ASCORBATE AS A CO-FACTOR FOR FE- AND 2-OXOGLUTARATE DEPENDENT DIOXYGENASES: PHYSIOLOGICAL ACTIVITY IN TUMOR GROWTH AND PROGRESSION, FRONTIERS IN ONCOLOGY, 4, (2014); LOENARZ C., SCHOFIELD C.J., PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS OF HYDROXYLATIONS AND DEMETHYLATIONS CATALYZED BY HUMAN 2-OXOGLUTARATE OXYGENASES, TRENDS IN BIOCHEMAL SCIENCES, 36, 1, PP. 7-18, (2011); FLASHMAN E., DAVIES S.L., YEOH K.K., SCHOFIELD C.J., INVESTIGATING THE DEPENDENCE OF THE HYPOXIA-INDUCIBLE FACTOR HYDROXYLASES (FACTOR INHIBITING HIF AND PROLYL HYDROXYLASE DOMAIN 2) ON ASCORBATE AND OTHER REDUCING AGENTS, BIOCHEMAL JOURNAL, 427, 1, PP. 135-142, (2010); KUIPER C., DACHS G.U., CURRIE M.J., VISSERS M.C.M., INTRACELLULAR ASCORBATE ENHANCES HYPOXIA-INDUCIBLE FACTOR (HIF)-HYDROXYLASE ACTIVITY AND PREFERENTIALLY SUPPRESSES THE HIF-1 TRANSCRIPTIONAL RESPONSE, FREE RADICAL BIOLOGY AND MEDICINE, 69, PP. 308-317, (2014); RAGHAVAN P.R., METADICHOL®, VITAMIN C AND GULO GENE EXPRESSION IN MOUSE ADIPOCYTES, BIOLOGY AND MEDICINE, 10, 1, (2017); RAGHAVAN P.R., METADICHOL® AND VITAMIN C INCREASE IN VIVO, AN OPEN-LABEL STUDY, VITAMINS AND MINERALS, 6, (2017); RAGHAVAN P.R., METADICHOL® INDUCED HIGH LEVELS OF VITAMIN C: CASE STUDIES, VITAMINS AND MINERALS, 6, (2017); CREIXELL P., REIMAND J., HAIDER S., WU G., SHIBATA T., VAZQUEZ M., MUSTONEN V., GONZALEZ-PEREZ A., PEARSON J., SANDER C., RAPHAEL B.J., MARKS D.S., OUELLETTE B.F.F., VALENCIA A., BADER G.D., BOUTROS P.C., STUART J.M., LINDING R., LOPEZ-BIGAS N., STEIN L.D., CONSEQUENCES AND PATHWAY ANALYSIS WORKING GROUP OF THE INTERNATIONAL CANCER GENOME CONSORTIUM M., PATHWAY AND NETWORK ANALYSIS OF CANCER GENOMES, NATURE METHODS, 12, 7, PP. 615-621, (2015); BARABASI A.L., GULBAHCE N., LOSCALZO J., NETWORK MEDI0000CINE: A NETWORK-BASED APPROACH TO HUMAN DISEASE, NATURE REVIEWS GENETICS, 12, 1, PP. 56-68, (2011); DAVIS A.P., GRONDIN C.J., JOHNSON R.J., SCIAKY D., MCMORRAN R., WIEGERS J., WIEGERS T.C., MATTINGLY C.J., THE COMPARATIVE TOXICOGENOMICS DATABASE: UPDATE 2019, NUCLEIC ACIDS RESEARCH, 47, D1, PP. D948-D954, (2019); BREUER K., FOROUSHANI A.K., LAIRD M.R., CHEN C., SRIBNAIA A., LO R., WINSOR G.L., HANCOCK R.E.W., BRINKMAN F.S.L., LYNN D.J., INNATEDB: SYSTEMS BIOLOGY OF INNATE IMMUNITY AND BEYOND-RECENT UPDATES AND CONTINUING CURATION, NUCLEIC ACIDS RESEARCH, 41, D1, PP. D1228-D1233, (2013); GLINSKY G., GENOMICS-GUIDED MOLECULAR MAPS OF CORONAVIRUS TARGETS IN HUMAN CELLS: A PATH TOWARD THE REPURPOSING OF EXISTING DRUGS TO MITIGATE THE PANDEMIC; MEYER M.B., GOETSCH P.D., PIKE J.W., VDR/RXR AND TCF4/ Β -CATENIN CISTROMES IN COLONIC CELLS OF COLORECTAL TUMOR ORIGIN: IMPACT ON C-FOS AND C-MYC GENE EXPRESSION, MOLECULAR ENDOCRINOLOGY, 26, 1, PP. 37-51, (2012); AN B.S., TAVERA-MENDOZA L.E., DIMITROV V., WANG X., CALDERON M.R., WANG H.J., WHITE J.H., STIMULATION OF SIRT1-REGULATED FOXO PROTEIN FUNCTION BY THE LIGAND-BOUND VITAMIN D RECEPTOR, MOLECULAR AND CELLULAR BIOLOGY, 30, 20, PP. 4890-4900, (2010); LIN Z., LI J., FANG D., SIRT INVOLVEMENT IN VIRUS-MEDIATED DISEASES, JSM MICROBIOLOGY, 1, 2, (2013); FU M., LIU M., SAUVE A.A., JIAO X., ZHANG X., WU X., POWELL M.J., YANG T., GU W., AVANTAGGIATI M.L., PATTABIRAMAN N., PESTELL T.G., WANG F., QUONG A.A., WANG C., PESTELL R.G., HORMONAL CONTROL OF ANDROGEN RECEPTOR FUNCTION THROUGH SIRT1, MOLECULAR AND CELLULAR BIOLOGY, 26, 21, PP. 8122-8135, (2006); RODCHENKOV I., BABUR O., LUNA A., AKSOY B.A., WONG J.V., FONG D., FRANZ M., SIPER M.C., CHEUNG M., WRANA M., MISTRY H., MOSIER L., DLIN J., WEN Q., O'CALLAGHAN C., LI W., ELDER G., SMITH P.T., DALLAGO C., CERAMI E., GROSS B., DOGRUSOZ U., DEMIR E., BADER G.D., SANDER C., PATHWAY COMMONS 2019 UPDATE: INTEGRATION, ANALYSIS AND EXPLORATION OF PATHWAY DATA, NUCLEIC ACIDS RESEARCH, 48, D1, PP. D489-D497, (2020); WAMBIER C.G., GOREN A., SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION IS LIKELY TO BE ANDROGEN MEDIATED, JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 83, 1, PP. 308-309, (2020); MA Y.C., SHI C., ZHANG Y.N., WANG L.G., LIU H., JIA H.T., ZHANG Y.X., SARKAR F.H., WANG Z.S., THE TYROSINE KINASE C-SRC DIRECTLY MEDIATES GROWTH FACTOR-INDUCED NOTCH-1 AND FURIN INTERACTION AND NOTCH-1 ACTIVATION IN PANCREATIC CANCER CELLS, PLOS ONE, 7, 3, ARTICLE E33414, (2012); BUITRAGO C., VAZQUEZ G., DE BOLAND A.R., BOLAND R.L., ACTIVATION OF SRC KINASE IN SKELETAL MUSCLE CELLS BY 1,25-(OH)2-VITAMIN D3 CORRELATES WITH TYROSINE PHOSPHORYLATION OF THE VITAMIN D RECEPTOR (VDR) AND VDR-SRC INTERACTION, JOURNAL OF CELLULAR BIOCHEMISTRY, 79, 2, PP. 274-281, (2000); MARCHWICKA A., MARCINKOWSKA E., REGULATION OF EXPRESSION OF CEBP GENES BY VARIABLY EXPRESSED VITAMIN D RECEPTOR AND RETINOIC ACID RECEPTOR Α IN HUMAN ACUTE MYELOID LEUKEMIA CELL LINES, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19, 7, (2018); ARCIDIACONO M.V., YANG J., FERNANDEZ E., DUSSO A., THE INDUCTION OF C/EBP Β CONTRIBUTES TO VITAMIN D INHIBITION OF ADAM17 EXPRESSION AND PARATHYROID HYPERPLASIA IN KIDNEY DISEASE, NEPHROLOGY DIALYSIS TRANSPLANTATION, 30, 3, PP. 423-433, (2015); ULRICH H., PILLAT M.M., CD147 AS A TARGET FOR COVID-19 TREATMENT: SUGGESTED EFFECTS OF AZITHROMYCIN AND STEM CELL ENGAGEMENT, STEM CELL REVIEWS AND REPORTS, 16, 3, PP. 434-440, (2020); CROSNIER C., BUSTAMANTE L.Y., BARTHOLDSON S.J., BEI A.K., THERON M., UCHIKAWA M., MBOUP S., NDIR O., KWIATKOWSKI D.P., DURAISINGH M.T., RAYNER J.C., WRIGHT G.J., BASIGIN IS A RECEPTOR ESSENTIAL FOR ERYTHROCYTE INVASION BY _PLASMODIUM FALCIPARUM_, NATURE, 480, 7378, PP. 534-537, (2011); KUBA K., IMAI Y., RAO S., GAO H., GUO F., GUAN B., HUAN Y., YANG P., ZHANG Y., DENG W., BAO L., ZHANG B., LIU G., WANG Z., CHAPPELL M., LIU Y., ZHENG D., LEIBBRANDT A., WADA T., SLUTSKY A.S., LIU D., QIN C., JIANG C., PENNINGER J.M., A CRUCIAL ROLE OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) IN SARS CORONAVIRUS-INDUCED LUNG INJURY, NATURE MEDICINE, 11, 8, PP. 875-879, (2005); EGUCHI S., KAWAI T., SCALIA R., RIZZO V., UNDERSTANDING ANGIOTENSIN II TYPE 1 RECEPTOR SIGNALING IN VASCULAR PATHOPHYSIOLOGY, HYPERTENSION, 71, 5, PP. 804-810, (2018); MURAKAMI M., KAMIMURA D., HIRANO T., PLEIOTROPY AND SPECIFICITY: INSIGHTS FROM THE INTERLEUKIN 6 FAMILY OF CYTOKINES, IMMUNITY, 50, 4, PP. 812-831, (2019); DE WIT E., VAN DOREMALEN N., FALZARANO D., MUNSTER V.J., SARS AND MERS: RECENT INSIGHTS INTO EMERGING CORONAVIRUSES, NATURE REVIEWS MICROBIOLOGY, 14, 8, PP. 523-534, (2016); PEDERSEN S.F., HO Y.C., SARS-COV-2: A STORM IS RAGING, THE JOURNAL OF CLINICAL INVESTIGATION, 130, 5, PP. 2202-2205, (2020); GUO W., LI M., DONG Y., IN RESPONSE: DIABETES IS A RISK FACTOR FOR THE PROGRESSION AND PROGNOSIS OFCOVID-19, DIABETES/METABOLISM RESEARCH AND REVIEWS, 36, 7, ARTICLE E3319, (2020); WU C., CHEN X., CAI Y., XIA J.'., ZHOU X., XU S., HUANG H., ZHANG L., ZHOU X., DU C., ZHANG Y., SONG J., WANG S., CHAO Y., YANG Z., XU J., ZHOU X., CHEN D., XIONG W., XU L., ZHOU F., JIANG J., BAI C., ZHENG J., SONG Y., RISK FACTORS ASSOCIATED WITH ACUTE RESPIRATORY DISTRESS SYNDROME AND DEATH IN PATIENTS WITH CORONAVIRUS DISEASE 2019 PNEUMONIA IN WUHAN, CHINA, JAMA INTERNAL MEDICINE, 180, 7, PP. 934-943, (2020); RAGHAVAN P.R., SYSTOLIC AND DIASTOLIC BP CONTROL IN METABOLIC SYNDROME PATIENTS WITH METADICHOL® A NOVEL NANO EMULSION LIPID, JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY, 555, (2017); RAGHAVAN P.R., METADICHOL AND TYPE 2 DIABETES A CASE REPORT, JOURNAL OF THE SCIENCE OF HEALING OUTCOMES, 8, PP. 5-10, (2016); RAGHAVAN P.R., METADICHOL®, A NOVEL NANO LIPID FORMULATION THAT INHIBITS SARS-COV-2 AND A MULTITUDE OF PATHOLOGICAL VIRUSES IN VITRO","P.R. RAGHAVAN; NANORX INC, CHAPPAQUA, P.O. BOX 131, 10514, UNITED STATES; EMAIL: RAGHAVAN@NANORXINC.COM","HINDAWI LIMITED","ENGLISH","BIOMED RES. INT.","ARTICLE","ISI","2-S2.0-85123566813","BIOMED RES INT",NA,"NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"RAGHAVAN PR, 2022, BIOMED RES INT","RAGHAVAN PR, 2022, BIOMED RES INT"
"CHEUNG B;SIKAND G;DINEEN E;MALIK S;BARSEGHIAN E A","CHEUNG, BRIAN (58115841400); SIKAND, GEETA (6602561882); DINEEN, ELIZABETH H. (57218118487); MALIK, SHAISTA (8872460600); BARSEGHIAN EL-FARRA, AILIN (36959606400)","LIPIDLOWERING NUTRACEUTICALS FOR AN INTEGRATIVE APPROACH TO DYSLIPIDEMIA",2023,"JOURNAL OF CLINICAL MEDICINE","12","",4,"10.3390/jcm12103414","SUSAN SAMUELI INTEGRATIVE HEALTH INSTITUTE, 856 HEALTH SCIENCES ROAD, IRVINE, 92617, CA, UNITED STATES, DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, 92521, CA, UNITED STATES;DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, 92521, CA, UNITED STATES;SUSAN SAMUELI INTEGRATIVE HEALTH INSTITUTE, 856 HEALTH SCIENCES ROAD, IRVINE, 92617, CA, UNITED STATES, DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, 92521, CA, UNITED STATES;SUSAN SAMUELI INTEGRATIVE HEALTH INSTITUTE, 856 HEALTH SCIENCES ROAD, IRVINE, 92617, CA, UNITED STATES, DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, 92521, CA, UNITED STATES;SUSAN SAMUELI INTEGRATIVE HEALTH INSTITUTE, 856 HEALTH SCIENCES ROAD, IRVINE, 92617, CA, UNITED STATES, DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, 92521, CA, UNITED STATES","DYSLIPIDEMIA IS A TREATABLE RISK FACTOR FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE THAT CAN BE ADDRESSED THROUGH LIFESTYLE CHANGES AND/OR LIPID-LOWERING THERAPIES. ADHERENCE TO STATINS CAN BE A CLINICAL CHALLENGE IN SOME PATIENTS DUE TO STATIN-ASSOCIATED MUSCLE SYMPTOMS AND OTHER SIDE EFFECTS. THERE IS A GROWING INTEREST IN INTEGRATIVE CARDIOLOGY AND NUTRACEUTICALS IN THE MANAGEMENT OF DYSLIPIDEMIA, AS SOME PATIENTS DESIRE OR ARE ACTIVELY SEEKING A MORE NATURAL APPROACH. THESE AGENTS HAVE BEEN USED IN PATIENTS WITH AND WITHOUT ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. WE PROVIDE AN UPDATED REVIEW OF THE EVIDENCE ON MANY NEW AND EMERGING NUTRACEUTICALS. WE DESCRIBE THE MECHANISM OF ACTION, LIPID-LOWERING EFFECTS, AND SIDE EFFECTS OF MANY NUTRACEUTICALS, INCLUDING RED YEAST RICE, BERGAMOT AND OTHERS. © 2023 BY THE AUTHORS.","APOLIPOPROTEIN B; ATHEROSCLEROSIS; CARDIOMETABOLIC; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK REDUCTION; COMPLEMENTARY MEDICINE; INTEGRATIVE MEDICINE; LIPOPROTEIN (A)","ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ANTHOCYANIN; ANTILIPEMIC AGENT; ARTICHOKE EXTRACT; BERBERINE; BETA GLUCAN; CARNITINE; CHITOSAN; CHOLESTIN; CHROMIUM; CONJUGATED LINOLEIC ACID; CREATININE; CURCUMIN; DOCOSAHEXAENOIC ACID; FLAVONOID; GAMMA GLUTAMYLTRANSFERASE; GAMMA ORYZANOL; GARLIC EXTRACT; GUAR GUM; ICOSAPENTAENOIC ACID; ISPAGULA; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUPIN PROTEIN; MAGNESIUM; MANNAN; NICOTINIC ACID; NIGELLA SATIVA EXTRACT; NUTRACEUTICAL; OLIVE EXTRACT; OMEGA 3 FATTY ACID; PANTETHINE; PECTIN; PHYCOCYANIN; PHYTOSTEROL; PLANT EXTRACT; POLICOSANOL; POLYSACCHARIDE; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; RESVERATROL; SILYMARIN; SINECATECHINS; SOYBEAN PROTEIN; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; VEGETABLE OIL; XUEZHIKANG; ALKALINE PHOSPHATASE LEVEL; ALLERGY; ALTERNATIVE MEDICINE; ANAPHYLAXIS; ANEMIA; ARTHROSPIRA; ARTHROSPIRA MAXIMA; ARTICHOKE; BERGAMOT; BLACK CUMIN; BLEEDING; BODY ODOR; BODY WEIGHT GAIN; BRAIN HEMORRHAGE; CAMELLIA SINENSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CITRUS BERGAMIA RISSO; CITRUS FRUIT; COMPARATIVE EFFECTIVENESS; CONFUSION; CORONARY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DERMATITIS; DIABETES MELLITUS; DIABETIC COMPLICATION; DIETARY FIBER; DIZZINESS; DRUG SAFETY; DRY SKIN; DYSLIPIDEMIA; DYSPEPSIA; ELEVATED BLOOD PRESSURE; ENDOCRINE DISEASE; ESOPHAGUS OBSTRUCTION; FATIGUE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEART ARREST; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEMOLYTIC ANEMIA; HIPPOPHAE RHAMNOIDES; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERREFLEXIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; INSOMNIA; INSULIN AUTOIMMUNE SYNDROME; INTEGRATIVE MEDICINE; INTESTINE OBSTRUCTION; IRRITABILITY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER TOXICITY; LUNG EDEMA; LUPIN; MEDITERRANEAN DIET; MENSTRUATION DISORDER; MUSCLE CRAMP; MYALGIA; MYOPATHY; NAUSEA; NEW-ONSET ATRIAL FIBRILLATION; NOCTURIA; NONHUMAN; OLIVE TREE; OUTCOME ASSESSMENT; PEPTIC ULCER; PHOTOPHOBIA; PLANT LEAF; POLYDIPSIA; POLYHYDRAMNIOS; PROSTATE CANCER; RASH; RESPIRATION DEPRESSION; RESPIRATORY TRACT INFECTION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; SOMNOLENCE; SPIRULINA; SPONTANEOUS ABORTION; TACHYCARDIA; TEA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; URETER STONE","","","GRUNDY S.M., STONE N.J., BAILEY A.L., BEAM C., BIRTCHER K.K., BLUMENTHAL R.S., BRAUN L.T., DE FERRANTI S., FAIELLA-TOMMASINO J., FORMAN D.E., ET AL., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, J. AM. COLL. CARDIOL, 73, PP. E285-E350, (2019); AMBROSINO P., BACHETTI T., D'ANNA S.E., GALLOWAY B., BIANCO A., D'AGNANO V., PAPA A., MOTTA A., PERROTTA F., MANISCALCO M., MECHANISMS AND CLINICAL IMPLICATIONS OF ENDOTHELIAL DYSFUNCTION IN ARTERIAL HYPERTENSION, J. CARDIOVASC. DEV. DIS, 9, (2022); MUCKA S., MIODONSKA M., JAKUBIAK G.K., STARZAK M., CIESLAR G., STANEK A., ENDOTHELIAL FUNCTION ASSESSMENT BY FLOW-MEDIATED DILATION METHOD: A VALUABLE TOOL IN THE EVALUATION OF THE CARDIOVASCULAR SYSTEM, INT. J. ENV. RES. PUBLIC HEALTH, 19, (2022); JAKUBIAK G.K., CIESLAR G., STANEK A., NITROTYROSINE, NITRATED LIPOPROTEINS, AND CARDIOVASCULAR DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES: WHAT DO WE KNOW AND WHAT REMAINS TO BE EXPLAINED?, ANTIOXIDANTS, 11, (2022); FERENCE B.A., GINSBERG H.N., GRAHAM I., RAY K.K., PACKARD C.J., BRUCKERT E., HEGELE R.A., KRAUSS R.M., RAAL F.J., SCHUNKERT H., ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR. HEART J, 38, PP. 2459-2472, (2017); MACH F., BAIGENT C., CATAPANO A.L., KOSKINAS K.C., CASULA M., BADIMON L., CHAPMAN M.J., DE BACKER G.G., DELGADO V., FERENCE B.A., ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR. HEART J, 41, PP. 111-188, (2020); GIDDING S.S., CHAMPAGNE M.A., DE FERRANTI S.D., DEFESCHE J., ITO M.K., KNOWLES J.W., MCCRINDLE B., RAAL F., RADER D., SANTOS R.D., ET AL., THE AGENDA FOR FAMILIAL HYPERCHOLESTEROLEMIA: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 132, PP. 2167-2192, (2015); GRUNDY S.M., STONE N.J., GUIDELINE G., WRITING COMMITTEE FOR THE CHOLESTEROL. 2018 CHOLESTEROL CLINICAL PRACTICE GUIDELINES: SYNOPSIS OF THE 2018 AMERICAN HEART ASSOCIATION/AMERICAN COLLEGE OF CARDIOLOGY/MULTISOCIETY CHOLESTEROL GUIDELINE, ANN. INTERN MED, 170, PP. 779-783, (2019); CHEELEY M.K., SASEEN J.J., AGARWALA A., RAVILLA S., CIFFONE N., JACOBSON T.A., DIXON D.L., MAKI K.C., NLA SCIENTIFIC STATEMENT ON STATIN INTOLERANCE: A NEW DEFINITION AND KEY CONSIDERATIONS FOR ASCVD RISK REDUCTION IN THE STATIN INTOLERANT PATIENT, J. CLIN. LIPIDOL, 16, PP. 361-375, (2022); BYTYCI I., PENSON P.E., MIKHAILIDIS D.P., WONG N.D., HERNANDEZ A.V., SAHEBKAR A., THOMPSON P.D., MAZIDI M., RYSZ J., PELLA D., ET AL., PREVALENCE OF STATIN INTOLERANCE: A META-ANALYSIS, EUR. HEART J, 43, PP. 3213-3223, (2022); CHEUNG B., THE INTERSECTION OF THE TWO COMPLIMENTARY FIELDS OF PREVENTIVE CARDIOLOGY AND INTEGRATIVE CARDIOLOGY: A FELLOW’S VOICE, AM. J. PREV. CARDIOL, 12, (2022); BIN Y.S., KIAT H., PREVALENCE OF DIETARY SUPPLEMENT USE IN PATIENTS WITH PROVEN OR SUSPECTED CARDIOVASCULAR DISEASE, EVID.-BASED COMPLEMENT. ALTERNAT. MED, 2011, (2011); BANACH M., CATAPANO A.L., CICERO A.F.G., ESCOBAR C., FOGER B., KATSIKI N., LATKOVSKIS G., RAKOWSKI M., REINER Z., SAHEBKAR A., ET AL., RED YEAST RICE FOR DYSLIPIDAEMIAS AND CARDIOVASCULAR RISK REDUCTION: A POSITION PAPER OF THE INTERNATIONAL LIPID EXPERT PANEL, PHARMACOL. RES, 183, (2022); OSADNIK T., GOLAWSKI M., LEWANDOWSKI P., MORZE J., OSADNIK K., PAWLAS N., LEJAWA M., JAKUBIAK G.K., MAZUR A., SCHWINGSCHACKL L., ET AL., A NETWORK META-ANALYSIS ON THE COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE IN ADULTS, PHARMACOL. RES, 183, (2022); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., FRAS Z., KATSIKI N., LANGLOIS M., LATKOVSKIS G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR. REV, 75, PP. 731-767, (2017); PARK S., KANG S., JEONG D.Y., JEONG S.Y., PARK J.J., YUN H.S., CYANIDIN AND MALVIDIN IN AQUEOUS EXTRACTS OF BLACK CARROTS FERMENTED WITH ASPERGILLUS ORYZAE PREVENT THE IMPAIRMENT OF ENERGY, LIPID AND GLUCOSE METABOLISM IN ESTROGEN-DEFICIENT RATS BY AMPK ACTIVATION, GENES NUTR, 10, (2015); ARAKI R., YADA A., UEDA H., TOMINAGA K., ISODA H., DIFFERENCES IN THE EFFECTS OF ANTHOCYANIN SUPPLEMENTATION ON GLUCOSE AND LIPID METABOLISM ACCORDING TO THE STRUCTURE OF THE MAIN ANTHOCYANIN: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTRIENTS, 13, (2021); KAPADIA V., EMBERS D., WELLS E., LEMLER M., ROSENFELD C.R., PRENATAL CLOSURE OF THE DUCTUS ARTERIOSUS AND MATERNAL INGESTION OF ANTHOCYANINS, J. PERINATOL, 30, PP. 291-294, (2010); RANGBOO V., NOROOZI M., ZAVOSHY R., REZADOOST S.A., MOHAMMADPOORASL A., THE EFFECT OF ARTICHOKE LEAF EXTRACT ON ALANINE AMINOTRANSFERASE AND ASPARTATE AMINOTRANSFERASE IN THE PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS, INT. J. HEPATOL, 2016, (2016); SAHEBKAR A., PIRRO M., BANACH M., MIKHAILIDIS D.P., ATKIN S.L., CICEO A.F.G., LIPID-LOWERING ACTIVITY OF ARTICHOKE EXTRACTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, CRIT. REV. FOOD SCI. NUTR, 58, PP. 2549-2556, (2018); (2022); LI H., DONG B., PARK S.W., LEE H.S., CHEN W., LIU J., HEPATOCYTE NUCLEAR FACTOR 1ALPHA PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINE, J. BIOL. CHEM, 284, PP. 28885-28895, (2009); ABIDI P., ZHOU Y., JIANG J.D., LIU J., EXTRACELLULAR SIGNAL-REGULATED KINASE-DEPENDENT STABILIZATION OF HEPATIC LOW-DENSITY LIPOPROTEIN RECEPTOR MRNA BY HERBAL MEDICINE BERBERINE, ARTER. THROMB. VASC. BIOL, 25, PP. 2170-2176, (2005); LI X.Y., ZHAO Z.X., HUANG M., FENG R., HE C.Y., MA C., LUO S.H., FU J., WEN B.Y., REN L., ET AL., EFFECT OF BERBERINE ON PROMOTING THE EXCRETION OF CHOLESTEROL IN HIGH-FAT DIET-INDUCED HYPERLIPIDEMIC HAMSTERS, J. TRANSL. MED, 13, (2015); LOH K., TAM S., MURRAY-SEGAL L., HUYNH K., MEIKLE P.J., SCOTT J.W., VAN DENDEREN B., CHEN Z., STEEL R., LEBLOND N.D., ET AL., INHIBITION OF ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE-3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE SIGNALING LEADS TO HYPERCHOLESTEROLEMIA AND PROMOTES HEPATIC STEATOSIS AND INSULIN RESISTANCE, HEPATOL. COMMUN, 3, PP. 84-98, (2019); KIM W.S., LEE Y.S., CHA S.H., JEONG H.W., CHOE S.S., LEE M.R., OH G.T., PARK H.S., LEE K.U., LANE M.D., ET AL., BERBERINE IMPROVES LIPID DYSREGULATION IN OBESITY BY CONTROLLING CENTRAL AND PERIPHERAL AMPK ACTIVITY, AM. J. PHYSIOL. ENDOCRINOL. METAB, 296, PP. E812-E819, (2009); WANG C., LI J., LV X., ZHANG M., SONG Y., CHEN L., LIU Y., AMELIORATIVE EFFECT OF BERBERINE ON ENDOTHELIAL DYSFUNCTION IN DIABETIC RATS INDUCED BY HIGH-FAT DIET AND STREPTOZOTOCIN, EUR. J. PHARMACOL, 620, PP. 131-137, (2009); BERTUCCIOLI A., MORICOLI S., AMATORI S., ROCCHI M.B.L., VICI G., SISTI D., BERBERINE AND DYSLIPIDEMIA: DIFFERENT APPLICATIONS AND BIOPHARMACEUTICAL FORMULATIONS WITHOUT STATIN-LIKE MOLECULES-A META-ANALYSIS, J. MED. FOOD, 23, PP. 101-113, (2020); JU J., LI J., LIN Q., XU H., EFFICACY AND SAFETY OF BERBERINE FOR DYSLIPIDAEMIAS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, PHYTOMEDICINE, 50, PP. 25-34, (2018); LINN Y.C., LU J., LIM L.C., SUN H., SUN J., ZHOU Y., NG H.S., BERBERINE-INDUCED HAEMOLYSIS REVISITED: SAFETY OF RHIZOMA COPTIDIS AND CORTEX PHELLODENDRI IN CHRONIC HAEMATOLOGICAL DISEASES, PHYTOTHER. RES, 26, PP. 682-686, (2012); MUSOLINO V., GLIOZZI M., CARRESI C., MAIUOLO J., MOLLACE R., BOSCO F., SCARANO F., SCICCHITANO M., MARETTA A., PALMA E., ET AL., LIPID-LOWERING EFFECT OF BERGAMOT POLYPHENOLIC FRACTION: ROLE OF PANCREATIC CHOLESTEROL ESTER HYDROLASE, J. BIOL. REGUL. HOMEOST. AGENTS, 31, PP. 1087-1093, (2017); CAPPELLO A.R., DOLCE V., IACOPETTA D., MARTELLO M., FIORILLO M., CURCIO R., MUTO L., DHANYALAYAM D., BERGAMOT (CITRUS BERGAMIA RISSO) FLAVONOIDS AND THEIR POTENTIAL BENEFITS IN HUMAN HYPERLIPIDEMIA AND ATHEROSCLEROSIS: AN OVERVIEW, MINI REV. MED. CHEM, 16, PP. 619-629, (2016); LAMIQUIZ-MONEO I., GINE-GONZALEZ J., ALISENTE S., BEA A.M., PEREZ-CALAHORRA S., MARCO-BENEDI V., BAILA-RUEDA L., JARAUTA E., CENARRO A., CIVEIRA F., ET AL., EFFECT OF BERGAMOT ON LIPID PROFILE IN HUMANS: A SYSTEMATIC REVIEW, CRIT. REV. FOOD SCI. NUTR, 60, PP. 3133-3143, (2020); ASKARPOUR M., HADI A., SYMONDS M.E., MIRAGHAJANI M., SADEGHI O., SHEIKHI A., GHAEDI E., EFFICACY OF L-CARNITINE SUPPLEMENTATION FOR MANAGEMENT OF BLOOD LIPIDS: A SYSTEMATIC REVIEW AND DOSE-RESPONSE META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS, 29, PP. 1151-1167, (2019); CRUCIANI R.A., DVORKIN E., HOMEL P., MALAMUD S., CULLINEY B., LAPIN J., PORTENOY R.K., ESTEBAN-CRUCIANI N., SAFETY, TOLERABILITY AND SYMPTOM OUTCOMES ASSOCIATED WITH L-CARNITINE SUPPLEMENTATION IN PATIENTS WITH CANCER, FATIGUE, AND CARNITINE DEFICIENCY: A PHASE I/II STUDY, J. PAIN SYMPTOM. MANAG, 32, PP. 551-559, (2006); SEONG S.H., CHO S.C., PARK Y., CHA Y.S., L-CARNITINE-SUPPLEMENTED PARENTERAL NUTRITION IMPROVES FAT METABOLISM BUT FAILS TO SUPPORT COMPENSATORY GROWTH IN PREMATURE KOREAN INFANTS, NUTR. RES, 30, PP. 233-239, (2010); KELLER U., VAN DER WAL C., SELIGER G., SCHELER C., ROPKE F., EDER K., CARNITINE STATUS OF PREGNANT WOMEN: EFFECT OF CARNITINE SUPPLEMENTATION AND CORRELATION BETWEEN IRON STATUS AND PLASMA CARNITINE CONCENTRATION, EUR. J. CLIN. NUTR, 63, PP. 1098-1105, (2009); TARRAHI M.J., TARRAHI M.A., RAFIEE M., MANSOURIAN M., THE EFFECTS OF CHROMIUM SUPPLEMENTATION ON LIPID PROFILE IN HUMANS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL. RES, 164, (2021); ASBAGHI O., NAEINI F., ASHTARY-LARKY D., MORADI S., ZAKERI N., ESLAMPOUR E., KELISHADI M.R., NAEINI A.A., EFFECTS OF CHROMIUM SUPPLEMENTATION ON LIPID PROFILE IN PATIENTS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND DOSE-RESPONSE META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J. TRACE ELEM. MED. BIOL, 66, (2021); (2022); YLITALO R., LEHTINEN S., WUOLIJOKI E., YLITALO P., LEHTIMAKI T., CHOLESTEROL-LOWERING PROPERTIES AND SAFETY OF CHITOSAN, ARZNEIMITTELFORSCHUNG, 52, PP. 1-7, (2002); MORARU C., MINCEA M.M., FRANDES M., TIMAR B., OSTAFE V., A META-ANALYSIS ON RANDOMISED CONTROLLED CLINICAL TRIALS EVALUATING THE EFFECT OF THE DIETARY SUPPLEMENT CHITOSAN ON WEIGHT LOSS, LIPID PARAMETERS AND BLOOD PRESSURE, MEDICINA, 54, (2018); ARENAS-JAL M., SUNE-NEGRE J.M., GARCIA-MONTOYA E., COENZYME Q10 SUPPLEMENTATION: EFFICACY, SAFETY, AND FORMULATION CHALLENGES, COMPR. REV. FOOD SCI. FOOD SAF, 19, PP. 574-594, (2020); SHARIFI N., TABRIZI R., MOOSAZADEH M., MIRHOSSEINI N., LANKARANI K.B., AKBARI M., CHAMANI M., KOLAHDOOZ F., ASEMI Z., THE EFFECTS OF COENZYME Q10 SUPPLEMENTATION ON LIPID PROFILES AMONG PATIENTS WITH METABOLIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CURR. PHARMACOL. DES, 24, PP. 2729-4272, (2018); JORAT M.V., TABRIZI R., MIRHOSSEINI N., LANKARANI K.B., AKBARI M., HEYDARI S.T., MOTTAGHI R., ASEMI Z., THE EFFECTS OF COENZYME Q10 SUPPLEMENTATION ON LIPID PROFILES AMONG PATIENTS WITH CORONARY ARTERY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, LIPIDS HEALTH DIS, 17, (2018); VAISAR T., WANG S., OMER M., IRWIN A.D., STOREY C., TANG C., DEN HARTIGH L.J., 10,12-CONJUGATED LINOLEIC ACID SUPPLEMENTATION IMPROVES HDL COMPOSITION AND FUNCTION IN MICE, J. LIPID RES, 63, (2022); DERAKHSHANDE-RISHEHRI S.M., MANSOURIAN M., KELISHADI R., HEIDARI-BENI M., ASSOCIATION OF FOODS ENRICHED IN CONJUGATED LINOLEIC ACID (CLA) AND CLA SUPPLEMENTS WITH LIPID PROFILE IN HUMAN STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS, PUBLIC HEALTH NUTR, 18, PP. 2041-2054, (2015); JOSEPH S.V., JACQUES H., PLOURDE M., MITCHELL P.L., MCLEOD R.S., JONES P.J., CONJUGATED LINOLEIC ACID SUPPLEMENTATION FOR 8 WEEKS DOES NOT AFFECT BODY COMPOSITION, LIPID PROFILE, OR SAFETY BIOMARKERS IN OVERWEIGHT, HYPERLIPIDEMIC MEN, J. NUTR, 141, PP. 1286-1291, (2011); AL M.D., VAN HOUWELINGEN A.C., BADART-SMOOK A., HORNSTRA G., SOME ASPECTS OF NEONATAL ESSENTIAL FATTY ACID STATUS ARE ALTERED BY LINOLEIC ACID SUPPLEMENTATION OF WOMEN DURING PREGNANCY, J NUTR, 125, PP. 2822-2830, (1995); KUMAR P., MALHOTRA P., MA K., SINGLA A., HEDROUG O., SAKSENA S., DUDEJA P.K., GILL R.K., ALREFAI W.A., SREBP2 MEDIATES THE MODULATION OF INTESTINAL NPC1L1 EXPRESSION BY CURCUMIN, AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL, 301, PP. G148-G155, (2011); TAI M.H., CHEN P.K., CHEN P.Y., WU M.J., HO C.T., YEN J.H., CURCUMIN ENHANCES CELL-SURFACE LDLR LEVEL AND PROMOTES LDL UPTAKE THROUGH DOWNREGULATION OF PCSK9 GENE EXPRESSION IN HEPG2 CELLS, MOL. NUTR. FOOD RES, 58, PP. 2133-2145, (2014); LIN X.L., LIU M.H., HU H.J., FENG H.R., FAN X.J., ZOU W.W., PAN Y.Q., HU X.M., WANG Z., CURCUMIN ENHANCED CHOLESTEROL EFFLUX BY UPREGULATING ABCA1 EXPRESSION THROUGH AMPK-SIRT1-LXRALPHA SIGNALING IN THP-1 MACROPHAGE-DERIVED FOAM CELLS, DNA CELL BIOL, 34, PP. 561-572, (2015); SAHEBKAR A., A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS INVESTIGATING THE EFFECTS OF CURCUMIN ON BLOOD LIPID LEVELS, CLIN. NUTR, 33, PP. 406-414, (2014); DEVARAJ R.D., REDDY C.K., XU B., HEALTH-PROMOTING EFFECTS OF KONJAC GLUCOMANNAN AND ITS PRACTICAL APPLICATIONS: A CRITICAL REVIEW, INT. J. BIOL. MACROMOL, 126, PP. 273-281, (2019); HO H.V.T., JOVANOVSKI E., ZURBAU A., BLANCO MEJIA S., SIEVENPIPER J.L., AU-YEUNG F., JENKINS A.L., DUVNJAK L., LEITER L., VUKSAN V., A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF THE EFFECT OF KONJAC GLUCOMANNAN, A VISCOUS SOLUBLE FIBER, ON LDL CHOLESTEROL AND THE NEW LIPID TARGETS NON-HDL CHOLESTEROL AND APOLIPOPROTEIN B, AM. J. CLIN. NUTR, 105, PP. 1239-1247, (2017); HENRION M., FRANCEY C., LE K.A., LAMOTHE L., CEREAL B-GLUCANS: THE IMPACT OF PROCESSING AND HOW IT AFFECTS PHYSIOLOGICAL RESPONSES, NUTRIENTS, 11, (2019); YU J., XIA J., YANG C., PAN D., XU D., SUN G., XIA H., EFFECTS OF OAT BETA-GLUCAN INTAKE ON LIPID PROFILES IN HYPERCHOLESTEROLEMIC ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTRIENTS, 14, (2022); LIN J., SUN Y., SANTOS H.O., GAMAN M.A., BHAT L.T., CUI Y., EFFECTS OF GUAR GUM SUPPLEMENTATION ON THE LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS, 31, PP. 3271-3281, (2021); GYLLING H., RIIKONEN S., NIKKILA K., SAVONIUS H., MIETTINEN T.A., ORAL GUAR GUM TREATMENT OF INTRAHEPATIC CHOLESTASIS AND PRURITUS IN PREGNANT WOMEN: EFFECTS ON SERUM CHOLESTANOL AND OTHER NON-CHOLESTEROL STEROLS, EUR. J. CLIN. INVESTIG, 28, PP. 359-363, (1998); JOVANOVSKI E., YASHPAL S., KOMISHON A., ZURBAU A., BLANCO MEJIA S., HO H.V.T., LI D., SIEVENPIPER J., DUVNJAK L., VUKSAN V., EFFECT OF PSYLLIUM (PLANTAGO OVATA) FIBER ON LDL CHOLESTEROL AND ALTERNATIVE LIPID TARGETS, NON-HDL CHOLESTEROL AND APOLIPOPROTEIN B: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR, 108, PP. 922-932, (2018); CHEN C., SHANG C., XIN L., XIANG M., WANG Y., SHEN Z., JIAO L., DING F., CUI X., BENEFICIAL EFFECTS OF PSYLLIUM ON THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC DISEASES, FOOD FUNCT, 13, PP. 7473-7486, (2022); SHIRAH B.H., SHIRAH H.A., FALLATA A.H., ALOBIDY S.N., AL HAWSAWI M.M., HEMORRHOIDS DURING PREGNANCY: SITZ BATH VS. ANO-RECTAL CREAM: A COMPARATIVE PROSPECTIVE STUDY OF TWO CONSERVATIVE TREATMENT PROTOCOLS, WOMEN BIRTH, 31, PP. E272-E277, (2018); BORLINGHAUS J., ALBRECHT F., GRUHLKE M.C., NWACHUKWU I.D., SLUSARENKO A.J., ALLICIN: CHEMISTRY AND BIOLOGICAL PROPERTIES, MOLECULES, 19, PP. 12591-12618, (2014); SUN Y.E., WANG W., QIN J., ANTI-HYPERLIPIDEMIA OF GARLIC BY REDUCING THE LEVEL OF TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN: A META-ANALYSIS, MEDICINE, 97, (2018); RIED K., TOBEN C., FAKLER P., EFFECT OF GARLIC ON SERUM LIPIDS: AN UPDATED META-ANALYSIS, NUTR. REV, 71, PP. 282-299, (2013); BANACH M., PATTI A.M., GIGLIO R.V., CICERO A.F.G., ATANASOV A.G., BAJRAKTARI G., BRUCKERT E., DESCAMPS O., DJURIC D.M., EZHOV M., ET AL., THE ROLE OF NUTRACEUTICALS IN STATIN INTOLERANT PATIENTS, J. AM. COLL. CARDIOL, 72, PP. 96-118, (2018); HUANG S., CHEN H., TENG J., WU Z.L., WEI L., XIA N., ANTIHYPERLIPIDEMIC EFFECT AND INCREASED ANTIOXIDANT ENZYME LEVELS OF AQUEOUS EXTRACTS FROM LIUPAO TEA AND GREEN TEA IN VIVO, J. FOOD SCI, 87, PP. 4203-4220, (2022); WENG X., ODOULI R., LI D.K., MATERNAL CAFFEINE CONSUMPTION DURING PREGNANCY AND THE RISK OF MISCARRIAGE: A PROSPECTIVE COHORT STUDY, AM. J. OBSTET. GYNECOL, 198, PP. 279.E1-279.E8, (2008); ERICKSON N., ZAFRON M., HARDING S.V., MARINANGELI C.P., RIDEOUT T.C., EVALUATING THE LIPID-LOWERING EFFECTS OF ALPHA-LIPOIC ACID SUPPLEMENTATION: A SYSTEMATIC REVIEW, J. DIET. SUPPL, 17, PP. 753-767, (2020); MAHMOUDINEZHAD M., FARHANGI M.A., ALPHA LIPOIC ACID SUPPLEMENTATION AFFECTS SERUM LIPIDS IN A DOSE AND DURATION-DEPENDENT MANNER IN DIFFERENT HEALTH STATUS, INT. J. VITAM. NUTR. RES, (2021); NAJAFI N., MEHRI S., GHASEMZADEH RAHBARDAR M., HOSSEINZADEH H., EFFECTS OF ALPHA LIPOIC ACID ON METABOLIC SYNDROME: A COMPREHENSIVE REVIEW, PHYTOTHER. RES, 36, PP. 2300-2323, (2022); LAMMI C., FASSI E.M.A., LI J., BARTOLOMEI M., BENIGNO G., RODA G., ARNOLDI A., GRAZIOSO G., COMPUTATIONAL DESIGN AND BIOLOGICAL EVALUATION OF ANALOGS OF LUPIN PEPTIDE P5 ENDOWED WITH DUAL PCSK9/HMG-COAR INHIBITING ACTIVITY, PHARMACEUTICS, 14, (2022); LAMMI C., BOLLATI C., LECCA D., ABBRACCHIO M.P., ARNOLDI A., LUPIN PEPTIDE T9 (GQEQSHQDEGVIVR) MODULATES THE MUTANT PCSK9(D374Y) PATHWAY: IN VITRO CHARACTERIZATION OF ITS DUAL HYPOCHOLESTEROLEMIC BEHAVIOR, NUTRIENTS, 11, (2019); LAMMI C., ZANONI C., SCIGLIUOLO G.M., D'AMATO A., ARNOLDI A., ARNOLDI. LUPIN PEPTIDES LOWER LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL THROUGH AN UP-REGULATION OF THE LDL RECEPTOR/STEROL REGULATORY ELEMENT BINDING PROTEIN 2 (SREBP2) PATHWAY AT HEPG2 CELL LINE, J. AGRIC. FOOD CHEM, 62, PP. 7151-7159, (2014); BAHR M., FECHNER A., KRAMER J., KIEHNTOPF M., JAHREIS G., LUPIN PROTEIN POSITIVELY AFFECTS PLASMA LDL CHOLESTEROL AND LDL:HDL CHOLESTEROL RATIO IN HYPERCHOLESTEROLEMIC ADULTS AFTER FOUR WEEKS OF SUPPLEMENTATION: A RANDOMIZED, CONTROLLED CROSSOVER STUDY, NUTR. J, 12, (2013); ZHANG Q., QIAN Z.Y., ZHOU P.H., ZHOU X.L., ZHANG D.L., HE N., ZHANG J., LIU Y.H., GU Q., EFFECTS OF ORAL SELENIUM AND MAGNESIUM CO-SUPPLEMENTATION ON LIPID METABOLISM, ANTIOXIDATIVE STATUS, HISTOPATHOLOGICAL LESIONS, AND RELATED GENE EXPRESSION IN RATS FED A HIGH-FAT DIET, LIPIDS HEALTH DIS, 17, (2018); ASBAGHI O., MORADI S., NEZAMOLESLAMI S., MOOSAVIAN S.P., HOJJATI KERMANI M.A., LAZARIDI A.V., MIRAGHAJANI M., THE EFFECTS OF MAGNESIUM SUPPLEMENTATION ON LIPID PROFILE AMONG TYPE 2 DIABETES PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, BIOL. TRACE ELEM. RES, 199, PP. 861-873, (2021); SIMENTAL-MENDIA L.E., SIMENTAL-MENDIA M., SAHEBKAR A., RODRIGUEZ-MORAN M., GUERRERO-ROMERO F., EFFECT OF MAGNESIUM SUPPLEMENTATION ON LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, EUR. J. CLIN. PHARMACOL, 73, PP. 525-536, (2017); LIU M., DUDLEY S.C., MAGNESIUM, OXIDATIVE STRESS, INFLAMMATION, AND CARDIOVASCULAR DISEASE, ANTIOXIDANTS, 9, (2020); VAN LAECKE S., HYPOMAGNESEMIA AND HYPERMAGNESEMIA, ACTA CLIN. BELG, 74, PP. 41-47, (2019); KAMANNA V.S., KASHYAP M.L., MECHANISM OF ACTION OF NIACIN, AM. J. CARDIOL, 101, PP. 20B-26B, (2008); EFFECTS OF EXTENDED-RELEASE NIACIN WITH LAROPIPRANT IN HIGH-RISK PATIENTS, N. ENGL. J. MED, 371, PP. 203-212, (2014); NIACIN IN PATIENTS WITH LOW HDL CHOLESTEROL LEVELS RECEIVING INTENSIVE STATIN THERAPY, N. ENGL. J. MED, 365, PP. 2255-2267, (2011); PALAWATHTHA S., ISLAM R.M., ILLIC D., RABEL K., LEE M., ROMERO L., LEUNG X.Y., KARIM M.N., EFFECT OF MATERNAL DIETARY NIACIN INTAKE ON CONGENITAL ANOMALIES: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR. J. NUTR, 61, PP. 1133-1142, (2022); ASGARY S., SAHEBKAR A., GOLI-MALEKABADI N., AMELIORATIVE EFFECTS OF NIGELLA SATIVA ON DYSLIPIDEMIA, J. ENDOCRINOL. INVESTIG, 38, PP. 1039-1046, (2015); HALLAJZADEH J., MILAJERDI A., MOBINI M., AMIRANI E., AZIZI S., NIKKHAH E., BAHADORI B., SHEIKHSOLEIMANI R., MIRHASHEMI S.M., EFFECTS OF NIGELLA SATIVA ON GLYCEMIC CONTROL, LIPID PROFILES, AND BIOMARKERS OF INFLAMMATORY AND OXIDATIVE STRESS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS, PHYTOTHER. RES, 34, PP. 2586-2608, (2020); JAHAN S., MOZUMDER Z.M., SHILL D.K., USE OF HERBAL MEDICINES DURING PREGNANCY IN A GROUP OF BANGLADESHI WOMEN, HELIYON, 8, (2022); LOCKYER S., YAQOOB P., SPENCER J.P.E., ROWLAND I., OLIVE LEAF PHENOLICS AND CARDIOVASCULAR RISK REDUCTION: PHYSIOLOGICAL EFFECTS AND MECHANISMS OF ACTION, NUTR. AGING, 1, PP. 125-140, (2012); LOCKYER S., ROWLAND I., SPENCER J.P.E., YAQOOB P., STONEHOUSE W., IMPACT OF PHENOLIC-RICH OLIVE LEAF EXTRACT ON BLOOD PRESSURE, PLASMA LIPIDS AND INFLAMMATORY MARKERS: A RANDOMISED CONTROLLED TRIAL, EUR. J. NUTR, 56, PP. 1421-1432, (2017); RAMAZANI E., AKABERI M., EMAMI S.A., TAYARANI-NAJARAN Z., BIOLOGICAL AND PHARMACOLOGICAL EFFECTS OF GAMMA-ORYZANOL: AN UPDATED REVIEW OF THE MOLECULAR MECHANISMS, CURR. PHARM. DES, 27, PP. 2299-2316, (2021); YAN S., CHEN J., ZHU L., GUO T., QIN D., HU Z., HAN S., ZHOU Y., AKAN O.D., WANG J., ET AL., ORYZANOL ATTENUATES HIGH FAT AND CHOLESTEROL DIET-INDUCED HYPERLIPIDEMIA BY REGULATING THE GUT MICROBIOME AND AMINO ACID METABOLISM, J. AGRIC. FOOD CHEM, 70, PP. 6429-6443, (2022); POURRAJAB B., SOHOULI M.H., AMIRINEJAD A., FATAHI S., GAMAN M.A., SHIDFAR F., THE IMPACT OF RICE BRAN OIL CONSUMPTION ON THE SERUM LIPID PROFILE IN ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CRIT. REV. FOOD SCI. NUTR, 62, PP. 6005-6015, (2022); EVANS M., RUMBERGER J.A., AZUMANO I., NAPOLITANO J.J., CITROLO D., KAMIYA T., PANTETHINE, A DERIVATIVE OF VITAMIN B5, FAVORABLY ALTERS TOTAL, LDL AND NON-HDL CHOLESTEROL IN LOW TO MODERATE CARDIOVASCULAR RISK SUBJECTS ELIGIBLE FOR STATIN THERAPY: A TRIPLE-BLINDED PLACEBO AND DIET-CONTROLLED INVESTIGATION, VASC. HEALTH RISK MANAG, 10, PP. 89-100, (2014); DONATI C., BARBI G., CAIRO G., PRATI G.F., DEGLI ESPOSTI E., PANTETHINE IMPROVES THE LIPID ABNORMALITIES OF CHRONIC HEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTER CLINICAL TRIAL, CLIN. NEPHROL, 25, PP. 70-74, (1986); BERTOLINI S., DONATI C., ELICIO N., DAGA A., CUZZOLARO S., MARCENARO A., SATURNINO M., BALESTRERI R., LIPOPROTEIN CHANGES INDUCED BY PANTETHINE IN HYPERLIPOPROTEINEMIC PATIENTS: ADULTS AND CHILDREN, INT. J. CLIN. PHARMACOL. THER. TOXICOL, 24, PP. 630-637, (1986); HARRIS W.S., BULCHANDANI S., WHY DO OMEGA-3 FATTY ACIDS LOWER SERUM TRIGLYCERIDES?, CURR. OPIN. LIPIDOL, 17, PP. 387-393, (2006); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO EPA, DHA, DPA AND MAINTENANCE OF NORMAL BLOOD PRESSURE (ID 502), MAINTENANCE OF NORMAL HDL-CHOLESTEROL CONCENTRATIONS (ID 515), MAINTENANCE OF NORMAL (FASTING) BLOOD CONCENTRATIONS OF TRIGLYCERIDES (ID 517), MAINTENANCE OF NORMAL LDL-CHOLESTEROL CONCENTRATIONS (ID 528, 698) AND MAINTENANCE OF JOINTS (ID 503, 505, 507, 511, 518, 524, 526, 535, 537) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 7, (2009); NICHOLLS S.J., LINCOFF A.M., GARCIA M., BASH D., BALLANTYNE C.M., BARTER P.J., DAVIDSON M.H., KASTELEIN J.J.P., KOENIG W., MCGUIRE D.K., ET AL., EFFECT OF HIGH-DOSE OMEGA-3 FATTY ACIDS VS CORN OIL ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AT HIGH CARDIOVASCULAR RISK: THE STRENGTH RANDOMIZED CLINICAL TRIAL, JAMA, 324, PP. 2268-2280, (2020); ZHANG H.J., GAO X., GUO X.F., LI K.L., LI S., SINCLAIR A.J., LI D., EFFECTS OF DIETARY EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID SUPPLEMENTATION ON METABOLIC SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS OF DATA FROM 33 RANDOMIZED CONTROLLED TRIALS, CLIN. NUTR, 40, PP. 4538-4550, (2021); BHATT D.L., STEG P.G., MILLER M., BRINTON E.A., JACOBSON T.A., KETCHUM S.B., DOYLE R.T., JULIANO R.A., JIAO L., GRANOWITZ C., ET AL., CARDIOVASCULAR RISK REDUCTION WITH ICOSAPENT ETHYL FOR HYPERTRIGLYCERIDEMIA, N. ENGL. J. MED, 380, PP. 11-22, (2019); SAHA S., SAHA S., THE EFFECTS OF PRENATAL DIETARY SUPPLEMENTS ON BLOOD GLUCOSE AND LIPID METABOLISM IN GESTATIONAL DIABETES MELLITUS PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS PROTOCOL OF RANDOMIZED CONTROLLED TRIALS, PLOS ONE, 17, (2022); BROUNS F., THEUWISSEN E., ADAM A., BELL M., BERGER A., MENSINK R.P., CHOLESTEROL-LOWERING PROPERTIES OF DIFFERENT PECTIN TYPES IN MILDLY HYPER-CHOLESTEROLEMIC MEN AND WOMEN, EUR. J. CLIN. NUTR, 66, PP. 591-599, (2012); HU H., ZHANG S., LIU F., ZHANG P., MUHAMMAD Z., PAN S., ROLE OF THE GUT MICROBIOTA AND THEIR METABOLITES IN MODULATING THE CHOLESTEROL-LOWERING EFFECTS OF CITRUS PECTIN OLIGOSACCHARIDES IN C57BL/6 MICE, J. AGRIC. FOOD CHEM, 67, PP. 11922-11930, (2019); FERMENTABLE FIBERS AND VITAMIN B12 DEPENDENCY, NUTR. REV, 49, PP. 119-120, (1991); SHAGHAGHI M.A., ABUMWEIS S.S., JONES P.J., CHOLESTEROL-LOWERING EFFICACY OF PLANT STEROLS/STANOLS PROVIDED IN CAPSULE AND TABLET FORMATS: RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS, J. ACAD. NUTR. DIET, 113, PP. 1494-14503, (2013); SABEVA N.S., MCPHAUL C.M., LI X., CORY T.J., FEOLA D.J., GRAF G.A., PHYTOSTEROLS DIFFERENTIALLY INFLUENCE ABC TRANSPORTER EXPRESSION, CHOLESTEROL EFFLUX AND INFLAMMATORY CYTOKINE SECRETION IN MACROPHAGE FOAM CELLS, J. NUTR. BIOCHEM, 22, PP. 777-783, (2011); HO S.S., PAL S., MARGARINE PHYTOSTEROLS DECREASE THE SECRETION OF ATHEROGENIC LIPOPROTEINS FROM HEPG2 LIVER AND CACO2 INTESTINAL CELLS, ATHEROSCLEROSIS, 182, PP. 29-36, (2005); GAO F., WANG G., WANG L., GUO N., PHYTOSTEROL NUTRITIONAL SUPPLEMENT IMPROVES PREGNANCY AND NEONATAL COMPLICATIONS OF GESTATIONAL DIABETES MELLITUS IN A DOUBLE-BLIND AND PLACEBO-CONTROLLED CLINICAL STUDY, FOOD FUNCT, 8, PP. 424-428, (2017); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL EXP. THER, 318, PP. 1020-1026, (2006); ZHAI Z., NIU K.M., LIU H., LIN C., TU Y., LIU Y., CAI L., OUYANG K., LIU J., POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6/MICE THROUGH AMPK-FXR-TGR5 CROSS-TALK, J. FOOD SCI, 86, PP. 5466-5478, (2021); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG. CARCINOG. MUTAGEN, 18, PP. 1-7, (1998); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG. CARCINOG. MUTAGEN, 14, PP. 107-113, (1994); KIM G.B., YI S.H., LEE B.H., PURIFICATION AND CHARACTERIZATION OF THREE DIFFERENT TYPES OF BILE SALT HYDROLASES FROM BIFIDOBACTERIUM STRAINS, J. DAIRY SCI, 87, PP. 258-266, (2004); YOON H., LEE Y., KANG H.J., JU J., JI Y., PARK H., LEE H., HOLZAPFEL W.H., TWO PUTATIVE PROBIOTIC STRAINS IMPROVE DIET-INDUCED HYPERCHOLESTEROLEMIA THROUGH MODULATING INTESTINAL CHOLESTEROL UPTAKE AND HEPATIC CHOLESTEROL EFFLUX, J. APPL. MICROBIOL, 132, PP. 562-570, (2022); YANG M., ZHENG J., ZONG X., YANG X., ZHANG Y., MAN C., JIANG Y., PREVENTIVE EFFECT AND MOLECULAR MECHANISM OF LACTOBACILLUS RHAMNOSUS JL1 ON FOOD-BORNE OBESITY IN MICE, NUTRIENTS, 13, (2021); SUN K., LIU Z., WANG H., THE EFFECT OF PROBIOTICS ON THE SERUM LIPID LEVELS IN NON-OBESE HEALTHY ADULTS WITH HYPERLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR. HOSP, 39, PP. 157-170, (2022); SIRTORI C.R., THE PHARMACOLOGY OF STATINS, PHARMACOL. RES, 88, PP. 3-11, (2014); STATINS: DRUG SAFETY COMMUNICATION–FDA REQUESTS REMOVAL OF STRONGEST WARNING AGAINST USING CHOLESTEROL-LOWERING STATINS DURING PREGNANCY, (2021); BANACH M., BRUCKERT E., DESCAMPS O.S., ELLEGARD L., EZHOV M., FOGER B., FRAS Z., KOVANEN P.T., LATKOVSKIS G., MARZ W., ET AL., THE ROLE OF RED YEAST RICE (RYR) SUPPLEMENTATION IN PLASMA CHOLESTEROL CONTROL: A REVIEW AND EXPERT OPINION, ATHEROSCLER. SUPPL, 39, PP. E1-E8, (2019); AHN J., CHO I., KIM S., KWON D., HA T., DIETARY RESVERATROL ALTERS LIPID METABOLISM-RELATED GENE EXPRESSION OF MICE ON AN ATHEROGENIC DIET, J. HEPATOL, 49, PP. 1019-1028, (2008); DONG W., WANG X., BI S., PAN Z., LIU S., YU H., LU H., LIN X., WANG X., MA T., ET AL., INHIBITORY EFFECTS OF RESVERATROL ON FOAM CELL FORMATION ARE MEDIATED THROUGH MONOCYTE CHEMOTACTIC PROTEIN-1 AND LIPID METABOLISM-RELATED PROTEINS, INT. J. MOL. MED, 33, PP. 1161-1168, (2014); SIMENTAL-MENDIA L.E., GUERRERO-ROMERO F., EFFECT OF RESVERATROL SUPPLEMENTATION ON LIPID PROFILE IN SUBJECTS WITH DYSLIPIDEMIA: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, NUTRITION, 58, PP. 7-10, (2019); CAO X., LIAO W., XIA H., WANG S., SUN G., THE EFFECT OF RESVERATROL ON BLOOD LIPID PROFILE: A DOSE-RESPONSE META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTRIENTS, 14, (2022); XIAO P.T., LIU S.Y., KUANG Y.J., JIANG Z.M., LIN Y., XIE Z.S., LIU E.H., NETWORK PHARMACOLOGY ANALYSIS AND EXPERIMENTAL VALIDATION TO EXPLORE THE MECHANISM OF SEA BUCKTHORN FLAVONOIDS ON HYPERLIPIDEMIA, J. ETHNOPHARMACOL, 264, (2022); GENG Y., WANG J., CHEN K., LI Q., PING Z., XUE R., ZHANG S., EFFECTS OF SEA BUCKTHORN (HIPPOPHAE RHAMNOIDES L.) ON FACTORS RELATED TO METABOLIC SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL, PHYTOTHER. RES, 36, PP. 4101-4114, (2022); WEN P., ZHAO P., QIN G., TANG S., LI B., ZHANG J., PENG L., GENOTOXICITY AND TERATOGENICITY OF SEABUCKTHORN (HIPPOPHAE RHAMNOIDES L.) BERRY OIL, DRUG CHEM. TOXICOL, 43, PP. 391-397, (2020); XIAO P., JI H., YE Y., ZHANG B., CHEN Y., TIAN J., LIU P., CHEN L., DU Z., DIETARY SILYMARIN SUPPLEMENTATION PROMOTES GROWTH PERFORMANCE AND IMPROVES LIPID METABOLISM AND HEALTH STATUS IN GRASS CARP (CTENOPHARYNGODON IDELLUS) FED DIETS WITH ELEVATED LIPID LEVELS, FISH PHYSIOL. BIOCHEM, 43, PP. 245-263, (2017); WANG L., ROTTER S., LADURNER A., HEISS E.H., OBERLIES N.H., DIRSCH V.M., ATANASOV A.G., SILYMARIN CONSTITUENTS ENHANCE ABCA1 EXPRESSION IN THP-1 MACROPHAGES, MOLECULES, 21, (2015); SOLEYMANI S., AYATI M.H., MANSOURZADEH M.J., NAMAZI N., ZARGARAN A., THE EFFECTS OF SILYMARIN ON THE FEATURES OF CARDIOMETABOLIC SYNDROME IN ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, PHYTOTHER. RES, 36, PP. 842-856, (2022); (2022); LI T.T., TONG A.J., LIU Y.Y., HUANG Z.R., WAN X.Z., PAN Y.Y., JIA R.B., LIU B., CHEN X.H., ZHAO C., POLYUNSATURATED FATTY ACIDS FROM MICROALGAE SPIRULINA PLATENSIS MODULATES LIPID METABOLISM DISORDERS AND GUT MICROBIOTA IN HIGH-FAT DIET RATS, FOOD CHEM. TOXICOL, 131, (2019); HATAMI E., GHALISHOURANI S.S., NAJAFGHOLIZADEH A., POURMASOUMI M., HADI A., CLARK C.C., ASSAROUDI M., SALEHI-SAHLABADI A., JOUKAR F., MANSOUR-GHANAEI F., THE EFFECT OF SPIRULINA ON TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. DIABETES METAB. DISORD, 20, PP. 883-892, (2021); MACCHI C., GRECO M.F., FERRI N., MAGNI P., ARNOLDI A., CORSINI A., SIRTORI C.R., RUSCICA M., LAMMI C., IMPACT OF SOY BETA-CONGLYCININ PEPTIDES ON PCSK9 PROTEIN EXPRESSION IN HEPG2 CELLS, NUTRIENTS, 14, (2021); CHO S.J., JUILLERAT M.A., LEE C.H., CHOLESTEROL LOWERING MECHANISM OF SOYBEAN PROTEIN HYDROLYSATE, J. AGRIC. FOOD CHEM, 55, PP. 10599-10604, (2007); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J. NUTR, 125, PP. 606S-611S, (1995); BUTTEIGER D.N., HIBBERD A.A., MCGRAW N.J., NAPAWAN N., HALL-PORTER J.M., KRUL E.S., SOY PROTEIN COMPARED WITH MILK PROTEIN IN A WESTERN DIET INCREASES GUT MICROBIAL DIVERSITY AND REDUCES SERUM LIPIDS IN GOLDEN SYRIAN HAMSTERS, J. NUTR, 146, PP. 697-705, (2016); NAPOLI C., LECCESE M., PALUMBO G., DE NIGRIS F., CHIARIELLO P., ZULIANI P., SOMMA P., DI LORETO M., DE MATTEIS C., CACCIATORE F., ET AL., EFFECTS OF VITAMIN E AND HMG-COA REDUCTASE INHIBITION ON CHOLESTERYL ESTER TRANSFER PROTEIN AND LECITHIN-CHOLESTEROL ACYLTRANSFERASE IN HYPERCHOLESTEROLEMIA, CORON. ARTERY DIS, 9, PP. 257-264, (1998); LI F., TAN W., KANG Z., WONG C.W., TOCOTRIENOL ENRICHED PALM OIL PREVENTS ATHEROSCLEROSIS THROUGH MODULATING THE ACTIVITIES OF PEROXISOME PROLIFERATORS-ACTIVATED RECEPTORS, ATHEROSCLEROSIS, 211, PP. 278-282, (2010); TRABER M.G., HEAD B., VITAMIN E: HOW MUCH IS ENOUGH, TOO MUCH AND WHY!, FREE RADIC. BIOL. MED, 177, PP. 212-225, (2021); ZUO S., WANG G., HAN Q., XIAO H., SANTOS H.O., RODRIGUEZ D.A., KHANI V., TANG J., THE EFFECTS OF TOCOTRIENOL SUPPLEMENTATION ON LIPID PROFILE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT THER. MED, 52, (2020)","A. BARSEGHIAN EL-FARRA; SUSAN SAMUELI INTEGRATIVE HEALTH INSTITUTE, IRVINE, 856 HEALTH SCIENCES ROAD, 92617, UNITED STATES; EMAIL: BARSEGHA@HS.UCI.EDU","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","J. CLIN. MED.","REVIEW","ISI","2-S2.0-85160543353","J CLIN MED","CA;UNIVERSITY OF CALIFORNIA;CA;CA;CA","NOTREPORTED;SUSAN SAMUELI INTEGRATIVE HEALTH INSTITUTE;NOTREPORTED",NA,"CHEUNG B, 2023, J CLIN MED","CHEUNG B, 2023, J CLIN MED"
"WO J","WO, JOHN (59027084600)","THE TREATMENT OF LICHEN PLANUS WITH ACUPUNCTURE AND CHINESE HERBAL MEDICINE A CASE REPORT",2023,"JOURNAL OF CHINESE MEDICINE","2023","6",0,"","HONOLULU, HI, UNITED STATES","LICHEN PLANUS (LP) IS A CHRONIC, INFLAMMATORY, IMMUNE-MEDIATED SKIN CONDITION WITH AN UNKNOWN AETIOLOGY AND PATHOGENESIS. ITS TREATMENT REMAINS CONTROVERSIAL, WITH NO EVIDENCE-BASED BEST PRACTICE. THIS CASE REPORT EXPLORES THE USE OF ACUPUNCTURE AND CHINESE HERBAL MEDICINE IN A 58-YEAR-OLD MALE PATIENT WITH LP PRESENTING WITH PURPLE, PRURITIC, LICHENOID PLAQUES ON HIS HANDS, ARMS, TORSO, LEGS AND FEET. OVER FORTY WEEKS, THE PATIENT RECEIVED 23 ACUPUNCTURE TREATMENTS AND UTILISED INTERNAL HERBAL THERAPY. HE EXPERIENCED COMPLETE RESOLUTION OF ITCHING, LICHENIFICATION AND HYPERPIGMENTATION OF HIS SKIN. THIS CASE ILLUSTRATES THE POSSIBILITY OF USING ACUPUNCTURE AND CHINESE HERBAL MEDICINE AS A VIABLE TREATMENT FOR LP. © 2023, JOURNAL OF CHINESE MEDICINE. ALL RIGHTS RESERVED.","ACUPUNCTURE; CHINESE HERBAL MEDICINE; DERMATOLOGY; LICHEN PLANUS; TCM; TRADITIONAL CHINESE MEDICINE","ACETYLSALICYLIC ACID; ANGELICA SINENSIS EXTRACT; ASCORBIC ACID; ATRACTYLODES MACROCEPHALA EXTRACT; BO HE; CHINESE MEDICINAL FORMULA; GLYCYRRHIZA URALENSIS ROOT; HYPOCHOLESTEROLEMIC AGENT; LYSINE; MOUTAN CORTEX; MULTIVITAMIN; NICOTINIC ACID; PANTOTHENIC ACID; POLICOSANOL; PORIA COCOS EXTRACT; PRASTERONE; RADIX BUPLEURI; RADIX PAEONIAE ALBA; THIOCTIC ACID; UBIQUINOL; UNCLASSIFIED DRUG; WEI JIANG; ZHI ZI; ACUPUNCTURE; ADULT; ARM; ARTICLE; CASE REPORT; CHEEK; CHINESE MEDICINE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; EMOTIONAL DISORDER; FAMILY HISTORY; FOOT; HAND; HUMAN; HYPERPIGMENTATION; LEG; LICHEN PLANUS; LICHENOID ERUPTION; MALE; MEDICAL HISTORY; MICROCAPSULE; MIDDLE AGED; ORAL LICHEN PLANUS; PHYSIOLOGICAL STRESS; PRURITUS; QI STAGNATION; SABAL; TONGUE; TREATMENT RESPONSE; TRUNK","","","SOLIMANI F., FORCHHAMMER S., SCHLOEGL A., ET AL., LICHEN PLANUS -A CLINICAL GUIDE, JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 19, 6, PP. 864-882, (2021); GOROUHI F., DAVARI P., FAZEL N., CUTANEOUS AND MUCOSAL LICHEN PLANUS: A COMPREHENSIVE REVIEW OF CLINICAL SUBTYPES, RISK FACTORS, DIAGNOSIS, AND PROGNOSIS, THE SCIENTIFIC WORLD JOURNAL, 2014, (2014); ALRASHDAN M.S., CIRILLO N., MCCULLOUGH M., ORAL LICHEN PLANUS: A LITERATURE REVIEW AND UPDATE, ARCHIVES OF DERMATOLOGICAL RESEARCH, 308, 8, PP. 539-551, (2016); SAMREEN A., LUQMAN N., ASGHER R., ET AL., FREQUENCY OF ORAL INVOLVEMENT IN CUTANEOUS LICHEN PLANUS PATIENTS, JOURNAL OF PAKISTAN ASSOCIATION OF DERMATOLOGISTS, 31, 3, PP. 454-458, (2021); WAGNER G., ROSE C., SACHSE M., CLINICAL VARIANTS OF LICHEN PLANUS, JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 11, 4, PP. 309-319, (2013); CHOLEWA K., MITAS K., ZAREMBA B., ET AL., CURRENT REVIEW OF CONECTIONS BETWEEN LICHEN PLANUS AND MENTAL DISORDERS, JOURNAL OF EDUCATION, HEALTH AND SPORT, 10, 3, PP. 57-65, (2020); FAZEL N., CUTANEOUS LICHEN PLANUS: A SYSTEMATIC REVIEW OF TREATMENTS, JOURNAL OF DERMATOLOGICAL TREATMENT, 26, 3, PP. 280-283, (2014); THANDAR Y., MAHARAJH R., HAFFEJEE F., ET AL., TREATMENT OF CUTANEOUS LICHEN PLANUS (PART 2): A REVIEW OF SYSTEMIC THERAPIES, JOURNAL OF DERMATOLOGICAL TREATMENT, 30, 7, PP. 633-647, (2018); UNSCHULD P., TESSENOW H., ZHENG J., HUANG DI NEI JING SU WEN: AN ANNOTATED TRANSLATION OF HUANG DI’S INNER CLASSIC --BASIC QUESTIONS, (2011); SHEN D., WU H., WANG N., MANUAL OF DERMATOLOGY IN CHINESE MEDICINE, (1995); XU X., DERMATOLOGY: VOLUME 16 OF THE ENGLISH-CHINESE ENCYCLOPEDIA OF PRACTICAL TRADITIONAL CHINESE MEDICINE, (1991); LIANG C., ZHANG T., FLAWS B., A HANDBOOK OF TRADITIONAL CHINESE DERMATOLOGY, (1988); LUO Y., CHEN J., KUAI L., ET AL., CHINESE HERBAL MEDICINE FOR PSORIASIS: EVIDENCE FROM 11 HIGH-QUALITY RANDOMIZED CONTROLLED TRIALS, FRONTIERS IN PHARMACOLOGY, (2020); LEI H., CHEN M., ZHANG N., ET AL., A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE EFFICACY AND SAFETY OF TRADITIONAL CHINESE MEDICINE BATH IN THE TREATMENT OF PSORIASIS VULGARIS, ANNALS OF PALLIATIVE MEDICINE, 10, 10, PP. 10674-10683, (2021); YANG X., YANG N., HUANG F., ET AL., EFFECTIVENESS OF ACUPUNCTURE ON ANXIETY DISORDER: A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMISED CONTROLLED TRIALS, ANNALS OF GENERAL PSYCHIATRY, 20, 1, (2021); ARMOUR M., SMITH C., WANG L., ET AL., ACUPUNCTURE FOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS, JOURNAL OF CLINICAL MEDICINE, 8, 8, (2019); XU Y., HONG S., ZHAO X., ET AL., ACUPUNCTURE ALLEVIATES RHEUMATOID ARTHRITIS BY IMMUNE-NETWORK MODULATION, THE AMERICAN JOURNAL OF CHINESE MEDICINE, 46, 5, PP. 997-1019, (2018); CHAE Y., HONG M., KIM G., ET AL., PROTEIN ARRAY ANALYSIS OF CYTOKINE LEVELS ON THE ACTION OF ACUPUNCTURE IN CARRAGEENAN-INDUCED INFLAMMATION, NEUROLOGICAL RESEARCH, 29, SUP1, PP. 55-58, (2007); DEADMAN P., AL-KHAFAJI M., BAKER K., A MANUAL OF ACUPUNCTURE, (2007); BENSKY D., GAMBLE A., CHINESE HERBAL MEDICINE: MATERIA MEDICA, (2004)","","JOURNAL OF CHINESE MEDICINE","ENGLISH","J. CHIN. MED.","ARTICLE","ISI","2-S2.0-85162744725","J CHIN MED",NA,"NOTREPORTED",NA,"WO J, 2023, J CHIN MED","WO J, 2023, J CHIN MED"
"KIM T;KIM S;PARK Y;LIM S;HA S;PARK S;LEE B;KIM J","KIM, TAE JIN (57202388112); KIM, SO YEON (57213778428); PARK, YOUNG JIN (57202422844); LIM, SUN-HYUNG (7404081419); HA, SUN-HWA (7202501231); PARK, SANG UN (7501831941); LEE, BUMKYU (57218489362); KIM, JAE KWANG (56892616700)","METABOLITE PROFILING REVEALS DISTINCT MODULATION OF COMPLEX METABOLIC NETWORKS IN NONPIGMENTED BLACK AND RED RICE ORYZA SATIVA L CULTIVARS",2021,"METABOLITES","11","",20,"10.3390/metabo11060367","DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;DIVISION OF HORTICULTURAL BIOTECHNOLOGY, SCHOOL OF BIOTECHNOLOGY, HANKYONG NATIONAL UNIVERSITY, ANSEONG, 17579, SOUTH KOREA;DEPARTMENT OF GENETIC ENGINEERING AND GRADUATE SCHOOL OF BIOTECHNOLOGY, KYUNG HEE UNIVERSITY, YONGIN, 17104, SOUTH KOREA;DEPARTMENT OF CROP SCIENCE, CHUNGNAM NATIONAL UNIVERSITY, 99 DAEHAK-RO, YUSEONG-GU, DAEJEON, 34134, SOUTH KOREA;DEPARTMENT OF ENVIRONMENT SCIENCE & BIOTECHNOLOGY, JEONJU UNIVERSITY, JEONJU, 55069, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA","COMPREHENSIVE PROFILING OF PRIMARY AND SECONDARY METABOLITES WAS PERFORMED TO UN-DERSTAND METABOLIC DIFFERENCES ASSOCIATED WITH COLOR FORMATION IN PIGMENTED RICE (ORYZA SATIVA L.). OVERALL, 110 METABOLITES FROM NON-PIGMENTED, BLACK, AND RED RICE CULTIVARS WERE IDENTIFIED. BLACK AND RED RICE CONTAINED HIGH LEVELS OF FLAVONOIDS ASSOCIATED WITH PLANT COLOR. BLACK RICE ALSO CONTAINED HIGH LEVELS OF TERPENOIDS (CAROTENOIDS, TOCOPHEROLS, PHYTOSTEROLS, AND MONOTERPENES). THE NON-PIGMENTED RICE CONTAINED RELATIVELY LOW LEVELS OF SECONDARY METABOLITES. MULTIVARIATE AND PATHWAY ANALYSES WERE PERFORMED TO DATA-MINE THE METABOLITE PROFILES. HIERARCHICAL CLUSTERING ANALYSIS OF CORRELATION COEFFICIENTS REVEALED METABOLITE CLUSTERS BASED ON NITROGEN AND CARBON SOURCES. THESE CLUSTERS SUGGESTED A NEGATIVE CORRELATION BETWEEN NITROGEN AND CARBON. PATHWAY ANALYSIS REVEALED THAT BLACK RICE WAS RICH IN CARBON-BASED SECONDARY METABOLITES, WITH RELATIVELY LOW LEVELS OF PRIMARY METABOLITES COMPARED WITH OTHER RICE CULTIVARS. THESE DATA HIGHLIGHT THE COMPLEX INTERACTIONS BETWEEN NITROGEN AND CARBON METABOLISM OF PRIMARY AND SECONDARY METABOLITES IN RICE. FOR THE FIRST TIME, THE RELATIONSHIPS AND METABOLIC DIFFERENCES IN TERPENOID CONTENT (MONOTERPENES, TRITERPENES, AND TETRATERPENES) OF NON-PIGMENTED AND PIGMENTED RICE CULTIVARS WERE ANALYZED. THESE FINDINGS SHOULD GREATLY CONTRIBUTE TO THE UNDERSTANDING OF PIGMENTED RICE METABOLOME AND INFORM BREEDING PROGRAMS FOR NEW RICE CULTIVARS. © 2021 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","CARBON; METABOLITE PROFILING; METABOLOMICS; MULTIVARIATE ANALYSIS; NITROGEN; PATHVISIO 3; PIGMENTED RICE; TERPENOID","ALANINE; ANTHOCYANIN; ARACHIDIC ACID; ARACHIDONIC ACID; ASCORBIC ACID; ASPARTIC ACID; CAMPESTEROL; CARBON; CARBOXYLIC ACID; CAROTENOID; CATECHIN; CHALCONE; CINNAMIC ACID; DOCOSAHEXAENOIC ACID; EPICATECHIN; ETHYLBENZENE; FATTY ACID ESTER; FERULIC ACID; FLAVONOID; GLUTAMIC ACID; GLYCINE; HEXANAL; LACTIC ACID; LIMONENE; LINOLEIC ACID; MONOTERPENE; NARINGENIN; NITROGEN; PENTADECANOIC ACID; PHENYLALANINE AMMONIA LYASE; PHYTOSTEROL; PINENE; POLICOSANOL; PROTOCATECHUIC ACID; SATURATED FATTY ACID; SERINE; SESQUITERPENE; STEARIC ACID; STIGMASTEROL; TERPENE; TERPENOID; TRITERPENE; TRYPTOPHAN; TYROSINE; VALINE; XANTHOPHYLL; ZEAXANTHIN; ARTICLE; BIOSYNTHESIS; BIOTRANSFORMATION; BLACK RICE; CARBON SOURCE; CORRELATION COEFFICIENT; ELECTROSPRAY MASS SPECTROMETRY; FATTY ACID ANALYSIS; GLYCOLYSIS; HIERARCHICAL CLUSTERING; LIMIT OF QUANTITATION; MASS FRAGMENTOGRAPHY; METABOLIC FINGERPRINTING; METABOLISM; METABOLOME; NONHUMAN; PERICARP; PRINCIPAL COMPONENT ANALYSIS; QUADRUPOLE MASS SPECTROMETRY; RED RICE; SAPONIFICATION; SOLID PHASE MICROEXTRACTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; VALIDATION PROCESS","INCHEON NATIONAL UNIVERSITY, INU","FUNDING: THIS WORK WAS SUPPORTED BY INCHEON NATIONAL UNIVERSITY RESEARCH CONCENTRATION PROFESSORS GRANT IN 2021.","HUSSAIN M., FAROOQ M., LEE D.J., EVALUATING THE ROLE OF SEED PRIMING IN IMPROVING DROUGHT TOLERANCE OF PIGMENTED AND NON-PIGMENTED RICE, J. AGRON. CROP SCI, 203, PP. 269-276, (2017); LAOKULDILOK T., SHOEMAKER C.F., JONGKAEWWATTANA S., TULYATHAN V., ANTIOXIDANTS AND ANTIOXIDANT ACTIVITY OF SEVERAL PIGMENTED RICE BRANS, J. AGRIC. FOOD CHEM, 59, PP. 193-199, (2011); KIM J.K., LEE S.Y., CHU S.M., LIM S.H., SUH S.-C., LEE Y.-T., CHO H.S., HA S.-H., VARIATION AND CORRELATION ANALYSIS OF FLAVONOIDS AND CAROTENOIDS IN KOREAN PIGMENTED RICE (ORYZA SATIVA L.) CULTIVARS, J. AGRIC. FOOD CHEM, 58, PP. 12804-12809, (2010); ZIEGLER V., FERREIRA C.D., HOFFMANN J.F., CHAVES F.C., VANIER N.L., DE OLIVEIRA M., ELIAS M.C., COOKING QUALITY PROPERTIES AND FREE AND BOUND PHENOLICS CONTENT OF BROWN, BLACK, AND RED RICE GRAINS STORED AT DIFFERENT TEMPERATURES FOR SIX MONTHS, FOOD CHEM, 242, PP. 427-434, (2018); SAMYOR D., DAS A.B., DEKA S.C., PIGMENTED RICE A POTENTIAL SOURCE OF BIOACTIVE COMPOUNDS: A REVIEW, INT. J. FOOD SCI. TECHNOL, 52, PP. 1073-1081, (2017); BISWAS S.K., KIM D.-E., KEUM Y.-S., SAINI R.K., METABOLITE PROFILING AND ANTIOXIDANT ACTIVITIES OF WHITE, RED, AND BLACK RICE (ORYZA SATIVA L.) GRAINS, J. FOOD MEAS. CHARACT, 12, PP. 2484-2492, (2018); PEREIRA-CARO G., CROS G., YOKOTA T., CROZIER A., PHYTOCHEMICAL PROFILES OF BLACK, RED, BROWN, AND WHITE RICE FROM THE CAMARGUE REGION OF FRANCE, J. AGRIC. FOOD CHEM, 61, PP. 7976-7986, (2013); PEREIRA-CARO G., WATANABE S., CROZIER A., FUJIMURA T., YOKOTA T., ASHIHARA H., PHYTOCHEMICAL PROFILE OF A JAPANESE BLACK–PURPLE RICE, FOOD CHEM, 141, PP. 2821-2827, (2013); SUKHONTHARA S., THEERAKULKAIT C., MIYAZAWA M., CHARACTERIZATION OF VOLATILE AROMA COMPOUNDS FROM RED AND BLACK RICE BRAN, J. OLEO SCI, 58, PP. 155-161, (2009); JUN H.I., SHIN J.W., SONG G.S., KIM Y.S., ISOLATION AND IDENTIFICATION OF PHENOLIC ANTIOXIDANTS IN BLACK RICE BRAN, J. FOOD SCI, 80, PP. C262-C268, (2015); KIM J.K., PARK S.-Y., LIM S.-H., YEO Y., CHO H.S., HA S.-H., COMPARATIVE METABOLIC PROFILING OF PIGMENTED RICE (ORYZA SATIVA L.) CULTIVARS REVEALS PRIMARY METABOLITES ARE CORRELATED WITH SECONDARY METABOLITES, J. CEREAL SCI, 57, PP. 14-20, (2013); GUNARATNE A., WU K., LI D., BENTOTA A., CORKE H., CAI Y.-Z., ANTIOXIDANT ACTIVITY AND NUTRITIONAL QUALITY OF TRADITIONAL RED-GRAINED RICE VARIETIES CONTAINING PROANTHOCYANIDINS, FOOD CHEM, 138, PP. 1153-1161, (2013); SRISAWAT U., PANUNTO W., KAENDEE N., TANUCHIT S., ITHARAT A., LERDVUTHISOPON N., HANSAKUL P., DETERMINATION OF PHENOLIC COMPOUNDS, FLAVONOIDS, AND ANTIOXIDANT ACTIVITIES IN WATER EXTRACTS OF THAI RED AND WHITE RICE CULTIVARS, J. MED. ASSOC. THAI, 93, PP. S83-S91, (2010); SHEN Y., JIN L., XIAO P., LU Y., BAO J., TOTAL PHENOLICS, FLAVONOIDS, ANTIOXIDANT CAPACITY IN RICE GRAIN AND THEIR RELATIONS TO GRAIN COLOR, SIZE AND WEIGHT, J. CEREAL SCI, 49, PP. 106-111, (2009); CHUMPOLSRI W., WIJIT N., BOONTAKHAM P., NIMMANPIPUG P., SOOKWONG P., LUANGKAMIN S., WONGPORNCHAI S., VARIATION OF TERPENOID FLAVOR ODORANTS IN BRAN OF SOME BLACK AND WHITE RICE VARIETIES ANALYZED BY GC×GC-MS, J. FOOD NUTR. RES, 3, PP. 114-120, (2015); CHOI S., SEO H.-S., LEE K.R., LEE S., LEE J., EFFECT OF MILLING DEGREES ON VOLATILE PROFILES OF RAW AND COOKED BLACK RICE (ORYZA SATIVA L. CV. SINTOHEUGMI), APPL. BIOL. CHEM, 61, PP. 91-105, (2018); PARK S.-Y., KIM J.K., LEE S.Y., OH S.-D., LEE S.M., JANG J.-S., YANG C.-I., WON Y.-J., YEO Y., COMPARATIVE ANALYSIS OF PHENOLIC ACID PROFILES OF RICE GROWN UNDER DIFFERENT REGIONS USING MULTIVARIATE, PLANT OMICS, 7, PP. 430-437, (2014); LIU Y., LIU J., LIU M., LIU Y., STRAPPE P., SUN H., ZHOU Z., COMPARATIVE NON-TARGETED METABOLOMIC ANALYSIS REVEALS INSIGHTS INTO THE MECHANISM OF RICE YELLOWING, FOOD CHEM, 308, (2020); YU O., JEZ J.M., NATURE’S ASSEMBLY LINE: BIOSYNTHESIS OF SIMPLE PHENYLPROPANOIDS AND POLYKETIDES, PLANT J, 54, PP. 750-762, (2008); KIM J.K., HA S.-H., PARK S.-Y., LEE S.M., KIM H.J., LIM S.H., SUH S.-C., KIM D.H., CHO H.S., DETERMINATION OF LIPOPHILIC COMPOUNDS IN GENETICALLY MODIFIED RICE USING GAS CHROMATOGRAPHY–TIME-OF-FLIGHT MASS SPECTROMETRY, J. FOOD COMPOS. ANAL, 25, PP. 31-38, (2012); CHOI S.-W., KANG W.-W., OSAWA T., ISOLATION AND IDENTIFICATION OF ANTHOCYANIN PIGMENTS IN BLACK RICE, FOOD SCI. BIOTECHNOL, 3, PP. 131-136, (1994); YOON H.-H., PAIK Y.-S., KIM J.-B., HAHN T.-R., IDENTIFICATION OF ANTHOCYANINS FROM KOREAN PIGMENTED RICE, APPL. BIOL. CHEM, 38, PP. 581-583, (1995); KONG L., WANG Y., CAO Y., DETERMINATION OF MYO-INOSITOL AND D-CHIRO-INOSITOL IN BLACK RICE BRAN BY CAPILLARY ELECTROPHORESIS WITH ELECTROCHEMICAL DETECTION, J. FOOD COMPOS. ANAL, 21, PP. 501-504, (2008); KUSANO M., FUKUSHIMA A., REDESTIG H., SAITO K., METABOLOMIC APPROACHES TOWARD UNDERSTANDING NITROGEN METABOLISM IN PLANTS, J. EXP. BOT, 62, PP. 1439-1453, (2011); ZHENG Z.-L., CARBON AND NITROGEN NUTRIENT BALANCE SIGNALING IN PLANTS, PLANT SIGNAL. BEHAV, 4, PP. 584-591, (2009); SHAO Y., HU Z., YU Y., MOU R., ZHU Z., BETA T., PHENOLIC ACIDS, ANTHOCYANINS, PROANTHOCYANIDINS, ANTIOXIDANT ACTIVITY, MINERALS AND THEIR CORRELATIONS IN NON-PIGMENTED, RED, AND BLACK RICE, FOOD CHEM, 239, PP. 733-741, (2018); HIEMORI M., KOH E., MITCHELL A.E., INFLUENCE OF COOKING ON ANTHOCYANINS IN BLACK RICE (ORYZA SATIVA L. JAPONICA VAR. SBR), J. AGRIC. FOOD CHEM, 57, PP. 1908-1914, (2009); CHATTHONGPISUT R., SCHWARTZ S.J., YONGSAWATDIGUL J., ANTIOXIDANT ACTIVITIES AND ANTIPROLIFERATIVE ACTIVITY OF THAI PURPLE RICE COOKED BY VARIOUS METHODS ON HUMAN COLON CANCER CELLS, FOOD CHEM, 188, PP. 99-105, (2015); KIM T.J., HYEON H., PARK N.I., YI T.G., LIM S.-H., PARK S.-Y., HA S.-H., KIM J.K., A HIGH-THROUGHPUT PLATFORM FOR INTERPRETATION OF METABOLITE PROFILE DATA FROM PEPPER (CAPSICUM) FRUITS OF 13 PHENOTYPES ASSOCIATED WITH DIFFERENT FRUIT MATURITY STATES, FOOD CHEM, 331, (2020); LISTER C.E., LANCASTER J.E., WALKER J.R., PHENYLALANINE AMMONIA-LYASE (PAL) ACTIVITY AND ITS RELATIONSHIP TO ANTHOCYANIN AND FLAVONOID LEVELS IN NEW ZEALAND-GROWN APPLE CULTIVARS, J. AM. SOC. HORTIC. SCI, 121, PP. 281-285, (1996); WANG H., ARAKAWA O., MOTOMURA Y., INFLUENCE OF MATURITY AND BAGGING ON THE RELATIONSHIP BETWEEN ANTHOCYANIN ACCUMULATION AND PHENYLALANINE AMMONIA-LYASE (PAL) ACTIVITY IN ‘JONATHAN’APPLES, POSTHARVEST BIOL. TECHNOL, 19, PP. 123-128, (2000); BENDOKAS V., SKEMIENE K., TRUMBECKAITE S., STANYS V., PASSAMONTI S., BORUTAITE V., LIOBIKAS J., ANTHOCYANINS: FROM PLANT PIGMENTS TO HEALTH BENEFITS AT MITOCHONDRIAL LEVEL, CRIT. REV. FOOD SCI. NUTR, 60, PP. 3352-3365, (2020); MARTIN C., STRUCTURE, FUNCTION, AND REGULATION OF THE CHALCONE SYNTHASE, INT. REV. CYTOL, 147, PP. 233-284, (1993); HYEON H., XU J.L., KIM J.K., CHOI Y., COMPARATIVE METABOLIC PROFILING OF CULTIVATED AND WILD BLACK SOYBEANS REVEALS DISTINCT METABOLIC ALTERATIONS ASSOCIATED WITH THEIR DOMESTICATION, FOOD RES. INT, 134, (2020); XU Z., HUA N., GODBER J.S., ANTIOXIDANT ACTIVITY OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL COMPONENTS FROM RICE BRAN AGAINST CHOLESTEROL OXIDATION ACCELERATED BY 2, 2<SUP>′</SUP>-AZOBIS (2-METHYLPROPIONAMIDINE) DIHYDROCHLORIDE, J. AGRIC. FOOD CHEM, 49, PP. 2077-2081, (2001); MINATEL I.O., HAN S.-I., ALDINI G., COLZANI M., MATTHAN N.R., CORREA C.R., FECCHIO D., YEUM K.-J., FAT-SOLUBLE BIOACTIVE COMPONENTS IN COLORED RICE VARIETIES, J. MED. FOOD, 17, PP. 1134-1141, (2014); FRANK T., REICHARDT B., SHU Q., ENGEL K.-H., METABOLITE PROFILING OF COLORED RICE (ORYZA SATIVA L.) GRAINS, J. CEREAL SCI, 55, PP. 112-119, (2012); KOTAMREDDY J.N.R., HANSDA C., MITRA A., SEMI-TARGETED METABOLOMIC ANALYSIS PROVIDES THE BASIS FOR ENHANCED ANTIOXIDANT CAPACITIES IN PIGMENTED RICE GRAINS, J. FOOD MEAS. CHARACT, 14, PP. 1-9, (2020); FERRI M., RIGHETTI L., TASSONI A., INCREASING SUCROSE CONCENTRATIONS PROMOTE PHENYLPROPANOID BIOSYNTHESIS IN GRAPEVINE CELL CULTURES, J. PLANT. PHYSIOL, 168, PP. 189-195, (2011); PAYYAVULA R.S., NAVARRE D.A., KUHL J.C., PANTOJA A., PILLAI S.S., DIFFERENTIAL EFFECTS OF ENVIRONMENT ON POTATO PHENYLPROPANOID AND CAROTENOID EXPRESSION, BMC PLANT BIOL, 12, (2012); KIM T.J., LEE K.B., BAEK S.-A., CHOI J., HA S.-H., LIM S.-H., PARK S.-Y., YEO Y., PARK S.U., KIM J.K., DETERMINATION OF LIPOPHILIC METABOLITES FOR SPECIES DISCRIMINATION AND QUALITY ASSESSMENT OF NINE LEAFY VEGETABLES, J. KOREAN SOC. APPL. BIOL. CHEM, 58, PP. 909-918, (2015); LEE J.H., HAM H., KIM M.Y., KO J.Y., SIM E.-Y., KIM H.-J., LEE C.K., JEON Y.H., JEONG H.S., WOO K.S., PHENOLIC COMPOUNDS AND ANTIOXIDANT ACTIVITY OF ADZUKI BEAN CULTIVARS, LEGUME RES, 41, PP. 681-688, (2018)","B. LEE; DEPARTMENT OF ENVIRONMENT SCIENCE & BIOTECHNOLOGY, JEONJU UNIVERSITY, JEONJU, 55069, SOUTH KOREA; EMAIL: LEEBK@JJ.AC.KR; J.K. KIM; DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA; EMAIL: KJKPJ@INU.AC.KR","MDPI AG","ENGLISH","METABOLITES","ARTICLE","ISI","2-S2.0-85108683224","METABOLITES","INCHEON NATIONAL UNIVERSITY;INCHEON NATIONAL UNIVERSITY;INCHEON NATIONAL UNIVERSITY;HANKYONG NATIONAL UNIVERSITY;KYUNG HEE UNIVERSITY;CHUNGNAM NATIONAL UNIVERSITY;JEONJU UNIVERSITY;INCHEON NATIONAL UNIVERSITY","NOTREPORTED;JEONJU UNIVERSITY;NOTREPORTED;NOTREPORTED;INCHEON NATIONAL UNIVERSITY;NOTREPORTED",NA,"KIM TJ, 2021, METABOLITES","KIM TJ, 2021, METABOLITES"
"DÍAZ D L R M;HERNÁNDEZ R E;GONZÁLEZ C V;VICENTE M R;PÉREZ C K;ZUMALACARREGUI D C L","DÍAZ DE LOS RÍOS, MANUEL (14630001300); HERNÁNDEZ RAMOS, EDUARDO (57224187955); GONZÁLEZ CANAVACIOLO, VÍCTOR (18433666300); VICENTE MURILLO, ROXANA (35410022700); PÉREZ CARRIÓN, KATHERINE (57852554500); ZUMALACARREGUI DE CÁRDENAS, LOURDES (6507929314)","OBTAINING A FRACTION OF SUGARCANE WAX RICH IN POLICOSANOL BY USING ETHANOL AS SOLVENT RESULTS INTERPRETATION THROUGH HANSENS SOLUBILITY THEORY",2022,"ACS OMEGA","7","9",4,"10.1021/acsomega.2c02314","INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA), VÍA BLANCA 804, ESQ. C. CENTRAL, SMP, LA HABANA, 11000, CUBA;INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA), VÍA BLANCA 804, ESQ. C. CENTRAL, SMP, LA HABANA, 11000, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), AVENIDA 25, ESQUINA 21-A, 15202, CUBANACÁN, PLAYA, LA HABANA, CP 11600, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), AVENIDA 25, ESQUINA 21-A, 15202, CUBANACÁN, PLAYA, LA HABANA, CP 11600, CUBA;INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA), VÍA BLANCA 804, ESQ. C. CENTRAL, SMP, LA HABANA, 11000, CUBA;FACULTAD DE INGENIERÍA QUÍMICA, UNIVERSIDAD TECNOLÓGICA DE LA HABANA (CUJAE), CALLE 114, NO. 11901. ENTRE 119 Y 129, MARIANAO, LA HABANA, CP 19390, CUBA","DETERMINATION OF THE BEST CONDITION FOR FRACTIONATION OF DEGREASED SUGARCANE WAX FOR POLICOSANOL PRODUCTION USING ETHANOL WAS INVESTIGATED IN THIS PAPER. THE OPTIMAL CONDITIONS RELATED TO THE DISPERSION TIME OF WAX IN THE SOLVENT, ETHANOL DEGREE, AND SOLVENT/WAX RATIO WERE 30 MIN, 90.03% V/V, AND 14:1 V/W, RESPECTIVELY. THE RESULTS WERE EVALUATED BY MEASURING SIX RESPONSE VARIABLES: HIGHER FATTY ALCOHOL CONCENTRATION, OCTACOSANOL CONCENTRATION, IMPURITY CONCENTRATION (MEASURED AS Α,Β UNSATURATED ALDEHYDES), YIELD, COST INDICATOR, AND THE RATIO OF OCTACOSANOL VS OTHER HIGHER FATTY ALCOHOLS (C30 + C32 + C34). OPTIMAL EXTRACTION CONDITIONS WERE DETERMINED WITH THE DESIRABILITY FUNCTION. THE COMPLEXITY OF SEPARATION OF THE HIGHER ALCOHOLS FRACTION FROM IMPURITIES, MAINLY Α,Β UNSATURATED ALDEHYDES, IS EXPLAINED WITH THE AID OF HANSEN'S SOLUBILITY PARAMETERS THEORY AND ITS VARIATION WITH TEMPERATURE.  © 2022 THE AUTHORS. PUBLISHED BY AMERICAN CHEMICAL SOCIETY.","","","CUBAN RESEARCH INSTITUTE FOR SUGARCANE DERIVATIVES; ICIDCA; NATIONAL CENTER FOR SCIENTIFIC RESEARCH; CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES, CNIC","THE CUBAN RESEARCH INSTITUTE FOR SUGARCANE DERIVATIVES (ICIDCA) AND NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC) SUPPORTED THE RESEARCH. ","MOHAN S., CHITHRA L., NAGESWARI R., MANIMOZHI SELVI V., MATHIALAGAN M., SUGARCANE WAX - A PAR EXCELLENT BY-PRODUCT OF SUGAR INDUSTRY - A REVIEW, AGRIC. REV., 42, PP. 315-321, (2021); AVEQUIN M., DE WASACHTIGE MATTER OF SUGARCANE, ANN. CHIM. PHYS., 75, PP. 218-222, (1840); RAY S.C., STUDIES OF CONVERSION OF CRUDE WASTE EXTRACTED FROM SUGAR CANE PRESSMUD IN INDUSTRIAL QUALITY WAX, (2003); LACHOS-PEREZ D., BARRALES F.M., MARTINEZ J., MACIEL FILHO R., SUPERCRITICAL CO2 EXTRACTION OF LIPOPHILIC MOLECULES FROM SUGARCANE STRAW, CHEM. ENG. TRANS., 80, PP. 313-318, (2020); GARCIA A., GARCIA M.A., RIBAS M., BROWN A., RECUPERACIÓN DE CERA DE CUTÍCULA DE CAÑA DE AZÚCAR MEDIANTE SEPARACIÓN MECÁNICA Y EXTRACCIÓN CON SOLVENTES, GRASAS ACEITES, 54, PP. 169-174, (2003); BHOSALE P.R., CHONDESONAL G., RAUT P.D., STUDIES ON EXTRACTION OF SUGARCANE WAX FROM PRESS MUD OF SUGAR FACTORIES FROM KOLHAPUR DISTRICT MAHARASHTRA, J. ENVIRON. RES. DEV., 6, PP. 715-720, (2012); SWENSON O.J., METHOD OF EXTRACTING WAX FROM CACHAZA, (1947); RHODES F.H., SWENSON O.J., (1947); LAKE A.W., RECOVERY OF SUGARCANE WAX, (1973); BALCH T.R., HARD WAXES AND FATTY PRODUCTS DERIVED FROM CRUDE SUGAR CANE WAXES, (1942); DIAZ M., HERNANDEZ E., COMPOSICIÓN DE LA CERA DE CAÑA DE AZÚCAR Y EL EMPLEO DE SOLVENTES PARA SU EXTRACCIÓN Y FRACCIONAMIENTO. ENFOQUE ORIENTADO A SU APLICACIÓN, ICIDCA SOBRE LOS DERIVADOS DE LA CAÑA DE AZÚCAR, 54, PP. 13-22, (2020); ATTARD T.M., MCELROY C.R., REZENDE C.A., POLIKARPOV I., CLARK J.H., HUNT A.J., SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES, IND. CROPS PROD., 76, PP. 95-103, (2015); INARKAR M.B., LELE S.S., EXTRACTION AND CHARACTERIZATION OF SUGARCANE PEEL WAX, ISRN AGRON., 2012, (2012); ASIKIN Y., WAXES, POLICOSANOLS AND ALDEHYDES IN SUGARCANE (SACCHARUM OFFICINARUM L.) AND OKINAWAN BROWN SUGAR (KOKUTO), BOGOR AGRICULTURAL UNIVERSITY, (2008); MARTINEZ R., CASTRO I., OLIVEROS M., CHARACTERIZATION OF PRODUCTS FROM SUGAR CANE MUD, REV. SOC. QUÍM. MÉX., 46, PP. 64-66, (2002); HERNANDEZ E., DIAZ M., PEREZ K., DETERMINATION OF HANSEN SOLUBILITY PARAMETERS FOR SUGARCANE OIL. USE OF ETHANOL IN SUGARCANE WAX REFINING, GRASAS ACEITES, 72, (2021); HANSEN C.M., HANSEN SOLUBILITY PARAMETERS: A USER'S HANDBOOK, PP. 1-26, (2007); TAYLOR T.I., LARSON L., JOHNSON W., MISCIBILITY OF ALCOHOL AND OILS, IND. ENG. CHEM., 28, PP. 616-618, (1936); FREITAS S.P., LAGO R.C.A., EQUILIBRIUM DATA FOR THE EXTRACTION OF COFFEE AND SUNFLOWER OILS WITH ETHANOL, BRAZ. J. FOOD TECHNOL., 10, PP. 220-224, (2007); DA SILVA C.A.S., SANAIOTTI G., LANZA M., FOLLEGATTI-ROMERO L.A., MEIRELLES A.J.A., BATISTA E.A.C., MUTUAL SOLUBILITY FOR SYSTEMS COMPOSED OF VEGETABLE OIL + ETHANOL + WATER AT DIFFERENT TEMPERATURES, J. CHEM. ENG. DATA, 55, PP. 440-447, (2010); DA COSTA RODRIGUES C.E., OLIVEIRA R., RESPONSE SURFACE METHODOLOGY APPLIED TO THE ANALYSIS OF RICE BRAN OIL EXTRACTION PROCESS WITH ETHANOL, INT. J. FOOD SCI. TECHNOL., 45, PP. 813-820, (2010); SHARIATI A., AZARIBENI A., HAJIGHAHRAMANZADEH P., LOGHMANI Z., LIQUID LIQUID EQUILIBRIA OF SYSTEMS CONTAINING SUNFLOWER OIL, ETHANOL AND WATER, APCBEE PROC., 5, PP. 486-490, (2013); HERNANDEZ E., DIAZ M., DETERMINATION OF HANSEN SOLUBILITY PARAMETERS OF REFINED SUGARCANE WAX, CHEM. PAP., 75, PP. 5313-5322, (2021); DEL PILLAR SANCHEZ-CAMARGO A., BUENO M., BALLESTEROS-VIVAS D., PARADA-ALFONSO F., CIFUENTES A., IBANEZ E., HANSEN SOLUBILITY PARAMETERS FOR SELECTION OF GREEN EXTRACTION SOLVENTS, TRAC, TRENDS ANAL. CHEM., 118, PP. 227-237, (2019); SICAIRE A.G., VIAN M., FINE F., JOFFRE F., CARRE P., TOSTAIN S., CHEMAT F., ALTERNATIVE BIO-BASED SOLVENTS FOR EXTRACTION OF FAT AND OILS, SOLUBILITY PREDICTION, GLOBAL YIELD, EXTRACTION KINETICS, CHEMICAL COMPOSITION AND COST OF MANUFACTURING, INT. J. MOL. SCI., 16, PP. 8430-8453, (2015); DEJOYE TANZI C., VAIN M.A., GINIES C., ELMAATAOUI M., CHEMAT F., TERPENES AS GREEN SOLVENTS FOR EXTRACTION OF OIL FROM MICROALGAE, MOLECULES, 17, PP. 8196-8205, (2012); ARAUJO DE OLIVEIRA R.M., AVALIAÇÃO DE TERPENOS COMO SOLVENTES NO PROCESSO DE EXTRAÇÃO DA CERA DE CANA-DE-AÇÚCAR, (2018); HOLSER R.A., AKIN D.E., EXTRACTION OF LIPIDS FROM FLAX PROCESSING WASTE USING HOT ETHANOL, IND. CROPS PROD., 27, PP. 236-240, (2008); HOLSER R.A., TEMPERATURE-DEPENDENT SOLUBILITY OF WAX COMPOUNDS IN ETHANOL, EUR. J. LIPID SCI. TECHNOL., 111, PP. 1049-1052, (2009); MYUNG K., PAROBEK A.P., GODBEY J.A., BOWLING A.J., PENCE H.E., INTERACTION OF ORGANIC SOLVENTS WITH THE EPICUTICULAR WAX LAYER OF WHEAT LEAVES, J. AGRIC. FOOD CHEM., 61, PP. 8737-8742, (2013); INES S., BEN MARZOUG I., SAKLI F., EFFECT OF SOLVENT EXTRACTION ON TUNISIAN ESPARTO WAX COMPOSITION, ALGER. J. NAT. PROD., 4, PP. 308-315, (2016); CHAKHATHANBORDEE R., KHOTAVIVATTANA S., SRIROTH K., DEVELOPMENT OF SUGARCANE WAX EXTRACTION METHODS FROM SUGARCANE FILTER CAKE FOR VALUE CREATION, RES. DEV. J. SCI. TECHNOL., 11, PP. 95-106, (2016); LIDE D.R., CRC HANDBOOK OF CHEMISTRY AND PHYSICS, INTERNET VERSION, (2006); CUEVAS M.S., CREVELIN E.J., DE MORAES L.A., OLIVEIRA A.L., RODRIGUES C.E., MEIRELLES A.J., SOLUBILITY OF COMMERCIAL OCTACOSANOL IN ORGANIC SOLVENTS AND THEIR CORRELATION BY THERMODYNAMIC MODELS AT DIFFERENT TEMPERATURES, J. CHEM. THERMODYN., 110, PP. 186-192, (2017); IVY FINE CHEMICAL COPORATION OCTACOSANOL DATA SHEET; STATGRAPHICS CENTURION SOFTWARE XV, (2007); MARRERO-DELANGE D., GONZALEZ-CANAVACIOLO V.L., SIERRA-PEREZ R., VELASQUEZ-G C., VALIDACIÓN DE UN NUEVO MÉTODO ANALÍTICO POR CG CON COLUMNA CAPILAR PARA LA DETERMINACIÓN DE ALCOHOLES DE ALTO PESO MOLECULAR EN POLICOSANOL INGREDIENTE ACTIVE, REV. COLOMB. CIENC. QUÍM. FARM., 37, PP. 62-68, (2008); LAMBERTON J.A., THE LONG-CHAIN ALDEHYDES OF SUGAR-CANE WAX, AUST. J. CHEM., 18, PP. 911-913, (1965); ABBOTT S., YAMAMOTO H., HSPIP SOFTWARE, (2015); SRISAIPET A., LUANGPITAK P., POTISEN P., THE POLICOSANOL EXTRACTION AND COMPOSITION CHARACTERIZATION FROM WHEAT STRAW BY-PRODUCT OF THAI WHEAT VARIETIES, INT. J. FOOD ENG., 5, PP. 99-103, (2019); SRISAIPET A., KEAWPROM P., EXTRACTION AND CHARACTERIZATION OF POLICOSANOL FROM WHEAT GERM, INT. J. ENG. TECHNOL., 7, PP. 1478-1482, (2018); ASIKIN Y., CHINEN T., TAKARA K., ET AL., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI. TECHNOL. RES., 14, PP. 583-588, (2008); SINGH A.K., CHANDRA A., KANDPAL J.B., OCTACOSANOL EXTRACTION, SYNTHESIS METHOD AND SOURCES: A REVIEW, CARPATHIAN J. FOOD SCI. TECHNOL., 12, PP. 27-41, (2020); LOUWERSE M.J., MALDONADO A., ROUSSEAU S., MOREAU-MASSELON C., ROUX B., ROTHENBERG G., REVISITING HANSEN SOLUBILITY PARAMETERS BY INCLUDING THERMODYNAMICS, CHEMPHYSCHEM, 18, PP. 2999-3006, (2017)","M. DÍAZ DE LOS RÍOS; INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA), LA HABANA, VÍA BLANCA 804, ESQ. C. CENTRAL, SMP, 11000, CUBA; EMAIL: MANUEL.DIAZ@ICIDCA.AZCUBA.CU","AMERICAN CHEMICAL SOCIETY","ENGLISH","ACS OMEGA","ARTICLE","ISI","2-S2.0-85136312983","ACS OMEGA","INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA);INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA);CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC);CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC);INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA);UNIVERSIDAD TECNOLÓGICA DE LA HABANA (CUJAE)","NOTREPORTED;INSTITUTO CUBANO DE INVESTIGACIONES DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR (ICIDCA);NOTREPORTED",NA,"DÍAZ DE LOS RÍOS M, 2022, ACS OMEGA","DÍAZ DE LOS RÍOS M, 2022, ACS OMEGA"
"TEIXEIRA F;COSTA P;SOARES A;FONTES A;PINTADO M;VIDIGAL S;PIMENTEL L;RODRÍGUEZ-ALCALÁ L","TEIXEIRA, FRANCISCA S. (57224100764); COSTA, PAULA T. (57224101718); SOARES, ANA M. S. (36437761200); FONTES, ANA LUIZA (57000067200); PINTADO, MANUELA E. (7004483898); VIDIGAL, SUSANA S. M. P. (11739488200); PIMENTEL, LÍGIA L. (22035944100); RODRÍGUEZ-ALCALÁ, LUÍS M. (19337562900)","NOVEL LIPIDS TO REGULATE OBESITY AND BRAIN FUNCTION COMPARING AVAILABLE EVIDENCE AND INSIGHTS FROM QSAR IN SILICO MODELS",2023,"FOODS","12","",0,"10.3390/foods12132576","CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL;CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, RUA DIOGO BOTELHO 1327, PORTO, 4169-005, PORTUGAL","LIPID MOLECULES, SUCH AS POLICOSANOL, ERGOSTEROL, SPHINGOMYELIN, OMEGA 3 RICH PHOSPHATIDYLCHOLINE, Α-TOCOPHEROL, AND SODIUM BUTYRATE, HAVE EMERGED AS NOVEL ADDITIONS TO THE PORTFOLIO OF BIOACTIVE LIPIDS. IN THIS STATE-OF-THE-ART REVIEW, WE DISCUSS THESE LIPIDS, AND THEIR ACTIVITY AGAINST OBESITY AND MENTAL OR NEUROLOGICAL DISORDERS, WITH A FOCUS ON THEIR PROPOSED CELLULAR TARGETS AND THE WAYS IN WHICH THEY PRODUCE THEIR BENEFICIAL EFFECTS. FURTHERMORE, THIS AVAILABLE INFORMATION IS COMPARED WITH THAT PROVIDED BY IN SILICO ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION, AND TOXICITY (ADMET) MODELS IN ORDER TO UNDERSTAND THE USEFULNESS OF THESE TOOLS FOR THE DISCOVERY OF NEW BIOACTIVE COMPOUNDS. ACCORDINGLY, IT WAS POSSIBLE TO HIGHLIGHT HOW THESE LIPIDS INTERACT WITH VARIOUS CELLULAR TARGETS RELATED TO THE MOLECULE TRANSPORTATION AND ABSORPTION (E.G., Α-TOCOPHEROL TRANSFER PROTEIN FOR Α-TOCOPHEROL, ATP-BINDING CASSETTE ABC TRANSPORTERS OR APOLIPOPROTEIN E FOR SPHINGOMYELINS AND PHOSPHOLIPIDS) OR OTHER PROCESSES, SUCH AS THE REGULATION OF GENE EXPRESSION (INVOLVING STEROL REGULATORY ELEMENT-BINDING PROTEINS FOR ERGOSTEROL OR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN THE CASE OF POLICOSANOL) AND INFLAMMATION (THE REGULATION OF INTERLEUKINS BY SODIUM BUTYRATE). WHEN COMPARING THE LITERATURE WITH IN SILICO QUANTITATIVE STRUCTURE–ACTIVITY RELATIONSHIP (QSAR) MODELS, IT WAS OBSERVED THAT ALTHOUGH THEY ARE USEFUL FOR SELECTING BIOACTIVE MOLECULES WHEN COMPARED IN BATCH, THE INFORMATION THEY PROVIDE DOES NOT COINCIDE WHEN ASSESSED INDIVIDUALLY. OUR REVIEW HIGHLIGHTS THE IMPORTANCE OF CONSIDERING A BROAD RANGE OF LIPIDS AS POTENTIAL BIOACTIVES AND THE NEED FOR ACCURATE PREDICTION OF ADMET PARAMETERS IN THE DISCOVERY OF NEW BIOMOLECULES. THE INFORMATION PRESENTED HERE PROVIDES A USEFUL RESOURCE FOR RESEARCHERS INTERESTED IN DEVELOPING NEW STRATEGIES FOR THE TREATMENT OF OBESITY AND MENTAL OR NEUROLOGICAL DISORDERS. © 2023 BY THE AUTHORS.","ADMET; ERGOSTEROL; IN SILICO QSAR; KRILL PHOSPHOLIPIDS; NEUROLOGICAL DISORDERS; OBESITY; POLICOSANOL; SPHINGOMYELIN","","AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA AND ESCOLA SUPERIOR DE BIOTECNOLOGIA; UNIVERSIDADE CATÓLICA PORTUGUESA, (POCI-01−0247-FEDER-027578); FUNDAÇÃO PARA A CIÊNCIA E A TECNOLOGIA, FCT, (UID/MULTI/50016/2019)","THIS WORK WAS SUPPORTED BY AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA AND ESCOLA SUPERIOR DE BIOTECNOLOGIA—UNIVERSIDADE CATÓLICA PORTUGUESA THROUGH THE ALCHEMY PROJECT, CAPTURING HIGH VALUE FROM INDUSTRIAL FERMENTATION BIO PRODUCTS (POCI-01−0247-FEDER-027578). THE AUTHORS WOULD ALSO LIKE TO THANK THE SCIENTIFIC COLLABORATION UNDER THE FCT PROJECT UID/MULTI/50016/2019.","GUIDELINE ON CLINICAL EVALUATION OF MEDICINAL PRODUCTS USED IN WEIGHT MANAGEMENT, (2016); WHO EUROPEAN REGIONAL OBESITY REPORT 2022, (2022); REFLECTION PAPER ON REGULATORY REQUIREMENTS FOR THE DEVELOPMENT OF MEDICINAL PRODUCTS FOR CHRONIC NON-INFECTIOUS LIVER DISEASES (PBC, PSC, NASH), (2019); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., MOTOMURA K., SHIMURA T., OKAJIMA Y., MIZUNOE Y., ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI. REP, 9, (2019); CAZZOLA R., RONDANELLI M., RUSSO-VOLPE S., FERRARI E., CESTARO B., DECREASED MEMBRANE FLUIDITY AND ALTERED SUSCEPTIBILITY TO PEROXIDATION AND LIPID COMPOSITION IN OVERWEIGHT AND OBESE FEMALE ERYTHROCYTES, J. LIPID RES, 45, PP. 1846-1851, (2004); PIMENTEL L.L., FONTES A.L., SALSINHA A.S., CARDOSO B.B., GOMES A.M., RODRIGUEZ-ALCALA L.M., MICROBIOLOGICAL IN VIVO PRODUCTION OF CLNA AS A TOOL IN THE REGULATION OF HOST MICROBIOTA IN OBESITY CONTROL, STUD. NAT. PROD. CHEM, 61, PP. 369-394, (2018); VEZZA T., CANET F., DE MARANON A.M., BANULS C., ROCHA M., VICTOR V.M., PHYTOSTEROLS: NUTRITIONAL HEALTH PLAYERS IN THE MANAGEMENT OF OBESITY AND ITS RELATED DISORDERS, ANTIOXIDANTS, 9, (2020); DAS M., GEETHA V., ZAREI M., HAROHALLY N.V., KUMAR G.S., MODULATION OF OBESITY ASSOCIATED METABOLIC DYSFUNCTION BY NOVEL LIPOPHILIC FRACTION OBTAINED FROM AGARICUS BISPORUS, LIFE SCI, 305, (2022); KANG J.G., PARK C.Y., ANTI-OBESITY DRUGS: A REVIEW ABOUT THEIR EFFECTS AND SAFETY, DIABETE METAB. J, 36, PP. 13-25, (2012); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTR. METAB. CARDIOVASC. DIS, 27, PP. 2-17, (2017); FENG S., DAI Z., LIU A.B., HUANG J., NARSIPUR N., GUO G., KONG B., REUHL K., LU W., LUO Z., ET AL., INTAKE OF STIGMASTEROL AND Β-SITOSTEROL ALTERS LIPID METABOLISM AND ALLEVIATES NAFLD IN MICE FED A HIGH-FAT WESTERN-STYLE DIET, BIOCHIM. BIOPHYS. ACTA MOL. CELL BIOL. LIPIDS, 1863, PP. 1274-1284, (2018); NORRIS G.H., PORTER C.M., JIANG C., MILLAR C.L., BLESSO C.N., DIETARY SPHINGOMYELIN ATTENUATES HEPATIC STEATOSIS AND ADIPOSE TISSUE INFLAMMATION IN HIGH-FAT-DIET-INDUCED OBESE MICE, J. NUTR. BIOCHEM, 40, PP. 36-43, (2017); CHUNG R.W.S., KAMILI A., TANDY S., WEIR J.M., GAIRE R., WONG G., MEIKLE P.J., COHN J.S., RYE K.-A., DIETARY SPHINGOMYELIN LOWERS HEPATIC LIPID LEVELS AND INHIBITS INTESTINAL CHOLESTEROL ABSORPTION IN HIGH-FAT-FED MICE, PLOS ONE, 8, (2013); MOREAU R.A., NYSTROM L., WHITAKER B.D., WINKLER-MOSER J.K., BAER D.J., GEBAUER S.K., HICKS K.B., PHYTOSTEROLS AND THEIR DERIVATIVES: STRUCTURAL DIVERSITY, DISTRIBUTION, METABOLISM, ANALYSIS, AND HEALTH-PROMOTING USES, PROG. LIPID RES, 70, PP. 35-61, (2018); DUPONT S., FLEURAT-LESSARD P., CRUZ R.G., LAFARGE C., GRANGETEAU C., YAHOU F., GERBEAU-PISSOT P., ABRAHAO JUNIOR O., GERVAIS P., SIMON-PLAS F., ET AL., ANTIOXIDANT PROPERTIES OF ERGOSTEROL AND ITS ROLE IN YEAST RESISTANCE TO OXIDATION, ANTIOXIDANTS, 10, (2021); PIVA G.G., CASALTA E., LEGRAS J.-L., TESNIERE C., SABLAYROLLES J.-M., FERREIRA D., ORTIZ-JULIEN A., GALEOTE V., MOURET J.-R., CHARACTERIZATION AND ROLE OF STEROLS IN SACCHAROMYCES CEREVISIAE DURING WHITE WINE ALCOHOLIC FERMENTATION, FERMENTATION, 8, (2022); DAS M., KUMAR G.S., POTENTIAL ROLE OF MYCOSTEROLS IN HYPERLIPIDEMIA—A REVIEW, STEROIDS, 166, (2021); ROSENHEIM O., WEBSTER T., THE SPECIFICITY OF ERGOSTEROL AS PARENT SUBSTANCE OF VITAMIN D, NATURE, 121, (1928); FOSS Y.J., VITAMIN D DEFICIENCY IS THE CAUSE OF COMMON OBESITY, MED. HYPOTHESES, 72, PP. 314-321, (2009); BAUR A.C., KUHN J., BRANDSCH C., HIRCHE F., STANGL G.I., INTAKE OF ERGOSTEROL INCREASES THE VITAMIN D CONCENTRATIONS IN SERUM AND LIVER OF MICE, J. STEROID BIOCHEM. MOL. BIOL, 194, (2019); PHILLIPS K.M., RUGGIO D.M., HORST R.L., MINOR B., SIMON R.R., FEENEY M.J., BYRDWELL W.C., HAYTOWITZ D.B., VITAMIN D AND STEROL COMPOSITION OF 10 TYPES OF MUSHROOMS FROM RETAIL SUPPLIERS IN THE UNITED STATES, J. AGRIC. FOOD CHEM, 59, PP. 7841-7853, (2011); ROUSTA N., ASLAN M., YESILCIMEN AKBAS M., OZCAN F., SAR T., TAHERZADEH M.J., EFFECTS OF FUNGAL BASED BIOACTIVE COMPOUNDS ON HUMAN HEALTH: REVIEW PAPER, CRIT. REV. FOOD SCI. NUTR, PP. 1-24, (2023); HELENO S.A., RUDKE A.R., CALHELHA R.C., CAROCHO M., BARROS L., GONCALVES O.H., BARREIRO M.F., FERREIRA I.C.F.R., DEVELOPMENT OF DAIRY BEVERAGES FUNCTIONALIZED WITH PURE ERGOSTEROL AND MYCOSTEROL EXTRACTS: AN ALTERNATIVE TO PHYTOSTEROL-BASED BEVERAGES, FOOD FUNCT, 8, PP. 103-110, (2017); LEE N.K., AAN B.Y., OPTIMIZATION OF ERGOSTEROL TO VITAMIN D2 SYNTHESIS IN AGARICUS BISPORUS POWDER USING ULTRAVIOLET-B RADIATION, FOOD SCI. BIOTECHNOL, 25, PP. 1627-1631, (2016); GIL A., VICTOR R., ROBERTO C., HERNANDEZ M., MARIN F.R., LARGO C., RODRIGUEZ A., TABERNERO M., RUIZ A., GUILLERMO R., MODULATION OF CHOLESTEROL—RELATED GENE EXPRESSION BY ERGOSTEROL AND ERGOSTEROL—ENRICHED EXTRACTS OBTAINED FROM AGARICUS BISPORUS, EUR. J. NUTR, 55, PP. 1041-1057, (2016); MAHDAVI A., BAGHERNIYA M., FAKHERAN O., REINER Z., XU S., SAHEBKAR A., MEDICINAL PLANTS AND BIOACTIVE NATURAL COMPOUNDS AS INHIBITORS OF HMG-COA REDUCTASE: A LITERATURE REVIEW, BIOFACTORS, 46, PP. 906-926, (2020); BURG J.S., ESPENSHADE P.J., PROGRESS IN LIPID RESEARCH REGULATION OF HMG-COA REDUCTASE IN MAMMALS AND YEAST, PROG. LIPID RES, 50, PP. 403-410, (2011); DAS M., GURUSIDDAIAH S.K., ERGOSTEROL FRACTION FROM AGARICUS BISPORUS MODULATES ADIPOGENESIS AND SKELETAL GLUCOSE UPTAKE IN HIGH FAT DIET INDUCED OBESE C57BL/6 MICE, LIFE SCI, 315, (2023); RA J., WOO S., LEE K., JA M., YOUNG H., MI H., CHUNG I., HYUN D., HWAN J., DUCK W., POLICOSANOL PROFILES AND ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME, FOOD CHEM, 317, (2020); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB, 37, PP. 33-38, (1993); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS, 43, PP. 109-115, (2008); ZHAI Z., LIU J., NIU K.M., LIN C., TU Y., LIU Y., CAI L., LIU H., OUYANG K., INTEGRATED METAGENOMICS AND METABOLOMICS TO REVEAL THE EFFECTS OF POLICOSANOL ON MODULATING THE GUT MICROBIOTA AND LIPID METABOLISM IN HYPERLIPIDEMIC C57BL/6 MICE, FRONT. ENDOCRINOL, 12, (2021); LEE S.-H., SCOTT S.D., PEKAS E.J., LEE J., PARK S., IMPROVEMENT OF LIPIDS AND REDUCTION OF OXIDATIVE STRESS WITH OCTACOSANOL AFTER TAEKWONDO TRAINING, INT. J. SPORT. PHYSIOL. PERFORM, 14, PP. 1297-1303, (2019); ARORA M.K., PANDEY S., TOMAR R., SAHOO J., KUMAR D., JANGRA A., THERAPEUTIC POTENTIAL OF POLICOSANOL IN THE CONCURRENT MANAGEMENT OF DYSLIPIDEMIA AND NON-ALCOHOLIC FATTY LIVER DISEASE, FUTURE J. PHARM. SCI, 8, (2022); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MED. J. NUTR. METAB, 1, PP. 77-83, (2008); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES, 32, PP. 8-12, (2001); IQBAL J., WALSH M.T., HAMMAD S.M., HUSSAIN M.M., SPHINGOLIPIDS AND LIPOPROTEINS IN HEALTH AND METABOLIC DISORDERS, TRENDS ENDOCRINOL. METAB, 28, PP. 506-518, (2017); NORRIS G.H., JIANG C., RYAN J., PORTER C.M., BLESSO C.N., MILK SPHINGOMYELIN IMPROVES LIPID METABOLISM AND ALTERS GUT MICROBIOTA IN HIGH FAT DIET-FED MICE, J. NUTR. BIOCHEM, 30, PP. 93-101, (2016); LO SASSO G., SCHLAGE W.K., BOUE S., VELJKOVIC E., PEITSCH M.C., HOENG J., THE APOE−/− MOUSE MODEL: A SUITABLE MODEL TO STUDY CARDIOVASCULAR AND RESPIRATORY DISEASES IN THE CONTEXT OF CIGARETTE SMOKE EXPOSURE AND HARM REDUCTION, J. TRANSL. MED, 14, (2016); MILLAR C.L., NORRIS G.H., VITOLS A., GARCIA C., SEIBEL S., ANTO L., BLESSO C.N., DIETARY EGG SPHINGOMYELIN PREVENTS AORTIC ROOT PLAQUE ACCUMULATION IN APOLIPOPROTEIN-E KNOCKOUT MICE, NUTRIENTS, 11, (2019); SMITH D.D., TAN X., TAWFIK O., MILNE G., STECHSCHULTE D.J., DILEEPAN K.N., INCREASED AORTIC ATHEROSCLEROTIC PLAQUE DEVELOPMENT IN FEMALE APOLIPOPROTEIN E-NULL MICE IS ASSOCIATED WITH ELEVATED THROMBOXANE A2 AND DECREASED PROSTACYCLIN PRODUCTION, J. PHYSIOL. PHARMACOL, 61, (2010); CHUNG R.W.S., WANG Z., BURSILL C.A., WU B.J., BARTER P.J., RYE K.A., EFFECT OF LONG-TERM DIETARY SPHINGOMYELIN SUPPLEMENTATION ON ATHEROSCLEROSIS IN MICE, PLOS ONE, 12, (2017); LONGO M., ZATTERALE F., NADERI J., PARRILLO L., FORMISANO P., RACITI G.A., BEGUINOT F., MIELE C., ADIPOSE TISSUE DYSFUNCTION AS DETERMINANT OF OBESITY-ASSOCIATED METABOLIC COMPLICATIONS, INT. J. MOL. SCI, 20, (2019); JIANG C., CHEONG L.Z., ZHANG X., ALI A.H., JIN Q., WEI W., WANG X., DIETARY SPHINGOMYELIN METABOLISM AND ROLES IN GUT HEALTH AND COGNITIVE DEVELOPMENT, ADVANCES IN NUTRITION, 13, PP. 474-491, (2022); BYRDWELL W.C., PERRY R.H., LIQUID CHROMATOGRAPHY WITH DUAL PARALLEL MASS SPECTROMETRY AND 31P NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY FOR ANALYSIS OF SPHINGOMYELIN AND DIHYDROSPHINGOMYELIN: I. BOVINE BRAIN AND CHICKEN EGG YOLK, J. CHROMATOGR. A, 1133, PP. 149-171, (2006); BYRDWELL W.C., PERRY R.H., LIQUID CHROMATOGRAPHY WITH DUAL PARALLEL MASS SPECTROMETRY AND 31P NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY FOR ANALYSIS OF SPHINGOMYELIN AND DIHYDROSPHINGOMYELIN: II. BOVINE MILK SPHINGOLIPIDS, J. CHROMATOGR. A, 1146, PP. 164-185, (2007); RIDGWAY N.D., INTERACTIONS BETWEEN METABOLISM AND INTRACELLULAR DISTRIBUTION OF CHOLESTEROL AND SPHINGOMYELIN, BIOCHIM. BIOPHYS. ACTA MOL. CELL BIOL. LIPIDS, 1484, PP. 129-141, (2000); YAMAUCHI I., UEMURA M., HOSOKAWA M., IWASHIMA-SUZUKI A., SHIOTA M., MIYASHITA K., THE DIETARY EFFECT OF MILK SPHINGOMYELIN ON THE LIPID METABOLISM OF OBESE/DIABETIC KK-AY MICE AND WILD-TYPE C57BL/6J MICE, FOOD FUNCT, 7, PP. 3854-3867, (2016); YANG F., CHEN G., MA M., QIU N., ZHU L., LI J., EGG-YOLK SPHINGOMYELIN AND PHOSPHATIDYLCHOLINE ATTENUATE CHOLESTEROL ABSORPTION IN CACO-2 CELLS, LIPIDS, 53, PP. 217-233, (2018); PATON C.M., NTAMBI J.M., BIOCHEMICAL AND PHYSIOLOGICAL FUNCTION OF STEAROYL-COA DESATURASE, AM. J. PHYSIOL. ENDOCRINOL. METAB, 297, (2009); OHLSSON L., BURLING H., NILSSON A., LONG TERM EFFECTS ON HUMAN PLASMA LIPOPROTEINS OF A FORMULATION ENRICHED IN BUTTER MILK POLAR LIPID, LIPIDS HEALTH DIS, 8, (2009); COCHRAN B.J., ONG K.L., MANANDHAR B., RYE K.A., APOA1: A PROTEIN WITH MULTIPLE THERAPEUTIC FUNCTIONS, CURR. ATHEROSCLER. REP, 23, (2021); OHLSSON L., BURLING H., DUAN R.D., NILSSON A., EFFECTS OF A SPHINGOLIPID-ENRICHED DAIRY FORMULATION ON POSTPRANDIAL LIPID CONCENTRATIONS, EUR. J. CLIN. NUTR, 64, PP. 1344-1349, (2010); RAMPRASATH V.R., JONES P.J.H., BUCKLEY D.D., WOOLLETT L.A., HEUBI J.E., EFFECT OF DIETARY SPHINGOMYELIN ON ABSORPTION AND FRACTIONAL SYNTHETIC RATE OF CHOLESTEROL AND SERUM LIPID PROFILE IN HUMANS, LIPIDS HEALTH DIS, 12, (2013); DUAN R.D., HERTERVIG E., NYBERG L., HAUGE T., STERNBY B., LILLIENAU J., FAROOQI A., NILSSON A., DISTRIBUTION OF ALKALINE SPHINGOMYELINASE ACTIVITY IN HUMAN BEINGS AND ANIMALS. TISSUE AND SPECIES DIFFERENCES, DIG. DIS. SCI, 41, PP. 1801-1806, (1996); DEUSCHL G., BEGHI E., FAZEKAS F., VARGA T., CHRISTOFORIDI K.A., SIPIDO E., BASSETTI C.L., VOS T., FEIGIN V.L., THE BURDEN OF NEUROLOGICAL DISEASES IN EUROPE: AN ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2017, LANCET PUBLIC HEALTH, 5, PP. E551-E567, (2020); DING C., WU Y., CHEN X., CHEN Y., WU Z., LIN Z., KANG D., FANG W., CHEN F., GLOBAL, REGIONAL, AND NATIONAL BURDEN AND ATTRIBUTABLE RISK FACTORS OF NEUROLOGICAL DISORDERS: THE GLOBAL BURDEN OF DISEASE STUDY 1990–2019, FRONT. PUBLIC HEALTH, 10, (2022); GLOBAL, REGIONAL, AND NATIONAL BURDEN OF NEUROLOGICAL DISORDERS, 1990–2016: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2016, LANCET, 18, PP. 459-480, (2019); DEUSCHL G., BEGHI E., VARGA T., FACT SHEET: THE BURDEN OF NEUROLOGICAL DISEASES IN EUROPE; CHARLSON F.J., BAXTER A.J., DUA T., DEGENHARDT L., WHITEFORD H.A., VOS T., EXCESS MORTALITY FROM MENTAL, NEUROLOGICAL AND SUBSTANCE USE DISORDERS IN THE GLOBAL BURDEN OF DISEASE STUDY 2010, EPIDEMIOL. PSYCHIATR. SCI, 24, PP. 121-140, (2015); PLANA-RIPOLL O., PEDERSEN C.B., AGERBO E., HOLTZ Y., ERLANGSEN A., CANUDAS-ROMO V., ANDERSEN P.K., CHARLSON F.J., CHRISTENSEN M.K., ERSKINE H.E., ET AL., A COMPREHENSIVE ANALYSIS OF MORTALITY-RELATED HEALTH METRICS ASSOCIATED WITH MENTAL DISORDERS: A NATIONWIDE, REGISTER-BASED COHORT STUDY, LANCET, 394, PP. 1827-1835, (2019); ZANG X., CHEN S., ZHU J., MA J., ZHAI Y., THE EMERGING ROLE OF CENTRAL AND PERIPHERAL IMMUNE SYSTEMS IN NEURODEGENERATIVE DISEASES, FRONT. AGING NEUROSCI, 14, (2022); TUCKER J.M., TOWNSEND D.M., ALPHA-TOCOPHEROL: ROLES IN PREVENTION AND THERAPY OF HUMAN DISEASE, BIOMED. PHARMACOTHER, 59, PP. 380-387, (2005); TORRES L.C.R., SARTORI A., SILVA A., ALENCAR S., BIOACCESSIBILITY AND UPTAKE/EPITHELIAL TRANSPORT OF VITAMIN E: DISCOVERIES AND CHALLENGES OF IN VITRO AND EX VIVO ASSAYS, FOOD RES. INT, 162, (2022); TRABER M.G., VITAMIN E REGULATORY MECHANISMS, ANNU. REV. NUTR, 27, PP. 347-362, (2007); GALLI F., BONOMINI M., BARTOLINI D., ZATINI L., REBOLDI G., MARCANTONINI G., GENTILE G., SIROLLI V., DI PIETRO N., VITAMIN E (ALPHA-TOCOPHEROL) METABOLISM AND NUTRITION IN CHRONIC KIDNEY DISEASE, ANTIOXIDANTS, 11, (2022); ARAI H., KONO N., Α-TOCOPHEROL TRANSFER PROTEIN (Α-TTP), FREE RADIC. BIOL. MED, 176, PP. 162-175, (2021); ZAABOUL F., LIU Y.F., VITAMIN E IN FOODSTUFF: NUTRITIONAL, ANALYTICAL, AND FOOD TECHNOLOGY ASPECTS, COMPR. REV. FOOD SCI. FOOD SAF, 21, PP. 964-998, (2022); SCIENTIFIC OPINION ON DIETARY REFERENCE VALUES FOR VITAMIN E AS A-TOCOPHEROL, EFSA J, 13, (2015); NOVOTNY J.A., FADEL J.G., HOLSTEGE D.M., FURR H.C., CLIFFORD A.J., THIS KINETIC, BIOAVAILABILITY, AND METABOLISM STUDY OF RRR-Α-TOCOPHEROL IN HEALTHY ADULTS SUGGESTS LOWER INTAKE REQUIREMENTS THAN PREVIOUS ESTIMATES, J. NUTR, 142, PP. 2105-2111, (2012); TRABER M.G., HEAD B., VITAMIN E: HOW MUCH IS ENOUGH, TOO MUCH AND WHY!, FREE RADIC. BIOL. MED, 177, PP. 212-225, (2021); GOHIL K., OOMMEN S., QUACH H.T., VASU V.T., AUNG H.H., SCHOCK B., CROSS C.E., VATASSERY G.T., MICE LACKING Α-TOCOPHEROL TRANSFER PROTEIN GENE HAVE SEVERE Α-TOCOPHEROL DEFICIENCY IN MULTIPLE REGIONS OF THE CENTRAL NERVOUS SYSTEM, BRAIN RES, 1201, PP. 167-176, (2008); ULATOWSKI L., GHELFI M., WEST R., ATKINSON J., FINNO C.J., MANOR D., THE TOCOPHEROL TRANSFER PROTEIN MEDIATES VITAMIN E TRAFFICKING BETWEEN CEREBELLAR ASTROCYTES AND NEURONS, J. BIOL. CHEM, 298, (2022); LEE P., ULATOWSKI L.M., VITAMIN E: MECHANISM OF TRANSPORT AND REGULATION IN THE CNS, IUBMB LIFE, 71, PP. 424-429, (2019); THAPA S., SHAH S., CHAND S., SAH S.K., GYAWALI P., PAUDEL S., KHANAL P., ATAXIA DUE TO VITAMIN E DEFICIENCY: A CASE REPORT AND UPDATED REVIEW, CLIN. CASE REP, 10, (2022); GERMAN L., KAHANA C., ROSENFELD V., ZABROWSKY I., WIEZER Z., FRASER D., SHAHAR D.R., DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH FOOD INSUFFICIENCY AND NUTRITIONAL DEFICIENCIES IN POOR COMMUNITY-DWELLING ELDERLY PEOPLE, J. NUTR. HEALTH AGING, 15, PP. 3-8, (2011); HUANG X., WU H., JIANG R., SUN G., SHEN J., MA M., MA C., ZHANG S., HUANG Z., WU Q., ET AL., THE ANTIDEPRESSANT EFFECTS OF Α-TOCOPHEROL ARE RELATED TO ACTIVATION OF AUTOPHAGY VIA THE AMPK/MTOR PATHWAY, EUR. J. PHARMACOL, 833, PP. 1-7, (2018); MANOSSO L.M., NEIS V.B., MORETTI M., DAUFENBACH J.F., FREITAS A.E., COLLA A.R., RODRIGUES A.L.S., ANTIDEPRESSANT-LIKE EFFECT OF Α-TOCOPHEROL IN A MOUSE MODEL OF DEPRESSIVE-LIKE BEHAVIOR INDUCED BY TNF-Α, PROG. NEUROPSYCHOPHARMACOL. BIOL. PSYCHIATRY, 46, PP. 48-57, (2013); LOBATO K.R., CARDOSO C.C., BINFARE R.W., BUDNI J., WAGNER C.L.R., BROCARDO P.S., DE SOUZA L.F., BROCARDO C., FLESCH S., FREITAS A.E., ET AL., Α-TOCOPHEROL ADMINISTRATION PRODUCES AN ANTIDEPRESSANT-LIKE EFFECT IN PREDICTIVE ANIMAL MODELS OF DEPRESSION, BEHAV. BRAIN RES, 209, PP. 249-259, (2010); BANIKAZEMI Z., MOKHBER N., SAFARIAN M., MAZIDI M., MIRZAEI H., ESMAILY H., AZARPAZHOOH M.R., GHAFOURI-TALEGHANI F., GHAYOUR-MOBARHAN M., FERNS G.A., DIETARY VITAMIN E AND FAT INTAKE ARE RELATED TO BECK’S DEPRESSION SCORE, CLIN. NUTR. ESPEN, 10, PP. E61-E65, (2015); SHIBATA H., KUMAGAI S., WATANABE S., SUZUKI T., RELATIONSHIP OF SERUM CHOLESTEROLS AND VITAMIN E TO DEPRESSIVE STATUS IN THE ELDERLY, J. EPIDEMIOL, 9, PP. 261-267, (1999); KENNIS M., GERRITSEN L., VAN DALEN M., WILLIAMS A., CUIJPERS P., BOCKTING C., PROSPECTIVE BIOMARKERS OF MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS, MOL. PSYCHIATRY, 25, PP. 321-338, (2020); MAES M., DE VOS N., PIOLI R., DEMEDTS P., WAUTERS A., NEELS H., CHRISTOPHE A., LOWER SERUM VITAMIN E CONCENTRATIONS IN MAJOR DEPRESSION, J. AFFECT. DISORD, 58, PP. 241-246, (2000); DAS A., CUMMING R.G., NAGANATHAN V., RIBEIRO R., LE COUTEUR D.G., HANDELSMAN D.J., WAITE L.M., HIRANI V., THE ASSOCIATION BETWEEN ANTIOXIDANT INTAKE, DIETARY PATTERN AND DEPRESSIVE SYMPTOMS IN OLDER AUSTRALIAN MEN: THE CONCORD HEALTH AND AGEING IN MEN PROJECT, EUR. J. NUTR, 60, PP. 443-454, (2021); LOHR J.B., CADET J.L., LOHR M.A., LARSON L., WASLL E., WADE L., HYLTON R., VLDONL C., JESTE D., WYATT R.J., VITAMIN E IN THE TREATMENT OF TARDIVE DYSKINESIA: THE POSSIBLE INVOLVEMENT OF FREE RADICAL MECHANISMS 291, SCHIZOPHR. BULL, 14, PP. 291-296, (1988); JAMILIAN M., SHOJAEI A., SAMIMI M., AFSHAR EBRAHIMI F., AGHADAVOD E., KARAMALI M., TAGHIZADEH M., JAMILIAN H., ALAEINASAB S., JAFARNEJAD S., ET AL., THE EFFECTS OF OMEGA-3 AND VITAMIN E CO-SUPPLEMENTATION ON PARAMETERS OF MENTAL HEALTH AND GENE EXPRESSION RELATED TO INSULIN AND INFLAMMATION IN SUBJECTS WITH POLYCYSTIC OVARY SYNDROME, J. AFFECT. DISORD, 229, PP. 41-47, (2018); MANOSSO L.M., CAMARGO A., DAFRE A.L., RODRIGUES A.L.S., VITAMIN E FOR THE MANAGEMENT OF MAJOR DEPRESSIVE DISORDER: POSSIBLE ROLE OF THE ANTI-INFLAMMATORY AND ANTIOXIDANT SYSTEMS, NUTR. NEUROSCI, 25, PP. 1310-1324, (2022); PETRA M.J.C., KUIJPERS HISTORY IN MEDICINE: THE STORY OF CHOLESTEROL, LIPIDS AND CARDIOLOGY, E-J. CARDIOL. PRACT, 19, PP. 1-5, (2021); ORKABY A.R., THE HIGHS AND LOWS OF CHOLESTEROL: A PARADOX OF HEALTHY AGING?, J. AM. GERIATR. SOC, 68, PP. 236-237, (2020); MAHLEY R.W., CENTRAL NERVOUS SYSTEM LIPOPROTEINS: APOE AND REGULATION OF CHOLESTEROL METABOLISM, ARTERIOSCLER. THROMB. VASC. BIOL, 36, PP. 1305-1315, (2016); CANTUTI-CASTELVETRI L., FITZNER D., BOSCH-QUERALT M., WEIL M.T., SU M., SEN P., RUHWEDEL T., MITKOVSKI M., TRENDELENBURG G., LUTJOHANN D., ET AL., DEFECTIVE CHOLESTEROL CLEARANCE LIMITS REMYELINATION IN THE AGED CENTRAL NERVOUS SYSTEM, SCIENCE, 359, PP. 684-688, (2018); HAMMEL G., ZIVKOVIC S., AYAZI M., REN Y., CONSEQUENCES AND MECHANISMS OF MYELIN DEBRIS UPTAKE AND PROCESSING BY CELLS IN THE CENTRAL NERVOUS SYSTEM, CELL. IMMUNOL, 380, (2022); PETROV A.M., KASIMOV M.R., ZEFIROV A.L., BRAIN CHOLESTEROL METABOLISM AND ITS DEFECTS: LINKAGE TO NEURODEGENERATIVE DISEASES AND SYNAPTIC DYSFUNCTION, ACTA NAT, 8, (2016); WANG K., LIU H., HU Q., WANG L., LIU J., ZHENG Z., ZHANG W., REN J., ZHU F., LIU G.H., EPIGENETIC REGULATION OF AGING: IMPLICATIONS FOR INTERVENTIONS OF AGING AND DISEASES, SIGNAL TRANSDUCT. TARGET. THER, 7, (2022); SAFAIYAN S., KANNAIYAN N., SNAIDERO N., BRIOSCHI S., BIBER K., YONA S., EDINGER A.L., JUNG S., ROSSNER M.J., SIMONS M., AGE-RELATED MYELIN DEGRADATION BURDENS THE CLEARANCE FUNCTION OF MICROGLIA DURING AGING, NAT. NEUROSCI, 19, PP. 995-998, (2016); HUSAIN M.A., LAURENT B., PLOURDE M., APOE AND ALZHEIMER’S DISEASE: FROM LIPID TRANSPORT TO PHYSIOPATHOLOGY AND THERAPEUTICS, FRONT. NEUROSCI, 15, (2021); BLANCHARD J.W., AKAY L.A., DAVILA-VELDERRAIN J., VON MAYDELL D., MATHYS H., DAVIDSON S.M., EFFENBERGER A., CHEN C.Y., MANER-SMITH K., HAJJAR I., ET AL., APOE4 IMPAIRS MYELINATION VIA CHOLESTEROL DYSREGULATION IN OLIGODENDROCYTES, NATURE, 611, PP. 769-779, (2022); FERNANDEZ-CALLE R., KONINGS S.C., FRONTINAN-RUBIO J., GARCIA-REVILLA J., CAMPRUBI-FERRER L., SVENSSON M., MARTINSON I., BOZA-SERRANO A., VENERO J.L., NIELSEN H.M., ET AL., APOE IN THE BULLSEYE OF NEURODEGENERATIVE DISEASES: IMPACT OF THE APOE GENOTYPE IN ALZHEIMER’S DISEASE PATHOLOGY AND BRAIN DISEASES, MOL. NEURODEGENER, 17, (2022); YAMAZAKI Y., ZHAO N., CAULFIELD T.R., LIU C.-C., BU G., APOLIPOPROTEIN E AND ALZHEIMER DISEASE: PATHOBIOLOGY AND TARGETING STRATEGIES, NAT. REV. NEUROL, 15, PP. 501-518, (2019); LINDNER K., BECKENBAUER K., VAN EK L.C., TITECA K., DE LEEUW S.M., AWWAD K., HANKE F., KOREPANOVA A., RYBIN V., VAN DER KAM E.L., ET AL., ISOFORM- AND CELL-STATE-SPECIFIC LIPIDATION OF APOE IN ASTROCYTES, CELL REP, 38, (2022); FERINGA F.M., VAN DER KANT R., CHOLESTEROL AND ALZHEIMER’S DISEASE; FROM RISK GENES TO PATHOLOGICAL EFFECTS, FRONT. AGING NEUROSCI, 13, (2021); LINDNER K., VAN EK L.C., AWWAD K., HANKE F., KOREPANOVA A., RYBIN V., BECKENBAUER K., GAVIN A.-C., IN VITRO AND IN CELLULO APOE PARTICLE FORMATION, ISOLATION, AND CHARACTERIZATION, STAR PROTOC, 3, (2022); FITZ N.F., NAM K.N., WOLFE C.M., LETRONNE F., PLAYSO B.E., IORDANOVA B.E., KOZAI T.D.Y., BIEDRZYCKI R.J., KAGAN V.E., TYURINA Y.Y., ET AL., PHOSPHOLIPIDS OF APOE LIPOPROTEINS ACTIVATE MICROGLIA IN AN ISOFORM-SPECIFIC MANNER IN PRECLINICAL MODELS OF ALZHEIMER’S DISEASE, NAT. COMMUN, 12, (2021); LI R.-Y., QIN Q., YANG H.-C., WANG Y.-Y., MI Y.-X., YIN Y.-S., WANG M., YU C.-J., TANG Y., TREM2 IN THE PATHOGENESIS OF AD: A LIPID METABOLISM REGULATOR AND POTENTIAL METABOLIC THERAPEUTIC TARGET, MOL. NEURODEGENER, 17, (2022); FREUND LEVI Y., VEDIN I., CEDERHOLM T., BASUN H., FAXEN IRVING G., ERIKSDOTTER M., HJORTH E., SCHULTZBERG M., VESSBY B., WAHLUND L.-O., ET AL., TRANSFER OF OMEGA-3 FATTY ACIDS ACROSS THE BLOOD-BRAIN BARRIER AFTER DIETARY SUPPLEMENTATION WITH A DOCOSAHEXAENOIC ACID-RICH OMEGA-3 FATTY ACID PREPARATION IN PATIENTS WITH ALZHEIMER’S DISEASE: THE OMEGAD STUDY, J. INTERN. MED, 275, PP. 428-436, (2014); FREUND-LEVI Y., ERIKSDOTTER-JONHAGEN M., CEDERHOLM T., BASUN H., FAXEN-IRVING G., GARLIND A., VEDIN I., VESSBY B., WAHLUND L.-O., PALMBLAD J., Ω-3 FATTY ACID TREATMENT IN 174 PATIENTS WITH MILD TO MODERATE ALZHEIMER DISEASE: OMEGAD STUDY, ARCH. NEUROL, 63, (2006); KO C.-W., QU J., BLACK D.D., TSO P., REGULATION OF INTESTINAL LIPID METABOLISM: CURRENT CONCEPTS AND RELEVANCE TO DISEASE, NAT. REV. GASTROENTEROL. HEPATOL, 17, PP. 169-183, (2020); SALSINHA A.S., RODRIGUEZ-ALCALA L.M., RELVAS J.B., PINTADO M.E., FATTY ACIDS ROLE ON OBESITY INDUCED HYPOTHALAMUS INFLAMMATION: FROM PROBLEM TO SOLUTION—A REVIEW, TRENDS FOOD SCI. TECHNOL, 112, PP. 592-607, (2021); PATRICK R.P., ROLE OF PHOSPHATIDYLCHOLINE-DHA IN PREVENTING APOE4-ASSOCIATED ALZHEIMER’S DISEASE, FASEB J, 33, PP. 1554-1564, (2019); CASTRO-GOMEZ M.P., HOLGADO F., RODRIGUEZ-ALCALA L.M., MONTERO O., FONTECHA J., COMPREHENSIVE STUDY OF THE LIPID CLASSES OF KRILL OIL BY FRACTIONATION AND IDENTIFICATION OF TRIACYLGLYCEROLS, DIACYLGLYCEROLS, AND PHOSPHOLIPID MOLECULAR SPECIES BY USING UPLC/QTOF-MS, FOOD ANAL. METHODS, 8, PP. 2568-2580, (2015); KIM J.H., MENG H.W., HE M.T., CHOI J.M., LEE D., CHO E.J., KRILL OIL ATTENUATES COGNITIVE IMPAIRMENT BY THE REGULATION OF OXIDATIVE STRESS AND NEURONAL APOPTOSIS IN AN AMYLOID Β-INDUCED ALZHEIMER’S DISEASE MOUSE MODEL, MOLECULES, 25, (2020); SCHEINMAN S.B., SUGASINI D., ZAYED M., YALAGALA P.C.R., MAROTTOLI F.M., SUBBAIAH P., TAI L.M., LPC-DHA/EPA-ENRICHED DIETS INCREASE BRAIN DHA AND MODULATE BEHAVIOR IN MICE THAT EXPRESS HUMAN APOE4, FRONT. NEUROSCI, 15, (2021); KONAGAI C., YANAGIMOTO K., HAYAMIZU K., HAN L., TSUJI T., KOGA Y., EFFECTS OF KRILL OIL CONTAINING N-3 POLYUNSATURATED FATTY ACIDS IN PHOSPHOLIPID FORM ON HUMAN BRAIN FUNCTION: A RANDOMIZED CONTROLLED TRIAL IN HEALTHY ELDERLY VOLUNTEERS, CLIN. INTERV. AGING, 8, (2013); MATT S.M., ALLEN J.M., LAWSON M.A., MAILING L.J., WOODS J.A., JOHNSON R.W., BUTYRATE AND DIETARY SOLUBLE FIBER IMPROVE NEUROINFLAMMATION ASSOCIATED WITH AGING IN MICE, FRONT IMMUNOL, 9, (2018); HODGKINSON K., EL ABBAR F., DOBRANOWSKI P., MANOOGIAN J., BUTCHER J., FIGEYS D., MACK D., STINTZI A., BUTYRATE’S ROLE IN HUMAN HEALTH AND THE CURRENT PROGRESS TOWARDS ITS CLINICAL APPLICATION TO TREAT GASTROINTESTINAL DISEASE, CLIN. NUTR, 42, PP. 61-75, (2023); QUEIROS O., PRETO A., PACHECO A., PINHEIRO C., AZEVEDO-SILVA J., MOREIRA R., PEDRO M., KO Y.H., PEDERSEN P.L., BALTAZAR F., ET AL., BUTYRATE ACTIVATES THE MONOCARBOXYLATE TRANSPORTER MCT4 EXPRESSION IN BREAST CANCER CELLS AND ENHANCES THE ANTITUMOR ACTIVITY OF 3-BROMOPYRUVATE, J. BIOENERG. BIOMEMBR, 44, PP. 141-153, (2012); SIDDIQUI M.T., CRESCI G.A.M., THE IMMUNOMODULATORY FUNCTIONS OF BUTYRATE, J. INFLAMM. RES, 14, PP. 6025-6041, (2021); LI H., SUN J., WANG F., DING G., CHEN W., FANG R., YAO Y., PANG M., LU Z.Q., LIU J., SODIUM BUTYRATE EXERTS NEUROPROTECTIVE EFFECTS BY RESTORING THE BLOOD-BRAIN BARRIER IN TRAUMATIC BRAIN INJURY MICE, BRAIN RES, 1642, PP. 70-78, (2016); SUN J., WANG F., LI H., ZHANG H., JIN J., CHEN W., PANG M., YU J., HE Y., LIU J., ET AL., NEUROPROTECTIVE EFFECT OF SODIUM BUTYRATE AGAINST CEREBRAL ISCHEMIA/REPERFUSION INJURY IN MICE, BIOMED. RES. INT, 2015, (2015); XU R.C., MIAO W.T., XU J.Y., XU W.X., LIU M.R., DING S.T., JIAN Y.X., LEI Y.H., YAN N., LIU H.D., NEUROPROTECTIVE EFFECTS OF SODIUM BUTYRATE AND MONOMETHYL FUMARATE TREATMENT THROUGH GPR109A MODULATION AND INTESTINAL BARRIER RESTORATION ON PD MICE, NUTRIENTS, 14, (2022); GAO L., DAVIES D.L., ASATRYAN L., SODIUM BUTYRATE SUPPLEMENTATION MODULATES NEUROINFLAMMATORY RESPONSE AGGRAVATED BY ANTIBIOTIC TREATMENT IN A MOUSE MODEL OF BINGE-LIKE ETHANOL DRINKING, INT. J. MOL. SCI, 23, (2022); JIANG Y., LI K., LI X., XU L., YANG Z., SODIUM BUTYRATE AMELIORATES THE IMPAIRMENT OF SYNAPTIC PLASTICITY BY INHIBITING THE NEUROINFLAMMATION IN 5XFAD MICE, CHEM. BIOL. INTERACT, 341, (2021); OTT M., GOGVADZE V., ORRENIUS S., ZHIVOTOVSKY B., MITOCHONDRIA, OXIDATIVE STRESS AND CELL DEATH, APOPTOSIS, 12, PP. 913-922, (2007); SHANDILYA S., KUMAR S., KUMAR JHA N., KUMAR KESARI K., RUOKOLAINEN J., INTERPLAY OF GUT MICROBIOTA AND OXIDATIVE STRESS: PERSPECTIVE ON NEURODEGENERATION AND NEUROPROTECTION, J. ADV. RES, 38, PP. 223-244, (2022); ROSE S., BENNURI S.C., DAVIS J.E., WYNNE R., SLATTERY J.C., TIPPETT M., DELHEY L., MELNYK S., KAHLER S.G., MACFABE D.F., ET AL., BUTYRATE ENHANCES MITOCHONDRIAL FUNCTION DURING OXIDATIVE STRESS IN CELL LINES FROM BOYS WITH AUTISM, TRANSL. PSYCHIATRY, 8, (2018); XING X., JIANG Z., TANG X., WANG P., LI Y., SUN Y., LE G., ZOU S., SODIUM BUTYRATE PROTECTS AGAINST OXIDATIVE STRESS IN HEPG2 CELLS THROUGH MODULATING NRF2 PATHWAY AND MITOCHONDRIAL FUNCTION, J. PHYSIOL. BIOCHEM, 73, PP. 405-414, (2016); LIU J., WANG F., LIU S., DU J., HU X., XIONG J., FANG R., CHEN W., SUN J., SODIUM BUTYRATE EXERTS PROTECTIVE EFFECT AGAINST PARKINSON’S DISEASE IN MICE VIA STIMULATION OF GLUCAGON LIKE PEPTIDE-1, J. NEUROL. SCI, 381, PP. 176-181, (2017); WANG C., ZHENG D., WENG F., JIN Y., HE L., SODIUM BUTYRATE AMELIORATES THE COGNITIVE IMPAIRMENT OF ALZHEIMER’S DISEASE BY REGULATING THE METABOLISM OF ASTROCYTES, PSYCHOPHARMACOLOGY, 239, PP. 215-227, (2022); KRATSMAN N., GETSELTER D., ELLIOTT E., SODIUM BUTYRATE ATTENUATES SOCIAL BEHAVIOR DEFICITS AND MODIFIES THE TRANSCRIPTION OF INHIBITORY/EXCITATORY GENES IN THE FRONTAL CORTEX OF AN AUTISM MODEL, NEUROPHARMACOLOGY, 102, PP. 136-145, (2016); XIE A., ENSINK E., LI P., GORDEVICIUS J., MARSHALL L.L., GEORGE S., POSPISILIK J.A., AHO V.T.E., HOUSER M.C., PEREIRA P.A.B., ET AL., BACTERIAL BUTYRATE IN PARKINSON’S DISEASE IS LINKED TO EPIGENETIC CHANGES AND DEPRESSIVE SYMPTOMS, MOV. DISORD, 37, PP. 1644-1653, (2022); ALPINO G.D.C.A., PEREIRA-SOL G.A., DIAS M.D.M.E., AGUIAR A.S.D., PELUZIO M.D.C.G., BENEFICIAL EFFECTS OF BUTYRATE ON BRAIN FUNCTIONS: A VIEW OF EPIGENETIC, CRIT. REV. FOOD SCI. NUTR, PP. 1-10, (2022); VAN DER HEE B., WELLS J.M., MICROBIAL REGULATION OF HOST PHYSIOLOGY BY SHORT-CHAIN FATTY ACIDS, TRENDS MICROBIOL, 29, PP. 700-712, (2021); ZHOU Z., XU N., MATEI N., MCBRIDE D.W., DING Y., LIANG H., TANG J., ZHANG J.H., SODIUM BUTYRATE ATTENUATED NEURONAL APOPTOSIS VIA GPR41/GΒΓ/PI3K/AKT PATHWAY AFTER MCAO IN RATS, J. CEREB. BLOOD FLOW METAB, 41, PP. 267-281, (2021); BRAAT S., KOOY R.F., THE GABAA RECEPTOR AS A THERAPEUTIC TARGET FOR NEURODEVELOPMENTAL DISORDERS, NEURON, 86, PP. 1119-1130, (2015); KIM S., CHEN J., CHENG T., GINDULYTE A., HE J., HE S., LI Q., SHOEMAKER B.A., THIESSEN P.A., YU B., ET AL., PUBCHEM IN 2021: NEW DATA CONTENT AND IMPROVED WEB INTERFACES, NUCLEIC ACIDS RES, 49, PP. D1388-D1395, (2021); SUSHKO I., NOVOTARSKYI S., KORNER R., PANDEY A.K., RUPP M., TEETZ W., BRANDMAIER S., ABDELAZIZ A., PROKOPENKO V.V., TANCHUK V.Y., ET AL., ONLINE CHEMICAL MODELING ENVIRONMENT (OCHEM): WEB PLATFORM FOR DATA STORAGE, MODEL DEVELOPMENT AND PUBLISHING OF CHEMICAL INFORMATION, J. COMPUT. AIDED MOL. DES, 25, PP. 533-554, (2011); LIPINSKI C.A., LOMBARDO F., DOMINY B.W., FEENEY P.J., EXPERIMENTAL AND COMPUTATIONAL APPROACHES TO ESTIMATE SOLUBILITY AND PERMEABILITY IN DRUG DISCOVERY AND DEVELOPMENT SETTINGS, ADV. DRUG DELIV. REV, 23, PP. 3-25, (1997); VEBER D.F., JOHNSON S.R., CHENG H.-Y., SMITH B.R., WARD K.W., KOPPLE K.D., MOLECULAR PROPERTIES THAT INFLUENCE THE ORAL BIOAVAILABILITY OF DRUG CANDIDATES, J. MED. CHEM, 45, PP. 2615-2623, (2002); BOS J.D., MEINARDI M.M.H.M., THE 500 DALTON RULE FOR THE SKIN PENETRATION OF CHEMICAL COMPOUNDS AND DRUGS, EXP. DERMATOL, 9, PP. 165-169, (2000); TARCSAY A., NYIRI K., KESERU G.M., IMPACT OF LIPOPHILIC EFFICIENCY ON COMPOUND QUALITY, J. MED. CHEM, 55, PP. 1252-1260, (2012); KOKATE A., LI X., JASTI B., EFFECT OF DRUG LIPOPHILICITY AND IONIZATION ON PERMEABILITY ACROSS THE BUCCAL MUCOSA: A TECHNICAL NOTE, AAPS PHARMSCITECH, 9, PP. 501-504, (2008); DAINA A., MICHIELIN O., ZOETE V., SWISSADME: A FREE WEB TOOL TO EVALUATE PHARMACOKINETICS, DRUG-LIKENESS AND MEDICINAL CHEMISTRY FRIENDLINESS OF SMALL MOLECULES, SCI. REP, 7, (2017); THAI N.Q., THEODORAKIS P.E., LI M.S., FAST ESTIMATION OF THE BLOOD–BRAIN BARRIER PERMEABILITY BY PULLING A LIGAND THROUGH A LIPID MEMBRANE, J. CHEM. INF. MODEL, 60, PP. 3057-3067, (2020); DAINA A., ZOETE V., A BOILED-EGG TO PREDICT GASTROINTESTINAL ABSORPTION AND BRAIN PENETRATION OF SMALL MOLECULES, CHEMMEDCHEM, 11, PP. 1117-1121, (2016); IYER M., TSENG Y.J., SENESE C.L., LIU J., HOPFINGER A.J., PREDICTION AND MECHANISTIC INTERPRETATION OF HUMAN ORAL DRUG ABSORPTION USING MI-QSAR ANALYSIS, MOL. PHARM, 4, PP. 218-231, (2007); HOPKINS A.L., KESERU G.M., LEESON P.D., REES D.C., REYNOLDS C.H., THE ROLE OF LIGAND EFFICIENCY METRICS IN DRUG DISCOVERY, NAT. REV. DRUG DISCOV, 13, PP. 105-121, (2014); BRAGA R.C., PRED-SKIN, LABMOL-LABORATÓRIO DE PLANEJAMENTO DE FÁRMACOS E MODELAGEM MOLECULAR; DAINA A., MICHIELIN O., ZOETE V., SWISSTARGETPREDICTION: UPDATED DATA AND NEW FEATURES FOR EFFICIENT PREDICTION OF PROTEIN TARGETS OF SMALL MOLECULES, NUCLEIC ACIDS RES, 47, PP. W357-W364, (2019); KEISER M.J., ROTH B.L., ARMBRUSTER B.N., ERNSBERGER P., IRWIN J.J., SHOICHET B.K., RELATING PROTEIN PHARMACOLOGY BY LIGAND CHEMISTRY, NAT. BIOTECHNOL, 25, PP. 197-206, (2007); KUNWITTAYA S., NANTASENAMAT C., TREERATANAPIBOON L., SRISARIN A., ISARANKURA-NA-AYUDHYA C., PRACHAYASITTIKUL V., INFLUENCE OF LOGBB CUT-OFF ON THE PREDICTION OF BLOOD-BRAIN BARRIER PERMEABILITY, BIOMED. APPL. TECHNOL. J, 1, PP. 16-34, (2013); AYRTON A., MORGAN P., ROLE OF TRANSPORT PROTEINS IN DRUG ABSORPTION, DISTRIBUTION AND EXCRETION, XENOBIOTICA, 31, PP. 469-497, (2008); KOUMANOV K.S., QUINN P.J., BEREZIAT G., WOLF C., CHOLESTEROL RELIEVES THE INHIBITORY EFFECT OF SPHINGOMYELIN ON TYPE II SECRETORY PHOSPHOLIPASE A2, BIOCHEM. J, 336, (1998); KOUMANOV K., WOLF C., BEREZIAT G., MODULATION OF HUMAN TYPE II SECRETORY PHOSPHOLIPASE A2 BY SPHINGOMYELIN AND ANNEXIN VI, BIOCHEM. J, 326, (1997); BERMAN H.M., WESTBROOK J., FENG Z., GILLILAND G., BHAT T.N., WEISSIG H., SHINDYALOV I.N., BOURNE P.E., THE PROTEIN DATA BANK, NUCLEIC ACIDS RES, 28, PP. 235-242, (2000); HUI D.Y., GROUP 1B PHOSPHOLIPASE A2 IN METABOLIC AND INFLAMMATORY DISEASE MODULATION, BIOCHIM. BIOPHYS. ACTA MOL. CELL BIOL. LIPIDS, 1864, PP. 784-788, (2019)","L.M. RODRÍGUEZ-ALCALÁ; CBQF—CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA—LABORATÓRIO ASSOCIADO, ESCOLA SUPERIOR DE BIOTECNOLOGIA, UNIVERSIDADE CATÓLICA PORTUGUESA, PORTO, RUA DIOGO BOTELHO 1327, 4169-005, PORTUGAL; EMAIL: LALCALA@UCP.PT","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","FOODS","REVIEW","ISI","2-S2.0-85164658512","FOODS","UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA;UNIVERSIDADE CATÓLICA PORTUGUESA","NOTREPORTED;UNIVERSIDADE CATÓLICA PORTUGUESA;NOTREPORTED",NA,"TEIXEIRA FS, 2023, FOODS","TEIXEIRA FS, 2023, FOODS"
"WONGWAIWECH D;KAMCHONEMENUKOOL S;HO C;DETYOTHIN S;KASEMWEERASAN P;WEERAWATANAKORN M","WONGWAIWECH, DONPORN (57202775373); KAMCHONEMENUKOOL, SUDTHIDA (57219992228); HO, CHI-TANG (56510763200); DETYOTHIN, SUKEEWAN (55882604500); KASEMWEERASAN, PATTANAN (57557234400); WEERAWATANAKORN, MONTHANA (55976489600)","ANALYTICAL PROCEDURAL VALIDATION OF POLICOSANOL COMPOUNDS",2022,"FOOD ANALYTICAL METHODS","15","9",1,"10.1007/s12161-022-02265-8","DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF FOOD SCIENCE, RUTGERS UNIVERSITY, 65 DUDLEY ROAD, NEW BRUNSWICK, 08901, NJ, UNITED STATES;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;NATIONAL BUREAU OF AGRICULTURAL COMMODITY AND FOOD STANDARDS, 50 PHAHOLYOTHIN ROAD, LADYAO CHATUCHAK, BANGKOK, 10900, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND","CURRENTLY, THE WIDELY ACCEPTED METHOD FOR DETERMINING POLICOSANOL CONTENTS IS GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC–MS), BUT MEASUREMENT METHOD VALIDATION IS LACKING. THE VALIDATION IS ESSENTIAL TO IMPROVE MEASUREMENT EFFICIENCY FOR GREATER ACCURACY AND PRECISION. THE AIM OF THE STUDY PURPOSED TO VALIDATE POLICOSANOL ANALYSIS BY GC–MS USING SILYLATION DERIVATIZATION TO IMPROVE MEASUREMENT EFFICIENCY. THE LINEARITY (CALIBRATION CURVE PERFORMANCE); THE LOWER LIMIT OF DETECTION; AND THE LOWER LIMIT OF QUANTIFICATION, ACCURACY, PRECISION, STABILITY, AND ROBUSTNESS OF POLICOSANOL EXTRACTED FROM STANDARD POLICOSANOL SOLUTIONS AND DEFATTED RICE BRAN WERE EVALUATED. THE PERCENTAGE OF RECOVERY OF EACH POLICOSANOL CONCENTRATION OF 50, 100, AND 150 MG/L RANGED FROM 98.90 TO 102.02%, 99.28 TO 101.37%, AND 99.67 TO 101.37%, RESPECTIVELY, WHICH IS UNDER THE AOAC ACCEPTANCE CRITERIA. THE ACCURACY OF METHOD BY RELATIVE STANDARD DEVIATIONS (RSD) SHOWED THAT INTRA-DAY RECOVERY PERCENTAGE AND INTER-DAY PRECISION ANALYSIS FOLLOWED THE AOAC ACCEPTANCE CRITERIA. LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTITATION (LOQ) OF POLICOSANOL WERE 0.6–0.84 MG/L AND 2.09–2.82 MG/L, RESPECTIVELY. POLICOSANOL DERIVATIZED WITH N, O-BIS(TRIMETHYLSILYL)-TRIFLUOROACETAMIDE WAS NOT STABLE UNDER STORAGE, WITH VARIATION IN EXCESS OF 15%. POLICOSANOL STANDARD STOCK SOLUTION STORED AT 4 °C FOR MORE THAN 1 WEEK WAS NOT RECOMMENDED FOR FURTHER USE. THE RUGGEDNESS OR ROBUSTNESS OF THE METHOD BY CHANGING THE TESTED PARAMETERS INCLUDING DERIVATIVE TEMPERATURE, LIGHT EXPOSURE, STORAGE TEMPERATURE SOLVENT TYPE, REACTION TIME, ANALYSIS TIME PERIOD, AND ULTRASONIC WAVE EXPOSURE WAS EXAMINED. THE RUGGEDNESS TEST SHOWED THAT CHANGES IN FACTORS RELATED TO POLICOSANOL ANALYSIS HAD NO SIGNIFICANT IMPACT (P < 0.05) ON CHANGES IN POLICOSANOL QUANTITIES. DETERMINATION OF POLICOSANOL BY GC–MS AFTER SILYLATION DERIVATIZATION WAS SUCCESSFULLY VALIDATED AND WAS A BENEFIT TO THE QUALITY CONTROL PROCESS OF POLICOSANOL AS ACTIVE INGREDIENT ANALYSIS. © 2022, THE AUTHOR(S), UNDER EXCLUSIVE LICENCE TO SPRINGER SCIENCE+BUSINESS MEDIA, LLC, PART OF SPRINGER NATURE.","GAS CHROMATOGRAPHY; METHOD VALIDATION; QUANTITATIVE ANALYSIS; SILYLATION DERIVATIZATION","EFFICIENCY; MASS SPECTROMETRY; QUALITY CONTROL; ULTRASONIC APPLICATIONS; ACCEPTANCE CRITERIA; ACCURACY AND PRECISION; DERIVATIZATIONS; GASCHROMATOGRAPHY-MASS SPECTROMETRY; MEASUREMENT EFFICIENCY; MEASUREMENT METHODS; METHOD VALIDATIONS; POLICOSANOLS; SILYLATION DERIVATIZATION; SILYLATIONS; GAS CHROMATOGRAPHY","NARESUAN UNIVERSITY, NU; FACULTY OF MEDICAL SCIENCE, NARESUAN UNIVERSITY, NU, (R2564B023); THAILAND SCIENCE RESEARCH AND INNOVATION, TSRI, (FRB640025)","FINANCIAL SUPPORT FOR THIS STUDY WAS PROVIDED BY A RESEARCH GRANT FROM NARESUAN UNIVERSITY (NO. R2564B023) AND THAILAND SCIENCE RESEARCH AND INNOVATION (FRB640025). ","AGILENT TECHNOLOGIES (2021) DB-5 GC COLUMNS 2021, (2021); ANTOLIN E.J.M., CANAVACIOLO V.L.G., PEREZ R.S., GAS CHROMATOGRAPHIC DETERMINATION OF HIGH MOLECULAR WEIGHT ALCOHOLS FROM POLICOSANOL IN OMEGA-3 FISH OIL BY ACYLATION WITH ACETYL CHLORIDE, J AOAC INT, 91, PP. 1013-1019, (2008); GUIDELINES FOR SINGLE LABORATORY VALIDATION OF CHEMICAL METHODS FOR DIETARY SUPPLEMENTS AND BOTANICALS, AOAC INT, PP. 1-38, (2002); ASIKIN Y., CHINEN T., KENSAKU T., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI TECHNOL RES, 14, PP. 583-588, (2008); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, PP. 583-591, (2012); ATTARD T.M., MCELROY C.R., REZENDE C.A., POLIKARPOV I., CLARK J.H., HUNT A.J., SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES, IND CROPS PROD, 76, PP. 95-103, (2015); BEDREGAL P., TORRES B., UBILLUS M., MENDOZA P., MONTOYA E., ROBUSTNESS IN NAA EVALUATED BY THE YOUDEN AND STEINER TEST, J RADIOANAL NUCL CHEM, 278, PP. 801-806, (2008); CHEN Y., DUNFORD N.T., EDWARDS J., CARVER B., GOAD C., POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, J SCI FOOD AGRIC, 89, PP. 310-314, (2009); CHOI S.J., PARK S.Y., PARK J.S., PARK S.K., JUNG M.Y., CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA (CAMELLIA SINENSIS) LEAVES, FOOD CHEM, 204, PP. 94-101, (2016); DEL RIO J.C., MARQUES G., LINO A.G., LIMA C.F., COLODETTE J.L., GUTIERREZ A., LIPOPHILIC PHYTOCHEMICALS FROM SUGARCANE BAGASSE AND STRAW, IND CROPS PROD, 77, PP. 992-1000, (2015); THE FITNESS FOR PURPOSE OF ANALYTICAL METHODS. A LABORATORY GUIDE TO METHOD VALIDATION AND RELATED TOPICS, (1998); EURACHEM GUIDE: THE FITNESS FOR PURPOSE OF ANALYTICAL METHODS – A LABORATORY GUIDE TO METHOD VALIDATION AND RELATED TOPICS, (2014); GUIDELINE ON BIOANALYTICAL METHOD VALIDATION. EMEA, COMM MED PROD HUM USE. 44, 1–23.EMEA/CHMP/EWP/192217/2009, (2014); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); KEUM T.H., JI E.K., WELLER C.L., POLICOSANOL CONTENTS AND COMPOSITIONS IN WAX-LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN, CEREAL CHEM, 82, PP. 242-245, (2005); KIM J.K., PARK S.Y., NA J.K., SEONG E.S., YU C.Y., METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA (PERILLA FRUTESCENS) CULTIVARS, J AGRIC FOOD CHEM, 60, PP. 2257-2263, (2012); MA J., MA L., ZHANG H., ZHANG Z., WANG Y., LI K., CHEN X., POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY, PLOS ONE, 13, PP. 1-14, (2018); MEEROD K., WEERAWATANAKORN M., PANSAK W., IMPACT OF SUGARCANE JUICE CLARIFICATION ON PHYSICOCHEMICAL PROPERTIES, SOME NUTRACEUTICALS AND ANTIOXIDANT ACTIVITIES OF NON-CENTRIFUGAL SUGAR, SUGAR TECH, 21, PP. 471-480, (2019); MEEROD K., WEERAWATANAKORN M., PANSAK W., EFFECT OF LIMING PROCESS ON PHYSICOCHEMICAL PROPERTIES AND PHYTOCHEMICAL COMPONENTS OF NON-CENTRIFUGAL SUGAR FROM DIFFERENT SUGARCANE CULTIVARS, AGRIC RES, 9, PP. 35-45, (2020); NOWATZKE W., WOOLF E., BEST PRACTICES DURING BIOANALYTICAL METHOD VALIDATION FOR THE CHARACTERIZATION OF ASSAY REAGENTS AND THE EVALUATION OF ANALYTE STABILITY IN ASSAY STANDARDS, QUALITY CONTROLS, AND STUDY SAMPLES, AAPS J, 9, PP. E117-E122, (2007); PIERRE A.E., SILYLATION OF ORGANIC COMPOUNDS, J CHROMATOGR SCI, 6, (1968); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUR J LIPID SCI TECHNOL, 112, PP. 373-379, (2010); SENGUL U., COMPARING DETERMINATION METHODS OF DETECTION AND QUANTIFICATION LIMITS FOR AFLATOXIN ANALYSIS IN HAZELNUT, J FOOD DRUG ANAL, 24, PP. 56-62, (2016); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., KANG H.W., NAM M.H., LEE H.J., LEE J.H., PARK K.H., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J AGRIC FOOD CHEM, 61, PP. 1117-1123, (2013); (2013); SRISAIPET A., KEAWPROM P., EXTRACTION AND CHARACTERIZATION OF POLICOSANOL FROM WHEAT GERM, INT J ENG TECHNOL, 7, PP. 1478-1482, (2019); WONGWAIWECH D., WEERAWATANAKORN M., BOONNOUN P., SUBCRITICAL DIMETHYL ETHER EXTRACTION AS A SIMPLE METHOD TO EXTRACT NUTRACEUTICALS FROM BYPRODUCTS FROM RICE BRAN OIL MANUFACTURE, SCI REP, 10, PP. 1-10, (2020); WONGWAIWECH D., WEERAWATANAKORN M., THARATHA S., HO C.T., COMPARATIVE STUDY ON AMOUNT OF NUTRACEUTICALS IN BY-PRODUCTS FROM SOLVENT AND COLD PRESSING METHODS OF RICE BRAN OIL PROCESSING, J FOOD DRUG ANAL, 27, 1, PP. 71-82, (2019)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, PHITSANULOK, 99 MOO 9, THA PHO, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","SPRINGER","ENGLISH","FOOD ANAL. METHODS.","ARTICLE","ISI","2-S2.0-85127315389","FOOD ANAL METHODS","NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;RUTGERS UNIVERSITY;NARESUAN UNIVERSITY;NATIONAL BUREAU OF AGRICULTURAL COMMODITY AND FOOD STANDARDS;NARESUAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"WONGWAIWECH D, 2022, FOOD ANAL METHODS","WONGWAIWECH D, 2022, FOOD ANAL METHODS"
"MELECCHI A;AMATO R;LAPI D;DAL M M;RUSCIANO D;BAGNOLI P;CAMMALLERI M","MELECCHI, ALBERTO (57256529000); AMATO, ROSARIO (57189664419); LAPI, DOMINGA (23091622300); DAL MONTE, MASSIMO (57225700130); RUSCIANO, DARIO (7003448855); BAGNOLI, PAOLA (7006921480); CAMMALLERI, MAURIZIO (6603409006)","INCREASED EFFICACY OF DIETARY SUPPLEMENT CONTAINING WAX ESTERRICH MARINE OIL AND XANTHOPHYLLS IN A MOUSE MODEL OF DRY MACULAR DEGENERATION",2022,"FRONTIERS IN PHARMACOLOGY","13","",1,"10.3389/fphar.2022.1038730","DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY;DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY;DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY;DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY, INTERDEPARTMENTAL RESEARCH CENTER NUTRAFOOD “NUTRACEUTICALS AND FOOD FOR HEALTH”, UNIVERSITY OF PISA, PISA, ITALY;RESEARCH CENTER, FIDIA FARMACEUTICI S.P.A, CATANIA, ITALY;DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY;DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY, INTERDEPARTMENTAL RESEARCH CENTER NUTRAFOOD “NUTRACEUTICALS AND FOOD FOR HEALTH”, UNIVERSITY OF PISA, PISA, ITALY","AGE-RELATED MACULAR DEGENERATION (AMD) IS NOWADAYS CONSIDERED AMONG THE RETINAL DISEASES WHOSE CLINICAL MANAGEMENT LACKS ESTABLISHED TREATMENT APPROACHES, MAINLY FOR ITS ATROPHIC (DRY) FORM. IN THIS RESPECT, THE USE OF DIETARY PATTERNS ENRICHED IN OMEGA-3 AND ANTIOXIDANT XANTHOPHYLLS HAS EMERGED AS A PROMISING APPROACH TO COUNTERACT DRY AMD PROGRESSION ALTHOUGH THE PROPHYLACTIC POTENTIAL OF OMEGA-3 OF FISH ORIGIN HAS BEEN DISCUSSED. WHETHER ENRICHED AVAILABILITY OF OMEGA-3 AND XANTHOPHYLLS MAY INCREASE THE EFFECTIVENESS OF DIET SUPPLEMENTATION IN PREVENTING DRY AMD REMAINS TO BE FULLY ESTABLISHED. THE PRESENT STUDY AIMS AT COMPARING THE EFFICACY OF AN EXISTING ORALLY ADMINISTERED FORMULATION BASED ON LUTEIN AND FISH OIL, AS A SOURCE OF OMEGA-3, WITH A NOVEL FORMULATION PROVIDING THE COMBINATION OF LUTEIN AND ASTAXANTHIN WITH CALANUS OIL (COIL), WHICH CONTAINS OMEGA-3 TOGETHER WITH THEIR PRECURSORS POLICOSANOLS. USING A MOUSE MODEL OF DRY AMD BASED ON SUBRETINAL INJECTION OF POLYETHYLENE GLYCOL (PEG)-400, WE ASSESSED THE COMPARATIVE EFFICACY OF BOTH FORMULATIONS ON PEG-INDUCED MAJOR HALLMARKS INCLUDING OXIDATIVE STRESS, INFLAMMATION, GLIAL REACTIVITY AND OUTER RETINAL THICKNESS. DIETARY SUPPLEMENTATION WITH BOTH MIXTURES HAS BEEN FOUND TO EXERT A SIGNIFICANT ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY AS REFLECTED BY THE OVERALL AMELIORATION OF THE PEG-INDUCED PATHOLOGICAL HALLMARKS. NOTEWORTHY, THE FORMULATION BASED ON COIL APPEARED TO BE MORE PROTECTIVE THAN THE ONE BASED ON FISH OIL, PRESUMABLY BECAUSE OF THE HIGHER BIOAVAILABILITY OF OMEGA-3 IN COIL. THESE RESULTS SUPPORT THE USE OF DIETARY SUPPLEMENTS COMBINING OMEGA-3 AND XANTHOPHYLLS IN THE PREVENTION AND TREATMENT OF AMD AND SUGGEST THAT THE SOURCE OF OMEGA-3 MIGHT CONTRIBUTE TO TREATMENT EFFICACY. COPYRIGHT © 2022 MELECCHI, AMATO, LAPI, DAL MONTE, RUSCIANO, BAGNOLI AND CAMMALLERI.","CALANUS OIL; CAROTENOIDS; GLIOSIS; INFLAMMATION; OMEGA-3 FATTY ACIDS; OXIDATIVE STRESS; RETINAL THICKNESS","ASTAXANTHIN; CALANUS OIL; EDIBLE OIL; FISH OIL; MACROGOL 400; OMEGA 3 FATTY ACID; POLICOSANOL; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN; AGE RELATED MACULAR DEGENERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOAVAILABILITY; CALANUS FINMARCHICUS; CHEMICAL COMPOSITION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET SUPPLEMENTATION; GEOGRAPHIC ATROPHY; GLIA; MALE; MOUSE; MOUSE MODEL; NONHUMAN; OUTER RETINAL THICKNESS; OXIDATIVE STRESS; RETINAL THICKNESS","FIDIA FARMACEUTICI, FIDIA","THIS RESEARCH WAS FUNDED BY GRANTS FROM FIDIA FARMACEUTICI SPA (ABANO TERME, PD, ITALY) TO MC. ","LUTEIN + ZEAXANTHIN AND OMEGA-3 FATTY ACIDS FOR AGE-RELATED MACULAR DEGENERATION: THE AGE-RELATED EYE DISEASE STUDY 2 (AREDS2) RANDOMIZED CLINICAL TRIAL, JAMA, 309, 19, PP. 2005-2015, (2013); A RANDOMIZED, PLACEBO-CONTROLLED, CLINICAL TRIAL OF HIGH-DOSE SUPPLEMENTATION WITH VITAMINS C AND E, BETA CAROTENE, AND ZINC FOR AGE-RELATED MACULAR DEGENERATION AND VISION LOSS: AREDS REPORT NO. 8, ARCH. OPHTHALMOL, 119, 10, PP. 1417-1436, (2001); AMBATI J., ANAND A., FERNANDEZ S., SAKURAI E., LYNN B.C., KUZIEL W.A., ET AL., AN ANIMAL MODEL OF AGE-RELATED MACULAR DEGENERATION IN SENESCENT CCL-2- OR CCR-2-DEFICIENT MICE, NAT. MED, 9, 11, PP. 1390-1397, (2003); BLOCK M.L., HONG J.S., MICROGLIA AND INFLAMMATION-MEDIATED NEURODEGENERATION: MULTIPLE TRIGGERS WITH A COMMON MECHANISM, PROG. NEUROBIOL, 76, 2, PP. 77-98, (2005); BURHOP M., SCHUCHARDT J.P., NEBL J., MULLER M., LICHTINGHAGEN R., HAHN A., MARINE OIL FROM C. FINMARCHICUS ENHANCES GLUCOSE HOMEOSTASIS AND LIVER INSULIN RESISTANCE IN OBESE PREDIABETIC INDIVIDUALS, NUTRIENTS, 14, 2, (2022); CABRAL DE GUIMARAES T.A., DAICH VARELA M., GEORGIOU M., MICHAELIDES M., TREATMENTS FOR DRY AGE-RELATED MACULAR DEGENERATION: THERAPEUTIC AVENUES, CLINICAL TRIALS AND FUTURE DIRECTIONS, BR. J. OPHTHALMOL, 106, 3, PP. 297-304, (2022); CAMMALLERI M., DAL MONTE M., LOCRI F., LARDNER E., KVANTA A., RUSCIANO D., ET AL., EFFICACY OF A FATTY ACIDS DIETARY SUPPLEMENT IN A POLYETHYLENE GLYCOL-INDUCED MOUSE MODEL OF RETINAL DEGENERATION, NUTRIENTS, 9, 10, (2017); CAMPOCHIARO P.A., RETINAL AND CHOROIDAL VASCULAR DISEASES: PAST, PRESENT, AND FUTURE: THE 2021 PROCTOR LECTURE, INVEST. OPHTHALMOL. VIS. SCI, 62, (2021); CAO Y., LI Y., GKERDI A., REILLY J., TAN Z., SHU X., ASSOCIATION OF NUTRIENTS, SPECIFIC DIETARY PATTERNS, AND PROBIOTICS WITH AGE-RELATED MACULAR DEGENERATION, CURR. MED. CHEM, 29, PP. 6141-6158, (2022); CHAKRAVARTHY U., ARMENDARIZ B.G., FAUSER S., 15 YEARS OF ANTI-VEGF TREATMENT FOR NAMD: SUCCESS OR FAILURE OR SOMETHING IN BETWEEN?, EYE, (2022); CHEW E.Y., CLEMONS T.E., AGRON E., DOMALPALLY A., KEENAN T.D.L., VITALE S., ET AL., LONG-TERM OUTCOMES OF ADDING LUTEIN/ZEAXANTHIN AND Ω-3 FATTY ACIDS TO THE AREDS SUPPLEMENTS ON AGE-RELATED MACULAR DEGENERATION PROGRESSION: AREDS2 REPORT 28, JAMA OPHTHALMOL, 140, 7, PP. 692-698, (2022); CHONG E.W., KREIS A.J., WONG T.Y., SIMPSON J.A., GUYMER R.H., DIETARY OMEGA-3 FATTY ACID AND FISH INTAKE IN THE PRIMARY PREVENTION OF AGE-RELATED MACULAR DEGENERATION: A SYSTEMATIC REVIEW AND META-ANALYSIS, ARCH. OPHTHALMOL, 126, 6, PP. 826-833, (2008); COOK C.M., LARSEN T.S., DERRIG L.D., KELLY K.M., TANDE K.S., WAX ESTER RICH OIL FROM THE MARINE CRUSTACEAN, CALANUS FINMARCHICUS, IS A BIOAVAILABLE SOURCE OF EPA AND DHA FOR HUMAN CONSUMPTION, LIPIDS, 51, 10, PP. 1137-1144, (2016); DATTA S., CANO M., EBRAHIMI K., WANG L., HANDA J.T., THE IMPACT OF OXIDATIVE STRESS AND INFLAMMATION ON RPE DEGENERATION IN NON-NEOVASCULAR AMD, PROG. RETIN. EYE RES, 60, PP. 201-218, (2017); DE ALMEIDA TORRES R.J., DOS ANJOS FERREIRA A.L., LUCHINI A., DE ALMEIDA TORRES R.J., CORREA C.R., THE ROLE OF NON-ENZYMATIC ANTIOXIDANTS ON AGE-RELATED MACULAR DEGENERATION, FRONT. DRUG CHEM. CLIN. RES, 5, PP. 1-19, (2022); EASTLAKE K., BANERJEE P.J., ANGBOHANG A., CHARTERIS D.G., KHAW P.T., LIMB G.A., MÜLLER GLIA AS AN IMPORTANT SOURCE OF CYTOKINES AND INFLAMMATORY FACTORS PRESENT IN THE GLIOTIC RETINA DURING PROLIFERATIVE VITREORETINOPATHY, GLIA, 64, 4, PP. 495-506, (2016); ELMASRY K., IBRAHIM A.S., ABDULMONEIM S., AL-SHABRAWEY M., BIOACTIVE LIPIDS AND PATHOLOGICAL RETINAL ANGIOGENESIS, BR. J. PHARMACOL, 176, 1, PP. 93-109, (2019); FLAXEL C.J., ADELMAN R.A., BAILEY S.T., FAWZI A., LIM J.I., VEMULAKONDA G.A., ET AL., AGE-RELATED MACULAR DEGENERATION PREFERRED PRACTICE PATTERN, OPHTHALMOLOGY, 127, 1, PP. P1-P65, (2020); GASMI A., MUJAWDIYA P.K., SHANAIDA M., ONGENAE A., LYSIUK R., DOSA M.D., ET AL., CALANUS OIL IN THE TREATMENT OF OBESITY-RELATED LOW-GRADE INFLAMMATION, INSULIN RESISTANCE, AND ATHEROSCLEROSIS, APPL. MICROBIOL. BIOTECHNOL, 104, 3, PP. 967-979, (2020); GIANNACCARE G., PELLEGRINI M., SENNI C., BERNABEI F., SCORCIA V., CICERO A.F.G., CLINICAL APPLICATIONS OF ASTAXANTHIN IN THE TREATMENT OF OCULAR DISEASES: EMERGING INSIGHTS, MAR. DRUGS, 18, 5, (2020); JANSEN K.M., MORENO S., GARCIA-ROVES P.M., LARSEN T.S., DIETARY CALANUS OIL RECOVERS METABOLIC FLEXIBILITY AND RESCUES POSTISCHEMIC CARDIAC FUNCTION IN OBESE FEMALE MICE, AM. J. PHYSIOL. HEART CIRC. PHYSIOL, 317, 2, PP. H290-H299, (2019); JIANG H., SHI X., FAN Y., WANG D., LI B., ZHOU J., ET AL., DIETARY OMEGA-3 POLYUNSATURATED FATTY ACIDS AND FISH INTAKE AND RISK OF AGE-RELATED MACULAR DEGENERATION, CLIN. NUTR, 40, 12, PP. 5662-5673, (2021); KANG Q., YANG C., OXIDATIVE STRESS AND DIABETIC RETINOPATHY: MOLECULAR MECHANISMS, PATHOGENETIC ROLE AND THERAPEUTIC IMPLICATIONS, REDOX BIOL, 37, (2020); KASPAR J.W., JAISWAL A.K., AN AUTOREGULATORY LOOP BETWEEN NRF2 AND CUL3-RBX1 CONTROLS THEIR CELLULAR ABUNDANCE, J. BIOL. CHEM, 285, 28, PP. 21349-21358, (2010); KIM S.Y., KAMBHAMPATI S.P., BHUTTO I.A., MCLEOD D.S., LUTTY G.A., KANNAN R.M., EVOLUTION OF OXIDATIVE STRESS, INFLAMMATION AND NEOVASCULARIZATION IN THE CHOROID AND RETINA IN A SUBRETINAL LIPID INDUCED AGE-RELATED MACULAR DEGENERATION MODEL, EXP. EYE RES, 203, (2021); KISHAN A.U., MODJTAHEDI B.S., MARTINS E.N., MODJTAHEDI S.P., MORSE L.S., LIPIDS AND AGE-RELATED MACULAR DEGENERATION, SURV. OPHTHALMOL, 56, 3, PP. 195-213, (2011); KLIFFEN M., VAN DER SCHAFT T.L., MOOY C.M., DE JONG P.T., MORPHOLOGIC CHANGES IN AGE-RELATED MACULOPATHY, MICROSC. RES. TECH, 36, 2, PP. 106-122, (1997); KOWLURU R.A., CHAN P.S., OXIDATIVE STRESS AND DIABETIC RETINOPATHY, EXP. DIABETES RES, 2007, (2007); LIU T., ZHANG L., JOO D., SUN S.C., NF-ΚB SIGNALING IN INFLAMMATION, SIGNAL TRANSDUCT. TARGET. THER, 2, (2017); LOMBARDO M., SERRAO S., LOMBARDO G., CHALLENGES IN AGE-RELATED MACULAR DEGENERATION: FROM RISK FACTORS TO NOVEL DIAGNOSTICS AND PREVENTION STRATEGIES, FRONT. MED, 9, (2022); LUHMANN U.F., ROBBIE S., MUNRO P.M., BARKER S.E., DURAN Y., LUONG V., ET AL., THE DRUSENLIKE PHENOTYPE IN AGING CCL2-KNOCKOUT MICE IS CAUSED BY AN ACCELERATED ACCUMULATION OF SWOLLEN AUTOFLUORESCENT SUBRETINAL MACROPHAGES, INVEST. OPHTHALMOL. VIS. SCI, 50, 12, PP. 5934-5943, (2009); LYZOGUBOV V.V., BORA N.S., TYTARENKO R.G., BORA P.S., POLYETHYLENE GLYCOL INDUCED MOUSE MODEL OF RETINAL DEGENERATION, EXP. EYE RES, 127, PP. 143-152, (2014); LYZOGUBOV V.V., TYTARENKO R.G., LIU J., BORA N.S., BORA P.S., POLYETHYLENE GLYCOL (PEG)-INDUCED MOUSE MODEL OF CHOROIDAL NEOVASCULARIZATION, J. BIOL. CHEM, 286, 18, PP. 16229-16237, (2011); NAGUIB Y.M., ANTIOXIDANT ACTIVITIES OF ASTAXANTHIN AND RELATED CAROTENOIDS, J. AGRIC. FOOD CHEM, 48, 4, PP. 1150-1154, (2000); NOWAK J.Z., OXIDATIVE STRESS, POLYUNSATURATED FATTY ACIDS-DERIVED OXIDATION PRODUCTS AND BISRETINOIDS AS POTENTIAL INDUCERS OF CNS DISEASES: FOCUS ON AGE-RELATED MACULAR DEGENERATION, PHARMACOL. REP, 65, 2, PP. 288-304, (2013); PEDERSEN A.M., VANG B., OLSEN R.L., OIL FROM CALANUS FINMARCHICUS - COMPOSITION AND POSSIBLE USE: A REVIEW, J. AQUATIC FOOD PROD. TECHNOL, 23, PP. 633-646, (2014); PROKOPIOU E., KOLOVOS P., KALOGEROU M., NEOKLEOUS A., PAPAGREGORIOU G., DELTAS C., ET AL., THERAPEUTIC POTENTIAL OF OMEGA-3 FATTY ACIDS SUPPLEMENTATION IN A MOUSE MODEL OF DRY MACULAR DEGENERATION, BMJ OPEN OPHTHALMOL, 1, 1, (2017); RABIN D.M., RABIN R.L., BLENKINSOP T.A., TEMPLE S., STERN J.H., CHRONIC OXIDATIVE STRESS UPREGULATES DRUSEN-RELATED PROTEIN EXPRESSION IN ADULT HUMAN RPE STEM CELL-DERIVED RPE CELLS: A NOVEL CULTURE MODEL FOR DRY AMD, AGING (ALBANY NY), 5, 1, PP. 51-66, (2013); RASHID K., AKHTAR-SCHAEFER I., LANGMANN T., MICROGLIA IN RETINAL DEGENERATION, FRONT. IMMUNOL, 10, (2019); ROSSINO M.G., AMATO R., AMADIO M., ROSINI M., BASAGNI F., CAMMALLERI M., ET AL., A NATURE-INSPIRED NRF2 ACTIVATOR PROTECTS RETINAL EXPLANTS FROM OXIDATIVE STRESS AND NEURODEGENERATION, ANTIOXIDANTS, 10, 8, (2021); RUDOLF X.V., LYZOGUBOV V.V., BORA N.S., BORA P.S., UNDERSTANDING THE POLYETHYLENE GLYCOL-INDUCED MOUSE MODEL OF RETINAL DEGENERATION AND CHOROIDAL NEOVASCULARIZATION, J. CELL MOL. PHARMACOL, 1, (2018); SALMA W., FRANEKOVA V., LUND T., HOPER A., LUDVIGSEN S., LUND J., ET AL., DIETARY CALANUS OIL ANTAGONIZES ANGIOTENSIN II-INDUCED HYPERTENSION AND TISSUE WASTING IN DIET-INDUCED OBESE MICE, PROSTAGL. LEUKOT. ESSENT. FAT. ACIDS, 108, PP. 13-21, (2016); SARKAR A., JAYESH SODHA S., JUNNUTHULA V., KOLIMI P., DYAWANAPELLY S., NOVEL AND INVESTIGATIONAL THERAPIES FOR WET AND DRY AGE-RELATED MACULAR DEGENERATION, DRUG DISCOV. TODAY, 27, 8, PP. 2322-2332, (2022); SCHOTS P.C., PEDERSEN A.M., EILERTSEN K.E., OLSEN R.L., LARSEN T.S., POSSIBLE HEALTH EFFECTS OF A WAX ESTER RICH MARINE OIL, FRONT. PHARMACOL, 11, (2020); SCHWEIGHOFER B., TESTORI J., STURTZEL C., SATTLER S., MAYER H., WAGNER O., ET AL., THE VEGF-INDUCED TRANSCRIPTIONAL RESPONSE COMPRISES GENE CLUSTERS AT THE CROSSROAD OF ANGIOGENESIS AND INFLAMMATION, THROMB. HAEMOST, 102, 3, PP. 544-554, (2009); SEDDON J.M., COTE J., ROSNER B., PROGRESSION OF AGE-RELATED MACULAR DEGENERATION: ASSOCIATION WITH DIETARY FAT, TRANSUNSATURATED FAT, NUTS, AND FISH INTAKE, ARCH. OPHTHALMOL, 121, 12, PP. 1728-1737, (2003); SHAW P.X., STILES T., DOUGLAS C., HO D., FAN W., DU H., ET AL., OXIDATIVE STRESS, INNATE IMMUNITY, AND AGE-RELATED MACULAR DEGENERATION, AIMS MOL. SCI, 3, 2, PP. 196-221, (2016); SOUIED E.H., ASLAM T., GARCIA-LAYANA A., HOLZ F.G., LEYS A., SILVA R., ET AL., OMEGA-3 FATTY ACIDS AND AGE-RELATED MACULAR DEGENERATION, OPHTHALMIC RES, 55, 2, PP. 62-69, (2015); STEPAN M., DADOVA K., MATOUS M., KRAUZOVA E., SONTAKOVA L., KOC M., ET AL., EXERCISE TRAINING COMBINED WITH CALANUS OIL SUPPLEMENTATION IMPROVES THE CENTRAL CARDIODYNAMIC FUNCTION IN OLDER WOMEN, NUTRIENTS, 14, 1, (2021); SWANSON D., BLOCK R., MOUSA S.A., OMEGA-3 FATTY ACIDS EPA AND DHA: HEALTH BENEFITS THROUGHOUT LIFE, ADV. NUTR, 3, 1, PP. 1-7, (2012); TAN C.S., NGO W.K., CHAY I.W., TING D.S., SADDA S.R., NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD): A REVIEW OF EMERGING TREATMENT OPTIONS, CLIN. OPHTHALMOL, 16, PP. 917-933, (2022); TELEGINA D.V., KOZHEVNIKOVA O.S., KOLOSOVA N.G., CHANGES IN RETINAL GLIAL CELLS WITH AGE AND DURING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION, BIOCHEMISTRY, 83, 9, PP. 1009-1017, (2018); TURPAEV K.T., KEAP1-NRF2 SIGNALING PATHWAY: MECHANISMS OF REGULATION AND ROLE IN PROTECTION OF CELLS AGAINST TOXICITY CAUSED BY XENOBIOTICS AND ELECTROPHILES, BIOCHEMISTRY, 78, 2, PP. 111-126, (2013); VECINO E., RODRIGUEZ F.D., RUZAFA N., PEREIRO X., SHARMA S.C., GLIA-NEURON INTERACTIONS IN THE MAMMALIAN RETINA, PROG. RETIN. EYE RES, 51, PP. 1-40, (2016); WASSERFURTH P., NEBL J., BOSSLAU T.K., KRUGER K., HAHN A., SCHUCHARDT J.P., INTAKE OF CALANUS FINMARCHICUS OIL FOR 12 WEEKS IMPROVES OMEGA-3 INDEX IN HEALTHY OLDER SUBJECTS ENGAGING IN AN EXERCISE PROGRAMME, BR. J. NUTR, 125, 4, PP. 432-439, (2021)","R. AMATO; DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY; EMAIL: ROSARIO.AMATO@UNIPI.IT; M. CAMMALLERI; DEPARTMENT OF BIOLOGY, UNIVERSITY OF PISA, PISA, ITALY; EMAIL: MAURIZIO.CAMMALLERI@UNIPI.IT","FRONTIERS MEDIA S.A.","ENGLISH","FRONT. PHARMACOL.","ARTICLE","ISI","2-S2.0-85140752835","FRONT PHARMACOL","UNIVERSITY OF PISA;UNIVERSITY OF PISA;UNIVERSITY OF PISA;UNIVERSITY OF PISA;RESEARCH CENTER;UNIVERSITY OF PISA;UNIVERSITY OF PISA","NOTREPORTED;UNIVERSITY OF PISA;NOTREPORTED;NOTREPORTED;UNIVERSITY OF PISA;NOTREPORTED",NA,"MELECCHI A, 2022, FRONT PHARMACOL","MELECCHI A, 2022, FRONT PHARMACOL"
"URINA-JASSIR M;PACHECO-PAEZ T;PAEZ-CANRO C;URINA-TRIANA M","URINA-JASSIR, MANUEL (57189386500); PACHECO-PAEZ, TATIANA (57210840114); PAEZ-CANRO, CAROL (53985157500); URINA-TRIANA, MIGUEL (6506505835)","STATIN ASSOCIATED ADVERSE REACTIONS IN LATIN AMERICA A SCOPING REVIEW",2021,"BMJ OPEN","11","",6,"10.1136/bmjopen-2021-050675","CLINICAL RESEARCH DEPARTMENT, FUNDACIÓN DEL CARIBE PARA LA INVESTIGACIÓN BIOMÉDICA, BARRANQUILLA, ATLANTICO, COLOMBIA;EVIDENCE-BASED THERAPEUTICS GROUP, CLINICAL PHARMACOLOGY, UNIVERSIDAD DE LA SABANA, CHIA, COLOMBIA;SEXUALLY TRANSMITTED INFECTIONS GROUP, COCHRANE COLLABORATION, UNIVERSIDAD NACIONAL DE COLOMBIA, BOGOTA, COLOMBIA;CLINICAL RESEARCH DEPARTMENT, FUNDACIÓN DEL CARIBE PARA LA INVESTIGACIÓN BIOMÉDICA, BARRANQUILLA, ATLANTICO, COLOMBIA, FACULTAD DE CIENCIAS DE LA SALUD, UNIVERSIDAD SIMÓN BOLÍVAR, BARRANQUILLA, ATLÁNTICO, COLOMBIA","OBJECTIVES WE AIM TO DESCRIBE THE FREQUENCY AND TYPE OF ADVERSE DRUG REACTIONS (ADRS) IN PATIENTS ON STATINS IN PUBLISHED STUDIES FROM LATIN AMERICAN (LATAM) COUNTRIES. DESIGN SCOPING REVIEW. METHODS A LITERATURE SEARCH WAS CONDUCTED IN THREE DATABASES (PUBMED, EMBASE AND LILACS) IN ADDITION TO A MANUAL SEARCH IN RELEVANT JOURNALS FROM LATAM UNIVERSITIES OR MEDICAL SOCIETIES. A SNOWBALLING TECHNIQUE WAS USED TO IDENTIFY FURTHER REFERENCES. RANDOMISED CONTROLLED TRIALS (RCTS) AND OBSERVATIONAL STUDIES BETWEEN 2000 AND 2020 WERE INCLUDED. STUDIES WERE CONSIDERED ELIGIBLE IF THEY INCLUDED ADULTS ON STATIN THERAPY FROM LATAM AND REPORTED DATA ON ADRS. DATA ON ADRS WERE ABSTRACTED AND PRESENTED BY STUDY DESIGN. RESULTS OUT OF 8076 ARTICLES, A TOTAL OF 20 STUDIES WERE INCLUDED (7 RCTS AND 13 OBSERVATIONAL STUDIES). WE IDENTIFIED THREE HEAD-TO-HEAD STATIN RCTS, TWO STATIN-VERSUS-POLICOSANOL RCTS AND ONLY TWO PLACEBO-CONTROLLED TRIALS. THE STATIN-RELATED ADRS FREQUENCY RANGED FROM 0% TO 35.1% IN RCTS AND 0% TO 28.4% IN OBSERVATIONAL STUDIES. THE MOST COMMON ADRS WERE MUSCLE-RELATED EVENTS INCLUDING MYALGIA AND ELEVATED CREATINE PHOSPHOKINASE. OTHER REPORTED ADRS WERE GASTROINTESTINAL SYMPTOMS, HEADACHE AND ALTERED FASTING PLASMA GLUCOSE. CONCLUSIONS WE IDENTIFIED DIFFERENCES IN THE FREQUENCY OF ADRS IN BOTH OBSERVATIONAL STUDIES AND RCTS FROM LATAM COUNTRIES. THIS COULD BE DUE TO THE ABSENCE OF STANDARD DEFINITIONS AND REPORTING OF ADRS AS WELL AS DIFFERENCES AMONG THE STUDY'S INTERVENTIONS, POPULATION CHARACTERISTICS OR DESIGN. THE VARIABILITY OF ADRS AND THE ABSENCE OF DEFINITIONS ARE SIMILAR TO STUDIES FROM OTHER GEOGRAPHICAL LOCATIONS. FURTHER PLACEBO-CONTROLLED TRIALS AND REAL-WORLD DATA REGISTRIES WITH UNIVERSAL DEFINITIONS SHOULD FOLLOW.  © AUTHOR(S) (OR THEIR EMPLOYER(S)) 2021.","ADULT CARDIOLOGY; CARDIOLOGY; INTERNAL MEDICINE; LIPID DISORDERS","ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LATIN AMERICA; ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATORVASTATIN; ATORVASTATIN PLUS EZETIMIBE; CREATINE KINASE; EZETIMIBE; EZETIMIBE PLUS ROSUVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MYOGLOBIN; PLACEBO; POLICOSANOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ABDOMINAL DISCOMFORT; ADULT; ADVERSE DRUG REACTION; AGED; BACK; CARDIOVASCULAR DISEASE; COLIC; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EMBASE; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LOW BACK PAIN; MALE; MEDICAL SOCIETY; MEDLINE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE CRAMP; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; TRIACYLGLYCEROL LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS; ADVERSE DRUG REACTION","HAART; FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO, FAPESP; CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO, CNPQ","FUNDING TEXT 1: ADLS, ACTIVITIES OF DAILY LIVING; ADRS, ADVERSE DRUG REACTIONS; ALT, ALANINE AMINOTRANSFERASE; BMI, BODY MASS INDEX; CAD, CORONARY ARTERY DISEASE; CHD, CORONARY HEART DISEASE; CKD, CHRONIC KIDNEY DISEASE; CNPQ, BRAZILIAN NATIONAL COUNCIL FOR SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT; CPK, CREATININE PHOSPHOKINASE; CVD, CARDIOVASCULAR DISEASE; DM, DIABETES MELLITUS; DYS, DYSLIPIDAEMIA; FAPESP, THE SÃO PAULO RESEARCH FOUNDATION; HAART, HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HTN, HYPERTENSION; LDL-C, LOW-DENSITY LIPOPROTEIN CHOLESTEROL; LFTS, LIVER FUNCTION TESTS; ND, NOT DEFINED; T2DM, TYPE 2 DIABETES MELLITUS; ULN, UPPER LIMIT OF NORMAL.; FUNDING TEXT 2: NON-INDUSTRY FUNDED (CNPQ)","ARNETT D.K., BLUMENTHAL R.S., ALBERT M.A., ET AL., 2019 ACC/AHA GUIDELINE ON THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: EXECUTIVE SUMMARY: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/ AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, CIRCULATION; GRUNDY S.M., STONE N.J., BAILEY A.L., ET AL., 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, J AM COLL CARDIOL, 73, PP. E285-E350, (2019); MACH F., BAIGENT C., CATAPANO A.L., ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR HEART J, 41, PP. 111-188, (2020); BYRNE P., CULLINAN J., SMITH S.M., STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BMJ, 8, PP. L5674-L5675, (2019); REDBERG R.F., KATZ M.H., STATINS FOR PRIMARY PREVENTION: THE DEBATE IS INTENSE, BUT THE DATA ARE WEAK, JAMA, 316, PP. 1979-1981, (2016); YEBYO H.G., ASCHMANN H.E., KAUFMANN M., ET AL., COMPARATIVE EFFECTIVENESS AND SAFETY OF STATINS AS A CLASS AND OF SPECIFIC STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW, META-ANALYSIS, AND NETWORK META-ANALYSIS OF RANDOMIZED TRIALS WITH 94, 283 PARTICIPANTS, AM HEART J, 210, PP. 18-28, (2019); KOSKINAS K.C., SIONTIS G.C.M., PICCOLO R., ET AL., EFFECT OF STATINS AND NON-STATIN LDL-LOWERING MEDICATIONS ON CARDIOVASCULAR OUTCOMES IN SECONDARY PREVENTION: A META-ANALYSIS OF RANDOMIZED TRIALS, EUR HEART J, 39, PP. 1172-1180, (2018); GUGLIELMI V., BELLIA A., PECCHIOLI S., ET AL., EFFECTIVENESS OF ADHERENCE TO LIPID LOWERING THERAPY ON LDL-CHOLESTEROL IN PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK: A REAL-WORLD EVIDENCE STUDY IN PRIMARY CARE, ATHEROSCLEROSIS, 263, PP. 36-41, (2017); HOPE H.F., BINKLEY G.M., FENTON S., ET AL., SYSTEMATIC REVIEW OF THE PREDICTORS OF STATIN ADHERENCE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, PLOS ONE, 14, PP. 1-38, (2019); KIM M.C., CHO J.Y., JEONG H.C., ET AL., IMPACT OF POSTDISCHARGE STATIN WITHDRAWAL ON LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, AM J CARDIOL, 115, PP. 1-7, (2015); INGERSGAARD M.V., HELMS ANDERSEN T., NORGAARD O., ET AL., REASONS FOR NONADHERENCE TO STATINS-A SYSTEMATIC REVIEW OF REVIEWS, PATIENT PREFER ADHERENCE, 14, PP. 675-691, (2020); THOMPSON P.D., PANZA G., ZALESKI A., ET AL., STATIN-ASSOCIATED SIDE EFFECTS, J AM COLL CARDIOL, 67, PP. 2395-2410, (2016); NAVAR A.M., PETERSON E.D., LI S., ET AL., PREVALENCE AND MANAGEMENT OF SYMPTOMS ASSOCIATED WITH STATIN THERAPY IN COMMUNITY PRACTICE: INSIGHTS FROM THE PALM (PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT) REGISTRY, CIRC CARDIOVASC QUAL OUTCOMES, 11, PP. 1-5, (2018); GANGA H.V., SLIM H.B., THOMPSON P.D., A SYSTEMATIC REVIEW OF STATIN-INDUCED MUSCLE PROBLEMS IN CLINICAL TRIALS, AM HEART J, 168, PP. 6-15, (2014); RIVERA-ANDRADE A., LUNA M.A., TRENDS AND HETEROGENEITY OF CARDIOVASCULAR DISEASE AND RISK FACTORS ACROSS LATIN AMERICAN AND CARIBBEAN COUNTRIES, PROG CARDIOVASC DIS, 57, PP. 276-285, (2014); PAGAN E., CHATENOUD L., RODRIGUEZ T., ET AL., COMPARISON OF TRENDS IN MORTALITY FROM CORONARY HEART AND CEREBROVASCULAR DISEASES IN NORTH AND SOUTH AMERICA: 1980 TO 2013, AM J CARDIOL, 119, PP. 862-871, (2017); VINUEZA R., BOISSONNET C.P., ACEVEDO M., ET AL., DYSLIPIDEMIA IN SEVEN LATIN AMERICAN CITIES: CARMELA STUDY, PREV MED, 50, PP. 106-111, (2010); ARKSEY H., O'MALLEY L., SCOPING STUDIES: TOWARDS A METHODOLOGICAL FRAMEWORK, INT J SOC RES METHODOL, 8, PP. 19-32, (2005); LEVAC D., COLQUHOUN H., O'BRIEN K.K., SCOPING STUDIES: ADVANCING THE METHODOLOGY, IMPLEMENTATION SCI, 5, PP. 1-9, (2010); TRICCO A.C., LILLIE E., ZARIN W., ET AL., PRISMA EXTENSION FOR SCOPING REVIEWS (PRISMA-SCR): CHECKLIST AND EXPLANATION, ANN INTERN MED, 169, PP. 467-473, (2018); ARONSON J.K., FERNER R.E., CLARIFICATION OF TERMINOLOGY IN DRUG SAFETY, DRUG SAF, 28, PP. 851-870, (2005); MILLER S.A., FORREST J.L., ENHANCING YOUR PRACTICE THROUGH EVIDENCE-BASED DECISION MAKING: PICO, LEARNING HOW TO ASK GOOD QUESTIONS, JOURNAL OF EVIDENCE BASED DENTAL PRACTICE, 1, PP. 136-141, (2001); OUZZANI M., HAMMADY H., FEDOROWICZ Z., ET AL., RAYYAN-A WEB AND MOBILE APP FOR SYSTEMATIC REVIEWS, SYST REV, 5, PP. 1-11, (2016); MOHER D., LIBERATI A., TETZLAFF J., ET AL., PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES: THE PRISMA STATEMENT, PLOS MED, 6, (2009); VATTIMO A.C.A., FONSECA F.A.H., MORAIS D.C., ET AL., EFFICACY AND TOLERABILITY OF A FIXED-DOSE COMBINATION OF ROSUVASTATIN AND EZETIMIBE COMPARED WITH A FIXED-DOSE COMBINATION OF SIMVASTATIN AND EZETIMIBE IN BRAZILIAN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA: A MULTICENTER, RANDOMIZED TRIAL, CURR THER RES CLIN EXP, 93, (2020); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-146, (2000); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVESTIG, 21, PP. 103-113, (2001); TALAVERA J.-O., MARTINEZ G., CERVANTES J.-L., ET AL., A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF STATIN THERAPY ON TRIGLYCERIDE LEVELS IN MEXICAN HYPERTRIGLYCERIDEMIC PATIENTS, CURR MED RES OPIN, 29, PP. 379-386, (2013); RODRIGUEZ-ROA E., TELLEZ R., RODRIGUEZ F., ET AL., EVALUACIÓN COMPARATIVA DE LA EFECTIVIDAD CLÍNICA DE DOS FORMULACIONES DE ATORVASTATINA EN PACIENTES CON O SIN ENFERMEDAD CARDIOVASCULAR, REV LATINOAM HIPERTENS, 3, PP. 129-135, (2008); FONSECA F.A.H., RUIZ A., CARDONA-MUNOZ E.G., ET AL., THE DISCOVERY PENTA STUDY: A DIRECT STATIN COMPARISON OF LDL-C VALUE-AN EVALUATION OF ROSUVASTATIN THERAPY COMPARED WITH ATORVASTATIN, CURR MED RES OPIN, 21, PP. 1307-1315, (2005); ALBERT M.A., GLYNN R.J., FONSECA F.A.H., ET AL., RACE, ETHNICITY, AND THE EFFICACY OF ROSUVASTATIN IN PRIMARY PREVENTION: THE JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION: AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER) TRIAL, AM HEART J, 162, PP. 106-114, (2011); RIDKER P.M., DANIELSON E., FONSECA F.A.H., ET AL., ROSUVASTATIN TO PREVENT VASCULAR EVENTS IN MEN AND WOMEN WITH ELEVATED C-REACTIVE PROTEIN, N ENGL J MED, 359, PP. 2195-2207, (2008); CUNEO C., KOTLIAR C., MEDRANO J.C., ET AL., LOGRO DE LOS OBJETIVOS DE COLESTEROL DE LIPOPROTEÍNAS DE BAJA DENSIDAD EN 18 PAÍSES FUERA DE EUROPA OCCIDENTAL: ESTUDIO INTERNACIONAL DE PRÁCTICAS DE MANEJO DEL COLESTEROL (ICLPS) SUB ANÁLISIS ARGENTINO, REV FED ARG CARDIOL, 48, PP. 86-91, (2019); SPALVIERI M.P., OYOLA M.E., ESTATINAS: INCIDENCIA DE EFECTOS ADVERSOS / STATINS: INCIDENCE OF ADVERSE EFFECTS / ESTATINAS: INCIDÊNCIA DE EFEITOS ADVERSOS, ACTA BIOQUÍM CLÍN LATINOAM, 45, PP. 727-765, (2011); GABRIEL BOTTARO E., OSCAR C., GUSTAVO SCAPELLATO P., ET AL., ROSUVASTATINA PARA TRATAMIENTO DE LA DISLIPIDEMIA EN PACIENTES INFECTADOS CON VIH EN TRATAMIENTO ANTIRRETROVIRAL DE GRAN ACTIVIDAD, EXPERIENCIA PRELIMINAR. ENFERM INFECC MICROBIOL CLIN, 26, PP. 325-329, (2008); DO NASCIMENTO R.C.R.M., GUERRA A.A., ALVARES J., ET AL., STATIN USE IN BRAZIL: FINDINGS AND IMPLICATIONS, CURR MED RES OPIN, 34, PP. 1809-1817, (2018); SMIDERLE L., LIMA L.O., HUTZ M.H., ET AL., EVALUATION OF SEXUAL DIMORPHISM IN THE EFFICACY AND SAFETY OF SIMVASTATIN/ATORVASTATIN THERAPY IN A SOUTHERN BRAZILIAN COHORT, ARQ BRAS CARDIOL, 103, PP. 33-40, (2014); FERREIRA CASTRO P., RIBEIRO E., LIMA DOREA E., ET AL., FACTORS ASSOCIATED WITH STATIN-RELATED ADVERSE MUSCULAR EVENTS IN ADULT DYSLIPIDEMIC OUTPATIENTS, BRAS J PHARM SCI, 53, (2017); SANTOS P.C.J.L., MORGAN A.C., JANNES C.E., ET AL., PRESENCE AND TYPE OF LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) MUTATION INFLUENCES THE LIPID PROFILE AND RESPONSE TO LIPID-LOWERING THERAPY IN BRAZILIAN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 233, PP. 206-210, (2014); ZULUAGA-QUINTERO N., ARCILA-HINCAPIE L., BEDOYA-LOPEZ D.F., ET AL., COMPORTAMIENTO DEL PERFIL LÍPIDICO EN PACIENTE CON DISLIPIDEMIA TRATADOS CON ESTATINAS EN UNA IPS, CES SALUD PÚBLICA, 6, PP. 63-69, (2015); RUIZ ALVARO J., VARGAS-URICOECHEA H., URINA-TRIANA M., ET AL., LAS DISLIPIDEMIAS Y SU TRATAMIENTO EN CENTROS DE ALTA COMPLEJIDAD EN COLOMBIA, CLIN E INVESTIG EN ARTERIOSCLER, 32, PP. 101-110, (2020); DIAZTAGLE J.J., CASTRO C.A., BUITRAGO D.C., EXPERIENCIA EN LA UTILIZACIÓN DE HIPOLIPEMIANTES EN UNA COHORTE DE PACIENTES EN 12 CIUDADES COLOMBIANAS, REV MEDICAS UIS, 32, PP. 13-20, (2019); TORO ESCOBAR J.M., TORO C.M.A., MAYA G.C., PREVALENCIA DE ALTERACIONES DE LA CREATINA-FOSFOQUINASA (CPK) SÉRICA EN PACIENTES QUE TOMAN ESTATINAS, MED LAB, 16, PP. 141-152, (2010); BELLO-CHAVOLLA O.Y., AGUILAR-SALINAS C.A., FACTORS INFLUENCING ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS IN MEXICO: THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY, REV INVEST CLIN, 71, PP. 408-416, (2019); CARRILLO-ALARCON L.C., CHAVEZ-GALLEGOS D., OCAMPO-TORRES M., ET AL., CHARACTERIZATION OF POLYPHARMACY IN THE ELDERLY IN THREE UNITS OF HEALTH SERVICES IN PACHUCA, HIDALGO, INT RES J PHARM, 6, PP. 25-30, (2015); FINEGOLD J.A., MANISTY C.H., GOLDACRE B., ET AL., WHAT PROPORTION OF SYMPTOMATIC SIDE EFFECTS IN PATIENTS TAKING STATINS ARE GENUINELY CAUSED BY THE DRUG? SYSTEMATIC REVIEW OF RANDOMIZED PLACEBO-CONTROLLED TRIALS TO AID INDIVIDUAL PATIENT CHOICE, EUR J PREV CARDIOL, 21, PP. 464-474, (2014); PENSON P.E., MANCINI G.B.J., TOTH P.P., ET AL., INTRODUCING THE 'DRUCEBO' EFFECT IN STATIN THERAPY: A SYSTEMATIC REVIEW OF STUDIES COMPARING REPORTED RATES OF STATIN-ASSOCIATED MUSCLE SYMPTOMS, UNDER BLINDED AND OPEN-LABEL CONDITIONS, J CACHEXIA SARCOPENIA MUSCLE, 9, PP. 1023-1033, (2018); GOLOMB B.A., MISINTERPRETATION OF TRIAL EVIDENCE ON STATIN ADVERSE EFFECTS MAY HARM PATIENTS, EUR J PREV CARDIOL, 22, PP. 492-493, (2015); HOVINGH G.K., GANDRA S.R., MCKENDRICK J., ET AL., IDENTIFICATION AND MANAGEMENT OF PATIENTS WITH STATIN-ASSOCIATED SYMPTOMS IN CLINICAL PRACTICE: A CLINICIAN SURVEY, ATHEROSCLEROSIS, 245, PP. 111-117, (2016); ROSENSON R.S., GANDRA S.R., MCKENDRICK J., ET AL., IDENTIFICATION AND MANAGEMENT OF STATIN-ASSOCIATED SYMPTOMS IN CLINICAL PRACTICE: EXTENSION OF A CLINICIAN SURVEY TO 12 FURTHER COUNTRIES, CARDIOVASC DRUGS THER, 31, PP. 187-195, (2017); GOLOMB B.A., EVANS M.A., STATIN ADVERSE EFFECTS : A REVIEW OF THE LITERATURE AND EVIDENCE FOR A MITOCHONDRIAL MECHANISM, AM J CARDIOVASC DRUGS, 8, PP. 373-418, (2008); BHARDWAJ S., SELVARAJAH S., SCHNEIDER E.B., MUSCULAR EFFECTS OF STATINS IN THE ELDERLY FEMALE: A REVIEW, CLIN INTERV AGING, 8, PP. 47-59, (2013); CHAM S., EVANS M.A., DENENBERG J.O., ET AL., STATIN-ASSOCIATED MUSCLE-RELATED ADVERSE EFFECTS: A CASE SERIES OF 354 PATIENTS, PHARMACOTHERAPY, 30, PP. 541-553, (2010); HOLBROOK A., WRIGHT M., SUNG M., ET AL., STATIN-ASSOCIATED RHABDOMYOLYSIS: IS THERE A DOSE-RESPONSE RELATIONSHIP?, CAN J CARDIOL, 27, PP. 146-151, (2011); ROSENSON R.S., TRIAL DESIGNS FOR STATIN MUSCLE INTOLERANCE, CURR OPIN LIPIDOL, 28, PP. 488-494, (2017); FALK DELGADO A., FALK DELGADO A., THE ASSOCIATION OF FUNDING SOURCE ON EFFECT SIZE IN RANDOMIZED CONTROLLED TRIALS: 2013-2015-A CROSS-SECTIONAL SURVEY AND META-ANALYSIS, TRIALS, 18, (2017); LEWIS S.C., WARLOW C.P., HOW TO SPOT BIAS AND OTHER POTENTIAL PROBLEMS IN RANDOMISED CONTROLLED TRIALS, J NEUROL NEUROSURG PSYCHIATRY, 75, PP. 181-187, (2004); HEMKENS L.G., HOW ROUTINELY COLLECTED DATA FOR RANDOMIZED TRIALS PROVIDE LONG-TERM RANDOMIZED REAL-WORLD EVIDENCE, JAMA NETW OPEN, 1, (2018); HENEGHAN C., GOLDACRE B., MAHTANI K.R., WHY CLINICAL TRIAL OUTCOMES FAIL TO TRANSLATE INTO BENEFITS FOR PATIENTS, TRIALS, 18, (2017)","M. URINA-TRIANA; CLINICAL RESEARCH DEPARTMENT, FUNDACIÓN DEL CARIBE PARA LA INVESTIGACIÓN BIOMÉDICA, BARRANQUILLA, ATLANTICO, COLOMBIA; EMAIL: MURINA1@UNISIMONBOLIVAR.EDU.CO","BMJ PUBLISHING GROUP","ENGLISH","BMJ OPEN","REVIEW","ISI","2-S2.0-85116513048","BMJ OPEN","CLINICAL RESEARCH DEPARTMENT;UNIVERSIDAD DE LA SABANA;UNIVERSIDAD NACIONAL DE COLOMBIA;UNIVERSIDAD SIMÓN BOLÍVAR","NOTREPORTED;CLINICAL RESEARCH DEPARTMENT;NOTREPORTED",NA,"URINA-JASSIR M, 2021, BMJ OPEN","URINA-JASSIR M, 2021, BMJ OPEN"
"MOTA M;WAKTOLA H;NOLVACHAI Y;MARRIOTT P","MOTA, MARIA FERNANDA S. (57203369338); WAKTOLA, HABTEWOLD D. (56734514100); NOLVACHAI, YADA (55524341000); MARRIOTT, PHILIP J. (57204817577)","GAS CHROMATOGRAPHY MASS SPECTROMETRY FOR CHARACTERISATION ASSESSMENT OF QUALITY AND AUTHENTICATION OF SEED AND VEGETABLE OILS",2021,"TRAC - TRENDS IN ANALYTICAL CHEMISTRY","138","",48,"10.1016/j.trac.2021.116238","AV. ATHOS DA SILVEIRA RAMOS 149, CT BL E, RIO DE JANEIRO, 21941-909, BRAZIL;AUSTRALIAN CENTRE FOR RESEARCH ON SEPARATION SCIENCE, SCHOOL OF CHEMISTRY, MONASH UNIVERSITY, WELLINGTON ROAD, CLAYTON, 3800, VIC, AUSTRALIA;AUSTRALIAN CENTRE FOR RESEARCH ON SEPARATION SCIENCE, SCHOOL OF CHEMISTRY, MONASH UNIVERSITY, WELLINGTON ROAD, CLAYTON, 3800, VIC, AUSTRALIA;AUSTRALIAN CENTRE FOR RESEARCH ON SEPARATION SCIENCE, SCHOOL OF CHEMISTRY, MONASH UNIVERSITY, WELLINGTON ROAD, CLAYTON, 3800, VIC, AUSTRALIA","SEED AND VEGETABLE OILS ARE COMPLEX MIXTURES OF COMPONENTS, WITH THE MAJOR CLASSES INCLUDING MONO-, DI- AND TRIACYLGLYCEROLS, FATTY ACIDS, PHYTOSTEROLS, TOCOPHEROLS AND TOCOTRIENOLS. AN OVERVIEW OF RECENT ADVANCES IN THE ANALYSIS OF SEED AND VEGETABLE OILS BY BOTH ONE-DIMENSIONAL (1D) AND MULTIDIMENSIONAL GAS CHROMATOGRAPHY (MDGC) METHODOLOGIES IS PRESENTED. AUTHENTICITY OF FOOD OILS CONTINUES TO BE IMPORTANT, AND USE OF VARIOUS CLASSES OF COMPOUNDS AS MARKERS FOR ADULTERATION ARE HIGHLIGHTED. SELECTED APPLICATIONS OF CONTAMINANTS ANALYSIS, INCLUDING PESTICIDES, HYDROCARBONS AND PLASTICISERS, ARE EMPHASISED. A BRIEF COMPARISON OF THE SEPARATION TECHNOLOGIES GAS CHROMATOGRAPHY (GC) AND LIQUID CHROMATOGRAPHY (LC) IS ALSO INCLUDED. THE REVIEW CONCLUDES BY HIGHLIGHTING RECENT ADVANCES AND FUTURE TRENDS. © 2021 ELSEVIER B.V.","COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY; FOOD; GC×GC; GC–MS; MASS SPECTROMETRY","AUTHENTICATION; FATTY ACIDS; FOOD PRODUCTS; GAS OILS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; SOLVENTS; VEGETABLE OILS; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; EDIBLE OIL; HYDROCARBON; PESTICIDE; PHYTOSTEROL; PLASTICIZER; POLICOSANOL; STEROL; TOCOPHEROL; TRIACYLGLYCEROL; VEGETABLE OIL; VOLATILE ORGANIC COMPOUND; COMPLEX MIXTURE; COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY; DIACYLGLYCEROL; GAS CHROMATOGRAPHY/MASS SPECTROMETRY; GAS CHROMATOGRAPHY×GAS CHROMATOGRAPHY; GAS CHROMATOGRAPHY–MS; MULTIDIMENSIONAL GAS CHROMATOGRAPHY; ONE-DIMENSIONAL; TOCOTRIENOLS; TRIACYLGLYCEROLS; CONCENTRATION (PARAMETER); FOOD ANALYSIS; FOOD COMPOSITION; MASS FRAGMENTOGRAPHY; NONHUMAN; PLANT GROWTH; PLANT SEED; QUALITY CONTROL; REVIEW; SOIL POLLUTION; GAS CHROMATOGRAPHY","APERFEI?OAMENTO DE PESSOAL DE N?VEL SUPERIOR; AUSTRALIAN RESEARCH COUNCIL, ARC, (LP150100465); COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR, CAPES","FUNDING TEXT 1: WE ACKNOWLEDGE FUNDING FROM THE ARC LINKAGE PROGRAM GRANT LP150100465 . MFSM ACKNOWLEDGES COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - BRASIL (CAPES) - FINANCE CODE 001 FUNDING.; FUNDING TEXT 2: WE ACKNOWLEDGE FUNDING FROM THE ARC LINKAGE PROGRAM GRANT LP150100465. MFSM ACKNOWLEDGES COORDENA??O DE APERFEI?OAMENTO DE PESSOAL DE N?VEL SUPERIOR - BRASIL (CAPES) - FINANCE CODE 001 FUNDING.","O'BRIEN R.D., FATS AND OILS: FORMULATING AND PROCESSING FOR APPLICATIONS, (2004); GUNSTONE F.D., VEGETABLE OILS IN FOOD TECHNOLOGY: COMPOSITION, PROPERTIES AND USES, (2002); ORSAVOVA J., MISURCOVA L., AMBROZOVA J.V., VICHA R., MLCEK J., FATTY ACIDS COMPOSITION OF VEGETABLE OILS AND ITS CONTRIBUTION TO DIETARY ENERGY INTAKE AND DEPENDENCE OF CARDIOVASCULAR MORTALITY ON DIETARY INTAKE OF FATTY ACIDS, INT. J. MOL. SCI., 16, PP. 12871-12890, (2015); KARUNA M.S.L., PRASAD R.B.N., VEGETABLE OIL-BASED NUTRACEUTICALS, PLANT BIOLOGY AND BIOTECHNOLOGY, VOL. I, PP. 793-812, (2015); KAMATOU G.P.P., VILJOEN A.M., COMPARISON OF FATTY ACID METHYL ESTERS OF PALM AND PALMIST OILS DETERMINED BY GCXGC–TOF–MS AND GC–MS/FID, S. AFR. J. BOT., LE, 112, PP. 483-488, (2017); BELITZ H.D., GROSCH W., FOOD CHEMISTRY, (1999); ALBERDI-CEDENO J., IBARGOITIA M.L., GUILLEN M.D., MONITORING OF MINOR COMPOUNDS IN CORN OIL OXIDATION BY DIRECT IMMERSION-SOLID PHASE MICROEXTRACTION-GAS CHROMATOGRAPHY/MASS SPECTROMETRY. NEW OIL OXIDATION MARKERS, FOOD CHEM., 290, PP. 286-294, (2019); ALBERDI-CEDENO J., IBARGOITIA M.L., CRISTILLO G., SOPELANA P., GUILLEN M.D., A NEW METHODOLOGY CAPABLE OF CHARACTERIZING MOST VOLATILE AND LESS VOLATILE MINOR EDIBLE OILS COMPONENTS IN A SINGLE CHROMATOGRAPHIC RUN WITHOUT SOLVENTS OR REAGENTS. DETECTION OF NEW COMPONENTS, FOOD CHEM., 221, PP. 1135-1144, (2017); MONDELLO L., LEWIS A.C., BARTLE K.D., MULTIDIMENSIONAL CHROMATOGRAPHY, JOHN WILEY & SONS, ENGLAND, (2001); TRANCHIDA P.Q., SALIVO S., FRANCHINA F.A., BONACCORSI I., DUGO P., MONDELLO L., QUALITATIVE AND QUANTITATIVE ANALYSIS OF THE UNSAPONIFIABLE FRACTION OF VEGETABLE OILS BY USING COMPREHENSIVE 2D GC WITH DUAL MS/FID DETECTION, ANAL. BIOANAL. CHEM., 405, PP. 4655-4663, (2013); WAKTOLA H.D., KULSING C., NOLVACHAI Y., MARRIOTT P.J., HIGH TEMPERATURE MULTIDIMENSIONAL GAS CHROMATOGRAPHIC APPROACH FOR IMPROVED SEPARATION OF TRIACYLGLYCEROLS IN OLIVE OIL, J. CHROMATOGR. A, 1549, PP. 77-84, (2018); NOLVACHAI Y., KULSING C., MARRIOTT P.J., MULTIDIMENSIONAL GAS CHROMATOGRAPHY IN FOOD ANALYSIS, TRAC, TRENDS ANAL. CHEM., 96, PP. 124-137, (2017); AMARAL M.S.S., NOLVACHAI Y., MARRIOTT P.J., COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY ADVANCES IN TECHNOLOGY AND APPLICATIONS: BIENNIAL UPDATE, ANAL. CHEM., 92, PP. 85-104, (2020); SUTTIARPORN P., CHUMPOLSRI W., MAHATHEERANONT S., LUANGKAMIN S., TEEPSAWANG S., LEARDKAMOLKARN V., STRUCTURES OF PHYTOSTEROLS AND TRITERPENOIDS WITH POTENTIAL ANTI-CANCER ACTIVITY IN BRAN OF BLACK NON-GLUTINOUS RICE, NUTRIENTS, 7, PP. 1672-1687, (2015); DUVAL J., COLAS C., PECHER V., POUJOL M., TRANCHANT J.-F., É. LESELLIER, CONTRIBUTION OF SUPERCRITICAL FLUID CHROMATOGRAPHY COUPLED TO HIGH RESOLUTION MASS SPECTROMETRY AND UV DETECTIONS FOR THE ANALYSIS OF A COMPLEX VEGETABLE OIL – APPLICATION FOR CHARACTERIZATION OF A KNIPHOFIA UVARIA EXTRACT, C. R. CHIM., 19, PP. 1113-1123, (2016); WANG X., ZENG Q., DEL MAR CONTRERAS M., WANG L., PROFILING AND QUANTIFICATION OF PHENOLIC COMPOUNDS IN CAMELLIA SEED OILS: NATURAL TEA POLYPHENOLS IN VEGETABLE OIL, FOOD RES. INT., 102, PP. 184-194, (2017); POJJANAPORNPUN S., NOLVACHAI Y., ARYUSUK K., KULSING C., KRISNANGKURA K., MARRIOTT P.J., IONIC LIQUID PHASES WITH COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY OF FATTY ACID METHYL ESTERS, ANAL. BIOANAL. CHEM., 410, PP. 4669-4677, (2018); ZAVAHIR J.S., NOLVACHAI Y., MARRIOTT P.J., MOLECULAR SPECTROSCOPY – INFORMATION RICH DETECTION FOR GAS CHROMATOGRAPHY, TRAC, TRENDS ANAL. CHEM., 99, PP. 47-65, (2018); KALOGEROPOULOS N., KALIORA A.C., ARTEMIOU A., GIOGIOS I., COMPOSITION, VOLATILE PROFILES AND FUNCTIONAL PROPERTIES OF VIRGIN OLIVE OILS PRODUCED BY TWO-PHASE VS THREE-PHASE CENTRIFUGAL DECANTERS, LWT FOOD SCI. TECHNOL., 58, PP. 272-279, (2014); ZHANG R., SHEN W., WEI X., ZHANG F., SHEN C., WU B., ZHAO Z., LIU H., DENG X., SIMULTANEOUS DETERMINATION OF TOCOPHEROLS AND TOCOTRIENOLS IN VEGETABLE OILS BY GC-MS, ANAL. METHODS, 8, PP. 7341-7346, (2016); WAKTOLA H.D., KULSING C., NOLVACHAI Y., REZENDE C.M., BIZZO H.R., MARRIOTT P.J., GAS CHROMATOGRAPHY-MASS SPECTROMETRY OF SAPUCAINHA OIL (CARPOTROCHE BRASILIENSIS) TRIACYLGLYCEROLS COMPRISING STRAIGHT CHAIN AND CYCLIC FATTY ACIDS, ANAL. BIOANAL. CHEM., 411, PP. 1479-1489, (2019); SGHAIER L., VIAL J., SASSIAT P., THIEBAUT D., WATIEZ M., BRETON S., RUTLEDGE D.N., CORDELLA C.B.Y., AN OVERVIEW OF RECENT DEVELOPMENTS IN VOLATILE COMPOUNDS ANALYSIS FROM EDIBLE OILS: TECHNIQUE-ORIENTED PERSPECTIVES, EUR. J. LIPID SCI. TECHNOL., 118, PP. 1853-1879, (2016); OLMO-GARCIA L., KESSLER N., NEUWEGER H., WENDT K., OLMO-PEINADO J.M., FERNANDEZ-GUTI RREZ A., BAESSMANN C., CARRASCO-PANCORBO A., UNRAVELLING THE DISTRIBUTION OF SECONDARY METABOLITES IN OLEA EUROPAEA L.: EXHAUSTIVE CHARACTERIZATION OF EIGHT OLIVE-TREE DERIVED MATRICES BY COMPLEMENTARY PLATFORMS (LC-ESI/APCI-MS AND GC-APCI-MS), MOLECULES, 23, (2018); OLMO-GARCIA L., POLARI J.J., LI X., BAJOUB A., FERNANDEZ-GUTIERREZ A., WANG S.C., CARRASCO-PANCORBO A., DEEP INSIGHT INTO THE MINOR FRACTION OF VIRGIN OLIVE OIL BY USING LC-MS AND GC-MS MULTI-CLASS METHODOLOGIES, FOOD CHEM., 261, PP. 184-193, (2018); HIMAWAN C., STAROV V.M., STAPLEY A.G., THERMODYNAMIC AND KINETIC ASPECTS OF FAT CRYSTALLIZATION, ADV. COLLOID INTERFACE SCI., 122, PP. 3-33, (2006); DORNI C., SHARMA P., SAIKIA G., LONGVAH T., FATTY ACID PROFILE OF EDIBLE OILS AND FATS CONSUMED IN INDIA, FOOD CHEM., 238, PP. 9-15, (2018); KONUSKAN D.B., ARSLAN M., OKSUZ A., PHYSICOCHEMICAL PROPERTIES OF COLD PRESSED SUNFLOWER, PEANUT, RAPESEED, MUSTARD AND OLIVE OILS GROWN IN THE EASTERN MEDITERRANEAN REGION, SAUDI J. BIOL. SCI., 26, PP. 340-344, (2019); EDER K., GAS CHROMATOGRAPHIC ANALYSIS OF FATTY ACID METHYL ESTERS, J. CHROMATOGR. B BIOMED. SCI. APPL., 671, PP. 113-131, (1995); WAKTOLA H.D., ZENG A.X., CHIN S.-T., MARRIOTT P.J., ADVANCED GAS CHROMATOGRAPHY AND MASS SPECTROMETRY TECHNOLOGIES FOR FATTY ACIDS AND TRIACYLGLYCEROLS ANALYSIS, TRAC, TRENDS ANAL. CHEM., 129, (2020); INAGAKI S., NUMATA M., FAST GC ANALYSIS OF FATTY ACID METHYL ESTERS USING A HIGHLY POLAR IONIC LIQUID COLUMN AND ITS APPLICATION FOR THE DETERMINATION OF TRANS FATTY ACID CONTENTS IN EDIBLE OILS, CHROMATOGRAPHIA, 78, PP. 291-295, (2015); SANTOS M.F.G., MARMESAT S., BRITO E.S., ALVES R.E., DOBARGANES M.C., MAJOR COMPONENTS IN OILS OBTAINED FROM AMAZONIAN PALM FRUITS, GRASAS ACEITES, 64, PP. 328-334, (2013); HARYNUK J., WYNNE P.M., MARRIOTT P.J., EVALUATION OF NEW STATIONARY PHASES FOR THE SEPARATION OF FATTY ACID METHYL ESTERS, CHROMATOGRAPHIA, 63, PP. S61-S66, (2006); ZENG A.X., CHIN S.T., NOLVACHAI Y., KULSING C., SIDISKY L.M., MARRIOTT P.J., CHARACTERISATION OF CAPILLARY IONIC LIQUID COLUMNS FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY ANALYSIS OF FATTY ACID METHYL ESTERS, ANAL. CHIM. ACTA, 803, PP. 166-173, (2013); NOSHEEN A., MITREVSKI B., BANO A., MARRIOTT P.J., FAST COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY METHOD FOR FATTY ACID METHYL ESTER SEPARATION AND QUANTIFICATION USING DUAL IONIC LIQUID COLUMNS, J. CHROMATOGR. A, 1312, PP. 118-123, (2013); VYVIURSKA O., JANOSKOVA N., JAKUBIK T., SPANIK I., COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY ANALYSIS OF DIFFERENT TYPES OF VEGETABLE OILS, J. AM. OIL CHEM. SOC., 92, PP. 783-790, (2015); ZHU G., LIU F., LI P., HE S., ZHU S., GAO Q., FENG Y., PROFILING FREE FATTY ACIDS IN EDIBLE OILS VIA MAGNETIC DISPERSIVE EXTRACTION AND COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY, FOOD CHEM., 297, (2019); ZHU G.T., LIU F., HE S., HE X.M., ZHU S.K., FENG Y.Q., MAGNETIC EXTRACTANT WITH AN FE3O4@SIO2 CORE AND AQUEOUS AMMONIA COATING FOR MICROEXTRACTION OF PETROLEUM ACIDS, RSC ADV., 8, PP. 19486-19493, (2018); SATO K., UENO S., CRYSTALLIZATION, TRANSFORMATION AND MICROSTRUCTURES OF POLYMORPHIC FATS IN COLLOIDAL DISPERSION STATES, CURR. OPIN. COLLOID INTERFACE SCI., 16, PP. 384-390, (2011); RUIZ-SAMBLAS C., CUADROS-RODRIGUEZ L., GONZALEZ-CASADO A., RODRIGUEZ-GARCIA F.P., A STRAIGHTFORWARD QUANTIFICATION OF TRIACYLGLYCEROLS (AND FATTY ACIDS) IN MONOVARIETAL EXTRA VIRGIN OLIVE OILS BY HIGH-TEMPERATURE GC, ANAL. METHODS, 4, PP. 753-758, (2012); IDRUS S.I.S., LATIFF A.A., ISMAIL M.N., DETERMINATION OF TRIACYLGLYCEROLS IN FOOD BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, INSTRUM. SCI. TECHNOL., 45, PP. 577-591, (2017); RUIZ-SAMBLAS C., GONZALEZ-CASADO A., CUADROS-RODRIGUEZ L., TRIACYLGLYCEROLS DETERMINATION BY HIGH-TEMPERATURE GAS CHROMATOGRAPHY IN THE ANALYSIS OF VEGETABLE OILS AND FOODS: A REVIEW OF THE PAST 10 YEARS, CRIT. REV. FOOD SCI. NUTR., 55, PP. 1618-1631, (2015); RUIZ-LOPEZ N., MARTINEZ-FORCE E., GARCES R., SEQUENTIAL ONE-STEP EXTRACTION AND ANALYSIS OF TRIACYLGLYCEROLS AND FATTY ACIDS IN PLANT TISSUES, ANAL. BIOCHEM., 317, PP. 247-254, (2003); ANDRIKOPOULOS N.K., TRIGLYCERIDE SPECIES COMPOSITIONS OF COMMON EDIBLE VEGETABLE OILS AND METHODS USED FOR THEIR IDENTIFICATION AND QUANTIFICATION, FOOD REV. INT., 18, PP. 71-102, (2002); NOVAES F.J.M., KULSING C., BIZZO H.R., DE AQUINO NETO F.R., REZENDE C.M., MARRIOTT P.J., ANALYSIS OF UNDERIVATISED LOW VOLATILITY COMPOUNDS BY COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY WITH A SHORT PRIMARY COLUMN, J. CHROMATOGR. A, 1536, PP. 75-81, (2018); RUIZ-SAMBLAS C., GONZALEZ-CASADO A., CUADROS-RODRIGUEZ L., GARCIA F.P., APPLICATION OF SELECTED ION MONITORING TO THE ANALYSIS OF TRIACYLGLYCEROLS IN OLIVE OIL BY HIGH TEMPERATURE-GAS CHROMATOGRAPHY/MASS SPECTROMETRY, TALANTA, 82, PP. 255-260, (2010); RUIZ-SAMBLAS C., MARINI F., CUADROS-RODRIGUEZ L., GONZALEZ-CASADO A., QUANTIFICATION OF BLENDING OF OLIVE OILS AND EDIBLE VEGETABLE OILS BY TRIACYLGLYCEROL FINGERPRINT GAS CHROMATOGRAPHY AND CHEMOMETRIC TOOLS, J. CHROMATOGR. B: ANAL. TECHNOL. BIOMED. LIFE SCI., 910, PP. 71-77, (2012); JIA X., ZHOU Q., WANG J., LIU C., HUANG F., HUANG Y., IDENTIFICATION OF KEY AROMA-ACTIVE COMPOUNDS IN SESAME OIL FROM MICROWAVED SEEDS USING E-NOSE AND HS-SPME-GCXGC-TOF/MS, J. FOOD BIOCHEM., 43, (2019); XU L., YU X., LI M., CHEN J., WANG X., MONITORING OXIDATIVE STABILITY AND CHANGES IN KEY VOLATILE COMPOUNDS IN EDIBLE OILS DURING AMBIENT STORAGE THROUGH HS-SPME/GC–MS, INT. J. FOOD PROP., 20, PP. S2926-S2938, (2018); ZHANG W., CAO X., LIU S.Q., AROMA MODULATION OF VEGETABLE OILS-A REVIEW, CRIT. REV. FOOD SCI. NUTR., 60, PP. 1538-1551, (2020); KOSMA I., BADEKA A., VATAVALI K., KONTAKOS S., KONTOMINAS M., DIFFERENTIATION OF GREEK EXTRA VIRGIN OLIVE OILS ACCORDING TO CULTIVAR BASED ON VOLATILE COMPOUND ANALYSIS AND FATTY ACID COMPOSITION, EUR. J. LIPID SCI. TECHNOL., 118, PP. 849-861, (2016); MAGAGNA F., VALVERDE-SOM L., RUIZ-SAMBLAS C., CUADROS-RODRIGUEZ L., REICHENBACH S.E., BICCHI C., CORDERO C., COMBINED UNTARGETED AND TARGETED FINGERPRINTING WITH COMPREHENSIVE TWO-DIMENSIONAL CHROMATOGRAPHY FOR VOLATILES AND RIPENING INDICATORS IN OLIVE OIL, ANAL. CHIM. ACTA, 936, PP. 245-258, (2016); GRACKA A., RACZYK M., HRADECKY J., HAJSLOVA J., JEZIORSKI S., KARLOVITS G., MICHALAK B., BAKOWSKA N., JELEN H., VOLATILE COMPOUNDS AND OTHER INDICATORS OF QUALITY FOR COLD-PRESSED RAPESEED OILS OBTAINED FROM PEELED, WHOLE, FLAKED AND ROASTED SEEDS, EUR. J. LIPID SCI. TECHNOL., 119, (2017); ANGEROSA F., SERVILI M., SELVAGGINI R., TATICCHI A., ESPOSTO S., MONTEDORO G., VOLATILE COMPOUNDS IN VIRGIN OLIVE OIL: OCCURRENCE AND THEIR RELATIONSHIP WITH THE QUALITY, J. CHROMATOGR. A, 1054, PP. 17-31, (2004); STILO F., CORDERO C., SGORBINI B., BICCHI C., LIBERTO E., HIGHLY INFORMATIVE FINGERPRINTING OF EXTRA-VIRGIN OLIVE OIL VOLATILES: THE ROLE OF HIGH CONCENTRATION-CAPACITY SAMPLING IN COMBINATION WITH COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY, SEPARATIONS, 6, (2019); CAVALLI J.F., FERNANDEZ X., LIZZANI-CUVELIER L., LOISEAU A.M., COMPARISON OF STATIC HEADSPACE, HEADSPACE SOLID PHASE MICROEXTRACTION, HEADSPACE SORPTIVE EXTRACTION, AND DIRECT THERMAL DESORPTION TECHNIQUES ON CHEMICAL COMPOSITION OF FRENCH OLIVE OILS, J. AGRIC. FOOD CHEM., 51, PP. 7709-7716, (2003); CAJKA T., RIDDELLOVA K., KLIMANKOVA E., CERNA M., PUDIL F., HAJSLOVA J., TRACEABILITY OF OLIVE OIL BASED ON VOLATILES PATTERN AND MULTIVARIATE ANALYSIS, FOOD CHEM., 121, PP. 282-289, (2010); CECCHI L., MIGLIORINI M., GIAMBANELLI E., ROSSETTI A., CANE A., MELANI F., MULINACCI N., HEADSPACE SOLID-PHASE MICROEXTRACTION-GAS CHROMATOGRAPHY-MASS SPECTROMETRY QUANTIFICATION OF THE VOLATILE PROFILE OF MORE THAN 1200 VIRGIN OLIVE OILS FOR SUPPORTING THE PANEL TEST IN THEIR CLASSIFICATION: COMPARISON OF DIFFERENT CHEMOMETRIC APPROACHES, J. AGRIC. FOOD CHEM., 67, PP. 9112-9120, (2019); SANZ C., BELAJ A., SANCHEZ-ORTIZ A., PEREZ A.G., NATURAL VARIATION OF VOLATILE COMPOUNDS IN VIRGIN OLIVE OIL ANALYZED BY HS-SPME/GC-MS-FID, SEPARATIONS, 5, (2018); OGRAS S.S., KABAN G., KAYA M., VOLATILE COMPOUNDS OF OLIVE OILS FROM DIFFERENT GEOGRAPHIC REGIONS IN TURKEY, INT. J. FOOD PROP., 21, PP. 1833-1843, (2018); POULIAREKOU E., BADEKA A., TASIOULA-MARGARI M., KONTAKOS S., LONGOBARDI F., KONTOMINAS M.G., CHARACTERIZATION AND CLASSIFICATION OF WESTERN GREEK OLIVE OILS ACCORDING TO CULTIVAR AND GEOGRAPHICAL ORIGIN BASED ON VOLATILE COMPOUNDS, J. CHROMATOGR. A, 1218, PP. 7534-7542, (2011); GIUFFRE A.M., CAPOCASALE M., MACRI R., CARACCIOLO M., ZAPPIA C., POIANA M., VOLATILE PROFILES OF EXTRA VIRGIN OLIVE OIL, OLIVE POMACE OIL, SOYBEAN OIL AND PALM OIL IN DIFFERENT HEATING CONDITIONS, LWT FOOD SCI. TECHNOL., 117, (2020); ZHOU Q., LIU S., LIU Y., SONG H., COMPARATIVE ANALYSIS OF VOLATILES OF 15 BRANDS OF EXTRA-VIRGIN OLIVE OILS USING SOLID-PHASE MICRO-EXTRACTION AND SOLVENT-ASSISTED FLAVOR EVAPORATION, MOLECULES, 24, (2019); TURA D., PRENZLER P.D., BEDGOOD D.R., ANTOLOVICH M., ROBARDS K., VARIETAL AND PROCESSING EFFECTS ON THE VOLATILE PROFILE OF AUSTRALIAN OLIVE OILS, FOOD CHEM., 84, PP. 341-349, (2004); BELTRAN SANAHUJA A., RAMOS SANTONJA M., GRANE TERUEL N., MARTIN CARRATALA M.L., GARRIGOS SELVA M.C., CLASSIFICATION OF ALMOND CULTIVARS USING OIL VOLATILE COMPOUND DETERMINATION BY HS-SPME-GC-MS, J. AM. OIL CHEM. SOC., 88, PP. 329-336, (2011); PARK M.H., JEONG M.K., YEO J., SON H.J., LIM C.L., HONG E.J., NOH B.S., LEE J., APPLICATION OF SOLID PHASE-MICROEXTRACTION (SPME) AND ELECTRONIC NOSE TECHNIQUES TO DIFFERENTIATE VOLATILES OF SESAME OILS PREPARED WITH DIVERSE ROASTING CONDITIONS, J. FOOD SCI., 76, PP. C80-C88, (2011); TU D., LI H., WU Z., ZHAO B., LI Y., APPLICATION OF HEADSPACE SOLID-PHASE MICROEXTRACTION AND MULTIVARIATE ANALYSIS FOR THE DIFFERENTIATION BETWEEN EDIBLE OILS AND WASTE COOKING OIL, FOOD ANAL. METHODS, 7, PP. 1263-1270, (2014); LUKIC I., CARLIN S., HORVAT I., VRHOVSEK U., COMBINED TARGETED AND UNTARGETED PROFILING OF VOLATILE AROMA COMPOUNDS WITH COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY FOR DIFFERENTIATION OF VIRGIN OLIVE OILS ACCORDING TO VARIETY AND GEOGRAPHICAL ORIGIN, FOOD CHEM., 270, PP. 403-414, (2019); BACCOURI O., BENDINI A., CERRETANI L., GUERFEL M., BACCOURI B., LERCKER G., ZARROUK M., DAOUD BEN MILED D., COMPARATIVE STUDY ON VOLATILE COMPOUNDS FROM TUNISIAN AND SICILIAN MONOVARIETAL VIRGIN OLIVE OILS, FOOD CHEM., 111, PP. 322-328, (2008); PURCARO G., CORDERO C., LIBERTO E., BICCHI C., CONTE L.S., TOWARD A DEFINITION OF BLUEPRINT OF VIRGIN OLIVE OIL BY COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY, J. CHROMATOGR. A, 1334, PP. 101-111, (2014); VAZ-FREIRE L.T., DA SILVA M.D.R.G., FREITAS A.M.C., COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY FOR FINGERPRINT PATTERN RECOGNITION IN OLIVE OILS PRODUCED BY TWO DIFFERENT TECHNIQUES IN PORTUGUESE OLIVE VARIETIES GALEGA VULGAR, COBRANÇOSA E CARRASQUENHA, ANAL. CHIM. ACTA, 633, PP. 263-270, (2009); ZHAO F., LIU J., WANG X., LI P., ZHANG W., ZHANG Q., DETECTION OF ADULTERATION OF SESAME AND PEANUT OILS VIA VOLATILES BY GC×GC-TOF/MS COUPLED WITH PRINCIPAL COMPONENTS ANALYSIS AND CLUSTER ANALYSIS, EUR. J. LIPID SCI. TECHNOL., 115, PP. 337-347, (2013); HU W., ZHANG L., LI P., WANG X., ZHANG Q., XU B., SUN X., MA F., DING X., CHARACTERIZATION OF VOLATILE COMPONENTS IN FOUR VEGETABLE OILS BY HEADSPACE TWO-DIMENSIONAL COMPREHENSIVE CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROMETRY, TALANTA, 129, PP. 629-635, (2014); MOREAU R.A., WHITAKER B.D., HICKS K.B., PHYTOSTEROLS, PHYTOSTANOLS, AND THEIR CONJUGATES IN FOODS: STRUCTURAL DIVERSITY, QUANTITATIVE ANALYSIS, AND HEALTH-PROMOTING USES, PROG. LIPID RES., 41, PP. 457-500, (2002); MACKAY D.S., JONES P.J.H., PHYTOSTEROLS IN HUMAN NUTRITION: TYPE, FORMULATION, DELIVERY, AND PHYSIOLOGICAL FUNCTION, EUR, J. LIPID SCI. TECHNOL., 113, PP. 1427-1432, (2011); ABUMWEIS S.S., MARINANGELI C.P., FROHLICH J., JONES P.J., IMPLEMENTING PHYTOSTEROLS INTO MEDICAL PRACTICE AS A CHOLESTEROL-LOWERING STRATEGY: OVERVIEW OF EFFICACY, EFFECTIVENESS, AND SAFETY, CAN. J. CARDIOL., 30, PP. 1225-1232, (2014); CUNHA S.S., FERNANDES J.O., OLIVEIRA M.B., QUANTIFICATION OF FREE AND ESTERIFIED STEROLS IN PORTUGUESE OLIVE OILS BY SOLID-PHASE EXTRACTION AND GAS CHROMATOGRAPHY-MASS SPECTROMETRY, J. CHROMATOGR. A, 1128, PP. 220-227, (2006); TAN S., NIU Y., LIU L., SU A., HU C., MENG Y., DEVELOPMENT OF A GC-MS/SIM METHOD FOR THE DETERMINATION OF PHYTOSTERYL ESTERS, FOOD CHEM., 281, PP. 236-241, (2019); XU B., ZHANG L., MA F., ZHANG W., WANG X., ZHANG Q., LUO D., MA H., LI P., DETERMINATION OF FREE STEROIDAL COMPOUNDS IN VEGETABLE OILS BY COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY COUPLED TO TIME-OF-FLIGHT MASS SPECTROMETRY, FOOD CHEM., 245, PP. 415-425, (2018); SHAHIDI F., DE CAMARGO A.C., TOCOPHEROLS AND TOCOTRIENOLS IN COMMON AND EMERGING DIETARY SOURCES: OCCURRENCE, APPLICATIONS, AND HEALTH BENEFITS, INT. J. MOL. SCI., 17, (2016); RUPEREZ F.J., MARTIN D., HERRERA E., BARBAS C., CHROMATOGRAPHIC ANALYSIS OF ALPHA-TOCOPHEROL AND RELATED COMPOUNDS IN VARIOUS MATRICES, J. CHROMATOGR. A, 935, PP. 45-69, (2001); LU D., YANG Y., LI Y., SUN C., ANALYSIS OF TOCOPHEROLS AND TOCOTRIENOLS IN PHARMACEUTICALS AND FOODS: A CRITICAL REVIEW, CURR. PHARM. ANAL., 11, PP. 66-78, (2014); RIGAKOU A., DIAMANTAKOS P., MELLIOU E., MAGIATIS P., S-(E)-ELENOLIDE: A NEW CONSTITUENT OF EXTRA VIRGIN OLIVE OIL, J. SCI. FOOD AGRIC., 99, PP. 5319-5326, (2019); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS., 17, (2018); OLMO-GARCIA L., POLARI J.J., LI X., BAJOUB A., FERNANDEZ-GUTIERREZ A., WANG S.C., CARRASCO-PANCORBO A., STUDY OF THE MINOR FRACTION OF VIRGIN OLIVE OIL BY A MULTI-CLASS GC–MS APPROACH: COMPREHENSIVE QUANTITATIVE CHARACTERIZATION AND VARIETAL DISCRIMINATION POTENTIAL, FOOD RES. INT., 125, (2019); PURCARO G., BARP L., BECCARIA M., CONTE L.S., FINGERPRINTING OF VEGETABLE OIL MINOR COMPONENTS BY MULTIDIMENSIONAL COMPREHENSIVE GAS CHROMATOGRAPHY WITH DUAL DETECTION, ANAL. BIOANAL. CHEM., 407, PP. 309-319, (2015); ALOISI I., ZOCCALI M., DUGO P., TRANCHIDA P.Q., MONDELLO L., FINGERPRINTING OF THE UNSAPONIFIABLE FRACTION OF VEGETABLE OILS BY USING CRYOGENICALLY-MODULATED COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY-HIGH RESOLUTION TIME-OF-FLIGHT MASS SPECTROMETRY, FOOD ANAL. METHODS, 13, PP. 1523-1529, (2020); FANALI C., BECCARIA M., SALIVO S., TRANCHIDA P., TRIPODO G., FARNETTI S., DUGO L., DUGO P., MONDELLO L., NON-POLAR LIPIDS CHARACTERIZATION OF QUINOA (CHENOPODIUM QUINOA) SEED BY COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY WITH FLAME IONIZATION/MASS SPECTROMETRY DETECTION AND NON-AQUEOUS REVERSED-PHASE LIQUID CHROMATOGRAPHY WITH ATMOSPHERIC PRESSURE CHEMICAL IONIZATION MASS SPECTROMETRY DETECTION, J SEP. SCI., 38, PP. 3151-3160, (2015); KESEN S., MONITORING FATTY ACID AND STEROL PROFILE OF NIZIP YAGLIK OLIVE OIL ADULTERATED BY COTTON AND SUNFLOWER OIL, J. OLEO. SCI., 68, PP. 817-826, (2019); AZADMARD-DAMIRCHI S., TORBATI M., ADULTERATIONS IN SOME EDIBLE OILS AND FATS AND THEIR DETECTION METHODS, J. FOOD QUAL. HAZARDS CONTROL, 2, PP. 38-44, (2015); ZHANG L., LI P., SUN X., WANG X., XU B., WANG X., MA F., ZHANG Q., DING X., CLASSIFICATION AND ADULTERATION DETECTION OF VEGETABLE OILS BASED ON FATTY ACID PROFILES, J. AGRIC. FOOD CHEM., 62, PP. 8745-8751, (2014); SRIGLEY C.T., OLES C.J., KIA A.R.F., MOSSOBA M.M., AUTHENTICITY ASSESSMENT OF EXTRA VIRGIN OLIVE OIL: EVALUATION OF DESMETHYLSTEROLS AND TRITERPENE DIALCOHOLS, J. AM. OIL CHEM. SOC., 93, PP. 171-181, (2015); LIM S.Y., ABDUL MUTALIB M.S., KHAZA'AI H., CHANG S.K., DETECTION OF FRESH PALM OIL ADULTERATION WITH RECYCLED COOKING OIL USING FATTY ACID COMPOSITION AND FTIR SPECTRAL ANALYSIS, INT. J. FOOD PROP., 21, PP. 2428-2451, (2018); YADAV S., EDIBLE OIL ADULTERATIONS: CURRENT ISSUES, DETECTION TECHNIQUES, AND HEALTH HAZARDS, INT. J. CHEM. STUD., 6, PP. 1393-1397, (2018); YANG Y., FERRO M.D., CAVACO I., LIANG Y., DETECTION AND IDENTIFICATION OF EXTRA VIRGIN OLIVE OIL ADULTERATION BY GC-MS COMBINED WITH CHEMOMETRICS, J. AGRIC. FOOD CHEM., 61, PP. 3693-3702, (2013); GREEN H.S., WANG S.C., FIRST REPORT ON QUALITY AND PURITY EVALUATIONS OF AVOCADO OIL SOLD IN THE US, FOOD CONTR., 116, (2020); JABEUR H., ZRIBI A., MAKNI J., REBAI A., ABDELHEDI R., BOUAZIZ M., DETECTION OF CHEMLALI EXTRA-VIRGIN OLIVE OIL ADULTERATION MIXED WITH SOYBEAN OIL, CORN OIL, AND SUNFLOWER OIL BY USING GC AND HPLC, J. AGRIC. FOOD CHEM., 62, PP. 4893-4904, (2014); JABEUR H., ZRIBI A., BOUAZIZ M., EXTRA-VIRGIN OLIVE OIL AND CHEAP VEGETABLE OILS: DISTINCTION AND DETECTION OF ADULTERATION AS DETERMINED BY GC AND CHEMOMETRICS, FOOD ANAL. METHODS, 9, PP. 712-723, (2015); TFOUNI S.A.V., REIS R.M., AMARO N.D.P.L., PASCOAL C.R., DE CAMARGO M.C.R., BAGGIO S.R., RAUEN-MIGUEL A.M., FURLANI R.P.Z., ADULTERATION AND PRESENCE OF POLYCYCLIC AROMATIC HYDROCARBONS IN EXTRA VIRGIN OLIVE OIL SOLD ON THE BRAZILIAN MARKET, J. AM. OIL CHEM. SOC., 94, PP. 1351-1359, (2017); DE BLAS O.J., GONZALEZ A.V., DETERMINATION OF STEROLS BY CAPILLARY COLUMN GAS CHROMATOGRAPHY. DIFFERENTIATION AMONG DIFFERENT TYPES OF OLIVE OIL: VIRGIN, REFINED, AND SOLVENT-EXTRACTED, J. AM. OIL CHEM. SOC., 73, PP. 1685-1689, (1996); HEIDARI M., TALEBPOUR Z., ABDOLLAHPOUR Z., ADIB N., GHANAVI Z., ABOUL-ENEIN H.Y., DISCRIMINATION BETWEEN VEGETABLE OIL AND ANIMAL FAT BY A METABOLOMICS APPROACH USING GAS CHROMATOGRAPHY–MASS SPECTROMETRY COMBINED WITH CHEMOMETRICS, J. FOOD SCI. TECHNOL., 57, PP. 3415-3425, (2020); MANSUR A.R., JEONG H.-R., LEE B.H., KOO M., SEO D.-H., HWANG S.H., PARK J.S., KIM D.-O., NAM T.G., COMPARATIVE EVALUATION OF TRIACYLGLYCEROLS, FATTY ACIDS, AND VOLATILE ORGANIC COMPOUNDS AS MARKERS FOR AUTHENTICATING SESAME OIL, INT. J. FOOD PROP., 21, PP. 2509-2516, (2018); XING C., YUAN X., WU X., SHAO X., YUAN J., YAN W., CHEMOMETRIC CLASSIFICATION AND QUANTIFICATION OF SESAME OIL ADULTERATED WITH OTHER VEGETABLE OILS BASED ON FATTY ACIDS COMPOSITION BY GAS CHROMATOGRAPHY, LWT FOOD SCI. TECHNOL., 108, PP. 437-445, (2019); TIAN L., ZENG Y., ZHENG X., CHIU Y., LIU T., DETECTION OF PEANUT OIL ADULTERATION MIXED WITH RAPESEED OIL USING GAS CHROMATOGRAPHY AND GAS CHROMATOGRAPHY–ION MOBILITY SPECTROMETRY, FOOD ANAL. METHODS, 12, PP. 2282-2292, (2019); ZHAO H., WANG Y., XU X., REN H., LI L., XIANG L., ZHONG W., DETECTION OF ADULTERATED VEGETABLE OILS CONTAINING WASTE COOKING OILS BASED ON THE CONTENTS AND RATIOS OF CHOLESTEROL, BETA-SITOSTEROL, AND CAMPESTEROL BY GAS CHROMATOGRAPHY/MASS SPECTROMETRY, J. AOAC INT., 98, PP. 1645-1654, (2015); XU B., LI P., MA F., WANG X., MATTHAUS B., CHEN R., YANG Q., ZHANG W., ZHANG Q., DETECTION OF VIRGIN COCONUT OIL ADULTERATION WITH ANIMAL FATS USING QUANTITATIVE CHOLESTEROL BY GC X GC-TOF/MS ANALYSIS, FOOD CHEM., 178, PP. 128-135, (2015); CERT A., LANZON A., CARELLI A.A., ALBI T., FORMATION OF STIGMASTA-3,5-DIENE IN VEGETABLE OILS, FOOD CHEM., 49, PP. 287-293, (1994); SUN Y., DOU X., YUE X., YU L., ZHANG L., LI J., LI P., OPTIMIZATION OF HEADSPACE SPME GC × GC-TOF/MS ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IN EDIBLE OILS BY CENTRAL COMPOSITE DESIGN FOR ADULTERATION DETECTION OF EDIBLE OIL, FOOD ANAL. METHODS, 13, PP. 1328-1336, (2020); NOLVACHAI Y., KULSING C., MARRIOTT P.J., PESTICIDES ANALYSIS: ADVANTAGES OF INCREASED DIMENSIONALITY IN GAS CHROMATOGRAPHY AND MASS SPECTROMETRY, CRIT. REV. ENVIRON. SCI. TECHNOL., 45, PP. 2135-2173, (2015); LENTZA-RIZOS C., AVRAMIDES E.J., CHERASCO F., LOW-TEMPERATURE CLEAN-UP METHOD FOR THE DETERMINATION OF ORGANOPHOSPHORUS INSECTICIDES IN OLIVE OIL, J. CHROMATOGR. A, 912, PP. 135-142, (2001); ZAYATS M.F., LESCHEV S.M., ZAYATS M.A., A NOVEL METHOD FOR THE DETERMINATION OF SOME PESTICIDES IN VEGETABLE OILS BASED ON DISSOCIATION EXTRACTION FOLLOWED BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, FOOD ADDIT. CONTAM. PART A, 33, PP. 1337-1345, (2016); WILKOWSKA A., BIZIUK M., DETERMINATION OF PESTICIDE RESIDUES IN FOOD MATRICES USING THE QUECHERS METHODOLOGY, FOOD CHEM., 125, PP. 803-812, (2011); HE Z., WANG Y., WANG L., PENG Y., WANG W., LIU X., DETERMINATION OF 255 PESTICIDES IN EDIBLE VEGETABLE OILS USING QUECHERS METHOD AND GAS CHROMATOGRAPHY TANDEM MASS SPECTROMETRY, ANAL. BIOANAL. CHEM., 409, PP. 1017-1030, (2017); FLECKER T., SCHICHER M., LEITNER E., WAGNER F.S., RESIDUAL SOLVENT OR INTRINSICALLY FORMED DURING PRODUCTION: ANALYSING VOLATILE COMPOUNDS IN UNREFINED VEGETABLE OILS USING HEADSPACE GAS CHROMATOGRAPHY COUPLED WITH MASS SPECTROMETRY, FOOD ADDIT. CONTAM. PART A, 36, PP. 996-1008, (2019); MOREDA W., PEREZ-CAMINO M.C., CERT A., GAS AND LIQUID CHROMATOGRAPHY OF HYDROCARBONS IN EDIBLE VEGETABLE OILS, J. CHROMATOGR. A, 936, PP. 159-171, (2001); VICHI S., PIZZALE L., CONTE L.S., BUXADERAS S., LOPEZ-TAMAMES E., SIMULTANEOUS DETERMINATION OF VOLATILE AND SEMI-VOLATILE AROMATIC HYDROCARBONS IN VIRGIN OLIVE OIL BY HEADSPACE SOLID-PHASE MICROEXTRACTION COUPLED TO GAS CHROMATOGRAPHY/MASS SPECTROMETRY, J. CHROMATOGR. A, 1090, PP. 146-154, (2005); CACHO J.I., CAMPILLO N., VINAS P., HERNANDEZ-CORDOBA M., GAS CHROMATOGRAPHY-MASS SPECTROMETRY USING MICROVIAL INSERT THERMAL DESORPTION FOR THE DETERMINATION OF BTEX IN EDIBLE OILS, RSC ADV., 6, PP. 20886-20891, (2016); WU P., ZHANG L., YANG D., ZHANG J., HU Z., WANG L., MA B., ISOTOPE DILUTION GAS CHROMATOGRAPHY WITH MASS SPECTROMETRY FOR THE ANALYSIS OF 4-OCTYL PHENOL, 4-NONYLPHENOL, AND BISPHENOL A IN VEGETABLE OILS, J. SEP. SCI., 39, PP. 904-909, (2016); ZHOU R.Z., JIANG J., MAO T., ZHAO Y.S., LU Y., MULTIRESIDUE ANALYSIS OF ENVIRONMENTAL POLLUTANTS IN EDIBLE VEGETABLE OILS BY GAS CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, FOOD CHEM., 207, PP. 43-50, (2016)","P.J. MARRIOTT; AUSTRALIAN CENTRE FOR RESEARCH ON SEPARATION SCIENCE, SCHOOL OF CHEMISTRY, MONASH UNIVERSITY, CLAYTON, WELLINGTON ROAD, 3800, AUSTRALIA; EMAIL: PHILIP.MARRIOTT@MONASH.EDU","ELSEVIER B.V.","ENGLISH","TRAC TRENDS ANAL. CHEM.","REVIEW","ISI","2-S2.0-85101976346","TRAC TRENDS ANAL CHEM","MONASH UNIVERSITY;MONASH UNIVERSITY;MONASH UNIVERSITY","NOTREPORTED;MONASH UNIVERSITY;NOTREPORTED",NA,"MOTA MFS, 2021, TRAC TRENDS ANAL CHEM","MOTA MFS, 2021, TRAC TRENDS ANAL CHEM"
"KIM K;LIM Y;JANG W","KIM, KYEONG-MIN (57190987288); LIM, YOUNG-JU (57220206982); JANG, WON-GU (36948705500)","POLICOSANOL STIMULATES OSTEOBLAST DIFFERENTIATION VIA ADENOSINE MONOPHOSPHATEACTIVATED PROTEIN KINASEMEDIATED EXPRESSION OF INSULININDUCED GENES 1 AND 2",2023,"CELLS","12","",3,"10.3390/cells12141863","DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF ENGINEERING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA, RESEARCH INSTITUTE OF ANTI-AGING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF ENGINEERING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA, RESEARCH INSTITUTE OF ANTI-AGING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF ENGINEERING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA, RESEARCH INSTITUTE OF ANTI-AGING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA","POLICOSANOL IS KNOWN AS A HYPOCHOLESTEROLEMIC COMPOUND AND IS DERIVED FROM PLANTS SUCH AS SUGAR CANE AND CORN. POLICOSANOL CAN LOWER BLOOD PRESSURE OR INHIBIT ADIPOGENESIS, BUT ITS EFFECT ON OSTEOGENIC DIFFERENTIATION AND THE MOLECULAR MECHANISM IS UNCLEAR. THIS STUDY AIMS TO INVESTIGATE THE EFFECT OF POLICOSANOL ON OSTEOGENIC DIFFERENTIATION IN MC3T3-E1 CELLS AND ZEBRAFISH MODELS. ADMINISTRATION OF POLICOSANOL INTO MC3T3-E1 INDUCED THE EXPRESSION OF THE OSTEOGENIC GENES SUCH AS DISTAL-LESS HOMEOBOX 5 (DLX5) AND RUNT-RELATED TRANSCRIPTION FACTOR 2 (RUNX2). ALKALINE PHOSPHATASE ACTIVITY AND EXTRACELLULAR MINERALIZATION ALSO INCREASED. POLICOSANOL PROMOTED ACTIVATION OF ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) AND INSULIN-INDUCED GENES (INSIGS) EXPRESSION AND REGULATION OF INSIGS MODULATED OSTEOBLAST DIFFERENTIATION. AMPK ACTIVATION THROUGH TRANSFECTION OF THE CONSTITUTIVELY ACTIVE FORM OF AMPK (CA-AMPK) INCREASED INSIGS EXPRESSION, WHEREAS POLICOSANOL-INDUCED INSIGS EXPRESSION WAS SUPPRESSED BY INHIBITOR OF AMPK (COM. C). FURTHERMORE, THE OSTEOGENIC EFFECTS OF POLICOSANOL WERE VERIFIED IN ZEBRAFISH. AMPUTATED CAUDAL FIN RAYS WERE REGENERATED BY POLICOSANOL TREATMENT. TAKEN TOGETHER, THESE RESULTS SHOW THAT POLICOSANOL INCREASES OSTEOGENIC DIFFERENTIATION AND CONTRIBUTES TO FIN REGENERATION IN ZEBRAFISH VIA AMPK-MEDIATED INSIGS EXPRESSION, SUGGESTING THAT POLICOSANOL HAS POTENTIAL AS AN OSTEOGENIC AGENT. © 2023 BY THE AUTHORS.","AMPK; INSIG; OSTEOBLAST DIFFERENTIATION; POLICOSANOL; ZEBRAFISH","AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL DIFFERENTIATION; INSULINS; OSTEOBLASTS; OSTEOGENESIS; ZEBRAFISH; ADENOSINE PHOSPHATE; ALKALINE PHOSPHATASE; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE KINASE; INSULIN; POLICOSANOL; POTASSIUM HYDROXIDE; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN DERIVATIVE; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; BONE REGENERATION; GENE EXPRESSION; HUMAN CELL; IMMUNOBLOTTING; MC3T3-E1 CELL LINE; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; BONE DEVELOPMENT; CELL DIFFERENTIATION; METABOLISM; OSTEOBLAST","MINISTRY OF EDUCATION, MOE, (2021R1F1A1062502); NATIONAL RESEARCH FOUNDATION OF KOREA, NRF","THIS RESEARCH WAS SUPPORTED BY BASIC SCIENCE RESEARCH PROGRAM THROUGH THE NATIONAL RESEARCH FOUNDATION OF KOREA (NRF) FUNDED BY THE MINISTRY OF EDUCATION (NO. 2021R1F1A1062502).","ELENISTE P.P., PATEL V., POSRITONG S., ZERO O., LARGURA H., CHENG Y.H., HIMES E.R., HAMILTON M., BAUGHMAN J., KACENA M.A., ET AL., PYK2 AND MEGAKARYOCYTES REGULATE OSTEOBLAST DIFFERENTIATION AND MIGRATION VIA DISTINCT AND OVERLAPPING MECHANISMS, J. CELL. BIOCHEM, 117, PP. 1396-1406, (2016); ZHANG N.D., HAN T., HUANG B.K., RAHMAN K., JIANG Y.P., XU H.T., QIN L.P., XIN H.L., ZHANG Q.Y., LI Y.M., TRADITIONAL CHINESE MEDICINE FORMULAS FOR THE TREATMENT OF OSTEOPOROSIS: IMPLICATION FOR ANTIOSTEOPOROTIC DRUG DISCOVERY, J. ETHNOPHARMACOL, 189, PP. 61-80, (2016); XIONG J., ALMEIDA M., O'BRIEN C.A., THE YAP/TAZ TRANSCRIPTIONAL CO-ACTIVATORS HAVE OPPOSING EFFECTS AT DIFFERENT STAGES OF OSTEOBLAST DIFFERENTIATION, BONE, 112, PP. 1-9, (2018); KOMORI T., REGULATION OF OSTEOBLAST DIFFERENTIATION BY TRANSCRIPTION FACTORS, J. CELL. BIOCHEM, 99, PP. 1233-1239, (2006); RODAN G.A., NODA M., GENE EXPRESSION IN OSTEOBLASTIC CELLS, CRIT. REV. EUKARYOT. GENE EXPR, 1, PP. 85-98, (1991); NEVE A., CORRADO A., CANTATORE F.P., OSTEOBLAST PHYSIOLOGY IN NORMAL AND PATHOLOGICAL CONDITIONS, CELL TISSUE RES, 343, PP. 289-302, (2011); WOZNEY J.M., ROSEN V., CELESTE A.J., MITSOCK L.M., WHITTERS M.J., KRIZ R.W., HEWICK R.M., WANG E.A., NOVEL REGULATORS OF BONE FORMATION: MOLECULAR CLONES AND ACTIVITIES, SCIENCE, 242, PP. 1528-1534, (1988); JANG W.G., KIM E.J., BAE I.H., LEE K.N., KIM Y.D., KIM D.K., KIM S.H., LEE C.H., FRANCESCHI R.T., CHOI H.S., ET AL., METFORMIN INDUCES OSTEOBLAST DIFFERENTIATION VIA ORPHAN NUCLEAR RECEPTOR SHP-MEDIATED TRANSACTIVATION OF RUNX2, BONE, 48, PP. 885-893, (2011); SON H.E., KIM E.J., JANG W.G., CURCUMIN INDUCES OSTEOBLAST DIFFERENTIATION THROUGH MILD-ENDOPLASMIC RETICULUM STRESS-MEDIATED SUCH AS BMP2 ON OSTEOBLAST CELLS, LIFE SCI, 193, PP. 34-39, (2018); MIN H.Y., SON H.E., JANG W.G., ALPHA-PINENE PROMOTES OSTEOBLAST DIFFERENTIATION AND ATTENUATES TNFALPHA-INDUCED INHIBITION OF DIFFERENTIATION IN MC3T3-E1 PRE-OSTEOBLASTS, CLIN. EXP. PHARMACOL. PHYSIOL, 47, PP. 831-837, (2020); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES, 27, PP. 205-208, (1994); CHO K.H., BAE M.A., KIM J.R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC. THER, 2019, (2019); OKABE T., TODA T., INAFUKU M., WADA K., IWASAKI H., OKU H., ANTIATHEROSCLEROTIC FUNCTION OF KOKUTO, OKINAWAN NONCENTRIFUGAL CANE SUGAR, J. AGRIC. FOOD CHEM, 57, PP. 69-75, (2009); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP. BIOL. MED, 241, PP. 1943-1949, (2016); ZHAI Z., NIU K.M., LIU H., LIN C., TU Y., LIU Y., CAI L., OUYANG K., LIU J., POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6/MICE THROUGH AMPK-FXR-TGR5 CROSS-TALK, J. FOOD SCI, 86, PP. 5466-5478, (2021); NOA M., MAS R., MENDOZA S., GAMEZ R., MENDOZA N., GONZALEZ J., POLICOSANOL PREVENTS BONE LOSS IN OVARIECTOMIZED RATS, DRUGS EXP. CLIN. RES, 30, PP. 117-123, (2004); HARDIE D.G., AMPK—SENSING ENERGY WHILE TALKING TO OTHER SIGNALING PATHWAYS, CELL METAB, 20, PP. 939-952, (2014); SHARMA A., ANAND S.K., SINGH N., DWIVEDI U.N., KAKKAR P., AMP-ACTIVATED PROTEIN KINASE: AN ENERGY SENSOR AND SURVIVAL MECHANISM IN THE REINSTATEMENT OF METABOLIC HOMEOSTASIS, EXP. CELL RES, 428, (2023); ZHOU G., MYERS R., LI Y., CHEN Y., SHEN X., FENYK-MELODY J., WU M., VENTRE J., DOEBBER T., FUJII N., ET AL., ROLE OF AMP-ACTIVATED PROTEIN KINASE IN MECHANISM OF METFORMIN ACTION, J. CLIN. INVESTIG, 108, PP. 1167-1174, (2001); ABD EL-FATTAH E.E., SABER S., MOURAD A.A.E., EL-AHWANY E., AMIN N.A., CAVALU S., YAHYA G., SAAD A.S., ALSHARIDAH M., SHATA A., ET AL., THE DYNAMIC INTERPLAY BETWEEN AMPK/NFKAPPAB SIGNALING AND NLRP3 IS A NEW THERAPEUTIC TARGET IN INFLAMMATION: EMERGING ROLE OF DAPAGLIFLOZIN IN OVERCOMING LIPOPOLYSACCHARIDE-MEDIATED LUNG INJURY, BIOMED. PHARMACOTHER, 147, (2022); LIM Y.J., KIM K.M., JANG W.G., CHRYSOPHANOL INCREASES OSTEOBLAST DIFFERENTIATION VIA AMPK/SMAD1/5/9 PHOSPHORYLATION IN VITRO AND IN VIVO, CLIN. EXP. PHARMACOL. PHYSIOL, 48, PP. 515-523, (2021); CHAVA S., CHENNAKESAVULU S., GAYATRI B.M., REDDY A.B.M., A NOVEL PHOSPHORYLATION BY AMP-ACTIVATED KINASE REGULATES RUNX2 FROM UBIQUITINATION IN OSTEOGENESIS OVER ADIPOGENESIS, CELL DEATH DIS, 9, (2018); YABE D., KOMURO R., LIANG G., GOLDSTEIN J.L., BROWN M.S., LIVER-SPECIFIC MRNA FOR INSIG-2 DOWN-REGULATED BY INSULIN: IMPLICATIONS FOR FATTY ACID SYNTHESIS, PROC. NATL. ACAD. SCI. USA, 100, PP. 3155-3160, (2003); ENGELKING L.J., KURIYAMA H., HAMMER R.E., HORTON J.D., BROWN M.S., GOLDSTEIN J.L., LIANG G., OVEREXPRESSION OF INSIG-1 IN THE LIVERS OF TRANSGENIC MICE INHIBITS SREBP PROCESSING AND REDUCES INSULIN-STIMULATED LIPOGENESIS, J. CLIN. INVESTIG, 113, PP. 1168-1175, (2004); JO Y., LEE P.C., SGUIGNA P.V., DEBOSE-BOYD R.A., STEROL-INDUCED DEGRADATION OF HMG COA REDUCTASE DEPENDS ON INTERPLAY OF TWO INSIGS AND TWO UBIQUITIN LIGASES, GP78 AND TRC8, PROC. NATL. ACAD. SCI. USA, 108, PP. 20503-20508, (2011); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, PP. 425-430, (1990); LI J., TAKAISHI K., COOK W., MCCORKLE S.K., UNGER R.H., INSIG-1 “BRAKES” LIPOGENESIS IN ADIPOCYTES AND INHIBITS DIFFERENTIATION OF PREADIPOCYTES, PROC. NATL. ACAD. SCI. USA, 100, PP. 9476-9481, (2003); KA S.O., KIM K.A., KWON K.B., PARK J.W., PARK B.H., SILIBININ ATTENUATES ADIPOGENESIS IN 3T3-L1 PREADIPOCYTES THROUGH A POTENTIAL UPREGULATION OF THE INSIG PATHWAY, INT. J. MOL. MED, 23, PP. 633-637, (2009); CHEN K., JIN P., HE H.H., XIE Y.H., XIE X.Y., MO Z.H., OVEREXPRESSION OF INSIG-1 PROTECTS BETA CELL AGAINST GLUCOLIPOTOXICITY VIA SREBP-1C, J. BIOMED. SCI, 18, (2011); KIM K.M., KIM C.H., CHO K.H., JANG W.G., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN. EXP. PHARMACOL. PHYSIOL, 48, PP. 1336-1345, (2021); JANG W.G., KIM E.J., LEE K.N., SON H.J., KOH J.T., AMP-ACTIVATED PROTEIN KINASE (AMPK) POSITIVELY REGULATES OSTEOBLAST DIFFERENTIATION VIA INDUCTION OF DLX5-DEPENDENT RUNX2 EXPRESSION IN MC3T3E1 CELLS, BIOCHEM. BIOPHYS. RES. COMMUN, 404, PP. 1004-1009, (2011); SZULC P., MUNOZ F., DUBOEUF F., MARCHAND F., DELMAS P.D., BONE MINERAL DENSITY PREDICTS OSTEOPOROTIC FRACTURES IN ELDERLY MEN: THE MINOS STUDY, OSTEOPOROS. INT, 16, PP. 1184-1192, (2005); LEE M.H., KIM Y.J., KIM H.J., PARK H.D., KANG A.R., KYUNG H.M., SUNG J.H., WOZNEY J.M., KIM H.J., RYOO H.M., BMP-2-INDUCED RUNX2 EXPRESSION IS MEDIATED BY DLX5, AND TGF-BETA 1 OPPOSES THE BMP-2-INDUCED OSTEOBLAST DIFFERENTIATION BY SUPPRESSION OF DLX5 EXPRESSION, J. BIOL. CHEM, 278, PP. 34387-34394, (2003); OTTO F., THORNELL A.P., CROMPTON T., DENZEL A., GILMOUR K.C., ROSEWELL I.R., STAMP G.W., BEDDINGTON R.S., MUNDLOS S., OLSEN B.R., ET AL., CBFA1, A CANDIDATE GENE FOR CLEIDOCRANIAL DYSPLASIA SYNDROME, IS ESSENTIAL FOR OSTEOBLAST DIFFERENTIATION AND BONE DEVELOPMENT, CELL, 89, PP. 765-771, (1997); KEMPF H., KOMAROVA S., MURSHED M., EDITORIAL: ECTOPIC MINERALIZATION OF TISSUES: MECHANISMS, RISK FACTORS, DISEASES, AND PREVENTION, FRONT. CELL DEV. BIOL, 9, (2021); KIM A.R., LIM Y.J., JANG W.G., ZINGERONE STIMULATES OSTEOBLAST DIFFERENTIATION BY INCREASING SMAD1/5/9-MEDIATED HO-1 EXPRESSION IN MC3T3-E1 CELLS AND PRIMARY MOUSE CALVARIAL CELLS, CLIN. EXP. PHARMACOL. PHYSIOL, 49, PP. 1050-1058, (2022); LIM Y.J., MIN H.Y., JANG W.G., ZINGERONE ATTENUATES PI-INDUCED VASCULAR CALCIFICATION VIA AMPK-MEDIATED TIMP4 EXPRESSION, J. LIPID ATHEROSCLER, 10, PP. 62-73, (2021); WANG Y.G., HAN X.G., YANG Y., QIAO H., DAI K.R., FAN Q.M., TANG T.T., FUNCTIONAL DIFFERENCES BETWEEN AMPK ALPHA1 AND ALPHA2 SUBUNITS IN OSTEOGENESIS, OSTEOBLAST-ASSOCIATED INDUCTION OF OSTEOCLASTOGENESIS, AND ADIPOGENESIS, SCI. REP, 6, (2016); KIM D.Y., KIM E.J., JANG W.G., PIPERINE INDUCES OSTEOBLAST DIFFERENTIATION THROUGH AMPK-DEPENDENT RUNX2 EXPRESSION, BIOCHEM. BIOPHYS. RES. COMMUN, 495, PP. 1497-1502, (2018); NAM D.E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J. MED. FOOD, 22, PP. 1110-1117, (2019); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., KIM Y., SEO W.D., LEE S.J., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTR. RES, 43, PP. 89-99, (2017); YOU L., SHENG Z.Y., TANG C.L., CHEN L., PAN L., CHEN J.Y., HIGH CHOLESTEROL DIET INCREASES OSTEOPOROSIS RISK VIA INHIBITING BONE FORMATION IN RATS, ACTA PHARMACOL. SIN, 32, PP. 1498-1504, (2011); SUN L.P., LI L., GOLDSTEIN J.L., BROWN M.S., INSIG REQUIRED FOR STEROL-MEDIATED INHIBITION OF SCAP/SREBP BINDING TO COPII PROTEINS IN VITRO, J. BIOL. CHEM, 280, PP. 26483-26490, (2005); SUZUKI A., OGATA K., YOSHIOKA H., SHIM J., WASSIF C.A., PORTER F.D., IWATA J., DISRUPTION OF DHCR7 AND INSIG1/2 IN CHOLESTEROL METABOLISM CAUSES DEFECTS IN BONE FORMATION AND HOMEOSTASIS THROUGH PRIMARY CILIUM FORMATION, BONE RES, 8, (2020); HAN Y., HU Z., CUI A., LIU Z., MA F., XUE Y., LIU Y., ZHANG F., ZHAO Z., YU Y., ET AL., POST-TRANSLATIONAL REGULATION OF LIPOGENESIS VIA AMPK-DEPENDENT PHOSPHORYLATION OF INSULIN-INDUCED GENE, NAT. COMMUN, 10, (2019); ZHAO Z.H., WANG Z.X., ZHOU D., HAN Y., MA F., HU Z., XIN F.Z., LIU X.L., REN T.Y., ZHANG F., ET AL., SODIUM BUTYRATE SUPPLEMENTATION INHIBITS HEPATIC STEATOSIS BY STIMULATING LIVER KINASE B1 AND INSULIN-INDUCED GENE, CELL. MOL. GASTROENTEROL. HEPATOL, 12, PP. 857-871, (2021); BLUM N., BEGEMANN G., RETINOIC ACID SIGNALING SPATIALLY RESTRICTS OSTEOBLASTS AND CONTROLS RAY-INTERRAY ORGANIZATION DURING ZEBRAFISH FIN REGENERATION, DEVELOPMENT, 142, PP. 2888-2893, (2015); GEURTZEN K., KNOPF F., WEHNER D., HUITEMA L.F., SCHULTE-MERKER S., WEIDINGER G., MATURE OSTEOBLASTS DEDIFFERENTIATE IN RESPONSE TO TRAUMATIC BONE INJURY IN THE ZEBRAFISH FIN AND SKULL, DEVELOPMENT, 141, PP. 2225-2234, (2014); KNOPF F., HAMMOND C., CHEKURU A., KURTH T., HANS S., WEBER C.W., MAHATMA G., FISHER S., BRAND M., SCHULTE-MERKER S., ET AL., BONE REGENERATES VIA DEDIFFERENTIATION OF OSTEOBLASTS IN THE ZEBRAFISH FIN, DEV. CELL, 20, PP. 713-724, (2011)","W.-G. JANG; DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF ENGINEERING, DAEGU UNIVERSITY, GYEONGSAN, 38453, SOUTH KOREA; EMAIL: JANGWG@DAEGU.AC.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","CELLS","ARTICLE","ISI","2-S2.0-85166005742","CELLS","DAEGU UNIVERSITY;DAEGU UNIVERSITY;DAEGU UNIVERSITY","NOTREPORTED;DAEGU UNIVERSITY;NOTREPORTED",NA,"KIM K-M, 2023, CELLS","KIM K-M, 2023, CELLS"
"SAFARI S;MIRAZI N;AHMADI N;ASADBEGI M;NOURIAN A;GHADERI S;RASHNO M;KOMAKI A","SAFARI, SAMANEH (57222136611); MIRAZI, NASER (8247246600); AHMADI, NESA (57222143846); ASADBEGI, MASOUMEH (56974353600); NOURIAN, ALIREZA (56005452500); GHADERI, SHAHAB (56549693900); RASHNO, MASOME (56550020400); KOMAKI, ALIREZA (55881461900)","THE PROTECTIVE EFFECTS OF POLICOSANOL ON LEARNING AND MEMORY IMPAIRMENTS IN A MALE RAT MODEL OF ALZHEIMERS DISEASE",2023,"MOLECULAR NEUROBIOLOGY","60","12",3,"10.1007/s12035-023-03225-x","DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN, DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN;DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN;DEPARTMENT OF BIOLOGY, FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN, DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN;DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN;DEPARTMENT OF PATHOBIOLOGY, FACULTY OF VETERINARY SCIENCE, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN;DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN;STUDENT RESEARCH COMMITTEE, ASADABAD SCHOOL OF MEDICAL SCIENCES, ASADABAD, IRAN;DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN","ALZHEIMER’S DISEASE (AD), THE MOST COMMON FORM OF DEMENTIA, IS CHARACTERIZED BY A PROGRESSIVE DECLINE IN COGNITIVE PERFORMANCE AND MEMORY FORMATION. THE PRESENT STUDY WAS DESIGNED TO INVESTIGATE THE EFFECT OF POLICOSANOL (PCO) ON COGNITIVE FUNCTION, OXIDATIVE-ANTIOXIDATIVE STATUS, AND AMYLOID-BETA (AΒ) PLAQUE FORMATION IN AN AD RAT MODEL INDUCED BY INTRACEREBROVENTRICULAR (ICV) INJECTION OF AΒ1–40. HEALTHY ADULT MALE WISTAR RATS WERE RANDOMLY DIVIDED INTO SEVEN GROUPS: CONTROL, SHAM (5 ΜL, ICV INJECTION OF PHOSPHATE-BUFFERED SALINE), AD MODEL (5 ΜL, ICV INJECTION OF AΒ), ACACIA GUM (50 MG/KG, 8 WEEKS, GAVAGE), PCO (50 MG/KG, 8 WEEKS, GAVAGE), AD + ACACIA GUM (50 MG/KG, 8 WEEKS, GAVAGE), AND AD + PCO (50 MG/KG, 8 WEEKS, GAVAGE). DURING THE NINTH AND TENTH WEEKS OF THE STUDY, THE COGNITIVE FUNCTION OF THE RATS WAS ASSESSED BY COMMONLY USED BEHAVIORAL PARADIGMS. SUBSEQUENTLY, OXIDATIVE-ANTIOXIDATIVE STATUS WAS EXAMINED IN THE SERUM. MOREOVER, COMPACT AΒ PLAQUES WERE DETECTED BY CONGO RED STAINING. THE RESULTS SHOWED THAT INJECTION OF AΒ IMPAIRED RECOGNITION MEMORY IN THE NOVEL OBJECT RECOGNITION TEST, REDUCED THE SPATIAL COGNITIVE ABILITY IN THE MORRIS WATER MAZE, AND ALLEVIATED RETENTION AND RECALL CAPABILITY IN THE PASSIVE AVOIDANCE TASK. ADDITIONALLY, INJECTION OF AΒ RESULTED IN INCREASED TOTAL OXIDANT STATUS, DECREASED TOTAL ANTIOXIDANT CAPACITY, AND ENHANCED AΒ PLAQUE FORMATION IN THE RATS. INTRIGUINGLY, PCO TREATMENT IMPROVED ALL THE ABOVE-MENTIONED NEUROPATHOLOGICAL CHANGES IN THE AΒ-INDUCED AD RATS. THE RESULTS SUGGEST THAT PCO IMPROVES AΒ-INDUCED COGNITIVE DECLINE, POSSIBLY THROUGH MODULATION OF OXIDATIVE-ANTIOXIDATIVE STATUS AND INHIBITION OF AΒ PLAQUE FORMATION. © 2023, THE AUTHOR(S), UNDER EXCLUSIVE LICENCE TO SPRINGER SCIENCE+BUSINESS MEDIA, LLC, PART OF SPRINGER NATURE.","ALZHEIMER’S DISEASE; OXIDATIVE STRESS; POLICOSANOL, COGNITIVE DECLINE; RAT","ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; GUM ARABIC; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY DISORDERS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; CONGO RED; GUM ARABIC; PHOSPHATE BUFFERED SALINE; POLICOSANOL; AMYLOID BETA PROTEIN; ANTIOXIDANT; GUM ARABIC; PEPTIDE FRAGMENT; POLICOSANOL; ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR ASSESSMENT; COGNITION; COGNITION ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; LEARNING DISORDER; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OXIDATION REDUCTION POTENTIAL; PASSIVE AVOIDANCE TEST; RAT; RECALL; SPATIAL ANALYSIS; TOTAL ANTIOXIDANT CAPACITY; TREATMENT DURATION; WISTAR RAT; ANIMAL; COMPLICATION; DISEASE MODEL; HIPPOCAMPUS; MAZE TEST; MEMORY DISORDER; PATHOLOGY","NEUROPHYSIOLOGY RESEARCH CENTER, HAMADAN UNIVERSITY OF MEDICAL SCIENCES; BU-ALI SINA UNIVERSITY","FUNDING TEXT 1: THE AUTHORS ARE GRATEFUL TO THE STAFF OF THE NEUROPHYSIOLOGY RESEARCH CENTER, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, FOR THE ROLE THEY HAD IN DOING THIS PROJECT.; FUNDING TEXT 2: THE CURRENT STUDY WAS FUNDED (GRANT NO. IR.BASU.REC.1399.371) BY THE FACULTY OF BASIC SCIENCES, BU-ALI SINA UNIVERSITY, HAMEDAN, IRAN. ","RAMACHANDRAN A.K., DAS S., JOSEPH A., SHENOY G.G., ALEX A.T., MUDGAL J., NEURODEGENERATIVE PATHWAYS IN ALZHEIMER’S DISEASE: A REVIEW, CURR NEUROPHARMACOL, 19, PP. 679-692, (2021); WENK G.L., NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE, J CLIN PSYCHIATRY, 64, PP. 7-10, (2003); HUANG H.-C., JIANG Z.-F., ACCUMULATED AMYLOID-Β PEPTIDE AND HYPERPHOSPHORYLATED TAU PROTEIN: RELATIONSHIP AND LINKS IN ALZHEIMER’S DISEASE, J ALZHEIMER’S DIS, 16, PP. 15-27, (2009); SERRANO-POZO A., FROSCH M.P., MASLIAH E., HYMAN B.T., NEUROPATHOLOGICAL ALTERATIONS IN ALZHEIMER DISEASE, COLD SPRING HARB PERSPECT MED, 1, (2011); YAN Y., YANG H., XIE Y., DING Y., KONG D., YU H., RESEARCH PROGRESS ON ALZHEIMER’S DISEASE AND RESVERATROL, NEUROCHEM RES, 45, PP. 989-1006, (2020); BELVIRANLI M., OKUDAN N., VOLUNTARY, INVOLUNTARY AND FORCED EXERCISES ALMOST EQUALLY REVERSE BEHAVIORAL IMPAIRMENT BY REGULATING HIPPOCAMPAL NEUROTROPHIC FACTORS AND OXIDATIVE STRESS IN EXPERIMENTAL ALZHEIMER’S DISEASE MODEL, BEHAV BRAIN RES, 364, PP. 245-255, (2019); ABEYSINGHE A., DESHAPRIYA R., UDAWATTE C., ALZHEIMER’S DISEASE; A REVIEW OF THE PATHOPHYSIOLOGICAL BASIS AND THERAPEUTIC INTERVENTIONS, LIFE SCI, 256, (2020); IONESCU-TUCKER A., COTMAN C.W., EMERGING ROLES OF OXIDATIVE STRESS IN BRAIN AGING AND ALZHEIMER’S DISEASE, NEUROBIOL AGING, 107, PP. 86-95, (2021); BAI R., GUO J., YE X.Y., XIE Y., XIE T., OXIDATIVE STRESS: THE CORE PATHOGENESIS AND MECHANISM OF ALZHEIMER’S DISEASE, AGEING RES REV, 77, (2022); HALLIWELL B., OXIDATIVE STRESS AND NEURODEGENERATION: WHERE ARE WE NOW?, J NEUROCHEM, 97, PP. 1634-1658, (2006); LEE C.C., WU D.Y., CHEN S.Y., LIN Y.P., LEE T.M., EXERCISE INTENSITIES MODULATE COGNITIVE FUNCTION IN SPONTANEOUSLY HYPERTENSIVE RATS THROUGH OXIDATIVE MEDIATED SYNAPTIC PLASTICITY IN HIPPOCAMPUS, J CELL MOL MED, 25, PP. 8546-8557, (2021); SINGH A., KUKRETI R., SASO L., KUKRETI S., OXIDATIVE STRESS: A KEY MODULATOR IN NEURODEGENERATIVE DISEASES, MOLECULES, 24, (2019); RUMMEL N.G., BUTTERFIELD D.A., ALTERED METABOLISM IN ALZHEIMER DISEASE BRAIN: ROLE OF OXIDATIVE STRESS, ANTIOXID REDOX SIGNAL, 36, PP. 1289-1305, (2022); UDDIN M., KABIR M., OXIDATIVE STRESS IN ALZHEIMER’S DISEASE: MOLECULAR HALLMARKS OF UNDERLYING VULNERABILITY, BIOLOGICAL, DIAGNOSTIC AND THERAPEUTIC ADVANCES IN ALZHEIMER'S DISEASE: SPRINGER, P, PP. 91-115, (2019); ALIEV G., OBRENOVICH M.E., REDDY V.P., SHENK J.C., MOREIRA P.I., NUNOMURA A., ZHU X., SMITH M.A., PERRY G., ANTIOXIDANT THERAPY IN ALZHEIMER’S DISEASE: THEORY AND PRACTICE, MINI REV MED CHEM, 8, PP. 1395-1406, (2008); TADOKORO K., OHTA Y., INUFUSA H., LOON A.F.N., ABE K., PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER’S DISEASE BY NOVEL ANTIOXIDATIVE SUPPLEMENTS, INT J MOL SCI, 21, (2020); GUO T., ZHANG D., ZENG Y., HUANG T.Y., XU H., ZHAO Y., MOLECULAR AND CELLULAR MECHANISMS UNDERLYING THE PATHOGENESIS OF ALZHEIMER’S DISEASE, MOL NEURODEGENER, 15, (2020); CHEN J.X., YAN S.D., AMYLOID-BETA-INDUCED MITOCHONDRIAL DYSFUNCTION, J ALZHEIMERS DIS, 12, PP. 177-184, (2007); MISRANI A., TABASSUM S., YANG L., MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS IN ALZHEIMER’S DISEASE, FRONT AGING NEUROSCI, 13, (2021); FERREIRA S.T., KLEIN W.L., THE AΒ OLIGOMER HYPOTHESIS FOR SYNAPSE FAILURE AND MEMORY LOSS IN ALZHEIMER’S DISEASE, NEUROBIOL LEARN MEM, 96, PP. 529-543, (2011); RASHNO M., GHOLIPOUR P., SALEHI I., KOMAKI A., RASHIDI K., KHOSHNAM S.E., GHADERI S., P-COUMARIC ACID MITIGATES PASSIVE AVOIDANCE MEMORY AND HIPPOCAMPAL SYNAPTIC PLASTICITY IMPAIRMENTS IN ALUMINUM CHLORIDE-INDUCED ALZHEIMER’S DISEASE RAT MODEL, J FUNCT FOODS, 94, (2022); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J FUNCT FOODS, 57, PP. 351-360, (2019); MUSTO D., MARTORELLI L., RUSSO M., ESPOSITO G., AMATO M., ESPOSITO P., RIEGLER G., NON-ALCOHOLIC HEPATIC STEATOSIS: THE ROLE OF POLICOSANOLS IN ASSOCIATED HYPERLIPIDEMIA, MINERVA GASTROENTEROL DIETOL, 56, PP. 389-395, (2010); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES, 62, (2018); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ZHAO M., GAN J., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT MED THER, 21, (2021); MA J., LI K., ZHANG W., MA L., XU J., LIU L., CHEN X., ZHANG H., ACUTE TOXICITY AND CHROMOSOMAL ABERRATION TOXICITY OF INSECT WAX AND ITS POLICOSANOL, FOOD SCI HUMAN WELLNESS, 11, PP. 356-365, (2022); GUERRA Y.P., CUEVAS V.M., FERREIRO R.M., YERA A.O., DESPAIGNE S.J., EFFECTS OF POLICOSANOL PRE-TREATMENT ON BLOOD-BRAIN BARRIER DAMAGE INDUCED BY ISCHEMIA-REPERFUSION IN RATS, INT J PHARM SCI REV RES, 32, PP. 1-6, (2015); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP BIOL MED, 241, PP. 1943-1949, (2016); ASADBEGI M., KOMAKI A., SALEHI I., YAGHMAEI P., EBRAHIM-HABIBI A., SHAHIDI S., SARIHI A., SOLEIMANI ASL S., GOLIPOOR Z., EFFECTS OF THYMOL ON AMYLOID-Β-INDUCED IMPAIRMENTS IN HIPPOCAMPAL SYNAPTIC PLASTICITY IN RATS FED A HIGH-FAT DIET, BRAIN RES BULL, 137, PP. 338-350, (2018); LORENZO A., YANKNER B.A., BETA-AMYLOID NEUROTOXICITY REQUIRES FIBRIL FORMATION AND IS INHIBITED BY CONGO RED, PROC NATL ACAD SCI U S A, 91, PP. 12243-12247, (1994); PAXINOS G., WATSON C., THE RAT BRAIN IN STEREOTAXIC COORDINATES, (2005); ZARRINKALAM E., HEIDARIANPOUR A., SALEHI I., RANJBAR K., KOMAKI A., EFFECTS OF ENDURANCE, RESISTANCE, AND CONCURRENT EXERCISE ON LEARNING AND MEMORY AFTER MORPHINE WITHDRAWAL IN RATS, LIFE SCI, 157, PP. 19-24, (2016); BENZIE I.F., STRAIN J., 2 FERRIC REDUCING/ANTIOXIDANT POWER ASSAY: DIRECT MEASURE OF TOTAL ANTIOXIDANT ACTIVITY OF BIOLOGICAL FLUIDS AND MODIFIED VERSION FOR SIMULTANEOUS MEASUREMENT OF TOTAL ANTIOXIDANT POWER AND ASCORBIC ACID CONCENTRATION, METHODS ENZYMOL, 299, PP. 15-27, (1999); EREL O., A NEW AUTOMATED COLORIMETRIC METHOD FOR MEASURING TOTAL OXIDANT STATUS, CLIN BIOCHEM, 38, PP. 1103-1111, (2005); AHMADI N., SAFARI S., MIRAZI N., KARIMI S.A., KOMAKI A., EFFECTS OF VANILLIC ACID ON AΒ(1–40)-INDUCED OXIDATIVE STRESS AND LEARNING AND MEMORY DEFICIT IN MALE RATS, BRAIN RES BULL, 170, PP. 264-273, (2021); PARK J., LEE S.Y., SHON J., KIM K., LEE H.J., KIM K.A., LEE B.Y., OH S.H., KIM N.K., KIM O.J., ADALIMUMAB IMPROVES COGNITIVE IMPAIRMENT, EXERTS NEUROPROTECTIVE EFFECTS AND ATTENUATES NEUROINFLAMMATION IN AN AΒ(1–40)-INJECTED MOUSE MODEL OF ALZHEIMER’S DISEASE, CYTOTHERAPY, 21, PP. 671-682, (2019); AHMADI N., MIRAZI N., KOMAKI A., SAFARI S., HOSSEINI A., VANILLIC ACID ATTENUATES AMYLOID Β1-40-INDUCED LONG-TERM POTENTIATION DEFICIT IN MALE RATS: AN IN VIVO INVESTIGATION, NEUROL RES, 43, PP. 562-569, (2021); PREDIGER R.D., FRANCO J.L., PANDOLFO P., MEDEIROS R., DUARTE F.S., DI GIUNTA G., FIGUEIREDO C.P., FARINA M., CALIXTO J.B., TAKAHASHI R.N., DAFRE A.L., DIFFERENTIAL SUSCEPTIBILITY FOLLOWING BETA-AMYLOID PEPTIDE-(1–40) ADMINISTRATION IN C57BL/6 AND SWISS ALBINO MICE: EVIDENCE FOR A DISSOCIATION BETWEEN COGNITIVE DEFICITS AND THE GLUTATHIONE SYSTEM RESPONSE, BEHAV BRAIN RES, 177, PP. 205-213, (2007); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ZHAO M., GAN J., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); FONTANI G., LODI L., MIGLIORINI S., CORRADESCHI F., EFFECT OF OMEGA-3 AND POLICOSANOL SUPPLEMENTATION ON ATTENTION AND REACTIVITY IN ATHLETES, J AM COLL NUTR, 28, PP. 473S-481S, (2009); BETTERIDGE D.J., WHAT IS OXIDATIVE STRESS?, METAB, 49, PP. 3-8, (2000); GARBARINO V.R., ORR M.E., RODRIGUEZ K.A., BUFFENSTEIN R., MECHANISMS OF OXIDATIVE STRESS RESISTANCE IN THE BRAIN: LESSONS LEARNED FROM HYPOXIA TOLERANT EXTREMOPHILIC VERTEBRATES, ARCH BIOCHEM BIOPHYS, 576, PP. 8-16, (2015); GHOLIPOUR P., KOMAKI A., PARSA H., RAMEZANI M., THERAPEUTIC EFFECTS OF HIGH-INTENSITY INTERVAL TRAINING EXERCISE ALONE AND ITS COMBINATION WITH ECDYSTERONE AGAINST AMYLOID BETA-INDUCED RAT MODEL OF ALZHEIMER’S DISEASE: A BEHAVIORAL, BIOCHEMICAL, AND HISTOLOGICAL STUDY, NEUROCHEM RES, 47, PP. 2090-2108, (2022); GHOLIPOUR P., KOMAKI A., RAMEZANI M., PARSA H., EFFECTS OF THE COMBINATION OF HIGH-INTENSITY INTERVAL TRAINING AND ECDYSTERONE ON LEARNING AND MEMORY ABILITIES, ANTIOXIDANT ENZYME ACTIVITIES, AND NEURONAL POPULATION IN AN AMYLOID-BETA-INDUCED RAT MODEL OF ALZHEIMER’S DISEASE, PHYSIOL BEHAV, 251, (2022); HASANZADEH Z., NOURAZARIAN A., NIKANFAR M., LAGHOUSI D., VATANKHAH A.M., SADRIRAD S., EVALUATION OF THE SERUM DKK-1, TENASCIN-C, OXIDATIVE STRESS MARKERS LEVELS AND WNT SIGNALING PATHWAY GENES EXPRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE, J MOL NEUROSCI, 71, PP. 879-887, (2021); FRANZONI F., SCARFO G., GUIDOTTI S., FUSI J., ASOMOV M., PRUNETI C., OXIDATIVE STRESS AND COGNITIVE DECLINE: THE NEUROPROTECTIVE ROLE OF NATURAL ANTIOXIDANTS, FRONT NEUROSCI, 15, (2021); EREL O., A NOVEL AUTOMATED DIRECT MEASUREMENT METHOD FOR TOTAL ANTIOXIDANT CAPACITY USING A NEW GENERATION, MORE STABLE ABTS RADICAL CATION, CLIN BIOCHEM, 37, PP. 277-285, (2004); CAKIRCA G., MANAV V., CELIK H., SARACOGLU G., YETKIN E.N., EFFECTS OF ANXIETY AND DEPRESSION SYMPTOMS ON OXIDATIVE STRESS IN PATIENTS WITH ALOPECIA AREATA, POSTEPY DERMATOL ALERGOL, 37, PP. 412-416, (2020); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOL SIN, 31, PP. 765-774, (2010); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., MENDOZA N., VALLE M., JIMENEZ S., SANCHEZ J., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J PHARM SCI, 75, PP. 635-641, (2013); RAHMAN M.M., LENDEL C., EXTRACELLULAR PROTEIN COMPONENTS OF AMYLOID PLAQUES AND THEIR ROLES IN ALZHEIMER’S DISEASE PATHOLOGY, MOL NEURODEGENER, 16, (2021); ARAKI W., KAMETANI F., PROTECTION AGAINST AMYLOID-Β OLIGOMER NEUROTOXICITY BY SMALL MOLECULES WITH ANTIOXIDATIVE PROPERTIES: POTENTIAL FOR THE PREVENTION OF ALZHEIMER’S DISEASE DEMENTIA, ANTIOXIDANTS, 11, (2022); SIMUNKOVA M., ALWASEL S.H., ALHAZZA I.M., JOMOVA K., KOLLAR V., RUSKO M., VALKO M., MANAGEMENT OF OXIDATIVE STRESS AND OTHER PATHOLOGIES IN ALZHEIMER’S DISEASE, ARCH TOXICOL, 93, PP. 2491-2513, (2019); CALVO-RODRIGUEZ M., HOU S.S., SNYDER A.C., KHARITONOVA E.K., RUSS A.N., DAS S., FAN Z., MUZIKANSKY A., GARCIA-ALLOZA M., SERRANO-POZO A., HUDRY E., BACSKAI B.J., INCREASED MITOCHONDRIAL CALCIUM LEVELS ASSOCIATED WITH NEURONAL DEATH IN A MOUSE MODEL OF ALZHEIMER’S DISEASE, NAT COMMUN, 11, (2020); CASCELLA R., CECCHI C., CALCIUM DYSHOMEOSTASIS IN ALZHEIMER’S DISEASE PATHOGENESIS, INT J MOL SCI, 22, (2021); OLIVER D.M.A., REDDY P.H., SMALL MOLECULES AS THERAPEUTIC DRUGS FOR ALZHEIMER’S DISEASE, MOL CELL NEUROSCI, 96, PP. 47-62, (2019); GIORDANO C.R., TERLECKY L.J., BOLLIG-FISCHER A., WALTON P.A., TERLECKY S.R., AMYLOID-BETA NEUROPROTECTION MEDIATED BY A TARGETED ANTIOXIDANT, SCI REP, 4, (2014); MANCZAK M., MAO P., CALKINS M.J., CORNEA A., REDDY A.P., MURPHY M.P., SZETO H.H., PARK B., REDDY P.H., MITOCHONDRIA-TARGETED ANTIOXIDANTS PROTECT AGAINST AMYLOID-BETA TOXICITY IN ALZHEIMER’S DISEASE NEURONS, J ALZHEIMERS DIS, 20, PP. S609-S631, (2010); ONO K., HAMAGUCHI T., NAIKI H., YAMADA M., ANTI-AMYLOIDOGENIC EFFECTS OF ANTIOXIDANTS: IMPLICATIONS FOR THE PREVENTION AND THERAPEUTICS OF ALZHEIMER’S DISEASE, BIOCHIM BIOPHYS ACTA, 1762, PP. 575-586, (2006); RAJASEKHAR K., SAMANTA S., BAGOBAND V., MURUGAN N.A., GOVINDARAJU T., ANTIOXIDANT BERBERINE-DERIVATIVE INHIBITS MULTIFACETED AMYLOID TOXICITY, ISCIENCE, 23, (2020); TRAMUTOLA A., LANZILLOTTA C., PERLUIGI M., BUTTERFIELD D.A., OXIDATIVE STRESS, PROTEIN MODIFICATION AND ALZHEIMER DISEASE, BRAIN RES BULL, 133, PP. 88-96, (2017); MARSILLACH J., ADORNI M.P., ZIMETTI F., PAPOTTI B., ZULIANI G., CERVELLATI C., HDL PROTEOME AND ALZHEIMER’S DISEASE: EVIDENCE OF A LINK, ANTIOXIDANTS, 9, (2020); WINGO T.S., CUTLER D.J., WINGO A.P., LE N.A., RABINOVICI G.D., MILLER B.L., LAH J.J., LEVEY A.I., ASSOCIATION OF EARLY-ONSET ALZHEIMER DISEASE WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND RARE GENETIC CODING VARIANTS OF APOB, JAMA NEUROL, 76, PP. 809-817, (2019); LEWIS T.L., CAO D., LU H., MANS R.A., SU Y.R., JUNGBAUER L., LINTON M.F., FAZIO S., LADU M.J., LI L., OVEREXPRESSION OF HUMAN APOLIPOPROTEIN A-I PRESERVES COGNITIVE FUNCTION AND ATTENUATES NEUROINFLAMMATION AND CEREBRAL AMYLOID ANGIOPATHY IN A MOUSE MODEL OF ALZHEIMER DISEASE, J BIOL CHEM, 285, PP. 36958-36968, (2010); REITZ C., TANG M.X., SCHUPF N., MANLY J.J., MAYEUX R., LUCHSINGER J.A., ASSOCIATION OF HIGHER LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ELDERLY INDIVIDUALS AND LOWER RISK OF LATE-ONSET ALZHEIMER DISEASE, ARCH NEUROL, 67, PP. 1491-1497, (2010); ZHOU Z., LIANG Y., ZHANG X., XU J., LIN J., ZHANG R., KANG K., LIU C., ZHAO C., ZHAO M., LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, FRONT AGING NEUROSCI, 12, (2020); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTRI FOOD RES, 62, (2018)","A. KOMAKI; DEPARTMENT OF NEUROSCIENCE, SCHOOL OF SCIENCE AND ADVANCED TECHNOLOGIES IN MEDICINE, HAMADAN UNIVERSITY OF MEDICAL SCIENCES, HAMADAN, IRAN; EMAIL: ALIREZAKOMAKI@GMAIL.COM","SPRINGER","ENGLISH","MOL. NEUROBIOL.","ARTICLE","ISI","2-S2.0-85146593198","MOL NEUROBIOL","BU-ALI SINA UNIVERSITY;BU-ALI SINA UNIVERSITY;BU-ALI SINA UNIVERSITY;HAMADAN UNIVERSITY OF MEDICAL SCIENCES;BU-ALI SINA UNIVERSITY;HAMADAN UNIVERSITY OF MEDICAL SCIENCES;ASADABAD SCHOOL OF MEDICAL SCIENCES;HAMADAN UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;HAMADAN UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"SAFARI S, 2023, MOL NEUROBIOL","SAFARI S, 2023, MOL NEUROBIOL"
"ZEIN N;YASSIN F;MAKLED S;ALOTAIBI S;ALBOGAMI S;MOSTAFA-HEDEAB G;BATIHA G;ELEWA Y","ZEIN, NABILA (56556306000); YASSIN, FATHY (6602349572); MAKLED, SHAZA (57659760100); ALOTAIBI, SAQER S. (57195383213); ALBOGAMI, SARAH M. (57193993283); MOSTAFA-HEDEAB, GOMAA (55873188800); BATIHA, GABER EL-SABER (57200946172); ELEWA, YASER HOSNY ALI (35763517200)","ORAL SUPPLEMENTATION OF POLICOSANOL ALLEVIATES CARBON TETRACHLORIDEINDUCED LIVER FIBROSIS IN RATS",2022,"BIOMEDICINE AND PHARMACOTHERAPY","150","",7,"10.1016/j.biopha.2022.113020","BIOCHEMISTRY DIVISION, CHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;ORGANIC CHEMISTRY DIVISION, CHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;BIOCHEMISTRY DIVISION, CHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF SCIENCE, TAIF UNIVERSITY, P.O.BOX 11099, TAIF, 21944, SAUDI ARABIA;DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF SCIENCE, TAIF UNIVERSITY, P.O.BOX 11099, TAIF, 21944, SAUDI ARABIA;PHARMACOLOGY DEPARTMENT & HEALTH RESEARCH UNIT, MEDICAL COLLEGE, JOUF UNIVERSITY, JOUF, SAUDI ARABIA, PHARMACOLOGY DEPARTMENT, FACULTY OF MEDICINE, BENI-SUEF UNIVERSITY, EGYPT;DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS, FACULTY OF VETERINARY MEDICINE, DAMANHOUR UNIVERSITY, DAMANHOUR, 22511, EGYPT;DEPARTMENT OF HISTOLOGY AND CYTOLOGY, FACULTY OF VETERINARY MEDICINE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44511, EGYPT, LABORATORY OF ANATOMY, DEPARTMENT OF BASIC VETERINARY SCIENCES, FACULTY OF VETERINARY MEDICINE, HOKKAIDO UNIVERSITY, SAPPORO, 060-0818, JAPAN","LIVER FIBROSIS IS A PREVALENT LIVER DISEASE THAT REQUIRES RAPID AND EFFECTIVE TREATMENT PRIOR TO ITS PROGRESSION TO CIRRHOSIS AND LIVER DAMAGE. RECENTLY, SEVERAL REPORTS HAVE INVESTIGATED THE EFFICACY OF PHYTOTHERAPY USING NATURAL HERBAL EXTRACTS RATHER THAN SYNTHETIC DRUGS TO TREAT SEVERAL LIVER DISEASES. POLICOSANOL IS A HERBAL EXTRACT USED TO TREAT PATIENTS WITH CARDIOVASCULAR. HOWEVER, ITS THERAPEUTIC EFFECT ON LIVER FIBROSIS IS STILL UNKNOWN. THEREFORE, THE PRESENT STUDY AIMED TO ASSESS THE POTENTIAL ANTIFIBROTIC EFFECT OF POLICOSANOL COMPARED TO SILYMARIN AND THE POSSIBLE UNDERLYING MOLECULAR MECHANISMS. RATS WERE CATEGORIZED INTO FOUR GROUPS; NEGATIVE CONTROL GROUP ""NCG"", THE FIBROTIC GROUP ""FG"", SILYMARIN TREATED GROUP ""STG"", AND POLICOSANOL TREATED GROUP ""PTG"". SERUM LIVER ENZYMES, OXIDATIVE STRESS MARKERS, ANGIOGENIC GROWTH FACTORS, AND PRO-INFLAMMATORY CYTOKINES WERE MEASURED BIOCHEMICALLY. THE RELATIVE MRNA EXPRESSIONS OF LIVER CASPASE-3 AND ALPHA-SMOOTH MUSCLE ACTIN (Α-SMA) WERE ASSESSED. IMMUNOHISTOCHEMICAL STAINING WAS CARRIED OUT USING ANTI- Α-SMA, AND ANTI-CASPASE-3 ANTIBODIES. COMPARED TO NCG, THE FG GROUP DEMONSTRATED A SIGNIFICANT DECREASE IN THE LEVEL OF SERUM LIVER ENZYMES ""GSH, TAC, AND SDF. NEVERTHELESS, IT DEMONSTRATEDA SIGNIFICANT INCREASE IN THE LEVEL OF PRO-INFLAMMATORY CYTOKINES ""IL-6, TNF""; OXIDATIVE STRESS MARKERS ""NO, MDA"", AND ANGIOGENIC GROWTH FACTORS “VEGF AND PDGF” AND THE EXPRESSION OF Α-SMA, AND CASPASE-3. INTERESTINGLY, THE VALUES OF THESE MEASUREMENTS WERE RESTORED TO NORMAL LEVELS IN THE TREATED GROUPS, PARTICULARLY THE PTG. IN CONCLUSION, OUR DATA REVEALED THE BENEFICIAL EFFECTS OF CO-ADMINISTRATION OF POLICOSANOL OR SILYMARIN ON THE FIBROTIC LIVER RAT MODEL AND THUS COULD BE A PROMISING NATURAL THERAPEUTIC DRUG. © 2022 THE AUTHORS","CASPASE-3; CCL4; LIVER ENZYMES; LIVER FIBROSIS; POLICOSANOL; SILYMARIN","ANIMALS; ANTIOXIDANTS; BIOMARKERS; CARBON TETRACHLORIDE; CASPASE 3; CYTOKINES; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FIBROSIS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; RATS; SILYMARIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA SMOOTH MUSCLE ACTIN; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; CASPASE 3; CYTOKINE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; INTERLEUKIN 6; LIVER ENZYME; MALONALDEHYDE; MESSENGER RNA; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; POLICOSANOL; PROTEIN ANTIBODY; SILYMARIN; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ANTIOXIDANT; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; CASPASE 3; CYTOKINE; FATTY ALCOHOL; POLICOSANOL; SILYMARIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; ANTIFIBROTIC ACTIVITY; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; GENE EXPRESSION LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MOLECULAR BIOLOGY; MRNA EXPRESSION LEVEL; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION LEVEL; RAT; ANIMAL; DIETARY SUPPLEMENT; FIBROSIS; HUMAN; LIVER; LIVER CIRRHOSIS; LIVER DISEASE; METABOLISM","TAIF UNIVERSITY, TU, (TURSP-2020/38)","THIS RESEARCH WAS FUNDED BY TAIF UNIVERSITY RESEARCHERS SUPPORTING PROJECT NUMBER ( TURSP-2020/38 ), TAIF UNIVERSITY, TAIF, SAUDI ARABIA.","SERAG W.M., ELSAYED B.E., DETECTION OF LIVER FIBROSIS STAGES IN PATIENTS WITH HEPATITIS C VIRUS INFECTION BY NON-INVASIVE TOOL, EGYPT. LIVER J., 11, 1, (2021); OMARA E., EL-TOUMY S., SHABANA M., FARRAG A.-R., NADA S., SHAFEE N., PP. 129-143, (2018); SHARMA A., NAGALLI S., CHRONIC LIVER DISEASE, (2021); CLICHICI S., OLTEANU D., NAGY A.L., OROS A., FILIP A., MIRCEA P.A., SILYMARIN INHIBITS THE PROGRESSION OF FIBROSIS IN THE EARLY STAGES OF LIVER INJURY IN CCL(4)-TREATED RATS, J. MED. FOOD, 18, 3, PP. 290-298, (2015); XU Y., GUO W., ZHANG C., CHEN F., TAN H.Y., LI S., WANG N., FENG Y., HERBAL MEDICINE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASES-EFFICACY, ACTION MECHANISM, AND CLINICAL APPLICATION, FRONT. PHARMACOL., 11, (2020); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED., 45, PP. 89-97, (2019); KIM S.-J., YADAV D., PARK H.-J., KIM J.-R., CHO K.-H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL., 9, (2018); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED., 39, 4, PP. 889-899, (2017); CHO K.H., YADAV D., KIM S.J., KIM J.R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, 5, (2018); CAI X., WANG J., WANG J., ZHOU Q., YANG B., HE Q., WENG Q., INTERCELLULAR CROSSTALK OF HEPATIC STELLATE CELLS IN LIVER FIBROSIS: NEW INSIGHTS INTO THERAPY, PHARMACOL. RES., 155, (2020); RAMOS-TOVAR E., MURIEL P., MOLECULAR MECHANISMS THAT LINK OXIDATIVE STRESS, INFLAMMATION, AND FIBROSIS IN THE LIVER, ANTIOXIDANTS, 9, 12, (2020); GANDHI C.R., OXIDATIVE STRESS AND HEPATIC STELLATE CELLS: A PARADOXICAL RELATIONSHIP, TRENDS CELL MOL. BIOL., 7, PP. 1-10, (2012); LIU Y., WEN X.M., LUI E.L.H., FRIEDMAN S.L., CUI W., HO N.P.S., LI L., YE T., FAN S.T., ZHANG H., THERAPEUTIC TARGETING OF THE PDGF AND TGF-Β-SIGNALING PATHWAYS IN HEPATIC STELLATE CELLS BY PTK787/ZK22258, LAB. INVESTIG., 89, 10, PP. 1152-1160, (2009); ARORA M.K., PANDEY S., TOMAR R., SAHOO J., KUMAR D., JANGRA A., THERAPEUTIC POTENTIAL OF POLICOSANOL IN THE CONCURRENT MANAGEMENT OF DYSLIPIDEMIA AND NON-ALCOHOLIC FATTY LIVER DISEASE, FUTURE J. PHARM. SCI., 8, 1, (2022); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL. BEHAV., 67, 1, PP. 1-7, (1999); MCCARTY M.F., AN EZETIMIBE-POLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTS, MED. HYPOTHESES, 64, 3, PP. 636-645, (2005); OHTA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, J. CLIN. BIOCHEM. NUTR., 42, 2, PP. 118-125, (2008); SAYED H.E.S.A.E., MORSY L.E.S., EMARA T., GALHOM R.A.J.T.E.J.H.M., EFFECT OF CARBON TETRACHLORIDE (CCL4) ON LIVER IN ADULT ALBINO RATS: HISTOLOGICAL STUDY, EGYPT. J. HOSP. MED., 76, PP. 4254-4261, (2019); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., CORRECTION: CHO, K.H., ET AL. BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); CROWLEY L.V., THE REITMAN-FRANKEL COLORIMETRIC TRANSAMINASE PROCEDURE IN SUSPECTED MYOCARDIAL INFARCTION, CLIN. CHEM., 13, 6, PP. 482-487, (1967); BELFIELD A., GOLDBERG D.M., HUMAN SERUM GLUCOSE-6-PHOSPHATASE ACTIVITY: CONFIRMATION OF ITS PRESENCE AND LACK OF DIAGNOSTIC VALUE, CLIN. CHIM. ACTA; INT. J. CLIN. CHEM., 31, 1, PP. 81-85, (1971); CHIUEH C.C., HONG J.S., LEONG S.K., S.F.N. MEETING, NITRIC OXIDE: NOVEL ACTIONS, DELETERIOUS EFFECTS, AND CLINICAL POTENTIAL, (2002); AHMED A.E., HASSAN M.H., RASHWAN N.I., SAYED M.M., MEKI A.M.A., MYOCARDIAL INJURY INDUCED BY SCORPION STING ENVENOMING AND EVIDENCE OF OXIDATIVE STRESS IN EGYPTIAN CHILDREN, TOXICON OFF. J. INT. SOC. TOXINOL., 153, PP. 72-77, (2018); FISCHER A.H., JACOBSON K.A., ROSE J., ZELLER R., HEMATOXYLIN AND EOSIN STAINING OF TISSUE AND CELL SECTIONS, CSH PROTOC., 2008, (2008); ELEWA Y.H., BAREEDY M.H., ABU AL ATTA A.A., ICHII O., OTSUKA S., KANAZAWA T., LEE S.-H., HASHIMOTO Y., KON Y., CYTOARCHITECTURAL DIFFERENCES OF MYOEPITHELIAL CELLS AMONG GOAT MAJOR SALIVARY GLANDS, VET. RES. COMMUN., 34, 6, PP. 557-567, (2010); ELEWA Y.H.A., ICHII O., NAKAMURA T., KON Y., DUAL EFFECT OF BLEOMYCIN ON HISTOPATHOLOGICAL FEATURESOF LUNGS AND MEDIASTINAL FAT-ASSOCIATED LYMPHOID CLUSTERS IN AN AUTOIMMUNE DISEASE MOUSE MODEL, FRONT. IMMUNOL., 12, 2723, (2021); MEHTA P., REDDIVARI A.K.R., HEPATITIS, (2021); SAWAF B., ALI A.H., JAAFAR R.F., KANSO M., MUKHERJI D., KHALIFE M.J., FARAJ W., SPECTRUM OF LIVER DISEASES IN PATIENTS REFERRED FOR FIBROSCAN: A SINGLE CENTER EXPERIENCE IN THE MIDDLE EAST, ANN. MED. SURG., 57, 2020, PP. 166-170, (2012); ZHAO J., QI Y.-F., YU Y.-R., STAT3: A KEY REGULATOR IN LIVER FIBROSIS, ANN. HEPATOL., 21, (2021); SCHAEFER T.J., JOHN S., ACUTE HEPATITIS, (2021); ELNFARAWY A.A., NASHY A.E., ABOZAID A.M., KOMBER I.F., ELWESHAHY R.H., ABDELRAHMAN R.S., VINPOCETINE ATTENUATES THIOACETAMIDE-INDUCED LIVER FIBROSIS IN RATS, HUM. EXP. TOXICOL., 40, 2, PP. 355-368, (2020); EL-TOUMY S.A., SALIB J.Y., EL-KASHAK W.A., MARTY C., BEDOUX G., BOURGOUGNON N., ANTIVIRAL EFFECT OF POLYPHENOL RICH PLANT EXTRACTS ON HERPES SIMPLEX VIRUS TYPE 1, FOOD SCI. HUM. WELLNESS, 7, 1, PP. 91-101, (2018); WANG M., ZHANG X.J., FENG R., JIANG Y., ZHANG D.Y., HE C., LI P., WAN J.B., HEPATOPROTECTIVE PROPERTIES OF PENTHORUM CHINENSE PURSH AGAINST CARBON TETRACHLORIDE-INDUCED ACUTE LIVER INJURY IN MICE, CHIN. MED., 12, (2017); DAMIRIS K., TAFESH Z.H., PYRSOPOULOS N., EFFICACY AND SAFETY OF ANTI-HEPATIC FIBROSIS DRUGS, WORLD J. GASTROENTEROL., 26, 41, PP. 6304-6321, (2020); YIN K., LI X., LUO X., SHA Y., GONG P., GU J., TAN R., HEPATOPROTECTIVE EFFECT AND POTENTIAL MECHANISM OF AQUEOUS EXTRACT FROM PHYLLANTHUS EMBLICA ON CARBON-TETRACHLORIDE-INDUCED LIVER FIBROSIS IN RATS, EVID. BASED COMPLEMENT. ALTERN. MED. ECAM, (2021); GAO L.-J., ZHU Y.-Q., XU L., MECHANISMS OF PROTECTIVE EFFECTS OF ASTAXANTHIN IN NONALCOHOLIC FATTY LIVER DISEASE, HEPATOMA RES., 7, (2021); LIN L., QUE R., SHEN Y., CHEN Y., YAN N., LI Y., SAIKOSAPONIN‑D ALLEVIATES CARBON‑TETRACHLORIDE INDUCED ACUTE HEPATOCELLULAR INJURY BY INHIBITING OXIDATIVE STRESS AND NLRP3 INFLAMMASOME ACTIVATION IN THE HL‑7702 CELL LINE, MOL. MED. REP., 17, 6, PP. 7939-7946, (2018); FORLANO R., MULLISH B.H., NATHWANI R., DHAR A., THURSZ M.R., MANOUSOU P., NON-ALCOHOLIC FATTY LIVER DISEASE AND VASCULAR DISEASE, CURR. VASC. PHARMACOL., 19, 3, PP. 269-279, (2021); MUSSBACHER M., BRUNNTHALER L., PANHUBER A., STARLINGER P., ASSINGER A., TILL DEATH DO US PART-THE MULTIFACETED ROLE OF PLATELETS IN LIVER DISEASES, INT. J. MOL. SCI., 22, 6, (2021); LIEPELT A., TACKE F., STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AS A TARGET IN LIVER DISEASES, AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., 311, 2, PP. G203-G209, (2016); KHANAM A., SALEEB P.G., KOTTILIL S., PATHOPHYSIOLOGY AND TREATMENT OPTIONS FOR HEPATIC FIBROSIS: CAN IT BE COMPLETELY CURED?, CELLS, 10, 5, (2021); TSAI J.H., LIU J.Y., WU T.T., HO P.C., HUANG C.Y., SHYU J.C., HSIEH Y.S., TSAI C.C., LIU Y.C., EFFECTS OF SILYMARIN ON THE RESOLUTION OF LIVER FIBROSIS INDUCED BY CARBON TETRACHLORIDE IN RATS, J. VIRAL HEPAT., 15, 7, PP. 508-514, (2008); COHEN G.M., CASPASES: THE EXECUTIONERS OF APOPTOSIS, BIOCHEM. J., 326, PP. 1-16, (1997); NOA M., MENDOZA S., MAS R., MENDOZA N., EFFECT OF POLICOSANOL ON CARBON TETRACHLORIDE-INDUCED ACUTE LIVER DAMAGE IN SPRAGUE-DAWLEY RATS, DRUGS RD, 4, 1, PP. 29-35, (2003)","Y.H.A. ELEWA; LABORATORY OF ANATOMY, BASIC VETERINARY SCIENCES, FACULTY OF VETERINARY MEDICINE, HOKKAIDO UNIVERSITY, SAPPORO, KITA18-NISHI 9, KITA-KU, HOKKAIDO, 060-0818, JAPAN; EMAIL: Y-ELEWA@VETMED.HOKUDAI.AC.JP","ELSEVIER MASSON S.R.L.","ENGLISH","BIOMED. PHARMACOTHER.","ARTICLE","ISI","2-S2.0-85129333793","BIOMED PHARMACOTHER","ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;TAIF UNIVERSITY;TAIF UNIVERSITY;JOUF UNIVERSITY;DAMANHOUR UNIVERSITY;ZAGAZIG UNIVERSITY","NOTREPORTED;HOKKAIDO UNIVERSITY;NOTREPORTED",NA,"ZEIN N, 2022, BIOMED PHARMACOTHER","ZEIN N, 2022, BIOMED PHARMACOTHER"
"KHUKHLINA O;HRINYUK O;LIAKHOVYCH O","KHUKHLINA, O.S. (6504590908); HRINYUK, O.YE. (58481354900); LIAKHOVYCH, O.D. (57211213274)","INTENSITY OF SYSTEMIC PROTEOLYSIS AND ENDOTOXICOSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS ASSOCIATED WITH OBESITY AND COMORBID CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE DYNAMICS OF TREATMENT WITH HEPATOPROTECTORS",2020,"GASTROENTEROLOGY (UKRAINE)","54","5",1,"10.22141/2308-2097.54.2.2020.206228","BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE;BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE;BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE","BACKGROUND. THE PREVALENCE OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS GAINING GLOBAL SIGNIFICANCE IN THE POPULATION OF ECONOMICALLY DEVELOPED COUNTRIES WITH A GROWING TREND IN UKRAINE. THE PURPOSE WAS THE DETERMINATION OF THE INTENSITY OF SYSTEMIC PROTEOLYSIS AND ENDO GENOUS INTOXICATION BEFORE TREATMENT AND THE EFFICACY OF HEPATOPROTECTIVE THERAPY IN PATIENTS WITH NASH AGAINST THE BACKGROUND OF OBESITY, DEPENDING ON THE COMORBIDITY OF COPD. MATERIALS AND METHODS. SEVENTY-SIX PATIENTS WITH NASH, GRADE 1 OBESITY AND COPD 2–3 D WERE SCREENED AND DIVIDED INTO 3 GROUPS ACCORDING TO THE TREATMENT RECEIVED. THE CONTROL GROUP (C GROUP) CONSISTED OF 23 PATIENTS RECEIVING BASIC TREATMENT FOR NASH (ESSENTIAL FATTY ACIDS COMPLEX 300 MG 2 CAPSULES 3 TIMES DAILY) FOR 30 DAYS AND BASELINE COPD THERAPY. TWENTY-FIVE PATIENTS (GROUP 2 — PRIMARY, O1), IN ADDITION TO SIMILAR COPD THERAPY, FOR THE TREATMENT OF NASH, INSTEAD OF ESSENTIAL FATTY ACIDS COMPLEX, RECEIVED ANTRAL AT A DOSE OF 200 MG 3 TIMES A DAY FOR 30 DAYS. THE THIRD GROUP (BASIC, O2) INVOLVING 28 PATIENTS WITH NASH, GRADE 1 OBESITY AND COPD 2–3 D, IN ADDITION TO SIMILAR COPD THERAPY, FOR THE TREATMENT OF NASH, INSTEAD OF ESSENTIAL FATTY ACIDS COMPLEX, RECEIVED ANTRAL AT A DOSE OF 200 MG 3 TIMES DAILY AND, ADDITIO NALLY, POLICOSANOL AT A DOSE OF 20 MG AFTER THE DINNER FOR 30 DAYS. THE COMPARISON GROUP CONSISTED OF 30 APPARENTLY HEALTHY INDIVIDUALS. RESULTS. THE PROPOSED THERAPY WITH ANTRAL REDUCED THE INTENSITY OF LYSIS OF AZOALBUMIN, AZOCASEIN AND AZOCOL IN PATIENTS OF GROUP O2: AT DAY 30, THE DECREASE WAS 1.3, 1.2 AND 1.6 TIMES (P < 0.05), RESPECTIVELY, IN PATIENTS OF THE GROUP O1: ON DAY 30, THE DECREASE WAS 1.2, 1.2 AND 1.6 TIMES (P < 0.05), RESPECTIVELY, COMPARED TO THE PRE-TREATMENT VALUES. IN THE GROUP C, THE VALUES DECREASED LESS INTENSIVELY (P < 0.05): ONLY THE AZOCOL VALUES WERE LIKELY TO CHANGE — 1.3 TIMES (P < 0.05) WITH THE PRESENCE OF A SIGNIFICANT DIFFERENCE WITH THE GROUPS O1 AND O2 (P < 0.05). CONCLUSIONS. THE COMBINED ADMINISTRATION OF ANTRAL FOR 30 DAYS RESULTED IN A SIGNIFICANT CORRECTION OF PROTEINASE-INHIBITORY HOMEOSTASIS IN PATIENTS WITH NASH ASSOCIATED WITH OBESITY AND COPD, WHICH WAS ACCOMPANIED BY A SIGNIFICANT DECREASE IN ENDOTOXICOSIS (P < 0.05) AND DAMAGING EFFECT OF SYSTEMIC PROTEOLYSIS (P < 0.05). © 2020, ZASLAVSKY PUBLISHING HOUSE. ALL RIGHTS RESERVED.","CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ENDOTOXICOSIS; NON-ALCOHOLIC STEATOHEPATITIS; PROTEOLYSIS","","","","ANOKHINA GA., NON-ALCOHOLIC LIVER DISEASE MULTI-SYSTEMIC METABOLITIC DISEASE: PREVENTION AND TREATMENT, PRAKTYKUJUCHYJ LIKAR, 7, 3, PP. 35-40, (2018); HUKHLINA OS, ANTONIV AA, MANDRYK OJE, GRYNJUK OJE., NEALKOGOL'NA ZHYROVA HVOROBA PECHINKY TA KOMORBIDNI STANY: OS-OBLYVOSTI PATOGENEZU, KLINIKY, DIAGNOSTYKY, LIKUVANNJA: KOLEKTYVNA MONOGRAFIJA NON-ALCOHOLIC FATTY LIVER DISEASE AND COMORBID CON-DITIONS: FEATURES OF PATHOGENESIS, CLINIC, DIAGNOSIS, TREATMENT: COL-LECTIVE MONOGRAPH, PP. 58-61, (2018); KOBYLIAK NM, DYNNYK OB, KYRIIENKO DV., CURRENT APPROACHES TO THE DIAGNOSIS AND SCREENING FOR METABOLIC DISORDERS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE, MÌŽNARODNIJ ENDOKRINOLOGÌČNIJ ŽURNAL, 5, 69, PP. 89-99, (2015); YOUNOSSI ZM, BLISSETT D, BLISSETT R, ET AL., THE ECONOMIC AND CLINICAL BURDEN OF NONALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES AND EUROPE, HEPATOLOGY, 64, 5, PP. 1577-1586, (2016); FRIEDMAN SL, NEUSCHWANDER-TETRI BA, RINELLA M, SANYAL AJ., MECHANISMS OF NAFLD DEVELOPMENT AND THERAPEUTIC STRAT-EGIES, NAT MED, 24, 7, PP. 908-922, (2018); RINELLA ME., NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW, JAMA, 313, 22, PP. 2263-2273, (2015); EASL-EASD-EASO CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, OBES FACTS, 9, 2, PP. 65-90, (2016); ARMSTRONG MJ, HULL D, GUO K, ET AL., GLUCAGON-LIKE PEPTIDE 1 DECREASES LIPOTOXICITY IN NON-ALCOHOLIC STEATOHEPATITIS, J HEPATOL, 64, 2, PP. 399-408, (2016); JOY TR, MCKENZIE CA, TIRONA RG, ET AL., SITAGLIPTIN IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL, WORLD J GASTROENTEROL, 23, 1, PP. 141-150, (2017); SINGH S, KHERA R, ALLEN AM, MURAD MH, LOOMBA R., COMPARATIVE EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR NONALCOHOLIC STEATOHEPATITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS, HEPATOLOGY, 62, 5, PP. 1417-1432, (2015); SADIKOVA SI, TAGAEVA MH, DZHALILOVA SH, RUSTAMO-VA MT., CHRONIC DISEASES OF THE LIVER OF VIRAL ETIOLOGY-MODERN PRINCIPLES OF THERAPY WITH ANTRAL, TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI, 2, PP. 85-88, (2015); KUZMINOV BP, MATYSIK SI, ZAZULIAK TS, MYKYTCHAK TI., EVALUATION OF ANTRAL HEPATOPROTECTOR. ACUTE TOXICITY IN ALTERNATIVE TEST-SYSTEMS, DOVKILLIA TA ZDOROVIA, 2, PP. 43-46, (2016); DROGOVOZ SM, MISHCHENKO OYA, КАLKO KO, BOGDAN NS, GERUSH OV., CIRCADIAN DEVELOPMENTAL RHYTHMS OF THE EXPERIMENTAL PARACETAMOL HEPATITIS AND THE EFFECT OF HEPATOPROTECTORS ON THE ACTIVITY OF PRO-OXIDATIVE/ANTIOXIDANT AND CYTOLYTIC PROCESSES, CLINICAL PHARMACY, 23, 2, PP. 15-24, (2019); MARINANGELI CP, JONES PJ, KASSIS AN, ESKIN MN., POLICO-SANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, 3, PP. 259-267, (2010); CHALASANI N, YOUNOSSI Z, LAVINE JE, ET AL., THE DIAGNOSIS AND MANAGEMENT OF NONALCOHOLIC FATTY LIVER DISEASE: PRACTICE GUIDANCE FROM THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES, HEPATOLOGY, 67, 1, PP. 328-357, (2018); LABENZ C, HUBER Y, KALLIGA E, ET AL., PREDICTORS OF AD- VANCED FIBROSIS IN NON-CIRRHOTIC NON-ALCOHOLIC FATTY LIVER DISEASE IN GERMANY, ALIMENT PHARMACOL THER, 48, 10, PP. 1109-1116, (2018); KOLISHETSKA MA, VESKLYAROVA UP, ZASTRYZHNA ML., ASTH-MA: SHIFT SOME INDICATORS PROTEINASE-INHIBITORY SYSTEM IN THE LUNGS OF GUINEA PIGS AND THEIR CORRECTION OF THIOTRIAZOLIN, J EDUC HEALTH SPORT, 7, 2, PP. 328-336, (2017); MANTOVANI A, BYRNE CD, BONORA E, TARGHER G., NONALCOHOLIC FATTY LIVER DISEASE AND RISK OF INCIDENT TYPE 2 DIABETES: A META-ANALYSIS, DIABETES CARE, 41, 2, PP. 372-382, (2018); КRYSKIV OI, KUZIV PP, BABINETS LS., PROTEOLYSIS IN CONDI-TIONS OF TRADITIONAL TREATMENT AND CALORIE RESTRICTION DIET, ACHIEVE-MENTS OF CLINICAL AND EXPERIMENTAL MEDICINE, 4, PP. 69-73, (2018); PANG J, XU W, ZHANG X, ET AL., SIGNIFICANT POSITIVE ASSOCIATION OF ENDOTOXEMIA WITH HISTOLOGICAL SEVERITY IN 237 PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE, ALIMENT PHARMACOL THER, 46, 2, PP. 175-182, (2017); VIGLINO D, JULLIAN-DESAYES I, MINOVES M, ET AL., NONALCOHOLIC FATTY LIVER DISEASE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EUR RESPIR J, 49, 6, (2017); SINGH D, AGUSTI A, ANZUETO A, ET AL., GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE LUNG DISEASE: THE GOLD SCIENCE COMMITTEE REPORT 2019, EUR RESPIR J, 53, 5, (2019); ANOHINA GA, HARCHENKO VV, DYNNYK OB., THE ROLE OF INFLAMMATION AND METABOLIC DISORDERS IN THE PROGRESSION OF CHRONIC LIVER DISEASES: PREVENTION AND TREATMENT, ZDOROV’JA UKRAI'NY, 436-437, PP. 60-62, (2018); RYVAK TB, KOVAL AYA., STUDY OF THE ATTITUDE AMONG THE POPULATION TO SELF-TREATMENT WITH HEPATOTROPIC DRUGS, GEPATOLO-GIA, 1, PP. 35-46, (2019)","O.YE. HRINYUK; BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE; EMAIL: HRYNIUK.OLHA@GMAIL.COM","ZASLAVSKY PUBLISHING HOUSE","ENGLISH","GASTROENTEROLOGY.","ARTICLE","ISI","2-S2.0-85164408745","GASTROENTEROLOGY","BUKOVINIAN STATE MEDICAL UNIVERSITY;BUKOVINIAN STATE MEDICAL UNIVERSITY;BUKOVINIAN STATE MEDICAL UNIVERSITY","NOTREPORTED;BUKOVINIAN STATE MEDICAL UNIVERSITY;NOTREPORTED",NA,"KHUKHLINA OS, 2020, GASTROENTEROLOGY","KHUKHLINA OS, 2020, GASTROENTEROLOGY"
"BRIGHENTI V;VENTURELLI A;CAROLI C;ANCESCHI L;GJIKOLAJ M;DURANTE C;PELLATI F","BRIGHENTI, VIRGINIA (56162712900); VENTURELLI, ALBERTO (6603423752); CAROLI, CLARISSA (57893370400); ANCESCHI, LISA (57206770148); GJIKOLAJ, MEGI (58480049700); DURANTE, CATERINA (11939877300); PELLATI, FEDERICA (6507646450)","AN INNOVATIVE METHOD FOR THE EXTRACTION AND HPLC ANALYSIS OF BIOACTIVE POLICOSANOLS FROM NONPSYCHOACTIVE CANNABIS SATIVA L",2023,"JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS","234","",2,"10.1016/j.jpba.2023.115547","DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY;DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY;DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY, CLINICAL AND EXPERIMENTAL MEDICINE PHD PROGRAM, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA CAMPI 287, MODENA, 41125, ITALY;DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY, CLINICAL AND EXPERIMENTAL MEDICINE PHD PROGRAM, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA CAMPI 287, MODENA, 41125, ITALY;DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY;DEPARTMENT OF CHEMICAL AND GEOLOGICAL SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY;DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY","POLICOSANOLS (PCS) REFER TO A MIXTURE OF LONG-CHAIN ALIPHATIC ALCOHOLS. SUGAR CANE IS THE MAIN INDUSTRIAL SOURCE OF PCS, BUT OTHERS, INCLUDING BEESWAX AND CANNABIS SATIVA L., ARE ALSO KNOWN. IN THE RAW MATERIAL PCS ARE BONDED TO FATTY ACIDS TO FORM LONG-CHAIN ESTERS, KNOWN AS WAXES. PCS ARE MAINLY USED AS A CHOLESTEROL-LOWERING PRODUCT, EVEN THOUGH THEIR EFFICACY IS CONTROVERSIAL. MORE RECENTLY, THE PHARMACOLOGICAL INTEREST IN PCS HAS INCREASED, AS THEY HAVE BEEN INVESTIGATED AS ANTIOXIDANT, ANTI-INFLAMMATORY AND ANTI-PROLIFERATIVE AGENTS. GIVEN THEIR PROMISING BIOLOGICAL IMPLICATIONS, THE DEVELOPMENT OF EFFICIENT EXTRACTION AND ANALYTICAL METHODOLOGIES FOR THE DETERMINATION OF PCS IS EXTREMELY IMPORTANT TO IDENTIFY NEW POTENTIAL SOURCES OF THESE COMPOUNDS AND TO ENSURE THE REPRODUCIBILITY OF BIOLOGICAL DATA. CONVENTIONAL TECHNIQUES USED FOR THE EXTRACTION OF PCS INVOLVE TIME-CONSUMING APPROACHES LEADING TO LOW YIELDS, WHILE ANALYTICAL METHODS FOR THEIR QUANTIFICATION ARE BASED ON GAS-CHROMATOGRAPHIC (GC) TECHNIQUES, WHICH REQUIRE AN ADDITIONAL DERIVATIZATION STEP DURING THE SAMPLE PREPARATION TO INCREASE THEIR VOLATILITY. IN THE LIGHT OF ALL THE ABOVE, THIS WORK WAS AIMED AT THE DEVELOPMENT OF AN INNOVATIVE METHOD FOR THE EXTRACTION OF PCS FROM NON-PSYCHOACTIVE C. SATIVA (HEMP) INFLORESCENCES, TAKING ADVANTAGE OF THE MICROWAVE-ASSISTED TECHNOLOGY. IN ADDITION, A NEW ANALYTICAL METHOD BASED ON HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) COUPLED WITH AN EVAPORATIVE LIGHT SCATTERING DETECTOR (ELSD) WAS DEVELOPED FOR THE FIRST TIME FOR BOTH THE QUALITATIVE AND QUANTITATIVE ANALYSIS OF THESE COMPOUNDS IN THE EXTRACTS. THE METHOD WAS VALIDATED ACCORDING TO ICH GUIDELINES, AND IT WAS APPLIED TO THE ANALYSIS OF PCS IN HEMP INFLORESCENCES BELONGING TO DIFFERENT VARIETIES. THE RESULTS WERE ANALYZED USING PRINCIPAL COMPONENT ANALYSIS (PCA) AND HIERARCHICAL CLUSTERING ANALYSIS TO RAPIDLY IDENTIFY SAMPLES WITH THE HIGHEST CONTENT OF PCS, WHICH MIGHT FIND AN APPLICATION AS ALTERNATIVE SOURCES OF THESE BIOACTIVE COMPOUNDS IN BOTH THE PHARMACEUTICAL AND NUTRACEUTICAL FIELDS. © 2023 ELSEVIER B.V.","CANNABIS SATIVA L.; DATA ANALYSIS; ELSD; EXTRACTION; HEMP; HPLC; POLICOSANOLS","CANNABINOIDS; CANNABIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; REPRODUCIBILITY OF RESULTS; POLICOSANOL; CANNABINOID; CANNABIS; POLICOSANOL; ANALYTIC METHOD; ARTICLE; CANNABIS SATIVA; DERIVATIZATION; DRUG ISOLATION; GAS CHROMATOGRAPHY; HIERARCHICAL CLUSTERING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLORESCENCE; LIGHT SCATTERING; LIMIT OF QUANTITATION; MICROWAVE ASSISTED EXTRACTION; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY","","","WEERAWATANAKORN M., MEEROD K., WONGWAIWECH D., HO C.-T., POLICOSANOLS: CHEMISTRY, OCCURRENCE, AND HEALTH EFFECTS, CURR. PHARMACOL. REP., 5, PP. 131-149, (2019); MONTONE C.M., AITA S.E., CANNAZZA G., CAVALIERE C., CARRATO A., CITTI C., MONDELLO L., PIOVESANA S., LAGANA A., CAPRIOTTI A.L., TARGETED AND UNTARGETED CHARACTERIZATION OF UNDERIVATIZED POLICOSANOLS IN HEMP INFLORESCENCE BY LIQUID CHROMATOGRAPHY-HIGH RESOLUTION MASS SPECTROMETRY, TALANTA, 235, (2021); ARTECHE-HIDALGO L., FERNANDEZ-TRAVIESO J.C., SUAREZ-CAMEJO N., MARIN-PREVAL J., ALVAREZ-ACOSTA V., CHAVIANO-PEREIRA J., GARCIA-SANCHEZ M., ESQUIVEL-MOINELO I., DIAZ-GONZALEZ M., MATOS-REYES O., FERNANDEZ-DORTA L., ILLNAIT-FERRER J., MENDOZA-CASTANO S., MONZON-PEREZ M., SANCHEZ PEDROSO V., EFFECTS OF POLICOSANOL IN PATIENTS WITH METABOLIC SYNDROME: A SIX-MONTH STUDY, J. ENDOCRINOL. METAB., 10, PP. 36-44, (2020); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); OSADNIK T., GOLAWSKI M., LEWANDOWSKI P., MORZE J., OSADNIK K., PAWLAS N., LEJAWA M., JAKUBIAK G.K., MAZUR A., SCHWINGSCHACKL L., GASIOR M., BANACH M., A NETWORK META-ANALYSIS ON THE COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE IN ADULTS, PHARMACOL. RES., 183, (2022); JANG Y., KIM D., HAN E., JUNG J., PHYSIOLOGICAL ACTIVITIES OF POLICOSANOL EXTRACTED FROM SUGARCANE WAX, NAT. PROD. SCI., 25, PP. 293-297, (2019); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS., 17, (2018); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI., 24, (2023); SAFARI S., MIRAZI N., AHMADI N., ASADBEGI M., NOURIAN A., GHADERI S., RASHNO M., KOMAKI A., THE PROTECTIVE EFFECTS OF POLICOSANOL ON LEARNING AND MEMORY IMPAIRMENTS IN A MALE RAT MODEL OF ALZHEIMER'S DISEASE, MOL. NEUROBIOL., 60, PP. 2507-2519, (2023); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ZHAO M., GAN J., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); LEE S., LEE G.S., MOON J.H., JUNG J., POLICOSANOL SUPPRESSES TUMOR PROGRESSION IN A GASTRIC CANCER XENOGRAFT MODEL, TOXICOL. RES., 38, PP. 567-575, (2022); RAGHAVAN P.R., METADICHOL®: A NOVEL NANOLIPID FORMULATION THAT INHIBITS SARS-COV-2 AND A MULTITUDE OF PATHOLOGICAL VIRUSES IN VITRO, BIOMED. RES. INT, (2022); KAMCHONEMENUKOOL S., HO C.-T., BOONNOUN P., LI S., PAN M.-H., KLANGPETCH W., WEERAWATANAKORN M., HIGH LEVELS OF POLICOSANOLS AND PHYTOSTEROLS FROM SUGAR MILL WASTE BY SUBCRITICAL LIQUEFIED DIMETHYL ETHER, FOODS, 11, (2022); VENTURELLI A., BRIGHENTI V., MARCOLO D., PELLATI F., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL., 172, PP. 200-205, (2019); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); WONGWAIWECH D., KAMCHONEMENUKOOL S., HO C.-T., ANALYTICAL PROCEDURAL VALIDATION OF POLICOSANOL COMPOUNDS, FOOD ANAL. METHODS, 15, PP. 2059-2068, (2022); SRISAIPET A., LUANGPITAK P., POTISEN P., THE POLICOSANOL EXTRACTION AND COMPOSITION CHARACTERIZATION FROM WHEAT STRAW BY-PRODUCT OF THAI WHEAT VARIETY, INT. J. FOOD ENG., 2, PP. 99-103, (2019); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR. J. LIPID SCI. TECHNOL., 114, PP. 583-591, (2012); SUT S., FRANCESCHI C., PERON G., POLONIATO G., DALL'ACQUA S., DEVELOPMENT AND VALIDATION OF AN HPLC-ELSD METHOD FOR THE QUANTIFICATION OF 1-TRIACONTANOL IN SOLID AND LIQUID SAMPLES, MOLECULES, 23, (2018); (2022); LI VIGNI M., DURANTE C., COCCHI M., EXPLORATORY DATA ANALYSIS, DATA HANDLING IN SCIENCE AND TECHNOLOGY, PP. 55-126, (2013)","F. PELLATI; DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, MODENA, VIA G. CAMPI 103, 41125, ITALY; EMAIL: FEDERICA.PELLATI@UNIMORE.IT","ELSEVIER B.V.","ENGLISH","J. PHARM. BIOMED. ANAL.","ARTICLE","ISI","2-S2.0-85164345484","J PHARM BIOMED ANAL","UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF MODENA AND REGGIO EMILIA","NOTREPORTED;UNIVERSITY OF MODENA AND REGGIO EMILIA;NOTREPORTED",NA,"BRIGHENTI V, 2023, J PHARM BIOMED ANAL","BRIGHENTI V, 2023, J PHARM BIOMED ANAL"
"DA P C;NATOLINO A","DA PORTO, CARLA (6602735041); NATOLINO, ANDREA (36647764200)","POLICOSANOLS FROM GRAPE MARC A NEW STEP TOWARDS A SUSTAINABLE BIOREFINERY FOR THE WINE INDUSTRY BY SCCO2 EXTRACTION",2024,"JOURNAL OF CO2 UTILIZATION","82","",0,"10.1016/j.jcou.2024.102762","UNIVERSITY OF UDINE, DEPARTMENT OF AGRIFOOD, ENVIRONMENTAL AND ANIMAL SCIENCES, UDINE, 33100, ITALY;UNIVERSITY OF UDINE, DEPARTMENT OF AGRIFOOD, ENVIRONMENTAL AND ANIMAL SCIENCES, UDINE, 33100, ITALY","SUPERCRITICAL CARBON DIOXIDE (SC-CO2) EXTRACTION OF POLICOSANOL (PC) FROM GRAPE MARC WAS INVESTIGATED FOR THE FIRST TIME. EMPLOYING THE BROKEN PLUS INTACT CELLS (BIC) MODEL (SOVOVÁ'S MODEL) THE INVESTIGATION FOCUSED ON ANALYZING THE SC-CO2 PROCESS TO EXTRACT THE NONPOLAR FRACTION FROM GRAPE MARC EFFICIENTLY. OPERATING CONDITIONS FOR SC-CO2 EXTRACTION—280 BAR PRESSURE, 70 °C TEMPERATURE, AND A FLOW RATE OF 10 KGCO2/H—YIELDED THE HIGHEST POLICOSANOL CONTENT. THE EXTRACTED POLICOSANOL RANGED BETWEEN 3922 AND 4083 MG/KGDM, CONSTITUTING APPROXIMATELY 8 % OF THE TOTAL EXTRACTION YIELD. SURPRISINGLY, THIS AMOUNT OF PC WAS OF THE SAME ORDER OF MAGNITUDE FOUND IN BEESWAX YELLOW, A WELL-KNOWN RICH NATURAL SOURCE OF PC. THE PRIMARY ALIPHATIC ALCOHOLS FOUND IN THE PC FROM GRAPE MARC WERE HEXACOSANOL, OCTACOSANOL, AND TRIACONTANOL. THESE FINDINGS WERE CONSISTENT WITH GRAPE MARC SAMPLES FROM OTHER ITALIAN REGIONS. FURTHERMORE, A COMPARATIVE ANALYSIS BETWEEN SC-CO2 AND SOXHLET EXTRACTION METHODS FOR PC WAS CARRIED OUT. © 2024 THE AUTHORS","ALIPHATIC ALCOHOLS; BIOREFINERY; GRAPE MARC; MATHEMATICAL MODELING; POLICOSANOL; SFE","REFINING; SUPERCRITICAL FLUID EXTRACTION; WINE; ALIPHATIC ALCOHOL; BIOREFINERIES; GRAPE MARC; INTACT CELLS; MATHEMATICAL MODELING; POLICOSANOLS; SC CO 2; SFE; SUPERCRITICAL CARBONDIOXIDES; WINE INDUSTRY; CARBON DIOXIDE","","","ATTARD T.M., MCELROY C.R., GAMMONS R.J., SLATTERY J.M., SUPANCHAIYAMAT N., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION AS AN EFFECTIVE PRETREATMENT STEP FOR WAX EXTRACTION IN A MISCANTHUS BIOREFINERY, SUSTAIN. CHEM. ENG., 4, PP. 5979-5988, (2016); ATTARD T.M., MCELROY C.R., REZENDE C.A., POLIKARPOV I., CLARK J.H., HUNT A.J., SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES, IND. CROPS PROD., 76, PP. 95-103, (2015); BERES C., COSTA G.N., CABEZUDO I., DA SILVA-JAMES N.K., TELES A.S., CRUZ A.P., FREITAS S.P., TOWARDS INTEGRAL UTILIZATION OF GRAPE POMACE FROM WINEMAKING PROCESS: A REVIEW, WASTE MANAG., 68, PP. 581-594, (2017); BLASI F., TRINGANIELLO C., VERDUCCI G., COSSIGNANI L., BIOACTIVE MINOR COMPONENTS OF ITALIAN AND EXTRA-EUROPEAN HEMP SEED OILS, LWT-FOOD SCI. TECHNOL., 158, (2022); CALIGIANI A., BONZANINI F., PALLA G., CIRLINI M., BRUNI R., CHARACTERIZATION OF A POTENTIAL NUTRACEUTICAL INGREDIENT: POMEGRANATE (PUNICA GRANATUM L.) SEED OIL UNSAPONIFIABLE FRACTION, PLANT FOOD HUM. NUTR., 65, PP. 277-283, (2010); CHEUNG P.C.K., TEMPERATURE AND PRESSURE EFFECTS ON SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF N-3 FATTY ACIDS FROM RED SEAWEED, FOOD CHEM., 65, PP. 399-403, (1999); CHOI J.S., PARK S.Y., PARK J.S., PARK S.-K., JUNK M.Y., CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA (CAMELLIA SINENSIS) LEAVES, FOOD CHEM., 204, PP. 94-101, (2016); CONFORTIN T.C., TODERO I., CANABARRO N.I., LUFT L., UGALDE G.A., NETO J.R.C., MAZUTTI M.A., ZABOT G.L., TRES M.V., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF COMPOUNDS FROM DIFFERENT AERIAL PARTS OF SENECIO BRASILIENSIS: MATHEMATICAL MODELING AND EFFECTS OF PARAMETERS ON EXTRACT QUALITY, J. SUPERCRIT. FLUIDS, 153, (2019); DA PORTO C., NATOLINO A., SCALET M., IMPROVED SUSTAINABILITY IN WINE INDUSTRY BYPRODUCTS: A SCALE-UP AND ECONOMICAL FEASIBILITY STUDY FOR HIGH-VALUE COMPOUNDS EXTRACTION USING MODIFIED SC-CO<SUB>2</SUB>, ACS OMEGA, 38, PP. 33845-33857, (2022); DE MELO M.M.R., SILVESTRE A.J.D., SILVA C.M., SUPERCRITICAL FLUID EXTRACTION OF VEGETABLE MATRICES: APPLICATIONS, TRENDS AND FUTURE PERSPECTIVES OF A CONVINCING GREEN TECHNOLOGY, J. SUPERCRIT. FLUIDS, 92, PP. 115-176, (2014); DUNFORD N.T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOUR. TECHNOL., 101, PP. 422-425, (2010); FARIAS-CAMPOMANES A.M., ROSTAGNO M.A., MEIRELES M.A.A., PRODUCTION OF POLYPHENOL EXTRACTS FROM GRAPE BAGASSE USING SUPERCRITICAL FLUIDS: YIELD, EXTRACT COMPOSITION AND ECONOMIC EVALUATION, J. SUPERCRIT. FLUIDS, 77, PP. 70-78, (2013); BRUNNER G., (1994); GAO W., LIU D., SU S., HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY FOR QUANTIFICATION OF 1-OCTACOSANOL IN ANTARCTIC KRILL (EUPHAUSIA SUPERBA DANA), J. CHROMATOGR. SCI., 53, PP. 811-815, (2015); GIUFFRE A.M., CAPOCASALE M., POLICOSANOL IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, J. OLEO SCI., 64, PP. 625-631, (2015); HAIM D., BERRIOS M., VALENZUELA A., VIDELA L.A., TRACE QUANTIFICATION OF 1-OCTACOSANOL AND 1-TRIACONTANOL AND THEIR MAIN METABOLITES IN PLASMA BY LIQUID-LIQUID EXTRACTION COUPLED WITH GAS CHROMATOGRAPHY-MASS SPECTROMETRY, J. CHROMATOGR. B, 877, PP. 4154-4158, (2009); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS., 17, 1, (2018); HUANG Z., SHI X., JIANG W., THEORETICAL MODELS FOR SUPERCRITICAL FLUID EXTRACTION, J. CHROMATOGR. A, 1250, PP. 2-26, (2012); ILYAS T., CHOWDHARY P., CHAURASIA D., GNANSOUNOU E., PANDEY A., CHATURVEDI P., SUSTAINABLE GREEN PROCESSING OF GRAPE POMACE FOR THE PRODUCTION OF VALUE-ADDED PRODUCTS: AN OVERVIEW, ENVIRON. TECHNOL. INNOV., 23, (2021); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGARCANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); JIN B., KELLY J.M., WINE INDUSTRY RESIDUES, BIOTECHNOLOGY FOR AGRO-INDUSTRIAL RESIDUES UTILISATION: UTILISATION OF AGRO-RESIDUES, PP. 293-311, (2009); JIN Q., O'KEEFE S.F., STEWART A.C., NEILSON A.P., KIM Y.T., HUANG H., TECHNO-ECONOMIC ANALYSIS OF A GRAPE POMACE BIOREFINERY: PRODUCTION OF SEED OIL, POLYPHENOLS, AND BIOCHAR, FOOD BIOPROD. PROC., 127, PP. 139-151, (2021); JUNG D.M., LEE M.J., SUK S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J. FOOD SCI., 6, PP. C891-C899, (2011); LEE H.-G., WOO S.-Y., AHN H.-J., YANG J.-Y., LEE M.-J., KIM H.-Y., SONG S.-Y., LEE J.-H., SEO W.-D., COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT (AVENA SATIVA L.) CULTIVARS AND SCREENING FOR ADENOSINE 50-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION, PLANTS, 11, (2022); LIONG K.K., WELLS P.A., FOSTER N.R., DIFFUSION OF FATTY ACID ESTERS IN SUPERCRITICAL CARBON DIOXIDE, IND. ENG. CHEM. RES., 31, PP. 390-399, (1992); LOPEZ-PADILLA A., RUIZ-RODRIGUEZ A., REGLERO G., FORNARI T., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF CALENDULA OFFICINALIS: KINETIC MODELING AND SCALING UP STUDY, J. SUPERCRIT. FLUIDS, 130, PP. 292-300, (2017); LORENZ P., BERGER M., BERTRAMS J., WENDE K., WENZEL K., NATURAL WAX CONSTITUENTS OF A SUPERCRITICAL FLUID CO2 EXTRACT FROM QUINCE (CYDONIA OBLONGA MILL.) POMACE, ANAL. BIOANAL. CHEM., 391, PP. 633-646, (2008); MENDES J.A.S., PROZIL S.O., EVTUGUINA D.V., LOPES L.P.C., TOWARDS COMPREHENSIVE UTILIZATION OF WINEMAKING RESIDUES: CHARACTERIZATION OF GRAPE SKINS FROM RED GRAPE POMACES OF VARIETY TOURIGA NACIONAL, IND. CROPS PROD., 43, PP. 25-32, (2013); MOUAHID A., BOMBARDA I., CLAEYS-BRUNO M., AMA S.T., MYOTTE E., NISTERON J.P., CRAMPON C., BADENS E., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF MOROCCAN ARGAN (ARGANIA SPINOSA L.) OIL: EXTRACTION KINETICS AND SOLUBILITY DETERMINATION, UTIL., 46, (2021); (2022); OLATUNJI L.W., JIMOH A.O., MUHAMMAD T.U., IMAM M.U., A REVIEW OF THE EFFECTS OF POLICOSANOL ON METABOLIC SYNDROME, CCMP, 2, (2022); OU S., ZHAO J., WANG Y., TIAN Y., WANG J., PREPARATION OF OCTACOSANOL FROM FILTER MUD PRODUCED AFTER SUGARCANE JUICE CLARIFICATION, LWT-FOOD SCI., 45, PP. 295-298, (2012); PASHA I., SAEED F., WAQAS K., ANJUM F.M., ARSHAD M.U., NUTRACEUTICAL AND FUNCTIONAL SCENARIO OF WHEAT STRAW, CRIT REV FOOD SCI NUTR, 53, PP. 287-295, (2013); PEREIRA C.G., MEIRELES A.A.M., SUPERCRITICAL FLUID EXTRACTION OF BIOACTIVE COMPOUNDS: FUNDAMENTALS, APPLICATIONS AND ECONOMIC PERSPECTIVES, FOOD BIOPROCESS TECHNOL., 3, PP. 340-372, (2010); PERRA M., BACCHETTA G., MUNTONI A., DE GIOANNIS G., CASTANGI I., RAJHA H.N., MANCA M.L., MANCONI M., AN OUTLOOK ON MODERN AND SUSTAINABLE APPROACHES TO THE MANAGEMENT OF GRAPE POMACE BY INTEGRATING GREEN PROCESSES, BIOTECHNOLOGIES AND ADVANCED BIOMEDICAL APPROACHES, J. FUNCT. FOODS, 98, (2022); POVH N.P., MARQUES M.O.M., MEIRELES M.A.A., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF ESSENTIAL OIL AND OLEORESIN FROM CHAMOMILE (CHAMOMILLA RECUTITA L. RAUSCHERT), J. SUPERCRIT. FLUIDS, 21, PP. 245-248, (2001); REVERCHON E., DE MARCO I., SUPERCRITICAL FLUID EXTRACTION AND FRACTIONATION OF NATURAL MATTER, J. SUPERCRIT. FLUIDS, 38, PP. 146-166, (2006); RODRIGUES R.F., TASHIMA A.T., PEREIRA R.M.S., MOHAMED R.S., CABRAL F.A., COUMARIN SOLUBILITY AND EXTRACTION FROM EMBURANA (TORRESEA CEARENSIS) SEEDS WITH SUPERCRITICAL CARBON DIOXIDE, J. SUPERCRIT. FLUIDS, 43, PP. 375-382, (2008); SIN E.H.K., MARRIOTT R., HUNT A.J., CLARK J.H., IDENTIFICATION, QUANTIFICATION, AND CHRASTIL MODELLING OF WHEAT STRAW WAX EXTRACTION USING SUPERCRITICAL CARBON DIOXIDE, C. R. CHIM., 17, PP. 293-300, (2014); SOH S.H., AGARWAL S., JAIN A., LEE L.Y., CHIN S.K., JAYARAMAN S., MATHEMATICAL MODELING OF MASS TRANSFER IN SUPERCRITICAL FLUID EXTRACTION OF PATCHOULI OIL, ENG. REP., 1, (2019); SOVOVA H., RATE OF THE VEGETABLE OIL EXTRACTION WITH SUPERCRITICAL CO2-I. MODELLING OF EXTRACTION CURVES, CHEM. ENG. SCI., 49, PP. 409-414, (1994); SOVOVA H., MATHEMATICAL MODEL FOR SUPERCRITICAL FLUID EXTRACTION OF NATURAL PRODUCTS AND EXTRACTION CURVE EVALUATION, J. SUPERCRIT. FLUIDS, 33, PP. 35-52, (2005); WANG L., WELLER C.L., SCHLEGEL V.L., CARR T.P., CUPPETT S.R., COMPARISON OF SUPERCRITICAL CO2 AND HEXANE EXTRACTION OF LIPIDS FROM SORGHUM DISTILLERS’ GRAINS, EUR. J. LIPID SCI. TECHNOL., 109, PP. 567-574, (2007); YAASHIKA P.R., SENTHIL KUMAR P., VARJANI S., VALORIZATION OF AGRO-INDUSTRIAL WASTES FOR BIOREFINERY PROCESS AND CIRCULAR BIOECONOMY: A CRITICAL REVIEW, BIORESOUR. TECHNOL., 343, (2022); YANG M., LUO Z., GAO S., BELWAL T., WANG L., QI M., BAN Z., WU B., WANG F., LI L., THE CHEMICAL COMPOSITION AND POTENTIAL ROLE OF EPICUTICULAR AND INTRACUTICULAR WAX IN FOUR CULTIVARS OF TABLE GRAPES, POSTHARVEST BIOL. TECHNOL., 173, (2021); ZHANG M., ZHANG P., LU S., OU-YANG Q., ZHU-GE Y., TIAN R., JIA H., FANG J., COMPARATIVE ANALYSIS OF CUTICULAR WAX IN VARIOUS GRAPE CULTIVARS DURING BERRY DEVELOPMENT AND AFTER STORAGE, FRONT. NUTR., 8, (2021)","C. DA PORTO; UDINE, VIA SONDRIO 2/A, 33100, ITALY; EMAIL: CARLA.DAPORTO@UNIUD.IT","ELSEVIER LTD","ENGLISH","J. CO2 UTIL.","ARTICLE","ISI","2-S2.0-85190244917","J CO2 UTIL","UNIVERSITY OF UDINE;UNIVERSITY OF UDINE","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"DA PORTO C, 2024, J CO2 UTIL","DA PORTO C, 2024, J CO2 UTIL"
"CHO K;BAEK S;NAM H;KIM J;KANG D;NA H;ZEE S","CHO, KYUNG-HYUN (7403956966); BAEK, SEUNG HEE (58120142000); NAM, HYO-SEON (57301198400); KIM, JI-EUN (57881093800); KANG, DAE-JIN (57301198300); NA, HYEJEE (57880309200); ZEE, SEONGGEUN (58073681800)","CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT ANTIGLYCATION AND ANTIINFLAMMATORY ACTIVITY IN RECONSTITUTED HIGHDENSITY LIPOPROTEIN RHDL WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS COMPARISON OF VARIOUS POLICOSANOLS",2023,"INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES","24","",9,"10.3390/ijms24043186","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA","POLICOSANOLS FROM VARIOUS SOURCES, SUCH AS SUGAR CANE, RICE BRAN, AND INSECTS, HAVE BEEN MARKETED TO PREVENT DYSLIPIDEMIA, DIABETES, AND HYPERTENSION BY INCREASING THE BLOOD HIGH-DENSITY LIPOPROTEINS CHOLESTEROL (HDL-C) LEVELS. ON THE OTHER HAND, THERE HAS BEEN NO STUDY ON HOW EACH POLICOSANOL INFLUENCES THE QUALITY OF HDL PARTICLES AND THEIR FUNCTIONALITY. RECONSTITUTED HIGH-DENSITY LIPOPROTEINS (RHDLS) WITH APOLIPOPROTEIN (APO) A-I AND EACH POLICOSANOL WERE SYNTHESIZED USING THE SODIUM CHOLATE DIALYSIS METHOD TO COMPARE THE POLICOSANOLS IN LIPOPROTEIN METABOLISM. EACH RHDL WAS COMPARED REGARDING THE PARTICLE SIZE AND SHAPE, ANTIOXIDANT ACTIVITY, AND ANTI-INFLAMMATORY ACTIVITY IN VITRO AND IN ZEBRAFISH EMBRYOS. THIS STUDY COMPARED FOUR POLICOSANOLS INCLUDING ONE POLICOSANOL FROM CUBA (RAYDEL® POLICOSANOL) AND THREE POLICOSANOLS FROM CHINA (XI’AN NATURAL SUGAR CANE, XI’AN REALIN SUGAR CANE, AND SHAANXI RICE BRAN). THE SYNTHESIS OF RHDLS WITH VARIOUS POLICOSANOLS (PCO) FROM CUBA OR CHINA USING A MOLAR RATIO OF 95:5:1:1 WITH PALMITOYLOLEOYL PHOSPHATIDYLCHOLINE (POPC): FREE CHOLESTEROL (FC): APOA-I:PCO (WT:WT) SHOWED THAT RHDL CONTAINING CUBAN POLICOSANOL (RHDL-1) SHOWED THE LARGEST PARTICLE SIZE AND THE MOST DISTINCT PARTICLE SHAPE. THE RHDL-1 SHOWED A 23% LARGER PARTICLE DIAMETER AND INCREASED APOA-I MOLECULAR WEIGHT WITH A 1.9 NM BLUE SHIFT OF THE MAXIMUM WAVELENGTH FLUORESCENCE THAN RHDL ALONE (RHDL-0). OTHER RHDLS CONTAINING CHINESE POLICOSANOLS (RHDL-2, RHDL-3, AND RHDL-4) SHOWED SIMILAR PARTICLE SIZES WITH AN RHDL-0 AND 1.1–1.3 NM BLUE SHIFT OF WAVELENGTH MAXIMUM FLUORESCENCE (WMF). AMONG ALL RHDLS, THE RHDL-1 SHOWED THE STRONGEST ANTIOXIDANT ABILITY TO INHIBIT CUPRIC ION-MEDIATED LDL OXIDATION. THE RHDL-1-TREATED LDL SHOWED THE MOST DISTINCT BAND INTENSITY AND PARTICLE MORPHOLOGY COMPARED WITH THE OTHER RHDLS. THE RHDL-1 ALSO EXERTED THE HIGHEST ANTI-GLYCATION ACTIVITY TO INHIBIT THE FRUCTOSE-MEDIATED GLYCATION OF HUMAN HDL2 WITH THE PROTECTION OF APOA-I FROM PROTEOLYTIC DEGRADATION. AT THE SAME TIME, OTHER RHDLS SHOWED A LOSS OF ANTI-GLYCATION ACTIVITY WITH SEVERE DEGRADATION. A MICROINJECTION OF EACH RHDL ALONE SHOWED THAT RHDL-1 HAD THE HIGHEST SURVIVABILITY OF APPROXIMATELY 85 ± 3%, WITH THE FASTEST DEVELOPMENTAL SPEED AND MORPHOLOGY. IN CONTRAST, RHDL-3 SHOWED THE LOWEST SURVIVABILITY, AROUND 71 ± 5%, WITH THE SLOWEST DEVELOPMENTAL SPEED. A MICROINJECTION OF CARBOXYMETHYLLYSINE (CML), A PRO-INFLAMMATORY ADVANCED GLYCATED END PRODUCT, INTO ZEBRAFISH EMBRYOS RESULTED IN SEVERE EMBRYO DEATH OF APPROXIMATELY 30 ± 3% AND DEVELOPMENTAL DEFECTS WITH THE SLOWEST DEVELOPMENTAL SPEED. ON THE OTHER HAND, THE PHOSPHATE BUFFERED SALINE (PBS)-INJECTED EMBRYO SHOWED 83 ± 3% SURVIVABILITY. A CO-INJECTION OF CML AND EACH RHDL INTO ADULT ZEBRAFISH SHOWED THAT RHDL-1 (CUBAN POLICOSANOL) INDUCED THE HIGHEST SURVIVABILITY, AROUND 85 ± 3%, WHILE RHDL-0 SHOWED 67 ± 7% SURVIVABILITY. IN ADDITION, RHDL-2, RHDL-3, AND RHDL-4 SHOWED 67 ± 5%, 62 ± 37, AND 71 ± 6% SURVIVABILITY, RESPECTIVELY, WITH A SLOWER DEVELOPMENTAL SPEED AND MORPHOLOGY. IN CONCLUSION, CUBAN POLICOSANOL SHOWED THE STRONGEST ABILITY TO FORM RHDLS WITH THE MOST DISTINCT MORPHOLOGY AND THE LARGEST SIZE. THE RHDL-CONTAINING CUBAN POLICOSANOL (RHDL-1) SHOWED THE STRONGEST ANTIOXIDANT ABILITY AGAINST LDL OXIDATION, ANTI-GLYCATION ACTIVITY TO PROTECT APOA-I FROM DEGRADATION, AND THE HIGHEST ANTI-INFLAMMATORY ACTIVITY TO PROTECT EMBRYO DEATH UNDER THE PRESENCE OF CML. © 2023 BY THE AUTHORS.","APOA-I; APOLIPOPROTEIN A-I; EMBRYO; HDL; HIGH-DENSITY LIPOPROTEINS; POLICOSANOL; SUGAR CANE WAX ALCOHOL; ZEBRAFISH","ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; CHOLESTEROL; EMBRYO LOSS; ETHANOL; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; PREGNANCY; SACCHARUM; SUGAR ALCOHOLS; ZEBRAFISH; 6 N CARBOXYMETHYLLYSINE; ALCOHOL DERIVATIVE; APOLIPOPROTEIN A1; CHOLESTEROL; CHOLIC ACID; CUPRIC ION; FRUCTOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LOW DENSITY LIPOPROTEIN; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLCHOLINE; POLICOSANOL; WAX; ALCOHOL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN; POLICOSANOL; SUGAR ALCOHOL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; CUBA; EMBRYO; EMBRYO DEATH; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; FLUORESCENCE; GLYCATION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MOLECULAR WEIGHT; MORPHOLOGY; NONHUMAN; OXIDATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN DEGRADATION; RICE BRAN; STRUCTURE ANALYSIS; SUGARCANE; SURVIVAL; SYNTHESIS; ZEBRA FISH; ANIMAL; FEMALE; HUMAN; METABOLISM; PREGNANCY","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES, 69, PP. 321-327, (1993); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT. J. CLIN. PHARMACOL. THER, 34, PP. 134-137, (1996); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., ALEMAN C., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES, 16, PP. 67-72, (1996); LEE H.G., WOO S.Y., AHN H.J., YANG J.Y., LEE M.J., KIM H.Y., SONG S.Y., LEE J.H., SEO W.D., COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT (AVENA SATIVA L.) CULTIVARS AND SCREENING FOR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION, PLANTS, 11, (2022); MUTHUSAMY M., KIM J.H., KIM S.H., KIM J.Y., HEO J.W., LEE H., LEE K.S., SEO W.D., PARK S., KIM J.A., ET AL., CHANGES IN BENEFICIAL C-GLYCOSYLFLAVONES AND POLICOSANOL CONTENT IN WHEAT AND BARLEY SPROUTS SUBJECTED TO DIFFERENTIAL LED LIGHT CONDITIONS, PLANTS, 9, (2020); SUN L., LI X., MA C., HE Z., ZHANG X., WANG C., ZHAO M., GAN J., FENG Y., IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE, FOODS, 11, (2022); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT MED. THER, 21, (2021); VENTURELLI A., BRIGHENTI V., MASCOLO D., PELLATI F., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL, 172, PP. 200-205, (2019); WONG W.T., ISMAIL M., TOHIT E.R., ABDULLAH R., ZHANG Y.D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVID. BASED COMPLEMENT ALTERN. MED, 2016, (2016); ISHAKA A., UMAR IMAM M., MAHAMUD R., ZUKI A.B., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT. J. NANOMED, 9, PP. 2261-2269, (2014); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT, PHYTOTHER. RES, 27, PP. 264-271, (2013); PARK H.J., YADAV D., JEONG D.J., KIM S.J., BAE M.A., KIM J.R., CHO K.H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT THER. MED, 45, PP. 89-97, (2019); KIM J.H., LIM D.K., SUH Y.H., CHANG K.A., LONG-TERM TREATMENT OF CUBAN POLICOSANOL ATTENUATES ABNORMAL OXIDATIVE STRESS AND INFLAMMATORY RESPONSE VIA AMYLOID PLAQUES REDUCTION IN 5XFAD MICE, ANTIOXIDANTS, 10, (2021); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED, 39, PP. 889-899, (2017); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED. CELL. LONGEV, 2018, (2018); HUI N., BARTER P.J., ONG K.L., RYE K.A., ALTERED HDL METABOLISM IN METABOLIC DISORDERS: INSIGHTS INTO THE THERAPEUTIC POTENTIAL OF HDL, CLIN. SCI, 133, PP. 2221-2235, (2019); CHO K.H., BAE M.A., KIM J.R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC. THER, 2019, (2019); PARK K.-H., KIM J.-Y., CHOI I., KIM J.-R., WON K.C., CHO K.-H., FRUCTATED APOLIPOPROTEIN A-I EXACERBATES CELLULAR SENESCENCE IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS ACCOMPANIED BY IMPAIRED INSULIN SECRETION ACTIVITY AND EMBRYO TOXICITY, BIOCHEM. CELL BIOL, 94, PP. 337-345, (2016); SUAREZ G., RAJARAM R., ORONSKY A.L., GAWINOWICZ M.A., NONENZYMATIC GLYCATION OF BOVINE SERUM ALBUMIN BY FRUCTOSE (FRUCTATION). COMPARISON WITH THE MAILLARD REACTION INITIATED BY GLUCOSE, J. BIOL. CHEM, 264, PP. 3674-3679, (1989); DEVARAJ S., DASU M.R., ROCKWOOD J., WINTER W., GRIFFEN S.C., JIALAL I., INCREASED TOLL-LIKE RECEPTOR (TLR) 2 AND TLR4 EXPRESSION IN MONOCYTES FROM PATIENTS WITH TYPE 1 DIABETES: FURTHER EVIDENCE OF A PROINFLAMMATORY STATE, J. CLIN. ENDOCRINOL. METAB, 93, PP. 578-583, (2008); DASU M.R., DEVARAJ S., PARK S., JIALAL I., INCREASED TOLL-LIKE RECEPTOR (TLR) ACTIVATION AND TLR LIGANDS IN RECENTLY DIAGNOSED TYPE 2 DIABETIC SUBJECTS, DIABETES CARE, 33, PP. 861-868, (2010); BASTA G., SCHMIDT A.M., DE CATERINA R., ADVANCED GLYCATION END PRODUCTS AND VASCULAR INFLAMMATION: IMPLICATIONS FOR ACCELERATED ATHEROSCLEROSIS IN DIABETES, CARDIOVASC. RES, 63, PP. 582-592, (2004); TREDE N.S., ZAPATA A., ZON L.I., FISHING FOR LYMPHOID GENES, TRENDS IMMUNOL, 22, PP. 302-307, (2001); NOVOA B., BOWMAN T.V., ZON L., FIGUERAS A., LPS RESPONSE AND TOLERANCE IN THE ZEBRAFISH (DANIO RERIO), FISH SHELLFISH. IMMUNOL, 26, (2009); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS” VERSUS GENUINE POLICOSANOL, REV. CENIC CIENC. QUÍMICAS, 38, PP. 207-213, (2007); OSADNIK T., GOLAWSKI M., LEWANDOWSKI P., MORZE J., OSADNIK K., PAWLAS N., LEJAWA M., JAKUBIAK G.K., MAZUR A., SCHWINGSCHACKL L., ET AL., A NETWORK META-ANALYSIS ON THE COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE IN ADULTS, PHARMACOL. RES, 183, (2022); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J. FOOD SCI, 76, PP. C891-C899, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, J. AM. MED. ASSOC, 295, PP. 2262-2269, (2006); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL, 50, PP. 255-262, (2000); EGGERMAN T.L., HOEG J.M., MENG M.S., TOMBRAGEL A., BOJANOVSKI D., BREWER H.B., DIFFERENTIAL TISSUE-SPECIFIC EXPRESSION OF HUMAN APOA-I AND APOA-II, J. LIPID. RES, 32, PP. 821-828, (1991); CHO K.H., THE CURRENT STATUS OF RESEARCH ON HIGH-DENSITY LIPOPROTEINS (HDL): A PARADIGM SHIFT FROM HDL QUANTITY TO HDL QUALITY AND HDL FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); CHO K.-H., KIM J.-R., LEE I.-C., KWON H.-J., NATIVE HIGH-DENSITY LIPOPROTEINS (HDL) WITH HIGHER PARAOXONASE EXERTS A POTENT ANTIVIRAL EFFECT AGAINST SARS-COV-2 (COVID-19), WHILE GLYCATED HDL LOST THE ANTIVIRAL ACTIVITY, ANTIOXIDANTS, 10, (2021); PARK K.-H., JANG W., KIM K.-Y., KIM J.-R., CHO K.-H., FRUCTATED APOLIPOPROTEIN A-I SHOWED SEVERE STRUCTURAL MODIFICATION AND LOSS OF BENEFICIAL FUNCTIONS IN LIPID-FREE AND LIPID-BOUND STATE WITH ACCELERATION OF ATHEROSCLEROSIS AND SENESCENCE, BIOCHEM. BIOPHYS. RES. COMMUN, 392, PP. 295-300, (2010); MAHAMAT-SALEH Y., FIOLET T., REBEAUD M.E., MULOT M., GUIHUR A., EL FATOUHI D., LAOUALI N., PEIFFER-SMADJA N., AUNE D., SEVERI G., DIABETES, HYPERTENSION, BODY MASS INDEX, SMOKING AND COVID-19-RELATED MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES, BMJ OPEN, 11, (2021); AGOURIDIS A.P., PAGKALI A., ZINTZARAS E., RIZOS E.C., NTZANI E.E., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: A MARKER OF COVID-19 INFECTION SEVERITY?, ATHEROSCLER. PLUS, 44, PP. 1-9, (2021); GAO W., XIONG Y., LI Q., YANG H., INHIBITION OF TOLL-LIKE RECEPTOR SIGNALING AS A PROMISING THERAPY FOR INFLAMMATORY DISEASES: A JOURNEY FROM MOLECULAR TO NANO THERAPEUTICS, FRONT. PHYSIOL, 8, (2017); FOIT L., THAXTON C.S., SYNTHETIC HIGH-DENSITY LIPOPROTEIN-LIKE NANOPARTICLES POTENTLY INHIBIT CELL SIGNALING AND PRODUCTION OF INFLAMMATORY MEDIATORS INDUCED BY LIPOPOLYSACCHARIDE BINDING TOLL-LIKE RECEPTOR 4, BIOMATERIALS, 100, PP. 67-75, (2016); FOTAKIS P., KOTHARI V., THOMAS D.G., WESTERTERP M., MOLUSKY M.M., ALTIN E., ABRAMOWICZ S., WANG N., HE Y., HEINECKE J.W., ET AL., ANTI-INFLAMMATORY EFFECTS OF HDL (HIGH-DENSITY LIPOPROTEIN) IN MACROPHAGES PREDOMINATE OVER PROINFLAMMATORY EFFECTS IN ATHEROSCLEROTIC PLAQUES, ARTERIOSCLER. THROMB. VASC. BIOL, 39, PP. E253-E272, (2019); CHO K.H., KIM J.E., NAM H.S., KANG D.J., NA H.J., ANTI-INFLAMMATORY ACTIVITY OF CIGB-258 AGAINST ACUTE TOXICITY OF CARBOXYMETHYLLYSINE IN PARALYZED ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS STABILITY AND FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); PARK K.H., CHO K.H., HIGH-DENSITY LIPOPROTEIN (HDL) FROM ELDERLY AND RECONSTITUTED HDL CONTAINING GLYCATED APOLIPOPROTEINS A-I SHARE PROATHEROSCLEROTIC AND PROSENESCENT PROPERTIES WITH INCREASED CHOLESTEROL INFLUX, J. GERONTOL. SER. A BIOL. SCI. MED. SCI, 66, PP. 511-520, (2011); LEE S., LEE G.S., MOON J.H., JUNG J., POLICOSANOL SUPPRESSES TUMOR PROGRESSION IN A GASTRIC CANCER XENOGRAFT MODEL, TOXICOL. RES, 38, PP. 567-575, (2022); PARK K.H., SHIN D.G., KIM J.R., CHO K.H., SENESCENCE-RELATED TRUNCATION AND MULTIMERIZATION OF APOLIPOPROTEIN A-I IN HIGH-DENSITY LIPOPROTEIN WITH AN ELEVATED LEVEL OF ADVANCED GLYCATED END PRODUCTS AND CHOLESTERYL ESTER TRANSFER ACTIVITY, J. GERONTOL. A. BIOL. SCI. MED. SCI, 65, PP. 600-610, (2010); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVESTIG, 34, PP. 1345-1353, (1955); BREWER H.B., RONAN R., MENG M., BISHOP C., ISOLATION AND CHARACTERIZATION OF APOLIPOPROTEINS A-I, A-II, AND A-IV, METHODS ENZYMOL, 128, PP. 223-246, (1986); CHO K.H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOL. CELLS, 27, PP. 291-297, (2009); MARKWELL M.A., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM, 87, PP. 206-210, (1978); CHO K.H., JONAS A., A KEY POINT MUTATION (V156E) AFFECTS THE STRUCTURE AND FUNCTIONS OF HUMAN APOLIPOPROTEIN A-I, J. BIOL. CHEM, 275, PP. 26821-26827, (2000); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); NOBLE R.P., ELECTROPHORETIC SEPARATION OF PLASMA LIPOPROTEINS IN AGAROSE GEL, J. LIPID. RES, 9, PP. 693-700, (1968); CHO K.H., KANG D.J., NAM H.S., KIM J.H., KIM S.Y., LEE J.O., KIM B.J., OZONATED SUNFLOWER OIL EXERTED PROTECTIVE EFFECT FOR EMBRYO AND CELL SURVIVAL VIA POTENT REDUCTION POWER AND ANTIOXIDANT ACTIVITY IN HDL WITH STRONG ANTIMICROBIAL ACTIVITY, ANTIOXIDANTS, 10, (2021); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); NUSSLEIN-VOLHARD C., DAHM R., ZEBRAFISH: A PRACTICAL APPROACH, (2002); GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS, (2010); PARK K.H., CHO K.H., A ZEBRAFISH MODEL FOR THE RAPID EVALUATION OF PRO-OXIDATIVE AND INFLAMMATORY DEATH BY LIPOPOLYSACCHARIDE, OXIDIZED LOW-DENSITY LIPOPROTEINS, AND GLYCATED HIGH-DENSITY LIPOPROTEINS, FISH SHELLFISH IMMUNOL, 31, PP. 904-910, (2011)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","INT. J. MOL. SCI.","ARTICLE","ISI","2-S2.0-85149020171","INT J MOL SCI","GYEONGSAN;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2023, INT J MOL SCI","CHO K-H, 2023, INT J MOL SCI-a"
"CHEMELEWSKI R;MCKINLEY B;FINLAYSON S;MULLET J","CHEMELEWSKI, ROBERT (57205584375); MCKINLEY, BRIAN A. (56665280200); FINLAYSON, SCOTT (7004188821); MULLET, JOHN E. (7006153284)","EPICUTICULAR WAX ACCUMULATION AND REGULATION OF WAX PATHWAY GENE EXPRESSION DURING BIOENERGY SORGHUM STEM DEVELOPMENT",2023,"FRONTIERS IN PLANT SCIENCE","14","",4,"10.3389/fpls.2023.1227859","DEPARTMENT OF BIOCHEMISTRY & BIOPHYSICS, TEXAS A&M UNIVERSITY, COLLEGE STATION, TX, UNITED STATES;DEPARTMENT OF BIOCHEMISTRY & BIOPHYSICS, TEXAS A&M UNIVERSITY, COLLEGE STATION, TX, UNITED STATES;DEPARTMENT OF SOIL AND CROP SCIENCES, TEXAS A&M UNIVERSITY, COLLEGE STATION, TX, UNITED STATES;DEPARTMENT OF BIOCHEMISTRY & BIOPHYSICS, TEXAS A&M UNIVERSITY, COLLEGE STATION, TX, UNITED STATES","BIOENERGY SORGHUM IS A DROUGHT-TOLERANT HIGH-BIOMASS C4 GRASS TARGETED FOR PRODUCTION ON ANNUAL CROPLAND MARGINAL FOR FOOD CROPS DUE PRIMARILY TO ABIOTIC CONSTRAINTS. TO BETTER UNDERSTAND THE OVERALL CONTRIBUTION OF STEM WAX TO BIOENERGY SORGHUM’S RESILIENCE, THE CURRENT STUDY CHARACTERIZED SORGHUM STEM CUTICULAR WAX LOADS, COMPOSITION, MORPHOMETRICS, WAX PATHWAY GENE EXPRESSION AND REGULATION USING VEGETATIVE PHASE WRAY, R07020, AND TX08001 GENOTYPES. WAX LOADS ON SORGHUM STEMS (~103-215 ΜG/CM2) WERE MUCH HIGHER THAN ARABIDOPSIS STEM AND LEAF WAX LOADS. WAX ON DEVELOPING SORGHUM STEM INTERNODES WAS ENRICHED IN C28/30 PRIMARY ALCOHOLS (~65%) WHILE STEM WAX ON FULLY DEVELOPED STEMS WAS ENRICHED IN C28/30 ALDEHYDES (~80%). SCANNING ELECTRON MICROSCOPY SHOWED MINIMAL WAX ON INTERNODES PRIOR TO THE ONSET OF ELONGATION AND THAT WAX TUBULES FIRST APPEAR ASSOCIATED WITH CORK-SILICA CELL COMPLEXES WHEN INTERNODE CELL ELONGATION IS COMPLETE. SORGHUM HOMOLOGS OF GENES INVOLVED IN WAX BIOSYNTHESIS/TRANSPORT WERE DIFFERENTIALLY EXPRESSED IN THE STEM EPIDERMIS. EXPRESSION OF MANY WAX PATHWAY GENES (I.E., SBKCS6, SBCER3-1, SBWSD1, SBABCG12, SBABCG11) IS LOW IN IMMATURE APICAL INTERNODES THEN INCREASES AT THE ONSET OF STEM WAX ACCUMULATION. SBCER4 IS EXPRESSED RELATIVELY EARLY IN STEM DEVELOPMENT CONSISTENT WITH ACCUMULATION OF C28/30 PRIMARY ALCOHOLS ON DEVELOPING APICAL INTERNODES. HIGH EXPRESSION OF TWO SBCER3 HOMOLOGS IN FULLY ELONGATED INTERNODES IS CONSISTENT WITH A ROLE IN PRODUCTION OF C28/30 ALDEHYDES. GENE REGULATORY NETWORK ANALYSIS AIDED THE IDENTIFICATION OF SORGHUM HOMOLOGS OF TRANSCRIPTION FACTORS THAT REGULATE WAX BIOSYNTHESIS (I.E., SBSHN1, SBWRI1/3, SBMYB94/96/30/60, MYS1) AND OTHER TRANSCRIPTION FACTORS THAT COULD REGULATE AND SPECIFY EXPRESSION OF THE WAX PATHWAY IN EPIDERMAL CELLS DURING CUTICLE DEVELOPMENT. COPYRIGHT © 2023 CHEMELEWSKI, MCKINLEY, FINLAYSON AND MULLET.","BIOENERGY; GENE REGULATORY NETWORK ANALYSIS; POLICOSANOL; SCANNING ELECTRON MICROSCOPY; SORGHUM; STEM CUTICULAR WAX; WAX LOAD","","U.S. DEPARTMENT OF ENERGY JOINT GENOME INSTITUTE; U.S. DEPARTMENT OF ENERGY, USDOE, (DE-AC02-05CH11231); OFFICE OF SCIENCE, SC, (DE-SC0018409); GREAT LAKES BIOENERGY RESEARCH CENTER, GLBRC","FUNDING TEXT 1: THE AUTHORS THANK KERRIE BARRY AND THE JOINT GENOME INSTITUTE FOR CONTRIBUTING TO RNA-SEQ ANALYSIS. THE WORK (PROPOSAL: 10.46936/10.25585/60001026 AND 10.46936/10.25585/60000987) CONDUCTED BY THE U.S. DEPARTMENT OF ENERGY JOINT GENOME INSTITUTE ( HTTPS://ROR.ORG/04XM1D337 ), A DOE OFFICE OF SCIENCE USER FACILITY, SUPPORTED BY THE OFFICE OF SCIENCE OF THE US DEPARTMENT OF ENERGY OPERATED UNDER CONTRACT NO. DE-AC02-05CH11231. THE AUTHORS ACKNOWLEDGE THE TEXAS A&M MICROSCOPY AND IMAGING CENTER’S HELP WITH MICROSCOPIC ANALYSES. HIGH TEMPERATURE MASS SPECTROMETRY WAS PERFORMED IN COLLABORATION WITH AMIT GUJAR AND KENNETH FREE AT THERMO FISHER SCIENTIFIC IN AUSTIN, TEXAS. ADDITIONAL MASS SPECTROMETRY VALIDATION WAS DONE WITH MACHINE TIME DONATED BY TIM DEVARENNE. IS AN ARTIST RENDERING OF THE DEVELOPING PHYTOMERS (AS 3 PRECURSORS TO THE FIRST INTERNODE) BY VERONICA CHEMELEWSKI. ; FUNDING TEXT 2: THIS WORK WAS FUNDED BY THE DOE GREAT LAKES BIOENERGY RESEARCH CENTER (DOE BER OFFICE OF SCIENCE GRANT/AWARD: DE-SC0018409). ACKNOWLEDGMENTS ","AHARONI A., DIXIT S., JETTER R., THOENES E., ARKEL VAN G., PEREIRA A., THE SHINE CLADE OF AP2 DOMAIN TRANSCRIPTION FACTORS ACTIVATES WAX BIOSYNTHESIS, ALTERS CUTICLE PROPERTIES, AND CONFERS DROUGHT TOLERANCE WHEN OVEREXPRESSED IN ARABIDOPSIS, PLANT CELL, 16, 9, PP. 2463-2480, (2004); ALEXANDER L.E., OKAZAKI Y., SCHELLING M.A., DAVIS A., ZHENG X., RIZHSKY L., ET AL., MAIZE GLOSSY2 AND GLOSSY2-LIKE GENES HAVE OVERLAPPING AND DISTINCT FUNCTIONS IN CUTICULAR LIPID DEPOSITION, PLANT PHYSIOL, 183, 3, PP. 840-853, (2020); ARACHCHILAGE M.H., MULLET J.E., MARSHALL-COLON A., SORGHUM BICOLOR CULTIVARS HAVE DIVERGENT AND DYNAMIC GENE REGULATORY NETWORKS THAT CONTROL THE TEMPORAL EXPRESSION OF GENES IN STEM TISSUE, BIORXIV, (2020); AVATO P., GIORGIO B., MARIANI G., EPICUTICULAR WAXES OF SORGHUM AND SOME COMPOSITIONAL CHANGES WITH PLANT AGE, PHYTOCHEMISTRY, 23, 12, PP. 2843-2846, (1984); AWIKA H.O., HAYS D.B., MULLET J.E., ROONEY W.L., WEER B.D., QTL MAPPING AND LOCI DISSECTION FOR LEAF EPICUTICULAR WAX LOAD AND CANOPY TEMPERATURE DEPRESSION AND THEIR ASSOCIATION WITH QTL FOR STAYGREEN IN SORGHUM BICOLOR UNDER STRESS, EUPHYTICA, 213, 9, (2017); BAO S.-G., SHI J.-X., LUO F., DING B., HAO J.-Y., XIE X.-D., ET AL., OVEREXPRESSION OF SORGHUM WINL1 GENE CONFERS DROUGHT TOLERANCE IN ARABIDOPSIS THALIANA THROUGH THE REGULATION OF CUTICULAR BIOSYNTHESIS, PLANT CELL TISSUE ORGAN CULTURE (PCTOC), 128, 2, PP. 347-356, (2016); BATSALE M., BAHAMMOU D., FOUILLEN L., MONGRAND S., JOUBES J., DOMERGUE F., BIOSYNTHESIS AND FUNCTIONS OF VERY-LONG-CHAIN FATTY ACIDS IN THE RESPONSES OF PLANTS TO ABIOTIC AND BIOTIC STRESSES, CELLS, 10, 6, (2021); BERNARD A., JOUBES J., ARABIDOPSIS CUTICULAR WAXES: ADVANCES IN SYNTHESIS, EXPORT AND REGULATION, PROG. LIPID RES, 52, 1, PP. 110-129, (2013); BERNAYS E., CHANGES IN THE FIRST INSTAR CUTICLE OF SCHISTOCERCA GREGARIA BEFORE AND ASSOCIATED WITH HATCHIN, J. INSECT PHYSIOL, 18, 5, PP. 897-912, (1972); BERNHARDT C., LEE M.M., GONZALEZ A., ZHANG F., LLOYD A., SCHIEFELBEIN J., THE BHLH GENES GLABRA3 (GL3) AND ENHANCER OF GLABRA3 (EGL3) SPECIFY EPIDERMAL CELL FATE IN THE ARABIDOPSIS ROOT, DEVELOPMENT, 130, 26, PP. 6431-6439, (2003); BOURGAULT R., VASQUEZ M., QIAO P., SONNTAG A., CHARLEBOIS C., MOHAMMADI M., ET AL., CONSTRUCTING FUNCTIONAL CUTICLES: ANALYSIS OF RELATIONSHIPS BETWEEN CUTICLE LIPID COMPOSITION, ULTRASTRUCTURE AND WATER BARRIER FUNCTION IN DEVELOPING ADULT MAIZE LEAVES, ANN. BOT, 125, 1, PP. 79-91, (2020); BOYLES R.E., BRENTON Z.W., KRESOVICH S., GENETIC AND GENOMIC RESOURCES OF SORGHUM TO CONNECT GENOTYPE WITH PHENOTYPE IN CONTRASTING ENVIRONMENTS, PLANT J, 97, 1, PP. 19-39, (2019); BROUN P., POINDEXTER P., OSBORNE E., JIANG C.Z., RIECHMANN J.L., WIN1, A TRANSCRIPTIONAL ACTIVATOR OF EPIDERMAL WAXACCUMULATION INARABIDOPSIS, PNAS, 101, 13, PP. 4706-4711, (2004); BUROW G.B., FRANKS C.D., ACOSTA-MARTINEZ V., XIN Z., MOLECULAR MAPPING AND CHARACTERIZATION OF BLMC, A LOCUS FOR PROFUSE WAX (BLOOM) AND ENHANCED CUTICULAR FEATURES OF SORGHUM (SORGHUM BICOLOR (L.) MOENCH.), THEOR. APPL. GENET, 118, 3, PP. 423-431, (2009); BUROW G.B., FRANKS C.D., XIN Z., GENETIC AND PHYSIOLOGICAL ANALYSIS OF AN IRRADIATED BLOOMLESS MUTANT (EPICUTICULAR WAX MUTANT) OF SORGHUM, CROP SCI, 48, 1, PP. 41-48, (2008); BUSCHHAUS C., JETTER R., COMPOSITION DIFFERENCES BETWEEN EPICUTICULAR AND INTRACUTICULAR WAX SUBSTRUCTURES: HOW DO PLANTS SEAL THEIR EPIDERMAL SURFACES, J. EXP. BOT, 62, 3, PP. 841-853, (2011); BUSTA L., HEGEBARTH D., KROC E., JETTER R., CHANGES IN CUTICULAR WAX COVERAGE AND COMPOSITION ON DEVELOPING ARABIDOPSIS LEAVES ARE INFLUENCED BY WAX BIOSYNTHESIS GENE EXPRESSION LEVELS AND TRICHOME DENSITY, PLANTA, 245, 2, PP. 297-311, (2017); BUSTA L., SCHMITZ E., KOSMA D.K., SCHNABLE J.C., CAHOON E.B., A CO-OPTED STEROID SYNTHESIS GENE, MAINTAINED IN SORGHUM BUT NOT MAIZE, IS ASSOCIATED WITH A DIVERGENCE IN LEAF WAX CHEMISTRY, PROC. NATL. ACAD. SCI. U. S. A, 118, 12, (2021); CARDONA J.B., GROVER S., BUSTA L., SATTLER S.E., LOUIS J., SORGHUM CUTICULAR WAXES INFLUENCE HOST PLANT SELECTION BY APHIDS, PLANTA, 257, 1, (2022); CASTO A.L., MCKINLEY B.A., YU K.M.J., ROONEY W.L., J, MULLET E., SORGHUM STEM AERENCHYMA FORMATION IS REGULATED BY SBNAC_D DURING INTERNODE DEVELOPMENT, PLANT DIRECT, 2, 11, (2018); CHAMBERS T.C., RITCHIE I.M., BOOTH M.A., CHEMICAL MODELS FOR PLANT WAX MORPHOGENESIS, NEW PHYTOL, 77, 1, PP. 43-49, (1975); CHOW C.N., LEE T.Y., HUNG Y.C., LI G.Z., TSENG K.C., LIU Y.H., ET AL., PLANTPAN3.0: A NEW AND UPDATED RESOURCE FOR RECONSTRUCTING TRANSCRIPTIONAL REGULATORY NETWORKS FROM CHIP-SEQ EXPERIMENTS IN PLANTS, NUCLEIC ACIDS RES, 47, D1, PP. D1155-D1163, (2019); COMINELLI E., SALA T., CALVI D., GUSMAROLI G., TONELLI C., OVER-EXPRESSION OF THE ARABIDOPSIS ATMYB41 GENE ALTERS CELL EXPANSION AND LEAF SURFACE PERMEABILITY, PLANT J, 53, 1, PP. 53-64, (2008); ELANGO D., XUE W., CHOPRA S., ET AL., GENOME WIDE ASSOCIATION MAPPING OF EPI-CUTICULAR WAX GENES IN SORGHUM BICOLOR, PHYSIOL. MOL. BIOL. PLANTS, 26, 8, PP. 1727-1737, (2020); FICHMAN Y., MITTLER R., RAPID SYSTEMIC SIGNALING DURING ABIOTIC AND BIOTIC STRESSES: IS THE ROS WAVE MASTER OF ALL TRADES, PLANT J, 102, 5, PP. 887-896, (2020); FU J., MCKINLEY B., JAMES B., CHRISLER W., MARKILLIE L.M., GAFFREY M.J., ET AL., THE STEM CELL-TYPE TRANSCRIPTOME OF BIOENERGY SORGHUM REVEALS THE SPATIAL REGULATION OF SECONDARY CELL WALL NETWORKS, BIORXIV, (2023); GARSMEUR O., DROC G., ANTONISE R., GRIMWOOD J., POTIER B., AITKEN K., ET AL., A MOSAIC MONOPLOID REFERENCE SEQUENCE FOR THE HIGHLY COMPLEX GENOME OF SUGARCANE, NAT. COMMUN, 9, 1, (2018); GREER S., WEN M., BIRD D., WU X., SAMUELS L., KUNST L., ET AL., THE CYTOCHROME P450 ENZYME CYP96A15 IS THE MIDCHAIN ALKANE HYDROXYLASE RESPONSIBLE FOR FORMATION OF SECONDARY ALCOHOLS AND KETONES IN STEM CUTICULAR WAX OF ARABIDOPSIS, PLANT PHYSIOL, 145, 3, PP. 653-667, (2007); GUO H.S., ZHANG Y.M., SUN X.Q., LI M.M., HANG Y.Y., XUE J.Y., ET AL., EVOLUTION OF THE KCS GENE FAMILY IN PLANTS: THE HISTORY OF GENE DUPLICATION, SUB/NEOFUNCTIONALIZATION AND REDUNDANCY, MOL. GENET. GENOMICS, 291, 2, PP. 739-752, (2016); HARRON A.F., POWELL M.J., NUNEZ A., MOREAU R.A., ANALYSIS OF SORGHUM WAX AND CARNAUBA WAX BY REVERSED PHASE LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, IND. CROPS PROD, 98, PP. 116-129, (2017); HASLAM T.M., GERELLE W.K., GRAHAM S.W., KUNST L., THE UNIQUE ROLE OF THE ECERIFERUM2-LIKE CLADE OF THE BAHD ACYLTRANSFERASE SUPERFAMILY IN CUTICULAR WAX METABOLISM, PLANTS (BASEL), 6, 2, (2017); HASLAM T.M., HASLAM R., THORAVAL D., PASCAL S., DELUDE C., DOMERGUE F., ET AL., ECERIFERUM2-LIKE PROTEINS HAVE UNIQUE BIOCHEMICAL AND PHYSIOLOGICAL FUNCTIONS IN VERY-LONG-CHAIN FATTY ACID ELONGATION, PLANT PHYSIOL, 167, 3, PP. 682-692, (2015); HENNET L., BERGER A., TRABANCO N., RICCIUTI E., DUFAYARD J.-F., BOCS S., ET AL., TRANSCRIPTIONAL REGULATION OF SORGHUM STEM COMPOSITION: KEY PLAYERS IDENTIFIED THROUGH CO-EXPRESSION GENE NETWORK AND COMPARATIVE GENOMICS ANALYSES, FRONT. PLANT SCI, 11, (2020); HOOKER T.S., LAM P., ZHENG H., KUNST L., A CORE SUBUNIT OF THE RNA-PROCESSING/DEGRADING EXOSOME SPECIFICALLY INFLUENCES CUTICULAR WAX BIOSYNTHESIS IN ARABIDOPSIS, PLANT CELL, 19, 3, PP. 904-913, (2007); HUANG H., AYAZ A., ZHENG M., YANG X., ZAMAN W., ZHAO H., ET AL., ARABIDOPSISKCS5 AND KCS6 PLAY REDUNDANT ROLES IN WAX SYNTHESIS, INT. J. MOL. SCI, 23, 8, (2022); HUNG F.Y., CHEN J.H., FENG Y.R., LAI Y.C., YANG S., WU K., ARABIDOPSIS JMJ29 IS INVOLVED IN TRICHOME DEVELOPMENT BY REGULATING THE CORE TRICHOME INITIATION GENE GLABRA3, PLANT J, 103, 5, PP. 1735-1743, (2020); HUSSAIN S., ZHANG N., WANG W., AHMED S., CHENG Y., CHEN S., ET AL., INVOLVEMENT OF ABA RESPONSIVE SVB GENES IN THE REGULATION OF TRICHOME FORMATION IN ARABIDOPSIS, INT. J. MOL. SCI, 22, 13, (2021); HWANG K., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPERATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, J. SEPARATION SCI, 25, 9, PP. 619-623, (2002); INARKAR M.B., LELE S.S., EXTRACTION AND CHARACTERIZATION OF SUGARCANE PEEL WAX, ISRN AGRON, 2012, PP. 1-6, (2012); JENKS M.A., RICH P.J., RHODES D., ASHWORTH E.N., AXTELL J.D., DING C.K., LEAF SHEATH CUTICULAR WAXES ON BLOOMLESS AND SPARSE-BLOOM MUTANTS OF SORGHUM BICOLOR, PHYTOCHEMISTRY, 54, 6, PP. 577-584, (2000); JENKS M.A., JOLY R.J., PETERS P.J., RICH P.J., AXTELL J.D., ASHWORTH E.N., CHEMICALLY INDUCED CUTICLE MUTATION AFFECTING EPIDERMAL CONDUCTANCE TO WATER VAPOR AND DISEASE SUSCEPTIBILITY IN SORGHUM BICOLOR (L.) MOENCH, PLANT PHYSIOL, 105, 4, PP. 1239-1245, (1994); JENKS M.A.R., PETERS P.J., AXTELL J.D., ASHWORTH E.N., EPICUTICULAR WAX MORPHOLOGY OF BLOOMLESS (BM) MUTANTS IN SORGHUM BICOLOR, INT. J. PLANT SCI, 153, 3, PP. 311-319, (1992); JESSEN D., OLBRICH A., KNUFER J., KRUGER A., HOPPERT M., POLLE A., ET AL., COMBINED ACTIVITY OF LACS1 AND LACS4 IS REQUIRED FOR PROPER POLLEN COAT FORMATION IN ARABIDOPSIS, PLANT J, 68, 4, PP. 715-726, (2011); JETTER R., KUNST L., PLANT SURFACE LIPID BIOSYNTHETIC PATHWAYS AND THEIR UTILITY FOR METABOLIC ENGINEERING OF WAXES AND HYDROCARBON BIOFUELS, PLANT J, 54, 4, PP. 670-683, (2008); JIAO Y., BUROW G., GLADMAN N., ACOSTA-MARTINEZ V., CHEN J., BURKE J., ET AL., EFFICIENT IDENTIFICATION OF CAUSAL MUTATIONS THROUGH SEQUENCING OF BULKED F (2) FROM TWO ALLELIC BLOOMLESS MUTANTS OF SORGHUM BICOLOR, FRONT. PLANT SCI, 8, (2017); JORDAN W.R., BLUM A., MILLER F.R., MONK R.L., ENVIRONMENTAL PHYSIOLOGY OF SORGHUM. II. EPICUTICULAR WAX LOAD AND CUTICULAR TRANSPIRATION, CROP SCI, 24, 6, PP. 1168-1173, (1984); KANNANGARA R., BUROW G., GLADMAN N., ACOSTA-MARTINEZ V., CHEN J., BURKE J., ET AL., THE TRANSCRIPTION FACTOR WIN1/SHN1 REGULATES CUTIN BIOSYNTHESIS IN ARABIDOPSIS THALIANA, PLANT CELL, 19, 4, PP. 1278-1294, (2007); KAWAHARA Y., DE LA BASTIDE M., HAMILTON J.P., KANAMORI H., MCCOMBIE W.R., OUYANG S., ET AL., IMPROVEMENT OF THE ORYZA SATIVA NIPPONBARE REFERENCE GENOME USING NEXT GENERATION SEQUENCE AND OPTICAL MAP DATA, RICE (NY), 6, 4, (2013); KEBROM T.H., MCKINLEY B., MULLET J.E., DYNAMICS OF GENE EXPRESSION DURING DEVELOPMENT AND EXPANSION OF VEGETATIVE STEM INTERNODES OF BIOENERGY SORGHUM, BIOTECHNOL. BIOFUELS, 10, (2017); KLEIN J., SAEDLER H., HUIJSER P., A NEW FAMILY OF DNA BINDING PROTEINS INCLUDES PUTATIVE TRANSCRIPTIONAL REGULATORS OF THE ANTIRRHINUM MAJUS FLORAL MERISTEM IDENTITY GENE SQUAMOSA, MOL. GEN. GENET, 250, PP. 7-16, (1996); KOCH K., ENSIKAT H.J., THE HYDROPHOBIC COATINGS OF PLANT SURFACES: EPICUTICULAR WAX CRYSTALS AND THEIR MORPHOLOGIES, CRYSTALLINITY AND MOLECULAR SELF-ASSEMBLY, MICRON, 39, 7, PP. 759-772, (2008); KOLATTUKUDY P., ENZYMATIC SYNTHESIS OF FATTY ALCOHOLS IN BRASSICA OLERACEA, ARCH. BIOCHEM. BIOPHYS, 142, 2, PP. 701-709, (1971); KUMAR S., STECHER G., LI M., KNYAZ C., TAMURA K., MEGA X: MOLECULAR EVOLUTIONARY GENETICS ANALYSIS ACROSS COMPUTING PLATFORMS, MOL. BIOL. EVOL, 35, 6, PP. 1547-1549, (2018); LEE S.B., KIM H.U., SUH M.C., MYB94 AND MYB96 ADDITIVELY ACTIVATE CUTICULAR WAX BIOSYNTHESIS IN ARABIDOPSIS, PLANT CELL PHYSIOL, 57, 11, PP. 2300-2311, (2016); LEE S.B., SUH M.C., ADVANCES IN THE UNDERSTANDING OF CUTICULAR WAXES IN ARABIDOPSIS THALIANA AND CROP SPECIES, PLANT CELL REP, 34, 4, PP. 557-572, (2015); LEWANDOWSKA M., KEYL A., FEUSSNER I., WAX BIOSYNTHESIS IN RESPONSE TO DANGER: ITS REGULATION UPON ABIOTIC AND BIOTIC STRESS, NEW PHYTOL, 227, 3, PP. 698-713, (2020); LI F., WU X., LAM P., BIRD D., ZHENG H., SAMUELS L., ET AL., IDENTIFICATION OF THE WAX ESTER SYNTHASE/ACYL-COENZYME A: DIACYLGLYCEROL ACYLTRANSFERASE WSD1 REQUIRED FOR STEM WAX ESTER BIOSYNTHESIS IN ARABIDOPSIS, PLANT PHYSIOL, 148, 1, PP. 97-107, (2008); LI R.J., LI L.M., LIU X.L., KIM J.C., JENKS M.A., LU S., ET AL., DIURNAL REGULATION OF PLANT EPIDERMAL WAX SYNTHESIS THROUGH ANTAGONISTIC ROLES OF THE TRANSCRIPTION FACTORS SPL9 AND DEWAX, PLANT CELL, 31, 11, PP. 2711-2733, (2019); LI L., DU Y., HE C.C., DIETRICH R., LI J., MA X., ET AL., MAIZE GLOSSY6 IS INVOLVED IN CUTICULAR WAX DEPOSITION AND DROUGHT TOLERANCE, J. EXP. BOT, 70, 12, PP. 3089-3099, (2019); LI P., LIN P., ZHAO Z., LI Z., LIU Y., HUANG C., ET AL., GENE CO-EXPRESSION ANALYSIS REVEALS TRANSCRIPTOME DIVERGENCE BETWEEN WILD AND CULTIVATED SUGARCANE UNDER DROUGHT STRESS, INT. J. MOL. SCI, 23, 1, (2022); LIU X., BOURGAULT R., GALLI M., STRABLE J., CHEN Z., FENG F., ET AL., THE FUSED LEAVES1-ADHERENT1 REGULATORY MODULE IS REQUIRED FOR MAIZE CUTICLE DEVELOPMENT AND ORGAN SEPARATION, NEW PHYTOL, 229, 1, PP. 388-402, (2021); LIU Q., HUANG H., CHEN Y., YUE Z., WANG Z., QU T., ET AL., TWO ARABIDOPSIS MYB-SHAQKYF TRANSCRIPTION REPRESSORS REGULATE LEAF WAX BIOSYNTHESIS VIA TRANSCRIPTIONAL SUPPRESSION ON DEWAX, NEW PHYTOL, 236, 6, PP. 2115-2130, (2022); LU S., SONG T., KOSMA D.K., PARSONS E.P., ROWLAND O., JENKS M.A., ARABIDOPSIS CER8 ENCODES LONG-CHAIN ACYL-COA SYNTHETASE 1 (LACS1) THAT HAS OVERLAPPING FUNCTIONS WITH LACS2 IN PLANT WAX AND CUTIN SYNTHESIS, PLANT J, 59, 4, PP. 553-564, (2009); LYKHOLAT Y.V., DIDUR O.O., ALEXEYEVA A.A., LYKHOLAT T.Y., MODIFICATION OF THE EPICUTICULAR WAXES OF PLANT LEAVES DUE TO INCREASED SUNLIGHT INTENSITY, BIOSYS. DIVERSITY, 28, 1, PP. 29-33, (2020); MAKITA Y., SHIMADA S., KAWASHIMA M., KONDOU-KURIYAMA T., TOYODA T., MATSUI M., MOROKOSHI: TRANSCRIPTOME DATABASE IN SORGHUM BICOLOR, PLANT CELL PHYSIOL, 56, 1, (2015); MCCORMICK R.F., TRUONG S.K., SREEDASYAM A., JENKINS J., SHU S., SIMS D., ET AL., THE SORGHUM BICOLOR REFERENCE GENOME: IMPROVED ASSEMBLY, GENE ANNOTATIONS, A TRANSCRIPTOME ATLAS, AND SIGNATURES OF GENOME ORGANIZATION, PLANT J, 93, 2, PP. 338-354, (2018); MCWHORTER C., PAUL R., BARRENTINE W., MORPHOLOGY, DEVELOPMENT, AND RECRYSTALLIZATION OF EPICUTICULAR WAXES OF JOHNSONGRASS (SORGHUM HALEPENSE), WEED SCI, 38, 1, PP. 22-33, (1990); MCWHORTER C.G.P., REX N., THE INVOLVEMENT OF CORK-SILICA CELL PAIRS IN THE PRODUCTION OF WAX FILAMENTS IN JOHNSONGRASS (SORGHUM HALEPENSE) LEAVES, WEED SCI, 37, 3, PP. 458-470, (1989); MECHAN-LLONTOP M.E., MULLET J., SHADE A., PHYLLOSPHERE EXUDATES SELECT FOR DISTINCT MICROBIOME MEMBERS IN SORGHUM EPICUTICULAR WAX AND AERIAL ROOT MUCILAGE, PHYTOBIOMES J, PP. 1-14, (2023); MEDEIROS C.D., ALMEIDA-CORTEZ J., SANTOS D.Y.A.C., OLIVEIRA A.F.M., SANTOS M.G., LEAF EPICUTICULAR WAX CONTENT CHANGES UNDER DIFFERENT RAINFALL REGIMES, AND ITS REMOVAL AFFECTS THE LEAF CHLOROPHYLL CONTENT AND GAS EXCHANGES OF ASPIDOSPERMA PYRIFOLIUM IN A SEASONALLY DRY TROPICAL FOREST, SOUTH AFR. J. BOT, 111, PP. 267-274, (2017); MIZUNO H., KAWAHIGASHI H., OGATA J., MINAMI H., KANAMORI H., NAKAGAWA H., ET AL., GENOMIC INVERSION CAUSED BY GAMMA IRRADIATION CONTRIBUTES TO DOWNREGULATION OF A WBC11 HOMOLOG IN BLOOMLESS SORGHUM, THEOR. APPL. GENET, 126, 6, PP. 1513-1520, (2013); MULLET J., MORISHIGE D., MCCORMICK R., TRUONG S., HILLEY J., MCKINLEY B., ET AL., ENERGY SORGHUM–A GENETIC MODEL FOR THE DESIGN OF C4 GRASS BIOENERGY CROPS, J. EXP. BOT, 65, 13, PP. 3479-3489, (2014); NAGATA K., ABE M., A CONSERVED MECHANISM DETERMINES THE ACTIVITY OF TWO PIVOTAL TRANSCRIPTION FACTORS THAT CONTROL EPIDERMAL CELL DIFFERENTIATION IN ARABIDOPSIS THALIANA, J. PLANT RES, 136, 3, PP. 349-358, (2023); NAKAMURA M., KATSUMATA H., ABE M., YABE N., KOMEDA Y., YAMAMOTO K.T., ET AL., CHARACTERIZATION OF THE CLASS IV HOMEODOMAIN-LEUCINE ZIPPER GENE FAMILY IN ARABIDOPSIS, PLANT PHYSIOL, 141, 4, PP. 1363-1375, (2006); NEGRUK V., YANG P., SUBRAMANIAN M., MCNEVIN J.P., LEMIEUX B., MOLECULAR CLONING AND CHARACTERIZATION OF THE CER2 GENE OF ARABIDOPSIS THALIANA, PLANT J, 9, 2, PP. 137-145, (1996); NOBEL P.S., JORDAN P.W., TRANSPIRATION STREAM OF DESERT SPECIES: RESISTANCES AND CAPACITANCES FOR A C3, A C4, AND A CAM PLANT, J. EXP. BOT, 34, 147, PP. 1379-1391, (1983); NWANZE K.F.S., BUTLER D.R., REDDY D.D.R., REDDY Y.V.R., SOMAN P., THE DYNAMICS OF LEAF SURFACE WETNESS OF SORGHUM SEEDLINGS IN RELATION TO RESISTANCE TO THE SHOOT FLY, ATHERIGONA SOCCATA, ENTOMOL. EXPERIMENTALIS APPL, 64, 2, PP. 151-160, (1992); OGAWA E., YAMADA Y., SEZAKI N., KOSAKA S., KONDO H., KAMATA N., ET AL., ATML1 AND PDF2 PLAY A REDUNDANT AND ESSENTIAL ROLE IN ARABIDOPSIS EMBRYO DEVELOPMENT, PLANT CELL PHYSIOL, 56, 6, PP. 1183-1192, (2015); OLSON S.N., RITTER K., ROONEY W., KEMANIAN A., MCCARL B.A., ZHANG Y., ET AL., HIGH BIOMASS YIELD ENERGY SORGHUM: DEVELOPING A GENETIC MODEL FOR C4 GRASS BIOENERGY CROPS, BIOFUELS BIOPROD. BIOREF, 6, 6, PP. 640-655, (2012); PARK J.S., KIM J.B., CHO K.J., CHEON C.I., SUNG M.K., CHOUNG M.G., ET AL., ARABIDOPSIS R2R3-MYB TRANSCRIPTION FACTOR ATMYB60 FUNCTIONS AS A TRANSCRIPTIONAL REPRESSOR OF ANTHOCYANIN BIOSYNTHESIS IN LETTUCE (LACTUCA SATIVA), PLANT CELL REP, 27, 6, PP. 985-994, (2008); PARK C.S., GO Y.S., SUH M.C., CUTICULAR WAX BIOSYNTHESIS IS POSITIVELY REGULATED BY WRINKLED4, AN AP2/ERF-TYPE TRANSCRIPTION FACTOR, IN ARABIDOPSIS STEMS, PLANT J, 88, 2, PP. 257-270, (2016); PASCAL S., SOREL M., PERVENT M., VILE D., HASLAM R.P., NAPIER J.A., ET AL., THE ARABIDOPSIS CER26 MUTANT, LIKE THE CER2 MUTANT, IS SPECIFICALLY AFFECTED IN THE VERY LONG CHAIN FATTY ACID ELONGATION PROCESS, PLANT J, 73, 5, PP. 733-746, (2013); PETERS P.J., RICH P.J., AXTELL J.D., EJETA G., MUTAGENESIS, SELECTION, AND ALLELIC ANALYSIS OF EPICUTICULAR WAX MUTANTS IN SORGHUM, CROP SCI, 49, 4, PP. 1250-1258, (2009); PUNNURI S., HARRIS-SHULTZ K., KNOLL J., NI X., WANG H., THE GENES BM2 AND BLMC THAT AFFECT EPICUTICULAR WAX DEPOSITION IN SORGHUM ARE ALLELIC, CROP SCI, 57, 3, PP. 1552-1556, (2017); RAFFAELE S., VAILLEAU F., LEGER A., JOUBES J., MIERSCH O., HUARD C., ET AL., A MYB TRANSCRIPTION FACTOR REGULATES VERY-LONG-CHAIN FATTY ACID BIOSYNTHESIS FOR ACTIVATION OF THE HYPERSENSITIVE CELL DEATH RESPONSE IN ARABIDOPSIS, PLANT CELL, 20, 3, PP. 752-767, (2008); ROONEY W.L., BLUMENTHAL J., BEAN B., MULLET J.E., DESIGNING SORGHUM AS A DEDICATED BIOENERGY FEEDSTOCK, BIOFUELS BIOPROD. BIOREF, 1, 2, PP. 147-157, (2007); RUSCONI F., SIMEONI F., FRANCIA P., COMINELLI E., CONTI L., RIBONI M., ET AL., THE ARABIDOPSIS THALIANA MYB60 PROMOTER PROVIDES A TOOL FOR THE SPATIO-TEMPORAL CONTROL OF GENE EXPRESSION IN STOMATAL GUARD CELLS, J. EXP. BOT, 64, 11, PP. 3361-3371, (2013); SAMUELS L., KUNST L., JETTER R., SEALING PLANT SURFACES: CUTICULAR WAX FORMATION BY EPIDERMAL CELLS, ANNU. REV. PLANT BIOL, 59, PP. 683-707, (2008); SANEOKA H., OGATA S., RELATIONSHIP BETWEEN WATER USE EFFICIENCY AND CUTICULAR WAX DEPOSITION IN WARM SEASON FORAGE CROPS GROWN UNDER WATER DEFICIT CONDITIONS, SOIL SCI. PLANT NUTR, 33, 3, PP. 439-448, (1987); SCULLY ED G.T., SARATH G., PALMER N.A., BAIRD L., SERAPIGLIA M.J., DIEN B.S., ET AL., OVEREXPRESSION OF SBMYB60 IMPACTS PHENYLPROPANOID BIOSYNTHESIS AND ALTERS SECONDARY CELL WALL COMPOSITION IN SORGHUM BICOLOR, PLANT J, 85, 3, PP. 378-395, (2016); SEO P.J., LEE S.B., SUH M.C., PARK M.J., GO Y.S., PARK C.M., THE MYB96 TRANSCRIPTION FACTOR REGULATES CUTICULAR WAX BIOSYNTHESIS UNDER DROUGHT CONDITIONS IN ARABIDOPSIS, PLANT CELL, 23, 3, PP. 1138-1152, (2011); SINGH V., KUMAR N., DWIVEDI A.K., SHARMA R., SHARMA M.K., PHYLOGENOMIC ANALYSIS OF R2R3 MYB TRANSCRIPTION FACTORS IN SORGHUM AND THEIR ROLE IN CONDITIONING BIOFUEL SYNDROME, CURR. GENOMICS, 21, 2, PP. 138-154, (2020); SUH M.C., SAMUELS A.L., JETTER R., KUNST L., POLLARD M., OHLROGGE J., ET AL., CUTICULAR LIPID COMPOSITION, SURFACE STRUCTURE, AND GENE EXPRESSION IN ARABIDOPSIS STEM EPIDERMIS, PLANT PHYSIOL, 139, 4, PP. 1649-1665, (2005); TACKE E., KORFHAGE C., MICHEL D., MADDALONI M., MOTTO M., LANZINI S., ET AL., TRANSPOSON TAGGING OF THE MAIZE GLOSSY2 LOCUS WITH THE TRANSPOSABLE ELEMENT EN/SPM, PLANT J, 8, 6, PP. 907-917, (1995); TADA A., ISHIZUKI K., YAMAZAKI T., SUGIMOTO N., AKIYAMA H., METHOD FOR THE DETERMINATION OF NATURAL ESTER-TYPE GUM BASES USED AS FOOD ADDITIVES VIA DIRECT ANALYSIS OF THEIR CONSTITUENT WAX ESTERS USING HIGH-TEMPERATURE GC/MS, FOOD SCI. NUTR, 2, 4, PP. 417-425, (2014); TAMURA K., PETERSON D., PETERSON N., STECHER G., NEI M., KUMAR S., MEGA5: MOLECULAR EVOLUTIONARY GENETICS ANALYSIS USING MAXIMUM LIKELIHOOD, EVOLUTIONARY DISTANCE, AND MAXIMUM PARSIMONY METHODS, MOL. BIOL. EVOL, 28, 10, PP. 2731-2739, (2011); TAMURA K., STECHER G., KUMAR S., MEGA11: MOLECULAR EVOLUTIONARY GENETICS ANALYSIS VERSION 11, MOL. BIOL. EVOL, 38, 7, PP. 3022-3027, (2021); TANG W., LIAO L., XIAO Y., ZHAI J., SU H., CHEN Y., ET AL., EPICUTICULAR WAX OF SWEET SORGHUM INFLUENCED THE MICROBIAL COMMUNITY AND FERMENTATION QUALITY OF SILAGE, FRONT. MICROBIOL, 13, (2022); TAO Y., LUO H., XU J., CRUICKSHANK A., ZHAO X., TENG F., ET AL., EXTENSIVE VARIATION WITHIN THE PAN-GENOME OF CULTIVATED AND WILD SORGHUM, NAT. PLANTS, 7, 6, PP. 766-773, (2021); TAYLOR-TEEPLES M., LIN L., DE LUCAS M., TURCO G., TOAL T.W., GAUDINIER A., ET AL., AN ARABIDOPSIS GENE REGULATORY NETWORKFOR SECONDARY CELL WALL SYNTHESIS, NATURE, 2015, 517, PP. 571-575, (2015); TO A., JOUBES J., BARTHOLE G., LECUREUIL A., SCAGNELLI A., JASINSKI S., ET AL., WRINKLED TRANSCRIPTION FACTORS ORCHESTRATE TISSUE-SPECIFIC REGULATION OF FATTY ACID BIOSYNTHESIS IN ARABIDOPSIS, PLANT CELL, 24, 12, PP. 5007-5023, (2012); TRENKAMP S., MARTIN W., TIETJEN K., SPECIFIC AND DIFFERENTIAL INHIBITION OF VERY-LONG-CHAINFATTY ACID ELONGASES FROMARABIDOPSIS THALIANABYDIFFERENT HERBICIDES, PNAS, 101, 32, PP. 11903-11908, (2004); UTTAM G.A., PRAVEEN M., RAO Y.V., TONAPI V.A., MADHUSUDHANA R., MOLECULAR MAPPING AND CANDIDATE GENE ANALYSIS OF A NEW EPICUTICULAR WAX LOCUS IN SORGHUM (SORGHUM BICOLOR L. MOENCH), THEOR. APPL. GENET, 130, 10, PP. 2109-2125, (2017); VARALA K., MARSHALL-COLON A., CIRRONE J., BROOKS M.D., PASQUINO A.V., LERAN S., ET AL., TEMPORAL TRANSCRIPTIONAL LOGIC OF DYNAMIC REGULATORY NETWORKS UNDERLYING NITROGEN SIGNALING AND USE IN PLANTS, PROC. NATL. ACAD. SCI. U.S.A, 115, 25, PP. 6494-6499, (2018); WANG Y., WANG J., CHAI G., LI C., HU Y., CHEN X., ET AL., DEVELOPMENTAL CHANGES IN COMPOSITION AND MORPHOLOGY OF CUTICULAR WAXES ON LEAVES AND SPIKES OF GLOSSY AND GLAUCOUS WHEAT (TRITICUM AESTIVUM L.), PLOS ONE, 10, 10, (2015); WEN M., JETTER R., COMPOSITION OF SECONDARY ALCOHOLS, KETONES, ALKANEDIOLS, AND KETOLS IN ARABIDOPSIS THALIANA CUTICULAR WAXES, J. EXP. BOT, 60, 6, PP. 1811-1821, (2009); WENG H., MOLINA I., SHOCKEY J., BROWSE J., ORGAN FUSION AND DEFECTIVE CUTICLE FUNCTION IN A LACS1 LACS2 DOUBLE MUTANT OF ARABIDOPSIS, PLANTA, 231, 5, PP. 1089-1100, (2010); WESSELS B., SEYFFERTH C., ESCAMEZ S., VAIN T., ANTOS K., VAHALA J., ET AL., AN AP2/ERF TRANSCRIPTION FACTOR ERF139 COORDINATES XYLEM CELL EXPANSION AND SECONDARY CELL WALL DEPOSITION, NEW PHYTOL, 224, 4, PP. 1585-1599, (2019); WETTSTEIN-KNOWLES P., GENETIC CONTROL OF Β-DIKETONE AND HYDROXY-Β-DIKETONE SYNTHESIS IN EPICUTICULAR WAXES OF BARLEY, PLANTA, 106, PP. 113-130, (1972); XIAO Y., LI X., YAO L., XU D., LI Y., ZHANG X., ET AL., CHEMICAL PROFILES OF CUTICULAR WAXES ON VARIOUS ORGANS OF SORGHUM BICOLOR AND THEIR ANTIFUNGAL ACTIVITIES, PLANT PHYSIOL. BIOCHEM, 155, PP. 596-604, (2020); XIN Z., WANG M.L., BUROW G., BURKE J., AN INDUCED SORGHUM MUTANT POPULATION SUITABLE FOR BIOENERGY RESEARCH, BIOENERGY RES, 2, 1-2, PP. 10-16, (2009); XIN Z., WANG M., CUEVAS H.E., CHEN J., HARRISON M., PUGH N.A., ET AL., SORGHUM GENETIC, GENOMIC, AND BREEDING RESOURCES, PLANTA, 254, 6, (2021); XUE D., ZHANG X., LU X., CHEN G., CHEN Z.H., MOLECULAR AND EVOLUTIONARY MECHANISMS OF CUTICULAR WAX FOR PLANT DROUGHT TOLERANCE, FRONT. PLANT SCI, 8, (2017); YAN Y., LI C., DONG X., LI H., ZHANG D., ZHOU Y., ET AL., MYB30 IS A KEY NEGATIVE REGULATOR OF ARABIDOPSIS PHOTOMORPHOGENIC DEVELOPMENT THAT PROMOTES PIF4 AND PIF5 PROTEIN ACCUMULATION IN THE LIGHT, PLANT CELL, 32, 7, PP. 2196-2215, (2020); YANG Y., ZHOU B., ZHANG J., WANG C., LIU C., LIU Y., ET AL., RELATIONSHIPS BETWEEN CUTICULAR WAXES AND SKIN GREASINESS OF APPLES DURING STORAGE, POSTHARVEST BIOL. TECHNOL, 131, PP. 55-67, (2017); YANG X., FENG T., LI S., ZHAO H., ZHAO S., MA C., ET AL., CER16 INHIBITS POST-TRANSCRIPTIONAL GENE SILENCING OF CER3 TO REGULATE ALKANE BIOSYNTHESIS, PLANT PHYSIOL, 182, 3, PP. 1211-1221, (2020); YE J.H., LV Y.Q., LIU S.R., JIN J., WANG Y.F., WEI C.L., ET AL., EFFECTS OF LIGHT INTENSITY AND SPECTRAL COMPOSITION ON THE TRANSCRIPTOME PROFILES OF LEAVES IN SHADE GROWN TEA PLANTS (CAMELLIA SINENSIS L.) AND REGULATORY NETWORK OF FLAVONOID BIOSYNTHESIS, MOLECULES, 26, 19, (2021); YEATS T.H., ROSE J.K., THE FORMATION AND FUNCTION OF PLANT CUTICLES, PLANT PHYSIOL, 163, 1, PP. 5-20, (2013); YEPHREMOV A., WISMAN E., HUIJSER P., HUIJSER C., WELLESEN K., SAEDLER H., CHARACTERIZATION OF THE FIDDLEHEAD GENE OF ARABIDOPSIS REVEALS A LINK BETWEEN ADHESION RESPONSE AND CELL DIFFERENTIATION IN THE EPIDERMIS, PLANT CELL, 11, 11, PP. 2187-2201, (1999); YU K.M.J., OLIVER J., MCKINLEY B., WEERS B., H, FABICH T., EVETTS N., ET AL., BIOENERGY SORGHUM STEM GROWTH REGULATION: INTERCALARY MERISTEM LOCALIZATION, DEVELOPMENT, AND GENE REGULATORY NETWORK ANALYSIS, PLANT J, 112, 2, PP. 476-492, (2022)","J.E. MULLET; DEPARTMENT OF BIOCHEMISTRY & BIOPHYSICS, TEXAS A&M UNIVERSITY, COLLEGE STATION, UNITED STATES; EMAIL: JOHN.MULLET@AG.TAMU.EDU","FRONTIERS MEDIA SA","ENGLISH","FRONT. PLANT SCI.","ARTICLE","ISI","2-S2.0-85175856834","FRONT PLANT SCI","TEXAS AANDM UNIVERSITY;TEXAS AANDM UNIVERSITY;TEXAS AANDM UNIVERSITY;TEXAS AANDM UNIVERSITY","NOTREPORTED;TEXAS AANDM UNIVERSITY;NOTREPORTED",NA,"CHEMELEWSKI R, 2023, FRONT PLANT SCI","CHEMELEWSKI R, 2023, FRONT PLANT SCI"
"WANG Z;FENG Y;SUN L;GAN J;LI X;DING W;CHEN X","WANG, ZHAN-DI (57193419635); FENG, YING (34770356600); SUN, LONG (37060218600); GAN, JIN (55234305200); LI, XIAN (55252109700); DING, WEI-FENG (56683747800); CHEN, XIAO-MING (55739155400)","ANTIANDROGENETIC ALOPECIA EFFECT OF POLICOSANOL FROM CHINESE WAX BY REGULATING ABNORMAL HORMONE LEVELS TO SUPPRESS PREMATURE HAIR FOLLICLE ENTRY INTO THE REGRESSION PHASE",2021,"BIOMEDICINE AND PHARMACOTHERAPY","136","",11,"10.1016/j.biopha.2021.111241","SCHOOL OF CHEMISTRY, BIOLOGY AND ENVIRONMENT OF YUXI NORMAL UNIVERSITY, YUXI, 653100, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA","PREVIOUSLY, WE HAVE DEMONSTRATED THAT POLICOSANOL FROM CHINESE WAX SUPPRESSED TESTOSTERONE(T)-INDUCED ALOPECIA IN MICE. HOWEVER, THE UNDERLYING MECHANISM REMAINED TO BE DETERMINED. HEREIN, WE INVESTIGATED THE MECHANISM OF POLICOSANOL AGAINST ANDROGENETIC ALOPECIA (AGA). AGA WAS INDUCED IN KUNMING MICE BY SUBCUTANEOUS ADMINISTRATION OF TESTOSTERONE PROPIONATE FOR 60 D. POLICOSANOL (0.5 %, 1% OR 2%) WAS APPLIED TOPICALLY ON THE BACK OF MICE. FINASTERIDE (2%) WAS APPLIED TOPICALLY AS A POSITIVE CONTROL. THE SERUM T AND ESTRADIOL (E2) CONCENTRATIONS WERE DETERMINED BY ELISA AFTER 28 AND 60 DAYS OF TREATMENT. THE CUTANEOUS EXPRESSION OR ACTIVITY OF KEY MEDIATORS OF HAIR GROWTH, SUCH AS ALKALINE PHOSPHATASE (ALP), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND EPIDERMAL GROWTH FACTOR (EGF), WAS MEASURED. MTS ASSAY WAS PERFORMED TO EVALUATE CELL PROLIFERATION IN CULTURED HUMAN DERMAL PAPILLA CELLS (DPCS) TREATED WITH DIHYDROTESTOSTERONE (DHT). WESTERN BLOTTING WAS PERFORMED TO EVALUATE THE PROTEIN EXPRESSION OF BAX, BCL2, TGF-Β2, CASPASE-9, AND CASPASE-3. WE FOUND LOWER T AND T/E2 RATIO IN MICE TREATED WITH POLICOSANOL THAN IN THE MODEL GROUP. POLICOSANOL SUPPRESSED PREMATURE HAIR FOLLICLE ENTRY INTO THE REGRESSION PHASE, AS SHOWN BY IMPROVING VEGF AND EGF EXPRESSION AND ALP ACTIVITY. THE MTS ASSAY SHOWED THAT POLICOSANOL MARKEDLY INHIBITED THE APOPTOSIS OF DHT-TREATED DPCS. WESTERN BLOTTING SHOWED THAT POLICOSANOL SIGNIFICANTLY REDUCED THE PROTEIN EXPRESSION OF TGF-Β2, CLEAVED CASPESE-9, CLEAVED CASPASE-3, AND BAX, AND INCREASED THAT OF BCL2. THE OPTIMAL EFFECT WAS OBTAINED WITH 12.50 G/ML POLICOSANOL. IN CONCLUSION, POLICOSANOL PREVENTS ANDROGENETIC ALOPECIA BY REGULATING HORMONE LEVELS AND SUPPRESSING PREMATURE HAIR FOLLICLE ENTRY INTO THE REGRESSION PHASE. © 2021","ANDROGEN; CYTOKINES; DERMAL PAPILLA CELLS; ESTRADIOL; POLICOSANOL; PROTEIN","ALKALINE PHOSPHATASE; ALOPECIA; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FATTY ALCOHOLS; HAIR FOLLICLE; HEMIPTERA; MALE; MICE; TESTOSTERONE; TESTOSTERONE PROPIONATE; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WAXES; ALKALINE PHOSPHATASE; ANDROSTANOLONE; CASPASE 3; CASPASE 9; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FINASTERIDE; HORMONE; POLICOSANOL; PROTEIN BAX; PROTEIN BCL 2; TESTOSTERONE; TESTOSTERONE PROPIONATE; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; WAX; ALKALINE PHOSPHATASE; APOPTOSIS REGULATORY PROTEIN; CYTOKINE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FATTY ALCOHOL; POLICOSANOL; TESTOSTERONE; TGFB2 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; HAIR FOLLICLE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MALE TYPE ALOPECIA; MOUSE; MTS ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; SKIN CELL; TESTOSTERONE BLOOD LEVEL; WESTERN BLOTTING; ALOPECIA; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEMIPTERA; ISOLATION AND PURIFICATION; METABOLISM; PATHOPHYSIOLOGY","FUNDANMENTAL RESEARCH FOUNDS OF CAF, (CAFYBB2018ZB007)","THIS STUDY WAS FUNDED BY FUNDANMENTAL RESEARCH FOUNDS OF CAF ( CAFYBB2018ZB007 ).","TANAKA Y., ASO T., ONO J., HOSOI R., KANEKO T., ANDROGENETIC ALOPECIA TREATMENT IN ASIAN MEN, J. CLIN. AESTHET. DERMATOL., 11, PP. 32-35, (2018); GENTILE P., SCIOLI M.G., BIELLI A., DE ANGELIS B., DE SIO C., DE FAZIO D., ET AL., PLATELET-RICH PLASMA AND MICROGRAFTS ENRICHED WITH AUTOLOGOUS HUMAN FOLLICLE MESENCHYMAL STEM CELLS IMPROVE HAIR RE-GROWTH IN ANDROGENETIC ALOPECIA. BIOMOLECULAR PATHWAY ANALYSIS AND CLINICAL EVALUATION, BIOMEDICINES, 7, PP. 1-17, (2019); YORK K., MEAH N., BHOYRUL B., SINCLAIR R., A REVIEW OF THE TREATMENT REVIEW FOR MALE PATTERN HAIR-LOSS, EXPERT OPIN. PHARMACOTHER., 21, 489, PP. 1-10, (2020); HUANG Y., ZHUO F., LI L., ENHANCING HAIR GROWTH IN MALE ANDROGENETIC ALOPECIA BY A COMBINATION OF FRACTIONAL CO2 LASER THERAPY AND HAIR GROWTH FACTORS, LASERS MED. SCI., PP. 1-8, (2017); KELLY Y., BLANCO A., TOSTI A., ANDROGENETIC ALOPECIA: AN UPDATE OF TREATMENT OPTIONS, DRUGS, 76, PP. 1349-1364, (2016); GENTILE P., DIONISI L., PIZZICANNELLA J., DE ANGELIS B., DE FAZIO D., GARCOVICH S., A RANDOMIZED BLINDED RETROSPECTIVE STUDY: THE COMBINED USE OF MICRO-NEEDLING TECHNIQUE, LOW-LEVEL LASER THERAPY AND AUTOLOGOUS NON-ACTIVATED PLATELET-RICH PLASMA IMPROVES HAIR RE-GROWTH IN PATIENTS WITH ANDROGENIC ALOPECIA, EXPERT OPIN. BIOL. THER., 20, PP. 1099-1109, (2020); GENTILE P., GARCOVICH S., ADVANCES IN REGENERATIVE STEM CELL THERAPY IN ANDROGENIC ALOPECIA AND HAIR LOSS: WNT PATHWAY, GROWTH-FACTOR, AND MESENCHYMAL STEM CELL SIGNALING IMPACT ANALYSIS ON CELL GROWTH AND HAIR FOLLICLE DEVELOPMENT, CELLS, 8, PP. 1-21, (2019); PIETRO G., JOHN C., MEGAN C., SIMONE G., ALESSANDRA B., MARIA S., ET AL., EVALUATION OF NOT-ACTIVATED AND ACTIVATED PRP IN HAIR LOSS TREATMENT: ROLE OF GROWTH FACTOR AND CYTOKINE CONCENTRATIONS OBTAINED BY DIFFERENT COLLECTION SYSTEMS, INT. J. MOL. SCI., 18, PP. 408-424, (2017); GENTILE P., GARCOVICH S., SYSTEMATIC REVIEW-THE POTENTIAL IMPLICATIONS OF DIFFERENT PLATELET-RICH PLASMA (PRP) CONCENTRATIONS IN REGENERATIVE MEDICINE FOR TISSUE REPAIR, INT. J. MOL. SCI., 21, 16, PP. 1-26, (2020); SAID M.A., AKANKSHA M., THE IMPACT OF 5Α-REDUCTASE INHIBITOR USE FOR MALE PATTERN HAIR LOSS ON MEN'S HEALTH, CURR. UROL. REP., 19, PP. 65-71, (2018); WANG Z.-D., FENG Y., L-Y M., LI X., DING W.-F., CHEN X.-M., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMED. PHARMACOTHER., 89, PP. 438-446, (2017); NOUBARANI M., ROSTAMKHANI H., ERFAN M., ET AL., EFFECT OF ADIANTUM CAPILLUS VENERIS LINN ON AN ANIMAL MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, IRAN. J. PHARM. RES., 13, PP. 113-118, (2014); PARK K.S., PARK D.H., COMPARISON OF SACCHARINA JAPONICA–UNDARIA PINNATIFIDA MIXTURE AND MINOXIDIL ON HAIR GROWTH PROMOTING EFFECT IN MICE, ARCH. PLAST. SURG., 43, PP. 498-505, (2016); CERUTI J.M., LEIROS G.J., BALANA M.E., ANDROGENS AND ANDROGEN RECEPTOR ACTION IN SKIN AND HAIR FOLLICLES, MOL. CELL. ENDOCRINOL., 465, PP. 122-133, (2018); INUI S., ITAMI S., ANDROGEN ACTIONS ON THE HUMAN HAIR FOLLICLE: PERSPECTIVES, EXP. DERMATOL., 22, PP. 168-171, (2013); HIBINO T., NISHIYAMA T., ROLE OF TGF-BETA2 IN THE HUMAN HAIR CYCLE, J. DERMATOL. SCI., 35, PP. 9-18, (2004); LOLLI F., PALLOTTI F., ROSSI A., FORTUNA M.C., CARO G., LENZI A., ET AL., ANDROGENETIC ALOPECIA: A REVIEW, ENDOCRINE, 57, PP. 9-17, (2017); CASERINI M., RADICIONI M., LEURATTI C., TERRAGNI E., IORIZZO M., PALMIERI R., EFFECTS OF A NOVEL FINASTERIDE 0.25% TOPICAL SOLUTION ON SCALP AND SERUM DIHYDROTESTOSTERONE IN HEALTHY MEN WITH ANDROGENETIC ALOPECIA, INT. J. CLIN. PHARMACOL. THER., 54, PP. 19-27, (2016); CERVELLI V., GARCOVICH S., BIELLI A., CERVELLI G., GENTILE P., THE EFFECT OF AUTOLOGOUS ACTIVATED PLATELET RICH PLASMA (AA-PRP) INJECTION ON PATTERN HAIR LOSS: CLINICAL AND HISTOMORPHOMETRIC EVALUATION, BIOMED RES. INT., 2014, (2014); HAN J.H., KWON O.S., CHUNG J.H., CHO K.H., EUN H.C., KIM K.H., EFFECT OF MINOXIDIL ON PROLIFERATION AND APOPTOSIS IN DERMAL PAPILLA CELLS OF HUMAN HAIR FOLLICLE, J. DERMATOL. SCI., 34, PP. 91-98, (2004); ANTONELLA T., PIRACCINI B., FINASTERIDE AND THE HAIR CYCLE, J. AM. ACAD. DERMATOL., 42, PP. 848-849, (2000); GENTILE P., GARCOVICH S., AUTOLOGOUS ACTIVATED PLATELET-RICH PLASMA (AA-PRP) AND NON-ACTIVATED (A-PRP) IN HAIR GROWTH: A RETROSPECTIVE, BLINDED, RANDOMIZED EVALUATION IN ANDROGENETIC ALOPECIA, EXPERT OPIN. BIOL. THER., 20, 3, PP. 5702-5724, (2020); P G, S G, A B, ET AL., THE EFFECT OF PLATELET-RICH PLASMA IN HAIR REGROWTH: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, STEM CELLS TRANSL. MED., 4, PP. 1317-1323, (2015); ZHENG J.L., CHOI H.I., CHOI D.K., SOHN K.C., LEE Y., AUTOLOGOUS PLATELET-RICH PLASMA: A POTENTIAL THERAPEUTIC TOOL FOR PROMOTING HAIR GROWTH, DERMATOL. SURG., 38, PP. 1040-1046, (2012); HOU C., MIAO Y., WANG J., WANG X., CHEN C.Y., HU Z.Q., COLLAGENASE IV PLAYS AN IMPORTANT ROLE IN REGULATING HAIR CYCLE BY INDUCING VEGF, IGF-1, AND TGF-Β EXPRESSION, DRUG DES. DEVEL. THER., 9, PP. 5373-5383, (2015); TANG J., SHEN Y., CHEN G., WAN Q., WANG K., ZHANG J., ET AL., ACTIVATION OF E-PROSTANOID 3 RECEPTOR IN MACROPHAGES FACILITATES CARDIAC HEALING AFTER MYOCARDIAL INFARCTION, NAT. COMMUN., 8, (2017); IIDA M., IHARA S., MATSUZAKI T., HAIR CYCLE-DEPENDENT CHANGES OF ALKALINE PHOSPHATASE ACTIVITY IN THE MESENCHYME AND EPITHELIUM IN MOUSE VIBRISSAL FOLLICLES, DEV. GROWTH DIFFER., 49, PP. 185-195, (2007); GENTILE P., SCIOLI M.G., BIELLI A., ORLANDI A., CERVELLI V., STEM CELLS FROM HUMAN HAIR FOLLICLES: FIRST MECHANICAL ISOLATION FOR IMMEDIATE AUTOLOGOUS CLINICAL USE IN ANDROGENETIC ALOPECIA AND HAIR LOSS, STEM CELL INVESTIG., 4, 7, (2017); PARK Y.O., KIM S.E., KIM Y.C., ACTION MECHANISM OF CHAMAECYPARIS OBTUSA OIL ON HAIR GROWTH, TOXICOL. RES., 29, PP. 241-247, (2013); LEE C.-Y., YANG C.-Y., LIN C.-C., YU M.-C., SHEU S.-J., KUAN Y.-H., HAIR GROWTH IS PROMOTED BY BEAUTOP VIA EXPRESSION OF EGF AND FGF‑7, MOL. MED. REP., 17, PP. 8047-8052, (2018); ZHANG H., NAN W., WANG S., ZHANG T., SI H., WANG D., ET AL., EPIDERMAL GROWTH FACTOR PROMOTES PROLIFERATION OF DERMAL PAPILLA CELLS VIA NOTCH SIGNALING PATHWAY, BIOCHIMIE, 127, PP. 10-18, (2016); DAVID E.S., CATHERINE L., ET AL., Β-CATENIN ACTIVITY IN THE DERMAL PAPILLA REGULATES MORPHOGENESIS AND REGENERATION OF HAIR, DEV. CELL, 18, 4, PP. 633-642, (2010); HU S., LI Z., LUTZ H., HUANG K., CHENG K., DERMAL EXOSOMES CONTAINING MIR-218-5P PROMOTE HAIR REGENERATION BY REGULATING Β-CATENIN SIGNALING, SCI. ADV., 6, (2020); TSUJI Y., DENDA S., SOMA T., RAFTERY L., MOMOI T., HIBINO T., A POTENTIAL SUPPRESSOR OF TGF-BETA DELAYS CATAGEN PROGRESSION IN HAIR FOLLICLES, J. INVESTIG. DERMATOL. SYMP. PROC., 8, PP. 65-68, (2003)","X.-M. CHEN; RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA; EMAIL: CAFCXM@139.COM","ELSEVIER MASSON S.R.L.","ENGLISH","BIOMED. PHARMACOTHER.","REVIEW","ISI","2-S2.0-85100105873","BIOMED PHARMACOTHER","BIOLOGY AND ENVIRONMENT OF YUXI NORMAL UNIVERSITY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY","NOTREPORTED;RESEARCH INSTITUTE OF RESOURCE INSECTS OF CHINESE ACADEMY OF FORESTRY;NOTREPORTED",NA,"WANG Z-D, 2021, BIOMED PHARMACOTHER","WANG Z-D, 2021, BIOMED PHARMACOTHER"
"LI C;DING Y;SI Q;LI K;XU K","LI, CHUNLIN (57194690437); DING, YU (59102020400); SI, QUANJIN (8629813000); LI, KAILIANG (56263381800); XU, KUN (57220999026)","MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY PATIENTS WITH DYSLIPIDEMIA",2020,"JOURNAL OF INTERNATIONAL MEDICAL RESEARCH","48","",8,"10.1177/0300060520936082","SECOND DEPARTMENT OF INTERNAL MEDICINE, 316 HOSPITAL OF PLA, BEIJING, CHINA;FIRST DEPARTMENT OF CARDIOVASCULAR DISEASES, SOUTH BUILDING, CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA;FIRST DEPARTMENT OF CARDIOVASCULAR DISEASES, SOUTH BUILDING, CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA;FIRST DEPARTMENT OF CARDIOVASCULAR DISEASES, SOUTH BUILDING, CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA;FIRST DEPARTMENT OF CARDIOVASCULAR DISEASES, SOUTH BUILDING, CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA","OBJECTIVE: TO DETERMINE THE MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY DYSLIPIDEMIA PATIENTS. METHODOLOGY: THERE WERE 294 ELDERLY DYSLIPIDEMIA PATIENTS ENROLLED INTO THIS CLINICAL STUDY. THEY WERE RANDOMLY DIVIDED INTO FOUR GROUPS, AS FOLLOWS: 20 MG POLICOSANOL (GROUP A, N = 64); 10 MG POLICOSANOL (GROUP B, N = 72); 20 MG ATORVASTATIN (GROUP C, N = 91); AND 10 MG POLICOSANOL + 20 MG ATORVASTATIN (GROUP D, N = 62). PLASMA PLATELET COUNT, PLATELET AGGREGATION RATE, CIRCULATING ENDOTHELIAL CELL (CEC) COUNT, HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP), AND CAROTID INTIMA–MEDIA THICKNESS (IMT) WERE MEASURED BEFORE THE STUDY (WEEK 0) AND AT WEEKS 12, 24, AND 52. RESULTS: IN GROUP A, THE PLATELET AGGREGATION RATE CAUSED BY ADENOSINE DIPHOSPHATE (ADP) AFTER TREATMENT WAS SIGNIFICANTLY DECREASED COMPARED WITH BEFORE TREATMENT (48.79% ± 20.29% VS. 40.37% ± 23.56%), BUT THE ARACHIDONIC ACID (AA)-INDUCED PLATELET AGGREGATION RATES WERE SIMILAR. THE PLATELET AGGREGATION RATES INDUCED BY AA AND ADP IN GROUPS B, C, AND D DID NOT CHANGE SIGNIFICANTLY. CEC COUNTS AND HS-CRP AND HOMOCYSTEINE LEVELS IN ALL GROUPS AFTER TREATMENT WERE SIGNIFICANTLY LOWER COMPARED WITH BEFORE TREATMENT, BUT CAROTID IMTS WERE SIMILAR. CONCLUSION: POLICOSANOL REGULATES BLOOD LIPID LEVELS AND IMPROVES ENDOTHELIAL CELL FUNCTION, AND IT COULD DELAY THE PROGRESS OF ATHEROSCLEROSIS. TRIAL REGISTRATION NUMBER: CHICTR-RRC-17013396 (RETROSPECTIVELY REGISTERED). © THE AUTHOR(S) 2020.","ATHEROSCLEROSIS; ATORVASTATIN; DYSLIPIDEMIA; ELDERLY; ENDOTHELIAL CELL; POLICOSANOL","AGED; CAROTID INTIMA-MEDIA THICKNESS; DYSLIPIDEMIAS; FATTY ALCOHOLS; HUMANS; PLATELET AGGREGATION; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ATORVASTATIN; HOMOCYSTEINE; LIPID; POLICOSANOL; FATTY ALCOHOL; POLICOSANOL; AGED; AMINO ACID BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; CELL COUNT; CELL FUNCTION; CIRCULATING ENDOTHELIAL CELL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ELDERLY CARE; ENDOTHELIUM CELL; FEMALE; GERIATRIC PATIENT; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PLATELET COUNT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; ARTERIAL WALL THICKNESS","","","CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAP RES, 57, PP. 691-699, (1996); MENENDEZ R., MARRERO D., MAS R., ET AL., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); KIM J.Y., KIM S.M., KIM S.J., ET AL., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT J MOL MED, 39, PP. 889-899, (2017); FERNANDEZ S., MAS R., GAMEZ R., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, PP. 219-229, (2004); FRANCINI-PESENTI F., SPINELLA P., CALO L.A., POTENTIAL ROLE OF PHYTOCHEMICALS IN METABOLIC SYNDROME PREVENTION AND THERAPY, DIABETES METAB SYNDR OBES, 12, PP. 1987-2002, (2019); JELLINGER P.S., AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE CLINICAL PRACTICE GUIDELINES, DIABETES SPECTR, 31, PP. 234-245, (2018); PING Y., XIAOYING L., CHINESE GERIATRIC SOCIETY, WRITING GROUP OF CHINESE EXPERT CONSENSUS ON THE TREATMENT OF SENSILE DYSLIPIDEMIA WITH POLICOSANOL. CHINESE EXPERT CONSENSUS ON THE TREATMENT OF SENSILE DYSLIPIDEMIA WITH POLICOSANOL, CHIN J GERIATRI, 36, PP. 831-835, (2017); PATTI A.M., AL-RASADI K., GIGLIO R.V., ET AL., NATURAL APPROACHES IN METABOLIC SYNDROME MANAGEMENT, ARCH MED SCI, 14, PP. 422-441, (2018); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR REV, 75, PP. 731-767, (2017); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); CICERO A.F.G., FOGACCI F., COLLETTI A., FOOD AND PLANT BIOACTIVES FOR REDUCING CARDIOMETABOLIC DISEASE RISK: AN EVIDENCE BASED APPROACH, FOOD FUNCT, 8, PP. 2076-2088, (2017); MAS R., CASTANO G., FERNANDEZ J., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE HYPERCHOLESTEROLEMIA, ASIA PAC J CLINIC NUTR, 13, PP. S102-S108, (2004); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); YUAN-LIN G., LI J.-J., HIGHLIGHTS OF THE GUIDELINES FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA IN CHINESE ADULTS (REVISED EDITION 2016), CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE (ELECTRONIC VERSION), 31, PP. 937-953, (2017); CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, 253, PP. 281-344, (2016); SINGH U., DASU M.R., YANCEY P.G., ET AL., HUMAN C-REACTIVE PROTEIN PROMOTES OXIDIZED LOW DENSITY LIPOPROTEIN UPTAKE AND MATRIX METAL-LOPROTEINASE-9 RELEASE IN WISTAR RATS, J LIPID RES, 49, PP. 1015-1023, (2008); HAN J.Q., LI B.W., YUAN X.C., ET AL., CIRCULATING ENDOTHELIAL CELLS: IMPORTANT BIOMARKERS FOR EVALUATING VASCULAR ENDOTHELIAL FUNCTIONS IN THE PATHOLOGICAL STATE, J CHIN MICROCIRC, 13, PP. 431-435, (2009); TAKAHASHI H., HARKER L.A., MEASUREMENT OF HUMAN ENDOTHELIAL CELLS IN WHOLE BLOOD, THROMB RES, 31, PP. 22-23, (1983); KAZEMI M.B., ESHRAGHIAN K., OMRANI G.R., ET AL., HOMOCYSTEINE LEVEL AND CORONARY ARTERY DISEASE, ANGIOLOGY, 57, PP. 9-14, (2006); ARENILLAS J.F., ALVAREZ-SABIN J., MOLINA C.A., ET AL., C-REACTIVE PROTEIN PREDICTS FURTHER ISCHEMIC EVENTS IN FIRST-EVER TRANSIENT ISCHEMIC ATTACK OR STROKE PATIENTS WITH INTRACRANIAL LARGE-ARTERY OCCLUSIVE DISEASE, STROKE, 34, PP. 2463-2468, (2003); LI J.J., TIAN N.L., ZHU Z.S., ET AL., CHARACTERIZATION OF THE MOLECULAR MECHANISM OF ANTI-ATHEROSCLEROTIC EFFECT OF POLICOSANOL IN ATHEROSCLEROSIS RATS, ACTA UNIV MED NANJING (NAT SCI), 23, PP. 650-654, (2012)","Q. SI; FIRST DEPARTMENT OF CARDIOVASCULAR DISEASES, SOUTH BUILDING, CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA; EMAIL: DPAVSZ@163.COM","SAGE PUBLICATIONS LTD","ENGLISH","J. INT. MED. RES.","ARTICLE","ISI","2-S2.0-85088482055","J INT MED RES","CHINESE PLA GENERAL HOSPITAL;CHINESE PLA GENERAL HOSPITAL;CHINESE PLA GENERAL HOSPITAL;CHINESE PLA GENERAL HOSPITAL","NOTREPORTED;CHINESE PLA GENERAL HOSPITAL;NOTREPORTED",NA,"LI C, 2020, J INT MED RES","LI C, 2020, J INT MED RES"
"KIM H;KIM Y;ANTONISAMY P;RYU D;LEE Y;LEE G;KWON K","KIM, HA-RIM (56136468300); KIM, YE-SEUL (57224073944); ANTONISAMY, PAULRAYER (26657889700); RYU, DO-GON (7103144228); LEE, YOUNG-RAE (35071356900); LEE, GUEMSAN (36604605000); KWON, KANG-BEOM (7201503187)","A 8WEEK RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED HUMAN TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SACCHARUM OFFICINARUM WAX ALCOHOLS POLICOSANOL ON IMPROVEMENT OF BLOOD CHOLESTEROL",2023,"JOURNAL OF KING SAUD UNIVERSITY - SCIENCE","35","",0,"10.1016/j.jksus.2023.102769","JEONBUK, IKSAN, SOUTH KOREA;JEONBUK, IKSAN, SOUTH KOREA;JEONBUK, IKSAN, SOUTH KOREA;DEPARTMENT OF PHYSIOLOGY, COLLEGE OF KOREAN MEDICINE, WONKWANG UNIVERSITY, JEONBUK, IKSAN, SOUTH KOREA;DEPARTMENT OF ORAL PHYSIOLOGY, & INSTITUTE OF BIOMATERIAL-IMPLANT, COLLEGE OF DENTISTRY, WONKWANG UNIVERSITY, JEONBUK, IKSAN, SOUTH KOREA;DEPARTMENT OF HERBOLOGY, COLLEGE OF KOREAN MEDICINE, WONKWANG UNIVERSITY, JEONBUK, IKSAN, SOUTH KOREA;JEONBUK, IKSAN, SOUTH KOREA","BACKGROUND: THE PREVALENCE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE APPEARS TO BE REDUCED, ACCORDING TO A LARGE BODY OF RESEARCH, BY LOWERING BLOOD LEVELS OF THE RATIO OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C)/ HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), TRIGLYCERIDE (TG)/HDL-C, AND LDL-C. OBJECTIVE: THE OBJECTIVE OF THE INVESTIGATION WAS TO DETERMINE THE SAFETY AND ENDURANCE OF POLICOSANOL (20 MG/D), AS WELL AS ITS EFFICACY IN HEALTHY INDIVIDUALS. TWO PARALLEL GROUPS IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HUMAN EXPERIMENT RECEIVED EITHER A POLICOSANOL (20 MG/D) OR A PLACEBO FOR EIGHT WEEKS. 80 PEOPLE WERE RANDOMLY ASSIGNED, WITH A MEAN (SD) AGE (YEARS) OF 42.61 (13.51), A MEAN (SD) BMI (KG/M2) OF 24.53 (3.57), A MEAN (SD) WEIGHT (KG) OF 66.71 (14.30), AND A MEAN (SD) HEIGHT (CM) OF 164.21. (7.99). RESULTS: AT 8 WEEKS, WHEN COMPARED TO THE BASELINE GROUP, THE POLICOSANOL (20 MG/D) BATCH DISPLAYED CONSIDERABLY GREATER LDL-C (-4.87 ± 11.30 MG/DL; P = 0.014), TOTAL CHOLESTEROL (-6.82 ± 14.32 MG/DL; P = 0.007), TRIGLYCERIDE (-9.37 ± 19.27 MG/DL; P = 0.008), NON HDL-C REDUCTIONS (-10.32 ± 13.75 MG/DL; P = 0.0001), AND SIGNIFICANTLY GREATER AUGMENTATION OF HDL-C (3.50 ± 4.55 MG/DL; P = 0.010). POLICOSANOL (20 MG/D) TREATMENT ALSO SIGNIFICANTLY REDUCING THE SERUM LEVELS OF TC/HDL-C (P = 0.0001) AND LDL-C/HDL-C (P = 0.0002), TRIGLYCERIDE/HDL-C (P = 0.001), AND T-CHOLESTEROL-HDL-C/HDL-C (P = 0.0001) RATIOS. CONCLUSION: IN HUMANS, POLICOSANOL DELIVERY RESULTED IN A LOWERING OF LDL-C LEVELS AND AN IMPROVEMENT IN OTHER LIPID MARKERS, DEMONSTRATING THE PRODUCT POTENTIAL TO REGULATE HYPERCHOLESTEROLEMIA. © 2023 THE AUTHOR(S)","CARDIOVASCULAR DISEASE; HYPERCHOLESTEROLEMIA; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIGLYCERIDE","","WONKWANG UNIVERSITY","THIS PRESENT STUDY WAS SUPPORTED BY WONKWANG UNIVERSITY, SOUTH KOREA IN 2021. ","ALEMAN C., RODEIRO I., NOA M., MENENDEZ R., GAMEZ R., HERNANDEZ C., MAS R., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J. APPL. TOXICOL., 21, 3, PP. 179-184, (2001); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES. CLIN. EXPTL., 56, PP. 176-182, (1995); ARNETT D.K., BLUMENTHAL R.S., ALBERT M.A., BUROKER A.B., GOLDBERGER Z.D., HAHN E.J., HIMMELFARB C.D., KHERA A., LLOYD-JONES D., MCEVOY J.W., MICHOS E.D., MIEDEMA M.D., MUNOZ D., SMITH S.C., VIRANI S.S., WILLIAMS K.A., YEBOAH J., ZIAEIAN B., 2019 ACC/AHA GUIDELINE ON THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, J. AM. COLL. CARDIOL., 74, 10, PP. E177-E232, (2019); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 20, 4, PP. 119-124, (1998); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES., 33, 7, PP. 835-840, (2000); AZEMAWAH V., MOVAHED M.R., CENTUORI P., PENAFLOR R., RIEL P.L., SITU S., SHADMEHR M., HASHEMZADEH M., STATE OF THE ART COMPREHENSIVE REVIEW OF INDIVIDUAL STATINS, THEIR DIFFERENCES, PHARMACOLOGY, AND CLINICAL IMPLICATIONS, CARDIOVASC. DRUGS THER., 33, 5, PP. 625-639, (2019); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, 4, PP. 311-321, (2011); CANETTI M., MORERA M.S., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR. THER. RES. CLIN. EXPTL., 58, PP. 868-875, (1997); CASTANO, G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CUR. THER. RES., 60, 7, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R. D., 3, 3, PP. 159-172, (2002); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 22, 3-4, PP. 89-99, (2002); FERENCE B.A., GINSBERG H.N., GRAHAM I., RAY K.K., PACKARD C.J., BRUCKERT E., HEGELE R.A., KRAUSS R.M., RAAL F.J., SCHUNKERT H., WATTS G.F., BOREN J., FAZIO S., HORTON J.D., MASANA L., NICHOLLS S.J., NORDESTGAARD B.G., VAN DE SLUIS B., TASKINEN M.R., TOKGOZOGLU L., CATAPANO A.L., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR. HEART J., 38, 32, PP. 2459-2472, (2017); FERNANDEZ S., MAS R., GAMEZ R., DIAZ A., FERNANDEZ J., DEIBIS ORTA S., ILLNAIT J., CASTANO G., MENDOZA S., VALDES F., ALVAREZ E., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM. J. GERIATR. PHARMACOTHER., 2, 4, PP. 219-229, (2004); FORD I., MURRAY H., MCCOWAN C., PACKARD C.J., LONG-TERM SAFETY AND EFFICACY OF LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH STATIN THERAPY: 20-YEAR FOLLOW-UP OF WEST OF SCOTLAND CORONARY PREVENTION STUDY, CIRCULATION, 133, 11, PP. 1073-1080, (2016); HEART PROTECTION STUDY COLLABORATIVE GROUP, MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET (LONDON, ENGLAND), 360, 9326, PP. 7-22, (2002); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB., 37, 1, PP. 33-38, (1993); KANG Y.R., CHOI H.Y., LEE J.Y., JANG S.I., OH J.B., KIM J.S., LEE J.W., JO S.H., HA K.S., LEE M.S., KIM Y.C., APOSTOLIDIS E., KWON Y.I., EFFECT OF SUPPLEMENTATION OF LOW-MOLECULAR-WEIGHT CHITOSAN OLIGOSACCHARIDE, GO2KA1, ON POSTPRANDIAL BLOOD GLUCOSE LEVELS IN HEALTHY INDIVIDUALS FOLLOWING BREAD CONSUMPTION, FOOD SCI. BIOTECHNOL., 25, 3, PP. 911-914, (2016); KAZI D.S., PENKO J.M., BIBBINS-DOMINGO K., STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: REVIEW OF EVIDENCE AND RECOMMENDATIONS FOR CLINICAL PRACTICE, MED. CLIN. NORTH AM., 101, 4, PP. 689-699, (2017); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED., 39, 4, PP. 889-899, (2017); KIM K., LEE S.H., EFFECTS OF STATINS FOR PRIMARY PREVENTION IN THE ELDERLY: RECENT EVIDENCE, J. LIPID ATHEROSCLER., 9, 1, PP. 1-7, (2020); KIM H.R., PAULRAYER A., KWON Y.G., RYU D.G., BAEK D.G., GEUM J.H., LEE J.H., LEE G.S., KWON K.B., ACUTE EFFECTS OF AMOMUM VILLOSUM LOUR. FRUIT EXTRACT ON POSTPRANDIAL GLYCEMIA AND INSULIN SECRETION: A SINGLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY IN HEALTHY SUBJECTS. SAUDI, J. BIOL. SCI., 27, 11, PP. 2968-2971, (2020); LLOYD S.M., STOTT D.J., DE CRAEN A.J., KEARNEY P.M., SATTAR N., PERRY I., PACKARD C.J., BRIGGS A., MARCHBANK L., COMBER H., JUKEMA J.W., WESTENDORP R.G., TROMPET S., BUCKLEY B.M., FORD I., LONG-TERM EFFECTS OF STATIN TREATMENT IN ELDERLY PEOPLE: EXTENDED FOLLOW-UP OF THE PROSPECTIVE STUDY OF PRAVASTATIN IN THE ELDERLY AT RISK (PROSPER), PLOS ONE, 8, 9, (2013); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, 4, PP. 439-447, (1999); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, 3, PP. 268-279, (2002); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, 3, PP. 255-262, (2000); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, 1, PP. 8-12, (2001); NYAMBE-SILAVWE H., WILLIAMSON G., POLYPHENOL- AND FIBRE-RICH DRIED FRUITS WITH GREEN TEA ATTENUATE STARCH-DERIVED POSTPRANDIAL BLOOD GLUCOSE AND INSULIN: A RANDOMISED, CONTROLLED, SINGLE-BLIND, CROSS-OVER INTERVENTION, BR. J. NUTR., 116, 3, PP. 443-450, (2016); OKOPIEN B., BULDAK L., BOLDYS A., BENEFITS AND RISKS OF THE TREATMENT WITH FIBRATES–A COMPREHENSIVE SUMMARY, EXPERT REV. CLIN. PHARMACOL., 11, 11, PP. 1099-1112, (2018); PACKARD C.J., FORD I., LONG-TERM FOLLOW-UP OF LIPID-LOWERING TRIALS, CURR. OPIN. LIPIDOL., 26, 6, PP. 572-579, (2015); REITER-BRENNAN C., OSEI A.D., IFTEKHAR UDDIN S.M., ORIMOLOYE O.A., OBISESAN O.H., MIRBOLOUK M., BLAHA M.J., DZAYE O., ACC/AHA LIPID GUIDELINES: PERSONALIZED CARE TO PREVENT CARDIOVASCULAR DISEASE, CLEVE. CLIN. J. MED., 87, 4, PP. 231-239, (2020); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER., 318, 3, PP. 1020-1026, (2006); VIRANI S.S., ALONSO A., BENJAMIN E.J., BITTENCOURT M.S., CALLAWAY C.W., CARSON A.P., CHAMBERLAIN A.M., CHANG A.R., CHENG S., DELLING F.N., DJOUSSE L., ELKIND M.S.V., FERGUSON J.F., FORNAGE M., KHAN S.S., KISSELA B.M., KNUTSON K.L., KWAN T.W., LACKLAND D.T., LEWIS T.T., AMERICAN HEART ASSOCIATION COUNCIL ON EPIDEMIOLOGY AND PREVENTION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE. HEART DISEASE AND STROKE STATISTICS-2020 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 141, 9, PP. E139-E596, (2020); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, 2, PP. 165-170, (2003); YANAI H., KATSUYAMA H., HAMASAKI H., ABE S., TADA N., SAKO A., EFFECTS OF DIETARY FAT INTAKE ON HDL METABOLISM, J. CLIN. MED. RES., 7, 3, PP. 145-149, (2015)","K.-B. KWON; ILWONBIO CO., LTD, & DEPARTMENT OF KOREAN PHYSIOLOGY, COLLEGE OF KOREAN MEDICINE, WONKWANG UNIVERSITY, IKSAN, 460 IKSANDAERO, JEONBUK, 54538, SOUTH KOREA; EMAIL: DESSON@WKU.AC.KR","ELSEVIER B.V.","ENGLISH","J. KING SAUD UNIV. SCI.","ARTICLE","ISI","2-S2.0-85164493604","J KING SAUD UNIV SCI","WONKWANG UNIVERSITY;WONKWANG UNIVERSITY;WONKWANG UNIVERSITY","NOTREPORTED;WONKWANG UNIVERSITY;NOTREPORTED",NA,"KIM H-R, 2023, J KING SAUD UNIV SCI","KIM H-R, 2023, J KING SAUD UNIV SCI"
"WENG G;DUAN Y;ZHONG Y;SONG B;ZHENG J;ZHANG S;YIN Y;DENG J","WENG, GUANGYING (57288099300); DUAN, YEHUI (57195245170); ZHONG, YINZHAO (57204452821); SONG, BO (57206637420); ZHENG, JIE (56861487700); ZHANG, SHIYU (57217146654); YIN, YULONG (57215375046); DENG, JINPING (37114287100)","PLANT EXTRACTS IN OBESITY A ROLE OF GUT MICROBIOTA",2021,"FRONTIERS IN NUTRITION","8","",13,"10.3389/fnut.2021.727951","GUANGDONG PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITION REGULATION, SOUTH CHINA AGRICULTURAL UNIVERSITY, GUANGZHOU, CHINA, CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA;CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA;CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA;CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA, COLLEGE OF ADVANCED AGRICULTURAL SCIENCES, UNIVERSITY OF CHINESE ACADEMY OF SCIENCES, BEIJING, CHINA;CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA, COLLEGE OF ADVANCED AGRICULTURAL SCIENCES, UNIVERSITY OF CHINESE ACADEMY OF SCIENCES, BEIJING, CHINA;CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA, COLLEGE OF ADVANCED AGRICULTURAL SCIENCES, UNIVERSITY OF CHINESE ACADEMY OF SCIENCES, BEIJING, CHINA;GUANGDONG PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITION REGULATION, SOUTH CHINA AGRICULTURAL UNIVERSITY, GUANGZHOU, CHINA, CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA;GUANGDONG PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITION REGULATION, SOUTH CHINA AGRICULTURAL UNIVERSITY, GUANGZHOU, CHINA","OBESITY HAS BECOME ONE OF THE MOST SERIOUS CHRONIC DISEASES THREATENING HUMAN HEALTH. ITS OCCURRENCE AND DEVELOPMENT ARE CLOSELY ASSOCIATED WITH GUT MICROBIOTA SINCE THE DISORDERS OF GUT MICROBIOTA CAN PROMOTE ENDOTOXIN PRODUCTION AND INDUCE INFLAMMATORY RESPONSE. RECENTLY, NUMEROUS PLANT EXTRACTS HAVE BEEN PROVEN TO MITIGATE LIPID DYSMETABOLISM AND OBESITY SYNDROME BY REGULATING THE ABUNDANCE AND COMPOSITION OF GUT MICROBIOTA. IN THIS REVIEW, WE SUMMARIZE THE POTENTIAL ROLES OF DIFFERENT PLANT EXTRACTS INCLUDING MULBERRY LEAF EXTRACT, POLICOSANOL, CORTEX MOUTAN, GREEN TEA, HONOKIOL, AND CAPSAICIN IN REGULATING OBESITY VIA GUT MICROBIOTA. BASED ON THE CURRENT FINDINGS, PLANT EXTRACTS MAY BE PROMISING AGENTS FOR THE PREVENTION AND TREATMENT OF OBESITY AND ITS RELATED METABOLIC DISEASES, AND THE MECHANISMS MIGHT BE ASSOCIATED WITH GUT MICROBIOTA. © COPYRIGHT © 2021 WENG, DUAN, ZHONG, SONG, ZHENG, ZHANG, YIN AND DENG.","GUT MICROBIOTA; LIPID METABOLISM; MECHANISMS; OBESITY; PLANT EXTRACTS","","CARS-35; CHANGSHA NATURAL SCIENCE FUNDS FOR DISTINGUISHED YOUNG SCHOLAR, (KQ2009020); MARA; OPEN FUND OF KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, CHINESE ACADEMY OF SCIENCES, (ISA2020203); SPECIAL FUNDS FOR THE CONSTRUCTION OF INNOVATIVE PROVINCES IN HUNAN PROJECT, (2019RS3022); NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, NSFC, (31802077, 31872985, H20551, U19A2037); CHINESE ACADEMY OF SCIENCES, CAS, (XDA24030204); NATURAL SCIENCE FOUNDATION OF GUANGXI PROVINCE, (2018JJB130239, 2020JJA130102); AGRICULTURE RESEARCH SYSTEM OF CHINA","THIS STUDY WAS JOINTLY SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (U19A2037, 31872985, 31802077), THE SERVICES OF ALTERNATIVE ANTIBIOTIC FEED AND BREEDING TECHNOLOGY (H20551), THE CHANGSHA NATURAL SCIENCE FUNDS FOR DISTINGUISHED YOUNG SCHOLAR (KQ2009020), THE NATURAL SCIENCE FOUNDATION OF GUANGXI PROVINCE (2020JJA130102, 2018JJB130239), SPECIAL FUNDS FOR THE CONSTRUCTION OF INNOVATIVE PROVINCES IN HUNAN PROJECT (2019RS3022), CHINA AGRICULTURE RESEARCH SYSTEM OF MOF AND MARA (CARS-35), THE STRATEGIC PRIORITY RESEARCH PROGRAM OF THE CHINESE ACADEMY OF SCIENCES (XDA24030204), AND OPEN FUND OF KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, CHINESE ACADEMY OF SCIENCES (ISA2020203).","DIBAISE J.K., ZHANG H., CROWELL M.D., KRAJMALNIK-BROWN R., DECKER G.A., RITTMANN B.E., GUT MICROBIOTA AND ITS POSSIBLE RELATIONSHIP WITH OBESITY, MAYO CLIN PROC, 83, PP. 460-469, (2008); WANG H.N., XIANG J.Z., QI Z., DU M., PLANT EXTRACTS IN PREVENTION OF OBESITY, CRIT REV FOOD SCI NUTR, 15, PP. 1-14, (2020); SCHOELER M., CAESAR R., DIETARY LIPIDS, GUT MICROBIOTA AND LIPID METABOLISM, REV ENDOCR METAB DISORD, 20, PP. 461-472, (2019); DUAN J., LIANG S., FENG L., YU Y., SUN Z., SILICA NANOPARTICLES TRIGGER HEPATIC LIPID-METABOLISM DISORDER IN VIVO AND IN VITRO, INT J NANOMEDICINE, 13, PP. 7303-7318, (2018); ORMAZABAL V., NAIR S., ELFEKY O., AGUAYO C., SALOMON C., ZUNIGA F.A., ASSOCIATION BETWEEN INSULIN RESISTANCE AND THE DEVELOPMENT OF CARDIOVASCULAR DISEASE, CARDIOVASC DIABETOL, 17, (2018); PERRY R.J., SAMUEL V.T., PETERSEN K.F., SHULMAN G.I., THE ROLE OF HEPATIC LIPIDS IN HEPATIC INSULIN RESISTANCE AND TYPE 2 DIABETES, NATURE, 510, PP. 84-91, (2014); YIN J., LI Y., HAN H., CHEN S., GAO J., LIU G., ET AL., MELATONIN REPROGRAMMING OF GUT MICROBIOTA IMPROVES LIPID DYSMETABOLISM IN HIGH-FAT DIET-FED MICE, J PINEAL RES, 65, (2018); NOLAND R.C., EXERCISE AND REGULATION OF LIPID METABOLISM, PROG MOL BIOL TRANSL SCI, 135, PP. 39-74, (2015); SCHWIERTZ A., TARAS D., SCHAFER K., BEIJER S., BOS N.A., DONUS C., ET AL., MICROBIOTA AND SCFA IN LEAN AND OVERWEIGHT HEALTHY SUBJECTS, OBESITY (SILVER SPRING), 18, PP. 190-195, (2010); BACKHED F., DING H., WANG T., HOOPER L.V., KOH G.Y., NAGY A., ET AL., THE GUT MICROBIOTA AS AN ENVIRONMENTAL FACTOR THAT REGULATES FAT STORAGE, PROC NATL ACAD SCI USA, 101, PP. 15718-15723, (2004); RIDAURA V.K., FAITH J.J., REY F.E., CHENG J., DUNCAN A.E., KAU A.L., ET AL., GUT MICROBIOTA FROM TWINS DISCORDANT FOR OBESITY MODULATE METABOLISM IN MICE, SCIENCE, 341, (2013); ZHOU D., PAN Q., SHEN F., CAO H.X., DING W.J., CHEN Y.W., ET AL., TOTAL FECAL MICROBIOTA TRANSPLANTATION ALLEVIATES HIGH-FAT DIET-INDUCED STEATOHEPATITIS IN MICE VIA BENEFICIAL REGULATION OF GUT MICROBIOTA, SCI REP, 7, (2017); LEY R.E., BACKHED F., TURNBAUGH P., LOZUPONE C.A., KNIGHT R.D., GORDON J.I., OBESITY ALTERS GUT MICROBIAL ECOLOGY, PROC NATL ACAD SCI USA, 102, PP. 11070-11075, (2005); LEY R.E., TURNBAUGH P.J., KLEIN S., GORDON J.I., MICROBIAL ECOLOGY: HUMAN GUT MICROBES ASSOCIATED WITH OBESITY, NATURE, 444, PP. 1022-1023, (2006); RABOT S., MEMBREZ M., BRUNEAU A., GERARD P., HARACH T., MOSER M., ET AL., GERM-FREE C57BL/6J MICE ARE RESISTANT TO HIGH-FAT-DIET-INDUCED INSULIN RESISTANCE AND HAVE ALTERED CHOLESTEROL METABOLISM, FASEB J, 24, PP. 4948-4959, (2010); BACKHED F., MANCHESTER J.K., SEMENKOVICH C.F., GORDON J.I., MECHANISMS UNDERLYING THE RESISTANCE TO DIET-INDUCED OBESITY IN GERM-FREE MICE, PROC NATL ACAD SCI USA, 104, PP. 979-984, (2007); ELLEKILDE M., SELFJORD E., LARSEN C.S., JAKESEVIC M., RUNE I., TRANBERG B., ET AL., TRANSFER OF GUT MICROBIOTA FROM LEAN AND OBESE MICE TO ANTIBIOTIC-TREATED MICE, SCI REP, 4, (2014); CHEN J., VITETTA L., GUT MICROBIOTA METABOLITES IN NAFLD PATHOGENESIS AND THERAPEUTIC IMPLICATIONS, INT J MOL SCI, 21, (2020); HU H., LIN A., KONG M., YAO X., YIN M., XIA H., ET AL., INTESTINAL MICROBIOME AND NAFLD: MOLECULAR INSIGHTS AND THERAPEUTIC PERSPECTIVES, J GASTROENTEROL, 55, PP. 142-158, (2020); DUAN Y., ZHONG Y., XIAO H., ZHENG C., SONG B., WANG W., ET AL., GUT MICROBIOTA MEDIATES THE PROTECTIVE EFFECTS OF DIETARY BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) AGAINST OBESITY INDUCED BY HIGH-FAT DIETS, FASEB J, 33, PP. 10019-10033, (2019); SHANG A., GAN R.-Y., XU X.-Y., MAO Q.-Q., ZHANG P.-Z., LI H.-B., EFFECTS AND MECHANISMS OF EDIBLE AND MEDICINAL PLANTS ON OBESITY: AN UPDATED REVIEW, CRIT REV FOOD SCI NUTR, 61, PP. 2061-2077, (2021); CAO S.-Y., ZHAO C.-N., XU X.-Y., TANG G.-Y., CORKE H., GAN R.-Y., ET AL., DIETARY PLANTS, GUT MICROBIOTA, AND OBESITY: EFFECTS AND MECHANISMS, TRENDS FOOD SCI TECHNOL, 92, PP. 194-204, (2019); MA Q., SANTHANAM R.K., XUE Z., GUO Q., GAO X., CHEN H., EFFECT OF DIFFERENT DRYING METHODS ON THE PHYSICOCHEMICAL PROPERTIES AND ANTIOXIDANT ACTIVITIES OF MULBERRY LEAVES POLYSACCHARIDES, INT J BIOL MACROMOL, 119, PP. 1137-1143, (2018); MENG Q., QI X., FU Y., CHEN Q., CHENG P., YU X., ET AL., FLAVONOIDS EXTRACTED FROM MULBERRY (MORUS ALBA L.) LEAF IMPROVE SKELETAL MUSCLE MITOCHONDRIAL FUNCTION BY ACTIVATING AMPK IN TYPE 2 DIABETES, J ETHNOPHARMACOL, 248, (2020); THAIPITAKWONG T., NUMHOM S., ARAMWIT P., MULBERRY LEAVES AND THEIR POTENTIAL EFFECTS AGAINST CARDIOMETABOLIC RISKS: A REVIEW OF CHEMICAL COMPOSITIONS, BIOLOGICAL PROPERTIES AND CLINICAL EFFICACY, PHARM BIOL, 56, PP. 109-108, (2018); SHU Y.-H., YUAN H.-H., XU M.-T., HONG Y.-T., GAO C.-C., WU Z.-P., ET AL., A NOVEL DIELS-ALDER ADDUCT OF MULBERRY LEAVES EXERTS ANTICANCER EFFECT THROUGH AUTOPHAGY-MEDIATED CELL DEATH, ACTA PHARMACOL SIN, 42, PP. 780-790, (2020); CHEN J., LI X., HYPOLIPIDEMIC EFFECT OF FLAVONOIDS FROM MULBERRY LEAVES IN TRITON WR-1339 INDUCED HYPERLIPIDEMIC MICE, ASIA PAC J CLIN NUTR, 16, PP. 290-294, (2007); ZHONG Y., SONG B., ZHENG C., ZHANG S., YAN Z., TANG Z., ET AL., FLAVONOIDS FROM MULBERRY LEAVES ALLEVIATE LIPID DYSMETABOLISM IN HIGH FAT DIET-FED MICE: INVOLVEMENT OF GUT MICROBIOTA, MICROORGANISMS, 8, (2020); HSU L.S., HO H.H., LIN M.C., CHYAU C.C., PENG J.S., WANG C.J., MULBERRY WATER EXTRACTS (MWES) AMELIORATED CARBON TETRACHLORIDE-INDUCED LIVER DAMAGES IN RAT, FOOD CHEM TOXICOL, 50, PP. 3086-3093, (2012); LIM H.H., LEE S.O., KIM S.Y., YANG S.J., LIM Y., ANTI-INFLAMMATORY AND ANTIOBESITY EFFECTS OF MULBERRY LEAF AND FRUIT EXTRACT ON HIGH FAT DIET-INDUCED OBESITY, EXP BIOL MED (MAYWOOD), 238, PP. 1160-1169, (2013); CHAN K.C., YANG M.Y., LIN M.C., LEE Y.J., CHANG W.C., WANG C.J., MULBERRY LEAF EXTRACT INHIBITS THE DEVELOPMENT OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS AND IN CULTURED AORTIC VASCULAR SMOOTH MUSCLE CELLS, J AGRIC FOOD CHEM, 61, PP. 2780-2788, (2013); MUROTA K., NAKAMURA Y., UEHARA M., FLAVONOID METABOLISM: THE INTERACTION OF METABOLITES AND GUT MICROBIOTA, BIOSCI BIOTECHNOL BIOCHEM, 82, PP. 600-610, (2018); SHENG Y., LIU J., ZHENG S., LIANG F., LUO Y., HUANG K., ET AL., MULBERRY LEAVES AMELIORATE OBESITY THROUGH ENHANCING BROWN ADIPOSE TISSUE ACTIVITY AND MODULATING GUT MICROBIOTA, FOOD FUNCT, 10, PP. 4771-4781, (2019); SHENG Y., ZHENG S., MA T., ZHANG C., OU X., HE X., ET AL., MULBERRY LEAF ALLEVIATES STREPTOZOTOCIN-INDUCED DIABETIC RATS BY ATTENUATING NEFA SIGNALING AND MODULATING INTESTINAL MICROFLORA, SCI REP, 7, (2017); KIMURA I., OZAWA K., INOUE D., IMAMURA T., KIMURA K., MAEDA T., ET AL., THE GUT MICROBIOTA SUPPRESSES INSULIN-MEDIATED FAT ACCUMULATION VIA THE SHORT-CHAIN FATTY ACID RECEPTOR GPR43, NAT COMMUN, 4, (2013); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J FOOD SCI, 76, PP. C891-C899, (2011); DE OLIVEIRA A.M., CONSERVA L.M., DE SOUZA FERRO J.N., DE ALMEIDA BRITO F., LYRA LEMOS R.P., BARRETO E., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INT J MOL SCI, 13, PP. 1598-1611, (2012); GUO T., LIN Q., LI X., NIE Y., WANG L., SHI L., ET AL., OCTACOSANOL ATTENUATES INFLAMMATION IN BOTH RAW264.7 MACROPHAGES AND A MOUSE MODEL OF COLITIS, J AGRIC FOOD CHEM, 65, PP. 3647-3658, (2017); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); WANG T., LIU Y., YANG N., JI C., CHAN P., ZUO P., ANTI-PARKINSONIAN EFFECTS OF OCTACOSANOL IN 1-METHYL-4-PHENYL-1,2,3,6 TETRAHYDROPYRIDINE-TREATED MICE, NEURAL REGEN RES, 7, PP. 1080-1087, (2012); WANG T., LIU Y.-Y., WANG X., YANG N., ZHU H.-B., ZUO P.-P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOL SIN, 31, PP. 765-774, (2010); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID MED CELL LONGEV, 2018, (2018); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI REP, 9, (2019); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT J MOL MED, 39, PP. 889-899, (2017); KATO S., KARINO K., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR J NUTR, 73, PP. 433-441, (1995); HAIM D., VALENZUELA A., BRANES M.C., FUENZALIDA M., VIDELA L.A., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASAS Y ACEITES, 63, PP. 345-354, (2012); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); RA J.E., WOO S.Y., LEE K.S., LEE M.J., KIM H.Y., HAM H.M., ET AL., POLICOSANOL PROFILES AND ADENOSINE 5'-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME, FOOD CHEM, 317, (2020); CHAMBERS K.F., DAY P.E., ABOUFARRAG H.T., KROON P.A., POLYPHENOL EFFECTS ON CHOLESTEROL METABOLISM VIA BILE ACID BIOSYNTHESIS, CYP7A1: A REVIEW, NUTRIENTS, 11, (2019); WINSTON J.A., THERIOT C.M., DIVERSIFICATION OF HOST BILE ACIDS BY MEMBERS OF THE GUT MICROBIOTA, GUT MICROBES, 11, PP. 158-171, (2020); ZHANG Y., LIMAYE P.B., RENAUD H.J., KLAASSEN C.D., EFFECT OF VARIOUS ANTIBIOTICS ON MODULATION OF INTESTINAL MICROBIOTA AND BILE ACID PROFILE IN MICE, TOXICOL APPL PHARMACOL, 277, PP. 138-145, (2014); JONES M.L., TOMARO-DUCHESNEAU C., PRAKASH S., THE GUT MICROBIOME, PROBIOTICS, BILE ACIDS AXIS, AND HUMAN HEALTH, TRENDS MICROBIOL, 22, PP. 306-308, (2014); THERIOT C.M., KOENIGSKNECHT M.J., CARLSON P.E., HATTON G.E., NELSON A.M., LI B., ET AL., ANTIBIOTIC-INDUCED SHIFTS IN THE MOUSE GUT MICROBIOME AND METABOLOME INCREASE SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION, NAT COMMUN, 5, (2014); DUBOC H., RAJCA S., RAINTEAU D., BENAROUS D., MAUBERT M.-A., QUERVAIN E., ET AL., CONNECTING DYSBIOSIS, BILE-ACID DYSMETABOLISM AND GUT INFLAMMATION IN INFLAMMATORY BOWEL DISEASES, GUT, 62, PP. 531-539, (2013); WU H., SONG A., HU W., DAI M., THE ANTI-ATHEROSCLEROTIC EFFECT OF PAEONOL AGAINST VASCULAR SMOOTH MUSCLE CELL PROLIFERATION BY UP-REGULATION OF AUTOPHAGY VIA THE AMPK/MTOR SIGNALING PATHWAY, FRONT PHARMACOL, 8, (2017); GAO L., WANG Z., LU D., HUANG J., LIU J., HONG L., PAEONOL INDUCES CYTOPROTECTIVE AUTOPHAGY VIA BLOCKING THE AKT/MTOR PATHWAY IN OVARIAN CANCER CELLS, CELL DEATH DIS, 10, (2019); LIN C., LIN H.-Y., CHEN J.-H., TSENG W.-P., KO P.-Y., LIU Y.-S., ET AL., EFFECTS OF PAEONOL ON ANTI-NEUROINFLAMMATORY RESPONSES IN MICROGLIAL CELLS, INT J MOL SCI, 16, PP. 8844-8860, (2015); XU F., XIAO H., LIU R., YANG Y., ZHANG M., CHEN L., ET AL., PAEONOL AMELIORATES GLUCOSE AND LIPID METABOLISM IN EXPERIMENTAL DIABETES BY ACTIVATING AKT, FRONT PHARMACOL, 10, (2019); YANG Q., WANG S., XIE Y., WANG J., LI H., ZHOU X., ET AL., EFFECT OF SALVIANOLIC ACID B AND PAEONOL ON BLOOD LIPID METABOLISM AND HEMORRHEOLOGY IN MYOCARDIAL ISCHEMIA RABBITS INDUCED BY PITUITRUIN, INT J MOL SCI, 11, PP. 3696-3704, (2010); JING X., SUN C., CHEN H., SUN J., ZHANG Y., WU J., PROTECTION OF PAEONOL AGAINST EPIRUBICIN-INDUCED HEPATOTOXICITY: A METABOLOMIC STUDY, BIOSCIENCE TRENDS, 13, PP. 253-260, (2019); HU S., SHEN G., ZHAO W., WANG F., JIANG X., HUANG D., PAEONOL, THE MAIN ACTIVE PRINCIPLES OF PAEONIA MOUTAN, AMELIORATES ALCOHOLIC STEATOHEPATITIS IN MICE, J ETHNOPHARMACOL, 128, PP. 100-106, (2010); LI H., DAI M., JIA W., PAEONOL ATTENUATES HIGH-FAT-DIET-INDUCED ATHEROSCLEROSIS IN RABBITS BY ANTI-INFLAMMATORY ACTIVITY, PLANTA MED, 75, PP. 7-11, (2009); IZUMI M., YOSHIDA T., NAKAMURA T., WAKAMORI A.M., PAEONOL, AN INGREDIENT OF KAMISHOYOSAN, REDUCES INTRACELLULAR LIPID ACCUMULATION BY INHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY IN 3T3-L1 CELLS, NUTRIENTS, 12, (2020); LI X., ZHOU Y., YU C., YANG H., ZHANG C., YE Y., ET AL., PAEONOL SUPPRESSES LIPID ACCUMULATION IN MACROPHAGES VIA UPREGULATION OF THE ATPBINDING CASSETTE TRANSPORTER A1 AND DOWNREGULATION OF THE CLUSTER OF DIFFERENTIATION 36, INT J ONCOL, 46, PP. 764-774, (2015); CHEN S., ZHANG J., WU L., WU H., DAI M., PAEONOL NANOEMULSION FOR ENHANCED ORAL BIOAVAILABILITY: OPTIMIZATION AND MECHANISM, NANOMEDICINE (LOND), 13, PP. 269-282, (2018); FENG R., CHEN J.-H., LIU C.-H., XIA F.-B., XIAO Z., ZHANG X., ET AL., A COMBINATION OF PUERARIA LOBATA AND SILYBUM MARIANUM PROTECTS AGAINST ALCOHOLIC LIVER DISEASE IN MICE, PHYTOMEDICINE, 58, (2019); CHUN S.C., JEE S.Y., LEE S.G., PARK S.J., LEE J.R., KIM S.C., ANTI-INFLAMMATORY ACTIVITY OF THE METHANOL EXTRACT OF MOUTAN CORTEX IN LPS-ACTIVATED RAW264.7 CELLS, EVID BASED COMPLEMENT ALTERNAT MED, 4, PP. 327-333, (2007); LIN S.J., CHEN C.S., LIN S.S., CHOU M.Y., SHIH H.C., LEE I.P., ET AL., IN VITRO ANTI-MICROBIAL AND IN VIVO CYTOKINE MODULATING EFFECTS OF DIFFERENT PREPARED CHINESE HERBAL MEDICINES, FOOD CHEM TOXICOL, 44, PP. 2078-2085, (2006); ZHONG L.-J., XIE Z.-S., YANG H., LI P., XU X.-J., MOUTAN CORTEX AND PAEONIAE RADIX RUBRA REVERSE HIGH-FAT-DIET-INDUCED METABOLIC DISORDER AND RESTORE GUT MICROBIOTA HOMEOSTASIS, CHIN J NATURAL MED, 15, PP. 210-219, (2017); WU J., WU D., MA K., WANG T., SHI G., SHAO J., ET AL., PAEONOL AMELIORATES MURINE ALCOHOL LIVER DISEASE VIA MYCOBIOTA-MEDIATED DECTIN-1/IL-1BETA SIGNALING PATHWAY, J LEUKOC BIOL, 108, PP. 199-214, (2020); WOLFRAM S., WANG Y., THIELECKE F., ANTI-OBESITY EFFECTS OF GREEN TEA: FROM BEDSIDE TO BENCH, MOL NUTR FOOD RES, 50, PP. 176-187, (2006); KOMORITA Y., IWASE M., FUJII H., OHKUMA T., IDE H., JODAI-KITAMURA T., ET AL., ADDITIVE EFFECTS OF GREEN TEA AND COFFEE ON ALL-CAUSE MORTALITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE FUKUOKA DIABETES REGISTRY, BMJ OPEN DIABETES RES CARE, 8, (2020); FURUYASHIKI T., NAGAYASU H., AOKI Y., BESSHO H., HASHIMOTO T., KANAZAWA K., ET AL., TEA CATECHIN SUPPRESSES ADIPOCYTE DIFFERENTIATION ACCOMPANIED BY DOWN-REGULATION OF PPARGAMMA2 AND C/EBPALPHA IN 3T3-L1 CELLS, BIOSCI BIOTECHNOL BIOCHEM, 68, PP. 2353-2359, (2004); MI Y., LIU X., TIAN H., LIU H., LI J., QI G., ET AL., EGCG STIMULATES THE RECRUITMENT OF BRITE ADIPOCYTES, SUPPRESSES ADIPOGENESIS AND COUNTERACTS TNF-ALPHA-TRIGGERED INSULIN RESISTANCE IN ADIPOCYTES, FOOD FUNCT, 9, PP. 3374-3386, (2018); NAGAO T., HASE T., TOKIMITSU I., A GREEN TEA EXTRACT HIGH IN CATECHINS REDUCES BODY FAT AND CARDIOVASCULAR RISKS IN HUMANS, OBESITY (SILVER SPRING, MD.), 15, PP. 1473-1483, (2007); CHEN I.J., LIU C.Y., CHIU J.P., HSU C.H., THERAPEUTIC EFFECT OF HIGH-DOSE GREEN TEA EXTRACT ON WEIGHT REDUCTION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, CLIN NUTR, 35, PP. 592-599, (2016); ROCHA A., BOLIN A.P., CARDOSO C.A., OTTON R., GREEN TEA EXTRACT ACTIVATES AMPK AND AMELIORATES WHITE ADIPOSE TISSUE METABOLIC DYSFUNCTION INDUCED BY OBESITY, EUR J NUTR, 55, PP. 2231-2244, (2016); OTTON R., BOLIN A.P., FERREIRA L.T., MARINOVIC M.P., ROCHA A.L.S., MORI M.A., POLYPHENOL-RICH GREEN TEA EXTRACT IMPROVES ADIPOSE TISSUE METABOLISM BY DOWN-REGULATING MIR-335 EXPRESSION AND MITIGATING INSULIN RESISTANCE AND INFLAMMATION, J NUTR BIOCHEM, 57, PP. 170-179, (2018); ZHOU J., MAO L., XU P., WANG Y., EFFECTS OF (-)-EPIGALLOCATECHIN GALLATE (EGCG) ON ENERGY EXPENDITURE AND MICROGLIA-MEDIATED HYPOTHALAMIC INFLAMMATION IN MICE FED A HIGH-FAT DIET, NUTRIENTS, 10, (2018); JANG H.J., RIDGEWAY S.D., KIM J.A., EFFECTS OF THE GREEN TEA POLYPHENOL EPIGALLOCATECHIN-3-GALLATE ON HIGH-FAT DIET-INDUCED INSULIN RESISTANCE AND ENDOTHELIAL DYSFUNCTION, AM J PHYSIOL ENDOCRINOL METAB, 305, PP. E1444-E1451, (2013); LIU Z., CHEN Z., GUO H., HE D., ZHAO H., WANG Z., ET AL., THE MODULATORY EFFECT OF INFUSIONS OF GREEN TEA, OOLONG TEA, AND BLACK TEA ON GUT MICROBIOTA IN HIGH-FAT-INDUCED OBESE MICE, FOOD FUNCT, 7, PP. 4869-4879, (2016); SINGH D.P., SINGH J., BOPARAI R.K., ZHU J., MANTRI S., KHARE P., ET AL., ISOMALTO-OLIGOSACCHARIDES, A PREBIOTIC, FUNCTIONALLY AUGMENT GREEN TEA EFFECTS AGAINST HIGH FAT DIET-INDUCED METABOLIC ALTERATIONS VIA PREVENTING GUT DYSBACTERIOSIS IN MICE, PHARMACOL RES, 123, PP. 103-113, (2017); DEY P., SASAKI G.Y., WEI P., LI J., WANG L., ZHU J., ET AL., GREEN TEA EXTRACT PREVENTS OBESITY IN MALE MICE BY ALLEVIATING GUT DYSBIOSIS IN ASSOCIATION WITH IMPROVED INTESTINAL BARRIER FUNCTION THAT LIMITS ENDOTOXIN TRANSLOCATION AND ADIPOSE INFLAMMATION, J NUTR BIOCHEM, 67, PP. 78-89, (2019); LIU J., HAO W., HE Z., KWEK E., ZHAO Y., ZHU H., ET AL., BENEFICIAL EFFECTS OF TEA WATER EXTRACTS ON THE BODY WEIGHT AND GUT MICROBIOTA IN C57BL/6J MICE FED WITH A HIGH-FAT DIET, FOOD FUNCT, 10, PP. 2847-2860, (2019); A H., ZHANG B., HU Y., WANG J., LIU J., QIN R., ET AL., CORRELATION ANALYSIS OF INTESTINAL REDOX STATE WITH THE GUT MICROBIOTA REVEALS THE POSITIVE INTERVENTION OF TEA POLYPHENOLS ON HYPERLIPIDEMIA IN HIGH FAT DIET FED MICE, J AGRIC FOOD CHEM, 67, PP. 7325-7335, (2019); RAUF A., IMRAN M., BUTT M.S., NADEEM M., PETERS D.G., MUBARAK M.S., RESVERATROL AS AN ANTI-CANCER AGENT: A REVIEW, CRIT REV FOOD SCI NUTR, 58, PP. 1428-1447, (2018); DYCK G.J.B., RAJ P., ZIEROTH S., DYCK J.R.B., EZEKOWITZ J.A., THE EFFECTS OF RESVERATROL IN PATIENTS WITH CARDIOVASCULAR DISEASE AND HEART FAILURE: A NARRATIVE REVIEW, INT J MOL SCI, 20, (2019); YAN Y., YANG H., XIE Y., DING Y., KONG D., YU H., RESEARCH PROGRESS ON ALZHEIMER'S DISEASE AND RESVERATROL, NEUROCHEM RES, 45, PP. 989-1006, (2020); MENG X., ZHOU J., ZHAO C.-N., GAN R.-Y., LI H.-B., HEALTH BENEFITS AND MOLECULAR MECHANISMS OF RESVERATROL: A NARRATIVE REVIEW, FOODS, 9, (2020); ALBERDI G., RODRIGUEZ V.M., MIRANDA J., MACARULLA M.T., CHURRUCA I., PORTILLO M.P., THERMOGENESIS IS INVOLVED IN THE BODY-FAT LOWERING EFFECTS OF RESVERATROL IN RATS, FOOD CHEM, 141, PP. 1530-1535, (2013); HUI S., LIU Y., HUANG L., ZHENG L., ZHOU M., LANG H., ET AL., RESVERATROL ENHANCES BROWN ADIPOSE TISSUE ACTIVITY AND WHITE ADIPOSE TISSUE BROWNING IN PART BY REGULATING BILE ACID METABOLISM VIA GUT MICROBIOTA REMODELING, INT J OBES (LOND), 44, PP. 1678-1690, (2020); WANG P., WANG J., LI D., KE W., CHEN F., HU X., TARGETING THE GUT MICROBIOTA WITH RESVERATROL: A DEMONSTRATION OF NOVEL EVIDENCE FOR THE MANAGEMENT OF HEPATIC STEATOSIS, J NUTR BIOCHEM, 81, (2020); YE G., CHEN G., GAO H., LIN Y., LIAO X., ZHANG H., ET AL., RESVERATROL INHIBITS LIPID ACCUMULATION IN THE INTESTINE OF ATHEROSCLEROTIC MICE AND MACROPHAGES, J CELL MOL MED, 23, PP. 4313-4325, (2019); WANG S., LIANG X., YANG Q., FU X., ZHU M., RODGERS B.D., ET AL., RESVERATROL ENHANCES BROWN ADIPOCYTE FORMATION AND FUNCTION BY ACTIVATING AMP-ACTIVATED PROTEIN KINASE (AMPK) ALPHA1 IN MICE FED HIGH-FAT DIET, MOL NUTR FOOD RES, 61, (2017); WANG S., LIANG X., YANG Q., FU X., ROGERS C.J., ZHU M., ET AL., RESVERATROL INDUCES BROWN-LIKE ADIPOCYTE FORMATION IN WHITE FAT THROUGH ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE (AMPK) ALPHA1, INT J OBES (LOND), 39, PP. 967-976, (2015); IMAMURA H., NAGAYAMA D., ISHIHARA N., TANAKA S., WATANABE R., WATANABE Y., ET AL., RESVERATROL ATTENUATES TRIGLYCERIDE ACCUMULATION ASSOCIATED WITH UPREGULATION OF SIRT1 AND LIPOPROTEIN LIPASE IN 3T3-L1 ADIPOCYTES, MOL GENET METAB REP, 12, PP. 44-50, (2017); SZKUDELSKA K., NOGOWSKI L., SZKUDELSKI T., RESVERATROL, A NATURALLY OCCURRING DIPHENOLIC COMPOUND, AFFECTS LIPOGENESIS, LIPOLYSIS AND THE ANTILIPOLYTIC ACTION OF INSULIN IN ISOLATED RAT ADIPOCYTES, J STEROID BIOCHEM MOL BIOL, 113, PP. 17-24, (2009); GOMEZ-ZORITA S., TREGUER K., MERCADER J., CARPENE C., RESVERATROL DIRECTLY AFFECTS IN VITRO LIPOLYSIS AND GLUCOSE TRANSPORT IN HUMAN FAT CELLS, J PHYSIOL BIOCHEM, 69, PP. 585-593, (2013); WANG P., LI D., KE W., LIANG D., HU X., CHEN F., RESVERATROL-INDUCED GUT MICROBIOTA REDUCES OBESITY IN HIGH-FAT DIET-FED MICE, INT J OBES (LOND), 44, PP. 213-225, (2020); WALLE T., BIOAVAILABILITY OF RESVERATROL, ANN N Y ACAD SCI, 1215, PP. 9-15, (2011); CHIMENTO A., DE AMICIS F., SIRIANNI R., SINICROPI M.S., PUOCI F., CASABURI I., ET AL., PROGRESS TO IMPROVE ORAL BIOAVAILABILITY AND BENEFICIAL EFFECTS OF RESVERATROL, INT J MOL SCI, 20, (2019); WANG P., GAO J., KE W., WANG J., LI D., LIU R., ET AL., RESVERATROL REDUCES OBESITY IN HIGH-FAT DIET-FED MICE VIA MODULATING THE COMPOSITION AND METABOLIC FUNCTION OF THE GUT MICROBIOTA, FREE RADIC BIOL MED, 156, PP. 83-98, (2020); QIAO Y., SUN J., XIA S., TANG X., SHI Y., LE G., EFFECTS OF RESVERATROL ON GUT MICROBIOTA AND FAT STORAGE IN A MOUSE MODEL WITH HIGH-FAT-INDUCED OBESITY, FOOD FUNCT, 5, PP. 1241-1249, (2014); LIAO W., YIN X., LI Q., ZHANG H., LIU Z., ZHENG X., ET AL., RESVERATROL-INDUCED WHITE ADIPOSE TISSUE BROWNING IN OBESE MICE BY REMODELING FECAL MICROBIOTA, MOLECULES, 23, (2018); CHEN M.L., YI L., ZHANG Y., ZHOU X., RAN L., YANG J., ET AL., RESVERATROL ATTENUATES TRIMETHYLAMINE-N-OXIDE (TMAO)-INDUCED ATHEROSCLEROSIS BY REGULATING TMAO SYNTHESIS AND BILE ACID METABOLISM VIA REMODELING OF THE GUT MICROBIOTA, MBIO, 7, PP. E02210-E02215, (2016); ETXEBERRIA U., ARIAS N., BOQUE N., MACARULLA M.T., PORTILLO M.P., MARTINEZ J.A., ET AL., RESHAPING FAECAL GUT MICROBIOTA COMPOSITION BY THE INTAKE OF TRANS-RESVERATROL AND QUERCETIN IN HIGH-FAT SUCROSE DIET-FED RATS, J NUTR BIOCHEM, 26, PP. 651-660, (2015); SUNG M.M., KIM T.T., DENOU E., SOLTYS C.-L.M., HAMZA S.M., BYRNE N.J., ET AL., IMPROVED GLUCOSE HOMEOSTASIS IN OBESE MICE TREATED WITH RESVERATROL IS ASSOCIATED WITH ALTERATIONS IN THE GUT MICROBIOME, DIABETES, 66, PP. 418-425, (2017); CHEN F., WANG H., ZHAO J., YAN J., MENG H., ZHAN H., ET AL., GRAPE SEED PROANTHOCYANIDIN INHIBITS MONOCROTALINE-INDUCED PULMONARY ARTERIAL HYPERTENSION VIA ATTENUATING INFLAMMATION: IN VIVO AND IN VITRO STUDIES, J NUTR BIOCHEM, 67, PP. 72-77, (2019); LIU W., ZHAO S., WANG J., SHI J., SUN Y., WANG W., ET AL., GRAPE SEED PROANTHOCYANIDIN EXTRACT AMELIORATES INFLAMMATION AND ADIPOSITY BY MODULATING GUT MICROBIOTA IN HIGH-FAT DIET MICE, MOL NUTR FOOD RES, 61, (2017); XU M., CHEN X., HUANG Z., CHEN D., YU B., CHEN H., ET AL., GRAPE SEED PROANTHOCYANIDIN EXTRACT PROMOTES SKELETAL MUSCLE FIBER TYPE TRANSFORMATION VIA AMPK SIGNALING PATHWAY, J NUTR BIOCHEM, 84, (2020); DOWNING L.E., HEIDKER R.M., CAIOZZI G.C., WONG B.S., RODRIGUEZ K., DEL REY F., ET AL., A GRAPE SEED PROCYANIDIN EXTRACT AMELIORATES FRUCTOSE-INDUCED HYPERTRIGLYCERIDEMIA IN RATS VIA ENHANCED FECAL BILE ACID AND CHOLESTEROL EXCRETION AND INHIBITION OF HEPATIC LIPOGENESIS, PLOS ONE, 10, (2015); PAJUELO D., QUESADA H., DIAZ S., FERNANDEZ-IGLESIAS A., AROLA-ARNAL A., BLADE C., ET AL., CHRONIC DIETARY SUPPLEMENTATION OF PROANTHOCYANIDINS CORRECTS THE MITOCHONDRIAL DYSFUNCTION OF BROWN ADIPOSE TISSUE CAUSED BY DIET-INDUCED OBESITY IN WISTAR RATS, BR J NUTR, 107, PP. 170-178, (2012); PASCUAL-SERRANO A., BLADE C., SUAREZ M., AROLA-ARNAL A., GRAPE SEED PROANTHOCYANIDINS IMPROVE WHITE ADIPOSE TISSUE EXPANSION DURING DIET-INDUCED OBESITY DEVELOPMENT IN RATS, INT J MOL SCI, 19, (2018); PONS Z., MARGALEF M., BRAVO F.I., AROLA-ARNAL A., MUGUERZA B., CHRONIC ADMINISTRATION OF GRAPE-SEED POLYPHENOLS ATTENUATES THE DEVELOPMENT OF HYPERTENSION AND IMPROVES OTHER CARDIOMETABOLIC RISK FACTORS ASSOCIATED WITH THE METABOLIC SYNDROME IN CAFETERIA DIET-FED RATS, BR J NUTR, 117, PP. 200-208, (2017); JIN G., ASOU Y., ISHIYAMA K., OKAWA A., KANNO T., NIWANO Y., PROANTHOCYANIDIN-RICH GRAPE SEED EXTRACT MODULATES INTESTINAL MICROBIOTA IN OVARIECTOMIZED MICE, J FOOD SCI, 83, PP. 1149-1152, (2018); WU Y., MA N., SONG P., HE T., LEVESQUE C., BAI Y., ET AL., GRAPE SEED PROANTHOCYANIDIN AFFECTS LIPID METABOLISM VIA CHANGING GUT MICROFLORA AND ENHANCING PROPIONATE PRODUCTION IN WEANED PIGS, J NUTR, 149, PP. 1523-1532, (2019); PINENT M., BLADE M.C., SALVADO M.J., AROLA L., HACKL H., QUACKENBUSH J., ET AL., GRAPE-SEED DERIVED PROCYANIDINS INTERFERE WITH ADIPOGENESIS OF 3T3-L1 CELLS AT THE ONSET OF DIFFERENTIATION, INT J OBES (LOND), 29, PP. 934-941, (2005); WEI S., ZHENG Y., ZHANG M., ZHENG H., YAN P., GRAPE SEED PROCYANIDIN EXTRACT INHIBITS ADIPOGENESIS AND STIMULATES LIPOLYSIS OF PORCINE ADIPOCYTES IN VITRO, J ANIM SCI, 96, PP. 2753-2762, (2018); TERRA X., MONTAGUT G., BUSTOS M., LLOPIZ N., ARDEVOL A., BLADE C., ET AL., GRAPE-SEED PROCYANIDINS PREVENT LOW-GRADE INFLAMMATION BY MODULATING CYTOKINE EXPRESSION IN RATS FED A HIGH-FAT DIET, J NUTR BIOCHEM, 20, PP. 210-218, (2009); CHACON M.R., CEPERUELO-MALLAFRE V., MAYMO-MASIP E., MATEO-SANZ J.M., AROLA L., GUITIERREZ C., ET AL., GRAPE-SEED PROCYANIDINS MODULATE INFLAMMATION ON HUMAN DIFFERENTIATED ADIPOCYTES IN VITRO, CYTOKINE, 47, PP. 137-142, (2009); CHAMBERS E.S., VIARDOT A., PSICHAS A., MORRISON D.J., MURPHY K.G., ZAC-VARGHESE S.E., ET AL., EFFECTS OF TARGETED DELIVERY OF PROPIONATE TO THE HUMAN COLON ON APPETITE REGULATION, BODY WEIGHT MAINTENANCE AND ADIPOSITY IN OVERWEIGHT ADULTS, GUT, 64, PP. 1744-1754, (2015); PSICHAS A., SLEETH M.L., MURPHY K.G., BROOKS L., BEWICK G.A., HANYALOGLU A.C., ET AL., THE SHORT CHAIN FATTY ACID PROPIONATE STIMULATES GLP-1 AND PYY SECRETION VIA FREE FATTY ACID RECEPTOR 2 IN RODENTS, INT J OBES (LOND), 39, PP. 424-429, (2015); SONG B., ZHONG Y.Z., ZHENG C.B., LI F.N., DUAN Y.H., DENG J.P., PROPIONATE ALLEVIATES HIGH-FAT DIET-INDUCED LIPID DYSMETABOLISM BY MODULATING GUT MICROBIOTA IN MICE, J APPL MICROBIOL, 127, PP. 1546-1555, (2019); WANG D., DONG X., WANG C., HONOKIOL AMELIORATES AMYLOIDOSIS AND NEUROINFLAMMATION AND IMPROVES COGNITIVE IMPAIRMENT IN ALZHEIMER'S DISEASE TRANSGENIC MICE, J PHARMACOL EXP THER, 366, PP. 470-478, (2018); BANIK K., RANAWARE A.M., DESHPANDE V., NALAWADE S.P., PADMAVATHI G., BORDOLOI D., ET AL., HONOKIOL FOR CANCER THERAPEUTICS: A TRADITIONAL MEDICINE THAT CAN MODULATE MULTIPLE ONCOGENIC TARGETS, PHARMACOL RES, 144, PP. 192-209, (2019); LEE I.H., IM E., LEE H.-J., SIM D.Y., LEE J.H., JUNG J.H., ET AL., APOPTOTIC AND ANTIHEPATOFIBROTIC EFFECT OF HONOKIOL VIA ACTIVATION OF GSK3Β AND SUPPRESSION OF WNT/Β-CATENIN PATHWAY IN HEPATIC STELLATE CELLS, PHYTOTHER RES, 35, PP. 452-462, (2021); ZHANG B., WANG P.-P., HU K.-L., LI L.-N., YU X., LU Y., ET AL., ANTIDEPRESSANT-LIKE EFFECT AND MECHANISM OF ACTION OF HONOKIOL ON THE MOUSE LIPOPOLYSACCHARIDE (LPS) DEPRESSION MODEL, MOLECULES, 24, (2019); CABALLERO E.P., MARIZ-PONTE N., RIGAZIO C.S., SANTAMARIA M.H., CORRAL R.S., HONOKIOL ATTENUATES OXIDATIVE STRESS-DEPENDENT HEART DYSFUNCTION IN CHRONIC CHAGAS DISEASE BY TARGETING AMPK / NFE2L2 / SIRT3 SIGNALING PATHWAY, FREE RADICBIOL MED, 156, PP. 113-124, (2020); DING Y., SONG Z., LI H., CHANG L., PAN T., GU X., ET AL., HONOKIOL AMELIORATES HIGH-FAT-DIET-INDUCED OBESITY OF DIFFERENT SEXES OF MICE BY MODULATING THE COMPOSITION OF THE GUT MICROBIOTA, FRONT IMMUNOL, 10, (2019); SUN J., FU X., LIU Y., WANG Y., HUO B., GUO Y., ET AL., HYPOGLYCEMIC EFFECT AND MECHANISM OF HONOKIOL ON TYPE 2 DIABETIC MICE, DRUG DES DEVEL THER, 9, PP. 6327-6342, (2015); KIM Y.-J., CHOI M.-S., CHA B.Y., WOO J.T., PARK Y.B., KIM S.R., ET AL., LONG-TERM SUPPLEMENTATION OF HONOKIOL AND MAGNOLOL AMELIORATES BODY FAT ACCUMULATION, INSULIN RESISTANCE, AND ADIPOSE INFLAMMATION IN HIGH-FAT FED MICE, MOL NUTR FOOD RES, 57, PP. 1988-1998, (2013); YANG J.Y., DELLA-FERA M.A., RAYALAM S., BAILE C.A., ENHANCED EFFECTS OF XANTHOHUMOL PLUS HONOKIOL ON APOPTOSIS IN 3T3-L1 ADIPOCYTES, OBESITY (SILVER SPRING), 16, PP. 1232-1238, (2008); LONE J., YUN J.W., HONOKIOL EXERTS DUAL EFFECTS ON BROWNING AND APOPTOSIS OF ADIPOCYTES, PHARMACOL REP, 69, PP. 1357-1365, (2017); CHOI S.S., CHA B.Y., IIDA K., SATO M., LEE Y.S., TERUYA T., ET AL., HONOKIOL ENHANCES ADIPOCYTE DIFFERENTIATION BY POTENTIATING INSULIN SIGNALING IN 3T3-L1 PREADIPOCYTES, J NAT MED, 65, PP. 424-430, (2011); STEVENS J.F., MAIER C.S., THE CHEMISTRY OF GUT MICROBIAL METABOLISM OF POLYPHENOLS, PHYTOCHEM REV, 15, PP. 425-444, (2016); AZIZ F., XIN M., GAO Y., CHAKROBORTY A., KHAN I., MONTS J., ET AL., INDUCTION AND PREVENTION OF GASTRIC CANCER WITH COMBINED AND CAPSAICIN ADMINISTRATION AND DFMO TREATMENT, RESPECTIVELY, CANCERS (BASEL), 12, (2020); BOTZ B., KRISZTA G., BOLCSKEI K., HORVATH A.I., MOCSAI A., HELYES Z., CAPSAICIN-SENSITIVE PEPTIDERGIC SENSORY NERVES ARE ANTI-INFLAMMATORY GATEKEEPERS IN THE HYPERACUTE PHASE OF A MOUSE RHEUMATOID ARTHRITIS MODEL, INT J MOL SCI, 22, (2021); CHIANG C., ZHANG M., WANG D., XIAO T., ZHU L., CHEN K., ET AL., THERAPEUTIC POTENTIAL OF TARGETING MKK3-P38 AXIS WITH CAPSAICIN FOR NASOPHARYNGEAL CARCINOMA, THERANOSTICS, 10, PP. 7906-7920, (2020); HSU Y.-J., HUANG W.-C., CHIU C.-C., LIU Y.-L., CHIU W.-C., CHIU C.-H., ET AL., CAPSAICIN SUPPLEMENTATION REDUCES PHYSICAL FATIGUE AND IMPROVES EXERCISE PERFORMANCE IN MICE, NUTRIENTS, 8, (2016); ARORA V., CAMPBELL J.N., CHUNG M.-K., FIGHT FIRE WITH FIRE: NEUROBIOLOGY OF CAPSAICIN-INDUCED ANALGESIA FOR CHRONIC PAIN, PHARMACOL THER, 220, (2021); YUAN L.J., QIN Y., WANG L., ZENG Y., CHANG H., WANG J., ET AL., CAPSAICIN-CONTAINING CHILI IMPROVED POSTPRANDIAL HYPERGLYCEMIA, HYPERINSULINEMIA, AND FASTING LIPID DISORDERS IN WOMEN WITH GESTATIONAL DIABETES MELLITUS AND LOWERED THE INCIDENCE OF LARGE-FOR-GESTATIONAL-AGE NEWBORNS, CLIN NUTR, 35, PP. 388-393, (2016); CHEN J., LIL LIY, LIANG X., SUN Q., YU H., ET AL., ACTIVATION OF TRPV1 CHANNEL BY DIETARY CAPSAICIN IMPROVES VISCERAL FAT REMODELING THROUGH CONNEXIN43-MEDIATED CA2+ INFLUX, CARDIOVASC DIABETOL, 14, (2015); WANG Y., TANG C., TANG Y., YIN H., LIU X., CAPSAICIN HAS AN ANTI-OBESITY EFFECT THROUGH ALTERATIONS IN GUT MICROBIOTA POPULATIONS AND SHORT-CHAIN FATTY ACID CONCENTRATIONS, FOOD NUTR RES, 64, (2020); BASKARAN P., KRISHNAN V., REN J., THYAGARAJAN B., CAPSAICIN INDUCES BROWNING OF WHITE ADIPOSE TISSUE AND COUNTERS OBESITY BY ACTIVATING TRPV1 CHANNEL-DEPENDENT MECHANISMS, BR J PHARMACOL, 173, PP. 2369-2389, (2016); KAWABATA F., INOUE N., MASAMOTO Y., MATSUMURA S., KIMURA W., KADOWAKI M., ET AL., NON-PUNGENT CAPSAICIN ANALOGS (CAPSINOIDS) INCREASE METABOLIC RATE AND ENHANCE THERMOGENESIS VIA GASTROINTESTINAL TRPV1 IN MICE, BIOSCI BIOTECHNOL BIOCHEM, 73, PP. 2690-2697, (2009); FAN L., XU H., YANG R., ZANG Y., CHEN J., QIN H., COMBINATION OF CAPSAICIN AND CAPSIATE INDUCES BROWNING IN 3T3-L1 WHITE ADIPOCYTES VIA ACTIVATION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA/BETA3-ADRENERGIC RECEPTOR SIGNALING PATHWAYS, J AGRIC FOOD CHEM, 67, PP. 6232-6240, (2019); HSU C.-L., YEN G.-C., EFFECTS OF CAPSAICIN ON INDUCTION OF APOPTOSIS AND INHIBITION OF ADIPOGENESIS IN 3T3-L1 CELLS, J AGRIC FOOD CHEM, 55, PP. 1730-1736, (2007); ZANG Y., FAN L., CHEN J., HUANG R., QIN H., IMPROVEMENT OF LIPID AND GLUCOSE METABOLISM BY CAPSIATE IN PALMITIC ACID-TREATED HEPG2 CELLS VIA ACTIVATION OF THE AMPK/SIRT1 SIGNALING PATHWAY, J AGRIC FOOD CHEM, 66, PP. 6772-6781, (2018); KANG J.H., KIM C.S., HAN I.S., KAWADA T., YU R., CAPSAICIN, A SPICY COMPONENT OF HOT PEPPERS, MODULATES ADIPOKINE GENE EXPRESSION AND PROTEIN RELEASE FROM OBESE-MOUSE ADIPOSE TISSUES AND ISOLATED ADIPOCYTES, AND SUPPRESSES THE INFLAMMATORY RESPONSES OF ADIPOSE TISSUE MACROPHAGES, FEBS LETT, 581, PP. 4389-4396, (2007); KANG C., WANG B., KALIANNAN K., WANG X., LANG H., HUI S., ET AL., GUT MICROBIOTA MEDIATES THE PROTECTIVE EFFECTS OF DIETARY CAPSAICIN AGAINST CHRONIC LOW-GRADE INFLAMMATION AND ASSOCIATED OBESITY INDUCED BY HIGH-FAT DIET, MBIO, 8, (2017); SHEN W., SHEN M., ZHAO X., ZHU H., YANG Y., LU S., ET AL., ANTI-OBESITY EFFECT OF CAPSAICIN IN MICE FED WITH HIGH-FAT DIET IS ASSOCIATED WITH AN INCREASE IN POPULATION OF THE GUT BACTERIUM AKKERMANSIA MUCINIPHILA, FRONT MICROBIOL, 8, (2017); CHUA M., BALDWIN T.C., HOCKING T.J., CHAN K., TRADITIONAL USES AND POTENTIAL HEALTH BENEFITS OF AMORPHOPHALLUS KONJAC K, KOCH EX N.E.BR. J ETHNOPHARMACOL, 128, PP. 268-278, (2010); LU Y., ZHANG J., ZHANG Z., LIANG X., LIU T., YI H., ET AL., KONJAC GLUCOMANNAN WITH PROBIOTICS ACTS AS A COMBINATION LAXATIVE TO RELIEVE CONSTIPATION IN MICE BY INCREASING SHORT-CHAIN FATTY ACID METABOLISM AND 5-HYDROXYTRYPTAMINE HORMONE RELEASE, NUTRITION, 84, (2021)","J. DENG; GUANGDONG PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITION REGULATION, SOUTH CHINA AGRICULTURAL UNIVERSITY, GUANGZHOU, CHINA; EMAIL: DENGJINPING@SCAU.EDU.CN; Y. DUAN; CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, HUNAN PROVINCIAL KEY LABORATORY OF ANIMAL NUTRITIONAL PHYSIOLOGY AND METABOLIC PROCESS, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, CHANGSHA, CHINA; EMAIL: DUANYEHUI@ISA.AC.CN","FRONTIERS MEDIA S.A.","ENGLISH","FRONT. NUTR.","REVIEW","ISI","2-S2.0-85116531663","FRONT NUTR","SOUTH CHINA AGRICULTURAL UNIVERSITY;INSTITUTE OF SUBTROPICAL AGRICULTURE;INSTITUTE OF SUBTROPICAL AGRICULTURE;UNIVERSITY OF CHINESE ACADEMY OF SCIENCES;UNIVERSITY OF CHINESE ACADEMY OF SCIENCES;UNIVERSITY OF CHINESE ACADEMY OF SCIENCES;SOUTH CHINA AGRICULTURAL UNIVERSITY;SOUTH CHINA AGRICULTURAL UNIVERSITY","NOTREPORTED;SOUTH CHINA AGRICULTURAL UNIVERSITY;NOTREPORTED;NOTREPORTED;INSTITUTE OF SUBTROPICAL AGRICULTURE;NOTREPORTED",NA,"WENG G, 2021, FRONT NUTR","WENG G, 2021, FRONT NUTR"
"GHOLAMREZAYI A;AMINI M;RASAEI N;AKHGARJAND C;KALANTAR Z;ASKARI G;HEKMATDOOST A","GHOLAMREZAYI, AFSANEH (57210450967); AMINI, MOHAMMAD REZA (57220716294); RASAEI, NILOUFAR (57202922204); AKHGARJAND, CAMELLIA (57222167325); KALANTAR, ZAHRA (57351399000); ASKARI, GHOLAMREZA (57189842487); HEKMATDOOST, AZITA (7801320384)","WHAT IS THE INFLUENCE OF POLICOSANOL SUPPLEMENTATION ON LIVER ENZYMES A SYSTEMATIC REVIEW AND DOSERESPONSE METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2024,"COMPLEMENTARY THERAPIES IN MEDICINE","80","",1,"10.1016/j.ctim.2024.103018","STUDENT RESEARCH COMMITTEE, DEPARTMENT OF CLINICAL NUTRITION AND DIETETICS, FACULTY OF NUTRITION SCIENCES AND FOOD TECHNOLOGY, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN;STUDENT RESEARCH COMMITTEE, DEPARTMENT OF CLINICAL NUTRITION AND DIETETICS, FACULTY OF NUTRITION SCIENCES AND FOOD TECHNOLOGY, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN, NUTRITION AND FOOD SECURITY RESEARCH CENTER, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS), TEHRAN, IRAN, NETWORK OF INTERDISCIPLINARITY IN NEONATES AND INFANTS (NINI), UNIVERSAL SCIENTIFIC EDUCATION AND RESEARCH NETWORK (USERN), TEHRAN, IRAN;DEPARTMENT OF CLINICAL NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS), TEHRAN, IRAN;DEPARTMENT OF CLINICAL NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS), TEHRAN, IRAN;NUTRITION AND FOOD SECURITY RESEARCH CENTER AND DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DEPARTMENT OF CLINICAL NUTRITION & DIETETICS, NATIONAL NUTRITION & FOOD TECHNOLOGY RESEARCH INSTITUTE, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN","OBJECTIVE: POLICOSANOL IS A MIXTURE OF LONG CHAIN ALCOHOLS REFINED FROM SUGAR CANE. SIGNIFICANT REDUCTIONS IN LIVER ENZYMES HAVE BEEN OBSERVED IN SOME STUDIES. HOWEVER, THE IMPACT OF POLICOSANOL ON LIVER ENZYMES REMAINED CONTROVERSIAL. THE CURRENT META-ANALYSIS AIMS TO EVALUATE THE EFFECT OF POLICOSANOL SUPPLEMENTATION ON THE LEVELS OF ALANINE TRANSAMINASE (ALT) AND ASPARTATE TRANSAMINASE (AST). METHODS: THE LITERATURE WAS SYSTEMATICALLY SEARCHED FOR STUDIES PUBLISHED UP TO NOVEMBER 2023 IN PUBMED/MEDLINE, GOOGLE SCHOLAR, EMBASE, AND SCOPUS. RANDOMIZED CONTROLLED TRIAL (RCT) STUDIES WERE INCLUDED TO EVALUATE THE INTERVENTION EFFECT OF POLICOSANOL COMPARED TO PLACEBO ON ALT AND AST. DERSIMONIAN AND LAIRD MODELS WERE USED TO CALCULATE EFFECT SIZES. RESULTS: TWENTY-THREE TRIALS INCLUDING 2535 PARTICIPANTS WERE INCLUDED IN THE STUDY. THE COMBINATION OF EFFECT SIZES, REGARDING THE RANDOM-EFFECTS MODEL, DEMONSTRATED SIGNIFICANT CHANGES IN ALT SERUM LEVELS AFTER INTERVENTION (WMD: −1.48 U/L; 95% CI: −2.33 TO −0.64; P = 0.001), AND AST (WMD: −1.10 U/L; 95% CI: −1.70 TO −0.51; P < 0.001). SUBGROUP ANALYSIS OF AST AND ALT SHOWED THAT THIS REDUCTION EFFECT WAS MOST OFTEN OBSERVED AT THE DOSE OF 20 MG/D. THE DOSE-RESPONSE ANALYSIS REPRESENTED A NON-SIGNIFICANT NON-LINEAR CONNECTION BETWEEN THE DOSAGE AND DURATION OF POLICOSANOL INTERVENTION IN ALT AND AST SERUM REDUCTION. CONCLUSION: POLICOSANOL SUPPLEMENTATION EXERTS A BENEFICIAL EFFECT ON LIVER ENZYMES AS WELL AS ALT AND AST CONCENTRATIONS IN ADULTS. HOWEVER, FURTHER LONG-TERM AND WELL-DESIGNED RCTS WITH BETTER QUALITY ARE NEEDED TO FURTHER ASSESS AND CONFIRM THESE RESULTS. © 2024 THE AUTHORS","ALANINE AMINOTRANSFERASE; ASPARTATE TRANSAMINASE; LIVER FUNCTION; META-ANALYSIS","ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; HUMANS; LIVER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; POLICOSANOL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ALCOHOL; POLICOSANOL; ALANINE AMINOTRANSFERASE LEVEL; ASPARTATE AMINOTRANSFERASE LEVEL; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EFFECT SIZE; HUMAN; LIVER FUNCTION; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; DIETARY SUPPLEMENT; LIVER; META ANALYSIS","SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, SBUMS","WE ALSO APPRECIATE THE “STUDENT RESEARCH COMMITTEE” AND “RESEARCH & TECHNOLOGY CHANCELLOR” IN SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES FOR THEIR FINANCIAL SUPPORT OF THIS STUDY. ","BOTROS M., SIKARIS K.A., THE DE RITIS RATIO: THE TEST OF TIME, CLIN BIOCHEM REV, 34, 3, PP. 117-130, (2013); PRATT D.S., KAPLAN M.M., EVALUATION OF ABNORMAL LIVER-ENZYME RESULTS IN ASYMPTOMATIC PATIENTS, N ENGL J MED, 342, 17, PP. 1266-1271, (2000); RUHL C.E., EVERHART J.E., ELEVATED SERUM ALANINE AMINOTRANSFERASE AND GAMMA-GLUTAMYLTRANSFERASE AND MORTALITY IN THE UNITED STATES POPULATION, GASTROENTEROLOGY, 136, 2, PP. 477-485, (2009); BAUMEISTER S.E., VOLZKE H., MARSCHALL P., ET AL., IMPACT OF FATTY LIVER DISEASE ON HEALTH CARE UTILIZATION AND COSTS IN A GENERAL POPULATION: A 5-YEAR OBSERVATION, GASTROENTEROLOGY, 134, 1, PP. 85-94, (2008); KIM H.C., NAM C.M., JEE S.H., HAN K.H., OH D.K., SUH I., NORMAL SERUM AMINOTRANSFERASE CONCENTRATION AND RISK OF MORTALITY FROM LIVER DISEASES: PROSPECTIVE COHORT STUDY, BMJ (CLINICAL RESEARCH ED), 328, 7446, (2004); LAZO M., HERNAEZ R., BONEKAMP S., ET AL., NON-ALCOHOLIC FATTY LIVER DISEASE AND MORTALITY AMONG US ADULTS: PROSPECTIVE COHORT STUDY, BMJ (CLINICAL RESEARCH ED), 343, (2011); OREN R., SERUM LIVER ENZYMES‐SHOULD WE COUNT ON THEM?, 34, PP. 171-173, (2014); BURGERT T.S., TAKSALI S.E., DZIURA J., ET AL., ALANINE AMINOTRANSFERASE LEVELS AND FATTY LIVER IN CHILDHOOD OBESITY: ASSOCIATIONS WITH INSULIN RESISTANCE, ADIPONECTIN, AND VISCERAL FAT, J CLIN ENDOCRINOL METAB, 91, 11, PP. 4287-4294, (2006); KOTRONEN A., WESTERBACKA J., BERGHOLM R., PIETILAINEN K.H., YKI-JARVINEN H., LIVER FAT IN THE METABOLIC SYNDROME, J CLIN ENDOCRINOL METAB, 92, 9, PP. 3490-3497, (2007); VOZAROVA B., STEFAN N., LINDSAY R.S., ET AL., HIGH ALANINE AMINOTRANSFERASE IS ASSOCIATED WITH DECREASED HEPATIC INSULIN SENSITIVITY AND PREDICTS THE DEVELOPMENT OF TYPE 2 DIABETES, DIABETES, 51, 6, PP. 1889-1895, (2002); HERNAEZ R., YEH H.C., LAZO M., ET AL., ELEVATED ALT AND GGT PREDICT ALL-CAUSE MORTALITY AND HEPATOCELLULAR CARCINOMA IN TAIWANESE MALE: A CASE-COHORT STUDY, HEPATOL INT, 7, 4, PP. 1040-1049, (2013); ZELBER-SAGI S., GODOS J., SALOMONE F., LIFESTYLE CHANGES FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE: A REVIEW OF OBSERVATIONAL STUDIES AND INTERVENTION TRIALS, THERAP ADV GASTROENTEROL, 9, 3, PP. 392-407, (2016); TOMASIEWICZ K., FLISIAK R., HALOTA W., ET AL., RECOMMENDATIONS FOR THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), CLIN EXP HEPATOL, 4, 3, PP. 153-157, (2018); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, 3-4, PP. 205-208, (1994); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, 3, PP. 1020-1026, (2006); ALEMAN C., RODEIRO I., NOA M., ET AL., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J APPL TOXICOL: JAT, 21, 3, PP. 179-184, (2001); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, 2, PP. 165-170, (2003); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, 1, PP. 8-12, (2001); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, 9, PP. 1084-1092, (1994); O'CONNOR P., FEELY J., SHEPHERD J., LIPID LOWERING DRUGS, BMJ (CLINICAL RESEARCH ED), 300, 6725, PP. 667-672, (1990); STEINER A., WEISSER B., VETTER W., A COMPARATIVE REVIEW OF THE ADVERSE EFFECTS OF TREATMENTS FOR HYPERLIPIDAEMIA, DRUG SAF, 6, 2, PP. 118-130, (1991); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, 7, PP. 568-577, (1996); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS IN R&D, 6, 4, PP. 207-219, (2005); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METAB CLIN EXP, 53, 10, PP. 1309-1314, (2004); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, 4, PP. 439-447, (1999); PAGE M.J., MCKENZIE J.E., BOSSUYT P.M., ET AL., THE PRISMA 2020 STATEMENT: AN UPDATED GUIDELINE FOR REPORTING SYSTEMATIC REVIEWS, BMJ (CLINICAL RESEARCH ED), 372, (2021); AMINI M.R., SHEIKHHOSSEIN F., NAGHSHI S., ET AL., EFFECTS OF BERBERINE AND BARBERRY ON ANTHROPOMETRIC MEASURES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT THER MED, 49, (2020); HIGGINS J.P., THOMPSON S.G., DEEKS J.J., ALTMAN D.G., MEASURING INCONSISTENCY IN META-ANALYSES, BMJ, 327, 7414, PP. 557-560, (2003); ARTECHE-HIDALGO L., FERNANDEZ-TRAVIESO J.C., SUAREZ-CAMEJO N., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH METABOLIC SYNDROME: A SIX-MONTH STUDY, J ENDOCRINOL METAB, 10, 2, PP. 36-44, (2020); WANG H.Y., JIAO Q.P., CHEN S.Y., ET AL., EFFICACY AND SAFETY OF POLICOSANOL PLUS FENOFIBRATE COMBINATION THERAPY IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA: A RANDOMIZED, CONTROLLED CLINICAL STUDY, AM J MED SCI, 356, 3, PP. 254-261, (2018); CORSINI A., BELLOSTA S., DAVIDSON M.H., PHARMACOKINETIC INTERACTIONS BETWEEN STATINS AND FIBRATES, AM J CARDIOL, 96, 9A, PP. 44K-49K, (2005); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, 15, PP. 5359-5362, (2006); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., ET AL., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); BANERJEE S., PORTER T.D., TEA AND POLICOSANOL ACT THROUGH DIFFERENT MECHANISMS TO ACTIVATE AMP‐KINASE AND SUPPRESS HMG‐COA REDUCTASE TO INHIBIT CHOLESTEROL SYNTHESIS, FASEB J, 24, (2010); SWANSON B., KEITHLEY J.K., SHA B.E., ET AL., POLICOSANOL FOR MANAGING HUMAN IMMUNODEFICIENCY VIRUS-RELATED DYSLIPIDEMIA IN A MEDICALLY UNDERSERVED POPULATION: A RANDOMIZED, CONTROLLED CLINICAL TRIAL, ALTERN THER HEALTH MED, 17, 2, PP. 30-35, (2011); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK., J GERONTOL SER A, BIOL SCI MED SCI, 56, 3, PP. M186-M192, (2001); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL, 22, 3-4, PP. 89-99, (2002); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, 3, PP. 255-262, (2000); WANG M., ZHANG X.J., FENG R., ET AL., HEPATOPROTECTIVE PROPERTIES OF PENTHORUM CHINENSE PURSH AGAINST CARBON TETRACHLORIDE-INDUCED ACUTE LIVER INJURY IN MICE, CHIN MED, PP. 12-32, (2017); CASTANO G., MAS R., ARRUZAZABALA M., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, 4, PP. 105-116, (1999); NOA M., MAS R., DE LA ROSA M., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, 4, PP. 289-291, (1995); CASTANO G., MAS R., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, 8, PP. 522-537, (2003); CASTANO G., MAS R., GAMEZ R., ET AL., CONCOMITANT USE OF POLICOSANOL AND BENZODIAZEPINES IN OLDER PATIENTS, REV CENIC CIENC BIOLÓGICAS, 38, 2, PP. 107-113, (2007); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, 7, PP. 568-577, (1996); CHO K.-H., NAM H.-S., BAEK S.-H., ET AL., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT J MOL SCI, 24, 6, (2023); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); GAENS K.H., NIESSEN P.M., RENSEN S.S., ET AL., ENDOGENOUS FORMATION OF NΕ-(CARBOXYMETHYL) LYSINE IS INCREASED IN FATTY LIVERS AND INDUCES INFLAMMATORY MARKERS IN AN IN VITRO MODEL OF HEPATIC STEATOSIS, J HEPATOL, 56, 3, PP. 647-655, (2012); YAGMUR E., TACKE F., WEISS C., ET AL., ELEVATION OF NΕ-(CARBOXYMETHYL) LYSINE-MODIFIED ADVANCED GLYCATION END PRODUCTS IN CHRONIC LIVER DISEASE IS AN INDICATOR OF LIVER CIRRHOSIS, CLIN BIOCHEM, 39, 1, PP. 39-45, (2006); YAGMUR E., TACKE F., WEISS C., ELEVATION OF NEPSILON-(CARBOXYMETHYL) LYSINE-MODIFIED ADVANCED GLYCATION END PRODUCTS IN CHRONNIC LIVER DISEASIS AN INDICATOR OF LIVER CIRRHOSIS, CLIN BIOCHEM, 39, PP. 39-45, (2006); ZEIN N., YASSIN F., MAKLED S., ET AL., ORAL SUPPLEMENTATION OF POLICOSANOL ALLEVIATES CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS IN RATS, BIOMED PHARMACOTHER, 150, (2022); YIN K., LI X., LUO X., ET AL., HEPATOPROTECTIVE EFFECT AND POTENTIAL MECHANISM OF AQUEOUS EXTRACT FROM PHYLLANTHUS EMBLICA ON CARBON-TETRACHLORIDE-INDUCED LIVER FIBROSIS IN RATS, EVID-BASED COMPLEMENT ALTERN MED, 2021, PP. 1-12, (2021); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVESTIG, 23, PP. 639-650, (2003); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, 2, PP. 176-182, (1995)","A. HEKMATDOOST; DEPARTMENT OF CLINICAL NUTRITION, FACULTY OF NUTRITION SCIENCES AND FOOD TECHNOLOGY, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN; EMAIL: AZITA.HEKMATDOOST@SBMU.AC.IR","CHURCHILL LIVINGSTONE","ENGLISH","COMPLEMENT. THER. MED.","REVIEW","ISI","2-S2.0-85182386450","COMPLEMENT THER MED","SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES;SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES;TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS);TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS);TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS);ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"GHOLAMREZAYI A, 2024, COMPLEMENT THER MED","GHOLAMREZAYI A, 2024, COMPLEMENT THER MED"
"KIM J;LIM D;SUH Y;CHANG K","KIM, JIN-HO (57221476735); LIM, DONG-KYUN (57235813800); SUH, YOO-HUN (7202260341); CHANG, KEUN-A (7404878332)","LONGTERM TREATMENT OF CUBAN POLICOSANOL ATTENUATES ABNORMAL OXIDATIVE STRESS AND INFLAMMATORY RESPONSE VIA AMYLOID PLAQUES REDUCTION IN 5XFAD MICE",2021,"ANTIOXIDANTS","10","",10,"10.3390/antiox10081321","DEPARTMENT OF HEALTH SCIENCES AND TECHNOLOGY, GACHON ADVANCED INSIUE FOR HEALH SCIENCES & TECHNOLOGY, GACHON UNIVERSITY, INCHEON, 21999, SOUTH KOREA;NEUROSCIENCE RESEARCH INSTITUTE, GACHON UNIVERSITY, INCHEON, 21565, SOUTH KOREA;NEUROSCIENCE RESEARCH INSTITUTE, GACHON UNIVERSITY, INCHEON, 21565, SOUTH KOREA, DEPARTMENT OF PHARMACOLOGY, COLLEGE OF MEDICINE, SEOUL NATIONAL UNIVERSITY, SEOUL, 03080, SOUTH KOREA;DEPARTMENT OF HEALTH SCIENCES AND TECHNOLOGY, GACHON ADVANCED INSIUE FOR HEALH SCIENCES & TECHNOLOGY, GACHON UNIVERSITY, INCHEON, 21999, SOUTH KOREA, NEUROSCIENCE RESEARCH INSTITUTE, GACHON UNIVERSITY, INCHEON, 21565, SOUTH KOREA, DEPARTMENT OF PHARMACOLOGY, COLLEGE OF MEDICINE, GACHON UNIVERSITY, INCHEON, 21999, SOUTH KOREA","ALZHEIMER’S DISEASE (AD) IS A PROGRESSIVE NEURODEGENERATIVE DISORDER RESULTING IN COGNITIVE DECLINE OR DEMENTIA, THE NUMBER OF PATIENTS WITH AD IS CONTINUOUSLY INCREASING. ALTHOUGH A LOT OF GREAT PROGRESS HAS BEEN MADE IN RESEARCH AND DEVELOPMENT OF AD THERAPEUTICS, THERE IS NO FUNDAMENTAL CURE FOR THIS DISEASE YET. THIS STUDY DEMONSTRATED THE MEMORY-IMPROVING EFFECTS OF CUBAN POLICOSANOL (PCO) IN 5XFAD MICE, WHICH IS AN ANIMAL MODEL OF AD. FOLLOWING 4-MONTHS OF TREATMENT WITH PCO IN 5XFAD MICE, WE FOUND THAT THE NUMBER OF AMYLOID PLAQUES DECREASED IN THE BRAIN COMPARED TO THE VEHICLE-TREATED 5XFAD MICE. LONG-TERM PCO TREATMENT IN 5XFAD MICE RESULTED IN THE REDUCTION OF GLIOSIS AND ABNORMAL INFLAMMATORY CYTOKINES LEVEL (INTERLEUKIN [IL]-1Β, IL-6, AND TUMOR NECROSIS FACTOR [TNF]-Α) IN THE CORTEX AND HIPPOCAMPUS. LEVELS OF LIPID PEROXIDE (4-HYDROXYNONENAL [4-HNE]) AND SUPEROXIDE DISMUTASE (SOD1 AND SOD2) LEVELS WERE ALSO RECOVERD IN THE BRAINS OF PCO-TREATED 5XFAD MICE. NOTABLY, PCO ADMINISTRATION REDUCED MEMORY DEFICITS IN THE PASSIVE AVOIDANCE TEST, AS WELL AS SYNAPTIC LOSS (PSD-95, SYNAPTOPHYSIN) IN 5XFAD MICE. COLLECTIVELY, WE IDENTIFIED THE POTENTIAL EFFECTS OF PCO AS A USEFUL SUPPLEMENT TO DELAY OR PREVENT AD PROGRESSION BY INHIBITING THE FORMATION OF AΒ PLAQUES IN THE BRAIN. © 2021 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND. THIS ARTICLE IS AN OPEN ACCESS ARTICLE DISTRIBUTED UNDER THE TERMS AND CONDITIONS OF THE CREATIVE COMMONS ATTRIBUTION (CC BY) LICENSE (HTTP://CREATIVECOMMONS.ORG/LICENSES /BY/4.0/).","5XFAD MICE; ALZHEIMER’S DISEASE; ANTI-INFLAMMATION; ANTIOXIDANT EFFECTS; MEMORY IMPROVEMENT; POLICOSANOL","","NATIONAL RESEARCH FOUNDATION OF KOREA, NRF; MINISTRY OF SCIENCE AND ICT, SOUTH KOREA, MSIT, (2020M3A9E4104384)","FUNDING: THIS STUDY WAS SUPPORTED BY THE BIO & MEDICAL TECHNOLOGY DEVELOPMENT PROGRAM OF THE NATIONAL RESEARCH FOUNDATION (NRF) & FUNDED BY THE KOREAN GOVERNMENT (MSIT) (2020M3A9E4104384). THE FUNDERS HAD NO ROLE IN STUDY DESIGN, DATA COLLECTION, AND ANALYSIS, DECISION TO PUBLISH, OR PREPARATION OF THE MANUSCRIPT.","MARTINPRINCE A.C.-H., KNAPP MARTIN, GUERCHET MAELENN, KARAGIANNIDOU MARIA, WORLD ALZHEIMER REPORT 2016: IMPOVING HEALTHCARE FOR PEOPLE LIVING WITH DEMENTIA: COVERAGE, QUALITY AND COSTS NOW AND IN THE FUTURE; SERRANO-POZO A., FROSCH M.P., MASLIAH E., HYMAN B.T., NEUROPATHOLOGICAL ALTERATIONS IN ALZHEIMER DISEASE, COLD SPRING HARB. PERSPECT MED, 1, (2011); HAQUE R.U., LEVEY A.I., ALZHEIMER’S DISEASE: A CLINICAL PERSPECTIVE AND FUTURE NONHUMAN PRIMATE RESEARCH OPPORTUNITIES, PROC. NATL. ACAD. SCI. USA, 116, PP. 26224-26229, (2019); CAMPORA M., FRANCESCONI V., SCHENONE S., TASSO B., TONELLI M., JOURNEY ON NAPHTHOQUINONE AND ANTHRAQUINONE DERIVATIVES: NEW INSIGHTS IN ALZHEIMER’S DISEASE, PHARMACEUTICALS, 14, (2021); CHEN G.F., XU T.H., YAN Y., ZHOU Y.R., JIANG Y., MELCHER K., XU H.E., AMYLOID BETA: STRUCTURE, BIOLOGY AND STRUCTURE-BASED THERAPEUTIC DEVELOPMENT, ACTA PHARMACOL. SIN, 38, PP. 1205-1235, (2017); BLOOM G.S., AMYLOID-BETA AND TAU: THE TRIGGER AND BULLET IN ALZHEIMER DISEASE PATHOGENESIS, JAMA NEUROL, 71, PP. 505-508, (2014); SELKOE D.J., ALZHEIMER’S DISEASE: GENES, PROTEINS, AND THERAPY, PHYSIOL. REV, 81, PP. 741-766, (2001); IWATSUBO T., ODAKA A., SUZUKI N., MIZUSAWA H., NUKINA N., IHARA Y., VISUALIZATION OF A BETA 42(43) AND A BETA 40 IN SENILE PLAQUES WITH END-SPECIFIC A BETA MONOCLONALS: EVIDENCE THAT AN INITIALLY DEPOSITED SPECIES IS A BETA 42(43), NEURON, 13, PP. 45-53, (1994); GUO T., ZHANG D., ZENG Y., HUANG T.Y., XU H., ZHAO Y., MOLECULAR AND CELLULAR MECHANISMS UNDERLYING THE PATHOGENESIS OF ALZHEIMER’S DISEASE, MOL. NEURODEGENER, 15, (2020); SELKOE D.J., HARDY J., THE AMYLOID HYPOTHESIS OF ALZHEIMER’S DISEASE AT 25 YEARS, EMBO MOL. MED, 8, PP. 595-608, (2016); KINNEY J.W., BEMILLER S.M., MURTISHAW A.S., LEISGANG A.M., SALAZAR A.M., LAMB B.T., INFLAMMATION AS A CENTRAL MECHANISM IN ALZHEIMER’S DISEASE, ALZHEIMERS DEMENT, 4, PP. 575-590, (2018); OLABARRIA M., NORISTANI H.N., VERKHRATSKY A., RODRIGUEZ J.J., CONCOMITANT ASTROGLIAL ATROPHY AND ASTROGLIOSIS IN A TRIPLE TRANSGENIC ANIMAL MODEL OF ALZHEIMER’S DISEASE, GLIA, 58, PP. 831-838, (2010); STALDER M., PHINNEY A., PROBST A., SOMMER B., STAUFENBIEL M., JUCKER M., ASSOCIATION OF MICROGLIA WITH AMYLOID PLAQUES IN BRAINS OF APP23 TRANSGENIC MICE, AM. J. PATHOL, 154, PP. 1673-1684, (1999); SWARDFAGER W., LANCTOT K., ROTHENBURG L., WONG A., CAPPELL J., HERRMANN N., A META-ANALYSIS OF CYTOKINES IN ALZHEIMER’S DISEASE, BIOL. PSYCHIATRY, 68, PP. 930-941, (2010); FROST G.R., LI Y.M., THE ROLE OF ASTROCYTES IN AMYLOID PRODUCTION AND ALZHEIMER’S DISEASE, OPEN BIOL, 7, (2017); PARAJULI B., SONOBE Y., HORIUCHI H., TAKEUCHI H., MIZUNO T., SUZUMURA A., OLIGOMERIC AMYLOID BETA INDUCES IL-1BETA PROCESSING VIA PRODUCTION OF ROS: IMPLICATION IN ALZHEIMER’S DISEASE, CELL DEATH DIS, 4, (2013); MARKESBERY W.R., THE ROLE OF OXIDATIVE STRESS IN ALZHEIMER DISEASE, ARCH. NEUROL, 56, PP. 1449-1452, (1999); PERSSON T., POPESCU B.O., CEDAZO-MINGUEZ A., OXIDATIVE STRESS IN ALZHEIMER’S DISEASE: WHY DID ANTIOXIDANT THERAPY FAIL?, OXID. MED. CELL LONGEV, 2014, (2014); CHAUHAN V., CHAUHAN A., OXIDATIVE STRESS IN ALZHEIMER’S DISEASE, PATHOPHYSIOLOGY, 13, PP. 195-208, (2006); WANG W., ZHAO F., MA X., PERRY G., ZHU X., MITOCHONDRIA DYSFUNCTION IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE: RECENT ADVANCES, MOL. NEURODEGENER, 15, (2020); SAYRE L.M., ZELASKO D.A., HARRIS P.L., PERRY G., SALOMON R.G., SMITH M.A., 4-HYDROXYNONENAL-DERIVED ADVANCED LIPID PEROXIDATION END PRODUCTS ARE INCREASED IN ALZHEIMER’S DISEASE, J. NEUROCHEM, 68, PP. 2092-2097, (1997); MARK R.J., LOVELL M.A., MARKESBERY W.R., UCHIDA K., MATTSON M.P., A ROLE FOR 4-HYDROXYNONENAL, AN ALDEHYDIC PRODUCT OF LIPID PEROXIDATION, IN DISRUPTION OF ION HOMEOSTASIS AND NEURONAL DEATH INDUCED BY AMYLOID BETA-PEPTIDE, J. NEUROCHEM, 68, PP. 255-264, (1997); ZEMLAN F.P., THIENHAUS O.J., BOSMANN H.B., SUPEROXIDE DISMUTASE ACTIVITY IN ALZHEIMER’S DISEASE: POSSIBLE MECHANISM FOR PAIRED HELICAL FILAMENT FORMATION, BRAIN RES, 476, PP. 160-162, (1989); MURAKAMI K., MURATA N., NODA Y., TAHARA S., KANEKO T., KINOSHITA N., HATSUTA H., MURAYAMA S., BARNHAM K.J., IRIE K., ET AL., SOD1 (COPPER/ZINC SUPEROXIDE DISMUTASE) DEFICIENCY DRIVES AMYLOID BETA PROTEIN OLIGOMERIZATION AND MEMORY LOSS IN MOUSE MODEL OF ALZHEIMER DISEASE, J. BIOL. CHEM, 286, PP. 44557-44568, (2011); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN. MED. REV, 7, PP. 203-217, (2002); PARK H.J., YADAV D., JEONG D.J., KIM S.J., BAE M.A., KIM J.R., CHO K.H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); KANG S., KIM J., CHANG K.A., SPATIAL MEMORY DEFICIENCY EARLY IN 6XTG ALZHEIMER’S DISEASE MOUSE MODEL, SCI. REP, 11, (2021); CROUZIN N., BARANGER K., CAVALIER M., MARCHALANT Y., COHEN-SOLAL C., ROMAN F.S., KHRESTCHATISKY M., RIVERA S., FERON F., VIGNES M., AREA-SPECIFIC ALTERATIONS OF SYNAPTIC PLASTICITY IN THE 5XFAD MOUSE MODEL OF ALZHEIMER’S DISEASE: DISSOCIATION BETWEEN SOMATOSENSORY CORTEX AND HIPPOCAMPUS, PLOS ONE, 8, (2013); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO CONTROLLED STUDY, OXID. MED. CELL LONGEV, 2018, (2018); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED, 39, PP. 889-899, (2017); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., MENDOZA N., VALLE M., JIMENEZ S., SANCHEZ J., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J. PHARM SCI, 75, PP. 635-641, (2013); ALZHEIMER'S A., ALZHEIMER’S DISEASE FACTS AND FIGURES, ALZHEIMERS DEMENT, 12, PP. 459-509, (2016); MARSILLACH J., ADORNI M.P., ZIMETTI F., PAPOTTI B., ZULIANI G., CERVELLATI C., HDL PROTEOME AND ALZHEIMER’S DISEASE: EVIDENCE OF A LINK, ANTIOXIDANTS, 9, (2020); WINGO T.S., CUTLER D.J., WINGO A.P., LE N.A., RABINOVICI G.D., MILLER B.L., LAH J.J., LEVEY A.I., ASSOCIATION OF EARLY-ONSET ALZHEIMER DISEASE WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND RARE GENETIC CODING VARIANTS OF APOB, JAMA NEUROL, 76, PP. 809-817, (2019); ZHOU Z., LIANG Y., ZHANG X., XU J., LIN J., ZHANG R., KANG K., LIU C., ZHAO C., ZHAO M., LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, FRONT. AGING NEUROSCI, 12, (2020); REITZ C., TANG M.X., SCHUPF N., MANLY J.J., MAYEUX R., LUCHSINGER J.A., ASSOCIATION OF HIGHER LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ELDERLY INDIVIDUALS AND LOWER RISK OF LATE-ONSET ALZHEIMER DISEASE, ARCH. NEUROL, 67, PP. 1491-1497, (2010); LEWIS T.L., CAO D., LU H., MANS R.A., SU Y.R., JUNGBAUER L., LINTON M.F., FAZIO S., LADU M.J., LI L., OVEREXPRESSION OF HUMAN APOLIPOPROTEIN A-I PRESERVES COGNITIVE FUNCTION AND ATTENUATES NEUROINFLAMMATION AND CEREBRAL AMYLOID ANGIOPATHY IN A MOUSE MODEL OF ALZHEIMER DISEASE, J. BIOL. CHEM, 285, PP. 36958-36968, (2010); DAL MAGRO R., SIMONELLI S., COX A., FORMICOLA B., CORTI R., CASSINA V., NARDO L., MANTEGAZZA F., SALERNO D., GRASSO G., ET AL., THE EXTENT OF HUMAN APOLIPOPROTEIN A-I LIPIDATION STRONGLY AFFECTS THE BETA-AMYLOID EFFLUX ACROSS THE BLOOD-BRAIN BARRIER IN VITRO, FRONT. NEUROSCI, 13, (2019); PATERNO R., RUOCCO A., POSTIGLIONE A., HUBSCH A., ANDRESEN I., LANG M.G., RECONSTITUTED HIGH-DENSITY LIPOPROTEIN EXHIBITS NEUROPROTECTION IN TWO RAT MODELS OF STROKE, CEREBROVASC. DIS, 17, PP. 204-211, (2004); BUTTON E.B., BOYCE G.K., WILKINSON A., STUKAS S., HAYAT A., FAN J., WADSWORTH B.J., ROBERT J., MARTENS K.M., WELLINGTON C.L., APOA-I DEFICIENCY INCREASES CORTICAL AMYLOID DEPOSITION, CEREBRAL AMYLOID ANGIOPATHY, CORTICAL AND HIPPOCAMPAL ASTROGLIOSIS, AND AMYLOID-ASSOCIATED ASTROCYTE REACTIVITY IN APP/PS1 MICE, ALZHEIMERS RES. THER, 11, (2019); BUTTON E.B., ROBERT J., CAFFREY T.M., FAN J., ZHAO W., WELLINGTON C.L., HDL FROM AN ALZHEIMER’S DISEASE PERSPECTIVE, CURR. OPIN. LIPIDOL, 30, PP. 224-234, (2019); ZIMETTI F., ADORNI M.P., MARSILLACH J., MARCHI C., TRENTINI A., VALACCHI G., CERVELLATI C., CONNECTION BETWEEN THE ALTERED HDL ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES AND THE RISK TO DEVELOP ALZHEIMER’S DISEASE: A NARRATIVE REVIEW, OXID. MED. CELL LONGEV, 2021, (2021); SASAGURI H., NILSSON P., HASHIMOTO S., NAGATA K., SAITO T., DE STROOPER B., HARDY J., VASSAR R., WINBLAD B., SAIDO T.C., APP MOUSE MODELS FOR ALZHEIMER’S DISEASE PRECLINICAL STUDIES, EMBO J, 36, PP. 2473-2487, (2017); RIES M., SASTRE M., MECHANISMS OF ABETA CLEARANCE AND DEGRADATION BY GLIAL CELLS, FRONT. AGING NEUROSCI, 8, (2016); MINTER M.R., TAYLOR J.M., CRACK P.J., THE CONTRIBUTION OF NEUROINFLAMMATION TO AMYLOID TOXICITY IN ALZHEIMER’S DISEASE, J. NEUROCHEM, 136, PP. 457-474, (2016); HU J., AKAMA K.T., KRAFFT G.A., CHROMY B.A., VAN ELDIK L.J., AMYLOID-BETA PEPTIDE ACTIVATES CULTURED ASTROCYTES: MORPHOLOGICAL ALTERATIONS, CYTOKINE INDUCTION AND NITRIC OXIDE RELEASE, BRAIN RES, 785, PP. 195-206, (1998); FUHRMANN M., BITTNER T., JUNG C.K., BURGOLD S., PAGE R.M., MITTEREGGER G., HAASS C., LAFERLA F.M., KRETZSCHMAR H., HERMS J., MICROGLIAL CX3CR1 KNOCKOUT PREVENTS NEURON LOSS IN A MOUSE MODEL OF ALZHEIMER’S DISEASE, NAT. NEUROSCI, 13, PP. 411-413, (2010); MANDREKAR-COLUCCI S., LANDRETH G.E., MICROGLIA AND INFLAMMATION IN ALZHEIMER’S DISEASE, CNS NEUROL. DISORD. DRUG TARGETS, 9, PP. 156-167, (2010); VILLA V., THELLUNG S., BAJETTO A., GATTA E., ROBELLO M., NOVELLI F., TASSO B., TONELLI M., FLORIO T., NOVEL CELECOXIB ANALOGUES INHIBIT GLIAL PRODUCTION OF PROSTAGLANDIN E2, NITRIC OXIDE, AND OXYGEN RADICALS REVERTING THE NEUROINFLAMMATORY RESPONSES INDUCED BY MISFOLDED PRION PROTEIN FRAGMENT 90-231 OR LIPOPOLYSACCHARIDE, PHARMACOL. RES, 113, PP. 500-514, (2016); HUANG W.J., ZHANG X., CHEN W.W., ROLE OF OXIDATIVE STRESS IN ALZHEIMER’S DISEASE, BIOMED. REP, 4, PP. 519-522, (2016); BUTTERFIELD D.A., BOYD-KIMBALL D., OXIDATIVE STRESS, AMYLOID-BETA PEPTIDE, AND ALTERED KEY MOLECULAR PATHWAYS IN THE PATHOGENESIS AND PROGRESSION OF ALZHEIMER’S DISEASE, J. ALZHEIMERS DIS, 62, PP. 1345-1367, (2018); QIN Y., ZHU W., ZHAN C., ZHAO L., WANG J., TIAN Q., WANG W., INVESTIGATION ON POSITIVE CORRELATION OF INCREASED BRAIN IRON DEPOSITION WITH COGNITIVE IMPAIRMENT IN ALZHEIMER DISEASE BY USING QUANTITATIVE MR R2’ MAPPING, J. HUAZHONG UNIV. SCI. TECHNOLOG. MED. SCI, 31, (2011); NIZZARI M., THELLUNG S., CORSARO A., VILLA V., PAGANO A., PORCILE C., RUSSO C., FLORIO T., NEURODEGENERATION IN ALZHEIMER DISEASE: ROLE OF AMYLOID PRECURSOR PROTEIN AND PRESENILIN 1 INTRACELLULAR SIGNALING, J. TOXICOL, 2012, (2012); SULTANA R., PERLUIGI M., BUTTERFIELD D.A., LIPID PEROXIDATION TRIGGERS NEURODEGENERATION: A REDOX PROTEOMICS VIEW INTO THE ALZHEIMER DISEASE BRAIN, FREE RADIC BIOL. MED, 62, PP. 157-169, (2013); MONTINE T.J., NEELY M.D., QUINN J.F., BEAL M.F., MARKESBERY W.R., ROBERTS L.J., MORROW J.D., LIPID PEROXIDATION IN AGING BRAIN AND ALZHEIMER’S DISEASE, FREE RADIC. BIOL. MED, 33, PP. 620-626, (2002); PRATICO D., URYU K., LEIGHT S., TROJANOSWKI J.Q., LEE V.M., INCREASED LIPID PEROXIDATION PRECEDES AMYLOID PLAQUE FORMATION IN AN ANIMAL MODEL OF ALZHEIMER AMYLOIDOSIS, J. NEUROSCI, 21, PP. 4183-4187, (2001); BUTTERFIELD D.A., LAUDERBACK C.M., LIPID PEROXIDATION AND PROTEIN OXIDATION IN ALZHEIMER’S DISEASE BRAIN: POTENTIAL CAUSES AND CONSEQUENCES INVOLVING AMYLOID BETA-PEPTIDE-ASSOCIATED FREE RADICAL OXIDATIVE STRESS, FREE RADIC BIOL. MED, 32, PP. 1050-1060, (2002); MECOCCI P., MACGARVEY U., BEAL M.F., OXIDATIVE DAMAGE TO MITOCHONDRIAL DNA IS INCREASED IN ALZHEIMER’S DISEASE, ANN. NEUROL, 36, PP. 747-751, (1994); AKSENOV M.Y., AKSENOVA M.V., BUTTERFIELD D.A., GEDDES J.W., MARKESBERY W.R., PROTEIN OXIDATION IN THE BRAIN IN ALZHEIMER’S DISEASE, NEUROSCIENCE, 103, PP. 373-383, (2001); MARKESBERY W.R., LOVELL M.A., FOUR-HYDROXYNONENAL, A PRODUCT OF LIPID PEROXIDATION, IS INCREASED IN THE BRAIN IN ALZHEIMER’S DISEASE, NEUROBIOL. AGING, 19, PP. 33-36, (1998); MCGRATH L.T., MCGLEENON B.M., BRENNAN S., MCCOLL D., MC I.S., PASSMORE A.P., INCREASED OXIDATIVE STRESS IN ALZHEIMER’S DISEASE AS ASSESSED WITH 4-HYDROXYNONENAL BUT NOT MALONDIALDEHYDE, QJM, 94, PP. 485-490, (2001); LOVELL M.A., XIE C., MARKESBERY W.R., ACROLEIN IS INCREASED IN ALZHEIMER’S DISEASE BRAIN AND IS TOXIC TO PRIMARY HIPPOCAMPAL CULTURES, NEUROBIOL. AGING, 22, PP. 187-194, (2001); SHOEB M., ANSARI N.H., SRIVASTAVA S.K., RAMANA K.V., 4-HYDROXYNONENAL IN THE PATHOGENESIS AND PROGRESSION OF HUMAN DISEASES, CURR. MED. CHEM, 21, PP. 230-237, (2014); MARCUS D.L., THOMAS C., RODRIGUEZ C., SIMBERKOFF K., TSAI J.S., STRAFACI J.A., FREEDMAN M.L., INCREASED PEROXIDATION AND REDUCED ANTIOXIDANT ENZYME ACTIVITY IN ALZHEIMER’S DISEASE, EXP. NEUROL, 150, PP. 40-44, (1998); ZHAO Y., ZHAO B., OXIDATIVE STRESS AND THE PATHOGENESIS OF ALZHEIMER’S DISEASE, OXID MED. CELL LONGEV, 2013, (2013); CHOI J., REES H.D., WEINTRAUB S.T., LEVEY A.I., CHIN L.S., LI L., OXIDATIVE MODIFICATIONS AND AGGREGATION OF CU,ZN-SUPEROXIDE DISMUTASE ASSOCIATED WITH ALZHEIMER AND PARKINSON DISEASES, J. BIOL. CHEM, 280, PP. 11648-11655, (2005); GRINAN-FERRE C., SARROCA S., IVANOVA A., PUIGORIOL-ILLAMOLA D., AGUADO F., CAMINS A., SANFELIU C., PALLAS M., EPIGENETIC MECHANISMS UNDERLYING COGNITIVE IMPAIRMENT AND ALZHEIMER DISEASE HALLMARKS IN 5XFAD MICE, AGING, 8, PP. 664-684, (2016); ESPOSITO L., RABER J., KEKONIUS L., YAN F., YU G.Q., BIEN-LY N., PUOLIVALI J., SCEARCE-LEVIE K., MASLIAH E., MUCKE L., REDUCTION IN MITOCHONDRIAL SUPEROXIDE DISMUTASE MODULATES ALZHEIMER’S DISEASE-LIKE PATHOLOGY AND ACCELERATES THE ONSET OF BEHAVIORAL CHANGES IN HUMAN AMYLOID PRECURSOR PROTEIN TRANSGENIC MICE, J. NEUROSCI, 26, PP. 5167-5179, (2006); LEE H.P., PANCHOLI N., ESPOSITO L., PREVILL L.A., WANG X., ZHU X., SMITH M.A., LEE H.G., EARLY INDUCTION OF OXIDATIVE STRESS IN MOUSE MODEL OF ALZHEIMER DISEASE WITH REDUCED MITOCHONDRIAL SUPEROXIDE DISMUTASE ACTIVITY, PLOS ONE, 7, (2012); TONNIES E., TRUSHINA E., OXIDATIVE STRESS, SYNAPTIC DYSFUNCTION, AND ALZHEIMER’S DISEASE, J. ALZHEIMERS DIS, 57, PP. 1105-1121, (2017); FERRETTI M.T., IULITA M.F., CAVEDO E., CHIESA P.A., SCHUMACHER DIMECH A., SANTUCCIONE CHADHA A., BARACCHI F., GIROUARD H., MISOCH S., GIACOBINI E., ET AL., SEX DIFFERENCES IN ALZHEIMER DISEASE—THE GATEWAY TO PRECISION MEDICINE, NAT. REV. NEUROL, 14, PP. 457-469, (2018); SVENSSON T., SAWADA N., MIMURA M., NOZAKI S., SHIKIMOTO R., TSUGANE S., THE ASSOCIATION BETWEEN MIDLIFE SERUM HIGH-DENSITY LIPOPROTEIN AND MILD COGNITIVE IMPAIRMENT AND DEMENTIA AFTER 19 YEARS OF FOLLOW-UP, TRANSL. PSYCHIATRY, 9, (2019)","K.-A. CHANG; DEPARTMENT OF HEALTH SCIENCES AND TECHNOLOGY, GACHON ADVANCED INSIUE FOR HEALH SCIENCES & TECHNOLOGY, GACHON UNIVERSITY, INCHEON, 21999, SOUTH KOREA; EMAIL: KEUNA705@GACHON.AC.KR","MDPI","ENGLISH","ANTIOXIDANTS","ARTICLE","ISI","2-S2.0-85113808422","ANTIOXIDANTS","GACHON UNIVERSITY;GACHON UNIVERSITY;GACHON UNIVERSITY;GACHON UNIVERSITY","NOTREPORTED;GACHON UNIVERSITY;NOTREPORTED",NA,"KIM J-H, 2021, ANTIOXIDANTS","KIM J-H, 2021, ANTIOXIDANTS"
"ZHAI Z;NIU K;LIU H;LIN C;TU Y;LIU Y;CAI L;OUYANG K;LIU J","ZHAI, ZHENYA (57189509834); NIU, KAI-MIN (57190128221); LIU, HUIPING (57218118479); LIN, CHONG (57248069600); TU, YUE (57312304800); LIU, YICHUN (57247420300); CAI, LICHUANG (54407998100); OUYANG, KEXIAN (57202031966); LIU, JIANPING (57202034035)","POLICOSANOL ALLEVIATES HEPATIC LIPID ACCUMULATION BY REGULATING BILE ACIDS METABOLISM IN C57BL6MICE THROUGH AMPKFXRTGR5 CROSSTALK",2021,"JOURNAL OF FOOD SCIENCE","86","12",14,"10.1111/1750-3841.15951","JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA, CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, CHANGSHA, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA, CAS KEY LABORATORY OF AGRO-ECOLOGICAL PROCESSES IN SUBTROPICAL REGION, INSTITUTE OF SUBTROPICAL AGRICULTURE, CHINESE ACADEMY OF SCIENCES, NATIONAL ENGINEERING LABORATORY FOR POLLUTION CONTROL AND WASTE UTILIZATION IN LIVESTOCK AND POULTRY PRODUCTION, CHANGSHA, CHINA;SHENZHEN, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA;JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA","POLICOSANOL EXHIBITS A LIPID ACCUMULATION ALLEVIATING EFFECT, BUT THE UNDERLYING MECHANISMS REMAINS UNCLEAR. BILE ACIDS ARE A SIGNIFICANT FACTOR IN REGULATING CHOLESTEROL AND LIPID METABOLISM HOMEOSTASIS IN MAMMALS. THIS STUDY WAS AIMED TO ELUCIDATE THE ALLEVIATING EFFECT AND UNDERLYING MECHANISMS OF POLICOSANOL ON HEPATIC LIPID ACCUMULATION THROUGH BILE ACID (BA) METABOLISM. POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY REDUCED HEPATIC TRIGLYCERIDES (19.29%), CHOLESTEROL (30.38%) IN HIGH FAT DIET (HFD) INDUCED OBESE MICE (P < 0.05). FURTHERMORE, COMPARED WITH THE CONTROL GROUP, HFD DECREASED THE LEVELS OF TOTAL BAS (TBAS, 37.67%) AND CHOLIC ACID (CA, 62.74%) IN THE SERUM OF MICE (P < 0.05). MEANWHILE, COMPARED TO HFD GROUP, POLICOSANOL ALSO INCREASED THE LEVEL OF SECONDARY BAS (SBAS) AND MURICHOLIC ACIDS (MCAS, P < 0.05). QRT-PCR COMBINED WITH PROTEIN LEVEL ANALYSIS REVEALED THAT POLICOSANOL SIGNIFICANTLY DECREASED STEROL REGULATORY ELEMENT-BINDING PROTEIN (SREBP-1C) AND CD36, AND INCREASED THE EXPRESSION LEVEL OF CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) AND CYTOCHROME P450 FAMILY 27 SUBFAMILY A MEMBER 1 (CYP27A1, P < 0.05). ADDITIONALLY, IN THE LIVER, POLICOSANOL WAS FOUND DOWNREGULATED THE EXPRESSION OF FARNESOID X RECEPTOR (FXR)-SMALL HETERODIMER PARTNER (SHP), AND ACTIVATE THE TAKEDA G-COUPLED PROTEIN RECEPTOR 5 (TGR5)-ADENOSINE-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (APMK) SIGNALING PATHWAY (P < 0.05). PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR)-Α, HORMONE SENSITIVE LIPASE (HSL), AND CARNITINE PALMITOYLTRANSFERASE (CPT)-1Α ALSO SIGNIFICANTLY INCREASED IN HP GROUP (P < 0.05). THE AFOREMENTIONED RESULTS REVEAL THAT THE POTENTIAL MECHANISM OF POLICOSANOL IN ALLEVIATING LIVER LIPID ACCUMULATION IS TO PROMOTE BA SYNTHESIS AND LIPOLYSIS THROUGH REGULATING THE CROSS-TALK OF THE AMPK–FXR–TGR5. NEW INSIGHT FOR THE APPLICATION OF POLICOSANOL AS AN ANTI-FATTY LIVER FUNCTIONAL FOOD INGREDIENT OR SUPPLEMENT IS ALSO PROVIDED. PRACTICAL APPLICATION: POLICOSANOL IS AN IMPORTANT ACTIVE COMPONENT OF CEREALS AND INSECT WAXES (15–80%). HOWEVER, ALMOST NO POLICOSANOL IN REFINED FOODS SUCH AS CLEAR CORN GERM OIL AND WHEAT FLOUR. THIS STUDY SHOWED THAT ORAL ADMINISTRATION OF POLICOSANOL CAN SIGNIFICANTLY REDUCE TRIGLYCERIDE AND CHOLESTEROL LEVELS IN THE LIVER THROUGH AFFECTING AMPK–TGR5–FXR CROSS-TALK, WHEREAS NO SIGNIFICANT TOXICOLOGICAL EFFECT IS REPORTED IN HUMAN AND MOUSE MODELS. THIS STUDY MAY PROVIDE THEORETICAL SUPPORT FOR THE THEORY OF DIETARY STRUCTURE AND THE DEVELOPMENT OF DIETARY SUPPLEMENTS TO IMPROVE LIPID METABOLISM TARGETING THE “BILE ACID–AMPK–TGR5” PATHWAY. © 2021 INSTITUTE OF FOOD TECHNOLOGISTS®","AMPK–FXR–TGR5 PATHWAY; BILE ACIDS; LIVER LIPID ACCUMULATION; POLICOSANOL","AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BILE ACIDS AND SALTS; FATTY ALCOHOLS; FLOUR; LIPID METABOLISM; LIPIDS; LIVER; MICE; TRITICUM; BILE ACID; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; POLICOSANOL; ANIMAL; FLOUR; GENETICS; LIPID METABOLISM; LIVER; MOUSE; WHEAT","GENERAL PROJECTS OF KEY RESEARCH AND DEVELOPMENT PLAN IN JIANGXI PROVINCE, (20203BBFL63054); GUANGDONG PROVINCE ENTERPRISE SPECIAL PERSON SPECIAL PLAN PROJECT, (GDKTP2020054600); RESEARCH AND DEVELOPMENT PROJECT OF JIANGXI ACADEMY OF SCIENCES, (2020‐YYB‐01); CHINA POSTDOCTORAL SCIENCE FOUNDATION, (2020M682108)","THE PROJECT WAS FUNDED BY GENERAL PROJECTS OF KEY RESEARCH AND DEVELOPMENT PLAN IN JIANGXI PROVINCE (20203BBFL63054), PROJECT FUNDED BY CHINA POSTDOCTORAL SCIENCE FOUNDATION (2020M682108), GUANGDONG PROVINCE ENTERPRISE SPECIAL PERSON SPECIAL PLAN PROJECT (GDKTP2020054600), AND RESEARCH AND DEVELOPMENT PROJECT OF JIANGXI ACADEMY OF SCIENCES ‐ DOCTORAL FUND PROJECT (2020‐YYB‐01). ","BHATT D.L., STEG P.G., MILLER M., BRINTON E.A., JACOBSON T.A., KETCHUM S.B., DOYLE R.J., JULIANO R.A., JIAO L., GRANOWITZ C., TARDIF J.C., BALLANTYNE C.M., CARDIOVASCULAR RISK REDUCTION WITH ICOSAPENT ETHYL FOR HYPERTRIGLYCERIDEMIA, THE NEW ENGLAND JOURNAL OF MEDICINE, 380, 1, PP. 11-22, (2019); BROEDERS E.P.M., NASCIMENTO E.B.M., HAVEKES B., BRANS B., ROUMANS K.H.M., TAILLEUX A., SCHAART G., KOUACH M., CHARTON J., DEPREZ B., BOUVY N.D., MOTTAGHY F., STAELS B., LICHTENBELT W.D.V.M., SCHRAUWEN P., THE BILE ACID CHENODEOXYCHOLIC ACID INCREASES HUMAN BROWN ADIPOSE TISSUE ACTIVITY, CELL METABOLISM, 22, 3, PP. 418-426, (2015); CHALASANI N., YOUNOSSI Z., LAVINE J.E., CHARLTON M., CUSI K., RINELLA M., HARRISON S.A., BRUNT E.M., SANYAL A.J., THE DIAGNOSIS AND MANAGEMENT OF NONALCOHOLIC FATTY LIVER DISEASE: PRACTICE GUIDANCE FROM THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES, HEPATOLOGY, 67, 1, PP. 328-357, (2018); EL-TANTAWY W.H., TEMRAZ A., NATURAL PRODUCTS FOR CONTROLLING HYPERLIPIDEMIA: REVIEW, ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 125, 2, PP. 128-135, (2019); GANGWISCH J.E., HALE L., ST-ONGE M., CHOI L., LEBLANC E.S., MALASPINA D., OPLER M.G., SHADYAB A.H., SHIKANY J.M., SNETSELAAR L., ZASLAVSKY O., LANE D., HIGH GLYCEMIC INDEX AND GLYCEMIC LOAD DIETS AS RISK FACTORS FOR INSOMNIA: ANALYSES FROM THE WOMEN'S HEALTH INITIATIVE, AMERICAN JOURNAL OF CLINICAL NUTRITION, 111, 2, PP. 429-439, (2020); GROSS B., PAWLAK M., LEFEBVRE P., STAELS B., PPARS IN OBESITY-INDUCED T2DM, DYSLIPIDAEMIA AND NAFLD, NATURE REVIEWS ENDOCRINOLOGY, 13, 1, PP. 36-49, (2017); HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE-AN ENERGY SENSOR THAT REGULATES ALL ASPECTS OF CELL FUNCTION, GENES & DEVELOPMENT, 25, 18, PP. 1895-1908, (2011); HUNTER P.M., HEGELE R.A., FUNCTIONAL FOODS AND DIETARY SUPPLEMENTS FOR THE MANAGEMENT OF DYSLIPIDAEMIA, NATURE REVIEWS ENDOCRINOLOGY, 13, 5, PP. 278-288, (2017); INAGAKI T., CHOI M., MOSCHETTA A., PENG L., CUMMINS C.L., MCDONALD J.G., LUO G., JONES S.A., GOODWIN B., RICHARDSON J.A., GERARD R.D., REPA J.J., MANGELSDORF D.J., KLIEWER S.A., FIBROBLAST GROWTH FACTOR 15 FUNCTIONS AS AN ENTEROHEPATIC SIGNAL TO REGULATE BILE ACID HOMEOSTASIS, CELL METABOLISM, 2, 4, PP. 217-225, (2005); INGE T.H., JENKINS T.M., XANTHAKOS S.A., DIXON J.B., DANIELS S.R., ZELLER M.H., HELMRATH M.A., LONG-TERM OUTCOMES OF BARIATRIC SURGERY IN ADOLESCENTS WITH SEVERE OBESITY (FABS-5+): A PROSPECTIVE FOLLOW-UP ANALYSIS, LANCET DIABETES & ENDOCRINOLOGY, 5, 3, PP. 165-173, (2017); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); JAACKS L.M., VANDEVIJVERE S., PAN A., MCGOWAN C.J., WALLACE C., IMAMURA F., MOZAFFARIAN D., SWINBURN B., EZZATI M., THE OBESITY TRANSITION: STAGES OF THE GLOBAL EPIDEMIC, THE LANCET DIABETES & ENDOCRINOLOGY, 7, 3, PP. 231-240, (2019); JIAO N., BAKER S.S., CHAPA-RODRIGUEZ A., LIU W., NUGENT C.A., TSOMPANA M., MASTRANDREA L., BUCK M.J., BAKER R.D., GENCO R.J., ZHU R., ZHU L., SUPPRESSED HEPATIC BILE ACID SIGNALLING DESPITE ELEVATED PRODUCTION OF PRIMARY AND SECONDARY BILE ACIDS IN NAFLD, GUT, 67, 10, PP. 1881-1891, (2018); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANNALS OF NUTRITION AND METABOLISM, 39, 5, PP. 279-284, (1995); KONG B., WANG L., CHIANG J.Y.L., ZHANG Y., KLAASSEN C.D., GUO G.L., MECHANISM OF TISSUE-SPECIFIC FARNESOID X RECEPTOR IN SUPPRESSING THE EXPRESSION OF GENES IN BILE-ACID SYNTHESIS IN MICE, HEPATOLOGY, 56, 3, PP. 1034-1043, (2012); LI C., DING Y., SI Q., LI K., XU K., MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY PATIENTS WITH DYSLIPIDEMIA, JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 48, (2020); LI X., YUAN Z., LIU R., HASSAN H.M., YANG H., SUN R., ZHANG L., JIANG Z., UDCA AND CDCA ALLEVIATE 17ALPHA-ETHINYLESTRADIOL-INDUCED CHOLESTASIS THROUGH PKA-AMPK PATHWAYS IN RATS, TOXICOLOGY AND APPLIED PHARMACOLOGY, 311, PP. 12-25, (2016); LIEN F., BERTHIER A., BOUCHAERT E., GHEERAERT C., ALEXANDRE J., POREZ G., PRAWITT J., DEHONDT H., PLOTON M., COLIN S., LUCAS A., PATRICE A., PATTOU F., DIEMER H., VAN DORSSELAER A., RACHEZ C., KAMILIC J., GROEN A.K., STAELS B., LEFEBVRE P., METFORMIN INTERFERES WITH BILE ACID HOMEOSTASIS THROUGH AMPK-FXR CROSSTALK, JOURNAL OF CLINICAL INVESTIGATION, 124, 3, PP. 1037-1051, (2014); MA J., MA L., ZHANG Z., LI K., WANG Y., CHEN X., ZHANG H., IN VIVO EVALUATION OF INSECT WAX FOR HAIR GROWTH POTENTIAL, PLOS ONE, 13, E01926122, (2018); MARECHAL L., LAVIOLETTE M., RODRIGUE-WAY A., SOW B., BROCHU M., CARON V., TREMBLAY A., THE CD36-PPARGAMMA PATHWAY IN METABOLIC DISORDERS, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19, 5, (2018); NAM D.E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, JOURNAL OF MEDICINAL FOOD, 22, 11, PP. 1110-1117, (2019); OLIARO-BOSSO S., GAUDINO E.C., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, 10, PP. 907-916, (2009); RA J., WOO S., LEE K., LEE M.J., KIM H.Y., HAM H.M., CHUNG I., KIM D.H., LEE J.H., SEO W.D., POLICOSANOL PROFILES AND ADENOSINE 5 '-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION POTENTIAL OF KOREAN WHEAT SEEDLING EXTRACTS ACCORDING TO CULTIVAR AND GROWTH TIME, FOOD CHEMISTRY, 317, (2020); RAGHOW R., YELLATURU C., DENG X., PARK E.A., ELAM M.B., SREBPS: THE CROSSROADS OF PHYSIOLOGICAL AND PATHOLOGICAL LIPID HOMEOSTASIS, TRENDS IN ENDORCRINOLOGY AND METABOLISM, 19, 2, PP. 65-73, (2008); SHAPIRO H., KOLODZIEJCZYK A.A., HALSTUCH D., ELINAV E., BILE ACIDS IN GLUCOSE METABOLISM IN HEALTH AND DISEASE, JOURNAL OF EXPERIMENTAL MEDICINE, 215, 2, PP. 383-396, (2018); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, JOURNAL OF FUNCTIONAL FOODS, 57, PP. 351-360, (2019); SOTO-ACOSTA R., BAUTISTA-CARBAJAL P., CERVANTES-SALAZAR M., ANGEL-AMBROCIO A.H., DEL ANGEL R.M., DENV UP-REGULATES THE HMG-COA REDUCTASE ACTIVITY THROUGH THE IMPAIRMENT OF AMPK PHOSPHORYLATION: A POTENTIAL ANTIVIRAL TARGET, PLOS PATHOGENS, 13, 4, (2017); TIAN Y., ACEVEDO N., ROLE OF SUPRAMOLECULAR POLICOSANOL OLEOGELS IN THE PROTECTION OF RETINYL PALMITATE AGAINST PHOTODEGRADATION, RSC ADVANCES, 10, 5, PP. 2526-2535, (2020); WAHLSTROM A., SAYIN S.I., MARSCHALL H.U., BACKHED F., INTESTINAL CROSSTALK BETWEEN BILE ACIDS AND MICROBIOTA AND ITS IMPACT ON HOST METABOLISM, CELL METABOLISM, 24, 1, PP. 41-50, (2016); WANG M., LIAN H., MAO L., ZHOU J., GONG H., QIAN B., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 14, PP. 5552-5558, (2007); WATANABE M., HOUTEN S.M., MATAKI C., CHRISTOFFOLETE M.A., KIM B.W., SATO H., MESSADDEQ N., HARNEY J.W., EZAKI O., KODAMA T., SCHOONJANS K., BIANCO A.C., AUWERX J., BILE ACIDS INDUCE ENERGY EXPENDITURE BY PROMOTING INTRACELLULAR THYROID HORMONE ACTIVATION, NATURE, 439, 7075, PP. 484-489, (2006); YOUNOSSI Z., ANSTEE Q.M., MARIETTI M., HARDY T., HENRY L., ESLAM M., GEORGE J., BUGIANESI E., GLOBAL BURDEN OF NAFLD AND NASH: TRENDS, PREDICTIONS, RISK FACTORS AND PREVENTION, NATURE REVIEWS GASTROENTEROLOGY AND HEPATOLOGY, 15, 1, PP. 11-20, (2018); YOUNOSSI Z., TACKE F., ARRESE M., CHANDER S.B., MOSTAFA I., BUGIANESI E., WAI-SUN W.V., YILMAZ Y., GEORGE J., FAN J., VOS M.B., GLOBAL PERSPECTIVES ON NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS, HEPATOLOGY, 69, 6, PP. 2672-2682, (2019); ZHAI Z., NI X., JIN C., REN W., LI J., DENG J., DENG B., YIN Y., CECROPIN A MODULATES TIGHT JUNCTION-RELATED PROTEIN EXPRESSION AND ENHANCES THE BARRIER FUNCTION OF PORCINE INTESTINAL EPITHELIAL CELLS BY SUPPRESSING THE MEK/ERK PATHWAY, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19, 7, (2018); ZHAI Z., ZHANG F., CAO R., NI X., XIN Z., DENG J., WU G., REN W., YIN Y., DENG B., CECROPIN A ALLEVIATES INFLAMMATION THROUGH MODULATING THE GUT MICROBIOTA OF C57BL/6 MICE WITH DSS-INDUCED IBD, FRONTIERS IN MICROBIOLOGY, 10, (2019); ZHANG J., GUPTE J., GONG Y., WEISZMANN J., ZHANG Y., LEE K.J., RICHARDS W.G., LI Y., CHRONIC OVER-EXPRESSION OF FIBROBLAST GROWTH FACTOR 21 INCREASES BILE ACID BIOSYNTHESIS BY OPPOSING FGF15/19 ACTION, EBIOMEDICINE, 15, PP. 173-183, (2017); ZHENG X., CHEN T., JIANG R., ZHAO A., WU Q., KUANG J., SUN D., REN Z., LI M., ZHAO M., WANG S., BAO Y., LI H., HU C., DONG B., LI D., WU J., XIA J., WANG X., JIA W., HYOCHOLIC ACID SPECIES IMPROVE GLUCOSE HOMEOSTASIS THROUGH A DISTINCT TGR5 AND FXR SIGNALING MECHANISM, CELL METABOLISM, (2020); ZHENG X., CHEN T., ZHAO A., NING Z., KUANG J., WANG S., YOU Y., BAO Y., MA X., YU H., ZHOU J., JIANG M., LI M., WANG J., MA X., ZHOU S., LI Y., GE K., RAJANI C., JIA W., HYOCHOLIC ACID SPECIES AS NOVEL BIOMARKERS FOR METABOLIC DISORDERS, NATURE COMMUNICATIONS, 12, 1, (2021); ZHOU S., ZHOU H., LIU R., ZHANG F., WANG X., LU L., TGR5-MEDIATED AMPK/MTOR SIGNALING REGULATES MACROPHAGE MIGRATION AND POLARIZATION IN LIVER ISCHEMIA REPERFUSION, AMERICAN JOURNAL OF TRANSPLANTATION, 184, SI, (2018)","J. LIU; JIANGXI FUNCTIONAL FEED ADDITIVE ENGINEERING LABORATORY, INSTITUTE OF BIOLOGICAL RESOURCE, JIANGXI ACADEMY OF SCIENCES, NANCHANG, CHINA; EMAIL: STEPHENLAU1983@FOXMAIL.COM","JOHN WILEY AND SONS INC","ENGLISH","J. FOOD. SCI.","ARTICLE","ISI","2-S2.0-85118424980","J FOOD SCI","INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE;INSTITUTE OF BIOLOGICAL RESOURCE","NOTREPORTED;INSTITUTE OF BIOLOGICAL RESOURCE;NOTREPORTED",NA,"ZHAI Z, 2021, J FOOD SCI","ZHAI Z, 2021, J FOOD SCI"
"LEE S;LEE G;MOON J;JUNG J","LEE, SUNYI (56732119800); LEE, GA SEUL (57208798689); MOON, JEONG HEE (55802376600); JUNG, JOOHEE (8858539100)","POLICOSANOL SUPPRESSES TUMOR PROGRESSION IN A GASTRIC CANCER XENOGRAFT MODEL",2022,"TOXICOLOGICAL RESEARCH","38","8",6,"10.1007/s43188-022-00139-z","DUKSUNG INNOVATIVE DRUG CENTER, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, SOUTH KOREA;COLLEGE OF PHARMACY, CHUNGBUK NATIONAL UNIVERSITY, CHEONGJU, SOUTH KOREA, DISEASE TARGET STRUCTURE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE & BIOTECHNOLOGY, DAEJEON, SOUTH KOREA;DISEASE TARGET STRUCTURE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE & BIOTECHNOLOGY, DAEJEON, SOUTH KOREA;DUKSUNG INNOVATIVE DRUG CENTER, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, SOUTH KOREA, COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, 33, SAMYANG-RO 144-GIL, DOBONG-GU, SEOUL, 01369, SOUTH KOREA","GASTRIC CANCER (GC) IS THE MOST COMMON CANCER WORLDWIDE AND THE THIRD LEADING CAUSE OF CANCER DEATH, WITH THE FIFTH HIGHEST INCIDENCE. THE DEVELOPMENT OF EFFECTIVE CHEMOTHERAPEUTIC AGENTS IS NEEDED TO DECREASE GC MORTALITY. POLICOSANOL (PC) EXTRACTED FROM CUBAN SUGAR CANE WAX IS A HEALTHY FUNCTIONAL FOOD INGREDIENT THAT HELPS IMPROVE BLOOD CHOLESTEROL LEVELS AND BLOOD PRESSURE. ITS VARIOUS PHYSIOLOGICAL ACTIVITIES, SUCH AS ANTIOXIDANT, ANTI-INFLAMMATORY, AND ANTICANCER ACTIVITIES, HAVE BEEN REPORTED RECENTLY. NEVERTHELESS, THE THERAPEUTIC EFFICACY OF PC IN GASTRIC XENOGRAFT MODELS IS UNCLEAR. WE AIMED TO INVESTIGATE THE ANTICANCER EFFECT OF PC ON HUMAN GC SNU-16 CELLS AND A XENOGRAFT MOUSE MODEL. PC SIGNIFICANTLY INHIBITED GC CELL VIABILITY AND DELAYED TUMOR GROWTH WITHOUT TOXICITY IN THE SNU-16–DERIVED XENOGRAFT MODEL. THEREFORE, WE INVESTIGATED PROTEIN EXPRESSION LEVELS IN TUMOR TISSUES; THE EXPRESSION LEVELS OF KI-67, A PROLIFERATION MARKER, AND CDC2 WERE DECREASED. IN ADDITION, WE PERFORMED PROTEOMIC ANALYSIS AND FOUND THIRTEEN DIFFERENTIALLY EXPRESSED PROTEINS. OUR RESULTS SUGGESTED THAT PC INHIBITED GC PROGRESSION VIA CDC2 SUPPRESSION AND EXTRACELLULAR MATRIX PROTEIN REGULATION. NOTABLY, OUR FINDINGS MIGHT CONTRIBUTE TO THE DEVELOPMENT OF NOVEL AND EFFECTIVE THERAPEUTIC STRATEGIES FOR GC. © 2022, THE AUTHOR(S) UNDER EXCLUSIVE LICENCE TO KOREAN SOCIETY OF TOXICOLOGY.","EXTRACELLULAR MATRIX; GASTRIC CANCER; HEALTHY FUNCTIONAL FOOD; POLICOSANOL; XENOGRAFT MOUSE MODEL","","MINISTRY OF EDUCATION, MOE, (2021R1A6A3A01086368); MINISTRY OF EDUCATION, MOE; NATIONAL RESEARCH FOUNDATION OF KOREA, NRF, (2016R1A6A1A03007648, 2021R1A2C200453511); NATIONAL RESEARCH FOUNDATION OF KOREA, NRF; MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY, MEST","TIS RESEARCH WAS FUNDED BY MINISTRY OF EDUCATION, GRANT NO [2021R1A6A3A01086368], NRF BY KOREA, GRANT NO [2021R1A2C200453511] AND THE PRIORITY RESEARCH CENTERS PROGRAM THROUGH THE NRF, GRANT NO [2016R1A6A1A03007648]. ","SUNG H., FERLAY J., SIEGEL R.L., LAVERSANNE M., SOERJOMATARAM I., JEMAL A., BRAY F., GLOBAL CANCER STATISTICS 2020: GLOBOCAN ESTIMATES OF INCIDENCE AND MORTALITY WORLDWIDE FOR 36 CANCERS IN 185 COUNTRIES, CA CANCER J CLIN, 71, PP. 209-249, (2021); PETRILLO A., SMYTH E.C., BIOMARKERS FOR PRECISION TREATMENT IN GASTRIC CANCER, VISC MED, 36, PP. 364-372, (2020); XU H.B., HUANG F., SU R., SHEN F.M., LV Q.Z., CAPECITABINE PLUS OXALIPLATIN (XELOX) COMPARED WITH 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOXS) IN ADVANCED GASTRIC CANCER: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, EUR J CLIN PHARMACOL, 71, PP. 589-601, (2015); SUDO K., YAMADA Y., ADVANCING PHARMACOLOGICAL TREATMENT OPTIONS FOR ADVANCED GASTRIC CANCER, EXPERT OPIN PHARMACOTHER, 16, PP. 2293-2305, (2015); JOSHI S.S., BADGWELL B.D., CURRENT TREATMENT AND RECENT PROGRESS IN GASTRIC CANCER, CA CANCER J CLIN, 71, PP. 264-279, (2021); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J FUNCT FOOD, 57, PP. 351-360, (2019); JANG Y.S., KIM D.E., HAN E., JUNG J., PHYSIOLOGICAL ACTIVITIES OF POLICOSANOL EXTRACTED FROM SUGARCANE WAX, NAT PROD SCI, 25, PP. 293-297, (2019); DE OLIVEIRA A.M., CONSERVA L.M., DE SOUZA FERRO J.N., DE ALMEIDA BRITO F., LYRA LEMOS R.P., BARRETO E., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INT J MOL SCI, 13, PP. 1598-1611, (2012); THIPPESWAMY G., SHEELA M.L., SALIMATH B.P., OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-ΚB AND ITS DNA BINDING ACTIVITY, EUR J PHARMACOL, 588, PP. 141-150, (2008); GUO T., LIN Q., LI X., NIE Y., WANG L., SHI L., XU W., HU T., GUO T., LUO F., OCTACOSANOL ATTENUATES INFLAMMATION IN BOTH RAW264.7 MACROPHAGES AND A MOUSE MODEL OF COLITIS, J AGRIC FOOD CHEM, 65, PP. 3647-3658, (2017); PARK J.G., FRUCHT H., LAROCCA R.V., BLISS D.P., KURITA Y., CHEN T.R., HENSLEE J.G., TREPEL J.B., JENSEN R.T., JOHNSON B.E., ET AL., CHARACTERISTICS OF CELL LINES ESTABLISHED FROM HUMAN GASTRIC CARCINOMA, CANCER RES, 50, PP. 2773-2780, (1990); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); ISHAKA A., UMAR IMAM M., MAHAMUD R., ZUKI A.B., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT J NANOMED, 9, PP. 2261-2269, (2014); KIM J.Y., LEE J.H., JEONG D.Y., JANG D.K., SEO T.R., LIM S.T., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYDR POLYM, 121, PP. 140-146, (2015); OH S., KWON H.J., JUNG J., ESTROGEN EXPOSURE CAUSES THE PROGRESSIVE GROWTH OF SK-HEP1-DERIVED TUMOR IN OVARIECTOMIZED MICE, TOXICOL RES, 38, PP. 1-7, (2022); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., KIM Y., SEO W.D., LEE S.J., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTR RES, 43, PP. 89-99, (2017); LIU Y.W., ZUO P.Y., ZHA X.N., CHEN X.L., ZHANG R., HE X.X., LIU C.Y., OCTACOSANOL ENHANCES THE PROLIFERATION AND MIGRATION OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS VIA ACTIVATION OF THE PI3K/AKT AND MAPK/ERK PATHWAYS, LIPIDS, 50, PP. 241-251, (2015); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); WANG T., LIU Y., YANG N., JI C., CHAN P., ZUO P., ANTI-PARKINSONIAN EFFECTS OF OCTACOSANOL IN 1-METHYL-4-PHENYL-1,2,3,6 TETRAHYDROPYRIDINE-TREATED MICE, NEURAL REGEN RES, 7, PP. 1080-1087, (2012); SU C.C., TANSHINONE IIA INHIBITS GASTRIC CARCINOMA AGS CELLS THROUGH INCREASING P-P38, P-JNK AND P53 BUT REDUCING P-ERK, CDC2 AND CYCLIN B1 EXPRESSION, ANTICANCER RES, 34, PP. 7097-7110, (2014); ZHOU B., BU G., ZHOU Y., ZHAO Y., LI W., LI M., KNOCKDOWN OF CDC2 EXPRESSION INHIBITS PROLIFERATION, ENHANCES APOPTOSIS, AND INCREASES CHEMOSENSITIVITY TO TEMOZOLOMIDE IN GLIOBLASTOMA CELLS, MED ONCOL, 32, (2015); HENKE E., NANDIGAMA R., ERGUN S., EXTRACELLULAR MATRIX IN THE TUMOR MICROENVIRONMENT AND ITS IMPACT ON CANCER THERAPY, FRONT MOL BIOSCI, 6, (2019); NALLANTHIGHAL S., HEISERMAN J.P., CHEON D.J., THE ROLE OF THE EXTRACELLULAR MATRIX IN CANCER STEMNESS, FRONT CELL DEV BIOL, 7, (2019); RABAJDOVA M., URBAN P., SPAKOVA I., SAKSUN L., DUDIC R., OSTRO A., CAPRNDA M., KRUZLIAK P., ADAMEK M., MAREKOVA M., THE CRUCIAL ROLE OF EMILIN 1 GENE EXPRESSION DURING PROGRESSION OF TUMOR GROWTH, J CANCER RES CLIN ONCOL, 142, PP. 2397-2402, (2016); DANUSSI C., PETRUCCO A., WASSERMANN B., MODICA T.M., PIVETTA E., DEL BEL BELLUZ L., COLOMBATTI A., SPESSOTTO P., AN EMILIN1-NEGATIVE MICROENVIRONMENT PROMOTES TUMOR CELL PROLIFERATION AND LYMPH NODE INVASION, CANCER PREV RES (PHILA), 5, PP. 1131-1143, (2012); AMOR LOPEZ A., MAZARIEGOS M.S., CAPUANO A., XIMENEZ-EMBUN P., HERGUETA-REDONDO M., RECIO J., MUNOZ E., AL-SHAHROUR F., MUNOZ J., MEGIAS D., DOLIANA R., SPESSOTTO P., PEINADO H., INACTIVATION OF EMILIN-1 BY PROTEOLYSIS AND SECRETION IN SMALL EXTRACELLULAR VESICLES FAVORS MELANOMA PROGRESSION AND METASTASIS, INT J MOL SCI, 22, (2021); QI Y., LV J., LIU S., SUN L., WANG Y., LI H., QI W., QIU W., TSPAN9 AND EMILIN1 SYNERGISTICALLY INHIBIT THE MIGRATION AND INVASION OF GASTRIC CANCER CELLS BY INCREASING TSPAN9 EXPRESSION, BMC CANCER, 19, (2019); LIU J., SHEN J.X., WU H.T., LI X.L., WEN X.F., DU C.W., ZHANG G.J., COLLAGEN 1A1 (COL1A1) PROMOTES METASTASIS OF BREAST CANCER AND IS A POTENTIAL THERAPEUTIC TARGET, DISCOV MED, 25, PP. 211-223, (2018); ZHANG Z., WANG Y., ZHANG J., ZHONG J., YANG R., COL1A1 PROMOTES METASTASIS IN COLORECTAL CANCER BY REGULATING THE WNT/PCP PATHWAY, MOL MED REP, 17, PP. 5037-5042, (2018); HOU L., LIN T., WANG Y., LIU B., WANG M., COLLAGEN TYPE 1 ALPHA 1 CHAIN IS A NOVEL PREDICTIVE BIOMARKER OF POOR PROGRESSION-FREE SURVIVAL AND CHEMORESISTANCE IN METASTATIC LUNG CANCER, J CANCER, 12, PP. 5723-5731, (2021); DONG X.Z., ZHAO Z.R., HU Y., LU Y.P., LIU P., ZHANG L., LNCRNA COL1A1-014 IS INVOLVED IN THE PROGRESSION OF GASTRIC CANCER VIA REGULATING CXCL12-CXCR4 AXIS, GASTRIC CANCER, 23, PP. 260-272, (2020); YU Y., LIU D., LIU Z., LI S., GE Y., SUN W., LIU B., THE INHIBITORY EFFECTS OF COL1A2 ON COLORECTAL CANCER CELL PROLIFERATION, MIGRATION, AND INVASION, J CANCER, 9, PP. 2953-2962, (2018); YOSHIDA T., AKATSUKA T., IMANAKA-YOSHIDA K., TENASCIN-C AND INTEGRINS IN CANCER, CELL ADH MIGR, 9, PP. 96-104, (2015); ZHAO S.F., YIN X.J., ZHAO W.J., LIU L.C., WANG Z.P., BIGLYCAN AS A POTENTIAL DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN MULTIPLE HUMAN CANCERS, ONCOL LETT, 19, PP. 1673-1682, (2020); YEUNG T.L., LEUNG C.S., YIP K.P., SHENG J., VIEN L., BOVER L.C., BIRRER M.J., WONG S.T.C., MOK S.C., ANTICANCER IMMUNOTHERAPY BY MFAP5 BLOCKADE INHIBITS FIBROSIS AND ENHANCES CHEMOSENSITIVITY IN OVARIAN AND PANCREATIC CANCER, CLIN CANCER RES, 25, PP. 6417-6428, (2019); HUANG H., HAO Z., LONG L., YIN Z., WU C., ZHOU X., ZHANG B., DERMATOPONTIN AS A POTENTIAL PATHOGENIC FACTOR IN ENDOMETRIAL CANCER, ONCOL LETT, 21, (2021); TILLEMENT V., HAREN L., ROULLET N., ETIEVANT C., MERDES A., THE CENTROSOME PROTEIN NEDD1 AS A POTENTIAL PHARMACOLOGICAL TARGET TO INDUCE CELL CYCLE ARREST, MOL CANCER, 8, (2009); RODRIGUEZ P.C., QUICENO D.G., ZABALETA J., ORTIZ B., ZEA A.H., PIAZUELO M.B., DELGADO A., CORREA P., BRAYER J., SOTOMAYOR E.M., ANTONIA S., OCHOA J.B., OCHOA A.C., ARGINASE I PRODUCTION IN THE TUMOR MICROENVIRONMENT BY MATURE MYELOID CELLS INHIBITS T-CELL RECEPTOR EXPRESSION AND ANTIGEN-SPECIFIC T-CELL RESPONSES, CANCER RES, 64, PP. 5839-5849, (2004); ZHOU Q., ANDERSSON R., HU D., BAUDEN M., KRISTL T., SASOR A., PAWLOWSKI K., PLA I., HILMERSSON K.S., ZHOU M., LU F., MARKO-VARGA G., ANSARI D., QUANTITATIVE PROTEOMICS IDENTIFIES BRAIN ACID SOLUBLE PROTEIN 1 (BASP1) AS A PROGNOSTIC BIOMARKER CANDIDATE IN PANCREATIC CANCER TISSUE, EBIOMEDICINE, 43, PP. 282-294, (2019)","J. JUNG; COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 33, SAMYANG-RO 144-GIL, DOBONG-GU, 01369, SOUTH KOREA; EMAIL: JOOHEE@DUKSUNG.AC.KR","SPRINGER","ENGLISH","TOXICOL. RES.","ARTICLE","ISI","2-S2.0-85133466161","TOXICOL RES","DUKSUNG WOMEN’S UNIVERSITY;CHUNGBUK NATIONAL UNIVERSITY;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;DUKSUNG WOMEN’S UNIVERSITY","NOTREPORTED;DUKSUNG WOMEN’S UNIVERSITY;NOTREPORTED",NA,"LEE S, 2022, TOXICOL RES","LEE S, 2022, TOXICOL RES"
"MA C;FENG Y;LI X;SUN L;HE Z;GAN J;HE M;ZHANG X;CHEN X","MA, CHENJING (57217217257); FENG, YING (34770356600); LI, XIAN (55252109700); SUN, LONG (37060218600); HE, ZHAO (55223278500); GAN, JIN (55234305200); HE, MINJIE (57200988854); ZHANG, XIN (56376070800); CHEN, XIAOMING (55739155400)","POTENTIAL THERAPEUTIC EFFECTS OF POLICOSANOL FROM INSECT WAX ON CAENORHABDITIS ELEGANS MODELS OF PARKINSONS DISEASE",2023,"JOURNAL OF NEUROIMMUNE PHARMACOLOGY","18","17",4,"10.1007/s11481-022-10057-4","KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;HEALTH MANAGEMENT CENTER, THE FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIVERSITY, YUNNAN PROVINCE, KUNMING, 650000, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, PANLONG DISTRICT, YUNNAN PROVINCE, KUNMING, 650224, CHINA","PARKINSON'S DISEASE (PD) IS THE SECOND MOST COMMON NEURODEGENERATIVE DISEASE WORLDWIDE. THE STANDARD TREATMENTS FOR PD FOCUS ON SYMPTOM RELIEF RATHER THAN ATTEMPTING TO ADDRESS THE UNDERLYING DEGENERATIVE PROCESSES COMPLETELY. THIS STUDY AIMED TO EVALUATE THE POTENTIAL THERAPEUTIC EFFECTS OF POLICOSANOL DERIVED FROM INSECT WAX (PIW) BY INVESTIGATING IMPROVEMENTS IN DISEASE SYMPTOMS REPRESENTED IN CAENORHABDITIS ELEGANS MODELS OF PD. FOR OUR ASSESSMENTS, WE USED THE FOLLOWING THREE MODELS: NL5901, WHICH IS A TRANSGENIC MODEL FOR Α-SYNUCLEIN AGGREGATION; WILD-TYPE N2 INDUCED WITH 6-HYDROXYDOPAMINE (6-OHDA); AND 6-OHDA-INDUCED BZ555 AS A MODEL FOR LOSS OF DOPAMINERGIC NEURONS (DNS). SPECIFICALLY, WE EXAMINED THE EFFECTS OF PIW TREATMENT ON Α-SYNUCLEIN AGGREGATION, THE LOSS OF DNS, LIPID ABUNDANCE, AND THE LIFESPAN OF TREATED ORGANISMS. FURTHER, WE EXAMINED TREATMENT-RELATED CHANGES IN THE LEVELS OF REACTIVE OXYGEN SPECIES (ROS), MALONDIALDEHYDE (MDA), ADENOSINE TRIPHOSPHATE (ATP), GLUTATHIONE S-TRANSFERASE (GST), AND SUPEROXIDE DISMUTASE (SOD), AS WELL AS THE MRNA PRODUCTION PROFILES OF RELEVANT GENES. A 10 ΜG/ML DOSE OF PIW REDUCED THE AGGREGATION OF Α-SYNUCLEIN IN NL5901 AND SUPPRESSED THE LOSS OF DNS IN 6-OHDA-INDUCED BZ555. OVERALL, PIW TREATMENT DECREASED ROS AND MDA LEVELS, RESTORED LIPID ABUNDANCE, AND PROLONGED THE LIFESPANS OF WORMS IN ALL THE THREE MODELS, WHICH MAY BE ASSOCIATED WITH CHANGES IN THE EXPRESSION PROFILES OF GENES RELATED TO CELL SURVIVAL AND OXIDATIVE STRESS RESPONSE PATHWAYS. OUR FINDINGS SHOW THAT PIW ALLEVIATED THE SYMPTOMS OF PD IN THESE MODELS, POSSIBLY BY REGULATING THE STRESS RESPONSES INITIATED BY INJURIES SUCH AS Α-SYNUCLEIN AGGREGATION OR 6-OHDA TREATMENT. GRAPHICAL ABSTRACT: [FIGURE NOT AVAILABLE: SEE FULLTEXT.] © 2022, THE AUTHOR(S), UNDER EXCLUSIVE LICENCE TO SPRINGER SCIENCE+BUSINESS MEDIA, LLC, PART OF SPRINGER NATURE.","6-OHDA; CAENORHABDITIS ELEGANS; PARKINSON'S DISEASE; POLICOSANOL FROM INSECT WAX; Α-SYNUCLEIN","ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FATTY ALCOHOLS; NEURODEGENERATIVE DISEASES; OXIDOPAMINE; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; ANTIOXIDANT; FLOXURIDINE; GLUTATHIONE TRANSFERASE; GREEN FLUORESCENT PROTEIN; HYPOCHLORITE SODIUM; MALONALDEHYDE; NEUROTOXIN; OXIDOPAMINE; POLICOSANOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TETRAMISOLE; YELLOW FLUORESCENT PROTEIN; ALPHA SYNUCLEIN; FATTY ALCOHOL; OXIDOPAMINE; POLICOSANOL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS NL5901; CELL AGGREGATION; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ESCHERICHIA COLI; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GLUTATHIONE METABOLISM; HAZARD RATIO; HOMEOSTASIS; INJURY; INSECT; LIPID STORAGE; LONGEVITY; LUMINESCENCE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; THERAPY EFFECT; ANIMAL; CAENORHABDITIS ELEGANS; DEGENERATIVE DISEASE; DISEASE MODEL; GENETICS; METABOLISM; TRANSGENIC ANIMAL","KUNMING UNIVERSITY, YUNNAN, CHINA, (BZ555, NL5901); CHINESE ACADEMY OF FORESTRY, CAF, (CAFYBB2019SZ005)","FUNDING TEXT 1: WE WOULD LIKE TO ACKNOWLEDGE DR. DING AIJUN (KUNMING UNIVERSITY, YUNNAN, CHINA.) PROVIDED THE C. ELEGANS STRAINS INCLUDING N2, BZ555, AND NL5901.; FUNDING TEXT 2: THIS WORK WAS SUPPORTED BY GRANTS FROM THE CHINESE ACADEMY OF FORESTRY (NO. CAFYBB2019SZ005). ","ANGELOVA P.R., HORROCKS M.H., KLENERMAN D., GANDHI S., ABRAMOV A.Y., SHCHEPINOV M.S., LIPID PEROXIDATION IS ESSENTIAL FOR ALPHA-SYNUCLEIN-INDUCED CELL DEATH, J NEUROCHEM, 133, PP. 582-589, (2015); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT THER MED, 45, PP. 89-97, (2019); BARTELS T., ALPHA-SYNUCLEIN METHODS AND PROTOCOLS, (2019); BLUM D., TORCH S., LAMBENG N., NISSOU M., BENABID A.L., SADOUL R., VERNA J.M., MOLECULAR PATHWAYS INVOLVED IN THE NEUROTOXICITY OF 6-OHDA, MOLECULAR PATHWAYS INVOLVED IN THE NEUROTOXICITY OF 6-OHDA, PROG NEUROBIOL, 65, PP. 135-172, (2001); CASTANO G., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., MOLINA V., ILLNAIT J., MENDOZA S., GAMEZ R., MESA M., FERNANDES S., EFFECTS OF COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON PLATELET AGGREGATION A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY, CURR THER RES CLIN EXP, 67, PP. 174-192, (2006); CHALORAK P., JATTUJAN P., NOBSATHIAN S., POOMTONG T., SOBHON P., MEEMON K., HOLOTHURIA SCABRA EXTRACTS EXHIBIT ANTI-PARKINSON POTENTIAL IN C. ELEGANS: A MODEL FOR ANTI-PARKINSON TESTING, NUTR NEUROSCI, 21, PP. 427-438, (2018); CHALORAK P., DHARMASAROJA P., MEEMON K., DOWNREGULATION OF EEF1A/EFT3–4 ENHANCES DOPAMINERGIC NEURODEGENERATION AFTER 6-OHDA EXPOSURE IN C. ELEGANS MODEL, FRONT NEUROSCI, 14, (2020); CHANG C.H., WEI C.C., HO C.T., LIAO V.H., N-GAMMA-(L-GLUTAMYL)-L-SELENOMETHIONINE SHOWS NEUROPROTECTIVE EFFECTS AGAINST PARKINSON'S DISEASE ASSOCIATED WITH SKN-1/NRF2 AND TRXR-1 IN CAENORHABDITIS ELEGANS, PHYTOMEDICINE, 92, (2021); CHEN X.M., NATURAL POPULATION ECOLOGY OF ERICERUS PELA, (2011); CHEN X.M., FENG Y., AN INTRODUCTION TO RESOURCE ENTOMOLOGY, (2009); CHEN F., HERSH B.M., CONRADT B., ZHOU Z., RIEMER D., GRUENBAUM Y., HORVITZ H.R., TRANSLOCATION OF C. ELEGANS CED-4 TO NUCLEAR MEMBRANES DURING PROGRAMMED CELL DEATH, SCIENCE, 287, PP. 1485-1489, (2000); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID MED CELL LONGEV, 2018, (2018); CIULLA M., MARINELLI L., CACCIATORE I., STEFANO A.D., ROLE OF DIETARY SUPPLEMENTS IN THE MANAGEMENT OF PARKINSON'S DISEASE, BIOMOLECULES, 9, (2019); COOPER J.F., VAN RAAMSDONK J.M., MODELING PARKINSON'S DISEASE IN C. ELEGANS, J PARKINSONS DIS, 8, PP. 17-32, (2018); DE LAU L.M.L., BRETELER M.M.B., EPIDEMIOLOGY OF PARKINSON'S DISEASE, LANCET NEUROL, 5, PP. 525-535, (2006); DEVOS D., HIRSCH E., WYSE R., SEVEN SOLUTIONS FOR NEUROPROTECTION IN PARKINSON'S DISEASE, MOV DISORD, 36, PP. 306-316, (2021); DUANGJAN C., RANGSINTH P., GU X., ZHANG S., WINK M., TENCOMNAO T., GLOCHIDION ZEYLANICUM LEAF EXTRACTS EXHIBIT LIFESPAN EXTENDING AND OXIDATIVE STRESS RESISTANCE PROPERTIES IN CAENORHABDITIS ELEGANS VIA DAF-16/FOXO AND SKN-1/NRF-2 SIGNALING PATHWAYS, PHYTOMEDICINE, 64, (2019); ESCORCIA W., RUTER D.L., NHAN J., CURRAN S.P., QUANTIFICATION OF LIPID ABUNDANCE AND EVALUATION OF LIPID DISTRIBUTION IN CAENORHABDITIS ELEGANS BY NILE RED AND OIL RED O STAINING, J VIS EXP, (2018); FARRER M.J., GENETICS OF PARKINSON DISEASE: PARADIGM SHIFTS AND FUTURE PROSPECTS, NAT REV GENET, 7, PP. 306-318, (2006); FLOWER T.R., CHESNOKOVA L.S., FROELICH C.A., DIXON C., WITT S.N., HEAT SHOCK PREVENTS ALPHA-SYNUCLEIN-INDUCED APOPTOSIS IN A YEAST MODEL OF PARKINSON'S DISEASE, J MOL BIOL, 351, PP. 1081-1100, (2005); GALVAGNION C., THE ROLE OF LIPIDS INTERACTING WITH ALPHA-SYNUCLEIN IN THE PATHOGENESIS OF PARKINSON'S DISEASE, J PARKINSONS DIS, 7, PP. 433-450, (2017); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., HUANG Z., DONG H., LU F., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES, 62, (2018); GONZALEZ R., PAZ M., AMIELA T., MORERA F., ILLNAIT J., EFFECT OF POLICOSANOL (20 MG/D) ON THE FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE: A ONE YEAR STUDY, REVISTA CENIC CIENCIAS BIOLOGICAS, 49, PP. 1-14, (2018); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GRANJA A.L., HERNANDEZ J.M., QUINTANA D.C., VALMANA L.A., FERREIRO R.M., MESA M.G., A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACEUTICAL USES, (1999); HARTMAN J.H., GONZALEZ-HUNT C., HALL S.M., RYDE I.T., CALDWELL K.A., CALDWELL G.A., MEYER J.N., GENETIC DEFECTS IN MITOCHONDRIAL DYNAMICS IN CAENORHABDITIS ELEGANS IMPACT ULTRAVIOLET C RADIATION- AND 6-HYDROXYDOPAMINE-INDUCED NEURODEGENERATION, INT J MOL SCI, 20, (2019); HAYES M.T., PARKINSON'S DISEASE AND PARKINSONISM, AM J MED, 132, PP. 802-807, (2019); KABIR Y., HEALTH BENEFITS OF OCTACOSANOL AND OTHER LONG-CHAIN ALIPHATIC FATTY ALCOHOLS FROM PLANTS, (2020); KAMPKOTTER A., PIELARSKI T., ROHRIG R., TIMPEL C., CHOVOLOU Y., WATJEN W., KAHL R., THE GINKGO BILOBA EXTRACT EGB761 REDUCES STRESS SENSITIVITY, ROS ACCUMULATION AND EXPRESSION OF CATALASE AND GLUTATHIONE S-TRANSFERASE 4 IN CAENORHABDITIS ELEGANS, PHARMACOL RES, 55, PP. 139-147, (2007); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT J MOL MED, 39, PP. 889-899, (2017); KIM S.K., VAN HAM T.J., THIJSSEN K.L., BREITLING R., HOFSTRA R.M.W., PLASTERK R.H.A., NOLLEN E.A.A., C. ELEGANS MODEL IDENTIFIES GENETIC MODIFIERS OF Α-SYNUCLEIN INCLUSION FORMATION DURING AGING, PLOS GENETICS, 4, (2008); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT PHYSIOL, 9, (2018); LANG A.E., ESPAY A.J., DISEASE MODIFICATION IN PARKINSON'S DISEASE: CURRENT APPROACHES, CHALLENGES, AND FUTURE CONSIDERATIONS, MOV DISORD, 33, PP. 660-677, (2018); LI H., SHI R., DING F., WANG H., HAN W., MA F., HU M., MA C.W., HUANG Z., ASTRAGALUS POLYSACCHARIDE SUPPRESSES 6-HYDROXYDOPAMINE-INDUCED NEUROTOXICITY IN CAENORHABDITIS ELEGANS, OXID MED CELL LONGEV, 2016, (2016); LIGAARD J., SANNAES J., PIHLSTROM L., DEEP BRAIN STIMULATION AND GENETIC VARIABILITY IN PARKINSON'S DISEASE: A REVIEW OF THE LITERATURE, NPJ PARKINSONS DIS, 5, (2019); LU L., SHU C., CHEN L., YANG Y., MA S., ZHU K., SHI B., INSECTICIDAL ACTIVITY AND MECHANISM OF CINNAMALDEHYDE IN C. ELEGANS, FITOTERAPIA, 146, (2020); LUDTMANN M.H.R., ABRAMOV A.Y., MITOCHONDRIAL CALCIUM IMBALANCE IN PARKINSON'S DISEASE, NEUROSCI LETT, 663, PP. 86-90, (2018); MA J.J., MA L.Y., ZHANG H., ZHANG Z.Q., WANG Y.Q., THE PREPARATION AND EVALUATION OF EFFICACY ON SKIN WOUND HEALING IN MICE OF INSECT WAX COMPOUND OINTMENT, JOURNAL OF ENVIRONMENTAL ENTOMOLOGY, 40, PP. 1238-1247, (2018); MA J., WANG R., CHEN T., JIANG S., XU A., PROTECTIVE EFFECTS OF BAICALIN IN A CAENORHABDITIS ELEGANS MODEL OF PARKINSON'S DISEASE, TOXICOL RES (CAMB), 10, PP. 409-417, (2021); MA J.J., LI K., ZHANG W.W., MA L.Y., XU J., LIU L.X., CHEN X.M., ZHANG H., ACUTE TOXICITY AND CHROMOSOMAL ABERRATION TOXICITY OF INSECT WAX AND ITS POLICOSANOL, FOOD SCI HUMAN WELLNESS, 11, PP. 356-365, (2022); MA J.J., MA L.Y., ZHANG H., ZHANG Z.Q., WANG Y.Q., LI K., CHEN X.M., POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY, PLOS ONE, 13, (2018); MALAIWONG N., CHALORAK P., JATTUJAN P., MANOHONG P., NIAMNONT N., SUPHAMUNGMEE W., SOBHON P., MEEMON K., ANTI-PARKINSON ACTIVITY OF BIOACTIVE SUBSTANCES EXTRACTED FROM HOLOTHURIA LEUCOSPILOTA, BIOMED PHARMACOTHER, 109, PP. 1967-1977, (2019); MAO Q., QIN W.Z., ZHANG A., YE N., RECENT ADVANCES IN DOPAMINERGIC STRATEGIES FOR THE TREATMENT OF PARKINSON'S DISEASE, ACTA PHARMACOL SIN, 41, PP. 471-482, (2020); MARQUES N.F., MASSARI C.M., TASCA C.I., GUANOSINE PROTECTS STRIATAL SLICES AGAINST 6-OHDA-INDUCED OXIDATIVE DAMAGE, MITOCHONDRIAL DYSFUNCTION, AND ATP DEPLETION, NEUROTOX RES, 35, PP. 475-483, (2019); MEHRA S., SAHAY S., MAJI S.K., Α-SYNUCLEIN MISFOLDING AND AGGREGATION: IMPLICATIONS IN PARKINSON’S DISEASE PATHOGENESIS, BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS AND PROTEOMICS, 1867, PP. 890-908, (2019); MOORE D.J., WEST A.B., DAWSON V.L., DAWSON T.M., MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE, ANNU REV NEUROSCI, 28, PP. 57-87, (2005); NASUTI C., BRUNORI G., EUSEPI P., MARINELLI L., CICCOCIOPPO R., GABBIANELLI R., EARLY LIFE EXPOSURE TO PERMETHRIN: A PROGRESSIVE ANIMAL MODEL OF PARKINSON'S DISEASE, J PHARMACOL TOXICOL METHODS, 83, PP. 80-86, (2017); NEEF D.W., JAEGER A.M., THIELE D.J., HEAT SHOCK TRANSCRIPTION FACTOR 1 AS A THERAPEUTIC TARGET IN NEURODEGENERATIVE DISEASES, NAT REV DRUG DISCOVERY, 10, PP. 930-944, (2011); OFFENBURGER S.L., GARTNER A., 6-HYDROXYDOPAMINE (6-OHDA) OXIDATIVE STRESS ASSAY FOR OBSERVING DOPAMINERGIC NEURON LOSS IN CAENORHABDITIS ELEGANS, BIO PROTOC, 8, (2018); PARK H.J., YADAV D., JEONG D.J., KIM S.J., BAE M.A., KIM J.R., CHO K.H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT J ENVIRON RES PUBLIC HEALTH, 16, (2019); POURKARIMI E., GREISS S., GARTNER A., EVIDENCE THAT CED-9/BCL2 AND CED-4/APAF-1 LOCALIZATION IS NOT CONSISTENT WITH THE CURRENT MODEL FOR C. ELEGANS APOPTOSIS INDUCTION, CELL DEATH DIFFER, 19, PP. 406-415, (2012); RANGO M., BRESOLIN N., BRAIN MITOCHONDRIA AGING AND PARKINSON’S DISEASE, GENES, 9, 5, (2018); RASHIDI R., GHORBANI A., RAKHSHANDEH H., MOUSAVI S.H., PROTECTIVE EFFECT OF ARTEMISIA ABSINTHIUM ON 6-HYDROXYDOPAMINE-INDUCED TOXICITY IN SH-SY5Y CELL LINE, AVICENNA J PHYTOMED, 11, PP. 238-246, (2021); RAZA C., ANJUM R., SHAKEEL N.U.A., PARKINSON'S DISEASE: MECHANISMS, TRANSLATIONAL MODELS AND MANAGEMENT STRATEGIES, LIFE SCI, 226, PP. 77-90, (2019); RENOUDET V.V., COSTA-MALLEN P., HOPKINS E., A DIET LOW IN ANIMAL FAT AND RICH IN N-HEXACOSANOL AND FISETIN IS EFFECTIVE IN REDUCING SYMPTOMS OF PARKINSON'S DISEASE, J MED FOOD, 15, PP. 758-761, (2012); ROCHA E.M., DE MIRANDA B., SANDERS L.H., ALPHA-SYNUCLEIN: PATHOLOGY, MITOCHONDRIAL DYSFUNCTION AND NEUROINFLAMMATION IN PARKINSON'S DISEASE, NEUROBIOL DIS, 109, PP. 249-257, (2018); RODRIGUEZ M., SNOEK L.B., DE BONO M., KAMMENGA J.E., WORMS UNDER STRESS: C. ELEGANS STRESS RESPONSE AND ITS RELEVANCE TO COMPLEX HUMAN DISEASE AND AGING, TRENDS GENET, 29, PP. 367-374, (2013); RUIPEREZ V., DARIOS F., DAVLETOV B., ALPHA-SYNUCLEIN, LIPIDS AND PARKINSON'S DISEASE, PROG LIPID RES, 49, PP. 420-428, (2010); SALARI S., BAGHERI M., IN VIVO, IN VITRO AND PHARMACOLOGIC MODELS OF PARKINSON'S DISEASE, PHYSIOL RES, 68, PP. 17-24, (2019); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., FERNANDEZ L., MESA M., VEGA H., FERNANDEZ J., REYES P., RUIZ D., LONG-TERM EFFECT OF POLICOSANOL ON THE FUNCTIONAL RECOVERY OF NON-CARDIOEMBOLIC ISCHEMIC STROKE PATIENTS: A ONE YEAR STUDY, REV NEUROL, 64, PP. 153-161, (2017); SANCHEZ LOPEZ J., FERNANDEZ TRAVIESO J.C., ILLNAIT FERRER J., FERNANDEZ DORTA L., MENDOZA CASTANO S., MAS FERREIRO R., MESA ANGARICA M., REYES SUAREZ P., EFECTOS DEL POLICOSANOL EN LA RECUPERACIÓN FUNCIONAL DE PACIENTES HIPERTENSOS CON ICTUS ISQUÉMICO NO CARDIOEMBÓLICO, REVISTA DE NEUROLOGÍA, 67, PP. 331-338, (2018); SEGURA-AGUILAR J., PARIS I., MUNOZ P., FERRARI E., ZECCA L., ZUCCA F.A., PROTECTIVE AND TOXIC ROLES OF DOPAMINE IN PARKINSON'S DISEASE, J NEUROCHEM, 129, PP. 898-915, (2014); SHARMA S., TRIVEDI S., PANDEY T., RANJAN S., TRIVEDI M., PANDEY R., WEDELOLACTONE MITIGATES PARKINSONISM VIA ALLEVIATING OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION THROUGH NRF2/SKN-1, MOL NEUROBIOL, 58, PP. 65-77, (2021); TEISMANN P., SCHULZ J.B., CELLULAR PATHOLOGY OF PARKINSON'S DISEASE: ASTROCYTES, MICROGLIA AND INFLAMMATION, CELL TISSUE RES, 318, PP. 149-161, (2004); URBAN N., TSITSIPATIS D., HAUSIG F., KREUZER K., ERLER K., STEIN V., RISTOW M., STEINBRENNER H., KLOTZ L.O., NON-LINEAR IMPACT OF GLUTATHIONE DEPLETION ON C. ELEGANS LIFE SPAN AND STRESS RESISTANCE, REDOX BIOL, 11, PP. 502-515, (2017); VAN DEN EEDEN S.K., TANNER C.M., BERNSTEIN A.L., FROSS R.D., LEIMPETER A., BLOCH D.A., NELSON L.M., INCIDENCE OF PARKINSON'S DISEASE: VARIATION BY AGE, GENDER, AND RACE/ETHNICITY, AM J EPIDEMIOL, 157, PP. 1015-1022, (2003); VANDUYN N., SETTIVARI R., WONG G., NASS R., SKN-1/NRF2 INHIBITS DOPAMINE NEURON DEGENERATION IN A CAENORHABDITIS ELEGANS MODEL OF METHYLMERCURY TOXICITY, TOXICOL SCI, 118, PP. 613-624, (2010); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOL SIN, 31, PP. 765-774, (2010); WANG Z.D., FENG Y., MA L.Y., LI X., DING W.F., CHEN X.M., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMED PHARMACOTHER, 89, PP. 438-446, (2017); WANG H.Y., JIAO Q.P., CHEN S.Y., SHENG J., JIANG H., LU J., ZHENG S.B., FANG N.Y., EFFICACY AND SAFETY OF POLICOSANOL PLUS FENOFIBRATE COMBINATION THERAPY IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA: A RANDOMIZED, CONTROLLED CLINICAL STUDY, AM J MED SCI, 356, PP. 254-261, (2018); WANG Z.D., FENG Y., SUN L., GAN J., LI X., DING W.F., CHEN X.M., ANTI-ANDROGENETIC ALOPECIA EFFECT OF POLICOSANOL FROM CHINESE WAX BY REGULATING ABNORMAL HORMONE LEVELS TO SUPPRESS PREMATURE HAIR FOLLICLE ENTRY INTO THE REGRESSION PHASE, BIOMED PHARMACOTHER, 136, (2021); WANG T., LIU Y., YANG N., JI C., CHAN P., ZUO P., ANTI-PARKINSONIAN EFFECTS OF OCTACOSANOL IN 1-METHYL-4-PHENYL-1,2,3,6 TETRAHYDROPYRIDINE-TREATED MICE, NEURAL REGEN RES, 7, (2012); YAN N., CHAI J., LEE E.S., GU L., LIU Q., HE J., WU J.W., KOKEL D., LI H., HAO Q., XUE D., SHI Y., STRUCTURE OF THE CED-4-CED-9 COMPLEX PROVIDES INSIGHTS INTO PROGRAMMED CELL DEATH IN CAENORHABDITIS ELEGANS, NATURE, 437, PP. 831-837, (2005); ZHANG K., ZHU S., LI J., JIANG T., FENG L., PEI J., WANG G., OUYANG L., LIU B., TARGETING AUTOPHAGY USING SMALL-MOLECULE COMPOUNDS TO IMPROVE POTENTIAL THERAPY OF PARKINSON’S DISEASE, ACTA PHARMACEUTICA SINICA B, (2021); ZHANG X., MA C.J., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X.M., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID BETA-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER'S DISEASE, BMC COMPLEMENT MED THER, 21, (2021); ZHAO J.J., ZHONG Q.J., ZHANG J.Y., LI Z.G., HU Y.P., DOU W.L., WANG H., LU Q.W., WU M.Z., INVESTIGATION ON THE PRODUCTION STATUS IN SEED INSECTS OF ERICERUS PELA, MOD AGRIC SCI TECHNOL, 6, PP. 193-201, (2021); ZHOU Y., THE HISTORY OF ENTOMOLOGY IN CHINA, (1980); ZOU S.W., A HISTORY OF CHINESE ENTOMOLOGY, (1982)","X. ZHANG; KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS OF NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, PANLONG DISTRICT, YUNNAN PROVINCE, 650224, CHINA; EMAIL: ZHANGXINCINDY126@126.COM","SPRINGER","ENGLISH","J. NEUROIMMUNE PHARMACOL.","ARTICLE","ISI","2-S2.0-85146249848","J NEUROIMMUNE PHARMACOL","INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;THE FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIVERSITY;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE","NOTREPORTED;INSTITUTE OF HIGHLAND FOREST SCIENCE;NOTREPORTED",NA,"MA C, 2023, J NEUROIMMUNE PHARMACOL","MA C, 2023, J NEUROIMMUNE PHARMACOL"
"MANOCHA S;DHIMAN S;GREWAL A;GUARVE K","MANOCHA, SAKSHI (57703088300); DHIMAN, SHIVANI (57702022900); GREWAL, AJMER SINGH (55648613900); GUARVE, KUMAR (36930372500)","NANOTECHNOLOGY AN APPROACH TO OVERCOME BIOAVAILABILITY CHALLENGES OF NUTRACEUTICALS",2022,"JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY","72","",19,"10.1016/j.jddst.2022.103418","GURU GOBIND SINGH COLLEGE OF PHARMACY, HARYANA, YAMUNA NAGAR, 135001, INDIA;GURU GOBIND SINGH COLLEGE OF PHARMACY, HARYANA, YAMUNA NAGAR, 135001, INDIA;GURU GOBIND SINGH COLLEGE OF PHARMACY, HARYANA, YAMUNA NAGAR, 135001, INDIA;GURU GOBIND SINGH COLLEGE OF PHARMACY, HARYANA, YAMUNA NAGAR, 135001, INDIA","NUTRACEUTICALS ARE FOOD VARIETIES AND FOOD CONSTITUENTS THAT GIVE MEDICINAL ADVANTAGES ALONG WITH NOURISHMENT. MOST ORGANIC COMPOUNDS SUCH AS TANNINS, AND FLAVONOIDS ARE EASILY SOLUBLE IN WATER BUT FACE DIFFICULTY IN ABSORPTION, AS THEY CANNOT PASS THE CELL'S LIPID FILM, HAVE AN ABNORMALLY LARGE MAGNITUDE THAT RESULTS IN BIOAVAILABILITY AND ADEQUACY LOSS. NANOTECHNOLOGY PROVIDES OPPORTUNITIES IN ALL SECTORS OF SCIENTIFIC INVESTIGATION INCLUDING HEALTH. NUTRACEUTICALS ADDRESS A QUICKLY DEVELOPING/EMERGING FIELD IN NANO-RESEARCH. IN THIS STUDY, EXTENSIVE LITERATURE SEARCH WAS CARRIED OUT ON APPLICATION OF NANOTECHNOLOGY TO OVERCOME THE BIOAVAILABILITY ISSUES RELATED TO NUTRACEUTICALS IN VARIOUS SCIENTIFIC DATABASES AND COMPILED. THE EXCLUSIVE PROPERTIES OF NANOPARTICLES SUCH AS THEIR SMALL SIZE AND HIGH SURFACE/VOLUME RATIO MAKE IT A BEST APPROACH IN THE HEALTH SECTOR. NUTRACEUTICALS CAN BE COMBINED WITH NANOTECHNOLOGY BECAUSE NANOSTRUCTURED FRAMEWORKS MAY HAVE THE ABILITY OF ENHANCING THE EFFECTIVENESS OF PLANT EXTRACTED PRODUCT, REDUCE REQUIRED QUANTITY, REDUCE THE ADVERSE EFFECTS, AS WELL AS INCREASE BIOLOGICAL ACTION. NANOLIPOSOMES, NANO-EMULSIONS, LIPID NANOCARRIERS, MICELLES, AND POLYLACTIDE CO-GLYCOLIDE NANOPARTICLES ARE SOME OF THE MOST COMMON BIOCOMPATIBLE AND BIODEGRADABLE NANOPARTICLES. THE QUICK DEVELOPMENT OF NUTRACEUTICAL AND NANOSCIENCE HAS IMMENSE IMPACT ON DIVERSE FIELDS OF SCIENCE LIKE MEDICINE AND FOOD SECTOR. IN THIS REVIEW ARTICLE, WE CONSTRAIN TO ELABORATE NANONUTRACEUTICALS WITH ENHANCED BIOAVAILABILITY, SOLUBILITY, STABILITY IMPROVED ENCAPSULATION, SUSTAINED AND TARGETED DELIVERY WITH IMPROVED THERAPEUTIC ACTIVITY, CHARACTERIZATION, SAFETY STUDIES, REGULATORY ISSUES AND THEIR APPLICATIONS IN HEALTH SECTOR AS WELL. © 2022 ELSEVIER B.V.","ALKALOIDS; FLAVONOIDS; NANOCARRIERS; NANOLIPOSOMES; NOURISHMENT; NUTRACEUTICALS; TANNINS; VITAMINS","ADEMETIONINE; ISOFLAVONE DERIVATIVE; LEVACECARNINE; LIPID NANOPARTICLE; LIPOSOME; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; NUTRACEUTICAL; OCTACOSANOL; PHYTOCHEMICAL; POLICOSANOL; POLYMER; POLYMER NANOPARTICLE; PRASTERONE; XANTHOPHYLL; ZEAXANTHIN; CLINICAL EXAMINATION; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FIRST PASS EFFECT; HUMAN; IN VITRO STUDY; JOINT; MENTAL HEALTH; MICELLE; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PROPHYLAXIS; REVIEW; SOY FOOD; SURFACE PROPERTY; SUSTENANCE","","","YU H., PARK J.Y., KWON C.W., HONG S.C., PARK K.M., CHANG P.S., AN OVERVIEW OF NANOTECHNOLOGY IN FOOD SCIENCE: PREPARATIVE METHODS, PRACTICAL APPLICATIONS, AND SAFETY, J. CHEM., 2018, (2018); MARQUES M.R., CHOO Q., ASHTIKAR M., ROCHA T.C., BREMER-HOFFMANN S., WACKER M.G., NANOMEDICINES-TINY PARTICLES AND BIG CHALLENGES, ADV. DRUG DELIV. REV., 151-152, PP. 23-43, (2019); KALRA E.K., NUTRACEUTICAL-DEFINITION AND INTRODUCTION, AAPS PHARMSCI, 5, 3, PP. 27-28, (2003); CHENTHAMARA D., SUBRAMANIAM S., RAMAKRISHNAN S.G., KRISHNASWAMY S., ESSA M.M., LIN F.H., QORONFLEH M.W., THERAPEUTIC EFFICACY OF NANOPARTICLES AND ROUTES OF ADMINISTRATION, BIOMATER. RES., 23, 1, PP. 1-29, (2019); HUANG J., WANG Q., LI T., XIA N., XIA Q., NANOSTRUCTURED LIPID CARRIER (NLC) AS A STRATEGY FOR ENCAPSULATION OF QUERCETIN AND LINSEED OIL: PREPARATION AND IN VITRO CHARACTERIZATION STUDIES, J. FOOD ENG., 215, PP. 1-12, (2017); MCCLEMENTS D.J., LI F., XIAO H., THE NUTRACEUTICAL BIOAVAILABILITY CLASSIFICATION SCHEME: CLASSIFYING NUTRACEUTICALS ACCORDING TO FACTORS LIMITING THEIR ORAL BIOAVAILABILITY. ANNUAL REVIEW OF, FOOD SCI. TECHNOL., 6, PP. 299-327, (2015); HELAL N.A., EASSA H.A., AMER A.M., ELTOKHY M.A., EDAFIOGHO I., NOUNOU M.I., NUTRACEUTICALS' NOVEL FORMULATIONS: THE GOOD, THE BAD, THE UNKNOWN AND PATENTS INVOLVED, RECENT PAT. DRUG DELIV. FORMULATION, 13, 2, PP. 105-156, (2019); JONES D., CABALLERO S., DAVIDOV-PARDO G., BIOAVAILABILITY OF NANOTECHNOLOGY-BASED BIOACTIVES AND NUTRACEUTICALS, ADV. FOOD NUTR. RES., 88, PP. 235-273, (2019); KAUR K., NUTRACEUTICALS: NANOTECHNOLOGY IN THE AGRI-FOOD INDUSTRY, PP. 41-78, (2016); MEENAMBAL R., BHARATH M.S., NANOCARRIERS FOR EFFECTIVE NUTRACEUTICAL DELIVERY TO THE BRAIN, NEUROCHEM. INT., 1, 140, (2020); PAOLINO D., MANCUSO A., CRISTIANO M.C., FROIIO F., LAMMARI N., CELIA C., FRESTA M., NANONUTRACEUTICALS: THE NEW FRONTIER OF SUPPLEMENTARY FOOD, NANOMATERIALS, 11, 3, (2021); GORANTLA S., WADHWA G., JAIN S., SANKAR S., NUWAL K., MAHMOOD A., DUBEY S.K., TALIYAN R., KESHARWANI P., SINGHVI G., RECENT ADVANCES IN NANOCARRIERS FOR NUTRIENT DELIVERY, DRUG DELIV. TRANSL. RES., (2021); ARSHAD R., GULSHAD L., HAQ I.U., FAROOQ M.A., AL-FARGA A., SIDDIQUE R., MANZOOR M.F., KARRAR E., NANOTECHNOLOGY: A NOVEL TOOL TO ENHANCE THE BIOAVAILABILITY OF MICRONUTRIENTS, FOOD SCI. NUTR., 9, 6, PP. 3354-3361, (2021); HUANG Q., GIVEN P., MICRO/NANO ENCAPSULATION OF ACTIVE FOOD INGREDIENTS, (2009); ISRAELI-LEV G., LIVNEY Y.D., SELF-ASSEMBLY OF HYDROPHOBIN AND ITS CO-ASSEMBLY WITH HYDROPHOBIC NUTRACEUTICALS IN AQUEOUS SOLUTIONS: TOWARDS APPLICATION AS DELIVERY SYSTEMS, FOOD HYDROCOLLOIDS, 35, PP. 28-35, (2014); PEREZ-MASIA R., LOPEZ-NICOLAS R., PERIAGO M.J., ROS G., LAGARON J.M., LOPEZ-RUBIO A., ENCAPSULATION OF FOLIC ACID IN FOOD HYDROCOLLOIDS THROUGH NANOSPRAY DRYING AND ELECTROSPRAYING FOR NUTRACEUTICAL APPLICATIONS, FOOD CHEM., 168, PP. 124-133, (2015); ZAMBRANO-ZARAGOZA M.L., MERCADO-SILVA E., GUTIERREZ-CORTEZ E., CASTANO-TOSTADO E., QUINTANAR-GUERRERO D., OPTIMIZATION OF NANOCAPSULES PREPARATION BY THE EMULSION–DIFFUSION METHOD FOR FOOD APPLICATIONS, LWT - FOOD SCI. TECHNOL. (LEBENSMITTEL-WISSENSCHAFT -TECHNOL.), 44, 6, PP. 1362-1368, (2011); ABBASI A., EMAM-DJOMEH Z., MOUSAVI M.A., DAVOODI D., STABILITY OF VITAMIN D3 ENCAPSULATED IN NANOPARTICLES OF WHEY PROTEIN ISOLATE, FOOD CHEM., 143, PP. 379-383, (2014); KIM T.H., OH J.M., DUAL NUTRACEUTICAL NANOHYBRIDS OF FOLIC ACID AND CALCIUM CONTAINING LAYERED DOUBLE HYDROXIDES, J. SOLID STATE CHEM., 233, PP. 125-132, (2016); HOSSEINI S.M., EMAM-DJOMEH Z., SABATINO P., VAN DER MEEREN P., NANOCOMPLEXES ARISING FROM PROTEIN-POLYSACCHARIDE ELECTROSTATIC INTERACTION AS A PROMISING CARRIER FOR NUTRACEUTICAL COMPOUNDS, FOOD HYDROCOLLOIDS, 50, PP. 16-26, (2015); ZHOU H., LIU G., ZHANG J., SUN N., DUAN M., YAN Z., XIA Q., NOVEL LIPID-FREE NANOFORMULATION FOR IMPROVING ORAL BIOAVAILABILITY OF COENZYME Q10, BIOMED RES. INT., (2014); YU H., HUANG Q., IMPROVING THE ORAL BIOAVAILABILITY OF CURCUMIN USING NOVEL ORGANOGEL-BASED NANOEMULSIONS, J. AGRIC. FOOD CHEM., 60, 21, PP. 5373-5379, (2012); CHO H.T., SALVIA-TRUJILLO L., KIM J., PARK Y., XIAO H., MCCLEMENTS D.J., DROPLET SIZE AND COMPOSITION OF NUTRACEUTICAL NANOEMULSIONS INFLUENCES BIOAVAILABILITY OF LONG CHAIN FATTY ACIDS AND COENZYME Q10, FOOD CHEM., 156, PP. 117-122, (2014); CAMPARDELLI R., REVERCHON E., Α-TOCOPHEROL NANOSUSPENSIONS PRODUCED USING A SUPERCRITICAL ASSISTED PROCESS, J. FOOD ENG., 149, PP. 131-136, (2015); LACATUSU I., BADEA N., NICULAE G., BORDEI N., STAN R., MEGHEA A., LIPID NANOCARRIERS BASED ON NATURAL COMPOUNDS: AN EVOLVING ROLE IN PLANT EXTRACT DELIVERY, EUR. J. LIPID SCI. TECHNOL., 116, 12, PP. 1708-1717, (2014); MATALANIS A., JONES O.G., MCCLEMENTS D.J., STRUCTURED BIOPOLYMER-BASED DELIVERY SYSTEMS FOR ENCAPSULATION, PROTECTION, AND RELEASE OF LIPOPHILIC COMPOUNDS, FOOD HYDROCOLLOIDS, 25, 8, PP. 1865-1880, (2011); WANG S., SU R., NIE S., SUN M., ZHANG J., WU D., MOUSTAID-MOUSSA N., APPLICATION OF NANOTECHNOLOGY IN IMPROVING BIOAVAILABILITY AND BIOACTIVITY OF DIET-DERIVED PHYTOCHEMICALS, J. NUTR. BIOCHEM., 25, 4, PP. 363-376, (2014); JAFARI S.M., FATHI M., MANDALA I., EMERGING PRODUCT FORMATION, FOOD WASTE RECOVERY: PROCESSING TECHNOLOGIES, INDUSTRIAL TECHNIQUES, AND APPLICATIONS, PP. 257-275, (2021); MCCLEMENTS D.J., NANOEMULSION-BASED ORAL DELIVERY SYSTEMS FOR LIPOPHILIC BIOACTIVE COMPONENTS: NUTRACEUTICALS AND PHARMACEUTICALS, THER. DELIV., 4, 7, PP. 841-857, (2013); OEHLKE K., ADAMIUK M., BEHSNILIAN D., GRAF V., MAYER-MIEBACH E., WALZ E., GREINER R., POTENTIAL BIOAVAILABILITY ENHANCEMENT OF BIOACTIVE COMPOUNDS USING FOOD-GRADE ENGINEERED NANOMATERIALS: A REVIEW OF THE EXISTING EVIDENCE, FOOD FUNCT., 5, 7, PP. 1341-1359, (2014); PATHAK K., RAGHUVANSHI S., ORAL BIOAVAILABILITY: ISSUES AND SOLUTIONS VIA NANOFORMULATIONS, CLIN. PHARMACOKINET., 54, PP. 325-357, (2015); NILE S.H., BASKAR V., SELVARAJ D., NILE A., XIAO J., KAI G., NANOTECHNOLOGIES IN FOOD SCIENCE: APPLICATIONS, RECENT TRENDS, AND FUTURE PERSPECTIVES, NANO-MICRO LETT., 12, 1, PP. 1-34, (2020); RIZWANULLAH M., AMIN S., MIR S.R., FAKHRI K.U., RIZVI M.M., PHYTOCHEMICAL BASED NANOMEDICINES AGAINST CANCER: CURRENT STATUS AND FUTURE PROSPECTS, J. DRUG TARGET., 26, 9, PP. 731-752, (2018); XU Z.P., ZENG Q.H., LU G.Q., YU A.B., INORGANIC NANOPARTICLES AS CARRIERS FOR EFFICIENT CELLULAR DELIVERY, CHEM. ENG. SCI., 61, 3, PP. 1027-1040, (2006); HOFMANN-AMTENBRINK M., GRAINGER D.W., HOFMANN H., NANOPARTICLES IN MEDICINE: CURRENT CHALLENGES FACING INORGANIC NANOPARTICLE TOXICITY ASSESSMENTS AND STANDARDIZATIONS, NANOMEDICINE, 11, 7, PP. 1689-1694, (2015); BHATTACHARYYA S., KUDGUS R.A., BHATTACHARYA R., MUKHERJEE P., INORGANIC NANOPARTICLES IN CANCER THERAPY, PHARM. RES. (N. Y.), 28, 2, PP. 237-259, (2011); SON K.H., HONG J.H., LEE J.W., CARBON NANOTUBES AS CANCER THERAPEUTIC CARRIERS AND MEDIATORS, INT. J. NANOMED., 11, PP. 5163-5185, (2016); WEISS J., MCCLEMENTS D.J., MASS TRANSPORT PHENOMENA IN EMULSIONS CONTAINING SURFACTANTS, LANGMUIR, 16, 17, PP. 6833-6838, (2000); LUNT J., LARGE-SCALE PRODUCTION, PROPERTIES AND COMMERCIAL APPLICATIONS OF POLYLACTIC ACID POLYMERS, POLYM. DEGRAD. STABIL., 59, 1-3, PP. 145-152, (1998); TAYLOR T.M., WEISS J., DAVIDSON P.M., BRUCE B.D., LIPOSOMAL NANOCAPSULES IN FOOD SCIENCE AND AGRICULTURE, CRIT. REV. FOOD SCI. NUTR., 45, 7-8, PP. 587-605, (2005); NAKAJIMA M., DEVELOPMENT OF NANOTECHNOLOGY AND MATERIALS FOR INNOVATIVE UTILIZATION OF BIOLOGICAL FUNCTIONS, PROCEEDINGS OF THE 34TH UNITED STATES AND JAPAN NATURAL RESOURCES (UJNR) FOOD AND AGRICULTURE PANEL, SUSONO, JAPAN, (2005); CURRENT DEVELOPMENTS/ACTIVITIES ON THE SAFETY OF MANUFACTURED NANOMATERIALS, ENVIRONMENT, HEALTH AND SAFETY PUBLICATIONS: SERIES ON THE SAFETY OF MANUFACTURED NANOMATERIALS, (2008); GUIDANCE ON THE RISK ASSESSMENT OF THE APPLICATION OF NANOSCIENCE AND NANOTECHNOLOGIES IN THE FOOD AND FEED CHAIN, J. EFSA., 9, 5, (2011); ZHANG Z., KONG F., VARDHANABHUTI B., MUSTAPHA A., LIN M., DETECTION OF ENGINEERED SILVER NANOPARTICLE CONTAMINATION IN PEARS, J. AGRIC. FOOD CHEM., 60, 43, PP. 10762-10767, (2012); LOZANO O., MEJIA J., TABARRANT T., MASEREEL B., DOGNE J.M., TOUSSAINT O., LUCAS S., QUANTIFICATION OF NANOPARTICLES IN AQUEOUS FOOD MATRICES USING PARTICLE-INDUCED X-RAY EMISSION, ANAL. BIOANAL. CHEM., 403, 10, PP. 2835-2841, (2012); GEISS O., CASCIO C., GILLILAND D., FRANCHINI F., BARRERO-MORENO J., SIZE AND MASS DETERMINATION OF SILVER NANOPARTICLES IN AN AQUEOUS MATRIX USING ASYMMETRIC FLOW FIELD FLOW FRACTIONATION COUPLED TO INDUCTIVELY COUPLED PLASMA MASS SPECTROMETER AND ULTRAVIOLET–VISIBLE DETECTORS, J. CHROMATOGR. A, 1321, PP. 100-108, (2013); PARADA J., AGUILERA J.M., FOOD MICROSTRUCTURE AFFECTS THE BIOAVAILABILITY OF SEVERAL NUTRIENTS, J. FOOD SCI., 72, 2, PP. R21-R32, (2007); YAO M., XIAO H., MCCLEMENTS D.J., DELIVERY OF LIPOPHILIC BIOACTIVES: ASSEMBLY, DISASSEMBLY, AND REASSEMBLY OF LIPID NANOPARTICLES, ANNU. REV. FOOD SCI. TECHNOL., 5, PP. 53-81, (2014); QIAN C., DECKER E.A., XIAO H., MCCLEMENTS D.J., NANOEMULSION DELIVERY SYSTEMS: INFLUENCE OF CARRIER OIL ON Β-CAROTENE BIOACCESSIBILITY, FOOD CHEM., 135, 3, PP. 1440-1447, (2012); PORTER C.J., CHARMAN W.N., IN VITRO ASSESSMENT OF ORAL LIPID BASED FORMULATIONS, ADV. DRUG DELIV. REV., 50, PP. S127-S147, (2001); SALVIA-TRUJILLO L., QIAN C., MARTIN-BELLOSO O., MCCLEMENTS D.J., INFLUENCE OF PARTICLE SIZE ON LIPID DIGESTION AND Β-CAROTENE BIOACCESSIBILITY IN EMULSIONS AND NANOEMULSIONS, J. FOOD CHEM., 141, 2, PP. 1472-1480, (2013); THANATUKSORN P., KAWAI K., HAYAKAWA M., HAYASHI M., KAJIWARA K., IMPROVEMENT OF THE ORAL BIOAVAILABILITY OF COENZYME Q10 BY EMULSIFICATION WITH FATS AND EMULSIFIERS USED IN THE FOOD INDUSTRY, LWT - FOOD SCI. TECHNOL. (LEBENSMITTEL-WISSENSCHAFT -TECHNOL.), 42, 1, PP. 385-390, (2009); YAO M., CHEN J., ZHENG J., SONG M., MCCLEMENTS D.J., XIAO H., ENHANCED LYMPHATIC TRANSPORT OF BIOACTIVE LIPIDS: CELL CULTURE STUDY OF POLYMETHOXYFLAVONE INCORPORATION INTO CHYLOMICRONS, FOOD FUNCT., 4, 11, PP. 1662-1667, (2013); ACOSTA E., BIOAVAILABILITY OF NANOPARTICLES IN NUTRIENT AND NUTRACEUTICAL DELIVERY, CURR. OPIN. COLLOID INTERFACE SCI., 14, 1, PP. 3-15, (2009); JAIN D., RATURI R., JAIN V., BANSAL P., SINGH R., RECENT TECHNOLOGIES IN PULSATILE DRUG DELIVERY SYSTEMS, BIOMATTER, 1, 1, PP. 57-65, (2011); YEN F.L., WU T.H., LIN L.T., CHAM T.M., LIN C.C., NANOPARTICLES FORMULATION OF CUSCUTACHINENSIS PREVENTS ACETAMINOPHEN-INDUCED HEPATOTOXICITY IN RATS, FOOD CHEM. TOXICOL., 46, 5, PP. 1771-1777, (2008); TIWARI G., TIWARI R., SRIWASTAWA B., BHATI L., PANDEY S., PANDEY P., BANNERJEE S.K., DRUG DELIVERY SYSTEMS: AN UPDATED REVIEW, INT. J. PHARM. INVESTIG., 2, 1, PP. 2-11, (2012); FISCHER S., FOREG C., MERKLE P.H., GANDER B., CHITOSAN COATED PLGA-MICROSPHERES-A MODULAR SYSTEM FOR TARGETTING DRUG DELIVERY, EUR. CELL. MATER., 7, 1, PP. 11-12, (2004); GARG R., GUPTA G.D., GASTRORETENTIVE FLOATING MICROSPHERES OF SILYMARIN: PREPARATION AND IN VITRO EVALUATION, TROP. J. PHARMACEUT. RES., 9, 1, PP. 59-66, (2010); KUNDU P., MOHANTY C., SAHOO S.K., RETRACTION NOTICE TO ‘‘ANTIGLIOMA ACTIVITY OF CURCUMIN-LOADED LIPID NANOPARTICLES AND ITS ENHANCED BIOAVAILABILITY IN BRAIN TISSUE FOR EFFECTIVE GLIOBLASTOMA THERAPY, ACTA BIOMATER., 8, PP. 2670-2687, (2012); DONHOWE E.G., FLORES F.P., KERR W.L., WICKER L., KONG F., CHARACTERIZATION AND IN VITRO BIOAVAILABILITY OF Β-CAROTENE: EFFECTS OF MICROENCAPSULATION METHOD AND FOOD MATRIX, LWT - FOOD SCI. TECHNOL. (LEBENSMITTEL-WISSENSCHAFT -TECHNOL.), 57, 1, PP. 42-48, (2014); FENG M., BETTI M., TRANSEPITHELIAL TRANSPORT EFFICIENCY OF BOVINE COLLAGEN HYDROLYSATES IN A HUMAN CACO-2 CELL LINE MODEL, FOOD CHEM., 224, PP. 242-250, (2017); SESSA M., BALESTRIERI M.L., FERRARI G., SERVILLO L., CASTALDO D., D'ONOFRIO N., DONSI F., TSAO R., BIOAVAILABILITY OF ENCAPSULATED RESVERATROL INTO NANOEMULSION-BASED DELIVERY SYSTEMS, FOOD CHEM., 147, PP. 42-50, (2014); DING L., WANG L., YU Z., ZHANG T., LIU J., DIGESTION AND ABSORPTION OF AN EGG WHITE ACE-INHIBITORY PEPTIDE IN HUMAN INTESTINAL CACO-2 CELL MONOLAYERS, INT. J. FOOD SCI. NUTR., 67, 2, PP. 111-116, (2016); WEIS C.P., LAVELLE J.M., CHARACTERISTICS TO CONSIDER WHEN CHOOSING AN ANIMAL MODEL FOR THE STUDY OF LEAD BIOAVAILABILITY, CHEM. SPEC., 3, 3-4, PP. 113-119, (1991); BAKER D.H., ANIMAL MODELS IN NUTRITION RESEARCH, J. NUTR., 138, 2, PP. 391-396, (2008); REBOUL E., RICHELLE M., PERROT E., DESMOULINS-MALEZET C., PIRISI V., BOREL P., BIOACCESSIBILITY OF CAROTENOIDS AND VITAMIN E FROM THEIR MAIN DIETARY SOURCES, J. AGRIC. FOOD CHEM., 54, 23, PP. 8749-8755, (2006); COMSTOCK J.M., PHENOLIC COMPOUNDS IN FOOD: AN OVERVIEW, PHENOLIC COMPOUNDS IN FOOD AND THEIR EFFECTS ON HEALTH I: ANALYSIS, OCCURRENCE, AND CHEMISTRY, PP. 2-7, (1992); WILDMAN R.E., HANDBOOK OF NUTRACEUTICALS AND FUNCTIONAL FOODS, (2016); MANACH C., WILLIAMSON G., MORAND C., SCALBERT A., REMESY C., BIOAVAILABILITY AND BIOEFFICACY OF POLYPHENOLS IN HUMANS. I. REVIEW OF 97 BIOAVAILABILITY STUDIES, AM. J. CLIN. NUTR., 81, 1, PP. 230S-242S, (2005); GARTI N., SPERNATH A., ASERIN A., LUTZ R., NANO-SIZED SELF-ASSEMBLIES OF NONIONIC SURFACTANTS AS SOLUBILIZATION RESERVOIRS AND MICROREACTORS FOR FOOD SYSTEMS, SOFT MATTER, 1, 3, PP. 206-218, (2005); MCCLEMENTS D.J., DECKER E.A., LIPID OXIDATION IN OIL-IN-WATER EMULSIONS: IMPACT OF MOLECULAR ENVIRONMENT ON CHEMICAL REACTIONS IN HETEROGENEOUS FOOD SYSTEMS, J. FOOD SCI., 65, 8, PP. 1270-1282, (2000); SPERNATH A., YAGHMUR A., ASERIN A., HOFFMAN R.E., GARTI N., FOOD-GRADE MICROEMULSIONS BASED ON NONIONIC EMULSIFIERS: MEDIA TO ENHANCE LYCOPENE SOLUBILIZATION, J. AGRIC. FOOD CHEM., 50, 23, PP. 6917-6922, (2002); XIA S., XU S., ZHANG X., ZHONG F., EFFECT OF COENZYME Q10 INCORPORATION ON THE CHARACTERISTICS OF NANOLIPOSOMES, J. PHYS. CHEM. B, 111, 9, PP. 2200-2207, (2007); SHARMA O.P., ANTIOXIDANT ACTIVITY OF CURCUMIN AND RELATED COMPOUNDS, BIOCHEM. PHARMACOL., 25, 15, PP. 1811-1812, (1976); SRIMAL R.C., DHAWAN B.N., PHARMACOLOGY OF DIFERULOYL METHANE (CURCUMIN), A NON-STEROIDAL ANTI-INFLAMMATORY AGENT, J. PHARM. PHARMACOL., 25, 6, PP. 447-452, (1973); MILLER M., CHEN S., WOODLIFF J., KANSRA S., CURCUMIN (DIFERULOYLMETHANE) INHIBITS CELL PROLIFERATION, INDUCES APOPTOSIS, AND DECREASES HORMONE LEVELS AND SECRETION IN PITUITARY TUMOR CELLS, ENDOCRINOLOGY, 149, 8, PP. 4158-4167, (2008); KUTTAN R., BHANUMATHY P., NIRMALA K., GEORGE M.C., POTENTIAL ANTICANCER ACTIVITY OF TURMERIC (CURCUMA LONGA), CANCER LETT., 29, 2, PP. 197-202, (1985); HSU C.H., CHENG A.L., CLINICAL STUDIES WITH CURCUMIN, THE MOLECULAR TARGETS AND THERAPEUTIC USES OF CURCUMIN IN HEALTH AND DISEASE, PP. 471-480, (2007); HONG J., BOSE M., JU J., RYU J.H., CHEN X., SANG S., LEE M.J., YANG C.S., MODULATION OF ARACHIDONIC ACID METABOLISM BY CURCUMIN AND RELATED Β-DIKETONE DERIVATIVES: EFFECTS ON CYTOSOLIC PHOSPHOLIPASE A 2, CYCLOOXYGENASES AND 5-LIPOXYGENASE, CARCINOGENESIS, 25, 9, PP. 1671-1679, (2004); JOE B., VIJAYKUMAR M., LOKESH B.R., BIOLOGICAL PROPERTIES OF CURCUMIN-CELLULAR AND MOLECULAR MECHANISMS OF ACTION, CRIT. REV. FOOD SCI. NUTR., 44, 2, PP. 97-111, (2004); DUVOIX A., BLASIUS R., DELHALLE S., SCHNEKENBURGER M., MORCEAU F., HENRY E., DICATO M., DIEDERICH M., CHEMOPREVENTIVE AND THERAPEUTIC EFFECTS OF CURCUMIN, CANCER LETT., 223, 2, PP. 181-190, (2005); HOWITZ K.T., SINCLAIR D.A., XENOHORMESIS: SENSING THE CHEMICAL CUES OF OTHER SPECIES, CELL, 133, 3, PP. 387-391, (2008); HUANG M.T., NEWMARK H.L., FRENKEL K., INHIBITORY EFFECTS OF CURCUMIN ON TUMORIGENESIS IN MICE, J. CELL. BIOCHEM., 67, S27, PP. 26-34, (1997); ANAND P., KUNNUMAKKARA A.B., NEWMAN R.A., AGGARWAL B.B., BIOAVAILABILITY OF CURCUMIN: PROBLEMS AND PROMISES, MOL. PHARM., 4, 6, PP. 807-818, (2007); BISHT S., FELDMANN G., SONI S., RAVI R., KARIKAR C., MAITRA A., MAITRA A., POLYMERIC NANOPARTICLE-ENCAPSULATED CURCUMIN (“ NANOCURCUMIN”): A NOVEL STRATEGY FOR HUMAN CANCER THERAPY, J. NANOBIOTECHNOL., 5, 1, PP. 1-8, (2007); TIYABOONCHAI W., TUNGPRADIT W., PLIANBANGCHANG P., FORMULATION AND CHARACTERIZATION OF CURCUMINOIDS LOADED SOLID LIPID NANOPARTICLES, INT. J. PHARM., 337, 1-2, PP. 299-306, (2007); LI L., BRAITEH F.S., KURZROCK R., LIPOSOME-ENCAPSULATED CURCUMIN: IN VITRO AND IN VIVO EFFECTS ON PROLIFERATION, APOPTOSIS, SIGNALING, AND ANGIOGENESIS, CANCER, 104, 6, PP. 1322-1331, (2005); IWUNZE M.O., BINDING AND DISTRIBUTION CHARACTERISTICS OF CURCUMIN SOLUBILIZED IN CTAB MICELLE, J. MOL. LIQ., 111, 1-3, PP. 161-165, (2004); WANG F., WU X., WANG F., LIU S., JIA Z., YANG J., THE SENSITIVE FLUORIMETRIC METHOD FOR THE DETERMINATION OF CURCUMIN USING THE ENHANCEMENT OF MIXED MICELLE, J. FLUORESC., 16, 1, PP. 53-59, (2006); MA Z., HADDADI A., MOLAVI O., LAVASANIFAR A., LAI R., SAMUEL J., MICELLES OF POLY (ETHYLENE OXIDE)-B-POLY (Ε-CAPROLACTONE) AS VEHICLES FOR THE SOLUBILIZATION, STABILIZATION, AND CONTROLLED DELIVERY OF CURCUMIN, J. BIOMED. MATER. RES., 86, 2, PP. 300-310, (2008); SAHU A., BORA U., KASOJU N., GOSWAMI P., SYNTHESIS OF NOVEL BIODEGRADABLE AND SELF-ASSEMBLING METHOXY POLY (ETHYLENE GLYCOL)–PALMITATE NANOCARRIER FOR CURCUMIN DELIVERY TO CANCER CELLS, ACTA BIOMATER., 4, 6, PP. 1752-1761, (2008); LIU A., LOU H., ZHAO L., FAN P., VALIDATED LC/MS/MS ASSAY FOR CURCUMIN AND TETRAHYDROCURCUMIN IN RAT PLASMA AND APPLICATION TO PHARMACOKINETIC STUDY OF PHOSPHOLIPID COMPLEX OF CURCUMIN, J. PHARM. BIOMED. ANAL., 40, 3, PP. 720-727, (2006); LIN W., HONG J.L., SHEN G., WU R.T., WANG Y., HUANG M.T., NEWMARK H.L., HUANG Q., KHOR T.O., HEIMBACH T., KONG A.N., PHARMACOKINETICS OF DIETARY CANCER CHEMOPREVENTIVE COMPOUND DIBENZOYLMETHANE IN RATS AND THE IMPACT OF NANOEMULSION AND GENETIC KNOCKOUT OF NRF2 ON ITS DISPOSITION, BIOPHARM DRUG DISPOS., 32, 2, PP. 65-75, (2011); CARVALHO G.C., SABIO R.M., CHORILLI M., AN OVERVIEW OF PROPERTIES AND ANALYTICAL METHODS FOR LYCOPENE IN ORGANIC NANOCARRIERS, CRIT. REV. ANAL. CHEM., 51, 7, PP. 674-686, (2021); GUO Y., MAO X., ZHANG J., SUN P., WANG H., ZHANG Y., MA Y., XU S., LV R., LIU X., ORAL DELIVERY OF LYCOPENE-LOADED MICROEMULSION FOR BRAIN-TARGETING: PREPARATION, CHARACTERIZATION, PHARMACOKINETIC EVALUATION AND TISSUE DISTRIBUTION, DRUG DELIV., 26, 1, PP. 1191-1205, (2019); LOBO V., PATIL A., PHATAK A., CHANDRA N., FREE RADICALS, ANTIOXIDANTS AND FUNCTIONAL FOODS: IMPACT ON HUMAN HEALTH, PHARMACOGN. REV., 4, 8, (2010); NASRI H., BARADARAN A., SHIRZAD H., RAFIEIAN-KOPAEI M., NEW CONCEPTS IN NUTRACEUTICALS AS ALTERNATIVE FOR PHARMACEUTICALS, INT. J. PREV. MED., 5, 12, PP. 1487-1499, (2014); HARDY G., NUTRACEUTICALS AND FUNCTIONAL FOODS: INTRODUCTION AND MEANING, NUTRITION, 16, 7-8, PP. 688-689, (2000); BORKAR N., SAURABH S.S., RATHORE K.S., PANDIT A., KHANDELWAL K.R., AN INSIGHT ON NUTRACEUTICALS, PHARMATUTOR, 3, 8, PP. 13-23, (2015); EL SOHAIMY S.A., FUNCTIONAL FOODS AND NUTRACEUTICALS-MODERN APPROACH TO FOOD SCIENCE, WORLD APPL. SCI. J., 20, 5, PP. 691-708, (2012); BROWER V., A NUTRACEUTICAL A DAY MAY KEEP THE DOCTOR AWAY: CONSUMERS ARE TURNING INCREASINGLY TO FOOD SUPPLEMENTS TO IMPROVE WELL-BEING WHEN PHARMACEUTICALS FAIL, EMBO REP., 6, 8, PP. 708-711, (2005); PANDEY M., VERMA R.K., SARAF S.A., NUTRACEUTICALS: NEW ERA OF MEDICINE AND HEALTH, ASIAN J. PHARMACEUT. CLIN. RES., 3, 1, PP. 11-15, (2010); PRADHAN N., SINGH S., OJHA N., SHRIVASTAVA A., BARLA A., RAI V., BOSE S., FACETS OF NANOTECHNOLOGY AS SEEN IN FOOD PROCESSING, PACKAGING, AND PRESERVATION INDUSTRY, BIOMED RES. INT., 2015, (2015); QI L., XU Z., JIANG X., HU C., ZOU X., PREPARATION AND ANTIBACTERIAL ACTIVITY OF CHITOSAN NANOPARTICLES, CARBOHYDR. RES., 339, 16, PP. 2693-2700, (2004); JAVERI I., APPLICATION OF “NANO” NUTRACEUTICALS IN MEDICINE, PP. 189-192, (2016); SCAMPICCHIO M., BALLABIO D., ARECCHI A., COSIO S.M., MANNINO S., AMPEROMETRIC ELECTRONIC TONGUE FOR FOOD ANALYSIS, MICROCHIM. ACTA, 163, 1-2, PP. 11-21, (2008); XU Z.R., HAN X.Y., WANG Y.Z., EFFECTS ON GROWTH AND CADMIUM RESIDUES FROM FEEDING CADMIUM-ADDED DIETS WITH AND WITHOUT MONTMORILLONITE NANOCOMPOSITE TO GROWING PIGS, VET. HUM. TOXICOL., 46, 5, PP. 238-241, (2004); BAI H., LIU X., FOOD NANOTECHNOLOGY AND NANO FOOD SAFETY, 2015 IEEE NANOTECHNOLOGY MATERIALS AND DEVICES CONFERENCE, PP. 1-4, (2015); MARTINS J.T., RAMOS O.L., PINHEIRO A.C., BOURBON A.I., SILVA H.D., RIVERA M.C., CERQUEIRA M.A., PASTRANA L., MALCATA F.X., GONZALEZ-FERNANDEZ A., VICENTE A.A., EDIBLE BIO-BASED NANOSTRUCTURES: DELIVERY, ABSORPTION AND POTENTIAL TOXICITY, FOOD ENG. REV., 7, 4, PP. 491-513, (2015); CHOU Y.C., CHENG Y.S., HSU Y.H., YU Y.H., LIU S.J., BIODEGRADABLE NANOFIBER-MEMBRANE FOR SUSTAINABLE RELEASE OF LIDOCAINE AT THE FEMORAL FRACTURE SITE AS A PERIOSTEAL BLOCK: IN VITRO AND IN VIVO STUDIES IN A RABBIT MODEL, COLLOIDS SURF., B, 140, PP. 332-341, (2016); DHAPTE V., KADAM S., POKHARKAR V., KHANNA P.K., DHAPTE V., VERSATILE SIO2 NANOPARTICLES@ POLYMER COMPOSITES WITH PRAGMATIC PROPERTIES, INT. SCH. RES. NOTICES, 2014, PP. 1-8, (2014); KATOUZIAN I., JAFARI S.M., NANO-ENCAPSULATION AS A PROMISING APPROACH FOR TARGETED DELIVERY AND CONTROLLED RELEASE OF VITAMINS, TRENDS FOOD SCI. TECHNOL., 53, PP. 34-48, (2016); DESAI N., CHALLENGES IN DEVELOPMENT OF NANOPARTICLE-BASED THERAPEUTICS, AAPS J., 14, 2, PP. 282-295, (2012); DUNCAN R., GASPAR R., NANOMEDICINE (S) UNDER THE MICROSCOPE, MOL. PHARM., 8, 6, PP. 2101-2141, (2011); WEI A., MEHTALA J.G., PATRI A.K., CHALLENGES AND OPPORTUNITIES IN THE ADVANCEMENT OF NANOMEDICINES, J. CONTR. RELEASE, 164, 2, PP. 236-246, (2012); JAIN R.K., STYLIANOPOULOS T., DELIVERING NANOMEDICINE TO SOLID TUMORS, NAT. REV. CLIN. ONCOL., 7, 11, PP. 653-664, (2010); SRINIVAS P.R., PHILBERT M., VU T.Q., HUANG Q., KOKINI J.L., SAOS E., CHEN H., PETERSON C.M., FRIEDL K.E., MCDADE-NGUTTER C., HUBBARD V., NANOTECHNOLOGY RESEARCH: APPLICATIONS IN NUTRITIONAL SCIENCES, J. NUTR., 140, 1, PP. 119-124, (2010); CHENG Z., AL ZAKI A., HUI J.Z., MUZYKANTOV V.R., TSOURKAS A., MULTIFUNCTIONAL NANOPARTICLES: COST VERSUS BENEFIT OF ADDING TARGETING AND IMAGING CAPABILITIES, SCIENCE, 338, 6109, PP. 903-910, (2012)","S. DHIMAN; GURU GOBIND SINGH COLLEGE OF PHARMACY, YAMUNA NAGAR, HARYANA, 135001, INDIA; EMAIL: SHIVANIDHIMAN007@GMAIL.COM","EDITIONS DE SANTE","ENGLISH","J. DRUG DELIV. SCI. TECHNOL.","REVIEW","ISI","2-S2.0-85130455472","J DRUG DELIV SCI TECHNOL","GURU GOBIND SINGH COLLEGE OF PHARMACY;GURU GOBIND SINGH COLLEGE OF PHARMACY;GURU GOBIND SINGH COLLEGE OF PHARMACY;GURU GOBIND SINGH COLLEGE OF PHARMACY","NOTREPORTED;GURU GOBIND SINGH COLLEGE OF PHARMACY;NOTREPORTED",NA,"MANOCHA S, 2022, J DRUG DELIV SCI TECHNOL","MANOCHA S, 2022, J DRUG DELIV SCI TECHNOL"
"CHABI I;ZANNOU O;DEDEHOU E;AYEGNON B;OSCAR O O;MAQSOOD S;GALANAKIS C;PIERRE P K A","CHABI, IFAGBÉMI BIENVENUE (57216964776); ZANNOU, OSCAR (57207455747); DEDEHOU, EMMANUELLE S.C.A. (58863205200); AYEGNON, BERNOLDE PAUL (56521608500); OSCAR ODOUARO, OLOUDÉ B. (58863669800); MAQSOOD, SAJID (26767951000); GALANAKIS, CHARIS M. (35077043100); PIERRE POLYCARPE KAYODÉ, ADÉCHOLA (58864128500)","TOMATO POMACE AS A SOURCE OF VALUABLE FUNCTIONAL INGREDIENTS FOR IMPROVING PHYSICOCHEMICAL AND SENSORY PROPERTIES AND EXTENDING THE SHELF LIFE OF FOODS A REVIEW",2024,"HELIYON","10","",2,"10.1016/j.heliyon.2024.e25261","LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN;LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN;ECOLE DES SCIENCES ET TECHNIQUES DE CONSERVATION ET DE TRANSFORMATION DES PRODUITS AGRICOLES, UNIVERSITÉ NATIONALE D'AGRICULTURE (UNA), SAKÉTÉ, BP 114, BENIN;LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN;LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN;FOOD SCIENCE DEPARTMENT, COLLEGE OF AGRICULTURE AND VETERINARY MEDICINE, UNITED ARAB EMIRATES UNIVERSITY, AL-AIN, 15551, UNITED ARAB EMIRATES, NATIONAL WATER AND ENERGY CENTER, UNITED ARAB EMIRATES UNIVERSITY, AL-AIN, 15551, UNITED ARAB EMIRATES;RESEARCH & INNOVATION DEPARTMENT, GALANAKIS LABORATORIES, CHANIA, GREECE, FOOD WASTE RECOVERY GROUP, ISEKI FOOD ASSOCIATION, VIENNA, AUSTRIA, COLLEGE OF SCIENCE, TAIF UNIVERSITY, TAIF, SAUDI ARABIA;LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN","DUE TO ITS NUTRITIONAL AND BIOACTIVE CONTENT, TOMATO POMACE (TP) REMAINS AMONG THE WORLD'S RICHEST FRUITS AND VEGETABLES. TOMATOES AND TP (GENERATED COPRODUCT) ARE A VERY RICH SOURCE OF LYCOPENE AND OTHER CAROTENOID COMPOUNDS AND CONTAIN AN ESSENTIAL AMOUNT OF POLYPHENOLS, POLICOSANOL, PHYTOSTEROLS, ORGANIC ACIDS, DIETARY FIBERS, MINERALS, AND VITAMINS. TP IS A PROMISING SOURCE OF SIGNIFICANT BIOACTIVE COMPOUNDS WITH ANTIOXIDANT AND ANTIMICROBIAL POTENTIAL. THEREFORE, THEIR CONSUMPTION IS KNOWN TO BE EFFECTIVE IN PREVENTING CERTAIN CHRONIC DISEASES. FOR EXAMPLE, LYCOPENE PREVENTS PROSTATE CANCER AND ACTS AS A HEPATOPROTECTOR AND GENOPROTECTOR AGAINST MYCOTOXINS, PESTICIDE RESIDUES, AND HEAVY METALS. THUS, THE VALORIZATION OF TP AS A FOOD INGREDIENT CAN BE OF GREAT HEALTH, ECONOMIC AND ENVIRONMENTAL INTEREST AND CONTRIBUTE TO IMPROVING NUTRITION AND FOOD SECURITY. DURING THE LAST DECADES, CONSIDERABLE EFFORTS HAVE BEEN MADE TO VALORIZE TP AS A CRUCIAL FUNCTIONAL INGREDIENT IN IMPROVING: (I) THE NUTRITIONAL AND FUNCTIONAL PROPERTIES, (II) SENSORY CHARACTERISTICS AND (III) THE SHELF LIFE OF MANY FOODS. THE CURRENT REVIEW AIMS TO UPDATE AND SUMMARIZE THE KNOWLEDGE ON THE RECENT FOOD APPLICATIONS OF TP, PARTICULARLY ITS USE AS A FUNCTIONAL INGREDIENT TO IMPROVE THE FUNCTIONAL PROPERTIES AND SHELF LIFE OF FOODS. © THE AUTHORS","ANTIOXIDANT; BIOACTIVE COMPOUNDS; HEALTH BENEFITS; SENSORY PROPERTIES; SHELF LIFE; TOMATO POMACE","","INTERNATIONAL FOUNDATION FOR SCIENCE, IFS, (I-3-E-6622-1)","THIS RESEARCH WAS SUPPORTED BY A GRANT FROM THE INTERNATIONAL SCIENCE FOUNDATION (GRANT NO. I-3-E-6622-1 ) AWARDED TO THE FIRST AUTHOR. HE WOULD LIKE TO THANK MS. NATHALIE PERSSON ANDRIANASITERA AND MS. SIRILAK PONGPATIPAT FOR THEIR INVALUABLE ASSISTANCE. THE AUTHORS WOULD ALSO LIKE TO THANK MR. SAMSON ADÉKIMBI FOR HIS TECHNICAL ASSISTANCE.","PESTICIDES, (2017); LARDINOIS C.K., KARR S., CLINICAL STRATEGIES FOR REDUCING CHOLESTEROL LEVELS, (2022); NAVARRO-GONZALEZ I., GARCIA-VALVERDE V., GARCIA-ALONSO J., PERIAGO M.J., CHEMICAL PROFILE, FUNCTIONAL AND ANTIOXIDANT PROPERTIES OF TOMATO PEEL FIBER, FOOD RES. INT., 44, PP. 1528-1535, (2011); PATARO G., CARULLO D., BAKAR SIDDIQUE M.A., FALCONE M., DONSI F., FERRARI G., IMPROVED EXTRACTABILITY OF CAROTENOIDS FROM TOMATO PEELS AS SIDE BENEFITS OF PEF TREATMENT OF TOMATO FRUIT FOR MORE ENERGY-EFFICIENT STEAM-ASSISTED PEELING, J. FOOD ENG., 233, PP. 65-73, (2018); PINELA J., BARROS L., CARVALHO A.M., FERREIRA I.C.F.R., NUTRITIONAL COMPOSITION AND ANTIOXIDANT ACTIVITY OF FOUR TOMATO (LYCOPERSICON ESCULENTUM L.) FARMER’ VARIETIES IN NORTHEASTERN PORTUGAL HOMEGARDENS, FOOD CHEM. TOXICOL., 50, PP. 829-834, (2012); LU Z., WANG J., GAO R., YE F., ZHAO G., SUSTAINABLE VALORISATION OF TOMATO POMACE: A COMPREHENSIVE REVIEW, TRENDS FOOD SCI. TECHNOL., 86, PP. 172-187, (2019); ZHU R., CHEN B., BAI Y., MIAO T., RUI L., ZHANG H., XIA B., LI Y., GAO S., WANG X.D., ZHANG D., LYCOPENE IN PROTECTION AGAINST OBESITY AND DIABETES: A MECHANISTIC REVIEW, PHARMACOL. RES., 159, (2020); ZUORRO A., FIDALEO M., LAVECCHIA R., ENZYME-ASSISTED EXTRACTION OF LYCOPENE FROM TOMATO PROCESSING WASTE, ENZYM. MICROB. TECHNOL., 49, PP. 567-573, (2011); SAINI R.K., MOON S.H., KEUM Y.S., AN UPDATED REVIEW ON USE OF TOMATO POMACE AND CRUSTACEAN PROCESSING WASTE TO RECOVER COMMERCIALLY VITAL CAROTENOIDS, FOOD RES. INT., 108, PP. 516-529, (2018); CARILLO P., D'AMELIA L., DELL'AVERSANA E., FAIELLA D., CACACE D., GIULIANO B., MORRONE B., ECO-FRIENDLY USE OF TOMATO PROCESSING RESIDUES FOR LACTIC ACID PRODUCTION IN CAMPANIA, CHEM. ENG. TRANS., 64, PP. 223-228, (2018); LIADAKIS G., KEKES T., FRAKOLAKI G., GIANNOU V., TZIA C., INGREDIENTS FOR FOOD PRODUCTS, (2022); SHEA N.O., ARENDT E.K., GALLAGHER E., DIETARY FI BRE AND PHYTOCHEMICAL CHARACTERISTICS OF FRUIT AND VEGETABLE BY-PRODUCTS AND THEIR RECENT APPLICATIONS AS NOVEL INGREDIENTS IN FOOD PRODUCTS, INNOVAT. FOOD SCI. EMERG. TECHNOL., 16, PP. 1-10, (2012); ALLISON B.J., SIMMONS C.W., VALORIZATION OF TOMATO POMACE BY SEQUENTIAL LYCOPENE EXTRACTION AND ANAEROBIC DIGESTION, BIOMASS BIOENERGY, 105, PP. 331-341, (2017); CARVALHO G.C., DE CAMARGO B.A.F., DE ARAUJO J.T.C., CHORILLI M., LYCOPENE: FROM TOMATO TO ITS NUTRACEUTICAL USE AND ITS ASSOCIATION WITH NANOTECHNOLOGY, TRENDS FOOD SCI. TECHNOL., 118, PP. 447-458, (2021); BINSUWAIDAN R., SULTAN A.A., NEGM W.A., ATTALLAH N.G.M., ALQAHTANI M.J., HUSSEIN I.A., SHALDAM M.A., EL-SHERBENI S.A., ELEKHNAWY E., BILOSOMES AS NANOPLATFORM FOR ORAL DELIVERY AND MODULATED IN VIVO ANTIMICROBIAL ACTIVITY OF LYCOPENE, PHARMACEUTICALS, 15, PP. 1-23, (2022); ISIK C., TOPKAYA F., EFFECTS OF TOMATO POMACE SUPPLEMENTATION ON CHEMICAL AND EFFECTS OF TOMATO POMACE SUPPLEMENTATION ON CHEMICAL AND NUTRITIONAL PROPERTIES, ITAL. J. FOOD SCI., 28, PP. 525-535, (2016); ABID Y., AZABOU S., JRIDI M., KHEMAKHEM I., BOUAZIZ M., ATTIA H., STORAGE STABILITY OF TRADITIONAL TUNISIAN BUTTER ENRICHED WITH ANTIOXIDANT EXTRACT FROM TOMATO PROCESSING BY-PRODUCTS, FOOD CHEM., 233, PP. 476-482, (2017); PETROTOS K., GERASOPOULOS K., 12. SUSTAINABLE USE OF TOMATO POMACE FOR THE PRODUCTION OF HIGH ADDED VALUE FOOD, FEED, AND NUTRACEUTICAL PRODUCTS, (2022); NAKOV G., BRANDOLINI A., ESTIVI L., BERTUGLIA K., IVANOVA N., JUKIC M., KOMLENIC D.K., LUKINAC J., HIDALGO A., EFFECT OF TOMATO POMACE ADDITION ON CHEMICAL, TECHNOLOGICAL, NUTRITIONAL, AND SENSORIAL PROPERTIES OF CREAM CRACKERS, ANTIOXIDANTS, 11, PP. 1-15, (2022); YAGCI S., CALISKAN R., GUNES Z.S., CAPANOGLU E., TOMAS M., IMPACT OF TOMATO POMACE POWDER ADDED TO EXTRUDED SNACKS ON THE IN VITRO GASTROINTESTINAL BEHAVIOUR AND STABILITY OF BIOACTIVE COMPOUNDS, FOOD CHEM., 368, (2022); ELBADRAWY E., SELLO A., EVALUATION OF NUTRITIONAL VALUE AND ANTIOXIDANT ACTIVITY OF TOMATO PEEL EXTRACTS, ARAB. J. CHEM., 9, PP. S1010-S1018, (2016); ERBA D., CASIRAGHI M.C., RIBAS-AGUSTI A., CACERES R., MARFA O., CASTELLARI M., NUTRITIONAL VALUE OF TOMATOES (SOLANUM LYCOPERSICUM L.) GROWN IN GREENHOUSE BY DIFFERENT AGRONOMIC TECHNIQUES, J. FOOD COMPOS. ANAL., 31, PP. 245-251, (2013); RAIGON M.D., GARCIA-MARTINEZ M.D., CHIRIAC O.P., NUTRITIONAL CHARACTERIZATION OF A TRADITIONAL CULTIVAR OF TOMATO GROWN UNDER ORGANIC CONDITIONS—CV, “MALACARA,” FRONT. NUTR., 8, PP. 1-13, (2022); ABDULLAHI I.I., ABDULLAHI N., ABDU A.M., IBRAHIM A.S., PROXIMATE, MINERAL AND VITAMIN ANALYSIS OF FRESH AND CANNED TOMATO, BIOSCI. BIOTECHNOL. RES. ASIA., 13, PP. 1163-1169, (2016); OBOULBIGA E.B., PARKOUDA C., SAWADOGO-LINGANI H., COMPAORE E.W.R., SAKIRA A.K., TRAORE A.S., NUTRITIONAL COMPOSITION, PHYSICAL CHARACTERISTICS AND SANITARY QUALITY OF THE TOMATO VARIETY MONGOL F1 FROM BURKINA FASO, FOOD NUTR. SCI., 8, PP. 444-455, (2017); RAMOS-BUENO R.P., ROMERO-GONZALEZ R., GONZALEZ-FERNANDEZ M.J., GUIL-GUERRERO J.L., PHYTOCHEMICAL COMPOSITION AND IN VITRO ANTI-TUMOUR ACTIVITIES OF SELECTED TOMATO VARIETIES, J. SCI. FOOD AGRIC., 97, PP. 488-496, (2017); DURANOVA H., VALKOVA V., GABRINY L., CHILI PEPPERS (CAPSICUM SPP.): THE SPICE NOT ONLY FOR CUISINE PURPOSES: AN UPDATE ON CURRENT KNOWLEDGE, (2022); ALI M.Y., SINA A.A.I., KHANDKER S.S., NEESA L., TANVIR E.M., KABIR A., KHALIL M.I., GAN S.H., NUTRITIONAL COMPOSITION AND BIOACTIVE COMPOUNDS IN TOMATOES AND THEIR IMPACT ON HUMAN HEALTH AND DISEASE: A REVIEW, FOODS, (2021); KABORE K., KONATE K., BAZIE D., DAKUYO R., SANOU A., SAMA H., SANTARA B., DICKO M.H., EFFECTS OF GROWING ZONES ON NUTRITIONAL AND BIOACTIVE COMPOUNDS OF BY-PRODUCTS OF TWO TOMATO CULTIVARS, J. AGRIC. FOOD RES., 10, (2022); SILVA Y.P.A., BORBA B.C., PEREIRA V.A., REIS M.G., CALIARI M., BROOKS M.S.L., FERREIRA T.A.P.C., CHARACTERIZATION OF TOMATO PROCESSING BY-PRODUCT FOR USE AS A POTENTIAL FUNCTIONAL FOOD INGREDIENT: NUTRITIONAL COMPOSITION, ANTIOXIDANT ACTIVITY AND BIOACTIVE COMPOUNDS, INT. J. FOOD SCI. NUTR., 70, PP. 150-160, (2019); DUBEY P., THAKUR V., CHATTOPADHYAY M., ROLE OF MINERALS AND TRACE ELEMENTS IN DIABETES AND INSULIN RESISTANCE, NUTRIENTS, 12, PP. 1-17, (2020); RAPA S.F., DI IORIO B.R., CAMPIGLIA P., HEIDLAND A., MARZOCCO S., INFLAMMATION AND OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE—POTENTIAL THERAPEUTIC ROLE OF MINERALS, VITAMINS AND PLANT-DERIVED METABOLITES, INT. J. MOL. SCI., 21, (2020); RAMESH K., PAUL V., PANDEY R., DYNAMICS OF MINERAL NUTRIENTS IN TOMATO (SOLANUM LYCOPERSICUM L.) FRUITS DURING RIPENING: PART II—OFF THE PLANT, PLANT PHYSIOL. REPORTS., 26, PP. 284-300, (2021); CARUSO G., DE PASCALE S., COZZOLINO E., CUCINIELLO A., CENVINZO V., BONINI P., COLLA G., ROUPHAEL Y., YIELD AND NUTRITIONAL QUALITY OF VESUVIAN PIENNOLO TOMATO PDO AS AFFECTED BY FARMING SYSTEM AND BIOSTIMULANT APPLICATION, AGRONOMY, 9, PP. 1-14, (2019); AKUBOR P.I., OWUSE A.U., CHEMICAL COMPOSITION, FUNCTIONAL AND BISCUIT MAKING PROPERTIES OF TOMATO PEEL FLOUR, SOUTH ASIAN J. FOOD TECHNOL. ENVIRON., 6, PP. 874-884, (2020); ISIK F., YAPAR A., EFFECT OF TOMATO SEED SUPPLEMENTATION ON CHEMICAL AND NUTRITIONAL PROPERTIES OF TARHANA, J. FOOD MEAS. CHAR., 11, PP. 667-674, (2017); MEHTA D., PRASAD P., SANGWAN R.S., YADAV S.K., TOMATO PROCESSING BYPRODUCT VALORIZATION IN BREAD AND MUFFIN: IMPROVEMENT IN PHYSICOCHEMICAL PROPERTIES AND SHELF LIFE STABILITY, J. FOOD SCI. TECHNOL., 55, PP. 2560-2568, (2018); CARVALHO M.E.A., PIOTTO F.A., GAZIOLA S.A., JACOMINO A.P., JOZEFCZAK M., CUYPERS A., AZEVEDO R.A., NEW INSIGHTS ABOUT CADMIUM IMPACTS ON TOMATO: PLANT ACCLIMATION, NUTRITIONAL CHANGES, FRUIT QUALITY AND YIELD, FOOD ENERGY SECUR., 7, PP. 1-16, (2018); KUMAR M., CHANDRAN D., TOMAR M., BHUYAN D.J., GRASSO S., SA A.G.A., CARCIOFI B.A.M., RADHA, DHUMAL S., SINGH S., SENAPATHY M., CHANGAN S., DEY A., PANDISELVAM R., MAHATO D.K., AMAROWICZ R., RAJALINGAM S., VISHVANATHAN M., SALEENA L.A.K., MEKHEMAR M., VALORIZATION POTENTIAL OF TOMATO (SOLANUM LYCOPERSICUM L.) SEED: NUTRACEUTICAL QUALITY, FOOD PROPERTIES, SAFETY ASPECTS, AND APPLICATION AS A HEALTH-PROMOTING INGREDIENT IN FOODS, HORTICULTURAE, 8, (2022); PEREIRA R., COSTA M., VELASCO C., CUNHA L.M., LIMA R.C., BAIAO L.F., BATISTA S., MARQUES A., SA T., CAMPOS D.A., PEREIRA M., JESUS D., FERNANDEZ-BOO S., COSTAS B., PINTADO M., VALENTE L.M.P., COMPARATIVE ANALYSIS BETWEEN SYNTHETIC VITAMIN E AND NATURAL ANTIOXIDANT SOURCES FROM TOMATO, CARROT AND CORIANDER IN DIETS FOR MARKET-SIZED DICENTRARCHUS LABRAX, ANTIOXIDANTS, 11, (2022); AMER F., ELKASSAS N., SALIM I., EL-MEDANY S., ABOELENIN S.M., SHUKRY M., TAHA A.E., PERIS S., SOLIMAN M., MAHROSE K., IMPACTS OF DIETARY SUPPLEMENTATIONS OF ORANGE PEEL AND TOMATO POMACE EXTRACTS AS NATURAL SOURCES FOR ASCORBIC ACID ON GROWTH PERFORMANCE, CARCASS CHARACTERISTICS, PLASMA BIOCHEMICALS AND ANTIOXIDANT STATUS OF GROWING RABBITS, ANIMALS, 11, (2021); EL MASHAD H.M., ZHAO L., ZHANG R., PAN Z., TOMATO, (2019); ZHU Z., ZHANG Y., LIU J., CHEN Y., ZHANG X., EXPLORING THE EFFECTS OF SELENIUM TREATMENT ON THE NUTRITIONAL QUALITY OF TOMATO FRUIT, FOOD CHEM., 252, PP. 9-15, (2018); SUN C., JIN L., CAI Y., HUANG Y., ZHENG X., YU T., L-GLUTAMATE TREATMENT ENHANCES DISEASE RESISTANCE OF TOMATO FRUIT BY INDUCING THE EXPRESSION OF GLUTAMATE RECEPTORS AND THE ACCUMULATION OF AMINO ACIDS, FOOD CHEM., 293, PP. 263-270, (2019); OMS-OLIU G., HERTOG M.L.A.T.M., VAN DE POEL B., AMPOFO-ASIAMA J., GEERAERD A.H., NICOLAI B.M., METABOLIC CHARACTERIZATION OF TOMATO FRUIT DURING PREHARVEST DEVELOPMENT, RIPENING, AND POSTHARVEST SHELF-LIFE, POSTHARVEST BIOL. TECHNOL., 62, PP. 7-16, (2011); BOGGIO S.B., PALATNIK J.F., HELDT H.W., VALLE E.M., CHANGES IN AMINO ACID COMPOSITION AND NITROGEN METABOLIZING ENZYMES IN RIPENING FRUITS OF LYCOPERSICON ESCULENTUM MILL, PLANT SCI., 159, PP. 125-133, (2000); NOUR V., PANAITE T.D., ROPOTA M., TURCU R., TRANDAFIR I., CORBU A.R., NUTRITIONAL AND BIOACTIVE COMPOUNDS IN DRIED TOMATO PROCESSING WASTE, CYTA - J. FOOD, 16, PP. 222-229, (2018); KNOBLICH M., ANDERSON B., LATSHAW D., ANALYSES OF TOMATO PEEL AND SEED BYPRODUCTS AND THEIR USE AS A SOURCE OF CAROTENOIDS, J. SCI. FOOD AGRIC., 85, PP. 1166-1170, (2005); FIBIANI M., PAOLO D., LETEO F., CAMPANELLI G., PICCHI V., BIANCHI G., LO SCALZO R., INFLUENCE OF YEAR, GENOTYPE AND CULTIVATION SYSTEM ON NUTRITIONAL VALUES AND BIOACTIVE COMPOUNDS IN TOMATO (SOLANUM LYCOPERSICUM L.), FOOD CHEM., 389, (2022); GALANAKIS C.M., SUSTAINABLE APPLICATIONS FOR THE VALORIZATION OF CEREAL, FOODS, PP. 1-15, (2022); MISURCOVA L., AMBROZOVA J., SAMEK D., SEAWEED LIPIDS AS NUTRACEUTICALS, ADV. FOOD NUTR. RES., 64, PP. 339-355, (2011); MOBRATEN K., HAUG T.M., KLEIVELAND C.R., LEA T., OMEGA-3 AND OMEGA-6 PUFAS INDUCE THE SAME GPR120-MEDIATED SIGNALLING EVENTS, BUT WITH DIFFERENT KINETICS AND INTENSITY IN CACO-2 CELLS, LIPIDS HEALTH DIS., 12, PP. 1-7, (2013); ORSAVOVA J., MISURCOVA L., VAVRA AMBROZOVA J., VICHA R., MLCEK J., FATTY ACIDS COMPOSITION OF VEGETABLE OILS AND ITS CONTRIBUTION TO DIETARY ENERGY INTAKE AND DEPENDENCE OF CARDIOVASCULAR MORTALITY ON DIETARY INTAKE OF FATTY ACIDS, INT. J. MOL. SCI., 16, PP. 12871-12890, (2015); KHAN I., AZAM A., MAHMOOD A., THE IMPACT OF ENHANCED ATMOSPHERIC CARBON DIOXIDE ON YIELD, PROXIMATE COMPOSITION, ELEMENTAL CONCENTRATION, FATTY ACID AND VITAMIN C CONTENTS OF TOMATO (LYCOPERSICON ESCULENTUM), ENVIRON. MONIT. ASSESS., 185, PP. 205-214, (2013); NAGARAJAN J., KAY H.P., KRISHNAMURTHY N.P., RAMAKRISHNAN N.R., ALDAWOUD T.M.S., GALANAKIS C.M., WEI O.C., EXTRACTION OF CAROTENOIDS FROM TOMATO POMACE VIA WATER-INDUCED HYDROCOLLOIDAL COMPLEXATION, BIOMOLECULES, 10, PP. 1-16, (2020); CONCHA-MEYER A., PALOMO I., PLAZA A., TARONE A.G., MAROSTICA JUNIOR M.R., SAYAGO-AYERDI S.G., FUENTES E., PLATELET ANTI-AGGREGANT ACTIVITY AND BIOACTIVE COMPOUNDS OF ULTRASOUND-ASSISTED EXTRACTS FROM WHOLE AND SEEDLESS TOMATO POMACE, FOODS, 9, (2020); PALOMO I., CONCHA-MEYER A., LUTZ M., SAID M., SAEZ B., VASQUEZ A., FUENTES E., CHEMICAL CHARACTERIZATION AND ANTIPLATELET POTENTIAL OF BIOACTIVE EXTRACT FROM TOMATO POMACE (BYPRODUCT OF TOMATO PASTE), NUTRIENTS, 11, (2019); STORY E.N., KOPEC R.E., SCHWARTZ S.J., KEITH HARRIS G., AN UPDATE ON THE HEALTH EFFECTS OF TOMATO LYCOPENE, ANNU. REV. FOOD SCI. TECHNOL., 1, PP. 189-210, (2010); HEDAYATI N., NAEINI M.B., NEZAMI A., HOSSEINZADEH H., WALLACE HAYES A., HOSSEINI S., IMENSHAHIDI M., KARIMI G., PROTECTIVE EFFECT OF LYCOPENE AGAINST CHEMICAL AND NATURAL TOXINS: A REVIEW, BIOFACTORS, 45, PP. 5-23, (2019); CONCHA-MEYER A.A., DURHAM C.A., COLONNA A.E., HASENBECK A., SAEZ B., ADAMS M.R., CONSUMER RESPONSE TO TOMATO POMACE POWDER AS AN INGREDIENT IN BREAD: IMPACT OF SENSORY LIKING AND BENEFIT INFORMATION ON PURCHASE INTENT, J. FOOD SCI., 84, PP. 3774-3783, (2019); VAGI E., SIMANDI B., VASARHELYINE K.P., DAOOD H., KERY A., DOLESCHALL F., NAGY B., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF CAROTENOIDS, TOCOPHEROLS AND SITOSTEROLS FROM INDUSTRIAL TOMATO BY-PRODUCTS, J. SUPERCRIT. FLUIDS, 40, PP. 218-226, (2007); ZHANG K.S., JIANG H., REN Y.X., THE EFFECT OF TECHNICAL PARAMETERS ON LYCOPENE EXTRACTION IN SUPERCRITICAL FLUID EXTRACTION FROM FREEZE-DRIED TOMATO POMACE (PEELS AND SEEDS), ADV. MATER. RES., 236-238, PP. 2868-2871, (2011); EH A.L.S., TEOH S.G., NOVEL MODIFIED ULTRASONICATION TECHNIQUE FOR THE EXTRACTION OF LYCOPENE FROM TOMATOES, ULTRASON. SONOCHEM., 19, PP. 151-159, (2012); CHADA P.S.N., SANTOS P.H., RODRIGUES L.G.G., GOULART G.A.S., AZEVEDO DOS SANTOS J.D., MARASCHIN M., LANZA M., NON-CONVENTIONAL TECHNIQUES FOR THE EXTRACTION OF ANTIOXIDANT COMPOUNDS AND LYCOPENE FROM INDUSTRIAL TOMATO POMACE (SOLANUM LYCOPERSICUM L.) USING SPOUTED BED DRYING AS A PRE-TREATMENT, FOOD CHEM. X., 13, (2022); BAO Y., REDDIVARI L., HUANG J.Y., DEVELOPMENT OF COLD PLASMA PRETREATMENT FOR IMPROVING PHENOLICS EXTRACTABILITY FROM TOMATO POMACE, INNOVAT. FOOD SCI. EMERG. TECHNOL., 65, (2020); PLAZA A., RODRIGUEZ L., CONCHA-MEYER A.A., CABEZAS R., ZUROB E., MERLET G., PALOMO I., FUENTES E., EFFECTS OF EXTRACTION METHODS ON PHENOLIC CONTENT, ANTIOXIDANT AND ANTIPLATELET ACTIVITIES OF TOMATO POMACE EXTRACTS, PLANTS, 12, PP. 1-20, (2023); PEREA-DOMINGUEZ X.P., HERNANDEZ-GASTELUM L.Z., OLIVAS-OLGUIN H.R., ESPINOSA-ALONSO L.G., VALDEZ-MORALES M., MEDINA-GODOY S., PHENOLIC COMPOSITION OF TOMATO VARIETIES AND AN INDUSTRIAL TOMATO BY-PRODUCT: FREE, CONJUGATED AND BOUND PHENOLICS AND ANTIOXIDANT ACTIVITY, J. FOOD SCI. TECHNOL., 55, PP. 3453-3461, (2018); VALDEZ-MORALES M., ESPINOSA-ALONSO L.G., ESPINOZA-TORRES L.C., DELGADO-VARGAS F., MEDINA-GODOY S., PHENOLIC CONTENT AND ANTIOXIDANT AND ANTIMUTAGENIC ACTIVITIES IN TOMATO PEEL, SEEDS, AND BYPRODUCTS, J. AGRIC. FOOD CHEM., 62, PP. 5281-5289, (2014); VOROBYOVA V., SKIBA M., VASYLIEV G., EXTRACTION OF PHENOLIC COMPOUNDS FROM TOMATO POMACE USING CHOLINE CHLORIDE–BASED DEEP EUTECTIC SOLVENTS, J. FOOD MEAS. CHAR., 16, PP. 1087-1104, (2022); VASYLIEV G., LYUDMYLA K., HLADUN K., SKIBA M., VOROBYOVA V., VALORIZATION OF TOMATO POMACE: EXTRACTION OF VALUE-ADDED COMPONENTS BY DEEP EUTECTIC SOLVENTS AND THEIR APPLICATION IN THE FORMULATION OF COSMETIC EMULSIONS, BIOMASS CONVERS. BIOREFINERY., 12, PP. 95-111, (2022); ABBASI-PARIZAD P., DE NISI P., ADANI F., SCIARRIA T.P., SQUILLACE P., SCARAFONI A., IAMETTI S., SCAGLIA B., ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES OF THE CRUDE EXTRACTS OF RAW AND FERMENTED TOMATO POMACE AND THEIR CORRELATIONS WITH AGLYCATE-POLYPHENOLS, ANTIOXIDANTS, 9, (2020); KING A.J., ZEIDLER G., TOMATO POMACE MAY BE A GOOD SOURCE OF VITAMIN E IN BROILER DIETS, CALIF, AGRIC. FOR., 58, PP. 59-62, (2004); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT.FOODS, 57, PP. 351-360, (2019); SHAO D., VENKITASAMY C., LI X., PAN Z., SHI J., WANG B., TEH H.E., MCHUGH T.H., THERMAL AND STORAGE CHARACTERISTICS OF TOMATO SEED OIL, LWT, 63, PP. 191-197, (2015); SUJITH KUMAR M.S., MAWLONG I., SINGH D., PHYTOSTEROL RECOVERY FROM OILSEEDS: RECENT ADVANCES, J. FOOD PROCESS. ENG., 40, PP. 1-9, (2017); NANDASIRI R., ESKIN N.A.M., CANOLOL AND ITS DERIVATIVES: A NOVEL BIOACTIVE WITH ANTIOXIDANT AND ANTICANCER PROPERTIES, (2022); WIDJAJA G., IQBAL DOEWES R., RUDIANSYAH M., SULTAN M.Q., ANSARI M.J., IZZAT S.E., AL JABER M.S., KZAR H.H., MUSTAFA Y.F., HAMMID A.T., TURKI JALIL A., ARAVINDHAN S., EFFECT OF TOMATO CONSUMPTION ON INFLAMMATORY MARKERS IN HEALTH AND DISEASE STATUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS, CLIN. NUTR. ESPEN., 50, PP. 93-100, (2022); SHAO D., BARTLEY G.E., YOKOYAMA W., PAN Z., ZHANG H., ZHANG A., PLASMA AND HEPATIC CHOLESTEROL-LOWERING EFFECTS OF TOMATO POMACE, TOMATO SEED OIL AND DEFATTED TOMATO SEED IN HAMSTERS FED WITH HIGH-FAT DIETS, FOOD CHEM., 139, PP. 589-596, (2013); OLATUNJI L.K., JIMOH A.O., TUKUR U.M., IMAM M.U., A REVIEW OF THE EFFECTS OF POLICOSANOL ON METABOLIC SYNDROME, CLIN. COMPLEMENT. MED. PHARMACOL., 2, (2022); FERREIRA-SANTOS P., APARICIO R., CARRON R., MONTERO M.J., SEVILLA M.A., LYCOPENE-SUPPLEMENTED DIET AMELIORATES METABOLIC SYNDROME INDUCED BY FRUCTOSE IN RATS, J. FUNCT.FOODS, 73, (2020); LI J., YANG Z., ZHANG Y., GAO B., NIU Y., THE STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF SOLUBLE DIETARY FIBERS MODIFIED FROM TOMATO POMACE WITH INCREASED CONTENT OF LYCOPENE, FOOD CHEM., 382, (2022); GHASEMI BAGHABRISHAMI R., GOLI S.A.H., TOMATO SEED OIL-ENRICHED TOMATO JUICE: EFFECT OF OIL ADDITION TYPE AND HEAT TREATMENT ON LYCOPENE BIOACCESSIBILITY AND OXIDATIVE STABILITY, FOOD CHEM., 402, (2023); KAPALA A., SZLENDAK M., MOTACKA E., THE ANTI-CANCER ACTIVITY OF LYCOPENE: A SYSTEMATIC REVIEW OF HUMAN AND ANIMAL STUDIES, NUTRIENTS, 14, PP. 1-14, (2022); MIRAHMADI M., AZIMI-HASHEMI S., SABURI E., KAMALI H., PISHBIN M., HADIZADEH F., POTENTIAL INHIBITORY EFFECT OF LYCOPENE ON PROSTATE CANCER, BIOMED. PHARMACOTHER., 129, (2020); SUN Y.-H., PROSTATE CANCER RISK PREDICTION MODELS IN EASTERN ASIAN POPULATIONS: CURRENT STATUS, RACIAL DIFFERENCE, AND FUTURE DIRECTIONS, ASIAN J. ANDROL., 21, PP. 1-4, (2019); SOARES N.D.C.P., DE BARROS ELIAS M., MACHADO C.L., TRINDADE B.B., BOROJEVIC R., TEODORO A.J., COMPARATIVE ANALYSIS OF LYCOPENE CONTENT FROM DIFFERENT TOMATO-BASED FOOD PRODUCTS ON THE CELLULAR ACTIVITY OF PROSTATE CANCER CELL LINES, FOODS, 8, (2019); MORAN N.E., THOMAS-AHNER J.M., WAN L., ZUNIGA K.E., ERDMAN J.W., CLINTON S.K., TOMATOES L., PROSTATE CANCER, WHAT HAVE WE LEARNED FROM EXPERIMENTAL MODELS?, J. NUTR., 152, PP. 1381-1403, (2022); SHIVASHANGARI K.S., RAVIKUMAR V., VINODHKUMAR R., ABDUL S., SHERIFF A., DEVAKI T., HEPATOPROTECTIVE POTENTIAL OF LYCOPENE ON D-GALACTOSAMINE/LIPOPOLYSACCHARIDE INDUCED HEPATITIS IN RATS, 170, PP. 151-170, (2006); GHAFFARI M.A., GHIASVAND T., THE STUDY OF KINETIC INHIBITION OF COPPER (II)-INDUCED OXIDATION OF LOW-DENSITY LIPOPROTEIN BY LYCOPENE, J. FOOD BIOCHEM., 35, PP. 228-240, (2011); SHARMA S., VIJAYA P., CARDIOPROTECTIVE EFFECTS OF LYCOPENE AGAINST CADMIUM INDUCED TOXICITY IN ALBINO MICE, INT. J. HEALTH SCI. RES., 5, PP. 507-513, (2015); SCOLASTICI C., ALVES DE LIMA R.O., BARBISAN L.F., FERREIRA A.L.A., RIBEIRO D.A., SALVADORI D.M.F., ANTIGENOTOXICITY AND ANTIMUTAGENICITY OF LYCOPENE IN HEPG2 CELL LINE EVALUATED BY THE COMET ASSAY AND MICRONUCLEUS TEST, TOXICOL. VITRO, 22, PP. 510-514, (2008); SHEIK ABDULAZEEZ S., THIRUVENGADAM D., EFFECT OF LYCOPENE ON OXIDATIVE STRESS INDUCED DURING D-GALACTOSAMINE/LIPOPOLYSACCHARIDE-SENSITIZED LIVER INJURY IN RATS, PHARM. BIOL., 51, PP. 1592-1599, (2013); SRINIVASAN M., SUDHEER A.R., PILLAI K.R., KUMAR P.R., SUDHAKARAN P.R., MENON V.P., LYCOPENE AS A NATURAL PROTECTOR AGAINST Γ-RADIATION INDUCED DNA DAMAGE, LIPID PEROXIDATION AND ANTIOXIDANT STATUS IN PRIMARY CULTURE OF ISOLATED RAT HEPATOCYTES IN VITRO, BIOCHIM. BIOPHYS. ACTA GEN. SUBJ., 1770, PP. 659-665, (2007); GALANAKIS C.M., SEPARATION OF FUNCTIONAL MACROMOLECULES AND MICROMOLECULES: FROM ULTRAFILTRATION TO THE BORDER OF NANOFILTRATION, TRENDS FOOD SCI. TECHNOL., 42, PP. 44-63, (2015); GALANAKIS C.M., PHENOLS RECOVERED FROM OLIVE MILL WASTEWATER AS ADDITIVES IN MEAT PRODUCTS, TRENDS FOOD SCI. TECHNOL., 79, PP. 98-105, (2018); AHMAD BHAT M., AHSAN H., PHYSICO-CHEMICAL CHARACTERISTICS OF COOKIES PREPARED WITH TOMATO POMACE POWDER, J. FOOD PROCESS. TECHNOL., 7, PP. 1-4, (2016); MIRONEASA S., CODINA G.G., MIRONEASA C., EFFECT OF COMPOSITE FLOUR MADE FROM TOMATO SEED AND WHEAT OF 650 TYPE OF A STRONG QUALITY FOR BREAD MAKING ON BREAD QUALITY AND ALVEOGRAPH RHEOLOGICAL PROPERTIES, ETP INT. J. FOOD ENG., 4, PP. 22-26, (2018); MIRONEASA S., GABRIELA G., TOMATO SEED FLOURS, (2019); ALAZB B.R., EL-SAHY K.M., YOUSSIF M.R., PHYSICOCHEMICAL AND ORGANOLEPTIC CHARACTERISTICS OF CAKES SUPPLEMENTED WITH TOMATO POMACE, MANGO SEEDS KERNEL AND POMEGRANATE PEELS POWDERS, PLANT ARCH, 21, PP. 432-439, (2021); SALEM B., USE OF TOMATO POMACE, MANGO SEEDS KERNEL AND POMEGRANATE PEELS POWDERS FOR THE PRODUCTION OF FUNCTIONAL BISCUITS, ZAGAZIG J. AGRIC. RES., 47, PP. 1011-1023, (2020); CONTE A P.L., LIKYOVA D L.A., S V PELLICANO TM, DURUM WHEAT WHOLE-MEAL SPAGHETTI WITH TOMATO PEELS: HOW BY-PRODUCT PARTICLES SIZE CAN AFFECT FINAL QUALITY OF PASTA, J. FOOD PROCESS. TECHNOL., 6, (2015); NOUR V., IONICA M.E., TRANDAFIR I., BREAD ENRICHED IN LYCOPENE AND OTHER BIOACTIVE COMPOUNDS BY ADDITION OF DRY TOMATO WASTE, J. FOOD SCI. TECHNOL., 52, PP. 8260-8267, (2015); KHEDR A.A., M A, ABDELGALEEL M.A., BESSAR B.A., SALAMA, EFFECT OF USING TOMATO PEELS AS A FAT REPLACER ON THE SENSORY, NUTRITIONAL AND PHYSICAL PROPERTIES OF BEEF BURGER AND SAUSAGES, J. SUSTAIN. AGRIC. SCI., 42, PP. 469-490, (2016); NAMIR M., SILIHA H., RAMADAN M.F., FIBER PECTIN FROM TOMATO POMACE: CHARACTERISTICS, FUNCTIONAL PROPERTIES AND APPLICATION IN LOW-FAT BEEF BURGER, J. FOOD MEAS. CHAR., 9, PP. 305-312, (2015); YADAV S., MALIK A., PATHERA A., ISLAM R.U., SHARMA D., DEVELOPMENT OF DIETARY FIBRE ENRICHED CHICKEN SAUSAGES BY INCORPORATING CORN BRAN, DRIED APPLE POMACE AND DRIED TOMATO POMACE, NUTR. FOOD SCI., 46, PP. 16-29, (2016); EL-ARABY G.M., MARK C., JOURNAL OF FOOD AND DAIRY SCIENCES PROCESSING UNTRADITIONAL FORMULA FROM SNACKS USING APPLE AND TOMATO POMACE POWDER AS A SOURCE OF DIETARY FIBER AND ANTIOXIDANTS, 13, PP. 59-64, (2022); ALTAN A., MCCARTHY K.L., MASKAN M., EVALUATION OF SNACK FOODS FROM BARLEY-TOMATO POMACE BLENDS BY EXTRUSION PROCESSING, J. FOOD ENG., 84, PP. 231-242, (2008); SAVADKOOHI S., HOOGENKAMP H., SHAMSI K., FARAHNAKY A., COLOR, SENSORY AND TEXTURAL ATTRIBUTES OF BEEF FRANKFURTER, BEEF HAM AND MEAT-FREE SAUSAGE CONTAINING TOMATO POMACE, MEAT SCI., 97, PP. 410-418, (2014); MAJZOOBI M., GHAVI F.S., FARAHNAKY A., JAMALIAN J., MESBAHI G., EFFECT OF TOMATO POMACE POWDER ON THE PHYSICOCHEMICAL PROPERTIES OF FLAT BREAD (BARBARI BREAD), J. FOOD PROCESS. PRESERV., 35, PP. 247-256, (2011); ANDRES A.I., PETRON M.J., DELGADO-ADAMEZ J., LOPEZ M., TIMON M., EFFECT OF TOMATO POMACE EXTRACTS ON THE SHELF-LIFE OF MODIFIED ATMOSPHERE-PACKAGED LAMB MEAT, J. FOOD PROCESS. PRESERV., 41, (2016); BELOVIC M., TORBICA A., PAJIC LIJAKOVIC I., TOMIC J., LONCAREVIC I., PETROVIC J., TOMATO POMACE POWDER AS A RAW MATERIAL FOR KETCHUP PRODUCTION, FOOD BIOSCI., 26, PP. 193-199, (2018); LU Y., MU K., MCCLEMENTS D.J., LIANG X., LIU X., LIU F., FERMENTATION OF TOMATO JUICE IMPROVES IN VITRO BIOACCESSIBILITY OF LYCOPENE, J. FUNCT.FOODS, 71, (2020); ZANNOU O., AGOSSOU D.J., MIASSI Y., AGANI O.B., DARINO AISSO M., CHABI I.B., EULOGE KPOCLOU Y., AZOKPOTA P., KOCA I., TRADITIONAL FERMENTED FOODS AND BEVERAGES: INDIGENOUS PRACTICES OF FOOD PROCESSING IN BENIN REPUBLIC, INT. J. GASTRON. FOOD SCI., 27, (2022); ANIBARRO-ORTEGA M., PINELA J., CIRIC A., MARTINS V., ROCHA F., SOKOVIC M.D., BARATA A.M., CARVALHO A.M., BARROS L., FERREIRA I.C.F.R., VALORISATION OF TABLE TOMATO CROP BY-PRODUCTS: PHENOLIC PROFILES AND IN VITRO ANTIOXIDANT AND ANTIMICROBIAL ACTIVITIES, FOOD BIOPROD. PROCESS., 124, PP. 307-319, (2020); SKWAREK P., KARWOWSKA M., FATTY ACIDS PROFILE AND ANTIOXIDANT PROPERTIES OF RAW FERMENTED SAUSAGES WITH THE ADDITION OF TOMATO POMACE, BIOMOLECULES, 12, (2022); ANIHOUVI V.B., KINDOSSI J.M., HOUNHOUIGAN J.D., PROCESSING AND QUALITY CHARACTERISTICS OF SOME MAJOR FERMENTED FISH PRODUCTS FROM AFRICA: A CRITICAL REVIEW, INT. RES. J. BIOL. SCI., 1, PP. 72-84, (2012); ZANNOU O., CHABI I.B., KPOCLOU Y.E., KAYODE A.P.P., GALANAKIS C.M., SELLI S., TRADITIONAL FERMENTED FOODS OF BENIN REPUBLIC: MICROBIOLOGICAL SAFETY AND HEALTH BENEFITS, DISCOV. FOOD., 3, (2023); IGILE G.O., IGILE G.O., BASSEY N.M., AGIANG S.C., QUALITY CHARACTERISTICS OF TOMATO JUICE PRODUCED AND PRESERVED WITH AND WITHOUT ITS SEEDS, DONNISH J. FOOD SCI. TECHNOL., 2, (2016); WESTPHAL A., BAUERFEIND J., ROHRER C., ERNAWITA, BOHM V., ANALYTICAL CHARACTERISATION OF THE SEEDS OF TWO TOMATO VARIETIES AS A BASIS FOR RECYCLING OF WASTE MATERIALS IN THE FOOD INDUSTRY, EUR. FOOD RES. TECHNOL., 239, PP. 613-620, (2014); SZABO K., CATOI A.F., VODNAR D.C., BIOACTIVE COMPOUNDS EXTRACTED FROM TOMATO PROCESSING BY-PRODUCTS AS A SOURCE OF VALUABLE NUTRIENTS, PLANT FOODS HUM. NUTR., 73, PP. 268-277, (2018); MIRONEASA S., CODINA G.G., OROIAN M.A., BREAD QUALITY CHARACTERISTICS AS INFLUENCED BY THE ADDITION OF TOMATO SEED FLOUR, BULL. UNIV. AGRIC. SCI. VET. MED. CLUJ-NAPOCA. FOOD SCI. TECHNOL., 73, (2016); REHAL J.K., AGGARWAL P., DHALIWAL I., SHARMA M., KAUSHIK P., A TOMATO POMACE ENRICHED GLUTEN-FREE READY-TO-COOK SNACK'S NUTRITIONAL PROFILE, QUALITY, AND SHELF LIFE EVALUATION, HORTICULTURAE, 8, (2022)","O. ZANNOU; LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN; EMAIL: ZANNOUOSCAR@GMAIL.COM; I.B. CHABI; LABORATORY OF HUMAN NUTRITION AND VALORIZATION OF FOOD BIO-INGREDIENTS, FACULTY OF AGRICULTURAL SCIENCES, UNIVERSITY OF ABOMEY-CALAVI, JERICHO COTONOU, 03 BP 2819, BENIN; EMAIL: CHABIFAGBEMI@GMAIL.COM","ELSEVIER LTD","ENGLISH","HELIYON","REVIEW","ISI","2-S2.0-85184058720","HELIYON","UNIVERSITY OF ABOMEY-CALAVI;UNIVERSITY OF ABOMEY-CALAVI;UNIVERSITÉ NATIONALE D'AGRICULTURE (UNA);UNIVERSITY OF ABOMEY-CALAVI;UNIVERSITY OF ABOMEY-CALAVI;UNITED ARAB EMIRATES UNIVERSITY;TAIF UNIVERSITY;UNIVERSITY OF ABOMEY-CALAVI","NOTREPORTED;UNIVERSITY OF ABOMEY-CALAVI;NOTREPORTED;NOTREPORTED;UNIVERSITY OF ABOMEY-CALAVI;NOTREPORTED",NA,"CHABI IB, 2024, HELIYON","CHABI IB, 2024, HELIYON"
"CHO K;KIM J;NAM H;KANG D;BAEK S","CHO, KYUNG-HYUN (7403956966); KIM, JI-EUN (57881093800); NAM, HYO-SEON (57301198400); KANG, DAE-JIN (57301198300); BAEK, SEUNG-HEE (58120142000)","COMPARISON OF POLICOSANOLS VIA INCORPORATION INTO RECONSTITUTED HIGHDENSITY LIPOPROTEINS CUBAN POLICOSANOL RAYDEL EXERTS THE HIGHEST ANTIOXIDANT ANTIGLYCATION AND ANTIINFLAMMATORY ACTIVITY",2023,"MOLECULES","28","",3,"10.3390/molecules28186715","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA","RECONSTITUTED HIGH-DENSITY LIPOPROTEINS (RHDL) CONTAINING EACH POLICOSANOL FROM CUBA (RAYDEL®), CHINA (SHAANXI PIONEER), AND THE UNITED STATES (LESSTANOL®) WERE SYNTHESIZED TO COMPARE THE PHYSIOLOGICAL PROPERTIES OF POLICOSANOL DEPENDING ON SOURCES AND ORIGIN COUNTRIES. AFTER SYNTHESIS WITH APOLIPOPROTEINA-I (APOA-I) INTO RHDL, ALL POLICOSANOLS BOUND WELL WITH PHOSPHOLIPID AND APOA-I TO FORM DISCOIDAL RHDL. AN RHDL CONTAINING CUBAN POLICOSANOL (RHDL-1) SHOWED THE LARGEST RHDL PARTICLE SIZE OF AROUND 83 ± 3 NM, WHILE RHDL CONTAINING CHINESE POLICOSANOL (RHDL-2) OR AMERICAN POLICOSANOL (RHDL-3) SHOWED SMALLER PARTICLES AROUND 63 ± 3 NM AND 60 ± 2 NM IN DIAMETER, RESPECTIVELY. THE RHDL-1 SHOWED THE STRONGEST ANTI-GLYCATION ACTIVITY TO PROTECT THE APOA-I DEGRADATION OF HDL FROM FRUCTOSE-MEDIATED GLYCATION: APPROXIMATELY 2.7-TIMES HIGHER ABILITY TO SUPPRESS GLYCATION AND 1.4-TIMES HIGHER PROTECTION ABILITY OF APOA-I THAN THAT OF RHDL-2 AND RHDL-3. THE RHDL-1 SHOWED THE HIGHEST ANTIOXIDANT ABILITY TO INHIBIT CUPRIC ION-MEDIATED LDL OXIDATION IN ELECTROMOBILITY AND THE QUANTIFICATION OF OXIDIZED SPECIES. A MICROINJECTION OF EACH RHDL INTO A ZEBRAFISH EMBRYO IN THE PRESENCE OF CARBOXYMETHYLLYSINE (CML) SHOWED THAT RHDL-1 DISPLAYED THE STRONGEST ANTI-OXIDANT ACTIVITY WITH THE HIGHEST EMBRYO SURVIVABILITY, WHEREAS RHDL-2 AND RHDL-3 SHOWED MUCH WEAKER PROTECTION ABILITY, SIMILAR TO RHDL ALONE (RHDL-0). AN INTRAPERITONEAL INJECTION OF CML (250 ΜG) INTO ADULT ZEBRAFISH CAUSED ACUTE DEATH AND HYPERINFLAMMATION WITH AN ELEVATION OF INFILTRATION OF NEUTROPHILS AND IL-6 PRODUCTION IN THE LIVER. ON THE OTHER HAND, A CO-INJECTION OF RHDL-1 RESULTED IN THE HIGHEST SURVIVABILITY AND THE STRONGEST ANTI-INFLAMMATORY ABILITY TO SUPPRESS IL-6 PRODUCTION WITH AN IMPROVEMENT OF THE BLOOD LIPID PROFILE, SUCH AS ELEVATION OF HDL-C AND LOWERING OF THE TOTAL CHOLESTEROL, LDL-CHOLESTEROL, AND TRIGLYCERIDE. IN CONCLUSION, CUBAN POLICOSANOL EXHIBITED THE MOST DESIRABLE PROPERTIES FOR THE IN VITRO SYNTHESIS OF RHDL WITH THE STABILIZATION OF APOA-I, THE LARGEST PARTICLE SIZE, ANTI-GLYCATION AGAINST FRUCTATION, AND ANTIOXIDANT ACTIVITIES TO PREVENT LDL OXIDATION. CUBAN POLICOSANOL IN RHDL ALSO EXHIBITED THE STRONGEST IN VIVO ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES WITH THE HIGHEST SURVIVABILITY IN ZEBRAFISH EMBRYOS AND ADULTS VIA THE PREVENTION OF HYPERINFLAMMATION IN THE PRESENCE OF CML. © 2023 BY THE AUTHORS.","APOLIPOPROTEIN A-I; EMBRYO; HDL; HIGH-DENSITY LIPOPROTEINS; POLICOSANOL; SUGAR CANE WAX ALCOHOL; ZEBRAFISH","ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIOXIDANTS; APOLIPOPROTEIN A-I; INTERLEUKIN-6; LIPOPROTEINS, HDL; MAILLARD REACTION; ZEBRAFISH; ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; POLICOSANOL; ANIMAL; GLYCATION; ZEBRA FISH","","","MILMAN S., ATZMON G., CRANDALL J., BARZILAI N., PHENOTYPES AND GENOTYPES OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN EXCEPTIONAL LONGEVITY, CURR. VASC. PHARMACOL, 12, PP. 690-697, (2014); WANG J., SHI L., ZOU Y., TANG J., CAI J., WEI Y., QIN J., ZHANG Z., POSITIVE ASSOCIATION OF FAMILIAL LONGEVITY WITH THE MODERATE-HIGH HDL-C CONCENTRATION IN BAMA AGING STUDY, AGING, 10, PP. 3528-3540, (2018); CHO K.-H., THE CURRENT STATUS OF RESEARCH ON HIGH-DENSITY LIPOPROTEINS (HDL): A PARADIGM SHIFT FROM HDL QUANTITY TO HDL QUALITY AND HDL FUNCTIONALITY, INT. J. MOL. SCI, 23, (2022); XUE H., ZHANG M., LIU J., WANG J., REN G., STRUCTURE-BASED MECHANISM AND INHIBITION OF CHOLESTERYL ESTER TRANSFER PROTEIN, CURR. ATHEROSCLER. REP, 25, PP. 155-166, (2023); TALL A.R., RADER D.J., TRIALS AND TRIBULATIONS OF CETP INHIBITORS, CIRC. RES, 122, PP. 106-112, (2018); JOHNS D.G., WANG S., ROSA R., HUBERT J., XU S., CHEN Y., BATEMAN T., BLAUSTEIN R.O., IMPACT OF DRUG DISTRIBUTION INTO ADIPOSE ON TISSUE FUNCTION: THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR ANACETRAPIB AS A TEST CASE, PHARMACOL. RES. PERSPECT, 7, (2019); SITARZ R., JUCHNOWICZ D., KARAKULA K., FORMA A., BAJ J., ROG J., KARPINSKI R., MACHROWSKA A., KARAKULA-JUCHNOWICZ H., NIACIN SKIN FLUSH BACKS—FROM THE ROOTS OF THE TEST TO NOWADAYS HOPE, J. CLIN. MED, 12, (2023); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); CHO K.-H., KIM J.-E., KOMATSU T., UEHARA Y., PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED STUDY WITH HEALTHY AND MIDDLE-AGED JAPANESE PARTICIPANTS, LIFE, 13, (2023); ARRUZAZABALA M., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES, 69, PP. 321-327, (1993); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS” VERSUS GENUINE POLICOSANOL, REV. CENIC CIENC. QUÍMICAS, 38, PP. 207-213, (2007); LEE H.G., WOO S.Y., AHN H.J., YANG J.Y., LEE M.J., KIM H.Y., SONG S.Y., LEE J.H., SEO W.D., COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT (AVENA SATIVA L.) CULTIVARS AND SCREENING FOR ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATION, PLANTS, 11, (2022); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT. MED. THER, 21, (2021); VENTURELLI A., BRIGHENTI V., MASCOLO D., PELLATI F., COSTI M.P., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL, 172, PP. 200-205, (2019); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT, PHYTOTHER. RES, 27, PP. 264-271, (2013); WONG W.-T., ISMAIL M., TOHIT E.R.M., ABDULLAH R., ZHANG Y.-D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVID. -BASED COMPLEMENT. ALTERN. MED, 2016, (2016); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI, 24, (2023); GUGLIUCCI A., FORMATION OF FRUCTOSE-MEDIATED ADVANCED GLYCATION END PRODUCTS AND THEIR ROLES IN METABOLIC AND INFLAMMATORY DISEASES, ADV. NUTR. INT. REV. J, 8, PP. 54-62, (2017); SUAREZ G., RAJARAM R., ORONSKY A.L., GAWINOWICZ M.A., NONENZYMATIC GLYCATION OF BOVINE SERUM ALBUMIN BY FRUCTOSE (FRUCTATION). COMPARISON WITH THE MAILLARD REACTION INITIATED BY GLUCOSE, J. BIOL. CHEM, 264, PP. 3674-3679, (1989); DASU M.R., DEVARAJ S., PARK S., JIALAL I., INCREASED TOLL-LIKE RECEPTOR (TLR) ACTIVATION AND TLR LIGANDS IN RECENTLY DIAGNOSED TYPE 2 DIABETIC SUBJECTS, DIABETES CARE, 33, PP. 861-868, (2010); WATTRUS S.J., ZON L.I., BLOOD IN THE WATER: RECENT USES OF ZEBRAFISH TO STUDY MYELOID BIOLOGY, CURR. OPIN. HEMATOL, 28, PP. 43-49, (2021); ABBATE F., MAUGERI A., LAURA R., LEVANTI M., NAVARRA M., CIRMI S., GERMANA A., ZEBRAFISH AS A USEFUL MODEL TO STUDY OXIDATIVE STRESS-LINKED DISORDERS: FOCUS ON FLAVONOIDS, ANTIOXIDANTS, 10, (2021); CHO K.H., NAM H.S., KIM J.E., NA H.J., DEL CARMEN DOMINGUEZ-HORTA M., MARTINEZ-DONATO G., CIGB-258 EXERTS POTENT ANTI-INFLAMMATORY ACTIVITY AGAINST CARBOXYMETHYLLYSINE-INDUCED ACUTE INFLAMMATION IN HYPERLIPIDEMIC ZEBRAFISH VIA THE PROTECTION OF APOLIPOPROTEIN A-I, INT. J. MOL. SCI, 24, (2023); MADSEN C.M., VARBO A., NORDESTGAARD B.G., EXTREME HIGH HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IS PARADOXICALLY ASSOCIATED WITH HIGH MORTALITY IN MEN AND WOMEN: TWO PROSPECTIVE COHORT STUDIES, EUR. HEART J, 38, PP. 2478-2486, (2017); LIU C., DHINDSA D., ALMUWAQQAT Z., SUN Y.V., QUYYUMI A.A., VERY HIGH HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND CARDIOVASCULAR MORTALITY, AM. J. CARDIOL, 167, PP. 43-53, (2022); CHO K.-H., KIM S.-J., YADAV D., KIM J.-R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED. CELL. LONGEV, 2018, (2018); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); QIAO Q., BOUWMAN F.G., VAN BAAK M.A., ROUMANS N.J.T., VINK R.G., MARIMAN E.C.M., PLASMA LEVELS OF TRIGLYCERIDES AND IL-6 ARE ASSOCIATED WITH WEIGHT REGAIN AND FAT MASS EXPANSION, J. CLIN. ENDOCRINOL. METAB, 107, PP. 1920-1929, (2022); TOADER M.P., TARANU T., CONSTANTIN M.M., OLINICI D., MOCANU M., COSTAN V.V., TOADER S., HIGH SERUM LEVEL OF INTERLEUKIN-6 IS LINKED WITH DYSLIPIDEMIA IN ORAL LICHEN PLANUS, EXP. THER. MED, 22, PP. 1-8, (2021); PIETRZAK A., CHABROS P., GRYWALSKA E., PIETRZAK D., KANDZIERSKI G., WAWRZYCKI B., ROLINSKI J., GAWEDA K., KRASOWSKA D., SERUM CONCENTRATION OF INTERLEUKIN 6 IS RELATED TO INFLAMMATION AND DYSLIPIDEMIA IN PATIENTS WITH PSORIASIS, ADV. DERMATOL. ALLERGOL, 37, PP. 41-45, (2020); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVESTIG, 34, PP. 1345-1353, (1955); BREWER H.B., RONAN R., MENG M., BISHOP C., ISOLATION AND CHARACTERIZATION OF APOLIPOPROTEINS A-I, A-II, AND A-IV, METHODS ENZYMOL, 128, PP. 223-246, (1986); MARKWELL M.A.K., HAAS S.M., BIEBER L., TOLBERT N., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM, 87, PP. 206-210, (1978); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); NOBLE R.P., ELECTROPHORETIC SEPARATION OF PLASMA LIPOPROTEINS IN AGAROSE GEL, J. LIPID RES, 9, PP. 693-700, (1968); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); NUSSLEIN-VOLHARD C., DAHM R., ZEBRAFISH: A PRACTICAL APPROACH, (2002); GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS, (2010); BURRIS B., JENSEN N., MOKALLED M.H., ASSESSMENT OF SWIM ENDURANCE AND SWIM BEHAVIOR IN ADULT ZEBRAFISH, J. VIS. EXP, 177, (2021); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT. GENET, 40, PP. 356-361, (2008); HAYASHI M., SOFUNI T., ISHIDATE M., AN APPLICATION OF ACRIDINE ORANGE FLUORESCENT STAINING TO THE MICRONUCLEUS TEST, MUTAT. RES. LETT, 120, PP. 241-247, (1983)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","MOLECULES","ARTICLE","ISI","2-S2.0-85172768590","MOLECULES","GYEONGSAN;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2023, MOLECULES","CHO K-H, 2023, MOLECULES-a"
"OSADNIK T;GOŁAWSKI M;LEWANDOWSKI P;MORZE J;OSADNIK K;PAWLAS N;LEJAWA M;JAKUBIAK G;MAZUR A;SCHWINGSCHACKL L;GĄSIOR M;BANACH M","OSADNIK, TADEUSZ (14038071900); GOŁAWSKI, MARCIN (57387455200); LEWANDOWSKI, PIOTR (24343948100); MORZE, JAKUB (57193612224); OSADNIK, KAMILA (55744682800); PAWLAS, NATALIA (24081418300); LEJAWA, MATEUSZ (57204192229); JAKUBIAK, GRZEGORZ K. (57215335811); MAZUR, AGNIESZKA (57856194600); SCHWINGSCHACKL, LUCAS (57855153400); GĄSIOR, MARIUSZ (7005055488); BANACH, MACIEJ (22936699500)","A NETWORK METAANALYSIS ON THE COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE IN ADULTS",2022,"PHARMACOLOGICAL RESEARCH","183","",21,"10.1016/j.phrs.2022.106402","DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF HUMAN NUTRITION, FACULTY OF FOOD SCIENCES, UNIVERSITY OF WARMIA AND MAZURY, OLSZTYN, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND, DEPARTMENT AND CLINIC OF INTERNAL MEDICINE, ANGIOLOGY, AND PHYSICAL MEDICINE, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, POLAND;DEPARTMENT OF PHARMACOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;GERMAN INSTITUTE FOR EVIDENCE IN MEDICINE, FACULTY OF MEDICINE AND MEDICAL CENTER, UNIVERSITY OF FREIBURG, FREIBURG, GERMANY;3RD DEPARTMENT OF CARDIOLOGY, FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND;DEPARTMENT OF PREVENTIVE CARDIOLOGY AND LIPIDOLOGY, MEDICAL UNIVERSITY OF LODZ (MUL), LODZ, POLAND","IT IS ESTIMATED THAT 2.6 MILLION DEATHS WORLDWIDE CAN BE ATTRIBUTED TO HYPERCHOLESTEROLEMIA. THE MAIN REASON FOR NON-ADHERENCE TO STATIN THERAPY ARE THE STATIN-ASSOCIATED MUSCLE SYMPTOMS (INCLUDING NOCEBO/DRUCEBO EFFECT). IN THIS CASE, APART FROM EZETIMIBE, NUTRACEUTICALS ARE PRESCRIBED. WE AIMED TO ASSESS THE COMPARATIVE EFFICACY OF DIFFERENT NUTRACEUTICALS IN TERMS OF LOWERING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND IMPROVING LIPID PROFILE. ELECTRONIC AND HAND SEARCHES WERE PERFORMED UNTIL FEBRUARY 2021. THE INCLUSION CRITERIA WERE THE FOLLOWING: (1) RANDOMIZED TRIAL WITH ANY OF THE REPORTEDLY LDL-C LOWERING NUTRACEUTICAL: ARTICHOKE, BERBERINE, BERGAMOT, GARLIC, GREEN TEA EXTRACT, PLANT STEROLS/STANOLS, POLICOSANOLS, RED YEAST RICE (RYR), SILYMARIN OR SPIRULINA. (2) OUTCOME EITHER LDL-C (PRIMARY OUTCOME), TOTAL CHOLESTEROL (TC), HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) OR SERUM TRIGLYCERIDES (TG). RANDOM EFFECTS NETWORK META-ANALYSIS (NMA) WAS PERFORMED TO RANK THE EFFECT OF EACH INTERVENTION USING FREQUENTIST APPROACH. FINALLY, A TOTAL OF 131 TRIALS ENROLLING 13,062 PARTICIPANTS WERE INCLUDED. ALL ANALYSED NUTRACEUTICALS EXCEPT FOR POLICOSANOLS WERE MORE EFFECTIVE IN LOWERING LDL-C (−1.21 [−46.8 MG/DL] TO −0.17 [−6.6 MG/DL] MMOL/L REDUCTION) AND TC (−1.75 [−67.7 MG/DL] TO −0.18 [7 MG/DL] MMOL/L REDUCTION) THAN PLACEBO/NO INTERVENTION. THE MOST EFFECTIVE APPROACHES IN TERMS OF LDL-C- AND TC-LOWERING WERE BERGAMOT AND RYR (−1.21 [−46.8 MG/DL] AND −0.94 [−36.4 MG/DL] MMOL/L) REDUCTION RESPECTIVELY. IN CONCLUSION, BERGAMOT AND RYR APPEAR TO BE THE MOST EFFECTIVE NUTRACEUTICALS IN TERMS OF LDL-C AND TC REDUCTION. EVIDENCE FOR BERGAMOT EFFECT WAS BASED ON RELATIVELY SMALL STUDY GROUP AND MAY REQUIRE FURTHER INVESTIGATIONS. POLICOSANOLS HAVE NO EFFECT ON THE LIPID PROFILE. © 2022 THE AUTHORS","LIPID-LOWERING THERAPY; META-ANALYSIS; NATURAL PRODUCTS; NUTRACEUTICALS; STATINS","ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; NETWORK META-ANALYSIS; ANTILIPEMIC AGENT; ARTICHOKE EXTRACT; BERBERINE; BERGAMOT OIL; CHOLESTEROL; CHOLESTIN; GARLIC EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; PLANT EXTRACT; POLICOSANOL; SILYMARIN; SINECATECHINS; SPIRULINA EXTRACT; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; ANALYSIS; ARTICHOKE; BERGAMOT JUICE; BIBLIOGRAPHIC DATABASE; COMPARATIVE STUDY; DATA EXTRACTION; DRUG COMPARISON; DRUG EFFICACY; GARLIC; GEOMETRY; HUMAN; LIPID FINGERPRINTING; META ANALYSIS; NETWORK META-ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES; PUBLICATION BIAS; QUALITY ASSESSMENT TOOL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RICE; RISK FACTOR; SPIRULINA; STATISTICAL ANALYSIS; TEA; TRANSITIVITY TEST; YEAST; DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA; NETWORK META-ANALYSIS","KRKA; MYLAN/VIATRIS; NOMI BIOTECH CORPORATION; SANOFI AND VALEANT; AMGEN; NOVARTIS; SANOFI; TEVA PHARMACEUTICAL INDUSTRIES; NOVO NORDISK","WE THANK CHAN WAH KHEONG, PH.D.; MEREDITH L. WILCOX, M.P.H.; TATIANA V. KIRICHENKO, PH.D.; MARTIN PRØVEN BOGSRUD, PH.D.; JAVAD NASROLLAHZADEH, PH.D.; BAHRAM POURGHASSEM GARGARI, PH.D.; SHILA NAYEBIFAR, PH.D.; HASSAN FALLAH HUSEINI, PH.D.; MANUEL GONZÁLEZ-ORTIZ, PH.D.; AND CHANTACHA SITTICHAROON, PH.D. FOR PROVIDING ADDITIONAL DATA ABOUT THEIR STUDIES. MB: SPEAKERS BUREAU: AMGEN, DAICHII SANKYO, HERBAPOL, KOGEN, KRKA, POLPHARMA, MYLAN/VIATRIS, NOVARTIS, NOVO-NORDISK, SANOFI, TEVA, ZENTIVA; CONSULTANT TO ADAMED, AMGEN, DAICHII SANKYO, ESPERION, FREIA PHARMACEUTICALS, NOVARTIS, POLFARMEX, SANOFI; GRANTS FROM AMGEN, MYLAN/VIATRIS, SANOFI AND VALEANT; CMO AT THE NOMI BIOTECH CORPORATION. ALL OTHER AUTHORS HAVE NOTHING TO DECLARE. NONE OF THE ABOVE-MENTIONED PHARMACEUTICAL COMPANIES HAD ANY ROLE IN THIS ARTICLE, WHICH HAS BEEN WRITTEN INDEPENDENTLY, WITHOUT ANY FINANCIAL OR PROFESSIONAL HELP, AND REFLECTS ONLY THE OPINION OF THE AUTHORS, WITHOUT ANY ROLE OF THE INDUSTRY.","NCD RISK FACTOR COLLABORATION, TADDEI C., ZHOU B., BIXBY H., CARRILLO-LARCO R.M., DANAEI G., JACKSON R.T., ET AL., REPOSITIONING OF THE GLOBAL EPICENTRE OF NON-OPTIMAL CHOLESTEROL, NATURE, 582, PP. 73-77, (2020); RAY K.K., MOLEMANS B., SCHOONEN W.M., GIOVAS P., BRAY S., KIRU G., MURPHY J., BANACH M., DE SERVI S., GAITA D., GOUNI-BERTHOLD I., HOVINGH G.K., JOZWIAK J.J., JUKEMA J.W., KISS R.G., KOWNATOR S., IVERSEN H.K., MAHER V., MASANA L., PARKHOMENKO A., PEETERS A., CLIFFORD P., RASLOVA K., SIOSTRZONEK P., ROMEO S., TOUSOULIS D., VLACHOPOULOS C., VRABLIK M., CATAPANO A.L., POULTER N.R., THE D.V. STUDY, EU-WIDE CROSS-SECTIONAL OBSERVATIONAL STUDY OF LIPID-MODIFYING THERAPY USE IN SECONDARY AND PRIMARY CARE: THE DA VINCI STUDY, EUR. J. PREV. CARDIOL., 28, PP. 1279-1289, (2021); KRAHENBUHL S., PAVIK-MEZZOUR I., VON ECKARDSTEIN A., UNMET NEEDS IN LDL-C LOWERING: WHEN STATINS WON'T DO!, DRUGS, 76, PP. 1175-1190, (2016); BANACH M., BURCHARDT P., CHLEBUS K., DOBROWOLSKI P., DUDEK D., DYRBUS K., GASIOR M., JANKOWSKI P., JOZWIAK J., KLOSIEWICZ-LATOSZEK L., KOWALSKA I., MALECKI M., PREJBISZ A., RAKOWSKI M., RYSZ J., SOLNICA B., SITKIEWICZ D., SYGITOWICZ G., SYPNIEWSKA G., TOMASIK T., WINDAK A., ZOZULINSKA-ZIOLKIEWICZ D., CYBULSKA B., POLA/CFPIP/PCS/PSLD/PSD/PSH GUIDELINES ON DIAGNOSIS AND THERAPY OF LIPID DISORDERS IN POLAND 2021, ARCH. MED. SCI., 17, PP. 1447-1547, (2021); CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS, MIHAYLOVA B., EMBERSON J., BLACKWELL L., KEECH A., SIMES J., BARNES E.H., ET AL., THE EFFECTS OF LOWERING LDL CHOLESTEROL WITH STATIN THERAPY IN PEOPLE AT LOW RISK OF VASCULAR DISEASE: META-ANALYSIS OF INDIVIDUAL DATA FROM 27 RANDOMISED TRIALS, THE LANCET, 380, PP. 581-590, (2012); CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS, FULCHER J., O'CONNELL R., VOYSEY M., EMBERSON J., BLACKWELL L., MIHAYLOVA B., ET AL., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN: META-ANALYSIS OF INDIVIDUAL DATA FROM 174 000 PARTICIPANTS IN 27 RANDOMISED TRIALS, THE LANCET, 385, PP. 1397-1405, (2015); DE VERA M.A., BHOLE V., BURNS L.C., LACAILLE D., IMPACT OF STATIN ADHERENCE ON CARDIOVASCULAR DISEASE AND MORTALITY OUTCOMES: A SYSTEMATIC REVIEW, BR. J. CLIN. PHARMACOL., 78, PP. 684-698, (2014); KONES R., MOLECULAR SOURCES OF RESIDUAL CARDIOVASCULAR RISK, CLINICAL SIGNALS, AND INNOVATIVE SOLUTIONS: RELATIONSHIP WITH SUBCLINICAL DISEASE, UNDERTREATMENT, AND POOR ADHERENCE: IMPLICATIONS OF NEW EVIDENCE UPON OPTIMIZING CARDIOVASCULAR PATIENT OUTCOMES, VASC. HEALTH RISK MANAG., 9, PP. 617-670, (2013); MANN D.M., WOODWARD M., MUNTNER P., FALZON L., KRONISH I., PREDICTORS OF NONADHERENCE TO STATINS: A SYSTEMATIC REVIEW AND META-ANALYSIS, ANN. PHARMACOTHER., 44, PP. 1410-1421, (2010); DYRBUS K., GASIOR M., DESPERAK P., NOWAK J., OSADNIK T., BANACH M., CHARACTERISTICS OF LIPID PROFILE AND EFFECTIVENESS OF MANAGEMENT OF DYSLIPIDAEMIA IN PATIENTS WITH ACUTE CORONARY SYNDROMES – DATA FROM THE TERCET REGISTRY WITH 19,287 PATIENTS, PHARMACOL. RES., 139, PP. 460-466, (2019); STROES E.S., THOMPSON P.D., CORSINI A., VLADUTIU G.D., RAAL F.J., RAY K.K., RODEN M., STEIN E., TOKGOZOTLU L., NORDESTGAARD B.G., BRUCKERT E., DE BACKER G., KRAUSS R.M., LAUFS U., SANTOS R.D., HEGELE R.A., HOVINGH G.K., LEITER L.A., MACH F., MARZ W., NEWMAN C.B., WIKLUND O., JACOBSON T.A., CATAPANO A.L., CHAPMAN M.J., GINSBERG H.N., STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY - EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR. HEART J., 36, PP. 1012-1022, (2015); LAUFS U., SCHARNAGL H., MARZ W., STATIN INTOLERANCE, CURR. OPIN. LIPIDOL., 26, PP. 492-501, (2015); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., GREENFIELD R.S., HOVINGH G.K., KOSTNER K., SERBAN C., LIGHEZAN D., FRAS Z., MORIARTY P.M., MUNTNER P., GOUDEV A., CESKA R., NICHOLLS S.J., BRONCEL M., NIKOLIC D., PELLA D., PURI R., RYSZ J., WONG N.D., BAJNOK L., JONES S.R., RAY K.K., MIKHAILIDIS D.P., STATIN INTOLERANCE - AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH. MED SCI., 11, PP. 1-23, (2015); RUSCICA M., FERRI N., BANACH M., SIRTORI C.R., CORSINI A., SIDE EFFECTS OF STATINS: FROM PATHOPHYSIOLOGY AND EPIDEMIOLOGY TO DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS, CARDIOVASC. RES., (2022); BRADLEY C.K., WANG T.Y., LI S., ROBINSON J.G., ROGER V.L., GOLDBERG A.C., VIRANI S.S., LOUIE M.J., LEE L.V., PETERSON E.D., NAVAR A.M., PATIENT‐REPORTED REASONS FOR DECLINING OR DISCONTINUING STATIN THERAPY: INSIGHTS FROM THE PALM REGISTRY, J. AM. HEART ASSOC., 8, (2019); PENSON P.E., MANCINI G.B.J., TOTH P.P., MARTIN S.S., WATTS G.F., SAHEBKAR A., ET AL., (2018); BANACH M., PENSON P.E., DRUCEBO EFFECT - THE CHALLENGE WE SHOULD ALL DEFINITELY FACE!, ARCH. MED. SCI., 17, PP. 542-543, (2021); XIAO F., GAO F., ZHOU S., WANG L., THE THERAPEUTIC EFFECTS OF SILYMARIN FOR PATIENTS WITH GLUCOSE/LIPID METABOLIC DYSFUNCTION: A META-ANALYSIS, MEDICINE, 99, (2020); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., HUANG Z., DONG H., LU F., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES., 62, (2018); SUN Y.E., WANG W., QIN J., ANTI-HYPERLIPIDEMIA OF GARLIC BY REDUCING THE LEVEL OF TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN, MED. (U. S.), 97, (2018); JU J., LI J., LIN Q., XU H., EFFICACY AND SAFETY OF BERBERINE FOR DYSLIPIDAEMIAS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, PHYTOMEDICINE, 50, PP. 25-34, (2018); SAHEBKAR A., PIRRO M., BANACH M., MIKHAILIDIS D.P., ATKIN S.L., CICERO A.F.G., LIPID-LOWERING ACTIVITY OF ARTICHOKE EXTRACTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, CRIT. REV. FOOD SCI. NUTR., 58, PP. 2549-2556, (2018); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); PENG D., FONG A., VAN PELT A., THE EFFECTS OF RED YEAST RICE SUPPLEMENTATION ON CHOLESTEROL LEVELS IN ADULTS, AJN AM. J. NURS., 117, PP. 46-54, (2017); MARINANGELI C.P.F., JONES P.J.H., KASSIS A.N., ESKIN M.N.A., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR., 50, PP. 259-267, (2010); BANACH M., PATTI A.M., GIGLIO R.V., CICERO A.F.G., ATANASOV A.G., BAJRAKTARI G., ET AL., (2018); BANACH M., CATAPANO A.L., CICERO A.F.G., ESCOBAR C., FOGER B., KATSIKI N., ET AL., (2022); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., ET AL., (2017); MACH F., BAIGENT C., CATAPANO A.L., KOSKINAS K.C., CASULA M., BADIMON L., CHAPMAN M.J., DE BACKER G.G., DELGADO V., FERENCE B.A., GRAHAM I.M., HALLIDAY A., LANDMESSER U., MIHAYLOVA B., PEDERSEN T.R., RICCARDI G., RICHTER D.J., SABATINE M.S., TASKINEN M.-R., TOKGOZOGLU L., WIKLUND O., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR. HEART J., 41, PP. 111-188, (2020); LEUCHT S., CHAIMANI A., CIPRIANI A.S., DAVIS J.M., FURUKAWA T.A., SALANTI G., NETWORK META-ANALYSES SHOULD BE THE HIGHEST LEVEL OF EVIDENCE IN TREATMENT GUIDELINES, EUR. ARCH. PSYCHIATRY CLIN. NEUROSCI., 266, PP. 477-480, (2016); MORZE J., OSADNIK T., OSADNIK K., LEJAWA M., JAKUBIAK G., PAWLAS N., GASIOR M., SCHWINGSHACKL L., BANACH M., COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE: A PROTOCOL FOR SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS, BMJ OPEN, 10, (2020); HUTTON B., SALANTI G., CALDWELL D.M., CHAIMANI A., SCHMID C.H., CAMERON C., IOANNIDIS J.P.A., STRAUS S., THORLUND K., JANSEN J.P., MULROW C., CATALA-LOPEZ F., GOTZSCHE P.C., DICKERSIN K., BOUTRON I., ALTMAN D.G., MOHER D., THE PRISMA EXTENSION STATEMENT FOR REPORTING OF SYSTEMATIC REVIEWS INCORPORATING NETWORK META-ANALYSES OF HEALTH CARE INTERVENTIONS: CHECKLIST AND EXPLANATIONS, ANN. INTERN. MED., 162, PP. 777-784, (2015); PAGE M.J., MCKENZIE J.E., BOSSUYT P.M., BOUTRON I., HOFFMANN T.C., MULROW C.D., SHAMSEER L., TETZLAFF J.M., AKL E.A., BRENNAN S.E., CHOU R., GLANVILLE J., GRIMSHAW J.M., HROBJARTSSON A., LALU M.M., LI T., LODER E.W., MAYO-WILSON E., MCDONALD S., MCGUINNESS L.A., STEWART L.A., THOMAS J., TRICCO A.C., WELCH V.A., WHITING P., MOHER D., THE PRISMA 2020 STATEMENT: AN UPDATED GUIDELINE FOR REPORTING SYSTEMATIC REVIEWS, BMJ, 372, (2021); MAJITHIA A., BHATT D.L., FRIEDMAN A.N., MILLER M., STEG P.G., BRINTON E.A., JACOBSON T.A., KETCHUM S.B., JULIANO R.A., JIAO L., DOYLE R.T., GRANOWITZ C., BUDOFF M., PRESTON MASON R., TARDIF J.C., BODEN W.E., BALLANTYNE C.M., BENEFITS OF ICOSAPENT ETHYL ACROSS THE RANGE OF KIDNEY FUNCTION IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE OR DIABETES: REDUCE-IT RENAL, CIRCULATION, 144, PP. 1750-1759, (2021); STERNE J.A.C., SAVOVIC J., PAGE M.J., ELBERS R.G., BLENCOWE N.S., BOUTRON I., CATES C.J., CHENG H.Y., CORBETT M.S., ELDRIDGE S.M., EMBERSON J.R., HERNAN M.A., HOPEWELL S., HROBJARTSSON A., JUNQUEIRA D.R., JUNI P., KIRKHAM J.J., LASSERSON T., LI T., MCALEENAN A., REEVES B.C., SHEPPERD S., SHRIER I., STEWART L.A., TILLING K., WHITE I.R., WHITING P.F., HIGGINS J.P.T., ROB 2: A REVISED TOOL FOR ASSESSING RISK OF BIAS IN RANDOMISED TRIALS, BMJ, 366, (2019); RILEY R.D., JACKSON D., SALANTI G., BURKE D.L., PRICE M., KIRKHAM J., WHITE I.R., MULTIVARIATE AND NETWORK META-ANALYSIS OF MULTIPLE OUTCOMES AND MULTIPLE TREATMENTS: RATIONALE, CONCEPTS, AND EXAMPLES, BMJ, 358, (2017); HIGGINS J.P.T., THOMAS J., CHANDLER J., CUMPSTON M., LI T., (2020); WAN X., WANG W., LIU J., TONG T., ESTIMATING THE SAMPLE MEAN AND STANDARD DEVIATION FROM THE SAMPLE SIZE, MEDIAN, RANGE AND/OR INTERQUARTILE RANGE, BMC MED. RES. METHODOL., 14, (2014); VIECHTBAUER W., CONDUCTING META-ANALYSES IN R WITH THE METAFOR PACKAGE, J. STAT. SOFTW., 36, PP. 1-48, (2010); SCHWARZER G., CARPENTER J.R., RUCKER G., META-ANALYSIS WITH R, (2015); DIAS S., WELTON N.J., CALDWELL D.M., ADES A.E., CHECKING CONSISTENCY IN MIXED TREATMENT COMPARISON META-ANALYSIS, STAT. MED., 29, PP. 932-944, (2010); PETERS J.L., SUTTON A.J., JONES D.R., ABRAMS K.R., RUSHTON L., CONTOUR-ENHANCED META-ANALYSIS FUNNEL PLOTS HELP DISTINGUISH PUBLICATION BIAS FROM OTHER CAUSES OF ASYMMETRY, J. CLIN. EPIDEMIOL., 61, PP. 991-996, (2008); GUYAT G.H., OXMAN A.D., AKL E.A.A., REGINA K., VIST G.E., BRZOZEK J., NORRIS S., FALCK-YTTER Y., GLASZIOU P., DEBEER H., JAESCHKE R., RIND D., MEERPOHL J., DAHM P., SCHUNEMANN H.J., BALSHEM H., HELFAND M., ALONSO-COELLO P., MONTORI V., AKL E.A., DJULBEGOVIC B., WILLIAMS J.W., ATKINS D., DEVEREAUX P.J., FREYSCHUSS B., MURAD M.H., SINCLAIR D., CRAIG W., THORLUND K., ANDREWS J., GRADE GUIDELINES: 1-11, J. OF CLIN. EPIDEMIOL., PP. 64-66, (2011); BRIGNARDELLO-PETERSEN R., BONNER A., ALEXANDER P.E., SIEMIENIUK R.A., FURUKAWA T.A., ROCHWERG B., HAZLEWOOD G.S., ALHAZZANI W., MUSTAFA R.A., MURAD M.H., PUHAN M.A., SCHUNEMANN H.J., GUYATT G.H., ADVANCES IN THE GRADE APPROACH TO RATE THE CERTAINTY IN ESTIMATES FROM A NETWORK META-ANALYSIS, J. CLIN. EPIDEMIOL., 93, PP. 36-44, (2018); KHAN S.U., MICHOS E.D., CARDIOVASCULAR MORTALITY AFTER INTENSIVE LDL-CHOLESTEROL LOWERING: DOES BASELINE LDL-CHOLESTEROL REALLY MATTER?, AM. J. PREV., CARDIOL., 1, (2020); PENSON P.E., BRUCKERT E., MARAIS D., ET AL., (2022); LI P., WANG Q., CHEN K., ZOU S., SHU S., LU C., WANG S., JIANG Y., FAN C., LUO Y., RED YEAST RICE FOR HYPERLIPIDEMIA: A META-ANALYSIS OF 15 HIGH-QUALITY RANDOMIZED CONTROLLED TRIALS, FRONT. PHARMACOL., 12, (2022); CICERO A.F.G., FOGACCI F., BANACH M., RED YEAST RICE FOR HYPERCHOLESTEROLEMIA, METHODIST DEBAKEY CARDIOVASC. J., 15, PP. 192-199, (2019); BANACH M., KATSIKI N., LATKOVSKIS G., RIZZO M., PELLA D., PENSON P.E., REINER Z., CICERO A.F.G., POSTMARKETING NUTRIVIGILANCE SAFETY PROFILE: A LINE OF DIETARY FOOD SUPPLEMENTS CONTAINING RED YEAST RICE FOR DYSLIPIDEMIA, ARCH. MED. SCI., 17, (2021); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H.W., GERDES V.E.A., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN - A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); PENSON P.E., BANACH M., THE ROLE OF NUTRACEUTICALS IN THE OPTIMIZATION OF LIPID-LOWERING THERAPY IN HIGH-RISK PATIENTS WITH DYSLIPIDAEMIA, CURR. ATHEROSCLER. REP., 22, PP. 1-9, (2020); DI DONNA L., DE LUCA G., MAZZOTTI F., NAPOLI A., SALERNO R., TAVERNA D., SINDONA G., STATIN-LIKE PRINCIPLES OF BERGAMOT FRUIT (CITRUS BERGAMIA): ISOLATION OF 3-HYDROXYMETHYLGLUTARYL FLAVONOID GLYCOSIDES, J. NAT. PROD., 72, PP. 1352-1354, (2009); PARAFATI M., LASCALA A., MORITTU V.M., TRIMBOLI F., RIZZUTO A., BRUNELLI E., COSCARELLI F., COSTA N., BRITTI D., EHRLICH J., ISIDORO C., MOLLACE V., JANDA E., BERGAMOT POLYPHENOL FRACTION PREVENTS NONALCOHOLIC FATTY LIVER DISEASE VIA STIMULATION OF LIPOPHAGY IN CAFETERIA DIET-INDUCED RAT MODEL OF METABOLIC SYNDROME, J. NUTR. BIOCHEM., 26, PP. 938-948, (2015); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., ET AL., (2017); LI H., DONG B., PARK S.W., LEE H.S., CHEN W., LIU J., HEPATOCYTE NUCLEAR FACTOR 1ALPHA PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINE, J. BIOL. CHEM., 284, PP. 28885-28895, (2009); RAS R.T., HIEMSTRA H., LIN Y., VERMEER M.A., DUCHATEAU G.S.M.J.E., TRAUTWEIN E.A., CONSUMPTION OF PLANT STEROL-ENRICHED FOODS AND EFFECTS ON PLASMA PLANT STEROL CONCENTRATIONS–A META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES, ATHEROSCLEROSIS, 230, PP. 336-346, (2013); DEMONTY I., RAS R.T., VAN DER KNAAP H.C.M., MEIJER L., ZOCK P.L., GELEIJNSE J.M., TRAUTWEIN E.A., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUR. J. NUTR., 52, (2013)","M. BANACH; DEPARTMENT OF PREVENTIVE CARDIOLOGY AND LIPIDOLOGY, MEDICAL UNIVERSITY OF LODZ (MUL), LODZ, RZGOWSKA 281/289, 93-338, POLAND; EMAIL: MACIEJ.BANACH@ICLOUD.COM","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","REVIEW","ISI","2-S2.0-85136497851","PHARMACOL RES","MEDICAL UNIVERSITY OF SILESIA;MEDICAL UNIVERSITY OF SILESIA;MEDICAL UNIVERSITY OF SILESIA;UNIVERSITY OF WARMIA AND MAZURY;MEDICAL UNIVERSITY OF SILESIA;MEDICAL UNIVERSITY OF SILESIA;MEDICAL UNIVERSITY OF SILESIA;MEDICAL UNIVERSITY OF SILESIA;MEDICAL UNIVERSITY OF SILESIA;UNIVERSITY OF FREIBURG;KATOWICE;MEDICAL UNIVERSITY OF LODZ (MUL)","NOTREPORTED;MEDICAL UNIVERSITY OF LODZ (MUL);NOTREPORTED",NA,"OSADNIK T, 2022, PHARMACOL RES","OSADNIK T, 2022, PHARMACOL RES"
"KIM T;HWANG Y;PARK Y;LEE J;KIM J;LEE M","KIM, TAE JIN (57202388112); HWANG, YE JI (55279513600); PARK, YOUNG JIN (57202422844); LEE, JONG SUNG (58726057500); KIM, JAE KWANG (56892616700); LEE, MI-HWA (55535507900)","METABOLOMICS REVEALS LYSINIBACILLUSCAPSICI TT41INDUCED METABOLIC SHIFTS ENHANCING DROUGHT STRESS TOLERANCE IN KIMCHI CABBAGE BRASSICA RAPA L SUBSP PEKINENSIS",2024,"METABOLITES","14","",0,"10.3390/metabo14020087","BIO-RESOURCE INDUSTRIALIZATION CENTER, NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES, SANGJU, 37242, SOUTH KOREA;BIO-RESOURCE INDUSTRIALIZATION CENTER, NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES, SANGJU, 37242, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;BIO-RESOURCE INDUSTRIALIZATION CENTER, NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES, SANGJU, 37242, SOUTH KOREA","CLIMATE CHANGE HAS INCREASED VARIABLE WEATHER PATTERNS THAT AFFECT PLANTS. TO ADDRESS THESE ISSUES, WE DEVELOPED A MICROBIAL BIOCONTROL AGENT AGAINST DROUGHT STRESS IN KIMCHI CABBAGE (BRASSICA RAPA L. SUBSP. PEKINENSIS). WE SELECTED THREE BACTERIAL STRAINS (LEIFSONIA SP. CS9, BACILLUS TOYONENSIS TSJ7, AND LYSINIBACILLUS CAPSICI TT41) BECAUSE THEY SHOWED A SURVIVAL RATE OF UP TO 50% AND GOOD GROWTH RATE WHEN TREATED WITH 30% PEG 6000. THE THREE STRAINS WERE TREATED WITH KIMCHI CABBAGE TO CONFIRM THEIR ENHANCED DROUGHT STRESS RESISTANCE UNDER NON-WATERING CONDITIONS. AMONG THE THREE STRAINS, THE TT41 TREATED GROUP SHOWED A SIGNIFICANT INCREASE IN VARIOUS PLANT PARAMETERS COMPARED WITH THE NEGATIVE CONTROL ON THE 7TH DAY. WE PERFORMED EXTENSIVE PROFILING OF PRIMARY AND SECONDARY METABOLITES FROM KIMCHI CABBAGE AND THE TT41 STRAIN. MULTIVARIATE AND PATHWAY ANALYSES REVEALED THAT ONLY THE TT41 GROUP CLUSTERED WITH THE WELL-WATERED GROUP AND SHOWED ALMOST THE SAME METABOLOME ON THE 7TH DAY. WHEN TREATED WITH TT41, LACTIC ACID WAS IDENTIFIED AS AN INDICATOR METABOLITE THAT SIGNIFICANTLY IMPROVED DROUGHT STRESS TOLERANCE. FURTHERMORE, LACTIC ACID TREATMENT EFFECTIVELY INDUCED DROUGHT STRESS TOLERANCE IN KIMCHI CABBAGE, SIMILAR TO THAT ACHIEVED WITH THE TT41 STRAIN. © 2024 BY THE AUTHORS.","ABIOTIC STRESS; BRASSICA RAPAL; CABBAGE; DROUGHT STRESS; LACTIC ACID; METABOLOMICS","ALANINE; AMINO ACID; ASPARTIC ACID; AUXIN; CAROTENOID; CITRIC ACID; GLUCOSINOLATE; GLUTAMIC ACID; GLUTAMINE; GLYCERIC ACID; LACTIC ACID; MALIC ACID; PHYTOSTEROL; POLICOSANOL; PROLINE; SITOSTEROL; ABIOTIC STRESS; AMINO ACID METABOLISM; ARTICLE; BACTERIAL STRAIN; BRASSICA RAPA; CABBAGE; CHLOROPHYLL CONTENT; CONTROLLED STUDY; DROUGHT; DROUGHT STRESS; GAS CHROMATOGRAPHY; GLYCOLYSIS; GROWTH RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEIFSONIA; LYSINIBACILLUS; MASS FRAGMENTOGRAPHY; METABOLOMICS; NONHUMAN; OSMOTIC STRESS; PHOTOSYNTHESIS; PLANT DEFENSE; PLANT LEAF; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; PSEUDOMONAS; RHIZOSPHERE; ROOT GROWTH; TRANSCRIPTOMICS; WATER CONTENT","MINISTRY OF ENVIRONMENT, MOE, (NNIBR NNIBR20243110); MINISTRY OF ENVIRONMENT, MOE; NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES, NNIBR","THIS WORK WAS SUPPORTED BY A GRANT FROM THE NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES (NNIBR), FUNDED BY THE MINISTRY OF ENVIRONMENT (MOE) OF KOREA (NNIBR NNIBR20243110).","MATA A.T., JORGE T.F., PIRES M.V., ANTONIO C., DROUGHT STRESS TOLERANCE IN PLANTS: INSIGHTS FROM METABOLOMICS, DROUGHT STRESS TOLERANCE IN PLANTS, 2, PP. 187-216, (2016); SINGH A., MAZAHAR S., CHAPADGAONKAR S.S., GIRI P., SHOURIE A., PHYTO-MICROBIOME TO MITIGATE ABIOTIC STRESS IN CROP PLANTS, FRONT. MICROBIOL, 14, (2023); WANG L., CHAI B., FATE OF ANTIBIOTIC RESISTANCE GENES AND CHANGES IN BACTERIAL COMMUNITY WITH INCREASING BREEDING SCALE OF LAYER MANURE, FRONT. MICROBIOL, 13, (2022); NAUREEN Z., REHMAN N.U., HUSSAIN H., HUSSAIN J., GILANI S.A., AL HOUSNI S.K., MABOOD F., KHAN A.L., FAROOQ S., ABBAS G., ET AL., EXPLORING THE POTENTIALS OF LYSINIBACILLUS SPHAERICUS ZA9 FOR PLANT GROWTH PROMOTION AND BIOCONTROL ACTIVITIES AGAINST PHYTOPATHOGENIC FUNGI, FRONT. MICROBIOL, 8, (2017); JHA C.K., SARAF M., PLANT GROWTH PROMOTING RHIZOBACTERIA (PGPR): A REVIEW, J. AGRIC. RES. DEVE, 5, PP. 108-119, (2015); OJIAMBO P.S., SCHERM H., BIOLOGICAL AND APPLICATION-ORIENTED FACTORS INFLUENCING PLANT DISEASE SUPPRESSION BY BIOLOGICAL CONTROL: A META-ANALYTICAL REVIEW, PHYTOPATHOLOGY, 96, PP. 1168-1174, (2006); DAYAN F.E., CANTRELL C.L., DUKE S.O., NATURAL PRODUCTS IN CROP PROTECTION, BIOORG. MED. CHEM, 17, PP. 4022-4034, (2009); MASHABELA M.D., PIATER L.A., DUBERY I.A., TUGIZIMANA F., MHLONGO M.I., RHIZOSPHERE TRIPARTITE INTERACTIONS AND PGPR-MEDIATED METABOLIC REPROGRAMMING TOWARDS ISR AND PLANT PRIMING: A METABOLOMICS REVIEW, BIOLOGY, 11, (2022); CARLSON R., TUGIZIMANA F., STEENKAMP P.A., DUBERY I.A., LABUSCHAGNE N., DIFFERENTIAL METABOLIC REPROGRAMMING IN PAENIBACILLUS ALVEI-PRIMED SORGHUM BICOLOR SEEDLINGS IN RESPONSE TO FUSARIUM PSEUDOGRAMINEARUM INFECTION, METABOLITES, 9, (2019); KANG D., KIRIENKO D.R., WEBSTER P., FISHER A.L., KIRIENKO N.V., PYOVERDINE, A SIDEROPHORE FROM PSEUDOMONAS AERUGINOSA, TRANSLOCATES INTO C. ELEGANS, REMOVES IRON, AND ACTIVATES A DISTINCT HOST RESPONSE, VIRULENCE, 9, PP. 804-817, (2018); AKRAM W., ASLAM H., AHMAD S.R., ANJUM T., YASIN N.A., KHAN W.U., AHMAD A., GUO J., WU T., LUO W., ET AL., BACILLUS MEGATERIUM STRAIN A12 AMELIORATES SALINITY STRESS IN TOMATO PLANTS THROUGH MULTIPLE MECHANISMS, J. PLANT INTERACT, 14, PP. 506-518, (2019); KUMAR A., SINGH V.K., TRIPATHI V., SINGH P.P., SINGH A.K., PLANT GROWTH-PROMOTING RHIZOBACTERIA (PGPR): PERSPECTIVE IN AGRICULTURE UNDER BIOTIC AND ABIOTIC STRESS, CROP IMPROVEMENT THROUGH MICROBIAL BIOTECHNOLOGY, PP. 333-342, (2018); KHAN N., BANO A., RAHMAN M.A., GUO J., KANG Z., BABAR M.A., COMPARATIVE PHYSIOLOGICAL AND METABOLIC ANALYSIS REVEALS A COMPLEX MECHANISM INVOLVED IN DROUGHT TOLERANCE IN CHICKPEA (CICER ARIETINUM L.) INDUCED BY PGPR AND PGRS, SCI. REP, 9, (2019); ROZIER C., HAMZAOUI J., LEMOINE D., CZARNES S., LEGENDRE L., FIELD-BASED ASSESSMENT OF THE MECHANISM OF MAIZE YIELD ENHANCEMENT BY AZOSPIRILLUM LIPOFERUM CRT1, SCI. REP, 7, (2017); MHLONGO M.I., PIATER L.A., STEENKAMP P.A., LABUSCHAGNE N., DUBERY I.A., METABOLIC PROFILING OF PGPR-TREATED TOMATO PLANTS REVEAL PRIMING-RELATED ADAPTATIONS OF SECONDARY METABOLITES AND AROMATIC AMINO ACIDS, METABOLITES, 10, (2020); FRED E.B., WAKSMAN S.A., LABORATORY MANUAL OF GENERAL MICROBIOLOGY, WITH SPECIAL REFERENCE TO THE MICROORGANISMS OF THE SOIL, (1928); YOON S.H., HA S.M., KWON S., LIM J., KIM Y., SEO H., CHUN J., INTRODUCING EZBIOCLOUD: A TAXONOMICALLY UNITED DATABASE OF 16S RRNA GENE SEQUENCES AND WHOLE-GENOME ASSEMBLIES, INT. J. SYST. EVOL. MICROBIOL, 67, PP. 1613-1617, (2017); PATANE C., COSENTINO S.L., ROMANO D., TOSCANO S., RELATIVE WATER CONTENT, PROLINE, AND ANTIOXIDANT ENZYMES IN LEAVES OF LONG SHELF-LIFE TOMATOES UNDER DROUGHT STRESS AND REWATERING, PLANTS, 11, (2022); ZHOU F., SUN W., ZHAO M., CONTROLLED FORMATION OF EMULSION GELS STABILIZED BY SALTED MYOFIBRILLAR PROTEIN UNDER MALONDIALDEHYDE (MDA)-INDUCED OXIDATIVE STRESS, J. AGRIC. FOOD CHEM, 63, PP. 3766-3777, (2015); QI H., WU Z., ZHANG L., LI J., ZHOU J., JUN Z., ZHU B., MONITORING OF PEANUT LEAVES CHLOROPHYLL CONTENT BASED ON DRONE-BASED MULTISPECTRAL IMAGE FEATURE EXTRACTION, COMPUT ELECTRON AGRIC, 187, (2021); LICHTENTHALER H.K., 34 CHLOROPHYLLS AND CAROTENOIDS: PIGMENTS OF PHOTOSYNTHETIC BIOMEMBRANES, METHODS IN ENZYMOLOGY, 148, PP. 350-382, (1987); BAEK S.-A., KIM K.W., KIM J.O., KIM T.J., AHN S.K., CHOI J., KIM J., AHN J., KIM J.K., METABOLIC PROFILING REVEALS AN INCREASE IN STRESS-RELATED METABOLITES IN ARABIDOPSIS THALIANA EXPOSED TO HONEYBEES, J. APPL. BIOL. CHEM, 64, PP. 141-151, (2021); JUNG J.W., OH S.-D., PARK S.-Y., JANG Y., LEE S.-K., YUN D.-W., CHANG A., PARK S.U., HA S.-H., KIM J.K., METABOLIC PROFILING AND ANTIOXIDANT PROPERTIES OF HYBRID SOYBEANS WITH DIFFERENT SEED COAT COLORS, OBTAINED BY CROSSING Β-CAROTENE-ENHANCED (GLYCINE MAX) AND WILD (GLYCINE SOJA) SOYBEANS, PLANT BIOTECHNOL. REP, 16, PP. 449-463, (2022); BAEK S.A., JUNG Y.H., LIM S.H., PARK S.U., KIM J.K., METABOLIC PROFILING IN CHINESE CABBAGE (BRASSICA RAPA L. SUBSP. PEKINENSIS) CULTIVARS REVEALS THAT GLUCOSINOLATE CONTENT IS CORRELATED WITH CAROTENOID CONTENT, J. AGRIC. FOOD. CHEM, 64, PP. 4426-4434, (2016); KIM T.J., LEE K.B., BAEK S.-A., CHOI J., HA S.-H., LIM S.-H., PARK S.-Y., YEO Y., PARK S.U., KIM J.K., DETERMINATION OF LIPOPHILIC METABOLITES FOR SPECIES DISCRIMINATION AND QUALITY ASSESSMENT OF NINE LEAFY VEGETABLES, J. KOREAN SOC. APPL. BIOL. CHEM, 58, PP. 909-918, (2015); KIM T.J., HYEON H., PARK N.I., YI T.G., LIM S.H., PARK S.Y., HA S.H., KIM J.K., A HIGH-THROUGHPUT PLATFORM FOR INTERPRETATION OF METABOLITE PROFILE DATA FROM PEPPER (CAPSICUM) FRUITS OF 13 PHENOTYPES ASSOCIATED WITH DIFFERENT FRUIT MATURITY STATES, FOOD CHEM, 331, (2020); KUTMON M., VAN IERSEL M.P., BOHLER A., KELDER T., NUNES N., PICO A.R., EVELO C.T., PATHVISIO 3: AN EXTENDABLE PATHWAY ANALYSIS TOOLBOX, PLOS COMPUT. BIOL, 11, (2015); ZHOU G., YANG L.-T., LI Y.-R., ZOU C.-L., HUANG L.-P., QIU L.-H., HUANG X., SRIVASTAVA M.K., PROTEOMIC ANALYSIS OF OSMOTIC STRESS-RESPONSIVE PROTEINS IN SUGARCANE LEAVES, PLANT MOL. BIOL. REP, 30, PP. 349-359, (2012); CARLSON R., TUGIZIMANA F., STEENKAMP P.A., DUBERY I.A., HASSEN A.I., LABUSCHAGNE N., RHIZOBACTERIA-INDUCED SYSTEMIC TOLERANCE AGAINST DROUGHT STRESS IN SORGHUM BICOLOR (L.) MOENCH, MICROBIOL. RES, 232, (2020); KUMAR M., KUMAR PATEL M., KUMAR N., BAJPAI A.B., SIDDIQUE K.H.M., METABOLOMICS AND MOLECULAR APPROACHES REVEAL DROUGHT STRESS TOLERANCE IN PLANTS, INT. J. MOL. SCI, 22, (2021); LI Z., CHENG B., YONG B., LIU T., PENG Y., ZHANG X., MA X., HUANG L., LIU W., NIE G., METABOLOMICS AND PHYSIOLOGICAL ANALYSES REVEAL Β-SITOSTEROL AS AN IMPORTANT PLANT GROWTH REGULATOR INDUCING TOLERANCE TO WATER STRESS IN WHITE CLOVER, PLANTA, 250, PP. 2033-2046, (2019); PANTOJA-GUERRA M., BURKETT-CADENA M., CADENA J., DUNLAP C.A., RAMIREZ C.A., LYSINIBACILLUS SPP.: AN IAA-PRODUCING ENDOSPORE FORMING-BACTERIA THAT PROMOTES PLANT GROWTH, ANTONIE VAN LEEUWENHOEK, 116, PP. 615-630, (2023); ZHAO Y., AUXIN BIOSYNTHESIS AND ITS ROLE IN PLANT DEVELOPMENT, ANNU. REV. PLANT BIOL, 61, PP. 49-64, (2010); IMRAN M., MPOVO C.L., AAQIL KHAN M., SHAFFIQUE S., NINSON D., BILAL S., KHAN M., KWON E.H., KANG S.M., YUN B.W., ET AL., SYNERGISTIC EFFECT OF MELATONIN AND LYSINIBACILLUS FUSIFORMIS L. (PLT16) TO MITIGATE DROUGHT STRESS VIA REGULATION OF HORMONAL, ANTIOXIDANTS SYSTEM, AND PHYSIO-MOLECULAR RESPONSES IN SOYBEAN PLANTS, INT. J. MOL. SCI, 24, (2023); RAMAN J., KIM J.S., CHOI K.R., EUN H., YANG D., KO Y.J., KIM S.J., APPLICATION OF LACTIC ACID BACTERIA (LAB) IN SUSTAINABLE AGRICULTURE: ADVANTAGES AND LIMITATIONS, INT. J. MOL. SCI, 23, (2022); CHEN W., HE P., ZHANG H., DUAN H., SHAO L., LU F., THE LOW DOSE OF L-LACTIC ACID AS LOESS SOIL AMENDMENT ENHANCES WHEAT RHIZOSPHERE MICROECOSYSTEM, RHIZOSPHERE, 28, (2023); LEE S.-M., KIM S.-K., LEE N., AHN C.-Y., RYU C.-M., D-LACTIC ACID SECRETED BY CHLORELLA FUSCA PRIMES PATTERN-TRIGGERED IMMUNITY AGAINST PSEUDOMONAS SYRINGAE IN ARABIDOPSIS, PLANT J, 102, PP. 761-778, (2020)","M.-H. LEE; BIO-RESOURCE INDUSTRIALIZATION CENTER, NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES, SANGJU, 37242, SOUTH KOREA; EMAIL: BLUME96@NNIBR.RE.KR; J.K. KIM; DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA; EMAIL: KJKPJ@INU.AC.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","METABOLITES","ARTICLE","ISI","2-S2.0-85185700878","METABOLITES","NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES;NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES;INCHEON NATIONAL UNIVERSITY;INCHEON NATIONAL UNIVERSITY;INCHEON NATIONAL UNIVERSITY;NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES","NOTREPORTED;NAKDONGGANG NATIONAL INSTITUTE OF BIOLOGICAL RESOURCES;NOTREPORTED;NOTREPORTED;INCHEON NATIONAL UNIVERSITY;NOTREPORTED",NA,"KIM TJ, 2024, METABOLITES","KIM TJ, 2024, METABOLITES"
"AL-OKBI S;AL-SIEDY E","AL-OKBI, SAHAR Y. (6506387258); AL-SIEDY, ENAS S.K. (57204603965)","POTENTIAL ANTIDYSLIPIDEMIA AND HEPATOPROTECTION OF FUNCTIONAL FOOD COMPONENTS REPRESENTED BY TETRACOSANOL AND MIXTURE OF POLICOSANOL IN TRITON X100 INDUCED DYSLIPIDEMIC RATS",2022,"EGYPTIAN JOURNAL OF CHEMISTRY","65","8",3,"10.21608/EJCHEM.2022.121634.5452","NUTRITION AND FOOD SCIENCES DEPARTMENT, NATIONAL RESEARCH CENTRE, CAIRO, EGYPT;NUTRITION AND FOOD SCIENCES DEPARTMENT, NATIONAL RESEARCH CENTRE, CAIRO, EGYPT","THE ELEVATED PLASMA TRIGLYCERIDES (TGS), TOTAL CHOLESTEROL (TC) AND LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) WITH CONCOMITANT REDUCTION OF HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) ARE DESIGNATED AS DYSLIPIDEMIA. THE AIM OF THE PRESENT RESEARCH WAS TO STUDY THE PROTECTIVE EFFECT OF TETRACOSANOL AND POLICOSANOL MIXTURE TOWARDS TRITON X-100 INDUCED DYSLIPIDEMIA ALONG WITH THEIR HEPATOPROTECTIVE EFFECT IN RATS. THE POLICOSANOL MIXTURE WAS PREPARED FROM TETRACOSANOL, HEXACOSANOL, OCTACOSANOL AND HEPTACOSANOL IN THE RATIO OF 3:1:1:1. RATS WERE DIVIDED INTO 4 GROUPS; A NORMAL CONTROL (NC), DYSLIPIDEMIC CONTROL (DC) AND TWO TEST GROUPS WITH DYSLIPIDEMIA AND TREATED WITH EITHER TETRACOSANOL OR POLICOSANOL MIXTURE IN THE FORM OF EMULSIONS. THE DETERMINED BIOCHEMICAL PARAMETERS WERE PLASMA TGS, TC, LDL-C, HDL-C, MALONDIALDEHYDE (MDA) AND THE ACTIVITIES OF ALANINE TRANSAMINASE (ALT) AND ASPARTATE TRANSAMINASE (AST). IN ADDITION TO CALCULATION OF TC/HDL-C AND LDL-C/HDL-C AS THE ELEVATION OF SUCH RATIOS ARE CONSIDERED RISK FACTORS FOR CARDIOVASCULAR DISEASES (CVDS). HISTOPATHOLOGICAL EXAMINATION OF LIVER WAS ALSO CARRIED OUT. RESULTS SHOWED SIGNIFICANT DYSLIPIDEMIA AND ELEVATED LDL-C/HDL-C, TC/HDL-C, MDA, ALT AND AST WITH LIVER HISTOPATOLOGICAL CHANGES IN THE DC GROUP COMPARED TO THE NC GROUP. BOTH TETRACOSANOL AND POLICOSANOL MIXTURE REDUCED THE RISK FACTORS FOR CVDS AND IMPROVED THE DYSLIPIDEMIA, OXIDATIVE STRESS AND LIVER FUNCTION. TETRACOSANOL WAS SUPERIOR IN REDUCING TC, ALT AND AST AND IMPROVING LIVER HISTOPATHOLOGY WHILE POLICOSANOL MIXTURE WAS MORE EFFICIENT IN REDUCING OXIDATIVE STRESS. © 2022 NATIONAL INFORMATION AND DOCUMENTATION CENTER (NIDOC).","DYSLIPIDEMIA; LIVER HISTOPATHOLOGY; MALONDIALDEHYDE; POLICOSANOL MIXTURE; RATS; TETRACOSANOL; TRITON X-100","","NATIONAL RESEARCH CENTRE, NRC","THIS WORK WAS IMPLEMENTED IN NUTRITION AND FOOD SCIENCES DEPARTMENT, NATIONAL RESEARCH CENTRE, EGYPT.","NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), THIRD REPORT, CIRCULATION, 106, PP. 3143-421, (2002); TEN KATE G.R., BOS S., DEDIC A., NEEFJES L.A., KURATA A., LANGENDONK J.G., LIEM A., MOELKER A., KRESTIN G.P., DE FEYTER P.J., VAN LENNEP J.E.R., NIEMAN K, SIJBRANDS E.J., INCREASED AORTIC VALVE CALCIFICATION IN FAMILIAL HYPERCHOLESTEROLEMIA: PREVALENCE, EXTENT, AND ASSOCIATED RISK FACTORS, J AM COLL CARDIOL, 66, 24, PP. 2687-2695, (2015); KATZ J., CHAUSHU G., SHARABI Y., ON THE ASSOCIATION BETWEEN HYPERCHOLESTEROLEMIA, CARDIOVASCULAR DISEASE AND SEVERE PERIODONTAL DISEASE, J CLIN PERIODONTOL, 28, 9, PP. 865-868, (2001); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); JACKSON M.A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYZED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, J SUPERCRIT FLUIDS, 37, PP. 173-177, (2006); AL-OKBI S.Y., AMMAR N.M., MOHAMED D.A., HAMED I.M., DESOKY A.H., EL-BAKRY H.F., HELAL A.M., EGYPTIAN RICE BRAN OIL: CHEMICAL ANALYSIS OF THE MAIN PHYTOCHEMICALS, LA RIVISTA ITALIANA DELLE SOSTANZE GRASSE, 91, 1, PP. 47-58, (2014); MONTSERRAT DE LA PAZ S., GARCIA-GIMENEZ M.D., ANGEL-MARTIN M., PEREZ-CAMINO M.C., FERNANDEZ ARCHE A., LONG-CHAIN FATTY ALCOHOLS FROM EVENING PRIMROSE OIL INHIBIT THE INFLAMMATORY RESPONSE IN MURINE PERITONEAL MACROPHAGES, J ETHNOPHARMACOL, 151, PP. 131-136, (2014); GRANJA A.L., HERNANDEZ J.M., QUINTANA D.C., VALMANA L.A., FERREIRO R.M., MESA MG., MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOL, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACEUTICAL USES, (1999); KATZ D., (1989); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); VERGARA M., OLIVARES A., ALTAMIRANO C., ANTIPROLIFERATIVE EVALUATION OF TALL-OIL DOCOSANOL AND TETRACOSANOL OVER CHO-K1 AND HUMAN MELANOMA CELLS, ELECTRONIC JOURNAL OF BIOTECHNOLOGY, 18, PP. 291-294, (2015); MAKHAFOLA T.J., ELGORASHI E.E., MCGAW L.J., AWOUAFACK M.D., VERSCHAEVE L., ELOFF J.N., ISOLATION AND CHARACTERIZATION OF THE COMPOUNDS RESPONSIBLE FOR THE ANTIMUTAGENIC ACTIVITY OF COMBRETUM MICROPHYLLUM (COMBRETACEAE) LEAF EXTRACTS, BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 17, (2017); HSU C.Y., SHIH H.Y., CHANG Y.C., HUANG Z.L., TSAI M.J., CHIA Y.C., CHEN C., LAI Y.K., WENG C.F., THE BENEFICIAL EFFECTS OF TETRACOSANOL ON INSULIN-RESISTANCE BY INSULIN RECEPTOR KINASE SENSIBILISATION, JOURNAL OF FUNCTIONAL FOODS, 14, PP. 174-182, (2015); AMMAR H.O., AL-OKBI S.Y., MOSTAFA D.M., HELAL A.M., RICE BRAN OIL: PREPARATION AND EVALUATION OF NOVEL LIQUISOLID AND SEMISOLID FORMULATIONS, INTERNATIONAL JOURNAL OF PHARMACEUTICAL COMPOUNDING, 16, 6, PP. 516-523, (2012); AL-OKBI S.Y., MOHAMED D.A., HAMED T.E., ESMAIL R.S.H., RICE BRAN OIL AND PUMPKIN SEED OIL ALLEVIATE OXIDATIVE INJURY AND FATTY LIVER IN RATS FED HIGH FRUCTOSE DIET, POLISH JOURNAL OF FOOD AND NUTRITION SCIENCES, 64, 2, PP. 127-133, (2014); AL-OKBI S.Y., MOHAMED D.A., HAMED T.E., AL-SIEDY E.S.K., RICE BRAN AS SOURCE OF NUTRACEUTICALS FOR MANAGEMENT OF CARDIOVASCULAR DISEASES, CARDIO-RENAL SYNDROME AND HEPATIC CANCER, J HERBMED PHARMACOL, 9, 1, PP. 68-74, (2020); NAM D-E., YUN J.M., KIM D., KIM O.K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J MED FOOD, 22, 11, PP. 1110-1117, (2019); GUNDAMARAJU R., HWI K.K., SINGLA R.K., VEMURI R.C., MULAPALLI SB., ANTIHYPERLIPIDEMIC POTENTIAL OF ALBIZIA AMARA (ROXB) BOIV. BARK AGAINST TRITON X-100 INDUCED HYPERLIPIDEMIC CONDITION IN RATS, PHARMACOGNOSY RES, 6, 4, PP. 267-273, (2014); RICHMOND W., PREPARATION AND PROPERTIES OF A CHOLESTEROL OXIDASE FROM NOCARDIA SP. AND ITS APPLICATION TO THE ENZYMATIC ASSAY OF TOTAL CHOLESTEROL IN SERUM, CLIN CHEM, 19, 12, PP. 1350-1356, (1973); LOPES-VIRELLA M. F., STONE P., ELLIS S., COLWELL J.A., CHOLESTEROL DETERMINATION IN HIGH-DENSITY LIPOPROTEINS SEPARATED BY THREE DIFFERENT METHODS, CLIN CHEM, 23, 5, PP. 882-884, (1977); BUCOLO G., DAVID H., QUANTITATIVE DETERMINATION OF SERUM TRIGLYCERIDES BY THE USE OF ENZYMES, CLIN CHEM, 19, 5, PP. 476-482, (1973); SCHRIEWER H., KOHNERT U., ASSMANN G., DETERMINATION OF LDL CHOLESTEROL AND LDL APOLIPOPROTEIN B FOLLOWING PRECIPITATION OF VLDL IN BLOOD SERUM WITH PHOSPHOTUNGSTIC ACID/MGCL2, J CLIN CHEM CLIN BIOCHEM, 22, 1, PP. 35-40, (1984); SATOH K., SERUM LIPID PEROXIDE IN CEREBROVASCULAR DISORDERS DETERMINED BY A NEW COLORIMETRIC METHOD, CLIN CHIM ACTA, 90, 1, PP. 37-43, (1978); REITMAN S., FRANKEL S., A COLORIMETRIC METHOD FOR THE DETERMINATION OF SERUM GLUTAMIC OXALACETIC AND GLUTAMIC PYRUVIC TRANSAMINASES, AM J CLIN PATHOL, 28, 1, PP. 56-63, (1957); BANCROFT J.D., GAMBLE M., THEORY AND PRACTICE OF HISTOLOGICAL TECHNIQUES, (2008); KELLNER A., CORRELL J.W., LADD A.T., SUSTAINED HYPERLIPEMIA INDUCED IN RABBITS BY MEANS OF INTRAVENOUSLY INJECTED SURFACE-ACTIVE AGENTS, J EXP MED, 93, PP. 373-384, (1951); OTWAY S., ROBINSON D.S., THE EFFECT OF A NON-IONIC DETERGENT (TRITON WR 1339) ON THE REMOVAL OF TRIGLYCERIDE FATTY ACIDS FROM THE BLOOD OF THE RAT, J PHYSIOL, 190, PP. 309-319, (1967); MOSS J.N., DAJANI E.Z., ANTIHYPERLIPIDEMIC AGENTS IN SCREENING METHODS IN PHARMACOLOGY, (1971); KOYAMA H., MAENO T., FUKUMOTO S., SHOJI T., YAMANE T., YOKOYAMA H., EMOTO M., SHOJI T., TAHARA H., INABA M., HINO M., SHIOI A., MIKI T., NISHIZAWA Y., PLATELET P-SELECTIN EXPRESSION IS ASSOCIATED WITH ATHEROSCLEROTIC WALL THICKNESS IN CAROTID ARTERY IN HUMANS, CIRCULATION, 108, PP. 524-529, (2003); HOFMANN A.F., BILE ACIDS: THE GOOD, THE BAD, AND THE UGLY, NEWS PHYSIOL SCI, 14, PP. 24-29, (1999); GALLAHER C.M., MUNION J., HESSLINK R., WISE J., GALLAHER DD., CHOLESTEROL REDUCTION BY GLUCOMANNAN AND CHITOSAN IS MEDIATED BY CHANGES IN CHOLESTEROL ABSORPTION AND BILE ACID AND FAT EXCRETION IN RATS, J NUTR, 130, PP. 2753-2759, (2000); SINGH UN, KUMAR S, DHAKAL S., STUDY OF OXIDATIVE STRESS IN HYPERCHOLESTEROLEMIA, INTERNATIONAL JOURNAL OF CONTEMPORARY MEDICAL RESEARCH, 4, 5, PP. 1204-1207, (2017); ENGLEMAN B., CHANGES OF MEMBRANE PHOSPHOLIPIDS COMPOSITION OF HUMAN ERYTHROCYTES IN HYPERLIPIDEMIA. INCREASED PHOSPHATIDYLCHOLINE AND REDUCED SPHINGOMYELIN IN PATIENTS WITH ELEVATED LEVELS OF TRIACYLGLYCEROL RICH LIPOPROTEINS, BIOCHEM BIOPHYS ACTA, 1165, PP. 32-37, (1992); LUDWIG P.W., INCREASED LEUKOCYTE OXIDATIVE METABOLISM IN HYPERLIPOPROTEINEMIA, LANCET, 2, 8294, PP. 348-350, (1982); DAVEY M.W., STALS E., PANIS B., KEULEMANS J., SWENNEN R.L., HIGH THROUGHPUT DETERMINATION OF MALONDIALDEHYDE IN PLANT TISSUES, ANALYTICAL BIOCHEMISTRY, 347, PP. 201-207, (2005); DEL RIO D., STEWART A.J., PELLEGRINI N., A REVIEW OF RECENT STUDIES ON MALONDIALDEHYDE AS TOXIC MOLECULE AND BIOLOGICAL MARKER OF OXIDATIVE STRESS, NUTR METAB CARDIOVASC DIS, 15, 4, PP. 316-328, (2005); DINIZ Y.S., FERNANDES A.A.H., CAMPUS K.E., MANI F., RIBAS B.O., NOVELLI E.L.B., TOXICITY OF HYPERCALORIC DIET AND MONOSODIUM GLUTAMATE OXIDATIVE STRESS AND METABOLIC SHIFTING IN HEPATIC TISSUE, FOOD CHEM TOXICOL, 42, 2, PP. 313-319, (2004); MORIS D., SPARTALIS M., TZATZAKI E., SPARTALIS E., KARACHALIOU G-S., TRIANTAFYLLIS A.S., KARAOLANIS G.I., TSILIMIGRAS D.I., THEOCHARIS S., THE ROLE OF REACTIVE OXYGEN SPECIES IN MYOCARDIAL REDOX SIGNALING AND REGULATION, ANNALS OF TRANSLATIONAL MEDICINE, 5, 16, (2017); AL-OKBI S.Y., MOHAMED D.A., HAMED T.E., EDRIS A.E., POTENTIAL PROTECTIVE EFFECT OF NIGELLA SATIVA CRUDE OILS TOWARDS FATTY LIVER IN RATS, EUR J LIPID SCI TECHNOL, 115, PP. 774-782, (2013); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS IN HEALTH AND DISEASE, 17, 1, (2018)","S.Y. AL-OKBI; NUTRITION AND FOOD SCIENCES DEPARTMENT, NATIONAL RESEARCH CENTRE, CAIRO, EGYPT; EMAIL: S_Y_ALOKBI@HOTMAIL.COM","NIDOC (NAT.INFORM.DOCUMENT.CENTRE)","ENGLISH","EGYPT. J. CHEM.","ARTICLE","ISI","2-S2.0-85140877178","EGYPT J CHEM","NUTRITION AND FOOD SCIENCES DEPARTMENT;NUTRITION AND FOOD SCIENCES DEPARTMENT","NOTREPORTED;NUTRITION AND FOOD SCIENCES DEPARTMENT;NOTREPORTED",NA,"AL-OKBI SY, 2022, EGYPT J CHEM","AL-OKBI SY, 2022, EGYPT J CHEM"
"SADEGHI-DEHSAHRAEI H;ESMAEILI G G H;MIRNEJAD R;PARASTOUEI K","SADEGHI-DEHSAHRAEI, HAMED (57929489100); ESMAEILI GOUVARCHIN GHALEH, HADI (57201457215); MIRNEJAD, REZA (55936169200); PARASTOUEI, KARIM (14012236000)","THE EFFECT OF BERGAMOT KOKSALGARRY SUPPLEMENTATION ON LIPID PROFILES A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2022,"PHYTOTHERAPY RESEARCH","36","15",3,"10.1002/ptr.7647","DEPARTMENT OF BASIC SCIENCES, SCHOOL OF VETERINARY MEDICINE, SHIRAZ UNIVERSITY, SHIRAZ, IRAN;APPLIED VIROLOGY RESEARCH CENTER, BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN;MOLECULAR BIOLOGY RESEARCH CENTER, SYSTEM BIOLOGY AND POISONING INSTITUTE, BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN;HEALTH RESEARCH CENTER, LIFE STYLE INSTITUTE, BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN","THIS SYSTEMATIC REVIEW AND META-ANALYSIS WERE CONDUCTED TO EVALUATE THE IMPACT OF BERGAMOT (KOKSALGARRY) AND ITS NUTRACEUTICAL COMPOUNDS ON LIPID PROFILES. PUBMED, WEB OF KNOWLEDGE, SCOPUS, AND GOOGLE SCHOLAR SEARCHED FOR RELEVANT ARTICLES. TRIALS INVESTIGATING THE EFFECT OF ORAL BERGAMOT SUPPLEMENTATION ON SERUM LEVELS OF TOTAL CHOLESTEROL (TC), TRIGLYCERIDE (TG), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) IN ADULTS WERE INCLUDED. THE MEAN DIFFERENCES AND STANDARD DEVIATIONS WERE POOLED USING A RANDOM-EFFECTS MODEL. FOURTEEN TRIALS WERE INCLUDED IN THIS SYSTEMATIC REVIEW AND META-ANALYSIS. BERGAMOT SUPPLEMENTATION SIGNIFICANTLY DECREASED SERUM LEVELS OF TC (WEIGHTED MEAN DIFFERENCE (WMD): −63.60 MG/DL; 95% CI: −78.03 TO −49.18; P <.001), TG (WMD: −74.72 MG/DL; 95% CI: −83.58 TO −65.87; P <.001), LDL-C (WMD: −55.43 MG/DL; 95% CI: −67.26 TO −43.60; P <.001), AND INCREASED HDL-C (WMD: 5.78 MG/DL; 95% CI: 3.27 TO 8.28; P <.001), RESPECTIVELY. OUR SYSTEMATIC REVIEW OF THE EFFECTS OF NUTRACEUTICALS CONTAINING BERGAMOT ON LIPID MARKERS SHOWED INCONSISTENT RESULTS. THE RESULTS SHOWED THAT BERGAMOT SUPPLEMENTATION MIGHT IMPROVE LIPID PROFILES. THE FINDINGS FOR NUTRACEUTICAL COMPOUNDS CONTAINING BERGAMOT WERE INCONSISTENT. HOWEVER, THE CLINICAL EFFICACY OF BERGAMOT ON LIPID PROFILES NEEDS TO BE FURTHER ESTABLISHED THROUGH HIGHER-QUALITY STUDIES. © 2022 JOHN WILEY & SONS LTD.","BERGAMOT; KOKSALGARRY; LIPID PROFILE; META-ANALYSIS; SYSTEMATIC REVIEW","CHOLESTEROL, LDL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ARTICHOKE EXTRACT; ASCORBIC ACID; ASTAXANTHIN; BERBAMOT EXTRACT; BERBERINE; BERGAMOT EXTRACT; CHOLESTEROL; CHOLESTIN; CHROMIUM DERIVATIVE; EURYCOMA LONGIFOLIA EXTRACT; FENUGREEK EXTRACT; FOLIC ACID; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; OLIVE LEAF EXTRACT; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; PLANT EXTRACT; POLICOSANOL; SIMVASTATIN; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MEDICAL RESEARCH; MEDITERRANEAN DIET; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL","","","ALISSA E.M., FERNS G.A., FUNCTIONAL FOODS AND NUTRACEUTICALS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES, JOURNAL OF NUTRITION AND METABOLISM, 2012, (2012); ALSHEIKH-ALI A.A., KARAS R.H., THE RELATIONSHIP OF STATINS TO RHABDOMYOLYSIS, MALIGNANCY, AND HEPATIC TOXICITY: EVIDENCE FROM CLINICAL TRIALS, CURRENT ATHEROSCLEROSIS REPORTS, 11, 2, PP. 100-104, (2009); ARCUSA R., CARRILLO J.A., XANDRI-MARTINEZ R., CERDA B., VILLANO D., MARHUENDA J., ZAFRILLA M.P., EFFECTS OF A FRUIT AND VEGETABLE-BASED NUTRACEUTICAL ON BIOMARKERS OF INFLAMMATION AND OXIDATIVE STATUS IN THE PLASMA OF A HEALTHY POPULATION: A PLACEBO-CONTROLLED, DOUBLE-BLIND, AND RANDOMIZED CLINICAL TRIAL, MOLECULES, 26, 12, (2021); ATHYROS G.V., TZIOMALOS K., KARAGIANNIS A., P MIKHAILIDIS D.P., HYPOLIPIDAEMIC DRUG TREATMENT: YESTERDAY IS NOT GONE YET, TODAY IS CHALLENGING AND TOMORROW IS COMING SOON; LET US COMBINE THEM ALL, CURRENT PHARMACEUTICAL DESIGN, 20, 40, PP. 6350-6357, (2014); BAIGENT C., CHOLESTEROL TREATMENT TRIALISTS'(CTT) COLLABORATORS: EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMIZED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); BENAVENTE-GARCIA O., CASTILLO J., UPDATE ON USES AND PROPERTIES OF CITRUS FLAVONOIDS: NEW FINDINGS IN ANTICANCER, CARDIOVASCULAR, AND ANTI-INFLAMMATORY ACTIVITY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 56, 15, PP. 6185-6205, (2008); BOK S.-H., LEE S.-H., PARK Y.-B., BAE K.-H., SON K.-H., JEONG T.-S., CHOI M.-S., PLASMA AND HEPATIC CHOLESTEROL AND HEPATIC ACTIVITIES OF 3-HYDROXY-3-METHYL-GLUTARYL-COA REDUCTASE AND ACYL COA: CHOLESTEROL TRANSFERASE ARE LOWER IN RATS FED CITRUS PEEL EXTRACT OR A MIXTURE OF CITRUS BIOFLAVONOIDS, THE JOURNAL OF NUTRITION, 129, 6, PP. 1182-1185, (1999); BORENSTEIN M., HEDGES L.V., HIGGINS J.P., ROTHSTEIN H.R., INTRODUCTION TO META-ANALYSIS, (2021); BRUNO A., PANDOLFO G., CRUCITTI M., CACCIOLA M., SANTORO V., SPINA E., MUSCATELLO M.R., LOW-DOSE OF BERGAMOT-DERIVED POLYPHENOLIC FRACTION (BPF) DID NOT IMPROVE METABOLIC PARAMETERS IN SECOND GENERATION ANTIPSYCHOTICS-TREATED PATIENTS: RESULTS FROM A 60-DAYS OPEN-LABEL STUDY, FRONTIERS IN PHARMACOLOGY, 8, (2017); BRUNO A., ZOCCALI R.A., PANDOLFO G., CEDRO C., GUARNA C., MUSCATELLO M.R.A., BERGAMOT POLYPHENOLIC FRACTION FOR THE TREATMENT OF METABOLIC SYNDROME IN SCHIZOPHRENIA: A PILOT STUDY, RIVISTA DI PSICHIATRIA, 53, 5, PP. 256-260, (2018); CAI G., SHI G., XUE S., LU W., THE ATHEROGENIC INDEX OF PLASMA IS A STRONG AND INDEPENDENT PREDICTOR FOR CORONARY ARTERY DISEASE IN THE CHINESE HAN POPULATION, MEDICINE, 96, 37, (2017); CAI Y., XING G., SHEN T., ZHANG S., RAO J., SHI R., EFFECTS OF 12-WEEK SUPPLEMENTATION OF CITRUS BERGAMIA EXTRACTS-BASED FORMULATION CITRICHOLESS ON CHOLESTEROL AND BODY WEIGHT IN OLDER ADULTS WITH DYSLIPIDEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, LIPIDS IN HEALTH AND DISEASE, 16, 1, PP. 1-13, (2017); CAMPOLONGO G., RICCIONI C.V., RAPARELLI V., SPOLETINI I., MARAZZI G., VITALE C., VOLTERRANI M., THE COMBINATION OF NUTRACEUTICAL AND SIMVASTATIN ENHANCES THE EFFECT OF SIMVASTATIN ALONE IN NORMALIZING LIPID PROFILE WITHOUT SIDE EFFECTS IN PATIENTS WITH ISCHEMIC HEART DISEASE, IJC METABOLIC & ENDOCRINE, 11, PP. 3-6, (2016); CAPOMOLLA A.S., JANDA E., PAONE S., PARAFATI M., SAWICKI T., MOLLACE R., MOLLACE V., ATHEROGENIC INDEX REDUCTION AND WEIGHT LOSS IN METABOLIC SYNDROME PATIENTS TREATED WITH A NOVEL PECTIN-ENRICHED FORMULATION OF BERGAMOT POLYPHENOLS, NUTRIENTS, 11, 6, (2019); CHA J.-Y., CHO Y.-S., KIM I., ANNO T., RAHMAN S., YANAGITA T., EFFECT OF HESPERETIN, A CITRUS FLAVONOID, ON THE LIVER TRIACYLGLYCEROL CONTENT AND PHOSPHATIDATE PHOSPHOHYDROLASE ACTIVITY IN OROTIC ACID-FED RATS, PLANT FOODS FOR HUMAN NUTRITION, 56, 4, PP. 349-358, (2001); CHIU H.-F., SHEN Y.-C., VENKATAKRISHNAN K., WANG C.-K., POPULAR FUNCTIONAL FOODS AND NUTRACEUTICALS WITH LIPID LOWERING ACTIVITY AND IN RELATION TO CARDIOVASCULAR DISEASE, DYSLIPIDEMIA, AND RELATED COMPLICATIONS: AN OVERVIEW, JOURNAL OF FOOD BIOACTIVES, 2, PP. 16-27, (2018); CICERO A.F.G., FOGACCI F., BOVE M., GIOVANNINI M., BORGHI C., THREE-ARM, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL EVALUATING THE METABOLIC EFFECT OF A COMBINED NUTRACEUTICAL CONTAINING A BERGAMOT STANDARDIZED FLAVONOID EXTRACT IN DYSLIPIDEMIC OVERWEIGHT SUBJECTS, PHYTOTHERAPY RESEARCH, 33, 8, PP. 2094-2101, (2019); DAHLBERG C.J., OU J.J., BABISH J.G., LAMB J.J., ELIASON S., BRABAZON H., TRIPP M.L., A 13-WEEK LOW GLYCEMIC LOAD DIET AND LIFESTYLE MODIFICATION PROGRAM COMBINING LOW GLYCEMIC LOAD PROTEIN SHAKES AND TARGETED NUTRACEUTICALS IMPROVED WEIGHT LOSS AND CARDIO-METABOLIC RISK FACTORS, CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 95, 12, PP. 1414-1425, (2017); DERSIMONIAN R., KACKER R., RANDOM-EFFECTS MODEL FOR META-ANALYSIS OF CLINICAL TRIALS: AN UPDATE, CONTEMPORARY CLINICAL TRIALS, 28, 2, PP. 105-114, (2007); DI DONNA L., DE LUCA G., MAZZOTTI F., NAPOLI A., SALERNO R., TAVERNA D., SINDONA G., STATIN-LIKE PRINCIPLES OF BERGAMOT FRUIT (CITRUS BERGAMIA): ISOLATION OF 3-HYDROXYMETHYLGLUTARYL FLAVONOID GLYCOSIDES, JOURNAL OF NATURAL PRODUCTS, 72, 7, PP. 1352-1354, (2009); DI DONNA L., IACOPETTA D., CAPPELLO A.R., GALLUCCI G., MARTELLO E., FIORILLO M., SINDONA G., HYPOCHOLESTEROLAEMIC ACTIVITY OF 3-HYDROXY-3-METHYL-GLUTARYL FLAVANONES ENRICHED FRACTION FROM BERGAMOT FRUIT (CITRUS BERGAMIA):“IN VIVO” STUDIES, JOURNAL OF FUNCTIONAL FOODS, 7, PP. 558-568, (2014); DI FOLCO U., POLLAKOVA D., DE FALCO D., NARDONE M.R., TUBILI F., TUBILI C., EFFECTS OF A NUTRACEUTICAL MULTICOMPOUND INCLUDING BERGAMOT (CITRUS BERGAMIA RISSO) JUICE ON METABOLIC SYNDROME: A PILOT STUDY, MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM, 11, 2, PP. 119-126, (2018); FARRAS M., VALLS R.M., FERNANDEZ-CASTILLEJO S., GIRALT M., SOLA R., SUBIRANA I., FITO M., OLIVE OIL POLYPHENOLS ENHANCE THE EXPRESSION OF CHOLESTEROL EFFLUX RELATED GENES IN VIVO IN HUMANS. A RANDOMIZED CONTROLLED TRIAL, THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 24, 7, PP. 1334-1339, (2013); FEDOROV S., GETDATA GRAPH DIGITIZER VERSION 2.24. AVAILABLE AT WWW. GETDATA-GRAPH-DIGITIZER. COM, (2002); FERLAZZO N., CIRMI S., CALAPAI G., VENTURA-SPAGNOLO E., GANGEMI S., NAVARRA M., ANTI-INFLAMMATORY ACTIVITY OF CITRUS BERGAMIA DERIVATIVES: WHERE DO WE STAND?, MOLECULES, 21, 10, (2016); FERRO Y., MONTALCINI T., MAZZA E., FOTI D., ANGOTTI E., GLIOZZI M., AVERSA I., RANDOMIZED CLINICAL TRIAL: BERGAMOT CITRUS AND WILD CARDOON REDUCE LIVER STEATOSIS AND BODY WEIGHT IN NON-DIABETIC INDIVIDUALS AGED OVER 50 YEARS, FRONTIERS IN ENDOCRINOLOGY, 11, (2020); FLORENTIN M., LIBEROPOULOS E., ELISAF M.S., TSIMIHODIMOS V., NO EFFECT OF FENUGREEK, BERGAMOT AND OLIVE LEAF EXTRACT ON GLUCOSE HOMEOSTASIS IN PATIENTS WITH PREDIABETES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY, ARCHIVES OF MEDICAL SCIENCES. ATHEROSCLEROTIC DISEASES, 4, (2019); GARDANA C., NALIN F., SIMONETTI P., EVALUATION OF FLAVONOIDS AND FURANOCOUMARINS FROM CITRUS BERGAMIA (BERGAMOT) JUICE AND IDENTIFICATION OF NEW COMPOUNDS, MOLECULES, 13, 9, PP. 2220-2228, (2008); GIELEN S., SANDRI M., SCHULER G., TEUPSER D., RISK FACTOR MANAGEMENT: ANTIATHEROGENIC THERAPIES, EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 16, PP. S29-S36, (2009); GLIOZZI M., WALKER R., MUSCOLI S., VITALE C., GRATTERI S., CARRESI C., RAGUSA S., BERGAMOT POLYPHENOLIC FRACTION ENHANCES ROSUVASTATIN-INDUCED EFFECT ON LDL-CHOLESTEROL, LOX-1 EXPRESSION AND PROTEIN KINASE B PHOSPHORYLATION IN PATIENTS WITH HYPERLIPIDEMIA, INTERNATIONAL JOURNAL OF CARDIOLOGY, 170, 2, PP. 140-145, (2013); GORINSTEIN S., LEONTOWICZ H., LEONTOWICZ M., KRZEMINSKI R., GRALAK M., MARTIN-BELLOSO O., PARK Y.-S., FRESH ISRAELI JAFFA BLOND (SHAMOUTI) ORANGE AND ISRAELI JAFFA RED STAR RUBY (SUNRISE) GRAPEFRUIT JUICES AFFECT PLASMA LIPID METABOLISM AND ANTIOXIDANT CAPACITY IN RATS FED ADDED CHOLESTEROL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 52, 15, PP. 4853-4859, (2004); GUYATT G.H., OXMAN A.D., VIST G.E., KUNZ R., FALCK-YTTER Y., ALONSO-COELLO P., SCHUNEMANN H.J., GRADE: AN EMERGING CONSENSUS ON RATING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS, BMJ, 336, 7650, PP. 924-926, (2008); HANCKE J., SRIVASTAVA S., CACERES D.D., BURGOS R.A., ALARCON P., AN EXPLORATORY DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY OF CITRUSLIM ON BODY COMPOSITION AND LIPID PARAMETERS IN OBESE INDIVIDUALS, PHYTOTHERAPY RESEARCH, 35, 12, (2021); HIGGINS J.P., THOMPSON S.G., QUANTIFYING HETEROGENEITY IN A META-ANALYSIS, STATISTICS IN MEDICINE, 21, 11, PP. 1539-1558, (2002); HOZO S.P., DJULBEGOVIC B., HOZO I., ESTIMATING THE MEAN AND VARIANCE FROM THE MEDIAN, RANGE, AND THE SIZE OF A SAMPLE, BMC MEDICAL RESEARCH METHODOLOGY, 5, 1, PP. 1-10, (2005); IMAFIDON K., AMAECHINA F., EFFECTS OF AQUEOUS SEED EXTRACT OF PERSEA AMERICANA MILL.(AVOCADO) ON BLOOD PRESSURE AND LIPID PROFILE IN HYPERTENSIVE RATS, ADV BIOLOGICAL RESEARCH, 4, 2, PP. 116-121, (2010); INTHOUT J., IOANNIDIS J., BORM G.F., THE HARTUNG-KNAPP-SIDIK-JONKMAN METHOD FOR RANDOM EFFECTS META-ANALYSIS IS STRAIGHTFORWARD AND CONSIDERABLY OUTPERFORMS THE STANDARD DERSIMONIAN-LAIRD METHOD, BMC MEDICAL RESEARCH METHODOLOGY, 14, 1, PP. 1-12, (2014); IZZO A., DA ARIENZO M., SERGIACOMI P., MARRESE C., BONUCCI M., RICCIONI C., PROSPECTIVE OBSERVATIONAL STUDY: THE ROLE OF A BERGAMOT BASED NUTRACEUTICAL IN DYSLIPIDAEMIA AND ARTHRALGIA FOR SUBJECTS UNDERGOING AROMATASE INHIBITORS BASED THERAPY, ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2017, 7, (2017); IZZO A.A., HOON-KIM S., RADHAKRISHNAN R., WILLIAMSON E.M., A CRITICAL APPROACH TO EVALUATING CLINICAL EFFICACY, ADVERSE EVENTS AND DRUG INTERACTIONS OF HERBAL REMEDIES, PHYTOTHERAPY RESEARCH, 30, 5, PP. 691-700, (2016); JONES P.H., EXPERT PERSPECTIVE: REDUCING CARDIOVASCULAR RISK IN METABOLIC SYNDROME AND TYPE 2 DIABETES MELLITUS BEYOND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING, THE AMERICAN JOURNAL OF CARDIOLOGY, 102, 12, PP. 41L-47L, (2008); KELLEY D.S., ADKINS Y.C., ZUNINO S.J., WOODHOUSE L.R., BONNEL E.L., BREKSA A.P., MACKEY B.E., CITRUS LIMONIN GLUCOSIDE SUPPLEMENTATION DECREASED BIOMARKERS OF LIVER DISEASE AND INFLAMMATION IN OVERWEIGHT HUMAN ADULTS, JOURNAL OF FUNCTIONAL FOODS, 12, PP. 271-281, (2015); KUMAR A., CHAMBERS T., CLOUD-HEFLIN B., MEHTA K., PHORBOL ESTER-INDUCED LOW DENSITY LIPOPROTEIN RECEPTOR GENE EXPRESSION IN HEPG2 CELLS INVOLVES PROTEIN KINASE C-MEDIATED P42/44 MAP KINASE ACTIVATION, JOURNAL OF LIPID RESEARCH, 38, 11, PP. 2240-2248, (1997); LA RUSSA D., GIORDANO F., MARRONE A., PARAFATI M., JANDA E., PELLEGRINO D., OXIDATIVE IMBALANCE AND KIDNEY DAMAGE IN CAFETERIA DIET-INDUCED RAT MODEL OF METABOLIC SYNDROME: EFFECT OF BERGAMOT POLYPHENOLIC FRACTION, ANTIOXIDANTS, 8, 3, (2019); LANDI F., MARTONE A.M., SALINI S., ZAZZARA B., CALVANI R., MARZETTI E., SANTORO L., EFFECTS OF A NEW COMBINATION OF MEDICAL FOOD ON ENDOTHELIAL FUNCTION AND LIPID PROFILE IN DYSLIPIDEMIC SUBJECTS: A PILOT RANDOMIZED TRIAL, BIOMED RESEARCH INTERNATIONAL, 2019, (2019); LEOPOLDINI M., MALAJ N., TOSCANO M., SINDONA G., RUSSO N., ON THE INHIBITOR EFFECTS OF BERGAMOT JUICE FLAVONOIDS BINDING TO THE 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGR) ENZYME, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, 19, PP. 10768-10773, (2010); LI X.-J., ZHU Z., HAN S.-L., ZHANG Z.-L., BERGAPTEN EXERTS INHIBITORY EFFECTS ON DIABETES-RELATED OSTEOPOROSIS VIA THE REGULATION OF THE PI3K/AKT, JNK/MAPK AND NF-ΚB SIGNALING PATHWAYS IN OSTEOPROTEGERIN KNOCKOUT MICE, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 38, 6, PP. 1661-1672, (2016); MARE R., MAZZA E., FERRO Y., GLIOZZI M., NUCERA S., PAONE S., MUSOLINO V., A NEW BREAKFAST BRIOCHE CONTAINING BERGAMOT FIBER PREVENTS INSULIN AND GLUCOSE INCREASE IN HEALTHY VOLUNTEERS: A PILOT STUDY, MINERVA ENDOCRINOLOGICA, 46, 2, (2020); MAZIDI M., KATSIKI N., MIKHAILIDIS D.P., BANACH M., ASSOCIATION OF IDEAL CARDIOVASCULAR HEALTH METRICS WITH SERUM URIC ACID, INFLAMMATION AND ATHEROGENIC INDEX OF PLASMA: A POPULATION-BASED SURVEY, ATHEROSCLEROSIS, 284, PP. 44-49, (2019); MOHER D., ALTMAN D.G., LIBERATI A., TETZLAFF J., PRISMA STATEMENT, EPIDEMIOLOGY, 22, 1, (2011); MOLLACE V., SACCO I., JANDA E., MALARA C., VENTRICE D., COLICA C., MUSCOLI C., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, 3, PP. 309-316, (2011); MOLLACE V., SCICCHITANO M., PAONE S., CASALE F., CALANDRUCCIO C., GLIOZZI M., NUCERA S., HYPOGLYCEMIC AND HYPOLIPEMIC EFFECTS OF A NEW LECITHIN FORMULATION OF BERGAMOT POLYPHENOLIC FRACTION: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, ENDOCRINE, METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (FORMERLY CURRENT DRUG TARGETS-IMMUNE, ENDOCRINE & METABOLIC DISORDERS), 19, 2, PP. 136-143, (2019); MUSOLINO V., GLIOZZI M., CARRESI C., MAIUOLO J., MOLLACE R., BOSCO F., PALMA E., LIPID-LOWERING EFFECT OF BERGAMOT POLYPHENOLIC FRACTION: ROLE OF PANCREATIC CHOLESTEROL ESTER HYDROLASE, JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 31, 4, PP. 1087-1093, (2017); NELSON R.H., HYPERLIPIDEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE, PRIMARY CARE; CLINICS IN OFFICE PRACTICE, 40, 1, PP. 195-211, (2013); ONAKPOYA I., O'SULLIVAN J., HENEGHAN C., THOMPSON M., THE EFFECT OF GRAPEFRUITS (CITRUS PARADISI) ON BODY WEIGHT AND CARDIOVASCULAR RISK FACTORS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 57, 3, PP. 602-612, (2017); PARAFATI M., LASCALA A., LA RUSSA D., MIGNOGNA C., TRIMBOLI F., MORITTU V.M., BRUNELLI E., BERGAMOT POLYPHENOLS BOOST THERAPEUTIC EFFECTS OF THE DIET ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) INDUCED BY “JUNK FOOD”: EVIDENCE FOR ANTI-INFLAMMATORY ACTIVITY, NUTRIENTS, 10, 11, (2018); PARAFATI M., LASCALA A., MORITTU V.M., TRIMBOLI F., RIZZUTO A., BRUNELLI E., EHRLICH J., BERGAMOT POLYPHENOL FRACTION PREVENTS NONALCOHOLIC FATTY LIVER DISEASE VIA STIMULATION OF LIPOPHAGY IN CAFETERIA DIET-INDUCED RAT MODEL OF METABOLIC SYNDROME, THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 26, 9, PP. 938-948, (2015); PERRONE M.A., DONATUCCI B., PIERI M., SALIMEI C., MARINI S., BERNARDINI S., IELLAMO F., THE ANTI-INFLAMMATORY AND ANTIOXIDANT EFFECTS OF BERGAMOT (CITRUS BERGAMIA) IN PROFESSIONAL ATHLETES DURING ENDURANCE TRAINING, ACTA MEDICA MEDITERRANEA, 36, 4, PP. 2491-2497, (2020); PIRRO M., MANNARINO M.R., MINISTRINI S., FALLARINO F., LUPATTELLI G., BIANCONI V., MANNARINO E., EFFECTS OF A NUTRACEUTICAL COMBINATION ON LIPIDS, INFLAMMATION AND ENDOTHELIAL INTEGRITY IN PATIENTS WITH SUBCLINICAL INFLAMMATION: A RANDOMIZED CLINICAL TRIAL, SCIENTIFIC REPORTS, 6, 1, PP. 1-9, (2016); PLA-PAGA L., COMPANYS J., CALDERON-PEREZ L., LLAURADO E., SOLA R., VALLS R., PEDRET A., EFFECTS OF HESPERIDIN CONSUMPTION ON CARDIOVASCULAR RISK BIOMARKERS: A SYSTEMATIC REVIEW OF ANIMAL STUDIES AND HUMAN RANDOMIZED CLINICAL TRIALS, NUTRITION REVIEWS, 77, 12, PP. 845-864, (2019); RICCIONI G., GAMMONE M.A., CURRENTI W., D'ORAZIO N., EFFECTIVENESS AND SAFETY OF DIETETIC SUPPLEMENTATION OF A NEW NUTRACEUTICAL ON LIPID PROFILE AND SERUM INFLAMMATION BIOMARKERS IN HYPERCHOLESTEROLEMIC PATIENTS, MOLECULES, 23, 5, (2018); RONDANELLI M., PERONI G., RIVA A., PETRANGOLINI G., ALLEGRINI P., FAZIA T., TARTARA A., BERGAMOT PHYTOSOME IMPROVED VISCERAL FAT AND PLASMA LIPID PROFILES IN OVERWEIGHT AND OBESE CLASS I SUBJECT WITH MILD HYPERCHOLESTEROLEMIA: A RANDOMIZED PLACEBO CONTROLLED TRIAL, PHYTOTHERAPY RESEARCH, 35, 4, PP. 2045-2056, (2021); SALERNO R., CASALE F., CALANDRUCCIO C., PROCOPIO A., CHARACTERIZATION OF FLAVONOIDS IN CITRUS BERGAMIA (BERGAMOT) POLYPHENOLIC FRACTION BY LIQUID CHROMATOGRAPHY–HIGH RESOLUTION MASS SPECTROMETRY (LC/HRMS), PHARMANUTRITION, 4, PP. S1-S7, (2016); SERBAN M.-C., COLANTONIO L.D., MANTHRIPRAGADA A.D., MONDA K.L., BITTNER V.A., BANACH M., KENT S.T., STATIN INTOLERANCE AND RISK OF CORONARY HEART EVENTS AND ALL-CAUSE MORTALITY FOLLOWING MYOCARDIAL INFARCTION, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69, 11, PP. 1386-1395, (2017); SHI Y.-S., ZHANG Y., LI H.-T., WU C.-H., EL-SEEDI H.R., YE W.-K., KAI G.-Y., LIMONOIDS FROM CITRUS: CHEMISTRY, ANTI-TUMOR POTENTIAL, AND OTHER BIOACTIVITIES, JOURNAL OF FUNCTIONAL FOODS, 75, (2020); TAN C.X., CHONG G.H., HAMZAH H., GHAZALI H.M., EFFECT OF VIRGIN AVOCADO OIL ON DIET-INDUCED HYPERCHOLESTEROLEMIA IN RATS VIA 1 H NMR-BASED METABOLOMICS APPROACH, PHYTOTHERAPY RESEARCH, 32, 11, PP. 2264-2274, (2018); TOTH P.P., PATTI A.M., NIKOLIC D., GIGLIO R.V., CASTELLINO G., BIANCUCCI T., RIZVI A., BERGAMOT REDUCES PLASMA LIPIDS, ATHEROGENIC SMALL DENSE LDL, AND SUBCLINICAL ATHEROSCLEROSIS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA: A 6 MONTHS PROSPECTIVE STUDY, FRONTIERS IN PHARMACOLOGY, 6, (2016); TRIALISTS C.T., EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90 056 PARTICIPANTS IN 14 RANDOMIZED TRIALS OF STATINS, THE LANCET, 366, 9493, PP. 1267-1278, (2005); WILCOX L.J., BORRADAILE N.M., DE DREU L.E., HUFF M.W., SECRETION OF HEPATOCYTE APOB IS INHIBITED BY THE FLAVONOIDS, NARINGENIN AND HESPERETIN, VIA REDUCED ACTIVITY AND EXPRESSION OF ACAT2 AND MTP, JOURNAL OF LIPID RESEARCH, 42, 5, PP. 725-734, (2001); WILLIAMSON E.M., LIU X., IZZO A.A., TRENDS IN USE, PHARMACOLOGY, AND CLINICAL APPLICATIONS OF EMERGING HERBAL NUTRACEUTICALS, BRITISH JOURNAL OF PHARMACOLOGY, 177, 6, PP. 1227-1240, (2020); WU T.-T., GAO Y., ZHENG Y.-Y., MA Y.-T., XIE X., ATHEROGENIC INDEX OF PLASMA (AIP): A NOVEL PREDICTIVE INDICATOR FOR THE CORONARY ARTERY DISEASE IN POSTMENOPAUSAL WOMEN, LIPIDS IN HEALTH AND DISEASE, 17, 1, PP. 1-7, (2018); YU J., WANG L., WALZEM R.L., MILLER E.G., PIKE L.M., PATIL B.S., ANTIOXIDANT ACTIVITY OF CITRUS LIMONOIDS, FLAVONOIDS, AND COUMARINS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 6, PP. 2009-2014, (2005)","K. PARASTOUEI; HEALTH RESEARCH CENTER, LIFE STYLE INSTITUTE, BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, 1435915371, IRAN; EMAIL: PARASTOUEI@GMAIL.COM","JOHN WILEY AND SONS LTD","ENGLISH","PHYTOTHER. RES.","REVIEW","ISI","2-S2.0-85139974360","PHYTOTHER RES","SHIRAZ UNIVERSITY;BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES;BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES;BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"SADEGHI-DEHSAHRAEI H, 2022, PHYTOTHER RES","SADEGHI-DEHSAHRAEI H, 2022, PHYTOTHER RES"
"CHO K;KIM J;NAM H;BAEK S;BAHUGUNA A","CHO, KYUNG-HYUN (7403956966); KIM, JI-EUN (57881093800); NAM, HYO-SEON (57301198400); BAEK, SEUNG-HEE (58120142000); BAHUGUNA, ASHUTOSH (35224624000)","CONSUMPTION OF POLICOSANOL RAYDEL IMPROVES HEPATIC RENAL AND REPRODUCTIVE FUNCTIONS IN ZEBRAFISH IN VIVO COMPARISON STUDY AMONG CUBAN CHINESE AND AMERICAN POLICOSANOL",2024,"PHARMACEUTICALS","17","",2,"10.3390/ph17010066","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DONG-GU, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DONG-GU, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DONG-GU, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DONG-GU, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DONG-GU, DAEGU, 41061, SOUTH KOREA","THE CURRENT STUDY COMPARED THREE POLICOSANOLS FROM CUBA (SUGARCANE, RAYDEL®, POLICOSANOL (1), CHINA (RICE BRAN, SHAANXI, POLICOSANOL (2), AND THE USA (SUGARCANE, LESSTANOL®, POLICOSANOL (3) IN THE TREATMENT OF DYSLIPIDEMIA AND PROTECTION OF THE LIVER, OVARY, AND TESTIS IN HYPERCHOLESTEROLEMIC ZEBRAFISH. AFTER TWELVE WEEKS OF SUPPLEMENTATION OF EACH POLICOSANOL (PCO, FINAL 0.1% IN DIET, W/W) WITH A HIGH CHOLESTEROL DIET (HCD, FINAL 4%, W/W), THE RAYDEL POLICOSANOL (PCO1) GROUP SHOWED THE HIGHEST SURVIVABILITY, APPROXIMATELY 89%. IN CONTRAST, SHAANXI POLICOSANOL (PCO2) AND LESSTANOL POLICOSANOL (PCO3) PRODUCED 73% AND 87% SURVIVABILITY, RESPECTIVELY, WHILE THE HCD ALONE GROUP SHOWED 75% SURVIVABILITY. IN THE 12TH WEEK, THE PCO1 GROUP DEMONSTRATED THE MOST MODEST INCREASE IN BODY WEIGHT ALONG WITH SIGNIFICANTLY LOWER LEVELS OF TOTAL CHOLESTEROL (TC) AND TRIGLYCERIDES (TG) IN COMPARISON TO THE HCD CONTROL GROUP. ADDITIONALLY, THE PCO1 GROUP EXHIBITED THE HIGHEST PROPORTION OF HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL WITHIN TC. NOTABLY, THE PCO1 GROUP DISPLAYED THE LOWEST LEVEL OF ASPARTATE AMINOTRANSFERASE AND ALANINE AMINOTRANSFERASE, MINIMAL INFILTRATION OF INFLAMMATORY CELLS, REDUCED INTERLEUKIN (IL)-6 PRODUCTION IN THE LIVER, A NOTABLE DECLINE IN REACTIVE OXYGEN SPECIES (ROS) GENERATION AND MITIGATED FATTY LIVER CHANGES. HCD SUPPLEMENTATION INDUCED IMPAIRMENT OF KIDNEY MORPHOLOGY WITH THE GREATEST EXTENT OF ROS PRODUCTION AND APOPTOSIS. ON THE OTHER HAND, THE PCO 1 GROUP SHOWED A REMARKABLY IMPROVED MORPHOLOGY WITH THE LEAST ROS GENERATION AND APOPTOSIS. WITHIN THE OVARIAN CONTEXT, THE PCO1 GROUP EXHIBITED THE MOST SUBSTANTIAL PRESENCE OF MATURE VITELLOGENIC OOCYTES, ACCOMPANIED BY MINIMAL LEVELS OF ROS AND APOPTOSIS. SIMILARLY, IN THE TESTICULAR DOMAIN, THE PCO1 GROUP SHOWCASED OPTIMAL MORPHOLOGY FOR SPERMATOGENESIS, CHARACTERIZED BY THE LEAST INTERSTITIAL AREA AND DIMINISHED PRODUCTION OF ROS IN TESTICULAR CELLS. AT WEEK 8, THE PCO1 GROUP SHOWED THE HIGHEST EGG-LAYING ABILITY, WITH AROUND 244 EGGS PRODUCED PER MATING. IN CONTRAST, THE HCD ALONE, PCO2, AND PCO3 GROUPS SHOWED SIGNIFICANTLY LOWER EGG-LAYING ABILITY (49, 59, AND 86 EGGS, RESPECTIVELY). THE EMBRYOS FROM THE PCO1 GROUP EXHIBITED THE HIGHEST SURVIVABILITY WITH THE FASTEST SWIMMING ABILITY AND DEVELOPMENTAL SPEED. THESE RESULTS SUGGEST THAT PCO1 CONSUMPTION SIGNIFICANTLY ENHANCED THE REPRODUCTION SYSTEM, EGG-LAYING ABILITY, AND EMBRYO SURVIVABILITY. IN CONCLUSION, AMONG THE THREE POLICOSANOLS, CUBAN (RAYDEL®) POLICOSANOL HAD THE STRONGEST EFFECT ON SURVIVABILITY, IMPROVING DYSLIPIDEMIA, LIVER PROTECTION, KIDNEY, OVARY, AND TESTIS WITH A RESTORATION OF THE CELL MORPHOLOGY, AND THE LEAST ROS PRODUCTION AND APOPTOSIS-INDUCED BY HCD SUPPLEMENTATION. © 2023 BY THE AUTHORS.","APOLIPOPROTEINA-I (APOA-I); HIGH-CHOLESTEROL DIET (HCD); HIGH-DENSITY LIPOPROTEINS (HDL); INFLAMMATION; INTERLEUKIN-6; KIDNEY; LIVER; OVARY; POLICOSANOL; TESTIS","ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 6; POLICOSANOL; REACTIVE OXYGEN METABOLITE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; EGG LAYING; EGG PRODUCTION; FEMALE; FERTILITY; GAS CHROMATOGRAPHY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY FUNCTION; LIVER FUNCTION; MALE; NONHUMAN; OVARY; OXIDATIVE STRESS; REPRODUCTION; RICE BRAN; RISK FACTOR; SPERMATOGENESIS; SUGARCANE; SWIMMING; TESTICULAR CELL LINE; TESTIS; TESTIS WEIGHT; TRIACYLGLYCEROL BLOOD LEVEL; ZEBRA FISH","","","MILMAN S., ATZMON G., CRANDALL J., BARZILAI N., PHENOTYPES AND GENOTYPES OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN EXCEPTIONAL LONGEVITY, CURR. VASC. PHARMACOL, 12, PP. 690-697, (2013); WANG J., SHI L., ZOU Y., TANG J., CAI J., WEI Y., QIN J., ZHANG Z., POSITIVE ASSOCIATION OF FAMILIAL LONGEVITY WITH THE MODERATE-HIGH HDL-C CONCENTRATION IN BAMA AGING STUDY, AGING, 10, PP. 3528-3540, (2018); VENEGAS-TAMAYO A.R., PENA-VEITES O.M., HERNANDEZ-GONZALEZ M.A., BARRIENTOS-ALVARADO C., DECREASED HDL-C LEVELS AS A PREDICTOR OF ORGAN FAILURE IN ACUTE PANCREATITIS IN THE EMERGENCY DEPARTMENT, LIFE, 13, (2023); DE GEEST B., MISHRA M., IMPACT OF HIGH-DENSITY LIPOPROTEINS ON SEPSIS, INT. J. MOL. SCI, 23, (2022); ARIAS A., QUIROZ A., SANTANDER N., MORSELLI E., BUSSO D., IMPLICATIONS OF HIGH-DENSITY CHOLESTEROL METABOLISM FOR OOCYTE BIOLOGY AND FEMALE FERTILITY, FRONT. CELL DEV. BIOL, 10, (2022); KAYA E., SIKKA S.C., GUR S., A COMPREHENSIVE REVIEW OF METABOLIC SYNDROME AFFECTING ERECTILE DYSFUNCTION, J. SEX. MED, 12, PP. 856-875, (2015); CRUDELE L., DE MATTEIS C., PICCININ E., GADALETA R.M., CARIELLO M., DI BUDUO E., PIAZZOLLA G., SUPPRESSA P., BERARDI E., SABBA C., ET AL., LOW HDL-CHOLESTEROL LEVELS PREDICT HEPATOCELLULAR CARCINOMA DEVELOPMENT IN INDIVIDUALS WITH LIVER FIBROSIS, JHEP REP, 5, (2022); IDZIOR-WALUS B., TROJAK A., WALUS-MIARKA M., WOZNIAKIEWICZ E., MALECKI M.T., NONALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH LOW HDL CHOLESTEROL AND CORONARY ANGIOPLASTY IN PATIENTS WITH TYPE 2 DIABETES, MED. SCI. MONIT, 19, PP. 1167-1172, (2013); YOU A., LI Y., TOMLINSON B., YUE L., ZHAO K., FAN H., LIU Z., ZHANG Y., ZHENG L., ASSOCIATION BETWEEN RENAL DYSFUNCTION AND LOW HDL CHOLESTEROL AMONG THE ELDERLY IN CHINA, FRONT. CARDIOVASC. MED, 8, (2021); OSADNIK T., GOLAWSKI M., LEWANDOWSKI P., MORZE J., OSADNIK K., PAWLAS N., LEJAWA M., JAKUBIAK G.K., MAZUR A., SCHWINGSCHACKL L., ET AL., A NETWORK META-ANALYSIS ON THE COMPARATIVE EFFECT OF NUTRACEUTICALS ON LIPID PROFILE IN ADULTS, PHARMACOL. RES, 183, (2022); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED, 45, PP. 89-97, (2019); ARRUZAZABALA M., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES, 69, PP. 321-327, (1993); ISHAKA A., IMAM M.U., ISMAIL M., NANOEMULSIFICATION OF RICE BRAN WAX POLICOSANOL ENHANCES ITS CARDIO-PROTECTIVE EFFECTS VIA MODULATION OF HEPATIC PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN HYPERLIPIDEMIC RATS, J. OLEO SCI, 69, PP. 1287-1295, (2020); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT. MED. THER, 21, (2021); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI, 24, (2023); CHO K.-H., KIM J.-E., NAM H.-S., KANG D.-J., BAEK S.-H., COMPARISON OF POLICOSANOLS VIA INCORPORATION INTO RECONSTITUTED HIGH-DENSITY LIPOPROTEINS: CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) EXERTS THE HIGHEST ANTIOXIDANT, ANTI-GLYCATION, AND ANTI-INFLAMMATORY ACTIVITY, MOLECULES, 28, (2023); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR. REV, 61, PP. 376-383, (2003); DULLENS S.P.J., MENSINK R.P., BRAGT M.C.E., KIES A.K., PLAT J., EFFECTS OF EMULSIFIED POLICOSANOLS WITH DIFFERENT CHAIN LENGTHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTOR-DEFICIENT MICE, J. LIPID RES, 49, PP. 790-796, (2008); CHO K.-H., KIM J.-E., BAEK S.H., CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) POTENTLY PROTECTS THE LIVER, OVARY, AND TESTIS WITH AN IMPROVEMENT IN DYSLIPIDEMIA IN HYPERLIPIDEMIC ZEBRAFISH: A COMPARATIVE STUDY WITH THREE CHINESE POLICOSANOLS, MOLECULES, 28, (2023); PARK H.-J., YADAV D., JEONG D.-J., KIM S.-J., BAE M.-A., KIM J.-R., CHO K.-H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); YEON J., LEE J., KIM Y., COMPARISON OF PHYTOCHEMICAL CONTENTS AND CYTOPROTECTIVE EFFECTS OF DIFFERENT RICE BRAN EXTRACTS FROM INDICA AND JAPONICA RICE CULTIVARS, PREV. NUTR. FOOD SCI, 25, PP. 432-439, (2020); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT, PHYTOTHER. RES, 27, PP. 264-271, (2012); WONG W.-T., ISMAIL M., TOHIT E.R.M., ABDULLAH R., ZHANG Y.-D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVID. BASED COMPLEMENT. ALTERN. MED, 2016, (2016); SCHLEGEL A., ZEBRAFISH MODELS FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS RESEARCH, FRONT. ENDOCRINOL, 7, (2016); KA J., JIN S.-W., ZEBRAFISH AS AN EMERGING MODEL FOR DYSLIPIDEMIA AND ASSOCIATED DISEASES, J. LIPID ATHEROSCLER, 10, PP. 42-56, (2021); PATTON E.E., ZON L.I., LANGENAU D.M., ZEBRAFISH DISEASE MODELS IN DRUG DISCOVERY: FROM PRECLINICAL MODELLING TO CLINICAL TRIALS, NAT. REV. DRUG DISCOV, 20, PP. 611-628, (2021); JUAN-GARCIA A., BIND M.-A., ENGERT F., LARVAL ZEBRAFISH AS AN IN VITRO MODEL FOR EVALUATING TOXICOLOGICAL EFFECTS OF MYCOTOXINS, ECOTOXICOL. ENVIRON. SAF, 202, (2020); GUPTA H.R., PATIL Y., SINGH D., THAKUR M., EMBRYONIC ZEBRAFISH MODEL—A WELL-ESTABLISHED METHOD FOR RAPIDLY ASSESSING THE TOXICITY OF HOMEOPATHIC DRUGS–TOXICITY EVALUATION OF HOMEOPATHIC DRUGS USING ZEBRAFISH EMBRYO MODEL, J. PHARMACOPUNCT, 19, PP. 319-328, (2016); FANG L., LIU C., MILLER Y.I., ZEBRAFISH MODELS OF DYSLIPIDEMIA: RELEVANCE TO ATHEROSCLEROSIS AND ANGIOGENESIS, TRANSL. RES, 163, PP. 99-108, (2014); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2017); OLATUNJI L.K., JIMOH A.O., TUKUR U.M., IMAM M.U., A REVIEW OF THE EFFECTS OF POLICOSANOL ON METABOLIC SYNDROME, CLIN. COMPLEMENT. MED. PHARMACOL, 2, (2022); SILVESTRIS E., LOVERO D., PALMIROTTA R., NUTRITION AND FEMALE FERTILITY: AN INTERDEPENDENT CORRELATION, FRONT. ENDOCRINOL, 10, (2019); DREVET J., WHITFIELD M., POLLET-VILLARD X., LEVY R., SAEZ F., POSTTESTICULAR SPERM MATURATION, INFERTILITY, AND HYPERCHOLESTEROLEMIA, ASIAN J. ANDROL, 17, PP. 742-748, (2015); LAINEZ N.M., COSS D., OBESITY, NEUROINFLAMMATION, AND REPRODUCTIVE FUNCTION, ENDOCRINOLOGY, 160, PP. 2719-2736, (2019); GAO Y., ZOU Y., WU G., ZHENG L., OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION OF GRANULOSA CELLS IN POLYCYSTIC OVARIAN SYNDROME, FRONT. MED, 10, (2023); SHI J.F., LI Y.K., REN K., XIE Y.J., YIN W.D., MO Z.C., CHARACTERIZATION OF CHOLESTEROL METABOLISM IN SERTOLI CELLS AND SPERMATOGENESIS (REVIEW), MOL. MED. REP, 17, PP. 705-713, (2018); LI M., MA Z., ZHANG X., GUO L., YUAN M., SIGNIFICANCE OF BLOOD LIPID PARAMETERS AS EFFECTIVE MARKERS FOR ARTERIOGENIC ERECTILE DYSFUNCTION, ANDROLOGY, 8, PP. 1086-1094, (2020); FOFANA M., MABOUNDOU J.-C., BOCQUET J., LE GOFF D., TRANSFER OF CHOLESTEROL BETWEEN HIGH DENSITY LIPOPROTEINS AND CULTURED RAT SERTOLI CELLS, BIOCHEM. CELL BIOL, 74, PP. 681-686, (1996); CHO K.-H., KIM J.-R., RAPID DECREASE IN HDL-C IN THE PUBERTY PERIOD OF BOYS ASSOCIATED WITH AN ELEVATION OF BLOOD PRESSURE AND DYSLIPIDEMIA IN KOREAN TEENAGERS: AN EXPLANATION OF WHY AND WHEN MEN HAVE LOWER HDL-C LEVELS THAN WOMEN, MED. SCI, 9, (2021); YANNAS D., FRIZZA F., VIGNOZZI L., CORONA G., MAGGI M., RASTRELLI G., ERECTILE DYSFUNCTION IS A HALLMARK OF CARDIOVASCULAR DISEASE: UNAVOIDABLE MATTER OF FACT OR OPPORTUNITY TO IMPROVE MEN’S HEALTH?, J. CLIN. MED, 10, (2021); CAO H., HUANG W., HDL AND SEPSIS, ADV. EXP. MED. BIOL, 1377, PP. 129-139, (2022); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); CHO K.-H., KIM J.-E., KOMATSU T., UEHARA Y., PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED STUDY WITH HEALTHY AND MIDDLE-AGED JAPANESE PARTICIPANTS, LIFE, 13, (2023); CHO K.-H., NAM H.-S., BAEK S.-H., KANG D.-J., NA H., KOMATSU T., UEHARA Y., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT. J. MOL. SCI, 24, (2023); NUSSLEIN-VOLHARD C., DAHM R., ZEBRAFISH, (2002); DU SERT N.P., HURST V., AHLUWALIA A., ALAM S., AVEY M.T., BAKER M., BROWNE W.J., CLARK A., CUTHILL I.C., DIRNAGL U., ET AL., THE ARRIVE GUIDELINES 2.0: UPDATED GUIDELINES FOR REPORTING ANIMAL RESEARCH, BMC VETER. RES, 16, (2020); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT. GENET, 40, PP. 356-361, (2008); GEWIESE-RABSCH J., DRUCKER C., MALCHOW S., SCHELLER J., ROSE-JOHN S., ROLE OF IL-6 TRANS-SIGNALING IN CCL<SUB>4</SUB> INDUCED LIVER DAMAGE, BIOCHIM. BIOPHYS. ACTA MOL. BASIS DIS, 1802, PP. 1054-1061, (2010); HAYASHI M., SOFUNI T., ISHIDATE M., AN APPLICATION OF ACRIDINE ORANGE FLUORESCENT STAINING TO THE MICRONUCLEUS TEST, MUTAT. RES. LETT, 120, PP. 241-247, (1983); PATEL U.N., PATEL U.D., KHADAYATA A.V., VAJA R.K., MODI C.M., PATEL H.B., LONG-TERM EXPOSURE OF THE BINARY MIXTURE OF CADMIUM AND MERCURY DAMAGES THE DEVELOPED OVARY OF ADULT ZEBRAFISH, ENVIRON. SCI. POLLUT. RES, 29, PP. 44928-44938, (2022); SUTHA J., ANILA P.A., GAYATHRI M., RAMESH M., LONG TERM EXPOSURE TO TRIS (2-CHLOROETHYL) PHOSPHATE (TCEP) CAUSES ALTERATIONS IN REPRODUCTIVE HORMONES, VITELLOGENIN, ANTIOXIDANT ENZYMES, AND HISTOLOGY OF GONADS IN ZEBRAFISH (DANIO RERIO): IN VIVO AND COMPUTATIONAL ANALYSIS, COMP. BIOCHEM. PHYSIOL. PART C TOXICOL. PHARMACOL, 254, (2022); SABALIAUSKAS N.A., FOUTZ C.A., MEST J.R., BUDGEON L.R., SIDOR A.T., GERSHENSON J.A., JOSHI S.B., CHENG K.C., HIGH-THROUGHPUT ZEBRAFISH HISTOLOGY, METHODS, 39, PP. 246-254, (2006); TAIB I.S., BUDIN S.B., GHAZALI A.R., JAYUSMAN P.A., LOUIS S.R., MOHAMED J., FENITROTHION INDUCED OXIDATIVE STRESS AND MORPHOLOGICAL ALTERATIONS OF SPERM AND TESTES IN MALE SPRAGUE-DAWLEY RATS, CLINICS, 68, PP. 93-100, (2013); KOC N.D., TEKSOZ N., URAL M., AKBULUT C., HISTOLOGICAL STRUCTURE OF ZEBRAFISH (DANIO RERIO, HAMILTON, 1822) TESTICLES, ELIXIR AQUAC, 46, PP. 8117-8120, (2012); TEST NO. 236: FISH EMBRYO ACUTE TOXICITY (FET) TEST, OECD GUIDELINES FOR THE TESTING OF CHEMICALS, (2013)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, DONG-GU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","PHARMACEUTICALS","ARTICLE","ISI","2-S2.0-85183092067","PHARMACEUTICALS","RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2024, PHARMACEUTICALS","CHO K-H, 2024, PHARMACEUTICALS-a"
"CHEN G;CHEN W;XU J;MA G;HU X;CHEN G","CHEN, GONG (57194852100); CHEN, WANBO (57194190946); XU, JINHONG (58176325100); MA, GUODONG (58176514900); HU, XINGE (57227374100); CHEN, GUOXUN (7406542711)","THE CURRENT TREND AND CHALLENGES OF DEVELOPING RED YEAST RICEBASED FOOD SUPPLEMENTS FOR HYPERCHOLESTEROLEMIA",2023,"JOURNAL OF FUTURE FOODS","3","17",4,"10.1016/j.jfutfo.2023.03.003","DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS, DALLAS, 75390, UNITED STATES;CLINICAL SCHOOL OF CHINESE MEDICINE, HUBEI UNIVERSITY OF CHINESE MEDICINE, WUHAN, 430022, CHINA;COLLEGE OF PHARMACY, SOUTH-CENTRAL UNIVERSITY FOR NATIONALITIES, WUHAN, 430074, CHINA;DEPARTMENT OF NUTRITION, UNIVERSITY OF TENNESSEE AT KNOXVILLE, KNOXVILLE, 37996, UNITED STATES;DEPARTMENT OF NUTRITION, UNIVERSITY OF TENNESSEE AT KNOXVILLE, KNOXVILLE, 37996, UNITED STATES;DEPARTMENT OF NUTRITION, UNIVERSITY OF TENNESSEE AT KNOXVILLE, KNOXVILLE, 37996, UNITED STATES","HYPERCHOLESTEROLEMIA IS A RISK FACTOR OF CARDIOVASCULAR DISEASES, WHICH HAVE BEEN MANAGED USING STATIN DRUGS. RED YEAST RICE (RYR) AS A TRADITIONAL FOOD IN THE EASTERN ASIA COUNTRIES HAS ANTI-HYPERLIPIDEMIA ACTIVITY. RECENTLY, A VARIETY OF FOOD SUPPLEMENT PRODUCTS CONTAINING RYR HAVE BEEN DEVELOPED TO LOWER BLOOD CHOLESTEROL, WHICH IS ATTRIBUTED TO THE PRESENCE OF MONACOLINS, ESPECIALLY MONACOLIN K (LOVASTATIN, A STATIN DRUG). THIS REVIEW WAS AIMED TO SUMMARIZE THE CLINICAL TRIALS USING RYR PRODUCTS TO INVESTIGATE THEIR EFFECTS ON LIPID PROFILES IN HUMANS. RELEVANT ARTICLES OF HUMAN CLINICAL TRIALS WERE RETRIEVED FROM PUBMED AND DISCUSSED HERE. RESULTS SHOWED THAT RYR AND ITS EXTRACTS HAVE BEEN INCLUDED IN COMMERCIALLY AVAILABLE PRODUCTS ALONE AND IN COMBINATIONS WITH VARIOUS OTHER MATERIALS, WHICH INCLUDE BIOACTIVE COMPOUNDS SUCH AS COENZYME Q10 AND BERBERINE, VITAMINS, EXTRACTS FROM OTHER PLANTS SUCH AS PHYTOSTEROLS, POLYUNSATURATED FATTY ACIDS OR EVEN PROBIOTICS. THE DURATIONS OF THE TRIALS RANGED FROM 4 WEEKS TO 60 MONTHS. THE CONTENT OF MONACOLIN K RANGED FROM 0.32 MG/PACK TO 10 MG/PACK. THE DATA OF THESE HUMAN CLINICAL TRIALS DEMONSTRATED THAT THESE RYR SUPPLEMENT PRODUCTS WERE SUFFICIENT TO REDUCE BLOOD CHOLESTEROL IN DIFFERENT POPULATIONS. HOWEVER, THE INCLUSIONS OF CERTAIN MATERIALS MIGHT NOT HAVE ADDITIVE EFFECT. ADDITIONALLY, STUDIES INCLUDING A LOVASTATIN ONLY POSITIVE CONTROL GROUP WITH THE EQUIVALENT DOSE AS THAT OF MONACOLIN K IN THE RYR PRODUCTS REMAIN TO BE DONE. FURTHERMORE, VARIATIONS OF MONACOLIN K CONTENTS AND PRESENCE OF TOXIC CITRININ ARE STILL CONCERNS. LAST, BIOACTIVITIES OF OTHER COMPONENTS IN RYR SHOULD BE INVESTIGATED AS WELL. MORE FUTURE STUDIES WILL CERTAINLY HELP TO FULLY EXPLORE THE POTENTIALS OF THIS TRADITIONAL FOOD IN THE COMBAT AGAINST CARDIOVASCULAR AND OTHER METABOLIC DISEASES. © 2023","CARDIOVASCULAR DISEASES; CHOLESTEROL; FOOD SUPPLEMENT; HUMAN CLINICAL TRIALS; HYPERCHOLESTEROLEMIA; MONACOLINS; RED YEAST RICE; STATINS","ARTICHOKE EXTRACT; ASTAXANTHIN; BANABA EXTRACT; BERBERINE; BLACK PEPPER EXTRACT; CAMPESTEROL; CANGZHU; CHINESE DRUG; CHITOSAN; CHOLESTEROL; CHOLESTIN; CHROMIUM; CHROMIUM PICOLINATE; CITRININ; CURCUMA LONGA EXTRACT; CYANOCOBALAMIN; EZETIMIBE; FOLIC ACID; GRAPE SEED EXTRACT; GUGGULSTERONE; HEYE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYTYROSOL; LIPID; MEVINOLIN; NICOTINAMIDE; NICOTINIC ACID; OLIVE FRUIT EXTRACT; PHOSPHATIDYLCHOLINE; PHYTOSTEROL; PLANT EXTRACT; POLICOSANOL; POLYUNSATURATED FATTY ACID; PRAVASTATIN; PROBIOTIC AGENT; PROCYANIDIN DERIVATIVE; PYRIDOXINE; RESVERATROL; SIMVASTATIN; SITOSTEROL; STIGMASTEROL; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN; ABDOMINAL PAIN; BACKACHE; BIFIDOBACTERIUM LONGUM; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DATA BASE; DIETARY SUPPLEMENT; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSLIPIDEMIA; FLATULENCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOCHOLESTEROLEMIC ACTIVITY; LACTOBACILLUS CASEI; LIPID FINGERPRINTING; LOOSE FECES; MONASCUS PURPUREUS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NONHUMAN; POPULATION RESEARCH; REVIEW; RICE; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREND STUDY","DIABETES ACTION RESEARCH AND EDUCATION FOUNDATION, DAREF, (466)","THE AUTHORS WOULD LIKE TO THANK THE DIABETES ACTION RESEARCH AND EDUCATION FOUNDATION FOR THE RESEARCH GRANT (#466) TO G. CHEN.","MENSAH GEORGE A., ROTH GREGORY A., FUSTER V., THE GLOBAL BURDEN OF CARDIOVASCULAR DISEASES AND RISK FACTORS, J. AM. COLL. CARDIOL., 74, PP. 2529-2532, (2019); DEMASI M., STATIN WARS: HAVE WE BEEN MISLED ABOUT THE EVIDENCE? A NARRATIVE REVIEW, BR. J. SPORTS MED., 52, PP. 905-909, (2018); DONG C., BU X., LIU J., ET AL., CARDIOVASCULAR DISEASE BURDEN ATTRIBUTABLE TO DIETARY RISK FACTORS FROM 1990 TO 2019: A SYSTEMATIC ANALYSIS OF THE GLOBAL BURDEN OF DISEASE STUDY, NUTR. METAB. CARDIOVASC. DIS., 32, PP. 897-907, (2022); FUKAMI H., HIGA Y., HISANO T., ET AL., A REVIEW OF RED YEAST RICE, A TRADITIONAL FERMENTED FOOD IN JAPAN AND EAST ASIA: ITS CHARACTERISTIC INGREDIENTS AND APPLICATION IN THE MAINTENANCE AND IMPROVEMENT OF HEALTH IN LIPID METABOLISM AND THE CIRCULATORY SYSTEM, MOLECULES, 26, (2021); SONG J., LUO J., MA Z., ET AL., QUALITY AND AUTHENTICITY CONTROL OF FUNCTIONAL RED YEAST RICE-A REVIEW, MOLECULES, 24, (2019); MA J., LI Y., YE Q., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGRIC. FOOD CHEM., 48, PP. 5220-5225, (2000); ZHU B., QI F., WU J., ET AL., RED YEAST RICE: A SYSTEMATIC REVIEW OF THE TRADITIONAL USES, CHEMISTRY, PHARMACOLOGY, AND QUALITY CONTROL OF AN IMPORTANT CHINESE FOLK MEDICINE, FRONT. PHARMACOL., 10, (2019); ZHANG Z., ALI Z., KHAN S.I., ET AL., CYTOTOXIC MONACOLINS FROM RED YEAST RICE, A CHINESE MEDICINE AND FOOD, FOOD CHEM, 202, PP. 262-268, (2016); TSUKAHARA M., SHINZATO N., TAMAKI Y., ET AL., RED YEAST RICE FERMENTATION BY SELECTED MONASCUS SP. WITH DEEP-RED COLOR, LOVASTATIN PRODUCTION BUT NO CITRININ, AND EFFECT OF TEMPERATURE-SHIFT CULTIVATION ON LOVASTATIN PRODUCTION, APPL. BIOCHEM. BIOTECHNOL., 158, PP. 476-482, (2009); SHIMIZU T., KINOSHITA H., ISHIHARA S., ET AL., POLYKETIDE SYNTHASE GENE RESPONSIBLE FOR CITRININ BIOSYNTHESIS IN MONASCUS PURPUREUS, APPL. ENVIRON. MICROBIOL., 71, PP. 3453-3457, (2005); SUH S.H., RHEEM S., MAH J.H., ET AL., OPTIMIZATION OF PRODUCTION OF MONACOLIN K FROM Γ-IRRADIATED MONASCUS MUTANT BY USE OF RESPONSE SURFACE METHODOLOGY, J.MED. FOOD, 10, PP. 408-415, (2007); GOLDSTEIN J.L., BROWN M.S., A CENTURY OF CHOLESTEROL AND CORONARIES: FROM PLAQUES TO GENES TO STATINS, CELL, 161, PP. 161-172, (2015); APOSTOLOPOULOU M., CORSINI A., RODEN M., THE ROLE OF MITOCHONDRIA IN STATIN-INDUCED MYOPATHY, EUR. J. CLIN INVEST., 45, PP. 745-754, (2015); HARGREAVES I.P., UBIQUINONE: CHOLESTEROL'S RECLUSIVE COUSIN, ANN. CLIN. BIOCHEM., 40, PP. 207-218, (2003); STEFELY J.A., PAGLIARINI D.J., BIOCHEMISTRY OF MITOCHONDRIAL COENZYME Q BIOSYNTHESIS, TRENDS BIOCHEM. SCI., 42, PP. 824-843, (2017); SOOD B., KEENAGHAN M.; ZOU J., YAN C., WAN J.B., RED YEAST RICE AMELIORATES NON-ALCOHOLIC FATTY LIVER DISEASE THROUGH INHIBITING LIPID SYNTHESIS AND NF-ΚB/NLRP3 INFLAMMASOME-MEDIATED HEPATIC INFLAMMATION IN MICE, CHIN. MED., 17, (2022); MA K.Y., ZHANG Z.S., ZHAO S.X., ET AL., RED YEAST RICE INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, BIOMED. ENVIRON. SCI., 22, PP. 269-277, (2009); LI T., LIU X., YAN L., SEPARATION AND PURIFICATION OF MONASCUS PIGMENTS FROM RED YEAST RICE, AGRICULTURAL BIOTECHNOLOGY, 8, PP. 177-184, (2019); WEI Y., POPOVICH D.G., RED AZAPHILONE PIGMENTS EXTRACTED FROM RED YEAST RICE INDUCES CELLULAR SENESCENCE AND REDUCES VIABILITY IN HEPG2 CELLS, BIOMED. PREV. NUTR., 3, PP. 331-337, (2013); ZHOU W., GUO R., GUO W., ET AL., MONASCUS YELLOW, RED AND ORANGE PIGMENTS FROM RED YEAST RICE AMELIORATE LIPID METABOLIC DISORDERS AND GUT MICROBIOTA DYSBIOSIS IN WISTAR RATS FED ON A HIGH-FAT DIET, FOOD FUNCT, 10, PP. 1073-1084, (2019); CHEN C.H., YANG J.C., UANG Y.S., ET AL., IMPROVED DISSOLUTION RATE AND ORAL BIOAVAILABILITY OF LOVASTATIN IN RED YEAST RICE PRODUCTS, INT. J. PHARM., 444, PP. 18-24, (2013); HEINZ T., SCHUCHARDT J.P., MOLLER K., ET AL., LOW DAILY DOSE OF 3 MG MONACOLIN K FROM RYR REDUCES THE CONCENTRATION OF LDL-C IN A RANDOMIZED, PLACEBO-CONTROLLED INTERVENTION, NUTR. RES., 36, PP. 1162-1170, (2016); BRUNO A., PANDOLFO G., CRUCITTI M., ET AL., RED YEAST RICE (RYR) SUPPLEMENTATION IN PATIENTS TREATED WITH SECOND-GENERATION ANTIPSYCHOTICS, COMPLEMENT THER. MED., 37, PP. 167-171, (2018); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM. J. CARDIOL., 101, PP. 1689-1693, (2008); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM. J. CLIN. NUTR., 69, PP. 231-236, (1999); BECKER D.J., GORDON R.Y., HALBERT S.C., ET AL., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN. INTERN. MED., 150, PP. 830-839, (2009); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM. J. CARDIOL., 105, PP. 198-204, (2010); BOGSRUD M.P., OSE L., LANGSLET G., ET AL., HYPOCOL (RED YEAST RICE) LOWERS PLASMA CHOLESTEROL-A RANDOMIZED PLACEBO CONTROLLED STUDY, SCAND. CARDIOVASC. J., 44, PP. 197-200, (2010); MORIARTY P.M., ROTH E.M., KARNS A., ET AL., EFFECTS OF XUEZHIKANG IN PATIENTS WITH DYSLIPIDEMIA: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY, J. CLIN. LIPIDOL., 8, PP. 568-575, (2014); MINAMIZUKA T., KOSHIZAKA M., SHOJI M., ET AL., LOW DOSE RED YEAST RICE WITH MONACOLIN K LOWERS LDL CHOLESTEROL AND BLOOD PRESSURE IN JAPANESE WITH MILD DYSLIPIDEMIA: A MULTICENTER, RANDOMIZED TRIAL, ASIA PAC, J. CLIN. NUTR., 30, PP. 424-435, (2021); HUANG C.F., LI T.C., LIN C.C., ET AL., EFFICACY OF MONASCUS PURPUREUS WENT RICE ON LOWERING LIPID RATIOS IN HYPERCHOLESTEROLEMIC PATIENTS, EUR. J. CARDIOVASC. PREV. REHABIL., 14, PP. 438-440, (2007); HANDE L.N., KJELLMO C., PETTERSEN K., ET AL., EFFECT OF N-3 POLYUNSATURATED FATTY ACIDS ON LIPID COMPOSITION IN FAMILIAL HYPERCHOLESTEROLEMIA: A RANDOMIZED CROSSOVER TRIAL, BIOMEDICINES, 10, (2022); PARRA-VIRTO A., TORRES DO REGO A., DEMELO-RODRIGUEZ P., ET AL., USEFULNESS OF COMPOUNDS WITH MONACOLIN K IN A CASE OF STATINS INTOLERANCE, CLIN. INVESTIG. ARTERIOSCLER., 30, PP. 268-270, (2018); VERHOEVEN V., LOPEZ HARTMANN M., REMMEN R., ET AL., RED YEAST RICE LOWERS CHOLESTEROL IN PHYSICIANS-A DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED TRIAL, BMC COMPLEMENT ALTERN. MED., 13, (2013); BENJIAN C., XIAODAN H., HUITING P., ET AL., EFFECTIVENESS AND SAFETY OF RED YEAST RICE PREDOMINATED BY MONACOLIN K Β-HYDROXY ACID FORM FOR HYPERLIPIDEMIA TREATMENT AND MANAGEMENT, J. TRADIT. CHIN. MED., 42, PP. 264-271, (2022); RUSCICA M., PAVANELLO C., GANDINI S., ET AL., NUTRACEUTICAL APPROACH FOR THE MANAGEMENT OF CARDIOVASCULAR RISK-A COMBINATION CONTAINING THE PROBIOTIC BIFIDOBACTERIUM LONGUM BB536 AND RED YEAST RICE EXTRACT: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. J., 18, (2019); CICOLARI S., PAVANELLO C., OLMASTRONI E., ET AL., INTERACTIONS OF OXYSTEROLS WITH ATHEROSCLEROSIS BIOMARKERS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA AND EFFECTS OF A NUTRACEUTICAL COMBINATION (BIFIDOBACTERIUM LONGUM BB536, RED YEAST RICE EXTRACT) (RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY), NUTRIENTS, (2021); FEUERSTEIN J.S., BJERKE W.S., POWDERED RED YEAST RICE AND PLANT STANOLS AND STEROLS TO LOWER CHOLESTEROL, J. DIET. SUPPL., 9, PP. 110-115, (2012); LEE C.Y., YU M.C., PERNG W.T., ET AL., NO ADDITIONAL CHOLESTEROL-LOWERING EFFECT OBSERVED IN THE COMBINED TREATMENT OF RED YEAST RICE AND LACTOBACILLUS CASEI IN HYPERLIPIDEMIC PATIENTS: A DOUBLE-BLIND RANDOMIZED CONTROLLED CLINICAL TRIAL, CHIN. J. INTEGR. MED., 23, PP. 581-588, (2017); CIMAGLIA P., VIECELI DALLA SEGA F., VITALI F., ET AL., EFFECTIVENESS OF A NOVEL NUTRACEUTICAL COMPOUND CONTAINING RED YEAST RICE, POLYMETHOXYFLAVONES AND ANTIOXIDANTS IN THE MODULATION OF CHOLESTEROL LEVELS IN SUBJECTS WITH HYPERCHOLESTEROLEMIA AND LOW-MODERATE CARDIOVASCULAR RISK: THE NIRVANA STUDY, FRONT. PHYSIOL., 10, (2019); LEE I.T., LEE W.J., TSAI C.M., ET AL., COMBINED EXTRACTIVES OF RED YEAST RICE, BITTER GOURD, CHLORELLA, SOY PROTEIN, AND LICORICE IMPROVE TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDE IN SUBJECTS WITH METABOLIC SYNDROME, NUTR. RES., 32, PP. 85-92, (2012); CICERO A.F.G., FOGACCI F., ROSTICCI M., ET AL., EFFECT OF A SHORT-TERM DIETARY SUPPLEMENTATION WITH PHYTOSTEROLS, RED YEAST RICE OR BOTH ON LIPID PATTERN IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS: A THREE-ARM, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL, NUTR. METAB. (LOND), 14, (2017); SPIGONI V., ALDIGERI R., ANTONINI M., ET AL., EFFECTS OF A NEW NUTRACEUTICAL FORMULATION (BERBERINE, RED YEAST RICE AND CHITOSAN) ON NON-HDL CHOLESTEROL LEVELS IN INDIVIDUALS WITH DYSLIPIDEMIA: RESULTS FROM A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY, INT. J. MOL. SCI., 18, (2017); PUATO M., ZAMBON A., NARDIN C., ET AL., LIPID PROFILE AND VASCULAR REMODELLING IN YOUNG DYSLIPIDEMIC SUBJECTS TREATED WITH NUTRACEUTICALS DERIVED FROM RED YEAST RICE, CARDIOVASC. THER., 2021, (2021); MAZZA A., LENTI S., SCHIAVON L., ET AL., EFFECT OF MONACOLIN K AND COQ10 SUPPLEMENTATION IN HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS WITH METABOLIC SYNDROME, BIOMED. PHARMACOTHER., 105, PP. 992-996, (2018); ISKANDAR I., HARAHAP Y., WIJAYANTI T.R., ET AL., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION OF RED YEAST RICE, GUGGULIPID, AND CHROMIUM PICOLINATE EVALUATED IN A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY, COMPLEMENT THER. MED., 48, (2020); HERMANS N., VAN DER AUWERA A., BREYNAERT A., ET AL., A RED YEAST RICE-OLIVE EXTRACT SUPPLEMENT REDUCES BIOMARKERS OF OXIDATIVE STRESS, OXLDL AND LP-PLA(2), IN SUBJECTS WITH METABOLIC SYNDROME: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, TRIALS, 18, (2017); VERHOEVEN V., VAN DER AUWERA A., VAN GAAL L., ET AL., CAN RED YEAST RICE AND OLIVE EXTRACT IMPROVE LIPID PROFILE AND CARDIOVASCULAR RISK IN METABOLIC SYNDROME?: A DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED TRIAL, BMC COMPLEMENT ALTERN. MED., 15, (2015); TSHONGO MUHINDO C., AHN S.A., ROUSSEAU M.F., ET AL., EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE AND OLIVE EXTRACT IN HYPERCHOLESTEROLEMIC PATIENTS WITH AND WITHOUT STATIN-ASSOCIATED MYALGIA, COMPLEMENT THER. MED., 35, PP. 140-144, (2017); CICERO A.F., DEROSA G., PARINI A., ET AL., RED YEAST RICE IMPROVES LIPID PATTERN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND VASCULAR REMODELING PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC ITALIAN SUBJECTS, NUTR. RES., 33, PP. 622-628, (2013); BECKER D.J., FRENCH B., MORRIS P.B., ET AL., PHYTOSTEROLS, RED YEAST RICE, AND LIFESTYLE CHANGES INSTEAD OF STATINS: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL, AM. HEART J., 166, PP. 187-196, (2013); SARTORE G., BURLINA S., RAGAZZI E., ET AL., MEDITERRANEAN DIET AND RED YEAST RICE SUPPLEMENTATION FOR THE MANAGEMENT OF HYPERLIPIDEMIA IN STATIN-INTOLERANT PATIENTS WITH OR WITHOUT TYPE 2 DIABETES, EVID. BASED COMPLEMENT ALTERNAT. MED., 2013, (2013); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. METAB. CARDIOVASC. DIS., 20, PP. 656-661, (2010); DEROSA G., CATENA G., RADDINO R., ET AL., EFFECTS ON ORAL FAT LOAD OF A NUTRACEUTICAL COMBINATION OF FERMENTED RED RICE, STEROL ESTERS AND STANOLS, CURCUMIN, AND OLIVE POLYPHENOLS: A RANDOMIZED, PLACEBO CONTROLLED TRIAL, PHYTOMEDICINE, 42, PP. 75-82, (2018); CICERO A.F.G., FOGACCI F., BOVE M., ET AL., SHORT-TERM EFFECTS OF A COMBINED NUTRACEUTICAL ON LIPID LEVEL, FATTY LIVER BIOMARKERS, HEMODYNAMIC PARAMETERS, AND ESTIMATED CARDIOVASCULAR DISEASE RISK: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL, ADV. THER., 34, PP. 1966-1975, (2017); CICERO A.F., COLLETTI A., FOGACCI F., ET AL., EFFECTS OF A COMBINED NUTRACEUTICAL ON LIPID PATTERN, GLUCOSE METABOLISM AND INFLAMMATORY PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS: A DOUBLE-BLIND, CROSS-OVER, RANDOMIZED CLINICAL TRIAL, HIGH BLOOD PRESS, CARDIOVASC. PREV., 24, PP. 13-18, (2017); CICERO A.F., MORBINI M., ROSTICCI M., ET AL., MIDDLE-TERM DIETARY SUPPLEMENTATION WITH RED YEAST RICE PLUS COENZYME Q10 IMPROVES LIPID PATTERN, ENDOTHELIAL REACTIVITY AND ARTERIAL STIFFNESS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS, ANN. NUTR. METAB., 68, PP. 213-219, (2016); KASLIWAL R.R., BANSAL M., GUPTA R., ET AL., ESSENS DYSLIPIDEMIA: A PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A NUTRITIONAL SUPPLEMENT CONTAINING RED YEAST RICE IN SUBJECTS WITH NEWLY DIAGNOSED DYSLIPIDEMIA, NUTRITION, 32, PP. 767-776, (2016); MARAZZI G., PELLICCIA F., CAMPOLONGO G., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM. J. CARDIOL., 116, PP. 1798-1801, (2015); GONNELLI S., CAFFARELLI C., STOLAKIS K., ET AL., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR. THER. RES. CLIN. EXP., 77, PP. 1-6, (2015); SOLA R., VALLS R.M., PUZO J., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J. CLIN. LIPIDOL., 8, PP. 61-68, (2014); AFFUSO F., MERCURIO V., RUVOLO A., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J. CARDIOL., 4, PP. 77-83, (2012); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS., 21, PP. 424-429, (2011); PIRRO M., FRANCISCI D., BIANCONI V., ET AL., NUTRACEUTICAL TREATMENT FOR HYPERCHOLESTEROLEMIA IN HIV-INFECTED PATIENTS: THE NU-TRY(HIV) RANDOMIZED CROSS-OVER TRIAL, ATHEROSCLEROSIS, 280, PP. 51-57, (2019); CICERO A.F., DEROSA G., PISCIOTTA L., ET AL., TESTING THE SHORT-TERM EFFICACY OF A LIPID-LOWERING NUTRACEUTICAL IN THE SETTING OF CLINICAL PRACTICE: A MULTICENTER STUDY, J. MED. FOOD, 18, PP. 1270-1273, (2015); BARRAT E., ZAIR Y., SIRVENT P., ET AL., EFFECT ON LDL-CHOLESTEROL OF A LARGE DOSE OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH UNTREATED MODERATE HYPERCHOLESTEROLAEMIA: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EUR. J. NUTR., 52, PP. 1843-1852, (2013); OGIER N., AMIOT M.J., GEORGE S., ET AL., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR. J. NUTR., 52, PP. 547-557, (2013); BARRAT E., ZAIR Y., OGIER N., ET AL., A COMBINED NATURAL SUPPLEMENT LOWERS LDL CHOLESTEROL IN SUBJECTS WITH MODERATE UNTREATED HYPERCHOLESTEROLEMIA: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, INT. J. FOOD SCI. NUTR., 64, PP. 882-889, (2013); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV. THER., 28, PP. 1105-1113, (2011); CICERO A.F.G., D'ADDATO S., BORGHI C., A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY OF THE EFFECTS OF A NUTRACEUTICAL COMBINATION (LEVELIP DUO®) ON LDL CHOLESTEROL LEVELS AND LIPID PATTERN IN SUBJECTS WITH SUB-OPTIMAL BLOOD CHOLESTEROL LEVELS (NATCOL STUDY), NUTRIENTS, 12, (2020); CICERO A.F.G., BOVE M., CINCIONE R.I., ET AL., EFFECT OF COMBINED LIPID-LOWERING AND ANTIOXIDANT NUTRACEUTICAL ON PLASMA LIPIDS, ENDOTHELIAL FUNCTION, AND ESTIMATED CARDIOVASCULAR DISEASE RISK IN MODERATELY HYPERCHOLESTEROLEMIC PATIENTS: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL, ARCH. MED. SCI. ATHEROSCLER. DIS., 6, PP. E145-E151, (2021); NAFRIALDI N., HUDYONO J., SUYATNA F.D., ET AL., SAFETY AND EFFICACY OF NC120 FOR IMPROVING LIPID PROFILE: A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL, ACTA MED. INDONES., 51, PP. 19-25, (2019); GUERRERO-BONMATTY R., GIL-FERNANDEZ G., RODRIGUEZ-VELASCO F.J., ET AL., A COMBINATION OF LACTOPLANTIBACILLUS PLANTARUM STRAINS CECT7527, CECT7528, AND CECT7529 PLUS MONACOLIN K REDUCES BLOOD CHOLESTEROL: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTRIENTS, 13, (2021); TRIMARCO V., IZZO R., STABILE E., ET AL., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE, INSULIN SENSITIVITY AND ENDOTELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS. A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND TRIAL, HIGH BLOOD PRESS, CARDIOVASC. PREV., 22, PP. 149-154, (2015); GRASSI D., NECOZIONE S., DESIDERI G., ET AL., ACUTE AND LONG TERM EFFECTS OF A NUTRACEUTICAL COMBINATION ON LIPID PROFILE, GLUCOSE METABOLISM AND VASCULAR FUNCTION IN PATIENTS WITH DYSLIPIDAEMIA WITH AND WITHOUT CIGARETTE SMOKING, HIGH BLOOD PRESS, CARDIOVASC. PREV, 28, PP. 483-491, (2021); ADORNI M.P., FERRI N., MARCHIANO S., ET AL., EFFECT OF A NOVEL NUTRACEUTICAL COMBINATION ON SERUM LIPOPROTEIN FUNCTIONAL PROFILE AND CIRCULATING PCSK9, THER. CLIN. RISK. MANAG., 13, PP. 1555-1562, (2017); ESPOSITO R., SORRENTINO R., GIUGLIANO G., ET AL., DIFFERENT AGE-INDEPENDENT EFFECTS OF NUTRACEUTICAL COMBINATIONS ON ENDOTHELIUM-MEDIATED CORONARY FLOW RESERVE, IMMUN AGEING, 15, (2018); PECCHIOLI V., CICERO A.F.G., LOMARTIRE N., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF A COMBINED NUTRACEUTICAL ON ENDOTHELIAL FUNCTION IN PATIENTS WITH MILD-TO-MODERATE HYPERCHOLESTEROLAEMIA, ARCH. MED. SCI. ATHEROSCLER. DIS., 5, PP. E36-E42, (2020); MAZZA A., SCHIAVON L., RIGATELLI G., ET AL., THE SHORT-TERM SUPPLEMENTATION OF MONACOLIN K IMPROVES THE LIPID AND METABOLIC PATTERNS OF HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS AT LOW CARDIOVASCULAR RISK, FOOD FUNCT, 9, PP. 3845-3852, (2018); KARL M., RUBENSTEIN M., RUDNICK C., ET AL., A MULTICENTER STUDY OF NUTRACEUTICAL DRINKS FOR CHOLESTEROL (EVALUATING EFFECTIVENESS AND TOLERABILITY), J. CLIN. LIPIDOL., 6, PP. 150-158, (2012); BECKER D.J., GORDON R.Y., MORRIS P.B., ET AL., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN. PROC., 83, PP. 758-764, (2008); DI PIERRO F., PUTIGNANO P., VILLANOVA N., RETROSPECTIVE ANALYSIS OF THE EFFECTS OF A HIGHLY STANDARDIZED MIXTURE OF BERBERIS ARISTATA, SILYBUM MARIANUM, AND MONACOLINS K AND KA IN DIABETIC PATIENTS WITH DYSLIPIDEMIA, ACTA BIOMED, 88, PP. 462-469, (2018); DI PIERRO F., PUTIGNANO P., FERRARA T., ET AL., RETROSPECTIVE ANALYSIS OF THE EFFECTS OF A HIGHLY STANDARDIZED MIXTURE OF BERBERIS ARISTATA, SILYBUM MARIANUM, AND MONACOLINS K AND KA IN PATIENTS WITH DYSLIPIDEMIA, CLIN. PHARMACOL., 9, PP. 1-7, (2017); D'ADDATO S., SCANDIANI L., MOMBELLI G., ET AL., EFFECT OF A FOOD SUPPLEMENT CONTAINING BERBERINE, MONACOLIN K, HYDROXYTYROSOL AND COENZYME Q(10) ON LIPID LEVELS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY, DRUG DES. DEVEL. THER., 11, PP. 1585-1592, (2017); LANDI F., MARTONE A.M., SALINI S., ET AL., EFFECTS OF A NEW COMBINATION OF MEDICAL FOOD ON ENDOTHELIAL FUNCTION AND LIPID PROFILE IN DYSLIPIDEMIC SUBJECTS: A PILOT RANDOMIZED TRIAL, BIOMED. RES. INT., 2019, (2019); GHAEDI E., FOSHATI S., ZIAEI R., ET AL., EFFECTS OF PHYTOSTEROLS SUPPLEMENTATION ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS, CLIN. NUTR., 39, PP. 2702-2710, (2020); SANGOUNI A.A., TAGHDIR M., MIRAHMADI J., ET AL., EFFECTS OF CURCUMIN AND/OR COENZYME Q10 SUPPLEMENTATION ON METABOLIC CONTROL IN SUBJECTS WITH METABOLIC SYNDROME: A RANDOMIZED CLINICAL TRIAL, NUTR. J., 21, (2022); CHANG W., CHEN L., HATCH G.M., BERBERINE AS A THERAPY FOR TYPE 2 DIABETES AND ITS COMPLICATIONS: FROM MECHANISM OF ACTION TO CLINICAL STUDIES, BIOCHEM. CELL. BIOL., 93, PP. 479-486, (2015); SINGH N., SHARMA B., TOXICOLOGICAL EFFECTS OF BERBERINE AND SANGUINARINE, FRONT. MOL. BIOSCI., 5, (2018); YIN J., XING H., YE J., EFFICACY OF BERBERINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, METABOLISM, 57, PP. 712-717, (2008); SUKSOMBOON N., POOLSUP N., JUANAK N., EFFECTS OF COENZYME Q10 SUPPLEMENTATION ON METABOLIC PROFILE IN DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. CLIN. PHARM. THER, 40, PP. 413-418, (2015); PIRRO M., MANNARINO M.R., BIANCONI V., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL. RES., 110, PP. 76-88, (2016); OZTURK E., ARSLAN A.K.K., YERER M.B., ET AL., RESVERATROL AND DIABETES: A CRITICAL REVIEW OF CLINICAL STUDIES, BIOMED. PHARMACOTHER., 95, PP. 230-234, (2017); NEUVONEN P.J., BACKMAN J.T., NIEMI M., PHARMACOKINETIC COMPARISON OF THE POTENTIAL OVER-THE-COUNTER STATINS SIMVASTATIN, LOVASTATIN, FLUVASTATIN AND PRAVASTATIN, CLIN. PHARMACOKINET., 47, PP. 463-474, (2008); GUTIERREZ-MARISCAL F.M., DE LA CRUZ-ARES S., TORRES-PENA J.D., ET AL., COENZYME Q10 AND CARDIOVASCULAR DISEASES, ANTIOXIDANTS (BASEL), 10, (2021); LITTLEFIELD N., BECKSTRAND R.L., LUTHY K.E., STATINS' EFFECT ON PLASMA LEVELS OF COENZYME Q10 AND IMPROVEMENT IN MYOPATHY WITH SUPPLEMENTATION, J. AM. ASSOC. NURSE PRACT., 26, PP. 85-90, (2014); QU H., GUO M., CHAI H., ET AL., EFFECTS OF COENZYME Q10 ON STATIN-INDUCED MYOPATHY: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J. AM. HEART ASSOC., 7, (2018); SKARLOVNIK A., JANIC M., LUNDER M., ET AL., COENZYME Q10 SUPPLEMENTATION DECREASES STATIN-RELATED MILD-TO-MODERATE MUSCLE SYMPTOMS: A RANDOMIZED CLINICAL STUDY, MED. SCI. MONIT., 20, PP. 2183-2188, (2014); CASO G., KELLY P., MCNURLAN M.A., ET AL., EFFECT OF COENZYME Q10 ON MYOPATHIC SYMPTOMS IN PATIENTS TREATED WITH STATINS, AM. J. CARDIOL., 99, PP. 1409-1412, (2007); DOHLMANN T.L., KUHLMAN A.B., MORVILLE T., ET AL., COENZYME Q10 SUPPLEMENTATION IN STATIN TREATED PATIENTS: A DOUBLE-BLINDED RANDOMIZED PLACEBO-CONTROLLED TRIAL, ANTIOXIDANTS (BASEL), 11, (2022); ZHANG Y., LI X., ZOU D., ET AL., TREATMENT OF TYPE 2 DIABETES AND DYSLIPIDEMIA WITH THE NATURAL PLANT ALKALOID BERBERINE, J. CLIN. ENDOCRINOL. METAB., 93, PP. 2559-2565, (2008); GE Y., ZHANG Y., LI R., ET AL., BERBERINE REGULATED GCK, G6PC, PCK1 AND SREBP-1C EXPRESSION AND ACTIVATED AMP-ACTIVATED PROTEIN KINASE IN PRIMARY RAT HEPATOCYTES, INT. J. BIOL. SCI., 7, PP. 673-684, (2011); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT. MED., 10, PP. 1344-1351, (2004); TURNER N., LI J.Y., GOSBY A., ET AL., BERBERINE AND ITS MORE BIOLOGICALLY AVAILABLE DERIVATIVE, DIHYDROBERBERINE, INHIBIT MITOCHONDRIAL RESPIRATORY COMPLEX I, DIABETES, 57, PP. 1414-1418, (2008); ZHAO J.V., YEUNG W.F., CHAN Y.H., ET AL., EFFECT OF BERBERINE ON CARDIOVASCULAR DISEASE RISK FACTORS: A MECHANISTIC RANDOMIZED CONTROLLED TRIAL, NUTRIENTS, 13, (2021); DJURICIC I., CALDER P.C., BENEFICIAL OUTCOMES OF OMEGA-6 AND OMEGA-3 POLYUNSATURATED FATTY ACIDS ON HUMAN HEALTH: AN UPDATE FOR 2021, NUTRIENTS, 13, (2021); YANG F., CHEN G., EDITORIAL: NUTRIENTS, GUT MICROBIOME, AND INTESTINAL INFLAMMATION, FRONT. NUTR., 9, (2022); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY—EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR. HEART J., 36, PP. 1012-1022, (2015); PEDRO-BOTET J., MILLAN NUNEZ-CORTES J., CHILLARON J.J., ET AL., SEVERITY OF STATIN-INDUCED ADVERSE EFFECTS ON MUSCLE AND ASSOCIATED CONDITIONS: DATA FROM THE DAMA STUDY, EXPERT OPIN. DRUG SAF., 15, PP. 1583-1587, (2016); GUPTA R., ALCANTARA R., POPLI T., ET AL., MYOPATHY ASSOCIATED WITH STATINS AND SGLT2-A REVIEW OF LITERATURE, CURR. PROBL. CARDIOL., 46, (2021); ALLEN S.C., MAMOTTE C.D.S., PLEIOTROPIC AND ADVERSE EFFECTS OF STATINS-DO EPIGENETICS PLAY A ROLE?, J. PHARMACOL. EXP. THER., 362, PP. 319-326, (2017); VENERO C.V., VENERO J.V., WORTHAM D.C., ET AL., LIPID-LOWERING EFFICACY OF RED YEAST RICE IN A POPULATION INTOLERANT TO STATINS, AM. J. CARDIOL., 105, PP. 664-666, (2010); KUMARI S., SHERRIFF J.M., SPOONER D., ET AL., PERIPHERAL NEUROPATHY INDUCED BY RED YEAST RICE IN A PATIENT WITH A KNOWN SMALL BOWEL GASTROINTESTINAL TUMOUR, BMJ CASE REP, 2013, (2013); HANTSCHEL O., RIX U., SUPERTI-FURGA G., PP. 615-619, (2008); JANDA E., NEPVEU F., CALAMINI B., ET AL., MOLECULAR PHARMACOLOGY OF NRH:QUINONE OXIDOREDUCTASE 2: A DETOXIFYING ENZYME ACTING AS AN UNDERCOVER TOXIFYING ENZYME, MOL. PHARMACOL., 98, (2020); BJORNSSON E.S., HEPATOTOXICITY OF STATINS AND OTHER LIPID-LOWERING AGENTS, LIVER INT, 37, PP. 173-178, (2017); LOUBSER L., WEIDER K.I., DRAKE S.M., ACUTE LIVER INJURY INDUCED BY RED YEAST RICE SUPPLEMENT, BMJ CASE REP, 12, (2019); GRIECO A., MIELE L., POMPILI M., ET AL., ACUTE HEPATITIS CAUSED BY A NATURAL LIPID-LOWERING PRODUCT: WHEN ""ALTERNATIVE"" MEDICINE IS NO ""ALTERNATIVE"" AT ALL, J. HEPATOL., 50, PP. 1273-1277, (2009); HEBER D., LEMBERTAS A., LU Q.Y., ET AL., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J. ALTERN. COMPLEMENT. MED., 7, PP. 133-139, (2001); GORDON R.Y., COOPERMAN T., OBERMEYER W., ET AL., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS: BUYER BEWARE!, ARCH. INTERN. MED., 170, PP. 1722-1727, (2010); COHEN P.A., AVULA B., KHAN I.A., VARIABILITY IN STRENGTH OF RED YEAST RICE SUPPLEMENTS PURCHASED FROM MAINSTREAM RETAILERS, EUR. J. PREV. CARDIOL., 24, PP. 1431-1434, (2017); HACHEM R., ASSEMAT G., BALAYSSAC S., ET AL., COMPARATIVE CHEMICAL PROFILING AND MONACOLINS QUANTIFICATION IN RED YEAST RICE DIETARY SUPPLEMENTS BY <SUP>1</SUP>H-NMR AND UHPLC-DAD-MS, MOLECULES, 25, (2020); FENG D., SUN J.G., SUN R.B., ET AL., ISOFLAVONES AND PHYTOSTEROLS CONTAINED IN XUEZHIKANG CAPSULES MODULATE CHOLESTEROL HOMEOSTASIS IN HIGH-FAT DIET MICE, ACTA PHARMACOL. SIN., 36, PP. 1462-1472, (2015)","","BEIJING ACADEMY OF FOOD SCIENCES","ENGLISH","J. FUTURE FOODS","REVIEW","ISI","2-S2.0-85152093506","J FUTURE FOODS",NA,"NOTREPORTED",NA,"CHEN G, 2023, J FUTURE FOODS","CHEN G, 2023, J FUTURE FOODS"
"AMANTE C;ESPOSITO T;LUCCHEO G;LUCCHEO L;RUSSO P;DEL G P","AMANTE, CHIARA (57211021060); ESPOSITO, TIZIANA (59026437000); LUCCHEO, GIANNI (57876878600); LUCCHEO, LUIGI (57877077200); RUSSO, PAOLA (57191567298); DEL GAUDIO, PASQUALE (55898038300)","RECAPSOMA A NOVEL MIXTURE BASED ON BERGAMOT IPOMOEA BATATAS POLICOSANOL EXTRACTS AND LIPOSOMAL BERBERINE FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA",2022,"LIFE","12","",4,"10.3390/life12081162","DEPARTMENT OF PHARMACY, UNIVERSITY OF SALERNO, VIA GIOVANNI PAOLO II, FISCIANO, 132, 84084, ITALY;DEPARTMENT OF PHARMACY, UNIVERSITY OF SALERNO, VIA GIOVANNI PAOLO II, FISCIANO, 132, 84084, ITALY;LABORATORI NUTRIPHYT S.R.L, VIA ROSARIO LIVATINO, CASTEL SAN GIORGIO, 84083, ITALY;LABORATORI NUTRIPHYT S.R.L, VIA ROSARIO LIVATINO, CASTEL SAN GIORGIO, 84083, ITALY;DEPARTMENT OF PHARMACY, UNIVERSITY OF SALERNO, VIA GIOVANNI PAOLO II, FISCIANO, 132, 84084, ITALY;DEPARTMENT OF PHARMACY, UNIVERSITY OF SALERNO, VIA GIOVANNI PAOLO II, FISCIANO, 132, 84084, ITALY","CARDIOVASCULAR DISEASE (CVD) IS CONSIDERED ONE OF THE MAJOR CAUSES OF MORTALITY WORLDWIDE. EPIDEMIOLOGICAL STUDIES HAVE SHOWN THAT REGULAR CONSUMPTION OF PHENOLS IS INVERSELY ASSOCIATED WITH CARDIOVASCULAR DISEASE, AND THE USE OF NUTRACEUTICALS AND FUNCTIONAL FOODS CAN PROVIDE PROTECTIVE, PREVENTIVE, AND POSSIBLY CURATIVE EFFECTS IN CVD. A NOVEL MIXTURE OF DIFFERENT NATURAL SUBSTANCES NAMED RECAPSOMA® (BERGAMOT, LIPOSOMAL BERBERINE, IPOMOEA BATATAS, OLEUROPEIN, POLYCOSANOLS, AND VITAMIN E) HAS BEEN PRODUCED, AND ITS ANTI-DYSLIPIDAEMIC EFFICACY HAS BEEN TESTED, SPECIFICALLY STUDYING THE IN VITRO EFFECTS ON THE MECHANISMS OF ACTION UNDERLYING CHOLESTEROL SYNTHESIS, TRIGLYCERIDES, AND LDL-CHOLESTEROL OXIDATION. THE WORK HAS DEMONSTRATED THE ABILITY OF THIS HERBAL EXTRACT MIXTURE TO INHIBIT THE ACTION OF PCSK, ACAT, PAP, AND HMGR AND TO INCREASE THE LDL RECEPTOR (LDLR), UNDERLYING THE SYNERGISTIC EFFECT OF THE MIXTURE OVER THE SINGLE COMPONENTS. SUCH RESULTS SUGGEST THAT THE RECAPSOMA® MIXTURE COULD BE USED AS A TOOL FOR CONTROLLING HYPERCHOLESTEROLEMIA, AND AN ALTERNATIVE TO STATINS, ESPECIALLY FOR THOSE PATIENTS WITH METABOLIC SYNDROME. © 2022 BY THE AUTHORS.","BERGAMOT EXTRACT; CHOLESTEROL PATHWAY; HYPERCHOLESTEROLEMIC ACTIVITY; IPOMEA BATATAS EXTRACT; LDLR EXPRESSION; LIPOSOMAL BERBERINE; OLEUROPEIN; POLICOSANOL EXTRACT; RECAPSOMA<SUP>®</SUP>; VITAMIN E","","","","ROTH G.A., ABATE D., ABATE K.H., ABAY S.M., ABBAFATI C., ABBASI N., ABBASTABAR H., ABD-ALLAH F., ABDELA J., ABDELALIM A., ET AL., GLOBAL, REGIONAL, AND NATIONAL AGE-SEX-SPECIFIC MORTALITY FOR 282 CAUSES OF DEATH IN 195 COUNTRIES AND TERRITORIES, 1980–2017: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2017, LANCET, 392, PP. 1736-1788, (2018); GO A.S., MOZAFFARIAN D., ROGER V.L., BENJAMIN E.J., BERRY J.D., BLAHA M.J., DAI S., FORD E.S., FOX C.S., FRANCO S., ET AL., HEART DISEASE AND STROKE STATISTICS—2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 129, PP. E28-E292, (2014); KANNEL W.B., DAWBER T.R., KAGAN A., REVOTSKIE N., STOKES J., FACTORS OF RISK IN THE DEVELOPMENT OF CORONARY HEART DISEASE—SIX-YEAR FOLLOW-UP EXPERIENCE: THE FRAMINGHAM STUDY, ANN. INTERN. MED, 55, PP. 33-50, (1961); STAMLER J., WENTWORTH D., NEATON J.D., IS RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND RISK OF PREMATURE DEATH FROM CORONARY HEART DISEASE CONTINUOUS AND GRADED? FINDINGS IN 356,222 PRIMARY SCREENEES OF THE MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT), JAMA, 256, PP. 2823-2828, (1986); KEYS A., MIENOTTI A., KARVONEN M.J., ARAVANIS C., BLACKBURN H., BUZINA R., DJORDJEVIC B.S., DONTAS A.S., FIDANZA F., KEYS M.H., ET AL., THE DIET AND 15-YEAR DEATH RATE IN THE SEVEN COUNTRIES STUDY, AM. J. EPIDEMIOL, 124, PP. 903-915, (1986); CHAIT A., ECKEL R.H., LIPIDS, LIPOPROTEINS, AND CARDIOVASCULAR DISEASE: CLINICAL PHARMACOLOGY NOW AND IN THE FUTURE, J. CLIN. ENDOCRINOL. METAB, 101, PP. 804-814, (2016); GORDON T., CASTELLI W.P., HJORTLAND M.C., KANNEL W.B., DAWBER T.R., HIGH DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART DISEASE: THE FRAMINGHAM STUDY, AM. J. MED, 62, PP. 707-714, (1977); KANNEL W.B., CASTELLI W.P., GORDON T., CHOLESTEROL IN THE PREDICTION OF ATHEROSCLEROTIC DISEASE: NEW PERSPECTIVES BASED ON THE FRAMINGHAM STUDY, ANN. INTERN. MED, 90, PP. 85-91, (1979); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR. HEART J, 37, PP. 2999-3058, (2016); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., ET AL., STATIN INTOLERANCE—AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, EXPERT OPIN. DRUG SAF, 14, PP. 935-955, (2015); STOCLET J.-C., CHATAIGNEAU T., NDIAYE M., OAK M.-H., EL BEDOUI J., CHATAIGNEAU M., SCHINI-KERTH V.B., VASCULAR PROTECTION BY DIETARY POLYPHENOLS, EUR. J. PHARMACOL, 500, PP. 299-313, (2004); SHAHIDI F., NUTRACEUTICALS AND FUNCTIONAL FOODS IN HEALTH PROMOTION AND DISEASE PREVENTION, PROCEEDINGS OF THE III WOCMAP CONGRESS ON MEDICINAL AND AROMATIC PLANTS, 6, PP. 13-24; HUANG Y., TOCMO R., NAUMAN M.C., HAUGHAN M.A., JOHNSON J.J., DEFINING THE CHOLESTEROL LOWERING MECHANISM OF BERGAMOT (CITRUS BERGAMIA) EXTRACT IN HEPG2 AND CACO-2 CELLS, NUTRIENTS, 13, (2021); MUSOLINO V., GLIOZZI M., SCARANO F., BOSCO F., SCICCHITANO M., NUCERA S., CARRESI C., RUGA S., ZITO M.C., MAIUOLO J., ET AL., BERGAMOT POLYPHENOLS IMPROVE DYSLIPIDEMIA AND PATHOPHYSIOLOGICAL FEATURES IN A MOUSE MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE, SCI. REP, 10, (2020); MUSOLINO V., GLIOZZI M., NUCERA S., CARRESI C., MAIUOLO J., MOLLACE R., PAONE S., BOSCO F., SCARANO F., SCICCHITANO M., ET AL., THE EFFECT OF BERGAMOT POLYPHENOLIC FRACTION ON LIPID TRANSFER PROTEIN SYSTEM AND VASCULAR OXIDATIVE STRESS IN A RAT MODEL OF HYPERLIPEMIA, LIPIDS HEALTH DIS, 18, (2019); TOTH P.P., PATTI A.M., NIKOLIC D., GIGLIO R.V., CASTELLINO G., BIANCUCCI T., GERACI F., DAVID S., MONTALTO G., RIZVI A., ET AL., BERGAMOT REDUCES PLASMA LIPIDS, ATHEROGENIC SMALL DENSE LDL, AND SUBCLINICAL ATHEROSCLEROSIS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA: A 6 MONTHS PROSPECTIVE STUDY, FRONT. PHARMACOL, 6, (2016); DONG B., LI H., SINGH A.B., CAO A., LIU J., INHIBITION OF PCSK9 TRANSCRIPTION BY BERBERINE INVOLVES DOWN-REGULATION OF HEPATIC HNF1Α PROTEIN EXPRESSION THROUGH THE UBIQUITIN-PROTEASOME DEGRADATION PATHWAY, J. BIOL. CHEM, 290, PP. 4047-4058, (2015); CHEN W., MIAO Y.-Q., FAN D.-J., YANG S.-S., LIN X., MENG L.-K., TANG X., BIOAVAILABILITY STUDY OF BERBERINE AND THE ENHANCING EFFECTS OF TPGS ON INTESTINAL ABSORPTION IN RATS, AAPS PHARMSCITECH, 12, PP. 705-711, (2011); ZHANG X., QIU F., JIANG J., GAO C., TAN Y., INTESTINAL ABSORPTION MECHANISMS OF BERBERINE, PALMATINE, JATEORHIZINE, AND COPTISINE: INVOLVEMENT OF P-GLYCOPROTEIN, XENOBIOTICA, 41, PP. 290-296, (2011); DUONG T., ISOMAKI A., PAAVER U., LAIDMAE I., TONISOO A., YEN T., KOGERMANN K., RAAL A., HEINAMAKI J., PHAM T.-M., NANOFORMULATION AND EVALUATION OF ORAL BERBERINE-LOADED LIPOSOMES, MOLECULES, 26, (2021); DUONG T.T., YEN T.T.H., NGUYEN L.T., NGUYEN T.D., PHAM H.T., RAAL A., HEINAMAKI J., BERBERINE-LOADED LIPOSOMES FOR ORAL DELIVERY: PREPARATION, PHYSICOCHEMICAL CHARACTERIZATION AND IN-VIVO EVALUATION IN AN ENDOGENOUS HYPERLIPIDEMIC ANIMAL MODEL, INT. J. PHARM, 616, (2022); CHARMAN W., STELLA V., ESTIMATING THE MAXIMAL POTENTIAL FOR INTESTINAL LYMPHATIC TRANSPORT OF LIPOPHILIC DRUG MOLECULES, INT. J. PHARM, 34, PP. 175-178, (1986); NTCHAPDA F., TCHATCHOUANG F.C., MIAFFO D., MAIDADI B., VECCHIO L., TALLA R.E., BONABE C., ETET P.F.S., DIMO T., HYPOLIPIDEMIC AND ANTI-ATHEROSCLEROGENIC EFFECTS OF AQUEOUS EXTRACT OF IPOMOEA BATATAS LEAVES IN DIET-INDUCED HYPERCHOLESTEROLEMIC RATS, J. INTEGR. MED, 19, PP. 243-250, (2021); LOCKYER S., ROWLAND I., SPENCER J.P.E., YAQOOB P., STONEHOUSE W., IMPACT OF PHENOLIC-RICH OLIVE LEAF EXTRACT ON BLOOD PRESSURE, PLASMA LIPIDS AND INFLAMMATORY MARKERS: A RANDOMISED CONTROLLED TRIAL, EUR. J. NUTR, 56, PP. 1421-1432, (2017); HADRICH F., MAHMOUDI A., BOUALLAGUI Z., FEKI I., ISODA H., FEVE B., SAYADI S., EVALUATION OF HYPOCHOLESTEROLEMIC EFFECT OF OLEUROPEIN IN CHOLESTEROL-FED RATS, CHEM.-BIOL. INTERACT, 252, PP. 54-60, (2016); OLIARO-BOSSO S., GAUDINO E.C., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); MEYDANI M., VITAMIN E AND ATHEROSCLEROSIS: BEYOND PREVENTION OF LDL OXIDATION, J. NUTR, 131, PP. 366S-368S, (2001); PRINCEN H.M., VAN DUYVENVOORDE W., BUYTENHEK R., VAN DER LAARSE A., VAN POPPEL G., LEUVEN J.A.G., VAN HINSBERGH V.W., SUPPLEMENTATION WITH LOW DOSES OF VITAMIN E PROTECTS LDL FROM LIPID PEROXIDATION IN MEN AND WOMEN, ARTERIOSCLER. THROMB. VASC. BIOL, 15, PP. 325-333, (1995); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); SUI G.-G., XIAO H.-B., LU X.-Y., SUN Z.-L., NARINGIN ACTIVATES AMPK RESULTING IN ALTERED EXPRESSION OF SREBPS, PCSK9, AND LDLR TO REDUCE BODY WEIGHT IN OBESE C57BL/6J MICE, J. AGRIC. FOOD CHEM, 66, PP. 8983-8990, (2018); MCNUTT M.C., KWON H.J., CHEN C., CHEN J.R., HORTON J.D., LAGACE T.A., ANTAGONISM OF SECRETED PCSK9 INCREASES LOW DENSITY LIPOPROTEIN RECEPTOR EXPRESSION IN HEPG2 CELLS, J. BIOL. CHEM, 284, PP. 10561-10570, (2009); FAN J., RONE M.B., PAPADOPOULOS V., TRANSLOCATOR PROTEIN 2 IS INVOLVED IN CHOLESTEROL REDISTRIBUTION DURING ERYTHROPOIESIS, J. BIOL. CHEM, 284, PP. 30484-30497, (2009); LADA A.T., DAVIS M., KENT C., CHAPMAN J., TOMODA H., OMURA S., RUDEL L.L., IDENTIFICATION OF ACAT1- AND ACAT2-SPECIFIC INHIBITORS USING A NOVEL, CELL-BASED FLUORESCENCE ASSAY: INDIVIDUAL ACAT UNIQUENESS, LIPID RES, 45, PP. 378-386, (2004); WANG Y., YI X., GHANAM K., ZHANG S., ZHAO T., ZHU X., BERBERINE DECREASES CHOLESTEROL LEVELS IN RATS THROUGH MULTIPLE MECHANISMS, INCLUDING INHIBITION OF CHOLESTEROL ABSORPTION, METABOLISM, 63, PP. 1167-1177, (2014); CHARMAN W., STELLA V., EFFECTS OF LIPID CLASS AND LIPID VEHICLE VOLUME ON THE INTESTINAL LYMPHATIC TRANSPORT OF DDT, INT. J. PHARM, 33, PP. 165-172, (1986); HEIDARIAN E., RAFIEIAN-KOPAEI M., KHOSHDEL A., BAKHSHESH M., METABOLIC EFFECTS OF BERBERINE ON LIVER PHOSPHATIDATE PHOSPHOHYDROLASE IN RATS FED ON HIGH LIPOGENIC DIET: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, ASIAN PAC. J. TROP. BIOMED, 4, PP. S429-S435, (2014); NAM D.-E., YUN J.-M., KIM D., KIM O.-K., POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS, J. MED. FOOD, 22, PP. 1110-1117, (2019); LEOPOLDINI M., MALAJ N., TOSCANO M., SINDONA G., RUSSO N., ON THE INHIBITOR EFFECTS OF BERGAMOT JUICE FLAVONOIDS BINDING TO THE 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGR) ENZYME, J. AGRIC. FOOD CHEM, 58, PP. 10768-10773, (2010); PARKER R.A., PEARCE B.C., CLARK R.W., GORDON D.A., WRIGHT J.J., TOCOTRIENOLS REGULATE CHOLESTEROL PRODUCTION IN MAMMALIAN CELLS BY POST-TRANSCRIPTIONAL SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, J. BIOL. CHEM, 268, PP. 11230-11238, (1993); SANTINI A., TENORE G.C., NOVELLINO E., NUTRACEUTICALS: A PARADIGM OF PROACTIVE MEDICINE, EUR. J. PHARM. SCI, 96, PP. 53-61, (2017); KUMAR S., PANDEY A.K., CHEMISTRY AND BIOLOGICAL ACTIVITIES OF FLAVONOIDS: AN OVERVIEW, SCI. WORLD J, 2013, (2013); ASHRAFIZADEH M., FEKRI H.S., AHMADI Z., FARKHONDEH T., SAMARGHANDIAN S., THERAPEUTIC AND BIOLOGICAL ACTIVITIES OF BERBERINE: THE INVOLVEMENT OF NRF2 SIGNALING PATHWAY, J. CELL. BIOCHEM, 121, PP. 1575-1585, (2019)","P. DEL GAUDIO; DEPARTMENT OF PHARMACY, UNIVERSITY OF SALERNO, FISCIANO, VIA GIOVANNI PAOLO II, 132, 84084, ITALY; EMAIL: PDELGAUDIO@UNISA.IT","MDPI","ENGLISH","LIFE","ARTICLE","ISI","2-S2.0-85137316611","LIFE","UNIVERSITY OF SALERNO;UNIVERSITY OF SALERNO;LABORATORI NUTRIPHYT S.R.L;LABORATORI NUTRIPHYT S.R.L;UNIVERSITY OF SALERNO;UNIVERSITY OF SALERNO","NOTREPORTED;UNIVERSITY OF SALERNO;NOTREPORTED",NA,"AMANTE C, 2022, LIFE","AMANTE C, 2022, LIFE"
"SUN L;LI X;MA C;HE Z;ZHANG X;WANG C;ZHAO M;GAN J;FENG Y","SUN, LONG (37060218600); LI, XIAN (55252109700); MA, CHENJING (57217217257); HE, ZHAO (55223278500); ZHANG, XIN (56376070800); WANG, CHENGYE (49662604600); ZHAO, MIN (55361761700); GAN, JIN (55234305200); FENG, YING (34770356600)","IMPROVING EFFECT OF THE POLICOSANOL FROM ERICERUS PELA WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE",2022,"FOODS","11","",9,"10.3390/foods11142095","KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA;KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA","POLICOSANOL (PC) IS A MIXTURE OF LONG-CHAIN FATTY ALCOHOLS THAT EXHIBITS MULTIPLE BIOLOGICAL ACTIVITIES, SUCH AS REDUCING BLOOD LIPID AND CHOLESTEROL LEVELS, LOWERING BLOOD PRESSURE, AND EXTENUATING LIVER INFLAMMATION. TO ASSESS PC’S IMPACT ON COGNITIVE BEHAVIOR AND FUNCTION, PC WAS PREPARED FROM ERICERUS PELA WAX USING A REDUCTION METHOD AND ANALYZED USING GAS CHROMATOGRAPHY (GC). A TOTAL OF 60 MICE WERE RANDOMLY DIVIDED INTO SIX GROUPS OF 10 ANIMALS EACH: CONTROL (0.5% CMC-NA SOLUTION, I.G.), MODEL (0.5% CMC-NA SOLUTION, I.G.), DONEPEZIL (3 MG/KG, I.G.), PC LOW- (2 G/KG, I.G.), MEDIUM (4 G/KG, I.G.), AND HIGH- (6 G/KG, I.G.) DOSE GROUPS. ALL THE GROUPS WERE ADMINISTERED DAILY FOR 28 CONSECUTIVE DAYS. THERE WERE FOUR PARAMETERS—ESCAPE LATENCY, CROSSINGS OF PLATFORM, SWIMMING DISTANCE, AND TIME SPENT IN THE TARGET QUADRANT—THAT WERE RECORDED TO EVALUATE THE COGNITIVE PERFORMANCE OF MICE IN THE MORRIS WATER MAZE (MWM). AFTER MWM TESTING, THE LEVELS OF ACETYLCHOLINE (ACH), ACETYLCHOLINESTERASE (ACHE), SUPEROXIDE DISMUTASE (SOD), MALONDIALDEHYDE (MDA), AND GLUTATHIONE (GSH) THAT WERE PRESENT IN BRAIN TISSUE WERE DETERMINED USING ASSAY KITS. THE GC DATA SHOWED THAT PC CONSISTED OF FOUR MAJOR COMPONENTS: TETRACOSANOL (14.40%), HEXACOSANOL (48.97%), OCTACOSANOL (25.40%), AND TRIACONTANOL (4.80%). IN THE MWM TEST, PC SIGNIFICANTLY DECREASED THE ESCAPE LATENCY (P < 0.05) AND INCREASED THE CROSSINGS OF THE PLATFORM (P < 0.05) AND SWIMMING DISTANCE (P < 0.05) AND TIME IN THE TARGET QUADRANT (P < 0.05) IN RODENTS COMPARED TO THAT IN THE MODEL GROUP. MOREOVER, PC INCREASED THE LEVELS OF ACH, SOD, AND GSH; INHIBITED ACHE; AND REDUCED MDA IN THE BRAIN TISSUE OF THE TESTED ANIMALS. THIS IS THE FIRST REPORT TO EVALUATE THE EFFICACY OF PC FOR COGNITIVE BEHAVIOR AND FUNCTION IN ANIMALS. OUR FINDINGS DEMONSTRATE THAT PC FROM E. PELA WAX IS LIKELY TO EXERT AN ENHANCING EFFECT ON LEARNING AND MEMORY BY PROMOTING THE CHOLINERGIC SYSTEM AND ATTENUATING OXIDATIVE STRESS, WHICH WILL PROVIDE A NEW INSIGHT INTO THE EFFICACY OF PC AND EXPAND ITS APPLICATION IN THE FOOD, NUTRACEUTICAL, AND BEVERAGE INDUSTRIES. © 2022 BY THE AUTHORS.","ALZHEIMER’S DISEASE; CHOLINERGIC SYSTEM; COGNITIVE IMPAIRMENT; ERICERUS PELA WAX; MORRIS WATER MAZE; OXIDATIVE STRESS; POLICOSANOL","","CHINESE ACADEMY OF FORESTRY, CAF, (CAFYBB2018ZB007, CAFYBB2019SZ005)","THIS STUDY WAS FINANCIALLY SUPPORTED BY THE FUNDAMENTAL RESEARCH FUNDS OF CHINESE ACADEMY OF FORESTRY (NO. CAFYBB2019SZ005, NO. CAFYBB2018ZB007).","BARNHAM K.J., MASTERS C.L., BUSH A.I., NEURODEGENERATIVE DISEASES AND OXIDATIVE STRESS, NAT. REV. DRUG DISCOV, 3, PP. 205-214, (2004); ROBINSON L., TANG E., TAYLOR J.P., DEMENTIA: TIMELY DIAGNOSIS AND EARLY INTERVENTION, BR. MED. J, 350, (2015); MENDIOLA-PRECOMA J., BERUMEN L.C., PADILLA K., GARCIA-ALCOCER G., THERAPIES FOR PREVENTION AND TREATMENT OF ALZHEIMER’S DISEASE, BIOMED. RES. INT, 2016, PP. 1-17, (2016); DU X., WANG X., GENG M., ALZHEIMER′S DISEASE HYPOTHESIS AND RELATED THERAPIES, TRANSL. NEURODEGENER, 7, PP. 1-7, (2018); KAWANISHI K., AOKI K., HASHIMOTO Y., MATSUNOBU A., FREE PRIMARY ALCOHOLS IN OILS AND WAXES FROM GERMS, KERNELS AND OTHER COMPONENTS OF NUTS, SEEDS, FRUITS AND CEREALS, J. AM. OIL CHEM. SOC, 68, PP. 869-872, (1991); GUO Z., XU L., THE NATURAL MIXTURE OF POLICOSANOLS: A NEW CHOLESTEROL-LOWERING DRUG FROM SUGAR CANE WAX, WORLD NOTES PLANT MED, 16, PP. 231-236, (2001); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., FRAGA V., MENENDEZ R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ. J. MED. BIOL. RES, 32, PP. 1269-1276, (1999); WEERAWATANAKORN M., MEEROD K., WONGWAIWECH D., HO C., POLICOSANOLS: CHEMISTRY, OCCURRENCE, AND HEALTH EFFECTS, CURR. PHARMACOL. REP, 5, PP. 131-149, (2019); ASKARPOUR M., GHAEDI E., ROSHANRAVAN N., HADI A., MOHAMMADI H., SYMONDS M.E., MIRAGHAJANI M., POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED, 45, PP. 89-97, (2019); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); PARK H., YADAV D., JEONG D., KIM S., BAE M., KIM J., CHO K., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENV. RES. PUBLIC HEALTH, 16, (2019); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., MOTOMURA K., SHIMURA T., OKAJIMA Y., MIZUNOE Y., ET AL., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI. REP, 9, (2019); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES, 56, PP. 176-182, (1995); KIM K., KIM C., CHO K., JANG W., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN. EXP. PHARMACOL. PHYSIOL, 48, PP. 1336-1345, (2021); WANG Z., FENG Y., SUN L., GAN J., LI X., DING W., CHEN X., ANTI-ANDROGENETIC ALOPECIA EFFECT OF POLICOSANOL FROM CHINESE WAX BY REGULATING ABNORMAL HORMONE LEVELS TO SUPPRESS PREMATURE HAIR FOLLICLE ENTRY INTO THE REGRESSION PHASE, BIOMED. PHARMACOTHER, 136, (2021); MA J., LI K., ZHANG W., MA L., XU J., LIU L., CHEN X., ZHANG H., FOOD SCIENCE AND HUMAN WELLNESS, FOOD SCI. HUM. WELLNESS, 11, PP. 356-365, (2022); MA J., MA L., LI K., ZHANG W., ZHANG Y., YANG M., CHEN X., ZHANG H., PREPARATION OF MICROEMULSION WITH POLICOSANOL DERIVED FROM INSECT WAX AND ITS APPLICATION IN FUNCTIONAL BEVERAGE, FOOD SCI, 40, PP. 78-84, (2019); CHEN X., WANG Z., CHEN Y., YE S., WANG S., FENG Y., THE MAIN CLIMATE FACTORS AFFECTING WAX EXCRETION OF ERICERUS PELA CHAVANNES (HOMOPETERA: COCCIDAE) AND AN ANALYSIS OF ITS ECOLOGICAL ADAPTABILITY, ACTA ENTOMOL. SIN, 50, PP. 136-143, (2007); QIN T., THE PELA WAX SCALE AND COMMERCIAL WAX PRODUCTION, SOFT SCALE INSECTS THEIR BIOLOGY, NATURAL ENEMIES AND CONTROL, 7A, PP. 303-321, (1997); TAKAHASHI S., NOMURA Y., WAX COMPOSITION OF THE SOFT SCALE ERICERUS PELA (HEMIPTERA: COCCIDAE), ENTOMOL. GEN, 7, PP. 313-316, (1982); MA L., WANG Y., ZHANG Z., GAN J., ZHENG H., GUO Y., ZHAO H., DUAN Q., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, CHEM. IND. FOREST PRODUCT, 29, PP. 6-10, (2009); HAMPEL H., MESULAM M.M., CUELLO A.C., KHACHATURIAN A.S., VERGALLO A., FARLOW M.R., SNYDER P.J., GIACOBINI E., KHACHATURIAN Z.S., REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH, J. ALZHEIMER′S DIS, 6, PP. 2-15, (2019); KASA P., RAKONCZAY Z., GULYA K., THE CHOLINERGIC SYSTEM IN ALZHEIMER′S DISEASE, PROG. NEUROBIOL, 52, PP. 511-535, (1997); FROLICH L., THE CHOLINERGIC PATHOLOGY IN ALZHEIMER′S DISEASE--DISCREPANCIES BETWEEN CLINICAL EXPERIENCE AND PATHOPHYSIOLOGICAL FINDINGS, J. NEURAL TRANSM, 109, PP. 1003-1013, (2002); RAMSAY R., TIPTON K., ASSESSMENT OF ENZYME INHIBITION: A REVIEW WITH EXAMPLES FROM THE DEVELOPMENT OF MONOAMINE OXIDASE AND CHOLINESTERASE INHIBITORY DRUGS, MOLECULES, 22, (2017); LI D., JIN-ZHAO W., LI Y., CHENG L., CHOLINE TRANSPORTERS AND THE PATHOGENESIS OF ALZHEIMER′S DISEASE, PROG. BIOCHEM. BIOPHYS, 41, PP. 1207-1213, (2014); LONG J.M., HOLTZMAN D.M., ALZHEIMER DISEASE: AN UPDATE ON PATHOBIOLOGY AND TREATMENT STRATEGIES, CELL, 179, PP. 312-339, (2019); CASETTA I., GOVONI V., GRANIERI E., OXIDATIVE STRESS, ANTIOXIDANTS AND NEURODEGENERATIVE DISEASES, CURR. PHARM. DESIGN, 11, PP. 2033-2052, (2005); ROCHETTE L., ZELLER M., COTTIN Y., VERGELY C., DIABETES, OXIDATIVE STRESS AND THERAPEUTIC STRATEGIES, BIOCHIM. BIOPHYS. ACTA GEN. SUBJ, 1840, PP. 2709-2729, (2014); BOUAYED J., BOHN T., EXOGENOUS ANTIOXIDANTS—DOUBLE-EDGED SWORDS IN CELLULAR REDOX STATE: HEALTH BENEFICIAL EFFECTS AT PHYSIOLOGIC DOSES VERSUS DELETERIOUS EFFECTS AT HIGH DOSES, OXID. MED. CELL LONGEV, 3, PP. 228-237, (2010); POCERNICH C.B., BUTTERFIELD D.A., ELEVATION OF GLUTATHIONE AS A THERAPEUTIC STRATEGY IN ALZHEIMER DISEASE, BIOCHIM. BIOPHYS. ACTA MOL. BASIS. DIS, 1822, PP. 625-630, (2012); LINTONA S., DAVIES M.J., DEAN R.T., PROTEIN OXIDATION AND AGEING, EXP. GERONTOL, 36, PP. 1503-1518, (2001); OHTA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, J. CLIN. BIOCHEM. NUTR, 42, PP. 118-125, (2008); ZHANG X., MA C., SUN L., HE Z., FENG Y., LI X., GAN J., CHEN X., EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID Β-PEPTIDE-INDUCED TOXICITY IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE, BMC COMPLEMENT. THER. MED, 21, (2021); BORG J., KESSLAK P.J., COTMAN C.W., PERIPHERAL ADMINISTRATION OF A LONG-CHAIN FATTY ALCOHOL PROMOTES SEPTAL CHOLINERGIC NEURONS SURVIVAL AFTER FIMBRIA-FORNIX TRANSECTION, BRAIN RES, 518, (1990); AZZOUZ M., KENNEL P.F., WARTER J., POINDRON P., BORG J., ENHANCEMENT OF MOUSE SCIATIC NERVE REGENERATION BY THE LONG CHAIN FATTY ALCOHOL, N-HEXACOSANOL, EXP. NEUROL, 138, PP. 189-197, (1996); KIM H., PARK S., HAN D.S., PARK T., OCTACOSANOL SUPPLEMENTATION INCREASES RUNNING ENDURANCE TIME AND IMPROVES BIOCHEMICAL PARAMETERS AFTER EXHAUSTION IN TRAINED RATS, J. MED. FOOD, 6, PP. 345-351, (2003); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB, 37, PP. 33-38, (1993)","Y. FENG; KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL, FORESTRY AND GRASSLAND ADMINISTRATION, INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650224, CHINA; EMAIL: RIRIFY@139.COM","MDPI","ENGLISH","FOODS","ARTICLE","ISI","2-S2.0-85136239596","FOODS","INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE","NOTREPORTED;INSTITUTE OF HIGHLAND FOREST SCIENCE;NOTREPORTED",NA,"SUN L, 2022, FOODS","SUN L, 2022, FOODS"
"LIU Y;ZHANG H;XU J;HE R;MA J;CHEN C;LIU L","LIU, YIWEN (57215609301); ZHANG, HONG (55070241500); XU, JUAN (57189688812); HE, RUI (58387617800); MA, JINJU (56149760100); CHEN, CHIQING (58179667800); LIU, LANXIANG (55565702000)","A NEW STRATEGY FOR CONSUMPTION OF FUNCTIONAL LIPIDS FROM ERICERUS PELA CHAVANNES STUDY ON MICROCAPSULES AND EFFERVESCENT TABLETS CONTAINING INSECT WAXDERIVED POLICOSANOL",2023,"FOODS","12","",1,"10.3390/foods12193567","INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA, RESEARCH CENTER OF EFFICIENT BREEDING AND DEEP PROCESSING ENGINEERING TECHNOLOGY OF GALLNUT, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, WUFENG, 443400, CHINA;INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA;INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA;INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA, KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, KUNMING, 650233, CHINA;INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA, KEY LABORATORY OF BREEDING AND UTILIZATION OF RESOURCE INSECTS, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, KUNMING, 650233, CHINA;RESEARCH CENTER OF EFFICIENT BREEDING AND DEEP PROCESSING ENGINEERING TECHNOLOGY OF GALLNUT, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, WUFENG, 443400, CHINA;INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA, RESEARCH CENTER OF ENGINEERING AND TECHNOLOGY OF CHARACTERISTIC FOREST RESOURCES, NATIONAL FORESTRY AND GRASSLAND ADMINISTRATION, KUNMING, 650233, CHINA","IN THIS STUDY, WE ADDRESSED VARIOUS CHALLENGES ASSOCIATED WITH THE CONSUMPTION OF FUNCTIONAL LIPIDS FROM THE ERICERUS PELA (CHAVANNES), INCLUDING UNFAVORABLE TASTE, INSOLUBILITY IN WATER, DIFFICULTY IN ORAL INTAKE, LOW BIOAVAILABILITY, AND LOW PSYCHOLOGICAL ACCEPTANCE. OUR STUDY FOCUSED ON THE MICROENCAPSULATION OF POLICOSANOL, THE KEY ACTIVE COMPONENT OF INSECT WAX, WHICH IS A MIXTURE OF FUNCTIONAL LIPIDS SECRETED BY THE ERICERUS PELA (CHAVANNES). WE DEVELOPED TWO INNOVATIVE POLICOSANOL PRODUCTS, MICROCAPSULES, AND EFFERVESCENT TABLETS, AND OPTIMIZED THEIR PREPARATION CONDITIONS. WE SUCCESSFULLY PREPARED MICROCAPSULES CONTAINING INSECT WAX–DERIVED POLICOSANOL USING THE SPRAY-DRYING METHOD. WE ACHIEVED 92.09% MICROENCAPSULATION EFFICIENCY AND 61.67% POWDER YIELD UNDER THE FOLLOWING CONDITIONS: MALTODEXTRIN, STARCH SODIUM OCTENYL SUCCINATE, AND (2-HYDROXY)PROPYL-Β-CYCLODEXTRIN (HPΒCD) AT A RATIO OF 1:1:1, CORE-TO-WALL MATERIALS AT A RATIO OF 1:10, 15% SOLID CONTENT, SPRAY DRYER FEED TEMPERATURE AT 60 °C, INLET AIR TEMPERATURE AT 140 °C, AND HOT-AIR FLOW RATE AT 0.5 M3/MIN. THE MICROCAPSULES EXHIBITED A REGULAR SPHERICAL SHAPE WITH A MINIMAL WATER CONTENT (1.82%) AND RAPID DISPERSION IN WATER (WITHIN 143.5 S). THESE MICROCAPSULES RELEASED POLICOSANOL RAPIDLY IN SIMULATED STOMACH FLUID. MOREOVER, EFFERVESCENT TABLETS WERE PREPARED USING THE POLICOSANOL-CONTAINING MICROCAPSULES. THE TABLETS SHOWED LOW FRIABILITY (0.32%), QUICK DISINTEGRATION IN WATER (WITHIN 99.5 S), AND HIGH BUBBLE VOLUME. THE MICROCAPSULES AND EFFERVESCENT TABLETS DEVELOPED IN THIS STUDY PRESENTED EFFECTIVE SOLUTIONS TO THE INSOLUBILITY OF POLICOSANOL IN WATER. THESE PRODUCTS WERE PORTABLE AND OFFERED CUSTOMIZABLE TASTES TO ADDRESS THE PSYCHOLOGICAL DISCOMFORT RELATED TO INSECT-BASED FOODS, THUS PROVIDING A NOVEL STRATEGY FOR THE CONSUMPTION AND SECONDARY PROCESSING OF INSECT LIPIDS. © 2023 BY THE AUTHORS.","EDIBLE INSECT; EFFERVESCENT TABLETS; FUNCTIONAL INSECT LIPIDS; INSECT WAX–DERIVED POLICOSANOL; MICROCAPSULES","","FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF, (CAFYBB2018SY025, CAFYBB2021SY011)","THIS RESEARCH WAS FUNDED BY THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF, GRANT NUMBER CAFYBB2021SY011 AND THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF, GRANT NUMBER CAFYBB2018SY025.","VAN HUIS A., INSECTS AS FOOD AND FEED, A NEW EMERGING AGRICULTURAL SECTOR: A REVIEW, J. INSECTS FOOD FEED, 6, PP. 27-44, (2020); FENG Y., CHEN X., ZHAO M., EDIBLE INSECTS OF CHINA, (2016); MEYER-ROCHOW V.B., GAHUKAR R.T., GHOSH S., JUNG C., CHEMICAL COMPOSITION, NUTRIENT QUALITY AND ACCEPTABILITY OF EDIBLE INSECTS ARE AFFECTED BY SPECIES, DEVELOPMENTAL STAGE, GENDER, DIET, AND PROCESSING METHOD, FOODS, 10, (2021); BAEK S., MAE A.S., NAM I., OPTIMIZATION OF THE HEAT-DRYING CONDITIONS OF DRONE PUPAE BY RESPONSE SURFACE METHODOLOGY (RSM), FOODS, 12, (2023); YANG Q., LIU G., WEI M., RESEARCH ADVANCES IN NUTRITION AND DEVELOPMENT OF INSECT OIL, FOOD SCI. TECHNOL, 33, PP. 246-249, (2008); PEREZ-SANTAESCOLASTICA C., DE WINNE A., DEVAERE J., FRAEYE I., THE FLAVOUR OF EDIBLE INSECTS: A COMPREHENSIVE REVIEW ON VOLATILE COMPOUNDS AND THEIR ANALYTICAL ASSESSMENT, TRENDS FOOD SCI. TECHNOL, 127, PP. 352-367, (2022); LANGE K.W., NAKAMURA Y., EDIBLE INSECTS AS FUTURE FOOD: CHANCES AND CHALLENGES, J. FUTURE FOODS, 1, PP. 38-46, (2021); CHINARAK K., PANPIPAT W., PANYA A., PHONSATTA N., CHEONG L.-Z., CHAIJAN M., A NOVEL STRATEGY FOR THE PRODUCTION OF EDIBLE INSECTS: EFFECT OF DIETARY PERILLA SEED SUPPLEMENTATION ON NUTRITIONAL COMPOSITION, GROWTH PERFORMANCE, LIPID METABOLISM AND DESATURASE GENE EXPRESSION OF SAGO PALM WEEVIL (RHYNCHOPHORUS FERRUGINEUS) LARVAE, FOODS, 11, (2022); YANG P., ZHU J., CHEN X., LI M., ISOLATION AND CHARACTERIZATION OF MICROSATELLITE LOCI FROM THE CHINESE WHITE WAX SCALE ERICERUS PELA CHAVANNES (HOMOPETERA: COCCIDAE), AFR. J. MICROBIOL. RES, 5, PP. 1246-1248, (2011); YANG P., ZHU J., MENG L., LI J., CHEN X., SOLUBLE PROTEOME ANALYSIS OF MALE ERICERUS PELA CHAVANNES CUTICLE AT THE STAGE OF THE SECOND INSTAR LARVA, AFR. J. MICROBIOL. RES, 5, PP. 1108-1118, (2011); LIN L., ZHOU Y., LI H., PANG D., ZHANG L., LU X., CHEN Z., ZHAO X., ZUO D., SUN L., POLYSACCHARIDE EXTRACTED FROM CHINESE WHITE WAX SCALE AMELIORATES 2,4-DINITROCHLOROBENZENE-INDUCED ATOPIC DERMATITIS-LIKE SYMPTOMS IN BALB/C MICE, SAUDI PHARM. J, 25, PP. 625-632, (2017); HU Y.-H., CHEN X.-M., YANG P., DING W.-F., CHARACTERIZATION AND FUNCTIONAL ASSAY OF A FATTY ACYL-COA REDUCTASE GENE IN THE SCALE INSECT, ERICERUS PELA CHAVANNES (HEMIPTERA: COCCOIDAE), ARCH. INSECT BIOCHEM. PHYSIOL, 97, (2018); FENG Y., CHEN X., MA Y., HE Z., EXPERIMENTAL STUDY ON IMMUNOMODULATION OF WHITE WAX SCALE (ERICERUS PELA CHAVANNES), FOR. RES, 19, PP. 221-224, (2006); FENG Y., HE Z., LI X., CHEN Z., SUN L., IMMUNOMODULATORY AND ANTITUMOR ACTIVITIES OF POLYSACCHARIDE FROM CHINESE WHITE WAX SCALE, FOR. RES, 27, PP. 388-392, (2014); CHEN X., NATURAL POPULATION ECOLOGY OF ERICERUS PELA, (2011); MA J., LI K., ZHANG W., MA L., XU J., LIU L., CHEN X., ZHANG H., ACUTE TOXICITY AND CHROMOSOMAL ABERRATION TOXICITY OF INSECT WAX AND ITS POLICOSANOL, FOOD SCI. HUM. WELLNESS, 11, PP. 356-365, (2022); MA J., MA L., ZHANG H., ZHANG Z., WANG Y., LI K., CHEN X., POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY, PLOS ONE, 13, (2018); MA J., MA L., ZHANG H., ZHANG Z., WANG Y., THE PREPARATION AND EVALUATION OF EFFICACY ON SKIN WOUND HEALING IN MICE OF INSECT WAX COMPOUND OINTMENT, J. ENVIRON. ENTOMOL, 40, PP. 1238-1247, (2018); MA J., MA L., LI K., ZHANG W., ZHANG Y., YANG M., CHEN X., ZHANG H., PREPARATION OF MICROEMULSION WITH POLICOSANOL DERIVED FROM INSECT WAX AND ITS APPLICATION IN FUNCTIONAL BEVERAGE, FOOD SCI, 40, PP. 78-84, (2019); WANG Z., FENG Y., MA L., LI X., DING W., CHEN X., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMED. PHARMACOTHER, 89, PP. 438-446, (2017); MA L., WANG Y., ZHANG Z., ZHENG H., GAN J., LI Z., DUAN Q., PREPARATION OF POLICOSANOL FROM INSECT WAX, SCI. TECHNOL. FOOD IND, 29, PP. 179-181, (2008); MA L., WANG Y., ZHANG Z., GAN J., ZHENG H., GUO Y., ZHAO H., QIONGFEN D., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, CHEM. IND. FOR. PROD, 29, PP. 6-10, (2009); VENTURELLI A., BRIGHENTI V., MASCOLO D., PELLATI F., A NEW STRATEGY BASED ON MICROWAVE-ASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND, J. PHARM. BIOMED. ANAL, 172, PP. 200-205, (2019); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); ZHANG W., ZHENG H., FENG Y., XU J., HOU B., LIU L., ZHANG H., MICROENCAPSULATION OF PHYLLANTHUS EMBLICA L. FRUIT JUICE, FOOD SCI, 36, PP. 25-29, (2015); SANCHEZ C.A.O., ZAVALETA E.B., GARCIA G.R.U., SOLANO G.L., DIAZ M.P.R., KRILL OIL MICROENCAPSULATION: ANTIOXIDANT ACTIVITY, ASTAXANTHIN RETENTION, ENCAPSULATION EFFICIENCY, FATTY ACIDS PROFILE, IN VITRO BIOACCESSIBILITY AND STORAGE STABILITY, LWT-FOOD SCI. TECHNOL, 147, (2021); LI Y., STUDY OF EXTRACTION OF OCTACOSANOL FROM RICE BRAN AND ITS MICROENCAPSULATION, MASTER’S THESIS, (2013); LUO C., CHENG Y., YI Y., XIA B., ZHOU H., CAO X., OPTIMIZATION OF PREPARATION PROCESS FOR BLEND MICROCAPSULES OF PHYTOSTEROL ESTERS AND PUERARIN, FOOD SCI, 37, PP. 26-33, (2016); RODRIGUEZ-CORTINA A., RODRIGUEZ-CORTINA J., HERNANDEZ-CARRION M., OBTENTION OF SACHA INCHI (PLUKENETIA VOLUBILIS LINNEO) SEED OIL MICROCAPSULES AS A STRATEGY FOR THE VALORIZATION OF AMAZONIAN FRUITS: PHYSICOCHEMICAL, MORPHOLOGICAL, AND CONTROLLED RELEASE CHARACTERIZATION, FOODS, 11, (2022); CHEN F., STUDY ON THE EXTRACTION, PURIFICATION AND THE ANTI-FATIGUE FUNCTION OF OCTACOSANOL FROM RICE BRAN, PH.D. THESIS, (2003); CHINESE PHARMACOPOEIA (PART IV), (2015); ZHANG Y., GONG C., STUDY ON SODIUM OCTENYLSUCCINATE STARCH WITH LOW VISCOSITY USED AS WALL MATERIALS TO MICROENCAPSULATE OIL, FOOD SCI, 27, PP. 148-152, (2006); HE H., HONG Y., GU Z., LIU G., CHENG L., LI Z., IMPROVED STABILITY AND CONTROLLED RELEASE OF CLA WITH SPRAY-DRIED MICROCAPSULES OF OSA-MODIFIED STARCH AND XANTHAN GUM, CARBOHYDR. POLYM, 147, PP. 243-250, (2016); SWEEDMAN M.C., TIZZOTTI M.J., SCHAFER C., GILBERT R.G., STRUCTURE AND PHYSICOCHEMICAL PROPERTIES OF OCTENYL SUCCINIC ANHYDRIDE MODIFIED STARCHES: A REVIEW, CARBOHYDR. POLYM, 92, PP. 905-920, (2013); ILHAN DINCER E., TEMIZ H., INVESTIGATION OF PHYSICOCHEMICAL, MICROSTRUCTURE AND ANTIOXIDANT PROPERTIES OF FIRETHORN (PYRACANTHA COCCINEA VAR. LALANDI) MICROCAPSULES PRODUCED BY SPRAY-DRIED AND FREEZE-DRIED METHODS, S. AFR. J. BOT, 155, PP. 340-354, (2023); MAURY M., MURPHY K., KUMAR S., SHI L., LEE G., EFFECTS OF PROCESS VARIABLES ON THE POWDER YIELD OF SPRAY-DRIED TREHALOSE ON A LABORATORY SPRAY-DRYER, EUR. J. PHARM. BIOPHARM, 59, PP. 565-573, (2005); VILLALOBOS-ESPINOSA J.C., GARCIA-ARMENTA E., ALAMILLA-BELTRAN L., QUINTANILLA-CARVAJAL M.X., AZUARA-NIETO E., HERNANDEZ-SANCHEZ H., PEREA-FLORES M., GUTIERREZ-LOPEZ G.F., EFFECT OF PUMPING AND ATOMISATION ON THE STABILITY OF OIL/WATER EMULSIONS, J. FOOD ENG, 327, (2022); LIU Z., CAO Y., TAN F., MICROENCAPSULATION OF EVENING PRIMROSE OIL WITH STARCH SODIUM OCTENYLSUCCINATE, J. DALIAN INST. LIGHT IND, 26, PP. 337-341, (2007); SAIFULLAH M., YUSOF Y.A., CHIN N.L., AZIZ M.G., MOHAMMED M.A.P., AZIZ N.A., DISSOLUTION PROFILING AND ITS COMPARISON OF NATURAL FRUIT POWDER EFFERVESCENT TABLETS, J. FOOD ENG, 178, PP. 60-70, (2016); BARBOSA-CANOVAS G.V., ORTEGA-RIVAS E., JULIANO P., YAN H., FOOD POWDERS: PHYSICAL PROPERTIES, PROCESSING, AND FUNCTIONALITY, 86, (2005)","J. MA; INSTITUTE OF HIGHLAND FOREST SCIENCE, CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA; EMAIL: MAJINJU1231KM@HOTMAIL.COM","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","FOODS","ARTICLE","ISI","2-S2.0-85173893562","FOODS","INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;INSTITUTE OF HIGHLAND FOREST SCIENCE;RESEARCH CENTER OF EFFICIENT BREEDING AND DEEP PROCESSING ENGINEERING TECHNOLOGY OF GALLNUT;INSTITUTE OF HIGHLAND FOREST SCIENCE","NOTREPORTED;INSTITUTE OF HIGHLAND FOREST SCIENCE;NOTREPORTED",NA,"LIU Y, 2023, FOODS","LIU Y, 2023, FOODS"
"RENDINA D;D′ELIA L;ABATE V;REBELLATO A;BUONDONNO I;SUCCOIO M;MARTINELLI F;MUSCARIELLO R;DE F G;D′AMELIO P;FALLO F;STRAZZULLO P;FARAONIO R","RENDINA, DOMENICO (6603061135); D′ELIA, LANFRANCO (57013454700); ABATE, VERONICA (57219130640); REBELLATO, ANDREA (55987515900); BUONDONNO, ILARIA (56652542200); SUCCOIO, MARIANGELA (55565851900); MARTINELLI, FABIO (57765428900); MUSCARIELLO, RICCARDO (36059690000); DE FILIPPO, GIANPAOLO (9940221500); D′AMELIO, PATRIZIA (6506336673); FALLO, FRANCESCO (7006055453); STRAZZULLO, PASQUALE (7005192838); FARAONIO, RAFFAELLA (6601983560)","VITAMIN D STATUS CARDIOVASCULAR RISK PROFILE AND MIRNA21 LEVELS IN HYPERTENSIVE PATIENTS RESULTS OF THE HYPODD STUDY",2022,"NUTRIENTS","14","",7,"10.3390/nu14132683","DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;DEPARTMENT OF MEDICINE, CLINICA MEDICA 3, UNIVERSITY OF PADOVA, PADOVA, 35122, ITALY;DEPARTMENT OF MEDICAL SCIENCE, GERIATRIC AND BONE DISEASES UNIT, UNIVERSITY OF TURIN, TORINO, 10124, ITALY;DEPARTMENT OF MOLECULAR MEDICINE AND MEDICAL BIOTECHNOLOGY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;DEPARTMENT OF MOLECULAR MEDICINE AND MEDICAL BIOTECHNOLOGY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, HÔPITAL ROBERT DEBRÉ, SERVICE D’ENDOCRINOLOGIE ET DIABÉTOLOGIE PÉDIATRIQUE, PARIS, 75015, FRANCE;DEPARTMENT OF MEDICAL SCIENCE, GERIATRIC AND BONE DISEASES UNIT, UNIVERSITY OF TURIN, TORINO, 10124, ITALY, DEPARTMENT OF INTERNAL MEDICINE, SERVICE OF GERIATRIC MEDICINE AND GERIATRIC REHABILITATION, UNIVERSITY OF LAUSANNE HOSPITAL CENTRE, LAUSANNE, 1011, SWITZERLAND;DEPARTMENT OF MEDICINE, CLINICA MEDICA 3, UNIVERSITY OF PADOVA, PADOVA, 35122, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY;DEPARTMENT OF MOLECULAR MEDICINE AND MEDICAL BIOTECHNOLOGY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY","THE VITAMIN D AND MICRORNA (MIR) SYSTEMS MAY PLAY A ROLE IN THE PATHOGENESIS OF CARDIOMETABOLIC DISORDERS, INCLUDING HYPERTENSION. THE HYPODD STUDY WAS A DOUBLE-BLIND PLACEBOCONTROLLED TRIAL AIMING TO ASSESS THE EFFECTS OF CHOLECALCIFEROL TREATMENT IN PATIENTS WITH WELL-CONTROLLED HYPERTENSION AND HYPOVITAMINOSIS D (25OHD LEVELS < 50 NMOL/L). IN ADDITION TO THIS CLINICAL TRIAL, WE ALSO EVALUATED THE EFFECTS OF CHOLECALCIFEROL AND CALCITRIOL TREATMENT ON MIR-21 EXPRESSION IN VIVO AND IN VITRO, RESPECTIVELY. CHANGES IN THE CARDIOVASCULAR RISK PROFILES WERE EVALUATED IN HYPODD PATIENTS TREATED WITH CHOLECALCIFEROL (C-COHORT) OR WITH PLACEBO (P-COHORT). THE MIR-21CIRCULATING LEVELS WERE MEASURED IN FOUR C-COHORT PATIENTS AND FIVE P-COHORT PATIENTS. IN VITRO, THE MIR-21 LEVELS WERE MEASURED IN HEK-293 CELLS TREATED WITH CALCITRIOL OR WITH ETHANOL VEHICLE CONTROL. CHOLECALCIFEROL TREATMENT INCREASED 25OHD LEVELS AND REDUCED PARATHORMONE, TOTAL CHOLESTEROL, AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN C-COHORT PATIENTS, WHEREAS NO SIGNIFICANT CHANGES IN THESE PARAMETERS WERE OBSERVED IN P-COHORT PATIENTS. THE MIR-21 CIRCULATING LEVELS DID NOT CHANGE IN THE C-OR THE P-COHORT PATIENTS UPON TREATMENT. CALCITRIOL TREATMENT DID NOT AFFECT MIR-21 LEVELS IN HEK-293 CELLS. IN CONCLUSION, HYPOVITAMINOSIS D CORRECTION AMELIORATED THE CARDIOVASCULAR RISK PROFILES IN HYPERTENSIVE PATIENTS TREATED WITH CHOLECALCIFEROL BUT DID NOT INFLUENCE THE MIR-21 EXPRESSION. © 2022 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","CALCITRIOL; CHOLECALCIFEROL; CLINICAL TRIAL; HYPERTENSION; HYPOVITAMINOSIS D; INFLAMMATION; MIR-21","CALCITRIOL; CARDIOVASCULAR DISEASES; CHOLECALCIFEROL; CHOLESTEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HEART DISEASE RISK FACTORS; HEK293 CELLS; HUMANS; HYPERTENSION; MICRORNAS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BERBERINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM ANTAGONIST; CHOLESTIN; COLECALCIFEROL; COMPLEMENTARY DNA; CYTOCHROME P450 FAMILY 24; DIURETIC AGENT; MICRORNA; MICRORNA 21; NUTRACEUTICAL; PARATHYROID HORMONE; PLACEBO; POLICOSANOL; RNA; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL; CHOLESTEROL; COLECALCIFEROL; MICRORNA; MIRN21 MICRORNA, HUMAN; VITAMIN; VITAMIN D; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FEMALE; GENE EXPRESSION; HEART VENTRICLE REMODELING; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYPERTENSION; HYPERTENSIVE PATIENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASE; DIETARY SUPPLEMENT; RISK FACTOR","SIOMMMS; SOCIETÀ ITALIANA OSTEOPOROSI, MALATTIE DEL METABOLISMO MINERALE E DELLO SCHELETRO; SOCIETÀ ITALIANA DELL'IPERTENSIONE ARTERIOSA, SIIA; FONDAZIONE CARIPLO","FUNDING TEXT 1: ACKNOWLEDGMENTS: ABIOGEN INDUSTRIES SUPPORTED THE STUDY BY PROVIDING THE DRUG AND PLACEBO PREPARATIONS; THEY WERE ALSO IN CHARGE OF THE PARTICIPANTS’ RANDOM ALLOCATION TO ONE OR THE OTHER TREATMENT ARM. IB WAS SUPPORTED BY A CARIPLO FOUNDATION GRANT.; FUNDING TEXT 2: FUNDING: HYPODD IS A NO-PROFIT STUDY. THE STUDY COSTS ARE PARTIALLY COVERED BY A SIIA RESEARCH GRANT 2011 (TO L.D.) AND BY A SOCIETÀ ITALIANA OSTEOPOROSI, MALATTIE DEL METABOLISMO MINERALE E DELLO SCHELETRO (SIOMMMS) RESEARCH GRANT 2014 (TO R.M.).","WILLIAMS B., MANCIA G., SPIERING W., AGABITI ROSEI E., AZIZI M., BURNIER M., CLEMENT D.L., COCA A., DE SIMONE G., DOMINICZAK A., ET AL., 2018 ESC/ESH GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION, EUR. HEART J, 39, PP. 3021-3104, (2018); OLSEN M.H., ANGELL S.Y., ASMA S., BOUTOUYRIE P., BURGER D., A CHIRINOS J., DAMASCENO A., DELLES C., GIMENEZ-ROQUEPLO A.-P., HERING D., ET AL., A CALL TO ACTION AND A LIFECOURSE STRATEGY TO ADDRESS THE GLOBAL BURDEN OF RAISED BLOOD PRESSURE ON CURRENT AND FUTURE GENERATIONS: THE LANCET COMMISSION ON HYPERTENSION, LANCET, 388, PP. 2665-2712, (2016); E BAUER U., A BRISS P., A GOODMAN R., A BOWMAN B., PREVENTION OF CHRONIC DISEASE IN THE 21ST CENTURY: ELIMINATION OF THE LEADING PREVENTABLE CAUSES OF PREMATURE DEATH AND DISABILITY IN THE USA, LANCET, 384, PP. 45-52, (2014); BROMFIELD S., MUNTNER P., HIGH BLOOD PRESSURE: THE LEADING GLOBAL BURDEN OF DISEASE RISK FACTOR AND THE NEED FOR WORLDWIDE PREVENTION PROGRAMS, CURR. HYPERTENS. REP, 15, PP. 134-136, (2013); KIENREICH K., DEKKER J.M., PILZ S., ZITTERMANN A., MEINITZER A., MARZ W., LERCHBAUM E., TOMASCHITZ A., VITAMIN D AND CARDIOVASCULAR DISEASE: UPDATE AND OUTLOOK, SCAND. J. CLIN. LAB. INVESTIG. SUPPL, 243, PP. 83-91, (2012); RENDINA D., DE FILIPPO G., MUSCARIELLO R., DE PALMA D., FIENGO A., DE PASCALE F., STRAZZULLO P., VITAMIN D AND CARDIOMETABOLIC DISORDERS, HIGH BLOOD PRESS. CARDIOVASC. PREV, 21, PP. 251-256, (2014); BOUILLON R., VITAMIN D AND CARDIOVASCULAR DISORDERS, OSTEOPOROS. INT, 30, PP. 2167-2181, (2019); HOLICK M.F., VITAMIN D DEFICIENCY, N. ENGL. J. MED, 357, PP. 266-281, (2007); CHEN N.-C., HSU C.-Y., MAO P.C.-M., DREYER G., WU F.-Z., CHEN C.-L., THE EFFECTS OF CORRECTION OF VITAMIN D DEFICIENCY ON ARTERIAL STIFFNESS: A SYSTEMATIC REVIEW AND UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J. STEROID BIOCHEM. MOL. BIOL, 198, (2019); CAMPBELL M.J., VITAMIN D AND THE RNA TRANSCRIPTOME: MORE THAN MRNA REGULATION, FRONT. PHYSIOL, 5, (2014); LISSE T.S., ADAMS J.S., HEWISON M., VITAMIN D AND MICRORNAS IN BONE, CRIT. REV. EUKARYOT. GENE EXPR, 23, PP. 195-214, (2013); MA Y., TRUMP D.L., JOHNSON C.S., VITAMIN D AND MIRNAS IN CANCER, CURR. GENE THER, 14, PP. 269-275, (2014); LIU B., LI J., CAIRNS M.J., IDENTIFYING MIRNAS, TARGETS AND FUNCTIONS, BRIEF. BIOINFORM, 15, PP. 1-19, (2014); WOJCIECHOWSKA A., BRANIEWSKA A., KOZAR-KAMINSKA K., MICRORNA IN CARDIOVASCULAR BIOLOGY AND DISEASE, ADV. CLIN. EXP. MED, 26, PP. 868-874, (2017); JUSIC A., DEVAUX Y., EU-CARDIORNA COST ACTION (CA17129) NONCODING RNAS IN HYPERTENSION, HYPERTENSION, 74, PP. 477-492, (2019); KONTARAKI J.E., MARKETOU M.E., PARTHENAKIS F.I., MARAGKOUDAKIS S., ZACHARIS E.A., PETOUSIS S., KOCHIADAKIS G.E., VARDAS P.E., HYPERTROPHIC AND ANTIHYPERTROPHIC MICRORNA LEVELS IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND THEIR RELATIONSHIP TO LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION, J. AM. SOC. HYPERTENS, 9, PP. 802-810, (2015); LI X., WEI Y., WANG Z., MICRORNA-21 AND HYPERTENSION, HYPERTENS. RES, 41, PP. 649-661, (2018); CENGIZ M., YAVUZER S., AVCI B.K., YURUYEN M., YAVUZER H., DIKICI S.A., KARATAS F., OZEN M., UZUN H., ONGEN Z., CIRCULATING MIR-21 AND ENOS IN SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION, CLIN. EXP. HYPERTENS, 37, PP. 643-649, (2015); BEN-NUN D., BUJA L.M., FUENTES F., PREVENTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF): REEXAMINING MICRORNA-21 INHIBITION IN THE ERA OF OLIGONUCLEOTIDE-BASED THERAPEUTICS, CARDIOVASC. PATHOL, 49, (2020); WATANABE K., NARUMI T., WATANABE T., OTAKI Y., TAKAHASHI T., AONO T., GOTO J., TOSHIMA T., SUGAI T., WANEZAKI M., ET AL., THE ASSOCIATION BETWEEN MICRORNA-21 AND HYPERTENSION-INDUCED CARDIAC REMODELING, PLOS ONE, 15, (2020); SHEANE B., SMYTH P., SCOTT K., AZIZ R., BUCKLEY M., LODGE E., KIELY N., KINGSTON M., MCGOVERN E., HEALY M., ET AL., AN ASSOCIATION BETWEEN MICRORNA-21 EXPRESSION AND VITAMIN D DEFICIENCY IN CORONARY ARTERY DISEASE, MICRORNA, 4, PP. 57-63, (2015); KOCIC H., DAMIANI G., STAMENKOVIC B., TIRANT M., JOVIC A., TIODOROVIC D., PERIS K., DIETARY COMPOUNDS AS POTENTIAL MODULATORS OF MICRORNA EXPRESSION IN PSORIASIS, THER. ADV. CHRONIC. DIS, 10, (2019); GOLMOHAMMADI M.G., BANAEI S., NEJATI K., CHINIFROUSH-ASL M.M., VITAMIN D3 AND ERYTHROPOIETIN PROTECT AGAINST RENAL ISCHEMIA-REPERFUSION INJURY VIA HEAT SHOCK PROTEIN 70 AND MICRORNA-21 EXPRESSION, SCI. REP, 10, (2020); LOBODA A., SOBCZAK M., JOZKOWICZ A., DULAK J., TGF-Β1/SMADS AND MIR-21 IN RENAL FIBROSIS AND INFLAMMATION, MEDIAT. INFLAMM, 2016, (2016); ERKUS E., AKTAS G., ATAK B.M., KOCAK M.Z., DUMAN T.T., SAVLI H., HAEMOGRAM PARAMETERS IN VITAMIN D DEFICIENCY, J. COLL. PHYSICIANS SURG. PAK, 28, PP. 779-782, (2018); AKTAS G., KHALID A., KURTKULAGI O., DUMAN T.T., BILGIN S., KAHVECI G., TEL B.M.A., SINCER I., GUNES Y., POORLY CONTROLLED HYPERTENSION IS ASSOCIATED WITH ELEVATED SERUM URIC ACID TO HDL-CHOLESTEROL RATIO: A CROSS-SECTIONAL COHORT STUDY, POSTGRAD. MED, 134, PP. 297-302, (2022); RENDINA D., IPPOLITO R., D'ELIA L., GIACCHETTI G., LONATI C., GIANFRANCESCO F., FALLO F., REBELLATO A., RUGGIERO C., RUBATTU S.D., ET AL., HYPOVITAMINOSIS D AND ORGAN DAMAGE IN PATIENTS WITH ARTERIAL HYPERTENSION: A MULTICENTER DOUBLE BLIND RANDOMISED CONTROLLED TRIAL OF CHOLECALCIFEROL SUPPLEMENTATION (HYPODD), HIGH BLOOD PRESS. CARDIOVASC. PREV, 22, PP. 135-142, (2015); LIVAK K.J., SCHMITTGEN T.D., ANALYSIS OF RELATIVE GENE EXPRESSION DATA USING REAL-TIME QUANTITATIVE PCR AND THE 2<SUP>−∆∆CT</SUP> METHOD, METHODS, 25, PP. 402-408, (2001); WANG X., ZHANG X., YUAN J., WU J., DENG X., PENG J., WANG S., YANG C., GE J., ZOU Y., EVALUATION OF THE PERFORMANCE OF SERUM MIRNAS AS NORMALIZERS IN MICRORNA STUDIES FOCUSED ON CARDIOVASCULAR DISEASE, J. THORAC. DIS, 10, PP. 2599-2607, (2018); PIRAS S., FURFARO A.L., CAGGIANO R., BRONDOLO L., GARIBALDI S., IVALDO C., MARINARI U.M., PRONZATO M.A., FARAONIO R., NITTI M., MICRORNA-494 FAVORS HO-1 EXPRESSION IN NEUROBLASTOMA CELLS EXPOSED TO OXIDATIVE STRESS IN A BACH1-INDEPENDENT WAY, FRONT. ONCOL, 8, (2018); VERONE-BOYLE A.R., SHOEMAKER S., ATTWOOD K., MORRISON C.D., MAKOWSKI A.J., BATTAGLIA S., HERSHBERGER P.A., DIET-DERIVED 25-HYDROXYVITAMIN D3 ACTIVATES VITAMIN D RECEPTOR TARGET GENE EXPRESSION AND SUPPRESSES EGFR MUTANT NON-SMALL CELL LUNG CANCER GROWTH IN VITRO AND IN VIVO, ONCOTARGET, 7, PP. 995-1013, (2016); BARRIOS V., ESCOBAR C., CICERO A.F.G., BURKE D., FASCHING P., BANACH M., BRUCKERT E., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER. SUPPL, 24, PP. 1-15, (2017); SACHECK J.M., HUANG Q., I VAN ROMPAY M., CHOMITZ V.R., ECONOMOS C.D., ELIASZIW M., GORDON C.M., GOODMAN E., VITAMIN D SUPPLEMENTATION AND CARDIOMETABOLIC RISK FACTORS AMONG DIVERSE SCHOOLCHILDREN: A RANDOMIZED CLINICAL TRIAL, AM. J. CLIN. NUTR, 115, PP. 73-82, (2021); SWART K.M., LIPS P., BROUWER I., JORDE R., HEYMANS M.W., GRIMNES G., GRUBLER M.R., GAKSCH M., TOMASCHITZ A., PILZ S., ET AL., EFFECTS OF VITAMIN D SUPPLEMENTATION ON MARKERS FOR CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR, 107, PP. 1043-1053, (2018); LI Y., TONG C.H., ROWLAND C.M., RADCLIFF J., BARE L.A., MCPHAUL M.J., DEVLIN J.J., ASSOCIATION OF CHANGES IN LIPID LEVELS WITH CHANGES IN VITAMIN D LEVELS IN A REAL-WORLD SETTING, SCI. REP, 11, (2021); LIU W., WU Z., ZHU D., CHEN G., YAN G., ZHANG S., CHEN F., KHAN B.A., HOU K., VITAMIN D AND LIPID PROFILES IN POSTMENOPAUSAL WOMEN: A META-ANALYSIS AND SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS, FRONT. MOL. BIOSCI, 8, (2021); ZHANG W., YI J., LIU D., WANG Y., JAMILIAN P., GAMAN M.-A., PRABAHAR K., FAN J., THE EFFECT OF VITAMIN D ON THE LIPID PROFILE AS A RISK FACTOR FOR CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN: A META-ANALYSIS AND SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS, EXP. GERONTOL, 161, (2022); TOURNIS S., MAKRIS K., CAVALIER E., TROVAS G., CARDIOVASCULAR RISK IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM, CURR. PHARM. DES, 26, PP. 5628-5636, (2020); ALTAY H., ZORLU A., BINICI S., BILGI M., YILMAZ M.B., COLKESEN Y., EROL T., MUDERRISOGLU H., RELATION OF SERUM PARATHYROID HORMONE LEVEL TO SEVERITY OF HEART FAILURE, AM. J. CARDIOL, 109, PP. 252-256, (2012); DEO R., KATZ R., SHLIPAK M.G., SOTOODEHNIA N., PSATY B.M., SARNAK M.J., FRIED L.F., CHONCHOL M., DE BOER I.H., ENQUOBAHRIE D., ET AL., VITAMIN D, PARATHYROID HORMONE, AND SUDDEN CARDIAC DEATH: RESULTS FROM THE CARDIOVASCULAR HEALTH STUDY, HYPERTENSION, 58, PP. 1021-1028, (2011); YILDIRIM E., KALKAN K., IPEK E., AKSU U., DEMIRELLI S., ERMIS E., OZTURK M., HAMUR H., OP-049 A NOVEL MARKER FOR ASYMPTOMATIC ORGAN DAMAGE IN THE PATIENTS WITH HYPERTENSION: MIR-21, AM. J. CARDIOL, 117, (2016); ZHANG B.-H., SHEN C.-A., ZHU B.-W., AN H.-Y., ZHENG B., XU S.-B., SUN J.-C., SUN P.-C., ZHANG W., WANG J., ET AL., INSIGHT INTO MIRNAS RELATED WITH GLUCOMETABOLIC DISORDER, BIOMED. PHARMACOTHER, 111, PP. 657-665, (2019); YANG Z., CAPPELLO T., WANG L., EMERGING ROLE OF MICRORNAS IN LIPID METABOLISM, ACTA PHARM. SIN. B, 5, PP. 145-150, (2015); ZHOU W., SU L., DUAN X., CHEN X., HAYS A., UPADHYAYULA S., SHIVDE J., WANG H., LI Y., HUANG D., ET AL., MICRORNA-21 DOWN-REGULATES INFLAMMATION AND INHIBITS PERIODONTITIS, MOL. IMMUNOL, 101, PP. 608-614, (2018); ERKUS E., AKTAS G., KOCAK M.Z., DUMAN T.T., ATAK B.M., SAVLI H., DIABETIC REGULATION OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS IS ASSOCIATED WITH SERUM VITAMIN D LEVELS, REV. ASSOC. MED. BRAS, 65, PP. 51-55, (2019); RENDINA D., DE FILIPPO G., STRAZZULLO P., SHOULD VITAMIN D STATUS BE ASSESSED IN PATIENTS WITH CONGESTIVE HEART FAILURE?, NUTR. METAB. CARDIOVASC. DIS, 20, PP. 627-632, (2010); VERDOIA M., GIOSCIA R., NARDIN M., ROGNONI A., DE LUCA G., LOW LEVELS OF VITAMIN D AND CORONARY ARTERY DISEASE: IS IT TIME FOR THERAPY?, KARDIOLOGIA POLSKA, 80, PP. 409-416, (2022); FILLINGIM R.B., PRICE D.D., WHAT IS CONTROLLED FOR IN PLACEBO-CONTROLLED TRIALS?, MAYO CLIN. PROC, 80, PP. 1119-1121, (2005)","R. FARAONIO; DEPARTMENT OF MOLECULAR MEDICINE AND MEDICAL BIOTECHNOLOGY, FEDERICO II UNIVERSITY, NAPLES, 80131, ITALY; EMAIL: RAFFAELLA.FARAONIO@UNINA.IT","MDPI","ENGLISH","NUTRIENTS","ARTICLE","ISI","2-S2.0-85132855013","NUTRIENTS","FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;PADOVA;UNIVERSITY OF TURIN;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;UNIVERSITY OF TURIN;PADOVA;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY","NOTREPORTED;FEDERICO II UNIVERSITY;NOTREPORTED",NA,"RENDINA D, 2022, NUTRIENTS","RENDINA D, 2022, NUTRIENTS"
"CAI Y;XIN Q;LU J;MIAO Y;LIN Q;CONG W;CHEN K","CAI, YUN (57222628070); XIN, QIQI (57189643472); LU, JINJIN (57199238656); MIAO, YU (23498014500); LIN, QIAN (57194138254); CONG, WEIHONG (8306440200); CHEN, KEJI (24754798100)","A NEW THERAPEUTIC CANDIDATE FOR CARDIOVASCULAR DISEASES BERBERINE",2021,"FRONTIERS IN PHARMACOLOGY","12","",39,"10.3389/fphar.2021.631100","DOCTORAL CANDIDATE, DONGZHIMEN HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE, BEIJING, CHINA;LABORATORY OF CARDIOVASCULAR DISEASES, XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES, BEIJING, CHINA, NATIONAL CLINICAL RESEARCH CENTER FOR CHINESE MEDICINE CARDIOLOGY, BEIJING, CHINA;DONGFANG HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE, BEIJING, CHINA;LABORATORY OF CARDIOVASCULAR DISEASES, XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES, BEIJING, CHINA, NATIONAL CLINICAL RESEARCH CENTER FOR CHINESE MEDICINE CARDIOLOGY, BEIJING, CHINA;DONGZHIMEN HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE, BEIJING, CHINA;LABORATORY OF CARDIOVASCULAR DISEASES, XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES, BEIJING, CHINA, NATIONAL CLINICAL RESEARCH CENTER FOR CHINESE MEDICINE CARDIOLOGY, BEIJING, CHINA;LABORATORY OF CARDIOVASCULAR DISEASES, XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES, BEIJING, CHINA, NATIONAL CLINICAL RESEARCH CENTER FOR CHINESE MEDICINE CARDIOLOGY, BEIJING, CHINA","CARDIOVASCULAR DISEASES (CVD) ARE THE LEADING CAUSE OF DEATH IN THE WORLD. HOWEVER, DUE TO THE LIMITED EFFECTIVENESS AND POTENTIAL ADVERSE EFFECTS OF CURRENT TREATMENTS, THE LONG-TERM PROGNOSIS OF CVD PATIENTS IS STILL DISCOURAGING. IN RECENT YEARS, SEVERAL STUDIES HAVE FOUND THAT BERBERINE (BBR) HAS BROAD APPLICATION PROSPECTS IN THE PREVENTION AND TREATMENT OF CVD. DUE TO ITS EFFECTIVENESS AND SAFETY FOR GASTROENTERITIS AND DIARRHEA CAUSED BY BACTERIAL INFECTIONS, BBR HAS BEEN WIDELY USED IN CHINA AND OTHER ASIAN COUNTRIES SINCE THE MIDDLE OF THE LAST CENTURY. THE DEVELOPMENT OF PHARMACOLOGY ALSO PROVIDES EVIDENCE FOR THE MULTI-TARGETS OF BBR IN TREATING CVD. RESEARCHES ON CVD, SUCH AS ARRHYTHMIA, ATHEROSCLEROSIS, DYSLIPIDEMIA, HYPERTENSION, ISCHEMIC HEART DISEASE, MYOCARDITIS AND CARDIOMYOPATHY, HEART FAILURE, ETC., REVEALED THE CARDIOVASCULAR PROTECTIVE MECHANISMS OF BBR. THIS REVIEW SYSTEMATICALLY SUMMARIZES THE PHARMACOLOGICAL RESEARCH PROGRESS OF BBR IN THE TREATMENT OF CVD IN RECENT YEARS, CONFIRMING THAT BBR IS A PROMISING THERAPEUTIC OPTION FOR CVD. © COPYRIGHT © 2021 CAI, XIN, LU, MIAO, LIN, CONG AND CHEN.","BERBERINE; CARDIOVASCULAR DISEASES; NATURAL PRODUCT; SAFETY; THERAPEUTIC EFFECTS","AMIODARONE; ANTIHYPERTENSIVE AGENT; ASTAXANTHIN; ATORVASTATIN; BERBERINE; DOXORUBICIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; POLICOSANOL; TRIMETAZIDINE; URSODEOXYCHOLIC ACID; ANTIARRHYTHMIC ACTIVITY; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MYOCARDITIS; NONHUMAN; REVIEW","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, NSFC, (81874458); CHINA ACADEMY OF CHINESE MEDICAL SCIENCES, CACMS, (ZZ13–036–4)","THIS WORK WAS SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (GRANT NUMBER 81874458) AND THE AUTHORIZED PROJECT OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (ZZ13–036–4).","ABUDUREYIMU M., YU W., CAO R.Y., ZHANG Y., LIU H., ZHENG H., BERBERINE PROMOTES CARDIAC FUNCTION BY UPREGULATING PINK1/PARKIN-MEDIATED MITOPHAGY IN HEART FAILURE, FRONT. PHYSIOL, 11, (2020); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. METAB. CARDIOVASC. DIS, 20, PP. 656-661, (2010); ASHRAFIZADEH M., FEKRI H.S., AHMADI Z., FARKHONDEH T., SAMARGHANDIAN S., THERAPEUTIC AND BIOLOGICAL ACTIVITIES OF BERBERINE: THE INVOLVEMENT OF NRF2 SIGNALING PATHWAY, J. CELL BIOCHEM, 121, PP. 1575-1585, (2020); BANAEI P., NAZEM F., NAZARI A., ARJOMAND A., PRECONDITIONING EFFECT OF HIGH-INTENSITY INTERVAL TRAINING (HIIT) AND BERBERINE SUPPLEMENTATION ON THE GENE EXPRESSION OF ANGIOGENESIS REGULATORS AND CASPASE-3 PROTEIN IN THE RATS WITH MYOCARDIAL ISCHEMIA-REPERFUSION (IR) INJURY, BIOMED. RES. INT, 2020, (2020); BLESSBERGER H., KAMMLER J., DOMANOVITS H., SCHLAGER O., WILDNER B., AZAR D., ET AL., PERIOPERATIVE BETA-BLOCKERS FOR PREVENTING SURGERY-RELATED MORTALITY AND MORBIDITY, COCHRANE DATABASE SYST. REV, 3, (2018); BUCHANAN B., MENG Q., POULIN M.-M., ZUCCOLO J., AZIKE C.G., GABRIELE J., ET AL., COMPARATIVE PHARMACOKINETICS AND SAFETY ASSESSMENT OF TRANSDERMAL BERBERINE AND DIHYDROBERBERINE, PLOS ONE, 13, (2018); CAO J.X., FU L., DONG Y.H., DONG Y.L., THE EFFECT OF BERBERINE ON ARRHYTHMIA CAUSED BY STRETCH OF ISOLATED MYOCARDIAL INFARCTED HEARTS IN RATS, HEART, 98, PP. E1-E319, (2012); CHANG W., ZHANG M., LI J., MENG Z., XIAO D., WEI S., ET AL., BERBERINE ATTENUATES ISCHEMIA-REPERFUSION INJURY VIA REGULATION OF ADENOSINE-5ʹ-MONOPHOSPHATE KINASE ACTIVITY IN BOTH NON-ISCHEMIC AND ISCHEMIC AREAS OF THE RAT HEART, CARDIOVASC. DRUGS THER, 26, PP. 467-478, (2012); CHANG W., ZHANG M., MENG Z., YU Y., YAO F., HATCH G.M., ET AL., BERBERINE TREATMENT PREVENTS CARDIAC DYSFUNCTION AND REMODELING THROUGH ACTIVATION OF 5ʹ-ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE IN TYPE 2 DIABETIC RATS AND IN PALMITATE-INDUCED HYPERTROPHIC H9C2 CELLS, EUR. J. PHARMACOL, 769, PP. 55-63, (2015); CHATTERJEE K., ZHANG J., HONBO N., KARLINER J.S., DOXORUBICIN CARDIOMYOPATHY, CARDIOLOGY, 115, PP. 155-162, (2010); CHEN K., LI G., GENG F., ZHANG Z., LI J., YANG M., ET AL., BERBERINE REDUCES ISCHEMIA/REPERFUSION-INDUCED MYOCARDIAL APOPTOSIS VIA ACTIVATING AMPK AND PI3K-AKT SIGNALING IN DIABETIC RATS, APOPTOSIS, 19, PP. 946-957, (2014); CHEN X., JIANG X., CHENG C., CHEN J., HUANG S., XU M., ET AL., BERBERINE ATTENUATES CARDIAC HYPERTROPHY THROUGH INHIBITION OF MTOR SIGNALING PATHWAY, CARDIOVASC. DRUGS THER, 34, PP. 463-473, (2020); CHEN X.W., DI Y.M., ZHANG J., ZHOU Z.W., LI C.G., ZHOU S.F., INTERACTION OF HERBAL COMPOUNDS WITH BIOLOGICAL TARGETS: A CASE STUDY WITH BERBERINE, SCI.WORLD J, 2012, (2012); CHI L., PENG L., HU X., PAN N., ZHANG Y., BERBERINE COMBINED WITH ATORVASTATIN DOWNREGULATES LOX-1 EXPRESSION THROUGH THE ET-1 RECEPTOR IN MONOCYTE/MACROPHAGES, INT. J. MOL. MED, 34, PP. 283-290, (2014); CHO B.J., IM E.K., KWON J.H., LEE K.H., SHIN H.J., OH J., ET AL., BERBERINE INHIBITS THE PRODUCTION OF LYSOPHOSPHATIDYLCHOLINE-INDUCED REACTIVE OXYGEN SPECIES AND THE ERK1/2 PATHWAY IN VASCULAR SMOOTH MUSCLE CELLS, MOL. CELLS, 20, PP. 429-434, (2005); CHUNG N.A., BEEVERS D.G., LIP G., EFFECTS OF LOSARTAN VERSUS HYDROCHLOROTHIAZIDE ON INDICES OF ENDOTHELIAL DAMAGE/DYSFUNCTION, ANGIOGENESIS AND TISSUE FACTOR IN ESSENTIAL HYPERTENSION, BLOOD PRESS, 13, PP. 183-189, (2004); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); COELHO A.R., MARTINS T.R., COUTO R., DEUS C., PEREIRA C.V., SIMOES R.F., ET AL., BERBERINE-INDUCED CARDIOPROTECTION AND SIRT3 MODULATION IN DOXORUBICIN-TREATED H9C2 CARDIOMYOBLASTS, BIOCHIM. BIOPHYS. ACTA, 1863, PP. 2904-2923, (2017); CUI Y.-J., YANG P., DAI D.-Z., GAO L., XIAO D.-W., WANG Y.-Q., CPU 86017 SUPPRESSES TACHYARRHYTHMIAS INDUCED BY OUABAIN AND MYOCARDIAL INFARCTION: CONCENTRATIONS IN PLASMA AND DIFFERENT AREAS OF THE HEART IN DOGS, DRUG DEV. RES, 58, PP. 131-137, (2003); DAI P., WANG J., LIN L., ZHANG Y., WANG Z., RENOPROTECTIVE EFFECTS OF BERBERINE AS ADJUVANT THERAPY FOR HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS: EVALUATION VIA BIOCHEMICAL MARKERS AND COLOR DOPPLER ULTRASONOGRAPHY, EXP. THER. MED, 10, PP. 869-876, (2015); DAI Q., ZHANG D., YU H., XIE W., XIN R., WANG L., ET AL., BERBERINE RESTRICTS COXSACKIEVIRUS B TYPE 3 REPLICATION VIA INHIBITION OF C-JUN N-TERMINAL KINASE (JNK) AND P38 MAPK ACTIVATION IN VITRO, MED. SCI. MONIT, 23, PP. 1448-1455, (2017); DAI H., MUCH A.A., MAOR E., ASHER E., YOUNIS A., XU Y., ET AL., GLOBAL, REGIONAL, AND NATIONAL BURDEN OF ISCHAEMIC HEART DISEASE AND ITS ATTRIBUTABLE RISK FACTORS, 1990–2017: RESULTS FROM THE GLOBAL BURDEN OF DISEASE STUDY 2017, EUR. HEART J. QUAL. CARE CLIN. OUTCOMES, 76, (2020); DAI Q., HE X., YU H., BAI Y., JIANG L., SHENG H., ET AL., BERBERINE IMPAIRS COXSACKIEVIRUS B3‐INDUCED MYOCARDITIS THROUGH THE INHIBITION OF VIRUS REPLICATION AND HOST PRO‐INFLAMMATORY RESPONSE, J. MED. VIROL, (2020); DI BISCEGLIE A.M., WATTS G.F., LAVIN P., YU M., BAI R., LIU L., PHARMACOKINETICS AND PHARMACODYNAMICS OF HTD1801 (BERBERINE URSODEOXYCHOLATE, BUDCA) IN PATIENTS WITH HYPERLIPIDEMIA, LIPIDS HEALTH DIS, 19, (2020); DONG S., ZHANG S., CHEN Z., ZHANG R., TIAN L., CHENG L., ET AL., BERBERINE COULD AMELIORATE CARDIAC DYSFUNCTION VIA INTERFERING MYOCARDIAL LIPIDOMIC PROFILES IN THE RAT MODEL OF DIABETIC CARDIOMYOPATHY, FRONT. PHYSIOL, 9, (2018); FENG X., SUREDA A., JAFARI S., MEMARIANI Z., TEWARI D., ANNUNZIATA G., ET AL., BERBERINE IN CARDIOVASCULAR AND METABOLIC DISEASES: FROM MECHANISMS TO THERAPEUTICS, THERANOSTICS, 9, PP. 1923-1951, (2019); FREY N., OLSON E.N., CARDIAC HYPERTROPHY: THE GOOD, THE BAD, AND THE UGLY, ANNU. REV. PHYSIOL, 65, PP. 45-79, (2003); GOTTLIEB R.A., MENTZER R.M., AUTOPHAGY DURING CARDIAC STRESS: JOYS AND FRUSTRATIONS OF AUTOPHAGY, ANNU. REV. PHYSIOL, 72, PP. 45-59, (2010); HANSELMANN A., VELTMANN C., BAUERSACHS J., BERLINER D., DILATED CARDIOMYOPATHIES AND NON-COMPACTION CARDIOMYOPATHY, HERZ, 45, PP. 212-220, (2020); HASHEMZAEI M., ENTEZARI HERAVI R., REZAEE R., ROOHBAKHSH A., KARIMI G., REGULATION OF AUTOPHAGY BY SOME NATURAL PRODUCTS AS A POTENTIAL THERAPEUTIC STRATEGY FOR CARDIOVASCULAR DISORDERS, EUR. J. PHARMACOL, 802, PP. 44-51, (2017); HASHMI S., AL-SALAM S., ACUTE MYOCARDIAL INFARCTION AND MYOCARDIAL ISCHEMIA-REPERFUSION INJURY: A COMPARISON, INT. J. CLIN. EXP. PATHOL, 8, PP. 8786-8796, (2015); HAUSENLOY D.J., YELLON D.M., MYOCARDIAL ISCHEMIA-REPERFUSION INJURY: A NEGLECTED THERAPEUTIC TARGET, J. CLIN. INVEST, 123, PP. 92-100, (2013); HUA Z., WANG X.L., INHIBITORY EFFECT OF BERBERINE ON POTASSIUM CHANNELS IN GUINEA PIG VENTRICULAR MYOCYTES, YAO XUE XUE BAO, 29, PP. 576-580, (1994); HUANG W.M., WU Z.D., GAN Y.Q., EFFECTS OF BERBERINE ON ISCHEMIC VENTRICULAR ARRHYTHMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 17, PP. 300-319, (1989); HUANG Z., HAN Z., YE B., DAI Z., SHAN P., LU Z., ET AL., BERBERINE ALLEVIATES CARDIAC ISCHEMIA/REPERFUSION INJURY BY INHIBITING EXCESSIVE AUTOPHAGY IN CARDIOMYOCYTES, EUR. J. PHARMACOL, 762, PP. 1-10, (2015); HUANG Z., MENG S., WANG L., WANG Y., CHEN T., WANG C., SUPPRESSION OF OXLDL-INDUCED MMP-9 AND EMMPRIN EXPRESSION BY BERBERINE VIA INHIBITION OF NF-ΚB ACTIVATION IN HUMAN THP-1 MACROPHAGES, ANAT. REC, 295, PP. 78-86, (2012); HUBER S.A., VIRAL MYOCARDITIS AND DILATED CARDIOMYOPATHY: ETIOLOGY AND PATHOGENESIS, CURR. PHARM. DES, 22, PP. 408-426, (2016); JIA G., HILL M.A., SOWERS J.R., DIABETIC CARDIOMYOPATHY: AN UPDATE OF MECHANISMS CONTRIBUTING TO THIS CLINICAL ENTITY, CIRC. RES, 122, PP. 624-638, (2018); JIN Y., KHADKA D.B., CHO W.J., PHARMACOLOGICAL EFFECTS OF BERBERINE AND ITS DERIVATIVES: A PATENT UPDATE, EXPERT. OPIN. THER. PAT, 26, PP. 229-243, (2016); JU J., LI J., LIN Q., XU H., EFFICACY AND SAFETY OF BERBERINE FOR DYSLIPIDAEMIAS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, PHYTOMEDICINE, 50, PP. 25-34, (2018); KE X., HUANG Y., LI L., XIN F., XU L., ZHANG Y., ET AL., BERBERINE ATTENUATES ARTERIAL PLAQUE FORMATION IN ATHEROSCLEROTIC RATS WITH DAMP-HEAT SYNDROME VIA REGULATING AUTOPHAGY, DRUG DES. DEVEL. THER, 14, PP. 2449-2460, (2020); KONSTAM M.A., KRAMER D.G., PATEL A.R., MARON M.S., UDELSON J.E., LEFT VENTRICULAR REMODELING IN HEART FAILURE: CURRENT CONCEPTS IN CLINICAL SIGNIFICANCE AND ASSESSMENT, JACC. CARDIOVASC. IMAGING, 4, PP. 98-108, (2011); LAN J., ZHAO Y., DONG F., YAN Z., ZHENG W., FAN J., ET AL., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J. ETHNOPHARMACOL, 161, PP. 69-81, (2015); LEE S., LIM H.J., PARK H.Y., LEE K.S., PARK J.H., JANG Y., BERBERINE INHIBITS RAT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION IN VITRO AND IMPROVES NEOINTIMA FORMATION AFTER BALLOON INJURY IN VIVO. BERBERINE IMPROVES NEOINTIMA FORMATION IN A RAT MODEL, ATHEROSCLEROSIS, 186, PP. 29-37, (2006); LI M.H., ZHANG Y.J., YU Y.H., YANG S.H., IQBAL J., MI Q.Y., ET AL., BERBERINE IMPROVES PRESSURE OVERLOAD-INDUCED CARDIAC HYPERTROPHY AND DYSFUNCTION THROUGH ENHANCED AUTOPHAGY, EUR. J. PHARMACOL, 728, PP. 67-76, (2014); LI P., KANG Y., WANG G.X., THE STUDY OF THE EFFECTS OF BERBERINE ON REPERFUSION-INDUCED ARRHYTHMIAS AND ON MODULATING CALCIUM IN RAT, CHIN. PHARMACOL. BULL, 11, PP. 217-220, (1995); LI Y., ZHAO X., FENG X., LIU X., DENG C., HU C.H., BERBERINE ALLEVIATES OLANZAPINE-INDUCED ADIPOGENESIS VIA THE AMPKΑ-SREBP PATHWAY IN 3T3-L1 CELLS, INT. J. MOL. SCI, 17, (2016); LIN X., ZHANG N., BERBERINE: PATHWAYS TO PROTECT NEURONS, PHYTOTHER. RES, 32, PP. 1501-1510, (2018); LIU L., LIU J., HUANG Z., YU X., ZHANG X., DOU D., ET AL., BERBERINE IMPROVES ENDOTHELIAL FUNCTION BY INHIBITING ENDOPLASMIC RETICULUM STRESS IN THE CAROTID ARTERIES OF SPONTANEOUSLY HYPERTENSIVE RATS, BIOCHEM. BIOPHYS. RES. COMMUN, 458, PP. 796-801, (2015); LIU S.J., YIN C.X., DING M.C., XIA S.Y., SHEN Q.M., WU J.D., BERBERINE SUPPRESSES IN VITRO MIGRATION OF HUMAN AORTIC SMOOTH MUSCLE CELLS THROUGH THE INHIBITIONS OF MMP-2/9, U-PA, AP-1, AND NF-ΚB, BMB. REP, 47, PP. 388-392, (2014); LIU X., ZHANG X., YE L., YUAN H., PROTECTIVE MECHANISMS OF BERBERINE AGAINST EXPERIMENTAL AUTOIMMUNE MYOCARDITIS IN A RAT MODEL, BIOMED. PHARMACOTHER, 79, PP. 222-230, (2016); LOMBARD D.B., ALT F.W., CHENG H.L., BUNKENBORG J., STREEPER R.S., MOSTOSLAVSKY R., ET AL., MAMMALIAN SIR2 HOMOLOG SIRT3 REGULATES GLOBAL MITOCHONDRIAL LYSINE ACETYLATION, MOL. CELL. BIOL, 27, PP. 8807-8814, (2007); MA L., ZHANG L., WANG B., WEI J., LIU J., ZHANG L., BERBERINE INHIBITS CHLAMYDIA PNEUMONIAE INFECTION-INDUCED VASCULAR SMOOTH MUSCLE CELL MIGRATION THROUGH DOWNREGULATING MMP3 AND MMP9 VIA PI3K, EUR. J. PHARMACOL, 755, PP. 102-109, (2015); MA X., ZHANG T., LUO Z., LI X., LIN M., LI R., ET AL., FUNCTIONAL NANO-VECTOR BOOST ANTI-ATHEROSCLEROSIS EFFICACY OF BERBERINE IN APOE(<SUP>−/−</SUP>) MICE, ACTA PHARM. SIN. B, 10, PP. 1769-1783, (2020); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV. THER, 28, PP. 1105-1113, (2011); MARIN-NETO J.A., MACIEL B.C., SECCHES A.L., GALLO JUNIOR L., CARDIOVASCULAR EFFECTS OF BERBERINE IN PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE, CLIN. CARDIOL, 11, PP. 253-260, (1988); MCMONAGLE M.P., THE QUEST FOR EFFECTIVE PHARMACOLOGICAL SUPPRESSION OF NEOINTIMAL HYPERPLASIA, CURR. PROBL. SURG, 57, (2020); MIRHADI E., REZAEE M., MALAEKEH-NIKOUEI B., NANO STRATEGIES FOR BERBERINE DELIVERY, A NATURAL ALKALOID OF BERBERIS, BIOMED. PHARMACOTHER, 104, PP. 465-473, (2018); MOZAFFARIAN D., BENJAMIN E.J., GO A.S., ARNETT D.K., BLAHA M.J., CUSHMAN M., ET AL., HEART DISEASE AND STROKE STATISTICS–2015 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 131, PP. E29-E322, (2015); NAKAI A., YAMAGUCHI O., TAKEDA T., HIGUCHI Y., HIKOSO S., TANIIKE M., ET AL., THE ROLE OF AUTOPHAGY IN CARDIOMYOCYTES IN THE BASAL STATE AND IN RESPONSE TO HEMODYNAMIC STRESS, NAT. MED, 13, PP. 619-624, (2007); PEI C., ZHANG Y., WANG P., ZHANG B., FANG L., LIU B., ET AL., BERBERINE ALLEVIATES OXIDIZED LOW-DENSITY LIPOPROTEIN-INDUCED MACROPHAGE ACTIVATION BY DOWNREGULATING GALECTIN-3 VIA THE NF-ΚB AND AMPK SIGNALING PATHWAYS, PHYTOTHER. RES, 33, PP. 294-308, (2019); PERRICONE A.J., VANDER HEIDE R.S., NOVEL THERAPEUTIC STRATEGIES FOR ISCHEMIC HEART DISEASE, PHARMACOL. RES, 89, PP. 36-45, (2014); PIRRO M., MANNARINO M.R., BIANCONI V., SIMENTAL-MENDIA L.E., BAGAGLIA F., MANNARINO E., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL. RES, 110, PP. 76-88, (2016); QIU H., WU Y., WANG Q., LIU C., XUE L., WANG H., ET AL., EFFECT OF BERBERINE ON PPARΑ-NO SIGNALLING PATHWAY IN VASCULAR SMOOTH MUSCLE CELL PROLIFERATION INDUCED BY ANGIOTENSIN IV, PHARM. BIOL, 55, PP. 227-232, (2017); RATZ P.H., BERG K.M., URBAN N.H., MINER A.S., REGULATION OF SMOOTH MUSCLE CALCIUM SENSITIVITY: KCL AS A CALCIUM-SENSITIZING STIMULUS, AM. J. PHYSIOL. CELL PHYSIOL, 288, PP. C769-C783, (2005); ROMERO C.D., VARMA T.K., HOBBS J.B., REYES A., DRIVER B., SHERWOOD E.R., THE TOLL-LIKE RECEPTOR 4 AGONIST MONOPHOSPHORYL LIPID A AUGMENTS INNATE HOST RESISTANCE TO SYSTEMIC BACTERIAL INFECTION, INFECT. IMMUN, 79, PP. 3576-3587, (2011); SAGAR S., LIU P.P., COOPER L.T., MYOCARDITIS, LANCET, 379, PP. 738-747, (2012); SAINZ J., SATA M., CXCR4, A KEY MODULATOR OF VASCULAR PROGENITOR CELLS, ARTERIOSCLER. THROMB. VASC. BIOL, 27, PP. 263-265, (2007); SARNA L.K., WU N., HWANG S.Y., SIOW Y.L., O K., BERBERINE INHIBITS NADPH OXIDASE MEDIATED SUPEROXIDE ANION PRODUCTION IN MACROPHAGES, CAN. J. PHYSIOL. PHARMACOL, 88, PP. 369-378, (2010); SCHRODER M., KAUFMAN R.J., THE MAMMALIAN UNFOLDED PROTEIN RESPONSE, ANNU. REV. BIOCHEM, 74, PP. 739-789, (2005); SHAO Y.J., TAO J., YU B.B., MENG D., YANG X.L., SUN J.P., ET AL., BERBERINE-PROMOTED CXCR4 EXPRESSION ACCELERATES ENDOTHELIAL REPAIR CAPACITY OF EARLY ENDOTHELIAL PROGENITOR CELLS IN PERSONS WITH PREHYPERTENSION, CHIN. J. INTEGR. MED, 24, PP. 897-904, (2018); SONG D., HAO J., FAN D., BIOLOGICAL PROPERTIES AND CLINICAL APPLICATIONS OF BERBERINE, FRONT. MED, 14, PP. 564-582, (2020); SPENCE J.D., RECENT ADVANCES IN PATHOGENESIS, ASSESSMENT, AND TREATMENT OF ATHEROSCLEROSIS, F1000RES, 5, (2016); SQUIZZATO A., KELLER T., ROMUALDI E., MIDDELDORP S., DONADINI M.P., CLOPIDOGREL PLUS ASPIRIN VERSUS ASPIRIN ALONE FOR PREVENTING CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV, 12, (2017); TAJIRI K., IMANAKA-YOSHIDA K., MATSUBARA A., TSUJIMURA Y., HIROE M., NAKA T., ET AL., SUPPRESSOR OF CYTOKINE SIGNALING 1 DNA ADMINISTRATION INHIBITS INFLAMMATORY AND PATHOGENIC RESPONSES IN AUTOIMMUNE MYOCARDITIS, J. IMMUNOL, 189, PP. 2043-2053, (2012); TAN W., WANG Y., WANG K., WANG S., LIU J., QIN X., ET AL., IMPROVEMENT OF ENDOTHELIAL DYSFUNCTION OF BERBERINE IN ATHEROSCLEROTIC MICE AND MECHANISM EXPLORING THROUGH TMT-BASED PROTEOMICS, OXID. MED. CELL. LONGEV, 2020, (2020); TIMMIS A., TOWNSEND N., GALE C., GROBBEE R., MANIADAKIS N., FLATHER M., ET AL., EUROPEAN SOCIETY OF CARDIOLOGY: CARDIOVASCULAR DISEASE STATISTICS 2017, EUR. HEART J, 39, PP. 508-579, (2018); TSUI H., ZI M., WANG S., CHOWDHURY S.K., PREHAR S., LIANG Q., ET AL., SMAD3 COUPLES PAK1 WITH THE ANTIHYPERTROPHIC PATHWAY THROUGH THE E3 UBIQUITIN LIGASE, FBXO32, HYPERTENSION, 66, PP. 1176-1183, (2015); UEDA T., SHIKANO M., KAMIYA T., JOH T., UGAWA S., THE TRPV4 CHANNEL IS A NOVEL REGULATOR OF INTRACELLULAR CA2<SUP>+</SUP> IN HUMAN ESOPHAGEAL EPITHELIAL CELLS, AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL, 301, PP. G138-G147, (2011); VAN DER LAAN A.M., PIEK J.J., VAN ROYEN N., TARGETING ANGIOGENESIS TO RESTORE THE MICROCIRCULATION AFTER REPERFUSED MI, NAT. REV. CARDIOL, 6, PP. 515-523, (2009); VENTURA H.O., LAVIE C.J., EDITORIAL: EPIDEMIOLOGY AND MANAGING ASPECTS OF HYPERTENSION, CURR. OPIN. CARDIOL, 34, PP. 329-330, (2019); VIRANI S.S., ALONSO A., BENJAMIN E.J., BITTENCOURT M.S., CALLAWAY C.W., CARSON A.P., ET AL., HEART DISEASE AND STROKE STATISTICS-2020 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 141, PP. E139-E596, (2020); WAN Q., LIU Z., YANG Y., CUI X., SUPPRESSIVE EFFECTS OF BERBERINE ON ATHEROSCLEROSIS VIA DOWNREGULATING VISFATIN EXPRESSION AND ATTENUATING VISFATIN-INDUCED ENDOTHELIAL DYSFUNCTION, INT. J. MOL. MED, 41, PP. 1939-1948, (2018); WANDE Y., JIE L., AIKAI Z., YAGUO Z., LINLIN Z., YUE G., ET AL., BERBERINE ALLEVIATES PULMONARY HYPERTENSION THROUGH TRX1 AND Β-CATENIN SIGNALING PATHWAYS IN PULMONARY ARTERY SMOOTH MUSCLE CELLS, EXP. CELL. RES, 390, (2020); WANG L.H., YU C.H., FU Y., LI Q., SUN Y.Q., BERBERINE ELICITS ANTI-ARRHYTHMIC EFFECTS VIA IK1/KIR2.1 IN THE RAT TYPE 2 DIABETIC MYOCARDIAL INFARCTION MODEL, PHYTOTHER. RES, 25, PP. 33-37, (2011); WANG J., GUO T., PENG Q.S., YUE S.W., WANG S.X., BERBERINE VIA SUPPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID 4 CHANNEL IMPROVES VASCULAR STIFFNESS IN MICE, J. CELL. MOL. MED, 19, PP. 2607-2616, (2015); WANG Y., LIU J., MA A., CHEN Y., CARDIOPROTECTIVE EFFECT OF BERBERINE AGAINST MYOCARDIAL ISCHEMIA/REPERFUSION INJURY VIA ATTENUATING MITOCHONDRIAL DYSFUNCTION AND APOPTOSIS, INT. J. CLIN. EXP. MED, 8, PP. 14513-14519, (2015); WANG K., FENG X., CHAI L., CAO S., QIU F., THE METABOLISM OF BERBERINE AND ITS CONTRIBUTION TO THE PHARMACOLOGICAL EFFECTS, DRUG METAB. REV, 49, PP. 139-157, (2017); WANG L., DENG L., LIN N., SHI Y., CHEN J., ZHOU Y., ET AL., BERBERINE INHIBITS PROLIFERATION AND APOPTOSIS OF VASCULAR SMOOTH MUSCLE CELLS INDUCED BY MECHANICAL STRETCH VIA THE PDI/ERS AND MAPK PATHWAYS, LIFE SCI, 259, (2020); WANG Y., DING Y., BERBERINE PROTECTS VASCULAR ENDOTHELIAL CELLS IN HYPERTENSIVE RATS, INT. J. CLIN. EXP. MED, 8, PP. 14896-14905, (2015); WANG Y., ZIDICHOUSKI J.A., UPDATE ON THE BENEFITS AND MECHANISMS OF ACTION OF THE BIOACTIVE VEGETAL ALKALOID BERBERINE ON LIPID METABOLISM AND HOMEOSTASIS, CHOLESTEROL, 2018, (2018); WEI S., ZHANG M., YU Y., LAN X., YAO F., YAN X., ET AL., BERBERINE ATTENUATES DEVELOPMENT OF THE HEPATIC GLUCONEOGENESIS AND LIPID METABOLISM DISORDER IN TYPE 2 DIABETIC MICE AND IN PALMITATE-INCUBATED HEPG2 CELLS THROUGH SUPPRESSION OF THE HNF-4Α MIR122 PATHWAY, PLOS ONE, 11, (2016); WEI X., WANG C., HAO S., SONG H., YANG L., THE THERAPEUTIC EFFECT OF BERBERINE IN THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE: A META-ANALYSIS, EVID. BASED. COMPLEMENT. ALTERNAT. MED, 2016, (2016); WENG T.C., YANG Y.H., LIN S.J., TAI S.H., A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE THERAPEUTIC EQUIVALENCE OF STATINS, J. CLIN. PHARM. THER, 35, PP. 139-151, (2010); WU M., YANG S., WANG S., CAO Y., ZHAO R., LI X., ET AL., EFFECT OF BERBERINE ON ATHEROSCLEROSIS AND GUT MICROBIOTA MODULATION AND THEIR CORRELATION IN HIGH-FAT DIET-FED APOE<SUP>−/−</SUP> MICE, FRONT. PHARMACOL, 11, (2020); WU Y.Z., ZHANG L., WU Z.X., SHAN T.T., XIONG C., BERBERINE AMELIORATES DOXORUBICIN-INDUCED CARDIOTOXICITY VIA A SIRT1/P66SHC-MEDIATED PATHWAY, OXID. MED. CELL. LONGEV, 2019, (2019); XIAO H.B., SUN Z.L., ZHANG H.B., ZHANG D.S., BERBERINE INHIBITS DYSLIPIDEMIA IN C57BL/6 MICE WITH LIPOPOLYSACCHARIDE INDUCED INFLAMMATION, PHARMACOL. REP, 64, PP. 889-895, (2012); XIONG C., WU Y.Z., ZHANG Y., WU Z.X., CHEN X.Y., JIANG P., ET AL., PROTECTIVE EFFECT OF BERBERINE ON ACUTE CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICIN TREATMENT, ONCOL. LETT, 15, PP. 5721-5729, (2018); XU S., PELISEK J., JIN Z.G., ATHEROSCLEROSIS IS AN EPIGENETIC DISEASE, TRENDS ENDOCRINOL. METAB, 29, PP. 739-742, (2018); XU S., XU Y., YIN M., ZHANG S., LIU P., KOROLEVA M., ET AL., FLOW-DEPENDENT EPIGENETIC REGULATION OF IGFBP5 EXPRESSION BY H3K27ME3 CONTRIBUTES TO ENDOTHELIAL ANTI-INFLAMMATORY EFFECTS, THERANOSTICS, 8, PP. 3007-3021, (2018); YAO W., WANG X., XIAO K., PROTECTIVE EFFECT OF BERBERINE AGAINST CARDIAC ISCHEMIA/REPERFUSION INJURY BY INHIBITING APOPTOSIS THROUGH THE ACTIVATION OF SMAD7, MOL. CELL. PROBES, 38, PP. 38-44, (2018); YE M., FU S., PI R., HE F., NEUROPHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES OF BERBERINE: A REVIEW OF RECENT RESEARCH, J. PHARM. PHARMACOL, 61, PP. 831-837, (2009); YU L., LI F., ZHAO G., YANG Y., JIN Z., ZHAI M., ET AL., PROTECTIVE EFFECT OF BERBERINE AGAINST MYOCARDIAL ISCHEMIA REPERFUSION INJURY: ROLE OF NOTCH1/HES1-PTEN/AKT SIGNALING, APOPTOSIS, 20, PP. 796-810, (2015); YU L., LI Q., YU B., YANG Y., JIN Z., DUAN W., ET AL., BERBERINE ATTENUATES MYOCARDIAL ISCHEMIA/REPERFUSION INJURY BY REDUCING OXIDATIVE STRESS AND INFLAMMATION RESPONSE: ROLE OF SILENT INFORMATION REGULATOR 1, OXID. MED. CELL. LONGEV, 2016, (2016); ZENG X.H., ZENG X.J., LI Y.Y., EFFICACY AND SAFETY OF BERBERINE FOR CONGESTIVE HEART FAILURE SECONDARY TO ISCHEMIC OR IDIOPATHIC DILATED CARDIOMYOPATHY, AM. J. CARDIOL, 92, PP. 173-176, (2003); ZHANG G., LIN X., SHAO Y., SU C., TAO J., LIU X., BERBERINE REDUCES ENDOTHELIAL INJURY AND ARTERIAL STIFFNESS IN SPONTANEOUSLY HYPERTENSIVE RATS, CLIN. EXP. HYPERTENS, 42, PP. 257-265, (2020); ZHANG H., NIU H., YUAN X., CHANG J., WANG X., TRIMETAZIDINE COMBINED WITH BERBERINE ON ENDOTHELIAL FUNCTION OF PATIENTS WITH CORONARY HEART DISEASE COMBINED WITH PRIMARY HYPERTENSION, EXP. THER. MED, 16, PP. 1318-1322, (2018); ZHANG J., BAO L.H., DONG X.C., YANG B.F., HE S.Z., LI W.H., PROTECTIVE EFFECT OF DIHYDROBERBERINE ON ACUTE ISCHEMIA AND ARRHYTHMIA, J. HARBIN MED. UNIV, 31, PP. 121-123, (1997); ZHANG X.D., REN H.M., LIU L., EFFECTS OF DIFFERENT DOSE BERBERINE ON HEMODYNAMIC PARAMETERS AND CA<SUP>2+</SUP>I OF CARDIAC MYOCYTES OF DIASTOLIC HEART FAILURE RAT MODEL, ZHONGGUO ZHONG YAO ZA ZHI, 33, PP. 818-821, (2008); ZHAO G.L., YU L.M., GAO W.L., DUAN W.X., JIANG B., LIU X.D., ET AL., BERBERINE PROTECTS RAT HEART FROM ISCHEMIA/REPERFUSION INJURY VIA ACTIVATING JAK2/STAT3 SIGNALING AND ATTENUATING ENDOPLASMIC RETICULUM STRESS, ACTA PHARMACOL. SIN, 37, PP. 354-367, (2016); ZHAO M., KLIPSTEIN-GROBUSCH K., WANG X., REITSMA J.B., ZHAO D., GROBBEE D.E., ET AL., PREVALENCE OF CARDIOVASCULAR MEDICATION ON SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION IN CHINA BETWEEN 1995-2015: A SYSTEMATIC REVIEW AND META-ANALYSIS, PLOS ONE, 12, (2017); ZHENG H., ZHU F., MIAO P., MAO Z., REDFEARN D.P., CAO R.Y., ANTIMICROBIAL NATURAL PRODUCT BERBERINE IS EFFICACIOUS FOR THE TREATMENT OF ATRIAL FIBRILLATION, BIOMED. RES. INT, 2017, (2017); ZHOU Z.W., ZHENG H.C., ZHAO L.F., LI W., HOU J.W., YU Y., ET AL., EFFECT OF BERBERINE ON ACETYLCHOLINE-INDUCED ATRIAL FIBRILLATION IN RABBIT, AM. J. TRANSL. RES, 7, PP. 1450-1457, (2015); ZHU M.L., YIN Y.L., PING S., YU H.Y., WAN G.R., JIAN X., ET AL., BERBERINE PROMOTES ISCHEMIA-INDUCED ANGIOGENESIS IN MICE HEART VIA UPREGULATION OF MICRORNA-29B, CLIN. EXP. HYPERTENS, 39, PP. 672-679, (2017); ZHU N., LI J., LI Y., ZHANG Y., DU Q., HAO P., BERBERINE PROTECTS AGAINST SIMULATED ISCHEMIA/REPERFUSION INJURY-INDUCED H9C2 CARDIOMYOCYTES APOPTOSIS IN VITRO AND MYOCARDIAL ISCHEMIA/REPERFUSION-INDUCED APOPTOSIS IN VIVO BY REGULATING THE MITOPHAGY-MEDIATED HIF-1Α/BNIP3 PATHWAY, FRONT. PHARMACOL, 11, (2020)","W. CONG; LABORATORY OF CARDIOVASCULAR DISEASES, XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES, BEIJING, CHINA; EMAIL: CONGCAO@188.COM; W. CONG; NATIONAL CLINICAL RESEARCH CENTER FOR CHINESE MEDICINE CARDIOLOGY, BEIJING, CHINA; EMAIL: CONGCAO@188.COM; Q. LIN; DONGZHIMEN HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE, BEIJING, CHINA; EMAIL: LINQIAN62@126.COM","FRONTIERS MEDIA S.A.","ENGLISH","FRONT. PHARMACOL.","REVIEW","ISI","2-S2.0-85103477725","FRONT PHARMACOL","DONGZHIMEN HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE;XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES;DONGFANG HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE;XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES;DONGZHIMEN HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE;XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES;XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES","NOTREPORTED;XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES;NOTREPORTED;NOTREPORTED;NATIONAL CLINICAL RESEARCH CENTER FOR CHINESE MEDICINE CARDIOLOGY;NOTREPORTED;NOTREPORTED;DONGZHIMEN HOSPITAL OF BEIJING UNIVERSITY OF CHINESE MEDICINE;NOTREPORTED",NA,"CAI Y, 2021, FRONT PHARMACOL","CAI Y, 2021, FRONT PHARMACOL"
"CEYLAN M;AKDAS S;YAZIHAN N","CEYLAN, MERVE NUR (57216936828); AKDAS, SEVGINUR (57210803672); YAZIHAN, NURAY (16644265800)","THE EFFECTS OF ZINC SUPPLEMENTATION ON CREACTIVE PROTEIN AND INFLAMMATORY CYTOKINES A METAANALYSIS AND SYSTEMATICAL REVIEW",2021,"JOURNAL OF INTERFERON AND CYTOKINE RESEARCH","41","20",13,"10.1089/jir.2020.0209","INSTITUTE OF HEALTH SCIENCES, INTERDISCIPLINARY FOOD, METABOLISM AND CLINICAL NUTRITION DEPARTMENT, ANKARA, TURKEY;INSTITUTE OF HEALTH SCIENCES, INTERDISCIPLINARY FOOD, METABOLISM AND CLINICAL NUTRITION DEPARTMENT, ANKARA, TURKEY;INSTITUTE OF HEALTH SCIENCES, INTERDISCIPLINARY FOOD, METABOLISM AND CLINICAL NUTRITION DEPARTMENT, ANKARA, TURKEY, FACULTY OF MEDICINE, PATHOPHYSIOLOGY DEPARTMENT, ANKARA UNIVERSITY, MORFOLOJI BUILDING, SIHHIYE, ANKARA, 06100, TURKEY","ZINC IS KNOWN FOR ANTI-INFLAMMATORY AND ANTIOXIDANT ROLES. IN THIS META-ANALYSIS, WE AIM TO EVALUATE THE IMPACT OF ZINC SUPPLEMENTATION ON INFLAMMATORY MARKERS, ACUTE-PHASE REACTANTS, AND SERUM ZINC LEVEL DURING INFLAMMATORY AND INFECTIOUS DISEASES. PUBMED, SCOPUS, AND WEB OF SCIENCE DATABASES WERE SCREENED SYSTEMATICALLY WITH THE TERMS ""ZINC SUPPLEMENTATION""AND ""CRP""OR ""IL-1Β""OR ""IL-2""OR ""IL-6""OR ""IL-10""OR ""IL-12""OR ""TNF-Α""OR ""TGF-Β""OR ""IFN-Γ""OR ""WBC (CLINICAL TRIAL)""OR ""MACROPHAGE (CLINICAL TRIAL)""OR ""LYMPHOCYTE (CLINICAL TRIAL)""OR ""NEUTROPHIL (CLINICAL TRIAL)""OR ""VIRUS (CLINICAL TRIAL)""OR ""ANTIVIRAL (CLINICAL TRIAL)""FOR ALL DATABASES. A TOTAL OF 2,258 PUBLICATIONS WERE SCREENED, AND 73 ARTICLES HAD SUITABLE DATA FOR THE META-ANALYSIS. SERUM ZINC LEVEL WAS SIGNIFICANTLY HIGHER IN SUPPLEMENTATION GROUP COMPARED WITH CONTROLS [P = 0.0006, MEAN DIFFERENCE: 11.35 (4.84, 17.87)] (N = 37). ZINC SUPPLEMENTATION DOWNREGULATES ACUTE-PHASE REACTANTS, ESPECIALLY SERUM C-REACTIVE PROTEIN (CRP) IN ADULTS [P < 0.00001, MEAN DIFFERENCE:-0.75 (-0.98,-0.52)] (N = 22) AND PREGNANT WOMEN [FEM P < 0.00001, MEAN DIFFERENCE:-1.77 (-2.53,-1.00)] (N = 3) BUT NOT IN CHILDREN [REM P = 0.10, MEAN DIFFERENCE:-0.85 (-1.86, 0.17)] (N = 3). IN SUBGROUPS ANALYSIS OF CHRONIC INFLAMMATORY DISEASES, SERUM CRP [REM P < 0.00001, MEAN DIFFERENCE:-0.57 (-0.76,-0.38)] WERE SIGNIFICANTLY LOWER IN ZINC-SUPPLEMENTED PATIENTS COMPARED WITH NO INTERVENTION GROUP. ZINC SUPPLEMENTATION (MG/DAY) CORRELATED WITH SERUM INTERFERON-GAMMA (IFN-Γ) LEVEL (P = 0.018, R = 1,000). IN THE NONSUPPLEMENTED GROUP, SERUM ZINC CORRELATED WITH SERUM INTERLEUKIN-6 (IL-6) LEVEL (P = 0.041, R =-0.829) AND SERUM TUMOR NECROSIS FACTOR ALPHA (TNF-Α) LEVEL (P = 0.063, R = 0.730). ZINC INTAKE CORRELATED WITH SERUM ZINC (P = 0.0428, R = 0.5115) AND TNF-Α (P = 0.0043, R =-0.9461). THIS META-ANALYSIS SHOWS THAT ZINC SUPPLEMENTATION IMPROVES CRP LEVELS IN ADULTS AND PREGNANT WOMEN. IT MIGHT HAVE MODULATORY EFFECTS ON CYTOKINE SECRETIONS AND BLOOD CELLS IN INFLAMMATORY AND INFECTIOUS DISEASES. FOR THE FIRST TIME, WE INVESTIGATED THE EFFECTS OF ZINC SUPPLEMENTATION ON INFLAMMATORY CYTOKINE.  © COPYRIGHT 2021, MARY ANN LIEBERT, INC., PUBLISHERS 2021.","C-REACTIVE PROTEIN (CRP); CYTOKINE; INFECTION; INFLAMMATION; ZINC","ADULT; C-REACTIVE PROTEIN; CHILD, PRESCHOOL; CYTOKINES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MODELS, BIOLOGICAL; PUBLICATION BIAS; RISK; VIRUS DISEASES; ZINC; ACUTE PHASE PROTEIN; ALPHA CAROTENE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ARCTIGENIN; ARGININE; ASCORBIC ACID; BERBERINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CARNOSINE; CIPROFLOXACIN; COPPER; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GAMMA INTERFERON; GLUCONATE ZINC; HYDROXYTYROSOL; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; IRON; LINOLENIC ACID; LYCOPENE; MAGNESIUM; MEVINOLIN; MULTIVITAMIN; NUTRITION SUPPLEMENT; POLAPREZINC; POLICOSANOL; RESVERATROL; RETINOL; RETINOL ACETATE; RETINOL PALMITATE; RIBAVIRIN; ROPEGINTERFERON ALPHA2B; ROSUVASTATIN; SELENIUM; SEROTONIN UPTAKE INHIBITOR; THIOCTIC ACID; TOCOPHEROL; TRACE ELEMENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VITAMIN; XANTHOPHYLL; ZINC; ZINC ACETATE; ZINC SULFATE; AUTACOID; C REACTIVE PROTEIN; CYTOKINE; ZINC; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; CHILD; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON ADENOMA; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; END STAGE RENAL DISEASE; FEMALE; HEAD AND NECK CANCER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOCOMPETENT CELL; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY DISEASE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALIGNANT NEOPLASM; MALNUTRITION; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTMENOPAUSE; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM ADENOMA; STUNTING; SYSTEMATIC REVIEW; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; ZINC BLOOD LEVEL; ZINC INTAKE; BIOLOGICAL MODEL; BLOOD; DIETARY SUPPLEMENT; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; PUBLISHING; RISK; VIRUS INFECTION","","","ABBASINAZARI M, ALAVIAN SM, BEHNAVA B, ASGHARINIA M, SALIMI S, KESHVARI M, MEHRNOUSH L, KARIM P., EFFECT OF ZINC SUPPLEMENTATION ON VIRAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C AND BETA THALASSEMIA MAJOR, A PILOT STUDY, J CLIN DIAGN RES, 8, 12, (2014); ADRIANI M, WIRJATMADI B., THE EFFECT OF ADDING ZINC TO VITAMIN A ON IGF-1, BONE AGE AND LINEAR GROWTH IN STUNTED CHILDREN, J TRACE ELEM MED BIOL, 28, 4, PP. 431-435, (2014); ADU-AFARWUAH S, LARTEY A, OKRONIPA H, ASHORN P, ZEILANI M, BALDIVIEZ LM, OAKS BM, VOSTI S, DEWEY KG., IMPACT OF SMALL-QUANTITY LIPID-BASED NUTRIENT SUPPLEMENT ON HEMOGLOBIN, IRON STATUS AND BIOMARKERS OF INFLAMMATION IN PREGNANT GHANAIAN WOMEN, MATERN CHILD NUTR, 13, 2, (2017); AHMAD I, AL-AHMARE K., EFFECT OF VITAMIN A AND ZINC ON CIRCULATING PROFILE OF IL-2, IL-12, AND IFNG CYTOKINES IN PULMONARY TUBERCULOSIS PATIENTS, INT J NUTR PHARMACOL NEUROL DIS, 6, 2, (2016); AKDAS S, TURAN B, DURAK A, AYRAL PA, YAZIHAN N., THE RELATIONSHIP BETWEEN METABOLIC SYNDROME DEVELOPMENT AND TISSUE TRACE ELEMENTS STATUS AND INFLAMMATORY MARKERS, BIOL TRACE ELEM RES, 198, 1, PP. 16-24, (2020); AKDAS S, YAZIHAN N., CORD BLOOD ZINC STATUS EFFECTS ON PREGNANCY OUTCOMES AND ITS RELATION WITH MATERNAL SERUM ZINC LEVELS: A SYSTEMATIC REVIEW AND META-ANALYSIS, WORLD J PEDIATR, 16, 4, PP. 366-376, (2020); AKDAS S, YAZIHAN N., SERUM ZINC LEVEL AND DIETARY ZINC INTAKE STATUS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A METAANALYSIS AND SYSTEMATIC REVIEW, HEPATOL FORUM, 2, PP. 59-67, (2020); ARMIJOS RX, WEIGEL MM, CHACON R, FLORES L, CAMPOS A., ADJUNCTIVE MICRONUTRIENT SUPPLEMENTATION FOR PULMONARY TUBERCULOSIS, SALUD PÚBLICA MÉX, 52, PP. 185-189, (2010); AYDEMIR TB, CHANG S-M, GUTHRIE GJ, MAKI AB, RYU M-S, KARABIYIK A, COUSINS RJ., ZINC TRANSPORTER ZIP14 FUNCTIONS IN HEPATIC ZINC, IRON AND GLUCOSE HOMEOSTASIS DURING THE INNATE IMMUNE RESPONSE (ENDOTOXEMIA), PLOS ONE, 7, 10, (2012); BAO B, PRASAD AS, BECK FW, FITZGERALD JT, SNELL D, BAO GW, SINGH T, CARDOZO LJ., ZINC DECREASES C-REACTIVE PROTEIN, LIPID PEROXIDATION, AND INFLAMMATORY CYTOKINES IN ELDERLY SUBJECTS: A POTENTIAL IMPLICATION OF ZINC AS AN ATHEROPROTECTIVE AGENT, AM J CLIN NUTR, 91, 6, PP. 1634-1641, (2010); BAO B, PRASAD AS, BECK FW, SNELL D, SUNEJA A, SARKAR FH, DOSHI N, FITZGERALD JT, SWERDLOW P., ZINC SUPPLEMENTATION DECREASES OXIDATIVE STRESS, INCIDENCE OF INFECTION, AND GENERATION OF INFLAMMATORY CYTOKINES IN SICKLE CELL DISEASE PATIENTS, TRANSL RES, 152, 2, PP. 67-80, (2008); BARNETT JB, DAO MC, HAMER DH, KANDEL R, BRANDEIS G, WU D, DALLAL GE, JACQUES PF, SCHREIBER R, KONG E, MEYDANI SN., EFFECT OF ZINC SUPPLEMENTATION ON SERUM ZINC CONCENTRATION AND T CELL PROLIFERATION IN NURSING HOME ELDERLY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM J CLIN NUTR, 103, 3, PP. 942-951, (2016); BOGDEN J, OLESKE J, LAVENHAR M, MUNVES E, KEMP F, BRUENING KS, HOLDING KJ, DENNY TN, GUARINO MA, KRIEGER LM, ET AL., ZINC AND IMMUNOCOMPETENCE IN ELDERLY PEOPLE: EFFECTS OF ZINC SUPPLEMENTATION FOR 3 MONTHS, AM J CLIN NUTR, 48, 3, PP. 655-663, (1988); BORENSTEIN M, HEDGES LV, HIGGINS JP, ROTHSTEIN HR., FIXED-EFFECT VERSUS RANDOM-EFFECTS MODELS, INTRODUCTION TO META-ANALYSIS, 77, (2009); BRAUNSCHWEIG CL, SOWERS M, KOVACEVICH DS, HILL GM, AUGUST DA., PARENTERAL ZINC SUPPLEMENTATION IN ADULT HUMANS DURING THE ACUTE PHASE RESPONSE INCREASES THE FEBRILE RESPONSE, J NUTR, 127, 1, PP. 70-74, (1997); BRIGNOLA C, BELLOLI C, DE SIMONE G, EVANGELISTI A, PARENTE R, MANCINI R, IANNONE P, MOCHEGGIANI E, FABRIS N, MORINI MC, ET AL., ZINC SUPPLEMENTATION RESTORES PLASMA CONCENTRATIONS OF ZINC AND THYMULIN IN PATIENTS WITH CROHN'S DISEASE, ALIMENT PHARMACOL THER, 7, 3, PP. 275-280, (1993); CEYLAN MN, AKDAS S, YAZIHAN N., IS ZINC AN IMPORTANT TRACE ELEMENT ON BONE TURNOVER RELATED COMPLICATIONS: A META-ANALYSIS AND SYSTEMATIC REVIEW FROM SERUM LEVEL, DIETARY INTAKE AND SUPPLEMENTATION ASPECTS, BIOL TRACE ELEM RES, 199, 2, PP. 535-549, (2021); COSTARELLI L, GIACCONI R, MALAVOLTA M, BASSO A, PIACENZA F, DEMARTIIS M, GIANNANDREA E, RENIERI C, BUSCO F, GALEAZZI R, MOCCHEGIANI E., EFFECTS OF ZINC-FORTIFIED DRINKING SKIM MILK (AS FUNCTIONAL FOOD) ON CYTOKINE RELEASE AND THYMIC HORMONE ACTIVITY IN VERY OLD PERSONS: A PILOT STUDY, AGE, 36, 3, (2014); DE MOURA MSB, SOARES NRM, DE LIMA BARROS SE, DE PINHO FA, SILVA TMC, BRAZ DC, VIEIRA EC, LIMA MM, PARENTE JML, DO NASCIMENTO MARREIRO D, DA SILVA AS, DO NASCIMENTO NOGUEIRA N., ZINC GLUCONATE SUPPLEMENTATION IMPACTS THE CLINICAL IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS, BIOMETALS, 33, 1, PP. 15-27, (2020); DEROSA G, D'ANGELO A, ROMANO D, MAFFIOLI P., A CLINICAL TRIAL ABOUT A FOOD SUPPLEMENT CONTAINING A-LIPOIC ACID ON OXIDATIVE STRESS MARKERS IN TYPE 2 DIABETIC PATIENTS, INT J MOL SCI, 17, 11, (2016); DIAS PCS, SENA-EVANGELISTA KCM, DE OLIVEIRA PAIVA MSM, FERREIRA DQC, URURAHY MAG, REZENDE AA, ABDALLA DSP, PEDROSA LFC., THE BENEFICIAL EFFECTS OF ROSUVASTATIN ARE INDEPENDENT OF ZINC SUPPLEMENTATION IN PATIENTS WITH ATHEROSCLEROSIS, J TRACE ELEM MED BIOL, 28, 2, PP. 194-199, (2014); DIOUF A, BADIANE A, MANGA NM, IDOHOU-DOSSOU N, SOW PS, WADE S., DAILY CONSUMPTION OF READY-TO-USE PEANUTBASED THERAPEUTIC FOOD INCREASED FAT FREE MASS, IMPROVED ANEMIC STATUS BUT HAS NO IMPACT ON THE ZINC STATUS OF PEOPLE LIVING WITH HIV/AIDS: A RANDOMIZED CONTROLLED TRIAL, BMC PUBLIC HEALTH, 16, 1, (2016); DUCHATEAU J, DELEPESSE G, VRIJENS R, COLLET H., BENEFICIAL EFFECTS OF ORAL ZINC SUPPLEMENTATION ON THE IMMUNE RESPONSE OF OLD PEOPLE, AM J MED, 70, 5, PP. 1001-1004, (1981); EBRAHIMI FA, FOROOZANFARD F, AGHADAVOD E, BAHMANI F, ASEMI Z., THE EFFECTS OF MAGNESIUM AND ZINC COSUPPLEMENTATION ON BIOMARKERS OF INFLAMMATION AND OXIDATIVE STRESS, AND GENE EXPRESSION RELATED TO INFLAMMATION IN POLYCYSTIC OVARY SYNDROME: A RANDOMIZED CONTROLLED CLINICAL TRIAL, BIOL TRACE ELEM RES, 184, 2, PP. 300-307, (2018); FARIAS MS, BUDNI P, RIBEIRO CM, PARISOTTO EB, SANTOS CEI, DIAS JF, DALMARCO EM, FRODE TS, PEDROSA RC, WILHELM FILHO D., ANTIOXIDANT SUPPLEMENTATION ATTENUATES OXIDATIVE STRESS IN CHRONIC HEPATITIS C PATIENTS, GASTROENTEROL HEPATOL, 35, 6, PP. 386-394, (2012); FOSTER M, PETOCZ P, SAMMAN S., INFLAMMATION MARKERS PREDICT ZINC TRANSPORTER GENE EXPRESSION IN WOMEN WITH TYPE 2 DIABETES MELLITUS, J NUTR BIOCHEM, 24, 9, PP. 1655-1661, (2013); FUKUDA S, KOYAMA H, KONDO K, FUJII H, HIRAYAMA Y, TABATA T, OKAMURA M, YAMAKAWA T, OKADA S, HIRATA S, KIYAMA H, KAJIMOTO O, WATANABE Y, INABA M, NISHIZAWA Y., EFFECTS OF NUTRITIONAL SUPPLEMENTATION ON FATIGUE, AND AUTONOMIC AND IMMUNE DYSFUNCTION IN PATIENTS WITH END-STAGE RENAL DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, PLOS ONE, 10, 3, (2015); GERMOLEC DR, FRAWLEY RP, EVANS E., MARKERS OF INFLAMMATION, IMMUNOTOXICITY TESTING, PP. 53-73, (2010); GHAFFARI H, TAVAKOLI A, MORADI A, TABARRAEI A, BOKHARAEI-SALIM F, ZAHMATKESHAN M, FARAHMAND M, JAVANMARD D, KIANI SJ, ESGHAEI M, PIRHAJATI-MAHABADI V, MONAVARI SH, ATAEI-PIRKOOH A., INHIBITION OF H1N1 INFLUENZA VIRUS INFECTION BY ZINC OXIDE NANOPARTICLES: ANOTHER EMERGING APPLICATION OF NANOMEDICINE, J BIOMED SCI, 26, 1, (2019); GLOSZ CM, SCHAFFNER AA, REAVES SK, MANARY MJ, PAPATHAKIS PC., EFFECT OF NUTRITIONAL INTERVENTIONS ON MICRONUTRIENT STATUS IN PREGNANT MALAWIAN WOMEN WITH MODERATE MALNUTRITION: A RANDOMIZED, CONTROLLED TRIAL, NUTRIENTS, 10, 7, (2018); GREEN J, LEWIN S, WIGHTMAN F, LEE M, RAVINDRAN S, PATON N., A RANDOMISED CONTROLLED TRIAL OF ORAL ZINC ON THE IMMUNE RESPONSE TO TUBERCULOSIS IN HIV-INFECTED PATIENTS, INT J TUBERC LUNG DIS, 9, 12, PP. 1378-1384, (2005); HIGGINS J., COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, (2011); HIGGINS JP, THOMPSON SG, DEEKS JJ, ALTMAN DG., MEASURING INCONSISTENCY IN META-ANALYSES, BMJ, 327, 7414, PP. 557-560, (2003); HIMOTO T, HOSOMI N, NAKAI S, DEGUCHI A, KINEKAWA F, MATSUKI M, YACHIDA M, MASAKI T, KUROKOCHI K, WATANABE S, SENDA S, KURIYAMA S., EFFICACY OF ZINC ADMINISTRATION IN PATIENTS WITH HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE, SCAND J GASTROENTEROL, 42, 9, PP. 1078-1087, (2007); HODKINSON CF, KELLY M, ALEXANDER HD, BRADBURY I, ROBSON PJ, BONHAM MP, O'CONNOR JM, COUDRAY C, STRAIN JJ, WALLACE JMW., EFFECT OF ZINC SUPPLEMENTATION ON THE IMMUNE STATUS OF HEALTHY OLDER INDIVIDUALS AGED 55-70 YEARS: THE ZENITH STUDY, J GERONTOL A BIOL SCI MED SCI, 62, 6, PP. 598-608, (2007); HOLTKAMP W, BRODERSEN H-P, STOLLBERG T, THIERY J, FALKNER C., ZINC SUPPLEMENTATION STIMULATES TETANUS ANTIBODY FORMATION AND SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN CHRONIC HEMODIALYSIS PATIENTS, CLIN INVESTIG, 71, 7, PP. 537-541, (1993); HOPKINS MH, FEDIRKO V, JONES DP, TERRY PD, BOSTICK RM., ANTIOXIDANT MICRONUTRIENTS AND BIOMARKERS OF OXIDATIVE STRESS AND INFLAMMATION IN COLORECTAL ADENOMA PATIENTS: RESULTS FROM A RANDOMIZED, CONTROLLED CLINICAL TRIAL, CANCER EPIDEMIOL BIOMARKERS PREV, 19, 3, PP. 850-858, (2010); ISAKOV VA, BOGDANOVA AA, BESSONOV VV, SENTSOVA TB, TUTELYAN VA, LIN Y, KAZLOVA V, HONG J, VELLIQUETTE RA., EFFECTS OF MULTIVITAMIN, MULTIMINERAL AND PHYTONUTRIENT SUPPLEMENTATION ON NUTRIENT STATUS AND BIOMARKERS OF HEART HEALTH RISK IN A RUSSIAN POPULATION: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY, NUTRIENTS, 10, 2, (2018); ISBANIAH F, WIYONO WH, YUNUS F, SETIAWATI A, TOTZKE U, VERBRUGGEN M., ECHINACEA PURPUREA ALONG WITH ZINC, SELENIUM AND VITAMIN C TO ALLEVIATE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL, J CLIN PHARM THER, 36, 5, PP. 568-576, (2011); ISLAM MR, ATTIA J, ALI L, MCEVOY M, SELIM S, SIBBRITT D, AKHTER A, AKTER S, PEEL R, FARUQUE O, MONA T, LONA H, MILTON AH., ZINC SUPPLEMENTATION FOR IMPROVING GLUCOSE HANDLING IN PRE-DIABETES: A DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PILOT STUDY, DIABETES RES CLIN PRACT, 115, PP. 39-46, (2016); JAMILIAN M, FOROOZANFARD F, BAHMANI F, TALAEE R, MONAVARI M, ASEMI Z., EFFECTS OF ZINC SUPPLEMENTATION ON ENDOCRINE OUTCOMES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, BIOL TRACE ELEM RES, 170, 2, PP. 271-278, (2016); KAHMANN L, UCIECHOWSKI P, WARMUTH S, MALAVOLTA M, MOCCHEGIANI E, RINK L., EFFECT OF IMPROVED ZINC STATUS ON T HELPER CELL ACTIVATION AND TH1/TH2 RATIO IN HEALTHY ELDERLY INDIVIDUALS, BIOGERONTOLOGY, 7, 5-6, PP. 429-435, (2006); KARAMALI M, HEIDARZADEH Z, SEIFATI S-M, SAMIMI M, TABASSI Z, TALAEE N, BAHARDOOST H, ASEMI Z., ZINC SUPPLEMENTATION AND THE EFFECTS ON PREGNANCY OUTCOMES IN GESTATIONAL DIABETES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EXP CLIN ENDOCRINOL DIABETES, 124, 1, PP. 28-33, (2016); KAWAGUCHI T, NAGAO Y, ABE K, IMAZEKI F, HONDA K, YAMASAKI K, MIYANISHI K, TANIGUCHI E, KAKUMA T, KATO J, SEIKE M, YOKOSUKA O, OHIRA H, SATA M., EFFECTS OF BRANCHEDCHAIN AMINO ACIDS AND ZINC-ENRICHED NUTRIENTS ON PROGNOSTICATORS IN HCV-INFECTED PATIENTS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL, MOL MED REP, 11, 3, PP. 2159-2166, (2015); KELISHADI R, HASHEMIPOUR M, ADELI K, TAVAKOLI N, MOVAHEDIAN-ATTAR A, SHAPOURI J, POURSAFA P, ROUZBAHANI A., EFFECT OF ZINC SUPPLEMENTATION ON MARKERS OF INSULIN RESISTANCE, OXIDATIVE STRESS, AND INFLAMMATION AMONG PREPUBESCENT CHILDREN WITH METABOLIC SYNDROME, METAB SYNDR RELAT DISORD, 8, 6, PP. 505-510, (2010); KHAN MI, SIDDIQUE KU, ASHFAQ F, ALI W, REDDY HD, MISHRA A., EFFECT OF HIGH-DOSE ZINC SUPPLEMENTATION WITH ORAL HYPOGLYCEMIC AGENTS ON GLYCEMIC CONTROL AND INFLAMMATION IN TYPE-2 DIABETIC NEPHROPATHY PATIENTS, J NAT SCI BIOL MED, 4, 2, (2013); KHAZDOUZ M, MAZIDI M, EHSAEI M-R, FERNS G, KENGNE AP, NOROUZY A-R., IMPACT OF ZINC SUPPLEMENTATION ON THE CLINICAL OUTCOMES OF PATIENTS WITH SEVERE HEAD TRAUMA: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL, J DIET SUPPL, 15, 1, PP. 1-10, (2018); KHORSANDI H, NIKPAYAM O, YOUSEFI R, PARANDOOSH M, HOSSEINZADEH N, SAIDPOUR A, GHORBANI A., ZINC SUPPLEMENTATION IMPROVES BODY WEIGHT MANAGEMENT, INFLAMMATORY BIOMARKERS AND INSULIN RESISTANCE IN INDIVIDUALS WITH OBESITY: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL, DIABETOL METAB SYNDR, 11, 1, (2019); KILIC M, BALTACI AK, GUNAY M., EFFECT OF ZINC SUPPLEMENTATION ON HEMATOLOGICAL PARAMETERS IN ATHLETES, BIOL TRACE ELEM RES, 100, 1, PP. 31-38, (2004); KIM J, AHN J., EFFECT OF ZINC SUPPLEMENTATION ON INFLAMMATORY MARKERS AND ADIPOKINES IN YOUNG OBESE WOMEN, BIOL TRACE ELEM RES, 157, 2, PP. 101-106, (2014); KIM KI, KIM SR, SASASE N, AKIMOTO Y, SHIKATA M, OHTANI A, HIROOKA T, TANAKA K., BLOOD CELL, LIVER FUNCTION, AND RESPONSE CHANGES BY PEG-INTERFERON-A2B PLUS RIBAVIRIN WITH POLAPREZINC THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C, HEPATOL INT, 2, 1, PP. 111-115, (2008); KO W-S, GUO C-H, HSU G-SW, CHIOU Y-L, YEH M-S, YAUN S-R., THE EFFECT OF ZINC SUPPLEMENTATION ON THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH INTERFERON AND RIBAVIRIN, CLIN BIOCHEM, 38, 7, PP. 614-620, (2005); KULOG?LU Z, K?RBAS X G, ERDEN E, KANSU A., INTERFERON-ALPHA-2A AND ZINC COMBINATION THERAPY IN CHILDREN WITH CHRONIC HEPATITIS B INFECTION, BIOL TRACE ELEM RES, 143, 3, PP. 1302-1309, (2011); LIUZZI JP, LICHTEN LA, RIVERA S, BLANCHARD RK, AYDEMIR TB, KNUTSON MD, GANZ T, COUSINS RJ., INTERLEUKIN-6 REGULATES THE ZINC TRANSPORTER ZIP14 IN LIVER AND CONTRIBUTES TO THE HYPOZINCEMIA OF THE ACUTE-PHASE RESPONSE, PROC NATL ACAD SCI U S A, 102, 19, PP. 6843-6848, (2005); MARIANI E, NERI S, CATTINI L, MOCCHEGIANI E, MALAVOLTA M, DEDOUSSIS GV, KANONI S, RINK L, JAJTE J, FACCHINI A., (2008); EFFECT OF ZINC SUPPLEMENTATION ON PLASMA IL-6 AND MCP-1 PRODUCTION AND NK CELL FUNCTION IN HEALTHY ELDERLY: INTERACTIVE INFLUENCE OF +647 MT1A AND-174 IL-6 POLYMORPHIC ALLELES, EXP GERONTOL, 43, 5, PP. 462-471; MATSUMURA H, NIREI K, NAKAMURA H, ARAKAWA Y, HIGUCHI T, HAYASHI J, YAMAGAMI H, MATSUOKA S, OGAWA M, NAKAJIMA N, TANAKA N, MORIYAMA M., ZINC SUPPLEMENTATION THERAPY IMPROVES THE OUTCOME OF PATIENTS WITH CHRONIC HEPATITIS C, J CLIN BIOCHEM NUTR, 51, 3, PP. 178-184, (2012); MAYWALD M, WANG F, RINK L., ZINC SUPPLEMENTATION PLAYS A CRUCIAL ROLE IN T HELPER 9 DIFFERENTIATION IN ALLOGENEIC IMMUNE REACTIONS AND NON-ACTIVATED T CELLS, J TRACE ELEM MED BIOL, 50, PP. 482-488, (2018); MAZZATTI D, MALAVOLTA M, WHITE A, COSTARELLI L, GIACCONI R, MUTI E, CIPRIANO C, POWELL JR, MOCCHEGIANI E., EFFECTS OF INTERLEUKIN-6-174C/G AND METALLOTHIONEIN 1A +647A/C SINGLE-NUCLEOTIDE POLYMORPHISMS ON ZINC-REGULATED GENE EXPRESSION IN AGEING, EXP GERONTOL, 43, 5, PP. 423-432, (2008); MEKSAWAN K, SERMSRI U, CHANVORACHOTE P., ZINC SUPPLEMENTATION IMPROVES ANTICANCER ACTIVITY OF MONOCYTES IN TYPE-2 DIABETIC PATIENTS WITH METABOLIC SYNDROME, ANTICANCER RES, 34, 1, PP. 295-299, (2014); MELICHAR B, MAL?R F, TICHY M., URINARY ZINC EXCRETION IN PATIENTS WITH DIFFERENT DISORDERS: THE ACUTE PHASE RESPONSE IN THE KIDNEY, SB VED PR LEK FAK KARLOVY UNIVERZITY HRADCI KRALOVE, 36, 4-5, PP. 325-335, (1993); MESDAGHINIA E, NADERI F, BAHMANI F, CHAMANI M, GHADERI A, ASEMI Z., THE EFFECTS OF ZINC SUPPLEMENTATION ON CLINICAL RESPONSE AND METABOLIC PROFILES IN PREGNANT WOMEN AT RISK FOR INTRAUTERINE GROWTH RESTRICTION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, J MATERN FETAL NEONATAL MED, PP. 1-7, (2019); MIKIROVA NA, KESARI S, ICHIM TE, RIORDAN NH., EFFECT OF INFLA-KINE SUPPLEMENTATION ON THE GENE EXPRESSION OF INFLAMMATORY MARKERS IN PERIPHERAL MONONUCLEAR CELLS AND ON C-REACTIVE PROTEIN IN BLOOD, J TRANSL MED, 15, 1, (2017); MURAKAMI Y, KOYABU T, KAWASHIMA A, KAKIBUCHI N, KAWAKAMI T, TAKAGUCHI K, KITA K, OKITA M., ZINC SUPPLEMENTATION PREVENTS THE INCREASE OF TRANSAMINASE IN CHRONIC HEPATITIS C PATIENTS DURING COMBINATION THERAPY WITH PEGYLATED INTERFERON A-2B AND RIBAVIRIN, J NUTR SCI VITAMINOL (TOKYO), 53, 3, PP. 213-218, (2007); NAGAMINE T, TAKAGI H, TAKAYAMA H, KOJIMA A, KAKIZAKI S, MORI M, NAKAJIMA K., PRELIMINARY STUDY OF COMBINATION THERAPY WITH INTERFERON-A AND ZINC IN CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1B, BIOL TRACE ELEM RES, 75, 1-3, PP. 53-63, (2000); PAKASI TA, KARYADI E, SURATIH NMD, SALEAN M, DARMAWIDJAJA N, BOR H, VAN DER VELDEN K, DOLMANS WMV, VAN DER MEER JWM., ZINC AND VITAMIN A SUPPLEMENTATION FAILS TO REDUCE SPUTUM CONVERSION TIME IN SEVERELY MALNOURISHED PULMONARY TUBERCULOSIS PATIENTS IN INDONESIA, NUTR J, 9, 1, (2010); POURTEYMOUR FTF, ALIPOOR B, OSTADRAHIMI A, MEHRZAD SM., EFFECT OF ZINC SUPPLEMENTATION ON INFLAMMATORY MARKERS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, SHIRAZ E MED J, 12, 1, PP. 30-38, (2011); PRASAD AS, BAO B, BECK FW, KUCUK O, SARKAR FH., ANTIOXIDANT EFFECT OF ZINC IN HUMANS, FREE RADIC BIOL MED, 37, 8, PP. 1182-1190, (2004); PRASAD AS, BAO B, BECK FW, SARKAR FH., ZINC-SUPPRESSED INFLAMMATORY CYTOKINES BY INDUCTION OF A20-MEDIATED INHIBITION OF NUCLEAR FACTOR-KB, NUTRITION, 27, 7-8, PP. 816-823, (2011); PRASAD AS, BECK FW, BAO B, FITZGERALD JT, SNELL DC, STEINBERG JD, CARDOZO LJ., ZINC SUPPLEMENTATION DECREASES INCIDENCE OF INFECTIONS IN THE ELDERLY: EFFECT OF ZINC ON GENERATION OF CYTOKINES AND OXIDATIVE STRESS, AM J CLIN NUTR, 85, 3, PP. 837-844, (2007); PRASAD AS, BECK FW, KAPLAN J, CHANDRASEKAR PH, ORTEGA J, FITZGERALD JT, SWERDLOW P., EFFECT OF ZINC SUPPLEMENTATION ON INCIDENCE OF INFECTIONS AND HOSPITAL ADMISSIONS IN SICKLE CELL DISEASE (SCD), AM J HEMATOL, 61, 3, PP. 194-202, (1999); PROVINCIALI M, MONTENOVO A, STEFANO GD, COLOMBO M, DAGHETTA L, CAIRATI M, VERONI C, CASSINO R, DELLA TORRE F, FABRIS N., EFFECT OF ZINC OR ZINC PLUS ARGININE SUPPLEMENTATION ON ANTIBODY TITRE AND LYMPHOCYTE SUBSETS AFTER INFLUENZA VACCINATION IN ELDERLY SUBJECTS: A RANDOMIZED CONTROLLED TRIAL, AGE AGEING, 27, 6, PP. 715-722, (1998); RAHFILUDIN MZ, GINANDJAR P., THE EFFECT OF ZINC AND VITAMIN C SUPPLEMENTATION ON HEMOGLOBIN AND HEMATOCRIT LEVELS AND IMMUNE RESPONSE IN PATIENTS WITH PLASMODIUM VIVAX MALARIA, SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH, 44, 5, (2013); RANJBAR E, SHAMS J, SABETKASAEI M, M-SHIRAZI M, RASHIDKHANI B, MOSTAFAVI A, BORNAK E, NASROLLAHZADEH J., EFFECTS OF ZINC SUPPLEMENTATION ON EFFICACY OF ANTIDEPRESSANT THERAPY, INFLAMMATORY CYTOKINES, AND BRAIN-DERIVED NEUROTROPHIC FACTOR IN PATIENTS WITH MAJOR DEPRESSION, NUTR NEUROSCI, 17, 2, PP. 65-71, (2014); RASHIDI AA, SALEHI M, PIROOZMAND A, SAGHEB MM., EFFECTS OF ZINC SUPPLEMENTATION ON SERUM ZINC AND C-REACTIVE PROTEIN CONCENTRATIONS IN HEMODIALYSIS PATIENTS, J REN NUTR, 19, 6, PP. 475-478, (2009); REINHOLD D, ANSORGE S, GRUNGREIFF K., ZINC REGULATES DNA SYNTHESIS AND IL-2, IL-6, AND IL-10 PRODUCTION OF PWM-STIMULATED PBMC AND NORMALIZES THE PERIPHERE CYTOKINE CONCENTRATION IN CHRONIC LIVER DISEASE, J TRACE ELEM EXP MED, 10, 1, PP. 19-27, (1997); RICCIONI G, GAMMONE MA, CURRENTI W, D'ORAZIO N., EFFECTIVENESS AND SAFETY OF DIETETIC SUPPLEMENTATION OF A NEW NUTRACEUTICAL ON LIPID PROFILE AND SERUM INFLAMMATION BIOMARKERS IN HYPERCHOLESTEROLEMIC PATIENTS, MOLECULES, 23, 5, (2018); ROSENKRANZ E, HILGERS R-D, UCIECHOWSKI P, PETERSEN A, PLU-MAKERS B, RINK L., ZINC ENHANCES THE NUMBER OF REGULATORY T CELLS IN ALLERGEN-STIMULATED CELLS FROM ATOPIC SUBJECTS, EUR J NUTR, 56, 2, PP. 557-567, (2017); SANGTHAWAN D, PHUNGRASSAMI T, SINKITJARURNCHAI W., EFFECTS OF ZINC SULFATE SUPPLEMENTATION ON CELL-MEDIATED IMMUNE RESPONSE IN HEAD AND NECK CANCER PATIENTS TREATED WITH RADIATION THERAPY, NUTR CANCER, 67, 3, PP. 449-456, (2015); SENA-EVANGELISTA KCM, PEDROSA LFC, PAIVA MSMO, DIAS PCS, FERREIRA DQC, COZZOLINO SMF, FAULIN TES, ABDALLA DSP., THE HYPOLIPIDEMIC AND PLEIOTROPIC EFFECTS OF ROSUVASTATIN ARE NOT ENHANCED BY ITS ASSOCIATION WITH ZINC AND SELENIUM SUPPLEMENTATION IN CORONARY ARTERY DISEASE PATIENTS: A DOUBLE BLIND RANDOMIZED CONTROLLED STUDY, PLOS ONE, 10, 3, (2015); SINGH A, FAILLA ML, DEUSTER PA., EXERCISE-INDUCED CHANGES IN IMMUNE FUNCTION: EFFECTS OF ZINC SUPPLEMENTATION, J APPL PHYSIOL, 76, 6, PP. 2298-2303, (1994); SKALNY AV, RINK L, AJSUVAKOVA OP, ASCHNER M, GRITSENKO VA, ALEKSEENKO SI, SVISTUNOV AA, PETRAKIS D, SPANDIDOS DA, AASETH J, TSATSAKIS A, TINKOV AA., ZINC AND RESPIRATORY TRACT INFECTIONS: PERSPECTIVES FOR COVID-19, INT J MOL MED, 46, 1, PP. 17-26, (2020); SOARES NRM, DE MOURA MSB, DE PINHO FA, SILVA TMC, DE LIMA BARROS SE, DE CASTRO AMORIM A, VIEIRA EC, NETO JMM, PARENTE JML, E CRUZ MD SP, MARREIRO DN, NOGUEIRA NDN., ZINC SUPPLEMENTATION REDUCES INFLAMMATION IN ULCERATIVE COLITIS PATIENTS BY DOWNREGULATING GENE EXPRESSION OF ZN METALLOPROTEINS, PHARMANUTRITION, 6, 3, PP. 119-124, (2018); SOMEYA Y, TANIHATA J, SATO S, KAWANO F, SHIRATO K, SUGIYAMA M, KAWASHIMA Y, NOMURA S, TACHIYASHIKI K, IMAIZUMI K., ZINC-DEFICIENCY INDUCED CHANGES IN THE DISTRIBUTION OF RAT WHITE BLOOD CELLS, J NUTR SCI VITAMINOL, 55, 2, PP. 162-169, (2009); SUGAWARA K, TAKAHASHI H, KASHIWAGURA T, YAMADA K, YANAGIDA S, HOMMA M, DAIRIKI K, SASAKI H, KAWAGOSHI A, SATAKE M, SHIOYA T., EFFECT OF ANTI-INFLAMMATORY SUPPLEMENTATION WITH WHEY PEPTIDE AND EXERCISE THERAPY IN PATIENTS WITH COPD, RESPIR MED, 106, 11, PP. 1526-1534, (2012); SULIBURSKA J, SKRYPNIK K, SZULINSKA M, KUPSZ J, BOGDANSKI P., EFFECT OF HYPOTENSIVE THERAPY COMBINED WITH MODIFIED DIET OR ZINC SUPPLEMENTATION ON BIOCHEMICAL PARAMETERS AND MINERAL STATUS IN HYPERTENSIVE PATIENTS, J TRACE ELEM MED BIOL, 47, PP. 140-148, (2018); SUZUKI H, TAKAGI H, SOHARA N, KANDA D, KAKIZAKI S, SATO K, MORI M., TRIPLE THERAPY OF INTERFERON AND RIBAVIRIN WITH ZINC SUPPLEMENTATION FOR PATIENTS WITH CHRONIC HEPATITIS C: A RANDOMIZED CONTROLLED CLINICAL TRIAL, WORLD J GASTROENTEROL, 12, 8, (2006); TAKAGI H, NAGAMINE T, ABE T, TAKAYAMA H, SATO K, OTSUKA T, KAKIZAKI S, HASHIMOTO Y, MATSUMOTO T, KOJIMA A, TAKEZAWA J, SUZUKI K, SATO S, MORI M., ZINC SUPPLEMENTATION ENHANCES THE RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C, J VIRAL HEPAT, 8, 5, PP. 367-371, (2001); TE VELTHUIS AJ, VAN DEN WORM SH, SIMS AC, BARIC RS, SNIJDER EJ, VAN HEMERT MJ., ZN2+ INHIBITS CORONAVIRUS AND ARTERIVIRUS RNA POLYMERASE ACTIVITY IN VITRO AND ZINC IONOPHORES BLOCK THE REPLICATION OF THESE VIRUSES IN CELL CULTURE, PLOS PATHOG, 6, 11, (2010); UNVER N, MCALLISTER F., IL-6 FAMILY CYTOKINES: KEY INFLAMMATORY MEDIATORS AS BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS, CYTOKINE GROWTH FACTOR REV, 41, PP. 10-17, (2018); VINODKUMAR M, ERHARDT JG, RAJAGOPALAN S., IMPACT OF A MULTIPLE-MICRONUTRIENT FORTIFIED SALT ON THE NUTRITIONAL STATUS AND MEMORY OF SCHOOLCHILDREN, INT JVITAMNUTRRES, 79, 56, PP. 348-361, (2009); WANG LS, LIN HY, CHANG CJ, FAHN HJ, HUANG MH, LIN CFJ., EFFECTS OF EN BLOC ESOPHAGECTOMY ON NUTRITIONAL AND IMMUNE STATUS IN PATIENTS WITH ESOPHAGEAL CARCINOMA, J SURG ONCOL, 67, 2, PP. 90-98, (1998); WEIDE M, ZHAOMING D, BAOLIANG L, HUIBI X., STUDY OF IMMUNE FUNCTION OF CANCER PATIENTS INFLUENCED BY SUPPLEMENTAL ZINC OR SELENIUM-ZINC COMBINATION, BIOL TRACE ELEM RES, 28, 1, PP. 11-19, (1991); WILLERSHAUSEN B, ROSS A, FORSCH M, WILLERSHAUSEN I, MOHAUPT P, CALLAWAY A., THE INFLUENCE OF MICRONUTRIENTS ON ORAL AND GENERAL HEALTH, EUR J MED RES, 16, 11, (2011)","N. YAZIHAN; FACULTY OF MEDICINE, PATHOPHYSIOLOGY DEPARTMENT, ANKARA UNIVERSITY, SIHHIYE, ANKARA, MORFOLOJI BUILDING, 06100, TURKEY; EMAIL: NURAYYAZIHAN@YAHOO.COM","MARY ANN LIEBERT INC.","ENGLISH","J. INTERFERON CYTOKINE RES.","ARTICLE","ISI","2-S2.0-85103127949","J INTERFERON CYTOKINE RES","INSTITUTE OF HEALTH SCIENCES;INSTITUTE OF HEALTH SCIENCES;ANKARA UNIVERSITY","NOTREPORTED;ANKARA UNIVERSITY;NOTREPORTED",NA,"CEYLAN MN, 2021, J INTERFERON CYTOKINE RES","CEYLAN MN, 2021, J INTERFERON CYTOKINE RES"
"SÁNCHEZ-HERNÁNDEZ E;MARTÍN-RAMOS P;NIÑO-SÁNCHEZ J;DIEZ-HERMANO S;ÁLVAREZ-TABOADA F;PÉREZ-GARCÍA R;SANTIAGO-ALISTE A;MARTÍN-GIL J;DIEZ-CASERO J","SÁNCHEZ-HERNÁNDEZ, EVA (57224442066); MARTÍN-RAMOS, PABLO (41862034200); NIÑO-SÁNCHEZ, JONATAN (56682023100); DIEZ-HERMANO, SERGIO (56602914100); ÁLVAREZ-TABOADA, FLOR (56005218700); PÉREZ-GARCÍA, RODRIGO (58220704900); SANTIAGO-ALISTE, ALBERTO (57457539500); MARTÍN-GIL, JESÚS (11040001200); DIEZ-CASERO, JULIO JAVIER (7201552675)","CHARACTERIZATION OF LEPTOGLOSSUS OCCIDENTALIS EGGS AND EGG GLUE",2023,"INSECTS","14","",0,"10.3390/insects14040396","DEPARTMENT OF AGRICULTURAL AND FORESTRY ENGINEERING, ETSIIAA, UNIVERSITY OF VALLADOLID, AVENIDA DE MADRID 44, PALENCIA, 34004, SPAIN;DEPARTMENT OF AGRICULTURAL AND FORESTRY ENGINEERING, ETSIIAA, UNIVERSITY OF VALLADOLID, AVENIDA DE MADRID 44, PALENCIA, 34004, SPAIN;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR), UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN, DEPARTAMENTO DE PRODUCCIÓN VEGETAL Y RECURSOS FORESTALES, ETSIIAA, UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR), UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN, DEPARTAMENTO DE PRODUCCIÓN VEGETAL Y RECURSOS FORESTALES, ETSIIAA, UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN;SCHOOL OF AGRARIAN AND FOREST ENGINEERING, DRACONES, UNIVERSIDAD DE LEÓN, AVENIDA DE PORTUGAL 41, PONFERRADA, 24401, SPAIN;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR), UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN, DEPARTAMENTO DE PRODUCCIÓN VEGETAL Y RECURSOS FORESTALES, ETSIIAA, UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN;DEPARTMENT OF AGRICULTURAL AND FORESTRY ENGINEERING, ETSIIAA, UNIVERSITY OF VALLADOLID, AVENIDA DE MADRID 44, PALENCIA, 34004, SPAIN;DEPARTMENT OF AGRICULTURAL AND FORESTRY ENGINEERING, ETSIIAA, UNIVERSITY OF VALLADOLID, AVENIDA DE MADRID 44, PALENCIA, 34004, SPAIN;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR), UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN, DEPARTAMENTO DE PRODUCCIÓN VEGETAL Y RECURSOS FORESTALES, ETSIIAA, UNIVERSIDAD DE VALLADOLID, AVENIDA DE MADRID 57, PALENCIA, 34071, SPAIN","THE WESTERN CONIFER SEED BUG (LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN, 1910, HETEROPTERA: COREIDAE) HAS A SIGNIFICANT ECONOMIC IMPACT DUE TO THE REDUCTION IN THE QUALITY AND VIABILITY OF CONIFER SEED CROPS; IT CAN FEED ON UP TO 40 DIFFERENT SPECIES OF CONIFERS, SHOWING A CLEAR PREDILECTION FOR PINUS PINEA L. IN EUROPE. ITS INCIDENCE IS ESPECIALLY RELEVANT FOR THE PINE NUT-PRODUCING INDUSTRY, GIVEN THAT THE ACTION OF THIS PEST INSECT CAN REDUCE THE PRODUCTION OF PINE NUTS BY UP TO 25%. AS PART OF ONGOING EFFORTS AIMED AT THE DESIGN OF CONTROL STRATEGIES FOR THIS INSECT, THIS WORK FOCUSES ON THE CHARACTERIZATION (BY SCANNING ELECTRON MICROSCOPY–ENERGY-DISPERSIVE X-RAY SPECTROSCOPY, FOURIER-TRANSFORM INFRARED SPECTROSCOPY, AND GAS CHROMATOGRAPHY–MASS SPECTROSCOPY, GC–MS) OF THE COMPOUNDS RELEASED BY THESE INSECTS DURING OVIPOSITION, WITH EMPHASIS ON THE ADHESIVE SECRETION THAT HOLDS L. OCCIDENTALIS EGGS TOGETHER. ELEMENTAL ANALYSIS POINTED TO THE PRESENCE OF SIGNIFICANT AMOUNTS OF COMPOUNDS WITH HIGH NITROGEN CONTENT. FUNCTIONAL GROUPS IDENTIFIED BY INFRARED SPECTROSCOPY WERE COMPATIBLE WITH THE PRESENCE OF CHITIN, SCLEROPROTEINS, LNSP-LIKE AND GELATIN PROTEINS, SHELLAC WAX ANALOGS, AND POLICOSANOL. REGARDING THE CHEMICAL SPECIES IDENTIFIED BY GC–MS, EGGS AND GLUE HYDROMETHANOLIC EXTRACTS SHARED CONSTITUENTS SUCH AS BUTYL CITRATE, DIBUTYL ITACONATE, TRIBUTYL ACONITATE, OLEIC ACID, OLEAMIDE, ERUCAMIDE, AND PALMITIC ACID, WHILE EGGS ALSO SHOWED STEARIC AND LINOLEIC ACID-RELATED COMPOUNDS. KNOWLEDGE OF THIS COMPOSITION MAY ALLOW ADVANCES IN NEW STRATEGIES TO ADDRESS THE PROBLEM CAUSED BY L. OCCIDENTALIS. © 2023 BY THE AUTHORS.","EDIBLE PINE; EGGS; FTIR; GC–MS; GLUE; OVIPOSITION; PINE NUTS; SEM-EDS; SEMIOCHEMICALS; WCSB; WESTERN CONIFER SEED BUG","","","","HILKER M., MEINERS T., CHEMOECOLOGY OF INSECT EGGS AND EGG DEPOSITION, (2003); SOLDI R.A., RODRIGUES M.A.C.M., ALDRICH J.R., ZARBIN P.H.G., THE MALE-PRODUCED SEX PHEROMONE OF THE TRUE BUG, PHTHIA PICTA, IS AN UNUSUAL HYDROCARBON, J. CHEM. ECOL, 38, PP. 814-824, (2012); MICHEREFF M.F.F., BORGES M., AQUINO M.F.S., LAUMANN R.A., MENDES GOMES A.C.M., BLASSIOLI-MORAES M.C., THE INFLUENCE OF VOLATILE SEMIOCHEMICALS FROM STINK BUG EGGS AND OVIPOSITION-DAMAGED PLANTS ON THE FORAGING BEHAVIOUR OF THE EGG PARASITOID TELENOMUS PODISI, BULL. ENTOMOL. RES, 106, PP. 663-671, (2016); LI D., HUSON M.G., GRAHAM L.D., PROTEINACEOUS ADHESIVE SECRETIONS FROM INSECTS, AND IN PARTICULAR THE EGG ATTACHMENT GLUE OF OPODIPHTHERA SP. MOTHS, ARCH. INSECT BIOCHEM. PHYSIOL, 69, PP. 85-105, (2008); LEI Y., GUO K., ZHANG Y., ZHANG X., QIN L., WANG X., ZHU H., GUO Y., YANG W., LI B., ET AL., ADHESIVE PROPERTY AND MECHANISM OF SILKWORM EGG GLUE PROTEIN, ACTA BIOMATER, 134, PP. 499-512, (2021); OLIVEIRA FARINHA A.C., IMPACT AND ECOLOGICAL ADAPTATION OF LEPTOGLOSSUS OCCIDENTALIS (HEMIPTERA, COREIDAE) ON PINUS PINEA, (2019); CONNELLY A.E., SCHOWALTER T.D., SEED LOSSES TO FEEDING BY LEPTOGLOSSUS OCCIDENTALIS (HETEROPTERA: COREIDAE) DURING TWO PERIODS OF SECOND-YEAR CONE DEVELOPMENT IN WESTERN WHITE PINE, J. ECON. ENTOMOL, 84, PP. 215-217, (1991); BATES S.L., BORDEN J.H., LIFE TABLE FOR LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN (HETEROPTERA: COREIDAE) AND PREDICTION OF DAMAGE IN LODGEPOLE PINE SEED ORCHARDS, AGRIC. FOR. ENTOMOL, 7, PP. 145-151, (2005); MUTKE S., LEPTOGLOSSUS, LA CHINCHE DEL PIÑÓN EN EL MUNDO Y CÓMO AFECTA AL PIÑÓN MEDITERRÁNEO, FORESTALIS, 32, PP. 26-29, (2019); PONCE HERRERO L., DOMINGUEZ ALONSO J.C., EL CHINCHE DE LAS PIÑAS LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN, REV. FOR, 79, PP. 90-99, (2020); BARTA M., BIOLOGY AND TEMPERATURE REQUIREMENTS OF THE INVASIVE SEED BUG LEPTOGLOSSUS OCCIDENTALIS (HETEROPTERA: COREIDAE) IN EUROPE, J. PEST SCI, 89, PP. 31-44, (2015); MAS H., NAYA M., PEREZ-LAORGA E., AGUADO A., MARCO M., ARAGONESES J., RODRIGO E., ESTUDIO DEL CICLO BIOLÓGICO DE LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN, 1910 (HEMIPTERA, COREIDAE) EN LA COMUNITAT VALENCIANA, PROCEEDINGS OF THE 6TH SPANISH FOREST CONGRESS, PP. 10-14; BERNARDINELLI I., ZANDIGIACOMO P., LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN (HETEROPTERA, COREIDAE): A CONIFER SEED BUG RECENTLY FOUND IN NORTHERN ITALY, J. FOR. SCI, 47, PP. 56-58, (2001); NAVES P., NOBREGA F., DE SOUSA E., AN ADULT LEPTOGLOSSUS OCCIDENTALIS (HETEROPTERA: COREIDAE) PARASITIZED IN PORTUGAL BY THE NATIVE TACHINID FLY ELOMYA LATERALIS (DIPTERA: TACHINIDAE), ANN. SOC. ENTOMOL. FR. (N.S.), 58, PP. 287-291, (2022); STRONG W., BC CONE AND SEED PEST RESEARCH PROGRAM, (2010); BLATT S., AN UNUSUALLY LARGE AGGREGATION OF THE WESTERN CONIFER SEED BUG, LEPTOGLOSSUS OCCIDENTALIS (HEMIPTERA: COREIDAE), IN A MAN-MADE STRUCTURE, J. ENTOMOL. SOC. B. C, 91, PP. 71-72, (1994); BLATT S.E., BORDEN J.H., EVIDENCE FOR A MALE-PRODUCED AGGREGATION PHEROMONE IN THE WESTERN CONIFER SEED BUG, LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN (HEMIPTERA: COREIDAE), CAN. ENTOMOL, 128, PP. 777-778, (1996); BLATT S.E., BORDEN J.H., PIERCE J.H.D., GRIES R., GRIES G., ALARM PHEROMONE SYSTEM OF THE WESTERN CONIFER SEED BUG, LEPTOGLOSSUS OCCIDENTALIS, J. CHEM. ECOL, 24, PP. 1013-1031, (1998); MILLAR J.G., ZOU Y., HALL D.R., HALLORAN S., PAJARES J.A., PONCE-HERRERO L., SHATES T., WILSON H., DAANE K.M., IDENTIFICATION AND SYNTHESIS OF LEPTOTRIENE, A UNIQUE SESQUITERPENE HYDROCARBON FROM MALES OF THE LEAF-FOOTED BUGS LEPTOGLOSSUS ZONATUS AND L. OCCIDENTALIS, J. NAT. PROD, 85, PP. 2062-2070, (2022); TAKACS S., BOTTOMLEY H., ANDRELLER I., ZARADNIK T., SCHWARZ J., BENNETT R., STRONG W., GRIES G., INFRARED RADIATION FROM HOT CONES ON COOL CONIFERS ATTRACTS SEED-FEEDING INSECTS, PROC. R. SOC. B BIOL. SCI, 276, PP. 649-655, (2008); FRANCO-ARCHUNDIA S., GONZAGA-SEGURA A., JIMENEZ-PEREZ A., CASTREJON-GOMEZ V., BEHAVIORAL RESPONSE OF LEPTOGLOSSUS ZONATUS (HETEROPTERA: COREIDAE) TO STIMULI BASED ON COLORS AND ITS AGGREGATION PHEROMONE, INSECTS, 9, (2018); WILSON H., MACCARO J., DAANE K., OPTIMIZING TRAP CHARACTERISTICS TO MONITOR THE LEAF-FOOTED BUG LEPTOGLOSSUS ZONATUS (HETEROPTERA: COREIDAE) IN ORCHARDS, INSECTS, 11, (2020); INOUE K., VIDAL D., SAAD E., MARTINS C., ZARBIN P., IDENTIFICATION OF THE ALARM AND SEX PHEROMONES OF THE LEAF-FOOTED BUG, LEPTOGLOSSUS ZONATUS (HETEROPTERA: COREIDAE), J. BRAZ. CHEM. SOC, 30, PP. 939-947, (2018); MITCHELL P.L., LEAF-FOOTED BUGS (COREIDAE), HETEROPTERA OF ECONOMIC IMPORTANCE, PP. 337-403, (2000); KIM J.H., LEE D.E., PARK S., CLARK J.M., LEE S.H., CHARACTERIZATION OF NIT SHEATH PROTEIN FUNCTIONS AND TRANSGLUTAMINASE-MEDIATED CROSS-LINKING IN THE HUMAN HEAD LOUSE, PEDICULUS HUMANUS CAPITIS, PARASITES VECTORS, 14, (2021); MA J., MA L., ZHANG H., ZHANG Z., WANG Y., LI K., CHEN X., POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY, PLOS ONE, 13, (2018); YAN G., CAO Z., DEVINE D., PENNING M., GATELY N.M., PHYSICAL PROPERTIES OF SHELLAC MATERIAL USED FOR HOT MELT EXTRUSION WITH POTENTIAL APPLICATION IN THE PHARMACEUTICAL INDUSTRY, POLYMERS, 13, (2021); ANDRONIE L., COROIAN A., MIRESAN V., POP I., RADUCU C., ROTARU A., OLAR L., RESULTS OBTAINED BY INVESTIGATING SAFFRON USSING FT-IR SPECTROSCOPY, BULL. UNIV. AGRIC. SCI. VET. MED. CLUJ-NAPOCA ANIM. SCI. BIOTECHNOL, 73, (2016); MARIOD A.A., FADUL H., EXTRACTION AND CHARACTERIZATION OF GELATIN FROM TWO EDIBLE SUDANESE INSECTS AND ITS APPLICATIONS IN ICE CREAM MAKING, FOOD SCI. TECHNOL. INT, 21, PP. 380-391, (2015); VENDITTI A., WHAT IS AND WHAT SHOULD NEVER BE: ARTIFACTS, IMPROBABLE PHYTOCHEMICALS, CONTAMINANTS AND NATURAL PRODUCTS, NAT. PROD. RES, 34, PP. 1014-1031, (2018); CHAOS A., SANGRONIZ A., GONZALEZ A., IRIARTE M., SARASUA J.-R., DEL RIO J., ETXEBERRIA A., TRIBUTYL CITRATE AS AN EFFECTIVE PLASTICIZER FOR BIODEGRADABLE POLYMERS: EFFECT OF PLASTICIZER ON FREE VOLUME AND TRANSPORT AND MECHANICAL PROPERTIES, POLYM. INT, 68, PP. 125-133, (2019); TSOCHATZIS E.D., ALBERTO LOPES J., HOEKSTRA E., EMONS H., DEVELOPMENT AND VALIDATION OF A MULTI-ANALYTE GC-MS METHOD FOR THE DETERMINATION OF 84 SUBSTANCES FROM PLASTIC FOOD CONTACT MATERIALS, ANAL. BIOANAL. CHEM, 412, PP. 5419-5434, (2020); YU Y., WANG S., YANG Z., WANG F., DENG L., A NOVEL ENVIRONMENT-FRIENDLY SYNTHETIC TECHNOLOGY OF DIBUTYL ITACONATE, J. CHEM. TECHNOL. BIOTECHNOL, 95, PP. 2879-2885, (2020); RENTHAL R., LOHMEYER K., BORGES L.M.F., PEREZ DE LEON A.A., SURFACE LIPIDOME OF THE LONE STAR TICK, AMBLYOMMA AMERICANUM, PROVIDES LEADS ON SEMIOCHEMICALS AND LIPID METABOLISM, TICKS TICK-BORNE DIS, 10, PP. 138-145, (2019); JIANG X.-C., WEN-XIA D., CHEN B., XIAO C., GUI F.-R., NAI-SHENG Y.A.N., QIAN L., LI Z.-Y., ELECTROPHYSIOLOGICAL AND OVIPOSITION RESPONSES OF ASIAN CORN BORER, OSTRINIA FURNACALIS (LEPIDOPTERA: CRAMBIDAE), TO COMPOUNDS RINSED FROM THE SURFACES OF SUGARCANE AND MAIZE LEAVES, EUR. J. ENTOMOL, 112, PP. 295-301, (2015); MCAFEE A., CHAPMAN A., IOVINELLA I., GALLAGHER-KURTZKE Y., COLLINS T.F., HIGO H., MADILAO L.L., PELOSI P., FOSTER L.J., A DEATH PHEROMONE, OLEIC ACID, TRIGGERS HYGIENIC BEHAVIOR IN HONEY BEES (APIS MELLIFERA L.), SCI. REP, 8, (2018); CHOW Y.S., TSAI R.S., PROTECTIVE CHEMICALS IN CATERPILLAR SURVIVAL, EXPERIENTIA, 45, PP. 390-392, (1989); HONDA K., OSMETERIAL SECRETIONS OF PAPILIONID LARVAE IN THE GENERA LUEHDORFIA, GRAPHIUM AND ATROPHANEURA (LEPIDOPTERA), INSECT BIOCHEM, 10, PP. 583-588, (1980); ALDRICH J.R., SCHAEFER P.W., OLIVER J.E., PUAPOOMCHAREON P., LEE C.-J., MEER R.K.V., BIOCHEMISTRY OF THE EXOCRINE SECRETION FROM GYPSY MOTH CATERPILLARS (LEPIDOPTERA: LYMANTRIIDAE), ANN. ENTOMOL. SOC. AM, 90, PP. 75-82, (1997); MURPHY M.P., O'NEILL L.A.J., KREBS CYCLE REIMAGINED: THE EMERGING ROLES OF SUCCINATE AND ITACONATE AS SIGNAL TRANSDUCERS, CELL, 174, PP. 780-784, (2018); LIU R., XU B., CHARACTERIZATION OF ESSENTIAL OIL IN PINE NUT SHELLS FROM COMMODITY WASTE IN CHINA BY STEAM DISTILLATION AND GC-MS, FOOD ANAL. METHODS, 5, PP. 435-440, (2011); KADRI N., KHETTAL B., AID Y., KHERFELLAH S., SOBHI W., BARRAGAN-MONTERO V., SOME PHYSICOCHEMICAL CHARACTERISTICS OF PINUS (PINUS HALEPENSIS MILL., PINUS PINEA L., PINUS PINASTER AND PINUS CANARIENSIS) SEEDS FROM NORTH ALGERIA, THEIR LIPID PROFILES AND VOLATILE CONTENTS, FOOD CHEM, 188, PP. 184-192, (2015); EL OMARI N., EZZAHRAE GUAOUGUAOU F., EL MENYIY N., BENALI T., AANNIZ T., CHAMKHI I., BALAHBIB A., TAHA D., SHARIATI M.A., ZENGIN G., ET AL., PHYTOCHEMICAL AND BIOLOGICAL ACTIVITIES OF PINUS HALEPENSIS MILL., AND THEIR ETHNOMEDICINAL USE, J. ETHNOPHARMACOL, 268, (2021); MOHAMED A.A., BEHIRY S.I., ALI H.M., EL-HEFNY M., SALEM M.Z.M., ASHMAWY N.A., PHYTOCHEMICAL COMPOUNDS OF BRANCHES FROM P. HALEPENSIS OILY LIQUID EXTRACT AND S. TEREBINTHIFOLIUS ESSENTIAL OIL AND THEIR POTENTIAL ANTIFUNGAL ACTIVITY, PROCESSES, 8, (2020); DHIBI M., MECHRI B., BRAHMI F., SKHIRI F., ALSAIF M.A., HAMMAMI M., FATTY ACID PROFILES, ANTIOXIDANT COMPOUNDS AND ANTIRADICAL PROPERTIES OF PINUS HALEPENSIS MILL. CONES AND SEEDS, J. SCI. FOOD AGRIC, 92, PP. 1702-1708, (2012); ANTTONEN S., HERRANEN J., PEURA P., KARENLAMPI L., FATTY ACIDS AND ULTRASTRUCTURE OF OZONE-EXPOSED ALEPPO PINE (PINUS HALEPENSIS MILL.) NEEDLES, ENVIRON. POLLUT, 87, PP. 235-242, (1995); CAMPBELL B.E., PEREIRA R.M., KOEHLER P.G., COMPLICATIONS WITH CONTROLLING INSECT EGGS, INSECTICIDES RESISTANCE, PP. 83-96, (2016); BRUNS F.H., WERNERS P.H., DEHYDROGENASES: GLUCOSE-6-PHOSPHATE DEHYDROGENASE, 6-PHOSPHOGLUCONATE DEHYDROGENASE, GLUTATHIONE REDUCTASE, METHEMOGLOBIN REDUCTASE, POLYOL DEHYDROGENASES, ADVANCES IN CLINICAL CHEMISTRY, 5, PP. 237-294, (1963)","E. SÁNCHEZ-HERNÁNDEZ; DEPARTMENT OF AGRICULTURAL AND FORESTRY ENGINEERING, ETSIIAA, UNIVERSITY OF VALLADOLID, PALENCIA, AVENIDA DE MADRID 44, 34004, SPAIN; EMAIL: EVA.SANCHEZ.HERNANDEZ@UVA.ES; P. MARTÍN-RAMOS; DEPARTMENT OF AGRICULTURAL AND FORESTRY ENGINEERING, ETSIIAA, UNIVERSITY OF VALLADOLID, PALENCIA, AVENIDA DE MADRID 44, 34004, SPAIN; EMAIL: PMR@UVA.ES","MDPI","ENGLISH","INSECTS","ARTICLE","ISI","2-S2.0-85156135144","INSECTS","UNIVERSITY OF VALLADOLID;UNIVERSITY OF VALLADOLID;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR);INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR);UNIVERSIDAD DE LEÓN;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR);UNIVERSITY OF VALLADOLID;UNIVERSITY OF VALLADOLID;INSTITUTO UNIVERSITARIO DE INVESTIGACIÓN EN GESTIÓN FORESTAL SOSTENIBLE (IUFOR)","NOTREPORTED;UNIVERSITY OF VALLADOLID;NOTREPORTED;NOTREPORTED;UNIVERSITY OF VALLADOLID;NOTREPORTED",NA,"SÁNCHEZ-HERNÁNDEZ E, 2023, INSECTS","SÁNCHEZ-HERNÁNDEZ E, 2023, INSECTS"
"PANDOLSOOK S;KUPONGSAK S","PANDOLSOOK, SAWANYA (57194774079); KUPONGSAK, SASIKAN (15060246200)","POTENTIAL USE OF POLICOSANOL EXTRACT FROM THAI BLEACHED RICE BRAN WAX AS AN ORGANOGELATOR",2020,"JOURNAL OF FOOD MEASUREMENT AND CHARACTERIZATION","14","8",5,"10.1007/s11694-020-00455-8","CULINARY INDUSTRY PROGRAM, SCHOOL OF CULINARY ARTS, SUAN DUSIT UNIVERSITY, 295 NAKHON RATCHASIMA ROAD, DUSIT, BANGKOK, 10300, THAILAND;DEPARTMENT OF FOOD TECHNOLOGY, FACULTY OF SCIENCE, CHULALONGKORN UNIVERSITY, 254 PHYATHAI ROAD, PATUMWAN, BANGKOK, 10330, THAILAND","RICE BRAN WAX IS AN IMPORTANT SOURCE OF POLICOSANOL (PC). PC EXTRACTED FROM THAI BLEACHED RICE BRAN WAX WAS USED. THE YIELD OF EXTRACTED PC WAS 31.21 WT%. POLICOSANOL ORGANOGELS (PCOS) WERE PREPARED BY MIXING RICE BRAN OIL WITH PC EXTRACTED AT THE CONCENTRATIONS OF 12, 13.5, AND 15 WT%. IT WAS DETERMINED THAT PCO PREPARED USING THE 15% CONCENTRATION OF PC EXHIBITED THE BEST PROPERTIES, SUCH AS THE OIL-BINDING CAPACITY, TEXTURE PARAMETERS, THERMAL BEHAVIOUR, AND SOLID FAT CONTENT (SFC). THE CHARACTERISTICS OF PCOS WERE ALTERED BY THE PC CONCENTRATION (P < 0.05). PCOS EXHIBITED DENDRITE-LIKE CRYSTALS, WHICH CHANGED TO SPHERULITE CRYSTALS WITH AN INCREASE IN THE STORAGE TIME. THE EMULSION PRODUCED FROM PCO AT THE 15% CONCENTRATION OF PC (PCE) SHOWED EMULSION STABILITY. THE RESULTS OF THIS STUDY SHOW THAT PC EXTRACTED FROM THAI BLEACHED RICE BRAN WAX ARE POTENTIAL ORGANOGELATORS FOR ORGANOGELS AND CAN BE USED IN W/O EMULSIONS PRODUCED WITHOUT THE ADDITION OF AN EMULSIFIER OR A STABILIZER. © 2020, SPRINGER SCIENCE+BUSINESS MEDIA, LLC, PART OF SPRINGER NATURE.","EMULSION; ORGANOGELS; POLICOSANOL; THAI BLEACHED RICE BRAN WAX","BLEACHING; CRYSTALS; EMULSIFICATION; TEXTURES; DENDRITE-LIKE CRYSTAL; EMULSION STABILITY; ORGANO-GELATOR; ORGANOGELATORS; SOLID FAT CONTENT; TEXTURE PARAMETERS; THERMAL BEHAVIOURS; W/O EMULSIONS; CLEANING","RATCHADAPHISEKSOMPHOT ENDOWMENT FUND; THAI EDIBLE OIL CO., LTD.; CHULALONGKORN UNIVERSITY, CU","THIS WORK WAS SUPPORTED BY THE 90 ANNIVERSARY OF CHULALONGKORN UNIVERSITY FUND (RATCHADAPHISEKSOMPHOT ENDOWMENT FUND), 2017, GRADUATE SCHOOL, CHULALONGKORN UNIVERSITY, AND THE RAW MATERIAL WAS SUPPORTED BY THAI EDIBLE OIL CO., LTD., THAILAND. TH ","DOAN C.D., VAN DE WALLE D., DEWETTINCK K., PATEL A.R., J. AM. OIL CHEM. SOC., 92, 6, PP. 801-811, (2015); ROGERS M.A., WRIGHT A.J., MARANGONI A.G., CERAMIDE ORGANOGELS, EDIBLE ORGANOGELS: STRUCTURE AND HEALTH IMPLICATIONS, PP. 221-234, (2011); PANDOLSOOK S., KUPONGSAK S., J. FOOD ENG., 214, PP. 182-192, (2017); GARG T., BILANDI A., KAPOOR B., KUMAR S., JOSHI R., INT. RES. J. PHARM., 2, 12, PP. 15-21, (2011); JANG A., BAE W., HWANG H.S., LEE H.G., LEE S., FOOD CHEM., 187, PP. 525-529, (2015); MERT B., DEMIRKESEN I., LWT-FOOD SCI. TECHNOL., 68, PP. 477-484, (2016); HWANG H.S., SINGH M., LEE S., J. FOOD SCI., 81, 5, PP. C1045-C1054, (2016); YILMAZ E., OGUTCU M., J. FOOD SCI., 79, PP. E1732-E1738, (2014); YILMAZ E., OGUTCU M., FOOD FUNCT., 6, PP. 1194-1204, (2015); PATEL A.R., RAJARETHINEM P.S., GREDOWSKA A., TURHAN O., LESAFFER A., DE VOS W.H., VAN DE WALLE D., DEWETTINCK K., FOOD FUNCT., 5, PP. 645-652, (2014); LUPI F.R., GABRIELE D., SETA L., BALDINO N., CINDIO B., EUR. J. LIPID SCI. TECHNOL., 116, PP. 1734-1744, (2014); BOTEGA D.C.Z., MARANGONI A.G., SMITH A.K., GOFF H.D., J. FOOD SCI., 78, PP. C1334-C1339, (2013); YILMAZ E., OGUTCU M., J. AM. OIL CHEM. SOC., 91, PP. 1007-1017, (2014); IRMAK S., DUNFORD N.T., MILLIGAN J., FOOD CHEM., 95, PP. 312-318, (2006); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., FOOD CHEM., 115, PP. 918-923, (2009); SCHAINK H.M., VAN MALSSEM K.F., MORGADO-ALVES S., KALNIN D., VAN DER LINDEN E., FOOD RES. INT., 40, PP. 1185-1193, (2007); CO E.D., MARANGONI A.G., J. AM. OIL CHEM. SOC., 89, PP. 749-780, (2012); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., FOOD RES. INT., 51, PP. 1512-1520, (2013); LUPI F.R., GABRIELE D., BALDINO N., MIJOVIC P., PARISIC O.I., PUOCIC F., FOOD FUNCT., 4, PP. 1512-1520, (2013); VALOPPI F., CALLIGARIS S., MARANGONI A.G., EUR. J. LIPID SCI. TECHNOL., (2017); TIAN Y., ACEVEDO N.C., FOOD CHEM., 255, PP. 252-259, (2018); DASSANAYAKE L.S.K., KODALI D.R., UENO S., SATO K., J. AM. OIL CHEM. SOC., 86, PP. 1163-1173, (2009); PATEL A.R., SCHATTEMA D., VOS W.H.D., LESAFFER A., DEWETTINCK K., J. COLLOID INTERFACE SCI., 411, PP. 114-121, (2013); HWANG H.S., SINGH M., BAKOTA E.L., MOSER J.K.W., KIM S., LIU S.X., J. AM. OIL CHEM. SOC., 90, PP. 1705-1712, (2013); MIRHOSSEINI H., TAN C., AGHLARA A., HAMID N., YUSOF S., CHERN B., CARBOHYDR. POLYM., 73, 1, PP. 83-91, (2008); TORO-VAZQUEZ J.F., CHARO-ALONSO M.A., PEREZ-MARTINEZ J.D., MORALES-RUEDA J.A., EDIBLE ORGANOGELS: STRUCTURE AND HEALTH IMPLICATIONS, PP. 119-148, (2011); PUENGTHAM J., ARYUSUK K., KITTIRATANAPIBOON K., JEYASHOKE N., KRISNANGKURA K., KMUTT R&D J., 31, 2, PP. 305-317, (2008); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., INT. J. NANOMEDICINE, 9, PP. 2261-2269, (2014); MADHAVI D.L., KAGAN D.I., (2013); KIM J.Y., LEE J.H., JEONG D.Y., JANGC D.K., SEO T.R., LIM S.T., J. CARB. POL., 121, PP. 140-146, (2015); GANDOLFO F.G., BOT A., FLӦTER E., J. AM. OIL CHEM. SOC., 81, PP. 1-6, (2004); DOAN C.D., TO C.M., DE VRIEZE M., LYNEN F., DANTHINE S., BROWN A., DEWETTINCK K., PATEL A.R., FOOD CHEM., 214, PP. 717-725, (2017); MCCLEMENTS D.J., ADV. COLLOID INTERFAC., 97, PP. 63-89, (2002); OGUTCU M., YILMAZ E., INT. J. FOOD PROP., 18, PP. 1741-1755, (2015)","S. KUPONGSAK; DEPARTMENT OF FOOD TECHNOLOGY, FACULTY OF SCIENCE, CHULALONGKORN UNIVERSITY, BANGKOK, 254 PHYATHAI ROAD, PATUMWAN, 10330, THAILAND; EMAIL: SASIKAN.K@CHULA.AC.TH","SPRINGER","ENGLISH","J. FOOD MEAS. CHARACT.","ARTICLE","ISI","2-S2.0-85083172852","J FOOD MEAS CHARACT","SUAN DUSIT UNIVERSITY;CHULALONGKORN UNIVERSITY","NOTREPORTED;CHULALONGKORN UNIVERSITY;NOTREPORTED",NA,"PANDOLSOOK S, 2020, J FOOD MEAS CHARACT","PANDOLSOOK S, 2020, J FOOD MEAS CHARACT"
"WONGWAIWECH D;WEERAWATANAKORN M;BOONNOUN P","WONGWAIWECH, DONPORN (57202775373); WEERAWATANAKORN, MONTHANA (55976489600); BOONNOUN, PANATPONG (35742804700)","SUBCRITICAL DIMETHYL ETHER EXTRACTION AS A SIMPLE METHOD TO EXTRACT NUTRACEUTICALS FROM BYPRODUCTS FROM RICE BRAN OIL MANUFACTURE",2020,"SCIENTIFIC REPORTS","10","",15,"10.1038/s41598-020-78011-z","DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF INDUSTRIAL ENGINEERING, CHEMICAL ENGINEERING PROGRAM, FACULTY OF ENGINEERING, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, MUEANG, PHITSANULOK, 65000, THAILAND","THE BYPRODUCTS OF RICE BRAN OIL PROCESSES ARE A GOOD SOURCE OF FAT-SOLUBLE NUTRACEUTICALS, INCLUDING Γ-ORYZANOL, PHYTOSTEROL, AND POLICOSANOLS. THIS STUDY AIMED TO INVESTIGATE THE EFFECTS OF GREEN TECHNOLOGY WITH LOW PRESSURE AS THE SUBCRITICAL FLUID EXTRACTION WITH DIMETHYL ETHER (SUBFDME) ON THE AMOUNT OF Γ-ORYZANOL, PHYTOSTEROL, AND POLICOSANOL EXTRACTED FROM THE BYPRODUCTS AND TO INCREASE THE PURITY OF POLICOSANOLS. THE SUBFDME EXTRACTION APPARATUS WAS OPERATED UNDER PRESSURES BELOW 1 MPA. COMPARED TO THE CHEMICAL EXTRACTION METHOD, SUBFDME GAVE THE HIGHEST CONTENT OF Γ-ORYZANOL AT 924.51 MG/100 G FROM DEFATTED RICE BRAN, FOLLOWED BY 829.88 MG/100 G FROM THE FILTER CAKE, WHILE THE HIGHEST PHYTOSTEROL CONTENT WAS 367.54 MG/100 G. TRANSESTERIFICATION GAVE THE HIGHEST EXTRACTION YIELD OF 43.71% WITH THE HIGHEST POLICOSANOL CONTENT (30,787 MG/100 G), AND THE SUBFDME METHOD INCREASED THE POLICOSANOL LEVEL FROM TRANSESTERIFIED RICE BRAN WAX TO 84,913.14 MG/100 G. THE RESULTS INDICATE THAT THE SUBFDME METHOD IS A PROMISING TOOL TO EXTRACT Γ-ORYZANOL AND PHYTOSTEROL AND A SIMPLE AND EFFECTIVE TECHNIQUE TO INCREASE THE PURITY OF POLICOSANOL. THE STUDY PRESENTED A NOVEL TECHNIQUE FOR THE POTENTIAL USE OF SUBSFDME AS AN ALTERNATIVE LOW-PRESSURE AND LOW-TEMPERATURE TECHNIQUE TO EXTRACT Γ-ORYZANOL AND PHYTOSTEROL. THE COMBINATION OF TRANSESTERIFICATION AND THE SUBFDME TECHNIQUE IS A POTENTIAL SIMPLE TWO-STEP METHOD TO EXTRACT AND PURIFY POLICOSANOL, WHICH IS BENEFICIAL FOR THE MANUFACTURE OF DIETARY SUPPLEMENTS, FUNCTIONAL FOODS AND PHARMACEUTICAL PRODUCTS. © 2020, THE AUTHOR(S).","","","NATIONAL RESEARCH COUNCIL OF THAILAND, NRCT, (R2562B033); THAILAND SCIENCE RESEARCH AND INNOVATION, TSRI, (FRB630011/0179)","FINANCIAL SUPPORT FOR THIS STUDY WAS PROVIDED BY A RESEARCH GRANT FROM THE NATIONAL RESEARCH COUNCIL OF THAILAND (NO. R2562B033) AND THAILAND SCIENCE RESEARCH AND INNOVATION (FRB630011/0179).","WONGWAIWECH D., WEERAWATANAKORN M., THARATHA S., HO C.T., COMPARATIVE STUDY ON AMOUNT OF NUTRACEUTICALS IN BY-PRODUCTS FROM SOLVENT AND COLD PRESSING METHODS OF RICE BRAN OIL PROCESSING, J. FOOD DRUG ANAL., 27, PP. 71-82, (2019); NIJJAR P.S., BURKE F.M., BLOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, J. CLIN. LIPIDOL., 4, PP. 248-258, (2010); PATEL M., NAIK S.N., GAMMA-ORYZANOL FROM RICE BRAN OIL—A REVIEW, J. SCI. IND. RES. (INDIA), 63, PP. 569-578, (2004); UDDIN M.S., ET AL., TECHNIQUES FOR THE EXTRACTION OF PHYTOSTEROLS AND THEIR BENEFITS IN HUMAN HEALTH: A REVIEW, SEP. SCI. TECHNOL., 53, PP. 2206-2223, (2018); WEERAWATANAKORN M., MEEROD K., WONGWAIWECH D., HO C., POLICOSANOLS: CHEMISTRY, OCCURRENCE, AND HEALTH EFFECTS, CURR. PHARMACOL. REP., 5, PP. 131-149, (2019); AFFUSO F., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J. CARDIOL., 4, (2012); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM., 115, PP. 918-923, (2009); OHTA Y., ET AL., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, J. CLIN. BIOCHEM. NUTR., 42, PP. 118-125, (2008); RAVELO Y., ET AL., EVALUATION OF ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECTS OF D-002 (BEESWAX ALCOHOLS), J. NAT. MED., 65, PP. 330-335, (2011); NYAM K.L., TAN C.P., LAI O.M., LONG K., MAN Y.B.C., OPTIMIZATION OF SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF PHYTOSTEROL-ENRICHED OIL FROM KALAHARI MELON SEEDS, FOOD BIOPROCESS TECHNOL., 4, PP. 1432-1441, (2011); NYAM K.L., TAN C.P., LAI O.M., LONG K., CHE MAN Y.B., OPTIMIZATION OF SUPERCRITICAL FLUID EXTRACTION OF PHYTOSTEROL FROM ROSELLE SEEDS WITH A CENTRAL COMPOSITE DESIGN MODEL, FOOD BIOPROD. PROCESS., 88, PP. 239-246, (2010); HUNG C.C., WENG Y.M., YU Z.R., WANG B.J., OPTIMAL SELECTIVITY OF Γ-ORYZANOL AND TOTAL PHENOLIC COMPOUNDS FROM RICE BRAN USING SUPERCRITICAL CARBON DIOXIDE FRACTIONATION TECHNIQUE, INT. FOOD RES. J., 26, PP. 639-647, (2019); SAJFRTOVA M., LICKOVA I., WIMMEROVA M., SOVOVA H., WIMMER Z., Β-SITOSTEROL: SUPERCRITICAL CARBON DIOXIDE EXTRACTION FROM SEA BUCKTHORN (HIPPOPHAE RHAMNOIDES L.) SEEDS, INT. J. MOL. SCI., 11, PP. 1842-1850, (2010); SNYDER J.M., KING J.W., TAYLOR S.L., NEESE A.L., CONCENTRATION OF PHYTOSTEROLS FOR ANALYSIS BY SUPERCRITICAL FLUID EXTRACTION, J. AM. OIL CHEM. SOC., 76, PP. 717-721, (1999); EKINCI M.S., GURU M., EXTRACTION OF PHYTOSTEROLS FROM MELON (CUCUMIS MELO) SEEDS BY SUPERCRITICAL CO<SUB>2</SUB> AS A CLEAN TECHNOLOGY, GREEN PROCESS. SYNTH., 8, PP. 677-682, (2019); KANDA H., KAMO Y., MACHMUDAH S., WAHYUDIONO, GOTO M., EXTRACTION OF FUCOXANTHIN FROM RAW MACROALGAE EXCLUDING DRYING AND CELL WALL DISRUPTION BY LIQUEFIED DIMETHYL ETHER, MAR. DRUGS, 12, PP. 2383-2396, (2014); MA Y.-X., ET AL., SUBCRITICAL FLUID EXTRACTION OF CHINESE QUINCE SEED: OPTIMIZATION AND PRODUCT CHARACTERIZATION, MOLECULES, 22, (2017); LU J., FENG X., HAN Y., XUE C., OPTIMIZATION OF SUBCRITICAL FLUID EXTRACTION OF CAROTENOIDS AND CHLOROPHYLL A FROM LAMINARIA JAPONICA ARESCH BY RESPONSE SURFACE METHODOLOGY, J. SCI. FOOD AGRIC., 94, PP. 139-145, (2014); HOSHINO R., WAHYUDIONO, MACHMUDAH S., KANDA H., GOTO M., SIMULTANEOUS EXTRACTION OF WATER AND ESSENTIAL OILS FROM CITRUS LEAVES AND PEELS USING LIQUEFIED DIMETHYL ETHER, J. NUTR. FOOD SCI., 4, PP. 1-5, (2014); SCIENTIFIC OPINION OF THE PANEL ON FOOD CONTACT MATERIALS, ENZYMES, FLAVOURINGS AND PROCESSING AIDS (CEF) ON DIMETHYL ETHER AS AN EXTRACTION SOLVENT, EUR. FOOD SAF. AUTH. J., 984, PP. 1-13, (2009); FURUKAWA H., ET AL., USE OF LIQUEFIED DIMETHYL ETHER FOR THE EXTRACTION OF PROTEINS FROM VEGETABLE TISSUES, SOLVENT EXTR. RES. DEV., 23, PP. 127-135, (2016); ARYUSUK K., WAX: CO-PRODUCT OF RICE BRAN OIL REFINING; SEO I., SHIN H.S., DETERMINATION OF TOLUENE AND OTHER RESIDUAL SOLVENTS IN VARIOUS FOOD PACKAGING MATERIALS BY GAS CHROMATOGRAPHY/MASS SPECTROMETRY (GC/MS), FOOD SCI. BIOTECHNOL., 19, PP. 1429-1434, (2010); GUL K., YOUSUF B., SINGH A.K., SINGH P., WANI A.A., RICE BRAN: NUTRITIONAL VALUES AND ITS EMERGING POTENTIAL FOR DEVELOPMENT OF FUNCTIONAL FOOD—A REVIEW, BIOACT. CARBOHYDR. DIET. FIBRE, 6, PP. 24-30, (2015); RENUKA DEVI R., ARUMUGHAN C., PHYTOCHEMICAL CHARACTERIZATION OF DEFATTED RICE BRAN AND OPTIMIZATION OF A PROCESS FOR THEIR EXTRACTION AND ENRICHMENT, BIORESOUR. TECHNOL., 98, PP. 3037-3043, (2007); DERAKHSHAN-HONARPARVAR M., HAMEDI M.M., PIROUZIFARD M.K., RICE BRAN PHYTOSTEROLS OF THREE WIDESPREAD IRANIAN CULTIVARS, J. AGRIC. SCI. TECHNOL., 12, PP. 167-172, (2010); SAWADIKIAT P., HONGSPRABHAS P., PHYTOSTEROLS AND Γ-ORYZANOL IN RICE BRAN OILS AND DISTILLATES FROM PHYSICAL REFINING PROCESS, INT. J. FOOD SCI. TECHNOL., 49, PP. 2030-2036, (2014); MINGYAI S., KETTAWAN A., SRIKAEO K., SINGANUSONG R., PHYSICOCHEMICAL AND ANTIOXIDANT PROPERTIES OF RICE BRAN OILS PRODUCED FROM COLORED RICE USING DIFFERENT EXTRACTION METHODS, J. OLEO SCI., 572, PP. 565-572, (2017); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT. J. NANOMEDICINE, 9, PP. 2261-2269, (2014); PUENGTHAM J., ARYUSUK K., KITTIRATANAPIBOON K., JEYASHOKE N., KRISNANGKURA K., EXTRACTION PURIFICATION AND CHARACTERIZATION OF POLICOSANOL FROM THAI RICE BRAN WAX, KMUTT RES. DEV. J., 31, PP. 305-318, (2008); SHEN J., LUO F., LIN Q., POLICOSANOL: EXTRACTION AND BIOLOGICAL FUNCTIONS, J. FUNCT. FOODS, 57, PP. 351-360, (2019); WANG M.F., ET AL., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM., 55, PP. 5552-5558, (2007); NING-NING S., HAI-RONG G., GAN-LIN C., GUO-LIANG Y., EXTRACTION OF HIGHER ALIPHATIC ALKANOLS FROM SUGARCANE WAX USING TRANSESTERIFICATION, FOOD RES. DEV., 28, PP. 28-30, (2008); GOTO M., KANDA H., WAHYUDIONO, MACHMUDAH S., EXTRACTION OF CAROTENOIDS AND LIPIDS FROM ALGAE BY SUPERCRITICAL CO<SUB>2</SUB> AND SUBCRITICAL DIMETHYL ETHER, J. SUPERCRIT. FLUIDS, 96, PP. 245-251, (2015); POOJARY M.M., ET AL., INNOVATIVE ALTERNATIVE TECHNOLOGIES TO EXTRACT CAROTENOIDS FROM MICROALGAE AND SEAWEEDS, MAR. DRUGS, 14, PP. 1-34, (2016); MANDAL S.C., MANDAL V., DAS A.K., CLASSIFICATION OF EXTRACTION METHODS, ESSENTIALS OF BOTANICAL EXTRACTION, PP. 83-136, (2015); LIU Y., YU J., WANG X., EXTRACTION OF POLICOSANOLS FROM HYDROLYSED RICE BRAN WAX BY HIGH-INTENSITY ULTRASOUND, INT. J. FOOD SCI. TECHNOL., 43, PP. 763-769, (2008); CHOTIMARKORN C., BENJAKUL S., SILALAI N., ANTIOXIDANT COMPONENTS AND PROPERTIES OF FIVE LONG-GRAINED RICE BRAN EXTRACTS FROM COMMERCIAL AVAILABLE CULTIVARS IN THAILAND, FOOD CHEM., 111, PP. 636-641, (2008); LILITCHAN S., ET AL., PARTIAL EXTRACTION METHOD FOR THE RAPID ANALYSIS OF TOTAL LIPIDS AND Γ-ORYZANOL CONTENTS IN RICE BRAN, FOOD CHEM., 106, PP. 752-759, (2008); LAI P., LI K.Y., LU S., CHEN H.H., PHYTOCHEMICALS AND ANTIOXIDANT PROPERTIES OF SOLVENT EXTRACTS FROM JAPONICA RICE BRAN, FOOD CHEM., 117, PP. 538-544, (2009); BHATNAGAR A.S., PRABHAKAR D.S., PRASANTH KUMAR P.K., RAJA RAJAN R.G., GOPALA KRISHNA A.G., PROCESSING OF COMMERCIAL RICE BRAN FOR THE PRODUCTION OF FAT AND NUTRACEUTICAL RICH RICE BROKENS, RICE GERM AND PURE BRAN, LWT FOOD SCI. TECHNOL., 58, PP. 306-311, (2014); CHEN F., ET AL., PURIFICATION PROCESS OF OCTACOSANOL EXTRACTS FROM RICE BRAN WAX BY MOLECULAR DISTILLATION, J. FOOD ENG., 79, PP. 63-68, (2007); LORENZ P., ET AL., NATURAL WAX CONSTITUENTS OF A SUPERCRITICAL FLUID CO<SUB>2</SUB> EXTRACT FROM QUINCE (CYDONIA OBLONGA MILL) POMACE, ANAL. BIOANAL. CHEM., 391, PP. 633-646, (2008); INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH), ICH Q3C MAINTENANCE PROCEDURES FOR THE GUIDANCE FOR INDUSTRY Q3C IMPURITIES: RESIDUAL SOLVENTS, (2017); PATNAIK P., A COMPREHENSIVE GUIDE TO THE HAZARDOUS PROPERTIES OF CHEMICAL SUBSTANCES, (2006); EVALUATION REPORT OF FOOD ADDITIVES ACETALDEHYDE. FOOD SAFETY COMMISSION OF JAPAN, (2005)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, PHITSANULOK, 99 MOO 9, THA PHO, MUEANG, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","NATURE RESEARCH","ENGLISH","SCI. REP.","ARTICLE","ISI","2-S2.0-85097045016","SCI REP","NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;NARESUAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"WONGWAIWECH D, 2020, SCI REP","WONGWAIWECH D, 2020, SCI REP"
"IACOBINI C;FASSINO V;MAZZAFERRO S;TARTAGLIONE L","IACOBINI, CARLA (6603485891); FASSINO, VALERIA (6505838771); MAZZAFERRO, SANDRO (7003416740); TARTAGLIONE, LIDA (36673965500)","IN VITRO EVALUATION OF THE CALCIFICATION INHIBITORY PROPERTIES OF POLICOSANOL GENISTEIN AND VITAMIN D REDUPLAXIN EITHER ALONE OR IN COMBINATION",2024,"KIDNEY AND BLOOD PRESSURE RESEARCH","49","6",0,"10.1159/000535810","DEPARTMENT OF CLINICAL AND MOLECULAR MEDICINE, SAPIENZA UNIVERSITY, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, SAPIENZA UNIVERSITY, ROME, ITALY;DEPARTMENT OF TRANSLATION AND PRECISION MEDICINE, SAPIENZA UNIVERSITY, ROME, ITALY, DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALITIES, POLICLINICO UMBERTO, ROME, ITALY;DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALITIES, POLICLINICO UMBERTO, ROME, ITALY","INTRODUCTION: THE PROCESS OF VASCULAR CALCIFICATION HAS SEVERE CLINICAL CONSEQUENCES IN A NUMBER OF DISEASES, INCLUDING DIABETES, ATHEROSCLEROSIS, AND END-STAGE RENAL DISEASE. IN THE PRESENT STUDY, WE INVESTIGATED THE EFFECT OF POLICOSANOL (POLI), GENISTEIN (GEN), AND VITAMIN D (VITD) SEPARATELY AND IN ASSOCIATION TO EVALUATE THE POSSIBLE SYNERGISTIC ACTION ON INORGANIC PHOSPHATE (PI)-INDUCED CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS (VSMCS). METHODS: PRIMARY HUMAN VSMCS WERE CULTURED WITH EITHER GROWTH MEDIUM OR GROWTH MEDIUM SUPPLEMENTED WITH CALCIUM AND PHOSPHORUS (CALCIFICATION MEDIUM) IN COMBINATION WITH POLI, GEN, AND VITD. ALIZARIN RED STAINING, MINERALIZATION, AND THE PROTEIN EXPRESSION OF RUNX2 AND SUPEROXIDE DISMUTASE-2 (SOD2) WERE INVESTIGATED. RESULTS: ALL THREE SUBSTANCES TESTED WERE EFFECTIVE AT REDUCING OSTEOGENIC DIFFERENTIATION OF VSMCS IN A DOSE-DEPENDENT MANNER. POLI+GEN, POLI+VITD, GEN+VITD TREATMENT INDUCED A GREATER INHIBITION OF CALCIFICATION AND RUNX2 EXPRESSION COMPARED TO SINGLE COMPOUNDS TREATMENTS. MOREOVER, THE ASSOCIATION OF POLI+GEN+VITD (REDUPLAXIN ) WAS MORE EFFECTIVE AT INHIBITING VSMCS MINERALIZATION AND PREVENTING THE INCREASE IN RUNX2 EXPRESSION INDUCED BY CALCIFICATION MEDIUM BUT NOT MODIFIED SOD2 EXPRESSION. CONCLUSIONS: THE ASSOCIATION OF POL, GEN, AND VITD (REDUPLAXIN ) HAS AN ADDITIVE INHIBITORY EFFECT ON THE CALCIFICATION PROCESS OF VSMCS INDUCED IN VITRO BY A PROCALCIFYING MEDIUM.  © 2024 THE AUTHOR(S). PUBLISHED BY S. KARGER AG, BASEL.","GENISTEIN; POLICOSANOL; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE CELLS TRANS-DIFFERENTIATION; VITAMIN D","CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FATTY ALCOHOLS; GENISTEIN; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SUPEROXIDE DISMUTASE; VASCULAR CALCIFICATION; VITAMIN D; CALCIUM; GENISTEIN; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHATE; PHOSPHORUS; POLICOSANOL; TRANSCRIPTION FACTOR RUNX2; VITAMIN D; FATTY ALCOHOL; GENISTEIN; MANGANESE SUPEROXIDE DISMUTASE; POLICOSANOL; RUNX2 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RUNX2; VITAMIN D; AORTIC SMOOTH MUSCLE CELL; ARTICLE; BLOOD VESSEL CALCIFICATION; CELL CULTURE; CELL DIFFERENTIATION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MINERALIZATION; MONOTHERAPY; PROTEIN EXPRESSION; BLOOD VESSEL CALCIFICATION; CYTOLOGY; METABOLISM; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE","","","STEITZ S.A., SPEER M.Y., CURINGA G., YANG H.Y., HAYNES P., AEBERSOLD R., ET AL., SMOOTH MUSCLE CELL PHENOTYPIC TRANSITION ASSOCIATED WITH CALCIFICATION: UPREGULATION OF CBFA1 AND DOWNREGULATION OF SMOOTH MUSCLE LINEAGE MARKERS, CIRC RES., 89, 12, PP. 1147-1154, (2001); DEMER L.L., TINTUT Y., VASCULAR CALCIFICATION: PATHOBIOLOGY OF A MULTIFACETED DISEASE, CIRCULATION., 117, 22, PP. 2938-2948, (2008); KARWOWSKI W., NAUMNIK B., SZCZEPASKI M., MYLIWIEC M., THE MECHANISM OF VASCULAR CALCIFICATION-A SYSTEMATIC REVIEW, MED SCI MONIT., 18, 1, PP. RA1-RA11, (2012); GIACHELLI C.M., THE EMERGING ROLE OF PHOSPHATE IN VASCULAR CALCIFICATION, KIDNEY INT., 75, 9, PP. 890-897, (2009); SHEEN C.R., KUSS P., NARISAWA S., YADAV M.C., NIGRO J., WANG W., ET AL., PATHOPHYSIOLOGICAL ROLE OF VASCULAR SMOOTH MUSCLE ALKALINE PHOSPHATASE IN MEDIAL ARTERY CALCIFICATION, J BONE MINER RES., 30, 5, PP. 824-836, (2015); ABEDIN M., TINTUT Y., DEMER L.L., VASCULAR CALCIFICATION: MECHANISMS AND CLINICAL RAMIFICATIONS, ARTERIOSCLER THROMB VASC BIOL., 24, 7, PP. 1161-1170, (2004); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY., 25, 2, PP. 171-183, (2005); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION., 19, 2, PP. 192-195, (2003); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES., 27, 3-4, PP. 205-208, (1994); CHO K.H., BAE M.A., KIM J.R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC THER., 2019, (2019); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGHDENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES., 19, 2, PP. 149-158, (2016); RIETJENS I.M.C.M., LOUISSE J., BEEKMANN K., THE POTENTIAL HEALTH EFFECTS OF DIETARY PHYTOESTROGENS, BR J PHARMACOL., 174, 11, PP. 1263-1280, (2017); WANG J., ZHOU J.J., ROBERTSON G.R., LEE V.W., VITAMIN D IN VASCULAR CALCIFICATION: A DOUBLEEDGED SWORD?, NUTRIENTS., 10, 5, (2018); COVIC A., VERVLOET M., MASSY Z.A., TORRES P.U., GOLDSMITH D., BRANDENBURG V., ET AL., BONE AND MINERAL DISORDERS IN CHRONIC KIDNEY DISEASE: IMPLICATIONS FOR CARDIOVASCULAR HEALTH AND AGEING IN THE GENERAL POPULATION, LANCET DIABETES ENDOCRINOL., 6, 4, PP. 319-331, (2018); MAZZAFERRO S., DE MARTINI N., CANNATA-ANDIA J., COZZOLINO M., MESSA P., ROTONDI S., ET AL., FOCUS ON THE POSSIBLE ROLE OF DIETARY SODIUM, POTASSIUM, PHOSPHATE, MAGNESIUM, AND CALCIUM ON CKD PROGRESSION, J CLIN MED., 10, 5, (2021); KIM K.M., KIM C.H., CHO K.H., JANG W.G., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN EXP PHARMACOL PHYSIOL., 48, 10, PP. 1336-1345, (2021); SHEN C., YUAN Y., LI F., HU Y., SONG Y., ZHAO S., ET AL., MECHANISM OF GENISTEIN REGULATING THE DIFFERENTIATION OF VASCULAR SMOOTH MUSCLE CELLS INTO OSTEOBLASTS VIA THE OPG/RANKL PATHWAY ONCOTARGET, ONCOTARGET., 8, 44, PP. 76857-76864, (2017); KIM J.H., LIM D.K., SUH Y.H., CHANG K.A., LONGTERM TREATMENT OF CUBAN POLICOSANOL ATTENUATES ABNORMAL OXIDATIVE STRESS AND INFLAMMATORY RESPONSE VIA AMYLOID PLAQUES REDUCTION IN 5XFAD MICE, ANTIOXIDANTS., 10, 8, (2021); ZIELONKA J., GEBICKI J., GRYNKIEWICZ G., RADICAL SCAVENGING PROPERTIES OF GENISTEIN, FREE RADIC BIOL MED., 35, 8, PP. 958-965, (2003)","L. TARTAGLIONE; DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALITIES, POLICLINICO UMBERTO, ROME, ITALY; EMAIL: L.TARTAGLIONE@POLICLINICOUMBERTO1.IT","S. KARGER AG","ENGLISH","KIDNEY BLOOD PRESS. RES.","ARTICLE","ISI","2-S2.0-85191616665","KIDNEY BLOOD PRESS RES","SAPIENZA UNIVERSITY;SAPIENZA UNIVERSITY;SAPIENZA UNIVERSITY;POLICLINICO UMBERTO","NOTREPORTED;POLICLINICO UMBERTO;NOTDECLARED",NA,"IACOBINI C, 2024, KIDNEY BLOOD PRESS RES","IACOBINI C, 2024, KIDNEY BLOOD PRESS RES"
"CICERO A;D'ADDATO S;BORGHI C","CICERO, ARRIGO F. G. (7003403707); D’ADDATO, SERGIO (55234172300); BORGHI, CLAUDIO (7102731762)","A RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED CLINICAL STUDY OF THE EFFECTS OF A NUTRACEUTICAL COMBINATION LEVELIP DUO ON LDL CHOLESTEROL LEVELS AND LIPID PATTERN IN SUBJECTS WITH SUBOPTIMAL BLOOD CHOLESTEROL LEVELS NATCOL STUDY",2020,"NUTRIENTS","12","9",12,"10.3390/nu12103127","MEDICAL AN SURGERY SCIENCES DEPARTMENT, DYSLIPIDEMIA AND ATHEROSCLEROSIS RESEARCH UNIT, ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, ITALY;MEDICAL AN SURGERY SCIENCES DEPARTMENT, DYSLIPIDEMIA AND ATHEROSCLEROSIS RESEARCH UNIT, ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, ITALY;MEDICAL AN SURGERY SCIENCES DEPARTMENT, DYSLIPIDEMIA AND ATHEROSCLEROSIS RESEARCH UNIT, ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, ITALY","PHYTOSTEROLS AND RED YEAST RICE ARE LARGELY STUDIED CHOLESTEROL-LOWERING NUTRACEUTICALS, RESPECTIVELY INHIBITING THE BOWEL ABSORPTION AND LIVER SYNTHESIS OF CHOLESTEROL. OUR AIM WAS TO TEST THE EFFECT OF COMBINED NUTRACEUTICAL-CONTAINING PHYTOSTEROLS AND RED YEAST RICE VS. A PLACEBO ON THE LIPID PROFILE. WE PERFORMED A PARALLEL ARMS, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, RANDOMIZING 88 MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS TO TREATMENT WITH A COMBINED NUTRACEUTICAL CONTAINING PHYTOSTEROLS (800 MG) AND RED YEAST RICE, STANDARDIZED TO CONTAIN 5 MG OF MONACOLINS FROM MONASCUS PURPUREUS, WITH ADDED NIACIN (27 MG) AND POLICOSANOLS (10 MG) (LEVELIP DUO® ), OR PLACEBO. THE MEAN LDL-CHOLESTEROL (LDL-C) CHANGE AT WEEK 8 WAS −32.5 ± 30.2 MG/DL (−19.8%) IN THE COMBINED NUTRACEUTICAL GROUP AND 2.5 ± 19.4 MG/DL (2.3%) IN THE PLACEBO GROUP. THE ESTIMATED BETWEEN-GROUP DIFFERENCE OF −39.2 MG/DL (95% CI: −48.6; −29.8) INDICATES A STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN TREATMENTS IN FAVOR OF THE COMBINED NUTRACEUTICAL (P < 0.0001). TOTAL CHOLESTEROL (TC), NON-HDL CHOLESTEROL (NON-HDL-C), APOLIPOPROTEIN B, TC/HDL-C AND LDL-C/HDL-C IMPROVED IN A SIMILAR WAY IN THE COMBINED NUTRACEUTICAL GROUP ONLY. NO SIGNIFICANT CHANGES IN OTHER CLINICAL AND LABORATORY PARAMETERS WERE OBSERVED. IN CONCLUSION, THE TESTED COMBINED NUTRACEUTICAL WAS WELL TOLERATED, WHILE SIGNIFICANTLY REDUCING THE PLASMA LEVELS OF LDL-C, TC, NON-HDL-C, APOB, TC/HDL-C AND LDL-C/HDL-C RATIOS IN MILDLY HYPERCHOLESTEROLEMIC PATIENTS. TRIAL REGISTRATION (CLINICALTRIALS.GOV): NCT03739242. © 2020 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","CLINICAL TRIAL; ENDOTHELIAL FUNCTION; LDL-CHOLESTEROL; MONACOLINS; NUTRACEUTICALS; PHYTOSTEROLS; RED YEAST RICE","ADULT; AGED; BIOLOGICAL PRODUCTS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; PHYTOSTEROLS; TREATMENT OUTCOME; APOLIPOPROTEIN B; CHOLESTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVELIP DUO; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NUTRACEUTICAL; PHYTOSTEROL; PLACEBO; POLICOSANOL; BIOLOGICAL PRODUCT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID FINGERPRINTING; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; MONASCUS PURPUREUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; BLOOD; DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MIDDLE AGED; TREATMENT OUTCOME","MENARINI IFR","FUNDING: THIS RESEARCH WAS FUNDED BY MENARINI IFR, FIRENZE, ITALY.","BITTNER V.A., THE NEW 2019 ACC/AHA GUIDELINE ON THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, CIRCULATION, (2019); MICHOS E.D., MCEVOY J.W., BLUMENTHAL R.S., LIPID MANAGEMENT FOR THE PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, N. ENGL. J. MED, 381, PP. 1557-1567, (2019); FERRARO R.A., FISCHER N.M., XUN H., MICHOS E.D., NUTRITION AND PHYSICAL ACTIVITY RECOMMENDATIONS FROM THE UNITED STATES AND EUROPEAN CARDIOVASCULAR GUIDELINES: A COMPARATIVE REVIEW, CURR. OPIN. CARDIOL, 35, PP. 508-516, (2020); CICERO A.F., FOGACCI F., COLLETTI A., FOOD AND PLANT BIOACTIVES FOR REDUCING CARDIOMETABOLIC DISEASE RISK: AN EVIDENCE BASED APPROACH, FOOD FUNCT, 8, PP. 2076-2088, (2017); CICERO A.F., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., FRAS Z., KATSIKI N., LANGLOIS M., LATKOVSKIS G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR. REV, 75, PP. 731-767, (2017); 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, ATHEROSCLEROSIS, 290, PP. 140-205, (2019); GOLDSTEIN M.R., EFFECTS OF DIETARY PHYTOSTEROLS ON CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS, AM. J. MED, 109, PP. 72-73, (2000); CEDO L., FARRAS M., LEE-RUECKERT M., ESCOLA-GIL J.C., MOLECULAR INSIGHTS INTO THE MECHANISMS UNDERLYING THE CHOLESTEROL-LOWERING EFFECTS OF PHYTOSTEROLS, CURR. MED. CHEM, 26, PP. 6704-6723, (2019); RAS R.T., GELEIJNSE J.M., TRAUTWEIN E.A., LDL-CHOLESTEROL-LOWERING EFFECT OF PLANT STEROLS AND STANOLS ACROSS DIFFERENT DOSE RANGES: A META-ANALYSIS OF RANDOMISED CONTROLLED STUDIES, BR. J. NUTR, 112, PP. 214-219, (2014); HAN S., JIAO J., XU J., ZIMMERMANN D., ACTIS-GORETTA L., GUAN L., ZHAO Y., QIN L., EFFECTS OF PLANT STANOL OR STEROL-ENRICHED DIETS ON LIPID PROFILES IN PATIENTS TREATED WITH STATINS: SYSTEMATIC REVIEW AND META-ANALYSIS, SCI. REP, 6, (2016); FUMERON F., BARD J.M., LECERF J.M., INTERINDIVIDUAL VARIABILITY IN THE CHOLESTEROL-LOWERING EFFECT OF SUPPLEMENTATION WITH PLANT STEROLS OR STANOLS, NUTR. REV, 75, PP. 134-145, (2017); SCIENTIFIC OPINION ON THE MODIFICATION OF THE AUTHORISATION OF A HEALTH CLAIM RELATED TO PLANT STEROL ESTERS AND LOWERING BLOOD LDL-CHOLESTEROL; HIGH BLOOD LDL-CHOLESTEROL IS A RISK FACTOR IN THE DEVELOPMENT OF (CORONARY) HEART DISEASE PURSUANT TO ARTICLE 14 OF REGULATION (EC) NO 1924/2006, FOLLOWING A REQUEST IN ACCORDANCE WITH ARTICLE 19 OF REGULATION (EC) NO 1924/2006, EFSA J, 12, (2014); CICERO A.F., FOGACCI F., BANACH M., RED YEAST RICE FOR HYPERCHOLESTEROLEMIA, METHODIST DEBAKEY CARDIOVASC. J, 15, PP. 192-199, (2019); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ZHANG D., COOPER R., CHANG M., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGRIC. FOOD CHEM, 48, PP. 5220-5225, (2000); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN—A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13 OF REGULATION (EC) NO 1924/20061; EFSA PANEL ON DIETETIC PRODUCTS, NUTRITION AND ALLERGIES (NDA), EUROPEAN FOOD SAFETY AUTHORITY (EFSA), PARMA, ITALY, EFSA J, 9, (2011); SCIENTIFIC OPINION ON THE SAFETY OF MONACOLINS IN RED YEAST RICE, EFSA J, 16, (2018); FOGACCI F., BANACH M., MIKHAILIDIS D.P., BRUCKERT E., TOTH P.P., WATTS G.F., REINER Z., MANCINI J., RIZZO M., MITCHENKO O., ET AL., SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL. RES, 143, PP. 1-16, (2019); CICERO A.F., FOGACCI F., BOVE M., GIOVANNINI M., BORGHI C., THREE-ARM, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL EVALUATING THE METABOLIC EFFECT OF A COMBINED NUTRACEUTICAL CONTAINING A BERGAMOT STANDARDIZED FLAVONOID EXTRACT IN DYSLIPIDEMIC OVERWEIGHT SUBJECTS, PHYTOTHER. RES, 33, PP. 2094-2101, (2019); NASI M., PATRIZI G., PIZZI C., LANDOLFO M., BORIANI G., DEI CAS A., CICERO A.F., FOGACCI F., RAPEZZI C., SISCA G., ET AL., THE ROLE OF PHYSICAL ACTIVITY IN INDIVIDUALS WITH CARDIOVASCULAR RISK FACTORS: AN OPINION PAPER FROM ITALIAN SOCIETY OF CARDIOLOGY-EMILIA ROMAGNA-MARCHE AND SIC-SPORT, J. CARDIOVASC. MED, 20, PP. 631-639, (2019); CICERO A.F., DEROSA G., PISCIOTTA L., BARBAGALLO C., SISA-PUFACOL STUDY GROUP. TESTING THE SHORT-TERM EFFICACY OF A LIPID-LOWERING NUTRACEUTICAL IN THE SETTING OF CLINICAL PRACTICE: A MULTICENTER STUDY, J. MED. FOOD, 18, PP. 1270-1273, (2015); CICERO A.F., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENT. THER. MED, 13, PP. 273-278, (2005); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., MEIJER L., ZOCK P.L., GELEIJNSE J.M., TRAUTWEIN E.A., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUR. J. NUTR, 52, PP. 153-160, (2013); CICERO A.F., FOGACCI F., BOVE M., VERONESI M., RIZZO M., GIOVANNINI M., BORGHI C., SHORT-TERM EFFECTS OF A COMBINED NUTRACEUTICAL ON LIPID LEVEL, FATTY LIVER BIOMARKERS, HEMODYNAMIC PARAMETERS, AND ESTIMATED CARDIOVASCULAR DISEASE RISK: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL, ADV. THER, 34, PP. 1966-1975, (2017); CICERO A.F., FOGACCI F., MORBINI M., COLLETTI A., BOVE M., VERONESI M., GIOVANNINI M., BORGHI C., NUTRACEUTICAL EFFECTS ON GLUCOSE AND LIPID METABOLISM IN PATIENTS WITH IMPAIRED FASTING GLUCOSE: A PILOT, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL ON A COMBINED PRODUCT, HIGH. BLOOD PRESS CARDIOVASC. PREV, 24, PP. 283-288, (2017); PALMIERI L., DONFRANCESCO C., GIAMPAOLI S., TROJANI M., PANICO S., VANUZZO D., PILOTTO L., CESANA G., FERRARIO M., CHIODINI P., ET AL., FAVORABLE CARDIOVASCULAR RISK PROFILE AND 10-YEAR CORONARY HEART DISEASE INCIDENCE IN WOMEN AND MEN: RESULTS FROM THE PROGETTO CUORE, EUR. J. CARDIOVASC. PREV. REHABIL, 13, PP. 562-570, (2006); CICERO A.F., COLLETTI A., COMBINATIONS OF PHYTOMEDICINES WITH DIFFERENT LIPID LOWERING ACTIVITY FOR DYSLIPIDEMIA MANAGEMENT: THE AVAILABLE CLINICAL DATA, PHYTOMEDICINE, 23, PP. 1113-1118, (2016); ROSATO V., TEMPLE N.J., LA VECCHIA C., CASTELLAN G., TAVANI A., GUERCIO V., MEDITERRANEAN DIET AND CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES, EUR. J. NUTR, 58, PP. 173-191, (2019); EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); CICERO A.F., FOGACCI F., ROSTICCI M., PARINI A., GIOVANNINI M., VERONESI M., D'ADDATO S., BORGHI C., EFFECT OF A SHORT-TERM DIETARY SUPPLEMENTATION WITH PHYTOSTEROLS, RED YEAST RICE OR BOTH ON LIPID PATTERN IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS: A THREE-ARM, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL, NUTR. METAB, 14, (2017); BAILA-RUEDA L., PEREZ-RUIZ M.R., JARAUTA E., TEJEDOR M.T., MATEO-GALLEGO R., LAMIQUIZ-MONEO I., DE CASTRO-OROS I., CENARRO A., CIVEIRA F., COSEGREGATION OF SERUM CHOLESTEROL WITH CHOLESTEROL INTESTINAL ABSORPTION MARKERS IN FAMILIES WITH PRIMARY HYPERCHOLESTEROLEMIA WITHOUT MUTATIONS IN LDLR, APOB, PCSK9 AND APOE GENES, ATHEROSCLEROSIS, 246, PP. 202-207, (2016); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO NIACIN AND ENERGY-YIELDING METABOLISM (ID 43, 49, 54), FUNCTION OF THE NERVOUS SYSTEM (ID 44, 53), MAINTENANCE OF THE SKIN AND MUCOUS MEMBRANES (ID 45, 48, 50, 52), MAINTENANCE OF NORMAL LDL-CHOLESTEROL, HDL-CHOLESTEROL AND TRIGLYCERIDE CONCENTRATIONS (ID 46), MAINTENANCE OF BONE (ID 50), MAINTENANCE OF TEETH (ID 50), MAINTENANCE OF HAIR (ID 50, 2875) AND MAINTENANCE OF NAILS (ID 50, 2875) PURSUANT TO ARTICLE 13 OF REGULATION (EC) NO 1924/2006 ON REQUEST FROM EUROPEAN COMMISSION, EFSA J, 7, (2009)","A.F.G. CICERO; MEDICAL AN SURGERY SCIENCES DEPARTMENT, DYSLIPIDEMIA AND ATHEROSCLEROSIS RESEARCH UNIT, ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, ITALY; EMAIL: ARRIGO.CICERO@UNIBO.IT","MDPI AG","ENGLISH","NUTRIENTS","ARTICLE","ISI","2-S2.0-85092476851","NUTRIENTS","ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA","NOTREPORTED;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA;NOTREPORTED",NA,"CICERO AFG, 2020, NUTRIENTS","CICERO AFG, 2020, NUTRIENTS"
"AKBARI A;ISLAMPANAH M;ARHAMINIYA H;FARD M;JAMIALAHMADI T;SAHEBKAR A","AKBARI, ABOLFAZL (57373568900); ISLAMPANAH, MUHAMMAD (57699295400); ARHAMINIYA, HADISE (58895743300); FARD, MOHAMMAD MAHDI ALVANDI (58895080800); JAMIALAHMADI, TANNAZ (57208751391); SAHEBKAR, AMIRHOSSEIN (26639699900)","IMPACT OF STATIN OR FIBRATE THERAPY ON HOMOCYSTEINE CONCENTRATIONS A SYSTEMATIC REVIEW AND METAANALYSIS",2024,"CURRENT MEDICINAL CHEMISTRY","31","20",1,"10.2174/0929867330666230413090416","STUDENT RESEARCH COMMITTEE, FACULTY OF MEDICINE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;STUDENT RESEARCH COMMITTEE, FACULTY OF MEDICINE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;STUDENT RESEARCH COMMITTEE, FACULTY OF MEDICINE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;STUDENT RESEARCH COMMITTEE, FACULTY OF MEDICINE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;APPLIED BIOMEDICAL RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;APPLIED BIOMEDICAL RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN, BIOTECHNOLOGY RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN","INTRODUCTION: STATINS AND FIBRATES ARE TWO LIPID-LOWERING DRUGS USED IN PATIENTS WITH DYSLIPIDEMIA. THIS SYSTEMATIC REVIEW AND META-ANALYSIS WERE CONDUCTED TO DETERMINE THE MAGNITUDE OF THE EFFECT OF STATIN AND FIBRATE THERAPY ON SERUM HOMOCYSTEINE LEVELS. METHODS: A SEARCH WAS UNDERTAKEN OF THE PUBMED, SCOPUS, WEB OF SCIENCE, EMBASE, AND GOOGLE SCHOLAR ELECTRONIC DATABASES UP TO 15 JULY 2022. PRIMARY ENDPOINTS FOCUSED ON PLASMA HOMOCYSTEINE LEVELS. DATA WERE QUANTITATIVELY ANALYZED USING FIXED OR RAN-DOM-EFFECT MODELS, AS APPROPRIATE. SUBGROUP ANALYSES WERE CONDUCTED BASED ON THE DRUGS AND HYDROPHILIC-LIPOPHILIC BALANCE OF STATINS. RESULTS: AFTER SCREENING 1134 PAPERS, 52 STUDIES WITH A TOTAL OF 20651 PARTICIPANTS WERE INCLUDED IN THE META-ANALYSIS. THE ANALYSIS SHOWED A SIGNIFICANT DECREASE IN PLASMA HO-MOCYSTEINE LEVELS AFTER STATIN THERAPY (WMD:-1.388 ΜMOL/L, 95% CI: [-2.184,-0.592], P = 0.001; I2 = 95%). HOWEVER, FIBRATE THERAPY SIGNIFICANTLY INCREASED PLASMA HOMOCYS-TEINE LEVELS (WMD: 3.459 ΜMOL/L, 95% CI: [2.849, 4.069], P < 0.001; I2 = 98%). THE EFFECT OF ATORVASTATIN AND SIMVASTATIN DEPENDED ON THE DOSE AND DURATION OF TREATMENT (ATOR-VASTATIN [COEFFICIENT: 0.075 [0.0132, 0.137]; P = 0.017, COEFFICIENT: 0.103 [0.004, 0.202]; P = 0.040, RESPECTIVELY] AND SIMVASTATIN [COEFFICIENT:-0.047 [-0.063,-0.031]; P < 0.001, COEFFICIENT: 0.046 [0.016, 0.078]; P = 0.004]), WHEREAS THE EFFECT OF FENOFIBRATE PERSISTED OVER TIME (COEFFICIENT: 0.007 [-0.011, 0.026]; P = 0.442) AND WAS NOT ALTERED BY A CHANGE IN DOSAGE (COEFFICIENT:-0.004 [-0.031, 0.024]; P = 0.798). IN ADDITION, THE GREATER HOMO-CYSTEINE-LOWERING EFFECT OF STATINS WAS ASSOCIATED WITH HIGHER BASELINE PLASMA HOMOCYS-TEINE CONCENTRATIONS (COEFFICIENT:-0.224 [-0.340,-0.109]; P < 0.001). CONCLUSION: FIBRATES SIGNIFICANTLY INCREASED HOMOCYSTEINE LEVELS, WHEREAS STATINS SIGNIFICANTLY DECREASED THEM. © 2024 BENTHAM SCIENCE PUBLISHERS.","ATHEROSCLEROSIS; DYSLIPIDEMIA; FIBRATE; HOMOCYSTEINE; LIPID-LOWERING DRUGS; STATIN","DYSLIPIDEMIAS; FIBRIC ACIDS; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; ACETYLSALICYLIC ACID; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; CLOPIDOGREL; CYANOCOBALAMIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUVASTATIN; FOLIC ACID; GEMFIBROZIL; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN ASPART; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PEMAFIBRATE; PITAVASTATIN; POLICOSANOL; PRAVASTATIN; PYRIDOXINE; ROSUVASTATIN; SIMVASTATIN; TESTOSTERONE; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; XUEZHITONG; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ADULT; AGED; AMINO ACID BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; EMBASE; FEMALE; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MALE; MEDLINE; META ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SCOPUS; SEARCH ENGINE; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEB OF SCIENCE; BLOOD; DYSLIPIDEMIA","","","MANGGE H., BECKER K., FUCHS D., GOSTNER J.M., ANTIOXI-DANTS, INFLAMMATION AND CARDIOVASCULAR DISEASE, WORLD J. CARDIOL, 6, 6, PP. 462-477, (2014); CHEN P.J., LU Y.C., WANG P.M., HUANG C.F., LOKE S.S., FACTORS ASSOCIATED WITH HYPERHOMOCYSTEINEMIA IN RELATIVE-LY HEALTHY TAIWANESE ADULTS, MEDICINE, 100, 3, (2021); LIU R., XU F., ZHOU Y., LIU T., THE CHARACTERISTICS OF RISK FACTORS IN CHINESE YOUNG WOMEN WITH ACUTE CORONARY SYNDROME, BMC CARDIOVASC. DISORD, 20, 1, (2020); AKBARI A., RAFIEE M., SATHYAPALAN T., SAHEBKAR A., IM-PACTS OF SODIUM/GLUCOSE COTRANSPORTER-2 INHIBITORS ON CIRCULATING URIC ACID CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. DIABETES RES, 2022, PP. 1-17, (2022); VENES D., TABER’S CYCLOPEDIC MEDICAL DICTIONARY, (2017); FAEH D., CHIOLERO A., PACCAUD F., HOMOCYSTEINE AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE: SHOULD WE (STILL) WORRY ABOUT?, SWISS MED. WKLY, 136, 47-48, PP. 745-756, (2006); GANGULY P., ALAM S.F., ROLE OF HOMOCYSTEINE IN THE DEVELOPMENT OF CARDIOVASCULAR DISEASE, NUTR. J, 14, 1, (2015); ZHAO J., CHEN H., LIU N., CHEN J., GU Y., CHEN J., YANG K., ROLE OF HYPERHOMOCYSTEINEMIA AND HYPER-URICEMIA IN PATHOGENESIS OF ATHEROSCLEROSIS, J. STROKE CERE-BROVASC. DIS, 26, 12, PP. 2695-2699, (2017); GATT A., MAKRIS M., HYPERHOMOCYSTEINEMIA AND VENOUS THROMBOSIS, SEMIN. HEMATOL, 44, 2, PP. 70-76, (2007); DURAND P., PROST M., LOREAU N., LUSSIER-CACAN S., BLACHE D., IMPAIRED HOMOCYSTEINE METABOLISM AND ATHEROTHROMBOTIC DISEASE, LAB. INVEST, 81, 5, PP. 645-672, (2001); SELHUB J., JACQUES P.F., ROSENBERG I.H., ROGERS G., BOWMAN B.A., GUNTER E.W., WRIGHT J.D., JOHNSON C.L., SERUM TOTAL HOMOCYSTEINE CONCENTRATIONS IN THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (1991-1994): POPULATION REFERENCE RANGES AND CONTRIBUTION OF VITAMIN STATUS TO HIGH SERUM CONCENTRATIONS, ANN. INTERN. MED, 131, 5, PP. 331-339, (1999); KIM J., KIM H., ROH H., KWON Y., CAUSES OF HYPERHO-MOCYSTEINEMIA AND ITS PATHOLOGICAL SIGNIFICANCE, ARCH. PHARM. RES, 41, 4, PP. 372-383, (2018); SAHEBKAR A., PIRRO M., REINER Z., CICERO A., FERRETTI G., SIMENTAL-MENDIA M., SIMENTAL-MENDIA L., A SYSTEMATIC REVIEW AND META-ANALYSIS OF CONTROLLED TRIALS ON THE EFFECTS OF STATIN AND FIBRATE THERAPIES ON PLASMA HOMOCYS-TEINE LEVELS, CURR. MED. CHEM, 23, 39, PP. 4490-4503, (2016); ZINELLU A., MANGONI A.A., EFFECT OF STATIN TREATMENT ON HO-MOCYSTEINE CONCENTRATIONS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS WITH META-REGRESSION, EXPERT REV. CLIN. PHARMACOL, 15, 4, PP. 443-459, (2022); BAHRAMI A., BO S., JAMIALAHMADI T., SAHEBKAR A., EFFECTS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUC-TASE INHIBITORS ON AGEING: MOLECULAR MECHANISMS, AGEING RES. REV, 58, (2020); BLAND A.R., PAYNE F.M., ASHTON J.C., JAMIALAHMADI T., SAHEBKAR A., THE CARDIOPROTECTIVE ACTIONS OF STATINS IN TAR-GETING MITOCHONDRIAL DYSFUNCTION ASSOCIATED WITH MYOCAR-DIAL ISCHAEMIA-REPERFUSION INJURY, PHARMACOL. RES, 175, (2022); GORABI A.M., KIAIE N., BIANCONI V., PIRRO M., JAMIALAH-MADI T., SAHEBKAR A., STATINS ATTENUATE FIBROTIC MANIFESTA-TIONS OF CARDIAC TISSUE DAMAGE, CURR. MOL. PHARMACOL, 14, 5, PP. 782-797, (2021); SOHREVARDI S., NASAB F., MIRJALILI M., BAGHERNIYA M., TAFTI A., JARRAHZADEH M., AZARPAZHOOH M., SAEIDMA-NESH M., BANACH M., JAMIALAHMADI T., SAHEBKAR A., EFFECT OF ATORVASTATIN ON DELIRIUM STATUS OF PATIENTS IN THE INTENSIVE CARE UNIT: A RANDOMIZED CONTROLLED TRIAL, ARCH. MED. SCI, 17, 5, PP. 1423-1428, (2019); VAHEDIAN-AZIMI A., MOHAMMADI S., BENI F., BANACH M., GUEST P., JAMIALAHMADI T., SAHEBKAR A., IMPROVED COVID-19 ICU ADMISSION AND MORTALITY OUTCOMES FOLLOW-ING TREATMENT WITH STATINS: A SYSTEMATIC REVIEW AND META-A-NALYSIS, ARCH. MED. SCI, 17, 3, PP. 579-595, (2021); BOTTA M., AUDANO M., SAHEBKAR A., SIRTORI C., MITRO N., RUSCICA M., PPAR AGONISTS AND METABOLIC SYNDROME: AN ESTABLISHED ROLE?, INT. J. MOL. SCI, 19, 4, (2018); DEROSA G., SAHEBKAR A., MAFFIOLI P., THE ROLE OF VARIOUS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS AND THEIR LI-GANDS IN CLINICAL PRACTICE, J. CELL. PHYSIOL, 233, 1, PP. 153-161, (2018); SAHEBKAR A., CHEW G.T., WATTS G.F., RECENT ADVANCES IN PHARMACOTHERAPY FOR HYPERTRIGLYCERIDEMIA, PROG. LIPID RES, 56, 1, PP. 47-66, (2014); BANACH M., SERBAN C., URSONIU S., RYSZ J., MUNTNER P., TOTH P.P., JONES S.R., RIZZO M., GLASSER S.P., WATTS G.F., BLUMENTHAL R.S., LIP G.Y.H., MIKHAILIDIS D.P., SA-HEBKAR A., STATIN THERAPY AND PLASMA COENZYME Q<SUB>10</SUB> CONCEN-TRATIONS-A SYSTEMATIC REVIEW AND META-ANALYSIS OF PLACEBO-CONTROLLED TRIALS, PHARMACOL. RES, 99, PP. 329-336, (2015); BYTYCI I., PENSON P.E., MIKHAILIDIS D.P., WONG N.D., HERNANDEZ A.V., SAHEBKAR A., THOMPSON P.D., MAZIDI M., RYSZ J., PELLA D., REINER Z., TOTH P.P., BANACH M., PREVALENCE OF STATIN INTOLERANCE: A META-ANALYSIS, EUR. HEART J, 43, 34, PP. 3213-3223, (2022); SAHEBKAR A., CICERO A.F.G., DI GIOSIA P., POMILIO I., STAMERRA C.A., GIORGINI P., FERRI C., HAEHLING S., BA-NACH M., JAMIALAHMADI T., PATHOPHYSIOLOGICAL MECHANISMS OF STATIN-ASSOCIATED MYOPATHIES: POSSIBLE ROLE OF THE UBIQUITIN-PROTEASOME SYSTEM, J. CACHEXIA SARCOPENIA MUSCLE, 11, 5, PP. 1177-1186, (2020); SCOTT R., O'BRIEN R., FULCHER G., PARDY C., D'EMDEN M., TSE D., TASKINEN M.R., EHNHOLM C., KEECH A., EFFECTS OF FENOFIBRATE TREATMENT ON CARDIOVASCULAR DISEASE RISK IN 9,795 INDIVIDUALS WITH TYPE 2 DIABETES AND VARIOUS COMPONENTS OF THE METABOLIC SYNDROME: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY, DIABETES CARE, 32, 3, PP. 493-498, (2009); YEBYO H.G., ASCHMANN H.E., KAUFMANN M., PUHAN M.A., COMPARATIVE EFFECTIVENESS AND SAFETY OF STATINS AS A CLASS AND OF SPECIFIC STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW, META-ANALYSIS, AND NETWORK META-ANALYSIS OF RANDOMIZED TRIALS WITH 94,283 PARTICIPANTS, AM. HEART J, 210, PP. 18-28, (2019); SAHEBKAR A., CHEW G.T., WATTS G.F., NEW PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS: POTENTIAL TREAT-MENTS FOR ATHEROGENIC DYSLIPIDEMIA AND NON-ALCOHOLIC FATTY LIVER DISEASE, EXPERT OPIN. PHARMACOTHER, 15, 4, PP. 493-503, (2014); IBARRA-LARA L., SANCHEZ-AGUILAR M., SANCHEZ-MENDOZA A., DEL VALLE-MONDRAGON L., SORIA-CASTRO E., CARREON-TORRES E., DIAZ-DIAZ E., VAZQUEZ-MEZA H., GUARN-ER-LANS V., RUBIO-RUIZ M., FENOFIBRATE THERAPY RESTORES ANTIOXIDANT PROTECTION AND IMPROVES MYOCARDIAL INSULIN RE-SISTANCE IN A RAT MODEL OF METABOLIC SYNDROME AND MYOCAR-DIAL ISCHEMIA: THE ROLE OF ANGIOTENSIN II, MOLECULES, 22, 1, (2016); TZIOMALOS K., ATHYROS V., KARAGIANNIS A., MIKHAILIDIS D., ANTI-INFLAMMATORY EFFECTS OF FIBRATES: AN OVERVIEW, CURR. MED. CHEM, 16, 6, PP. 676-684, (2009); FERRETTI G., BACCHETTI T., SAHEBKAR A., EFFECT OF STATIN THERAPY ON PARAOXONASE-1 STATUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 25 CLINICAL TRIALS, PROG. LIPID RES, 60, PP. 50-73, (2015); PARIZADEH S.M.R., AZARPAZHOOH M.R., MOOHEBATI M., NEMATY M., GHAYOUR-MOBARHAN M., TAVALLAIE S., RAHSE-PAR A.A., AMINI M., SAHEBKAR A., MOHAMMADI M., FERNS G.A.A., SIMVASTATIN THERAPY REDUCES PROOXIDANT-AN-TIOXIDANT BALANCE: RESULTS OF A PLACEBO-CONTROLLED CROSSOVER TRIAL, LIPIDS, 46, 4, PP. 333-340, (2011); SAHEBKAR A., KOTANI K., SERBAN C., URSONIU S., MIKHAI-LIDIS D.P., JONES S.R., RAY K.K., BLAHA M.J., RYSZ J., TOTH P.P., MUNTNER P., LIP G.Y.H., BANACH M., STATIN THERAPY REDUCES PLASMA ENDOTHELIN-1 CONCENTRATIONS: A ME-TA-ANALYSIS OF 15 RANDOMIZED CONTROLLED TRIALS, ATHEROSCLE-ROSIS, 241, 2, PP. 433-442, (2015); SAHEBKAR A., SERBAN C., MIKHAILIDIS D.P., UNDAS A., LIP G.Y.H., MUNTNER P., BITTNER V., RAY K.K., WATTS G.F., HOVINGH G.K., RYSZ J., KASTELEIN J.J., BANACH M., ASSOCIATION BETWEEN STATIN USE AND PLASMA D-DIMER LEVELS. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, THROMB. HAEMOST, 114, 3, PP. 546-557, (2015); PAGE M.J., MOHER D., BOSSUYT P.M., BOUTRON I., HOFF-MANN T.C., MULROW C.D., SHAMSEER L., TETZLAFF J.M., AKL E.A., BRENNAN S.E., CHOU R., GLANVILLE J., GRIMSHAW J.M., HROBJARTSSON A., LALU M.M., LI T., LODER E.W., MAYO-WILSON E., MCDONALD S., MCGUIN-NESS L.A., STEWART L.A., THOMAS J., TRICCO A.C., WELCH V.A., WHITING P., MCKENZIE J.E., PRISMA 2020 EXPLANATION AND ELABORATION: UPDATED GUIDANCE AND EXEM-PLARS FOR REPORTING SYSTEMATIC REVIEWS, BMJ, 372, (2021); 33781993 WAN X., WANG W., LIU J., TONG T., ESTIMATING THE SAMPLE MEAN AND STANDARD DEVIATION FROM THE SAMPLE SIZE, ME-DIAN, RANGE AND/OR INTERQUARTILE RANGE, BMC MED. RES. METHODOL, 14, 1, (2014); BISSONNETTE R., TREACY E., ROZEN R., BOUCHER B., COHN J.S., GENEST J., FENOFIBRATE RAISES PLASMA HOMOCYSTEINE LEVELS IN THE FASTED AND FED STATES, ATHEROSCLEROSIS, 155, 2, PP. 455-462, (2001); CHAN N., CHAN J.C.N., IMPLICATION OF FIBRATE THERAPY FOR HOMOCYSTEINE, LANCET, 354, 9185, PP. 1208-1209, (1999); CICERO A.F.G., DEROSA G., MICONI A., LAGHI L., NASCET-TI S., GADDI A., POSSIBLE ROLE OF UBIQUINONE IN THE TREATMENT OF MASSIVE HYPERTRIGLYCERIDEMIA RESISTANT TO PUFA AND FIBRATES, BIOMED. PHARMACOTHER, 59, 6, PP. 312-317, (2005); JAKOB T., NORDMANN A.J., SCHANDELMAIER S., FERREIRA-GONZALEZ I., BRIEL M., FIBRATES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE EVENTS, COCHRANE LIBR, 2017, 3, (2016); KOUTOUZIS M., NOMIKOS A., NIKOLIDAKIS S., TZAVARA V., ANDRIKOPOULOS V., NIKOLAOU N., BARBATIS C., KYRIAKIDES Z.S., STATIN TREATED PATIENTS HAVE REDUCED INTRAPLAQUE ANGIO-GENESIS IN CAROTID ENDARTERECTOMY SPECIMENS, ATHEROSCLE-ROSIS, 192, 2, PP. 457-463, (2007); LEVER M., GEORGE P.M., SLOW S., ELMSLIE J.L., SCOTT R.S., RICHARDS A.M., FINK J.N., CHAMBERS S.T., FIBRATES MAY CAUSE AN ABNORMAL URINARY BETAINE LOSS WHICH IS ASSOCIATED WITH ELEVATIONS IN PLASMA HOMOCYSTEINE, CARDIO-VASC. DRUGS THER, 23, 5, PP. 395-401, (2009); MAKOWKA A., DRYJA P., CHWATKO G., BALD E., NOWICKI M., TREATMENT OF CHRONIC HEMODIALYSIS PATIENTS WITH LOW-DOSE FENOFIBRATE EFFECTIVELY REDUCES PLASMA LIPIDS AND AF-FECTS PLASMA REDOX STATUS, LIPIDS HEALTH DIS, 11, 1, (2012); MALIK J., MELENOVSKY V., WICHTERLE D., HAAS T., SIMEK J., CESKA R., HRADEC J., BOTH FENOFIBRATE AND ATORVASTATIN IMPROVE VASCULAR REACTIVITY IN COMBINED HYPERLIPIDAEMIA (FENOFIBRATE VERSUS ATORVASTATIN TRIAL-FAT), CARDIOVASC. RES, 52, 2, PP. 290-298, (2001); 11684077 MAYER O., SIMON J., HOLUBEC L., PIKNER R., TREFIL L., FOLATE CO-ADMINISTRATION IMPROVES THE EFFECTIVENESS OF FENOFIBRATE TO DECREASE THE LIPOPROTEIN OXIDATION AND ENDOTHELIAL DYSFUNCTION SURROGATES, PHYSIOL. RES, 55, 5, PP. 475-481, (2006); MAYER O., SIMON J., HOLUBEC L., PIKNER R., SUBRT I., FENOFIBRATE-INDUCED HYPERHOMOCYSTEINEMIA MAY BE PRE-VENTED BY FOLATE CO-ADMINISTRATION, EUR. J. CLIN. PHARMA-COL, 59, 5-6, PP. 367-371, (2003); NANAYAKKARA P.W.B., KIEFTE-DE JONG J.C., STEHOUWER C.D.A., VAN ITTERSUM F.J., OLTHOF M.R., KOK R.M., BLOM H.J., VAN GULDENER C., TER WEE P.M., SMULDERS Y.M., ASSOCIATION BETWEEN GLOBAL LEUKOCYTE DNA METHYLA-TION, RENAL FUNCTION, CAROTID INTIMA-MEDIA THICKNESS AND PLASMA HOMOCYSTEINE IN PATIENTS WITH STAGE 2-4 CHRONIC KIDNEY DISEASE, NEPHROL. DIAL. TRANSPLANT, 23, 8, PP. 2586-2592, (2008); NANAYAKKARA P.W.B., KIEFTE-DE JONG J.C., TER WEE P.M., STEHOUWER C.D.A., VAN ITTERSUM F.J., OLTHOF M.R., TEER-LINK T., TWISK J.W.R., VAN GULDENER C., SMULDERS Y.M., RANDOMIZED PLACEBO-CONTROLLED TRIAL ASSESSING A TREATMENT STRATEGY CONSISTING OF PRAVASTATIN, VITAMIN E, AND HOMOCYS-TEINE LOWERING ON PLASMA ASYMMETRIC DIMETHYLARGININE CONCENTRATION IN MILD TO MODERATE CKD, AM. J. KIDNEY DIS, 53, 1, PP. 41-50, (2009); SBAROUNI E., KYRIAKIDES Z.S., KREMASTINOS D.T., THE EF-FECT OF HORMONE REPLACEMENT THERAPY AND SIMVASTATIN ON PLASMA HOMOCYSTEINE, J. WOMENS HEALTH, 14, 2, PP. 154-158, (2005); SINZINGER H., STEINER S., DERFLER K., PLEIOTROPIC EFFECTS OF REGULAR LIPOPROTEIN-APHERESIS, ATHEROSCLER. SUPPL, 30, PP. 122-127, (2017); VERINGA S.J.E., NANAYAKKARA P.W.B., ITTERSUM F.J., VEGT-ING I.L., GULDENER C., WEE Y.M.S.P.M., STEHOUWER C.D.A., STEHOUWER C.D., EFFECT OF A TREATMENT STRATEGY CONSISTING OF PRAVASTATIN, VITAMIN E, AND HOMOCYSTEINE LOWERING ON ARTERIAL COMPLIANCE AND DISTENSIBILITY IN PATIENTS WITH MILD-TO-MODERATE CHRONIC KIDNEY DISEASE, CLIN. NEPHROL, 78, 10, PP. 263-272, (2012); WENAWESER P., WINDECKER S., BILLINGER M., COOK S., TOGNI M., MEIER B., HAEBERLI A., HESS O.M., EFFECT OF ATORVASTATIN AND PRAVASTATIN ON PLATELET INHIBITION BY ASPIRIN AND CLOPIDOGREL TREATMENT IN PATIENTS WITH CORONARY STENT THROMBOSIS, AM. J. CARDIOL, 99, 3, PP. 353-356, (2007); HOVLAND A., AAGNES I., BREKKE O.L., FLAGE J.H., LAPPEGARD K.T., NO EVIDENCE OF IMPAIRED ENDOTHELIAL FUNCTION OR ALTERED INFLAMMATORY STATE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH STATINS, J. CLIN. LIPIDOL, 4, 4, PP. 288-292, (2010); EL OUDI M., AOUNI Z., OUERTANI H., MAZIGH C., MACHGHOUL S., EFFECT OF LIPOPENIC AND HYPOTENSIVE TREATMENT ON HOMOCYSTEINE LEVELS IN TYPE 2 DIABETICS, VASC. HEALTH RISK MANAG, 6, PP. 327-332, (2010); STULC T., CESKA R., KOZICH V., SKRHA J., 2P-0372 FENOFI-BRATE BUT NOT SIMVASTATIN INCREASES SERUM HOMOCYSTEINE AND CREATININE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, ATHEROSCLER. SUPPL, 4, 2, (2003); DIERKES J., WESTPHAL S., LULEY C., SERUM HOMOCYSTEINE INCREASES AFTER THERAPY WITH FENOFIBRATE OR BEZAFIBRATE, LANCET, 354, 9174, PP. 219-220, (1999); FENG Y., LIANG W., LIANG W., XIAO X., ZHANG Y., EFFECTS OF XUEZHITONG CAPSULES ON CHRONIC KIDNEY DISEASE PATIENTS WITH DYSLIPIDEMIA, TROP. J. PHARM. RES, 21, 1, PP. 177-183, (2022); POTACZEK D.P., UNDAS A., CELINSKA-LOWENHOFF M., SZCZEKLIK A., THE I ALLELE OF THE ANGIOTENSIN-CONVERTING EN-ZYME GENE POLYMORPHISM MAY DETERMINE AN INCREASE IN HO-MOCYSTEINE LEVELS IN FIBRATE-TREATED SUBJECTS, CARDIOVASC. DRUGS THER, 20, 3, PP. 229-232, (2006); PYTEL E., JACKOWSKA P., CHWATKO G., OLSZEWSKA-BA-NASZCZYK M., KOTER-MICHALAK M., KUBALCZYK P., BRON-CEL M., INTENSIVE STATIN THERAPY, USED ALONE OR IN COMBINATION WITH EZETIMIBE, IMPROVES HOMOCYSTEINE LEVEL AND LIPID PEROXIDATION TO A SIMILAR DEGREE IN PATIENTS WITH CORONARY ARTERY DISEASES, PHARMACOL. REP, 68, 2, PP. 344-348, (2016); VLADIMIROVA-KITOVA L.G., DENEVA-KOYCHEVA T.I., THE EF-FECT OF SIMVASTATIN ON ASYMMETRIC DIMETHYLARGININE AND FLOW-MEDIATED VASODILATION AFTER OPTIMIZING THE LDL LEVEL-A RANDOMIZED, PLACEBO-CONTROLLED STUDY, VASCUL. PHARMA-COL, 56, 3-4, PP. 122-130, (2012); ZHOU T., MEI J., HOU M., CLINICAL STUDY OF DOUBLE ANTI-PLATELET THERAPY COMBINED WITH DIFFERENT DOSES OF STATIN IN THE TREATMENT OF ACUTE CEREBRAL INFARCTION COMPLICATED WITH MICROHEMORRHAGE, AM. J. TRANSL. RES, 13, 10, PP. 12043-12050, (2021); PENG Y., OU B.Q., LI H.H., ZHOU Z., MO J.L., HUANG J., LIANG F.L., SYNERGISTIC EFFECT OF ATORVASTATIN AND FOLIC ACID ON CARDIAC FUNCTION AND VENTRICULAR REMODELING IN CHRONIC HEART FAILURE PATIENTS WITH HYPERHOMOCYSTEINEMIA, MED. SCI. MONIT, 24, PP. 3744-3751, (2018); GENEST J., FROHLICH J., STEINER G., EFFECT OF FENOFIBRATE-MEDIATED INCREASE IN PLASMA HOMOCYSTEINE ON THE PROGRESSION OF CORONARY ARTERY DISEASE IN TYPE 2 DIABETES MELLITUS, AM. J. CARDIOL, 93, 7, PP. 848-853, (2004); KRYSIAK R., KOWALCZE K., BEDNARSKA-CZERWINSKA A., OKOPIEN B., THE EFFECT OF ATORVASTATIN ON CARDIOMETABOLIC RISK FACTORS IN WOMEN WITH NON-CLASSIC CONGENITAL ADRENAL HYPERPLASIA: A PILOT STUDY, PHARMACOL. REP, 71, 3, PP. 417-421, (2019); MOK C.C., WONG C.K., TO C.H., LAI J.P.S., LAM C.S., EFFECTS OF ROSUVASTATIN ON VASCULAR BIOMARKERS AND CAROTID ATHEROSCLEROSIS IN LUPUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ARTHRITIS CARE RES, 63, 6, PP. 875-883, (2011); PINCHBECK J.L., MOXON J.V., ROWBOTHAM S.E., BOURKE M., LAZZARONI S., MORTON S.K., MATTHEWS E.O., HENDY K., JONES R.E., BOURKE B., JAEGGI R., FAVOT D., QUIGLEY F., JENKINS J.S., REID C.M., VELU R., GOLLEDGE J., RANDOMIZED PLACEBO-CONTROLLED TRIAL ASSESSING THE EFFECT OF 24-WEEK FENOFIBRATE THERAPY ON CIRCULATING MARKERS OF ABDOMINAL AORTIC ANEURYSM: OUTCOMES FROM THE FAME-2 TRIAL, J. AM. HEART ASSOC, 7, 19, (2018); VAN DER LOO B., SPRING S., KOPPENSTEINER R., HIGH-DOSE ATORVASTATIN TREATMENT IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: EFFECTS ON PLATELET AGGREGATION, BLOOD RHEOLOGY AND PLASMA HOMOCYSTEINE, CLIN. HEMORHEOL. MICROCIRC, 47, 4, PP. 241-251, (2011); JANATUINEN T., LAAKSO J., LAAKSONEN R., VESALAINEN R., NUUTILA P., LEHTIMAKI T., RAITAKARI O.T., KNUUTI J., PLASMA ASYMMETRIC DIMETHYLARGININE MODIFIES THE EFFECT OF PRA-VASTATIN ON MYOCARDIAL BLOOD FLOW IN YOUNG ADULTS, VASC. MED, 8, 3, PP. 185-189, (2003); LI C., DING Y., SI Q., LI K., XU K., MULTIPLE FUNCTIONS OF POLICOSANOL IN ELDERLY PATIENTS WITH DYSLIPIDEMIA, J. INT. MED. RES, 48, 7, (2020); MACCALLUM P.K., COOPER J.A., RUMLEY A., LOWE G.D.O., MEADE T.W., EFFECT OF BEZAFIBRATE ON PLASMA HO-MOCYSTEINE CONCENTRATION IN MEN WITH LOWER EXTREMITY ARTERIAL DISEASE, J. THROMB. HAEMOST, 2, 2, PP. 346-379, (2004); MILIONIS H.J., PAPAKOSTAS J., KAKAFIKA A., CHASIOTIS G., SEFERIADIS K., ELISAF M.S., COMPARATIVE EFFECTS OF ATORVAS-TATIN, SIMVASTATIN, AND FENOFIBRATE ON SERUM HOMOCYSTEINE LEVELS IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA, J. CLIN. PHARMACOL, 43, 8, PP. 825-830, (2003); NANAYAKKARA P.W.B., VAN GULDENER C., TER WEE P.M., SCHEFFER P.G., VAN ITTERSUM F.J., TWISK J.W., TEERLINK T., VAN DORP W., STEHOUWER C.D., EFFECT OF A TREATMENT STRATEGY CONSISTING OF PRAVASTATIN, VITAMIN E, AND HOMOCYS-TEINE LOWERING ON CAROTID INTIMA-MEDIA THICKNESS, ENDOTHELIAL FUNCTION, AND RENAL FUNCTION IN PATIENTS WITH MILD TO MODERATE CHRONIC KIDNEY DISEASE: RESULTS FROM THE AN-TI-OXIDANT THERAPY IN CHRONIC RENAL INSUFFICIENCY (ATIC) STUDY, ARCH. INTERN. MED, 167, 12, PP. 1262-1270, (2007); NIEMINEN T., KNUUTI J., HAMELAHTI P., KAHONEN M., LAAKSONEN R., JANATUINEN T., VESALAINEN R., NUUTILA P., JOKELA H., LEHTIMAKI T., CORONARY REACTIVITY, HOMOCYS-TEINE AND METHYLENETETRAHYDROFOLATE REDUCTASE GENE VARIA-TION IN YOUNG MEN DURING PRAVASTATIN THERAPY, VASCUL. PHARMACOL, 47, 2-3, PP. 113-117, (2007); RIDKER P.M., SHIH J., COOK T.J., CLEARFIELD M., DOWNS J.R., PRADHAN A.D., WEIS S.E., GOTTO A.M., PLASMA HO-MOCYSTEINE CONCENTRATION, STATIN THERAPY, AND THE RISK OF FIRST ACUTE CORONARY EVENTS, CIRCULATION, 105, 15, PP. 1776-1779, (2002); LI C., BU X., LIU Y., EFFECT OF FOLIC ACID COMBINED WITH PRAVASTATIN ON ARTERIOSCLEROSIS IN ELDERLY HYPERTENSIVE PATIENTS WITH LACUNAR INFARCTION, MEDICINE, 100, 28, (2021); DENG Y., ZOU W., CHEN G., SHANGGUAN S., ZHOU F., JIANG W., LI X., COMPARATIVE STUDIES ON THE EFFECTS OF DIFFERENT DOSES OF ATORVASTATIN COMBINED WITH ASPIRIN ON INFLAMMATORY CYTOKINES AND CAROTID PLAQUES IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR DISEASE, INT. J. NEUROSCI, 129, 11, PP. 1133-1138, (2019); TAN Q., ZHANG S., ZOU X., ZHAO J., HAO J., SUN Q., FLU-VASTATIN THERAPY COULD NOT DECREASE PROGRESSION OF PAROXYS-MAL ATRIAL FIBRILLATION IN NON-VALVULAR DISEASE PATIENTS, ANA-TOL. J. CARDIOL, 18, 2, PP. 103-107, (2017); SEBESTJEN M., KEBER I., ZEGURA B., SIMCIC S., BOZIC M., FRESSART M.M., STEGNAR M., STATIN AND FIBRATE TREATMENT OF COMBINED HYPERLIPIDEMIA: THE EFFECTS ON SOME NOVEL RISK FACTORS, THROMB. HAEMOST, 92, 5, PP. 1129-1135, (2004); PLAYFORD D.A., WATTS G.F., CROFT K.D., BURKE V., COM-BINED EFFECT OF COENZYME Q10 AND FENOFIBRATE ON FOREARM MICROCIRCULATORY FUNCTION IN TYPE 2 DIABETES, ATHEROSCLE-ROSIS, 168, 1, PP. 169-179, (2003); NIAFAR M, BAHRAMI A, LOTFI YAGIN N, NAJAFIPOUR F, AGHAMOHAMMADZADEH N, SADRA V., EFFECT OF HIGH DOSE VERSUS LOW DOSE OF ATORVASTATIN THERAPY ON INFLAMMATION AND COAGULATION FACTORS IN TYPE 2 DIABETIC PATIENTS; A RANDOMIZED CLINICAL TRIAL STUDY, IMMUNOPATHOL PERSA, 5, 1, (2019); KRYSIAK R., GILOWSKI W., OKOPIEN B., THE EFFECT OF TES-TOSTERONE AND FENOFIBRATE, ADMINISTERED ALONE OR IN COMBI-NATION, ON CARDIOMETABOLIC RISK FACTORS IN MEN WITH LATE-ONSET HYPOGONADISM AND ATHEROGENIC DYSLIPIDEMIA, CARDIO-VASC. THER, 33, 5, PP. 270-274, (2015); WESTPHAL S., DIERKES J., LULEY C., EFFECTS OF FENOFIBRATE AND GEMFIBROZIL ON PLASMA HOMOCYSTEINE, LANCET, 358, 9275, PP. 39-40, (2001); CARRERO J.J., LOPEZ-HUERTAS E., SALMERON L.M., RAMOS V.E., BARO L., ROS E., SIMVASTATIN AND SUPPLEMENTATION WITH Ω-3 POLYUNSATURATED FATTY ACIDS AND VITAMINS IMPROVES CLAUDICATION DISTANCE IN A RANDOMIZED PILOT STUDY IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE, NUTR. RES, 26, 12, PP. 637-643, (2006); GIRAL P., BRUCKERT E., JACOB N., CHAPMAN M.J., FOGLIET-TI M.J., TURPIN G., HOMOCYSTEINE AND LIPID LOWERING AGENTS. A COMPARISON BETWEEN ATORVASTATIN AND FENOFIBRATE IN PATIENTS WITH MIXED HYPERLIPIDEMIA, ATHEROSCLEROSIS, 154, 2, PP. 421-427, (2001); HARATS D., YODFAT O., DOOLMAN R., GAVENDO S., MARKO D., SHAISH A., SELA B.A., HOMOCYSTEINE ELEVATION WITH FI-BRATES: IS IT A CLASS EFFECT?, ISR. MED. ASSOC. J, 3, 4, PP. 243-246, (2001); HERRMANN M., WHITING M.J., VEILLARD A.S., EHNHOLM C., SULLIVAN D.R., KEECH A.C., PLASMA HOMOCYSTEINE AND THE RISK OF VENOUS THROMBOEMBOLISM: INSIGHTS FROM THE FIELD STUDY, CLIN. CHEM. LAB. (CCLM), 50, 12, PP. 2213-2219, (2012); KAYA C., CENGIZ S.D., BERKER B., DEMIRTAS S., CESUR M., ERDOGAN G., COMPARATIVE EFFECTS OF ATORVASTATIN AND SIMVASTATIN ON THE PLASMA TOTAL HOMOCYSTEINE LEVELS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PROSPECTIVE RANDOMIZED STUDY, FERTIL. STERIL, 92, 2, PP. 635-642, (2009); LU T.M., DING Y.A., LEU H.B., YIN W.H., SHEU W.H.H., CHU K.M., EFFECT OF ROSUVASTATIN ON PLASMA LEVELS OF ASYMMETRIC DIMETHYLARGININE IN PATIENTS WITH HYPERC-HOLESTEROLEMIA, AM. J. CARDIOL, 94, 2, PP. 157-161, (2004); MELENOVSKY V., MALIK J., WICHTERLE D., SIMEK J., PISARIKOVA A., SKRHA J., POLEDNE R., STAVEK P., CESKA R., COMPARISON OF THE EFFECTS OF ATORVASTATIN OR FENOFIBRATE ON NONLIPID BIOCHEMICAL RISK FACTORS AND THE LDL PARTICLE SIZE IN SUBJECTS WITH COMBINED HYPERLIPIDEMIA, AM. HEART J, 144, 4, (2002); SANTINI E., MADEC S., CORRETTI V., FERRANNINI E., SOLINI A., EFFECT OF STATINS ON SOLUBLE CD40 LIGAND IN HYPERCHOLES-TEROLEMIC TYPE 2 DIABETIC PATIENTS, J. ENDOCRINOL. INVEST, 31, 7, PP. 660-665, (2008); SYVANNE M., WHITTALL R.A., TURPEINEN U., NIEMINEN M.S., FRICK M.H., KESANIEMI Y.A., PASTERNACK A., HUM-PHRIES S.E., TASKINEN M.R., SERUM HOMOCYSTEINE CONCEN-TRATIONS, GEMFIBROZIL TREATMENT, AND PROGRESSION OF CORONARY ATHEROSCLEROSIS, ATHEROSCLEROSIS, 172, 2, PP. 267-272, (2004); VIGNA G.B., DONEGA P., ZANCA R., BARBAN A., PASSARO A., PANSINI F., BONACCORSI G., MOLLICA G., FELLIN R., SIM-VASTATIN, TRANSDERMAL PATCH, AND ORAL ESTROGEN-PROGESTOGEN PREPARATION IN EARLY-POSTMENOPAUSAL HYPERCHOLESTEROLEMIC WOMEN: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL, METABOLISM, 51, 11, PP. 1463-1470, (2002); VLADIMIROVA-KITOVA L.G., DENEVA T.I., MARINOV B., EFFECT OF MODERATE AND HIGH-DOSE SIMVASTATIN ON ASYMMETRIC DIMETHYLARGININE-HOMOCYSTEINE METABOLIC PATHWAYS IN PATIENTS WITH NEWLY DETECTED SEVERE HYPERCHOLESTEROLEMIA, CARDIOVASC. THER, 29, 5, PP. 340-348, (2011); HAAK E., ABLETSHAUSER C., WEBER S., GOEDICKE C., MARTIN N., HERMANNS N., LACKNER K., KUSTERER K., US-ADEL K.H., HAAK T., FLUVASTATIN THERAPY IMPROVES MICROCIR-CULATION IN PATIENTS WITH HYPERLIPIDAEMIA, ATHEROSCLEROSIS, 155, 2, PP. 395-401, (2001); DEROSA G., MAFFIOLI P., SALVADEO S.A.T., FERRARI I., GRAV-INA A., MEREU R., PALUMBO I., D'ANGELO A., CICERO A.F.G., FENOFIBRATE, SIMVASTATIN AND THEIR COMBINATION IN THE MANAGEMENT OF DYSLIPIDAEMIA IN TYPE 2 DIABETIC PA-TIENTS, CURR. MED. RES. OPIN, 25, 8, PP. 1973-1983, (2009); DAVIDSON M.H., ROONEY M.W., DRUCKER J., EUGENE GRIFFIN H., OOSMAN S., BECKERT M., EFFICACY AND TOLERABIL-ITY OF ATORVASTATIN/FENOFIBRATE FIXED-DOSE COMBINATION TABLET COMPARED WITH ATORVASTATIN AND FENOFIBRATE MONOTHERAPIES IN PATIENTS WITH DYSLIPIDEMIA: A 12-WEEK, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY, CLIN. THER, 31, 12, PP. 2824-2838, (2009); FENG T., HUANG X., LIANG Q., LIANG Y., YUAN Y., FENG L., WU W., XIAO X., HAN Y., EFFECTS OF PITAVASTATIN ON LIPID-RICH CAROTID PLAQUES STUDIED USING HIGH-RESOLUTION MAGNETIC RESONANCE IMAGING, CLIN. THER, 39, 3, PP. 620-629, (2017); ISHIBASHI S., ARAI H., YOKOTE K., ARAKI E., SUGANAMI H., YAMASHITA S., EFFICACY AND SAFETY OF PEMAFIBRATE (K-877), A SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Α MODULATOR, IN PATIENTS WITH DYSLIPIDEMIA: RESULTS FROM A 24-WEEK, RANDOMIZED, DOUBLE BLIND, ACTIVE-CON-TROLLED, PHASE 3 TRIAL, J. CLIN. LIPIDOL, 12, 1, PP. 173-184, (2018); KIM D.W., KIM H.K., BAE E.K., THE EFFECTS OF LIFESTYLE MODIFICATION AND STATIN THERAPY ON THE CIRCULATORY MARKERS FOR VASCULAR RISK IN PATIENTS WITH EPILEPSY, EPILEPSY BEHAV, 76, PP. 133-135, (2017); LEE S.H., CHO K.I., KIM J.Y., AHN Y.K., RHA S.W., KIM Y.J., CHOI Y.S., CHOI S.W., JEON D.W., MIN P.K., CHOI D.J., BAEK S.H., KIM K.S., BYUN Y.S., JANG Y., NON-LIPID EFFECTS OF ROSUVASTATIN–FENOFIBRATE COMBINATION THERAPY IN HIGH-RISK ASIAN PATIENTS WITH MIXED HYPERLIPI-DEMIA, ATHEROSCLEROSIS, 221, 1, PP. 169-175, (2012); WANG G., HE L., LIU J., YU J., FENG X., LI F., HAO Y., MAO J., HONG T., CHEN A.F., WANG X., CORONARY FLOW VE-LOCITY RESERVE IS IMPROVED BY PPAR-Α AGONIST FENOFIBRATE IN PATIENTS WITH HYPERTRIGLYCERIDEMIA, CARDIOVASC. THER, 31, 3, PP. 161-167, (2013); WANG H., ZHANG Z., SUN J., THE CLINICAL EVALUATION OF COMBINED DETECTION OF MICROCIRCULATION, LIPID METABOLISM, AND INFLAMMATORY-RELATED FACTORS IN THE TREATMENT OF DIABETIC NEPHROPATHY WITH ATORVASTATIN, EUR. J. INFLAMM, 17, (2019); CHEN W., TIAN T., WANG S., XUE Y., SUN Z., WANG S., CHARACTERISTICS OF CAROTID ATHEROSCLEROSIS IN ELDERLY PATIENTS WITH TYPE 2 DIABETES AT DIFFERENT DISEASE COURSE, AND THE INTERVENTION BY STATINS IN VERY ELDERLY PATIENTS, J. DIABETES IN-VESTIG, 9, 2, PP. 389-395, (2018); DE LORGERIL M., SALEN P., PAILLARD F., LACAN P., RICHARD G., LIPID-LOWERING DRUGS AND HOMOCYSTEINE, LANCET, 353, 9148, PP. 209-210, (1999); ANSQUER J.C., DALTON R.N., CAUSSE E., CRIMET D., LE MALICOT K., FOUCHER C., EFFECT OF FENOFIBRATE ON KIDNEY FUNCTION: A 6-WEEK RANDOMIZED CROSSOVER TRIAL IN HEALTHY PEOPLE, AM. J. KIDNEY DIS, 51, 6, PP. 904-913, (2008); WUSTMANN K., KLAEY M., BUROW A., SHAW S.G., HESS O.M., ALLEMANN Y., ADDITIVE EFFECT OF HOMOCYSTEINE-AND CHOLESTEROL-LOWERING THERAPY ON ENDOTHELIUM-DEPENDENT VA-SODILATION IN PATIENTS WITH CARDIOVASCULAR DISEASE, CARDIO-VASC. THER, 30, 5, PP. 277-286, (2012); CHONG P.H., SEEGER J.D., FRANKLIN C., CLINICALLY RELEVANT DIFFERENCES BETWEEN THE STATINS: IMPLICATIONS FOR THERAPEU-TIC SELECTION, AM. J. MED, 111, 5, PP. 390-400, (2001); PODDAR R., SIVASUBRAMANIAN N., DIBELLO P.M., ROBIN-SON K., JACOBSEN D.W., HOMOCYSTEINE INDUCES EXPRESSION AND SECRETION OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND INTERLEUKIN-8 IN HUMAN AORTIC ENDOTHELIAL CELLS: IMPLICATIONS FOR VASCULAR DISEASE, CIRCULATION, 103, 22, PP. 2717-2723, (2001); ZENG X., GUAN Y., REMICK D.G., WANG X., SIGNAL PATHWAYS UNDERLYING HOMOCYSTEINE-INDUCED PRODUCTION OF MCP-1 AND IL-8 IN CULTURED HUMAN WHOLE BLOOD, ACTA PHARMACOL. SIN, 26, 1, PP. 85-91, (2005); CAI T., ABEL L., LANGFORD O., MONAGHAN G., ARONSON J.K., STEVENS R.J., LAY-FLURRIE S., KOSHIARIS C., MC-MANUS R.J., HOBBS F.D.R., SHEPPARD J.P., ASSOCIATIONS BETWEEN STATINS AND ADVERSE EVENTS IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: SYSTEMATIC REVIEW WITH PAIRWISE, NETWORK, AND DOSE-RESPONSE META-ANALYSES, BMJ, 374, 1537, (2021); KOUSHKI K., SHAHBAZ S.K., MASHAYEKHI K., SADEGHI M., ZAYERI Z.D., TABA M.Y., BANACH M., AL-RASADI K., JOHN-STON T.P., SAHEBKAR A., ANTI-INFLAMMATORY ACTION OF STATINS IN CARDIOVASCULAR DISEASE: THE ROLE OF INFLAMMA-SOME AND TOLL-LIKE RECEPTOR PATHWAYS, CLIN. REV. ALLERGY IMMUNOL, 60, 2, PP. 175-199, (2021); BAHRAMI A., PARSAMANESH N., ATKIN S.L., BANACH M., SAHEBKAR A., EFFECT OF STATINS ON TOLL-LIKE RECEPTORS: A NEW INSIGHT TO PLEIOTROPIC EFFECTS, PHARMACOL. RES, 135, PP. 230-238, (2018); KHALIFEH M., PENSON P., BANACH M., SAHEBKAR A., STATINS AS ANTI-PYROPTOTIC AGENTS, ARCH. MED. SCI, 17, 5, PP. 1414-1417, (2021); 34522271 SHAKOUR N., RUSCICA M., HADIZADEH F., CIRTORI C., BA-NACH M., JAMIALAHMADI T., SAHEBKAR A., STATINS AND C-RE-ACTIVE PROTEIN: IN SILICO EVIDENCE ON DIRECT INTERACTION, ARCH. MED. SCI, 16, 6, PP. 1432-1439, (2020); MORITA H., SAITO Y., OHASHI N., YOSHIKAWA M., KATOH M., ASHIDA T., KURIHARA H., NAKAMURA T., KURABAYASHI M., NAGAI R., FLUVASTATIN AMELIORATES THE HYPERHOMOCYS-TEINEMIA-INDUCED ENDOTHELIAL DYSFUNCTION: THE ANTIOXIDA-TIVE PROPERTIES OF FLUVASTATIN, CIRC. J, 69, 4, PP. 475-480, (2005); SAHEBKAR A., PECIN I., TEDESCHI-REINER E., DEROSA G., MAFFIOLI P., REINER Z., EFFECTS OF STATIN THERAPY ON AUGMEN-TATION INDEX AS A MEASURE OF ARTERIAL STIFFNESS: A SYSTEMATIC REVIEW AND META-ANALYSIS, INT. J. CARDIOL, 212, PP. 160-168, (2016); REDFEARN D.P., TRIM G.M., SKANES A.C., PETRELLIS B., KRAHN A.D., YEE R., KLEIN G.J., ESOPHAGEAL TEMPERATURE MONITORING DURING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLA-TION, J. CARDIOVASC. ELECTROPHYSIOL, 16, 6, PP. 589-593, (2005); SCHROECKSNADEL K., FRICK B., WINKLER C., WIRLEITNER B., WEISS G., FUCHS D., ATORVASTATIN SUPPRESSES HOMOCYS-TEINE FORMATION IN STIMULATED HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS, CLIN. CHEM. LAB. MED, 43, 12, PP. 1373-1376, (2005); AMIOKA N., MIYOSHI T., FIBRATES: A POSSIBLE TREATMENT OP-TION FOR PATIENTS WITH ABDOMINAL AORTIC ANEURYSM?, BIO-MOLECULES, 12, 1, (2022); INOUE I., GOTO S., MATSUNAGA T., NAKAJIMA T., AWATA T., HOKARI S., KOMODA T., KATAYAMA S., THE LIGANDS/ACTI-VATORS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Α (P-PARΑ) AND PPARΓ INCREASE CU<SUP>2+</SUP>, ZN<SUP>2+</SUP>-SUPEROXIDE DISMU-TASE AND DECREASE P22PHOX MESSAGE EXPRESSIONS IN PRIMARY ENDOTHELIAL CELLS, METABOLISM, 50, 1, PP. 3-11, (2001); ZINELLU A., MANGONI A.A., A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECT OF STATINS ON GLUTATHIONE PEROXIDASE, SUPEROXIDE DISMUTASE, AND CATALASE, ANTIOXIDANTS, 10, 11, (2021); MORILLAS-RUIZ J.M., RUBIO-PEREZ J.M., ALBALADEJO M.D., ZAFRILLA P., PARRA S., VIDAL-GUEVARA M.L., EFFECT OF AN AN-TIOXIDANT DRINK ON HOMOCYSTEINE LEVELS IN ALZHEIMER’S PA-TIENTS, J. NEUROL. SCI, 299, 1-2, PP. 175-178, (2010); PENG X., GAO Q., ZHOU J., MA J., ZHAO D., HAO L., ASSOCIATION BETWEEN DIETARY ANTIOXIDANT VITAMINS INTAKE AND HOMOCYSTEINE LEVELS IN MIDDLE-AGED AND OLDER ADULTS WITH HYPERTENSION: A CROSS-SECTIONAL STUDY, BMJ OPEN, 11, 10, (2021); GOUEDARD C., KOUM-BESSON N., BAROUKI R., MOREL Y., OPPOSITE REGULATION OF THE HUMAN PARAOXONASE-1 GENE PON-1 BY FENOFIBRATE AND STATINS, MOL. PHARMACOL, 63, 4, PP. 945-956, (2003); FOUCHER C., BRUGERE L., ANSQUER J.C., FENOFIBRATE, HOMO-CYSTEINE AND RENAL FUNCTION, CURR. VASC. PHARMACOL, 8, 5, PP. 589-603, (2010); HADJIVASILIS A., KOUIS P., KOUSIOS A., PANAYIOTOU A., THE EFFECT OF FIBRATES ON KIDNEY FUNCTION AND CHRONIC KIDNEY DISEASE PROGRESSION: A SYSTEMATIC REVIEW AND META-A-NALYSIS OF RANDOMISED STUDIES, J. CLIN. MED, 11, 3, (2022); GOFFIN E., JAMAR F., DESAGER J.P., DEVUYST O., IMPLICA-TION OF FIBRATE THERAPY FOR HOMOCYSTEINE, LANCET, 354, 9185, (1999); ZHANG Z., GU X., FANG X., TANG Z., GUAN S., LIU H., WU X., WANG C., ZHAO Y., HOMOCYSTEINE AND THE RISK OF CARDIOVASCULAR EVENTS AND ALL-CAUSE DEATH IN ELDERLY POPULA-TION: A COMMUNITY-BASED PROSPECTIVE COHORT STUDY, THER. CLIN. RISK MANAG, 16, PP. 471-481, (2020); HUO Y., LI J., QIN X., HUANG Y., WANG X., GOTTESMAN R.F., TANG G., WANG B., CHEN D., HE M., FU J., CAI Y., SHI X., ZHANG Y., CUI Y., SUN N., LI X., CHENG X., WANG J., YANG X., YANG T., XIAO C., ZHAO G., DONG Q., ZHU D., WANG X., GE J., ZHAO L., HU D., LIU L., HOU F.F., EFFICACY OF FOLIC ACID THERAPY IN PRIMARY PREVENTION OF STROKE AMONG ADULTS WITH HYPERTENSION IN CHINA: THE CSPPT RANDOMIZED CLINICAL TRIAL, JAMA, 313, 13, PP. 1325-1335, (2015); BLAIS J.E., TONG G.K.Y., PATHADKA S., MOK M., WONG I.C.K., CHAN E.W., COMPARATIVE EFFICACY AND SAFETY OF STATIN AND FIBRATE MONOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIALS, PLOS ONE, 16, 2, (2021); TERRA S.G., FRANCONE O.L., CONTANT C.F., GAO X., LEWIN A.J., NGUYEN T.T., EFFICACY AND SAFETY OF A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AL-PHA AGONIST IN SUBJECTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, AM. J. CARDIOL, 102, 4, PP. 434-439, (2008)","A. SAHEBKAR; APPLIED BIOMEDICAL RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN; EMAIL: AMIR_SAHEB2000@YAHOO.COM","BENTHAM SCIENCE PUBLISHERS","ENGLISH","CURR. MED. CHEM.","REVIEW","ISI","2-S2.0-85185510357","CURR MED CHEM","MASHHAD UNIVERSITY OF MEDICAL SCIENCES;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;MASHHAD UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"AKBARI A, 2024, CURR MED CHEM","AKBARI A, 2024, CURR MED CHEM"
"CHO K;KIM J;LEE M;BAHUGUNA A","CHO, KYUNG-HYUN (7403956966); KIM, JI-EUN (57881093800); LEE, MYEONG-SUNG (58848437800); BAHUGUNA, ASHUTOSH (35224624000)","CUBAN POLICOSANOL RAYDEL EXERTS HIGHER ANTIOXIDANT AND ANTIGLYCATION ACTIVITIES THAN CHINESE POLICOSANOL BOC SCIENCES IN RECONSTITUTED HIGHDENSITY LIPOPROTEINS IN VIVO ANTIINFLAMMATORY ACTIVITIES IN ZEBRAFISH AND ITS EMBRYOS",2024,"PHARMACEUTICALS","17","",0,"10.3390/ph17040406","RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA;RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA","THE PRESENT STUDY COMPARES SUGARCANE-WAX PURIFIED POLICOSANOLS SOURCED FROM CUBA (RAYDEL®) AND CHINA (BOC SCIENCES) AND UTILIZED FOLLOWING THE SYNTHESIS OF RECONSTITUTED HIGH-DENSITY LIPOPROTEINS (RHDL). THE TWO POLICOSANOLS EXHIBITED DISTINCTLY DIFFERENT INGREDIENT RATIOS OF LONG-CHAIN ALIPHATIC ALCOHOLS, PARTICULARLY 1-OCTACOSANOL (C28) AND 1-TETRATRIACOTANOL (C34). AFTER SYNTHESIZING RHDL WITH APOLIPOPROTEIN A-I (APOA-I), THE TWO POLICOSANOLS BOUND WELL WITH PHOSPHOLIPID AND APOA-I TO FORM THE DISCOIDAL RHDL. NOTABLY, RHDL-1, CONTAINING CUBAN POLICOSANOL, DISPLAYED THE LARGEST PARTICLE DIAMETER AT APPROXIMATELY 78 ± 3 NM. IN CONTRAST, BOTH CONTROL RHDL (RHDL-0) AND RHDL CONTAINING CHINESE POLICOSANOL (RHDL-2) EXHIBITED SMALLER PARTICLES, WITH DIAMETERS OF APPROXIMATELY 58 ± 3 NM AND 61 ± 2 NM, RESPECTIVELY. FURTHERMORE, RHDL-1 DEMONSTRATED ENHANCED ANTI-GLYCATION ACTIVITY, SAFEGUARDING APOA-I FROM DEGRADATION WITHIN HDL, AND DISPLAYED THE ANTIOXIDANT ABILITY TO INHIBIT LDL OXIDATION. A MICROINJECTION OF EACH RHDL INTO ZEBRAFISH EMBRYOS IN THE PRESENCE OF CARBOXYMETHYLLYSINE (CML) REVEALED RHDL-1 TO HAVE THE STRONGEST ANTIOXIDANT ACTIVITY WITH THE HIGHEST EMBRYO SURVIVABILITY AND NORMAL DEVELOPMENTAL MORPHOLOGY. DERMAL APPLICATION TO RECOVER THE WOUND REVEALED RHDL-1 TO HAVE THE HIGHEST WOUND-HEALING ACTIVITY (75%) AND SURVIVABILITY (92%) IN THE CUTANEOUS WOUND AREA IN THE PRESENCE OF CML. IN ADULT ZEBRAFISH, INJECTING CML (250 ΜG) CAUSED ACUTE DEATH AND HYPERINFLAMMATION, MARKED BY HEIGHTENED NEUTROPHIL INFILTRATION AND INTERLEUKIN (IL)-6 PRODUCTION IN LIVER. HOWEVER, CO-ADMINISTERING RHDL-1 NOTABLY INCREASED SURVIVAL (85%) AND EXHIBITED STRONG ANTI-INFLAMMATORY PROPERTIES, REDUCING IL-6 PRODUCTION WHILE IMPROVING THE BLOOD LIPID PROFILE. HOWEVER, A CO-INJECTION OF RHDL-2 RESULTED IN THE LOWEST SURVIVABILITY (47%) WITH MORE HEPATIC INFLAMMATION. IN CONCLUSION, CUBAN POLICOSANOL (RAYDEL®) HAS MORE DESIRABLE PROPERTIES FOR THE IN VITRO SYNTHESIS OF RHDL WITH STRONGER ANTI-GLYCATION AND ANTIOXIDANT ACTIVITIES THAN THOSE OF CHINESE POLICOSANOL (BOC SCIENCES). MOREOVER, RAYDEL-POLICOSANOL-INTEGRATED RHDL DEMONSTRATES A NOTEWORTHY EFFECT ON ACCELERATED WOUND HEALING AND ROBUST ANTI-INFLAMMATORY PROPERTIES, LEADING TO INCREASED SURVIVABILITY IN ZEBRAFISH EMBRYOS AND ADULTS BY EFFECTIVELY SUPPRESSING CML-INDUCED HYPERINFLAMMATION. © 2024 BY THE AUTHORS.","APOLIPOPROTEIN A-I (APOA-I); APOPTOSIS; CARBOXYMETHYLLYSINE (CML); INTERLEUKIN (IL)-6; NEUROTOXICITY; OXIDATIVE STRESS; TRANSMISSION ELECTRON MICROSCOPY (TEM); WOUND HEALING","1 OCTACOSANOL; 1 TETRATRIACOTANOL; 6 N CARBOXYMETHYLLYSINE; ALANINE AMINOTRANSFERASE; ANTIGLYCATION AGENT; APOLIPOPROTEIN A; CHEMICAL COMPOUND; DOTRIACOTANOL; HEPTACOSANOL; HEXACOSANOL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; NONACOSANOL; OCTACOSANOL; POLICOSANOL; TETRATRIACOTANOL; TRIACOTANOL; UNCLASSIFIED DRUG; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; CUBAN; EMBRYO; GLYCATION; HISTOLOGY; HYPERINFLAMMATION; IMMUNOHISTOCHEMISTRY; LIPID FINGERPRINTING; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEIZURE; SWIMMING TIME; THREE-DIMENSIONAL IMAGING; TRANSMISSION ELECTRON MICROSCOPY; WOUND HEALING; WOUND INFECTION; ZEBRA FISH","NATIONAL CENTER FOR SCIENTIFIC RESEARCH; COMPUTER NETWORK INFORMATION CENTER, CHINESE ACADEMY OF SCIENCES, CNIC; BOC SCIENCES","THE CUBAN POLICOSANOL (PCL-1) WAS PROVIDED BY THE NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC, HAVANA, CUBA), WHEREAS THE CHINESE ORIGIN POLICOSANOL (PCL-2) WAS PROCURED FROM BOC SCIENCES (SHIRLEY, NY, USA). BOTH POLICOSANOLS WERE EXTRACTED FROM SUGARCANE WAX. ALL OTHER CHEMICALS WERE OF ANALYTICAL GRADE AND USED AS SUPPLIED. DETAILED MATERIALS ARE LISTED IN THE . ","YANG Y., HAN K., PARK S.H., KIM M.K., YOON K.-H., LEE S.-H., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND THE RISK OF MYOCARDIAL INFARCTION, STROKE, AND CAUSE-SPECIFIC MORTALITY: A NATIONWIDE COHORT STUDY IN KOREA, J. LIPID ATHEROSCLER, 10, (2021); ZULIANI G., CAVALIERI M., GALVANI M., VOLPATO S., CHERUBINI A., BANDINELLI S., CORSI A., LAURETANI F., GURALNIK J., FELLIN R., RELATIONSHIP BETWEEN LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND DEMENTIA IN THE ELDERLY. THE INCHIANTI STUDY, J. GERONTOL. B-PSYCHOL, 65, PP. 559-564, (2010); HAMER M., O'DONOVAN G., STAMATAKIS E., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND MORTALITY: TOO MUCH OF A GOOD THING?, ARTERIOSCLER. THROMB. VASC. BIOL, 38, PP. 669-672, (2018); CHO Y.K., JUNG C.H., HDL-C AND CARDIOVASCULAR RISK: YOU DON’T NEED TO WORRY ABOUT EXTREMELY HIGH HDL-C LEVELS, J. LIPID ATHEROSCLER, 10, (2021); BONIZZI A., PIURI G., CORSI F., CAZZOLA R., MAZZUCCHELLI S., HDL DYSFUNCTIONALITY: CLINICAL RELEVANCE OF QUALITY RATHER THAN QUANTITY, BIOMEDICINES, 9, (2021); LIM S.-M., YOO J.-A., LEE E.-Y., CHO K.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); PARK H.-J., YADAV D., JEONG D.-J., KIM S.-J., BAE M.-A., KIM J.-R., CHO K.-H., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT. J. ENVIRON. RES. PUBLIC HEALTH, 16, (2019); CHO K.-H., NAM H.-S., BAEK S.-H., KANG D.-J., NA H., KOMATSU T., UEHARA Y., BENEFICIAL EFFECT OF CUBAN POLICOSANOL ON BLOOD PRESSURE AND SERUM LIPOPROTEINS ACCOMPANIED WITH LOWERED GLYCATED HEMOGLOBIN AND ENHANCED HIGH-DENSITY LIPOPROTEIN FUNCTIONALITIES IN A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED TRIAL WITH HEALTHY JAPANESE, INT. J. MOL. SCI, 24, (2023); CHO K.-H., KIM J.-E., KOMATSU T., UEHARA Y., PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED, PLACEBO-CONTROLLED, AND DOUBLE-BLINDED STUDY WITH HEALTHY AND MIDDLE-AGED JAPANESE PARTICIPANTS, LIFE, 13, (2023); SHARMA R., MATSUZAKA T., KAUSHIK M.K., SUGASAWA T., OHNO H., WANG Y., MOTOMURA K., SHIMURA T., OKAJIMA Y., MIZUNOE Y., OCTACOSANOL AND POLICOSANOL PREVENT HIGH-FAT DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM, SCI. REP, 9, (2019); CHO K.-H., KIM J.-E., NAM H.-S., KANG D.-J., BAEK S.-H., COMPARISON OF POLICOSANOLS VIA INCORPORATION INTO RECONSTITUTED HIGH-DENSITY LIPOPROTEINS: CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) EXERTS THE HIGHEST ANTIOXIDANT, ANTI-GLYCATION, AND ANTI-INFLAMMATORY ACTIVITY, MOLECULES, 28, (2023); CHO K.-H., BAEK S.H., NAM H.-S., KIM J.-E., KANG D.-J., NA H., ZEE S., CUBAN SUGAR CANE WAX ALCOHOL EXHIBITED ENHANCED ANTIOXIDANT, ANTI-GLYCATION AND ANTI-INFLAMMATORY ACTIVITY IN RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) WITH IMPROVED STRUCTURAL AND FUNCTIONAL CORRELATIONS: COMPARISON OF VARIOUS POLICOSANOLS, INT. J. MOL. SCI, 24, (2023); CHO K.-H., KIM J.-E., BAEK S.H., CUBAN POLICOSANOL (RAYDEL<SUP>®</SUP>) POTENTLY PROTECTS THE LIVER, OVARY, AND TESTIS WITH AN IMPROVEMENT IN DYSLIPIDEMIA IN HYPERLIPIDEMIC ZEBRAFISH: A COMPARATIVE STUDY WITH THREE CHINESE POLICOSANOLS, MOLECULES, 28, (2023); CHO K.-H., KIM J.-E., NAM H.-S., BAEK S.-H., BAHUGUNA A., CONSUMPTION OF POLICOSANOL (RAYDEL<SUP>®</SUP>) IMPROVES HEPATIC, RENAL, AND REPRODUCTIVE FUNCTIONS IN ZEBRAFISH: IN VIVO COMPARISON STUDY AMONG CUBAN, CHINESE, AND AMERICAN POLICOSANOL, PHARMACEUTICALS, 17, (2023); KIM K.-M., LIM Y.-J., JANG W.-G., POLICOSANOL STIMULATES OSTEOBLAST DIFFERENTIATION VIA ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE-MEDIATED EXPRESSION OF INSULIN-INDUCED GENES 1 AND 2, CELLS, 12, (2023); KIM K.M., KIM C.H., CHO K.-H., JANG W.G., POLICOSANOL ATTENUATES PI-INDUCED CALCIFICATION VIA AMPK-MEDIATED INSIGS EXPRESSION IN RAT VSMCS, CLIN. EXP. PHARMACOL. PHYSIOL, 48, PP. 1336-1345, (2021); ZHENG W., LI H., GO Y., CHAN X.H., HUANG Q., WU J., RESEARCH ADVANCES ON THE DAMAGE MECHANISM OF SKIN GLYCATION AND RELATED INHIBITORS, NUTRIENTS, 14, (2022); TREDE N.S., ZAPATA A., ZON L.I., FISHING FOR LYMPHOID GENES, TRENDS IMMUNOL, 22, PP. 302-307, (2001); NOVOA B., BOWMAN T., ZON L., FIGUERAS A., LPS RESPONSE AND TOLERANCE IN THE ZEBRAFISH (DANIO RERIO), FISH SHELLFISH IIMMUNOL, 26, PP. 326-331, (2009); KIM J., KIM S., CHOI W.J., NON-INVASIVE MONITORING OF CUTANEOUS WOUND HEALING IN NON-DIABETIC AND DIABETIC MODEL OF ADULT ZEBRAFISH USING OCT ANGIOGRAPHY, BIOENGINEERING, 10, (2023); GEMBERLING M., BAILEY T.J., HYDE D.R., POSS K.D., THE ZEBRAFISH AS A MODEL FOR COMPLEX TISSUE REGENERATION, TRENDS GENET, 29, PP. 611-620, (2013); ZANANDREA R., BONAN C.D., CAMPOS M.M., ZEBRAFISH AS A MODEL FOR INFLAMMATION AND DRUG DISCOVERY, DRUG DISCOV. TODAY, 25, PP. 2201-2211, (2020); BELO M.A., OLIVEIRA M.F., OLIVEIRA S.L., ARACATI M.F., RODRIGUES L.F., COSTA C.C., CONDE G., GOMES J.M., PRATA M.N., BARRA A., ZEBRAFISH AS A MODEL TO STUDY INFLAMMATION: A TOOL FOR DRUG DISCOVERY, BIOMED. PHARMACOTHER, 144, (2021); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS” VERSUS GENUINE POLICOSANOL, REV. CENIC CIENC. QUÍMICAS, 38, PP. 207-213, (2007); LIU L., LI X., DONG G., ZHANG H., TAO Y.-F., HE R., XU J., MA J., TANG B., ZHOU B., BIOINSPIRED NATURAL SHELLAC DRESSING FOR RAPID WOUND SEALING AND HEALING, ACS APPL. MATER. INTERFACES, 15, PP. 43294-43308, (2023); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); HARRABI S., FERCHICHI A., FELLAH H., FEKI M., HOSSEINIAN F., CHEMICAL COMPOSITION AND IN VITRO ANTI-INFLAMMATORY ACTIVITY OF WHEAT GERM OIL DEPENDING ON THE EXTRACTION PROCEDURE, J. OLEO SCI, 70, PP. 1051-1058, (2021); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS HEALTH DIS, 17, (2018); GIUFFRE A.M., CAPOCASALE M., POLICOSANOL IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, J. OLEO SCI, 64, PP. 625-631, (2015); JOHNS D.G., DUFFY J., FISHER T., HUBBARD B.K., FORREST M.J., ON-AND OFF-TARGET PHARMACOLOGY OF TORCETRAPIB: CURRENT UNDERSTANDING AND IMPLICATIONS FOR THE STRUCTURE ACTIVITY RELATIONSHIPS (SAR), DISCOVERY AND DEVELOPMENT OF CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS, DRUGS, 72, PP. 491-507, (2012); TALL A.R., RADER D.J., TRIALS AND TRIBULATIONS OF CETP INHIBITORS, CIRC. RES, 122, PP. 106-112, (2018); GHOLAMREZAYI A., AMINI M.R., RASAEI N., AKHGARJAND C., KALANTAR Z., ASKARI G., HEKMATDOOST A., WHAT IS THE INFLUENCE OF POLICOSANOL SUPPLEMENTATION ON LIVER ENZYMES? A SYSTEMATIC REVIEW AND DOSE-RESPONSE META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, COMPLEMENT. THER. MED, 80, (2024); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVESTIG, 34, PP. 1345-1353, (1955); MARKWELL M.A.K., HAAS S.M., BIEBER L., TOLBERT N., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM, 87, PP. 206-210, (1978); BREWER H.B., RONAN R., MENG M., BISHOP C., 10 ISOLATION AND CHARACTERIZATION OF APOLIPOPROTEINS AI, A-II, AND A-IV, METHODS IN ENZYMOLOGY, 128, PP. 223-246, (1986); MATZ C.E., JONAS A., MICELLAR COMPLEXES OF HUMAN APOLIPOPROTEIN AI WITH PHOSPHATIDYLCHOLINES AND CHOLESTEROL PREPARED FROM CHOLATE-LIPID DISPERSIONS, J. BIOL. CHEM, 257, PP. 4535-4540, (1982); DAVIDSON W.S., HAZLETT T., MANTULIN W.W., JONAS A., THE ROLE OF APOLIPOPROTEIN AI DOMAINS IN LIPID BINDING, PROC. NATL. ACAD. SCI. USA, 93, PP. 13605-13610, (1996); NOBLE R.P., ELECTROPHORETIC SEPARATION OF PLASMA LIPOPROTEINS IN AGAROSE GEL, J. LIPID RES, 9, PP. 693-700, (1968); ZHANG L., SONG J., CAVIGIOLIO G., ISHIDA B.Y., ZHANG S., KANE J.P., WEISGRABER K.H., ODA M.N., RYE K.-A., POWNALL H.J., MORPHOLOGY AND STRUCTURE OF LIPOPROTEINS REVEALED BY AN OPTIMIZED NEGATIVE-STAINING PROTOCOL OF ELECTRON MICROSCOPY S, J. LIPID RES, 52, PP. 175-184, (2011); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); NUSSLEIN-VOLHARD C., DAHM R., ZEBRAFISH, (2002); PERCIE DU SERT N., HURST V., AHLUWALIA A., ALAM S., AVEY M.T., BAKER M., BROWNE W.J., CLARK A., CUTHILL I.C., DIRNAGL U., THE ARRIVE GUIDELINES 2.0: UPDATED GUIDELINES FOR REPORTING ANIMAL RESEARCH, J. CEREB. BLOOD FLOW METAB, 40, PP. 1769-1777, (2020); NAOMI R., BAHARI H., YAZID M.D., EMBONG H., OTHMAN F., ZEBRAFISH AS A MODEL SYSTEM TO STUDY THE MECHANISM OF CUTANEOUS WOUND HEALING AND DRUG DISCOVERY: ADVANTAGES AND CHALLENGES, PHARMACEUTICALS, 14, (2021); RICHARDSON R.J., PARALLELS BETWEEN VERTEBRATE CARDIAC AND CUTANEOUS WOUND HEALING AND REGENERATION, NPJ REGEN. MED, 3, (2018); BURRIS B., JENSEN N., MOKALLED M.H., ASSESSMENT OF SWIM ENDURANCE AND SWIM BEHAVIOR IN ADULT ZEBRAFISH, J. VIS. EXP, 177, (2021); TEST NO. 203: FISH, ACUTE TOXICITY TESTING, OECD GUIDELINES FOR THE TESTING OF CHEMICALS, SECTION 2, (2019); GEWIESE-RABSCH J., DRUCKER C., MALCHOW S., SCHELLER J., ROSE-JOHN S., ROLE OF IL-6 TRANS-SIGNALING IN CCL4 INDUCED LIVER DAMAGE, BIOCHIM. BIOPHYS. ACTA. MOL. BASIS DIS, 1802, PP. 1054-1061, (2010); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT. GENET, 40, PP. 356-361, (2008); HAYASHI M., SOFUNI T., ISHIDATE M., AN APPLICATION OF ACRIDINE ORANGE FLUORESCENT STAINING TO THE MICRONUCLEUS TEST, MUTAT. RES. LETT, 120, PP. 241-247, (1983)","K.-H. CHO; RAYDEL RESEARCH INSTITUTE, MEDICAL INNOVATION COMPLEX, DAEGU, 41061, SOUTH KOREA; EMAIL: CHOK@RAYDEL.CO.KR","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","PHARMACEUTICALS","ARTICLE","ISI","2-S2.0-85191326179","PHARMACEUTICALS","RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE;RAYDEL RESEARCH INSTITUTE","NOTREPORTED;RAYDEL RESEARCH INSTITUTE;NOTREPORTED",NA,"CHO K-H, 2024, PHARMACEUTICALS","CHO K-H, 2024, PHARMACEUTICALS-a-b"
"CAPRA M;BIASUCCI G;BANDERALI G;VANIA A;PEDERIVA C","CAPRA, MARIA ELENA (57200591334); BIASUCCI, GIACOMO (57202895877); BANDERALI, GIUSEPPE (6602000083); VANIA, ANDREA (6701666901); PEDERIVA, CRISTINA (18134025000)","DIET AND LIPIDLOWERING NUTRACEUTICALS IN PEDIATRIC PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA",2024,"CHILDREN","11","",0,"10.3390/children11020250","CENTRE FOR PEDIATRIC DYSLIPIDEMIAS, PEDIATRICS AND NEONATOLOGY UNIT, UNIVERSITY OF PARMA, GUGLIELMO DA SALICETO HOSPITAL, PIACENZA, 29121, ITALY, DEPARTMENT OF TRANSLATIONAL MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF PARMA, PARMA, 43126, ITALY;CENTRE FOR PEDIATRIC DYSLIPIDEMIAS, PEDIATRICS AND NEONATOLOGY UNIT, UNIVERSITY OF PARMA, GUGLIELMO DA SALICETO HOSPITAL, PIACENZA, 29121, ITALY, DEPARTMENT OF MEDICINE AND SURGERY, UNIVERSITY OF PARMA, PARMA, 43126, ITALY;CLINICAL SERVICE FOR DYSLIPIDEMIAS, STUDY AND PREVENTION OF ATHEROSCLEROSIS IN CHILDHOOD, PEDIATRICS UNIT, ASST-SANTI PAOLO E CARLO, MILAN, 20142, ITALY;INDEPENDENT RESEARCHER, MEMBER OF SINUPE (ITALIAN SOCIETY OF PEDIATRIC NUTRITION) DIRECTORY BOARD, ROME, 00162, ITALY;CLINICAL SERVICE FOR DYSLIPIDEMIAS, STUDY AND PREVENTION OF ATHEROSCLEROSIS IN CHILDHOOD, PEDIATRICS UNIT, ASST-SANTI PAOLO E CARLO, MILAN, 20142, ITALY","FAMILIAL HYPERCHOLESTEROLEMIA IS A GENETICALLY DETERMINED DISEASE CHARACTERIZED BY ELEVATED PLASMA TOTAL AND LDL CHOLESTEROL LEVELS FROM THE VERY FIRST YEARS OF LIFE, LEADING TO EARLY ATHEROSCLEROSIS. NUTRITIONAL INTERVENTION IS THE FIRST-LINE TREATMENT, COMPLEMENTED WITH NUTRACEUTICALS AND DRUG THERAPY WHEN NECESSARY. NUTRACEUTICALS WITH A LIPID-LOWERING EFFECT HAVE BEEN EXTENSIVELY STUDIED IN THE PAST FEW DECADES, AND HAVE BEEN RECENTLY INCLUDED IN INTERNATIONAL GUIDELINES AS A COMPLEMENT TO NUTRITIONAL AND PHARMACOLOGICAL TREATMENT IN SUBJECTS WITH DYSLIPIDEMIA. IN THIS REVIEW, WE EXPLORE CURRENT NUTRITIONAL INTERVENTIONS FOR DYSLIPIDEMIA IN CHILDHOOD, WITH A SPECIFIC FOCUS ON THE MAIN NUTRACEUTICALS STUDIED FOR TREATING SEVERE DYSLIPIDEMIA IN PEDIATRIC PATIENTS. ADDITIONALLY, WE BRIEFLY DESCRIBE THEIR PRIMARY MECHANISMS OF ACTION AND HIGHLIGHT THE ADVANTAGES AND RISKS ASSOCIATED WITH THE USE OF LIPID-LOWERING NUTRACEUTICALS IN CHILDHOOD. © 2024 BY THE AUTHORS.","CARDIOVASCULAR DISEASE; CHILDREN; DIET; DYSLIPIDEMIA; NUTRACEUTICALS; NUTRITIONAL INTERVENTION","ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DASH DIET; DATA EXTRACTION; DIET; DIETARY PATTERN; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; LOW FAT DIET; OBESITY; PRACTICE GUIDELINE; REVIEW","","","TOWNSEND N., WILSON L., BHATNAGAR P., WICKRAMASINGHE K., RAYNER M., NICHOLS M., CARDIOVASCULAR DISEASE IN EUROPE: EPIDEMIOLOGICAL UPDATE 2016, EUR. HEART J, 37, PP. 3232-3245, (2016); DE JESUS J.M., EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS: SUMMARY REPORT, PEDIATRICS, 128, PP. 213-256, (2011); WIEGMAN A., GIDDING S.S., WATTS G.F., CHAPMAN M.J., GINSBERG H.N., CUCHEL M., OSE L., AVERNA M., BOILEAU C., BOREN J., ET AL., FAMILIAL HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS: GAINING DECADES OF LIFE BY OPTIMIZING DETECTION AND TREATMENT, EUR. HEART J, 36, PP. 2425-2437, (2015); MACH F., BAIGENT C., CATAPANO A.L., KOSKINAS K.C., CASULA M., BADIMON L., CHAPMAN M.J., DE BACKER G.G., DELGADO V., FERENCE B.A., ET AL., 2019 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK, EUR. HEART J, 41, PP. 111-118, (2020); HU P., DHARMAYAT K.I., STEVENS C.A., SHARABIANI M.T., JONES R.S., WATTS G.F., GENEST J., RAY K.K., VALLEJO-VAZ A.J., PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA AMONG THE GENERAL POPULATION AND PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, CIRCULATION, 141, PP. 1742-1759, (2020); VRABLIK M., TICHY L., FREIBERGER T., BLAHA V., SATNY M., HUBACEK J.A., GENETICS OF FAMILIAL HYPERCHOLESTEROLEMIA: NEW INSIGHTS, FRONT. GENET, 11, (2020); FAMILIAL HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS FROM 48 COUNTRIES: A CROSS-SECTIONAL STUDY, LANCET, 403, PP. 55-66, (2023); WIDHALM K., BINDER C.B., KREISSL A., ALDOVER-MACASAET E., FRITSCH M., KROISBOECK S., GEIGER H., SUDDEN DEATH IN A 4-YEAR-OLD BOY: A NEAR-COMPLETE OCCLUSION OF THE CORONARY ARTERY CAUSED BY AN AGGRESSIVE LOW-DENSITY LIPOPROTEIN RECEPTOR MUTATION (W556R) IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, J. PEDIATR, 158, (2011); WILEMON K.A., PATEL J., AGUILAR-SALINAS C., AHMED C.D., ALKHNIFSAWI M., ALMAHMEED W., ALONSO R., AL-RASADI K., BADIMON L., BERNAL L.M., ET AL., REDUCING THE CLINICAL AND PUBLIC HEALTH BURDEN OF FAMILIAL HYPERCHOLESTEROLEMIA: A GLOBAL CALL TO ACTION, JAMA CARDIOL, 5, PP. 217-229, (2020); CAPRA M.E., PEDERIVA C., VIGGIANO C., DE SANTIS R., BANDERALI G., BIASUCCI G., NUTRITIONAL APPROACH TO PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE IN CHILDHOOD, NUTRIENTS, 13, (2021); POLONSKY S.M., BELLET P.S., SPRECHER D.L., PRIMARY HYPERLIPIDEMIA IN A PEDIATRIC POPULATION: CLASSIFICATION AND EFFECT OF DIETARY TREATMENT, PEDIATRICS, 91, PP. 92-96, (1993); ASTRUP A., MAGKOS F., BIER D.M., BRENNA J.T., DE OLIVEIRA OTTO M.C., HILL J.O., KING J.C., MENTE A., ORDOVAS J.M., VOLEK J.S., ET AL., SATURATED FATS AND HEALTH: A REASSESSMENT AND PROPOSAL FOR FOOD-BASED RECOMMENDATIONS: JACC STATE-OF-THE-ART REVIEW, J. AM. COLL. CARDIOL, 76, PP. 844-857, (2020); SHANNON B.M., TERSHAKOVEC A.M., MARTEL J.R., ACHTERBERG C.L., CORTNER J.A., SMICIKLAS-WRIGHT H.S., STALLINGS V.A., STOLLEY P.D., REDUCTION OF ELEVATED LDL-CHOLESTEROL LEVELS OF 4 TO 10-YEAR-OLD CHILDREN THROUGH HOME-BASED DIETARY EDUCATION, PEDIATRICS, 94, PP. 923-927, (1994); OBARZANEK E., HUNSBERGER S.A., SIMONS-MORTON D.G., LAUER R.M., VAN HORN L., HARTMULLER V.V., BARTON B.A., STEVENS V.J., KWITEROVICH P.O., FRANKLIN F.A., ET AL., SAFETY OF A FAT-REDUCED DIET: THE DIETARY INTERVENTION STUDY IN CHILDREN (DISC), PEDIATRICS, 100, PP. 51-59, (1997); RASK-NISSILA L., JOKINEN E., TERHO P., TAMMI A., HAKANEN M., RONNEMAA T., VIIKARI J., SEPPANEN R., VALIMAKI I., HELENIUS H., ET AL., EFFECTS OF DIET ON THE NEUROLOGIC DEVELOPMENT OF CHILDREN AT 5 YEARS OF AGE: THE STRIP PROJECT, J. PEDIATR, 140, PP. 328-333, (2002); CAPRA M.E., BIASUCCI G., BANDERALI G., PEDERIVA C., DIETARY INTERVENTION FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA, ITAL. J. PEDIATR, 49, (2023); LARN—LIVELLI DI ASSUNZIONE DI RIFERIMENTO DI NUTRIENTI ED ENERGIA PER LA POPOLAZIONE ITALIANA, (2014); OWEN C.G., WHINCUP P., KAYE S.J., MARTIN R.M., SMITH G.D., COOK D., BERGSTROM E., BLACK S., WADSWORTH M.E.J., FALL C.H., ET AL., DOES INITIAL BREASTFEEDING LEAD TO LOWER BLOOD CHOLESTEROL IN ADULT LIFE? A QUANTITATIVE REVIEW OF THE EVIDENCE, AM. J. CLIN. NUTR, 88, PP. 305-314, (2008); OWEN C.G., WHINCUP P., GILG J.A., COOK D., EFFECT OF BREAST FEEDING IN INFANCY ON BLOOD PRESSURE IN LATER LIFE: SYSTEMATIC REVIEWAND META-ANALYSIS, BMJ, 327, PP. 1189-1195, (2003); OWEN C.G., MARTIN R.M., WHINCUP P., SMITH G.D., COOK D., EFFECT OF INFANT FEEDING ON THE RISK OF OBESITY ACROSS THE LIFE COURSE: A QUANTITATIVE REVIEW OF PUBLISHED EVIDENCE, PEDIATRICS, 115, PP. 1367-1377, (2005); PAPOUTSOU S., SAVVA S.C., HUNSBERGER M., JILANI H., MICHELS N., AHRENS W., TORNARITIS M., VEIDEBAUM T., MOLNAR D., SIANI A., ET AL., TIMING OF SOLID FOOD INTRODUCTION AND ASSOCIATION WITH LATER CHILDHOOD OVERWEIGHT AND OBESITY: THE IDEFICS STUDY, MATERN. CHILD. NUTR, 14, (2017); CAPRA M.E., MONOPOLI D., DECAROLIS N.M., GIUDICE A., STANYEVIC B., ESPOSITO S., BIASUCCI G., DIETARY MODELS AND CARDIOVASCULAR RISK PREVENTION IN PEDIATRIC PATIENTS, NUTRIENTS, 15, (2023); DANIELS L., HEATH A.-L.M., WILLIAMS S.M., CAMERON S.L., FLEMING E.A., TAYLOR B., WHEELER B.J., GIBSON R.S., TAYLOR R.W., BABY-LED INTRODUCTION TO SOLIDS (BLISS) STUDY: A RANDOMISED CONTROLLED TRIAL OF A BABY-LED APPROACH TO COMPLEMENTARY FEEDING, BMC PEDIATR, 15, (2015); VENTURA A.K., DOES BREASTFEEDING SHAPE FOOD PREFERENCES LINKS TO OBESITY, ANN. NUTR. METAB, 70, PP. 8-15, (2017); WILLIAMS L., BAKER-SMITH C.M., BOLICK J., CARTER J., KIRKPATRICK C., LEY S.L., PETERSON A.L., SHAH A.S., SIKAND G., WARE A.L., ET AL., NUTRITION INTERVENTIONS FOR YOUTH WITH DYSLIPIDEMIA: A NATIONAL LIPID ASSOCIATION CLINICAL PERSPECTIVE, J. CLIN. LIPIDIDOL, 16, PP. 776-796, (2022); GIOVANNINI M., DE CARLIS S., RACCOMANDAZIONI PER LA PREVENZIONE IN ETÀ PEDIATRICA DELL’ATEROSCLEROSI, RIV. ITAL. PEDIAT, 26, PP. 13-28, (2000); GIDDING S.S., DENNISON B.A., BIRCH L.L., DANIELS S.R., GILMAN M.W., LICHTENSTEIN A.H., RATTAY K.T., STEINBERGER J., STETTLER N., VAN HORN L., DIETARY RECOMMENDATIONS FOR CHILDREN AND ADOLESCENTS, CIRCULATION, 112, PP. 2061-2075, (2005); MATEO-GALLEGO R., MARCO-BENEDI V., PEREZ-CALAHORRA S., BEA A.M., BAILA-RUEDA L., LAMIQUIZ-MONEO I., DE CASTRO-OROS I., CENARRO A., CIVEIRA F., ENERGY-RESTRICTED, HIGH-PROTEIN DIETS MORE EFFECTIVELY IMPACT CARDIOMETABOLIC PROFILE IN OVERWEIGHT AND OBESE WOMEN THAN LOWER-PROTEIN DIETS, CLIN. NUTR, 36, PP. 371-379, (2016); SHAH M., ADAMS-HUET B., FRANKLIN B., PHILLIPS M., MITCHELL J., THE EFFECTS OF HIGH-PROTEIN AND HIGH-MONOUNSATURATED FAT MEALS ON POSTPRANDIAL LIPIDS, LIPOPROTEIN PARTICLE NUMBERS, CYTOKINES, AND LEPTIN RESPONSES IN OVERWEIGHT/OBESE SUBJECTS, METAB. SYNDR. RELAT. DISORD, 16, PP. 150-158, (2018); (2018); MENSINK R.P., ZOCK P.L., KESTER A.D., KATAN M.B., EFFECTS OF DIETARY FATTY ACIDS AND CARBOHYDRATES ON THE RATIO OF SERUM TOTAL TO HDL CHOLESTEROL AND ON SERUM LIPIDS AND APOLIPOPROTEINS: A META-ANALYSIS OF 60 CONTROLLED TRIALS, AM. J. CLIN. NUTR, 77, PP. 1146-1155, (2003); SCHULZE M.B., MARTINEZ-GONZALEZ M.A., FUNG T.T., LICHTENSTEIN A.H., FOROUHI N.G., FOOD BASED DIETARY PATTERNS AND CHRONIC DISEASE PREVENTION, BMJ, 361, (2018); STEFFEN L.M., FOLSOM A.R., RIMM E.B., WILLETT W.C., SOLOMON S.D., DIETARY CARBOHYDRATE INTAKE AND MORTALITY: A PROSPECTIVE COHORT STUDY AND META-ANALYSIS, LANCET PUBLIC HEALTH, 3, PP. 419-428, (2018); REYNOLDS A., MANN J., CUMMINGS J., WINTER N., METE E., TE MORENGA L., CARBOHYDRATE QUALITY AND HUMAN HEALTH: A SERIES OF SYSTEMATIC REVIEWS AND META-ANALYSES, LANCET, 393, PP. 434-445, (2019); MARTINEZ-GONZALEZ M.A., GEA A., RUIZ-CANELA M., THE MEDITERRANEAN DIET AND CARDIOVASCULAR HEALTH, A CRITICAL REVIEW, CIRC. RES, 124, PP. 779-798, (2019); FERNANDEZ-LAZARO C.I., TOLEDO E., BUIL-COSIALES P., SALAS-SALVADO J., CORELLA D., FITO M., MARTINEZ J.A., ALONSO-GOMEZ A.M., WARNBERG J., VIOQUE J., ET AL., FACTORS ASSOCIATED WITH SUCCESSFUL DIETARY CHANGES IN AN ENERGY REDUCED MEDITERRANEAN DIET INTERVENTION: A LONGITUDINAL ANALYSIS IN THE PREDIMED-PLUS TRIAL, EUR. J. NUTR, 61, PP. 1457-1475, (2021); LEMMING E.W., BYBERG L., WOLK A., MICHAELSSON K., A COMPARISON BETWEEN TWO HEALTHY DIET SCORES, THE MODIFIED MEDITERRANEAN DIET SCORE AND THE HEALTHY NORDIC FOOD INDEX, IN RELATION TO ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY, BR. J. NUTR, 119, PP. 836-846, (2018); SIERVO M., LARA J., CHOWDHURY S., ASHOR A., OGGIONI C., MATHERS J.C., EFFECTS OF THE DIETARY APPROACH TO STOP HYPERTENSION (DASH) DIET ON CARDIOVASCULAR RISK FACTORS: A SYSTEMATIC REVIEW AND META-ANALYSIS, BR. J. NUTR, 113, PP. 1-15, (2015); RODRIGUEZ-BORJABAD C., NARVEUD I., CHRISTENSEN J.J., ULVEN S.M., MALO A.I., IBARRETXE D., GIRONA J., TORVIK K., BOGSRUD M.P., RETTERSTOL K., ET AL., DIETARY INTAKE AND LIPID LEVELS IN NORWEGIAN AND SPANISH CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, NUTR. METAB. CARDIOVASC. DIS, 31, PP. 1299-1307, (2021); SAHEBKAR A., SERBAN M.-C., GLUBA-BRZOZKA A., MIKHAILIDIS D.P., CICERO A.F., RYSZ J., BANACH M., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); WILLIAMSON E.M., LIU X., IZZO A.A., TRENDS IN USE, PHARMACOLOGY, AND CLINICAL APPLICATIONS OF EMERGING HERBAL NUTRACEUTICALS, BR. J. PHARMACOL, 177, PP. 1227-1240, (2020); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., ET AL., STATIN INTOLERANCE—AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH. MED. SCI, 11, PP. 1-23, (2015); PENSON P.E., BANACH M., NUTRACEUTICALS FOR THE CONTROL OF DYSLIPIDAEMIAS IN CLINICAL PRACTICE, NUTRIENTS, 13, (2021); BANDERALI G., CAPRA M.E., VIGGIANO C., BIASUCCI G., PEDERIVA C., NUTRACEUTICALS IN PAEDIATRIC PATIENTS WITH DYSLIPIDAEMIA, NUTRIENTS, 14, (2022); VISSEREN F.L.J., MACH F., SMULDERS Y.M., CARBALLO D., KOSKINAS K.C., BACK M., BENETOS A., BIFFI A., BOAVIDA J.M., CAPODANNO D., ET AL., 2021 ESC GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUR. HEART J, 42, PP. 3227-3337, (2021); ASHFAQ R., RASUL A., ASGHAR S., KOVACS A., BERKO S., BUDAI-SZUCS M., LIPID NANOPARTICLES: AN EFFECTIVE TOOL TO IMPROVE THE BIOAVAILABILITY OF NUTRACEUTICALS, INT. J. MOL. SCI, 24, (2023); AMANTE C., ESPOSITO T., LUCCHEO G., LUCCHEO L., RUSSO P., DEL GAUDIO P., RECAPSOMA<SUP>®</SUP>: A NOVEL MIXTURE BASED ON BERGAMOT, IPOMOEA BATATAS, POLICOSANOL EXTRACTS AND LIPOSOMAL BERBERINE FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, LIFE, 12, (2022); VUKSAN V., JENKINS A.L., ROGOVIK A.L., FAIRGRIEVE C.D., JOVANOVSKI E., LEITER L.A., VISCOSITY RATHER THAN QUANTITY OF DIETARY FIBRE PREDICTS CHOLESTEROL-LOWERING EFFECT IN HEALTHY INDIVIDUALS, BR. J. NUTR, 106, PP. 1349-1352, (2011); ASSMANN G., BUONO P., DANIELE A., DELLA VALLE E., FARINARO E., FERNS G., KROGH V., KROMHOUT D., MASANA L., MERINO J., ET AL., FUNCTIONAL FOODS AND CARDIOMETABOLIC DISEASES* INTERNATIONAL TASK FORCE FOR PREVENTION OF CARDIOMETABOLIC DISEASES, NUTR. METAB. CARDIOVASC. DIS, 24, PP. 1272-1300, (2014); HARTLEY L., MAY M.D., LOVEMAN E., COLQUITT J.L., REES K., DIETARY FIBRE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV, (2016); SCIENTIFIC OPINION ON DIETARY REFERENCE VALUES FOR CARBOHYDRATES AND DIETARY FIBER, EFSA J, 8, (2010); BAZZANO L.A., THOMPSON A.M., TEES M.T., NGUYEN C.H., WINHAM D.M., NONSOY LEGUME CONSUMPTION LOWERS CHOLESTEROL LEVELS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 94-103, (2011); ESTRUCH R., MARTINEZ-GONZALEZ M., CORELLA D., BASORA-GALLISA J., RUIZ-GUTIERREZ V., COVAS M., FIOL M., GOMEZ-GRACIA E., LOPEZ-SABATER M.C., ESCODA R., ET AL., PREDIMED STUDY INVESTIGATORS. EFFECTS OF DIETARY FIBRE INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK, J. EPIDEMIOL. COMMUNITY HEALTH, 63, PP. 582-588, (2009); SETTE S., LE DONNE C., PICCINELLI R., ARCELLA D., TURRINI A., LECLERCQ C., INRAN-SCAI 2005-6 STUDY GROUP. THE THIRD ITALIAN NATIONAL FOOD CONSUMPTION SURVEY, INRAN-SCAI 2005-06-PART 1, NUTRIENT INTAKES IN ITALY, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 922-932, (2011); WHITEHEAD A., BECK E.J., TOSH S., WOLEVER T.M., CHOLESTEROL-LOWERING EFFECTS OF OAT Β-GLUCAN: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR, 100, PP. 1413-1421, (2014); MADSEN M.T.B., LANDBERG R., NIELSEN D.S., ZHANG Y., ANNEBERG O.M.R., LAURITZEN L., DAMSGAARD C.T., EFFECTS OF WHOLE GRAIN COMPARED TO REFINED GRAIN INTAKE ON CARDIOMETABOLIC RISK MARKERS, GUT MICROBIOTA AND GASTROINTESTINAL SYMPTOMS IN CHILDREN: A RANDOMIZED CROSSOVER TRIAL, AM. J. CLIN. NUTR, 119, PP. 18-28, (2024); RIBAS S., CUNHA D.B., SICHIERI R., DA SILVA L.C.S., EFFECTS OF PSYLLIUM ON LDL-CHOLESTEROL CONCENTRATIONS IN BRAZILIAN CHILDREN AND ADOLESCENTS: A RANDOMISED, PLACEBO-CONTROLLED, PARALLEL CLINICAL TRIAL, BR. J. NUTR, 113, PP. 134-141, (2015); HO H.V.T., JOVANOVSKI E., ZURBAU A., BLANCO MEJIA S., SIEVENPIPER J.L., AU-YEUNG F., JENKINS A.L., DUVNJAK L., LEITER L., VUKSAN V., A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF THE EFFECT OF KONJAC GLUCOMANNAN, A VISCOUS SOLUBLE FIBER, ON LDL CHOLESTEROL AND THE NEW LIPID TARGETS NON-HDL CHOLESTEROL AND APOLIPOPROTEIN B, AM. J. CLIN. NUTR, 105, PP. 1239-1247, (2017); GUARDAMAGNA O., ABELLO F., CAGLIERO P., VISIOLI F., COULD DYSLIPIDEMIC CHILDREN BENEFIT FROM GLUCOMANNAN INTAKE?, NUTRITION, 29, PP. 1060-1065, (2013); FONTANE L., PEDRO-BOTET J., GARCIA-RIBERA S., CLIMENT E., MUNS M.D., BALLESTA S., SATORRA P., FLORES-LE ROUX J.A., BENAIGES D., USE OF PHYTOSTEROL-FORTIFIED FOODS TO IMPROVE LDL CHOLESTEROL LEVELS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR. METAB. CARDIOVASC. DIS, 33, PP. 1472-1480, (2023); RIBAS S., SICHIERI R., MOREIRA A., SOUZA D., CABRAL C., GIANINNI D., CUNHA D., PHYTOSTEROL-ENRICHED MILK LOWERS LDL-CHOLESTEROL LEVELS IN BRAZILIAN CHILDREN AND ADOLESCENTS: DOUBLE-BLIND, CROSS-OVER TRIAL, NUTR. METAB. CARDIOVASC. DIS, 27, PP. 971-977, (2017); GAROUFI A., VORRE S., SOLDATOU A., TSENTIDIS C., KOSSIVA L., DRAKATOS A., MARMARINOS A., GOURGIOTIS D., PLANT STEROLS-ENRICHED DIET DECREASES SMALL, DENSE LDL-CHOLESTEROL LEVELS IN CHILDREN WITH HYPERCHOLESTEROLEMIA: A PROSPECTIVE STUDY, ITAL. J. PEDIATR, 40, (2014); PEDERIVA C., BIASUCCI G., BANDERALI G., CAPRA M.E., PLANT STEROLS AND STANOLS FOR PEDIATRIC PATIENTS WITH INCREASED CARDIOVASCULAR RISK, CHILDREN, 11, (2024); GUARDAMAGNA O., AMARETTI A., PUDDU P.E., RAIMONDI S., ABELLO F., CAGLIERO P., ROSSI M., BIFIDOBACTERIA SUPPLEMENTATION: EFFECTS ON PLASMA LIPID PROFILES IN DYSLIPIDEMIC CHILDREN, NUTRITION, 30, PP. 831-836, (2014); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ZHANG D., COOPER R., CHANG M., CONSTITUENTS OF READ YEAST RICE A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGIC. FOOD CHEM, 48, PP. 5220-5533, (2000); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR. ATHEROSCLER. REP, 17, (2015); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, 253, PP. 281-344, (2016); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTR. METAB. CARDIOVASC. DIS, 27, PP. 2-17, (2017); (2022); SCIENTIFIC OPINION ON THE RISKS FOR PUBLIC AND ANIMAL HEALTH RELATED TO THE PRESENCE OF CITRININ IN FOOD AND FEED EFSA PANEL OF CONTAMINANTS IN THE FOOD CHAIN (CONTAM). EUROPEAN FOOD SAFETY AUTHORITY (EFSA), PARMA, ITALY, EFSA J, 10, (2012); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 424-429, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 268-279, (2002); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MED. CELL. LONGEV, 2018, (2018); BARKAS F., NOMIKOS T., LIBEROPOULOS E., PANAGIOTAKOS D., DIET AND CARDIOVASCULAR DISEASE RISK AMONG INDIVIDUALS WITH FAMILIAL HYPERCHOLESTEROLEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS, NUTRIENTS, 12, (2020); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATION (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL-CHOLESTEROL CONCENTRATION (ID 1474, 1478, 1684, 1951, 1954, 4693) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, (2011); RUSCICA M., PAVANELLO C., GANDINI S., GOMARASCHI M., VITALI C., MACCHI C., MORLOTTI B., AIELLO G., BOSISIO R., CALABRESI L., ET AL., EFFECT OF SOY ON METABOLIC SYNDROME AND CARDIOVASCULAR RISK FACTORS: A RANDOMIZED CONTROLLED TRIAL, EUR. J. NUTR, 57, PP. 499-511, (2018); HELK O., WIDHALM K., EFFECTS OF A LOW-FAT DIETARY REGIMEN ENRICHED WITH SOY IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, CLIN. NUTR, 36, PP. 150-156, (2020); BAHR M., FECHNER A., KIEHNTOPF M., JAHREIS G., CONSUMING A MIXED DIET ENRICHED WITH LUPIN PROTEIN BENEFICIALLY AFFECTS PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC SUBJECTS: A RANDOMIZED CONTROLLED TRIAL, CLIN. NUTR, 34, PP. 7-14, (2015); PANEL ON DIETETIC PRODUCTS, EFSA J, 8, PP. 1796-1828, (2010); GRUNDY S.M., STONE N.J., BAILEY A.L., BEAM C., BIRTCHER K.K., BLUMENTHAL R.S., BRAUN L.T., DE FERRANTI S., FAIELLA-TOMMASINO J., FORMAN D.E., ET AL., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, CIRCULATION, 139, PP. 1082-1143, (2019); HOWE P., MORI T., BUCKLEY J., LONG CHAIN OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE-FNSAZ CONSIDERATION OF A COMMISIONED REVEW, BR. J. NUTR, 107, PP. S201-S213, (2012); AGOSTONI C., BREAEGGER C., DECSI T., KOLACEK S., MIHATSCH W., MORENO L.A., PUNTIS J., SHAMIR R., SZAJEWSKA H., TURCK D., ET AL., SUPPLEMENTATION OF N-3 LPUFA IN THE DIET OF CHILDREN OLDER THAN 2 YEARS: A COMMENTARY BY THE ESPGHAN COMMITTEE ON NUTRITION, J. PEDIATR. GASTROENTEROL. NUTR, 53, PP. 2-10, (2011); ENGLER M.M., ENGLER M.B., MALLOY M.J., PAUL S.M., KULKARNI K.R., MIETUS-SNYDER M.L., EFFECT OF DOCOSAHEXAENOIC ACID ON LIPOPROTEIN SUBCLASSES IN HYPERLIPIDEMIC CHILDREN (THE EARLY STUDY), AM. J. CARDIOL, 95, PP. 869-871, (2005); BANACH M., STULC T., DENT R., TOTH P.P., STATIN NON-ADHERENCE AND RESIDUAL CARDIOVASCULAR RISK: THERE IS NEED FOR SUBSTANTIAL IMPROVEMENT, INT. J. CARDIOL, 225, PP. 184-196, (2016); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., FRAS Z., KATSIKI N., LANGLOIS M., LATKOVSKIS G., ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH. MED. SCI, 13, PP. 965-1005, (2017); BANACH M., PATTI A.M., GIGLIO R.V., CICERO A.F.G., ATANASOV A.G., BAJRAKTARI G., BRUCKERT E., DESCAMPS O., DJURIC D.M., EZHOV M., ET AL., THE ROLE OF NUTRACEUTICALS IN STATIN INTOLERANT PATIENTS, J. AM. COLL. CARDIOL, 72, PP. 96-118, (2018); PEDERIVA C., CAPRA M.E., VIGGIANO C., ROVELLI V., BANDERALI G., BIASUCCI G., EARLY PREVENTION OF ATHEROSCLEROSIS: DETECTION AND MANAGEMENT OF HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS, LIFE, 11, (2021)","A. VANIA; INDEPENDENT RESEARCHER, MEMBER OF SINUPE (ITALIAN SOCIETY OF PEDIATRIC NUTRITION) DIRECTORY BOARD, ROME, 00162, ITALY; EMAIL: ANDREA.VANIA57@GMAIL.COM","MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE (MDPI)","ENGLISH","CHILD.","REVIEW","ISI","2-S2.0-85186123551","CHILD","UNIVERSITY OF PARMA;UNIVERSITY OF PARMA;CLINICAL SERVICE FOR DYSLIPIDEMIAS;INDEPENDENT RESEARCHER;CLINICAL SERVICE FOR DYSLIPIDEMIAS","NOTREPORTED;INDEPENDENT RESEARCHER;NOTREPORTED",NA,"CAPRA ME, 2024, CHILD","CAPRA ME, 2024, CHILD"
"ASKARPOUR M;GHAEDI E;ROSHANRAVAN N;HADI A;MOHAMMADI H;SYMONDS M;MIRAGHAJANI M","ASKARPOUR, MOEIN (57208885126); GHAEDI, EHSAN (56598108600); ROSHANRAVAN, NEDA (56320238500); HADI, AMIR (57191495714); MOHAMMADI, HAMED (57209349457); SYMONDS, MICHAEL E (57203081823); MIRAGHAJANI, MARYAM (53983219200)","POLICOSANOL SUPPLEMENTATION SIGNIFICANTLY IMPROVES BLOOD PRESSURE AMONG ADULTS A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2019,"COMPLEMENTARY THERAPIES IN MEDICINE","45","8",19,"10.1016/j.ctim.2019.05.023","DEPARTMENT OF CELLULAR AND MOLECULAR NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN;DEPARTMENT OF CELLULAR AND MOLECULAR NUTRITION, SCHOOL OF NUTRITIONAL SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN, STUDENTS’ SCIENTIFIC RESEARCH CENTER (SSRC), TEHRAN UNIVERSITY OF MEDICAL SCIENCES (TUMS), TEHRAN, IRAN;CARDIOVASCULAR RESEARCH CENTER, TABRIZ UNIVERSITY OF MEDICAL SCIENCES TABRIZ, IRAN;HALAL RESEARCH CENTER OF IRI, FDA, TEHRAN, IRAN, DEPARTMENT OF CLINICAL NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;STUDENT RESEARCH COMMITTEE, DEPARTMENT OF CLINICAL NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;THE EARLY LIFE RESEARCH UNIT, ACADEMIC DIVISION OF CHILD HEALTH, OBSTETRICS AND GYNAECOLOGY, AND NOTTINGHAM DIGESTIVE DISEASE CENTRE AND BIOMEDICAL RESEARCH CENTRE, THE SCHOOL OF MEDICINE, UNIVERSITY OF NOTTINGHAM, NOTTINGHAM, NG7 2UH, UNITED KINGDOM;THE EARLY LIFE RESEARCH UNIT, ACADEMIC DIVISION OF CHILD HEALTH, OBSTETRICS AND GYNAECOLOGY, AND NOTTINGHAM DIGESTIVE DISEASE CENTRE AND BIOMEDICAL RESEARCH CENTRE, THE SCHOOL OF MEDICINE, UNIVERSITY OF NOTTINGHAM, NOTTINGHAM, NG7 2UH, UNITED KINGDOM, CANCER RESEARCH CENTER, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCE, TEHRAN, IRAN, THE EARLY LIFE RESEARCH UNIT, DIVISION OF CHILD HEALTH, OBSTETRICS AND GYNAECOLOGY, UNIVERSITY OFNOTTINGHAM, NOTTINGHAM, UNITED KINGDOM","BACKGROUND AND AIMS: POLICOSANOL CONTAINS A MIXTURE OF CONCENTRATED PRIMARY ALIPHATIC ALCOHOLS EXTRACTED FROM SUGAR CANE WAX AND IS RECOGNIZED AS A CHOLESTEROL-LOWERING DRUG BUT PREVIOUS STUDIES REPORTED THAT IT COULD BE HELPFUL FOR REDUCING BLOOD PRESSURE AS WELL. WE AIMED TO SYSTEMATICALLY REVIEW ALL RANDOMIZED CONTROL TRIALS (RCTS) EVALUATING THE EFFICACY OF POLICOSANOL SUPPLEMENTATION FOR LOWERING HIGH BLOOD PRESSURE. METHODS AND RESULTS: THE FOLLOWING DATABASES WERE SEARCHED UP TO MARCH 2019: PUBMED, SCOPUS, ISI WEB OF SCIENCE AND THE COCHRANE LIBRARY. ELIGIBLE RCTS WERE INCLUDED IF THEY INVESTIGATE THE EFFECTS OF POLICOSANOL SUPPLEMENTATION ON SYSTOLIC (SBP) AND DIASTOLIC (DBP) BLOOD PRESSURE. POOLED EFFECT SIZE WAS MEASURED USING RANDOM EFFECT MODEL (DERSIMMONON METHOD). A TOTAL OF NINETEEN STUDIES WITH TWENTY-FOUR ARMS WERE CONSIDERED. POOLED EFFECT SIZE SHOWED THAT SBP (WMD: −3.423 MMHG, 95% CI: −5.315, −1.531; P < 0.001) AND DBP (WMD: −1.468 MMHG 95% CI: −2.632, −0.304, P = 0.013). DECREASE SIGNIFICANTLY AFTER POLICOSANOL SUPPLEMENTATION WITH SIGNIFICANT HETEROGENEITY AMONG INCLUDED STUDIES (I2 = 78.5% AND 78.9% FOR SBP AND DBP RESPECTIVELY). ALL SUBGROUPS SHOWED A SIGNIFICANT EFFECT OF POLICOSANOL SUPPLEMENTATION EXCEPT PATIENTS WITH MIXED DYSLIPIDEMIA FOR SBP AND DBP AND OVERWEIGHT SUBJECTS FOR DBP. CONCLUSION: POLICOSANOL COULD LOWER SBP AND DBP SIGNIFICANTLY; FUTURE LONG TERM STUDIES ARE REQUIRED TO CONFIRM THESE FINDINGS IN THE GENERAL POPULATION. © 2019 ELSEVIER LTD","BLOOD PRESSURE; HYPERTENSION; META-ANALYSIS; POLICOSANOL","ADULT; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; FATTY ALCOHOLS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; POLICOSANOL; FATTY ALCOHOL; POLICOSANOL; BLOOD PRESSURE REGULATION; CLINICAL OUTCOME; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; EFFECT SIZE; HUMAN; HYPERTENSION; META ANALYSIS; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPPLEMENTATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; ADULT; BLOOD PRESSURE; CLINICAL TRIAL; DIETARY SUPPLEMENT; DRUG EFFECT; MULTICENTER STUDY","","","LURBE I.F.E., 2016 - EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN AND ADOLESCENTS, ANALES DE PEDIATRIA (BARCELONA, SPAIN: 2003), 85, 4, PP. 167-169, (2016); WORLDWIDE TRENDS IN BLOOD PRESSURE FROM 1975 TO 2015: A POOLED ANALYSIS OF 1479 POPULATION-BASED MEASUREMENT STUDIES WITH 19.1 MILLION PARTICIPANTS, LANCET, 389, 10064, PP. 37-55, (2017); AMES R.P., HYPERLIPIDEMIA IN HYPERTENSION: CAUSES AND PREVENTION, AM HEART J, 122, 4, PP. 1219-1224, (1991); BONAA K.H., THELLE D.S., ASSOCIATION BETWEEN BLOOD PRESSURE AND SERUM LIPIDS IN A POPULATION. THE TROMSO STUDY, CIRCULATION, 83, 4, PP. 1305-1314, (1991); LEE J.S., CHANG P.Y., ZHANG Y., KIZER J.R., BEST L.G., HOWARD B.V., TRIGLYCERIDE AND HDL-C DYSLIPIDEMIA AND RISKS OF CORONARY HEART DISEASE AND ISCHEMIC STROKE BY GLYCEMIC DYSREGULATION STATUS: THE STRONG HEART STUDY, DIABETES CARE, 40, 4, PP. 529-537, (2017); CICERO A.F., FOGACCI F., COLLETTI A., FOOD AND PLANT BIOACTIVES FOR REDUCING CARDIOMETABOLIC DISEASE RISK: AN EVIDENCE BASED APPROACH, FOOD FUNCT, 8, 6, PP. 2076-2088, (2017); CHRYSANT S.G., CHRYSANT G.S., HERBS USED FOR THE TREATMENT OF HYPERTENSION AND THEIR MECHANISM OF ACTION, CURR HYPERTENS REP, 19, 9, (2017); MOURA MDEL G., LOPES L.C., BIAVATTI M.W., ET AL., BRAZILIAN ORAL HERBAL MEDICATION FOR OSTEOARTHRITIS: A SYSTEMATIC REVIEW PROTOCOL, SYST REV, 5, (2016); MAITI B., P NB, SINGH R., RECENT TRENDS IN HERBAL DRUGS: A REVIEW. 2017, (2017); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, 3, PP. 259-267, (2010); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID MED CELL LONGEV, 2018, (2018); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT PHYSIOL, 9, (2018); PARK H.J., YADAV D., JEONG D.J., ET AL., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT J ENVIRON RES PUBLIC HEALTH, 16, 5, (2019); CASTANO G., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECTS OF COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON PLATELET AGGREGATION: A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY, CURR THER RES, 67, 3, PP. 174-192, (2006); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, 8, PP. 819-828, (1995); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, 4, PP. 207-219, (2005); CASTANO G., MAS R., FERNANDEZ J., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, 3, (2001); CASTANO G., MAS R., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, 8, PP. 522-537, (2003); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., FERNANDEZ J.C., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES, 62, 3, PP. 194-208, (2001); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, 3, PP. 296-304, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, 9, PP. 691-699, (1996); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON—INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, 1, PP. 44-51, (1997); GRANJA A.L., HERNANDEZ J.M., QUINTANA D.C., VALMANA L.A., FERREIRO R.M., MESA M.G., (1999); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, 9, PP. 1084-1092, (1994); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, 7, PP. 568-577, (1996); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, 61, 6, PP. 346-357, (2000); H-Y W., Q-P J., S-Y C., ET AL., EFFICACY AND SAFETY OF POLICOSANOL PLUS FENOFIBRATE COMBINATION THERAPY IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA: A RANDOMIZED, CONTROLLED CLINICAL STUDY, AM J MED SCI, 356, 3, PP. 254-261, (2018); PICOT J., HARTWELL D., HARRIS P., MENDES D., CLEGG A., TAKEDA A., THE PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES CHECKLIST, (2012); HIGGINS J.P., GREEN S., COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, (2011); BORENSTEIN M., HEDGES L.V., HIGGINS J.P., ROTHSTEIN H.R., INTRODUCTION TO META-ANALYSIS, (2011); HIGGINS J.P., THOMPSON S.G., DEEKS J.J., ALTMAN D.G., MEASURING INCONSISTENCY IN META-ANALYSES, BMJ: BR MED J, 327, 7414, (2003); MITCHELL M.N., INTERPRETING AND VISUALIZING REGRESSION MODELS USING STATA, (2012); TOBIAS A., ASSESSING THE INFLUENCE OF A SINGLE STUDY IN THE META-ANYALYSIS ESTIMATE, STATA TECHNICAL BULLETIN, 8, 47, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, 4, PP. 439-447, (1999); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVESTIG, 21, 7, PP. 485-497, (2001); SAIZ L.C., GORRICHO J., GARJON J., CELAYA M.C., ERVITI J., LEACHE L., BLOOD PRESSURE TARGETS FOR THE TREATMENT OF PEOPLE WITH HYPERTENSION AND CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 7, (2018); MENENDEZ R., FERNANDEZ S., DEL A.R., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, 3-4, PP. 199-203, (1994); JOHNSON H.M., BARTELS C.M., THORPE C.T., SCHUMACHER J.R., PANDHI N., SMITH M.A., DIFFERENTIAL DIAGNOSIS AND TREATMENT RATES BETWEEN SYSTOLIC AND DIASTOLIC HYPERTENSION IN YOUNG ADULTS: A MULTIDISCIPLINARY OBSERVATIONAL STUDY, J CLIN HYPERTENS (GREENWICH), 17, 11, PP. 885-894, (2015); YAXLEY J.P., THAMBAR S.V., RESISTANT HYPERTENSION: AN APPROACH TO MANAGEMENT IN PRIMARY CARE, J FAMILY MED PRIM CARE, 4, 2, PP. 193-199, (2015); HU J., ZHAO L., THOMPSON B., ZHANG Y., WU Y., EFFECTS OF SALT SUBSTITUTE ON HOME BLOOD PRESSURE DIFFERS ACCORDING TO AGE AND DEGREE OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS AND THEIR FAMILIES, CLIN EXP HYPERTENS (NEW YORK, NY: 1993), 40, 7, PP. 664-672, (2018); PEREZ P.P., (2001); GONG J., QIN X., YUAN F., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES, 62, 1, (2018); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, 10, PP. 923-929, (2011); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 13, 5, PP. 965-1005, (2017); SUN G.Q., LI Y.B., DU B., MENG Y., RESVERATROL VIA ACTIVATION OF AMPK LOWERS BLOOD PRESSURE IN DOCA-SALT HYPERTENSIVE MICE, CLI EXP HYPERTENS (NEW YORK, NY:1993), 37, 8, PP. 616-621, (2015); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT J MOL MED, 39, 4, PP. 889-899, (2017); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, 1, PP. 31-41, (2001); FERNANDEZ S., MAS R., GAMEZ R., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, 4, PP. 219-229, (2004); EHRET G.B., MUNROE P.B., RICE K.M., ET AL., GENETIC VARIANTS IN NOVEL PATHWAYS INFLUENCE BLOOD PRESSURE AND CARDIOVASCULAR DISEASE RISK, NATURE, 478, 7367, (2011); CAMPO C., SEGURA J., RUILOPE L.M., FACTORS INFLUENCING THE SYSTOLIC BLOOD PRESSURE RESPONSE TO DRUG THERAPY, J CLIN HYPERTENS (GREENWICH), 4, 1, PP. 35-40, (2002); MIDHA T., LALCHANDANI A., NATH B., KUMARI R., PANDEY U., PREVALENCE OF ISOLATED DIASTOLIC HYPERTENSION AND ASSOCIATED RISK FACTORS AMONG ADULTS IN KANPUR, INDIA, INDIAN HEART J, 64, 4, PP. 374-379, (2012)","E. GHAEDI; DEPARTMENT OF CELLULAR AND MOLECULAR NUTRITION, SCHOOL OF NUTRITION SCIENCES AND DIETETICS, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, PO BOX: 14155-6446, POORSINA STREET, ENGHELAB AVENUE, IRAN; EMAIL: EHSANGHAEDI073@YAHOO.COM","CHURCHILL LIVINGSTONE","ENGLISH","COMPLEMENT. THER. MED.","REVIEW","ISI","2-S2.0-85066113449","COMPLEMENT THER MED","TEHRAN UNIVERSITY OF MEDICAL SCIENCES;TEHRAN UNIVERSITY OF MEDICAL SCIENCES;TABRIZ UNIVERSITY OF MEDICAL SCIENCES TABRIZ;ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;UNIVERSITY OF NOTTINGHAM;UNIVERSITY OF NOTTINGHAM","NOTREPORTED;TEHRAN UNIVERSITY OF MEDICAL SCIENCES;NOTREPORTED",NA,"ASKARPOUR M, 2019, COMPLEMENT THER MED","ASKARPOUR M, 2019, COMPLEMENT THER MED"
"CICERO A;COLLETTI A","CICERO, ARRIGO F.G. (7003403707); COLLETTI, ALESSANDRO (56538296200)","COMBINATIONS OF PHYTOMEDICINES WITH DIFFERENT LIPID LOWERING ACTIVITY FOR DYSLIPIDEMIA MANAGEMENT THE AVAILABLE CLINICAL DATA",2016,"PHYTOMEDICINE","23","5",50,"10.1016/j.phymed.2015.10.011","DISEASES RESEARCH CENTER, MEDICINE & SURGERY DEPARTMENT, ALMA MATER STUDIORUM ATHEROSCLEROSIS AND METABOLIC UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;DISEASES RESEARCH CENTER, MEDICINE & SURGERY DEPARTMENT, ALMA MATER STUDIORUM ATHEROSCLEROSIS AND METABOLIC UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY","BACKGROUND CARDIOVASCULAR DISEASES ARE THE PRIMARY CAUSE OF DEATH AND THE LEADING CAUSE OF DISABILITY IN INDUSTRIALIZED COUNTRIES. DYSLIPIDEMIA IS A MAJOR INDEPENDENT AND REVERSIBLE RISK FACTOR FOR THESE DISEASES: IT IS ESTIMATED THAT A REDUCTION OF 1 MMOL/L (38 MG/DL) OF LDL CHOLESTEROL IS ASSOCIATED WITH A RISK OF DEVELOPING A CARDIOVASCULAR COMPLICATION REDUCED BY 25%, A REDUCTION POTENTIALLY ACHIEVED BY LIFE-STYLE IMPROVEMENT ASSOCIATED TO ADEQUATE DIETARY SUPPLEMENTATION WITH BIOACTIVE SUBSTANCES. AIM THE AIM OF THIS REVIEW IS TO FOCUS ON THE MAJOR PHYTOCHEMICAL NUTRACEUTICALS COMBINATIONS SUPPORTED BY CLINICAL TRIALS THAT HAVE DEMONSTRATED POSITIVE EFFECTS IN THE TREATMENT OF DYSLIPIDEMIA. MAIN TEXT THERE ARE MANY NUTRACEUTICALS WITH SIGNIFICANT LIPID-LOWERING PROPERTIES: MOST OF THEM ARE USED IN ASSOCIATION WITH A LOW DOSAGE, BECAUSE THAT PERMITS TO REDUCE THE RISK OF SIDE EFFECTS AND THEORETICALLY TO IMPROVE EFFICACY. IN FACT, NATURAL PRODUCTS WITH DIFFERENT SYNERGETIC LIPID-LOWERING COULD BE COMBINED: THEY CAN REDUCE THE ABSORPTION OF LIPIDS FROM THE BOWEL AND/OR INCREASE THEIR EXCRETION (SOLUBLE FIBERS, PLANT STEROLS, PROBIOTICS), ENHANCE THE HEPATIC UPTAKE OF CHOLESTEROL (BERBERINE, SOYBEAN PROTEINS), INHIBIT HYDROXY-METHIL-GGLUTARYL COENZYME A REDUCTASE ENZYME AND CONSEQUENTLY THE HEPATIC SYNTHESIS OF CHOLESTEROL (MONACOLINS, POLICOSANOLS, ALLICIN, SOYBEAN PROTEINS, BERGAMOT); FURTHERMORE SOME PRODUCTS ARE ABLE TO REDUCE THE OXIDATION OF THE LDL AND INCREASE THE THERMOGENESIS AND LIPID METABOLISM (CHLOROGENIC ACID). CONCLUSION RATIONAL COMBINATIONS OF NUTRACEUTICALS WITH DIFFERENT LIPID-LOWERING ACTIVITIES, WHETHER ASSOCIATED WITH AN APPROPRIATE LIFESTYLE, SHOULD PROVIDE AN ALTERNATIVE TO DRUG TREATMENT IN PATIENTS IN PRIMARY CARDIOVASCULAR DISEASE PREVENTION WITH MILDLY ADDED CARDIOVASCULAR RISK AND IN SOME STATIN-INTOLERANT PATIENTS. © 2015 ELSEVIER GMBH","CHOLESTEROL; COMBINATION; DYSLIPIDEMIA; HYPERTRIGLYCERIDEMIA; NUTRACEUTICALS; PHYTOCHEMICALS","BERBERINE; BIOLOGICAL PRODUCTS; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY ALCOHOLS; HUMANS; LIPIDS; PHYTOSTEROLS; PHYTOTHERAPY; PLANT PROTEINS; SILYMARIN; ANTILIPEMIC AGENT; BERBERINE; CHITOSAN; CHOLESTIN; FISH OIL; GAMMA ORYZANOL; ISPAGULA; LUPIN PROTEIN; MANNAN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PEA PROTEIN; PHYTOSTEROL; PLANT MEDICINAL PRODUCT; POLICOSANOL; PROANTHOCYANIDIN DERIVATIVE; RHO ISO ALPHA ACID DERIVATIVE; SILYMARIN; SOYBEAN PROTEIN; UNCLASSIFIED DRUG; VEGETABLE PROTEIN; BERBERINE; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; FATTY ALCOHOL; LIPID; PHYTOSTEROL; PLANT PROTEIN; POLICOSANOL; SILYMARIN; ARTICHOKE; ARTICLE; DIETARY FIBER; DRUG EFFICACY; DYSLIPIDEMIA; GARLIC; HUMAN; LIPID ABSORPTION; LIPID METABOLISM; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERMOGENESIS; BLOOD; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; DYSLIPIDEMIAS; METABOLISM; PHYTOTHERAPY; PROCEDURES","","","ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK, (2013); ADLER A.J., HOLUB B.J., EFFECT OF GARLIC AND FISH-OIL SUPPLEMENTATION ON SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS IN HYPERCHOLESTEROLEMIC MEN, AM. J. CLIN. NUTR., 65, 2, PP. 445-450, (1997); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. METAB. CARDIOVASC. DIS., 20, 9, PP. 656-661, (2010); ACCINNI R., ROSINA M., BAMONTI F., DELLA NOCE C., TONINI A., BERNACCHI F., CAMPOLO J., CARUSO R., NOVEMBRINO C., GHERSI L., LONATI S., GROSSI S., IPPOLITO S., LORENZANO E., CIANI A., GORINI M., EFFECTS OF COMBINED DIETARY SUPPLEMENTATION ON OXIDATIVE AND INFLAMMATORY STATUS IN DYSLIPIDEMIC SUBJECTS, NUTR. METAB. CARDIOVASC. DIS., 16, 2, PP. 121-127, (2006); ARCA M., PIGNA G., TREATING STATIN-INTOLERANT PATIENTS, DIABETES METAB. SYNDR. OBES., 4, PP. 155-166, (2011); BADIMON L., VILAHUR G., PADRO T., NUTRACEUTICALS AND ATHEROSCLEROSIS: HUMAN TRIALS, CARDIOVASC. THER., 28, PP. 202-215, (2010); BAIGENT C., KEECH A., KEARNEY P.M., BLACKWELL L., BUCK G., POLLICINO C., KIRBY A., SOURJINA T., PETO R., COLLINS R., SIMES R., CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS, EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); BANERJEE S.K., SUBIR K.M., EFFECT OF GARLIC ON CARDIOVASCULAR DISORDERS: A REVIEW, NUTRITION, J1, (2002); BERGER A., REIN D., SCHAFER A., MONNARD I., GREMAUD G., LAMBELET P., BERTOLI C., SIMILAR CHOLESTEROL-LOWERING PROPERTIES OF RICE BRAN OIL, WITH VARIED GAMMA-ORYZANOL, IN MILDLY HYPERCHOLESTEROLEMIC MEN, EUR. J. NUTR., 44, 3, PP. 163-173, (2005); BRUSQ J.M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINILLAN Y., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP-KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPEMIC EFFECT OF BERBERINE, J. LIPID. RES. FEB., 47, 6, PP. 1281-1288, (2006); CICERO A.F., GADDI A., RICE BRAN OIL AND GAMMA-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHER. RES., 15, 4, PP. 277-289, (2001); CICERO A.F., FIORITO A., PANOURGIA M.P., SANGIORGI Z., GADDI A., EFFECTS OF A NEW SOY/BETA-SITOSTEROL SUPPLEMENT ON PLASMA LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS, J. AM. DIET. ASSOC., 102, 12, PP. 1807-1811, (2002); CICERO A.F., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENT THER. MED., 13, 4, PP. 273-278, (2005); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); CICERO A.F., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN. LIPIDOL., 4, 5, PP. 553-563, (2009); CICERO A.F., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN. DRUG SAF., 11, 5, PP. 753-766, (2012); CICERO A.F., PARINI A., ROSTICCI M., BRANCALEONI B., DEROSA G., GRANDI E., BORGHI C., EFFECT OF A LIPID-LOWERING NUTRACEUTICAL ON PULSE-WAVE-VELOCITY IN HYPERCHOLESTEROLEMIC PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE, TOJH, 5, PP. 18-22, (2013); CICERO A.F., PARINI A., ROSTICCI M., NUTRACEUTICALS AND CHOLESTEROL-LOWERING ACTION, INT. J. CARDIOL. MET. ENDOCR., 6, PP. 1-4, (2015); CICERO A.F., ROSTICCI M., PARINI A., MORBINI M., URSO R., GRANDI E., BORGHI C., SHORT-TERM EFFECTS OF A COMBINED NUTRACEUTICAL OF INSULIN-SENSITIVITY, LIPID LEVEL AND INDEXES OF LIVER STEATOSIS: A DOUBLE-BLIND, RANDOMIZED, CROSS-OVER CLINICAL TRIAL, NUTR. J, 14, (2015); CICERO A.F., DEROSA G., PISCIOTTA L., BARBAGALLO C., TESTING THE SHORT-TERM EFFICACY OF A LIPID-LOWERING NUTRACEUTICAL IN THE SETTING OF CLINICAL PRACTICE: A MULTICENTER STUDY, J. MED. FOOD, 18, 11, PP. 1270-1273, (2015); CICERO A.F., COLLETTI A., STATINS AND NUTRACEUTICALS/FUNCTIONAL FOOD: COULD THEY BE COMBINED?, COMBINATION THERAPY IN DYSLIPIDEMIA, PP. 127-142, (2015); DEROSA G., BONAVENTURA A., BIANCHI L., ROMANO D., D'ANGELO A., FOGARI E., MAFFIOLI P., BERBERIS ARISTATA/SILYBUM MARIANUM FIXED COMBINATION ON LIPID PROFILE AND INSULIN SECRETION IN DYSLIPIDEMIC PATIENTS, EXPERT. OPIN. BIOL. THER., 13, 11, PP. 1495-1506, (2013); DEROSA G., BONAVENTURA A., BIANCHI L., ROMANO D., D'ANGELO A., FOGARI E., MAFFIOLI P., A RANDOMIZED, PLACEBO-CONTROLLED STUDY ON THE EFFECTS OF A NUTRACEUTICAL COMBINATION OF RED YEAST RICE, SILYBUM MARIANUM AND OCTASONOL ON LIPID PROFILE, ENDOTHELIAL AND INFLAMMATORY PARAMETERS, J. BIOL. REGUL. HOMEOST. AGENTS, 28, 2, PP. 317-324, (2014); DI PIERRO F., BELLONE I., RAPACIOLI G., PUTIGNANO P., CLINICAL ROLE OF A FIXED COMBINATION OF STANDARDIZED BERBERIS ARISTATA AND SILYBUM MARIANUM EXTRACTS IN DIABETIC AND HYPERCHOLESTEROLEMIC PATIENTS INTOLERANT TO STATINS, DIABETES METAB. SYNDR. OBES., 8, PP. 89-96, (2015); EFSA, SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO EICOSAPENTAENOIC ACID (EPA), DOCOSAHEXAENOIC ACID (DHA), DOCOSAPENTAENOIC ACID (DPA) AND MAINTENANCE OF NORMAL CARDIAC FUNCTION (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325) … PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J., 8, (2010); EFSA, SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, PP. 2304-2319, (2011); FEUERSTEIN J.S., BJERKE W.S., POWDERED RED YEAST RICE AND PLANT STANOLS AND STEROLS TO LOWER CHOLESTEROL, J. DIET. SUPPL., 9, 2, PP. 110-115, (2012); FORMAN D.T., GARVIN J.E., FORESTNER J.E., TAYLOR C.B., INCREASED EXCRETION OF FECAL BILE ACIDS BY AN ORAL HYDROPHILIC COLLOID, PROC. SOC. EXP. BIOL. MED., 127, PP. 1060-1063, (1968); GALLAHER C.M., MUNION J., HESSLINK R., WISE J., GALLAHER D.D., CHOLESTEROL REDUCTION BY GLUCOMANNAN AND CHITOSAN IS MEDIATED BY CHANGES IN CHOLESTEROL ABSORPTION AND BILE ACID AND FAT EXCRETION IN RATS, J. NUTR., 130, 11, PP. 2753-2759, (2000); GEBHARDT R., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN PRIMARY CULTURED RAT HEPATOCYTES BY ARTICHOKE (CYNARA SCOLYMUS L.) EXTRACTS, J. PHARMACOL. EXP. THER., 286, 3, PP. 1122-1128, (1998); GELISSEN I.C., BRODIE B., EASTWOOD M.A., EFFECT OF PLANTAGO OVATA (PSYLLIUM) HUSK AND SEEDS ON STEROL METABOLISM: STUDIES IN NORMAL AND ILEOSTOMY SUBJECTS, AM. J. CLIN. NUTR., 59, 2, PP. 395-400, (1994); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS., 21, 6, PP. 424-429, (2011); HARRIS W.S., FISH OILS AND PLASMA LIPID AND LIPOPROTEIN METABOLISM IN HUMANS: A CRITICAL REVIEW, J. LIPID RES., 30, PP. 785-807, (1989); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., LIANG V., GO W., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST RICE DIETARY SUPPLEMENT, AM. J. CLIN. NUTR., 69, PP. 231-236, (1999); JENKINS D.J., KENDALL C.W., MARCHIE A., FAULKNER D., VIDGEN E., LAPSLEY K.G., TRAUTWEIN E.A., PARKER T.L., JOSSE R.G., LEITER L.A., CONNELLY P.W., THE EFFECT OF COMBINING PLANT STEROLS, SOY PROTEIN, VISCOUS FIBERS, AND ALMONDS IN TREATING HYPERCHOLESTEROLEMIA, METABOLISM, 52, 11, PP. 1478-1483, (2003); JENKINS D., MARCHIE C.K.A., FAULKNER D., WONG J., SOUZA R., EMAM A., PARKER T., VIDGEN E., TRAUTWEIN E., DIRECT COMPARISON OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS WITH A STATIN IN HYPERCHOLESTEROLEMIC PARTICIPANTS, AM. J. CLIN. NUTR., 81, PP. 380-387, (2005); JULIANO C., COSSU M., ALAMANNI M.C., PIU L., ANTIOXIDANT ACTIVITY OF GAMMA-ORYZANOL: MECHANISM OF ACTION AND ITS EFFECT ON OXIDATIVE STABILITY OF PHARMACEUTICAL OILS, INT. J. PHARM., 299, 1-2, PP. 146-154, (2005); KALRA E.K., NUTRACEUTICAL - DEFINITION AND INTRODUCTION, AAPS PHARM. SCI., 5, 3, (2003); KAMAL-ELDIN A., MOAZZAMI A., PLANT STEROLS AND STANOLS AS CHOLESTEROL-LOWERING INGREDIENTS IN FUNCTIONAL FOODS, RECENT PAT. FOOD. NUTR. AGRIC., 1, 1, PP. 1-14, (2009); KREN V., WALTEROVA D., SILYBIN AND SILYMARIN- NEW EFFECTS AND APPLICATIONS, BIOMED PAPERS, 149, PP. 29-41, (2005); LAMMI C., ZANONI C., SCIGLIUOLO G.M., D'AMATO A., ARNOLDI A., LUPIN PEPTIDES LOWER LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL THROUGH AN UP-REGULATION OF THE LDL RECEPTOR/STEROL REGULATORY ELEMENT BINDING PROTEIN 2 (SREBP2) PATHWAY AT HEPG2 CELL LINE, J. AGRIC. FOOD. CHEM., 62, 29, PP. 7151-7159, (2014); LERMAN R.H., MINICH D.M., DARLAND G., LAMB J.J., CHANG J.L., HSI A., BLAND J.S., TRIPP M.L., SUBJECTS WITH ELEVATED LDL CHOLESTEROL AND METABOLIC SYNDROME BENEFIT FROM SUPPLEMENTATION WITH SOY PROTEIN, PHYTOSTEROLS, HOPS RHO ISO-ALPHA ACIDS, AND ACACIA NILOTICA PROANTHOCYANIDINS, J. CLIN. LIPIDOL., 4, 1, PP. 59-68, (2010); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR. J. INTERN. MED., 25, 7, PP. 592-599, (2014); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV. THER., 28, 12, PP. 1105-1113, (2011); MCCARTY M.F., GLUCOMANNAN MINIMIZES THE POSTPRANDIAL INSULIN SURGE: A POTENTIAL ADJUVANT FOR HEPATOTHERMIC THERAPY, MED. HYPOTHESES, 58, 6, PP. 487-490, (2002); MENG S., CAO J., FENG Q., PENG J., HU Y., ROLES OF CHLOROGENIC ACID ON REGULATING GLUCOSE AND LIPIDS METABOLISM: A REVIEW, EVID. BASED COMPLEMENT ALTERNAT. MED., 2013, (2013); MINICH D.M., LERMAN R.H., DARLAND G., BABISH J.G., PACIORETTY L.M., BLAND J.S., TRIPP M.L., HOP AND ACACIA PHYTOCHEMICALS DECREASED LIPOTOXICITY IN 3T3-L1 ADIPOCYTES, DB/DB MICE, AND INDIVIDUALS WITH METABOLIC SYNDROME, J. NUTR. METAB., 2010, (2010); MUNDAY J.S., JAMES K.A., FRAY L.M., KIRKWOOD S.W., THOMPSON K.G., DAILY SUPPLEMENTATION WITH AGED GARLIC EXTRACT, BUT NOT RAW GARLIC, PROTECTS LOW-DENSITY LIPOPROTEIN AGAINST IN VITRO OXIDATION, ATHEROSCLEROSIS, 143, PP. 399-404, (1999); OGIER N., AMIOT M.J., GEORGE S., MAILLOT M., MALLMANN C., MARANINCHI M., MORANGE S., LESCUYER J.F., PELTIER S.L., CARDINAULT N., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR. J. NUTR., 52, 2, PP. 547-557, (2013); O'NEILL F.H., SANDERS T.A., THOMPSON G.R., COMPARISON OF EFFICACY OF PLANT STANOL ESTER AND STEROL ESTER: SHORT-TERM AND LONGER-TERM STUDIES, AM. J. CARDIOL., 96, PP. 29D-36D, (2005); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J. NUTR., 125, 3, PP. 606S-611S, (1995); QIANG Z., LEE S.O., YE Z., WU X., HENDRICH S., ARTICHOKE EXTRACT LOWERED PLASMA CHOLESTEROL AND INCREASED FECAL BILE ACIDS IN GOLDEN SYRIAN HAMSTERS, PHYTOTHER. RES., 26, 7, PP. 1048-1052, (2012); RODRIGUEZ DE SOTILLO D.V., HADLEY M., CHLOROGENIC ACID MODIFIES PLASMA AND LIVER CONCENTRATIONS OF: CHOLESTEROL, TRIACYLGLYCEROL, AND MINERALS IN (FA/FA) ZUCKER RATS, J. NUTR. BIOCHEM., 13, 12, PP. 717-726, (2002); ROMERO A.L., WEST K.L., ZERN T., FERNANDEZ M.L., THE SEEDS FROM PLANTAGO OVATA LOWER PLASMA LIPIDS BY ALTERING HEPATIC AND BILE ACID METABOLISM IN GUINEA PIGS, J. NUTR., 132, 6, PP. 1194-1198, (2002); RUSCICA M., GOMARASCHI M., MOMBELLI G., MACCHI C., BOSISIO R., PAZZUCCONI F., PAVANELLO C., CALABRESI L., ARNOLDI A., SIRTORI C.R., MAGNI P., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J. CLIN. LIPIDOL., 8, 1, PP. 61-68, (2014); SCAVARIELLO E.M., ARELLANO D.B., GAMMA-ORYZANOL: AN IMPORTANT COMPONENT IN RICE BRAIN OIL, ARCH. LATINOAM. NUTR., 48, 1, PP. 7-12, (1998); SCHNABEL R.B., YIN X., GONA P., LARSON M.G., BEISER A.S., MCMANUS D.D., NEWTON-CHEH C., LUBITZ S.A., MAGNANI J.W., ELLINOR P.T., SESHADRI S., WOLF P.A., VASAN R.S., BENJAMIN E.J., LEVY D., 50 YEAR TRENDS IN ATRIAL FIBRILLATION PREVALENCE, INCIDENCE, RISK FACTORS, AND MORTALITY IN THE FRAMINGHAM HEART STUDY: A COHORT STUDY, LANCET, 386, 9989, PP. 154-162, (2015); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); SIRTORI C.R., TRIOLO M., BOSISIO R., BONDIOLI A., CALABRESI L., DE VERGORI V., GOMARASCHI M., MOMBELLI G., PAZZUCCONI F., ZACHERL C., ARNOLDI A., HYPOCHOLESTEROLAEMIC EFFECTS OF LUPIN PROTEIN AND PEA PROTEIN/FIBRE COMBINATIONS IN MODERATELY HYPERCHOLESTEROLAEMIC INDIVIDUALS, BR. J. NUTR., 107, 8, PP. 1176-1183, (2012); SHRESTHA S., VOLEK J.S., UDANI J., WOOD R.J., GREENE C.M., AGGARWAL D., CONTOIS J.H., KAVOUSSI B., FERNANDEZ M.L., A COMBINATION THERAPY INCLUDING PSYLLIUM AND PLANT STEROLS LOWERS LDL CHOLESTEROL BY MODIFYING LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC INDIVIDUALS, J. NUTR., 136, 10, PP. 2492-2497, (2006); SHRESTHA S., FREAKE H.C., MCGRANE M.M., VOLEK J.S., FERNANDEZ M.L., A COMBINATION OF PSYLLIUM AND PLANT STEROLS ALTERS LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC SUBJECTS BY MODIFYING THE INTRAVASCULAR PROCESSING OF LIPOPROTEINS AND INCREASING LDL UPTAKE, J. NUTR., 137, 5, PP. 1165-1170, (2007); SOBOLOVA L., SKOTTOVA N., VECERA R., URBANEK K., EFFECT OF SILYMARIN AND ITS POLYPHENOLIC FRACTION ON CHOLESTEROL ABSORPTION IN RATS, PHARMACOL. RES., 53, 2, PP. 104-112, (2006); STEFANUTTI C., MAZZA F., VIVENZIO A., DI GIACOMO S., PERRONE G., SERRA M., BUCCI A., COMBINED TREATMENT WITH DIF1STAT AND DIET REDUCE PLASMA LIPID INDICATORS OF MODERATE HYPERCHOLESTEROLEMIA MORE EFFECTIVELY THAN DIET ALONE: A RANDOMIZED TRIAL IN PARALLEL GROUPS, LIPIDS, 44, 12, PP. 1141-1148, (2009); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED. J. NUTR. METAB, 4, 2, PP. 133-139, (2011); VASANTHI H.R., PARAMESWARI P., DAS D.K., MULTIFACETED ROLE OF TOCOTRIENOLS IN CARDIOPROTECTION SUPPORTS THEIR STRUCTURE: FUNCTION RELATION, GENES NUTR., 7, 1, PP. 19-28, (2012); VUKSAN V., SIEVENPIPER J.L., XU Z., WONG E.Y., JENKINS A.L., BELJAN-ZDRAVKOVIC U., LEITER L.A., JOSSE R.G., STAVRO M.P., KONJAC-MANNAN AND AMERICAN GINSING: EMERGING ALTERNATIVE THERAPIES FOR TYPE 2 DIABETES MELLITUS, J. AM. COLL. NUTR., 20, S5, PP. 370S-380S, (2001); WAGNER H., HORHAMMER L., MUNSTER R., ON THE CHEMISTRY OF SILYMARIN (SILYBIN), THE ACTIVE PRINCIPLE OF THE FRUITS FROM SILYBUM MARIANUM (L.) GAERTN. (CARDUUS MARIANUS L.), ARZNEIMITTELFORSCHUNG, 18, 6, PP. 688-696, (1968); YOSHIDA M., VANSTONE C.A., PARSONS W.D., ZAWISTOWSKI J., JONES P.J., EFFECT OF PLANT STEROLS AND GLUCOMANNAN ON LIPIDS IN INDIVIDUALS WITH AND WITHOUT TYPE II DIABETES, EUR. J. CLIN. NUTR., 60, 4, PP. 529-537, (2006)","A.F.G. CICERO; SANT'ORSOLA-MALPIGHI UNIVERSITY HOSPITAL, BOLOGNA, BUILDING 2 –IV FLOOR, VIA ALBERTONI 15, 40138, ITALY; EMAIL: ARRIGO.CICERO@UNIBO.IT","ELSEVIER GMBH","ENGLISH","PHYTOMEDICINE","ARTICLE","ISI","2-S2.0-84982180019","PHYTOMEDICINE","ALMA MATER STUDIORUM ATHEROSCLEROSIS AND METABOLIC UNIVERSITY OF BOLOGNA;ALMA MATER STUDIORUM ATHEROSCLEROSIS AND METABOLIC UNIVERSITY OF BOLOGNA","NOTREPORTED;SANT'ORSOLA-MALPIGHI UNIVERSITY HOSPITAL;NOTREPORTED",NA,"CICERO AFG, 2016, PHYTOMEDICINE","CICERO AFG, 2016, PHYTOMEDICINE"
"NAM D;YUN J;KIM D;KIM O","NAM, DA-EUN (55150091700); YUN, JEONG-MOON (56056286400); KIM, DAKYUNG (57200501538); KIM, OK-KYUNG (35484503100)","POLICOSANOL ATTENUATES CHOLESTEROL SYNTHESIS VIA AMPK ACTIVATION IN HYPERCHOLESTEROLEMIC RATS",2019,"JOURNAL OF MEDICINAL FOOD","22","7",19,"10.1089/jmf.2019.4491","CARTER IMMUNOLOGY CENTER, UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE, CHARLOTTESVILLE, VA, UNITED STATES;RESEARCH INSTITUTE OF CLINICAL NUTRITION, KYUNG HEE UNIVERSITY, SEOUL, SOUTH KOREA;RESEARCH INSTITUTE OF CLINICAL NUTRITION, KYUNG HEE UNIVERSITY, SEOUL, SOUTH KOREA;DIVISION OF FOOD AND NUTRITION AND HUMAN ECOLOGY RESEARCH INSTITUTE, CHONNAM NATIONAL UNIVERSITY, 77 YONGBONG-DONG, BUK-GU, GWANGJU, 61186, SOUTH KOREA","THIS STUDY WAS CARRIED OUT TO INVESTIGATE THE EFFECTS OF POLICOSANOL ON HIGH-FAT AND HIGH-CHOLESTEROL DIET-INDUCED HYPERCHOLESTEROLEMIC RATS TO PROVIDE STRONG EVIDENCE IN SUPPORT OF ITS HYPOCHOLESTEROLEMIC EFFECT. THE HYPERCHOLESTEROLEMIC RATS SHOWED ELEVATIONS IN LIVER WEIGHT, TOTAL TRIGLYCERIDES, TOTAL CHOLESTEROL, AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL IN SERUM; HOWEVER, POLICOSANOL SUPPLEMENTATION REDUCED THESE MARKERS SIGNIFICANTLY. IN ADDITION, WE FOUND THAT POLICOSANOL SUPPLEMENTATION STIMULATED AN INCREASE IN FECAL CHOLESTEROL AND BILE ACID CONTENTS AND DEACTIVATED 3-HYDROXY-3-METHYLGLUTARYL-COA (HMG-COA) REDUCTASE BY AMP-ACTIVATED PROTEIN KINASE (AMPK) PHOSPHORYLATION DURING HIGH-FAT AND HIGH-CHOLESTEROL-CONTAINING DIET-INDUCED DEVELOPMENT OF HYPERCHOLESTEROLEMIA. POLICOSANOL SUPPLEMENTATION DECREASED APOB LEVELS AND INCREASED LDL-RECEPTOR EXPRESSION, BUT IT DID NOT AFFECT THE HEPATIC ACAT2 LEVEL IN LIVERS FROM HYPERCHOLESTEROLEMIC RATS. MOREOVER, SUPPLEMENTATION WITH POLICOSANOL SIGNIFICANTLY DECREASED AORTIC WALL THICKNESS AND LEVELS OF P-SELECTIN AND SOLUBLE VASCULAR CELL ADHESION MOLECULE (SVCAM-1) IN SERUM. IN CONCLUSION, WE SUGGEST THAT POLICOSANOL SUPPLEMENTATION INDUCES ANTIHYPERCHOLESTEROLEMIA BY INHIBITING CHOLESTEROL BIOSYNTHESIS, LDL CHOLESTEROL UPTAKE, AND CHOLESTEROL EXCRETION. © COPYRIGHT 2019, MARY ANN LIEBERT, INC., PUBLISHERS, AND KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION 2019.","AMPK; HMG-COA REDUCTASE; HYPERCHOLESTEROLEMIA; LDL CHOLESTEROL; POLICOSANOL","AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; APOLIPOPROTEIN B-100; CHOLESTEROL; CHOLESTEROL, HDL; DIET, HIGH-FAT; FATTY ALCOHOLS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERCHOLESTEROLEMIA; LIVER; MALE; P-SELECTIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; STEROL O-ACYLTRANSFERASE; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1; ACYLTRANSFERASE; ACYLTRANSFERASE 2; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BILE ACID; CHOLESTEROL; HEXACOSANOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; OCTACOSANOL; PADGEM PROTEIN; POLICOSANOL; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; APOLIPOPROTEIN B100; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; PADGEM PROTEIN; POLICOSANOL; STEROL O-ACYLTRANSFERASE 2; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMPK SIGNALING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVATION; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIC ACTIVITY; IN VIVO STUDY; LIPID DIET; LIPID FINGERPRINTING; LIVER WEIGHT; MALE; MRNA EXPRESSION LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; AORTA; BIOSYNTHESIS; BLOOD; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; LIVER; METABOLISM; SPRAGUE DAWLEY RAT","","","KATZ J., CHAUSHU G., SHARABI Y., ON THE ASSOCIATION BETWEEN HYPERCHOLESTEROLEMIA, CARDIOVASCULAR DISEASE AND SEVERE PERIODONTAL DISEASE, J CLIN PERIODONTOL, 28, PP. 865-868, (2001); TEN KATE G.R., BOS S., DEDIC A., ET AL., INCREASED AORTIC VALVE CALCIFICATION IN FAMILIAL HYPERCHOLESTEROLEMIA: PREVALENCE, EXTENT, AND ASSOCIATED RISK FACTORS, J AM COLL CARDIOL, 66, PP. 2687-2695, (2015); LI T., CHIANG J.Y., REGULATION OF BILE ACID AND CHOLESTEROL METABOLISM BY PPARS, PPAR RES, 2009, (2009); NISHINA P.M., FREEDLAND R.A., THE EFFECTS OF DIETARY FIBER FEEDING ON CHOLESTEROL METABOLISM IN RATS, J NUTR, 120, PP. 800-805, (1990); BURG J.S., ESPENSHADE P.J., REGULATION OF HMG-COA REDUCTASE IN MAMMALS AND YEAST, PROG LIPID RES, 50, PP. 403-410, (2011); SINGHDK BANERJEE S., PORTER T.D., GREEN AND BLACK TEA EXTRACTS INHIBIT HMG-COA REDUCTASE AND ACTIVATE AMP KINASE TO DECREASE CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS, J NUTR BIOCHEM, 20, PP. 816-822, (2009); BROWN M.S., GOLDSTEIN J.L., THE SREBP PATHWAY: REGULATION OF CHOLESTEROL METABOLISM BY PROTEOLYSIS OF A MEMBRANE-BOUND TRANSCRIPTION FACTOR, CELL, 89, PP. 331-340, (1997); THOMPSON P.D., PANZA G., ZALESKI A., TAYLOR B., STATIN-ASSOCIATED SIDE EFFECTS, J AM COLL CARDIOL, 67, PP. 2395-2410, (2016); BALLARD K.D., TAYLOR B.A., THOMPSON P.D., STATIN-ASSOCIATED MUSCLE INJURY, EUR J PREV CARDIOL, 22, (2015); KOH J.H., KIM J.M., CHANG U.J., SUH H.J., HYPOCHOLESTEROLEMIC EFFECT OF HOT-WATER EXTRACT FROM MYCELIA OF CORDYCEPS SINENSIS, BIOL PHARM BULL, 26, PP. 84-87, (2003); AHMED I., LAKHANI M.S., GILLETT M., JOHN A., RAZA H., HYPOTRIGLYCERIDEMIC AND HYPOCHOLESTEROLEMIC EFFECTS OF ANTI-DIABETIC MOMORDICA CHARANTIA (KARELA) FRUIT EXTRACT IN STREPTOZOTOCININDUCED DIABETIC RATS, DIABETES RES CLIN PRACT, 51, PP. 155-161, (2001); LUO Q.F., SUN L., SI J.Y., CHEN D.H., HYPOCHOLESTEROLEMIC EFFECT OF STILBENES CONTAINING EXTRACT-FRACTION FROM CAJANUS CAJAN L. ON DIET-INDUCED HYPERCHOLESTEROLEMIA IN MICE, PHYTOMEDICINE, 15, PP. 932-939, (2008); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); ZHENG S., HOOS L., COOK J., ET AL., EZETIMIBE IMPROVES HIGH FAT AND CHOLESTEROL DIET-INDUCED NON-ALCOHOLIC FATTY LIVER DISEASE IN MICE, EUR J PHARMACOL, 584, PP. 118-124, (2008); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); STILLEMARK-BILLTON P., BECK C., BOREN J., OLOFSSON S.O., RELATION OF THE SIZE AND INTRACELLULAR SORTING OF APOB TO THE FORMATION OF VLDL 1 AND VLDL 2, J LIPID RES, 46, PP. 104-114, (2005); CAPRON L., ATHEROSCLEROSIS IS AN INFLAMMATORY DISEASE, REV MED INTERNE, 9, PP. 359-361, (1988); PAIK H.D., PARK J.S., PARK E., EFFECTS OF BACILLUS POLYFERMENTICUS SCD ON LIPID AND ANTIOXIDANT METABOLISMS IN RATS FED A HIGH-FAT AND HIGH-CHOLESTEROL DIET, BIOL PHARM BULL, 28, PP. 1270-1274, (2005); TANG L.Q., WEI W., CHEN L.M., LIU S., EFFECTS OF BERBERINE ON DIABETES INDUCED BY ALLOXAN AND A HIGH-FAT/HIGH-CHOLESTEROL DIET IN RATS, J ETHNOPHARMACOL, 108, PP. 109-115, (2006); GALLAHER C.M., MUNION J., HESSLINK R., WISE J., GALLAHER D.D., CHOLESTEROL REDUCTION BY GLUCOMANNAN AND CHITOSAN IS MEDIATED BY CHANGES IN CHOLESTEROL ABSORPTION AND BILE ACID AND FAT EXCRETION IN RATS, J NUTR, 130, PP. 2753-2759, (2000); HOFMANN A.F., BILE ACIDS: THE GOOD, THE BAD, AND THE UGLY, NEWS PHYSIOL SCI, 14, PP. 24-29, (1999); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); TEMEL R.E., HOU L., RUDEL L.L., SHELNESS G.S., ACAT2 STIMULATES CHOLESTERYL ESTER SECRETION IN APOB-CONTAINING LIPOPROTEINS, J LIPID RES, 48, PP. 1618-1627, (2007); LEE J.H., LEE S.Y., KIM B., ET AL., BARLEY SPROUT EXTRACT CONTAINING POLICOSANOLS AND POLYPHENOLS REGULATE AMPK SREBP2 AND ACAT2 ACTIVITY AND CHOLESTEROL AND GLUCOSE METABOLISM IN VITRO AND IN VIVO, FOOD RES INT, 72, PP. 174-183, (2015); KOYAMA H., MAENO T., FUKUMOTO S., ET AL., PLATELET P-SELECTIN EXPRESSION IS ASSOCIATED WITH ATHEROSCLEROTIC WALL THICKNESS IN CAROTID ARTERY IN HUMANS, CIRCULATION, 108, PP. 524-529, (2003)","O.-K. KIM; DIVISION OF FOOD AND NUTRITION AND HUMAN ECOLOGY RESEARCH INSTITUTE, CHONNAM NATIONAL UNIVERSITY, BUK-GU, GWANGJU, 77 YONGBONG-DONG, 61186, SOUTH KOREA; EMAIL: 20WOSKXM@CHONNAM.AC.KR","MARY ANN LIEBERT INC.","ENGLISH","J. MED. FOOD","ARTICLE","ISI","2-S2.0-85075093387","J MED FOOD","UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE;KYUNG HEE UNIVERSITY;KYUNG HEE UNIVERSITY;CHONNAM NATIONAL UNIVERSITY","NOTREPORTED;CHONNAM NATIONAL UNIVERSITY;NOTREPORTED",NA,"NAM D-E, 2019, J MED FOOD","NAM D-E, 2019, J MED FOOD"
"TIAN Y;ACEVEDO N","TIAN, YIXING (57212702762); ACEVEDO, NURIA C. (57197166068)","ROLE OF SUPRAMOLECULAR POLICOSANOL OLEOGELS IN THE PROTECTION OF RETINYL PALMITATE AGAINST PHOTODEGRADATION",2020,"RSC ADVANCES","10","9",7,"10.1039/c9ra07820g","DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, IOWA STATE UNIVERSITY, 2543 FOOD SCIENCE BUILDING, AMES, 50011, IA, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, IOWA STATE UNIVERSITY, 2543 FOOD SCIENCE BUILDING, AMES, 50011, IA, UNITED STATES","EXPOSURE OF RETINYL PALMITATE (RP) TO ULTRAVIOLET RADIATION CAN LEAD TO ITS PHOTO-DEGRADATION AND LOSS OF BIOLOGICAL ACTIVITY. THEREFORE, THERE IS A DEMAND TO EXPLORE NEW APPROACHES TO PROTECT RP IN AN EASY, ECONOMICAL AND EFFICIENT WAY. THE OBJECTIVE OF THIS STUDY WAS TO EXPLORE THE ROLE OF POLICOSANOL OLEOGELS (PCOS) IN THE PROTECTION OF RP FROM PHOTODEGRADATION. UV-BLOCKING ACTION WAS TESTED BY PLACING A LAYER OF PCO AS A BARRIER BETWEEN A UVA (365 NM) SOURCE AND 1% RP IN SOYBEAN OIL. EFFECTS OF STRUCTURAL CHARACTERISTICS OF PCOS COOLED AT DIFFERENT RATES ON RP PHOTOSTABILITY WERE ALSO STUDIED. THE ABILITY OF PCOS TO PREVENT RADICAL-MEDIATED REACTIONS WAS ASSESSED BY MEASURING OIL OXIDATIVE STABILITY OVER STORAGE TIME AT 40 °C. THE REMAINING % RP WAS MEASURED BY HPLC DURING 4 DAYS OF UVA IRRADIATION. PCO BLOCKED ENERGY ABSORPTION FROM UVA AND FURTHER DAMPENED THE UVA MEDIATED IONIC PHOTODISSOCIATION AND FREE RADICAL REACTIONS DUE TO MATRIX IMMOBILIZATION. AFTER 4 DAYS OF UV EXPOSURE, PHOTODEGRADATION OF RP WAS REDUCED BY 64% WHEN A PCO LAYER WAS USED AS A BARRIER. PEROXIDE VALUES (PV) AND P-ANISIDINE VALUES (P-A.V.) OF SOYBEAN OIL (SO) WERE SIGNIFICANTLY HIGHER THAN THOSE OF PCOS OVER STORAGE TIME. COOLING RATE PROCESSING PLAYED A SIGNIFICANT ROLE IN RP PROTECTION; THE FASTER THE COOLING RATE, THE HIGHER THE RP PHOTOSTABILITY. THIS STUDY DEMONSTRATED THAT THE PROTECTIVE MECHANISM OF RP IN PCOS IS A COMBINED EFFECT OF PHYSICAL UV-BARRIER ACTION, MOLECULAR IMMOBILIZATION AND INHIBITION OF THE FREE RADICAL-MEDIATED REACTION. THIS JOURNAL IS © THE ROYAL SOCIETY OF CHEMISTRY.","","BIOACTIVITY; COOLING; FREE RADICAL REACTIONS; FREE RADICALS; IRRADIATION; PALMITIC ACID; REACTION KINETICS; COMBINED EFFECT; MEDIATED REACTIONS; MOLECULAR IMMOBILIZATION; OXIDATIVE STABILITY; PHOTO-STABILITY; RETINYL PALMITATE; STRUCTURAL CHARACTERISTICS; UVA IRRADIATIONS; SOYBEAN OIL","HATCH ACT AND STATE OF IOWA","THE AUTHORS ACKNOWLEDGE DR ANN PERERA, DR LUCAS SHOWMAN, AND DR KIRTHI NARAYANASWAMY, FROM W. M. KECK METABOLOMICS RESEARCH LABORATORY FOR ASSISTING WITH THE HPLC METHOD FOR RETINYL PALMITATE ANALYSIS. THIS PAPER IS A PRODUCT OF THE IOWA AGRICULTURE AND HOME ECONOMICS EXPERIMENT STATION, AMES, IOWA. PROJECT NO. IOW03902 SPONSORED BY HATCH ACT AND STATE OF IOWA FUNDS.","TEE E.S., LEE C., CAROTENOIDS AND RETINOIDS IN HUMAN NUTRITION, CRIT. REV. FOOD SCI. NUTR., 31, 12, PP. 103-163, (1992); DERITTER E., VITAMINS IN PHARMACEUTICAL FORMULATIONS, J. PHARM. SCI., 71, 10, PP. 1073-1096, (1982); JI H.-G., SEO B.S., RETINYL PALMITATE AT 5% IN A CREAM: ITS STABILITY, EFFICACY AND EFFECT, COSMET. TOILETRIES, 114, 3, PP. 61-68, (1999); MCBEE J.K., KUKSA V., ALVAREZ R., DE LERA A.R., PREZHDO O., HAESELEER F., SOKAL I., PALCZEWSKI K., ISOMERIZATION OF ALL-TRANS-RETINOL TO CIS-RETINOLS IN BOVINE RETINAL PIGMENT EPITHELIAL CELLS: DEPENDENCE ON THE SPECIFICITY OF RETINOID-BINDING PROTEINS, BIOCHEM, 39, 37, (2000); ROZANOWSKA M., CANTRELL A., EDGE R., LAND E.J., SARNA T., TRUSCOTT T.G., PULSE RADIOLYSIS STUDY OF THE INTERACTION OF RETINOIDS WITH PEROXYL RADICALS, FREE RADIC. BIOL. MED., 39, 10, PP. 1399-1405, (2005); TOLLESON W.H., CHERNG S.-H., XIA Q., BOUDREAU M., YIN J.J., WAMER W.G., HOWARD P.C., YU H., FU P.P., PHOTODECOMPOSITION AND PHOTOTOXICITY OF NATURAL RETINOIDS, INT. J. ENVIRON. RES. PUBLIC HEALTH, 2, 1, PP. 147-155, (2005); IHARA H., HASHIZUME N., HIRASE N., SUZUE R., ESTERIFICATION MAKES RETINOL MORE LABILE TO PHOTOLYSIS, J. NUTR. SCI. VITAMINOL., 45, 3, PP. 353-358, (1999); FU P.P., XIA Q., YIN J.J., CHERNG S.H., YAN J., MEI N., CHEN T., BOUDREAU M.D., HOWARD P.C., WAMER W.G., PHOTODECOMPOSITION OF VITAMIN A AND PHOTOBIOLOGICAL IMPLICATIONS FOR THE SKIN, PHOTOCHEM. PHOTOBIOL., 83, 2, PP. 409-424, (2007); CRANK G., PARDIJANTO M.S., PHOTO-OXIDATIONS AND PHOTOSENSITIZED OXIDATIONS OF VITAMIN A AND ITS PALMITATE ESTER, J. PHOTOCHEM. PHOTOBIOL., A, 85, 12, PP. 93-100, (1995); MOUSSERON-CANET M., PHOTOCHEMICAL TRANSFORMATION OF VITAMIN A, METHODS ENZYMOL., 18, PP. 591-615, (1971); MOUSSERON-CANET M., MANI J., FAVIE C., LERNER D., ON THE PHOTOCHEMICAL ISOMERIZATION OF VITAMIN A, C. R. CHIM., 262, PP. 153-155, (1966); TSUJIMOTO K., HOZOJI H., OHASHI M., WATANABE M., HATTORI H., WAVELENGTH-DEPENDENT PEROXIDE FORMATION UPON IRRADIATION OF ALL-TRANS RETINAL IN AN AERATED SOLUTION, CHEM. LETT., 13, 10, PP. 1673-1676, (1984); XIA Q., YIN J.J., WAMER W.G., CHERNG S.-H., BOUDREAU M.D., HOWARD P.C., YU H., FU P.P., PHOTOIRRADIATION OF RETINYL PALMITATE IN ETHANOL WITH ULTRAVIOLET LIGHT-FORMATION OF PHOTODECOMPOSITION PRODUCTS, REACTIVE OXYGEN SPECIES, AND LIPID PEROXIDES, INT. J. ENVIRON. RES. PUBLIC HEALTH, 3, 2, PP. 185-190, (2006); CARLOTTI M., ROSSATTO V., GALLARATE M., VITAMIN A AND VITAMIN A PALMITATE STABILITY OVER TIME AND UNDER UVA AND UVB RADIATION, INT. J. PHARM., 240, 1, PP. 85-94, (2002); CARLOTTI M., ROSSATTO V., GALLARATE M., TROTTA M., DEBERNARDI F., VITAMIN A PALMITATE PHOTOSTABILITY AND STABILITY OVER TIME, INT. J. COSMET. SCI., 26, 5, (2004); CARLOTTI M., SAPINO S., TROTTA M., BATTAGLIA L., VIONE D., PELIZZETTI E., PHOTOSTABILITY AND STABILITY OVER TIME OF RETINYL PALMITATE IN AN O/W EMULSION AND IN SLN INTRODUCED IN THE EMULSION, J. DISPERSION SCI. TECHNOL., 26, 2, PP. 125-138, (2005); JENNING V., GOHLA S.H., ENCAPSULATION OF RETINOIDS IN SOLID LIPID NANOPARTICLES (SLN), J. MICROENCAPSULATION, 18, 2, PP. 149-158, (2001); DUCLAIROIR C., IRACHE J.M., NAKACHE E., ORECCHIONI A.M., CHABENAT C., POPINEAU Y., GLIADIN NANOPARTICLES: FORMATION, ALL-TRANS-RETINOIC ACID ENTRAPMENT AND RELEASE, SIZE OPTIMIZATION, POLYM. INT., 48, 4, PP. 327-333, (1999); CIRPANLI Y., UNLU N., CALIS S., HINCAL A., FORMULATION AND IN VITRO CHARACTERIZATION OF RETINOIC ACID LOADED POLY (LACTIC-CO-GLYCOLIC ACID) MICROSPHERES, J. MICROENCAPSULATION, 22, PP. 877-889, (2005); SEMENZATO A., BAU A., DALL'AGLIO C., NICOLINI M., BETTERO A., CALLIARI I., STABILITY OF VITAMIN A PALMITATE IN COSMETIC EMULSIONS: INFLUENCE OF PHYSICAL PARAMETERS, INT. J. COSMET. SCI., 16, 4, PP. 139-147, (1994); WANG H., FANG F., LI X., FU C., YANG Y., IMPROVED PHOTOSTABILITY OF VITAMIN A PALMITATE ORIGINATING FROM SELF-ASSEMBLED SUPRAMOLECULAR GELS, CHIN. SCI. BULL., 57, 33, PP. 4257-4263, (2012); MARANGONI A.G., GARTI N., EDIBLE OLEOGELS: STRUCTURE AND HEALTH IMPLICATIONS, (2011); YU H., SHI K., LIU D., HUANG Q., DEVELOPMENT OF A FOOD-GRADE ORGANOGEL WITH HIGH BIOACCESSIBILITY AND LOADING OF CURCUMINOIDS, FOOD CHEM., 131, 1, PP. 48-54, (2012); MURDAN S., ANDRYSEK T., SON D., NOVEL GELS AND THEIR DISPERSIONS-ORAL DRUG DELIVERY SYSTEMS FOR CICLOSPORIN, INT. J. PHARM., 300, 1, PP. 113-124, (2005); IWANAGA K., SUMIZAWA T., MIYAZAKI M., KAKEMI M., CHARACTERIZATION OF ORGANOGEL AS A NOVEL ORAL CONTROLLED RELEASE FORMULATION FOR LIPOPHILIC COMPOUNDS, INT. J. PHARM., 388, 1, PP. 123-128, (2010); SULLIVAN C.M., DAVIDOVICH-PINHAS M., WRIGHT A.J., BARBUT S., MARANGONI A.G., ETHYLCELLULOSE OLEOGELS FOR LIPOPHILIC BIOACTIVE DELIVERY-EFFECT OF OLEOGELATION ON IN VITRO BIOACCESSIBILITY AND STABILITY OF BETA-CAROTENE, FOOD FUNCT., 8, 4, PP. 1438-1451, (2017); TIAN Y., ACEVEDO N.C., KINETIC STUDY ON PHOTOSTABILITY OF RETINYL PALMITATE ENTRAPPED IN POLICOSANOL OLEOGELS, FOOD CHEM., 255, PP. 252-259, (2018); LUPI F.R., GABRIELE D., BALDINO N., SETA L., DE CINDIO B., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RES. INT., 51, PP. 510-517, (2013); SCALZO M., SANTUCCI E., CERRETO F., CARAFA M., MODEL LIPOPHILIC FORMULATIONS OF RETINYL PALMITATE: INFLUENCE OF CONSERVATIVE AGENTS ON LIGHT-INDUCED DEGRADATION, J. PHARM. BIOMED. ANAL., 34, 5, PP. 921-931, (2004); CARR H.Y., PURCELL E.M., EFFECTS OF DIFFUSION ON FREE PRECESSION IN NUCLEAR MAGNETIC RESONANCE EXPERIMENTS, PHYS. REV., 94, PP. 630-638, (1954); MEIBOOM S., GILL D., MODIFIED SPIN-ECHO METHOD FOR MEASURING NUCLEAR RELAXATION TIMES, REV. SCI. INSTRUM., 29, PP. 668-691, (1958); AOCS OFFICIAL METHOD CD 8B-90, (2011); MURPHY P.A., ENGELHARDT R., SMITH S.E., ISOMERIZATION OF RETINYL PALMITATE IN FORTIFIED SKIM MILK UNDER RETAIL FLUORESCENT LIGHTING, J. AGRIC. FOOD CHEM., 36, 3, PP. 592-595, (1988); ROGERS M.A., MARANGONI A.G., NON-ISOTHERMAL NUCLEATION AND CRYSTALLIZATION OF 12-HYDROXYSTEARIC ACID IN VEGETABLE OILS, CRYST. GROWTH DES., 8, 12, PP. 4596-4601, (2008); BLAKE A.I., MARANGONI A.G., STRUCTURE AND PHYSICAL PROPERTIES OF PLANT WAX CRYSTAL NETWORKS AND THEIR RELATIONSHIP TO OIL BINDING CAPACITY, J. AM. OIL CHEM. SOC., 91, 6, PP. 885-903, (2014); DIBILDOX-ALVARADO E., RODRIGUES J.N., GIOIELLI L.A., TORO-VAZQUEZ J.F., MARANGONI A.G., EFFECTS OF CRYSTALLINE MICROSTRUCTURE ON OIL MIGRATION IN A SEMISOLID FAT MATRIX, CRYST. GROWTH DES., 4, 4, PP. 731-736, (2004); LAREDO T., BARBUT S., MARANGONI A.G., MOLECULAR INTERACTIONS OF POLYMEROLEOGELATION, SOFT MATTER, 7, 6, PP. 2734-2743, (2011); GRAVELLE A., DAVIDOVICH-PINHAS M., ZETZL A., BARBUT S., MARANGONI A., INFLUENCE OF SOLVENT QUALITY ON THE MECHANICAL STRENGTH OF ETHYLCELLULOSE OLEOGELS, CARBOHYDR. POLYM., 135, PP. 169-179, (2016); PIGNITTER M., DUMHART B., GARTNER S., JIRSA F., STEIGER G., KRAEMER K., SOMOZA V., VITAMIN A IS RAPIDLY DEGRADED IN RETINYL PALMITATE-FORTIFIED SOYBEAN OIL STORED UNDER HOUSEHOLD CONDITIONS, J. AGRIC. FOOD CHEM., 62, 30, PP. 7559-7566, (2014); STEELE R., UNDERSTANDING AND MEASURING THE SHELF-LIFE OF FOOD, (2004)","","ROYAL SOCIETY OF CHEMISTRY","ENGLISH","RSC ADV.","ARTICLE","ISI","2-S2.0-85078251639","RSC ADV",NA,"NOTREPORTED",NA,"TIAN Y, 2020, RSC ADV","TIAN Y, 2020, RSC ADV"
"MACH F;BAIGENT C;CATAPANO A;KOSKINA K;CASULA M;BADIMON L;CHAPMAN M;DE B G;DELGADO V;FERENCE B;GRAHAM I;HALLIDAY A;LANDMESSER U;MIHAYLOVA B;PEDERSEN T;RICCARDI G;RICHTER D;SABATINE M;TASKINEN M;TOKGOZOGLU L;WIKLUND O;WINDECKER S;ABOYANS V;COLLET J;DEAN V;FITZSIMONS D;GALE C;GROBBEE D;HALVORSEN S;HINDRICKS G;IUNG B;JÜNI P;KATUS H;LECLERCQ C;LETTINO M;LEWIS B;MERKELY B;MUELLER C;PETERSEN S;PETRONIO A;ROFFI M;SHLYAKHTO E;SIMPSON I;SOUSA-UVA M;TOUYZ R;NIBOUCHE D;ZELVEIAN P;SIOSTRZONEK P;NAJAFOV R;VAN D B P;POJSKIC B;POSTADZHIYAN A;KYPRIS L;ŠPINAR J;LARSEN M;ELDIN H;VIIGIMAA M;STRANDBERG T;FERRIÈRES J;AGLADZE R;LAUFS U;RALLIDIS L;BAJNOK L;GUDJÓNSSON T;MAHER V;HENKIN Y;GULIZIA M;MUSSAGALIYEVA A;BAJRAKTARI G;KERIMKULOVA A;LATKOVSKIS G;HAMOUI O;SLAPIKAS R;VISSER L;DINGLI P;IVANOV V;BOSKOVIC A;NAZZI M;VISSEREN F;MITEVSKA I;RETTERSTØL K;JANKOWSKI P;FONTES-CARVALHO R;GAITA D;EZHOV M;FOSCOLI M;GIGA V;PELLA D;FRAS Z;PEREZ D I L;HAGSTRÖM E;LEHMANN R;ABID L;OZDOGAN O;MITCHENKO O;PATEL R","MACH, FRANÇOIS (7005352638); BAIGENT, COLIN (56673911800); CATAPANO, ALBERICO L. (7006246941); KOSKINA, KONSTANTINOS C. (57211147519); CASULA, MANUELA (36173674300); BADIMON, LINA (7102141956); CHAPMAN, M. JOHN (7401435980); DE BACKER, GUY G. (24288352300); DELGADO, VICTORIA (24172709900); FERENCE, BRIAN A. (6506040626); GRAHAM, IAN M. (35373661800); HALLIDAY, ALISON (7102593623); LANDMESSER, ULF (6602879397); MIHAYLOVA, BORISLAVA (8764800900); PEDERSEN, TERJE R. (7202189829); RICCARDI, GABRIELE (7102385746); RICHTER, DIMITRIOS J. (35434226200); SABATINE, MARC S. (6701496870); TASKINEN, MARJA-RIITTA (57193256111); TOKGOZOGLU, LALE (57208489485); WIKLUND, OLOV (7005459783); WINDECKER, STEPHAN (7003473419); ABOYANS, VICTOR (56214736500); COLLET, JEAN-PHILIPPE (7102328222); DEAN, VERONICA (57223410945); FITZSIMONS, DONNA (57203953034); GALE, CHRIS P. (35837808000); GROBBEE, DIEDERICK (7103100613); HALVORSEN, SIGRUN (9039942100); HINDRICKS, GERHARD (35431335000); IUNG, BERNARD (55785385300); JÜNI, PETER (7004263326); KATUS, HUGO A. (24299225600); LECLERCQ, CHRISTOPHE (7006426549); LETTINO, MADDALENA (6602951700); LEWIS, BASIL S. (7401867678); MERKELY, BELA (7004434435); MUELLER, CHRISTIAN (57638261900); PETERSEN, STEFFEN (35430477200); PETRONIO, ANNA SONIA (56604816300); ROFFI, MARCO (7004532440); SHLYAKHTO, EVGENY (16317213100); SIMPSON, IAIN A. (7102735784); SOUSA-UVA, MIGUEL (7003661979); TOUYZ, RHIAN M. (7005833567); NIBOUCHE, DJAMALEDDINE (25642009800); ZELVEIAN, PAROUNAK H. (6603421475); SIOSTRZONEK, PETER (7005389696); NAJAFOV, RUSLAN (56313816900); VAN DE BORNE, PHILIPPE (7003816724); POJSKIC, BELMA (25623457000); POSTADZHIYAN, ARMAN (55900865700); KYPRIS, LAMBROS (57211147081); ŠPINAR, JINDŘICH (55941877300); LARSEN, MOGENS LYTKEN (35377542700); ELDIN, HESHAM SALAH (57211145783); VIIGIMAA, MARGUS (57221665512); STRANDBERG, TIMO E. (56962715500); FERRIÈRES, JEAN (7006559388); AGLADZE, RUSUDAN (24922963900); LAUFS, ULRICH (26643295500); RALLIDIS, LOUKIANOS (7003545638); BAJNOK, LÁSZLÓ (6602851367); GUDJÓNSSON, THORBJÖRN (6603103726); MAHER, VINCENT (7101603639); HENKIN, YAAKOV (7003459016); GULIZIA, MICHELE MASSIMO (57214295362); MUSSAGALIYEVA, AISULU (57189660403); BAJRAKTARI, GANI (12764374400); KERIMKULOVA, ALINA (6507541067); LATKOVSKIS, GUSTAVS (6507756746); HAMOUI, OMAR (8560691700); SLAPIKAS, RIMVYDAS (12779751400); VISSER, LAURENT (57208476343); DINGLI, PHILIP (56595252100); IVANOV, VICTORIA (57208476688); BOSKOVIC, ANETA (25935849200); NAZZI, MBAREK (57211147634); VISSEREN, FRANK (6603837396); MITEVSKA, IRENA (56698414500); RETTERSTØL, KJETIL (6603600207); JANKOWSKI, PIOTR (57190678466); FONTES-CARVALHO, RICARDO (23097322300); GAITA, DAN (26537386100); EZHOV, MARAT (57218254057); FOSCOLI, MARINA (57202252938); GIGA, VOJISLAV (55924460200); PELLA, DANIEL (57207570055); FRAS, ZLATKO (35615293100); PEREZ DE ISLA, LEOPOLDO (6701463383); HAGSTRÖM, EMIL (56618352100); LEHMANN, ROGER (14022858600); ABID, LEILA (24334239900); OZDOGAN, ONER (16231154400); MITCHENKO, OLENA (57193516360); PATEL, RIYAZ S. (23985899500)","2019 ESCEAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK",2019,"ATHEROSCLEROSIS","290","65",655,"10.1016/j.atherosclerosis.2019.08.014","CARDIOLOGY DEPARTMENT, GENEVA UNIVERSITY HOSPITAL, 4 GABRIELLE-PERRET-GENTIL, GENEVA, 1211, SWITZERLAND;NUFFIELD DEPARTMENT OF POPULATION HEALTH, UNIVERSITY OF OXFORD, RICHARD DOLL BUILDING, ROOSEVELT DRIVE, OXFORD OX3 7LF, UNITED KINGDOM, UNITED KINGDOM;DEPARTMENT OF PHARMACOLOGICAL AND BIOMOLECULAR SCIENCES, UNIVERSITY OF MILAN, MULTIMEDICA IRCCS, VIA BALZARETTI, 9, MILAN, 20133, ITALY;CARDIOLOGY, BERN UNIVERSITY HOSPITAL (INSELSPITAL), BERN, SWITZERLAND;EPIDEMIOLOGY AND PREVENTIVE PHARMACOLOGY SERVICE (SEFAP), DEPARTMENT OF PHARMACOLOGICAL AND BIOMOLECULAR SCIENCES (DISFEB), UNIVERSITY OF MILAN, MILAN, ITALY, IRCCS MULTIMEDICA, SESTO S. GIOVANNI, MILAN, ITALY;CARDIOVASCULAR PROGRAM-ICCC AND CIBERCV, IR-HOSPITAL DE LA SANTA CREU I SANT PAU, BARCELONA, SPAIN;NATIONAL INSTITUTE FOR HEALTH AND MEDICAL RESEARCH (INSERM), PARIS, FRANCE, DIVISION OF ENDOCRINOLOGY- METABOLISM, PITIE-SALPETRIERE UNIVERSITY HOSPITAL, PARIS, FRANCE, SORBONNE UNIVERSITY, PARIS, FRANCE;PUBLIC HEALTH AND PRIMARY CARE, FACULTY OF MEDICINE AND HEALTH SCIENCES, GHENT UNIVERSITY, GHENT, BELGIUM;CARDIOLOGY, LEIDEN UNIVERSITY MEDICAL CENTER, LEIDEN, NETHERLANDS, NETHERLANDS;CENTRE FOR NATURALLY RANDOMIZED TRIALS, DEPARTMENT OF PUBLIC HEALTH AND PRIMARY CARE, UNIVERSITY OF CAMBRIDGE, CAMBRIDGE, UNITED KINGDOM;CARDIOLOGY, TRINITY COLLEGE, DUBLIN, IRELAND;NUFFIELD DEPARTMENT OF SURGERY, UNIVERSITY OF OXFORD, NIHR OXFORD BIOMEDICAL RESEARCH CENTRE, OXFORD, UNITED KINGDOM;DEPARTMENT OF CARDIOLOGY, CHARITE UNIVERSITÄTSMEDIZIN BERLIN, BERLIN, GERMANY, BERLIN INSTITUTE OF HEALTH (BIH), BERLIN, GERMANY, GERMAN CENTER OF CARDIOVASCULAR RESEARCH (DZHK), BERLIN, GERMANY, GERMANY;NUFFIELD DEPARTMENT OF POPULATION HEALTH, NIHR OXFORD BIOMEDICAL RESEARCH CENTRE, UNIVERSITY OF OXFORD, OXFORD, UNITED KINGDOM, BARTS AND THE LONDON SCHOOL OF MEDICINE AND DENTISTRY, QUEEN MARY UNIVERSITY OF LONDON, LONDON, UNITED KINGDOM;PREVENTIVE CARDIOLOGY, OSLO UNIVERSITY HOSPITAL, AKER, OSLO, NORWAY;CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY, NAPLES, ITALY;CARDIAC DEPARTMENT, EUROCLINIC, ATHENS, GREECE, GREECE;TIMI STUDY GROUP, DIVISION OF CARDIOVASCULAR MEDICINE, BRIGHAM, WOMEN'S HOSPITAL AND HARVARD MEDICAL SCHOOL, BOSTON, MA, UNITED STATES;RESEARCH PROGRAM FOR CLINICAL AND MOLECULAR METABOLISM, UNIVERSITY OF HELSINKI, HELSINKI, FINLAND;CARDIOLOGY, HACETTEPE UNIVERSITY, ANKARA, TURKEY;INSTITUTE OF MEDICINE, THE SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG, GOTHENBURG, SWEDEN;SWITZERLAND;FRANCE;FRANCE;FRANCE;UNITED KINGDOM;UNITED KINGDOM;NETHERLANDS;NORWAY;GERMANY;FRANCE;CANADA;GERMANY;FRANCE;ITALY;ISRAEL;HUNGARY;SWITZERLAND;UNITED KINGDOM;ITALY;SWITZERLAND;RUSSIAN FEDERATION;UNITED KINGDOM;PORTUGAL;UNITED KINGDOM;ALGERIAN SOCIETY OF CARDIOLOGY, ALGERIA;ARMENIAN CARDIOLOGISTS ASSOCIATION, ARMENIA;AUSTRIAN SOCIETY OF CARDIOLOGY, AUSTRIA;AZERBAIJAN SOCIETY OF CARDIOLOGY, AZERBAIJAN;BELGIAN SOCIETY OF CARDIOLOGY, BELGIUM;ASSOCIATION OF CARDIOLOGISTS OF BOSNIA AND HERZEGOVINA, BOSNIA AND HERZEGOVINA;BULGARIAN SOCIETY OF CARDIOLOGY, BULGARIA;CYPRUS SOCIETY OF CARDIOLOGY, CYPRUS;CZECH SOCIETY OF CARDIOLOGY, CZECH REPUBLIC;DANISH SOCIETY OF CARDIOLOGY, DENMARK;EGYPTIAN SOCIETY OF CARDIOLOGY, EGYPT;ESTONIAN SOCIETY OF CARDIOLOGY, ESTONIA;FINNISH CARDIAC SOCIETY, FINLAND;FRENCH SOCIETY OF CARDIOLOGY, FRANCE;GEORGIAN SOCIETY OF CARDIOLOGY, GEORGIA;GERMAN CARDIAC SOCIETY, GERMANY;HELLENIC SOCIETY OF CARDIOLOGY, GREECE;HUNGARIAN SOCIETY OF CARDIOLOGY, HUNGARY;ICELANDIC SOCIETY OF CARDIOLOGY, ICELAND;IRISH CARDIAC SOCIETY, IRELAND;ISRAEL HEART SOCIETY, ISRAEL;ITALIAN FEDERATION OF CARDIOLOGY, ITALY;ASSOCIATION OF CARDIOLOGISTS OF KAZAKHSTAN, KAZAKHSTAN;KOSOVO SOCIETY OF CARDIOLOGY, SERBIA;KYRGYZ SOCIETY OF CARDIOLOGY, KYRGYZSTAN;LATVIAN SOCIETY OF CARDIOLOGY, LATVIA;LEBANESE SOCIETY OF CARDIOLOGY, LEBANON;LITHUANIAN SOCIETY OF CARDIOLOGY, LITHUANIA;LUXEMBOURG SOCIETY OF CARDIOLOGY, LUXEMBOURG;MALTESE CARDIAC SOCIETY, MALTA;MOLDAVIAN SOCIETY OF CARDIOLOGY, MOLDOVA;MONTENEGRO SOCIETY OF CARDIOLOGY, MONTENEGRO;MOROCCAN SOCIETY OF CARDIOLOGY, MOROCCO;NETHERLANDS SOCIETY OF CARDIOLOGY, NETHERLANDS;NORTH MACEDONIAN SOCIETY OF CARDIOLOGY, NORTH MACEDONIA;NORWEGIAN SOCIETY OF CARDIOLOGY, NORWAY;POLISH CARDIAC SOCIETY, POLAND;PORTUGUESE SOCIETY OF CARDIOLOGY, PORTUGAL;ROMANIAN SOCIETY OF CARDIOLOGY, ROMANIA;RUSSIAN SOCIETY OF CARDIOLOGY, RUSSIAN FEDERATION;SAN MARINO SOCIETY OF CARDIOLOGY, SAN MARINO;CARDIOLOGY SOCIETY OF SERBIA, SERBIA;SLOVAK SOCIETY OF CARDIOLOGY, SLOVAKIA;SLOVENIAN SOCIETY OF CARDIOLOGY, SLOVENIA;SPANISH SOCIETY OF CARDIOLOGY, SPAIN;SWEDISH SOCIETY OF CARDIOLOGY, SWEDEN;SWISS SOCIETY OF CARDIOLOGY, SWITZERLAND;TUNISIAN SOCIETY OF CARDIOLOGY AND CARDIO-VASCULAR SURGERY, TUNISIA;TURKISH SOCIETY OF CARDIOLOGY, TURKEY;UKRAINIAN ASSOCIATION OF CARDIOLOGY, UKRAINE;BRITISH CARDIOVASCULAR SOCIETY, IRELAND","[NO ABSTRACT AVAILABLE]","APOLIPOPROTEIN B; CHOLESTEROL; DYSLIPIDAEMIAS; FAMILIAL HYPERCHOLESTEROLAEMIA; GUIDELINES; HIGH-DENSITY LIPOPROTEINS; LIPOPROTEIN REMNANTS; LIPOPROTEIN(A); LOW-DENSITY LIPOPROTEINS; TOTAL CARDIOVASCULAR RISK; TREATMENT (ADHERENCE); TREATMENT (DRUGS); TREATMENT (LIFESTYLE); TRIGLYCERIDES; VERY LOW-DENSITY LIPOPROTEINS","ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; CONSENSUS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; ANTILIPEMIC AGENT; BERBERINE; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTIN; ENZYME; ESTROGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; MONACOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR; SOYBEAN PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LIPID; ABDOMINAL AORTIC ANEURYSM; ACUTE CORONARY SYNDROME; ACUTE PANCREATITIS; ADVERSE DRUG REACTION; AGING; ALCOHOL CONSUMPTION; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; BRAIN HEMORRHAGE; CARBOHYDRATE DIET; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIETARY FIBER; DIETARY SUPPLEMENT; DISEASE SEVERITY; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FASTING; FAT INTAKE; FUNCTIONAL FOOD; GENETIC DISORDER; HEALTHY LIFESTYLE; HEART FAILURE; HEREDITY; HETEROZYGOSITY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HIGH RISK POPULATION; HOMOZYGOSITY; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPID FINGERPRINTING; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; LOWER LIMB; MEDICATION COMPLIANCE; MORBIDITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; ONSET AGE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RETINAL VASCULAR DISEASE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; TRANSPLANTATION; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LEVEL; VALVULAR HEART DISEASE; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; COMBINATION DRUG THERAPY; CONSENSUS; DYSLIPIDEMIA; FEMALE; MALE; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME","","","CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., REINER Z., RICCARDI G., TASKINEN M.R., TOKGOZOGLU L., VERSCHUREN W.M.M., VLACHOPOULOS C., WOOD D.A., ZAMORANO J.L., COONEY M.T., ESC SCIENTIFIC DOCUMENT GROUP, ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR. HEART J., 37, PP. 2999-3058, (2016); FERENCE B.A., GINSBERG H.N., GRAHAM I., RAY K.K., PACKARD C.J., BRUCKERT E., HEGELE R.A., KRAUSS R.M., RAAL F.J., SCHUNKERT H., WATTS G.F., BOREN J., FAZIO S., HORTON J.D., MASANA L., NICHOLLS S.J., NORDESTGAARD B.G., VAN DE SLUIS B., TASKINEN M.R., TOKGOZOGLU L., LANDMESSER U., LAUFS U., WIKLUND O., STOCK J.K., CHAPMAN M.J., CATAPANO A.L., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR. HEART J., 38, PP. 2459-2472, (2017); TOWNSEND N., NICHOLS M., SCARBOROUGH P., RAYNER M., CARDIOVASCULAR DISEASE IN EUROPE--EPIDEMIOLOGICAL UPDATE 2015, EUR. HEART J., 36, PP. 2696-2705, (2015); COONEY M.T., DUDINA A., WHINCUP P., CAPEWELL S., MENOTTI A., JOUSILAHTI P., NJOLSTAD I., OGANOV R., THOMSEN T., TVERDAL A., WEDEL H., WILHELMSEN L., GRAHAM I., INVESTIGATORS S.C.O.R.E., RE-EVALUATING THE ROSE APPROACH: COMPARATIVE BENEFITS OF THE POPULATION AND HIGH-RISK PREVENTIVE STRATEGIES, EUR. J. CARDIOVASC. PREV. REHABIL., 16, PP. 541-549, (2009); WORLD HEALTH ORGANIZATION, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2014, WORLD HEALTH ORGANIZATION, (2014); COONEY M.T., DUDINA A.L., GRAHAM I.M., VALUE AND LIMITATIONS OF EXISTING SCORES FOR THE ASSESSMENT OF CARDIOVASCULAR RISK: A REVIEW FOR CLINICIANS, J. AM. COLL. CARDIOL., 54, PP. 1209-1227, (2009); HAJIFATHALIAN K., UEDA P., LU Y., WOODWARD M., AHMADVAND A., AGUILAR-SALINAS C.A., AZIZI F., CIFKOVA R., DI CESARE M., ERIKSEN L., FARZADFAR F., IKEDA N., KHALILI D., KHANG Y.H., LANSKA V., LEON-MUNOZ L., MAGLIANO D., MSYAMBOZA K.P., OH K., RODRIGUEZ-ARTALEJO F., ROJAS-MARTINEZ R., SHAW J.E., STEVENS G.A., TOLSTRUP J., ZHOU B., SALOMON J.A., EZZATI M., DANAEI G., A NOVEL RISK SCORE TO PREDICT CARDIOVASCULAR DISEASE RISK IN NATIONAL POPULATIONS (GLOBORISK): A POOLED ANALYSIS OF PROSPECTIVE COHORTS AND HEALTH EXAMINATION SURVEYS, LANCET DIABETES ENDOCRINOL, 3, PP. 339-355, (2015); COONEY M.T., DUDINA A., D'AGOSTINO R., GRAHAM I.M., CARDIOVASCULAR RISK-ESTIMATION SYSTEMS IN PRIMARY PREVENTION: DO THEY DIFFER? DO THEY MAKE A DIFFERENCE? CAN WE SEE THE FUTURE?, CIRCULATION, 122, PP. 300-310, (2010); PERK J., DE BACKER G., GOHLKE H., GRAHAM I., REINER Z., VERSCHUREN M., ALBUS C., BENLIAN P., BOYSEN G., CIFKOVA R., DEATON C., EBRAHIM S., FISHER M., GERMANO G., HOBBS R., HOES A., KARADENIZ S., MEZZANI A., PRESCOTT E., RYDEN L., SCHERER M., SYVANNE M., SCHOLTE OP REIMER W.J., VRINTS C., WOOD D., ZAMORANO J.L., ZANNAD F., EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION; ESC COMMITTEE FOR PRACTICE GUIDELINES (CPG). EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (VERSION 2012). THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR. HEART J., 33, PP. 1635-1701, (2012); PIEPOLI M.F., HOES A.W., AGEWALL S., ALBUS C., BROTONS C., CATAPANO A.L., COONEY M.T., CORRA U., COSYNS B., DEATON C., GRAHAM I., HALL M.S., HOBBS F.D., LOCHEN M.L., LOLLGEN H., MARQUES-VIDAL P., PERK J., PRESCOTT E., REDON J., RICHTER D.J., SATTAR N., SMULDERS Y., TIBERI M., VAN DER WORP H.B., VAN DIS I., VERSCHUREN W.M., AUTHORS/TASK FORCE M., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: THE SIXTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF 10 SOCIETIES AND BY INVITED EXPERTS)DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), EUR. HEART J., 37, PP. 2315-2381, (2016); COONEY M.T., SELMER R., LINDMAN A., TVERDAL A., MENOTTI A., THOMSEN T., DEBACKER G., DE BACQUER D., TELL G.S., NJOLSTAD I., GRAHAM I.M., SCORE AND CONOR INVESTIGATORS, CARDIOVASCULAR RISK ESTIMATION IN OLDER PERSONS: SCORE O.P, EUR J PREV CARDIOL, 23, PP. 1093-1103, (2016); BERRY J.D., DYER A., CAI X., GARSIDE D.B., NING H., THOMAS A., GREENLAND P., VAN HORN L., TRACY R.P., LLOYD-JONES D.M., LIFETIME RISKS OF CARDIOVASCULAR DISEASE, N. ENGL. J. MED., 366, PP. 321-329, (2012); FOSTER H.M.E., CELIS-MORALES C.A., NICHOLL B.I., PETERMANN-ROCHA F., PELL J.P., GILL J.M.R., O'DONNELL C.A., MAIR F.S., THE EFFECT OF SOCIOECONOMIC DEPRIVATION ON THE ASSOCIATION BETWEEN AN EXTENDED MEASUREMENT OF UNHEALTHY LIFESTYLE FACTORS AND HEALTH OUTCOMES: A PROSPECTIVE ANALYSIS OF THE UK BIOBANK COHORT, LANCET PUBLIC HEALTH, 3, PP. E576-E585, (2018); KAVOUSI M., ELIAS-SMALE S., RUTTEN J.H., LEENING M.J., VLIEGENTHART R., VERWOERT G.C., KRESTIN G.P., OUDKERK M., DE MAAT M.P., LEEBEEK F.W., MATTACE-RASO F.U., LINDEMANS J., HOFMAN A., STEYERBERG E.W., VAN DER LUGT A., VAN DEN MEIRACKER A.H., WITTEMAN J.C., EVALUATION OF NEWER RISK MARKERS FOR CORONARY HEART DISEASE RISK CLASSIFICATION: A COHORT STUDY, ANN. INTERN. MED., 156, PP. 438-444, (2012); VLACHOPOULOS C., XAPLANTERIS P., ABOYANS V., BRODMANN M., CIFKOVA R., COSENTINO F., DE CARLO M., GALLINO A., LANDMESSER U., LAURENT S., LEKAKIS J., MIKHAILIDIS D.P., NAKA K.K., PROTOGEROU A.D., RIZZONI D., SCHMIDT-TRUCKSASS A., VAN BORTEL L., WEBER T., YAMASHINA A., ZIMLICHMAN R., BOUTOUYRIE P., COCKCROFT J., O'ROURKE M., PARK J.B., SCHILLACI G., SILLESEN H., TOWNSEND R.R., THE ROLE OF VASCULAR BIOMARKERS FOR PRIMARY AND SECONDARY PREVENTION. A POSITION PAPER FROM THE EUROPEAN SOCIETY OF CARDIOLOGY WORKING GROUP ON PERIPHERAL CIRCULATION: ENDORSED BY THE ASSOCIATION FOR RESEARCH INTO ARTERIAL STRUCTURE AND PHYSIOLOGY (ARTERY) SOCIETY, ATHEROSCLEROSIS, 241, PP. 507-532, (2015); YEBOAH J., MCCLELLAND R.L., POLONSKY T.S., BURKE G.L., SIBLEY C.T., O'LEARY D., CARR J.J., GOFF D.C., GREENLAND P., HERRINGTON D.M., COMPARISON OF NOVEL RISK MARKERS FOR IMPROVEMENT IN CARDIOVASCULAR RISK ASSESSMENT IN INTERMEDIATE-RISK INDIVIDUALS, J. AM. MED. ASSOC., 308, PP. 788-795, (2012); MADSEN C.M., VARBO A., NORDESTGAARD B.G., EXTREME HIGH HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IS PARADOXICALLY ASSOCIATED WITH HIGH MORTALITY IN MEN AND WOMEN: TWO PROSPECTIVE COHORT STUDIES, EUR. HEART J., 38, PP. 2478-2486, (2017); MORTENSEN M.B., FALK E., LI D., NASIR K., BLAHA M.J., SANDFORT V., RODRIGUEZ C.J., OUYANG P., BUDOFF M., STATIN TRIALS, CARDIOVASCULAR EVENTS, AND CORONARY ARTERY CALCIFICATION: IMPLICATIONS FOR A TRIAL-BASED APPROACH TO STATIN THERAPY IN MESA, JACC CARDIOVASC IMAGING, 11, PP. 221-230, (2018); LIN J.S., EVANS C.V., JOHNSON E., REDMOND N., COPPOLA E.L., SMITH N., NONTRADITIONAL RISK FACTORS IN CARDIOVASCULAR DISEASE RISK ASSESSMENT: UPDATED EVIDENCE REPORT AND SYSTEMATIC REVIEW FOR THE US PREVENTIVE SERVICES TASK FORCE, J. AM. MED. ASSOC., 320, PP. 281-297, (2018); BABER U., MEHRAN R., SARTORI S., SCHOOS M.M., SILLESEN H., MUNTENDAM P., GARCIA M.J., GREGSON J., POCOCK S., FALK E., FUSTER V., PREVALENCE, IMPACT, AND PREDICTIVE VALUE OF DETECTING SUBCLINICAL CORONARY AND CAROTID ATHEROSCLEROSIS IN ASYMPTOMATIC ADULTS: THE BIOIMAGE STUDY, J. AM. COLL. CARDIOL., 65, PP. 1065-1074, (2015); MCDERMOTT M.M., KRAMER C.M., TIAN L., CARR J., GURALNIK J.M., POLONSKY T., CARROLL T., KIBBE M., CRIQUI M.H., FERRUCCI L., ZHAO L., HIPPE D.S., WILKINS J., XU D., LIAO Y., MCCARTHY W., YUAN C., PLAQUE COMPOSITION IN THE PROXIMAL SUPERFICIAL FEMORAL ARTERY AND PERIPHERAL ARTERY DISEASE EVENTS, JACC CARDIOVASC IMAGING, 10, PP. 1003-1012, (2017); SILLESEN H., SARTORI S., SANDHOLT B., BABER U., MEHRAN R., FUSTER V., CAROTID PLAQUE THICKNESS AND CAROTID PLAQUE BURDEN PREDICT FUTURE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC ADULT AMERICANS, EUR HEART J CARDIOVASC IMAGING, 19, PP. 1042-1050, (2018); PERRONE-FILARDI P., ACHENBACH S., MOHLENKAMP S., REINER Z., SAMBUCETI G., SCHUIJF J.D., VAN DER WALL E., KAUFMANN P.A., KNUUTI J., SCHROEDER S., ZELLWEGER M.J., CARDIAC COMPUTED TOMOGRAPHY AND MYOCARDIAL PERFUSION SCINTIGRAPHY FOR RISK STRATIFICATION IN ASYMPTOMATIC INDIVIDUALS WITHOUT KNOWN CARDIOVASCULAR DISEASE: A POSITION STATEMENT OF THE WORKING GROUP ON NUCLEAR CARDIOLOGY AND CARDIAC CT OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUR. HEART J., 32, PP. 1986-1993, (2011); DEN RUIJTER H.M., PETERS S.A., ANDERSON T.J., BRITTON A.R., DEKKER J.M., EIJKEMANS M.J., ENGSTROM G., EVANS G.W., DE GRAAF J., GROBBEE D.E., HEDBLAD B., HOFMAN A., HOLEWIJN S., IKEDA A., KAVOUSI M., KITAGAWA K., KITAMURA A., KOFFIJBERG H., LONN E.M., LORENZ M.W., MATHIESEN E.B., NIJPELS G., OKAZAKI S., O'LEARY D.H., POLAK J.F., PRICE J.F., ROBERTSON C., REMBOLD C.M., ROSVALL M., RUNDEK T., SALONEN J.T., SITZER M., STEHOUWER C.D., WITTEMAN J.C., MOONS K.G., BOTS M.L., COMMON CAROTID INTIMA-MEDIA THICKNESS MEASUREMENTS IN CARDIOVASCULAR RISK PREDICTION: A META-ANALYSIS, J. AM. MED. ASSOC., 308, PP. 796-803, (2012); LORENZ M.W., SCHAEFER C., STEINMETZ H., SITZER M., IS CAROTID INTIMA MEDIA THICKNESS USEFUL FOR INDIVIDUAL PREDICTION OF CARDIOVASCULAR RISK? TEN-YEAR RESULTS FROM THE CAROTID ATHEROSCLEROSIS PROGRESSION STUDY (CAPS), EUR. HEART J., 31, PP. 2041-2048, (2010); GARG P.K., JORGENSEN N.W., MCCLELLAND R.L., LEIGH J.A., GREENLAND P., BLAHA M.J., YOON A.J., WONG N.D., YEBOAH J., BUDOFF M.J., USE OF CORONARY ARTERY CALCIUM TESTING TO IMPROVE CORONARY HEART DISEASE RISK ASSESSMENT IN A LUNG CANCER SCREENING POPULATION: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), J CARDIOVASC COMPUT TOMOGR, 12, PP. 493-499, (2018); HONG J.C., BLANKSTEIN R., SHAW L.J., PADULA W.V., ARRIETA A., FIALKOW J.A., BLUMENTHAL R.S., BLAHA M.J., KRUMHOLZ H.M., NASIR K., IMPLICATIONS OF CORONARY ARTERY CALCIUM TESTING FOR TREATMENT DECISIONS AMONG STATIN CANDIDATES ACCORDING TO THE ACC/AHA CHOLESTEROL MANAGEMENT GUIDELINES: A COST-EFFECTIVENESS ANALYSIS, JACC CARDIOVASC IMAGING, 10, PP. 938-952, (2017); CHO I., AL'AREF S.J., BERGER A.B.O.H., GRANSAR H., VALENTI V., LIN F.Y., ACHENBACH S., BERMAN D.S., BUDOFF M.J., CALLISTER T.Q., AL-MALLAH M.H., CADEMARTIRI F., CHINNAIYAN K., CHOW B.J.W., DELAGO A., VILLINES T.C., HADAMITZKY M., HAUSLEITER J., LEIPSIC J., SHAW L.J., KAUFMANN P.A., FEUCHTNER G., KIM Y.J., MAFFEI E., RAFF G., PONTONE G., ANDREINI D., MARQUES H., RUBINSHTEIN R., CHANG H.J., MIN J.K., PROGNOSTIC VALUE OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY FINDINGS IN ASYMPTOMATIC INDIVIDUALS: A 6-YEAR FOLLOW-UP FROM THE PROSPECTIVE MULTICENTRE INTERNATIONAL CONFIRM STUDY, EUR. HEART J., 39, PP. 934-941, (2018); KAVOUSI M., DESAI C.S., AYERS C., BLUMENTHAL R.S., BUDOFF M.J., MAHABADI A.A., IKRAM M.A., VAN DER LUGT A., HOFMAN A., ERBEL R., KHERA A., GEISEL M.H., JOCKEL K.H., LEHMANN N., HOFFMANN U., O'DONNELL C.J., MASSARO J.M., LIU K., MOHLENKAMP S., NING H., FRANCO O.H., GREENLAND P., PREVALENCE AND PROGNOSTIC IMPLICATIONS OF CORONARY ARTERY CALCIFICATION IN LOW-RISK WOMEN: A META-ANALYSIS, J. AM. MED. ASSOC., 316, PP. 2126-2134, (2016); BOEKHOLDT S.M., HOVINGH G.K., MORA S., ARSENAULT B.J., AMARENCO P., PEDERSEN T.R., LAROSA J.C., WATERS D.D., DEMICCO D.A., SIMES R.J., KEECH A.C., COLQUHOUN D., HITMAN G.A., BETTERIDGE D.J., CLEARFIELD M.B., DOWNS J.R., COLHOUN H.M., GOTTO A.M., RIDKER P.M., GRUNDY S.M., KASTELEIN J.J., VERY LOW LEVELS OF ATHEROGENIC LIPOPROTEINS AND THE RISK FOR CARDIOVASCULAR EVENTS: A META-ANALYSIS OF STATIN TRIALS, J. AM. COLL. CARDIOL., 64, PP. 485-494, (2014); BRUGTS J.J., YETGIN T., HOEKS S.E., GOTTO A.M., SHEPHERD J., WESTENDORP R.G., DE CRAEN A.J., KNOPP R.H., NAKAMURA H., RIDKER P., VAN DOMBURG R., DECKERS J.W., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS: META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 338, (2009); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., MCCAGG A., WHITE J.A., THEROUX P., DARIUS H., LEWIS B.S., OPHUIS T.O., JUKEMA J.W., DE FERRARI G.M., RUZYLLO W., DE LUCCA P., IM K., BOHULA E.A., REIST C., WIVIOTT S.D., TERSHAKOVEC A.M., MUSLINER T.A., BRAUNWALD E., CALIFF R.M., IMPROVE-IT INVESTIGATORS, EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, N. ENGL. J. MED., 372, PP. 2387-2397, (2015); CHOLESTEROL TREATMENT TRIALISTS COLLABORATION, BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., BHALA N., PETO R., BARNES E.H., KEECH A., SIMES J., COLLINS R., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); CHOLESTEROL TREATMENT TRIALISTS COLLABORATION, FULCHER J., O'CONNELL R., VOYSEY M., EMBERSON J., BLACKWELL L., MIHAYLOVA B., SIMES J., COLLINS R., KIRBY A., COLHOUN H., BRAUNWALD E., LA ROSA J., PEDERSEN T.R., TONKIN A., DAVIS B., SLEIGHT P., FRANZOSI M.G., BAIGENT C., KEECH A., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN: META-ANALYSIS OF INDIVIDUAL DATA FROM 174,000 PARTICIPANTS IN 27 RANDOMISED TRIALS, LANCET, 385, PP. 1397-1405, (2015); CHOLESTEROL TREATMENT TRIALISTS COLLABORATION, MIHAYLOVA B., EMBERSON J., BLACKWELL L., KEECH A., SIMES J., BARNES E.H., VOYSEY M., GRAY A., COLLINS R., BAIGENT C., THE EFFECTS OF LOWERING LDL CHOLESTEROL WITH STATIN THERAPY IN PEOPLE AT LOW RISK OF VASCULAR DISEASE: META-ANALYSIS OF INDIVIDUAL DATA FROM 27 RANDOMISED TRIALS, LANCET, 380, PP. 581-590, (2012); HEGELE R.A., GINSBERG H.N., CHAPMAN M.J., NORDESTGAARD B.G., KUIVENHOVEN J.A., AVERNA M., BOREN J., BRUCKERT E., CATAPANO A.L., DESCAMPS O.S., HOVINGH G.K., HUMPHRIES S.E., KOVANEN P.T., MASANA L., PAJUKANTA P., PARHOFER K.G., RAAL F.J., RAY K.K., SANTOS R.D., STALENHOEF A.F., STROES E., TASKINEN M.R., TYBJAERG-HANSEN A., WATTS G.F., WIKLUND O., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL. THE POLYGENIC NATURE OF HYPERTRIGLYCERIDAEMIA: IMPLICATIONS FOR DEFINITION, DIAGNOSIS, AND MANAGEMENT, LANCET DIABETES ENDOCRINOL, 2, PP. 655-666, (2014); MILLS E.J., RACHLIS B., WU P., DEVEREAUX P.J., ARORA P., PERRI D., PRIMARY PREVENTION OF CARDIOVASCULAR MORTALITY AND EVENTS WITH STATIN TREATMENTS: A NETWORK META-ANALYSIS INVOLVING MORE THAN 65,000 PATIENTS, J. AM. COLL. CARDIOL., 52, PP. 1769-1781, (2008); PEDERSEN T.R., FAERGEMAN O., KASTELEIN J.J., OLSSON A.G., TIKKANEN M.J., HOLME I., LARSEN M.L., BENDIKSEN F.S., LINDAHL C., SZAREK M., TSAI J., INCREMENTAL DECREASE IN END POINTS THROUGH AGGRESSIVE LIPID LOWERING (IDEAL) STUDY GROUP. HIGH-DOSE ATORVASTATIN VS USUAL-DOSE SIMVASTATIN FOR SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION: THE IDEAL STUDY: A RANDOMIZED CONTROLLED TRIAL, J. AM. MED. ASSOC., 294, PP. 2437-2445, (2005); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., BAIREY MERZ C.N., BLUM C.B., ECKEL R.H., GOLDBERG A.C., GORDON D., LEVY D., LLOYD-JONES D.M., MCBRIDE P., SCHWARTZ J.S., SHERO S.T., SMITH S.C., WATSON K., WILSON P.W., EDDLEMAN K.M., JARRETT N.M., LABRESH K., NEVO L., WNEK J., ANDERSON J.L., HALPERIN J.L., ALBERT N.M., BOZKURT B., BRINDIS R.G., CURTIS L.H., DEMETS D., HOCHMAN J.S., KOVACS R.J., OHMAN E.M., PRESSLER S.J., SELLKE F.W., SHEN W.K., SMITH S.C., TOMASELLI G.F., AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, PP. S1-S45, (2013); VALLEJO-VAZ A.J., ROBERTSON M., CATAPANO A.L., WATTS G.F., KASTELEIN J.J., PACKARD C.J., FORD I., RAY K.K., LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE AMONG MEN WITH PRIMARY ELEVATIONS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS OF 190 MG/DL OR ABOVE: ANALYSES FROM THE WOSCOPS (WEST OF SCOTLAND CORONARY PREVENTION STUDY) 5-YEAR RANDOMIZED TRIAL AND 20-YEAR OBSERVATIONAL FOLLOW-UP, CIRCULATION, 136, PP. 1878-1891, (2017); TABAS I., WILLIAMS K.J., BOREN J., SUBENDOTHELIAL LIPOPROTEIN RETENTION AS THE INITIATING PROCESS IN ATHEROSCLEROSIS: UPDATE AND THERAPEUTIC IMPLICATIONS, CIRCULATION, 116, PP. 1832-1844, (2007); BOREN J., WILLIAMS K.J., THE CENTRAL ROLE OF ARTERIAL RETENTION OF CHOLESTEROL-RICH APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS IN THE PATHOGENESIS OF ATHEROSCLEROSIS: A TRIUMPH OF SIMPLICITY, CURR. OPIN. LIPIDOL., 27, PP. 473-483, (2016); FERENCE B.A., GRAHAM I., TOKGOZOGLU L., CATAPANO A.L., IMPACT OF LIPIDS ON CARDIOVASCULAR HEALTH: JACC HEALTH PROMOTION SERIES, J. AM. COLL. CARDIOL., 72, PP. 1141-1156, (2018); EMERGING RISK FACTORS COLLABORATION, DI ANGELANTONIO E., GAO P., PENNELLS L., KAPTOGE S., CASLAKE M., THOMPSON A., BUTTERWORTH A.S., SARWAR N., WORMSER D., SALEHEEN D., BALLANTYNE C.M., PSATY B.M., SUNDSTROM J., RIDKER P.M., NAGEL D., GILLUM R.F., FORD I., DUCIMETIERE P., KIECHL S., KOENIG W., DULLAART R.P., ASSMANN G., D'AGOSTINO R.B., DAGENAIS G.R., COOPER J.A., KROMHOUT D., ONAT A., TIPPING R.W., GOMEZ-DE-LA-CAMARA A., ROSENGREN A., SUTHERLAND S.E., GALLACHER J., FOWKES F.G., CASIGLIA E., HOFMAN A., SALOMAA V., BARRETT-CONNOR E., CLARKE R., BRUNNER E., JUKEMA J.W., SIMONS L.A., SANDHU M., WAREHAM N.J., KHAW K.T., KAUHANEN J., SALONEN J.T., HOWARD W.J., NORDESTGAARD B.G., WOOD A.M., THOMPSON S.G., BOEKHOLDT S.M., SATTAR N., PACKARD C., GUDNASON V., DANESH J., LIPID-RELATED MARKERS AND CARDIOVASCULAR DISEASE PREDICTION, J. AM. MED. ASSOC., 307, PP. 2499-2506, (2012); WILLER C.J., SCHMIDT E.M., SENGUPTA S., PELOSO G.M., GUSTAFSSON S., KANONI S., GANNA A., CHEN J., BUCHKOVICH M.L., MORA S., BECKMANN J.S., BRAGG-GRESHAM J.L., CHANG H.Y., DEMIRKAN A., DEN HERTOG H.M., DO R., DONNELLY L.A., EHRET G.B., ESKO T., FEITOSA M.F., FERREIRA T., FISCHER K., FONTANILLAS P., FRASER R.M., FREITAG D.F., GURDASANI D., HEIKKILA K., HYPPONEN E., ISAACS A., JACKSON A.U., JOHANSSON A., JOHNSON T., KAAKINEN M., KETTUNEN J., KLEBER M.E., LI X., LUAN J., LYYTIKAINEN L.P., MAGNUSSON P.K.E., MANGINO M., MIHAILOV E., MONTASSER M.E., MULLER-NURASYID M., NOLTE I.M., O'CONNELL J.R., PALMER C.D., PEROLA M., PETERSEN A.K., SANNA S., SAXENA R., SERVICE S.K., SHAH S., SHUNGIN D., SIDORE C., SONG C., STRAWBRIDGE R.J., SURAKKA I., TANAKA T., TESLOVICH T.M., THORLEIFSSON G., VAN DEN HERIK E.G., VOIGHT B.F., VOLCIK K.A., WAITE L.L., WONG A., WU Y., ZHANG W., ABSHER D., ASIKI G., BARROSO I., BEEN L.F., BOLTON J.L., BONNYCASTLE L.L., BRAMBILLA P., BURNETT M.S., CESANA G., DIMITRIOU M., DONEY A.S.F., DORING A., ELLIOTT P., EPSTEIN S.E., INGI EYJOLFSSON G., GIGANTE B., GOODARZI M.O., GRALLERT H., GRAVITO M.L., GROVES C.J., HALLMANS G., HARTIKAINEN A.L., HAYWARD C., HERNANDEZ D., HICKS A.A., HOLM H., HUNG Y.J., ILLIG T., JONES M.R., KALEEBU P., KASTELEIN J.J.P., KHAW K.T., KIM E., KLOPP N., KOMULAINEN P., KUMARI M., LANGENBERG C., LEHTIMAKI T., LIN S.Y., LINDSTROM J., LOOS R.J.F., MACH F., MCARDLE W.L., MEISINGER C., MITCHELL B.D., MULLER G., NAGARAJA R., NARISU N., NIEMINEN T.V.M., NSUBUGA R.N., OLAFSSON I., ONG K.K., PALOTIE A., PAPAMARKOU T., POMILLA C., POUTA A., RADER D.J., REILLY M.P., RIDKER P.M., RIVADENEIRA F., RUDAN I., RUOKONEN A., SAMANI N., SCHARNAGL H., SEELEY J., SILANDER K., STANCAKOVA A., STIRRUPS K., SWIFT A.J., TIRET L., UITTERLINDEN A.G., VAN PELT L.J., VEDANTAM S., WAINWRIGHT N., WIJMENGA C., WILD S.H., WILLEMSEN G., WILSGAARD T., WILSON J.F., YOUNG E.H., ZHAO J.H., ADAIR L.S., ARVEILER D., ASSIMES T.L., BANDINELLI S., BENNETT F., BOCHUD M., BOEHM B.O., BOOMSMA D.I., BORECKI I.B., BORNSTEIN S.R., BOVET P., BURNIER M., CAMPBELL H., CHAKRAVARTI A., CHAMBERS J.C., CHEN Y.I., COLLINS F.S., COOPER R.S., DANESH J., DEDOUSSIS G., DE FAIRE U., FERANIL A.B., FERRIERES J., FERRUCCI L., FREIMER N.B., GIEGER C., GROOP L.C., GUDNASON V., GYLLENSTEN U., HAMSTEN A., HARRIS T.B., HINGORANI A., HIRSCHHORN J.N., HOFMAN A., HOVINGH G.K., HSIUNG C.A., HUMPHRIES S.E., HUNT S.C., HVEEM K., IRIBARREN C., JARVELIN M.R., JULA A., KAHONEN M., KAPRIO J., KESANIEMI A., KIVIMAKI M., KOONER J.S., KOUDSTAAL P.J., KRAUSS R.M., KUH D., KUUSISTO J., KYVIK K.O., LAAKSO M., LAKKA T.A., LIND L., LINDGREN C.M., MARTIN N.G., MARZ W., MCCARTHY M.I., MCKENZIE C.A., MENETON P., METSPALU A., MOILANEN L., MORRIS A.D., MUNROE P.B., NJOLSTAD I., PEDERSEN N.L., POWER C., PRAMSTALLER P.P., PRICE J.F., PSATY B.M., QUERTERMOUS T., RAURAMAA R., SALEHEEN D., SALOMAA V., SANGHERA D.K., SARAMIES J., SCHWARZ P.E.H., SHEU W.H., SHULDINER A.R., SIEGBAHN A., SPECTOR T.D., STEFANSSON K., STRACHAN D.P., TAYO B.O., TREMOLI E., TUOMILEHTO J., UUSITUPA M., VAN DUIJN C.M., VOLLENWEIDER P., WALLENTIN L., WAREHAM N.J., WHITFIELD J.B., WOLFFENBUTTEL B.H.R., ORDOVAS J.M., BOERWINKLE E., PALMER C.N.A., THORSTEINSDOTTIR U., CHASMAN D.I., ROTTER J.I., FRANKS P.W., RIPATTI S., CUPPLES L.A., SANDHU M.S., RICH S.S., BOEHNKE M., DELOUKAS P., KATHIRESAN S., MOHLKE K.L., INGELSSON E., ABECASIS G.R., GLOBAL LIPIDS GENETICS CONSORTIUM. DISCOVERY AND REFINEMENT OF LOCI ASSOCIATED WITH LIPID LEVELS, NAT. GENET., 45, PP. 1274-1283, (2013); NIKPAY M., GOEL A., WON H.H., HALL L.M., WILLENBORG C., KANONI S., SALEHEEN D., KYRIAKOU T., NELSON C.P., HOPEWELL J.C., WEBB T.R., ZENG L., DEHGHAN A., ALVER M., ARMASU S.M., AURO K., BJONNES A., CHASMAN D.I., CHEN S., FORD I., FRANCESCHINI N., GIEGER C., GRACE C., GUSTAFSSON S., HUANG J., HWANG S.J., KIM Y.K., KLEBER M.E., LAU K.W., LU X., LU Y., LYYTIKAINEN L.P., MIHAILOV E., MORRISON A.C., PERVJAKOVA N., QU L., ROSE L.M., SALFATI E., SAXENA R., SCHOLZ M., SMITH A.V., TIKKANEN E., UITTERLINDEN A., YANG X., ZHANG W., ZHAO W., DE ANDRADE M., DE VRIES P.S., VAN ZUYDAM N.R., ANAND S.S., BERTRAM L., BEUTNER F., DEDOUSSIS G., FROSSARD P., GAUGUIER D., GOODALL A.H., GOTTESMAN O., HABER M., HAN B.G., HUANG J., JALILZADEH S., KESSLER T., KONIG I.R., LANNFELT L., LIEB W., LIND L., LINDGREN C.M., LOKKI M.L., MAGNUSSON P.K., MALLICK N.H., MEHRA N., MEITINGER T., MEMON F.U., MORRIS A.P., NIEMINEN M.S., PEDERSEN N.L., PETERS A., RALLIDIS L.S., RASHEED A., SAMUEL M., SHAH S.H., SINISALO J., STIRRUPS K.E., TROMPET S., WANG L., ZAMAN K.S., ARDISSINO D., BOERWINKLE E., BORECKI I.B., BOTTINGER E.P., BURING J.E., CHAMBERS J.C., COLLINS R., CUPPLES L.A., DANESH J., DEMUTH I., ELOSUA R., EPSTEIN S.E., ESKO T., FEITOSA M.F., FRANCO O.H., FRANZOSI M.G., GRANGER C.B., GU D., GUDNASON V., HALL A.S., HAMSTEN A., HARRIS T.B., HAZEN S.L., HENGSTENBERG C., HOFMAN A., INGELSSON E., IRIBARREN C., JUKEMA J.W., KARHUNEN P.J., KIM B.J., KOONER J.S., KULLO I.J., LEHTIMAKI T., LOOS R.J.F., MELANDER O., METSPALU A., MARZ W., PALMER C.N., PEROLA M., QUERTERMOUS T., RADER D.J., RIDKER P.M., RIPATTI S., ROBERTS R., SALOMAA V., SANGHERA D.K., SCHWARTZ S.M., SEEDORF U., STEWART A.F., STOTT D.J., THIERY J., ZALLOUA P.A., O'DONNELL C.J., REILLY M.P., ASSIMES T.L., THOMPSON J.R., ERDMANN J., CLARKE R., WATKINS H., KATHIRESAN S., MCPHERSON R., DELOUKAS P., SCHUNKERT H., SAMANI N.J., FARRALL M., A COMPREHENSIVE 1,000 GENOMES-BASED GENOME-WIDE ASSOCIATION META-ANALYSIS OF CORONARY ARTERY DISEASE, NAT. GENET., 47, PP. 1121-1130, (2015); FERENCE B.A., YOO W., ALESH I., MAHAJAN N., MIROWSKA K.K., MEWADA A., KAHN J., AFONSO L., WILLIAMS K.A., FLACK J.M., EFFECT OF LONG-TERM EXPOSURE TO LOWER LOW-DENSITY LIPOPROTEIN CHOLESTEROL BEGINNING EARLY IN LIFE ON THE RISK OF CORONARY HEART DISEASE: A MENDELIAN RANDOMIZATION ANALYSIS, J. AM. COLL. CARDIOL., 60, PP. 2631-2639, (2012); HOLMES M.V., ASSELBERGS F.W., PALMER T.M., DRENOS F., LANKTREE M.B., NELSON C.P., DALE C.E., PADMANABHAN S., FINAN C., SWERDLOW D.I., TRAGANTE V., VAN IPEREN E.P., SIVAPALARATNAM S., SHAH S., ELBERS C.C., SHAH T., ENGMANN J., GIAMBARTOLOMEI C., WHITE J., ZABANEH D., SOFAT R., MCLACHLAN S., CONSORTIUM U., DOEVENDANS P.A., BALMFORTH A.J., HALL A.S., NORTH K.E., ALMOGUERA B., HOOGEVEEN R.C., CUSHMAN M., FORNAGE M., PATEL S.R., REDLINE S., SISCOVICK D.S., TSAI M.Y., KARCZEWSKI K.J., HOFKER M.H., VERSCHUREN W.M., BOTS M.L., VAN DER SCHOUW Y.T., MELANDER O., DOMINICZAK A.F., MORRIS R., BEN-SHLOMO Y., PRICE J., KUMARI M., BAUMERT J., PETERS A., THORAND B., KOENIG W., GAUNT T.R., HUMPHRIES S.E., CLARKE R., WATKINS H., FARRALL M., WILSON J.G., RICH S.S., DE BAKKER P.I., LANGE L.A., DAVEY SMITH G., REINER A.P., TALMUD P.J., KIVIMAKI M., LAWLOR D.A., DUDBRIDGE F., SAMANI N.J., KEATING B.J., HINGORANI A.D., CASAS J.P., MENDELIAN RANDOMIZATION OF BLOOD LIPIDS FOR CORONARY HEART DISEASE, EUR. HEART J., 36, PP. 539-550, (2015); SILVERMAN M.G., FERENCE B.A., IM K., WIVIOTT S.D., GIUGLIANO R.P., GRUNDY S.M., BRAUNWALD E., SABATINE M.S., ASSOCIATION BETWEEN LOWERING LDL-C AND CARDIOVASCULAR RISK REDUCTION AMONG DIFFERENT THERAPEUTIC INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. AM. MED. ASSOC., 316, PP. 1289-1297, (2016); BAIGENT C., KEECH A., KEARNEY P.M., BLACKWELL L., BUCK G., POLLICINO C., KIRBY A., SOURJINA T., PETO R., COLLINS R., SIMES R., CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS, EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); COHEN J.C., BOERWINKLE E., MOSLEY T.H., HOBBS H.H., SEQUENCE VARIATIONS IN PCSK9, LOW LDL, AND PROTECTION AGAINST CORONARY HEART DISEASE, N. ENGL. J. MED., 354, PP. 1264-1272, (2006); FERENCE B.A., KASTELEIN J.J.P., RAY K.K., GINSBERG H.N., CHAPMAN M.J., PACKARD C.J., LAUFS U., OLIVER-WILLIAMS C., WOOD A.M., BUTTERWORTH A.S., DI ANGELANTONIO E., DANESH J., NICHOLLS S.J., BHATT D.L., SABATINE M.S., CATAPANO A.L., ASSOCIATION OF TRIGLYCERIDE-LOWERING LPL VARIANTS AND LDL-C-LOWERING LDLR VARIANTS WITH RISK OF CORONARY HEART DISEASE, J. AM. MED. ASSOC., 321, PP. 364-373, (2019); FERENCE B.A., MAJEED F., PENUMETCHA R., FLACK J.M., BROOK R.D., EFFECT OF NATURALLY RANDOM ALLOCATION TO LOWER LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON THE RISK OF CORONARY HEART DISEASE MEDIATED BY POLYMORPHISMS IN NPC1L1, HMGCR, OR BOTH: A 2 X 2 FACTORIAL MENDELIAN RANDOMIZATION STUDY, J. AM. COLL. CARDIOL., 65, PP. 1552-1561, (2015); FERENCE B.A., ROBINSON J.G., BROOK R.D., CATAPANO A.L., CHAPMAN M.J., NEFF D.R., VOROS S., GIUGLIANO R.P., DAVEY SMITH G., FAZIO S., SABATINE M.S., VARIATION IN PCSK9 AND HMGCR AND RISK OF CARDIOVASCULAR DISEASE AND DIABETES, N. ENGL. J. MED., 375, PP. 2144-2153, (2016); TRIGLYCERIDE CORONARY DISEASE GENETICS CONSORTIUM, EMERGING RISK FACTORS COLLABORATION, SARWAR N., SANDHU M.S., RICKETTS S.L., BUTTERWORTH A.S., DI ANGELANTONIO E., BOEKHOLDT S.M., OUWEHAND W., WATKINS H., SAMANI N.J., SALEHEEN D., LAWLOR D., REILLY M.P., HINGORANI A.D., TALMUD P.J., DANESH J., TRIGLYCERIDE-MEDIATED PATHWAYS AND CORONARY DISEASE: COLLABORATIVE ANALYSIS OF 101 STUDIES, LANCET, 375, PP. 1634-1639, (2010); VARBO A., BENN M., TYBJAERG-HANSEN A., JORGENSEN A.B., FRIKKE-SCHMIDT R., NORDESTGAARD B.G., REMNANT CHOLESTEROL AS A CAUSAL RISK FACTOR FOR ISCHEMIC HEART DISEASE, J. AM. COLL. CARDIOL., 61, PP. 427-436, (2013); LEWIS G.F., XIAO C., HEGELE R.A., HYPERTRIGLYCERIDEMIA IN THE GENOMIC ERA: A NEW PARADIGM, ENDOCR. REV., 36, PP. 131-147, (2015); DRON J.S., HEGELE R.A., COMPLEXITY OF MECHANISMS AMONG HUMAN PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 VARIANTS, CURR. OPIN. LIPIDOL., 28, PP. 161-169, (2017); PROSPECTIVE STUDIES COLLABORATION, LEWINGTON S., WHITLOCK G., CLARKE R., SHERLIKER P., EMBERSON J., HALSEY J., QIZILBASH N., PETO R., COLLINS R., BLOOD CHOLESTEROL AND VASCULAR MORTALITY BY AGE, SEX, AND BLOOD PRESSURE: A META-ANALYSIS OF INDIVIDUAL DATA FROM 61 PROSPECTIVE STUDIES WITH 55,000 VASCULAR DEATHS, LANCET, 370, PP. 1829-1839, (2007); FRIKKE-SCHMIDT R., NORDESTGAARD B.G., STENE M.C., SETHI A.A., REMALEY A.T., SCHNOHR P., GRANDE P., TYBJAERG-HANSEN A., ASSOCIATION OF LOSS-OF-FUNCTION MUTATIONS IN THE ABCA1 GENE WITH HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND RISK OF ISCHEMIC HEART DISEASE, J. AM. MED. ASSOC., 299, PP. 2524-2532, (2008); VOIGHT B.F., PELOSO G.M., ORHO-MELANDER M., FRIKKE-SCHMIDT R., BARBALIC M., JENSEN M.K., HINDY G., HOLM H., DING E.L., JOHNSON T., SCHUNKERT H., SAMANI N.J., CLARKE R., HOPEWELL J.C., THOMPSON J.F., LI M., THORLEIFSSON G., NEWTON-CHEH C., MUSUNURU K., PIRRUCCELLO J.P., SALEHEEN D., CHEN L., STEWART A., SCHILLERT A., THORSTEINSDOTTIR U., THORGEIRSSON G., ANAND S., ENGERT J.C., MORGAN T., SPERTUS J., STOLL M., BERGER K., MARTINELLI N., GIRELLI D., MCKEOWN P.P., PATTERSON C.C., EPSTEIN S.E., DEVANEY J., BURNETT M.S., MOOSER V., RIPATTI S., SURAKKA I., NIEMINEN M.S., SINISALO J., LOKKI M.L., PEROLA M., HAVULINNA A., DE FAIRE U., GIGANTE B., INGELSSON E., ZELLER T., WILD P., DE BAKKER P.I., KLUNGEL O.H., MAITLAND-VAN DER ZEE A.H., PETERS B.J., DE BOER A., GROBBEE D.E., KAMPHUISEN P.W., DENEER V.H., ELBERS C.C., ONLAND-MORET N.C., HOFKER M.H., WIJMENGA C., VERSCHUREN W.M., BOER J.M., VAN DER SCHOUW Y.T., RASHEED A., FROSSARD P., DEMISSIE S., WILLER C., DO R., ORDOVAS J.M., ABECASIS G.R., BOEHNKE M., MOHLKE K.L., DALY M.J., GUIDUCCI C., BURTT N.P., SURTI A., GONZALEZ E., PURCELL S., GABRIEL S., MARRUGAT J., PEDEN J., ERDMANN J., DIEMERT P., WILLENBORG C., KONIG I.R., FISCHER M., HENGSTENBERG C., ZIEGLER A., BUYSSCHAERT I., LAMBRECHTS D., VAN DE WERF F., FOX K.A., EL MOKHTARI N.E., RUBIN D., SCHREZENMEIR J., SCHREIBER S., SCHAFER A., DANESH J., BLANKENBERG S., ROBERTS R., MCPHERSON R., WATKINS H., HALL A.S., OVERVAD K., RIMM E., BOERWINKLE E., TYBJAERG-HANSEN A., CUPPLES L.A., REILLY M.P., MELANDER O., MANNUCCI P.M., ARDISSINO D., SISCOVICK D., ELOSUA R., STEFANSSON K., O'DONNELL C.J., SALOMAA V., RADER D.J., PELTONEN L., SCHWARTZ S.M., ALTSHULER D., KATHIRESAN S., PLASMA HDL CHOLESTEROL AND RISK OF MYOCARDIAL INFARCTION: A MENDELIAN RANDOMISATION STUDY, LANCET, 380, PP. 572-580, (2012); LINCOFF A.M., NICHOLLS S.J., RIESMEYER J.S., BARTER P.J., BREWER H.B., FOX K.A.A., GIBSON C.M., GRANGER C., MENON V., MONTALESCOT G., RADER D., TALL A.R., MCERLEAN E., WOLSKI K., RUOTOLO G., VANGEROW B., WEERAKKODY G., GOODMAN S.G., CONDE D., MCGUIRE D.K., NICOLAU J.C., LEIVA-PONS J.L., PESANT Y., LI W., KANDATH D., KOUZ S., TAHIRKHELI N., MASON D., NISSEN S.E., ACCELERATE INVESTIGATORS. EVACETRAPIB AND CARDIOVASCULAR OUTCOMES IN HIGH-RISK VASCULAR DISEASE, N. ENGL. J. MED., 376, PP. 1933-1942, (2017); HPS/TIMI/REVEAL COLLABORATIVE GROUP, BOWMAN L., HOPEWELL J.C., CHEN F., WALLENDSZUS K., STEVENS W., COLLINS R., WIVIOTT S.D., CANNON C.P., BRAUNWALD E., SAMMONS E., LANDRAY M.J., EFFECTS OF ANACETRAPIB IN PATIENTS WITH ATHEROSCLEROTIC VASCULAR DISEASE, N. ENGL. J. MED., 377, PP. 1217-1227, (2017); SCHWARTZ G.G., OLSSON A.G., ABT M., BALLANTYNE C.M., BARTER P.J., BRUMM J., CHAITMAN B.R., HOLME I.M., KALLEND D., LEITER L.A., LEITERSDORF E., MCMURRAY J.J., MUNDL H., NICHOLLS S.J., SHAH P.K., TARDIF J.C., WRIGHT R.S., INVESTIGATORS D.-O.U.T.C.O.M.E.S., EFFECTS OF DALCETRAPIB IN PATIENTS WITH A RECENT ACUTE CORONARY SYNDROME, N. ENGL. J. MED., 367, PP. 2089-2099, (2012); AIM-HIGH INVESTIGATORS, BODEN W.E., PROBSTFIELD J.L., ANDERSON T., CHAITMAN B.R., DESVIGNES-NICKENS P., KOPROWICZ K., MCBRIDE R., TEO K., WEINTRAUB W., NIACIN IN PATIENTS WITH LOW HDL CHOLESTEROL LEVELS RECEIVING INTENSIVE STATIN THERAPY, N. ENGL. J. MED., 365, PP. 2255-2267, (2011); GROUP H.T.C., LANDRAY M.J., HAYNES R., HOPEWELL J.C., PARISH S., AUNG T., TOMSON J., WALLENDSZUS K., CRAIG M., JIANG L., COLLINS R., ARMITAGE J., EFFECTS OF EXTENDED-RELEASE NIACIN WITH LAROPIPRANT IN HIGH-RISK PATIENTS, N. ENGL. J. MED., 371, PP. 203-212, (2014); ANDREWS J., JANSSAN A., NGUYEN T., PISANIELLO A.D., SCHERER D.J., KASTELEIN J.J., MERKELY B., NISSEN S.E., RAY K., SCHWARTZ G.G., WORTHLEY S.G., KEYSERLING C., DASSEUX J.L., BUTTERS J., GIRARDI J., MILLER R., NICHOLLS S.J., EFFECT OF SERIAL INFUSIONS OF RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (CER-001) ON CORONARY ATHEROSCLEROSIS: RATIONALE AND DESIGN OF THE CARAT STUDY, CARDIOVASC. DIAGN. THER., 7, PP. 45-51, (2017); TARDIF J.C., BALLANTYNE C.M., BARTER P., DASSEUX J.L., FAYAD Z.A., GUERTIN M.C., KASTELEIN J.J., KEYSERLING C., KLEPP H., KOENIG W., L'ALLIER P.L., LESPERANCE J., LUSCHER T.F., PAOLINI J.F., TAWAKOL A., WATERS D.D., CAN HDL INFUSIONS SIGNIFICANTLY QUICKEN ATHEROSCLEROSIS REGRESSION (CHI-SQUARE) INVESTIGATORS. EFFECTS OF THE HIGH-DENSITY LIPOPROTEIN MIMETIC AGENT CER-001 ON CORONARY ATHEROSCLEROSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A RANDOMIZED TRIAL, EUR. HEART J., 35, PP. 3277-3286, (2014)","F. MACH; CARDIOLOGY DEPARTMENT, GENEVA UNIVERSITY HOSPITAL, GENEVA, 4 GABRIELLE-PERRET-GENTIL, 1211, SWITZERLAND; EMAIL: FRANCOIS.MACH@HCUGE.CH","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","ARTICLE","ISI","2-S2.0-85072794956","ATHEROSCLEROSIS","GENEVA UNIVERSITY HOSPITAL;UNIVERSITY OF OXFORD;UNIVERSITY OF MILAN;BERN UNIVERSITY HOSPITAL (INSELSPITAL);UNIVERSITY OF MILAN;IR-HOSPITAL DE LA SANTA CREU I SANT PAU;PITIE-SALPETRIERE UNIVERSITY HOSPITAL;GHENT UNIVERSITY;LEIDEN UNIVERSITY MEDICAL CENTER;UNIVERSITY OF CAMBRIDGE;TRINITY COLLEGE;UNIVERSITY OF OXFORD;CHARITE UNIVERSITÄTSMEDIZIN BERLIN;UNIVERSITY OF OXFORD;OSLO UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY;EUROCLINIC;WOMEN'S HOSPITAL AND HARVARD MEDICAL SCHOOL;UNIVERSITY OF HELSINKI;HACETTEPE UNIVERSITY;THE SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG;ARMENIAN CARDIOLOGISTS ASSOCIATION;ASSOCIATION OF CARDIOLOGISTS OF BOSNIA AND HERZEGOVINA;ASSOCIATION OF CARDIOLOGISTS OF KAZAKHSTAN;UKRAINIAN ASSOCIATION OF CARDIOLOGY","NOTREPORTED;GENEVA UNIVERSITY HOSPITAL;NOTREPORTED",NA,"MACH F, 2019, ATHEROSCLEROSIS","MACH F, 2019, ATHEROSCLEROSIS"
"HARRABI S;FERCHICHI A;BACHELI A;FELLAH H","HARRABI, SAOUSSEM (23110559100); FERCHICHI, AZZA (57201646098); BACHELI, ASMA (57192714621); FELLAH, HAYET (6602366023)","POLICOSANOL COMPOSITION ANTIOXIDANT AND ANTIARTHRITIC ACTIVITIES OF MILK THISTLE SILYBIUM MARIANUM L OIL AT DIFFERENT SEED MATURITY STAGES",2018,"LIPIDS IN HEALTH AND DISEASE","17","",40,"10.1186/s12944-018-0682-z","LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE TUNIS, UNIVERSITY OF TUNIS EL MANAR, 15 STREET DJEBEL LAKHDAR, TUNIS, RABTA, 1007, TUNISIA;LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE TUNIS, UNIVERSITY OF TUNIS EL MANAR, 15 STREET DJEBEL LAKHDAR, TUNIS, RABTA, 1007, TUNISIA;LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE TUNIS, UNIVERSITY OF TUNIS EL MANAR, 15 STREET DJEBEL LAKHDAR, TUNIS, RABTA, 1007, TUNISIA;LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE TUNIS, UNIVERSITY OF TUNIS EL MANAR, 15 STREET DJEBEL LAKHDAR, TUNIS, RABTA, 1007, TUNISIA","BACKGROUND: SEVERAL ANTI-ARTHRITIC DRUGS AND SYNTHETIC ANTIOXIDANTS HAVE WIDE PHARMACEUTICAL USES AND ARE OFTEN ASSOCIATED WITH VARIOUS SIDE EFFECTS ON THE HUMAN HEALTH. DIETARY SEED OILS AND THEIR MINOR COMPONENTS LIKE POLICOSANOL MAY OFFER AN EFFECTIVE ALTERNATIVE TREATMENT FOR ARTHRITIC AND OXIDATIVE-STRESS RELATED DISEASES. THE BIOLOGICAL EFFECTS OF SEED OILS WERE AFFECTED BY DIFFERENT PARAMETERS SUCH AS THE STAGE OF SEED MATURITY. HENCE, THIS STUDY SEEKS TO DETERMINE THE POLICOSANOL CONTENT, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL EXTRACTED AT VARIOUS STAGES OF SEED MATURATION. METHODS: MILK THISTLE OIL SAMPLES WERE EXTRACTED FROM SEEDS COLLECTED AT THREE MATURATION STAGES (IMMATURE, INTERMEDIATE, AND MATURE). THE 2,2-DIPHENYL-1-PICRYLHYDRAZYL (DPPH) AND 2,2′-AZINO-BIS (3-ETHYL-BENZTHIAZOLINE-6-SULFONIC ACID) (ABTS) RADICAL SCAVENGING ASSAYS WERE USED TO DETERMINE THE ANTIOXIDANT ACTIVITY OF THE EXTRACTED OILS. THE ANTI-ARTHRITIC ACTIVITY OF OIL SAMPLES WAS EVALUATED WITH BOVINE SERUM PROTEIN DENATURATION AND EGG ALBUMIN DENATURATION METHODS. GAS CHROMATOGRAPHY COUPLED TO MASS SPECTROMETRY (GC-MS) WAS EMPLOYED TO DETERMINE THE POLICOSANOL PROFILE. RESULTS: POLICOSANOL PROFILE, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE OIL WERE INFLUENCED BY THE SEED MATURITY STAGES. THE OIL EXTRACTED FROM THE IMMATURE SEEDS HAD THE HIGHEST TOTAL POLICOSANOL CONTENT (987.68 MG/KG OF OIL) AND DISPLAYED THE MAXIMUM ANTIRADICAL ACTIVITY (96.42% AND 90.35% FOR DPPH TEST AND ABTS ASSAY, RESPECTIVELY). NINE ALIPHATIC ALCOHOLS WERE IDENTIFIED IN THE MILK THISTLE OIL. THE DOMINANT POLIOSANOL IN THE MATURE SEED OIL WAS OCTACOSANOL (75.44%), WHILE TRIACONTANOL WAS THE MAJOR COMPOUND (40.25%) IN THE IMMATURE SEED OIL. ADDITIONALLY, THE MAXIMUM INHIBITION OF BOVINE SERUM PROTEIN DENATURATION (92.53%) AND EGG ALBUMIN DENATURATION (86.36%) WERE OBSERVED IN IMMATURE SEED OIL AS COMPARED TO MATURE SEED OIL. A HIGH CORRELATION WAS FOUND BETWEEN THE TOTAL POLICOSANOL CONTENT, ANTI-ARTHRITIC ACTIVITY AND ANTIOXIDANT CAPACITY OF OIL. CONCLUSIONS: THE MILK THISTLE OIL EXHIBITED A POTENTIAL ANTI-ARTHRITIC AND ANTIOXIDANT ACTIVITIES AND THAT IT MIGHT CONTRIBUTE TO THE PROTECTION OF HUMANS FROM A VARIETY OF DISEASES LIKE RHEUMATOID ARTHRITIS. ALSO, IT COULD SERVE AS NATURAL ANTIOXIDANT AND ANTI-ARTHRITIC AGENTS FOR APPLICATION IN THE FOOD INDUSTRIES AND PHARMACEUTIC. POLICOSANOL LEVEL IN THE SEED OILS MIGHT CONTRIBUTE TO THEIR ANTI-ARTHRITIC AND ANTIOXIDANT ACTIVITIES. © 2018 THE AUTHOR(S).","ANTI-ARTHRITIC ACTIVITY; ANTIOXIDANT CAPACITY; MATURITY STAGE; MILK THISTLE; OIL; POLICOSANOL","ANIMALS; ANTIOXIDANTS; ARTHRITIS; CATTLE; CHICKENS; FATTY ALCOHOLS; MILK THISTLE; PLANT OILS; PROTEIN DENATURATION; SEEDS; SERUM ALBUMIN, BOVINE; 1,1 DIPHENYL 2 PICRYLHYDRAZYL; 2,2' AZINOBIS(3 ETHYLBENZOTHIAZOLINE 6 SULFONIC ACID); ALKANOL; OCTACOSANOL; OVALBUMIN; PLANT EXTRACT; POLICOSANOL; PROTEIN; SILYBIUM MARIANUM EXTRACT; TRIACONTANOL; UNCLASSIFIED DRUG; ANTIOXIDANT; BOVINE SERUM ALBUMIN; FATTY ALCOHOL; POLICOSANOL; VEGETABLE OIL; ABTS RADICAL SCAVENGING ASSAY; ANTIARTHRITIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CYCLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; GENE MUTATION; IMMATURE STAGE; IN VITRO STUDY; INTERMEDIATE STAFE; MATURE STAGE; MATURITY; NONHUMAN; PLANT SEED; PROTEIN BLOOD LEVEL; PROTEIN DENATURATION; SILYBUM MARIANUM; ANIMAL; ARTHRITIS; BOVINE; CHEMISTRY; CHICKEN; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PLANT SEED; SILYBUM MARIANUM","","","MURUGANANTHAN G., SUDHEER K.G., SATHYA C.P., MOHAN S., ANTI-ARTHRITIC AND ANTI-INFLAMMATORY CONSTITUENTS FROM MEDICINAL PLANTS, J APPL PHARM SCI, 3, PP. 161-164, (2013); ELISHA I.L., DZOYEM J.P., MCGAW L.J., BOTHA F.S., ELOFF J.N., THE ANTI-ARTHRITIC, ANTI-INFLAMMATORY, ANTIOXIDANT ACTIVITY AND RELATIONSHIPS WITH TOTAL PHENOLICS AND TOTAL FLAVONOIDS OF NINE SOUTH AFRICAN PLANTS USED TRADITIONALLY TO TREAT ARTHRITIS, BMC COMPLEMENT ALTERN MED, 16, PP. 307-317, (2016); SINGH G., RAMEY D.R., MORFELD D., SHI H., HATOUM H.T., FRIES J.F., GASTROINTESTINAL TRACT COMPLICATIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG TREATMENT IN RHEUMATOID ARTHRITIS: A PROSPECTIVE OBSERVATIONAL COHORT STUDY, ARCH INTERN MED, 156, PP. 1530-1536, (1996); SARAFIAN T.A., KOUYOUMJIAN S., TASHKIN D., ROTH M.D., SYNERGISTIC CYTOTOXICITY OF DELTA(9)-TETRAHYDROCANNABINOL AND BUTYLATED HYDROXYANISOLE, TOXICOL LETT, 133, PP. 171-179, (2002); SAITO M., SAKAGAMI H., FUJISAWA S., CYTOTOXICITY AND APOPTOSIS INDUCTION BY BUTYLATED HYDROXYANISOLE (BHA) AND BUTYLATED HYDROXYTOLUENE (BHT), ANTICANCER RES, 23, PP. 4693-4701, (2003); GULCIN I., ANTIOXIDANT ACTIVITY OF FOOD CONSTITUENTS: AN OVERVIEW, ARCH TOXICOL, 86, PP. 345-391, (2012); ADEDAYO B.C., OBOH G., AKINDAHUNSI A.A., CHANGES IN THE TOTAL PHENOL CONTENT AND ANTIOXIDANT PROPERTIES OF PEPPER FRUIT (DENNETTIATRIPETALA) WITH RIPENING. AFR, J FOOD SCI, 4, PP. 403-409, (2010); BENCHIKH Y., LOUAILECHE H., GEORGE B., MERLIN A., CHANGES IN BIOACTIVE PHYTOCHEMICAL CONTENT AND IN VITRO ANTIOXIDANT ACTIVITY OF CAROB (CERATONIASILIQUAL.) AS INFLUENCED BY FRUIT RIPENING, IND CROP PROD, 60, PP. 298-303, (2014); GULL J., SULTANA B., ANWAR F., NASEER R., ASHRAF M., ASHRAFUZZAMAN M., VARIATION IN ANTIOXIDANT ATTRIBUTES AT THREE RIPENING STAGES OF GUAVA (PSIDIUMGUAJAVA L.) FRUIT FROM DIFFERENT GEOGRAPHICAL REGIONS OF PAKISTAN, MOLECULES, 17, PP. 3165-3180, (2012); LUCINI L., KANE D., PELLIZZONI M., FERRARI A., TREVISI E., RUZICKOVA G., ET AL., PHENOLIC PROFILE AND IN VITRO ANTIOXIDANT POWER OF DIFFERENT MILK THISTLE SILYBUMMARIANUM (L.) GAERTN. CULTIVARS, IND CROP PROD, 83, PP. 11-16, (2016); GIACOMETTI J., DETERMINATION OF ALIPHATIC ALCOHOLS, SQUALENE, A-TOCOPHEROL AND STEROLS IN OLIVE OILS: DIRECT METHOD INVOLVING GAS CHROMATOGRAPHY OF THE UNSAPONIFIABLE FRACTION FOLLOWING SILYLATION, ANALYST, 126, PP. 472-475, (2001); HARRABI S., MAYER M.P., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); MONTSERRAT-DE LA PAZ S., GARCIA-GIMENEZ M., ANGEL-MARTIN M., PEREZ-CAMINO M., ARCHE A.F., LONG-CHAIN FATTY ALCOHOLS FROM EVENING PRIMROSE OIL INHIBIT THE INFLAMMATORY RESPONSE IN MURINE PERITONEAL MACROPHAGES, J ETHNOPHARMACOL, 151, PP. 131-136, (2014); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HAM H., YOON S.W., KIM I.H., KWAK J., LEE J.S., JEONG H.S., ET AL., PROTECTIVE EFFECTS OF UNSAPONIFIABLE MATTER FROM RICE BRAN ON OXIDATIVE DAMAGE BY MODULATING ANTIOXIDANT ENZYME ACTIVITIES IN HEPG2 CELLS. LWT-FOOD, SCI TECHNOL, 61, PP. 602-608, (2015); AMD O., CONSERVA L.M., JNDS F., FDA B., RPL L., BARRETO E., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEAGRISEA VAR. GRISEA IN MICE, INT J MOL SCI, 13, PP. 1598-1611, (2012); WANG T., LIU Y., YANG N., JI C., CHAN P., ZUO P., ANTI-PARKINSONIAN EFFECTS OF OCTACOSANOL IN 1-METHYL-4-PHENYL-1, 2, 3, 6 TETRAHYDROPYRIDINE-TREATED MICE, NEURAL REGENER RES, 7, PP. 1080-1087, (2012); WARREN P.R., BURGER R.A., SIDWELL R.W., CLARK L.L., EFFECT OF TRIACONTANOL ON NUMBERS AND FUNCTIONS OF CELLS INVOLVED IN INFLAMMATORY RESPONSES, PROC SOC EXP BIOL MED, 200, PP. 349-352, (1992); RAMANARAYAN K., BHAT A., SHRIPATHI V., SWAMY G.S., RAO K.S., TRIACONTANOL INHIBITS BOTH ENZYMATIC AND NONENZYMATIC LIPID PEROXIDATION, PHOTOCHEM, 55, PP. 59-66, (2000); MILLAN J., CICERO A.F.G., TORRES F., ANGUERA A., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLÍN INVESTIGACIÓNENARTERIOSCLEROSIS, 28, PP. 178-187, (2016); CHOI S.J., PARK S.Y., PARK J.S., PARK S.K., JUNG M.Y., CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA (CAMELLIA SINENSIS) LEAVES, FOOD CHEM, 204, PP. 94-101, (2016); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J FOOD SCI, 76, PP. C891-C899, (2011); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNAN M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEM, 81, PP. 345-349, (2004); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M., A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACOLOGICAL USES.US 5663156 A, (1997); HARRABI S., ROMDHANE H., DAASSA M., FELLAH H., FATTY ACID AND TRIACYLGLYCEROL COMPOSITIONS OF MILK THISTLE SEEDS GROWING WILD IN TUNISIA (SILYBUMMARIANUM L.), ACTAALIMENTARIA, 44, PP. 304-310, (2015); RUZICKOVA G., FOJTOVA J., SOUCKOVA M., THE YIELD AND QUALITY OF MILK THISTLE (SILYBUMMARIANUM (L). GAERTN.) SEED OIL FROM THE PERSPECTIVE OF ENVIRONMENT AND GENOTYPE - A PILOT STUDY, ACTAFYTOTECHNICAETZOOTECHNICA, 1, PP. 9-12, (2011); BAHL J.R., BANSAL R.P., GOEL R., KUMAR S., PROPERTIES OF THE SEED OIL OF A DWARF CULTIVAR OF THE PHARMACEUTICAL SILYMARIN PRODUCING PLANT SILYBUMMARIANUM (L.) GAERTN. DEVELOPED IN INDIA, I J NAT PROD RES, 6, PP. 127-133, (2015); HARRABI S., CURTIS S., HAYET F., MAYER P.M., CHANGES IN THE STEROL COMPOSITIONS OF MILK THISTLE OIL (SILYBIUMMARIANUM L.) DURING SEED MATURATION, GRASAS ACEITES, 67, (2016); FATHI-ACHACHLOUEI B., AZADMARD-DAMIRCHI S., MILK THISTLE SEED OIL CONSTITUENTS FROM DIFFERENT VARIETIES GROWN IN IRAN, J AM OIL CHEM SOC, 86, PP. 643-649, (2009); DABBOUR I.R., AL-ISMAIL K.M., TAKRURI H.R., AZZEH F.S., CHEMICAL CHARACTERISTICS AND ANTIOXIDANT CONTENT PROPERTIES OF COLD PRESSED SEED OIL OF WILD MILK THISTLE PLANT GROWN IN JORDAN, PAK J NUTR, 13, PP. 67-78, (2014); HASANLOO T., BAHMANEI M., SEPEHRIFAR R., KALANTARI F., DETERMINATION OF TOCOPHEROLS AND FATTY ACIDS IN SEEDS OF SILYBUMMARIANUM (L.) GAERTH, J MED PLANTS, 7, PP. 69-75, (2008); FOLCH J., LEES M., SGM S., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDS FROM ANIMAL TISSUES, J BIOL CHEM, 226, PP. 497-509, (1957); KOZLOWSKA M., GRUCZYNSKA E., SCIBISZ I., RUDZINSKA M., FATTY ACIDS AND STEROLS COMPOSITION, AND ANTIOXIDANT ACTIVITY OF OILS EXTRACTED FROM PLANT SEEDS, FOOD CHEM, 213, PP. 450-456, (2016); RUBALYA V.S., NEELAMEGAM P., SELECTIVE ABTS AND DPPH- RADICAL SCAVENGING ACTIVITY OF PEROXIDE FROM VEGETABLE OILS, INT FOOD RES J, 22, PP. 289-294, (2015); RAHMAN H., ESWARAIAH M.C., DUTTA A.M., IN-VITRO ANTI-INFLAMMATORY AND ANTI-ARTHRITIC ACTIVITY OF ORYZA SATIVA VAR JOHA RICE (AN AROMATIC INDIGENOUS RICE OF ASSAM), AM EURASIAN J AGRIC ENVIRON SCI, 15, PP. 115-121, (2015); KUMARI C.S., YASMIN N., HUSSAIN M.R., BABUSELVAM M., IN VITRO ANTI-INFLAMMATORY AND ANTI-ARTHRITIC PROPERTY OF RHIZOPORAMUCRONATA LEAVES, INT J PHARMA SCI RES, 6, PP. 482-485, (2015); GULZ P.G., MULLER E., PRASAD B.N., DEVELOPMENTAL AND SEASONAL VARIATIONS IN THE EPICUTICULAR WAXES OF TILIATOMENTOSA LEAVES, PHYTOCHEMISTRY, 30, PP. 769-773, (1991); IRMAK S., JONNAL R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, J CEREAL SCI, 48, PP. 20-26, (2008); NAEEM M., KHAN M.M.A., MOINUDDIN. TRIACONTANOL: A POTENT PLANT GROWTH REGULATOR IN AGRICULTURE, J PLANT INTERAC, 7, PP. 129-142, (2012); KLRALAN M., BAYRAK A., OZKAYA M.T., OXIDATION STABILITY OF VIRGIN OLIVE OILS FROM SOME IMPORTANT CULTIVARS IN EAST MEDITERRANEAN AREA IN TURKEY, J AM OIL CHEM SOC, 86, PP. 247-252, (2009); RAMADAN M.F., MORSEL J.T., SCREENING OF THE ANTIRADICAL ACTION OF VEGETABLE OILS, J FOOD COMPOS ANAL, 19, PP. 838-842, (2006); NAZ R., AYUB H., NAWAZ S., ISLAM Z.U., YASMIN T., BANO A., WAKEEL A., ZIA S., ROBERTS T.H., ANTIMICROBIAL ACTIVITY, TOXICITY AND ANTIINFLAMMATORY POTENTIAL OF METHANOLIC EXTRACTS OF FOUR ETHNOMEDICINAL PLANT SPECIES FROM PUNJAB, PAKISTAN, BMC COMPLEMENT ALTERN MED, 17, (2017); KAMBLE A.A., KHAN N.D., KHAN Z.H., MULAR S.M., SOHAIL S., IN VITRO ANTI-ARTHRITIC ACTIVITY OF VITEXNEGUNDO AND PUNICAGRANATUM, RES J PHARM SCI, 6, PP. 5-7, (2017); YADAV N.V., SADASHIVAIAH, RAMAIYAN B., ACHARYA P., BELUR L., TALAHALLI R.R., SESAME OIL AND RICE BRAN OIL AMELIORATES ADJUVANT-INDUCED ARTHRITIS IN RATS: DISTINGUISHING THE ROLE OF MINOR COMPONENTS AND FATTY ACIDS, LIPIDS, 51, PP. 1385-1395, (2016)","S. HARRABI; LABORATORY OF CLINICAL BIOCHEMISTRY, LR99ES11, FACULTY OF MEDICINE TUNIS, UNIVERSITY OF TUNIS EL MANAR, TUNIS, RABTA, 15 STREET DJEBEL LAKHDAR, 1007, TUNISIA; EMAIL: SAWSEMTAHAR@YAHOO.FR","BIOMED CENTRAL LTD.","ENGLISH","LIPIDS HEALTH DIS.","ARTICLE","ISI","2-S2.0-85045510823","LIPIDS HEALTH DIS","TUNIS;TUNIS;TUNIS;TUNIS","NOTREPORTED;UNIVERSITY OF TUNIS EL MANAR;NOTREPORTED",NA,"HARRABI S, 2018, LIPIDS HEALTH DIS","HARRABI S, 2018, LIPIDS HEALTH DIS"
"PATEL S","PATEL, SEEMA (35750270400)","FUNCTIONAL FOOD RED YEAST RICE RYR FOR METABOLIC SYNDROME AMELIORATION A REVIEW ON PROS AND CONS",2016,"WORLD JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY","32","",68,"10.1007/s11274-016-2035-2","BIOINFORMATICS AND MEDICAL INFORMATICS RESEARCH CENTER, SAN DIEGO STATE UNIVERSITY, 5500 CAMPANILE DR, SAN DIEGO, 92182, CA, UNITED STATES","ABSTRACT: RED YEAST RICE (RYR), THE FERMENTATION PRODUCT OF MOLD MONASCUS PURPUREUS HAS BEEN AN INTEGRAL PART OF ORIENTAL FOOD AND TRADITIONAL CHINESE MEDICINE, LONG BEFORE THE DISCOVERY OF THEIR MEDICINAL ROLES. WITH THE IDENTIFICATION OF BIOACTIVE COMPONENTS AS POLYKETIDE PIGMENTS (STATINS), AND UNSATURATED FATTY ACIDS, RYR HAS GAINED A NUTRACEUTICAL STATUS. HYPERCHOLESTEROLEMIC EFFECT OF THIS FERMENTED COMPOUND HAS BEEN VALIDATED AND MONACOLIN K HAS BEEN RECOGNIZED AS THE PIVOTAL COMPONENT IN CHOLESTEROL ALLEVIATION. FUNCTIONAL SIMILARITY WITH COMMERCIAL DRUG LOVASTATIN SANS THE SIDE EFFECTS HAS CATAPULTED ITS POPULARITY IN OTHER PARTS OF THE WORLD AS WELL. APART FROM THE HYPOTENSIVE ROLE, AMELIORATIVE BENEFITS OF RYR AS ANTI-INFLAMMATORY, ANTIDIABETIC, ANTICANCER AND OSTEOGENIC AGENT HAVE EMERGED, FUELING INTENSE RESEARCH ON IT. MECHANISTIC STUDIES HAVE REVEALED THEIR INTERACTION WITH FUNCTIONAL AGENTS LIKE COENZYME Q10, ASTAXANTHIN, VITAMIN D, FOLIC ACID, POLICOSANOL, AND BERBERINE. ON THE OTHER HAND, CONCURRENCE OF MYCOTOXIN CITRININ AND VARIABLE CONTENT OF STATIN HAS MARRED ITS INTEGRATION IN MAINSTREAM MEDICATION. IN THIS DISPUTABLE SCENARIO, EVALUATION OF THE SCOPES AND LACUNAE TO OVERCOME SEEMS TO CONTRIBUTE TO AN EMINENT AREA OF HEALTHCARE. GRAPHICAL ABSTRACT: RED YEAST RICE (RYR), THE RICE-BASED FERMENTATION PRODUCT OF MOLD MONASCUS PURPUREUS IS A FUNCTIONAL FOOD. ITS BIOACTIVE COMPONENT MONACOLIN K ACTS LIKE SYNTHETIC DRUG LOVASTATIN, WITHOUT THE SEVERE SIDE EFFECTS OF THE LATTER. RYR HAS BEEN VALIDATED TO LOWER CHOLESTEROL, CONTROL HIGH BLOOD PRESSURE; CONFER ANTI-FLAMMATION, HYPOGLYCAEMIC, ANTICANCER AND OSTEOGENIC PROPERTIES. HOWEVER, DOSE INCONSISTENCY AND CO-OCCURRENCE OF TOXIN CITRININ HAMPERS ITS DIETARY SUPPLEMENTATION PROSPECT. FURTHER RESEARCH MIGHT FACILITATE DEVELOPMENT OF RYR AS A NUTRACEUTICAL.[FIGURE NOT AVAILABLE: SEE FULLTEXT.] © 2016, SPRINGER SCIENCE+BUSINESS MEDIA DORDRECHT.","DYSLIPIDEMIA; LOVASTATIN; MONACOLIN; MONASCUS; RED YEAST RICE","ANIMALS; BIOLOGICAL PRODUCTS; FUNCTIONAL FOOD; HUMANS; METABOLIC SYNDROME X; MONASCUS; ORYZA; BLOOD PRESSURE; CHOLESTEROL; DIETARY SUPPLEMENTS; FATTY ACIDS; FERMENTATION; KETONES; MEDICAL APPLICATIONS; MEDICINE; MOLDS; PIGMENTS; UNSATURATED FATTY ACIDS; YEAST; BIOLOGICAL PRODUCT; CHOLESTIN; DYSLIPIDEMIAS; LOVASTATIN; MONACOLIN; MONASCUS; RED YEAST RICE; ADVERSE EFFECTS; ANALYSIS; ANIMAL; CHEMISTRY; DIET THERAPY; FUNCTIONAL FOOD; HUMAN; METABOLIC SYNDROME X; METABOLISM; MICROBIOLOGY; MONASCUS; ORYZA; FUNCTIONAL FOOD","","","ABDELBASET M., SAFAR M.M., MAHMOUD S.S., ET AL., RED YEAST RICE AND COENZYME Q10 AS SAFE ALTERNATIVES TO SURMOUNT ATORVASTATIN-INDUCED MYOPATHY IN HYPERLIPIDEMIC RATS, CAN J PHYSIOL PHARMACOL, 92, PP. 481-489, (2014); AFFUSO F., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, (2012); AGGARWAL S., QAMAR A., SHARMA V., SHARMA A., ABDOMINAL AORTIC ANEURYSM: A COMPREHENSIVE REVIEW, EXP CLIN CARDIOL, 16, PP. 11-15, (2011); ATAR N., EREN T., YOLA M.L., A MOLECULAR IMPRINTED SPR BIOSENSOR FOR SENSITIVE DETERMINATION OF CITRININ IN RED YEAST RICE, FOOD CHEM, 184, PP. 7-11, (2015); AVULA B., COHEN P.A., WANG Y.-H., ET AL., CHEMICAL PROFILING AND QUANTIFICATION OF MONACOLINS AND CITRININ IN RED YEAST RICE COMMERCIAL RAW MATERIALS AND DIETARY SUPPLEMENTS USING LIQUID CHROMATOGRAPHY-ACCURATE QTOF MASS SPECTROMETRY: CHEMOMETRICS APPLICATION, J PHARM BIOMED ANAL, 100, PP. 243-253, (2014); BALAKRISHNAN B., KARKI S., CHIU S.-H., ET AL., GENETIC LOCALIZATION AND IN VIVO CHARACTERIZATION OF A MONASCUS AZAPHILONE PIGMENT BIOSYNTHETIC GENE CLUSTER, APPL MICROBIOL BIOTECHNOL, 97, PP. 6337-6345, (2013); BOGSRUD M.P., OSE L., LANGSLET G., ET AL., HYPOCOL (RED YEAST RICE) LOWERS PLASMA CHOLESTEROL—A RANDOMIZED PLACEBO CONTROLLED STUDY, SCAND CARDIOVASC J, 44, PP. 197-200, (2010); BRANTLEY S.J., ARGIKAR A.A., LIN Y.S., ET AL., HERB–DRUG INTERACTIONS: CHALLENGES AND OPPORTUNITIES FOR IMPROVED PREDICTIONS, DRUG METAB DISPOS, 42, PP. 301-317, (2014); CALDERON R.M., CUBEDDU L.X., GOLDBERG R.B., SCHIFF E.R., STATINS IN THE TREATMENT OF DYSLIPIDEMIA IN THE PRESENCE OF ELEVATED LIVER AMINOTRANSFERASE LEVELS: A THERAPEUTIC DILEMMA, MAYO CLIN PROC, 85, PP. 349-356, (2010); CHAUVIN B., DROUOT S., BARRAIL-TRAN A., TABURET A.-M., DRUG-DRUG INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS (STATINS) AND ANTIVIRAL PROTEASE INHIBITORS, CLIN PHARMACOKINET, 52, PP. 815-831, (2013); CHEN R.-J., HUNG C.-M., CHEN Y.-L., ET AL., MONASCUSPILOIN INDUCES APOPTOSIS AND AUTOPHAGIC CELL DEATH IN HUMAN PROSTATE CANCER CELLS VIA THE AKT AND AMPK SIGNALING PATHWAYS, J AGRIC FOOD CHEM, 60, PP. 7185-7193, (2012); CHEN G., SHI K., SONG D., ET AL., THE PIGMENT CHARACTERISTICS AND PRODUCTIVITY SHIFTING IN HIGH CELL DENSITY CULTURE OF MONASCUS ANKA MYCELIA, BMC BIOTECHNOL, 15, (2015); CHEN H.-H.S., NEHER J., SAFRANEK S., CLINICAL INQUIRY: IS RED-YEAST RICE A SAFE AND EFFECTIVE ALTERNATIVE TO STATINS?, J FAM PRACT, 64, PP. 128-135, (2015); CHENG M.-J., WU M.-D., CHEN I.-S., YUAN G.-F., A NEW SESQUITERPENE ISOLATED FROM THE EXTRACTS OF THE FUNGUS MONASCUS PILOSUS-FERMENTED RICE, NAT PROD RES, 24, PP. 750-758, (2010); CHILDRESS L., GAY A., ZARGAR A., ITO M.K., REVIEW OF RED YEAST RICE CONTENT AND CURRENT FOOD AND DRUG ADMINISTRATION OVERSIGHT, J CLIN LIPIDOL, 7, PP. 117-122, (2013); CHIU H.-W., FANG W.-H., CHEN Y.-L., ET AL., MONASCUSPILOIN ENHANCES THE RADIATION SENSITIVITY OF HUMAN PROSTATE CANCER CELLS BY STIMULATING ENDOPLASMIC RETICULUM STRESS AND INDUCING AUTOPHAGY, PLOS ONE, 7, (2012); CHO Y.-E., ALCANTARA E., KUMARAN S., ET AL., RED YEAST RICE STIMULATES OSTEOBLAST PROLIFERATION AND INCREASES ALKALINE PHOSPHATASE ACTIVITY IN MC3T3-E1 CELLS, NUTR RES, 30, PP. 501-510, (2010); DEBOSE-BOYD R.A., FEEDBACK REGULATION OF CHOLESTEROL SYNTHESIS: STEROL-ACCELERATED UBIQUITINATION AND DEGRADATION OF HMG COA REDUCTASE, CELL RES, 18, PP. 609-621, (2008); DEROSA G., BONAVENTURA A., BIANCHI L., ET AL., A RANDOMIZED, PLACEBO-CONTROLLED STUDY ON THE EFFECTS OF A NUTRACEUTICAL COMBINATION OF RED YEAST RICE, SILYBUM MARIANUM AND OCTASONOL ON LIPID PROFILE, ENDOTHELIAL AND INFLAMMATORY PARAMETERS, J BIOL REGUL HOMEOST AGENTS, 28, PP. 317-324, (2013); DILL J.A., FUCIARELLI A.F., LEE K.M., ET AL., SINGLE ADMINISTRATION TOXICOKINETIC STUDIES OF DECALIN (DECAHYDRONAPHTHALENE) IN RATS AND MICE, TOXICOL SCI, 72, PP. 210-222, (2003); DING M., SI D., ZHANG W., ET AL., RED YEAST RICE REPAIRS KIDNEY DAMAGE AND REDUCES INFLAMMATORY TRANSCRIPTION FACTORS IN RAT MODELS OF HYPERLIPIDEMIA, EXP THER MED, 8, PP. 1737-1744, (2014); EREN T., ATAR N., YOLA M.L., KARIMI-MALEH H., A SENSITIVE MOLECULARLY IMPRINTED POLYMER BASED QUARTZ CRYSTAL MICROBALANCE NANOSENSOR FOR SELECTIVE DETERMINATION OF LOVASTATIN IN RED YEAST RICE, FOOD CHEM, 185, PP. 430-436, (2015); FASINU P.S., BOUIC P.J., ROSENKRANZ B., AN OVERVIEW OF THE EVIDENCE AND MECHANISMS OF HERB–DRUG INTERACTIONS, FRONT PHARMACOL, 3, (2012); FENG Y., SHAO Y., CHEN F., MONASCUS PIGMENTS, APPL MICROBIOL BIOTECHNOL, 96, PP. 1421-1440, (2012); FEUERSTEIN J.S., BJERKE W.S., POWDERED RED YEAST RICE AND PLANT STANOLS AND STEROLS TO LOWER CHOLESTEROL, J DIET SUPPL, 9, PP. 110-115, (2012); FINEGOLD J.A., ASARIA P., FRANCIS D.P., MORTALITY FROM ISCHAEMIC HEART DISEASE BY COUNTRY, REGION, AND AGE: STATISTICS FROM WORLD HEALTH ORGANISATION AND UNITED NATIONS, INT J CARDIOL, 168, PP. 934-945, (2013); FISHMAN J.A., OPPORTUNISTIC INFECTIONS—COMING TO THE LIMITS OF IMMUNOSUPPRESSION?, COLD SPRING HARB PERSPECT MED, 3, (2013); FLAJS D., PERAICA M., TOXICOLOGICAL PROPERTIES OF CITRININ, ARCH IND HYG TOXICOL, 60, PP. 457-464, (2009); FUNG W.T., SUBRAMANIAM G., LEE J., ET AL., ASSESSMENT OF EXTRACTS FROM RED YEAST RICE FOR HERB-DRUG INTERACTION BY IN VITRO AND IN VIVO ASSAYS, SCI REP, 2, (2012); GARRIDO-MARAVER J., CORDERO M.D., OROPESA-AVILA M., ET AL., CLINICAL APPLICATIONS OF COENZYME Q10, FRONT BIOSCI (LANDMARK ED), 19, PP. 619-633, (2014); GERARDS M.C., TERLOU R.J., YU H., ET AL., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN—A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS: BUYER BEWARE!, ARCH INTERN MED, 170, PP. 1722-1727, (2010); GURLEY B.J., SWAIN A., WILLIAMS D.K., ET AL., GAUGING THE CLINICAL SIGNIFICANCE OF P-GLYCOPROTEIN-MEDIATED HERB-DRUG INTERACTIONS: COMPARATIVE EFFECTS OF ST. JOHN’S WORT, ECHINACEA, CLARITHROMYCIN, AND RIFAMPIN ON DIGOXIN PHARMACOKINETICS, MOL NUTR FOOD RES, 52, PP. 772-779, (2008); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); HONG M.Y., SEERAM N.P., ZHANG Y., HEBER D., ANTICANCER EFFECTS OF CHINESE RED YEAST RICE VERSUS MONACOLIN K ALONE ON COLON CANCER CELLS, J NUTR BIOCHEM, 19, PP. 448-458, (2008); HONG M.Y., HENNING S., MORO A., ET AL., CHINESE RED YEAST RICE INHIBITION OF PROSTATE TUMOR GROWTH IN SCID MICE, CANCER PREV RES (PHILA), 4, PP. 608-615, (2011); HSIEH C.-W., LU Y.-R., LIN S.-M., ET AL., STABILITY OF MONACOLIN K AND CITRININ AND BIOCHEMICAL CHARACTERIZATION OF RED-KOJI VINEGAR DURING FERMENTATION, J AGRIC FOOD CHEM, 61, PP. 7276-7283, (2013); ISTVAN E., STATIN INHIBITION OF HMG-COA REDUCTASE: A 3-DIMENSIONAL VIEW, ATHEROSCLER SUPPL, 4, PP. 3-8, (2003); JAMES P.A., OPARIL S., CARTER B.L., ET AL., 2014 EVIDENCE-BASED GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS: REPORT FROM THE PANEL MEMBERS APPOINTED TO THE EIGHTH JOINT NATIONAL COMMITTEE (JNC 8), JAMA, 311, PP. 507-520, (2014); JERNBERG E., THYSELL E., BOVINDER YLITALO E., ET AL., CHARACTERIZATION OF PROSTATE CANCER BONE METASTASES ACCORDING TO EXPRESSION LEVELS OF STEROIDOGENIC ENZYMES AND ANDROGEN RECEPTOR SPLICE VARIANTS, PLOS ONE, 8, (2013); JIA X.Q., XU Z.N., ZHOU L.P., SUNG C.K., ELIMINATION OF THE MYCOTOXIN CITRININ PRODUCTION IN THE INDUSTRIAL IMPORTANT STRAIN MONASCUS PURPUREUS SM001, METAB ENG, 12, PP. 1-7, (2010); JIRASATID S., NOPHARATANA M., KITSUBUN P., TONGTA A., DEGRADATION KINETICS OF MONACOLIN K IN RED YEAST RICE POWDER USING MULTIRESPONSE MODELING APPROACH, J FOOD ENG, 116, PP. 436-443, (2013); KARL M., RUBENSTEIN M., RUDNICK C., BREJDA J., A MULTICENTER STUDY OF NUTRACEUTICAL DRINKS FOR CHOLESTEROL (EVALUATING EFFECTIVENESS AND TOLERABILITY), J CLIN LIPIDOL, 6, PP. 150-158, (2012); KHAYZNIKOV M., HEMACHRANDRA K., PANDIT R., ET AL., STATIN INTOLERANCE BECAUSE OF MYALGIA, MYOSITIS, MYOPATHY, OR MYONECROSIS CAN IN MOST CASES BE SAFELY RESOLVED BY VITAMIN D SUPPLEMENTATION, N AM J MED SCI, 7, PP. 86-93, (2015); KLIMEK M., WANG S., OGUNKANMI A., SAFETY AND EFFICACY OF RED YEAST RICE (MONASCUS PURPUREUS) AS AN ALTERNATIVE THERAPY FOR HYPERLIPIDEMIA, P T, 34, PP. 313-327, (2009); LACHENMEIER D.W., MONAKHOVA Y.B., KUBALLA T., ET AL., NMR EVALUATION OF TOTAL STATIN CONTENT AND HMG-COA REDUCTASE INHIBITION IN RED YEAST RICE (MONASCUS SPP.) FOOD SUPPLEMENTS, CHIN MED, 7, (2012); LAM D.W., LEROITH D., THE WORLDWIDE DIABETES EPIDEMIC, CURR OPIN ENDOCRINOL DIABETES OBES, 19, PP. 93-96, (2012); LEE I.-T., LEE W.-J., TSAI C.-M., ET AL., COMBINED EXTRACTIVES OF RED YEAST RICE, BITTER GOURD, CHLORELLA, SOY PROTEIN, AND LICORICE IMPROVE TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDE IN SUBJECTS WITH METABOLIC SYNDROME, NUTR RES, 32, PP. 85-92, (2012); LEE C.-I., SHIH C.-D., LEE C.-L., ET AL., EFFECT OF RED MOLD RICE ON BLOOD COAGULATION AND ANTICOAGULATION FACTORS IN A RAT MODEL OF HYPERLIPIDEMIA, J FUNCT FOODS, 5, PP. 1956-1965, (2013); LI Z., SEERAM N.P., LEE R., ET AL., PLASMA CLEARANCE OF LOVASTATIN VERSUS CHINESE RED YEAST RICE IN HEALTHY VOLUNTEERS, J ALTERN COMPLEMENT MED, 11, PP. 1031-1038, (2005); LI J.-J., SHANG X.-Y., LI L.-L., ET AL., NEW CYTOTOXIC AZAPHILONES FROM MONASCUS PURPUREUS-FERMENTED RICE (RED YEAST RICE), MOLECULES, 15, PP. 1958-1966, (2010); LI P., YANG Y., LIU M., XUEZHIKANG, EXTRACT OF RED YEAST RICE, INHIBITED TISSUE FACTOR AND HYPERCOAGULABLE STATE THROUGH SUPPRESSING NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE AND EXTRACELLULAR SIGNAL-REGULATED KINASE ACTIVATION, J CARDIOVASC PHARMACOL, 58, PP. 307-318, (2011); LI Y., WU H., GUO L., ET AL., MICROSPHERE-BASED FLOW CYTOMETRIC IMMUNOASSAY FOR THE DETERMINATION OF CITRININ IN RED YEAST RICE, FOOD CHEM, 134, PP. 2540-2545, (2012); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); LIU Y., GUO X., DUAN W., ET AL., ACCELERATED SOLVENT EXTRACTION OF MONACOLIN K FROM RED YEAST RICE AND PURIFICATION BY HIGH-SPEED COUNTER-CURRENT CHROMATOGRAPHY, J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI, 878, PP. 2881-2885, (2010); LU L.-P., ZHANG B.-B., XU G.-R., EFFICIENT CONVERSION OF HIGH CONCENTRATION OF GLYCEROL TO MONACOLIN K BY SOLID-STATE FERMENTATION OF MONASCUS PURPUREUS USING BAGASSE AS CARRIER, BIOPROCESS BIOSYST ENG, 36, PP. 293-299, (2013); MA J., LI Y., YE Q., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5225, (2000); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); MCCARTY M.F., O'KEEFE J.H., DINICOLANTONIO J.J., RED YEAST RICE PLUS BERBERINE: PRACTICAL STRATEGY FOR PROMOTING VASCULAR AND METABOLIC HEALTH, ALTERN THER HEALTH MED, 21, PP. 40-45, (2015); MORENO P.R., BERNARDI V.H., LOPEZ-CUELLAR J., ET AL., MACROPHAGES, SMOOTH MUSCLE CELLS, AND TISSUE FACTOR IN UNSTABLE ANGINA. IMPLICATIONS FOR CELL-MEDIATED THROMBOGENICITY IN ACUTE CORONARY SYNDROMES, CIRCULATION, 94, PP. 3090-3097, (1996); MORIARTY P.M., ROTH E.M., KARNS A., ET AL., EFFECTS OF XUEZHIKANG IN PATIENTS WITH DYSLIPIDEMIA: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY, J CLIN LIPIDOL, 8, PP. 568-575, (2014); MORNAR A., SERTIC M., NIGOVIC B., DEVELOPMENT OF A RAPID LC/DAD/FLD/MS N METHOD FOR THE SIMULTANEOUS DETERMINATION OF MONACOLINS AND CITRININ IN RED FERMENTED RICE PRODUCTS, J AGRIC FOOD CHEM, 61, PP. 1072-1080, (2013); NIGOVIC B., SERTIC M., MORNAR A., SIMULTANEOUS DETERMINATION OF LOVASTATIN AND CITRININ IN RED YEAST RICE SUPPLEMENTS BY MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY, FOOD CHEM, 138, PP. 531-538, (2013); ODEGAARD J.I., CHAWLA A., THE IMMUNE SYSTEM AS A SENSOR OF THE METABOLIC STATE, IMMUNITY, 38, PP. 644-654, (2013); OGIER N., AMIOT M.-J., GEORGE S., ET AL., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR J NUTR, 52, PP. 547-557, (2013); PARK H.-J., KIM I.-S., ANTIOXIDANT ACTIVITIES AND ANTICANCER EFFECTS OF RED YEAST RICE GROWN IN THE MEDIUM CONTAINING GARLIC, FOOD SCI BIOTECHNOL, 20, PP. 297-302, (2011); PATAKOVA P., MONASCUS SECONDARY METABOLITES: PRODUCTION AND BIOLOGICAL ACTIVITY, J IND MICROBIOL BIOTECHNOL, 40, PP. 169-181, (2013); PIRILLO A., CATAPANO A.L., STATIN INTOLERANCE: DIAGNOSIS AND REMEDIES, CURR CARDIOL REP, 17, (2015); SANGUANKEO A., UPALA S., CHEUNGPASITPORN W., ET AL., EFFECTS OF STATINS ON RENAL OUTCOME IN CHRONIC KIDNEY DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, PLOS ONE, 10, (2015); SARTORE G., GIOVANNI S., BURLINA S., ET AL., MEDITERRANEAN DIET AND RED YEAST RICE SUPPLEMENTATION FOR THE MANAGEMENT OF HYPERLIPIDEMIA IN STATIN-INTOLERANT PATIENTS WITH OR WITHOUT TYPE 2 DIABETES, EVID BASED COMPLEMENT ALTERNAT MED, 2013, (2013); SEENIVASAN A., SUBHAGAR S., ARAVINDAN R., VIRUTHAGIRI T., MICROBIAL PRODUCTION AND BIOMEDICAL APPLICATIONS OF LOVASTATIN, INDIAN J PHARM SCI, 70, PP. 701-709, (2008); SHAM T.-T., CHAN C.-O., WANG Y.-H., ET AL., A REVIEW ON THE TRADITIONAL CHINESE MEDICINAL HERBS AND FORMULAE WITH HYPOLIPIDEMIC EFFECT, BIOMED RES INT, 2014, (2014); SHANG Q., LIU Z., CHEN K., ET AL., A SYSTEMATIC REVIEW OF XUEZHIKANG, AN EXTRACT FROM RED YEAST RICE, FOR CORONARY HEART DISEASE COMPLICATED BY DYSLIPIDEMIA, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012); SHARMA J.N., AL-OMRAN A., PARVATHY S.S., ROLE OF NITRIC OXIDE IN INFLAMMATORY DISEASES, INFLAMMOPHARMACOLOGY, 15, PP. 252-259, (2007); SHI Y.-C., PAN T.-M., BENEFICIAL EFFECTS OF MONASCUS PURPUREUS NTU 568-FERMENTED PRODUCTS: A REVIEW, APPL MICROBIOL BIOTECHNOL, 90, PP. 1207-1217, (2011); SHIMIZU T., KINOSHITA H., ISHIHARA S., ET AL., POLYKETIDE SYNTHASE GENE RESPONSIBLE FOR CITRININ BIOSYNTHESIS IN MONASCUS PURPUREUS, APPL ENVIRON MICROBIOL, 71, PP. 3453-3457, (2005); SRIVASTAVA R.A.K., PINKOSKY S.L., FILIPPOV S., ET AL., AMP-ACTIVATED PROTEIN KINASE: AN EMERGING DRUG TARGET TO REGULATE IMBALANCES IN LIPID AND CARBOHYDRATE METABOLISM TO TREAT CARDIO-METABOLIC DISEASES: THEMATIC REVIEW SERIES: NEW LIPID AND LIPOPROTEIN TARGETS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, J LIPID RES, 53, PP. 2490-2514, (2012); TAM E.W.T., TSANG C.-C., LAU S.K.P., WOO P.C.Y., POLYKETIDES, TOXINS AND PIGMENTS IN PENICILLIUM MARNEFFEI, TOXINS (BASEL), 7, PP. 4421-4436, (2015); THAPAR M., RUSSO M.W., BONKOVSKY H.L., STATINS AND LIVER INJURY, GASTROENTEROL HEPATOL (N Y), 9, PP. 605-606, (2013); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTRITION METAB, 4, PP. 133-139, (2011); TRIMARCO V., CIMMINO C.S., SANTORO M., ET AL., NUTRACEUTICALS FOR BLOOD PRESSURE CONTROL IN PATIENTS WITH HIGH-NORMAL OR GRADE 1 HYPERTENSION, HIGH BLOOD PRESS CARDIOVASC PREV, 19, PP. 117-122, (2012); UPCHURCH G.R., SCHAUB T.A., ABDOMINAL AORTIC ANEURYSM, AM FAM PHYSICIAN, 73, PP. 1198-1204, (2006); VENERO C.V., VENERO J.V., WORTHAM D.C., THOMPSON P.D., LIPID-LOWERING EFFICACY OF RED YEAST RICE IN A POPULATION INTOLERANT TO STATINS, AM J CARDIOL, 105, PP. 664-666, (2010); VERHOEVEN V., VAN DER AUWERA A., VAN GAAL L., ET AL., CAN RED YEAST RICE AND OLIVE EXTRACT IMPROVE LIPID PROFILE AND CARDIOVASCULAR RISK IN METABOLIC SYNDROME?: A DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED TRIAL, BMC COMPLEMENT ALTERN MED, 15, (2015); WANG J., JIANG W., ZHONG Y., ET AL., XUEZHIKANG ATTENUATED THE FUNCTIONAL AND MORPHOLOGICAL IMPAIRMENT OF PANCREATIC ISLETS IN DIABETIC MICE VIA THE INHIBITION OF OXIDATIVE STRESS, J CARDIOVASC PHARMACOL, 63, PP. 282-289, (2014); WANG Y.F., LIU W.T., CHEN C.Y., ET AL., ANTI-OSTEOPOROSIS ACTIVITY OF RED YEAST RICE EXTRACT ON OVARIECTOMY-INDUCED BONE LOSS IN RATS, GENET MOL RES, 14, PP. 8137-8146, (2015); WEI Y., POPOVICH D.G., RED AZAPHILONE PIGMENTS EXTRACTED FROM RED YEAST RICE INDUCES CELLULAR SENESCENCE AND REDUCES VIABILITY IN HEPG2 CELLS, BIOMED PREV NUTR, 3, PP. 331-337, (2013); WONG R.W.K., RABIE B., CHINESE RED YEAST RICE (MONASCUS PURPUREUS-FERMENTED RICE) PROMOTES BONE FORMATION, CHIN MED, 3, (2008); WU M.-D., CHENG M.-J., YECH Y.-J., ET AL., MONASCUSAZAPHILONES A-C, THREE NEW AZAPHILONE ANALOGUES ISOLATED FROM THE FUNGUS MONASCUS PURPUREUS BCRC 38108, NAT PROD RES, 27, PP. 1145-1152, (2013); XIE X., WANG Y., ZHANG S., ET AL., CHINESE RED YEAST RICE ATTENUATES THE DEVELOPMENT OF ANGIOTENSIN II-INDUCED ABDOMINAL AORTIC ANEURYSM AND ATHEROSCLEROSIS, J NUTR BIOCHEM, 23, PP. 549-556, (2012); XIONG X., WANG P., LI X., THE EFFECTS OF RED YEAST RICE DIETARY SUPPLEMENT ON BLOOD PRESSURE, LIPID PROFILE AND C-REACTIVE PROTEIN IN HYPERTENSION: A SYSTEMATIC REVIEW. CRIT REV FOOD SCI NUTR, DOI:10.1080/10408398.2015.1018987, (2015); YANG C.W., MOUSA S.A., THE EFFECT OF RED YEAST RICE (MONASCUS PURPUREUS) IN DYSLIPIDEMIA AND OTHER DISORDERS, COMPLEMENT THER MED, 20, PP. 466-474, (2012); YANG N.-C., CHOU C.-W., CHEN C.-Y., ET AL., COMBINED NATTOKINASE WITH RED YEAST RICE BUT NOT NATTOKINASE ALONE HAS POTENT EFFECTS ON BLOOD LIPIDS IN HUMAN SUBJECTS WITH HYPERLIPIDEMIA, ASIA PAC J CLIN NUTR, 18, PP. 310-317, (2009); ZANARDI M., QUIRICO E., BENVENUTI C., PEZZANA A., USE OF A LIPID-LOWERING FOOD SUPPLEMENT IN PATIENTS ON HORMONE THERAPY FOLLOWING BREAST CANCER, MINERVA GINECOL, 64, PP. 431-435, (2012); ZHANG B.-B., LU L.-P., XU G.-R., WHY SOLID-STATE FERMENTATION IS MORE ADVANTAGEOUS OVER SUBMERGED FERMENTATION FOR CONVERTING HIGH CONCENTRATION OF GLYCEROL INTO MONACOLIN K BY MONASCUS PURPUREUS 9901: A MECHANISTIC STUDY, J BIOTECHNOL, 206, PP. 60-65, (2015); ZHOU G., FU L., LI X., OPTIMISATION OF ULTRASOUND-ASSISTED EXTRACTION CONDITIONS FOR MAXIMAL RECOVERY OF ACTIVE MONACOLINS AND REMOVAL OF TOXIC CITRININ FROM RED YEAST RICE BY A FULL FACTORIAL DESIGN COUPLED WITH RESPONSE SURFACE METHODOLOGY, FOOD CHEM, 170, PP. 186-192, (2015); ZHU L., LU J.-G., LI T., ET AL., IMMUNOSUPPRESSIVE DECALIN DERIVATIVES FROM RED YEAST RICE, J NAT PROD, 75, PP. 567-571, (2012); ZHU L., YAU L.-F., LU J.-G., ET AL., CYTOTOXIC DEHYDROMONACOLINS FROM RED YEAST RICE, J AGRIC FOOD CHEM, 60, PP. 934-939, (2012); ZHU L., HAN Q.-B., HO A., ET AL., CHARACTERIZATION AND SIMULTANEOUS DETERMINATION OF IMMUNOSUPPRESSIVE DECALINS IN RED YEAST RICE BY ULTRA-HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY HYPHENATED WITH MASS SPECTROMETRY, J CHROMATOGR A, 1303, PP. 54-61, (2013); ZHU X.-Y., LI P., YANG Y.-B., LIU M.-L., XUEZHIKANG, EXTRACT OF RED YEAST RICE, IMPROVED ABNORMAL HEMORHEOLOGY, SUPPRESSED CAVEOLIN-1 AND INCREASED ENOS EXPRESSION IN ATHEROSCLEROTIC RATS, PLOS ONE, 8, (2013)","S. PATEL; BIOINFORMATICS AND MEDICAL INFORMATICS RESEARCH CENTER, SAN DIEGO STATE UNIVERSITY, SAN DIEGO, 5500 CAMPANILE DR, 92182, UNITED STATES; EMAIL: SEEMABIOTECH83@GMAIL.COM","SPRINGER NETHERLANDS","ENGLISH","WORLD J. MICROBIOL. BIOTECHNOL.","REVIEW","ISI","2-S2.0-84962168129","WORLD J MICROBIOL BIOTECHNOL","SAN DIEGO STATE UNIVERSITY","NOTREPORTED;SAN DIEGO STATE UNIVERSITY;NOTDECLARED",NA,"PATEL S, 2016, WORLD J MICROBIOL BIOTECHNOL","PATEL S, 2016, WORLD J MICROBIOL BIOTECHNOL"
"MEEROD K;WEERAWATANAKORN M;PANSAK W","MEEROD, KANYAPHAT (57203131668); WEERAWATANAKORN, MONTHANA (55976489600); PANSAK, WANWISA (58327045300)","IMPACT OF SUGARCANE JUICE CLARIFICATION ON PHYSICOCHEMICAL PROPERTIES SOME NUTRACEUTICALS AND ANTIOXIDANT ACTIVITIES OF NONCENTRIFUGAL SUGAR",2019,"SUGAR TECH","21","9",18,"10.1007/s12355-018-0646-7","DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRICULTURAL SCIENCE, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND","IN THAILAND, NON-CENTRIFUGAL SUGAR (NCS) PRODUCT IS NOT YET PROCESSED ON AN INDUSTRIAL SCALE AND ALL OF IT IS PRODUCED BY FAMERS ON A SMALL SCALE USING A TRADITIONAL EVAPORATION PROCESS WITH OPEN IRON PANS. SINCE THE WHOLE SUGARCANE STALK IS DIRECTLY PRESSED BY A MILLING MACHINE, IMPURITIES FROM THE RIND CONTAMINATE THE RAW JUICE. THEREFORE, SUBSEQUENT CLARIFICATION OF THE RAW JUICE IS A CRUCIAL STEP TO PRODUCE THE HIGH-QUALITY NCS PRODUCT. THE FARMERS NORMALLY USE TRADITIONAL FILTRATION, AND SOMETIMES NON-FOOD-SAFE ADDITIVES TO REMOVE SUSPENDED IMPURITIES FROM THE RAW JUICE. THIS STUDY EXAMINED AND ANALYSED THE EFFECTS OF THE FOOD ADDITIVES CALCIUM OXIDE (CAO) AND SODIUM HYDROGEN CARBONATE (NAHCO3) ON THE PHYSICOCHEMICAL PROPERTIES OF NCS, AND THE RESULTS WILL BE USED TO GUIDE AND IMPROVE TRADITIONAL-LEVEL PRODUCTION. CLARIFYING THE JUICE AT PH 8.5 WITH CAO GAVE THE GREATEST MUD WEIGHT (47.52 G) AND THE LOWEST SEDIMENT VALUE OF NCS (0.68%), WHILE CLARIFYING THE JUICE WITH THE MAXIMUM STUDIED LEVEL (0.1% W/V) OF NAHCO3 GAVE THE MUD WEIGHT AND SEDIMENT VALUES OF 30.28 G AND 0.71%, RESPECTIVELY. THE HIGHER THE AMOUNT OF CLARIFIER, THE CLEANER THE JUICE OBTAINED. CLARIFICATION BY NAHCO3 OR CAO CAUSED DIFFERENT EFFECTS ON THE MOISTURE CONTENT, WATER ACTIVITY AND COLOUR OF THE NCS, BUT HAD NO IMPACT ON ITS SOLUBILITY. TOTAL PHENOLIC CONTENT AND TOTAL FLAVONOID CONTENT WERE POSITIVELY CORRELATED WITH ANTIOXIDANT ACTIVITY BY THE ABTS RADICAL SCAVENGING ASSAY. CLARIFYING THE JUICE WITH CAO OR SODIUM NAHCO3 CAUSED LOSS OF POLICOSANOL AND TRICIN CONTENTS. © 2018, SOCIETY FOR SUGAR RESEARCH & PROMOTION.","FLAVONOID; FOOD ADDITIVE; LIMING PROCESS; PHYTOCHEMICALS; POLICOSANOL","","NARE-SUAN UNIVERSITY; NATIONAL RESEARCH COUNCIL OF THAILAND, NRCT, (R2560B031, RDG5950040); NARESUAN UNIVERSITY, NU","ACKNOWLEDGEMENTS THIS STUDY WAS FINANCIALLY SUPPORTED BY NARE-SUAN UNIVERSITY AND THE NATIONAL RESEARCH COUNCIL OF THAILAND FOR RESEARCH PROJECT NUMBERS R2560B031, RDG5950040, AND THE THESIS GRANT FOR MASTER DEGREE STUDENT OF NARESUAN UNIVERSITY, 2018. THE AUTHORS ALSO THANK THE NULC WRITING CLINIC FOR REVIEWING THE LANGUAGE OF THE PAPER.","ASIKIN Y., CHINEN T., TAKARA K., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCIENCE AND TECHNOLOGY RESEARCH, 14, PP. 583-588, (2008); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, LIPID SCIENCE TECHNOLOGY, 114, PP. 583-591, (2012); ASIKIN Y., KAMIYA A., MIZU M., TAKARA K., TAMAKI H., CHANGES IN THE PHYSICOCHEMICAL CHARACTERISTICS, INCLUDING FLAVOR COMPONENTS AND MAILLARD REACTION PRODUCTS, OF NON-CENTRIFUGAL CANE BROWN SUGAR DURING STORAGE, FOOD CHEMISTRY, 149, PP. 170-177, (2014); ASIKIN Y., TAKAHARA W., TAKAHASHI M., HIROSE N., ITO S., WADA K., COMPOSITIONAL AND ELECTRONIC DISCRIMINATION ANALYSES OF TASTE AND AROMA PROFILES OF NON-CENTRIFUGAL CANE BROWN SUGARS, FOOD ANALYTICAL METHODS, 6, PP. 1844-1856, (2017); AHRARI F., HASANZADEH N., RAJABI O., FOROUZANNEJAD Z., EFFECTIVENESS OF SODIUM BICARBONATE COMBINED WITH HYDROGEN PEROXIDE AND CPP-ACPF IN WHITENING AND MICROHARDNESS OF ENAMEL, JOURNAL OF CLINICAL AND EXPERIMENTAL DENTISTRY, 9, PP. E344-E350, (2017); BINKLEY W.W., WOLFORM M.L., COMPOSITION OF CAME JUICE AND CANE FINAL MOLASSES, ADVANCES IN CARBOHYDRATE CHEMISTRY, 8, PP. 291-314, (1953); CAI H., STEWARD W.P., GESCHER A.J., DETERMINATION OF THE PUTATIVE CANCER CHEMOPREVENTIVE FLAVONE TRICIN IN PLASMA AND TISSUE OF MICE BY HPLC WITH UV–VISIBLE DETECTION, BIOMEDICAL CHROMATOGRAPHY, 19, PP. 518-522, (2005); COLOMBO R., YARIWAKE J.H., QUEIROZ E.F., NDJOKO K., HOSTETTMANN K., ON-LINE IDENTIFICATION OF SUGARCANE (SACCHARUM OFFICINARUM L.) METHOXY FLAVONES BY LIQUID CHROMATOGRAPHY–UV DETECTION USING POST-COLUMN DERIVATIZATION AND LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY, CHROMATOGRAPHY, 1082, PP. 51-59, (2005); DUARTE-ALMEIDA J.M., SALATINO A., GENOVESE M.I., LAJOLO F.M., PHENOLIC COMPOSITION AND ANTIOXIDANT ACTIVITY OF CULMS AND SUGARCANE (SACCHARUM OFFICINARUM L.) PRODUCTS, FOOD CHEMISTRY, 125, PP. 660-664, (2011); DOHERTY W., EDYE L.A., AN OVERVIEW ON THE CHEMISTRY OF CLARIFICATION OF CANE SUGAR JUICE, PROCEEDINGS: INTERNATIONAL SOCIETY OF SUGAR CANE TECHNOLOGISTS, 21, PP. 381-388, (1999); FENG S., LUO Z., ZHANG Y., ZHONG Z., LU B., PHYTOCHEMICAL CONTENTS AND ANTIOXIDANT CAPACITIES OF DIFFERENT PARTS OF TWO SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, FOOD CHEMISTRY, 151, PP. 452-458, (2014); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); JAFFE W.R., HEALTH EFFECTS OF NON-CENTRIFUGAL SUGAR (NCS): A REVIEW, SUGAR TECH, 14, PP. 85-94, (2012); KHUENPET K., CHAROENJARASRERK N., JAIJIT S., ARAYAPOONPONG S., JITTANIT W., INVESTIGATION OF SUITABLE SPRAY DRYING CONDITIONS FOR SUGARCANE JUICE POWDER PRODUCTION WITH AN ENERGY CONSUMPTION STUDY, AGRICULTURE AND NATURAL RESOURCES, 50, PP. 139-145, (2016); MUNGARE T.S., JADHAV H.D., PATIL J.P., HASURE R.R., JADHAV B.S., SINGH J., CLARIFICATION TECHNIQUE FOR PRODUCING QUALITY JAGGERY, COOPERATIVE SUGAR, 32, PP. 283-285, (2000); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCHIVES OF MEDICAL RESEARCH, 36, PP. 441-447, (2005); NAYAKA M.A.H., SATHISHA U.V., MANOHAR M.P., CHANDRASHEKAR K.B., DHARMESH S.M., CYTOPROTECTIVE AND ANTIOXIDANT ACTIVITY STUDIES OF JAGGERY SUGAR, FOOD CHEMISTRY, 115, PP. 113-118, (2009); PATIL J.P., SHINDE U.S., NEVKAR G.S., SINGH J., CLARIFICATION EFFICIENCY OF SYNTHETIC AND HERBAL CLARIFICANTS IN QUALITY JAGGERY PRODUCTION, SUGAR TECH, 7, PP. 77-81, (2005); PAYET B., CHEONG A.S., SMADJA J., ASSESSMENT OF ANTIOXIDANT ACTIVITY OF CANE BROWN SUGARS BY ABTS AND DPPH RADICAL SCAVENGING ASSAYS: DETERMINATION OF THEIR POLYPHENOLIC AND VOLATILE CONSTITUENTS, AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 10074-10079, (2005); RAEL L.T., THOMAS G.W., CRAUN M.L., CURTIS C.G., BAR-OR R., BAR-OR D., LIPID PEROXIDATION AND THE THIOBARBITURIC ACID ASSAY: STANDARDIZATION OF THE ASSAY WHEN USING SATURATED AND UNSATURATED FATTY ACIDS, BMB REPORT, 37, PP. 749-752, (2004); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, PHARMACOLOGY AND EXPERIMENTAL, 318, PP. 1020-1026, (2006); STEINDL R.J., CLARIFICATION OF CANE JUICE FOR FERMENTATION, PROCEEDINGS INTERNATIONAL SOCIETY OF SUGAR CANE TECHNOLOGISTS, 27, PP. 1-10, (2010); SHITTU T.A., LAWAL M.O., FACTORS AFFECTING INSTANT PROPERTIES OF POWDERED COCOA BEVERAGES, FOOD CHEMISTRY, 1, PP. 91-98, (2007); XU R.Y., NIIMI Y., HAN D.S., CHANGES IN ENDOGENOUS ABSCISIC ACID AND SOLUBLE SUGARS LEVELS DURING DORMANCY-RELEASE IN BULBS OF LILIUM RUBELLUM, SCIENTIA HORTICULTURAE, 111, PP. 68-72, (2006); TAKARA K., KINJYO A., MATSUI D., WADA K., NAKASONE Y., YOGI S., NEW ANTIOXIDATIVE PHENOLIC GLYCOSIDES ISOLATED FROM KOKUTO, NON-CENTRIFUGED CANE SUGAR, BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, 66, PP. 29-35, (2002); TANG Y., MIN J., WU X., SELECTION OF CONVECTIVE MOISTURE TRANSFER DRIVING POTENTIAL AND ITS IMPACTS UPON POROUS PLATE AIR-DRYING CHARACTERISTICS, INTERNATIONAL HEAT AND MASS TRANSFER, 116, PP. 371-376, (2018); TAKAHASHI M., ISHMAEL M., ASIKIN Y., HIROSE N., MIZU M., SHIKANAI T., TAMAKI H., WADA K., COMPOSITION, TASTE, AROMA, AND ANTIOXIDANT ACTIVITY OF SOLIDIFIED NONCENTRIFUGAL BROWN SUGARS PREPARED FROM WHOLE STALK AND SEPARATED PITH OF SUGARCANE (SACCHARUM OFFICINARUM L.), JOURNAL OF FOOD SCIENCE, 81, PP. C2647-C2655, (2016); VERSCHOYLE R.E., GREAVES P., CAI H., ARNDT B., BROGGINI M., D'INCALCI M., RICCIO E., DOPPALAPEED R., KAPETANOVIC I.M., STEWAND W.P., GESCHER A.J., PRELIMINARY SAFETY EVALUATION OF THE PUTATIVE CANCER CHEMO PREVENTIVE AGENT TRICIN, A NATURALLY OCCURRING FLAVONE, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 57, PP. 1-6, (2006); WEERAWATANAKORN M., ASIKIN Y., TAKAHASHI M., TAMAKI H., WADA K., HO C.T., CHUEKITTISAK R., PHYSICO-CHEMICAL PROPERTIES, WAX COMPOSITION, AROMA PROFILES, AND ANTIOXIDANT ACTIVITY OF GRANULATED NON-CENTRIFUGAL SUGARS FROM SUGARCANE CULTIVARS OF THAILAND, FOOD SCIENCE AND TECHNOLOGY, 53, PP. 4084-4092, (2016)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, PHITSANULOK, 99 MOO 9, THA PHO, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","SPRINGER","ENGLISH","SUGAR TECH","ARTICLE","ISI","2-S2.0-85050639367","SUGAR TECH","NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;NARESUAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"MEEROD K, 2019, SUGAR TECH","MEEROD K, 2019, SUGAR TECH"
"TALEBI S;BAGHERNIYA M;ATKIN S;ASKARI G;ORAFAI H;SAHEBKAR A","TALEBI, SEPIDE (57211624279); BAGHERNIYA, MOHAMMAD (56667719200); ATKIN, STEPHEN L. (7005293560); ASKARI, GHOLAMREZA (57189842487); ORAFAI, HOSSEIN M. (6507418100); SAHEBKAR, AMIRHOSSEIN (26639699900)","THE BENEFICIAL EFFECTS OF NUTRACEUTICALS AND NATURAL PRODUCTS ON SMALL DENSE LDL LEVELS LDL PARTICLE NUMBER AND LDL PARTICLE SIZE A CLINICAL REVIEW",2020,"LIPIDS IN HEALTH AND DISEASE","19","",33,"10.1186/s12944-020-01250-6","RESEARCH COMMITTEE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN, DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, FOOD SECURITY RESEARCH CENTER, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, FOOD SECURITY RESEARCH CENTER, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;WEILL CORNELL MEDICINE QATAR, DOHA, QATAR;FOOD SECURITY RESEARCH CENTER, DEPARTMENT OF COMMUNITY NUTRITION, SCHOOL OF NUTRITION AND FOOD SCIENCE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN;DEPARTMENT OF PHARMACEUTICS, FACULTY OF PHARMACY, AL-ZAHRAA UNIVERSITY, KARBALA, IRAQ;HALAL RESEARCH CENTER OF IRI, FDA, TEHRAN, IRAN, BIOTECHNOLOGY RESEARCH CENTER, PHARMACEUTICAL TECHNOLOGY INSTITUTE, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN, NEUROGENIC INFLAMMATION RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN","CARDIOVASCULAR DISEASES (CVDS) ARE GLOBALLY THE MAJOR CAUSES OF MORBIDITY AND MORTALITY. EVIDENCE SHOWS THAT SMALLER AND DENSER LOW-DENSE LIPOPROTEIN (SDLDL) PARTICLES ARE INDEPENDENT ATHEROGENIC RISK FACTORS FOR CVD DUE TO THEIR GREATER SUSCEPTIBILITY TO OXIDATION, AND PERMEABILITY IN THE ENDOTHELIUM OF ARTERIAL WALLS. SDLDL LEVELS ARE AN INDEPENDENT RISK FACTOR AND OF MORE PREDICTIVE VALUE THAN TOTAL LDL-C FOR THE ASSESSMENT OF CORONARY ARTERY DISEASE AND METABOLIC SYNDROME. FUNCTIONAL FOOD INGREDIENTS HAVE ATTRACTED SIGNIFICANT ATTENTION FOR THE MANAGEMENT OF DYSLIPIDEMIA AND SUBSEQUENTLY INCREASE CARDIO-METABOLIC HEALTH. HOWEVER, TO DATE THERE IS NO STUDY THAT HAS INVESTIGATED THE EFFECT OF THESE BIOACTIVE NATURAL COMPOUNDS ON SDLDL LEVELS. THEREFORE, THE AIM OF THE PRESENT REVIEW IS TO SUMMARIZE THE EVIDENCE ACCRUED ON THE EFFECT OF SPECIAL DIETARY INGREDIENTS SUCH AS OMEGA-3 POLYUNSATURATED FATTY ACIDS, NUTRACEUTICALS AND HERBAL MEDICINES ON THE LEVELS OF SDLDL, LDL PARTICLE NUMBER, AND LDL PARTICLE SIZE. BASED ON THE RESULTS OF THE EXISTING CLINICAL TRIALS THIS REVIEW SUGGESTS THAT NATURAL PRODUCTS SUCH AS MEDICINAL PLANTS, NUTRACEUTICALS AND OMEGA-3 FATTY ACIDS CAN BE USED AS ADJUNCT OR COMPLEMENTARY THERAPEUTIC AGENTS TO REDUCE SDLDL LEVELS, LDL PARTICLE NUMBERS OR INCREASE LDL PARTICLE SIZE AND SUBSEQUENTLY MAY PREVENT AND TREAT CVD, WITH THE ADVANTAGE THAT THESES NATURAL AGENTS ARE GENERALLY SAFE, ACCESSIBLE, AND INEXPENSIVE. © 2020 THE AUTHOR(S).","ATHEROSCLEROSIS; LIPOPROTEIN; MEDICINAL PLANT; NUTRITION; PHYTOCHEMICAL","ANIMALS; BIOLOGICAL PRODUCTS; CHOLESTEROL, LDL; DIET; DIETARY SUPPLEMENTS; HUMANS; LIPID METABOLISM; PARTICLE SIZE; ARMOLIPID PLUS; ASTAXANTHIN; BERBERINE; CHITOSAN; CITRULLINE; CURCUMIN; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; HERBACEOUS AGENT; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NATURAL PRODUCT; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; UBIDECARENONE; VEGETABLE OIL; BIOLOGICAL PRODUCT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ALTERNATIVE MEDICINE; ARTERY ENDOTHELIUM; BLOOD VESSEL PERMEABILITY; BROWN RICE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DRUG EFFECT; DYSLIPIDEMIA; FOOD COMPOSITION; FRUIT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; MORBIDITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUT; PARTICLE SIZE; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; TEA; ANIMAL; CHEMISTRY; DIET; DIETARY SUPPLEMENT; LIPID METABOLISM","","","DHUNGANA R.R., THAPA P., DEVKOTA S., BANIK P.C., GURUNG Y., MUMU S.J., SHAYAMI A., ALI L., PREVALENCE OF CARDIOVASCULAR DISEASE RISK FACTORS: A COMMUNITY-BASED CROSS-SECTIONAL STUDY IN A PERI-URBAN COMMUNITY OF KATHMANDU, NEPAL, INDIAN HEART J, 70, PP. S20-S27, (2018); BENJAMIN E.J., MUNTNER P., ALONSO A., BITTENCOURT M.S., CALLAWAY C.W., CARSON A.P., CHAMBERLAIN A.M., CHANG A.R., CHENG S., DAS S.R., ET AL., HEART DISEASE AND STROKE STATISTICS-2019 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 139, PP. E56-E528, (2019); PLETCHER M.J., MORAN A.E., CARDIOVASCULAR RISK ASSESSMENT, MED CLIN NORTH AM, 101, PP. 673-688, (2017); ARIYANTI R., BESRAL B., DYSLIPIDEMIA ASSOCIATED WITH HYPERTENSION INCREASES THE RISKS FOR CORONARY HEART DISEASE: A CASE-CONTROL STUDY IN HARAPAN KITA HOSPITAL, NATIONAL CARDIOVASCULAR CENTER, JAKARTA J LIPIDS, 2019, (2019); IVANOVA E.A., MYASOEDOVA V.A., MELNICHENKO A.A., GRECHKO A.V., OREKHOV A.N., SMALL DENSE LOW-DENSITY LIPOPROTEIN AS BIOMARKER FOR ATHEROSCLEROTIC DISEASES, OXIDATIVE MED CELL LONGEV, 2017, (2017); AUSTIN M.A., BRESLOW J.L., HENNEKENS C.H., BURING J.E., WILLETT W.C., KRAUSS R.M., LOW-DENSITY LIPOPROTEIN SUBCLASS PATTERNS AND RISK OF MYOCARDIAL INFARCTION, JAMA, 260, PP. 1917-1921, (1988); YEE M.S., PAVITT D.V., TAN T., VENKATESAN S., GODSLAND I.F., RICHMOND W., JOHNSTON D.G., LIPOPROTEIN SEPARATION IN A NOVEL IODIXANOL DENSITY GRADIENT, FOR COMPOSITION, DENSITY, AND PHENOTYPE ANALYSIS, J LIPID RES, 49, PP. 1364-1371, (2008); WITTE D.R., TASKINEN M.R., PERTTUNEN-NIO H., VAN TOL A., LIVINGSTONE S., COLHOUN H.M., STUDY OF AGREEMENT BETWEEN LDL SIZE AS MEASURED BY NUCLEAR MAGNETIC RESONANCE AND GRADIENT GEL ELECTROPHORESIS, J LIPID RES, 45, PP. 1069-1076, (2004); HOEFNER D.M., HODEL S.D., O'BRIEN J.F., BRANUM E.L., SUN D., MEISSNER I., MCCONNELL J.P., DEVELOPMENT OF A RAPID, QUANTITATIVE METHOD FOR LDL SUBFRACTIONATION WITH USE OF THE QUANTIMETRIX LIPOPRINT LDL SYSTEM, CLIN CHEM, 47, PP. 266-274, (2001); JELLINGER P., SMITH D., MEHTA A., GANDA O., HANDELSMAN Y., RODBARD H., SHEPHERD M., SEIBEL J., AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS' GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF ATHEROSCLEROSIS, ENDOCR PRACT, 18, PP. 1-78, (2012); OHMURA H., MOKUNO H., SAWANO M., HATSUMI C., MITSUGI Y., WATANABE Y., DAIDA H., YAMAGUCHI H., LIPID COMPOSITIONAL DIFFERENCES OF SMALL, DENSE LOW-DENSITY LIPOPROTEIN PARTICLE INFLUENCE ITS OXIDATIVE SUSCEPTIBILITY: POSSIBLE IMPLICATION OF INCREASED RISK OF CORONARY ARTERY DISEASE IN SUBJECTS WITH PHENOTYPE B, METABOLISM, 51, PP. 1081-1087, (2002); HIRAYAMA S., MIIDA T., SMALL DENSE LDL: AN EMERGING RISK FACTOR FOR CARDIOVASCULAR DISEASE, CLIN CHIM ACTA, 414, PP. 215-224, (2012); TOFT-PETERSEN A.P., TILSTED H.H., AAROE J., RASMUSSEN K., CHRISTENSEN T., GRIFFIN B.A., AARDESTRUP I.V., ANDREASEN A., SCHMIDT E.B., SMALL DENSE LDL PARTICLES-A PREDICTOR OF CORONARY ARTERY DISEASE EVALUATED BY INVASIVE AND CT-BASED TECHNIQUES: A CASE-CONTROL STUDY, LIPIDS HEALTH DIS, 10, (2011); AI M., OTOKOZAWA S., ASZTALOS B.F., ITO Y., NAKAJIMA K., WHITE C.C., CUPPLES L.A., WILSON P.W., SCHAEFER E.J., SMALL DENSE LDL CHOLESTEROL AND CORONARY HEART DISEASE: RESULTS FROM THE FRAMINGHAM OFFSPRING STUDY, CLIN CHEM, 56, PP. 967-976, (2010); FAN J., LIU Y., YIN S., CHEN N., BAI X., KE Q., SHEN J., XIA M., SMALL DENSE LDL CHOLESTEROL IS ASSOCIATED WITH METABOLIC SYNDROME TRAITS INDEPENDENTLY OF OBESITY AND INFLAMMATION, NUTR METAB, 16, (2019); LAMARCHE B., TCHERNOF A., MAURIEGE P., CANTIN B., DAGENAIS G.R., LUPIEN P.J., DESPRES J.P., FASTING INSULIN AND APOLIPOPROTEIN B LEVELS AND LOW-DENSITY LIPOPROTEIN PARTICLE SIZE AS RISK FACTORS FOR ISCHEMIC HEART DISEASE, JAMA, 279, PP. 1955-1961, (1998); LINTON M.F., YANCEY P.G., DAVIES S.S., JEROME W.G., LINTON E.F., SONG W.L., DORAN A.C., VICKERS K.C., THE ROLE OF LIPIDS AND LIPOPROTEINS IN ATHEROSCLEROSIS, SOUTH DARTMOUTH: IN: ENDOTEXT: MDTEXT, (2019); THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, PP. 3143-3421, (2002); ELLSWORTH D., COSTANTINO N., BLACKBURN H., ENGLER R., KASHANI M., VERNALIS M., LIFESTYLE MODIFICATION INTERVENTIONS DIFFERING IN INTENSITY AND DIETARY STRINGENCY IMPROVE INSULIN RESISTANCE THROUGH CHANGES IN LIPOPROTEIN PROFILES, OBES SCI PRACT, 2, PP. 282-292, (2016); CHIUVE S.E., COOK N.R., SHAY C.M., REXRODE K.M., ALBERT C.M., MANSON J.E., WILLETT W.C., RIMM E.B., LIFESTYLE-BASED PREDICTION MODEL FOR THE PREVENTION OF CVD: THE HEALTHY HEART SCORE, J AM HEART ASSOC, 3, (2014); MANNU G.S., ZAMAN M.J., GUPTA A., REHMAN H.U., MYINT P.K., EVIDENCE OF LIFESTYLE MODIFICATION IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA, CURR CARDIOL REV, 9, PP. 2-14, (2013); ALISSA E.M., FERNS G.A., FUNCTIONAL FOODS AND NUTRACEUTICALS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES, J NUTR METAB, 2012, (2012); RAMAA C., SHIRODE A., MUNDADA A., KADAM V., NUTRACEUTICALS-AN EMERGING ERA IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES, CURR PHARM BIOTECHNOL, 7, PP. 15-23, (2006); ZUCHI C., AMBROSIO G., LUSCHER T.F., LANDMESSER U., NUTRACEUTICALS IN CARDIOVASCULAR PREVENTION: LESSONS FROM STUDIES ON ENDOTHELIAL FUNCTION, CARDIOVASC THER, 28, PP. 187-201, (2010); BADIMON L., VILAHUR G., PADRO T., NUTRACEUTICALS AND ATHEROSCLEROSIS: HUMAN TRIALS, CARDIOVASC THER, 28, PP. 202-215, (2010); MCCARTY M.F., NUTRACEUTICAL RESOURCES FOR DIABETES PREVENTION-AN UPDATE, MED HYPOTHESES, 64, PP. 151-158, (2005); DAVI G., SANTILLI F., PATRONO C., NUTRACEUTICALS IN DIABETES AND METABOLIC SYNDROME, CARDIOVASC THER, 28, PP. 216-226, (2010); BAGHERNIYA M., NOBILI V., BLESSO C.N., SAHEBKAR A., MEDICINAL PLANTS AND BIOACTIVE NATURAL COMPOUNDS IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A CLINICAL REVIEW, PHARMACOL RES, 130, PP. 213-240, (2018); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., TRIMARCO B., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, PP. 1482-1487, (2010); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J CLIN HYPERTENS (GREENWICH), 14, PP. 121-132, (2012); SCICCHITANO P., CAMELI M., MAIELLO M., MODESTI P.A., MUIESAN M.L., NOVO S., PALMIERO P., SABA P.S., PEDRINELLI R., CICCONE M.M., NUTRACEUTICALS AND DYSLIPIDAEMIA: BEYOND THE COMMON THERAPEUTICS, J FUNCT FOODS, 6, PP. 11-32, (2014); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR J INTERN MED, 25, PP. 592-599, (2014); CICERO A.F., COLLETTI A., BAJRAKTARI G., DESCAMPS O., DJURIC D.M., EZHOV M., FRAS Z., KATSIKI N., LANGLOIS M., LATKOVSKIS G., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR REV, 75, PP. 731-767, (2017); PATTI A.M., AL-RASADI K., GIGLIO R.V., NIKOLIC D., MANNINA C., CASTELLINO G., CHIANETTA R., BANACH M., CICERO A.F., LIPPI G., NATURAL APPROACHES IN METABOLIC SYNDROME MANAGEMENT, ARCH MED SCI, 14, (2018); SAHEBKAR A., SERBAN M.-C., GLUBA-BRZOZKA A., MIKHAILIDIS D.P., CICERO A.F., RYSZ J., BANACH M., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); CHOUDHARY S.P., TRAN L.S., PHYTOSTEROLS: PERSPECTIVES IN HUMAN NUTRITION AND CLINICAL THERAPY, CURR MED CHEM, 18, PP. 4557-4567, (2011); CHEN Q., GRUBER H., SWIST E., COVILLE K., PAKENHAM C., RATNAYAKE W.M., SCOGGAN K.A., DIETARY PHYTOSTEROLS AND PHYTOSTANOLS DECREASE CHOLESTEROL LEVELS BUT INCREASE BLOOD PRESSURE IN WKY INBRED RATS IN THE ABSENCE OF SALT-LOADING, NUTR METAB (LOND), 7, (2010); AWAD A., DOWNIE A., FINK C., KIM U., DIETARY PHYTOSTEROL INHIBITS THE GROWTH AND METASTASIS OF MDA-MB-231 HUMAN BREAST CANCER CELLS GROWN IN SCID MICE, ANTICANCER RES, 20, PP. 821-824, (2000); HERNANDEZ-MIJARES A., BANULS C., JOVER A., SOLA E., BELLOD L., MARTINEZ-TRIGUERO M.L., LAGARDA M.J., VICTOR V.M., ROCHA M., LOW INTESTINAL CHOLESTEROL ABSORPTION IS ASSOCIATED WITH A REDUCED EFFICACY OF PHYTOSTEROL ESTERS AS HYPOLIPEMIC AGENTS IN PATIENTS WITH METABOLIC SYNDROME, CLIN NUTR, 30, PP. 604-609, (2011); MORUISI K.G., OOSTHUIZEN W., OPPERMAN A.M., PHYTOSTEROLS/STANOLS LOWER CHOLESTEROL CONCENTRATIONS IN FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS: A SYSTEMATIC REVIEW WITH META-ANALYSIS, J AM COLL NUTR, 25, PP. 41-48, (2006); WU T., FU J., YANG Y.-X., ZHANG L.-S., HAN J.-H., THE EFFECTS OF PHYTOSTEROLS/STANOLS ON BLOOD LIPID PROFILES: A SYSTEMATIC REVIEW WITH META-ANALYSIS, ASIA PAC J CLIN NUTR, 18, PP. 179-186, (2009); BANULS C., ROVIRA-LLOPIS S., FALCON R., VESES S., MONZO N., VICTOR V.M., ROCHA M., HERNANDEZ-MIJARES A., CHRONIC CONSUMPTION OF AN INOSITOL-ENRICHED CAROB EXTRACT IMPROVES POSTPRANDIAL GLYCAEMIA AND INSULIN SENSITIVITY IN HEALTHY SUBJECTS: A RANDOMIZED CONTROLLED TRIAL, CLIN NUTR, 35, PP. 600-607, (2016); HERNAEZ A., REMALEY A.T., FARRAS M., FERNANDEZ-CASTILLEJO S., SUBIRANA I., SCHRODER H., FERNANDEZ-MAMPEL M., MUNOZ-AGUAYO D., SAMPSON M., SOLA R., OLIVE OIL POLYPHENOLS DECREASE LDL CONCENTRATIONS AND LDL ATHEROGENICITY IN MEN IN A RANDOMIZED CONTROLLED TRIAL, J NUTR, 145, PP. 1692-1697, (2015); SIALVERA T., POUNIS G., KOUTELIDAKIS A., RICHTER D., YFANTI G., KAPSOKEFALOU M., GOUMAS G., CHIOTINIS N., DIAMANTOPOULOS E., ZAMPELAS A., PHYTOSTEROLS SUPPLEMENTATION DECREASES PLASMA SMALL AND DENSE LDL LEVELS IN METABOLIC SYNDROME PATIENTS ON A WESTERNIZED TYPE DIET, NUTR METAB CARDIOVASC DIS, 22, PP. 843-848, (2012); GAROUFI A., VORRE S., SOLDATOU A., TSENTIDIS C., KOSSIVA L., DRAKATOS A., MARMARINOS A., GOURGIOTIS D., PLANT STEROLS-ENRICHED DIET DECREASES SMALL, DENSE LDL-CHOLESTEROL LEVELS IN CHILDREN WITH HYPERCHOLESTEROLEMIA: A PROSPECTIVE STUDY, ITAL J PEDIATR, 40, (2014); KRATZ M., GULBAHCE E., VON ECKARDSTEIN A., CULLEN P., CIGNARELLA A., ASSMANN G., WAHRBURG U., DIETARY MONO-AND POLYUNSATURATED FATTY ACIDS SIMILARLY AFFECT LDL SIZE IN HEALTHY MEN AND WOMEN, J NUTR, 132, PP. 715-718, (2002); SHRESTHA S., FREAKE H.C., MCGRANE M.M., VOLEK J.S., FERNANDEZ M.L., A COMBINATION OF PSYLLIUM AND PLANT STEROLS ALTERS LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC SUBJECTS BY MODIFYING THE INTRAVASCULAR PROCESSING OF LIPOPROTEINS AND INCREASING LDL UPTAKE, J NUTR, 137, PP. 1165-1170, (2007); SHRESTHA S., VOLEK J.S., UDANI J., WOOD R.J., GREENE C.M., AGGARWAL D., CONTOIS J.H., KAVOUSSI B., FERNANDEZ M.L., A COMBINATION THERAPY INCLUDING PSYLLIUM AND PLANT STEROLS LOWERS LDL CHOLESTEROL BY MODIFYING LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC INDIVIDUALS, J NUTR, 136, PP. 2492-2497, (2006); EARNEST C.P., MIKUS C.R., LEMIEUX I., ARSENAULT B.J., CHURCH T.S., EXAMINATION OF ENCAPSULATED PHYTOSTEROL ESTER SUPPLEMENTATION ON LIPID INDICES ASSOCIATED WITH CARDIOVASCULAR DISEASE, NUTRITION, 23, PP. 625-633, (2007); MATVIENKO O.A., LEWIS D.S., SWANSON M., ARNDT B., RAINWATER D.L., STEWART J., ALEKEL D.L., A SINGLE DAILY DOSE OF SOYBEAN PHYTOSTEROLS IN GROUND BEEF DECREASES SERUM TOTAL CHOLESTEROL AND LDL CHOLESTEROL IN YOUNG, MILDLY HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 76, PP. 57-64, (2002); THEUWISSEN E., PLAT J., VAN DER KALLEN C.J., VAN GREEVENBROEK M.M., MENSINK R.P., PLANT STANOL SUPPLEMENTATION DECREASES SERUM TRIACYLGLYCEROLS IN SUBJECTS WITH OVERT HYPERTRIGLYCERIDEMIA, LIPIDS, 44, PP. 1131-1140, (2009); UTARWUTHIPONG T., KOMINDR S., PAKPEANKITVATANA V., SONGCHITSOMBOON S., THONGMUANG N., SMALL DENSE LOW-DENSITY LIPOPROTEIN CONCENTRATION AND OXIDATIVE SUSCEPTIBILITY CHANGES AFTER CONSUMPTION OF SOYBEAN OIL, RICE BRAN OIL, PALM OIL AND MIXED RICE BRAN/PALM OIL IN HYPERCHOLESTEROLAEMIC WOMEN, J INT MED RES, 37, PP. 96-104, (2009); CICCONE M.M., SCICCHITANO P., GESUALDO M., ZITO A., CARBONARA S., RICCI G., CORTESE F., GIORDANO P., THE ROLE OF OMEGA-3 POLYUNSATURATED FATTY ACIDS SUPPLEMENTATION IN CHILDHOOD: A REVIEW, RECENT PAT CARDIOVASC DRUG DISCOV, 8, PP. 42-55, (2013); PARKER H.M., JOHNSON N.A., BURDON C.A., COHN J.S., O'CONNOR H.T., GEORGE J., OMEGA-3 SUPPLEMENTATION AND NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, J HEPATOL, 56, PP. 944-951, (2012); CHEN C., YU X., SHAO S., EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON GLUCOSE CONTROL AND LIPID LEVELS IN TYPE 2 DIABETES: A META-ANALYSIS, PLOS ONE, 10, (2015); DJOUSSE L., AKINKUOLIE A.O., WU J.H., DING E.L., GAZIANO J.M., FISH CONSUMPTION, OMEGA-3 FATTY ACIDS AND RISK OF HEART FAILURE: A META-ANALYSIS, CLIN NUTR, 31, PP. 846-853, (2012); KWAK S.M., MYUNG S.-K., LEE Y.J., SEO H.G., EFFICACY OF OMEGA-3 FATTY ACID SUPPLEMENTS (EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID) IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS, ARCH INTERN MED, 172, PP. 686-694, (2012); PIOLOT A., BLACHE D., BOULET L., FORTIN L.J., DUBREUIL D., MARCOUX C., DAVIGNON J., LUSSIER-CACAN S., EFFECT OF FISH OIL ON LDL OXIDATION AND PLASMA HOMOCYSTEINE CONCENTRATIONS IN HEALTH, J LAB CLIN MED, 141, PP. 41-49, (2003); MORI T.A., EFFECT OF FISH AND FISH OIL-DERIVED OMEGA-3 FATTY ACIDS ON LIPID OXIDATION, REDOX REP, 9, PP. 193-197, (2004); HIGGINS S., CARROLL Y.L., MCCARTHY S.N., CORRIDAN B.M., ROCHE H.M., WALLACE J.M., O'BRIEN N.M., MORRISSEY P.A., SUSCEPTIBILITY OF LDL TO OXIDATIVE MODIFICATION IN HEALTHY VOLUNTEERS SUPPLEMENTED WITH LOW DOSES OF N-3 POLYUNSATURATED FATTY ACIDS, BR J NUTR, 85, PP. 23-31, (2001); OUELLETTE C., RUDKOWSKA I., LEMIEUX S., LAMARCHE B., COUTURE P., VOHL M.-C., GENE-DIET INTERACTIONS WITH POLYMORPHISMS OF THE MGLL GENE ON PLASMA LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND SIZE FOLLOWING AN OMEGA-3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION: A CLINICAL TRIAL, LIPIDS HEALTH DIS, 13, (2014); OELRICH B., DEWELL A., GARDNER C., EFFECT OF FISH OIL SUPPLEMENTATION ON SERUM TRIGLYCERIDES, LDL CHOLESTEROL AND LDL SUBFRACTIONS IN HYPERTRIGLYCERIDEMIC ADULTS, NUTR METAB CARDIOVASC DIS, 23, PP. 350-357, (2013); PETERSEN M., PEDERSEN H., MAJOR-PEDERSEN A., JENSEN T., MARCKMANN P., EFFECT OF FISH OIL VERSUS CORN OIL SUPPLEMENTATION ON LDL AND HDL SUBCLASSES IN TYPE 2 DIABETIC PATIENTS, DIABETES CARE, 25, PP. 1704-1708, (2002); SUZUKAWA M., ABBEY M., HOWE P.R., NESTEL P.J., EFFECTS OF FISH OIL FATTY ACIDS ON LOW DENSITY LIPOPROTEIN SIZE, OXIDIZABILITY, AND UPTAKE BY MACROPHAGES, J LIPID RES, 36, PP. 473-484, (1995); ASZTALOS I.B., GLEASON J.A., SEVER S., GEDIK R., ASZTALOS B.F., HORVATH K.V., DANSINGER M.L., LAMON-FAVA S., SCHAEFER E.J., EFFECTS OF EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID ON CARDIOVASCULAR DISEASE RISK FACTORS: A RANDOMIZED CLINICAL TRIAL, METABOLISM, 65, PP. 1636-1645, (2016); SATOH N., SHIMATSU A., KOTANI K., SAKANE N., YAMADA K., SUGANAMI T., KUZUYA H., OGAWA Y., PURIFIED EICOSAPENTAENOIC ACID REDUCES SMALL DENSE LDL, REMNANT LIPOPROTEIN PARTICLES, AND C-REACTIVE PROTEIN IN METABOLIC SYNDROME, DIABETES CARE, 30, PP. 144-146, (2007); MORI T.A., BURKE V., PUDDEY I.B., WATTS G.F., O'NEAL D.N., BEST J.D., BEILIN L.J., PURIFIED EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS HAVE DIFFERENTIAL EFFECTS ON SERUM LIPIDS AND LIPOPROTEINS, LDL PARTICLE SIZE, GLUCOSE, AND INSULIN IN MILDLY HYPERLIPIDEMIC MEN, AM J CLIN NUTR, 71, PP. 1085-1094, (2000); KELLEY D.S., SIEGEL D., VEMURI M., MACKEY B.E., DOCOSAHEXAENOIC ACID SUPPLEMENTATION IMPROVES FASTING AND POSTPRANDIAL LIPID PROFILES IN HYPERTRIGLYCERIDEMIC MEN, AM J CLIN NUTR, 86, PP. 324-333, (2007); MAKI K.C., VAN ELSWYK M.E., MCCARTHY D., HESS S.P., VEITH P.E., BELL M., SUBBAIAH P., DAVIDSON M.H., LIPID RESPONSES TO A DIETARY DOCOSAHEXAENOIC ACID SUPPLEMENT IN MEN AND WOMEN WITH BELOW AVERAGE LEVELS OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL, J AM COLL NUTR, 24, PP. 189-199, (2005); KAWAKAMI Y., YAMANAKA-OKUMURA H., NANIWA-KUROKI Y., SAKUMA M., TAKETANI Y., TAKEDA E., FLAXSEED OIL INTAKE REDUCES SERUM SMALL DENSE LOW-DENSITY LIPOPROTEIN CONCENTRATIONS IN JAPANESE MEN: A RANDOMIZED, DOUBLE BLIND, CROSSOVER STUDY, NUTR J, 14, (2015); HARPER C.R., EDWARDS M.C., JACOBSON T.A., FLAXSEED OIL SUPPLEMENTATION DOES NOT AFFECT PLASMA LIPOPROTEIN CONCENTRATION OR PARTICLE SIZE IN HUMAN SUBJECTS, J NUTR, 136, PP. 2844-2848, (2006); LIU Y., ZHANG L., SONG H., JI G., UPDATE ON BERBERINE IN NONALCOHOLIC FATTY LIVER DISEASE, EVID BASED COMPLEMENT ALTERNAT MED, 2013, (2013); PIRILLO A., CATAPANO A.L., BERBERINE, A PLANT ALKALOID WITH LIPID- A ND GLUCOSE-LOWERING PROPERTIES: FROM IN VITRO EVIDENCE TO CLINICAL STUDIES, ATHEROSCLEROSIS, 243, PP. 449-461, (2015); JOFFE M., ROBERTSON A., THE POTENTIAL CONTRIBUTION OF INCREASED VEGETABLE AND FRUIT CONSUMPTION TO HEALTH GAIN IN THE EUROPEAN UNION, PUBLIC HEALTH NUTR, 4, PP. 893-901, (2001); RIMM E.B., ASCHERIO A., GIOVANNUCCI E., SPIEGELMAN D., STAMPFER M.J., WILLETT W.C., VEGETABLE, FRUIT, AND CEREAL FIBER INTAKE AND RISK OF CORONARY HEART DISEASE AMONG MEN, JAMA, 275, PP. 447-451, (1996); WANG L., BORDI P.L., FLEMING J.A., HILL A.M., KRIS-ETHERTON P.M., EFFECT OF A MODERATE FAT DIET WITH AND WITHOUT AVOCADOS ON LIPOPROTEIN PARTICLE NUMBER, SIZE AND SUBCLASSES IN OVERWEIGHT AND OBESE ADULTS: A RANDOMIZED, CONTROLLED TRIAL, J AM HEART ASSOC, 4, (2015); PARK E., EDIRISINGHE I., BURTON-FREEMAN B., AVOCADO FRUIT ON POSTPRANDIAL MARKERS OF CARDIO-METABOLIC RISK: A RANDOMIZED CONTROLLED DOSE RESPONSE TRIAL IN OVERWEIGHT AND OBESE MEN AND WOMEN, NUTRIENTS, 10, (2018); BASU A., FU D.X., WILKINSON M., SIMMONS B., WU M., BETTS N.M., DU M., LYONS T.J., STRAWBERRIES DECREASE ATHEROSCLEROTIC MARKERS IN SUBJECTS WITH METABOLIC SYNDROME, NUTR RES, 30, PP. 462-469, (2010); BASU A., BETTS N.M., NGUYEN A., NEWMAN E.D., FU D., LYONS T.J., FREEZE-DRIED STRAWBERRIES LOWER SERUM CHOLESTEROL AND LIPID PEROXIDATION IN ADULTS WITH ABDOMINAL ADIPOSITY AND ELEVATED SERUM LIPIDS, J NUTR, 144, PP. 830-837, (2014); ZUNINO S.J., PARELMAN M.A., FREYTAG T.L., STEPHENSEN C.B., KELLEY D.S., MACKEY B.E., WOODHOUSE L.R., BONNEL E.L., EFFECTS OF DIETARY STRAWBERRY POWDER ON BLOOD LIPIDS AND INFLAMMATORY MARKERS IN OBESE HUMAN SUBJECTS, BR J NUTR, 108, PP. 900-909, (2012); ZUNINO S.J., PEERSON J.M., FREYTAG T.L., BREKSA A.P., BONNEL E.L., WOODHOUSE L.R., STORMS D.H., DIETARY GRAPE POWDER INCREASES IL-1BETA AND IL-6 PRODUCTION BY LIPOPOLYSACCHARIDE-ACTIVATED MONOCYTES AND REDUCES PLASMA CONCENTRATIONS OF LARGE LDL AND LARGE LDL-CHOLESTEROL PARTICLES IN OBESE HUMANS, BR J NUTR, 112, PP. 369-380, (2014); TOTH P.P., PATTI A.M., NIKOLIC D., GIGLIO R.V., CASTELLINO G., BIANCUCCI T., GERACI F., DAVID S., MONTALTO G., RIZVI A., RIZZO M., BERGAMOT REDUCES PLASMA LIPIDS, ATHEROGENIC SMALL DENSE LDL, AND SUBCLINICAL ATHEROSCLEROSIS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA: A 6 MONTHS PROSPECTIVE STUDY, FRONT PHARMACOL, 6, (2016); GLIOZZI M., CARRESI C., MUSOLINO V., PALMA E., MUSCOLI C., VITALE C., GRATTERI S., MUSCIANISI G., JANDA E., MUSCOLI S., THE EFFECT OF BERGAMOT-DERIVED POLYPHENOLIC FRACTION ON LDL SMALL DENSE PARTICLES AND NON ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME, ADV BIOL CHEM, 4, (2014); GALLETTI F., FAZIO V., GENTILE M., SCHILLACI G., PUCCI G., BATTISTA F., MERCURIO V., BOSSO G., BONADUCE D., BRAMBILLA N., EFFICACY OF A NUTRACEUTICAL COMBINATION ON LIPID METABOLISM IN PATIENTS WITH METABOLIC SYNDROME: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL, LIPIDS HEALTH DIS, 18, (2019); DE SOUZA R.G.M., SCHINCAGLIA R.M., PIMENTEL G.D., MOTA J.F., NUTS AND HUMAN HEALTH OUTCOMES: A SYSTEMATIC REVIEW, NUTRIENTS, 9, (2017); DEL GOBBO L.C., FALK M.C., FELDMAN R., LEWIS K., MOZAFFARIAN D., EFFECTS OF TREE NUTS ON BLOOD LIPIDS, APOLIPOPROTEINS, AND BLOOD PRESSURE: SYSTEMATIC REVIEW, META-ANALYSIS, AND DOSE-RESPONSE OF 61 CONTROLLED INTERVENTION TRIALS, AM J CLIN NUTR, 102, PP. 1347-1356, (2015); LOPEZ-URIARTE P., BULLO M., CASAS-AGUSTENCH P., BABIO N., SALAS-SALVADO J., NUTS AND OXIDATION: A SYSTEMATIC REVIEW, NUTR REV, 67, PP. 497-508, (2009); YUCESAN F.B., OREM A., KURAL B.V., OREM C., TURAN I., HAZELNUT CONSUMPTION DECREASES THE SUSCEPTIBILITY OF LDL TO OXIDATION, PLASMA OXIDIZED LDL LEVEL AND INCREASES THE RATIO OF LARGE/SMALL LDL IN NORMOLIPIDEMIC HEALTHY SUBJECTS, ANADOLU KARDIYOL DERG, 10, PP. 28-35, (2010); HERNANDEZ-ALONSO P., SALAS-SALVADO J., BALDRICH-MORA M., MALLOL R., CORREIG X., BULLO M., EFFECT OF PISTACHIO CONSUMPTION ON PLASMA LIPOPROTEIN SUBCLASSES IN PRE-DIABETIC SUBJECTS, NUTR METAB CARDIOVASC DIS, 25, PP. 396-402, (2015); CHEN C.Y., HOLBROOK M., DUESS M.A., DOHADWALA M.M., HAMBURG N.M., ASZTALOS B.F., MILBURY P.E., BLUMBERG J.B., VITA J.A., EFFECT OF ALMOND CONSUMPTION ON VASCULAR FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE: A RANDOMIZED, CONTROLLED, CROSS-OVER TRIAL, NUTR J, 14, (2015); ALMARIO R.U., VONGHAVARAVAT V., WONG R., KASIM-KARAKAS S.E., EFFECTS OF WALNUT CONSUMPTION ON PLASMA FATTY ACIDS AND LIPOPROTEINS IN COMBINED HYPERLIPIDEMIA, AM J CLIN NUTR, 74, PP. 72-79, (2001); LEE Y., BERRYMAN C.E., WEST S.G., CHEN C.Y.O., BLUMBERG J.B., LAPSLEY K.G., PRESTON A.G., FLEMING J.A., KRIS-ETHERTON P.M., EFFECTS OF DARK CHOCOLATE AND ALMONDS ON CARDIOVASCULAR RISK FACTORS IN OVERWEIGHT AND OBESE INDIVIDUALS: A RANDOMIZED CONTROLLED-FEEDING TRIAL, J AM HEART ASSOC, 6, (2017); DAMASCENO N.R., SALA-VILA A., COFAN M., PEREZ-HERAS A.M., FITO M., RUIZ-GUTIERREZ V., MARTINEZ-GONZALEZ M.A., CORELLA D., AROS F., ESTRUCH R., ROS E., MEDITERRANEAN DIET SUPPLEMENTED WITH NUTS REDUCES WAIST CIRCUMFERENCE AND SHIFTS LIPOPROTEIN SUBFRACTIONS TO A LESS ATHEROGENIC PATTERN IN SUBJECTS AT HIGH CARDIOVASCULAR RISK, ATHEROSCLEROSIS, 230, PP. 347-353, (2013); HOLLIGAN S.D., WEST S.G., GEBAUER S.K., KAY C.D., KRIS-ETHERTON P.M., A MODERATE-FAT DIET CONTAINING PISTACHIOS IMPROVES EMERGING MARKERS OF CARDIOMETABOLIC SYNDROME IN HEALTHY ADULTS WITH ELEVATED LDL LEVELS, BR J NUTR, 112, PP. 744-752, (2014); MARTIN R.C., AIYER H.S., MALIK D., LI Y., EFFECT ON PRO-INFLAMMATORY AND ANTIOXIDANT GENES AND BIOAVAILABLE DISTRIBUTION OF WHOLE TURMERIC VS CURCUMIN: SIMILAR ROOT BUT DIFFERENT EFFECTS, FOOD CHEM TOXICOL, 50, PP. 227-231, (2012); LEE H.Y., KIM S.W., LEE G.H., CHOI M.K., CHUNG H.W., LEE Y.C., KIM H.R., KWON H.J., CHAE H.J., CURCUMIN AND CURCUMA LONGA L EXTRACT AMELIORATE LIPID ACCUMULATION THROUGH THE REGULATION OF THE ENDOPLASMIC RETICULUM REDOX AND ER STRESS, SCI REP, 7, (2017); PANAHI Y., KHALILI N., HOSSEINI M.S., ABBASINAZARI M., SAHEBKAR A., LIPID-MODIFYING EFFECTS OF ADJUNCTIVE THERAPY WITH CURCUMINOIDS-PIPERINE COMBINATION IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED CONTROLLED TRIAL, COMPLEMENT THER MED, 22, PP. 851-857, (2014); ABDOLLAHI E., MOMTAZI A.A., JOHNSTON T.P., SAHEBKAR A., THERAPEUTIC EFFECTS OF CURCUMIN IN INFLAMMATORY AND IMMUNE-MEDIATED DISEASES: A NATURE-MADE JACK-OF-ALL-TRADES?, J CELL PHYSIOL, 233, PP. 830-848, (2018); KARIMIAN M.S., PIRRO M., MAJEED M., SAHEBKAR A., CURCUMIN AS A NATURAL REGULATOR OF MONOCYTE CHEMOATTRACTANT PROTEIN-1, CYTOKINE GROWTH FACTOR REV, 33, PP. 55-63, (2017); MOLLAZADEH H., CICERO A.F.G., BLESSO C.N., PIRRO M., MAJEED M., SAHEBKAR A., IMMUNE MODULATION BY CURCUMIN: THE ROLE OF INTERLEUKIN-10, CRIT REV FOOD SCI NUTR, 59, PP. 89-101, (2019); MOMTAZI A.A., DEROSA G., MAFFIOLI P., BANACH M., SAHEBKAR A., ROLE OF MICRORNAS IN THE THERAPEUTIC EFFECTS OF CURCUMIN IN NON-CANCER DISEASES, MOL DIAGN THER, 20, PP. 335-345, (2016); PANAHI Y., KIANPOUR P., MOHTASHAMI R., JAFARI R., SIMENTAL-MENDIA L.E., SAHEBKAR A., EFFICACY AND SAFETY OF PHYTOSOMAL CURCUMIN IN NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL, DRUG RES, 67, PP. 244-251, (2017); REZAEE R., MOMTAZI A.A., MONEMI A., SAHEBKAR A., CURCUMIN: A POTENTIALLY POWERFUL TOOL TO REVERSE CISPLATIN-INDUCED TOXICITY, PHARMACOL RES, 117, PP. 218-227, (2017); IRANSHAHI M., SAHEBKAR A., TAKASAKI M., KONOSHIMA T., TOKUDA H., CANCER CHEMOPREVENTIVE ACTIVITY OF THE PRENYLATED COUMARIN, UMBELLIPRENIN, IN VIVO, EUR J CANCER PREV, 18, PP. 412-415, (2009); SAHEBKAR A., MOLECULAR MECHANISMS FOR CURCUMIN BENEFITS AGAINST ISCHEMIC INJURY, FERTIL STERIL, 94, PP. E75-E76, (2010); MAHFOUZ M.M., ZHOU S.Q., KUMMEROW F.A., CURCUMIN PREVENTS THE OXIDATION AND LIPID MODIFICATION OF LDL AND ITS INHIBITION OF PROSTACYCLIN GENERATION BY ENDOTHELIAL CELLS IN CULTURE, PROSTAGLANDINS OTHER LIPID MEDIAT, 90, PP. 13-20, (2009); KANG Q., CHEN A., CURCUMIN ELIMINATES OXIDIZED LDL ROLES IN ACTIVATING HEPATIC STELLATE CELLS BY SUPPRESSING GENE EXPRESSION OF LECTIN-LIKE OXIDIZED LDL RECEPTOR-1, LAB INVESTIG, 89, (2009); MOOHEBATI M., YAZDANDOUST S., SAHEBKAR A., MAZIDI M., SHARGHI-SHAHRI Z., FERNS G., GHAYOUR-MOBARHAN M., INVESTIGATION OF THE EFFECT OF SHORT-TERM SUPPLEMENTATION WITH CURCUMINOIDS ON CIRCULATING SMALL DENSE LOW-DENSITY LIPOPROTEIN CONCENTRATIONS IN OBESE DYSLIPIDEMIC SUBJECTS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CROSS-OVER TRIAL, ARYA ATHEROSCLER, 10, (2014); NG K.-W., CAO Z.-J., CHEN H.-B., ZHAO Z.-Z., ZHU L., YI T., OOLONG TEA: A CRITICAL REVIEW OF PROCESSING METHODS, CHEMICAL COMPOSITION, HEALTH EFFECTS, AND RISK, CRIT REV FOOD SCI NUTR, 58, PP. 2957-2980, (2018); YANG M.-H., WANG C.-H., CHEN H.-L., GREEN, OOLONG AND BLACK TEA EXTRACTS MODULATE LIPID METABOLISM IN HYPERLIPIDEMIA RATS FED HIGH-SUCROSE DIET, J NUTR BIOCHEM, 12, PP. 14-20, (2001); SHIMADA K., KAWARABAYASHI T., TANAKA A., FUKUDA D., NAKAMURA Y., YOSHIYAMA M., TAKEUCHI K., SAWAKI T., HOSODA K., YOSHIKAWA J., OOLONG TEA INCREASES PLASMA ADIPONECTIN LEVELS AND LOW-DENSITY LIPOPROTEIN PARTICLE SIZE IN PATIENTS WITH CORONARY ARTERY DISEASE, DIABETES RES CLIN PRACT, 65, PP. 227-234, (2004); MOONGNGARM A., SAETUNG N., COMPARISON OF CHEMICAL COMPOSITIONS AND BIOACTIVE COMPOUNDS OF GERMINATED ROUGH RICE AND BROWN RICE, FOOD CHEM, 122, PP. 782-788, (2010); ARAKI R., USHIO R., FUJIE K., UEYAMA Y., SUZUKI H., NAKATA Y., HASHIMOTO K., EFFECT OF PARTIALLY-ABRADED BROWN RICE CONSUMPTION ON BODY WEIGHT AND THE INDICATORS OF GLUCOSE AND LIPID METABOLISM IN PRE-DIABETIC ADULTS: A RANDOMIZED CONTROLLED TRIAL, CLIN NUTR ESPEN, 19, PP. 9-15, (2017); CRINI G., HISTORICAL REVIEW ON CHITIN AND CHITOSAN BIOPOLYMERS, ENVIRON CHEM LETT, 17, PP. 1623-1643, (2019); RINAUDO M., CHITIN AND CHITOSAN: PROPERTIES AND APPLICATIONS, PROG POLYM SCI, 31, PP. 603-632, (2006); HUANG H., ZOU Y., CHI H., LIAO D., LIPID-MODIFYING EFFECTS OF CHITOSAN SUPPLEMENTATION IN HUMANS: A POOLED ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS, MOL NUTR FOOD RES, 62, (2018); BAKER W., TERCIUS A., ANGLADE M., WHITE C., COLEMAN C., A META-ANALYSIS EVALUATING THE IMPACT OF CHITOSAN ON SERUM LIPIDS IN HYPERCHOLESTEROLEMIC PATIENTS, ANN NUTR METABOL, 55, PP. 368-374, (2009); RIZZO M., GIGLIO R.V., NIKOLIC D., PATTI A.M., CAMPANELLA C., COCCHI M., KATSIKI N., MONTALTO G., EFFECTS OF CHITOSAN ON PLASMA LIPIDS AND LIPOPROTEINS: A 4-MONTH PROSPECTIVE PILOT STUDY, ANGIOLOGY, 65, PP. 538-542, (2014); ALLERTON T., PROCTOR D., STEPHENS J., DUGAS T., SPIELMANN G., IRVING B., L-CITRULLINE SUPPLEMENTATION: IMPACT ON CARDIOMETABOLIC HEALTH, NUTRIENTS, 10, (2018); MIRENAYAT M.S., MORADI S., MOHAMMADI H., ROUHANI M.H., EFFECT OF L-CITRULLINE SUPPLEMENTATION ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS, CURR HYPERTENS REP, 20, (2018); MORITA M., SAKURADA M., WATANABE F., YAMASAKI T., EZAKI H., MORISHITA K., MIYAKE T., EFFECTS OF ORAL L-CITRULLINE SUPPLEMENTATION ON LIPOPROTEIN OXIDATION AND ENDOTHELIAL DYSFUNCTION IN HUMANS WITH VASOSPASTIC ANGINA, IMMUNOL ENDOCR METAB AGENTS MED CHEM, 13, PP. 214-220, (2013); GENTILE M., CALCATERRA I., STRAZZULLO A., PAGANO C., PACIONI D., SPERANZA E., RUBBA P., MAROTTA G., EFFECTS OF ARMOLIPID PLUS ON SMALL DENSE LDL PARTICLES IN A SAMPLE OF PATIENTS AFFECTED BY FAMILIAL COMBINED HYPERLIPIDEMIA, CLIN LIPIDOL, 10, PP. 475-480, (2015)","A. SAHEBKAR; HALAL RESEARCH CENTER OF IRI, FDA, TEHRAN, IRAN; EMAIL: SAHEBKARA@MUMS.AC.IR","BIOMED CENTRAL LTD.","ENGLISH","LIPIDS HEALTH DIS.","REVIEW","ISI","2-S2.0-85083187754","LIPIDS HEALTH DIS","ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;ISFAHAN UNIVERSITY OF MEDICAL SCIENCES;AL-ZAHRAA UNIVERSITY;MASHHAD UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;HALAL RESEARCH CENTER OF IRI;NOTREPORTED",NA,"TALEBI S, 2020, LIPIDS HEALTH DIS","TALEBI S, 2020, LIPIDS HEALTH DIS"
"WARD N;SAHEBKAR A;BANACH M;WATTS G","WARD, NATALIE (56782965900); SAHEBKAR, AMIRHOSSEIN (26639699900); BANACH, MACIEJ (22936699500); WATTS, GERALD (7202153447)","RECENT PERSPECTIVES ON THE ROLE OF NUTRACEUTICALS AS CHOLESTEROLLOWERING AGENTS",2017,"CURRENT OPINION IN LIPIDOLOGY","28","6",31,"10.1097/MOL.0000000000000455","SCHOOL OF BIOMEDICAL SCIENCES, CURTIN HEALTH INNOVATION RESEARCH INSTITUTE, CURTIN UNIVERSITY, AUSTRALIA, FACULTY OF HEALTH AND MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, SCHOOL OF BIOMEDICAL SCIENCES, CURTIN UNIVERSITY, GPO BOX U1987, PERTH, 6845, WA, AUSTRALIA;BIOTECHNOLOGY RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;DEPARTMENT OF HYPERTENSION, WAM UNIVERSITY HOSPITAL IN LODZ, MEDICAL UNIVERSITY OF LODZ, POLAND, POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE (PMMHRI), LODZ, POLAND;FACULTY OF HEALTH AND MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, SCHOOL OF BIOMEDICAL SCIENCES, CURTIN UNIVERSITY, GPO BOX U1987, PERTH, 6845, WA, AUSTRALIA, LIPID DISORDERS CLINIC, DEPARTMENT OF CARDIOLOGY, ROYAL PERTH HOSPITAL, PERTH, AUSTRALIA","PURPOSE OF REVIEW REDUCTION IN CIRCULATING CHOLESTEROL IS AN IMPORTANT STEP IN LOWERING CARDIOVASCULAR RISK. ALTHOUGH STATINS ARE THE MOST FREQUENTLY PRESCRIBED CHOLESTEROL-LOWERING MEDICATION, THERE REMAINS A SIGNIFICANT PORTION OF PATIENTS WHO REQUIRE ALTERNATIVE TREATMENT OPTIONS. NUTRACEUTICALS ARE INCREASINGLY POPULAR AS CHOLESTEROL-LOWERING AGENTS. DESPITE THE LACK OF LONG-TERM TRIALS EVALUATING THEIR USE ON CARDIOVASCULAR ENDPOINTS AND MORTALITY, SEVERAL STUDIES HAVE DEMONSTRATED THEIR POTENTIAL CHOLESTEROL-LOWERING EFFECTS. THE PURPOSE OF THIS REVIEW IS TO PROVIDE AN UPDATE ON THE ROLE OF NUTRACEUTICALS AS CHOLESTEROL-LOWERING AGENTS. THE PRESENT REVIEW WILL FOCUS ON INDIVIDUAL NUTRACEUTICAL COMPOUNDS, WHICH HAVE SHOWN MODEST CHOLESTEROL-LOWERING ABILITIES, AS WELL AS COMBINATION NUTRACEUTICALS, WHICH MAY OFFER POTENTIAL ADDITIVE AND/OR SYNERGISTIC EFFECTS. RECENT FINDINGS BERBERINE, RED YEAST RICE, AND PLANT STEROLS HAVE MODERATE POTENTIAL AS CHOLESTEROL-LOWERING AGENTS. COMBINATION NUTRACEUTICALS, INCLUDING THE PROPRIETARY FORMULATION, ARMOLIPID PLUS, APPEAR TO CONFER ADDITIONAL BENEFIT ON PLASMA LIPID PROFILES, EVEN WHEN TAKEN WITH STATINS AND OTHER AGENTS. SUMMARY ALTHOUGH ROBUST, LONG-TERM CLINICAL TRIALS TO EXAMINE THE EFFECTS OF NUTRACEUTICALS ON CLINICAL OUTCOMES ARE STILL REQUIRED, THEIR CHOLESTEROL-LOWERING ABILITY, TOGETHER WITH THEIR REPORTED TOLERANCE AND SAFETY, OFFER A PRAGMATIC OPTION FOR LOWERING PLASMA CHOLESTEROL LEVELS. © 2017 WOLTERS KLUWER HEALTH, INC. ALL RIGHTS RESERVED.","DYSLIPIDEMIA; LOW-DENSITY LIPOPROTEIN; NUTRACEUTICALS; TOTAL CHOLESTEROL","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; HUMANS; BERBERINE; CHOLESTIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIETARY FIBER; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BLOOD; DIETARY SUPPLEMENT; DRUG INTERACTION","","","WILSON P.W., D'AGOSTINO R.B., LEVY D., ET AL., PREDICTION OF CORONARY HEART DISEASE USING RISK FACTOR CATEGORIES, CIRCULATION, 97, PP. 1837-1847, (1998); SILVERMAN M.G., FERENCE B.A., IM K., ET AL., ASSOCIATION BETWEEN LOWERING LDL-C AND CARDIOVASCULAR RISK REDUCTION AMONG DIFFERENT THERAPEUTIC INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 316, PP. 1289-1297, (2016); REINER Z., CATAPANO A.L., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); WIGGINS B.S., SASEEN J.J., PAGE I.I.R.L., ET AL., RECOMMENDATIONS FOR MANAGEMENT OF CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTIONS WITH STATINS AND SELECT AGENTS USED IN PATIENTS WITH CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 134, PP. E468-E495, (2016); SABATINE M.S., GIUGLIANO R.P., KEECH A.C., ET AL., EVOLOCUMAB AND CLINICAL OUTCOMES IN PATIENTS WITH CARDIOVASCULAR DISEASE, N ENGL J MED, 376, PP. 1713-1722, (2017); BANACH M., STULC T., DENT R., TOTH P.P., STATIN NONADHERENCE AND RESIDUAL CARDIOVASCULAR RISK: THERE IS NEED FOR SUBSTANTIAL IMPROVEMENT, INT J CARDIOL, 225, PP. 184-196, (2016); SERBAN M.C., COLANTONIO L.D., MANTHRIPRAGADA A.D., ET AL., STATIN INTOLERANCE AND RISK OF CORONARY HEART EVENTS AND ALL-CAUSE MORTALITY FOLLOWING MYOCARDIAL INFARCTION, J AM COLLEGE OF CARDIOL, 69, PP. 1386-1395, (2017); BARBAGALLO C.M., CEFALU A.B., NOTO D., AVERNA M.R., ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY, FRONT CARDIOVASC MED, 2, (2015); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); MANNARINO M.M.S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLAEMIA, EUR J INTERNAL MED, 25, PP. 592-599, (2014); HUNTER P.M., HEGELE R.A., FUNCTIONAL FOODS AND DIETARY SUPPLEMENTS FOR THE MANAGEMENT OF DYSLIPIDAEMIA, NAT REV ENDOCRINOL, 13, PP. 278-288, (2017); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); DONG H., ZHAO Y., ZHAO L., LU F., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); KONG W.J., WEI J., ZUO Z.Y., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFICACY, METABOLISM, 57, PP. 1029-1037, (2008); DONG H., WANG N., ZHAO L., LU F., BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A SYSTEMIC REVIEW AND META-ANALYSIS, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); BROUWERS J.R., ROETERS VAN LENNEP J.E., MAAS A.H., RED YEAST RICE' AS A CHOLESTEROL-LOWERING SUBSTANCE? CAUTION IS WARRANTED, NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, 160, (2016); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); GYLLING H., PLAT J., TURLEY S., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, PP. 346-360, (2014); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); BAYS H.E., BALLANTYNE C.M., KASTELEIN J.J., ET AL., EICOSAPENTAENOIC ACID ETHYL ESTER (AMR101) THERAPY IN PATIENTS WITH VERY HIGH TRIGLYCERIDE LEVELS (FROM THE MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, 12-WEEK STUDY WITH AN OPEN-LABEL EXTENSION MARINE TRIAL), AM J CARDIOL, 108, PP. 682-690, (2011); BALLANTYNE C.M., BAYS H.E., KASTELEIN J.J., ET AL., EFFICACY AND SAFETY OF EICOSAPENTAENOIC ACID ETHYL ESTER (AMR101) THERAPY IN STATIN-TREATED PATIENTS WITH PERSISTENT HIGH TRIGLYCERIDES (FROM THE ANCHOR STUDY), AM J CARDIOL, 110, PP. 984-992, (2012); BHATT D.L., STEG P.G., BRINTON E.A., ET AL., RATIONALE AND DESIGN OF REDUCE-IT: REDUCTION OF CARDIOVASCULAR EVENTS WITH ICOSAPENT ETHYL-INTERVENTION TRIAL, CLIN CARDIOL, 40, PP. 138-148, (2017); PANAHI Y., KHALILI N., HOSSEINI M.S., ET AL., LIPID-MODIFYING EFFECTS OF ADJUNCTIVE THERAPY WITH CURCUMINOIDS-PIPERINE COMBINATION IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED CONTROLLED TRIAL, COMPL THERAP MED, 22, PP. 851-857, (2014); HOOPER L., KROON P.A., RIMM E.B., ET AL., FLAVONOIDS, FLAVONOID-RICH FOODS, AND CARDIOVASCULAR RISK: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 88, PP. 38-50, (2008); TAKU K., UMEGAKI K., SATO Y., ET AL., SOY ISOFLAVONES LOWER SERUM TOTAL AND LDL CHOLESTEROL IN HUMANS: A META-ANALYSIS OF 11 RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 85, PP. 1148-1156, (2007); ZHENG X.X., XU Y.L., LI S.H., ET AL., GREEN TEA INTAKE LOWERS FASTING SERUM TOTAL AND LDL CHOLESTEROL IN ADULTS: A META-ANALYSIS OF 14 RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 94, PP. 601-610, (2011); KIM A., CHIU A., BARONE M.K., ET AL., GREEN TEA CATECHINS DECREASE TOTAL AND LOWDENSITY LIPOPROTEIN CHOLESTEROL: A SYSTEMATIC REVIEW AND META-ANALYSIS, J AM DIET ASSOC, 111, PP. 1720-1729, (2011); ONAKPOYA I., SPENCER E., HENEGHAN C., THOMPSON M., THE EFFECT OF GREEN TEA ON BLOOD PRESSURE AND LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, NUTR METAB CARDIOVASC DIS, 24, PP. 823-836, (2014); MOMOSE Y., MAEDA-YAMAMOTO M., NABETANI H., SYSTEMATIC REVIEW OF GREEN TEA EPIGALLOCATECHIN GALLATE IN REDUCING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS OF HUMANS, INT J FOOD SCI NUTR, 67, PP. 606-613, (2016); PAN A., YU D., DEMARK-WAHNEFRIED W., ET AL., META-ANALYSIS OF THE EFFECTS OF FLAXSEED INTERVENTIONS ON BLOOD LIPIDS, AM J CLIN NUTR, 90, PP. 288-297, (2009); ABU M., WEIS S.S., JEW S., AMES N.P., BETA-GLUCAN FROM BARLEY AND ITS LIPID-LOWERING CAPACITY: A META-ANALYSIS OF RANDOMIZED, CONTROLLED TRIALS, EUR J CLIN NUTR, 64, PP. 1472-1480, (2010); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 88, PP. 1167-1175, (2008); CICERO A.F., COLLETTI A., COMBINATIONS OF PHYTOMEDICINES WITH DIFFERENT LIPID LOWERING ACTIVITY FOR DYSLIPIDEMIA MANAGEMENT: THE AVAILABLE CLINICAL DATA, PHYTOMEDICINE, 23, PP. 1113-1118, (2016); PATTI A.M., TOTH P.P., GIGLIO R.V., ET AL., NUTRACEUTICALS AS AN IMPORTANT PART OF COMBINATION THERAPY IN DYSLIPIDAEMIA, CURR PHARMA DESIGN, (2017); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); CICERO A.F., DEROSA G., PISCIOTTA L., ET AL., TESTING THE SHORT-TERM EFFICACY OF A LIPID-LOWERING NUTRACEUTICAL IN THE SETTING OF CLINICAL PRACTICE: A MULTICENTER STUDY, J MED FOOD, 18, PP. 1270-1273, (2015); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); GRCV C., RAPARELLI V., SPOLETINI I., ET AL., THE COMBINATION OF NUTRACEUTICAL AND SIMVASTATIN ENHANCES THE EFFECT OF SIMVASTATIN ALONE IN NORMALISING LIPID PROFILE WITHOUT SIDE EFFECTS IN PATIENTS WITH ISCHEMIC HEART DISEASE, IJC METAB ENDOCRINE, 11, PP. 3-6, (2016); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, PP. 61-68, (2014); SOLA R., VALLS R.M., PUZO J., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); PIRRO M., MANNARINO M.R., BIANCONI V., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); MILLAN J., CICERO A.F., TORRES F., ANGUERA A., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 28, PP. 178-187, (2016); BARRIOS V., ESCOBAR C., CICERO A.F., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); MOSS J.W., RAMJI D.P., NUTRACEUTICAL THERAPIES FOR ATHEROSCLEROSIS, NAT REV CARDIOL, 13, PP. 513-532, (2016); FUENTES M.C., LAJO T., CARRION J.M., CUNE J., CHOLESTEROL-LOWERING EFFICACY OF LACTOBACILLUS PLANTARUM CECT 7527, 7528 AND 7529 IN HYPERCHOLESTEROLAEMIC ADULTS, BR J NUTR, 109, PP. 1866-1872, (2013); BOSCH M., FUENTES M.C., AUDIVERT S., ET AL., LACTOBACILLUS PLANTARUM CECT 7527, 7528 AND 7529: PROBIOTIC CANDIDATES TO REDUCE CHOLESTEROL LEVELS, J SCI FOOD AGRIC, 94, PP. 803-809, (2014); PANAHI Y., KIANPOUR P., MOHTASHAMI R., ET AL., EFFICACY AND SAFETY OF PHYTOSOMAL CURCUMIN IN NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL, DRUG RES (STUTTG), 67, PP. 244-251, (2017); DAVI G., SANTILLI F., PATRONO C., NUTRACEUTICALS IN DIABETES AND METABOLIC SYNDROME, CARDIOVASC THERAP, 28, PP. 216-226, (2010); CICERO A.C.A., BAJRAKTARI G., DECAMPS O., ET AL., LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI NUTR REV, (2017)","G. WATTS; FACULTY OF HEALTH AND MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, SCHOOL OF BIOMEDICAL SCIENCES, CURTIN UNIVERSITY, PERTH, GPO BOX U1987, 6845, AUSTRALIA; EMAIL: NATALIE.WARD@CURTIN.EDU.AU","LIPPINCOTT WILLIAMS AND WILKINS","ENGLISH","CURR. OPIN. LIPIDOLOGY","REVIEW","ISI","2-S2.0-85030711401","CURR OPIN LIPIDOLOGY","CURTIN UNIVERSITY;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;WAM UNIVERSITY HOSPITAL IN LODZ;UNIVERSITY OF WESTERN AUSTRALIA","NOTREPORTED;UNIVERSITY OF WESTERN AUSTRALIA;NOTREPORTED",NA,"WARD N, 2017, CURR OPIN LIPIDOLOGY","WARD N, 2017, CURR OPIN LIPIDOLOGY"
"MILLÁN J;CICERO A;TORRES F;ANGUERA A","MILLÁN, JESUS (55177496800); CICERO, ARRIGO F.G. (7003403707); TORRES, FRANCISCO (57225692440); ANGUERA, ANNA (6603274608)","EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE BRB POLICOSANOL AND RED YEAST RICE RYR ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS A METAANALYSIS OF RANDOMISED CONTROLLED TRIALS EFECTOS DE LA COMBINACIÓN DE PRODUCTOS NUTRICÉUTICOS CON BERBERINA POLICOSANOL Y ARROZ DE LEVADURA ROJA EN EL LIPIDOGRAMA DE PACIENTES CON HIPERCOLESTEROLEMIA UN METAANÁLISIS DE ENSAYOS CLÍNICOS ALEATORIZADOS",2016,"CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS","28","9",24,"10.1016/j.arteri.2016.03.002","LIPID RESEARCH UNIT, INTERNAL MEDICINE SERVICE, GENERAL UNIVERSITY HOSPITAL “GREGORIO MARAÑÓN”, MADRID, SPAIN;DYSLIPIDEMIA RESEARCH UNIT, MEDICAL AND SURGICAL SCIENCES DEPARTMENT, UNIVERSITY OF BOLOGNA, ITALY;BIOSTATISTICS AND DATA MANAGEMENT CORE FACILITY, IDIBAPS, HOSPITAL CLINIC BARCELONA, BARCELONA, SPAIN, BIOSTATISTICS UNIT, FACULTY OF MEDICINE, UNIVERSITAT AUTÒNOMA DE BARCELONA, BARCELONA, SPAIN;LIPID RESEARCH UNIT, INTERNAL MEDICINE SERVICE, GENERAL UNIVERSITY HOSPITAL “GREGORIO MARAÑÓN”, MADRID, SPAIN","BACKGROUND AND AIM A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE, POLICOSANOL, AND RED YEAST RICE, LARGELY MARKETED IN EUROPE (ARMOLIPID PLUS®) (AP), HAS BEEN REPORTED TO INDUCE SIGNIFICANT IMPROVEMENTS IN PLASMA LIPIDS, INSULIN RESISTANCE AND OTHER COMPONENTS OF THE METABOLIC SYNDROME. HOWEVER, LITERATURE STUDY DESIGNS AND RESULTS WERE HETEROGENEOUS AND IT WAS THUS NECESSARY TO SYSTEMATICALLY REVIEW AND META-ANALYSE ALL RELEVANT RANDOMISED CLINICAL TRIALS (RCTS) TO EXPLORE AND QUANTIFY THE EFFECTS OF THE DIETARY SUPPLEMENT AP ON LIPID PROFILE. THE AIM OF OUR META-ANALYSIS WAS THE EVALUATION OF THE EFFECT OF AP ON LIPID PROFILE. METHODS AND RESULTS WE CONDUCTED A STRUCTURES SEARCH ON PUBMED AND GOOGLE SCHOLAR TO IDENTIFY ELIGIBLE ARTICLES PUBLISHED PRIOR TO 2015. ELEVEN RCTS WERE SUBJECTED TO META-ANALYSIS BY MEANS OF RANDOM EFFECTS MODELS USING THE STANDARDISED MEAN DIFFERENCES APPROACH (HEDGES’ METHOD) AND THE MEAN DIFFERENCES APPROACH AS A SENSITIVITY ANALYSIS. DATA FROM 11 RANDOMISED CLINICAL TRIALS, CORRESPONDING TO 1970 NUTRACEUTICAL COMBINATION AND 1954 CONTROL PATIENTS (3924 TOTAL PATIENTS), WERE INCLUDED AFTER THE PEER EVALUATION AND DATA EXTRACTION OF TWO INDEPENDENT EVALUATORS. HETEROGENEITY WAS SIGNIFICANT IN ALL MODELS. A SIGNIFICANT EFFECT WAS FOUND FOR ALL LIPID PARAMETERS. THE EFFECT SIZE (RELATIVE CHANGE FROM BASELINE (%)) WAS −1.3 (9.9%) FOR TOTAL CHOLESTEROL, −1.17 (−13.7%) FOR LDL-C, +0.17 (+3.7%) FOR HDL-C AND −0.24 (−7.0%) FOR TRIGLYCERIDES. CONCLUSION THIS META-ANALYSIS CONFIRMS THAT THE NUTRACEUTICAL COMBINATION CONTAINING BERBERINE, POLICOSANOL, AND RED YEAST RICE HAS SHOWN TO BE AN EFFECTIVE PRODUCT FOR THE IMPROVEMENT OF THE LIPID PROFILE. © 2016 SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS","BERBERINE; HYPERCHOLESTEROLEMIC; NUTRACEUTICAL; POLICOSANOL","BERBERINE; BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ARMOLIPID PLUS; BERBERINE; CHOLESTEROL; CHOLESTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BERBERINE; BIOLOGICAL PRODUCT; FATTY ALCOHOL; LIPID; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MIXTURE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA","LABORATORIOS ROTTAPHARM","THE META-ANALYSIS WAS FUNDED BY LABORATORIOS ROTTAPHARM, BARCELONA, SPAIN. ","(2012); YUSUF S., HAWKEN S., OUNPUR S., DANS T., AVEZUM A., LANAS F., ET AL., EFFECT OF POTENTIALLY MODIFIABLE RISK FACTORS ASSOCIATED WITH MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): CASE–CONTROL STUDY, LANCET, 364, PP. 937-952, (2004); KOENIG W., KHUSEYINOVA N., BIOMARKERS OF ATHEROSCLEROTIC PLAQUE INSTABILITY AND RUPTURE, ARTERIOSCLER THROMB VASC BIOL, 27, PP. 15-26, (2007); VAN GAAL L.F., MERTENS L., DE LOCK C.E., MECHANISMS LINKING OBESITY WITH CARDIOVASCULAR DISEASE, NATURE, 444, PP. 875-880, (2006); WISSE B.E., KIM F., SCHWARTZ M.W., PHYSIOLOGY. AN INTEGRATIVE VIEW OF OBESITY, SCIENCE, 318, PP. 928-929, (2007); CLEEMAN J.I., EXECUTIVE SUMMARY OF THE TRIAL REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); PROSSER L.A., STINNETT A.A., GOLDMAN P.A., WILLIAMS L.W., HUNINK M.G., GOLDMAN L., ET AL., COST-EFFECTIVENESS OF CHOLESTEROL LOWERING THERAPIES ACCORDING TO PATIENT CHARACTERISTICS, ANN INTERN MED, 132, PP. 769-774, (2000); FOOD U.S., DRUG ADMINISTRATION, (2010); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, PP. 1482-1487, (2010); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTR METAB, 4, PP. 133-139, (2011); MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES: THE PRISMA STATEMENT, ANN INTERN MED, 151, (2009); HEDGES L.V., OLKIN I., STATISTICAL METHODS FOR META-ANALYSIS, (1985); COHEN J., STATISTICAL POWER ANALYSIS FOR THE BEHAVIORAL SCIENCES, (1988); COHEN J., A POWER PRIMER, PSYCHOL BULL, 112, PP. 155-159, (1992); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); AFUSSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); CICERO A.F.G., DE SANDO V., BENEDETTO D., CEVENINI M., GRANDI E., BORGHI C., LONG-TERM EFFICACY AND TOLERABILITY OF A MULTICOMPONENT LIPID-LOWERING NUTRACEUTICAL IN OVERWEIGHT PATIENTS, NUTRAFOODS, 11, PP. 55-61, (2012); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, PP. 1482-1487, (2010); MACCHI A., FRANZONI I., BUZZETTI F., PEDRIGI M.C., ROSA I., GAUDIO G.V., ET AL., COMPLEMENTO NUTRICIONLAL DE LEVADURA ROJA, POLICOSANOLES, BERBERINA, ÁCIDO FÓLICO Y ANTIOXIDANTES, EN PACIENTES CON HIPERCOLESTEROLEMIA EN PREVENCIÓN SECUNDARIA, 41 CONGRESO NACIONAL DE CARDIOLOGÍA ANMCO 2010, 19–22 MAYO 2010, FLORENCIA, (2010); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., ET AL., EFFECTS OF COMBINED BIOACTIVE COMPOUNDS ON LIPID PROFILE AND CLINICAL CRITERIA FOR METABOLIC SYNDROME IN A HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, AUGUST (8), (2014); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTR METAB, 4, PP. 133-139, (2011); PIRRO M., LUPATTELLI G., DEL GIORNO R., SCHILLACI G., BERISHA S., MANNARINO M.R., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW-MODERATE RISK HYPERCHOLESTERLOEMIC PATIENTS, PHARMANUTRITION, PP. 73-77, (2013); PELLICIA F., MARAZZI G., PASCERI V., ARRIVI A., TANZILLI G., MANGIERI E., ET AL., RANDOMIZED TRIAL OF NUTRACEUTICALS IN STATIN-INTOLERANT PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION, CIRCULATION, 124, (2011); PUZO J., VALLS R.M., SOLA R., BREA A., CALABUIG J.R., VILLAR J., ET AL., EFECTOS DE UNA COMBINACIÓN DE SUSTANCIAS BIOACTIVAS (ARMOLIPID PLUS) SOBRE EL PERFIL LIPÍDICO Y LOS CRITERIOS CLÍNICOS DEL SÍNDROME METABÓLICO. ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO CONTROLADO CON PLACEBO, COMUNICACIÓN EN XXVI CONGRESO NACIONAL DE LA SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS, 22–24 MAYO 2013, ZARAGOZA, (2013); CICERO A.F., PARINI A., ROSTICCI, BRANCALEONI B., DEROSA G., GRANDI E., ET AL., EFFECT OF A LIPID-LOWERING NUTRACEUTICAL ON PULSE-WAVE-VELOCITY IN HYPERCHOLESTEROLEMIC PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE, OPEN HYPERTENS J, 5, PP. 18-22, (2013); NIJJAR P.S., BURKE F.M., BLOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL, J CLIN LIPIDOL, 4, PP. 248-258, (2010); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTEL-FORSCHUNG (DRUG RES), 55, PP. 312-317, (2005); LEE Y.S., KIM W.S., KIM K.H., YOON M.J., CHO H.J., SHEN Y., ET AL., BERBERINE, A NATURAL PLANT PRODUCT, ACTIVATES AMPC-ACTIVATED PROTEIN KINASE WITH BENEFICIAL METABOLIC EFFECTS IN DIABETIC AND INSULIN-RESISTANT STATES, DIABETES, 55, PP. 2256-2264, (2006); SHAH B.H., NAWAZ Z., SAEED S.A., GILANI A.H., AGONIST-DEPENDENT DIFFERENTIAL EFFECTS OF BERBERINE IN HUMAN PLATELET AGGREGATION, PHYTOTHER RES, 12, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); DEROSA G., MAFFIOLI P., CICERO A.F.G., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPIN BIOL THER, 12, PP. 1113-1124, (2012); CICERO A.F.G., DEROSA G., MAFFIOLI P., REGGI A., PARINI A., ROSTICCI M., ET AL., BERBERINE INDUCED IMPROVEMENT IN HEPATIC STATEATOSIS INDEX IN OVERWEIGHT DYSLIPIDAEMIC PATIENTS TREATED WITH LIPID-LOWERING NUTRACEUTICALS, CURR TOP NUTRACEUTICAL RES, 11, PP. 41-46, (2013); CICERO A.F.G., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN LIPIDOL, 4, PP. 553-563, (2009); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-995, (2006); CICERO A.F., DEROSA G., BOVE M., IMOLA F., BORGUI C., GADDI A.V., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOP NUTRACEUTICAL RES, 7, PP. 121-126, (2009); CICERO A.F., REGGI A., PARINI A., MORBINI M., ROSTICCI M., GRANDI E., ET AL., BERBERINE AND MONACOLIN EFFECTS ON THE CARDIOVASCULAR RISK PROFILE OF WOMEN WITH OESTROPROGESTIN-INDUCED HYPERCHOLESTEROLEMIA, HIGH BLOOD PRESS CARDIOVASC PREV, (2014); CICERO A.F., DEROSA G., PARINI A., BARONIO C., BORGHI C., FACTORS ASSOCIATED WITH 2-YEAR PERSISTENCE IN FULLY NON REIMBURSED LIPID-LOWERING TREATMENTS, ATHEROSCLEROSIS, 235, PP. 81-83, (2014); GAGNIER J.J., MOHER D., BOON H., BEYENE J., BOMBARDIER C., INVESTIGATING CLINICAL HETEROGENEITY IN SYSTEMATIC REVIEWS: A METHODOLOGIC REVIEW OF GUIDANCE IN THE LITERATURE, BMC MED RES METHODOL, 12, (2012); MANDREKAR J.N., MANDREKAR S.J., SYSTEMATIC REVIEWS AND META ANALYSIS OF PUBLISHED STUDIES: AN OVERVIEW AND BEST PRACTICES, J THORAC ONCOL, 6, PP. 1301-1303, (2011)","J. MILLÁN; LIPID RESEARCH UNIT, INTERNAL MEDICINE SERVICE, GENERAL UNIVERSITY HOSPITAL “GREGORIO MARAÑÓN”, MADRID, SPAIN; EMAIL: ARRIGO.CICERO@UNIBO.IT","ELSEVIER DOYMA","ENGLISH","CLIN. INVEST. ARTERIOSCLER.","ARTICLE","ISI","2-S2.0-84964576074","CLIN INVEST ARTERIOSCLER","GENERAL UNIVERSITY HOSPITAL “GREGORIO MARAÑÓN”;UNIVERSITY OF BOLOGNA;UNIVERSITAT AUTÒNOMA DE BARCELONA;GENERAL UNIVERSITY HOSPITAL “GREGORIO MARAÑÓN”","NOTREPORTED;GENERAL UNIVERSITY HOSPITAL “GREGORIO MARAÑÓN”;NOTREPORTED",NA,"MILLÁN J, 2016, CLIN INVEST ARTERIOSCLER","MILLÁN J, 2016, CLIN INVEST ARTERIOSCLER"
"LEE E;YOO J;LIM S;CHO K","LEE, EUN-YOUNG (57204082360); YOO, JEONG-AH (56949637200); LIM, SO-MANG (56443072000); CHO, KYUNG-HYUN (7403956966)","ANTIAGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPIDLOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGHDENSITY LIPOPROTEIN FUNCTIONALITY",2016,"REJUVENATION RESEARCH","19","9",35,"10.1089/rej.2015.1745","SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA","WE INVESTIGATED THE TISSUE REGENERATION AND LIPID-LOWERING EFFECTS OF POLICOSANOL (PCO) BY EMPLOYING A HYPERLIPIDEMIC ZEBRAFISH MODEL. A RECONSTITUTED HIGH-DENSITY LIPOPROTEIN CONTAINING POLICOSANOL (PCO-RHDL) FACILITATED GREATER CELL GROWTH AND REPLICATION WITH LESS APOPTOSIS AND REACTIVE OXYGEN SPECIES (ROS) PRODUCTION IN BV-2 MICROGLIAL CELL LINES. FROM IN VIVO STUDY, INJECTION OF RHDL CONTAINING APOLIPOPROTEIN A-I (APOA-I) CAUSED 76 ± 4% (P = 0.01) GREATER TISSUE REGENERATION ACTIVITY THAN THE PHOSPHATE-BUFFERED SALINE (PBS) CONTROL, WHEREAS PCO-RHDL CAUSED 94 ± 7% (P = 0.002) INCREASED REGENERATION. PCO IN ETHANOL (ETOH) SHOWED LOWER CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITORY ABILITY THAN DID ANACETRAPIB, WHEREAS PCO-RHDL SHOWED HIGHER INHIBITORY ABILITY THAN ANACETRAPIB, SUGGESTING A SYNERGISTIC EFFECT BETWEEN PCO AND RHDL. FOLLOWING 9 WEEKS OF PCO CONSUMPTION, THE PCO GROUP (0.003% PCO IN TETRABIT) SHOWED THE HIGHEST SURVIVABILITY (80%), WHEREAS NORMAL DIET (ND) AND HIGH-CHOLESTEROL DIET (HCD) CONTROL GROUPS SHOWED 67% AND 70% SURVIVAL RATES, RESPECTIVELY. SUPPLEMENTATION WITH A HCD RESULTED IN TWO-FOLD ELEVATION OF CETP ACTIVITY ALONG WITH 3- AND 2.5-FOLD INCREASES IN SERUM TOTAL CHOLESTEROL (TC) AND TRIGLYCERIDES (TGS) LEVELS, RESPECTIVELY. CONSUMPTION OF PCO FOR 9 WEEKS RESULTED IN 40 ± 5% (P = 0.01 VS. HCD) AND 33 ± 4% (P = 0.02 VS. HCD) REDUCTION OF TC AND TGS LEVELS, RESPECTIVELY. SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVEL INCREASED UP TO 37 ± 2 MG/DL (P = 0.004), WHEREAS THE PERCENTAGE OF HDL-C/TC INCREASED UP TO 20 ± 2% FROM 5 ± 1% COMPARED TO THE HCD CONTROL. THE SERUM GLUCOSE LEVEL WAS REDUCED TO 47 ± 2% (P = 0.002) COMPARED TO THE HCD CONTROL. FATTY LIVER CHANGE AND HEPATIC INFLAMMATION LEVELS WERE REMARKABLY INCREASED UPON HCD CONSUMPTION AND WERE TWO-FOLD HIGHER THAN THAT UNDER ND. HOWEVER, THE PCO GROUP SHOWED 58 ± 5% (P = 0.001) AND 50 ± 3% (P = 0.006) REDUCTION OF INFLAMMATION ENZYME LEVELS AND LIPID CONTENT IN HEPATIC TISSUE UNDER HCD. IN CONCLUSION, PCO SUPPLEMENTATION SHOWED LIPID-LOWERING AND HDL-C-ELEVATING EFFECTS WITH AMELIORATING FATTY LIVER CHANGE. THESE IN VIVO ANTI-ATHEROSCLEROTIC AND ANTI-DIABETIC EFFECTS OF PCO ARE WELL ASSOCIATED WITH IN VITRO ANTI-APOPTOTIC ACTIVITIES. © EUN-YOUNG LEE ET AL., 2016; PUBLISHED BY MARY ANN LIEBERT, INC. 2016.","","AGING; ANIMALS; ANTIOXIDANTS; BRAIN; CHOLESTEROL ESTER TRANSFER PROTEINS; CYTOPROTECTION; FATTY ALCOHOLS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; IRON; LIPOPROTEINS, HDL; LIVER; REGENERATION; ZEBRAFISH; ANACETRAPIB; ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; PHOSPHATE BUFFERED SALINE; POLICOSANOL; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN; IRON; POLICOSANOL; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIVISION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL HEPATITIS; FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE REGENERATION; ZEBRA FISH; AGING; ANIMAL; BLOOD; BRAIN; CELL PROTECTION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HYPERLIPIDEMIAS; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION","","","WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS, AND PHYTOSTEROLS ON LIPID LEVELS, AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCHCASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES, FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); NOA M., DE LA ROSA M.C., MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); EGHDAMIAN B., GHOSE K., MODE OF ACTION, AND ADVERSE EFFECTS OF LIPID LOWERING DRUGS, DRUGS TODAY (BARC, 34, PP. 943-956, (1998); TSUTSUMI K., HAGI A., INOUE Y., THE RELATIONSHIP BETWEEN PLASMA HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, AND CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY IN SIX SPECIES OF HEALTHY EXPERIMENTAL ANIMALS, BIOL PHARM BULL, 24, PP. 579-581, (2001); BARZILAI N., ATZMON G., SCHECHTER C., SCHAEFER E.J., CUPPLES A.L., LIPTON R., CHENG S., SHULDINER A.R., UNIQUE LIPOPROTEIN PHENOTYPE, AND GENOTYPE ASSOCIATED WITH EXCEPTIONAL LONGEVITY, JAMA, 290, PP. 2030-2040, (2003); CHO K.H., BIOMEDICINAL IMPLICATIONS OF HIGH-DENSITY LIPOPROTEIN: ITS COMPOSITION, STRUCTURE, FUNCTIONS, AND CLINICAL APPLICATIONS, BMB REP, 42, PP. 393-400, (2009); REITZ C., TANG M.X., SCHUPF N., MANLY J.J., MAYEUX R., LUCHSINGER J.A., ASSOCIATION OF HIGHER LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ELDERLY INDIVIDUALS, AND LOWER RISK OF LATE-ONSET ALZHEIMER DISEASE, ARCH NEUROL, 67, PP. 1491-1497, (2010); VITALI C., WELLINGTON C.L., CALABRESI L., HDL, AND CHOLESTEROL HANDLING IN THE BRAIN, CARDIOVASC RES, 103, PP. 405-413, (2014); KIM J.Y., SEO J., CHO K.H., ASPARTAME-FED ZEBRAFISH EXHIBIT ACUTE DEATHS WITH SWIMMING DEFECTS, AND SACCHARIN-FED ZEBRAFISH HAVE ELEVATION OF CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY IN HYPERCHOLESTEROLEMIA, FOOD CHEM TOXICOL, 49, PP. 2899-2905, (2011); STOLETOV K., FANG L., CHOI S.H., HARTVIGSEN K., HANSEN L.F., HALL C., PATTISON J., JULIANO J., MILLER E.R., ALMAZAN F., CROSIER P., WITZTUM J.L., KLEMKE R.L., MILLER Y.I., VASCULAR LIPID ACCUMULATION, LIPOPROTEIN OXIDATION, AND MACROPHAGE LIPID UPTAKE IN HYPERCHOLESTEROLEMIC ZEBRAFISH, CIRC RES, 104, PP. 952-960, (2009); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION, AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J CLIN INVEST, 34, PP. 1345-1353, (1955); PONGOR S., ULRICH P.C., BENCSATH F.A., CERAMI A., AGING OF PROTEINS: ISOLATION, AND IDENTIFICATION OF A FLUORESCENT CHROMOPHORE FROM THE REACTION OF POLYPEPTIDES WITH GLUCOSE, PROC NATL ACAD SCI USA, 81, PP. 2684-2688, (1984); CHO K.H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I, AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOL CELLS, 27, PP. 291-297, (2009); YOON J.H., CHO K.H., A POINT MUTANT OF APOLIPOPROTEIN A-I (V156K) SHOWED ENHANCEMENT OF CELLULAR INSULIN SECRETION, AND POTENT ACTIVITY OF FACULTATIVE REGENERATION IN ZEBRAFISH, REJUVENATION RES, 15, PP. 313-321, (2012); KIM S.M., KIM J.M., SHIN D.G., KIM J.R., CHO K.H., RELATION OF ATRIAL FIBRILLATION (AF), AND CHANGE OF LIPOPROTEINS: MALE PATIENTS WITH AF EXHIBITED SEVERE PRO-INFLAMMATORY, AND PRO-ATHEROGENIC PROPERTIES IN LIPOPROTEINS, CLIN BIOCHEM, 47, PP. 869-875, (2014); PARK K.H., CHO K.H., A ZEBRAFISH MODEL FOR THE RAPID EVALUATION OF PRO-OXIDATIVE, AND INFLAMMATORY DEATH BY LIPOPOLYSACCHARIDE, OXIDIZED LOW-DENSITY LIPOPROTEINS, AND GLYCATED HIGH-DENSITY LIPOPROTEINS, FISH SHELLFISH IMMUNOL, 31, PP. 904-910, (2011); KIM S.H., LEE E.Y., CHO K.H., INCORPORATION OF HUMAN GROWTH HORMONE-2 INTO PROTEOLIPOSOME ENHANCES TISSUE REGENERATION WITH ANTI-OXIDANT, AND ANTI-SENESCENCE ACTIVITIES, REJUVENATION RES, 18, PP. 20-29, (2015); PARK K.H., KIM J.M., CHO K.H., ELAIDIC ACID (EA) GENERATES DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS, AND CONSUMPTION OF EA EXACERBATES HYPERLIPIDEMIA, AND FATTY LIVER CHANGE IN ZEBRAFISH, MOL NUTR FOOD RES, 58, PP. 1537-1545, (2014); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT GENET, 4, PP. 356-361, (2008); BLOIS M.S., ANTIOXIDANT DETERMINATION BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-2000, (1958); MINEO C., DEGUCHI H., GRIFFIN J.H., SHAUL P.W., ENDOTHELIAL, AND ANTITHROMBOTIC ACTIONS OF HDL, CIRC RES, 98, PP. 1352-1364, (2006); ZHANG M., CHARLES R., TONG H., ZHANG L., PATEL M., WANG F., RAMES M.J., REN A., RYE K.A., QIU X., JOHNS D.G., CHARLES M.A., REN G., HDL SURFACE LIPIDS MEDIATE CETP BINDING AS REVEALED BY ELECTRON MICROSCOPY, AND MOLECULAR DYNAMICS SIMULATION, SCI REP, 5, (2015); RANALLETTA M., BIERILO K.K., CHEN Y., MILOT D., CHEN Q., TUNG E., HOUDE C., ELOWE N.H., GARCIA-CALVO M., PORTER G., EVELAND S., FRANTZ-WATTLEY B., KAVANA M., ADDONA G., SINCLAIR P., SPARROW C., O'NEILL E.A., KOBLAN K.S., SITLANI A., HUBBARD B., FISHER T.S., BIOCHEMICAL CHARACTERIZATION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, J LIPID RES, 51, PP. 2739-2752, (2010); CILPA-KARHU G., JAUHIAINEN M., RIEKKOLA M.L., ATOMISTIC MD SIMULATION REVEALS THE MECHANISM BY WHICH CETP PENETRATES INTO HDL ENABLING LIPID TRANSFER FROM HDL TO CETP, J LIPID RES, 56, PP. 98-108, (2015); IHM J., QUINN D.M., BUSCH S.J., CHATAING B., HARMONY J.A., KINETICS OF PLASMA PROTEIN-CATALYZED EXCHANGE OF PHOSPHATIDYLCHOLINE, AND CHOLESTERYL ESTER BETWEEN PLASMA LIPOPROTEINS, J LIPID RES, 23, PP. 1328-1341, (1982); POTTER L.K., SPRECHER D.L., WALKER M.C., TOBIN F.L., MECHANISM OF INHIBITION DEFINES CETP ACTIVITY: A MATHEMATICAL MODEL FOR CETP IN VITRO, J LIPID RES, 50, PP. 2222-2234, (2009); WANG S., KUSSIE P., DENG L., TALL A., DEFECTIVE BINDING OF NEUTRAL LIPIDS BY A CARBOXYL-TERMINAL DELETION MUTANT OF CHOLESTERYL ESTER TRANSFER PROTEIN. EVIDENCE FOR A CARBOXYLTERMINAL CHOLESTERYL ESTER BINDING SITE ESSENTIAL FOR NEUTRAL LIPID TRANSFER ACTIVITY, J BIOL CHEM, 270, PP. 612-618, (1995); IHM S., YOO J.A., CHO K.H., ENHANCEMENT OF HDL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE, AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, (2015); GRIFFIN A., WOMEN'S HEALTH, AND THE ARTICULATION OF POLICY PREFERENCES SETTING THE TERMS OF DISCUSSION, ANN NY ACAD SCI, 736, PP. 205-216, (1994); PARK K.H., JANG W., KIM K.Y., KIM J.R., CHO K.H., FRUCTATED APOLIPOPROTEIN A-I SHOWED SEVERE STRUCTURAL MODIFICATION, AND LOSS OF BENEFICIAL FUNCTIONS IN LIPID-FREE, AND LIPID-BOUND STATE WITH ACCELERATION OF ATHEROSCLEROSIS, AND SENESCENCE, BIOCHEM BIOPHYS RES COMMUN, 392, PP. 295-300, (2010); PARK K.H., CHO K.H., HIGH-DENSITY LIPOPROTEIN (HDL) FROM ELDERLY, AND RECONSTITUTED HDL CONTAINING GLYCATED APOLIPOPROTEINS A-I SHARE PROATHEROSCLEROTIC, AND PROSENESCENT PROPERTIES WITH INCREASED CHOLESTEROL INFLUX, J GERONTOL A BIOL SCI MED SCI, 66, PP. 511-520, (2011); KARADAG A.S., TUTAL E., ERTUGRUL D.T., INSULIN RESISTANCE IS INCREASED IN PATIENTS WITH VITILIGO, ACTA DERM VENEREOL, 91, PP. 541-544, (2011); MCMAHON M., GROSSMAN J., FITZGERALD J., DAHLIN-LEE E., WALLACE D.J., THONG B.Y., BADSHA H., KALUNIAN K., CHARLES C., NAVAB M., FOGELMAN A.M., HAHN B.H., PROINFLAMMATORY HIGHDENSITY LIPOPROTEIN AS A BIOMARKER FOR ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, AND RHEUMATOID ARTHRITIS, ARTHRITIS RHEUM, 54, PP. 2541-2549, (2006); INAZU A., BROWN M.L., HESLER C.B., AGELLON L.B., KOIZUMI J., TAKATA K., MARUHAMA Y., MABUCHI H., TALL A.R., INCREASED HIGH-DENSITY LIPOPROTEIN LEVELS CAUSED BY A COMMON CHOLESTERYL-ESTER TRANSFER PROTEIN GENE MUTATION, N ENGL J MED, 323, PP. 1234-1238, (1990); GARCIA-GONZALEZ V., MAS-OLIVA J., AMYLOID FIBRIL FORMATION OF PEPTIDES DERIVED FROM THE C-TERMINUS OF CETP MODULATED BY LIPIDS, BIOCHEM BIOPHYS RES COMMUN, 434, PP. 54-59, (2013); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY, AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPIDLOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006)","K.-H. CHO; SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","MARY ANN LIEBERT INC.","ENGLISH","REJUVENATION RES.","ARTICLE","ISI","2-S2.0-84964770321","REJUVENATION RES","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"LEE E-Y, 2016, REJUVENATION RES","LEE E-Y, 2016, REJUVENATION RES"
"CHO K;KIM S;YADAV D;KIM J;KIM J","CHO, KYUNG-HYUN (7403956966); KIM, SUK-JEONG (57193310178); YADAV, DHANANJAY (55779022200); KIM, JAE-YONG (54179286000); KIM, JAE-RYONG (7601360934)","CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS RANDOMIZED DOUBLEBLINDED AND PLACEBOCONTROLLED STUDY",2018,"OXIDATIVE MEDICINE AND CELLULAR LONGEVITY","2018","",28,"10.1155/2018/4809525","DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, SMART-AGING CONVERGENCE RESEARCH CENTER, COLLEGE OF MEDICINE, YEUNGNAM UNIVERSITY, DAEGU, 705-717, SOUTH KOREA","POLICOSANOL HAS BEEN REPORTED TO IMPROVE BLOOD PRESSURE, LIPID PROFILE, AND HDL FUNCTIONALITY VIA INHIBITION OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) BOTH IN VITRO AND IN VIVO IN ZEBRAFISH AND HUMAN MODELS. HOWEVER, THERE ARE LIMITED REPORTS AND RANDOMIZED, DOUBLE-BLINDED TRIALS ON POLICOSANOL THAT COULD ADVOCATE THE BLOOD PRESSURE-LOWERING EFFECT IN PREHYPERTENSIVE PARTICIPANTS. THEREFORE, WE PERFORMED IN VITRO, IN VIVO, AND EX VIVO EXPERIMENTS TO PROVIDE MORE SUBSTANTIAL AND CONCRETE DATA ON THE BLOOD PRESSURE-LOWERING EFFECT OF POLICOSANOL. CONSUMPTION OF POLICOSANOL FOR 8 WEEKS ENHANCED PLASMA ANTIOXIDANT ACTIVITY. IN THE POLICOSANOL GROUP, PLASMA TOTAL CHOLESTEROL (TC) AND TRIGLYCERIDE (TG) LEVELS WERE REDUCED UP TO 20% AND 14%, RESPECTIVELY, AND HDL-C LEVEL WAS ELEVATED UP TO 1.3-FOLD COMPARED TO THAT AT WEEK 0. TG/HDL-C AND CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITIES WERE REDUCED UP TO 36% AND 20%, RESPECTIVELY. UPTAKE OF OXIDIZED LDL IN MACROPHAGES WAS REDUCED AS OXIDIZED SPECIES LEVELS WERE REDUCED, AND HDL2-ASSOCIATED PARAOXONASE ACTIVITIES WERE ENHANCED BY 60% COMPARED TO THOSE AT WEEK 0. ENCAPSULATION OF POLICOSANOL INTO RECONSTITUTED HDL (PCO-RHDL) ENHANCED CHOLESTEROL EFFLUX ACTIVITY AND INSULIN SECRETION CAPACITY. IN CONCLUSION, CONSUMPTION OF POLICOSANOL FOR 8 WEEKS IN HEALTHY FEMALE SUBJECTS RESULTED IN LOWERED BLOOD PRESSURE AND CETP ACTIVITY VIA ELEVATION OF HDL/APOA-I CONTENTS AND ENHANCEMENT OF HDL FUNCTIONALITIES, INCLUDING CHOLESTEROL EFFLUX AND INSULIN SECRETION. THESE FUNCTIONAL ENHANCEMENTS OF HDL CAN CONTRIBUTE TO THE PREVENTION OF AGING-RELATED DISEASES, HYPERTENSION, AND STROKE. COPYRIGHT © 2018 KYUNG-HYUN CHO ET AL.","","BLOOD; CONSUMPTION; ESTERS; PRESSURE; PROFILES; PROTEINS; STEROLS; ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERTENSION; LIPIDS; LIPOPROTEINS, HDL; MIDDLE AGED; PLACEBO EFFECT; TRIGLYCERIDES; YOUNG ADULT; BLOOD; BLOOD PRESSURE; CHOLESTEROL; ESTERS; INSULIN; PROTEINS; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; FATTY ALCOHOL; HDL-TRIGLYCERIDE; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPID; POLICOSANOL; TRIACYLGLYCEROL; CHOLESTEROL EFFLUX; CHOLESTERYL ESTER TRANSFER PROTEINS; FUNCTIONAL ENHANCEMENTS; INSULIN SECRETION; LIPID PROFILE; PLASMA ANTIOXIDANT ACTIVITIES; TOTAL CHOLESTEROLS; TRIGLYCERIDE LEVELS; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INTRA-ABDOMINAL FAT; KOREAN (PEOPLE); MACROPHAGE; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; BLOOD; BLOOD PRESSURE; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; PLACEBO EFFECT; YOUNG ADULT; PRESSURE EFFECTS","MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING OF KOREA; NATIONAL RESEARCH FOUNDATION; MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP; NATIONAL RESEARCH FOUNDATION OF KOREA, NRF","THIS WORK WAS SUPPORTED BY THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF), FUNDED BY THE MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING OF KOREA. THE AUTHORS THANK KI-HOON PARK AND SEONG-MIN KIM FOR THEIR TECHNICAL ASSISTANCE.","RYE K.-A., BURSILL C.A., LAMBERT G., TABET F., BARTER P.J., THE METABOLISM AND ANTI-ATHEROGENIC PROPERTIES OF HDL, JOURNAL OF LIPID RESEARCH, 50, PP. S195-S200, (2009); CHO K.-H., BIOMEDICINAL IMPLICATIONS OF HIGH-DENSITY LIPOPROTEIN: ITS COMPOSITION, STRUCTURE, FUNCTIONS, AND CLINICAL APPLICATIONS, BMB REPORTS, 42, 7, PP. 393-400, (2009); DRAGAN S., SERBAN C., BANACH M., CAN WE CHANGE THE FUNCTIONALITY OF HDL CHOLESTEROL WITH NONPHARMACOLOGICAL AND PHARMACOLOGICAL AGENTS?, CURRENT MEDICINAL CHEMISTRY, 21, 25, PP. 2927-2946, (2014); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); FERNANDEZ S., ROSA M., GAMEZ R., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, THE AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2, 4, PP. 219-229, (2004); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE? (POLICOSANOL), ALTERNATIVE MEDICINE REVIEW, 7, 3, PP. 203-217, (2002); LIM S.-M., YOO J.-A., LEE E.-Y., CHO K.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RESEARCH, 19, 1, PP. 59-70, (2016); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RESEARCH, 19, 2, PP. 149-158, (2016); KIM J.-Y., KIM S.-M., KIM S.-J., LEE E.-Y., KIM J.-R., CHO K.-H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 39, 4, PP. 889-899, (2017); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT, PHYTOTHERAPY RESEARCH, 27, 2, PP. 264-271, (2013); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHERAPY RESEARCH, 22, 3, PP. 318-322, (2008); GONG J., QIN X., YUAN F., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOLECULAR NUTRITION & FOOD RESEARCH, 62, 1, (2018); LI W., WANG X., LU L., LI H., DISCREPANCY OF BLOOD PRESSURE BETWEEN THE BRACHIAL ARTERY AND RADIAL ARTERY, WORLD JOURNAL OF EMERGENCY MEDICINE, 4, 4, PP. 294-297, (2013); SHARMAN J.E., LAURENT S., CENTRAL BLOOD PRESSURE IN THE MANAGEMENT OF HYPERTENSION: SOON REACHING THE GOAL?, JOURNAL OF HUMAN HYPERTENSION, 27, 7, PP. 405-411, (2013); CHEN S.-L., ZHANG F.-F., XU J., ET AL., PULMONARY ARTERY DENERVATION TO TREAT PULMONARY ARTERIAL HYPERTENSION: THE SINGLE-CENTER, PROSPECTIVE, FIRST-IN-MAN PADN-1 STUDY (FIRST-IN-MAN PULMONARY ARTERY DENERVATION FOR TREATMENT OF PULMONARY ARTERY HYPERTENSION), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 62, 12, PP. 1092-1100, (2013); YASMIN, BROWN M.J., SIMILARITIES AND DIFFERENCES BETWEEN AUGMENTATION INDEX AND PULSE WAVE VELOCITY IN THE ASSESSMENT OF ARTERIAL STIFFNESS, QJM, 92, 10, PP. 595-600, (1999); BUTLIN M., QASEM A., LARGE ARTERY STIFFNESS ASSESSMENT USING SPHYGMOCOR TECHNOLOGY, PULSE, 4, 4, PP. 180-192, (2017); BENZIE I.F.F., STRAIN J.J., THE FERRIC REDUCING ABILITY OF PLASMA (FRAP) AS A MEASURE OF “ANTIOXIDANT POWER”: THE FRAP ASSAY, ANALYTICAL BIOCHEMISTRY, 239, 1, PP. 70-76, (1996); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, THE JOURNAL OF CLINICAL INVESTIGATION, 34, 9, PP. 1345-1353, (1955); MARKWELL M.A.K., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANALYTICAL BIOCHEMISTRY, 87, 1, PP. 206-210, (1978); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, 4617, PP. 1199-1200, (1958); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, 6, PP. 1901-1907, (1988); CHO K.-H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOLECULES AND CELLS, 27, 3, PP. 291-297, (2009); ECKERSON H.W., WYTE C.M., LA DU B., THE HUMAN SERUM PARAOXONASE/ARYLESTERASE POLYMORPHISM, AMERICAN JOURNAL OF HUMAN GENETICS, 35, 6, PP. 1126-1138, (1983); PARK K.-H., SHIN D.-G., KIM J.-R., HONG J.-H., CHO K.-H., THE FUNCTIONAL AND COMPOSITIONAL PROPERTIES OF LIPOPROTEINS ARE ALTERED IN PATIENTS WITH METABOLIC SYNDROME WITH INCREASED CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 25, 1, PP. 129-136, (2010); PARK K.-H., JANG W., KIM K.-Y., KIM J.-R., CHO K.-H., FRUCTATED APOLIPOPROTEIN A-I SHOWED SEVERE STRUCTURAL MODIFICATION AND LOSS OF BENEFICIAL FUNCTIONS IN LIPID-FREE AND LIPID-BOUND STATE WITH ACCELERATION OF ATHEROSCLEROSIS AND SENESCENCE, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 392, 3, PP. 295-300, (2010); ASZTALOS B.F., DE LA LLERA-MOYA M., DALLAL G.E., HORVATH K.V., SCHAEFER E.J., ROTHBLAT G.H., DIFFERENTIAL EFFECTS OF HDL SUBPOPULATIONS ON CELLULAR ABCA1- AND SR-BI-MEDIATED CHOLESTEROL EFFLUX, JOURNAL OF LIPID RESEARCH, 46, 10, PP. 2246-2253, (2005); PARK K.-H., KIM J.-Y., CHOI I., KIM J.-R., WON K.C., CHO K.-H., FRUCTATED APOLIPOPROTEIN A-I EXACERBATES CELLULAR SENESCENCE IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS ACCOMPANIED BY IMPAIRED INSULIN SECRETION ACTIVITY AND EMBRYO TOXICITY, BIOCHEMISTRY AND CELL BIOLOGY, 94, 4, PP. 337-345, (2016); YOON J.-H., CHO K.-H., A POINT MUTANT OF APOLIPOPROTEIN A-I (V156K) SHOWED ENHANCEMENT OF CELLULAR INSULIN SECRETION AND POTENT ACTIVITY OF FACULTATIVE REGENERATION IN ZEBRAFISH, REJUVENATION RESEARCH, 15, 3, PP. 313-321, (2012); LEE H.H., PARK J.E., CHOI I.H., CHO K.H., ENHANCED FUNCTIONAL AND STRUCTURAL PROPERTIES OF HIGH-DENSITY LIPOPROTEINS FROM RUNNERS AND WRESTLERS COMPARED TO THROWERS AND LIFTERS, BMB REPORTS, 42, 9, PP. 605-610, (2009); CUELLAR L.A., PRIETO E.D., CABALEIRO L.V., GARDA H.A., APOLIPOPROTEIN A-I CONFIGURATION AND CELL CHOLESTEROL EFFLUX ACTIVITY OF DISCOIDAL LIPOPROTEINS DEPEND ON THE RECONSTITUTION PROCESS, BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1841, 1, PP. 180-189, (2014); VON ECKARDSTEIN A., WIDMANN C., HIGH-DENSITY LIPOPROTEIN, BETA CELLS, AND DIABETES, CARDIOVASCULAR RESEARCH, 103, 3, PP. 384-394, (2014); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERREIRO R.M., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, 3, PP. 393-397, (1995); XU K., LIU X., LI Y., ET AL., SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ON-TREATMENT PLATELET REACTIVITY AFTER DRUG-ELUTING STENT IMPLANTATION: TWO-YEAR FOLLOW-UP RESULTS, CARDIOVASCULAR THERAPEUTICS, 34, 5, PP. 337-342, (2016); LEE J.H., JIA Y., THACH T.T., ET AL., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTRITION RESEARCH, 43, PP. 89-99, (2017); FULLERTON M.D., FORD R.J., MCGREGOR C.P., ET AL., SALICYLATE IMPROVES MACROPHAGE CHOLESTEROL HOMEOSTASIS VIA ACTIVATION OF AMPK, JOURNAL OF LIPID RESEARCH, 56, 5, PP. 1025-1033, (2015); MA A., WANG J., YANG L., AN Y., ZHU H., AMPK ACTIVATION ENHANCES THE ANTI-ATHEROGENIC EFFECTS OF HIGH DENSITY LIPOPROTEINS IN APOE<SUP>−</SUP>/<SUP>−</SUP> MICE, JOURNAL OF LIPID RESEARCH, 58, 8, PP. 1536-1547, (2017); KIM J.-Y., LEE E.-Y., PARK J.K., SONG Y.W., KIM J.-R., CHO K.-H., PATIENTS WITH RHEUMATOID ARTHRITIS SHOW ALTERED LIPOPROTEIN PROFILES WITH DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS THAT CAN EXACERBATE INFLAMMATORY AND ATHEROGENIC PROCESS, PLOS ONE, 11, 10, (2016); BOTTA E., MERONO T., SAUCEDO C., ET AL., ASSOCIATIONS BETWEEN DISEASE ACTIVITY, MARKERS OF HDL FUNCTIONALITY AND ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS, ATHEROSCLEROSIS, 251, PP. 438-444, (2016); ARAI T., YAMASHITA S., HIRANO K., ET AL., INCREASED PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN IN OBESE SUBJECTS. A POSSIBLE MECHANISM FOR THE REDUCTION OF SERUM HDL CHOLESTEROL LEVELS IN OBESITY, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 14, 7, PP. 1129-1136, (1994); ZHOU M., ZHU L., CUI X., ET AL., THE TRIGLYCERIDE TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (TG/HDL-C) RATIO AS A PREDICTOR OF INSULIN RESISTANCE BUT NOT OF Β CELL FUNCTION IN A CHINESE POPULATION WITH DIFFERENT GLUCOSE TOLERANCE STATUS, LIPIDS IN HEALTH AND DISEASE, 15, 1, (2016); CATRYSSE L., VAN LOO G., INFLAMMATION AND THE METABOLIC SYNDROME: THE TISSUE-SPECIFIC FUNCTIONS OF NF-ΚB, TRENDS IN CELL BIOLOGY, 27, 6, PP. 417-429, (2017); HUANG C.Y., HUANG H.L., YANG K.C., ET AL., SERUM TRIGLYCERIDE LEVELS INDEPENDENTLY CONTRIBUTE TO THE ESTIMATION OF VISCERAL FAT AMOUNT AMONG NONDIABETIC OBESE ADULTS, MEDICINE, 94, 23, (2015); YILDIRIM B., SABIR N., KALELI B., RELATION OF INTRA-ABDOMINAL FAT DISTRIBUTION TO METABOLIC DISORDERS IN NONOBESE PATIENTS WITH POLYCYSTIC OVARY SYNDROME, FERTILITY AND STERILITY, 79, 6, PP. 1358-1364, (2003); MATSUZAWA Y., SHIMOMURA I., NAKAMURA T., KENO Y., KOTANI K., TOKUNAGA K., PATHOPHYSIOLOGY AND PATHOGENESIS OF VISCERAL FAT OBESITY, OBESITY RESEARCH, 3, S2, PP. 187S-194S, (1995); SHANTHA G.P.S., KUMAR A.A., KAHAN S., IRUKULLA P.K., CHESKIN L.J., TRIGLYCERIDE/HDL RATIO AS A SCREENING TOOL FOR PREDICTING SUCCESS AT REDUCING ANTI-DIABETIC MEDICATIONS FOLLOWING WEIGHT LOSS, PLOS ONE, 8, 7, (2013); KANAI H., MATSUZAWA Y., KOTANI K., ET AL., CLOSE CORRELATION OF INTRA-ABDOMINAL FAT ACCUMULATION TO HYPERTENSION IN OBESE WOMEN, HYPERTENSION, 16, 5, PP. 484-490, (1990); FEINGOLD K.R., GRUNFELD C., EFFECT OF INFLAMMATION ON HDL STRUCTURE AND FUNCTION, CURRENT OPINION IN LIPIDOLOGY, 27, 5, PP. 521-530, (2016); MCNULTY M., MAHMUD A., FEELY J., ADVANCED GLYCATION END-PRODUCTS AND ARTERIAL STIFFNESS IN HYPERTENSION, AMERICAN JOURNAL OF HYPERTENSION, 20, 3, PP. 242-247, (2007); LIU C.Y., HUANG Q.F., CHENG Y.B., ET AL., A COMPARATIVE STUDY ON SKIN AND PLASMA ADVANCED GLYCATION END PRODUCTS AND THEIR ASSOCIATIONS WITH ARTERIAL STIFFNESS, PULSE, 4, 4, PP. 208-218, (2017); GANJALI S., BLESSO C.N., BANACH M., PIRRO M., MAJEED M., SAHEBKAR A., EFFECTS OF CURCUMIN ON HDL FUNCTIONALITY, PHARMACOLOGICAL RESEARCH, 119, PP. 208-218, (2017); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTRITION REVIEWS, 75, 9, PP. 731-767, (2017); SERBAN C., SAHEBKAR A., URSONIU S., ANDRICA F., BANACH M., EFFECT OF SOUR TEA (HIBISCUS SABDARIFFA L.) ON ARTERIAL HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, JOURNAL OF HYPERTENSION, 33, 6, PP. 1119-1127, (2015); TEOH C.L., GRIFFIN M.D.W., HOWLETT G.J., APOLIPOPRO-TEINS AND AMYLOID FIBRIL FORMATION IN ATHEROSCLEROSIS, PROTEIN & CELL, 2, 2, PP. 116-127, (2011); DAS M., WILSON C.J., MEI X., WALES T.E., ENGEN J.R., GURSKY O., STRUCTURAL STABILITY AND LOCAL DYNAMICS IN DISEASE-CAUSING MUTANTS OF HUMAN APOLIPOPROTEIN A-I: WHAT MAKES THE PROTEIN AMYLOIDOGENIC?, JOURNAL OF MOLECULAR BIOLOGY, 428, 2, PP. 449-462, (2016); ISHIGURO N., MAEDA K., SAITO A., ET AL., ESTABLISHMENT OF A SET OF DOUBLE TRANSFECTANTS COEXPRESSING ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3 AND HEPATIC EFFLUX TRANSPORTERS FOR THE CHARACTERIZATION OF THE HEPATOBILIARY TRANSPORT OF TELMISARTAN ACYLGLUCURONIDE, DRUG METABOLISM AND DISPOSITION, 36, 4, PP. 796-805, (2008); WEISS J., SAUER A., DIVAC N., ET AL., INTERACTION OF ANGIOTENSIN RECEPTOR TYPE 1 BLOCKERS WITH ATP-BINDING CASSETTE TRANSPORTERS, BIOPHARMACEUTICS & DRUG DISPOSITION, 31, 2-3, PP. 150-161, (2010); PERLSTEIN T.S., GUMIENIAK O., WILLIAMS G.H., ET AL., URIC ACID AND THE DEVELOPMENT OF HYPERTENSION: THE NORMATIVE AGING STUDY, HYPERTENSION, 48, 6, PP. 1031-1036, (2006); SAITO I., SARUTA T., KONDO K., ET AL., SERUM URIC ACID AND THE RENIN-ANGIOTENSIN SYSTEM IN HYPERTENSION, JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 26, 6, PP. 241-247, (1978); XANTHAKIS V., VASAN R.S., ALDOSTERONE AND THE RISK OF HYPERTENSION, CURRENT HYPERTENSION REPORTS, 15, 2, PP. 102-107, (2013)","K.-H. CHO; DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","HINDAWI LIMITED","ENGLISH","OXIDATIVE MED. CELL. LONGEVITY","ARTICLE","ISI","2-S2.0-85050383568","OXIDATIVE MED CELL LONGEVITY","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"CHO K-H, 2018, OXIDATIVE MED CELL LONGEVITY","CHO K-H, 2018, OXIDATIVE MED CELL LONGEVITY"
"ISHAKA A;IMAM M;ISMAIL M","ISHAKA, AMINU (55944603100); IMAM, MUSTAPHA UMAR (57469476100); ISMAIL, MAZNAH (57191087465)","NANOEMULSIFICATION OF RICE BRAN WAX POLICOSANOL ENHANCES ITS CARDIOPROTECTIVE EFFECTS VIA MODULATION OF HEPATIC PEROXISOME PROLIFERATORACTIVATED RECEPTOR GAMMA IN HYPERLIPIDEMIC RATS",2020,"JOURNAL OF OLEO SCIENCE","69","8",4,"10.5650/jos.ess20098","DEPARTMENT OF MEDICAL BIOCHEMISTRY, COLLEGE OF HEALTH SCIENCES, USMANU DANFODIYO UNIVERSITY, SOKOTO, NIGERIA;DEPARTMENT OF MEDICAL BIOCHEMISTRY, COLLEGE OF HEALTH SCIENCES, USMANU DANFODIYO UNIVERSITY, SOKOTO, NIGERIA, CENTRE FOR ADVANCE MEDICAL RESEARCH AND TRAINING (CAMRET), NIGERIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, SELANGOR, MALAYSIA","POLICOSANOL, A MIXTURE OF LONG-CHAIN ALCOHOLS FOUND IN ANIMAL AND PLANT WAXES, HAS SEVERAL BIOLOGICAL EFFECTS INCLUDING LIPID-LOWERING THAT HAVE BEEN EXTENSIVELY STUDIED. HOWEVER, ITS BIOAVAILABILITY IS LOW. TO INVESTIGATE THE EFFECT OF NANOEMULSIFIED RICE BRAN WAX POLICOSANOL (NPOL) ON PLASMA HOMOCYSTEINE, HEART AND LIVER HISTOLOGY IN HYPERLIPIDEMIC RATS, HIGH-FAT DIET CONTAINING 2.5% CHOLESTEROL WAS USED TO INDUCE HYPERLIPIDEMIA IN SPRAGUE DAWLEY RATS. THE HYPERLIPIDEMIC RATS WERE TREATED WITH NPOL AND RICE BRAN WAX POLICOSANOL (POL) IN COMPARISON WITH NORMAL DIET (ND), HIGH-CHOLESTEROL DIET (HCD) AND SIMVASTATIN-TREATED RATS. PLASMA HOMOCYSTEINE, HEART AND LIVER HISTOLOGY, AND HEPATIC MRNA EXPRESSION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) WERE EVALUATED. THE NPOL GROUP, SIMILAR TO THE SIMVASTATIN GROUP, SHOWED REDUCED PLASMA HOMOCYSTEINE, PRESERVED HEART AND LIVER HISTOLOGY, AND DOWN-REGULATED HEPATIC PPARG MRNA IN COMPARISON TO THE CONTROL GROUP, AND WAS BETTER THAN THE POL GROUP. THE RESULTS SUGGEST THAT THE MODEST EFFECT OF NPOL ON HOMOCYSTEINE AND PRESERVATION OF HEART AND LIVER HISTOLOGY COULD BE THROUGH THE REGULATION OF PPARG EXPRESSION ON A BACKGROUND OF INCREASED ASSIMILATION OF RICE BRAN WAX POLICOSANOL. © 2020 BY JAPAN OIL CHEMISTS’ SOCIETY.","HEART AND LIVER HISTOLOGY; HOMOCYSTEINE; NANOEMULSION; POLICOSANOL; PPARG","ANIMALS; CARDIOTONIC AGENTS; DIET, HIGH-FAT; FATTY ALCOHOLS; GENE EXPRESSION; HOMOCYSTEINE; HYPERLIPIDEMIAS; LIVER; MALE; MYOCARDIUM; ORYZA; PHYTOTHERAPY; PPAR GAMMA; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; WAXES; BIOCHEMISTRY; CHOLESTEROL; CYTOLOGY; HEART; HISTOLOGY; CARDIOTONIC AGENT; FATTY ALCOHOL; HOMOCYSTEINE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLICOSANOL; WAX; BIOLOGICAL EFFECTS; HIGH CHOLESTEROLS; LONG CHAIN ALCOHOLS; MRNA EXPRESSION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PLASMA HOMOCYSTEINE; PROTECTIVE EFFECTS; SPRAGUE-DAWLEY RATS; ADVERSE EVENT; ANIMAL; BLOOD; CARDIAC MUSCLE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION; GENETICS; HYPERLIPIDEMIA; LIPID DIET; LIVER; MALE; METABOLISM; ORYZA; PATHOLOGY; PHYTOTHERAPY; SPRAGUE DAWLEY RAT; RATS","BERNAS; PADI BERAS NATIONA; PADI BERAS NATIONAL; UNIVERSITY PUTRA MALAYSI; UNIVERSITI PUTRA MALAYSIA, (6364705)","FUNDING TEXT 1: THE AUTHORS THANK THE SPONSORS OF THIS STUDY: THE PADI BERAS NATIONA（L BERNAS）RICE COMPANY IN MALAYSIA AND UNIVERSITY PUTRA MALAYSI（A UPM）（ GRANT NO.6364705）. WE ALSO WISH TO THANK THE STAFF OF THE LABORATORY OF MOLECULAR BIOMEDICINE FOR THEIR SUPPORT IN THIS STUDY.; FUNDING TEXT 2: THE AUTHORS THANK THE SPONSORS OF THIS STUDY: THE PADI BERAS NATIONAL(BERNAS)RICE COMPANY IN MALAYSIA AND UNIVERSITY PUTRA MALAYSIA (UPM)(GRANT NO. 6364705). WE ALSO WISH TO THANK THE STAFF OF THE LABORATORY OF MOLECULAR BIOMEDICINE FOR THEIR SUPPORT IN THIS STUDY.","ASSMANN G., CULLEN P., JOSSA F., LEWIS B., MANCINI M., CORONARY HEART DISEASE: REDUCING THE RISK. THE SCIENTIFIC BACKGROUND TO PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE. A WORLDWIDE VIEW, ARTERIO-SCLER THROMB. VASC. BIOL, 19, PP. 1819-1824, (1999); LUCAS A.J., ATHEROSCLEROSIS, NATURE, 407, PP. 233-241, (2000); KANDA T., YOKOSUKA O., KOJIMA H., IMAZEKI F., NAGAO K., TATSUNO I., ET AL., SEVERE HYPERCHOLESTEROL-EMIA ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS IN A 44-YEAR-OLD JAPANESE WOMAN, WORLD J. GASTROENTEROL, 10, PP. 2607-2608, (2004); KANG B.-Y., WANG W., PALADE P., SHARMA S.G., MEHTA J.L., CARDIAC HYPERTROPHY DURING HYPERCHOLESTEROLEMIA AND ITS AMELIORATION WITH ROSUVASTATIN AND AMLODIPINE, J. CARDIOVASC. PHARMACOL, 54, 4, PP. 327-334, (2009); KALRA D.K., HOMOCYSTEINE AND CARDIOVASCULAR DISEASE, CURR. ATHEROSCLER. REP, 6, 2, PP. 101-106, (2004); REFSUM H., UELAND P.M., NYGARD O., VOLLSET S.E., HO-MOCYSTEINE AND CARDIOVASCULAR DISEASE, ANNU. REV. MED, 49, PP. 31-62, (1998); KARMIN O., LYNN E.G., CHUNG Y.H., SIOW Y.L., MAN R.Y.K., CHOY P.C., HOMOCYSTEINE STIMULATES THE PRODUCTION AND SECRETION OF CHOLESTEROL IN HEPATIC CELLS, BIOCHIM. BIOPHYS. ACTA, 1393, PP. 317-324, (1998); WANG Q., IMAM M.U., YIDA Z., WANG F., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA（PPARΓ）AS A TARGET FOR CONCURRENT MANAGEMENT OF DIABETES AND OBESITY-RELATED CANCER, CURR. PHARM. DES, 23, PP. 3677-3688, (2017); LEE C.-H., OLSON P., EVANS R.M., MINIREVIEW: LIPID METABOLISM, METABOLIC DISEASES, AND PEROXISOME PRO-LIFERATOR-ACTIVATED RECEPTORS, ENDOCRINOLOGY, 144, PP. 2201-2207, (2003); BISHOP-BAILEY D., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN THE CARDIOVASCULAR SYSTEM, BR. J. PHAR-MACOL, 129, PP. 823-834, (2000); SCHARNAGL H., MARZ W., NEW LIPID-LOWERING AGENTS ACT-ING ON LDL RECEPTORS, CURR. TOP MED. CHEM, 5, 3, PP. 233-242, (2005); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP. BIOL. MED, 241, PP. 1943-1949, (2016); LEE J.-Y., CHOI H.-Y., KANG Y.-R., CHANG H.-B., CHUN H.-S., LEE M.-S., ET AL., EFFECTS OF LONG-TERM SUPPLEMEN-TATION OF POLICOSANOL ON BLOOD CHOLESTEROL/GLUCOSE LEVELS AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUC-TASE ACTIVITY IN A RAT MODEL FED HIGH CHOLESTEROL DIETS, FOOD SCI. BIOTECHNOL, 25, PP. 899-904, (2016); SOLA R., VALLS R.-M., PUZO J., CALABUIG J.-R., BREA A., PEDRET A., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HY-PERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, 8, (2014); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROL-AEMIC PATIENTS, CLIN. DRUG INVESTIG, 25, 11, PP. 701-707, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON HYPER-CHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIO-CHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES, 57, PP. 568-577, (1996); KATO S., KARINO K.I., HASEGAWA S., NAGASAWA J., NA-GASAKI A., EGUCHI M., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR. J. NUTR, 73, PP. 433-442, (1995); ARRUZAZABALA M., DE L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES, 27, PP. 205-208, (1993); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LI-POPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BU-LITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, J. AM. MED. ASSOC, 295, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTRE-PO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RAN-DOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM. HEART J, 152, PP. E1-E5, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPER-CHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR, 84, PP. 1543-1548, (2006); SWANSON B., KEITHLEY J., POLICOSANOL TO MANAGE DYSLIP-IDEMIA IN OLDER ADULTS, COMPLEMENT. ALTERN. THER AG-ING POPUL. AN EVIDENCE-BASED APPROACH, PP. 117-134, (2009); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB, 37, PP. 33-38, (1993); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSA-NOL AND ITS NANOEMULSION FORMULATION, INT. J. NANO-MEDICINE, 9, (2014); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPO-PROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAM-STERS, J. AGRIC. FOOD CHEM, 53, PP. 6289-6293, (2005); HARINI M., ASTIRIN O.P., BLOOD CHOLESTEROL LEVELS OF HY-PERCHOLESTEROLEMIC RAT（RATTUS NORVEGICUS）AFTER VCO TREATMENT, NUSANT. BIOSCI, 1, 2, PP. 53-58, (2009); CHONG S.C., DOLLAH M.A., CHONG P.P., MAHA A., PHAL-ERIA MACROCARPA（SCHEFF.）BOERL FRUIT AQUEOUS EXTRACT ENHANCES LDL RECEPTOR AND PCSK9 EXPRESSION IN VIVO AND IN VITRO, J ETHNOPHARMACOL, 137, PP. 817-827, (2011); D'MELLO P.M., DARJI K.K., SHETGIRI P.P., EVALUATION OF ANTIOBESITY ACTIVITY OF VARIOUS PLANT EXTRACTS, PHARMA-COGN J, 3, 21, PP. 56-59, (2011); MATOS S.L., PAULA H. DE, PEDROSA M.L., SANTOS R.C., OLIVEIRA E.L., CHIANCA JUNIOR D.A., ET AL., DIETARY MODELS FOR INDUCING HYPERCHOLESTEROLEMIA IN RATS, BRAZILIAN ARCH. BIOL. TECHNOL, 48, PP. 203-209, (2005); BALZAN S., HERNANDES A., REICHERT C.L., DONADUZZI C., PIRES V.A., GASPAROTTO A., ET AL., LIPID-LOWERING EFFECTS OF STANDARDIZED EXTRACTS OF ILEX PARAGUARIENSIS IN HIGH-FAT-DIET RATS, FITOTERAPIA, 86, PP. 115-122, (2013); LIU S., TAN M.Y., ZHAO S.P., RONG H., EFFECTS OF POLI-COSANOL ON SERUM LIPIDS AND HEME OXYGENASE-1 IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 40, PP. 840-843, (2012); PANG W.-Y., HE F.-Y., WEI X.-M., EFFECTS OF POLICOSANOL ON SERUM CHOLESTEROL LEVELS IN HYPERLIPIDEMIA RATS, CHIN. J. PHARM. TOXICOL, 23, PP. 443-449, (2009); TANG M., WU S.Z., GONG X., EFFECTS OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA, ZHON-GHUA XIN XUE GUAN BING ZA ZHI, 41, PP. 488-492, (2013); CHOI W.-S., KIM Y.-S., PARK B.-S., KIM J.-E., LEE S.-E., HYPOLIPIDAEMIC EFFECT OF HERICIUM ERINACEUM GROWN IN ARTEMISIA CAPILLARIS ON OBESE RATS, MYCOBIOLOGY, 41, PP. 94-99, (2013); PANDE S., PLATEL K., SRINIVASAN K., ANTIHYPERCHOLES-TEROLAEMIC INFLUENCE OF DIETARY TENDER CLUSTER BEANS （CYAMOPSIS TETRAGONOLOBA）IN CHOLESTEROL FED RATS, INDIAN J. MED. RES, 135, 3, (2012); TUGRUL CABIOGLU M., ERGENE N., ELECTROACUPUNCTURE THERAPY FOR WEIGHT LOSS REDUCES SERUM TOTAL CHOLESTER-OL, TRIGLYCERIDES, AND LDL CHOLESTEROL LEVELS IN OBESE WOMEN, AM. J. CHIN. MED, 33, PP. 525-533, (2005); GRAHAM I.M., DALY L.E., REFSUM H.M., ROBINSON K., BRATTSTROM L.E., UELAND P.M., ET AL., PLASMA HOMOCYS-TEINE AS A RISK FACTOR FOR VASCULAR DISEASE: THE EUROPE-AN CONCERTED ACTION PROJECT, J. AM. MED. ASSOC, 277, PP. 1775-1781, (1997); WARD M., MCNULTY H., MCPARTLIN J., STRAIN J.J., WEIR D.G., SCOTT J.M., PLASMA HOMOCYSTEINE, A RISK FACTOR FOR CARDIOVASCULAR DISEASE, IS LOWERED BY PHYSIOLOGICAL DOSES OF FOLIC ACID, QJM, 90, PP. 519-524, (1997); JIANG S., CHEN Q., VENNERS S.A., ZHONG G., HSU Y., XING H., ET AL., EFFECT OF SIMVASTATIN ON PLASMA HOMO-CYSTEINE LEVELS AND ITS MODIFICATION BY MTHFR C677T POLYMORPHISM IN CHINESE PATIENTS WITH PRIMARY HYPER-LIPIDEMIA, CARDIOVASC. THER, 31, PP. E27-E33, (2013); RODEN M., ANDERWALD C., FURNSINN C., WALDHAUSL W., LOHNINGER A., EFFECTS OF SHORT-TERM LEPTIN EXPOSURE ON TRIGLYCERIDE DEPOSITION IN RAT LIVER, HEPATOLOGY, 32, PP. 1045-1049, (2000); BROWNING J.D., HORTON J.D., MOLECULAR MEDIATORS OF HEPATIC STEATOSIS AND LIVER INJURY, J. CLIN. INVEST, 114, PP. 147-152, (2004); CSONT T., BERECZKI E., BENCSIK P., FODOR G., GORBE A., ZVARA A., ET AL., HYPERCHOLESTEROLEMIA INCREASES MYO-CARDIAL OXIDATIVE AND NITROSATIVE STRESS THEREBY LEADING TO CARDIAC DYSFUNCTION IN APOB-100 TRANSGENIC MICE, CARDIOVASC. RES, 76, PP. 100-109, (2007); LIEBER C.S., LEO M.A., MAK K.M., XU Y., CAO Q., REN C., ET AL., MODEL OF NONALCOHOLIC STEATOHEPATITIS, AM. J. CLIN. NUTR, 79, PP. 502-509, (2004); NEUSCHWANDER-TETRI B.A., CALDWELL S.H., NONALCOHOLIC STEATOHEPATITIS: SUMMARY OF AN AASLD SINGLE TOPIC CONFERENCE, HEPATOLOGY, 37, PP. 1202-1219, (2003); PAN H., YANG Q., HUANG G., DING C., CAO P., HUANG L., ET AL., HYPOLIPIDEMIC EFFECTS OF CHITOSAN AND ITS DERIVATIVES IN HYPERLIPIDEMIC RATS INDUCED BY A HIGH-FAT DIET, FOOD NUTR. RES, 60, (2016); CEYLAN A., KARASU C., AKTAN F., GUVEN C., CAN B., OZANSOY G., EFFECTS OF SIMVASTATIN TREATMENT ON OXI-DANT/ANTIOXIDANT STATE AND ULTRASTRUCTURE OF DIABETIC RAT MYOCARDIUM, GEN. PHYSIOL. BIOPHYS, 22, PP. 535-548, (2003); TONTONOZ P., SPIEGELMAN B.M., FAT AND BEYOND: THE DIVERSE BIOLOGY OF PPARΓ, ANNU. REV. BIOCHEM, 77, PP. 289-312, (2008); LEHRKE M., LAZAR M.A., THE MANY FACES OF PPARΓ, CELL, 123, PP. 993-999, (2005); ROSEN E.D., SPIEGELMAN B.M., PPARΓ: A NUCLEAR REGU-LATOR OF METABOLISM, DIFFERENTIATION, AND CELL GROWTH, J. BIOL. CHEM, 276, PP. 37731-37734, (2001); MEDINA-GOMEZ G., GRAY S.L., YETUKURI L., SHIMOMU-RA K., VIRTUE S., CAMPBELL M., ET AL., PPAR GAMMA 2 PREVENTS LIPOTOXICITY BY CONTROLLING ADIPOSE TISSUE EX-PANDABILITY AND PERIPHERAL LIPID METABOLISM, PLOS GENET, 3, 4, (2007); IMAM M.U., ISHAKA A., OOI D.-J., ZAMRI N.D.M., SARE-GA N., ISMAIL M., ET AL., GERMINATED BROWN RICE REGU-LATES HEPATIC CHOLESTEROL METABOLISM AND CARDIOVASCULAR DISEASE RISK IN HYPERCHOLESTEROLAEMIC RATS, J. FUNCT. FOODS, 8, PP. 193-203, (2014); SEN U., RODRIGUEZ W.E., TYAGI N., KUMAR M., KUNDU S., TYAGI S.C., CIGLITAZONE, A PPARΓ AGONIST, AMELIO-RATES DIABETIC NEPHROPATHY IN PART THROUGH HOMOCYS-TEINE CLEARANCE, AM. J. PHYSIOL. METAB, 295, PP. E1205-E1212, (2008); ZHOU J.Y., ZHOU S.W., ZHANG K. BIN., TANG J.L., GUANG L.X., YING Y., ET AL., CHRONIC EFFECTS OF BERBERINE ON BLOOD, LIVER GLUCOLIPID METABOLISM AND LIVER PPARS EXPRESSION IN DIABETIC HYPERLIPIDEMIC RATS, BIOL. PHARM. BULL, 31, PP. 1169-1176, (2008); QIN Y., YE P., HE J., SHENG L., WANG L., DU J., SIMV-ASTATIN INHIBITED CARDIAC HYPERTROPHY AND FIBROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE FED A“WESTERN-STYLE DIET”BY INCREASING PPAR Α AND Γ EXPRESSION AND REDUCING TC, MMP-9, AND CAT S LEVELS, ACTA PHARMACOL. SIN, 31, (2010); LEE J., HONG E.M., KOH D.H., CHOI M.H., JANG H.J., KAE S.H., ET AL., HMG-COA REDUCTASE INHIBITORS （STATINS）ACTIVATE EXPRESSION OF PPARΑ/PPARΓ AND ABCA1 IN CULTURED GALLBLADDER EPITHELIAL CELLS, DIG. DIS. SCI, 55, PP. 292-299, (2010); ALMEIDA M., AMBROGINI E., HAN L., MANOLAGAS S.C., JILKA R.L., INCREASED LIPID OXIDATION CAUSES OXIDATIVE STRESS, INCREASED PEROXISOME PROLIFERATOR-ACTIVATED RE-CEPTOR-Γ EXPRESSION, AND DIMINISHED PRO-OSTEOGENIC WNT SIGNALING IN THE SKELETON, J. BIOL. CHEM, 284, PP. 27438-27448, (2009)","A. ISHAKA; DEPARTMENT OF MEDICAL BIOCHEMISTRY, COLLEGE OF HEALTH SCIENCES, USMANU DANFODIYO UNIVERSITY, SOKOTO, NIGERIA; EMAIL: ISHAKA.AMINU@UDUSOK.EDU.NG","JAPAN OIL CHEMISTS SOCIETY","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","2-S2.0-85092220697","J OLEO SCI","USMANU DANFODIYO UNIVERSITY;USMANU DANFODIYO UNIVERSITY;UNIVERSITY PUTRA MALAYSIA","NOTREPORTED;USMANU DANFODIYO UNIVERSITY;NOTREPORTED",NA,"ISHAKA A, 2020, J OLEO SCI","ISHAKA A, 2020, J OLEO SCI"
"CATAPANO A;GRAHAM I;DE B G;WIKLUND O;JOHN C M;DREXEL H;HOES A;JENNINGS C;LANDMESSER U;PEDERSEN T;REINER Ž;RICCARDI G;TASKINEN M;TOKGOZOGLU L;MONIQUE V W;VLACHOPOULOS C;WOOD D;ZAMORANO J;BADIMON L;FUNCK-BRENTANO C;AGEWALL S;BARÓN-ESQUIVIAS G;BORÉN J;BRUCKERT E;CORDERO A;CORSINI A;GIANNUZZI P;GUEYFFIER F;KRSTAČIĆ G;LETTINO M;LIONIS C;LIP G;MARQUES-VIDAL P;MILICIC D;PEDRO-BOTET J;PIEPOLI M;RIGOPOULOS A;RUSCHITZKA F;TUÑÓN J;VON E A;VRABLIK M;WEISS T;WILLIAMS B;WINDECKER S;ZIMLICHMAN R;ABOYANS V;ACHENBACH S;BAUMGARTNER H;BAX J;BUENO H;CARERJ S;DEAN V;EROL Ç;FITZSIMONS D;GAEMPERLI O;KIRCHHOF P;KOLH P;LANCELLOTTI P;NIHOYANNOPOULOS P;PONIKOWSKI P;ROFFI M;TORBICKI A;VAZ C A;ZELVEIAN P;SIOSTRZONEK P;IBRAHIMOV F;SUJAYEVA V;CLAEYS M;POJSKIĆ B;POSTADZHIYAN A;GEORGIOU G;ROSOLOVA H;KLAUSEN C;VIIGIMAA M;KERVINEN K;KEDEV S;FERRIÈRES J;PETRIASHVILI S;KINTSCHER U;RALLIDIS L;KISS R;GUÐNASON T;MAHER V;HENKIN Y;MUREDDU G;MUSSAGALIYEVA A;IBRAHIMI P;MIRRAKHIMOV E;LATKOVSKIS G;LAMIN H;SLAPIKAS R;VISSER L;DINGLI P;IVANOV V;WITTEKOEK J;HOVLAND A;RYNKIEWICZ A;RATO Q;EZHOV M;ZAVATTA M;NEDELJKOVIC M;PELLA D;FRAS Z;MARZAL D;NILSSON L;MACH F;ADDAD F;KAYIKCIOGLU M;MITCHENKO O;WALD D","CATAPANO, ALBERICO L. (7006246941); GRAHAM, IAN (35373661800); DE BACKER, GUY (24288352300); WIKLUND, OLOV (7005459783); JOHN CHAPMAN, M. (56414737800); DREXEL, HEINZ (55162866700); HOES, ARNO W. (35370614300); JENNINGS, CATRIONA S. (57214815491); LANDMESSER, ULF (6602879397); PEDERSEN, TERJE R. (7202189829); REINER, ŽELJKO (55411641000); RICCARDI, GABRIELE (7102385746); TASKINEN, MARJA-RIITA (57193256111); TOKGOZOGLU, LALE (7004724917); MONIQUE VERSCHUREN, W.M. (57189073142); VLACHOPOULOS, CHARALAMBOS (7003866217); WOOD, DAVID A. (58763955500); ZAMORANO, JOSE LUIS (7101735283); BADIMON, LINA (7102141956); FUNCK-BRENTANO, CHRISTIAN (55358887600); AGEWALL, STEFAN (7006435302); BARÓN-ESQUIVIAS, GONZALO (55879449800); BORÉN, JAN (57203198460); BRUCKERT, ERIC (55539414500); CORDERO, ALBERTO (10043917400); CORSINI, ALBERTO (7005085224); GIANNUZZI, PANTALEO (56211992200); GUEYFFIER, FRANÇOIS (26642876400); KRSTAČIĆ, GORAN (6603170043); LETTINO, MADDALENA (6602951700); LIONIS, CHRISTOS (7005768464); LIP, GREGORY Y. H. (57216675273); MARQUES-VIDAL, PEDRO (55651163200); MILICIC, DAVOR (56503365500); PEDRO-BOTET, JUAN (7004796457); PIEPOLI, MASSIMO F. (7005292730); RIGOPOULOS, ANGELOS G. (6701402043); RUSCHITZKA, FRANK (7003359126); TUÑÓN, JOSÉ (57201276466); VON ECKARDSTEIN, ARNOLD (7102254047); VRABLIK, MICHAL (6701669648); WEISS, THOMAS W. (35316560600); WILLIAMS, BRYAN (7404503273); WINDECKER, STEPHAN (7003473419); ZIMLICHMAN, REUVEN (7005717468); ABOYANS, VICTOR (56214736500); ACHENBACH, STEPHAN (7005749805); BAUMGARTNER, HELMUT (7103268433); BAX, JEROEN J. (55429494700); BUENO, HÉCTOR (57218323754); CARERJ, SCIPIONE (56251394000); DEAN, VERONICA (57223410945); EROL, ÇETIN (57208376764); FITZSIMONS, DONNA (57203953034); GAEMPERLI, OLIVER (11141900500); KIRCHHOF, PAULUS (7004270127); KOLH, PHILIPPE (7003878264); LANCELLOTTI, PATRIZIO (7003380556); NIHOYANNOPOULOS, PETROS (55959198800); PONIKOWSKI, PIOTR (7005331011); ROFFI, MARCO (7004532440); TORBICKI, ADAM (7006862069); VAZ CARNEIRO, ANTÓNIO (57195735661); ZELVEIAN, PAROUNAK H. (6603421475); SIOSTRZONEK, PETER (7005389696); IBRAHIMOV, FIRDOVSI (14045359000); SUJAYEVA, VOLHA (57202159560); CLAEYS, MARC J. (7102514922); POJSKIĆ, BELMA (25623457000); POSTADZHIYAN, ARMAN (55900865700); GEORGIOU, GEORGE C. (23093966200); ROSOLOVA, HANA (7004856615); KLAUSEN, CHRISTIAN (57208476297); VIIGIMAA, MARGUS (57221665512); KERVINEN, KARI (35837805100); KEDEV, SASKO (23970691700); FERRIÈRES, JEAN (7006559388); PETRIASHVILI, SHALVA (57201180309); KINTSCHER, ULRICH (7004012758); RALLIDIS, LOUKIANOS (7003545638); KISS, RÓBERT GÁBOR (56351597000); GUÐNASON, THORARINN (37052190500); MAHER, VINCENT (7101603639); HENKIN, YAAKOV (7003459016); MUREDDU, GIAN FRANCESCO (6701629155); MUSSAGALIYEVA, AISULU (57189660403); IBRAHIMI, PRANVERA (55486226500); MIRRAKHIMOV, ERKIN (57216202888); LATKOVSKIS, GUSTAVS (6507756746); LAMIN, HISHAM BEN (57202248341); SLAPIKAS, RIMVYDAS (12779751400); VISSER, LAURENT (57208476343); DINGLI, PHILIP (56595252100); IVANOV, VICTORIA (57208476688); WITTEKOEK, JANNEKE (16027317900); HOVLAND, ANDERS (36729313500); RYNKIEWICZ, ANDRZEJ (56261255000); RATO, QUITERIA (24734327400); EZHOV, MARAT (57218254057); ZAVATTA, MARCO (57202042031); NEDELJKOVIC, MILAN A. (7004488186); PELLA, DANIEL (57207570055); FRAS, ZLATKO (35615293100); MARZAL, DOMINGO (57193080470); NILSSON, LENNART (56225430600); MACH, FRANCOIS (7005352638); ADDAD, FAOUZI (55845847700); KAYIKCIOGLU, MERAL (57202353075); MITCHENKO, OLENA (57193516360); WALD, DAVID (7005483943)","2016 ESCEAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS",2016,"EUROPEAN HEART JOURNAL","37","59",2315,"10.1093/eurheartj/ehw272","ITALY;IRELAND;BELGIUM;SWEDEN;FRANCE;AUSTRIA;NETHERLANDS;UNITED KINGDOM;GERMANY;NORWAY;CROATIA;ITALY;FINLAND;TURKEY;NETHERLANDS;GREECE;UNITED KINGDOM;SPAIN;SPAIN;FRANCE;NORWAY;SPAIN;SWEDEN;FRANCE;SPAIN;ITALY;ITALY;FRANCE;CROATIA;ITALY;GREECE;UNITED KINGDOM;SWITZERLAND;CROATIA, CROATIAN CARDIAC SOCIETY, CROATIA;SPAIN;ITALY;GERMANY;SWITZERLAND;SPAIN;SWITZERLAND;CZECH REPUBLIC;AUSTRIA;UNITED KINGDOM;SWITZERLAND;ISRAEL;FRANCE;GERMANY;GERMANY;NETHERLANDS;SPAIN;ITALY;FRANCE;TURKEY;UNITED KINGDOM;SWITZERLAND;UNITED KINGDOM;BELGIUM;BELGIUM;UNITED KINGDOM;POLAND;SWITZERLAND;POLAND;PORTUGAL;ARMENIAN CARDIOLOGISTS ASSOCIATION, ARMENIA;AUSTRIAN SOCIETY OF CARDIOLOGY, AUSTRIA;AZERBAIJAN SOCIETY OF CARDIOLOGY, AZERBAIJAN;BELORUSSIAN SCIENTIFIC SOCIETY OF CARDIOLOGISTS, BELARUS;BELGIAN SOCIETY OF CARDIOLOGY, BELGIUM;ASSOCIATION OF CARDIOLOGISTS OF BOSNIA AND HERZEGOVINA, BOSNIA AND HERZEGOVINA;BULGARIAN SOCIETY OF CARDIOLOGY, BULGARIA;CYPRUS SOCIETY OF CARDIOLOGY, CYPRUS;CZECH SOCIETY OF CARDIOLOGY, CZECH REPUBLIC;DANISH SOCIETY OF CARDIOLOGY, DENMARK;ESTONIAN SOCIETY OF CARDIOLOGY, ESTONIA;FINNISH CARDIAC SOCIETY, FINLAND;MACEDONIAN FYR SOCIETY OF CARDIOLOGY, NORTH MACEDONIA;FRENCH SOCIETY OF CARDIOLOGY, FRANCE;GEORGIAN SOCIETY OF CARDIOLOGY, GEORGIA;GERMAN CARDIAC SOCIETY, GERMANY;HELLENIC CARDIOLOGICAL SOCIETY, GREECE;HUNGARIAN SOCIETY OF CARDIOLOGY, HUNGARY;ICELANDIC SOCIETY OF CARDIOLOGY, ICELAND;IRISH CARDIAC SOCIETY, IRELAND;ISRAEL HEART SOCIETY, ISRAEL;ITALIAN FEDERATION OF CARDIOLOGY, ITALY;ASSOCIATION OF CARDIOLOGISTS OF KAZAKHSTAN, KAZAKHSTAN;KOSOVO SOCIETY OF CARDIOLOGY, KAZAKHSTAN;KYRGYZ SOCIETY OF CARDIOLOGY, KYRGYZSTAN;LATVIAN SOCIETY OF CARDIOLOGY, LATVIA;LIBYAN CARDIAC SOCIETY, LIBYA;LITHUANIAN SOCIETY OF CARDIOLOGY, LITHUANIA;LUXEMBOURG SOCIETY OF CARDIOLOGY, LUXEMBOURG;MALTESE CARDIAC SOCIETY, MALTA;MOLDAVIAN SOCIETY OF CARDIOLOGY, MOLDOVA;NETHERLANDS SOCIETY OF CARDIOLOGY, NETHERLANDS;NORWEGIAN SOCIETY OF CARDIOLOGY, NORWAY;POLISH CARDIAC SOCIETY, POLAND;PORTUGUESE SOCIETY OF CARDIOLOGY, PORTUGAL;RUSSIAN SOCIETY OF CARDIOLOGY, RUSSIAN FEDERATION;SAN MARINO SOCIETY OF CARDIOLOGY, SAN MARINO;CARDIOLOGY SOCIETY OF SERBIA, SERBIA;SLOVAK SOCIETY OF CARDIOLOGY, SLOVAKIA;SLOVENIAN SOCIETY OF CARDIOLOGY, SLOVENIA;SPANISH SOCIETY OF CARDIOLOGY, SPAIN;SWEDISH SOCIETY OF CARDIOLOGY, SWEDEN;SWISS SOCIETY OF CARDIOLOGY, SWITZERLAND;TUNISIAN SOCIETY OF CARDIOLOGY AND CARDIO-VASCULAR SURGERY, TUNISIA;TURKISH SOCIETY OF CARDIOLOGY, TURKEY;UKRAINIAN ASSOCIATION OF CARDIOLOGY, UKRAINE;BRITISH CARDIOVASCULAR SOCIETY, UNITED KINGDOM","[NO ABSTRACT AVAILABLE]","APOLIPOPROTEIN B; CHOLESTEROL; DYSLIPIDAEMIAS; HIGH-DENSITY LIPOPROTEINS; LIPOPROTEIN REMNANTS; LOW-DENSITY LIPOPROTEINS; TOTAL CARDIOVASCULAR RISK; TREATMENT, ADHERENCE; TREATMENT, DRUGS; TREATMENT, LIFESTYLE; TRIGLYCERIDES","CARDIOLOGY; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; EUROPE; HUMANS; RISK; SEX FACTORS; SOCIETIES, MEDICAL; ALCOHOL; ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BERBERINE; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONACOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; SOYBEAN PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ACUTE PANCREATITIS; ADVERSE OUTCOME; ARTERY DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BODY WEIGHT; CARBOHYDRATE DIET; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CHOLELITHIASIS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIET RESTRICTION; DIETARY FIBER; DIETARY SUPPLEMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; DYSPEPSIA; EARLY INTERVENTION; FAMILIAL COMBINED HYPERLIPIDAEMIA; FAMILIAL DISEASE; FAMILIAL DYSBETALIPOPROTEINAEMIA; FAT INTAKE; FLATULENCE; FUNCTIONAL FOOD; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; GENETIC DISORDER; GENOTYPE; HEALTH STATUS; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER DISEASE; LUNG EMBOLISM; MANAGED CARE; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MENTAL DISEASE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; MYALGIA; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARTICLE SIZE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RENOVASCULAR ATHEROSCLEROSIS; RENOVASCULAR DISEASE; RETINA DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VALVULAR HEART DISEASE; CARDIOVASCULAR DISEASE; COMPLICATION; DYSLIPIDEMIA; EUROPE; PRACTICE GUIDELINE; RISK; SEX FACTOR","BELGIAN SOCIETY OF CARDIOLOGY; BULGARIAN SOCIETY OF CARDIOLOGY; CARDIOLOGY SOCIETY OF SERBIA; CROATIAN CARDIAC SOCIETY; DANISH SOCIETY OF CARDIOLOGY; ESC/EAS; ESTONIAN SOCIETY OF CARDIOLOGY; FINNISH CARDIAC SOCIETY; FRENCH SOCIETY OF CARDIOLOGY; GERMAN CARDIAC SOCIETY; HUNGARIAN SOCIETY OF CARDIOLOGY; IRISH CARDIAC SOCIETY; ISRAEL HEART SOCIETY; ITALIAN FEDERATION OF CARDIOLOGY; POLISH CARDIAC SOCIETY; SLOVAK SOCIETY OF CARDIOLOGY; SLOVENIAN SOCIETY OF CARDIOLOGY; SWEDISH SOCIETY OF CARDIOLOGY; SWISS SOCIETY OF CARDIOLOGY; TURKISH SOCIETY OF CARDIOLOGY; VINCENT MAHER; BRITISH CARDIOVASCULAR SOCIETY; EUROPEAN SOCIETY OF CARDIOLOGY; HELLENIC CARDIOLOGICAL SOCIETY","  IMAGE 49 A CLASS OF RECOMMENDATION. B LEVEL OF EVIDENCE.   APPENDIX ESC COMMITTEE FOR PRACTICE GUIDELINES (CPG) : JOSE LUIS ZAMORANO (CHAIRPERSON) (SPAIN), VICTOR ABOYANS (FRANCE), STEPHAN ACHENBACH (GERMANY), STEFAN AGEWALL (NORWAY), LINA BADIMON (SPAIN), GONZALO BARÓN-ESQUIVIAS (SPAIN), HELMUT BAUMGARTNER (GERMANY), JEROEN J. BAX (THE NETHERLANDS), HÉCTOR BUENO (SPAIN), SCIPIONE CARERJ (ITALY), VERONICA DEAN (FRANCE), ÇETIN EROL (TURKEY), DONNA FITZSIMONS (UK), OLIVER GAEMPERLI (SWITZERLAND), PAULUS KIRCHHOF (UK/GERMANY), PHILIPPE KOLH (BELGIUM), PATRIZIO LANCELLOTTI (BELGIUM), GREGORY Y. H. LIP (UK), PETROS NIHOYANNOPOULOS (UK), MASSIMO F. PIEPOLI (ITALY), PIOTR PONIKOWSKI (POLAND), MARCO ROFFI (SWITZERLAND), ADAM TORBICKI (POLAND), ANTÓNIO VAZ CARNEIRO (PORTUGAL), STEPHAN WINDECKER (SWITZERLAND). ESC NATIONAL CARDIAC SOCIETIES ACTIVELY INVOLVED IN THE REVIEW PROCESS OF THE 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: ARMENIA: ARMENIAN CARDIOLOGISTS ASSOCIATION, PAROUNAK H. ZELVEIAN; AUSTRIA: AUSTRIAN SOCIETY OF CARDIOLOGY, PETER SIOSTRZONEK; AZERBAIJAN: AZERBAIJAN SOCIETY OF CARDIOLOGY, FIRDOVSI IBRAHIMOV; BELARUS: BELORUSSIAN SCIENTIFIC SOCIETY OF CARDIOLOGISTS, VOLHA SUJAYEVA; BELGIUM: BELGIAN SOCIETY OF CARDIOLOGY, MARC J. CLAEYS; BOSNIA AND HERZEGOVINA: ASSOCIATION OF CARDIOLOGISTS OF BOSNIA AND HERZEGOVINA, BELMA POJSKIĆ; BULGARIA: BULGARIAN SOCIETY OF CARDIOLOGY, ARMAN POSTADZHIYAN; CROATIA: CROATIAN CARDIAC SOCIETY, DAVOR MILIČIĆ; CYPRUS: CYPRUS SOCIETY OF CARDIOLOGY, GEORGE C. GEORGIOU; CZECH REPUBLIC: CZECH SOCIETY OF CARDIOLOGY, HANA ROSOLOVA; DENMARK: DANISH SOCIETY OF CARDIOLOGY, CHRISTIAN KLAUSEN; ESTONIA: ESTONIAN SOCIETY OF CARDIOLOGY, MARGUS VIIGIMAA; FINLAND: FINNISH CARDIAC SOCIETY, KARI KERVINEN; FORMER YUGOSLAV REPUBLIC OF MACEDONIA: MACEDONIAN FYR SOCIETY OF CARDIOLOGY, SASKO KEDEV; FRANCE: FRENCH SOCIETY OF CARDIOLOGY, JEAN FERRIÈRES; GEORGIA: GEORGIAN SOCIETY OF CARDIOLOGY, SHALVA PETRIASHVILI; GERMANY: GERMAN CARDIAC SOCIETY, ULRICH KINTSCHER; GREECE: HELLENIC CARDIOLOGICAL SOCIETY, LOUKIANOS RALLIDIS; HUNGARY: HUNGARIAN SOCIETY OF CARDIOLOGY, RÓBERT GÁBOR KISS; ICELAND: ICELANDIC SOCIETY OF CARDIOLOGY, THORARINN GUÐNASON; IRELAND: IRISH CARDIAC SOCIETY, VINCENT MAHER; ISRAEL: ISRAEL HEART SOCIETY, YAAKOV HENKIN; ITALY: ITALIAN FEDERATION OF CARDIOLOGY, GIAN FRANCESCO MUREDDU; KAZAKHSTAN: ASSOCIATION OF CARDIOLOGISTS OF KAZAKHSTAN, AISULU MUSSAGALIYEVA; KOSOVO: KOSOVO SOCIETY OF CARDIOLOGY, PRANVERA IBRAHIMI; KYRGYZSTAN: KYRGYZ SOCIETY OF CARDIOLOGY, ERKIN MIRRAKHIMOV; LATVIA: LATVIAN SOCIETY OF CARDIOLOGY, GUSTAVS LATKOVSKIS; LIBYA: LIBYAN CARDIAC SOCIETY, HISHAM BEN LAMIN; LITHUANIA: LITHUANIAN SOCIETY OF CARDIOLOGY, RIMVYDAS SLAPIKAS; LUXEMBOURG: LUXEMBOURG SOCIETY OF CARDIOLOGY, LAURENT VISSER; MALTA: MALTESE CARDIAC SOCIETY, PHILIP DINGLI; MOLDOVA: MOLDAVIAN SOCIETY OF CARDIOLOGY, VICTORIA IVANOV; THE NETHERLANDS: NETHERLANDS SOCIETY OF CARDIOLOGY, JANNEKE WITTEKOEK; NORWAY: NORWEGIAN SOCIETY OF CARDIOLOGY, ANDERS HOVLAND; POLAND: POLISH CARDIAC SOCIETY, ANDRZEJ RYNKIEWICZ; PORTUGAL: PORTUGUESE SOCIETY OF CARDIOLOGY, QUITERIA RATO; RUSSIAN FEDERATION: RUSSIAN SOCIETY OF CARDIOLOGY, MARAT EZHOV; SAN MARINO: SAN MARINO SOCIETY OF CARDIOLOGY, MARCO ZAVATTA; SERBIA: CARDIOLOGY SOCIETY OF SERBIA, MILAN A. NEDELJKOVIC; SLOVAKIA: SLOVAK SOCIETY OF CARDIOLOGY, DANIEL PELLA; SLOVENIA: SLOVENIAN SOCIETY OF CARDIOLOGY, ZLATKO FRAS; SPAIN: SPANISH SOCIETY OF CARDIOLOGY, DOMINGO MARZAL; SWEDEN: SWEDISH SOCIETY OF CARDIOLOGY, LENNART NILSSON; SWITZERLAND: SWISS SOCIETY OF CARDIOLOGY, FRANCOIS MACH; TUNISIA: TUNISIAN SOCIETY OF CARDIOLOGY AND CARDIO-VASCULAR SURGERY, FAOUZI ADDAD; TURKEY: TURKISH SOCIETY OF CARDIOLOGY, MERAL KAYIKCIOGLU; UKRAINE: UKRAINIAN ASSOCIATION OF CARDIOLOGY, OLENA MITCHENKO; UNITED KINGDOM: BRITISH CARDIOVASCULAR SOCIETY, DAVID WALD. APPENDIX A ","TOWNSEND N., NICHOLS M., SCARBOROUGH P., RAYNER M., CARDIOVASCULAR DISEASE IN EUROPE-EPIDEMIOLOGICAL UPDATE 2015, EUR HEART J, 36, PP. 2696-2705, (2015); COONEY M.T., DUDINA A., WHINCUP P., CAPEWELL S., MENOTTI A., JOUSILAHTI P., NJOLSTAD I., OGANOV R., THOMSEN T., TVERDAL A., WEDEL H., WILHELMSEN L., GRAHAM I., REEVALUATING THE ROSE APPROACH:COMPARATIVE BENEFITS OF THE POPULATION AND HIGHRISK PREVENTIVE STRATEGIES, EUR J CARDIOVASC PREV REHABIL, 16, PP. 541-549, (2009); LIU K., DAVIGLUS M.L., LORIA C.M., COLANGELO L.A., SPRING B., MOLLER A.C., LLOYD-JONES D.M., HEALTHY LIFESTYLE THROUGH YOUNG ADULTHOOD AND THE PRESENCE OF LOW CARDIOVASCULAR DISEASE RISK PROFILE IN MIDDLE AGE:THE CORONARY ARTERY RISK DEVELOPMENT IN (YOUNG) ADULTS (CARDIA) STUDY, CIRCULATION, 125, PP. 996-1004, (2012); EZZATI M., LOPEZ A.D., RODGERS A., MURRAY C.J.L., COMPARATIVE QUANTIFICATION OF HEALTH RISKS:GLOBAL AND REGIONAL BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISK FACTORS, (2004); GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES, (2010); PERK J., DE BACKER G., GOHLKE H., GRAHAM I., REINER Z., VERSCHUREN M., ALBUS C., BENLIAN P., BOYSEN G., CIFKOVA R., DEATON C., EBRAHIM S., FISHER M., GERMANO G., HOBBS R., HOES A., KARADENIZ S., MEZZANI A., PRESCOTT E., RYDEN L., SCHERER M., SYVANNE M., SCHOLTE OP REIMER W.J., VRINTS C., WOOD D., ZAMORANO J.L., ZANNAD F., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (VERSION 2012 THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS, EUR HEART J, 33, PP. 1635-1701, (2012); MISTRY H., MORRIS S., DYER M., KOTSEVA K., WOOD D., BUXTON M., COST-EFFECTIVENESS OF A EUROPEAN PREVENTIVE CARDIOLOGY PROGRAMME IN PRIMARY CARE:A MARKOV MODELLING APPROACH, BMJ OPEN, 2, (2012); NICHOLS M., TOWNSEND N., LUENGO-FERNANDEZ R., LEAL J., GRAY A., SCARBOROUGH P., RAYNER M., EUROPEAN CARDIOVASCULAR DISEASE STATISTICS, (2012); HEIDENREICH P.A., TROGDON J.G., KHAVJOU O.A., BUTLER J., DRACUP K., EZEKOWITZ M.D., FINKELSTEIN E.A., HONG Y., JOHNSTON S.C., KHERA A., LLOYD-JONES D.M., NELSON S.A., NICHOL G., ORENSTEIN D., WILSON P.W., WOO Y.J., FORECASTING THE FUTURE OF CARDIOVASCULAR DISEASE IN THE UNITED STATES:A POLICY STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 933-944, (2011); MCCONNACHIE A., WALKER A., ROBERTSON M., MARCHBANK L., PEACOCK J., PACKARD C.J., COBBE S.M., FORD I., LONG-TERM IMPACT ON HEALTHCARE RESOURCE UTILIZATION OF STATIN TREATMENT, AND ITS COST EFFECTIVENESS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:A RECORD LINKAGE STUDY, EUR HEART J, 35, PP. 290-298, (2014); WARD S., LLOYD JONES M., PANDOR A., HOLMES M., ARA R., RYAN A., YEO W., PAYNE N., A SYSTEMATIC REVIEW AND ECONOMIC EVALUATION OF STATINS FOR THE PREVENTION OF CORONARY EVENTS, HEALTH TECHNOL ASSESS, 11, PP. 1-160, (2007); PLANS-RUBIO P., THE COST EFFECTIVENESS OF STATIN THERAPIES IN SPAIN IN 2010, AFTER THE INTRODUCTION OF GENERICS AND REFERENCE PRICES, AM J CARDIOVASC DRUGS, 10, PP. 369-382, (2010); BJORCK L., ROSENGREN A., BENNETT K., LAPPAS G., CAPEWELL S., MODELLING THE DECREASING CORONARY HEART DISEASE MORTALITY IN SWEDEN BETWEEN 1986 AND 2002, EUR HEART J, 30, PP. 1046-1056, (2009); ASPELUND T., GUDNASON V., MAGNUSDOTTIR B.T., ANDERSEN K., SIGURDSSON G., THORSSON B., STEINGRIMSDOTTIR L., CRITCHLEY J., BENNETT K., O'FLAHERTY M., CAPEWELL S., ANALYSING THE LARGE DECLINE IN CORONARY HEART DISEASE MORTALITY IN THE ICELANDIC POPULATION AGED 25-74 BETWEEN THE YEARS 1981 AND 2006, PLOS ONE, 5, (2010); PEREIRA M., AZEVEDO A., LUNET N., CARREIRA H., O'FLAHERTY M., CAPEWELL S., BENNETT K., EXPLAINING THE DECLINE IN CORONARY HEART DISEASE MORTALITY IN PORTUGAL BETWEEN 1995 AND 2008, CIRC CARDIOVASC QUAL OUTCOMES, 6, PP. 634-642, (2013); UNAL B., SOZMEN K., ARIK H., GERCEKLIOGLU G., ALTUN D.U., SIMSEK H., DOGANAY S., DEMIRAL Y., ASLANOBENNETT K., O'FLAHERTY M., CAPEWELL S., CRITCHLEY J., EXPLAINING THE DECLINE IN CORONARY HEART DISEASE MORTALITY IN TURKEY BETWEEN 1995 AND 2008, BMC PUBLIC HEALTH, 13, (2013); ROTH G.A., FOROUZANFAR M.H., MORAN A.E., BARBER R., NGUYEN G., FEIGIN V.L., NAGHAVI M., MENSAH G.A., MURRAY C.J., DEMOGRAPHIC AND EPIDEMIOLOGIC DRIVERS OF GLOBAL CARDIOVASCULAR MORTALITY, N ENGL J MED, 372, PP. 1333-1341, (2015); COBIAC L.J., MAGNUS A., LIM S., BARENDREGT J.J., CARTER R., VOS T., WHICH INTERVENTIONS OFFER BEST VALUE FOR MONEY IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE?, PLOS ONE, 7, (2012); COLLINS M., MASON H., O'FLAHERTY M., GUZMAN-CASTILLO M., CRITCHLEY J., CAPEWELL S., AN ECONOMIC EVALUATION OF SALT REDUCTION POLICIES TO REDUCE CORONARY HEART DISEASE IN ENGLAND:A POLICY MODELING STUDY, VALUE HEALTH, 17, PP. 517-524, (2014); MASON H., SHOAIBI A., GHANDOUR R., O'FLAHERTY M., CAPEWELL S., KHATIB R., JABR S., UNAL B., SOZMEN K., ARFA C., AISSI W., BEN ROMDHANE H., FOUAD F., AL-ALI R., HUSSEINI A., A COST EFFECTIVENESS ANALYSIS OF SALT REDUCTION POLICIES TO REDUCE CORONARY HEART DISEASE IN FOUR EASTERN MEDITERRANEAN COUNTRIES, PLOS ONE, 9, (2014); O'KEEFFE C., KABIR Z., O'FLAHERTY M., WALTON J., CAPEWELL S., PERRY I.J., MODELLING THE IMPACT OF SPECIFIC FOOD POLICY OPTIONS ON CORONARY HEART DISEASE AND STROKE DEATHS IN IRELAND, BMJ OPEN, 3, (2013); MOREIRA P.V., BARALDI L.G., MOUBARAC J.C., MONTEIRO C.A., NEWTON A., CAPEWELL S., O'FLAHERTY M., COMPARING DIFFERENT POLICY SCENARIOS TO REDUCE THE CONSUMPTION OF ULTRA-PROCESSED FOODS IN UK:IMPACT ON CARDIOVASCULAR DISEASE MORTALITY USING A MODELLING APPROACH, PLOS ONE, 10, (2015); NEYT M., DE LAET C., VAN BRABANDT H., FRANCO O., RAMAEKERS D., COST-EFFECTIVENESS OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:A SYSTEMATIC REVIEW AND ECONOMIC ANALYSIS FOR BELGIUM, ACTA CARDIOL, 64, PP. 1-10, (2009); PEURA P., MARTIKAINEN J., SOINI E., HALLINEN T., NISKANEN L., COST-EFFECTIVENESS OF STATINS IN THE PREVENTION OF CORONARY HEART DISEASE EVENTS IN MIDDLE-AGED FINNISH MEN, CURR MED RES OPIN, 24, PP. 1823-1832, (2008); ITO M.K., NANCHEN D., RODONDI N., PACCAUD F., WAEBER G., VOLLENWEIDER P., MARQUES-VIDAL P., STATINS FOR CARDIOVASCULAR PREVENTION ACCORDING TO DIFFERENT STRATEGIES:A COST ANALYSIS, AM J CARDIOVASC DRUGS, 11, PP. 33-44, (2011); STEVANOVIC J., O'PRINSEN A.C., VERHEGGEN B.G., SCHUILING-VENINGA N., POSTMA M.J., PECHLIVANOGLOU P., ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES IN MILD HYPERTENSION:A SCENARIO ANALYSIS FOR THE NETHERLANDS, CLIN THER, 36, PP. 368-384, (2014); WISLOFF T., SELMER R.M., HALVORSEN S., FRETHEIM A., NORHEIM O.F., KRISTIANSEN I.S., CHOICE OF GENERIC ANTIHYPERTENSIVE DRUGS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE-A COST-EFFECTIVENESS ANALYSIS, BMC CARDIOVASC DISORD, 12, (2012); BANEGAS J.R., LOPEZ-GARCIA E., DALLONGEVILLE J., GUALLAR E., HALCOX J.P., BORGHI C., MASSO-GONZALEZ E.L., JIMENEZ F.J., PERK J., STEG P.G., DE BACKER G., RODRIGUEZ-ARTALEJO F., ACHIEVEMENT OF TREATMENT GOALS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE ACROSS EUROPE:THE EURIKA STUDY, EUR HEART J, 32, PP. 2143-2152, (2011); KOTSEVA K., WOOD D., DE BACKER G., DE BACQUER D., PYORALA K., REINER Z., KEIL U., MANAGEMENT OF CARDIOVASCULAR RISK FACTORS IN ASYMPTOMATIC HIGH-RISK PATIENTS IN GENERAL PRACTICE:CROSS-SECTIONAL SURVEY IN 12 EUROPEAN COUNTRIES, EUR J CARDIOVASC PREV REHABIL, 17, PP. 530-540, (2010); CHERRY S.B., BENNER J.S., HUSSEIN M.A., TANG S.S., NICHOL M.B., THE CLINICAL AND ECONOMIC BURDEN OF NONADHERENCE WITH ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY IN HYPERTENSIVE PATIENTS, VALUE HEALTH, 12, PP. 489-497, (2009); CORRAO G., SCOTTI L., ZAMBON A., BAIO G., NICOTRA F., CONTI V., CAPRI S., TRAGNI E., MERLINO L., CATAPANO A.L., MANCIA G., COST-EFFECTIVENESS OF ENHANCING ADHERENCE TO THERAPY WITH STATINS IN THE SETTING OF PRIMARY CARDIOVASCULAR PREVENTION EVIDENCE FROM AN EMPIRICAL APPROACH BASED ON ADMINISTRATIVE DATABASES, ATHEROSCLEROSIS, 217, PP. 479-485, (2011); DRAGOMIR A., COTE R., ROY L., BLAIS L., LALONDE L., BERARD A., PERREAULT S., IMPACT OF ADHERENCE TO ANTIHYPERTENSIVE AGENTS ON CLINICAL OUTCOMES AND HOSPITALIZATION COSTS, MED CARE, 48, PP. 418-425, (2010); WALD N.J., LAW M.R., A STRATEGY TO REDUCE CARDIOVASCULAR DISEASE BY MORE THAN 80%, BMJ, 326, (2003); GAZIANO T.A., OPIE L.H., WEINSTEIN M.C., CARDIOVASCULAR DISEASE PREVENTION WITH A MULTIDRUG REGIMEN IN THE DEVELOPING WORLD:A COST-EFFECTIVENESS ANALYSIS, LANCET, 368, PP. 679-686, (2006); VAN GILS P.F., OVER E.A., HAMBERG-VAN REENEN H.H., DE WIT G.A., VAN DEN BERG M., SCHUIT A.J., ENGELFRIET P.M., THE POLYPILL IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:COST-EFFECTIVENESS IN THE DUTCH POPULATION, BMJ OPEN, 1, (2011); FRIEDEN T.R., A FRAMEWORK FOR PUBLIC HEALTH ACTION:THE HEALTH IMPACT PYRAMID, AM J PUBLIC HEALTH, 100, PP. 590-595, (2010); BROWN M.T., BUSSELL J.K., MEDICATION ADHERENCE:WHO CARES?, MAYO CLIN PROC, 86, PP. 304-314, (2011); NICE PUBLIC HEALTH GUIDANCE, (2010); CAPEWELL S., FORD E.S., CROFT J.B., CRITCHLEY J.A., GREENLUND K.J., LABARTHE D.R., CARDIOVASCULAR RISK FACTOR TRENDS AND POTENTIAL FOR REDUCING CORONARY HEART DISEASE MORTALITY IN THE UNITED STATES OF AMERICA, BULL WORLD HEALTH ORG, 88, PP. 120-130, (2010); MOZAFFARIAN D., CAPEWELL S., UNITED NATIONS' DIETARY POLICIES TO PREVENT CARDIOVASCULAR DISEASE, BMJ, 343, (2011); D'AGOSTINO R.B., VASAN R.S., PENCINA M.J., WOLF P.A., COBAIN M., MASSARO J.M., KANNEL W.B., GENERAL CARDIOVASCULAR RISK PROFILE FOR USE IN PRIMARY CARE:THE FRAMINGHAM HEART STUDY, CIRCULATION, 117, PP. 743-753, (2008); CONROY R.M., PYORALA K., FITZGERALD A.P., SANS S., MENOTTI A., DE BACKER G., DE BACQUER D., DUCIMETIERE P., JOUSILAHTI P., KEIL U., NJOLSTAD I., OGANOV R.G., THOMSEN T., TUNSTALL-PEDOE H., TVERDAL A., WEDEL H., WHINCUP P., WILHELMSEN L., GRAHAM I.M., ESTIMATION OF TEN-YEAR RISK OF FATAL CARDIOVASCULAR DISEASE IN EUROPE:THE SCORE PROJECT, EUR HEART J, 24, PP. 987-1003, (2003); WOODWARD M., BRINDLE P., TUNSTALL-PEDOE H., ADDING SOCIAL DEPRIVATION AND FAMILY HISTORY TO CARDIOVASCULAR RISK ASSESSMENT:THE ASSIGN SCORE FROM THE SCOTTISH HEART HEALTH EXTENDED COHORT (SHHEC, HEART, 93, PP. 172-176, (2007); HIPPISLEY-COX J., COUPLAND C., VINOGRADOVA Y., ROBSON J., MINHAS R., SHEIKH A., BRINDLE P., PREDICTING CARDIOVASCULAR RISK IN ENGLAND ANDWALES:PROSPECTIVE DERIVATION AND VALIDATION OF QRISK2, BMJ, 336, PP. 1475-1482, (2008); ASSMANN G., CULLEN P., SCHULTE H., SIMPLE SCORING SCHEME FOR CALCULATING THE RISK OF ACUTE CORONARY EVENTS BASED ON THE 10-YEAR FOLLOW-UP OF THE PROSPECTIVE CARDIOVASCULAR MUNSTER (PROCAM) STUDY, CIRCULATION, 105, PP. 310-315, (2002); RIDKER P.M., PAYNTER N.P., RIFAI N., GAZIANO J.M., COOK N.R., C-REACTIVE PROTEIN AND PARENTAL HISTORY IMPROVE GLOBAL CARDIOVASCULAR RISK PREDICTION:THE REYNOLDS RISK SCORE FOR MEN, CIRCULATION, 118, PP. 2243-2251, (2008); RIDKER P.M., BURING J.E., RIFAI N., COOK N.R., DEVELOPMENT AND VALIDATION OF IMPROVED ALGORITHMS FOR THE ASSESSMENT OF GLOBAL CARDIOVASCULAR RISK IN WOMEN:THE REYNOLDS RISK SCORE, JAMA, 297, PP. 611-619, (2007); FERRARIO M., CHIODINI P., CHAMBLESS L.E., CESANA G., VANUZZO D., PANICO S., SEGA R., PILOTTO L., PALMIERI L., GIAMPAOLI S., PREDICTION OF CORONARY EVENTS IN A LOW INCIDENCE POPULATION. ASSESSING ACCURACY OF THE CUORE COHORT STUDY PREDICTION EQUATION, INT J EPIDEMIOL, 34, PP. 413-421, (2005); GOFF D.C., LLOYD-JONES D.M., BENNETT G., COADY S., D'AGOSTINO R.B., GIBBONS R., GREENLAND P., LACKLAND D.T., LEVY D., O'DONNELL C.J., ROBINSON J.G., SCHWARTZ J.S., SHERO S.T., SMITH S.C., SORLIE P., STONE N.J., WILSON P.W., JORDAN H.S., NEVO L., WNEK J., ANDERSON J.L., HALPERIN J.L., ALBERT N.M., BOZKURT B., BRINDIS R.G., CURTIS L.H., DEMETS D., HOCHMAN J.S., KOVACS R.J., OHMAN E.M., PRESSLER S.J., SELLKE F.W., SHEN W.K., SMITH S.C., TOMASELLI G.F., 2013 ACC/AHA GUIDELINE ON THE ASSESSMENT OF CARDIOVASCULAR RISK:A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, 25, PP. S49-S73, (2014); HAJIFATHALIAN K., UEDA P., LU Y., WOODWARD M., AHMADVAND A., AGUILAR-SALINAS C.A., AZIZI F., CIFKOVA R., DI CESARE M., ERIKSEN L., FARZADFAR F., IKEDA N., KHALILI D., KHANG Y.H., LANSKA V., LEON-MUNOZ L., MAGLIANO D., MSYAMBOZA K.P., OH K., RODRIGUEZ-ARTALEJO F., ROJAS-MARTINEZ R., SHAW J.E., STEVENS G.A., TOLSTRUP J., ZHOU B., SALOMON J.A., EZZATI M., DANAEI G., A NOVEL RISK SCORE TO PREDICT CARDIOVASCULAR DISEASE RISK IN NATIONAL POPULATIONS (GLOBORISK):A POOLED ANALYSIS OF PROSPECTIVE COHORTS AND HEALTH EXAMINATION SURVEYS, LANCET DIABETES ENDOCRINOL, 3, PP. 339-355, (2015); COONEY M.T., DUDINA A.L., GRAHAM I.M., VALUE AND LIMITATIONS OF EXISTING SCORES FOR THE ASSESSMENT OF CARDIOVASCULAR RISK:A REVIEW FOR CLINICIANS, J AM COLL CARDIOL, 54, PP. 1209-1227, (2009); COONEY M.T., DUDINA A., D'AGOSTINO R., GRAHAM I.M., CARDIOVASCULAR RISK-ESTIMATION SYSTEMS IN PRIMARY PREVENTION:DO THEY DIFFER? DO THEY MAKE A DIFFERENCE? CAN WE SEE THE FUTURE, CIRCULATION, 122, PP. 300-310, (2010); LLOYD-JONES D.M., LEIP E.P., LARSON M.G., D'AGOSTINO R.B., BEISER A., WILSON P.W., WOLF P.A., LEVY D., PREDICTION OF LIFETIME RISK FOR CARDIOVASCULAR DISEASE BY RISK FACTOR BURDEN AT 50 YEARS OF AGE, CIRCULATION, 113, PP. 791-798, (2006); COONEY M.T., SELMER R., LINDMAN A., TVERDAL A., MENOTTI A., THOMSEN T., DEBACKER G., DE BACQUER D., TELL G.S., NJOLSTAD I., GRAHAM I.M., CARDIOVASCULAR RISK ESTIMATION IN OLDER PERSONS:SCORE OP, EUR J PREV CARDIOL, 23, PP. 1093-1103, (2016); COONEY M.T., DUDINA A., DE BACQUER D., WILHELMSEN L., SANS S., MENOTTI A., DE BACKER G., JOUSILAHTI P., KEIL U., THOMSEN T., WHINCUP P., GRAHAM I.M., HDL CHOLESTEROL PROTECTS AGAINST CARDIOVASCULAR DISEASE IN BOTH GENDERS, AT ALL AGES AND AT ALL LEVELS OF RISK, ATHEROSCLEROSIS, 206, PP. 611-616, (2009); COONEY M.T., DUDINA A., DE BACQUER D., FITZGERALD A., CONROY R., SANS S., MENOTTI A., DE BACKER G., JOUSILAHTI P., KEIL U., THOMSEN T., WHINCUP P., GRAHAM I., HOW MUCH DOES HDL CHOLESTEROL ADD TO RISK ESTIMATION? A REPORT FROM THE SCORE INVESTIGATORS, EUR J CARDIOVASC PREV REHABIL, 16, PP. 304-314, (2009); MORTENSEN M.B., AFZAL S., NORDESTGAARD B.G., FALK E., THE HIGH-DENSITY LIPOPROTEIN-ADJUSTED SCORE MODEL WORSENS SCORE-BASED RISK CLASSIFICATION IN A CONTEMPORARY POPULATION OF 30, 824 EUROPEANS:THE COPENHAGEN GENERAL POPULATION STUDY, EUR HEART J, 36, PP. 2446-2453, (2015); KAVOUSI M., ELIAS-SMALE S., RUTTEN J.H., LEENING M.J., VLIEGENTHART R., VERWOERT G.C., KRESTIN G.P., OUDKERK M., DE MAAT M.P., LEEBEEK F.W., MATTACE-RASO F.U., LINDEMANS J., HOFMAN A., STEYERBERG E.W., VAN DER LUGT A., VAN DEN MEIRACKER A.H., WITTEMAN J.C., EVALUATION OF NEWER RISK MARKERS FOR CORONARY HEART DISEASE RISK CLASSIFICATION:A COHORT STUDY, ANN INTERN MED, 156, PP. 438-444, (2012); YEBOAH J., MCCLELLAND R.L., POLONSKY T.S., BURKE G.L., SIBLEY C.T., O'LEARY D., CARR J.J., GOFF D.C., GREENLAND P., HERRINGTON D.M., COMPARISON OF NOVEL RISK MARKERS FOR IMPROVEMENT IN CARDIOVASCULAR RISK ASSESSMENT IN INTERMEDIATE-RISK INDIVIDUALS, JAMA, 308, PP. 788-795, (2012); VLACHOPOULOS C., XAPLANTERIS P., ABOYANS V., BRODMANN M., CIFKOVA R., COSENTINO F., DE CARLO M., GALLINO A., LANDMESSER U., LAURENT S., LEKAKIS J., MIKHAILIDIS D.P., NAKA K.K., PROTOGEROU A.D., RIZZONI D., SCHMIDT-TRUCKSASS A., VAN BORTEL L., WEBER T., YAMASHINA A., ZIMLICHMAN R., BOUTOUYRIE P., COCKCROFT J., O'ROURKE M., PARK J.B., SCHILLACI G., SILLESEN H., TOWNSEND R.R., THE ROLE OF VASCULAR BIOMARKERS FOR PRIMARY AND SECONDARY PREVENTION A POSITION PAPER FROM THE EUROPEAN SOCIETY OF CARDIOLOGY WORKING GROUP ON PERIPHERAL CIRCULATION:ENDORSED BY THE ASSOCIATION FOR RESEARCH INTO ARTERIAL STRUCTURE AND PHYSIOLOGY (ARTERY) SOCIETY, ATHEROSCLEROSIS, 241, PP. 507-532, (2015); BOEKHOLDT S.M., HOVINGH G.K., MORA S., ARSENAULT B.J., AMARENCO P., PEDERSEN T.R., LAROSA J.C., WATERS D.D., DEMICCO D.A., SIMES R.J., KEECH A.C., COLQUHOUN D., HITMAN G.A., BETTERIDGE D.J., CLEARFIELD M.B., DOWNS J.R., COLHOUN H.M., GOTTO A.M., RIDKER P.M., GRUNDY S.M., KASTELEIN J.J., VERY LOW LEVELS OF ATHEROGENIC LIPOPROTEINS AND THE RISK FOR CARDIOVASCULAR EVENTS:A META-ANALYSIS OF STATIN TRIALS, J AM COLL CARDIOL, 64, PP. 485-494, (2014); BRUGTS J.J., YETGIN T., HOEKS S.E., GOTTO A.M., SHEPHERD J., WESTENDORP R.G., DE CRAEN A.J., KNOPP R.H., NAKAMURA H., RIDKER P., VAN DOMBURG R., DECKERS J.W., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS:META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 338, (2009); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., MCCAGG A., WHITE J.A., THEROUX P., DARIUS H., LEWIS B.S., OPHUIS T.O., JUKEMA J.W., DE FERRARI G.M., RUZYLLO W., DE LUCCA P., IM K., BOHULA E.A., REIST C., WIVIOTT S.D., TERSHAKOVEC A.M., MUSLINER T.A., BRAUNWALD E., CALIFF R.M., EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, N ENGL J MED, 372, PP. 2387-2397, (2015); BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., BHALA N., PETO R., BARNES E.H., KEECH A., SIMES J., COLLINS R., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL:A META-ANALYSIS OF DATA FROM 170, 000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); FULCHER J., O'CONNELL R., VOYSEY M., EMBERSON J., BLACKWELL L., MIHAYLOVA B., SIMES J., COLLINS R., KIRBY A., COLHOUN H., BRAUNWALD E., LA ROSA J., PEDERSEN T.R., TONKIN A., DAVIS B., SLEIGHT P., FRANZOSI M.G., BAIGENT C., KEECH A., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN:META-ANALYSIS OF INDIVIDUAL DATA FROM 174, 000 PARTICIPANTS IN 27 RANDOMISED TRIALS, LANCET, 385, PP. 1397-1405, (2015); MIHAYLOVA B., EMBERSON J., BLACKWELL L., KEECH A., SIMES J., BARNES E.H., VOYSEY M., GRAY A., COLLINS R., BAIGENT C., THE EFFECTS OF LOWERING LDL CHOLESTEROL WITH STATIN THERAPY IN PEOPLE AT LOW RISK OF VASCULAR DISEASE:META-ANALYSIS OF INDIVIDUAL DATA FROM 27 RANDOMISED TRIALS, LANCET, 380, PP. 581-590, (2012); HEGELE R.A., GINSBERG H.N., CHAPMAN M.J., NORDESTGAARD B.G., KUIVENHOVEN J.A., AVERNA M., BOREN J., BRUCKERT E., CATAPANO A.L., DESCAMPS O.S., HOVINGH G.K., HUMPHRIES S.E., KOVANEN P.T., MASANA L., PAJUKANTA P., PARHOFER K.G., RAAL F.J., RAY K.K., SANTOS R.D., STALENHOEF A.F., STROES E., TASKINEN M.R., TYBJAERG-HANSEN A., WATTS G.F., WIKLUND O., THE POLYGENIC NATURE OF HYPERTRIGLYCERIDAEMIA:IMPLICATIONS FOR DEFINITION, DIAGNOSIS, AND MANAGEMENT, LANCET DIABETES ENDOCRINOL, 2, PP. 655-666, (2014); MILLS E.J., RACHLIS B., WU P., DEVEREAUX P.J., ARORA P., PERRI D., PRIMARY PREVENTION OF CARDIOVASCULAR MORTALITY AND EVENTS WITH STATIN TREATMENTS:A NETWORK META-ANALYSIS INVOLVING MORE THAN 65, 000 PATIENTS, J AM COLL CARDIOL, 52, PP. 1769-1781, (2008); PEDERSEN T.R., FAERGEMAN O., KASTELEIN J.J., OLSSON A.G., TIKKANEN M.J., HOLME I., LARSEN M.L., BENDIKSEN F.S., LINDAHL C., SZAREK M., TSAI J., HIGH-DOSE ATORVASTATIN VS USUAL-DOSE SIMVASTATIN FOR SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION:THE IDEAL STUDY:A RANDOMIZED CONTROLLED TRIAL, JAMA, 294, PP. 2437-2445, (2005); WRIGHT J.T., WILLIAMSON J.D., WHELTON P.K., SNYDER J.K., SINK K.M., ROCCO M.V., REBOUSSIN D.M., RAHMAN M., OPARIL S., LEWIS C.E., KIMMEL P.L., JOHNSON K.C., GOFF D.C., FINE L.J., CUTLER J.A., CUSHMAN W.C., CHEUNG A.K., AMBROSIUS W.T., A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL, N ENGL J MED, 373, PP. 2103-2116, (2015); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., BAIREY MERZ C.N., BLUM C.B., ECKEL R.H., GOLDBERG A.C., GORDON D., LEVY D., LLOYD-JONES D.M., MCBRIDE P., SCHWARTZ J.S., SHERO S.T., SMITH S.C., WATSON K., WILSON P.W., EDDLEMAN K.M., JARRETT N.M., LABRESH K., NEVO L., WNEK J., ANDERSON J.L., HALPERIN J.L., ALBERT N.M., BOZKURT B., BRINDIS R.G., CURTIS L.H., DEMETS D., HOCHMAN J.S., KOVACS R.J., OHMAN E.M., PRESSLER S.J., SELLKE F.W., SHEN W.K., SMITH S.C., TOMASELLI G.F., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS:A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, 25, PP. S1-S45, (2014); LANGLOIS M.R., DESCAMPS O.S., VAN DER LAARSE A., WEYKAMP C., BAUM H., PULKKI K., VON ECKARDSTEIN A., DE BACQUER D., BOREN J., WIKLUND O., LAITINEN P., OOSTERHUIS W.P., COBBAERT C., CLINICAL IMPACT OF DIRECT HDLC AND LDLC METHOD BIAS IN HYPERTRIGLYCERIDEMIA A SIMULATION STUDY OF THE EAS-EFLM COLLABORATIVE PROJECT GROUP, ATHEROSCLEROSIS, 233, PP. 83-90, (2014); KOLOVOU G.D., MIKHAILIDIS D.P., KOVAR J., LAIRON D., NORDESTGAARD B.G., OOI T.C., PEREZ-MARTINEZ P., BILIANOU H., ANAGNOSTOPOULOU K., PANOTOPOULOS G., ASSESSMENT AND CLINICAL RELEVANCE OF NON-FASTING AND POSTPRANDIAL TRIGLYCERIDES:AN EXPERT PANEL STATEMENT, CURR VASC PHARMACOL, 9, PP. 258-270, (2011); MIHAS C., KOLOVOU G.D., MIKHAILIDIS D.P., KOVAR J., LAIRON D., NORDESTGAARD B.G., OOI T.C., PEREZ-MARTINEZ P., BILIANOU H., ANAGNOSTOPOULOU K., PANOTOPOULOS G., DIAGNOSTIC VALUE OF POSTPRANDIAL TRIGLYCERIDE TESTING IN HEALTHY SUBJECTS:A META-ANALYSIS, CURR VASC PHARMACOL, 9, PP. 271-280, (2011); NORDESTGAARD B.G., VARBO A., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE, LANCET, 384, PP. 626-635, (2014); JORGENSEN A.B., FRIKKE-SCHMIDT R., WEST A.S., GRANDE P., NORDESTGAARD B.G., TYBJAERG-HANSEN A., GENETICALLY ELEVATED NON-FASTING TRIGLYCERIDES AND CALCULATED REMNANT CHOLESTEROL AS CAUSAL RISK FACTORS FOR MYOCARDIAL INFARCTION, EUR HEART J, 34, PP. 1826-1833, (2013); LANGSTED A., NORDESTGAARD B.G., NONFASTING LIPIDS, LIPOPROTEINS, AND APOLIPOPROTEINS IN INDIVIDUALS WITH AND WITHOUT DIABETES 58 434 INDIVIDUALS FROM THE COPENHAGEN GENERAL POPULATION STUDY, CLIN CHEM, 57, PP. 482-489, (2011); MARTI-SOLER H., GUBELMANN C., AESCHBACHER S., ALVES L., BOBAK M., BONGARD V., CLAYS E., DE GAETANO G., DI CASTELNUOVO A., ELOSUA R., FERRIERES J., GUESSOUS I., IGLAND J., JORGENSEN T., NIKITIN Y., O'DOHERTY M.G., PALMIERI L., RAMOS R., SIMONS J., SULO G., VANUZZO D., VILA J., BARROS H., BORGLYKKE A., CONEN D., DE BACQUER D., DONFRANCESCO C., GASPOZ J.M., GIAMPAOLI S., GILES G.G., IACOVIELLO L., KEE F., KUBINOVA R., MALYUTINA S., MARRUGAT J., PRESCOTT E., RUIDAVETS J.B., SCRAGG R., SIMONS L.A., TAMOSIUNAS A., TELL G.S., VOLLENWEIDER P., MARQUES-VIDAL P., SEASONALITY OF CARDIOVASCULAR RISK FACTORS:AN ANALYSIS INCLUDING OVER 230 000 PARTICIPANTS IN 15 COUNTRIES, HEART, 100, PP. 1517-1523, (2014); RABAR S., HARKER M., O'FLYNN N., WIERZBICKI A.S., LIPID MODIFICATION AND CARDIOVASCULAR RISK ASSESSMENT FOR THE PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE:SUMMARY OF UPDATED NICE GUIDANCE, BMJ, 349, (2014); HEART, 100, PP. II1-II67, (2014); KNOPFHOLZ J., DISSEROL C.C., PIERIN A.J., SCHIRR F.L., STREISKY L., TAKITO L.L., MASSUCHETO LEDESMA P., FARIA-NETO J.R., OLANDOSKI M., DA CUNHA C.L., BANDEIRA A.M., VALIDATION OF THE FRIEDEWALD FORMULA IN PATIENTS WITH METABOLIC SYNDROME, CHOLESTEROL, 2014, (2014); LIPID MODIFICATION:CARDIOVASCULAR RISK ASSESSMENT AND THE MODIFICATION OF BLOOD LIPIDS FOR THE PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, (2014); DI ANGELANTONIO E., GAO P., PENNELLS L., KAPTOGE S., CASLAKE M., THOMPSON A., BUTTERWORTH A.S., SARWAR N., WORMSER D., SALEHEEN D., BALLANTYNE C.M., PSATY B.M., SUNDSTROM J., RIDKER P.M., NAGEL D., GILLUM R.F., FORD I., DUCIMETIERE P., KIECHL S., KOENIG W., DULLAART R.P., ASSMANN G., D'AGOSTINO R.B., DAGENAIS G.R., COOPER J.A., KROMHOUT D., ONAT A., TIPPING R.W., GOMEZ-DE-LA-CAMARA A., ROSENGREN A., SUTHERLAND S.E., GALLACHER J., FOWKES F.G., CASIGLIA E., HOFMAN A., SALOMAA V., BARRETT-CONNOR E., CLARKE R., BRUNNER E., JUKEMA J.W., SIMONS L.A., SANDHU M., WAREHAM N.J., KHAW K.T., KAUHANEN J., SALONEN J.T., HOWARD W.J., NORDESTGAARD B.G., WOOD A.M., THOMPSON S.G., BOEKHOLDT S.M., SATTAR N., PACKARD C., GUDNASON V., DANESH J., LIPID-RELATED MARKERS AND CARDIOVASCULAR DISEASE PREDICTION, JAMA, 307, PP. 2499-2506, (2012); BOEKHOLDT S.M., ARSENAULT B.J., MORA S., PEDERSEN T.R., LAROSA J.C., NESTEL P.J., SIMES R.J., DURRINGTON P., HITMAN G.A., WELCH K.M., DEMICCO D.A., ZWINDERMAN A.H., CLEARFIELD M.B., DOWNS J.R., TONKIN A.M., COLHOUN H.M., GOTTO A.M., RIDKER P.M., KASTELEIN J.J., ASSOCIATION OF LDL CHOLESTEROL, NON-HDL CHOLESTEROL, AND APOLIPOPROTEIN B LEVELS WITH RISK OF CARDIOVASCULAR EVENTS AMONG PATIENTS TREATED WITH STATINS:A META-ANALYSIS, JAMA, 307, PP. 1302-1309, (2012); ROBINSON J.G., WANG S., JACOBSON T.A., META-ANALYSIS OF COMPARISON OF EFFECTIVENESS OF LOWERING APOLIPOPROTEIN B VERSUS LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND NONHIGH-DENSITY LIPOPROTEIN CHOLESTEROL FOR CARDIOVASCULAR RISK REDUCTION IN RANDOMIZED TRIALS, AM J CARDIOL, 110, PP. 1468-1476, (2012); VARBO A., BENN M., TYBJAERG-HANSEN A., JORGENSEN A.B., FRIKKE-SCHMIDT R., NORDESTGAARD B.G., REMNANT CHOLESTEROL AS A CAUSAL RISK FACTOR FOR ISCHEMIC HEART DISEASE, J AM COLL CARDIOL, 61, PP. 427-436, (2013); SARWAR N., SANDHU M.S., RICKETTS S.L., BUTTERWORTH A.S., DI ANGELANTONIO E., BOEKHOLDT S.M., OUWEHAND W., WATKINS H., SAMANI N.J., SALEHEEN D., LAWLOR D., REILLY M.P., HINGORANI A.D., TALMUD P.J., DANESH J., TRIGLYCERIDEMEDIATED PATHWAYS AND CORONARY DISEASE:COLLABORATIVE ANALYSIS OF 101 STUDIES, LANCET, 375, PP. 1634-1639, (2010); DO R., WILLER C.J., SCHMIDT E.M., SENGUPTA S., GAO C., PELOSO G.M., GUSTAFSSON S., KANONI S., GANNA A., CHEN J., BUCHKOVICH M.L., MORA S., BECKMANN J.S., BRAGG-GRESHAM J.L., CHANG H.Y., DEMIRKAN A., DEN HERTOG H.M., DONNELLY L.A., EHRET G.B., ESKO T., FEITOSA M.F., FERREIRA T., FISCHER K., FONTANILLAS P., FRASER R.M., FREITAG D.F., GURDASANI D., HEIKKILA K., HYPPONEN E., ISAACS A., JACKSON A.U., JOHANSSON A., JOHNSON T., KAAKINEN M., KETTUNEN J., KLEBER M.E., LI X., LUAN J., LYYTIKAINEN L.P., MAGNUSSON P.K., MANGINO M., MIHAILOV E., MONTASSER M.E., MULLER-NURASYID M., NOLTE I.M., O'CONNELL J.R., PALMER C.D., PEROLA M., PETERSEN A.K., SANNA S., SAXENA R., SERVICE S.K., SHAH S., SHUNGIN D., SIDORE C., SONG C., STRAWBRIDGE R.J., SURAKKA I., TANAKA T., TESLOVICH T.M., THORLEIFSSON G., VAN DEN HERIK E.G., VOIGHT B.F., VOLCIK K.A., WAITE L.L., WONG A., WU Y., ZHANG W., ABSHER D., ASIKI G., BARROSO I., BEEN L.F., BOLTON J.L., BONNYCASTLE L.L., BRAMBILLA P., BURNETT M.S., CESANA G., DIMITRIOU M., DONEY A.S., DORING A., ELLIOTT P., EPSTEIN S.E., EYJOLFSSON G.I., GIGANTE B., GOODARZI M.O., GRALLERT H., GRAVITO M.L., GROVES C.J., COMMON VARIANTS ASSOCIATED WITH PLASMA TRIGLYCERIDES AND RISK FOR CORONARY ARTERY DISEASE, NAT GENET, 45, PP. 1345-1352, (2013); HOLMES M.V., ASSELBERGS F.W., PALMER T.M., DRENOS F., LANKTREE M.B., NELSON C.P., DALE C.E., PADMANABHAN S., FINAN C., SWERDLOW D.I., TRAGANTE V., VAN IPEREN E.P., SIVAPALARATNAM S., SHAH S., ELBERS C.C., SHAH T., ENGMANN J., GIAMBARTOLOMEI C., WHITE J., ZABANEH D., SOFAT R., MCLACHLAN S., MENDELIAN RANDOMIZATION OF BLOOD LIPIDS FOR CORONARY HEART DISEASE, EUR HEART J, 36, PP. 539-550, (2015); DI ANGELANTONIO E., SARWAR N., PERRY P., KAPTOGE S., RAY K.K., THOMPSON A., WOOD A.M., LEWINGTON S., SATTAR N., PACKARD C.J., COLLINS R., THOMPSON S.G., DANESH J., MAJOR LIPIDS, APOLIPOPROTEINS, AND RISK OF VASCULAR DISEASE, JAMA, 302, PP. 1993-2000, (2009); HAASE C.L., TYBJAERG-HANSEN A., GRANDE P., FRIKKE-SCHMIDT R., GENETICALLY ELEVATED APOLIPOPROTEIN A-I, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, AND RISK OF ISCHEMIC HEART DISEASE, J CLIN ENDOCRINOL METAB, 95, PP. E500-510, (2010); VOIGHT B.F., PELOSO G.M., ORHO-MELANDER M., FRIKKE-SCHMIDT R., BARBALIC M., JENSEN M.K., HINDY G., HOLM H., DING E.L., JOHNSON T., SCHUNKERT H., SAMANI N.J., CLARKE R., HOPEWELL J.C., THOMPSON J.F., LI M., THORLEIFSSON G., NEWTON-CHEH C., MUSUNURU K., PIRRUCCELLO J.P., SALEHEEN D., CHEN L., STEWART A., SCHILLERT A., THORSTEINSDOTTIR U., THORGEIRSSON G., ANAND S., ENGERT J.C., MORGAN T., SPERTUS J., STOLL M., BERGER K., MARTINELLI N., GIRELLI D., MCKEOWN P.P., PATTERSON C.C., EPSTEIN S.E., DEVANEY J., BURNETT M.S., MOOSER V., RIPATTI S., SURAKKA I., NIEMINEN M.S., SINISALO J., LOKKI M.L., PEROLA M., HAVULINNA A., DE FAIRE U., GIGANTE B., INGELSSON E., ZELLER T., WILD P., DE BAKKER P.I., KLUNGEL O.H., MAITLAND-VAN DER ZEE A.H., PETERS B.J., DE BOER A., GROBBEE D.E., KAMPHUISEN P.W., DENEER V.H., ELBERS C.C., ONLAND-MORET N.C., HOFKER M.H., WIJMENGA C., VERSCHUREN W.M., BOER J.M., VAN DER SCHOUW Y.T., RASHEED A., FROSSARD P., DEMISSIE S., WILLER C., DO R., ORDOVAS J.M., ABECASIS G.R., BOEHNKE M., MOHLKE K.L., DALY M.J., GUIDUCCI C., BURTT N.P., SURTI A., GONZALEZ E., PURCELL S., GABRIEL S., MARRUGAT J., PEDEN J., ERDMANN J., PLASMA HDL CHOLESTEROL AND RISK OF MYOCARDIAL INFARCTION:A MENDELIAN RANDOMISATION STUDY, LANCET, 380, PP. 572-580, (2012); KHERA A.V., CUCHEL M., DE LA LLERA-MOYA M., RODRIGUES A., BURKE M.F., JAFRI K., FRENCH B.C., PHILLIPS J.A., MUCKSAVAGE M.L., WILENSKY R.L., MOHLER E.R., ROTHBLAT G.H., RADER D.J., CHOLESTEROL EFFLUX CAPACITY, HIGH-DENSITY LIPOPROTEIN FUNCTION, AND ATHEROSCLEROSIS, N ENGL J MED, 364, PP. 127-135, (2011); LI X.M., TANG W.H., MOSIOR M.K., HUANG Y., WU Y., MATTER W., GAO V., SCHMITT D., DIDONATO J.A., FISHER E.A., SMITH J.D., HAZEN S.L., PARADOXICAL ASSOCIATION OF ENHANCED CHOLESTEROL EFFLUX WITH INCREASED INCIDENT CARDIOVASCULAR RISKS, ARTERIOSCLER THROMB VASC BIOL, 33, PP. 1696-1705, (2013); ROHATGI A., KHERA A., BERRY J.D., GIVENS E.G., AYERS C.R., WEDIN K.E., NEELAND I.J., YUHANNA I.S., RADER D.R., DE LEMOS J.A., SHAUL P.W., HDL CHOLESTEROL EFFLUX CAPACITY AND INCIDENT CARDIOVASCULAR EVENTS, N ENGL J MED, 371, PP. 2383-2393, (2014); SARWAR N., DANESH J., EIRIKSDOTTIR G., SIGURDSSON G., WAREHAM N., BINGHAM S., BOEKHOLDT S.M., KHAW K.T., GUDNASON V., TRIGLYCERIDES AND THE RISK OF CORONARY HEART DISEASE 10, 158 INCIDENT CASES AMONG 262, 525 PARTICIPANTS IN 29 WESTERN PROSPECTIVE STUDIES, CIRCULATION, 115, PP. 450-458, (2007); HOKANSON J.E., AUSTIN M.A., PLASMA TRIGLYCERIDE LEVEL IS A RISK FACTOR FOR CARDIOVASCULAR DISEASE INDEPENDENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL:A META-ANALYSIS OF POPULATION-BASED PROSPECTIVE STUDIES, J CARDIOVASC RISK, 3, PP. 213-219, (1996); BANSAL S., BURING J.E., RIFAI N., MORA S., SACKS F.M., RIDKER P.M., FASTING COMPARED WITH NONFASTING TRIGLYCERIDES AND RISK OF CARDIOVASCULAR EVENTS IN WOMEN, JAMA, 298, PP. 309-316, (2007); NORDESTGAARD B.G., BENN M., SCHNOHR P., TYBJAERG-HANSEN A., NONFASTING TRIGLYCERIDES AND RISK OF MYOCARDIAL INFARCTION, ISCHEMIC HEART DISEASE, AND DEATH IN MEN AND WOMEN, JAMA, 298, PP. 299-308, (2007); CHARLTON-MENYS V., BETTERIDGE D.J., COLHOUN H., FULLER J., FRANCE M., HITMAN G.A., LIVINGSTONE S.J., NEIL H.A., NEWMAN C.B., SZAREK M., DEMICCO D.A., DURRINGTON P.N., TARGETS OF STATIN THERAPY:LDL CHOLESTEROL, NON-HDL CHOLESTEROL, AND APOLIPOPROTEIN B IN TYPE 2 DIABETES IN THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS, CLIN CHEM, 55, PP. 473-480, (2009); INGELSSON E., SCHAEFER E.J., CONTOIS J.H., MCNAMARA J.R., SULLIVAN L., KEYES M.J., PENCINA M.J., SCHOONMAKER C., WILSON P.W., D'AGOSTINO R.B., VASAN R.S., CLINICAL UTILITY OF DIFFERENT LIPID MEASURES FOR PREDICTION OF CORONARY HEART DISEASE IN MEN AND WOMEN, JAMA, 298, PP. 776-785, (2007); TASKINEN M.R., BARTER P.J., EHNHOLM C., SULLIVAN D.R., MANN K., SIMES J., BEST J.D., HAMWOOD S., KEECH A.C., ABILITY OF TRADITIONAL LIPID RATIOS AND APOLIPOPROTEIN RATIOS TO PREDICT CARDIOVASCULAR RISK IN PEOPLE WITH TYPE 2 DIABETES, DIABETOLOGIA, 53, PP. 1846-1855, (2010); SNIDERMAN A.D., WILLIAMS K., CONTOIS J.H., MONROE H.M., MCQUEEN M.J., DE GRAAF J., FURBERG C.D., A META-ANALYSIS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL, NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, AND APOLIPOPROTEIN B AS MARKERS OF CARDIOVASCULAR RISK, CIRC CARDIOVASC QUAL OUTCOMES, 4, PP. 337-345, (2011); ONAT A., HERGENC G., SANSOY V., FOBKER M., CEYHAN K., TOPRAK S., ASSMANN G., APOLIPOPROTEIN C-III A STRONG DISCRIMINANT OF CORONARY RISK IN MEN AND A DETERMINANT OF THE METABOLIC SYNDROME IN BOTH GENDERS, ATHEROSCLEROSIS, 168, PP. 81-89, (2003); SACKS F.M., ALAUPOVIC P., MOYE L.A., COLE T.G., SUSSEX B., STAMPFER M.J., PFEFFER M.A., BRAUNWALD E., VLDL, APOLIPOPROTEINS B, CIII, AND E, AND RISK OF RECURRENT CORONARY EVENTS IN THE CHOLESTEROL AND RECURRENT EVENTS (CARE) TRIAL, CIRCULATION, 102, PP. 1886-1892, (2000)","A.L. CATAPANO; DEPARTMENT OF PHARMACOLOGICAL AND BIOMOLECULAR SCIENCES, UNIVERSITY OF MILAN, MILAN, VIA BALZARETTI 9, 20133, ITALY; EMAIL: ALBERICO.CATAPANO@UNIMI.IT","OXFORD UNIVERSITY PRESS","ENGLISH","EUR. HEART J.","REVIEW","ISI","2-S2.0-84994296486","EUR HEART J","ARMENIAN CARDIOLOGISTS ASSOCIATION;BELORUSSIAN SCIENTIFIC SOCIETY OF CARDIOLOGISTS;ASSOCIATION OF CARDIOLOGISTS OF BOSNIA AND HERZEGOVINA;ASSOCIATION OF CARDIOLOGISTS OF KAZAKHSTAN;UKRAINIAN ASSOCIATION OF CARDIOLOGY","NOTREPORTED;UNIVERSITY OF MILAN;NOTREPORTED",NA,"CATAPANO AL, 2016, EUR HEART J","CATAPANO AL, 2016, EUR HEART J"
"LANDI F;MARTONE A;SALINI S;ZAZZARA B;CALVANI R;MARZETTI E;NESCI A;DI G A;GIUPPONI B;SANTORO L;SANTOLIQUIDO A","LANDI, FRANCESCO (7005782335); MARTONE, ANNA MARIA (55699422400); SALINI, SARA (57192820385); ZAZZARA, BEATRICE (57212172447); CALVANI, RICCARDO (36787471200); MARZETTI, EMANUELE (6506978724); NESCI, ANTONIO (24076942500); DI GIORGIO, ANGELA (55243670400); GIUPPONI, BIANCA (24366748600); SANTORO, LUCA (7101809163); SANTOLIQUIDO, ANGELO (7004578350)","EFFECTS OF A NEW COMBINATION OF MEDICAL FOOD ON ENDOTHELIAL FUNCTION AND LIPID PROFILE IN DYSLIPIDEMIC SUBJECTS A PILOT RANDOMIZED TRIAL",2019,"BIOMED RESEARCH INTERNATIONAL","2019","",11,"10.1155/2019/1970878","DEPARTMENT OF GERIATRICS, NEUROSCIENCES AND ORTHOPEDICS, FONDAZIONE POLICLINICO GEMELLI IRCCS, ROMA, ITALY;DEPARTMENT OF GERIATRICS, NEUROSCIENCES AND ORTHOPEDICS, FONDAZIONE POLICLINICO GEMELLI IRCCS, ROMA, ITALY;DEPARTMENT OF GERIATRICS, NEUROSCIENCES AND ORTHOPEDICS, FONDAZIONE POLICLINICO GEMELLI IRCCS, ROMA, ITALY;DEPARTMENT OF GERIATRICS, NEUROSCIENCES AND ORTHOPEDICS, FONDAZIONE POLICLINICO GEMELLI IRCCS, ROMA, ITALY;DEPARTMENT OF GERIATRICS, NEUROSCIENCES AND ORTHOPEDICS, FONDAZIONE POLICLINICO GEMELLI IRCCS, ROMA, ITALY;DEPARTMENT OF GERIATRICS, NEUROSCIENCES AND ORTHOPEDICS, FONDAZIONE POLICLINICO GEMELLI IRCCS, ROMA, ITALY;DIVISION OF VASCULAR MEDICINE, DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS, ROMA, ITALY;DIVISION OF VASCULAR MEDICINE, DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS, ROMA, ITALY;MEDICINA D'URGENZA E PRONTO SOCCORSO, FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS, ROMA, ITALY;DIVISION OF VASCULAR MEDICINE, DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS, ROMA, ITALY;UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY","NUTRITIONAL APPROACHES TO IMPROVE DYSLIPIDEMIAS HAVE BEEN RECENTLY DEVELOPED, BUT EVIDENCES ON DIFFERENT MEDICAL FOODS ARE OFTEN INCOMPLETE. THE MAIN AIM OF OUR STUDY WAS TO EVALUATE THE EFFECTS ON ENDOTHELIAL FUNCTION, LIPID PROFILE, AND GLUCOSE METABOLISM OF TWO DIFFERENT COMBINATIONS OF NUTRACEUTICALS, FIRST ONE CONTAINING BERGAVIT (200 MG CITRUS BERGAMIA), OMEGA-3 (400 MG), CROMINEX 3+ (10 MCG TRIVALENT CHROMIUM), AND RED YEAST RICE (100 MG; 5 MG MONACOLIN K) AND SECOND ONE CONTAINING RED YEAST RICE (200 MG; 3 MG MONACOLIN K), BERBERINE (500 MG), ASTAXANTHIN (0.5 MG), FOLIC ACID (200 MCG), COENZYME Q10 (2 MG), AND POLICOSANOL (10 MG). FIFTY SUBJECTS AFFECTED BY DYSLIPIDEMIA NOT REQUIRING STATIN TREATMENT WERE ENROLLED IN THIS RANDOMIZED, BLIND, CONTROLLED TRIAL AND SUBMITTED TO BLOOD SAMPLING FOR LIPID AND GLUCOSE PROFILES AND INSTRUMENTAL EVALUATION OF ENDOTHELIAL FUNCTION BEFORE AND AFTER 6 WEEKS OF TREATMENT WITH NUTRACEUTICALS. BOTH NUTRACEUTICAL COMBINATIONS IMPROVED THE LIPID PROFILE; THE NUTRACEUTICAL CONTAINING 5 MG OF MONACOLIN K, 200 MG OF THE EXTRACT CITRUS BERGAMIA, 400 MG OF OMEGA-3, AND 10 MCG OF TRIVALENT CHROMIUM ENTAILED A SIGNIFICANT IMPROVEMENT OF ENDOTHELIAL FUNCTION WITH ENHANCED CHOLESTEROL LOWERING EFFECT. IN CONCLUSION, THIS STUDY CONFIRMS THE POSITIVE EFFECT OF FUNCTIONAL FOOD ON LIPID PROFILE AND ENDOTHELIAL FUNCTION IN ABSENCE OF MAJOR UNDESIRABLE EFFECTS. © 2019 FRANCESCO LANDI ET AL.","","ADULT; AGED; BIOLOGICAL PRODUCTS; CHROMIUM; CITRUS; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; ENDOTHELIAL CELLS; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; UBIQUINONE; XANTHOPHYLLS; ASTAXANTHIN; BERBERINE; BERGAVIT; CHOLESTIN; CROMINEX; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; CHROMIUM; FATTY ALCOHOL; LIPID; OMEGA 3 FATTY ACID; UBIQUINONE; XANTHOPHYLL; ADULT; ARTICLE; BERGAMOT JUICE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; FOLLOW UP; FUNCTIONAL FOOD; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; BLOOD; CITRUS; CLASSIFICATION; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM CELL; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PATHOLOGY","ERREKAPPA EUROTER-APICI","THE STUDY WAS SUPPORTED BY GRANT FROM ERREKAPPA EUROTER-APICI.","RAY K.K., KASTELEIN J.J.P., BOEKHOLDT S.M., ET AL., THE ACC/AHA2013 GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN ADULTS: THE GOOD THE BAD AND THE UNCERTAIN: A COMPARISON WITH ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS 2011, EUROPEANHEART JOURNAL, 35, 15, PP. 960-968, (2014); LAAKSONEN M., TALALA K., MARTELIN T., ET AL., HEALTH BEHAVIOURS AS EXPLANATIONS FOR EDUCATIONAL LEVEL DIFFERENCES IN CARDIOVASCULAR AND ALL-CAUSE MORTALITY: A FOLLOW-UP OF 60 000 MEN AND WOMEN OVER 23 YEARS, EUROPEAN JOURNAL OF PUBLIC HEALTH, 18, 1, PP. 38-43, (2008); ROGER V.L., GO A.S., LLOYD-JONES D.M., ET AL., EXECUTIVE SUMMARY: HEART DISEASE AND STROKE STATISTICS-2012 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 125, PP. 188-197, (2012); OSE D., ROCHON J., CAMPBELL S.M., ET AL., HEALTH-RELATED QUALITY OF LIFE AND RISK FACTOR CONTROL: THE IMPORTANCE OF EDUCATIONAL LEVEL IN PREVENTION OF CARDIOVASCULAR DISEASES, EUROPEAN JOURNAL OF PUBLIC HEALTH, 24, 4, PP. 679-684, (2014); BURDEN OF CARDIOVASCULAR DISEASES IN THE EASTERN MEDITERRANEAN REGION, 1990-2015: FINDINGS FROM THE GLOBAL BURDEN OF DISEASE 2015 STUDY, INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 3, PP. 137-149, (2018); UPMEIER E., LAVONIUS S., LEHTONEN A., VIITANEN M., ISOAHO H., ARVE S., SERUM LIPIDS AND THEIR ASSOCIATION WITH MORTALITY IN THE ELDERLY: A PROSPECTIVE COHORT STUDY, AGING CLINICAL AND EXPERIMENTAL RESEARCH, 21, 6, PP. 424-430, (2009); HAMER M., O'DONOVAN G., STAMATAKIS E., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND MORTALITY: TOO MUCH OF A GOOD THING?, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 38, 3, PP. 669-672, (2018); ZOCCALI C., MALLAMACI F., CHOLESTEROL: ANOTHER SALTY PATHWAY TO CARDIOVASCULAR DISEASE?, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 37, 3, PP. 383-384, (2017); LIU F., PRABHAKAR M., JU J., LONG H., ZHOU H.-W., EFFECT OF INULIN-TYPE FRUCTANS ON BLOOD LIPID PROFILE AND GLUCOSE LEVEL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 71, 1, PP. 9-20, (2017); WOFFORD M.R., REBHOLZ C.M., REYNOLDS K., ET AL., EFFECT OF SOY AND MILK PROTEIN SUPPLEMENTATION ON SERUM LIPID LEVELS: A RANDOMIZED CONTROLLED TRIAL, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 66, 4, PP. 419-425, (2012); GYLLING H., SIMONEN P., PHYTOSTEROLS, PHYTOSTANOLS, AND LIPOPROTEIN METABOLISM, NUTRIENTS, 7, 9, PP. 7965-7977, (2015); CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUROPEAN HEART JOURNAL, 37, 39, PP. 2999-3058, (2016); LANDI F., CALVANI R., PICCA A., ET AL., CARDIOVASCULAR HEALTH METRICS, MUSCLE MASS AND FUNCTION AMONG ITALIAN COMMUNITYDWELLERS: THE LOOKUP 7+ PROJECT, EUROPEAN JOURNAL OF PUBLIC HEALTH, 28, 4, PP. 766-772, (2018); VETRANO D.L., MARTONE A.M., MASTROPAOLO S., ET AL., PREVALENCE OF THE SEVEN CARDIOVASCULAR HEALTH METRICS IN A MEDITERRANEAN COUNTRY: RESULTS FROMA CROSS-SECTIONAL STUDY, EUROPEAN JOURNAL OF PUBLIC HEALTH, 23, 5, PP. 858-862, (2013); BARRIOS V., ESCOBAR C., CICERO A.F.G., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLEROSIS SUPPLEMENTS, 24, PP. 1-15, (2017); MATTHEWS D.R., HOSKER J.P., RUDENSKI A.S., NAYLOR B.A., TREACHER D.F., TURNER R.C., HOMEOSTASIS MODEL ASSESSMENT: INSULIN RESISTANCE AND CELL FUNCTION FROM FASTING PLASMA GLUCOSE AND INSULIN CONCENTRATIONS IN MAN, DIABETOLOGIA, 28, 7, PP. 412-419, (1985); THIJSSEN D.H.J., BLACK M.A., PYKE K.E., ET AL., ASSESSMENT OF FLOW-MEDIATED DILATION IN HUMANS: A METHODOLOGICAL AND PHYSIOLOGICAL GUIDELINE, AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 300, 1, PP. H2-H12, (2011); ROSS R., ATHEROSCLEROSIS-AN INFLAMMATORY DISEASE, THE NEW ENGLAND JOURNAL OF MEDICINE, 340, 2, PP. 115-126, (1999); GREWAL J., CHAN S., FROHLICH J., MANCINI G.B., ASSESSMENT OF A NOVEL RISK FACTORS IN PATIENTS AT OW RISK FOR CARDIOVASCULAR EVENTS BASED ON FRAMINGHAM RISK STRATIFICATION, CLINICAL AND INVESTIGATIVE MEDICINE, 36, PP. 158-165, (2003); CHAN S.Y., MANCINI G.B.J., KURAMOTO L., SCHULZER M., FROHLICH J., IGNASZEWSKI A., THE PROGNOSTIC IMPORTANCE OF ENDOTHELIAL DYSFUNCTION AND CAROTID ATHEROMA BURDEN IN PATIENTS WITH CORONARY ARTERY DISEASE, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 42, 6, PP. 1037-1043, (2003); SANTORO L., D'ONOFRIO F., CAMPO S., ET AL., ENDOTHELIAL DYSFUNCTION BUT NOT INCREASED CAROTID INTIMA-MEDIA THICKNESS IN YOUNG EUROPEAN WOMEN WITH ENDOMETRIOSIS, HUMAN REPRODUCTION, 27, 5, PP. 320-326, (2012); CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, REVISTA ESPAÑOLA DE CARDIOLOGÍA, 70, 2, (2017); HEINZ T., SCHUCHARDT J.P., MOLLER K., HADJI P., HAHN A., LOW DAILY DOSE OF 3 MG MONACOLIN K FROM RYR REDUCES THE CONCENTRATION OF LDL-C IN A RANDOMIZED, PLACEBO-CONTROLLED INTERVENTION, NUTRITION RESEARCH, 36, 10, PP. 1162-1170, (2016); DEROSA G., D'ANGELO A., ROMANO D., MAFFIOLI P., EFFECTS OF A COMBINATION OF BERBERIS ARISTATA, SILYBUM MARIANUM AND MONACOLIN ON LIPID PROFILE IN SUBJECTS AT LOW CARDIOVASCULAR RISK; A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18, 2, (2017); MOLLACE V., RAGUSA S., SACCO I., ET AL., THE PROTECTIVE EFFECT OF BERGAMOT OIL EXTRACT ON LECITINE-LIKE OXYLDL RECEPTOR-1 EXPRESSION IN BALLOON INJURY-RELATED NEOINTIMA FORMATION, JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 13, 2, PP. 120-129, (2008); SPIGONI V., MENA P., FANTUZZI F., ET AL., BIOAVAILABILITY OF BERGAMOT (CITRUS BERGAMIA) FLAVANONES AND BIOLOGICAL ACTIVITY OF THEIR CIRCULATING METABOLITES IN HUMAN PRO-ANGIOGENIC CELLS, NUTRIENTS, 9, 12, (2017); RISITANO R., CURRO M., CIRMI S., ET AL., FLAVONOID FRACTION OF BERGAMOT JUICE REDUCES LPS-INDUCED INFLAMMATORY RESPONSE THROUGH SIRT1-MEDIATED NF-B INHIBITION IN THP-1 MONOCYTES, PLOS ONE, 9, (2014); TOTH P.P., PATTI A.M., NIKOLIC D., ET AL., BERGAMOT REDUCES PLASMA LIPIDS, ATHEROGENIC SMALL DENSE LDL, AND SUBCLINICAL ATHEROSCLEROSIS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA: A 6MONTHS PROSPECTIVE STUDY, FRONTIERS IN PHARMACOLOGY, 6, (2016); SEALLS W., PENQUE B.A., ELMENDORF J.S., EVIDENCE THAT CHROMIUM MODULATES CELLULAR CHOLESTEROL HOMEOSTASIS AND ABCA1 FUNCTIONALITY IMPAIRED BY HYPERINSULINEMIA-BRIEF REPORT, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 1, PP. 1139-1140, (2011); WEI M.Y., JACOBSON T.A., EFFECTS OF EICOSAPENTAENOIC ACID VERSUS DOCOSAHEXAENOIC ACID ON SERUMLIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, CURRENT ATHEROSCLEROSIS REPORTS, 13, 6, PP. 474-483, (2011); SCHUMACHER T.L., BURROWS T.L., ROLLO M.E., WOOD L.G., CALLISTER R., COLLINS C.E., COMPARISON OF FATTY ACID INTAKES ASSESSED BY A CARDIOVASCULAR-SPECIFIC FOOD FREQUENCY QUESTIONNAIRE WITH RED BLOOD CELL MEMBRANE FATTY ACIDS IN HYPERLIPIDAEMIC AUSTRALIAN ADULTS: A VALIDATION STUDY, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 70, 12, PP. 1433-1438, (2016); LAUBERTOVA L., KONARIKOVA K., GBELCOVA H., ET AL., FISH OIL EMULSION SUPPLEMENTATION MIGHT IMPROVE QUALITY OF LIFE OF DIABETIC PATIENTS DUE TO ITS ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES, NUTRITION RESEARCH, 46, PP. 49-58, (2017); DAWSON S.L., BOWE S.J., CROWE T.C., A COMBINATION OF OMEGA-3 FATTY ACIDS, FOLIC ACID AND B-GROUP VITAMINS IS SUPERIOR AT LOWERING HOMOCYSTEINE THAN OMEGA-3 ALONE: A META-ANALYSIS, NUTRITION RESEARCH, 36, PP. 499-508, (2016); ZANETTI M., CAPPELLARI G.G., BARBETTA D., SEMOLIC A., BARAZZONI R., OMEGA 3 POLYUNSATURATED FATTY ACIDS IMPROVE ENDOTHELIAL DYSFUNCTION IN CHRONIC RENAL FAILURE: ROLE OF ENOS ACTIVATION AND OF OXIDATIVE STRESS, NUTRIENTS, 9, (2017); POLI A., BARBAGALLO C.M., CICERO A.F.G., ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOLOGICAL RESEARCH, 134, PP. 51-60, (2018); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTRITION REVIEWS, 75, 9, PP. 731-767, (2017)","L. SANTORO; DIVISION OF VASCULAR MEDICINE, DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS, ROMA, ITALY; EMAIL: LUCA.SANTORO@POLICLINICOGEMELLI.IT","HINDAWI LIMITED","ENGLISH","BIOMED RES. INT.","ARTICLE","ISI","2-S2.0-85060552186","BIOMED RES INT","NEUROSCIENCES AND ORTHOPEDICS;NEUROSCIENCES AND ORTHOPEDICS;NEUROSCIENCES AND ORTHOPEDICS;NEUROSCIENCES AND ORTHOPEDICS;NEUROSCIENCES AND ORTHOPEDICS;NEUROSCIENCES AND ORTHOPEDICS;DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS;DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS;FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS;DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS;UNIVERSITÀ CATTOLICA DEL SACRO CUORE","NOTREPORTED;DEPARTMENT OF MEDICINE-FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS;EMAIL: LUCA.SANTORO@POLICLINICOGEMELLI.IT",NA,"LANDI F, 2019, BIOMED RES INT","LANDI F, 2019, BIOMED RES INT"
"LUPI F;SHAKEEL A;GRECO V;OLIVIERO R C;BALDINO N;GABRIELE D","LUPI, FRANCESCA R. (24768180600); SHAKEEL, AHMAD (57190130082); GRECO, VALERIA (57190121462); OLIVIERO ROSSI, CESARE (57221375979); BALDINO, NOEMI (24767432700); GABRIELE, DOMENICO (6507587673)","A RHEOLOGICAL AND MICROSTRUCTURAL CHARACTERISATION OF BIGELS FOR COSMETIC AND PHARMACEUTICAL USES",2016,"MATERIALS SCIENCE AND ENGINEERING C","69","7",115,"10.1016/j.msec.2016.06.098","DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF CHEMISTRY AND CHEMICAL TECHNOLOGIES, UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 14D, CS, RENDE, I-87036, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY","BIGELS ARE BIPHASIC SYSTEMS FORMED BY WATER-BASED HYDROGELS AND OIL-BASED ORGANOGELS, MAINLY STUDIED, IN THE LAST FEW YEARS, FOR PHARMACEUTICAL AND COSMETIC APPLICATION FOCUSED ON THE CONTROLLED DELIVERY OF BOTH LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS. THE RHEOLOGICAL PROPERTIES OF BIGELS DEPEND ON BOTH THE AMOUNT AND THE RHEOLOGICAL CHARACTERISTICS OF SINGLE STRUCTURED PHASES. MOREOVER, IT CAN BE EXPECTED THAT, AT LARGE FRACTIONS OF ONE OF THE STARTING GELS, SYSTEMS MORE COMPLEX THAN OIL-IN-WATER OR WATER-IN-OIL CAN BE OBTAINED, YIELDING BICONTINUOUS OR MATRIX-IN-MATRIX ARRANGEMENT. MODEL BIGELS WERE INVESTIGATED FROM A MICROSTRUCTURAL (I.E. MICROSCOPY AND ELECTRICAL CONDUCTIVITY TESTS) AND RHEOLOGICAL POINT OF VIEW. THE HYDROGEL WAS PREPARED BY USING A LOW-METHOXYL PECTIN WHEREAS THE ORGANOGEL WAS PREPARED BY USING OLIVE OIL AND, AS GELATOR, A MIXTURE OF GLYCERYL STEARATE AND POLICOSANOL. MODEL BIGELS WERE OBTAINED BY INCREASING THE AMOUNT OF ORGANOGEL MIXED WITH THE HYDROGEL, AND MICROSTRUCTURAL CHARACTERISATION EVIDENCED AN ORGANOGEL-IN-HYDROGEL BEHAVIOUR FOR ALL INVESTIGATED SAMPLES, EVEN THOUGH AT THE HIGHEST ORGANOGEL CONTENT A MORE COMPLEX STRUCTURE SEEMS TO ARISE. A SEMI-EMPIRICAL MODEL, BASED ON THEORETICAL EQUATIONS DEVELOPED FOR SUSPENSIONS OF ELASTIC SPHERES IN ELASTIC MEDIA, WAS PROPOSED TO RELATE BIGEL RHEOLOGICAL PROPERTIES TO SINGLE PHASE PROPERTIES AND FRACTIONS. © 2016 ELSEVIER B.V.","BIGEL; COSMETICS; HYDROGEL; OLIVE OIL; ORGANOGEL; RHEOLOGY","COSMETICS; DRUG CARRIERS; ELECTRIC CONDUCTIVITY; HYDROGELS; MICROSCOPY; OLIVE OIL; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; RHEOLOGY; TEMPERATURE; COSMETICS; OLIVE OIL; RHEOLOGY; COSMETIC; DRUG; DRUG CARRIER; HYDROGEL; OLIVE OIL; BIGEL; ELECTRICAL CONDUCTIVITY; LOW-METHOXYL PECTINS; MICROSTRUCTURAL CHARACTERISATION; ORGANOGELS; RHEOLOGICAL CHARACTERISTICS; SEMI-EMPIRICAL MODELING; THEORETICAL EQUATION; CHEMISTRY; ELECTRIC CONDUCTIVITY; FLOW KINETICS; HYDROGEL; MICROSCOPY; PARTICLE SIZE; TEMPERATURE; HYDROGELS","","","SATAPATHY S., SINGH V.K., SAGIRI S.S., AGARWAL T., BANERJEE I., BHATTACHARYA M.K., KUMAR N., PAL K., J. APPL. POLYM. SCI., 132, (2015); BEHERA B., SINGH V.K., KULANTHAIVEL S., BHATTACHARYA M.K., PARAMANIK K., BANERJEE I., PAL K., EUR. POLYM. J., 64, PP. 253-264, (2015); WAKHET S., SINGH V.K., SAHOO S., SAGIRI S.S., KULANTHAIVEL S., BHATTACHARYA M.K., KUMAR N., BANERJEE I., PAL K., J. MATER. SCI. MATER. MED., 26, (2015); SINGH V.K., ANIS A., BANERJEE I., PRAMANIK K., BHATTACHARYA M.K., PAL K., MATER. SCI. ENG. C, 44, PP. 151-158, (2014); REHMAN K., ZULFAKAR M.H., DRUG DEV. IND. PHARM., 40, PP. 433-440, (2014); REHMAN K., AMIN M.C.I.M., ZULFAKAR M.H., J. OLEO SCI., 63, PP. 961-970, (2014); SINGH V.K., BANERJEE I., AGARWAL T., PRAMANIK K., BHATTACHARYA M.K., PAL K., COLLOIDS SURF. B: BIOINTERFACES, 123, PP. 582-592, (2014); SAGIRI S.S., SINGH V.K., KULANTHAIVEL S., BANERJEE I., BASAK P., BATTACHRYA M.K., PAL K., J. MECH. BEHAV. BIOMED. MATER., 43, PP. 1-17, (2015); SOARES P.A.G., BOURBON A.I., VICENTE A.A., ANDRADE C.A.S., BARROS W., CORREIA M.T.S., PESSOA A., CARNEIRO-DA-CUNHA M.G., MATER. SCI. ENG., C, 42, PP. 219-226, (2014); REHMAN K., ALUWI M.F.F.M., RULLAH K., WAI L.K., AMIN M.C.I.M., ZULFAKAR M.H., INT. J. PHARM., 490, PP. 131-141, (2015); SINGH V.K., ANIS A., AL-ZAHRANI S.M., PRADHAN D.K., PAL K., INT. J. ELECTROCHEM. SCI., 9, PP. 5640-5650, (2014); BEHERA B., SAGIRI S.S., SINGH V.K., PAL K., ANIS A., STARCH-STARKE, 66, PP. 865-879, (2014); IBRAHIM M.M., HAFEZ S.A., MAHDY M.M., ASIAN J. PHARM. SCI., 8, PP. 48-57, (2013); PATEL A.R., MANKOC B., BIN SINTANG M.D., LESAFFER A., DEWETTINCK K., RSC ADV., 5, PP. 9703-9708, (2015); LUPI F.R., GENTILE L., GABRIELE D., MAZZULLA S., BALDINO N., DE CINDIO B., J. COLLOID INTERFACE SCI., 459, PP. 70-78, (2015); GARG T., RATH G., GOYAL A.K., DRUG DELIV., 22, PP. 969-987, (2015); ZHOU W., LIU W., ZOU L., LIU W., LIU C., LIANG R., CHEN J., COLLOIDS SURF. B BIOINTERFACES, 117, PP. 330-337, (2014); NAJMI M., SHARIATPANAHI Z.V., TOLOUEI M., AMIRI Z., BURNS, 41, PP. 493-496, (2015); DANBY S.G., ALENEZI T., SULTAN A., LAVENDER T., CHITTOCK J., BROWN K., CORK M.J., PEDIATR. DERMATOL., 30, PP. 42-50, (2013); BOUYER E., MEKHLOUFI G., ROSILIO V., GROSSIORD J.-L., AGNELY F., INT. J. PHARM., 436, PP. 359-378, (2012); LUPI F.R., GABRIELE D., BALDINO N., MIJOVIC P., PARISI O.I., PUOCI F., FOOD FUNCT., 4, PP. 1512-1520, (2013); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., FOOD RES. INT., 51, PP. 510-517, (2013); LUPI F.R., GABRIELE D., SETA L., BALDINO N., DE CINDIO B., MARINO R., RHEOL. ACTA, 54, PP. 41-52, (2015); THAKUR B.R., SINGH R.K., HANDA A.K., CRIT. REV. FOOD SCI. NUTR., 37, PP. 47-73, (1997); LUPI F.R., GABRIELE D., SETA L., BALDINO N., DE CINDIO B., EUR. J. LIPID SCI. TECHNOL., 116, PP. 1734-1744, (2014); SETA L., BALDINO N., GABRIELE D., LUPI F.R., DE CINDIO B., FOOD HYDROCOLL., 32, PP. 373-382, (2013); LUPI F.R., GABRIELE D., DE CINDIO B., SANCHEZ M.C., GALLEGOS C., J. FOOD ENG., 107, PP. 296-303, (2011); GABRIELE D., DE CINDIO B., D'ANTONA P., RHEOL. ACTA, 40, PP. 120-127, (2001); SNABRE P., MILLS P., COLLOIDS SURF. A PHYSICOCHEM. ENG. ASP., 152, PP. 79-88, (1999); LUPI F.R., GABRIELE D., BALDINO N., SETA L., DE CINDIO B., DE ROSE C., EUR. J. LIPID SCI. TECHNOL., 114, PP. 1381-1389, (2012); BADOLATO G.G., AGUILAR F., SCHUCHMANN H.P., SOBISCH T., LERCHE D., PROGR COLLOID POLYM SCI, 134, PP. 66-73, (2008); BARNES H.A., J. NON-NEWTONIAN FLUID MECH., 81, PP. 133-178, (1999); MARINO R., GIOVANDO S., GABRIELE D., APPL. RHEOL., 4, PP. 1-10, (2014); PAL R., ELECTROMAGNETIC, MECHANICAL, AND TRANSPORT PROPERTIES OF COMPOSITE MATERIALS, (2014); PAL R., J. COLLOID INTERFACE SCI., 245, PP. 171-177, (2002); VAN VLIET T., COLLOID POLYM. SCI., 266, PP. 518-524, (1988); LORENZO G., ZARITZKY N., CALIFANO A., FOOD HYDROCOLL., 30, PP. 672-680, (2013); PALIERNE J.F., RHEOL. ACTA, 29, PP. 204-214, (1990); DICKINSON E., FOOD HYDROCOLL., 28, PP. 224-241, (2012); VAN DER POEL C., RHEOL. ACTA, 1, PP. 198-205, (1958)","D. GABRIELE; DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), ARCAVACATA DI RENDE, VIA P. BUCCI, CUBO 39C, I-87036, ITALY; EMAIL: DOMENICO.GABRIELE@UNICAL.IT","ELSEVIER LTD","ENGLISH","MATER. SCI. ENG. C","ARTICLE","ISI","2-S2.0-84977509528","MATER SCI ENG C","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA","NOTREPORTED;ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.);NOTREPORTED",NA,"LUPI FR, 2016, MATER SCI ENG C","LUPI FR, 2016, MATER SCI ENG C"
"WEERAWATANAKORN M;TAMAKI H;ASIKIN Y;WADA K;TAKAHASHI M;HO C;PAN M","WEERAWATANAKORN, M. (55976489600); TAMAKI, H. (7103290853); ASIKIN, Y. (35092077000); WADA, K. (7401668452); TAKAHASHI, M. (56287823400); HO, C.T. (56510763200); PAN, M.H. (7202544934)","POLICOSANOL CONTENTS VOLATILE PROFILE AND TOXICITY TEST OF GRANULATED CANE SUGAR ENRICHED WITH RICE BRAN MATERIALS",2017,"INTERNATIONAL FOOD RESEARCH JOURNAL","24","9",5,"","DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, MUANG, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA, 903-0213, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA, 903-0213, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA, 903-0213, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA, 903-0213, JAPAN;DEPARTMENT OF FOOD SCIENCE, RUTGERS UNIVERSITY, 65 DUDLEY ROAD, NEW BRUNSWICK, 08901, NJ, UNITED STATES;INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, NATIONAL TAIWAN UNIVERSITY, TAIPEI, 10617, TAIWAN","SUGARCANE AND RICE BRAN ARE THE MOST IMPORTANT SOURCES OF COMMERCIAL POLICOSANOL (PC) WAX WHICH EXHIBITS A CHOLESTEROL LOWERING BIOACTIVITY. BOTH DEFATTED RICE BRAN (DRB) AS AGRICULTURAL WASTE AND RICE BRAN OIL (RBO) RETAIN A VARYING BUT SIGNIFICANT AMOUNT OF PC WAX. NON-CENTRIFUGAL CANE SUGAR (NCS) HAS BEEN CONSUMED WORLDWIDE, AND POSSESSES VARIOUS HEALTH BENEFITS. IT IS MOSTLY PRODUCED IN HARDENED BLOCK FORM, WHICH IS NOT CONVENIENT FOR USE COMPARED WITH GRANULAR FORM. WE AIMED TO INCREASE PC CONTENTS OF THE GRANULAR SUGAR BY ADDING WAX EXTRACTED FROM DRB AND RBO AND TO INVESTIGATE THE TOXICITY OF THE PRODUCTS. THE RESULTS SHOWED THAT THE TOTAL PC CONTENTS INCLUDING LONG CHAIN ALDEHYDE OF PRODUCTS WERE INCREASED TO THE MAXIMUM LEVEL OF 147.97 MG/100 G. DRB IS PROMISING SOURCE OF POLICOSANOL (6,044.7 MG/100 G). THE MAIN VOLATILE COMPONENTS OF DEVELOPED SUGAR PRODUCT WAS ALDEHYDE AND ALCOHOL COMPOUNDS. THE 28 DAY TOXICITY EVALUATIONS OF THE DEVELOPED SUGAR REVEALED NO ADVERSE EFFECTS. © ALL RIGHTS RESERVED.","CANE BROWN SUGAR; ENRICHMENT; POLICOSANOLS; RICE BRAN; WAX","","","","ALEMAN C.L., MAS R., HERNANDEZ C., RODIERO I., CEREJIDO E., NOA M., CAPOTE A., MENENDEZ R., AMOR A., FRAGA V., SOTOLONGO V., JIMENEZ S., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAUGE DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOLOGICAL RESEARCH, 34, 5-6, PP. 181-185, (1996); ASKIN Y., CHINEN T., TAKARA K., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCIENCE AND TECHNOLOGY RESEARCH, 14, 6, PP. 583-588, (2008); ASIKIN Y., KAMIYA A., MIZU M., TAKARA K., TAMAKI H., WADA K., CHANGES IN THE PHYSICOCHEMICAL CHARACTERISTICS, INCLUDING FLAVOR COMPONENTS AND MAILLARD REACTION PRODUCTS, OF NON-CENTRIFUGAL CANE BROWN SUGAR DURING STORAGE, FOOD CHEMISTRY, 149, PP. 170-177, (2014); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONGCHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L. ) CULTIVARS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, PP. 583-591, (2012); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLEBLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, 4, PP. 361-371, (2004); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROLLOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 56, PP. 8761-8773, (2008); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUROPEAN JOURNAL LIPID SCIENCE TECHNOLOGY, 106, PP. 147-151, (2004); FRANCINI-PESENTI F., BELTRAMOLLI D., ACQUA D.S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHERAPY RESEARCH, 22, PP. 318-322, (2008); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., HERNANDEZ C., MENENDEZ R., AGUILAR C., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, JOURNAL OF MEDICINAL FOOD, 4, PP. 57-65, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEMISTRY, 115, PP. 918-923, (2009); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INTERNATIONAL JOURNAL OF NANOMEDICINE, 9, PP. 2261-2269, (2014); JAFFE W.R., HEALTH EFFECTS OF NON-CENTRIFUGAL SUGAR (NCS): A REVIEW, SUGAR TECH, 14, 2, PP. 87-94, (2012); JANIKULA M., CANDIDATE POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERNATIVE MEDICINE REVIEW, 7, 3, PP. 203-217, (2002); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANNAL OF NUTRITION AND METABOLISM, 37, 1, PP. 33-38, (1993); KAEWKOOL P., KRISNANGKURA K., TRANSESTERIFICATION/ACETYLATION OF LONG CHAIN ALCOHOLS WITH ALKYL ACETATE, CHEMISTRY OF PHYSICS LIPIDS, 163, PP. 685-688, (2010); KATO S., KARINO K., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., HAMATANI K., TAKAHASHI M., OGASAWARA J., MASUSHIGE S., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BRITISH JOURNAL OF NUTRITION, 73, 3, PP. 433-441, (1995); KIM S.M., CHUNG H.J., LIM S.T., EFFECT OF VARIOUS HEAT TREATMENTS ON RANCIDITY AND SOME BIOACTIVE COMPOUNDS OF RICE BRAN, JOURNAL OF CEREAL SCIENCE, 60, PP. 243-248, (2014); LIANG Y., GAO Y., LIN Q., LUO F., WU W., LU Q., LIU Y., A REVIEW OF THE RESEARCH PROGRESS ON THE BIOACTIVE INGREDIENTS AND PHYSIOLOGICAL ACTIVITIES OF RICE BRAN OIL, EUROPEAN FOOD RESEARCH AND TECHNOLOGY, 238, PP. 169-176, (2014); MARRISON W.B., HOLSER R., AKIN D.E., CUTICULAR WAX FROM FLAX PROCESSING WASTE WITH HEXANE AND SUPER CRITICAL CARBON DIOXIDE EXTRACTIONS, INDUSTRIAL CROPS AND PRODUCTS, 24, PP. 119-122, (2006); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCHIVES OF MEDICAL RESEARCH, 36, PP. 113-119, (2005); PEREZ-CAMINO M.C., MOREDA W., MATEOS R., CERT A., SIMULTANEOUS DETERMINATION OF LONG-CHAIN ALIPHATIC ALDEHYDES AND WAXES IN OLIVE OILS, JOURNAL CHROMATOGRAPHY A, 983, PP. 283-288, (2003); POPE L.E., MARCELLETTI J.F., KATZ L.R., LIN J.Y., KATZ D.H., PARISH M.L., SPEAR P.G., THE ANTIHERPES SIMPLEX VIRUS ACTIVITY OF N-DOCOSANOL INCLUDES INHIBITION OF THE VIRAL ENTRY PROCESS, ANTIVIRAL RESEARCH, 40, 1-2, PP. 85-94, (1998); REDDI P.B.V., MURTI K.S., FEUGE R.O., RICE BRAIN OIL I. OIL OBTAINED BY SOLVENT EXTRACTION, JOURNAL OF AMERICAN OIL CHEMIST'S SOCIETY, 25, 6, PP. 206-211, (1948); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CRITICAL REVIEWS IN FOOD SCIENCE NUTRITION, 25, 11, PP. 701-707, (2005); SAYRE R.N., SAUNDERS R.M., RICE BRAN AND RICE BRAN OIL, LIPID TECHNOLOGY, 2, 3, PP. 72-76, (1990); SHARIF M.K., BUTT M.S., ANJUM F.M., KHAN S.H., RICE BRAN: A NOVEL FUNCTIONAL INGREDIENT, CRITICAL REVIEWS IN FOOD SCIENCE NUTRITION, 54, PP. 807-816, (2014); THANONKAEW A., WONGYAI S., MCCLEMENTS D.J., DECKER E.A., EFFECT OF STABILIZATION OF RICE BRAN BY DOMESTIC HEATING ON MECHANICAL EXTRACTION YIELD, QUALITY, AND ANTIOXIDANT PROPERTIES OF COLD-PRESSED RICEBRAN OIL (ORYZA SALTIVA L), LWT-FOOD SCIENCE AND TECHNOLOGY, 48, PP. 231-236, (2012); VALI S.R., JU Y., KAIMAL T.N.B., CHERN Y., A PROCESS FOR THE PREPARATION OF FOOD-GRADE RICE BRAN WAX AND THE DETERMINATION OF ITS COMPOSITION, JOURNAL OF AMERICAN OIL CHEMIST'S SOCIETY, 82, 1, PP. 57-64, (2005)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, MUANG, PHITSANULOK, 99 MOO 9, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","UNIVERSITI PUTRA MALAYSIA","ENGLISH","INT. FOOD RES. J.","ARTICLE","ISI","2-S2.0-85024092613","INT FOOD RES J","NARESUAN UNIVERSITY;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;RUTGERS UNIVERSITY;NATIONAL TAIWAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"WEERAWATANAKORN M, 2017, INT FOOD RES J","WEERAWATANAKORN M, 2017, INT FOOD RES J"
"MEEROD K;WEERAWATANAKORN M;PANSAK W","MEEROD, KANYAPHAT (57203131668); WEERAWATANAKORN, MONTHANA (55976489600); PANSAK, WANWISA (58327045300)","EFFECT OF LIMING PROCESS ON PHYSICOCHEMICAL PROPERTIES AND PHYTOCHEMICAL COMPONENTS OF NONCENTRIFUGAL SUGAR FROM DIFFERENT SUGARCANE CULTIVARS",2020,"AGRICULTURAL RESEARCH","9","10",8,"10.1007/s40003-019-00409-7","DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRICULTURAL SCIENCE, FACULTY OF AGRICULTURE NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND","NON-CENTRIFUGAL SUGAR PRODUCT (NCS) IS PRODUCED WITHOUT MOLASSES REMOVAL AND CONTAINS NUTRIENTS AND PHYTOCHEMICALS INHERENTLY FOUND IN SUGARCANE. TO OBTAIN A HIGH-QUALITY PRODUCT, CLARIFYING RAW CANE JUICE, ESPECIALLY FOLLOWING THE TRADITIONAL PROCESS, IS THE MOST IMPORTANT STEP TO REMOVE CONTAMINATION AS INSOLUBLE AND SUSPENDED MATTER IMPURITIES FROM THE RIND DURING HARVESTING AND PRESSING. CALCIUM OXIDE (CAO) IS A PROMISING CHEMICAL, WIDELY USED AS A LIMING AGENT TO CLARIFY RAW JUICE BY THE TRADITIONAL NON-CENTRIFUGAL SUGAR PROCESS. HOWEVER, USE OF TRADITIONAL METHODS AND DIFFERENT CANE CULTIVARS AFFECT THE QUALITY OF SUGAR PRODUCTS. CLARIFICATION BY CALCIUM OXIDE AT DIFFERENT PH LEVELS AND THE DIVERSITY OF CANE CULTIVARS ALSO AFFECT PHYSICOCHEMICAL COMPONENTS. BIOACTIVE COMPOUNDS AMONG THE OBTAINED PRODUCTS WERE EVALUATED. CLARIFYING JUICE AT PH 8.5 GAVE HIGHEST INSOLUBLE SOLIDS (47.52 G) REMOVED FROM CANE JUICE AND LOWEST SEDIMENT VALUE (0.68%) OF NON-CENTRIFUGAL SUGAR BUT CAUSED GREATEST LOSS OF POLICOSANOL AND TRICIN CONTENTS. USING CALCIUM OXIDE CLARIFICATION, SUPHANBURI 50 CULTIVAR GAVE NCS WITH THE HIGHEST SUGAR YIELD (17.75%) BUT LOWEST COLOR VALUE (2100 IU) AND PHYTOCHEMICAL CONTENTS. LK 92-11 CANE CULTIVAR PRODUCED NCS WITH THE HIGHEST COLOR VALUE (6533.3 IU), TOTAL PHENOLIC CONTENT (1124.09 MG GAE/100 G), TOTAL FLAVONOID CONTENT (143.82 MG RUE/100 G), POLICOSANOL CONTENT (4.13 MG/100 G) AND TRICIN CONTENT (50.82 ΜG/100 G). © 2019, NAAS (NATIONAL ACADEMY OF AGRICULTURAL SCIENCES).","ANTIOXIDANT ACTIVITIES; POLICOSANOL; SUGARCANE CULTIVAR; TRICIN","CENTRIFUGATION; CLARIFIERS; LIME; PHYSICOCHEMICAL PROPERTIES; REMOVAL; SUGAR CANE; ANTI-OXIDANT ACTIVITIES; BIOACTIVE COMPOUNDS; HIGH-QUALITY PRODUCTS; POLICOSANOL; SUSPENDED MATTERS; TOTAL FLAVONOID CONTENTS; TOTAL PHENOLIC CONTENT; TRICIN; ANTIOXIDANT; BIOACTIVITY; CULTIVAR; LIMING; PHYSICOCHEMICAL PROPERTY; PHYTOCHEMISTRY; SUGAR; SUGAR CANE; CLARIFICATION","NATIONAL RESEARCH COUNCIL OF THAILAND, NRCT, (R2560B031, RDG5950040)","THIS STUDY WAS FINANCIALLY SUPPORTED BY THE NATIONAL RESEARCH COUNCIL OF THAILAND FOR RESEARCH PROJECT NUMBERS R2560B031 AND RDG5950040. WE EXPRESS OUR THANKS TO THE NULC WRITING CLINIC FOR REVIEWING THE LANGUAGE AND SYNTAX OF OUR PAPER.","ASIKIN Y., CHINEN T., TAKARA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI TECHNOL RES, 14, PP. 583-588, (2008); ASIKIN Y., KAMIYA A., MIZU M., TAKARA K., TAMAKI H., CHANGES IN THE PHYSICOCHEMICAL CHARACTERISTICS, INCLUDING FLAVOR COMPONENTS AND MAILLARD REACTION PRODUCTS, OF NON-CENTRIFUGAL CANE BROWN SUGAR DURING STORAGE, FOOD CHEM, 149, PP. 170-177, (2014); ASIKIN Y., TAKAHARA W., TAKAHASHI M., HIROSE N., ITO S., WADA K., COMPOSITIONAL AND ELECTRONIC DISCRIMINATION ANALYSES OF TASTE AND AROMA PROFILES OF NON-CENTRIFUGAL CANE BROWN SUGARS, FOOD ANAL METHODS, 10, 6, PP. 1844-1856, (2017); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, 5, PP. 583-591, (2012); BRAND-WILLIAMS W., CUVELIER M.E., BERSET C., USE OF A FREE RADICAL METHOD TO EVALUATE ANTIOXIDANT ACTIVITY, LEBENSM-WISS TECHNOL, 28, 1, PP. 25-30, (1995); CAI H., STEWARD W.P., GESCHER A.J., DETERMINATION OF THE PUTATIVE CANCER CHEMOPREVENTIVE FLAVONE TRICIN IN PLASMA AND TISSUE OF MICE BY HPLC WITH UV–VISIBLE DETECTION, BIOMED CHROMATOGR, 19, PP. 518-522, (2005); COLOMBO R., YARIWAKE J.H., QUEIROZ E.F., NDJOKO K., HOSTETTMANN K., ON-LINE IDENTIFICATION OF SUGARCANE (SACCHARUM OFFICINARUM L.) METHOXY FLAVONES BY LIQUID CHROMATOGRAPHY–UV DETECTION USING POST-COLUMN DERIVATIZATION AND LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY, J CHROMATOGR A, 1082, 1, PP. 51-59, (2005); DOHERTY W.O.S., EDYE L.A., AN OVERVIEW ON THE CHEMISTRY OF CLARIFICATION OF CANE SUGAR JUICE, PROC AUST SOC SUGAR CANE TECHNOL, 21, PP. 381-388, (1999); DUARTE-ALMEIDA J.M., SALATINO M., GENOVESE M.I., LAJOLO F.M., PHENOLIC COMPOSITION AND ANTIOXIDANT ACTIVITY OF CULMS AND SUGARCANE (SACCHARUM OFFICINARUM L) PRODUCTS, FOOD CHEM, 125, 2, PP. 660-664, (2011); FENG S., LUO Z., ZHANG Y., ZHONG Z., LU B., PHYTOCHEMICAL CONTENTS AND ANTIOXIDANT CAPACITIES OF DIFFERENT PARTS OF TWO SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, FOOD CHEM, 515, PP. 452-458, (2014); FOWLER S.P., WILLIAMS K., RESENDEZ R.G., HUNT K.J., HAZUDA H.P., STERN M.P., FUELING THE OBESITY EPIDEMIC? ARTIFICIALLY SWEETENED BEVERAGE USE AND LONG-TERM WEIGHT GAIN, OBES J, 16, 8, PP. 1894-1900, (2008); GUERRA K., PELLEGRINO J., DREWES J.E., IMPACT OF OPERATING CONDITIONS ON PERMEATE FLUX AND PROCESS ECONOMICS FOR CROSS FLOW CERAMIC MEMBRANE ULTRAFILTRATION OF SURFACE WATER, SEP PURIF TECHNOL, 87, PP. 47-53, (2012); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); JAFFE W.R., HEALTH EFFECTS OF NON-CENTRIFUGAL SUGAR (NCS): A REVIEW, SUGAR TECHNOL, 14, 2, PP. 85-94, (2012); JEGATHEESAN V., SHU L., KEIR G., PHONG D.D., EVALUATING MEMBRANE TECHNOLOGY FOR CLARIFICATION OF SUGARCANE JUICE, REV ENVIRON SCI BIOTECHNOL, 11, PP. 109-124, (2012); KHUENPET K., CHAROENJARASRERK N., JAIJIT S., ARAYAPOONPONG S., JITTANIT W., INVESTIGATION OF SUITABLE SPRAY DRYING CONDITIONS FOR SUGARCANE JUICE POWDER PRODUCTION WITH AN ENERGY CONSUMPTION STUDY, AGRIC NATL RESOUR, 50, 2, PP. 39-145, (2016); MALTINI E., TORREGGIANI D., VENIR E., BERTOLO G., WATER ACTIVITY AND THE PRESERVATION OF PLANT FOODS, FOOD CHEM, 82, 1, PP. 79-86, (2003); MANOHAR C.M., XUE J., MURAYYAN A., NEETHIRAJAN S., SHI J., ANTIOXIDANT ACTIVITY OF POLYPHENOLS FROM ONTARIO GROWN ONION VARIETIES USING PRESSURIZED LOW POLARITY WATER TECHNOLOGY, J FUNCT FOOD, 31, PP. 52-62, (2017); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH MED RES, 36, PP. 441-447, (2005); PAWAR D.A., JADHAV M.S., NIMBALKAR C.A., TECHNIQUES AND ADVANCES IN JAGGERY PROCESSING: A REVIEW DILIP, RES J CHEM ENVIRON SCI, 5, PP. 14-20, (2017); PAYET B., SING A.S.C., SMADJA J., ASSESSMENT OF ANTIOXIDANT ACTIVITY OF CANE BROWN SUGARS BY ABTS AND DPPH RADICAL SCAVENGING ASSAYS: DETERMINATION OF THEIR POLYPHENOLIC AND VOLATILE CONSTITUENTS, J AGRIC FOOD CHEM, 53, PP. 10074-10079, (2005); RAEL L.T., THOMAS G.W., CRAUN M.L., CRAUN M.L., CURTIS C.G., BAR-OR R., BAR-OR D., LIPID PEROXIDATION AND THE THIOBARBITURIC ACID ASSAY: STANDARDIZATION OF THE ASSAY WHEN USING SATURATED AND UNSATURATED FATTY ACIDS, BMB REPORT, 37, PP. 749-752, (2004); SHAHIDI F., NACZK M., PHENOLICS IN FOOD AND NUTRACEUTICALS, (2004); SHITTU T.A., LAWAL M.O., FACTORS AFFECTING INSTANT PROPERTIES OF POWDERED COCOA BEVERAGES, FOOD CHEM, 1, PP. 91-98, (2007); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP, 318, PP. 1020-1026, (2006); STEINDL R.J., CLARIFICATION OF CANE JUICE FOR FERMENTATION, PROC INT SOC SUGAR CANE TECHNOL, 27, PP. 1-10, (2010); VERSCHOYLE R.E., GREAVES P., CAI H., ARNDT B., BROGGINI M., D'INCALCI M., RICCIO E., DOPPALAPEED R., KAPETANOVIC I.M., STEWAND W.P., GESCHER A.J., PRELIMINARY SAFETY EVALUATION OF THE PUTATIVE CANCER CHEMO PREVENTIVE AGENT TRICIN, A NATURALLY OCCURRING FLAVONE, CANCER CHEMOTHER PHARMACOL, 57, PP. 1-6, (2006); VIJAY V.K., AGARWAL U.S., STUDIES ON CENTRIFUGAL CLARIFICATION OF SUGARCANE JUICE—POSSIBILITIES AND LIMITATIONS, AGRIC ENG INT: CIGRE J, 10, PP. 1-11, (2008); WEERAWATANAKORN M., ASIKIN Y., TAKAHASHI M., TAMAKI H., WADA K., HO C.T., CHUEKITTISAK R., PHYSICO-CHEMICAL PROPERTIES, WAX COMPOSITION, AROMA PROFILES, AND ANTIOXIDANT ACTIVITY OF GRANULATED NON-CENTRIFUGAL SUGARS FROM SUGARCANE CULTIVARS OF THAILAND, FOOD SCI TECHNOL, 53, 11, PP. 4084-4092, (2016); XU R.Y., NIIMI Y., HAN D.S., CHANGES IN ENDOGENOUS ABSCISIC ACID AND SOLUBLE SUGARS LEVELS DURING DORMANCY-RELEASE IN BULBS OF LILIUM RUBELLUM, SCI HORTIC, 111, PP. 68-72, (2006)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, PHITSANULOK, 99 MOO 9, THA PHO, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","SPRINGER","ENGLISH","AGRIC. RES.","ARTICLE","ISI","2-S2.0-85065790652","AGRIC RES","NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;NARESUAN UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"MEEROD K, 2020, AGRIC RES","MEEROD K, 2020, AGRIC RES"
"MARAZZI G;CAMPOLONGO G;PELLICCIA F;CALABRÒ M P;CACCIOTTI L;VITALE C;MASSARO R;VOLTERRANI M;ROSANO G","MARAZZI, GIUSEPPE (6602583977); CAMPOLONGO, GIUSEPPE (8575747900); PELLICCIA, FRANCESCO (7005360685); CALABRÒ MD, PAOLO (57205105336); CACCIOTTI, LUCA (6506023158); VITALE, CRISTIANA (7005091702); MASSARO, ROSALBA (26649541500); VOLTERRANI, MAURIZIO (7004062259); ROSANO, GIUSEPPE (7007131876)","USEFULNESS OF LOWDOSE STATIN PLUS EZETIMIBE ANDOR NUTRACEUTICALS IN PATIENTS WITH CORONARY ARTERY DISEASE INTOLERANT TO HIGHDOSE STATIN TREATMENT",2019,"AMERICAN JOURNAL OF CARDIOLOGY","123","5",15,"10.1016/j.amjcard.2018.09.041","INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY;UNIVERSITY OF ROME “LA SAPIENZA”, ROME, ITALY;UNIVERSITY OF CAMPANIA, CASERTA, ITALY;INSTITUTE OF CARDIOLOGY, MADRE GIUSEPPINA VANNINI HOSPITAL, ROME, ITALY;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY, ST GEORGE'S HOSPITAL NHS TRUST MEDICAL SCHOOL, LONDON, UNITED KINGDOM;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY, ST GEORGE'S HOSPITAL NHS TRUST MEDICAL SCHOOL, LONDON, UNITED KINGDOM","HIGH-DOSE STATIN (HDS) THERAPY IS RECOMMENDED TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C); HOWEVER, SOME PATIENTS ARE UNABLE TO TOLERATE THE ASSOCIATED SIDE EFFECTS. NUTRACEUTICALS HAVE SHOWN EFFICACY IN LOWERING LDL-C. THE AIM OF THIS STUDY WAS TO EVALUATE WHETHER THE COMBINATION OF LOW-DOSE STATIN (LDS) PLUS EZETIMIBE (EZE) OR LDS PLUS NUTRACEUTICAL (ARMOLIPID PLUS [ALP] CONTAINING RED YEAST RICE, POLICOSANOL, AND BERBERINE) CAN LEAD TO A HIGHER PROPORTION OF HIGH-RISK PATIENTS ACHIEVING TARGET LDL-C. A SECONDARY OBJECTIVE WAS TO ASSESS THE EFFICACY OF TRIPLE COMBINATION LDS + EZE + ALP IN RESISTANT PATIENTS (LDL-C >70 MG/DL). A RANDOMIZED, PROSPECTIVE, PARALLEL-GROUP, SINGLE-BLIND STUDY WAS CONDUCTED IN PATIENTS WITH CORONARY ARTERY DISEASE (N = 100) WHO HAD UNDERGONE PERCUTANEOUS CORONARY INTERVENTION IN THE PRECEDING 12 MONTHS, WERE HDS-INTOLERANT, AND WERE NOT AT LDL-C TARGET (<70 MG/DL) WITH LDS ALONE. PATIENTS RECEIVED EITHER LDS + EZE OR LDS + ALP. OF THE 100 PATIENTS, 33 PATIENTS (66%) TREATED WITH LDS + EZE AND 31 PATIENTS (62%) TREATED WITH LDS + ALP ACHIEVED TARGET LDL-C AFTER 3 MONTHS, WHICH WAS MAINTAINED AT 6 MONTHS. PATIENTS WHO DID NOT ACHIEVE THE THERAPEUTIC GOAL RECEIVED A TRIPLE COMBINATION OF LDS + EZE + ALP FOR A FURTHER 3 MONTHS. AT 6 MONTHS, 28 OF 36 PATIENTS (78%) ACHIEVED LDL-C TARGET. OVERALL, 92% OF PATIENTS ENROLLED IN THIS STUDY WERE AT TARGET LDL-C AT 6 MONTHS. NO PATIENTS IN ANY GROUP EXPERIENCED MAJOR SIDE EFFECTS. IN CONCLUSION, IN HDS-INTOLERANT CORONARY ARTERY DISEASE PATIENTS, THE COMBINATION OF LDS PLUS EZE AND/OR ALP REPRESENTS A VALUABLE THERAPEUTIC OPTION ALLOWING MOST PATIENTS TO REACH TARGET LDL-C WITHIN 3 TO 6 MONTHS. © 2018","","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BERBERINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; BLOOD; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENT; DOSE RESPONSE; MIDDLE AGED","MINISTERO DELL’ISTRUZIONE, DELL’UNIVERSITÀ E DELLA RICERCA, MIUR; EUROPEAN REGIONAL DEVELOPMENT FUND, ERDF; PROJECTS FOR SCIENTIFIC RESEARCH AND INDUSTRIAL COMPETITIVENESS, (PON03PE_00078)","FUNDING TEXT 1: FUNDING: THIS WORK WAS SUPPORTED BY THE ITALIAN MINISTRY OF EDUCATION, UNIVERSITY AND RESEARCH, ITALY. THE NATIONAL OPERATIONAL PROGRAM (PON) FOR RESEARCH AND COMPETITIVENESS IS CO-FUNDED WITH THE EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF) AND NATIONAL RESOURCES. IT PROMOTES INITIATIVES AND PROJECTS FOR SCIENTIFIC RESEARCH AND INDUSTRIAL COMPETITIVENESS, GRANTNUMBER PON03PE_00078.; FUNDING TEXT 2: FUNDING: THIS WORK WAS SUPPORTED BY THE ITALIAN MINISTRY OF EDUCATION, UNIVERSITY AND RESEARCH, ITALY . THE NATIONAL OPERATIONAL PROGRAM (PON) FOR RESEARCH AND COMPETITIVENESS IS CO-FUNDED WITH THE EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF) AND NATIONAL RESOURCES. IT PROMOTES INITIATIVES AND PROJECTS FOR SCIENTIFIC RESEARCH AND INDUSTRIAL COMPETITIVENESS, GRANTNUMBER PON03PE_00078. ","PARRIS E.S., LAWRENCE D.B., MOHN L.A., LONG L.B., ADHERENCE TO STATIN THERAPY AND LDL CHOLESTEROL GOAL ATTAINMENT BY PATIENTS WITH DIABETES AND DYSLIPIDEMIA, DIABETES CARE, 28, PP. 595-599, (2005); PIRRO M., DEL GIORNO R., LUPATTELLI G., MANNARINO M.R., ROSCINI A.R., COVELLI D., SCHILLACI G., PASQUALINI L., BAGAGLIA F., SIEPI D., MANNARINO E., CARDIOVASCULAR RISK FACTORS AND RECOMMENDED LIPID GOALS ATTAINMENT AMONG PATIENTS REFERRED IN A TERTIARY CARE LIPID CLINIC, EUR J INTERN MED, 22, PP. 412-417, (2011); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., REINER Z., RICCARDI G., TASKINEN M.R., TOKGOZOGLU L., VERSCHUREN W.M., VLACHOPOULOS C., WOOD D.A., ZAMORANO J.L., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), EUR HEART J, 37, PP. 2999-3058, (2016); WARD N.C., PANG J., RYAN J.D.M., WATTS G.F., NUTRACEUTICALS IN THE MANAGEMENT OF PATIENTS WITH STATIN-ASSOCIATED MUSCLE SYMPTOMS, WITH A NOTE ON REAL-WORLD EXPERIENCE, CLIN CARDIOL, 41, PP. 159-165, (2018); WARD N., SAHEBKAR A., BANACH M., WATTS G., RECENT PERSPECTIVES ON THE ROLE OF NUTRACEUTICALS AS CHOLESTEROL-LOWERING AGENTS, CURR OPIN LIPIDOL, 28, PP. 495-501, (2017); CICERO A.F., DEROSA G., BOVE M., IMOLA F., BORGI C., GADDI A.V., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOP NUTRACEUTICAL RES, 7, PP. 121-126, (2009); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); BARRIOS V., ESCOBAR C., CICERO A.F.G., BURKE D., FASCHING P., BANACH M., BRUCKERT E., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., TRIMARCO B., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, PP. 1482-1487, (2010); PIRRO M., MANNARINO M.R., BIANCONI V., SIMENTAL-MENDIA L.E., BAGAGLIA F., MANNARINO E., SAHEBKAR A., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); MARAZZI G., PELLICCIA F., CAMPOLONGO G., QUATTRINO S., CACCIOTTI L., VOLTERRANI M., GAUDIO C., ROSANO G., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM J CARDIOL, 116, PP. 1798-1801, (2015); MARAZZI G., CAMPOLONGO G., PELLICCIA F., QUATTRINO S., VITALE C., CACCIOTTI L., MASSARO R., VOLTERRANI M., ROSANO G., COMPARISON OF LOW-DOSE STATIN VERSUS LOW-DOSE STATIN + ARMOLIPID PLUS IN HIGH-INTENSITY STATIN-INTOLERANT PATIENTS WITH A PREVIOUS CORONARY EVENT AND PERCUTANEOUS CORONARY INTERVENTION (ADHERENCE TRIAL), AM J CARDIOL, 120, PP. 893-897, (2017); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., MORINA D., VILLAR J., MILLAN J., ANGUERA A., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); PANDOR A., ARA R.M., TUMUR I., WILKINSON A.J., PAISLEY S., DUENAS A., DURRINGTON P.N., CHILCOTT J., EZETIMIBE MONOTHERAPY FOR CHOLESTEROL LOWERING IN 2,722 PEOPLE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J INTERN MED, 265, PP. 568-580, (2009); ENDO A., CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS, KLIN WOCHENSCHR, 66, PP. 421-427, (1988); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); POLICOSANOL, ALTERN MED REV, 9, PP. 312-317, (2004); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); DOGGRELL S.A., BERBERINE—A NOVEL APPROACH TO CHOLESTEROL LOWERING, EXPERT OPIN INVESTIG DRUGS, 14, PP. 683-685, (2005); GUARININ G., MARZILLI M., DEFINING THE ROLE OF HIGH-DOSE STATINS IN PCI, AM J CARDIOVASC DRUGS, 13, PP. 189-197, (2013); MANSI I.A., MORTENSEN E.M., PUGH M.J., WEGNER M., FREI C.R., INCIDENCE OF MUSCULOSKELETAL AND NEOPLASTIC DISEASES IN PATIENTS ON STATIN THERAPY: RESULTS OF A RETROSPECTIVE COHORT ANALYSIS, AM J MED SCI, 345, PP. 343-348, (2013); DORMUTH C.R., FILION K.B., PATERSON J.M., JAMES M.T., TEARE G.F., RAYMOND C.B., RAHME E., TAMIM H., LIPSCOMBE L., HIGHER POTENCY STATINS AND THE RISK OF NEW DIABETES: MULTICENTRE, OBSERVATIONAL STUDY OF ADMINISTRATIVE DATABASES, BMJ, 348, (2014); HUANG X., ALONSO A., GUO X., UMBACH D.M., LICHTENSTEIN M.L., BALLANTYNE C.M., MAILMAN R.B., MOSLEY T.H., CHEN H., STATINS, PLASMA CHOLESTEROL, AND RISK OF PARKINSON'S DISEASE: A PROSPECTIVE STUDY, MOV DISORD, 30, PP. 552-559, (2015); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., GREENFIELD R.S., HOVINGH G.K., KOSTNER K., SERBAN C., LIGHEZAN D., FRAS Z., MORIARTY P.M., MUNTNER P., GOUDEV A., CESKA R., NICHOLLS S.J., BRONCEL M., NIKOLIC D., PELLA D., PURI R., RYSZ J., WONG N.D., BAJNOK L., JONES S.R., RAY K.K., MIKHAILIDIS D.P., STATIN INTOLERANCE—AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015)","G. MARAZZI; INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE, ROME, ITALY; EMAIL: GIUSEPPE.MARAZZI@SANRAFFAELE.IT","ELSEVIER INC.","ENGLISH","AM. J. CARDIOL.","ARTICLE","ISI","2-S2.0-85056219051","AM J CARDIOL","INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE;UNIVERSITY OF ROME “LA SAPIENZA”;UNIVERSITY OF CAMPANIA;INSTITUTE OF CARDIOLOGY;ST GEORGE'S HOSPITAL NHS TRUST MEDICAL SCHOOL;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE;ST GEORGE'S HOSPITAL NHS TRUST MEDICAL SCHOOL","NOTREPORTED;INSTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE;NOTREPORTED",NA,"MARAZZI G, 2019, AM J CARDIOL","MARAZZI G, 2019, AM J CARDIOL"
"LIU T;WU C;HE F;YUAN W;LI S;LI H;YU H;WU M","LIU, T.N. (57189852314); WU, C.T. (57189848246); HE, F. (57189851313); YUAN, W. (57189842951); LI, S.X. (57189848185); LI, H.W. (57189848948); YU, H.Y. (57189852751); WU, M. (57189843683)","RELATIONSHIP BETWEEN THE G75A POLYMORPHISM IN THE APOLIPOPROTEIN A1 APOA1 GENE AND THE LIPID REGULATORY EFFECTS OF PRAVASTATIN IN PATIENTS WITH HYPERLIPIDEMIA",2016,"GENETICS AND MOLECULAR RESEARCH","15","",5,"10.4238/gmr.15028216","CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;CARDIOVASCULAR DIVISION, AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY, TANGSHAN, HEBEI, CHINA;THE PEOPLE’S HOSPITAL OF TANGSHAN, TANGSHAN, CHINA","IN THIS STUDY, WE INVESTIGATED THE RELATIONSHIP BETWEEN THE G75A POLYMORPHISM IN THE APOLIPOPROTEIN A1 (APOA1) GENE AND THE LIPID REGULATORY EFFECT OF PRAVASTATIN IN PATIENTS WITH HYPERLIPIDEMIA. A TOTAL OF 179 PATIENTS WERE DIVIDED INTO TWO GROUPS: THE PRAVASTATIN (N = 97) AND POLICOSANOL (N = 82) TREATMENT GROUPS. THE TOTAL CHOLESTEROL (TC), TRIGLYCERIDE, LOW-DENSITY LIPOPROTEIN (LDL-C), HIGH-DENSITY LIPOPROTEIN, APOA, AND APOB CONCENTRATIONS IN THE SERUM WERE MEASURED USING AN AUTOMATIC BIOCHEMICAL ANALYZER BEFORE AND AFTER TREATMENT FOR 12 WEEKS. THE GENOTYPES OF THE APOA1 G75A SNP WERE DETECTED BY POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM, AND WERE SUBSEQUENTLY STATISTICALLY ANALYZED. PRAVASTATIN TREATMENT INDUCED A SIGNIFICANT DECREASE IN THE TC, LDL-C, AND APOB LEVELS IN PATIENTS EXPRESSING THE APOA1 AA+GA GENOTYPE (P < 0.05), AND NOT IN THOSE EXPRESSING THE GG GENOTYPE (P > 0.05). HOWEVER, POLICOSANOL TREATMENT INDUCED A NON-SIGNIFICANT DECREASE IN THE SERUM TC LEVELS (P > 0.05) AND A SIGNIFICANT DECREASE IN THE APOB LEVELS (P < 0.05), AND DID NOT INDUCE A DECREASE IN THE LDL-C (P > 0.05) LEVELS IN PATIENTS WITH THE AA+GA GENOTYPE. POLICOSANOL ALSO INDUCED A SIGNIFICANT DECREASE IN THE TC AND LDL-C LEVELS IN PATIENTS WITH THE GG GENOTYPE (P < 0.05). THE VARIOUS GENOTYPES OF THE APOA1 G75A SNP INFLUENCE THE EFFICACY OF LIPID REGULATION BY PRAVASTATIN AND POLICOSANOL IN PATIENTS WITH HYPERLIPIDEMIA. © FUNPEC-RP.","APOLIPOPROTEIN A1; GENE POLYMORPHISM; HYPERLIPIDEMIA; POLICOSANOL; PRAVASTATIN; TOTAL CHOLESTEROL","ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; FATTY ALCOHOLS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; PRAVASTATIN; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN A1; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; POLICOSANOL; PRAVASTATIN; APOA1 GENE; ARTICLE; AUTOANALYZER; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG ACTIVITY; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIPID REGULATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; GENETICS; HYPERLIPIDEMIAS","","","CANNIOTO Z., STATINS, HYPERLIPEMIA AND OBESITY: STATE OF THE ART, MEDICO E BAMBINO, 27, PP. 309-318, (2008); FAN Y., CHEN Y.H., LIU M.L., THE THERAPEUTIC EFFICACY AND SAFETY OF DIFFERENT STATINS IN ELDERLY, ZHONGHUA LAONIAN XIN-NAO-XUEGUANBING ZAZHI, 42, PP. 910-915, (2010); GAMEZ R., ALEMAN C.L., MAS R., NOA M., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J. MED. FOOD, 4, PP. 57-65, (2001); GOMEZ P., PEREZ-MARTINEZ P., MARIN C., CAMARGO A., ET AL., APOA1 AND APOA4 GENE POLYMORPHISMS INFLUENCE THE EFFECTS OF DIETARY FAT ON LDL PARTICLE SIZE AND OXIDATION IN HEALTHY YOUNG ADULTS, J. NUTR., 140, PP. 773-778, (2010); JEENAH M., KESSLING A., MILLER N., HUMPHRIES S., G TO A SUBSTITUTION IN THE PROMOTER REGION OF THE APOLIPOPROTEIN AI GENE IS ASSOCIATED WITH ELEVATED SERUM APOLIPOPROTEIN AI AND HIGH DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATIONS, MOL. BIOL. MED., 7, PP. 233-241, (1990); LAHOZ C., PENA R., MOSTAZA J.M., JIMENEZ J., ET AL., APO A-I PROMOTER POLYMORPHISM INFLUENCES BASAL HDL-CHOLESTEROL AND ITS RESPONSE TO PRAVASTATIN THERAPY, ATHEROSCLEROSIS, 168, PP. 289-295, (2003); MATSUNAGA A., SASAKI J., MORI T., MORIYAMA K., ET AL., APOLIPOPROTEIN A-I GENE PROMOTER POLYMORPHISM IN PATIENTS WITH CORONARY ARTERY DISEASE AND HEALTHY CONTROLS, NUTR. METAB. CARDIOVASC. DIS., 5, PP. 269-275, (1995); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); MARSH J.B., DRABKIN D.L., EXPERIMENTAL RECONSTRUCTION OF METABOLIC PATTERN OF LIPID NEPHROSIS: KEY ROLE OF HEPATIC PROTEIN SYNTHESIS IN HYPERLIPEMIA, METABOLISM, 9, PP. 946-955, (1960); NORDOY A., HANSEN J.B., BROX J., SVENSSON B., EFFECTS OF ATORVASTATIN AND OMEGA-3 FATTY ACIDS ON LDL SUBFRACTIONS AND POSTPRANDIAL HYPERLIPEMIA IN PATIENTS WITH COMBINED HYPERLIPEMIA, NUTR. METAB. CARDIOVASC. DIS., 11, PP. 7-16, (2001); PAGANI F., SIDOLI A., GIUDICI G.A., BARENGHI L., ET AL., HUMAN APOLIPOPROTEIN A-I GENE PROMOTER POLYMORPHISM: ASSOCIATION WITH HYPERALPHALIPOPROTEINEMIA, J. LIPID RES., 31, PP. 1371-1377, (1990); SMITH J.D., BRINTON E.A., BRESLOW J.L., POLYMORPHISM IN HUMAN APOLIPOPROTEIN A1 GENE PROMOTER REGION, J. CLIN. INVEST., 89, PP. 1796-1800, (1992); STANCU C., SIMA A., STATINS: MECHANISM OF ACTION AND EFFECTS, J. CELL. MOL. MED., 5, PP. 378-387, (2001); VAUGHAN C.J., DELANTY N., NEUROPROTECTIVE PROPERTIES OF STATINS IN CEREBRAL ISCHEMIA AND STROKE, STROKE, 30, PP. 1969-1973, (1999)","M. WU; THE PEOPLE’S HOSPITAL OF TANGSHAN, TANGSHAN, CHINA; EMAIL: WUMAN_L@163.COM","FUNDACAO DE PESQUISAS CIENTIFICAS DE RIBEIRAO PRETO","ENGLISH","GENET. MOL. RES.","ARTICLE","ISI","2-S2.0-84975229387","GENET MOL RES","AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;AFFILIATED HOSPITAL OF THE NORTH CHINA UNIVERSITY OF TECHNOLOGY;THE PEOPLE’S HOSPITAL OF TANGSHAN","NOTREPORTED;THE PEOPLE’S HOSPITAL OF TANGSHAN;NOTREPORTED",NA,"LIU TN, 2016, GENET MOL RES","LIU TN, 2016, GENET MOL RES"
"RUSSO R;GALLELLI L;CANNATARO R;PERRI M;CALIGNANO A;CITRARO R;RUSSO E;GARERI P;CORSONELLO A;DE S G","RUSSO, ROBERTO (35300514700); GALLELLI, LUCA (6602177838); CANNATARO, ROBERTO (56342206300); PERRI, MARIARITA (24480172900); CALIGNANO, ANTONIO (7003942979); CITRARO, RITA (13806486700); RUSSO, EMILIO (57200140760); GARERI, PIETRO (55893048200); CORSONELLO, ANDREA (7004506315); DE SARRO, GIOVAMBATTISTA (57201386594)","WHEN NUTRACEUTICALS REINFORCE DRUGS SIDE EFFECTS A CASE REPORT",2016,"CURRENT DRUG SAFETY","11","2",15,"10.2174/1574886311666160201152047","DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY FEDERICO II NAPLES, NAPLES, ITALY;DEPARTMENT OF HEALTH SCIENCE, SCHOOL OF MEDICINE, UNIVERSITY OF CATANZARO, CLINICAL PHARMACOLOGY UNIT, MATER DOMINI UNIVERSITY HOSPITAL, CATANZARO, CATANZARO, ITALY;DEPARTMENT OF PHARMACY, NUTRITION AND HEALTH SCIENCES, UNIVERSITY OF CALABRIA, RENDE (CS), RENDE, CS, ITALY;DEPARTMENT OF PHARMACY, NUTRITION AND HEALTH SCIENCES, UNIVERSITY OF CALABRIA, RENDE (CS), RENDE, CS, ITALY;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY FEDERICO II NAPLES, NAPLES, ITALY;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY FEDERICO II NAPLES, NAPLES, ITALY;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY FEDERICO II NAPLES, NAPLES, ITALY;ELDERLY HEALTH CARE, AMBULATORY CENTER FOR DEMENTIA, ASP CATANZARO, CATANZARO, ITALY;INRCA COSENZA, COSENZA, ITALY;DEPARTMENT OF HEALTH SCIENCE, SCHOOL OF MEDICINE, UNIVERSITY OF CATANZARO, CLINICAL PHARMACOLOGY UNIT, MATER DOMINI UNIVERSITY HOSPITAL, CATANZARO, CATANZARO, ITALY","INTRODUCTION: NUTRACEUTICAL IS A TERM APPLIED FOR A PLETHORA OF PRODUCTS RANGING FROM ISOLATED NUTRIENTS, HERBAL PRODUCTS TO DIETARY SUPPLEMENTS AND RECENTLY, THE INTEREST FOR A NUTRACEUTICAL APPROACH TO LIPID AND METABOLIC DISORDERS IS GROWING. PATIENTS WITH METABOLIC CONDITIONS SEEM TO APPRECIATE A THERAPEUTIC MANAGEMENT THAT DOES NOT INVOLVE DRUG TREATMENT, PARTICULARLY FOR THE SIDE EFFECTS DUE TO STATINS, A CLASS OF DRUG USED FOR LIPID DISORDERS. STATINS DIRECTLY INDUCE SKELETAL MUSCLE INJURY AND IN THE ELDERLY PATIENTS, UNDER POLYTHERAPY TREATMENTS, THIS RISK RELIES TO AN INCREASE IN ADVERSE DRUG REACTIONS DUE TO DRUG INTERACTIONS. CASE DESCRIPTION: HEREIN WE REPORT A 70-YEAR-OLD WOMAN UNDER POLYTHERAPY WHO DEVELOPED RHABDOMYOLYSIS AFTER STARTING THE ADMINISTRATION OF A DIETARY SUPPLEMENT CONTAINING MONACOLIN K. USING THE DRUG INTERACTION PROBABILITY SCALE, WE POSTULATED THAT RHABDOMYOLYSIS WAS POSSIBLY RELATED TO A DRUG INTERACTION BETWEEN SERTRALINE, ROSUVASTATIN AND MONACOLIN K. THESE TREATMENTS WERE DISCONTINUED LEADING TO A REMISSION OF BOTH CLINICAL SYMPTOMS AND BIOCHEMICAL PARAMETERS. CONCLUSION: THIS CASE REPORT HIGHLIGHTS HOW PHARMACOLOGICAL TREATMENT MUST BE PERIODICALLY REASSESSED, SINCE ELDERLY PEOPLE COULD TAKE DRUGS BY THEMSELVES WHEN THEY DONOT NEED. © 2016 BENTHAM SCIENCE PUBLISHERS.","INTERACTION; NUTRACEUTICAL; RED YEAST RICE; RHABDOMYOLYSIS; ROSUVASTATIN; SERTRALINE","AGED; DIETARY SUPPLEMENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; RHABDOMYOLYSIS; ROSUVASTATIN CALCIUM; ASTAXANTHIN; BERBERINE; CHOLESTEROL; CHOLESTIN; ESCITALOPRAM; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE PLUS PERINDOPRIL; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; POLICOSANOL; PRAMIPEXOLE; ROSUVASTATIN; SERTRALINE; UBIDECARENONE; ROSUVASTATIN; AGED; ARTICLE; ASSESSMENT OF HUMANS; BEDTIME DOSAGE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DIETARY SUPPLEMENT; DRUG INTERACTION; DRUG INTERACTION PROBABILITY SCALE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERIATRIC DEPRESSION SCALE; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; MOBILIZATION; MORNING DOSAGE; MUSCLE WEAKNESS; MYALGIA; PARKINSON DISEASE; PRIORITY JOURNAL; REMISSION; RHABDOMYOLYSIS; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOOD DRUG INTERACTION; METABOLISM; PHYSIOLOGY; RHABDOMYOLYSIS","","","GEORGIOU N.A., GARSSEN J., WITKAMP R.F., PHARMA-NUTRITION INTERFACE: THE GAP IS NARROWING, EUR J PHARMACOL, 651, 1-3, PP. 1-8, (2011); GELLER A.I., SHEHAB N., WEIDLE N.J., ET AL., EMERGENCY DEPARTMENT VISITS FOR ADVERSE EVENTS RELATED TO DIETARY SUPPLEMENTS, NEW ENGL J MED, 373, 16, PP. 1531-1540, (2015); FELIX T.M., KARPA K.D., LEWIS P.R., ADVERSE EFFECTS OF COMMON DRUGS:DIETARY SUPPLEMENTS, FP ESSEN, 436, PP. 31-40, (2015); LEE C.L., HUNG Y.P., HSU Y.W., PAN T.M., MONASCIN AND ANKAFLAVIN HAVE MORE ANTI-ATHEROSCLEROSIS EFFECT AND LESS SIDE EFFECT INVOLVING INCREASING CREATININE PHOSPHOKINASE ACTIVITY THAN MONACOLIN K UNDER THE SAME DOSAGES, J AGRIC FOOD CHEM, 61, 1, PP. 143-150, (2013); HORN J.R., HANSTEN P.D., CHAN L.N., PROPOSAL FOR A NEW TOOL TO EVALUATE DRUG INTERACTION CASES, ANN PHARMACOTH, 41, 4, PP. 674-680, (2007); GALLELLI L., DE FAZIO S., CORACE E., DE SARRO G., GARCIA C.S., DE FAZIO P., GENERALISED URTICARIA IN A YOUNG WOMAN TREATED WITH CLOMIPRAMINE AND AFTER INGESTION OF CODFISH, PHARMACOPSYCHIATRY, 39, 4, PP. 154-156, (2006); GARERI P., SEGURA-GARCIA C., DE FAZIO P., DE FAZIO S., DE SARRO G., SERTRALINE-INDUCED RHABDOMYOLYSIS IN AN ELDERLY PATIENT WITH DEMENTIA AND COMORBIDITIES, ANN PHARMACOTHER, 43, 7, PP. 1354-1359, (2009); GALLELLI L., FERRARO M., SPAGNUOLO V., RENDE P., MAURO G.F., DE SARRO G., ROSUVASTATIN-INDUCED RHABDOMYOLYSIS PROBABLY VIA CYP2C9 SATURATION, DRUG METABOL DRUG INTERACT, 24, 1, PP. 83-87, (2009); LAROSA J.C., HE J., VUPPUTURI S., EFFECT OF STATINS ON RISK OF CORONARY DISEASE - A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, JAMA-J AM MED ASSOC, 282, 24, PP. 2340-2346, (1999); BALLANTYNE C.M., CORSINI A., DAVIDSON M.H., ET AL., RISK FOR MYOPATHY WITH STATIN THERAPY IN HIGH-RISK PATIENTS, ARCH INTERN MED, 163, 5, PP. 553-564, (2003); RHABDOMYOLYSIS LINKED TO CHINESE RED YEAST RICE, PRESCRIRE INTERNATIONAL, 17, 94, (2008); MASTAGLIA F.L., NEEDHAM M., UPDATE ON TOXIC MYOPATHIES, CURR NEUROL NEUROSCI, 12, 1, PP. 54-61, (2012); PHILIBERT C., BRES V., JEAN-PASTOR M.J., ET AL., READ YEAST RICE INDUCED MUSCULAR INJURIES: ANALYSIS OF FRENCH PHARMACOVIGILANCE DATABASE AND LITERATURE REVIEW, THERAPIE, 15, (2015); CURRY S.C., CHANG D., CONNOR D., DRUG- AND TOXIN-INDUCED RHABDOMYOLYSIS, ANN EMERG MED, 18, 10, PP. 1068-1084, (1989); LABOTZ M., WOLFF T.K., NAKASONE K.T., KIMURA I.F., HETZLER R.K., NICHOLS A.W., SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND RHABDOMYOLYSIS AFTER ECCENTRIC EXERCISE, MED SCI SPORTS EXERC, 38, 9, PP. 1539-1542, (2006); WILSON A.D., HOWELL C., WARING W.S., VENLAFAXINE INGESTION IS ASSOCIATED WITH RHABDOMYOLYSIS IN ADULTS: A CASE SERIES, THE JOURNAL OF TOXICOLOGICAL SCIENCES, 32, 1, PP. 97-101, (2007); HUANG S.S., YANG H.Y., LIN Y.C., CHAN C.H., LOW-DOSE VENLAFAXINEINDUCED SEVERE RHABDOMYOLYSIS: A CASE REPORT, GEN HOSP PSYCHIATRY, 34, 4, (2012); GALLELLI L., GALLELLI G., CODAMO G., ET AL., RECOGNIZING SEVERE ADVERSE DRUG REACTIONS: TWO CASE REPORTS AFTER SWITCHING THERAPIES TO THE SAME GENERIC COMPANY, CURR DRUG SAF, 10, 3, (2015); GALLELLI L., STALTARI O., PALLERIA C., DI MIZIO G., DE SARRO G., CAROLEO B., A CASE OF ADVERSE DRUG REACTION INDUCED BY DISPENSING ERROR, J FORENSIC LEG MED, 19, 8, PP. 497-498, (2012)","L. GALLELLI; DEPARTMENT OF HEALTH SCIENCE, SCHOOL OF MEDICINE, UNIVERSITY OF CATANZARO, CLINICAL PHARMACOLOGY UNIT, MATER DOMINI UNIVERSITY HOSPITAL, CATANZARO, VIALE EUROPA - GERMANETO, 88100, ITALY; EMAIL: GALLELLI@UNICZ.IT","BENTHAM SCIENCE PUBLISHERS B.V.","ENGLISH","CURR. DRUG SAF.","ARTICLE","ISI","2-S2.0-84989257141","CURR DRUG SAF","UNIVERSITY FEDERICO II NAPLES;UNIVERSITY OF CATANZARO;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY FEDERICO II NAPLES;UNIVERSITY FEDERICO II NAPLES;UNIVERSITY FEDERICO II NAPLES;AMBULATORY CENTER FOR DEMENTIA;UNIVERSITY OF CATANZARO","NOTREPORTED;UNIVERSITY OF CATANZARO;NOTREPORTED",NA,"RUSSO R, 2016, CURR DRUG SAF","RUSSO R, 2016, CURR DRUG SAF"
"PIRRO M;VETRANI C;BIANCHI C;MANNARINO M;BERNINI F;RIVELLESE A","PIRRO, M. (22036502300); VETRANI, C. (55351068000); BIANCHI, C. (7202398564); MANNARINO, M.R. (26643162800); BERNINI, F. (7005062280); RIVELLESE, A.A. (7004398863)","JOINT POSITION STATEMENT ON NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA OF THE ITALIAN SOCIETY OF DIABETOLOGY SID AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS SISA",2017,"NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES","27","15",88,"10.1016/j.numecd.2016.11.122","UNIT OF INTERNAL MEDICINE, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY, ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, “FEDERICO II” UNIVERSITY, NAPLES, ITALY, ITALIAN SOCIETY OF DIABETOLOGY (SID), ITALY;ITALIAN SOCIETY OF DIABETOLOGY (SID), ITALY, UNIT OF DIABETOLOGY AND METABOLIC DISEASES, DEPARTMENT OF MEDICAL AREA “AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA”, PISA, ITALY;UNIT OF INTERNAL MEDICINE, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY, ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), ITALY;ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), ITALY, DEPARTMENT OF PHARMACY, UNIVERSITY OF PARMA, PARMA, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, “FEDERICO II” UNIVERSITY, NAPLES, ITALY, ITALIAN SOCIETY OF DIABETOLOGY (SID), ITALY","AIM EVIDENCE SHOWED THAT LDL-CHOLESTEROL LOWERING IS ASSOCIATED WITH A SIGNIFICANT CARDIOVASCULAR RISK REDUCTION. THE INITIAL THERAPEUTIC APPROACH TO HYPERCHOLESTEROLEMIA INCLUDES DIETARY MODIFICATIONS BUT THE COMPLIANCE TO RECOMMENDATIONS IS OFTEN INADEQUATE. SOME DIETARY COMPONENTS WITH POTENTIAL CHOLESTEROL-LOWERING ACTIVITY ARE PRESENT IN SMALL AMOUNTS IN FOOD. THEREFORE, IN RECENT YEARS THE USE OF “NUTRACEUTICALS” (I.E., NUTRIENTS AND/OR BIOACTIVE COMPOUNDS WITH POTENTIAL BENEFICIAL EFFECTS ON HUMAN HEALTH) HAS BECOME WIDESPREAD. SUCH SUBSTANCES MAY BE ADDED TO FOODS AND BEVERAGES, OR TAKEN AS DIETARY SUPPLEMENTS (LIQUID PREPARATIONS, TABLETS, CAPSULES). IN THE PRESENT MANUSCRIPT, THE CHOLESTEROL-LOWERING ACTIVITY OF SOME NUTRACEUTICALS (I.E. FIBER, PHYTOSTEROLS, SOY, POLICOSANOL, RED YEAST RICE AND BERBERINE) WILL BE DISCUSSED ALONG WITH: 1) THE LEVEL OF EVIDENCE ON THE CHOLESTEROL-LOWERING EFFICACY EMERGING FROM CLINICAL TRIAL; 2) THE POSSIBLE SIDE EFFECTS ASSOCIATED WITH THEIR USE; 3) THE CATEGORIES OF PATIENTS WHO COULD BENEFIT FROM THEIR USE. DATA SYNTHESIS BASED ON THE CURRENT LITERATURE, THE CHOLESTEROL-LOWERING EFFECT OF FIBER, PHYTOSTEROLS AND RED YEAST RICE IS CONSISTENT AND SUPPORTED BY A GOOD LEVEL OF EVIDENCE. OVER BERBERINE, THERE IS SUFFICIENT EVIDENCE SHOWING SIGNIFICANT CHOLESTEROL-LOWERING EFFECTS, ALTHOUGH THE RESULTS COME FROM STUDIES CARRIED OUT ALMOST EXCLUSIVELY IN ASIAN POPULATIONS. DATA ON THE EFFECTS OF SOY ARE CONFLICTING AND, THEREFORE, THE STRENGTH OF RECOMMENDATION IS QUITE LOW. THE EVIDENCE ON POLICOSANOL IS INCONCLUSIVE. CONCLUSION ALTHOUGH HEALTH BENEFITS MAY ARISE FROM THE USE OF NUTRACEUTICALS WITH CHOLESTEROL-LOWERING ACTIVITY, THEIR USE MIGHT BE ALSO ASSOCIATED WITH POSSIBLE RISKS AND PITFALLS, SOME OF WHICH ARE COMMON TO ALL NUTRACEUTICALS WHEREAS OTHERS ARE RELATED TO SPECIFIC NUTRACEUTICALS. © 2016 THE ITALIAN SOCIETY OF DIABETOLOGY, THE ITALIAN SOCIETY FOR THE STUDY OF ATHEROSCLEROSIS, THE ITALIAN SOCIETY OF HUMAN NUTRITION, AND THE DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY","BERBERINE; CHOLESTEROL; FIBER; NUTRACEUTICALS; PHYTOSTEROLS; POLICOSANOL; RED YEAST RICE; SOY","BIOMARKERS; CHOLESTEROL, LDL; CONSENSUS; DIETARY SUPPLEMENTS; DOWN-REGULATION; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME; BERBERINE; BETA GLUCAN; CHITOSAN; CHOLESTIN; GUAR GUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; NUTRACEUTICAL; PECTIN; PHYTOSTEROL; PLACEBO; POLICOSANOL; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK; DIETARY FIBER; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JOINT; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); POSITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOYBEAN; ADVERSE EFFECTS; BLOOD; CONSENSUS; DIETARY SUPPLEMENT; DOWN REGULATION; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; PRACTICE GUIDELINE; RISK FACTOR; TREATMENT OUTCOME","","","CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, PP. 1-64, (2016); STAMLER J., WENTWORTH D., NEATON J.D., IS RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND RISK OF PREMATURE DEATH FROM CORONARY HEART DISEASE CONTINUOUS AND GRADED? FINDINGS IN 356,222 PRIMARY SCREENEES OF THE MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT), JAMA, 256, PP. 2823-2828, (1986); CASTELLI W.P., CHOLESTEROL AND LIPIDS IN THE RISK OF CORONARY ARTERY DISEASE–THE FRAMINGHAM HEART STUDY, CAN J CARDIOL, 4, PP. 5A-10A, (1988); NACI H., BRUGTS J.J., FLEURENCE R., TSOI B., TOOR H., ADES A.E., COMPARATIVE BENEFITS OF STATINS IN THE PRIMARY AND SECONDARY PREVENTION OF MAJOR CORONARY EVENTS AND ALL-CAUSE MORTALITY: A NETWORK META-ANALYSIS OF PLACEBO-CONTROLLED AND ACTIVE-COMPARATOR TRIALS, EUR J PREV CARDIOL, 20, PP. 641-657, (2013); REMBOLD C.M., TO STATIN OR TO NON-STATIN IN CORONARY DISEASE–CONSIDERING ABSOLUTE RISK IS THE ANSWER, ATHEROSCLEROSIS, 195, PP. 1-6, (2007); BRUCKERT E., FERRIERES J., EVIDENCE SUPPORTING PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES WITH STATINS: GAPS BETWEEN UPDATED CLINICAL RESULTS AND ACTUAL PRACTICE, ARCH CARDIOVASC DIS, 107, PP. 188-200, (2014); BRAAMSKAMP M.J., HUTTEN B.A., WIEGMAN A., EARLY INITIATION OF STATIN TREATMENT IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA, CURR OPIN LIPIDOL, 26, PP. 236-239, (2015); CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATION, FULCHER J., O'CONNELL R., VOYSEY M., EMBERSON J., BLACKWELL L., MIHAYLOVA B., ET AL., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN: META-ANALYSIS OF INDIVIDUAL DATA FROM 174,000 PARTICIPANTS IN 27 RANDOMISED TRIALS, LANCET, 385, PP. 1397-1405, (2015); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., MCCAGG A., WHITE J.A., THEROUX P., ET AL., EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, N ENGL J MED, 372, PP. 2387-2397, (2015); HORTON J.D., COHEN J.C., HOBBS H.H., PCSK9: A CONVERTASE THAT COORDINATES LDL CATABOLISM, J LIPID RES, 50, PP. S172-S177, (2009); SCHULZ R., SCHLUTER K.D., LAUFS U., MOLECULAR AND CELLULAR FUNCTION OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9), BASIC RES CARDIOL, 110, (2015); SMITH C.S., CANNON C.P., MCCABE C.H., MURPHY S.A., BENTLEY J., BRAUNWALD E., EARLY INITIATION OF LIPID-LOWERING THERAPY FOR ACUTE CORONARY SYNDROMES IMPROVES COMPLIANCE WITH GUIDELINE RECOMMENDATIONS: OBSERVATIONS FROM THE ORBOFIBAN IN PATIENTS WITH UNSTABLE CORONARY SYNDROMES (OPUS-TIMI 16) TRIAL, AM HEART J, 149, PP. 444-450, (2005); NAVARESE E.P., KOWALEWSKI M., ANDREOTTI F., VAN WELY M., CAMARO C., KOLODZIEJCZAK M., ET AL., META-ANALYSIS OF TIME-RELATED BENEFITS OF STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION, AM J CARDIOL, 113, PP. 1753-1764, (2014); CHAPMAN K., CAN PEOPLE MAKE HEALTHY CHANGES TO THEIR DIET AND MAINTAIN THEM IN THE LONG TERM? A REVIEW OF THE EVIDENCE, APPETITE, 54, PP. 433-441, (2010); MCRORIE J.W., EVIDENCE-BASED APPROACH TO FIBER SUPPLEMENTS AND CLINICALLY MEANINGFUL HEALTH BENEFITS, PART 1: WHAT TO LOOK FOR AND HOW TO RECOMMEND AN EFFECTIVE FIBER THERAPY, NUTR TODAY, 50, PP. 82-89, (2015); CHUTKAN R., FAHEY G., WRIGHT W.L., MCRORIE J., VISCOUS VERSUS NONVISCOUS SOLUBLE FIBER SUPPLEMENTS: MECHANISMS AND EVIDENCE FOR FIBER-SPECIFIC HEALTH BENEFITS, J AM ACAD NURSE PRACT, 24, PP. 476-487, (2012); VUKSAN V., JENKINS A.L., ROGOVIK A.L., FAIRGRIEVE C.D., JOVANOVSKI E., LEITER L.A., VISCOSITY RATHER THAN QUANTITY OF DIETARY FIBRE PREDICTS CHOLESTEROL-LOWERING EFFECT IN HEALTHY INDIVIDUALS, BR J NUTR, 106, PP. 1349-1352, (2011); ASSMANN G., BUONO P., DANIELE A., DELLA VALLE E., FARINARO E., FERNS G., ET AL., FUNCTIONAL FOODS AND CARDIOMETABOLIC DISEASES* INTERNATIONAL TASK FORCE FOR PREVENTION OF CARDIOMETABOLIC DISEASES, NUTR METAB CARDIOVASC DIS, 24, PP. 1272-1300, (2014); YANG Y., ZHAO L.G., WU Q.J., MA X., XIANG Y.B., ASSOCIATION BETWEEN DIETARY FIBER AND LOWER RISK OF ALL-CAUSE MORTALITY: A META-ANALYSIS OF COHORT STUDIES, AM J EPIDEMIOL, 181, PP. 83-91, (2015); MORENO FRANCO B., LEON LATRE M., ANDRES ESTEBAN E.M., ORDOVAS J.M., CASASNOVAS J.A., PENALVO J.L., SOLUBLE AND INSOLUBLE DIETARY FIBRE INTAKE AND RISK FACTORS FOR METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE IN MIDDLE-AGED ADULTS: THE AWHS COHORT, NUTR HOSP, 30, PP. 1279-1288, (2014); PEREIRA M.A., O'REILLY E., AUGUSTSSON K., FRASER G.E., GOLDBOURT U., HEITMANN B.L., ET AL., DIETARY FIBER AND RISK OF CORONARY HEART DISEASE: A POOLED ANALYSIS OF COHORT STUDIES, ARCH INTERN MED, 164, PP. 370-376, (2004); BAZZANO L.A., THOMPSON A.M., TEES M.T., NGUYEN C.H., WINHAM D.M., NON-SOY LEGUME CONSUMPTION LOWERS CHOLESTEROL LEVELS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR METAB CARDIOVASC DIS, 21, PP. 94-103, (2011); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., BASORA-GALLISA J., RUIZ-GUTIERREZ V., COVAS M.I., ET AL., EFFECTS OF DIETARY FIBRE INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK, J EPIDEMIOL COMMUNITY HEALTH, 63, PP. 582-588, (2009); RICCARDI G., RIVELLESE A.A., EFFECTS OF DIETARY FIBER AND CARBOHYDRATE ON GLUCOSE AND LIPOPROTEIN METABOLISM IN DIABETIC PATIENTS, DIABETES CARE, 14, PP. 1115-1125, (1991); GROOMS K.N., OMMERBORN M.J., PHAM DO Q., DJOUSSE L., CLARK C.R., DIETARY FIBER INTAKE AND CARDIOMETABOLIC RISKS AMONG US ADULTS, NHANES 1999–2010, AM J MED, 126, PP. 1059-1067, (2013); SETTE S., LE DONNE C., PICCINELLI R., ARCELLA D., TURRINI A., LECLERCQ C., THE THIRD ITALIAN NATIONAL FOOD CONSUMPTION SURVEY, INRAN-SCAI 2005-06–PART 1: NUTRIENT INTAKES IN ITALY, NUTR METAB CARDIOVASC DIS, 21, PP. 922-932, (2011); CUST A.E., SKILTON M.R., VAN BAKEL M.M., HALKJAER J., OLSEN A., AGNOLI C., ET AL., TOTAL DIETARY CARBOHYDRATE, SUGAR, STARCH AND FIBRE INTAKES IN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION, EUR J CLIN NUTR, 63, PP. S37-S60, (2009); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); WHITEHEAD A., BECK E.J., TOSH S., WOLEVER T.M., CHOLESTEROL-LOWERING EFFECTS OF OAT Β-GLUCAN: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 100, PP. 1413-1421, (2014); WEI Z.H., WANG H., CHEN X.Y., WANG B.S., RONG Z.X., WANG B.S., ET AL., TIME- AND DOSE-DEPENDENT EFFECT OF PSYLLIUM ON SERUM LIPIDS IN MILD-TO-MODERATE HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, EUR J CLIN NUTR, 63, PP. 821-827, (2009); SOLA R., BRUCKERT E., VALLS R.M., NAREJOS S., LUQUE X., CASTRO-CABEZAS M., ET AL., SOLUBLE FIBRE (PLANTAGO OVATA HUSK) REDUCES PLASMA LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL, TRIGLYCERIDES, INSULIN, OXIDISED LDL AND SYSTOLIC BLOOD PRESSURE IN HYPERCHOLESTEROLAEMIC PATIENTS: A RANDOMISED TRIAL, ATHEROSCLEROSIS, 211, PP. 630-637, (2010); JULL A.B., NI MHURCHU C., BENNETT D.A., DUNSHEA-MOOIJ C.A., RODGERS A., CHITOSAN FOR OVERWEIGHT OR OBESITY, COCHRANE DATABASE SYST REV, 3, (2008); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 88, PP. 1167-1175, (2008); REPPAS C., SWIDAN S.Z., TOBEY S.W., TUROWSKI M., DRESSMAN J.B., HYDROXYPROPYLMETHYLCELLULOSE SIGNIFICANTLY LOWERS BLOOD CHOLESTEROL IN MILDLY HYPERCHOLESTEROLEMIC HUMAN SUBJECTS, EUR J CLIN NUTR, 63, PP. 71-77, (2009); MAKI K.C., CARSON M.L., MILLER M.P., ANDERSON W.H., TUROWSKI M., REEVES M.S., ET AL., HYDROXYPROPYLMETHYLCELLULOSE LOWERS CHOLESTEROL IN STATIN-TREATED MEN AND WOMEN WITH PRIMARY HYPERCHOLESTEROLEMIA, EUR J CLIN NUTR, 63, PP. 1001-1007, (2009); DE NATALE C., ANNUZZI G., BOZZETTO L., MAZZARELLA R., COSTABILE G., CIANO O., ET AL., EFFECTS OF A PLANT-BASED HIGH-CARBOHYDRATE/HIGH-FIBER DIET VERSUS HIGH-MONOUNSATURATED FAT/LOW-CARBOHYDRATE DIET ON POSTPRANDIAL LIPIDS IN TYPE 2 DIABETIC PATIENTS, DIABETES CARE, 32, PP. 2168-2173, (2009); GIACCO R., COSTABILE G., DELLA PEPA G., ANNIBALLI G., GRIFFO E., MANGIONE A., ET AL., A WHOLE-GRAIN CEREAL-BASED DIET LOWERS POSTPRANDIAL PLASMA INSULIN AND TRIGLYCERIDE LEVELS IN INDIVIDUALS WITH METABOLIC SYNDROME, NUTR METAB CARDIOVASC DIS, 24, PP. 837-844, (2014); SCIENTIFIC OPINION ON DIETARY REFERENCE VALUES FOR CARBOHYDRATES AND DIETARY FIBRE, EFSA J, 8, (2010); DAHL W.J., STEWART M.L., POSITION OF THE ACADEMY OF NUTRITION AND DIETETICS: HEALTH IMPLICATIONS OF DIETARY FIBER, J ACAD NUTR DIET, 115, PP. 1861-1870, (2015); GYLLING H., PLAT J., TURLEY S., GINSBERG H.N., ELLEGARD L., JESSUP W., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, PP. 346-360, (2014); CHEN Z.Y., MA K.Y., LIANG Y., PENG C., ZUO Y., ROLE AND CLASSIFICATION OF CHOLESTEROL-LOWERING FUNCTIONAL FOODS, J FUNCT FOODS, 3, PP. 61-69, (2011); ANDERSSON S.W., SKINNER J., ELLEGARD L., WELCH A.A., BINGHAM S., MULLIGAN A., ET AL., INTAKE OF DIETARY PLANT STEROLS IS INVERSELY RELATED TO SERUM CHOLESTEROL CONCENTRATION IN MEN AND WOMEN IN THE EPIC NORFOLK POPULATION: A CROSS-SECTIONAL STUDY, EUR J CLIN NUTR, 58, PP. 1378-1385, (2004); KLINGBERG S., ELLEGARD L., JOHANSSON I., HALLMANS G., WEINEHALL L., ANDERSSON H., ET AL., INVERSE RELATION BETWEEN DIETARY INTAKE OF NATURALLY OCCURRING PLANT STEROLS AND SERUM CHOLESTEROL IN NORTHERN SWEDEN, AM J CLIN NUTR, 87, PP. 993-1001, (2008); WANG P., CHEN Y.M., HE L.P., CHEN C.G., ZHANG B., XUE W.Q., ET AL., ASSOCIATION OF NATURAL INTAKE OF DIETARY PLANT STEROLS WITH CAROTID INTIMA-MEDIA THICKNESS AND BLOOD LIPIDS IN CHINESE ADULTS: A CROSS-SECTION STUDY, PLOS ONE, 7, (2012); MANNARINO E., PIRRO M., CORTESE C., LUPATTELLI G., SIEPI D., MEZZETTI A., ET AL., EFFECTS OF A PHYTOSTEROL-ENRICHED DAIRY PRODUCT ON LIPIDS, STEROLS AND 8-ISOPROSTANE IN HYPERCHOLESTEROLEMIC PATIENTS: A MULTICENTER ITALIAN STUDY, NUTR METAB CARDIOVASC DIS, 19, PP. 84-90, (2009); ABUMWEIS S.S., BARAKE R., JONES P.J., PLANT STEROLS/STANOLS AS CHOLESTEROL LOWERING AGENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, FOOD NUTR RES, 52, (2008); WU T., FU J., YANG Y., ZHANG L., HAN J., THE EFFECTS OF PHYTOSTEROLS/STANOLS ON BLOOD LIPID PROFILES: A SYSTEMATIC REVIEW WITH META-ANALYSIS, ASIA PAC J CLIN NUTR, 18, PP. 179-186, (2009); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., DUCHATEAU G.S., MEIJER L., ZOCK P.L., ET AL., CONTINUOUS DOSE-RESPONSE RELATIONSHIP OF THE LDL-CHOLESTEROL-LOWERING EFFECT OF PHYTOSTEROL INTAKE, J NUTR, 139, PP. 271-284, (2009); RAS R.T., HIEMSTRA H., LIN Y., VERMEER M.A., DUCHATEAU G.S., TRAUTWEIN E.A., CONSUMPTION OF PLANT STEROL-ENRICHED FOODS AND EFFECTS ON PLASMA PLANT STEROL CONCENTRATIONS–A META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES, ATHEROSCLEROSIS, 230, PP. 336-346, (2013); RAS R.T., GELEIJNSE J.M., TRAUTWEIN E.A., LDL-CHOLESTEROL-LOWERING EFFECT OF PLANT STEROLS AND STANOLS ACROSS DIFFERENT DOSE RANGES: A META-ANALYSIS OF RANDOMISED CONTROLLED STUDIES, BR J NUTR, 112, PP. 214-219, (2014); MALHOTRA A., SHAFIQ N., ARORA A., SINGH M., KUMAR R., MALHOTRA S., DIETARY INTERVENTIONS (PLANT STEROLS, STANOLS, OMEGA-3 FATTY ACIDS, SOY PROTEIN AND DIETARY FIBERS) FOR FAMILIAL HYPERCHOLESTEROLAEMIA, COCHRANE DATABASE SYST REV, 6, (2014); BAKER W.L., BAKER E.L., COLEMAN C.I., THE EFFECT OF PLANT STEROLS OR STANOLS ON LIPID PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS, DIABETES RES CLIN PRACT, 84, PP. E33-E37, (2009); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., MEIJER L., ZOCK P.L., GELEIJNSE J.M., ET AL., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUR J NUTR, 52, PP. 153-160, (2013); KETOMAKI A., GYLLING H., MIETTINEN T.A., EFFECTS OF PLANT STANOL AND STEROL ESTERS ON SERUM PHYTOSTEROLS IN A FAMILY WITH FAMILIAL HYPERCHOLESTEROLEMIA INCLUDING A HOMOZYGOUS SUBJECT, J LAB CLIN MED, 143, PP. 255-262, (2004); MUSA-VELOSO K., POON T.H., ELLIOT J.A., CHUNG C., A COMPARISON OF THE LDL-CHOLESTEROL LOWERING EFFICACY OF PLANT STANOLS AND PLANT STEROLS OVER A CONTINUOUS DOSE RANGE: RESULTS OF A META-ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 85, PP. 9-28, (2011); LICHTENSTEIN A.H., DECKELBAUM R.J., AHA SCIENCE ADVISORY. STANOL/STEROL ESTER-CONTAINING FOODS AND BLOOD CHOLESTEROL LEVELS. A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE NUTRITION COMMITTEE OF THE COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM OF THE AMERICAN HEART ASSOCIATION, CIRCULATION, 103, PP. 1177-1179, (2001); PERK J., DE BACKER G., GOHLKE H., GRAHAM I., REINER Z., VERSCHUREN M., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (VERSION 2012). THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR HEART J, 33, PP. 1635-1701, (2012); AJAGBE B.O., OTHMAN R.A., MYRIE S.B., PLANT STEROLS, STANOLS, AND SITOSTEROLEMIA, J AOAC INT, 98, PP. 716-723, (2015); VAN EE J.H., SOY CONSTITUENTS: MODES OF ACTION IN LOW-DENSITY LIPOPROTEIN MANAGEMENT, NUTR REV, 67, 4, PP. 222-234, (2009); SETCHELL K.D.R., PHYTOESTROGENS: THE BIOCHEMISTRY, PHYSIOLOGY, AND IMPLICATIONS FOR HUMAN HEALTH OF SOY ISOFLAVONES, AM J CLIN NUTR, 68, PP. 1333S-1346S, (1998); WANG H., MURPHY P.A., ISOFLAVONE CONTENT IN COMMERCIAL SOYBEAN FOODS, J AGRIC FOOD CHEM, 42, PP. 1666-1673, (1994); DESCOVICH G.C., CEREDI C., GADDI A., BENASSI M.S., MANNINO G., COLOMBO L., ET AL., MULTICENTRE STUDY OF SOYBEAN PROTEIN DIET FOR OUTPATIENT HYPER-CHOLESTEROLAEMIC PATIENTS, LANCET, 2, PP. 709-712, (1980); MARLETT J.A., SITES AND MECHANISM FOR THE HYPOCHOLESTEROLEMIC ACTIONS OF SOLUBLE DIETARY FIBER SOURCES, ADV EXP MED BIOL, 427, PP. 109-121, (1997); TORRES N., TORRE-VILLALVAZO I., TOVAR A.R., REGULATION OF LIPID METABOLISM BY SOY PROTEIN AND ITS IMPLICATION IN DISEASES MEDIATED BY LIPID DISORDERS, J NUTR BIOCHEM, 17, PP. 365-373, (2006); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY-PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); FOOD U.S., (2014); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); ZHUO X.-G., MELBY M.K., WATANABE S., SOY ISOFLAVONES INTAKE LOWERS SERUM LDL CHOLESTEROL: A META-ANALYSIS OF 8 RANDOMIZED CONTROLLED TRIALS IN HUMANS, J NUTR, 134, PP. 2395-2400, (2004); ZHAN S., HO S.C., META-ANALYSIS OF THE EFFECTS OF SOY-PROTEIN CONTAINING ISOFLAVONES ON THE LIPID PROFILE, AM J CLIN NUTR, 81, PP. 397-408, (2005); REYNOLDS K., CHIN A., LEES K.A., KGUYEN A., BUJNOWSKI D., HE J., A METAANALYSIS OF THE EFFECT OF SOY PROTEIN SUPPLEMENTATION ON SERUM LIPIDS, AM J CARDIOL, 98, PP. 633-640, (2006); TAKU K., UMEGAKI K., SATO Y., SOY ISOFLAVONES LOWER SERUM TOTAL AND LDL CHOLESTEROL IN HUMANS: A META-ANALYSIS OF 11 RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 85, PP. 1148-1156, (2007); HARLAND J.I., HAFFNER T.A., SYSTEMATIC REVIEW, META-ANALYSIS AND REGRESSION OF RANDOMISED CONTROLLED TRIALS REPORTING AN ASSOCIATION BETWEEN AN INTAKE OF CIRCA 25 G SOYA PROTEIN PER DAY AND BLOOD CHOLESTEROL, ATHEROSCLEROSIS, 200, PP. 13-27, (2008); ANDERSON J.W., BUSH H.M., SOY PROTEIN EFFECTS ON SERUM LIPOPROTEINS: A QUALITY ASSESSMENT AND META-ANALYSIS OF RANDOMIZED, CONTROLLED STUDIES, J AM COLL NUTR, 30, PP. 79-91, (2011); YANG B., CHEN Y., XU T., YU Y., HUANG T., HU X., ET AL., SYSTEMATIC REVIEW AND META-ANALYSIS OF SOY PRODUCTS CONSUMPTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, ASIA PAC J CLIN NUTR, 20, 4, PP. 593-602, (2011); EUROPEAN FOOD SAFETY AUTHORITY, SCIENTIFIC OPINION ON THE SUBSTANTIATION OF A HEALTH CLAIM RELATED TO ISOLATED SOY PROTEIN AND REDUCTION OF BLOOD LDL-CHOLESTEROL CONCENTRATIONS PURSUANT TO ARTICLE 14 OF REGULATION (EC) NO 1924/2006, EFSA J, 10, 2, (2012); BENKHEDDA K., BOUDRAULT C., SINCLAIR S.E., MARLES R.J., XIAO C.W., UNDERHILL L., HEALTH CANADA'S PROPOSAL TO ACCEPT A HEALTH CLAIM ABOUT SOY PRODUCTS AND CHOLESTEROL LOWERING, INT FOOD RISK ANAL J, 4, PP. 1-12, (2014); SACKS F.M., LICHTENSTEIN A., VAN HORN L., HARRIS W., KRIS-ETHERTON P., WINSTON M., SOY-PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH: AN AMERICAN HEART ASSOCIATION ADVISORY PANEL FOR PROFESSIONALS FROM THE NUTRITION COMMITTEE, CIRCULATION, 113, PP. 1034-1044, (2006); GIRGIH A.T., MYRIE S.B., ALUKO R.E., JONES P.J.H., IS CATEGORY ‘A’ STATUS ASSIGNED TO SOY-PROTEIN AND CORONARY HEART DISEASE RISK REDUCTION HEALTH CLAIM BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION STILL JUSTIFIABLE?, TRENDS FOOD SCI TECHNOL, 30, PP. 121-132, (2013); PADHI E.M., BLEWETT H.J., DUNCAN A.M., GUZMAN R.P., HAWKE A., SEETHARAMAN K., ET AL., WHOLE SOY FLOUR INCORPORATED INTO A MUFFIN AND CONSUMED AT 2 DOSES OF SOY PROTEIN DOES NOT LOWER LDL CHOLESTEROL IN A RANDOMIZED, DOUBLE-BLIND CONTROLLED TRIAL OF HYPERCHOLESTEROLEMIC ADULTS, J NUTR, 145, 12, PP. 2665-2674, (2015); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE—POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); MAS R., CASTANO G., FERNANDEZ J., GAMEZ R., ILLNAIT J., FERNANDEZ L., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH TYPE 2 DIABETES, ASIA PAC J CLIN NUTR, 13, (2004); HEAD K.A., POLICOSANOL MONOGRAPH, 9, PP. 312-317, (2004); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, PP. 207-219, (2005); MAS R., CASTANO G., FERNANDEZ J., GAMEZ R., ILLNAIT J., FERNANDEZ L., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA PAC J CLIN NUTR, 13, (2004); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. M186-M192, (2001); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R., FERNANDEZ J.C., RODEIRO I., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); EUROPEAN FOOD SAFETY AUTHORITY, SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, 6, (2011); GORDON R.Y., BECKER D.J., THE ROLE OF RED YEAST RICE FOR THE PHYSICIAN, CURR ATHEROSCLER REP, 13, PP. 73-80, (2011); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR ATHEROSCLER REP, 17, (2015); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5522, (2000); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR J INTERN MED, 25, PP. 592-599, (2014); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); LI Y., JIANG L., JIA Z., XIN W., YANG S., YANG Q., ET AL., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, (2014); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN - A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); XIONG X., WANG P., LI X., ZHANG Y., LI S., THE EFFECTS OF RED YEAST RICE DIETARY SUPPLEMENT ON BLOOD PRESSURE, LIPID PROFILE AND C-REACTIVE PROTEIN IN HYPERTENSION: A SYSTEMATIC REVIEW, CRIT REV FOOD SCI NUTR, (2015); HALBERT S.C., FRENCH B., GORDON R.Y., FARRAR J.T., SCHMITZ K., MORRIS P.B., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); ZHAO S.P., LIU L., CHENG Y.C., SHISHEHBOR M.H., LIU M.H., PENG D.Q., ET AL., XUEZHIKANG, AN EXTRACT OF CHOLESTIN, PROTECTS ENDOTHELIAL FUNCTION THROUGH ANTIINFLAMMATORY AND LIPID-LOWERING MECHANISMS IN PATIENTS WITH CORONARY HEART DISEASE, CIRCULATION, 110, PP. 915-920, (2004); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS, ARCH INTERN MED, 170, PP. 1722-1727, (2010); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, PP. 133-139, (2001); IMANSHAHIDI M., HOSSEINZADEH H., PHARMACOLOGICAL AND THERAPEUTIC EFFECTS OF BERBERIS VULGARIS AND ITS ACTIVE CONSTITUENT, BERBERINA, PHYTOTHER RES, 22, PP. 999-1012, (2008); PIRILLO A., CATAPANO A.L., BERBERINE, A PLANT ALKALOID WITH LIPID- AND GLUCOSE-LOWERING PROPERTIES: FROM IN VITRO EVIDENCE TO CLINICAL STUDIES, ATHEROSCLEROSIS, 243, PP. 449-461, (2015); LEE S., LIM H.J., PARK J.H., LEE K.S., JANG Y., PARK H.Y., BERBERINE INDUCED LDLR UPREGULATION INVOLVES JNK PATHWAY, BIOCHEM BIOPHYS RES COMMUN, 362, PP. 853-857, (2007); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASE PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); BRUSQ J.M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINTILLAN Y., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-2188, (2006); DONG H., WANG N., ZHAO L., LU F., BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A SYSTEMIC REVIEW AND META-ANALYSIS, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012); DONG H., ZHAO Y., ZHAO L., LU F., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); LAN J., ZHAO Y., DONG F., YAN Z., ZHENG W., FAN J., ET AL., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J ETHNOPHARMACOL, 161, PP. 69-81, (2015); KONG W.J., WEI J., ZUO Z.Y., WANG Y.M., SONG D.Q., YOU X.F., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFICACY, METABOLISM, 57, PP. 1029-1037, (2008); GUO Y., CHEN Y., TAN Z.R., KLAASSEN C.D., ZHOU H.H., REPEATED ADMINISTRATION OF BERBERINE INHIBITS CYTOCHROMES P450 MRNA EXPRESSION AND ACTIVITIES IN MICE, J ETHNOPHARMACOL, 138, PP. 111-118, (2011); CASTELLANOS-JANKIEWICZ A., DEL BOSQUE-PLATA L., TEJERO M.E., COMBINED EFFECT OF PLANT STEROLS AND DIETARY FIBER FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, PLANT FOODS HUM NUTR, 69, PP. 93-100, (2014); CLIFTON P.M., NOAKES M., SULLIVAN D., ERICHSEN N., ROSS D., ANNISON G., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PLANT STEROL ESTERS DIFFER IN MILK, YOGHURT, BREAD AND CEREAL, EUR J CLIN NUTR, 58, PP. 503-509, (2004); THEUWISSEN E., MENSINK R.P., SIMULTANEOUS INTAKE OF BETA-GLUCAN AND PLANT STANOL ESTERS AFFECTS LIPID METABOLISM IN SLIGHTLY HYPERCHOLESTEROLEMIC SUBJECTS, J NUTR, 137, PP. 583-588, (2007); BECKER D.J., FRENCH B., MORRIS P.B., SILVENT E., GORDON R.Y., PHYTOSTEROLS, RED YEAST RICE, AND LIFESTYLE CHANGES INSTEAD OF STATINS: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL, AM HEART J, 166, PP. 187-196, (2013); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); PIRRO M., LUPATTELLI G., DEL GIORNO R., SCHILLACI G., BERISHA S., MANNARINO M.R., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, PHARMA NUTR, 1, PP. 73-77, (2013); RUSCICA M., GOMARASCHI M., MOMBELLI G., MACCHI C., BOSISIO R., PAZZUCCONI F., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, PP. 61-68, (2014); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES CLIN EXP, 77, PP. 1-6, (2014); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); MARAZZI G., PELLICCIA F., CAMPOLONGO G., QUATTRINO S., CACCIOTTI L., VOLTERRANI M., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM J CARDIOL, 116, PP. 1798-1801, (2015); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); PIRRO M., MANNARINO M.R., BIANCONI V., SIMENTAL-MENDIA L.E., BAGAGLIA F., MANNARINO E., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); PIRRO M., MANNARINO M.R., MINISTRINI S., FALLARINO F., LUPATTELLI G., BIANCONI V., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION ON LIPIDS, INFLAMMATION AND ENDOTHELIAL INTEGRITY IN PATIENTS WITH SUBCLINICAL INFLAMMATION: A RANDOMIZED CLINICAL TRIAL, SCI REP, 6, (2016); ALEVIZOS A., MIHAS C., MARIOLIS A., ADVERTISING CAMPAIGNS OF STEROL-ENRICHED FOOD. AN OFTEN NEGLECTED CAUSE OF REDUCED COMPLIANCE TO LIPID LOWERING DRUG THERAPY, CARDIOVASC DRUGS THER, 21, PP. 133-134, (2007); EUSSEN S.R., DE JONG N., ROMPELBERG C.J., GARSSEN J., VERSCHUREN W.M., KLUNGEL O.H., EFFECTS OF THE USE OF PHYTOSTEROL/-STANOL-ENRICHED MARGARINES ON ADHERENCE TO STATIN THERAPY, PHARMACOEPIDEMIOL DRUG SAF, 19, PP. 1225-1232, (2010)","A.A. RIVELLESE; DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, “FEDERICO II” UNIVERSITY, NAPLES, 5, S. PANSINI, 80131, ITALY; EMAIL: RIVELLES@UNINA.IT","ELSEVIER B.V.","ENGLISH","NUTR. METAB. CARDIOVASC. DIS.","REVIEW","ISI","2-S2.0-85008210389","NUTR METAB CARDIOVASC DIS","UNIVERSITY OF PERUGIA;“FEDERICO II” UNIVERSITY;DEPARTMENT OF MEDICAL AREA “AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA”;UNIVERSITY OF PERUGIA;UNIVERSITY OF PARMA;“FEDERICO II” UNIVERSITY","NOTREPORTED;“FEDERICO II” UNIVERSITY;NOTREPORTED",NA,"PIRRO M, 2017, NUTR METAB CARDIOVASC DIS","PIRRO M, 2017, NUTR METAB CARDIOVASC DIS"
"DHYANI A;CHOPRA R;GARG M","DHYANI, AKRITI (57210133501); CHOPRA, RAJNI (56649788300); GARG, MEENAKSHI (57202017471)","A REVIEW ON NUTRITIONAL VALUE FUNCTIONAL PROPERTIES AND PHARMACOLOGICAL APPLICATION OF PERILLA PERILLA FRUTESCENS L",2019,"BIOMEDICAL AND PHARMACOLOGY JOURNAL","12","11",53,"10.13005/bpj/1685","DEPARTMENT OF FOODS AND NUTRITION, INSTITUTE OF HOME ECONOMICS, UNIVERSITY OF DELHI, F-4 HAUZ KHAS ENCLAVE, NEW DELHI, 110016, INDIA;DEPARTMENT OF FOODS AND NUTRITION, INSTITUTE OF HOME ECONOMICS, UNIVERSITY OF DELHI, F-4 HAUZ KHAS ENCLAVE, NEW DELHI, 110016, INDIA;DEPARTMENT OF FOOD TECHNOLOGY, BHASKARACHARYA COLLEGE OF APPLIED SCIENCES, UNIVERSITY OF DELHI, DWARKA, NEW DELHI, 110075, INDIA","PERILLA FRUTESCENS IS AN ANNUAL HERB BELONGING TO THE MINT FAMILY (LAMIACEAE). IT IS MAJORLY PRODUCED IN COUNTRIES LIKE CHINA, JAPAN, INDIA, THAILAND AND KOREA. RECENTLY, PERILLA PLANT IS GAINING MORE ATTENTION BECAUSE OF ITS MEDICINAL BENEFITS AND PHYTOCHEMICAL CONTENTS. THE MAJOR PHYTOCHEMICAL COMPOUNDS REPORTED IN THIS SPECIES ARE PHENOLIC COMPOUNDS (ROSMARINIC ACID, CAFFEIC ACID, FERULIC ACID), FLAVONOIDS (LUTEOLIN, APIGENIN), PHYTOSTEROLS, TOCOPHEROLS, POLICOSANOLS AND FATTY ACID. PERILLA SEED OIL IS ALSO A RICH SOURCE OF ESSENTIAL FATTY ACID SUCH AS Á-LINOLENIC ACID (54-64%) AND LINOLEIC ACID (14%). PERILLA SEEDS AND ITS OILS HAVE BEEN WIDELY USED IN TRADITIONAL NUTRITIONAL AND MEDICINAL FORMULATIONS. BIOLOGICAL ANALYSIS OF PERILLA SEEDS REVEALED THAT IT SHOWED ANTICANCER, ANT-DIABETIC, ANTIASTHMA, ANTIMICROBIAL, ANTI-INFLAMMATORY, ANTIOXIDANT AND CARDIOPROTECTIVE EFFECT. THE AIM OF THIS REVIEW IS TO PROVIDE AN UPDATE ON THE NUTRITIONAL COMPOSITION, PHYTOCHEMICAL PROFILE AND PHARMACOLOGICAL RESEARCH OF PERILLA SEED. © 2019 ORIENTAL SCIENTIFIC PUBLISHING COMPANY. ALL RIGHTS RESERVED.","ANTIOXIDANT; BIOACTIVE COMPOUNDS; FATTY ACID; LINOLENIC ACID; PERILLA SEED","ALANINE AMINOTRANSFERASE; ANTIASTHMATIC AGENT; APIGENIN; ASPARTATE AMINOTRANSFERASE; CAFFEIC ACID; CHLOROGENIC ACID; ESSENTIAL OIL; FATTY ACID; FERULIC ACID; FLAVONOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KAEMPFEROL; LINOLEIC ACID; LINOLENIC ACID; LUTEOLIN; OMEGA 3 FATTY ACID; PALMITIC ACID; PHENOL DERIVATIVE; PHOSPHATIDYLSERINE; PHYTOCHEMICAL; PHYTOSTEROL; POLICOSANOL; ROSMARINIC ACID; STEARIC ACID; TOCOPHEROL; TRIACYLGLYCEROL; ABDOMINAL PAIN; ABTS RADICAL SCAVENGING ASSAY; ANTIDIABETIC ACTIVITY; ANTIDIARRHEAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHEWABLE TABLET; COGNITION; CONSTIPATION; CYTOTOXICITY; DIABETES MELLITUS; FOOD INTAKE; GASTROINTESTINAL MOTILITY; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; LIPID COMPOSITION; LIPID METABOLISM; LIPID PEROXIDATION; MEDICINAL PLANT; NEUROTOXICITY; NONALCOHOLIC FATTY LIVER; NUTRITIONAL VALUE; OXIDATIVE STRESS; PERILLA FRUTESCENS; PHYTOCHEMISTRY; THROMBOCYTE AGGREGATION; TRADITIONAL MEDICINE; VOMITING","UNIVERSITY GRANT COMMISSION","THE AUTHORS ARE GRATEFUL TO UNIVERSITY GRANT COMMISSION (UGC), INDIA FOR THE DOCTORATE FELLOWSHIPAND FOR THE FINANCIAL SUPPORT.","NITTA M., LEE J.K., OHNISHI O., ASIANPERILLACROPS AND THEIR WEEDY FORMS/: THEIR CULTIVATION, UTILIZATION AND GENETIC RELATIONSHIPS, ECON. BOT., 57, PP. 245-253, (2003); NITTA M., LEE J.K., KANG C.W., KATSUTA M., YASUMOTO S., LIU D., NAGAMINE T., OHNISHI O., THE DISTRIBUTION OF PERILLA SPECIES, GENETIC RESOURCES AND CROP EVOLUTION, 52, PP. 797-804, (2005); PANDEY A., BHATT K.C., DIVERSITY DISTRIBUTION AND COLLECTION OF GENETIC RESOURCES OF CULTIVATED AND WEEDY TYPE IN PERILLA FRUTESCENS (L.) BRITTON VAR. FRUTESCENS AND THEIR USES IN INDIAN HIMALAYA, GENET. RESOUR. CROP EVOL., 55, PP. 883-892, (2008); PENG Y., YE J., KONG J., DETERMINATION OF PHENOLIC COMPOUNDS IN PERILLA FRUTESCENS L. BY CAPILLARY ELECTROPHORESIS WITH ELECTROCHEMICAL DETECTION, J. AGRIC. FOOD CHEM., 53, PP. 8141-8147, (2005); MENG L., LOZANO Y., BOMBARDA I., GAYDOU E.M., LI B., POLYPHENOL EXTRACTION FROM EIGHT PERILLA FRUTESCENS CULTIVARS, COMPTES RENDUS CHIM, 12, PP. 602-611, (2009); CIFTCI O.N., PRZYBYLSKI R., RUDZINSKA M., LIPID COMPONENTS OF FLAX,PERILLA, AND CHIA SEEDS, EUR. J. LIPID SCI. TECHNOL., 114, PP. 794-800, (2012); LUO L., WANG J.N., KONG L.D., JIANG Q.G., TAN R.X., ANTIDEPRESSANT EFFECTS OF BANXIA HOUPU DECOCTION, A TRADITIONAL CHINESE MEDICINAL EMPIRICAL FORMULA, J. ETHNOPHARMACOL., 73, PP. 277-281, (2000); KIM H.K., CHOI S., CHOI H., SUPPRESSION OF HEPATIC FATTY ACID SYNTHASE BY FEEDING Á-LINOLENIC ACID-RICHPERILLA OIL LOWERS PLASMA TRIACYLGLYCEROL LEVEL IN RATS, J. NUTR. BIOCHEM., 15, PP. 485-492, (2004); UEDA H., YAMAZAKI M., INHIBITION OF TUMOR NECROSIS FACTOR- Á PRODUCTION BY ORALLY ADMINISTERING A PERILLA LEAF EXTRACT, BIOSCI. BIOTECHNOL. BIOCHEM., 61, PP. 1292-1295, (1997); CHAUHAN N.K., SINGH S., ZAFAR HAIDER S., LOHANI H., KUSHWAHA B.L., COMPOSITIONAL VARIABILITY IN VOLATILES FROM DIFFERENT PLANT ORGANS OF PERILLA FRUTESCENS L. CULTIVATED IN UTTARAKHAND (INDIA), J. PHARM. RES., 6, PP. 361-363, (2013); BACHHETI K., JOSHI A., AHMED T., REVIEW ARTICLE A PHYTOPHARMACOLOGICAL OVERVIEW ON PERILLA FRUTESCENS, INT. J. PHARM. SCI. REV. RES., 26, PP. 55-61, (2014); YU H., QIU J., MA L., HU Y., LI P., WAN J., PHYTOCHEMICAL AND PHYTOPHARMACOLOGICAL REVIEW OF PERILLA FRUTESCENS L(LABIATAE), A TRADITIONAL EDIBLE-MEDICINAL HERB IN CHINA, FOOD CHEM. TOXICOL., 108, PP. 375-391, (2017); ASIF M., NUTRITIONAL IMPORTANCE OF MONOUNSATURATED AND POLYUNSATURATED FATTY ACIDS OF PERILLA OIL, INT. J. PHYTOPHARM., 2, PP. 154-161, (2012); IGARASHI M., MIYAZAKI Y., A REVIEW ON BIOACTIVITIES OF PERILLA: PROGRESS IN RESEARCH ON THE FUNCTIONS OF PERILLA AS MEDICINE AND FOOD, EVIDENCE-BASED COMPLEMENT, ALTERN. MED., PP. 1-7, (2013); ASIF M., BIOLOGICAL IMPORTANCE AND HEALTH EFFECT OF PERILLA FRUTESCENS PLANT, INDONESIA. J. PHARM., 23, PP. 113-121, (2012); SINGH G., PERILLA; ASIF M., HEALTH EFFECTS OF OMEGA-3,6,9 FATTY ACIDS: PERILLA FRUTESCENS IS A GOOD EXAMPLE OF PLANT OILS, ORIENT. PHARM. EXP. MED., 11, PP. 51-59, (2011); BHANDARI S.R., LEE J.K., LEE Y., PHYTONUTRIENT PROFILE OF PURPLE PERILLA (PERILLA FRUTESCENS VARCRISPA) SEEDS, KOREAN J. CROP SCI., 56, PP. 199-204, (2011); KANG N.S., LEE J.H., CHARACTERISATION OF PHENOLIC PHYTOCHEMICALS AND QUALITY CHANGES RELATED TO THE HARVEST TIMES FROM THE LEAVES OF KOREAN PURPLE PERILLA (PERILLA FRUTESCENS), FOOD CHEM, 124, PP. 556-562, (2011); XUAN T.D., GANGQIANG G., MINH T.N., QUY T.N., KHANH T.D., AN OVERVIEW OF CHEMICAL PROFILES, ANTIOXIDANT AND ANTIMICROBIAL ACTIVITIES OF COMMERCIAL VEGETABLE EDIBLE OILS MARKETED IN JAPAN, FOODS, 7, PP. 1-14, (2018); TADAO K., TAMURA H., YOSHIDA K., GOTO T., STRUCTURE OF MALONYLSHISONIN, A GENUINE PIGMENT IN PURPLE LEAVES OF PERILLAOCIMOIDES L. VAR. CRISPA BENTH, AGRIC. BIOL. CHEM., 53, PP. 797-800, (1989); MARTINETTI L., FERRANTE A., PODETTA N., BASSOLI A., BORGONOVO G., TOSCA A., SPOLETO P., EFFECT OF STORAGE ON THE QUALITATIVE CHARACTERISTICS OF PERILLA, A POTENTIAL NEW MINIMALLY PROCESSED LEAFY VEGETABLE, J. FOOD PROCESS. PRESERV., 41, (2017); YANG J., KIM H., CHUNG L., SENSORYCHARACTERISTICS AND CONSUMERACCEPTABILITY OF PERILLA PORRIDGES, FOOD SCI. BIOTECHNOL., 21, PP. 785-797, (2012); HYE-RYUN K., SANJEEV K.D., IL-DOO K., IN-JOO P., PHYSICOCHEMICAL AND SENSORY CHARACTERISTICS OF PEPPER OIL SAUCE PREPARED FROM PERILLA OIL, AFRICAN J. FOOD SCI., 10, PP. 352-358, (2016); KUMAR S., THE ECONOMIC PLANTS OF NORTH EAST INDIA, (1999); LONGVAH T., DEOSTHALE Y.G., CHEMICAL AND NUTRITIONAL STUDIES ON HANSHI (PERILLA FRUTESCENS), A TRADITIONAL OILSEED FROM NORTHEAST INDIA, J. AM. OIL CHEM. SOC., 68, PP. 781-784, (1991); VAN DER VALK J.M.A., LEON C.J., NESBITT M., MACROSCOPIC AUTHENTICATION OF CHINESE MATERIA MEDICA (CMM)/: A UK MARKET STUDY OF SEEDS AND FRUITS, 8, PP. 40-51, (2017); HUANG Z., MAO Q.Q., ZHONG X.M., FENG C.R., PAN A.J., LI Z.Y., HERBAL FORMULA SYJN PROTECT PC12 CELLS FROM NEUROTOXICITY INDUCED BY CORTICOSTERONE, J. ETHNOPHARMACOL., 125, PP. 456-460, (2009); IKARASHI Y., YUZURIHARA M., SAKAKIBARA I., TAKAHASHI A., ISHIMARU H., MARUYAMA Y., EFFECTS OF AN ORIENTAL HERBAL MEDICINE, “SAIBOKU-TO “, AND ITS CONSTITUENT HERBS ON COMPOUND 48 / 80-INDUCED HISTAMINE RELEASE FROM PERITONEAL MAST CELLS IN RATS, PHYTOMEDICINE, 8, PP. 8-15, (2001); MAKINO T., FURUTA Y., FUJII H., NAKAGAWA T., WAKUSHIMA H., EFFECT OF ORAL TREATMENT OF PERILLA FRUTESCENS AND ITS CONSTITUENTS ON TYPE-I ALLERGY IN MICE, BIOL. PHARM. BULL., 24, PP. 1206-1209, (2001); BAE J.S., HAN M., SHIN H.S., KIM M.K., SHIN C.Y., LEE D.H., CHUNG J.H., PERILLA FRUTESCENS LEAVES EXTRACT AMELIORATES ULTRAVIOLET RADIATION-INDUCED EXTRACELLULAR MATRIX DAMAGE IN HUMAN DERMAL FIBROBLASTS AND HAIRLESS MICE SKIN, J. ETHNOPHARMACOL., 195, PP. 334-342, (2017); CHUNG M.S., BAE W.J., CHOI S.W., LEE K.W., JEONG H.C., BASHRAHEEL F., JEON S.H., JUNG J.W., YOON B.I., KWON E.B., OH H.A., HWANG S.Y., KIM S.W., AN ASIAN TRADITIONAL HERBAL COMPLEX CONTAINING HOUTTUYNIA CORDATA THUNB, PERILLA FRUTESCENS VAR. ACUTA AND GREEN TEA STIMULATES HAIR GROWTH IN MICE, BMC COMPLEMENT. ALTERN. MED., 17, (2017); LI N., ZHANG Z.-J., LI X.-J., LI H.-Z., CUI L.-X., HE D.-L., MICROCAPSULES BIOLOGICALLY PREPARED USING PERILLA FRUTESCENS (L.) BRITT. ESSENTIAL OIL AND THEIR USE FOR EXTENSION OF FRUIT SHELF LIFE, J. SCI. FOOD AGRIC., 98, PP. 1033-1041, (2018); NEGI V., RAWAT L., PHONDANI P., CHANDRA A., PERILLA FRUTESCENS IN TRANSITION/: A MEDICINAL AND OIL YIELDING PLANT NEED INSTANT CONSERVATION, A CASE STUDY FROM CENTRAL HIMALAYA, INDIA, ENVIRON. WE INT. J. SCI. TECH., 6, PP. 193-200, (2011); WU J., YANG C., RONG Y., WANG Z., PREPARATION AND NUTRITIONAL CHARACTERIZATION OF PERILLA CHEWABLE TABLET, PROCEDIA ENG, 37, PP. 202-207, (2012); LI Y., GONG J., LIU C., WANG Z., WU Y., PHYTOCHEMICALS, NUTRITIONAL ANALYSIS AND IN VITRO ANTIOXIDANT ACTIVITIES OF PICKLED PERILLA FRUTESCENS ETHANOLIC LEAF EXTRACT, EUROPEAN J. MED. PLANTS., 4, PP. 303-314, (2014); SCHIRRMACHER G., SKURK T., HAUNER H., GRASSMANN J., EFFECT OF SPINACIA OLERACEAE L. AND PERILLA FRUTESCENS L. AND ANTIOXIDANTS AND LIPID PEROXIDATION IN AN INTERVENTION STUDY IN HEALTHY INDIVIDUALS, PLANT FOODS HUM. NUTR., 65, PP. 71-76, (2010); LONGVAH T., DEOSTHALE Y.G., EFFECT OF DEHULLING, COOKING AND ROASTING ON THE PROTEIN QUALITY OF PERILLA FRUTESCENS SEED, FOOD CHEM, 63, PP. 519-523, (1998); SARGI S.C., SILVA B.C., SANTOS H.M.C., MONTANHER P.F., BOEING J.S., SANTOS O.O., SOUZA N.E., VISENTAINER J.V., ANTIOXIDANT CAPACITY AND CHEMICAL COMPOSITION IN SEEDS RICH IN OMEGA-3: CHIA, FLAX, AND PERILLA, FOOD SCI. TECHNOL., 33, PP. 541-548, (2013); SHIN H.S., KIM S.W., LIPID COMPOSITION OF PERILLA SEED, J. AM. OIL CHEM. SOC., 71, PP. 619-622, (1994); SCAPIN G., ABAIDE E.R., MARTINS R.F., VENDRUSCOLO R.G., MAZUTTI M.A., WAGNER R., DA ROSA C.S., QUALITY OF PERILLA OIL (PERILLA FRUTESCENS) EXTRACTED WITH COMPRESSED CO2 AND LPG, J. SUPERCRIT. FLUIDS., 130, PP. 176-182, (2017); JUNG D.M., YOON S.H., JUNG M.Y., CHEMICAL PROPERTIES AND OXIDATIVE STABILITY OF PERILLA OILS OBTAINED FROM ROASTED PERILLA SEEDS AS AFFECTED BY EXTRACTION METHODS, J. FOOD SCI., 77, PP. C1249-C1255, (2012); KO W.C., SHIH C.M., LEU I.J., CHEN T.T., CHANG J.P., MECHANISMS OF RELAXANT ACTION OF LUTEOLIN IN ISOLATED GUINEA PIG TRACHEA, PLANTA MED, 71, PP. 406-411, (2005); OKAMOTO M., MITSUNOBU F., ASHIDA K., MIFUNE T., HOSAKI Y., TSUGENO H., HARADA S., TANIZAKI Y., EFFECTS OF DIETARY SUPPLEMENTATION WITH N-3 FATTY ACIDS COMPARED WITH N-6 FATTY ACIDS ON BRONCHIAL ASTHMA, INTERN. MED., 39, PP. 107-111, (2000); CHANG H.H., CHEN C.S., LIN J.Y., DIETARY PERILLA OIL INHIBITS PROINFLAMMATORY CYTOKINE PRODUCTION IN THE BRONCHOALVEOLAR LAVAGE FLUID OF OVALBUMIN-CHALLENGED MICE, LIPIDS, 43, PP. 499-506, (2008); DENG Y.M., XIE Q.M., ZHANG S.J., YAO H.Y., ZHANG H., ANTI-ASTHMATIC EFFECTS OF PERILLA SEED OIL IN THE GUINEA PIG IN VITRO AND IN VIVO, PLANTA MED, 73, PP. 53-58, (2007); KIM D., KIM S.J., YU K., JEONG S., KIM S., ANTI-HYPERGLYCEMIC EFFECTS AND SIGNALING MECHANISM OF PERILLA FRUTESCENS SPROUT EXTRACT, NUTR. RES. PRACT., 12, PP. 20-28, (2018); PAEK J.H., SHIN K.H., KANG Y.-H., LEE J.-Y., LIM S.S., RAPID IDENTIFICATION OF ALDOSE REDUCTASE INHIBITORY COMPOUNDS FROM PERILLA FRUTESCENS, BIOMED RES. INT., (2013); WANG F., ZHU H., HU M., WANG J., XIA H., YANG X., SUN G., PERILLA OIL SUPPLEMENTATION IMPROVES HYPERTRIGLYCERIDEMIA AND GUT DYSBIOSIS IN DIABETIC KKAY MICE, MOLECULAR NUTRITION & FOOD RESEARCH, 62, 24, (2018); TAKEDA H., TSUJI M., INAZU M., EGASHIRA T., MATSUMIYA T., ROSMARINIC ACID AND CAFFEIC ACID PRODUCE ANTIDEPRESSIVE-LIKE EFFECT IN THE FORCED SWIMMING TEST IN MICE, EUR. J. PHARMACOL., 449, PP. 261-267, (2002); DENG Y.M., XIE Q.M., ZHANG S.J., YAO H.Y., ZHANG H., ANTI-ASTHMATIC EFFECTS OF PERILLA SEED OIL IN THE GUINEA PIG IN VITRO AND IN VIVO, PLANTA MED, 73, PP. 53-58, (2007); NAKAZAWA T., YASUDA T., UEDA J., OHSAWA K., ANTIDEPRESSANT-LIKE EFFECTS OF APIGENIN AND 2, 4, 5-TRIMETHOXYCINNAMIC ACID FROM PERILLA FRUTESCENS IN THE FORCED SWIMMING TEST, BIOL. PHARM. BULL., 26, PP. 474-480, (2003); NARISAWA T., FUKAURA Y., YAZAWA K., ISHIKAWA C., ISODA Y., NISHIZAWA Y., COLON CANCER PREVENTION WITH A SMALL AMOUNT OF DIETARY PERILLA OIL HIGH IN ALPHA- LINOLENIC ACID IN AN ANIMAL MODEL, CANCER, 73, PP. 2069-2075, (1994); KOMAKI C., ONOGI N., OKUNO M., MORIWAKI H., KAWAMORI T., TANAKA T., MORI H., MUTO Y., SUPPRESSING EFFECT OF PERILLA OIL ON AZOXYMETHANE-INDUCED FOCI OF COLONIC ABERRANT CRYPTS IN RATS, CARCINOGENESIS, 17, PP. 1291-1296, (1996); YAMAMOTO H., OGAWA T., ANTIMICROBIAL ACTIVITY OF PERILLA SEED POLYPHENOLS AGAINST ORAL PATHOGENIC BACTERIA, BIOSCI. BIOTECHNOL. BIOCHEM., 66, PP. 921-924, (2002); LIN E.-S., LI C.-C., CHOU H.-J., EVALUATION OF THE ANTIOXIDANT AND ANTIRADICAL ACTIVITIES OF PERILLA SEED, LEAF AND STALK EXTRACTS, J. MED. PLANTS RES., 8, PP. 109-115, (2014); RYAN E., GALVIN K., CONNOR T.P.O., MAGUIRE A.R., PHYTOSTEROL,SQUALENE, TOCOPHEROL CONTENT AND FATTY ACID PROFILE OF SELECTED SEEDS,GRAINS, AND LEGUMES, PLANT FOODS HUM. NUTR., 62, PP. 85-91, (2007); GU L., WU T., WANG Z., TLC BIOAUTOGRAPHY-GUIDED ISOLATION OF ANTIOXIDANTS FROM FRUIT OF PERILLA FRUTESCENS VAR. ACUTA, FOOD SCI. TECHNOL., 42, PP. 131-136, (2009); REN P., JIANG H., LI R., WANG J., SONG N., XU H.M., XIE J.X., ROSMARINIC ACID INHIBITS 6-OHDA-INDUCED NEUROTOXICITY BY ANTI-OXIDATION IN MES23. 5 CELLS, JOURNAL OF MOLECULAR NEUROSCIENCE, 39, 1-2, PP. 220-225, (2009); ZHAO G., YAO-YUE C., QIN G.W., GUO L.H., LUTEOLIN FROM PURPLE PERILLA MITIGATES ROS INSULT PARTICULARLY IN PRIMARY NEURONS, NEUROBIOLOGY OF AGING, 33, 1, PP. 176-186, (2012); YANG J., HU L., CAI T., CHEN Q., MA Q., YANG J., HONG J., PURIFICATION AND IDENTIFICATION OF TWO NOVEL ANTIOXIDANT PEPTIDES FROM PERILLA (PERILLA FRUTESCENS L. BRITTON) SEED PROTEIN HYDROLYSATES, PLOS ONE, 13, 7, (2018); KIM S.R., JE J., JEONG K., KIM S.J., LEE K.Y., CHOI S.G., PARK S.W., PERILLA OIL DECREASES AORTIC AND HEPATIC LIPID ACCUMULATION BY MODULATING LIPOGENESIS AND LIPOLYSIS IN HIGH-FAT DIET-FED MICE, JOURNAL OF MEDICINAL FOOD, (2018); IHARA-WATANABE M., UMEKAWA H., TAKAHASHI T., FURUICHI Y., COMPARATIVE EFFECTS OF SAFFLOWER OIL AND PERILLA OIL ON SERUM AND HEPATIC LIPID LEVELS, FATTY ACID COMPOSITIONS OF SERUM AND HEPATIC PHOSPHOLIPIDS, AND HEPATIC MRNA EXPRESSIONS OF 3-HYDROXY-3- METHYLGLUTARYL COA REDUCTASE, LDL RECEPTOR, AND CHOLESTEROL, FOOD RES. INT., 33, PP. 893-900, (2000); CHUNG K.H., HWANG H.J., SHIN K.O., JEON W.M., CHOI K.S., EFFECTS OF PERILLA OIL ON PLASMA CONCENTRATIONS OF CARDIOPROTECTIVE (N-3) FATTY ACIDS AND LIPID PROFILES IN MICE, NUTR RES PR, 7, PP. 256-261, (2013); EZAKI O., TAKAHASHI M., SHIGEMATSU T., SHIMAMURA K., KIMURA J., GOTOH T., LONG-TERM EFFECTS OF DIETARY A-LINOLENIC ACID FROM PERILLA OIL ON SERUM FATTY ACIDS COMPOSITION AND ON THE RISK FACTORS OF CORONARY HEART DISEASE IN JAPANESE ELDERLY SUBJECTS, J. NUTR. SCI VITAMINOL., 45, PP. 759-772, (1999); MYOUNG H.-J., KIM G., NAM K.-W., APIGENIN ISOLATED FROM THE SEEDS OF PERILLA FRUTESCENS BRITTON VAR CRISPA (BENTH .) INHIBITS FOOD INTAKE IN C57BL / 6J MICE, ARCH PHARM RES, 33, PP. 1741-1746; MOPURI R., ISLAM S., MEDICINAL PLANTS AND PHYTOCHEMICALS WITH ANTI-OBESOGENIC POTENTIALS/: AREVIEW, BIOMED. PHARMACOTHER., 89, PP. 1442-1452, (2017); JANG J.Y., KIM T.S., CAI J., KIM J., KIM Y., SHIN K., RHEE M.H., PERILLA OIL IMPROVES BLOOD FLOW THROUGH INHIBITION OF PLATELET AGGREGATION AND THROMBUS FORMATION, LABORATORY ANIMAL RESEARCH, 30, 1, PP. 21-27, (2014); LONGVAH T., DEOSTHALE Y.G., UDAY KUMAR P., NUTRITIONAL AND SHORT TERM TOXICOLOGICAL EVALUATIONOFPERILLASEEDOIL, FOODCHEM, 70, PP. 13-16, (2000); JO H., KIM M., LEE J., KIM H., SONG Y.O., ANTI-ATHEROGENIC PROPERTIES OF EMULSIFIED PERILLA OIL (EPO) IN APO E KO MICE AND PLASMA LIPID LOWERING EFFECTS OF RICE PORRIDGE CONTAINING EPO IN HEALTHY YOUNG ADULTS, FOOD SCIENCE AND BIOTECHNOLOGY, 22, 1, PP. 79-85, (2013); ASIF M., KUMAR A., NUTRITIONAL AND FUNCTIONAL CHARACTERISATIONS OF PERILLA FRUTESCENS SEED OIL AND EVALUATION OF ITS EFFECT ON GASTROINTESTINAL MOTILITY, J. PHARM. SCI., 8, PP. 1-12, (2010); ARYA E., SAHA S., SARAF S.A., KAITHWAS G., EFFECT OF PERILLA FRUTESCENS FIXED OIL ON EXPERIMENTAL ESOPHAGITIS IN ALBINO WISTAR RATS, BIOMED RESEARCH INTERNATIONAL, (2013); SEONG J., SONG Y.O., PERILLA OIL RICH IN ALPHA-LINOLENIC ACID INHIBITS NEURONAL APOPTOSIS AND THE EXPRESSION OF INFLAMMATION-MEDIATOR PROTEIN IN APOE KO MICE, BIOCATAL. AGRIC. BIOTECHNOL., 1, PP. 167-173, (2012); ECKERT G.P., FRANKE C., NOLDNER M., RAU O., WURGLICS M., SCHUBERT-ZSILAVECZ M., MULLER W.E., PLANT DERIVED OMEGA-3-FATTY ACIDS PROTECT MITOCHONDRIAL FUNCTION IN THE BRAIN, PHARMACOL. RES., 61, PP. 234-241, (2010); KAMALASHIRAN C., PATTARAARCHACHAI J., MUENGTAWEEPONGSA S., FEASIBILITY AND SAFETY OF PERILLA SEED OIL AS AN ADDITIONAL ANTIOXIDATIVE THERAPY IN PATIENTS WITH MILD TO MODERATE DEMENTIA, JOURNAL OF AGING RESEARCH, (2018); SENAVONG P., KONGKHAM S., SAELIM S., SUANGKAVATHIN V., NEUROPROTECTIVE EFFECT OF PERILLA EXTRACTS ON PC12 CELLS, J MED ASSOC THAI, 99, PP. 256-264, (2016); HASHIMOTO M., YAMASHITA K., MATSUZAKI K., KATO S., SHIDO O., BENEFICIAL EFFECTS OF PERILLA OIL AND BRAIN TRAINING INTERVENTION ON COGNITION IN ELDERLY JAPANESE, (2017); XU B., LI X.X., HE G.R., HU J.J., MU X., TIAN S., DU G.H., LUTEOLIN PROMOTES LONG-TERM POTENTIATION AND IMPROVES COGNITIVE FUNCTIONS IN CHRONIC CEREBRAL HYPOPERFUSED RATS, EUR. J. PHARMACOL., 627, PP. 99-105, (2010); ZHAO G., QIN G.W., WANG J., CHU W.J., GUO L.H., FUNCTIONAL ACTIVATION OF MONOAMINE TRANSPORTERS BY LUTEOLIN AND APIGENIN ISOLATED FROM THE FRUIT OF PERILLA FRUTESCENS (L.) BRITT, NEUROCHEMISTRY INTERNATIONAL, 56, 1, PP. 168-176, (2010); ZHANG Y., MEI X., ZHANG Q., LI M., WU X., MA C., PROTECTIVE EFFECT OF A ROSMARINIC ACID–RICH EXTRACT FROM COLD-PRESSED PERILLA FRUTESCENS SEED FLOUR ON OXIDATIVE HEPATOTOXICITY IN VITRO AND IN VIVO, J. FOOD BIOCHEM., 42, (2018); TIAN Y., WANG H., YUAN F., LI N., HUANG Q., HE L., LIU Z., PERILLA OIL HAS SIMILAR PROTECTIVE EFFECTS OF FISH OIL ON HIGH-FAT DIET-INDUCED NONALCOHOLIC FATTY LIVER DISEASE AND GUT DYSBIOSIS, BIOMED RESEARCH INTERNATIONAL, (2016); KIM E.Y., CHOI H.J., CHUNG T.W., CHOI J.Y., KIM H.S., JUNG Y.S., LEE S.O., HA K.T., WATER-EXTRACTED PERILLA FRUTESCENS INCREASES ENDOMETRIAL RECEPTIVITY THOUGH LEUKEMIA INHIBITORY FACTOR-DEPENDENT EXPRESSION OF INTEGRINS, J. PHARMACOL. SCI., 131, PP. 259-266, (2016)","R. CHOPRA; DEPARTMENT OF FOODS AND NUTRITION, INSTITUTE OF HOME ECONOMICS, UNIVERSITY OF DELHI, NEW DELHI, F-4 HAUZ KHAS ENCLAVE, 110016, INDIA; EMAIL: RAJN145IHE@GMAIL.COM","ORIENTAL SCIENTIFIC PUBLISHING COMPANY","ENGLISH","BIOMED. PHARMACOL. J.","ARTICLE","ISI","2-S2.0-85069558041","BIOMED PHARMACOL J","UNIVERSITY OF DELHI;UNIVERSITY OF DELHI;UNIVERSITY OF DELHI","NOTREPORTED;UNIVERSITY OF DELHI;NOTREPORTED",NA,"DHYANI A, 2019, BIOMED PHARMACOL J","DHYANI A, 2019, BIOMED PHARMACOL J"
"MA J;MA L;ZHANG H;ZHANG Z;WANG Y;LI K;CHEN X","MA, JINJU (56149760100); MA, LIYI (56332101700); ZHANG, HONG (55070241500); ZHANG, ZHONGQUAN (55806093000); WANG, YOUQIONG (36174758400); LI, KAI (57001344700); CHEN, XIAOMING (55739155400)","POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY",2018,"PLOS ONE","13","",14,"10.1371/journal.pone.0197343","RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA","BACKGROUND INSECT WAX IS A FAMOUS BIOLOGICAL RESOURCE FOR THE ROLE IN ECONOMIC PRODUCTION IN CHINA. INSECT WAX IS A GOOD SOURCE OF POLICOSANOL, WHICH MAY IS A CANDIDATE SUPPLEMENT IN FOODSTUFF AND PHARMACEUTICALS THAT HAS IMPORTANT PHYSIOLOGICAL ACTIVITIES. THEREFORE, THIS WORK AIMS TO INVESTIGATE A HIGH-YIELD AND RAPID METHOD FOR POLICOSANOL FABRICATION FROM INSECT WAX. RESULTS THE CONDITIONS FOR POLICOSANOL FABRICATION WERE OPTIMIZED AS FOLLOWS: AN OIL BATH TEMPERATURE OF 112.7C AND REDUCTANT DOSAGE OF 0.97 G (USED FOR THE REDUCTION OF 10.00 G OF INSECT WAX). THE YIELD OF POLICOSANOL REACHED 83.20%, WHICH WAS 4 TIMES GREATER THAN THAT OF EXISTING METHODS, SUCH AS SAPONIFICATION. THE TOTAL CONTENT OF POLICOSANOL OBTAINED UNDER THE OPTIMAL CONDITIONS REACHED 87%. IN OTHER WORDS, A HIGH YIELD OF POLICOSANOL WAS OBTAINED FROM INSECT WAX (723.84 MG/G), THAT WAS 55 TIMES HIGHER THAN THAT GENERATED FROM BEESWAX-BROWN VIA SAPONIFICATION. THE CONCENTRATIONS OF METAL RESIDUES IN POLICOSANOL WERE WITHIN THE LIMITS OF THE EUROPEAN UNION REGULATIONS AND EFSA STIPULATION. THE LD50 VALUES FOR ORAL DOSES OF INSECT WAX AND POLICOSANOL WERE BOTH > 5 G/KG. CONCLUSION POLICOSANOL WAS FABRICATED VIA SOLVENT-FREE REDUCTION FROM INSECT WAX USING LIALH4 AT A HIGH YIELD. THE FABRICATION CONDITIONS WERE OPTIMIZED. POLICOSANOL AND INSECT WAX SHOWED HIGH SECURITY, WHICH MADE THEM POTENTIAL CANDIDATES AS SUPPLEMENTS IN FOODS, PHARMACEUTICALS AND COSMETICS. THE RAPID AND HIGH-YIELD METHOD HAS GREAT POTENTIAL FOR COMMERCIAL MANUFACTURING OF POLICOSANOL. © 2018 MA ET AL. THIS IS AN OPEN ACCESS ARTICLE DISTRIBUTED UNDER THE TERMS OF THE CREATIVE COMMONS ATTRIBUTION LICENSE, WHICH PERMITS UNRESTRICTED USE, DISTRIBUTION, AND REPRODUCTION IN ANY MEDIUM, PROVIDED THE ORIGINAL AUTHOR AND SOURCE ARE CREDITED.","","ADMINISTRATION, ORAL; ALUMINUM COMPOUNDS; ANIMALS; FATTY ALCOHOLS; FEMALE; INSECTA; LITHIUM COMPOUNDS; RATS, SPRAGUE-DAWLEY; TEMPERATURE; WAXES; INSECT WAX; METAL; OIL; POLICOSANOL; PROPOLIS; REDUCING AGENT; STIFFENER; UNCLASSIFIED DRUG; ALUMINUM DERIVATIVE; ALUMINUM LITHIUM HYDRIDE; FATTY ALCOHOL; LITHIUM DERIVATIVE; POLICOSANOL; WAX; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATMOSPHERIC PRESSURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EUROPEAN UNION; FEMALE; LD50; NONHUMAN; RAT; REACTION OPTIMIZATION; REDUCTION (CHEMISTRY); SAPONIFICATION; TEMPERATURE; ANIMAL; CHEMISTRY; INSECT; ISOLATION AND PURIFICATION; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT","SCIENTIFIC RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAM OF GUANGXI; NATIONAL HIGH-TECH RESEARCH AND DEVELOPMENT PROGRAM, (2014AA021801); FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL UNIVERSITIES, (CAFYBB2018SY025)","THIS WORK WAS FINANCIALLY SUPPORTED BY THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NON-PROFIT RESEARCH INSTITUTION OF CAF (CAFYBB2018SY025) HTTP://WWW.CAF.AC.CN/, AND NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (863 PROGRAM) (2014AA021801) HTTP://PROGRAM.MOST.GOV.CN/. WE ACKNOWLEDGED OUR SINCERE GRATITUDE TO ALL STAFF MEMBERS OF THE DEPARTMENT FOR THEIR KIND ASSISTANT.","YANG P., ZHU J.Y., GONG Z.J., XU D.L., CHEN X.M., LIU W.W., ET AL., TRANSCRIPTOME ANALYSIS OF THE CHINESE WHITE WAX SCALE ERICERUS PELA WITH FOCUS ON GENES INVOLVED IN WAX BIOSYNTHESIS, PLOS ONE, 7, 4, PP. E35719-E35728, (2012); YANG P., ZHU J., CHEN X., LI M., ISOLATION AND CHARACTERIZATION OF MICROSATELLITE LOCI FROM THE CHINESE WHITE WAX SCALE ERICERUS PELA CHAVANNES (HOMOPETERA: COCCIDAE), AFRICAN JOURNAL OF MICROBIOLOGY RESEARCH, 5, 10, PP. 1246-1248, (2011); LONG C., THE CULTURING OF ERICERUS PELA (CHAVANNES) IN CHINA AND THE TRANSMISSION OF CHINESE WAX INTO EUROPE, AGRIC HISTORY CHINA, 4, PP. 18-23, (2004); CHEN X.M., FENG Y., THE CHINESE WHITE WAX SCALE ERICERUS PELA CHAVANNES, PP. 29-30, (2009); HOU X.Y., CAO M.Y., GONG J., LI N., OVERVIEW OF PHARMACOLOGICAL RESEARCH OF INSECT WAX, JOURNAL OF ANHUI AGRI SCI, 39, 5, PP. 2817-2818, (2011); WANG Z.D., FENG Y., MA L.Y., LI X., DING W.F., CHEN X.M., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMEDICINE & PHARMA-COTHERAPY, 89, PP. 438-446, (2017); MOOSBRUGGER I., BISCHOFF P., BECK J., LUU B., BORG J., STUDIES ON THE IMMUNOLOGICAL EFFECTS OF FATTY ALCOHOLS —I. EFFECTS OF N-HEXACOSANOL ON MURINE MACROPHAGES IN CULTURE, INTERNATIONAL JOURNAL OF IMMUNOPHAR-MACOLOGY, 14, 2, PP. 293-302, (1992); BORG J., KESSLAK P.J., COTMAN C.W., PERIPHERAL ADMINISTRATION OF A LONG-CHAIN FATTY ALCOHOL PROMOTES SEPTAL CHOLINERGIC NEURONS SURVIVAL AFTER FIMBRIA-FORNIX TRANSECTION, BRAIN RESEARCH, 518, 1, PP. 295-298, (1990); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); LUPI F.R., GABRIELE D., BALDINO N., MIJOVIC P., PARISI O.I., PUOCI F., OLIVE OIL/POLICOSANOL ORGANOGELS FOR NUTRA-CEUTICAL AND DRUG DELIVERY PURPOSES, FOOD & FUNCTION, 4, 10, PP. 1512-1520, (2013); DUAN Q.F., MA L.Y., ZHENG H., CHEN X.M., A REVIEW ON RESEARCH PROGRESS OF SOME POLICOSANOLS, JOURNAL OF CHEMICAL INDUSTRY OF FOREST PRODUCTS, 39, 2, PP. 42-47, (2005); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 16, 2, PP. 61-65, (2008); CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, 23, PP. 12143-12148, (2010); ARRUZAZABALA MD.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, 3, PP. 321-327, (1993); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); CHEN H., STUDY ON ISOLATION AND PURIFICATION OF HIGH-LEVEL FATTY ALCOHOL FROM BRAN-WAX, (2003); PANDOLSOOK S., KUPONGSAK S., INFLUENCE OF BLEACHED RICE BRAN WAX ON THE PHYSICOCHEMICAL PROPERTIES OF ORGANOGELS AND WATER-IN-OIL EMULSIONS, JOURNAL OF FOOD ENGINEERING, (2017); CHEN X.J., STUDY ON THE PREPARATION AND APPLICATION OF REFINED RICE BRAN WAX, (2011); BRAVO L.G., DELANGE D.M., GRANJA A.L., FERREIRO R.M.M., VALMANA M.D.L.A., QUINTANA D.C., ET AL., MIXTURE OF PRIMARY FATTY ACIDS OBTAINED FROM SUGAR CANE WAX, (2002); LIU Y., YU J., WANG X., EXTRACTION OF POLICOSANOLS FROM HYDROLYSED RICE BRAN WAX BY HIGH-INTENSITY ULTRASOUND, INTERNATIONAL JOURNAL OF FOOD SCIENCE & TECHNOLOGY, 43, 5, PP. 763-769, (2008); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., ET AL., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 14, PP. 5552-5558, (2007); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 106, 3, PP. 147-151, (2004); MOTWANI S.K., CHOPRA S., TALEGAONKAR S., KOHLI K., AHMAD F.J., KHAR R.K., CHITOSAN–SODIUM ALGINATE NANOPARTICLES AS SUBMICROSCOPIC RESERVOIRS FOR OCULAR DELIVERY: FORMULATION, OPTIMISATION AND IN VITRO CHARAC-TERISATION, EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 68, 3, PP. 513-525, (2008); KALAM M., SULTANA Y., ALI A., AQIL M., MISHRA A.K., ALJUFFALI I.A., ET AL., PART I: DEVELOPMENT AND OPTIMIZATION OF SOLID-LIPID NANOPARTICLES USING BOX–BEHNKEN STATISTICAL DESIGN FOR OCULAR DELIVERY OF GATIFLOXACIN, JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 101, 6, PP. 1813-1827, (2013); REGULATION (EC) NO 882/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 29 APRIL 2004; COMMISSION REGULATION (EC) NO 333/2007 OF 28 MARCH 2007 LAYING DOWN THE METHODS OF SAMPLING AND ANALYSIS FOR THE OFFICIAL CONTROL OF THE LEVELS OF LEAD, CADMIUM, MERCURY, INORGANIC TIN, 3-MCPD AND BENZO(A)PYRENE IN FOODSTUFFS, (2007); COMMISSION REGULATION (EU) 2016/582 OF 15 APRIL 2016 AMENDING REGULATION (EC) NO 333/2007 AS REGARDS THE ANALYSIS OF INORGANIC ARSENIC, LEAD AND POLYCYCLIC AROMATIC HYDROCARBONS AND CERTAIN PERFORMANCE CRITERIA FOR ANALYSIS, (2016); GUIDELINE FOR TESTING OF CHEMICALS, 420 ACUTE ORAL TOXICITY–FIXED DOSE PROCEDURE, (2001); FANG H., DONG H., CAI T., ZHENG P., LI H., ZHANG D., ET AL., IN VITRO OPTIMIZATION OF ENZYMES INVOLVED IN PRE-CORRIN-2 SYNTHESIS USING RESPONSE SURFACE METHODOLOGY, PLOS ONE, 11, 3, PP. E0151149-E0151161, (2016); HOU W., ZHANG W., CHEN G., LUO Y., OPTIMIZATION OF EXTRACTION CONDITIONS FOR MAXIMAL PHENOLIC, FLAVO-NOID AND ANTIOXIDANT ACTIVITY FROM MELALEUCA BRACTEATA LEAVES USING THE RESPONSE SURFACE METHODOLOGY, PLOS ONE, 11, 9, PP. E0162139-E0162154, (2016); ZHENG Y., LIU Y., WANG A., FAST REMOVAL OF AMMONIUM ION USING A HYDROGEL OPTIMIZED WITH RESPONSE SURFACE METHODOLOGY, CHEMICAL ENGINEERING JOURNAL, 171, 3, PP. 1201-1208, (2011); ZHU J., SU J., YIN Y.-S., OCTACOSANOL PRODUCTION AND PURIFICATION WITH CERA CHINENSIS, JOURNAL OF SOUTHWEST UNIVERSITY FOR NATIONALITIES (NATURAL SCIENCE EDITION), 34, 1, PP. 144-148, (2008); AUTHORITY E.F.S., STATEMENT OF EFSA ON THE EVALUATION OF A NEW STUDY RELATED TO THE BIOAVAILABILITY OF ALUMINIUM IN FOOD, EUROPEAN FOOD SAFTY AUTHORITY JOURNAL, 9, 5, PP. 2157-2172, (2011); BORG J., THE NEUROTROPHIC FACTOR, N-HEXACOSANOL, REDUCES THE NEURONAL DAMAGE INDUCED BY THE NEURO-TOXIN, KAINIC ACID, JOURNAL OF NEUROSCIENCE RESEARCH, 29, 1, PP. 62-67, (1991); DAMGE C., HILLAIRE-BUYS D., KOENIG M., GROSS R., HOELTZEL A., CHAPAL J., ET AL., EFFECT OF N-HEXACOSANOL ON INSULIN SECRETION IN THE RAT, EUROPEAN JOURNAL OF PHARMACOLOGY, 274, 1, PP. 133-139, (1995); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDO-PAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOLO-GICA SINICA, 31, 7, (2010); MARKRACK G., CERTIFIED MEDICAL PHARMANEX REPRESENTATIVE, POLICOSANOL IN DIETARY SUPPLEMENTS; COMMISSION REGULATION (EC) NO 1881/2006 OF 19 DECEMBER 2006 SETTING MAXIMUM LEVELS FOR CERTAIN CONTAMINANTS IN FOODSTUFFS, (2006); COMMISSION REGULATION (EU) 2015/1006 OF 25 JUNE 2015 AMENDING REGULATION (EC) NO 1881/2006 AS REGARDS MAXIMUM LEVELS OF INORGANIC ARSENIC IN FOODSTUFFS, (2015); UNION E., COMMISSION IMPLEMENTING REGULATION (EU) NO 718/2014 OF 27 JUNE 2014 AMENDING REGULATION (EC) NO 669/2009 IMPLEMENTING REGULATION (EC) NO 882/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL AS REGARDS THE INCREASED LEVEL OF OFFICIAL CONTROLS ON IMPORTS OF CERTAIN FEED AND FOOD OF NON-ANIMAL ORIGIN, (2014); COMMISSION REGULATION (EU) NO 380/2012 OF 3 MAY 2012 AMENDING ANNEX II TO REGULATION (EC) NO 1333/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL AS REGARDS THE CONDITIONS OF USE AND THE USE LEVELS FOR ALUMINIUM-CONTAINING FOOD ADDITIVES, (2012); LIPNICK R., COTRUVO J., HILL R., BRUCE R., STITZEL K., WALKER A.P., ET AL., COMPARISON OF THE UP-AND-DOWN, CONVENTIONAL LD 50, AND FIXED-DOSE ACUTE TOXICITY PROCEDURES, FOOD AND CHEMICAL TOXICOLOGY, 33, 3, PP. 223-231, (1995); GUIDELINE FOR TESTING OF CHEMICALS, ACUTE ORAL TOXICITY–FIXED DOSE PROCEDURE, (2001); GLOBALLY HARMONIZED SYSTEM OF CLASSIFICATION AND LABELLING OF CHEMICALS (GHS), (2011); QIN Y., WU X., HUANG W., GONG G., LI D., HE Y., ET AL., ACUTE TOXICITY AND SUB-CHRONIC TOXICITY OF STEROIDAL SAPONINS FROM DIOSCOREA ZINGIBERENSIS CH WRIGHT IN RODENTS, JOURNAL OF ETHNOPHARMACOLOGY, 126, 3, PP. 543-550, (2009)","L. MA; RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, CHINA; EMAIL: LINHUASHI510@OUTLOOK.COM","PUBLIC LIBRARY OF SCIENCE","ENGLISH","PLOS ONE","ARTICLE","ISI","2-S2.0-85047117760","PLOS ONE","RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS","NOTREPORTED;RESEARCH INSTITUTE OF RESOURCES INSECTS;NOTREPORTED",NA,"MA J, 2018, PLOS ONE","MA J, 2018, PLOS ONE"
"ANASTASI U;SORTINO O;TUTTOBENE R;GRESTA F;GIUFFRÈ A;SANTONOCETO C","ANASTASI, UMBERTO (23970161200); SORTINO, ORAZIO (36136205300); TUTTOBENE, ROSALENA (24757310300); GRESTA, FABIO (13410420800); GIUFFRÈ, ANGELO M. (9279506500); SANTONOCETO, CARMELO (23971013900)","AGRONOMIC PERFORMANCE AND GRAIN QUALITY OF SESAME SESAMUM INDICUM L LANDRACES AND IMPROVED VARIETIES GROWN IN A MEDITERRANEAN ENVIRONMENT",2017,"GENETIC RESOURCES AND CROP EVOLUTION","64","10",22,"10.1007/s10722-015-0338-z","DIPARTIMENTO DI AGRICOLTURA, ALIMENTAZIONE E AMBIENTE, UNIVERSITÀ DEGLI STUDI DI CATANIA, VIA VALDISAVOIA 5, CATANIA, 95123, ITALY;DIPARTIMENTO DI AGRICOLTURA, ALIMENTAZIONE E AMBIENTE, UNIVERSITÀ DEGLI STUDI DI CATANIA, VIA VALDISAVOIA 5, CATANIA, 95123, ITALY;DIPARTIMENTO DI AGRICOLTURA, ALIMENTAZIONE E AMBIENTE, UNIVERSITÀ DEGLI STUDI DI CATANIA, VIA VALDISAVOIA 5, CATANIA, 95123, ITALY;DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, LOC. FEO DI VITO, REGGIO CALABRIA, 89122, ITALY;DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, LOC. FEO DI VITO, REGGIO CALABRIA, 89122, ITALY;DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, LOC. FEO DI VITO, REGGIO CALABRIA, 89122, ITALY","SESAME SEEDS ARE AN EXCELLENT FOOD AND NON-FOOD RAW MATERIAL, FOR WHICH THERE IS A CONSOLIDATED DEFICIT IN ITALY AND IN OTHER EUROPEAN UNION COUNTRIES. FOR THIS REASON, A 2-YEARS EXPERIMENT WAS CONDUCTED IN SICILY TO COMPARE THE AGRONOMIC PERFORMANCE (PHENOLOGY, MORPHOLOGICAL AND PRODUCTIVE TRAITS) AND GRAIN QUALITY (OIL AND ITS MAIN CONSTITUENTS, PROTEIN OF DEFATTED FLOUR, FIBRE) OF THREE LANDRACES, ONE OF TURKISH ORIGIN AND TWO SICILIAN (“ISPICA” AND “MODICA”), AND TWO IMPROVED VARIETIES (‘PACHEQUINO’ AND ‘YORI 77’). THE LANDRACES EVIDENCED EARLINESS (115 DAYS) AND THE GREATER HEIGHT OF INSERTION OF FIRST CAPSULE (0.52 M), WHEREAS THE VARIETY ‘PACHEQUINO’ WAS THE MOST PRODUCTIVE (3.5 T HA−1). TURKISH AND “ISPICA” LANDRACES AND ‘YORI 77’ VARIETY PROVIDED SEEDS WITH GREATER LIPID (54 %, ON AVERAGE) AND PROTEIN CONTENTS (44 % ON DEFATTED FLOUR, ON AVERAGE). ‘PACHEQUINO’ AND BOTH SICILIAN LANDRACES PRODUCED SEEDS RICHER IN FIBRE FRACTIONS. AS REGARD TO OIL QUALITY, THE OLEIC ACID/LINOLEIC ACID WAS FOUND BALANCED (ABOUT 1) FOR TURKISH LANDRACE, AND IT DECREASED FOR THE OTHER CULTIVARS REACHING THE LOWEST VALUE FOR ‘PACHEQUINO’. “MODICA” HAD HIGHER QUANTITY OF UNSAPONIFIABLE MATTER (1.98 %) IN THE OIL, WHEREAS ‘YORI 77’ HAD THE MAXIMUM CONCENTRATION OF PHYTOSTEROLS (5532.8 MG KG−1). POLICOSANOL FRACTION PREVAILED IN OIL OF “ISPICA” (205.8 MG KG−1). MOREOVER, THERE WAS VARIABILITY IN THE FATTY ACID, STEROL AND POLICOSANOL COMPOSITIONS WITH DIFFERENCES AMONG THE CULTIVARS. RESEARCH PROVIDE INFORMATION TO EXPLOIT SESAME WITHIN AGROSYSTEMS UNDER MEDITERRANEAN CLIMATES, AND MAY BE A STARTING POINT FOR BREEDING ACTIVITY TO ENHANCE CROP PRODUCTIVITY AND GRAIN QUALITY. © 2015, SPRINGER SCIENCE+BUSINESS MEDIA DORDRECHT.","FIBRE; LANDRACE; LIPID COMPOSITION; PROTEIN; SEED YIELD; SESAMUM INDICUM L","ISPICA; ITALY; RAGUSA [SICILY]; SICILY; SESAMUM INDICUM; AGRONOMY; BIOCHEMICAL COMPOSITION; CROP IMPROVEMENT; CROP PERFORMANCE; CROP YIELD; CULTIVAR; EUROPEAN UNION; FOOD QUALITY; HERB; LIPID; MEDITERRANEAN ENVIRONMENT; OIL; PROTEIN; SEED; STEROL","","","ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, PP. 5359-5362, (2006); ANASTASI U., CAMMARATA M., ABBATE V., YIELD POTENTIAL AND OIL QUALITY OF SUNFLOWER (OLEIC AND STANDARD) GROWN BETWEEN AUTUMN AND SUMMER, ITAL J AGRON, 4, PP. 23-36, (2000); ANASTASI U., SANTONOCETO C., GIUFFRE A.M., SORTINO O., GRESTA F., ABBATE V., YIELD PERFORMANCE AND GRAIN LIPID COMPOSITION OF STANDARD AND OLEIC SUNFLOWER AS AFFECTED BY WATER SUPPLY, FIELD CROPS RES, 119, PP. 145-153, (2010); ANILAKUMAR K.R., PAL A., KHANUM F., BAWA A.S., NUTRITIONAL, MEDICINAL AND INDUSTRIAL USES OF SESAME (SESAMUM INDICUM L.) SEEDS—AN OVERVIEW, AGRIC CONSPEC SCI, 75, PP. 159-168, (2010); ASHRI A., SESAME, OIL CROPS OF THE WORLD: THEIR BREEDING AND UTILIZATION, PP. 375-387, (1989); BAHKALI A.H., HUSSAIN M.A., BASAHY A.Y., PROTEIN AND OIL COMPOSITION OF SESAME (SESAMUM INDICUM L.) GROWN IN THE GIZAN AREA OF SAUDI ARABIA, INT J FOOD SCI NUTR, 49, PP. 409-414, (1998); BARREYRO A.A., DE SOUZA T.R., MARISCAL-LANDIN G., MARIA DE JESUS G.C., GARCIA K.E., SANTOS G.B., GASCA T.G., MORPH-PHYSIOLOGICAL ADAPTATIONS OF THE GASTROINTESTINAL TRACT IN PIGLETS FED A SESAME MEAL OR SOYBEAN MEAL DIET, AM J ANIM VET SCI, 9, PP. 28-35, (2014); BAYDAR H., BREEDING FOR THE IMPROVEMENT OF THE IDEAL PLANT TYPE OF SESAME, PLANT BREED, 124, PP. 263-267, (2005); BAYDAR H., TURGUT I., TURGUT K., VARIATION OF CERTAIN CHARACTERS AND LINE SELECTION FOR YIELD, OIL, OLEIC AND LINOLEIC ACIDS IN THE TURKISH SESAME (SESAMUM INDICUM L.) POPULATIONS, TURK J AGRIC FOR, 23, PP. 431-441, (1999); BEDIGIAN D., EVOLUTION OF SESAME REVISITED: DOMESTICATION, DIVERSITY AND PROSPECTS, GENET RESOUR CROP EVOL, 50, PP. 779-787, (2003); CHUNG C.H., YEE Y.J., KIM D.H., KIM H.K., CHUNG D.S., CHANGES OF LIPID, PROTEIN, RNA AND FATTY ACID COMPOSITION IN DEVELOPING SESAME (SESAMUM INDICUM L.) SEEDS, PLANT SCI, 109, PP. 237-243, (1995); CODEX STANDARD FOR NAMED VEGETABLE OILS CURRENT OFFICIAL STANDARDS (AMENDED 2003, 2005), FAO/WHO FOOD STANDARDS CODEX ALIMENTARIUS, (1999); COSTANTINI E.A.C., FANTAPPIE M., L'ABATE G., CLIMATE AND PEDOCLIMATE OF ITALY, THE SOILS OF ITALY. WORLD SOILS BOOK SERIES, PP. 19-37, (2013); ELLEUCH M., BESBES S., ROISEUX O., BLECKER C., ATTIA H., QUALITY CHARACTERISTICS OF SESAME SEEDS AND BY-PRODUCTS, FOOD CHEM, 103, PP. 641-650, (2007); HARDY R.W.F., THE BIO-BASED ECONOMY, TRENDS IN NEW CROPS AND NEW USES, PP. 11-16, (2002); KANU P.J., ZHUA K., KANUB J.B., ZHOUA H., QIANA H., ZHU K., BIOLOGICALLY ACTIVE COMPONENTS AND NUTRACEUTICALS IN SESAME AND RELATED PRODUCTS: A REVIEWED PROSPECT, TRENDS FOOD SCI TECHNOL, 18, PP. 599-608, (2007); KIM J.K., PARK S.Y., NA J.K., SEONG E.S., YU C.Y., METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA (PERILLA FRUTESCENS) CULTIVARS, J AGRIC FOOD CHEM, 60, PP. 2257-2263, (2012); MOHAMED H.M.A., AWATIF I.I., THE USE OF SESAME OIL UNSAPONIFIABLE MATTER AS A NATURAL ANTIOXIDANT, FOOD CHEM, 62, PP. 267-276, (1998); MORRIS J.B., FOOD, INDUSTRIAL, NUTRACEUTICAL, AND PHARMACEUTICAL USES OF SESAME GENETIC RESOURCES, TRENDS IN NEW CROPS AND NEW USES, PP. 153-156, (2002); STUCHLIK M., ZAK S., VEGETABLE LIPIDS AS COMPONENTS OF FUNCTIONAL FOODS, BIOMED PAP, 146, PP. 3-10, (2002); TIR R., DUTTA P.C., BADJAH-HADJ-AHMED A.Y., EFFECT OF THE EXTRACTION SOLVENT POLARITY ON THE SESAME SEEDS OIL COMPOSITION, EUR J LIPID SCI TECHNOL, 114, PP. 1427-1438, (2012); UZUN B., ASRLAN C., FURAT S., VARIATION IN FATTY ACID COMPOSITION, OIL CONTENT AND OIL YIELD IN A GERMPLASM COLLECTION OF SESAME (SESAMUM INDICUM L.), J AM OIL CHEM SOC, 85, PP. 1135-1142, (2008); UZUN B., CAGIRGAN M.I., COMPARISON OF DETERMINATE AND INDETERMINATE LINES OF SESAME FOR AGRONOMIC TRAITS, FIELD CROPS RES, 96, PP. 13-18, (2006); VAN SOEST P.J., ROBERTSON J., LEWIS B.A., METHODS FOR DIETARY FIBER NEUTRAL DETERGENT FIBER AND NON-STARCH POLYSACCHARIDES IN RELATION TO ANIMAL NUTRITION, J DAIRY SCI, 74, PP. 3583-3597, (1991); WEISS E.A., SESAME. IN: OILSEED CROPS LONGMAN INC., PP. 282-340, (1983); WERE B.A., ONKWARE A.O., GUDU S., WELANDE R.M., CARLSSON A.S., SEED OIL CONTENT AND FATTY ACID COMPOSITION IN EAST AFRICAN SESAME (SESAMUM INDICUM L.) ACCESSIONS EVALUATED OVER 3 YEARS, FIELD CROPS RES, 97, PP. 254-260, (2006); YOL E., UZUN B., GEOGRAPHICAL PATTERNS OF SESAME ACCESSIONS GROWN UNDER MEDITERRANEAN ENVIRONMENTAL CONDITIONS, AND ESTABLISHMENT OF A CORE COLLECTION, CROP SCI, 52, PP. 2206-2214, (2012); ZAVAREHA M., HOOGENBOOMB G., RAHIMIAN M.H., ARABD A., A DECIMAL CODE TO DESCRIBE THE GROWTH STAGES OF SESAME (SESAMUM ORIENTALE L.), INT J PLANT PROD, 2, PP. 193-206, (2008)","U. ANASTASI; DIPARTIMENTO DI AGRICOLTURA, ALIMENTAZIONE E AMBIENTE, UNIVERSITÀ DEGLI STUDI DI CATANIA, CATANIA, VIA VALDISAVOIA 5, 95123, ITALY; EMAIL: UMBERTO.ANASTASI@UNICT.IT","SPRINGER NETHERLANDS","ENGLISH","GENET. RESOUR. CROP. EVOL.","ARTICLE","ISI","2-S2.0-84945243124","GENET RESOUR CROP EVOL","UNIVERSITÀ DEGLI STUDI DI CATANIA;UNIVERSITÀ DEGLI STUDI DI CATANIA;UNIVERSITÀ DEGLI STUDI DI CATANIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA","NOTREPORTED;UNIVERSITÀ DEGLI STUDI DI CATANIA;NOTREPORTED",NA,"ANASTASI U, 2017, GENET RESOUR CROP EVOL","ANASTASI U, 2017, GENET RESOUR CROP EVOL"
"MANFRIN A;TRIMARCO V;MANZI M;ROZZA F;IZZO R","MANFRIN, ANDREA (56613307500); TRIMARCO, VALENTINA (6602355473); MANZI, MARIA VIRGINIA (55484916200); ROZZA, FRANCESCO (23498918300); IZZO, RAFFAELE (7004640234)","A SINGLE BLIND MULTICENTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS AND COST OF A NOVEL NUTRACEUTICAL LOPIGLIK LOWERING CARDIOVASCULAR DISEASE RISK",2018,"CLINICOECONOMICS AND OUTCOMES RESEARCH","10","8",2,"10.2147/CEOR.S172838","SUSSEX PHARMACY, SCHOOL OF LIFE SCIENCES, UNIVERSITY OF SUSSEX, FALMER, BRIGHTON, UNITED KINGDOM;HYPERTENSION RESEARCH CENTRE, UNIVERSITY OF NAPLES FEDERICO II, NAPLES, ITALY, DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTRE, UNIVERSITY OF NAPLES FEDERICO II, NAPLES, ITALY, DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTRE, UNIVERSITY OF NAPLES FEDERICO II, NAPLES, ITALY, DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTRE, UNIVERSITY OF NAPLES FEDERICO II, NAPLES, ITALY, DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCE SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY","CONTEXT: CARDIOVASCULAR DISEASE (CVD) COSTS THE ECONOMY €210 BILLION PER YEAR IN EUROPE. THERE IS AN ASSOCIATION BETWEEN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND CVD RISK. OBJECTIVE: TO EVALUATE THE COST AND EFFECTIVENESS OF LOPIGLIK® (LOPI) IN LOWERING LDL-C AND CVD RISK. DESIGN: SINGLE BLIND MULTICENTER RANDOMIZED CONTROLLED TRIAL; PATIENTS WERE DIVIDED INTO TWO GROUPS, SUBJECTED TO CENTRALIZED RANDOMIZATION. SETTING: FOUR ITALIAN REGIONS. PARTICIPANTS: THIRTY-ONE PHYSICIANS ENROLLED 573 ADULT PATIENTS WITH MILD HYPERCHOLESTEROLEMIA BETWEEN JANUARY 2016 AND JANUARY 2018. INTERVENTION: PATIENTS WERE TREATED FOR 16 WEEKS EITHER WITH LOPI (INTERVENTION) OR ARMOLIPID PLUS® (AP; CONTROL). OUTCOME MEASURES: PRIMARY OUTCOME: PERCENTAGE OF PATIENTS WHO ACHIEVED LDL-C <130 MG/DL. SECONDARY OUTCOMES: REDUCTION OF HBA1C, SURVIVAL ANALYSIS AND HR LINKED TO 38.67 MG/DL REDUCTION OF LDL-C AND 1% REDUCTION OF HBA1C. COSTS WERE ASSESSED PER UNIT AND CURE. RESULTS: THREE HUNDRED AND SEVENTY PATIENTS TREATED WITH LOPI AND 203 TREATED WITH AP WERE RANDOMIZED AND COMPLETED THE STUDY. AT BASELINE 8.9% (N=18) PATIENTS TREATED WITH AP AND 9.5% (N=35) TREATED WITH LOPI HAD LDL-C LEVELS <130 MG/DL (P=0.815). AT THE 16-WEEK FOLLOW-UP, 41.4% (N=84) OF PATIENTS TREATED WITH AP AND 67.6% (N=250) WITH LOPI ACHIEVED LDL-C LEVELS <130 MG/DL (P<0.001). LOPI PATIENTS WERE THREE TIMES MORE LIKELY TO ACHIEVE LDL-C LEVELS <130 MG/DL; ADJUSTED OR 2.97 (95% CI; 2.08–4.24; P<0.001), NUMBER NEEDED TO TREAT WAS FOUR (95% CI; 5.60–2.90; P<0.001). SURVIVAL ANALYSIS DEMONSTRATED THE SUPERIORITY OF LOPI VS AP RELATIVE TO 38.67 MG/DL LDL-C REDUCTION (P<0.002); HR WAS 0.761 (95% CI; 0.62–0.94; P<0.001). BOTH PRODUCTS REDUCED THE HBA1C WITHOUT A SIGNIFICANT DIFFERENCE BETWEEN THEM (P=0.156). SURVIVAL ANALYSIS AND HR (0.91; 95% CI; 0.70–1.18) ESTIMATED FOR 1% HBA1C REDUCTION, SHOWED DIFFERENCES BETWEEN LOPI AND AP, WHICH WERE NOT SIGNIFICANT (P=0.411; P=0.464). THE COST OF LOPI WAS €2.11 (UNIT), €211 (CURE), AND AP €3.77 AND €377, RESPECTIVELY. CONCLUSION: LOPI APPEARED MORE EFFECTIVE AND LESS EXPENSIVE THAN AP IN LOWERING LDL-C AND CVD RISK. © 2018 MANFRIN ET AL.","CARDIOVASCULAR RISK REDUCTION; EFFECTIVENESS; HYPERCHOLESTEROLEMIA; NUTRACEUTICALS","ALANINE AMINOTRANSFERASE; ARMOLIPID PLUS; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; BERBERINE; CHOLESTIN; CREATINE KINASE; FOLIC ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOPIGLIK; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MULBERRY EXTRACT; NUTRACEUTICAL; PLACEBO; POLICOSANOL; UBIDECARENONE; UNCLASSIFIED DRUG; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; ITALY; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE BLIND PROCEDURE; SURVIVAL; TABLET; TREATMENT DURATION","AKADEMY-PHARMA","THE AUTHORS ARE GRATEFUL TO THE ITALIAN GENERAL PRACTITIONERS, HOSPITAL CONSULTANTS, AND PATIENTS FOR THEIR PARTICIPATION IN THIS STUDY, AND TO PROFESSOR BUGEWA APAMPA FOR EDITING THE MANUSCRIPT. THIS TRIAL WAS FUNDED BY AKADEMY-PHARMA. TRIAL PROTOCOL: HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/ NCT02898805.","CARDIOVASCULAR DISEASES (CVDS), (2015); WILKINS E., WILSON L., WICKRAMASINGHE K., EUROPEAN CARDIOVASCULAR DISEASE STATISTICS 2017 EDITION, (2017); BERNIK S., DAVIS C., THE ECONOMIC COSTS OF CVD FROM 2014-2020 IN SIX EUROPEAN ECONOMIES, (2014); YUSUF S., HAWKEN S., OUNPUU S., ET AL., EFFECT OF POTENTIALLY MODIFIABLE RISK FACTORS ASSOCIATED WITH MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): CASE-CONTROL STUDY, LANCET, 364, 9438, PP. 937-952, (2004); WILSON P.W., D'AGOSTINO R.B., LEVY D., PREDICTION OF CORONARY HEART DISEASE USING RISK FACTOR CATEGORIES, CIRCULATION, 97, PP. 1837-1847, (1998); WADHERA R.K., STEEN D.L., KHAN I., GIUGLIANO R.P., FOODY JM. A REVIEW OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL, TREATMENT STRATEGIES, AND ITS IMPACT ON CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY, J CLIN LIPIDOL, 10, 3, PP. 472-489, (2016); SHARRETT A.R., BALLANTYNE C.M., COADY S.A., ET AL., CORONARY HEART DISEASE PREDICTION FROM LIPOPROTEIN CHOLESTEROL LEVELS, TRIGLYCERIDES, LIPOPROTEIN(A), APOLIPOPROTEINS A-I AND B, AND HDL DENSITY SUBFRAC-TIONS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY, CIRCULATION, 104, 10, PP. 1108-1113, (2001); CTT: CHOLESTEROL TREATMENT TRIALISTS’ COLLABORATION, NUFFIELD DEPARTMENT OF POPULATION AND HEALTH. UNIT; CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR HEART J, 37, 39, PP. 2999-3058, (2016); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTR METAB CARDIOVASC DIS, 27, 1, PP. 2-17, (2017); PIRRO M., MANNARINO M.R., BIANCONI V., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); TRIMARCO V., IZZO R., STABILE E., ET AL., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE, INSULIN SENSITIVITY AND ENDOTELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS. A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND TRIAL, HIGH BLOOD PRESS CARDIOVASC PREV, 22, 2, PP. 149-154, (2015); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, 1, PP. 61E8-68, (2014); MILLAN J., CICERO A.F., TORRES F., ANGUERA A., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLIN INVESTIG ARTERIOSCLER, 28, 4, PP. 178-187, (2016); BARRIOS V., ESCOBAR C., CICERO A.F., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); SILVERMAN M.G., FERENCE B.A., IM K., ET AL., ASSOCIATION BETWEEN LOWERING LDL-C AND CARDIOVASCULAR RISK REDUCTION AMONG DIFFERENT THERAPEUTIC INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 316, 12, (2016); KHAW K.T., WAREHAM N., BINGHAM S., LUBEN R., WELCH A., DAY N., ASSOCIATION OF HEMOGLOBIN A1C WITH CARDIOVASCULAR DISEASE AND MORTALITY IN ADULTS: THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER IN NORFOLK, ANN INTERN MED, 141, 6, PP. 413-420, (2004); CHEN Y.-Y., LIN Y.-J., CHONG E., ET AL., THE IMPACT OF DIABETES MELLITUS AND CORRESPONDING HBA1C LEVELS ON THE FUTURE RISKS OF CARDIOVASCULAR DISEASE AND MORTALITY: A REPRESENTATIVE COHORT STUDY IN TAIWAN, PLOS ONE, 10, 4, (2015); LUSCHER T.F., PREVENTION IS BETTER THAN CURE: THE NEW ESC GUIDELINES, EUR HEART J, 37, 29, PP. 2291-2293, (2016); TRIMARCO V., BATTISTONI A., TOCCI G., ET AL., SINGLE BLIND, MULTICENTRE, RANDOMIZED, CONTROLLED TRIAL TESTING THE EFFECTS OF A NOVEL NUTRACEUTICAL COMPOUND ON PLASMA LIPID AND CARDIOVASCULAR RISK FACTORS: RESULTS OF THE INTERIM ANALYSIS, NUTR METAB CARDIOVASC DIS, 27, 10, PP. 850-857, (2017); STERNE J.A., WHITE I.R., CARLIN J.B., ET AL., MULTIPLE IMPUTATION FOR MISSING DATA IN EPIDEMIOLOGICAL AND CLINICAL RESEARCH: POTENTIAL AND PITFALLS, BMJ, 338, 1, PP. B2393-B2393, (2009); MCCRUM-GARDNER E., WHICH IS THE CORRECT STATISTICAL TEST TO USE?, BR J ORAL MAXILLOFAC SURG, 46, 1, PP. 38-41, (2008); VELENTGAS P., DREYER N.A., NOURJAH P., DEVELOPING A PROTOCOL FOR OBSERVATIONAL COMPARATIVE EFFECTIVENESS RESEARCH: A USER’S GUIDE, PP. 135-144, (2013); CENTRE FOR EVIDENCE-BASED MEDICINE TORONTO. KT CLEARINGHOUSE; BANG H., ZHAO H., AVERAGE COST-EFFECTIVENESS RATIO WITH CENSORED DATA, J BIOPHARM STAT, 22, 2, PP. 401-415, (2012); FORD E.S., AJANI U.A., CROFT J.B., ET AL., EXPLAINING THE DECREASE IN U.S. DEATHS FROM CORONARY DISEASE, 1980-2000, N ENGL J MED, 356, 23, PP. 2388-2398, (2007); WIJEYSUNDERA H.C., MACHADO M., FARAHATI F., ET AL., ASSOCIATION OF TEMPORAL TRENDS IN RISK FACTORS AND TREATMENT UPTAKE WITH CORONARY HEART DISEASE MORTALITY, 1994-2005, JAMA, 303, 18, PP. 1841-1847, (2010); BJORCK L., ROSENGREN A., BENNETT K., LAPPAS G., CAPEWELL S., MODELLING THE DECREASING CORONARY HEART DISEASE MORTALITY IN SWEDEN BETWEEN 1986 AND 2002, EUR HEART J, 30, 9, PP. 1046-1056, (2009); BANDOSZ P., O'FLAHERTY M., DRYGAS W., ET AL., DECLINE IN MORTALITY FROM CORONARY HEART DISEASE IN POLAND AFTER SOCIOECONOMIC TRANSFORMATION: MODELLING STUDY, BMJ, 344, (2012); FLORES-MATEO G., GRAU M., O'FLAHERTY M., ET AL., ANALYZING THE CORONARY HEART DISEASE MORTALITY DECLINE IN A MEDITERRANEAN POPULATION: SPAIN 1988-2005, REV ESP CARDIOL, 64, 11, PP. 988-996, (2011); HUGHES J., KEE F., O'FLAHERTY M., ET AL., MODELLING CORONARY HEART DISEASE MORTALITY IN NORTHERN IRELAND BETWEEN 1987 AND 2007: BROADER LESSONS FOR PREVENTION, EUR J PREV CARDIOL, 20, 2, PP. 310-321, (2013); ASPELUND T., GUDNASON V., MAGNUSDOTTIR B.T., ET AL., ANALYSING THE LARGE DECLINE IN CORONARY HEART DISEASE MORTALITY IN THE ICELANDIC POPULATION AGED 25-74 BETWEEN THE YEARS 1981 AND 2006, PLOS ONE, 5, 11, (2010); PALMIERI L., BENNETT K., GIAMPAOLI S., CAPEWELL S., EXPLAINING THE DECREASE IN CORONARY HEART DISEASE MORTALITY IN ITALY BETWEEN 1980 AND 2000, AM J PUBLIC HEALTH, 100, 4, PP. 684-692, (2010); HOTCHKISS J.W., DAVIES C.A., DUNDAS R., ET AL., EXPLAINING TRENDS IN SCOTTISH CORONARY HEART DISEASE MORTALITY BETWEEN 2000 AND 2010 USING IMPACTSEC MODEL: RETROSPECTIVE ANALYSIS USING ROUTINE DATA, BMJ, 348, (2014); BAJEKAL M., SCHOLES S., LOVE H., ET AL., ANALYSING RECENT SOCIOECONOMIC TRENDS IN CORONARY HEART DISEASE MORTALITY IN ENGLAND, 2000-2007: A POPULATION MODELLING STUDY, PLOS MED, 9, 6, (2012); DE SMEDT D., KOTSEVA K., DE BACQUER D., ET AL., COST-EFFECTIVENESS OF OPTIMIZING PREVENTION IN PATIENTS WITH CORONARY HEART DISEASE: THE EUROASPIRE III HEALTH ECONOMICS PROJECT, EUR HEART J, 33, 22, PP. 2865-2872, (2012); EEG-OLOFSSON K., CEDERHOLM J., NILSSON P.M., ET AL., NEW ASPECTS OF HBA1C AS A RISK FACTOR FOR CARDIOVASCULAR DISEASES IN TYPE 2 DIABETES: AN OBSERVATIONAL STUDY FROM THE SWEDISH NATIONAL DIABETES REGISTER (NDR), J INTERN MED, 268, 5, PP. 471-482, (2010); SELVIN E., STEFFES M.W., ZHU H., ET AL., GLYCATED HEMOGLOBIN, DIABETES, AND CARDIOVASCULAR RISK IN NONDIABETIC ADULTS, N ENGL J MED, 362, 9, PP. 800-811, (2010); OH H.G., RHEE E.J., KIM T.W., ET AL., HIGHER GLYCATED HEMOGLOBIN LEVEL IS ASSOCIATED WITH INCREASED RISK FOR ISCHEMIC STROKE IN NON-DIABETIC KOREAN MALE ADULTS, DIABETES METAB J, 35, 5, PP. 551-557, (2011); CHEN Y.Y., LIN Y.J., CHONG E., ET AL., THE IMPACT OF DIABETES MELLITUS AND CORRESPONDING HBA1C LEVELS ON THE FUTURE RISKS OF CARDIOVASCULAR DISEASE AND MORTALITY: A REPRESENTATIVE COHORT STUDY IN TAIWAN, PLOS ONE, 10, 4, (2015)","A. MANFRIN; SUSSEX PHARMACY, SCHOOL OF LIFE SCIENCES, UNIVERSITY OF SUSSEX, FALMER, BRIGHTON, BN1 9RH, UNITED KINGDOM; EMAIL: A.MANFRIN@SUSSEX.AC.UK","DOVE MEDICAL PRESS LTD","ENGLISH","CLIN. OUTCOMES RES.","ARTICLE","ISI","2-S2.0-85059025158","CLIN OUTCOMES RES","UNIVERSITY OF SUSSEX;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II","NOTREPORTED;UNIVERSITY OF SUSSEX;NOTREPORTED",NA,"MANFRIN A, 2018, CLIN OUTCOMES RES","MANFRIN A, 2018, CLIN OUTCOMES RES"
"VENTURELLI A;BRIGHENTI V;MASCOLO D;PELLATI F","VENTURELLI, ALBERTO (6603423752); BRIGHENTI, VIRGINIA (56162712900); MASCOLO, DANILO (57208791908); PELLATI, FEDERICA (6507646450)","A NEW STRATEGY BASED ON MICROWAVEASSISTED TECHNOLOGY FOR THE EXTRACTION AND PURIFICATION OF BEESWAX POLICOSANOLS FOR PHARMACEUTICAL PURPOSES AND BEYOND",2019,"JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS","172","5",14,"10.1016/j.jpba.2019.04.015","STRADA GHERBELLA, 294, MODENA, 41126, ITALY;STRADA GHERBELLA, 294, MODENA, 41126, ITALY, DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY;CONFINDUSTRIA EMILIA-ROMAGNA, VIA BARBERIA 13, BOLOGNA, 40123, ITALY;DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, VIA G. CAMPI 103, MODENA, 41125, ITALY","                             POLICOSANOLS (PCS) ARE A MIXTURE OF LONG CHAIN PRIMARY ALIPHATIC ALCOHOLS MAINLY KNOWN FOR THEIR ABILITY TO REDUCE CHOLESTEROL LEVEL. DUE TO THIS PROPERTY, THERE IS AN INCREASING INTEREST IN THE EXTRACTION PROCESS OF THESE COMPOUNDS. IN THIS CONTEXT, BEESWAX, A NATURAL PRODUCT PRODUCED BY HONEY BEES OF THE GENUS APIS, IS A PROMISING SOURCE FOR THEIR EXTRACTION AND PURIFICATION. THE PRESENT RESEARCH WORK WAS AIMED AT THE DEVELOPMENT OF A NEW PROCEDURE FOR THE EXTRACTION AND PURIFICATION OF PCS FROM YELLOW BEESWAX BY USING MICROWAVE-ASSISTED TECHNOLOGY, WHICH HITHERTO HAS NEVER BEEN APPLIED TO THIS MIXTURE. THE DEVELOPED PROCESS COMPRISES THREE MAIN STEPS: 1) MICROWAVE-ASSISTED TRANS-ESTERIFICATION; 2) MICROWAVE-ASSISTED HYDROLYSIS; 3) FINAL PURIFICATION BY MEANS OF PREPARATIVE LIQUID CHROMATOGRAPHY. THE FINAL STEP IS RESPONSIBLE FOR THE INCREASED PURITY OF PCS, THANKS TO THE REMOVAL OF UNDESIRED COMPOUNDS, SUCH AS NATURAL PARAFFINS. THE PREDOMINANT ALCOHOLS INVESTIGATED IN THIS WORK ARE TETRACOSANOL (C                             24                             OH), HEXACOSANOL (C                             26                             OH), OCTACOSANOL (C                             28                             OH), TRIACONTANOL (C                             30                             OH) AND DOTRIACONTANOL (C                             32                             OH). COMPOUND IDENTIFICATION WAS PERFORMED USING GC-EI-MS, WHILE GC-FID ANALYSIS WAS CHOSEN FOR THE QUANTIFICATION OF THE MAIN FATTY ALCOHOLS PRESENT IN THE PRODUCT. THIS NEW METHOD REPRESENTS A USEFUL TOOL FOR THE PRODUCTION OF PCS FROM BEESWAX TO BE USED IN PHARMACEUTICALS AND NUTRACEUTICALS FOR HUMAN USE, FEED AND VETERINARY SUPPLEMENTS.                          © 2019 ELSEVIER B.V.","BEESWAX; GAS CHROMATOGRAPHY; MICROWAVE-ASSISTED EXTRACTION; POLICOSANOLS; PREPARATIVE LIQUID CHROMATOGRAPHY","ALCOHOLS; ANIMALS; BEES; BIOLOGICAL PRODUCTS; FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MICROWAVES; TECHNOLOGY, PHARMACEUTICAL; WAXES; DOTRIACONTANOL; FATTY ALCOHOL; HEXACOSANOL; OCTACOSANOL; PARAFFIN; POLICOSANOL; PROPOLIS; TETRACOSANOL; TRIACONTANOL; UNCLASSIFIED DRUG; 1-OCTACOSANOL; 1-TRIACONTANOL; ALCOHOL DERIVATIVE; BIOLOGICAL PRODUCT; FATTY ALCOHOL; POLICOSANOL; PROPOLIS; WAX; ARTICLE; DRUG HYDROLYSIS; DRUG ISOLATION; DRUG PURIFICATION; GAS CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MICROWAVE ASSISTED EXTRACTION; PRIORITY JOURNAL; TRANSESTERIFICATION; ANIMAL; BEE; CHEMISTRY; DEVICES; MICROWAVE RADIATION; PHARMACEUTICS; PROCEDURES","EUROPEAN UNION HORIZON 2020 RESEARCH AND INNOVATION PROGRAM; HORIZON 2020 FRAMEWORK PROGRAMME, H2020, (854590)","THIS WORK WAS CARRIED OUT IN THE PROJECT “NEW POLI PHARMA NET” IN THE AMBIT OF THE REGIONAL PROGRAM “DAI DISTRETTI PRODUTTIVI AI DISTRETTI TECNOLOGICI 2 PER IL DISTRETTO 5-FARMACEUTICA E BIOTECNOLOGIE”, FUNDED BY EMILIA-ROMAGNA REGION, ITALY. ","IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MED. J. NUTR. METAB., 1, PP. 77-83, (2008); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., FERNANDEZ J.C., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY, CURR. THER. RES., 62, PP. 194-208, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); GUPTA H., PAWAR D., RIVA A., BOMBARDELLI E., MORAZZONI P., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE EFFICACY AND TOLERABILITY OF AN OPTIMIZED BOTANICAL COMBINATION IN THE MANAGEMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA, PHYTOTHER. RES., 26, PP. 265-272, (2012); BARRAT E., ZAIR Y., SIRVENT P., CHAUVEAU P., MAUDET C., HOUSEZ B., DERBORD E., LESCUYER J., BARD J., CAZAUBIEL M., PELTIER S.L., EFFECT ON LDL-CHOLESTEROL OF A LARGE DOSE OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH UNTREATED MODERATE HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EUR. J. NUTR., 52, PP. 1843-1852, (2013); ILLNAIT J., LOPEZ E., FERNANDEZ L., MAS R., GAMEZ R., MESA M., MENDOZA S., FERNANDEZ J.C., EFFECTS OF POLICOSANOL (5 AND 10 MG/DAY) IN ADULTS WITH SERUM CHOLESTEROL LEVELS ≤ 5.9 MMOL/L, INT. J. PHARM. SCI. REV. RES., 54, PP. 303-309, (2013); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER., 318, PP. 1020-1026, (2006); PATTI A.M., TOTH P.P., GIGLIO R.V., BANACH M., NOTO M., NIKOLIC D., MONTALTO G., RIZZO M., NUTRACEUTICALS AS AN IMPORTANT PART OF COMBINATION THERAPY IN DYSLIPIDAEMIA, CURR. PHARM. DES., 23, PP. 2496-2503, (2017); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., KIM Y., SEO W.D., LEE S.J., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTR. RES., 43, PP. 89-99, (2017); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR., 84, PP. 1543-1548, (2006); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT. THER. MED., 16, PP. 61-65, (2008); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH. MED. RES., 36, PP. 441-447, (2005); ORTEGA L.L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE: A PILOT OPEN STUDY, J. MED. FOOD, 9, PP. 378-385, (2006); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR. REV., 61, PP. 376-383, (2003); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR. J. LIPID SCI. TECHNOL., 106, PP. 147-151, (2004); WANG M., LIAN H., MAO L., ZHOU J., GONG H., QIAN B., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM., 55, PP. 5552-5558, (2007); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURIZED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM AND BRAN, FOOD CHEM., 119, PP. 1246-1249, (2010); SIN E.H.K., MARRIOT R., HUNT A.J., CLARK J.H., IDENTIFICATION, QUANTIFICATION AND CHRASTIL MODELLING OF WHEAT STRAW WAX EXTRACTION USING SUPERCRITICAL CARBON DIOXIDE, CR. CHIM., 17, PP. 293-300, (2014); ATTARD T.M., MCELROY C., REZENDE C.A., POLIKARPOV I., CLARK J.H., HUNT A.J., SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES, IND. CROP. PROD., 76, PP. 95-103, (2015); JACKSON M.A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYZED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, J. SUPERCRIT. FLUIDS, 37, PP. 173-177, (2006); PEREZ P.P., (2001); GAMBLE W.R., LIU Z., BAILEY D.T., PEREZ P.P., STULL D.P., RICHHEIMER S.L., NICHOLS R.L., LENOBLE R., (2006); SRISAIPET A., PHROMCHAN S., JAIPAENG T., POLICOSANOL EXTRACTION FROM BEESWAX AND IMPROVEMENT OF THE PURITY, MATEC WEB OF CONFERENCES 111, (2017); GIL-CHAVEZ G.J., VILLA J.A., AYALA-ZAVALA F.J., BASILIO HEREDIA J., SEPULVEDA D., YAHIA E.M., GUSTAVO A., GONZALEZ-AGUILAR G.A., TECHNOLOGIES FOR EXTRACTION AND PRODUCTION OF BIOACTIVE COMPOUNDS TO BE USED AS NUTRACEUTICALS AND FOOD INGREDIENTS, COMPR. REV. FOOD SCI. F, 12, PP. 5-23, (2013); PELLATI F., MASCOLO D., VENTURELLI A., BARBATO A., RIGHI D., CASTALDI P., (2017); TULLOCH A.P., BEESWAX-COMPOSITION AND ANALYSIS, BEE WORLD, 61, PP. 47-62, (1980); CANCELA A., MACEIRAS R., URREJOLAS S., SANCHEZ A., MICROWAVE-ASSISTED TRANSESTERIFICATION OF MACROALGAE, ENERGIES, 5, PP. 862-871, (2012); BONADUCE I., COLOMBINI M.P., CHARACTERIZATION OF BEESWAX ION WORKS OF ART BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY AND PYROLYSIS-GAS CHROMATOGRAPHY-MASS SPECTROMETRY PROCEDURES, J. CHROMATOGR. A, 1028, PP. 297-306, (2004)","F. PELLATI; DEPARTMENT OF LIFE SCIENCES, UNIVERSITY OF MODENA AND REGGIO EMILIA, MODENA, VIA G. CAMPI 103, 41125, ITALY; EMAIL: FEDERICA.PELLATI@UNIMORE.IT","ELSEVIER B.V.","ENGLISH","J. PHARM. BIOMED. ANAL.","ARTICLE","ISI","2-S2.0-85065100656","J PHARM BIOMED ANAL","ITALY;UNIVERSITY OF MODENA AND REGGIO EMILIA","NOTREPORTED;UNIVERSITY OF MODENA AND REGGIO EMILIA;NOTREPORTED",NA,"VENTURELLI A, 2019, J PHARM BIOMED ANAL","VENTURELLI A, 2019, J PHARM BIOMED ANAL"
"XU K;LIU X;LI Y;WANG Y;ZANG H;GUO L;WANG Y;ZHAO W;WANG X;HAN Y","XU, KAI (56510776700); LIU, XINMING (56873048500); LI, YI (55914058500); WANG, YUNUO (56606658400); ZANG, HONGYUN (34772286100); GUO, LIANG (56493560600); WANG, YUAN (57191506758); ZHAO, WEI (57719434500); WANG, XIAOZENG (8296963700); HAN, YALING (7404095618)","SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ONTREATMENT PLATELET REACTIVITY AFTER DRUGELUTING STENT IMPLANTATION TWOYEAR FOLLOWUP RESULTS",2016,"CARDIOVASCULAR THERAPEUTICS","34","5",9,"10.1111/1755-5922.12204","DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, NO. 463 HOSPITAL OF PLA, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, SHENZHOU HOSPITAL AFFILIATED TO SHENYANG MEDICAL COLLEGE, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA;DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA","OBJECTIVES: TO INVESTIGATE SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ON-TREATMENT PLATELET REACTIVITY AFTER DRUG-ELUTING STENT IMPLANTATION. BACKGROUND: CERTAIN NUMBER OF PATIENTS HAS HIGH RESIDUAL PLATELET REACTIVITY ON CLOPIDOGREL AFTER CORONARY INTERVENTION, AND THEIR RISK OF THROMBOTIC EVENTS IS HIGH. METHOD: IN THIS PROSPECTIVE, RANDOMIZED TRIAL CONDUCTED IN FOUR CHINESE SITES, 350 PATIENTS WITH HIGH ON-TREATMENT PLATELET REACTIVITY (HPR, DEFINED AS PLATELET AGGREGATION >65%) WERE RANDOMIZED BY THE RATIO OF 1:3:3 TO: GROUP A, CLOPIDOGREL 75 MG/D FOR 1 YEAR (N=50); GROUP B, CLOPIDOGREL 150 MG/D FOR 30 DAYS FOLLOWED BY 75 MG/D UNTIL 1 YEAR (N=150); OR GROUP C, POLICOSANOL 40 MG/D FOR 6 MONTH AND CLOPIDOGREL 75 MG/D FOR 1 YEAR (N=150). ALL OF THEM WERE TREATED WITH ASPIRIN. THE PRIMARY ENDPOINT WAS THE REVERSION RATE OF HPR AT 1 MONTH (REVERSION WAS DEFINED AS PLATELET AGGREGATION <65%). THE SECONDARY ENDPOINTS WERE 6-MONTH MAJOR ADVERSE CARDIAC EVENTS (MACE), WHICH INCLUDED CARDIAC DEATH, NONFATAL MYOCARDIAL INFARCTION, OR ISCHEMIC SYMPTOMS DRIVEN TARGET VESSEL REVASCULARIZATION. RESULTS: AT 30 DAYS, THE REVERSION RATE OF HPR WAS 34.0%, 55.2%, AND 48.7% IN GROUP A, GROUP B, AND GROUP C, RESPECTIVELY (P=.029). MAJOR ADVERSE CARDIAC EVENTS OCCURRED IN 4 (8.0%), 6(4.0%), AND 5(3.3%) PATIENTS (P=.342). THERE WAS 1 (0.7%) MAJOR BLEEDING AND 1 (0.7%) MINOR BLEEDING EVENT IN HIGH MAINTENANCE DOSE CLOPIDOGREL GROUP, NO MAJOR OR MODERATE BLEEDING IN THE OTHER TWO GROUPS. THE MINIMAL BLEEDING IN GROUP B WAS SIGNIFICANTLY HIGHER THAN GROUP C (10.7% VS 2.7%, P=.022). AT 2-YEAR FOLLOW-UP, THE BENEFITS OF POLICOSANOL ON BLEEDINGS PERSISTED COMPARED WITH GROUP B. CONCLUSIONS: POLICOSANOL REDUCED PLATELET REACTIVITY TO A SIMILAR EXTENT AS HIGH MAINTENANCE DOSE OF CLOPIDOGREL WITHOUT INCREASING BLEEDING RATE. © 2016 JOHN WILEY & SONS LTD","BLEEDING; DRUG-ELUTING STENT; PLATELET REACTIVITY; POLICOSANOL","ACETYLSALICYLIC ACID; CLOPIDOGREL; POLICOSANOL; ADULT; AGED; ARTICLE; BLEEDING; CHINA; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; THROMBOCYTE AGGREGATION","","","YUSUF S., ZHAO F., MEHTA S.R., CHROLAVICIUS S., TOGNONI G., FOX K.K., EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION, N ENGL J MED, 34, PP. 494-502, (2001); MEHTA S.R., YUSUF S., PETER R.J., ET AL., EFFECTS OF PRETREATMENT WITH CLOPIDOGREL AND ASPIRIN FOLLOWED BY LONG TERM THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THE PCI-CURE STUDY, LANCET, 358, PP. 527-533, (2005); CHEN Z.M., JIANG L.X., CHEN Y.P., ET AL., ADDITION OF CLOPIDOGREL TO ASPIRIN IN 45,852 PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: RANDOMIZED PLACEBO CONTROLLED TRIAL, LANCET, 366, PP. 1607-1621, (2005); SABATINE M.S., CANNON C.P., GIBSON C.M., ET AL., ADDITION OF CLOPIDOGREL TO ASPIRIN AND FIBRINOLYTIC THERAPY FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION, N ENGL J MED, 352, PP. 1179-1189, (2005); MATETZKY S., SHENKMAN B., GUETTA V., ET AL., CLOPIDOGREL RESISTANCE IS ASSOCIATED WITH INCREASED RISK OF RECURRENT ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, CIRCULATION, 109, PP. 3171-3175, (2004); BUONAMICI P., MARCUCCI R., MIGLIORINI A., ET AL., IMPACT OF PLATELET REACTIVITY AFTER CLOPIDOGREL ADMINISTRATION ON DRUG-ELUTING STENT THROMBOSIS, J AM COLL CARDIOL, 49, PP. 2312-2317, (2007); GURBEL P.A., BLIDEN K.P., GUYER K., ET AL., PLATELET REACTIVITY IN PATIENTS AND RECURRENT EVENTS POST-STENTING: RESULTS OF THE PREPARE POSTSTENTING STUDY, J AM COLL CARDIOL, 46, PP. 1820-1826, (2005); CUISSET T., FRERE C., QUILICI J., ET AL., HIGH POST-TREATMENT PLATELET REACTIVITY IDENTIFIED LOW-RESPONDERS TO DUAL ANTIPLATELET THERAPY AT INCREASED RISK OF RECURRENT CARDIOVASCULAR EVENTS AFTER STENTING FOR ACUTE CORONARY SYNDROME, J THROMB HAEMOST, 4, PP. 542-549, (2006); AJZENBERG N., AUBRY P., HUISSE M.G., ET AL., ENHANCED SHEAR-INDUCED PLATELET AGGREGATION IN PATIENTS WHO EXPERIENCE SUBACUTE STENT THROMBOSIS: A CASE-CONTROL STUDY, J AM COLL CARDIOL, 45, PP. 1753-1756, (2005); GURBEL P.A., BLIDEN K.P., ZAMAN K.A., ET AL., CLOPIDOGREL LOADING WITH EPTIFIBATIDE TO ARREST THE REACTIVITY OF PLATELETS: RESULTS OF THE CLOPIDOGREL LOADING WITH EPTIFIBATIDE TO ARREST THE REACTIVITY OF PLATELETS (CLEAR PLATELETS) STUDY, CIRCULATION, 111, PP. 1153-1159, (2005); MULLER SEYFARTH M., RUDIGER S., ET AL., EFFECT OF HIGH LOADING DOSE OF CLOPIDOGREL ON PLATELET FUNCTION IN PATIENTS UNDERGOING CORONARY STENT PLACEMENT, HEART, 85, PP. 92-93, (2001); CUISSET T., FRERE C., QUILICI J., ET AL., BENEFIT OF A 600-MG LOADING DOSE OF CLOPIDOGREL ON PLATELET REACTIVITY AND CLINICAL OUTCOMES IN PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME UNDERGOING CORONARY STENTING, J AM COLL CARDIOL, 48, PP. 1339-1345, (2006); ANGIOLILLO D.J., COSTA M.A., SHOEMAKER S.B., ET AL., FUNCTION EFFECTS OF HIGH CLOPIDOGREL MAINTENANCE DOSING IN PATIENTS WITH INADEQUATE PLATELET INHIBITION ON STANDARD DOSE TREATMENT, AM J CARDIOL, 101, PP. 440-445, (2008); VON BECKERATH N., KASTRATI A., WIECZOREK A., ET AL., A DOUBLE-BLIND, RANDOMIZED STUDY ON PLATELET AGGREGATION IN PATIENTS TREATED WITH A DAILY DOSE OF 150 OR 75 MG OF CLOPIDOGREL FOR 30 DAYS, EUR HEART J, 28, PP. 1814-1819, (2007); ANGIOLILLO D.J., SHOEMAKER S.B., DESAI B., ET AL., RANDOMIZED COMPARISON OF A HIGH CLOPIDOGREL MAINTENANCE DOSE IN PATIENTS WITH DIABETES MELLITUS AND CORONARY ARTERY DISEASE: A RESULT OF THE OPTIMIZING ANTIPLATELET THERAPY IN DIABETES MELLITUS (OPTIMUS) STUDY, CIRCULATION, 115, PP. 708-716, (2007); PATTI G., COLONNA G., PASCERI V., ET AL., RANDOMIZED TRIAL OF HIGH LOADING DOSE OF CLOPIDOGREL FOR REDUCTION OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN PATIENTS UNDERGOING CORONARY INTERVENTION: RESULTS FROM THE ARMYDA-2(ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) STUDY, CIRCULATION, 111, PP. 2099-2106, (2005); GURBEL P.A., TANTRY U.S., DELIVERY OF GLYCOPROTEIN IIB/IIIA INHIBITOR THERAPY FOR PERCUTANEOUS CORONARY INTERVENTION: WHY NOT TAKE THE INTRACORONARY HIGHWAY?, CIRCULATION, 121, PP. 739-741, (2010); TAYEB H.M., NELSON A.J., WILLOUGHBY S.R., ET AL., ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES: CURRENT AGENTS AND IMPACT ON PATIENT OUTCOMES, PATIENT RELAT OUTCOME MEAS, 2, PP. 7-16, (2011); CANNON C.P., BATTLER A., BRINDIS R.G., ET AL., AMERICAN COLLEGE OF CARDIOLOGY KEY DATA ELEMENTS AND DEFINITIONS FOR MEASURING THE CLINICAL MANAGEMENT AND OUTCOMES OF PATIENTS WITH ACUTE CORONARY SYNDROMES: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY TASK FORCE ON CLINICAL DATA STANDARDS (ACUTE CORONARY SYNDROMES WRITING COMMITTEE), J AM COLL CARDIOL, 38, PP. 2114-2130, (2001); CUTLIP D.E., WINDECKER S., MEHRAN R., ET AL., CLINICAL END POINTS IN CORONARY STENT TRIALS: A CASE FOR STANDARDIZED DEFINITIONS, CIRCULATION, 115, PP. 2344-2351, (2007); GURBEL P.A., BECKER R.C., MANN K.G., ET AL., PLATELET FUNCTION MONITORING IN PATIENTS WITH CORONARY ARTERY DISEASE, J AM COLL CARDIOL, 50, PP. 1822-1834, (2007); BREET N.J., VAN WERKUM J.W., BOUMAN H.J., ET AL., COMPARISON OF PLATELET FUNCTION TESTS IN PREDICTING CLINICAL OUTCOME IN PATIENTS UNDERGOING CORONARY STENT IMPLANTATION, JAMA, 303, PP. 754-762, (2010); BONELLO L., TANTRY U.S., MARCUCCI R., ET AL., CONSENSUS AND FUTURE DIRECTIONS ON THE DEFINITION OF HIGH ON-TREATMENT PLATELET REACTIVITY TO ADENOSINE DIPHOSPHATE, J AM COLL CARDIOL, 56, PP. 919-933, (2010); GURBEL P.A., BLIDEN K.P., SAMARA W., ET AL., CLOPIDOGREL EFFECT ON PLATELET REACTIVITY IN PATIENTS WITH STENT THROMBOSIS RESULTS OF THE CREST STUDY, J AM COLL CARDIOL, 46, PP. 1827-1832, (2005); MARCUCCI R., GORI A.M., PANICCIA R., ET AL., CARDIOVASCULAR DEATH AND NONFATAL MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING CORONARY STENTING ARE PREDICTED BY RESIDUAL PLATELET REACTIVITY TO ADP DETECTED BY A POINT-OF-CARE ASSAY A 12-MONTH FOLLOW-UP, CIRCULATION, 119, PP. 237-242, (2009); ANGIOLILLO D.J., FERNANDEZ-ORTIZ A., BERNARDO E., ET AL., VARIABILITY IN INDIVIDUAL RESPONSIVENESS TO CLOPIDOGREL CLINICAL IMPLICATIONS, MANAGEMENT, AND FUTURE PERSPECTIVES, J AM COLL CARDIOL, 49, PP. 1505-1516, (2007); MANGIACAPRA F., BARBATO E., PATTI G., ET AL., POINT-OF-CARE ASSESSMENT OF PLATELET REACTIVITY AFTER CLOPIDOGREL TO PREDICT MYONECROSIS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION, JACC CARDIOVASC INTERV, 3, PP. 318-323, (2010); CAMPO G., FILETI L., DE CESARE N., ET AL., LONG-TERM CLINICAL OUTCOME BASED ON ASPIRIN AND CLOPIDOGREL RESPONSIVENESS STATUS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION A 3T/2R (TAILORING TREATMENT WITH TIROFIBAN IN PATIENTS SHOWING RESISTANCE TO ASPIRIN AND/OR RESISTANCE TO CLOPIDOGREL) TRIAL SUBSTUDY, J AM COLL CARDIOL, 56, PP. 1447-1455, (2010); PARK K.W., PARK J.J., JEON K.H., ET AL., CLINICAL PREDICTORS OF HIGH POSTTREATMENT PLATELET REACTIVITY TO CLOPIDOGREL IN KOREANS, CARDIOVASC THER, 30, PP. 5-11, (2012); PARODI G., MARCUCCI R., VALENTI R., ET AL., HIGH RESIDUAL PLATELET REACTIVITY AFTER CLOPIDOGREL LOADING AND LONG-TERM CARDIOVASCULAR EVENTS AMONG PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PCI, JAMA, 306, PP. 1215-1223, (2011); PRICE M.J., BERGER P.B., TEIRSTEIN P.S., ET AL., STANDARD-VS HIGH-DOSE CLOPIDOGREL BASED ON PLATELET FUNCTION TESTING AFTER PERCUTANEOUS CORONARY INTERVENTION: THE GRAVITAS RANDOMIZED TRIAL, JAMA, 305, PP. 1097-1105, (2011); MENDOZA S., GAMEZ R., NOA M., ET AL., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES, 62, PP. 209-220, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. M186-M193, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1993); GAMEZ R., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS, DRUGS R D, 6, PP. 11-19, (2005)","Y. HAN; DEPARTMENT OF CARDIOLOGY, GENERAL HOSPITAL OF SHENYANG MILITARY REGION, SHENYANG, CHINA; EMAIL: HANYALINGNH@126.COM","BLACKWELL PUBLISHING LTD","ENGLISH","CARDIOVASC. THER.","ARTICLE","ISI","2-S2.0-84991092523","CARDIOVASC THER","GENERAL HOSPITAL OF SHENYANG MILITARY REGION;GENERAL HOSPITAL OF SHENYANG MILITARY REGION;GENERAL HOSPITAL OF SHENYANG MILITARY REGION;GENERAL HOSPITAL OF SHENYANG MILITARY REGION;FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY;SHENZHOU HOSPITAL AFFILIATED TO SHENYANG MEDICAL COLLEGE;GENERAL HOSPITAL OF SHENYANG MILITARY REGION;GENERAL HOSPITAL OF SHENYANG MILITARY REGION;GENERAL HOSPITAL OF SHENYANG MILITARY REGION","NOTREPORTED;GENERAL HOSPITAL OF SHENYANG MILITARY REGION;NOTREPORTED",NA,"XU K, 2016, CARDIOVASC THER","XU K, 2016, CARDIOVASC THER"
"VESZA Z;PIRES C;DA S P","VESZA, ZSÓFIA (24437418700); PIRES, CATARINA (58144701100); DA SILVA, PEDRO MARQUES (7102059443)","STATINRELATED LICHENOID DERMATOSIS AN UNCOMMON ADVERSE REACTION TO A COMMON TREATMENT",2018,"EUROPEAN JOURNAL OF CASE REPORTS IN INTERNAL MEDICINE","5","",7,"10.12890/2018_000844","HYPERTENSION AND DYSLIPIDEMIA OUTPATIENT CLINIC, MEDICINE 4, SANTA MARTA'S HOSPITAL, CHLC, LISBON, PORTUGAL;HYPERTENSION AND DYSLIPIDEMIA OUTPATIENT CLINIC, MEDICINE 4, SANTA MARTA'S HOSPITAL, CHLC, LISBON, PORTUGAL;HYPERTENSION AND DYSLIPIDEMIA OUTPATIENT CLINIC, MEDICINE 4, SANTA MARTA'S HOSPITAL, CHLC, LISBON, PORTUGAL","3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS (STATINS) ARE GENERALLY SAFE AND WELL-TOLERATED DRUGS THAT ARE EXTENSIVELY USED FOR THE PRIMARY AND SECONDARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR EVENTS. MUSCLE AND LIVER ADVERSE REACTIONS ARE THE BEST RECOGNIZED, WHILE CUTANEOUS SIDE EFFECTS ARE EXCEEDINGLY RARE. WE PRESENT THE CASE OF A 65-YEAR-OLD WOMAN WITH SEVERE HYPERCHOLESTEROLEMIA, WHO DEVELOPED GENERALIZED ERYTHEMATOUS CUTANEOUS LESIONS WITH PRURITUS, RESEMBLING LICHEN PLANUS, MONTHS AFTER STARTING TREATMENT WITH SIMVASTATIN. THE SYMPTOMS DISAPPEARED ON WITHDRAWAL OF SIMVASTATIN AND REAPPEARED WITHIN 3 MONTHS UPON RECHALLENGE WITH ROSUVASTATIN. IN ADDITION TO DESCRIBING A RARE ADVERSE EFFECT OF STATINS, THE AUTHORS ALSO DISCUSS THE NUTRACEUTICAL APPROACH TO THE MANAGEMENT OF A STATIN-INTOLERANT PATIENT. © EFIM 2018.","DYSLIPIDEMIA; LICHENOID DRUG ERUPTION; NUTRACEUTICALS; RED YEAST RICE; STATINS","APOLIPOPROTEIN B; ASTAXANTHIN; BERBERINE; EZETIMIBE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UBIDECARENONE; YEAST EXTRACT; AGED; ARTICLE; CASE REPORT; CLINICAL ARTICLE; DESQUAMATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LICHENOID ERUPTION; LIFESTYLE; LYMPHOCYTIC INFILTRATION; PAPULE; PARAKERATOSIS; PRICK TEST; PRURITUS; PSORIASIS; PUSTULE; PUVA; REMISSION; SKIN BIOPSY; TREATMENT RESPONSE","","","GOLOMB B.A., EVANS M.A., STATIN ADVERSE EFFECTS: A REVIEW OF THE LITERATURE AND EVIDENCE FOR A MITOCHONDRIAL MECHANISM, AM J CARDIOVASC DRUGS, 8, PP. 373-418, (2008); JOWKAR F., NAMAZI M.R., STATINS IN DERMATOLOGY, INT J DERMATOL, 49, PP. 1235-1243, (2010); JAIN S., DERMATOLOGY. ILLUSTRATED STUDY GUIDE AND COMPREHENSIVE BOARD REVIEW, PP. 106-109, (2017); GOOD PHARMACOVIGILANCE PRACTICE GUIDE, PP. 29-48, (2009); BARRIOS V., ESCOBAR C., CICERO A.F., BURKE D., FASCHING P., BANACH M., BRUCKERT E., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR ATHEROSCLER REP, 17, (2015)","","SMC MEDIA SRL","ENGLISH","EUR. J. CASE REP. INTERN. MED.","ARTICLE","ISI","2-S2.0-85073226900","EUR J CASE REP INTERN MED",NA,"NOTREPORTED",NA,"VESZA Z, 2018, EUR J CASE REP INTERN MED","VESZA Z, 2018, EUR J CASE REP INTERN MED"
"PAGE M;WATTS G","PAGE, MICHAEL M. (55372050200); WATTS, GERALD F. (7202153447)","PCSK9 IN CONTEXT A CONTEMPORARY REVIEW OF AN IMPORTANT BIOLOGICAL TARGET FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE",2018,"DIABETES, OBESITY AND METABOLISM","20","12",18,"10.1111/dom.13070","DEPARTMENT OF CLINICAL BIOCHEMISTRY, PATHWEST LABORATORY MEDICINE, FIONA STANLEY HOSPITAL, PERTH, WA, AUSTRALIA, SCHOOL OF MEDICINE, FACULTY OF HEALTH AND MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA;LIPID DISORDERS CLINIC, DEPARTMENT OF CARDIOLOGY, ROYAL PERTH HOSPITAL, PERTH, WA, AUSTRALIA, SCHOOL OF MEDICINE, FACULTY OF HEALTH AND MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA","THE IDENTIFICATION OF THE CRITICAL ROLE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) HAS RAPIDLY LED TO THE DEVELOPMENT OF PCSK9 INHIBITION WITH MONOCLONAL ANTIBODIES (MABS). PCSK9 MABS ARE ALREADY IN LIMITED CLINICAL USE AND ARE THE SUBJECT OF MAJOR CARDIOVASCULAR OUTCOMES TRIALS, WHICH, IF UNIVERSALLY POSITIVE, COULD SEE MUCH WIDER CLINICAL APPLICATION OF THESE AGENTS. PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA ARE THE MOST OBVIOUS CANDIDATES FOR THESE DRUGS, BUT OTHER PATIENTS WITH ELEVATED CARDIOVASCULAR RISK, STATIN INTOLERANCE OR HYPERLIPOPROTEINAEMIA(A) MAY ALSO BENEFIT. PCSK9 MABS, ADMINISTERED ONCE OR TWICE MONTHLY, REDUCE LDL CHOLESTEROL LEVELS BY 50% TO 70%, AND APPEAR TO BE SAFE AND ACCEPTABLE TO PATIENTS OVER AT LEAST 2 YEARS OF TREATMENT; HOWEVER, TREATMENT-EMERGENT ADVERSE EFFECTS ARE NOT ALWAYS IDENTIFIED IN CLINICAL TRIALS, AS WELL-EVIDENCED BY STATIN MYOPATHY. INCLISIRAN IS A PROMISING RNA-BASED THERAPY THAT PROMOTES THE DEGRADATION OF PCSK9 MRNA TRANSCRIPTS AND HAS SIMILAR EFFICACY TO MABS, BUT WITH A MUCH LONGER DURATION OF ACTION. THE COST-EFFECTIVENESS AND LONG-TERM SAFETY OF THERAPIES TARGETED AT INHIBITING PCSK9 REMAIN TO BE DEMONSTRATED IF THEY ARE TO BE USED WIDELY IN CORONARY PREVENTION. © 2017 JOHN WILEY & SONS LTD","CARDIOVASCULAR DISEASE; LIPID-LOWERING THERAPY","ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; BIOMEDICAL RESEARCH; DRUGS, INVESTIGATIONAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PROPROTEIN CONVERTASE 9; RISK; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; ACETYLSALICYLIC ACID; ALIROCUMAB; ANACETRAPIB; APOLIPOPROTEIN B100; ATORVASTATIN; BERBERINE; BOCOCIZUMAB; CHOLESTIN; COLESEVELAM; CREATINE KINASE; DRUG ANTIBODY; ESTROGEN; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCLISIRAN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; PLACEBO; POLICOSANOL; PROPROTEIN CONVERTASE 9; ROSUVASTATIN; ALN-PCS; ANTILIPEMIC AGENT; MONOCLONAL ANTIBODY; NEW DRUG; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SMALL INTERFERING RNA; APHERESIS; BACKACHE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; LIPOPROTEIN METABOLISM; MONOTHERAPY; MUSCLE DISEASE; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; RISK REDUCTION; RNAI THERAPEUTICS; SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BIOLOGICAL MODEL; FAMILIAL HYPERCHOLESTEROLEMIA; GENETICS; MEDICAL RESEARCH; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; RISK; TRENDS","AUSTRALIAN GOVERNMENT RESEARCH TRAINING PROGRAM; COOPERATIVE RESEARCH CENTRES, AUSTRALIAN GOVERNMENT DEPARTMENT OF INDUSTRY","FUNDING TEXT 1: THIS WORK WAS SUPPORTED BY AN AUSTRALIAN GOVERNMENT RESEARCH; FUNDING TEXT 2: THIS WORK WAS SUPPORTED BY AN AUSTRALIAN GOVERNMENT RESEARCH TRAINING PROGRAM (RTP) SCHOLARSHIP.","SEIDAH N.G., BENJANNET S., WICKHAM L., ET AL., THE SECRETORY PROPROTEIN CONVERTASE NEURAL APOPTOSIS-REGULATED CONVERTASE 1 (NARC-1): LIVER REGENERATION AND NEURONAL DIFFERENTIATION, PROC NATL ACAD SCI U S A, 100, 3, PP. 928-933, (2003); BROWN M.S., GOLDSTEIN J.L., A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS, SCIENCE, 232, PP. 34-47, (1986); GOLDSTEIN J.L., BROWN M.S., THE LDL RECEPTOR, ARTERIOSCLER THROMB VASC BIOL, 29, 4, PP. 431-438, (2009); WATTS G.F., CHAN D.C., DENT R.E., ET AL., FACTORIAL EFFECTS OF EVOLOCUMAB AND ATORVASTATIN ON LIPOPROTEIN METABOLISM, CIRCULATION, 135, 4, PP. 338-351, (2016); CUNNINGHAM D., DANLEY D.E., GEOGHEGAN K.F., ET AL., STRUCTURAL AND BIOPHYSICAL STUDIES OF PCSK9 AND ITS MUTANTS LINKED TO FAMILIAL HYPERCHOLESTEROLEMIA, NAT STRUCT MOL BIOL, 14, 5, PP. 413-419, (2007); COHEN J.C., BOERWINKLE E., MOSLEY T.H., HOBBS H.H., SEQUENCE VARIATIONS IN PCSK9, LOW LDL, AND PROTECTION AGAINST CORONARY HEART DISEASE, N ENGL J MED, 354, 12, PP. 1264-1272, (2006); FERENCE B.A., MAHAJAN N., THE ROLE OF EARLY LDL LOWERING TO PREVENT THE ONSET OF ATHEROSCLEROTIC DISEASE, CURR ATHEROSCLER REP, 15, 4, (2013); ABIFADEL M., VARRET M., RABES J.-P., ET AL., MUTATIONS IN PCSK9 CAUSE AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA, NAT GENET, 34, 2, PP. 154-156, (2003); ZHANG D.-W., LAGACE T.A., GARUTI R., ET AL., BINDING OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 TO EPIDERMAL GROWTH FACTOR-LIKE REPEAT A OF LOW DENSITY LIPOPROTEIN RECEPTOR DECREASES RECEPTOR RECYCLING AND INCREASES DEGRADATION, J BIOL CHEM, 282, 25, PP. 18602-18612, (2007); LEREN T.P., SORTING AN LDL RECEPTOR WITH BOUND PCSK9 TO INTRACELLULAR DEGRADATION, ATHEROSCLEROSIS, 237, 1, PP. 76-81, (2014); TAVORI H., FAN D., BLAKEMORE J.L., ET AL., SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 AND CELL SURFACE LOW-DENSITY LIPOPROTEIN RECEPTOR: EVIDENCE FOR A RECIPROCAL REGULATION, CIRCULATION, 127, PP. 2403-2413, (2013); SUN H., SAMARGHANDI A., ZHANG N., ET AL., PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INTERACTS WITH APOLIPOPROTEIN B AND PREVENTS ITS INTRACELLULAR DEGRADATION, IRRESPECTIVE OF THE LOW-DENSITY LIPOPROTEIN RECEPTOR, ARTERIOSCLER THROMB VASC BIOL, 32, PP. 1585-1595, (2012); STEIN E.A., HONARPOUR N., WASSERMAN S.M., ET AL., EFFECT OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, AMG 145, IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, CIRCULATION, 128, PP. 2113-2120, (2013); POIRIER S., MAYER G., POUPON V., ET AL., DISSECTION OF THE ENDOGENOUS CELLULAR PATHWAYS OF PCSK9-INDUCED LOW DENSITY LIPOPROTEIN RECEPTOR DEGRADATION, J BIOL CHEM, 284, 42, PP. 28856-28864, (2009); FERRI N., TIBOLLA F., PIRILLO A., ET AL., PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) SECRETED BY CULTURED SMOOTH MUSCLE CELLS REDUCES MACROPHAGES LDLR LEVELS, ATHEROSCLEROSIS, 220, PP. 381-386, (2012); LANGHI C., MAY C.L., GMYR V., ET AL., PCSK9 IS EXPRESSED IN PANCREATIC DELTA CELLS AND DOES NOT ALTER INSULIN SECRETION, BIOCHEM BIOPHYS RES COMMUN, 390, PP. 1288-1293, (2009); LAKOSKI S.G., LAGACE T.A., COHEN J.C., ET AL., GENETIC AND METABOLIC DETERMINANTS OF PLASMA PCSK9 LEVELS, J CLIN ENDOCRINOL METAB, 94, PP. 2537-2543, (2009); KOSENKO T., GOLDER M., LEBLOND G., ET AL., LOW DENSITY LIPOPROTEIN BINDS TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE-9 (PCSK9) IN HUMAN PLASMA AND INHIBITS PCSK9-MEDIATED LOW DENSITY LIPOPROTEIN RECEPTOR DEGRADATION, J BIOL CHEM, 288, 12, PP. 8279-8288, (2013); FAN D., YANCEY P.G., QIU S., ET AL., SELF-ASSOCIATION OF HUMAN PCSK9 CORRELATES WITH ITS LDLR-DEGRADING ACTIVITY, BIOCHEMISTRY, 47, PP. 1631-1639, (2008); LAMBERT G., UNRAVELLING THE FUNCTIONAL SIGNIFICANCE OF PCSK9, CURR OPIN LIPIDOL, 18, PP. 304-309, (2007); URBAN D., POSS J., BOHM M., LAUFS U., TARGETING THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FOR THE TREATMENT OF DYSLIPIDEMIA AND ATHEROSCLEROSIS, J AM COLL CARDIOL, 62, 16, PP. 1401-1408, (2013); KOREN M.J., SABATINE M.S., GIUGLIANO R.P., ET AL., LONG-TERM LOW-DENSITY LIPOPROTEIN CHOLESTEROL-LOWERING EFFICACY, PERSISTENCE, AND SAFETY OF EVOLOCUMAB IN TREATMENT OF HYPERCHOLESTEROLEMIA: RESULTS UP TO 4 YEARS FROM THE OPEN-LABEL OSLER-1 EXTENSION STUDY, JAMA CARDIOL, 2, 6, PP. 598-607, (2017); ROBINSON J.G., FARNIER M., KREMPF M., ET AL., EFFICACY AND SAFETY OF ALIROCUMAB IN REDUCING LIPIDS AND CARDIOVASCULAR EVENTS, N ENGL J MED, 372, 16, PP. 1489-1499, (2015); FERENCE B.A., ROBINSON J.G., BROOK R.D., ET AL., VARIATION IN PCSK9 AND HMGCR AND RISK OF CARDIOVASCULAR DISEASE AND DIABETES, N ENGL J MED, 375, 22, PP. 2144-2153, (2016); SILVERMAN M.G., FERENCE B.A., IM K., ET AL., ASSOCIATION BETWEEN LOWERING LDL-C AND CARDIOVASCULAR RISK REDUCTION AMONG DIFFERENT THERAPEUTIC INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 316, 12, PP. 1289-1297, (2016); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY-EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR HEART J, 36, 17, PP. 1012-1022, (2015); ELLIS K.L., HOOPER A.J., BURNETT J.R., WATTS G.F., PROGRESS IN THE CARE OF COMMON INHERITED ATHEROGENIC DISORDERS OF APOLIPOPROTEIN B METABOLISM, NAT REV ENDOCRINOL, 12, 8, PP. 467-484, (2016); BAIGENT C., BLACKWELL L., EMBERSON J., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, 9753, PP. 1670-1681, (2010); PAGE M.M., STEFANUTTI C., SNIDERMAN A., WATTS G.F., RECENT ADVANCES IN THE UNDERSTANDING AND CARE OF FAMILIAL HYPERCHOLESTEROLAEMIA: SIGNIFICANCE OF THE BIOLOGY AND THERAPEUTIC REGULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, CLIN SCI, 129, 1, PP. 63-79, (2015); SJOUKE B., KUSTERS D.M., KINDT I., ET AL., HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLAEMIA IN THE NETHERLANDS: PREVALENCE, GENOTYPE-PHENOTYPE RELATIONSHIP, AND CLINICAL OUTCOME, EUR HEART J, 36, 9, PP. 560-565, (2015); BENN M., WATTS G.F., TYBJAERG-HANSEN A., NORDESTGAARD B.G., MUTATIONS CAUSATIVE OF FAMILIAL HYPERCHOLESTEROLAEMIA: SCREENING OF 98 098 INDIVIDUALS FROM THE COPENHAGEN GENERAL POPULATION STUDY ESTIMATED A PREVALENCE OF 1 IN 217, EUR HEART J, 37, 17, PP. 1384-1394, (2016); ABUL-HUSN N.S., MANICKAM K., JONES L.K., ET AL., GENETIC IDENTIFICATION OF FAMILIAL HYPERCHOLESTEROLEMIA WITHIN A SINGLE U.S. HEALTH CARE SYSTEM, SCIENCE, 354, 6319, (2016); PEREZ DE ISLA L., ALONSO R., WATTS G.F., ET AL., ATTAINMENT OF LDL-CHOLESTEROL TREATMENT GOALS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: 5-YEAR SAFEHEART REGISTRY FOLLOW-UP, J AM COLL CARDIOL, 67, 11, PP. 1278-1285, (2016); PAGE M.M., BELL D.A., HOOPER A.J., ET AL., LIPOPROTEIN APHERESIS AND NEW THERAPIES FOR SEVERE FAMILIAL HYPERCHOLESTEROLEMIA IN ADULTS AND CHILDREN, BEST PRACT RES CLIN ENDOCRINOL METAB, 28, 3, PP. 387-403, (2014); PAGE M.M., EKINCI E.I., JONES R.M., ET AL., LIVER TRANSPLANTATION FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN AN ERA OF EMERGING LIPID-LOWERING THERAPIES, INTERN MED J, 44, 6, PP. 601-604, (2014); ITO M.K., WATTS G.F., CHALLENGES IN THE DIAGNOSIS AND TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, DRUGS, 75, 15, PP. 1715-1724, (2015); KOSCHINSKY M., BOFFA M., LIPOPROTEIN(A) AS A THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASE, EXPERT OPIN THER TARGETS, 18, 7, PP. 747-757, (2014); NORDESTGAARD B.G., CHAPMAN M.J., RAY K., ET AL., LIPOPROTEIN(A) AS A CARDIOVASCULAR RISK FACTOR: CURRENT STATUS, EUR HEART J, 31, 23, PP. 2844-2853, (2010); KOSCHINSKY M.L., BOFFA M.B., LIPOPROTEIN(A): AN IMPORTANT CARDIOVASCULAR RISK FACTOR AND A CLINICAL CONUNDRUM, ENDOCRINOL METAB CLIN NORTH AM, 43, 4, PP. 949-962, (2014); LI J., LANGE L.A., SABOURIN J., ET AL., GENOME- AND EXOME-WIDE ASSOCIATION STUDY OF SERUM LIPOPROTEIN (A) IN THE JACKSON HEART STUDY, J HUM GENET, 60, 12, PP. 755-761, (2015); KAMSTRUP P.R., TYBJAERG-HANSEN A., STEFFENSEN R., NORDESTGAARD B.G., GENETICALLY ELEVATED LIPOPROTEIN(A) AND INCREASED RISK OF MYOCARDIAL INFARCTION, JAMA, 301, 22, PP. 2331-2339, (2009); NESTEL P.J., BARNES E.H., TONKIN A.M., ET AL., PLASMA LIPOPROTEIN(A) CONCENTRATION PREDICTS FUTURE CORONARY AND CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE CORONARY HEART DISEASE, ARTERIOSCLER THROMB VASC BIOL, 33, 12, PP. 2902-2908, (2013); O'DONOGHUE M.L., MORROW D.A., TSIMIKAS S., ET AL., LIPOPROTEIN(A) FOR RISK ASSESSMENT IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE, J AM COLL CARDIOL, 63, 6, PP. 520-527, (2014); DESHMUKH H.A., COLHOUN H.M., JOHNSON T., ET AL., GENOME-WIDE ASSOCIATION STUDY OF GENETIC DETERMINANTS OF LDL-C RESPONSE TO ATORVASTATIN THERAPY: IMPORTANCE OF LP(A), J LIPID RES, 53, 5, PP. 1000-1011, (2012); BOS S., YAYHA R., VAN LENNEP J.E., LATEST DEVELOPMENTS IN THE TREATMENT OF LIPOPROTEIN(A), CURR OPIN LIPIDOL, 25, 6, PP. 452-460, (2014); LANDRAY M.J., HAYNES R., HOPEWELL J.C., ET AL., EFFECTS OF EXTENDED-RELEASE NIACIN WITH LAROPIPRANT IN HIGH-RISK PATIENTS, N ENGL J MED, 371, 3, PP. 203-212, (2014); BODEN W.E., PROBSTFIELD J.L., ANDERSON T., ET AL., NIACIN IN PATIENTS WITH LOW HDL CHOLESTEROL LEVELS RECEIVING INTENSIVE STATIN THERAPY, N ENGL J MED, 365, 24, PP. 2255-2267, (2011); MAMPUYA W.M., FRID D., ROCCO M., ET AL., TREATMENT STRATEGIES IN PATIENTS WITH STATIN INTOLERANCE: THE CLEVELAND CLINIC EXPERIENCE, AM HEART J, 166, 3, PP. 597-603, (2013); KEEN H.I., KRISHNARAJAH J., BATES T.R., WATTS G.F., STATIN MYOPATHY: THE FLY IN THE OINTMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE 21ST CENTURY?, EXPERT OPIN DRUG SAF, 13, 9, PP. 1227-1239, (2014); JOY T.R., HEGELE R.A., NARRATIVE REVIEW: STATIN-RELATED MYOPATHY, ANN INTERN MED, 150, 12, PP. 858-868, (2009); MANCINI G.B., TASHAKKOR A.Y., BAKER S., ET AL., DIAGNOSIS, PREVENTION, AND MANAGEMENT OF STATIN ADVERSE EFFECTS AND INTOLERANCE: CANADIAN WORKING GROUP CONSENSUS UPDATE, CAN J CARDIOL, 29, 12, PP. 1553-1568, (2013); MANCINI G.B., BAKER S., BERGERON J., ET AL., DIAGNOSIS, PREVENTION, AND MANAGEMENT OF STATIN ADVERSE EFFECTS AND INTOLERANCE: CANADIAN CONSENSUS WORKING GROUP UPDATE (2016), CAN J CARDIOL, 32, 7, PP. S35-S65, (2016); KASHANI A., PHILLIPS C.O., FOODY J.M., ET AL., RISKS ASSOCIATED WITH STATIN THERAPY: A SYSTEMATIC OVERVIEW OF RANDOMIZED CLINICAL TRIALS, CIRCULATION, 114, 25, PP. 2788-2797, (2006); BRUCKERT E., HAYEM G., DEJAGER S., ET AL., MILD TO MODERATE MUSCULAR SYMPTOMS WITH HIGH-DOSAGE STATIN THERAPY IN HYPERLIPIDEMIC PATIENTS–THE PRIMO STUDY, CARDIOVASC DRUGS THER, 19, 6, PP. 403-414, (2005); COLLINS R., REITH C., EMBERSON J., ET AL., INTERPRETATION OF THE EVIDENCE FOR THE EFFICACY AND SAFETY OF STATIN THERAPY, LANCET, 388, 10059, PP. 2532-2561, (2016); PAIVA H., THELEN K.M., VAN COSTER R., ET AL., HIGH-DOSE STATINS AND SKELETAL MUSCLE METABOLISM IN HUMANS: A RANDOMIZED, CONTROLLED TRIAL, CLIN PHARMACOL THER, 78, 1, PP. 60-68, (2005); PHILLIPS P.S., CIARALDI T.P., KIM D.L., ET AL., MYOTOXIC REACTIONS TO LIPID-LOWERING THERAPY ARE ASSOCIATED WITH ALTERED OXIDATION OF FATTY ACIDS, ENDOCRINE, 35, 1, PP. 38-46, (2009); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., ET AL., EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, NEW ENGL J MED, 372, 25, PP. 2387-2397, (2015); GORDON T., CASTELLI W.P., HJORTLAND M.C., ET AL., HIGH DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART DISEASE. THE FRAMINGHAM STUDY, AM J MED, 62, 5, PP. 707-714, (1977); ASSMANN G., SCHULTE H., VON ECKARDSTEIN A., HUANG Y., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AS A PREDICTOR OF CORONARY HEART DISEASE RISK. THE PROCAM EXPERIENCE AND PATHOPHYSIOLOGICAL IMPLICATIONS FOR REVERSE CHOLESTEROL TRANSPORT, ATHEROSCLEROSIS, 124, PP. S11-S20, (1996); BROWN B.G., ZHAO X.Q., CHEUNG M.C., SHOULD BOTH HDL-C AND LDL-C BE TARGETS FOR LIPID THERAPY? A REVIEW OF CURRENT EVIDENCE, J CLIN LIPIDOL, 1, 1, PP. 88-94, (2007); VOIGHT B.F., PELOSO G.M., ORHO-MELANDER M., ET AL., PLASMA HDL CHOLESTEROL AND RISK OF MYOCARDIAL INFARCTION: A MENDELIAN RANDOMISATION STUDY, LANCET, 380, 9841, PP. 572-580, (2012); LEE M., SAVER J.L., TOWFIGHI A., ET AL., EFFICACY OF FIBRATES FOR CARDIOVASCULAR RISK REDUCTION IN PERSONS WITH ATHEROGENIC DYSLIPIDEMIA: A META-ANALYSIS, ATHEROSCLEROSIS, 217, 2, PP. 492-498, (2011); JUN M., FOOTE C., LV J., ET AL., EFFECTS OF FIBRATES ON CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS, LANCET, 375, 9729, PP. 1875-1884, (2010); BARBAGALLO C.M., CEFALU A.B., NOTO D., AVERNA M.R., ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY, FRONT CARDIOVASC MED, 2, (2015); PIRILLO A., CATAPANO A.L., BERBERINE, A PLANT ALKALOID WITH LIPID- AND GLUCOSE-LOWERING PROPERTIES: FROM IN VITRO EVIDENCE TO CLINICAL STUDIES, ATHEROSCLEROSIS, 243, 2, PP. 449-461, (2015); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, 11-12, PP. 1179-1192, (2016); PAGE M.M., HOOPER A.J., BURNETT J.R., ANACETRAPIB FOR THE TREATMENT OF DYSLIPIDAEMIA: THE LAST BASTION OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS?, EXPERT OPIN PHARMACOTHER, 17, 2, PP. 275-281, (2016); ROSS S., D'MELLO M., ANAND S.S., ET AL., EFFECT OF BILE ACID SEQUESTRANTS ON THE RISK OF CARDIOVASCULAR EVENTS: A MENDELIAN RANDOMIZATION ANALYSIS, CIRC CARDIOVASC GENET, 8, 4, PP. 618-627, (2015); FITZGERALD K., WHITE S., BORODOVSKY A., ET AL., A HIGHLY DURABLE RNAI THERAPEUTIC INHIBITOR OF PCSK9, N ENGL J MED, 376, 1, PP. 41-51, (2017); REYES-SOFFER G., PAVLYHA M., NGAI C., ET AL., EFFECTS OF PCSK9 INHIBITION WITH ALIROCUMAB ON LIPOPROTEIN METABOLISM IN HEALTHY HUMANS, CIRCULATION, 135, 4, PP. 352-362, (2016); RIDKER P.M., REVKIN J., AMARENCO P., ET AL., CARDIOVASCULAR EFFICACY AND SAFETY OF BOCOCIZUMAB IN HIGH-RISK PATIENTS, N ENGL J MED, 376, 16, PP. 1527-1539, (2017); RIDKER P.M., TARDIF J.C., AMARENCO P., ET AL., LIPID-REDUCTION VARIABILITY AND ANTIDRUG-ANTIBODY FORMATION WITH BOCOCIZUMAB, N ENGL J MED, 376, 16, PP. 1517-1526, (2017); RAAL F.J., STEIN E.A., DUFOUR R., ET AL., PCSK9 INHIBITION WITH EVOLOCUMAB (AMG 145) IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, LANCET, 385, 9965, PP. 331-340, (2015); RAAL F.J., HONARPOUR N., BLOM D.J., ET AL., INHIBITION OF PCSK9 WITH EVOLOCUMAB IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (TESLA PART B): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, LANCET, 385, 9965, PP. 341-350, (2015); KOREN M.J., GIUGLIANO R.P., RAAL F.J., ET AL., EFFICACY AND SAFETY OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB (AMG 145) IN PATIENTS WITH HYPERCHOLESTEROLEMIA: 52-WEEK RESULTS FROM THE OPEN-LABEL STUDY OF LONG-TERM EVALUATION AGAINST LDL-C (OSLER) RANDOMIZED TRIAL, CIRCULATION, 129, 2, PP. 234-243, (2014); BLOM D.J., HALA T., BOLOGNESE M., ET AL., A 52-WEEK PLACEBO-CONTROLLED TRIAL OF EVOLOCUMAB IN HYPERLIPIDEMIA, N ENGL J MED, 370, 19, PP. 1809-1819, (2014); STROES E., COLQUHOUN D., SULLIVAN D., ET AL., ANTI-PCSK9 ANTIBODY EFFECTIVELY LOWERS CHOLESTEROL IN PATIENTS WITH STATIN INTOLERANCE: THE GAUSS-2 RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL OF EVOLOCUMAB, J AM COLL CARDIOL, 63, 23, PP. 2541-2548, (2014); NISSEN S.E., STROES E., DENT-ACOSTA R.E., ET AL., EFFICACY AND TOLERABILITY OF EVOLOCUMAB VS EZETIMIBE IN PATIENTS WITH MUSCLE-RELATED STATIN INTOLERANCE: THE GAUSS-3 RANDOMIZED CLINICAL TRIAL, JAMA, 315, 15, PP. 1580-1590, (2016); STEIN E.A., GIPE D., BERGERON J., ET AL., EFFECT OF A MONOCLONAL ANTIBODY TO PCSK9, REGN727/SAR236553, TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA ON STABLE STATIN DOSE WITH OR WITHOUT EZETIMIBE THERAPY: A PHASE 2 RANDOMISED CONTROLLED TRIAL, LANCET, 380, 9836, PP. 29-36, (2012); KASTELEIN J.J., GINSBERG H.N., LANGSLET G., ET AL., ODYSSEY FH I AND FH II: 78 WEEK RESULTS WITH ALIROCUMAB TREATMENT IN 735 PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA, EUR HEART J, 36, 43, PP. 2996-3003, (2015); TERAMOTO T., KOBAYASHI M., TASAKI H., ET AL., EFFICACY AND SAFETY OF ALIROCUMAB IN JAPANESE PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR AT HIGH CARDIOVASCULAR RISK WITH HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH STATINS – ODYSSEY JAPAN RANDOMIZED CONTROLLED TRIAL, CIRC J, 80, 9, PP. 1980-1987, (2016); ROTH E.M., TASKINEN M.R., GINSBERG H.N., ET AL., MONOTHERAPY WITH THE PCSK9 INHIBITOR ALIROCUMAB VERSUS EZETIMIBE IN PATIENTS WITH HYPERCHOLESTEROLEMIA: RESULTS OF A 24WEEK, DOUBLE-BLIND, RANDOMIZED PHASE 3 TRIAL, INT J CARDIOL, 176, 1, PP. 55-61, (2014); RAY K.K., LANDMESSER U., LEITER L.A., ET AL., INCLISIRAN IN PATIENTS AT HIGH CARDIOVASCULAR RISK WITH ELEVATED LDL CHOLESTEROL, N ENGL J MED, 376, 15, PP. 1430-1440, (2017); CANNON C.P., CARIOU B., BLOM D., ET AL., EFFICACY AND SAFETY OF ALIROCUMAB IN HIGH CARDIOVASCULAR RISK PATIENTS WITH INADEQUATELY CONTROLLED HYPERCHOLESTEROLAEMIA ON MAXIMALLY TOLERATED DOSES OF STATINS: THE ODYSSEY COMBO II RANDOMIZED CONTROLLED TRIAL, EUR HEART J, 36, 19, PP. 1186-1194, (2015); VILLARD E.F., THEDREZ A., BLANKENSTEIN J., ET AL., PCSK9 MODULATES THE SECRETION BUT NOT THE CELLULAR UPTAKE OF LIPOPROTEIN(A) EX VIVO, JACC BASIC TRANSL SCI, 1, 6, PP. 419-427, (2016); ARGRAVES K.M., KOZARSKY K.F., FALLON J.T., ET AL., THE ATHEROGENIC LIPOPROTEIN LP(A) IS INTERNALIZED AND DEGRADED IN A PROCESS MEDIATED BY THE VLDL RECEPTOR, J CLIN INVEST, 100, 9, PP. 2170-2181, (1997); NIEMEIER A., WILLNOW T., DIEPLINGER H., ET AL., IDENTIFICATION OF MEGALIN/GP330 AS A RECEPTOR FOR LIPOPROTEIN(A) IN VITRO, ARTERIOSCLER THROMB VASC BIOL, 19, 3, PP. 552-561, (1999); HRZENJAK A., FRANK S., WO X., ET AL., GALACTOSE-SPECIFIC ASIALOGLYCOPROTEIN RECEPTOR IS INVOLVED IN LIPOPROTEIN (A) CATABOLISM, BIOCHEM J, 376, PP. 765-771, (2003); SHARMA M., REDPATH G.M., WILLIAMS M.J., MCCORMICK S.P., RECYCLING OF APOLIPOPROTEIN(A) AFTER PLGRKT-MEDIATED ENDOCYTOSIS OF LIPOPROTEIN(A), CIRC RES, 120, 7, PP. 1091-1102, (2017); SATTAR N., PREISS D., ROBINSON J.G., ET AL., LIPID-LOWERING EFFICACY OF THE PCSK9 INHIBITOR EVOLOCUMAB (AMG 145) IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF INDIVIDUAL PATIENT DATA, LANCET DIABETES ENDOCRINOL, 4, 5, PP. 403-410, (2016); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL-LOWERING WITH SIMVASTATIN IN 5963 PEOPLE WITH DIABETES: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 361, PP. 2005-2016, (2003); MULLER-WIELAND D., LEITER L.A., CARIOU B., ET AL., DESIGN AND RATIONALE OF THE ODYSSEY DM-DYSLIPIDEMIA TRIAL: LIPID-LOWERING EFFICACY AND SAFETY OF ALIROCUMAB IN INDIVIDUALS WITH TYPE 2 DIABETES AND MIXED DYSLIPIDAEMIA AT HIGH CARDIOVASCULAR RISK, CARDIOVASC DIABETOL, 16, 1, (2017); HENRY R.R., ALIROCUMAB VERSUS USUAL CARE IN TYPE 2 DIABETES WITH MIXED DYSLIPIDEMIA – ODYSSEY DM-DYSLIPIDEMIA STUDY, PROCEEDINGS OF THE AMERICAN DIABETES ASSOCIATION 77TH SCIENTIFIC SESSIONS, (2017); NICHOLLS S.J., PURI R., ANDERSON T., ET AL., EFFECT OF EVOLOCUMAB ON PROGRESSION OF CORONARY DISEASE IN STATIN-TREATED PATIENTS: THE GLAGOV RANDOMIZED CLINICAL TRIAL, JAMA, 316, 22, PP. 2373-2384, (2016); RAAL F.J., STEIN E.A., DUFOUR R., ET AL., PCSK9 INHIBITION WITH EVOLOCUMAB (AMG 145) IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (RUTHERFORD-2): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, LANCET, 385, 9965, PP. 331-340, (2015); MORIARTY P.M., PARHOFER K.G., BABIRAK S.P., ET AL., ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA UNDERGOING LIPOPROTEIN APHERESIS: THE ODYSSEY ESCAPE TRIAL, EUR HEART J, 37, 48, PP. 3588-3595, (2016); MORIARTY P.M., PARHOFER K.G., BABIRAK S.P., ET AL., ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPOPROTEIN APHERESIS: RATIONALE AND DESIGN OF THE ODYSSEY ESCAPE TRIAL, J CLIN LIPIDOL, 10, 3, PP. 627-634, (2016); WATTS G.F., STEFANUTTI C., ODYSSEY ESCAPE: IS PCSK9 INHIBITION THE TROJAN HORSE FOR THE USE OF LIPOPROTEIN APHERESIS IN FAMILIAL HYPERCHOLESTEROLAEMIA?, EUR HEART J, 37, 48, PP. 3596-3599, (2016); RAAL F.J., HOVINGH G.K., BLOM D., ET AL., LONG-TERM TREATMENT WITH EVOLOCUMAB ADDED TO CONVENTIONAL DRUG THERAPY, WITH OR WITHOUT APHERESIS, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: AN INTERIM SUBSET ANALYSIS OF THE OPEN-LABEL TAUSSIG STUDY, LANCET DIABETES ENDOCRINOL, 5, 4, PP. 280-290, (2017); SABATINE M.S., GIUGLIANO R.P., WIVIOTT S.D., ET AL., EFFICACY AND SAFETY OF EVOLOCUMAB IN REDUCING LIPIDS AND CARDIOVASCULAR EVENTS, N ENGL J MED, 372, 16, PP. 1500-1509, (2015); ROBINSON J.G., HUIJGEN R., RAY K., ET AL., DETERMINING WHEN TO ADD NONSTATIN THERAPY: A QUANTITATIVE APPROACH, J AM COLL CARDIOL, 68, 22, PP. 2412-2421, (2016); SABATINE M.S., GIUGLIANO R.P., KEECH A.C., ET AL., EVOLOCUMAB AND CLINICAL OUTCOMES IN PATIENTS WITH CARDIOVASCULAR DISEASE, N ENGL J MED, 376, 18, PP. 1713-1722, (2017); KEARNEY P.M., BLACKWELL L., COLLINS R., ET AL., EFFICACY OF CHOLESTEROL-LOWERING THERAPY IN 18,686 PEOPLE WITH DIABETES IN 14 RANDOMISED TRIALS OF STATINS: A META-ANALYSIS, LANCET, 371, 9607, PP. 117-125, (2008); JONES P.H., BAYS H.E., CHAUDHARI U., ET AL., SAFETY OF ALIROCUMAB (A PCSK9 MONOCLONAL ANTIBODY) FROM 14 RANDOMIZED TRIALS, AM J CARDIOL, 118, 12, PP. 1805-1811, (2016); EVERETT B.M., MORA S., GLYNN R.J., ET AL., SAFETY PROFILE OF SUBJECTS TREATED TO VERY LOW LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS (<30 MG/DL) WITH ROSUVASTATIN 20 MG DAILY (FROM JUPITER), AM J CARDIOL, 114, 11, PP. 1682-1689, (2014); SCHMIDT A.F., SWERDLOW D.I., HOLMES M.V., ET AL., PCSK9 GENETIC VARIANTS AND RISK OF TYPE 2 DIABETES: A MENDELIAN RANDOMISATION STUDY, LANCET DIABETES ENDOCRINOL, 5, 2, PP. 97-105, (2017); LOTTA L.A., SHARP S.J., BURGESS S., ET AL., ASSOCIATION BETWEEN LOW-DENSITY LIPOPROTEIN CHOLESTEROL-LOWERING GENETIC VARIANTS AND RISK OF TYPE 2 DIABETES: A META-ANALYSIS, JAMA, 316, 13, PP. 1383-1391, (2016); BESSELING J., KASTELEIN J.J., DEFESCHE J.C., ET AL., ASSOCIATION BETWEEN FAMILIAL HYPERCHOLESTEROLEMIA AND PREVALENCE OF TYPE 2 DIABETES MELLITUS, JAMA, 313, 10, PP. 1029-1036, (2015); FUENTES F., ALCALA-DIAZ J.F., WATTS G.F., MATA P., DIABETES, STATINS AND FH, INT J CARDIOL, 203, (2016); COLHOUN H.M., GINSBERG H.N., ROBINSON J.G., ET AL., NO EFFECT OF PCSK9 INHIBITOR ALIROCUMAB ON THE INCIDENCE OF DIABETES IN A POOLED ANALYSIS FROM 10 ODYSSEY PHASE 3 STUDIES, EUR HEART J, 37, 39, PP. 2981-2989, (2016); LEITER L.A., ALIROCUMAB AND INSULIN-TREATED DIABETES - INSIGHTS FROM THE ODYSSEY DM-INSULIN STUDY, PROCEEDINGS OF THE AMERICAN DIABETES ASSOCIATION 77TH SCIENTIFIC SESSIONS; GIUGLIANO R.P., MACH F., ZAVITZ K., ET AL., DESIGN AND RATIONALE OF THE EBBINGHAUS TRIAL: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFECT OF EVOLOCUMAB ON COGNITIVE FUNCTION IN PATIENTS WITH CLINICALLY EVIDENT CARDIOVASCULAR DISEASE AND RECEIVING STATIN BACKGROUND LIPID-LOWERING THERAPY-A COGNITIVE STUDY OF PATIENTS ENROLLED IN THE FOURIER TRIAL, CLIN CARDIOL, 40, 2, PP. 59-65, (2017); EBBINGHAUS NO EFFECT ON NEUROCOGNITION WITH EVOLOCUMAB INTERNET, (2017); KAZI D.S., MORAN A.E., COXSON P.G., ET AL., COST-EFFECTIVENESS OF PCSK9 INHIBITOR THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, JAMA, 316, 7, PP. 743-753, (2016); VILLA G., LOTHGREN M., KUTIKOVA L., ET AL., COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN, CLIN THER, 39, 4, PP. 771-786.E3, (2017); EVOLOCUMAB FOR TREATING PRIMARY HYPERCHOLESTEROLAEMIA AND MIXED DYSLIPIDAEMIA INTERNET, NICE, (2016); BAUM S.J., TOTH P.P., UNDERBERG J.A., ET AL., PCSK9 INHIBITOR ACCESS BARRIERS-ISSUES AND RECOMMENDATIONS: IMPROVING THE ACCESS PROCESS FOR PATIENTS, CLINICIANS AND PAYERS, CLIN CARDIOL, 40, 4, PP. 243-254, (2017); LLOYD-JONES D.M., MORRIS P.B., BALLANTYNE C.M., ET AL., ACC EXPERT CONSENSUS DECISION PATHWAY ON THE ROLE OF NON-STATIN THERAPIES FOR LDL-CHOLESTEROL LOWERING IN THE MANAGEMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY TASK FORCE ON CLINICAL EXPERT CONSENSUS DOCUMENTS, J AM COLL CARDIOL, 68, 1, PP. 92-125, (2016); ORRINGER C.E., JACOBSON T.A., SASEEN J.J., ET AL., UPDATE ON THE USE OF PCSK9 INHIBITORS IN ADULTS: RECOMMENDATIONS FROM AN EXPERT PANEL OF THE NATIONAL LIPID ASSOCIATION, J CLIN LIPIDOL., (2017); LANDMESSER U., JOHN CHAPMAN M., FARNIER M., ET AL., EUROPEAN SOCIETY OF CARDIOLOGY/EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE CONSENSUS STATEMENT ON PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS: PRACTICAL GUIDANCE FOR USE IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK, EUR HEART J., 38, 29, PP. 2245-2255, (2017); FOURIER OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH CLINICALLY EVIDENT CARDIOVASCULAR DISEASE IN SELECTED EUROPEAN COUNTRIES INTERNET, (2017); FURTHER CARDIOVASCULAR OUTCOMES RESEARCH WITH PCSK9 INHIBITION IN SUBJECTS WITH ELEVATED RISK OPEN-LABEL EXTENSION INTERNET, (2016)","G.F. WATTS; LIPID DISORDERS CLINIC, DEPARTMENT OF CARDIOLOGY, ROYAL PERTH HOSPITAL, PERTH, AUSTRALIA; EMAIL: GERALD.WATTS@UWA.EDU.AU","BLACKWELL PUBLISHING LTD","ENGLISH","DIABETES OBES. METAB.","REVIEW","ISI","2-S2.0-85040744065","DIABETES OBES METAB","UNIVERSITY OF WESTERN AUSTRALIA;UNIVERSITY OF WESTERN AUSTRALIA","NOTREPORTED;ROYAL PERTH HOSPITAL;NOTREPORTED",NA,"PAGE MM, 2018, DIABETES OBES METAB","PAGE MM, 2018, DIABETES OBES METAB"
"SÁNCHEZ-LÓPEZ J;FERNÁNDEZ-TRAVIESO J;ILLNAIT-FERRER J;FERNÁNDEZ-DORTA L;MENDOZA-CASTAÑO S;MAS-FERREIRO R;MESA-ANGARICA M;REYES-SUÁREZ P","SÁNCHEZ-LÓPEZ, JAVIER (55915666200); FERNÁNDEZ-TRAVIESO, JULIO CÉSAR (9432805500); ILLNAIT-FERRER, JOSÉ (6508234896); FERNÁNDEZ-DORTA, LILIA (57204307516); MENDOZA-CASTAÑO, SARAHÍ (57204328829); MAS-FERREIRO, ROSA (6602148780); MESA-ANGARICA, MEILIS (57204306979); REYES-SUÁREZ, PABLO (57204315330)","EFFECTS OF POLICOSANOL IN THE FUNCTIONAL RECOVERY OF NONCARDIOEMBOLIC ISCHEMIC STROKE HYPERTENSIVE PATIENTS EFECTOS DEL POLICOSANOL EN LA RECUPERACIÓN FUNCIONAL DE PACIENTES HIPERTENSOS CON ICTUS ISQUÉMICO NO CARDIOEMBÓLICO",2018,"REVISTA DE NEUROLOGIA","67","7",6,"10.33588/rn.6709.2018063","INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA, LA HABANA, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS, LA HABANA, CUBA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA","INTRODUCTION. CLINICAL STUDIES RESULTS SHOW THAT POLICOSANOL (20 MG/DAY) + ASPIRIN THERAPY HAD BENEFITS VERSUS PLACEBO + ASPIRIN TO PATIENTS WITH RECENT NON-CARDIOEMBOLIC ISCHEMIC STROKE. AIM. TO ANALYZE THE POLICOSANOL TREATMENT EFFECTS IN THE HYPERTENSIVE PATIENTS INCLUDED IN TWO NON-CARDIOEMBOLIC ISCHEMIC STROKE RECOVERY TRIALS. PATIENTS AND METHODS. HYPERTENSIVE PATIENTS WITH A MODIFIED RANKIN SCALE (MRS) SCORE 2 TO 4 WERE RANDOMIZED, WITHIN 30 DAYS OF ONSET, TO POLICOSANOL + ASPIRIN OR PLACEBO + ASPIRIN, FOR SIX MONTHS. THE PRIMARY OUTCOME WAS MRS SCORE REDUCTION. RESULTS. ONE HUNDRED FORTY TWO HYPERTENSIVE PATIENTS (MEAN AGE: 66 YEARS) WERE INCLUDED IN THE ANALYSIS. POLICOSANOL + ASPIRIN DECREASED SIGNIFICANTLY THE MRS SCORE MEAN FROM THE FIRST INTERIM CHECK-UP. THE POLICOSANOL TREATMENT EFFECT DID NOT WEAR OFF, ON THE CONTRARY, EVEN IMPROVED AFTER SIX MONTHS THERAPY. MORE OVER, POLICOSANOL + ASPIRIN (80.3%) TREATMENT ACHIEVED SIGNIFICANT RESULTS (MRS ≤ 1), WHEREAS THE PLACEBO + ASPIRIN DID NOT (8.5%). TWO PATIENTS DISCONTINUED AND FOUR (TWO FROM EACH GROUP) REFERRED MILD ADVERSE EVENTS. CONCLUSIONS. THE TREATMENT FOR SIX MONTHS WITH POLICOSANOL + ASPIRIN IN HYPERTENSIVE PATIENTS WHO HAD SUFFERED A NON-CARDIOEMBOLIC ISCHEMIC STROKE PROVED TO BE MORE EFFECTIVE THAN THE PLACEBO + ASPIRIN TREATMENT IN THE FUNCTIONAL RECOVERY OF THESE PATIENTS. © 2018 REVISTA DE NEUROLOGÍA.","ASPIRIN; HYPERTENSION; NON-CARDIOEMBOLIC ISCHEMIC STROKE; POLICOSANOL; RECOVERY","AGED; ASPIRIN; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERTENSION; MALE; PLATELET AGGREGATION INHIBITORS; RECOVERY OF FUNCTION; STROKE; ACETYLSALICYLIC ACID; POLICOSANOL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FATTY ALCOHOL; POLICOSANOL; AGED; ARTICLE; BRAIN ISCHEMIA; DRUG EFFECT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; RANKIN SCALE; SCORING SYSTEM; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; CONVALESCENCE; DOUBLE BLIND PROCEDURE; FEMALE; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIAL","","","AMARENCO P., BOGOUSSLAVSKY J., CAPLAN L.R., DONNAN G.A., HENNERICI M.G., CLASSIFICATION OF STROKE SUBTYPES, CEREBROVASC DIS, 27, PP. 493-501, (2009); AMANTEA D., NAPPI G., BERNARDI G., BAGETTA G., CORASANITI M.T., POST-ISCHEMIC BRAIN DAMAGE: PATHOPHYSIOLOGY AND ROLE OF INFLAMMATORY MEDIATORS, FEBS J, 276, PP. 13-26, (2009); DI CARLO A., HUMAN AND ECONOMIC BURDEN OF STROKE, AGE AGEING, 38, PP. 4-5, (2009); ROGER V.L., GO A.S., LLOYD-JONES D.M., BENJAMIN E.J., BERRY J.D., BORDEN W.B., ET AL., HEART DISEASE AND STROKE STATISTICS-2012 UPDATE, CIRCULATION, 125, PP. E2-E220, (2012); COUILLARD P., POPPE A.Y., COUTTS S.B., PREDICTING RECURRENT STROKE AFTER MINOR STROKE AND TRANSIENT ISCHEMIC ATTACK, EXPERT REV CARDIOVASC THER, 7, PP. 1273-1281, (2009); ARBOIX A., CARDIOVASCULAR RISK FACTORS FOR ACUTE STROKE: RISK PROFILES IN THE DIFFERENT SUBTYPES OF ISCHEMIC STROKE, WORLD J CLIN CASES, 3, PP. 418-429, (2015); COLLABORATIVE META-ANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE IN HIGH/ RISK PATIENTS, BMJ, 324, PP. 71-86, (2000); LEVI M., THROMBOPROPHYLAXIS FOR CEREBROVASCULAR DISORDERS: ACETYLSALICYLIC ACID REMAINS THE CORNERSTONE, NED TIJDSCHR GENEESKD, 152, PP. 423-425, (2008); LIKOSKY D.J., LEE K., BROWN D.M., AMIN A., DRESSLER D.D., KRAKOW D., ET AL., EVIDENCE-BASED MEDICINE: REVIEW OF GUIDELINES AND TRIALS IN THE PREVENTION OF SECONDARY STROKE, J HOSP MED, 3, PP. S6-S19, (2008); PATRONO C., ROCCA B., ASPIRIN: PROMISE AND RESISTANCE IN THE NEW MILLENNIUM, ARTERIOSCLER THROMB VASC BIOL, 28, PP. 25-32, (2008); AMARENCO P., LABREUCHE J., LIPID MANAGEMENT IN THE PREVENTION OF STROKE: REVIEW AND UPDATED META-ANALYSIS OF STATINS FOR STROKE PREVENTION, LANCET NEUROL, 8, PP. 453-463, (2009); NACI H., BRUGTS J.J., FLEURENCE R., ADES A.E., COMPARATIVE EFFECTS OF STATINS ON MAJOR CEREBROVASCULAR EVENTS: A MULTIPLE-TREATMENTS META-ANALYSIS OF PLACEBO-CONTROLLED AND ACTIVE-COMPARATOR TRIALS, QJM, 106, PP. 299-306, (2013); HJALMARSSON C., BOKEMARK L., MANHEM K., MEHLIG K., ANDERSSON B., THE EFFECT OF STATINS ON ACUTE AND LONG-TERM OUTCOME AFTER ISCHEMIC STROKE IN THE ELDERLY, AM J GERIATR PHARMACOTHER, 10, PP. 313-322, (2012); SONG B., WANG Y., ZHAO X., LIU L., WANG C., WANG A., ET AL., ASSOCIATION BETWEEN STATIN USE AND SHORT-TERM OUTCOME BASED ON SEVERITY OF ISCHEMIC STROKE: A COHORT STUDY, PLOS ONE, 9, (2014); NI CHROININ D., ASPLUND K., ASBERG S., CALLALY E., CUADRADO E., DIEZ-TEJEDOR E., ET AL., STATIN THERAPY AND OUTCOME AFTER ISCHEMIC STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES AND RANDOMIZED TRIALS, STROKE, 44, PP. 448-456, (2013); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., ET AL., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J PHARM SCI, 75, PP. 635-641, (2013); SANCHEZ J., FERNANDEZ L., ILLNAIT J., ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., EFFECTS OF POLICOSANOL ON THE RECOVERY OF ISCHEMIC STROKE: A RANDOMIZED CONTROLLED STUDY, IOSR JOURNAL OF PHARMACY, 2, PP. 14-24, (2012); SANCHEZ J., ILLNAIT J., MAS R., PEREZ Y., MENDOZA S., CABRERA C., ET AL., EFFECTS OF POLICOSANOL PLUS ASPIRIN THERAPY ON THE NEUROLOGICAL RECOVERY AND PLASMA OXIDATIVE MARKERS OF PATIENTS WITH ISCHEMIC STROKE, IOSR JOURNAL OF PHARMACY, 4, PP. 31-40, (2013); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., VEGA H., FERNANDEZ L., ET AL., POLICOSANOL VERSUS ATORVASTATIN ON THE FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE, INT J PHAR SCI REV RES, 37, PP. 7-14, (2016); ORTEGA L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE. A PILOT OPEN STUDY, J MED FOOD, 9, PP. 378-385, (2006); SANCHEZ J., MAS R., MENDOZA S., FERNANDEZ J., RUIZ D., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE WITH PREVIOUS TRANSIENT ISCHEMIC ATTACK: A LONG-TERM FOLLOW-UP, REVISTA CENIC CIENCIAS BIOLÓGICAS, 41, PP. 23-29, (2010); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., FERNANDEZ L., MESA M., ET AL., EFECTO A LARGO PLAZO DEL POLICOSANOL EN LA RECUPERACIÓN FUNCIONAL DE PACIENTES CON ICTUS ISQUÉMICO NO CARDIOEMBÓLICO: ESTUDIO DE UN AÑO, REV NEUROL, 64, PP. 153-161, (2017); RANKIN J., CEREBRAL VASCULAR ACCIDENTS IN PATIENTS OVER THE AGE OF 60. II. PROGNOSIS, SCOTT MED J, 2, PP. 200-215, (1957); LIKOSKY D.J., LEE K., BROWN D.M., AMIN A., DRESSLER D.D., KRAKOW D., ET AL., EVIDENCE-BASED MEDICINE: REVIEW OF GUIDELINES AND TRIALS IN THE PREVENTION OF SECONDARY STROKE, J HOSP MED, 3, PP. S6-S19, (2008); O'BRIEN P.C., SHAMPO M.A., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); GHANDEHARI K., CHALLENGING COMPARISON OF STROKE SCALES, J RES MED SCI, 18, PP. 906-910, (2013); TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE, N ENGL J MED, 333, PP. 1581-1587, (1995); LEE Y.C., CHEN S.S., KOH C.L., HSUEH I.P., YAO K.P., HSIEH C.L., DEVELOPMENT OF TWO BARTHEL INDEX-BASED SUPPLEMENTARY SCALES FOR PATIENTS WITH STROKE, PLOS ONE, 9, (2014); MAR J., MASJUAN J., OLIVA-MORENO J., GONZALEZ-ROJAS N., BECERRA V., CASADO M.A., ET AL., CONOCES INVESTIGATORS GROUP. OUTCOMES MEASURED BY MORTALITY RATES, QUALITY OF LIFE AND DEGREE OF AUTONOMY IN THE FIRST YEAR IN STROKE UNITS IN SPAIN, HEALTH QUAL LIFE OUTCOMES, 13, (2015); FRANCINI PESENTI F., BELTRAMOLLI D., DALL'ACQUABROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPER-CHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); NIKITIN I.P., SLEPCHENKO N.V., GRATSIANSKII N.A., NECHAEV A.S., SYRKIN A.L., POLTAVSKAIA M.G., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC POLICOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); WANG Y., KUANMAN K.E., WANG H.L., JIAO Y., ZHAO X., SUN N., ET AL., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); LIU S., TAN M.Y., ZHAO S.P., RONG H., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND HEME OXYGENASE-1 IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 40, PP. 840-843, (2012); TANG M., WU S.Z., GONG X., EFFECTS OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 4, PP. 488-492, (2013); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMBO HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGL LEUKOTR ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPER-CHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, INT J PHARM SCI REV RES, 19, PP. 18-23, (2013); PARK J.H., LEE J., OVBIAGELE B., NONTRADITIONAL SERUM LIPID VARIABLES AND RECURRENT STROKE RISK, STROKE, 45, PP. 3269-3274, (2014); ARBOIX A., GARCIA-EROLES L., OLIVERES M., TARGA C., BALCELLS M., MASSONS J., PRETREATMENT WITH STATINS IMPROVES EARLY OUTCOME IN PATIENTS WITH FIRST-EVER ISCHAEMIC STROKE: A PLEIOTROPIC EFFECT OF STATINS OR A BENEFICIAL EFFECT OF HYPERCHOLESTEROLEMIA?, BMC NEUROL, 10, PP. 47-54, (2010); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL THER, 318, PP. 1020-1025, (2006); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); CHO K.H., LIM S., YOO J., LEE E., ENHANCEMENT OF HDL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016)","J.C. FERNÁNDEZ-TRAVIESO; CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, AVENIDA 25 Y 158, CUBANACÁN, PLAYA, CUBA; EMAIL: JULIO.FERNANDEZ@CNIC.CU","REVISTA DE NEUROLOGIA","SPANISH","REV. NEUROL.","ARTICLE","ISI","2-S2.0-85055139214","REV NEUROL","INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS","NOTREPORTED;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;NOTREPORTED",NA,"SÁNCHEZ-LÓPEZ J, 2018, REV NEUROL","SÁNCHEZ-LÓPEZ J, 2018, REV NEUROL"
"SHEN J;LUO F;LIN Q","SHEN, JUNJUN (57191926274); LUO, FEIJUN (23025317600); LIN, QINLU (57194683507)","POLICOSANOL EXTRACTION AND BIOLOGICAL FUNCTIONS",2019,"JOURNAL OF FUNCTIONAL FOODS","57","9",40,"10.1016/j.jff.2019.04.024","NATIONAL ENGINEERING LABORATORY FOR DEEP PROCESS OF RICE AND BYPRODUCTS, HUNAN KEY LABORATORY OF GRAIN-OIL DEEP PROCESS AND QUALITY CONTROL, HUNAN KEY LABORATORY OF PROCESSED FOOD FOR SPECIAL MEDICAL PURPOSE, COLLEGE OF FOOD SCIENCE AND ENGINEERING, CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY, CHANGSHA, 410004, HUNAN, CHINA, COLLEGE OF LIFE SCIENCE AND BIOTECHNOLOGY, CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY, CHANGSHA, 410004, HUNAN, CHINA;NATIONAL ENGINEERING LABORATORY FOR DEEP PROCESS OF RICE AND BYPRODUCTS, HUNAN KEY LABORATORY OF GRAIN-OIL DEEP PROCESS AND QUALITY CONTROL, HUNAN KEY LABORATORY OF PROCESSED FOOD FOR SPECIAL MEDICAL PURPOSE, COLLEGE OF FOOD SCIENCE AND ENGINEERING, CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY, CHANGSHA, 410004, HUNAN, CHINA;NATIONAL ENGINEERING LABORATORY FOR DEEP PROCESS OF RICE AND BYPRODUCTS, HUNAN KEY LABORATORY OF GRAIN-OIL DEEP PROCESS AND QUALITY CONTROL, HUNAN KEY LABORATORY OF PROCESSED FOOD FOR SPECIAL MEDICAL PURPOSE, COLLEGE OF FOOD SCIENCE AND ENGINEERING, CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY, CHANGSHA, 410004, HUNAN, CHINA","POLICOSANOL IS WIDELY DISTRIBUTED NATURALLY AND CAN BE ISOLATED AND PURIFIED FROM RICE BRAN, SUGARCANE, APPLES, GRAPES ETC. DUE TO ITS FUNCTIONAL SIGNIFICANCE AND EASE OF BIOAVAILABILITY, TECHNIQUES FOR THE EXTRACTION OF POLICOSANOL ARE OF GREAT SIGNIFICANCE TO INVESTIGATORS, OF WHICH SAPONIFICATION, SOLVENT EXTRACTION, TRANSESTERIFICATION, MOLECULAR DISTILLATION, SUPERCRITICAL CARBON DIOXIDE EXTRACTION, ULTRASONIC-ASSISTED EXTRACTION AND OTHER EXTRACTION METHODS ARE EVALUATED. POLICOSANOL HAS BEEN USUALLY APPLIED IN FUNCTIONAL FOODS BECAUSE IT HAS MULTIPLE HEALTH-IMPROVING PROPERTIES, INCLUDING THE LOWERING OF LIPIDS, ANTI-AGING, TISSUE REGENERATION, CYTO-, LIVER, CARDIOVASCULAR AND CEREBROVASCULAR PROTECTION, AND PROTECTION AGAINST DIABETES, HYPERCHOLESTEROLEMIA, PARKINSON'S DISEASE, INFLAMMATION, ULCERS AND CANCER. ADDITIONALLY, THE SIGNALING PATHWAYS AMPK, MAPK AND PI3K/AKT INVOLVED IN ITS EFFECTS ARE INVESTIGATED. THIS REVIEW COMPILED THE MOST INTERESTING REFERENCES FOR SCIENTIFICS ENGAGED IN POLICOSANOL HEALTH-IMPROVING EFFECTS, INCLUDING EXTRACTION PROCEDURES. TO SUM UP, IT WILL HELP TO DEVELOP ANCILLARY DRUGS AND FUNCTIONAL FOODS IN THE FUTURE. © 2019 ELSEVIER LTD","BIOAVAILABILITY; DIETARY SUPPLEMENTATION; EXTRACTION METHODS; FUNCTIONAL FOODS; HEALTH-IMPROVING ACTIVITIES; POLICOSANOL","","2011 COLLABORATIVE INNOVATION CENTER OF HUNAN PROVINCE, (448); KEY RESEARCH AND DEVELOP PLAN PROJECT OF HUNAN PROVINCE, (2017SK2190); NATURAL SCIENCE FOUNDATION OF HUNAN PROVINCE, (2017JJ3528, 2018JJ2672); PROGRAM FOR SCIENCE & TECHNOLOGY INNOVATION TALENTS OF HUNAN PROVINCE, (2017TP1021, KC1704007); EDUCATION DEPARTMENT OF HUNAN PROVINCE, (13A124); EDUCATION DEPARTMENT OF HUNAN PROVINCE; NATURAL SCIENCE FOUNDATION OF HUNAN PROVINCE","FUNDING TEXT 1: THIS WORK WAS SUPPORTED BY THE PROJECT “2011 COLLABORATIVE INNOVATION CENTER OF HUNAN PROVINCE” (2013, NO. 448), THE KEY PROJECT OF THE EDUCATION DEPARTMENT OF HUNAN PROVINCE (NO. 13A124), THE KEY RESEARCH AND DEVELOP PLAN PROJECT OF HUNAN PROVINCE (2017SK2190), NATURAL SCIENCE FOUNDATION OF HUNAN PROVINCE (2018JJ2672 AND 2017JJ3528), PROGRAM FOR SCIENCE & TECHNOLOGY INNOVATION TALENTS OF HUNAN PROVINCE (2017TP1021; KC1704007).; FUNDING TEXT 2: THIS WORK WAS SUPPORTED BY THE PROJECT “ 2011 COLLABORATIVE INNOVATION CENTER OF HUNAN PROVINCE ” (2013, NO. 448 ), THE KEY PROJECT OF THE EDUCATION DEPARTMENT OF HUNAN PROVINCE (NO. 13A124 ), THE KEY RESEARCH AND DEVELOP PLAN PROJECT OF HUNAN PROVINCE ( 2017SK2190 ), NATURAL SCIENCE FOUNDATION OF HUNAN PROVINCE ( 2018JJ2672 AND 2017JJ3528 ), PROGRAM FOR SCIENCE & TECHNOLOGY INNOVATION TALENTS OF HUNAN PROVINCE ( 2017TP1021 ; KC1704007 ).","AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD JOURNAL OF CARDIOLOGY, 4, PP. 77-83, (2012); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTRITION METABABOLISM AND CARDIOVASCULAR DISEASES, 9, PP. 656-661, (2010); AFINISHA DEEPAM L.S., ARUMUGHAN C., JOURNAL OF OLEO SCIENCE, 61, PP. 241-247, (2012); AHSAN H., AHAD A., SIDDIQUI W.A., A REVIEW OF CHARACTERIZATION OF TOCOTRIENOLS FROM PLANT OILS AND FOODS, JOURNAL OF CHEMICAL BIOLOGY, 8, PP. 45-59, (2015); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, PP. 205-208, (1994); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY & PHYSIOLOGY, 29, PP. 891-897, (2002); ATTARD T.M., MCELROY C.R., GAMMONS R.J., SLATTERY J.M., SUPANCHAIYAMAT N., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION AS AN EFFECTIVE PRETREATMENT STEP FOR WAX EXTRACTION IN A MISCANTHUS BIOREFINERY, SUSTAINABLE CHEMISTRY & ENGINEERING, 4, PP. 5979-5988, (2016); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, THE JOURNAL OF PHARMACY AND PHARMACOLOGY, 47, PP. 731-733, (1995); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLINICAL DRUG INVESTIGATION, 23, PP. 639-650, (2003); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 21, PP. 43-57, (2001); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATINON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 22, PP. 89-99, (2002); CHEN F., CAI T., ZHAO G., LIAO X., GUO L., HU X., OPTIMIZING CONDITIONS FOR THE PURIFICATION OF CRUDE OCTACOSANOL EXTRACT FROM RICE BRAN WAX BY MOLECULAR DISTILLATION ANALYZED USING RESPONSE SURFACE METHODOLOGY, JOURNAL OF FOOD ENGINEERING, 70, PP. 47-53, (2005); CHEN F., CAI T., ZHAO G., LIAO X., GUO L., HU X., PURIFICATION PROCESS OF OCTACOSANOL EXTRACTS FROM RICE BRAN WAX BY MOLECULAR DISTILLATION, JOURNAL OF FOOD ENGINEERING, 79, PP. 63-68, (2007); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2018, (2018); CHO K.H., YADAV D., KIM S.J., KIM J.R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 3, (2018); CHU B., QU Y., HUANG Y., ZHANG L., CHEN X., LONG C., ET AL., PEG-DERIVATIZED OCTACOSANOL AS MICELLAR CARRIER FOR PACLITAXEL DELIVERY, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 500, PP. 345-359, (2016); CICERO A.F., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 13, PP. 273-278, (2005); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 106, PP. 147-151, (2004); DE OLIVEIRA A.M., CONSERVA L.M., DE SOUZA FERRO J.N., DE ALMEIDA BRITO F., LYRA LEMOS R.P., BARRETO E., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 13, PP. 1598-1611, (2012); DUNFORD N.T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOURCE TECHNNOLOGY, 101, PP. 422-425, (2010); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM AND BRAN, FOOD CHEMISTRY, 119, PP. 1246-1249, (2010); ELSEWEIDY M.M., AMIN R.S., ATTEIA H.H., EL-ZEIKY R.R., AL-GABRI N.A., NEW INSIGHT ON A COMBINATION OF POLICOSANOL AND 10-DEHYDROGINGERDIONE PHYTOCHEMICALS AS INHIBITORS FOR PLATELET ACTIVATION BIOMARKERS AND ATHEROGENICITY RISK IN DYSLIPIDEMIC RABBITS: ROLE OF CETP AND PCSK9 INHIBITION, APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, (2018); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., VAZQUEZ R., PERONA J., TERENCIO C., PEREZ-CAMINO C., ET AL., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, THE JOURNAL OF NUTRITION BIOCHEMISTRY, 20, PP. 155-162, (2009); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCHIVES MEDICAL RESEARCH, 28, PP. 355-360, (1997); GAO W., LIU D., SU S., HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY FOR QUANTIFICATION OF 1-OCTACOSANOL IN ANTARCTIC KRILL (EUPHAUSIA SUPERBA DANA), JOURNAL OF CHROMATOGRAPHIC SCIENCE, 53, PP. 811-815, (2015); GIUFFRE A.M., CAPOCASALE M., POLICOSANOL IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, JOURNAL OF OLEO SCIENCE, 64, PP. 625-631, (2015); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOLECULAR NUTROTION & FOOD RESEARCH, 62, PP. 1700280-1700292, (2018); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTRITION, METABOLISM, CARDIOVASCULAR DISEASES, 21, PP. 424-429, (2011); GUO T., LIN Q., LI X., NIE Y., WANG L., SHI L., ET AL., OCTACOSANOL ATTENUATES INFLAMMATION IN BOTH RAW264.7 MACROPHAGES AND A MOUSE MODEL OF COLITIS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 5, PP. 3647-3658, (2017); GUPTA S.S., GHOSH M., OCTACOSANOL EDUCES PHYSICO-CHEMICAL ATTRIBUTES, RELEASE AND BIOAVAILABILITY AS MODIFIED NANOCRYSTALS, EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 119, PP. 201-214, (2017); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXPERIMENTAL BIOLOGY AND MEDICINE, 229, PP. 215-226, (2004); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., POLICOSANOL COMPOSITION, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL AT DIFFERENT SEED MATURITY STAGES, LIPIDS AND HEALTH DISEASES, 17, (2018); HARRINGTON A.W., LEINER B., BLECHSCHMITT C., AREVALO J.C., LEE R., MORL K., ET AL., SECRETED PRONGF IS A PATHOPHYSIOLOGICAL DEATH-INDUCING LIGAND AFTER ADULT CNS INJURY, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 101, PP. 6226-6230, (2004); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTICAL RESEARCH, 51, PP. 568-575, (1992); HERRERO M., CIFUENTES A., IBANEZ E., SUB- AND SUPERCRITICAL FLUID EXTRACTION OF FUNCTIONAL INGREDIENTS FROM DIFFERENT NATURAL SOURCES: PLANTS, FOOD-BY-PRODUCTS, ALGAE AND MICROALGAE, A REVIEW, FOOD CHEMISTRY, 98, PP. 136-148, (2006); HSU C.Y., SHIH H.Y., CHANG Y.C., HUANG Z.L., TSAI M.J., CHIA Y., ET AL., THE BENEFICIAL EFFECTS OF TETRACOSANOL ON INSULIN-RESISTANCE BY INSULIN RECEPTOR KINASE SENSIBILIZATION, JOURNAL OF FUNCTIONAL FOODS, 14, PP. 174-182, (2015); HUNTER P.M., HEGELE R.A., FUNCTIONAL FOODS AND DIETARY SUPPLEMENTS FOR THE MANAGEMENT OF DYSLIPIDAEMIA, NATURE REVIEWS ENDOCRINOLOGY, 13, PP. 278-288, (2017); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTRAL AND FOOD CHEMISTRY, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); ISHAKA A., UMAR I.M., MAHAMUD R., ZUKI A.B., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INTERNATIONAL JOURNAL OF NANOMEDICINE, 9, PP. 2261-2269, (2014); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, JOURNAL OF HYPERTENSION, 28, PP. 1482-1487, (2010); JACKSON M.A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYZED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, THE JOURNAL OF SUPERCRITICAL FLUIDS, 37, PP. 173-177, (2006); JUNG D.M., YOON S.H., JUNG M.Y., CHEMICAL PROPERTIES AND OXIDATIVE STABILITY OF PERILLA OILS OBTAINED FROM ROASTED PERILLA SEEDS AS AFFECTED BY EXTRACTION METHODS, JOURNAL OF FOOD SCIENCE, 77, PP. C1249-C1255, (2012); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANNALS OF NUTRITION AND METABOLISM, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8–14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANNALS OF NUTRITION AND METABOLISM, 39, PP. 279-284, (1995); KATO S., KARINO K., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, THE BRITISH JOURNAL OF NUTRITION, 73, PP. 433-441, (1995); KAUSHIK M.K., ARITAKE K., TAKEUCHI A., YANAGISAWA M., URADE Y., OCTACOSANOL RESTORES STRESS-AFFECTED SLEEP IN MICE BY ALLEVIATING STRESS, SCIENTIFIC REPORTS, 7, PP. 8892-8899, (2017); KIM H., PARK S., HAN D.S., PARK T., OCTACOSANOL SUPPLEMENTATION INCREASES RUNNING ENDURANCE TIME AND IMPROVES BIOCHEMICAL PARAMETERS AFTER EXHAUSTION IN TRAINED RATS, JOURNAL OF MEDICINAL FOOD, 6, PP. 345-351, (2003); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONTIERS IN PHYSIOLOGY, 9, (2018); KOUBAA M., ROSELLO-SOTO E., SIC-ZLABUR J., REZEK-JAMBRAK A., BRNCIC M., GRIMI N., ET AL., CURRENT AND NEW INSIGHTS IN THE SUSTAINABLE AND GREEN RECOVERY OF NUTRITIONALLY VALUABLE COMPOUNDS FROM STEVIA REBAUDIANA BERTONI, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 63, PP. 6835-6846, (2015); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., ET AL., HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN HEPG2 AND C57BL/6J MICE, NUTRION RESEARCH, 43, PP. 89-99, (2017); LEE R., KERMANI P., TENG K.K., HEMPSTEAD B.L., REGULATION OF CELL SURVIVAL BY SECRETEDPRONEUROTROPHINS, SCIENCE, 294, PP. 1945-1948, (2001); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RESEARCH, 19, PP. 149-158, (2016); LI J., SUN D., QIAN L., LIU Y., SUBCRITICAL BUTANE EXTRACTION OF WHEAT GERM OIL AND ITS DEACIDIFICATION BY MOLECULAR DISTILLATION, MOLECULES, 21, (2016); LI Q., THOMSON A.B., CLANDININ M.T., CHOLESTEROL ESTER AND FREE FATTY ACIDS ARE MODULATED BY POLICOSANOL IN CACO-2 INTESTINAL CELLS, JOURNAL OF THE AMERICAN COLLEGE OF NUTROTION, 30, PP. 201-209, (2011); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RESEARCH, 19, PP. 59-70, (2016); LIN S.R., FU Y.S., TSAI M.J., CHENG H., WENG C.F., NATURAL COMPOUNDS FROM HERBS THAT CAN POTENTIALLY EXECUTE AS AUTOPHAGY INDUCERS FOR CANCER THERAPY, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE, 18, (2017); LIU Y., YU J., WANG X., EXTRACTION OF POLICOSANOLS FROM HYDROLYSED RICE BRAN WAX BY HIGH-INTENSITY ULTRASOUND, INTERNATIONAL JOURNAL OF FOOD SCIENCE & TECHNOLOGY, 43, PP. 763-769, (2008); LIU Y.W., ZUO P.Y., ZHA X.N., CHEN X.L., ZHANG R., HE X.X., ET AL., OCTACOSANOL ENHANCES THE PROLIFERATION AND MIGRATION OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS VIA ACTIVATION OF THE PI3K/AKT AND MAPK/ERK PATHWAYS, LIPIDS, 50, PP. 241-251, (2015); LONG L., GAO M.Z., PENG K., SUN J., WANG X.S., EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON PRODUCTION PERFORMANCE AND BLOOD PARAMETERS IN WEANLING PIGLETS, JOURNAL OF CHINESE CEREALS OILS ASSOCIATION, 30, PP. 94-100, (2015); LONG L., WU S.G., SUN J., WANG J., ZHANG H.J., QI G.H., EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON BLOOD HORMONE LEVELS AND GENE EXPRESSIONS OF GLUCOSE TRANSPORTER PROTEIN-4 AND ADENOSINE MONOPHOSPHATE PROTEIN KINASE IN WEANING PIGLETS, ANIMAL NUTRITION, 4, PP. 293-298, (2015); LORENZ P., BERGER M., BERTRAMS J., WENDE K., WENZEL K., NATURAL WAX CONSTITUENTS OF A SUPERCRITICAL FLUID CO<SUB>2</SUB> EXTRACT FROM QUINCE (CYDONIA OBLONGA MILL.) POMACE, ANALYTIC BIOANALYTICAL CHEMISTRY, 391, PP. 633-646, (2008); LUKASHEVICH V., DAVIDSON M.H., MOREINES J., BERLIN R.G., BEESWAX POLICOSANOL FAILED TO DEMONSTRATE LIPID-ALTERING EFFECTS IN WELL-CONTROLLED CLINICAL TRIALS, CIRCULATION, 114, (2006); LUQUE-GARCIA J.L., LUQUE DE CASTRO M.D., ULTRASOUND: A POWERFUL TOOL FOR LEACHING, TRENDS IN ANALYTICAL CHEMISTRY, 22, PP. 41-47, (2003); MA J., MA L., ZHANG H., ZHANG Z., WANG Y., LI K., ET AL., POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY, PLOS ONE, 13, (2018); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADVANCES IN THERAPY, 28, PP. 1105-1113, (2011); MARAZZI G., PELLICCIA F., CAMPOLONGO G., QUATTRINO S., CACCIOTTI L., VOLTERRANI M., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, THE AMERICAN JOURNAL OF CARDIOLOGY, 116, PP. 1798-1801, (2015); MARCHITTO N., SINDONA F., FABRIZIO A., MAUTI M., ANDREOZZI S., DALMASO S., EFFECT OF NEW NUTRACEUTICAL FORMULATION WITH POLICOSANOL, BERBERINE, RED YEAST RICE, CASSIA NOMAME, ASTAXANTINE AND Q10 COENZYME IN PATIENTS WITH LOW-MODERATE DYSLIPIDEMIA ASSOCIATED WITH INTOLERANCE TO STATINS AND METABOLIC SYNDROME, MINERVA CARDIOANGIOLOGICA, 66, PP. 124-125, (2018); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRITICAL REVIEW OF FOOD SCIENCE AND NUTRITION, 50, PP. 259-267, (2010); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLINICAL PHARMACOLOGY AND THERAPEUTICS, 65, PP. 439-447, (1999); MAZZA A., LENTI S., SCHIAVON L., ZUIN M., D'AVINO M., RAMAZZINA E., NUTRACEUTICALS FOR SERUM LIPID AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS AT LOW CARDIOVASCULAR RISK, ADVANCES IN THERAPY, 32, PP. 680-690, (2015); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., EFFECT OF POLICOSANOL ON CEREBRALISCHEMIA IN MONGOLIAN GERBILS, BRAZILIAN JOURNAL OF MEDICAL BIOLOGICAL RESEARCH, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 75, PP. 635-641, (2013); MONTSERRAT-DE LA PAZ S., GARCIA-GIMENEZ M.D., ANGEL-MARTIN M., PEREZ-CAMINO M.C., FERNANDEZ A.A., LONG-CHAIN FATTY ALCOHOLS FROM EVENING PRIMROSE OIL INHIBIT THE INFLAMMATORY RESPONSEIN MURINE PERITONEAL MACROPHAGES, JOURNAL OF ETHNOPHARMACOLOGY, 151, PP. 131-136, (2014); NOA M., HERRERA M., MAGRANER J., MAS R., FRAGA V., MENENDEZ R., EFFECT OF POLICOSANOLON ISOPRENALINE-INDUCED MYOCARDIAL NECROSIS IN RATS, THE JOURNAL OF PHARMACY AND PHARMACOLOGY, 46, PP. 282-285, (1994); NOA M., MAS R., LARIOT C., PROTECTIVE EFFECT OF POLICOSANOLON ENDOTHELIUMAND INTIMAL THICKNESS INDUCED BY FORCEPS IN RABBITS, JOURNAL OF MEDICINAL FOOD, 10, PP. 452-459, (2007); NOA M., MENDOZA S., MAS R., MENDOZA N., EFFECT OF POLICOSANOL ON CARBON TETRACHLORIDE-INDUCEDACUTE LIVER DAMAGE IN SPRAGUE-DAWLEY RATS, DRUGS IN R & D, 4, PP. 29-35, (2003); NYKJAER A., LEE R., TENG K.K., JANSEN P., MADSEN P., NIELSEN M.S., ET AL., SORTILIN IS ESSENTIAL FOR PRONGF-INDUCED NEURONAL CELL DEATH, NATURE, 427, PP. 843-848, (2004); OHTA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 42, PP. 118-125, (2008); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., ET AL., REGULATION OF HMG-COA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); OROZCO-SOLANO M., RUIZ-JIMENEZ J., LUQUE DE CASTRO M.D., CHARACTERIZATION OF FATTY ALCOHOL AND STEROL FRACTIONS IN OLIVE TREE, JOURNAL OF AGRICULTURE AND FOOD CHEMISTRY, 58, PP. 7539-7546, (2010); OU S., ZHAO J., WANG Y., TIAN Y., WANG J., PREPARATION OF OCTACOSANOL FROM FILTER MUD PRODUCED AFTER SUGARCANE JUICE CLARIFICATION, LWT-FOOD SCIENCE AND TECHNOLOGY, 45, PP. 295-298, (2012); PASHA I., SAEED F., WAQAS K., ANJUM F.M., ARSHAD M.U., NUTRACEUTICAL AND FUNCTIONAL SCENARIO OF WHEAT STRAW, CRITICAL REVIEWS OF FOOD SCIENCE AND NUTRITION, 53, PP. 287-295, (2013); PENG K., LONG L., WANG Y., WANG S., EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON THE LAYING PERFORMANCE, EGG QUALITY AND BLOOD METABOLITES OF LAYING HENS, ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES, 4, PP. 293-298, (2015); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASE, 27, PP. 2-17, (2017); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS IN HEALTH AND DISEASE, 11, (2012); PRADO J.M., PRADO G.H.C., MEIRELES M.A.A., SCALE-UP STUDY OF SUPERCRITICAL FLUID EXTRACTION PROCESS FOR CLOVE AND SUGARCANE RESIDUE, JOURNAL OF SUPERCRITICAL FLUIDS, 56, PP. 231-237, (2011); RAVELO Y., MOLINA V., CARBAJAL D., FERNANDEZ L., FERNANDEZ J.C., ARRUZAZABALA M.L., EVALUATION OF ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECTS OF D-002 (BEESWAX ALCOHOLS), JOURNAL OF NATURAL MEDICINE, 65, PP. 330-335, (2011); RODRIGUES M.J., CUSTODIO L., LOPES A., OLIVEIRA M., NENG N.R., NOGUEIRA J.M., ET AL., UNLOCKING THE IN VITRO ANTI-INFLAMMATORY AND ANTIDIABETIC POTENTIAL OF POLYGONUM MARITIMUM, PHARMACEUTICAL BIOLOGY, 55, PP. 1348-1357, (2017); ROSELLO-SOTO E., KOUBAA M., MOUBARIK A., LOPES R.P., SARAIVA J.A., BOUSSETTA N., ET AL., EMERGING OPPORTUNITIES FOR THE EFFECTIVE VALORIZATION OF WASTES AND BY-PRODUCTS GENERATED DURING OLIVE OIL PRODUCTION PROCESS: NON-CONVENTIONAL METHODS FOR THE RECOVERY OF HIGH-ADDED VALUE COMPOUNDS, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 45, PP. 296-310, (2015); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., FERNANDEZ L., MESA M., LONG-TERM EFFECT OF POLICOSANOL ON THE FUNCTIONAL RECOVERY OF NON-CARDIOEMBOLIC ISCHEMIC STROKE PATIENTS: A ONE YEAR STUDY, REVISTA DE NEUROLOGIA, 64, PP. 153-161, (2017); SIN E.H.K., MARRIOTT R., HUNT A.J., CLARK J.H., IDENTIFICATION, QUANTIFICATION AND CHRASTIL MODELLING OF WHEAT STRAW WAX EXTRACTION USING SUPERCRITICAL CARBON DIOXIDE, COMPTES RENDUS CHIMIE, 17, PP. 293-300, (2014); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); SONG N., GUO H., CHEN G., YANG G., EXTRACTION OF HIGHER ALIPHATIC ALKANOLS FROM SUGARCANE WAX USING TRANSESTERIFICATION, FOOD RESEARCH AND DEVELOPMENT, 29, PP. 28-30, (2008); TANG M., WU S.Z., GONG X., EFFECTS OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA, CHINESE JOURNAL OF CARDIOVASCULAR, 41, PP. 488-492, (2013); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); TCHAKAM P.D., LUNGA P.K., KOWA T.K., LONFOUO A.H., WABO H.K., ANTIMICROBIAL AND ANTIOXIDANT ACTIVITIES OF THE EXTRACTS AND COMPOUNDS FROM THE LEAVES OF PSOROSPERMUM AURANTIACUM ENGL. AND HYPERICUM LANCEOLATUM LAM, BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 12, PP. 136-143, (2012); TENG H.K., TENG K.K., LEE R., WRIGHT S., TEVAR S., ALMEIDA R.D., ET AL., PROBDNF INDUCES NEURONAL APOPTOSIS VIA ACTIVATION OF A RECEPTOR COMPLEX OF P75NTR AND SORTILIN, JOURNAL OF NEUROSCIENCE, 25, PP. 5455-5463, (2005); THIPPESWAMY G., SHEELA M.L., SALIMATH B.P., OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-KAPPAB AND ITS DNA BINDING ACTIVITY, EUROPEAN JOURNAL OF PHARMACOLOGY, 588, PP. 141-150, (2008); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); TRIMARCO V., IZZO R., STABILE E., ROZZA F., SANTORO M.M., MANZI M.V., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE, INSULIN SENSITIVITY AND ENDOTELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS. A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND TRIAL, HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 22, PP. 149-154, (2015); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, PP. 376-383, (2003); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., ET AL., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, PP. 5552-5558, (2007); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., PROTECTIVE EFFECTS OF OCTACOSANOL ON 6-HYDROXYDOPAMINE-INDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING, ACTA PHARMACOLOGICA SINICA, 31, PP. 765-774, (2010); WANG T., LIU Y., YANG N., JI C., CHAN P., ZUO P., ANTI-PARKINSONIAN EFFECTS OF OCTACOSANOL IN 1-METHYL-4-PHENYL-1,2,3,6 TETRAHYDROPYRIDINE-TREATED MICE, NEURAL REGENERATION RESEARCH, 14, PP. 1080-1087, (2012); WANG L.J., WELLER C.L., RECENT ADVANCES IN EXTRACTION OF NUTRACEUTICALS FROM PLANTS, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 17, PP. 300-312, (2006); WEERAWATANAKORN M., ASIKIN Y., TAKAHASHI M., TAMAKI H., WADA K., HO C.T., ET AL., PHYSICO-CHEMICAL PROPERTIES, WAX COMPOSITION, AROMA PROFILES, AND ANTIOXIDANT ACTIVITY OF GRANULATED NON-CENTRIFUGAL SUGARS FROM SUGARCANE CULTIVARS OF THAILAND, JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 55, PP. 4684-4692, (2016); WONG W.T., ISMAIL M., TOHIT E.R., ABDULLAH R., ZHANG Y.D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, (2016); YANG H., CHANG Y., WU F., STUDY ON SUPERCRITICAL EXTRACTION OF 1-OCTACOSANOL FROM SUGAR CANE SKIN, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, 33, PP. 168-170, (2008)","F. LUO; COLLEGE OF FOOD SCIENCE AND ENGINEERING, CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY, CHANGSHA, NO. 498, SHAOSHAN ROAD, 410004, CHINA; EMAIL: LUOFEIJUN888@CSUFT.EDU.CN","ELSEVIER LTD","ENGLISH","J. FUNCT. FOODS","REVIEW","ISI","2-S2.0-85064467936","J FUNCT FOODS","CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY;CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY;CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY","NOTREPORTED;CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY;NOTREPORTED",NA,"SHEN J, 2019, J FUNCT FOODS","SHEN J, 2019, J FUNCT FOODS"
"EZZ M;IBRAHIM N;SAID M;FARRAG M","EZZ, MAGDA K. (54400956600); IBRAHIM, NASHWA K. (57210524762); SAID, MAHMOUD M. (7103287033); FARRAG, MOSTAFA A. (57198426776)","THE BENEFICIAL RADIOPROTECTIVE EFFECT OF TOMATO SEED OIL AGAINST GAMMA RADIATIONINDUCED DAMAGE IN MALE RATS",2018,"JOURNAL OF DIETARY SUPPLEMENTS","15","15",24,"10.1080/19390211.2017.1406427","BIOCHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, AIN SHAMS UNIVERSITY, CAIRO, EGYPT;BIOLOGICAL RADIATION RESEARCH DEPARTMENT, NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY (NCRRT), CAIRO, EGYPT;BIOCHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, AIN SHAMS UNIVERSITY, CAIRO, EGYPT;BIOLOGICAL RADIATION RESEARCH DEPARTMENT, NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY (NCRRT), CAIRO, EGYPT","RADIATION PROTECTION RESEARCH RECEIVES INTENSE FOCUS DUE TO ITS SIGNIFICANT IMPACT ON HUMAN HEALTH. THE PRESENT STUDY WAS UNDERTAKEN TO INVESTIGATE THE PROTECTIVE EFFECT OF PRETREATMENT WITH TOMATO SEED OIL (TSO) AGAINST GAMMA RADIATION–INDUCED DAMAGE IN RATS. MALE WISTAR RATS WERE DIVIDED INTO FOUR GROUPS: (1) UNTREATED CONTROL; (2) TSO-SUPPLEMENTED; (3) GAMMA-IRRADIATED; (4) TSO-PRETREATED AND GAMMA-IRRADIATED. ACUTE EXPOSURE OF ANIMALS TO A SINGLE GAMMA RADIATION DOSE (6 GY) INDUCED OXIDATIVE STRESS IN MAJOR BODY ORGANS, ALTERED SERUM LIPID HOMEOSTASIS, SIGNIFICANTLY INCREASED SERUM TESTOSTERONE AND SORBITOL DEHYDROGENASE LEVELS, AND ELICITED A SYSTEMIC INFLAMMATION AS MANIFESTED BY THE INDUCTION OF SERUM VASCULAR CELL ADHESION MOLECULE-1. ORAL PRETREATMENT WITH TSO (1 ML/KG; 3 TIMES/WEEK FOR 8 WEEKS) BEFORE EXPOSURE TO GAMMA RADIATION PROTECTED RATS AGAINST IONIZING RADIATION-INDUCED OXIDATIVE STRESS, RESTORED LIPID HOMEOSTASIS, AND SUPPRESSED SYSTEMIC INFLAMMATION. HISTOLOGICAL FINDINGS OF TARGET TISSUES VERIFIED BIOCHEMICAL DATA. THE RADIOPROTECTIVE ABILITY OF TSO WAS ATTRIBUTED TO ITS CONTENT OF PHYTOSTEROLS, POLICOSANOL, AND ANTIOXIDANTS, INCLUDING LYCOPENE, Β-CAROTENE, LUTEIN, AND TOCOPHEROLS. TSO IS CONSIDERED A PROMISING RADIOPROTECTIVE AGENT THAT CAN BE EFFECTIVELY USED TO PROTECT THE BODY FROM THE DAMAGING EFFECTS OF HARMFUL RADIATION. © 2018, © 2018 TAYLOR & FRANCIS GROUP, LLC.","GAMMA RADIATION; INFLAMMATION; OXIDATIVE STRESS; TOMATO SEED OIL","ANIMALS; ANTIOXIDANTS; GAMMA RAYS; INFLAMMATION; KIDNEY; L-IDITOL 2-DEHYDROGENASE; LIPID PEROXIDATION; LIPIDS; LIVER; LYCOPERSICON ESCULENTUM; MALE; OXIDATIVE STRESS; PLANT OILS; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RATS; RATS, WISTAR; SEEDS; SUPEROXIDE DISMUTASE; TESTIS; TESTOSTERONE; VASCULAR CELL ADHESION MOLECULE-1; ANTIOXIDANT; IDITOL DEHYDROGENASE; LIPID; RADIOPROTECTIVE AGENT; SUPEROXIDE DISMUTASE; TESTOSTERONE; VASCULAR CELL ADHESION MOLECULE 1; VEGETABLE OIL; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL RADIATION INJURY; GAMMA RADIATION; INFLAMMATION; KIDNEY; LIPID PEROXIDATION; LIVER; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PLANT SEED; RAT; TESTIS; TOMATO; WISTAR RAT","ATOMIC ENERGY AUTHORITY, CAIRO, EGYPT","THE AUTHORS ACKNOWLEDGE THE VALUABLE COMMENTS IN HISTOLOGY PROVIDED BY DR. SAID SOLIMAN, PROFESSOR OF HISTOLOGY, NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY (NCRRT), ATOMIC ENERGY AUTHORITY, CAIRO, EGYPT.","ADARAMOYE O.A., ADEDARA I.A., POPOOLA B., FAROMBI E.O., EXTRACT OF XYLOPIA AETHIOPICA (ANNONACEAE) PROTECTS AGAINST GAMMA-RADIATION INDUCED TESTICULAR DAMAGE IN WISTAR RATS, J BASIC CLIN PHYSIOL PHRAMACOL, 21, PP. 295-313, (2010); ALA A., DHILLON A.P., HODGSON H.J., ROLE OF CELL ADHESION MOLECULES IN LEUKOCYTE RECRUITMENT IN THE LIVER AND GUT, INT J EXP PATHOL, 84, PP. 1-16, (2003); AL-MASRI S.A., EFFECT OF PUMPKIN OIL AND VITAMIN E ON LEAD INDUCED TESTICULAR TOXICITY IN MALE RATS, J ANIM PLANT SCI., 25, PP. 72-77, (2015); AYTAC E., AYAN F., SAYGILI S., GENC H., KARACA C., BAYRAK I., UZUN H., SALIHOGLU Z., ERDAMAR S., SOZER V., ALTUG T., SEYMEN P., SEYMEN H.O., EFFECTS OF LYCOPENE ON OXIDATIVE STRESS AND REMNANT LIVER HISTOLOGY AFTER PARTIAL HEPATECTOMY IN RATS, TURK J GASTROENTEROL, 22, PP. 408-413, (2011); BARTELS H., BOHMER M., HEIERLI C., SERUM CREATININE DETERMINATION WITHOUT PROTEIN PRECIPITATION, CLIN CHIM ACTA, 37, PP. 193-197, (1972); BOEIRA S.P., FUNCK V.R., BORGES FILHO C., DEL'FABBRO L., DE GOMES M.G., DONATO F., ROYES L.F., OLIVEIRA M.S., JESSE C.R., FURIAN A.F., LYCOPENE PROTECTS AGAINST ACUTE ZEARALENONE-INDUCED OXIDATIVE, ENDOCRINE, INFLAMMATORY AND REPRODUCTIVE DAMAGES IN MALE MICE, CHEM BIOL INTERACT, 230, PP. 50-57, (2015); GUIDE TO THE CARE AND USE OF EXPERIMENTAL ANIMALS, 1, (1993); CLIFTON D.K., BREMNER W.J., THE EFFECT OF TESTICULAR X-IRRADIATION ON SPERMATOGENESIS IN MAN. A COMPARISON WITH THE MOUSE, J ANDROL., 4, PP. 387-392, (1983); DOGUKAN A., TUZCU M., AGCA C.A., GENCOGLU H., SAHIN N., ONDERCI M., OZERCAN I.H., ILHAN N., KUCUK O., SAHIN K., A TOMATO LYCOPENE COMPLEX PROTECTS THE KIDNEY FROM CISPLATIN-INDUCED INJURY VIA AFFECTING OXIDATIVE STRESS AS WELL AS BAX, BCL-2, AND HSPS EXPRESSION, NUTR CANCER, 63, PP. 427-434, (2011); EL-HABIT O.H., SAADA H.N., AZAB K.S., ABDEL-RAHMAN M., EL-MALAH D.F., THE MODIFYING EFFECT OF BETA-CAROTENE ON GAMMA RADIATION-INDUCED ELEVATION OF OXIDATIVE REACTIONS AND GENOTOXICITY IN MALE RATS, MUTAT RES, 466, PP. 179-186, (2000); ELLER F.J., MOSER J.K., KENAR J.A., TAYLOR S.L., EXTRACTION AND ANALYSIS OF TOMATO SEED OIL, J AM OIL CHEM SOC, 87, PP. 755-762, (2010); EL-SEIFI S.A., ABOU-SAFI H.M., ABDEL-HAMID G.R., EFFECT OF DEHYDROEPIANDROSTERONE SULFATE ADMINISTRATION ON THE LEVELS OF THYROID HORMONES AND TESTOSTERONE IN THE Γ-IRRADIATED RAT, J NUCL TECH APPL SCI, 3, PP. 43-54, (2015); FAHIMDANES M., BAHRAMI M.E., EVALUATION OF PHYSICOCHEMICAL PROPERTIES OF IRANIAN TOMATO SEED OIL, J NUTR FOOD SCI, 3, PP. 1-4, (2013); FAWCETT J.K., SCOTT J.E., A RAPID AND PRECISE METHOD FOR THE DETERMINATION OF UREA, J CLIN PATHOL, 13, PP. 156-159, (1960); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, 3, PP. 155-162, (2009); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GIUFFRE A.M., CAPOCASALE M., POLICOSANOL IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, J OLEO SCI, 64, PP. 625-631, (2015); GIUFFRE A.M., CAPOCASALE M., PHYSICOCHEMICAL COMPOSITION OF TOMATO SEED OIL FOR AN EDIBLE USE: THE EFFECT OF CULTIVAR, INT FOOD RES J, 23, PP. 583-591, (2016); GIUFFRE A.M., CAPOCASALE M., N-ALKANES IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE CULTIVAR EFFECT, INT FOOD RES J, 23, PP. 979-985, (2016); GIUFFRE A.M., CAPOCASALE M., ZAPPIA C., TOMATO SEED OIL FOR EDIBLE USE: COLD BREAK, HOT BREAK, AND HARVEST SOURCE EFFECTS, J FOOD PROCESS PRESERV, 41, (2017); GOANS R.E., FLYNN D.F., ACUTE RADIATION SYNDROME IN HUMANS, MEDICAL CONSEQUENCES OF RADIOLOGICAL AND NUCLEAR WEAPONS, (2012); GUPTA G.S., BAWA S.R., RADIATION EFFECTS ON RAT TESTES. IX. STUDIES ON OXIDATIVE ENZYMES AFTER PARTIAL BODY GAMMA IRRADIATION, STRAHLENTHERAPIE., 150, PP. 158-161, (1975); HACKMAN A., ABE Y., INSULL W., POWNALL H., SMITH L., DUNN K., GOTTO A.M., BALLANTYNE C.M., LEVELS OF SOLUBLE CELL ADHESION MOLECULES IN PATIENTS WITH DYSLIPIDEMIA.CIRCULATION, 93, PP. 1334-1338, (1996); HAMZAA R.G., EL SHAHAT A.N., MEKAWEY H.M.S., THE ANTIOXIDANT ROLE OF MULBERRY (MORUS ALBA L.) FRUITS IN AMELIORATING THE OXIDATIVE STRESS INDUCED IN Γ-IRRADIATED MALE RATS, BIOCHEM ANAL BIOCHEM, 1, PP. 1-6, (2012); HECKMANN M., DOUWES K., PETER R., DEGITZ K., VASCULAR ACTIVATION OF ADHESION MOLECULE MRNA AND CELL SURFACE EXPRESSION BY IONIZING RADIATION, EXP CELL RES, 238, PP. 148-154, (1998); HOLMES D.T., FROHLICH J., BUHR K.A., THE CONCEPT OF PRECISION EXTENDED TO THE ATHEROGENIC INDEX OF PLASMA, CLIN BIOCHEM, 41, PP. 631-635, (2008); JAGETIA G.C., RADIOPROTECTIVE POTENTIAL OF PLANTS AND HERBS AGAINST THE EFFECTS OF IONIZING RADIATION, J CLIN BIOCHEM NUTR., 40, PP. 74-81, (2007); KAMRAN M.Z., RANJAN A., KAUR N., SUR S., TANDON V., RADIOPROTECTIVE AGENTS: STRATEGIES AND TRANSLATIONAL ADVANCES, MED RES REV, 36, PP. 461-493, (2016); KAVAZARAKIS E., MOUSTAKI M., GOURGIOTIS D., ZEIS P.M., BOSSIOS A., MAVRI A., CHRONOPOULOU A., KARPATHIOS T., THE IMPACT OF SERUM LIPID LEVELS ON CIRCULATING SOLUBLE ADHESION MOLECULES IN CHILDHOOD, PEDIATR RES, 52, PP. 454-458, (2002); KIM H., CAROTENOIDS PROTECT CULTURED RAT HEPATOCYTES FROM INJURY CAUSED BY CARBON TETRACHLORIDE, INT J BIOCHEM CELL BIOL., 27, PP. 1303-1309, (1995); KMA L., PLANT EXTRACTS AND PLANT-DERIVED COMPOUNDS: PROMISING PLAYERS IN COUNTERMEASURE STRATEGY AGAINST RADIOLOGICAL EXPOSURE. A REVIEW, ASIAN PAC J CANCER PREV., 15, PP. 2405-2425, (2014); LAZOS E.S., TSAKNIS J., LALAS S., CHARACTERISTICS AND COMPOSITION OF TOMATO SEED OIL, GRASAS Y ACEITES, 49, PP. 440-445, (1998); MANSOUR H.H., PROTECTIVE ROLE OF CARNITINE ESTER AGAINST RADIATION-INDUCED OXIDATIVE STRESS IN RATS, PHARMACOL RES., 54, PP. 165-171, (2006); MATHUR A., SHARMA J., RADIOPROTECTIVE ROLE OF PUNICA GRANATUM FRUIT RIND EXTRACT: A BIOCHEMICAL STUDY ON MOUSE TESTIS, INT J RADIAT RES, 11, PP. 99-109, (2013); MIHANDOOST E., SHIRAZI A., MAHDAVI S.R., ALIASGHARZADEH A., CONSEQUENCES OF LETHAL-WHOLE-BODY GAMMA RADIATION AND POSSIBLE AMELIORATIVE ROLE OF MELATONIN, 2014, PP. 1-9; MINAMI M., YOSHIKAWA H., A SIMPLIFIED ASSAY METHOD OF SUPEROXIDE DISMUTASE ACTIVITY FOR CLINICAL USE, CLIN CHIM ACTA, 92, PP. 337-342, (1979); MOTAWI T.M.K., SADIK N.A.H., REFAAT A., CYTOPROTECTIVE EFFECTS OF DL-ALPHA-LIPOIC ACID OR SQUALENE ON CYCLOPHOSPHAMIDE-INDUCED OXIDATIVE INJURY: AN EXPERIMENTAL STUDY ON RAT MYOCARDIUM, TESTICLES AND URINARY BLADDER, FOOD CHEM TOXICOL, 48, PP. 2326-2336, (2010); MULLER L., CATALANO A., SIMONE R., CITTADINI A., FROHLICH K., BOHM V., PALOZZA P., ANTIOXIDANT CAPACITY OF TOMATO SEED OIL IN SOLUTION AND ITS REDOX PROPERTIES IN CULTURED MACROPHAGES, J AGRIC FOOD CHEM, 61, PP. 346-354, (2013); NAGIUB N.I., ALKADY M.M., EMAM W.A., THE PROTECTIVE ROLE OF CURCUMIN AGAINST GAMMA-IRRADIATION INDUCED OXIDATIVE STRESS IN DIABETIC MICE, J RAD RES APPL SCI, 5, PP. 903-924, (2012); O'BRIEN K.D., ALLEN M.D., MCDONALD T.O., CHAIT A., HARLAN J.M., FISHBEIN D., MCCARTY J., FERGUSON M., HUDKINS K., BENJAMIN C.D., VASCULAR CELL ADHESION MOLECULE-1 IS EXPRESSED IN HUMAN CORONARY ATHEROSCLEROTIC PLAQUES: IMPLICATIONS FOR THE MODE OF PROGRESSION OF ADVANCED CORONARY ATHEROSCLEROSIS, J CLIN INVEST, 92, PP. 945-951, (1993); GUIDELINES FOR THE TESTING OF CHEMICALS /SECTION 4: HEALTH EFFECTS TEST NO. 423: ACUTE ORAL TOXICITY–ACUTE TOXIC CLASS METHOD, PP. 1-14, (2001); PANT N., PRASAD A.K., SRIVASTAVA S.C., SHANKAR R., SRIVASTAVA S.P., EFFECT OF ORAL ADMINISTRATION OF CARBOFURAN ON MALE REPRODUCTIVE SYSTEM OF RAT, HUM EXP TOXICOL, 14, PP. 889-894, (1995); RAMADAN L.A., ROUSHDY H.M., ABU SENNA G.M., AMIN N.E., EL-DESHW O.A., RADIOPROTECTIVE EFFECT OF SILYMARIN AGAINST RADIATION INDUCED HEPATOTOXICITY, PHARMACOL RES, 45, PP. 447-454, (2002); REEVES P.G., NIELSEN F.H., FAHEY G.C., AIN-93 PURIFIED DIETS FOR LABORATORY RODENTS: FINAL REPORT OF THE AMERICAN INSTITUTE OF NUTRITION AD HOC WRITING COMMITTEE ON THE REFORMULATION OF THE AIN-76A RODENT DIET, J NUTR, 123, PP. 1939-1951, (1993); REITMAN S., FRANKEL S., A COLORIMETRIC METHOD FOR THE DETERMINATION OF SERUM GLUTAMIC OXALACETIC AND GLUTAMIC PYRUVIC TRANSAMINASES, AM J CLIN PATHOL, 28, PP. 56-63, (1957); RICHARDSON M., HADCOCK S.J., DERESKE M., CYBULSKY M.I., INCREASED EXPRESSION IN VIVO VCAM-1 AND E-SELECTIN BY THE AORTIC ENDOTHELIUM OF NORMOLIPEMIC AND HYPERLIPEMIC DIABETIC RABBITS, ARTERIOSCLER THROMB, 14, PP. 760-769, (1994); ROBBINS M.E., ZHAO W., DAVIS C.S., TOYOKUNI S., BONSIB S.M., RADIATION-INDUCED KIDNEY INJURY: A ROLE FOR CHRONIC OXIDATIVE STRESS?, MICRON, 33, PP. 133-141, (2002); SHAO D., BARTLEY G.E., YOKOYAMA W., PAN Z., ZHANG H., ZHANG A., PLASMA AND HEPATIC CHOLESTEROL-LOWERING EFFECTS OF TOMATO POMACE, TOMATO SEED OIL AND DEFATTED TOMATO SEED IN HAMSTERS FED WITH HIGH-FAT DIETS, FOOD CHEM, 139, PP. 589-596, (2013); SHARMA P., GOYAL P.K., PROTECTIVE ACTION OF TINOSPORA CORDIFOLIA EXTRACT AGAINST RADIATION INDUCED BIOCHEMICAL ALTERATIONS IN LIVER, INT J PHARM PHARM SCI, 6, PP. 305-311, (2014); SHIRAZI A., MIHANDOOST E., GHOBADI G., MOHSENI M., GHAZI-KHANSARI M., EVALUATION OF RADIO-PROTECTIVE EFFECT OF MELATONIN ON WHOLE BODY IRRADIATION INDUCED LIVER TISSUE DAMAGE, CELL J, 14, PP. 292-297, (2013); SILVA L.S., DE MIRANDA A.M., DE BRITO MAGALHAES C.L., DOS SANTOS R.C., PEDROSA M.L., SILVA M.E., DIET SUPPLEMENTATION WITH BETA-CAROTENE IMPROVES THE SERUM LIPID PROFILE IN RATS FED A CHOLESTEROL-ENRICHED DIET, J PHYSIOL BIOCHEM, 69, PP. 811-820, (2013); SRINIVASAN M., KALPANAB K.B., DEVIPRIYA N., MENON V.P., PROTECTIVE EFFECT OF LYCOPENE ON WHOLE BODY IRRADIATION INDUCED LIVER DAMAGE OF SWISS ALBINO MICE, PATHOLOGICAL EVALUATION. BIOMED PREV NUTR., 4, PP. 87-94, (2014); SRINIVASAN M., SUDHEER A.R., PILLAI K.R., KUMAR P.R., SUDHAKARAN P.R., MENON V.P., LYCOPENE AS A NATURAL PROTECTOR AGAINST GAMMA-RADIATION INDUCED DNA DAMAGE, LIPID PEROXIDATION AND ANTIOXIDANT STATUS IN PRIMARY CULTURE OF ISOLATED RAT HEPATOCYTES IN VITRO, BIOCHIMBIOPHYS ACTA, 1770, PP. 659-665, (2007); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); WANG Y., GAO Y., YU W., JIANG Z., QU J., LI K., LYCOPENE PROTECTS AGAINST LPS-INDUCED PROINFLAMMATORY CYTOKINE CASCADE IN HUVECS, PHARMAZIE, 68, PP. 681-684, (2013); YANG H.S., HAN D.K., KIM J.R., SIM J.C., EFFECTS OF ALPHA-TOCOPHEROL ON CADMIUM-INDUCED TOXICITY IN RAT TESTIS AND SPERMATOGENESIS, J KOREAN MED SCI, 21, PP. 445-451, (2006); YOSHIOKA T., KAWADA K., SHIMADA T., MORI M., LIPID PEROXIDATION IN MATERNAL AND CORD BLOOD AND PROTECTIVE MECHANISM AGAINST ACTIVATED-OXYGEN TOXICITY IN THE BLOOD, AM J OBSTET GYNECOL, 135, PP. 372-376, (1979); YOUNG D.S., EFFECTS OF DRUGS ON CLINICAL LABORATORY TESTS, (1990); ZIZKOVA E., DOBREV P.I., MUHOVSKI Y., HOSEK P., HOYEROVA K., HAISEL D., PROCHAZKOVA D., LUTTS S., MOTYKA V., HICHRI I., TOMATO (SOLANUM LYCOPERSICUM L.) SLIPT3 AND SLIPT4 ISOPENTENYLTRANSFERASES MEDIATE SALT STRESS RESPONSE IN TOMATO, BMC PLANT BIOL, 15, (2015); ZUORRO A., LAVECCHIA R., MEDICI F., PIGA L., ENZYME-ASSISTED PRODUCTION OF TOMATO SEED OIL ENRICHED WITH LYCOPENE FROM TOMATO POMACE, FOOD BIOPROCESS TECHNOL, 6, PP. 3499-3509, (2013)","M.M. SAID; BIOCHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, AIN SHAMS UNIVERSITY, ABBASSIA, 11566, EGYPT; EMAIL: MAHMOUDMSAID@SCI.ASU.EDU.EG","TAYLOR AND FRANCIS LTD","ENGLISH","J. DIETARY SUPPL.","ARTICLE","ISI","2-S2.0-85040970077","J DIETARY SUPPL","AIN SHAMS UNIVERSITY;NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY (NCRRT);AIN SHAMS UNIVERSITY;NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY (NCRRT)","NOTREPORTED;AIN SHAMS UNIVERSITY;EMAIL: MAHMOUDMSAID@SCI.ASU.EDU.EG",NA,"EZZ MK, 2018, J DIETARY SUPPL","EZZ MK, 2018, J DIETARY SUPPL"
"BÉLIARD S;BONNET F;BOUHANICK B;BRUCKERT E;CARIOU B;CHARRIÈRE S;DURLACH V;MOULIN P;VALÉRO R;VERGÈS B","BÉLIARD, S. (15080605400); BONNET, F. (35394000800); BOUHANICK, B. (11440294400); BRUCKERT, E. (55539414500); CARIOU, B. (6602130037); CHARRIÈRE, S. (8935050000); DURLACH, V. (7003707674); MOULIN, P. (7102943887); VALÉRO, R. (7007008835); VERGÈS, B. (7004980109)","CONSENSUS STATEMENT ON THE MANAGEMENT OF DYSLIPIDAEMIAS IN ADULTS",2017,"ANNALES D'ENDOCRINOLOGIE","78","10",5,"10.1016/j.ando.2016.11.001","SERVICE DE NUTRITION, MALADIES MÉTABOLIQUES, ENDOCRINOLOGIE, HÔPITAL DE LA CONCEPTION, CHU DE MARSEILLE, AP–HM, MARSEILLE, 13009, FRANCE;SERVICE D'ENDOCRINOLOGIE-DIABÉTOLOGIE, INSERM U1018, UNIVERSITÉ RENNES 1, CHU DE RENNES, RENNES, FRANCE;PÔLE CVM, SERVICE D'HTA ET THÉRAPEUTIQUE, CHU RANGUEIL, UNIVERSITÉ DE TOULOUSE 3, TOULOUSE, 331059, FRANCE;SERVICE D'ENDOCRINOLOGIE, HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS, FRANCE;INSERM UMR 1087, CLINIQUE D'ENDOCRINOLOGIE, INSTITUT DU THORAX, UNIVERSITÉ DE NANTES, CHU DE NANTES, NANTES, 44000, FRANCE;FÉDÉRATION D'ENDOCRINOLOGIE, GHE, HCL, UNIVERSITÉ DE LYON 1, INSERM UMR 1060 CARMEN, LYON, 60003, FRANCE;PÔLE THORACIQUE CARDIOVASCULAIRE ET NEUROLOGIQUE, HÔPITAL ROBERT-DEBRÉ, REIMS, 51092, FRANCE;FÉDÉRATION D'ENDOCRINOLOGIE, GHE, HCL, UNIVERSITÉ DE LYON 1, INSERM UMR 1060 CARMEN, LYON, 60003, FRANCE;SERVICE DE NUTRITION, MALADIES MÉTABOLIQUES, ENDOCRINOLOGIE, HÔPITAL DE LA CONCEPTION, CHU DE MARSEILLE, AP–HM, MARSEILLE, 13009, FRANCE;PÔLE THORACIQUE CARDIOVASCULAIRE ET NEUROLOGIQUE, HÔPITAL ROBERT-DEBRÉ, REIMS, 51092, FRANCE, SERVICE D'ENDOCRINOLOGIE, DIABÉTOLOGIE ET MALADIES MÉTABOLIQUES, CHU DE DIJON, INSERM LNC UMR 866, UNIVERSITÉ BOURGOGNE FRANCHE-CONTÉ, DIJON, 21000, FRANCE","[NO ABSTRACT AVAILABLE]","CARDIOVASCULAR RISK; CONSENSUS STATEMENT; DYSLIPIDEMIA; FIBRATES; LDLC GOAL; STATINS","ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CONSENSUS; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DYSLIPIDEMIAS; ENDOCRINOLOGY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR DIAGNOSTIC TECHNIQUES; CHOLESTIN; MONOUNSATURATED FATTY ACID; PHYTOSTEROL; POLICOSANOL; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRANS FATTY ACID; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; AGE; ALCOHOL CONSUMPTION; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONSENSUS; CORONARY ANGIOGRAPHY; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; DYSLIPIDEMIA; FAMILY HISTORY; GENDER; GENOTYPE; HIGH FIBER DIET; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MYOCARDIAL PERFUSION IMAGING; PATIENT CARE; PHARMACOLOGIC STRESS TESTING; PRIMARY PREVENTION; PULSE WAVE; SECONDARY PREVENTION; STRESS ECHOCARDIOGRAPHY; TOBACCO USE; ADULT; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; CONSENSUS; DIAGNOSTIC IMAGING; DYSLIPIDEMIA; ENDOCRINE SYSTEM EXAMINATION; ENDOCRINOLOGY; MOLECULAR DIAGNOSIS; PRACTICE GUIDELINE; PROCEDURES; STANDARDS","","","CATAPANO A.L., REINER Z., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIAS THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), ATHEROSCLEROSIS, 217, PP. 3-46, (2011); PERK J., DE BACKER G., GOHLKE H., GRAHAM I., REINER Z., VERSCHUREN W.M., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL: THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), ATHEROSCLEROSIS, 223, PP. 1-68, (2012); EXPERT PANEL ON DYSLIPIDEMIA, AN INTERNATIONAL ATHEROSCLEROSIS SOCIETY POSITION PAPER: GLOBAL RECOMMENDATIONS FOR THE MANAGEMENT OF DYSLIPIDEMIA. EXECUTIVE SUMMARY, ATHEROSCLEROSIS, 232, PP. 410-413, (2014); PIEPOLI M.F., HOES A.W., AGEWALL S., ALBUS C., BROTONS C., CATAPANO A.L., ET AL., AUTHORS/TASK FORCE MEMBERS. 2016 EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: THE SIXTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF 10 SOCIETIES AND BY INVITED EXPERTS): DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), EUR HEART J, (2016); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., BAIREY MERZ C.N., BLUM C.B., ECKEL R.H., ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, 25 SUPPL. 2, PP. S49-S73, (2014); LLOYD-JONES D.M., MORRIS P.B., BALLANTYNE C.M., BIRTCHER K.K., DALY D.D., DEPALMA S.M., ET AL., ACC EXPERT CONSENSUS DECISION PATHWAY ON THE ROLE OF NON-STATIN THERAPIES FOR LDL-CHOLESTEROL LOWERING IN THE MANAGEMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK, J AM COLL CARDIOL, (2016); GUIDELINE DEVELOPMENT GROUP, LIPID MODIFICATION AND CARDIOVASCULAR RISK ASSESSMENT FOR THE PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: SUMMARY OF UPDATED NICE GUIDANCE, BMJ, 349, (2014); FARNIER M., BRUCKERT E., BOILEAU C., KREMPF M., NOUVELLE SOCIÉTÉ FRANÇAISE D'ATHÉROSCLÉROSE. DIAGNOSTIC AND TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA (FH) IN ADULTS: GUIDELINES FROM THE NEW FRENCH SOCIETY OF ATHEROSCLEROSIS (NSFA), PRESSE MED, 42, PP. 930-950, (2013); NORDESTGAARD B.G., CHAPMAN M.J., HUMPHRIES S.E., GINSBERG H.N., MASANA L., DESCAMPS O.S., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL. FAMILIAL HYPERCHOLESTEROLEMIA IS UNDERDIAGNOSED AND UNDERTREATED IN THE GENERAL POPULATION: GUIDANCE FOR CLINICIANS TO PREVENT CORONARY HEART DISEASE: CONSENSUS STATEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY, EUR HEART J, 34, PP. 3478-3490, (2013); WIEGMAN A., GIDDING S.S., WATTS G.F., CHAPMAN M.J., GINSBERG H.N., CUCHEL M., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR HEART J, 36, PP. 2425-2437, (2015); ADA POSITION STATEMENT CARDIOVASCULAR DISEASE AND RISK MANAGEMENT, DIABETES CARE, 38, PP. S49-S57, (2015); RYDEN L., GRANT P.J., ANKER S.D., BERNE C., COSENTINO F., DANCHIN N., ET AL., ESC GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES DEVELOPED IN COLLABORATION WITH THE EASD, EUR HEART J, 34, PP. 3035-3087, (2013); NORDESTGAARD B.G., LANGSTED A., MORA S., KOLOVOU G., BAUM H., BRUCKERT E., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) AND THE EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE (EFLM) JOINT CONSENSUS INITIATIVE. FASTING IS NOT ROUTINELY REQUIRED FOR DETERMINATION OF A LIPID PROFILE: CLINICAL AND LABORATORY IMPLICATIONS INCLUDING FLAGGING AT DESIRABLE CONCENTRATION CUT-POINTS – A JOINT CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, EUR HEART J, (2016); BREWER H.B., CLINICAL REVIEW: THE EVOLVING ROLE OF HDL IN THE TREATMENT OF HIGH RISK PATIENTS WITH CARDIOVASCULAR DISEASE, J CLIN ENDOCRINOL METAB, 96, PP. 1246-1257, (2011); RAMJEE V., SPERLING L.S., JACOBSON T.A., NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL VERSUS APOLIPOPROTEIN B IN CARDIOVASCULAR RISK STRATIFICATION: DO THE MATH, J AM COLL CARDIOL, 58, PP. 457-463, (2011); NORDESTGAARD B.G., LIPOPROTEIN(A) AS A CARDIOVASCULAR RISK FACTOR: CURRENT STATUS, EUR HEART J, 31, PP. 2844-2853, (2010); SHAH T., CASAS J.P., COOPER J.A., TZOULAKI I., SOFAT R., MCCORMACK V., ET AL., CRITICAL APPRAISAL OF CRP MEASUREMENT FOR THE PREDICTION OF CORONARY HEART DISEASE EVENTS: NEW DATA AND SYSTEMATIC REVIEW OF 31 PROSPECTIVE COHORTS, INT J EPIDEMIOL, 38, PP. 217-231, (2009); THOMPSON A., GAO P., ORFEI L., WATSON S., DI ANGELANTONIO E., KAPTOGE S., ET AL., LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2) AND RISK OF CORONARY DISEASE, STROKE, AND MORTALITY: COLLABORATIVE ANALYSIS OF 32 PROSPECTIVE STUDIES, LANCET, 375, PP. 1536-1544, (2010); PAYNTER N.P., CHASMAN D.I., PARE G., BURING J.E., COOK N.R., MILETICH J.P., ET AL., ASSOCIATION BETWEEN A LITERATURE-BASED GENETIC RISK SCORE AND CARDIOVASCULAR EVENTS IN WOMEN, JAMA, 303, PP. 631-637, (2010); TADA H., MELANDER O., LOUIE J.Z., TANESE J.J., ROWLAND C.M., DEVLIN J.J., ET AL., RISK PREDICTION BY GENETIC RISK SCORES FOR CORONARY HEART DISEASE IS INDEPENDENT OF SELF-REPORTED FAMILY HISTORY, EUR HEART J, 37, PP. 561-567, (2016); GREENLAND P., ALPERT J.S., BELLER G.A., BENJAMIN E.J., BUDOFF M.J., FAYAD Z.A., ET AL., AMERICAN HEART ASSOCIATION. 2010 ACCF/AHA GUIDELINE FOR ASSESSMENT OF CARDIOVASCULAR RISK IN ASYMPTOMATIC ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, 56, PP. E50-E103, (2010); MANCIA G., FAGARD R., NARKIEWICZ K., REDON J., ZANCHETTI A., BOHM M., ET AL., ESH/ESC GUIDELINES FOR THE MANAGEMENT OF HYPERTENSION, J HYPERTENS, 31, PP. 1281-1357, (2013); KAVOUSI M., ELIAS-SMALE S., RUTTEN J.H., LEENING M.J., VLIEGENTHART R., VERWOERT G.C., ET AL., EVALUATION OF NEWER RISK MARKERS FOR CORONARY HEART DISEASE RISK CLASSIFICATION: A COHORT STUDY, ANN INTERN MED, 156, PP. 438-444, (2012); YEBOAH J., YOUNG R., MCCLELLAND R.L., DELANEY J.C., POLONSKY T.S., DAWOOD F.Z., ET AL., UTILITY OF NON-TRADITIONAL RISK MARKERS IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK ASSESSMENT, J AM COLL CARDIOL, 67, PP. 139-147, (2016); DEGOMA E.M., DUNBAR R.L., JACOBY D., FRENCH B., DIFFERENCES IN ABSOLUTE RISK OFCARDIOVASCULAR EVENTS USING RISK-REFINEMENT TESTS: A SYSTEMATIC ANALYSIS OF FOUR CARDIOVASCULAR RISK EQUATIONS, ATHEROSCLEROSIS, 227, PP. 172-177, (2013); INABA Y., CHEN J.A., BERGMANN S.R., CAROTID PLAQUE, COMPARED WITH CAROTID INTIMA MEDIA THICKNESS, MORE ACCURATELY PREDICTS CORONARY ARTERY DISEASE EVENTS: A META-ANALYSIS, ATHEROSCLEROSIS, 220, PP. 128-133, (2012); BROTT T.G., HALPERIN J.L., ABBARA S., BACHARACH J.M., BARR J.D., BUSH R.L., ET AL., ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS GUIDELINE ON THE MANAGEMENT OF PATIENTS WITH EXTRACRANIAL CAROTID AND VERTEBRAL ARTERY DISEASE: EXECUTIVE SUMMARY, CIRCULATION, 124, PP. 489-532, (2011); ROBERTS E.T., HORNE A., MARTIN S.S., ET AL., COST-EFFECTIVENESS OF CORONARY ARTERY CALCIUM TESTING FOR CORONARY HEART AND CARDIOVASCULAR DISEASE RISK PREDICTION TO GUIDE STATIN ALLOCATION: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), PLOS ONE, 10, (2015); MONTALESCOT G., SECHTEM U., ACHENBACH S., ET AL., 2013 ESC GUIDELINES ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE: THE TASK FORCE ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUR HEART J, 34, PP. 2949-3003, (2013); MENTE A., DE KONING L., SHANNON H.S., ANAND S.S., A SYSTEMATIC REVIEW OF THE EVIDENCE SUPPORTING A CAUSAL LINK BETWEEN DIETARY FACTORS AND CORONARY HEART DISEASE, ARCH INTERN MED, 169, PP. 659-669, (2009); HU F., WILLETT W.C., OPTIMAL DIETS FOR PREVENTION OF CORONARY HEART DISEASE, JAMA, 288, PP. 2569-2578, (2002); SPRING B., MOLLER A.C., COLANGELO L.A., SIDDIQUE J., ROEHRIG M., DAVIGLUS M.L., ET AL., HEALTHY LIFESTYLE CHANGE AND SUBCLINICAL ATHEROSCLEROSIS IN YOUNG ADULTS: CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY, CIRCULATION, 130, PP. 10-17, (2014); ESTRUCH R., ROS E., SALAS-SALVADO J., COVAS M.I., CORELLA D., AROS F., ET AL., PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE WITH A MEDITERRANEAN DIET, N ENGL J MED, 168, PP. 1279-1990, (2013); ASTRUP A., DYERBERG J., ELWOOD P., HERMANSEN K., HU F.B., JAKOBSEN M.U., ET AL., THE ROLE OF REDUCING INTAKES OF SATURATED FAT IN THE PREVENTION OF CARDIOVASCULAR DISEASE: WHERE DOES THE EVIDENCE STAND IN 2010?, AM J CLIN NUTR, 93, PP. 684-688, (2011); SIRI TARINO P.W., SUN Q., HU F.B., KRAUSS R.M., META-ANALYSIS OF PROSPECTIVE COHORT STUDIES EVALUATING THE ASSOCIATION OF SATURATED FAT WITH CARDIOVASCULAR DISEASE, AM J CLIN NUTR, 91, PP. 535-546, (2010); AL-KHUDAIRY L., HARTLEY L., CLAR C., FLOWERS N., HOOPER L., REES K., OMEGA-6 FATTY ACIDS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 11, (2015); MOZAFFARIAN D., KATAN M.B., ASCHERIO A., STAMPFER M.J., WILLETT W.C., TRANS FATTY ACIDS AND CARDIOVASCULAR DISEASE, N ENGL J MED, 354, PP. 1601-1613, (2006); HARRIS W.S., MOZAFFARIAN D., RIMM E., KRIS-ETHERTON P., RUDEL L.L., APPEL L.J., ET AL., OMEGA-6 FATTY ACIDS AND RISK FOR CARDIOVASCULAR DISEASE: A SCIENCE ADVISORY FROM THE AMERICAN HEART ASSOCIATION NUTRITION SUBCOMMITTEE OF THE COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM; COUNCIL ON CARDIOVASCULAR NURSING; AND COUNCIL ON EPIDEMIOLOGY AND PREVENTION, CIRCULATION, 119, PP. 902-907, (2009); RIZOS E.C., NTZANI E.E., BIKA E., KOSTAPANOS M.S., ELISAF M.S., ASSOCIATION BETWEEN Ω-3 FATTY ACID SUPPLEMENTATION AND RISK OF MAJOR CARDIOVASCULAR DISEASE EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 308, PP. 1024-1033, (2012); HARTLEY L., MAY M.D., LOVEMAN E., COLQUITT J.L., REES K., DIETARY FIBRE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 1, (2016); DAUCHET L., AMOUYEL P., HERCBERG S., DALLONGEVILLE J., FRUIT AND VEGETABLE CONSUMPTION AND RISK OF CORONARY HEART DISEASE: A META-ANALYSIS OF COHORT STUDIES, J NUTR, 136, PP. 2588-2593, (2006); RIMM E.B., WILLIAMS P., FOSHER K., CRIQUI M., STAMPFER M.J., MODERATE ALCOHOL INTAKE AND LOWER RISK OF CORONARY HEART DISEASE: META-ANALYSIS OF EFFECTS ON LIPIDS AND HAEMOSTATIC FACTORS, BMJ, 319, PP. 1523152-1523158, (1999); ZHENG Y.L., LIAN F., SHI Q., ZHANG C., CHEN Y.W., ZHOU Y.H., ET AL., ALCOHOL INTAKE AND ASSOCIATED RISK OF MAJOR CARDIOVASCULAR OUTCOMES IN WOMEN COMPARED WITH MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDIES, BMC PUBLIC HEALTH, 15, PP. 773-779, (2015); DE JONG A., PLAT J., BAST A., GODSCHALK R.W., BASU S., MENSINK R.P., EFFECTS OF PLANT STEROL AND STANOL ESTER CONSUMPTION ON LIPID METABOLISM, ANTIOXIDANT STATUS AND MARKERS OF OXIDATIVE STRESS, ENDOTHELIAL FUNCTION AND LOW-GRADE INFLAMMATION IN PATIENTS ON CURRENT STATIN TREATMENT, EUR J CLIN NUTR, 62, PP. 263-273, (2008); BARD J.M., PAILLARD F., LECERF J.M., EFFECT OF PHYTOSTEROLS/STANOLS ON LDL CONCENTRATION AND OTHER SURROGATE MARKERS OF CARDIOVASCULAR RISK, DIABETES METAB, 41, PP. 69-75, (2015); VERGES B., FUMERON F., POTENTIAL RISKS ASSOCIATED WITH INCREASED PLASMA PLANT STEROL LEVELS, DIABETES METAB, 41, PP. 76-81, (2015); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); HEGELE R.A., GINSBERG H.N., CHAPMAN M.J., NORDESTGAARD B.G., KUIVENHOVEN J.A., AVERNA M., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL. THE POLYGENIC NATURE OF HYPERTRIGLYCERIDEMIA: IMPLICATIONS FOR DEFINITION, DIAGNOSIS, AND MANAGEMENT, LANCET DIABETES ENDOCRINOL, 2, PP. 655-666, (2014); STROES E.S., THOMPSON P.D., CORSINI A., VLADUTIU G.D., RAAL F.J., RAY K.K., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL. STATIN-ASSOCIATED MUSCLE SYMPTOMS:IMPACT ON STATIN THERAPY-EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR HEART J, 36, PP. 1012-1022, (2015); YUSUF S., BOSCH J., DAGENAIS G., ZHU J., XAVIER D., LIU L., ET AL., CHOLESTEROL LOWERING IN INTERMEDIATE-RISK PERSONS WITHOUT CARDIOVASCULAR DISEASE, N ENGL J MED, (2016); YUSUF S., LONN E., PAIS P., BOSCH J., LOPEZ-JARAMILLO P., ZHU J., ET AL., BLOOD-PRESSURE AND CHOLESTEROL LOWERING IN PERSONS WITHOUT CARDIOVASCULAR DISEASE, N ENGL J MED, (2016); HOKANSON J.E., AUSTIN M.A., PLASMA TRIGLYCERIDE LEVEL IS A RISK FACTOR FOR CARDIOVASCULAR DISEASE INDEPENDENT OF HIGH- DENSITY LIPOPROTEIN CHOLESTEROL LEVEL: A META-ANALYSIS OF POPULATION-BASED PROSPECTIVE STUDIES, J CARDIOVASC RISK, 3, PP. 213-219, (1996); SARWAR N., DANESH J., EIRIKSDOTTIR G., SIGURDSSON G., WAREHAM N., BINGHAM S., ET AL., TRIGLYCERIDES AND THE RISK OF CORONARY HEART DISEASE: 10,158 INCIDENT CASES AMONG 262,525 PARTICIPANTS IN 29 WESTERN PROSPECTIVE STUDIES, CIRCULATION, 115, PP. 450-458, (2007); TIROSH A., RUDICH A., SHOCHAT T., TEKES-MANOVA D., ISRAELI E., HENKIN Y., ET AL., CHANGES IN TRIGLYCERIDE LEVELS AND RISK FOR CORONARY HEART DISEASE IN YOUNG MEN, ANN INTERN MED, 147, PP. 377-385, (2007); CHAPMAN M.J., GINSBERG H.N., AMARENCO P., ANDREOTTI F., BOREN J., CATAPANO A.L., ET AL., 2013 ACC/AHA GUIDELINE ON THE ASSESSMENT. TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR RISK: A REPORT DISEASE: EVIDENCE AND GUIDANCE FOR MANAGEMENT, EUR HEART J, 32, PP. 1345-1361, (2011); MILLER M., STONE N.J., BALLANTYNE C., BITTNER V., CRIQUI M.H., GINSBERG H.N., ET AL., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 2292-2333, (2011); BERGLUND L., BRUNZEL J.D., GOLDBERG A.V., GOLDBERG I.J., SACKS F., MURAD M.H., ET AL., EVALUATION AND TREATMENT OF HYPERTRIGLYCERIDEMIA: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE, J CLIN ENDOCRINOL METAB, 97, PP. 2969-2989, (2012); REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIAS: THE AMERICAN COLLEGETASK FORCE FOR THE MANAGEMENT OF DYSLIPIDEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES. CIRCULATION 2014;129:S49–73. (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); RABAR S., HARKER M., O'FLYNN N., WIERZBICKI A.S., LIPID MODIFICATION AND CARDIOVASCULAR RISK ASSESSMENT FOR THE PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: SUMMARY OF UPDATED NICE GUIDANCE, BMJ, 349, (2014); THE FIELD STUDY INVESTIGATORS, EFFECTS OF LONG-TERM FENOFIBRATE THERAPY ON CARDIOVASCULAR EVENTS IN 9795 PEOPLE WITH TYPE 2 DIABETES MELLITUS (THE FIELD STUDY): RANDOMISED CONTROLLED TRIAL, LANCET, 366, PP. 1849-1861, (2005); SACKS F.M., CAREY V.J., FRUCHART J.C., COMBINATION LIPID THERAPY IN TYPE 2 DIABETES, N ENGL J MED, 363, PP. 692-694, (2010); GINSBERG H.N., ELAM M.B., LOVATO L.C., CROUSE J.R., LEITER L.A., LINZ P., ET AL., EFFECTS OF COMBINATION LIPID THERAPY IN TYPE 2 DIABETES MELLITUS, N ENGL J MED, 362, PP. 1563-1574, (2010); BERGLUND L., BRUNZELL J.D., GOLDBERG A.C., GOLDBERG I.J., STALENHOEF A., TREATMENT OPTIONS FOR HYPERTRIGLYCERIDEMIA: FROM RISK REDUCTION TO PANCREATITIS, BEST PRACT RES CLIN ENDOCRINOL METAB, 28, PP. 423-437, (2014); KOREN M.J., HUNNINGHAKE D.B., INVESTIGATORS A., CLINICAL OUTCOMES IN MANAGED-CARE PATIENTS WITH CORONARY HEART DISEASE TREATED AGGRESSIVELY IN LIPID-LOWERING DISEASE MANAGEMENT CLINICS: THE ALLIANCE STUDY, J AM COLL CARDIOL, 44, PP. 1772-1779, (2004); CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATION, BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL-CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); ARMITAGE J., BOWMAN L., WALLENDSZUS K., ARMITAGE J., BOWMAN L., WALLENDSZUS K., ET AL., STUDY OF THE EFFECTIVENESS OF ADDITIONAL REDUCTIONS IN CHOLESTEROL AND HOMOCYSTEINE (SEARCH) INTENSIVE LOWERING OF LDL-CHOLESTEROL WITH 80 MG VERSUS 20 MG SIMVASTATIN DAILY IN 12,064 SURVIVORS OF MYOCARDIAL INFARCTION: A DOUBLE-BLIND RANDOMISED TRIAL, LANCET, 376, PP. 1658-1669, (2010); DE LEMOS J.A., BLAZING M.A., WIVIOTT S.D., LEWIS E.F., FOX K.A., WHITE H.D., ET AL., EARLY INTENSIVE VS A DELAYED CONSERVATIVE SIMVASTATIN STRATEGY IN PATIENTS WITH ACUTE CORONARY SYNDROMES: PHASE Z OF THE A TO Z TRIAL, JAMA, 292, PP. 1307-1316, (2004); LAROSA J.C., GRUNDY S.M., WATERS D.D., SHEAR C., BARTER P., FRUCHART J.C., ET AL., INTENSIVE LIPID LOWERING WITH ATORVASTATIN IN PATIENTS WITH STABLE CORONARY DISEASE, N ENGL J MED, 352, PP. 1425-1435, (2005); PEDERSEN T.R., CATER N.B., FAERGEMAN O., KASTELEIN J.J., OLSSON A.G., TIKKANEN M.J., ET AL., COMPARISON OF ATORVASTATIN 80 MG/DAY VERSUS SIMVASTATIN 20 TO 40 MG/DAY ON FREQUENCY OF CARDIOVASCULAR EVENTS LATE (FIVE YEARS) AFTER ACUTE MYOCARDIAL INFARCTION (FROM THE INCREMENTAL DECREASE IN END POINTS THROUGH AGGRESSIVE LIPID LOWERING IDEAL TRIAL), AM J CARDIOL, 106, PP. 354-359, (2010); CANNON C.P., BRAUNWALD E., MCCABE C.H., RADER D.J., ROULEAU J.L., BELDER R., ET AL., INTENSIVE VERSUS MODERATE LIPID LOWERING WITH STATINS AFTER ACUTE CORONARY SYNDROMES, N ENGL J MED, 350, PP. 1495-1504, (2004); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., MCCAGG A., WHITE J.A., THEROUX P., ET AL., EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, N ENGL J MED, 372, PP. 2387-2397, (2015); CANNON C.P., STEINBERG B.A., MURPHY S.A., MEGA J.L., BRAUNWALD E., META-ANALYSIS OF CARDIOVASCULAR OUTCOMES TRIALS COMPARING INTENSIVE VERSUS MODERATE STATIN THERAPY, J AM COLL CARDIOL, 48, PP. 438-445, (2006); JOSAN K., MAJUMDAR S.R., MCALISTER F.A., THE EFFICACY AND SAFETY OF INTENSIVE STATIN THERAPY: A META-ANALYSIS OF RANDOMIZED TRIALS, CMAJ, 178, PP. 576-584, (2008); SPECTOR R., SNAPINN S.M., STATINS FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: THE RIGHT DOSE, PHARMACOLOGY, 87, PP. 63-69, (2011); RUBINS H.B., ROBINS S.J., COLLINS D., FYE C.L., ANDERSON J.W., ELAM M.B., ET AL., GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL. VETERANS AFFAIRS HIGH-DENSITY LIPOPROTEIN, CHOLESTEROL INTERVENTION TRIAL STUDY GROUP, N ENGL J MED, 341, PP. 410-418, (1999); FRICK M.H., ELO O., HAAPA K., HEINONEN O.P., HEINSALMI P., HELO P., ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA – SAFETY TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); CORTI M.C., GURALNIK J.M., SALIVE M.E., HARRIS T., FERRUCCI L., GLYNN R.J., ET AL., CLARIFYING THE DIRECT RELATION BETWEEN TOTAL CHOLESTEROL LEVELS AND DEATH FROM CORONARY HEART DISEASE IN OLDER PERSONS, ANN INTERN MED, 126, PP. 753-760, (1997); RUBIN S.M., SIDNEY S., BLACK D.M., BROWNER W.S., HULLEY S.B., CUMMINGS S.R., HIGH BLOOD CHOLESTEROL IN ELDERLY MEN AND THE EXCESS RISK FOR CORONARY HEART DISEASE, ANN INTERN MED, 113, PP. 916-920, (1990); HOUTERMAN S., VERSCHUREN W.M., HOFMAN A., WITTEMAN J.C., SERUM CHOLESTEROL IS A RISK FACTOR FOR MYOCARDIAL INFARCTION IN ELDERLY MEN AND WOMEN: THE ROTTERDAM STUDY, J INTERN MED, 246, PP. 25-33, (1999); SIMONS L.A., FRIEDLANDER Y., MCCALLUM J., SIMONS J., RISK FACTORS FOR CORONARY HEART DISEASE IN THE PROSPECTIVE DUBBO STUDY OF AUSTRALIAN ELDERLY, ATHEROSCLEROSIS, 117, PP. 107-118, (1995); BAIGENT C., KEECH A., KEARNEY P.M., BLACKWELL L., BUCK G., POLLICINO C., ET AL., CHOLESTEROL TREATMENT TRIALISTS’ (CTT) COLLABORATORS. EFFICACY AND SAFETY OF CHOLESTEROL LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); BRUGTS J.J., YETGIN T., HOEKS S.E., GOTTO A.M., SHEPHERD J., WESTENDORP R.G., ET AL., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS: META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 338, (2009); SHEPHERD J., BLAUW G.J., MURPHY M.B., BOLLEN E.L., BUCKLEY B.M., COBBE S.M., ET AL., PROSPECTIVE STUDY OF PRAVASTATIN IN THE ELDERLY AT RISK. PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED TRIAL, LANCET, 360, PP. 1623-1630, (2002)","P. MOULIN; FÉDÉRATION D'ENDOCRINOLOGIE, LYON, HÔPITAL CARDIOVASCULAIRE LOUIS-PRADEL, GHE, BOULEVARD PINEL, 60003, FRANCE; EMAIL: PHILIPPE.MOULIN@CHU-LYON.FR","ELSEVIER MASSON SAS","ENGLISH","ANN. ENDOCRINOL.","ARTICLE","ISI","2-S2.0-85009724703","ANN ENDOCRINOL","CHU DE NANTES;FRANCE","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"BÉLIARD S, 2017, ANN ENDOCRINOL","BÉLIARD S, 2017, ANN ENDOCRINOL"
"LEE J;CHOI H;KANG Y;CHANG H;CHUN H;LEE M;KWON Y","LEE, JUNG-YUN (57203144320); CHOI, HWANG-YONG (56599405900); KANG, YU-RI (56645417000); CHANG, HUNG-BAE (57189899272); CHUN, HYOUNG-SIK (58434455500); LEE, MEE-SOOK (37022732600); KWON, YOUNG-IN (8647925900)","EFFECTS OF LONGTERM SUPPLEMENTATION OF POLICOSANOL ON BLOOD CHOLESTEROLGLUCOSE LEVELS AND 3HYDROXY3METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY IN A RAT MODEL FED HIGH CHOLESTEROL DIETS",2016,"FOOD SCIENCE AND BIOTECHNOLOGY","25","5",13,"10.1007/s10068-016-0147-y","DEPARTMENT OF FOOD AND NUTRITION, HANNAM UNIVERSITY, DAEJEON, 34054, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, HANNAM UNIVERSITY, DAEJEON, 34054, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, HANNAM UNIVERSITY, DAEJEON, 34054, SOUTH KOREA;DEPARTMENT OF BIO QUALITY CONTROL, KOREA BIO POLYTECHNIC, NONSAN, CHUNGNAM, 32943, SOUTH KOREA;DEPARTMENT OF BIO QUALITY CONTROL, KOREA BIO POLYTECHNIC, NONSAN, CHUNGNAM, 32943, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, HANNAM UNIVERSITY, DAEJEON, 34054, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, HANNAM UNIVERSITY, DAEJEON, 34054, SOUTH KOREA","POLICOSANOL IS A WELL-DEFINED NUTRACEUTICAL FOR THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS. THE PRESENT STUDY EXAMINED (I) THE EFFECT OF POLICOSANOL SUPPLEMENTATION ON BLOOD CHOLESTEROL AND GLUCOSE LEVELS AND (II) CHANGES IN HEPATIC CHOLESTEROL BIOSYNTHESIS USING 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (HMG-COA REDUCTASE) ACTIVITY IN WISTAR RATS FED HIGH CHOLESTEROL DIETS. THE WISTAR RATS WERE ASSIGNED RANDOMLY TO HIGH-CHOLESTEROL DIETS (1.25% CHOLESTEROL) WITH OR WITHOUT POLICOSANOL (8.0 MG/KG BODY WEIGHT) FOR 6 WEEKS. COMPARED WITH THE CONTROL GROUP, DIETARY TREATMENT WITH POLICOSANOL RESULTED IN A SIGNIFICANT DECREASE OF BLOOD CHOLESTEROL (P<0.01), BLOOD GLUCOSE (P<0.01), TRIGLYCERIDE (P<0.001), AND LOW DENSITY LIPOPROTEIN-CHOLESTEROL LEVELS (P<0.01) AND HMG-COA REDUCTASE ACTIVITY (P<0.001) IN THE LIVER. THESE RESULTS INDICATE THAT POLICOSANOL DECREASES BLOOD CHOLESTEROL LEVELS BY SUPPRESSING CHOLESTEROL BIOSYNTHESIS VIA DECREASE OF HMG-COA ACTIVITY. POLICOSANOL HAS THE POTENTIAL TO BE DEVELOPED INTO AN EFFECTIVE DIETARY STRATEGY FOR BOTH POSTPRANDIAL HYPERGLYCEMIA AND HYPERCHOLESTEROLEMIA. © 2016, THE KOREAN SOCIETY OF FOOD SCIENCE AND TECHNOLOGY AND SPRINGER SCIENCE+BUSINESS MEDIA DORDRECHT.","BLOOD GLUCOSE; HMG-COA REDUCTASE; HYPERCHOLESTEROLEMIA; LOW DENSITY LIPOPROTEIN-CHOLESTEROL; POLICOSANOL","BIOCHEMISTRY; BIOSYNTHESIS; BLOOD; GLUCOSE; LIPOPROTEINS; RATS; BLOOD GLUCOSE; HMG-COA REDUCTASE; HYPERCHOLESTEROLEMIA; LOW DENSITY LIPOPROTEINS; POLICOSANOL; CHOLESTEROL","","","MOZAFFARIAN D., BENJAMIN E.J., GO A.S., ARNETT D.K., BLAHA M.J., CUSHMAN M., DE FERRANTI S., DESPRES J.P., FULLERTON H.J., HOWARD V.J., HUFFMAN M.D., JUDD S.E., KISSELA B.M., LACKLAND D.T., LICHTMAN J.H., LISABETH L.D., LIU S., MACKEY R.H., MATCHAR D.B., MCGUIRE D.K., MOHLER E.R., MOY C.S., MUNTNER P., MUSSOLINO M.E., NASIR K., NEUMAR R.W., NICHOL G., PALANIAPPAN L., PANDEY D.K., REEVES M.J., RODRIGUEZ C.J., SORLIE P.D., STEIN J., TOWFIGHI A., TURAN T.N., VIRANI S.S., WILLEY J.Z., WOO D., YEH R.W., TURNER M.B., AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE. HEART DISEASE AND STROKE STATISTICS-2015 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 131, PP. E29-E322, (2014); LIOYD-JONES D.M., HONG Y., LABARTHE D., MOZAFFARIAN D., APPEL L.J., VAN HORN L., GREENLUND K., DANIELS S., NICHOL G., TOMASELLI G.F., ARNETT D.K., FONAROW G.C., HO P.M., LAUER M.S., MASOUDI F.A., ROBERTSON R.M., ROGER V., SCHWAMM L.H., SORLIE P., YANCY C.W., ROSAMOND W.D., DEFINING AND SETTING NATIONAL GOALS FOR CARDIOVASCULAR HEALTH PROMOTION AND DISEASE REDUCTION: THE AMERICAN HEART ASSOCIATION’S STRATEGIC IMPACT GOAL THROUGH 2020 AND BEYOND, CIRCULATION, 121, PP. 568-613, (2010); GRUNDY S.M., HMG-COA REDUCTASE INHIBITORS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, NEW ENGL. J. MED., 319, PP. 24-32, (1988); ENDO A., THE DISCOVERY AND DEVELOPMENT OF HMG-COA REDUCTASE INHIBITORS, J. LIPID RES., 33, PP. 1569-1582, (1992); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-573, (1992); MENEDEZ R., ARRUZARABALA L., MAS R., DEL RIO A., AMOR A., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, PP. 923-932, (1997); YANAI H., KATSUYAMA H., HAMASAKI H., ABE S., TADA N., SAKO A., EFFECTS OF DIETARY FAT INTAKE ON HDL METABOLISM, J. CLIN. MED. RES., 7, PP. 145-149, (2015); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); SINGH D.K., POSTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER., 318, PP. 1020-1026, (2006); BEG Z.H., STONIK J.A., BREWER H.B., 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A REDUCTASE: REGULATION OF ENZYMATIC ACTIVITY BY PHOSPHORYLATION AND DEPHOSPHORYLATION, P. NATL. ACAD. SCI. USA, 75, PP. 3678-3682, (1978); MENENDEZ R., AMOR A.M., CONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL. RES., 29, PP. 253-257, (1996); OLIARO-BOSSO S., CALCIO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMG-COA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); SHAW R.J., LAMIA K.A., VASQUEZ D., KOO S.H., BARDEESY N., DEPINHO R.A., MONTMINY M., CANTLEY L.C., THE KINASE LKB1 MEDIATES GLUCOSE HOMEOSTASIS IN LIVER AND THERAPEUTIC EFFECTS OF METFORMIN, SCIENCE, 310, PP. 1642-1646, (2005); TOWLER M.C., HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE IN METABOLIC CONTROL AND INSULIN SIGNALING, CIRC. RES., 100, PP. 328-341, (2007); BANERJEE S., GHOSHAL S., PORTER D.T., PHOSPHORYLATION OF HEPATIC AMP-ACTIVATED PROTEIN KINASE AND LIVER KINASE B1 IS INCREASED AFTER A SINGLE ORAL DOSE OF GREEN TEA EXTRACT TO MICE, NUTR. RES., 32, PP. 985-990, (2012); XIE Z., DONG R., SCHOLZ D., NEUMANN M., ZOU H., PHOSPHORYLATION OF LKB1 AT SERINE 428 BY PROTEIN KINASE C-ZETA IS REQUIRED FOR METFORMIN-ENHANCED ACTIVATION OF THE AMP-ACTIVATED PROTEIN KINASE IN ENDOTHELIAL CELLS, CIRCULATION, 117, PP. 952-962, (2008); ZATARA G., BAR-TANA J., KALDERON B., SUTER M., MORAD E., SAMOVSKI D., NEUMANN D., HERTZ R., AMPK ACTIVATION BY LONG CHAIN FATTY ACYL ANALOGS, BIOCHEM. PHARMACOL., 76, PP. 1263-1275, (2008); RENU A., SHREWSBURY A.M., 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE FROM RAT LIVER, J. BIOL. CHEM., 251, PP. 3815-3822, (1976); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); CASTANO G., FERNADEZ L., MAS R., IIINAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN. DRUG INVEST., 23, PP. 639-650, (2003); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT. J. CLIN. PHARM. RES., 21, PP. 43-57, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); HEINER K.B., SUSANNE U., RALF D., MICHAEL B.D., IOANNA G.B., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA-J. AM. MED. ASSOC., 295, PP. 2262-2269, (2006); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARM. RES., 14, PP. 27-33, (1994); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F.C., GMETA-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); BARRAT E., ZAIR Y., SIRVENT P., CHAUVEAU P., MAUDET C., HOUSEZ B., DERBORD E., LESCUYER J.F., BARD J.M., CAZAUBIEL M., PELTIER S.L., EFFECT ON LDL-CHOLESTEROL OF A LARGE DOSE OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH UNTREATED MODERATE HYPERCHOLESTEROLAEMIA: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EUR. J. NUTR., 52, PP. 1843-1852, (2013); OGIER N., AMIOT M.J., GEORGE S., MAILLOT M., MALLMANN C., MARANINCHI M., MORANGE S., LESCUYER J.F., PELTIER S.L., CARDINAULT N., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR. J. NUTR., 52, PP. 547-557, (2013); LI Q., THOMSON A.B., CLANDININ M.T., CHOLESTEROL ESTER AND FREE FATTY ACIDS ARE MODULATED BY POLICOSANOL IN CACO-2 INTESTINAL CELL, J. AM. COLL. NUTR., 30, PP. 201-209, (2011); CHI H.N., KA Y.L., YU H., ZHEN Y.C., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASE EXCRETION OF BILE ACIDS IN HAMSTERS, J. AGR. FOOD CHEM., 53, PP. 6289-6293, (2005)","Y.-I. KWON; DEPARTMENT OF FOOD AND NUTRITION, HANNAM UNIVERSITY, DAEJEON, 34054, SOUTH KOREA; EMAIL: YOUNGK@HNU.KR","KLUWER ACADEMIC PUBLISHERS","ENGLISH","FOOD SCI. BIOTECHNOL.","ARTICLE","ISI","2-S2.0-84975815564","FOOD SCI BIOTECHNOL","HANNAM UNIVERSITY;HANNAM UNIVERSITY;HANNAM UNIVERSITY;KOREA BIO POLYTECHNIC;KOREA BIO POLYTECHNIC;HANNAM UNIVERSITY;HANNAM UNIVERSITY","NOTREPORTED;HANNAM UNIVERSITY;NOTREPORTED",NA,"LEE J-Y, 2016, FOOD SCI BIOTECHNOL","LEE J-Y, 2016, FOOD SCI BIOTECHNOL"
"WARD N;PANG J;RYAN J;WATTS G","WARD, NATALIE C. (56782965900); PANG, JING (55218561500); RYAN, JACQUELINE D.M. (56834958200); WATTS, GERALD F. (7202153447)","NUTRACEUTICALS IN THE MANAGEMENT OF PATIENTS WITH STATINASSOCIATED MUSCLE SYMPTOMS WITH A NOTE ON REALWORLD EXPERIENCE",2018,"CLINICAL CARDIOLOGY","41","6",25,"10.1002/clc.22862","SCHOOL OF MEDICINE, FACULTY OF HEALTH & MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA, SCHOOL OF BIOMEDICAL SCIENCES AND CURTIN HEALTH INNOVATION RESEARCH INSTITUTE, PERTH, AUSTRALIA;SCHOOL OF MEDICINE, FACULTY OF HEALTH & MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA, LIPID DISORDERS CLINIC, DEPARTMENT OF CARDIOLOGY, ROYAL PERTH HOSPITAL, PERTH, AUSTRALIA;SCHOOL OF MEDICINE, FACULTY OF HEALTH & MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA, PERTH LIPID CLINIC, PRIMARY CARE, PERTH, AUSTRALIA;SCHOOL OF MEDICINE, FACULTY OF HEALTH & MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA, LIPID DISORDERS CLINIC, DEPARTMENT OF CARDIOLOGY, ROYAL PERTH HOSPITAL, PERTH, AUSTRALIA","THERE IS CONSIDERABLE EVIDENCE FOR THE ROLE OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN THE DEVELOPMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. ALTHOUGH STATIN THERAPY REMAINS THE MOST FREQUENCY PRESCRIBED MEDICATION TO REDUCE LDL-C AND LOWER RISK OF CARDIOVASCULAR DISEASE, A CONSIDERABLE NUMBER OF PATIENTS DEVELOP MUSCLE-RELATED SIDE AFFECTS. THIS REVIEW SUMMARIZES RECENT LITERATURE SUPPORTING THE ROLE OF NUTRACEUTICALS AS LDL-C–LOWERING THERAPY IN STATIN-INTOLERANT PATIENTS, WITH EVIDENCE FROM OUR OWN CLINICAL PRACTICES. © 2018 WILEY PERIODICALS, INC.","LOW-DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICALS; SAMS; STATIN MYOPATHY","CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DISEASE MANAGEMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES; ANTHOCYANIN; BERBERINE; CARNITINE; CHOLESTIN; CURCUMINOID; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; PHYTOSTEROL; POLICOSANOL; POLYPHENOL DERIVATIVE; RESVERATROL; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN D; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CLINICAL PRACTICE; DIET THERAPY; DIETARY SUPPLEMENT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FAMILIAL HYPERLIPEMIA; HUMAN; MUSCLE RIGIDITY; MYALGIA; MYOPATHY; NOCICEPTION; REVIEW; STATIN ASSOCIATED MUSCLE SYMPTOM; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DIETARY SUPPLEMENT; DISEASE MANAGEMENT; DRUG EFFECT; MUSCLE DISEASE; SKELETAL MUSCLE","","","FERENCE B.A., GINSBERG H.N., GRAHAM I., ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR HEART J., 38, PP. 2459-2472, (2017); CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR HEART J., 37, PP. 2999-3058, (2016); SIMIC I., REINER Z., ADVERSE EFFECTS OF STATINS—MYTHS AND REALITY, CURR PHARM DES., 21, PP. 1220-1226, (2015); REINER Z., RESISTANCE AND INTOLERANCE TO STATINS, NUTR METAB CARDIOVASC DIS., 24, PP. 1057-1066, (2014); ROSENSON R.S., TRIAL DESIGNS FOR STATIN MUSCLE INTOLERANCE, CURR OPIN LIPIDOL., 28, PP. 488-494, (2017); ROSENSON R.S., BAKER S., BANACH M., ET AL., OPTIMIZING CHOLESTEROL TREATMENT IN PATIENTS WITH MUSCLE COMPLAINTS, J AM COLL CARDIOL., 70, PP. 1290-1301, (2017); LAUFS U., SCHARNAGL H., MARZ W., STATIN INTOLERANCE, CURR OPIN LIPIDOL., 26, PP. 492-501, (2015); KEEN H.I., KRISHNARAJAH J., BATES T.R., ET AL., STATIN MYOPATHY: THE FLY IN THE OINTMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE 21ST CENTURY?, EXP OPIN DRUG SAF., 13, PP. 1227-1239, (2014); CAMPOLONGO G., COSTANZA V.R., RAPARELLI V., ET AL., THE COMBINATION OF NUTRACEUTICAL AND SIMVASTATIN ENHANCES THE EFFECT OF SIMVASTATIN ALONE IN NORMALISING LIPID PROFILE WITHOUT SIDE EFFECTS IN PATIENTS WITH ISCHEMIC HEART DISEASE, INT J CARDIOL METABOL ENDOCRINE., 11, PP. 3-6, (2016); MANCINI G.B., TASHAKKOR A.Y., BAKER S., ET AL., DIAGNOSIS, PREVENTION, AND MANAGEMENT OF STATIN ADVERSE EFFECTS AND INTOLERANCE: CANADIAN WORKING GROUP CONSENSUS UPDATE, CAN J CARDIOL., 29, PP. 1553-1568, (2013); GUYTON J.R., BAYS H.E., GRUNDY S.M., ET AL., AN ASSESSMENT BY THE STATIN INTOLERANCE PANEL: 2014 UPDATE, J CLIN LIPIDOL., 8, 3, PP. S72-S81, (2014); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY—EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT. EUR HEART J., 36, PP. 1012-1022, (2015); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR J INTERN MED., 25, PP. 592-599, (2014); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTR REV., 75, PP. 731-767, (2017); BARBAGALLO C.M., CEFALU A.B., NOTO D., ET AL., ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY, FRONT CARDIOVASC MED., 2, PP. 1-22, (2015); JOHNSTON T.P., KOROLENKO T.A., PIRRO M., ET AL., PREVENTING CARDIOVASCULAR HEART DISEASE: PROMISING NUTRACEUTICAL AND NON-NUTRACEUTICAL TREATMENTS FOR CHOLESTEROL MANAGEMENT, PHARMACOL RES., 120, PP. 219-225, (2017); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION., 32, PP. 1179-1192, (2016); SAHEBKAR A., HENROTIN Y., ANALGESIC EFFICACY AND SAFETY OF CURCUMINOIDS IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PAIN MED., 17, PP. 1192-1202, (2016); GYLLING H., PLAT J., TURLEY S., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS., 232, PP. 346-360, (2014); PIRILLO A., CATAPANO A.L., STATIN INTOLERANCE: DIAGNOSIS AND REMEDIES, CURR CARDIOL REP., 17, PP. 1-9, (2015); SAXON D.R., ECKEL R.H., STATIN INTOLERANCE: A LITERATURE REVIEW AND MANAGEMENT STRATEGIES, PROG CARDIOVASC DIS., 59, PP. 153-164, (2016); DONG H., ZHAO Y., ZHAO L., ET AL., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED., 79, PP. 437-446, (2013); TAI M.H., CHEN P.K., CHEN P.Y., ET AL., CURCUMIN ENHANCES CELL-SURFACE LDLR LEVEL AND PROMOTES LDL UPTAKE THROUGH DOWNREGULATION OF PCSK9 GENE EXPRESSION IN HEPG2 CELLS, MOL NUTR FOOD RES., 58, PP. 2133-2145, (2014); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL., 8, PP. 61-68, (2014); MILLAN J., CICERO A.F., TORRES F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLIN INVESTIG ARTERIOSCLER., 28, PP. 178-187, (2016); CICERO A.F., COLLETTI A., COMBINATIONS OF PHYTOMEDICINES WITH DIFFERENT LIPID LOWERING ACTIVITY FOR DYSLIPIDEMIA MANAGEMENT: THE AVAILABLE CLINICAL DATA, PHYTOMEDICINE., 23, PP. 1113-1118, (2016); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS., 20, PP. 656-661, (2010); DE CASTRO-OROS I., SOLA R., VALLS R.M., ET AL., GENETIC VARIANTS OF LDLR AND PCSK9 ASSOCIATED WITH VARIATIONS IN RESPONSE TO ANTIHYPERCHOLESTEROLEMIC EFFECTS OF ARMOLIPID PLUS WITH BERBERINE, PLOS ONE., 11, (2016); WARD N., SAHEBKAR A., BANACH M., ET AL., RECENT PERSPECTIVES ON THE ROLE OF NUTRACEUTICALS AS CHOLESTEROL-LOWERING AGENTS, CURR OPIN LIPIDOL., 28, PP. 495-501, (2017); ARCA M., PIGNA G., TREATING STATIN-INTOLERANT PATIENTS, DIABETES METAB SYNDR OBES., 4, PP. 155-166, (2011); VENERO C.V., VENERO J.V., WORTHAM D.C., ET AL., LIPID-LOWERING EFFICACY OF RED YEAST RICE IN A POPULATION INTOLERANT TO STATINS, AM J CARDIOL., 105, PP. 664-666, (2010); BECKER D.J., GORDON R.Y., HALBERT S.C., ET AL., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED., 150, PP. 830-839, (2009); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2400 MG TWICE DAILY) VS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL., 105, PP. 198-204, (2010); STEFANUTTI C., MAZZA F., MESCE D., ET AL., MONASCUS PURPUREUS FOR STATIN AND EZETIMIBE INTOLERANT HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA PATIENTS: A CLINICAL STUDY, ATHEROSCLER SUPPL., 30, PP. 86-91, (2017); CICERO A.F., MORBINI M., BOVE M., ET AL., ADDITIONAL THERAPY FOR CHOLESTEROL LOWERING IN EZETIMIBE-TREATED, STATIN-INTOLERANT PATIENTS IN CLINICAL PRACTICE: RESULTS FROM AN INTERNAL AUDIT OF A UNIVERSITY LIPID CLINIC, CURR MED RES OPIN., 32, PP. 1-6, (2016); MARAZZI G., PELLICCIA F., CAMPOLONGO G., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM J CARDIOL., 116, PP. 1798-1801, (2015); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS., 11, (2012); MARAZZI G., CAMPOLONGO G., PELLICCIA F., ET AL., COMPARISON OF LOW-DOSE STATIN VERSUS LOW-DOSE STATIN + ARMOLIPID PLUS IN HIGH-INTENSITY STATIN-INTOLERANT PATIENTS WITH A PREVIOUS CORONARY EVENT AND PERCUTANEOUS CORONARY INTERVENTION (ADHERENCE TRIAL), AM J CARDIOL., 120, PP. 893-897, (2017); BANACH M., SERBAN C., SAHEBKAR A., ET AL., EFFECTS OF COENZYME Q10 ON STATIN-INDUCED MYOPATHY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MAYO CLINIC PROC., 90, PP. 24-34, (2015); TAYLOR B.A., LORSON L., WHITE C.M., ET AL., A RANDOMIZED TRIAL OF COENZYME Q10 IN PATIENTS WITH CONFIRMED STATIN MYOPATHY, ATHEROSCLEROSIS., 238, PP. 329-335, (2015); GUPTA A., THOMPSON P.D., THE RELATIONSHIP OF VITAMIN D DEFICIENCY TO STATIN MYOPATHY, ATHEROSCLEROSIS., 215, PP. 23-29, (2011); KANG J.H., NGUYEN Q.N., MUTKA J., ET AL., RECHALLENGING STATIN THERAPY IN VETERANS WITH STATIN-INDUCED MYOPATHY POST VITAMIN D REPLENISHMENT, J PHARM PRACT., 30, PP. 521-527, (2017); SAHEBKAR A., SABONI N., PIRRO M., ET AL., CURCUMIN: AN EFFECTIVE ADJUNCT IN PATIENTS WITH STATIN-ASSOCIATED MUSCLE SYMPTOMS?, J CACHEXIA SARCOPENIA MUSCLE., 8, PP. 19-24, (2017)","N.C. WARD; SCHOOL OF MEDICINE, FACULTY OF HEALTH & MEDICAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA; EMAIL: NATALIE.WARD@CURTIN.EDU.AU","JOHN WILEY AND SONS INC.","ENGLISH","CLIN. CARDIOL.","REVIEW","ISI","2-S2.0-85040980021","CLIN CARDIOL","UNIVERSITY OF WESTERN AUSTRALIA;UNIVERSITY OF WESTERN AUSTRALIA;UNIVERSITY OF WESTERN AUSTRALIA;UNIVERSITY OF WESTERN AUSTRALIA","NOTREPORTED;UNIVERSITY OF WESTERN AUSTRALIA;NOTREPORTED",NA,"WARD NC, 2018, CLIN CARDIOL","WARD NC, 2018, CLIN CARDIOL"
"ELSEWEIDY M;MOHAMED H;ELRASHIDY R;ATTEIA H;ELNAGAR G","ELSEWEIDY, MOHAMED M. (55600488100); MOHAMED, HODA E. (7102602761); ELRASHIDY, RANIA A. (55151392300); ATTEIA, HEBATALLAH H. (53983712700); ELNAGAR, GEHAD M. (56613221500)","INHIBITION OF AORTIC CALCIFICATION BY POLICOSANOL IN DYSLIPIDEMIC RABBITS IS ENHANCED BY PENTOXIFYLLINE POTENTIAL ROLE OF PCSK9",2018,"JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS","23","9",11,"10.1177/1074248418775377","DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT;DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, EGYPT","POLICOSANOL (POL) IS A HYPOCHOLESTEROLEMIC DRUG OF NATURAL ORIGIN AND HAS BEEN SHOWN TO REDUCE CIRCULATING LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN HEALTHY PARTICIPANTS. RECENTLY, WE HAVE REPORTED THAT POL CAN ATTENUATE AORTIC CALCIFICATION IN DIABETIC DYSLIPIDEMIC RATS; HOWEVER, THE UNDERLYING MECHANISM IS NOT FULLY ELUCIDATED. WE AIMED TO INVESTIGATE THE EFFECT OF POL ON AORTIC CALCIFICATION AND WHETHER PCSK9 HAS A CONTRIBUTORY ROLE AND ALSO TO EXAMINE WHETHER THE COMBINATION OF POL WITH PENTOXIFYLLINE (PTX) AS ANTI–TUMOR NECROSIS FACTOR Α WOULD OFFER ADDITIONAL BENEFITS. THIRTY ADULT MALE NEW ZEALAND RABBITS WEIGHING 1.5 TO 2 KG WERE RANDOMLY ASSIGNED TO 5 GROUPS. ONE GROUP RECEIVED STANDARD CHOW DIET AND SERVED AS NORMAL CONTROL GROUP (NC). THE OTHER 4 GROUPS RECEIVED 0.5% WT/WT CHOLESTEROL-RICH DIET FOR 12 WEEKS AND CONCURRENTLY TREATED WITH PLACEBO, POL, PTX, OR A COMBINATION OF POL AND PTX. SERA SAMPLES AND AORTIC TISSUE WERE COLLECTED FOR BIOCHEMICAL MEASUREMENTS AND HISTOLOGICAL ASSESSMENT. RABBITS FED A CHOLESTEROL-RICH DIET DEMONSTRATED DYSLIPIDEMIA, INCREASED INFLAMMATORY STATE, AND ELEVATED SERUM LEVELS OF PCSK9, COMPARED TO THE NC GROUP. AORTIC CALCIFICATION WAS EVIDENT IN DYSLIPIDEMIC RABBITS, REPRESENTED BY INCREASED CALCIUM DEPOSITION AND OSTEOPONTIN EXPRESSION IN AORTIC TISSUE, ALONG WITH ELEVATED SERUM LEVELS OF ALKALINE PHOSPHATASE AND OSTEOCALCIN. DYSLIPIDEMIC RABBITS SHOWED A SIGNIFICANT UPREGULATION OF WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY 3A AND BONE MORPHOGENETIC PROTEIN 2 GENES IN THEIR AORTIC TISSUE. POLICOSANOL SIGNIFICANTLY REDUCED CIRCULATING PCSK9 LEVELS, SUPPRESSED CALCIFICATION MARKERS, AND ATTENUATED AORTIC CALCIFICATION. COMBINATION OF POL WITH PTX ALLEVIATED AORTIC CALCIFICATION TO A GREATER EXTENT THAN EITHER MONOTHERAPY, WHICH MAY BE ATTRIBUTED TO FURTHER SUPPRESSION OF PCSK9 AND CALCIFICATION MARKERS. THESE FINDINGS SUGGESTED THAT POL EXERTED ANTICALCIFYING EFFECT PARTLY VIA INHIBITION OF PCSK9. COMBINATION OF POL AND PTX OFFERED ADDITIONAL BENEFITS AND MIGHT REPRESENT A PROMISING THERAPEUTIC OPTION FOR AORTIC CALCIFICATION. © THE AUTHOR(S) 2018.","AORTIC CALCIFICATION; BMP-2; PCSK9; PENTOXIFYLLINE; POLICOSANOL","ALKALINE PHOSPHATASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; AORTIC DISEASES; BIOMARKERS; BONE MORPHOGENETIC PROTEIN 2; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY ALCOHOLS; LIPIDS; MALE; OSTEOCALCIN; OSTEOPONTIN; PENTOXIFYLLINE; PROPROTEIN CONVERTASE 9; RABBITS; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CALCIFICATION; WNT3A PROTEIN; ALKALINE PHOSPHATASE; CALCIUM; OSTEOCALCIN; OSTEOPONTIN; PENTOXIFYLLINE; PLACEBO; POLICOSANOL; PROPROTEIN CONVERTASE 9; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LIPID; OSTEOCALCIN; OSTEOPONTIN; PENTOXIFYLLINE; POLICOSANOL; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR; WNT3A PROTEIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC CALCIFICATION; AORTIC CALCIFICATION; ARTICLE; BMP 2 GENE; CALCIFICATION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DYSLIPIDEMIA; GENE; LEPORIDAE; LIPID DIET; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WNT3A GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; AORTIC DISEASE; BLOOD; BLOOD VESSEL CALCIFICATION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; DYSLIPIDEMIA; ENZYMOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION","","","MACKEY R.H., VENKITACHALAM L., SUTTON-TYRRELL K., CALCIFICATIONS, ARTERIAL STIFFNESS AND ATHEROSCLEROSIS, ADV CARDIOL, 44, PP. 234-244, (2007); JOHNSON R.C., LEOPOLD J.A., LOSCALZO J., VASCULAR CALCIFICATION: PATHOBIOLOGICAL MECHANISMS AND CLINICAL IMPLICATIONS, CIRC RES, 99, 10, PP. 1044-1059, (2006); HSU H.H., CULLEY N.C., ACCUMULATION OF LOW DENSITY LIPOPROTEIN ASSOCIATED CHOLESTEROL IN CALCIFYING VESICLE FRACTIONS CORRELATES WITH INTIMAL THICKENING IN THORACIC AORTAS OF JUVENILE RABBITS FED A SUPPLEMENTAL CHOLESTEROL DIET, LIPIDS HEALTH DIS, 5, (2006); FANTUS D., AWAN Z., SEIDAH N.G., ET AL., AORTIC CALCIFICATION: NOVEL INSIGHTS FROM FAMILIAL HYPERCHOLESTEROLEMIA AND POTENTIAL ROLE FOR THE LOW-DENSITY LIPOPROTEIN RECEPTOR, ATHEROSCLEROSIS, 226, 1, PP. 9-15, (2013); KOSTNER K., CORONARY CALCIFICATION IN FAMILIAL HYPERCHOLESTEROLEMIA: NOT ALL ABOUT LDL, ATHEROSCLEROSIS, 254, PP. 303-304, (2016); MOHLER E.R., WANG H., MEDENILLA E., SCOTT C., EFFECT OF STATIN TREATMENT ON AORTIC VALVE AND CORONARY ARTERY CALCIFICATION, J HEART VALVE DIS, 16, 4, PP. 378-386, (2007); AWAN Z., ALRASADI K., FRANCIS G.A., ET AL., VASCULAR CALCIFICATIONS IN HOMOZYGOTE FAMILIAL HYPERCHOLESTEROLEMIA, ARTERIOSCLER THROMB VASC BIOL, 28, 4, PP. 777-785, (2008); AWAN Z., DENIS M., BAILEY D., ET AL., THE LDLR DEFICIENT MOUSE AS A MODEL FOR AORTIC CALCIFICATION AND QUANTIFICATION BY MICRO-COMPUTED TOMOGRAPHY, ATHEROSCLEROSIS, 219, 2, PP. 455-462, (2011); ALRASADI K., ALWAILI K., AWAN Z., VALENTI D., COUTURE P., GENEST J., AORTIC CALCIFICATIONS IN FAMILIAL HYPERCHOLESTEROLEMIA: POTENTIAL ROLE OF THE LOW-DENSITY LIPOPROTEIN RECEPTOR GENE, AM HEART J, 157, 1, PP. 170-176, (2009); SCHMIDT R.J., BEYER T.P., BENSCH W.R., ET AL., SECRETED PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 REDUCES BOTH HEPATIC AND EXTRAHEPATIC LOW-DENSITY LIPOPROTEIN RECEPTORS IN VIVO, BIOCHEM BIOPHYS RES COMMUN, 370, 4, PP. 634-640, (2008); RASHID H., MEREDITH I.T., NASIS A., PCSK9 MONOCLONAL ANTIBODIES IN 2016: CURRENT STATUS AND FUTURE CHALLENGES, HEART LUNG CIRC, 26, 8, PP. 786-798, (2017); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); GUO Y.L., XU R.X., ZHU C.G., WU N.Q., CUI Z.P., LI J.J., POLICOSANOL ATTENUATES STATIN-INDUCED INCREASES IN SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WHEN COMBINED WITH ATORVASTATIN, EVID BASED COMPLEMENT ALTERNAT MED, (2014); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS, EXP BIOL MED (MAYWOOD), 241, 17, PP. 1943-1949, (2016); AGHARAZII M., ST-LOUIS R., GAUTIER-BASTIEN A., ET AL., INFLAMMATORY CYTOKINES AND REACTIVE OXYGEN SPECIES AS MEDIATORS OF CHRONIC KIDNEY DISEASE-RELATED VASCULAR CALCIFICATION, AM J HYPERTENS, 28, 6, PP. 746-755, (2015); TINTUT Y., PATEL J., PARHAMI F., DEMER L.L., TUMOR NECROSIS FACTOR-ALPHA PROMOTES IN VITRO CALCIFICATION OF VASCULAR CELLS VIA THE CAMP PATHWAY, CIRCULATION, 102, 21, PP. 2636-2642, (2000); MCCARTY M.F., O'KEEFE J.H., DINICOLANTONIO J.J., PENTOXIFYLLINE FOR VASCULAR HEALTH: A BRIEF REVIEW OF THE LITERATURE, OPEN HEART, 3, 1, (2016); RAJAMANNAN N.M., SUBRAMANIAM M., STOCK S., ET AL., ATORVASTATIN INHIBITS CALCIFICATION AND ENHANCES NITRIC OXIDE SYNTHASE PRODUCTION IN THE HYPERCHOLESTEROLAEMIC AORTIC VALVE, HEART, 91, 6, PP. 806-810, (2005); GAMEZ R., MAZ R., ARRUZAZABALA M.L., MENDOZA S., CASTANO G., EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS, DRUGS R D, 6, 1, PP. 11-19, (2005); PRASAD K., LEE P., SUPPRESSION OF HYPERCHOLESTEROLEMIC ATHEROSCLEROSIS BY PENTOXIFYLLINE AND ITS MECHANISM, ATHEROSCLEROSIS, 192, 2, PP. 313-322, (2007); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLINICAL CHEMISTRY, 18, 6, PP. 499-502, (1972); SCHMITTGEN T.D., LIVAK K.J., ANALYZING REAL-TIME PCR DATA BY THE COMPARATIVE CT METHOD, NATURE PROTOCOLS, 3, 6, PP. 1101-1108, (2008); SHI S.R., CHAIWUN B., YOUNG L., COTE R.J., TAYLOR C.R., ANTIGEN RETRIEVAL TECHNIQUE UTILIZING CITRATE BUFFER OR UREA SOLUTION FOR IMMUNOHISTOCHEMICAL DEMONSTRATION OF ANDROGEN RECEPTOR IN FORMALIN-FIXED PARAFFIN SECTIONS, J HISTOCHEM CYTOCHEM, 41, 11, PP. 1599-1604, (1993); CARSON W.P., PETERSON C.J., THE ROLE OF LITTER IN AN OLD-FIELD COMMUNITY: IMPACT OF LITTER QUANTITY IN DIFFERENT SEASONS ON PLANT SPECIES RICHNESS AND ABUNDANCE, OECOLOGIA, 85, 1, PP. 8-13, (1990); FAN J., KITAJIMA S., WATANABE T., ET AL., RABBIT MODELS FOR THE STUDY OF HUMAN ATHEROSCLEROSIS: FROM PATHOPHYSIOLOGICAL MECHANISMS TO TRANSLATIONAL MEDICINE, PHARMACOL THER, 146, PP. 104-119, (2015); MAKKENA B., SALTI H., SUBRAMANIAM M., ET AL., ATORVASTATIN DECREASES CELLULAR PROLIFERATION AND BONE MATRIX EXPRESSION IN THE HYPERCHOLESTEROLEMIC MITRAL VALVE, J AM COLL CARDIOL, 45, 4, PP. 631-633, (2005); SAHEBKAR A., SIMENTAL-MENDIA L.E., GUERRERO-ROMERO F., GOLLEDGE J., WATTS G.F., EFFECT OF STATIN THERAPY ON PLASMA PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS, DIABETES OBES METAB, 17, 11, PP. 1042-1055, (2015); WELDER G., ZINEH I., PACANOWSKI M.A., TROUTT J.S., CAO G., KONRAD R.J., HIGH-DOSE ATORVASTATIN CAUSES A RAPID SUSTAINED INCREASE IN HUMAN SERUM PCSK9 AND DISRUPTS ITS CORRELATION WITH LDL CHOLESTEROL, J LIPID RES, 51, 9, PP. 2714-2721, (2010); CARESKEY H.E., DAVIS R.A., ALBORN W.E., TROUTT J.S., CAO G., KONRAD R.J., ATORVASTATIN INCREASES HUMAN SERUM LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, J LIPID RES, 49, 2, PP. 394-398, (2008); NOZUE T., LIPID LOWERING THERAPY AND CIRCULATING PCSK9 CONCENTRATION, J ATHEROSCLER THROMB, 24, 9, PP. 895-907, (2017); ZHAO X., ZHANG H.W., LI S., ET AL., ASSOCIATION BETWEEN PLASMA PROPROTEIN CONVERTASE SUBTISILIN/KEXIN TYPE 9 CONCENTRATION AND CORONARY ARTERY CALCIFICATION, ANN CLIN BIOCHEM, 5, 51, PP. 158-164, (2018); GOETTSCH C., HUTCHESON J.D., HAGITA S., ET AL., A SINGLE INJECTION OF GAIN-OF-FUNCTION MUTANT PCSK9 ADENO-ASSOCIATED VIRUS VECTOR INDUCES CARDIOVASCULAR CALCIFICATION IN MICE WITH NO GENETIC MODIFICATION, ATHEROSCLEROSIS, 251, PP. 109-118, (2016); WANG W.G., HE Y.F., CHEN Y.L., ET AL., PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND AORTIC VALVE CALCIFICATION: A PROSPECTIVE, CROSS SECTIONAL STUDY, J INT MED RES, 44, 4, PP. 865-874, (2016); RAJAMANNAN N.M., THE ROLE OF LRP5/6 IN CARDIAC VALVE DISEASE: EXPERIMENTAL HYPERCHOLESTEROLEMIA IN THE APOE-/- /LRP5-/- MICE, J CELL BIOCHEM, 112, 10, PP. 2987-2991, (2011); CAI T., SUN D., DUAN Y., ET AL., WNT/BETA-CATENIN SIGNALING PROMOTES VSMCS TO OSTEOGENIC TRANSDIFFERENTIATION AND CALCIFICATION THROUGH DIRECTLY MODULATING RUNX2 GENE EXPRESSION, EXP CELL RES, 345, 2, PP. 206-217, (2016); RAWADI G., VAYSSIERE B., DUNN F., BARON R., ROMAN-ROMAN S., BMP-2 CONTROLS ALKALINE PHOSPHATASE EXPRESSION AND OSTEOBLAST MINERALIZATION BY A WNT AUTOCRINE LOOP, J BONE MINER RES, 18, 10, PP. 1842-1853, (2003); CAVERZASIO J., MANEN D., ESSENTIAL ROLE OF WNT3A-MEDIATED ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE P38 FOR THE STIMULATION OF ALKALINE PHOSPHATASE ACTIVITY AND MATRIX MINERALIZATION IN C3H10T1/2 MESENCHYMAL CELLS, ENDOCRINOLOGY, 148, 11, PP. 5323-5330, (2007); ZHANG R., OYAJOBI B.O., HARRIS S.E., ET AL., WNT/BETA-CATENIN SIGNALING ACTIVATES BONE MORPHOGENETIC PROTEIN 2 EXPRESSION IN OSTEOBLASTS, BONE, 52, 1, PP. 145-156, (2013); MBALAVIELE G., SHEIKH S., STAINS J.P., ET AL., BETA-CATENIN AND BMP-2 SYNERGIZE TO PROMOTE OSTEOBLAST DIFFERENTIATION AND NEW BONE FORMATION, J CELL BIOCHEM, 94, 2, PP. 403-418, (2005); ALONSO R., MATA P., MUNIZ O., ET AL., PCSK9 AND LIPOPROTEIN (A) LEVELS ARE TWO PREDICTORS OF CORONARY ARTERY CALCIFICATION IN ASYMPTOMATIC PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 254, PP. 249-253, (2016); RUSCICA M., RICCI C., MACCHI C., ET AL., SUPPRESSOR OF CYTOKINE SIGNALING-3 (SOCS-3) INDUCES PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) EXPRESSION IN HEPATIC HEPG2 CELL LINE, J BIOL CHEM, 291, 7, PP. 3508-3519, (2016); AL-ALY Z., ARTERIAL CALCIFICATION: A TUMOR NECROSIS FACTOR-ALPHA MEDIATED VASCULAR WNT-OPATHY, TRANSL RES, 151, 5, PP. 233-239, (2008); COLA C., ALMEIDA M., LI D., ROMEO F., MEHTA J.L., REGULATORY ROLE OF ENDOTHELIUM IN THE EXPRESSION OF GENES AFFECTING ARTERIAL CALCIFICATION, BIOCHEM BIOPHYS RES COMMUN, 320, 2, PP. 424-427, (2004)","M.M. ELSEWEIDY; DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT; EMAIL: RA_ELRASHIDY@YAHOO.COM","SAGE PUBLICATIONS LTD","ENGLISH","J. CARDIOVASC. PHARMACOL. THER.","ARTICLE","ISI","2-S2.0-85054987148","J CARDIOVASC PHARMACOL THER","ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY","NOTREPORTED;ZAGAZIG UNIVERSITY;NOTREPORTED",NA,"ELSEWEIDY MM, 2018, J CARDIOVASC PHARMACOL THER","ELSEWEIDY MM, 2018, J CARDIOVASC PHARMACOL THER"
"CHOI S;PARK S;PARK J;PARK S;JUNG M","CHOI, SOL JI (57131654300); PARK, SU YEON (57203275903); PARK, JI SU (55387373700); PARK, SANG-KYU (55428970500); JUNG, MUN YHUNG (35336963900)","CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA CAMELLIA SINENSIS LEAVES",2016,"FOOD CHEMISTRY","204","7",21,"10.1016/j.foodchem.2016.02.027","DEPARTMENT OF FOOD AND BIOTECHNOLOGY, GRADUATE SCHOOL, COLLEGE OF FOOD SCIENCE, WOOSUK UNIVERSITY, WANJU-KUN, SAMREA-UP, 565-701, JEONBUK PROVINCE, SOUTH KOREA;DEPARTMENT OF FOOD AND BIOTECHNOLOGY, GRADUATE SCHOOL, COLLEGE OF FOOD SCIENCE, WOOSUK UNIVERSITY, WANJU-KUN, SAMREA-UP, 565-701, JEONBUK PROVINCE, SOUTH KOREA;KOREA FOOD RESEARCH INSTITUTE, KYONGKI, SONGNAM-SI, SOUTH KOREA;DEPARTMENT OF FOOD NUTRITION, NAMBU UNIVERSITY, GWANGJU, SOUTH KOREA;DEPARTMENT OF FOOD AND BIOTECHNOLOGY, GRADUATE SCHOOL, COLLEGE OF FOOD SCIENCE, WOOSUK UNIVERSITY, WANJU-KUN, SAMREA-UP, 565-701, JEONBUK PROVINCE, SOUTH KOREA","POLICOSANOL (PC) IS A MIXTURE OF HEALTH PROMOTING BIOACTIVE LONG-CHAIN ALIPHATIC ALCOHOLS. HERE, WE REPORT THAT GREEN TEA (CAMELLIA SINENSIS) LEAVES ARE THE EXCEPTIONALLY RICH PLANT-SOURCES OF PC. YOUNG AND TENDER LEAVES AND OLD AND TURF LEAVES OF C. SINENSIS WERE HAND-PICKED IN SPRING AND AUTUMN. THE TOTAL CONTENTS OF PC IN THE LEAVES WERE IN THE RANGE OF 726.2-1363.6 MG/KG AS DETERMINED BY A GC-MS/MS. THE COMPOSITIONS OF PC IN THE LEAVES WERE DIFFERENT WITH HARVEST SEASON AND TYPES. THE TOTAL CONTENTS OF PC IN COMMERCIAL GREEN TEA LEAVES WERE FOUND TO BE IN THE RANGE OF 856.7-1435.1 MG/KG. INTERESTINGLY, THE INFUSED GREEN TEA LEAVES CONTAINED THE HIGHER PC THAN THE NON-INFUSED GREEN TEA PRODUCT, REACHING TO 1629.4 MG/KG. THIS REPRESENTS THE FIRST REPORT ON THE CONTENTS AND COMPOSITIONS OF PC IN GREEN TEA LEAVES, SHOWING UNAMBIGUOUS EVIDENCE OF THEIR POTENTIAL AS RICH SOURCES OF PC. © 2016 ELSEVIER LTD. ALL RIGHTS RESERVED.","CAMELLIA SINENSIS LEAVES; GC-TANDEM MASS SPECTROMETRY; GREEN TEA; INFUSION; POLICOSANOLS","CAMELLIA SINENSIS; FATTY ALCOHOLS; PLANT LEAVES; SEASONS; TANDEM MASS SPECTROMETRY; TEA; BEVERAGES; DRUG INFUSION; MASS SPECTROMETRY; POLICOSANOL; FATTY ALCOHOL; POLICOSANOL; CAMELLIA SINENSIS; GREEN TEA; HARVEST SEASON; LONG CHAIN ALIPHATIC ALCOHOLS; POLICOSANOL; POLICOSANOLS; TANDEM MASS SPECTROMETRY; TOTAL CONTENT; ARTICLE; AUTUMN; CAMELLIA SINENSIS; CHEMICAL COMPOSITION; GAS CHROMATOGRAPHY; HARVEST; NONHUMAN; PLANT LEAF; SAPONIFICATION; SEASON; SPRING; TANDEM MASS SPECTROMETRY; CAMELLIA SINENSIS; CHEMISTRY; PLANT LEAF; TEA; PLANTS (BOTANY)","MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, MIFAFF","THIS RESEARCH WAS FINANCIALLY SUPPORTED BY KOREAN MINISTRY FOR FOOD, AGRICULTURE, FORESTRY, AND FISHERIES THROUGH IPET . ","ABDALLAH I.B., TLILI N., MARTINEZ-FORCE E., RUBCO A.G.P., PEREZ-CAMINO M.C., ALBOUCHI A., BOUKCHINA S., CONTENTS OF CAROTENOIDS, TOCOPHEROLS, STEROLS, TRITERPENIC AND ALIPHATIC ALCOHOLS, AND VOLATILE COMPOUNDS IN SIX WALUTS (JUGLANS REGIA L.) VARIETIES, FOOD CHEMISTRY, 173, PP. 972-978, (2015); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 5359-5362, (2006); ARRUZAZABALA M.L., CARNAJAL D., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNADEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATLET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUMTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, PP. 891-897, (2002); BANERJEE B., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); BERHOLDER H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHHOLD I., EFFECTS OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, PP. 2262-2269, (2006); BUSCHHAUS C., JETTER R., COMPOSITION AND PHYSIOLOGICAL FUNCTION OF THE WAX LAYERS COATING ARABIDOPSIS LEAVES: Β-AMYRIN NEGATIVELY AFFECTS THE INTRACUTICULAR WATER BARRIER, PLANT PHYSIOLOGY, 160, PP. 1120-1129, (2012); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MARS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 85, PP. 61-64, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHELESTEMIC PATIENTS, INTERNATIONAL JOURNAL OF CLINICAL PHAMACOLOGY RESEARCH, 19, PP. 105-116, (1999); CHEN Y., DUNFORD N.T., EDWARDS J., CARVEN B., GOAD C., POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 89, PP. 310-314, (2009); CHERIF A.O., MESSAOUDA M.B., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, PP. 12143-12148, (2010); CRESPY V., WILLAMSON G., A REVIEW OF THE HEALTH EFFECTS OF GREEN TEA CATECHINS IN IN VIVO ANIMAL MODELS, JOURNAL OF NUTRITION, 134, PP. 3431S-3440S, (2004); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, PP. 1543-1548, (2006); GIACOMETTI J., DETERMINATION OF ALIPHATIC ALCOHOLS, SQUALENE, Α-TOCOPHEROL AND STEROLS IN OLIVE OILS: DIRECT METHOD INVOLVING GAS CHROMATOGRAPHY OF THE UNSAPONIFIABLE FRACTION FOLLOWING SILYLATION, ANALYST, 126, PP. 472-475, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); GULZ P.G., MULLER E., SEASONAL VARIATION IN THE COMPOSITION OF EPICUTICULAR WAXES OF QUEVCUS ROBUR LEAVES, ZEITSCHRIFT FÜR NATURFORSCHUNG, 47, PP. 800-806, (1992); HARRABI S., BOUKHCHINA S., MAYER M.P., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEMISTRY, 115, PP. 918-923, (2009); HOFFMANN R., KAHMEN A., CERNUSAK L.A., ARNDT S.K., SACHSE D., ABUNDANCE AND DISTRIBUTION OF LEAF WAX N-ALKANES IN LEAVES OF ACACIA AND EUCLYPTUS TREES ALONG A STRONG HUMIDITY GRADIENT IN NORTHERN AUSTRALIA, ORGANIC GEOCHEMISTRY, 62, PP. 62-67, (2013); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPARATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, JOURNAL OF SEPARATION SCIENCE, 25, PP. 619-623, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 79, PP. 529-533, (2002); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNAN M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEMISTRY, 81, PP. 345-349, (2004); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITION OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEEWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); IRMAK S., JONNALA R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, JOURNAL OF CEREAL SCIENCE, 48, PP. 20-26, (2008); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, JOURNAL OF FOOD SCIENCE, 76, PP. C891-C899, (2011); JUNG D.M., YOON S.H., JUNG M.Y., CHEMICAL PROPERTIES AND OXIDATIVE STABILITY OF PERILLA SEED OILS OBTAINED FROM ROASTED PERILLA SEEDS AS AFFECTED BY EXTRACTION METHODS, JOURNAL OF FOOD SCIENCE, 77, PP. C1249-C1255, (2012); KIM J.K., HA S., PARK S., LEE S., KIM H.J., LIM S.H., SUH S., ET AL., DETERMINATION OF LIPOPHILIC COMPOUNDS IN GENETICALLY MODIFIED RICE USING GAS CHROMATOGRAPHY-TIME-OF-FLIGHT MASS SPECTROMETRY, JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 25, PP. 31-38, (2012); KIM H.J., PARK S.H., HAN D.S., PARK T.S., OCTACOSANOL SUPPLEMENTATION INCREASES RUNNING ENDURANCE TIME AND IMPROVES BIOCHEMICAL PARAMETERS AFTER EXHAUSTION IN TRAINED RATS, JOURNAL OF MEDICINAL FOOD, 6, PP. 345-351, (2003); KIM J.K., PARK S., JUNG J.Y., HA S., LEE S.M., WOO H., PARK S.U., ET AL., POLICOSANOL CONTENT AND COMPOSITION OF KOREAN RICE (ORYZSATIVA L) CULTIVARS, CEREAL CHEMISTRY, 89, PP. 151-154, (2012); MARINANGELI C.P.F., JONES P.J.H., KASSIS A.N., ESKIN M.N.A., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 50, PP. 259-267, (2010); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, PP. 8-12, (2001); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 50, PP. 255-262, (2000); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 6289-6293, (2005); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 112, PP. 373-379, (2010); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); WANG M., LIAN H., MAO H., ZHOU J., GONG H., QIAN B., FANG Y., ET AL., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, PP. 5552-5558, (2007); ZAVERI N.T., GREEN TEA AND ITS POLYPHENOLIC CATECHINS: MEDICINAL USES IN CANCER AND NONCANCER APPLICATIONS, LIFE SCIENCES, 78, PP. 2073-2080, (2006)","M.Y. JUNG; DEPARTMENT OF FOOD AND BIOTECHNOLOGY, GRADUATE SCHOOL, COLLEGE OF FOOD SCIENCE, WOOSUK UNIVERSITY, WANJU-KUN, SAMREA-UP, 565-701, SOUTH KOREA; EMAIL: MUNJUNG@WOOSUK.AC.KR","ELSEVIER LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-84958957426","FOOD CHEM","WOOSUK UNIVERSITY;WOOSUK UNIVERSITY;KOREA FOOD RESEARCH INSTITUTE;NAMBU UNIVERSITY;WOOSUK UNIVERSITY","NOTREPORTED;WOOSUK UNIVERSITY;NOTREPORTED",NA,"CHOI SJ, 2016, FOOD CHEM","CHOI SJ, 2016, FOOD CHEM"
"WONGWAIWECH D;WEERAWATANAKORN M;THARATHA S;HO C","WONGWAIWECH, DONPORN (57202775373); WEERAWATANAKORN, MONTHANA (55976489600); THARATHA, SOMSAK (24339236300); HO, CHI-TANG (56510763200)","COMPARATIVE STUDY ON AMOUNT OF NUTRACEUTICALS IN BYPRODUCTS FROM SOLVENT AND COLD PRESSING METHODS OF RICE BRAN OIL PROCESSING",2019,"JOURNAL OF FOOD AND DRUG ANALYSIS","27","11",33,"10.1016/j.jfda.2018.06.006","DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, 99 MOO 9, THA PHO, PHITSANULOK, 65000, THAILAND;164/86 MOO 3, DONKAEW, MAERIM, CHIANGMAI, 50180, THAILAND;DEPARTMENT OF FOOD SCIENCE, RUTGERS UNIVERSITY, 65 DUDLEY ROAD, NEW BRUNSWICK, 08901, NJ, UNITED STATES","RICE BRAN OIL (RBO) HAS BECOME A POPULAR OIL GLOBALLY. HOWEVER, THE RBO EXTRACTION PROCESS LEAVES VARIOUS RESIDUE PRODUCTS, WHICH CONTAIN BIOACTIVE SUBSTANCES OF VARYING POTENCY WHICH COULD BE SIGNIFICANT SOURCES OF FUNCTIONAL INGREDIENTS FOR BOTH FOOD PRODUCTION AND PHARMACEUTICAL MANUFACTURE. THE OBJECTIVE OF OUR STUDY WAS TO COMPARE THE BIOACTIVE SUBSTANCES IN VARIOUS BY-PRODUCTS DERIVED FROM THE TWO RICE BRAN OIL PROCESSING METHODS; SOLVENT EXTRACTION AND COLD PRESSING. THE RESIDUES FROM SOLVENT EXTRACTION PROCESSING CONTAINED UP TO 97.37 MG/100 G OF Γ-AMINOBUTYRIC ACID IN DEFATTED RICE BRAN, AND THE RICE ACID OIL CONTAINED HIGH LEVELS OF VITAMIN E (TOCOPHEROLS, TOCOTRIENOLS), UP TO 120.59 MG/100 G, AS WELL AS Γ-ORYZANOL (3829.65 MG/100 G), PHYTOSTEROL (599.40 MG/100 G), AND POLICOSANOL COMPOUNDS (332.79 MG/100 G). ALL OF THESE VALUES ARE HIGHER THAN IN THE RESIDUES DERIVED FROM COLD PRESSING. IMPORTANTLY, HIGH AMOUNTS OF TOTAL NUTRACEUTICALS (8.3 KG/100 KG) WERE FOUND IN RESIDUES FROM BOTH PROCESSING METHODS, INDICATING THE COMMERCIAL POTENTIAL OF THESE RESIDUES AS A SOURCE OF FUNCTIONAL INGREDIENTS FOR FOOD PRODUCTION, AS DIETARY SUPPLEMENTS, AND IN PHARMACEUTICAL MANUFACTURE. © 2018","BY-PRODUCTS; COLD PRESSING PROCESS; NUTRACEUTICAL; REFINING PROCESS; RICE BRAN OIL","CHEMICAL FRACTIONATION; DIETARY SUPPLEMENTS; FOOD HANDLING; ORYZA; PHENYLPROPIONATES; RICE BRAN OIL; SEEDS; VITAMIN E; WASTE PRODUCTS; 4 AMINOBUTYRIC ACID; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; BEHENYL ALCOHOL; CAMPESTEROL; GAMMA ORYZANOL; HEXACOSANOL; NUTRACEUTICAL; OCTACOSANOL; PHYTOSTEROL; POLICOSANOL; RICE BRAN OIL; SITOSTANOL; SITOSTEROL; SOLVENT; STIGMASTEROL; TOCOPHEROL; ALPHA TOCOPHEROL; GAMMA-ORYZANOL; PHENYLPROPIONIC ACID DERIVATIVE; RICE BRAN OIL; ARTICLE; COMPARATIVE STUDY; DIETARY SUPPLEMENT; FOOD INDUSTRY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; PLANT OIL PROCESSING; RICE BRAN; SOLVENT EXTRACTION; CHEMISTRY; FOOD HANDLING; FRACTIONATION; ISOLATION AND PURIFICATION; ORYZA; PLANT SEED; PROCEDURES; WASTE","NARESUAN UNIVERSITY LANGUAGE CENTRE; NATIONAL RESEARCH COUNCIL OF THAILAND, NRCT, (R2559B019)","FUNDING TEXT 1: THIS STUDY WAS CARRIED OUT AS PART OF PROJECT NUMBER R2559B019 AND NRCT 32208 (2561) OF THE NATIONAL RESEARCH COUNCIL OF THAILAND . MANY THANKS TO MR. ROY MORIEN OF THE NARESUAN UNIVERSITY LANGUAGE CENTRE FOR HIS EDITING ASSISTANCE AND ADVICE ON ENGLISH EXPRESSION IN THIS DOCUMENT. ; FUNDING TEXT 2: THIS STUDY WAS CARRIED OUT AS PART OF PROJECT NUMBER R2559B019 AND NRCT 32208 (2561) OF THE NATIONAL RESEARCH COUNCIL OF THAILAND. MANY THANKS TO MR. ROY MORIEN OF THE NARESUAN UNIVERSITY LANGUAGE CENTRE FOR HIS EDITING ASSISTANCE AND ADVICE ON ENGLISH EXPRESSION IN THIS DOCUMENT.","THAI RICE EXPORTERS ASSOCIATION, THAI RICE PRODUCTION, CONSUMPTION, AND STOCKS, (2016); SAMAD N., RICE BRAN OIL PREVENTS NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SYMPTOMS IN RATS: POSSIBLE ANTIOXIDANT MECHANISMS, J FOOD DRUG ANAL, 23, PP. 370-375, (2015); PRASAD M.N., SANJAY K., KHATOKAR M.S., VISMAYA M., SWAMY S.N., HEALTH BENEFITS OF RICE BRAN - A REVIEW, J NUTR FOOD SCI, 1, PP. 1-7, (2011); PESTANA V.R., ZAMBIAZI R.C., MENDONCA C.R.B., BRUSCATTO M.H., RAMIS-RAMOS G., THE INFLUENCE OF INDUSTRIAL PROCESSING ON THE PHYSICO-CHEMICAL CHARACTERISTICS AND LIPID AND ANTIOXIDANT CONTENTS OF RICE BRAN, GRASAS ACEITES, 60, PP. 184-193, (2009); PESTANA-BAUER V.R., ZAMBIAZI R.C., MENDONCA C.R.B., BENEITO-CAMBRA M., RAMIS-RAMOS G., Γ-ORYZANOL AND TOCOPHEROL CONTENTS IN RESIDUES OF RICE BRAN OIL REFINING, FOOD CHEM, 134, PP. 1479-1483, (2012); BHOSLE B.M., SUBRAMANIAN R., NEW APPROACHES IN DEACIDIFICATION OF EDIBLE OILS - A REVIEW, J FOOD ENG, 69, PP. 481-494, (2005); ORTHOEFER F.T., RICE BRAN OIL, BAILEY'S IND. OIL FAT PROD., VOL. 2. 6TH ED, PP. 465-489, (2005); MOREAU R.A., KAMAL-ELDIN A., INTRODUCTION, GOURMET HEAL. SPEC. OILS, VOL. 1, PP. 1-13, (2009); LIU Y., YU J., WANG X., EXTRACTION OF POLICOSANOLS FROM HYDROLYSED RICE BRAN WAX BY HIGH-INTENSITY ULTRASOUND, INT J FOOD SCI TECHNOL, 43, PP. 763-769, (2008); LERMA-GARCIA M.J., HERRERO-MARTINEZ J.M., SIMO-ALFONSO E.F., MENDONCA C.R.B., RAMIS-RAMOS G., COMPOSITION, INDUSTRIAL PROCESSING AND APPLICATIONS OF RICE BRAN Γ-ORYZANOL, FOOD CHEM, 115, PP. 389-404, (2009); HUANG Y.P., LAI H.M., BIOACTIVE COMPOUNDS AND ANTIOXIDATIVE ACTIVITY OF COLORED RICE BRAN, J FOOD DRUG ANAL, 24, PP. 564-574, (2016); REISIGE K., GORZELANNY C., DANIELS U., MOERSCHBACHER B.M., THE C28 ALDEHYDE OCTACOSANAL IS A MORPHOGENETICALLY ACTIVE COMPONENT INVOLVED IN HOST PLANT RECOGNITION AND INFECTION STRUCTURE DIFFERENTIATION IN THE WHEAT STEM RUST FUNGUS, PHYSIOL MOL PLANT PATHOL, 68, PP. 33-40, (2006); HARGROVE J., GREENSPAN P., HARTLE D., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); ARRUZAZABALA M., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); KARLADEE D., SURIYONG S., Γ-AMINOBUTYRIC ACID (GABA) CONTENT IN DIFFERENT VARIETIES OF BROWN RICE DURING GERMINATION, SCI ASIA, 38, PP. 13-17, (2012); KUGLER F., GRANEIS S., SCHREITER P.P., STINTZING F.C., CARLE R., DETERMINATION OF FREE AMINO COMPOUNDS IN BETALAINIC FRUITS AND VEGETABLES BY GAS CHROMATOGRAPHY WITH FLAME IONIZATION AND MASS SPECTROMETRIC DETECTION, J AGRIC FOOD CHEM, 54, PP. 4311-4318, (2006); SHIGEMATSU T.S., MURAKAMI M.M., NAKAJIMA K.N., UNO Y.U., SAKANO A.S., NARAHARA Y.N., ET AL., BIOCONVERSION OF GLUTAMIC ACID TO Γ -AMINOBUTYRIC ACID (GABA) IN BROWN RICE GRAINS INDUCED BY HIGH PRESSURE TREATMENT, JAPAN J FOOD ENG, 11, PP. 189-199, (2010); AZRINA A., MAZNAH I., AZIZAH A.H., EXTRACTION AND DETERMINATION OF ORYZANOL IN RICE BRAN OF MIXED HERBARIUM UKMB; AZ 6807: MR 185, AZ 6808: MR 211, AZ6809: MR 29, ASEAN FOOD J, 15, PP. 89-96, (2008); SAKUNPAK A., SUKSAEREE J., PATHOMPAK P., SERMKAEW N., ANTIOXIDANT INDIVIDUAL Y-ORYZANOL SCREENING IN COLD PRESSED RICE BRAN OIL OF DIFFERENT THAI RICE VARIETIES BY HPLC-DPPH METHOD, INT J PHARM PHARMACEUT SCI, 6, PP. 2-7, (2014); CHEN M.H., BERGMAN C.J., A RAPID PROCEDURE FOR ANALYSING RICE BRAN TOCOPHEROL, TOCOTRIENOL AND Y -ORYZANOL CONTENTS, J FOOD COMPOS ANAL, 18, PP. 139-151, (2005); BEVERIDGE T.H.J., LI T.S.C., DROVER J.C.G., PHYTOSTEROL CONTENT IN AMERICAN GINSENG SEED OIL, J AGRIC FOOD CHEM, 50, PP. 744-750, (2002); THANH T.T., VERGNES M.F., KALOUSTIAN J., EL-MOSELHY T.F., AMIOT-CARLIN M.J., PORTUGAL H., EFFECT OF STORAGE AND HEATING ON PHYTOSTEROL CONCENTRATIONS IN VEGETABLE OILS DETERMINED BY GC/MS, J SCI FOOD AGRIC, 86, PP. 220-225, (2006); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT J NANOMEDICINE, 9, PP. 2261-2269, (2014); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, PP. 583-591, (2012); ASIKIN Y., CHINEN T., KENSAKU T., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI TECHNOL RES, 14, PP. 583-588, (2008); RENUKA DEVI R., ARUMUGHAN C., PHYTOCHEMICAL CHARACTERIZATION OF DEFATTED RICE BRAN AND OPTIMIZATION OF A PROCESS FOR THEIR EXTRACTION AND ENRICHMENT, BIORESOUR TECHNOL, 98, PP. 3037-3043, (2007); PERRETTI G., MINIATI E., MONTANARI L., FANTOZZI P., IMPROVING THE VALUE OF RICE BY-PRODUCTS BY SFE, J SUPERCRIT FLUIDS, 26, PP. 63-71, (2003); KIM J.Y., SEO W.D., PARK D., JANG K.C., CHOI K., KIM S., ET AL., COMPARATIVE STUDIES ON MAJOR NUTRITIONAL COMPONENTS OF BLACK WAXY RICE WITH GIANT EMBRYOS AND ITS RICE BRAN, FOOD SCI BIOTECHNOL, 22, PP. 121-128, (2013); PRAMAI P., ABDUL HAMID N.A., MEDIANI A., MAULIDIANI M., ABAS F., JIAMYANGYUEN S., METABOLITE PROFILING, ANTIOXIDANT, AND Α-GLUCOSIDASE INHIBITORY ACTIVITIES OF GERMINATED RICE: NUCLEAR-MAGNETIC-RESONANCE-BASED METABOLOMICS STUDY, J FOOD DRUG ANAL, 26, PP. 47-57, (2018); ZHAO K., LIN L., LI C., DU S., HUANG C., QIN Y., ET AL., MEASUREMENT AND CORRELATION OF SOLUBILITY OF Γ-AMINOBUTYRIC ACID IN DIFFERENT BINARY SOLVENTS, J CHEM ENG DATA, 61, PP. 1210-1220, (2016); YOON S.H., KIM S.K., OXIDATIVE STABILITY OF HIGH-FATTY ACID RICE BRAN OIL AT DIFFERENT STAGES OF REFINING, J AM OIL CHEM SOC, 71, PP. 227-229, (1994); PESTANA V.R., ZAMBIAZI R.C., MENDONC C.R.B., BRUSCATTO M.H., LERMA-GARCIA M.J., RAMIS-RAMOS G., QUALITY CHANGES AND TOCOPHEROLS AND GAMMA-ORIZANOL CONCENTRATIONS IN RICE BRAN OIL DURING THE REFINING PROCESS, J AM OIL CHEM SOC, PP. 1013-1019, (2008); BHATNAGAR A.S., PRABHAKAR D.S., PRASANTH KUMAR P.K., RAJA RAJAN R.G., GOPALA KRISHNA A.G., PROCESSING OF COMMERCIAL RICE BRAN FOR THE PRODUCTION OF FAT AND NUTRACEUTICAL RICH RICE BROKENS, RICE GERM AND PURE BRAN, LWT - FOOD SCI TECHNOL, 58, PP. 306-311, (2014); REVILLA E., SANTA C., MIRAMONTES E., BAUTISTA J., GARCIA-MARTINEZ A., CREMADES O., ET AL., NUTRACEUTICAL COMPOSITION, ANTIOXIDANT ACTIVITY AND HYPOCHOLESTEROLEMIC EFFECT OF A WATER-SOLUBLE ENZYMATIC EXTRACT FROM RICE BRAN, FOOD RES INT, 42, PP. 387-393, (2009); SAWADIKIAT P., HONGSPRABHAS P., PHYTOSTEROLS AND Γ-ORYZANOL IN RICE BRAN OILS AND DISTILLATES FROM PHYSICAL REFINING PROCESS, INT J FOOD SCI TECHNOL, 49, PP. 2030-2036, (2014); DERAKHSHAN-HONARPARVAR M., HAMEDI M.M., PIROUZIFARD M.K., RICE BRAN PHYTOSTEROLS OF THREE WIDESPREAD IRANIAN CULTIVARS, J AGRIC SCI TECHNOL, 12, PP. 167-172, (2010); NORMEN L., ELLEGARD L., BRANTS H., DUTTA P., ANDERSSON H., A PHYTOSTEROL DATABASE: FATTY FOODS CONSUMED IN SWEDEN AND THE NETHERLANDS, J FOOD COMPOS ANAL, 20, PP. 193-201, (2007); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR J LIPID SCI TECHNOL, 106, PP. 147-151, (2004); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); CHEN Z., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); FRANCINI-PESENTI F., BELTRAMOLLI D., ACQUA D.S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTHER RES, 22, PP. 318-322, (2008); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, J CLIN THERAPEUT, 7, PP. 203-217, (2002); KIM J.K., PARK S.-Y., JUNG J.Y., HA S.-H., LIM S.-H., LEE S.M., ET AL., POLICOSANOL CONTENT AND COMPOSITION OF KOREAN RICE (ORYZA SATIVA L.) CULTIVARS, CEREAL CHEM, 89, PP. 151-154, (2012); WEERAWATANAKORN M., TAMAKI H., ASIKIN Y., WADA K., TAKAHASHI M., HO C.T., ET AL., POLICOSANOL CONTENTS, VOLATILE PROFILE AND TOXICITY TEST OF GRANULATED CANE SUGAR ENRICHED WITH RICE BRAN MATERIALS, INT FOOD RES J, 24, PP. 1019-1028, (2017); IQBAL J., MINHAJUDDIN M., BEG Z., SUPPRESSION OF 7,12- DIMETHYLBENZALPHAANTHRACENE-INDUCED CARCINOGENESIS AND HYPERCHOLESTEROLAEMIA IN RATS BY TOCOTRIENOL-RICH FRACTION ISOLATED FROM RICE BRAN OIL, EUR J CANCER PREV, 12, PP. 447-453, (2003); XU Z., HUA N., GODBER S., ANTIOXIDANT ACTIVITY OF TOCOPHEROLS, TOCOTRIENOLS, AND Y-ORYZANOL COMPONENTS FROM RICE BRAN AGAINST CHOLESTEROL OXIDATION ACCELERATED BY 2,2’-AZOBIS(2-METHYLPROPIONAMIDINE) DIHYDROCHLORIDE, J AGRIC FOOD CHEM, 49, PP. 2077-2081, (2001)","M. WEERAWATANAKORN; DEPARTMENT OF AGRO-INDUSTRY, NARESUAN UNIVERSITY, PHITSANULOK, 99 MOO 9, THA PHO, 65000, THAILAND; EMAIL: MONTHANAC@NU.AC.TH","ELSEVIER TAIWAN LLC","ENGLISH","J. FOOD DRUG ANAL.","ARTICLE","ISI","2-S2.0-85049327208","J FOOD DRUG ANAL","NARESUAN UNIVERSITY;NARESUAN UNIVERSITY;RUTGERS UNIVERSITY","NOTREPORTED;NARESUAN UNIVERSITY;NOTREPORTED",NA,"WONGWAIWECH D, 2019, J FOOD DRUG ANAL","WONGWAIWECH D, 2019, J FOOD DRUG ANAL"
"TIAN Y;ACEVEDO N","TIAN, YIXING (57212702762); ACEVEDO, NURIA C. (57197166068)","KINETIC STUDY ON PHOTOSTABILITY OF RETINYL PALMITATE ENTRAPPED IN POLICOSANOL OLEOGELS",2018,"FOOD CHEMISTRY","255","7",19,"10.1016/j.foodchem.2018.02.025","DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, IOWA STATE UNIVERSITY, AMES, 50011, IA, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, IOWA STATE UNIVERSITY, AMES, 50011, IA, UNITED STATES","PHOTOSTABILITY OF ALL-TRANS RETINYL PALMITATE (RP) (100% BIOACTIVITY) WAS STUDIED IN POLICOSANOL OLEOGELS (PCOS) (7–12% W/W POLICOSANOL IN SOYBEAN OIL) AFTER UVA IRRADIATION. RP WAS INCORPORATED INTO PCOS AT LEVELS OF 0.04%, 0.1% AND 1% (W/W). PCOS EFFICIENTLY PROTECTED RP FROM UVA-MEDIATED DEGRADATION. OVER 75% RP-ACTIVITY REMAINED IN PCOS AFTER 4 DAYS OF UVA IRRADIATION, WHILE 12% RP-ACTIVITY REMAINED IN SOYBEAN OIL. HPLC ANALYSIS SHOWED THAT CIS-RP WAS FORMED IN LIQUID SOYBEAN OIL AFTER 2 DAYS OF UVA IRRADIATION WHILE IT WAS ABSENT IN PCOS MATRICES. PCOS BLOCKED THE ENERGY ABSORPTION FROM UVA AND FURTHER DAMPENED THE UVA-MEDIATED IONIC PHOTODISSOCIATION AND FREE RADICAL REACTION DUE TO MATRIX IMMOBILIZATION. FOR ALL SAMPLES, RP PHOTODEGRADATION FOLLOWED A 2ND ORDER REACTION. FROM THE REACTION KINETICS, IT WOULD BE POSSIBLE TO PREDICT THE RP PHOTODEGRADATION RATE IN PCO MATRICES. PCOS WERE SHOWN TO BE A PROMISING MATRIX TO PROTECT RP FROM PHOTODEGRADATION. © 2018 ELSEVIER LTD","OLEOGEL; PHOTOSTABILITY; POLICOSANOL; RETINYL PALMITATE","CHEMICAL REACTIONS; FREE RADICAL REACTIONS; IRRADIATION; PALMITIC ACID; REACTION KINETICS; POLICOSANOL; POLICOSANOL OLEOGEL; RETINOL PALMITATE; SOYBEAN OIL; UNCLASSIFIED DRUG; KINETIC STUDY; OLEOGEL; ORDER REACTIONS; PHOTO-STABILITY; PHOTODEGRADATION RATE; POLICOSANOL; RETINYL PALMITATE; UVA IRRADIATIONS; ARTICLE; CHEMICAL REACTION KINETICS; CHEMICAL STRUCTURE; ENERGY ABSORPTION; ENTHALPY; FLOW KINETICS; GELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MELTING POINT; PHOTODEGRADATION; THERMOSTABILITY; ULTRAVIOLET A RADIATION; SOYBEAN OIL","","","ABDALLAH D.J., LU L., WEISS R.G., THERMOREVERSIBLE ORGANOGELS FROM ALKANE GELATORS WITH ONE HETEROATOM, CHEMISTRY OF MATERIALS, 11, 10, PP. 2907-2911, (1999); ACEVEDO N.C., BLOCK J.M., MARANGONI A.G., CRITICAL LAMINAR SHEAR-TEMPERATURE EFFECTS ON THE NANO-AND MESOSCALE STRUCTURE OF A MODEL FAT AND ITS RELATIONSHIP TO OIL BINDING AND RHEOLOGICAL PROPERTIES, FARADAY DISCUSSIONS, 158, 1, PP. 171-194, (2012); AGUILERA J., MICHEL M., MAYOR G., FAT MIGRATION IN CHOCOLATE: DIFFUSION OR CAPILLARY FLOW IN A PARTICULATE SOLID?—A HYPOTHESIS PAPER, JOURNAL OF FOOD SCIENCE, 69, 7, PP. 167-174, (2004); ALLWOOD M., PLANE J., THE WAVELENGTH-DEPENDENT DEGRADATION OF VITAMIN A EXPOSED TO ULTRAVIOLET RADIATION, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 31, 1-2, PP. 1-7, (1986); BLAKE A.I., MARANGONI A.G., STRUCTURE AND PHYSICAL PROPERTIES OF PLANT WAX CRYSTAL NETWORKS AND THEIR RELATIONSHIP TO OIL BINDING CAPACITY, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 91, 6, PP. 885-903, (2014); CARLOTTI M., ROSSATTO V., GALLARATE M., VITAMIN A AND VITAMIN A PALMITATE STABILITY OVER TIME AND UNDER UVA AND UVB RADIATION, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 240, 1, PP. 85-94, (2002); CARLOTTI M., SAPINO S., TROTTA M., BATTAGLIA L., VIONE D., PELIZZETTI E., PHOTOSTABILITY AND STABILITY OVER TIME OF RETINYL PALMITATE IN AN O/W EMULSION AND IN SLN INTRODUCED IN THE EMULSION, JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, 26, 2, PP. 125-138, (2005); CIRPANLI Y., UNLU N., CALIS S., ATILLA HINCAL A., FORMULATION AND IN-VITRO CHARACTERIZATION OF RETINOIC ACID LOADED POLY (LACTIC-CO-GLYCOLIC ACID) MICROSPHERES, JOURNAL OF MICROENCAPSULATION, 22, 8, PP. 877-889, (2005); COATES P.M., BLACKMAN M.R., CRAGG G.M., LEVINE M., MOSS J., WHITE J.D., ENCYCLOPEDIA OF DIETARY SUPPLEMENTS, (2004); DUCLAIROIR C., IRACHE J.M., NAKACHE E., ORECCHIONI A.M., CHABENAT C., POPINEAU Y., GLIADIN NANOPARTICLES: FORMATION, ALL-TRANS-RETINOIC ACID ENTRAPMENT AND RELEASE, SIZE OPTIMIZATION, POLYMER INTERNATIONAL, 48, 4, PP. 327-333, (1999); FLANAGAN J., SINGH H., MICROEMULSIONS: A POTENTIAL DELIVERY SYSTEM FOR BIOACTIVES IN FOOD, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 46, 3, PP. 221-237, (2006); GANDOLFO F.G., BOT A., FLOTER E., STRUCTURING OF EDIBLE OILS BY LONG-CHAIN FA, FATTY ALCOHOLS, AND THEIR MIXTURES, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 81, 1, PP. 1-6, (2004); GRAVELLE A., DAVIDOVICH-PINHAS M., ZETZL A., BARBUT S., MARANGONI A., INFLUENCE OF SOLVENT QUALITY ON THE MECHANICAL STRENGTH OF ETHYLCELLULOSE OLEOGELS, CARBOHYDRATE POLYMERS, 135, PP. 169-179, (2016); IHARA H., HASHIZUME N., HIRASE N., SUZUE R., ESTERIFICATION MAKES RETINOL MORE LABILE TO PHOTYOLYSIS, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 45, 3, PP. 353-358, (1999); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); JANG A., BAE W., HWANG H.-S., LEE H.G., LEE S., EVALUATION OF CANOLA OIL OLEOGELS WITH CANDELILLA WAX AS AN ALTERNATIVE TO SHORTENING IN BAKED GOODS, FOOD CHEMISTRY, 187, PP. 525-529, (2015); JENNING V., GOHLA S.H., ENCAPSULATION OF RETINOIDS IN SOLID LIPID NANOPARTICLES (SLN), JOURNAL OF MICROENCAPSULATION, 18, 2, PP. 149-158, (2001); JEONG Y.-I., SONG J.-G., KANG S.-S., RYU H.-H., LEE Y.-H., CHOI C., JUNG S., PREPARATION OF POLY (DL-LACTIDE-CO-GLYCOLIDE) MICROSPHERES ENCAPSULATING ALL-TRANS RETINOIC ACID, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 259, 1, PP. 79-91, (2003); JUNG M., LEE K., KIM S., RETINYL PALMITATE ISOMERS IN SKIM MILK DURING LIGHT STORAGE AS AFFECTED BY ASCORBIC ACID, JOURNAL OF FOOD SCIENCE, 63, 4, PP. 597-600, (1998); LIM S.-J., LEE M.-K., KIM C.-K., ALTERED CHEMICAL AND BIOLOGICAL ACTIVITIES OF ALL-TRANS RETINOIC ACID INCORPORATED IN SOLID LIPID NANOPARTICLE POWDERS, JOURNAL OF CONTROLLED RELEASE, 100, 1, PP. 53-61, (2004); LOVEDAY S.M., SINGH H., RECENT ADVANCES IN TECHNOLOGIES FOR VITAMIN A PROTECTION IN FOODS, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 19, 12, PP. 657-668, (2008); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RESEARCH INTERNATIONAL, 51, 2, PP. 510-517, (2013); MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 89, 5, PP. 749-780, (2012); MARANGONI A.G., GARTI N., EDIBLE OLEOGELS: STRUCTURE AND HEALTH IMPLICATIONS, (2011); MURPHY P.A., ENGELHARDT R., SMITH S.E., ISOMERIZATION OF RETINYL PALMITATE IN FORTIFIED SKIM MILK UNDER RETAIL FLUORESCENT LIGHTING, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 36, 3, PP. 592-595, (1988); OMONOV T.S., BOUZIDI L., NARINE S.S., QUANTIFICATION OF OIL BINDING CAPACITY OF STRUCTURING FATS: A NOVEL METHOD AND ITS APPLICATION, CHEMISTRY AND PHYSICS OF LIPIDS, 163, 7, PP. 728-740, (2010); ROGERS M.A., WRIGHT A.J., MARANGONI A.G., NANOSTRUCTURING FIBER MORPHOLOGY AND SOLVENT INCLUSIONS IN 12-HYDROXYSTEARIC ACID/CANOLA OIL ORGANOGELS, CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 14, 1, PP. 33-42, (2009); RUSSEL R., BEARD J., COUSINS R.J., DUNN J.T., FERLAND G., HAMBRIDGE K.M., ET AL., DIETARY REFERENCES INTAKES FOR VIATMIN A, VITAMIN K, ARSENIC, ORON, CHROMIUM, COPPER, IODINE, IRON, MANGANESE, MOLYBDENUM, NICKEL, SILICON, VANADIUM, AND ZINC, (2001); SATAPATHY D., BISWAS D., BEHERA B., SAGIRI S.S., PAL K., PRAMANIK K., SUNFLOWER-OIL-BASED LECITHIN ORGANOGELS AS MATRICES FOR CONTROLLED DRUG DELIVERY, JOURNAL OF APPLIED POLYMER SCIENCE, 129, 2, PP. 585-594, (2013); SCALZO M., SANTUCCI E., CERRETO F., CARAFA M., MODEL LIPOPHILIC FORMULATIONS OF RETINYL PALMITATE: INFLUENCE OF CONSERVATIVE AGENTS ON LIGHT-INDUCED DEGRADATION, JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 34, 5, PP. 921-931, (2004); SEMENZATO A., BAU A., DALL'AGLIO C., NICOLINI M., BETTERO A., CALLIARI I., STABILITY OF VITAMIN A PALMITATE IN COSMETIC EMULSIONS: INFLUENCE OF PHYSICAL PARAMETERS, INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 16, 4, PP. 139-147, (1994); VITHANAGE C.R., GRIMSON M.J., SMITH B.G., THE EFFECT OF TEMPERATURE ON THE RHEOLOGY OF BUTTER, A SPREADABLE BLEND AND SPREADS, JOURNAL OF TEXTURE STUDIES, 40, 3, PP. 346-369, (2009); WANG H., FANG F., LI X., FU C., YANG Y., IMPROVED PHOTOSTABILITY OF VITAMIN A PALMITATE ORIGINATING FROM SELF-ASSEMBLED SUPRAMOLECULAR GELS, CHINESE SCIENCE BULLETIN, 57, 33, PP. 4257-4263, (2012); YAGHMUR A., DE CAMPO L., SAGALOWICZ L., LESER M., GLATTER O., MICHEL M.; YOSHIDA K., SEKINE T., MATSUZAKI F., YANAKI T., YAMAGUCHI M., STABILITY OF VITAMIN A IN OIL-IN-WATER-IN-OIL-TYPE MULTIPLE EMULSIONS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 76, 2, PP. 1-6, (1999); YU H., SHI K., LIU D., HUANG Q., DEVELOPMENT OF A FOOD-GRADE ORGANOGEL WITH HIGH BIOACCESSIBILITY AND LOADING OF CURCUMINOIDS, FOOD CHEMISTRY, 131, 1, PP. 48-54, (2012)","N.C. ACEVEDO; IOWA STATE UNIVERSITY, AMES, 2543 FOOD SCIENCE BUILDING, 50011, UNITED STATES; EMAIL: NACEVEDO@IASTATE.EDU","ELSEVIER LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-85042293209","FOOD CHEM","IOWA STATE UNIVERSITY;IOWA STATE UNIVERSITY","NOTREPORTED;IOWA STATE UNIVERSITY;NOTREPORTED",NA,"TIAN Y, 2018, FOOD CHEM","TIAN Y, 2018, FOOD CHEM"
"ESPOSITO R;SORRENTINO R;GIUGLIANO G;AVVEDIMENTO M;PAOLILLO R;SANTORO C;SCALAMOGNA M;ESPOSITO M;ILARDI F;ROZZA F;ESPOSITO G;GALDERISI M;TRIMARCO V","ESPOSITO, ROBERTA (15843137300); SORRENTINO, REGINA (58766999800); GIUGLIANO, GIUSEPPE (14029912800); AVVEDIMENTO, MARISA (57031880600); PAOLILLO, ROBERTA (57189262925); SANTORO, CIRO (54795845800); SCALAMOGNA, MARIA (57211254113); ESPOSITO, MAFALDA (57221854718); ILARDI, FEDERICA (41561578200); ROZZA, FRANCESCO (23498918300); ESPOSITO, GIOVANNI (55482395100); GALDERISI, MAURIZIO (57203882101); TRIMARCO, VALENTINA (6602355473)","DIFFERENT AGEINDEPENDENT EFFECTS OF NUTRACEUTICAL COMBINATIONS ON ENDOTHELIUMMEDIATED CORONARY FLOW RESERVE",2018,"IMMUNITY AND AGEING","15","",4,"10.1186/s12979-018-0138-3","DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY, INTERDEPARTMENTAL LABORATORY OF CARDIAC IMAGING, FEDERICO II UNIVERSITY HOSPITAL, VIA PANSINI 5, NAPLES, 80131, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, ITALY","BACKGROUND: SOME COMPONENTS OF NUTRACEUTICALS (NUT) SUCH AS RED YEAST RICE AND MORUS ALBA HAVE DEMONSTRATED POSITIVE EFFECTS ON THE ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLEMIC SUBJECTS. OUR AIM WAS TO COMPARE THE EFFECTS OF TWO DIFFERENT NUT COMBINATIONS ON COLD PRESSURE TEST (CPT) DERIVED CORONARY FLOW RESERVE (CFR) ASSESSED BY TRANSTHORACIC ECHO-DOPPLER. RESULTS: IN A RANDOMIZED, SINGLE-BLIND STUDY, 28 CONSECUTIVE PATIENTS WITH A VARIETY OF CARDIOVASCULAR RISK FACTORS RECEIVED NUT A (LOPIGLIK®: BERBERINE, RED YEAST RICE POWDER, AND LEAF EXTRACT OF MORUS ALBA) OR B (ARMOLIPID PLUS®: POLICOSANOL, RED YEAST RICE, BERBERINE, ASTAXANTINE, FOLIC ACIDANDCOENZYME Q10). AN ECHO-DOPPLER EXAM WITH EVALUATION OF CFR WAS PERFORMED AT BASELINE, 2 H (ACUTE TEST) AND 30 DAYS AFTER DAILY NUT ASSUMPTION. BLOOD SAMPLING FOR METABOLIC PROFILE AND PLATELET AGGREGOMETRY WAS PERFORMED AT BASELINE AND AFTER 30 DAYS OF DAILY NUT ASSUMPTION. CFR WAS NOT SIGNIFICANTLY MODIFIED AT THE ACUTE TEST. AFTER 30 DAYS, CFR IMPROVED WITH NUT A (P < 0.0001), BECAUSE OF THE INCREASE OF HYPEREMIC FLOW VELOCITY (P = 0.007), BUT NOT WITH NUT B. CFR WAS COMPARABLE BETWEEN THE TWO GROUPS AT BASELINE BUT BECAME SIGNIFICANTLY HIGHER AFTER 30 DAYS IN NUT A (P < 0.02), WITH A HIGHER CFR PERCENT VARIATION VERSUS BASELINE (P = 0.008). TOTAL CHOLESTEROL AND LDL-CHOLESTEROL WERE REDUCED WITH BOTH NUT A (P < 0.001 AND P < 0.002, RESPECTIVELY) AND B (BOTH P < 0.02), WHEREAS PLATELET AGGREGATION DID NOT SIGNIFICANTLY CHANGE. IN THE POOLED GROUP OF PATIENTS, AFTER ADJUSTING FOR AGE AND PERCENT CHANGES OF SYSTOLIC BLOOD PRESSURE, HEART RATE, LDL-CHOLESTEROL AND GLYCEMIA, NUT A – BUT NOT NUT B - WAS INDEPENDENTLY ASSOCIATED WITH CFR CHANGES (Β = 0.599, P = 0.003). CONCLUSIONS: LOPIGLIK® IMPROVED ENDOTHELIAL-DERIVED CFR, INDEPENDENTLY OF THE BENEFICIAL EFFECTS EXERTED ON THE LIPID PROFILE. THESE FINDINGS CAN HAVE CLINICAL REFLECTIONS ON THE PREVENTION OF AGE-RELATED INFLAMMATORY DISEASES INCLUDING CORONARY ARTERY DISEASE. TRIAL REGISTRATION: (NUTRENDO)″(CLINICALTRIALS.GOV, NCT02969070). © 2018, THE AUTHOR(S).","CHOLESTEROL-LOWERING; COLD PRESSURE TEST; CORONARY FLOW RESERVE; ENDOTHELIAL FUNCTION; NUTRACEUTICAL THERAPY","ARMOLIPID PLUS; ASTAXANTINE; BERBERINE; CARDIAC AGENT; CHOLESTIN; FOLIC ACID; LOPIGLIK; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULBERRY EXTRACT; NUTRACEUTICAL; POLICOSANOL; UBIDECARENONE; UNCLASSIFIED DRUG; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CARDIOVASCULAR RISK FACTOR; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; CORONARY FLOW RESERVE; DOPPLER ULTRASONOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPEREMIA; LIPID FINGERPRINTING; MALE; METABOLIC FINGERPRINTING; MIDDLE AGED; MONOTHERAPY; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; TRANSTHORACIC ECHOCARDIOGRAPHY; VASCULAR ENDOTHELIUM","","","CAMICI P.G., CREA F., CORONARY MICROVASCULAR DYSFUNCTION, N ENGL J MED, 35, PP. 830-840, (2007); GALDERISI M., D'ERRICO A., BETA-BLOCKERS AND CORONARY FLOW RESERVE: THE IMPORTANCE OF A VASODILATORY ACTION, DRUGS, 68, PP. 579-590, (2008); SCHACHINGER V., BRITTEN M.B., ZEIHER A.M., PROGNOSTIC IMPACT OF CORONARY VASODILATOR DYSFUNCTION ON ADVERSE LONG-TERM OUTCOMES OF CORONARY ARTERY DISEASE, CIRCULATION, 101, PP. 1899-1906, (2000); POLI A., BARBAGALLO C.M., CICERO A.F.G., CORSINI A., MANZATO E., TRIMARCO B., ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOL RES, 134, PP. 51-60, (2018); ADORNI M.P., FERRI N., MARCHIANO S., TRIMARCO V., ROZZA F., IZZO R., EFFECT OF A NOVEL NUTRACEUTICAL COMBINATION ON SERUM LIPOPROTEIN FUNCTIONAL PROFILE AND CIRCULATING PCSK9, THER CLIN RISK MANAG, 13, PP. 1555-1562, (2017); TRIMARCO V., IZZO R., STABILE E., ROZZA F., SANTORO M., MANZI M.V., ET AL., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE, INSULIN SENSITIVITY AND ENDOTHELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS. A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND TRIAL, HIGH BLOOD PRESS CARDIOVASC PREV, 22, PP. 149-154, (2015); MILLAN J., CICERO A.F., TORRES F., ANGUERA A., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLIN INVESTIG ARTERIOSCLER, 28, PP. 178-187, (2016); PIRRO M., MANNARINO M.R., BIANCONI V., SIMENTAL-MENDIA L.E., BAGAGLIA F., MANNARINO E., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR HEART J, 2016, 37, (2016); REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., ET AL., COMMITTEE FOR PRACTICE GUIDELINES (CPG)2008–2010 AND 2010–2012 COMMITTEES. ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NMCD, 27, (2017); CARRIZZO A., AMBROSIO M., DAMATO A., MADONNA M., STORTO M., CAPOCCI L., ET AL., MORUS ALBA EXTRACT MODULATES BLOOD PRESSURE HOMEOSTASIS THROUGH ENOS SIGNALING, MOL NUTR FOOD RES, 60, PP. 2304-2311, (2016); DAYANIKLI F., GRAMBOW D., MUZIK O., MOSCA L., RUBENFIRE M., SCHWAIGER M., EARLY DETECTION OF ABNORMAL CORONARY FLOW RESERVE IN ASYMPTOMATIC MEN AT HIGH RISK FOR CORONARY ARTERY DISEASE USING POSITRON EMISSION TOMOGRAPHY, CIRCULATION, 90, PP. 808-817, (1994); GOULD K.L., MARTUCCI J.P., GOLDBERG D.I., HESS M.J., EDENS R.P., LATIFI R., ET AL., SHORT-TERM CHOLESTEROL LOWERING DECREASES SIZE AND SEVERITY OF PERFUSION ABNORMALITIES BY POSITRON EMISSION TOMOGRAPHY AFTER DIPYRIDAMOLE IN PATIENTS WITH CORONARY ARTERY DISEASE, CIRCULATION, 89, PP. 1530-1538, (1994); LEMBO M., ESPOSITO R., LO IUDICE F., SANTORO C., IZZO R., DE LUCA N., ET AL., IMPACT OF PULSE PRESSURE ON LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN IN NORMOTENSIVE AND NEWLY DIAGNOSED, UNTREATED HYPERTENSIVE PATIENTS, J HYPERTENS, 34, PP. 1201-1207, (2016); LANG R.M., BADANO L.P., MOR-AVI V., AFILALO J., ARMSTRONG A., ERNANDE L., ET AL., RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY IN ADULTS: AN UPDATE FROM THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY AND THE EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING, EUR HEART J CARDIOVASC IMAGING, 15, PP. 233-270, (2015); NAGUEH S.F., SMISETH O.A., APPLETON C.P., BYRD B.F., DOKAINISH H., EDVARDSEN T., ET AL., RECOMMENDATIONS FOR THE EVALUATION OF LEFT VENTRICULAR DIASTOLIC FUNCTION BY ECHOCARDIOGRAPHY: AN UPDATE FROM THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY AND THE EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING, J AM SOC ECHOCARDIOGR, 29, PP. 277-314, (2016); ZEIHER A.M., DREXLER H., WOLLSCHLAEGER H., SAURBIER B., JUST H., CORONARY VASOMOTION IN RESPONSE TO SYMPATHETIC STIMULATION IN HUMANS: IMPORTANCE OF THE FUNCTIONAL INTEGRITY OF THE ENDOTHELIUM, J AM COLL CARDIOL, 141, PP. 181-1190, (1989); EGASHIRA K., INOU T., HIROOKA Y., YAMADA A., URABE Y., TAKESHITA A., EVIDENCE OF IMPAIRED ENDOTHELIUM-DEPENDENT CORONARY VASODILATATION IN PATIENTS WITH ANGINA PECTORIS AND NORMAL CORONARY ANGIOGRAMS, N ENGL J MED, 328, PP. 1659-1664, (1993); CICALA S., GALDERISI M., GRIECO M., LAMBERTI A., COSIMI R., PELLEGRINI F., ET AL., TRANSTHORACIC ECHO-DOPPLER ASSESSMENT OF CORONARY MICROVASCULAR FUNCTION LATE AFTER KAWASAKI DISEASE, PEDIATR CARDIOL, 29, PP. 321-327, (2008); BIONDI B., GALDERISI M., PAGANO L., SIDIROPULOS M., PULCRANO M., D'ERRICO A., ET AL., ENDOTHELIAL-MEDIATED CORONARY FLOW RESERVE IN PATIENTS WITH MILD THYROID HORMONE DEFICIENCY, EUR J ENDOCRINOL, 161, PP. 323-329, (2009); IPPOLITO S., IPPOLITO R., PEIRCE C., ESPOSITO R., ARPAIA D., SANTORO C., PONTIERI G., COCOZZA S., GALDERISI M., BIONDI B., RECOMBINANT HUMAN THYROTROPIN IMPROVES ENDOTHELIAL CORONARY FLOW RESERVE IN THYROIDECTOMIZED PATIENTS WITH DIFFERENTIATED THYROID CANCER, THYROID, 26, PP. 1528-1534, (2016); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); ILARDI F., GARGIULO G., SCHIATTARELLA G.G., GIUGLIANO G., PAOLILLO R., MENAFRA G., ET AL., EFFECTS OF CARVEDILOL VERSUS METOPROLOL ON PLATELET AGGREGATION IN PATIENTS WITH ACUTE CORONARY SYNDROME. THE PLATE-BLOCK STUDY, AM J CARDIOL, 122, PP. 6-11, (2018); MINGANT F., DIDIER R., GILARD M., MARTIN F., NICOL P.P., UGO V., ET AL., COMPARISON OF FOUR METHODS TO ASSESS HIGH-ON PLATELET REACTIVITY UNDER P2Y12 RECEPTOR INHIBITOR, PLATELETS, 29, PP. 257-264, (2018); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NMCD, 20, PP. 656-661, (2010); LEE J.J., YANG H., YOO Y.M., HONG S.S., LEE D., LEE H.J., ET AL., MORUSINOL EXTRACTED FROM MORUS ALBA INHIBITS ARTERIAL THROMBOSIS AND MODULATES PLATELET ACTIVATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, J ATHEROSCLER THROMB, 19, PP. 516-522, (2012); KIM D.-S., JI H.D., RHEE M.H., SUNG Y.-Y., YANG W.-K., KIM S.H., KIM H.-K., ANTIPLATELET ACTIVITY OFMORUS ALBALEAVES EXTRACT, MEDIATED VIA INHIBITING GRANULE SECRETION AND BLOCKING THE PHOSPHORYLATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE AND AKT, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, PP. 1-11, (2014); KIM D.-S., IRFAN M., SUNG Y.-Y., KIM S.H., PARK S.H., CHOI Y.H., RHEE M.H., KIM H.K., SCHISANDRA CHINENSIS AND MORUS ALBA SYNERGISTICALLY INHIBIT IN VIVO THROMBUS FORMATION AND PLATELET AGGREGATION BY IMPAIRING THE GLYCOPROTEIN VI PATHWAY, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, PP. 1-10, (2017); FAN L.M., CAHILL-SMITH S., GENG L., DU J., BROOKS G., LI J.M., AGING-ASSOCIATED METABOLIC DISORDERS INDUCES NOX2 ACTIVATION AND OXIDATIVE DAMAGE ON ENDOTHELIAL FUNCTION, FREE RADIC BIOL MED, 108, PP. 940-951, (2017); PANENI F., DIAZ CANESTRO C., LIBBY P., LUSCHER T.F., CAMICI G.G., THE AGING CARDIOVASCULAR SYSTEM: UNDERSTANDING IT AT THE CELLULAR AND CLINICAL LEVELS, J AM COLL CARDIOL., 69, PP. 1952-1967, (2017); HWANG S.H., LI H.M., LIM S.S., WANG Z., HONG J.-S., HUANG B., EVALUATION OF A STANDARDIZED EXTRACT FROMMORUS ALBAAGAINSTΑ-GLUCOSIDASE INHIBITORY EFFECT AND POSTPRANDIAL ANTIHYPERGLYCEMIC IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE: A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, PP. 1-10, (2016); PIRRO M., MANNARINO M.R., MINISTRINI S., FALLARINO F., LUPATTELLI G., BIANCONI V., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION ON LIPIDS, INFLAMMATION AND ENDOTHELIAL INTEGRITY IN PATIENTS WITH SUBCLINICAL INFLAMMATION: A RANDOMIZED CLINICAL TRIAL, SCI REP, 6, (2016); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., TRIMARCO B., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, JOURNAL OF HYPERTENSION, 28, 7, PP. 1482-1487, (2010)","M. GALDERISI; INTERDEPARTMENTAL LABORATORY OF CARDIAC IMAGING, FEDERICO II UNIVERSITY HOSPITAL, NAPLES, VIA PANSINI 5, 80131, ITALY; EMAIL: MGALDERI@UNINA.IT","BIOMED CENTRAL LTD","ENGLISH","IMMUN. AGEING","ARTICLE","ISI","2-S2.0-85066439352","IMMUN AGEING","FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY HOSPITAL","NOTREPORTED;FEDERICO II UNIVERSITY HOSPITAL;NOTREPORTED",NA,"ESPOSITO R, 2018, IMMUN AGEING","ESPOSITO R, 2018, IMMUN AGEING"
"HUNTER P;HEGELE R","HUNTER, PAOLA M. (56998228900); HEGELE, ROBERT A. (35399481100)","FUNCTIONAL FOODS AND DIETARY SUPPLEMENTS FOR THE MANAGEMENT OF DYSLIPIDAEMIA",2017,"NATURE REVIEWS ENDOCRINOLOGY","13","10",153,"10.1038/nrendo.2016.210","DEPARTMENT OF MEDICINE, ROBARTS RESEARCH INSTITUTE, SCHULICH SCHOOL OF MEDICINE AND DENTISTRY, WESTERN UNIVERSITY, 4288A-1151 RICHMOND STREET NORTH, LONDON, N6A 5B7, ON, CANADA;DEPARTMENT OF MEDICINE, ROBARTS RESEARCH INSTITUTE, SCHULICH SCHOOL OF MEDICINE AND DENTISTRY, WESTERN UNIVERSITY, 4288A-1151 RICHMOND STREET NORTH, LONDON, N6A 5B7, ON, CANADA","DYSLIPIDAEMIA IS CHARACTERIZED BY INCREASED BLOOD LEVELS OF TOTAL OR LDL CHOLESTEROL AND TRIGLYCERIDES, OR DECREASED HDL CHOLESTEROL LEVELS, AND IS A RISK FACTOR FOR CARDIOVASCULAR DISEASE. DYSLIPIDAEMIA HAS A HIGH WORLDWIDE PREVALENCE, AND MANY PATIENTS ARE TURNING TO ALTERNATIVES TO PHARMACOTHERAPY TO MANAGE THEIR LIPID LEVELS. LIFESTYLE MODIFICATION SHOULD BE EMPHASIZED IN ALL PATIENTS TO REDUCE CARDIOVASCULAR RISK AND CAN BE INITIATED BEFORE PHARMACOTHERAPY IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE. MANY FUNCTIONAL FOODS AND NATURAL HEALTH PRODUCTS HAVE BEEN INVESTIGATED FOR POTENTIAL LIPID-LOWERING PROPERTIES. THOSE WITH GOOD EVIDENCE FOR A BIOCHEMICAL EFFECT ON PLASMA LIPID LEVELS INCLUDE SOY PROTEIN, GREEN TEA, PLANT STEROLS, PROBIOTIC YOGURT, MARINE-DERIVED OMEGA-3 FATTY ACIDS AND RED YEAST RICE. OTHER PRODUCTS SUCH AS SEAWEED, BERBERINE, HAWTHORN AND GARLIC MIGHT CONFER SOME LIMITED BENEFIT IN CERTAIN PATIENT GROUPS. ALTHOUGH NONE OF THESE PRODUCTS CAN REDUCE LIPID LEVELS TO THE SAME EXTENT AS STATINS, MOST ARE SAFE TO USE IN ADDITION TO OTHER LIFESTYLE MODIFICATIONS AND PHARMACOTHERAPY. NATURAL HEALTH PRODUCTS MARKETED AT INDIVIDUALS WITH DYSLIPIDAEMIA, SUCH AS POLICOSANOL, GUGGULSTERONE AND RESVERATROL, HAVE MINIMAL DEFINITIVE EVIDENCE OF A BIOCHEMICAL BENEFIT. ADDITIONAL RESEARCH IS REQUIRED IN THIS FIELD, WHICH SHOULD INCLUDE LARGE, HIGH-QUALITY RANDOMIZED CONTROLLED TRIALS WITH LONG FOLLOW-UP PERIODS TO INVESTIGATE ASSOCIATIONS WITH CARDIOVASCULAR END POINTS. © 2017 MACMILLAN PUBLISHERS LIMITED, PART OF SPRINGER NATURE. ALL RIGHTS RESERVED.","","ANIMALS; DIETARY SUPPLEMENTS; DISEASE MANAGEMENT; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; FUNCTIONAL FOOD; HUMANS; PLANT EXTRACTS; TEA; ALGAL EXTRACT; ALLICIN; BERBERINE; BILE ACID; CHOLESTIN; CRATAEGUS EXTRACT; DOCOSAHEXAENOIC ACID; FISH OIL; GARLIC EXTRACT; GARLIC OIL; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NATURAL PRODUCT; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; POLICOSANOL; PROBIOTIC AGENT; PROPROTEIN CONVERTASE 9; RESVERATROL; SHORT CHAIN FATTY ACID; SIMVASTATIN; SINECATECHINS; SOYBEAN PROTEIN; UNINDEXED DRUG; YOGHURT; OMEGA 3 FATTY ACID; PLANT EXTRACT; TEA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; DIETARY SUPPLEMENT; DRUG BINDING SITE; DRUG FATALITY; DRUG PROTEIN BINDING; DRUG SAFETY; DYSLIPIDEMIA; FUNCTIONAL FOOD; GASTROINTESTINAL SYMPTOM; HALITOSIS; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); MONOTHERAPY; MYOPATHY; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK REDUCTION; ANIMAL; DIET THERAPY; DISEASE MANAGEMENT; DYSLIPIDEMIA; METABOLISM; TEA","GENOME CANADA, (4530); CANADIAN INSTITUTES OF HEALTH RESEARCH, CIHR; HEART AND STROKE FOUNDATION OF CANADA, HSF, (T-000353)","HE HAS RECEIVED OPERATING GRANTS FROM THE CANADIAN INSTITUTES OF HEALTH RESEARCH (FOUNDATION GRANT), THE HEART AND STROKE FOUNDATION OF ONTARIO (T-000353) AND GENOME CANADA THROUGH GENOME QUEBEC (AWARD 4530).","WORLD HEALTH STATISTICS 2012, (2012); VAZQUEZ-BENITEZ G., ET AL., PREVENTABLE MAJOR CARDIOVASCULAR EVENTS ASSOCIATED WITH UNCONTROLLED GLUCOSE, BLOOD PRESSURE, AND LIPIDS AND ACTIVE SMOKING IN ADULTS WITH DIABETES WITH AND WITHOUT CARDIOVASCULAR DISEASE: A CONTEMPORARY ANALYSIS, DIABETES CARE, 38, PP. 905-912, (2015); HUBERT H.B., FEINLEIB M., MCNAMARA P.M., CASTELLI W.P., OBESITY AS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR DISEASE: A 26-YEAR FOLLOW-UP OF PARTICIPANTS IN THE FRAMINGHAM HEART STUDY, CIRCULATION, 67, PP. 968-977, (1983); TOTH P.P., POTTER D., MING E.E., PREVALENCE OF LIPID ABNORMALITIES IN THE UNITED STATES: THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2003-2006, J. CLIN. LIPIDOL., 6, PP. 325-330, (2012); MRC/ BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); LAW M.R., WALD N.J., RUDNICKA A.R., QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS, BMJ, 326, (2003); HEGELE R.A., PLASMA LIPOPROTEINS: GENETIC INFLUENCES AND CLINICAL IMPLICATIONS, NAT. REV. GENET., 10, PP. 109-121, (2009); MILLER M., ET AL., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 2292-2333, (2011); THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, PP. 3143-3421, (2002); ECKEL R.H., ET AL., 2013 AHA/ACC GUIDELINE ON LIFESTYLE MANAGEMENT TO REDUCE CARDIOVASCULAR RISK: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J. AM. COLL. CARDIOL., 63, PP. 2960-2984, (2014); MARTIROSYAN D.M., SINGH J., A NEW DEFINITION OF FUNCTIONAL FOOD BY FFC: WHAT MAKES A NEW DEFINITION UNIQUE?, FUNCT. FOODS HEALTH DIS., 5, PP. 209-223, (2015); WHAT IS A DIETARY SUPPLEMENT?, (2015); DICKINSON A., BLATMAN J., EL-DASH N., FRANCO J.C., CONSUMER USAGE AND REASONS FOR USING DIETARY SUPPLEMENTS: REPORT OF A SERIES OF SURVEYS, J. AM. COLL. NUTR., 33, PP. 176-182, (2014); ELLEGARD L., ANDERSSON H., OAT BRAN RAPIDLY INCREASES BILE ACID EXCRETION AND BILE ACID SYNTHESIS: AN ILEOSTOMY STUDY, EUR. J. CLIN. NUTR., 61, PP. 938-945, (2007); CHEN W.J., ANDERSON J.W., JENNINGS D., PROPIONATE MAY MEDIATE THE HYPOCHOLESTEROLEMIC EFFECTS OF CERTAIN SOLUBLE PLANT FIBERS IN CHOLESTEROL-FED RATS, PROC. SOC. EXP. BIOL. MED., 175, PP. 215-218, (1984); WHITEHEAD A., BECK E.J., TOSH S., WOLEVER T.M., CHOLESTEROL-LOWERING EFFECTS OF OAT Β-GLUCAN: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR., 100, PP. 1413-1421, (2014); GOFF L.M., COWLAND D.E., HOOPER L., FROST G.S., LOW GLYCAEMIC INDEX DIETS AND BLOOD LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS., 23, PP. 1-10, (2013); TALATI R., BAKER W.L., PABILONIA M.S., WHITE C.M., COLEMAN C.I., THE EFFECTS OF BARLEY-DERIVED SOLUBLE FIBER ON SERUM LIPIDS, ANN. FAM. MED., 7, PP. 157-163, (2009); WEI Z.H., ET AL., TIME- AND DOSE-DEPENDENT EFFECT OF PSYLLIUM ON SERUM LIPIDS IN MILD-TO-MODERATE HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, EUR. J. CLIN. NUTR., 63, PP. 821-827, (2009); ANDERSON J.W., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM. J. CLIN. NUTR., 71, PP. 472-479, (2000); HARTLEY L., MAY M.D., LOVEMAN E., COLQUITT J.L., REES K., DIETARY FIBRE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV., (2016); ANDERSON T.J., ET AL., 2012 UPDATE OF THE CANADIAN CARDIOVASCULAR SOCIETY GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIA FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE ADULT, CAN. J. CARDIOL., 29, PP. 151-167, (2013); DEMONTY I., ET AL., CONTINUOUS DOSE-RESPONSE RELATIONSHIP OF THE LDL-CHOLESTEROL-LOWERING EFFECT OF PHYTOSTEROL INTAKE, J. NUTR., 139, PP. 271-284, (2009); NORMEN L., DUTTA P., LIA A., ANDERSSON H., SOY STEROL ESTERS AND Β-SITOSTANOL ESTER AS INHIBITORS OF CHOLESTEROL ABSORPTION IN HUMAN SMALL BOWEL, AM. J. CLIN. NUTR., 71, PP. 908-913, (2000); BAKER W.L., BAKER E.L., COLEMAN C.I., THE EFFECT OF PLANT STEROLS OR STANOLS ON LIPID PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS, DIABETES RES. CLIN. PRACT., 84, PP. E33-E37, (2009); MALHOTRA A., ET AL., DIETARY INTERVENTIONS (PLANT STEROLS, STANOLS, OMEGA-3 FATTY ACIDS, SOY PROTEIN AND DIETARY FIBERS) FOR FAMILIAL HYPERCHOLESTEROLAEMIA, COCHRANE DATABASE SYST. REV., (2014); DEMONTY I., ET AL., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUR. J. NUTR., 52, PP. 153-160, (2013); HUBACEK J.A., BERGE K.E., COHEN J.C., HOBBS H.H., MUTATIONS IN ATP-CASSETTE BINDING PROTEINS G5 (ABCG5) AND G8 (ABCG8) CAUSING SITOSTEROLEMIA, HUM. MUTAT., 18, PP. 359-360, (2001); ABUMWEIS S.S., MARINANGELI C.P., FROHLICH J., JONES P.J., IMPLEMENTING PHYTOSTEROLS INTO MEDICAL PRACTICE AS A CHOLESTEROL-LOWERING STRATEGY: OVERVIEW OF EFFICACY, EFFECTIVENESS, AND SAFETY, CAN. J. CARDIOL., 30, PP. 1225-1232, (2014); ESLICK G.D., HOWE P.R., SMITH C., PRIEST R., BENSOUSSAN A., BENEFITS OF FISH OIL SUPPLEMENTATION IN HYPERLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS, INT. J. CARDIOL., 136, PP. 4-16, (2009); HARTWEG J., FARMER A.J., PERERA R., HOLMAN R.R., NEIL H.A., META-ANALYSIS OF THE EFFECTS OF N-3 POLYUNSATURATED FATTY ACIDS ON LIPOPROTEINS AND OTHER EMERGING LIPID CARDIOVASCULAR RISK MARKERS IN PATIENTS WITH TYPE 2 DIABETES, DIABETOLOGIA, 50, PP. 1593-1602, (2007); WEI M.Y., JACOBSON T.A., EFFECTS OF EICOSAPENTAENOIC ACID VERSUS DOCOSAHEXAENOIC ACID ON SERUM LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, CURR. ATHEROSCLER. REP., 13, PP. 474-483, (2011); HOOPER L., ET AL., OMEGA 3 FATTY ACIDS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV., (2004); BERGE K., MUSA-VELOSO K., HARWOOD M., HOEM N., BURRI L., KRILL OIL SUPPLEMENTATION LOWERS SERUM TRIGLYCERIDES WITHOUT INCREASING LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADULTS WITH BORDERLINE HIGH OR HIGH TRIGLYCERIDE LEVELS, NUTR. RES., 34, PP. 126-133, (2014); ULVEN S.M., ET AL., METABOLIC EFFECTS OF KRILL OIL ARE ESSENTIALLY SIMILAR TO THOSE OF FISH OIL BUT AT LOWER DOSE OF EPA AND DHA, IN HEALTHY VOLUNTEERS, LIPIDS, 46, PP. 37-46, (2011); SHEARER G.C., SAVINOVA O.V., HARRIS W.S., FISH OIL - HOW DOES IT REDUCE PLASMA TRIGLYCERIDES?, BIOCHIM. BIOPHYS. ACTA, 1821, PP. 843-851, (2012); MARIK P.E., VARON J., OMEGA-3 DIETARY SUPPLEMENTS AND THE RISK OF CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW, CLIN. CARDIOL., 32, PP. 365-372, (2009); WEINTRAUB H., UPDATE ON MARINE OMEGA-3 FATTY ACIDS: MANAGEMENT OF DYSLIPIDEMIA AND CURRENT OMEGA-3 TREATMENT OPTIONS, ATHEROSCLEROSIS, 230, PP. 381-389, (2013); MCCARTHY M., FDA BANS RED YEAST RICE PRODUCT, LANCET, 351, (1998); CICERO A.F., ET AL., RED YEAST RICE IMPROVES LIPID PATTERN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND VASCULAR REMODELING PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC ITALIAN SUBJECTS, NUTR. RES., 33, PP. 622-628, (2013); BECKER D.J., FRENCH B., MORRIS P.B., SILVENT E., GORDON R.Y., PHYTOSTEROLS, RED YEAST RICE, AND LIFESTYLE CHANGES INSTEAD OF STATINS: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL, AM. HEART J., 166, PP. 187-196, (2013); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS., 21, PP. 424-429, (2011); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR. J. ENDOCRINOL., 153, PP. 679-686, (2005); BECKER D.J., ET AL., SIMVASTATIN VERSUS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN. PROC., 83, PP. 758-764, (2008); BECKER D.J., ET AL., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN. INTERN. MED., 150, PP. 830-839, (2009); HALBERT S.C., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM. J. CARDIOL., 105, PP. 198-204, (2010); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP. BIOL. MED. (MAYWOOD), 229, PP. 215-226, (2004); CASTANO G., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); TORRES O., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER. RES., 22, PP. 318-322, (2008); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); SWANSON B., ET AL., POLICOSANOL FOR MANAGING HUMAN IMMUNODEFICIENCY VIRUS-RELATED DYSLIPIDEMIA IN A MEDICALLY UNDERSERVED POPULATION: A RANDOMIZED, CONTROLLED CLINICAL TRIAL, ALTERN. THER. HEALTH MED., 17, PP. 30-35, (2011); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT. THER. MED., 16, PP. 61-65, (2008); LIN Y., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR., 84, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR. J. NUTR., 95, PP. 968-975, (2006); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR., 50, PP. 259-267, (2010); KONG W., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT. MED., 10, PP. 1344-1351, (2004); DONG B., LI H., SINGH A.B., CAO A., LIU J., INHIBITION OF PCSK9 TRANSCRIPTION BY BERBERINE INVOLVES DOWN-REGULATION OF HEPATIC HNF1Α PROTEIN EXPRESSION THROUGH THE UBIQUITIN-PROTEASOME DEGRADATION PATHWAY, J. BIOL. CHEM., 290, PP. 4047-4058, (2015); POIRIER S., ET AL., THE PROPROTEIN CONVERTASE PCSK9 INDUCES THE DEGRADATION OF LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) AND ITS CLOSEST FAMILY MEMBERS VLDLR AND APOER2, J. BIOL. CHEM., 283, PP. 2363-2372, (2008); LI H., ET AL., HEPATOCYTE NUCLEAR FACTOR 1Α PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINE, J. BIOL. CHEM., 284, PP. 28885-28895, (2009); DONG H., ZHAO Y., ZHAO L., LU F., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED., 79, PP. 437-446, (2013); LAN J., ET AL., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J. ETHNOPHARMACOL., 161, PP. 69-81, (2015); DEROSA G., MAFFIOLI P., CICERO A.F., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPIN. BIOL. THER., 12, PP. 1113-1124, (2012); SHI K.Q., ET AL., TRADITIONAL CHINESE MEDICINES BENEFIT TO NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, MOL. BIOL. REP., 39, PP. 9715-9722, (2012); YEH G.Y., DAVIS R.B., PHILLIPS R.S., USE OF COMPLEMENTARY THERAPIES IN PATIENTS WITH CARDIOVASCULAR DISEASE, AM. J. CARDIOL., 98, PP. 673-680, (2006); HA A.W., YING T., KIM W.K., THE EFFECTS OF BLACK GARLIC (ALLIUM SATVIUM) EXTRACTS ON LIPID METABOLISM IN RATS FED A HIGH FAT DIET, NUTR. RES. PRACT., 9, PP. 30-36, (2015); SINGH D.K., PORTER T.D., INHIBITION OF STEROL 4Α-METHYL OXIDASE IS THE PRINCIPAL MECHANISM BY WHICH GARLIC DECREASES CHOLESTEROL SYNTHESIS, J. NUTR., 136, PP. 759S-764S, (2006); LIN M.C., ET AL., GARLIC INHIBITS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN GENE EXPRESSION IN HUMAN LIVER AND INTESTINAL CELL LINES AND IN RAT INTESTINE, J. NUTR., 132, PP. 1165-1168, (2002); KWON M.J., ET AL., CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY AND ATHEROGENIC PARAMETERS IN RABBITS SUPPLEMENTED WITH CHOLESTEROL AND GARLIC POWDER, LIFE SCI., 72, PP. 2953-2964, (2003); MOHAMMADI A., BAZRAFSHANI M.R., OSHAGHI E.A., EFFECT OF GARLIC EXTRACT ON SOME SERUM BIOCHEMICAL PARAMETERS AND EXPRESSION OF NPC1L1, ABCA1, ABCG5 AND ABCG8 GENES IN THE INTESTINE OF HYPERCHOLESTEROLEMIC MICE, INDIAN J. BIOCHEM. BIOPHYS., 50, PP. 500-504, (2013); MALEKPOUR-DEHKORDI Z., ET AL., S-ALLYLCYSTEINE, A GARLIC COMPOUND, INCREASES ABCA1 EXPRESSION IN HUMAN THP-1 MACROPHAGES, PHYTOTHER. RES., 27, PP. 357-361, (2013); HWANG Y.P., ET AL., S-ALLYL CYSTEINE ATTENUATES FREE FATTY ACID-INDUCED LIPOGENESIS IN HUMAN HEPG2 CELLS THROUGH ACTIVATION OF THE AMP-ACTIVATED PROTEIN KINASE-DEPENDENT PATHWAY, J. NUTR. BIOCHEM., 24, PP. 1469-1478, (2013); MORIHARA N., HINO A., YAMAGUCHI T., SUZUKI J.I., AGED GARLIC EXTRACT SUPPRESSES THE DEVELOPMENT OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, J. NUTR., 146, PP. 460S-463S, (2016); LAU B.H., SUPPRESSION OF LDL OXIDATION BY GARLIC COMPOUNDS IS A POSSIBLE MECHANISM OF CARDIOVASCULAR HEALTH BENEFIT, J. NUTR., 136, PP. 765S-768S, (2006); KHOO Y.S., AZIZ Z., GARLIC SUPPLEMENTATION AND SERUM CHOLESTEROL: A META-ANALYSIS, J. CLIN. PHARM. THER., 34, PP. 133-145, (2009); RIED K., TOBEN C., FAKLER P., EFFECT OF GARLIC ON SERUM LIPIDS: AN UPDATED META-ANALYSIS, NUTR. REV., 71, PP. 282-299, (2013); ZENG T., ET AL., A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS FOR THE EFFECTS OF GARLIC ON SERUM LIPID PROFILES, J. SCI. FOOD AGR., 92, PP. 1892-1902, (2012); REINHART K.M., TALATI R., WHITE C.M., COLEMAN C.I., THE IMPACT OF GARLIC ON LIPID PARAMETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR. RES. REV., 22, PP. 39-48, (2009); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA. A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN. INTERN. MED., 133, PP. 420-429, (2000); KWAK J.S., ET AL., GARLIC POWDER INTAKE AND CARDIOVASCULAR RISK FACTORS: A META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS, NUTR. RES. PRACT., 8, PP. 644-654, (2014); MAHDAVI-ROSHAN M., ET AL., EFFECT OF GARLIC POWDER TABLET ON CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH CORONARY ARTERY DISEASE: A PRELIMINARY RANDOMIZED CONTROLLED TRIAL, NUTR. HEALTH, 22, PP. 143-155, (2013); RIED K., GARLIC LOWERS BLOOD PRESSURE IN HYPERTENSIVE INDIVIDUALS, REGULATES SERUM CHOLESTEROL, AND STIMULATES IMMUNITY: AN UPDATED META-ANALYSIS AND REVIEW, J. NUTR., 146, PP. 389S-396S, (2016); GALEONE C., TAVANI A., PELUCCHI C., NEGRI E., LA VECCHIA C., ALLIUM VEGETABLE INTAKE AND RISK OF ACUTE MYOCARDIAL INFARCTION IN ITALY, EUR. J. NUTR., 48, PP. 120-123, (2009); ULBRICHT C., ET AL., GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENT. THER. MED., 13, PP. 279-290, (2005); URIZAR N.L., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, PP. 1703-1706, (2002); CUI J., ET AL., GUGGULSTERONE IS A FARNESOID X RECEPTOR ANTAGONIST IN COACTIVATOR ASSOCIATION ASSAYS BUT ACTS TO ENHANCE TRANSCRIPTION OF BILE SALT EXPORT PUMP, J. BIOL. CHEM., 278, PP. 10214-10220, (2003); SINGH B.B., ET AL., AYURVEDIC AND COLLATERAL HERBAL TREATMENTS FOR HYPERLIPIDEMIA: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND QUASI-EXPERIMENTAL DESIGNS, ALTERN. THER. HEALTH MED., 13, PP. 22-28, (2007); NOHR L.A., RASMUSSEN L.B., STRAAND J., RESIN FROM THE MUKUL MYRRH TREE, GUGGUL, CAN IT BE USED FOR TREATING HYPERCHOLESTEROLEMIA? A RANDOMIZED, CONTROLLED STUDY, COMPLEMENT. THER. MED., 17, PP. 16-22, (2009); SZAPARY P.O., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); KIECHL S., ET AL., ALCOHOL CONSUMPTION AND ATHEROSCLEROSIS: WHAT IS THE RELATION? PROSPECTIVE RESULTS FROM THE BRUNECK STUDY, STROKE, 29, PP. 900-907, (1998); BAUR J.A., SINCLAIR D.A., THERAPEUTIC POTENTIAL OF RESVERATROL: THE IN VIVO EVIDENCE, NAT. REV. DRUG DISCOV., 5, PP. 493-506, (2006); GUO R., ET AL., RESVERATROL SUPPRESSES OXIDISED LOW-DENSITY LIPOPROTEIN-INDUCED MACROPHAGE APOPTOSIS THROUGH INHIBITION OF INTRACELLULAR REACTIVE OXYGEN SPECIES GENERATION, LOX-1, AND THE P38 MAPK PATHWAY, CELL PHYSIOL. BIOCHEM., 34, PP. 603-616, (2014); CHO I.J., AHN J.Y., KIM S., CHOI M.S., HA T.Y., RESVERATROL ATTENUATES THE EXPRESSION OF HMG-COA REDUCTASE MRNA IN HAMSTERS, BIOCHEM. BIOPHYS. RES. COMMUN., 367, PP. 190-194, (2008); FRANKEL E.N., WATERHOUSE A.L., TEISSEDRE P.L., PRINCIPAL PHENOLIC PHYTOCHEMICALS IN SELECTED CALIFORNIA WINES AND THEIR ANTIOXIDANT ACTIVITY IN INHIBITING OXIDATION OF HUMAN LOW-DENSITY LIPOPROTEINS, J. AGR. FOOD CHEM., 43, PP. 890-894, (1995); SAHEBKAR A., EFFECTS OF RESVERATROL SUPPLEMENTATION ON PLASMA LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR. REV., 71, PP. 822-835, (2013); KUMAR B.J., JOGHEE N.M., RESVERATROL SUPPLEMENTATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE, OPEN LABEL, RANDOMIZED CONTROLLED TRIAL, INT. RES. J. PHARM., 4, PP. 245-249, (2013); MOVAHED A., ET AL., ANTIHYPERGLYCEMIC EFFECTS OF SHORT TERM RESVERATROL SUPPLEMENTATION IN TYPE 2 DIABETIC PATIENTS, EVID. BASED COMPLEMENT. ALTERNAT. MED., 2013, (2013); GOH K.P., ET AL., EFFECTS OF RESVERATROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON SKELETAL MUSCLE SIRT1 EXPRESSION AND ENERGY EXPENDITURE, INT. J. SPORT NUTR. EXERC. METAB., 24, PP. 2-13, (2014); ISHIMWE N., DALIRI E.B., LEE B.H., FANG F., DU G., THE PERSPECTIVE ON CHOLESTEROL-LOWERING MECHANISMS OF PROBIOTICS, MOL. NUTR. FOOD RES., 59, PP. 94-105, (2015); ASEMI Z., ET AL., EFFECT OF DAILY CONSUMPTION OF PROBIOTIC YOGHURT ON LIPID PROFILES IN PREGNANT WOMEN: A RANDOMIZED CONTROLLED CLINICAL TRIAL, J. MATERN. FETAL NEONATAL MED., 25, PP. 1552-1556, (2012); SADRZADEH-YEGANEH H., ET AL., THE EFFECTS OF PROBIOTIC AND CONVENTIONAL YOGHURT ON LIPID PROFILE IN WOMEN, BR. J. NUTR., 103, PP. 1778-1783, (2010); FABIAN E., ELMADFA I., INFLUENCE OF DAILY CONSUMPTION OF PROBIOTIC AND CONVENTIONAL YOGHURT ON THE PLASMA LIPID PROFILE IN YOUNG HEALTHY WOMEN, ANN. NUTR. METAB., 50, PP. 387-393, (2006); CHO Y.A., KIM J., EFFECT OF PROBIOTICS ON BLOOD LIPID CONCENTRATIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MEDICINE (BALTIMORE), 94, (2015); GUO Z., ET AL., INFLUENCE OF CONSUMPTION OF PROBIOTICS ON THE PLASMA LIPID PROFILE: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, NUTR. METAB. CARDIOVASC. DIS., 21, PP. 844-850, (2011); SUN J., BUYS N., EFFECTS OF PROBIOTICS CONSUMPTION ON LOWERING LIPIDS AND CVD RISK FACTORS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ANN. MED., 47, PP. 430-440, (2015); HOLDT S.L., KRAAN S., BIOACTIVE COMPOUNDS IN SEAWEED: FUNCTIONAL FOOD APPLICATIONS AND LEGISLATION, J. APPL. PHYCOL., 23, PP. 543-597, (2011); CHEN J., JIANG Y., MA K.Y., CHEN F., CHEN Z.Y., MICROALGA DECREASES PLASMA CHOLESTEROL BY DOWN-REGULATION OF INTESTINAL NPC1L1, HEPATIC LDL RECEPTOR, AND HMG-COA REDUCTASE, J. AGR. FOOD CHEM., 59, PP. 6790-6797, (2011); KU C.S., ET AL., HYPOLIPIDEMIC EFFECT OF A BLUE-GREEN ALGA (NOSTOC COMMUNE) IS ATTRIBUTED TO ITS NONLIPID FRACTION BY DECREASING INTESTINAL CHOLESTEROL ABSORPTION IN C57BL/6J MICE, J. MED. FOOD, 18, PP. 1214-1222, (2015); CHEN Z., ET AL., 24(S)-SARINGOSTEROL FROM EDIBLE MARINE SEAWEED SARGASSUM FUSIFORME IS A NOVEL SELECTIVE LXRΒ AGONIST, J. AGR. FOOD CHEM., 62, PP. 6130-6137, (2014); KIM M.S., KIM J.Y., CHOI W.H., LEE S.S., EFFECTS OF SEAWEED SUPPLEMENTATION ON BLOOD GLUCOSE CONCENTRATION, LIPID PROFILE, AND ANTIOXIDANT ENZYME ACTIVITIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, NUTR. RES. PRACT., 2, PP. 62-67, (2008); PANLASIGUI L.N., BAELLO O.Q., DIMATANGAL J.M., DUMELOD B.D., BLOOD CHOLESTEROL AND LIPID-LOWERING EFFECTS OF CARRAGEENAN ON HUMAN VOLUNTEERS, ASIA PAC. J. CLIN. NUTR., 12, PP. 209-214, (2003); KONDO I., ET AL., ASSOCIATION BETWEEN FOOD GROUP INTAKE AND SERUM TOTAL CHOLESTEROL IN THE JAPANESE POPULATION: NIPPON DATA 80/90, J. EPIDEMIOL., 20, PP. S576-S581, (2010); BERNSTEIN A.M., DING E.L., WILLETT W.C., RIMM E.B., A META-ANALYSIS SHOWS THAT DOCOSAHEXAENOIC ACID FROM ALGAL OIL REDUCES SERUM TRIGLYCERIDES AND INCREASES HDL-CHOLESTEROL AND LDL-CHOLESTEROL IN PERSONS WITHOUT CORONARY HEART DISEASE, J. NUTR., 142, PP. 99-104, (2012); ZHANG Y., ZHANG L., GENG Y., GENG Y., HAWTHORN FRUIT ATTENUATES ATHEROSCLEROSIS BY IMPROVING THE HYPOLIPIDEMIC AND ANTIOXIDANT ACTIVITIES IN APOLIPOPROTEIN E-DEFICIENT MICE, J. ATHEROSCLER. THROMB., 21, PP. 119-128, (2014); RAJENDRAN S., DEEPALAKSHMI P.D., PARASAKTHY K., DEVARAJ H., DEVARAJ S.N., EFFECT OF TINCTURE OF CRATAEGUS ON THE LDL-RECEPTOR ACTIVITY OF HEPATIC PLASMA MEMBRANE OF RATS FED AN ATHEROGENIC DIET, ATHEROSCLEROSIS, 123, PP. 235-241, (1996); ZHANG Z., HO W.K., HUANG Y., CHEN Z.Y., HYPOCHOLESTOLEMIC ACTIVITY OF HAWTHORN FRUIT IS MEDIATED BY REGULATION OF CHOLESTEROL-7Α-HYDROXYLASE AND ACYL COA: CHOLESTEROL ACYLTRANSFERASE, FOOD RES. INT., 35, PP. 885-891, (2002); ZHANG Z., ET AL., HAWTHORN FRUIT IS HYPOLIPIDEMIC IN RABBITS FED A HIGH CHOLESTEROL DIET, J. NUTR., 132, PP. 5-10, (2002); DALLI E., ET AL., CRATAEGUS LAEVIGATA DECREASES NEUTROPHIL ELASTASE AND HAS HYPOLIPIDEMIC EFFECT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, PHYTOMEDICINE, 18, PP. 769-775, (2011); BEVERAGE CHOICES OF US ADULTS, (2011); USDA DATABASE FOR THE FLAVONOID CONTENT OF SELECTED FOODS. RELEASE 2.1, (2007); ONAKPOYA I., SPENCER E., HENEGHAN C., THOMPSON M., THE EFFECT OF GREEN TEA ON BLOOD PRESSURE AND LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, NUTR. METAB. CARDIOVASC. DIS., 24, PP. 823-836, (2014); KIM A., ET AL., GREEN TEA CATECHINS DECREASE TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. AM. DIET. ASSOC., 111, PP. 1720-1729, (2011); ZHENG X.X., ET AL., GREEN TEA INTAKE LOWERS FASTING SERUM TOTAL AND LDL CHOLESTEROL IN ADULTS: A META-ANALYSIS OF 14 RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR., 94, PP. 601-610, (2011); SUZUKI-SUGIHARA N., ET AL., GREEN TEA CATECHINS PREVENT LOW-DENSITY LIPOPROTEIN OXIDATION VIA THEIR ACCUMULATION IN LOW-DENSITY LIPOPROTEIN PARTICLES IN HUMANS, NUTR. RES., 36, PP. 16-23, (2016); ABE I., ET AL., GREEN TEA POLYPHENOLS: NOVEL AND POTENT INHIBITORS OF SQUALENE EPOXIDASE, BIOCHEM. BIOPHYS. RES. COMMUN., 268, PP. 767-771, (2000); KOO S.I., NOH S.K., GREEN TEA AS INHIBITOR OF THE INTESTINAL ABSORPTION OF LIPIDS: POTENTIAL MECHANISM FOR ITS LIPID-LOWERING EFFECT, J. NUTR. BIOCHEM., 18, PP. 179-183, (2007); ZHENG X.X., ET AL., EFFECTS OF GREEN TEA CATECHINS WITH OR WITHOUT CAFFEINE ON GLYCEMIC CONTROL IN ADULTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR., 97, PP. 750-762, (2013); HARTLEY L., ET AL., GREEN AND BLACK TEA FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV., (2013); HOOPER L., ET AL., FLAVONOIDS, FLAVONOID-RICH FOODS, AND CARDIOVASCULAR RISK: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR., 88, PP. 38-50, (2008); WANG D., CHEN C., WANG Y., LIU J., LIN R., EFFECT OF BLACK TEA CONSUMPTION ON BLOOD CHOLESTEROL: A META-ANALYSIS OF 15 RANDOMIZED CONTROLLED TRIALS, PLOS ONE, 9, (2014); ZHAO Y., ASIMI S., WU K., ZHENG J., LI D., BLACK TEA CONSUMPTION AND SERUM CHOLESTEROL CONCENTRATION: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CLIN. NUTR., 34, PP. 612-619, (2015); TANG J., ET AL., TEA CONSUMPTION AND MORTALITY OF ALL CANCERS, CVD AND ALL CAUSES: A META-ANALYSIS OF EIGHTEEN PROSPECTIVE COHORT STUDIES, BR. J. NUTR., 114, PP. 673-683, (2015); JENKINS D.J., ET AL., SOY PROTEIN REDUCES SERUM CHOLESTEROL BY BOTH INTRINSIC AND FOOD DISPLACEMENT MECHANISMS, J. NUTR., 140, PP. 2302S-2311S, (2010); WU Z.Y., WU X.K., ZHANG Y.W., RELATIONSHIP OF MENOPAUSAL STATUS AND SEX HORMONES TO SERUM LIPIDS AND BLOOD PRESSURE, INT. J. EPIDEMIOL., 19, PP. 297-302, (1990); MULLEN E., BROWN R.M., OSBORNE T.F., SHAY N.F., SOY ISOFLAVONES AFFECT STEROL REGULATORY ELEMENT BINDING PROTEINS (SREBPS) AND SREBP-REGULATED GENES IN HEPG2 CELLS, J. NUTR., 134, PP. 2942-2947, (2004); SHUKLA A., ET AL., ISOFLAVONE-POOR SOY PROTEIN ALTERS THE LIPID METABOLISM OF RATS BY SREBP-MEDIATED DOWN-REGULATION OF HEPATIC GENES, J. NUTR. BIOCHEM., 18, PP. 313-321, (2007); MANZONI C., ET AL., SUBCELLULAR LOCALIZATION OF SOYBEAN 7S GLOBULIN IN HEPG2 CELLS AND LDL RECEPTOR UP-REGULATION BY ITS ALPHA' CONSTITUENT SUBUNIT, J. NUTR., 133, PP. 2149-2155, (2003); YU D., ET AL., ASSOCIATION OF SOY FOOD INTAKE WITH RISK AND BIOMARKERS OF CORONARY HEART DISEASE IN CHINESE MEN, INT. J. CARDIOL., 172, PP. E285-E287, (2014); ZHANG X., ET AL., SOY FOOD CONSUMPTION IS ASSOCIATED WITH LOWER RISK OF CORONARY HEART DISEASE IN CHINESE WOMEN, J. NUTR., 133, PP. 2874-2878, (2003); ANDERSON J.W., BUSH H.M., SOY PROTEIN EFFECTS ON SERUM LIPOPROTEINS: A QUALITY ASSESSMENT AND META-ANALYSIS OF RANDOMIZED, CONTROLLED STUDIES, J. AM. COLL. NUTR., 30, PP. 79-91, (2011); QIN Y., ET AL., ISOFLAVONES FOR HYPERCHOLESTEROLAEMIA IN ADULTS, COCHRANE DATABASE SYST. REV., (2013); REYNOLDS K., ET AL., A META-ANALYSIS OF THE EFFECT OF SOY PROTEIN SUPPLEMENTATION ON SERUM LIPIDS, AM. J. CARDIOL., 98, PP. 633-640, (2006); TAKU K., ET AL., SOY ISOFLAVONES LOWER SERUM TOTAL AND LDL CHOLESTEROL IN HUMANS: A META-ANALYSIS OF 11 RANDOMIZED CONTROLLED TRIALS, AM. J. CLIN. NUTR., 85, PP. 1148-1156, (2007); TOKEDE O.A., ONABANJO T.A., YANSANE A., GAZIANO J.M., DJOUSSE L., SOYA PRODUCTS AND SERUM LIPIDS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BR. J. NUTR., 114, PP. 831-843, (2015); YANG B., ET AL., SYSTEMATIC REVIEW AND META-ANALYSIS OF SOY PRODUCTS CONSUMPTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, ASIA PAC. J. CLIN. NUTR., 20, PP. 593-602, (2011); ZHAN S., HO S.C., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN CONTAINING ISOFLAVONES ON THE LIPID PROFILE, AM. J. CLIN. NUTR., 81, PP. 397-408, (2005); JENKINS D.J., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS VERSUS LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, JAMA, 290, PP. 502-510, (2003); SAX J.K., DIETARY SUPPLEMENTS ARE NOT ALL SAFE AND NOT ALL FOOD: HOW THE LOW COST OF DIETARY SUPPLEMENTS PREYS ON THE CONSUMER, AM. J. LAW MED., 41, PP. 374-394, (2015)","R.A. HEGELE; DEPARTMENT OF MEDICINE, ROBARTS RESEARCH INSTITUTE, SCHULICH SCHOOL OF MEDICINE AND DENTISTRY, WESTERN UNIVERSITY, LONDON, 4288A-1151 RICHMOND STREET NORTH, N6A 5B7, CANADA; EMAIL: HEGELE@ROBARTS.CA","NATURE PUBLISHING GROUP","ENGLISH","NAT. REV. ENDOCRIONOL.","REVIEW","ISI","2-S2.0-85010952315","NAT REV ENDOCRIONOL","WESTERN UNIVERSITY;WESTERN UNIVERSITY","NOTREPORTED;WESTERN UNIVERSITY;NOTREPORTED",NA,"HUNTER PM, 2017, NAT REV ENDOCRIONOL","HUNTER PM, 2017, NAT REV ENDOCRIONOL"
"WEERAWATANAKORN M;ASIKIN Y;TAKAHASHI M;TAMAKI H;WADA K;HO C;CHUEKITTISAK R","WEERAWATANAKORN, MONTHANA (55976489600); ASIKIN, YONATHAN (35092077000); TAKAHASHI, MAKOTO (56287823400); TAMAKI, HAJIME (7103290853); WADA, KOJI (7401668452); HO, CHI-TANG (56510763200); CHUEKITTISAK, RAWEEWAN (57192115023)","PHYSICOCHEMICAL PROPERTIES WAX COMPOSITION AROMA PROFILES AND ANTIOXIDANT ACTIVITY OF GRANULATED NONCENTRIFUGAL SUGARS FROM SUGARCANE CULTIVARS OF THAILAND",2016,"JOURNAL OF FOOD SCIENCE AND TECHNOLOGY","53","8",33,"10.1007/s13197-016-2415-5","DEPARTMENT OF AGRO-INDUSTRY, FACULTY OF AGRICULTURE, NATURAL RESOURCES AND ENVIRONMENT, NARESUAN UNIVERSITY, 99 MOO 9, MUANG PHITSANULOK, 65000, THAILAND;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, 1 SENBARU, NISHIHARA, 903-0213, OKINAWA, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, 1 SENBARU, NISHIHARA, 903-0213, OKINAWA, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, 1 SENBARU, NISHIHARA, 903-0213, OKINAWA, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, 1 SENBARU, NISHIHARA, 903-0213, OKINAWA, JAPAN;DEPARTMENT OF FOOD SCIENCE, RUTGERS UNIVERSITY, 65 DUDLEY ROAD, NEW BRUNSWICK, 08901, NJ, UNITED STATES;SUKHOTHAI AGRICULTURAL RESEARCH AND DEVELOPMENT CENTER, KHONGTAN, SRISAMRONG, 64120, SUKHOTHAI, THAILAND","NON-CENTRIFUGAL CANE SUGAR (NCS) IS GLOBALLY CONSUMED AND HAS VARIOUS HEALTH BENEFITS. IT IS MOSTLY PRODUCED IN HARDENED BLOCK FORM, WHICH IS LESS CONVENIENT THAN IN GRANULATED FORM FOR FOOD APPLICATIONS. IN TERMS OF THE TRADITIONAL PROCESSING OF NCS, PREPARATION OF GRANULATED PRODUCTS IS DIFFICULT DUE TO THE IMPURITIES FOUND IN THE CANE JUICE EXTRACTED FROM THE WHOLE STALK. THEREFORE, THE AIM OF THIS STUDY WAS TO CHARACTERIZE AND DETERMINE THE PHYSICO-CHEMICAL PROPERTIES, WAX COMPOSITION (POLICOSANOLS AND LONG-CHAIN ALDEHYDES), VOLATILE AROMA PROFILES, AND ANTIOXIDANT ACTIVITY OF TRADITIONAL NCS IN GRANULAR FORM MADE FROM FOUR DIFFERENT CANE CULTIVARS OF THAILAND. THE TOTAL SOLUBLE SOLID, PH, COLOR, AND MINERAL CONTENT VARIED AMONG THE SUGARCANE CULTIVARS, WHEREAS THERE WAS NO SIGNIFICANT DIFFERENCE IN THE TOTAL SUGAR, PHENOLIC AND FLAVONOID CONTENT. THE TOTAL POLICOSANOL, A CHOLESTEROL-LOWERING NUTRACEUTICAL WAX COMPONENT, AND LONG-CHAIN ALDEHYDE CONTENTS WERE SIMILAR IN THE NCS PRODUCTS AMONGST THREE CULTIVARS, AND RANGED FROM 2.63 TO 3.69 MG/100 G. THE GRANULATED NCS PRODUCTS, IN WHICH ACETALDEHYDE AND DIMETHYL SULFIDE WERE THE MAIN VOLATILE COMPOUNDS, GAVE LESS AROMA COMPONENTS THAN TRADITIONAL NCS. THE USE OF DIFFERENT SUGARCANE CULTIVARS THUS INFLUENCED THE QUALITY ATTRIBUTES OF GRANULATED NON-CENTRIFUGAL SUGAR PRODUCTS. © 2016, ASSOCIATION OF FOOD SCIENTISTS & TECHNOLOGISTS (INDIA).","ANTIOXIDANT ACTIVITY; NON-CENTRIFUGAL CANE SUGAR; PHYSICO-CHEMICAL PROPERTIES; POLICOSANOL; VOLATILE AROMA COMPONENTS","ACETALDEHYDE; ALDEHYDES; ANTIOXIDANTS; CENTRIFUGATION; CHAINS; CHEMICAL PROPERTIES; MOLASSES; ODORS; SUGAR CANE; VOLATILE ORGANIC COMPOUNDS; ANTI-OXIDANT ACTIVITIES; CHOLESTEROL LOWERING; LONG-CHAIN ALDEHYDE; PHYSICOCHEMICAL PROPERTY; POLICOSANOL; TOTAL SOLUBLE SOLIDS; TRADITIONAL PROCESSING; VOLATILE AROMA COMPONENTS; PLANTS (BOTANY)","NATIONAL RESEARCH COUNCIL OF THAILAND, NRCT, (R2559B016); NARESUAN UNIVERSITY, NU","THIS WORK WAS SUPPORTED BY THE NATIONAL RESEARCH COUNCIL OF THAILAND (NRCT) (NO. R2559B016) AND NARESUAN UNIVERSITY, THAILAND. ","ABURTO N.J., HANSON S., GUTIERREZ H., HOOPER L., ELLIOTT P., CAPPUCCIO F.P., EFFECT OF INCREASED POTASSIUM INTAKE ON CARDIOVASCULAR RISK FACTORS AND DISEASE: SYSTEMATIC REVIEW AND META-ANALYSES, BMJ, 346, (2013); ASIKIN Y., CHINEN T., TAKARA K., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI TECHNOL RES, 14, PP. 583-588, (2008); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, PP. 583-591, (2012); ASIKIN Y., KAMIYA A., MIZU M., TAKARA K., TAMAKI H., WADA K., CHANGES IN THE PHYSICOCHEMICAL CHARACTERISTICS, INCLUDING FLAVOR COMPONENTS AND MAILLARD REACTION PRODUCTS, OF NON-CENTRIFUGAL CANE BROWN SUGAR DURING STORAGE, FOOD CHEM, 149, PP. 170-177, (2014); ASIKIN Y., HIROSE N., TAMAKI H., ITO S., OKU H., WADA K., EFFECTS OF DIFFERENT DRYING–SOLIDIFICATION PROCESSES ON PHYSICAL PROPERTIES, VOLATILE FRACTION, AND ANTIOXIDANT ACTIVITY OF NON-CENTRIFUGAL CANE BROWN SUGAR, LWT-FOOD SCI TECHNOL, 66, PP. 340-347, (2016); OFFICIAL METHODS OF ANALYSIS OF THE AOAC, (2005); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); CHEN Y., DUNFORD N.T., EDWARD J., CARVER B., GOAD C., POLICOSANOL CONTENTS AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, J SCI FOOD AGRIC, 89, PP. 310-314, (2009); CHENG H., VOLATILE FLAVOR COMPOUNDS IN YOGURT: A REVIEW, CRIT REV FOOD SCI NUTR, 50, PP. 938-950, (2010); CHO I., LEE S., JUN H., ROH H., KIM Y., COMPARISON OF VOLATILE MAILLARD REACTION PRODUCTS FROM TAGATOSE AND OTHER REDUCING SUGARS WITH AMINO ACIDS, FOOD SCI BIOTECHNOL, 19, PP. 431-438, (2010); DUARTE-ALMEIDA J.M., NEGRI G., SALATINO A., DE CARVALHO J.E., LAJOLO F.M., ANTIPROLIFERATIVE AND ANTIOXIDANT ACTIVITIES OF A TRICIN ACYLATED GLYCOSIDE FROM SUGARCANE (SACCHARUM OFFICINARUM) JUICE, PHYTOCHEM, 68, PP. 1165-1171, (2007); DUARTE-ALMEIDA J.M., SALATINO A., GENOVESE M.I., LAJOLO F.M., PHENOLIC COMPOSITION AND ANTIOXIDANT ACTIVITY OF CULMS AND SUGARCANE (SACCHARUM OFFICINARUM L.) PRODUCTS, FOOD CHEM, 125, PP. 660-664, (2011); FENG S., LUO Z., ZHANG Y., ZHONG Z., LU B., PHYTOCHEMICAL CONTENTS AND ANTIOXIDANT CAPACITIES OF DIFFERENT PARTS OF TWO SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, FOOD CHEM, 151, PP. 452-458, (2014); ICUMSA METHODS BOOK SUPPLEMENT 2002, (2003); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEEWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); JAFFE W.R., HEALTH EFFECTS OF NON-CENTRIFUGAL SUGAR (NCS): A REVIEW, SUGAR TECHNOL, 14, PP. 87-94, (2012); MEDA A., LAMIEN C.E., ROMITO M., DETERMINATION OF THE TOTAL PHENOLIC, FLAVONOID AND PROLINE CONTENTS IN BURKINA FASAN HONEY, AS WELL AS THEIR RADICAL SCAVENGING ACTIVITY, FOOD CHEM, 91, PP. 571-577, (2005); MEDINI F., FELLAH H., KSOURI R., ABDELLY C., TOTAL PHENOLIC, FLAVONOID AND TANNIN CONTENTS AND ANTIOXIDANT ANDANTIMICROBIAL ACTIVITIES OF ORGANIC EXTRACTS OF SHOOTS OF THE PLANT LIMONIUM DELICATULUM, J TAIBAH UNIV SCI, 8, PP. 216-224, (2014); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); PAYET B., CHEONG A.S., SMADJA J., ASSESSMENT OF ANTIOXIDANT ACTIVITY OF CANE BROWN SUGARS BY ABTS AND DPPH RADICAL SCAVENGING ASSAYS: DETERMINATION OF THEIR POLYPHENOLIC AND VOLATILE CONSTITUENTS, J AGRIC FOOD CHEM, 53, PP. 10074-10079, (2005); PEREZ-CAMINO M.C., MOREDA W., MATEOS R., CERT A., SIMULTANEOUS DETERMINATION OF LONG-CHAIN ALIPHATIC ALDEHYDES AND WAXES IN OLIVE OILS, J CHROMATOGR A, 983, PP. 283-288, (2003); QUDSIEH H.Y.M., YUSOF S., OSMAN A., RAHMAN R.A., PHYSICO-CHEMICAL CHANGES IN SUGARCANE (SACCHARUM OFFICINARUM VAR YELLOW CANE) AND THE EXTRACTED JUICE AT DIFFERENT PORTIONS OF THE STEM DURING DEVELOPMENT AND MATURATION, FOOD CHEM, 75, PP. 131-137, (2001); TAKARA K., OTSUKA K., WADA K., IWASAKI H., YAMASHITA M., 1,1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL SCAVENGING ACTIVITY AND TYROSINASE INHIBITORY EFFECTS OF CONSTITUENTS OF SUGARCANE MOLASSES, BIOSCI BIOTECHNOL BIOCHEM, 71, PP. 183-191, (2007); THAKUR A.K., POTENTIAL OF JAGGERY (GUR) MANUFACTURING IN PUNJAB STATE. IN: PROCEEDINGS OF THE NATIONAL SEMINAR ON STATUS, PROBLEMS AND PROSPECTS OF JAGGERY AND KHANDSARI INDUSTRY IN INDIA, PP. 70-76, (1999); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J AGRIC FOOD CHEM, 55, PP. 5552-5558, (2007); WEERAWATANAKORN M., DICARBONYL COMPOUNDS AND SUGAR CONTENTS OF THAI COMMERCIAL BEVERAGES, SONGKLANAKARIN J SCI TECHNOL, 35, PP. 631-639, (2013)","Y. ASIKIN; DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, 1 SENBARU, 903-0213, JAPAN; EMAIL: YONATHAN.ASIKIN@GMAIL.COM","SPRINGER INDIA","ENGLISH","J FOOD SCI TECHNOL","ARTICLE","ISI","2-S2.0-84997610387","J FOOD SCI TECHNOL","NARESUAN UNIVERSITY;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;RUTGERS UNIVERSITY;SUKHOTHAI AGRICULTURAL RESEARCH AND DEVELOPMENT CENTER","NOTREPORTED;UNIVERSITY OF THE RYUKYUS;NOTREPORTED",NA,"WEERAWATANAKORN M, 2016, J FOOD SCI TECHNOL","WEERAWATANAKORN M, 2016, J FOOD SCI TECHNOL"
"CICERO A;COLLETTI A;BAJRAKTARI G;DESCAMPS O;DJURIC D;EZHOV M;FRAS Z;KATSIKI N;LANGLOIS M;LATKOVSKIS G;PANAGIOTAKOS D;PARAGH G;MIKHAILIDIS D;MITCHENKO O;PAULWEBER B;PELLA D;PITSAVOS C;REINER Z;RAY K;RIZZO M;SAHEBKAR A;SERBAN M;SPERLING L;TOTH P;VINEREANU D;VRABLÍK M;WONG N;BANACH M","CICERO, ARRIGO F.G. (7003403707); COLLETTI, ALESSANDRO (56538296200); BAJRAKTARI, GANI (12764374400); DESCAMPS, OLIVIER (6701764714); DJURIC, DRAGAN M. (36016317400); EZHOV, MARAT (57218254057); FRAS, ZLATKO (35615293100); KATSIKI, NIKI (25421628400); LANGLOIS, MICHEL (56355464300); LATKOVSKIS, GUSTAVS (6507756746); PANAGIOTAKOS, DEMOSTHENES B. (7005977027); PARAGH, GYORGY (7003269524); MIKHAILIDIS, DIMITRI P. (36042757800); MITCHENKO, OLENA (57193516360); PAULWEBER, BERNHARD (36519500600); PELLA, DANIEL (57207570055); PITSAVOS, CHRISTOS (35399739300); REINER, ŽELJKO (55411641000); RAY, KAUSIK K. (35303190300); RIZZO, MANFREDI (7202023733); SAHEBKAR, AMIRHOSSEIN (26639699900); SERBAN, MARIA-CORINA (56497645100); SPERLING, LAURENCE S. (56785421900); TOTH, PETER P. (7102285226); VINEREANU, DRAGOS (6603080279); VRABLÍK, MICHAL (6701669648); WONG, NATHAN D. (7202836669); BANACH, MACIEJ (22936699500)","LIPIDLOWERING NUTRACEUTICALS IN CLINICAL PRACTICE POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL",2017,"NUTRITION REVIEWS","75","36",228,"10.1093/nutrit/nux047","DEPARTMENT OF MEDICINE AND SURGERY SCIENCES, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY, ITALIAN SOCIETY OF NUTRACEUTICALS, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;DEPARTMENT OF MEDICINE AND SURGERY SCIENCES, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY, ITALIAN SOCIETY OF NUTRACEUTICALS, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;CLINIC OF CARDIOLOGY, UNIVERSITY CLINICAL CENTRE OF KOSOVO, PRISHTINA, KOSOVO, SERBIA, MEDICAL FACULTY, UNIVERSITY OF PRISHTINA, PRISHTINA, KOSOVO, SERBIA, KOSOVO SOCIETY OF CARDIOLOGY, KOSOVO, SERBIA;DEPARTMENT OF INTERNAL MEDICINE, CENTRES HOSPITALIERS JOLIMONT, HAINE SAINT-PAUL, BELGIUM, BELGIAN ATHEROSCLEROSIS SOCIETY, BELGIUM;INSTITUTE OF MEDICAL PHYSIOLOGY 'RICHARD BURIAN', FACULTY OF MEDICINE, UNIVERSITY OF BELGRADE, BELGRADE, SERBIA, SERBIAN ASSOCIATION FOR ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY RESEARCH, SERBIA;RUSSIAN CARDIOLOGY RESEARCH AND PRODUCTION CENTRE, MOSCOW, RUSSIAN FEDERATION, RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY, RUSSIAN FEDERATION;PREVENTIVE CARDIOLOGY UNIT, DEPARTMENT OF VASCULAR MEDICINE, DIVISION OF INTERNAL MEDICINE, UNIVERSITY MEDICAL CENTRE LJUBLJANA, LJUBLJANA, SLOVENIA, CHAIR FOR INTERNAL MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF LJUBLJANA, LJUBLJANA, SLOVENIA, SLOVENIAN SOCIETY OF CARDIOLOGY, SLOVENIA;SECOND DEPARTMENT OF PROPAEDEUTIC INTERNAL MEDICINE, MEDICAL SCHOOL, ARISTOTLE UNIVERSITY OF THESSALONIKI, HIPPOCRATION HOSPITAL, THESSALONIKI, GREECE;DEPARTMENT OF LABORATORY MEDICINE, AZ SINT-JAN HOSPITAL, BRUGES, BELGIUM, BELGIAN ATHEROSCLEROSIS SOCIETY, BELGIUM;FACULTY OF MEDICINE, INSTITUTE OF CARDIOLOGY AND REGENERATIVE MEDICINE, UNIVERSITY OF LATVIA, RIGA, LATVIA, BALTIC ATHEROSCLEROSIS SOCIETY, LATVIA;SCHOOL OF HEALTH SCIENCE AND EDUCATION, DEPARTMENT OF NUTRITION AND DIETETICS, HAROKOPIO UNIVERSITY OF ATHENS, ATHENS, GREECE;DEPARTMENT OF INTERNAL MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF DEBRECEN, DEBRECEN, HUNGARY, HUNGARIAN ATHEROSCLEROSIS SOCIETY, HUNGARY;DEPARTMENT OF CLINICAL BIOCHEMISTRY, ROYAL FREE CAMPUS, UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM;DYSLIPIDAEMIA DEPARTMENT, INSTITUTE OF CARDIOLOGY AMS OF UKRAINE, KIEV, UKRAINE, UKRAINIAN ATHEROSCLEROSIS SOCIETY, UKRAINE;1ST DEPARTMENT OF INTERNAL MEDICINE, PARACELSUS PRIVATE MEDICAL UNIVERSITY, SALZBURG, AUSTRIA, AUSTRIAN ATHEROSCLEROSIS SOCIETY, AUSTRIA;1ST DEPARTMENT OF INTERNAL MEDICINE, FACULTY OF MEDICINE, PAVOL JOZEF SAFARIK UNIVERSITY, KOŠICE, SLOVAKIA, SLOVAK ASSOCIATION OF ATHEROSCLEROSIS, SLOVAKIA;CARDIOLOGY CLINIC, SCHOOL OF MEDICINE, UNIVERSITY OF ATHENS, ATHENS, GREECE, HELLENIC ATHEROSCLEROSIS SOCIETY, GREECE;UNIVERSITY HOSPITAL CENTRE ZAGREB, SCHOOL OF MEDICINE UNIVERSITY OF ZAGREB, DEPARTMENT OF INTERNAL MEDICINE, ZAGREB, CROATIA, CROATIAN ATHEROSCLEROSIS SOCIETY, CROATIA;DEPARTMENT OF PRIMARY CARE AND PUBLIC HEALTH, IMPERIAL COLLEGE, LONDON, UNITED KINGDOM;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, PALERMO, ITALY, EURO-MEDITERRANEAN INSTITUTE OF SCIENCE AND TECHNOLOGY, PALERMO, ITALY;BIOTECHNOLOGY RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;CENTER FOR INTERDISCIPLINARY RESEARCH, DEPARTMENT OF FUNCTIONAL SCIENCES, UNIVERSITY OF MEDICINE AND PHARMACY 'VICTOR BABES', TIMISOARA, IRAN;DIVISION OF CARDIOLOGY, EMORY UNIVERSITY, EMORY CLINICAL CARDIOVASCULAR RESEARCH INSTITUTE, ATLANTA, GA, UNITED STATES;JOHNS HOPKINS CICCARONE CENTER FOR THE PREVENTION OF HEART DISEASE, BALTIMORE, MD, UNITED STATES, PREVENTIVE CARDIOLOGY, CGH MEDICAL CENTER, STERLING, IL, UNITED STATES;UNIVERSITY OF MEDICINE AND PHARMACY 'CAROL DAVILA', BUCHAREST, ROMANIA, DEPARTMENT OF CARDIOLOGY, UNIVERSITY AND EMERGENCY HOSPITAL, BUCHAREST, ROMANIA, ROMANIAN SOCIETY OF CARDIOLOGY, ROMANIA;THIRD DEPARTMENT OF INTERNAL MEDICINE, FIRST MEDICAL FACULTY, CHARLES UNIVERSITY, PRAGUE, CZECH REPUBLIC, CZECH ATHEROSCLEROSIS SOCIETY, CZECH REPUBLIC;HEART DISEASE PREVENTION PROGRAM, DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, VA, UNITED STATES;DEPARTMENT OF HYPERTENSION, CHAIR OF NEPHROLOGY AND HYPERTENSION, MEDICAL UNIVERSITY OF LODZ, POLAND, POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE, LODZ, POLAND, CARDIOVASCULAR RESEARCH CENTRE, UNIVERSITY OF ZIELONA GORA, ZIELONA GORA, POLAND, LIPID AND BLOOD PRESSURE META-ANALYSIS COLLABORATION GROUP, POLAND, POLISH LIPID ASSOCIATION, POLAND","IN RECENT YEARS, THERE HAS BEEN GROWING INTEREST IN THE POSSIBLE USE OF NUTRACEUTICALS TO IMPROVE AND OPTIMIZE DYSLIPIDEMIA CONTROL AND THERAPY. BASED ON THE DATA FROM AVAILABLE STUDIES, NUTRACEUTICALS MIGHT HELP PATIENTS OBTAIN THERAPUTIC LIPID GOALS AND REDUCE CARDIOVASCULAR RESIDUAL RISK. SOME NUTRACEUTICALS HAVE ESSENTIAL LIPIDLOWERING PROPERTIES CONFIRMED IN STUDIES; SOME MIGHT ALSO HAVE POSSIBLE POSITIVE EFFECTS ON NONLIPID CARDIOVASCULAR RISK FACTORS AND HAVE BEEN SHOWN TO IMPROVE EARLY MARKERS OF VASCULAR HEALTH SUCH AS ENDOTHELIAL FUNCTION AND PULSE WAVE VELOCITY. HOWEVER, THE CLINICAL EVIDENCE SUPPORTING THE USE OF A SINGLE LIPID-LOWERING NUTRACEUTICAL OR A COMBINATION OF THEM IS LARGELY VARIABLE AND, FOR MANY OF THE NUTRACEUTICALS, THE EVIDENCE IS VERY LIMITED AND, THEREFORE, OFTEN DEBATABLE. THE PURPOSE OF THIS POSITION PAPER IS TO PROVIDE CONSENSUS-BASED RECOMMENDATIONS FOR THE OPTIMAL USE OF LIPID-LOWERING NUTRACEUTICALS TO MANAGE DYSLIPIDEMIA IN PATIENTS WHO ARE STILL NOT ON STATIN THERAPY, PATIENTS WHO ARE ON STATIN OR COMBINATION THERAPY BUT HAVE NOT ACHIEVED LIPID GOALS, AND PATIENTS WITH STATIN INTOLERANCE. THIS STATEMENT IS INTENDED FOR PHYSICIANS AND OTHER HEALTHCARE PROFESSIONALS ENGAGED IN THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH LIPID DISORDERS, ESPECIALLY IN THE PRIMARY CARE SETTING. © THE AUTHOR(S) 2017. PUBLISHED BY OXFORD UNIVERSITY PRESS ON BEHALF OF THE INTERNATIONAL LIFE SCIENCES INSTITUTE. ALL RIGHTS RESERVED.","DYSLIPIDEMIA; LIPID; NUTRACEUTICALS; POSITION PAPER; RECOMMENDATIONS","CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, UNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; LIFE STYLE; LIVER; META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; PHYTOCHEMICALS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRIGLYCERIDES; ALPHA TOCOPHEROL; ANTHOCYANIN; ANTILIPEMIC AGENT; BERBERINE; BETA GLUCAN; CARNITINE; CHITOSAN; CHOLESTIN; CONJUGATED LINOLEIC ACID; CURCUMIN; CYNARA ACOLYMUS EXTRACT; GAMMA ORYZANOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPAGULA; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PANTETHINE; PHYCOCYANIN; PHYTOSTEROL; POLICOSANOL; PROBIOTIC AGENT; SILYMARIN; SINECATECHINS; SOYBEAN PROTEIN; STANOZOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; XUEZHIKANG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOCHEMICAL; PROBIOTIC AGENT; TRIACYLGLYCEROL; UNSATURATED FATTY ACID; ARTICHOKE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHLORELLA; CITRUS BERGANIA; CITRUS FRUIT; CLINICAL PRACTICE; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ECONOMIC ASPECT; ENDOTHELIUM; GARLIC; GLYCYRRHIZA; HEALTH CARE PERSONNEL; HUMAN; INTESTINE ABSORPTION; LIFESTYLE MODIFICATION; LUPIN; MOMORDICA CHARANTIA; NONHUMAN; PATIENT CARE; PHYSICIAN; PREVALENCE; PRIMARY MEDICAL CARE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SILYBUM MARIANUM; SPIRULINA; BLOOD; CARDIOVASCULAR DISEASE; DIETARY SUPPLEMENT; DRUG EFFECTS; DRUG INTERACTION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; LIFESTYLE; LIVER; META ANALYSIS (TOPIC); METABOLISM; OBSERVATIONAL STUDY","SIEMENS LABORATORIES; AMGEN; PFIZER; ASTRAZENECA; BAYER; NOVARTIS; SANOFI; BOEHRINGER INGELHEIM; NOVO NORDISK; SERVIER","DECLARATION OF INTEREST. M.B. HAS BEEN ON THE SPEAKERS BUREAU OF ABBOTT/MYLAN, ABBOTT VASCULAR, ACTAVIS, AKCEA, AMGEN, BIOFARM, KRKA, MSD, SANOFI-AVENTIS, AND VALEANT; SERVED AS A CONSULTANT TO ABBOTT VASCULAR, AKCEA, AMGEN, DAICHII SANKYO, ESPERION, LILLY, MSD, RESVERLOGIX, AND SANOFI-AVENTIS; AND RECEIVED GRANTS FROM SANOFI AND VALEANT. A.F.G.C. HAS SERVED AS A CONSULTANT FOR THE R&D OF MEDA SPA AND RECEIVED RESEARCH GRANTS FROM IBSA SPA. O.D. HAS BEEN ON THE SPEAKERS BUREAU OF AMGEN, MSD, AND SANOFI-AVENTI; SERVED AS A CONSULTANT TO AMGEN, ASTRAZENECA, MSD, SANOFI-AVENTIS, AND PHACOBEL; AND RECEIVED GRANTS FROM SANOFI, MSD, AND AMGEN. N.K. HAS GIVEN TALKS, ATTENDED CONFERENCES, AND PARTICIPATED IN TRIALS SPONSORED BY AMGEN, ANGELINI, ASTRA ZENECA, BOEHRINGER INGELHEIM, MSD, NOVARTIS, NOVO NORDISK, SANOFI, AND WINMEDICA. G.L. HAS BEEN ON THE SPEAKERS BUREAU OF AMGEN, ASTRA-ZENECA, BAYER, BERLIN-CHEMIE/MENARINI, BOEHRINGER INGELHEIM, GLAXOSMITHCLINE, MYLAN, NOVO NORDISK, PFIZER, SANOFI-AVENTIS, SERVIER, AND SIEMENS LABORATORIES AND RECEIVED A RESEARCH GRANT ON THE TOPIC OF POLYPRENOLS AND COENZYME Q10 FROM PHARMA AND CHEMISTRY COMPETENCE CENTER OF LATVIA. D.P.M. HAS GIVEN TALKS AND ATTENDED CONFERENCES SPONSORED BY MSD, ASTRAZENECA, AND LIBYTEC. P.P.T. HAS BEEN ON THE SPEAKERS BUREAU OF AMARIN, AMGEN, KOWA, MERCK, NOVARTIS, REGENERON, AND SANOFI-AVENTIS AND SERVED AS A CONSULTANT TO AMGEN, ASTRAZENECA, KOWA, MERCK, AND REGENERON. D.V. HAS GIVEN TALKS AND ATTENDED CONFERENCES SPONSORED BY BMS/PFIZER, NOVARTIS, SERVIER, AMGEN, BAYER, AND ASTRAZENECA AND RECEIVED SPEAKER FEES FROM PFIZER, NOVARTIS, SERVIER, BAYER, ASTRAZENECA, AND TERAPIA. M.V. REPORTS PERSONAL FEES FROM ABBOTT, ACTAVIS, ASTRAZENECA, AMGEN, BMS, GENZYME, KRKA, MSD, NOVARTIS, PFIZER, AND SANOFI-REGENERON. G.B., A.C., D.M.D., M.E., Z.F., K.K.R., M.L., O.M., D.B.P., G.P., B.P., D.P., C.P., Z.R.,≤ M.R., A.S., M.-C.S., L.S.S., AND N.D.W. HAVE NO RELEVANT INTERESTS TO DECLARE.","CARDIOVASCULAR DISEASES (CVDS), (2015); PERK J., DE BACKER G., GOHLKE H., ET AL., THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR HEART J, 33, PP. 1635-1701, (2012); BLOOM D.E., CAFIERO E.T., JANE-LLOPIS E., ET AL., THE GLOBAL ECONOMIC BURDEN OF NONCOMMUNICABLE DISEASES, (2011); RISK ESTIMATION AND THE PREVENTION OF CARDIOVASCULAR DISEASE, (2007); THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, PP. 3143-3421, (2002); HIGH BLOOD CHOLESTEROL, (2012); COLANTONIO L.D., BITTNER V., REYNOLDS K., ET AL., ASSOCIATION OF SERUM LIPIDS AND CORONARY HEART DISEASE IN CONTEMPORARY OBSERVATIONAL STUDIES, CIRCULATION, 133, PP. 256-264, (2016); FORD E.S., LI C., PEARSON W.S., ET AL., TRENDS IN HYPERCHOLESTEROLEMIA, TREATMENT AND CONTROL AMONG UNITED STATES ADULTS, INT J CARDIOL, 140, PP. 226-235, (2010); MOZAFFARIAN D., BENJAMIN E.J., GO A.S., ET AL., AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE; STROKE STATISTICS SUBCOMMITTEE. HEART DISEASE AND STROKE STATISTICS-2016 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 133, PP. E38-E360, (2016); BAIGENT C., KEECH A., KEARNEY P.M., ET AL., CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATOR. EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE METAANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); ZDROJEWSKI T., SOLNICA B., CYBULSKA B., BANDOSZ P., RUTKOWSKI M., STOKWISZEWSKI J., GACIONG Z., BANACH M., WOJTYNIAK B., PENCINA M., WYRZYKOWSKI B., PREVALENCE OF LIPID ABNORMALITIES IN POLAND. THE NATPOL 2011 SURVEY, KARDIOL POL, 74, PP. 213-223, (2016); HOBBS F.D., BANACH M., MIKHAILIDIS D.P., ET AL., IS STATIN-MODIFIED REDUCTION IN LIPIDS THE MOST IMPORTANT PREVENTIVE THERAPY FOR CARDIOVASCULAR DISEASE?. A PRO/CON DEBATE, BMC MED, 14, (2016); BAIGENT C., BLACKWELL L., EMBERSON J., ET AL., CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATIO. EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PROSPER STUDY GROUP. PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED TRIAL, LANCET, 360, PP. 1623-1630, (2002); JACOBSON T.A., ITO M.K., MAKI K.C., ET AL., NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT-CENTERED MANAGEMENT OF DYSLIPIDEMIA: PART 1-FULL REPORT, J CLIN LIPIDOL, 9, PP. 129-169, (2015); LAW M.R., WALD N.J., THOMPSON S.G., BY HOW MUCH AND HOW QUICKLY DOES REDUCTION IN SERUM CHOLESTEROL CONCENTRATION LOWER RISK OF ISCHAEMIC HEART DISEASE?, BMJ, 308, PP. 367-372, (1994); CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., AUTHORS/TASK FORCE MEMBERS 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, 253, PP. 281-344, (2016); REINER Z., HYPERTRIGLYCERIDEMIA AND RISK OF CORONARY ARTERY DISEASE, NAT REV CARDIOL, 14, PP. 401-411, (2017); BOOTH J.N., COLANTONIO L.D., HOWARD G., ET AL., HEALTHY LIFESTYLE FACTORS AND INCIDENT HEART DISEASE AND MORTALITY IN CANDIDATES FOR PRIMARY PREVENTION WITH STATIN THERAPY, INT J CARDIOL, 207, PP. 196-202, (2016); BANACH M., JANKOWSKI P., JOZWIAK J., ET AL., POLA/CFPIP/PCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS FOR FAMILY PHYSICIANS 2016, ARCH MED SCI, 13, PP. 1-45, (2017); PIEPOLI M.F., HOES A.W., AGEWALL S., ET AL., EUR J PREV CARDIOL, 23, PP. NP1-NP96, (2016); VANHEES L., GELADAS N., HANSEN D., ET AL., ON BEHALF OF THE WRITING GROUP IMPORTANCE OF CHARACTERISTICS AND MODALITIES OF PHYSICAL ACTIVITY AND EXERCISE IN THE MANAGEMENT OF CARDIOVASCULAR HEALTH IN INDIVIDUALS WITH CARDIOVASCULAR RISK FACTORS: RECOMMENDATIONS FROM THE EACPR (PART II), EUR J PREV CARDIOL, 19, PP. 1005-1033, (2012); LICHTENSTEIN A.H., APPEL L.J., BRANDS M., ET AL., AMERICAN HEART ASSOCIATION NUTRITION COMMITTE. DIET AND LIFESTYLE RECOMMENDATIONS REVISION 2006: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 114, PP. 82-96, (2006); APPEL L.J., SACKS F.M., CAREY V.J., ET AL., OMNIHEART COLLABORATIVE RESEARCH GROUP. EFFECTS OF PROTEIN, MONOUNSATURATED FAT, AND CARBOHYDRATE INTAKE ON BLOOD PRESSURE AND SERUM LIPIDS: RESULTS OF THE OMNIHEART RANDOMIZED TRIAL, JAMA, 294, PP. 2455-2464, (2005); BROWN M.S., GOLDSTEIN J.L., BIOMEDICINE. LOWERING LDL-NOT ONLY HOW LOW, BUT HOW LONG?, SCIENCE, 311, PP. 1721-1731, (2006); BRINTON E.A., MANAGEMENT OF HYPERTRIGLYCERIDEMIA FOR PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, ENDOCRINOL METAB CLIN NORTH AM, 45, PP. 185-204, (2016); PATTI A.M., TOTH P.P., GIGLIO R.V., ET AL., NUTRACEUTICALS AS AN IMPORTANT PART OF COMBINATION THERAPY IN DYSLIPIDAEMIA, CURR PHARM DES, (2017); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); CICERO A.F., COLLETTI A., ROLE OF PHYTOCHEMICALS IN THE MANAGEMENT OF METABOLIC SYNDROME, PHYTOMEDICINE, 23, PP. 1134-1144, (2016); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J CLIN HYPERTENS, 14, PP. 121-132, (2012); CICERO A.F., FOGACCI F., COLLETTI A., FOOD AND PLANT BIOACTIVES FOR REDUCING CARDIOMETABOLIC DISEASE RISK: AN EVIDENCE BASED APPROACH, FOOD FUNCT, 8, PP. 2076-2088, (2017); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL. STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY-EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR HEART J, 36, PP. 1012-1022, (2015); BANGALORE S., FAYYAD R., HOVINGH G.K., ET AL., TREATING TO NEW TARGETS STEERING COMMITTEE AND INVESTIGATORS. STATIN AND THE RISK OF RENAL-RELATED SERIOUS ADVERSE EVENTS: ANALYSIS FROM THE IDEAL, TNT, CARDS, ASPEN, SPARCL, AND OTHER PLACEBO-CONTROLLED TRIALS, AM J CARDIOL, 113, PP. 2018-2020, (2014); REINER Z., RESISTANCE AND INTOLERANCE TO STATINS, NUTR METAB CARDIOVASC DIS, 24, PP. 1057-1066, (2014); BANACH M., RIZZO M., TOTH P.P., FARNIER M., ET AL., STATIN INTOLERANCE-AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015); PATEL J., MARTIN S.S., BANACH M., EXPERT OPINION: THE THERAPEUTIC CHALLENGES FACED BY STATIN INTOLERANCE, EXPERT OPIN PHARMACOTHER, 17, PP. 1497-1507, (2016); BANACH M., SERBAN M.C., DISCUSSION AROUND STATIN DISCONTINUATION IN OLDER ADULTS AND PATIENTS WITH WASTING DISEASES, J CACHEXIA SARCOPENIA MUSCLE, 7, PP. 396-399, (2016); BANACH M., ARONOW W.S., SERBAN M.C., ET AL., LIPIDS, BLOOD PRESSURE AND KIDNEY UPDATE, LIPIDS HEALTH DIS, 14, (2015); DEVARAJ S., JIALAL I., THE ROLE OF DIETARY SUPPLEMENTATION WITH PLANT STEROLS AND STANOLS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, NUTR REV, 64, 7, PP. 348-354, (2006); LAW M., PLANT STEROL AND STANOL MARGARINES AND HEALTH, BR MED J, 320, PP. 861-864, (2000); RAS R.T., HIEMSTRA H., LIN Y., ET AL., CONSUMPTION OF PLANT STEROL-ENRICHED FOODS AND EFFECTS ON PLASMA PLANT STEROL CONCENTRATIONS-A META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES, ATHEROSCLEROSIS, 230, PP. 336-346, (2013); FERGUSON J.J., STOJANOVSKI E., MACDONALD-WICKS L., ET AL., FAT TYPE IN PHYTOSTEROL PRODUCTS INFLUENCE THEIR CHOLESTEROL-LOWERING POTENTIAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS, PROG LIPID RES, 64, PP. 16-29, (2016); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., ET AL., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUR J NUTR, 52, PP. 153-160, (2013); ATHYROS V.G., KAKAFIKA A.I., PAPAGEORGIOU A.A., ET AL., EFFECT OF A PLANT STANOL ESTERCONTAINING SPREAD, PLACEBO SPREAD, OR MEDITERRANEAN DIET ON ESTIMATED CARDIOVASCULAR RISK AND LIPID, INFLAMMATORY AND HAEMOSTATIC FACTORS, NUTR METAB CARDIOVASC DIS, 21, PP. 213-221, (2011); TALATI R., SOBIERAJ D.M., MAKANJI S.S., ET AL., THE COMPARATIVE EFFICACY OF PLANT STEROLS AND STANOLS ON SERUM LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J AM DIET ASSOC, 110, PP. 719-726, (2010); RAS R.T., FUCHS D., KOPPENOL W.P., ET AL., THE EFFECT OF A LOW-FAT SPREAD WITH ADDED PLANT STEROLS ON VASCULAR FUNCTION MARKERS: RESULTS OF THE INVESTIGATING VASCULAR FUNCTION EFFECTS OF PLANT STEROLS (INVEST) STUDY, AM J CLIN NUTR, 101, PP. 733-741, (2015); GYLLING H., HALONEN J., LINDHOLM H., ET AL., THE EFFECTS OF PLANT STANOL ESTER CONSUMPTION ON ARTERIAL STIFFNESS AND ENDOTHELIAL FUNCTION IN ADULTS: A RANDOMISED CONTROLLED CLINICAL TRIAL, BMC CARDIOVASC DISORD, 13, (2013); BROWN L., ROSNER B., WILLETT W.W., ET AL., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); DOI K., EFFECT OF KONJAC FIBRE (GLUCOMANNAN) ON GLUCOSE AND LIPIDS, EUR J CLIN NUTR, 49, PP. S190-S197, (1995); ZHU X., SUN X., WANG M., ET AL., QUANTITATIVE ASSESSMENT OF THE EFFECTS OF BETAGLUCAN CONSUMPTION ON SERUM LIPID PROFILE AND GLUCOSE LEVEL IN HYPERCHOLESTEROLEMIC SUBJECTS, NUTR METAB CARDIOVASC DIS, 25, PP. 714-723, (2015); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF A HEALTH CLAIM RELATED TO OAT BETA-GLUCAN AND LOWERING BLOOD CHOLESTEROL AND REDUCED RISK OF (CORONARY) HEART DISEASE PURSUANT TO ARTICLE 14 OF REGULATION (EC) NO 1924/2006, EFSA J, 8, (2010); REINER Z., CATAPANO A., DE BACKER G., ET AL., THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS). ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR HEART J, 32, PP. 1769-1818, (2011); CLEEMAN J., GRUNDY S., BECKER D., ET AL., EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) ADULT TREATMENT PANEL (ATP III), JAMA, 285, PP. 2486-2497, (2001); TABESH F., SANEI H., JAHANGIRI M., ET AL., THE EFFECTS OF BETA-GLUCAN RICH OAT BREAD ON SERUM NITRIC OXIDE AND VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA, BIOMED RES INT, 2014, (2014); ANDERSON J.W., DIETARY FIBRE, COMPLEX CARBOHYDRATE AND CORONARY ARTERY DISEASE, CAN J CARDIOL, 11, PP. 55G-62G, (1995); WEI Z.H., WANG H., CHEN X.Y., ET AL., TIME-AND DOSE-DEPENDENT EFFECT OF PSYLLIUM ON SERUM LIPIDS IN MILD-TO-MODERATE HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, EUR J CLIN NUTR, 63, PP. 821-827, (2009); RIBAS S.A., CUNHA D.B., SICHIERI R., ET AL., EFFECTS OF PSYLLIUM ON LDL-CHOLESTEROL CONCENTRATIONS IN BRAZILIAN CHILDREN AND ADOLESCENTS: A RANDOMISED, PLACEBOCONTROLLED, PARALLEL CLINICAL TRIAL, BR J NUTR, 113, PP. 134-141, (2015); ANDERSON J.W., ZETTWOCH N., FELDMAN T., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM HYDROPHILIC MUCILLOID FOR HYPERCHOLESTEROLEMIC MEN, ARCH INTERN MED, 148, PP. 292-296, (1988); GIBB R.D., MCRORIE J.W., RUSSELL D.A., ET AL., PSYLLIUM FIBER IMPROVES GLYCEMIC CONTROL PROPORTIONAL TO LOSS OF GLYCEMIC CONTROL: A META-ANALYSIS OF DATA IN EUGLYCEMIC SUBJECTS, PATIENTS AT RISK OF TYPE 2 DIABETES MELLITUS, AND PATIENTS BEING TREATED FOR TYPE 2 DIABETES MELLITUS, AM J CLIN NUTR, 102, PP. 1604-1614, (2015); PAL S., KHOSSOUSI A., BINNS C., ET AL., THE EFFECTS OF 12-WEEK PSYLLIUM FIBRE SUPPLEMENTATION OR HEALTHY DIET ON BLOOD PRESSURE AND ARTERIAL STIFFNESS IN OVERWEIGHT AND OBESE INDIVIDUALS, BR J NUTR, 107, PP. 725-734, (2012); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); BEHERA S.S., RAY R.C., KONJAC GLUCOMANNAN, A PROMISING POLYSACCHARIDE OF AMORPHOPHALLUS KONJAC K. KOCH IN HEALTH CARE, INT J BIOL MACROMOL, 92, PP. 942-956, (2016); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 88, PP. 1167-1175, (2008); ONAKPOYA I., POSADZKI P., ERNST E., THE EFFICACY OF GLUCOMANNAN SUPPLEMENTATION IN OVERWEIGHT AND OBESITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, J AM COLL NUTR, 33, PP. 70-78, (2014); GUARDAMAGNA O., ABELLO F., CAGLIERO P., ET AL., COULD DYSLIPIDEMIC CHILDREN BENEFIT FROM GLUCOMANNAN INTAKE?, NUTRITION, 29, PP. 1060-1065, (2013); MARTINO F., MARTINO E., MORRONE F., ET AL., EFFECT OF DIETARY SUPPLEMENTATION WITH GLUCOMANNAN ON PLASMA TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC CHILDREN, NUTR METAB CARDIOVASC DIS, 15, PP. 174-180, (2005); MARTINO F., PUDDU P.E., PANNARALE G., ET AL., LOW DOSE CHROMIUM-POLYNICOTINATE OR POLICOSANOL IS EFFECTIVE IN HYPERCHOLESTEROLEMIC CHILDREN ONLY IN COMBINATION WITH GLUCOMANNAN, ATHEROSCLEROSIS, 228, PP. 198-202, (2013); BAKER W.L., TERCIUS A., ANGLADE M., ET AL., A META-ANALYSIS EVALUATING THE IMPACT OF CHITOSAN ON SERUM LIPIDS IN HYPERCHOLESTEROLEMIC PATIENTS, ANN NUTR METAB, 55, PP. 368-374, (2008); RIZZO M., GIGLIO R.V., NIKOLIC D., ET AL., EFFECTS OF CHITOSAN ON PLASMA LIPIDS AND LIPOPROTEINS: A 4-MONTH PROSPECTIVE PILOT STUDY, ANGIOLOGY, 65, PP. 538-542, (2014); JULL A.B., NI MHURCHU C., BENNETT D.A., ET AL., CHITOSAN FOR OVERWEIGHT OR OBESITY, COCHRANE DATABASE SYST REV, 3, (2008); KIM H.J., AHN H.Y., KWAK J.H., ET AL., THE EFFECTS OF CHITOSAN OLIGOSACCHARIDE (GO2KA1) SUPPLEMENTATION ON GLUCOSE CONTROL IN SUBJECTS WITH PREDIABETES, FOOD FUNCT, 10, PP. 2662-2669, (2014); MHURCHU C.N., POPPITT S., MCGILL A., ET AL., THE EFFECT OF THE DIETARY SUPPLEMENT, CHITOSAN, ON BODY WEIGHT: A RANDOMISED CONTROLLED TRIAL IN 250 OVERWEIGHT AND OBESE ADULTS, INT J OBES, 28, PP. 1149-1156, (2004); GUARNER F., SCHAAFSMA G.J., PROBIOTICS, INT J FOOD MICROBIOL, 39, PP. 237-238, (1998); GILLILAND S.E., NELSON C.R., MAXWELL C., ASSIMILATION OF CHOLESTEROL BY LACTOBACILLUS ACIDOPHILUS, APPL ENVIRON MICROBIOL, 49, PP. 377-381, (1985); MISTRY P., NATURAL CHOLESTEROL-LOWERING PRODUCTS: FOCUS ON PROBIOTICS, BR J COMMUNITY NURS, 19, PP. S14-S18, (2014); KIM G.B., YI S.H., LEE B.H., PURIFICATION AND CHARACTERIZATION OF THREE DIFFERENT TYPES OF BILE SALT HYDROLASES FROM BIFIDOBACTERIUM STRAINS, J DAIRY SCI, 87, PP. 258-266, (2004); LIONG M.T., DUNSHEA F.R., SHAH N.P., EFFECTS OF A SYNBIOTIC CONTAINING LACTOBACILLUS ACIDOPHILUS ATCC 4962 ON PLASMA LIPID PROFILES AND MORPHOLOGY OF ERYTHROCYTES IN HYPERCHOLESTEROLAEMIC PIGS ON HIGH-AND LOW-FAT DIETS, BR J NUTR, 98, PP. 736-744, (2007); CHO Y.A., KIM J., EFFECT OF PROBIOTICS ON BLOOD LIPID CONCENTRATIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MEDICINE, 94, (2015); AGERHOLM-LARSEN L., BELL M.L., GRUNWALD G.K., ET AL., THE EFFECT OF A PROBIOTIC MILK PRODUCT ON PLASMA CHOLESTEROL: A META-ANALYSIS OF SHORT-TERM INTERVENTION STUDIES, EUR J CLIN NUTR, 54, PP. 856-860, (2000); SHIMIZU M., HASHIGUCHI M., SHIGA T., ET AL., META-ANALYSIS: EFFECTS OF PROBIOTIC SUPPLEMENTATION ON LIPID PROFILES IN NORMAL TOMILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, PLOS ONE, 10, (2015); DORON S., SNYDMAN D.R., RISK AND SAFETY OF PROBIOTICS, CLIN INFECT DIS (REVIEW), 60, PP. S129-S134, (2015); MA J., LI Y., YE Q., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5225, (2000); GORDON R.Y., COOPERMAN T., OBERMEYER W., ET AL., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS: BUYER BEWARE!, ARCH INTERN MED, 170, PP. 1722-1727, (2010); WANG R.W., KARI P.H., LU A.Y., ET AL., BIOTRANSFORMATION OF LOVASTATI. IV. IDENTIFICATION OF CYTOCHROME P450 3A PROTEINS AS THE MAJOR ENZYMES RESPONSIBLE FOR THE OXIDATIVE METABOLISM OF LOVASTATIN IN RAT AND HUMAN LIVER MICROSOMES, ARCH BIOCHEM BIOPHYS, 290, PP. 355-361, (1991); LI Y.G., ZHANG F., WANG Z.T., ET AL., IDENTIFICATION AND CHEMICAL PROFILING OF MONACOLINS IN RED YEAST RICE USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH PHOTODIODE ARRAY DETECTOR AND MASS SPECTROMETRY, J PHARM BIOMED ANAL, 35, PP. 1101-1112, (2004); GERARDS M.C., TERLOU R.J., YU H., ET AL., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN-A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); MAZZANTI G., MORO P.A., RASCHI E., ET AL., ADVERSE REACTIONS TO DIETARY SUPPLEMENTS CONTAINING RED YEAST RICE: ASSESSMENT OF CASES FROM THE ITALIAN SURVEILLANCE SYSTEM, BR J CLIN PHARMACOL, 83, PP. 894-908, (2017); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); ZHAO S.P., LIU L., CHENG Y.C., ET AL., XUEZHIKANG, AN EXTRACT OF CHOLESTIN, PROTECTS ENDOTHELIAL FUNCTION THROUGH ANTIINFLAMMATORY AND LIPID-LOWERING MECHANISMS IN PATIENTS WITH CORONARY HEART DISEASE, CIRCULATION, 110, PP. 915-920, (2004); KANTOLA T., KIVISTO K.T., NEUVONEN P.J., GRAPEFRUIT JUICE GREATLY INCREASES SERUM CONCENTRATIONS OF LOVASTATIN AND LOVASTATIN ACID, CLIN PHARMACOL THER, 63, PP. 397-402, (1998); TOXICOLOGICAL EVALUATION OF RED MOULD RICE: AN UPDATE, (2012); PRASAD G.V., WONG T., MELITON G., ET AL., RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, PP. 1200-1201, (2002); RASHEVA T.V., NEDEVA T.S., HALLET J.N., ET AL., CHARACTERIZATION OF A NON-PIGMENT PRODUCING MONASCUS PURPUREUS MUTANT STRAIN, ANTONIE VAN LEEUWENHOEK, 83, PP. 333-340, (2003); ARAI M., HIBINO T., TUMORIGENICITY OF CITRININ IN MALE F344 RATS, CANCER LETT, 17, PP. 281-287, (1983); CHAN W.H., SHIAO N.H., EFFECT OF CITRININ ON MOUSE EMBRYONIC DEVELOPMENT IN VITRO AND IN VIVO, REPROD TOXICOL, 24, PP. 120-125, (2007); SINGH N.D., SHARMA A.K., DWIVEDI P., ET AL., EXPERIMENTALLY INDUCED CITRININ AND ENDOSULFAN TOXICITY IN PREGNANT WISTAR RATS: HISTOPATHOLOGICAL ALTERATIONS IN LIVER AND KIDNEYS OF FETUSES, J APPL TOXICOL, 28, PP. 901-907, (2008); SCIENTIFIC OPINION ON THE RISKS FOR PUBLIC AND ANIMAL HEALTH RELATED TO THE PRESENCE OF CITRININ IN FOOD AND FEED, EFSA J, 10, (2012); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/20061, EFSA J, 9, (2011); BORLINGHAUS J., ALBRECHT F., GRUNHLKE M.C.H., ET AL., ALLICIN: CHEMISTRY AND BIOLOGICAL PROPERTIES, MOLECULES, 19, PP. 12591-12618, (2014); RIED K., TOBEN C., FAKLER P., EFFECT ON GARLIC ON SERUM LIPIDS: AN UPDATED META-ANALYSIS, NUTR REV, 71, PP. 282-299, (2013); ACKERMANN R.T., MULROW C.D., RAMIREZ G., ET AL., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCH INTERN MED, 161, PP. 813-824, (2001); RIED K., GARLIC LOWERS BLOOD PRESSURE IN HYPERTENSIVE INDIVIDUALS, REGULATES SERUM CHOLESTEROL, AND STIMULATES IMMUNITY: AN UPDATED META-ANALYSIS AND REVIEW, J NUTR, 146, PP. 389S-396S, (2016); JUNG E.S., PARK S.H., CHOI E.K., ET AL., REDUCTION OF BLOOD LIPID PARAMETERS BY A 12-WK SUPPLEMENTATION OF AGED BLACK GARLIC: A RANDOMIZED CONTROLLED TRILA, NUTRITION, 30, PP. 1034-1039, (2014); SAHEBKAR A., SERBAN C., URSONIU S., ET AL., EFFECT OF GARLIC ON PLASMA LIPOPROTEIN(A) CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS, NUTRITION, 32, PP. 33-40, (2016); MORIHARA N., HINO A., AGED GARLIC EXTRACT SUPPRESSES PLATELET AGGREGATION BY CHANGING THE FUNCTIONAL PROPERTY OF PLATELETS, J NAT MED, 71, PP. 249-256, (2017); CIGHETTI G., DEL PUPPO M., PARONI R., ET AL., MODULATION OF HMG-COA REDUCTASE ACTIVITY BY PANTETHEINE/PANTETHINE, BIOCHIM BIOPHYS ACTA, 963, PP. 389-393, (1988); CIGHETTI G., DEL PUPPO M., PARONI R., ET AL., PANTETHINE INHIBITS CHOLESTEROL AND FATTY ACID SYNTHESES AND STIMULATES CARBON DIOXIDE FORMATION IN ISOLATED RAT HEPATOCYTES, J LIPID RES, 28, PP. 152-161, (1987); ETO M., WATANABE K., CHONAN N., ET AL., LOWERING EFFECT OF PANTETHINE ON PLASMA BETA-THROMBOGLOBULIN AND LIPIDS IN DIABETES MELLITUS, ARTERY, 15, PP. 1-12, (1987); BINAGHI P., CELLINA G., LO CICERO G., ET AL., EVALUATION OF THE CHOLESTEROL-LOWERING EFFECTIVENESS OF PANTETHINE IN WOMEN IN PERIMENOPAUSAL AGE, MINERVA MED, 81, PP. 475-479, (1990); RUMBERGER J.A., NAPOLITANO J., AZUMANO I., ET AL., PANTETHINE, A DERIVATIVE OF VITAMIN B(5) USED AS A NUTRITIONAL SUPPLEMENT, FAVORABLY ALTERS LOW-DENSITY LIPOPROTEIN CHOLESTEROL METABOLISM IN LOW-TO MODERATE-CARDIOVASCULAR RISK NORTH AMERICAN SUBJECTS: A TRIPLE-BLINDED PLACEBO AND DIET-CONTROLLED INVESTIGATION, NUTR RES, 31, PP. 608-615, (2011); EVANS M., RUMBERGER J.A., AZUMANO I., ET AL., PANTETHINE, A DERIVATIVE OF VITAMIN B5, FAVORABLY ALTERS TOTAL, LDL AND NON-HDL CHOLESTEROL IN LOW TO MODERATE CARDIOVASCULAR RISK SUBJECTS ELIGIBLE FOR STATIN THERAPY: A TRIPLE-BLINDED PLACEBO AND DIET-CONTROLLED INVESTIGATION, VASC HEALTH RISK MANAG, 10, PP. 89-100, (2014); BERTOLINI S., DONATI C., ELICIO N., ET AL., LIPOPROTEIN CHANGES INDUCED BY PANTETHINE IN HYPERLIPOPROTEINEMIC PATIENTS: ADULTS AND CHILDREN, INT J CLIN PHARMACOL THER TOXICOL, 24, PP. 630-637, (1986); DONATI C., BARBI G., CAIRO G., ET AL., PANTETHINE IMPROVES THE LIPID ABNORMALITIES OF CHRONIC HEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTER CLINICAL TRIAL, CLIN NEPHROL, 25, PP. 70-74, (1986); GIGLIO R.V., PATTI A.M., NIKOLIC D., ET AL., THE EFFECT OF BERGAMOT ON DYSLIPIDEMIA, PHYTOMEDICINE, 23, PP. 1175-1181, (2016); DI DONNA L., DE LUCA G., MAZZOTTI F., ET AL., STATIN-LIKE PRINCIPLES OF BERGAMOT FRUIT (CITRUS BERGAMIA): ISOLATION OF 3-HYDROXYMETHYLGLUTARYL FLAVONOID GLYCOSIDES, J NAT PROD, 72, PP. 1352-1354, (2009); MICELI N., MONDELLO M.R., MONFORTE M.T., ET AL., HYPOLIPIDEMIC EFFECTS OF CITRUS BERGAMIA RISSO ET POITEAU JUICE IN RATS FED A HYPERCHOLESTEROLEMIC DIET, J AGRIC FOOD CHEM, 55, PP. 10671-10677, (2007); GLIOZZI M., WALKER R., MUSCOLI S., ET AL., BERGAMOT POLYPHENOLIC FRACTION ENHANCES ROSUVASTATIN-INDUCED EFFECT ON LDL-CHOLESTEROL, LOX-1 EXPRESSION AND PROTEIN KINASE B PHOSPHORYLATION IN PATIENTS WITH HYPERLIPIDEMIA, INT J CARDIOL, 170, PP. 140-145, (2013); GLIOZZI M., CARRESI C., MUSOLINO V., ET AL., THE EFFECT OF BERGAMOT-DERIVED POLYPHENOLIC FRACTION ON LDL SMALL DENSE PARTICLES AND NON ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME, ADV BIOL CHEM, 4, PP. 129-137, (2014); ATHYROS V.G., TZIOMALOS K., KATSIKI N., ET AL., CARDIOVASCULAR RISK ACROSS THE HISTOLOGICAL SPECTRUM AND THE CLINICAL MANIFESTATIONS OF NON-ALCOHOLIC FATTY LIVER DISEASE: AN UPDATE, WORLD J GASTROENTEROL, 21, PP. 6820-6834, (2015); MOLLACE V., SACCO I., JANDA E., ET AL., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, PP. 309-316, (2011); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., ET AL., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 25, PP. 701-707, (2005); REINER Z., TEDESCHI-REINER E., RICE POLICOSANOL DOES NOT HAVE ANY EFFECTS ON BLOOD COAGULATION FACTORS IN HYPERCHOLESTEROLEMIC PATIENTS, COLL ANTROPOL, 31, PP. 315-319, (2007); LIU C.S., ZHENG Y.R., ZHANG Y.F., ET AL., RESEARCH PROGRESS ON BERBERINE WITH A SPECIAL FOCUS ON ITS ORAL BIOAVAILABILITY, FITOTERAPIA, 109, PP. 274-282, (2016); ABIDI P., ZHOU Y., JIANG J.D., ET AL., EXTRACELLULAR SIGNAL-REGULATED KINASE-DEPENDENT STABILIZATION OF HEPATIC LOW-DENSITY LIPOPROTEIN RECEPTOR MRNA BY HERBAL MEDICINE BERBERINE, ARTERIOSCLER THROMB VASC BIOL, 25, PP. 2170-2176, (2005); LI H., DONG B., PARK S.W., ET AL., HEPATOCYTE NUCLEAR FACTOR 1ALPHA PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINE, J BIOL CHEM, 284, PP. 28885-28895, (2009); LI X.Y., ZHAO Z.X., HUANG M., ET AL., EFFECT OF BERBERINE ON PROMOTING THE EXCRETION OF CHOLESTEROL IN HIGH-FAT DIET-INDUCED HYPERLIPIDEMIC HAMSTERS, J TRANSL MED, 13, (2015); QIANG X., XU L., ZHANG M., ET AL., DEMETHYLENEBERBERINE ATTENUATES NON-ALCOHOLIC FATTY LIVER DISEASE WITH ACTIVATION OF AMPK AND INHIBITION OF OXIDATIVE STRESS, BIOCHEM BIOPHYS RES COMMUN, 472, PP. 603-609, (2016); KIM W.S., LEE Y.S., CHA S.H., ET AL., BERBERINE IMPROVES LIPID DYSREGULATION IN OBESITY BY CONTROLLING CENTRAL AND PERIPHERAL AMPK ACTIVITY, AM J PHYSIOL ENDOCRINOL METAB, 296, PP. E812-E819, (2009); ZAREI A., CHANGIZI-ASHTIYANI S., TAHERI S., ET AL., A QUICK OVERVIEW ON SOME ASPECTS OF ENDOCRINOLOGICAL AND THERAPEUTIC EFFECTS OF BERBERIS VULGARIS L, AVICENNA J PHYTOMED, 5, PP. 485-497, (2015); MENG S., WANG L.S., HUANG Z.Q., ET AL., BERBERINE AMELIORATES INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION, CLIN EXP PHARMACOL PHYSIOL, 39, PP. 406-411, (2012); LAN J., ZHAO Y., DONG F., ET AL., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J ETHNOPHARMACOL, 161, PP. 69-81, (2015); DEROSA G., MAFFIOLI P., CICERO A.F., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPIN BIOL THER, 12, PP. 1113-1124, (2012); SOSNOWSKA B., PENSON P., BANACH M., THE ROLE OF NUTRACEUTICALS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASC DIAGN THER, 7, PP. S21-S31, (2017); WAY T.D., LIN H.Y., KUO D.H., ET AL., PU-ERH TEA ATTENUATES HYPERLIPOGENESIS AND INDUCES HEPATOMA CELLS GROWTH ARREST THROUGH ACTIVATING AMP-ACTIVATED PROTEIN KINASE (AMPK) IN HUMAN HEPG2 CELLS, J AGRIC FOOD CHEM, 57, PP. 5257-5264, (2009); SHISHIKURA Y., KHOKHAR S., MURRAY B.S., EFFECTS OF TEA POLYPHENOLS ON EMULSIFICATION OF OLIVE OIL IN A SMALL INTESTINE MODEL SYSTEM, J AGRIC FOOD CHEM, 54, PP. 1906-1913, (2006); ONAKPOYA I., SPENCER E., HENEGHAN C., ET AL., THE EFFECT OF GREEN TEA ON BLOOD PRESSURE AND LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, NUTR METAB CARDIOVASC DIS, 24, PP. 823-836, (2014); PARK C.S., KIM W., WOO J.S., ET AL., GREEN TEA CONSUMPTION IMPROVES ENDOTHELIAL FUNCTION BUT NOT CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH CHRONIC RENAL FAILURE, INT J CARDIOL, 145, PP. 261-262, (2010); LIN Q.F., QIU C.S., WANG S.L., ET AL., A CROSS-SECTIONAL STUDY OF THE RELATIONSHIP BETWEEN HABITUAL TEA CONSUMPTION AND ARTERIAL STIFFNESS, J AM COLL NUTR, 35, PP. 354-361, (2016); SERBAN C., SAHEBKAR A., ANTAL D., ET AL., EFFECTS OF SUPPLEMENTATION WITH GREEN TEA CATECHINS ON PLASMA C-REACTIVE PROTEIN CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTRITION, 31, PP. 1061-1071, (2015); ZHANG C., QIN Y.Y., WEI X., ET AL., TEA CONSUMPTION AND RISK OF CARDIOVASCULAR OUTCOMES AND TOTAL MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDIES, EUR J EPIDEMIOL, 30, PP. 103-113, (2015); CICERO A.F., FOGACCI F., COLLETTI A., POTENTIAL ROLE OF BIOACTIVE PEPTIDES IN PREVENTION AND TREATMENT OF CHRONIC DISEASES: A NARRATIVE REVIEW, BR J PHARMACOL, 174, PP. 1378-1394, (2017); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); CHO S.J., JUILLERAT M.A., LEE C.H., CHOLESTEROL LOWERINGMECHANISM OF SOYBEAN PROTEIN HYDROLYSATE, J AGRIC FOOD CHEM, 55, PP. 10599-10604, (2007); GRIECO A., MIELE L., POMPILI M., ET AL., ACUTE HEPATITIS CAUSED BY A NATURAL LIPIDLOWERING PRODUCT: WHEN 'ALTERNATIVE' MEDICINE IS NO 'ALTERNATIVE' AT ALL, J HEPATOL, 50, PP. 1273-1277, (2009); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J NUTR, 125, 3, PP. 606S-611S, (1995); LAMMI C., ZANONI C., SCIGLIUOLO G.M., ET AL., LUPIN PEPTIDES LOWER LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL THROUGH AN UP-REGULATION OF THE LDL RECEPTOR/STEROL REGULATORY ELEMENT BINDING PROTEIN 2 (SREBP2) PATHWAY AT HEPG2 CELL LINE, J AGRIC FOOD CHEM, 62, PP. 7151-7159, (2014); TOKEDE O.A., ONABANJO T.A., YANSANE A., ET AL., SOYA PRODUCTS AND SERUM LIPIDS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BR J NUTR, 114, PP. 831-843, (2015); BEAVERS D.P., BEAVERS K.M., MILLER M., ET AL., EXPOSURE TO ISOFLAVONE-CONTAINING SOY PRODUCTS AND ENDOTHELIAL FUNCTION: A BAYESIAN META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR METAB CARDIOVASC DIS, 22, PP. 182-191, (2012); HAZIM S., CURTIS P.J., SCHAR M.Y., ET AL., ACUTE BENEFITS OF THE MICROBIAL-DERIVED ISOFLAVONE METABOLITE EQUOL ON ARTERIAL STIFFNESS IN MEN PROSPECTIVELY RECRUITED ACCORDING TO EQUOL PRODUCER PHENOTYPE: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 103, PP. 694-702, (2016); ARNOLDI A., GRECO S., NUTRACEUTICAL CHARACTERISTICS OF LUPIN PROTEIN, NUTRAFOODS, 10, PP. 23-29, (2011); BAHR M., FECHNER A., KRAMER J., ET AL., LUPIN PROTEIN POSITIVELY AFFECTS PLASMA LDL CHOLESTEROL AND LDL:HDL CHOLESTEROL RATIO IN HYPERCHOLESTEROLEMIC ADULTS AFTER FOUR WEEKS OF SUPPLEMENTATION: A RANDOMIZED, CONTROLLED CROSSOVER STUDY, NUTR J, 12, (2013); BAHR M., FECHNER A., KIEHNTOPF M., ET AL., CONSUMING A MIXED DIET ENRICHED WITH LUPIN PROTEIN BENEFICIALLY AFFECTS PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC SUBJECTS: A RANDOMIZED CONTROLLED TRIAL, CLIN NUTR, 34, PP. 7-14, (2015); FECHNER A., KIEHNTOPF M., JAHREIS G., THE FORMATION OF SHORT-CHAIN FATTY ACIDS IS POSITIVELY ASSOCIATED WITH THE BLOOD LIPID-LOWERING EFFECT OF LUPIN KERNEL FIBER IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS, J NUTR, 144, PP. 599-607, (2014); EFSA J, 7, PP. 1263-1289, (2009); EFSA J, 8, PP. 1796-1828, (2010); HOWE P., MORI T., BUCKLEY J., LONG CHAIN OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE-FSANZ CONSIDERATION OF A COMMISSIONED REVIEW; MILLER M., STONE N.J., BALLANTYNE C., ET AL., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 2292-2333, (2011); HARRIS W.S., BULCHANDANI D., WHY DO OMEGA-3 FATTY ACIDS LOWER SERUM TRIGLYCERIDES?, CURR OPIN LIPIDOL, 17, PP. 387-393, (2006); ESLICK G.D., HOWE P.R., SMITH C., ET AL., BENEFITS OF FISH OIL SUPPLEMENTATION IN HYPERLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS, INT J CARDIOL, 136, PP. 4-16, (2009); LESLIE M.A., COHEN D.J., LIDDLE D.M., ET AL., A REVIEW OF THE EFFECT OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON BLOOD TRIACYLGLYCEROL LEVELS IN NORMOLIPIDEMIC AND BORDERLINE HYPERLIPIDEMIC INDIVIDUALS, LIPIDS HEALTH DIS, 14, (2015); DI STASI D., BERNASCONI R., MARCHIOLI R., ET AL., EARLY MODIFICATIONS OF FATTY ACID COMPOSITION IN PLASMA PHOSPHOLIPIDS, PLATELETS AND MONONUCLEATES OF HEALTHY VOLUNTEERS AFTER LOW DOSES OF N-3 POLYUNSATURATED FATTY ACIDS, EUR J CLIN PHARMACOL, 60, PP. 183-190, (2004)","A.F.G. CICERO; ATHEROSCLEROSIS RESEARCH CENTER, BOLOGNA, VIA ALBERTONI, 15, 40138, ITALY; EMAIL: ARRIGO.CICERO@UNIBO.IT","OXFORD UNIVERSITY PRESS","ENGLISH","NUTR. REV.","ARTICLE","ISI","2-S2.0-85031902306","NUTR REV","UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA;UNIVERSITY CLINICAL CENTRE OF KOSOVO;CENTRES HOSPITALIERS JOLIMONT;UNIVERSITY OF BELGRADE;RUSSIAN CARDIOLOGY RESEARCH AND PRODUCTION CENTRE;UNIVERSITY MEDICAL CENTRE LJUBLJANA;ARISTOTLE UNIVERSITY OF THESSALONIKI;AZ SINT-JAN HOSPITAL;UNIVERSITY OF LATVIA;HAROKOPIO UNIVERSITY OF ATHENS;UNIVERSITY OF DEBRECEN;UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL;INSTITUTE OF CARDIOLOGY AMS OF UKRAINE;SALZBURG;KOŠICE;UNIVERSITY OF ATHENS;UNIVERSITY HOSPITAL CENTRE ZAGREB;IMPERIAL COLLEGE;UNIVERSITY OF PALERMO;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;UNIVERSITY OF MEDICINE AND PHARMACY 'VICTOR BABES';EMORY UNIVERSITY;JOHNS HOPKINS CICCARONE CENTER FOR THE PREVENTION OF HEART DISEASE;UNIVERSITY OF MEDICINE AND PHARMACY 'CAROL DAVILA';CHARLES UNIVERSITY;UNIVERSITY OF CALIFORNIA;MEDICAL UNIVERSITY OF LODZ","NOTREPORTED;ATHEROSCLEROSIS RESEARCH CENTER;NOTREPORTED",NA,"CICERO AFG, 2017, NUTR REV","CICERO AFG, 2017, NUTR REV"
"CHO K;BAE M;KIM J","CHO, KYUNG-HYUN (7403956966); BAE, MYUNG-AE (7005711682); KIM, JAE-RYONG (7601360934)","CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGHDENSITY LIPOPROTEINS FUNCTIONALITY",2019,"CARDIOVASCULAR THERAPEUTICS","2019","",11,"10.1155/2019/8496409","DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DRUG DISCOVERY PLATFORM TECHNOLOGY TEAM, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, TAEJON, 305-343, SOUTH KOREA;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, SMART-AGING CONVERGENCE RESEARCH CENTER, COLLEGE OF MEDICINE, YEUNGNAM UNIVERSITY, DAEGU, 705-717, SOUTH KOREA","BACKGROUND. CUBAN SUGARCANE WAX ACIDS (SCWA) AND POLICOSANOL (PCO) ARE MIXTURES OF HIGHER ALIPHATIC ACIDS AND ALCOHOLS, RESPECTIVELY, PURIFIED FROM SUGARCANE WAX WITH DIFFERENT CHIEF COMPONENTS. ALTHOUGH IT HAS BEEN KNOWN THAT THEY HAVE ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES, PHYSIOLOGICAL PROPERTIES ON MOLECULAR MECHANISM OF SCWA HAVE BEEN LESS STUDIED THAN PCO. METHODS. IN THIS STUDY, WE COMPARED ANTIATHEROGENIC ACTIVITIES OF SCWA AND PCO VIA ENCAPSULATION WITH RECONSTITUTED HIGH-DENSITY LIPOPROTEINS (RHDL). RESULTS. AFTER RECONSTITUTION, SCWA-RHDL SHOWED SMALLER PARTICLE SIZE THAN PCO-RHDL WITH INCREASE OF CONTENT. PCO-RHDL OR SCWA-RHDL SHOWED DISTINCT INHIBITION OF GLYCATION WITH SIMILAR EXTENT IN THE PRESENCE OF FRUCTOSE. PCO-RHDL OR SCWA-RHDL SHOWED STRONG ANTIOXIDANT ACTIVITY AGAINST CUPRIC ION-MEDIATED OXIDATION OF LOW-DENSITY LIPOPROTEINS (LDL), AND INHIBITION OF OXLDL UPTAKE INTO MACROPHAGES. ALTHOUGH PCO-RHDL SHOWED 1.2-FOLD STRONGER INHIBITION AGAINST CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY THAN SCWA-RHDL, SCWA-RHDL ENHANCED 15% MORE BRAIN CELL (BV-2) GROWTH AND 23% MORE REGENERATION OF TAIL FIN IN ZEBRAFISH. CONCLUSION. PCO AND SCWA BOTH ENHANCE THE BENEFICIAL FUNCTIONS OF HDL TO MAXIMIZE ITS ANTIOXIDANT, ANTIGLYCATION, AND ANTIATHEROSCLEROTIC ACTIVITIES AND THE INHIBITION OF CETP. THESE ENHANCEMENTS OF HDL FUNCTIONALITY BY PCO AND SCWA COULD EXERT ANTIAGING AND REJUVENATION ACTIVITY. © 2019 KYUNG-HYUN CHO ET AL.","","ACIDS; ANIMAL FINS; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CHOLESTEROL ESTER TRANSFER PROTEINS; FATTY ALCOHOLS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICROGLIA; OXIDATION-REDUCTION; PLANT EXTRACTS; REGENERATION; SACCHARUM; THP-1 CELLS; WAXES; YOUNG ADULT; ZEBRAFISH; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CUPRIC ION; FRUCTOSE; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; POLICOSANOL; SUGAR CANE WAX ACID; UNCLASSIFIED DRUG; ACID; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; PLANT EXTRACT; POLICOSANOL; WAX; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIAGING ACTIVITY; ANTIATHEROSCLEROTIC ACTIVITY; ANTIGLYCATION ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BV-2 CELL LINE; CAUDAL FIN; CELL GROWTH; CELL REGENERATION; CONTROLLED STUDY; DENSITOMETRY; DRUG ACTIVITY; DRUG EFFECT; EMBRYO; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID OXIDATION; LIPID TRANSPORT; MACROPHAGE; MALE; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; REJUVENATION; SPECTROFLUOROMETRY; WOUND HEALING; YOUNG ADULT; ZEBRA FISH; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; FIN (ORGAN); GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; METABOLISM; MICROGLIA; OXIDATION REDUCTION REACTION; PATHOLOGY; REGENERATION; SUGARCANE; THP-1 CELL LINE","NATIONAL RESEARCH FOUNDATION, (NRF); MINISTRY OF TRADE, INDUSTRY AND ENERGY, MOTIE, (2015R1A5A2009124, 2016-10063396); MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP","THIS WORK WAS SUPPORTED BY A GRANT FROM THE MINISTRY OF TRADE, INDUSTRY AND ENERGY, KOREA (GRANT NO. 2016-10063396) AND THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF), FUNDED BY THE MINISTRY OF SCIENCE, ICT, AND FUTURE PLANNING OF KOREA.","ALI K.M., WONNERTH A., HUBER K., WOJTA J., CARDIOVASCULAR DISEASE RISK REDUCTION BY RAISING HDL CHOLESTEROL-CURRENT THERAPIES AND FUTURE OPPORTUNITIES, BRITISH JOURNAL OF PHARMACOLOGY, 167, 6, PP. 1177-1194, (2012); ODDEN M.C., TAGER I.B., GANSEVOORT R.T., ET AL., HYPERTENSION AND LOW HDL CHOLESTEROL WERE ASSOCIATED WITH REDUCED KIDNEY FUNCTION ACROSS THE AGE SPECTRUM: A COLLABORATIVE STUDY, ANNALS OF EPIDEMIOLOGY, 23, 3, PP. 106-111, (2013); BROUSSEAU M.E., SCHAEFER E.J., WOLFE M.L., ET AL., EFECTS OF AN INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN ON HDL CHOLESTEROL, THE NEW ENGLAND JOURNAL OF MEDICINE, 350, 15, PP. 1505-1515, (2004); KRISHNA R., ANDERSON M.S., BERGMAN A.J., ET AL., EFECT OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, ANACETRAPIB, ON LIPOPROTEINS IN PATIENTS WITH DYSLIPIDAEMIA AND ON 24-H AMBULATORY BLOOD PRESSURE IN HEALTHY INDIVIDUALS: TWO DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED PHASE I STUDIES, THE LANCET, 370, 9603, PP. 1907-1914, (2007); DODANI S., GRICE D.G., JOSHI S., IS HDL FUNCTION AS IMPORTANT AS HDL QUANTITY IN THE CORONARY ARTERY DISEASE RISK ASSESSMENT?, JOURNAL OF CLINICAL LIPIDOLOGY, 3, 2, PP. 70-77, (2009); TZIOMALOS K., HIGH-DENSITY LIPOPROTEIN: QUANTITY OR QUALITY?, JOURNAL OF THORACIC DISEASE, 8, 11, PP. 2975-2977, (2016); RADER D.J., MOLECULAR REGULATION OF HDL METABOLISM AND FUNCTION: IMPLICATIONS FOR NOVEL THERAPIES, THE JOURNAL OF CLINICAL INVESTIGATION, 116, 12, PP. 3090-3100, (2006); KHERA A.V., RADER D.J., FUTURE THERAPEUTIC DIRECTIONS IN REVERSE CHOLESTEROL TRANSPORT, CURRENT ATHEROSCLEROSIS REPORTS, 12, 1, PP. 73-81, (2010); LIM S.-M., YOO J.-A., LEE E.-Y., CHO K.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RESEARCH, 19, 1, PP. 59-70, (2016); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFECT IN HYPERLIPIDEMIC ZEBRAFSH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RESEARCH, 19, 2, PP. 149-158, (2016); CHO K.-H., YADAV D., KIM S.-J., KIM J.-R., BLOOD PRESSURE LOWERING EFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFAMMATION, LIPOPROTEIN PROFLE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, 5, (2018); KIM J.-Y., KIM S.-M., KIM S.-J., LEE E.-Y., KIM J.-R., CHO K.-H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 39, 4, PP. 889-899, (2017); CHO K.-H., KIM S.-J., YADAV D., KIM J.-Y., KIM J.-R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFLE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2018, (2018); KIM S.-J., YADAV D., PARK H.-J., KIM J.-R., CHO K.-H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFLE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONTIERS IN PHYSIOLOGY, 9, (2018); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 21, PP. 43-57, (2001); MARINANGELI C.P.F., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.H., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BRITISH JOURNAL OF NUTRITION, 97, 2, PP. 381-388, (2007); MENENDEZ R., MAS R., AMOR A.M., ET AL., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 80, 1, PP. 13-21, (2002); GAMEZ R., MENDOZA S., MAS R., ET AL., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 61, 7, PP. 460-468, (2000); RODRIGUEZ M.D., GONZALEZ J.E., ALEMAN C., ET AL., EVALUATION OF THE REPRODUCTIVE AND DEVELOPMENTAL TOXICITY OF THE D-003, A MIXTURE OF LONG-CHAIN FATTY ACIDS, IN RATS AND RABBITS, FOOD AND CHEMICAL TOXICOLOGY, 42, 12, PP. 1977-1985, (2004); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFECTS OF D-003, A MIXTURE OF VERY LONG CHAIN FATTY ACIDS PURIFED FROM SUGAR CANE WAX, AT 5 AND 10 MG/DAY ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 25, 1, PP. 29-39, (2005); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIV-ITY IN VITRO, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH, 19, 2, PP. 18-23, (2013); CHO K.-H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOLECULES AND CELLS, 27, 3, PP. 291-297, (2009); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPRO-TEINS IN HUMAN SERUM, THE JOURNAL OF CLINICAL INVESTIGATION, 34, 9, PP. 1345-1353, (1955); ESTERBAUER H., STRIEGL G., PUHL H., ROTHENEDER M., CONTINUOUS MONITORING OF IN VZTRO OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN, FREE RADICAL RESEARCH COMMUNICATIONS, 6, 1, PP. 67-75, (1989); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUC-TOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, 6, PP. 1901-1907, (1988); PARK K.-H., CHO K.-H., HIGH-DENSITY LIPOPROTEIN (HDL) FROM ELDERLY AND RECONSTITUTED HDL CONTAINING GLYCATED APOLIPOPROTEINS A-I SHARE PRO ATHEROSCLEROTIC AND PROSENESCENT PROPERTIES WITH INCREASED CHOLESTEROL INFUX, THE JOURNALS OF GERONTOLOGY. SERIES A, BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 66, 5, PP. 511-520, (2011); CHO K.-H., LEE J.-Y., CHOI M.-S., CHO J.M., LIM J.-S., PARK Y.B., A PEPTIDE FROM HOG PLASMA THAT INHIBITS HUMAN CHOLESTERYLESTERTRANSFER PROTEIN, BIOCHIMICA ETBIOPHYSICA ACTA (BBA)-LIPIDS AND LIPID METABOLISM, 1391, 2, PP. 133-144, (1998); YOON J.-H., CHO K.-H., A POINT MUTANT OF APOLIPOPROTEIN A-I (V156K) SHOWED ENHANCEMENT OF CELLULAR INSULIN SECRETION AND POTENT ACTIVITY OF FACULTATIVE REGENERATION IN ZEBRAFSH, REJUVENATION RESEARCH, 15, 3, PP. 313-321, (2012); GONG J., QIN X., YUAN F., ET AL., EFCACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOLECULARNUTRITION & FOOD RESEARCH, 62, (2018); CICERO A.F.G., COLLETTI A., BAJRAKTARI G., ET AL., LIPID-LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE: POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, NUTRITION REVIEWS, 75, 9, PP. 731-767, (2017); SAHEBKAR A., SERBAN M.-C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED AP-PROACH, NUTRITION JOURNAL, 32, 11-12, PP. 1179-1192, (2016); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPER-LIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); EREN E., YILMAZ N., AYDIN O., FUNCTIONALLY DEFECTIVE HIGH-DENSITY LIPOPROTEIN AND PARAOXONASE: A COUPLE FOR ENDOTHELIAL DYSFUNCTION IN ATHEROSCLEROSIS, CHOLESTEROL, 2013, (2013); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFCATION IN VITRO, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 50, 3, PP. 255-262, (2000); CHO K.-H., SHIN D.-G., BAEK S.-H., KIM J.-R., MYOCARDIAL INFARCTION PATIENTS SHOW ALTERED LIPOPROTEIN PROPERTIES AND FUNCTIONS WHEN COMPARED WITH STABLE ANGINA PECTORIS PATIENTS, EXPERIMENTAL & MOLECULAR MEDICINE, 41, 2, PP. 67-76, (2009); ZHANG M., CHARLES R., TONG H., ET AL., HDL SURFACE LIPIDS MEDIATE CETP BINDING AS REVEALED BY ELECTRON MICROSCOPY AND MOLECULAR DYNAMICS SIMULATION, SCIENTIFIC REPORTS, 5, (2015); BARKOWSKI R.S., FRISHMAN W.H., HDL METABOLISM AND CETP INHIBITION, CARDIOLOGY IN REVIEW, 16, 3, PP. 154-162, (2008); CILPA-KARHU G., JAUHIAINEN M., RIEKKOLA M.-L., ATOMISTIC MD SIMULATION REVEALS THE MECHANISM BY WHICH CETP PEN-ETRATES INTO HDL ENABLING LIPID TRANSFER FROM HDL TO CETP, JOURNAL OF LIPID RESEARCH, 56, 1, PP. 98-108, (2015); POTTER L.K., SPRECHER D.L., WALKER M.C., TOBIN F.L., MECHANISM OF INHIBITION DEFNES CETP ACTIVITY: A MATHEMATICAL MODEL FOR CETP IN VITRO, JOURNAL OF LIPID RESEARCH, 50, 11, PP. 2222-2234, (2009); WANG S., KUSSIE P., DENG L., TALL A., DEFECTIVE BINDING OF NEUTRAL LIPIDS BY A CARBOXYL-TERMINAL DELETION MUTANT OF CHOLESTERYL ESTER TRANSFER PROTEIN. EVIDENCE FOR A CARBOXYL-TERMINAL CHOLESTERYL ESTER BINDING SITE ESSENTIAL FOR NEUTRAL LIPID TRANSFER ACTIVITY, THE JOURNAL OF BIOLOGICAL CHEMISTRY, 270, 2, PP. 612-618, (1995); DE GROOTH G.J., KLERKX A.H.E.M., STROES E.S.G., STALENHOEF A.F.H., KASTELEIN J.J.P., KUIVENHOVEN J.A., A REVIEW OF CETP AND ITS RELATION TO ATHEROSCLEROSIS, JOURNAL OF LIPID RESEARCH, 45, 11, PP. 1967-1974, (2004); CASTANO G., MAS R., FERNANDEZ L., ET AL., ASSESSMENT OF THE EFECTS OF D-003, A NEW ANTIPLATELET AND LIPID-LOWERING COM-POUND, IN HEALTHY VOLUNTEERS: A PHASE I CLINICAL STUDY, DRUGS IN R&D, 3, 5, PP. 337-348, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, 1, PP. 8-12, (2001); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOLOGICAL RESEARCH, 44, 4, PP. 299-304, (2001)","K.-H. CHO; DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","HINDAWI LIMITED","ENGLISH","CARDIOVASC. THER.","ARTICLE","ISI","2-S2.0-85064381447","CARDIOVASC THER","YEUNGNAM UNIVERSITY;KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"CHO K-H, 2019, CARDIOVASC THER","CHO K-H, 2019, CARDIOVASC THER"
"ISHAKA A;ISMAIL M;IMAM M;ROZI M;MUHAMMAD S;ZAKARIA Z","ISHAKA, AMINU (55944603100); ISMAIL, MAZNAH (57191087465); IMAM, MUSTAPHA UMAR (57469476100); ROZI, MAHMUD (57194112195); MUHAMMAD, SANI ISMAILA (55808810700); ZAKARIA, ZUKI ABU BAKAR (36490970900)","TOXICITY EVALUATION HETCAM IRRITATION AND ANTIIRRITANT POTENTIAL OF RICE BRAN WAX POLICOSANOL NANOEMULSION",2017,"JOURNAL OF NANO RESEARCH","49","11",5,"10.4028/www.scientific.net/JNanoR.49.44","LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, MALAYSIA, DEPARTMENT OF MEDICAL BIOCHEMISTRY, COLLEGE OF HEALTH SCIENCES, USMANU DANFODIYO UNIVERSITY, SOKOTO, NIGERIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, MALAYSIA;PRECISION NUTRITION INNOVATION INSTITUTE, COLLEGE OF PUBLIC HEALTH, ZHENGZHOU UNIVERSITY, ZHENGZHOU, HENAN PROVINCE, 450001, CHINA;FACULTY OF MEDICINE AND HEALTH SCIENCES, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, MALAYSIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, MALAYSIA;FACULTY OF VETERINARY MEDICINE, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, MALAYSIA","POLICOSANOL, A MIXTURE OF LONG-CHAIN ALCOHOLS FOUND IN ANIMAL AND PLANT WAXES, HAS SEVERAL BIOLOGICAL EFFECTS. HOWEVER, IT HAS A BIOAVAILABILITY OF LESS THAN 10%. ONE OF THE WAYS OF IMPROVING BIOAVAILABILITY IS BY NANOEMULSION FORMULATION. WE DEVELOPED RICE BRAN WAX POLICOSANOL NANOEMULSION (NPOL) USING HIGH-PRESSURE HOMOGENIZATION. EVEN THOUGH EARLIER TOXICOLOGICAL STUDIES DID NOT SHOW POLICOSANOL-RELATED TOXICITY, IT IS AN ESSENTIAL PART OF THE DEVELOPMENT OF THE THERAPEUTIC FORMULATION TO EVALUATE ITS TOXICITY STATUS. IN THIS STUDY, IN VITRO, IN VIVO TOXICITY, AND IRRITATION AND ANTI-IRRITATION POTENTIAL OF THE NPOL WERE EVALUATED. 3T3-L1 CELLS AND SPRAGUE DAWLEY RATS WERE TREATED WITH NPOL IN THE IN VITRO AND ACUTE ORAL TOXICITY TESTS; WHILE THE HEN'S EGG TEST CHORIO-ALLANTOIC MEMBRANE (HET-CAM) WAS USED TO TEST FOR ITS IRRITATION AND ANTI-IRRITATION POTENTIAL. NPOL AT 2MG/ML SHOWED LOWER TOXICITY TO 3T3-L1 CELLS BY MTT ASSAY COMPARED TO THE SAME CONCENTRATION OF POLICOSANOL AFTER 24 (60 AND 50% VIABILITIES), 48 (62 AND 58% VIABILITIES), AND 72 (110 AND 89% VIABILITIES) HOURS, RESPECTIVELY. NPOL WAS NON-IRRITANT AND HAS SLIGHTLY ANTIIRRITANT POTENTIAL BASED ON THE HET-CAM TEST. THERE WAS ALSO NO SIGNIFICANT TOXICITY TO A LIMIT TEST DOSE OF 40 ML/KG BODY WEIGHT OF NPOL (CONTAINING 2000 MG/KG BODY WEIGHT OF POLICOSANOL) IN ACUTE ORAL TOXICITY TEST ON SPRAGUE-DAWLY RATS. THE RESULTS SUGGEST THAT POLICOSANOL NANOEMULSION IS A SAFE FORMULATION DEVOID OF TOXICITY AND IRRITATION POTENTIAL. © 2017 TRANS TECH PUBLICATIONS, SWITZERLAND.","ANTI-IRRITATION; HET-CAM; IRRITATION; NANOEMULSION; RICE BRAN WAX POLICOSANOL; TOXICITY","ANTHROPOMETRY; BIOCHEMISTRY; CAMS; CELL CULTURE; RATS; TESTING; ANTI-IRRITATION; CHORIO-ALLANTOIC MEMBRANES; HIGH PRESSURE HOMOGENIZATION; IRRITATION; LONG CHAIN ALCOHOLS; NANOEMULSION; POLICOSANOL; SPRAGUE-DAWLEY RATS; TOXICITY","","","FRANK N., ANDREWS F.M., ELLIOTT S.B., LEW J., BOSTON R.C., EFFECTS OF RICE BRAN OIL ON PLASMA LIPID CONCENTRATIONS, LIPOPROTEIN COMPOSITION, AND GLUCOSE DYNAMICS IN MARES, JOURNAL OF ANIMAL SCIENCE, 83, 11, PP. 2509-2518, (2005); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA A METAANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANNALS OF INTERNAL MEDICINE, 133, 6, PP. 420-429, (2000); TEMPLE N.J., ANTIOXIDANTS AND DISEASE: MORE QUESTIONS THAN ANSWERS, NUTRITION RESEARCH, 20, 3, PP. 449-459, (2000); CHAUDHARY A., ET AL., ENHANCEMENT OF SOLUBILIZATION AND BIOAVAILABILITY OF POORLY SOLUBLE DRUGS BY PHYSICAL AND CHEMICAL MODIFICATIONS: A RECENT REVIEW, JOURNAL OF ADVANCED PHARMACY EDUCATION & RESEARCH, 2, 1, PP. 32-67, (2012); CHENG W.P., ET AL., POLYELECTROLYTE NANOPARTICLES WITH HIGH DRUG LOADING ENHANCE THE ORAL UPTAKE OF HYDROPHOBIC COMPOUNDS, BIOMACROMOLECULES, 7, 5, PP. 1509-1520, (2006); FARINHA A., BICA A., TAVARES P., IMPROVED BIOAVAILABILITY OF A MICRONIZED MEGESTROL ACETATE TABLET FORMULATION IN HUMANS, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 26, 5, PP. 567-570, (2000); HU J., JOHNSTON K.P., WILLIAMS R.O., NANOPARTICLE ENGINEERING PROCESSES FOR ENHANCING THE DISSOLUTION RATES OF POORLY WATER SOLUBLE DRUGS, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 30, 3, PP. 233-245, (2004); KUMAR A., AHUJA A., ALI J., BABOOTA S., CONUNDRUM AND THERAPEUTIC POTENTIAL OF CURCUMIN IN DRUG DELIVERY, CRITICAL REVIEWS™ IN THERAPEUTIC DRUG CARRIER SYSTEMS, 27, 4, (2010); GUIDELINE I.H.T., GUIDANCE ON NONCLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS AND MARKETING AUTHORIZATION FOR PHARMACEUTICALS M3 (R2), INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (2009); BERRIDGE M.V., ET AL., THE BIOCHEMICAL AND CELLULAR BASIS OF CELL PROLIFERATION ASSAYS THAT USE TETRAZOLIUM SALTS, BIOCHEMICA, 4, 1, PP. 15-19, (1996); VAN MEERLOO J., KASPERS G.J., CLOOS J., CELL SENSITIVITY ASSAYS: THE MTT ASSAY, CANCER CELL CULTURE., PP. 237-245, (2011); BABICH H., BORENFREUND E., CYTOTOXIC EFFECTS OF FOOD ADDITIVES AND PHARMACEUTICALS ON CELLS IN CULTURE AS DETERMINED WITH THE NEUTRAL RED ASSAY, JOURNAL OF PHARMACEUTICAL SCIENCES, 79, 7, PP. 592-594, (1990); BORENFREUND E., PUERNER J.A., A SIMPLE QUANTITATIVE PROCEDURE USING MONOLAYER CULTURES FOR CYTOTOXICITY ASSAYS (HTD/NR-90), JOURNAL OF TISSUE CULTURE METHODS, 9, 1, PP. 7-9, (1985); HANEKE K.E., TICE R.R., CARSON B.L., MARGOLIN B.H., STOKES W.S., ICCVAM EVALUATION OF THE MURINE LOCAL LYMPH NODE ASSAY: III. DATA ANALYSES COMPLETED BY THE NATIONAL TOXICOLOGY PROGRAM INTERAGENCY CENTER FOR THE EVALUATION OF ALTERNATIVE TOXICOLOGICAL METHODS, REGULATORY TOXICOLOGY AND PHARMACOLOGY, 34, 3, PP. 274-286, (2001); SPIELMANN H., GENSCHOW E., LIEBSCH M., HALLE W., DETERMINATION OF THE STARTING DOSE FOR ACUTE ORAL TOXICITY (LD50) TESTING IN THE UP AND DOWN PROCEDURE (UDP) FROM CYTOTOXICITY DATA, ATLA. ALTERNATIVES TO LABORATORY ANIMALS, 27, 6, PP. 957-966, (1999); SHETTY AKHILA J., ALWAR M., ACUTE TOXICITY STUDIES AND DETERMINATION OF MEDIAN LETHAL DOSE, CURRENT SCIENCE., 93, PP. 917-920, (2007); LUEPKE N., HEN'S EGG CHORIOALLANTOIC MEMBRANE TEST FOR IRRITATION POTENTIAL, FOOD AND CHEMICAL TOXICOLOGY, 23, 2, PP. 287-291, (1985); WILSON T.D., STECK W.F., A MODIFIED HET-CAM ASSAY APPROACH TO THE ASSESSMENT OF ANTI-IRRITANT PROPERTIES OF PLANT EXTRACTS, FOOD CHEM TOXICOLOGY, 38, 10, PP. 867-872, (2000); STEILING W., BRACHER M., COURTELLEMONT P., DE SILVA O., THE HET-CAM, A USEFUL IN UITRO ASSAY FOR ASSESSING THE EYE IRRITATION PROPERTIES OF COSMETIC FORMULATIONS AND INGREDIENTS, TOXICOLOGY IN VITRO, 13, 2, PP. 375-384, (1999); BAGLEY D., CERVEN D., HARBELL J., ASSESSMENT OF THE CHORIOALLANTOIC MEMBRANE VASCULAR ASSAY (CAMVA) IN THE COLIPA IN VITRO EYE IRRITATION VALIDATION STUDY, TOXICOLOGY IN VITRO, 13, 2, PP. 285-293, (1999); DEMIRCI F., PAPER D.H., FRANZ G., BASER K.H.C., INVESTIGATION OF THE ORIGANUM ONITES L. ESSENTIAL OIL USING THE CHORIOALLANTOIC MEMBRANE (CAM) ASSAY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 52, 2, PP. 251-254, (2004); FREI B., HEINRICH M., BORK P.M., HERRMANN D., JAKI B., KATO T., KUHNT M., SCHMITT J., SCHUHLY W., VOLKEN C., STICHER O., MULTIPLE SCREENING OF MEDICINAL PLANTS FROM OAXACA, MEXICO: ETHNOBOTANY AND BIOASSAYS AS A BASIS FOR PHYTOCHEMICAL INVESTIGATION, PHYTOMEDICINE, 5, 3, PP. 177-186, (1998); BERNARDI D.S., PEREIRA T.A., MACIEL N.R., BORTOLOTO J., VIERA G.S., OLIVEIRA G.C., ROCHA-FILHO P.A., FORMATION AND STABILITY OF OIL-IN-WATER NANOEMULSIONS CONTAINING RICE BRAN OIL: IN VITRO AND IN VIVO ASSESSMENTS, JOURNAL OF NANOBIOTECHNOLOGY, 9, (2011); MOURA DO CARMO D.F., AMARAL A.C.F., MACHADO G., LEON L.L., SILVA J.R.D.A., CHEMICAL AND BIOLOGICAL ANALYSES OF THE ESSENTIAL OILS AND MAIN CONSTITUENTS OF PIPER SPECIES, MOLECULES, 17, 2, PP. 1819-1829, (2012); SCHARNAGL H., MARZ W., NEW LIPID-LOWERING AGENTS ACTING ON LDL RECEPTORS, CURRENT TOPICS IN MEDICINAL CHEMISTRY, 5, 3, PP. 233-242, (2005); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, 3-4, PP. 205-208, (1993); KATO S., KARINO K.-I., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BRITISH JOURNAL OF NUTRITION, 73, 3, PP. 433-442, (1995); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., FERNANDEZ L., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURRENT THERAPEUTIC RESEARCH, 57, 7, PP. 568-577, (1996); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); ARRUZAZABALA M.D.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOLOGICAL RESEARCH, 34, 5, PP. 181-185, (1996); POPE L.E., MARCELLETTI J.F., KATZ L.R., LIN J.Y., KATZ D.H., PARISH M.L., SPEAR P.G., THE ANTI-HERPES SIMPLEX VIRUS ACTIVITY OF <I> N</I>-DOCOSANOL INCLUDES INHIBITION OF THE VIRAL ENTRY PROCESS, ANTIVIRAL RESEARCH, 40, 1, PP. 85-94, (1998); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, 4, PP. 361-371, (2004); WONG W.T., ISMAIL M., IMAM M.U., ZHANG Y.D., MODULATION OF PLATELET FUNCTIONS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT, BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 16, 1, (2016); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, 10, PP. 923-929, (2011); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AMERICAN HEART JOURNAL, 152, 5, PP. 982E1-982E5, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BRITISH JOURNAL OF NUTRITION, 95, 5, PP. 968-975, (2006); SWANSON B., KEITHLEY J.K., BEVERLY E.S., FOGG L., NERAD J., NOVAK R.M., SPEAR G.T., POLICOSANOL FOR MANAGING HUMAN IMMUNODEFICIENCY VIRUS-RELATED DYSLIPIDEMIA IN A MEDICALLY UNDERSERVED POPULATION: A RANDOMIZED, CONTROLLED CLINICAL TRIAL, ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 17, 2, (2011); SWANSON B., KEITHLEY J., POLICOSANOL TO MANAGE DYSLIPIDEMIA IN OLDER ADULTS, COMPLEMENTARY AND ALTERNATIVE THERAPIES AND THE AGING POPULATION: AN EVIDENCE-BASED APPROACH, (2011); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANNALS OF NUTRITION AND METABOLISM, 37, 1, PP. 33-38, (1993); GUGLIELMINI G., NANOSTRUCTURED NOVEL CARRIER FOR TOPICAL APPLICATION, CLINICS IN DERMATOLOGY, 26, 4, PP. 341-346, (2008); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INTERNATIONAL JOURNAL OF NANOMEDICINE, 9, (2014); CAZEDEY E.C.L., CARVALHO F.C., FIORENTINO F.A.M., GREMIAO M.P.D., SALGADO H.R.N., CORROSITEX, BCOP AND HET-CAM AS ALTERNATIVE METHODS TO ANIMAL EXPERIMENTATION, BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 45, 4, PP. 759-766, (2009); OECD GUIDELINE 425: ACUTE ORAL TOXICITY - UP-AND-DOWN PROCEDURE, OECD GUIDELINE FOR THE TESTING OF CHEMICALS, SECTION 4, (2008); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., AGUILAR C., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, JOURNAL OF MEDICINAL FOOD, 4, 2, PP. 57-65, (2001); LU L., ZHANG L., WAI M.S.M., YEW D.T.W., XU J., EXOCYTOSIS OF MTT FORMAZAN COULD EXACERBATE CELL INJURY, TOXICOLOGY IN VITRO, 26, 4, PP. 636-644, (2012); RISS T.L., MORAVEC R.A., NILES A.L., BENINK H.A., WORZELLA T.J., MINOR L., CELL VIABILITY ASSAYS, (2015); MEHLING A., KLEBER M., HENSEN H., COMPARATIVE STUDIES ON THE OCULAR AND DERMAL IRRITATION POTENTIAL OF SURFACTANTS, FOOD AND CHEMICAL TOXICOLOGY, 45, 5, PP. 747-758, (2007); HONG T.-K., TRIPATHY N., SON H.J., HA K.T., JEONG H.S., HAHN Y.B., A COMPREHENSIVE IN VITRO AND IN VIVO STUDY OF ZNO NANOPARTICLES TOXICITY, JOURNAL OF MATERIALS CHEMISTRY B, 1, 23, PP. 2985-2992, (2013); FIELDS D., PAUL H., PHYSIOLOGICAL MECHANISMS IMPACTING WEIGHT REGULATION, HANDBOOK OF CHILDHOOD AND ADOLESCENT OBESITY, PP. 109-126, (2008); ALEMAN C.L., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOLOGY LETTERS, 70, 1, PP. 77-87, (1994); ABDELATIF A.M., ELSAYED S.A., HASSAN Y.M., EFFECT OF STATE OF HYDRATION ON BODY WEIGHT, BLOOD CONSTITUENTS AND URINE EXCRETION IN NUBIAN GOATS (CAPRA HIRCUS), WORLD JOURNAL OF AGRICULTURAL SCIENCES, 6, 2, PP. 178-188, (2010); HER M., LEE Y., JUNG E., KIM T., KIM D., LIVER ENZYME LIVER ENZYME ABNORMALITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A FOCUS ON TOXIC HEPATITIS, RHEUMATOLOGY INTERNATIONAL, 31, 1, PP. 79-84, (2011); LI S.-D., HUANG L., PHARMACOKINETICS AND BIODISTRIBUTION OF NANOPARTICLES, MOLECULAR PHARMACEUTICS, 5, 4, PP. 496-504, (2008); GIBONEY P.T., MILDLY ELEVATED LIVER TRANSAMINASE LEVELS IN THE ASYMPTOMATIC PATIENT, AM FAM PHYSICIAN, 71, 6, PP. 1105-1110, (2005); ABBOUD G., KAPLOWITZ N., DRUG-INDUCED LIVER INJURY, DRUG SAFETY, 30, 4, PP. 277-294, (2007); NAUGHTON C.A., DRUG-INDUCED NEPHROTOXICITY, AMERICAN FAMILY PHYSICIAN, 78, 6, PP. 743-750, (2008)","M. ISMAIL; LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, 43400, MALAYSIA; EMAIL: MAZNAHIS@UPM.EDU.MY","TRANS TECH PUBLICATIONS LTD","ENGLISH","J. NANO. RES.","ARTICLE","ISI","2-S2.0-85029575232","J NANO RES","UNIVERSITY PUTRA MALAYSIA;UNIVERSITY PUTRA MALAYSIA;ZHENGZHOU UNIVERSITY;UNIVERSITY PUTRA MALAYSIA;UNIVERSITY PUTRA MALAYSIA;UNIVERSITY PUTRA MALAYSIA","NOTREPORTED;UNIVERSITY PUTRA MALAYSIA;NOTREPORTED",NA,"ISHAKA A, 2017, J NANO RES","ISHAKA A, 2017, J NANO RES"
"FRANCINI-PESENTI F;SPINELLA P;CALÒ L","FRANCINI-PESENTI, FRANCESCO (23392494300); SPINELLA, PAOLO (6601990894); CALÒ, LORENZO A. (7006843777)","POTENTIAL ROLE OF PHYTOCHEMICALS IN METABOLIC SYNDROME PREVENTION AND THERAPY",2019,"DIABETES, METABOLIC SYNDROME AND OBESITY","12","15",39,"10.2147/DMSO.S214550","DEPARTMENT OF MEDICINE (DIMED), NUTRITION UNIT, UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA, PADOVA, ITALY;DEPARTMENT OF MEDICINE (DIMED), NUTRITION UNIT, UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA, PADOVA, ITALY;DEPARTMENT OF MEDICINE (DIMED), NEPHROLOGY, DIALYSIS AND TRANSPLANTATION UNIT, UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA, PADOVA, ITALY","METABOLIC SYNDROME (METS) IS A SET OF CARDIOVASCULAR RISK FACTORS WHICH SEVERELY INCREASES THE RISK OF TYPE II DIABETES, RENAL DISEASE AND CARDIOVASCULAR DISEASE. OVER THE LAST DECADES, THE ROLE OF DIETARY BIOACTIVE SUBSTANCES IN FEATURES OF METS HAS BEEN EXTENSIVELY INVESTIGATED. DUE TO THEIR MULTIPLE PROPERTIES, THESE PLANT-DERIVED NATURAL COMPOUNDS HAVE DEMONSTRATED TO PROVIDE POSITIVE EFFECTS IN OBESITY, DIABETES, RENAL AND IN CARDIOVASCULAR DISEASE. CATECHINS OF GREEN TEA AND CAFFEINE REDUCE BODY MASS INDEX AND WAIST CIRCUMFERENCE. CATECHINS, ANTHOCYANINS AND PROANTHOCYANIDINS OF COCOA REDUCE BLOOD PRESSURE AND BLOOD GLUCOSE. CURCUMIN AND SILYMARIN EXERT HEPATOPROTECTIVE EFFECTS. MONACOLINS OF RED YEAST RICE ARE EFFECTIVE CHOLESTEROL-LOWERING AGENTS. HOWEVER, INCONSISTENT OR CONFLICTING RESULTS HAVE BEEN FOUND IN CLINICAL TRIALS WHEN OTHER PROMISING COMPOUNDS IN VITRO OR IN ANIMAL STUDIES, SUCH AS POLICOSANOL, CURCUMIN OR SILYMARIN, WERE USED. LOW ORAL BIOAVAILABILITY OF SUBSTANCES, INEFFECTIVE DOSAGES, INADEQUATE TREATMENT DURATION AND INSUFFICIENT STATISTICAL APPROACH MAY EXPLAIN THE LACK OF EFFECTIVENESS OBSERVED IN SOME HUMAN STUDIES. FURTHER CLINICAL STUDIES ARE NEEDED TO BETTER UNDERSTAND THE ROLE OF BIOACTIVE COMPOUNDS IN THE PREVENTION AND MANAGEMENT OF METS. © 2019 FRANCINI-PESENTI ET AL.","BIOACTIVE SUBSTANCES; CARDIOVASCULAR RISK; METABOLIC SYNDROME; NUTRITION","ANTHOCYANIN; BENZOIC ACID; CINNAMIC ACID; COUMARIC ACID; CURCUMIN; FLAVONOID; LIGNAN DERIVATIVE; MEVINOLIN; OLIVE OIL; PHYTOCHEMICAL; PHYTOSTEROL; POLICOSANOL; POLYPHENOL DERIVATIVE; STEROL; STILBENE DERIVATIVE; TERPENOID DERIVATIVE; BLUEBERRY; DIET SUPPLEMENTATION; DIETARY INTAKE; FRUIT; HUMAN; METABOLIC SYNDROME X; NONHUMAN; NUTRITION; POMEGRANATE; PROPHYLAXIS; REVIEW; SILYBUM MARIANUM; VEGETABLE","","","ERVIN R.B., PREVALENCE OF METABOLIC SYNDROME AMONG ADULTS 20 YEARS OF AGE AND OVER, BY SEX, AGE, RACE AND ETHNICITY, AND BODY MASS INDEX: UNITED STATES, NATL HEALTH STAT REPORT, 5, PP. 1-7, (2009); ALBERTI K.G., ZIMMET P.Z., DEFINITION, DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS AND ITS COMPLICATIONS. PART 1: DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS PROVISIONAL REPORT OF A WHO CONSULTATION, DIABET MED, 15, PP. 539-553, (1998); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); FORD E.S., PREVALENCE OF THE METABOLIC SYNDROME DEFINED BY THE INTERNATIONAL DIABETES FEDERATION AMONG ADULTS IN THE. U.S. DIABET CARE, 28, PP. 2745-2749, (2005); GRUNDY S.M., BREWER H.B., CLEEMAN J.I., SMITH S.C., LENFANT C., AMERICAN HEART ASSOCIATION; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE. DEFINITION OF METABOLIC SYNDROME. REPORT OF THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE/AMERICAN HEART ASSOCIATION CONFERENCE ON SCIENTIFIC ISSUES RELATED TO DEFINITION, CIRCULATION., 109, PP. 433-438, (2004); YANG L., COLDITZ G.A., PREVALENCE OF OVERWEIGHT AND OBESITY IN THE UNITED STATES, 2007–2012, JAMA INTERN MED, 175, PP. 1412-1413, (2015); RANASINGHE P., MATHANGASINGHE Y., JAYAWARDENA R., HILLS A.P., MISRA A., PREVALENCE AND TRENDS OF METABOLIC SYNDROME AMONG ADULTS IN THE ASIA-PACIFIC REGION: A SYSTEMATIC REVIEW, BMC PUBLIC HEALTH, 17, (2017); FARRELL G.C., HACZEYNI F., CHITTURI S., PATHOGENESIS OF NASH: HOW METABOLIC COMPLICATIONS OF OVERNUTRITION FAVOUR LIPOTOXICITY AND PRO-INFLAMMATORY FATTY LIVER DISEASE, ADV EXP MED BIOL, 1061, PP. 19-44, (2018); SOLEIMANI M., INSULIN RESISTANCE AND HYPERTENSION: NEW INSIGHTS, KIDNEY INT, 87, PP. 497-499, (2015); HENAO-MEJIA J., ELINAV E., ELINAV E., JIN C., ET AL., INFLAMMASOME-MEDIATED DYSBIOSIS REGULATES PROGRESSION OF NAFLD AND OBESITY, NATURE, 482, PP. 179-185, (2012); SKURK T., ALBERTI-HUBER C., HERDER C., HAUNER H., RELATIONSHIP BETWEEN ADIPOCYTE SIZE AND ADIPOKINE EXPRESSION AND SECRETION, J CLIN ENDOCRINOL METAB, 92, PP. 1023-1033, (2007); HIROSUMI G., TUNCMAN L., CHAN L., ET AL., A CENTRAL ROLE FOR JNK IN OBESITY AND INSULIN RESISTANCE, NATURE, 420, PP. 333-336, (2002); MARCHESINI G., BUGIANESI E., FORLANI G., ET AL., NONALCOHOLIC FATTY LIVER, STEATOHEPATITIS, AND THE METABOLIC SYNDROME, HEPATOLOGY, 37, PP. 917-923, (2003); PROPST A., PROPST T., JUDMAIER G., VOGEL W., PROGNOSIS IN NONALCOHOLIC STEATOHEPATITIS, GASTROENTEROLOGY, 108, (1995); LAU L.H.S., WONG S.H., MICROBIOTA, OBESITY AND NAFLD, ADV EXP MED BIOL, 106, PP. 111-125, (2018); MEHTA N.N., MCGILLICUDDY F.C., ANDERSON P.D., ET AL., EXPERIMENTAL ENDOTOXEMIA INDUCES ADIPOSE INFLAMMATION AND INSULIN RESISTANCE IN HUMANS, DIABETES, 59, PP. 172-181, (2010); KIM J.J., SEARS D.D., TLR4 AND INSULIN RESISTANCE, GASTROENTEROL RES PRACT, 2010, (2010); BABIO N., BULLO M., SALAS-SALVADO J., MEDITERRANEAN DIET AND METABOLIC SYNDROME: THE EVIDENCE, PUBLIC HEALTH NUTR, 12, PP. 1607-1617, (2009); MACREADY A.L., GEORGE T.W., CHONG M.F., ET AL., FLAVONOID-RICH FRUIT AND VEGETABLES IMPROVE MICROVASCULAR REACTIVITY AND INFLAMMATORY STATUS IN MEN AT RISK OF CARDIOVASCULAR DISEASE-FLAVURS: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 99, PP. 479-489, (2014); MARTINEZ-GONZALEZ M.A., SALAS-SALVADO J., ESTRUCH R., CORELLA D., FITO M., ROS E., BENEFITS OF THE MEDITERRANEAN DIET: INSIGHTS FROM THE PREDIMED STUDY, PROG CARDIOVASC DIS, 58, PP. 50-60, (2015); KARALIS D.G., ACHIEVING OPTIMAL LIPID GOALS IN THE METABOLIC SYNDROME: A GLOBAL HEALTH PROBLEM, ATHEROSCLEROSIS, 237, PP. 191-193, (2014); SCALBERT A., MANACH C., MORAND C., REMESY C., DIETARY POLYPHENOLS AND THE PREVENTION OF DISEASES, CRIT REV FOOD SCI NUTR, 45, PP. 287-306, (2005); SHAHIDI F., NACZK M., FOOD PHENOLICS, SOURCES, CHEMISTRY, EFFECTS, APPLICATIONS, (1995); CLIFFORD M.N., SCALBERT A., ELLAGITANNINS-OCCURRENCE IN FOOD, BIOAVAILABILITY AND CANCER PREVENTION, J FOOD SCI AGRICOL, 80, PP. 118-125, (2000); ABOURASHED E.A., REVIEW OF STILBENES: APPLICATIONS IN CHEMISTRY, LIFE SCIENCES AND MATERIALS SCIENCE, J NAT PROD, 80, (2017); THOMPSON L.U., ROBB P., SERRAINO M., CHEUNG F., MAMMALIAN LIGNAN PRODUCTION FROM VARIOUS FOODS, NUTR CANCER, 16, PP. 43-52, (1991); BEUKES N., LEVENDAL R.A., FROST C.L., SELECTED TERPENOIDS FROM MEDICINAL PLANTS MODULATE ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISORDERS, J PHARM PHARMACOL, 66, PP. 1505-1525, (2014); PATEL M.D., THOMPSON P.D., PHYTOSTEROLS AND VASCULAR DISEASE, ATHEROSCLEROSIS, 186, PP. 12-19, (2006); WANG T.H., LIN T.F., MONASCUS RICE PRODUCTS, ADV FOOD NUTR RES, 53, PP. 123-159, (2007); MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR J NUTR, 97, PP. 381-388, (2007); DEL RIO D., RODRIGUEZ-MATEOS A., SPENCER J.P., TOGNOLINI M., CROZIER B.G.A., DIETARY (POLY)PHENOLICS IN HUMAN HEALTH: STRUCTURES, BIOAVAILABILITY, AND EVIDENCE OF PROTECTIVE EFFECTS AGAINST CHRONIC DISEASES, ANTIOXID REDOX SIGNAL, 18, PP. 1818-1892, (2013); NAGAO T., KOMINE Y., SOGA S., ET AL., INGESTION OF A TEA RICH IN CATECHINS LEADS TO A REDUCTION IN BODY FAT AND MALONDIALDEHYDE MODIFIED LDL IN MEN, AM J CLIN NUTR, 81, PP. 122-129, (2005); HARPAZ E., TAMIR S., WEINSTEIN A., WEINSTEIN Y., THE EFFECT OF CAFFEINE ON ENERGY BALANCE, J BASIC CLIN PHYSIOL PHARMACOL, 28, PP. 1-10, (2017); BASU A., SANCHEZ K., LEYVA M.J., ET AL., GREEN TEA SUPPLEMENTATION AFFECTS BODY WEIGHT, LIPIDS, AND LIPID PEROXIDATION IN OBESE SUBJECTS WITH METABOLIC SYNDROME, J AM COLL NUTR, 29, PP. 31-40, (2010); SULIBURSKA J., BOGDANSKI P., SZULINSKA M., STEPIEN M., PUPEK-MUSIALIK D., JABLECKA A., EFFECTS OF GREEN TEA SUPPLEMENTATION ON ELEMENTS, TOTAL ANTIOXIDANTS, LIPIDS, AND GLUCOSE VALUES IN THE SERUM OF OBESE PATIENTS, BIOL TRACE ELEM RES, 149, PP. 315-322, (2012); DIEPVENS K., WESTERTERP K.R., WESTERTERP-PLANTENGA M.S., OBESITY AND THERMOGENESIS RELATED TO THE CONSUMPTION OF CAFFEINE, EPHE-DRINE, CAPSAICIN, AND GREEN TEA, AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, 292, PP. 77-85, (2007); EVANS B.A., SATO M., SARWAR M., HUTCHINSON D.S., SUMMERS R.J., LIGAND-DIRECTED SIGNALLING AT BETA-ADRENOCEPTORS, BR J PHARMACOL, 159, PP. 1022-1038, (2010); COLLINS L., CORNELIUS M., VOEGEL L.R., WALKER J.F., STAMFORD B.A., EFFECT OF CAFFEINE AND/OR CIGARETTE SMOKING ON RESTING ENERGY EXPENDITURE, INT J OBES RELAT METAB DISORD, 18, PP. 551-556, (1994); SHIXIAN Q., VANCREY B., SHI J., KAKUDA Y., JIANG Y., GREEN TEA EXTRACT THERMOGENESIS-INDUCED WEIGHT LOSS BY EPIGALLOCATECHIN GALLATE INHIBITION OF CATECHOL-O-METHYLTRANSFERASE, J MED FOOD, 9, PP. 451-458, (2006); GREGERSEN N.T., BITZ C., KROG-MIKKELSEN I., ET AL., EFFECT OF MODERATE INTAKES OF DIFFERENT TEA CATECHINS AND CAFFEINE ON ACUTE MEASURES OF ENERGY METABOLISM UNDER SEDENTARY CONDITIONS, BR J NUTR, 102, PP. 1187-1194, (2009); BROWN A.L., LANE J., COVERLY J., ET AL., EFFECTS OF DIETARY SUPPLEMENTATION WITH THE GREEN TEA POLYPHENOL EPIGALLOCATECHIN-3-GALLATE ON INSULIN RESISTANCE AND ASSOCIATED METABOLIC RISK FACTORS: RANDOMIZED CONTROLLED TRIAL, BR J NUTR, 101, PP. 886-894, (2009); BERUBE-PARENT S., PELLETIER C., DORE J., TREMBLAY A., EFFECTS OF ENCAPSULATED GREEN TEA AND GUARANA EXTRACTS CONTAINING A MIXTURE OF EPIGALLOCATECHIN-3-GALLATE AND CAFFEINE ON 24 H ENERGY EXPENDITURE AND FAT OXIDATION IN MEN, BR J NUTR, 94, PP. 432-436, (2005); BOSCHMANN M., THIELECKE F., THE EFFECTS OF EPIGALLOCATECHIN-3-GALLATE ON THERMOGENESIS AND FAT OXIDATION IN OBESE MEN: A PILOT STUDY, J AM COLL NUTR, 26, PP. 389-395, (2007); RUDELLE S., FERRUZZI M.G., CRISTIANI I., MOULIN J., MACE K., ACHESON K., EFFECT OF A THERMOGENIC BEVERAGE ON 24 HR ENERGY METABOLISM IN HUMANS, OBESITY (SILVER SPRING), 15, PP. 349-355, (2007); WESTERTERP-PLANTENGA M.S., LEJEUNE M.P., KOVACS E.M., BODY WEIGHT LOSS AND WEIGHT MAINTENANCE IN RELATION TO HABITUAL CAFFEINE INTAKE AND GREEN TEA SUPPLEMENTATION, OBES RES, 13, PP. 1195-1204, (2005); CHU S.L., FU H., YANG J.X., ET AL., A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF PU’ER TEA EXTRACT ON THE REGULATION OF METABOLIC SYNDROME, CHIN J INTEGR MED, 17, PP. 492-498, (2011); BELCARO G., LEDDA A., HU S., CESARONE M.R., FERAGALLI B., DUGALL M., GREENSELECT PHYTOSOME FOR BORDERLINE METABOLIC SYNDROME, EVID BASED COMPLEMENT ALTERNAT MED, PP. 1-7, (2013); MAKI K.C., REEVES M.S., FARMER M., ET AL., GREEN TEA CATECHIN CONSUMPTION ENHANCES EXERCISE-INDUCED ABDOMINAL FAT LOSS IN OVERWEIGHT AND OBESE ADULTS, J NUTR, 139, PP. 264-270, (2009); VIEIRA SENGER A.E., SCHWANKE C.H.A., GOMES I., VALLE GOTTLIEB M.G., EFFECT OF GREEN TEA (CAMELLIA SINENSIS) CONSUMPTION ON THE COMPONENTS OF METABOLIC SYNDROME IN ELDERLY, J NUTR HEALTH AGING, 16, PP. 738-742, (2012); YANG T.Y., CHOU J.I., UENG K.C., CHOU M.Y., YANG J.J., LIN-SHIAU S.Y., WEIGHT REDUCTION EFFECT OF PUERH TEA IN MALE PATIENTS WITH METABOLIC SYNDROME, PHYTOTHER RES, 28, PP. 1096-1101, (2014); CALO L.A., VERTOLLI U., DAVIS P.A., ET AL., MOLECULAR BIOLOGY BASED ASSESSMENT OF GREEN TEA EFFECTS ON OXIDATIVE STRESS AND CARDIAC REMODELLING IN DIALYSIS PATIENTS, CLIN NUTR, 33, PP. 437-442, (2014); MANDEL S.A., WEINREB O., AMIT T., YOUDIM M.B., MOLECULAR MECHANISMS OF THE NEUROPROTECTIVE/NEURORESCUE ACTION OF MULTI-TARGET GREEN TEAPOLYPHENOLS, FRONT BIOSCI (SCHOL ED), 1, PP. 581-598, (2012); WANG H., NAIR M.G., STRASBURG G.M., ET AL., ANTIOXIDANT AND ANTIIN-FLAMMATORY ACTIVITIES OF ANTHOCYANINS AND THEIR AGLYCON, CYANIDIN, FROM TART CHERRIES, J NAT PROD, 62, PP. 294-296, (1999); HUANG W.Y., LIU Y.M., WANG J., WANG X.N., LI C.Y., ANTI-INFLAMMATORY EFFECT OF THE BLUEBERRY ANTHOCYANINS MALVIDIN-3-GLUCOSIDE AND MAL-VIDIN-3-GALACTOSIDE IN ENDOTHELIAL CELLS, MOLECULES, 19, PP. 12827-12841, (2014); LAU F.C., BIELINSKI D.F., JOSEPH J.A., INHIBITORY EFFECTS OF BLUEBERRY EXTRACT ON THE PRODUCTION OF INFLAMMATORY MEDIATORS IN LIPOPOLY-SACCHARIDEACTIVATED BV2 MICROGLIA, J NEUROSCI RES, 85, PP. 1010-1017, (2007); KALEA A.Z., CLARK K., SCHUSCHKE D.A., KLIMIS-ZACAS D.J., VASCULAR REACTIVITY IS AFFECTED BY DIETARY CONSUMPTION OF WILD BLUEBERRIES IN THE SPRAGUE-DAWLEY RAT, J MED FOOD, 12, PP. 21-28, (2009); MARTINEAU L.C., COUTURE A., SPOOR D., ET AL., ANTI-DIABETIC PROPERTIES OF THE CANADIAN LOWBUSH BLUEBERRY VACCINIUM ANGUSTIFOLIUM AIT, PHYTOMEDICINE, 13, PP. 612-623, (2006); VENDRAME S., DAUGHERTY A., KRISTO A.S., RISO P., KLIMIS-ZACAS D., WILD BLUEBERRY (VACCINIUM ANGUSTIFOLIUM) CONSUMPTION IMPROVES INFLAMMATORY STATUS IN THE OBESE ZUCKER RAT MODEL OF THE METABOLIC SYNDROME, J NUTR BIOCHEM, 24, PP. 1508-1512, (2013); SEYMOUR E.M., SINGER A.A., KIRAKOSYAN A., URCUYO-LLANES D.E., KAUFMAN P.B., BOLLING S.F., ALTERED HYPERLIPIDEMIA, HEPATIC STEATOSIS, AND HEPATIC PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN RATS WITH INTAKE OF TART CHERRY, J MED FOOD, 11, PP. 252-259, (2008); YANG L., LING W., DU Z., ET AL., EFFECTS OF ANTHOCYANINS ON CARDIOMETABOLIC HEALTH: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ADV NUTR, 8, PP. 684-693, (2017); BASU A., FU D.X., WILKINSON M., ET AL., STRAWBERRIES DECREASE ATHEROSCLEROTIC MARKERS IN SUBJECTS WITH METABOLIC SYNDROME, NUTR RES, 30, PP. 462-469, (2010); CASTRO-ACOSTA M.L., STONE S.G., MOK J.E., ET AL., APPLE AND BLACKCURRANT POLYPHENOL-RICH DRINKS DECREASE POSTPRANDIAL GLUCOSE, INSULIN AND INCRETIN RESPONSE TO A HIGHCARBOHYDRATE MEAL IN HEALTHY MEN AND WOMEN, J NUTR BIOCHEM, 49, PP. 53-62, (2017); KIM H., SIMBO S., FANG C., ET AL., AÇAÍ (EUTERPE OLERACEA MART.) BEVERAGE CONSUMPTION IMPROVES BIOMARKERS FOR INFLAMMATION BUT NOT GLUCOSE-OR LIPID-METABOLISM IN INDIVIDUALS WITH METABOLIC SYNDROME IN A RANDOMIZED, DOUBLE BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL, FOOD FUNCT, 9, PP. 3097-3103, (2018); MEDJAKOVIC S., JUNGBAUER A., POMEGRANATE: A FRUIT THAT AMELIORATES METABOLIC SYNDROME, FOOD FUNCT, 4, 1, PP. 19-39, (2013); MOAZZEN H., ALIZADEH M., EFFECTS OF POMEGRANATE JUICE ON CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH METABOLIC SYNDROME: A DOUBLE-BLINDED, RANDOMIZED CROSSOVER CONTROLLED TRIAL, PLANT FOODS HUM NUTR, 72, 2, PP. 126-133, (2017); APROTOSOAIE A.C., MIRON A., TRIFAN A., LUCA V.S., COSTACHE I.I., THE CARDIOVASCULAR EFFECTS OF COCOA POLYPHENOLS-AN OVERVIEW, DISEASES, 17, (2016); FISHER N.D., HUGHES M., GERHARD-HERMAN M., HOLLENBERGH N.K., FLAVANOL-RICH COCOA INDUCES NITRIC-OXIDE-DEPENDENT VASODILATION IN HEALTHY HUMANS, J HYPERTENS, 21, PP. 2281-2286, (2003); FARIDI Z., NJIKE V.Y., DUTTA S., ALI A., KATZ D.L., ACUTE DARK CHOCOLATE AND COCOA INGESTION AND ENDOTHELIAL FUNCTION: A RANDOMIZED CONTROLLED CROSSOVER TRIAL, AM J CLIN NUTR, 88, PP. 58-63, (2008); MAGRONE T., RUSSO M.A., JIRILLO E., COCOA AND DARK CHOCOLATE POLYPHENOLS: FROM BIOLOGY TO CLINICAL APPLICATIONS, FRONT IMMUNOL, 8, (2017); SHIINA Y., FUNABASHI N., LEE K., MURAYAMA T., NAKAMURA K., WAKATSUKI Y., ACUTE EFFECT OF ORAL FLAVONOID-RICH DARK CHOCOLATE INTAKE ON CORONARY CIRCULATION, AS COMPARED WITH NON-FLAVONOID WHITE CHOCOLATE, BY TRANSTHORACIC DOPPLER ECHOCARDIOGRAPHY IN HEALTHY ADULTS, INT J CARDIOL, 131, PP. 424-429, (2009); NAPOLI C., IGNARRO L.J., NITRIC OXIDE AND PATHOGENIC MECHANISMS INVOLVED IN THE DEVELOPMENT OF VASCULAR DISEASES, ARCH PHARM RES, 32, PP. 1103-1108, (2009); ACTIS-GORETTA L., OTTAVIANI J.I., FRAGA C.G., INHIBITION OF ANGIOTENSIN CONVERTING ENZYME ACTIVITY BY FLAVANOL-RICH FOODS, J AGRIC FOOD CHEM, 54, PP. 229-234, (2006); GRASSI D., LIPPI C., NECOZIONE S., DESIDERI G., FERRI C., SHORT-TERM ADMINISTRATION OF DARK CHOCOLATE IS FOLLOWED BY A SIGNIFICANT INCREASE IN INSULIN SENSITIVITY AND A DECREASE IN BLOOD PRESSURE IN HEALTHY PERSONS, AM J CLIN NUTR, 81, PP. 611-614, (2005); DESIDERI G., KWIK-URIBE C., GRASSI D., ET AL., BENEFITS IN COGNITIVE FUNCTION, BLOOD PRESSURE, AND INSULIN RESISTANCE THROUGH COCOA FLAVANOL CONSUMPTION IN ELDERLY SUBJECTS WITH MILD COGNITIVE IMPAIRMENT: THE COCOA, COGNITION, AND AGING (COCOA) STUDY, HYPERTENSION, 60, PP. 794-801, (2012); HAGHIGHAT N., ROSTAMI A., EGHTESADI S., SHIDFAR F., HEIDARI I., HOSEINI A., THE EFFECTS OF DARK CHOCOLATE ON GLYCEMIC CONTROL AND BLOOD PRESSURE IN HYPERTENSIVE DIABETIC PATIENTS: A RANDOMIZED CLINICAL TRIAL, RAZI J MED SCI, 20, PP. 78-86, (2013); RAMIREZ-SANCHEZ I., TAUB P.R., TAUB P.R., CIARALDI T.P., ET AL., EPICATECHIN RICH COCOA MEDIATED MODULATION OF OXIDATIVE STRESS REGULATORS IN SKELETAL MUSCLE OF HEART FAILURE AND TYPE 2 DIABETES PATIENTS, INT J CARDIOL, 168, PP. 3982-3990, (2013); MELLOR D.D., SATHYAPALAN T., KILPATRICK E.S., BECKETT S., ATKIN S.L., HIGH-COCOA POLYPHENOL-RICH CHOCOLATE IMPROVES HDL CHOLESTEROL IN TYPE 2 DIABETES PATIENTS, DIABET MED, 27, PP. 1318-1321, (2010); DORENKOTT M.R., GRIFFIN L.E., GOODRICH K.M., ET AL., OLIGOMERIC COCOA PROCYANIDINS POSSESS ENHANCED BIOACTIVITY COMPARED TO MONOMERIC AND POLYMERIC COCOA PROCYANIDINS FOR PREVENTING THE DEVELOPMENT OF OBESITY, INSULIN RESISTANCE, AND IMPAIRED GLUCOSE TOLERANCE DURING HIGH-FAT FEEDING, J AGRIC FOOD CHEM, 62, PP. 2216-2227, (2014); STRAT K.M., ROWLEY T.J., SMITHSON A.T., ET AL., MECHANISMS BY WHICH COCOA FLAVANOLS IMPROVE METABOLIC SYNDROME AND RELATED DISORDERS, J NUTR BIOCHEM, 35, PP. 1-21, (2016); EPSTEIN J., SANDERSON I.R., MACDONALD T.T., CURCUMIN AS A THERAPEUTIC AGENT: THE EVIDENCE FROM IN VITRO, ANIMAL AND HUMAN STUDIES, BR J NUTR, 103, PP. 1545-1557, (2010); LIU W., ZHAI Y., HENG X., CHE F.Y., CHEN W., SUN D., ORAL BIOAVAILABILITY OF CURCUMIN: PROBLEMS AND ADVANCEMENTS, J DRUG TARGET, 24, PP. 694-702, (2016); GUPTA S.C., PATCHVA S., AGGARWAL B.B., THERAPEUTIC ROLES OF CURCUMIN: LESSONS LEARNED FROM CLINICAL TRIALS, AAPS J, 15, PP. 195-218, (2013); KUNNUMAKKARA A.B., BORDOLOI D., PADMAVATHI G., ET AL., CURCUMIN, THE GOLDEN NUTRACEUTICAL: MULTITARGETING FOR MULTIPLE CHRONIC DISEASES, BR J PHARMACOL, 174, PP. 1325-1348, (2017); MILANI A., BASIRNEJAD M., SHAHBAZI S., BOLHASSANI A., CAROTENOIDS: BIOCHEMISTRY, PHARMACOLOGY AND TREATMENT, BR J PHARMACOL, 174, PP. 1290-1324, (2017); YANG Y.S., SU Y.F., YANG W., LEE Y.H., CHOU J.I., UENG K.C., LIPID-LOWERING EFFECTS OF CURCUMIN IN PATIENTS WITH METABOLIC SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, PHYTOTHER RES, 28, PP. 1770-1777, (2014); ALWI I., SANTOSO T., SUYONO S., ET AL., THE EFFECT OF CURCUMIN ON LIPID LEVEL IN PATIENTS WITH ACUTE CORONARY SYNDROME, ACTA MED INDONES, 40, PP. 201-210, (2008); MELO I.S.V., SANTOS A.F.D., BUENO N.B., CURCUMIN OR COMBINED CURCUMINOIDS ARE EFFECTIVE IN LOWERING THE FASTING BLOOD GLUCOSE CONCENTRATIONS OF INDIVIDUALS WITH DYSGLYCEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 128, PP. 137-144, (2018); ANAND P., KUNNUMAKKARA A.B., NEWMAN R.A., AGGARWAL B.B., BIOAVAILABILITY OF CURCUMIN: PROBLEMS AND PROMISES, MOL PHARM, 4, PP. 807-818, (2007); SHAKERI A., SAHEBKAR A., OPINION PAPER: PHYTOSOME: A FATTY SOLUTION FOR EFFICIENT FORMULATION OF PHYTOPHARMACEUTICALS, RECENT PAT DRUG DELIV FORMUL, 10, PP. 7-10, (2016); PANAHI Y., KHALILI N., SAHEBI E., NAMAZI S., SIMENTAL-MENDIA L.E., MAJEED M.A., EFFECTS OF CURCUMINOIDS PLUS PIPERINE ON GLYCEMIC, HEPATIC AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL, DRUG RES, 68, PP. 403-409, (2018); CICERO A.F.G., SAHEBKAR A., FOGACCI F., BOVE M., GIOVANNINI M., BORGHI C., EFFECTS OF PHYTOSOMAL CURCUMIN ON ANTHROPOMETRIC PARAMETERS, INSULIN RESISTANCE, CORTISOLEMIA AND NON-ALCOHOLIC FATTY LIVER DISEASE INDICES: A DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, EUR J NUTR, (2019); TUCK K.L., HAYBALL P.J., MAJOR PHENOLIC COMPOUNDS IN OLIVE OIL: METABOLISM AND HEALTH EFFECTS, J NUTR BIOCHEM, 13, PP. 636-644, (2002); RUIZ-CANELA M., MARTINEZ-GONZALEZ M.A., OLIVE OIL IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, MATURITAS, 68, PP. 245-250, (2011); VISIOLI F., BERNARDINI E., EXTRA VIRGIN OLIVE OIL’S POLYPHENOLS: BIOLOGICAL ACTIVITIES, CURR PHARM DES, 17, PP. 786-804, (2011); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., ET AL., EFFECTS OF A MEDITERRANEAN-STYLE DIET ON CARDIOVASCULAR RISK FACTORS: A RANDOMIZED TRIAL, ANN INTERN MED, 145, PP. 1-11, (2006); COVAS M.I., NYYSSONEN K., POULSEN H.E., ET AL., THE EFFECT OF POLYPHENOLS IN OLIVE OIL ON HEART DISEASE RISK FACTORS: A RANDOMIZED TRIAL, ANN INTERN MED, 145, PP. 333-341, (2006); TSARTSOU E., PROUTSOS N., CASTANAS E., KAMPA M., NETWORK META-ANALYSIS OF METABOLIC EFFECTS OF OLIVE-OIL IN HUMANS SHOWS THE IMPORTANCE OF OLIVE OIL CONSUMPTION WITH MODERATE POLYPHENOL LEVELS AS PART OF THE MEDITERRANEAN DIET, FRONT NUTR, 12, (2019); HO G.T., KASE E.T., WANGENSTEEN H., BARSETT H., EFFECT OF PHENOLIC COMPOUNDS FROM ELDERFLOWERS ON GLUCOSE-AND FATTY ACID UPTAKE IN HUMAN MYOTUBES AND HEPG2-CELLS, MOLECULES, 6, (2017); SAYIN F.K., BUYUKBAS S., BASARALI K., ALP H., TOY H., UGURCU V., EFFECTS OF SILYBUM MARIANUM EXTRACT ON HIGH FAT DIET INDUCED METABOLIC DISORDERS IN RATS, POLISH J FOOD NUTR SCI, 66, PP. 43-49, (2016); BAHMANI M., SHIRZAD H., RAFIEIAN S., RAFIEIAN-KOPAEI M., SILYBUM MARIANUM: BEYOND HEPATOPROTECTION, J EVID BASED COMPLEMENTARY ALTERN MED, 20, PP. 292-301, (2015); FEHER J., LENGYEL G., SILYMARIN IN THE PREVENTION AND TREATMENT OF LIVER DISEASES AND PRIMARY LIVER CANCER, CURR PHARM BIOTECHNOL, 13, PP. 210-217, (2012); TAJMOHAMMADI A., RAZAVI B.M., HOSSEINZADEH H., SILYBUM MARIANUM (MILK THISTLE) AND ITS MAIN CONSTITUENT, SILYMARIN, AS A POTENTIAL THERAPEUTIC PLANT IN METABOLIC SYNDROME: A REVIEW, PHYTOTHER RES, 32, PP. 1933-1949, (2018); DE AVELAR C.R., PEREIRA E.M., DE FARIAS COSTA P.R., DE JESUS R.P., DE OLIVEIRA L.P.M., EFFECT OF SILYMARIN ON BIOCHEMICAL INDICATORS IN PATIENTS WITH LIVER DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS, WORLD J GASTROENTEROL, 23, PP. 5004-5017, (2017); ZHONG S., FAN Y., YAN Q., ET AL., THE THERAPEUTIC EFFECT OF SILYMARIN IN THE TREATMENT OF NONALCOHOLIC FATTY DISEASE: A META-ANALYSIS (PRISMA) OF RANDOMIZED CONTROL TRIALS, MEDICINE, 96, (2017); FALLAHZADEH M.K., DORMANESH B., SAGHEB M.M., ET AL., EFFECT OF ADDITION OF SILYMARINTO RENNIN ANGIOTENSIN SYSTEM INHIBITORS ON PROTEINURIA IN TYPE 2 DIABETIC PATIENTS WITH OVERT NEPHROPATHY: A RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED TRIAL, AM J KIDNEY DIS, 60, PP. 896-903, (2012); ZARVANDI M., RAKHSHANDEH H., ABAZARI M., SHAFIEE-NICK R., GHORBANI A., SAFETY AND EFFICACY OF A POLYHERBAL FORMULATION FOR THE MANAGEMENT OF DYSLIPIDEMIA AND HYPERGLYCEMIA IN PATIENTS WITH ADVANCED STAGE OF TYPE 2 DIABETES, BIOMED PHARMACOTHER, 89, PP. 69-75, (2017); MENENDEZ R., MAS R., AMOR M.A., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-326, (2000); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); KASSIS A.N., KUBOW S., JONES P.J., SUGAR CANE POLICOSANOLS DO NOT REDUCE LDL OXIDATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS, LIPIDS, 44, PP. 391-396, (2009); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHE-LEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVEST, 21, PP. 103-113, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT THER MED, 16, PP. 61-65, (2008); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) PURSUANT TO ARTICLE 13 (1)OF REGULATION (EC) NO 1924/2006, EFSA J, 9, 6, (2011); RACETTE S.B., LIN X., MA L., OSTLUND R.E., NATURAL DIETARY PHYTOSTEROLS, J AOAC INT, 98, PP. 679-684, (2015); CHO K.H., YADAV D., KIM S.J., KIM J.R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 3, (2018); PARK H.J., YADAV D., JEONG D.J., ET AL., SHORT-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, INT J ENVIRON RES PUBLIC HEALTH, 16, 5, (2019); VANHANEN H.T., MIETTINEN T.A., EFFECTS OF UNSATURATED AND SATURATED DIETARY PLANT STEROLS ON THEIR SERUM CONTENTS, CLIN CHIM ACTA, 205, PP. 97-107, (1992); OSTLUND R.E., MCGILL J.B., ZENG C.M., ET AL., GASTROINTESTINAL ABSORPTION AND PLASMA KINETICS OF SOY DELTA(5)-PHYTOSTEROLS AND PHYTOSTA-NOLS IN HUMANS, AM J PHYSIOL ENDOCRINOL METAB, 282, PP. E911-E916, (2002); OSTLUND R.E., PHYTOSTEROLS, CHOLESTEROL ABSORPTION AND HEALTHY DIETS, LIPIDS, 42, PP. 41-45, (2007); IKEDA I., TANAKA K., SUGANO M., VAHOUNY G.V., GALLO L.L., INHIBITION OF CHOLESTEROL ABSORPTION IN RATS BY PLANT STEROLS, J LIPID RES, 29, PP. 1573-1582, (1988); POLLAK O.J., REDUCTION OF BLOOD CHOLESTEROL IN MAN, CIRCULATION, 7, PP. 702-706, (1953); ROZNER S., GARTI N., THE ACTIVITY AND ABSORPTION RELATIONSHIP OF CHOLESTEROL AND PHYTOSTEROLS, COLLOIDS SURF A, 282-283, PP. 435-456, (2006); SHAGHAGHI M.A., ABUMWEIS S.S., JONES P.J.H., CHOLESTEROL-LOWERING EFFICACY OF PLANT STEROLS/STANOLS PROVIDED IN CAPSULE AND TABLET FORMATS: RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS, J ACAD NUTR DIET, 113, PP. 1494-1503, (2013); RIDEOUT T.C., MARINANGELI C.P., HARDING S.V., TRIGLYCERIDE-LOWERING RESPONSE TO PLANT STEROL AND STANOL CONSUMPTION, J AOAC INT, 98, PP. 707-715, (2015); ROCHA V.Z., RAS R.T., GAGLIARDI A.C., MANGILI L.C., TRAUTWEIN E.A., SANTOS R.D., EFFECTS OF PHYTOSTEROLS ON MARKERS OF INFLAMMATION: A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 248, PP. 76-83, (2016); RAS R.T., FUCHS D., KOPPENOL W.P., ET AL., THE EFFECT OF A LOW-FAT SPREAD WITH ADDED PLANT STEROLS ON VASCULAR FUNCTION MARKERS: RESULTS OF THE INVESTIGATING VASCULAR FUNCTION EFFECTS OF PLANT STEROLS (INVEST) STUDY, AM J CLIN NUTR, 101, PP. 733-741, (2015); SUDHOP T., GOTTWALD B.M., VON BERGMANN K., SERUM PLANT STEROLS AS A POTENTIAL RISK FACTOR FOR CORONARY HEART DISEASE, METABOLISM, 51, PP. 1519-1521, (2002); ASSMANN G., CULLEN P., ERBEY J., RAMEY D.R., KANNENBERG F., SCHULTE H., PLASMA SITOSTEROL ELEVATIONS ARE ASSOCIATED WITH AN INCREASED INCIDENCE OF CORONARY EVENTS IN MEN: RESULTS OF A NESTED CASE-CONTROL ANALYSIS OF THE PROSPECTIVE CARDIOVASCULAR MUNSTER (PROCAM) STUDY, NUTR METAB CARDIOVASC DIS, 16, PP. 13-21, (2006); SILBERNAGEL G., FAULER G., HOFFMANN M.M., ET AL., THE ASSOCIATIONS OF CHOLESTEROL METABOLISM AND PLASMA PLANT STEROLS WITH ALL-CAUSE AND CARDIOVASCULAR MORTALITY, J LIPID RES, 51, PP. 2384-2393, (2010); WINDLER E., ZYRIAX B.C., KUIPERS F., LINSEISEN J., BOEING H., ASSOCIATION OF PLASMA PHYTOSTEROL CONCENTRATIONS WITH INCIDENT CORONARY HEART DISEASE DATA FROM THE CORA STUDY, A CASE-CONTROL STUDY OF CORONARY ARTERY DISEASE IN WOMEN, ATHEROSCLEROSIS, 203, PP. 284-290, (2009); GENSER B., SILBERNAGEL G., DE BACKER G., ET AL., PLANT STEROLS AND CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR HEART J, 33, PP. 444-451, (2012); RAS R.T., VAN DER SCHOUW Y.T., TRAUTWEIN E.A., SIOEN I., DALMEIJER G., ZOCK P.L., INTAKE OF PHYTOSTEROLS FROM NATURAL SOURCES AND RISK OF CARDIOVASCULAR DISEASE IN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION-THE NETHERLANDS (EPIC-NL) POPULATION, EUR J PREV CARDIOL, 22, PP. 1067-1075, (2015); BAUMGARTNER S., RAS R.T., TRAUTWEIN E.A., MENSINK R.P., PLAT J., PLASMA FAT-SOLUBLE VITAMIN AND CAROTENOID CONCENTRATIONS AFTER PLANT STEROL AND PLANT STANOL CONSUMPTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, EUR J NUTR, 56, PP. 909-923, (2017); TAO C., SHKUMATOV A.A., ALEXANDER S.T., ASON B.L., ZHOU M., STIGMASTEROL ACCUMULATION CAUSES CARDIAC INJURY AND PROMOTES MORTALITY, COMMUN BIOL, 2, (2019)","L.A. CALÒ; DEPARTMENT OF MEDICINE, NEPHROLOGY, DIALYSIS AND TRANSPLANTATION UNIT, UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA, PADOVA, VIA GIUSTINIANI 2, 35128, ITALY; EMAIL: RENZCALO@UNIPD.IT","DOVE MEDICAL PRESS LTD","ENGLISH","DIABETES METAB. SYNDR. OBES.","REVIEW","ISI","2-S2.0-85073504044","DIABETES METAB SYNDR OBES","UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA;UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA;UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA","NOTREPORTED;UNIVERSITY OF PADOVA-AZIENDA OSPEDALIERA;NOTREPORTED",NA,"FRANCINI-PESENTI F, 2019, DIABETES METAB SYNDR OBES","FRANCINI-PESENTI F, 2019, DIABETES METAB SYNDR OBES"
"LLABRÉS J;URCOLA I;BOADA J;ARAUJO J;DURÁN J","LLABRÉS, JOSEP MANUEL (57200174093); URCOLA, IMANOL (57189373819); BOADA, JOSÉ MARÍA (57200179192); ARAUJO, JUAN CARLOS (57200184795); DURÁN, JOSÉ (57200175808)","EFFECT OF POLICOL ONE IN THE REDUCTION OF MIDHIGH CHOLESTEROL LEVELS EFEITO DE POLICOL ONE NA REDUÇÃO DOS NÍVEIS DE HIPERCOLESTEROLÉMIA LIGEIRA A MODERADA ESTUDIO PILOTO SOBRE EL EFECTO DE POLICOL ONE EN LA HIPERCOLESTEROLEMIA LEVEMODERADA",2017,"REVISTA DE FITOTERAPIA","17","7",1,"","DEPARTAMENTO DE I+D DE PLAMECA (PLANTAS MEDICINALES Y COMPLEMENTOS ALIMENTICIOS, S.A), SPAIN;MÉDICO DE FAMILIA, CONSULTA PARTICULAR DE MEDICINA GENERAL, BARCELONA, SPAIN;MÉDICO DE FAMILIA, CONSULTA PARTICULAR DE MEDICINA GENERAL, BARCELONA, SPAIN;CENTRE MÈDIC ARAUJO, MOLINS DE REI, BARCELONA, SPAIN;RESIDÈNCIA HOSPITAL SANT JOAN BAPTISTA DE SITGES, SITGES, BARCELONA, SPAIN","HIGH SERUM-CHOLESTEROL LEVELS REPRESENT ONE OF THE MOST CRITICAL RISK FACTORS IN THE DEVELOPMENT OF CARDIOVASCULAR DISEASES ALL OVER THE WORLD. IN THIS PAPER, THE RESULTS OF AN OBSERVATIONAL PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF THE PRODUCT POLICOL® ONE TO REDUCE LOW-MODERATE HYPERCHOLESTEROLEMIA ARE SHOWN. THE PRODUCT CONTAINS RED YEAST RICE (MONASCUS PURPUREUS), POLICOSANOL, COENZYME Q10 AND HYPOLIPIDEMIC AND HEPATOPROTECTIVE PLANTS USED IN FOLK MEDICINE: EXTRACTS OF GUGGUL (COMMIPHORA MUKUL), ARTICHOKE (CYNARA SCOLYMUS) AND DANDELION (TARAXACUM OFFICINALE), AND BIRDSEED POWDER (PHALARIS CANARIENSIS). AT A DOSAGE OF 1 CAPSULE PER DAY FOR 3 MONTHS, THE PARTICIPANTS SIGNIFICANTLY REDUCED THEIR TOTAL CHOLESTEROL (16,8%) AND LDL-CHOLESTEROL (23,8%); WITH AN ADDITIONAL DECREASE IN LEVELS (13,4%) AND INCREASING THEIR HDL-CHOLESTEROL LEVELS (9,1%). NO SIDE EFFECTS WERE REPORTED IN ANY CASE. THESE RESULTS INDICATE THAT THE PRODUCT IS EFFECTIVE AND SAFE TO REDUCE LOW-MODERATE CHOLESTEROL LEVELS, AND IT MAY REPRESENT A NATURAL COMPLEMENT TO OTHER TREATMENTS FOR THESE PATIENTS. © 2017, CITA PUBLICACIONES Y DOCUMENTACION. ALL RIGHTS RESERVED.","CHOLESTEROL; COENZYME Q<SUB>10</SUB>; FOLK MEDICINE; MONASCUS PURPUREUS; POLICOL<SUP>®</SUP> ONE; POLICOSANOL","","","","CENTRO DE PRENSA. ENFERMEDADES CARDIOVASCULARES, (2015); PEDRO-BOTET J., BENAIGES D., PEDRAGOSA A., DISLIPIDEMIA DIABÉTICA, MACRO Y MICROANGIOPATÍA, CLÍNICA E INVESTIGACIÓN EN ARTERIOSCLEROSIS, 24, 6, PP. 299-305, (2012); CASTELLI W.P., CHOLESTEROL AND LIPIDS IN THE RISK OF CORONARY ARTERY DISEASE--THE FRAMINGHAM HEART STUDY, THE CANADIAN JOURNAL OF CARDIOLOGY, 4, PP. 5AA-10A, (1988); CORDERO A., FACILA L., SITUACIÓN ACTUAL DE LA DISLIPEMIA EN ESPAÑA: LA VISIÓN DEL CARDIÓLOGO, REVISTA ESPAÑOLA DE CARDIOLOGÍA 2015; SUPLEMENTOS, 15, PP. 2-7; GUALLAR-CASTILLON P., GIL-MONTERO M., LEON-MUNOZ L.M., GRACIANI A., BAYAN-BRAVO A., TABOADA J.M., ET AL., MAGNITUD Y MANEJO DE LA HIPERCOLESTEROLEMIA EN LA POBLACIÓN ADULTA DE ESPAÑA, 2008-2010: EL ESTUDIO ENRICA, REVISTA ESPAÑOLA DE CARDIOLOGÍA, 65, 6, PP. 551-558, (2012); OLSON R.E., DISCOVERY OF THE LIPOPROTEINS, THEIR ROLE IN FAT TRANSPORT AND THEIR SIGNIFICANCE AS RISK FACTORS, THE JOURNAL OF NUTRITION, 128, 2, PP. 439S-443S, (1998); MOLINA M.T., VAZQUEZ C.M., RUIZ GUTIERREZ V., METABOLISMO DEL COLESTEROL. SU REGULACIÓN A NIVEL HEPÁTICO E INTESTINAL, (1991); ONG Y.C., AZIZ Z., SYSTEMATIC REVIEW OF RED YEAST RICE COMPARED WITH SIMVASTATIN IN DYSLIPIDAEMIA, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 41, 2, PP. 170-179, (2016); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEASTRICE DIETARY SUPPLEMENT, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 69, 2, PP. 231-236, (1999); NGUYEN T., KARL M., SANTINI A., RED YEAST RICE, FOODS, 6, 3, (2017); ALTERNATIVE MEDICINE REVIEWS, 9, 3, PP. 312-317, (2004); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 39, 4, PP. 889-899, (2017); BUETTNER C., GREENMAN R.L., NGO L.H., WU J.S., EFFECTS OF COENZYME Q10 ON SKELETAL MUSCLE OXIDATIVE METABOLISM IN STATIN USERS ASSESSED USING 31P MAGNETIC RESONANCE SPECTROSCOPY: A RANDOMIZED CONTROLLED STUDY, JOURNAL OF NATURE AND SCIENCE, 2, 8, (2016); ALTERNATIVE MEDICINE REVIEWS, 12, 2, PP. 159-168, (2007); ERNSTER L., DALLNER G., BIOCHEMICAL, PHYSIOLOGICAL AND MEDICAL ASPECTS OF UBIQUINONE FUNCTION, BIOCHIMICA ET BIOPHYSICA ACTA, 1271, 1, PP. 195-204, (1995); RAMESH B., KARUNA R., REDDY S.S., SUDHAKARA G., SARALAKUMARI D., ETHANOLIC EXTRACT OF COMMIPHORA MUKUL GUM RESIN ATTENUATES STREPTOZOTOCIN-INDUCED ALTERATIONS IN CARBOHYDRATE AND LIPID METABOLISM IN RATS, EXCLI JOURNAL, 12, (2013); HASANI-RANJBAR S., NAYEBI N., MORADI L., MEHRI A., LARIJANI B., ABDOLLAHI M., THE EFFICACY AND SAFETY OF HERBAL MEDICINES USED IN THE TREATMENT OF HYPERLIPIDEMIA; A SYSTEMATIC REVIEW, CURRENT PHARMACEUTICAL DESIGN, 16, 26, PP. 2935-2947, (2010); VYAS K.Y., BEDARKAR P., GALIB R., PRAJAPATI P.K., COMPARATIVE ANTIHYPERLIPIDAEMIC ACTIVITY OF NAVĪNA (FRESH) AND PURĀṆA (OLD) GUGGULU, ANCIENT SCIENCE OF LIFE, 35, 2, (2015); BHAT A.A., PRABHU K.S., KUTTIKRISHNAN S., KRISHNANKUTTY R., BABU J., MOHAMMAD R.M., ET AL., POTENTIAL THERAPEUTIC TARGETS OF GUGGULSTERONE IN CANCER, NUTRITION & METABOLISM, 14, 1, (2017); VANACLOCHA B., CANIGUERAL S., VADEMÉCUM DE FITOTERAPIA; WHO MONOGRAPHS ON SELECTED MEDICINAL PLANTS VOL. 3; GERARDS M.C., TERLOU R.J., YU H., KOKS C., GERDES V.E.A., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN-A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, 2, PP. 415-423, (2015); MARIN JIMENEZ F., MARTIN ALMENDROS M., SACRISTAN A., OCANA TABERNERO J.C., LLOPIS B., FERNANDEZ BARRERA V., ET AL., EFECTO REDUCTOR DEL COLESTEROL DE UNA COMBINACIÓN DE LEVADURA ROJA DE ARROZ Y POLICOSANOL, REVISTA DE FITOTERAPIA, 16, 1, PP. 5-14, (2016); AHN N., KIM K., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) IN CARDIOVASCULAR DISEASE: EFFECT OF EXERCISE TRAINING, INTEGRATIVE MEDICINE RESEARCH, 5, 3, PP. 212-215, (2016); COCA A., CEA-CALVO L., LOZANO J.V., INARAJA V., FERNANDEZ-PEREZ C., NAVARRO J., ET AL., COLESTEROL HDL Y ENFERMEDAD CARDIOVASCULAR EN MUJERES HIPERTENSAS DE ESPAÑA. ESTUDIO RIMHA, REVISTA ESPAÑOLA DE CARDIOLOGÍA, 62, 9, PP. 1022-1031, (2009); ALFONSO J., ARIZA I.D.S., ELEVANDO EL COLESTEROL HDL: ¿CUÁL ES LA MEJOR ESTRATEGIA?, REV ASSOC MED BRAS, 54, 4, PP. 369-376, (2008); WEB DE SCISTATCALC","J.M. LLABRÉS; PLANTAS MEDICINALES Y COMPLEMENTOS ALIMENTICIOS, PALLEJÀ, S. A. AVDA. PRAT DE LA RIBA S/N, ANTIGUA CARRETERA N-II KM 600, 08780, SPAIN; EMAIL: JMLLABRES@PLAMECA.COM","CITA PUBLICACIONES Y DOCUMENTACION","SPANISH","REV. FITOTERAPIA","ARTICLE","ISI","2-S2.0-85040081177","REV FITOTERAPIA","CENTRE MÈDIC ARAUJO;RESIDÈNCIA HOSPITAL SANT JOAN BAPTISTA DE SITGES","J.M. LLABRÉS;NOTREPORTED;EMAIL: JMLLABRES@PLAMECA.COM",NA,"LLABRÉS JM, 2017, REV FITOTERAPIA","LLABRÉS JM, 2017, REV FITOTERAPIA"
"ZENTI M;STEFANUTTI C;SANGA V;ALTOMARI A;FABRIS A;DAURIZ M;BONORA E","ZENTI, M.G. (6602739661); STEFANUTTI, C. (56055363600); SANGA, V. (57216782994); ALTOMARI, A. (57201586817); FABRIS, A. (57224702686); DAURIZ, M. (55757721100); BONORA, E. (7004495052)","EVOLOCUMAB AND LIPOPROTEIN APHERESIS COMBINATION THERAPY MAY HAVE SYNERGIC EFFECTS TO REDUCE LOWDENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA A CASE REPORT",2018,"JOURNAL OF CLINICAL APHERESIS","33","4",4,"10.1002/jca.21632","DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY;EXTRACORPOREAL THERAPEUTIC TECHNIQUES UNIT, LIPID CLINIC AND ATHEROSCLEROSIS PREVENTION CENTRE, IMMUNOHEMATOLOGY AND TRANSFUSION MEDICINE, DEPARTMENT OF MOLECULAR MEDICINE, ‘‘SAPIENZA’’ UNIVERSITY OF ROME, ‘‘UMBERTO I’’ HOSPITAL, ROME, ITALY;DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY;DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY;SECTION OF NEPHROLOGY, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY;DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY;DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY","A 49 YEARS OLD WOMAN (WEIGHT 68 KG, BMI 27.3 KG/M2) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) AND MULTIPLE STATIN INTOLERANCE WITH MUSCLE ACHES AND CREATINE KINASE ELEVATION, PRESENTED AT THE OUTPATIENT LIPID CLINIC OF VERONA UNIVERSITY HOSPITAL IN MAY 2015. HYPERCHOLESTEROLEMIA WAS FIRSTLY DIAGNOSED DURING ADOLESCENCE, FOLLOWED IN ADULTHOOD BY A DIAGNOSIS OF COGAN'S SYNDROME, A RHEUMATOLOGIC DISORDER CHARACTERIZED BY CORNEAL AND INNER EAR INFLAMMATION. NO XANTHOMAS, CORNEAL ARCUS, OR VASCULAR BRUITS WERE DETECTABLE AT PHYSICAL EXAMINATION. SCREENING FOR MACROVASCULAR COMPLICATIONS DID NOT REVEAL RELEVANT DAMAGES. ONGOING MEDICAL THERAPY INCLUDED SALICYLIC ACID, METHYLPREDNISOLONE, METHOTREXATE, AND PROTONIC-PUMP INHIBITOR. IN THE ABSENCE OF SPECIFIC LIPID-LOWERING THERAPY, PLASMA LIPID LEVELS AT FIRST VISIT WERE: TOTAL-CHOLESTEROL = 522 MG/DL, LDL-CHOLESTEROL = 434 MG/DL, HDL-CHOLESTEROL = 84 MG/DL, TRIGLYCERIDES = 120 MG/DL, LP(A) = 13 MG/DL. ON DECEMBER 2015, EVOLOCUMAB 140 MG SC EVERY 2 WEEKS WAS INITIATED. AFTER A 24-WEEK TREATMENT, THE LDL-CHOLESTEROL LEVELS DECREASED BY AN AVERAGE OF 21.2% TO 342 ± 22 MG/DL (MEAN ± SD). ON MAY 2016, LDL-APHERESIS (H.E.L.P.SYSTEM) WAS STARTED AS ADD-ON THERAPY. COMPARED TO THE AVERAGE LEVELS OBTAINED DURING THE EVOLOCUMAB MONOTHERAPY PERIOD, THE LDL-CHOLESTEROL WAS REDUCED BY 49.4%, THUS REACHING AN INTER-APHERESIS LEVEL (MEAN ± SD) OF 173 ± 37 MG/DL. THIS REPORT SUGGESTS THAT A COMBINATION THERAPY WITH EVOLOCUMAB AND LIPOPROTEIN-APHERESIS MAY HAVE SYNERGIC EFFECTS ON CIRCULATING LIPID LEVELS. ITS RELEVANCE AS A HIGHLY EFFECTIVE TREATMENT OPTION FOR HYPERLIPIDEMIA IN HEFH PATIENTS WARRANTS FURTHER INVESTIGATION IN LARGER DATASETS. © 2018 WILEY PERIODICALS, INC.","ANTI-PCSK9 ANTIBODY; EVOLOCUMAB; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; LIPOPROTEIN APHERESIS; STATIN INTOLERANCE","ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; MIDDLE AGED; ALANINE AMINOTRANSFERASE; ARMOLIPID PLUS; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; BERBERINE; COLESTYRAMINE; EVOLOCUMAB; EZETIMIBE; FLUINDOSTATIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; METHYLPREDNISOLONE; MYOGLOBIN; PANTOPRAZOLE; POLICOSANOL; PRAVASTATIN; PROTON PUMP INHIBITOR; SALICYLIC ACID; TRIACYLGLYCEROL; UBIDECARENONE; EVOLOCUMAB; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DOPPLER ULTRASONOGRAPHY; DRUG POTENTIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENETIC SCREENING; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LDLR GENE; MIDDLE AGED; MONOTHERAPY; MUTATIONAL ANALYSIS; MYALGIA; MYOGLOBINURIA; OUTCOME ASSESSMENT; RECEPTOR GENE; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; APHERESIS; BLOOD; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; ISOLATION AND PURIFICATION; MULTIMODALITY CANCER THERAPY; PROCEDURES","","","GOLDSTEIN J.L., KITA T., BROWN M.S., DEFECTIVE LIPOPROTEIN RECEPTORS AND ATHEROSCLEROSIS. LESSONS FROM AN ANIMAL COUNTERPART OF FAMILIAL HYPERCHOLESTEROLEMIA, N ENGL J MED., 309, 5, PP. 288-296, (1983); NORDESTGAARD B.G., CHAPMAN M.J., HUMPHRIES S.E., ET AL., FAMILIAL HYPERCHOLESTEROLAEMIA IS UNDERDIAGNOSED AND UNDERTREATED IN THE GENERAL POPULATION: GUIDANCE FOR CLINICIANS TO PREVENT CORONARY HEART DISEASE: CONSENSUS STATEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY, EUR HEART J., 34, 45, PP. 3478-3490A, (2013); WIEGMAN A., GIDDING S.S., WATTS G.F., ET AL., FAMILIAL HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS: GAINING DECADES OF LIFE BY OPTIMIZING DETECTION AND TREATMENT, EUR HEART J., 36, 36, PP. 2425-2437, (2015); PIEPOLI M.F., HOES A.W., AGEWALL S., ET AL., 2016 EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: THE SIXTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF 10 SOCIETIES AND BY INVITED EXPERTS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS., 252, PP. 207-274, (2016); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY-EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR HEART J., 36, 17, PP. 1012-1022, (2015); MORIARTY P.M., THOMPSON P.D., CANNON C.P., ET AL., EFFICACY AND SAFETY OF ALIROCUMAB VS EZETIMIBE IN STATIN-INTOLERANT PATIENTS, WITH A STATIN RECHALLENGE ARM: THE ODYSSEY ALTERNATIVE RANDOMIZED TRIAL, J CLIN LIPIDOL., 9, 6, PP. 758-769, (2015); NISSEN S.E., STROES E., DENT-ACOSTA R.E., ET AL., EFFICACY AND TOLERABILITY OF EVOLOCUMAB VS EZETIMIBE IN PATIENTS WITH MUSCLE-RELATED STATIN INTOLERANCE: THE GAUSS-3 RANDOMIZED CLINICAL TRIAL, JAMA., 315, 15, PP. 1580-1590, (2016); MEHTA P.K., BAER J., NELL C., SPERLING L.S., LOW-DENSITY LIPOPROTEIN APHERESIS AS A TREATMENT OPTION FOR HYPERLIPIDEMIA, CURR TREAT OPTIONS CARDIOVASC MED., 11, 4, PP. 279-288, (2009); STEFANUTTI C., THOMPSON G.R., LIPOPROTEIN APHERESIS IN THE MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA: HISTORICAL PERSPECTIVE AND RECENT ADVANCES, CURR ATHEROSCLER REP., 17, 1, (2015); BARRIOS V., ESCOBAR C., CICERO A.F., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL., 24, PP. 1-15, (2017); ARMSTRONG V.W., WINDISCH M., WIELAND H., ET AL., SELECTIVE CONTINUOUS EXTRACORPORAL ELIMINATION OF LOW-DENSITY LIPOPROTEINS WITH HEPARIN AT ACIDIC PH, TRANS AM SOC ARTIF INTERN ORGANS., 29, PP. 323-328, (1983); KROON A.A., VAN'T HOF M.A., DEMACKER P.N., STALENHOEF A.F., THE REBOUND OF LIPOPROTEINS AFTER LDL-APHERESIS. KINETICS AND ESTIMATION OF MEAN LIPOPROTEIN LEVELS, ATHEROSCLEROSIS., 152, 2, PP. 519-526, (2000); GALEMA-BOERS A.M.H., LENZEN M.J., SIJBRANDS E.J., ROETERS VAN LENNEP J.E., PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 INHIBITION IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: INITIAL CLINICAL EXPERIENCE, J CLIN LIPIDOL., 11, 3, PP. 674-681, (2017); PFOHL M., NAOUMOVA R.P., KLASS C., ET AL., ACUTE AND CHRONIC EFFECTS ON CHOLESTEROL BIOSYNTHESIS OF LDL-APHERESIS WITH OR WITHOUT CONCOMITANT HMG-COA REDUCTASE INHIBITOR THERAPY, J LIPID RES., 35, 11, PP. 1946-1955, (1994); ZENTI M.G., STEFANUTTI C., EFFECTS OF SELECTIVE H.E.L.P. LDL-APHERESIS ON PLASMA INFLAMMATORY MARKERS CONCENTRATION IN SEVERE DYSLIPIDEMIA: IMPLICATION FOR ANTI-INFLAMMATORY RESPONSE, CYTOKINE., 56, 3, PP. 850-854, (2011); BECKER D.M., CHAMBERLAIN B., SWANK R., ET AL., RELATIONSHIP BETWEEN CORTICOSTEROID EXPOSURE AND PLASMA LIPID LEVELS IN HEART TRANSPLANT RECIPIENTS, AM J MED., 85, 5, PP. 632-638, (1988)","M.G. ZENTI; DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM, DEPARTMENT OF MEDICINE, UNIVERSITY HOSPITAL OF VERONA, VERONA, ITALY; EMAIL: MARIAGRAZIA.ZENTI@UNIVR.IT","WILEY-LISS INC.","ENGLISH","J. CLIN. APHERESIS","ARTICLE","ISI","2-S2.0-85045297276","J CLIN APHERESIS","UNIVERSITY HOSPITAL OF VERONA;‘‘SAPIENZA’’ UNIVERSITY OF ROME;UNIVERSITY HOSPITAL OF VERONA;UNIVERSITY HOSPITAL OF VERONA;UNIVERSITY HOSPITAL OF VERONA;UNIVERSITY HOSPITAL OF VERONA;UNIVERSITY HOSPITAL OF VERONA","NOTREPORTED;UNIVERSITY HOSPITAL OF VERONA;EMAIL: MARIAGRAZIA.ZENTI@UNIVR.IT",NA,"ZENTI MG, 2018, J CLIN APHERESIS","ZENTI MG, 2018, J CLIN APHERESIS"
"MARCHITTO N;SINDONA F;FABRIZIO A;MAUTI M;ANDREOZZI S;DALMASO S;RAIMONDI G","MARCHITTO, NICOLA (57202017640); SINDONA, FRANCESCO (57200374389); FABRIZIO, ALESSANDRA (58441155900); MAUTI, MONICA (57200370495); ANDREOZZI, SIMONA (57200364383); DALMASO, SERENELLA (57205088512); RAIMONDI, GIANFRANCO (7006380287)","EFFECT OF NUTRACEUTICAL WITH POLICOSANOL BERBERINE RED YEAST RICE CASSIA NOMAME ASTAXANTINE AND Q10 COENZYME IN PATIENTS WITH LOWMODERATE DYSLIPIDEMIA ASSOCIATED WITH INTOLERANCE TO STATINS AND METABOLIC SYNDROME",2018,"GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE","177","3",0,"10.23736/s0393-3660.17.03616-6","ALFREDO FIORINI HOSPITAL, DEPARTMENT OF INTERNAL MEDICINE, TERRACINA, LATINA, ITALY;FACULTY OF INTERNAL MEDICINE, SAPIENZA UNIVERSITY OF ROME, ROME, ITALY;DEPARTMENT OF NURSING SCIENCES, SAPIENZA UNIVERSITY OF ROME, ROME, ITALY;DEPARTMENT OF NURSING SCIENCES, SAPIENZA UNIVERSITY OF ROME, ROME, ITALY;FACULTY OF MEDICINE AND SURGERY, SAPIENZA UNIVERSITY OF ROME, ROME, ITALY;ALFREDO FIORINI HOSPITAL, DEPARTMENT OF INTERNAL MEDICINE, TERRACINA, LATINA, ITALY;DEPARTMENT OF MEDICO-SURGICAL SCIENCES AND BIOTECHNOLOGIES, FACULTY OF INTERNAL MEDICINE, SAPIENZA UNIVERSITY OF ROME, ROME, ITALY","BACKGROUND: THE METABOLIC SYNDROME IS A FREQUENT RISK FACTOR FOR CARDIOVASCULAR DISEASES AND TYPE 2 DIABETES AND CONSIST OF DIFFERENT METABOLIC DISORDERS LIKE CENTRAL OBESITY, INSULIN RESISTANCE, HYPERTENSION AND DYSLIPIDEMIA ASSOCIATED TO HIGH VALUE OF TRIGLYCERIDES (TG) AND LOW LEVEL OF HIGH-DENSITY LIPOPROTEIN (HDL). THE PREVALENCE OF METABOLIC SYNDROME INCREASES WITH AGE, DEGREE OF OBESITY AND PROPENSITY TO TYPE 2 DIABETES. THE AIM OF THIS STUDY WAS TO EVALUATE THE EFFECT OF NUTRACEUTICAL WITH POLICOSANOL, BERBERINA, RED YEAST RISE, CASSIA NOMAME, ASTAXANTINA, Q10 COENZIME AND FOLIC ACID IN PATIENTS WITH LOW TO MODERATE DYSLIPIDEMIA, INTOLERANCE TO STATINS AND METABOLIC SYNDROME. METHODS: WE HAVE ENROLLED 30 PATIENTS (15 MALES AND 15 FEMALES WITH RANGE AGE 19-90 YEARS, MEAN 71±19 YEARS) THAT SATISFYING THE NCEP: ATPIII 2001 CRITERIA FOR METABOLIC SYNDROME. ONLY 27 PATIENTS HAVE COMPLETED ALL THE PROTOCOL PHASES. ALL COMPLIANT PATIENTS WERE UNDERWENT TO THE EVALUATION OF TOTAL CHOLESTEROL (T-CHOL), LOW-DENSITY LIPOPROTEIN (LDL), HDL, TG, HEART RATE VARIABILITY, T-PEAK TO T-END INDEX, QTC VALUE AND T-PEAK-END/QTC RATIO, AND SIDE EFFECTS BEFORE AND POSTADMINISTRATION OF STANDARD TREATMENT WITH POLICOSANOL, BERBERINA, RED YEAST RISE, CASSIA NOMANE, ASTAXANTINA, Q10 COENZIME AND FOLIC ACID. RESULTS: OUR STUDY HAVE SHOWN A STATISTICALLY SIGNIFICANT CHANGE IN T-CHOL (23033 MG VS. 180 MG±44 MG WITH P<0.001), LOW-DENSITY OF LIPOPROTEIN (155±44 MG VS. 116±42 MG WITH P<0.001), HDL (43±18 MG VS. 49±18 MG WITH P<0.024) AND TG (141±71 MG VS. 124±70 MG WITH P<0.012) WITH STATISTICALLY SIGNIFICANT CORRELATION. OUR DATA DID NOT SHOWN A STATISTICALLY SIGNIFICANT DIFFERENCE IN THE HEART RATE VARIABILITY (P=0.978), SDNN (P=0.954), PNN (P=0.784), LF (P=0.990), HF (P=0.952), LF/HF INDEX (P=0.842), T-PEAK TO T-END (P=0.741), QTC (P=0.689) AND T-PEAK TO T-END/QTC RATIO (P=0.542). CONCLUSIONS: NUTRACEUTICAL COULD BE A NEW USEFUL APPROACH IN THE TREATMENT OF PATIENTS WITH METABOLIC SYNDROME AND LOW OR MODERATE DYSLIPIDEMIA WITH INTOLERANCE TO STATINS AND NOT RESPONSIVE TO NON-PHARMACOLOGICAL TREATMENT (LIFESTYLE, DIET, BEHAVIOR MODIFICATION AND PHYSICAL ACTIVITY). OUR PRELIMINARY DATA GIVES COMFORTABLE RESULTS. © 2017 EDIZIONI MINERVA MEDICA.","AGED; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; HEART RATE; METABOLIC SYNDROME X","ASTAXANTHIN; BERBERINE; CHOLESTIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; ADULT; AGED; ARTICLE; BEHAVIOR MODIFICATION; CASSIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIETARY SUPPLEMENT; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; FEMALE; HEART RATE VARIABILITY; HUMAN; MALE; METABOLIC SYNDROME X; QTC INTERVAL; SIDE EFFECT; T-PEAK TO T-END","","","JOHNSTON T.P., KOROLENKO T.A., PIRRO M., SAHEBKAR A., PREVENTING CARDIOVASCULAR HEART DISEASE: PROMISING NUTRACEUTICAL AND NON-NUTRACEUTICAL TREATMENTS FOR CHOLESTEROL MANAGEMENT, PHARMACOL RES, 120, PP. 219-225, (2017); HUNTER P.M., HEGELE R.A., FUNCTIONA L FOODS AND DIETARY SUPPLEMENTS FOR MANAGEMENT OF DYSLIPIDAEMIA, NAT REV ENDOCRINOL, 13, PP. 278-288, (2017); BARRIOS V., ESCOBAR C., CICERO A.F., BURKE D., FASCHING P., BANACH M., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); DI PIERRO F., PUTIGNANO P., FERRARA T., RAIOLA C., RAPACIOLI G., VILLANOVA N., RETROSPECTIVE ANALYSIS OF THE EFFECTS OF A HIGHLY STANDARDIZED MIXTURE OF BERBERIS ARISTATA, SILYBUM MARIANUM, AND MONOCOLINS K AND KA IN PATIENTS WITH DYSLIPIDEMIA, CLIN PHARMACOL, 9, PP. 1-7, (2016); MOEBUS S., HANISCH J.U., NEUHAUSER M., AIDELSBURGER P., WASEM J., JOCKEL K.H., ASSESSING THE PREVALENCE OF THE METABOLIC SYNDROME ACCORDING TO NCEP-ATP III IN GERMANY: FEASIBILITY AND QUALITY ASPECTS OF A TWO-STEP APPROACH IN 1550 RANDOMLY SELECTED PRIMARY HEALTH CARE PRACTICES, GER MED SCI, 4, (2006); CHANG Y.M., SHIAO C.C., HUANG Y.T., CHEN I.L., YANG C.L., SC L., ET AL., IMPACT OF METABOLIC SYNDROME AND ITS COMPONENTS ON HEART RATE VARIABILITY DURING HEMODIALISYS: A CROSS-SECTIONAL STUDY, CARDIOVASC DIABETOL, 15, (2016); GELLERT K.S., RAUTAHARJU P., SNYDER M.L., WHITSEL E.A., MATSUSHITA K., HEISS G., ET AL., SHORT-THERM REPEATABILITY OF ELECRTROCARDIOGRAPHIC TPEAK-TEND AND QT INTERVALS, J ELECTROCARDIOL, 47, PP. 356-361, (2014); STULC T., CESKA R., GOTTO A.M., STATIN INTOLERANCE: THE CLINICIAN'S PERSPECTIVE, CURR ATHEROSCLER REP, 17, (2015)","N. MARCHITTO; ALFREDO FIORINI HOSPITAL, DEPARTMENT OF INTERNAL MEDICINE, TERRACINA, LATINA, ITALY; EMAIL: N.MARCHITTO@AUSL.LATINA.IT","EDIZIONI MINERVA MEDICA","ENGLISH","GAZZ. MED. ITAL. ARCH. SCI. MED.","ARTICLE","ISI","2-S2.0-85045320258","GAZZ MED ITAL ARCH SCI MED","ALFREDO FIORINI HOSPITAL;SAPIENZA UNIVERSITY OF ROME;SAPIENZA UNIVERSITY OF ROME;SAPIENZA UNIVERSITY OF ROME;SAPIENZA UNIVERSITY OF ROME;ALFREDO FIORINI HOSPITAL;SAPIENZA UNIVERSITY OF ROME","N. MARCHITTO;ALFREDO FIORINI HOSPITAL;EMAIL: N.MARCHITTO@AUSL.LATINA.IT",NA,"MARCHITTO N, 2018, GAZZ MED ITAL ARCH SCI MED","MARCHITTO N, 2018, GAZZ MED ITAL ARCH SCI MED"
"MAZZANTI G;MORO P;RASCHI E;DA C R;MENNITI-IPPOLITO F","MAZZANTI, GABRIELA (7006187288); MORO, PAOLA ANGELA (24468375900); RASCHI, EMANUEL (23968271400); DA CAS, ROBERTO (57190089328); MENNITI-IPPOLITO, FRANCESCA (55913474600)","ADVERSE REACTIONS TO DIETARY SUPPLEMENTS CONTAINING RED YEAST RICE ASSESSMENT OF CASES FROM THE ITALIAN SURVEILLANCE SYSTEM",2017,"BRITISH JOURNAL OF CLINICAL PHARMACOLOGY","83","14",60,"10.1111/bcp.13171","DEPARTMENT OF PHYSIOLOGY AND PHARMACOLOGY ‘VITTORIO ERSPAMER’, SAPIENZA UNIVERSITY OF ROME, PIAZZALE ALDO MORO 5, ROME, 00185, ITALY;POISON CONTROL CENTER, NIGUARDA CA' GRANDE HOSPITAL, PIAZZA OSPEDALE MAGGIORE 3, MILAN, 20162, ITALY;PHARMACOLOGY UNIT, DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF BOLOGNA, VIA IRNERIO 48, BOLOGNA, 40126, ITALY;CENTRE FOR EPIDEMIOLOGY, NATIONAL INSTITUTE OF HEALTH, VIALE REGINA ELENA 299, ROME, 00161, ITALY;CENTRE FOR EPIDEMIOLOGY, NATIONAL INSTITUTE OF HEALTH, VIALE REGINA ELENA 299, ROME, 00161, ITALY","AIMS: RED YEAST RICE (RYR) IS CONTAINED IN DIETARY SUPPLEMENTS FOR PATIENTS WITH DYSLIPIDEMIA. RYR SUPPLEMENTS CONTAIN MONACOLIN K, WHICH IS CHEMICALLY IDENTICAL TO LOVASTATIN, A LICENSED DRUG WITH A WELL-KNOWN RISK PROFILE. WE AIM TO DESCRIBE THE SAFETY PROFILE OF RYR BY ANALYSING SPONTANEOUS REPORTS OF SUSPECTED ADVERSE REACTIONS (ARS). METHODS: WITHIN THE ITALIAN SURVEILLANCE SYSTEM OF NATURAL HEALTH PRODUCTS, SUSPECTED ARS WERE COLLECTED AND EVALUATED BY A MULTIDISCIPLINARY GROUP OF EXPERTS TO ASSESS CAUSALITY USING THE WHO-UMC SYSTEM OR THE CIOMS/RUCAM SCORE, FOR HEPATIC REACTIONS. THE PUBLIC VERSION OF THE WHO-VIGIBASE WAS ALSO QUERIED. RESULTS: FROM APRIL 2002 TO SEPTEMBER 2015, OUT OF 1261 TOTAL REPORTS, 52 REPORTS CONCERNING 55 ARS TO RYR DIETARY SUPPLEMENTS WERE COLLECTED. ARS CONSISTED IN MYALGIA AND/OR INCREASE IN CREATINE PHOSPHOKINASE (19), RHABDOMYOLYSIS (1), LIVER INJURY (10), GASTROINTESTINAL REACTIONS (12), CUTANEOUS REACTIONS (9) AND OTHER REACTIONS (4). WOMEN WERE INVOLVED IN 70% OF CASES. IN 13 CASES, THE REACTION REQUIRED HOSPITALIZATION, AND 28 PATIENTS WERE TAKING OTHER MEDICATIONS. DECHALLENGE WAS POSITIVE IN 40 REACTIONS (73%), RECHALLENGE WAS POSITIVE IN 7. CAUSALITY RESULTED AS CERTAIN (1), PROBABLE (31, 56%), POSSIBLE (18, 34%), UNLIKELY (3) OR UNASSESSABLE (2). SIMILAR DISTRIBUTION EMERGED FROM THE WHO-VIGIBASE. CONCLUSIONS: THE POTENTIAL SAFETY SIGNALS OF MYOPATHIES AND LIVER INJURY RAISE THE HYPOTHESIS THAT THE SAFETY PROFILE OF RYR IS SIMILAR TO THAT OF STATINS. CONTINUOUS MONITORING OF DIETARY SUPPLEMENTS SHOULD BE PROMOTED TO FINALLY CHARACTERIZE THEIR RISK PROFILE, THUS SUPPORTING REGULATORY BODIES FOR APPROPRIATE ACTIONS. © 2017 THE BRITISH PHARMACOLOGICAL SOCIETY","ADVERSE REACTIONS; DIETARY SUPPLEMENTS; MONACOLIN; MONASCUS PURPUREUS; RED YEAST RICE; STATINS","ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; ALPHA TOCOPHEROL; ASTAXANTHIN; BERBERIS ARISTATA DRY EXTRACT; CARVEDILOL; CHOLESTIN; CREATINE KINASE; CYANOCOBALAMIN; FISH OIL; FOLIC ACID; GLYCERYL TRINITRATE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; MEVINOLIN; MIANSERIN; NATURAL PRODUCT; PLANT EXTRACT; POLICOSANOL; PROPOLIS; PYRIDOXINE; RAMIPRIL; RESVERATROL; ROYAL JELLY; SALMETEROL; SNAKE VENOM ANTISERUM; THEOPHYLLINE; TIOTROPIUM BROMIDE; TORASEMIDE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT; CHOLESTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; ASSESSMENT OF HUMANS; BERBERIS ARISTATA; CAUSALITY; CIOMS RUCAM SCORE; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA COLLECTION METHOD; DIETARY SUPPLEMENT; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HEPATOBILIARY DISEASE; HERPES SIMPLEX; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ITALY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE INJURY; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NAUSEA; PEMPHIGUS VULGARIS; PHARMACOGNOSY; PRIORITY JOURNAL; PRURITUS; RHABDOMYOLYSIS; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; STEATOSIS; TACHYCARDIA; TEA; THORAX PAIN; URTICARIA; VERTIGO; VERY ELDERLY; VOMITING; WORLD HEALTH ORGANIZATION; DIETARY SUPPLEMENT; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; FACTUAL DATABASE; STATISTICS AND NUMERICAL DATA","","","SOUTHAN C., SHARMAN J.L., BENSON H.E., FACCENDA E., PAWSON A.J., ALEXANDER S.P., ET AL., THE IUPHAR/BPS GUIDE TO PHARMACOLOGY IN 2016: TOWARDS CURATED QUANTITATIVE INTERACTIONS BETWEEN 1300 PROTEIN TARGETS AND 6000 LIGANDS, NUCL ACIDS RES, 44, PP. D1054-D1068, (2016); ALEXANDER S.P.H., FABBRO D., KELLY E., MARRION N., PETERS J.A., BENSON H.E., ET AL., THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: ENZYMES, BR J PHARMACOL, 172, PP. 6024-6109, (2015); GELLER A.I., SHEHAB N., WEIDLE N.J., LOVEGROVE M.C., WOLPERT B.J., TIMBO B.B., ET AL., EMERGENCY DEPARTMENT VISITS FOR ADVERSE EVENTS RELATED TO DIETARY SUPPLEMENTS, N ENGL J MED, 373, PP. 1531-1540, (2015); MENNITI-IPPOLITO F., MAZZANTI G., SANTUCCIO C., MORO P.A., CALAPAI G., FIRENZUOLI F., ET AL., SURVEILLANCE OF SUSPECTED ADVERSE REACTIONS TO NATURAL HEALTH PRODUCTS IN ITALY, PHARMACOEPIDEMIOL DRUG SAF, 17, PP. 626-635, (2008); LEE J.Y., JUN S.A., HONG S.S., AHN Y.C., LEE D.S., SON C.G., SYSTEMATIC REVIEW OF ADVERSE EFFECTS FROM HERBAL DRUGS REPORTED IN RANDOMIZED CONTROLLED TRIALS, PHYTOTHER RES, 30, PP. 1412-1419, (2016); DI LORENZO C., CESCHI A., KUPFERSCHMIDT H., LUDE S., DE SOUZA NASCIMENTO E., DOS SANTOS A., ET AL., ADVERSE EFFECTS OF PLANT FOOD SUPPLEMENTS AND BOTANICAL PREPARATIONS: A SYSTEMATIC REVIEW WITH CRITICAL EVALUATION OF CAUSALITY, BR J CLIN PHARMACOL, 79, PP. 578-592, (2015); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5225, (2000); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); VENERO C.V., VENERO J.V., WORTHAM D.C., THOMPSON P.D., LIPID-LOWERING EFFICACY OF RED YEAST RICE IN A POPULATION INTOLERANT TO STATINS, AM J CARDIOL, 105, PP. 664-666, (2010); MORIARTY P.M., ROTH E.M., KARNS A., YE P., ZHAO S.P., LIAO Y., ET AL., EFFECTS OF XUEZHIKANG IN PATIENTS WITH DYSLIPIDEMIA: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY, J CLIN LIPIDOL, 8, PP. 568-575, (2014); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES CLIN EXP, 77, PP. 1-6, (2014); HALBERT S.C., FRENCH B., GORDON R.Y., FARRAR J.T., SCHMITZ K., MORRIS P.B., ET AL., TOLERABILITY OF RED YEAST RICE (2, 400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); MARAZZI G., PELLICCIA F., CAMPOLONGO G., QUATTRINO S., CACCIOTTI L., VOLTERRANI M., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM J CARDIOL, 116, PP. 1798-1801, (2015); ONG Y.C., AZIZ Z., SYSTEMATIC REVIEW OF RED YEAST RICE COMPARED WITH SIMVASTATIN IN DYSLIPIDAEMIA, J CLIN PHARM THER, 41, PP. 170-179, (2016); CHILDRESS L., GAY A., ZARGAR A., ITO M.K., REVIEW OF RED YEAST RICE CONTENT AND CURRENT FOOD AND DRUG ADMINISTRATION OVERSIGHT, J CLIN LIPIDOL, 7, PP. 117-122, (2013); WILD D., TOTH G., HUMPF H.U., NEW MONASCUS METABOLITE ISOLATED FROM RED YEAST RICE (ANGKAK, RED KOJI), J AGRIC FOOD CHEM, 50, PP. 3999-4002, (2002); FLAJS D., PERAICA M., TOXICOLOGICAL PROPERTIES OF CITRININ, ARH HIG RADA TOKSIKOL, 60, PP. 457-464, (2009); GORDON R.Y., BECKER D.J., THE ROLE OF RED YEAST RICE FOR THE PHYSICIAN, CURR ATHEROSCLER REP, 13, PP. 73-80, (2011); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR ATHEROSCLER REP, 17, (2015); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN – A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); LAPI F., GALLO E., BERNASCONI S., VIETRI M., MENNITI-IPPOLITO F., RASCHETTI R., ET AL., MYOPATHIES ASSOCIATED WITH RED YEAST RICE AND LIQUORICE: SPONTANEOUS REPORTS FROM THE ITALIAN SURVEILLANCE SYSTEM OF NATURAL HEALTH PRODUCTS, BR J CLIN PHARMACOL, 66, PP. 572-574, (2008); GRIECO A., MIELE L., POMPILI M., BIOLATO M., VECCHIO F.M., GRATTAGLIANO I., ET AL., ACUTE HEPATITIS CAUSED BY A NATURAL LIPID-LOWERING PRODUCT: WHEN ‘ALTERNATIVE’ MEDICINE IS NO ‘ALTERNATIVE’ AT ALL, J HEPATOL, 50, PP. 1273-1277, (2009); SMITH D.J., OLIVE K.E., CHINESE RED RICE-INDUCED MYOPATHY, SOUTH MED J, 96, PP. 1265-1267, (2003); MUELLER P.S., SYMPTOMATIC MYOPATHY DUE TO RED YEAST RICE, ANN INTERN MED, 145, PP. 474-475, (2006); VERCELLI L., MONGINI T., OLIVERO N., RODOLICO C., MUSUMECI O., PALMUCCI L., CHINESE RED RICE DEPLETES MUSCLE COENZYME Q10 AND MAINTAINS MUSCLE DAMAGE AFTER DISCONTINUATION OF STATIN TREATMENT, J AM GERIATR SOC, 54, PP. 718-720, (2006); POLSANI V.R., JONES P.H., BALLANTYNE C.M., NAMBI V., A CASE REPORT OF MYOPATHY FROM CONSUMPTION OF RED YEAST RICE, J CLIN LIPIDOL, 2, PP. 60-62, (2008); ARONSON J.K., HAUBEN M., ANECDOTES THAT PROVIDE DEFINITIVE EVIDENCE, BMJ, 333, PP. 1267-1269, (2006); TESCHKE R., FRENZEL C., GLASS X., SCHULZE J., EICKHOFF A., HERBAL HEPATOTOXICITY: A CRITICAL REVIEW, BR J CLIN PHARMACOL, 75, PP. 630-636, (2013); EDWARDS I.R., ARONSON J.K., ADVERSE DRUG REACTIONS: DEFINITIONS, DIAGNOSIS, AND MANAGEMENT, LANCET, 356, PP. 1255-1259, (2000); WILSON A.D., HOWELL C., WARING W.S., VENLAFAXINE INGESTION IS ASSOCIATED WITH RHABDOMYOLYSIS IN ADULTS: A CASE SERIES, J TOXICOL SCI, 32, PP. 97-101, (2007); HUANG S.S., YANG H.Y., LIN Y.C., CHAN C.H., LOW-DOSE VENLAFAXINE-INDUCED SEVERE RHABDOMYOLYSIS: A CASE REPORT, GEN HOSP PSYCHIATRY, 34, PP. 436-437, (2012); AITHAL G.P., WATKINS P.B., ANDRADE R.J., LARREY D., MOLOKHIA M., TAKIKAWA H., ET AL., CASE DEFINITION AND PHENOTYPE STANDARDIZATION IN DRUG-INDUCED LIVER INJURY, CLIN PHARMACOL THER, 89, PP. 806-815, (2011); DANAN G., BENICHOU C., CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS – I. A NOVEL METHOD BASED ON THE CONCLUSIONS OF INTERNATIONAL CONSENSUS MEETINGS: APPLICATION TO DRUG-INDUCED LIVER INJURIES, J CLIN EPIDEMIOL, 46, PP. 1323-1330, (1993); BENICHOU C., DANAN G., FLAHAULT A., CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS – II. AN ORIGINAL MODEL FOR VALIDATION OF DRUG CAUSALITY ASSESSMENT METHODS: CASE REPORTS WITH POSITIVE RECHALLENGE, J CLIN EPIDEMIOL, 46, PP. 1331-1336, (1993); THESTRUP-PEDERSEN K., ADVERSE REACTIONS IN THE SKIN FROM ANTI-HYPERTENSIVE DRUGS, DAN MED BULL, 34, PP. 3-5, (1987); GONZALEZ P., SORIANO V., LOPEZ P., NIVEIRO E., ANAPHYLAXIS TO PROTON PUMP INHIBITORS, ALLERGOL IMMUNOPATHOL (MADR), 30, PP. 342-343, (2002); AVANCINI J., MARAGNO L., SANTI C.G., CRIADO P.R., DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS/DRUG-INDUCED HYPERSENSITIVITY SYNDROME: CLINICAL FEATURES OF 27 PATIENTS, CLIN EXP DERMATOL, 40, PP. 851-859, (2015); DESCAMPS V., RANGER-ROGEZ S., DRESS SYNDROME, JOINT BONE SPINE, 81, PP. 15-21, (2014); GRESSIER L., PRUVOST-BALLAND C., DUBERTRET L., VIGUIER M., ATORVASTATIN-INDUCED DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ANN DERMATOL VENEREOL, 136, PP. 50-53, (2009); BOURNEAU-MARTIN D., LECLECH C., JAMET A., DRABLIER G., TRENQUE T., JUENGEL K., ET AL., OMEPRAZOLE-INDUCED DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EUR J DERMATOL, 24, PP. 413-415, (2014); NACI H., BRUGTS J., ADES T., COMPARATIVE TOLERABILITY AND HARMS OF INDIVIDUAL STATINS: A STUDY-LEVEL NETWORK META-ANALYSIS OF 246 955 PARTICIPANTS FROM 135 RANDOMIZED, CONTROLLED TRIALS, CIRC CARDIOVASC QUAL OUTCOMES, 6, PP. 390-399, (2013); BRUGUERA M., JOYA P., RODES J., HEPATITIS ASSOCIATED WITH TREATMENT WITH LOVASTATIN. PRESENTATION OF 2 CASES, GASTROENTEROL HEPATOL, 21, PP. 127-128, (1998); BJORNSSON E., JACOBSEN E.I., KALAITZAKIS E., HEPATOTOXICITY ASSOCIATED WITH STATINS: REPORTS OF IDIOSYNCRATIC LIVER INJURY POST-MARKETING, J HEPATOL, 56, PP. 374-380, (2012); PERDICES E.V., MEDINA-CALIZ I., HERNANDO S., ORTEGA A., MARTIN-OCANA F., NAVARRO J.M., ET AL., HEPATOTOXICITY ASSOCIATED WITH STATIN USE: ANALYSIS OF THE CASES INCLUDED IN THE SPANISH HEPATOTOXICITY REGISTRY, REV ESP ENFERM DIG, 106, PP. 246-254, (2014); GOLDBERG I., ISMAN G., SHIRAZI I., BRENNER S., INTERFERON-GAMMA (INF-GAMMA) RELEASE TEST CAN DETECT CUTANEOUS ADVERSE EFFECTS TO STATINS, INT J DERMATOL, 48, PP. 1370-1375, (2009); ADAMS A.E., BOBROVE A.M., GILLIAM A.C., STATINS AND ‘CHAMELEON-LIKE’ CUTANEOUS ERUPTIONS: SIMVASTATIN-INDUCED ACRAL CUTANEOUS VESICULOBULLOUS AND PUSTULAR ERUPTION IN A 70-YEAR-OLD MAN, J CUTAN MED SURG, 14, PP. 207-211, (2010); TAN J., PRETORIUS C.F., FLANAGAN P.V., PAIS A., ADVERSE DRUG REACTION: ROSUVASTATIN AS A CAUSE FOR ISCHAEMIC COLITIS IN A 64-YEAR-OLD WOMAN, BMJ CASE REP, 2012, (2012); WILINSKI J., DABROWSKI M., SAFETY AND TOLERABILITY OF THE USE OF ATORVASTATIN 40 MG IN COMMON DAILY PRACTICE IN SHORT-TERM OBSERVATION IN 3227 PATIENTS, PRZEGL LEK, 70, PP. 373-376, (2013); MARQUES-VIDAL P., PECOUD A., HAYOZ D., PACCAUD F., MOOSER V., WAEBER G., ET AL., PREVALENCE AND CHARACTERISTICS OF VITAMIN OR DIETARY SUPPLEMENT USERS IN LAUSANNE, SWITZERLAND: THE COLAUS STUDY, EUR J CLIN NUTR, 63, PP. 273-281, (2009); SCHWAB S., HEIER M., SCHNEIDER A., FISCHER B., HUTH C., PETERS A., ET AL., THE USE OF DIETARY SUPPLEMENTS AMONG OLDER PERSONS IN SOUTHERN GERMANY – RESULTS FROM THE KORA-AGE STUDY, J NUTR HEALTH AGING, 18, PP. 510-519, (2014); BARNES J., MILLS S.Y., ABBOT N.C., WILLOUGHBY M., ERNST E., DIFFERENT STANDARDS FOR REPORTING ADRS TO HERBAL REMEDIES AND CONVENTIONAL OTC MEDICINES: FACE-TO-FACE INTERVIEWS WITH 515 USERS OF HERBAL REMEDIES, BR J CLIN PHARMACOL, 45, PP. 496-500, (1998); BARNES J., PHARMACOVIGILANCE OF HERBAL MEDICINES: A UK PERSPECTIVE, DRUG SAF, 26, PP. 829-851, (2003); PRASAD G.V., WONG T., MELITON G., BHALOO S., RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, PP. 1200-1201, (2002); ROSELLE H., EKATAN A., TZENG J., SAPIENZA M., KOCHER J., SYMPTOMATIC HEPATITIS ASSOCIATED WITH THE USE OF HERBAL RED YEAST RICE, ANN INTERN MED, 149, PP. 516-517, (2008); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, (2011); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS: BUYER BEWARE!, ARCH INTERN MED, 170, PP. 1722-1727, (2010); AVULA B., COHEN P.A., WANG Y.H., SAGI S., FENG W., WANG M., ET AL., CHEMICAL PROFILING AND QUANTIFICATION OF MONACOLINS AND CITRININ IN RED YEAST RICE COMMERCIAL RAW MATERIALS AND DIETARY SUPPLEMENTS USING LIQUID CHROMATOGRAPHY-ACCURATE QTOF MASS SPECTROMETRY: CHEMOMETRICS APPLICATION, J PHARM BIOMED ANAL, 100, PP. 243-253, (2014)","G. MAZZANTI; DEPARTMENT OF PHYSIOLOGY AND PHARMACOLOGY ‘VITTORIO ERSPAMER’, SAPIENZA UNIVERSITY OF ROME, ROME, PIAZZALE ALDO MORO 5, 00185, ITALY; EMAIL: GABRIELA.MAZZANTI@UNIROMA1.IT","BLACKWELL PUBLISHING LTD","ENGLISH","BR. J. CLIN. PHARMACOL.","ARTICLE","ISI","2-S2.0-85010216408","BR J CLIN PHARMACOL","SAPIENZA UNIVERSITY OF ROME;POISON CONTROL CENTER;UNIVERSITY OF BOLOGNA;NATIONAL INSTITUTE OF HEALTH;NATIONAL INSTITUTE OF HEALTH","NOTREPORTED;SAPIENZA UNIVERSITY OF ROME;NOTREPORTED",NA,"MAZZANTI G, 2017, BR J CLIN PHARMACOL","MAZZANTI G, 2017, BR J CLIN PHARMACOL"
"KIM J;KIM S;KIM S;LEE E;KIM J;CHO K","KIM, JAE-YONG (54179286000); KIM, SEONG-MIN (47461469300); KIM, SUK-JEONG (57193310178); LEE, EUN-YOUNG (57204082360); KIM, JAE-RYONG (7601360934); CHO, KYUNG-HYUN (7403956966)","CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLEAGED SUBJECTS",2017,"INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE","39","10",32,"10.3892/ijmm.2017.2907","DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, COLLEGE OF MEDICINE, YEUNGNAM UNIVERSITY, DAEGU, 705-717, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA","IT IS WELL-KNOWN THAT POLICOSANOL CAN IMPROVE SERUM LIPID PROFILES, ALTHOUGH THE PHYSIOLOGICAL MECHANISM IS STILL UNKNOWN. HERE, WE INVESTIGATED FUNCTIONAL AND STRUCTURAL CHANGES IN LIPOPROTEINS AFTER CONSUMPTION OF POLICOSANOL. TO INVESTIGATE THE PHYSIOLOGICAL EFFECT OF POLICOSANOL, WE ANALYZED SERUM PARAMETERS IN YOUNG NON-SMOKER (YN; N=7, 24.0±2.4 YEARS), YOUNG SMOKER (YS; N=7, 26.3±1.5 YEARS), AND MIDDLE-AGED SUBJECTS (MN; N=11, 52.5±9.8 YEARS) WHO CONSUMED POLICOSANOL DAILY (10 MG/DAY) FOR 8 WEEKS. AFTER 8 WEEKS, SYSTOLIC BLOOD PRESSURE WAS SIGNIFICANTLY LOWERED TO 4% (7 MMHG, P=0.022) FROM INITIAL LEVELS IN THE YS AND MN GROUPS. MOISTURE CONTENT OF FACIAL SKIN INCREASED UP TO 38 AND 18% FROM INITIAL LEVELS IN THE YS AND MN GROUPS, RESPECTIVELY. SERUM TRIGLYCERIDE (TG) LEVELS DECREASED TO 28 AND 26% FROM INITIAL LEVELS IN THE YN AND MN GROUPS, RESPECTIVELY. THE PERCENTAGE OF HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) IN TOTAL CHOLESTEROL WAS ELEVATED IN ALL SUBJECTS (YN, 36%; YS, 35%; MN, 8%) AFTER 8 WEEKS OF POLICOSANOL CONSUMPTION. ALL GROUPS SHOWED A REDUCTION IN SERUM GLUCOSE AND URIC ACID LEVELS. SERUM CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY WAS SIGNIFICANTLY DIMINISHED UP TO 21 AND 32% FROM INITIAL LEVELS IN THE YN AND MN GROUPS, RESPECTIVELY. AFTER 8 WEEKS, OXIDATION OF THE LOW-DENSITY LIPOPROTEIN FRACTION WAS MARKEDLY REDUCED ACCOMPANIED BY DECREASED APOLIPOPROTEIN B (APOB) FRAGMENTATION. IN THE HDL FRACTION, PARAOXONASE ACTIVITY WAS ELEVATED BY 17% ALONG WITH ELEVATION OF APOA-I AND CHOLESTEROL CONTENTS. ELECTRON MICROSCOPY REVEALED THAT THE SIZE AND NUMBER OF HDL PARTICLES INCREASED AFTER 8 WEEKS, AND THE YS GROUP SHOWED A 2-FOLD INCREASE IN PARTICLE SIZE. DAILY CONSUMPTION OF POLICOSANOL FOR 8 WEEKS RESULTED IN LOWERED BLOOD PRESSURE, REDUCED SERUM TG LEVEL AND CETP ACTIVITY, AND ELEVATED HDL-C CONTENTS. THESE FUNCTIONAL ENHANCEMENTS OF HDL CAN PREVENT AND/OR ATTENUATE AGING-RELATED DISEASES, HYPERTENSION, DIABETES AND CORONARY HEART DISEASE.","APOA-I; BLOOD PRESSURE; CHOLESTERYL ESTER TRANSFER PROTEIN; FUNCTIONALITY; HIGH-DENSITY LIPOPROTEIN; POLICOSANOL","ADULT; BLOOD PRESSURE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS; FATTY ALCOHOLS; HUMANS; HYPERTENSION; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; TIME FACTORS; TRIGLYCERIDES; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; URIC ACID; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; BODY FAT; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FRACTIONATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRAPERITONEAL FAT; LIPID PEROXIDATION; MALE; MIDDLE AGED; NORMAL HUMAN; PARTICLE SIZE; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CORONARY DISEASE; DIABETES MELLITUS; DRUG EFFECTS; HYPERTENSION; INTRAABDOMINAL FAT; METABOLISM; TIME FACTOR","","","CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); OLIARO-BOSSO S., CALCIO G.E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); GUO Y.L., XU R.X., ZHU C.G., WU N.Q., CUI Z.P., LI J.J., POLICOSANOL ATTENUATES STATIN-INDUCED INCREASES IN SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WHEN COMBINED WITH ATORVASTATIN, EVID BASED COMPLEMENT ALTERNAT MED, 2014, (2014); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); KRESANOV P., VASANKARI T., AHOTUPA M., KAIKKONEN J., HUTRI-KAHONEN N., JUONALA M., KAHONEN M., LEHTIMAKI T., VIIKARI J., RAITAKARI O.T., PARAOXONASE-1 AND OXIDIZED LIPOPROTEIN LIPIDS THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY, ATHEROSCLEROSIS, 241, PP. 502-506, (2015); MANI P., UNO K., ST JOHN J., TUZCU E.M., NISSEN S.E., NICHOLLS S.J., RELATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: APOLIPOPROTEIN A-I RATIO TO PROGRESSION OF CORONARY ATHEROSCLEROSIS IN STATIN-TREATED PATIENTS, AM J CARDIOL, 114, PP. 681-685, (2014); CHANTEPIE S., BOCHEM A.E., CHAPMAN M.J., HOVINGH G.K., KONTUSH A., HIGH-DENSITY LIPOPROTEIN (HDL) PARTICLE SUBPOPULATIONS IN HETEROZYGOUS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) DEFICIENCY: MAINTENANCE OF ANTIOXIDATIVE ACTIVITY, PLOS ONE, 7, (2012); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); BENZIE I.F., STRAIN J.J., THE FERRIC REDUCING ABILITY OF PLASMA (FRAP) AS A MEASURE OF 'ANTIOXIDANT POWER': THE FRAP ASSAY, ANAL BIOCHEM, 239, PP. 70-76, (1996); PARK K.H., KIM J.R., LEE J.S., LEE H., CHO K.H., ETHANOL OR WATER EXTRACT OF PURPLE SWEET POTATO EXHIBITS ANTI-ATHEROSCLEROTIC ACTIVITY AND INHIBITORY ACTIVITY AGAINST PROTEIN GLYCATION, J MED FOOD, 13, PP. 91-98, (2010); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J CLIN INVEST, 34, PP. 1345-1353, (1955); MARKWELL M.A., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-210, (1978); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); CHO K.H., SYNTHESIS OF RECONSTITUTED HIGH-DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOL CELLS, 27, PP. 291-297, (2009); CHO K.H., SHIN D.G., BAEK S.H., KIM J.R., MYOCARDIAL INFARCTION PATIENTS SHOWED ALTERED LIPOPROTEIN PROPERTIES AND FUNCTIONS WHEN COMPARED WITH STABLE ANGINA PECTORIS PATIENTS, EXP MOL MED, 41, PP. 67-76, (2009); ECKERSON H.W., WYTE C.M., LA DU B.N., THE HUMAN SERUM PARAOXONASE/ARYLESTERASE POLYMORPHISM, AM J HUM GENET, 35, PP. 1126-1138, (1983); PARK K.H., SHIN D.G., KIM J.R., HONG J.H., CHO K.H., THE FUNCTIONAL AND COMPOSITIONAL PROPERTIES OF LIPOPROTEINS ARE ALTERED IN PATIENTS WITH METABOLIC SYNDROME WITH INCREASED CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY, J MOL MED, 25, PP. 129-136, (2010); PARK K.H., KIM J.Y., CHOI I., KIM J.R., CHO K.H., Ω-6 (18:2) AND Ω-3 (18:3) FATTY ACIDS IN RECONSTITUTED HIGH-DENSITY LIPOPROTEINS SHOW DIFFERENT FUNCTIONALITY OF ANTI-ATHEROSCLEROTIC PROPERTIES AND EMBRYO TOXICITY, J NUTR BIOCHEM, 26, PP. 1613-1621, (2015); CHO K.H., PARK S.H., PARK J.E., KIM Y.O., CHOI I., KIM J.J., KIM J.R., THE FUNCTION, COMPOSITION, AND PARTICLE SIZE OF HIGH-DENSITY LIPOPROTEIN WERE SEVERELY IMPAIRED IN AN OLIGURIC PHASE OF HEMORRHAGIC FEVER WITH RENAL SYNDROME, CLIN BIOCHEM, 41, PP. 56-64, (2008); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. M186-M192, (2001); MINAMI J., ISHIMITSU T., MATSUOKA H., EFFECTS OF SMOKING CESSATION ON BLOOD PRESSURE AND HEART RATE VARIABILITY IN HABITUAL SMOKERS, HYPERTENSION, 33, PP. 586-590, (1999); KIM J.H., SHIM K.W., YOON Y.S., LEE S.Y., KIM S.S., OH S.W., CIGARETTE SMOKING INCREASES ABDOMINAL AND VISCERAL OBESITY BUT NOT OVERALL FATNESS: AN OBSERVATIONAL STUDY, PLOS ONE, 7, (2012); FEIG D.I., SERUM URIC ACID AND THE RISK OF HYPERTENSION AND CHRONIC KIDNEY DISEASE, CURR OPIN RHEUMATOL, 26, PP. 176-185, (2014); LIMA W.G., MARTINS-SANTOS M.E., CHAVES V.E., URIC ACID AS A MODULATOR OF GLUCOSE AND LIPID METABOLISM, BIOCHIMIE, 116, PP. 17-23, (2015); PARK K.H., SHIN D.G., KIM J.R., CHO K.H., SENESCENCE-RELATED TRUNCATION AND MULTIMERIZATION OF APOLIPOPROTEIN A-I IN HIGH-DENSITY LIPOPROTEIN WITH AN ELEVATED LEVEL OF ADVANCED GLYCATED END PRODUCTS AND CHOLESTERYL ESTER TRANSFER ACTIVITY, J GERONTOL A BIOL SCI MED SCI, 65, PP. 600-610, (2015); MICHEL C.C., NANJEE M.N., OLSZEWSKI W.L., MILLER N.E., LDL AND HDL TRANSFER RATES ACROSS PERIPHERAL MICROVASCULAR ENDOTHELIUM AGREE WITH THOSE PREDICTED FOR PASSIVE ULTRAFILTRATION IN HUMANS, J LIPID RES, 56, PP. 122-128, (2015); MARSCHE G., HOLZER M., WOLF P., ANTIPSORIATIC TREATMENT EXTENDS BEYOND THE SKIN: RECOVERING OF HIGH-DENSITY LIPOPROTEIN FUNCTION, EXP DERMATOL, 23, PP. 701-704, (2014); FUJIOKA Y., ISHIKAWA Y., REMNANT LIPOPROTEINS AS STRONG KEY PARTICLES TO ATHEROGENESIS, J ATHEROSCLER THROMB, 16, PP. 145-154, (2009); BARZILAI N., ATZMON G., SCHECHTER C., SCHAEFER E.J., CUPPLES A.L., LIPTON R., CHENG S., SHULDINER A.R., UNIQUE LIPOPROTEIN PHENOTYPE AND GENOTYPE ASSOCIATED WITH EXCEPTIONAL LONGEVITY, JAMA, 290, PP. 2030-2040, (2003); KIM S.M., LIM S.M., YOO J.A., WOO M.J., CHO K.H., CONSUMPTION OF HIGH-DOSE VITAMIN C (1250 MG PER DAY) ENHANCES FUNCTIONAL AND STRUCTURAL PROPERTIES OF SERUM LIPOPROTEIN TO IMPROVE ANTI-OXIDANT, ANTI-ATHEROSCLEROTIC, AND ANTI-AGING EFFECTS VIA REGULATION OF ANTI-INFLAMMATORY MICRORNA, FOOD FUNCT, 6, PP. 3604-3612, (2015); GOTTO A.M., MOON J.E., PHARMACOTHERAPIES FOR LIPID MODIFICATION: BEYOND THE STATINS, NAT REV CARDIOL, 10, PP. 560-570, (2013); HAAS M.J., ONSTEAD-HAAS L.M., SZAFRAN-SWIETLIK A., KOJANIAN H., DAVIS T., ARMSTRONG P., WONG N.C., MOORADIAN A.D., INDUCTION OF HEPATIC APOLIPOPROTEIN A-I GENE EXPRESSION BY THE ISOFLAVONES QUERCETIN AND ISOQUERCETRIN, LIFE SCI, 110, PP. 8-14, (2014); EGERT S., BOSY-WESTPHAL A., SEIBERL J., KURBITZ C., SETTLER U., PLACHTA-DANIELZIK S., WAGNER A.E., FRANK J., SCHREZENMEIR J., RIMBACH G., ET AL., QUERCETIN REDUCES SYSTOLIC BLOOD PRESSURE AND PLASMA OXIDISED LOW-DENSITY LIPOPROTEIN CONCENTRATIONS IN OVERWEIGHT SUBJECTS WITH A HIGH-CARDIOVASCULAR DISEASE RISK PHENOTYPE: A DOUBLE-BLINDED, PLACEBO-CONTROLLED CROSS-OVER STUDY, BR J NUTR, 102, PP. 1065-1074, (2009); NAZRATUN N., MAHMOOD A.A., KUPPUSAMY U.R., AHMAD T.S., TAN S.Y., DIABETES MELLITUS EXACERBATES ADVANCED GLYCATION END PRODUCT ACCUMULATION IN THE VEINS OF END-STAGE RENAL FAILURE PATIENTS, VASC MED, 11, PP. 245-250, (2006); SEMBA R.D., SUN K., SCHWARTZ A.V., VARADHAN R., HARRIS T.B., SATTERFIELD S., GARCIA M., FERRUCCI L., NEWMAN A.B., SERUM CARBOXYMETHYL-LYSINE, AN ADVANCED GLYCATION END PRODUCT, IS ASSOCIATED WITH ARTERIAL STIFFNESS IN OLDER ADULTS, J HYPERTENS, 33, PP. 797-803, (2015); PHILLIPS C.M., PERRY I.J., LIPOPROTEIN PARTICLE SUBCLASS PROFILES AMONG METABOLICALLY HEALTHY AND UNHEALTHY OBESE AND NON-OBESE ADULTS: DOES SIZE MATTER, ATHEROSCLEROSIS, 242, PP. 399-406, (2015); KONTUSH A., CHAPMAN M.J., WHY IS HDL FUNCTIONALLY DEFICIENT IN TYPE 2 DIABETES, CURR DIAB REP, 8, PP. 51-59, (2008); KASTELEIN J.J., BESSELING J., SHAH S., BERGERON J., LANGSLET G., HOVINGH G.K., AL-SAADY N., KOEIJVOETS M., HUNTER J., JOHNSON-LEVONAS A.O., ET AL., ANACETRAPIB AS LIPID-MODIFYING THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (REALIZE): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY, LANCET, 385, PP. 2153-2161, (2015)","K.-H. CHO; DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","SPANDIDOS PUBLICATIONS","ENGLISH","INT. J. MOL. MED.","ARTICLE","ISI","2-S2.0-85018527976","INT J MOL MED","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"KIM J-Y, 2017, INT J MOL MED","KIM J-Y, 2017, INT J MOL MED"
"YUK H;RYU H;KIM D;PARK M;SEO W;JEONG S;OH S","YUK, HEUNG JOO (36969874600); RYU, HYUNG WON (9042289900); KIM, DOO-YOUNG (55791606600); PARK, MI HYEON (57204519428); SEO, WOO DUCK (8921329600); JEONG, SEONG HUN (57212175840); OH, SEI-RYANG (55573210200)","COMPARISON OF FLAVONOID AND POLICOSANOL PROFILES IN KOREAN WINTERSPINACH SPINACIA OLERACEA L CULTIVATED IN DIFFERENT REGIONS",2019,"FOOD CHEMISTRY","279","6",18,"10.1016/j.foodchem.2018.11.143","NATURAL MEDICINE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, CHEONG-JU SI, 28116, CHUNGCHEONGBUK-DO, SOUTH KOREA;NATURAL MEDICINE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, CHEONG-JU SI, 28116, CHUNGCHEONGBUK-DO, SOUTH KOREA;NATURAL MEDICINE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, CHEONG-JU SI, 28116, CHUNGCHEONGBUK-DO, SOUTH KOREA;NATURAL MEDICINE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, CHEONG-JU SI, 28116, CHUNGCHEONGBUK-DO, SOUTH KOREA;DIVISION OF CROP FOUNDATION, NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, 55365, JEOLLABUK-DO, SOUTH KOREA;NAMHAE GARLIC RESEARCH INSTITUTE, NAMHAE, 52430, GYEONGNAM, SOUTH KOREA;NATURAL MEDICINE RESEARCH CENTER, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, CHEONG-JU SI, 28116, CHUNGCHEONGBUK-DO, SOUTH KOREA","SPINACH INTAKE HAS LONG BEEN HIGHLIGHTED GLOBALLY BECAUSE OF ITS OUTSTANDING NUTRITIONAL ASPECTS. IN THIS STUDY, CHANGES IN FLAVONOIDS, A REPRESENTATIVE FUNCTIONAL PHYTOCHEMICAL GROUP, WERE INVESTIGATED BY UPLC–QTOF MS WITH MULTIVARIATE ANALYSIS OF WINTER-SPINACH SAMPLES FROM THREE DIFFERENT CULTIVATION REGIONS IN KOREA. FROM THE PARTIAL LEAST SQUARES DISCRIMINANT ANALYSIS (PLS-DA), THE DIFFERENCES OF FLAVONOIDS AMONG THE GEOGRAPHIC LOCATIONS WERE CLEARLY DISTINGUISHED. SEVEN SPINACH FLAVONOIDS (2, PATULETIN-3-O-GLUCOSYL-(1 → 6)-GLUCOSIDE; 4, SPINACETIN-3-O-GLUCOSYL-(1 → 6)-[APIOSYL-(1 → 2)]-GLUCOSIDE; 8, PATULETIN 3-O-(2″-FERULOYLGLUCOSYL)-(1 → 6)-[APIOSYL-(1 → 2)]-GLUCOSIDE; 11, SPINACETIN 3-O-(2″-FERULOYLGLUCOSYL)-(1 → 6)-[APIOSYL-(1 → 2)]-GLUCOSIDE; 12, PATULETIN 3-O-(2′’-FERULOYLGLUCOSYL)-(1 → 6)-GLUCOSIDE; 18, 5,3′,4′-TRIHYDROXY−3-METHOXY-6:7-METHYLENDIOXYFLAVONE-4′-GLUCURONIDE; 20, 5,4′-DIHYDROXY-3,3′-DIMETHOXY-6:7-METHYLENDIOXYFLAVONE-4′-GLUCURONIDE) WERE EVALUATED AS KEY MARKERS AMONG 20 ISOLATED METABOLITES. INTERESTINGLY, THE CONTENTS OF INDIVIDUAL MARKER WERE SIGNIFICANTLY DIFFERENT AMONG THE GROUPS, THOUGH TOTAL AMOUNT OF FLAVONOIDS WERE ALMOST SAME. ADDITIONALLY, POLICOSANOLS (PCS) IN THE WINTER-SPINACH WAS EXAMINED QUANTITATIVELY USING GC–MS FOR THE FIRST TIME. THE PCS WERE ANALYZED AS THE RANGE OF 53.6–59.2 MG/100 G, INDICATE THAT THE WINTER-SPINACH IS A BENEFICIAL SOURCE OF PCS. © 2018 ELSEVIER LTD","FLAVONOID; POLICOSANOL; SPINACH; SPINACIA OLERACEA L.; UPLC–QTOF MS","BIOMARKERS; FATTY ALCOHOLS; FLAVONOIDS; FOOD ANALYSIS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; REPUBLIC OF KOREA; SPINACIA OLERACEA; DISCRIMINANT ANALYSIS; FLAVONOIDS; LEAST SQUARES APPROXIMATIONS; MULTIVARIANT ANALYSIS; FLAVONOID; PATULETIN 3 O (2'' FERULOYLGLUCOSYL) (1-6) [APIOSYL (1-2)] GLUCOSIDE; PATULETIN 3 O GLUCOSYL (1-6) GLUCOSIDE; PATULETIN 3 O GLUCOSYL (1-6) [APIOSYL (1-2)] GLUCOSIDE; POLICOSANOL; RHAMNETIN 3 O GLUCOSYL (1-5) [APIOSYL (1-2)] GLUCOSIDE; SPINACETIN 3 O (2'' FERULOYLGLUCOSYL) (1-6) [APIOSYL (1-2)] GLUCOSIDE; SPINACETIN 3 O GLUCOSYL (1-6) [APIOSYL (1-2)] GLUCOSIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FATTY ALCOHOL; FLAVONOID; POLICOSANOL; FLAVONOID; GEOGRAPHIC LOCATION; MULTI VARIATE ANALYSIS; PARTIAL LEAST SQUARES DISCRIMINANT ANALYSES (PLSDA); PHYTOCHEMICAL; POLICOSANOL; SPINACH; SPINACIA OLERACEA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; GEOGRAPHY; GERMINATION; KOREA; METABOLOMICS; MULTIPLE SCLEROSIS; NONHUMAN; PARTIAL LEAST SQUARES REGRESSION; PLANT GROWTH; QUALITY CONTROL; SPINACH; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WINTER; CHEMISTRY; FOOD ANALYSIS; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM; MULTIVARIATE ANALYSIS; PROCEDURES; SOUTH KOREA; SPINACH; STATISTICS AND NUMERICAL DATA; CARBOHYDRATES","MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP; KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, KRIBB","THIS WORK WAS SUPPORTED BY THE KRIBB RESEARCH INITIATIVE PROGRAM FUNDED BY THE MINISTRY OF SCIENCE AND ICT (MSIT) OF REPUBLIC OF KOREA. ","ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 5359-5362, (2006); AISYAH S., VINCKEN J.P., ANDINI S., MARDIAH Z., GRUPPEN H., COMPOSITIONAL CHANGES IN (ISO)FLAVONOIDS AND ESTROGENIC ACTIVITY OF THREE EDIBLE LUPINUS SPECIES BY GERMINATION AND RHIZOPUS-ELICITATION, PHYTOCHEMISTRY, 122, PP. 65-75, (2016); AN H.H., YUK H.J., LIM D.Y., NHO C.W., LEE D.H., RYU H.W., OH S.R., EVALUATION OF PHYTOCHEMICALS IN AGASTACHE RUGOSA (FISCH. & C.A.MEY.) KUNTZE AT DIFFERENT GROWTH STAGES BY UPLC-QTOF-MS, INDUSTRIAL CROPS & PRODUCTS, 112, PP. 608-616, (2018); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, PP. 583-591, (2012); BERGQUIST S.A., GERTSSON U.E., KNUTHSEN P., OLSSON M.E., FLAVONOIDS IN BABY SPINACH (SPINACIA OLERACEA L.): CHANGES DURING PLANT GROWTH AND STORAGE, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 9459-9464, (2005); BRERETON R.G., LLOYD G.R., PARTIAL LEASE SQUARES DISCRIMINANT ANALYSIS: TAKING THE MAGIC AWAY, JOURNAL OF CHEMOMETRICS, 28, PP. 213-225, (2014); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLINICAL DRUG INVESTIGATION, 23, PP. 639-650, (2003); CHO M.J., HOWARD L.R., PRIOR R.L., MORELOCK T., FLAVONOID CONTENT AND ANTIOXIDANT CAPACITY OF SPINACH GENOTYPES DETERMINED BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 88, PP. 1099-1106, (2008); CHOI S.J., PARK S.Y., PARK J.S., PARK S.K., JUNG M.Y., CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA (CAMELLIA SINENSIS) LEAVES, FOOD CHEMISTRY, 204, PP. 94-101, (2016); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM AND BRAN, FOOD CHEMISTRY, 119, PP. 1246-1249, (2010); FERRERES F., CASTANER M., TOMAS-BARBERAN F.A., ACYLATED FLAVONOL GLYCOSIDES FROM SPINACH LEAVES (SPINACIA OLERACEA), PHYTOCHEMISTRY, 45, PP. 1701-1705, (1997); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); HOWARD L.R., PANDJAITAN N., MORELOCK T., GIL M.I., ANTIOXIDANT CAPACITY AND PHENOLIC CONTENT OF SPINACH AS AFFECTED BY GENETICS AND GROWING SEASON, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 50, PP. 5891-5896, (2002); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEEWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); ISHAKA A., UMAR IMAM M., MAHAMUD R., ZUKI A.B., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INTERNATIONAL JOURNAL OF NANOMEDICINE, 9, PP. 2261-2269, (2014); JUANIZ I., LUDWIG I.A., HUARTE E., PEREIRA-CARO G., MORENO-ROJAS J.M., CID C., DE PENA M.P., INFLUENCE OF HEAT TREATMENT ON ANTIOXIDANT CAPACITY AND (POLY)PHENOLIC COMPOUNDS OF SELECTED VEGETABLES, FOOD CHEMISTRY, 197, PP. 466-473, (2016); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, JOURNAL OF FOOD SCIENCE, 76, PP. 891-899, (2011); JUSTESEN U., COLLISION-INDUCED FRAGMENTATION OF DEPROTONATED METHOXYLATED FLAVONOIDS, OBTAINED BY ELECTROSPRAY IONIZATION MASS SPECTROMETRY, JOURNAL OF MASS SPECTROMETRY, 36, PP. 169-178, (2001); KIM D.Y., KIM S.H., AHN H.M., LIM S.R., OH J.S., CHOI S.G., CHOI H.K., DIFFERENTIATION OF HIGHBUSH BLUEBERRY (VACCINIUM CORYMBOSUM L.) FRUIT CULTIVARS BY GC–MS-BASED METABOLIC PROFILING, JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY, 58, PP. 21-28, (2015); KIM T.J., LEE K.B., BAEK S.A., CHOI J.H., HA S.H., LIM S.H., KIM J.K., DETERMINATION OF LIPOPHILIC METABOLITES FOR SPECIES DISCRIMINATION AND QUALITY ASSESSMENT OF NINE LEAFY VEGETABLES, JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY, 58, PP. 909-918, (2015); LISIEWSK Z., KMIECIK W., GEBCZYNSKI P., SOBCZYNSKA L., AMINO ACID PROFILE OF RAW AND AS-EATEN PRODUCTS OF SPINACH (SPINACIA OLERACEA L.), FOOD CHEMISTRY, 126, PP. 460-465, (2011); MACIEJEWSKA U., BOGATEK R., GLUCOSE CATABOLISM IN LEAVES OF COLD-TREATED WINTER RAPE PLANTS, JOURNAL OF PLANT PHYSIOLOGY, 159, PP. 397-402, (2002); MANACH C., SCALBERT A., MORAND C., REMESY C., JIMENEZ L., POLYPHENOLS: FOOD SOURCES AND BIOAVAILABILITY, AMERICAN JOURNAL OF CLINICAL NUTRITION, 79, PP. 727-747, (2004); RYU H.W., SONG H.W., KIM K.O., PARK Y.J., KIM D.Y., KIM J.H., OH S.R., SECONDARY METABOLITE PROFILING AND MODULATION OF ANTIOXIDANTS INWILD AND CULTIVATED EUPHORBIA SUPINA, INDUSTRIAL CROPS AND PRODUCTS, 89, PP. 215-224, (2016); RYU H.W., YUK H.J., AN J.H., KIM D.Y., SONG H.H., OH S.R., COMPARISON OF SECONDARY METABOLITE CHANGES IN CAMELLIA SINENSIS LEAVES DEPENDING ON THE GROWTH STAGE, FOOD CONTROL, 73, PP. 916-921, (2017); SCHULZ E., TOHGE T., ZUTHER E., FERNIE A.R., HINCHA D.K., FLAVONOIDS ARE DETERMINANTS OF FREEZING TOLERANCE AND COLD ACCLIMATION IN ARABIDOPSIS THALIANA, SCIENTIFIC REPORTS, 6, (2016); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., PARK K.H., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5’-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 61, PP. 1117-1123, (2013); SHEPHERD T., WYNNE GRIFFITHS D., THE EFFECTS OF STRESS ON PLANT CUTICULAR WAXES, NEW PHYTOLOGIST, 171, PP. 469-499, (2006); SONG H.H., RYU H.W., KIM H.S., KIM C.S., HYUN H.J., LEE H.K., OH S.R., A METABOLOMICS APPROACH TO IDENTIFY FACTORS INFLUENCING THEIR ACTIVITY RELATIVE TO OLEANOLIC ACID CONTENTS IN KOREAN MISTLETOE TYPES, JOURNAL OF FUNCTIONAL FOODS, 22, PP. 64-72, (2016); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, PP. 5552-5558, (2007); WATANABE M., AYUGASE J., EFFECT OF LOW TEMPERATURE ON FLAVONOIDS, OXYGEN RADICAL ABSORBANCE CAPACITY VALUES AND MAJOR COMPONENTS OF WINTER SWEET SPINACH (SPINACIA OLERACEA L.), JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 95, PP. 2095-2104, (2015); YOON Y.E., KUPPUSAMY S., CHO K.M., KIM P.J., KWACK Y.B., LEE Y.B., INFLUENCE OF COLD STRESS ON CONTENTS OF SOLUBLE SUGARS, VITAMIN C AND FREE AMINO ACIDS INCLUDING GAMMA-AMINOBUTYRIC ACID (GABA) IN SPINACH (SPINACIA OLERACEA), FOOD CHEMISTRY, 215, PP. 185-192, (2017)","S.H. JEONG; NAMHAE GARLIC RESEARCH INSTITUTE, NAMHAE, 52430, SOUTH KOREA; EMAIL: POI1977@HANMAIL.NET","ELSEVIER LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-85058435998","FOOD CHEM","KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;NATIONAL INSTITUTE OF CROP SCIENCE;NAMHAE GARLIC RESEARCH INSTITUTE;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY","NOTREPORTED;NAMHAE GARLIC RESEARCH INSTITUTE;NOTREPORTED",NA,"YUK HJ, 2019, FOOD CHEM","YUK HJ, 2019, FOOD CHEM"
"DAS G;PATRA J;CHOI J;BAEK K","DAS, GITISHREE (55994808400); PATRA, JAYANTA KUMAR (24076666800); CHOI, JAEHYUK (55722494300); BAEK, KWANG-HYUN (13303283100)","RICE GRAIN A RICH SOURCE OF NATURAL BIOACTIVE COMPOUNDS",2017,"PAKISTAN JOURNAL OF AGRICULTURAL SCIENCES","54","11",12,"10.21162/PAKJAS/17.2973","RESEARCH INSTITUTE OF BIOTECHNOLOGY & MEDICAL CONVERGED SCIENCE, DONGGUK UNIVERSITY, ILSANDONG-GU, SEOUL, 10326, GYEONGGI-DO, SOUTH KOREA;RESEARCH INSTITUTE OF BIOTECHNOLOGY & MEDICAL CONVERGED SCIENCE, DONGGUK UNIVERSITY, ILSANDONG-GU, SEOUL, 10326, GYEONGGI-DO, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, GYEONGBUK, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, GYEONGBUK, SOUTH KOREA","RICE, WHICH IS THE MOST CULTIVATED CROP WORLDWIDE, IS MAINLY GROWN AS A STAPLE FOOD. THOUSANDS OF RICE VARIETIES ARE CULTIVATED; HOWEVER, THEIR NUTRITIONAL AND MEDICINAL VALUES HAVE NOT BEEN THOROUGHLY INVESTIGATED. RICE GRAIN IS RICH IN VARIOUS BIOACTIVE COMPOUNDS SUCH AS PHENOLIC COMPOUNDS, PHYTOSTEROLS, GALLIC ACID, POLYCOSANOL, ORYZANOL, TOCOPHEROL, TOCOTRIENOLS AND FERULIC ACID. FURTHERMORE, SEVERAL TYPES OF RICE AND THEIR BYPRODUCTS ARE EFFECTIVE FOR TREATMENT OF A NUMBER OF DETERIORATING DISEASES INCLUDING DYSENTERY, CANCER, DIABETES AND HEART DISEASE. THEREFORE, THE PRESENT REVIEW WAS CONDUCTED TO HIGHLIGHT DIFFERENT VARIETIES OF RICE AND THEIR MEDICINAL POTENTIALS ALONG WITH THE NUTRITIONAL COMPOSITION, BIOACTIVE COMPOUNDS AND NUTRACEUTICAL POTENTIALS OF RICE GRAIN. THE INTEGRAL INFORMATION COMBINING RICE NATURAL BIOACTIVE COMPOUNDS WITH DISEASE TREATMENT PROVIDED HEREIN WILL BE USEFUL FOR DEVELOPMENT OF DRUGS FOR THE TREATMENT OF VARIOUS DISEASES USING THE RICE-DERIVED BIOACTIVE COMPOUNDS. © 2017, UNIVERSITY OF AGRICULTURE. ALL RIGHTS RESERVED.","ANTHOCYANINS; ANTIOXIDANT; NUTRACEUTICAL; ORYZA SATIVA; PHENOLIC COMPOUNDS","","","","ABBAS A., MURTAZA S., ASLAM F., KHAWAR A., RAFIQUE S., NAHEED S., EFFECT OF PROCESSING ON NUTRITIONAL VALUE OF RICE (ORYZA SATIVA), WORLD. J. MED. SCI., 6, PP. 68-73, (2011); ABDEL A.E., YOUNG J.C., RABALSKI I., ANTHOCYANIN COMPOSITION IN BLACK, BLUE, PINK AND RED CEREAL GRAINS, J. AGRIC. FOOD CHEM., 54, PP. 4696-4704, (2006); ABUBAKAR T., MARIKKAR N., SALLEH A., AZLAN A., JIVAN M., EVALUATION OF BRANS OF DIFFERENT RICE VARIETIES FOR THEIR ANTIOXIDATIVE AND ANTIHYPERGLYCEMIC POTENTIALS, J. FOOD BIOCHEM., (2017); ANJUM F.M., PASHA I., BUGTI M.A., BUTT M.S., MINERAL COMPOSITION OF DIFFERENT RICE VARIETIES AND THEIR MILLING FRACTIONS, PAK. J. AGRI. SCI., 44, PP. 332-336, (2007); ARAB F., ALEMZADEHB I., MAGHSOUDIB V., DETERMINATION OF ANTIOXIDANT COMPONENT AND ACTIVITY OF RICE BRAN EXTRACT, SCIENTIA IRANICA C., 18, PP. 1402-1406, (2011); ASYIFAH M.N., ABD-AZIZ S., PHANG L.Y., AZLIAN M.N., BROWN RICE AS A POTENTIAL FEEDSTUFF FOR POULTRY, J. APPL. POULT. RES., 21, PP. 103-110, (2012); BERGER A., REIN D., SCHAFER A., MONNARD I., GREMAUD G., LAMBELET P., SIMILAR CHOLESTEROL-LOWERING PROPERTIES OF RICE BRAN OIL, WITH VARIED Γ-ORYZANOL, IN MILDLY HYPERCHOLESTEROLEMIC MEN, EUR. J. NUTR., 44, PP. 163-173, (2005); BHAT F.M., RIAR C.S., HEALTH BENEFITS OF TRADITIONAL RICE VARIETIES OF TEMPERATE REGIONS, MED. AROMA. PLANT., 4, 198, (2015); BOUE S.M., DAIGLE K.W., CHEN M.H., CAO H., HEIMAN M.L., ANTIDIABETIC POTENTIAL OF PURPLE AND RED RICE (ORYZA SATIVA L.) BRAN EXTRACTS, J. AGRIC. FOOD CHEM., (2016); BUNNOY A., SAENPHET K., LUMYONG S., SAENPHET S., CHOMDEJ S., MONASCUS PURPUREUS-FERMENTED THAI GLUTINOUS RICE REDUCES BLOOD AND HEPATIC CHOLESTEROL AND HEPATIC STEATOSIS CONCENTRATIONS IN DIET-INDUCED HYPER CHOLESTEROLEMIC RATS, BMC COMPLEM. ALTERN. M., 15, PP. 1-11, (2015); CHEN M.H., BERGMAN C.J., A RAPID PROCEDURE FOR ANALYSING RICE BRAN TOCOPHEROL, TOCOTRIENOL AND Γ-ORYZANOL CONTENTS, J. FOOD COMPOS. ANAL., 18, PP. 139-151, (2005); CHEN M.H., CHOI S.H., KOZUKUE N., KIM H.J., FRIEDMAN M., GROWTH INHIBITORY EFFECTS OF PIGMENTED RICE BRAN EXTRACTS AND THREE RED BRAN FRACTIONS AGAINST HUMAN CANCER CELLS: RELATIONSHIPS WITH COMPOSITION AND ANTIOXIDATIVE ACTIVITIES, J. AGRIC. FOOD CHEM., 60, PP. 9151-9161, (2012); CHEN P.N., CHU S.C., CHIOU H.L., CHIANG C.L., YANG S.F., HSIEH Y.S., CYANIDIN 3-GLUCOSIDE AND PEONIDIN 3-GLUCOSIDE INHIBIT TUMOR CELL GROWTH AND INDUCE APOPTOSIS IN VITRO AND SUPPRESS TUMOR GROWTH IN VIVO, NUTR. CANCER, 53, PP. 232-243, (2005); CHEN P., KUO W., CHIANG C., CHIOU H., HSIEH Y., CHU S., BLACK RICE ANTHOCYANINS INHIBIT CANCER CELLS INVASION VIA REPRESSIONS OF MMPS AND U-PA EXPRESSION, CHEM-BIOL. INTERACT., 163, PP. 218-229, (2006); CHO D.H., LIM S.T., GERMINATED BROWN RICE AND ITS BIO-FUNCTIONAL COMPOUNDS, FOOD CHEM, 196, PP. 259-271, (2016); CHO J.Y., MOON J.H., SEONG K.Y., PARK K.H., ANTIMICROBIAL ACTIVITY OF 4-HYDOXYBENZOIC ACID AND TRANS 4-HYDROXY BENZOIC ACID ISOLATED AND IDENTIFIED FROM RICE HULL, BIOSCI. BIOTECHNOL. BIOCHEM., 62, PP. 2273-2276, (1998); CHUNG I.M., KIM J.K., LEE J.K., KIM S.H., DISCRIMINATION OF GEOGRAPHICAL ORIGIN OF RICE (ORYZA SATIVA L.) BY MULTIELEMENT ANALYSIS USING INDUCTIVELY COUPLED PLASMA ATOMIC EMISSION SPECTROSCOPY AND MULTIVARIATE ANALYSIS, J.CEREAL SCI., 65, PP. 252-259, (2015); DAIPONMAKA W., PIYADA T., PORNTHAP T., APICHART V., PREECHA P., CHANGES OF ANTHOCYANIN CYANIDIN-3-GLUCOSIDE CONTENT AND ANTIOXIDANT ACTIVITY IN THAI RICE VARIETIES UNDER SALINITY STRESS, SCI. ASIA J., 36, PP. 286-291, (2010); DEVINDRA S., LONGVAH T., ANALYSIS OF DIGESTIBLE CARBOHYDRATES IN DIFFERENT VARIETIES OF BASMATI RICE AND OTHER POPULAR CEREAL SAMPLES BY USING HPLC-RI, WORLD J. DAIRY FOOD SCI., 6, PP. 146-151, (2011); DIMITRIOS B., SOURCES OF NATURAL PHENOLIC ANTIOXIDANTS, TRENDS FOOD SCI. TECHNOL., 17, PP. 505-512, (2006); DOUGHARI J.H., THE OCCURRENCE, PROPERTIES AND SIGNIFICANCE OF CITRININ MYCOTOXIN, J. PLANT PATHOL. MICROBIOL., 6, PP. 1-6, (2015); DUTTA H., MAHANTA C.L., SINGH V., CHANGES IN THE PROPERTIES OF RICE VARIETIES WITH DIFFERENT AMYLOSE CONTENT ON DRY HEAT PARBOILING, J. CEREAL SCI., 65, PP. 227-235, (2015); DYKES L., ROONEY L.W., PHENOLIC COMPOUNDS IN CEREAL GRAINS AND THEIR HEALTH BENEFITS, CEREAL FOODS WORLD, 52, PP. 105-111, (2007); EKASIT O., JIRAPORN B., SOME PHYSICAL CHARACTERISTICS AND BIOACTIVE COMPOUNDS OF YOUNG FLATTENED RICE (KHAO-MAO), INT. FOOD RES. J., 20, PP. 1323-1328, (2013); FEBLES C.I., ARIAS A., HARDISSON A., RODRIGUEZ-ALVAREZ C., SIERRA A., PHYTIC ACID LEVEL IN WHEAT FLOURS, J. CEREAL SCI., 36, PP. 19-23, (2002); GHOSE B., KPOGHOMOU M.A., SHAMSITDINOV H., MONDAL A.K., SARKER S., NUTRACEUTICAL POTENTIAL OF RICE AND WHEAT ANTIOXIDANTS AND THEIR IMPACTS ON HEALTH, OXID. ANTIOXID. MED. SCI., 2, PP. 245-249, (2013); GOFFMAN F.D., BERGMAN C.J., RICE KERNEL PHENOLIC CONTENT AND ITS RELATIONSHIP WITH ANTIRADICAL EFFICIENCY, J. SCI. FOOD AGRIC., 84, PP. 235-1240, (2004); GOUFO P., TRINDADE H., RICE ANTIOXIDANTS: PHENOLIC ACIDS, FLAVONOIDS, ANTHOCYANINS, PROANTHOCYANIDINS, TOCOPHEROLS, TOCOTRIENOLS, Γ-ORYZANOL AND PHYTIC ACID, FOOD SCI. NUTR., 2, PP. 75-104, (2014); GUL K., YOUSUF B., SINGH A.K., SINGH P., WANI A.A., RICE BRAN: NUTRITIONAL VALUES AND ITS EMERGING POTENTIAL FOR DEVELOPMENT OF FUNCTIONAL FOOD-A REVIEW, BIOACT. CARBOHYD. DIET. FIBR., 6, PP. 24-30, (2015); HALVORSEN B.L., HOLTE K., MYHRSTAD M.C.W., BARIKMO I., HVATTUM E., REMBERG S.F., WOLD A.B., HAFFNER K., BAUGEROD H., ANDERSEN L.F., MOSKAUG O., JACOBS D.R., BLOMHOFF R., A SYSTEMATIC SCREENING OF TOTAL ANTIOXIDANTS IN DIETARY PLANTS, J. NUTR., 132, PP. 461-471, (2002); HAYASHI S., YANASE E., A STUDY ON THE COLOR DEEPENING IN RED RICE DURING STORAGE, FOOD CHEM, 199, PP. 457-462, (2016); HEINEMANN R.J.B., FAGUNDES P.L., PINTO E.A., PENTEADO M.V.C., LANFER-MARQUEZ U.M., COMPARATIVE STUDY OF NUTRIENT COMPOSITION OF COMMERCIAL BROWN PARBOILED AND MILLED RICE FROM BRAZIL, J. FOOD COMPOS. ANAL., 18, PP. 287-296, (2005); HENDERSON A.J., OLLILA C.A., KUMAR A., BORRESEN E.C., RAINA K., AGARWAL R., RYAN E.P., CHEMO PREVENTIVE PROPERTIES OF DIETARY RICE BRAN: CURRENT STATUS AND FUTURE PROSPECTS, ADV. NUTR., 3, PP. 643-653, (2012); HERNANDEZ N., RODRIGUEZ-ALEGRIA M.E., GONZALEZ F., LOPEZ-MUNGUIA A., ENZYMATIC TREATMENT OF RICE BRAN TO IMPROVE PROCESSING, J. AM. OIL CHEM. SOC., 77, PP. 177-180, (2000); HOLDEN J.M., BHAGWAT S.A., HAYTOWITZ D.B., GEBHARDT S.E., DWYEN J.T., PETERSON J., BEECHER G.R., ELDRIDGE A.L., BALENTINE D., DEVELOPMENT OF A DATABASE OF CRITICALLY EVALUATED FLAVONOIDS DATA: APPLICATION OF USDA’S DATA QUALITY EVALUATION SYSTEM, J. FOOD COMPOS. ANAL., 18, PP. 829-844, (2005); HONGSIBSONG S., SUTAN K., KERDNOI T., PRAPAMONTOL T., Γ-ORYZANOL CONTENT SCREENING IN LOCAL BROWN RICE SAMPLES FROM CHIANG MAI, THAILAND AND COMPARISON BETWEEN UNCOOKED AND COOKED BROWN RICE, INT. J. AGRIC. RES., 11, PP. 84-89, (2016); HU C., ZAWISTOWSKI J., LING W., KITTS D.D., BLACK RICE (ORYZA SATIVA L. INDICA) PIGMENTED FRACTION SUPPRESSES BOTH REACTIVE OXYGEN SPECIES AND NITRIC OXIDE IN CHEMICAL AND BIOLOGICAL MODEL SYSTEMS, J. AGRIC. FOOD CHEM., 51, PP. 5271-5277, (2003); HUANG Y.P., LAI H.M., BIOACTIVE COMPOUNDS AND ANTIOXIDATIVE ACTIVITY OF COLORED RICE BRAN, J. FOOD DRUG ANAL., (2016); HUDSON E.A., DINH P.A., KOKUBUN T., SIMMONDS M.S.J., GESCHER A., CHARACTERIZATION OF POTENTIALLY CHEMOPREVENTIVE PHENOLS IN EXTRACTS OF BROWN RICE THAT INHIBIT THE GROWTH OF HUMAN BREAST AND COLON CANCER CELLS, CANCER EPIDEMIOL. BIOMARKERS PREV., 9, PP. 1163-1170, (2000); ICHIKAWA H., ICHIYANAGI T., XU B., YOSHII Y., NAKAJIMA M., KONISHI T., ANTIOXIDANT ACTIVITY OF ANTHOCYANIN EXTRACT FROM PURPLE BLACK RICE, J. MED. FOOD, 4, PP. 211-218, (2001); IMAM M.U., AZMI N.H., BHANGER M.I., ISMAIL N., ISMAIL M., ANTIDIABETIC PROPERTIES OF GERMINATED BROWN RICE: A SYSTEMATIC REVIEW, EVID. BASED COMPL. ALTERNAT. MED., (2012); IQBAL J., MINHAJUDDIN M., BEG Z.H., SUPPRESSION OF DIETHYLNITROSAMINE AND 2 -ACETYLAMINOFLUORENE INDUCED HEPATOCARCINOGENESIS IN RATS BY TROCOTRIENOL- RICH FRACTION ISOLATED FROM RICE BRAN OIL, EUR. J. CANCER PREV., 13, PP. 515-520, (2004); JAYADEEP A., MALLESHI N.G., NUTRIENTS, COMPOSITION OF TOCOTRIENOLS, TOCOPHEROLS, AND Γ-ORYZANOL, AND ANTIOXIDANT ACTIVITY IN BROWN RICE BEFORE AND AFTER BIOTRANSFORMATION, CYTA- J. FOOD, 9, PP. 82-87, (2011); JEON K.I., PARK E.J., PARK H.R., JEON Y.J., CHA S.H., LEE S.C., ANTIOXIDANT ACTIVITY OF FAR-INFRARED RADIATED RICE HULL EXTRACTS ON REACTIVE OXYGEN SPECIES SCAVENGING AND OXIDATIVE DNA DAMAGE IN HUMAN LYMPHOCYTES, J. MED. FOOD, 9, PP. 42-48, (2006); JIDEANI I.A., DIGITARIA EXILIS (ACHA/FONIO), DIGITARIA IBURUA (IBURU/FONIO) AND ELUESINE CORACANA (TAMBA/FINGER MILLET) - NON-CONVENTIONAL CEREAL GRAINS WITH POTENTIALS, SCI. RES. ESSAYS, 7, PP. 3834-3843, (2012); JIRAPA K., JARAE Y., PHANEE R., JIRASAK K., CHANGES OF BIOACTIVE COMPONENTS IN GERMINATED PADDY RICE (ORYZA SATIVA L.), INT. FOOD RES. J., 23, PP. 229-236, (2016); KALE S.J., JHA S.K., JHA G.K., SINHA J.P., LAL S.B., SOAKING INDUCED CHANGES IN CHEMICAL COMPOSITION, GLYCEMIC INDEX AND STARCH CHARACTERISTICS OF BASMATI RICE, RICE SCI, 22, PP. 227-236, (2015); KANNAPPAN R., RAVINDRAN J., PRASAD S., GAMMA-TOCOTRIENOL PROMOTES TRAIL-INDUCED APOPTOSIS THROUGH REACTIVE OXYGEN SPECIES/ EXTRACELLULAR SIGNAL-REGULATED KINASE/P53-MEDIATED UPREGULATION OF DEATH RECEPTORS, MOL. CANCER THER., 9, PP. 2196-2207, (2010); KIM H.J., WEE J.H., YANG E.J., OPTIMAL CONDITIONS FOR ANTHOCYANIN EXTRACTION FROM BLACK RICE BRAN AND STORAGE STABILITY OF ANTHOCYANIN EXTRACT, J. KOREAN SOC. FOOD SCI. NUTR., 44, PP. 1543-1549, (2015); KIM J.S., RADICAL SCAVENGING CAPACITY AND ANTIOXIDANT ACTIVITY OF THE E VITAMER FRACTION IN RICE BRAN, J. FOOD SCI, 70, PP. 208-213, (2005); KIM J., SHIU S.H., THOMA S., LI W.H., PATTERSON S.E., PATTERNS OF EXPANSION AND EXPRESSION DIVERGENCE IN THE PLANT POLYGALACTURONASE GENE FAMILY, GENOME BIOL., 7, (2006); KOZUKA C., SUNAGAWA S., UEDA R., HIGA M., OHSHIRO Y., TANAKA H., SHIMIZU-OKABE C., TAKAYAMA C., MATSUSHITA M., TSUTSUI M., ISHIUCHI S., NAKATA M., YADA T., MIYAZAKI J., OYADOMARI S., SHIMABUKURO M., MASUZAKI H., A NOVEL INSULINOTROPIC MECHANISM OF WHOLE GRAIN-DERIVED Γ-ORYZANOL VIA THE SUPPRESSION OF LOCAL DOPAMINE D2 RECEPTOR SIGNALLING IN MOUSE ISLET, BRIT. J. PHARMACOL., 172, PP. 4519-4534, (2015); KUMAR N., PRUTHI V., POTENTIAL APPLICATIONS OF FERULIC ACID FROM NATURAL SOURCES, BIOTECH. REP., 4, PP. 86-93, (2014); LAI P., LI K.Y., LU S., CHEN H.H., PHYTOCHEMICALS AND ANTIOXIDANT PROPERTIES OF SOLVENT EXTRACTS FROM JAPONICA RICE BRAN, FOOD CHEM, 117, PP. 538-544, (2009); LEE H.H., LOH S.P., BONG C.F., SARBINI S.R., YIU P.H., IMPACT OF PHYTIC ACID ON NUTRIENT BIOACCESSIBILITY AND ANTIOXIDANT PROPERTIES OF DEHUSKED RICE, J. FOOD SCI. TECHNOL, 52, PP. 7806-7816, (2015); LIN Y.T., PAO C.C., CHANG C.Y., EFFECT OF DIFFERENT GERMINATION CONDITIONS ON ANTIOXIDATIVE PROPERTIES AND BIOACTIVE COMPOUNDS OF GERMINATED BROWN RICE, BIOMED RES. INT., 2015, PP. 1-11, (2015); LIU Z., CHENG F., ZHANG G., GRAIN PHYTIC ACID CONTENT IN JAPONICA RICE AS AFFECTED BY CULTIVAR AND ENVIRONMENT AND ITS RELATION TO PROTEIN CONTENT, FOOD CHEM, 89, PP. 49-52, (2005); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., MORGAN J.M., CAPUZZI D.M., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM. J. CARDIOL., 101, PP. 1689-1693, (2008); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ZHANG D., COOPER R., CHANG M., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J. AGRIC. FOOD CHEM., 48, PP. 5220-5225, (2000); MANACH C., SCALBERT A., MORAND C., JIMENEZ L., POLYPHENOLS: FOOD SOURCES AND BIOAVAILABILITY, AM. J. CLIN. NUTR., 79, PP. 727-747, (2004); MASSARETTO I.L., ALVES M.F.M., MIRA N.V.M., CARMONA A.K., MARQUEZ U.M.L., PHENOLIC COMPOUNDS IN RAW AND COOKED RICE (ORYZA SATIVA L.) AND THEIR INHIBITORY EFFECT ON THE ACTIVITY OF ANGIOTENSIN I-CONVERTING ENZYME, J. CEREAL SCI., 54, PP. 236-240, (2011); MATTILA P., PIHLAVA J.M., HELLSTROM J., CONTENTS OF PHENOLIC ACIDS, ALKYL AND ALKENYL-RESORCINOLS, AND AVENANTHRAMIDES IN COMMERCIAL GRAIN PRODUCTS, J. AGRIC. FOOD CHEM., 53, PP. 82-90, (2005); MAZZA G., GAO L., BLUE AND PURPLE GRAINS, SPECIALTY GRAINS FOR FOOD AND FEED, PP. 313-350, (2005); MCCARTY M.F., OKEEFE J.H., DINICOLANTONIO J.J., RED YEAST RICE PLUS BERBERINE: PRACTICAL STRATEGY FOR PROMOTING VASCULAR AND METABOLIC HEALTH, ALTERN. THER. HEALTH MED., 2, PP. 40-45, (2015); MCDONOUGH C.M., ROONEY L.W., SERNA-SALDIVAR S.O., HANDBOOK OF CEREAL SCIENCE AND TECHNOLOGY, PP. 177-201, (2000); MENG F., WEI Y., YANG X., IRON CONTENT AND BIOAVAILABILITY IN RICE, J. TRACE ELEM. MED. BIOL., 18, PP. 333-338, (2005); MIN B., MCCLUNG A.M., CHEN M.H., PHYTOCHEMICALS AND ANTIOXIDANT CAPACITIES IN RICE BRANS OF DIFFERENT COLOR, J. FOOD SCI., 76, PP. 117-126, (2011); MIN B., GU L., MCCLUNG A.M., BERGMAN C.J., CHEN M.H., FREE AND BOUND TOTAL PHENOLIC CONCENTRATIONS, ANTIOXIDANT CAPACITIES, AND PROFILES OF PROANTHOCYANIDINS AND ANTHOCYANINS IN WHOLE GRAIN RICE (ORYZA SATIVA L.) OF DIFFERENT BRAN COLOURS, FOOD CHEM, 133, PP. 715-722, (2012); MIR S.A., BOSCO S.J.D., SHAH M.A., MIR M.M., SUNOOJ K.V., VARIETY DIFFERENCE IN QUALITY CHARACTERISTICS, ANTIOXIDANT PROPERTIES AND MINERAL COMPOSITION OF BROWN RICE, J. FOOD MEASUR. CHARACTER., 10, PP. 177-184, (2016); MIYAZAWA M., OSHIMA T., KOSHIO K., ITSUZAKI Y., ANZAI J., TYROSINASE INHIBITOR FROM BLACK RICE BRAN, J. AGRIC. FOOD CHEM., 51, PP. 6953-6956, (2003); MIYAZAWA T., SHIBATA A., NAKAGAWA K., TSUZUKI T., ANTI-ANGIOGENIC FUNCTION OF TOCOTRIENOL, ASIA PAC. J. CLIN. NUTR., 1, PP. 253-256, (2008); NAGENDRA P.M.N., SANJAY K.R., SHRAVYA K.M., VISMAYA M.N., NANJUNDASWAMY S., HEALTH BENEFITS OF RICE BRAN- A REVIEW, J. NUTR. FOOD SCI., 1, PP. 1-7, (2011); OKI T., MASUDA M., KOBAYASHI M., NISHIBA Y., FURUTA S., SUDA I., POLYMERIC PROCYANIDINS AS RADICAL-SCAVENGING COMPONENTS IN RED-HULLED RICE, J. AGRIC. FOOD CHEM., 50, PP. 7524-7529, (2002); OUDHIA P., TRADITIONAL MEDICINAL KNOWLEDGE ABOUT GREEN LEAFHOPPER, (2000); PANDEY K.B., RIZVI S.I., PLANT POLYPHENOLS AS DIETARY ANTIOXIDANTS IN HUMAN HEALTH AND DISEASE, OXID. MED. CELL LONGEV., 2, PP. 270-278, (2009); PATEL M., NAIK S.N., GAMMA-ORYZANOL FROM RICE BRAN OIL- A REVIEW, J. SCI. IND. RES., 63, PP. 569-578, (2004); PAYAKAPOL L., MOONGNGARM A., DAOMUKDA N., NOISUWAN A., INFLUENCE OF DEGREE OF MILLING ON CHEMICAL COMPOSITIONS AND PHYSICOCHEMICAL PROPERTIES OF JASMINE RICE, INTERNATIONAL CONFERENCE ON BIOLOGY, ENVIRONMENT AND CHEMISTRY, PP. 83-86, (2011); PINHEIRO P.F., JUSTINO G.C., STRUCTURAL ANALYSIS OF FLAVONOIDS AND RELATED COMPOUNDS- A REVIEW OF SPECTROSCOPIC APPLICATIONS, PHYTOCHEMICALS- A GLOBAL PERSPECTIVE OF THEIR ROLE IN NUTRITION AND HEALTH, PP. 34-56, (2012); PITIJA K., NAKORNRIAB M., SRISEADKA T., VANAVICHIT A., WONGPORNCHAI S., ANTHOCYANIN CONTENT AND ANTIOXIDANT CAPACITY IN BRAN EXTRACTS OF SOME THAI BLACK RICE VARIETIES, INT. J. FOOD SCI. TECHNOL., 48, PP. 300-308, (2013); PODE R., POTENTIAL APPLICATIONS OF RICE HUSK ASH WASTE FROM RICE HUSK BIOMASS POWER PLANT, RENEW. SUSTAIN. ENER. REV., 53, PP. 1468-1485, (2016); PONGJANTA J., CHOMSRI N., MEECHOUI S., CORRELATION OF PASTING BEHAVIORS WITH TOTAL PHENOLIC COMPOUNDS AND STARCH DIGESTIBILITY OF INDIGENOUS PIGMENTED RICE GROWN IN UPPER NORTHERN THAILAND, FUNCT. FOODS HEALTH DIS., 6, PP. 133-143, (2016); PRAJAPATI C., PATEL R., IN-SILICO ANALYSIS AND HOMOLOGY MODELING OF ANTIOXIDANT PROTEINS OF ORYZA SATIVA SUBSP. JAPONICA (RICE), INT. J. PHARM. SCI. RES., 4, PP. 3992-4000, (2013); RAHMAN K., STUDIES ON FREE RADICALS, ANTIOXIDANTS, AND CO-FACTORS, CLIN. INTERVENTIONS AGING, 2, PP. 219-236, (2007); RAHMAN M.A., HASEGAWA H., RAHMAN M.A., RAHMAN M.M., MIAH M.A.M., INFLUENCE OF COOKING METHOD ON ARSENIC RETENTION IN COOKED RICE RELATED TO DIETARY EXPOSURE, SCI. TOTAL ENVIRON., 370, PP. 51-60, (2006); RAO S.M.V.S.S.T., MURALIKRISHNA G., EVALUATION OF THE ANTIOXIDANT PROPERTIES OF FREE AND BOUND PHENOLIC ACIDS FROM NATIVE AND MALTED FINGER MILLET (RAGI, ELEUSINE CORACANA INDAF-15), J. AGRIC. FOOD CHEM., 50, PP. 889-892, (2002); RODER W., KEOBOULAPHA B., VANNALATH K., PHOUARAVANH B., GLUTINOUS RICE AND ITS IMPORTANCE FOR HILL FARMERS IN LAOS, ECONOM. BOT., 50, PP. 401-408, (1996); ROSNIYANA A., RUKUNUDIN I.H., NORIN S.A.S., EFFECTS OF MILLING DEGREE ON THE CHEMICAL COMPOSITION, PHYSICOCHEMICAL PROPERTIES AND COOKING CHARACTERISTICS OF BROWN RICE, J. TROP. AGRIC. FD. SC., 34, PP. 37-44, (2006); ROY P., ORIKASA T., OKADOME H., NAKAMURA N., SHIINA T., PROCESSING CONDITIONS, RICE PROPERTIES, HEALTH AND ENVIRONMENT, INT. J. ENVIRON. RES. PUBLIC HEALTH, 8, PP. 1957-1976, (2011); RYAN E.P., HEUBERGER A.L., WEIR T.L., BARNETT B., BROECKLING C.D., PRENNI J.E., RICE BRAN FERMENTED WITH SACCHAROMYCES BOULARDII GENERATES NOVEL METABOLITE PROFILES WITH BIOACTIVITY, J. AGRIC. FOOD CHEM., 59, PP. 1862-1870, (2011); SAIKIA D., DEKA S.C., CEREALS: FROM STAPLE FOOD TO NUTRACEUTICALS, INT. FOOD RES. J., 18, PP. 21-30, (2011); SETYANINGSIH W., SAPUTRO I.E., PALMA M., BARROSO C.G., PRESSURIZED LIQUID EXTRACTION OF PHENOLIC COMPOUNDS FROM RICE (ORYZA SATIVA) GRAINS, FOOD CHEM, 192, PP. 452-459, (2016); SING S.X., LEE H.H., WONG S.C., BONG C.F.J., YIU P.H., FERULIC ACID, GAMMA ORYZANOL AND GABA CONTENT IN WHOLE GRAIN RICE AND THEIR VARIATION WITH BRAN COLOUR, EMIRATES J. FOOD AGRIC., 27, PP. 706-711, (2015); SOMINTARA S., LEARDKAMOLKARN V., SUTTIARPORN P., MAHATHEERANONT S., ANTI-TUMOR AND IMMUNE ENHANCING ACTIVITIES OF RICE BRAN GRAMISTEROL ON ACUTE MYELOGENOUS LEUKEMIA, PLOS ONE, 11, PP. 1-19, (2016); SUTTIARPORN P., CHUMPOLSRI W., MAHATHEERANONT S., LUANGKAMIN S., TEEPSAWANG S., LEARDKAMOLKARN V., STRUCTURES OF PHYTOSTEROLS AND TRITERPENOIDS WITH POTENTIAL ANTI-CANCER ACTIVITY IN BRAN OF BLACK NON-GLUTINOUS RICE, NUTRIENT, 7, PP. 1672-1687, (2015); THANONKAEWA A., WONGYAI S., MCCLEMENTS D.J., DECKER E.A., EFFECT OF STABILIZATION OF RICE BRAN BY DOMESTIC HEATING ON MECHANICAL EXTRACTION YIELD, QUALITY, AND ANTIOXIDANT PROPERTIES OF COLD-PRESSED RICE BRAN OIL (ORYZA SALTIVA L.), FOOD SCI. TECHNOL., 48, PP. 231-236, (2012); THITIPRAMOTE N., PRADMEETEEKUL P., NIMKAMNERD J., CHAIWUT P., PINTATHONG P., THITILERDECHA N., BIOACTIVE COMPOUNDS AND ANTIOXIDANT ACTIVITIES OF RED (BROWN RED JASMINE) AND BLACK (KAM LEUM PUA) NATIVE PIGMENTED RICE, INT. FOOD RES. J., 23, PP. 410-414, (2016); TIAN S., NAKAMURA K., KAYAHARA H., ANALYSIS OF PHENOLIC COMPOUNDS IN WHITE RICE, BROWN RICE AND GERMINATED BROWN RICE, J. AGRIC. FOOD CHEM., 52, PP. 4808-4813, (2004); TIAN S., NAKAMURA K., CUI T., KAYAHARA H., HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF PHENOLIC COMPOUNDS IN RICE, J. CHROMATOGR. A., 1063, PP. 121-128, (2005); USDA NATIONAL NUTRIENT DATABASE FOR STANDARD REFERENCE, (2013); UMADEVI M., PUSHPA R., SAMPATHKUMAR K.P., DEBJIT B., RICE-TRADITIONAL MEDICINAL PLANT IN INDIA, J. PHARMA PHOTOCHEM, 1, PP. 29-36, (2012); USUKI S., TSAI Y.Y., MORIKAWA K., NONAKA S., OKUHARA Y., KISE M., YU R.K., IGF-1 INDUCTION BY ACYLATED STERYL Β-GLUCOSIDES FOUND IN A PRE-GERMINATED BROWN RICE DIET REDUCES OXIDATIVE STRESS IN STREPTOZOTOCIN-INDUCED DIABETES, PLOS ONE, 6, (2011); VUCENIK I., SHAMSUDDIN A.M., CANCER INHIBITION BY INOSITOL HEXAPHOSPHATE (IP6) AND INOSITOL: FROM LABORATORY TO CLINIC, J. NUTR., 133, PP. 37785-37845, (2003); WALTER M., MARCHESAN E., PHENOLIC COMPOUNDS AND ANTIOXIDANT ACTIVITY OF RICE, BRAZ. ARCH. BIOL. TECHNOL., 54, PP. 371-377, (2011); WALTER M., MARCHESAN E., MASSONI P.F.S., SILVA L.P., SARTORI G.M.S., FERREIRA R.B., ANTIOXIDANT PROPERTIES OF RICE GRAINS WITH LIGHT BROWN, RED AND BLACK PERICARP COLORS AND THE EFFECT OF PROCESSING, FOOD RES. INT., 50, PP. 693-703, (2013); XIA X., LING W., MA J., XIA M., HOU M., WANG Q., ZHU H., TANG Z., AN ANTHOCYANIN-RICH EXTRACT FROM BLACK RICE ENHANCES ATHEROSCLEROTIC PLAQUE STABILIZATION IN APOLIPOPROTEIN E–DEFICIENT MICE, J. NUTR., 136, PP. 2220-2225, (2006); YANISHLIEVA-MASLAROVA N.N., HEINONEN M., SOURCES OF NATURAL ANTIOXIDANTS, ANTIOXIDANTS IN FOOD, PP. 210-249, (2001); YAWADIO R., TANIMORI S., MORITA N., IDENTIFICATION OF PHENOLIC COMPOUNDS ISOLATED FROM PIGMENTED RICES AND THEIR ALDOSE REDUCTASE INHIBITORY ACTIVITIES, FOOD CHEM., 101, PP. 1616-1625, (2007); YAWADIO R., TANIMORI S., MORITA N., IDENTIFICATION OF PHENOLIC COMPOUNDS ISOLATED FROM PIGMENTED RICES AND THEIR ALDOSE REDUCTASE INHIBITORY ACTIVITIES, FOOD CHEM., 101, PP. 1616-1625, (2007); ZENG Y.W., YANG J.Z., PU X.Y., DU J., YANG T., YANG S.M., ZHU W.H., STRATEGIES OF FUNCTIONAL FOOD FOR CANCER PREVENTION IN HUMAN BEINGS, ASIAN PAC. J. CANCER PREV., 14, PP. 1585-1592, (2013); ZHOU Z., ROBARDS K., HELLIWELL S., BLANCHARD C., THE DISTRIBUTION OF PHENOLIC ACIDS IN RICE, FOOD CHEM, 87, PP. 401-406, (2004)","K.-H. BAEK; DEPARTMENT OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 38541, SOUTH KOREA; EMAIL: KHBAEK@YNU.AC.KR","UNIVERSITY OF AGRICULTURE","ENGLISH","PAK. J. AGRIC. SCI.","REVIEW","ISI","2-S2.0-85030098204","PAK J AGRIC SCI","DONGGUK UNIVERSITY;DONGGUK UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"DAS G, 2017, PAK J AGRIC SCI","DAS G, 2017, PAK J AGRIC SCI"
"ARTECHE-HIDALGO L;FERNANDEZ-TRAVIESO J;SUAREZ-CAMEJO N;MARIN-PREVAL J;ALVAREZ-ACOSTA V;CHAVIANO-PEREIRA J;GARCIA-SANCHEZ M;ESQUIVEL-MOINELO I;DIAZ-GONZALEZ M;MATOS-REYES O;FERNANDEZ-DORTA L;ILLNAIT-FERRER J;MENDOZA-CASTANO S;MONZON-PEREZ M;PEDROSO V","ARTECHE-HIDALGO, LIUBA (57203965143); FERNANDEZ-TRAVIESO, JULIO CESAR (9432805500); SUAREZ-CAMEJO, NOYSBEL (57216746280); MARIN-PREVAL, JUAN (57216744200); ALVAREZ-ACOSTA, VICTOR (57216738436); CHAVIANO-PEREIRA, JULIAN (57216753669); GARCIA-SANCHEZ, MAURA (56682660000); ESQUIVEL-MOINELO, IDELSIS (57216746572); DIAZ-GONZALEZ, MARISOL (57216755520); MATOS-REYES, ODALYS (57216742952); FERNANDEZ-DORTA, LILIA (57204307516); ILLNAIT-FERRER, JOSE (6508234896); MENDOZA-CASTANO, SARAHI (57204328829); MONZON-PEREZ, MAICEL (57202851493); PEDROSO, VICTORIA SANCHEZ (57216742406)","EFFECTS OF POLICOSANOL IN PATIENTS WITH METABOLIC SYNDROME A SIXMONTH STUDY",2020,"JOURNAL OF ENDOCRINOLOGY AND METABOLISM","10","8",5,"10.14740/jem642","LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;LUIS DIAZ SOTO HOSPITAL, HAVANA, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CLINICAL TRIALS COORDINATOR CENTRE, HAVANA, CUBA;NATIONAL CLINICAL TRIALS COORDINATOR CENTRE, HAVANA, CUBA","BACKGROUND: THE METABOLIC SYNDROME COMPRISES A SET OF CARDIO-VASCULAR RISK FACTORS REPRESENTED BY OBESITY OF CENTRAL DISTRIBUTION, DYSLIPIDEMIAS, GLUCOSE METABOLISM ABNORMALITIES AND ARTERIAL HYPER-TENSION, CLOSELY ASSOCIATED WITH INSULIN RESISTANCE. POLICOSANOL IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALCOHOLS PURIFIED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING AND ANTIOXIDANT EFFECTS. THE AIM OF THIS STUDY IS TO INVESTIGATE IN THE MEDIUM TERM THE EFFECTS OF POLI-COSANOL IN PATIENTS WITH METABOLIC SYNDROME, AS WELL AS ITS SAFETY AND TOLERABILITY. METHODS: THIS PHASE IV STUDY HAD A DOUBLE-BLIND, RANDOMIZED AND CONTROLLED DESIGN, WITH TWO PARALLEL GROUPS THAT RECEIVED POLICOSANOL (10 MG/DAY) OR PLACEBO FOR 6 MONTHS. THE STUDY INCLUDED PATIENTS WITH METABOLIC SYNDROME, OF BOTH SEXES, AGED BETWEEN 25 AND 70 YEARS. AS A PRIMARY EFFICACY VARIABLE, THE EFFECTS ON OXIDATIVE STRESS WERE EVALUATED, WHILE THE EFFECTS ON LIPIDS PROFILE VARIABLES WERE CON-SIDERED AS A SECONDARY EFFICACY VARIABLE. STATISTICAL ANALYSIS OF THE DATA WAS PERFORMED ACCORDING TO THE INTENTION-TO-TREAT METHOD. RESULTS: THE STUDY INCLUDED 100 PATIENTS WITH METABOLIC SYNDROME (81 MEN, 19 WOMEN) (AVERAGE AGE: 51 YEARS). AT THE END OF 6 MONTHS OF TREATMENT, POLICOSANOL SIGNIFICANTLY REDUCED THE REDOX INDEX WITH RESPECT TO THE INITIAL VALUES AND WITH RESPECT TO THE PLACEBO GROUP. POLICOSANOL SIGNIFICANTLY REDUCED LEVELS OF TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), AS WELL AS INCREASED SERUM LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), WHILE TRIGLYCERIDE LEVELS ALTHOUGH REDUCED AT THE END OF TREATMENT, THIS REDUCTION WAS NOT SIGNIFICANT. THE POLICOSANOL WAS SAFE AND WELL TOLERATE; IT DID NOT AFFECT THE PHYSICAL AND LABORATORY PARAMETERS INVESTIGATED, WITH THE EXCEPTION OF A SIGNIFICANT AND FAVORABLE REDUCTION IN THE LEVELS OF APOLIPOPROTEIN (APO) B. CONCLUSIONS: IT IS CONCLUDED THAT POLICOSANOL THERAPY FOR 6 MONTHS PRODUCES IMPROVEMENTS ON OXIDATIVE STRESS IN PATIENTS WITH METABOLIC SYNDROME, IN ADDITION TO A BENEFICIAL EFFECT ON THEIR LIPID PROFILE, BEING SAFE AND WELL TOLERATED. © THE AUTHORS.","LIPID PROFILE; METABOLIC SYNDROME; OXIDATIVE STRESS; POLICOSANOL; RE-DOX INDEX","","CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CNRS","THIS STUDY WAS SUPPORT BY THE NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, AS PART OF ITS RESEARCH-DEVELOPMENT PROJECTS.","AGUILAR-SALINAS C.A., VIVEROS-RUIZ T., RECENT ADVANCES IN MANAGING/UNDERSTANDING THE METABOLIC SYNDROME, F1000RES, 8, (2019); DOMMERMUTH R., EWING K., METABOLIC SYNDROME, SYSTEMS THINKING IN HEART DISEASE. PRIM CARE., 45, 1, PP. 109-129, (2018); LIZAZABURI J., SINDROME METABOLICO: CONCEPTO Y APLICA-CION PRACTICA, AN FAC MED, 74, 4, PP. 315-320, (2013); GRUNDY S.M., METABOLIC SYNDROME UPDATE, TRENDS CARDIO-VASC MED, 26, 4, PP. 364-373, (2016); CARRIER A., METABOLIC SYNDROME AND OXIDATIVE STRESS: A COMPLEX RELATIONSHIP, ANTIOXID REDOX SIGNAL, 26, 9, PP. 429-431, (2017); SPAHIS S., BORYS J.M., LEVY E., METABOLIC SYNDROME AS A MULTIFACETED RISK FACTOR FOR OXIDATIVE STRESS, ANTIOXID RE-DOX SIGNAL, 26, 9, PP. 445-461, (2017); BONOMINI F., RODELLA L.F., REZZANI R., METABOLIC SYN-DROME, AGING AND INVOLVEMENT OF OXIDATIVE STRESS, AGING DIS, 6, 2, PP. 109-120, (2015); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PRO-GRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, 19, PP. 2486-2497, (2001); VONA R., GAMBARDELLA L., CITTADINI C., STRAFACE E., PIETRA-FORTE D., BIOMARKERS OF OXIDATIVE STRESS IN METABOLIC SYNDROME AND ASSOCIATED DISEASES, OXID MED CELL LONGEV, 2019, (2019); RANI V., DEEP G., SINGH R.K., PALLE K., YADAV U.C., OXIDATIVE STRESS AND METABOLIC DISORDERS: PATHOGENESIS AND THERAPEUTIC STRATEGIES, LIFE SCI, 148, PP. 183-193, (2016); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLES-TEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASES, J PHARMACOL EXP THER, 106, PP. 107-144, (2006); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMG-COA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADI-ENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, 10, PP. 907-916, (2009); BANERJEE S., PORTER T.D., TEA AND POLICOSANOL ACT THROUGH DIFFERENT MECHANISMS TO ACTIVATE AMP-KINASE AND SUP-PRESS HMG-COA REDUCTASE TO INHIBIT CHOLESTEROL SYN-THESIS. PROCEEDINGS OF THE FASEB MEETING, FASEB J., 24, 1, (2010); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOW-ERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHO-LESTEROLEMIA, CURR THER RES CLIN & EXPTL, 56, PP. 176-182, (1995); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALE-MAN C., PONTIGAS V., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, 4, PP. 439-447, (1999); CANETTI M., MORERA M.S., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPER-CHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR THER RES CLIN & EXPTL, 58, PP. 868-875, (1997); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PA-TIENTS, INT J TISSUE REACT, 20, 4, PP. 119-124, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., MOLINA V., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, 4, PP. 105-116, (1999); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MOD-IFICATION IN VITRO, BR J CLIN PHARMACOL, 50, 3, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSA-NOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HY-PERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION. A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR THER RES CLIN & EXPTL, 61, PP. 609-620, (2000); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, 3-4, PP. 89-99, (2002); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ L., FERNANDEZ J., ORTA S.D., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); FERNANDEZ S., MAS R., GAMEZ R., DIAZ A., FERNANDEZ J., ORTA S.D., ILLNAIT J., ET AL., A PHARMACOLOGICAL SURVILLANCE OF POLI-COSANOL TOLERABILITY IN THE ELDERLY, AM J GERONTOL PHAR-MACOTHER, 2, PP. 11-16, (2004); DECLARATION OF HELSINKI-ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS; REGULACION NO. 45-2007, CENTRO PARA EL CONTROL ESTATAL DE LOS MEDICAMENTOS, EQUIPOS Y DISPOSITIVOS MEDICOS (CECMED), MINSAP, (2007); ESTERBAUER H., CHEESEMAN K.H., DETERMINATION OF ALDEHY-DIC LIPID PEROXIDATION PRODUCTS: MALONALDEHYDE AND 4-HY-DROXYNONENAL, METHODS ENZYMOL, 186, PP. 407-421, (1990); WITKO-SARSAT V., FRIEDLANDER M., NGUYEN KHOA T., CAPEI-LLERE-BLANDIN C., NGUYEN A.T., CANTELOUP S., DAYER J.M., ET AL., ADVANCED OXIDATION PROTEIN PRODUCTS AS NOVEL MEDIA-TORS OF INFLAMMATION AND MONOCYTE ACTIVATION IN CHRONIC RENAL FAILURE, J IMMUNOL, 161, 5, PP. 2524-2532, (1998); BIOCHEMICAL ORGANIC COMPOUNDS, (1993); MANNHEIM B., BIOCHEMICAL INFORMATION. A REVISED BIOCHEMICAL REFERENCE SOURCES, PP. 15-16, (1987); CHO K.H., BAE M.A., KIM J.R., CUBAN SUGAR CANE WAX ACID AND POLICOSANOL SHOWED SIMILAR ATHEROPROTECTIVE EFFECTS WITH INHIBITION OF LDL OXIDATION AND CHOLESTERYL ESTER TRANSFER VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEINS FUNCTIONALITY, CARDIOVASC THER, 2019, (2019); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID MED CELL LONGEV, 2018, (2018); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOW-ERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, 2, PP. 149-158, (2016); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT J MOL MED, 39, 4, PP. 889-899, (2017)","J.C. FERNANDEZ-TRAVIESO; CLINICAL TRIALS UNIT, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, 25 AVENUE AND 158 ST, CUBANACAN, CUBA; EMAIL: JULIO.FERNANDEZ@CNIC.CU","ELMER PRESS","ENGLISH","J. ENDOCRINOL. METAB.","ARTICLE","ISI","2-S2.0-85084519592","J ENDOCRINOL METAB","LUIS DIAZ SOTO HOSPITAL;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;LUIS DIAZ SOTO HOSPITAL;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CLINICAL TRIALS COORDINATOR CENTRE;NATIONAL CLINICAL TRIALS COORDINATOR CENTRE","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"ARTECHE-HIDALGO L, 2020, J ENDOCRINOL METAB","ARTECHE-HIDALGO L, 2020, J ENDOCRINOL METAB"
"GALLETTI F;FAZIO V;GENTILE M;SCHILLACI G;PUCCI G;BATTISTA F;MERCURIO V;BOSSO G;BONADUCE D;BRAMBILLA N;VITALINI C;D'AMATO M;GIACOVELLI G","GALLETTI, FERRUCCIO (7006210155); FAZIO, VALERIA (35751928600); GENTILE, MARCO (7101638352); SCHILLACI, GIUSEPPE (7005176634); PUCCI, GIACOMO (8610916900); BATTISTA, FRANCESCA (55270369800); MERCURIO, VALENTINA (37026821800); BOSSO, GIORGIO (25824184100); BONADUCE, DOMENICO (7006681591); BRAMBILLA, NADIA (55550205800); VITALINI, CRISTINA (56968227600); D'AMATO, MASSIMO (7004499789); GIACOVELLI, GIAMPAOLO (6603336382)","EFFICACY OF A NUTRACEUTICAL COMBINATION ON LIPID METABOLISM IN PATIENTS WITH METABOLIC SYNDROME A MULTICENTER DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL",2019,"LIPIDS IN HEALTH AND DISEASE","18","",9,"10.1186/s12944-019-1002-y","DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, ESH EXCELLENCE CENTRE OF HYPERTENSION, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, ESH EXCELLENCE CENTRE OF HYPERTENSION, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, ESH EXCELLENCE CENTRE OF HYPERTENSION, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY","BACKGROUND: NUTRACEUTICALS REPRESENT A NEW THERAPEUTIC FRONTIER IN THE TREATMENT OF METABOLIC SYNDROM (METS) AND RELATED CARDIOVASCULAR RISK FACTORS. THE AIM OF THIS STUDY WAS TO EVALUATE THE POTENTIAL BENEFICIAL EFFECTS OF ARMOLIPID PLUS (AP) (BERBERINE 500 MG, RED YEST RICE, MONACOLIN K 3 MG AND POLICOSANOL 10 MG) ON INSULIN RESISTANCE, LIPID PROFILE, PARTICULARLY ON SMALL AND DENSE LDL CHOLESTEROL (SDLDL-C), REPRESENTING THE MOST ATHEROGENIC COMPONENTS, AS WELL AS ITS EFFECTS ON HIGH SENSITIVITY C-REACTIVE PROTEIN, A NOTABLE MARKER OF CARDIOVASCULAR RISK, BLOOD PRESSURE AND CARDIAC REMODELING IN SUBJECTS AFFECTED BY METS, WITH LEFT VENTRICULAR HYPERTROPHY. METHODS: THE STUDY WAS A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL. ONE HUNDRED AND FIFTY EIGHT PATIENTS, AGED BETWEEN 28 AND 76 YEARS OLD, WERE ENROLLED AND RANDOMIZED TO RECEIVE EITHER ONE TABLET OF AP OR PLACEBO (PL) ONCE DAILY FOR 24 WEEKS. ANTHROPOMETRIC AND VITAL PARAMETERS, TOTAL CHOLESTEROL (TOT-C), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), TRIGLYCERIDEMIA (TG), NON-HDL CHOLESTEROL (NHDL-C) AND SDLDL-C WERE EVALUATED. RESULTS: AFTER 24 WEEKS OF TREATMENT, THE ANALYSIS PERFORMED ON 141 SUBJECTS (71 IN AP ARM AND 70 IN PL ARM), SHOWED A SIGNIFICANT IMPROVEMENT OF LIPID PROFILE IN THE AP GROUP, WITH REDUCTION IN TOT-C (- 13.2 MG/DL), LDL-C (- 13.9 MG/DL) AND NHDL-C (- 15.3 MG/DL) AND INCREASE IN HDL-C (+ 2.0 MG/DL). THESE CHANGES WERE EQUALLY SIGNIFICANT COMPARED WITH PLACEBO (TOT-C: AP - 13.2 MG/DL VS PL + 2.7 MG/DL, P < 0.01; LDL-C: AP -13.9 MG/DL VS PL + 1.5 MG/DL, P < 0.01; NHDL-C: AP -15.3 MG/DL VS PL + 2.8 MG/DL, P < 0.01), ALTHOUGH NO SIGNIFICANT DIFFERENCE WAS OBSERVED BETWEEN THE TWO ARMS IN THE REDUCTION OF HDL-C NEVERTHELESS IT INCREASED SIGNIFICANTLY IN THE AP GROUP (AP + 2 MG/DL P < 0.05, PL 0.13 MG/DL). CONCLUSION: THE RESULTS OF THIS STUDY, APPLICABLE TO A SPECIFIC LOCAL POPULATION SHOW THAT, IN A POPULATION OF SUBJECTS AFFECTED BY METS, TREATMENT WITH AP IMPROVES THE LIPID PROFILE AND THE MOST ATHEROGENIC FACTORS, THUS SUGGESTING A REDUCTION IN THE RISK OF DEVELOPMENT AND PROGRESSION OF ATHEROSCLEROSIS, PARTICULARLY IN SUBJECTS WITH HIGH ATHEROGENIC RISK, DUE TO THE PRESENCE OF SDLDL-C. © 2019 THE AUTHOR(S).","","ADULT; AGED; BERBERINE; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; LIPID METABOLISM; LOVASTATIN; MALE; METABOLIC SYNDROME; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; ARMOLIPID PLUS; BERBERINE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; PLACEBO; POLICOSANOL; SMALL AND DENSE LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BERBERINE; FATTY ALCOHOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECT; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED","ROTTAPHARM SPA","THE STUDY WAS SPONSORED BY ROTTAPHARM SPA MONZA ITALY.","ISOMAA B., ALMGREN P., TUOMI T., FORSEN B., LAHTI K., NISSEN M., TASKINEN M.R., GROOP L., CARDIOVASCULAR MORBIDITY AND MORTALITY ASSOCIATED WITH THE METABOLIC SYNDROME, DIABETES CARE, 24, PP. 683-689, (2001); LAKKA H.M., LAAKSONEN D.E., LAKKA T.A., NISKANEN L.K., KUMPUSALO E., TUOMILEHTO J., SALONEN J.T., THE METABOLIC SYNDROME AND TOTAL AND CARDIO- VASCULAR DISEASE MORTALITY IN MIDDLE-AGED MEN, JAMA, 288, PP. 2709-2716, (2002); LAMARCHE B., TCHERNOF A., MOORJANI S., CANTIN B., DAGENAIS G.R., LUPIEN P.J., DESPRES J.P., SMALL, DENSE LOW-DENSITY LIPOPROTEIN PARTICLES AS A PREDICTOR OF THE RISK OF ISCHEMIC HEART DISEASE IN MEN. PROSPECTIVE RESULTS FROM THE QUEBEC CARDIOVASCULAR STUDY, CIRCULATION, 95, PP. 69-75, (1997); GARDNER C.D., FORTMANN S.P., KRAUSS R.M., ASSOCIATION OF SMALL LOW-DENSITY LIPOPROTEIN PARTICLES WITH THE INCIDENCE OF CORONARY ARTERY DISEASE IN MEN AND WOMEN, JAMA, 276, PP. 875-881, (1996); BJORNHEDEN T., BABYI A., BONDJERS G., WIKLUND O., ACCUMULATION OF LIPO- PROTEIN FRACTIONS AND SUBFRACTIONS IN THE ARTERIAL WALL, DETERMINED IN AN IN VITRO PERFUSION SYSTEM, ATHEROSCLEROSIS, 123, PP. 43-56, (1996); BERNEIS K.K., KRAUSS R.M., METABOLIC ORIGINS AND CLINICAL SIGNIFICANCE OF LDL HETEROGENEITY, J LIPID RES, 43, PP. 1363-1379, (2002); TRIBBLE D.L., RIZZO M., CHAIT A., LEWIS D.M., BLANCHE P.J., KRAUSS R.M., ENHANCED OXIDATIVE SUSCEPTIBILITY AND REDUCED ANTIOXIDANT CONTENT OF METABOLIC PRECURSORS OF SMALL, DENSE LOW-DENSITY LIPOPROTEINS, AM J MED, 110, PP. 103-110, (2001); SORAN H., DURRINGTON P.N., SUSCEPTIBILITY OF LDL AND ITS SUBFRACTIONS TO GLYCATION, CURR OPIN LIPIDOL, 22, PP. 254-261, (2011); YOUNIS N.N., SORAN H., PEMBERTON P., CHARLTON-MENYS V., ELSEWEDY M.M., DURRINGTON P.N., SMALL DENSE LDL IS MORE SUSCEPTIBLE TO GLYCATION THAN MORE BUOYANT LDL IN TYPE 2 DIABETES, CLIN SCI, 124, PP. 343-349, (2013); HURT-CAMEJO E., CAMEJO G., ROSENGREN B., LOPEZ F., WIKLUND O., BONDJERS G., DIFFERENTIAL UPTAKE OF PROTEOGLYCAN-SELECTED SUBFRACTIONS OF LOW DENSITY LIPOPROTEIN BY HUMAN MACROPHAGES, J LIPID RES, 31, PP. 1387-1398, (1990); MCNAMARA J.R., CAMPOS H., ORDOVAS J.M., PETERSON J., WILSON P.W., SCHAEFER E.J., EFFECT OF GENDER, AGE, AND LIPID STATUS ON LOW DENSITY LIPOPROTEIN SUBFRACTION DISTRIBUTION: RESULTS FROM THE FRAMINGHAM OFFSPRING STUDY, ARTERIOSCLEROSIS, 7, PP. 483-490, (1987); SWINKELS D.W., DEMACKER P.N., HENDRIKS J.C., VAN 'T LAAR A., LOW DENSITY LIPOPROTEIN SUBFRACTIONS AND RELATIONSHIP TO OTHER RISK FACTORS FOR CORONARY ARTERY DISEASE IN HEALTHY INDIVIDUALS, ARTERIOSCLEROSIS, 9, PP. 604-613, (1989); CHO Y., LEE S.G., JEE S.H., KIM J.H., HYPERTRIGLYCERIDEMIA IS A MAJOR FACTOR ASSOCIATED WITH ELEVATED LEVELS OF SMALL DENSE LDL CHOLESTEROL IN PATIENTS WITH METABOLIC SYNDROME, ANN LAB MED, 35, PP. 586-594, (2015); REAVEN G.M., CHEN Y.D., JEPPESEN J., MAHEUX P., KRAUSS R.M., INSULIN RESISTANCE AND HYPERINSULINEMIA IN INDIVIDUALS WITH SMALL, DENSE LOW DENSITY LIPOPROTEIN PARTICLES, J CLIN INVEST, 92, PP. 141-146, (1993); GAZI I., TSIMIHODIMOS V., FILIPPATOS T., BAIRAKTARI E., TSELEPIS A.D., ELISAF M., CONCENTRATION AND RELATIVE DISTRIBUTION OF LOW-DENSITY LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH METABOLIC SYNDROME DEFINED ACCORDING TO THE NATIONAL CHOLESTEROL EDUCATION PROGRAM CRITERIA, METABOLISM, 55, PP. 885-891, (2006); GENTILE M., PANICO S., JOSSA F., MATTIELLO A., UBALDI S., MAROTTA G., PAUCIULLO P., RUBBA P., SMALL DENSE LDL PARTICLES AND METABOLIC SYNDROME IN A SAMPLE OF MIDDLE-AGED WOMEN. FINDINGS FROM PROGETTO ATENA, CLIN CHIM ACTA, 388, PP. 179-183, (2008); BLAKE G.J., OTVOS J.D., RIFAI N., RIDKER P.M., LOW-DENSITY LIPOPROTEIN PARTICLE CONCENTRATION AND SIZE AS DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AS PREDICTORS OF CARDIOVASCULAR DISEASE IN WOMEN, CIRCULATION, 106, PP. 1930-1937, (2002); RIZZO M., PERNICE V., FRASHERI A., DI LORENZO G., RINI G.B., SPINAS G.A., ET AL., SMALL, DENSE LOW-DENSITY LIPOPROTEINS (LDL) ARE PREDICTORS OF CARDIO- AND CEREBRO-VASCULAR EVENTS IN SUBJECTS WITH THE METABOLIC SYNDROME, CLIN ENDOCRINOL, 70, PP. 870-875, (2009); AUSTIN M.A., BRESLOW J.L., HENNEKENS C.H., BURING J.E., WILLETT W.C., KRAUSS R.M., LOW-DENSITY LIPOPROTEIN SUBCLASS PATTERNS AND RISK OF MYOCARDIAL INFARCTION, JAMA, 260, PP. 1917-1921, (1988); AUSTIN M.A., KING M.-C., VRANIZAN K.M., KRAUSS R.M., ATHEROGENIC LIPOPROTEIN PHENOTYPE: A PROPOSED GENETIC MARKER FOR CORONARY HEART DISEASE RISK, CIRCULATION, 82, PP. 495-506, (1990); MILLER B.D., ALDERMAN E.L., HASKELL W.L., FAIR J.M., KRAUSS R.M., PREDOMINANCE OF DENSE LOW-DENSITY LIPOPROTEIN PARTICLES PREDICTS ANGIOGRAPHIC BENEFIT OF THERAPY IN THE STANFORD CORONARY RISK INTERVENTION PROJECT, CIRCULATION, 94, PP. 2146-2153, (1996); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); KANNEL W.B., RANGE OF SERUM CHOLESTEROL VALUES IN THE POPULATION DEVELOPING CORONARY ARTERY DISEASE, AM J CARDIOL, 76, PP. 69C-77C, (1995); GRUNDY S.M., OBESITY, METABOLIC SYNDROME, AND CARDIOVASCULAR DISEASE, J CLIN ENDOCRINOL METAB, 89, PP. 2595-2600, (2004); KAHN R., METABOLIC SYNDROME: IS IT A SYNDROME? DOES IT MATTER?, CIRCULATION, 115, PP. 1806-1810, (2007); ABD T.T., JACOBSON T.A., STATIN-INDUCED MYOPATHY: A REVIEW AND UPDATE, EXPERT OPIN DRUG SAF, 10, PP. 373-387, (2011); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES CLIN EXP, 77, PP. 1-6, (2014); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); LANG R.M., BIERIG M., DEVEREUX R.B., FLACHSKAMPF F.A., FOSTER E., PELLIKKA P.A., ET AL., RECOMMENDATIONS FOR CHAMBER QUANTIFICATION: A REPORT FROM THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY'S GUIDELINES AND STANDARDS COMMITTEE AND THE CHAMBER QUANTIFICATION WRITING GROUP, DEVELOPED IN CONJUNCTION WITH THE EUROPEAN ASSOCIATION OF ECHOCARDIOGRAPHY, A BRANCH OF THE EUROPEAN SOCIETY OF CARDIOLOGY, J AM SOC ECHOCARDIOGR, 18, PP. 1440-1463, (2005); BARRIOS V., ESCOBAR C., CICERO A.F., BURKE D., FASCHING P., BANACH M., BRUCKERT E., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); GENTILE M., CALCATERRA I., STRAZZULLO A., PAGANO C., PACIONI D., SPERANZA E., RUBBA P., MAROTTA G., EFFECTS OF ARMOLIPID PLUS ON SMALL DENSE LDL PARTICLES IN A SAMPLE OF PATIENTS AFFECTED BY FAMILIAL COMBINED HYPERLIPIDEMIA, CLIN LIPIDOL, 10, PP. 475-480, (2015)","F. GALLETTI; DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, ESH EXCELLENCE CENTRE OF HYPERTENSION, FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL, NAPLES, ITALY; EMAIL: GALLETTI@UNINA.IT","BIOMED CENTRAL LTD.","ENGLISH","LIPIDS HEALTH DIS.","ARTICLE","ISI","2-S2.0-85063148643","LIPIDS HEALTH DIS","FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;TERNI UNIVERSITY HOSPITAL;TERNI UNIVERSITY HOSPITAL;TERNI UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;ROTTAPHARM BIOTECH;ROTTAPHARM BIOTECH;ROTTAPHARM BIOTECH;ROTTAPHARM BIOTECH","NOTREPORTED;FEDERICO II UNIVERSITY OF NAPLES MEDICAL SCHOOL;NOTREPORTED",NA,"GALLETTI F, 2019, LIPIDS HEALTH DIS","GALLETTI F, 2019, LIPIDS HEALTH DIS"
"JANG Y;KIM D;HAN E;JUNG J","JANG, YEON-SU (57214465616); KIM, DAE-EUN (57214444560); HAN, EUNYOUNG (57204586830); JUNG, JOOHEE (8858539100)","PHYSIOLOGICAL ACTIVITIES OF POLICOSANOL EXTRACTED FROM SUGARCANE WAX",2019,"NATURAL PRODUCT SCIENCES","25","4",5,"10.20307/nps.2019.25.4.293","COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 01369, SOUTH KOREA;COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 01369, SOUTH KOREA;COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 01369, SOUTH KOREA, DUKSUNG INNOVATIVE DRUG CENTER, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 01369, SOUTH KOREA;COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 01369, SOUTH KOREA, DUKSUNG INNOVATIVE DRUG CENTER, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 01369, SOUTH KOREA","POLICOSANOL EXTRACTED FROM SUGARCANE WAX IS A GENERIC TERM USED FOR TOTAL FATTY ALCOHOLS OBTAINED FROM ESTERIFICATION OF FATTY ACIDS. IT HAS BEEN APPROVED AS A HEALTH FUNCTIONAL FOOD BY THE MINISTRY OF FOOD AND DRUG SAFETY OF KOREA IN 2006. POLICOSANOL IS WELL-KNOWN TO AID IN LOWERING BLOOD CHOLESTEROL LEVEL. RECENTLY, SEVERAL STUDIES HAVE REPORTED THE PHYSIOLOGICAL ACTIVITIES OF POLICOSANOL, SUCH AS ANTI-INFLAMMATORY EFFECTS, ANTIOXIDANT EFFECTS, AND LOWERING OF THE INCIDENCE OF AGEING-RELATED DISEASES, FOR EXAMPLE, HYPERTENSION, STROKE, AMONG OTHERS. THIS REVIEW DESCRIBES THE PHYSIOLOGICAL ACTIVITIES OF POLICOSANOL AND ITS APPLICATIONS IN THE FIELD OF HEALTH FUNCTIONAL FOODS. © 2019, KOREAN SOCIETY OF PHARMACOGNOSY. ALL RIGHTS RESERVED.","HEALTH FUNCTIONAL FOOD; PHYSIOLOGICAL ACTIVITIES; POLICOSANOL; SUGARCANE WAX","ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; FATTY ACID; FATTY ALCOHOL; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; POLICOSANOL; PRAVASTATIN; PROPROTEIN CONVERTASE 9; WAX; AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIETARY SUPPLEMENT; DISEASE COURSE; DRUG EFFICACY; DYSLIPIDEMIA; ESTERIFICATION; FATTY LIVER; FUNCTIONAL FOOD; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGNOSY; PHYSIOLOGICAL PROCESS; SUGARCANE","NATIONAL RESEARCH FOUNDATION OF KOREA, NRF; MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY, MEST, (2016R1A6A1A0300 7648)","THIS RESEARCH WAS FUNDED BY PRIORITY RESEARCH CENTERS PROGRAM THROUGH THE NRF FUNDED BY THE MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY (2016R1A6A1A0300 7648).","MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.B., J. NUTR., 97, PP. 381-388, (2007); KOREAN CIRC. J., 46, PP. 275-306, (2016); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., CRIT. REV. FOOD SCI. NUTR., 50, PP. 259-267, (2010); LIAO F., CHEN W., HUBEI AGRIC. SCI., 52, PP. 1125-1127, (2013); SINGH D.K., LI L., PORTER T.D., J. PHARMACOL. EXP. THER., 318, PP. 1020-1026, (2006); BANERJEE S., GHOSHAL S., PORTER T.D., LIPIDS, 46, PP. 311-321, (2011); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., BIOL. RES., 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., BR. J. NUTR; ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., BIOL. RES., 27, PP. 205-208, (1994); ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., REV. CENIC CIEN. BIOL., 22, PP. 60-61, (1991); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., CURR. THER. RES. CLIN. EXP., 51, PP. 568-575, (1992); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., MESA M., CURR. THER. RES. CLIN. EXP., 64, PP. 522-537, (2003); LOPEZ E., ILLNAIT J., FERNANDEZ J.C., FERNANDEZ L., GAMEZ R., MESA M., MENDOZA S., MAS R., RUIZ D., JARDINES, Y. REV. CRNIC CIEN. BIOL., 41, PP. 31-37, (2010); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., HERNANDEZ E., FERNANDEZ J., GAMEZ R., GUTIERREZ C., ALVAREZ E., CURR. THER. RES., 63, PP. 286-303, (2002); ILLNAIT J., LOPEZ E., FERNANDEZ L., MAS R., GAMEZ R., MESA M., MENDOZA S., FERNANDEZ J.C., INT. J. PHARM. SCI. REV. RES., 22, PP. 303-309, (2013); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., METABOLISM, 53, PP. 1309-1314, (2004); GOUNI-BERTHOLD I., BERTHOLD H.K., AM. HEART J., 143, PP. 356-365, (2002); TANG M., WU S.Z., GONG X., ZHONGHUA XIN XUE GUAN BING ZA ZHI, 41, PP. 488-492, (2013); WANG H.Y., JIAO Q.P., CHEN S.Y., SHENG J., JIANG H., LU J., ZHENG S.B., FANG N.Y., AM. J. MED. SCI., 356, PP. 254-261, (2018); CARESKEY H.E., DAVIS R.A., ALBORN W.E., TROUTT J.S., CAO G., KONRAD R.J., J. LIPID RES., 49, PP. 394-398, (2008); WELDER G., ZINEH I., PACANOWSKI M.A., TROUTT J.S., CAO G., KONRAD R.J., J. LIPID RES., 51, PP. 2714-2721, (2010); MOUSAVI S.A., BERGE K.E., LEREN T.P., J. INTERN. MED., 266, PP. 507-519, (2009); GUO Y.L., XU R.X., ZHU C.G., WU N.Q., CUI Z.P., LI J.J.E., BASED COMPLEMENT. ALTERNAT. MED., 2014, (2014); LEE H.Y., J. KOREAN MED. ASSOC., 6, PP. 485-492, (2018); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., FRONT. PHYSIOL., 9, (2018); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., OXID. MED. CELL. LONGEV., 2018, (2018); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., ARCH. MED. RES., 28, PP. 355-360, (1997); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., J. AGRIC. FOOD CHEM., 53, PP. 6289-6293, (2005); CICERO A.F., COLLETTI A., PHYTOMEDICINE, 23, PP. 1113-1118, (2016); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., INT. J. CLIN. PHARMACOL. RES., 22, PP. 89-99, (2002); HARRABI S., FERCHICHI A., BACHELI A., FELLAH H., LIPIDS HEALTH DIS, 17, (2018); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., CLIN. DRUG INVESTIG., 23, PP. 639-650, (2003); ELSEWEIDY M.M., ZEIN N., ALDHAMY S.E., ELSAWY M.M., SAEID S.A., EXP. BIOL. MED., 241, PP. 1943-1949, (2016); KAUP R.M., KHAYYAL M.T., VERSPOHL E.J., PHYTOTHER. RES., 27, PP. 264-271, (2013); ELSEWEIDY M.M., MOHAMED H.E., ELRASHIDY R.A., ATTEIA H.H., ELNAGAR G.M., J. CARDIOVASC. PHARMACOL. THER., 23, PP. 551-560, (2018); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., J. PHARM. PHARMACOL., 47, PP. 289-291, (1995); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., PROSTAGLANDINS, LEUKOT. ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., INT. J. TISSUE REACT., 20, PP. 119-124, (1998); WONG W.T., ISMAIL M., TOHIT E.R., ABDULLAH R., ZHANG Y.D.E., BASED COMPLEMENT. ALTERNAT. MED., 2016, (2016); WONG W.T., ISMAIL M., IMAM M.U., ZHANG Y.D., BMC COMPLEMENT. ALTERN. MED., 16, (2016); ILLNAIT J., CASTANO G., ALVAREZ E., FERNANDEZ L., MAS R., MENDOZA S., GAMEZ R., ANGIOLOGY, 59, PP. 269-277, (2008); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., MENDOZA N., VALLE M., JIMENEZ S., SANCHEZ J., INDIAN, J. PHARM. SCI, 75, PP. 635-641, (2013); ORTEGA L.L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., FERNANDEZ J.C., ILLNAIT J., ALVAREZ E.J., MED. FOOD, 9, PP. 378-385, (2006); SANCHEZ J., FERNANDEZ L., ILLNAIT J., DE LOURDES ARRUZAZABALA M., MOLINA V., MAS R., MENDOZA S., CARBAJAL D., MESA M., FERNANDEZ J., IOSR J. PHARM., 2, PP. 14-24, (2012); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., FERNANDEZ L., MESA M., VEGA H., FERNANDEZ J., REYES P., RUIZ D., REV. NEUROL., 64, PP. 153-161, (2017); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., VEGA H., FERNANDEZ L., MESA M., FERNANDEZ J., REYES P., RUIZ D., INT. J. PHARM. SCI. REV. RES., 37, PP. 7-14, (2016); SANCHEZ J., ILLNAIT J., MAS R., PEREZ Y., MENDOZA S., CABRERA L., FERNANDEZ L., MESA M., FERNANDEZ J., OYARZABAL A., MOLONA V., REYES P., IOSR J. PHAM., 3, PP. 31-40, (2013); SANCHEZ-LOPEZ J., FERNANDEZ-TRAVIESO J.C., ILLNAIT-FERRER J., FERNANDEZ-DORTA L., MENDOZA-CASTANO S., MAS-FERREIRO R., MESA-ANGARICA M., REYES-SUAREZ P., REV. DE NEURO, 67, PP. 331-338, (2018); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., REJUVENATION RES, 19, PP. 149-158, (2016); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., REJUVENATION RES, 19, PP. 59-70, (2016); LEE J.H., JIA Y., THACH T.T., HAN Y., KIM B., WU C., KIM Y., SEO W.D., LEE S., J. NUTR. RES., 43, PP. 89-99, (2017); LIM D., HA M., SONG I., J. KOREAN MED. SCI., 29, PP. 1597-1603, (2014)","J. JUNG; COLLEGE OF PHARMACY, DUKSUNG WOMEN’S UNIVERSITY, SEOUL, 33, SAMYANGRO 144-GIL, DOBONG-GU, 01369, SOUTH KOREA; EMAIL: JOOHEE@DUKSUNG.AC.KR","KOREAN SOCIETY OF PHARMACOGNOSY","ENGLISH","NAT. PROD. SCI.","ARTICLE","ISI","2-S2.0-85078795059","NAT PROD SCI","DUKSUNG WOMEN’S UNIVERSITY;DUKSUNG WOMEN’S UNIVERSITY;DUKSUNG WOMEN’S UNIVERSITY;DUKSUNG WOMEN’S UNIVERSITY","NOTREPORTED;DUKSUNG WOMEN’S UNIVERSITY;NOTREPORTED",NA,"JANG Y-S, 2019, NAT PROD SCI","JANG Y-S, 2019, NAT PROD SCI"
"LUPI F;GRECO V;BALDINO N;DE C B;FISCHER P;GABRIELE D","LUPI, FRANCESCA R. (24768180600); GRECO, VALERIA (57190121462); BALDINO, NOEMI (24767432700); DE CINDIO, BRUNO (6602864175); FISCHER, PETER (57202725832); GABRIELE, DOMENICO (6507587673)","THE EFFECTS OF INTERMOLECULAR INTERACTIONS ON THE PHYSICAL PROPERTIES OF ORGANOGELS IN EDIBLE OILS",2016,"JOURNAL OF COLLOID AND INTERFACE SCIENCE","483","10",98,"10.1016/j.jcis.2016.08.009","DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;INSTITUTE OF FOOD, NUTRITION AND HEALTH, ETH ZURICH, ZURICH, 8092, SWITZERLAND;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY","THE MICROSTRUCTURE OF ORGANOGELS BASED ON MONOGLYCERIDES OF FATTY ACIDS (MAGS) AND POLICOSANOL AND ON DIFFERENT EDIBLE OILS WAS INVESTIGATED BY USING DIFFERENT TECHNIQUES (CALORIMETRY, NUCLEAR MAGNETIC RESONANCE, INFRARED SPECTROSCOPY, RHEOLOGY, POLARIZED LIGHT MICROSCOPY) TOWARDS A BETTER UNDERSTANDING AND CONTROL OF THE OIL GELATION PHENOMENA. DYNAMIC MODULI WERE RELATED VIA A FRACTAL MODEL TO MICROSTRUCTURAL INFORMATION SUCH AS SOLID CONTENT AND FRACTAL DIMENSION. INFRARED SPECTROSCOPY EVIDENCED THAT NETWORK STRUCTURE IN MAGS GEL IS MAINLY DUE TO HYDROGEN BONDING, WHEREAS IN POLICOSANOL SYSTEM IS MAINLY GIVEN BY VAN DER WAALS INTERACTIONS. BECAUSE OF THE DIFFERENT RELATIVE CONTRIBUTION OF MOLECULAR INTERACTIONS, THE INVESTIGATED ORGANOGELATORS EXHIBIT A DISTINGUISHED MACROSCOPIC BEHAVIOR. MAGS ARE SENSITIVE TO THE UTILIZED OIL AND STRUCTURATION OCCURS QUICKLY, EVEN THOUGH AT A TEMPERATURE LOWER THAN POLICOSANOL. POLICOSANOL ORGANOGELS EXHIBIT A BEHAVIOR INDEPENDENT OF THE USED OIL AND A SLOWER GELATION RATE, AS A RESULT OF THE WEAKER VAN DER WAALS INTERACTIONS. NEVERTHELESS, AT LOWER CONCENTRATION A STRONGER FINAL GEL IS OBTAINED, PROBABLY DUE TO OF THE LARGE NUMBER OF INTERACTIONS ARISING AMONG THE LONG ALKYL CHAINS OF THE FATTY ALCOHOLS. OBTAINED RESULTS EVIDENCED THAT POLICOSANOL IS VERY EFFECTIVE IN GELATION OF DIFFERENT OILS AND SEEMS PROMISING FOR POTENTIAL COMMERCIAL USES. © 2016 ELSEVIER INC.","DSC; EDIBLE OILS; FT-IR; HYDROGEN BONDING; MONOGLYCERIDES OF FATTY ACIDS; ORGANOGEL; POLICOSANOL; RHEOLOGY; VAN DER WAALS INTERACTIONS","FATTY ACIDS; FATTY ALCOHOLS; FOOD TECHNOLOGY; GELS; HUMANS; HYDROGEN BONDING; MONOGLYCERIDES; OLIVE OIL; PHASE TRANSITION; PLANT OILS; RHEOLOGY; TEMPERATURE; ALCOHOLS; ELASTICITY; FRACTAL DIMENSION; FRACTALS; GELATION; HYDROGEN BONDS; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OILS AND FATS; RHEOLOGY; VAN DER WAALS FORCES; EDIBLE OIL; POLICOSANOL; FATTY ACID; FATTY ALCOHOL; GEL; MONOACYLGLYCEROL; OLIVE OIL; SUNFLOWER OIL; VEGETABLE OIL; INTERMOLECULAR INTERACTIONS; MACROSCOPIC BEHAVIORS; MICROSTRUCTURAL INFORMATION; MONOGLYCERIDES; ORGANOGELS; POLICOSANOL; RELATIVE CONTRIBUTION; VAN DER WAALS INTERACTIONS; ARTICLE; CALORIMETRY; CHEMICAL STRUCTURE; CONTROLLED STUDY; FLOW KINETICS; FRACTAL ANALYSIS; GEL; GELATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; LOW TEMPERATURE; MICROSCOPY; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE; ORGANOGEL; PHYSICAL CHEMISTRY; POLARIZED LIGHT MICROSCOPY; PRIORITY JOURNAL; SOLID; CHEMISTRY; FOOD HANDLING; GEL; HUMAN; PHASE TRANSITION; TEMPERATURE; FATTY ACIDS","","","SIRAJ N., SHABBIR M.A., AHMAD T., SAJJAD A., KHAN M.R., KHAN M.I., BUTT M.S., ORGANOGELATORS AS A SATURATED FAT REPLACER FOR STRUCTURING EDIBLE OILS, INT. J. FOOD PROP., 18, 9, PP. 1973-1989, (2015); LUPI F.R., GABRIELE D., DE CINDIO B., SANCHEZ M.C., GALLEGOS C., A RHEOLOGICAL ANALYSIS OF STRUCTURED WATER-IN-OLIVE OIL EMULSIONS, J. FOOD ENG., 107, 3-4, PP. 296-303, (2011); CO E.D., MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, J. AM. OIL CHEM. SOC., 89, 5, PP. 749-780, (2012); LUPI F.R., GENTILE L., GABRIELE D., MAZZULLA S., BALDINO N., DE CINDIO B., OLIVE OIL AND HYPERTHERMAL WATER BIGELS FOR COSMETIC USES, J. COLLOID INTERFACE SCI., 459, PP. 70-78, (2015); ZETZL A.K., MARANGONI A.G., BARBUT S., MECHANICAL PROPERTIES OF ETHYLCELLULOSE OLEOGELS AND THEIR POTENTIAL FOR SATURATED FAT REDUCTION IN FRANKFURTERS, FOOD FUNCT., 3, 3, PP. 327-337, (2012); LUPI F.R., GABRIELE D., SETA L., BALDINO N., DE CINDIO B., RHEOLOGICAL DESIGN OF STABILIZED MEAT SAUCES FOR INDUSTRIAL USES, EUR. J. LIPID SCI. TECHNOL., 116, 12, PP. 1734-1744, (2014); LUPI F.R., GABRIELE D., BALDINO N., SETA L., DE CINDIO B., DE ROSE C., STABILIZATION OF MEAT SUSPENSIONS BY ORGANOGELATION: A RHEOLOGICAL APPROACH, EUR. J. LIPID SCI. TECHNOL., 114, 12, PP. 1381-1389, (2012); TORO-VAZQUEZ J.F., MAURICIO-PEREZ R., GONZALEZ-CHAVEZ M.M., SANCHEZ-BECERRIL M., ORNELAS-PAZ J.D., PEREZ-MARTINEZ J.D., PHYSICAL PROPERTIES OF ORGANOGELS AND WATER IN OIL EMULSIONS STRUCTURED BY MIXTURES OF CANDELILLA WAX AND MONOGLYCERIDES, FOOD RES. INT., 54, 2, PP. 1360-1368, (2013); WANG F.C., GRAVELLE A.J., BLAKE A.I., MARANGONI A.G., NOVEL TRANS FAT REPLACEMENT STRATEGIES, CURR. OPIN. FOOD SCI., 7, PP. 27-34, (2016); PATEL A.R., DEWETTINCK K., EDIBLE OIL STRUCTURING: AN OVERVIEW AND RECENT UPDATES, FOOD FUNCT., 7, 1, PP. 20-29, (2016); LUPI F.R., GABRIELE D., BALDINO N., MIJOVIC P., PARISI O.I., PUOCI F., OLIVE OIL/POLICOSANOL ORGANOGELS FOR NUTRACEUTICAL AND DRUG DELIVERY PURPOSES, FOOD FUNCT., 4, 10, PP. 1512-1520, (2013); SAGIRI S.S., BEHERA B., RAFANAN R.R., BHATTACHARYA C., PAL K., BANERJEE I., ROUSSEAU D., ORGANOGELS AS MATRICES FOR CONTROLLED DRUG DELIVERY: A REVIEW ON THE CURRENT STATE, SOFT MATER., 12, 1, PP. 47-72, (2013); SAGIRI S.S., SETHY J., PAL K., BANERJEE I., PRAMANIK K., MAITI T.K., ENCAPSULATION OF VEGETABLE ORGANOGELS FOR CONTROLLED DELIVERY APPLICATIONS, DES. MONOMERS POLYM., 16, 4, PP. 366-376, (2013); SANZ R., CALPENA A.C., MALLANDRICH M., CLARES B., ENHANCING TOPICAL ANALGESIC ADMINISTRATION: REVIEW AND PROSPECT FOR TRANSDERMAL AND TRANSBUCCAL DRUG DELIVERY SYSTEMS, CURR. PHARM. DES., 21, 20, PP. 2867-2882, (2015); REHMAN K., ZULFAKAR M.H., RECENT ADVANCES IN GEL TECHNOLOGIES FOR TOPICAL AND TRANSDERMAL DRUG DELIVERY, DRUG DEV. IND. PHARM., 40, 4, PP. 433-440, (2014); ABDALLAH D.J., WEISS R.G., N-ALKANES GEL N-ALKANES (AND MANY OTHER ORGANIC LIQUIDS), LANGMUIR, 16, 2, PP. 352-355, (2000); VAN ESCH J.H., FERINGA B.L., NEW FUNCTIONAL MATERIALS BASED ON SELF-ASSEMBLING ORGANOGELS: FROM SERENDIPITY TOWARDS DESIGN, ANGEW. CHEM. INT. ED., 39, 13, PP. 2263-2266, (2000); WU Y., WU S., ZOU G., ZHANG Q., SOLVENT EFFECTS ON STRUCTURE, PHOTORESPONSE AND SPEED OF GELATION OF A DICHOLESTEROL-LINKED AZOBENZENE ORGANOGEL, SOFT MATTER, 7, 19, PP. 9177-9183, (2011); ZHU G., DORDICK J.S., SOLVENT EFFECT ON ORGANOGEL FORMATION BY LOW MOLECULAR WEIGHT MOLECULES, CHEM. MATER., 18, 25, PP. 5988-5995, (2006); LUBORADZKI R., GRONWALD O., IKEDA M., SHINKAI S., REINHOUDT D.N., AN ATTEMPT TO PREDICT THE GELATION ABILITY OF HYDROGEN-BOND-BASED GELATORS UTILIZING A GLYCOSIDE LIBRARY, TETRAHEDRON, 56, 49, PP. 9595-9599, (2000); BURKHARDT M., KINZEL S., GRADZIELSKI M., MACROSCOPIC PROPERTIES AND MICROSTRUCTURE OF HSA BASED ORGANOGELS: SENSITIVITY TO POLAR ADDITIVES, J. COLLOID INTERFACE SCI., 331, 2, PP. 514-521, (2009); CHEN C.H., TERENTJEV E.M., AGING AND METASTABILITY OF MONOGLYCERIDES IN HYDROPHOBIC SOLUTIONS, LANGMUIR, 25, 12, PP. 6717-6724, (2009); VALOPPI F., CALLIGARIS S., BARBA L., NICOLI M.C., STRUCTURAL AND VISCOELASTIC CHARACTERIZATION OF TERNARY MIXTURES OF SUNFLOWER OIL, SATURATED MONOGLYCERIDES AND AQUEOUS PHASES CONTAINING DIFFERENT BASES, FOOD RES. INT., 74, PP. 224-230, (2015); CALLIGARIS S., DA PIEVE S., ARRIGHETTI G., BARBA L., EFFECT OF THE STRUCTURE OF MONOGLYCERIDE-OIL-WATER GELS ON AROMA PARTITION, FOOD RES. INT., 43, 3, PP. 671-677, (2010); BATTE H.D., WRIGHT A.J., RUSH J.W., IDZIAK S.H.J., MARANGONI A.G., EFFECT OF PROCESSING CONDITIONS ON THE STRUCTURE OF MONO STEARIN-OIL-WATER GELS, FOOD RES. INT., 40, 8, PP. 982-988, (2007); CHEN C.H., VAN DAMME I., TERENTJEV E.M., PHASE BEHAVIOR OF C18 MONOGLYCERIDE IN HYDROPHOBIC SOLUTIONS, SOFT MATTER, 5, 2, PP. 432-439, (2009); DA PIEVE S., CALLIGARIS S., CO E., NICOLI M.C., MARANGONI A.G., SHEAR NANOSTRUCTURING OF MONOGLYCERIDE ORGANOGELS, FOOD BIOPHYS., 5, 3, PP. 211-217, (2010); KESSELMAN E., SHIMONI E., IMAGING OF OIL/MONOGLYCERIDE NETWORKS BY POLARIZING NEAR-FIELD SCANNING OPTICAL MICROSCOPY, FOOD BIOPHYS., 2, 2-3, PP. 117-123, (2007); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RES. INT., 51, 2, PP. 510-517, (2013); LUPI F.R., GABRIELE D., FACCIOLO D., BALDINO N., SETA L., DE CINDIO B., EFFECT OF ORGANOGELATOR AND FAT SOURCE ON RHEOLOGICAL PROPERTIES OF OLIVE OIL-BASED ORGANOGELS, FOOD RES. INT., 46, 1, PP. 177-184, (2012); OJIJO N.K., NEEMAN I., EGER S., SHIMONI E., EFFECTS OF MONOGLYCERIDE CONTENT, COOLING RATE AND SHEAR ON THE RHEOLOGICAL PROPERTIES OF OLIVE OIL/MONOGLYCERIDE GEL NETWORKS, J. SCI. FOOD AGRIC., 84, 12, PP. 1585-1593, (2004); LUPI F.R., GABRIELE D., DE CINDIO B., EFFECT OF SHEAR RATE ON CRYSTALLISATION PHENOMENA IN OLIVE OIL-BASED ORGANOGELS, FOOD BIOPROCESS TECHNOL., 5, 7, PP. 2880-2888, (2012); ALVAREZ-MITRE F.M., TORO-VAZQUEZ J.F., MOSCOSA-SANTILLAN M., SHEAR RATE AND COOLING MODELING FOR THE STUDY OF CANDELILLA WAX ORGANOGELS’ RHEOLOGICAL PROPERTIES, J. FOOD ENG., 119, 3, PP. 611-618, (2013); ALVAREZ-MITRE F.M., MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M.A., TORO-VAZQUEZ J.F., SHEARING AS A VARIABLE TO ENGINEER THE RHEOLOGY OF CANDELILLA WAX ORGANOGELS, FOOD RES. INT., 49, 1, PP. 580-587, (2012); OGUTCU M., YILMAZ E., OLEOGELS OF VIRGIN OLIVE OIL WITH CARNAUBA WAX AND MONOGLYCERIDE AS SPREADABLE PRODUCTS, GRASAS ACEITES, 65, 3, (2014); SCHAINK H.M., VAN MALSSEN K.F., MORGADO-ALVES S., KALNIN D., VAN DER LINDEN E., CRYSTAL NETWORK FOR EDIBLE OIL ORGANOGELS: POSSIBILITIES AND LIMITATIONS OF THE FATTY ACID AND FATTY ALCOHOL SYSTEMS, FOOD RES. INT., 40, 9, PP. 1185-1193, (2007); GANDOLFO F.G., BOT A., FLOTER E., STRUCTURING OF EDIBLE OILS BY LONG-CHAIN FA, FATTY ALCOHOLS, AND THEIR MIXTURES, J. AM. OIL CHEM. SOC., 81, 1, PP. 1-6, (2004); DA SILVA J.A.L., GONCALVES M.P., RAO M.A., KINETICS AND THERMAL BEHAVIOUR OF THE STRUCTURE FORMATION PROCESS IN HMP/SUCROSE GELATION, INT. J. BIOL. MACROMOL., 17, PP. 25-32, (1995); TORO-VAZQUEZ J.F., MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M., ALONZO-MACIAS M., GONZALEZ-CHAVEZ M.M., THERMAL AND TEXTURAL PROPERTIES OF ORGANOGELS DEVELOPED BY CANDELILLA WAX IN SAFFLOWER OIL, J. AM. OIL CHEM. SOC., 84, 11, PP. 989-1000, (2007); TORO-VAZQUEZ J.F., MORALES-RUEDA J., MALLIA V.A., WEISS R.G., RELATIONSHIP BETWEEN MOLECULAR STRUCTURE AND THERMO-MECHANICAL PROPERTIES OF CANDELILLA WAX AND AMIDES DERIVED FROM (R)-12-HYDROXYSTEARIC ACID AS GELATORS OF SAFFLOWER OIL, FOOD BIOPHYS., 5, 3, PP. 193-202, (2010); LOPEZ-MARTINEZ A., MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M.A., MARANGONI A.G., TORO-VAZQUEZ J.F., COMPARING THE CRYSTALLIZATION AND RHEOLOGICAL BEHAVIOR OF ORGANOGELS DEVELOPED BY PURE AND COMMERCIAL MONOGLYCERIDES IN VEGETABLE OIL, FOOD RES. INT., 64, PP. 946-957, (2014); VEREECKEN J., MEEUSSEN W., FOUBERT I., LESAFFER A., WOUTERS J., DEWETTINCK K., COMPARING THE CRYSTALLIZATION AND POLYMORPHIC BEHAVIOUR OF SATURATED AND UNSATURATED MONOGLYCERIDES, FOOD RES. INT., 42, 10, PP. 1415-1425, (2009); MARTINEZ L., URIBARRI E., LAGUNA A., CHARACTERIZATION AND COMPATIBILITY STUDIES BETWEEN POLICOSANOL, A NEW HYPOCHOLESTEROLEMIC DRUG, AND TABLET EXCIPIENTS USING DIFFERENTIAL SCANNING CALORIMETRY (DSC), ARCH. PHARM., 332, 12, PP. 439-441, (1999); GANDOLFO F.G., BOT A., FLOTER E., PHASE DIAGRAM OF MIXTURES OF STEARIC ACID AND STEARYL ALCOHOL, THERMOCHIM. ACTA, 404, 1-2, PP. 9-17, (2003); MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M.A., WEISS R.G., TORO-VAZQUEZ J.F., THERMO-MECHANICAL PROPERTIES OF CANDELILLA WAX AND DOTRIACONTANE ORGANOGELS IN SAFFLOWER OIL, EUR. J. LIPID SCI. TECHNOL., 111, 2, PP. 207-215, (2009); WENTZEL N., MILNER S.T., CRYSTAL AND ROTATOR PHASES OF N-ALKANES: A MOLECULAR DYNAMICS STUDY, J. CHEM. PHYS., 132, 4, (2010); SUZUKI M., NAKAJIMA Y., YUMOTO M., KIMURA M., SHIRAI H., HANABUSA K., EFFECTS OF HYDROGEN BONDING AND VAN DER WAALS INTERACTIONS ON ORGANOGELATION USING DESIGNED LOW-MOLECULAR-WEIGHT GELATORS AND GEL FORMATION AT ROOM TEMPERATURE, LANGMUIR, 19, 21, PP. 8622-8624, (2003); ADEL R.D., HEUSSEN P.C.M., BOT A., EFFECT OF WATER ON SELF-ASSEMBLED TUBULES IN Β-SITOSTEROL + Γ-ORYZANOL-BASED ORGANOGELS, J. PHYS. CONF. SER., 247, 1, (2010); ZWEEP N., HOPKINSON A., MEETSMA A., BROWNE W.R., FERINGA B.L., VAN ESCH J.H., BALANCING HYDROGEN BONDING AND VAN DER WAALS INTERACTIONS IN CYCLOHEXANE-BASED BISAMIDE AND BISUREA ORGANOGELATORS, LANGMUIR, 25, 15, PP. 8802-8809, (2009); SUZUKI M., NIGAWARA T., YUMOTO M., KIMURA M., SHIRAI H., HANABUSA K., L-LYSINE BASED GEMINI ORGANOGELATORS: THEIR ORGANOGELATION PROPERTIES AND THERMALLY STABLE ORGANOGELS, ORG. BIOMOL. CHEM., 1, 22, PP. 4124-4131, (2003); BLAKE A.I., CO E.D., MARANGONI A.G., STRUCTURE AND PHYSICAL PROPERTIES OF PLANT WAX CRYSTAL NETWORKS AND THEIR RELATIONSHIP TO OIL BINDING CAPACITY, J. AM. OIL CHEM. SOC., 91, 6, PP. 885-903, (2014); TARABUKINA E., JEGO F., HAUDIN J.M., NAVARD P., PEUVREL-DISDIER E., EFFECT OF SHEAR ON THE RHEOLOGY AND CRYSTALLIZATION OF PALM OIL, J. FOOD SCI., 74, 8, PP. E405-E416, (2009); TANG D., MARANGONI A.G., MODELING THE RHEOLOGICAL PROPERTIES AND STRUCTURE OF COLLOIDAL FAT CRYSTAL NETWORKS, TRENDS FOOD SCI. TECHNOL., 18, 9, PP. 474-483, (2007); TANG D., MARANGONI A.G., MODIFIED FRACTAL MODEL AND RHEOLOGICAL PROPERTIES OF COLLOIDAL NETWORKS, J. COLLOID INTERFACE SCI., 318, 2, PP. 202-209, (2008); NARINE S.S., MARANGONI A.G., RELATING STRUCTURE OF FAT CRYSTAL NETWORKS TO MECHANICAL PROPERTIES: A REVIEW, FOOD RES. INT., 32, 4, PP. 227-248, (1999); COMMISSION IMPLEMENTING REGULATION (EU) NO 1348/2013 OF 16 DECEMBER 2013, OFF. J. EUR. UNION, L338, PP. 31-36, (2013); SUZUKI M., ABE T., HANABUSA K., LOW-MOLECULAR-WEIGHT GELATORS BASED ON N(ALPHA)-ACETYL-N(EPSILON)-DODECYL-L-LYSINE AND THEIR AMPHIPHILIC GELATION PROPERTIES, J. COLLOID INTERFACE SCI., 341, 1, PP. 69-74, (2010); MONFREDA M., GOBBI L., GRIPPA A., BLENDS OF OLIVE OIL AND SUNFLOWER OIL: CHARACTERISATION AND OLIVE OIL QUANTIFICATION USING FATTY ACID COMPOSITION AND CHEMOMETRIC TOOLS, FOOD CHEM., 134, 4, PP. 2283-2290, (2012)","D. GABRIELE; DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), VIA P. BUCCI, CUBO 39C, I-87036 RENDE, ITALY; EMAIL: DOMENICO.GABRIELE@UNICAL.IT","ACADEMIC PRESS INC.","ENGLISH","J. COLLOID INTERFACE SCI.","ARTICLE","ISI","2-S2.0-84989316771","J COLLOID INTERFACE SCI","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;INSTITUTE OF FOOD;UNIVERSITY OF CALABRIA","NOTREPORTED;ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.);NOTREPORTED",NA,"LUPI FR, 2016, J COLLOID INTERFACE SCI","LUPI FR, 2016, J COLLOID INTERFACE SCI"
"LUPI F;DE S M;CIUCHI F;BALDINO N;GABRIELE D","LUPI, F.R. (24768180600); DE SANTO, M.P. (54790520200); CIUCHI, F. (55900943800); BALDINO, N. (24767432700); GABRIELE, D. (6507587673)","THE ROLE OF EDIBLE OILS IN LOW MOLECULAR WEIGHT ORGANOGELS RHEOLOGY AND STRUCTURE",2018,"FOOD RESEARCH INTERNATIONAL","111","8",15,"10.1016/j.foodres.2018.05.050","DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036 CS, ITALY;DEPARTMENT OF PHYSICS, UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 31C, RENDE, I-87036 CS, ITALY, CNR-NANOTEC C/O DEPARTMENT OF PHYSICS, UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 33B, RENDE, I-87036 CS, ITALY;CNR-NANOTEC C/O DEPARTMENT OF PHYSICS, UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 33B, RENDE, I-87036 CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036 CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036 CS, ITALY","IN THIS PAPER, THE ROLE OF SOLVENT CHARACTERISTICS ON THE RHEOLOGICAL AND PHYSICOCHEMICAL PROPERTIES OF ORGANOGELS WAS INVESTIGATED USING DIFFERENT TECHNIQUES. VEGETABLE OILS, SUCH AS RICE, SUNFLOWER AND CASTOR OIL WERE USED AS SOLVENTS, FOR PRODUCING ORGANOGELS WITH MONOGLYCERIDES OF FATTY ACIDS OR A MIXTURE OF FATTY ALCOHOLS (POLICOSANOL) AS GELATORS. MOREOVER, TWO NON-EDIBLE OILS (SILICON AND PARAFFIN OIL) WERE ALSO USED FOR ANALYSING THE PROPERTIES OF SOLVENTS COMPLETELY DIFFERENT IN NATURE WITH RESPECT TO THE EDIBLE ONES, FOR A BETTER INTERPRETATION OF THE GIVEN RESULTS. ORGANOGELS WERE INVESTIGATED FROM A RHEOLOGICAL POINT OF VIEW AND THROUGH A MICROSCOPIC ANALYSIS, GIVEN BY POLARISED LIGHT (POM) AND ATOMIC FORCE (AFM) MICROSCOPY, AND X-RAYS TO STUDY THE CRYSTALLINITY OF THE SYSTEM. THE IR TECHNIQUE WAS USED TO ANALYSE THE INTERMOLECULAR INTERACTIONS, RESULTING IN INTERESTING INFORMATION ABOUT THE EFFECT OF OIL POLARITY ON THE DRIVING FORCES PROMOTING STRUCTURATION. THIS INVESTIGATION SHOWED THAT WHEN SOLVENTS OF A SIMILAR CHEMICAL NATURE ARE USED, THEIR PHYSICAL PROPERTIES, MAINLY OIL POLARITY, ARE STRICTLY RELATED TO THE PROPERTIES OF THE ORGANOGEL, SUCH AS THE ONSET OF CRYSTALLISATION TEMPERATURE, THE STIFFNESS OF THE FINAL MATERIAL AND ITS CRYSTALLINITY. ANYWAY, THESE PHYSICAL PARAMETERS SEEM INSUFFICIENT TO DESCRIBE PROPERLY THE ROLE OF SOLVENTS WHEN OILS OF A DIFFERENT CHEMICAL NATURE ARE COMPARED. © 2018 ELSEVIER LTD","ATOMIC FORCE MICROSCOPY (AFM); FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR); INTERFACIAL TENSION (IFT); ORGANOGELS; POLARISED OPTICAL MICROSCOPY (POM); POLARITY; RHEOLOGY; X-RAY","CASTOR OIL; GELS; MOLECULAR WEIGHT; OILS; PARAFFIN; RHEOLOGY; RICE BRAN OIL; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUNFLOWER OIL; ALCOHOLS; ATOMIC FORCE MICROSCOPY; ELASTICITY; FATTY ACIDS; FOURIER TRANSFORM INFRARED SPECTROSCOPY; PARAFFIN OILS; RHEOLOGY; SOLVENTS; X RAYS; CASTOR OIL; LIQUID PARAFFIN; OIL; PARAFFIN; RICE BRAN OIL; SUNFLOWER OIL; INTERESTING INFORMATION; INTERMOLECULAR INTERACTIONS; LOW MOLECULAR WEIGHT ORGANOGELS; ORGANOGELS; PHYSICOCHEMICAL PROPERTY; POLARISED OPTICAL MICROSCOPY (POM); POLARITY; RHEOLOGY AND STRUCTURE; CHEMISTRY; FLOW KINETICS; GEL; INFRARED SPECTROSCOPY; MOLECULAR WEIGHT; SUNFLOWER OIL","UNIVERSITÀ DELLA CALABRIA, UNICAL; REGIONE CALABRIA, (CUPJ28C17000330006)","FUNDING TEXT 1: THE AUTHORS ARE GRATEFUL TO DR. Y. MARCHESANO FOR CARRYING OUT THE EXPERIMENTAL TESTS, TO PROF. N. SCARAMUZZA (UNIVERSITY OF CALABRIA) FOR IMPEDANCE MEASUREMENTS AND TO DR. I MUZZALUPO (CREA-OLI) FOR FATTY ACID PROFILES. THANKS ARE ALSO DUE, FOR ITS FINANCIAL SUPPORT, TO PROJECT “POR CALABRIA FESR FSE 2014-2020 “FAT FOR FIT” CUPJ28C17000330006, FUNDED BY REGIONE CALABRIA, AZIONE 1.2.2”.; FUNDING TEXT 2: THE AUTHORS ARE GRATEFUL TO DR. Y. MARCHESANO FOR CARRYING OUT THE EXPERIMENTAL TESTS, TO PROF. N. SCARAMUZZA ( UNIVERSITY OF CALABRIA ) FOR IMPEDANCE MEASUREMENTS AND TO DR. I MUZZALUPO (CREA-OLI) FOR FATTY ACID PROFILES. THANKS ARE ALSO DUE, FOR ITS FINANCIAL SUPPORT, TO PROJECT “POR CALABRIA FESR FSE 2014-2020 “FAT FOR FIT”, CUPJ28C17000330006 , FUNDED BY REGIONE CALABRIA , AZIONE 1.2.2”.  ","AZIZIAN H., KRAMER J.K.G., A RAPID METHOD FOR THE QUANTIFICATION OF FATTY ACIDS IN FATS AND OILS WITH EMPHASIS ON TRANS FATTY ACIDS USING FOURIER TRANSFORM NEAR INFRARED SPECTROSCOPY (FT-NIR), LIPIDS, 40, 8, PP. 855-867, (2005); BARSOUKOV E., MACDONALD J.R., IMPEDANCE SPECTROSCOPY: THEORY, EXPERIMENT, AND APPLICATIONS, (2005); BOT A., AGTEROF W.G.M., STRUCTURING OF EDIBLE OILS BY MIXTURES OF Γ-ORYZANOL WITH Β-SITOSTEROL OR RELATED PHYTOSTEROLS, JOURNAL OF THE AMERICAN OIL CHEMISTS’ SOCIETY, 83, 6, PP. 513-521, (2006); BOT A., DEN ADEL R., ROIJERS E.C., FIBRILS OF Γ-ORYZANOL + Β-SITOSTEROL IN EDIBLE OIL ORGANOGELS, JOURNAL OF THE AMERICAN OIL CHEMISTS’ SOCIETY, 85, 12, PP. 1127-1134, (2008); BRULLS M., FOLESTAD S., SPAREN A., RASMUSON A., SALOMONSSON J., APPLYING SPECTRAL PEAK AREA ANALYSIS IN NEAR-INFRARED SPECTROSCOPY MOISTURE ASSAYS, JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 44, 1, PP. 127-136, (2007); CALLIGARIS S., DA PIEVE S., ARRIGHETTI G., BARBA L., EFFECT OF THE STRUCTURE OF MONOGLYCERIDE-OIL-WATER GELS ON AROMA PARTITION, FOOD RESEARCH INTERNATIONAL, 43, 3, PP. 671-677, (2010); CALLIGARIS S., MIROLO G., DA PIEVE S., ARRIGHETTI G., NICOLI M.C., EFFECT OF OIL TYPE ON FORMATION, STRUCTURE AND THERMAL PROPERTIES OF GAMMA-ORYZANOL AND BETA-SITOSTEROL-BASED ORGANOGELS, FOOD BIOPHYSICS, 9, 1, PP. 69-75, (2014); CASALE M., OLIVERI P., CASOLINO C., SINELLI N., ZUNIN P., ARMANINO C., LANTERI S., CHARACTERISATION OF PDO OLIVE OIL CHIANTI CLASSICO BY NON-SELECTIVE (UV–VISIBLE, NIR AND MIR SPECTROSCOPY) AND SELECTIVE (FATTY ACID COMPOSITION) ANALYTICAL TECHNIQUES, ANALYTICA CHIMICA ACTA, 712, PP. 56-63, (2012); CHAVES K.F., BARRERA-ARELLANO D., RIBEIRO A.P.B., POTENTIAL APPLICATION OF LIPID ORGANOGELS FOR FOOD INDUSTRY, FOOD RESEARCH INTERNATIONAL, 105, PP. 863-872, (2018); CHEN C.H., TERENTJEV E.M., AGING AND METASTABILITY OF MONOGLYCERIDES IN HYDROPHOBIC SOLUTIONS, LANGMUIR, 25, 12, PP. 6717-6724, (2009); CO E.D., MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 89, 5, PP. 749-780, (2012); VAN ESCH J.H., FERINGA B.L., NEW FUNCTIONAL MATERIALS BASED ON SELF-ASSEMBLING ORGANOGELS: FROM SERENDIPITY TOWARDS DESIGN, ANGEWANDTE CHEMIE INTERNATIONAL EDITION, 39, 13, PP. 2263-2266, (2000); GALTIER O., DUPUY N., LE DREAU Y., OLLIVIER D., PINATEL C., KISTER J., ARTAUD J., GEOGRAPHIC ORIGINS AND COMPOSITIONS OF VIRGIN OLIVE OILS DETERMINATED BY CHEMOMETRIC ANALYSIS OF NIR SPECTRA, ANALYTICA CHIMICA ACTA, 595, 1, PP. 136-144, (2007); GROMPONE M.A., SUNFLOWER OIL, VEGETABLE OILS IN FOOD TECHNOLOGY, PP. 137-167, (2011); HWANG H.S., SINGH M., WINKLER-MOSER J.K., BAKOTA E.L., LIU S.X., PREPARATION OF MARGARINES FROM ORGANOGELS OF SUNFLOWER WAX AND VEGETABLE OILS, JOURNAL OF FOOD SCIENCE, 79, 10, PP. C1926-C1932, (2014); JOHNSON W., FINAL REPORT ON THE SAFETY ASSESSMENT OF RICINUS COMMUNIS (CASTOR) SEED OIL, HYDROGENATED CASTOR OIL, GLYCERYL RICINOLEATE, GLYCERYL RICINOLEATE SE, RICINOLEIC ACID, POTASSIUM RICINOLEATE, SODIUM RICINOLEATE, ZINC RICINOLEATE, CETYL RICINOLEATE, ETHYL RICINOLEATE, GLYCOL RICINOLEATE, ISOPROPYL RICINOLEATE, METHYL RICINOLEATE, AND OCTYLDODECYL RICINOLEATE, INTERNATIONAL JOURNAL OF TOXICOLOGY, 26, PP. 31-77, (2007); KIM J.-Y., LEE J.H., JEONG D.-Y., JANG D.-K., SEO T.-R., LIM S.-T., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYDRATE POLYMERS, 121, PP. 140-146, (2015); KOCHHAR S.P., MINOR AND SPECIALITY OILS, VEGETABLE OILS IN FOOD TECHNOLOGY, PP. 291-341, (2011); LUPI F., GABRIELE D., DE CINDIO B., SANCHEZ M., GALLEGOS C., A RHEOLOGICAL ANALYSIS OF STRUCTURED WATER-IN-OLIVE OIL EMULSIONS, JOURNAL OF FOOD ENGINEERING, 107, 3-4, PP. 296-303, (2011); LUPI F.R., GABRIELE D., FACCIOLO D., BALDINO N., SETA L., DE CINDIO B., EFFECT OF ORGANOGELATOR AND FAT SOURCE ON RHEOLOGICAL PROPERTIES OF OLIVE OIL-BASED ORGANOGELS, FOOD RESEARCH INTERNATIONAL, 46, 1, PP. 177-184, (2012); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RESEARCH INTERNATIONAL, 51, 2, PP. 510-517, (2013); LUPI F.R., GRECO V., BALDINO N., DE CINDIO B., FISCHER P., GABRIELE D., THE EFFECTS OF INTERMOLECULAR INTERACTIONS ON THE PHYSICAL PROPERTIES OF ORGANOGELS IN EDIBLE OILS, JOURNAL OF COLLOID AND INTERFACE SCIENCE, 483, PP. 154-164, (2016); LUPI F.R., SHAKEEL A., GRECO V., BALDINO N., CALABRO V., GABRIELE D., ORGANOGELATION OF EXTRA VIRGIN OLIVE OIL WITH FATTY ALCOHOLS, GLYCERYL STEARATE AND THEIR MIXTURE, LWT - FOOD SCIENCE AND TECHNOLOGY, 77, PP. 422-429, (2017); MARANGONI A.G., GARTI N., 1 - AN OVERVIEW OF THE PAST, PRESENT, AND FUTURE OF ORGANOGELS, EDIBLE OLEOGELS, PP. 1-17, (2011); MARANGONI A.G., IDZIAK S.H.J., VEGA C., BATTE H., OLLIVON M., JANTZI P.S., RUSH J.W.E., ENCAPSULATION-STUCTURING OF EDIBLE OIL ATTENUATES ACUTE ELEVATION OF BLOOD LIPIDS AND INSULIN IN HUMANS, SOFT MATTER, 3, 2, (2007); MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M.A., WEISS R.G., TORO-VAZQUEZ J.F., THERMO-MECHANICAL PROPERTIES OF CANDELILLA WAX AND DOTRIACONTANE ORGANOGELS IN SAFFLOWER OIL, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 111, 2, PP. 207-215, (2009); NOUREDDINI H., TEOH B.C., DAVIS CLEMENTS L., VISCOSITIES OF VEGETABLE OILS AND FATTY ACIDS, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 69, 12, PP. 1189-1191, (1992); OJIJO N.K., NEEMAN I., EGER S., SHIMONI E., EFFECTS OF MONOGLYCERIDE CONTENT, COOLING RATE AND SHEAR ON THE RHEOLOGICAL PROPERTIES OF OLIVE OIL/MONOGLYCERIDE GEL NETWORKS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 84, 12, PP. 1585-1593, (2004); PAROLO M.E., SAVINI M.C., LOEWY R.M., CHARACTERIZATION OF SOIL ORGANIC MATTER BY FT-IR SPECTROSCOPY AND ITS RELATIONSHIP WITH CHLORPYRIFOS SORPTION, JOURNAL OF ENVIRONMENTAL MANAGEMENT, 196, PP. 316-322, (2017); QUINCHIA L.A., DELGADO M.A., FRANCO J.M., SPIKES H.A., GALLEGOS C., LOW-TEMPERATURE FLOW BEHAVIOUR OF VEGETABLE OIL-BASED LUBRICANTS, INDUSTRIAL CROPS AND PRODUCTS, 37, 1, PP. 383-388, (2012); SAWALHA H., MARGRY G., DEN ADEL R., VENEMA P., BOT A., FLOTER E., VAN DER LINDEN E., THE INFLUENCE OF THE TYPE OF OIL PHASE ON THE SELF-ASSEMBLY PROCESS OF GAMMA-ORYZANOL PLUS BETA-SITOSTEROL TUBULES IN ORGANOGEL SYSTEMS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 115, 3, PP. 295-300, (2013); SCHAINK H.M., VAN MALSSEN K.F., MORGADO-ALVES S., KALNIN D., VAN DER LINDEN E., CRYSTAL NETWORK FOR EDIBLE OIL ORGANOGELS: POSSIBILITIES AND LIMITATIONS OF THE FATTY ACID AND FATTY ALCOHOL SYSTEMS, FOOD RESEARCH INTERNATIONAL, 40, 9, PP. 1185-1193, (2007); SETA L., BALDINO N., GABRIELE D., LUPI F.R., DE CINDIO B., THE EFFECT OF SURFACTANT TYPE ON THE RHEOLOGY OF OVALBUMIN LAYERS AT THE AIR/WATER AND OIL/WATER INTERFACES, FOOD HYDROCOLLOIDS, 29, 2, PP. 247-257, (2012); SETA L., BALDINO N., GABRIELE D., LUPI F.R., DE CINDIO B., RHEOLOGY AND ADSORPTION BEHAVIOUR OF BETA-CASEIN AND BETA-LACTOGLOBULIN MIXED LAYERS AT THE SUNFLOWER OIL/WATER INTERFACE, COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 441, PP. 669-677, (2014); SUZUKI M., NAKAJIMA Y., YUMOTO M., KIMURA M., SHIRAI H., HANABUSA K., EFFECTS OF HYDROGEN BONDING AND VAN DER WAALS INTERACTIONS ON ORGANOGELATION USING DESIGNED LOW-MOLECULAR-WEIGHT GELATORS AND GEL FORMATION AT ROOM TEMPERATURE, LANGMUIR, 19, 21, PP. 8622-8624, (2003); TORO-VAZQUEZ J.F., MAURICIO-PEREZ R., GONZALEZ-CHAVEZ M.M., SANCHEZ-BECERRIL M., ORNELAS-PAZ J.D., PEREZ-MARTINEZ J.D., PHYSICAL PROPERTIES OF ORGANOGELS AND WATER IN OIL EMULSIONS STRUCTURED BY MIXTURES OF CANDELILLA WAX AND MONOGLYCERIDES, FOOD RESEARCH INTERNATIONAL, 54, 2, PP. 1360-1368, (2013); DE VRIES A., GOMEZ Y.L., VAN DER LINDEN E., SCHOLTEN E., THE EFFECT OF OIL TYPE ON NETWORK FORMATION BY PROTEIN AGGREGATES INTO OLEOGELS, RSC ADVANCES, 7, 19, PP. 11803-11812, (2017); WANG T., SOYBEAN OIL, VEGETABLE OILS IN FOOD TECHNOLOGY, PP. 59-105, (2011); WU S., GAO J., EMGE T.J., ROGERS M.A., INFLUENCE OF SOLVENT ON THE SUPRAMOLECULAR ARCHITECTURES IN MOLECULAR GELS, SOFT MATTER, 9, 25, PP. 5942-5950, (2013); WU Y.P., WU S., ZOU G., ZHANG Q.J., SOLVENT EFFECTS ON STRUCTURE, PHOTORESPONSE AND SPEED OF GELATION OF A DICHOLESTEROL-LINKED AZOBENZENE ORGANOGEL, SOFT MATTER, 7, 19, PP. 9177-9183, (2011); ZHU G.Y., DORDICK J.S., SOLVENT EFFECT ON ORGANOGEL FORMATION BY LOW MOLECULAR WEIGHT MOLECULES, CHEMISTRY OF MATERIALS, 18, 25, PP. 5988-5995, (2006); ZWEEP N., HOPKINSON A., MEETSMA A., BROWNE W.R., FERINGA B.L., VAN ESCH J.H., BALANCING HYDROGEN BONDING AND VAN DER WAALS INTERACTIONS IN CYCLOHEXANE-BASED BISAMIDE AND BISUREA ORGANOGELATORS, LANGMUIR, 25, 15, PP. 8802-8809, (2009)","D. GABRIELE; DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), ARCAVACATA DI RENDE, VIA P. BUCCI – CUBO 39C, I-87036 CS, ITALY; EMAIL: DOMENICO.GABRIELE@UNICAL.IT","ELSEVIER LTD","ENGLISH","FOOD RES. INT.","ARTICLE","ISI","2-S2.0-85054168503","FOOD RES INT","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA","NOTREPORTED;ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.);NOTREPORTED",NA,"LUPI FR, 2018, FOOD RES INT","LUPI FR, 2018, FOOD RES INT"
"KHUKHLINA O;HRINYUK O;ANTONIV A;KAUSHANSKA O","KHUKHLINA, O.S. (6504590908); HRINYUK, O.YE. (58481354900); ANTONIV, A.A. (57197785166); KAUSHANSKA, O.V. (7801579006)","DISORDERS OF CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS OBESITY AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE НАРУШЕНИЕ УГЛЕВОДНОГО ОБМЕНА У БОЛЬНЫХ С НЕАЛКОГОЛЬНЫМ СТЕАТОГЕПАТИТОМ ОЖИРЕНИЕМ И ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ",2020,"MIZNARODNIJ ENDOKRINOLOGICNIJ ZURNAL","16","6",0,"10.22141/2224-0721.16.6.2020.215388","DEPARTMENT OF INTERNAL MEDICINE, CLINICAL PHARMACOLOGY AND OCCUPATIONAL DISEASES, BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE;DEPARTMENT OF INTERNAL MEDICINE, CLINICAL PHARMACOLOGY AND OCCUPATIONAL DISEASES, BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE;DEPARTMENT OF INTERNAL MEDICINE, CLINICAL PHARMACOLOGY AND OCCUPATIONAL DISEASES, BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE;DEPARTMENT OF INTERNAL MEDICINE, CLINICAL PHARMACOLOGY AND OCCUPATIONAL DISEASES, BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE","BACKGROUND. A SIGNIFICANT INCREASE IN THE INCIDENCE OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN OBESE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE WORLD REQUIRES THE STUDY OF THE MECHANISMS OF THEIR MUTUAL AGGRAVATION, AND CORRECTION OF THE METABOLIC COMPONENTS OF PATHOGENESIS AND THE CONSEQUENCES OF CONCOMITANT PATHOLOGY. THE PURPOSE WAS DETERMINATION OF THE STATE OF GLYCEMIC PARAMETERS, REGULATION OF CARBOHYDRATE METABOLISM AND EVALUATION OF THE EFFECTIVENESS OF ANTRAL AND THE COMBINATION OF ANTRAL WITH POLICOSANOL USE IN TERMS OF THE EFFECT ON THE STATE OF GLYCEMIA, THE DEGREE OF INSULIN RESISTANCE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AGAINST THE BACKGROUND OF OBESITY COMBINED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. MATERIALS AND METHODS. ONE HUNDRED AND SIXTY PATIENTS WERE SCREENED AND DIVIDED INTO 3 GROUPS. GROUP I CONSISTED OF 35 PEOPLE WITH NASH AGAINST THE BACKGROUND OF DEGREE I OBESITY. GROUP II INCLUDES 90 PATIENTS WITH NASH, DEGREE I OBESITY AND COPD 2–3 D, GROUP III — 35 INDIVIDUALS WITH COPD 2–3 D. ACCORDING TO THE TREATMENT RECEIVED, GROUP II OF PATIENTS WAS DIVIDED INTO 3 SUBGROUPS, OF WHICH 25 PEOPLE (SUBGROUP 1T — CONTROL ONE) RECEIVED NASH THERAPY (ESSENTIAL PHOSPHOLIPIDS 300 MG 2 CAPSULES 3 TIMES DAILY FOR 60 DAYS) AND BASELINE COPD THERAPY. SUBGROUP II (PRIMARY, 2T) — 35 PATIENTS, IN ADDITION TO SIMILAR COPD THERAPY, FOR THE TREATMENT OF NASH, INSTEAD OF ESSENTIAL PHOSPHOLIPIDS, THEY RECEIVED ANTRAL 200 MG 3 TIMES A DAY FOR 60 DAYS. SUBGROUP III (PRIMARY, 3T) — 30 PATIENTS, IN ADDITION TO SIMILAR COPD THERAPY, FOR THE TREATMENT OF NASH THEY RECEIVED ANTRAL 200 MG 3 TIMES DAILY AND, ADDITIONALLY, POLICOSANOL 20 MG AFTER THE DINNER FOR 60 DAYS. COMPARISON GROUP CONSISTED OF 30 APPARENTLY HEALTHY INDIVIDUALS. RESULTS. BEFORE TREATMENT, A SLIGHT INSIGNIFICANT INCREASE IN THE LEVEL OF FASTING GLYCEMIA BY 10.9 AND 14.3 %, RESPECTIVELY (P < 0.05), WAS ESTABLISHED IN PATIENTS OF GROUPS I AND II, IN THE CONTENT OF POSTPRANDIAL GLUCOSE IN THE BLOOD — BY 18.6 AND 34.4 % (P < 0.05), WHILE IN THE PATIENTS OF GROUP 3, THE CHANGES IN INDICATORS WERE INSIGNIFICANT. AFTER TREATMENT, IN PATIENTS FROM THE SUBGROUPS 2T AND 3T, A DECREASE IN FASTING GLUCOSE WAS 8.9 % (P < 0.05), WHILE IN THE SUBGROUP 1T, ITS SLIGHT DECREASE WAS REVEALED — 3.4 % (P > 0.05). THE CONTENT OF POSTPRANDIAL BLOOD GLUCOSE IN PATIENTS OF ALL GROUPS DECREASED, RESPECTIVELY, IN THE SUBGROUPS 1T, 2T AND 3T — BY 10.6, 21.3 AND 21.9 % COMPARED TO THE DATA BEFORE TREATMENT (P < 0.05). THE MAXIMUM DECREASE IN THE BLOOD INSULIN CONTENT (BY 1.9 TIMES) AND THE DEGREE OF INSULIN RESISTANCE (BY 46.8 %) WAS ALSO OBSERVED IN THE SUBGROUP 3T (P < 0.05). CONCLUSIONS. THE ADMINISTRATION OF ANTRAL FOR 60 DAYS LED TO A SIGNIFICANT CORRECTION OF GLYCEMIA IN NASH PATIENTS WITH OBESITY AND COPD THAT WAS ACCOMPANIED BY A SIGNIFICANT DECREASE IN INSULIN LEVELS (P < 0.05), POSTPRANDIAL GLUCOSE CONTENT AND THE INSULIN RESISTANCE DEGREE (P < 0.05). © 2020. THE AUTHORS.","ANTRAL; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; NON-ALCOHOLIC STEATOHEPATITIS; OBESITY; POLICOSANOL","","","","ANOKHINA AA., NON-ALCOHOLIC LIVER DISEASE AS A MULTI-SYSTEMIC METABOLITIC DISEASE: PREVENTION AND TREATMENT, PRAKTYKUJUCHYJ LIKAR, 7, 3, PP. 35-40, (2018); BRIL F, CUSI K., MANAGEMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: A CALL TO ACTION, DIABETES CARE, 40, 3, PP. 419-430, (2017); STEPANOV YUM, NEDZVETSKAYA NV, YAGMUR VB, KLENINA IA, OSHMYANSKAYA NYU., NONINVASIVE DIAGNOSIS OF LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE, GASTROENTEROLOGÌA, 51, 3, PP. 188-195, (2017); KHUKHLINA OS, ANTONIV AA, MANDRYK OY, SMANDYCH VS, MATUSHCHAK MR., THE ROLE OF ENDOTHELIAL DYSFUNCTION IN THE PROGRESSION MECHANISMS OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH OBESITY AND CHRONIC KIDNEY DISEASE, WIAD LEK, 72, 4, PP. 523-526, (2019); EASL-EASD-EASO CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, OBES FACTS, 9, 2, PP. 65-90, (2016); LONARDO A, MANTOVANI A, LUGARI S, TARGHER G., EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF THE ASSOCIATION BETWEEN NAFLD AND METABOLICALLY HEALTHY OR METABOLICALLY UNHEALTHY OBESITY, ANN HEPATOL, 19, 4, PP. 359-366, (2020); ANGULO P, KLEINER DE, DAM-LARSEN S, ET AL., LIVER FIBROSIS, BUT NO OTHER HISTOLOGIC FEATURES, IS ASSOCIATED WITH LONG-TERM OUTCOMES OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE, GASTROENTEROLOGY, 149, 2, PP. 389-397, (2015); LONARDO A, SOOKOIAN S, PIROLA CJ, TARGHER G., NON-ALCOHOLIC FATTY LIVER DISEASE AND RISK OF CARDIOVASCULAR DISEASE, METABOLISM, 65, 8, PP. 1136-1150, (2016); TARGHER G, BYRNE CD, LONARDO A, ZOPPINI G, BARBUI C., NONALCOHOLIC FATTY LIVER DISEASE AND RISK OF INCIDENT CARDIOVASCULAR DISEASE: A META-ANALYSIS, J HEPATOL, 65, 3, PP. 589-600, (2016); LONARDO A, NASCIMBENI F, PONZ DE LEON M., NONALCOHOLIC FATTY LIVER DISEASE AND COPD: IS IT TIME TO CROSS THE DIAPHRAGM?, EUR RESPIR J, 49, 6, (2017); AISF POSITION PAPER ON NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): UPDATES AND FUTURE DIRECTIONS, DIG LIVER DIS, 49, 5, PP. 471-483, (2017); FRIEDMAN SL, NEUSCHWANDER-TETRI BA, RINELLA M, SANYAL AJ., MECHANISMS OF NAFLD DEVELOPMENT AND THERAPEUTIC STRATEGIES, NAT MED, 24, 7, PP. 908-922, (2018); VIGLINO D, JULLIAN-DESAYES I, MINOVES M, ET AL., NONALCOHOLIC FATTY LIVER DISEASE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EUR RESPIR J, 49, 6, (2017); SADIKOVA SI, TAGAEVA MH, DZHALILOVA SH, RUSTAMOVA MT., CHRONIC LIVER DISEASE OF VIRAL ETIOLOGY - THERAPY WITH MODERN PRINCIPLES ANTRAL, BULLETIN OF MEDICAL ASSOCIATION OF UZBEKISTAN, 2, PP. 85-88, (2015); KUZMINOV BP, MATYSIK SI, ZAZULIAK TS, MYKYTCHAK TI., EVALUATION OF ANTRAL HEPATOPROTECTOR ACUTE TOXICITY IN ALTERNATIVE TEST-SYSTEMS, ENVIRONMENT AND HEALTH, 78, PP. 43-46, (2016); YOUNOSSI ZM, BLISSETT D, BLISSETT R, HENRY L, STEPANOVA M, YOUNOSSI Y, RACILA A, HUNT S, BECKERMAN R., THE ECONOMIC AND CLINICAL BURDEN OF NONALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES AND EUROPE, HEPATOLOGY, 64, 5, PP. 1577-1586, (2016); FADIEIENKO GD, KUSHNIR IE, CHERNOVA VM, ET AL., NUTRIGENETIC CHARACTERISTICS OF PATIENTS WITH NONALCOHOLIC LIVER DISEASE COMBINED WITH METABOLIC SYNDROME, MODERN GASTROENTEROLOGY, 104, PP. 7-13, (2018); YOUNOSSI ZM, KOENIG AB, ABDELATIF D, FAZEL Y, HENRY L, WYMER M., GLOBAL EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE-META-ANALYTIC ASSESSMENT OF PREVALENCE, INCIDENCE, AND OUTCOMES, HEPATOLOGY, 64, 1, PP. 73-84, (2016); SINGH S, KHERA R, ALLEN AM, MURAD MH, LOOMBA R., COMPARATIVE EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR NONALCOHOLIC STEATOHEPATITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS, HEPATOLOGY, 62, 5, PP. 1417-1432, (2015)","O.YE. HRINYUK; DEPARTMENT OF INTERNAL MEDICINE, CLINICAL PHARMACOLOGY AND OCCUPATIONAL DISEASES, HSEI OF UKRAINE “BUKOVINIAN STATE MEDICAL UNIVERSITY”, CHERNIVTSI, 2, THEATRALNA SQ., 58002, UKRAINE; EMAIL: HRYNIUK.OLHA@GMAIL.COM","ZASLAVSKY PUBLISHING HOUSE","ENGLISH","MIZNAR. ENDOKRINOL. ZURNAL.","ARTICLE","ISI","2-S2.0-85166036304","MIZNAR ENDOKRINOL ZURNAL","BUKOVINIAN STATE MEDICAL UNIVERSITY;BUKOVINIAN STATE MEDICAL UNIVERSITY;BUKOVINIAN STATE MEDICAL UNIVERSITY;BUKOVINIAN STATE MEDICAL UNIVERSITY","NOTREPORTED;HSEI OF UKRAINE “BUKOVINIAN STATE MEDICAL UNIVERSITY”;NOTREPORTED",NA,"KHUKHLINA OS, 2020, MIZNAR ENDOKRINOL ZURNAL","KHUKHLINA OS, 2020, MIZNAR ENDOKRINOL ZURNAL"
"GIUFFRÈ A;CAPOCASALE M;ZAPPIA C","GIUFFRÈ, ANGELO M. (9279506500); CAPOCASALE, MARCO (56664492000); ZAPPIA, CLOTILDE (56698351500)","TOMATO SEED OIL FOR EDIBLE USE COLD BREAK HOT BREAK AND HARVEST YEAR EFFECTS",2017,"JOURNAL OF FOOD PROCESSING AND PRESERVATION","41","",43,"10.1111/jfpp.13309","DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, REGGIO CALABRIA, ITALY;DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, REGGIO CALABRIA, ITALY;DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, REGGIO CALABRIA, ITALY","IN THE TOMATO JUICE AND SAUCE INDUSTRIES, TOMATOES ARE SUBMITTED TO A HOT BREAK OR A COLD BREAK THERMAL TREATMENT. TOMATO SEED IS CONSIDERED WASTE BUT COULD BECOME AN IMPORTANT SOURCE OF EDIBLE OIL. A 3-YEAR STUDY WAS CONDUCTED. THE STUDIED PROPERTIES WERE FREE ACIDITY (MAX 1.26%), PEROXIDE VALUE (MAX 6.14 MEQ O2/KG OIL), P-ANISIDINE VALUE (0.40–13.45), TOTOX (3.85–24.68), SAPONIFICATION VALUE (187.84–198.90), TOTAL PHENOLS (212–532 MG/KG), AND REFRACTIVE INDEX (1.4707–1.4723). DPPH· WAS ALWAYS HIGHER THAN 70%. ESSENTIAL FATTY ACIDS WERE HIGHER THAN 56% OF THE TOTAL FATTY ACID METHYL ESTER COMPOSITION CONTENT. TOTAL STEROLS RANGED FROM 1,546 TO 2,077 MG/KG. POLICOSANOL WERE HIGHER ON 2014 HARVEST YEAR. THE LOW FREE ACIDITY, PEROXIDE VALUE, SPECTROPHOTOMETRIC CHARACTERISTICS, THE HIGH PHENOL CONTENT, AND RADICAL SCAVENGING ACTIVITY VALUES SUGGEST THAT TOMATO SEED OIL IS POTENTIALLY EDIBLE. HOT BREAK AND COLD BREAK TREATMENTS DID NOT SIGNIFICANTLY INFLUENCE THE PHYSICOCHEMICAL PROPERTIES AND THE COLD BREAK IS RECOMMENDED BECAUSE CHEAPER. PRACTICAL APPLICATIONS: THIS STUDY GIVES INFORMATION ABOUT THE EFFECT ON THE PHYSICOCHEMICAL PROPERTIES OF THE TOMATO SEED OIL AS A FOOD AFTER COLD BREAK AND HOT BREAK TREATMENTS. IN ADDITION, IT IS EVIDENCED HOW THE HARVEST YEAR INFLUENCES THESE PARAMETERS. © 2017 WILEY PERIODICALS, INC.","","FATTY ACIDS; FRUITS; HARVESTING; OXIDATION; PEROXIDES; PHENOLS; REFRACTIVE INDEX; COMPOSITION CONTENT; ESSENTIAL FATTY ACIDS; FATTY ACID METHYL ESTER; PEROXIDE VALUE; PHENOL CONTENT; PHYSICOCHEMICAL PROPERTY; RADICAL SCAVENGING ACTIVITY; TOTAL PHENOLS; OILS AND FATS","","","AHMADI KAMAZANI N., TAVAKOLIPOUR H., HASANI M., AMIRI M., EVALUATION AND ANALYSIS OF THE ULTRASOUND-ASSISTED EXTRACTED TOMATO SEED OIL, JOURNAL OF FOOD BIOSCIENCES AND TECHNOLOGY, 4, PP. 57-66, (2014); ALBANESE D., ADILETTA G., D'ACUNTO M., CINQUANTA L., DI MATTEO M., TOMATO PEEL DRYING AND CAROTENOIDS STABILITY OF THE EXTRACTS, INTERNATIONAL JOURNAL OF FOOD SCIENCE, 49, PP. 2458-2463, (2014); ALONSO A., GARCIA-ALIAGA R., GARCIA-MARTINEZ S., RUIZ J.J., CARBONELL-BARRACHINA A.A., CHARACTERIZATION OF SPANISH TOMATOES USING AROMA COMPOSITION AND DISCRIMINANT ANALYSIS, FOOD SCIENCE AND TECHNOLOGY INTERNATIONAL, 15, PP. 47-55, (2009); ALONSO A., VAZQUEZ-ARAUJO L., GARCIA-MARTINEZ S., RUIZ J.J., CARBONELL-BARRACHINA A.A., VOLATILE COMPOUNDS OF TRADITIONAL AND VIRUS-RESISTANT BREEDING LINES OF MUCHAMIEL TOMATOES, EUROPEAN FOOD RESEARCH AND TECHNOLOGY, 230, PP. 315-323, (2009); ANASTASI U., SANTONOCETO C., GIUFFRE A.M., SORTINO O., GRESTA F., ABBATE V., YIELD PERFORMANCE AND GRAIN LIPID COMPOSITION OF STANDARD AND OLEIC SUNFLOWER AS AFFECTED BY WATER SUPPLY, FIELD CROPS RESEARCH, 119, PP. 145-153, (2010); ANDERSSON S.W., SKINNER J., ELLEGARD L., WELCH A.A., BINGHAM S., MULLIGAN A., KHAW K.T., INTAKE OF DIETARY PLANT STEROLS IS INVERSELY RELATED TO SERUM CHOLESTEROL CONCENTRATION IN MEN AND WOMEN IN THE EPIC NORFOLK POPULATION: A CROSS-SECTIONAL STUDY, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 58, PP. 1378-1385, (2004); ANDRIAMANANTENA R.W., ARTAUD J., GAYDOU E.M., IATRIDES M.C., CHEVALIER J.L., FATTY ACID AND STEROL COMPOSITION OF MALAGASY TAMARIND KERNEL OILS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 60, PP. 1318-1321, (1983); ANWAR F., NASEER R., BHANGER M.I., ASHRAF S., TALPU F.N., ADEKUNLE, ALADEDUNYE F., PHYSICO-CHEMICAL CHARACTERISTICS OF CITRUS SEEDS AND SEED OILS FROM PAKISTAN, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 85, PP. 321-330, (2008); SAPONIFICATION NUMBER OF OILS AND FATS., OFFICIAL METHODS OF ANALYSIS OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, (17TH ED.), (2000); OFFICIAL METHODS OF ANALYSIS OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, (17TH ED.), (2000); BOTINESTEAN C., HADARUGA N.G., HADARUGA D.I., JIANU I., FATTY ACIDS COMPOSITION BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS) AND MOST IMPORTANT PHYSICAL-CHEMICALS PARAMETERS OF TOMATO SEED OIL, JOURNAL OF AGROALIMENTARY PROCESSES AND TECHNOLOGIES, 18, PP. 89-94, (2012); BOTINESTEAN C., GRUIA A.T., JIANU I., UTILIZATION OF SEEDS FROM TOMATO PROCESSING WASTES AS RAW MATERIAL FOR OIL PRODUCTION, JOURNAL OF MATERIAL CYCLES AND WASTE MANAGEMENT, 17, PP. 118-124, (2015); CAMARA M., DEL VALLE M., TORIJA M.E., CASTILHO C., FATTY ACID COMPOSITION OF TOMATO POMACE, ACTA HORTICULTURAE, 542, PP. 175-181, (2001); CANTARELLI P.R., REGITANO-D'ARCE M.A.B., PALMA E.R., PHYSICOCHEMICAL CHARACTERISTICS AND FATTY ACID COMPOSITION OF TOMATO SEED OILS FROM PROCESSING WASTES, (PIRACICABA), 50, PP. 117-120, (1993); CARAMIA G., GORI A., VALLI E., CERRETANI L., VIRGIN OLIVE OIL IN PREVENTIVE MEDICINE: FROM LEGEND TO EPIGENETICS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, PP. 375-388, (2012); CASAL S., MALHEIRO R., SENDAS A., OLIVEIRA B.P.P., PEREIRA J.A., OLIVE OIL STABILITY UNDER DEEP-FRYING CONDITIONS, FOOD AND CHEMICAL TOXICOLOGY, 48, PP. 2972-2979, (2010); CECI L.N., CARELLI A.A., CHARACTERIZATION OF MONOVARIETAL ARGENTINIAN OLIVE OILS FROM NEW PRODUCTIVE ZONES, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 84, PP. 1125-1136, (2007); CERRETANI L., BENDINI A., RODRIGUEZ-ESTRADA M.T., CITTADINI E., CHIAVARO E., MICROWAVE HEATING OF DIFFERENT COMMERCIAL CATEGORIES OF OLIVE OIL: PART I. EFFECT ON CHEMICAL OXIDATIVE STABILITY INDICES AND PHENOLIC COMPOUNDS, FOOD CHEMISTRY, 115, PP. 1381-1388, (2009); CHIOFALO B., LO PRESTI V., CHIOFALO V., GRESTA F., THE PRODUCTIVE TRAITS, FATTY ACID PROFILE AND NUTRITIONAL INDICES OF THREE LUPIN (LUPINUS SPP.) SPECIES CULTIVATED IN A MEDITERRANEAN ENVIRONMENT FOR THE LIVESTOCK, ANIMAL FEED SCIENCE AND TECHNOLOGY, 171, PP. 230-239, (2012); CINQUANTA L., ALBANESE D., FRATIANNI A., LA FIANZA G., DI MATTEO M., ANTIOXIDANT ACTIVITY AND SENSORY ATTRIBUTES OF TOMATOES DEHYDRATED BY COMBINATION OF MICROWAVE AND CONVECTIVE HEATING, AGRO FOOD INDUSTRY HI-TECH, 24, PP. 35-38, (2014); CODEX STANDARD FOR NAMED VEGETABLE OILS, (2011); TRADE STANDARD APPLYING TO OLIVE OILS AND OLIVE-POMACE OILS, (2015); CONSOLIDATED TEXT, CONSLEG 1991R2568–01/11/2003, ON THE CHARACTERISTICS OF OLIVE OIL AND OLIVE-RESIDUE OIL AND ON THE RELEVANT METHODS OF ANALYSIS, (2003); DEMIRBAS A., OIL, MICRONUTRIENT AND HEAVY METAL CONTENTS OF TOMATOES, FOOD CHEMISTRY, 118, PP. 504-507, (2010); EL-GIBALY I., ABDEL-GHAFFAR S.K., EFFECT OF HEXACOSANOL ON THE CHARACTERISTICS OF NOVEL SUSTAINED-RELEASE ALLOPURINOL SOLID LIPOSPHERES (SLS): FACTORIAL DESIGN APPLICATION AND PRODUCT EVALUATION, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 294, PP. 33-51, (2005); FAHIMDANESH M., BAHRAMI M.E., EVALUATION OF PHYSICOCHEMICAL PROPERTIES OF IRANIAN TOMATO SEED OIL, JOURNAL OF NUTRITION AND FOOD SCIENCES, 3, PP. 1-4, (2013); FERNANDES L., CASAL S., PEREIRA J.A., RAMALHOSA E., SEED OILS OF TEN TRADITIONAL PORTUGUESE GRAPE VARIETIES WITH INTERESTING CHEMICAL AND ANTIOXIDANT PROPERTIES, FOOD RESEARCH INTERNATIONAL, 50, PP. 161-166, (2013); GARCIA-LLATAS G., RODRIGUEZ-ESTRADA M.T., CURRENT AND NEW INSIGHTS ON PHYTOSTEROL OXIDES IN PLANT STEROL-ENRICHED FOOD, CHEMISTRY AND PHYSICS OF LIPIDS, 164, PP. 607-624, (2011); GIUFFRE A.M., CHEMICAL COMPOSITION OF PURPLE PASSION FRUIT (PASSIFLORA EDULIS SIMS VAR. EDULIS) SEED OIL, RIVISTA ITALIANA DELLE SOSTANZE GRASSE, 84, PP. 87-93, (2007); GIUFFRE A.M., STEROLI, ERITRODIOLO E UVAOLO IN OLIO DI OLIVA DA CULTIVAR COLTIVATE IN CALABRIA, INDUSTRIE ALIMENTARI, 51, PP. 20-26, (2012); GIUFFRE A.M., ALCOLI ALIFATICI E TERPENICI IN OLIO DI OLIVA ESTRATTO DA CULTIVAR COLTIVATE IN CALABRIA, INDUSTRIE ALIMENTARI-ITALY, 52, PP. 28-35, (2013); GIUFFRE A.M., THE EFFECTS OF CULTIVAR AND HARVEST YEAR ON THE FATTY ALCOHOL COMPOSITION OF OLIVE OILS FROM SOUTHWEST CALABRIA (ITALY), GRASAS Y ACEITES, 65, (2014); GIUFFRE A.M., EVOLUTION OF FATTY ALCOHOLS IN OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY) DURING FRUIT RIPENING, JOURNAL OF OLEO SCIENCE, 63, PP. 486-496, (2014); GIUFFRE A.M., CAPOCASALE M., POLICOSANOL IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, JOURNAL OF OLEO SCIENCE, 64, PP. 625-631, (2015); GIUFFRE A.M., CAPOCASALE M., PHYSICOCHEMICAL COMPOSITION OF TOMATO SEED OIL FOR AN EDIBLE USE: THE EFFECT OF CULTIVAR, INTERNATIONAL FOOD RESEARCH JOURNAL, 23, PP. 583-591, (2016); GIUFFRE A.M., CAPOCASALE M., STEROL COMPOSITION OF TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, INTERNATIONAL FOOD RESEARCH JOURNAL, 23, PP. 116-122, (2016); GIUFFRE A.M., CAPOCASALE M.; GIUFFRE A.M., LOUADJ L., INFLUENCE OF CROP SEASON AND CULTIVAR ON STEROL COMPOSITION OF MONOVARIETAL OLIVE OILS IN REGGIO CALABRIA (ITALY), CZECH JOURNAL OF FOOD SCIENCES, 31, PP. 256-263, (2013); GIUFFRE A.M., LOUADJ L., POIANA M., MACARIO A., COMPOSITION EN STÉROLS DES HUILES EXTRAITES D'OLIVES DE CULTIVARS DE LA PROVINCE DE REGGIO CALABRIA (SUD D'ITALIE), RIVISTA ITALIANA DELLE SOSTANZE GRASSE, 89, PP. 177-183, (2012); GIUFFRE A.M., SICARI V., CAPOCASALE M., ZAPPIA C., PELLICANO T.M., POIANA M., PHYSICO-CHEMICAL PROPERTIES OF TOMATO SEED OIL (SOLANUM LYCOPERSICUM L.) FOR BIODIESEL PRODUCTION, ACTA HORTICULTURAE (SHS), 1081, PP. 237-244, (2015); GIUFFRE A.M., CAPOCASALE M., ZAPPIA C., SICARI V., PELLICANO T.M., POIANA M., PANZERA G., TOMATO SEED OIL FOR BIODIESEL PRODUCTION, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 118, PP. 640-650, (2016); ISLAM M.Z., KIM Y.S., KANG H.M., EFFECT OF BREATHABLE FILM FOR MODIFIED ATMOSPHERE PACKAGING MATERIAL ON THE QUALITY AND STORABILITY OF TOMATO IN LONG DISTANCE EXPORT CONDITION, JOURNAL OF BIO-ENVIRONMENT CONTROL, 20, PP. 221-226, (2011); KALANTZAKIS G., BLEKAS G., PEGKLIDOU K., BOSKOU D., STABILITY AND RADICAL-SCAVENGING ACTIVITY OF HEATED OLIVE OIL AND OTHER VEGETABLE OILS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 108, PP. 329-335, (2006); KULKARNI A.A., MORE V.I., KHOTPAL R.R., COMPOSITION AND LIPID CLASSES OF ORANGE, TOMATO AND PUMPKIN SEED OILS OF VIDARBHA REGION OF MAHARASHTRA, JOURNAL OF CHEMICAL AND PHARMACEUTICAL RESEARCH, 4, PP. 751-753, (2012); LAZOS E.S., TSAKNIS J., LALAS S., CHARACTERISTICS AND COMPOSITION OF TOMATO SEED OIL, GRASAS ACEITES, 49, PP. 440-445, (1998); LEE J., LEE Y., CHOE F., TEMPERATURE DEPENDENCE OF THE AUTOXIDATION AND ANTIOXIDANTS OF SOYBEAN, SUNFLOWER, AND OLIVE OIL, EUROPEAN FOOD RESEARCH AND TECHNOLOGY, 226, PP. 239-246, (2007); LOUADJ L., GIUFFRE A.M., ANALYTICAL CHARACTERISTICS OF OLIVE OIL PRODUCED WITH THREE DIFFERENT PROCESSES IN ALGERIA, RIVISTA ITALIANA DELLE SOSTANZE GRASSE, 87, PP. 186-195, (2010); LUKIC M., LUKIC I., SLADONJA B., PILIZOTA V., POLICOSANOL VARIATION IN OLIVE OIL AS A RESULT OF VARIETY, RIPENING, AND STORAGE, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 117, PP. 1248-1260, (2015); NEDERAL S., SKEVIN D., KRALJIC K., OBRANOVIC M., PAPES S., BATALJAKU A., CHEMICAL COMPOSITION AND OXIDATIVE STABILITY OF ROASTED AND COLD PRESSED PUMPKIN SEED OILS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 89, PP. 1177-1763, (2012); NORME GRASSI E DERIVATI – III EDIZIONE – NO 36–79. NORME ITALIANE PER IL CONTROLLO DEI GRASSI E DERIVATI, (1976); DECEMBER 16)., COMMISSION IMPLEMENTING REGULATION EU, (1348/2013), (2013); REDONDO-CUENCA A., VILLANUEVA-SUAREZ M.J., RODRIGUEZ-SEVILLA M.D., MATEOS-APARICIO I., CHEMICAL COMPOSITION AND DIETARY FIBRE OF YELLOW AND GREEN COMMERCIAL SOYBEANS (GLYCINE MAX), FOOD CHEMISTRY, 101, PP. 1216-1222, (2006); RAMADAN M.F., KROH L.W., MORSEL J.T., RADICAL SCAVENGING ACTIVITY OF BLACK CUMIN (NIGELLA SATIVA L.), CORIANDER (CORIANDRUM SATIVUM L.) AND NIGER (GUIZOTIA ABYSSINICA CASS.) CRUDE SEED OILS AND OIL FRACTIONS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 6961-6969, (2003); RONDANINI D.P., CASTRO D.N., SEARLES P.S., ROUSSEAUX M.C., FATTY ACID PROFILES OF VARIETAL VIRGIN OLIVE OILS (OLEA EUROPAEA L.) FROM MATURE ORCHARDS IN WARM ARID VALLEYS OF NORTHWESTERN ARGENTINA (LA RIOJA), GRASAS ACEITES, 62, PP. 399-409, (2011); SINGLETON V.L., ORTHOFER R., LAMUELA-RAVENTOS R.M., ANALYSIS OF TOTAL PHENOLS AND OTHER OXIDATION SUBSTRATES AND ANTIOXIDANTS BY MEANS OF FOLIN-CIOCALTEU REAGENT, METHODS IN ENZYMOLOGY, 299, PP. 152-178, (1999); SPAGNA G., TODARO A., PELUSO O., CATALANO A.E., BARBAGALLO R.N., EFFETTI DELL'ESSICCAMENTO SULL'ATTIVITÀ POLIFENOLOSSIDASICA E PATTERN ANTIOSSIDANTE DI POMODORO CILIEGINO, INDUSTRIE ALIMENTARI-ITALY, 59, PP. 25-29, (2010); TAKASOVA J., DRDAK M., MINAROVICOVA I., CHARACTERISTICS OF LIPIDS IN TOMATO SEEDS, MOLECULAR NUTRITION & FOOD RESEARCH, 39, PP. 244-245, (1995); TAYLOR J.C., RAPPORT L., LOCKWOOD G., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 191, PP. 192-195, (2003); ZUORRO A., LAVECCHIA R., MEDICI F., PIGA L., ENZYME-ASSISTED PRODUCTION OF TOMATO SEED OIL ENRICHED WITH LYCOPENE FROM TOMATO POMACE, FOOD AND BIOPROCESS TECHNOLOGY, 6, PP. 3499-3509, (2013); WASSNER D., LARRAN A., RONDANINI D., EVALUATION OF JATROPHA MACROCARPA AS AN OIL CROP FOR BIODIESEL PRODUCTION IN ARID LANDS OF THE DRY CHACO, ARGENTINA, JOURNAL OF ARID ENVIRONMENTS, 77, PP. 153-156, (2012)","A.M. GIUFFRÈ; DIPARTIMENTO DI AGRARIA, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, REGGIO CALABRIA, ITALY; EMAIL: AMGIUFFRE@UNIRC.IT","BLACKWELL PUBLISHING LTD","ENGLISH","J. FOOD PROCESS. PRESERV.","ARTICLE","ISI","2-S2.0-85017147750","J FOOD PROCESS PRESERV","UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA","NOTREPORTED;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;NOTREPORTED",NA,"GIUFFRÈ AM, 2017, J FOOD PROCESS PRESERV","GIUFFRÈ AM, 2017, J FOOD PROCESS PRESERV"
"SCOGNAMIGLIO M;COSTA D;SORRIENTO A;NAPOLI C","SCOGNAMIGLIO, MICHELE (57209565287); COSTA, DARIO (55779796400); SORRIENTO, ANTONIO (57202906770); NAPOLI, CLAUDIO (35430280800)","CURRENT DRUGS AND NUTRACEUTICALS FOR THE TREATMENT OF PATIENTS WITH DYSLIPIDEMIAS",2019,"CURRENT PHARMACEUTICAL DESIGN","25","10",11,"10.2174/1381612825666190130101108","U.O.C. DIVISION OF CLINICAL IMMUNOLOGY, IMMUNOHEMATOLOGY, TRANSFUSION MEDICINE AND TRANSPLANT IMMUNOLOGY, CLINICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS, DEPARTMENT OF MEDICAL, SURGICAL, NEUROLOGICAL, METABOLIC AND GERIATRIC SCIENCES, UNIVERSITY OF CAMPANIA “L. VANVITELLI”, NAPLES, ITALY;U.O.C. DIVISION OF CLINICAL IMMUNOLOGY, IMMUNOHEMATOLOGY, TRANSFUSION MEDICINE AND TRANSPLANT IMMUNOLOGY, CLINICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS, DEPARTMENT OF MEDICAL, SURGICAL, NEUROLOGICAL, METABOLIC AND GERIATRIC SCIENCES, UNIVERSITY OF CAMPANIA “L. VANVITELLI”, NAPLES, ITALY;U.O.C. DIVISION OF CLINICAL IMMUNOLOGY, IMMUNOHEMATOLOGY, TRANSFUSION MEDICINE AND TRANSPLANT IMMUNOLOGY, CLINICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS, DEPARTMENT OF MEDICAL, SURGICAL, NEUROLOGICAL, METABOLIC AND GERIATRIC SCIENCES, UNIVERSITY OF CAMPANIA “L. VANVITELLI”, NAPLES, ITALY;U.O.C. DIVISION OF CLINICAL IMMUNOLOGY, IMMUNOHEMATOLOGY, TRANSFUSION MEDICINE AND TRANSPLANT IMMUNOLOGY, CLINICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS, DEPARTMENT OF MEDICAL, SURGICAL, NEUROLOGICAL, METABOLIC AND GERIATRIC SCIENCES, UNIVERSITY OF CAMPANIA “L. VANVITELLI”, NAPLES, ITALY, IRCCS SDN, NAPLES, ITALY","CORONARY HEART DISEASE (CHD) REMAINS THE LEADING CAUSE OF DISABILITY AND DEATH IN INDUSTRIALIZED COUNTRIES. AMONG MANY CONDITIONS, WHICH CONTRIBUTE TO THE ETIOLOGY AND PROGRESSION OF CHD, THE PRESENCE OF HIGH LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) LEVELS REPRESENTS THE MAJOR RISK FACTOR. THEREFORE, THE REDUCTION OF LDL-C LEVELS PLAYS A KEY ROLE IN THE MANAGEMENT OF PATIENTS WITH HIGH OR VERY HIGH CARDIOVASCULAR RISK. ALTHOUGH STATINS REPRESENT THE GOLD STANDARD THERAPY FOR THE REDUCTION OF CHOLESTEROL LEVELS, THESE DRUGS DO NOT ALLOW TO ACHIEVE TARGET LEVELS OF LDL-C IN ALL PATIENTS. INDEED, A SIGNIFICANT NUMBER OF PATIENTS RESULTED INTOLERANTS, ESPECIALLY WHEN THE DOSAGE INCREASED. THE AVAILABILITY OF NEW LIPID-LOWERING DRUGS, SUCH AS EZETIMIBE AND PCSK9 INHIBITORS, MAY REPRESENT AN IMPORTANT ALTERNATIVE OR COMPLEMENT TO THE CONVENTIONAL LIPID-LOWERING THERAPIES. HOWEVER, LONG-TERM STUDIES ARE STILL NEEDED TO DEFINE BOTH EFFICACY AND SAFETY OF USE OF THESE LATTER NEW DRUGS. SOME NUTRACEUTICALS MAY BECOME AN ADEQUATE AND EFFECTIVE SUPPORT IN THE MANAGEMENT OF SOME PATIENTS. TO DATE, SEVERAL NUTRACEUTICALS WITH DIFFERENT MECHANISM OF ACTIONS THAT PROVIDE A GOOD TOLERABILITY ARE AVAILABLE AS LIPIDLOWERING AGENTS. IN PARTICULAR, THE MOST INVESTIGATED ARE RED YEAST RICE, PHYTOSTEROLS, BERBERINE, BETA-GLUCANS AND SOY. THE AIM OF THIS REVIEW WAS TO REPORT RECENT DATA ON THE EFFICACY AND SAFETY OF PRINCIPLE HYPOCHOLESTEROLEMIC DRUGS AVAILABLE AND TO EVALUATE THE POSSIBLE ROLE OF SOME NUTRACEUTICALS AS SUPPORT THERAPY IN THE MANAGEMENT OF PATIENTS WITH DYSLIPIDEMIAS. © 2019 BENTHAM SCIENCE PUBLISHERS.","CARDIOVASCULAR DISEASE; DYSLIPIDEMIAS; HYPERCHOLESTEROLEMIA; LDL CHOLESTEROL; LIPID-LOWERING AGENTS; NUTRACEUTICALS","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROPROTEIN CONVERTASE 9; ALIROCUMAB; BERBERINE; BETA GLUCAN; CHOLESTIN; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; NUTRACEUTICAL; PHYTOSTEROL; POLICOSANOL; POLYPHENOL; PROPROTEIN CONVERTASE 9; ROSUVASTATIN; SIMVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; ARTICLE; BLURRED VISION; DIARRHEA; DIETARY INTAKE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSLIPIDEMIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; HYPOCHOLESTEROLEMIC ACTIVITY; INTERMEDIATE RISK PATIENT; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING CESSATION; TREATMENT RESPONSE; DIETARY SUPPLEMENT; DYSLIPIDEMIA","","","NAPOLI C., CACCIATORE F., NOVEL PATHOGENIC INSIGHTS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, PROG CARDIOVASC DIS, 51, PP. 503-523, (2009); CRIMI E., IGNARRO L.J., CACCIATORE F., NAPOLI C., MECHANISMS BY WHICH EXERCISE TRAINING BENEFITS PATIENTS WITH HEART FAILURE, NAT REV CARDIOL, 6, PP. 292-300, (2009); NAPOLI C., DEVELOPMENTAL MECHANISMS INVOLVED IN THE PRIMARY PREVENTION OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 13, PP. 170-175, (2011); GIAMPAOLI S., PALMIERI L., DONFRANCESCO C., ET AL., CARDIOVASCULAR HEALTH IN ITAL. TEN-YEAR SURVEILLANCE OF CARDIOVASCULAR DISEASES AND RISK FACTORS: OSSERVATORIO EPIDEMIOLOGICO CARDIOVASCOLARE/HEALTH EXAMINATION SURVEY 1998-2012, EUR J PREV CARDIOL, 22, PP. 9-37, (2015); FERENCE B.A., GINSBERG H.N., GRAHAM I., ET AL., LOW-DENSITY LIPOPROTEINS CAUSE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. 1. EVIDENCE FROM GENETIC, EPIDEMIOLOGIC, AND CLINICAL STUDIES. A CONSENSUS STATEMENT FROM THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL, EUR HEART J, 38, PP. 2459-2472, (2017); NEATON J.D., BLACKBURN H., JACOBS D., ET AL., SERUM CHOLESTEROL LEVEL AND MORTALITY FINDINGS FOR MEN SCREENED IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL. MULTIPLE RISK FACTOR INTERVENTION TRIAL RESEARCH GROUP, ARCH INTERN MED., 152, PP. 1490-1500, (1992); D'AGOSTINO R.B., VASAN R.S., PENCINA M.J., ET AL., GENERAL CARDIOVASCULAR RISK PROFILE FOR USE IN PRIMARY CARE: THE FRAMINGHAM HEART STUDY, CIRCULATION, 117, PP. 743-753, (2008); DE NICOLA L., DONFRANCESCO C., MINUTOLO R., ET AL., PREVALENCE AND CARDIOVASCULAR RISK PROFILE OF CHRONIC KIDNEY DISEASE IN ITALY: RESULTS OF THE 2008-12 NATIONAL HEALTH EXAMINATION SURVEY, NEPHROL DIAL TRANSPLANT, 30, PP. 806-814, (2015); SAHEBKAR A., WATTS G.F., NEW LDL-CHOLESTEROL LOWERING THERAPIES:PHARMACOLOGY, CLINICAL TRIALS, AND RELEVANCE TO ACUTE CORONARY SYNDROMES, CLIN THER, 35, PP. 1082-1098, (2013); LIU C., LIU Q., XIAO X., EFFECTIVENESS AND SAFETY OF COMBINATIONAL THERAPY COMPARED WITH INTENSIFIED STATIN MONOTHERAPY IN PATIENTS WITH CORONARY HEART DISEASE, EXP THER MED, 15, PP. 4683-4688, (2018); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N ENGL J MED., 335, PP. 1001-1009, (1996); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); WANG W., ZHANG B., STATINS FOR THE PREVENTION OF STROKE: A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLOS ONE, 9, (2014); GULIZIA M.M., COLIVICCHI F., RICCIARDI G., ET AL., ANMCO/ ISS/AMD/ ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/ SIBIOC/SIC/ SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA JOINT CONSENSUS DOCUMENT ON CHOLESTEROL AND CARDIOVASCULAR RISK: DIAGNOSTIC-THERAPEUTIC PATHWAY IN ITALY, EUR HEART J SUPPL, 19, PP. D3-D54, (2017); POLI A., BARBAGALLO C.M., CICERO A.F.G., ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOL RES, 134, PP. 51-60, (2018); JOHNSTON T.P., KOROLENKO T.A., PIRRO M., SAHEBKAR A., PREVENTING CARDIOVASCULAR HEART DISEASE: PROMISING NUTRACEUTICAL AND NONNUTRACEUTICAL TREATMENTS FOR CHOLESTEROL MANAGEMENT, PHARMACOL RES, 120, PP. 219-225, (2017); NAPOLI C., SICA V., STATIN TREATMENT AND THE NATURAL HISTORY OF ATHEROSCLEROTIC- RELATED DISEASES: PATHOGENIC MECHANISMS AND THE RISKBENEFIT PROFILE, CURR PHARM DES, 10, PP. 425-432, (2004); BONETTI P.O., LERMAN L.O., NAPOLI C., LERMAN A., STATIN EFFECTS BEYOND LIPID LOWERING--ARE THEY CLINICALLY RELEVANT?, EUR HEART J, 24, PP. 225-248, (2003); LAW M.R., WALD N.J., RUDNICKA A.R., QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS, BMJ, 326, (2003); TIWARI V., KHOKHAR M., MECHANISM OF ACTION OF ANTIHYPERCHOLESTEROLEMIA DRUGS AND THEIR RESISTANCE, EUR J PHARMACOL, 741, PP. 156-170, (2014); GAZZERRO P., PROTO M.C., GANGEMI G., ET AL., PHARMACOLOGICAL ACTIONS OF STATINS: A CRITICAL APPRAISAL IN THE MANAGEMENT OF CANCER, PHARMACOL REV, 64, PP. 102-146, (2012); EZAD S., CHEEMA H., COLLINS N., STATIN-INDUCED RHABDOMYOLYSIS: A COMPLICATION OF A COMMONLY OVERLOOKED DRUG INTERACTION, OXF MED CASE REPORTS, (2018); SHAIK A.N., BOHNERT T., WILLIAMS D.A., GAN L.L., LEDUC B.W., MECHANISM OF DRUG-DRUG INTERACTIONS BETWEEN WARFARIN AND STATINS, J PHARM SCI, 105, PP. 1976-1986, (2016); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, 63, PP. 2889-2934, (2014); BAIGENT C., BLACKWELL L., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); FULCHER J., O'CONNELL R., ET AL., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN: META-ANALYSIS OF INDIVIDUAL DATA FROM 174,000 PARTICIPANTS IN 27 RANDOMISED TRIALS, LANCET, 385, PP. 1397-1405, (2015); BAIGENT C., KEECH A., KEARNEY P.M., ET AL., EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); TOWNSEND N., NICHOLS M., SCARBOROUGH P., RAYNER M., CARDIOVASCULAR DISEASE IN EUROPE--EPIDEMIOLOGICAL UPDATE 2015, EUR HEART J, 36, PP. 2696-2705, (2015); KARLSON B.W., PALMER M.K., NICHOLLS S.J., LUNDMAN P., BARTER P.J., DOSES OF ROSUVASTATIN, ATORVASTATIN AND SIMVASTATIN THAT INDUCE EQUAL REDUCTIONS IN LDL-C AND NON-HDL-C: RESULTS FROM THE VOYAGER META-ANALYSIS, EUR J PREV CARDIOL, 23, PP. 744-747, (2016); PASTERNAK R.C., SMITH S.C., BAIREY-MERZ C.N., ET AL., ACC/AHA/NHLBI CLINICAL ADVISORY ON THE USE AND SAFETY OF STATINS, STROKE, 33, PP. 2337-2341, (2002); LIEB W., ENSERRO D.M., LARSON M.G., VASAN R.S., RESIDUAL CARDIOVASCULAR RISK IN INDIVIDUALS ON LIPID-LOWERING TREATMENT: QUANTIFYING ABSOLUTE AND RELATIVE RISK IN THE COMMUNITY, OPEN HEART, 5, (2018); VIDT D.G., CRESSMAN M.D., HARRIS S., PEARS J.S., HUTCHINSON H.G., ROSUVASTATIN- INDUCED ARREST IN PROGRESSION OF RENAL DISEASE, CARDIOLOGY, 102, PP. 52-60, (2004); DAVIDSON M.H., CLARK J.A., GLASS L.M., KANUMALLA A., STATIN SAFETY: AN APPRAISAL FROM THE ADVERSE EVENT REPORTING SYSTEM, AM J CARDIOL, 97, PP. 32C-43, (2006); MCKENNEY J.M., DAVIDSON M.H., JACOBSON T.A., GUYTON J.R., FINAL CONCLUSIONS AND RECOMMENDATIONS OF THE NATIONAL LIPID ASSOCIATION STATIN SAFETY ASSESSMENT TASK FORCE, AM J CARDIOL, 97, PP. 89C-94, (2006); ARMITAGE J., THE SAFETY OF STATINS IN CLINICAL PRACTICE, LANCET, 370, PP. 1781-1790, (2007); SATTAR N., PREISS D., MURRAY H.M., ET AL., STATINS AND RISK OF INCIDENT DIABETES: A COLLABORATIVE META-ANALYSIS OF RANDOMISED STATIN TRIALS, LANCET, 375, PP. 735-742, (2010); PREISS D., SESHASAI S.R., WELSH P., ET AL., RISK OF INCIDENT DIABETES WITH INTENSIVE-DOSE COMPARED WITH MODERATE-DOSE STATIN THERAPY: A METAANALYSIS, JAMA, 305, PP. 2556-2564, (2011); GARCIA-CALVO M., LISNOCK J., BULL H.G., ET AL., THE TARGET OF EZETIMIBE IS NIEMANN-PICK C1-LIKE 1 (NPC1L1), PROC NATL ACAD SCI USA, 102, PP. 8132-8137, (2005); CANNON C.P., GIUGLIANO R.P., BLAZING M.A., ET AL., RATIONALE AND DESIGN OF IMPROVE-IT (IMPROVED REDUCTION OF OUTCOMES: VYTORIN EFFICACY INTERNATIONAL TRIAL): COMPARISON OF EZETIMBE/SIMVASTATIN VERSUS SIMVASTATIN MONOTHERAPY ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES, AM HEART J, 156, PP. 826-832, (2008); THONGTANG N., LIN J., SCHAEFER E.J., ET AL., EFFECTS OF EZETIMIBE ADDED TO STATIN THERAPY ON MARKERS OF CHOLESTEROL ABSORPTION AND SYNTHESIS AND LDL-C LOWERING IN HYPERLIPIDEMIC PATIENTS, ATHEROSCLEROSIS, 225, PP. 388-396, (2012); DAVIDSON M.H., MCGARRY T., BETTIS R., ET AL., EZETIMIBE COADMINISTERED WITH SIMVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, J AM COLL CARDIOL, 40, PP. 2125-2134, (2002); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., ET AL., EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, N ENGL J MED, 372, PP. 2387-2397, (2015); TORIMOTO K., OKADA Y., MORI H., ET AL., EFFICACY OF COMBINATION OF EZETIMIBE 10 MG AND ROSUVASTATIN 2.5 MG VERSUS ROSUVASTATIN 5 MG MONOTHERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH TYPE 2 DIABETES, LIPIDS HEALTH DIS, 12, (2013); FUJISUE K., NAGAMATSU S., SHIMOMURA H., ET AL., IMPACT OF STATINEZETIMIBE COMBINATION ON CORONARY ATHEROMA PLAQUE IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE - SUB-ANALYSIS OF PRECISE-IVUS TRIAL, INT J CARDIOL, 268, PP. 23-26, (2018); STANIFER J.W., CHARYTAN D.M., WHITE J., ET AL., BENEFIT OF EZETIMIBE ADDED TO SIMVASTATIN IN REDUCED KIDNEY FUNCTION, J AM SOC NEPHROL, 28, PP. 3034-3043, (2017); COMMITTEE W., LLOYD-JONES D.M., MORRIS P.B., ET AL., 2016 ACC EXPERT CONSENSUS DECISION PATHWAY ON THE ROLE OF NON-STATIN THERAPIES FOR LDL-CHOLESTEROL LOWERING IN THE MANAGEMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY TASK FORCE ON CLINICAL EXPERT CONSENSUS DOCUMENTS, J AM COLL CARDIOL, 68, PP. 92-125, (2016); LIPKA L.J., EZETIMIBE: A FIRST-IN-CLASS, NOVEL CHOLESTEROL ABSORPTION INHIBITOR, CARDIOVASC DRUG REV, 21, PP. 293-312, (2003); FITZGERALD G., KIERNAN T., PCSK9 INHIBITORS AND LDL REDUCTION:PHARMACOLOGY, CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES, EXPERT REV CARDIOVASC THER, 16, PP. 567-578, (2018); ABIFADEL M., VARRET M., RABES J.P., ET AL., MUTATIONS IN PCSK9 CAUSE AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA, NAT GENET, 34, PP. 154-156, (2003); DO R.Q., VOGEL R.A., SCHWARTZ G.G., PCSK9 INHIBITORS: POTENTIAL IN CARDIOVASCULAR THERAPEUTICS, CURR CARDIOL REP, 15, (2013); NAVARESE E.P., KOLODZIEJCZAK M., SCHULZE V., ET AL., EFFECTS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 ANTIBODIES IN ADULTS WITH HYPERCHOLESTEROLEMIA:A SYSTEMATIC REVIEW AND META-ANALYSIS, ANN INTERN MED, 163, PP. 40-51, (2015); KOREN M.J., LUNDQVIST P., BOLOGNESE M., ET AL., ANTI-PCSK9 MONOTHERAPY FOR HYPERCHOLESTEROLEMIA: THE MENDEL-2 RANDOMIZED, CONTROLLED PHASE III CLINICAL TRIAL OF EVOLOCUMAB. ANTI-PCSK9 MONOTHERAPY FOR HYPERCHOLESTEROLEMIA: THE MENDEL-2 RANDOMIZED, CONTROLLED PHASE III CLINICAL TRIAL OF EVOLOCUMAB, J AM COLL CARDIOL, 63, PP. 2531-2540, (2014); ROBINSON J.G., NEDERGAARD B.S., ROGERS W.J., ET AL., EFFECT OF EVOLOCUMAB OR EZETIMIBE ADDED TO MODERATE- OR HIGH-INTENSITY STATIN THERAPY ON LDL-C LOWERING IN PATIENTS WITH HYPERCHOLESTEROLEMIA:THE LAPLACE-2 RANDOMIZED CLINICAL TRIAL, JAMA, 311, PP. 1870-1882, (2014); STROES E., COLQUHOUN D., SULLIVAN D., ET AL., ANTI-PCSK9 ANTIBODY EFFECTIVELY LOWERS CHOLESTEROL IN PATIENTS WITH STATIN INTOLERANCE: THE GAUSS-2 RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL OF EVOLOCUMAB, J AM COLL CARDIOL, 63, PP. 2541-2548, (2014); KARATASAKIS A., DANEK B.A., KARACSONYI J., ET AL., EFFECT OF PCSK9 INHIBITORS ON CLINICAL OUTCOMES IN PATIENTS WITH HYPERCHOLESTEROLEMIA:A META-ANALYSIS OF 35 RANDOMIZED CONTROLLED TRIALS, J AM HEART ASSOC, 6, 12, (2017); ROSENSON R.S., JACOBSON T.A., PREISS D., ET AL., EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH MIXED HYPERLIPIDEMIA, CARDIOVASC DRUGS THER, 30, PP. 305-313, (2016); KEREIAKES D.J., ROBINSON J.G., CANNON C.P., ET AL., EFFICACY AND SAFETY OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR ALIROCUMAB AMONG HIGH CARDIOVASCULAR RISK PATIENTS ON MAXIMALLY TOLERATED STATIN THERAPY: THE ODYSSEY COMBO I STUDY, AM HEART J, 169, PP. 906-915, (2015); WATERS D.D., HSUE P.Y., BANGALORE S., PCSK9 INHIBITORS FOR STATIN INTOLERANCE?, JAMA, 315, PP. 1571-1572, (2016); SCHREML J., GOUNI-BERTHOLD I., ROLE OF ANTI-PCSK9 ANTIBODIES IN THE TREATMENT OF PATIENTS WITH STATIN INTOLERANCE, CURR MED CHEM, 25, PP. 1538-1548, (2018); CHAUDHARY R., GARG J., SHAH N., SUMNER A., PCSK9 INHIBITORS: A NEW ERA OF LIPID LOWERING THERAPY, WORLD J CARDIOL, 9, PP. 76-91, (2017); FEINGOLD K.R., MOSER A., SHIGENAGA J.K., GRUNFELD C., INFLAMMATION STIMULATES NIACIN RECEPTOR (GPR109A/HCA2) EXPRESSION IN ADIPOSE TISSUE AND MACROPHAGES, J LIPID RES, 55, PP. 2501-2508, (2014); WANG W., BASINGER A., NEESE R.A., ET AL., EFFECT OF NICOTINIC ACID ADMINISTRATION ON HEPATIC VERY LOW DENSITY LIPOPROTEIN-TRIGLYCERIDE PRODUCTION, AM J PHYSIOL ENDOCRINOL METAB, 280, PP. E540-E547, (2001); LE BLOC'H J., LERAY V., CHETIVEAUX M., ET AL., NICOTINIC ACID DECREASES APOLIPOPROTEIN B100-CONTAINING LIPOPROTEIN LEVELS BY REDUCING HEPATIC VERY LOW DENSITY LIPOPROTEIN SECRETION THROUGH A POSSIBLE DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITION IN OBESE DOGS, J PHARMACOL EXP THER, 334, PP. 583-589, (2010); PANG J., CHAN D.C., HAMILTON S.J., TENNETI V.S., WATTS G.F., BARRETT P.H., EFFECT OF NIACIN ON HIGH-DENSITY LIPOPROTEIN APOLIPOPROTEIN A-I KINETICS IN STATIN-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS, ARTERIOSCLER THROMB VASC BIOL, 34, PP. 427-432, (2014); LAMON-FAVA S., DIFFENDERFER M.R., BARRETT P.H., ET AL., EXTENDEDRELEASE NIACIN ALTERS THE METABOLISM OF PLASMA APOLIPOPROTEIN (APO) A-I AND APOB-CONTAINING LIPOPROTEINS, ARTERIOSCLER THROMB VASC BIOL, 28, PP. 1672-1678, (2008); ZHANG L.H., KAMANNA V.S., GANJI S.H., XIONG X.M., KASHYAP M.L., NIACIN INCREASES HDL BIOGENESIS BY ENHANCING DR4-DEPENDENT TRANSCRIPTION OF ABCA1 AND LIPIDATION OF APOLIPOPROTEIN A-I IN HEPG2 CELLS, J LIPID RES, 53, PP. 941-950, (2012); BAYS H.E., SHAH A., LIN J., SISK C.M., DONG Q., MACCUBBIN D., CONSISTENCY OF EXTENDED-RELEASE NIACIN /LAROPIPRANT EFFECTS ON LP(A), APOB, NON-HDL-C, APO A1, AND APOB/APOA1 RATIO ACROSS PATIENT SUBGROUPS, AM J CARDIOVASC DRUGS, 12, PP. 197-206, (2012); CENARRO A., PUZO J., FERRANDO J., ET AL., EFFECT OF NICOTINIC ACID/LAROPIPRANT IN THE LIPOPROTEIN(A) CONCENTRATION WITH REGARD TO BASELINE LIPOPROTEIN(A) CONCENTRATION AND LPA GENOTYPE, METABOLISM, 63, PP. 365-371, (2014); JULIUS U., NIACIN AS ANTIDYSLIPIDEMIC DRUG, CAN J PHYSIOL PHARMACOL, 93, PP. 1043-1054, (2015); BALLANTYNE C.M., DAVIDSON M.H., MCKENNEY J., KELLER L.H., BAJORUNAS D.R., KARAS R.H., COMPARISON OF THE SAFETY AND EFFICACY OF A COMBINATION TABLET OF NIACIN EXTENDED RELEASE AND SIMVASTATIN VS. SIMVASTATIN MONOTHERAPY IN PATIENTS WITH INCREASED NON-HDL CHOLESTEROL (FROM THE SEACOAST I STUDY), AM J CARDIOL, 101, PP. 1428-1436, (2008); KARAS R.H., KASHYAP M.L., KNOPP R.H., KELLER L.H., BAJORUNAS D.R., DAVIDSON M.H., LONG-TERM SAFETY AND EFFICACY OF A COMBINATION OF NIACIN EXTENDED RELEASE AND SIMVASTATIN IN PATIENTS WITH DYSLIPIDEMIA:THE OCEANS STUDY, AM J CARDIOVASC DRUGS, 8, PP. 69-81, (2008); TOTH P.P., THAKKER K.M., JIANG P., PADLEY R.J., NIACIN EXTENDEDRELEASE/ SIMVASTATIN COMBINATION THERAPY PRODUCES LARGER FAVORABLE CHANGES IN HIGH-DENSITY LIPOPROTEIN PARTICLES THAN ATORVASTATIN MONOTHERAPY, VASC HEALTH RISK MANAG, 8, PP. 39-44, (2012); SONG W.L., FITZGERALD G.A., NIACIN, AN OLD DRUG WITH A NEW TWIST, J LIPID RES, 54, PP. 2586-2594, (2013); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO EICOSAPENTAENOIC ACID (EPA), DOCOSAHEXAENOIC ACID (DHA), DOCOSAPENTAENOIC ACID (DPA) AND MAINTENANCE OF NORMAL CARDIAC FUNCTION (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), MAINTENANCE OF NORMAL BLOOD GLUCOSE CONCENTRATIONS (ID 566), EFSA J, 8, 10, (2010); MA J., LI Y., YE Q., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5225, (2000); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS:BUYER BEWARE!, ARCH INTERN MED, 170, PP. 1722-1727, (2010); CHEN C.H., UANG Y.S., WANG S.T., YANG J.C., LIN C.J., INTERACTION BETWEEN RED YEAST RICE AND CYP450 ENZYMES/P-GLYCOPROTEIN AND ITS IMPLICATION FOR THE CLINICAL PHARMACOKINETICS OF LOVASTATIN, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012); LI Y., JIANG L., JIA Z., ET AL., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, (2014); HEINZ T., SCHUCHARDT J.P., MOLLER K., HADJI P., HAHN A., LOW DAILY DOSE OF 3 MG MONACOLIN K FROM RYR REDUCES THE CONCENTRATION OF LDL-C IN A RANDOMIZED, PLACEBO-CONTROLLED INTERVENTION, NUTR RES, 36, PP. 1162-1170, (2016); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); BOGSRUD M.P., OSE L., LANGSLET G., ET AL., HYPOCOL (RED YEAST RICE) LOWERS PLASMA CHOLESTEROL - A RANDOMIZED PLACEBO CONTROLLED STUDY, SCAND CARDIOVASC J, 44, PP. 197-200, (2010); VERHOEVEN V., LOPEZ HARTMANN M., REMMEN R., WENS J., APERS S., VAN ROYEN P., RED YEAST RICE LOWERS CHOLESTEROL IN PHYSICIANS - A DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED TRIAL, BMC COMPLEMENT ALTERN MED, 13, (2013); MAGNO S., CECCARINI G., PELOSINI C., ET AL., LDL-CHOLESTEROL LOWERING EFFECT OF A NEW DIETARY SUPPLEMENT: AN OPEN LABEL, CONTROLLED, RANDOMIZED, CROSS-OVER CLINICAL TRIAL IN PATIENTS WITH MILD-TO-MODERATE HYPERCHOLESTEROLEMIA, LIPIDS HEALTH DIS, 17, (2018); CICERO A.F., DEROSA G., PARINI A., ET AL., RED YEAST RICE IMPROVES LIPID PATTERN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND VASCULAR REMODELING PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC ITALIAN SUBJECTS, NUTR RES, 33, PP. 622-628, (2013); MARANGONI F., POLI A., PHYTOSTEROLS AND CARDIOVASCULAR HEALTH, PHARMACOL RES, 61, PP. 193-199, (2010); HALLIKAINEN M., LYYRA-LAITINEN T., LAITINEN T., ET AL., ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLEMIC SUBJECTS: EFFECTS OF PLANT STANOL AND STEROL ESTERS, ATHEROSCLEROSIS, 188, PP. 425-432, (2006); RAS R.T., GELEIJNSE J.M., TRAUTWEIN E.A., LDL-CHOLESTEROL-LOWERING EFFECT OF PLANT STEROLS AND STANOLS ACROSS DIFFERENT DOSE RANGES: A META-ANALYSIS OF RANDOMISED CONTROLLED STUDIES, BR J NUTR, 112, PP. 214-219, (2014); RAS R.T., FUCHS D., KOPPENOL W.P., ET AL., EFFECT OF A PLANT STEROLENRICHED SPREAD ON BIOMARKERS OF ENDOTHELIAL DYSFUNCTION AND LOWGRADE INFLAMMATION IN HYPERCHOLESTEROLAEMIC SUBJECTS, J NUTR SCI, 5, (2016); ABUMWEIS S.S., MARINANGELI C.P., FROHLICH J., JONES P.J., IMPLEMENTING PHYTOSTEROLS INTO MEDICAL PRACTICE AS A CHOLESTEROL-LOWERING STRATEGY:OVERVIEW OF EFFICACY, EFFECTIVENESS, AND SAFETY, CAN J CARDIOL, 30, PP. 1225-1232, (2014); SARKKINEN E., LYYRA M., NIEMINEN S., KUUSISTO P., WESTER I., CEREALBASED SNACK BAR WITH ADDED PLANT STANOL ESTER (BENECOL®) CONSUMED BETWEEN MEALS LOWERS SERUM TOTAL AND LDL CHOLESTEROL EFFECTIVELY IN MILDLY TO MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS, CHOLESTEROL, 2018, (2018); GYLLING H., PLAT J., TURLEY S., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, PP. 346-360, (2014); MOMTAZI A.A., BANACH M., PIRRO M., KATSIKI N., SAHEBKAR A., REGULATION OF PCSK9 BY NUTRACEUTICALS, PHARMACOL RES, 120, PP. 157-169, (2017); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROLLOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); DEROSA G., D'ANGELO A., BONAVENTURA A., BIANCHI L., ROMANO D., MAFFIOLI P., EFFECTS OF BERBERINE ON LIPID PROFILE IN SUBJECTS WITH LOW CARDIOVASCULAR RISK, EXPERT OPIN BIOL THER, 13, PP. 475-482, (2013); LAN J., ZHAO Y., DONG F., ET AL., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J ETHNOPHARMACOL, 161, PP. 69-81, (2015); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES CLIN EXP, 77, PP. 1-6, (2014); MILLAN J., CICERO A.F., TORRES F., ANGUERA A., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS:A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLIN INVESTIG ARTERIOSCLER, 28, PP. 178-187, (2016); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); KONG W.J., WEI J., ZUO Z.Y., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFICACY, METABOLISM, 57, PP. 1029-1037, (2008); LIU C., WANG Z., SONG Y., ET AL., EFFECTS OF BERBERINE ON AMELIORATION OF HYPERGLYCEMIA AND OXIDATIVE STRESS IN HIGH GLUCOSE AND HIGH FAT DIET-INDUCED DIABETIC HAMSTERS IN VIVO, BIOMED RES INT, (2015); MENG S., WANG L.S., HUANG Z.Q., ET AL., BERBERINE AMELIORATES INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION, CLIN EXP PHARMACOL PHYSIOL, 39, PP. 406-411, (2012); LI Z., GENG Y.N., JIANG J.D., KONG W.J., ANTIOXIDANT AND ANTIINFLAMMATORY ACTIVITIES OF BERBERINE IN THE TREATMENT OF DIABETES MELLITUS, EVID BASED COMPLEMENT ALTERNAT MED, (2014); THANDAPILLY S.J., NDOU S.P., WANG Y., NYACHOTI C.M., AMES N.P., BARLEY Β-GLUCAN INCREASES FECAL BILE ACID EXCRETION AND SHORT CHAIN FATTY ACID LEVELS IN MILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, FOOD FUNCT, 9, PP. 3092-3096, (2018); REYNA-VILLASMIL N., BERMUDEZ-PIRELA V., MENGUAL-MORENO E., ET AL., OAT-DERIVED BETA-GLUCAN SIGNIFICANTLY IMPROVES HDLC AND DIMINISHES LDLC AND NON-HDL CHOLESTEROL IN OVERWEIGHT INDIVIDUALS WITH MILD HYPERCHOLESTEROLEMIA, AM J THER, 14, PP. 203-212, (2007); KEENAN J.M., GOULSON M., SHAMLIYAN T., KNUTSON N., KOLBERG L., CURRY L., THE EFFECTS OF CONCENTRATED BARLEY BETA-GLUCAN ON BLOOD LIPIDS IN A POPULATION OF HYPERCHOLESTEROLAEMIC MEN AND WOMEN, BR J NUTR, 97, PP. 1162-1168, (2007); QUEENAN K.M., STEWART M.L., SMITH K.N., THOMAS W., FULCHER R.G., SLAVIN J.L., CONCENTRATED OAT BETA-GLUCAN, A FERMENTABLE FIBER, LOWERS SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC ADULTS IN A RANDOMIZED CONTROLLED TRIAL, NUTR J, 6, (2007); WOLEVER T.M., GIBBS A.L., BRAND-MILLER J., ET AL., BIOACTIVE OAT Β- GLUCAN REDUCES LDL CHOLESTEROL IN CAUCASIANS AND NON-CAUCASIANS, NUTR J, 10, (2011); CICERO A.F.G., FOGACCI F., COLLETTI A., FOOD AND PLANT BIOACTIVES FOR REDUCING CARDIOMETABOLIC DISEASE RISK: AN EVIDENCE BASED APPROACH, FOOD FUNCT, 8, PP. 2076-2088, (2017); TESSARI P., LANTE A., A MULTIFUNCTIONAL BREAD RICH IN BETA GLUCANS AND LOW IN STARCH IMPROVES METABOLIC CONTROL IN TYPE 2 DIABETES: A CONTROLLED TRIAL, NUTRIENTS, 9, 3, (2017); GARDNER C.D., MESSINA M., KIAZAND A., MORRIS J.L., FRANKE A.A., EFFECT OF TWO TYPES OF SOY MILK AND DAIRY MILK ON PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC ADULTS: A RANDOMIZED TRIAL, J AM COLL NUTR, 26, PP. 669-677, (2007); CLERICI C., SETCHELL K.D., BATTEZZATI P.M., ET AL., PASTA NATURALLY ENRICHED WITH ISOFLAVONE AGLYCONS FROM SOY GERM REDUCES SERUM LIPIDS AND IMPROVES MARKERS OF CARDIOVASCULAR RISK, J NUTR, 137, PP. 2270-2278, (2007); WOFFORD M.R., REBHOLZ C.M., REYNOLDS K., ET AL., EFFECT OF SOY AND MILK PROTEIN SUPPLEMENTATION ON SERUM LIPID LEVELS: A RANDOMIZED CONTROLLED TRIAL, EUR J CLIN NUTR, 66, PP. 419-425, (2012); RAMDATH D.D., PADHI E.M., SARFARAZ S., RENWICK S., DUNCAN A.M., BEYOND THE CHOLESTEROL-LOWERING EFFECT OF SOY PROTEIN: A REVIEW OF THE EFFECTS OF DIETARY SOY AND ITS CONSTITUENTS ON RISK FACTORS FOR CARDIOVASCULAR DISEASE, NUTRIENTS, 9, 4, (2017); BABA S., NATSUME M., YASUDA A., ET AL., PLASMA LDL AND HDL CHOLESTEROL AND OXIDIZED LDL CONCENTRATIONS ARE ALTERED IN NORMO- AND HYPERCHOLESTEROLEMIC HUMANS AFTER INTAKE OF DIFFERENT LEVELS OF COCOA POWDER, J NUTR, 137, PP. 1436-1441, (2007); ZHU Y., XIA M., YANG Y., ET AL., PURIFIED ANTHOCYANIN SUPPLEMENTATION IMPROVES ENDOTHELIAL FUNCTION VIA NO-CGMP ACTIVATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS, CLIN CHEM, 57, PP. 1524-1533, (2011); QIN Y., XIA M., MA J., ET AL., ANTHOCYANIN SUPPLEMENTATION IMPROVES SERUM LDL- AND HDL-CHOLESTEROL CONCENTRATIONS ASSOCIATED WITH THE INHIBITION OF CHOLESTERYL ESTER TRANSFER PROTEIN IN DYSLIPIDEMIC SUBJECTS, AM J CLIN NUTR, 90, PP. 485-492, (2009); TOME-CARNEIRO J., VISIOLI F., POLYPHENOL-BASED NUTRACEUTICALS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE: REVIEW OF HUMAN EVIDENCE, PHYTOMEDICINE, 23, PP. 1145-1174, (2016); LEOPOLDINI M., MALAJ N., TOSCANO M., SINDONA G., RUSSO N., ON THE INHIBITOR EFFECTS OF BERGAMOT JUICE FLAVONOIDS BINDING TO THE 3- HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGR) ENZYME, J AGRIC FOOD CHEM, 58, PP. 10768-10773, (2010); YASHIRO T., NANMOKU M., SHIMIZU M., INOUE J., SATO R., RESVERATROL INCREASES THE EXPRESSION AND ACTIVITY OF THE LOW DENSITY LIPOPROTEIN RECEPTOR IN HEPATOCYTES BY THE PROTEOLYTIC ACTIVATION OF THE STEROL REGULATORY ELEMENT-BINDING PROTEINS, ATHEROSCLEROSIS, 220, PP. 369-374, (2012); BONDONNO C.P., YANG X., CROFT K.D., ET AL., FLAVONOID-RICH APPLES AND NITRATE-RICH SPINACH AUGMENT NITRIC OXIDE STATUS AND IMPROVE ENDOTHELIAL FUNCTION IN HEALTHY MEN AND WOMEN: A RANDOMIZED CONTROLLED TRIAL, FREE RADIC BIOL MED, 52, PP. 95-102, (2012); DOWER J.I., GELEIJNSE J.M., GIJSBERS L., ZOCK P.L., KROMHOUT D., HOLLMAN P.C., EFFECTS OF THE PURE FLAVONOIDS EPICATECHIN AND QUERCETIN ON VASCULAR FUNCTION AND CARDIOMETABOLIC HEALTH: A RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL, AM J CLIN NUTR, 101, PP. 914-921, (2015); TENORE G.C., CARUSO D., BUONOMO G., ET AL., ANNURCA (MALUS PUMILA MILLER CV. ANNURCA) APPLE AS A FUNCTIONAL FOOD FOR THE CONTRIBUTION TO A HEALTHY BALANCE OF PLASMA CHOLESTEROL LEVELS: RESULTS OF A RANDOMIZED CLINICAL TRIAL, J SCI FOOD AGRIC, 97, PP. 2107-2115, (2017); TOTH P.P., PATTI A.M., NIKOLIC D., ET AL., BERGAMOT REDUCES PLASMA LIPIDS, ATHEROGENIC SMALL DENSE LDL, AND SUBCLINICAL ATHEROSCLEROSIS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA: A 6 MONTHS PROSPECTIVE STUDY, FRONT PHARMACOL, 6, (2016); BASU A., PENUGONDA K., POMEGRANATE JUICE: A HEART-HEALTHY FRUIT JUICE, NUTR REV, 67, PP. 49-56, (2009); DE NIGRIS F., WILLIAMS-IGNARRO S., LERMAN L.O., ET AL., BENEFICIAL EFFECTS OF POMEGRANATE JUICE ON OXIDATION-SENSITIVE GENES AND ENDOTHELIAL NITRIC OXIDE SYNTHASE ACTIVITY AT SITES OF PERTURBED SHEAR STRESS, PROC NATL ACAD SCI USA, 102, PP. 4896-4901, (2005); DE NIGRIS F., WILLIAMS-IGNARRO S., BOTTI C., SICA V., IGNARRO L.J., NAPOLI C., POMEGRANATE JUICE REDUCES OXIDIZED LOW-DENSITY LIPOPROTEIN DOWNREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE IN HUMAN CORONARY ENDOTHELIAL CELLS, NITRIC OXIDE, 15, PP. 259-263, (2006); AVIRAM M., ROSENBLAT M., GAITINI D., ET AL., POMEGRANATE JUICE CONSUMPTION FOR 3 YEARS BY PATIENTS WITH CAROTID ARTERY STENOSIS REDUCES COMMON CAROTID INTIMA-MEDIA THICKNESS, BLOOD PRESSURE AND LDL OXIDATION, CLIN NUTR, 23, PP. 423-433, (2004); ESMAILLZADEH A., TAHBAZ F., GAIENI I., ALAVI-MAJD H., AZADBAKHT L., CONCENTRATED POMEGRANATE JUICE IMPROVES LIPID PROFILES IN DIABETIC PATIENTS WITH HYPERLIPIDEMIA, J MED FOOD, 7, PP. 305-308, (2004); MIRMIRAN P., FAZELI M.R., ASGHARI G., SHAFIEE A., AZIZI F., EFFECT OF POMEGRANATE SEED OIL ON HYPERLIPIDAEMIC SUBJECTS: A DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL, BR J NUTR, 104, PP. 402-406, (2010); HOSSEINI B., SAEDISOMEOLIA A., WOOD L.G., YASERI M., TAVASOLI S., EFFECTS OF POMEGRANATE EXTRACT SUPPLEMENTATION ON INFLAMMATION IN OVERWEIGHT AND OBESE INDIVIDUALS: A RANDOMIZED CONTROLLED CLINICAL TRIAL, COMPLEMENT THER CLIN PRACT, 22, PP. 44-50, (2016); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. M186-M192, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, PP. 31-44, (2005); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); YOO J.Y., KIM S.S., PROBIOTICS AND PREBIOTICS: PRESENT STATUS AND FUTURE PERSPECTIVES ON METABOLIC DISORDERS, NUTRIENTS, 8, (2016); MIELE L., GIORGIO V., ALBERELLI M.A., DE CANDIA E., GASBARRINI A., GRIECO A., IMPACT OF GUT MICROBIOTA ON OBESITY, DIABETES, AND CARDIOVASCULAR DISEASE RISK, CURR CARDIOL REP, 17, (2015); BERNINI L.J., SIMAO A.N., ALFIERI D.F., ET AL., BENEFICIAL EFFECTS OF BIFIDOBACTERIUM LACTIS ON LIPID PROFILE AND CYTOKINES IN PATIENTS WITH METABOLIC SYNDROME: A RANDOMIZED TRIAL. EFFECTS OF PROBIOTICS ON METABOLIC SYNDROME, NUTRITION, 32, PP. 716-719, (2016); COSTABILE A., BUTTARAZZI I., KOLIDA S., ET AL., AN IN VIVO ASSESSMENT OF THE CHOLESTEROL-LOWERING EFFICACY OF LACTOBACILLUS PLANTARUM ECGC 13110402 IN NORMAL TO MILDLY HYPERCHOLESTEROLAEMIC ADULTS, PLOS ONE, 12, (2017); TONUCCI L.B., OLBRICH DOS SANTOS K.M., LICURSI DE OLIVEIRA L., ROCHA RIBEIRO S.M., DUARTE MARTINO H.S., CLINICAL APPLICATION OF PROBIOTICS IN TYPE 2 DIABETES MELLITUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY, CLIN NUTR, 36, PP. 85-92, (2017); NAITO E., YOSHIDA Y., KUNIHIRO S., ET AL., EFFECT OF LACTOBACILLUS CASEI STRAIN SHIROTA-FERMENTED MILK ON METABOLIC ABNORMALITIES IN OBESE PREDIABETIC JAPANESE MEN: A RANDOMISED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL, BIOSCI MICROBIOTA FOOD HEALTH, 37, PP. 9-18, (2018); THUSHARA R.M., GANGADARAN S., SOLATI Z., MOGHADASIAN M.H., CARDIOVASCULAR BENEFITS OF PROBIOTICS: A REVIEW OF EXPERIMENTAL AND CLINICAL STUDIES, FOOD FUNCT, 7, PP. 632-642, (2016); AGERHOLM-LARSEN L., RABEN A., HAULRIK N., HANSEN A.S., MANDERS M., ASTRUP A., EFFECT OF 8 WEEK INTAKE OF PROBIOTIC MILK PRODUCTS ON RISK FACTORS FOR CARDIOVASCULAR DISEASES, EUR J CLIN NUTR, 54, PP. 288-297, (2000); KIESSLING G., SCHNEIDER J., JAHREIS G., LONG-TERM CONSUMPTION OF FERMENTED DAIRY PRODUCTS OVER 6 MONTHS INCREASES HDL CHOLESTEROL, EUR J CLIN NUTR, 56, PP. 843-849, (2002); SHIMIZU M., HASHIGUCHI M., SHIGA T., TAMURA H.O., MOCHIZUKI M., META-ANALYSIS: EFFECTS OF PROBIOTIC SUPPLEMENTATION ON LIPID PROFILES IN NORMAL TO MILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, PLOS ONE, 10, (2015); FLOCH M.H., WALKER W.A., SANDERS M.E., ET AL., RECOMMENDATIONS FOR PROBIOTIC USE--2015 UPDATE: PROCEEDINGS AND CONSENSUS OPINION, J CLIN GASTROENTEROL, 49, PP. S69-73, (2015); FITZGERALD K., WHITE S., BORODOVSKY A., ET AL., A HIGHLY DURABLE RNAI THERAPEUTIC INHIBITOR OF PCSK9, N ENGL J MED, 376, PP. 41-51, (2017); RAY K.K., LANDMESSER U., LEITER L.A., ET AL., INCLISIRAN IN PATIENTS AT HIGH CARDIOVASCULAR RISK WITH ELEVATED LDL CHOLESTEROL, N ENGL J MED, 376, PP. 1430-1440, (2017)","D. COSTA; U.O.C. IMMUNOHEMATOLOGY, TRANSFUSION MEDICINE AND TRANSPLANT IMMUNOLOGY, AZIENDA OSPEDALIERA UNIVERSITARIA (AOU), UNIVERSITY OF CAMPANIA “L. VANVITELLI” PIAZZA MIRAGLIA, NAPOLI, 2 80138, ITALY; EMAIL: DARIO.COSTA@POLICLINICONAPOLI.IT","BENTHAM SCIENCE PUBLISHERS","ENGLISH","CURR. PHARM. DES.","ARTICLE","ISI","2-S2.0-85067789858","CURR PHARM DES","UNIVERSITY OF CAMPANIA “L. VANVITELLI”;UNIVERSITY OF CAMPANIA “L. VANVITELLI”;UNIVERSITY OF CAMPANIA “L. VANVITELLI”;UNIVERSITY OF CAMPANIA “L. VANVITELLI”","NOTREPORTED;AZIENDA OSPEDALIERA UNIVERSITARIA (AOU);EMAIL: DARIO.COSTA@POLICLINICONAPOLI.IT",NA,"SCOGNAMIGLIO M, 2019, CURR PHARM DES","SCOGNAMIGLIO M, 2019, CURR PHARM DES"
"CHO D;LIM S","CHO, DONG-HWA (57193834086); LIM, SEUNG-TAIK (7404081168)","GERMINATED BROWN RICE AND ITS BIOFUNCTIONAL COMPOUNDS",2016,"FOOD CHEMISTRY","196","12",244,"10.1016/j.foodchem.2015.09.025","DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, 1, ANAM-DONG 5-GA, SUNGBUK-GU, SEOUL, 136-701, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, 1, ANAM-DONG 5-GA, SUNGBUK-GU, SEOUL, 136-701, SOUTH KOREA","BROWN RICE (BR) CONTAINS BRAN LAYERS AND EMBRYO, WHERE A VARIETY OF NUTRITIONAL AND BIOFUNCTIONAL COMPONENTS, SUCH AS DIETARY FIBERS, Γ-ORYZANOL, VITAMINS, AND MINERALS, EXIST. HOWEVER, BR IS CONSUMED LESS THAN WHITE RICE BECAUSE IT HAS AN INFERIOR EATING TEXTURE WHEN COOKED. GERMINATION IS ONE OF THE TECHNIQUES USED TO IMPROVE THE TEXTURE OF THE COOKED BR. IN ADDITION, IT INDUCES NUMEROUS CHANGES IN THE COMPOSITION AND CHEMICAL STRUCTURE OF THE BIOACTIVE COMPONENTS. MOREOVER, MANY STUDIES REPORTED THAT THE GERMINATION COULD INDUCE THE FORMATION OF NEW BIOACTIVE COMPOUNDS, SUCH AS GAMMA-AMINOBUTYRIC ACID (GABA). THE CONSUMPTION OF GERMINATED BROWN RICE (GBR) IS INCREASING IN MANY ASIAN COUNTRIES BECAUSE OF ITS IMPROVED EATING QUALITY AND POTENTIAL HEALTH-PROMOTING FUNCTIONS. HOWEVER, THERE IS STILL A LACK OF STUDIES ON THE COMPOSITIONAL AND FUNCTIONAL CHANGES OF THE BIOACTIVE COMPONENTS DURING GERMINATION. THIS REVIEW CONTAINS RECENT RESEARCH FINDINGS, ESPECIALLY ON THE BIOACTIVE COMPONENTS IN GBR. © 2015 ELSEVIER LTD. ALL RIGHTS RESERVED.","BROWN RICE; C-AMINOBUTYRIC ACID; C-ORYZANOL; GERMINATION; RICE BRAN OIL","COOKING; DIETARY FIBER; GAMMA-AMINOBUTYRIC ACID; GERMINATION; ORYZA; PHENYLPROPIONATES; AMINO ACIDS; NUTRITION; 4 AMINOBUTYRIC ACID; AMYLASE; GAMMA ORYZANOL; OIL; POLICOSANOL; TOCOL; 4 AMINOBUTYRIC ACID; GAMMA-ORYZANOL; PHENYLPROPIONIC ACID DERIVATIVE; AMINOBUTYRIC ACIDS; BROWN RICE; GERMINATION; ORYZANOL; RICE BRAN OIL; BROWN RICE; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CULTIVAR; DIETARY FIBER; ENZYME ACTIVITY; GERMINATION; NONHUMAN; REVIEW; RICE; CHEMISTRY; COOKING; GERMINATION; ORYZA; CULTIVATION","KOREA SCIENCE AND ENGINEERING FOUNDATION, KOSEF; MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY, MEST, (R01-2008-000-20409-0)","THIS WORK WAS FINANCIALLY SUPPORTED BY THE KOREA SCIENCE AND ENGINEERING FOUNDATION (KOSEF) GRANT FUNDED BY THE KOREA GOVERNMENT (MEST) (NO. R01-2008-000-20409-0).","AN M.K., AHN J.B., LEE S.H., LEE K.G., ANALYSIS OF Γ-AMINOBUTYRIC ACID (GABA) CONTENT IN GERMINATED PIGMENTED RICE, KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 42, PP. 632-636, (2010); BANCHUEN J., THAMMARUTWASIK P., OORAIKUL B., WUTTIJUMNONG P., SIRIVONGPAISAL P., EFFECT OF GERMINATING PROCESSES ON BIOACTIVE COMPONENT OF SANGYOD MUANG PHATTHALUNG RICE, THAI JOURNAL OF AGRICULTURAL SCIENCE, 42, PP. 191-199, (2009); BEWLEY J.D., SEED GERMINATION AND DORMANCY, PLANT CELL, 9, PP. 1055-1066, (1997); BOWN A.W., MACGREGOR K.B., SHELP B.J., GAMMA-AMINOBUTYRATE: DEFENSE AGAINST INVERTEBRATE PESTS?, TRENDS IN PLANT SCIENCE, 11, PP. 424-427, (2006); BRUFAU G., CANELA M.A., RAFECAS M., PHYTOSTEROLS: PHYSIOLOGIC AND METABOLIC ASPECTS RELATED TO CHOLESTEROL-LOWERING PROPERTIES, NUTRITION RESEARCH, 28, PP. 217-225, (2008); CAPANZANA M.V., BUCKLE K.A., OPTIMISATION OF GERMINATION CONDITIONS BY RESPONSE SURFACE METHODOLOGY OF A HIGH AMYLOSE RICE (ORYZA SATIVA) CULTIVAR, LWT - FOOD SCIENCE AND TECHNOLOGY, 30, PP. 155-163, (1997); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA; A 6-MONTH DOUBLE-BLIND STUDY, INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 21, PP. 43-57, (2001); CHENG H.H., TOTAL DIETARY FIBER CONTENT OF POLISHED, BROWN AND BRAN TYPES OF JAPONICA AND INDICA RICE IN TAIWAN: RESULTING PHYSIOLOGICAL EFFECTS OF CONSUMPTION, NUTRITION RESEARCH, 13, PP. 93-101, (1993); CHO H.Y., LIM S.T., KIM K.M., SON M.E., COMPOSITION FOR ANTI-DIABETES COMPRISING GERMINATED BROWN RICE EXTRACTS, (2009); CHOI H.D., KIM Y.S., CHOI I.U., PARK Y.G., PARK Y.D., HYPOTENSIVE EFFECT OF GERMINATED BROWN RICE ON SPONTANEOUSLY HYPERTENSIVE RATS, KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 38, PP. 448-451, (2006); CHOI H.D., KIM Y.S., CHOI I.U., SEOK H.M., PARK Y.D., ANTI-OBESITY AND CHOLESTEROL-LOWERING EFFECTS OF GERMINATED BROWN RICE IN RATS FED WITH HIGH FAT AND CHOLESTEROL DIETS, KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 38, PP. 674-678, (2006); CHOI I.D., KIM D.S., SON J.R., YANG C.I., CHUN J.Y., KIM K.J., PHYSICO-CHEMICAL PROPERTIES OF GIANT EMBRYO RICE (KEUNNUNBYEO), AGRICULTURAL CHEMISTRY AND BIOTECHNOLOGY, 49, PP. 95-100, (2006); CHOI H.D., PARK Y.K., KIM Y.S., CHUNG C.H., PARK Y.D., EFFECT OF PRETREATMENT CONDITIONS ON Γ-AMINOBUTYRIC ACID CONTENT OF BROWN RICE AND GERMINATED BROWN RICE, KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 36, PP. 761-764, (2004); FAO RICE MARKET MONITOR, FAO, (2013); HA T.-Y., HAN S., KIM S.-R., KIM I.-H., LEE H.-Y., KIM H.-K., BIOACTIVE COMPONENTS IN RICE BRAN OIL IMPROVE LIPID PROFILES IN RATS FED A HIGH-CHOLESTEROL DIET, NUTRITION RESEARCH, 25, PP. 597-606, (2005); HAGIWARA H., SEKI T., ARIGA T., THE EFFECT OF PRE-GERMINATED BROWN RICE INTAKE ON BLOOD GLUCOSE AND PAI-1 LEVELS IN STREPTOZOTOCIN-INDUCED DIABETIC RATS, BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, 2, PP. 444-447, (2004); HAYAKAWA K., KIMURA M., KAMATA K., MECHANISM UNDERLYING Γ-AMINOBUTYRIC ACID-INDUCED ANTIHYPERTENSIVE EFFECT IN SPONTANEOUSLY HYPERTENSIVE RATS, EUROPEAN JOURNAL OF PHARMACOLOGY, 438, PP. 107-113, (2002); HSU T.F., KISE M., WANG M.F., ITO Y., YANG M.D., AOTO H., YAMAMOTO S., EFFECTS OF PRE-GERMINATED BROWN RICE ON BLOOD GLUCOSE AND LIPID LEVELS IN FREE-LIVING PATIENTS WITH IMPAIRED FASTING GLUCOSE OR TYPE 2 DIABETES, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 54, PP. 163-168, (2008); IQBAL J., MINHAJUDDIN M., BEG Z.H., SUPPRESSION OF DIETHYLNITROSAMINE AND 2-ACETYLAMINOFLUORENE-INDUCED HEPATOCARCINOGENESIS IN RATS BY TOCOTRIENOL-RICH FRACTION ISOLATED FROM RICE BRAN OIL, EUROPEAN JOURNAL OF CANCER PREVENTION, 13, PP. 515-520, (2004); ITO Y., MIZUKUCHI A., KISE M., AOTO H., YAMAMOTO S., YOSHIHARA R., YOKOYAMA J., POSTPRANDIAL BLOOD GLUCOSE AND INSULIN RESPONSES TO PRE-GERMINATED BROWN RICE IN HEALTHY SUBJECTS, JOURNAL OF MEDICAL INVESTIGATION, 52, PP. 159-164, (2005); JAYADEEP A., MALLESHI N.G., NUTRIENTS, COMPOSITION OF TOCOTRIENOLS, TOCOPHEROLS, AND Γ-ORYZANOL, AND ANTIOXIDANT ACTIVITY IN BROWN RICE BEFORE AND AFTER BIOTRANSFORMATION, CYTA - JOURNAL OF FOOD, 9, PP. 82-87, (2011); JIAMYANGYUEN S., OORAIKUL B., THE PHYSICO-CHEMICAL, EATING AND SENSORIAL PROPERTIES OF GERMINATED BROWN RICE, JOURNAL OF FOOD, AGRICULTURE AND ENVIRONMENT, 6, PP. 119-124, (2008); JIANG Q., CHRISTEN S., SHIGENAGA M.K., AMES B.N., Γ-TOCOPHEROL, THE MAJOR FORM OF VITAMIN E IN THE US DIET, DESERVES MORE ATTENTION, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 74, PP. 714-722, (2001); JUNG H.Y., LEE D.H., BEAK H.Y., LEE Y.S., PRE- AND POST-GERMINATION CHANGES IN PHARMACEUTICAL COMPOUNDS OF GERMINATED BROWN RICE, KOREAN JOURNAL OF CROP SCIENCE, 53, PP. 37-43, (2008); KAHLON T.S., CHOW F.I., SAYRE R.N., BETSCHART A.A., CHOLESTEROL-LOWERING IN HAMSTERS FED RICE BRAN AT VARIOUS LEVELS, DEFATTED RICE BRAN AND RICE BRAN OIL, THE JOURNAL OF NUTRITION, 122, PP. 513-519, (1992); KAHLON T.S., WOODRUFF C.L., IN VITRO BINDING OF BILE ACIDS BY RICE BRAN, OAT BRAN, BARLEY AND Β-GLUCAN ENRICHED BARLEY, CEREAL CHEMISTRY, 80, PP. 260-263, (2003); KANAYA Y., DOI T., SASAKI H., FUJITA A., MATSUNO S., OKAMOTO K., NANJO K., RICE BRAN EXTRACT PREVENTS THE ELEVATION OF PLASMA PEROXYLIPID IN KKAY DIABETIC MICE, DIABETES RESEARCH AND CLINICAL PRACTICE, 66 S, PP. S157-S160, (2004); KANNAPPAN R., YADAV V.R., AGGARWAL B.B., GAMMA-TOCOTRIENOL BUT NOT GAMMA-TOCOPHEROL BLOCKS STAT3 CELL SIGNALING PATHWAY THROUGH INDUCTION OF PROTEIN-TYROSINE PHOSPHATASE SHP-1 AND SENSITIZES TUMOR CELLS TO CHEMOTHERAPEUTIC AGENTS, JOURNAL OF BIOLOGICAL CHEMISTRY, 285, PP. 33520-33528, (2010); KAWABATA K., TANAKA T., MURAKAMI T., OKADA T., MURAI H., YAMAMOTO T., MORI H., DIETARY PREVENTION OF AZOXYMETHANE-INDUCED COLON CARCINOGENESIS WITH RICE-GERM IN F344 RATS, CARCINOGENESIS, 20, PP. 2109-2115, (1999); KERCKHOFFS D.A., HORNSTRA G., MENSINK R.P., CHOLESTEROL LOWERING EFFECT OF Β-GLUCAN FROM OAT BRAN IN MILDLY HYPERCHOLESTEROLEMIC SUBJECTS MAY DECREASE WHEN Β-GLUCAN IS INCORPORATED INTO BREAD AND COOKIES, AMERICAN JOURNAL OF CLINICAL NUTRITION, 78, PP. 221-227, (2003); KIM J.K., PARK S.-Y., JUNG J.Y., HA S.-H., LIM S.-H., LEE S.M., SUH S.-C., POLICOSANOL CONTENT AND COMPOSITION OF KOREAN RICE (ORYZA SATIVA L.) CULTIVARS, CEREAL CHEMISTRY, 89, PP. 151-154, (2012); KIM S.L., SON Y.K., SON J.L., HUR H.S., EFFECT OF GERMINATION CONDITION AND DRYING METHODS ON PHYSICOCHEMICAL PROPERTIES OF SPROUTED BROWN RICE, KOREAN JOURNAL OF CROP SCIENCE, 46, PP. 221-228, (2001); KOHNO Y., EGAWA Y., ITOH S., NAGAOKA S., TAKAHASHI M., MUKAI K., KINETIC STUDY OF QUENCHING REACTION OF SINGLET OXYGEN AND SCAVENGING REACTION OF FREE RADICAL BY SQUALENE IN N-BUTANOL, BIOCHIMICA ET BIOPHYSICA ACTA - LIPIDS AND LIPID METABOLISM, 1256, PP. 52-56, (1995); KOMATSUZAKI N., TSUKAHARA K., TOYOSHIMA H., SUZUKI T., SHIMIZU N., KIMURA T., EFFECT OF SOAKING AND GASEOUS TREATMENT ON GABA CONTENT IN GERMINATED BROWN RICE, JOURNAL OF FOOD ENGINEERING, 78, PP. 556-560, (2007); KWAK J.-E., YOON S.-W., KIM D.-J., YOON M.-R., LEE J.-H., OH S.-K., CHANG J.-K., CHANGES IN NUTRACEUTICAL LIPID CONSTITUENTS OF PRE- AND POST-GERMINATED BROWN RICE OIL, KOREAN JOURNAL OF FOOD NUTRITION, 26, PP. 591-600, (2013); LATIFAH S.Y., ARMANIA N., TZE T.H., AZHAR Y., NORDIANA A.H., NORAZALINA S., MAZNAH I., GERMINATED BROWN RICE (GBR) REDUCES THE INCIDENCE OF ABERRANT CRYPT FOCI WITH THE INVOLVEMENT OF Β-CATENIN AND COX-2 IN AZOXYMETHANE-INDUCED COLON CANCER IN RATS, NUTRITION JOURNAL, 26, PP. 9-16, (2010); LEE Y.R., KIM C.E., KANG M.Y., NAM S.H., CHOLESTEROL-LOWERING AND ANTIOXIDANT STATUS-IMPROVING EFFICACY OF GERMINATED GIANT EMBRYONIC RICE (ORYZA SATIVA L.) IN HIGH CHOLESTEROL-FED RATS, ANNALS OF NUTRITION & METABOLISM, 51, PP. 519-526, (2007); LEE Y.R., KIM J.Y., WOO K.S., HWANG I.G., KIM K.H., KIM K.J., JEONG H.S., CHANGES IN THE CHEMICAL AND FUNCTIONAL COMPONENTS OF KOREAN ROUGH RICE BEFORE AND AFTER GERMINATION, FOOD SCIENCE AND BIOTECHNOLOGY, 16, PP. 1006-1010, (2007); LICHTENSTEIN A.H., AUSMAN L.M., CARRASCO W., RICE BRAN OIL CONSUMPTION AND PLASMA LIPID LEVELS IN MODERATELY HYPERCHOLESTEROLEMIC HUMANS, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 14, PP. 549-556, (1994); LU Z.H., ZHANG Y., LI L.T., CURTIS R.B., KONG X.L., FULCHER R.G., CAO W., INHIBITION OF MICROBIAL GROWTH AND ENRICHMENT OF GAMMA-AMINOBUTYRIC ACID DURING GERMINATION OF BROWN RICE BY ELECTROLYZED OXIDIZING WATER, JOURNAL OF FOOD PROTECTION, 73, PP. 483-487, (2010); MAMIYA T., ASANUMA T., KISE M., ITO Y., MIZUKUCHI A., AOTO H., UKAI M., EFFECTS OF PRE-GERMINATED BROWN RICE ON Β-AMYLOID PROTEIN-INDUCED LEARNING AND MEMORY DEFICITS IN MICE, BIOLOGICAL AND PHARMACEUTICAL BULLETIN, 27, PP. 1041-1045, (2004); MAMIYA T., KISE M., MORIKAWA K., AOTO H., UKAI M., NODA Y., EFFECTS OF PRE-GERMINATED BROWN RICE ON DEPRESSION-LIKE BEHAVIOR IN MICE, PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, 86, PP. 62-67, (2007); MIURA D., ITO Y., MIZUKUCHI A., KISE M., AOTO H., YAGASAKI K., HYPOCHOLESTEROLEMIC ACTION OF PRE-GERMINATED BROWN RICE IN HEPATOMA-BEARING RATS, LIFE SCIENCE, 79, PP. 259-264, (2006); MIYOSHI K., SATO T., TAKAHASHI N., DIFFERENCES IN THE EFFECTS OF DEHUSKING DURING FORMATION OF SEEDS ON THE GERMINATION OF SEEDS OF INDICA AND JAPONICA RICE (ORYZA SATIVA L.), ANNALS OF BOTANY, 77, PP. 599-604, (1996); MOHAN B.H., MALLESHI N.G., KOSEKI T., PHYSICO-CHEMICAL CHARACTERISTICS AND NON-STARCH POLYSACCHARIDE CONTENTS OF INDICA AND JAPONICA BROWN RICE AND THEIR MALTS, LWT - FOOD SCIENCE AND TECHNOLOGY, 42, PP. 784-791, (2010); MOONGNGARM A., INFLUENCE OF GERMINATION CONDITIONS ON STARCH, PHYSICOCHEMICAL PROPERTIES, AND MICROSCOPIC STRUCTURE OF RICE FLOUR, INTERNATIONAL CONFERENCE ON BIOLOGY, ENVIRONMENT AND CHEMISTRY, 1, PP. 78-82, (2010); MOONGNGARM A., SAETUNG N., COMPARISON OF CHEMICAL COMPOSITIONS AND BIOACTIVE COMPOUNDS OF GERMINATED ROUGH RICE AND BROWN RICE, FOOD CHEMISTRY, 122, PP. 782-788, (2010); MOST M.M., TULLEY R., MORALES S., LEFEVRE M., RICE BRAN OIL, NOT FIBER, LOWERS CHOLESTEROL IN HUMANS, AMERICAN SOCIETY FOR CLINICAL NUTRITION, 81, PP. 64-68, (2005); MULLER-FISCHER N., AGRICULTURAL SUSTAINABILITY, NUTRIENT-FOCUSED PROCESSING OF RICE, PP. 197-220, (2013); NAKAGAWA M., YAMAGUCHI T., FUKAWA H., OGATA J., KOMIYAMA S., AKIYAMA S., KUWANO M., POTENTIATION BY SQUALENE OF THE CYTOTOXICITY OF ANTICANCER AGENTS AGAINST CULTURED MAMMALIAN CELLS AND MURINE TUMOR, JAPANESE JOURNAL OF CANCER RESEARCH, 76, PP. 315-320, (1985); NICOLOSI R.J., AUSMAN L.M., HEGSTED D.M., RICE BRAN OIL LOWERS SERUM TOTAL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL AND APO B LEVELS IN NONHUMAN PRIMATES, ATHEROSCLEROSIS, 88, PP. 133-142, (1991); NONOGAKI H., BASSEL G.W., BEWLEY J.D., GERMINATION - STILL A MYSTERY, PLANT SCIENCE, 179, PP. 574-581, (2010); OH S.H., STIMULATION OF Γ-AMINOBUTYRIC ACID SYNTHESIS ACTIVITY IN BROWN RICE BY A CHITOSAN/GLUTAMIC ACID GERMINATION SOLUTION AND CALCIUM/CALMODULIN, JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 36, PP. 319-325, (2003); OH S.H., CHOI W.G., PRODUCTION OF THE QUALITY GERMINATED BROWN RICE CONTAINING HIGH Γ-AMINOBUTYRIC ACID BY CHITOSAN APPLICATION, KOREAN SOCIETY FOR BIOTECHNOLOGY AND BIOENGINEERING JOURNAL, 15, PP. 615-620, (2000); OH S.-H., OH C.-H., BROWN RICE EXTRACTS WITH ENHANCED LEVELS OF GABA STIMULATED IMMUNE CELLS, FOOD SCIENCE AND BIOTECHNOLOGY, 12, PP. 248-252, (2003); OH C.-H., OH S.-H., EFFECTS OF GERMINATED BROWN RICE EXTRACTS WITH ENHANCED LEVELS OF GABA ON CANCER CELL PROLIFERATION AND APOPTOSIS, JOURNAL OF MEDICINAL FOOD, 7, PP. 19-23, (2004); OH S.H., SOH J.R., CHA Y.S., GERMINATED BROWN RICE EXTRACT SHOWS A NUTRACEUTICAL EFFECT IN THE RECOVERY OF CHRONIC ALCOHOL-RELATED SYMPTOMS, JOURNAL OF MEDICINAL FOOD, 6, PP. 115-121, (2003); OHTSUBO K., SUZUKI K., YASUI Y., KASUMI K., BIO-FUNCTIONAL COMPONENTS IN THE PROCESSED PRE-GERMINATED BROWN RICE BY A TWIN-SCREW EXTRUDER, JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 18, PP. 303-316, (2005); OU S., KWOK K.-C., LI Y., FU L., IN VITRO STUDY OF POSSIBLE ROLE OF DIETARY FIBER IN LOWERING POSTPRANDIAL SERUM GLUCOSE, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 1026-1029, (2001); PALMIANO E.P., JULIANO O.J., BIOCHEMICAL CHANGES IN THE RICE GRAIN DURING GERMINATION, PLANT PHYSIOLOGY, 49, PP. 751-756, (1972); QURESHI A.A., SAMI S.A., SALSER W.A., KHAN F.A., DOSE-DEPENDENT SUPPRESSION OF SERUM CHOLESTEROL BY TOCOTRIENOL-RICH FRACTION (TRF25) OF RICE BRAN IN HYPERCHOLESTEROLEMIC HUMANS, ATHEROSCLEROSIS, 161, PP. 199-207, (2002); RAO R.S.P., MURALIKRISHNA G., NON-STARCH POLYSACCHARIDE-PHENOLIC ACID COMPLEXES FORM NATIVE AND GERMINATED CEREALS AND MILLET, FOOD CHEMISTRY, 84, PP. 527-531, (2004); REENA M.B., KRISHNAKANTHA T.P., LOKESH B.R., LOWERING OF PLATELET AGGREGATION AND SERUM EICOSANOID LEVELS IN RATS FED WITH A DIET CONTAINING COCONUT OIL BLENDS WITH RICE BRAN OIL OR SESAME OIL, PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 83, PP. 151-160, (2010); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLINICAL DRUG INVESTIGATION, 25, PP. 701-707, (2005); RONG N., AUSMAN L.M., NICOLOSI R.J., ORYZANOL DECREASES CHOLESTEROL ABSORPTION AND AORTIC FATTY STREAKS IN HAMSTERS, LIPIDS, 32, PP. 303-309, (1997); ROOHINEJAD S., OMIDIZADEH A., MIRHOSSEINI H., SAARI N., MUSTAFA S., MEOR HUSSIN A.S., ABD MANAP M.Y., EFFECT OF PRE-GERMINATION TIME ON AMINO ACID PROFILE AND GAMMA AMINO BUTYRIC ACID (GABA) CONTENTS IN DIFFERENT VARIETIES OF MALAYSIAN BROWN RICE, INTERNATIONAL JOURNAL OF FOOD PROPERTIES, 14, PP. 1386-1399, (2012); ROOHINEJAD S., OMIDIZADEH A., MIRHOSSEINI H., SAARI N., MUSTAFA S., YUSOF R.M., ABD MANAP M.Y., EFFECT OF PRE-GERMINATION TIME OF BROWN RICE ON SERUM CHOLESTEROL LEVELS OF HYPERCHOLESTEROLAEMIC RATS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 90, PP. 245-251, (2009); SAIKUSA T., HORINO T., MORI Y., ACCUMULATION OF Γ-AMINOBUTYRIC ACID (GABA) IN THE RICE GERM DURING WATER SOAKING, BIOSCIENCE, BIOTECHNOLOGY AND BIOCHEMISTRY, 58, PP. 2291-2292, (1994); SAYRE B.N., SAUNDERS R.M., RICE BRAN AND RICE BRAN OIL, LIPID TECHNOLOGY, 2, PP. 72-76, (1990); SEKI T., NAGASE R., TORIMITSU M., YANAGI M., ITO Y., KISE M., ARIGA T., INSOLUBLE FIBER IS A MAJOR CONSTITUENT RESPONSIBLE FOR LOWERING THE POST-PRANDIAL BLOOD GLUCOSE CONCENTRATION IN THE PRE-GERMINATED BROWN RICE, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 28, PP. 1539-1541, (2005); SERVINOVA E., KAGAN V., HAN D., PACKER L., FREE RADICAL RECYCLING AND INTRAMEMBRANE MOBILITY IN THE ANTIOXIDANT PROPERTIES OF ALPHA-TOCOPHEROL AND ALPHA-TOCOTRIENOL, FREE RADICAL BIOLOGY & MEDICINE, 10, PP. 263-275, (1991); SHIMODA H., NUTRITIONAL COSMETICS, NATURAL PRODUCTS SUPPORTING THE EXTRACELLULAR MATRIX: RICE CERAMIDE AND OTHER PLANT EXTRACTS FOR SKIN HEALTH, PP. 319-334, (2009); SHIN C.-K., HO C.-J., LI S.-C., YANG S.-H., HOU W.-C., CHENG H.-H., PREVENTIVE EFFECTS OF RICE BRAN OIL ON 1,2-DIMETHYLHYDRAZINE/DEXTRAN SODIUM SULPHATE-INDUCED COLON CARCINOGENESIS IN RATS, FOOD CHEMISTRY, 126, PP. 562-567, (2011); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); TORIMITSU M., NAGASE R., YANAGI M., HOMMA M., SASAI Y., ITO Y., ARIGA T., REPLACING WHITE RICE WITH PRE-GERMINATED BROWN RICE MILDLY AMELIORATES HYPERGLYCEMIA AND IMBALANCE OF ADIPOCYTOKINE LEVELS IN TYPE 2 DIABETES MODEL RATS, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 56, PP. 287-292, (2010); VELUPPILLAI S., NITHYANANTHARAJAH K., VASANTHARUBA S., BALAKUMAR S., ARASARATNAM V., BIOCHEMICAL CHANGES ASSOCIATED WITH GERMINATING RICE GRAINS AND GERMINATION IMPROVEMENT, RICE SCIENCE, 16, PP. 240-242, (2009); WARLETA F., CAMPOS M., ALLOUCHE Y., SANCHEZ-QUESADA C., RUIZ-MORA J., BELTRAN G., GAFORIO J.J., SQUALENE PROTECTS AGAINST OXIDATIVE DNA DAMAGE IN MCF10A HUMAN MAMMARY EPITHELIAL CELLS BUT NOT IN MCF7 AND MDA-MB-231 HUMAN BREAST CANCER CELLS, FOOD AND CHEMICAL TOXICOLOGY, 48, PP. 1092-1100, (2010); WATANABE M., MAEDA T., TSUKAHARA K., KAYAHARA H., MORITA N., APPLICATION OF PREGERMINATED BROWN RICE FOR BREADMAKING, CEREAL CHEMISTRY, 81, PP. 450-455, (2004); WILSON T.A., NICOLOSI R.J., WOOLFREY B., KRITCHEVSKY D., RICE BRAN OIL AND ORYZANOL REDUCE PLASMA LIPID AND LIPOPROTEIN CHOLESTEROL CONCENTRATIONS AND AORTIC CHOLESTEROL ESTER ACCUMULATION TO A GREATER EXTENT THAN FERULIC ACID IN HYPERCHOLESTEROLEMIC HAMSTERS, THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 18, PP. 105-112, (2007); XU Z., GODBER J.S., ANTIOXIDANT ACTIVITIES OF MAJOR COMPONENTS OF GAMMA-ORYZANOL FROM RICE BRAN USING A LINOLEIC ACID MODEL, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 78, PP. 465-469, (2001); XU Z., HUA N., GODBER J.S., ANTIOXIDANT ACTIVITY OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL COMPONENTS FROM RICE BRAN AGAINST CHOLESTEROL OXIDATION ACCELERATED BY 2,2′-AZINO(2-METHYLPROPIONAMIDINE) DIHYDROCHLORIDE, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 2077-2081, (2001)","S.-T. LIM; DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, SUNGBUK-GU, SEOUL, 1, ANAM-DONG 5-GA, 136-701, SOUTH KOREA; EMAIL: LIMST@KOREA.AC.KR","ELSEVIER LTD","ENGLISH","FOOD CHEM.","REVIEW","ISI","2-S2.0-84942279975","FOOD CHEM","KOREA UNIVERSITY;KOREA UNIVERSITY","NOTREPORTED;KOREA UNIVERSITY;NOTREPORTED",NA,"CHO D-H, 2016, FOOD CHEM","CHO D-H, 2016, FOOD CHEM"
"GONG J;QIN X;YUAN F;HU M;CHEN G;FANG K;WANG D;JIANG S;LI J;ZHAO Y;HUANG Z;DONG H;LU F","GONG, JING (57037621500); QIN, XIN (57190495070); YUAN, FEN (57200230199); HU, MEILIN (57191198750); CHEN, GUANG (56189719800); FANG, KE (56548154500); WANG, DINGKUN (56461609000); JIANG, SHUJUN (56443053000); LI, JINGBIN (55985398600); ZHAO, YAN (36987762700); HUANG, ZHAOYI (17345751000); DONG, HUI (55253002700); LU, FUER (7402968128)","EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2018,"MOLECULAR NUTRITION AND FOOD RESEARCH","62","",37,"10.1002/mnfr.201700280","INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA, DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA;INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA, DEPARTMENT OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA","SCOPE: THIS STUDY AIMED TO SYSTEMATICALLY INVESTIGATE WHETHER SUGARCANE POLICOSANOL WAS EFFECTIVE AND SAFE ON DYSLIPIDEMIA. METHODS AND RESULTS: A TOTAL OF 11 DATABASES INCLUDING THE PUBMED, WEB OF SCIENCE, EMBASE, SCOPUS, THE COCHRANE LIBRARY AND SINOMED DATABASES WERE SEARCHED FOR AVAILABLE STUDIES INVESTIGATING THE EFFECTS OF POLICOSANOL ON DYSLIPIDEMIA. A TOTAL OF 22 STUDIES INCLUDING 1886 SUBJECTS WERE INCLUDED IN THE ANALYSIS. THE POOLED RESULTS SHOWED THAT COMPARED WITH PLACEBO, SUGARCANE POLICOSANOL COULD SIGNIFICANTLY REDUCE TOTAL CHOLESTEROL (TC, 95% CI: −0.87 TO −0.30 MMOL/L) AND LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C, 95% CI: −1.02 TO −0.40 MMOL/L) AND INCREASE HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOWEVER, NO SIGNIFICANT EFFECTS WERE OBSERVED ON TRIGLYCERIDE (TG) AND BODY WEIGHT. SUBGROUP ANALYSIS SUGGESTED THE STUDIES FROM CUBA OBTAINED MORE EFFECTIVE DATA THAN THOSE OUTSIDE THIS COUNTRY, AND THE EFFECTS WERE NOT PROPORTIONAL TO THE DOSE. THE ADVERSE EFFECTS ANALYSIS DEMONSTRATED THAT SUGARCANE POLICOSANOL WAS SAFER THAN THE CONTROL AGENTS. CONCLUSION: THE POOLED RESULTS SUPPORTED THE LIPID-LOWERING EFFECTS AND SAFETY OF POLICOSANOL. BECAUSE OF THE HIGH HETEROGENEITY, THE BETTER TREATMENT EFFECTS OBSERVED IN THE CUBAN STUDIES AND THE INCONSISTENT DOSE-RESPONSE RELATIONSHIP, MORE CLINICAL TRIALS ARE NEEDED TO FURTHER CONFIRM THE EFFICACY OF POLICOSANOL ON DYSLIPIDEMIA. © 2017 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM","CHOLESTEROL; DYSLIPIDEMIA; META-ANALYSIS; SUGARCANE POLICOSANOL; TRIGLYCERIDE","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FATTY ALCOHOLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES; CHOLESTEROL; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; BLOOD; DYSLIPIDEMIA; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC)","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, NSFC, (81473637, 81673928)","THIS ARTICLE WAS SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (NO. 81473637, 81673928).","BIBBINS-DOMINGO K., GROSSMAN D.C., CURRY S.J., DAVIDSON K.W., ET AL., SCREENING FOR LIPID DISORDERS IN CHILDREN AND ADOLESCENTS: US PREVENTIVE SERVICES TASK FORCE RECOMMENDATION STATEMENT, JAMA., 316, PP. 625-633, (2016); KOENE R.J., PRIZMENT A.E., BLAES A., KONETY S.H., SHARED RISK FACTORS IN CARDIOVASCULAR DISEASE AND CANCER, CIRCULATION, 133, PP. 1104-1114, (2016); BHANDARI S., GUPTA P., QUINN P., SANDHU J., ET AL., PLEIOTROPIC EFFECTS OF STATINS IN HYPERCHOLESTEROLAEMIA: A PROSPECTIVE OBSERVATIONAL STUDY USING A LIPOPROTEOMIC BASED APPROACH, LANCET, 385, (2015); LEWINGTON S., WHITLOCK G., CLARKE R., SHERLIKER P., ET AL., BLOOD CHOLESTEROL AND VASCULAR MORTALITY BY AGE, SEX, AND BLOOD PRESSURE: A META-ANALYSIS OF INDIVIDUAL DATA FROM 61 PROSPECTIVE STUDIES WITH 55,000 VASCULAR DEATHS, LANCET, 370, PP. 1829-1839, (2007); RADER D.J., HOVINGH G.K., HDL AND CARDIOVASCULAR DISEASE, LANCET, 384, PP. 618-625, (2014); NORDESTGAARD B.G., VARBO A., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE, LANCET, 384, PP. 626-635, (2014); NORATA G.D., BALLANTYNE C.M., CATAPANO A.L., NEW THERAPEUTIC PRINCIPLES IN DYSLIPIDAEMIA: FOCUS ON LDL AND LP(A) LOWERING DRUGS, EUR. HEART J., 34, PP. 1783-1789, (2013); RIDKER P.M., LDL CHOLESTEROL: CONTROVERSIES AND FUTURE THERAPEUTIC DIRECTIONS, LANCET, 384, PP. 607-617, (2014); HUNTER P.M., HEGELE R.A., FUNCTIONAL FOODS AND DIETARY SUPPLEMENTS FOR THE MANAGEMENT OF DYSLIPIDAEMIA, NAT. REV. ENDOCRINOL., 30, (2017); LUKASHEVICH V., DAVIDSON M.H., MOREINES J., BERLIN R.G., BEESWAX POLICOSANOL FAILED TO DEMONSTRATE LIPID-ALTERING EFFECTS IN WELL-CONTROLLED CLINICAL TRIALS, CIRCULATION, 114, (2006); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR., 50, PP. 259-267, (2010); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J., 143, PP. 356-365, (2002); RESEARCH T., MONOGRAPH. POLICOSANOL, ALTERN MED REV., 9, PP. 312-317, (2004); PASHA I., SAEED F., WAQAS K., ANJUM F.M., ET AL., NUTRACEUTICAL AND FUNCTIONAL SCENARIO OF WHEAT STRAW, CRIT REV FOOD SCI NUTR., 53, PP. 287-295, (2013); FERNANDEZ J.C., MAS R., CATANO G., MENENDEZ R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLINICAL DRUG INVESTIGATION., 21, PP. 103-113, (2001); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA., 295, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS., 46, PP. 923-929, (2011); JADAD A.R., MOORE R.A., CARROLL D., JENKINSON C., ET AL., ASSESSING THE QUALITY OF REPORTS OF RANDOMIZED CLINICAL TRIALS: IS BLINDING NECESSARY?, CONTROL CLIN TRIALS., 17, PP. 1-12, (1996); SARRIS J., BYRNE G.J., A SYSTEMATIC REVIEW OF INSOMNIA AND COMPLEMENTARY MEDICINE, SLEEP MED REV., 15, PP. 99-106, (2011); FANG K., DONG H., WANG D., GONG J., ET AL., SOY ISOFLAVONES AND GLUCOSE METABOLISM IN MENOPAUSAL WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES., 60, PP. 1602-1614, (2016); GONG J., FANG K., DONG H., WANG D., ET AL., EFFECT OF FENUGREEK ON HYPERGLYCAEMIA AND HYPERLIPIDEMIA IN DIABETES AND PREDIABETES: A META-ANALYSIS, J ETHNOPHARMACOL., 194, PP. 260-268, (2016); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., ET AL., CURR. THERAPEUT. RES.– CLIN. EXPERIMENT., 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., ET AL., CURR. THERAPEUT. RES.– CLIN. EXPERIMENT., 56, PP. 176-182, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., ET AL., CURR. THERAPEUT. RES.– CLIN. EXPERIMENT., 58, PP. 44-51, (1997); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ET AL., CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 61, PP. 137-146, (2000); MENENDEZ R., MAS R., AMOR A.M., FERNANDEZ J.C., ET AL., CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 61, PP. 609-620, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., ET AL., CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 62, PP. 194-208, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., ET AL., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 63, PP. 286-303, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS IN R AND D, 6, PP. 207-219, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); ILLNAIT J., LOPEZ E., FERNANDEZ L., MAS R., ET AL., INTERNAT. J. PHARMACEUT. SCI. REV. RES., 22, PP. 303-309, (2013); ORTENSI G., GLADSTEIN J., VALLI H., TESONE P.A., CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 58, PP. 390-401, (1997); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 61, PP. 346-357, (2000); WANG Y., KE Y.-N., WANG J.L., JIAO Y., ET AL., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, ZHONGGUO XINYAO YU LINCHUANG ZAZHI., 27, PP. 124-128, (2008); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., ET AL., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J., 152, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR., 84, PP. 1543-1548, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES., 22, PP. 318-322, (2008); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., ET AL., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT THER MED., 16, PP. 61-65, (2008); ZARDOYA R., TULA L., CASTANO G., MAS R., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THERAPEUT. RES. CLIN. EXPERIMENT., 57, PP. 568-577, (1996); MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., ET AL., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR J NUTR., 97, PP. 381-388, (2007); DUNFORD N.T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOUR TECHNOL., 101, PP. 422-425, (2010); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER., 318, PP. 1020-1026, (2006); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL., 29, PP. 891-897, (2002); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., ET AL., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5'-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE ACTIVATION, J AGRIC FOOD CHEM., 61, PP. 1117-1123, (2013); MARTINO F., PUDDU P.E., PANNARALE G., COLANTONI C., ET AL., LOW DOSE CHROMIUM-POLYNICOTINATE OR POLICOSANOL IS EFFECTIVE IN HYPERCHOLESTEROLEMIC CHILDREN ONLY IN COMBINATION WITH GLUCOMANNAN, ATHEROSCLEROSIS., 228, PP. 198-202, (2013)","H. DONG; INSTITUTE OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, CHINA; EMAIL: TJHDONGHUI@163.COM","WILEY-VCH VERLAG","ENGLISH","MOL. NUTR. FOOD RES.","ARTICLE","ISI","2-S2.0-85040339437","MOL NUTR FOOD RES","HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY","NOTREPORTED;HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY;NOTREPORTED",NA,"GONG J, 2018, MOL NUTR FOOD RES","GONG J, 2018, MOL NUTR FOOD RES"
"WANG H;JIAO Q;CHEN S;SHENG J;JIANG H;LU J;ZHENG S;FANG N","WANG, HAI-YA (13105420000); JIAO, QING-PING (57204035561); CHEN, SHU-YAN (55161886600); SHENG, JING (35173700800); JIANG, HUA (57192403182); LU, JIE (57204037581); ZHENG, SONG-BAI (15063660700); FANG, NING-YUAN (35388238600)","EFFICACY AND SAFETY OF POLICOSANOL PLUS FENOFIBRATE COMBINATION THERAPY IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA A RANDOMIZED CONTROLLED CLINICAL STUDY",2018,"AMERICAN JOURNAL OF THE MEDICAL SCIENCES","356","7",8,"10.1016/j.amjms.2018.06.014","DEPARTMENT OF GERIATRICS, RENJI HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE, CHINA;DEPARTMENT OF GERIATRICS, HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY, CHINA;DEPARTMENT OF GERIATRICS, XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE, CHINA;DEPARTMENT OF GERIATRICS, SHANGHAI NINTH PEOPLE'S HOSPITAL AFFILIATED SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE, CHINA;DEPARTMENT OF GERIATRICS, EAST HOSPITAL AFFILIATED TO TONGJI UNIVERSITY SCHOOL OF MEDICINE, CHINA;DEPARTMENT OF GERIATRICS, MINHANG CENTRAL HOSPITAL, CHINA;DEPARTMENT OF GERIATRICS, HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY, CHINA;DEPARTMENT OF GERIATRICS, RENJI HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE, CHINA","BACKGROUND: POLICOSANOL IS A MIXTURE OF LONG-CHAIN ALCOHOLS ISOLATED FROM SUGAR CANE. THIS CONTROLLED, RANDOMIZED CLINICAL TRIAL WAS DESIGNED TO COMPARE THE EFFICACY AND SAFETY OF FENOFIBRATE, POLICOSANOL AND A COMBINATION OF THESE 2 IN LOWERING LOW-DENSITY-LIPOPROTEIN CHOLESTEROL (LDL-C) IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA. METHODS: A TOTAL OF 102 PATIENTS AGED ≥60 YEARS WERE RANDOMLY ASSIGNED INTO 3 GROUPS: PATIENTS RECEIVING A 24-WEEK THERAPY OF FENOFIBRATE (200 MG/DAY), POLICOSANOL (20 MG/DAY) OR FENOFIBRATE + POLICOSANOL COMBINATION. LIPIDS WERE EVALUATED AT BASELINE, AFTER 16 AND AFTER 24 WEEKS OF THERAPY. BRACHIAL-ANKLE PULSE WAVE VELOCITY (BA-PWV) WAS PERFORMED, AND SF-36 QUESTIONNAIRES WERE USED TO EVALUATE THE PATIENTS’ QUALITY OF LIFE. THE PRIMARY ENDPOINT WAS THE PERCENTAGE REDUCTION IN LDL-C. THE SECONDARY END POINTS INCLUDED PERCENTAGE CHANGE IN NONHIGH DENSITY LIPOPROTEIN CHOLESTEROL (NON-HDL-C), TOTAL CHOLESTEROL (TC), TRIGLYCERIDE, HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL (HDL-C), BA-PWV AND SF-36 SCORES. SAFETY WAS ASSESSED BY ADVERSE EVENTS AND LABORATORY PARAMETERS. RESULTS: LDL-C, NON-HDL-C AND TC WERE DECREASED, RESPECTIVELY AFTER TREATMENT WITH POLICOSANOL FOR 24 WEEKS (P < 0.01). TREATMENT WITH POLICOSANOL + FENOFIBRATE RESULTED IN SIGNIFICANTLY GREATER REDUCTIONS IN TC, NON-HDL-C AND LDL-C COMPARED TO FENOFIBRATE ALONE (P < 0.01, RESPECTIVELY). THERE WERE SIGNIFICANT INCREASES IN SF-36 SCORES IN THE POLICOSANOL AND POLICOSANOL + FENOFIBRATE GROUPS (P < 0.05), AND SIGNIFICANT IMPROVEMENTS OF BA-PWV IN THE 2 GROUPS (P < 0.01). THERE WERE NO SERIOUS ADVERSE EVENTS OR SIGNIFICANT CHANGES IN LABORATORY VARIABLES AFTER ANY OF THE TREATMENT REGIMENS. CONCLUSIONS: POLICOSANOL + FENOFIBRATE COMBINATION THERAPY SIGNIFICANTLY IMPROVED LIPID PARAMETERS, ARTERIAL STIFFNESS, AND QUALITY OF LIFE, WITH GOOD TOLERABILITY. © 2018","ELDERLY; FENOFIBRATE; MIXED DYSLIPIDEMIA; POLICOSANOL","AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; DYSLIPIDEMIAS; FATTY ALCOHOLS; FEMALE; FENOFIBRATE; HUMANS; LIPIDS; MALE; MIDDLE AGED; QUALITY OF LIFE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; FATTY ALCOHOL; FENOFIBRATE; LIPID; POLICOSANOL; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FUNCTIONAL STATUS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIXED DYSLIPIDEMIA; MONOTHERAPY; OUTCOME ASSESSMENT; PULSE PRESSURE; PULSE WAVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SHORT FORM 36; TOTAL CHOLESTEROL LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DYSLIPIDEMIA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; VERY ELDERLY","","","DURRINGTON P., DYSLIPIDAEMIA, LANCET, 362, PP. 717-731, (2003); GOMEZ-GERIQUE J.A., ROS E., OLIVAN J., ET AL., EFFECT OF ATORVASTATIN AND BEZAFIBRATE ON PLASMA LEVELS OF C-REACTIVE PROTEIN IN COMBINED (MIXED) HYPERLIPIDEMIA, ATHEROSCLEROSIS, 162, PP. 245-251, (2002); CORSINI A., BELLOSTA S., DAVIDSON M.H., PHARMACOKINETIC INTERACTIONS BETWEEN STATINS AND FIBRATES, AM J CARDIOL, 96, PP. 44K-49K, (2005); ADHIKARI P., HWANG K.T., PARK J.N., ET AL., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, PP. 5359-5362, (2006); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); BARRAT E., ZAIR Y., OGIER N., ET AL., A COMBINED NATURAL SUPPLEMENT LOWERS LDL CHOLESTEROL IN SUBJECTS WITH MODERATE UNTREATED HYPERCHOLESTEROLEMIA: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, INT J FOOD SCI NUTR, 64, PP. 882-889, (2013); NOA M., MAS R., DE LA ROSA M.C., ET AL., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., DE LA ROSA M.C., MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); MARCELLO S., GLADSTEIN J., TESONE P., ET AL., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, 61, PP. 346-357, (2000); LAURENT S., COCKCROFT J., VAN BORTEL L., ET AL., EXPERT CONSENSUS DOCUMENT ON ARTERIAL STIFFNESS: METHODOLOGICAL ISSUES AND CLINICAL APPLICATIONS, EUR HEART J, 27, PP. 2588-2605, (2006); CHIU Y.C., ARAND P.W., SHROFF S.G., ET AL., DETERMINATION OF PULSE WAVE VELOCITIES WITH COMPUTERIZED ALGORITHMS, AM HEART J, 121, PP. 1460-1470, (1991); WARE J.E., SNOW K.K., KOSINSKI M., ET AL., SF-36 HEALTH SURVEY: MANUAL AND INTERPRETATION GUIDE, (1993); TENENBAUM A., FISMAN E.Z., MOTRO M., ET AL., OPTIMAL MANAGEMENT OF COMBINED DYSLIPIDEMIA: WHAT HAVE WE BEHIND STATINS MONOTHERAPY, ADV CARDIOL, 45, PP. 127-153, (2008); MCCLURE D.L., VALUCK R.J., GLANZ M., ET AL., STATIN AND STATIN-FIBRATE USE WAS SIGNIFICANTLY ASSOCIATED WITH INCREASED MYOSITIS RISK IN A MANAGED CARE POPULATION, J CLIN EPIDEMIOL, 60, PP. 812-818, (2007); MARTIN S.S., BLAHA M.J., ELSHAZLY M.B., ET AL., COMPARISON OF A NOVEL METHOD VS THE FRIEDEWALD EQUATION FOR ESTIMATING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS FROM THE STANDARD LIPID PROFILE, JAMA, 310, PP. 2061-2068, (2013); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., TABARES I., COMPARATIVE STUDY OF POLICOSANOL, GEMFIBROZIL AND POLICOSANOL-GEMFIBROZIL COMBINATION THERAPY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 29, PP. 17-23, (1998); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH MED RES, 36, PP. 441-447, (2005); YANG X.Y., LIU H.G., LIN J.S., ET AL., EFFECT OF OCTACOSTYL ALCOHOL PREPARATION ON BLOOD FREE RADICAL METABOLISM AND CARDIAC ENDOCRINE FUNCTION OF RATS, NAN FANG YI KE DA XUE XUE BAO, 28, PP. 652-653, (2008); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002)","S.-B. ZHENG; DEPARTMENT OF GERIATRICS, RENJI HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE, DEPARTMENT OF GERIATRICS, HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY, SHANGHAI SHANGHAI, 145 MID. SHANDONG ROAD 221 YANAN XI ROAD, 200001, 200040, CHINA; EMAIL: FDHUADONG@163.COM","ELSEVIER B.V.","ENGLISH","AM. J. MED. SCI.","ARTICLE","ISI","2-S2.0-85054191748","AM J MED SCI","SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE;HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY;XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE;SHANGHAI NINTH PEOPLE'S HOSPITAL AFFILIATED SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE;EAST HOSPITAL AFFILIATED TO TONGJI UNIVERSITY SCHOOL OF MEDICINE;MINHANG CENTRAL HOSPITAL;HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY;SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE","NOTREPORTED;SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE;NOTREPORTED",NA,"WANG H-Y, 2018, AM J MED SCI","WANG H-Y, 2018, AM J MED SCI"
"LUPI F;SHAKEEL A;GRECO V;BALDINO N;CALABRÒ V;GABRIELE D","LUPI, FRANCESCA R. (24768180600); SHAKEEL, AHMAD (57190130082); GRECO, VALERIA (57190121462); BALDINO, NOEMI (24767432700); CALABRÒ, VINCENZA (7003809015); GABRIELE, DOMENICO (6507587673)","ORGANOGELATION OF EXTRA VIRGIN OLIVE OIL WITH FATTY ALCOHOLS GLYCERYL STEARATE AND THEIR MIXTURE",2017,"LWT","77","7",31,"10.1016/j.lwt.2016.11.082","DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, VIA P. BUCCI, CUBO 39C, RENDE, I-87036, CS, ITALY","THE FINAL PROPERTIES OF ORGANOGELS BASED ON A MIXTURE OF GELATORS CAN BE TUNED BY TAKING ADVANTAGE OF INTERACTIONS BETWEEN GELATORS. IN THIS WORK, EXTRA VIRGIN OLIVE OIL WAS STRUCTURED USING GLYCERYL STEARATE (GS), POLICOSANOL (P) AND THEIR MIXTURES AIMING AT INVESTIGATING THEIR EFFECTS ON THE RHEOLOGICAL PROPERTIES AND MICROSTRUCTURE OF OBTAINED GELS. RHEOLOGICAL TESTS EVIDENCED THAT P YIELDS A MORE CONSISTENT MATERIAL WITH HIGHER CRYSTALLIZATION AND GELATION TEMPERATURES WITH RESPECT TO GS. GELS BASED ON A MIXTURE OF GELATORS EXHIBIT INTERMEDIATE PROPERTIES BETWEEN THOSE OF “PURE” GELS, EVEN THOUGH CLOSER TO THOSE OF P ORGANOGELS. THE CRYSTALLIZATION AND GELATION PHENOMENA IN MIXED GELS SEEM TO BE DEPENDENT ONLY ON POLICOSANOL FRACTION, WHEREAS DYNAMIC MODULI ARE AFFECTED BY BOTH GELATORS. INTERMOLECULAR INTERACTIONS WERE INVESTIGATED WITH FT-IR FINDING THAT GS IS ABLE TO GIVE HYDROGEN BONDING WHEREAS P WORKS MAINLY THROUGH THE FORMATION OF VAN DER WAALS INTERACTIONS. MIXED GELS EXHIBIT A BEHAVIOR CLOSE TO THAT OF P GELS, EVEN THOUGH VAN DER WAALS INTERACTIONS SEEM LESS EVIDENT THAN IN PURE P GELS. AS A CONSEQUENCE, FROM A MACROSCOPIC POINT OF VIEW, THE USE OF THE MIXTURE YIELDS A WEAKER GEL THAN THAT OBTAINED WITH THE SAME CONCENTRATION OF PURE P. © 2016 ELSEVIER LTD","GLYCERYL STEARATE; INTERMOLECULAR INTERACTIONS; ORGANOGELS; POLICOSANOL; RHEOLOGY","ALCOHOLS; GELATION; HYDROGEN BONDS; MIXTURES; OLIVE OIL; RHEOLOGY; VAN DER WAALS FORCES; EXTRA VIRGIN OLIVE OIL; GELATION TEMPERATURE; GLYCERYL STEARATE; INTERMOLECULAR INTERACTIONS; ORGANOGELS; POLICOSANOL; RHEOLOGICAL PROPERTY; VAN DER WAALS INTERACTIONS; GELS","","","ALFUTIMIE A., CURTIS R., TIDDY G.J.T., GEL PHASE (LΒ) FORMATION BY MIXED SATURATED AND UNSATURATED MONOGLYCERIDES, COLLOIDS AND SURFACES A: PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 456, PP. 286-295, (2014); BALDINO N., GABRIELE D., LUPI F.R., OLIVIERO ROSSI C., CAPUTO P., FALVO T., RHEOLOGICAL EFFECTS ON BITUMEN OF POLYPHOSPHORIC ACID (PPA) ADDITION, CONSTRUCTION AND BUILDING MATERIALS, 40, PP. 397-404, (2013); BOT A., DEN ADEL R., REGKOS C., SAWALHA H., VENEMA P., FLOTER E., STRUCTURING IN Β-SITOSTEROL+Γ-ORYZANOL-BASED EMULSION GELS DURING VARIOUS STAGES OF A TEMPERATURE CYCLE, FOOD HYDROCOLLOIDS, 25, 4, PP. 639-646, (2011); CHAMBON F., WINTER H.H., LINEAR VISCOELASTICITY AT THE GEL POINT OF A CROSSLINKING PDMS WITH IMBALANCED STOICHIOMETRY, JOURNAL OF RHEOLOGY, 31, 8, PP. 683-697, (1987); CHEN C.H., TERENTJEV E.M., AGING AND METASTABILITY OF MONOGLYCERIDES IN HYDROPHOBIC SOLUTIONS, LANGMUIR, 25, 12, PP. 6717-6724, (2009); CO E.D., MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 89, 5, PP. 749-780, (2012); CURCIO S., GABRIELE D., GIORDANO V., CALABRO V., DE CINDIO B., IORIO G., A RHEOLOGICAL APPROACH TO THE STUDY OF CONCENTRATED MILK CLOTTING, RHEOLOGICA ACTA, 40, 2, PP. 154-161, (2001); DA PIEVE S., CALLIGARIS S., PANOZZO A., ARRIGHETTI G., NICOLI M.C., EFFECT OF MONOGLYCERIDE ORGANOGEL STRUCTURE ON COD LIVER OIL STABILITY, FOOD RESEARCH INTERNATIONAL, 44, 9, PP. 2978-2983, (2011); FRANCK A., MEASURING STRUCTURE OF LOW VISCOSITY FLUIDS IN OSCILLATIONS USING RHEOMETERS WITH AND WITHOUT A SEPARATE TORQUE TRANSDUCER, ANNUAL TRANSACTIONS OF THE NORDIC RHEOLOGY SOCIETY, 11, PP. 95-100, (2003); LOPEZ-MARTINEZ A., CHARO-ALONSO M.A., MARANGONI A.G., TORO-VAZQUEZ J.F., MONOGLYCERIDE ORGANOGELS DEVELOPED IN VEGETABLE OIL WITH AND WITHOUT ETHYLCELLULOSE, FOOD RESEARCH INTERNATIONAL, 72, PP. 37-46, (2015); LOPEZ-MARTINEZ A., MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M.A., MARANGONI A.G., TORO-VAZQUEZ J.F., COMPARING THE CRYSTALLIZATION AND RHEOLOGICAL BEHAVIOR OF ORGANOGELS DEVELOPED BY PURE AND COMMERCIAL MONOGLYCERIDES IN VEGETABLE OIL, FOOD RESEARCH INTERNATIONAL, 64, PP. 946-957, (2014); LUPI F.R., GABRIELE D., DE CINDIO B., EFFECT OF SHEAR RATE ON CRYSTALLISATION PHENOMENA IN OLIVE OIL-BASED ORGANOGELS, FOOD AND BIOPROCESS TECHNOLOGY, 5, 7, PP. 2880-2888, (2012); LUPI F.R., GABRIELE D., DE CINDIO B., SANCHEZ M.C., GALLEGOS C., A RHEOLOGICAL ANALYSIS OF STRUCTURED WATER-IN-OLIVE OIL EMULSIONS, JOURNAL OF FOOD ENGINEERING, 107, 3-4, PP. 296-303, (2011); LUPI F.R., GABRIELE D., FACCIOLO D., BALDINO N., SETA L., DE CINDIO B., EFFECT OF ORGANOGELATOR AND FAT SOURCE ON RHEOLOGICAL PROPERTIES OF OLIVE OIL-BASED ORGANOGELS, FOOD RESEARCH INTERNATIONAL, 46, 1, PP. 177-184, (2012); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., SETA L., DE CINDIO B., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RESEARCH INTERNATIONAL, 51, 2, PP. 510-517, (2013); LUPI F.R., GRECO V., BALDINO N., DE CINDIO B., FISCHER P., GABRIELE D., THE EFFECTS OF INTERMOLECULAR INTERACTIONS ON THE PHYSICAL PROPERTIES OF ORGANOGELS IN EDIBLE OILS, JOURNAL OF COLLOID AND INTERFACE SCIENCE, 483, PP. 154-164, (2016); LUPI F.R., SHAKEEL A., GRECO V., OLIVIERO ROSSI C., BALDINO N., GABRIELE D., A RHEOLOGICAL AND MICROSTRUCTURAL CHARACTERISATION OF BIGELS FOR COSMETIC AND PHARMACEUTICAL USES, MATERIALS SCIENCE AND ENGINEERING: C, 69, PP. 358-365, (2016); MARANGONI A.G., NOVEL STRATEGIES FOR NANOSTRUCTURING LIQUID OILS INTO FUNCTIONAL FATS, 5TH INTERNATIONAL SYMPOSIUM ON FOOD RHEOLOGY AND STRUCTURE - ISFRS, (2009); MERT B., DEMIRKESEN I., EVALUATION OF HIGHLY UNSATURATED OLEOGELS AS SHORTENING REPLACER IN A SHORT DOUGH PRODUCT, LWT - FOOD SCIENCE AND TECHNOLOGY, 68, PP. 477-484, (2016); MOSCHAKIS T., PANAGIOTOPOULOU E., KATSANIDIS E., SUNFLOWER OIL ORGANOGELS AND ORGANOGEL-IN-WATER EMULSIONS (PART I): MICROSTRUCTURE AND MECHANICAL PROPERTIES, LWT - FOOD SCIENCE AND TECHNOLOGY, 73, PP. 153-161, (2016); OJIJO N.K.O., NEEMAN I., EGER S., SHIMONI E., EFFECTS OF MONOGLYCERIDE CONTENT, COOLING RATE AND SHEAR ON THE RHEOLOGICAL PROPERTIES OF OLIVE OIL/MONOGLYCERIDE GEL NETWORKS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 84, 12, PP. 1585-1593, (2004); OGUTCU M., YILMAZ E., OLEOGELS OF VIRGIN OLIVE OIL WITH CARNAUBA WAX AND MONOGLYCERIDE AS SPREADABLE PRODUCTS, GRASAS Y ACEITES, 65, 3, (2014); PATEL A.R., DEWETTINCK K., EDIBLE OIL STRUCTURING: AN OVERVIEW AND RECENT UPDATES, FOOD & FUNCTION, 7, 1, PP. 20-29, (2016); RAO M.A., RHEOLOGY OF FLUID AND SEMISOLID FOODS PRINCIPLES AND APPLICATIONS, (1999); REN Y., WANG B., ZHANG X., SYNTHESIS OF PHOTORESPONSIVE CHOLESTEROL-BASED AZOBENZENE ORGANOGELS: DEPENDENCE ON DIFFERENT SPACER LENGTHS, BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 11, PP. 1089-1095, (2015); TANG D., MARANGONI A.G., MODELING THE RHEOLOGICAL PROPERTIES AND STRUCTURE OF COLLOIDAL FAT CRYSTAL NETWORKS, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 18, 9, PP. 474-483, (2007); TAY A., SINGH R.K., KRISHNAN S.S., GORE J.P., AUTHENTICATION OF OLIVE OIL ADULTERATED WITH VEGETABLE OILS USING FOURIER TRANSFORM INFRARED SPECTROSCOPY, LWT - FOOD SCIENCE AND TECHNOLOGY, 35, 1, PP. 99-103, (2002); TORO-VAZQUEZ J.F., MAURICIO-PEREZ R., GONZALEZ-CHAVEZ M.M., SANCHEZ-BECERRIL M., ORNELAS-PAZ J.D.J., PEREZ-MARTINEZ J.D., PHYSICAL PROPERTIES OF ORGANOGELS AND WATER IN OIL EMULSIONS STRUCTURED BY MIXTURES OF CANDELILLA WAX AND MONOGLYCERIDES, FOOD RESEARCH INTERNATIONAL, 54, 2, PP. 1360-1368, (2013); VLACHOS N., SKOPELITIS Y., PSAROUDAKI M., KONSTANTINIDOU V., CHATZILAZAROU A., TEGOU E., APPLICATIONS OF FOURIER TRANSFORM-INFRARED SPECTROSCOPY TO EDIBLE OILS, ANALYTICA CHIMICA ACTA, 573-574, PP. 459-465, (2006); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E–KNOCKOUT MICE, NUTRITION RESEARCH, 27, PP. 212-217, (2007)","D. GABRIELE; DEPARTMENT OF INFORMATION, MODELING, ELECTRONICS AND SYSTEM ENGINEERING (D.I.M.E.S.), UNIVERSITY OF CALABRIA, RENDE, VIA P. BUCCI, CUBO 39C, I-87036, ITALY; EMAIL: DOMENICO.GABRIELE@UNICAL.IT","ACADEMIC PRESS","ENGLISH","LWT","ARTICLE","ISI","2-S2.0-84999751860","LWT","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA","NOTREPORTED;UNIVERSITY OF CALABRIA;NOTREPORTED",NA,"LUPI FR, 2017, LWT","LUPI FR, 2017, LWT"
"SHARMA R;MATSUZAKA T;KAUSHIK M;SUGASAWA T;OHNO H;WANG Y;MOTOMURA K;SHIMURA T;OKAJIMA Y;MIZUNOE Y;MA Y;SABER Z;IWASAKI H;YATOH S;SUZUKI H;AITA Y;HAN S;TAKEUCHI Y;YAHAGI N;MIYAMOTO T;SEKIYA M;NAKAGAWA Y;SHIMANO H","SHARMA, RAHUL (57202762297); MATSUZAKA, TAKASHI (7006867430); KAUSHIK, MAHESH K. (35181386900); SUGASAWA, TAKEHITO (57190376535); OHNO, HIROSHI (57201505807); WANG, YUNONG (57193777301); MOTOMURA, KAORI (8506089000); SHIMURA, TAKUYA (57205461594); OKAJIMA, YUKA (56197274000); MIZUNOE, YUHEI (56051534500); MA, YANG (57207992626); SABER, ZAHARA M. (57207996825); IWASAKI, HITOSHI (59094445600); YATOH, SHIGERU (8046412900); SUZUKI, HIROAKI (55510316000); AITA, YUICHI (36460517300); HAN, SONG-IEE (56991705200); TAKEUCHI, YOSHINORI (8968208800); YAHAGI, NAOYA (7006607036); MIYAMOTO, TAKAFUMI (17343842700); SEKIYA, MOTOHIRO (7101963933); NAKAGAWA, YOSHIMI (35378591300); SHIMANO, HITOSHI (57538786600)","OCTACOSANOL AND POLICOSANOL PREVENT HIGHFAT DIETINDUCED OBESITY AND METABOLIC DISORDERS BY ACTIVATING BROWN ADIPOSE TISSUE AND IMPROVING LIVER METABOLISM",2019,"SCIENTIFIC REPORTS","9","",41,"10.1038/s41598-019-41631-1","DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN, TRANSBORDER MEDICAL RESEARCH CENTER, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;INTERNATIONAL INSTITUTE FOR INTEGRATIVE SLEEP MEDICINE (WPI-IIIS), UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN, TRANSBORDER MEDICAL RESEARCH CENTER, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN, INTERNATIONAL INSTITUTE FOR INTEGRATIVE SLEEP MEDICINE (WPI-IIIS), UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN;DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN, INTERNATIONAL INSTITUTE FOR INTEGRATIVE SLEEP MEDICINE (WPI-IIIS), UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN, LIFE SCIENCE CENTER FOR SURVIVAL DYNAMICS, TSUKUBA ADVANCED RESEARCH ALLIANCE (TARA), UNIVERSITY OF TSUKUBA, 1-1-1 TENNODAI, TSUKUBA, 305-8575, IBARAKI, JAPAN, AMED-CREST, JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT (AMED), 1-7-1, OHTE-MACHI, CHIYODA-KU, 100-0004, TOKYO, JAPAN","BROWN ADIPOSE TISSUE (BAT) IS AN ATTRACTIVE THERAPEUTIC TARGET FOR TREATING OBESITY AND METABOLIC DISEASES. OCTACOSANOL IS THE MAIN COMPONENT OF POLICOSANOL, A MIXTURE OF VERY LONG CHAIN ALIPHATIC ALCOHOLS OBTAINED FROM PLANTS. THE CURRENT STUDY AIMED TO INVESTIGATE THE EFFECT OF OCTACOSANOL AND POLICOSANOL ON HIGH-FAT DIET (HFD)-INDUCED OBESITY. MICE WERE FED ON CHOW, OR HFD, WITH OR WITHOUT OCTACOSANOL OR POLICOSANOL TREATMENT FOR FOUR WEEKS. HFD-FED MICE SHOWED SIGNIFICANTLY HIGHER BODY WEIGHT AND BODY FAT COMPARED WITH CHOW-FED MICE. HOWEVER, MICE FED ON HFD TREATED WITH OCTACOSANOL OR POLICOSANOL (HFDO/P) SHOWED LOWER BODY WEIGHT GAIN, BODY FAT GAIN, INSULIN RESISTANCE AND HEPATIC LIPID CONTENT. LOWER BODY FAT GAIN AFTER OCTACOSANOL OR POLICOSANOL WAS ASSOCIATED WITH INCREASED BAT ACTIVITY, REDUCED EXPRESSION OF GENES INVOLVED IN LIPOGENESIS AND CHOLESTEROL UPTAKE IN THE LIVER, AND AMELIORATION OF WHITE ADIPOSE TISSUE (WAT) INFLAMMATION. MOREOVER, OCTACOSANOL AND POLICOSANOL SIGNIFICANTLY INCREASED THE EXPRESSION OF FFAR4, A GENE ENCODING POLYUNSATURATED FATTY ACID RECEPTOR, WHICH ACTIVATES BAT THERMOGENESIS. TOGETHER, THESE RESULTS SUGGEST THAT OCTACOSANOL AND POLICOSANOL AMELIORATE DIET-INDUCED OBESITY AND METABOLIC DISORDERS BY INCREASING BAT ACTIVITY AND IMPROVING HEPATIC LIPID METABOLISM. THUS, THESE LIPIDS REPRESENT PROMISING THERAPEUTIC TARGETS FOR THE PREVENTION AND TREATMENT OF OBESITY AND OBESITY-RELATED METABOLIC DISORDERS. © 2019, THE AUTHOR(S).","","ADIPOCYTES; ADIPOSE TISSUE, BROWN; ADIPOSE TISSUE, WHITE; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; FATTY ALCOHOLS; FATTY LIVER; GENE EXPRESSION REGULATION; INFLAMMATION; INSULIN; LIVER; MALE; METABOLIC DISEASES; MICE, INBRED C57BL; OBESITY; UP-REGULATION; 1-OCTACOSANOL; FATTY ALCOHOL; INSULIN; POLICOSANOL; ADIPOCYTE; ANIMAL; BLOOD; BODY WEIGHT; BROWN ADIPOSE TISSUE; C57BL MOUSE; DRUG EFFECT; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; LIPID DIET; LIVER; MALE; METABOLIC DISORDER; METABOLISM; OBESITY; PATHOLOGY; UPREGULATION; WHITE ADIPOSE TISSUE","AMED-CREST; JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT, AMED, (15H02541, 15H03093, 17H06395); JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT, AMED; JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE, JSPS, (16J00187, 16K01811, 17K13217, 18H03189, 18H04051, 18K06206, 18K19724); JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE, JSPS; MINISTERIE VAN ONDERWIJS, CULTUUR EN WETENSCHAP, OCW","THIS WORK WAS SUPPORTED BY AMED-CREST, JAPAN AGENCY FOR MEDICAL RESEARCH DEVELOPMENT (TO H.S.), GRANTS-IN-AID FOR SCIENTIFIC RESEARCH 15H02541 (TO H.S.), 17H06395 (TO H.S.), 15H03093 (TO T.M.), 18H03189 (TO T.M.) AND PROGRAM TO DISSEMINATE TENURE TRACKING SYSTEM (TO T.M.) FROM THE MINISTRY OF SCIENCE, EDUCATION, CULTURE AND TECHNOLOGY OF JAPAN. THE AUTHORS THANK KATSUKO OKUBO AND CHIZUKO FUKUI FOR TECHNICAL ASSISTANCE; AND THE MEMBERS OF OUR LABORATORIES FOR DISCUSSION AND HELPFUL COMMENTS ON THE MANUSCRIPT. THE AUTHORS WOULD LIKE TO THANK ENAGO (WWW.ENAGO.JP) FOR THE ENGLISH LANGUAGE REVIEW.","MANNING S., PUCCI A., FINER N., PHARMACOTHERAPY FOR OBESITY: NOVEL AGENTS AND PARADIGMS, THER ADV CHRONIC DIS, 5, PP. 135-148, (2014); SHETTAR V., PATEL S., KIDAMBI S., EPIDEMIOLOGY OF OBESITY AND PHARMACOLOGIC TREATMENT OPTIONS, NUTR CLIN PRACT, 32, PP. 441-462, (2017); SIDOSSIS L., KAJIMURA S., BROWN AND BEIGE FAT IN HUMANS: THERMOGENIC ADIPOCYTES THAT CONTROL ENERGY AND GLUCOSE HOMEOSTASIS, J CLIN INVEST, 125, PP. 478-486, (2015); CYPESS A.M., ET AL., IDENTIFICATION AND IMPORTANCE OF BROWN ADIPOSE TISSUE IN ADULT HUMANS, N ENGL J MED, 360, PP. 1509-1517, (2009); SAITO M., ET AL., HIGH INCIDENCE OF METABOLICALLY ACTIVE BROWN ADIPOSE TISSUE IN HEALTHY ADULT HUMANS: EFFECTS OF COLD EXPOSURE AND ADIPOSITY, DIABETES, 58, PP. 1526-1531, (2009); CYPESS A.M., KAHN C.R., BROWN FAT AS A THERAPY FOR OBESITY AND DIABETES, CURR OPIN ENDOCRINOL DIABETES OBES, 17, PP. 143-149, (2010); NEDERGAARD J., CANNON B., THE CHANGED METABOLIC WORLD WITH HUMAN BROWN ADIPOSE TISSUE: THERAPEUTIC VISIONS, CELL METAB, 11, PP. 268-272, (2010); VAN MARKEN LICHTENBELT W.D., ET AL., COLD-ACTIVATED BROWN ADIPOSE TISSUE IN HEALTHY MEN, N ENGL J MED, 360, PP. 1500-1508, (2009); VIRTANEN K.A., ET AL., FUNCTIONAL BROWN ADIPOSE TISSUE IN HEALTHY ADULTS, N ENGL J MED, 360, PP. 1518-1525, (2009); DULLOO A.G., MILLER D.S., ENERGY BALANCE FOLLOWING SYMPATHETIC DENERVATION OF BROWN ADIPOSE TISSUE, CAN J PHYSIOL PHARMACOL, 62, PP. 235-240, (1984); KONTANI Y., ET AL., UCP1 DEFICIENCY INCREASES SUSCEPTIBILITY TO DIET-INDUCED OBESITY WITH AGE, AGING CELL, 4, PP. 147-155, (2005); FELDMANN H.M., GOLOZOUBOVA V., CANNON B., NEDERGAARD J., UCP1 ABLATION INDUCES OBESITY AND ABOLISHES DIET-INDUCED THERMOGENESIS IN MICE EXEMPT FROM THERMAL STRESS BY LIVING AT THERMONEUTRALITY, CELL METAB, 9, PP. 203-209, (2009); COHEN P., SPIEGELMAN B.M., BROWN AND BEIGE FAT: MOLECULAR PARTS OF A THERMOGENIC MACHINE, DIABETES, 64, PP. 2346-2351, (2015); KAJIMURA S., SPIEGELMAN B.M., SEALE P., BROWN AND BEIGE FAT: PHYSIOLOGICAL ROLES BEYOND HEAT GENERATION, CELL METAB, 22, PP. 546-559, (2015); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); KATO S., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR J NUTR, 73, PP. 433-441, (1995); ARRUZAZABALA M.L., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); LIN Y., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS, 43, PP. 109-115, (2008); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); FERNANDEZ-ARCHE A., ET AL., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, PP. 155-162, (2009); DE OLIVEIRA A.M., ET AL., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INT J MOL SCI, 13, PP. 1598-1611, (2012); GUO T., ET AL., OCTACOSANOL ATTENUATES INFLAMMATION IN BOTH RAW264.7 MACROPHAGES AND A MOUSE MODEL OF COLITIS, J AGRIC FOOD CHEM, 65, PP. 3647-3658, (2017); CONSOLAZIO C.F., MATOUSH L.O., NELSON R.A., ISAAC G.J., HURSH L.M., PHYSIOLOGICAL AND BIOCHEMICAL EVALUATION OF POTENTIAL ANTIFATIGUE DRUGS. III. THE EFFECT OF OCTACOSANOL, WHEAT GERM OIL AND VITAMIN E ON THE PERFORMANCE OF SWIMMING RATS, PP. 1-2, (1963); CONSOLAZIO C.F., MATOUSH L.O., NELSON R.A., ISAAC G.J., HURSH L.M., EFFECT OF OCTACOSANOL, WHEAT GERM OIL, AND VITAMIN E ON PERFORMANCE OF SWIMMING RATS, J APPL PHYSIOL, 19, PP. 265-267, (1964); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, PP. 469-473, (1998); KIM H., PARK S., HAN D.S., PARK T., OCTACOSANOL SUPPLEMENTATION INCREASES RUNNING ENDURANCE TIME AND IMPROVES BIOCHEMICAL PARAMETERS AFTER EXHAUSTION IN TRAINED RATS, J MED FOOD, 6, PP. 345-351, (2003); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J PHARM PHARMACOL, 47, PP. 731-733, (1995); KAUSHIK M.K., ARITAKE K., TAKEUCHI A., YANAGISAWA M., URADE Y., OCTACOSANOL RESTORES STRESS-AFFECTED SLEEP IN MICE BY ALLEVIATING STRESS, SCI REP, 7, (2017); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); MENENDEZ R., ET AL., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8–14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); LEE J., ELLIS J.M., WOLFGANG M.J., ADIPOSE FATTY ACID OXIDATION IS REQUIRED FOR THERMOGENESIS AND POTENTIATES OXIDATIVE STRESS-INDUCED INFLAMMATION, CELL REP, 10, PP. 266-279, (2015); GONZALEZ-HURTADO E., LEE J., CHOI J., WOLFGANG M.J., FATTY ACID OXIDATION IS REQUIRED FOR ACTIVE AND QUIESCENT BROWN ADIPOSE TISSUE MAINTENANCE AND THERMOGENIC PROGRAMING, MOL METAB, 7, PP. 45-56, (2018); SENYILMAZ D., ET AL., REGULATION OF MITOCHONDRIAL MORPHOLOGY AND FUNCTION BY STEAROYLATION OF TFR1, NATURE, 525, PP. 124-128, (2015); SENYILMAZ-TIEBE D., ET AL., DIETARY STEARIC ACID REGULATES MITOCHONDRIA IN VIVO IN HUMANS, NAT COMMUN, 9, (2018); TAN C.Y., ET AL., BROWN ADIPOSE TISSUE THERMOGENIC CAPACITY IS REGULATED BY ELOVL6, CELL REP, 13, PP. 2039-2047, (2015); LIU G., ET AL., REGULATION OF PLASMA LIPID HOMEOSTASIS BY HEPATIC LIPOPROTEIN LIPASE IN ADULT MICE, J LIPID RES, 57, PP. 1155-1161, (2016); ICHIHARA K., KUSUNOSE E., NODA Y., KUSUNOSE M., SOME PROPERTIES OF THE FATTY ALCOHOL OXIDATION SYSTEM AND RECONSTITUTION OF MICROSOMAL OXIDATION ACTIVITY IN INTESTINAL MUCOSA, BIOCHIM BIOPHYS ACTA, 878, PP. 412-418, (1986); ICHIHARA K., NODA Y., TANAKA C., KUSUNOSE M., PURIFICATION OF ALDEHYDE DEHYDROGENASE RECONSTITUTIVELY ACTIVE IN FATTY ALCOHOL OXIDATION FROM RABBIT INTESTINAL MICROSOMES, BIOCHIM BIOPHYS ACTA, 878, PP. 419-425, (1986); DUGRILLON A., IODOLACTONES AND IODOALDEHYDES–MEDIATORS OF IODINE IN THYROID AUTOREGULATION, EXP CLIN ENDOCRINOL DIABETES, 104, PP. 41-45, (1996); MUZIO G., MAGGIORA M., PAIUZZI E., ORALDI M., CANUTO R.A., ALDEHYDE DEHYDROGENASES AND CELL PROLIFERATION, FREE RADIC BIOL MED, 52, PP. 735-746, (2012); YU Y.H., ET AL., PKC-ALDH2 PATHWAY PLAYS A NOVEL ROLE IN ADIPOCYTE DIFFERENTIATION, PLOS ONE, 11, (2016); WESTERBERG R., ET AL., ELOVL3 IS AN IMPORTANT COMPONENT FOR EARLY ONSET OF LIPID RECRUITMENT IN BROWN ADIPOSE TISSUE, J BIOL CHEM, 281, PP. 4958-4968, (2006); ZADRAVEC D., ET AL., ABLATION OF THE VERY-LONG-CHAIN FATTY ACID ELONGASE ELOVL3 IN MICE LEADS TO CONSTRAINED LIPID STORAGE AND RESISTANCE TO DIET-INDUCED OBESITY, FASEB J, 24, PP. 4366-4377, (2010); QUESADA-LOPEZ T., ET AL., THE LIPID SENSOR GPR120 PROMOTES BROWN FAT ACTIVATION AND FGF21 RELEASE FROM ADIPOCYTES, NAT COMMUN, 7, (2016); KIM J., ET AL., EICOSAPENTAENOIC ACID POTENTIATES BROWN THERMOGENESIS THROUGH FFAR4-DEPENDENT UP-REGULATION OF MIR-30B AND MIR-378, J BIOL CHEM, 291, PP. 20551-20562, (2016); SCHILPEROORT M., ET AL., THE GPR120 AGONIST TUG-891 PROMOTES METABOLIC HEALTH BY STIMULATING MITOCHONDRIAL RESPIRATION IN BROWN FAT, EMBO MOL MED, 10, (2018); MCNELIS J.C., OLEFSKY J.M., MACROPHAGES, IMMUNITY, AND METABOLIC DISEASE, IMMUNITY, 41, PP. 36-48, (2014); OH D.Y., ET AL., A GPR120-SELECTIVE AGONIST IMPROVES INSULIN RESISTANCE AND CHRONIC INFLAMMATION IN OBESE MICE, NAT MED, 20, PP. 942-947, (2014); OH D.Y., WALENTA E., OMEGA-3 FATTY ACIDS AND FFAR4, FRONT ENDOCRINOL (LAUSANNE), 5, (2014); PONS P., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); MENENDEZ R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); DONNELLY K.L., ET AL., SOURCES OF FATTY ACIDS STORED IN LIVER AND SECRETED VIA LIPOPROTEINS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE, J CLIN INVEST, 115, PP. 1343-1351, (2005); MATSUZAKA T., ET AL., CRUCIAL ROLE OF A LONG-CHAIN FATTY ACID ELONGASE, ELOVL6, IN OBESITY-INDUCED INSULIN RESISTANCE, NAT MED, 13, PP. 1193-1202, (2007); OHNO H., ET AL., TRANSGENIC MICE OVEREXPRESSING SREBP-1A IN MALE OB/OB MICE EXHIBIT LIPODYSTROPHY AND EXACERBATE INSULIN RESISTANCE, ENDOCRINOLOGY, 159, PP. 2308-2323, (2018); ZHAO H., ET AL., ELOVL6 DEFICIENCY IMPROVES GLYCEMIC CONTROL IN DIABETIC DB/DB MICE BY EXPANDING BETA-CELL MASS AND INCREASING INSULIN SECRETORY CAPACITY, DIABETES, 66, PP. 1833-1846, (2017); NAKAGAWA Y., ET AL., HEPATIC CREB3L3 CONTROLS WHOLE-BODY ENERGY HOMEOSTASIS AND IMPROVES OBESITY AND DIABETES, ENDOCRINOLOGY, 155, PP. 4706-4719, (2014)","T. MATSUZAKA; DEPARTMENT OF INTERNAL MEDICINE (ENDOCRINOLOGY AND METABOLISM), FACULTY OF MEDICINE, UNIVERSITY OF TSUKUBA, TSUKUBA, 1-1-1 TENNODAI, 305-8575, JAPAN; EMAIL: T-MATSUZ@MD.TSUKUBA.AC.JP","NATURE PUBLISHING GROUP","ENGLISH","SCI. REP.","ARTICLE","ISI","2-S2.0-85063460384","SCI REP","UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA;UNIVERSITY OF TSUKUBA","NOTREPORTED;UNIVERSITY OF TSUKUBA;NOTREPORTED",NA,"SHARMA R, 2019, SCI REP","SHARMA R, 2019, SCI REP"
"HE W;LIU Q;YU H;SI X;ZHANG J","HE, WEN-SEN (36903215900); LIU, QIAO (57094273900); YU, HUAN (57094297700); SI, XIAO-JING (57094648200); ZHANG, JIN-KU (57095137200)","EFFICIENT SYNTHESIS OF OCTACOSANOL LINOLEATE CATALYZED BY IONIC LIQUID AND ITS STRUCTURE CHARACTERIZATION",2016,"JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY","93","8",13,"10.1007/s11746-016-2793-x","SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY CHINA, 301 XUEFU ROAD, ZHENJIANG, JIANGSU, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY CHINA, 301 XUEFU ROAD, ZHENJIANG, JIANGSU, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY CHINA, 301 XUEFU ROAD, ZHENJIANG, JIANGSU, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY CHINA, 301 XUEFU ROAD, ZHENJIANG, JIANGSU, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY CHINA, 301 XUEFU ROAD, ZHENJIANG, JIANGSU, 212013, CHINA","OCTACOSANOL, AS THE MAJOR ACTIVE POLICOSANOL, HAS ATTRACTED MUCH ATTENTION DUE TO THE POTENTIAL BENEFICIAL EFFECTS FOR HUMAN HEALTH. HOWEVER, FREE OCTACOSANOL HAS A HIGH MELTING POINT, POOR OIL SOLUBILITY AND LOW BIOAVAILABILITY, WHICH GREATLY RESTRICTS ITS PRACTICAL APPLICATION. IN THIS STUDY, WE REPORT A HIGHLY EFFICIENT METHOD FOR AN IONIC LIQUIDS (IL)-CATALYZED SYNTHESIS OF OCTACOSANOL ESTER BY DIRECT ESTERIFICATION WITH LINOLEIC ACID. THE SYNTHESIZED PRODUCT WAS PURIFIED, SUBSEQUENTLY CHARACTERIZED BY FT-IR, MS AND NMR AND FINALLY CONFIRMED TO BE OCTACOSANOL LINOLEATE. THE REACTION PARAMETERS WERE INVESTIGATED AND THE CONVERSION REACHED 91.3 ± 4.8 % UNDER THE OPTIMUM CONDITIONS: IL 1-BUTYLSULFONATE-3-METHYLIMIDAZOLIUM HYDROGEN SULFATE ([BSO3HMIM][HSO4]) AS CATALYST, IL DOSE 1.5 % (RELATED TO THE MASS OF BOTH REACTANTS), 1:1 MOLAR RATIO OF OCTACOSANOL TO LINOLEIC ACID, 80°C, AND 1 H. THE MELTING POINT AND OIL SOLUBILITY OF OCTACOSANOL WERE GREATLY IMPROVED BY ESTERIFICATION WITH LINOLEIC ACID, FACILITATING THE INCORPORATION INTO A VARIETY OF OIL-BASED SYSTEMS. © 2016 AOCS.","ESTERIFICATION; IONIC LIQUID; LINOLEIC ACID; OCTACOSANOL; POLICOSANOLS","BIOCHEMISTRY; CATALYSIS; ESTERS; LINOLEIC ACID; MELTING POINT; SOLUBILITY; SULFUR COMPOUNDS; BENEFICIAL EFFECTS; CATALYZED SYNTHESIS; DIRECT ESTERIFICATION; EFFICIENT SYNTHESIS; HIGH MELTING POINT; HUMAN HEALTH; OCTACOSANOL; OIL SOLUBILITIES; POLICOSANOLS; STRUCTURE CHARACTERIZATION; IONIC LIQUIDS","RESEARCH FUND FOR ADVANCED TALENTS OF JIANGSU UNIVERSITY, (13JDG070); NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, NSFC, (31401664); CHINA POSTDOCTORAL SCIENCE FOUNDATION, (2014M560406); PRIORITY ACADEMIC PROGRAM DEVELOPMENT OF JIANGSU HIGHER EDUCATION INSTITUTIONS, PAPD; SPECIALIZED RESEARCH FUND FOR THE DOCTORAL PROGRAM OF HIGHER EDUCATION OF CHINA, SRFDP, (20130093110010)","THIS STUDY WAS FINANCIALLY SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (31401664), THE CHINA POSTDOCTORAL SCIENCE FOUNDATION FUNDED PROJECT (2014M560406), THE RESEARCH FUND FOR THE DOCTORAL PROGRAM OF HIGHER EDUCATION OF CHINA (20130093110010), THE RESEARCH FUND FOR ADVANCED TALENTS OF JIANGSU UNIVERSITY (13JDG070) AND A PROJECT FUNDED BY THE PRIORITY ACADEMIC PROGRAM DEVELOPMENT OF JIANGSU HIGHER EDUCATION INSTITUTIONS (PAPD).","CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), J AGRIC FOOD CHEM, 58, PP. 12143-12148, (2010); FENG S., LUO Z., ZENG F., LIU S., KHAN Z.U., EFFECT OF WATER, METALLIC IONS, FATTY ACID AND TEMPERATURE ON OXIDATIVE STABILITY OF 1-OCTACOSANOL FROM SUGARCANE RIND, FOOD CHEM, 182, PP. 171-177, (2015); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR J INT MED, 25, PP. 592-599, (2014); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); ZHAO T., HA T.Y., LEE J., KIM B.H., KIM I.H., MODELING AND OPTIMIZATION OF LIPASE-CATALYZED ESTERIFICATION OF POLICOSANOLS WITH CONJUGATED LINOLEIC ACID BY RESPONSE SURFACE METHODOLOGY, BIOCATAL BIOTRANSFORM, 31, PP. 114-122, (2013); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, PP. 259-267, (2010); KIM J.Y., LEE J.H., JEONG D.Y., JANG D.K., SEO T.R., LIM S.T., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYD POLYM, 121, PP. 140-146, (2015); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); KUNKUMA V.L., KAKI S.S., RAO B.V., PRASAD R.B., PRABHAVATHI DEVI B.L., A SIMPLE AND FACILE METHOD FOR THE SYNTHESIS OF 1-OCTACOSANOL, EUR J LIPID SCI TECHNO, 115, PP. 921-927, (2013); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOL IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, PP. 583-591, (2012); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARM RES, 22, PP. 55-66, (2002); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); LEGUIZAMON C., WELLER C.L., SCHLEGEL V.L., CARR T.P., PLANT STEROL AND POLICOSANOL CHARACTERIZATION OF HEXANE EXTRACTS FROM GRAIN SORGHUM, CORN AND THEIR DDGS, J AM OIL CHEM SOC, 86, PP. 707-716, (2009); HAIM D., VALENZUELA A., BRANES M.C., FUENZALIDAD M., VIDELA L.A., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASAS ACEITES, 63, PP. 345-354, (2012); GORRETA F., BERNASCONI R., GALLIANI G., SALMONA M., TACCONI T., BIANCHI R., WAX ESTERS OF N-3 POLYUNSATURATED FATTY ACIDS: A NEW STABLE FORMULATION AS A POTENTIAL FOOD SUPPLEMENT. 1 F DIGESTION AND ABSORPTION IN RATS, LWT FOOD SCI TECHNOL, 35, PP. 458-465, (2002); LI Y., HU S., CHENG J., LOU W., ACIDIC IONIC LIQUID-CATALYZED ESTERIFICATION OF OLEIC ACID FOR BIODIESEL SYNTHESIS, CHIN J CATAL, 35, PP. 396-406, (2014); FAUZI A.H., AMIN N.A., OPTIMIZATION OF OLEIC ACID ESTERIFICATION CATALYZED BY IONIC LIQUID FOR GREEN BIODIESEL SYNTHESIS, ENERG CONV MANAGE, 76, PP. 818-827, (2013); YANG Y., HE W., JIA C., MA Y., ZHANG X., FENG B., EFFICIENT SYNTHESIS OF PHYTOSTERYL ESTERS USING THE LEWIS ACIDIC IONIC LIQUID, J MOL CATAL A CHEM, 357, PP. 39-43, (2012); GHIACI M., AGHABARARI B., HABIBOLLAHI S., GIL A., HIGHLY EFFICIENT BRØNSTED ACIDIC IONIC LIQUID-BASED CATALYSTS FOR BIODIESEL SYNTHESIS FROM VEGETABLE OILS, BIORESOUR TECHNOL, 102, PP. 1200-1204, (2011); HAN M., YI W., WU Q., LIU Y., HONG Y., WANG D., PREPARATION OF BIODIESEL FROM WASTE OILS CATALYZED BY A BRØNSTED ACIDIC IONIC LIQUID, BIORESOUR TECHNOL, 100, PP. 2308-2310, (2009); ZHANG L., XIAN M., HE Y., LI L., YANG J., YU S., XU X., A BRØNSTED ACIDIC IONIC LIQUID AS AN EFFICIENT AND ENVIRONMENTALLY BENIGN CATALYST FOR BIODIESEL SYNTHESIS FROM FREE FATTY ACIDS AND ALCOHOLS, BIORESOUR TECHNOL, 100, PP. 4368-4373, (2009); HE W., YIN J., XU H., QIAN Q., JIA C., MA H., FENG B., EFFICIENT SYNTHESIS AND CHARACTERIZATION OF ERGOSTEROL LAURATE IN A SOLVENT-FREE SYSTEM, J AGRIC FOOD CHEM, 62, PP. 11748-11755, (2014); SHAJI K.P., UMESHA S., BHARATHI P.S., SYNTHESIS OF 1-OCTACOSANOL FROM 1,12 DODECANEDIOL AND CETYL ALCOHOL, INT J CHEM PHARM SCI, 5, PP. 101-105, (2014); HE W., MA Y., PAN X., LI J., WANG M., YANG Y., JIA C., ZHANG X., FENG B., EFFICIENT SOLVENT-FREE SYNTHESIS OF PHYTOSTANYL ESTERS IN THE PRESENCE OF ACID-SURFACTANT-COMBINED CATALYST, J AGRIC FOOD CHEM, 60, PP. 9763-9769, (2012)","W.-S. HE; SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY CHINA, ZHENJIANG, JIANGSU, 301 XUEFU ROAD, 212013, CHINA; EMAIL: WSHE2013@163.COM","SPRINGER VERLAG","ENGLISH","JAOCS J AM OIL CHEM SOC","ARTICLE","ISI","2-S2.0-84956986841","JAOCS J AM OIL CHEM SOC","JIANGSU UNIVERSITY CHINA;JIANGSU UNIVERSITY CHINA;JIANGSU UNIVERSITY CHINA;JIANGSU UNIVERSITY CHINA;JIANGSU UNIVERSITY CHINA","NOTREPORTED;JIANGSU UNIVERSITY CHINA;NOTREPORTED",NA,"HE W-S, 2016, JAOCS J AM OIL CHEM SOC","HE W-S, 2016, JAOCS J AM OIL CHEM SOC"
"MA J;MA L;ZHANG Z;LI K;WANG Y;CHEN X;ZHANG H","MA, JINJU (56149760100); MA, LIYI (56332101700); ZHANG, ZHONGQUAN (55806093000); LI, KAI (57001344700); WANG, YOUQIONG (36174758400); CHEN, XIAOMING (55739155400); ZHANG, HONG (55070241500)","IN VIVO EVALUATION OF INSECT WAX FOR HAIR GROWTH POTENTIAL",2018,"PLOS ONE","13","",6,"10.1371/journal.pone.0192612","RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA","INSECT WAX IS SECRETED BY ERICERUS PELA CHAVANNESS. IT HAS BEEN TRADITIONALLY USED TO TREAT HAIR LOSS IN CHINA, BUT FEW REPORTS HAVE BEEN PUBLISHED ON THE HAIR GROWTH-PROMOTING EFFECT OF INSECT WAX. IN THIS WORK, WE EXAMINED THE HAIR GROWTH-PROMOTING EFFECTS OF INSECT WAX ON MODEL ANIMALS. DIFFERENT CONCENTRATIONS OF INSECT WAX WERE TOPICALLY APPLIED TO THE DENUDED BACKS OF MICE, AND 5% MINOXIDIL WAS APPLIED TOPICALLY AS A POSITIVE CONTROL. WE FOUND THAT INSECT WAX SIGNIFICANTLY PROMOTED HAIR GROWTH IN A DOSE-DEPENDENT MANNER, 45% AND 30% INSECT WAX BOTH INDUCED HAIR TO REGROW, WHILE LESS VISIBLE HAIR GROWTH WAS OBSERVED IN BLANK CONTROLS ON THE 16TH DAY. THE EXPERIMENTAL AREAS TREATED WITH 45% AND 30% INSECT WAX EXHIBITED SIGNIFICANT DIFFERENCES IN HAIR SCORES COMPARED TO BLANK CONTROLS, AND HAIR LENGTHS IN THE 45% AND 30% INSECT WAX GROUP WAS SIGNIFICANTLY LONGER THAN IN BLANK CONTROLS ON THE 16TH AND 20TH DAYS. THERE WERE NO NEW HAIR FOLLICLES FORMING IN THE TREATED AREAS, AND THE HAIR FOLLICLES WERE PREMATURELY CONVERTED TO THE ANAGEN PHASE FROM THE TELOGEN PHASE IN EXPERIMENTAL AREAS TREATED WITH 45% AND 30% INSECT WAX. BOTH 45% AND 30% INSECT WAX UPREGULATED VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION. THE RESULTS INDICATED THAT 45% AND 30% INSECT WAX SHOWED HAIR GROWTH-PROMOTING POTENTIAL APPROXIMATELY AS POTENT AS 5% MINOXIDIL BY INDUCING THE PREMATURE CONVERSION OF TELOGEN-TO-ANAGEN AND BY PROLONGING THE MATURE ANAGEN PHASE RATHER THAN INCREASING THE NUMBER OF HAIR FOLLICLES, WHICH WAS LIKELY RELATED TO THE UPREGULATION OF VEGF EXPRESSION. THE DISSOCIATIVE POLICOSANOL IN INSECT WAX WAS CONSIDERED THE KEY INGREDIENT MOST LIKELY RESPONSIBLE FOR THE HAIR GROWTH PROMOTING POTENTIAL. © 2018 MA ET AL. THIS IS AN OPEN ACCESS ARTICLE DISTRIBUTED UNDER THE TERMS OF THE CREATIVE COMMONS ATTRIBUTION LICENSE, WHICH PERMITS UNRESTRICTED USE, DISTRIBUTION, AND REPRODUCTION IN ANY MEDIUM, PROVIDED THE ORIGINAL AUTHOR AND SOURCE ARE CREDITED.","","ANIMALS; HAIR; INSECTA; MICE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WAXES; INSECT WAX; POLICOSANOL; UNCLASSIFIED DRUG; VASCULOTROPIN; WAX; VASCULOTROPIN A; ANIMAL TISSUE; ARTICLE; FEMALE; HAIR FOLLICLE; HAIR GROWTH; IN VIVO STUDY; INCUBATION TIME; MALE; MASS FRAGMENTOGRAPHY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCORING SYSTEM; UPREGULATION; ANIMAL; GROWTH, DEVELOPMENT AND AGING; HAIR; INSECT; METABOLISM","RESEARCH AND DEVELOPMENT, (2014AA021801); CENTRAL DRUG RESEARCH INSTITUTE, CDRI, (CAFYBB2018SY025)","THIS WORK WAS FINANCIALLY SUPPORTED BY THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NON-PROFIT RESEARCH INSTITUTION OF CAF (CAFYBB2018SY025), AND NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (863 PROGRAM) (2014AA021801). THE FUNDERS HAD NO ROLE IN STUDY DESIGN, DATA COLLECTION AND ANALYSIS, DECISION TO PUBLISH, OR PREPARATION OF THE MANUSCRIPT.","COTSARELIS G., MILLAR S.E., TOWARDS A MOLECULAR UNDERSTANDING OF HAIR LOSS AND ITS TREATMENT, TRENDS IN MOLECULAR MEDICINE, 7, 7, PP. 293-301, (2001); HARDY M.H., THE SECRET LIFE OF THE HAIR FOLLICLE, TRENDS IN GENETICS, 8, 2, PP. 55-61, (1992); STENN K.S., COMBATES N.J., EILERTSEN K.J., GORDON J.S., PARDINAS J.R., PARIMOO S., ET AL., HAIR FOLLICLE GROWTH CONTROLS DERMATOLOGIC CLINICS, 14, 4, PP. 543-558, (1996); MARYAM DASTAN N.N., ABEDELAHI A., SARVI M., NIAPOUR A., HUMAN PLATELET LYSATE VERSUS MINOXIDIL STIMULATES HAIR GROWTH BY ACTIVATING ANAGEN PROMOTING SIGNALING PATHWAYS, BIOMEDICINE & PHARMACOTHERAPY, 84, PP. 979-986, (2016); PAUS R., COTSARELIS G., THE BIOLOGY OF HAIR FOLLICLES, NEW ENGLAND JOURNAL OF MEDICINE, 341, 7, PP. 491-497, (1999); ALSANTALI A., ALOPECIA AREATA: A NEW TREATMENT PLAN, CLIN COSMET INVESTIG DERMATOL, 4, PP. 107-115, (2011); GORDON K.A., TOSTI A., ALOPECIA: EVALUATION AND TREATMENT, CLIN COSMET INVESTIG DERMATOL, 4, PP. 101-106, (2011); YAN ZHANG L.H., CHEN S.-S., GUAN J., QU F.-Z., ZHAO Y.-Q., HAIR GROWTH PROMOTING ACTIVITY OF CEDROL ISOLATED FROM THE LEAVES OF PLATYCLADUS ORIENTALIS, BIOMEDICINE & PHARMACOTHERAPY, 83, PP. 641-647, (2016); NIGEL HUNT S.M., THE PSYCHOLOGICAL IMPACT OF ALOPECIA, BRITISH MEDICAL JOURNAL, 331, PP. 951-953, (2005); PETERS E.M.J., MULLER Y., SNAGA W., FLIEGE H., REISSHAUER A., SCHMIDT-ROSE T., ET AL., HAIR AND STRESS: A PILOT STUDY OF HAIR AND CYTOKINE BALANCE ALTERATION IN HEALTHY YOUNG WOMEN UNDER MAJOR EXAM STRESS, PLOS ONE, 12, 4, PP. E0175904-E0175924, (2017); VENKATARAM MYSORE B.S., GUIDELINES ON THE USE OF FINASTERIDE IN ANDROGENETIC ALOPECIA, INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY AND LEPROLOGY, 82, 2, PP. 128-134, (2016); VESOULIS Z.A., ATTARIAN S.J., ZELLER B., COLE F.S., MINOXIDIL-ASSOCIATED ANOREXIA IN AN INFANT WITH REFRACTORY HYPERTENSION, PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, 34, 12, PP. E341-E344, (2014); LEE G.S., HONG E.J., GWAK K.S., PARK M.J., CHOI K.C., CHOI I.G., ET AL., THE ESSENTIAL OILS OF CHAMAECYPARIS OBTUSA PROMOTE HAIR GROWTH THROUGH THE INDUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR GENE, FITOTERAPIA, 81, 1, PP. 17-24, (2010); SEO S.R., KANG G., HA J.W., KIM J.C., IN VIVO HAIR GROWTH-PROMOTING EFFICACIES OF HERBAL EXTRACTS AND THEIR CUBOSOMAL SUSPENSIONS, JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, 19, 4, PP. 1331-1339, (2013); DHANOTIA R., CHAUHAN N.S., SARAF D.K., DIXIT V.K., EFFECT OF CITRULLUS COLOCYNTHIS SCHRAD FRUITS ON TESTOSTERONE-INDUCED ALOPECIA, NATURAL PRODUCT RESEARCH, 25, 15, PP. 1432-1443, (2011); BASSINO E., ANTONIOTTI S., GASPARRI F., MUNARON L., EFFECTS OF FLAVONOID DERIVATIVES ON HUMAN MICROVASCU-LAR ENDOTHELIAL CELLS, NATURAL PRODUCT RESEARCH, 30, 24, PP. 2831-2834, (2016); YANG P., ZHU J.Y., CHEN X.M., LI M., ISOLATION AND CHARACTERIZATION OF MICROSATELLITE LOCI FROM THE CHINESE WHITE WAX SCALE ERICERUS PELA CHAVANNES (HOMOPETERA: COCCIDAE), AFRICAN JOURNAL OF MICROBIOLOGY RESEARCH, 5, 10, PP. 1246-1248, (2011); YANG P., ZHU J.-Y., GONG Z.-J., XU D.-L., CHEN X.-M., LIU W.-W., ET AL., TRANSCRIPTOME ANALYSIS OF THE CHINESE WHITE WAX SCALE ERICERUS PELA WITH FOCUS ON GENES INVOLVED IN WAX BIOSYNTHESIS, PLOS ONE, 7, 4, PP. E35719-E35728, (2012); CHEN YF X.M., THE CHINESE WHITE WAX SCALE ERICERUS PELA CHAVANNES, PP. 29-30, (2009); ZHANG R.G., ZHENG H., ZHANG H., FENG Y., LI K., ZHANG W.W., THERMAL ANALYSIS OF FOUR INSECT WAXES BASED ON DIFFERENTIAL SCANNING CALORIMETRY (DSC), PROCEDIA ENGINEERING, 18, PP. 101-106, (2011); ZHENG H., TANG L.Y., ZHANG R.G., ZHANG H., BIO-WAX AND HUMAN HEALTH, NAT PROD RES DEV, 21, PP. 313-316, (2009); YANG P., CHEN X.-M., LIU W.-W., FENG Y., SUN T., TRANSCRIPTOME ANALYSIS OF SEXUALLY DIMORPHIC CHINESE WHITE WAX SCALE INSECTS REVEALS KEY DIFFERENCES IN DEVELOPMENTAL PROGRAMS AND TRANSCRIPTION FACTOR EXPRESSION, SCIENTIFIC REPORTS, 5, PP. 8141-8148, (2015); LIN L., ZHOU Y., LI H., PANG D., ZHANG L., LU X., ET AL., POLYSACCHARIDE EXTRACTED FROM CHINESE WHITE WAX SCALE AMELIORATES 2,4-DINITROCHLOROBENZENE-INDUCED ATOPIC DERMATITIS-LIKE SYMPTOMS IN BALB/C MICE, SAUDI PHARMACEUTICAL JOURNAL, 25, 4, PP. 625-632, (2017); HOU X.Y., CAO M.Y., GONG J., LI EA N., OVERVIEW OF PHARMACOLOGICAL RESEARCH OF INSECT WAX, JOURNAL OF ANHUI AGRI SCI, 39, 5, PP. 2817-2818, (2011); MA YQW L.Y., ZHANG Z.Q., ZHENG H., GAN J., LI Z.G., DUAN Q.F., PREPARATION OF POLICOSANOL FROM INSECT WAX SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, 29, 2, PP. 179-181, (2008); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCHIVES OF MEDICAL RESEARCH, 36, 5, PP. 441-447, (2005); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 16, PP. 6289-6293, (2005); SHI-ZHEN L., THE COMPENDIUM OF MATERIA MEDICA, (2006); MA YQW L.Y., ZHANG Z.Q., GAN J., ZHENG H., ET AL., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, 29, 5, PP. 6-10, (2009); RHO S.S., PARK S.J., HWANG S.L., LEE M.H., KIM C.D., LEE I.H., ET AL., THE HAIR GROWTH PROMOTING EFFECT OF ASIASARI RADIX EXTRACT AND ITS MOLECULAR REGULATION, JOURNAL OF DERMATOLOGICAL SCIENCE, 38, 2, PP. 89-97, (2005); HAN X.H., PRELIMINARY STUDIES ON THE PHARMACODYNAMICS AND MECHANISM OF SFJ, A NEW HAIR TONIC, (2001); WANG Z.-D., FENG Y., MA L.-Y., LI X., DING W.-F., CHEN X.-M., HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, BIOMEDICINE & PHARMACOTHERAPY, 89, PP. 438-446, (2017); ADHIRAJAN N., RAVI KUMAR T., SHANMUGASUNDARAM N., BABU M., IN VIVO AND IN VITRO EVALUATION OF HAIR GROWTH POTENTIAL OF HIBISCUS ROSA-SINENSIS LINN, JOURNAL OF ETHNOPHARMACOLOGY, 88, 2-3, PP. 235-239, (2003); DATTA A.T.S.K., MUKHERJEE A., BHAT B., RAMESH B., BURMAN A.C., ECLIPTA ALBA EXTRACT WITH POTENTIAL FOR HAIR GROWTH PROMOTING ACTIVITY, JOURNAL OF ETHNOPHARMACOLOGY, 124, 3, PP. 450-456, (2009); UNO S.K.H., CHEMICAL AGENTS AND PEPTIDES AFFECT HAIR GROWTH, JOURNAL OF INVESTIGATIVE DERMATOLOGY, 101, PP. 143S-147S, (1993); AVRAM M.R., COLE J.P., CHASE C., GANDELMAN M., HABER R., KNUDSEN R., ET AL., THE POTENTIAL ROLE OF MINOXIDIL IN THE HAIR TRANSPLANTATION SETTING, DERMATOLOGIC SURGERY, 28, 10, PP. 894-900, (2002); YINGGUO WANG Y.L., NI B., LUO Y., DISTRIBUTION AND FUNCTION OF OCTACOSANOL, CHINA OILS AND FATS, 27, 1, PP. 54-56, (2002); YANO K., BROWN L.F., DETMAR M., CONTROL OF HAIR GROWTH AND FOLLICLE SIZE BY VEGF-MEDIATED ANGIOGENESIS, THE JOURNAL OF CLINICAL INVESTIGATION, 107, 4, PP. 409-417, (2001); ANNA H., HERMAN A.P., MECHANISM OF ACTION OF HERBS AND THEIR ACTIVE CONSTITUENTS USED IN HAIR LOSS TREATMENT, FITOTERAPIA, (2016); LACHGAR S., CHARVERON M., GALL Y., BONAFE J.L., MINOXIDIL UPREGULATES THE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN HUMAN HAIR DERMAL PAPILLA CELLS, BRITISH JOURNAL OF DERMATOLOGY, 138, PP. 407-411, (1998); YOUNG-OK P., SU-EUN K., KIM Y.-C., ACTION MECHANISM OF CHAMAECYPARIS OBTUSA OIL ON HAIR GROWTH, TOXICOLOGICAL RESEARCH, 29, 4, PP. 241-247, (2013)","L. MA; RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA; EMAIL: LINHUASHI510@OUTLOOK.COM","PUBLIC LIBRARY OF SCIENCE","ENGLISH","PLOS ONE","ARTICLE","ISI","2-S2.0-85042043382","PLOS ONE","RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS;RESEARCH INSTITUTE OF RESOURCES INSECTS","NOTREPORTED;RESEARCH INSTITUTE OF RESOURCES INSECTS;NOTREPORTED",NA,"MA J, 2018, PLOS ONE","MA J, 2018, PLOS ONE-a"
"HE W;SI X;WANG H;GU Y;YU H;ZHANG J","HE, WEN-SEN (36903215900); SI, XIAO-JING (57094648200); WANG, HUI-HUI (57193326973); GU, YE-NAN (57193327270); YU, HUAN (57094297700); ZHANG, JIN-KU (57095137200)","REGULATION OF LIPID METABOLISM BY OCTACOSANOL IN RATS",2016,"MODERN FOOD SCIENCE AND TECHNOLOGY","32","5",1,"10.13982/j.mfst.1673-9078.2016.10.005","SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY, ZHENJIANG, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY, ZHENJIANG, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY, ZHENJIANG, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY, ZHENJIANG, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY, ZHENJIANG, 212013, CHINA;SCHOOL OF FOOD AND BIOLOGICAL ENGINEERING, JIANGSU UNIVERSITY, ZHENJIANG, 212013, CHINA","THE EFFECT OF OCTACOSANOL ON SERUM LIPIDS AND THE LIVER OF RATS FED A HIGH-FAT DIET WAS INVESTIGATED. THIRTY SPRAGUE-DAWLEY RATS WERE DIVIDED INTO THREE GROUPS: NORMAL CONTROL GROUP (N=10), HIGH-FAT CONTROL GROUP (N=10), AND OCTACOSANOL GROUP (N=10). THE CONTENT OF SERUM TOTAL CHOLESTEROL, TRIGLYCERIDES, LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C), HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C), ASPARTATE AMINOTRANSFERASE, ALANINE TRANSAMINASE AND THIOBARBITURIC ACID (TBA) WERE MEASURED AT THE MIDDLE (WEEKS 4 AND 8) AND END (WEEK 10) OF THE EXPERIMENT, AND THE CONDITION OF HEPATIC STEATOSIS WAS ANALYZED. THE RESULTS SHOWED THAT THE SERUM TRIGLYCERIDE CONTENT OF RATS IN THE OCTACOSANOL GROUP AT WEEKS 4, 8 AND 10 WERE SIGNIFICANTLY DECREASED BY 26.81% (P=0.08), 44.77% (P=0.03) AND 32.22% (P=0.03), RESPECTIVELY, COMPARED TO THOSE IN THE HIGH-FAT GROUP. THE TOTAL CHOLESTEROL (TC) CONTENT OF RATS AT WEEKS 4, 8 AND 10 IN THE OCTACOSANOL GROUP WERE SIGNIFICANTLY DECREASED BY 16.76% (P=0.18), 16.21% (P=0.043) AND 8.43% (P=0.07), RESPECTIVELY, COMPARED TO THOSE THE HIGH-FAT GROUP. THE SERUM HDL-C LEVEL, AVERAGE BODY WEIGHT, AND DAILY FOOD INTAKE WERE NOT AFFECTED BY OCTACOSANOL. PATHOLOGICAL SECTIONING AND LIVER FUNCTION ANALYSIS INDICATED THAT OCTACOSANOL COULD EFFECTIVELY PREVENT HEPATIC STEATOSIS WITHOUT NEGATIVELY AFFECTING LIVER FUNCTION. THE RESULTS INDICATE THAT OCTACOSANOL CAN BE USED TO REGULATE BLOOD LIPIDS AND PREVENT HEPATIC STEATOSIS. THEREFORE, OCTACOSANOL CAN BE USED AS A FUNCTIONAL FOOD INGREDIENT IN THE PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES. © 2016, SOUTH CHINA UNIVERSITY OF TECHNOLOGY. ALL RIGHT RESERVED.","LIVER; OCTACOSANOL; POLICOSANOL; SERUM LIPID","","","","FENG S.-M., LUO Z.-S., ZENG F.-F., ET AL., EFFECT OF WATER, METALLIC IONS, FATTY ACID AND TEMPERATURE ON OXIDATIVE STABILITY OF 1-OCTACOSANOL FROM SUGARCANE RIND, FOOD CHEMISTRY, 182, PP. 171-177, (2015); KIM J.-Y., LEE J.-H., JEONG D.-Y., ET AL., PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES, CARBOHYDRATE POLYMERS, 121, PP. 140-146, (2015); HAIM D., VALENZUELA A., BRANES M.C., ET AL., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASAS Y ACEITES, 63, PP. 345-354, (2012); NG C.H., LEUNG K.Y., HUANG Y., ET AL., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 6289-6293, (2005); BERTHOLD HEINER K., UNVERDOEBEN S., DEGENHARDT R., ET AL., EFFECT OF LIPIDS POLICOSANOL ON LIPID LEVELS AMONG WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, PP. 2262-2269, (2006); XU Z.-Y., EVELYN F., NATALIE R., ET AL., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, NUTRITION RESEARCH, 27, PP. 212-217, (2007); CHEN Z.-Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 56, PP. 8761-8773, (2008); JIA X.-M., CHEN Y.-F., JEFFREY Z., ET AL., CO-ADMINISTRATION OF BERBERINE AND PLANT STANOLS SYNERGISTICALLY REDUCES PLASMA CHOLESTEROL I.N RATS, ATHEROSCLEROSIS, 201, PP. 101-107, (2008)","","SOUTH CHINA UNIVERSITY OF TECHNOLOGY","CHINESE","MOD. FOOD SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-85012971997","MOD FOOD SCI TECHNOL",NA,"NOTREPORTED",NA,"HE W-S, 2016, MOD FOOD SCI TECHNOL","HE W-S, 2016, MOD FOOD SCI TECHNOL"
"ANGGA W;RIZAL Y;MAHATA M;YUNIZA A;MAYERNI R","ANGGA, WINGKI ARI (57192435411); RIZAL, YOSE (23670749700); MAHATA, MARIA ENDO (24830822000); YUNIZA, AHADIYA (48663330300); MAYERNI, RENI (57189389340)","POTENTIAL OF WASTE TEA LEAVES CAMELLIA SINENSIS IN WEST SUMATRA TO BE PROCESSED INTO POULTRY FEED",2018,"PAKISTAN JOURNAL OF NUTRITION","17","6",10,"10.3923/pjn.2018.287.293","DEPARTENT OF ANIMAL SCIENCE, UNIVERSITAS ANDALAS, PADANG, 25163, INDONESIA;DEPARTENT OF ANIMAL SCIENCE, UNIVERSITAS ANDALAS, PADANG, 25163, INDONESIA;DEPARTENT OF ANIMAL SCIENCE, UNIVERSITAS ANDALAS, PADANG, 25163, INDONESIA;DEPARTENT OF ANIMAL SCIENCE, UNIVERSITAS ANDALAS, PADANG, 25163, INDONESIA;DEPARTMENT OF AGRICULTURE, UNIVERSITAS ANDALAS, PADANG, 25163, INDONESIA","BACKGROUND AND OBJECTIVE: WEST SUMATRA IS THE THIRD LARGEST TEA-PRODUCING AREA IN INDONESIA. TEA PLANTATIONS IN THIS AREA PRODUCE TOP QUALITY LEAVES THAT CAN BE MARKETED BOTH DOMESTICALLY AND INTERNATIONALLY. TO MAINTAIN A HIGH LEVEL OF TEA LEAF PRODUCTIVITY, PLANTS SHOULD BE PRUNED EVERY 3 YEARS USING A ROTATION SYSTEM THAT INVOLVES MONTHLY PRUNINGS. THESE PRUNINGS PRODUCE WASTE TEA LEAVES THAT CAN SERVE AS ALTERNATIVE FEED RESOURCE FOR POULTRY AS THEY HAVE GOOD NUTRITIONAL VALUE. TEA LEAVES CONTAIN HIGH CONCENTRATIONS OF ANTIOXIDANTS, SUCH AS POLYPHENOLS AND POLICOSANOL AS WELL AS MINERALS AND VITAMINS, WHICH ARE KNOWN TO IMPROVE POULTRY HEALTH. UNFORTUNATELY, TEA LEAVES ALSO CONTAIN HIGH LEVELS OF TANNINS AND CRUDE FIBER-COMPONENTS KNOWN TO BE DETRIMENTAL TO POULTRY. THIS STUDY WAS DESIGNED TO EVALUATE THE POTENTIAL OF WASTE TEA LEAVES (CAMELLIA SINENSIS) AS POULTRY FEED IN WEST SUMATRA BY REDUCING THEIR TANNIN CONTENT THROUGH IMMERSION IN FRESH AND HOT WATER. MATERIALS AND METHODS: THIS RESEARCH CONSISTED OF TWO PHASES. THE FIRST PHASE WAS A SURVEY OF THE POTENTIAL OF WASTE TEA LEAVES AS POULTRY FEED THROUGH INTERVIEWS AND MEASUREMENT OF WASTE TEA LEAF PRODUCTION. THE SECOND PHASE WAS TO EXPERIMENTALLY PROCESS WASTE TEA LEAVES THROUGH IMMERSION IN FRESH AND HOT WATER. VARIABLES MEASURED DURING PHASE 1 INCLUDED THE SIZE OF TEA PLANTATIONS, OWNERSHIPS, TEA VARIETIES PRODUCED, WASTE TEA LEAF PRODUCTION AND ESTIMATED POTENTIAL FOR POULTRY FEED. THE EXPERIMENT CONDUCTED IN PHASE 2 WAS PERFORMED USING A COMPLETELY RANDOMIZED DESIGN INVOLVING 2×4 FACTORIAL ARRANGEMENT OF TREATMENTS WITH 4 REPLICATES. THE FIRST EXPERIMENTAL VARIABLE WAS WATER TEMPERATURE (ROOM TEMPERATURE OR 80ºC). THE SECOND EXPERIMENTAL VARIABLE WAS BASED ON IMMERSION AT 6, 12, 18 OR 24 H. RESPONSE VARIABLES MEASURED INCLUDED CHANGE IN TANNIN CONTENT, DRY MATTER (DM), ORGANIC MATTER (OM), CRUDE PROTEIN (CP) AND CRUDE FIBER (CF). RESULTS: THE RESULTS OF THE FIRST PHASE INDICATED THAT THE AREA OF TEA PLANTATIONS IN WEST SUMATRA WAS 4,246.6 HA, OWNERSHIP CONSISTED OF SMALL HOLDERS (2,172 HA), THE GOVERNMENT (604.58 HA) AND A PRIVATE COMPANY (1,470 HA), TOTAL WASTE TEA LEAF PRODUCTION WAS 25,208.28 T/YEAR, TEA VARIETIES OR CLONES WERE CAMELLIA SINENSIS ASSAMICA TRI 2024 AND ASSAMICA TRI 2025 AND WASTE TEA LEAVES HAD THE POTENTIAL TO FEED 4,201,380,000 LAYING HENS. THE RESULTS OF THE SECOND PHASE INDICATED THAT THERE WAS AN INTERACTION BETWEEN WATER TEMPERATURE AND IMMERSION DURATION ON TANNIN REDUCTION (P<0.05). WATER TEMPERATURE SIGNIFICANTLY INFLUENCED (P<0.01) REDUCTIONS IN OM AND CP CONTENT AND SIGNIFICANTLY AFFECTED (P<0.05) CF AUGMENTATION. IMMERSION DURATION SIGNIFICANTLY AFFECTED (P<0.05) DM REDUCTIONS AND HIGHLY SIGNIFICANTLY INFLUENCED (P<0.01) REDUCTIONS IN OM AND CP. CONCLUSION: WASTE TEA LEAVES CAN BE IMMERSED IN HOT WATER (80ºC) FOR 12 H TO REDUCE THEIR TANNIN CONTENT WITHOUT AFFECTING THEIR PROTEIN CONTENT. © 2018 WINGKI ARI ANGGA ET AL.","IMMERSION; POTENCY; POULTRY FEED; TANNIN; WASTE TEA LEAF","ASCORBIC ACID; CARBOHYDRATE; CATECHIN; FRESH WATER; ORGANIC MATTER; POLYPHENOL; PROTEIN; RETINOL; TANNIN; VITAMIN B GROUP; ARTICLE; CAMELLIA SINENSIS; CANAVALIA; DIETARY FIBER; NONHUMAN; NUTRITIONAL VALUE; PLANT LEAF; PLANTATION; POULTRY; TEA; WATER TEMPERATURE","KEMENTERIAN RISET TEKNOLOGI DAN PENDIDIKAN TINGGI REPUBLIK INDONESIA; KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI, (324/SP2H/LT/DRPM/IX/2016)","THIS STUDY WAS FUNDED BY THE MINISTRY OF RESEARCH, TECHNOLOGY AND HIGHER EDUCATION OF THE REPUBLIC OF INDONESIA THROUGH PMDSU NO: 324/SP2H/LT/DRPM/IX/2016. WE ARE VERY GRATEFUL TO THE MINISTER OF RESEARCH, TECHNOLOGY AND HIGHER EDUCATION OF THE REPUBLIC OF INDONESIA AND THE RECTOR OF UNIVERSITAS ANDALAS FOR THEIR SUPPORT.","INDONESIA TEA STATISTICS, (2015); EFFENDI D.S., SYAKIR M., YUSRONWIRATNO M., CULTIVATION AND POST HARVEST TEA, (2012); SETYAMIDJAJA D., TEA CULTIVATION & POSTHARVESTING PROCESSING, KEMENTERIAN PERTANIAN, (2000); HAQ M.S., EFFORTS TO INCREASE TEA PRODUCTION (CAMELLIA SINENSIS L. O. KUNTZE) THROUGH APPLICATION OF TECHNICAL CULTURE, WAR. PPTK., 17, 6, PP. 71-84, (2013); MURTIDJO A.B., GUIDELINES FOR FORMULATING POULTRY FEED, (1987); SAMYNATHAN R., PERISAMY S.K., GANDHI S., ANITHA J., SANMUGAM G., PADMANABHAN M., KANNIAPPAN G.V., BIOCHEMICAL AND MOLECULAR ANALYSIS OF CAMELLIA SINENSIS (L.) O. KUNTZE TEA FROM THE SELECTED P/11/15 CLONE, J. GENET. ENG. BIOTECHNOL., 14, PP. 69-75, (2016); CABRERA C., ARTACHO R., GIMENEZ R., BENEFICIAL EFFECTS OF GREEN TEA-A REVIEW, J. AM. COLL. NUTR., 25, PP. 79-99, (2006); RAVICHANDRAN R., CAROTENOID COMPOSITION, DISTRIBUTION AND DEGRADATION TO FLAVOUR VOLATILES DURING BLACK TEA MANUFACTURE AND THE EFFECT OF CAROTENOID SUPPLEMENTATION ON TEA QUALITY AND AROMA, FOOD CHEM, 78, PP. 23-28, (2002); SUNDARI D., NURATMI B., WINARNO M.W., ACUTE TOXICITY OF LD<SUB>50</SUB> AND TEST OF GREEN TEA LEAF EXTRACT (CAMELLIA SINENSIS L. KUNTZE) IN MICE, MEDIA LITBANG KESEHAT, 19, PP. 198-203, (2009); HAGERMAN A.E., ROBBINS C.T., WEERASURIYA Y., WILSON T.C., MCARTHUR C., TANNIN CHEMISTRY IN RELATION TO DIGESTION, J. RANGE. MANAGE., 45, PP. 57-62, (1992); WIHARTO A., POULTRY BREEDING GUIDELINES, (1986); WIDODO W., TOXIC PLANT IN LIVESTOCK LIFE, (2002); MUHARLIEN A., IMPROVING EGG QUALITY THROUGH THE ADDITION OF GREEN TEA IN LAYING CHICKENS FEED, J. ILMU DAN TEKNOL. HAS. TERNAK, 5, PP. 1-6, (2010); ANITA W., SUHARTO Y., ASTUTI I., THE INFLUENCE OF FLOUR TEA LEAF IN RATIONS ON PERFORMANCE AND ABDOMINAL FAT PERCENTAGE OF CHICKEN, TROP. ANIM. HUSB., 1, PP. 1-6, (2012); NARSIHHARIJONO Y., THE STUDY ON SORGHUM (SORGHUM BICOLOR L. MOENCH) SOAKING AND GERMINATION TIME TO PRODUCE LOW TANNIN AND PHYTIC ACID FLOUR, J. TEKNOLOGI PERTANIAN, 9, PP. 173-180, (2008); KAWAMOTO H., NAKATSUBO F., MURAKAMI K., SYNTHESIS OF CONDENSED TANNIN DERIVATIVES AND THEIR PROTEIN-PRECIPITATING CAPACITY, J. WOOD CHEM. TECHNOL., 10, PP. 59-74, (1990); GOODARZNIA I., GOVAR A.A., SUPERHEATED WATER EXTRACTION OF CATECHINS FROM GREEN TEA LEAVES: MODELING AND SIMULATION, TRANS. C: CHEM. CHEM. ENG., 16, PP. 99-107, (2009); OEMATAN Z.Z.B., EFFECT OF TEMPERATURE DIFFERENCE AND TIME OF EXTRACTION ON TANNIN CONTENT OF CASHEW LEAF EXTRACT, J. ILM. MHS. UNIV. SURABAYA, 4, PP. 1-12, (2015); SUBANDRIYOSETIANINGSIH N.I., EXTRACTION PROCESS FOR REDUCING TANNIN OF MANGROVE FRUIT BRUGUIERA GUMNORRHIZA (LAMARCK, 1798) AS A RAW MATERIAL FOR FOOD FLOUR, AQUAT. PROCEDIA, 7, PP. 231-235, (2016); SUDARMADJI S., BAMBANGSUHARDI H., PROCEDURE ANALYSIS FOR FOOD AND AGRICULTURE, (1984); OFFICIAL METHOD OF ANALYSIS, PP. 66-88, (1990); STEEL R.G.D., TORRIE J.H., PRINCIPLES AND PROCEDURE OF STATISTICS: A BIOMETRICAL APPROACH, (1990); SRIYADI B., SELECTION OF SUPERIOR ASSAMICA TEA CLONES WITH HIGH YIELD POTENTIAL AND HIGH CATECHINE CONTENTS, J. PENELITIAN TEH DAN KINA, 15, PP. 1-10, (2012); LU Y., GUO W.F., YANG X.Q., FLUORIDE CONTENT IN TEA AND ITS RELATIONSHIP WITH TEA QUALITY, J. AGRIC. FOOD CHEM., 52, PP. 4472-4476, (2004); KAMAU D.M., PRODUCTIVITY AND RESOURCE USE IN AGEING TEA PLANTATIONS. WAGENINGEN UNIVERSITY, THE NETHERLANDS, PAGES: 140, (2008); VAN DER VOSSEN H.A.M., WESSEL M., PROSEA: PLANT RESOURCES OF SOUTH-EAST ASIA NO. 16: STIMULANTS. BACKHUYS PUBLISHERS, PP. 55-63, (2000); KALITA R.M., DAS A.K., NATH A.J., COMPARATIVE STUDY ON GROWTH PERFORMANCE OF TWO SHADE TREES IN TEA AGROFORESTRY SYSTEM, J. ENVIRON. BIOL., 35, PP. 699-702, (2014); LIN X., ZHANG L., LEI H., ZHANG H., CHENG Y., ZHU R., RUAN R., EFFECT OF DRYING TECHNOLOGIES ON QUALITY OF GREEN TEA, INT. AGRIC. ENGIN. J., 19, PP. 30-37, (2010); KRISNAN R., THE EFFECT OF FEEDING TEA SHAKE (CAMELLIA SINENSIS) FERMENTATION WITH ASPERGILLUS NIGER IN BROILER CHICKENS, JITV, 10, PP. 1-5, (2005); MAKKAR H.P.S., BECKER K., EFFECT OF PH, TEMPERATURE AND TIME ON INACTIVATION OF TANNINS AND POSSIBLE IMPLICATIONS IN DETANNIFICATION STUDIES EFFECT OF PH, TEMPERATURE AND TIME ON INACTIVATION OF TANNINS AND POSSIBLE IMPLICATIONS IN DETANNIFICATION STUDIES, J. AGRIC. FOOD CHEM., 44, PP. 1291-1295, (1996); REHMAN S.U., ALMAS K., SHAHZADI N., BHATTI N., SALEEM A., EFFECT OF TIME AND TEMPERATURE ON INFUSION OF TANNINS FROM COMMERCIAL BRANDS OF TEA, INT. J. AGRIC. BIOL., 4, PP. 285-287, (2002); OETZEL G.R., VILLALBA F.P., GOODGER W.J., NORDLUND K.V., A COMPARISON OF ON-FARM METHODS FOR ESTIMATING THE DRY MATTER CONTENT OF FEED INGREDIENTS, J. DAIRY SCI., 76, PP. 293-299, (1993); CHALBOT M.C.G., CHITRANSHI P., COSTA G.G.D., POLLOCK E., KAVOURAS I.G., CHARACTERIZATION OF WATER-SOLUBLE ORGANIC MATTER IN URBAN AEROSOL BY<SUP>1</SUP>H-NMR SPECTROSCOPY, ATMOS. ENVIRON., 128, PP. 235-245, (2016); MARTINSON K., JUNG H., HATHAWAY M., SHEAFFER C., THE EFFECT OF SOAKING ON CARBOHYDRATE REMOVAL AND DRY MATTER LOSS IN ORCHARDGRASS AND ALFALFA HAYS, J. EQUINE VET. SCI., 32, PP. 332-338, (2012); MARTINSON K., HATHAWAY M., JUNG H., SHEAFFER C., HAY SOAKING: ALL WASHED UP OR A GOOD MANAGEMENT OPTION?, (2017); RUNYON J.R., SUNILKUMAR B.A., NILSSON L., RASCON A., BERGENSTAHL B., THE EFFECT OF HEAT TREATMENT ON THE SOLUBLE PROTEIN CONTENT OF OATS, J. CEREAL SCI., 65, PP. 119-124, (2015); SAMI R., LI Y., QI B., WANG S., ZHANG Q., ET AL., HPLC ANALYSIS OF WATER-SOLUBLE VITAMINS (B2, B3, B6, B12 AND C) AND FAT-SOLUBLE VITAMINS (E, K, D, A AND Β-CAROTENE) OF OKRA (ABELMOSCHUS ESCULENTUS), J. CHEM, (2014); YAN X., YE R., CHEN Y., BLASTING EXTRUSION PROCESSING: THE INCREASE OF SOLUBLE DIETARY FIBER CONTENT AND EXTRACTION OF SOLUBLE-FIBER POLYSACCHARIDES FROM WHEAT BRAN, FOOD CHEM, 180, PP. 106-115, (2015); PARAMITA O., EFFECT OF WATER TENDER TYPE ON VITAMIN C, FIBER AND MANGO FLOUR PROTEIN (MANGIFERA INDICA L.), J. BAHAN ALAM, 2, PP. 24-30, (2013); EKARIUS C., THE ESSENTIAL GUIDE TO HOBBY FARMING: THE HOW-TO MANUAL FOR CREATING A HOBBY FARM, (2015); ZUHRO M., LUTFI M., HAWA L.C., THE INFLUENCE OF IMMERSION TIME AND DRYING TEMPERATURE ON PSYCHOCHEMICAL CHARACTERISTIC OF TARO TUBER FLOUR (XANTHOSOMA SAGITTIFOLIUM), J. BIOPROSES KOMOD. TROP., 3, PP. 26-32, (2015); MORRISON J.E., PIRIE N.W., THE LARGE-SCALE PRODUCTION OF PROTEIN FROM LEAF EXTRACTS, J. SCI. FOOD AGRIC., 12, PP. 1-5, (1961); BAUTRIF E., RECENT DEVELOPMENT IN QUALITY EVALUATION. FOOD POLICY AND NUTRION DIVISION, (1990); DJAAFAR T.F., SANTOSA U., CAHYANTO M.N., RAHAYU E.S., THE EFFECT OF SOAKING AND BOILING ON PROTEIN, OLIGOSACCHARIDES, TOTAL PHENOLIC CONTENT AND ANTIOXIDANT ACTIVITY OF KERANDANG (CANAVALIA VIROSA), 32, PP. 294-300, (2012); KAJIHAUSA O.E., FASASI R.A., ATOLAGBE Y.M., EFFECT OF DIFFERENT SOAKING TIME AND BOILING ON THE PROXIMATE COMPOSITION AND FUNCTIONAL PROPERTIES OF SPROUTED SESAME SEED FLOUR, NIGER. FOOD J., 32, PP. 8-15, (2014); CHEN Y., MCGEE R., VANDEMARK G., BRICK M., THOMPSON H.J., DIETARY FIBER ANALYSIS OF FOUR PULSES USING AOAC 2011.25: IMPLICATIONS FOR HUMAN HEALTH, NUTRIENTS, 8, 12, (2016); ELE-EKOUNA J.P., PAU-ROBLOT C., COURTOIS B., COURTOIS J., CHEMICAL CHARACTERIZATION OF PECTIN FROM GREEN TEA (CAMELLIA SINENSIS), CARBOHYDR. POLYM., 83, PP. 1232-1239, (2011); GUO W., SHU Y., YANG X., TEA DIETARY FIBER IMPROVES SERUM AND HEPATIC LIPID PROFILES IN MICE FED A HIGH CHOLESTEROL DIET, PLANT FOODS HUM. NUTR., 71, PP. 145-150, (2016); CHRISTIANITA A.A.M., WIDJANARKO S.B., PURWANTININGRUM I.M., COLORED PECTIN PRODUCTION USING APPLE POMACE AND RED ROSE FILTRATE ADDITION, J. PANGAN DAN AGROINDUSTRI, 2, PP. 159-169, (2014)","","ASIAN NETWORK FOR SCIENTIFIC INFORMATION","ENGLISH","PAK. J. NUTR.","ARTICLE","ISI","2-S2.0-85048499521","PAK J NUTR",NA,"NOTREPORTED",NA,"ANGGA WA, 2018, PAK J NUTR","ANGGA WA, 2018, PAK J NUTR"
"ELSEWEIDY M;ZEIN N;ALDHAMY S;ELSAWY M;SAEID S","ELSEWEIDY, MOHAMED M (55600488100); ZEIN, NABILA (56556306000); ALDHAMY, SAMIH E (57191410067); ELSAWY, MARWA M (57191415745); SAEID, SAEID A (57191409591)","POLICOSANOL AS A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN DIABETIC HYPERLIPIDEMIC RATS",2016,"EXPERIMENTAL BIOLOGY AND MEDICINE","241","6",20,"10.1177/1535370216659943","BIOCHEMISTRY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;BIOCHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;PHARMACOGNOSY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;BIOCHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT;CHEMISTRY DEPARTMENT, FACULTY OF SCIENCE, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT","THIS WORK MAINLY AIMED TO INVESTIGATE THE PROBABLE CHANGES OF AORTIC CALCIFICATION BY POLICOSANOL, OMEGA-3 FATTY ACIDS IN COMPARISON WITH ATORVASTATIN AND SUBSEQUENT PROGRESSION OF ATHEROSCLEROSIS IN DIABETIC HYPERLIPEMIC RAT MODEL. ADULT MALE ALBINO RATS OF WISTAR STRAIN (30) WERE DIVIDED INTO FIVE GROUPS (N = 6/GROUP); ONE WAS FED NORMAL DIET AND WAS USED AS A NORMAL GROUP, THE OTHER GROUPS RECEIVED ALLOXAN, ATHEROGENIC DIET (CCT – RAT CHOW DIET SUPPLEMENTED WITH 4% CHOLESTEROL, 1% CHOLIC ACID, AND 0.5% THIOURACIL) AND CATEGORIZED AS FOLLOWS: THE SECOND GROUP RECEIVED NO TREATMENT AND KEPT AS CONTROL (DIABETIC HYPERLIPIDEMIC CONTROL GROUP (DHC)). THE OTHER GROUPS RECEIVED DAILY ORAL DOSES OF ATORVASTATIN, POLICOSANOL (10 MG/KG BODY WEIGHT) AND Ω-3 (50 MG/KG BODY WEIGHT), RESPECTIVELY, FOR EIGHT WEEKS. DIFFERENT BIOMARKERS WERE USED FOR THE EVALUATION THAT INCLUDED INFLAMMATORY (C REACTIVE PROTEIN (CRP), TUMOR NECROSIS FACTOR Α (TNF-Α)), OXIDATIVE STRESS (GLUTATHIONE (GSH), MALONDIALDEHYDE (MDA)) BONE CALCIFICATION MARKERS (ALKALINE PHOSPHATASE (ALP), VITAMIN D, PARATHYROID HORMONE (PTH)), LIPOGRAM PATTERN IN ADDITION TO HISTOCHEMICAL DEMONSTRATION OF CALCIUM IN THE AORTA. DIABETIC HYPERLIPEMIC GROUP DEMONSTRATED SIGNIFICANT HYPERGLYCEMIA, HYPERLIPIDEMIA, AND INCREASED INFLAMMATION, OXIDATIVE STRESS, CALCIFICATION, AND FINALLY ATHEROGENESIS PROGRESSION. TREATMENT OF DIABETIC HYPERLIPEMIC RATS WITH, POLICOSANOL, OMEGA-3 FATTY ACIDS (NATURAL PRODUCTS) AND ATORVASTATIN FOR EIGHT WEEKS SIGNIFICANTLY INCREASED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), VITAMIN D, DECREASED AORTIC VACUOLES NUMBER, AND INHIBITED CALCIFICATION PROCESS. POLICOSANOL INDUCED MORE REMARKABLE REDUCTION IN THE DENSITY AND NUMBER OF FOAM CELLS AND IMPROVED THE INTIMAL LESIONS OF THE AORTA AS COMPARED TO ATORVASTATIN. DRUGS UNDER STUDY EXERTED HYPOGLYCEMIC EFFECT ALONG WITH AN INHIBITION OF INFLAMMATION, OXIDATIVE STRESS, AND CALCIUM DEPOSITION WITH CERTAIN VARIATIONS BUT POLICOSANOL EFFECT WAS REMARKABLE IN COMPARISON WITH OTHER DRUGS. © 2016, © 2016 BY THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE.","AORTIC CALCIFICATION; ATORVASTATIN; DIABETIC HYPERLIPIDEMIA; INFLAMMATION; OMEGA-3 FATTY ACIDS; OXIDATIVE STRESS; POLICOSANOL","ANIMALS; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; C-REACTIVE PROTEIN; CALCIFICATION, PHYSIOLOGIC; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; HYPERLIPIDEMIAS; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CALCIFICATION; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLICOSANOL; C REACTIVE PROTEIN; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; TUMOR NECROSIS FACTOR; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; DIET; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFLAMMATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; ADVERSE EFFECTS; ANIMAL; BLOOD; BONE MINERALIZATION; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HYPERLIPIDEMIA; LIPID DIET; VASCULAR CALCIFICATION; WISTAR RAT","","","SCHMERMUND A., BAUMGART D., MOHLENKAMP S., KRIENER P., PUMP H., GRONEMEYER D., SEIBEL R., ERBEL R., NATURAL HISTORY AND TOPOGRAPHIC PATTERN OF PROGRESSION OF CORONARY CALCIFICATION IN SYMPTOMATIC PATIENTS: AN ELECTRON-BEAM CT STUDY, ARTERIOSCLER THROMB VASC BIOL, 21, PP. 421-426, (2001); SAGE A.P., TINTUT Y., DEMER L.L., REGULATORY MECHANISMS IN VASCULAR CALCIFICATION, NATURE REV CARDIOL, 7, PP. 528-536, (2010); SARIG S., WEISS T.A., KATZ I., KAHANA F., AZOURY R., OKON E., KRUTH H.S., DETECTION OF CHOLESTEROL ASSOCIATED WITH CALCIUM MINERAL USING CONFOCAL FLUORESCENCE MICROSCOPY, LAB INVESTIGAT, 71, PP. 782-787, (1994); DEMER L., TINTUT Y., THE ROLES OF LIPID OXIDATION PRODUCTS AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-ΚB SIGNALING IN ATHEROSCLEROTIC CALCIFICATION, CIRCULAT RES, 108, PP. 1482-1493, (2011); BOSTROM K., WATSON K., HORN S., WORTHAM C., HERMAN I., DEMER L., BONE MORPHOGENETIC PROTEIN EXPRESSION IN HUMAN ATHEROSCLEROTIC LESIONS, J CLIN INVESTIGAT, 91, (1993); TINTUT Y., PATEL J., PARHAMI F., DEMER L.L., TUMOR NECROSIS FACTOR-Α PROMOTES IN VITRO CALCIFICATION OF VASCULAR CELLS VIA THE CAMP PATHWAY, CIRCULATION, 102, PP. 2636-2642, (2000); AIKAWA E., NAHRENDORF M., FIGUEIREDO J.-L., SWIRSKI F.K., SHTATLAND T., KOHLER R.H., JAFFER F.A., AIKAWA M., WEISSLEDER R., OSTEOGENESIS ASSOCIATES WITH INFLAMMATION IN EARLY-STAGE ATHEROSCLEROSIS EVALUATED BY MOLECULAR IMAGING IN VIVO, CIRCULATION, 116, PP. 2841-2850, (2007); JOHNSON R.C., LEOPOLD J.A., LOSCALZO J., VASCULAR CALCIFICATION PATHOBIOLOGICAL MECHANISMS AND CLINICAL IMPLICATIONS, CIRCULAT RES, 99, PP. 1044-1059, (2006); BUDOFF M.J., YU D., NASIR K., MEHROTRA R., CHEN L., TAKASU J., AGRAWAL N., LIU S.T., BLUMENTHAL R.S., DIABETES AND PROGRESSION OF CORONARY CALCIUM UNDER THE INFLUENCE OF STATIN THERAPY, AM HEART J, 149, PP. 695-700, (2005); KIZU A., SHIOI A., JONO S., KOYAMA H., OKUNO Y., NISHIZAWA Y., STATINS INHIBIT IN VITRO CALCIFICATION OF HUMAN VASCULAR SMOOTH MUSCLE CELLS INDUCED BY INFLAMMATORY MEDIATORS, J CELL BIOCHEM, 93, PP. 1011-1019, (2004); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REV, 61, PP. 376-383, (2003); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THERAPEUT RES, 51, PP. 568-575, (1992); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THERAPEUT RES, 56, PP. 176-182, (1995); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1998); IQBAL M., KALSOOM JAFRI S.A., EFFECT OF PUNICA GRANATUM FLOWERS EXTRACT ON HYPERCHOLESTEROLEMIC AND ALLOXAN INDUCED DIABETIC RATS, GLOB J BIOTECHNOL BIOCHEM, 6, PP. 83-86, (2011); AHMED M.F., KAZIM S.M., GHORI S.S., MEHJABEEN S.S., AHMED S.R., ALI S.M., IBRAHIM M., ANTIDIABETIC ACTIVITY OF VINCA ROSEA EXTRACTS IN ALLOXAN-INDUCED DIABETIC RATS, INT J ENDOCRINOL, (2010); DESCO M.-C., ASENSI M., MARQUEZ R., MARTINEZ-VALLS J., VENTO M., PALLARDO F.V., SASTRE J., VINA J., XANTHINE OXIDASE IS INVOLVED IN FREE RADICAL PRODUCTION IN TYPE 1 DIABETES PROTECTION BY ALLOPURINOL, DIABETES, 51, PP. 1118-1124, (2002); SETHI A., PARMAR H.S., KUMAR A., THE EFFECT OF ASPIRIN ON ATHEROGENIC DIET-INDUCED DIABETES MELLITUS, BASIC CLIN PHARMACOL TOXICOL, 108, PP. 371-377, (2011); FISCHER A.H., JACOBSON K.A., ROSE J., ZELLER R., HEMATOXYLIN AND EOSIN STAINING OF TISSUE AND CELL SECTIONS, COLD SPRING HARBOR PROTOCOLS, 2008, (2008); CARSON W.P., PETERSON C.J., THE ROLE OF LITTER IN AN OLD-FIELD COMMUNITY: IMPACT OF LITTER QUANTITY IN DIFFERENT SEASONS ON PLANT SPECIES RICHNESS AND ABUNDANCE, OECOLOGIA, 85, PP. 8-13, (1990); INARKAR M.B., LELE S., EXTRACTION AND CHARACTERIZATION OF SUGARCANE PEEL WAX, ISRN AGRON, 2012, (2012); EL-SAID M., AMER M., OILS, FATS, WAXES AND SURFACTANTS. CAIRO, (1965); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MED J NUTRITION METABOL, 1, PP. 77-83, (2008); CARLING D., ZAMMIT V.A., HARDIE D.G., A COMMON BICYCLIC PROTEIN KINASE CASCADE INACTIVATES THE REGULATORY ENZYMES OF FATTY ACID AND CHOLESTEROL BIOSYNTHESIS, FEBS LETT, 223, PP. 217-222, (1987); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THERAPEUT, 318, PP. 1020-1026, (2006); MENENDEZ R., ARRUZAZABALA L., MAS R., RIO A.D., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTRITION, 77, PP. 923-932, (1997); MENENDEZ R., FERNANDEZ L., DEL RIO A., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THERAPEUT RES, 55, PP. 1084-1092, (1994); BOLEGO C., BAETTA R., BELLOSTA S., CORSINI A., PAOLETTI R., SAFETY CONSIDERATIONS FOR STATINS, CURR OPIN LIPIDOL, 13, PP. 637-644, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., MESA M., FERNANDEZ J., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R&D, 6, PP. 207-219, (2005); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1996); AL-ALY Z., SHAO S.-J., LAI C.-F., HUANG E., CAI J., BEHRMANN A., CHENG S.-L., TOWLER D.A., AORTIC MSX2-WNT CALCIFICATION CASCADE IS REGULATED BY TNF-Α-DEPENDENT SIGNALS IN DIABETIC LDLR<SUP>−/−</SUP> MICE, ARTERIOSCLER THROMB VASC BIOL, 27, PP. 2589-2596, (2007); SUN H., UNOKI H., WANG X., LIANG J., ICHIKAWA T., ARAI Y., SHIOMI M., MARCOVINA S.M., WATANABE T., FAN J., LIPOPROTEIN (A) ENHANCES ADVANCED ATHEROSCLEROSIS AND VASCULAR CALCIFICATION IN WHHL TRANSGENIC RABBITS EXPRESSING HUMAN APOLIPOPROTEIN (A), J BIOL CHEM, 277, PP. 47486-47492, (2002); MODY N., PARHAMI F., SARAFIAN T.A., DEMER L.L., OXIDATIVE STRESS MODULATES OSTEOBLASTIC DIFFERENTIATION OF VASCULAR AND BONE CELLS, FREE RADIC BIOL MED, 31, PP. 509-519, (2001); BOULETREAU P.J., WARREN S.M., SPECTOR J.A., PELED Z.M., GERRETS R.P., GREENWALD J.A., LONGAKER M.T., HYPOXIA AND VEGF UP-REGULATE BMP-2 MRNA AND PROTEIN EXPRESSION IN MICROVASCULAR ENDOTHELIAL CELLS: IMPLICATIONS FOR FRACTURE HEALING, PLAST RECONSTRUCT SURG, 109, PP. 2384-2397, (2002); COLA C., ALMEIDA M., LI D., ROMEO F., MEHTA J.L., REGULATORY ROLE OF ENDOTHELIUM IN THE EXPRESSION OF GENES AFFECTING ARTERIAL CALCIFICATION, BIOCHEM BIOPHYS RES COMMUN, 320, PP. 424-427, (2004); DELANAYE P., CAVALIER E., VASCULAR CALCIFICATIONS IN DIALYSIS PATIENTS, IN NEPHROLOGY, (2010); JURUTKA P.W., WHITFIELD G.K., HSIEH J.-C., THOMPSON P.D., HAUSSLER C.A., HAUSSLER M.R., MOLECULAR NATURE OF THE VITAMIN D RECEPTOR AND ITS ROLE IN REGULATION OF GENE EXPRESSION, REV ENDOCR METAB DISORD, 2, PP. 203-216, (2001); BROWN E., THE CALCIUM-SENSING RECEPTOR: PHYSIOLOGY, PATHOPHYSIOLOGY AND CAR-BASED THERAPEUTICS, CALCIUM SIGNALLING AND DISEASE, PP. 139-167, (2008); GRUSON D., BUGLIONI A., BURNETT J., PTH: POTENTIAL ROLE IN MANAGEMENT OF HEART FAILURE, CLIN CHIM ACTA, 433, PP. 290-296, (2014); TOMASCHITZ A., RITZ E., PIESKE B., FAHRLEITNER-PAMMER A., KIENREICH K., HORINA J.H., DRECHSLER C., MARZ W., OFNER M., PIEBER T.R., ALDOSTERONE AND PARATHYROID HORMONE: A PRECARIOUS COUPLE FOR CARDIOVASCULAR DISEASE, CARDIOVASC RES, 94, PP. 10-19, (2012); ZHOU G., MYERS R., LI Y., CHEN Y., SHEN X., FENYK-MELODY J., WU M., VENTRE J., DOEBBER T., FUJII N., ROLE OF AMP-ACTIVATED PROTEIN KINASE IN MECHANISM OF METFORMIN ACTION, J CLIN INVESTIGAT, 108, (2001); SHAW R.J., LAMIA K.A., VASQUEZ D., KOO S.-H., BARDEESY N., DEPINHO R.A., MONTMINY M., CANTLEY L.C., THE KINASE LKB1 MEDIATES GLUCOSE HOMEOSTASIS IN LIVER AND THERAPEUTIC EFFECTS OF METFORMIN, SCIENCE, 310, PP. 1642-1646, (2005)","M.M. ELSEWEIDY; BIOCHEMISTRY DEPARTMENT, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT; EMAIL: MMELSEWEIDY@YAHOO.COM","SAGE PUBLICATIONS INC.","ENGLISH","EXP. BIOL. MED.","ARTICLE","ISI","2-S2.0-84989833257","EXP BIOL MED","ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY;ZAGAZIG UNIVERSITY","NOTREPORTED;ZAGAZIG UNIVERSITY;NOTREPORTED",NA,"ELSEWEIDY MM, 2016, EXP BIOL MED","ELSEWEIDY MM, 2016, EXP BIOL MED"
"RAMOS-ZAMBRANO E;HERRERA-SERRANO P;GARCÍA-DÁVILA J;RÍOS-CORTÉS G;JIMÉNEZ-APARICIO A;MARTÍNEZ-AYALA A;PARASKEVA C","RAMOS-ZAMBRANO, EMILIA (57207244202); HERRERA-SERRANO, PEDRO (57207251548); GARCÍA-DÁVILA, JORGE (56298439500); RÍOS-CORTÉS, GABRIEL (57207259770); JIMÉNEZ-APARICIO, ANTONIO RUPERTO (6603471518); MARTÍNEZ-AYALA, ALMA LETICIA (55989766600); PARASKEVA, CHRISTAKIS (7005526738)","COCHINEAL WAXY RESIDUES AS SOURCE OF POLICOSANOL CHEMICAL HYDROLYSIS AND ENZYMATIC TRANSESTERIFICATION",2019,"JOURNAL OF CHEMISTRY","2019","",1,"10.1155/2019/4547378","INSTITUTO POLITÉCNICO NACIONAL, CENTRO DE DESARROLLO DE PRODUCTOS BIÓTICOS, CARRETERA YAUTEPEC-JOJUTLA, KM. 6, CALLE CEPROBI NO. 8, YAUTEPEC, MORELOS, 62731, MEXICO;INSTITUTO POLITÉCNICO NACIONAL, CENTRO DE DESARROLLO DE PRODUCTOS BIÓTICOS, CARRETERA YAUTEPEC-JOJUTLA, KM. 6, CALLE CEPROBI NO. 8, YAUTEPEC, MORELOS, 62731, MEXICO;UNIVERSIDAD POLITÉCNICA DE TLAXCALA, AV. UNIVERSIDAD POLITÉCNICA NO. 1, TEPEYANCO, TLAXCALA, 90180, MEXICO;INSTITUTO TECNOLÓGICO DE ORIZABA, AVENIDA ORIENTE 9 NO. 852, COLONIA EMILIANO ZAPATA, VERACRUZ, 94320, MEXICO;INSTITUTO POLITÉCNICO NACIONAL, CENTRO DE DESARROLLO DE PRODUCTOS BIÓTICOS, CARRETERA YAUTEPEC-JOJUTLA, KM. 6, CALLE CEPROBI NO. 8, YAUTEPEC, MORELOS, 62731, MEXICO;INSTITUTO POLITÉCNICO NACIONAL, CENTRO DE DESARROLLO DE PRODUCTOS BIÓTICOS, CARRETERA YAUTEPEC-JOJUTLA, KM. 6, CALLE CEPROBI NO. 8, YAUTEPEC, MORELOS, 62731, MEXICO; PARASKEVA C.","THE AIM OF THIS STUDY WAS TO OBTAIN AND CHARACTERISE THE LONG-CHAIN ALCOHOLS PRESENT IN POLICOSANOL DERIVED FROM WASTE FROM THE PRODUCTION OF CARMINIC ACID, A NATURAL COLOURING AGENT WIDELY USED IN THE FOOD INDUSTRY. THE EFFECTIVENESS OF DIFFERENT METHODS DESIGNED FOR EXTRACTION OF POLICOSANOL FROM WAXY WASTE WAS INVESTIGATED AND ITS CONTENT AND COMPOSITION WAS DETERMINED. TRIACONTANOL WAS THE MAIN COMPONENT IN POLICOSANOL PRODUCED BY CHEMICAL PROCESSES, AND IT YIELDS UP TO 13% BY ALKALINE HYDROLYSIS IN WATER AND CHLOROFORM EXTRACTION. REGARDING ENZYMATIC TRANSESTERIFICATION, POLICOSANOL WAS OBTAINED USING LIPASE CANDIDA ANTARCTICA RECOMBINANT IN ASPERGILLUS NIGER (CAL-BN) IN A REACTION MEDIUM WITH TOLUENE. TO IMPROVE THE REACTION, DIFFERENT ACYL RECEPTORS, PROPANOL, BUTANOL, AND ISOPROPANOL, WERE TESTED AND MOLECULAR SIEVES WERE EMPLOYED TO MAINTAIN AN ANHYDROUS REACTION MEDIUM. IN THIS CASE, THE POLICOSANOL WAS MADE UP OF OTHER LONG-CHAIN ALCOHOLS, BUT TRIACONTANOL WAS OBTAINED IN YIELDS OF UP TO 19% USING ISOPROPANOL AS AN ACYL RECEPTOR. TRIACONTANOL HAS A GREAT COMMERCIAL VALUE DUE TO ITS EFFECT AS A PROMOTER OF PLANT GROWTH, AND THESE RESULTS CONTRIBUTE TO THE USE AND APPLICATION OF THIS AGROINDUSTRIAL WASTE IN OBTAINING VALUE-ADDED PRODUCTS. © 2019 EMILIA RAMOS-ZAMBRANO ET AL.","","","INSTITUTO POLITÉCNICO NACIONAL, IPN; CONSEJO NACIONAL DE CIENCIA Y TECNOLOGÍA, CONACYT","WE ACKNOWLEDGE THE CONSEJO NACIONAL DE CIENCIA Y TECNOLOGÍA (CONACYT) AND INSTITUTO POLITÉCNICO NACIONAL (IPN) FOR THE SCHOLARSHIPS DURING THE COURSE OF THIS INVESTIGATION AND THE IPN FOR FINANCIAL SUPPORT FOR THE RESEARCH. MARTÍNEZ-AYALA A.L. AND ANTONIO R. JIMENEZ-APARICIO ARE FELLOWS OF COFAA AND EDI-IPN.","CHIBNALL A.C., LATNER A.L., WILLIAMS E.F., AYRE C.A., 0E CONSTITUTION OF COCCERIN, BIOCHEMICAL JOURNAL, 28, 1, PP. 313-325, (1934); HENDRICKSON C., MERKLE D., METHOD FOR HARVESTING COCHINEAL WAX FROM COCHINEAL INSECTS GROWN ON AN ARTIFICIAL MEDIUM, (2013); MENDEZ E., BLANCO M., LAGUNA A., GARCA E., ISOLATION AND CHARACTERIZATION OF A MIXTURE OF HIGHER PRIMARY ALCOHOLS OF HIGH MOLECULAR WEIGHT FROM HENEQUEN (AGAVE FURCROYDES L.) WAX, REVISTA CENIC CIENCIAS QUMICAS, 34, 1, PP. 35-38, (2003); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 14, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, 15, PP. 5359-5362, (2006); CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, 23, PP. 12143-12148, (2010); KAEWKOOL P., KRISNANGKURA K., TRANSESTERIFICATION/ ACETYLATION OF LONG CHAIN ALCOHOLS WITH ALKYL ACETATE, CHEMISTRY AND PHYSICS OF LIPIDS, 163, 7, PP. 685-688, (2010); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, EROMBOSIS RESEARCH, 69, 3, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 58, 1, PP. 61-64, (1998); MENENDEZ R., FRAGA V., AMOR A.M., GONZALES R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOLOGY & BEHAVIOR, 67, 1, PP. 1-7, (1994); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, 11, PP. 376-383, (2003); NAEEM M., KHAN M.M.A., MOINUDDIN K., TRIACONTANOL: A POTENT PLANT GROWTH REGULATOR IN AGRICULTURE, JOURNAL OF PLANT INTERACTIONS, 7, 2, PP. 129-142, (2012); MAGRANER H.J., LAGUNA G.A., MAS F.R., ET AL., NATURAL MIXTURE COMPOSED OF HIGHER PRIMARY ALIPHATIC ALCOHOLS OBTAINED FROM BEE WAX FOR THE TREATMENT OF GASTRIC AND DUODENAL ULCERS THAT ALSO PRESENT ANTI-INFLAMMATORY ACTIVITY, (2001); JIA Q., ZHAO J.-F., POLYCOSANOLS FROM ERICERUS PELA WAX, (2006); WANG M.-F., LIAN H.-Z., MAO L., ET AL., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 14, PP. 5552-5558, (2007); MA J., MA L., ZHANG H., ET AL., POLICOSANOL FABRICATION FROM INSECT WAX AND OPTIMIZATION BY RESPONSE SURFACE METHODOLOGY, PLOS ONE, 13, 5, (2018); FUKUDA H., KONDO A., NODA H., BIODIESEL FUEL PRODUCTION BY TRANSESTERIFICATION OF OILS, JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 92, 5, PP. 405-416, (2001); SYAKIRAH N., SULAIMAN S., OVERVIEW OF CATALYSTS IN BIODIESEL PRODUCTION, ARPN JOURNAL OF ENGINEERING AND APPLIED SCIENCES, 11, 1, PP. 439-448, (2016); TRODLER P., PLEISS J., MODELING STRUCTURE AND FLEXIBILITY OF CANDIDA ANTARCTICA LIPASE B IN ORGANIC SOLVENTS, BMC STRUCTURAL BIOLOGY, 8, 1, (2008); NUNES G.S., MARTY J.L., IMMOBILIZATION OF ENZYMES ON ELECTRODES, METHODS IN BIOTECHNOLOGY: IMMOBILIZATION OF ENZYMES AND CELLS, PP. 239-251, (2006); GROSOVA Z., ROSENBERG M., REBROS M., PERSPECTIVES AND APPLICATIONS OF IMMOBILISED Β-GALACTOSIDASE IN FOOD INDUSTRY-A REVIEW, CZECH JOURNAL OF FOOD SCIENCES, 26, 1, PP. 1-14, (2008); CHOWDARY G.V., PRAPULLA S.G., 0E INFLUENCE OF WATER ACTIVITY ON THE LIPASE CATALYZED SYNTHESIS OF BUTYL BUTYRATE BY TRANSESTERIFICATION, PROCESS BIOCHEMISTRY, 38, 3, PP. 393-397, (2002); NOUREDDINI H., GAO X., PHILKANA R.S., IMMOBILIZED PSEUDOMONAS CEPACIA LIPASE FOR BIODIESEL FUEL PRODUCTION FROM SOYBEAN OIL, BIORESOURCE TECHNOLOGY, 96, 7, PP. 769-777, (2005); HSU A.-F., JONES K., FOGLIA T.A., MARMER W.N., IMMOBILIZED LIPASE-CATALYSED PRODUCTION OF ALKYL ESTERS OF RESTAURANT GREASE AS BIODIESEL, BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 36, 3, PP. 181-186, (2002); SERDAKOWSKI A.L., DORDICK J.S., ENZYME ACTIVATION FOR ORGANIC SOLVENTS MADE EASY, TRENDS IN BIOTECHNOLOGY, 26, 1, PP. 48-54, (2008); BYRNE F.P., JIN S., PAGGIOLA G., ET AL., TOOLS AND TECHNIQUES FOR SOLVENT SELECTION: GREEN SOLVENT SELECTION GUIDES, SUSTAINABLE CHEMICAL PROCESSES, 4, 1, (2016); MASS SPECTRAL LIBRARY. MASS SPECTRAL LIBRARY WITH SEARCH PROGRAM (DATA VERSION: NIST 05, (2000); SRIVASTAVA N., KHATOON S., RAWAT A.K.S., RAI V., MEHROTRA S., CHROMATOGRAPHIC ESTIMATION OF P-COUMARIC ACID AND TRIACONTANOL IN AN AYURVEDIC ROOT DRUG PATALA (STEREOSPERMUM SUAVEOLENS ROXB.), JOURNAL OF CHROMATOGRAPHIC SCIENCE, 47, 10, PP. 936-939, (2009); MATTE C., BORDINHAO C., POPPE J., ET AL., PHYSICAL-CHEMICAL PROPERTIES OF THE SUPPORT IMMOBEAD 150 BEFORE AND AFTER THE IMMOBILIZATION PROCESS OF LIPASE, JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, 28, 8, PP. 1430-1439, (2017); CHEN B., HU J., MILLER E.M., XIE W., CAI M., GROSS R.A., CANDIDA ANTARCTICALIPASE B CHEMICALLY IMMOBILIZED ON EPOXY-ACTIVATED MICRO-AND NANOBEADS: CATALYSTS FOR POLYESTER SYNTHESIS, BIOMACROMOLECULES, 9, 2, PP. 463-471, (2008); POOJARI Y., CLARSON S.J., 0ERMAL STABILITY OF CANDIDA ANTARCTICA LIPASE B IMMOBILIZED ON MACROPOROUS ACRYLIC RESIN PARTICLES IN ORGANIC MEDIA, BIOCATALYSIS AND AGRICULTURAL BIOTECHNOLOGY, 2, 1, PP. 7-11, (2013); BLANCO R., TERREROS P., FERNANDEZ M., OTERO C., DAZ G., FUNCTIONALIZATION OF MESOPOROUS SILICA FOR LIPASE IMMOBILIZATION CHARACTERIZATION OF THE SUPPORT AND THE CATALYSTS, JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC, 30, 2, PP. 83-93, (2004); LI Y., GAO F., WEI W., QU J.-B., MA G.-H., ZHOU W.-Q., PORE SIZE OF MACROPOROUS POLYSTYRENE MICROSPHERES AFFECTS LIPASE IMMOBILIZATION, JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC, 66, 1-2, PP. 182-189, (2010); OGNJANOVIC N., SAPONJIC S., BEZBRADICA D., KNEZEVIC Z., LIPASE-CATALYZED BIODIESEL SYNTHESIS WITH DIFFERENT ACYL ACCEPTORS, ACTA PERIODICA TECHNOLOGICA, 39, PP. 161-169, (2008); NIE K., XIE F., WANG F., TAN T., LIPASE CATALYZED METHANOLYSIS TO PRODUCE BIODIESEL: OPTIMIZATION OF THE BIODIESEL PRODUCTION, JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC, 43, 1-4, PP. 142-147, (2006); AZOCAR L., NAVIA R., BEROIZ L., JEISON D., CIUDAD G., ENZYMATIC BIODIESEL PRODUCTION KINETICS USING CO-SOLVENT AND AN ANHYDROUS MEDIUM: A STRATEGY TO IMPROVE LIPASE PERFORMANCE IN A SEMI-CONTINUOUS REACTOR, NEW BIOTECHNOLOGY, 31, 5, PP. 422-429, (2014); NELSON L.A., FOGLIA T.A., MARMER W.N., LIPASECATALYZED PRODUCTION OF BIODIESEL, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 73, 9, PP. 1191-1195, (1996); KUMAR A., DHAR K., KANWAR S.S., ARORA P.K., LIPASE CATALYSIS IN ORGANIC SOLVENTS: ADVANTAGES AND APPLICATIONS, BIOLOGICAL PROCEDURES ONLINE, 18, 1, (2016); KIM J., CLARK D.S., DORDICK J.S., INTRINSIC EFFECTS OF SOLVENT POLARITY ON ENZYMIC ACTIVATION ENERGIES, BIOTECHNOLOGY AND BIOENGINEERING, 67, 1, PP. 112-116, (2000); KUMARI A., MAHAPATRA P., GARLAPATI V., BANERJEE R., ENZYMATIC TRANSESTERIFICATION OF JATROPHA OIL, BIOTECHNOLOGY FOR BIOFUELS, 2, 1, PP. 1-7, (2009); SINGH A.K., FERNANDO S.D., HERNANDEZ R., BASECATALYZED FAST TRANSESTERIFICATION OF SOYBEAN OIL USING ULTRASONICATION, ENERGY & FUELS, 21, 2, (2007); WANG J., HUANG Q.D., HUANG F.H., WANG J.W., HUANG Q.J., LIPASE-CATALYZED PRODUCTION OF BIODIESEL FROM HIGH ACID VALUE WASTE OIL USING ULTRASONIC ASSISTANT, CHINESE JOURNAL OF BIOTECHNOLOGY, 23, 6, PP. 1121-1128, (2007); VYAS A.P., VERMA J.L., SUBRAHMANYAM N., EFFECTS OF MOLAR RATIO, ALKALI CATALYST CONCENTRATION AND TEMPERATURE ON TRANSESTERIFICATION OF JATROPHA OIL WITH METHANOL UNDER ULTRASONIC IRRADIATION, ADVANCES IN CHEMICAL ENGINEERING AND SCIENCE, 1, 2, PP. 45-50, (2011); AZOCAR L., CIUDAD G., HEIPIEPER H.J., MUNOZ R., NAVIA R., LIPASE-CATALYZED PROCESS IN AN ANHYDROUS MEDIUM WITH ENZYME REUTILIZATION TO PRODUCE BIODIESEL WITH LOW ACID VALUE, JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 112, 6, PP. 583-589, (2011); JONES J., WERT V., RIES S., SPECIFICITY OF 1-TRIACONTANOL AS A PLANT GROWTH STIMULATOR AND INHIBITION OF ITS EFFECT BY OTHER LONG-CHAIN COMPOUNDS, PLANTA, 144, 3, PP. 277-282, (1979); RIES S.K., WERT V.F., RAPID ELICITATION OF SECOND MESSENGERS BY NANOMOLAR DOSES OF TRIACONTANOL AND OCTACOSANOL, PLANTA, 173, 1, PP. 79-87, (1988)","A.L. MARTÍNEZ-AYALA; INSTITUTO POLITÉCNICO NACIONAL, CENTRO DE DESARROLLO DE PRODUCTOS BIÓTICOS, YAUTEPEC, MORELOS, CARRETERA YAUTEPEC-JOJUTLA, KM. 6, CALLE CEPROBI NO. 8, 62731, MEXICO; EMAIL: ALAYALA@IPN.MX","HINDAWI LIMITED","ENGLISH","J. CHEM.","ARTICLE","ISI","2-S2.0-85062329060","J CHEM","INSTITUTO POLITÉCNICO NACIONAL;INSTITUTO POLITÉCNICO NACIONAL;UNIVERSIDAD POLITÉCNICA DE TLAXCALA;INSTITUTO TECNOLÓGICO DE ORIZABA;INSTITUTO POLITÉCNICO NACIONAL;INSTITUTO POLITÉCNICO NACIONAL","NOTREPORTED;INSTITUTO POLITÉCNICO NACIONAL;NOTREPORTED",NA,"RAMOS-ZAMBRANO E, 2019, J CHEM","RAMOS-ZAMBRANO E, 2019, J CHEM"
"AWAD K;PENSON P;BANACH M","AWAD, KAMAL (57191608451); PENSON, PETER (6506734112); BANACH, MACIEJ (22936699500)","D003 SACCHARUM OFFICINARUM THE FORGOTTEN LIPIDLOWERING AGENT",2016,"PHARMACOLOGICAL RESEARCH","114","4",5,"10.1016/j.phrs.2016.10.008","FACULTY OF MEDICINE, ZAGAZIG UNIVERSITY, EGYPT, STUDENT RESEARCH UNIT (SRU), ZAGAZIG UNIVERSITY, EGYPT;SCHOOL OF PHARMACY AND BIOMOLECULAR SCIENCES, LIVERPOOL JOHN MOORES UNIVERSITY, LIVERPOOL, UNITED KINGDOM;HEAD DEPARTMENT OF HYPERTENSION, WAM UNIVERSITY HOSPITAL IN LODZ, MEDICAL UNIVERSITY OF LODZ, ZEROMSKIEGO 113, LODZ, 90-549, POLAND, POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE, LODZ, POLAND","REDUCTION OF ELEVATED CHOLESTEROL LEVELS, PARTICULARLY LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), IS ESSENTIAL IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE (CVD). THEREFORE THERE IS STILL A LARGE NEED FOR NEW EFFECTIVE DRUGS, WHICH WOULD BE ABLE TO ESSENTIALLY REDUCE LDL-C AND IN THE CONSEQUENCE CV RESIDUAL RISK. D-003 IS A MIXTURE OF HIGH ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGARCANE (SACCHARUM OFFICINARUM) WAX. IT SHOWED PROMISING HYPOCHOLESTEROLEMIC EFFECTS IN BOTH ANIMAL AND HUMAN STUDIES; IT SIGNIFICANTLY LOWERS BOTH SERUM TOTAL CHOLESTEROL (TC) AND LDL-C, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C). IN ADDITION, IT SHOWED A FAVORABLE SAFETY PROFILE. IN THIS REVIEW, WE EVALUATED THE PROFILE OF D-003 AS A LIPID-LOWERING AGENT BASED ON DATA FROM AVAILABLE PRECLINICAL AND CLINICAL STUDIES. © 2016 ELSEVIER LTD","CARDIOVASCULAR DISEASES; CHOLESTEROL; FATTY ACIDS; HYPERCHOLESTEROLEMIA; LDL; SACCHARUM","ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FATTY ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; SACCHARUM; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; D 003; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CHOLESTEROL; D-003 SUGARCANE WAX ACID MIXTURE; FATTY ACID; HYPOCHOLESTEROLEMIC AGENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIC ACTIVITY; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHARUM OFFICINARUM; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; HYPERCHOLESTEROLEMIA; METABOLISM; SUGARCANE","","","BARQUERA S., PEDROZA-TOBIAS A., MEDINA C., HERNANDEZ-BARRERA L., BIBBINS-DOMINGO K., LOZANO R., MORAN A.E., GLOBAL OVERVIEW OF THE EPIDEMIOLOGY OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, ARCH. MED. RES., 46, PP. 328-338, (2015); COLANTONIO L.D., BITTNER V., REYNOLDS K., LEVITAN E.B., ROSENSON R.S., BANACH M., KENT S.T., DEROSE S.F., ZHOU H., SAFFORD M.M., MUNTNER P., ASSOCIATION OF SERUM LIPIDS AND CORONARY HEART DISEASE IN CONTEMPORARY OBSERVATIONAL STUDIES, CIRCULATION, 133, 3, PP. 256-264, (2016); BANACH M., SERBAN C., SAHEBKAR A., MIKHAILIDIS D.P., URSONIU S., RAY K.K., RYSZ J., TOTH P.P., MUNTNER P., MOSTEORU S., GARCIA-GARCIA H.M., HOVINGH G.K., KASTELEIN J.J., SERRUYS P.W., LIPID AND BLOOD PRESSURE META-ANALYSIS COLLABORATION (LBPMC) GROUP. IMPACT OF STATIN THERAPY ON CORONARY PLAQUE COMPOSITION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF VIRTUAL HISTOLOGY INTRAVASCULAR ULTRASOUND STUDIES, BMC MED., 13, (2015); HOBBS F.D., BANACH M., MIKHAILIDIS D.P., MALHOTRA A., CAPEWELL S., IS STATIN-MODIFIED REDUCTION IN LIPIDS THE MOST IMPORTANT PREVENTIVE THERAPY FOR CARDIOVASCULAR DISEASE? A PRO/CON DEBATE, BMC MED., 14, (2016); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., BROWN L., WARNICA J.W., ARNOLD J.M.O., WUN C.-C., DAVIS B.R., BRAUNWALD E., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, PP. 1001-1009, (1996); PEDERSEN T.R., OLSSON A.G., FAERGEMAN O., KJEKSHUS J., WEDEL H., BERG K., WILHELMSEN L., HAGHFELT T., THORGEIRSSON G., PYORALA K., MIETTINEN T., CHRISTOPHERSEN B., TOBERT J.A., MUSLINER T.A., COOK T.J., LIPOPROTEIN CHANGES AND REDUCTION IN THE INCIDENCE OF MAJOR CORONARY HEART DISEASE EVENTS IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), CIRCULATION, 97, PP. 1453-1460, (1998); BANACH M., ARONOW W.S., SERBAN M.C., RYSZ J., VORONEANU L., COVIC A., LIPIDS, BLOOD PRESSURE AND KIDNEY UPDATE 2015, LIPIDS HEALTH DIS., 14, (2015); CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATION, BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., BHALA N., PETO R., BARNES E.H., KEECH A., SIMES J., COLLINS R., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); GNANARAJ R., APPLICATIONS OF SUGARCANE WAX AND IT'S PRODUCTS: A REVIEW, INT. J. CHEMTECH RES., 4, PP. 705-712, (2012); ANTOLIN E.M., MARRERO DELANGE D., GONZALEZ CANAVACIOLO V., TEJEDA DIAZ Y., SIERRA PEREZ R., CORA MEDINA M., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ACIDS THAT COMPOSE D003 IN 10 MG FILM-COATED TABLETS, FARM. (SOCIETÀ CHIM. ITAL. 1989), 59, PP. 543-547, (2004); DRUGS R.D., 3, (2002); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL. RES., 44, PP. 299-304, (2001); ALEXANDRE H., MATHIEU B., CHARPENTIER C., ALTERATION IN MEMBRANE FLUIDITY AND LIPID COMPOSITION, AND MODULATION OF H(+)-ATPASE ACTIVITY IN SACCHAROMYCES CEREVISIAE CAUSED BY DECANOIC ACID, MICROBIOLOGY, PP. 469-475, (1996); LAU W.F., DAS N.P., IN VITRO MODULATION OF RAT ADIPOCYTE GHOST MEMBRANE FLUIDITY BY CHOLESTEROL OXYSTEROLS, EXPERIENTIA, 51, PP. 731-737, (1995); WHITCOMB R.W., LINEHAN W.M., KNAZEK R.A., EFFECTS OF LONG-CHAIN, SATURATED FATTY ACIDS ON MEMBRANE MICROVISCOSITY AND ADRENOCORTICOTROPIN RESPONSIVENESS OF HUMAN ADRENOCORTICAL CELLS IN VITRO, J. CLIN. INVEST., 81, PP. 185-188, (1988); BOROCHOV H., ZAHLER P., WILBRANDT W., SHINITZKY M., THE EFFECT OF PHOSPHATIDYLCHOLINE TO SPHINGOMYELIN MOLE RATIO ON THE DYNAMIC PROPERTIES OF SHEEP ERYTHROCYTE MEMBRANE, BIOCHIM. BIOPHYS. ACTA-BIOMEMBR., 470, PP. 382-388, (1977); DAVIS P.J., POZNANSKY M.J., MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE BY CHANGES IN MICROSOMAL CHOLESTEROL CONTENT OR PHOSPHOLIPID COMPOSITION, PROC. NATL. ACAD. SCI. U. S. A., 84, PP. 118-121, (1987); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, PP. 425-430, (1990); MENENDEZ R., MAS R., PEREZ J., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN FATTY ACIDS PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CAN. J. PHYSIOL. PHARMACOL., 82, PP. 22-29, (2004); GAMEZ R., MENDOZA S., MAS R., MESA R., CASTANO G., RODRIGUEZ B., MARRERO D., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR. THER. RES., 61, PP. 460-468, (2000); GAMEZ R., MENDOZA S., MAS R., NOA M., ARRUZAZABALA L., CARBAJAL D., CASTANO G., GOICOCHEA E., MESA M., MENDOZA N., COMPARISON OF THE CHOLESTEROL-LOWERING EFFECTS AND TOXICITY OF D-003 AND LOVASTATIN IN NORMOCHOLESTEROLAEMIC RABBITS, DRUGS R.D., 4, PP. 219-229, (2003); MENDOZA S., GAMEZ R., MAS R., GOICOCHEA E., EFFECTS OF D-003 A MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ACIDS, FLUVASTATIN AND THE COMBINED THERAPY OF D-003 PLUS FLUVASTATIN ON THE LIPID PROFILE OF NORMOCHOLESTEROLEMIC RABBITS, INT. J. TISSUE REACT., 25, PP. 81-89, (2003); MENDOZA S., GAMEZ R., NOA M., MAS R., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR. THER., (2001); CASTANO G., MAS R., FERNANDEZ L., LOPEZ E., GUTIERREZ J.A., ILLNAIT J., FERNANDEZ J.C., GAMEZ R., ALVAREZ E., ASSESSMENT OF THE EFFECTS OF D-003 A NEW ANTIPLATELET AND LIPID-LOWERING COMPOUND, IN HEALTHY VOLUNTEERS. A PHASE I CLINICAL STUDY, DRUGS R.D., 3, PP. 337-348, (2002); CASTANO G., MENENDEZ R., MAS R., LEDON N., EFFECTS OF D-003, A NEW HYPOCHOLESTEROLAEMIC AND ANTIPLATELET COMPOUND, ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY VOLUNTEERS, CLIN. DRUG INVESTIG., 23, PP. 193-203, (2003); MOLINA V., CARBAJAL D., ARRUZAZABALA L., MAS R., EFFECT OF D-003 ON INTRAVASCULAR PLATELET AGGREGATION INDUCED WITH COLLAGEN IN RATS, J. MED. FOOD, 8, PP. 232-236, (2005); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., FERNANDEZ L., MAS R., CASTANO G., ILLNAIT J., MENDOZA S., FERNANDEZ J., EFFECTS OF D-003 A MIXTURE OF VERY LONG CHAIN FATTY ACIDS PURIFIED FROM SUGAR CANE WAX, AT 5 AND 10 MG/DAY ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES., 25, PP. 29-39, (2005); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., FERNANDEZ L., ILLNAIT J., CASTANO G., FERNANDEZ J., MENDOZA S., EFFECTS OF D-003 A NEW SUBSTANCE PURIFIED FROM SUGAR CANE WAX, ON PLATELET AGGREGATION AND PLASMA LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES., 24, PP. 55-63, (2004); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., MAS R., D-003 AND WARFARIN INTERACTION ON THE BLEEDING TIME AND VENOUS THROMBOSIS EXPERIMENTALLY INDUCED IN RATS, J. MED. FOOD, 7, PP. 260-263, (2004); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., D-003, A POTENTIAL ANTITHROMBOTIC COMPOUND ISOLATED FROM SUGAR CANE WAX WITH EFFECTS ON ARACHIDONIC ACID METABOLITES, PROSTAGLANDINS LEUKOT. ESSENT. FAT. ACIDS, 67, PP. 19-24, (2002); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., VALDES S., ANTIPLATELET AND ANTITHROMBOTIC EFFECT OF D-003, PHARMACOL. RES., 42, PP. 137-143, (2000); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ J., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CAN. J. PHYSIOL. PHARMACOL., 80, PP. 13-21, (2002); PEREZ Y., MAS R., GONZALEZ R.M., JIMENEZ S., MOLINA V., EFFECTS OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, AND POLICOSANOL ON IN VIVO LIPID PEROXIDATION IN RATS, ARZNEIMITTELFORSCHUNG, 58, PP. 126-130, (2008); DE M., ARRUZAZABALA L., CARBAJAL D., MAS R., EFFECTS OF D-003, A NEW COMPOUND PURIFIED FROM SUGARCANE WAX, ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS: A RANDOMISED, DOUBLE-BLIND CLINICAL STUDY, CLIN. DRUG INVESTIG., 23, PP. 107-118, (2003); PEREZ Y., MENENDEZ R., FERRER J.I., LOPEZ E., CASTANO G., FERNANDEZ J., FERREIRO R.M., FERNANDEZ L., MENDOZA S., GONZALEZ R., MESA M., EFFECTS OF D-003, A MIXTURE OF HIGH-MOLECULAR-WEIGHT SUGAR CANE WAX ACIDS, ON LIPID PEROXIDATION MARKERS IN OLDER INDIVIDUALS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR. THER. RES. CLIN. EXP., 69, PP. 36-48, (2008); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., LOPEZ E., GAMEZ R., MENDOZA S., FERNANDEZ J., MESA M., EFFECTS OF D-003 ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA: A PHASE II CLINICAL STUDY, CLIN. DRUG INVESTIG., 23, PP. 789-802, (2003); DE M., ARRUZAZABALA L., MOLINA V., LOPEZ E., CASTANO G., FERNANDEZ L., CARBAJAL D., MAS R., FERRER J.I., MENDOZA S., RAMIREZ Y., EFFECTS OF D-003 A MIXTURE OF SUGARCANE WAX ACIDS, ON PLATELET AGGREGATION IN HYPERCHOLESTEROLEMIC PATIENTS. A DOSE-TITRATION, RANDOMISED, PLACEBO-CONTROLLED TRIAL, ARZNEIMITTELFORSCHUNG, 58, PP. 376-384, (2008); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY., DRUGS EXP, CLIN. RES., 31, PP. 31-44, (2005)","M. BANACH; HEAD DEPARTMENT OF HYPERTENSION, WAM UNIVERSITY HOSPITAL IN LODZ, MEDICAL UNIVERSITY OF LODZ, LODZ, ZEROMSKIEGO 113, 90-549, POLAND; EMAIL: MACIEJBANACH@AOL.CO.UK","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","REVIEW","ISI","2-S2.0-84992107995","PHARMACOL RES","ZAGAZIG UNIVERSITY;LIVERPOOL JOHN MOORES UNIVERSITY;WAM UNIVERSITY HOSPITAL IN LODZ","NOTREPORTED;WAM UNIVERSITY HOSPITAL IN LODZ;NOTREPORTED",NA,"AWAD K, 2016, PHARMACOL RES","AWAD K, 2016, PHARMACOL RES"
"TRIMARCO V;BATTISTONI A;TOCCI G;COLUCCIA R;MANZI M;IZZO R;VOLPE M","TRIMARCO, V. (6602355473); BATTISTONI, A. (36464853500); TOCCI, G. (6701829557); COLUCCIA, R. (34874767300); MANZI, M.V. (55484916200); IZZO, R. (7004640234); VOLPE, M. (7102295300)","SINGLE BLIND MULTICENTRE RANDOMIZED CONTROLLED TRIAL TESTING THE EFFECTS OF A NOVEL NUTRACEUTICAL COMPOUND ON PLASMA LIPID AND CARDIOVASCULAR RISK FACTORS RESULTS OF THE INTERIM ANALYSIS",2017,"NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES","27","7",11,"10.1016/j.numecd.2017.08.003","HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DIVISION OF CARDIOLOGY, DEPARTMENT OF CLINICAL AND MOLECULAR MEDICINE, FACULTY OF MEDICINE AND PSYCHOLOGY, UNIVERSITY OF ROME SAPIENZA, SANT'ANDREA HOSPITAL, ROME, ITALY;DIVISION OF CARDIOLOGY, DEPARTMENT OF CLINICAL AND MOLECULAR MEDICINE, FACULTY OF MEDICINE AND PSYCHOLOGY, UNIVERSITY OF ROME SAPIENZA, SANT'ANDREA HOSPITAL, ROME, ITALY, IRCCS NEUROMED, POZZILLI, IS, ITALY;IRCCS NEUROMED, POZZILLI, IS, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY;DIVISION OF CARDIOLOGY, DEPARTMENT OF CLINICAL AND MOLECULAR MEDICINE, FACULTY OF MEDICINE AND PSYCHOLOGY, UNIVERSITY OF ROME SAPIENZA, SANT'ANDREA HOSPITAL, ROME, ITALY, IRCCS NEUROMED, POZZILLI, IS, ITALY","BACKGROUND AND AIMS THE CLUSTERING OF HIGH LEVELS OF LDL CHOLESTEROL (LDL-C) AND OTHER RISK FACTORS REPRESENTS A PREDISPOSING CONDITION FOR ATHEROSCLEROTIC DISEASE DEVELOPMENT. CARDIOVASCULAR PREVENTION IS BASED ON EFFECTIVE CONTROL OF THESE CONDITIONS. IN ADULT SUBJECTS WITH MILD HYPERCHOLESTEROLEMIA WE COMPARED IN THE REAL LIFE THE EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS ON LIPID AND GLUCOSE METABOLISM AND BLOOD PRESSURE WITH THOSE OF AN ESTABLISHED NUTRACEUTICAL COMBINATION. METHOD AND RESULTS THIS MULTICENTER, CONTROLLED, RANDOMIZED, SINGLE-BLIND TRIAL WAS DESIGNED TO COMPARE THE EFFECT OF ARMOLIPID PLUS® VERSUS THAT OF LOPIGLIK® ON LIPID AND GLUCOSE LEVELS AND BLOOD PRESSURE (BP) IN SUBJECTS WITH MILD HYPERCHOLESTEROLEMIA NOT ON STATIN THERAPY. PRIMARY OUTCOME WAS THE PROPORTION OF SUBJECTS ACHIEVING THERAPEUTIC TARGETS OF LDL-C (<130 MG/DL); SECONDARY OUTCOMES WERE THE EFFECTS ON HDL-C, GLYCATED HAEMOGLOBIN AND INSULIN LEVELS. DATA FROM AN OVERALL SAMPLE OF 359 ADULT INDIVIDUALS (AGE 55.2 ± 11.1 YEARS, WOMEN 57.7%, LDL-C 157.3 ± 22.6 MG/DL, HDL-C 50.7 ± 13.0 MG/DL) ARE REPORTED. 72% OF SUBJECTS TREATED WITH LOPIGLIK® AND 43% TREATED WITH ARMOLIPID PLUS® ACHIEVED THE PRIMARY ENDPOINT (P < 0.0001). BOTH TREATMENTS REDUCED PLASMA LEVELS OF TOTAL AND LDL-C AND TRIGLYCERIDES (P < 0.001 FOR ALL COMPARISONS). THE TREATMENTS ALSO REDUCED SYSTOLIC AND DIASTOLIC BLOOD PRESSURE, PLASMA LEVELS OF GLYCATED HAEMOGLOBIN, INSULIN AND HOMA INDEX. THE CHANGES INDUCED BY LOPIGLIK® IN ALL THESE METABOLIC PARAMETERS WERE GREATER THAN THOSE OBTAINED WITH ARMOLIPID PLUS®. CONCLUSIONS THE PRESENT ANALYSIS SHOWS THAT LOPIGLIK® MAY REPRESENT A MORE EFFECTIVE TOOL FOR CLINICAL MANAGEMENT OF CV RISK FACTORS IN SUBJECTS WITH MILD HYPERCHOLESTEROLEMIA. © 2017 THE ITALIAN SOCIETY OF DIABETOLOGY, THE ITALIAN SOCIETY FOR THE STUDY OF ATHEROSCLEROSIS, THE ITALIAN SOCIETY OF HUMAN NUTRITION, AND THE DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY","ARMOLIPID PLUS<SUP>®</SUP>; CARDIOVASCULAR PREVENTION; HYPERCHOLESTEROLEMIA; LOPIGLIK<SUP>®</SUP>; NUTRACEUTICALS","ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INSULIN; ITALY; MALE; MIDDLE AGED; MORUS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RISK FACTORS; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; ARMOLIPID PLUS; ASTAXANTHIN; BERBERINE; FOLIC ACID; GLYCOSYLATED HEMOGLOBIN; LOPIGLIK; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULBERRY EXTRACT; NUTRACEUTICAL; PLACEBO; POLICOSANOL; UBIDECARENONE; XUEZHIKANG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIETARY SUPPLEMENT; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; ISOLATION AND PURIFICATION; ITALY; MEDICINAL PLANT; METABOLISM; MORUS; PHYTOTHERAPY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME","","","CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR HEART J, 2016, 37, PP. 2999-3058, (2016); PIRRO M., VETRANI C., BIANCHI C., MANNARINO M.R., BERNINI F., RIVELLESE A.A., JOINT POSITION STATEMENT ON “NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA” OF THE ITALIAN SOCIETY OF DIABETOLOGY (SID) AND OF THE ITALIAN SOCIETY FOR THE STUDY OF ARTERIOSCLEROSIS (SISA), NMCD, 27, PP. 2-17, (2017); CARRIZZO A., AMBROSIO M., DAMATO A., MADONNA M., STORTO M., CAPOCCI L., ET AL., MORUS ALBA EXTRACT MODULATES BLOOD PRESSURE HOMEOSTASIS THROUGH ENOS SIGNALING, MOL NUTR FOOD RES, 60, PP. 2304-2311, (2016); TRIMARCO V., IZZO R., STABILE E., ROZZA F., SANTORO M., MANZI M.V., ET AL., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE, INSULIN SENSITIVITY AND ENDOTELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS. A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND TRIAL, HIGH BLOOD PRESS CARDIOVASC PREV, 22, PP. 149-154, (2015); MANCIA G., FAGARD R., NARKIEWICZ K., REDON J., ZANCHETTI A., BOHM M., ET AL., 2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: THE TASK FORCE FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION (ESH) AND OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC), J HYPERTENS, 31, PP. 1281-1357, (2013); RUSCICA M., GOMARASCHI M., MOMBELLI G., MACCHI C., BOSISIO R., PAZZUCCONI F., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, PP. 61-68, (2014); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); PIRRO M., MANNARINO M.R., MINISTRINI S., FALLARINO F., LUPATTELLI G., BIANCONI V., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION ON LIPIDS, INFLAMMATION AND ENDOTHELIAL INTEGRITY IN PATIENTS WITH SUBCLINICAL INFLAMMATION: A RANDOMIZED CLINICAL TRIAL, SCI REP, 6, (2016); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); MILLAN J., CICERO A.F., TORRES F., ANGUERA A., EFFECTS OF A NUTRACEUTICAL COMBINATION CONTAINING BERBERINE (BRB), POLICOSANOL, AND RED YEAST RICE (RYR), ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, CLIN INVESTIG ARTERIOSCLER, 28, PP. 178-187, (2016); PIRRO M., MANNARINO M.R., BIANCONI V., SIMENTAL-MENDIA L.E., BAGAGLIA F., MANNARINO E., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); BARRIOS V., ESCOBAR C., CICERO A.F., BURKE D., FASCHING P., BANACH M., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); TRIMARCO V., ROZZA F., IZZO R., DE LEO V., CAPPELLI V., RICCARDI C., ET AL., EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS ON POSTMENOPAUSAL SYMPTOMS AND METABOLIC PROFILE: A CROSSOVER, RANDOMIZED, DOUBLE-BLIND TRIAL, INT J WOMENS HEALTH, 8, PP. 581-587, (2016); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NMCD, 20, PP. 656-661, (2010); HWANG S.H., LI H.M., LIM S.S., WANG Z., HONG J.S., HUANG B., EVALUATION OF A STANDARDIZED EXTRACT FROM MORUS ALBA AGAINST ALPHA-GLUCOSIDASE INHIBITORY EFFECT AND POSTPRANDIAL ANTIHYPERGLYCEMIC IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE: A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL, EVID BASED COMPL ALTERN MED ECAM, (2016); BALLETSHOFER B.M., RITTIG K., ENDERLE M.D., VOLK A., MAERKER E., JACOB S., ET AL., ENDOTHELIAL DYSFUNCTION IS DETECTABLE IN YOUNG NORMOTENSIVE FIRST-DEGREE RELATIVES OF SUBJECTS WITH TYPE 2 DIABETES IN ASSOCIATION WITH INSULIN RESISTANCE, CIRCULATION, 101, PP. 1780-1784, (2000); HSUEH W.A., QUINONES M.J., ROLE OF ENDOTHELIAL DYSFUNCTION IN INSULIN RESISTANCE, AM J CARDIOL, 92, PP. 10J-17J, (2003); VOLPE M., THE AGE OF NUTRACEUTICALS: EXPLORING NEW THERAPEUTIC TARGETS, HIGH BLOOD PRESS CARDIOVASC PREV, 23, PP. 337-339, (2016)","R. IZZO; HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY HOSPITAL, NAPOLI, VIA S. PANSINI 5, 80131, ITALY; EMAIL: RAFFAELE.IZZO@UNINA.IT","ELSEVIER B.V.","ENGLISH","NUTR. METAB. CARDIOVASC. DIS.","ARTICLE","ISI","2-S2.0-85030764623","NUTR METAB CARDIOVASC DIS","FEDERICO II UNIVERSITY;UNIVERSITY OF ROME SAPIENZA;UNIVERSITY OF ROME SAPIENZA;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;UNIVERSITY OF ROME SAPIENZA","NOTREPORTED;FEDERICO II UNIVERSITY HOSPITAL;NOTREPORTED",NA,"TRIMARCO V, 2017, NUTR METAB CARDIOVASC DIS","TRIMARCO V, 2017, NUTR METAB CARDIOVASC DIS"
"CICERO A;COLLETTI A;BAJRAKTARI G;DESCAMPS O;DJURIC D;EZHOV M;FRAS Z;KATSIKI N;LANGLOIS M;LATKOVSKIS G;PANAGIOTAKOS D;PARAGH G;MIKHAILIDIS D;MITCHENKO O;PAULWEBER B;PELLA D;PITSAVOS C;REINER Ž;RAY K;RIZZO M;SAHEBKAR A;SERBAN M;SPERLING L;TOTH P;VINEREANU D;VRABLÍK M;WONG N;BANACH M","CICERO, ARRIGO F.G. (7003403707); COLLETTI, ALESSANDRO (56538296200); BAJRAKTARI, GANI (12764374400); DESCAMPS, OLIVIER (6701764714); DJURIC, DRAGAN M. (36016317400); EZHOV, MARAT (57218254057); FRAS, ZLATKO (35615293100); KATSIKI, NIKI (25421628400); LANGLOIS, MICHEL (56355464300); LATKOVSKIS, GUSTAVS (6507756746); PANAGIOTAKOS, DEMOSTHENES B. (7005977027); PARAGH, GYORGY (7003269524); MIKHAILIDIS, DIMITRI P. (36042757800); MITCHENKO, OLENA (57193516360); PAULWEBER, BERNHARD (36519500600); PELLA, DANIEL (57207570055); PITSAVOS, CHRISTOS (35399739300); REINER, ŽELJKO (55411641000); RAY, KAUSIK K. (35303190300); RIZZO, MANFREDI (7202023733); SAHEBKAR, AMIRHOSSEIN (26639699900); SERBAN, MARIA-CORINA (56497645100); SPERLING, LAURENCE S. (56785421900); TOTH, PETER P. (7102285226); VINEREANU, DRAGOS (6603080279); VRABLÍK, MICHAL (6701669648); WONG, NATHAN D. (7202836669); BANACH, MACIEJ (22936699500)","LIPID LOWERING NUTRACEUTICALS IN CLINICAL PRACTICE POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL",2017,"ARCHIVES OF MEDICAL SCIENCE","13","40",204,"10.5114/aoms.2017.69326","DEPARTMENT OF MEDICINE AND SURGERY SCIENCES, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY, ITALIAN SOCIETY OF NUTRACEUTICALS (SINUT), ITALY, ATHEROSCLEROSIS RESEARCH CENTER, VIA ALBERTONI 15, BOLOGNA, 40138, ITALY;DEPARTMENT OF MEDICINE AND SURGERY SCIENCES, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY, ITALIAN SOCIETY OF NUTRACEUTICALS (SINUT), ITALY;CLINIC OF CARDIOLOGY, UNIVERSITY CLINICAL CENTRE OF KOSOVO, PRISHTINA, KOSOVO, SERBIA, MEDICAL FACULTY, UNIVERSITY OF PRISHTINA, PRISHTINA, KOSOVO, SERBIA, KOSOVO SOCIETY OF CARIDOLOGY, SERBIA;DEPARTMENT OF INTERNAL MEDICINE, CENTRES HOSPITALIERS JOLIMONT, HAINE SAINT-PAUL, BELGIUM, BELGIAN ATHEROCLEROSIS SOCIETY, BELGIUM;INSTITUTE OF MEDICAL PHYSIOLOGY 'RICHARD BURIAN', FACULTY OF MEDICINE, UNIVERSITY OF BELGRADE, BELGRADE, SERBIA, SERBIAN ASSOCIATION FOR ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY RESEARCH, SERBIA;RUSSIAN CARDIOLOGY RESEARCH AND PRODUCTION CENTRE, MOSCOW, RUSSIAN FEDERATION, RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY, RUSSIAN FEDERATION;DEPARTMENT OF VASCULAR MEDICINE, DIVISION OF INTERNAL MEDICINE, UNIVERSITY MEDICAL CENTRE LJUBLJANA, LJUBLJANA, SLOVENIA, DEPARTMENT FOR INTERNAL MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF LJUBLJANA, LJUBLJANA, SLOVENIA, SLOVENIAN SOCIETY OF CARDIOLOGY, SLOVENIA;SECOND DEPARTMENT OF PROPAEDEUTIC INTERNAL MEDICINE, ARISTOTLE UNIVERSITY OF THESSALONIKI, HIPPOCRATION HOSPITAL, THESSALONIKI, GREECE;DEPARTMENT OF LABORATORY MEDICINE, AZ SINT-JAN HOSPITAL, BRUGES, BELGIUM, BELGIAN ATHEROCLEROSI SOCIETY, BELGIUM;FACULTY OF MEDICINE, INSTITUTE OF CARDIOLOGY AND REGENERATIVE MEDICINE, UNIVERSITY OF LATVIA, RIGA, LATVIA, BALTIC ATHEROSCLEROSIS SOCIETY, LATVIA;SCHOOL OF HEALTH SCIENCE AND EDUCATION, DEPARTMENT OF NUTRITION AND DIETETICS, HAROKOPIO UNIVERSITY OF ATHENS, ATHENS, GREECE;DEPARTMENT OF INTERNAL MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF DEBRECEN, DEBRECEN, HUNGARY, HUNGARIAN ATHEROSCLEROSIS SOCIETY, HUNGARY;DEPARTMENT OF CLINICAL BIOCHEMISTRY, ROYAL FREE CAMPUS, UNIVERSITY COLLEGE LONDON (UCL), LONDON, UNITED KINGDOM;DYSLIPIDAEMIA DEPARTMENT, INSTITUTE OF CARDIOLOGY AMS OF UKRAINE, UKRAINE, UKRAINIAN ATHEROSCLEROSIS SOCIETY, UKRAINE;FIRST DEPARTMENT OF INTERNAL MEDICINE, PARACELSUS PRIVATE MEDICAL UNIVERSITY, SALZBURG, AUSTRIAAUSTRIAN ATHEROCLEROSIS SOCIETY (AAS), AUSTRIA;1ST DEPARTMENT OF INTERNAL MEDICINE, FACULTY OF MEDICINE, PAVOL JOZEF SAFARIK UNIVERSITY, KOŠICE, SLOVAKIA, SLOVAK ASSOCIATION OF ATHEROSCLEROSIS, SLOVAKIA;CARDIOLOGY CLINIC, SCHOOL OF MEDICINE, UNIVERSITY OF ATHENS, GREECE, HELLENIC ATHEROSCLEROSIS SOCIETY, GREECE;UNIVERSITY HOSPITAL CENTRE ZAGREB, SCHOOL OF MEDICINE UNIVERSITY OF ZAGREB, DEPARTMENT OF INTERNAL MEDICINE, ZAGREB, CROATIA, CROATIAN ATHEROSCLEROSIS SOCIETY, CROATIA;DEPARTMENT OF PRIMARY CARE AND PUBLIC HEALTH, IMPERIAL COLLEGE, LONDON, UNITED KINGDOM;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, PALERMO, ITALY, EURO-MEDITERRANEAN INSTITUTE OF SCIENCE AND TECHNOLOGY, PALERMO, ITALY;BIOTECHNOLOGY RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, IRAN;CENTER FOR INTERDISCIPLINARY RESEARCH, UNIVERSITY OF MEDICINE AND PHARMACY 'VICTOR BABES', TIMISOARA, ROMANIA, DEPARTMENT OF FUNCTIONAL SCIENCES, UNIVERSITY OF MEDICINE AND PHARMACY 'VICTOR BABES', TIMISOARA, ROMANIA;DIVISION OF CARDIOLOGY, EMORY UNIVERSITY, EMORY CLINICAL CARDIOVASCULAR RESEARCH INSTITUTE, ATLANTA, GA, UNITED STATES;JOHNS HOPKINS CICCARONE CENTER FOR THE PREVENTION OF HEART DISEASE, BALTIMORE, MD, UNITED STATES, PREVENTIVE CARDIOLOGY, CGH MEDICAL CENTER, STERLING, IL, UNITED STATES;UNIVERSITY OF MEDICINE AND PHARMACY 'CAROL DAVILA', BUCHAREST, ROMANIA, DEPARTMENT OF CARDIOLOGY, UNIVERSITY AND EMERGENCY HOSPITAL, BUCHAREST, ROMANIA, ROMANIAN SOCIETY OF CARDIOLOGY, ROMANIA;THIRD DEPARTMENT OF INTERNAL MEDICINE, FIRST MEDICAL FACULTY, CHARLES UNIVERSITY, PRAGUE, CZECH REPUBLIC, CZECH ATHEROSCLEROSIS SOCIETY, CZECH REPUBLIC;HEART DISEASE PREVENTION PROGRAM, DIVISION OF CARDIOLOGY, UNIVERSITY OF CALIFORNIA, IRVINE, UNITED STATES;DEPARTMENT OF HYPERTENSION, MEDICAL UNIVERSITY OF LODZ, POLAND, POLISH MOTHER'S MEMORIAL HOSPITAL RESEARCH INSTITUTE (PMMHRI), LODZ, POLAND, CARDIOVASCULAR RESEARCH CENTRE, UNIVERSITY OF ZIELONA GORA, ZIELONA GORA, POLAND, LIPID AND BLOOD PRESSURE META-ANALYSIS COLLABORATION (LBPMC) GROUP, POLAND, POLISH LIPID ASSOCIATION (POLA), POLAND","[NO ABSTRACT AVAILABLE]","","ALPHA TOCOPHEROL; ANTHOCYANIN; ANTILIPEMIC AGENT; BERBERINE; BETA GLUCAN; CARNITINE; CHITOSAN; CURCUMIN; CYNARA SCOLYMUS EXTRACT; EPIGALLOCATECHIN GALLATE; EZETIMIBE; GAMMA ORYZANOL; GARLIC EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPAGULA; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PANTETHINE; PLACEBO; POLICOSANOL; PROBIOTIC AGENT; ROSUVASTATIN; SILYMARIN; SINECATECHINS; TRIACYLGLYCEROL; UNINDEXED DRUG; XUEZHIKANG; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICHOKE; BIFIDOBACTERIUM ANIMALIS; CARDIOVASCULAR DISEASE; CITRUS; CITRUS BERGAMIA; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELEVATED BLOOD PRESSURE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FATIGUE; FLATULENCE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IRON DEFICIENCY; KIDNEY INJURY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PLANTARUM; LIFESTYLE MODIFICATION; LIVER DISEASE; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASE; MYOPATHY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; RASH; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SPIRULINA; VOMITING; WEIGHT REDUCTION","","","ORGANISATION WH. CARDIOVASCULAR DISEASES (CVDS), (2015); PERK J., DE BACKER G., GOHLKE H., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (VERSION 2012). THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR HEART J, 33, PP. 1635-1701, (2012); DE B., CAFIERO E.T., JANE-LLOPIS E., ET AL., THE GLOBAL ECONOMIC BURDEN OF NONCOMMUNICABLE DISEASES, (2011); RISK ESTIMATION AND THE PREVENTION OF CARDIOVASCULAR DISEASE; THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, PP. 3143-3421, (2002); HIGH BLOOD CHOLESTEROL; COLANTONIO L.D., BITTNER V., REYNOLDS K., ET AL., ASSOCIATION OF SERUM LIPIDS AND CORONARY HEART DISEASE IN CONTEMPORARY OBSERVATIONAL STUDIES, CIRCULATION, 133, PP. 256-264, (2016); FORD E.S., LI C., PEARSON W.S., ZHAO G., MOKDAD A.H., TRENDS IN HYPERCHOLESTEROLEMIA, TREATMENT AND CONTROL AMONG UNITED STATES ADULTS, INT J CARDIOL, 140, PP. 226-235, (2010); MOZAFFARIAN D., BENJAMIN E.J., GO A.S., ET AL., HEART DISEASE AND STROKE STATISTICS-2016 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 133, PP. E38-360, (2016); BAIGENT C., KEECH A., KEARNEY P.M., ET AL., EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE METAANALYSIS OF DATA FROM 90, 056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); TRENDS IN TOTAL CHOLESTEROL AND LIPID FRACTIONS IN 22 WESTERN AND ASIAN COUNTRIES, LANCET, (2017); HOBBS F.D., BANACH M., MIKHAILIDIS D.P., MALHOTRA A., CAPEWELL S., IS STATIN-MODIFIED REDUCTION IN LIPIDS THE MOST IMPORTANT PREVENTIVE THERAPY FOR CARDIOVASCULAR DISEASE? A PRO/CON DEBATE, BMC MED, 14, (2016); BAIGENT C., BLACKWELL L., EMBERSON J., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170, 000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20, 536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED TRIAL, LANCET, 360, PP. 1623-1630, (2002); JACOBSON T.A., ITO M.K., MAKI K.C., ET AL., NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT-CENTERED MANAGEMENT OF DYSLIPIDEMIA: PART 1-FULL REPORT, J CLIN LIPIDOL, 9, PP. 129-169, (2015); LAW M.R., WALD N.J., THOMPSON S.G., BY HOW MUCH AND HOW QUICKLY DOES REDUCTION IN SERUM CHOLESTEROL CONCENTRATION LOWER RISK OF ISCHAEMIC HEART DISEASE?, BMJ, 308, PP. 367-372, (1994); CATAPANO A.L., GRAHAM I., DE BACKER G., ET AL., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, 253, PP. 281-344, (2016); REINER Z., HYPERTRIGLYCERIDEMIA AND RISK OF CORONARY ARTERY DISEASE, NAT REV CARDIOL, (2017); BOOTH J.N., COLANTONIO L.D., HOWARD G., ET AL., HEALTHY LIFESTYLE FACTORS AND INCIDENT HEART DISEASE AND MORTALITY IN CANDIDATES FOR PRIMARY PREVENTION WITH STATIN THERAPY, INT J CARDIOL, 207, PP. 196-202, (2016); BANACH M., JANKOWSKI P., JOZWIAK J., ET AL., POLA/CFPIP/ PCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS FOR FAMILY PHYSICIANS 2016, ARCH MED SCI, 13, PP. 1-45, (2017); PIEPOLI M.F., HOES A.W., AGEWALL S., ET AL., 2016 EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUR J PREV CARDIOL, 23, PP. NP1-96, (2016); VANHEES L., GELADAS N., HANSEN D., ET AL., IMPORTANCE OF CHARACTERISTICS AND MODALITIES OF PHYSICAL ACTIVITY AND EXERCISE IN THE MANAGEMENT OF CARDIOVASCULAR HEALTH IN INDIVIDUALS WITH CARDIOVASCULAR RISK FACTORS: RECOMMENDATIONS FROM THE EACPR (PART II), EUR J PREV CARDIOL, 19, PP. 1005-1033, (2012); LICHTENSTEIN A.H., APPEL L.J., BRANDS M., ET AL., DIET AND LIFESTYLE RECOMMENDATIONS REVISION 2006: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 114, PP. 82-96, (2006); LIFESTYLE CHANGES AND CHOLESTEROL, (2017); APPEL L.J., SACKS F.M., CAREY V.J., ET AL., EFFECTS OF PROTEIN, MONOUNSATURATED FAT, AND CARBOHYDRATE INTAKE ON BLOOD PRESSURE AND SERUM LIPIDS: RESULTS OF THE OMNIHEART RANDOMIZED TRIAL, JAMA, 294, PP. 2455-2464, (2005); BROWN M.S., GOLDSTEIN J.L., BIOMEDICINE. LOWERING LDL - NOT ONLY HOW LOW, BUT HOW LONG?, SCIENCE, 311, PP. 1721-1731, (2006); BRINTON E.A., MANAGEMENT OF HYPERTRIGLYCERIDEMIA FOR PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, ENDOCRINOL METAB CLIN NORTH AM, 45, PP. 185-204, (2016); PATTI A.M., TOTH P.P., GIGLIO R.V., ET AL., NUTRACEUTICALS AS AN IMPORTANT PART OF COMBINATION THERAPY IN DYSLIPIDAEMIA, CURR PHARM DES, (2017); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); CICERO A.F., COLLETTI A., ROLE OF PHYTOCHEMICALS IN THE MANAGEMENT OF METABOLIC SYNDROME, PHYTOMEDICINE, 23, PP. 1134-1144, (2016); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J CLIN HYPERTENS, 14, PP. 121-132, (2012); CICERO A.F., FOGACCI F., COLLETTI A., FOOD AND PLANT BIOACTIVES FOR REDUCING CARDIOMETABOLIC DISEASE RISK: AN EVIDENCE BASED APPROACH, FOOD FUNCT, 8, PP. 2076-2088, (2017); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY - EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR HEART J, 36, PP. 1012-1022, (2015); BANGALORE S., FAYYAD R., HOVINGH G.K., ET AL., STATIN AND THE RISK OF RENAL-RELATED SERIOUS ADVERSE EVENTS: ANALYSIS FROM THE IDEAL, TNT, CARDS, ASPEN, SPARCL, AND OTHER PLACEBO-CONTROLLED TRIALS, AM J CARDIOL, 113, PP. 2018-2020, (2014); REINER Z., RESISTANCE AND INTOLERANCE TO STATINS, NUTR METAB CARDIOVASC DIS, 24, PP. 1057-1066, (2014); BANACH M., RIZZO M., TOTH P.P., ET AL., STATIN INTOLERANCE - AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015); PATEL J., MARTIN S.S., BANACH M., EXPERT OPINION: THE THERAPEUTIC CHALLENGES FACED BY STATIN INTOLERANCE, EXPERT OPIN PHARMACOTHER, 17, PP. 1497-1507, (2016); BANACH M., SERBAN M.C., DISCUSSION AROUND STATIN DISCONTINUATION IN OLDER ADULTS AND PATIENTS WITH WASTING DISEASES, J CACHEXIA SARCOPENIA MUSCLE, 7, PP. 396-399, (2016); BANACH M., ARONOW W.S., SERBAN M.C., RYSZ J., VORONEANU L., COVIC A., LIPIDS, BLOOD PRESSURE AND KIDNEY UPDATE 2015, LIPIDS HEALTH DIS, 14, (2015); DEVARAJ S., JIALAL I., THE ROLE OF DIETARY SUPPLEMENTATION WITH PLANT STEROLS AND STANOLS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, NUTR REV, 64, PP. 348-354, (2006); LAW M., PLANT STEROL AND STANOL MARGARINES AND HEALTH, BMJ, 320, PP. 861-864, (2000); RAS R.T., HIEMSTRA H., LIN Y., VERMEER M.A., DUCHATEAU G.S., TRAUTWEIN E.A., CONSUMPTION OF PLANT STEROL-ENRICHED FOODS AND EFFECTS ON PLASMA PLANT STEROL CONCENTRATIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES, ATHEROSCLEROSIS, 230, PP. 336-346, (2013); FERGUSON J.J., STOJANOVSKI E., MACDONALD-WICKS L., GARG M.L., FAT TYPE IN PHYTOSTEROL PRODUCTS INFLUENCE THEIR CHOLESTEROL-LOWERING POTENTIAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS, PROG LIPID RES, 64, PP. 16-29, (2016); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., ET AL., THE EFFECT OF PLANT STEROLS ON SERUM TRIGLYCERIDE CONCENTRATIONS IS DEPENDENT ON BASELINE CONCENTRATIONS: A POOLED ANALYSIS OF 12 RANDOMISED CONTROLLED TRIALS, EUR J NUTR, 52, PP. 153-160, (2013); ATHYROS V.G., KAKAFIKA A.I., PAPAGEORGIOU A.A., ET AL., EFFECT OF A PLANT STANOL ESTER-CONTAINING SPREAD, PLACEBO SPREAD, OR MEDITERRANEAN DIET ON ESTIMATED CARDIOVASCULAR RISK AND LIPID, INFLAMMATORY AND HAEMOSTATIC FACTORS, NUTR METAB CARDIOVASC DIS, 21, PP. 213-221, (2011); TALATI R., SOBIERAJ D.M., MAKANJI S.S., PHUNG O.J., COLEMAN C.I., THE COMPARATIVE EFFICACY OF PLANT STEROLS AND STANOLS ON SERUM LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J AM DIET ASSOC, 110, PP. 719-726, (2010); RAS R.T., FUCHS D., KOPPENOL W.P., ET AL., THE EFFECT OF A LOW-FAT SPREAD WITH ADDED PLANT STEROLS ON VASCULAR FUNCTION MARKERS: RESULTS OF THE INVESTIGATING VASCULAR FUNCTION EFFECTS OF PLANT STEROLS (INVEST) STUDY, AM J CLIN NUTR, 101, PP. 733-741, (2015); GYLLING H., HALONEN J., LINDHOLM H., ET AL., THE EFFECTS OF PLANT STANOL ESTER CONSUMPTION ON ARTERIAL STIFFNESS AND ENDOTHELIAL FUNCTION IN ADULTS: A RANDOMISED CONTROLLED CLINICAL TRIAL, BMC CARDIOVASC DISORD, 13, (2013); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); DOI K., EFFECT OF KONJAC FIBRE (GLUCOMANNAN) ON GLUCOSE AND LIPIDS, EUR J CLIN NUTR, 49, PP. S190-S197, (1995); ZHU X., SUN X., WANG M., ET AL., QUANTITATIVE ASSESSMENT OF THE EFFECTS OF BETA-GLUCAN CONSUMPTION ON SERUM LIPID PROFILE AND GLUCOSE LEVEL IN HYPERCHOLESTEROLEMIC SUBJECTS, NUTR METAB CARDIOVASC DIS, 25, PP. 714-723, (2015); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF A HEALTH CLAIM RELATED TO OAT BETA-GLUCAN AND LOWERING BLOOD CHOLESTEROL AND REDUCED RISK OF (CORONARY) HEART DISEASE PURSUANT TO ARTICLE 14 OF REGULATION (EC) NO 1924/2006, EFSA J, 8, (2010); REINER Z., CATAPANO A., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUR HEART J, 32, PP. 1769-1818, (2011); CLEEMAN J., GRUNDY S., BECKER D., CLARK L., EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) ADULT TREATMENT PANEL (ATP III), JAMA, 285, PP. 2486-2497, (2001); TABESH F., SANEI H., JAHANGIRI M., ET AL., THE EFFECTS OF BETA-GLUCAN RICH OAT BREAD ON SERUM NITRIC OXIDE AND VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA, BIOMED RES INT, 2014, (2014); ANDERSON J.W., DIETARY FIBRE, COMPLEX CARBOHYDRATE AND CORONARY ARTERY DISEASE, CAN J CARDIOL, 11, PP. 55G-62G, (1995); ZH W., WANG H., CHEN X.Y., ET AL., TIME- AND DOSE-DEPENDENT EFFECT OF PSYLLIUM ON SERUM LIPIDS IN MILD-TO-MODERATE HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, EUR J CLIN NUTR, 63, PP. 821-827, (2009); RIBAS S.A., CUNHA D.B., SICHIERI R., SANTANA DA SILVA L.C., EFFECTS OF PSYLLIUM ON LDL-CHOLESTEROL CONCENTRATIONS IN BRAZILIAN CHILDREN AND ADOLESCENTS: A RANDOMISED, PLACEBO-CONTROLLED, PARALLEL CLINICAL TRIAL, BR J NUTR, 113, PP. 134-141, (2015); ANDERSON J.W., ZETTWOCH N., FELDMAN T., TIETYEN-CLARK J., OELTGEN P., BISHOP C.W., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM HYDROPHILIC MUCILLOID FOR HYPERCHOLESTEROLEMIC MEN, ARCH INTERN MED, 148, PP. 292-296, (1988); GIBB R.D., MCRORIE J.W., RUSSELL D.A., HASSELBLAD V., D'ALESSIO D.A., PSYLLIUM FIBER IMPROVES GLYCEMIC CONTROL PROPORTIONAL TO LOSS OF GLYCEMIC CONTROL: A META-ANALYSIS OF DATA IN EUGLYCEMIC SUBJECTS, PATIENTS AT RISK OF TYPE 2 DIABETES MELLITUS, AND PATIENTS BEING TREATED FOR TYPE 2 DIABETES MELLITUS, AM J CLIN NUTR, 102, PP. 1604-1614, (2015); PAL S., KHOSSOUSI A., BINNS C., DHALIWAL S., RADAVELLI-BAGATINI S., THE EFFECTS OF 12-WEEK PSYLLIUM FIBRE SUPPLEMENTATION OR HEALTHY DIET ON BLOOD PRESSURE AND ARTERIAL STIFFNESS IN OVERWEIGHT AND OBESE INDIVIDUALS, BR J NUTR, 107, PP. 725-734, (2012); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); BEHERA S.S., RAY R.C., KONJAC GLUCOMANNAN, A PROMISING POLYSACCHARIDE OF AMORPHOPHALLUS KONJAC K. KOCH IN HEALTH CARE, INT J BIOL MACROMOL, 92, PP. 942-956, (2016); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 88, PP. 1167-1175, (2008); ONAKPOYA I., POSADZKI P., ERNST E., THE EFFICACY OF GLUCOMANNAN SUPPLEMENTATION IN OVERWEIGHT AND OBESITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, J AM COLL NUTR, 33, PP. 70-78, (2014); GUARDAMAGNA O., ABELLO F., CAGLIERO P., VISIOLI F., COULD DYSLIPIDEMIC CHILDREN BENEFIT FROM GLUCOMANNAN INTAKE?, NUTRITION, 29, PP. 1060-1065, (2013); MARTINO F., MARTINO E., MORRONE F., CARNEVALI E., FORCONE R., NIGLIO T., EFFECT OF DIETARY SUPPLEMENTATION WITH GLUCOMANNAN ON PLASMA TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC CHILDREN, NUTR METAB CARDIOVASC DIS, 15, PP. 174-180, (2005); MARTINO F., PUDDU P.E., PANNARALE G., ET AL., LOW DOSE CHROMIUM-POLYNICOTINATE OR POLICOSANOL IS EFFECTIVE IN HYPERCHOLESTEROLEMIC CHILDREN ONLY IN COMBINATION WITH GLUCOMANNAN, ATHEROSCLEROSIS, 228, PP. 198-202, (2013); BAKER W.L., TERCIUS A., ANGLADE M., WHITE C.M., COLEMAN C.I., A META-ANALYSIS EVALUATING THE IMPACT OF CHITOSAN ON SERUM LIPIDS IN HYPERCHOLESTEROLEMIC PATIENTS, ANN NUTR METAB, 55, PP. 368-374, (2008); RIZZO M., GIGLIO R.V., NIKOLIC D., ET AL., EFFECTS OF CHITOSAN ON PLASMA LIPIDS AND LIPOPROTEINS: A 4-MONTH PROSPECTIVE PILOT STUDY, ANGIOLOGY, 65, PP. 538-542, (2014); JULL A.B., NI MHURCHU C., BENNETT D.A., DUNSHEA-MOOIJ C.A., RODGERS A., CHITOSAN FOR OVERWEIGHT OR OBESITY, COCHRANE DATABASE SYST REV, 3, (2008); KIM H.J., AHN H.Y., KWAK J.H., ET AL., THE EFFECTS OF CHITOSAN OLIGOSACCHARIDE (GO2KA1) SUPPLEMENTATION ON GLUCOSE CONTROL IN SUBJECTS WITH PREDIABETES, FOOD FUNCT, 10, PP. 2662-2669, (2014); MHURCHU C.N., POPPITT S., MCGILL A., ET AL., THE EFFECT OF THE DIETARY SUPPLEMENT, CHITOSAN, ON BODY WEIGHT: A RANDOMISED CONTROLLED TRIAL IN 250 OVERWEIGHT AND OBESE ADULTS, INT J OBES, 28, PP. 1149-1156, (2004); GUARNER F., SCHAAFSMA G.J., PROBIOTICS, INT J FOOD MICROBIOL, 39, PP. 237-238, (1998); GILLILAND S.E., NELSON C.R., MAXWELL C., ASSIMILATION OF CHOLESTEROL BY LACTOBACILLUS ACIDOPHILUS, APPL ENVIRON MICROBIOL, 49, PP. 377-381, (1985); MISTRY P., NATURAL CHOLESTEROL-LOWERING PRODUCTS: FOCUS ON PROBIOTICS, BR J COMMUNITY NURS, 19, PP. S14-S18, (2014); KIM G.B., YI S.H., LEE B.H., PURIFICATION AND CHARACTERIZATION OF THREE DIFFERENT TYPES OF BILE SALT HYDROLASES FROM BIFIDOBACTERIUM STRAINS, J DAIRY SCI, 87, PP. 258-266, (2004); LIONG M.T., DUNSHEA F.R., SHAH N.P., EFFECTS OF A SYNBIOTIC CONTAINING LACTOBACILLUS ACIDOPHILUS ATCC 4962 ON PLASMA LIPID PROFILES AND MORPHOLOGY OF ERYTHROCYTES IN HYPERCHOLESTEROLAEMIC PIGS ON HIGH- AND LOW-FAT DIETS, BR J NUTR, 98, PP. 736-744, (2007); CHO Y.A., KIM J., EFFECT OF PROBIOTICS ON BLOOD LIPID CONCENTRATIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MEDICINE, 94, (2015); AGERHOLM-LARSEN L., BELL M.L., GRUNWALD G.K., ASTRUP A., THE EFFECT OF A PROBIOTIC MILK PRODUCT ON PLASMA CHOLESTEROL: A META-ANALYSIS OF SHORT-TERM INTERVENTION STUDIES, EUR J CLIN NUTR, 54, PP. 856-860, (2000); SHIMIZU M., HASHIGUCHI M., SHIGA T., TAMURA H.O., MOCHIZUKI M., META-ANALYSIS: EFFECTS OF PROBIOTIC SUPPLEMENTATION ON LIPID PROFILES IN NORMAL TO MILDLY HYPERCHOLESTEROLEMIC INDIVIDUALS, PLOS ONE, 10, (2015); DORON S., SNYDMAN D.R., RISK AND SAFETY OF PROBIOTICS, CLIN INFECT DIS (REVIEW), 60, PP. S129-S134, (2015); MA J., LI Y., YE Q., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5225, (2000); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS: BUYER BEWARE!, ARCH INTERN MED, 170, PP. 1722-1727, (2010); WANG R.W., KARI P.H., LU A.Y., THOMAS P.E., GUENGERICH F.P., VYAS K.P., BIOTRANSFORMATION OF LOVASTATIN. IV. IDENTIFICATION OF CYTOCHROME P450 3A PROTEINS AS THE MAJOR ENZYMES RESPONSIBLE FOR THE OXIDATIVE METABOLISM OF LOVASTATIN IN RAT AND HUMAN LIVER MICROSOMES, ARCH BIOCHEM BIOPHYS, 290, PP. 355-361, (1991); LI Y.G., ZHANG F., WANG Z.T., HU Z.B., IDENTIFICATION AND CHEMICAL PROFILING OF MONACOLINS IN RED YEAST RICE USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH PHOTODIODE ARRAY DETECTOR AND MASS SPECTROMETRY, J PHARM BIOMED ANAL, 35, PP. 1101-1112, (2004); GERARDS M.C., TERLOU R.J., YU H., CH K., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN - A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); MAZZANTI G., MORO P.A., RASCHI E., DA CAS R., MENNITI-IPPOLITO F., ADVERSE REACTIONS TO DIETARY SUPPLEMENTS CONTAINING RED YEAST RICE: ASSESSMENT OF CASES FROM THE ITALIAN SURVEILLANCE SYSTEM, BR J CLIN PHARMACOL, (2017); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); ZHAO S.P., LIU L., CHENG Y.C., ET AL., XUEZHIKANG, AN EXTRACT OF CHOLESTIN, PROTECTS ENDOTHELIAL FUNCTION THROUGH ANTIINFLAMMATORY AND LIPID-LOWERING MECHANISMS IN PATIENTS WITH CORONARY HEART DISEASE, CIRCULATION, 110, PP. 915-920, (2004); TOXICOLOGICAL EVALUATION OF RED MOULD RICE: AN UPDATE, (2012); KANTOLA T., KIVISTO K.T., NEUVONEN P.J., GRAPEFRUIT JUICE GREATLY INCREASES SERUM CONCENTRATIONS OF LOVASTATIN AND LOVASTATIN ACID, CLIN PHARMACOL THER, 63, PP. 397-402, (1998); PRASAD G.V., WONG T., MELITON G., BHALOO S., TRANSPLANTATION. RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, PP. 1200-1201, (2002); RASHEVA T.V., NEDEVA T.S., HALLET J.N., KUJUMDZIEVA A.V., CHARACTERIZATION OF A NON-PIGMENT PRODUCING MONASCUS PURPUREUS MUTANT STRAIN, ANTONIE VAN LEEUWENHOEK, 83, PP. 333-340, (2003); ARAI M., HIBINO T., TUMORIGENICITY OF CITRININ IN MALE F344 RATS, CANCER LETT, 17, PP. 281-287, (1983); CHAN W.H., SHIAO N.H., EFFECT OF CITRININ ON MOUSE EMBRYONIC DEVELOPMENT IN VITRO AND IN VIVO, REPROD TOXICOL, 24, PP. 120-125, (2007); SINGH N.D., SHARMA A.K., DWIVEDI P., PATIL R.D., KUMAR M., EXPERIMENTALLY INDUCED CITRININ AND ENDOSULFAN TOXICITY IN PREGNANT WISTAR RATS: HISTOPATHOLOGICAL ALTERATIONS IN LIVER AND KIDNEYS OF FETUSES, J APPL TOXICOL, 28, PP. 901-907, (2008); EFSA PANEL ON CONTAMINANTS IN THE FOOD CHAIN (CONTAM). EUROPEAN FOOD SAFETY AUTHORITY (EFSA), PARMA, ITALY, EFSA J, 10, (2012); EFSA J, 9, (2011); BORLINGHAUS J., ALBRECHT F., GRUNHLKE M.C.H., NWACHUKWU I.D., SLUSARENKO A., ALLICIN: CHEMISTRY AND BIOLOGICAL PROPERTIES, MOLECULES, 19, PP. 12591-12618, (2014); RIED K., TOBEN C., FAKLER P., EFFECT ON GARLIC ON SERUM LIPIDS: AN UPDATED META-ANALYSIS, NUTR REV, 71, PP. 282-299, (2013); ACKERMANN R.T., MULROW C.D., RAMIREZ G., GARDNER C.D., MORBIDONI L., LAWRENCE V.A., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCH INTERN MED, 161, PP. 813-824, (2001); RIED K., GARLIC LOWERS BLOOD PRESSURE IN HYPERTENSIVE INDIVIDUALS, REGULATES SERUM CHOLESTEROL, AND STIMULATES IMMUNITY: AN UPDATED META-ANALYSIS AND REVIEW, J NUTR, 146, PP. 389S-396S, (2016); JUNG E.S., PARK S.H., CHOI E.K., ET AL., REDUCTION OF BLOOD LIPID PARAMETERS BY A 12-WK SUPPLEMENTATION OF AGED BLACK GARLIC: A RANDOMIZED CONTROLLED TRILA, NUTRITION, 30, PP. 1034-1039, (2014); SAHEBKAR A., SERBAN C., URSONIU S., BANACH M., EFFECT OF GARLIC ON PLASMA LIPOPROTEIN(A) CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS, NUTRITION, 32, PP. 33-40, (2016); MORIHARA N., HINO A., AGED GARLIC EXTRACT SUPPRESSES PLATELET AGGREGATION BY CHANGING THE FUNCTIONAL PROPERTY OF PLATELETS, J NAT MED, 71, PP. 249-256, (2017); CIGHETTI G., DEL PUPPO M., PARONI R., GALLI KIENLE M., MODULATION OF HMG-COA REDUCTASE ACTIVITY BY PANTETHEINE/ PANTETHINE, BIOCHIM BIOPHYS ACTA, 963, PP. 389-393, (1988); CIGHETTI G., DEL PUPPO M., PARONI R., FIORICA E., GALLI KIENLE M., PANTETHINE INHIBITS CHOLESTEROL AND FATTY ACID SYNTHESES AND STIMULATES CARBON DIOXIDE FORMATION IN ISOLATED RAT HEPATOCYTES, J LIPID RES, 28, PP. 152-161, (1987); ETO M., WATANABE K., CHONAN N., ISHII K., LOWERING EFFECT OF PANTETHINE ON PLASMA BETA-THROMBOGLOBULIN AND LIPIDS IN DIABETES MELLITUS, ARTERY, 15, PP. 1-12, (1987); BINAGHI P., CELLINA G., LO CICERO G., BRUSCHI F., PORCARO E., PENOTTI M., EVALUATION OF THE CHOLESTEROL-LOWERING EFFECTIVENESS OF PANTETHINE IN WOMEN IN PERIMENOPAUSAL AGE, MINERVA MED, 81, PP. 475-479, (1990); RUMBERGER J.A., NAPOLITANO J., AZUMANO I., KAMIYA T., EVANS M., PANTETHINE, A DERIVATIVE OF VITAMIN B(5) USED AS A NUTRITIONAL SUPPLEMENT, FAVORABLY ALTERS LOW-DENSITY LIPOPROTEIN CHOLESTEROL METABOLISM IN LOW- TO MODERATE-CARDIOVASCULAR RISK NORTH AMERICAN SUBJECTS: A TRIPLE-BLINDED PLACEBO AND DIET-CONTROLLED INVESTIGATION, NUTR RES, 31, PP. 608-615, (2011); BERTOLINI S., DONATI C., ELICIO N., ET AL., LIPOPROTEIN CHANGES INDUCED BY PANTETHINE IN HYPERLIPOPROTEINEMIC PATIENTS: ADULTS AND CHILDREN, INT J CLIN PHARMACOL THER TOXICOL, 24, PP. 630-637, (1986); EVANS M., RUMBERGER J.A., AZUMANO I., NAPOLITANO J.J., CITROLO D., KAMIYA T., PANTETHINE, A DERIVATIVE OF VITAMIN B5, FAVORABLY ALTERS TOTAL, LDL AND NON-HDL CHOLESTEROL IN LOW TO MODERATE CARDIOVASCULAR RISK SUBJECTS ELIGIBLE FOR STATIN THERAPY: A TRIPLE-BLINDED PLACEBO AND DIET-CONTROLLED INVESTIGATION, VASC HEALTH RISK MANAG, 10, PP. 89-100, (2014); DONATI C., BARBI G., CAIRO G., PRATI G.F., DEGLI ESPOSTI E., PANTETHINE IMPROVES THE LIPID ABNORMALITIES OF CHRONIC HEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTER CLINICAL TRIAL, CLIN NEPHROL, 25, PP. 70-74, (1986); GIGLIO R.V., PATTI A.M., NIKOLIC D., ET AL., THE EFFECT OF BERGAMOT ON DYSLIPIDEMIA, PHYTOMEDICINE, 23, PP. 1175-1181, (2016); DI DONNA L., DE LUCA G., MAZZOTTI F., NAPOLI A., SALERNO R., TAVERNA D., SINDONA G., STATIN-LIKE PRINCIPLES OF BERGAMOT FRUIT (CITRUS BERGAMIA): ISOLATION OF 3-HYDROXYMETHYLGLUTARYL FLAVONOID GLYCOSIDES, J NAT PROD, 72, PP. 1352-1354, (2009); MICELI N., MONDELLO M.R., MONFORTE M.T., ET AL., HYPOLIPIDEMIC EFFECTS OF CITRUS BERGAMIA RISSO ET POITEAU JUICE IN RATS FED A HYPERCHOLESTEROLEMIC DIET, J AGRIC FOOD CHEM, 55, PP. 10671-10677, (2007); GLIOZZI M., WALKER R., MUSCOLI S., ET AL., BERGAMOT POLYPHENOLIC FRACTION ENHANCES ROSUVASTATIN-INDUCED EFFECT ON LDL-CHOLESTEROL, LOX-1 EXPRESSION AND PROTEIN KINASE B PHOSPHORYLATION IN PATIENTS WITH HYPERLIPIDEMIA, INT J CARDIOL, 170, PP. 140-145, (2013); GLIOZZI M., CARRESI C., MUSOLINO V., ET AL., THE EFFECT OF BERGAMOT-DERIVED POLYPHENOLIC FRACTION ON LDL SMALL DENSE PARTICLES AND NON ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME, ADV BIOL CHEM, 4, PP. 129-137, (2014); ATHYROS V.G., TZIOMALOS K., KATSIKI N., DOUMAS M., KARAGIANNIS A., MIKHAILIDIS D.P., CARDIOVASCULAR RISK ACROSS THE HISTOLOGICAL SPECTRUM AND THE CLINICAL MANIFESTATIONS OF NON-ALCOHOLIC FATTY LIVER DISEASE: AN UPDATE, WORLD J GASTROENTEROL, 21, PP. 6820-6834, (2015); MOLLACE V., SACCO I., JANDA E., ET AL., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, PP. 309-316, (2011); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 25, PP. 701-707, (2005); REINER Z., TEDESCHI-REINER E., RICE POLICOSANOL DOES NOT HAVE ANY EFFECTS ON BLOOD COAGULATION FACTORS IN HYPERCHOLESTEROLEMIC PATIENTS, COLL ANTROPOL, 31, PP. 315-319, (2007); LIU C.S., ZHENG Y.R., ZHANG Y.F., LONG X.Y., RESEARCH PROGRESS ON BERBERINE WITH A SPECIAL FOCUS ON ITS ORAL BIOAVAILABILITY, FITOTERAPIA, 109, PP. 274-282, (2016); ABIDI P., ZHOU Y., JIANG J.D., LIU J., EXTRACELLULAR SIGNAL-REGULATED KINASE-DEPENDENT STABILIZATION OF HEPATIC LOW-DENSITY LIPOPROTEIN RECEPTOR MRNA BY HERBAL MEDICINE BERBERINE, ARTERIOSCLER THROMB VASC BIOL, 25, PP. 2170-2176, (2005); LI H., DONG B., PARK S.W., LEE H.S., CHEN W., LIU J., HEPATOCYTE NUCLEAR FACTOR 1ALPHA PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINE, J BIOL CHEM, 284, PP. 28885-28895, (2009); LI X.Y., ZHAO Z.X., HUANG M., ET AL., EFFECT OF BERBERINE ON PROMOTING THE EXCRETION OF CHOLESTEROL IN HIGH-FAT DIET-INDUCED HYPERLIPIDEMIC HAMSTERS, J TRANSL MED, 13, (2015); QIANG X., XU L., ZHANG M., ET AL., DEMETHYLENEBERBERINE ATTENUATES NON-ALCOHOLIC FATTY LIVER DISEASE WITH ACTIVATION OF AMPK AND INHIBITION OF OXIDATIVE STRESS, BIOCHEM BIOPHYS RES COMMUN, 472, PP. 603-609, (2016); KIM W.S., LEE Y.S., CHA S.H., ET AL., BERBERINE IMPROVES LIPID DYSREGULATION IN OBESITY BY CONTROLLING CENTRAL AND PERIPHERAL AMPK ACTIVITY, AM J PHYSIOL ENDOCRINOL METAB, 296, PP. E812-E819, (2009); ZAREI A., CHANGIZI-ASHTIYANI S., TAHERI S., RAMEZANI M., A QUICK OVERVIEW ON SOME ASPECTS OF ENDOCRINOLOGICAL AND THERAPEUTIC EFFECTS OF BERBERIS VULGARIS L, AVICENNA J PHYTOMED, 5, PP. 485-497, (2015); MENG S., WANG L.S., HUANG Z.Q., ET AL., BERBERINE AMELIORATES INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION, CLIN EXP PHARMACOL PHYSIOL, 39, PP. 406-411, (2012); LAN J., ZHAO Y., DONG F., ET AL., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J ETHNOPHARMACOL, 161, PP. 69-81, (2015); DEROSA G., MAFFIOLI P., CICERO A.F., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPIN BIOL THER, 12, PP. 1113-1124, (2012); SOSNOWSKA B., PENSON P., BANACH M., THE ROLE OF NUTRACEUTICALS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASC DIAGN THER, 7, PP. S21-31, (2017); WAY T.D., LIN H.Y., KUO D.H., ET AL., PU-ERH TEA ATTENUATES HYPERLIPOGENESIS AND INDUCES HEPATOMA CELLS GROWTH ARREST THROUGH ACTIVATING AMP-ACTIVATED PROTEIN KINASE (AMPK) IN HUMAN HEPG2 CELLS, J AGRIC FOOD CHEM, 57, PP. 5257-5264, (2009); SHISHIKURA Y., KHOKHAR S., MURRAY B.S., EFFECTS OF TEA POLYPHENOLS ON EMULSIFICATION OF OLIVE OIL IN A SMALL INTESTINE MODEL SYSTEM, J AGRIC FOOD CHEM, 54, PP. 1906-1913, (2006); ONAKPOYA I., SPENCER E., HENEGHAN C., THOMPSON M., THE EFFECT OF GREEN TEA ON BLOOD PRESSURE AND LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, NUTR METAB CARDIOVASC DIS, 24, PP. 823-836, (2014); PARK C.S., KIM W., WOO J.S., ET AL., GREEN TEA CONSUMPTION IMPROVES ENDOTHELIAL FUNCTION BUT NOT CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH CHRONIC RENAL FAILURE, INT J CARDIOL, 145, PP. 261-262, (2010); LIN Q.F., QIU C.S., WANG S.L., ET AL., A CROSS-SECTIONAL STUDY OF THE RELATIONSHIP BETWEEN HABITUAL TEA CONSUMPTION AND ARTERIAL STIFFNESS, J AM COLL NUTR, 35, PP. 354-361, (2016); SERBAN C., SAHEBKAR A., ANTAL D., URSONIU S., BANACH M., EFFECTS OF SUPPLEMENTATION WITH GREEN TEA CATECHINS ON PLASMA C-REACTIVE PROTEIN CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTRITION, 31, PP. 1061-1071, (2015); ZHANG C., QIN Y.Y., WEI X., YU F.F., ZHOU Y.H., HE J., TEA CONSUMPTION AND RISK OF CARDIOVASCULAR OUTCOMES AND TOTAL MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDIES, EUR J EPIDEMIOL, 30, PP. 103-113, (2015); CICERO A.F., FOGACCI F., COLLETTI A., POTENTIAL ROLE OF BIOACTIVE PEPTIDES IN PREVENTION AND TREATMENT OF CHRONIC DISEASES: A NARRATIVE REVIEW, BR J PHARMACOL, 174, PP. 1378-1394, (2017); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); CHO S.J., JUILLERAT M.A., LEE C.H., CHOLESTEROL LOWERING MECHANISM OF SOYBEAN PROTEIN HYDROLYSATE, J AGRIC FOOD CHEM, 55, PP. 10599-10604, (2007); GRIECO A., MIELE L., POMPILI M., ET AL., ACUTE HEPATITIS CAUSED BY A NATURAL LIPID-LOWERING PRODUCT: WHEN ""ALTERNATIVE"" MEDICINE IS NO ""ALTERNATIVE"" AT ALL, J HEPATOL, 50, PP. 1273-1277, (2009); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J NUTR, 125, 3, PP. 606S-611S, (1995); LAMMI C., ZANONI C., SCIGLIUOLO G.M., D'AMATO A., ARNOLDI A., LUPIN PEPTIDES LOWER LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL THROUGH AN UP-REGULATION OF THE LDL RECEPTOR/STEROL REGULATORY ELEMENT BINDING PROTEIN 2 (SREBP2) PATHWAY AT HEPG2 CELL LINE, J AGRIC FOOD CHEM, 62, PP. 7151-7159, (2014); TOKEDE O.A., ONABANJO T.A., YANSANE A., GAZIANO J.M., DJOUSSE L., SOYA PRODUCTS AND SERUM LIPIDS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BR J NUTR, 114, PP. 831-843, (2015); BEAVERS D.P., BEAVERS K.M., MILLER M., STAMEY J., MESSINA M.J., EXPOSURE TO ISOFLAVONE-CONTAINING SOY PRODUCTS AND ENDOTHELIAL FUNCTION: A BAYESIAN META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR METAB CARDIOVASC DIS, 22, PP. 182-191, (2012); HAZIM S., CURTIS P.J., SCHAR M.Y., ET AL., ACUTE BENEFITS OF THE MICROBIAL-DERIVED ISOFLAVONE METABOLITE EQUOL ON ARTE RIAL STIFFNESS IN MEN PROSPECTIVELY RECRUITED ACCORDING TO EQUOL PRODUCER PHENOTYPE: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 103, PP. 694-702, (2016); ARNOLDI A., GRECO S., NUTRACEUTICAL CHARACTERISTICS OF LUPIN PROTEIN, NUTRAFOODS, 10, PP. 23-29, (2011); BAHR M., FECHNER A., KRAMER J., KIEHNTOPF M., JAHREIS G., LUPIN PROTEIN POSITIVELY AFFECTS PLASMA LDL CHOLESTEROL AND LDL:HDL CHOLESTEROL RATIO IN HYPERCHOLESTEROLEMIC ADULTS AFTER FOUR WEEKS OF SUPPLEMENTATION: A RANDOMIZED, CONTROLLED CROSSOVER STUDY, NUTR J, 12, (2013); BAHR M., FECHNER A., KIEHNTOPF M., JAHREIS G., CONSUMING A MIXED DIET ENRICHED WITH LUPIN PROTEIN BENEFICIALLY AFFECTS PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC SUBJECTS: A RANDOMIZED CONTROLLED TRIAL, CLIN NUTR, 34, PP. 7-14, (2015); FECHNER A., KIEHNTOPF M., JAHREIS G., THE FORMATION OF SHORT-CHAIN FATTY ACIDS IS POSITIVELY ASSOCIATED WITH THE BLOOD LIPID-LOWERING EFFECT OF LUPIN KERNEL FIBER IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS, J NUTR, 144, PP. 599-607, (2014); EFSA J, 7, PP. 1263-1289, (2009); EFSA J, 8, PP. 1796-1828, (2010); HOWE P., MORI T., BUCKLEY J., LONG CHAIN OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE - FSANZ CONSIDERATION OF A COMMISSIONED REVIEW, FSANZ, (2013); MILLER M., STONE N.J., BALLANTYNE C., ET AL., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 2292-2333, (2011); HARRIS W.S., BULCHANDANI D., WHY DO OMEGA-3 FATTY ACIDS LOWER SERUM TRIGLYCERIDES?, CURR OPIN LIPIDOL, 17, PP. 387-393, (2006); ESLICK G.D., HOWE P.R., SMITH C., PRIEST R., BENSOUSSAN A., BENEFITS OF FISH OIL SUPPLEMENTATION IN HYPERLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS, INT J CARDIOL, 136, PP. 4-16, (2009); LESLIE M.A., COHEN D.J., LIDDLE D.M., ROBINSON L.E., MA D.W., A REVIEW OF THE EFFECT OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON BLOOD TRIACYLGLYCEROL LEVELS IN NORMOLIPIDEMIC AND BORDERLINE HYPERLIPIDEMIC INDIVIDUALS, LIPIDS HEALTH DIS, 14, (2015); DI STASI D., BERNASCONI R., MARCHIOLI R., ET AL., EARLY MODIFICATIONS OF FATTY ACID COMPOSITION IN PLASMA PHOSPHOLIPIDS, PLATELETS AND MONONUCLEATES OF HEALTHY VOLUNTEERS AFTER LOW DOSES OF N-3 POLYUNSATURATED FATTY ACIDS, EUR J CLIN PHARMACOL, 60, PP. 183-190, (2004)","A.F.G. CICERO; ATHEROSCLEROSIS RESEARCH CENTER, BOLOGNA, VIA ALBERTONI 15, 40138, ITALY; EMAIL: ARRIGO.CICERO@UNIBO.IT","TERMEDIA PUBLISHING HOUSE LTD.","ENGLISH","ARCH. MED. SCI.","REVIEW","ISI","2-S2.0-85026820369","ARCH MED SCI","UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA;UNIVERSITY CLINICAL CENTRE OF KOSOVO;CENTRES HOSPITALIERS JOLIMONT;UNIVERSITY OF BELGRADE;RUSSIAN CARDIOLOGY RESEARCH AND PRODUCTION CENTRE;UNIVERSITY MEDICAL CENTRE LJUBLJANA;ARISTOTLE UNIVERSITY OF THESSALONIKI;AZ SINT-JAN HOSPITAL;UNIVERSITY OF LATVIA;HAROKOPIO UNIVERSITY OF ATHENS;UNIVERSITY OF DEBRECEN;UNIVERSITY COLLEGE LONDON (UCL);INSTITUTE OF CARDIOLOGY AMS OF UKRAINE;PARACELSUS PRIVATE MEDICAL UNIVERSITY;KOŠICE;UNIVERSITY OF ATHENS;UNIVERSITY HOSPITAL CENTRE ZAGREB;IMPERIAL COLLEGE;UNIVERSITY OF PALERMO;MASHHAD UNIVERSITY OF MEDICAL SCIENCES;UNIVERSITY OF MEDICINE AND PHARMACY 'VICTOR BABES';EMORY UNIVERSITY;JOHNS HOPKINS CICCARONE CENTER FOR THE PREVENTION OF HEART DISEASE;UNIVERSITY OF MEDICINE AND PHARMACY 'CAROL DAVILA';CHARLES UNIVERSITY;UNIVERSITY OF CALIFORNIA;MEDICAL UNIVERSITY OF LODZ","NOTREPORTED;ATHEROSCLEROSIS RESEARCH CENTER;NOTREPORTED",NA,"CICERO AFG, 2017, ARCH MED SCI","CICERO AFG, 2017, ARCH MED SCI"
"CHO K;YADAV D;KIM S;KIM J","CHO, KYUNG-HYUN (7403956966); YADAV, DHANANJAY (55779022200); KIM, SUK-JEONG (57193310178); KIM, JAE-RYONG (7601360934)","BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION LIPOPROTEIN PROFILE AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS",2018,"MOLECULES","23","",17,"10.3390/molecules23051080","DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, DAEHAK-RO 280, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, DAEHAK-RO 280, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, DAEHAK-RO 280, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, SMART-AGING CONVERGENCE RESEARCH CENTER, COLLEGE OF MEDICINE, YEUNGNAM UNIVERSITY, DAEGU, 705-717, SOUTH KOREA","WE INVESTIGATED THE ANTIHYPERTENSIVE EFFECT OF POLICOSANOL ON SPONTANEOUSLY HYPERTENSIVE RATS (SHR). FOR THIS, WE ANALYZED BLOOD PRESSURE, BLOOD LIPID, AND LIPOPROTEIN PROPERTIES IN MALE SHR AFTER CONSUMPTION OF CUBAN POLICOSANOL (PCO). THE EXPERIMENTAL GROUPS WERE AS FOLLOWS: NORMOTENSIVE WISTAR KYOTO (WKY) CONTROL, SHR GROUP FED NORMAL DIET (ND), SHR GROUP FED 20 MG OF PCO, SHR GROUP FED 100 MG OF PCO, AND SHR GROUP FED 200 MG OF PCO PER KG OF BODY WEIGHT. AFTER EIGHT WEEKS, THE SHR CONTROL GROUP SHOWED GRADUAL INCREASES UP TO 21% IN SYSTOLIC BLOOD PRESSURE (SBP) AND DIASTOLIC BLOOD PRESSURE (DBP) COMPARED WITH VALUES AT WEEK 0. HOWEVER, POLICOSANOL CONSUMPTION HAD A DOSE-DEPENDENT REDUCTION EFFECT ON SBP AND ALSO REDUCED DBP UP TO 17% IN A DOSE-DEPENDENT MANNER. HEART RATE (HR) BPM INCREASED BY SIX PERCENT IN THE SHR CONTROL, WHEREAS THE 20 MG, 100 MG, AND 200 MG OF POLICOSANOL GROUPS SHOWED A REDUCTION OF 36%, 28%, AND 34% RESPECTIVELY. ALTHOUGH SERUM TOTAL CHOLESTEROL (TC) LEVEL OF SHR WAS NOT AFFECTED BY POLICOSANOL CONSUMPTION (70–80 MG/DL), SERUM TRIGLYCERIDE (TG) LEVEL SIGNIFICANTLY DECREASED IN THE SHR + 200 MG OF PCO GROUP. SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVEL WAS ALSO SIGNIFICANTLY ELEVATED BY POLICOSANOL CONSUMPTION. THE % HDL-C/TC RATIO WAS ELEVATED IN THE POLICOSANOL GROUP UP TO 67–70%, WHEREAS THE SHR CONTROL GROUP SHOWED A RATIO OF 58%. SERUM CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY WAS REDUCED BY POLICOSANOL IN A DOSE-DEPENDENT MANNER. ALTHOUGH THE SERUM GLUTAMATE OXALOACETATE TRANSAMINASE (GOT)/ GLUTAMATE PYRUVATE TRANSAMINASE (GPT) WERE SIMILAR ACROSS ALL GROUPS, POLICOSANOL CONSUMPTION CAUSED REDUCTION OF REACTIVE OXYGEN SPECIES (ROS) LEVELS IN HEPATIC TISSUE. THE SHR CONTROL GROUP SHOWED A 2.1-FOLD HIGHER SERUM C-REACTIVE PROTEIN (CRP) LEVEL THAN THE WKY GROUP, WHEREAS THE CRP LEVEL DECREASED IN THE SHR + 200 MG OF PCO GROUP (UP TO 45%) THAN SHR CONTROL GROUP. ALDOSTERONE LEVEL WAS REDUCED IN THE POLICOSANOL GROUP (UP TO 34%) IN A DOSE-DEPENDENT MANNER COMPARED TO THE CONTROL. IN CONCLUSION, EIGHT WEEKS OF POLICOSANOL CONSUMPTION IN SHR RESULTED IN REMARKABLE REDUCTION OF BLOOD PRESSURE, SERUM ALDOSTERONE, AND SERUM TG LEVELS ALONG WITH THE ELEVATION OF HDL-C AND IMPROVEMENT OF HEPATIC INFLAMMATION. © 2018 BY THE AUTHORS.","HEPATIC INFLAMMATION; HYPERTENSION; LIPOPROTEINS; POLICOSANOL; SPONTANEOUSLY HYPERTENSIVE RATS","ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; HEART RATE; LIPID METABOLISM; LIPOPROTEINS; LIVER; RATS; RATS, INBRED SHR; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; POLICOSANOL; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DOSE RESPONSE; DRUG EFFECT; HEART RATE; LIPID METABOLISM; LIVER; METABOLISM; PATHOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT","GULF RESEARCH PROGRAM; MEDICAL RESEARCH CENTER, (2015R1A5A2009124); MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING; NATIONAL RESEARCH FOUNDATION; MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP","FUNDING TEXT 1: THIS WORK WAS SUPPORTED BY A GRANT FROM THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF) FUNDED BY THE MINISTRY OF SCIENCE, ICT, AND FUTURE PLANNING OF KOREA.; FUNDING TEXT 2: ACKNOWLEDGMENTS: THIS WORK WAS SUPPORTED BY A GRANT FROM THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF) FUNDED BY THE MINISTRY OF SCIENCE, ICT, AND FUTURE PLANNING OF KOREA.","LAAKSONEN D.E., NISKANEN L., NYYSSONEN K., LAKKA T.A., LAUKKANEN J.A., SALONEN J.T., DYSLIPIDAEMIA AS A PREDICTOR OF HYPERTENSION IN MIDDLE-AGED MEN, EUR. HEART J., 29, PP. 2561-2568, (2008); SANCHEZ-INIGO L., NAVARRO-GONZALEZ D., PASTRANA-DELGADO J., FERNANDEZ-MONTERO A., MARTINEZ J.A., ASSOCIATION OF TRIGLYCERIDES AND NEW LIPID MARKERS WITH THE INCIDENCE OF HYPERTENSION IN A SPANISH COHORT, J. HYPERTENS., 34, PP. 1257-1265, (2016); GONZALEZ J., VALLS N., BRITO R., RODRIGO R., ESSENTIAL HYPERTENSION AND OXIDATIVE STRESS: NEW INSIGHTS, WORLD J. CARDIOL., 6, PP. 353-366, (2014); BOYCE G., BUTTON E., SOO S., WELLINGTON C., THE PLEIOTROPIC VASOPROTECTIVE FUNCTIONS OF HIGH DENSITY LIPOPROTEINS (HDL), J. BIOMED. RES., (2017); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES., 62, (2018); LIM S.-M., YOO J.-A., LEE E.-Y., CHO K.-H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); LEE E.-Y., YOO J.-A., LIM S.-M., CHO K.-H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER., 318, PP. 1020-1026, (2006); KIM J.-Y., KIM S.-M., KIM S.-J., LEE E.-Y., KIM J.-R., CHO K.-H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED., 39, PP. 889-899, (2017); KIM S.-J., YADAV D., PARK H.-J., KIM J.-R., CHO K.-H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL., 9, (2018); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); TRIPPODO N.C., FROHLICH E.D., SIMILARITIES OF GENETIC (SPONTANEOUS) HYPERTENSION. MAN AND RAT, CIRC. RES., 48, PP. 309-319, (1981); LEMMER B., MATTES A., BOHM M., GANTEN D., CIRCADIAN BLOOD PRESSURE VARIATION IN TRANSGENIC HYPERTENSIVE RATS, HYPERTENSION, 22, PP. 97-101, (1993); LEONG X.-F., NG C.-Y., JAARIN K., ANIMAL MODELS IN CARDIOVASCULAR RESEARCH: HYPERTENSION AND ATHEROSCLEROSIS, BIOMED. RES. INT., 2015, (2015); BADYAL D., DADHICH A., LATA H., ANIMAL MODELS OF HYPERTENSION AND EFFECT OF DRUGS, INDIAN J. PHARMACOL., 35, PP. 349-362, (2003); ANDRZEJCZAK D., GORSKA D., THE EFFECTS OF CELIPROLOL ON SERUM CONCENTRATIONS OF PROINFLAMMATORY CYTOKINES IN HYPERTENSIVE (SHR) AND NORMOTENSIVE (WKY) RATS, PHARMACOL. REP., 66, PP. 68-73, (2014); WU M., PENG Z., ZU C., MA J., LU S., ZHONG J., ZHANG S., LOSARTAN ATTENUATES MYOCARDIAL ENDOTHELIAL-TO-MESENCHYMAL TRANSITION IN SPONTANEOUS HYPERTENSIVE RATS VIA INHIBITING TGF-Β/SMAD SIGNALING, PLOS ONE, 11, (2016); SIMIC B., HERMANN M., SHAW S.G., BIGLER L., STALDER U., DORRIES C., BESLER C., LUSCHER T.F., RUSCHITZKA F., TORCETRAPIB IMPAIRS ENDOTHELIAL FUNCTION IN HYPERTENSION, EUR. HEART J., 33, PP. 1615-1624, (2012); YANG S., CHEN X.Y., XU X.P., THE RELATIONSHIP BETWEEN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2), CHOLESTERYL ESTER TRANSFER PROTEIN AND LIPID PROFILE AND RISK OF ATHEROSCLEROSIS IN WOMEN WITH IRON DEFICIENCY ANAEMIA, CLIN. LAB., 61, PP. 1463-1469, (2015); CHO K.H., SHIN D.G., BAEK S.H., KIM J.R., MYOCARDIAL INFARCTION PATIENTS SHOW ALTERED LIPOPROTEIN PROPERTIES AND FUNCTIONS WHEN COMPARED WITH STABLE ANGINA PECTORIS PATIENTS, EXP. MOL. MED., 41, PP. 67-76, (2009); KIM S.M., LEE S.M., KIM S.J., KIM B.J., SHIN S., KIM J.R., CHO K.H., CORD AND MATERNAL SERA FROM SMALL NEONATES SHARE DYSFUNCTIONAL LIPOPROTEINS WITH PROATHEROGENIC PROPERTIES: EVIDENCE FOR BARKER’S HYPOTHESIS, J. CLIN. LIPIDOL., 11, (2017); HA Y.C., BARTER P.J., DIFFERENCES IN PLASMA CHOLESTERYL ESTER TRANSFER ACTIVITY IN SIXTEEN VERTEBRATE SPECIES, COMP. BIOCHEM. PHYSIOL. PART B COMP. BIOCHEM., 71, PP. 265-269, (1982); DAVIDSON M.H., UPDATE ON CETP INHIBITION, J. CLIN. LIPIDOL., 4, PP. 394-398, (2010); ZACHARIAH J.P., PENCINA M.J., LYASS A., KAUR G., D'AGOSTINO R.B., ORDOVAS J.M., VASAN R.S., CIRCULATING PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY AND BLOOD PRESSURE TRACKING IN THE COMMUNITY, J. HYPERTENS., 29, PP. 863-868, (2011); SUICO J.G., WANG M.D., FRIEDRICH S., CANNADY E.A., KONKOY C.S., RUOTOLO G., KRUEGER K.A., EFFECTS OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR EVACETRAPIB ON LIPOPROTEINS, APOLIPOPROTEINS AND 24‐H AMBULATORY BLOOD PRESSURE IN HEALTHY ADULTS, J. PHARM. PHARMACOL., 66, PP. 1576-1585, (2014); CANNON C.P., SHAH S., DANSKY H.M., DAVIDSON M., BRINTON E.A., GOTTO A.M., STEPANAVAGE M., LIU S.X., GIBBONS P., ASHRAF T.B., SAFETY OF ANACETRAPIB IN PATIENTS WITH OR AT HIGH RISK FOR CORONARY HEART DISEASE, N. ENGL. J. MED., 363, PP. 2406-2415, (2010); MAYER O., SEIDLEROVA J., FILIPOVSKY J., VAGOVICOVA P., WOHLFAHRT P., CIFKOVA R., WINDRICHOVA J., TOPOLCAN O., SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND INCREASED AORTIC STIFFNESS IN THE GENERAL POPULATION, HYPERTENS. RES., 39, PP. 266-271, (2016); MANDAI N., AKAZAWA K., HARA N., IDE Y., IDE K., DAZAI U., CHISHAKI A., CHISHAKI H., BODY WEIGHT REDUCTION RESULTS IN FAVORABLE CHANGES IN BLOOD PRESSURE, SERUM LIPIDS, AND BLOOD SUGAR IN MIDDLE-AGED JAPANESE PERSONS: A 5-YEAR INTERVAL OBSERVATIONAL STUDY OF 26,824 CASES, GLOB. J. HEALTH SCI., 7, PP. 159-170, (2015); BARTER P.J., RYE K.-A., CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION AS A STRATEGY TO REDUCE CARDIOVASCULAR RISK, J. LIPID RES., 53, PP. 1755-1766, (2012); TOMASCHITZ A., MAERZ W., PILZ S., RITZ E., SCHARNAGL H., RENNER W., BOEHM B.O., FAHRLEITNER-PAMMER A., WEIHRAUCH G., DOBNIG H., ALDOSTERONE/RENIN RATIO DETERMINES PERIPHERAL AND CENTRAL BLOOD PRESSURE VALUES OVER A BROAD RANGE, J. AM. COLL. CARDIOL., 55, PP. 2171-2180, (2010); VASAN R.S., EVANS J.C., LARSON M.G., WILSON P.W., MEIGS J.B., RIFAI N., BENJAMIN E.J., LEVY D., SERUM ALDOSTERONE AND THE INCIDENCE OF HYPERTENSION IN NONHYPERTENSIVE PERSONS, N. ENGL. J. MED., 351, PP. 33-41, (2004); MANRIQUE C., LASTRA G., GARDNER M., SOWERS J.R., THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM IN HYPERTENSION: ROLES OF INSULIN RESISTANCE AND OXIDATIVE STRESS, MED. CLIN. N. AM., 93, PP. 569-582, (2009); STREETEN D.P., CLIFT G.V., SCHLETTER F.E., DALAKOS T.S., THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSION, ANN. INTERN. MED., 68, (1968); MALKOFF J., NON-INVASIVE BLOOD PRESSURE FOR MICE AND RATS, ANIM. LAB NEWS KENT SCI. CORP., PP. 1-12, (2005); FOUAD-TARAZI F., CALCATTI J., CHRISTIAN R., ARMSTRONG R., DEPAUL M., BLOOD VOLUME MEASUREMENT AS A TOOL IN DIAGNOSING SYNCOPE, AM. J. MED. SCI., 334, PP. 53-56, (2007); YAMAGUCHI Y., YOSHIKAWA N., KAGOTA S., NAKAMURA K., HAGINAKA J., KUNITOMO M., ELEVATED CIRCULATING LEVELS OF MARKERS OF OXIDATIVE-NITRATIVE STRESS AND INFLAMMATION IN A GENETIC RAT MODEL OF METABOLIC SYNDROME, NITRIC OXIDE, 15, PP. 380-386, (2006); PRAVENEC M., KAJIYA T., ZIDEK V., LANDA V., MLEJNEK P., SIMAKOVA M., SILHAVY J., MALINSKA H., OLIYARNYK O., ET AL., EFFECTS OF HUMAN C-REACTIVE PROTEIN ON PATHOGENESIS OF FEATURES OF THE METABOLIC SYNDROME, HYPERTENSION, 57, (2011); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVESTIG., 34, PP. 1345-1353, (1955); MARKWELL M.A., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM., 87, PP. 206-210, (1978); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); ESTERBAUER H., STRIEGL G., PUHL H., ROTHENEDER M., CONTINUOUS MONITORING OF IN VITRO OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN, FREE RADIC. RES. COMMUN., 6, PP. 67-75, (1989); NOBLE R.P., ELECTROPHORETIC SEPARATION OF PLASMA LIPOPROTEINS IN AGAROSE GEL, J. LIPID RES., 9, PP. 693-700, (1968); CHO K.-H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOC-III: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOL. CELLS, 27, PP. 291-297, (2009); ECKERSON H.W., WYTE C.M., LA DU B., THE HUMAN SERUM PARAOXONASE/ARYLESTERASE POLYMORPHISM, AM. J. HUM. GENET., 35, PP. 1126-1138, (1983); PARK K.-H., SHIN D.-G., KIM J.-R., HONG J.-H., CHO K.-H., THE FUNCTIONAL AND COMPOSITIONAL PROPERTIES OF LIPOPROTEINS ARE ALTERED IN PATIENTS WITH METABOLIC SYNDROME WITH INCREASED CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY, INT. J. MOL. MED., 25, PP. 129-136, (2010); OWUSU-ANSAH E., YAVARI A., MANDAL S., BANERJEE U., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT. GENET., 40, PP. 356-361, (2008)","K.-H. CHO; DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","MDPI AG","ENGLISH","MOLECULES","ARTICLE","ISI","2-S2.0-85046655335","MOLECULES","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"CHO K-H, 2018, MOLECULES","CHO K-H, 2018, MOLECULES"
"TRABELSI H;RENAUD J;BOUALI I;MAYER P;BOUKHCHINA S","TRABELSI, HAJER (38362398500); RENAUD, JUSTIN (27268054600); BOUALI, INTIDHAR (54996526200); MAYER, PAUL (7203028266); BOUKHCHINA, SADOK (6507257738)","EFFECT OF RIPENING STAGE ON ALIPHATIC ALCOHOL 4MONOMETHYLSTEROL AND 44DIMETHYLSTEROL COMPOSITIONS OF PISTACIA LENTISCUS FRUIT LENTISC",2016,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","118","6",0,"10.1002/ejlt.201500079","FACULTÉ DES SCIENCES DE TUNIS, UNITÉ DE BIOCHIMIE DES LIPIDES, UNIVERSITÉ DE TUNIS EL MANAR, EL MANAR II, TUNISIA;DEPARTMENT OF CHEMISTRY, LABORATORY OF MASS SPECTROMETRY, UNIVERSITY OF OTTAWA, OTTAWA, ONTARIO, CANADA;FACULTÉ DES SCIENCES DE TUNIS, UNITÉ DE BIOCHIMIE DES LIPIDES, UNIVERSITÉ DE TUNIS EL MANAR, EL MANAR II, TUNISIA;DEPARTMENT OF CHEMISTRY, LABORATORY OF MASS SPECTROMETRY, UNIVERSITY OF OTTAWA, OTTAWA, ONTARIO, CANADA;FACULTÉ DES SCIENCES DE TUNIS, UNITÉ DE BIOCHIMIE DES LIPIDES, UNIVERSITÉ DE TUNIS EL MANAR, EL MANAR II, TUNISIA","FRUITS WERE COLLECTED FROM PISTACIA LENTISCUS TREES AT FIVE DISTINCT STAGES OF DEVELOPMENT, AND LIPID EXTRACT COMPOSITION OF 4-MONOMETHYLSTEROLS, 4,4-DIMETHYLSTEROLS, AND ALIPHATIC ALCOHOL WAS IDENTIFIED AND QUANTIFIED USING GC-MS. FOUR TRITERPENE ALCOHOLS AND TWO 4-METHYLSTEROLS WERE IDENTIFIED BY GC-MS DURING THE RIPENING OF THE LENTISC FRUIT. CYCLOARTENOL IS THE MAJOR COMPONENT OF THE 4,4-DIMETHYLSTEROL FRACTION WITH UP TO 1093 MG/100 G OF OIL IN THE 25TH DAF. THE ACCUMULATION OF MONOMETHYLSTEROLS BEGINS AT 60TH DAF AND PEAKED IN THE 75TH DAF. FURTHERMORE, THIRTEEN ALIPHATIC COMPOUNDS INCLUDING SEVEN BELONGING TO THE POLICOSANOL GROUP HAVE BEEN IDENTIFIED AND QUANTIFIED IN PISTACIA LENTISCUS OIL. DURING THE EARLY STAGES OF LENTISC FRUIT RIPENING, THE ALIPHATIC ALCOHOL FRACTION CONTAINS PREDOMINANTLY POLICOSANOL MOLECULES WHICH ARE HIGHLY PRIZED BY THE FOOD AND PHARMACEUTICAL INDUSTRIES FOR THEIR THERAPEUTIC AND NUTRITIONAL VALUE. PRACTICAL APPLICATIONS: ONE OF THE MAIN OBJECTIVES OF INDUSTRY IS TO IDENTIFY PLANT MATRICES RICH IN MOLECULES WITH GOOD NUTRITIONAL VALUE SUCH AS 4-MONOMETHYLSTEROLS AND 4,4-DIMETHYLSTEROLS. THIS STUDY ALLOWED IDENTIFICATION AND MONITORING OF THE DYNAMICS OF ACCUMULATION OF THE LENTISC UNSAPONIFIABLE FRACTION (4-MONOMETHYLSTEROLS, 4,4-DIMETHYLSTEROLS, AND ALIPHATIC ALCOHOLS), WHICH SHOULD CONTRIBUTE TO DETERMINATION OF THE MATURATION STAGES CORRESPONDING TO THE THRESHOLD ACCUMULATION OF CERTAIN MOLECULES WITH GOOD NUTRITIONAL VALUE. EVOLUTION OF 4-MONOMETHYLSTEROL, 4,4-DIMETHYLSTEROL, AND ALIPHATIC ALCOHOL COMPOSITION DURING MATURATION OF TUNISIAN PISTACIA LENTISCUS FRUIT WAS DETERMINED USING GC-MS METHODS. © 2015 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM","4,4-DIMETHYLSTEROLS; 4-MONOMETHYLSTEROLS; ALIPHATIC ALCOHOLS; PISTACIA LENTISCUS OIL; POLICOSANOL","","","","LE FLOC'H E., NABLI M.A., PP. 144-145, (1983); CLARDY J., WALSH C., LESSONS FROM NATURAL MOLECULES, NATURE, 432, PP. 829-837, (2004); KOEHN F.E., CARTER G.T., THE EVOLVING ROLE OF NATURAL PRODUCTS IN DRUG DISCOVERY, NAT. REV. DRUG DISCOV., 4, PP. 206-220, (2005); (2002); TRABELSI H., CHERIF O.A., SAKOUHI F., VILLENEUVE P., ET AL., TOTAL LIPID CONTENT, FATTY ACIDS AND 4-DESMETHYLSTEROLS ACCUMULATION IN DEVELOPING FRUIT OF PISTACIA LENTISCUS L. GROWING WILD IN TUNISIA, FOOD CHEM., 131, PP. 434-444, (2012); MALECKA M., ANTIOXIDANT PROPERTIES OF THE UNSAPONIFIABLE MATTER ISOLATED FROM TOMATO SEEDS, OAT GRAINS AND WHEAT GERM OIL, FOOD CHEM., 79, PP. 327-330, (2002); CHERIF A.O., BEN MESSAOUDA M., KAABI B., PELLERIN I., ET AL., CHARACTERISTICS AND PATHWAYS OF BIOACTIVE 4-DESMETHYLSTEROLS, TRITERPENE ALCOHOLS AND 4Α-MONOMETHYLSTEROLS, FROM DEVELOPING TUNISIAN CULTIVARS AND WILD PEANUT (ARACHIS HYPOGAEA L.), PLANT PHYS. BIOCHEM., 49, PP. 774-781, (2011); HARRABI S.; GOODWIN T.W., BIOSYNTHESIS OF TRITERPENOIDS, ANNU. REV. PLANT PHYS., 30, PP. 369-404, (1979); ILLNAIT J., MAS R., CASTANO G., FERANDEZ L., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); CHERIF O.A., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., ET AL., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), J. AGRIC. FOOD CHEM., 58, PP. 12143-12148, (2010); ABILIO L.G., 1998; MENENDEZ R., MA AMOR A., RODEIRO I., MA GONZALEZ R., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); WEBER N., MANGOLD H.K., METABOLISM OF LONG-CHAIN ALCOHOLS IN CELL SUSPENSION CULTURES OF SOYA AND RAPE, PLANTA, 155, PP. 225-230, (1982); KATZ H.D.","H. TRABELSI; FACULTÉ DES SCIENCES DE TUNIS, UNITÉ DE BIOCHIMIE DES LIPIDES, UNIVERSITÉ DE TUNIS EL MANAR, EL MANAR II, TUNISIA; EMAIL: HAJER_TRABELSI@YMAIL.COM","WILEY-VCH VERLAG","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-85083933530","EUR J LIPID SCI TECHNOL","UNIVERSITÉ DE TUNIS EL MANAR;UNIVERSITY OF OTTAWA;UNIVERSITÉ DE TUNIS EL MANAR;UNIVERSITY OF OTTAWA;UNIVERSITÉ DE TUNIS EL MANAR","NOTREPORTED;UNIVERSITÉ DE TUNIS EL MANAR;NOTREPORTED",NA,"TRABELSI H, 2016, EUR J LIPID SCI TECHNOL","TRABELSI H, 2016, EUR J LIPID SCI TECHNOL"
"WANG Z;FENG Y;LI X;DING W;MA L;CHEN X","WANG, ZHAN-DI (57193419635); FENG, YING (34770356600); LI, XIAN (55252109700); DING, WEI-FENG (56683747800); MA, LI-YI (56332101700); CHEN, XIAO-MING (55739155400)","EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX TWEEN AQUEOUS SOLUTION ON HFDPCS",2017,"FOREST RESEARCH","30","4",1,"10.13275/j.cnki.lykxyj.2017.01.006","RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCES INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650224, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCES INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650224, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCES INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650224, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCES INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650224, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCES INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650224, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCES INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650224, YUNNAN, CHINA","OBJECTIVE: TO INVESTIGATE THE CELL PROLIFERATION EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX TWEEN AQUEOUS SOLUTION IN HUMAN DERMAL PAPILLA CELLS (HFDPCS). METHOD: THE CELL SEEDING DENSITY WAS DECIDED BY TRYPAN BLUE TEST. NEXT DAY, CHANGE FRESH MEDIUM WHICH INCLUDING TREATMENT AGENT FOR HFDPCS. MTS ASSAY WAS USED TO COMPARE THE PROLIFERATION EFFECTS OF DIFFERENT CONCENTRATIONS OF TWEEN80, WHITE WAX AND POLICOSANOL FROM WHITE WAX TWEEN80 AQUEOUS SOLUTIONS ON HFDPCS TWEEN AQUEOUS SOLUTIONAFTER 48 H. RESULT: HFDPCS COULD GROW WELLWHENTHE CONCENTRATION OF TWEEN 80 WAS 1.56-6.25 ΜG·ML-1. IN THE CONCENTRATION RANGE, WHITE WAX (SOLUBILITY IN WATER WAS FROM 0.31-1.25 ΜG·ML-1) AND POLICOSANOL FROM WHITE WAX (SOLUBILITY IN WATER WAS 3.125-12.5 ΜG·ML-1) TWEEN AQUEOUS SOLUTIONS HAD THE CELL PROLIFERATION EFFECT FOR HFDPCS. IN WHICH, THE WHITE WAX AQUEOUS SOLUTION INCLUDING 6.25 ΜG·ML-1 TWEEN80 AND 1.25 ΜG·ML-1 WHITE WAX, AND THE POLICOSANOL AQUEOUS SOLUTION WHICH INCLUDING 6.25 ΜG·ML-1 TWEEN80 AND 12.5 ΜG·ML-1 POLICOSANOL INCREASED SIGNIFICANTLY THE PROLIFERATION OF HFDPCS COMPARING WITH FINASTERIDE. CONCLUSION: THE SELECTED CONCENTRATION OF TWEEN80 IS BELOW 6.25 ΜG·ML-1 IN HFDPCS CULTURE WHEN TWEEN80 IS USED AS A SOLUBILIZING AGENT. IN THE OPTIMISTIC CONCENTRATION RANGE OF TWEEN80, THE WHITE WAX AND POLICOSANOL FROM WHITE WAX COULD INCREASE THE PROLIFERATION OF HFDPCS REMARKABLY. © 2017, CHINESE ACADEMY OF FORESTRY. ALL RIGHT RESERVED.","HUMAN DERMAL PAPILLA CELLS; POLICOSANOL FROM WHITE WAX; TWEEN80; WHITE WAX","ALCOHOL; AQUEOUS SOLUTION; BIOASSAY; CELLS AND CELL COMPONENTS; CONCENTRATION (COMPOSITION); SEEDING; SKIN; SOLUBILITY; SURFACTANT; WAX","","","MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 50, 3, PP. 255-262, (2000); BORG J., THE NEUROTROPHIC FACTOR, N-HEXACOSANOL, REDUCES THE NEURONAL DAMAGE INDUCED BY THE NEUROTOXIN, KAINIC ACID, JOURNAL OF NEUROSCIENCE RESEARCH, 29, 1, PP. 62-67, (1991); LEE J., TUMBAR T., HAIRY TALE OF SIGNALING IN HAIR FOLLICLE DEVELOPMENT AND CYCLING, SEMINARS IN CELL&DEVELOPMENTAL BIOLOGY, 23, 8, PP. 906-916, (2012); BORG J., KESSLAK P.J., COTMAN C.W., PERIPHERAL ADMINISTRATION OF A LONG-CHAIN FATTY ALCOHOL PROMOTES SEPTAL CHOLINERGIC NEURONS SURVIVAL AFTER FIMBRIA-FORNIX TRANSECTION, BRAIN RESEARCH, 518, 1, PP. 295-298, (1990); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, 1, PP. 8-12, (2001); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, 4, PP. 311-321, (2011)","","CHINESE ACADEMY OF FORESTRY","CHINESE","FOR. RES.","ARTICLE","ISI","2-S2.0-85020710916","FOR RES",NA,"NOTREPORTED",NA,"WANG Z-D, 2017, FOR RES","WANG Z-D, 2017, FOR RES"
"WONG W;ISMAIL M;IMAM M;ZHANG Y","WONG, WAI-TENG (56991885100); ISMAIL, MAZNAH (57191087465); IMAM, MUSTAPHA UMAR (57469476100); ZHANG, YI-DA (57190386931)","MODULATION OF PLATELET FUNCTIONS BY CRUDE RICE ORYZA SATIVA BRAN POLICOSANOL EXTRACT",2016,"BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE","16","",7,"10.1186/s12906-016-1223-9","INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA, LABORATORY OF MOLECULAR BIOMEDICINE, SERDANG, SELANGOR, 43400, MALAYSIA;INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA, LABORATORY OF MOLECULAR BIOMEDICINE, SERDANG, SELANGOR, 43400, MALAYSIA, UNIVERSITI PUTRA MALAYSIA, DEPARTMENT OF NUTRITION AND DIETETICS, FACULTY OF MEDICINE AND HEALTH SCIENCES, SERDANG, SELANGOR, 43400, MALAYSIA;ZHENGZHOU UNIVERSITY, PRECISION NUTRITION INNOVATION INSTITUTE, COLLEGE OF PUBLIC HEALTH, ZHENGZHOU, HENAN PROVINCE, 450001, CHINA;AFFILIATED HOSPITAL OF CHENGDE MEDICAL UNIVERSITY, CARDIOLOGY DEPARTMENT, CHENGDE, HEBEI, 067000, CHINA","BACKGROUND: RICE BRAN IS BIOACTIVE-RICH AND HAS PROVEN HEALTH BENEFITS FOR HUMANS. MOREOVER, ITS SOURCE, THE BROWN RICE HAS ANTIOXIDANT, HYPOLIPIDEMIC AND OTHER FUNCTIONAL PROPERTIES THAT ARE INCREASINGLY MAKING IT A NUTRITIONAL STAPLE ESPECIALLY IN ASIAN COUNTRIES. THIS STUDY INVESTIGATED THE ANTIPLATELET AGGREGATION MECHANISMS OF CRUDE HEXANE/METHANOLIC RICE BRAN EXTRACT, IN WHICH POLICOSANOL WAS THE TARGETED BIOACTIVE. PLATELETS PLAY A VITAL ROLE IN PATHOGENESIS OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES, AND THEIR INCREASED ACTIVITIES COULD POTENTIALLY CAUSE ARTERIAL THROMBUS FORMATION OR SEVERE BLEEDING DISORDERS. THUS, IN THIS STUDY, PLATELET AGGREGATION AND ADHESION OF PLATELETS TO MAJOR COMPONENTS OF BASAL LAMINA WERE EXAMINED IN VITRO. IN ADDITION, CELLULAR PROTEIN SECRETION WAS QUANTIFIED AS A MEASUREMENT OF PLATELET ACTIVATION. METHODS: ADENOSINE DIPHOSPHATE (ADP), COLLAGEN, AND ARACHIDONIC ACID (AA)-INDUCED AGGREGATION WERE STUDIED USING THE MICROTITER TECHNIQUE. RAT PLATELETS WERE PRE-TREATED WITH VARIOUS CONCENTRATIONS OF POLICOSANOL EXTRACT, AND THE ADHESION OF PLATELETS ONTO COLLAGEN- AND LAMININ-COATED SURFACE (EXTRACELLULAR MATRIX) WAS STUDIED USING THE ACID PHOSPHATASE ASSAY. THE EFFECT OF CRUDE POLICOSANOL EXTRACT ON RELEASED PROTEINS FROM ACTIVATED PLATELETS WAS MEASURED USING MODIFIED LOWRY DETERMINATION METHOD. RESULTS: RICE BRAN POLICOSANOL EXTRACT SIGNIFICANTLY INHIBITED IN VITRO PLATELET AGGREGATION INDUCED BY DIFFERENT AGONISTS IN A DOSE DEPENDENT MANNER. THE IC50 OF ADP-, COLLAGEN-, AND AA-INDUCED PLATELET AGGREGATION WERE 533.37 ± 112.16, 635.94 ± 78.45 AND 693.86 ± 70.57 ΜG/ML, RESPECTIVELY. THE PRESENT STUDY SHOWED THAT CRUDE RICE BRAN POLICOSANOL EXTRACT SIGNIFICANTLY INHIBITED PLATELET ADHESION TO COLLAGEN IN A DOSE DEPENDENT MANNER. CONVERSELY, AT A LOW CONCENTRATION OF 15.625 ΜG/ML, THE EXTRACT SIGNIFICANTLY INHIBITED PLATELET ADHESION TO LAMININ STIMULATED BY DIFFERENT PLATELET AGONISTS. IN ADDITION TO THE ALTERATION OF CELL ADHESIVE PROPERTIES, CELLULAR PROTEIN SECRETION OF THE TREATED PLATELETS TOWARDS DIFFERENT STIMULANTS WERE DECREASED UPON CRUDE EXTRACT TREATMENT. CONCLUSION: OUR RESULTS SHOWED THAT CRUDE RICE BRAN POLICOSANOL EXTRACT COULD INHIBIT IN VITRO PLATELET ADHESION, AGGREGATION AND SECRETION UPON ACTIVATION USING AGONISTS. THESE FINDINGS SERVE AS A SCIENTIFIC PLATFORM TO FURTHER EXPLORE ALTERNATIVE THERAPIES IN CARDIOVASCULAR DISEASES RELATED TO PLATELET MALFUNCTION. © 2016 THE AUTHOR(S).","ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; LAMININ; PLATELET ADHESION; PLATELET AGGREGATION; PROTEIN SECRETION","ADENOSINE DIPHOSPHATE; ANIMALS; ARACHIDONIC ACID; COLLAGEN; DIETARY FIBER; FATTY ALCOHOLS; MALE; ORYZA; PLANT EXTRACTS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY; ACID PHOSPHATASE; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CELL PROTEIN; COLLAGEN; LAMININ; POLICOSANOL; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; FATTY ALCOHOL; PLANT EXTRACT; POLICOSANOL; ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; IC50; IN VITRO STUDY; MALE; NONHUMAN; PROTEIN SECRETION; RAT; RICE BRAN; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; ANIMAL; CHEMISTRY; DIETARY FIBER; DRUG EFFECTS; METABOLISM; ORYZA; SPRAGUE DAWLEY RAT; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION","MINISTRY OF HIGHER EDUCATION, MALAYSIA, MOHE, (6228130)","THE FINANCIAL SUPPORT FROM MINISTRY OF EDUCATION MALAYSIA (KNOWLEDGE TRANSFER PROGRAM-PROJECT NUMBER 6228130) IS GRATEFULLY ACKNOWLEDGED. THE AUTHORS THANK PADIBERAS NASIONAL BERHAD (SELANGOR, MALAYSIA) FOR PROVIDING RICE MILLING BY-PRODUCT AND THE STAFF OF INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA FOR THE KIND ASSISTANCE.","BRIERE J.B., ESSENTIAL THROMBOCYTHEMIA, ORPHANET J RARE DIS, 2, 3, PP. 1-17, (2007); SENER A., OZSAVCI D., OBA R., DEMIREL G.Y., URAS F., YARDIMCI K.T., DO PLATELET APOPTOSIS, ACTIVATION, AGGREGATION, LIPID PEROXIDATION AND PLATELET-LEUKOCYTE AGGREGATE FORMATION OCCUR SIMULTANEOUSLY IN HYPERLIPIDEMIA?, CLIN BIOCHEM, 38, 12, PP. 1081-1087, (2005); KAKOUROS N., RADE J.J., KOURLIOUROS A., RESAR J.R., PLATELET FUNCTION IN PATIENTS WITH DIABETES MELLITUS: FROM A THEORETICAL TO A PRACTICAL PERSPECTIVE, INT J ENDOCRINOL, (2011); MARKEL A., BROOK J.G., LEVY Y., AVIRAM M., YOUDIM M.B., INCREASED PLATELET ADHESION AND AGGREGATION IN HYPERTENSIVE PATIENTS: EFFECT OF ATENOLOL, BR J CLIN PHARMACOL, 16, 6, PP. 663-668, (1983); NARA Y., KIHARA M., NABIKA T., MANO M., HORIE R., YAMORI Y., DIETARY EFFECT ON PLATELET AGGREGATION IN MEN WITH AND WITHOUT A FAMILY HISTORY OF ESSENTIAL HYPERTENSION, HYPERTENSION, 6, 3, PP. 339-343, (1984); DAHLBACK B., BLOOD COAGULATION AND ITS REGULATION BY ANTICOAGULANT PATHWAYS: GENETIC PATHOGENESIS OF BLEEDING AND THROMBOTIC DISEASES, J INTERN MED, 257, 3, PP. 209-223, (2005); COPPINGER J.A., CAGNEY G., TOOMEY S., KISLINGER T., BELTON O., MCREDMOND J.P., CAHILL D.J., EMILI A., FITZGERALD D.J., MAGUIRE P.B., CHARACTERIZATION OF THE PROTEINS RELEASED FROM ACTIVATED PLATELETS LEADS TO LOCALIZATION OF NOVEL PLATELET PROTEINS IN HUMAN ATHEROSCLEROTIC LESIONS, BLOOD, 103, PP. 2096-2104, (2004); YEH J.J., TSAI S., WU D.C., WU J.Y., LIU T.C., CHEN A., P-SELECTIN-DEPENDENT PLATELET AGGREGATION AND APOPTOSIS MAY EXPLAIN THE DECREASE IN PLATELET COUNT DURING HELICOBACTER PYLORI INFECTION, BLOOD, 115, 21, PP. 4247-4253, (2010); HUBBARD G.P., STEVENS J.M., CICMIL M., SAGE T., JORDAN P.A., WILLIAMS C.M., LOVEGROVE J.A., GIBBINS J.M., QUERCETIN INHIBITS COLLAGEN STIMULATED PLATELET ACTIVATION THROUGH INHIBITION OF MULTIPLE COMPOUNDS OF THE GLYCOPROTEIN VI SIGNALING PATHWAY, J THROMB HAEMOST, 1, PP. 1079-1088, (2003); KERVER J., YANG E., BIANCHI L., SONG W., DIETARY PATTERNS ASSOCIATED WITH RISK FACTORS FOR CARDIOVASCULAR DISEASE IN HEALTHY US ADULTS, AM J CLIN NUTR, 78, PP. 1103-1110, (2003); OSGANIAN S., STAMPFER M., RIMM E., SPIEGELMAN D., MANSON J., WILLET W., DIETARY CAROTENOIDS AND RISK OF CORONARY ARTERY DISEASE IN WOMEN, AM J CLIN NUTR, 77, PP. 1390-1399, (2003); DUTTA-ROY A.K., DIETARY COMPONENTS AND HUMAN PLATELET ACTIVITY, PLATELETS, 13, 2, PP. 67-75, (2002); RAJARAM S., THE EFFECT OF VEGETARIAN DIET, PLANT FOODS, AND PHYTOCHEMICALS ON HEMOSTASIS AND THROMBOSIS, AM J CLIN NUTR, 78, PP. 552-558, (2003); HALLIWELL B., LIPID PEROXIDATION, ANTIOXIDANTS AND CARDIOVASCULAR DISEASE: HOW SHOULD WE MOVE FORWARD?, CARDIOVASC RES, 47, 3, PP. 410-418, (2000); VISIOLI F., BORSANI L., GALLI C., DIET AND PREVENTION OF CORONARY HEART DISEASE: THE POTENTIAL ROLE OF PHYTOCHEMICALS, CARDIOVASC RES, 479, 3, PP. 419-425, (2000); MEKHFI H., HAOUARI M.E., LEGSSYER A., BNOUHAM M., AZIZ M., ATMANI F., REMMAL A., ZIYYAT A., PLATELET ANTI-AGGREGANT PROPERTY OF SOME MOROCCAN MEDICINAL PLANTS, J ETHNOPHARMACOL, 94, PP. 317-322, (2004); SHIH F.F., AN UPDATE ON THE USE OF CO-PRODUCTS FROM THE MILLING OF RICE IN VALUE-ADDED FOOD PRODUCTS, J AM OIL CHEM SOC, 89, 1, PP. 1-8, (2012); PRASAD M.N., SANJAY K.R., SHRAVYA KHATOKAR M., VISMAYA M.N., NANJUNDA SWAMY S., HEALTH BENEFITS OF RICE BRAN - A REVIEW, J NUTR FOOD SCI, 1, (2011); KAHLON T.S., SAUNDERS R.M., SAYRE R.N., CHOW F.I., CHIU M.M., BETSCHART A.A., CHOLESTEROL-LOWERING EFFECTS OF RICE BRAN AND RICE BRAN OIL FRACTIONS IN HYPERCHOLESTEROLEMIC HAMSTERS, CEREAL CHEM, 69, (1992); MOST M.M., TULLEY R., MORALES S., LEFEVRE M., RICE BRAN OIL, NOT FIBER, LOWERS CHOLESTEROL IN HUMANS, AM J CLIN NUTR, 81, 1, PP. 64-68, (2005); TAKAKORI Z., ZARE M., IRANPARVARE M., MEHRABI Y., EFFECT OF RICE BRAN ON BLOOD GLUCOSE AND SERUM LIPID PARAMETERS IN DIABETES II PATIENTS, INTERNET J NUTR WELLNESS, 2, 1, PP. 1-5, (2004); HENDERSON A.J., OLLILA C.A., KUMAR A., BORRESEN E.C., RAINA K., AGARWAL R., RYAN E.P., CHEMOPREVENTIVE PROPERTIES OF DIETARY RICE BRAN: CURRENT STATUS AND FUTURE PROSPECTS, ADV NUTR, 3, 5, PP. 643-653, (2012); MANOSROI A., CHUTOPRAPAT R., ABE M., MANOSROI W., MANOSROI J., ANTI-AGING EFFICACY OF TOPICAL FORMULATIONS CONTAINING NIOSOMES ENTRAPPED WITH RICE BRAN BIOACTIVE COMPOUNDS, PHARM BIOL, 50, 2, PP. 208-224, (2012); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN DEL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAM TROMBOS HEMOST, 5, PP. 17-20, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., M'AS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 50, (1994); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., VALDES S., ANTIPLATELET AND ANTITHROMBOTIC EFFECT OF D-003, PHARMACOL RES, 42, 2, PP. 137-143, (2000); MOLINA V., ARRUZAZABALA M.L., CARBAJA D., MAS R., SYNERGISTIC EFFECT OF D-003 AND ASPIRIN ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 68, 5, PP. 305-310, (2003); MALIKI N.Z., EFFECTS OF ORYZANOL AND TOCOTRIENOL ON PLATELET AGGREGATION AND BLOOD LIPID PROFILE IN RATS, (2007); KIM H.H., LEE D.H., HONG J.H., INGKASUPART P., NAM G.S., OK W.J., KIM M.J., YU Y.B., KANG H.C., PARK H.J., INHIBITORY EFFECTS OF RICE BRAN WATER EXTRACT FERMENTED LACTOBACILLUS PLANTARUM DUE TO CAMP-DEPENDENT PHOSPHORYLATION OF VASP (SER157) ON HUMAN PLATELET AGGREGATION, BIOMED SCI LETT, 21, 2, PP. 103-114, (2015); KIM H.H., HONG J.H., INGKASUPART P., LEE D.H., PARK H.J., INHIBITORY EFFECTS OF WATER EXTRACT FROM RICE BRAN DUE TO CAMP-DEPENDENT PHOSPHORYLATION OF VASP (SER157) ON ADP-INDUCED PLATELET AGGREGATION, BIOMED SCI LETT, 20, 3, PP. 129-138, (2014); CICERO A.F.G., DEROSA G., RICE BRAN AND ITS MAIN COMPONENTS: POTENTIAL ROLE IN THE MANAGEMENT OF CORONARY RISK FACTORS, CURR TOPICS NUTRACEUTICAL RES, 3, 1, PP. 29-46, (2005); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, 5, PP. 583-591, (2012); ISHAKA A., IMAM M.U., MAHAMUD R., ZUKI A.B.Z., MAZNAH I., CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION, INT J NANOMEDICINE, 9, (2014); VAIYAPURI S., GIBBINS J.M., MINIATURISED PLATELET AGGREGATION ASSAYS USING NOVOSTAR MICROPLATE READER, BMG LABTECH APPL NOTE 215, REV. 04, (2011); MORAN N., KIERNAN A., DUNNE E., EDWARDS R.J., SHIELDS D.C., KENNY D., MONITORING MODULATORS OF PLATELET AGGREGATION IN A MICROTITER PLATE ASSAY, ANAL BIOCHEM, 357, 1, PP. 77-84, (2006); YAZDANPARAST R., SHAHRIYARY L., COMPARATIVE EFFECTS OF ARTEMISIA DRACUNCULUS, SATUREJA HORTENSIS AND ORIGANUM MAJORANA ON INHIBITION OF BLOOD PLATELET ADHESION, AGGREGATION AND SECRETION, VASCUL PHARMACOL, 48, 1, PP. 32-37, (2008); OLAS B., WACHOWICZ B., STOCHMAL A., OLESZEK W., INHIBITION OF BLOOD PLATELET ADHESION AND SECRETION BY DIFFERENT PHENOLICS FROM YUCCA SCHIDIGERA ROEZL, BARK NUTR, 21, PP. 199-206, (2005); SHAHRIYARY L., YAZDANPARAST R., INHIBITION OF BLOOD PLATELET ADHESION, AGGREGATION AND SECRETION BY ARTEMISIA DRACUNCULUS LEAVES EXTRACTS, J ETHNOPHARMACOL, 114, 2, PP. 194-198, (2007); LOWRY O.H., ROSEBROUGH N.J., FARR A.L., RANDALL R.J., PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT, J BIOL CHEM, 193, PP. 265-275, (1951); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, INT J PHARM SCI REV RES, 19, 2, PP. 18-23, (2013); CARBAJAL D., ARRUZAZABALA M.D.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, 1, PP. 61-64, (1998); FARNDALE R.W., COLLAGEN-INDUCED PLATELET ACTIVATION, BLOOD CELLS MOL DIS, 36, 2, PP. 162-165, (2006); YOSHIDA S., SUDO T., NIIMI M., TAO L., SUN B., KAMBAYASHI J., MATSUOKA H., INHIBITION OF COLLAGEN-INDUCED PLATELET AGGREGATION BY ANOPHELINE ANTIPLATELET PROTEIN, A SALIVA PROTEIN FROM A MALARIA VECTOR MOSQUITO, BLOOD, 111, 4, PP. 2007-2014, (2008); MOLINA-CUEVAS V., CARBAJAL-QUINTANA D., LOURDES ARRUZAZABALA-VALMANA M., RAVELO-CALZADO Y., MAS-FERREIRO R., COMPARATIVE STUDY OF POLICOSANOL AND GRAPE SEED EXTRACT ON PLATELET AGGREGATION IN RATS, REVISTA CENIC CIENCIAS BIOLÓGICAS, 42, 1, PP. 3-6, (2011); BELLAVITE P., ANDRIOLI G., GUZZO P., ARIGLIANO P., CHIRUMBOLO S., MANZATO F., SANTONASTASO C., A COLORIMETRIC METHOD FOR THE MEASUREMENT OF PLATELET ADHESION IN MICROTITER PLATES, ANAL BIOCHEM, 216, PP. 444-450, (1994); TANDON N.N., HOLLAND E.A., KRALISZ U., KLEINMAN H.K., ROBEY F.A., JAMIESON G.A., INTERACTION OF HUMAN PLATELETS WITH LAMININ AND IDENTIFICATION OF THE 67 KDA LAMININ RECEPTOR ON PLATELETS, BIOCHEM J, 274, PP. 535-542, (1991); BROBERG M., ERIKSSON C., NYGREN H., GPIIB/IIIA IS THE MAIN RECEPTOR FOR INITIAL PLATELET ADHESION TO GLASS AND TITANIUM SURFACES IN CONTACT WITH WHOLE BLOOD, J LAB CLIN MED, 139, 3, PP. 163-172, (2002); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997)","M. ISMAIL; UNIVERSITI PUTRA MALAYSIA, DEPARTMENT OF NUTRITION AND DIETETICS, FACULTY OF MEDICINE AND HEALTH SCIENCES, SERDANG, SELANGOR, 43400, MALAYSIA; EMAIL: MAZNAHIS@UPM.EDU.MY","BIOMED CENTRAL LTD.","ENGLISH","BMC COMPLEMENT. ALTERN. MED.","ARTICLE","ISI","2-S2.0-84979521164","BMC COMPLEMENT ALTERN MED","UNIVERSITI PUTRA MALAYSIA;UNIVERSITI PUTRA MALAYSIA;ZHENGZHOU UNIVERSITY;AFFILIATED HOSPITAL OF CHENGDE MEDICAL UNIVERSITY","NOTREPORTED;UNIVERSITI PUTRA MALAYSIA;NOTREPORTED",NA,"WONG W-T, 2016, BMC COMPLEMENT ALTERN MED","WONG W-T, 2016, BMC COMPLEMENT ALTERN MED"
"D'ADDATO S;SCANDIANI L;MOMBELLI G;FOCANTI F;PELACCHI F;SALVATORI E;DI L G;COMANDINI A;MAFFIOLI P;DEROSA G","D’ADDATO, SERGIO (55234172300); SCANDIANI, LUCIANA (6506167447); MOMBELLI, GIULIANA (23480174800); FOCANTI, FRANCESCA (57194323638); PELACCHI, FEDERICA (58332598500); SALVATORI, ENRICA (6603648112); DI LORETO, GIORGIO (57198391036); COMANDINI, ALESSANDRO (6508176142); MAFFIOLI, PAMELA (23985844600); DEROSA, GIUSEPPE (7005336159)","EFFECT OF A FOOD SUPPLEMENT CONTAINING BERBERINE MONACOLIN K HYDROXYTYROSOL AND COENZYME Q10 ON LIPID LEVELS A RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY",2017,"DRUG DESIGN, DEVELOPMENT AND THERAPY","11","7",27,"10.2147/DDDT.S128623","MEDICAL AND SURGICAL SCIENCE DEPARTMENT, S. ORSOLA MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;DEPARTMENT OF INTERNAL MEDICINE, AZIENDA OSPEDALIERA-POLO UNIVERSITARIO OSPEDALE LUIGI SACCO, MILAN, ITALY;DYSLIPIDEMIA CENTER, HOSPITAL NIGUARDA CA’ GRANDA, MILAN, ITALY;ACRAF S P A. ANGELINI RESEARCH CENTER RR & D, ANCONA, ITALY;ACRAF S P A. ANGELINI RESEARCH CENTER RR & D, ANCONA, ITALY;ACRAF S P A. ANGELINI RESEARCH CENTER RR & D, ANCONA, ITALY;ACRAF S P A. ANGELINI RESEARCH CENTER RR & D, ANCONA, ITALY;ACRAF S P A. ANGELINI RESEARCH CENTER RR & D, ANCONA, ITALY;CENTER OF DIABETES AND METABOLIC DISEASES, DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, FONDAZIONE IRCCS POLICLINICO SAN MATTEO UNIVERSITY OF PAVIA, PAVIA, ITALY;CENTER OF DIABETES AND METABOLIC DISEASES, DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, FONDAZIONE IRCCS POLICLINICO SAN MATTEO UNIVERSITY OF PAVIA, PAVIA, ITALY","PURPOSE: TO EVALUATE THE ABILITY OF THE NEW FOOD SUPPLEMENT, BODY LIPID (BL), CONTAINING RED YEAST RICE, BERBERINE, COENZYME Q10 AND HYDROXYTYROSOL, TO LOWER THE LDL-C IN PATIENTS WITH MILD-TO-MODERATE HYPERCHOLESTEROLEMIA AND TO ASSESS THE OVERALL SAFETY PROFILE OF THE PRODUCT. METHODS: IN THIS MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR (THE MARKETED ARMOLIPID PLUS®[AM]) CONTROLLED STUDY, 158 HYPERCHOLESTEROLEMIC PATIENTS WERE RANDOMIZED FOLLOWING A 4-WEEK DIETARY RUN-IN PERIOD. AFTER 4 WEEKS OF TREATMENT WITH A DAILY ORAL DOSE OF THE NEW FOOD SUPPLEMENT BL, AM OR PLACEBO, PLUS DIET, THE MAIN OUTCOME WAS THE DECREASE OF LDL-C, TOTAL CHOLESTEROL (TC), AND TRIGLYCERIDE LEVELS. FINDINGS: THE ABSOLUTE CHANGES OF LDL-C AND TC LEVELS FROM BASELINE, AT WEEK 4 WERE: -39.1 MG/DL ±17.76 AND -45.9 MG/DL ±21.54, RESPECTIVELY IN THE BL GROUP; 5.7 MG/DL ±14.98 AND 2.4 MG/DL ±18.43, RESPECTIVELY IN THE PLACEBO GROUP. RESULTS WERE STATISTICALLY SIGNIFICANT. IN TERMS OF MEAN PERCENTAGE, BL WAS SHOWN TO BE MORE EFFECTIVE IN LOWERING LDL-C LEVELS AS COMPARED TO PLACEBO AND THE ACTIVE COMPARATOR (AM), WITH A REDUCTION OF -26.3%, +4.2%, -18.3%, RESPECTIVELY. FIVE ADVERSE EVENTS (AES) WERE REPORTED BY FIVE PATIENTS AFTER THE INITIATION OF THE STUDY TREATMENT: TWO IN THE BL GROUP (INFLUENCE AND INSOMNIA), TWO IN THE AM GROUP (EAR PAIN AND RASH), AND ONE IN THE PLACEBO GROUP (BACK PAIN). ALL AES WERE MILD IN INTENSITY, EXCEPT FOR BACK PAIN (SEVERE). THE CASE OF INSOMNIA IN THE BL GROUP AND THE CASE OF RASH IN THE AM GROUP WERE JUDGED AS TREATMENT RELATED. THE SAFETY REVIEW OF THE LABORATORY (BLOOD AND URINE) ANALYSES, VITAL SIGNS AND PHYSICAL FINDINGS DID NOT SHOW ANY CLINICAL EFFECT OF THE STUDY PRODUCTS ON ANY OF THE PARAMETERS. IMPLICATIONS: BL SHOWED A GOOD EFFICACY AND SAFETY PROFILE AND, FOR THIS REASON, IT CAN BE CONSIDERED AN ALTERNATIVE TO PHARMACOLOGICAL TREATMENT, FOR PATIENTS WITH MILD-TO-MODERATE HYPERCHOLESTEROLEMIA. © 2017 D’ADDATO ET AL.","BERBERINE; COENZYME Q<SUB>10</SUB>; HYDROXYTYROSOL; LIPID PROFILE; RED YEAST RICE","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; ITALY; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ARMOLIPID PLUS; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; BERBERINE; CREATINE KINASE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYTYROSOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; UREA; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OTALGIA; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RASH; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOWN REGULATION; HYPERCHOLESTEROLEMIA; ITALY; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME","","","ROSAMOND W., FLEGAL K., FURIE K., ET AL., HEART DISEASE AND STROKE STATISTICS 2008 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE, CIRCULATION, 117, 4, PP. EE25-E146, (2008); THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, 25, PP. 3143-3421, (2002); KAMAL-BAHL S.J., BURKE T., WATSON D., WENTWORTH C., DISCONTINUATION OF LIPID MODIFYING DRUGS AMONG COMMERCIALLY INSURED UNITED STATES PATIENTS IN RECENT CLINICAL PRACTICE, AM J CARDIOL, 99, 4, PP. 530-534, (2007); BAYS H., STATIN SAFETY: AN OVERVIEW AND ASSESSMENT OF THE DATA - 2005, AM J CARDIOL, 97, 8A, PP. 6CC-26C, (2006); DEROSA G., ROMANO D., D'ANGELO A., MAFFIOLI P., BERBERIS ARISTATA COMBINED WITH SILYBUM MARIANUM ON LIPID PROFILE IN PATIENTS NOT TOLERATING STATINS AT HIGH DOSES, ATHEROSCLEROSIS, 239, 1, PP. 87-92, (2015); DEROSA G., BONAVENTURA A., BIANCHI L., ET AL., BERBERIS ARISTATA/SILYBUM MARIANUM FIXED COMBINATION ON LIPID PROFILE AND INSULIN SECRETION IN DYSLIPIDEMIC PATIENTS, EXPERT OPIN BIOL THER, 13, 11, PP. 1495-1506, (2013); CICERO A.F., DEROSA G., PARINI A., ET AL., RED YEAST RICE IMPROVES LIPID PATTERN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND VASCULAR REMODELING PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC ITALIAN SUBJECTS, NUTR RES, 33, 8, PP. 622-628, (2013); DEROSA G., BONAVENTURA A., BIANCHI L., ET AL., A RANDOMIZED, PLACEBO-CONTROLLED STUDY ON THE EFFECTS OF A NUTRACEUTICAL COMBINATION OF RED YEAST RICE, SILYBUM MARIANUM AND OCTASONOL ON LIPID PROFILE, ENDOTHELIAL AND INFLAMMATORY PARAMETERS, J BIOL REGUL HOMEOST AGENTS, 28, 2, PP. 317-324, (2014); DEROSA G., MAFFIOLI P., NUTRACEUTICALS FOR THE TREATMENT OF METABOLIC DISEASES: EVIDENCE FROM CLINICAL PRACTICE, EXPERT REV ENDOCRINOL METAB, 10, 3, PP. 297-304, (2015); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, 1, PP. 61-68, (2014); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, 12, PP. 1344-1351, (2004); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, 6, PP. 1281-1288, (2006); DEROSA G., D'ANGELO A., BONAVENTURA A., BIANCHI L., ROMANO D., MAFFIOLI P., EFFECTS OF BERBERINE ON LIPID PROFILE IN SUBJECTS WITH LOW CARDIOVASCULAR RISK, EXPERT OPIN BIOL THER, 13, 4, PP. 475-482, (2013); SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/20061, EFSA JOURNAL, 9, 7, (2011); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., ET AL., ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, 25, PP. SS1-S45, (2013); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, 12, PP. 830-839, (2009); VENERO C.V., VENERO J.V., WORTHAM D.C., THOMPSON P.D., LIPID-LOWERING EFFICACY OF RED YEAST RICE IN A POPULATION INTOLERANT TO STATINS, AM J CARDIOL, 105, 5, PP. 664-666, (2010); BORDEN W.B., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS, CURR ATHEROSCLER REP, 12, 1, PP. 11-13, (2010); MCCARTY M.F., O'KEEFE J.H., DINICOLANTONIO J.J., RED YEAST RICE PLUS BERBERINE: PRACTICAL STRATEGY FOR PROMOTING VASCULAR AND METABOLIC HEALTH, ALTERN THER HEALTH MED, 21, PP. 40-45, (2015)","G. DEROSA; DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PAVIA, FONDAZIONE IRCCS POLICLINICO SAN MATTEO, PAVIA, PIAZZALE GOLGI 2, 27100, ITALY; EMAIL: GIUSEPPE.DEROSA@UNIPV.IT","DOVE MEDICAL PRESS LTD.","ENGLISH","DRUG DES. DEV. THER.","ARTICLE","ISI","2-S2.0-85019671291","DRUG DES DEV THER","UNIVERSITY OF BOLOGNA;AZIENDA OSPEDALIERA-POLO UNIVERSITARIO OSPEDALE LUIGI SACCO;DYSLIPIDEMIA CENTER;ACRAF S P A. ANGELINI RESEARCH CENTER RR AND D;ACRAF S P A. ANGELINI RESEARCH CENTER RR AND D;ACRAF S P A. ANGELINI RESEARCH CENTER RR AND D;ACRAF S P A. ANGELINI RESEARCH CENTER RR AND D;ACRAF S P A. ANGELINI RESEARCH CENTER RR AND D;FONDAZIONE IRCCS POLICLINICO SAN MATTEO UNIVERSITY OF PAVIA;FONDAZIONE IRCCS POLICLINICO SAN MATTEO UNIVERSITY OF PAVIA","NOTREPORTED;UNIVERSITY OF PAVIA;NOTREPORTED",NA,"D'ADDATO S, 2017, DRUG DES DEV THER","D'ADDATO S, 2017, DRUG DES DEV THER"
"LEE J;JIA Y;THACH T;HAN Y;KIM B;WU C;KIM Y;SEO W;LEE S","LEE, JI HAE (56046902700); JIA, YAOYAO (41861604900); THACH, TRUNG THANH (56294535000); HAN, YURI (57194654959); KIM, BOBAE (55569996000); WU, CHUNYAN (56163311200); KIM, YEONJI (57203809362); SEO, WOO DUCK (8921329600); LEE, SUNG-JOON (23065729100)","HEXACOSANOL REDUCES PLASMA AND HEPATIC CHOLESTEROL BY ACTIVATION OF AMPACTIVATED PROTEIN KINASE AND SUPPRESSION OF STEROL REGULATORY ELEMENTBINDING PROTEIN2 IN HEPG2 AND C57BL6J MICE",2017,"NUTRITION RESEARCH","43","10",19,"10.1016/j.nutres.2017.05.013","DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA;DEPARTMENT OF FUNCTIONAL CROP, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RURAL DEVELOPMENT ADMINISTRATION (RDA), JEONJU, 55365, SOUTH KOREA;DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA","POLICOSANOLS HAVE HYPOCHOLESTEROLEMIC ACTIVITY; HOWEVER, THE MOLECULAR MECHANISM OF THE POLICOSANOL EFFECTS IS CURRENTLY POORLY CHARACTERIZED. WE HYPOTHESIZED THAT HEXACOSANOL, A POLICOSANOL COMPOUND DERIVED FROM BARLEY SPROUT, MAY DECREASE CELLULAR AND PLASMA CHOLESTEROL LEVELS; WE THUS INVESTIGATED THE HYPOCHOLESTEROLEMIC ACTIVITY AND MECHANISM OF HEXACOSANOL ON BOTH HEPATOCYTES AND HIGH-FAT–INDUCED OBESE C57BL/6J MICE. THE REDUCTION OF TOTAL CHOLESTEROL, FREE CHOLESTEROL, AND CHOLESTERYL ESTER CONCENTRATIONS WAS CONFIRMED IN HEXACOSANOL-STIMULATED HEPATOCYTES (−38%, −33%, AND −53%, RESPECTIVELY). PLASMA, HEPATIC CHOLESTEROL CONCENTRATIONS, AND HEPATIC STEATOSIS WERE SIGNIFICANTLY REDUCED IN HIGH-FAT–FED MICE ORALLY ADMINISTERED WITH HEXACOSANOL (0.7 MG/KG BODY WEIGHT A DAY) FOR 8 WEEKS COMPARED WITH THOSE OF VEHICLE-FED CONTROL MICE (−15% AND −40%, RESPECTIVELY). HEXACOSANOL IN FACT BOUND TO THE ALLOSTERIC REGULATION SITE OF AMP-ACTIVATED PROTEIN KINASE (AMPK)-Β SUBUNIT AND THUS ACTIVATED AMPK THAT INHIBITED THE ACTIVITY OF 3-HYDROXY-3-METHYL-GLUTARYL-COENZYME A REDUCTASE BY INHIBITORY PHOSPHORYLATION. IN ADDITION, ACTIVATION OF AMPK BY HEXACOSANOL INDUCED HEPATIC AUTOPHAGY ACTIVITY, WHICH COULD FURTHER REDUCE HEPATIC LIPID ACCUMULATION. ALTERNATIVELY, HEXACOSANOL SUPPRESSED THE NUCLEAR TRANSLOCATION AND ACTIVATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 (SREBP-2), A KEY TRANSCRIPTION FACTOR IN CHOLESTEROL BIOSYNTHESIS. THESE RESULTS COLLECTIVELY SUGGEST THAT HEXACOSANOL IS A MAJOR HYPOCHOLESTEROLEMIC COMPOUND IN BARLEY SPROUTS WITH REGULATION OF AMPK ACTIVATION AND SREBP-2 SUPPRESSION. THESE SUPPRESS 3-HYDROXY-3-METHYL-GLUTARYL-COENZYME A REDUCTASE AT BOTH MRNA EXPRESSION AND PROTEIN ACTIVITY LEVELS. IN CONCLUSION, HEXACOSANOL ACTIVATES AMPK AND HEPATIC AUTOPHAGY AND INHIBITS SREBP2, RESULTING IN HYPOCHOLESTEROLEMIC ACTIVITIES AND IMPROVEMENT OF HEPATIC STEATOSIS. © 2017","AMPK; HEXACOSANOL; HMG-COA REDUCTASE; HYPOCHOLESTEROLEMIA; SREBP-2","AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CHOLESTEROL; DIET, HIGH-FAT; FATTY ALCOHOLS; FATTY LIVER; HEP G2 CELLS; HEPATOCYTES; HORDEUM; HUMANS; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; MICE, OBESE; PHOSPHORYLATION; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTORS; AMP ACTIVATED PROTEIN KINASE BETA SUBUNIT; CHOLESTEROL ESTER; HEXACOSANOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG; 1-HEXACOSANOL; CHOLESTEROL; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SREBF2 PROTEIN, HUMAN; SREBF2 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR; 3 HYDROXY 3 METHYL GLUTARYL COENZYME A REDUCTASE GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BINDING SITE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE EXPRESSION; HEP-G2 CELL LINE; HYPERCHOLESTEROLEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; GENETICS; HORDEUM; HUMAN; LIPID DIET; LIPID METABOLISM; LIVER; LIVER CELL; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION","MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP, (NRF-2016R1A2A2A0500500 5483, PJ01125304); RURAL DEVELOPMENT ADMINISTRATION, RDA; NATIONAL RESEARCH FOUNDATION OF KOREA, NRF","THIS WORK WAS CARRIED OUT WITH THE SUPPORT OF THE NATIONAL RESEARCH FOUNDATION OF KOREA (NRF) GRANT FUNDED BY THE KOREAN GOVERNMENT (MSIP) (NRF-2016R1A2A2A0500500 5483), AND A GRANT (PJ01125304) FROM COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURE SCIENCE & TECHNOLOGY DEVELOPMENT, RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA.","MAXFIELD F.R., TABAS I., ROLE OF CHOLESTEROL AND LIPID ORGANIZATION IN DISEASE, NATURE, 438, PP. 612-621, (2005); NACI H., DIAS S., ADES A.E., INDUSTRY SPONSORSHIP BIAS IN RESEARCH FINDINGS: A NETWORK META-ANALYSIS OF LDL CHOLESTEROL REDUCTION IN RANDOMISED TRIALS OF STATINS, BMJ, 349, (2014); GUYTON J.R., BENEFIT VERSUS RISK IN STATIN TREATMENT, AM J CARDIOL, 97, PP. 95C-97C, (2006); BROWN M.S., GOLDSTEIN J.L., A PROTEOLYTIC PATHWAY THAT CONTROLS THE CHOLESTEROL CONTENT OF MEMBRANES, CELLS, AND BLOOD, PROC NATL ACAD SCI U S A, 96, PP. 11041-11048, (1999); KAWABE Y., HONDA M., WADA Y., YAZAKI Y., SUZUKI T., OHBA Y., ET AL., STEROL MEDIATED REGULATION OF SREBP-1A,1B,1C AND SREBP-2 IN CULTURED HUMAN CELLS, BIOCHEM BIOPHYS RES COMMUN, 202, PP. 1460-1467, (1994); CLARKE P.R., HARDIE D.G., REGULATION OF HMG-COA REDUCTASE: IDENTIFICATION OF THE SITE PHOSPHORYLATED BY THE AMP-ACTIVATED PROTEIN KINASE IN VITRO AND IN INTACT RAT LIVER, EMBO J, 9, PP. 2439-2446, (1990); LI Y., XU S.Q., MIHAYLOVA M.M., ZHENG B., HOU X.Y., JIANG B.B., ET AL., AMPK PHOSPHORYLATES AND INHIBITS SREBP ACTIVITY TO ATTENUATE HEPATIC STEATOSIS AND ATHEROSCLEROSIS IN DIET-INDUCED INSULIN-RESISTANT MICE, CELL METAB, 13, PP. 376-388, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GIUFFRE A.M., THE EFFECTS OF CULTIVAR AND HARVEST YEAR ON THE FATTY ALCOHOL COMPOSITION OF OLIVE OILS FROM SOUTHWEST CALABRIA (ITALY), GRASAS ACEITES, 65, (2014); GIUFFRE A.M., EVOLUTION OF FATTY ALCOHOLS IN OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY) DURING FRUIT RIPENING, J OLEO SCI, 63, PP. 485-496, (2014); GIUFFRE A.M., CAPOCASALE M., POLICOSANOL IN TOMATO (SOLANUM LYCOPERSICUM L.) SEED OIL: THE EFFECT OF CULTIVAR, J OLEO SCI, 64, PP. 625-631, (2015); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); WANG Y., EBINE N., JIA X., JONES P.J., FAIROW C., JAEGER R., VERY LONG CHAIN FATTY ACIDS (POLICOSANOLS) AND PHYTOSTEROLS AFFECT PLASMA LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, METABOLISM, 54, PP. 508-514, (2005); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, PP. 982.E1-982.E5, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); LEE J.H., LEE S.Y., KIM B., SEO W.D., JIA Y., WU C., ET AL., BARLEY SPROUT EXTRACT CONTAINING POLICOSANOLS AND POLYPHENOLS REGULATE AMPK, SREBP2 AND ACAT2 ACTIVITY AND CHOLESTEROL AND GLUCOSE METABOLISM IN VITRO AND IN VIVO, FOOD RES INT, 72, PP. 174-183, (2015); SEO W.D., YUK H.J., CURTIS-LONG M.J., JANG K.C., LEE J.H., HAN S.I., ET AL., EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5′-MONOPHOSPHATE–ACTIVATED PROTEIN KINASE ACTIVATION, J AGRIC FOOD CHEM, 61, PP. 1117-1123, (2013); SAITO M., KINOSHITA Y., SATOH I., SHINBORI C., KONO T., HANADA T., ET AL., N-HEXACOSANOL AMELIORATES STREPTOZOTOCIN-INDUCED DIABETIC RAT NEPHROPATHY, EUR J PHARMACOL, 544, PP. 132-137, (2006); SHINBORI C., SAITO M., KINOSHITA Y., SATOH I., KONO T., HANADA T., ET AL., N-HEXACOSANOL REVERSES DIABETIC INDUCED MUSCARINIC HYPERCONTRACTILITY OF ILEUM IN THE RAT, EUR J PHARMACOL, 545, PP. 177-184, (2006); DAVIES S.P., CARLING D., HARDIE D.G., TISSUE DISTRIBUTION OF THE AMP-ACTIVATED PROTEIN-KINASE, AND LACK OF ACTIVATION BY CYCLIC-AMP–DEPENDENT PROTEIN KINASE, STUDIED USING A SPECIFIC AND SENSITIVE PEPTIDE ASSAY, EUR J BIOCHEM, 186, PP. 123-128, (1989); JIA Y., KIM J.Y., JUN H.J., KIM S.J., LEE J.H., HOANG M.H., ET AL., THE NATURAL CAROTENOID ASTAXANTHIN, A PPAR-ALPHA AGONIST AND PPAR-GAMMA ANTAGONIST, REDUCES HEPATIC LIPID ACCUMULATION BY REWIRING THE TRANSCRIPTOME IN LIPID-LOADED HEPATOCYTES, MOL NUTR FOOD RES, 56, PP. 878-888, (2012); REAGAN-SHAW S., NIHAL M., AHMAD N., DOSE TRANSLATION FROM ANIMAL TO HUMAN STUDIES REVISITED, FASEB J, 22, PP. 659-661, (2008); JIA Y., KIM S., KIM J., KIM B., WU C., LEE J.H., ET AL., URSOLIC ACID IMPROVES LIPID AND GLUCOSE METABOLISM IN HIGH-FAT–FED C57BL/6J MICE BY ACTIVATING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AND HEPATIC AUTOPHAGY, MOL NUTR FOOD RES, 59, PP. 344-354, (2015); HOANG M.H., JIA Y., JUN H.J., LEE J.H., HWANG K.Y., CHOI D.W., ET AL., TAURINE IS A LIVER X RECEPTOR-ALPHA LIGAND AND ACTIVATES TRANSCRIPTION OF KEY GENES IN THE REVERSE CHOLESTEROL TRANSPORT WITHOUT INDUCING HEPATIC LIPOGENESIS, MOL NUTR FOOD RES, 56, PP. 900-911, (2012); FISCHER A.H., JACOBSON K.A., ROSE J., ZELLER R., HEMATOXYLIN AND EOSIN STAINING OF TISSUE AND CELL SECTIONS, CSH PROTOC, 2008, (2008); HECTOR A.L., JOLLEYS A., LEVASON W., REID G., TEX4 (X = F, CL, BR) AS LEWIS ACIDS-COMPLEXES WITH SOFT THIO- AND SELENO-ETHER LIGANDS, DALTON TRANS, 41, PP. 10988-10999, (2012); JUN H.J., LEE J.H., KIM J., JIA Y., KIM K.H., HWANG K.Y., ET AL., LINALOOL IS A PPAR-ALPHA LIGAND THAT REDUCES PLASMA TG LEVELS AND REWIRES THE HEPATIC TRANSCRIPTOME AND PLASMA METABOLOME, J LIPID RES, 55, PP. 1098-1110, (2014); MAHMOOD T., YANG P.C., WESTERN BLOT: TECHNIQUE, THEORY, AND TROUBLE SHOOTING, N AM J MED SCI, 4, PP. 429-434, (2012); MIZUSHIMA N., YOSHIMORI T., LEVINE B., METHODS IN MAMMALIAN AUTOPHAGY RESEARCH, CELL, 140, PP. 313-326, (2010); MIHAYLOVA M.M., SHAW R.J., THE AMPK SIGNALLING PATHWAY COORDINATES CELL GROWTH, AUTOPHAGY AND METABOLISM, NAT CELL BIOL, 13, PP. 1016-1023, (2011); CHRISTIAN P., SACCO J., ADELI K., AUTOPHAGY: EMERGING ROLES IN LIPID HOMEOSTASIS AND METABOLIC CONTROL, BIOCHIM BIOPHYS ACTA, 2013, PP. 819-824, (1831); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); BROWN M.S., GOLDSTEIN J.L., THE SREBP PATHWAY: REGULATION OF CHOLESTEROL METABOLISM BY PROTEOLYSIS OF A MEMBRANE-BOUND TRANSCRIPTION FACTOR, CELL, 89, PP. 331-340, (1997); ROTH A., LOOSER R., KAUFMANN M., BLATTLER S.M., RENCUREL F., HUANG W.D., ET AL., REGULATORY CROSS-TALK BETWEEN DRUG METABOLISM AND LIPID HOMEOSTASIS: CONSTITUTIVE ANDROSTANE RECEPTOR AND PREGNANE X RECEPTOR INCREASE INSIG-1 EXPRESSION, MOL PHARMACOL, 73, PP. 1282-1289, (2008); CZAJA M.J., AUTOPHAGY IN HEALTH AND DISEASE. 2. REGULATION OF LIPID METABOLISM AND STORAGE BY AUTOPHAGY: PATHOPHYSIOLOGICAL IMPLICATIONS, AM J PHYSIOL CELL PHYSIOL, 298, PP. C973-C978, (2010); DONG H., CZAJA M.J., REGULATION OF LIPID DROPLETS BY AUTOPHAGY, TRENDS ENDOCRINOL METAB, 22, PP. 234-240, (2011); LIPPAI M., LOW P., THE ROLE OF THE SELECTIVE ADAPTOR P62 AND UBIQUITIN-LIKE PROTEINS IN AUTOPHAGY, BIOMED RES INT, 2014, (2014); BRADLEY J.R., TNF-MEDIATED INFLAMMATORY DISEASE, J PATHOL, 214, PP. 149-160, (2008); PEPYS M.B., HIRSCHFIELD G.M., C-REACTIVE PROTEIN: A CRITICAL UPDATE, J CLIN INVEST, 111, PP. 1805-1812, (2003); SALMINEN A., HYTTINEN J.M., KAARNIRANTA K., AMP-ACTIVATED PROTEIN KINASE INHIBITS NF-KAPPAB SIGNALING AND INFLAMMATION: IMPACT ON HEALTHSPAN AND LIFESPAN, J MOL MED (BERL), 89, PP. 667-676, (2011); CACICEDO J.M., YAGIHASHI N., KEANEY J.F., RUDERMAN N.B., IDO Y., AMPK INHIBITS FATTY ACID-INDUCED INCREASES IN NF-KAPPAB TRANSACTIVATION IN CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS, BIOCHEM BIOPHYS RES COMMUN, 324, PP. 1204-1209, (2004); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., VAZQUEZ R.D., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., ET AL., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, PP. 155-162, (2009)","S.-J. LEE; DEPARTMENT OF BIOTECHNOLOGY, SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY FOR BK21 PLUS, KOREA UNIVERSITY, SEOUL, 02841, SOUTH KOREA; EMAIL: JUNELEE@KOREA.AC.KR","ELSEVIER INC.","ENGLISH","NUTR. RES.","ARTICLE","ISI","2-S2.0-85021419416","NUTR RES","SEOUL;SEOUL;SEOUL;SEOUL;SEOUL;SEOUL;SEOUL;NATIONAL INSTITUTE OF CROP SCIENCE (NICS);SEOUL","NOTREPORTED;KOREA UNIVERSITY;NOTREPORTED",NA,"LEE JH, 2017, NUTR RES","LEE JH, 2017, NUTR RES"
"SÁNCHEZ J;ILLNAIT J;MAS R;MENDOZA S;FERNÁNDEZ L;MESA M;VEGA H;FERNÁNDEZ J;REYES P;RUIZ D","SÁNCHEZ, JAVIER (57210524556); ILLNAIT, JOSÉ (8631465800); MAS, ROSA (7007164570); MENDOZA, SARAHÍ (7102759819); FERNÁNDEZ, LILIA (7202848319); MESA, MEILIS (36880545700); VEGA, HERMYS (57188666109); FERNÁNDEZ, JULIO (9432805500); REYES, PABLO (57196910548); RUIZ, DALMER (26425153000)","LONGTERM EFFECT OF POLICOSANOL ON THE FUNCTIONAL RECOVERY OF NONCARDIOEMBOLIC ISCHEMIC STROKE PATIENTS A ONE YEAR STUDY EFECTO A LARGO PLAZO DEL POLICOSANOL EN LA RECUPERACIÓN FUNCIONAL DE PACIENTES CON ICTUS ISQUÉMICO NO CARDIOEMBÓLICO ESTUDIO DE UN AÑO",2017,"REVISTA DE NEUROLOGIA","64","8",7,"10.33588/rn.6404.2016180","INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;GRUPO DE BASE DE DATOS, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA;GRUPO DE BASE DE DATOS, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, CUBA","INTRODUCTION. STROKE IS A LEADING CAUSE OF MORTALITY AND DISABILITY. POLICOSANOL HAS BEEN EFFECTIVE IN BRAIN ISCHEMIA MODELS. THE AIM OF THIS STUDY IS TO INVESTIGATE WHETHER POLICOSANOL, ADDED TO ASPIRIN THERAPY WITHIN 30 DAYS OF STROKE ONSET, IS BETTER THAN PLACEBO + ASPIRINE FOR THE LONG-TERM RECOVERY OF NON-CARDIOEMBOLIC ISCHEMIC STROKE SUBJECTS. PATIENTS AND METHODS. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. EIGHTY PATIENTS (MEAN AGE: 69 YEARS) WITHIN 30 DAYS OF ONSET, WITH A MODIFIED RANKIN SCALE SCORE (MRS) 2 TO 4, WERE INCLUDED. THEY WERE RANDOMIZED IN TWO GROUPS (POLICOSANOL + ASPIRINE OR PLACEBO + ASPIRINE) FOR 12 MONTHS. RESULTS. POLICOSANOL + ASPIRINE DECREASED SIGNIFICANTLY MEAN MRS FROM THE FIRST INTERIM CHECK-UP (1.5 MONTHS). THE TREATMENT EVEN IMPROVED AFTER LONG-TERM THERAPY. MORE POLICOSANOL + ASPIRIN (87.5%) THAN PLACEBO + ASPIRINE (0%) PATIENTS ACHIEVED MRSS ≤ 1. POLICOSANOL + ASPIRINE INCREASED SIGNIFICANTLY BARTHEL INDEX, LOWERED LDL-CHOLESTEROL AND INCREASED HDL-CHOLESTEROL VERSUS PLACEBO + ASPIRIN. CONCLUSIONS. LONG-TERM (12 MONTHS) ADMINISTRATION OF POLICOSANOL + ASPIRIN GIVEN AFTER SUFFERING NON-CARDIOEMBOLIC ISCHEMIC STROKE WAS SHOWN TO BE BETTER THAN PLACEBO + ASPIRIN IN IMPROVING FUNCTIONAL OUTCOMES WHEN USED AMONG PATIENTS WITH NON-CARDIOEMBOLIC ISCHEMIC STROKE OF MODERATE SEVERITY. © 2017 REVISTA DE NEUROLOGÍA.","ASPIRIN; BARTHEL INDEX; MODIFIED RANKIN SCALE; NON-CARDIOEMBOLIC ISCHEMIC STROKE; PLACEBO; POLICOSANOL","AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ASPIRIN; BRAIN DAMAGE, CHRONIC; BRAIN ISCHEMIA; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PATIENT COMPLIANCE; RECOVERY OF FUNCTION; TREATMENT OUTCOME; ACETYLSALICYLIC ACID; LOW DENSITY LIPOPROTEIN; PLACEBO; POLICOSANOL; ACETYLSALICYLIC ACID; CHOLESTEROL; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; AGED; ARTICLE; BARTHEL INDEX; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; BLOOD; BRAIN ISCHEMIA; CHRONIC BRAIN DISEASE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; CONVALESCENCE; DIET THERAPY; FEMALE; HYPERCHOLESTEROLEMIA; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME; VERY ELDERLY","","","AMARENCO P., BOGOUSSLAVSKY J., CAPLAN L.R., DONNAN G.A., HENNERICI M.G., CLASSIFICATION OF STROKE SUBTYPES, CEREBROVASC DIS, 27, PP. 493-501, (2009); AMANTEA D., NAPPI G., BERNARDI G., BAGETTA G., CORASANITI M.T., POST-ISCHEMIC BRAIN DAMAGE: PATHOPHYSIOLOGY AND ROLE OF INFLAMMATORY MEDIATORS, FEBS J, 276, PP. 13-26, (2009); DI CARLO A., HUMAN AND ECONOMIC BURDEN OF STROKE, AGE AGEING, 38, PP. 4-5, (2009); ROGER V.L., GO A.S., LLOYD-JONES D.M., BENJAMIN E.J., BERRY J.D., BORDEN W.B., ET AL., HEART DISEASE AND STROKE STATISTICS –2012 UPDATE, CIRCULATION, 125, PP. E2-E220, (2012); COUILLARD P., POPPE A.Y., COUTTS S.B., PREDICTING RECURRENT STROKE AFTER MINOR STROKE AND TRANSIENT ISCHEMIC ATTACK, EXPERT REV CARDIOVASC THER, 7, PP. 1273-1281, (2009); ARBOIX A., CARDIOVASCULAR RISK FACTORS FOR ACUTE STROKE: RISK PROFILES IN THE DIFFERENT SUBTYPES OF ISCHEMIC STROKE, WORLD J CLIN CASES, 3, PP. 418-429, (2015); COLLABORATIVE META-ANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE IN HIGH/RISK PATIENTS, BMJ, 324, PP. 71-86, (2000); LEVI M., TH ROMBOPROPHYLAXIS FOR CEREBROVASCULAR DISORDERS: ACETYLSALICYLIC ACID REMAINS THE CORNERSTONE, NED TIJDSCHR GENEESKD, 152, PP. 423-425, (2008); LIKOSKY D.J., LEE K., BROWN D.M., AMIN A., DRESSLER D.D., KRAKOW D., ET AL., EVIDENCE-BASED MEDICINE: REVIEW OF GUIDELINES AND TRIALS IN THE PREVENTION OF SECONDARY STROKE, J HOSP MED, 3, PP. S6-S19, (2008); PATRONO C., ROCCA B., ASPIRIN: PROMISE AND RESISTANCE IN THE NEW MILLENNIUM, ARTERIOSCLER TH ROMB VASC BIOL, 28, PP. S25-S32, (2008); AMARENCO P., LABREUCHE J., LIPID MANAGEMENT IN THE PREVENTION OF STROKE: REVIEW AND UPDATED META-ANALYSIS OF STATINS FOR STROKE PREVENTION, LANCET NEUROL, 8, PP. 453-463, (2009); NACI H., BRUGTS J.J., FLEURENCE R., ADES A.E., COMPARATIVE EFFECTS OF STATINS ON MAJOR CEREBROVASCULAR EVENTS: A MULTIPLETREATMENTS META-ANALYSIS OF PLACEBO-CONTROLLED AND ACTIVECOMPARATOR TRIALS, QJM, 106, PP. 299-306, (2013); HJALMARSSON C., BOKEMARK L., MANHEM K., MEHLIG K., ERSSON B., THE EFFECT OF STATINS ON ACUTE AND LONG-TERM OUTCOME AFTER ISCHEMIC STROKE IN THE ELDERLY, AM J GERIATR PHARMACOTHER, 10, PP. 313-322, (2012); SONG B., WANG Y., ZHAO X., LIU L., WANG C., WANG A., ET AL., ASSOCIATION BETWEEN STATIN USE AND SHORT-TERM OUTCOME BASED ON SEVERITY OF ISCHEMIC STROKE: A COHORT STUDY, PLOS ONE, (2014); NI CHROININ D., ASPLUND K., ASBERG S., CALLALY E., CUADRADO-GODIA E., DIEZ-TEJEDOR E., ET AL., STATIN THERAPY AND OUTCOME AFTER ISCHEMIC STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES AND RANDOMIZED TRIALS, STROKE, 44, PP. 448-456, (2013); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS. BRAZIL, J MED BIOL RES, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., ET AL., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J PHARM SCI, 75, PP. 635-641, (2013); SANCHEZ J., FERNANDEZ L., ILLNAIT J., ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., EFFECTS OF POLICOSANOL ON THE RECOVERY OF ISCHEMIC STROKE: A RANDOMIZED CONTROLLED STUDY, IOSR JOURNAL OF PHARMACY, 2, PP. 14-24, (2012); SANCHEZ J., ILLNAIT J., MAS R., PEREZ Y., MENDOZA S., CABRERA C., ET AL., EFFECTS OF POLICOSANOL PLUS ASPIRIN THERAPY ON THE NEUROLOGICAL RECOVERY AND PLASMA OXIDATIVE MARKERS OF PATIENTS WITH ISCHEMIC STROKE, IOSR JOURNAL OF PHARMACY, 4, PP. 31-40, (2013); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., VEGA H., FERNANDEZ L., ET AL., POLICOSANOL VERSUS ATORVASTATIN ON THE FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE, INT J PHARM SCI REV RES, 37, PP. 7-14, (2016); ORTEGA L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE. A PILOT OPEN STUDY, J MED FOOD, 9, PP. 378-385, (2006); SANCHEZ J., MAS R., MENDOZA S., FERNANDEZ J., RUIZ D., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE WITH PREVIOUS TRANSIENT ISCHEMIC ATTACK: A LONG-TERM FOLLOW-UP, REV CENIC CIEN BIOL, 41, PP. 23-29, (2010); RANKIN J., CEREBRAL VASCULAR ACCIDENTS IN PATIENTS OVER THE AGE OF 60. II. PROGNOSIS, SCOTT MED J, 2, PP. 200-215, (1957); QUINN T.J., LANGHORNE P., STOTT D.J., BARTHEL INDEX FOR STROKE TRIALS: DEVELOPMENT, PROPERTIES, AND APPLICATION, STROKE, 42, PP. 1146-1151, (2011); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); O'BRIEN P.C., SHAMPO M.A., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); GHANDEHARI K., CHALLENGING COMPARISON OF STROKE SCALES, J RES MED SCI, 18, PP. 906-910, (2013); ARBOIX A., BELL Y., GARCIA-EROLES L., MASSONS J., COMES E., BALCELLS M., ET AL., CLINICAL STUDY OF 35 PATIENTS WITH DYSARTHRIACLUMSY HAND SYNDROME, J NEUROL NEUROSURG PSYCHIATRY, 75, PP. 231-234, (2004); TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE, N ENGL J MED, 333, PP. 1581-1587, (1995); LEE Y.C., CHEN S.S., KOH C.L., HSUEH I.P., YAO K.P., HSIEH C.L., DEVELOPMENT OF TWO BARTHEL INDEX-BASED SUPPLEMENTARY SCALES FOR PATIENTS WITH STROKE, PLOS ONE, 9, (2014); MAR J., MASJUAN J., OLIVA-MORENO J., GONZALEZ-ROJAS N., BECERRA V., CASADO M.A., ET AL., CONOCES INVESTIGATORS GROUP. OUTCOMES MEASURED BY MORTALITY RATES, QUALITY OF LIFE AND DEGREE OF AUTONOMY IN THE FIRST YEAR IN STROKE UNITS IN SPAIN, HEALTH QUAL LIFE OUTCOMES, 13, (2015); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPER -CHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); NIKITIN I.P., SLEPCHENKO N.V., GRATSIANSKII N.A., NECHAEV A.S., SYRKIN A.L., POLTAVSKAIA M.G., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC POLICOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); WANG Y., KUANMAN K.E., WANG HIA L., JIAO Y., ZHAO X., SUN N., ET AL., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); LIU S., TAN M.Y., ZHAO S.P., RONG H., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND HEME OXYGENASE-1 IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 40, PP. 840-843, (2012); TANG M., WU S.Z., GONG X., EFFECTS OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 4, PP. 488-492, (2013); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, TH ROMB RES, 69, PP. 321-327, (1992); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMBO HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, INT J PHARM SCI REV RES, 19, PP. 18-23, (2013); PARK J.H., LEE J., OVBIAGELE B., NONTRADITIONAL SERUM LIPID VARIABLES AND RECURRENT STROKE RISK, STROKE, 45, PP. 3269-3274, (2014); ARBOIX A., GARCIA-EROLES L., OLIVERES M., TARGA C., BALCELLS M., MASSONS J., PRETREATMENT WITH STATINS IMPROVES EARLY OUTCOME IN PATIENTS WITH FIRST-EVER ISCHAEMIC STROKE: A PLEIOTROPIC EFFECT OF STATINS OR A BENEFICIAL EFFECT OF HYPERCHOLESTEROLEMIA?, BMC NEUROL, 10, PP. 47-54, (2010); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL THER, 318, PP. 1020-1025, (2006); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, PP. 311-321, (2011); CHO K.H., LIM S., YOO J., LEE E., ENHANCEMENT OF HDL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENATION RES, 19, PP. 59-70, (2016); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGHDENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, (2016)","S. MENDOZA; CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, LA HABANA, 125 Y 198, CUBANACAN, PLAYA, CUBA; EMAIL: SARAHI.MENDOZA@CNIC.EDU.CU","REVISTA DE NEUROLOGIA","SPANISH","REV. NEUROL.","ARTICLE","ISI","2-S2.0-85032497500","REV NEUROL","INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS;CENTRO DE INVESTIGACIONES MÉDICO-QUIRÚRGICAS;CENTRO DE PRODUCTOS NATURALES;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS","NOTREPORTED;CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS;NOTREPORTED",NA,"SÁNCHEZ J, 2017, REV NEUROL","SÁNCHEZ J, 2017, REV NEUROL"
"ELSEWEIDY M;AMIN R;ATTEIA H;EL-ZEIKY R;AL-GABRI N","ELSEWEIDY, MOHAMED MAHMOUD (55600488100); AMIN, RAWIA SARHAN (55166394200); ATTEIA, HEBATALLAH HUSSEINI (53983712700); EL-ZEIKY, REHAM RAAFAT (57201994307); AL-GABRI, NAIF A. (57201996110)","NEW INSIGHT ON A COMBINATION OF POLICOSANOL AND 10DEHYDROGINGERDIONE PHYTOCHEMICALS AS INHIBITORS FOR PLATELET ACTIVATION BIOMARKERS AND ATHEROGENICITY RISK IN DYSLIPIDEMIC RABBITS ROLE OF CETP AND PCSK9 INHIBITION",2018,"APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY","186","10",11,"10.1007/s12010-018-2776-5","EGYPT;EGYPT;EGYPT;EGYPT;EGYPT, VETERINARY MEDICINE DEPARTMENT, FACULTY OF AGRICULTURE AND VETERINARY MEDICINE, THAMAR UNIVERSITY, DHAMAR, YEMEN","PLATELET MARKERS [SOLUBLE P SELECTIN (SP-SELECTIN) AND SOLUBLE CD40 LIGAND (SCD40L)] ARE ASSOCIATED WITH PLATELET ACTIVATION AND CARDIOVASCULAR RISK. BOTH POLICOSANOL AND 10-DEHYDROGINGERDIONE ARE NATURAL PRODUCTS WITH PROVEN CETP INHIBITORY AND ANTIATHEROGENIC EFFECTS. PRESENT WORK AIMED MAINLY TO INVESTIGATE THE LEVELS OF PLATELET ACTIVATION BIOMARKERS IN THE SERUM OF DYSLIPIDEMIC RABBITS AND THE POTENTIAL OF THESE PHYTOCHEMICALS EITHER ALONE OR IN A COMBINATION FORM TO PROTECT AGAINST ATHEROGENICITY. ADDITIONALLY, THIS WORK CLARIFIED THEIR EFFECT ON PCSK9, A KEY PLAYER IN ATHEROSCLEROSIS PROGRESSION. DAILY ADMINISTRATION OF POLICOSANOL AND/OR 10-DEHYDROGINGERDIONE AT A DOSE LEVEL 10 MG/KG BW RESULTED IN A CETP INHIBITORY ACTIVITY, INCREASING HDL-C LEVEL. THIS PROTECTIVE EFFECT WAS ASSOCIATED WITH IMPROVEMENT IN LIPID PROFILE COMPONENTS AND A REDUCTION IN PCSK9 LEVEL. INTERESTINGLY, THIS COMBINATION STRENGTHENED THE CETP INHIBITORY ACTIVITY OF THESE PHYTOCHEMICALS, LEADING TO A GREATER INCREASE IN SERUM HDL-C LEVEL THAN MONOTHERAPY. HOWEVER, THIS COMBINATION DID NOT ENHANCE THE REDUCTION IN PCSK9 LEVEL. BOTH DRUGS ALSO DECREASED PLATELET ACTIVATION AND INFLAMMATION MARKERS SUCH AS SCD40L, SP-SELECTIN, AND INTERFERON-GAMMA (IFN-Γ), AND THEIR COMBINATION SHOWED A SYNERGISTIC EFFECT. THEREFORE, SUCH PHYTOCHEMICALS MAY BE REGARDED AS PROMISING AGENTS IN THE PROTECTION AGAINST ATHEROTHROMBOSIS RISK. © 2018, SPRINGER SCIENCE+BUSINESS MEDIA, LLC, PART OF SPRINGER NATURE.","ATHEROGENESIS; CETP; DYSLIPIDEMIA; PCSK9; POLICOSANOL","ANIMALS; BLOOD PLATELETS; CHOLESTEROL ESTER TRANSFER PROTEINS; FATTY ALCOHOLS; GUAIACOL; MALE; PHYTOCHEMICALS; PLATELET ACTIVATION; PROPROTEIN CONVERTASE 9; RABBITS; SERINE PROTEINASE INHIBITORS; BIOMARKERS; BODY FLUIDS; CHEMICAL ACTIVATION; DRUG DELIVERY; 10 DEHYDROGINGERDIONE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CD40 LIGAND; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; GAMMA INTERFERON; GINGER EXTRACT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; POLICOSANOL; PROPROTEIN CONVERTASE 9; UNCLASSIFIED DRUG; (10)-DEHYDROGINGERDIONE; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ALCOHOL; GUAIACOL; PHYTOCHEMICAL; POLICOSANOL; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR; ATHEROGENESIS; CETP; DYSLIPIDEMIAS; PCSK9; POLICOSANOL; ADULT; ALBINO RABBIT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GINGER; LEPORIDAE; MALE; MONOTHERAPY; NONHUMAN; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; METABOLISM; THROMBOCYTE; THROMBOCYTE ACTIVATION; PLATELETS","","","PUTTANANJAIAH M.K., DHALE M.A., GAONKAR V., KENI S., STATINS: 3-HYDROXY-3-METHYLGLUTARYL-COA (HMG-COA) REDUCTASE INHIBITORS DEMONSTRATE ANTI-ATHEROSCLEROTIC CHARACTER DUE TO THEIR ANTIOXIDANT CAPACITY, APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 163, 2, PP. 215-222, (2011); KLERKX A.H., EL HARCHAOUI K., VAN DER STEEG W.A., BOEKHOLDT S.M., STROES E.S., KASTELEIN J.J., KUIVENHOVEN J.A., CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION BEYOND RAISING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 26, 4, PP. 706-715, (2006); VOGEL R.A., PCSK9 INHIBITION: THE NEXT STATIN?, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 59, 25, PP. 2354-2355, (2012); LAMBERT G., SJOUKE B., CHOQUE B., KASTELEIN J.J., HOVINGH G.K., THE PCSK9 DECADE, THE JOURNAL OF LIPID RESEARCH, 53, 12, PP. 2515-2524, (2012); MARAIS A.D., KIM J.B., WASSERMAN S.M., LAMBERT G., PCSK9 INHIBITION IN LDL CHOLESTEROL REDUCTION: GENETICS AND THERAPEUTIC IMPLICATIONS OF VERY LOW PLASMA LIPOPROTEIN LEVELS, PHARMACOLOGY & THERAPEUTICS, 145, PP. 58-66, (2015); FAN L.L., LIN M.J., CHEN Y.Q., HUANG H., PENG D.Q., XIA K., ZHAO S.P., XIANG R., NOVEL MUTATIONS OF LOW-DENSITY LIPOPROTEIN RECEPTOR GENE IN CHINA PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA, APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 176, 1, PP. 101-109, (2015); GUERIN M., LE GOFF W., FRISDAL E., SCHNEIDER S., MILOSAVLJEVIC D., BRUCKERT E., CHAPMAN M.J., ACTION OF CIPROFIBRATE IN TYPE IIB HYPERLIPOPROTEINEMIA: MODULATION OF THE ATHEROGENIC LIPOPROTEIN PHENOTYPE AND STIMULATION OF HIGH-DENSITY LIPOPROTEIN-MEDIATED CELLULAR CHOLESTEROL EFFLUX, THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 88, 8, PP. 3738-3746, (2003); DONG B., SINGH A.B., CHIN FUNG K.K., LIU J., CETP INHIBITORS DOWNREGULATE HEPATIC LDL RECEPTOR AND PCSK9 EXPRESSION IN VITRO AND IN VIVO THROUGH A SREBP2 DEPENDENT MECHANISM, ATHEROSCLEROSIS, 235, 2, PP. 449-462, (2014); HANSSON G.K., INFLAMMATION, ATHEROSCLEROSIS, AND CORONARY ARTERY DISEASE, THE NEW ENGLAND JOURNAL OF MEDICINE, 352, 16, PP. 1685-1695, (2005); LIBBY P., RIDKER P.M., INFLAMMATION AND ATHEROTHROMBOSIS, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 48, 9, PP. 33-46, (2006); YU X.H., ZHANG J., ZHENG X.L., YANG Y.H., TANG C.K., INTERFERON-Γ IN FOAM CELL FORMATION AND PROGRESSION OF ATHEROSCLEROSIS, CLINICA CHIMICA ACTA, 441, PP. 33-43, (2015); WEBER C., NOELS H., ATHEROSCLEROSIS: CURRENT PATHOGENESIS AND THERAPEUTIC OPTIONS, NATURE MEDICINE, 17, 11, PP. 1410-1422, (2011); WAGNER D.D., NEW LINKS BETWEEN INFLAMMATION AND THROMBOSIS, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 25, 7, PP. 1321-1324, (2005); LIEVENS D., ZERNECKE A., SEIJKENS T., SOEHNLEIN O., BECKERS L., MUNNIX I.C., WIJNANDS E., GOOSSENS P., VAN KRUCHTEN R., THEVISSEN L., BOON L., FLAVELL R.A., NOELLE R.J., GERDES N., BIESSEN E.A., DAEMEN M.J., HEEMSKERK J.W., WEBER C., LUTGENS E., PLATELET CD40L MEDIATES THROMBOTIC AND INFLAMMATORY PROCESSES IN ATHEROSCLEROSIS, BLOOD, 116, 20, PP. 4317-4327, (2010); MCEVER R.P., PROPERTIES OF GMP-140, AN INDUCIBLE GRANULE MEMBRANE PROTEIN OF PLATELETS AND ENDOTHELIUM, BLOOD CELLS, 16, 1, PP. 73-80, (1990); HOLT J.C., NIEWIAROWSKI S., BIOCHEMISTRY OF ALPHA GRANULE PROTEINS, SEMINARS IN HEMATOLOGY, 22, 2, PP. 151-163, (1985); RIDKER P.M., BURING J.E., RIFAI N., SOLUBLE P-SELECTIN AND THE RISK OF FUTURE CARDIOVASCULAR EVENTS, CIRCULATION, 103, 4, PP. 491-495, (2001); HEESCHEN C., DIMMELER S., HAMM C.W., VAN DEN BRAND M.J., BOERSMA E., ZEIHER A.M., SIMOONS M.L., SOLUBLE CD40 LIGAND IN ACUTE CORONARY SYNDROMES, THE NEW ENGLAND JOURNAL OF MEDICINE, 348, 12, PP. 1104-1111, (2003); SCHONBECK U., VARO N., LIBBY P., BURING J., RIDKER P.M., SOLUBLE CD40L AND CARDIOVASCULAR RISK IN WOMEN, CIRCULATION, 104, 19, PP. 2266-2268, (2001); FERRONI P., SANTILLI F., GUADAGNI F., BASILI S., DAVI G., CONTRIBUTION OF PLATELET-DERIVED CD40 LIGAND TO INFLAMMATION, THROMBOSIS AND NEOANGIOGENESIS, CURRENT MEDICINAL CHEMISTRY, 14, 20, PP. 2170-2180, (2007); ANDRE P., PRASAD K.C., DENIS C.V., HE M., PAPALIA J.M., HYNES R.O., PHILLIPS D.R., WAGNER D.D., CD40L STABILIZES ARTERIAL THROMBI BY A 3 INTEGRIN–DEPENDENT MECHANISM, NATURE MEDICINE, 8, 3, PP. 247-252, (2002); ZIRLIK A., MAIER C., GERDES N., MACFARLANE L., SOOSAIRAJAH J., BAVENDIEK U., AHRENS I., ERNST S., BASSLER N., MISSIOU A., PATKO Z., AIKAWA M., SCHONBECK U., BODE C., LIBBY P., PETER K., CD40 LIGAND MEDIATES INFLAMMATION INDEPENDENTLY OF CD40 BY INTERACTION WITH MAC-1, CIRCULATION, 115, 12, PP. 1571-1580, (2007); EPPERSON T.K., PATEL K.D., MCEVER R.P., CUMMINGS R.D., NONCOVALENT ASSOCIATION OF P-SELECTIN GLYCOPROTEIN LIGAND-1 AND MINIMAL DETERMINANTS FOR BINDING TO P-SELECTIN, THE JOURNAL OF BIOLOGICAL CHEMISTRY, 275, 11, PP. 7839-7853, (2000); JOHNSTON G.I., COOK R.G., MCEVER R.P., CLONING OF GMP-140, A GRANULE MEMBRANE PROTEIN OF PLATELETS AND ENDOTHELIUM: SEQUENCE SIMILARITY TO PROTEINS INVOLVED IN CELL ADHESION AND INFLAMMATION, CELL, 56, 6, PP. 1033-1044, (1989); NORMAN K.E., KATOPODIS A.G., THOMA G., KOLBINGER F., HICKS A.E., COTTER M.J., POCKLEY A.G., HELLEWELL P.G., P-SELECTIN GLYCOPROTEIN LIGAND-1 SUPPORTS ROLLING ON E- AND P-SELECTIN IN VIVO, BLOOD, 96, 10, PP. 3585-3591, (2000); ARRUZAZABALA M.D.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 33, 7, PP. 835-840, (2000); GUO Y.L., XU R.X., ZHU C.G., WU N.Q., CUI Z.P., LI J.J., POLICOSANOL ATTENUATES STATIN-INDUCED INCREASES IN SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WHEN COMBINED WITH ATORVASTATIN, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, (2014); CHOI S.Y., PARK G.S., LEE S.Y., KIM J.Y., KIM Y.K., THE CONFORMATION AND CETP INHIBITORY ACTIVITY OF 10-DEHYDROGINGERDIONE ISOLATED FROM ZINGIBER OFFICINALE, ARCHIVES OF PHARMACAL RESEARCH, 34, 5, PP. 727-731, (2011); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLINICAL CHEMISTRY, 18, 6, PP. 499-502, (1972); LIU C.S., LIN C.C., LI T.C., THE RELATION OF WHITE BLOOD CELL COUNT AND ATHEROGENIC INDEX RATIO OF LDL-CHOLESTEROL TO HDL-CHOLESTEROL IN TAIWAN SCHOOL CHILDREN, ACTA PAEDIATRICA TAIWANICA, 40, 5, PP. 319-324, (1999); WHAYNE T.F., CORONARY ATHEROSCLEROSIS, LOW-DENSITY LIPOPROTEINS AND MARKERS OF THROMBOSIS, INFLAMMATION AND ENDOTHELIAL DYSFUNCTION, THE INTERNATIONAL JOURNAL OF ANGIOLOGY, 16, 1, PP. 12-16, (2007); DIAZ M.N., FREI B., VITA J.A., KEANEY J.F., ANTIOXIDANTS AND ATHEROSCLEROTIC HEART DISEASE, THE NEW ENGLAND JOURNAL OF MEDICINE, 337, 6, PP. 408-416, (1997); WONG W.T., ISMAIL M., TOHIT E.R., ABDULLAH R., ZHANG Y.D., ATTENUATION OF THROMBOSIS BY CRUDE RICE (ORYZA SATIVA) BRAN POLICOSANOL EXTRACT: EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, (2016); MOSA R.A., LAZARUS G.G., GWALA P.E., OYEDEJI A.O., OPOKU A.R., IN VITRO ANTI-PLATELET AGGREGATION, ANTIOXIDANT AND CYTOTOXIC ACTIVITY OF EXTRACTS OF SOME ZULU MEDICINAL PLANTS, JOURNAL OF NATURAL PRODUCTS, 4, PP. 136-146, (2011); STRAUS S.E., MAJUMDAR S.R., MCALISTER F.A., NEW EVIDENCE FOR STROKE PREVENTION: SCIENTIFIC REVIEW, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 288, 11, PP. 1388-1395, (2002); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, 10, PP. 891-897, (2002); HIRSCH G.E., VIECILI P.R.N., DE ALMEIDA A.S., NASCIMENTO S., PORTO F.G., OTERO J., SCHMIDT A., DA SILVA B., PARISI M.M., KLAFKE J.Z., NATURAL PRODUCTS WITH ANTIPLATELET ACTION, CURRENT PHARMACEUTICAL DESIGN, 23, 8, PP. 1228-1246, (2017); FAN J., KITAJIMA S., WATANABE T., XU J., ZHANG J., LIU E., CHEN Y.E., RABBIT MODELS FOR THE STUDY OF HUMAN ATHEROSCLEROSIS: FROM PATHOPHYSIOLOGICAL MECHANISMS TO TRANSLATIONAL MEDICINE, PHARMACOLOGY & THERAPEUTICS, 146, PP. 104-119, (2015); ROBERTS D.C.K., WEST C.E., REDGRAVE T.G., SMITH J.B., PLASMA CHOLESTEROL CONCENTRATION IN NORMAL AND CHOLESTEROL-FED RABBITS, ATHEROSCLEROSIS, 19, 3, PP. 369-380, (1974); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERNATIVE MEDICINE REVIEW, 7, 3, PP. 203-217, (2002); EL-SEWEIDY M.M., ASKER M.-S., ELDAHMY S.I., ATTEIA H.H., ABDALLAH M.A., HAEMOSTATIC RISK FACTORS IN DYSLIPIDEMIC RABBITS: ROLE OF 10-DEHYDROGINGERDIONE AS A NEW HYPOLIPEMIC AGENT, JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 39, 2, PP. 196-202, (2015); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 50, 3, PP. 255-262, (2000); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 39, 4, PP. 889-899, (2017); PACKARD R.R., LIBBY P., INFLAMMATION IN ATHEROSCLEROSIS: FROM VASCULAR BIOLOGY TO BIOMARKER DISCOVERY AND RISK PREDICTION, CLINICAL CHEMISTRY, 54, 1, PP. 24-38, (2008); YEH E.T., ANDERSON H.V., PASCERI V., WILLERSON J.T., C-REACTIVE PROTEIN: LINKING INFLAMMATION TO CARDIOVASCULAR COMPLICATIONS, CIRCULATION, 104, 9, PP. 974-975, (2001); RUBILA S., RANGANATHAN T.V., SAKTHIVEL K.M., PROTECTIVE EFFECT OF ZINGIBER OFFICINALE AGAINST DALTON’S LYMPHOMA ASCITES TUMOUR BY REGULATING INFLAMMATORY MEDIATOR AND CYTOKINES, APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 180, 8, PP. 1482-1496, (2016)","M.M. ELSEWEIDY; DEPARTMENT OF BIOCHEMISTRY, FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY, ZAGAZIG, 44519, EGYPT; EMAIL: MMELSEWEIDY@YAHOO.COM","HUMANA PRESS INC.","ENGLISH","APPL. BIOCHEM. BIOTECHNOL.","ARTICLE","ISI","2-S2.0-85046664602","APPL BIOCHEM BIOTECHNOL","THAMAR UNIVERSITY","NOTREPORTED;ZAGAZIG UNIVERSITY;NOTREPORTED",NA,"ELSEWEIDY MM, 2018, APPL BIOCHEM BIOTECHNOL","ELSEWEIDY MM, 2018, APPL BIOCHEM BIOTECHNOL"
"MERCURIO V;PUCCI G;BOSSO G;FAZIO V;BATTISTA F;IANNUZZI A;BRAMBILLA N;VITALINI C;D'AMATO M;GIACOVELLI G;VAUDO G;SCHILLACI G;GALLETTI F;BONADUCE D","MERCURIO, VALENTINA (37026821800); PUCCI, GIACOMO (8610916900); BOSSO, GIORGIO (25824184100); FAZIO, VALERIA (35751928600); BATTISTA, FRANCESCA (55270369800); IANNUZZI, ANGELA (59022570100); BRAMBILLA, NADIA (55550205800); VITALINI, CRISTINA (56968227600); D'AMATO, MASSIMO (7004499789); GIACOVELLI, GIAMPAOLO (6603336382); VAUDO, GAETANO (7003622597); SCHILLACI, GIUSEPPE (7005176634); GALLETTI, FERRUCCIO (7006210155); BONADUCE, DOMENICO (7006681591)","A NUTRACEUTICAL COMBINATION REDUCES LEFT VENTRICULAR MASS IN SUBJECTS WITH METABOLIC SYNDROME AND LEFT VENTRICULAR HYPERTROPHY A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED TRIAL",2020,"CLINICAL NUTRITION","39","5",16,"10.1016/j.clnu.2019.06.026","DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, ITALY;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY OF NAPLES, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, ITALY;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;ROTTAPHARM BIOTECH, MONZA, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, TERNI UNIVERSITY HOSPITAL, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, ITALY;DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, FEDERICO II UNIVERSITY OF NAPLES, ITALY;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY OF NAPLES, ITALY","BACKGROUND & AIMS: INCREASED LEFT VENTRICULAR MASS (LVM) IS OFTEN PRESENT IN METABOLIC SYNDROME (MS), ALSO IN THE SETTING OF WELL-CONTROLLED BLOOD PRESSURE (BP). AIM OF THE PRESENT STUDY WAS TO EVALUATE THE EFFICACY OF A NUTRACEUTICAL COMBINATION OF BERBERINE, RED YEAST RICE EXTRACT AND POLICOSANOL (ARMOLIPID PLUS™, AP) IN REDUCING LVM IN PATIENTS WITH MS AND LEFT VENTRICULAR HYPERTROPHY (LVH). METHODS: IN THIS MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, 158 PATIENTS WITH MS (IDF CRITERIA) AND LVH (LVM > 48 G/M2.7 IN MEN AND > 44 G/M2.7 IN WOMEN), WERE RANDOMIZED 1:1 TO RECEIVE AP OR PLACEBO FOR 24 WEEKS. REDUCTION OF LVM, REGRESSION OF LVH, AND CHANGES IN LIPIDS WERE ANALYSED. RESULTS: ONE-HUNDRED-AND-FORTY-FIVE PATIENTS (AP N = 74, PLACEBO N = 71) COMPLETED THE STUDY. A SIGNIFICANT PERCENTAGE REDUCTION IN LVM WAS OBSERVED IN AP GROUP VS BASELINE (−2.7%, P < 0.0001), AND COMPARED TO PLACEBO (−4.1%, P < 0.0001), AND REMAINED SIGNIFICANT AFTER ADJUSTMENT FOR AGE, SEX, BASELINE SYSTOLIC BP AND BMI AND THEIR CHANGES DURING THE STUDY PERIOD. THE PROPORTION OF SUBJECTS SHOWING LVM REDUCTION WAS HIGHER IN AP GROUP THAN IN THE PLACEBO GROUP (57% VS 28%, ADJUSTED P = 0.007). TREATMENT WITH AP WAS ASSOCIATED WITH IMPROVEMENT OF LIPID PROFILE. CONCLUSIONS: 24-WEEK OF TREATMENT WITH AP IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN LVM IN SUBJECTS WITH MS AND LVH, IN ADDITION TO FAVOURABLE EFFECTS ON LIPID PROFILE, AND COULD REPRESENT AN EFFECTIVE STRATEGY AIMING AT REDUCING THE ASSOCIATED CARDIOVASCULAR RISK. THE TRIAL WAS REGISTERED AT CLINICALTRIALS.GOV WITH ID NCT02295176. © 2019 ELSEVIER LTD AND EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM","ECHOCARDIOGRAPHY; LEFT VENTRICULAR HYPERTROPHY; METABOLIC SYNDROME; NUTRACEUTICAL COMBINATION","DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; ARMOLIPID PLUS; BERBERINE DERIVATIVE; NUTRACEUTICAL; PLACEBO; POLICOSANOL; XUEZHIKANG; ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENDER; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; DIETARY SUPPLEMENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; MIDDLE AGED; PATHOLOGY","","","LAAKSONEN D.E., LAKKA H.M., NISKANEN L.K., KAPLAN G.A., SALONEN J.T., LAKKA T.A., METABOLIC SYNDROME AND DEVELOPMENT OF DIABETES MELLITUS: APPLICATION AND VALIDATION OF RECENTLY SUGGESTED DEFINITIONS OF THE METABOLIC SYNDROME IN A PROSPECTIVE COHORT STUDY, AM J EPIDEMIOL, 156, PP. 1070-1077, (2002); SCHILLACI G., VERDECCHIA P., PORCELLATI C., CUCCURULLO O., COSCO C., PERTICONE F., CONTINUOUS RELATION BETWEEN LEFT VENTRICULAR MASS AND CARDIOVASCULAR RISK IN ESSENTIAL HYPERTENSION, HYPERTENSION, 35, PP. 580-586, (2000); CUSPIDI C., MEANI S., FUSI V., SEVERGNINI B., VALERIO C., CATINI E., ET AL., METABOLIC SYNDROME AND TARGET ORGAN DAMAGE IN UNTREATED ESSENTIAL HYPERTENSIVES, J HYPERTENS, 22, PP. 1991-1998, (2004); SCHILLACI G., PIRRO M., PUCCI G., MANNARINO M.R., GEMELLI F., SIEPI D., ET AL., DIFFERENT IMPACT OF THE METABOLIC SYNDROME ON LEFT VENTRICULAR STRUCTURE AND FUNCTION IN HYPERTENSIVE MEN AND WOMEN, HYPERTENSION, 47, PP. 881-886, (2006); DE SIMONE G., DEVEREUX R.B., CHINALI M., ROMAN M.J., LEE E.T., RESNICK H.E., ET AL., METABOLIC SYNDROME AND LEFT VENTRICULAR HYPERTROPHY IN THE PREDICTION OF CARDIOVASCULAR EVENTS: THE STRONG HEART STUDY, NUTR METAB CARDIOVASC DIS, 19, PP. 98-104, (2009); AL-DAYDAMONY M.M., EL-TAHLAWI M., WHAT IS THE EFFECT OF METABOLIC SYNDROME WITHOUT HYPERTENSION ON LEFT VENTRICULAR HYPERTROPHY?, ECHOCARDIOGRAPHY, 33, PP. 1284-1289, (2016); LONNEBAKKEN M.T., IZZO R., MANCUSI C., GERDTS E., LOSI M.A., CANCIELLO G., ET AL., LEFT VENTRICULAR HYPERTROPHY REGRESSION DURING ANTIHYPERTENSIVE TREATMENT IN AN OUTPATIENT CLINIC (THE CAMPANIA SALUTE NETWORK), J AM HEART ASSOC, 6, (2017); FORD E.S., RISKS FOR ALL-CAUSE MORTALITY CARDIOVASCULAR DISEASE, AND DIABETESASSOCIATED WITH THE METABOLIC SYNDROME: A SUMMARY OF THE EVIDENCE, DIABETES CARE, 28, PP. 1769-1778, (2005); SCHILLACI G., VAUDO G., REBOLDI G., VERDECCHIA P., LUPATTELLI G., PASQUALINI L., ET AL., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND LEFT VENTRICULAR HYPERTROPHY IN ESSENTIAL HYPERTENSION, J HYPERTENS, 19, PP. 2265-2270, (2001); DI BONITO P., MOIO N., SCILLA C., CAVUTO L., SIBILIO G., SANGUIGNO E., ET AL., USEFULNESS OF THE HIGH TRIGLYCERIDE-TO-HDL CHOLESTEROL RATIO TO IDENTIFY CARDIOMETABOLIC RISK FACTORS AND PRECLINICAL SIGNS OF ORGAN DAMAGE IN OUTPATIENT CHILDREN, DIABETES CARE, 35, PP. 158-162, (2012); ANAN F., YONEMOCHI H., MASAKI T., TAKAHASHI N., FUKUNAGA N., TESHIMA Y., ET AL., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INSULIN RESISTANCE ARE INDEPENDENT AND ADDITIVE MARKERS OF LEFT VENTRICULAR HYPERTROPHY IN ESSENTIAL HYPERTENSION, HYPERTENS RES, 30, PP. 125-131, (2007); LI M.H., ZHANG Y.J., YU Y.H., YANG S.H., IQBAL J., MI Q.Y., ET AL., BERBERINE IMPROVES PRESSURE OVERLOAD-INDUCED CARDIAC HYPERTROPHY AND DYSFUNCTION THROUGH ENHANCED AUTOPHAGY, EUR J PHARMACOL, 728, PP. 67-76, (2014); CARLOMAGNO G., PIROZZI C., MERCURIO V., RUVOLO A., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION ON LEFT VENTRICULAR REMODELING AND VASOREACTIVITY IN SUBJECTS WITH THE METABOLIC SYNDROME, NUTR METAB CARDIOVASC DIS, 22, PP. E13-E14, (2012); ALBERTI K.G., ZIMMET P., SHAW J., METABOLIC SYNDROME--A NEW WORLD-WIDE DEFINITION. A CONSENSUS STATEMENT FROM THE INTERNATIONAL DIABETES FEDERATION, DIABET MED, 23, PP. 469-480, (2006); LANG R.M., BADANO L.P., MOR-AVI V., AFILALO J., ARMSTRONG A., ERNANDE L., ET AL., RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY IN ADULTS: AN UPDATE FROM THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY AND THE EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING, J AM SOC ECHOCARDIOGR, 28, PP. 1-39, (2015); MATTHEWS D.R., HOSKER J.P., RUDENSKI A.S., NAYLOR B.A., TREACHER D.F., TURNER R.C., HOMEOSTASIS MODEL ASSESSMENT: INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA GLUCOSE AND INSULIN CONCENTRATIONS IN MAN, DIABETOLOGIA, 28, PP. 412-419, (1985); DE SIMONE G., DEVEREUX R.B., DANIELS S.R., KOREN M.J., MEYER R.A., LARAGH J.H., EFFECT OF GROWTH ON VARIABILITY OF LEFT VENTRICULAR MASS: ASSESSMENT OF ALLOMETRIC SIGNALS IN ADULTS AND CHILDREN AND THEIR CAPACITY TO PREDICT CARDIOVASCULAR RISK, J AM COLL CARDIOL, 25, (1995); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); DE SIMONE G., OKIN P.M., GERDTS E., OLSEN M.H., WACHTELL K., HILLE D.A., ET AL., CLUSTERED METABOLIC ABNORMALITIES BLUNT REGRESSION OF HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY: THE LIFE STUDY, NUTR METAB CARDIOVASC DIS, 19, PP. 634-640, (2009); HONG Y., HUI S.S., CHAN B.T., HOU J., EFFECT OF BERBERINE ON CATECHOLAMINE LEVELS IN RATS WITH EXPERIMENTAL CARDIAC HYPERTROPHY, LIFE SCI, 72, PP. 2499-2507, (2003); POLI A., BARBAGALLO C.M., CICERO A., CORSINI A., MANZATO E., TRIMARCO B., ET AL., NUTRACEUTICALS AND FUNCTIONAL FOODS FOR THE CONTROL OF PLASMA CHOLESTEROL LEVELS. AN INTERSOCIETY POSITION PAPER, PHARMACOL RES, 134, PP. 51-60, (2018); FAGARD R.H., CELIS H., THIJS L., WOUTERS S., REGRESSION OF LEFT VENTRICULAR MASS BY ANTIHYPERTENSIVE TREATMENT: A META-ANALYSIS OF RANDOMIZED COMPARATIVE STUDIES, HYPERTENSION, 54, PP. 1084-1091, (2009); BLIZIOTIS I.A., DESTOUNIS A., STERGIOU G.S., HOME VS. AMBULATORY AND OFFICE BLOOD PRESSURE IN PREDICTING TARGET ORGAN DAMAGE IN HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS, J HYPERTENS, 30, PP. 1289-1299, (2012)","V. MERCURIO; DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES. FEDERICO II UNIVERSITY, NAPLES, VIA SERGIO PANSINI 5, 80131, ITALY; EMAIL: VALENTINA.MERCURIO@UNINA.IT","CHURCHILL LIVINGSTONE","ENGLISH","CLIN. NUTR.","ARTICLE","ISI","2-S2.0-85069851432","CLIN NUTR","FEDERICO II UNIVERSITY OF NAPLES;TERNI UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY OF NAPLES;FEDERICO II UNIVERSITY OF NAPLES;TERNI UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY OF NAPLES;ROTTAPHARM BIOTECH;ROTTAPHARM BIOTECH;ROTTAPHARM BIOTECH;ROTTAPHARM BIOTECH;TERNI UNIVERSITY HOSPITAL;TERNI UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY OF NAPLES;FEDERICO II UNIVERSITY OF NAPLES","NOTREPORTED;DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES. FEDERICO II UNIVERSITY;NOTREPORTED",NA,"MERCURIO V, 2020, CLIN NUTR","MERCURIO V, 2020, CLIN NUTR"
"FERNÁNDEZ-TRAVIESO J;ILLNAIT-FERRER J;FERNÁNDEZ-DORTA L;MÁS-FERREIRO R;MENDOZA-CASTAÑO S;LÓPEZ-GONZÁLEZ E;GÁMEZ-MENÉNDEZ R;MESA-ANGARICA M","FERNÁNDEZ-TRAVIESO, JULIO C (9432805500); ILLNAIT-FERRER, JOSÉ (6508234896); FERNÁNDEZ-DORTA, LILIA (57204307516); MÁS-FERREIRO, ROSA (6602148780); MENDOZA-CASTAÑO, SARAHÍ (57204328829); LÓPEZ-GONZÁLEZ, ERNESTO (57205426141); GÁMEZ-MENÉNDEZ, RAFAEL (36898288000); MESA-ANGARICA, MEILIS (57204306979)","CONCOMITANT USE OF POLICOSANOL AND ANTIPLATELET DRUGS IN OLDER PATIENTS",2019,"GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE","178","7",0,"10.23736/S0393-3660.18.03709-9","NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA, CUBA","BACKGROUND: THE OBJECTIVE OF THE PRESENT ANALYSIS AS A PART OF A PREVENTION STUDY, WE INVESTIGATED WHETHER POLICOSANOL ADMINISTERED TO OLDER INDIVIDUALS TAKING ANTIPLATELET DRUGS SUPPOSES CONCERN REGARDING TO POTENTIAL RISK FOR ADVERSE DRUG-DRUG INTERACTIONS. METHODS: WE RANDOMIZED 1470 ELDERLY PATIENTS AT HIGH CORONARY RISK TO POLICOSANOL 5 MG/DAY OR PLACEBO FOR 3 YEARS. FOR THIS ANALYSIS, THE RECORDS OF ALL PATIENTS (N.=334) TAKING ANTIPLATELET DRUGS WERE INCLUDED. ANALYSIS WAS BY INTENTION-TO-TREAT. RESULTS: AFTER ONE YEAR, POLICOSANOL DECREASED SIGNIFICANTLY LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) (21.0%), TOTAL CHOLESTEROL (16.9%) AND TRIGLYCERIDES (19.6%), WHILE RAISED HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) (6.2%). POLICOSANOL EFFECTS WERE MAINTAINED, EVEN IMPROVED, DURING THE FOLLOW-UP. AT STUDY COMPLETION POLICOSANOL LOWERED LDL-C (34.3%), TOTAL CHOLESTEROL (23.9%), TRIGLYCERIDES (22.2%) AND RAISED HDL-C (14.5%). SIXTY PATIENTS (41 PLACEBO, 19 POLICOSANOL, P<0.01) WITHDREW FROM THE STUDY, 33 (23 PLACEBO, 10 POLICOSANOL) (P<0.01) DUE TO SOME ADVERSE EVENT, ALL SERIOUS. POLICOSANOL DID NOT IMPAIR SAFETY INDICATORS AND DID NOT INCREASE ANY ADVERSE EVENT RESPECT TO PLACEBO. CONCLUSIONS: THE POLICOSANOL CAN BE ADMINISTERED TO OLDER PATIENTS TAKING ANTIPLATELET DRUGS WITHOUT RISK OF RELEVANT ADVERSE DRUG-DRUG INTERACTIONS. © 2018 EDIZIONI MINERVA MEDICA.","AGED; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PLATELET AGGREGATION INHIBITORS; POLICOSANOL","ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY RISK; DEATH; DIABETES MELLITUS; DIETARY INTAKE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE DISEASE; ENZYME CHEMISTRY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HAZARD RATIO; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; PHYSICAL EXAMINATION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK; SKIN DISEASE; SMOKING; TOTAL CHOLESTEROL LEVEL; URINARY TRACT DISEASE; VASCULAR DISEASE","","","VILES-GONZALEZ J.F., FUSTER V., BADIMON J.J., ATHEROTHROMBOSIS: A WIDESPREAD DISEASE WITH UNPREDICTABLE AND LIFE-THREATENING CONSEQUENCES, EUR HEART J, 25, PP. 1197-1207, (2004); MOZAFFARIAN D., BENJAMIN E.J., GO A.S., ARNETT D.K., BLAHA M.J., CUSHMAN M., ET AL., HEART DISEASE AND STROKE STATISTICS-2016 UPDATE: AREPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 133, PP. 38-360, (2016); BOEKHOLDT S.M., HOVINGH G.K., MORA S., ARSENAULT B.J., AMARENCO P., PEDERSEN T.R., ET AL., VERY LOW LEVELS OF ATHEROGENIC LIPOPROTEINS AND THE RISK FOR CARDIOVASCULAR EVENTS: A META-ANALYSIS OF STATIN TRIALS, J AM COLL CARDIOL, 64, PP. 485-494, (2014); FULCHER J., O'CONNELL R., VOYSEY M., EMBERSON J., BLACKWELL L., MIHAYLOVA B., ET AL., EFFICACY AND SAFETY OF LDL-LOWERING THERAPY AMONG MEN AND WOMEN: META-ANALYSIS OF INDIVIDUAL DATA FROM 174000 PARTICIPANTS IN 27 RANDOMISED TRIALS, LANCET, 385, PP. 1397-1405, (2015); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., BAIREY MERZ C.N., BLUM C.B., ECKEL R.H., ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/ AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, 63, 25, PP. 2889-2934, (2014); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS ( ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); BRAHMA D.K., WAHLANG J.B., MARAK M.D., CH SANGMA M., ADVERSE DRUG REACTIONS IN THE ELDERLY, J PHARMACOL PHARMACOTHER, 4, PP. 91-94, (2013); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION. A RANDOMIZED DOUBLE-BLINDED PILOT STUDY, CURR THER RES CLIN EXP, 61, PP. 609-620, (2000); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); FERNANDEZ S., MAS R., GAMEZ R., DIAZ A., FERNANDEZ J., DEIBIS ORTA S., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, PP. 219-229, (2004); PALLERIA C., DI PAOLO A., GIOFRE C., CAGLIOTI C., LEUZZI G., SINISCALCHI A., ET AL., PHARMACOKINETIC DRUG-DRUG INTERACTION MED SCI, 18, PP. 601-610, (2013); RODEIRO I., ALEMAN C.L., MAS R., ACOSTA P.C., RODRIGUEZ M.D., GAMEZ R., ET AL., EFECTOS DEL POLICOSANOL SOBRE LAS ENZIMAS MICROSOMALES HEPÁTICAS EN RATAS SPRAGUE DAWLEY, REV CENIC CIEN BIOL, 31, PP. 113-116, (2000); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); UCHIYAMA S., ANTIPLATELET THERAPY: UPDATE IN SECONDARY STROKE PREVENTION, BRAIN NERVE, 65, PP. 771-782, (2013); PATRONO C., ROCCA B., ASPIRIN: PROMISE AND RESISTANCE IN THE NEW MILLENNIUM, ARTERIOSCLER THROMB VASC BIOL, 28, PP. 25-32, (2008); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); PATRONO C., BAIGENT C., HIRSH J., ROTH G., ANTIPLATELET DRUGS: AMERICAN COLLEGE OF CHEST PHYSICIANS EVIDENCE- BASED CLINICAL PRACTICE GUIDELINES (8TH EDITION), CHEST, 133, PP. 199S-233S, (2008); CADIOU G., ADAM M., CAUSSIN M., LANDRIN I., MARIETTE N., CAPET C., ET AL., ANTIPLATELET DRUGS IN THE ELDERLY: PRESCRIPTIONS OFTEN INAPPROPRIATE AND REDUCED TOLERANCE BY ASSOCIATED DISEASES AND DRUGS, FUNDAM CLIN PHARMACOL, 26, PP. 307-313, (2012); MAS R., CASTANO G., FERNANDEZ J., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON MORBIDITY AND MORTALITY IN OLDER HYPERCHOLESTEROLEMIC PATIENTS AND THEIR IMPLICATION IN CLINICAL MANAGEMENT. J RES, J AM COLL CARDIOL, 39, (2002); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); REQUERIMIENTOS PARA LA NOTIFICACION Y EL REPORTE DE EVENTOS ADVERSOS GRAVES E INESPERADOS EN LOS ENSAYOS CLÍNICOS, REGULACIÓN NO. 45- 2007, CENTRO PARA EL CONTROL ESTATAL DE LOS MEDICAMENTOS, EQUIPOS Y DISPOSITIVOS MÉDICOS (CECMED), (2007); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); CUBAN HEALTH STATISTICAL REPORTS, (2015); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., VEGA H., FERNANDEZ L., ET AL., POLICOSANOL VERSUS ATORVASTATIN ON THE FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE, INT J PHARM SCI REV RES, 37, PP. 7-14, (2016); SANCHEZ J., ILLNAIT J., MAS R., MENDOZA S., FERNANDEZ L., MESA M., ET AL., EFECTO A LARGO PLAZO DEL POLICOSANOL EN LA RECUPERACION FUNCIONAL DE PACIENTES CON ICTUS ISQUEMICO NO CARDIOEMBOLICO: ESTUDIO DE UN AÑO, REV NEUROL, 64, PP. 153-161, (2017)","J.C. FERNÁNDEZ-TRAVIESO; NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA; EMAIL: JULIO.FERNANDEZ@CNIC.EDU.CU","EDIZIONI MINERVA MEDICA","ENGLISH","GAZZ. MED. ITAL. ARCH. SCI. MED.","ARTICLE","ISI","2-S2.0-85059985458","GAZZ MED ITAL ARCH SCI MED","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;SURGICAL MEDICAL RESEARCH CENTER;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;SURGICAL MEDICAL RESEARCH CENTER","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"FERNÁNDEZ-TRAVIESO JC, 2019, GAZZ MED ITAL ARCH SCI MED","FERNÁNDEZ-TRAVIESO JC, 2019, GAZZ MED ITAL ARCH SCI MED"
"WANG Z;FENG Y;MA L;LI X;DING W;CHEN X","WANG, ZHAN-DI (57193419635); FENG, YING (34770356600); MA, LI-YI (56332101700); LI, XIAN (55252109700); DING, WEI-FENG (56683747800); CHEN, XIAO-MING (55739155400)","HAIR GROWTH PROMOTING EFFECT OF WHITE WAX AND POLICOSANOL FROM WHITE WAX ON THE MOUSE MODEL OF TESTOSTERONEINDUCED HAIR LOSS",2017,"BIOMEDICINE AND PHARMACOTHERAPY","89","8",30,"10.1016/j.biopha.2017.02.036","RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA, THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA, THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA, THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA, THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA, THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650233, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, YUNNAN, CHINA, THE KEY LABORATORY OF CULTIVATING AND UTILIZATION OF RESOURCE INSECTS OF STATE FORESTRY ADMINISTRATION, KUNMING, 650233, YUNNAN, CHINA","WHITE WAX (WW) HAS BEEN TRADITIONALLY USED TO TREAT HAIR LOSS IN CHINA. HOWEVER THERE HAS BEEN NO REPORTER WW AND ITS EXTRACT RESPONSIBLE FOR HAIR GROWTH-PROMOTING EFFECT ON ANDROGENETIC ALOPECIA. IN THIS PAPER, WE EXAMINED THE HAIR GROWTH-PROMOTING EFFECTS OF WW AND POLICOSANOL OF WHITE WAX (WWP) ON MODEL ANIMAL OF ANDROGENETIC ALOPECIA AND THE POTENTIAL TARGET CELL OF WW AND WWP. WW (1, 10 AND 20%) AND WWP (0.5, 1 AND 2%) WERE APPLIED TOPICALLY TO THE BACKS OF MICE. FINASTERIDE (2%) WAS APPLIED TOPICALLY AS A POSITIVE CONTROL. MTS ASSAYS WERE PERFORMED TO EVALUATE CELL PROLIFERATION IN CULTURE HUMAN FOLLICLE DERMAL PAPILLA CELLS (HFDPCS). THE INHIBITION OF WW AND WWP FOR 5Α- REDUCTASE WERE TESTED IN VITRO. RESULTS SHOWED MORE LOST HAIRS WERE CLEARLY SEEN IN MICE TREATED WITH TP ONLY AND TP PLUS VEHICLE. MICE WHICH RECEIVED TP PLUS WW AND WWP SHOWED LESS HAIR LOSS. WW AND WWP SHOWED AN OUTSTANDING HAIR GROWTH-PROMOTING ACTIVITY AS REFLECTED BY THE FOLLICULAR LENGTH, FOLLICULAR DENSITY, A/T RATIO, AND HAIR BULB DIAMETER. THE OPTIMAL TREATMENT EFFECT WAS OBSERVED AT 10% WW AND 1% WWP, WHICH WERE BETTER THAN 2% FINASTERIDE TREATMENT. MTS ASSAY RESULTS SUGGESTED THAT WW AND WWP REMARKABLY INCREASED THE PROLIFERATION OF HFDPCS. INHIBITOR ASSAY OF 5Α- REDUCTASE SHOWED THAT WW AND WWP INHIBITED SIGNIFICANTLY THE CONVERSION OF TESTOSTERONE TO DIHYDROTESTERONE, AND THE IC50 VALUES OF WW AND WWP WERE HIGHER THAN THAT OF FINASTERIDE. IN CONCLUSION, WW AND WWP COULD ACT AGAINST TESTOSTERONE-INDUCED ALOPECIA IN MICE, AND THEY PROMOTED HAIR GROWTH BY INHIBITING 5Α-REDUCTASE ACTIVITY AND HFDPCS PROLIFERATION. DPCS IS THE TARGET CELL OF WW AND WWP. © 2017 ELSEVIER MASSON SAS","5Α- REDUCTASE; ANDROGENETIC ALOPECIA; DERMAL PAPILLA CELLS; HAIR FOLLICLES; POLICOSANOL FROM WHITE WAX; WHITE WAX","5-ALPHA REDUCTASE INHIBITORS; ALOPECIA; ANIMALS; FATTY ALCOHOLS; FINASTERIDE; HAIR; HAIR FOLLICLE; MALE; MICE; PLANT EXTRACTS; RANDOM ALLOCATION; TESTOSTERONE PROPIONATE; WAXES; DIHYDROTESTERONE; FINASTERIDE; POLICOSANOL; PROPOLIS; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; UNCLASSIFIED DRUG; FATTY ALCOHOL; FINASTERIDE; PLANT EXTRACT; POLICOSANOL; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE PROPIONATE; WAX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HAIR FOLLICLE CELL; HAIR GROWTH; HAIR LOSS; HAIR ROOT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INHIBITORY CONCENTRATION; MALE; MALE TYPE ALOPECIA; MOUSE; MTS ASSAY; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; ALOPECIA; ANIMAL; CHEMISTRY; GROWTH, DEVELOPMENT AND AGING; HAIR; HAIR FOLLICLE; RANDOMIZATION","","","URYSIAK-CZUBATKA I., KMIEC M.L., BRONIARCZYK-DYLA G., ASSESSMENT OF THE USEFULNESS OF DIHYDROTESTOSTERONE IN THE DIAGNOSTICS OF PATIENTS WITH ANDROGENETIC ALOPECIA, POSTEPY DERMATOLOGII I ALERGOLOGII, 31, PP. 207-215, (2014); HAN J.H., KWON O.S., CHUNG J.H., CHO K.H., EUN H.C., KIM K.H., EFFECT OF MINOXIDIL ON PROLIFERATION AND APOPTOSIS IN DERMAL PAPILLA CELLS OF HUMAN HAIR FOLLICLE, J. DERMATOL. SCI., 34, PP. 91-98, (2004); LIBECCO J.F., BERGFELD W.F., FINASTERIDE IN THE TREATMENT OF ALOPECIA, EXPERT OPIN. PHARMACOTHER., 5, PP. 933-940, (2004); SATOH H., MORIKAW S., FUJIWARA C., TERADA H., UEHARA A., OHNO R., A CASE OF ACUTE MYOCARDIAL INFARCTION ASSOCIATED WITH TOPICAL USE OF MINOXIDIL (RIUP) FOR TREATMENT OF BALDNESS, JPN. HEART J., 41, PP. 519-523, (2000); VESOULIS Z.A., ATTARIAN S.J., BRANDY Z., FRANCIS SESSIONS C., MINOXIDIL-ASSOCIATED ANOREXIA IN AN INFANT WITH REFRACTORY HYPERTENSION, PHARMACOTHER. J. HUM. PHARMACOL. DRUG THER., 34, PP. E341-E344, (2014); MYSORE V., SHASHIKUMAR B.M., GUIDELINES ON THE USE OF FINASTERIDE IN ANDROGENETIC ALOPECIA, INDIAN JOURNAL OF DERMATOLOGY, VENEREOL. LEPROL., 82, PP. 128-134, (2016); YUN-FEI L., PEI L., YAN-RAN H., ET AL., RESEARCH PROGRESS IN REGULATION OF NATURAL MEDICINE ON INFLUENCE FACTOR FOR HAIR GROWTH CYCLE, CHIN. TRADITIONAL HERBAL DRUGS, 45, PP. 1655-1662, (2014); MING-NUAN H., YUE-FEI L., JIE L., RONG-HUA Z., ADVANCES IN STUDY ON REGULATION OF HAIR PIGMENT EXPRESSION BY NATURAL PRODUCTS, CHIN. TRADITIONAL HERBAL DRUGS, 36, PP. 1393-1398, (2015); XIAOMING C., NATURAL POPULATION ECOLOGY OF ERICERUS PELA, (2011); XIAO-YI H., MENG-HUA C., JIANG G., ET AL., OVERVIEW OF PHARMACOLOGICAL RESEARCH OF INSECT WAX, J. ANHUI AGRIC. SCI., 39, PP. 2817-2818, (2011); LI-YI M., YOU-QIONG W., ZHONG-QUAN Z., ET AL., PREPARATION OF POLICOSANOL FROM INSECT WAX BY REDUCTION METHOD, CHEM. IND. FOR. PROD., 29, PP. 6-10, (2009); SHI-ZHEN L., THE COMPENDIUM OF MATERIA MEDICA, (2006); NOUBARANI M., ROSTAMKHANI H., ERFAN M., ET AL., EFFECT OF ADIANTUM CAPILLUS VENERIS LINN ON AN ANIMAL MODEL OF TESTOSTERONE-INDUCED HAIR LOSS, IRAN. J. PHARM. RES., 13, PP. 113-118, (2014); MURATA K., TAKESHITA F., SAMUKAWA K., TANI T., MATSUDA H., EFFECTS OF GINSENG RHIZOME AND GINSENOSIDE RO ON TESTOSTERONE 5Α-REDUCTASE AND HAIR RE-GROWTH IN TESTOSTERONE-TREATED MICE, PHYTOTHER. RES., 26, PP. 48-53, (2012); PATEL S., SHARMA V., CHAUHAN N.S., THAKUR M., DIXIT V.K., EVALUATION OF HAIR GROWTH PROMOTING ACTIVITY OF PHYLLANTHUS NIRURI, AVICENNA J. PHYTOMED., 5, PP. 512-519, (2015); GUIQIUL D., BEI Z., XIUJUAN K., RONGWEN Z., ZIZHAO L., YUHUA W., GENG L., INHIBITORY EFFECT OF CARTHAMUS TINCTORIUS L. EXTRACT ON TYPE I AND II 5Α-REUCTASE ACTIVITY, CHINA PHARMACEUTICALS, 24, PP. 17-20, (2015); MULLER-ROVER S., HANDJISKI B., VAN DER VEEN C., ET AL., A COMPREHENSIVE GUIDE FOR THE ACCURATE CLASSIFICATION OF MURINE HAIR FOLLICLES IN DISTINCT HAIR CYCLE STAGES, J. INVEST. DERMATOL., 117, PP. 3-15, (2001); DHANOTIA R., CHAUHAN N.S., SARAF D.K., DIXIT V.K., EFFECT OF CITRULLUS COLOCYNTHIS SCHRAD FRUITS ON TESTOSTERONE-INDUCED ALOPECIA, NAT. PROD. RES., 25, PP. 1432-1443, (2011); YANHUA C., DANRONG L., HUAXIN H., ET AL., THE EFFECT ON THE RESULTS OF MTT ASSAY BY DIFFERENT ORGANIC SOLVENTS AND THE COLOR OF DRUGS TESTED, J. GUANGXI MED. UNIV., 1, PP. 17-19, (2007); YI W., RONGHUI Z., JUNNING Z., ET AL., THE CYTOTOXICITY OF THREE SURFACTANTS ON CACO-2, PHARMACOL. CLIN. CHIN. MATER. MED., 5, PP. 157-158, (2010); MEIDAN V.M., BONNER M.C., MICHNIAK B.B., TRANSFOLLICULAR DRUG DELIVERY–IS IT A REALITY?, INT. J. PHARM., 306, PP. 1-14, (2005); DRISKELL R.R., JUNEJA V.R., CONNELLY J.T., KRETZSCHMAR K., TAN D.W., WATT F.M., CLONAL GROWTH OF DERMAL PAPILLA CELLS IN HYDROGELS REVEALS INTRINSIC DIFFERENCES BETWEEN SOX2-POSITIVE AND −NEGATIVE CELLS IN VITRO AND IN VIVO, J. INVEST. DERMATOL., 132, PP. 1084-1093, (2012)","X.-M. CHEN; RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY, KUNMING, 650233, CHINA; EMAIL: CAFCXM@139.COM","ELSEVIER MASSON SAS","ENGLISH","BIOMED. PHARMACOTHER.","ARTICLE","ISI","2-S2.0-85013745452","BIOMED PHARMACOTHER","RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY","NOTREPORTED;RESEARCH INSTITUTE OF RESOURCE INSECTS OF THE CHINESE ACADEMY OF FORESTRY;NOTREPORTED",NA,"WANG Z-D, 2017, BIOMED PHARMACOTHER","WANG Z-D, 2017, BIOMED PHARMACOTHER"
"MARAZZI G;CAMPOLONGO G;PELLICCIA F;QUATTRINO S;VITALE C;CACCIOTTI L;MASSARO R;VOLTERRANI M;ROSANO G","MARAZZI, GIUSEPPE (6602583977); CAMPOLONGO, GIUSEPPE (8575747900); PELLICCIA, FRANCESCO (7005360685); QUATTRINO, SILVIA (53881852900); VITALE, CRISTIANA (7005091702); CACCIOTTI, LUCA (6506023158); MASSARO, ROSALBA (26649541500); VOLTERRANI, MAURIZIO (7004062259); ROSANO, GIUSEPPE (7007131876)","COMPARISON OF LOWDOSE STATIN VERSUS LOWDOSE STATINARMOLIPID PLUS IN HIGHINTENSITY STATININTOLERANT PATIENTS WITH A PREVIOUS CORONARY EVENT AND PERCUTANEOUS CORONARY INTERVENTION ADHERENCE TRIAL",2017,"AMERICAN JOURNAL OF CARDIOLOGY","120","4",29,"10.1016/j.amjcard.2017.06.015","ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;DEPARTMENT OF CARDIOVASCULAR SCIENCES, SAPIENZA UNIVERSITY, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;INSTITUTE OF CARDIOLOGY, MADRE GIUSEPPINA VANNINI HOSPITAL, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY","LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION IS ASSOCIATED WITH A SIGNIFICANT DECREASE IN MORTALITY, AND STATINS REPRESENT THE MOST EFFECTIVE DRUGS TO ACHIEVE THIS. HOWEVER, SIDE EFFECTS OF STATINS ARE VERY COMMON AND MAY LEAD TO TREATMENT DISCONTINUATION. NUTRACEUTICALS ARE A COMBINATION OF NATURAL COMPONENTS THAT HAVE SHOWN EFFICACY IN LOWERING LDL-C CONCENTRATION WHEN USED ALONE OR IN ASSOCIATION WITH OTHER AGENTS IN PATIENTS WHO ARE INTOLERANT TO HIGH-DOSE STATINS. OUR AIM WAS TO COMPARE THE EFFICACY AND TOLERABILITY OF LOW-DOSE STATIN (LDS) THERAPY VERSUS COMBINED THERAPY OF LDS PLUS A NUTRACEUTICAL COMBINATION CONTAINING RED YEAST RICE, POLICOSANOL, BERBERINE, FOLIC ACID, COENZYME Q10 AND ASTAXANTHIN (ARMOLIPID PLUS) IN HIGH-RISK PATIENTS. WE PERFORMED A RANDOMIZED (1:1), PROSPECTIVE, PARALLEL GROUP, SINGLE-BLIND TRIAL IN WHICH PARTICIPANTS HAD CORONARY ARTERY DISEASE (N = 100), HAD UNDERGONE PERCUTANEOUS CORONARY INTERVENTION IN THE PRECEDING 12 MONTHS, WERE HIGH-DOSE STATIN INTOLERANT, AND DID NOT ACHIEVE ≥50% REDUCTION IN LDL-C WITH LDS TREATMENT ALONE. AFTER 3 MONTHS, PATIENTS IN THE LDS + ARMOLIPID PLUS (N = 50) GROUP PRESENTED WITH A SIGNIFICANTLY GREATER REDUCTION OF LDL-C AND TOTAL CHOLESTEROL (P <0.0001), AND 70% OF PATIENTS IN THIS GROUP ACHIEVED THE THERAPEUTIC TARGET (LDL-C <70 MG/DL), WHEREAS PATIENTS IN THE LDS GROUP DID NOT. SIX PATIENTS (3 FROM EACH GROUP) DROPPED OUT DUE TO MYALGIA. IN CONCLUSION, IN PATIENTS WITH CORONARY ARTERY DISEASE AND HIGH-DOSE STATIN INTOLERANCE, THE COMBINATION OF LDS AND NUTRACEUTICALS REPRESENTS A VALUABLE THERAPEUTIC OPTION. © 2017 ELSEVIER INC.","","AGED; BIOLOGICAL PRODUCTS; CHOLESTEROL; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; ACETYLSALICYLIC ACID; AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARMOLIPID PLUS; ASTAXANTHIN; ATORVASTATIN; BERBERINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CHOLESTIN; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; CHOLESTEROL; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HUMAN; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG COMBINATION; DRUG TOLERANCE; FOLLOW UP; PROSPECTIVE STUDY; TREATMENT OUTCOME","MINISTERO DELL’ISTRUZIONE, DELL’UNIVERSITÀ E DELLA RICERCA, MIUR; EUROPEAN REGIONAL DEVELOPMENT FUND, ERDF","THIS WORK WAS SUPPORTED BY THE ITALIAN MINISTRY OF EDUCATION, UNIVERSITY AND RESEARCH . THE NATIONAL OPERATIONAL PROGRAM (PON) FOR RESEARCH AND COMPETITIVENESS IS CO-FUNDED WITH THE EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF) AND NATIONAL RESOURCES. IT PROMOTES INITIATIVES AND PROJECTS FOR SCIENTIFIC RESEARCH AND INDUSTRIAL COMPETITIVENESS. ","BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., BHALA N., PETO R., BARNES E.H., KEECH A., SIMES J., COLLINS R., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); DORMUTH C.R., HEMMELGARN B.R., PATERSON J.M., JAMES M.T., TEARE G.F., RAYMOND C.B., LAFRANCE J.P., LEVY A., GARG A.X., ERNST P., USE OF HIGH POTENCY STATINS AND RATES OF ADMISSION FOR ACUTE KIDNEY INJURY: MULTICENTER, RETROSPECTIVE OBSERVATIONAL ANALYSIS OF ADMINISTRATIVE DATABASES, BMJ, 346, (2013); MANSI I.A., MORTENSEN E.M., PUGH M.J., WEGNER M., FREI C.R., INCIDENCE OF MUSCULOSKELETAL AND NEOPLASTIC DISEASES IN PATIENTS ON STATIN THERAPY: RESULTS OF A RETROSPECTIVE COHORT ANALYSIS, AM J MED SCI, 345, PP. 343-348, (2013); DORMUTH C.R., FILION K.B., PATERSON J.M., JAMES M.T., TEARE G.F., RAYMOND C.B., RAHME E., TAMIM H., LIPSCOMBE L., HIGHER POTENCY STATINS AND THE RISK OF NEW DIABETES: MULTICENTRE, OBSERVATIONAL STUDY OF ADMINISTRATIVE DATABASES, BMJ, 348, (2014); ROSENBAUM D., DALLONGEVILLE J., SABOURET P., BRUCKERT E., DISCONTINUATION OF STATIN THERAPY DUE TO MUSCULAR SIDE EFFECTS: A SURVEY IN REAL LIFE, NUTR METAB CARDIOVASC DIS, 23, PP. 871-875, (2013); PIRRO M., DEL GIORNO R., LUPATTELLI G., MANNARINO M.R., ROSCINI A.R., COVELLI D., SCHILLACI G., PASQUALINI L., BAGAGLIA F., SIEPI D., MANNARINO E., CARDIOVASCULAR RISK FACTORS AND RECOMMENDED LIPID GOALS ATTAINMENT AMONG PATIENTS REFERRED IN A TERTIARY CARE LIPID CLINIC, EUR J INTERN MED, 22, PP. 412-417, (2011); CICERO A.F., DEROSA G., BOVE M., IMOLA F., BORGI C., GADDI A.V., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOP NUTRACEUTICAL RES, 7, PP. 121-126, (2009); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); BARRIOS V., ESCOBAR C., CICERO A.F.G., BURKE D., FASCHING P., BANACH M., BRUCKERT E., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLER SUPPL, 24, PP. 1-15, (2017); PIRRO M., MANNARINO M.R., BIANCONI V., SIMENTAL-MENDIA L.E., BAGAGLIA F., MANNARINO E., SAHEBKAR A., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); LEVEY A.S., CORESH J., GREENE T., STEVENS L.A., ZHANG Y.L., HENDRIKSEN S., KUSEK J.W., VAN LENTE F., USING STANDARDIZED SERUM CREATININE VALUES IN THE MODIFICATION OF DIET IN RENAL DISEASE STUDY EQUATION FOR ESTIMATING GLOMERULAR FILTRATION RATE, ANN INTERN MED, 145, PP. 247-254, (2006); MARAZZI G., PELLICCIA F., CAMPOLONGO G., QUATTRINO S., CACCIOTTI L., VOLTERRANI M., GAUDIO C., ROSANO G., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM J CARDIOL, 116, PP. 1798-1801, (2015); WENG T.C., YANG Y.H., LIN S.J., TAI S.H., A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE THERAPEUTIC EQUIVALENCE OF STATINS, J CLIN PHARM THER, 35, PP. 139-151, (2010); CATAPANO A.L., GRAHAM I., DE BACKER G., WIKLUND O., CHAPMAN M.J., DREXEL H., HOES A.W., JENNINGS C.S., LANDMESSER U., PEDERSEN T.R., REINER Z., RICCARDI G., TASKINEN M.R., TOKGOZOGLU L., VERSCHUREN W.M., VLACHOPOULOS C., WOOD D.A., ZAMORANO J.L., 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), EUR HEART J, 37, PP. 2999-3058, (2016); ENDO A., CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS, KLIN WOCHENSCHR, 66, PP. 421-427, (1988); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); HEINZ T., SCHUCHARDT J.P., MOLLER K., HADIJ P., HAHN A., LOW DAILY DOSE OF 3 MG MONACOLIN K FROM RYR REDUCES THE CONCENTRATION OF LDL-C IN A RANDOMIIZED, PLACEBO-CONTROLLED INTERVENTION, NUTR RES, 36, PP. 1162-1170, (2016); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVESTIG, 25, PP. 701-707, (2005); CICERO A., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN LIPIDOL, 4, PP. 553-563, (2009); LAN J., ZHAO Y., DONG F., YAN Z., ZHENG W., FAN J., SUN G., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J ETHNOPHARMACOL, 161, PP. 69-81, (2015); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN—A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 240, PP. 415-423, (2015); MAZZANTI G., MORO P.A., RASCHI E., DA CAS R., MENNITI-IPPOLITO F., ADVERSE REACTIONS TO DIETARY SUPPLEMENTS CONTAINING RED YEAST RICE: ASSESSMENT OF CASES FROM THE ITALIAN SURVEILLANCE SYSTEM, BR J CLIN PHARMACOL, 83, PP. 894-908, (2017); EFSA, PANEL OF DIETETIC PRODUCTS, SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, (2011); POIRIER S., MAYER G., BENJANNET S., BERGERON E., MARCINKIEWICZ J., NASSOURY N., MAYER H., NIMPF J., PRAT A., SEIDAH N.G., THE PROPROTEIN CONVERTASE PCSK9 INDUCES THE DEGRADATION OF LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) AND ITS CLOSEST FAMILY MEMBERS VLDLR AND APOER2, J BIOL CHEM, 283, PP. 2363-2372, (2008); KOREN M.J., GIUGLIANO R.P., RAAL F.J., SULLIVAN D., BOLOGNESE M., LANGSLET G., CIVEIRA F., SOMARATNE R., NELSON P., LIU T., SCOTT R., WASSERMAN S.M., SABATINE M.S., EFFICACY AND SAFETY OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB (AMG 145) IN PATIENTS WITH HYPERCHOLESTEROLEMIA: 52-WEEK RESULTS FROM THE OPEN-LABEL STUDY OF LONG-TERM EVALUATION AGAINST LDL-C (OSLER) RANDOMIZED TRIAL, CIRCULATION, 129, PP. 234-243, (2014); RAY K.K., GINSBERG H.N., DAVIDSON M.H., PORDY R., BESSAC L., MININI P., ECKEL R.H., CANNON C.P., REDUCTIONS IN ATHEROGENIC LIPIDS AND MAJOR CARDIOVASCULAR EVENTS. A POOLED ANALYSIS OF 10 ODYSSEY TRIALS COMPARING ALIROCUMAB WITH CONTROL, CIRCULATION, 134, PP. 1931-1943, (2016); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., GREENFIELD R.S., HOVINGH G.K., KOSTNER K., SERBAN C., LIGHEZAN D., FRAS Z., MORIARTY P.M., MUNTNER P., GOUDEV A., CESKA R., NICHOLLS S.J., BRONCEL M., NIKOLIC D., PELLA D., PURI R., RYSZ J., WONG N.D., BAJNOK L., JONES S.R., RAY K.K., MIKHAILIDIS D.P., STATIN INTOLERANCE—AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015)","G. MARAZZI; ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY; EMAIL: GIUSEPPE.MARAZZI@SANRAFFAELE.IT","ELSEVIER INC.","ENGLISH","AM. J. CARDIOL.","ARTICLE","ISI","2-S2.0-85028035759","AM J CARDIOL","ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;SAPIENZA UNIVERSITY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;INSTITUTE OF CARDIOLOGY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA","NOTREPORTED;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;NOTREPORTED",NA,"MARAZZI G, 2017, AM J CARDIOL","MARAZZI G, 2017, AM J CARDIOL"
"BAEK S;JUNG Y;LIM S;PARK S;KIM J","BAEK, SEUNG-A (56963292500); JUNG, YOUNG-HO (57189593897); LIM, SUN-HYUNG (7404081419); PARK, SANG UN (7501831941); KIM, JAE KWANG (56892616700)","METABOLIC PROFILING IN CHINESE CABBAGE BRASSICA RAPA L SUBSP PEKINENSIS CULTIVARS REVEALS THAT GLUCOSINOLATE CONTENT IS CORRELATED WITH CAROTENOID CONTENT",2016,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","64","8",38,"10.1021/acs.jafc.6b01323","DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA;BIOTECHNOLOGY INSTITUTE, NONGWOO BIO COMPANY, LIMITED, YEOJU, GYEONGGI, 12655, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, JEONJU, 54874, SOUTH KOREA;DEPARTMENT OF CROP SCIENCE, CHUNGNAM NATIONAL UNIVERSITY, 99 DAEHAK-RO, YUSEONG-GU, DAEJEON, 34134, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 22012, SOUTH KOREA","A TOTAL OF 38 BIOACTIVE COMPOUNDS, INCLUDING GLUCOSINOLATES, CAROTENOIDS, TOCOPHEROLS, STEROLS, AND POLICOSANOLS, WERE CHARACTERIZED FROM NINE VARIETIES OF CHINESE CABBAGE (BRASSICA RAPA L. SUBSP. PEKINENSIS) TO DETERMINE THEIR PHYTOCHEMICAL DIVERSITY AND ANALYZE THEIR ABUNDANCE RELATIONSHIPS. THE METABOLITE PROFILES WERE EVALUATED WITH PRINCIPAL COMPONENT ANALYSIS (PCA), PEARSON CORRELATION ANALYSIS, AND HIERARCHICAL CLUSTERING ANALYSIS (HCA). PCA AND HCA IDENTIFIED TWO DISTINCT VARIETIES OF CHINESE CABBAGE (CHEONSANGCHEONHA AND WALDONGCHEONHA) WITH HIGHER LEVELS OF GLUCOSINOLATES AND CAROTENOIDS. PAIRWISE COMPARISONS OF THE 38 METABOLITES WERE CALCULATED USING PEARSON CORRELATION COEFFICIENTS. THE HCA, WHICH USED THE CORRELATION COEFFICIENTS, CLUSTERED METABOLITES THAT ARE DERIVED FROM CLOSELY RELATED BIOCHEMICAL PATHWAYS. SIGNIFICANT CORRELATIONS WERE DISCOVERED BETWEEN CHLOROPHYLL AND CAROTENOIDS. ADDITIONALLY, ALIPHATIC GLUCOSINOLATE AND CAROTENOID LEVELS WERE POSITIVELY CORRELATED. THE CHEONSANGCHEONHA AND WALDONGCHEONHA VARIETIES APPEAR TO BE GOOD CANDIDATES FOR BREEDING BECAUSE THEY HAVE HIGH GLUCOSINOLATE AND CAROTENOID LEVELS. © 2016 AMERICAN CHEMICAL SOCIETY.","CAROTENOIDS; CHINESE CABBAGE; GLUCOSINOLATES; PHYTOSTEROL; POLICOSANOL","BRASSICA RAPA; BREEDING; CAROTENOIDS; GLUCOSINOLATES; METABOLOMICS; BIOMOLECULES; CORRELATION METHODS; DERIVATIVES; METABOLITES; PIGMENTS; CAROTENOID; GLUCOSINOLATE; CAROTENOIDS; CHINESE CABBAGE; GLUCOSINOLATES; PHYTOSTEROL; POLICOSANOL; BRASSICA RAPA; BREEDING; CHEMISTRY; CLASSIFICATION; GENETICS; METABOLISM; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS","INCHEON NATIONAL UNIVERSITY, INU; RURAL DEVELOPMENT ADMINISTRATION, RDA","THIS WORK WAS SUPPORTED BY A GRANT FROM THE NEXT-GENERATION BIOGREEN 21 PROGRAM (PJ011911022016), RURAL DEVELOPMENT ADMINISTRATION, AND THE INCHEON NATIONAL UNIVERSITY RESEARCH GRANT IN 2014.","JUNG H.J., MANOHARAN R.K., PARK J.I., CHUNG M.Y., LEE J., LIM Y.P., HUR Y.K., NOU I.S., IDENTIFICATION OF YELLOW PIGMENTATION GENES IN BRASSICA RAPA SSP. PEKINENSIS USING BR300 MICROARRAY, INT. J. GENOMICS, 2014, PP. 1-11, (2014); WATANABE M., MUSUMI K., AYUGASE J., CAROTENOID PIGMENT COMPOSITION, POLYPHENOL CONTENT, AND ANTIOXIDANT ACTIVITIES OF EXTRACTS FROM ORANGE-COLORED CHINESE CABBAGE, LWT-FOOD SCI. TECHNOL., 44, PP. 1971-1975, (2011); BYERS T., PERRY G., DIETARY CAROTENES, VITAMIN C, AND VITAMIN E AS PROTECTIVE ANTIOXIDANTS IN HUMAN CANCERS, ANNU. REV. NUTR., 12, PP. 139-159, (1992); YOUNG A.J., THE PHOTOPROTECTIVE ROLE OF CAROTENOIDS IN HIGHER PLANTS, PHYSIOL. PLANT., 83, PP. 702-708, (1991); LEE C.B., KOH S.C., MOON B.Y., PARK I.H., PARK P.B., CHUN H.S., PLANT PHYSIOLOGY, (2011); BJORKMAN M., KLINGEN I., BIRCH A.N.E., BONES A.M., BRUCE T.J.A., JOHANSEN T.J., MEADOW R., MOLMANN J., SELJAASEN R., SMART L.E., STEWART D., PHYTOCHEMICALS OF BRASSICACEAE IN PLANT PROTECTION AND HUMAN HEALTH - INFLUENCES OF CLIMATE, ENVIRONMENT AND AGRONOMIC PRACTICE, PHYTOCHEMISTRY, 72, PP. 538-556, (2011); DAS S., TYAGI A.K., KAUR H., CANCER MODULATION BY GLUCOSINOLATES: A REVIEW, CURR. SCI., 79, PP. 1665-1671, (2000); KUSHAD M.M., BROWN A.F., KURILICH A.C., JUVIK J.A., KLEIN B.P., WALLIG M.A., JEFFERY E.H., VARIATION OF GLUCOSINOLATES IN VEGETABLE CROPS OF BRASSICA OLERACEA, J. AGRIC. FOOD CHEM., 47, PP. 1541-1548, (1999); KURILICH A.C., TSAU G.J., BROWN A., HOWARD L., KLEIN B.P., JEFFERY E.H., KUSHAD M., WALLIG M.A., JUVIK J.A., CAROTENE, TOCOPHEROL, AND ASCORBATE CONTENTS IN SUBSPECIES OF BRASSICA OLERACEA, J. AGRIC. FOOD CHEM., 47, PP. 1576-1581, (1999); SINGH J., UPADHYAY A.K., PRASAD K., BAHADUR A., RAI M., VARIABILITY OF CAROTENES, VITAMIN C, E AND PHENOLICS IN BRASSICA VEGETABLES, J. FOOD COMPOS. ANAL., 20, PP. 106-112, (2007); HUSEBY S., KOPRIVOVA A., LEE B.R., SAHA S., MITHEN R., WOLD A., BENGTSSON G.B., KOPRIVA S., DIURNAL AND LIGHT REGULATION OF SULPHUR ASSIMILATION AND GLUCOSINOLATE BIOSYNTHESIS IN ARABIDOPSIS, J. EXP. BOT., 64, PP. 1039-1048, (2013); RODRIGUEZ-HERNANDEZ M.C., MORENO D.A., CARVAJAL M., MARTINEZ-BALLESTA M.C., GENOTYPE INFLUENCES SULFUR METABOLISM IN BROCCOLI (BRASSICA OLERACEA L.) UNDER ELEVATED CO<SUB>2</SUB> AND NACL STRESS, PLANT CELL PHYSIOL., 55, PP. 2047-2059, (2014); SAMS C.E., PANTHEE D.R., CHARRON C.S., KOPSELL D.A., YUAN J.S., SELENIUM REGULATES GENE EXPRESSION FOR GLUCOSINOLATE AND CAROTENOID BIOSYNTHESIS IN ARABIDOPSIS, J. AM. SOC. HORTIC. SCI., 136, PP. 23-34, (2011); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. PHYSIOL., 29, PP. 891-897, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J. AGRIC. FOOD CHEM., 53, PP. 6289-6293, (2005); ZANG Y.X., LIM M.H., PARK B.S., HONG S.B., KIM D.H., METABOLIC ENGINEERING OF INDOLE GLUCOSINOLATES IN CHINESE CABBAGE PLANTS BY EXPRESSION OF ARABIDOPSIS CYP79B2, CYP79B3, AND CYP83B1, MOL. CELLS, 25, PP. 231-241, (2008); ZANG Y.X., KIM J.H., PARK Y.D., KIM D.H., HONG S.B., METABOLIC ENGINEERING OF ALIPHATIC GLUCOSINOLATES IN CHINESE CABBAGE PLANTS EXPRESSING ARABIDOPSIS MAM1, CYP79F1, AND CYP83A1, BMB REP., 41, PP. 472-478, (2008); KIM J.K., CHU S.M., KIM S.J., LEE D.J., LEE S.Y., LIM S.Y., HA S.H., KWEON S.J., CHO H.S., VARIATION OF GLUCOSINOLATES IN VEGETABLE CROPS OF BRASSICA RAPA L. SSP. PEKINENSIS, FOOD CHEM., 119, PP. 423-428, (2010); OIL SEEDS-DETERMINATION OF GLUCOSINOLATES BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, OFF. J. EUR. COMMUNITIES: LEGIS., 170, PP. 27-34, (1990); PARK S.Y., CHOI S.R., LIM S.H., YEO Y.S., KWEON S.J., BAE Y.S., KIM K.W., IM K.H., AHN S.K., HA S.H., PARK S.U., KIM J.K., IDENTIFICATION AND QUANTIFICATION OF CAROTENOIDS IN PAPRIKA FRUITS AND CABBAGE, KALE, AND LETTUCE LEAVES, J. KOREAN SOC. APPL. BIOL. CHEM., 57, PP. 355-358, (2014); WELLBURN A.R., THE SPECTRAL DETERMINATION OF CHLOROPHYLLS A AND B, AS WELL AS TOTAL CAROTENOIDS, USING VARIOUS SOLVENTS WITH SPECTROPHOTOMETERS OF DIFFERENT RESOLUTION, J. PLANT PHYSIOL., 144, PP. 307-313, (1994); KIM T.J., LEE K.B., BAEK S.A., CHOI J.H., HA S.H., LIM S.H., PARK S.Y., YEO Y.S., PARK S.U., KIM J.K., DETERMINATION OF LIPOPHILIC METABOLITES FOR SPECIES DISCRIMINATION AND QUALITY ASSESSMENT OF NINE LEAFY VEGETABLES, J. KOREAN SOC. APPL. BIOL. CHEM., 58, PP. 909-918, (2015); KANG J.Y., IBRAHIM K.E., JUVIK J.A., KIM D.H., KANG W.J., GENETIC AND ENVIRONMENTAL VARIATION OF GLUCOSINOLATE CONTENT IN CHINESE CABBAGE, HORTSCIENCE, 41, PP. 1382-1385, (2006); PODSEDEK A., NATURAL ANTIOXIDANTS AND ANTIOXIDANT CAPACITY OF BRASSICA VEGETABLES: A REVIEW, LWT-FOOD SCI. TECHNOL., 40, PP. 1-11, (2007); KOPSELL D.A., KOPSELL D.E., LEFSRUD M.G., CURRAN-CELENTANO J., DUKACH L.E., VARIATION IN LUTEIN, Β-CAROTENE, AND CHLOROPHYLL CONCENTRATIONS AMONG BRASSICA OLERACEA CULTIGENS AND SEASONS, HORTSCIENCE, 39, PP. 361-364, (2004); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM., 53, PP. 5583-5586, (2005); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); AMARAL J.S., CASAL S., ALVES M.R., SEABRA R.M., OLIVEIRA B.P., TOCOPHEROL AND TOCOTRIENOL CONTENT OF HAZELNUT CULTIVARS GROWN IN PORTUGAL, J. AGRIC. FOOD CHEM., 54, PP. 1329-1336, (2006); STEUER R., KURTHS J., FIEHN O., WECKWERTH W., INTERPRETING CORRELATIONS IN METABOLOMIC NETWORKS, BIOCHEM. SOC. TRANS., 31, PP. 1476-1478, (2003); CHEN Y., PANG Q.Y., HE Y., ZHU N., BRANSTROM I., YAN X.F., CHEN S., PROTEOMICS AND METABOLOMICS OF ARABIDOPSIS RESPONSES TO PERTURBATION OF GLUCOSINOLATE BIOSYNTHESIS, MOL. PLANT, 5, PP. 1138-1150, (2012); KLAIBER J., DORN S., NAJAR-RODRIGUEZ A.J., ACCLIMATION TO ELEVATED CO2 INCREASES CONSTITUTIVE GLUCOSINOLATE LEVELS OF BRASSICA PLANTS AND AFFECTS THE PERFORMANCE OF SPECIALIZED HERBIVORES FROM CONTRASTING FEEDING GUILDS, J. CHEM. ECOL., 39, PP. 653-665, (2013); LAULE O., FURHOLZ A., CHANG H.S., ZHU T., WANG X., HEIFETZ P.B., GRUISSEM W., LANGE M., CROSSTALK BETWEEN CYTOSOLIC AND PLASTIDIAL PATHWAYS OF ISOPRENOID BIOSYNTHESIS IN ARABIDOPSIS THALIANA, PROC. NATL. ACAD. SCI. U. S. A., 100, PP. 6866-6871, (2003); JEFFERY E.H., BROWN A.F., KURILICH A.C., KECK A.S., MATUSHESKI N., KLEIN B.P., JUVIK J.A., VARIATION IN CONTENT OF BIOACTIVE COMPONENTS IN BROCCOLI, J. FOOD COMPOS. ANAL., 16, PP. 323-330, (2003); KLIEBENSTEIN D.J., KROYMANN J., BROWN P., FIGUTH A., PEDERSEN D., GERSHENZON J., OLDS T.M., GENETIC CONTROL OF NATURAL VARIATION IN ARABIDOPSIS GLUCOSINOLATE ACCUMULATION, PLANT PHYSIOL., 126, PP. 811-825, (2001); SCHONHOF I., KRUMBEIN A., BRUCKNER B., GENOTYPIC EFFECTS ON GLUCOSINOLATES AND SENSORY PROPERTIES OF BROCCOLI AND CAULIFLOWER, NAHRUNG, 48, PP. 25-33, (2004)","S.U. PARK; DEPARTMENT OF CROP SCIENCE, CHUNGNAM NATIONAL UNIVERSITY, YUSEONG-GU, DAEJEON, 99 DAEHAK-RO, 34134, SOUTH KOREA; EMAIL: SUPARK@CNU.AC.KR","AMERICAN CHEMICAL SOCIETY","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-84973400921","J AGRIC FOOD CHEM","INCHEON NATIONAL UNIVERSITY;BIOTECHNOLOGY INSTITUTE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;CHUNGNAM NATIONAL UNIVERSITY;INCHEON NATIONAL UNIVERSITY","NOTREPORTED;CHUNGNAM NATIONAL UNIVERSITY;NOTREPORTED",NA,"BAEK S-A, 2016, J AGRIC FOOD CHEM","BAEK S-A, 2016, J AGRIC FOOD CHEM"
"BARRIOS V;ESCOBAR C;CICERO A;BURKE D;FASCHING P;BANACH M;BRUCKERT E","BARRIOS, VIVENCIO (16030595200); ESCOBAR, CARLOS (15759886800); CICERO, ARRIGO FRANCESCO GIUSEPPE (7003403707); BURKE, DAVID (57192701087); FASCHING, PETER (59078005700); BANACH, MACIEJ (22936699500); BRUCKERT, ERIC (55539414500)","A NUTRACEUTICAL APPROACH ARMOLIPID PLUS TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA REVIEW OF THE CLINICAL EVIDENCE",2017,"ATHEROSCLEROSIS SUPPLEMENTS","24","14",82,"10.1016/j.atherosclerosissup.2016.10.003","DEPARTMENT OF CARDIOLOGY, HOSPITAL RAMON Y CAJAL, MADRID, SPAIN;DEPARTMENT OF CARDIOLOGY, HOSPITAL LA PAZ, MADRID, SPAIN;DISEASES RESEARCH CENTER, MEDICINE & SURGERY DEPARTMENT, ALMA MATER STUDIORUM ATHEROSCLEROSIS AND METABOLIC UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;BEACON HEART CENTRE, BEACON HOSPITAL, DUBLIN, IRELAND;5TH MEDICAL DEPARTMENT, WILHELMINENSPITAL, VIENNA, AUSTRIA;DEPARTMENT OF HYPERTENSION, CHAIR OF NEPHROLOGY AND HYPERTENSION, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND;DEPARTMENT OF ENDOCRINOLOGY AND CARDIOVASCULAR DISEASE PREVENTION, HÔPITAL PITIÉ-SALPÊTRIÈRE, PARIS, FRANCE","COMPELLING EVIDENCE SUPPORTS THE EFFECTIVENESS OF THE REDUCTION OF TOTAL AND LDL CHOLESTEROL (TC AND LDL-C) IN PRIMARILY PREVENTING CARDIOVASCULAR EVENTS, WITHIN THE FRAMEWORK OF LIFE-LONG PREVENTION PROGRAMS MAINLY CONSISTING IN LIFESTYLE CHANGES. PHARMACOLOGICAL TREATMENT SHOULD BE INTRODUCED WHEN LIFESTYLE CHANGES, INCLUDING USE OF NUTRACEUTICALS, HAVE FAILED. ESC/EAS GUIDELINES LIST A NUMBER OF NUTRACEUTICAL COMPOUNDS AND FUNCTIONAL FOODS WHICH HAVE BEEN INDIVIDUALLY STUDIED IN RANDOMIZED, CONTROLLED CLINICAL TRIALS (RCTS). TO DATE ONLY A PROPRIETARY FORMULATION OF THREE NATURALLY OCCURRING SUBSTANCES WITH PUTATIVE COMPLEMENTARY LIPID-LOWERING PROPERTIES − RED YEAST RICE, POLICOSANOL AND BERBERINE – COMBINED WITH FOLIC ACID, ASTAXANTHIN, AND COENZYME Q10 (ARMOLIPID PLUS®) HAS BEEN EXTENSIVELY INVESTIGATED IN SEVERAL RCTS, 7 OF WHICH WERE PLACEBO-CONTROLLED, 2 WERE EZETIMIBE COMPARATORS AND 4 WERE “REAL LIFE” STUDIES COMPARING DIET AND ARMOLIPID PLUS TO DIET ALONE. THE TRIALS INCLUDED MOSTLY PATIENTS WITH MILD TO MODERATE DYSLIPIDEMIA, TREATED FOR 6–48 WEEKS. THE TRIALS ALSO INCLUDED SPECIAL POPULATIONS AND PATIENTS IN WHOM STATINS WERE CONTRAINDICATED OR WHO COULD NOT TOLERATE THEM. ARMOLIPID PLUS HAS PROVED TO BE ABLE TO ACHIEVE SIGNIFICANT REDUCTIONS IN TC (11–21%) AND IN LDL-C (15–31%) LEVELS, WHICH IS EQUIVALENT TO EXPECTATIONS FROM LOW DOSE STATINS. IN PATIENTS INTOLERANT TO STATINS, WHO DO NOT ACHIEVE THEIR THERAPEUTIC TARGET WITH EZETIMIBE, ARMOLIPID PLUS CAN ACHIEVE A FURTHER 10% IMPROVEMENT IN TC AND LDL-C. THE SAFETY AND TOLERABILITY OF ARMOLIPID PLUS WERE EXCELLENT, THOUGHT LIKELY DUE TO THE INTENTIONAL COMBINATION OF LOW DOSES OF ITS ACTIVE INGREDIENTS: LOW ENOUGH NOT TO BE ASSOCIATED WITH UNTOWARD EFFECTS, BUT HIGH ENOUGH TO EXERT THERAPEUTIC EFFECTS IN COMBINATION WITH OTHER COMPLEMENTARY SUBSTANCES. CONSEQUENTLY, IN THE EVENT OF INTOLERANCE TO STATINS, ARMOLIPID PLUS OFFERS AN EFFECTIVE ALTERNATIVE, WHICH IS DEVOID OF THE SAFETY RISKS ASSOCIATED WITH SYNTHETIC PHARMACOLOGICAL THERAPY. IN CONCLUSION ARMOLIPID PLUS, IN ADDITION TO DIETARY MEASURES, COULD BE A RATIONAL CHOICE FOR INDIVIDUALS WITH MILD TO MODERATE HYPERLIPIDEMIA AND FOR ALL DYSLIPIDEMIC PATIENTS IN WHOM STATINS ARE NOT INDICATED OR WHO CANNOT TOLERATE THEM. © 2016 ELSEVIER IRELAND LTD","ARMOLIPID PLUS; FUNCTIONAL FOODS; HYPERCHOLESTEROLEMIA; LIFESTYLE CHANGE; NUTRACEUTICALS","ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; BIOMARKERS; CHOLESTEROL; CHOLESTEROL, LDL; DIET, FAT-RESTRICTED; DIETARY SUPPLEMENTS; DOWN-REGULATION; DRUG COMBINATIONS; DYSLIPIDEMIAS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; ASTAXANTHIN; BERBERINE; CAFFEINE; CHOLESTIN; EZETIMIBE; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; MIDAZOLAM; NUTRACEUTICAL; OMEPRAZOLE; POLICOSANOL; UBIDECARENONE; WARFARIN; ANTIOXIDANT; BIOLOGICAL MARKER; CHOLESTEROL; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; THERAPY EFFECT; ADVERSE EFFECTS; BLOOD; DIETARY SUPPLEMENT; DOWN REGULATION; DRUG COMBINATION; DYSLIPIDEMIAS; LOW FAT DIET; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME","","","EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (VERSION 2012), EUR HEART J, 33, PP. 1635-1701, (2012); ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS). DEVELOPED WITH THE SPECIAL CONTRIBUTION OF THE EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR), ATHEROSCLEROSIS, 253, PP. 281-344, (2016); LONGHI R., ALMEIDA R.F., MACHADO L., ET AL., EFFECT OF A TRANS FATTY ACID-ENRICHED DIET ON BIOCHEMICAL AND INFLAMMATORY PARAMETERS IN WISTAR RATS, EUR J NUTR, PP. 1-14, (2016); EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); DORMUTH C.R., HEMMELGARN B.R., PATERSON J.M., ET AL., USE OF HIGH POTENCY STATINS AND RATES OF ADMISSION FOR ACUTE KIDNEY INJURY: MULTICENTER, RETROSPECTIVE OBSERVATIONAL ANALYSIS OF ADMINISTRATIVE DATABASES, BMJ, 346, (2013); MANSI I.A., MORTENSEN E.M., PUGH M.J., ET AL., INCIDENCE OF MUSCULOSKELETAL AND NEOPLASTIC DISEASES IN PATIENTS ON STATIN THERAPY: RESULTS OF A RETROSPECTIVE COHORT ANALYSIS, AM J MED SCI, 345, PP. 343-348, (2013); CARTER A.A., GOMES T., CAMACHO X., ET AL., RISK OF INCIDENT DIABETES AMONG PATIENTS TREATED WITH STATINS: POPULATION BASED STUDY, BMJ, 346, (2013); DORMUTH C.R., FILION K.B., PATERSON J.M., ET AL., HIGHER POTENCY STATINS AND THE RISK OF NEW DIABETES: MULTICENTRE, OBSERVATIONAL STUDY OF ADMINISTRATIVE DATABASES, BMJ, 348, (2014); CEDERBERG H., STANCAKOVA A., YALURI N., ET AL., INCREASED RISK OF DIABETES WITH STATIN TREATMENT IS ASSOCIATED WITH IMPAIRED INSULIN SENSITIVITY AND INSULIN SECRETION: A 6 YEAR FOLLOW-UP STUDY OF THE METSIM COHORT, DIABETOLOGIA, (2015); HUANG X., ALONSO A., GUO X., ET AL., STATINS, PLASMA COLESTEROL AND RISK OF PARKINSON'S DISEASE: A PROSPECTIVE STUDY, MOV DISORD, (2015); TRIANTAFILLOS G., GIANNAKOPOULOS T.G., AVGERINOS E.D., ET AL., BIOMARKERS FOR DIAGNOSIS OF THE VULNERABLE ATHEROSCLEROTIC PLAQUE, INTERV CARDIOL, 3, PP. 223-233, (2011); MCCULLY K.S., HOMOCYSTEINE, VITAMINS, AND VASCULAR DISEASE PREVENTION, AM J CLIN NUTR, 86, PP. 1563S-1568S, (2007); ENDO A., CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS, KLIN WOCHENSCHR, 66, PP. 421-427, (1988); MAN R.Y., LYNN E.G., CHEUNG F., ET AL., CHOLESTIN INHIBITS CHOLESTEROL SYNTHESIS AND SECRETION IN HEPATIC CELLS (HEPG2), MOL CELL BIOCHEM, 233, PP. 153-158, (2002); LI Y., JIANG L., JIA Z., ET AL., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, (2014); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); POLICOSANOL ALTERN MED REV, 9, PP. 312-317, (2004); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A.BIOL..SCI MED SCI, 56, PP. M186-M192, (2001); ZARDOYA R., TULA L., CHAN T.Y., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); ORTENSI G., JULIO G., HECTOR V., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVESTIG, 25, PP. 701-707, (2005); CAMERON J., RANHEIM T., KULSETH M.A., ET AL., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); DOGGRELL S.A., BERBERINE – A NOVEL APPROACH TO CHOLESTEROL LOWERING, EXPERT OPIN INVESTIG DRUGS, 14, PP. 683-685, (2005); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); CICERO A., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN LIPIDOL, 4, PP. 553-563, (2009); IWAMOTO T., HOSODA K., HIRANO R., ET AL., INHIBITION OF LOW-DENSITY LIPOPROTEIN OXIDATION BY ASTAXANTHIN, J ATHEROSCLER THROMB, 7, PP. 216-222, (2000); ZENG X.H., ZENG X.J., LI Y.Y., EFFICACY AND SAFETY OF BERBERINE FOR CONGESTIVE HEART FAILURE SECONDARY TO ISCHEMIC OR IDIOPATHIC DILATED CARDIOMYOPATHY, AM J CARDIOL, 92, 2, PP. 173-176, (2003); KUMAR A., KAUR H., DEVI P., ET AL., ROLE OF COENZYME Q10 (COQ10) IN CARDIAC DISEASE, HYPERTENSION AND MENIERE-LIKE SYNDROME, PHARMACOL THER, 124, PP. 259-268, (2009); WYMAN M., LEONARD M., MORLEDGE T., COENZYME Q10: A THERAPY FOR HYPERTENSION AND STATIN-INDUCED MYALGIA?, CLEVE CLIN J MED, 77, PP. 435-442, (2010); BANACH M., SERBAN C., URSONIU S., ET AL., STATIN THERAPY AND PLASMA COENZYME Q10 CONCENTRATIONS–A SYSTEMATIC REVIEW AND META-ANALYSIS OF PLACEBO-CONTROLLED TRIALS, PHARMACOL RES, 99, PP. 329-336, (2015); PERSIANI S., SALA F., MANZOTTI C., ET AL., EFFECT OF A COMBINATION OF BERBERINE AND MONACOLIN ON CYP ENZYMES: AN ORAL COCKTAIL INTERACTION STUDY IN HEALTHY VOLUNTEERS, J PHARM PHARMACOL, 2, PP. 660-668, (2014); PERSIANI S., SALA F., ZANGARINI M., ET AL., EFFECT OF FOOD ON THE ORAL BIOAVAILABILITY OF BERBERINE AND MONACOLIN ADMINISTERED IN COMBINATION IN HEALTHY MALE VOLUNTEERS, J PHARM PHARMACOL, 2, PP. 703-712, (2014); TAN X.S., MA J.Y., FENG R., ET AL., TISSUE DISTRIBUTION OF BERBERINE AND ITS METABOLITES AFTER ORAL ADMINISTRATION IN RATS, PLOS ONE, 8, (2013); GUPTA P.K., GURLEY B.J., BARONE G., HENDRICKSON H.P., CLINICAL PHARMACOKINETICS AND METABOLISM OF BERBERINE AND HYDRASTINE FOLLOWING AN ORAL DOSE OF GOLDENSEAL SUPPLEMENT, PLANTA MED, (2010); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); CICERO A.F.G., DE SANDO V., BENEDETTO D., ET AL., LONG-TERM EFFICACY AND TOLERABILITY OF A MULTICOMPONENT LIPID-LOWERING NUTRACEUTICAL IN OVERWEIGHT AND NORMOWEIGHT PATIENTS, NUTRAFOODS, 11, PP. 55-61, (2012); AFFUSO F., MERCURIO V., RUVOLO A., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES, 77, PP. 1-6, (2015); RUSCICA M., GOMARASCHI M., MOMBETTI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, PP. 61-68, (2014); SOLA R., VALLS R.M., PUZO J., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MEDITERR J NUTR METAB, 4, PP. 133-139, (2011); IZZO R., DE S.G., GIUDICE R., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, PP. 1482-1487, (2010); WENG T.C., KAO-YANG Y.H., LIN S.J., ET AL., A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE THERAPEUTIC EQUIVALENCE OF STATINS, J CLIN PHARM THER, 35, PP. 139-151, (2010); EDWARDS J.E., MOORE R.A., STATINS IN HYPERCHOLESTEROLAEMIA: A DOSE-SPECIFIC META-ANALYSIS OF LIPID CHANGES IN RANDOMIZED, DOUBLE-BLIND TRIALS, BMC FAM PRACT, 4, (2003); NACI H., BRUGTS J.J., FLEURENCE R., ADES A.E., DOSE-COMPARATIVE EFFECTS OF DIFFERENT STATINS ON SERUM LIPID LEVELS: A NETWORK META-ANALYSIS OF 256,827 INDIVIDUALS IN 181 RANDOMIZED CONTROLLED TRIALS, EUR J PREV CARDIOL, 20, PP. 658-670, (2013); PIRRO M., MANNARINO M.R., BIANCONI V., ET AL., THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PHARMACOL RES, 110, PP. 76-88, (2016); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, PP. 123-132, (2012); MARAZZI G., PELLICCIA F., CAMPOLONGO G., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT DYSLIPIDEMIA PATIENTS WITH CORONARY HEART DISEASE, AM J CARDIOL, 116, 12, PP. 1798-1801, (2015); CICERO A.F.G., PARINI A., TOSTICCI M., ET AL., EFFECT OF LIPID-LOWERING NUTRACEUTICAL ON PULSE-WAVE-VELOCITY IN HYPERCHOLESTEROLEMIC PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE, OPEN HYPERTENS J, 5, PP. 18-22, (2013); CICERO A.F.G., DEROSA G., BOVE M., ET AL., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOP NUTRACEUTICAL RES, 7, PP. 121-126, (2009); BANACH M., RIZZO M., TOTH P.P., ET AL., STATIN INTOLERANCE - AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, 1, PP. 1-23, (2015); CICERO A.F.G., ROSTICCI M., DEROSA G., ET AL., SUBJECTIVE EFFECTS OF A COMBINED LIPID-LOWERING NUTRACEUTICAL OR EZETIMIBE ON WELL-BEING AND SEXUAL PERFORMANCE IN PATIENTS WITH PERCEIVED WORSENING OF ERECTILE FUNCTION DURING STATIN TREATMENT: A RANDOMIZED CLINICAL TRIAL, NUTRAFOODS, (2015); PIRRO M., MANNARINO M.R., MINISTRINI S., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION ON LIPIDS, INFLAMMATION AND ENDOTHELIAL INTEGRITY IN PATIENTS WITH SUBCLINICAL INFLAMMATION: A RANDOMIZED CLINICAL TRIAL, SCI REP, 6, (2016); HANLEY A.J., WILLIAMS K., STERN M.P., ET AL., HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE IN RELATION TO THE INCIDENCE OF CARDIOVASCULAR DISEASE: THE SAN ANTONIO HEART STUDY, DIABETES CARE, 25, PP. 1177-1184, (2002); BONORA E., FORMENTINI G., CALCATERRA F., ET AL., HOMA-ESTIMATED INSULIN RESISTANCE IS AN INDEPENDENT PREDICTOR OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETIC SUBJECTS: PROSPECTIVE DATA FROM THE VERONA DIABETES COMPLICATIONS STUDY, DIABETES CARE, 25, PP. 1135-1141, (2002); NAKAMURA K., SAKURAI M., MIURA K., ET AL., HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE AND THE RISK OF CARDIOVASCULAR EVENTS IN MIDDLE-AGED NON-DIABETIC JAPANESE MEN, DIABETOLOGIA, 53, PP. 1894-1902, (2010); BONORA E., KIECHL S., WILLEIT J., ET AL., INSULIN RESISTANCE AS ESTIMATED BY HOMEOSTASIS MODEL ASSESSMENT PREDICTS INCIDENT SYMPTOMATIC CARDIOVASCULAR DISEASE IN CAUCASIAN SUBJECTS FROM THE GENERAL POPULATION: THE BRUNECK STUDY, DIABETES CARE, 30, PP. 318-324, (2007); PIRRO M., LUPATELLI G., DEL GIORNO R., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, PHARMA NUTR, 1, PP. 73-77, (2013); TSUNODA T., NOZUE T., YAMADA M., ET AL., EFFECTS OF EZETIMIBE ON ATHEROGENIC LIPOPROTEINS AND GLUCOSE METABOLISM IN PATIENTS WITH DIABETES AND GLUCOSE INTOLERANCE, DIABETES RES CLIN PRACT, 100, PP. 46-52, (2013); ZHOU Y., YUAN Y., CAI R.R., ET AL., STATIN THERAPY ON GLYCAEMIC CONTROL IN TYPE 2 DIABETES: A META-ANALYSIS, EXPERT OPIN PHARMACOTHER, 14, PP. 1575-1584, (2013); MOUTZOURI E., LIBEROPOULOS E., MIKHAILIDIS D.P., ET AL., COMPARISON OF THE EFFECTS OF SIMVASTATIN VS ROSUVASTATIN VS SIMVASTATIN/EZETIMIBE ON PARAMETERS OF INSULIN RESISTANCE, INT J CLIN PRACT, 65, PP. 1141-1148, (2011); KEI A., LIBEROPOULOS E., ELISAF M., EFFECT OF HYPOLIPIDEMIC TREATMENT ON GLYCEMIC PROFILE IN PATIENTS WITH MIXED DYSLIPIDEMIA, WORLD J DIABETES, 4, PP. 365-371, (2013); CORNIER M.A., DABELEA D., HERNANDEZ T.L., ET AL., THE METABOLIC SYNDROME, ENDOCR REV, 29, PP. 777-822, (2008); MAZZA A., LENTI S., SCHIAVON L., ET AL., NUTRACEUTICALS FOR SERUM LIPID AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS AT LOW CARDIOVASCULAR RISK, ADV THER, 32, PP. 680-690, (2015)","V. BARRIOS; DEPARTMENT OF CARDIOLOGY, HOSPITAL RAMON Y CAJAL, MADRID, CTRA. DE COLMENAR VIEJO, KM. 9,100, 28034, SPAIN; EMAIL: VIVENCIOBARRIOS@GMAIL.COM","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLER. SUPPL.","ARTICLE","ISI","2-S2.0-85007418257","ATHEROSCLER SUPPL","HOSPITAL RAMON Y CAJAL;HOSPITAL LA PAZ;ALMA MATER STUDIORUM ATHEROSCLEROSIS AND METABOLIC UNIVERSITY OF BOLOGNA;BEACON HEART CENTRE;MEDICAL UNIVERSITY OF LODZ","NOTREPORTED;CTRA. DE COLMENAR VIEJO;NOTREPORTED",NA,"BARRIOS V, 2017, ATHEROSCLER SUPPL","BARRIOS V, 2017, ATHEROSCLER SUPPL"
"OINOTKINOVA O;NIKONOV E;KRYUKOV E;BARANOV A;VOEVODA M","OINOTKINOVA, O.S. (57194554643); NIKONOV, E.L. (57216680476); KRYUKOV, E.V. (57208311867); BARANOV, A.P. (7201565037); VOEVODA, M.I. (57195959148)","EVOLUTION OF DYSLIPIDEMIA FROM ETIOLOGICAL MECHANISMS TO NEW TARGETS OF PERSONALIZED PREVENTIVE NUTRACEUTICAL THERAPY WITH RED YEAST RICE ЭВОЛЮЦИЯ ДИСЛИПИДЕМИИ ОТ ЭТИОЛОГИЧЕСКИХ МЕХАНИЗМОВ К НОВЫМ МИШЕНЯМ ПЕРСОНАЛИЗИРОВАННОЙ ПРОФИЛАКТИЧЕСКОЙ НУТРИЦЕВТИЧЕСКОЙ ТЕРАПИИ КРАСНЫМ ДРОЖЖЕВЫМ РИСОМ",2019,"CARDIOVASCULAR THERAPY AND PREVENTION (RUSSIAN FEDERATION)","18","10",2,"10.15829/1728-8800-2019-6-88-98","MOSCOW STATE UNIVERSITY, MOSCOW, RUSSIAN FEDERATION, RESEARCH INSTITUTE OF PUBLIC HEALTH AND HEALTHCARE MANAGEMENT, MOSCOW, RUSSIAN FEDERATION;PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY, MOSCOW, RUSSIAN FEDERATION;BURDENKO MAIN MILITARY CLINICAL HOSPITAL, MOSCOW, RUSSIAN FEDERATION;MOSCOW STATE UNIVERSITY, MOSCOW, RUSSIAN FEDERATION, PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY, MOSCOW, RUSSIAN FEDERATION;RESEARCH CENTER FOR FUNDAMENTAL AND TRANSLATIONAL MEDICINE, NOVOSIBIRSK, RUSSIAN FEDERATION","THE REVIEW PRESENTS AN ANALYSIS OF STUDIES ON THE ROLE OF ARMOLIPID IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES. ARMOLIPID IS THE NUTRACEUTICAL THAT COMBINES THE LIPID-LOWERING COMPONENTS OF RED YEAST RICE (MONOCALIN K, POLICOSANOL) AND ANTIOXIDANTS (COENZYME Q, ASTAXANTHIN AND FOLIC ACID). THE MULTIFACTORIAL EVOLUTION OF ATHEROSCLEROTIC PLAQUE WITH DYSLIPIDEMIA, INFLAMMATION AND GENETIC MARKERS AND PRACTICABILITY OF PRIMARY PREVENTION IS SHOWN. THE PRESENTED DATA DEMONSTRATED THAT THE INTAKE OF NUTRACEUTICALS IS WELL TOLERATED. IT ALSO REDUCES THE LEVELS OF TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND INFLAMMATORY MARKERS AND IMPROVES VASCULAR ENDOTHELIAL FUNCTION. NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS CAN BE USED AS AN ALTERNATIVE METHOD OF PRIMARY PREVENTION IN PEOPLE WITH LOW AND BORDERLINE CARDIOVASCULAR RISK BEFORE STATIN THERAPY, WITH POOR ADHERENCE TO STATIN THERAPY, AS WELL AS WITH STATIN INTOLERANCE OR SIDE EFFECTS. © 2019 VSEROSSIISKOE OBSHCHESTVO KARDIOLOGOV. ALL RIGHTS RESERVED.","ARMOLIPID; DYSLIPIDEMIA; NUTRACEUTICALS; PRIMARY PREVENTION; RED YEAST RICE","ANTILIPEMIC AGENT; ARMOLIPID; ASTAXANTHIN; CHOLESTIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCALIN K; NUTRACEUTICAL; POLICOSANOL; UBIQUINONE; UNCLASSIFIED DRUG; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DYSLIPIDEMIA; GENETIC MARKER; HUMAN; INFLAMMATION; PERSONALIZED NUTRITION; REVIEW","RUSSIAN FOUNDATION FOR BASIC RESEARCH, RFBR","CONFLICTS OF INTEREST: THE STUDY WAS SUPPORTED BY THE RFBR GRANT","BULLETIN OF THE WORLD HEALTH ORGANIZATION, (2018); STATISTICAL INFORMATION OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: INCIDENCE OF THE ADULT POPULATION OF RUSSIA IN, (2016); SANIDAS E., THE ROLE OF NUTRACEUTICALS IN THE TREATMENT OF PRIMARY DYSLIPIDEMIA, HELLENIC JOURNAL OF CARDIOLOGY, (2018); MUROMTSEVA G.A., KONTSEVAYA A.V., KONSTANTINOV V.V., ET AL., PREVALENCE OF RISK FACTORS FOR NONCOMMUNICABLE DISEASES IN THE RUSSIAN POPULATION IN 2012-2013. RESULTS OF THE RUSSIAN ESSAY STUDY, CARDIOVASCULAR THERAPY AND PREVENTION, 13, 6, PP. 4-11, (2014); OINOTKINOVA O.S., MAMEDOV M.N., TSUKAEVA M.R., ET AL., THE ROLE OF TOTAL CARDIOVASCULAR RISK IN THE DEVELOPMENT OF DIABETES IN PERSONS OF HAZARDOUS OCCUPATIONS, JOURNAL OF NEW MEDICAL TECHNOLOGIES, 2, PP. 121-129, (2017); VIRMANI R., BURKE A.P., FARB A., ET AL., PATHOLOGY OF THE VULNERABLE PLAQUE, JACC, 47, 8, PP. 13-18, (2006); STARY H.C., CHANDLER A.B., DINSMORE R.E., ET AL., A DEFINITION OF ADVANCED TYPES OF ATHEROSCLEROTIC LESIONS AND A HISTOLOGICAL CLASSIFICATION OF ATHEROSCLEROSIS: A REPORT FROM THE COMMITTEE ON VASCULAR LESIONS OF THE COUNCIL ON ARTERIOSCLEROSIS, AM. HEART ASSOCIATION. CIRCULATION., 92, PP. 1355-1374, (1995); FAXON D.P., FUSTER V., LIBBY P., ET AL., ATHEROSCLEROTIC VASCULAR DISEASE CONFERENCE WRITING GROUP III: PATHOPHYSIOLOGY, CIRCULATION, 109, PP. 2617-2625, (2004); VIRMANI R., KOLODGIE F.D., BURKE A.P., ET AL., LESSONS FROM SUDDEN CORONARY DEATH: A COMPREHENSIVE MORPHOLOGICAL CLASSIFICATION SCHEME FOR ATHEROSCLEROTIC LESIONS, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 1262-1275, (2000); HANSSON G.K., INFLAMMATORY MECHANISMS IN ATHEROSCLEROSIS, J THROMB HAEMOST, 7, PP. 328-333, (2009); LIBBY P., INFLAMMATION IN ATHEROSCLEROSIS, NATURE, 420, 6917, PP. 868-874, (2002); PETRETTO E., LIU E.T., AITMAN T.A., GENE HARVEST REVEALING THE ARCHEOLOGY AND COMPLEXITY OF HUMAN DISEASE, NAT GENET, 39, PP. 1299-1301, (2007); ORHO-MELANDER M., GENETICS OF CORONARY HEART DISEASE: PATH TO ETIOLOGICAL MECHANISMS, NEW THERAPY TARGETS AND MORE PERSONALIZED PREVENTION, J INTERN MED, 278, PP. 433-446, (2015); PETERS D.T., MUSUNURU K., FUNCTIONAL EVALUATION OF GENETIC VARIATION IN COMPLEX HUMAN TRAITS, HUM MOL GENET, 21, PP. R18-R23, (2012); WILLER C.J., MOHLKE K., FINDING GENES AND VARIANTS FOR LIPID LEVELS AFTER GENOME WIDE ASSOCIATION ANALYSIS, CURR OPIN LIPIDOL, 23, PP. 98-103, (2012); HELGADOTTIR A., THORLEIFSSON G., MANOLESCU A., ET AL., A COMMON VARIANT ON CHROMOSOME 9P21 AFFECTS THE RISK OF MYOCARDIAL INFARCTION, SCIENCE, 316, PP. 1491-1493, (2007); MCPHERSON R., PERTSEMLIDIS A., KAVASLAR N., ET AL., A COMMON ALLELE ON CHROMOSOME 9 ASSOCIATED WITH CORONARY HEART DISEASE, SCIENCE, 316, PP. 1488-1491, (2007); SAMANI N., ERDMANN J., HALL A.S., ET AL., GENOMEWIDE ASSOCI- ATION ANALYSIS OF CORONARY ARTERY DISEASE, N ENGL J MED, 357, PP. 443-453, (2007); STRONG A., DING Q., EDMONDSON A.C., ET AL., HEPATIC SORTILIN REGULATES BOTH APOLIPOPROTEIN B SECRETION AND LDL CATABOLISM, J CLIN INVEST, 122, PP. 2807-2816, (2012); PATEL K.M., STRONG A., TOHYAMA J., ET AL., MACROPHAGE SORTILIN PROMOTES LDL UPTAKE, FOAM CELL FORMATION, AND ATHEROSCLEROSIS, CIRC RES, 116, PP. 789-796, (2015); GUSTAFSEN C., KJOLBY M., NYEGAARD M., ET AL., THE HYPERCHOLESTEROLEMIA-RISK GENE SORT1 FACILITATES PCSK9 SECRETION, CELL METAB, 19, PP. 310-318, (2014); HU D., YANG Y., PENG D.Q., INCREASED SORTILIN AND ITS INDEPENDENT EFFECT ON CIRCULATING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN STATIN-NAIVE PATIENTS WITH CORONARY ARTERY DISEASE, INT J CARDIOL, 227, PP. 61-65, (2017); URBAN D., POSS J., BOHM M., LAUFS U., TARGETING THE PROPROTEIN CONVERT AS ESUBTILISIN/KEXIN TYPE 9 FOR THE TREATMENT OF DYSLIPIDEMIA AND ATHEROSCLEROSIS, JACC, 62, PP. 1401-1408, (2013); NOZUE T., HATTORI H., OGAWA K., ET AL., EFFECTS OF STATIN THERAPY ON PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 AND SORTILIN LEVELS IN STATIN-NAIVE PATIENTS WITH CORONARY ARTERY DISEASE, J ATHEROSCLER THROMB, 23, PP. 848-856, (2016); OH T.J., AHN C.H., KIM B.R., ET AL., CIRCULATING SORTILIN LEVEL AS A POTENTIAL BIOMARKER FOR CORONARY ATHEROSCLEROSIS AND DIABETES MELLITUS, CARDIOVASC DIABETOL, 16, (2017); GOETTSCH C., KJOLBY M., AIKAWA E., SORTILIN AND ITS MULTIPLE ROLES IN CARDIOVASCULAR AND METABOLIC DISEASES ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 38, PP. 19-25, (2018); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON CLINICAL PRACTICE GUIDELINES, JACC, 73, 24, (2019); ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: LIPID MODIFICATION TO REDUCE CARDIOVASCULAR RISK: SUPPLEMENTARY DATA. THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, PP. 1-78, (2019); ADOURIDIS A., FILIPPATOS T., TSIMIHODIMOS V., ET AL., COMBINATIONS OF EZETIMIBE WITH NONSTATIN DRUG REGIMENS AFFECTING LIPID METABOLISM, EXPERT REV CARDIOVASC THER, 9, PP. 355-366, (2011); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR ATHEROSCLER REP, 17, (2015); CORSINI A., BELLOSTA S., BAETTA R., ET AL., NEW INSIGHTS INTO THE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF STATINS, PHARMACOL THER, 84, PP. 413-428, (1999); CHEN C.H., YANG J.C., UANG Y.S., ET AL., IMPROVED DISSOLUTION RATE AND ORAL BIOAVAILABILITY OF LOVASTATIN IN RED YEAST RICE PRODUCTS, INT J PHARM, 444, PP. 18-24, (2013); ZHAO S.P., LIU L., CHENG Y.C., ET AL., XUEZHIKANG, AN EXTRACT OF CHOLESTIN, PROTECTS ENDOTHELIAL FUNCTION THROUGH ANTIINFLAMMATORY AND LIPID-LOWERING MECHANISMS IN PATIENTS WITH CORONARY HEART DISEASE, CIRCULATION, 110, PP. 915-920, (2004); POLI A., PRIMARY PREVENTION AND HYPERCHOLESTEROLAEMIA: ‘DOC, PLEASE, GIVE ME THE NATURAL STATIN, EUR HEART J SUPPLEMENTS, 21, PP. B71-B72, (2019); ENDO A., KURODA M., TSUJITA Y., ML-236A, ML-236B, AND ML-236C, NEW INHIBITORS OF CHOLESTEROGENESIS PRODUCED BY PENICILLIUM CITRINUM, THE JOURNAL OF ANTIBIOTICS, 29, 12, PP. 1346-1348, (1976); KALRA E.K., NUTRACEUTICAL-DEFINITION AND INTRODUCTION, AAPS PHARM SCI, 5, (2003); BARRIOS V., ESCOBAR C., CICERO A.F., ET AL., A NUTRACEUTICAL APPROACH (ARMOLIPID PLUS) TO REDUCE TOTAL AND LDL CHOLESTEROL IN INDIVIDUALS WITH MILD TO MODERATE DYSLIPIDEMIA: REVIEW OF THE CLINICAL EVIDENCE, ATHEROSCLEROSIS, 24, PP. 1-15, (2017); CICERO A.F.G., BENVENUTI C., EFFICACY OF A RED YEAST RICE BASED NUTRACEUTICAL IN LARGE SUBGROUPS OF HYPERCHOLESTEROLEMIC SUBJECTS IN EVERY DAY CLINICAL PRACTICE, MEDITERR J NUTR METAB, 3, PP. 239-246, (2010); SOLA R., VALLS R.M., PUZO J., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, 8, (2014); NACI H., BRUGTS J.J., FLEURENCE R., ET AL., DOSE-COMPARATIVE EFFECTS OF DIFFERENT STATINS ON SERUM LIPID LEVELS: A NETWORK META-ANALYSIS OF 256,827 INDIVIDUALS IN 181 RANDOMIZED CONTROLLED TRIALS, EUR J PREV CARDIOL, 20, PP. 658-670, (2013); WENG T.C., YANG Y.H., LIN S.J., ET AL., A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE THERAPEUTIC EQUIVALENCE OF STATINS, J CLIN PHARM THERAPEUT, 35, PP. 139-151, (2010); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METABOL CARDIOVASC DIS, 20, PP. 656-661, (2010); TRIMARCO V., BATTISTONI A., TOCCI G., ET AL., SINGLE BLIND, MULTICENTRE, RANDOMIZED, CONTROLLED TRIAL TESTING THE EFFECTS OF A NOVEL NUTRACEUTICAL COMPOUND ON PLASMA LIPID AND CARDIOVASCULAR RISK FACTORS: RESULTS OF THE INTERIM ANALYSIS, NUTR METABOL CARDIOVASC DIS, 27, PP. 850-857, (2017); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); MARAZZI G., PELLICCIA F., CAMPOLONGO G., ET AL., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM J CARDIOL, 116, PP. 1798-1801, (2015); MARAZZI G., CAMPOLONGO G., PELLICCIA F., ET AL., COMPARISON OF LOW-DOSE STATIN VERSUS LOW-DOSE STATIN + ARMOLIPID PLUS IN HIGH-INTENSITY STATIN-INTOLERANT PATIENTS WITH A PREVIOUS CORONARY EVENT AND PERCUTANEOUS CORONARY INTERVENTION (ADHERENCE TRIAL), AM J CARDIOL, 120, PP. 893-897, (2017); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); AFFUSO F., MERCURIO V., RUVOLO A., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012)","O.S. OINOTKINOVA; MOSCOW STATE UNIVERSITY, MOSCOW, RUSSIAN FEDERATION; EMAIL: OLGA-OYNOTKINOVA@YANDEX.RU","VSEROSSIISKOE OBSHCHESTVO KARDIOLOGOV","RUSSIAN","CARDIOVASC. THER. PREV.","REVIEW","ISI","2-S2.0-85081073750","CARDIOVASC THER PREV","MOSCOW STATE UNIVERSITY;PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY;BURDENKO MAIN MILITARY CLINICAL HOSPITAL;MOSCOW STATE UNIVERSITY;RESEARCH CENTER FOR FUNDAMENTAL AND TRANSLATIONAL MEDICINE","NOTREPORTED;MOSCOW STATE UNIVERSITY;NOTREPORTED",NA,"OINOTKINOVA OS, 2019, CARDIOVASC THER PREV","OINOTKINOVA OS, 2019, CARDIOVASC THER PREV"
"TUFAIL T;SAEED F;IMRAN M;ARSHAD M;ANJUM F;AFZAAL M;AIN H;SHAHBAZ M;GONDAL T;HUSSAIN S","TUFAIL, TABUSSAM (57192363905); SAEED, FARHAN (37662112200); IMRAN, MUHAMMAD (58856300800); ARSHAD, MUHAMMAD UMAIR (57215062998); ANJUM, FAQIR MUHAMMAD (7003436069); AFZAAL, MUHAMMAD (57204578107); AIN, HUMA BADER UL (57204422886); SHAHBAZ, MUHAMMAD (57190817641); GONDAL, TANWEER ASLAM (57202777351); HUSSAIN, SHAHZAD (56660782800)","BIOCHEMICAL CHARACTERIZATION OF WHEAT STRAW CELL WALL WITH SPECIAL REFERENCE TO BIOACTIVE PROFILE",2018,"INTERNATIONAL JOURNAL OF FOOD PROPERTIES","21","7",23,"10.1080/10942912.2018.1484759","DEPARTMENT OF FOOD SCIENCE, INSTITUTE OF HOME & FOOD SCIENCES, GOVERNMENT COLLEGE UNIVERSITY, FAISALABAD, PAKISTAN;DEPARTMENT OF FOOD SCIENCE, INSTITUTE OF HOME & FOOD SCIENCES, GOVERNMENT COLLEGE UNIVERSITY, FAISALABAD, PAKISTAN;FACULTY OF ALLIED HEALTH SCIENCES, THE UNIVERSITY OF LAHORE, LAHORE, PAKISTAN;DEPARTMENT OF FOOD SCIENCE, INSTITUTE OF HOME & FOOD SCIENCES, GOVERNMENT COLLEGE UNIVERSITY, FAISALABAD, PAKISTAN;COLLEGE OF FOOD AND AGRICULTURAL SCIENCES, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA;DEPARTMENT OF FOOD SCIENCE, INSTITUTE OF HOME & FOOD SCIENCES, GOVERNMENT COLLEGE UNIVERSITY, FAISALABAD, PAKISTAN;DEPARTMENT OF FOOD SCIENCE, INSTITUTE OF HOME & FOOD SCIENCES, GOVERNMENT COLLEGE UNIVERSITY, FAISALABAD, PAKISTAN;DEPARTMENT OF FOOD SCIENCE & TECHNOLOGY, MNSUA, MULTAN, PAKISTAN;FACULTY OF HEALTH, DEAKIN UNIVERSITY, AUSTRALIA;COLLEGE OF FOOD AND AGRICULTURAL SCIENCES, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA","THE CORE OBJECTIVE OF THE CURRENT STUDY WAS TO EXTRACT AND CHARACTERIZE THE WHEAT STRAW CELL WALL FOR ITS NUTRITIONAL AND BIOACTIVE PROFILE. FOR THE PURPOSE, FOUR DIFFERENT WHEAT STRAW VARIETIES NAMELY UJALA-16, JOHAR-16, GOLD-16, AND GALAXY-13 WERE PROCURED FROM AYUB AGRICULTURE RESEARCH INSTITUTE, FAISALABAD, PAKISTAN. THE WHOLE RESEARCH WAS CONDUCTED IN THREE DIFFERENT PHASES. IN FIRST PHASE, NUTRITIONAL COMPOSITION AND MINERAL PROFILE OF STRAW OF DIFFERENT WHEAT VARIETIES WERE DETERMINED. IN SECOND PHASE, WHEAT STRAW CELL WALL OF DIFFERENT VARIETIES WAS ISOLATED AND CHARACTERIZED FOR ITS IMPORTANT BIOACTIVE CONSTITUENTS, SUCH AS LIGNIN, CELLULOSE, HEMICELLULOSES, PHYTOSTEROL, AND POLICOSANOL (PC) CONTENT. RESULTS SHOWED THAT STRAW OF DIFFERENT WHEAT VARIETIES CONTAINED 7.75–9.24, 3.98–5.06, 3.43–3.98, AND 1.60–2.24 G/100 G MOISTURE, ASH, PROTEIN, AND FAT CONTENTS, RESPECTIVELY, WHEREAS POTASSIUM, CALCIUM, PHOSPHORUS, AND MAGNESIUM WERE 1.19–2.03, 0.10–0.79, 0.10–0.98, 0.03–0.98 PPM, RESPECTIVELY. MOREOVER, LIGNOCELLULOSIC MASS: CELLULOSE 37.75–38.18 G/100 G RAW MATERIAL, LIGNIN 15.67–16.07 G/100 G RAW MATERIAL, HEMICELLULOSES 28.25–28.98 G/100 G RAW MATERIAL, WAS PRESENT IN WHEAT STRAW AND VARIED SIGNIFICANTLY AMONG DIFFERENT VARIETIES. IN ADDITION, PHYTOSTEROL RANGED FROM 854 TO 1176 MG/KG IN STRAW OF DIFFERENT WHEAT CULTIVARS, WHILST PC FROM 196.09 TO 236.48 MG/KG. CONCLUSIVELY, WHEAT STRAW WAS AN EXCELLENT SOURCE OF MANY IMPORTANT BIOACTIVE MOIETIES ESPECIALLY LIGNOCELLULOSES AND COULD HAVE FUNCTIONAL USE. © 2018 TABUSSAM TUFAIL, FARHAN SAEED, MUHAMMAD IMRAN, MUHAMMAD UMAIR ARSHAD, FAQIR MUHAMMAD ANJUM, MUHAMMAD AFZAAL, HUMA BADER UL AINA, MUHAMMAD SHAHBAZ, TANWEER ASLAM GONDAL, AND SHAHZAD HUSSAIN. PUBLISHED WITH LICENSE BY TAYLOR & FRANCIS.","LIGNOCELLULOSIC MASS; MONOSACCHARIDES; PHYTOSTEROL; POLICOSANOL; WHEAT STRAW","CELLULOSE; LIGNIN; LIGNOCELLULOSIC MASS; MONOSACCHARIDES; PHYTOSTEROL; POLICOSANOL; WHEAT STRAWS; STRAW","KING SAUD UNIVERSITY, KSU","THE AUTHORS ARE THANKFUL TO INSTITUTE OF HOME & FOOD SCIENCES GOVERNMENT COLLEGE UNIVERSITY FAISALABAD, PAKISTAN. WE ALSO EXTEND OUR THANKS TO DIRECTORATE OF POST HARVEST RESEARCH CENTER, AYUB AGRICULTURAL RESEARCH INSTITUTE FAISALABAD (AARI), PAKISTAN, FOR PROVIDING STRAW OF DIFFERENT WHEAT VARIETIES. THE AUTHORS ALSO EXTEND THEIR APPRECIATION TO THE INTERNATIONAL SCIENTIFIC PARTNERSHIP PROGRAM (ISPP) AT KING SAUD UNIVERSITY, FOR FUNDING THIS RESEARCH WORK.","ABOUDI K., ALVAREZ-GALLEGO C.-J., ROMERO-GARCIA L.-I., BIOMETHANIZATION OF SUGAR BEET BYPRODUCT BY SEMI-CONTINUOUS SINGLE DIGESTION AND CO-DIGESTION WITH COW MANURE, BIORESOURCE TECHNOLOGY, 200, PP. 311-319, (2016); DAVIDI L., MORAIS S., ARTZI L., KNOP D., HADAR Y., ARFI Y., BAYER E.-A., TOWARD COMBINED DELIGNIFICATION AND SACCHARIFICATION OF WHEAT STRAW BY A LACCASE-CONTAINING DESIGNER CELLULOSOME, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113, 39, PP. 10854-10859, (2016); KUMAR A.-K., SHARMA S., RECENT UPDATES ON DIFFERENT METHODS OF PRETREATMENT OF LIGNOCELLULOSIC FEEDSTOCKS, A REVIEW. BIORESOURCES AND BIOPROCESSINGS, 4, 1, (2017); BHARATHIRAJA S., SURIYA J., KRISHNAN M., MANIVASAGAN P., KIM S.-K., PRODUCTION OF ENZYMES FROM AGRICULTURAL WASTES AND THEIR POTENTIAL INDUSTRIAL APPLICATIONS, ADVANCES IN FOOD AND NUTRITION RESEARCH, 80, PP. 125-148, (2017); HEMDANE S., JACOBS P.-J., DORNEZ E., VERSPREET J., DELCOUR J.-A., COURTIN C.-M., WHEAT (TRITICUM AESTIVUM L.) BRAN IN BREAD MAKING, ACRITICAL REVIEW. COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY, 15, 1, PP. 28-42, (2016); REDDY N., YANG Y., BIOFIBERS FROM AGRICULTURAL BYPRODUCTS FOR INDUSTRIAL APPLICATIONS, TRENDS IN BIOTECHNOLOGY, 23, 1, PP. 22-27, (2005); GOVUMONI S.-P., KOTI S., KOTHAGOUNI S.-Y., VENKATESHWAR S., LINGA V.-R., EVALUATION OF PRETREATMENT METHODS FOR ENZYMATIC SACCHARIFICATION OF WHEAT STRAW FOR BIOETHANOL PRODUCTION, CARBOHYDRATE POLYMERS, 91, 2, PP. 646-650, (2013); SALVACHUA D., PRIETO A., LOPEZ-ABELAIRAS M., LU-CHAU T., MARTINEZ A.-T., MARTINEZ M.-J., FUNGAL PRETREATMENT: AN ALTERNATIVE IN SECOND-GENERATION ETHANOL FROM WHEAT STRAW, BIORESOURCE TECHNOLOGY, 102, PP. 7500-7506, (2011); TALEBNIA F., KARAKASHEV D., ANGELIDAKI I., PRODUCTION OF BIOETHANOL FROM WHEAT STRAW, AN OVERVIEW ON PRETREATMENT, HYDROLYSIS AND FERMENTATION. BIORESOURCE TECHNOLOGY, 101, 13, PP. 4744-4753, (2010); MCKEAN W.-T., JACOBS R.-S., WHEAT STRAW AS A PAPER FIBER SOURCE; TECH. REP., RECYCLING TECHNOLOGY ASSISTANCE PARTNERSHIP, CLEAN WASHINGTON CENTER, (1997); OIKONOMOU I., PLATANAKIS E., SUTCLIFFE C., MORE STABLE AND DIVERSIFIED SOCIALLY RESPONSIBLE INVESTMENT PORTFOLIOS, (2015); YASIN M., BHUTTO A.-W., BAZMI A.A., KARIM S., EFFICIENT UTILIZATION OF RICE-WHEAT STRAW TO PRODUCE VALUE ADDED COMPOSITE PRODUCTS, INTERNATIONAL JOURNAL OF CHEMICAL AND ENVIRONMENTAL ENGINEERING, 1, 2, PP. 136-143, (2010); PEREZ J., MUNOZ-DORADO J., RUBIA T.-D.-L., MARTINEZ J., BIODEGRADATION AND BIOLOGICAL TREATMENTS OF CELLULOSE, HEMICELLULOSE, AND LIGNIN, AN OVERVIEW. INTERNATIONAL MICROBIOLOGY, 5, PP. 53-63, (2012); MORAN J.-I., ALVAREZ V.-A., CYRAS V.-P., VAZQUEZ A., EXTRACTION OF CELLULOSE AND PREPARATION OF NANOCELLULOSE FROM SISAL FIBERS, CELLULOSE, 15, 1, PP. 149-159, (2008); THIMM J.-C., BURRITT D.-J., DUCKER W.-A., MELTON L.-D., CELERY (APIUM GRAVEOLENS L) PARENCHYMA CELL WALLS EXAMINED BY ATOMIC FORCE MICROSCOPY: EFFECT OF DEHYDRATION ON CELLULOSE MICROFIBRILS, PLANTA, 212, PP. 25-32, (2000); DING S.-Y., LIU Y.-S., ZENG Y., HIMMEL M.-E., BAKER J.-O., BAYER E.-A., HOW DOES PLANT CELL WALL NANOSCALE ARCHITECTURE CORRELATE WITH ENZYMATIC DIGESTIBILITY?, SCIENCE, 338, PP. 1055-1060, (2012); ROLLIN J.-A., ZHU Z., SATHITSUKSANOH N., ZHANG Y.-H.-P., INCREASING CELLULOSE ACCESSIBILITY IS MORE IMPORTANT THAN REMOVING LIGNIN: A COMPARISON OF CELLULOSE SOLVENT-BASED LIGNOCELLULOSE FRACTIONATION AND SOAKING IN AQUEOUS AMMONIA, BIOTECHNOLOGY AND BIOENGINEERING, 108, PP. 22-30, (2011); MARK H.-F., KROSCHWITZ, J.-I, ENCYCLOPEDIA OF POLYMER SCIENCE AND ENGINEERING, 3, (2003); SAEED F., PASHA I., ANJUM F.-M., SULTAN J.-I., ARSHAD M., ARABINOXYLAN AND ARABINOGALACTAN CONTENT IN DIFFERENT SPRING WHEAT, INTERNATIONAL JOURNAL OF FOOD PROPERTIES, 17, 4, PP. 713-721, (2014); PASHA I., KHAN Q.-A.-B., BUTT M.-S., SAEED M., RHEOLOGICAL AND FUNCTIONAL PROPERTIES OF PUMPKIN WHEAT COMPOSITE FLOUR, PAKISTAN JOURNAL OF FOOD SCIENCE, 23, 2, PP. 100-104, (2013); (2000); (1997); WOOD I.-P., ELLISTON A., COLLINS S.-R.-A., WILSON D., BANCROFT I., WALDRON K.-W., STEAM EXPLOSION OF OILSEED RAPE STRAW: ESTABLISHING KEY DETERMINANTS OF SACCHARIFICATION EFFICIENCY, BIORESOURCE TECHNOLOGY, 162, PP. 175-183, (2014); WADA M., SUGIYAMA J., OKANO T., THE MONOCLINIC PHASE IS DOMINANT IN WORD CELLULOSE, MOKUZAI GAKKAISHO, 40, 1, PP. 50-56, (1994); LAWTHER J.-M., SUN R., BANKS W.-B., EXTRACTION, FRACTIONATION, AND CHARACTERIZATION OF STRUCTURAL POLYSACCHARIDES FROM WHEAT STRAW, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 43, 3, PP. 667-675, (1995); IRMAK S., PAYERO J.-O., MARTIN D.-L., IRMAK A., HOWELL T.-A., SENSITIVITY ANALYSES AND SENSITIVITY COEFFICIENTS OF THE STANDARDIZED ASCE-PENMAN-MONTEITH EQUATION TO CLIMATE VARIABLES, JOURNAL OF IRRIGATION AND DRAINAGE ENGINEERING, 132, 6, PP. 564-578, (2006); BLAKENEY A.-B., HARRIS P.-J., HENRY R.-J., STONE B.-A., A SIMPLE AND RAPID PREPARATION OF ALDITOL ACETATES FOR MONOSACCHARIDE ANALYSIS, CARBOHYDRATE RESEARCH, 113, 2, PP. 291-299, (1983); STEEL R.-G.-D., TORRIE J.-H., DICKEY D., PRINCIPLES AND PROCEDURES OF STATISTICS: A BIOMETRICAL APPROACH, (1997); SNEDECOR G.-W., COCHRAN W.-G., STATISTICAL METHODS, (1980); SHRIVASTAVA B., JAIN K.K., KALRA A., KUHAD R.C., BIOPROCESSING OF WHEAT STRAW INTO NUTRITIONALLY RICH AND DIGESTED CATTLE FEED, SCIENCE REPORTS, 4, (2014); ANDERSON T., HOFFMAN P., NUTRIENT COMPOSITION OF STRAW USED IN DAIRY CATTLE DIETS; 2006-8(1) FOCUS ON FORAGE, UNIVERSITY OF WISCONSIN BOARD OF REGENTS, (2006); CHEN J., SPEAR S.-K., HUDDLESTON J.-G., ROGERS R.-D., POLYETHYLENE GLYCOL AND SOLUTIONS OF POLYETHYLENE GLYCOL AS GREEN REACTION MEDIA, GREEN CHEMISTRY, 7, 2, PP. 64-82, (2005); WATKINS D., NURUDDIN M.-D., HOSUR M., TCHERBI-NARTEH A., JEELANI S., EXTRACTION AND CHARACTERIZATION OF LIGNIN FROM DIFFERENT BIOMASS RESOURCES, JOURNAL OF MATERIALS RESEARCH AND TECHNOLOGY, 4, 1, PP. 26-32, (2015); LAWTHER J.M., SUN R., BANKS W.-B., EXTRACTION FRACTIONATION AND CHARACTERIZATION OF STRUCTURAL POLYSACCHARIDES FROM WHEAT STRAW, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 43, PP. 667-675, (1995); JAISAMUT K., PAULORA L., PATAKORA P., RYCHTERA M., MELZOCH K., OPTIMIZATION OF ALKALI PRETREATMENT OF WHEAT STRAW TO BE USED AS SUBSTRATE FOR BIOFUELS PRODUCTION, PLANT SOIL ENVIRONMENT, 59, 12, PP. 537-542, (2013); ZHANG J., DENG H., LIN L., SUN Y., CHUNSHENG P., LIU S., ISOLATION AND CHARACTERIZATION OF WHEAT STRAW LIGNIN WITH A FORMIC ACID PROCESS, BIORESOURCE TECHNOLOGY, 101, PP. 2311-2316, (2010); THAKUR S., SHRIVASTAVA B., INGALE S., KUHAD R.-C., GUPTE A., DEGRADATION AND SELECTIVE LIGNINOLYSIS OF WHEAT STRAW AND BANANA STEM FOR AN EFFICIENT BIOETHANOL PRODUCTION USING FUNGAL AND CHEMICAL PRETREATMENT, BIOTECHNOLOGY, 3, PP. 365-372, (2013); DUNFORD N.-T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOURCE TECHNOLOGY, 101, 1, PP. 422-425, (2010); KRISTENSEN J.-B., THYGESEN L.-G., FELBY C., JORGENSEN H., ELDER T., CELL-WALL STRUCTURAL CHANGES IN WHEAT STRAW PRETREATED FOR BIOETHANOL PRODUCTION, BIOTECHNOLOGY FOR BIOFUELS, 1, (2008); SAEED F., NAZIR A., NADEEM M.-T., QAMAR A., KHAN A.-U., TUFAIL T., EFFECT OF ARABINOXYLAN ON RHEOLOGICAL ATTRIBUTES AND BREAD QUALITY OF SPRING WHEATS, JOURNAL OF FOOD PROCESSING AND PRESERVATION, 40, 6, PP. 1164-1170, (2016)","F. SAEED; INSTITUTE OF HOME & FOOD SCIENCES, GOVERNMENT COLLEGE UNIVERSITY, FAISALABAD, PAKISTAN; EMAIL: F.SAEED@GCUF.EDU.PK","TAYLOR AND FRANCIS INC.","ENGLISH","INT. J. FOOD PROP.","ARTICLE","ISI","2-S2.0-85055482408","INT J FOOD PROP","GOVERNMENT COLLEGE UNIVERSITY;GOVERNMENT COLLEGE UNIVERSITY;THE UNIVERSITY OF LAHORE;GOVERNMENT COLLEGE UNIVERSITY;KING SAUD UNIVERSITY;GOVERNMENT COLLEGE UNIVERSITY;GOVERNMENT COLLEGE UNIVERSITY;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY;DEAKIN UNIVERSITY;KING SAUD UNIVERSITY","NOTREPORTED;GOVERNMENT COLLEGE UNIVERSITY;NOTREPORTED",NA,"TUFAIL T, 2018, INT J FOOD PROP","TUFAIL T, 2018, INT J FOOD PROP"
"PARK H;YADAV D;JEONG D;KIM S;BAE M;KIM J;CHO K","PARK, HYE-JEONG (57201722508); YADAV, DHANANJAY (55779022200); JEONG, DA-JEONG (57207577999); KIM, SUK-JEONG (57193310178); BAE, MYUNG-AE (7005711682); KIM, JAE-RYONG (7601360934); CHO, KYUNG-HYUN (7403956966)","SHORTTERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS AORTIC AND PERIPHERAL BLOOD PRESSURE AND AMELIORATES SERUM LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS RANDOMIZED DOUBLEBLINDED AND PLACEBOCONTROLLED STUDY",2019,"INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH","16","",19,"10.3390/ijerph16050809","RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA;DRUG DISCOVERY PLATFORM TECHNOLOGY TEAM, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, TAEJON, 305-343, SOUTH KOREA;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, SMART-AGING CONVERGENCE RESEARCH CENTER, COLLEGE OF MEDICINE, YEUNGNAM UNIVERSITY, DAEGU, 705-717, SOUTH KOREA;RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA","THE CURRENT STUDY WAS DESIGNED TO INVESTIGATE THE SHORT-TERM EFFECTS OF POLICOSANOL CONSUMPTION ON BLOOD PRESSURE (BP) AND THE LIPID PARAMETERS IN HEALTHY KOREAN PARTICIPANTS WITH PREHYPERTENSION. A TOTAL OF 84 HEALTHY PARTICIPANTS WERE RANDOMLY ALLOCATED TO THREE GROUPS RECEIVING PLACEBO, 10 MG OF POLICOSANOL, OR 20 MG OF POLICOSANOL FOR 12 WEEKS. BASED ON AN AVERAGE OF THREE MEASUREMENTS OF PERIPHERAL BP, THE POLICOSANOL 20 MG GROUP EXHIBITED THE MOST SIGNIFICANT REDUCTION, THAT IS, UP TO 7.7% REDUCTION OF AVERAGE SYSTOLIC BP (SBP) FROM 136.3 ± 6.1 MMHG (WEEK 0) TO 125.9 ± 8.6 MMHG (WEEK 12, P < 0.001). BETWEEN GROUP COMPARISONS USING REPEATED MEASURES ANOVA SHOWED THAT THE POLICOSANOL 20 MG GROUP HAD A SIGNIFICANT REDUCTION OF SBP AT 12 WEEKS (P = 0.020) AND A REDUCTION OF DIASTOLIC BP (DBP) AT 8 WEEKS (P = 0.041) AND 12 WEEKS (P = 0.035). THE POLICOSANOL 10 MG AND 20 MG GROUPS SHOWED SIGNIFICANT REDUCTIONS IN AORTIC SBP OF 7.4% AND 8.3%, RESPECTIVELY. THE POLICOSANOL GROUPS SHOWED SIGNIFICANT REDUCTIONS OF TOTAL CHOLESTEROL (TC) OF 9.6% AND 8.6% AND LOW-DENSITY LIPOPROTEINS (LDL-C) OF 21% AND 18% FOR 10 MG AND 20 MG OF POLICOSANOL, RESPECTIVELY. BETWEEN GROUP COMPARISONS USING REPEATED MEASURES ANOVA SHOWED THAT THE POLICOSANOL (10 MG AND 20 MG) GROUPS AT 12 WEEKS HAD A SIGNIFICANT REDUCTION OF TC (P = 0.0004 AND P = 0.001) AND LDL-C (P = 0.00005 AND P = 0.0001) AND ELEVATION OF %HDL-C (P = 0.048 AND P = 0.014). IN CONCLUSION, 12-WEEK CONSUMPTION OF POLICOSANOL RESULTED IN SIGNIFICANT REDUCTIONS OF PERIPHERAL SBP AND DBP, AORTIC SBP AND DBP, MEAN ARTERIAL PRESSURE (MAP), AND SERUM TC AND LDL-C WITH ELEVATION OF % HDL-C. © 2019 BY THE AUTHORS. LICENSEE MDPI, BASEL, SWITZERLAND.","BLOOD PRESSURE; HIGH-DENSITY LIPOPROTEINS; LOW-DENSITY LIPOPROTEINS; POLICOSANOL","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; YOUNG ADULT; KOREA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ANTIHYPERTENSIVE AGENT; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LIPID; POLICOSANOL; CHEMICAL COMPOUND; FOOD CONSUMPTION; HYPERTENSION; LIPID; PUBLIC HEALTH; SERUM; VARIANCE ANALYSIS; ADULT; AGED; AORTIC PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; SOUTH KOREAN; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BLOOD PRESSURE; MIDDLE AGED; YOUNG ADULT","NATIONAL RESEARCH FOUNDATION; MINISTRY OF TRADE, INDUSTRY AND ENERGY, MOTIE, (2015R1A5A2009124, 2016-10063396); MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP","AUTHOR CONTRIBUTIONS: DATA CURATION, H.-J.P., D.-J.J. AND S.-J.K.; FUNDING ACQUISITION, S.-J.K., M.-A.B. AND J.-R.K.; SUPERVISION, K.-H.C.; WRITING—ORIGINAL DRAFT, K.-H.C.; WRITING—REVIEW & EDITING, D.Y. AND K.-H.C FUNDING: THIS WORK WAS SUPPORTED BY A GRANT FROM THE MINISTRY OF TRADE, INDUSTRY AND ENERGY, KOREA (GRANT NO. 2016-10063396) AND THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF), FUNDED BY THE MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING OF KOREA.","NELSON R.H., HYPERLIPIDEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE, PRIM. CARE, 40, PP. 195-211, (2013); LEE J.S., CHANG P.Y., ZHANG Y., KIZER J.R., BEST L.G., HOWARD B.V., TRIGLYCERIDE AND HDL-C DYSLIPIDEMIA AND RISKS OF CORONARY HEART DISEASE AND ISCHEMIC STROKE BY GLYCEMIC DYSREGULATION STATUS: THE STRONG HEART STUDY, DIABETES CARE, 40, PP. 529-537, (2017); MCGROWDER D., RILEY C., MORRISON E.Y., GORDON L., THE ROLE OF HIGH-DENSITY LIPOPROTEINS IN REDUCING THE RISK OF VASCULAR DISEASES, NEUROGENERATIVE DISORDERS, AND CANCER, CHOLESTEROL, 2011, (2011); REITZ C., TANG M.X., SCHUPF N., MANLY J.J., MAYEUX R., LUCHSINGER J.A., ASSOCIATION OF HIGHER LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ELDERLY INDIVIDUALS AND LOWER RISK OF LATE-ONSET ALZHEIMER DISEASE, ARCH. NEUROL, 67, PP. 1491-1497, (2010); HIRANO M., NAKANISHI S., KUBOTA M., MAEDA S., YONEDA M., YAMANE K., KIRA S., SASAKI H., KOHNO N., LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IS A SIGNIFICANT RISK FACTOR FOR DEVELOPMENT OF TYPE 2 DIABETES: DATA FROM THE HAWAII-LOS ANGELES-HIROSHIMA STUDY, J. DIABETES INVESTIG, 5, PP. 501-506, (2014); HALPERIN R.O., SESSO H.D., MA J., BURING J.E., STAMPFER M.J., GAZIANO J.M., DYSLIPIDEMIA AND THE RISK OF INCIDENT HYPERTENSION IN MEN, J. HYPERTENS, 47, PP. 45-50, (2006); SUNG K.C., PARK H.Y., KIM M.J., REAVEN G., METABOLIC MARKERS ASSOCIATED WITH INSULIN RESISTANCE PREDICT TYPE 2 DIABETES IN KOREANS WITH NORMAL BLOOD PRESSURE OR PREHYPERTENSION, CARDIOVASC. DIABETOL, 15, (2016); TOHIDI M., HATAMI M., HADAEGH F., AZIZI F., TRIGLYCERIDES AND TRIGLYCERIDES TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO ARE STRONG PREDICTORS OF INCIDENT HYPERTENSION IN MIDDLE EASTERN WOMEN, J. HUM. HYPERTENS, 26, PP. 525-532, (2012); XIE D., BOLLAG W.B.O., HYPERTENSION AND ALDOSTERONE: IS LEPTIN THE LINK, J. ENDOCRINOL, 230, PP. FF7-F11, (2016); TSAI Y.Y., RAINEY W.E., BOLLAG W.B., VERY LOW-DENSITY LIPOPROTEIN (VLDL)-INDUCED SIGNALS MEDIATING ALDOSTERONE PRODUCTION, J. ENDOCRINOL, 232, PP. R115-R129, (2017); SAHA S., BORNSTEIN S.R., GRAESSLER J., KOPPRASCH S., CROSSTALK BETWEEN GLYCOXIDATIVE MODIFICATION OF LOW-DENSITY LIPOPROTEIN, ANGIOTENSIN II-SENSITIZATION, AND ADRENOCORTICAL ALDOSTERONE RELEASE, HORM. METAB. RES., 47, PP. 855-860, (2015); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL, 50, PP. 255-262, (2000); LIM S.M., YOO J.A., LEE E.Y., CHO K.H., ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTI-SENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTI-GLYCATION, ANTI-APOPTOSIS, AND CHOLESTERYL ESTER TRANSFER INHIBITION, REJUVENAT. RES, 19, PP. 59-70, (2016); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENAT. RES, 19, PP. 149-158, (2016); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED, 39, PP. 889-899, (2017); CHO K.H., KIM S.J., YADAV D., KIM J.Y., KIM J.R., CONSUMPTION OF CUBAN POLICOSANOL IMPROVES BLOOD PRESSURE AND LIPID PROFILE VIA ENHANCEMENT OF HDL FUNCTIONALITY IN HEALTHY WOMEN SUBJECTS: RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED STUDY, OXID. MED. CELL. LONGEV, 2018, (2018); CHO K.H., YADAV D., KIM S.J., KIM J.R., BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION, LIPOPROTEIN PROFILE, AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS, MOLECULES, 23, (2018); KIM S.J., YADAV D., PARK H.J., KIM J.R., CHO K.H., LONG-TERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS, FRONT. PHYSIOL, 9, (2018); CANAVACIOLO V.L.G., GOMEZ C.V., COPYCAT-POLICOSANOLS VERSUS GENUINE POLICOSANOL, REV. CENIC CIENC. QUÍMICAS, 38, (2007); YADAV D., KIM S.J., KIM J.R., CHO K.H., CORRELATION AMONG LIPID PARAMETERS, PULSE WAVE VELOCITY AND CENTRAL BLOOD PRESSURE IN YOUNG KOREAN POPULATION, CLIN. EXP. HYPERTENS, 41, PP. 20-27, (2019); VLACHOPOULOS C., AZNAOURIDIS K., O'ROURKE M.F., SAFAR M.E., BAOU K., STEFANADIS, C. PREDICTION OF CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY WITH CENTRAL HAEMODYNAMICS: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR. HEART J, 31, PP. 1865-1871, (2010); GRUNDY S.M., METABOLIC SYNDROME UPDATE. TRENDS CARDIOVASC, MED, 26, PP. 364-373, (2016); MATERSON B.J., GARCIA-ESTRADA M., DEGRAFF S.B., PRESTON R.A., PREHYPERTENSION IS REAL AND CAN BE ASSOCIATED WITH TARGET ORGAN DAMAGE, J. AM. SOC. HYPERTENS., 11, PP. 704-708, (2017); TSUKINOKI R., OKAMURA T., WATANABE M., KOKUBO Y., HIGASHIYAMA A., NISHIMURA K., TAKEGAMI M., MURAKAMI Y., OKAYAMA A., MIYAMOTO Y., BLOOD PRESSURE, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND INCIDENCES OF CORONARY ARTERY DISEASE AND ISCHEMIC STROKE IN JAPANESE: THE SUITA STUDY, AM. J. HYPERTENS, 27, PP. 1362-1369, (2014); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., WANG D., JIANG S., LI J., ZHAO Y., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, (2018); SESSO H.D., STAMPFER M.J., ROSNER B., HENNEKENS C.H., GAZIANO J.M., MANSON J.E., GLYNN R.J., SYSTOLIC AND DIASTOLIC BLOOD PRESSURE, PULSE PRESSURE, AND MEAN ARTERIAL PRESSURE AS PREDICTORS OF CARDIOVASCULAR DISEASE RISK IN MEN, J. HYPERTENS, 36, PP. 801-807, (2000); YADAV D., HYUN D.S., AHN S.V., KOH S.B., KIM J.Y., A PROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN TOTAL SLEEP DURATION AND INCIDENT HYPERTENSION, J. CLIN. HYPERTENS, 19, PP. 550-557, (2017); HSU C.H., CHANG J.B., LIU I.C., LAU S.C., YU S.M., HSIEH C.H., LIN J.D., LIANG Y.J., PEI D., CHEN Y.L., MEAN ARTERIAL PRESSURE IS BETTER AT PREDICTING FUTURE METABOLIC SYNDROME IN THE NORMOTENSIVE ELDERLY: A PROSPECTIVE COHORT STUDY IN TAIWAN, PREV. MED. REP., 72, PP. 76-82, (2015)","K.-H. CHO; RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, 712-749, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","MDPI AG","ENGLISH","INT. J. ENVIRON. RES. PUBLIC HEALTH","ARTICLE","ISI","2-S2.0-85062604994","INT J ENVIRON RES PUBLIC HEALTH","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"PARK H-J, 2019, INT J ENVIRON RES PUBLIC HEALTH","PARK H-J, 2019, INT J ENVIRON RES PUBLIC HEALTH"
"KIM C;SUNG J;LEE J;KIM W;LEE G;JEE S;JUNG I;RAH U;KIM B;CHOI K;KWON B;YOO S;BANG H;SHIN H;KIM Y;JUNG H;KIM E;LEE J;JUNG I;JUNG J;LEE J;HAN J;HAN E;WON Y;HAN W;BAEK S;JOA K;LEE S;KIM A;LEE S;KIM J;CHOI H;LEE B;KIM S","KIM, CHUL (55936526100); SUNG, JIDONG (57221027209); LEE, JONG HWA (55690046100); KIM, WON-SEOK (57028735900); LEE, GOO JOO (57202163296); JEE, SUNGJU (56487143900); JUNG, IL-YOUNG (56258604200); RAH, UEON WOO (6506563264); KIM, BYUNG OK (57199939573); CHOI, KYOUNG HYO (35200348300); KWON, BUM SUN (57212471437); YOO, SEUNG DON (40462932200); BANG, HEUI JE (55246577800); SHIN, HYUNG-IK (12792071400); KIM, YONG WOOK (36068177800); JUNG, HEEYOUNE (16175372000); KIM, EUNG JU (7404507139); LEE, JUNG HWAN (55690059900); JUNG, IN HYUN (57203216956); JUNG, JAE-SEUNG (55386327000); LEE, JONG-YOUNG (59096015900); HAN, JAE-YOUNG (15765035600); HAN, EUN YOUNG (8567466000); WON, YU HUI (55245926100); HAN, WOOSIK (57214136761); BAEK, SORA (55875523200); JOA, KYUNG-LIM (55245910100); LEE, SOOK JOUNG (35324572500); KIM, AE RYOUNG (57196257330); LEE, SO YOUNG (57202327370); KIM, JIHEE (55822889900); CHOI, HEE EUN (55246598500); LEE, BYEONG-JU (57201803768); KIM, SOON (57204417106)","CLINICAL PRACTICE GUIDELINE FOR CARDIAC REHABILITATION IN KOREA RECOMMENDATIONS FOR CARDIAC REHABILITATION AND SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME",2019,"KOREAN CIRCULATION JOURNAL","49","45",31,"10.4070/kcj.2019.0194","DEPARTMENT OF REHABILITATION MEDICINE, SANGGYE PAIK HOSPITAL, INJE UNIVERSITY SCHOOL OF MEDICINE, SEOUL, SOUTH KOREA;DIVISION OF CARDIOLOGY, DEPARTMENT OF MEDICINE, SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE-HEART VASCULAR STROKE INSTITUTE, SAMSUNG MEDICAL CENTER, SEOUL, SOUTH KOREA;DEPARTMENT OF PHYSICAL MEDICINE AND REHABILITATION, DONG-A UNIVERSITY COLLEGE OF MEDICINE-REGIONAL CARDIOCEREBROVASCULAR CENTER, DONG-A MEDICAL CENTER, BUSAN, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL, SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE, SEONGNAM, SOUTH KOREA, GYEONGGI REGIONAL CARDIOCEREBROVASCULAR CENTER, SEONGNAM, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, CHUNGBUK NATIONAL UNIVERSITY HOSPITAL, CHUNGBUK REGIONAL CARDIOCEREBROVASCULAR CENTER, CHUNGBUK NATIONAL UNIVERSITY COLLEGE OF MEDICINE, 776, 1SHUNHWAN-RO, CHEONGJU, 28644, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, CHUNGNAM NATIONAL UNIVERSITY COLLEGE OF MEDICINE, DAEJEON CHUNGCHEONG REGIONAL CARDIOCEREBROVASCULAR CENTER, CHUGNAM NATIONAL UNIVERSITY HOSPITAL, DAEJEON, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, CHUNGNAM NATIONAL UNIVERSITY COLLEGE OF MEDICINE, DAEJEON CHUNGCHEONG REGIONAL CARDIOCEREBROVASCULAR CENTER, CHUGNAM NATIONAL UNIVERSITY HOSPITAL, DAEJEON, SOUTH KOREA;DEPARTMENT OF PHYSICAL MEDICINE AND REHABILITATION, AJOU UNIVERSITY SCHOOL OF MEDICINE, SUWON, SOUTH KOREA;DEPARTMENT OF INTERNAL MEDICINE, SANGGYE PAIK HOSPITAL, INJE UNIVERSITY SCHOOL OF MEDICINE, SEOUL, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, ASAN MEDICAL CENTER, UNIVERSITY OF ULSAN COLLEGE OF MEDICINE, SEOUL, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, DONGGUK UNIVERSITY SCHOOL OF MEDICINE, GOYANG, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, KYUNG HEE UNIVERSITY COLLEGE OF MEDICINE, SEOUL, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, CHUNGBUK NATIONAL UNIVERSITY HOSPITAL, CHUNGBUK REGIONAL CARDIOCEREBROVASCULAR CENTER, CHUNGBUK NATIONAL UNIVERSITY COLLEGE OF MEDICINE, 776, 1SHUNHWAN-RO, CHEONGJU, 28644, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, SEOUL NATIONAL UNIVERSITY CHILDREN'S HOSPITAL, SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE, SEOUL, SOUTH KOREA;DEPARTMENT AND INSTITUTE OF REHABILITATION MEDICINE, YONSEI UNIVERSITY COLLEGE OF MEDICINE, SEOUL, SOUTH KOREA;NATIONAL TRAFFIC INJURY REHABILITATION HOSPITAL, YANGPYEONG, SOUTH KOREA;DIVISION OF CARDIOLOGY, DEPARTMENT OF MEDICINE, KOREA UNIVERSITY GURO HOSPITAL, KOREA UNIVERSITY COLLEGE OF MEDICINE, SEOUL, SOUTH KOREA;NAMDARUN REHABILITATION CLINIC, YONGIN, SOUTH KOREA;DEPARTMENT OF INTERNAL MEDICINE, SANGGYE PAIK HOSPITAL, INJE UNIVERSITY SCHOOL OF MEDICINE, SEOUL, SOUTH KOREA;DEPARTMENT OF THORACIC AND CARDIOVASCULAR SURGERY, ANAM HOSPITAL, KOREA UNIVERSITY MEDICAL CENTER, SEOUL, SOUTH KOREA;DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, KANGBUK SAMSUNG HOSPITAL, SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE, SEOUL, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, GWANGJU-JEONNAM REGIONAL CARDIOCEREBROVASCULAR CENTER, CHONNAM NATIONAL UNIVERSITY MEDICAL SCHOOL AND HOSPITAL, GWANGJU, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, JEJU NATIONAL UNIVERSITY HOSPITAL, JEJU NATIONAL UNIVERSITY SCHOOL OF MEDICINE, JEJU, SOUTH KOREA;DEPARTMENT OF PHYSICAL MEDICINE AND REHABILITATION, RESEARCH INSTITUTE OF CLINICAL MEDICINE OF CHONBUK NATIONAL UNIVERSITY, BIOMEDICAL RESEARCH INSTITUTE OF CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, SOUTH KOREA;DEPARTMENT OF THORACIC SURGERY, CHUNGNAM NATIONAL UNIVERSITY HOSPITAL, DAEJEON, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, KANGWON NATIONAL UNIVERSITY SCHOOL OF MEDICINE, KANGWON REGIONAL CARDIOCEREBROVASCULAR CENTER, KANGWON NATIONAL UNIVERSITY HOSPITAL, CHUNCHEON, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, INHA UNIVERSITY HOSPITAL, INCHEON, SOUTH KOREA;DAEJEON ST. MARY'S HOSPITAL, COLLEGE OF MEDICINE, CATHOLIC UNIVERSITY OF KOREA, DAEJEON, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, KYUNGPOOK NATIONAL UNIVERSITY SCHOOL OF MEDICINE, DAEGU, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, JEJU NATIONAL UNIVERSITY HOSPITAL, JEJU NATIONAL UNIVERSITY SCHOOL OF MEDICINE, JEJU, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, INSTITUTE OF WONKWANG MEDICAL SCIENCE, WONKWANG UNIVERSITY SCHOOL OF MEDICINE, IKSAN, SOUTH KOREA;DEPARTMENT OF PHYSICAL MEDICINE AND REHABILITATION, INJE UNIVERSITY HAEUNDAE PAIK HOSPITAL, INJE UNIVERSITY COLLEGE OF MEDICINE, BUSAN, SOUTH KOREA;DEPARTMENT OF REHABILITATION MEDICINE, PUSAN NATIONAL UNIVERSITY HOSPITAL, BUSAN, SOUTH KOREA;RESEARCH INSTITUTE FOR SOCIAL SCIENCE, EWHA WOMAN'S UNIVERSITY, SEOUL, SOUTH KOREA","THOUGH CLINICAL PRACTICE GUIDELINES (CPGS) FOR CARDIAC REHABILITATION (CR) ARE AN EFFECTIVE AND WIDELY USED TREATMENT METHOD WORLDWIDE, THEY ARE AS YET NOT WIDELY ACCEPTED IN KOREA. GIVEN THAT CARDIOVASCULAR (CV) DISEASE IS THE SECOND LEADING CAUSE OF DEATH IN KOREA, IT IS URGENT THAT CR PROGRAMS BE DEVELOPED. IN 2008, THE GOVERNMENT OF KOREA IMPLEMENTED CR PROGRAMS AT 11 UNIVERSITY HOSPITALS AS PART OF ITS REGIONAL CARDIO-CEREBROVASCULAR CENTER PROJECT, AND 3 ADDITIONAL MEDICAL FACILITIES WILL BE ADDED IN 2019. IN ADDITION, OWING TO THE PROMOTION OF CR NATIONWIDE AND THE INTRODUCTION OF CR INSURANCE BENEFITS, 40 MEDICAL INSTITUTIONS NATIONWIDE HAVE BEGUN CR PROGRAMS EVEN AS A GROWING NUMBER OF MEDICAL INSTITUTIONS ARE PREPARING TO OFFER CR. THE PURPOSE OF THIS RESEARCH WAS TO DEVELOP EVIDENCE-BASED CPGS TO SUPPORT CR IMPLEMENTATION IN KOREA. THIS STUDY IS BASED ON AN ANALYSIS OF CPGS ELSEWHERE IN THE WORLD, AN EXTENSIVE LITERATURE SEARCH, A SYSTEMATIC ANALYSIS OF MULTIPLE RANDOMIZED CONTROL TRIALS, AND A CPG MANAGEMENT, DEVELOPMENT, AND ASSESSMENT COMMITTEE COMPRISED OF THIRTY-THREE AUTHORS-PRIMARILY REHABILITATION SPECIALISTS, CARDIOLOGISTS, AND THORACIC SURGEONS IN 21 UNIVERSITY HOSPITALS AND 2 GENERAL HOSPITALS. TWELVE CONSULTANTS, PRIMARILY REHABILITATION, SPORTS MEDICINE, AND PREVENTIVE MEDICINE SPECIALISTS, CPG EXPERTS, NURSES, PHYSICAL THERAPISTS, CLINICAL NUTRITIONISTS, AND LIBRARY AND INFORMATION EXPERTS PARTICIPATED IN THE RESEARCH AND DEVELOPMENT OF THESE CPGS. AFTER THE DRAFT GUIDELINES WERE DEVELOPED, 3 ROUNDS OF PUBLIC HEARINGS WERE HELD WITH STAFF MEMBERS FROM RELEVANT ACADEMIC SOCIETIES AND STAKEHOLDERS, AFTER WHICH THE GUIDELINES WERE FURTHER REVIEWED AND MODIFIED. CR INVOLVES A MORE COST-EFFECTIVE USE OF HEALTHCARE RESOURCES RELATIVE TO THAT OF GENERAL TREATMENTS, AND THE EXERCISE COMPONENT OF CR LOWERS CV MORTALITY AND READMISSION RATES, REGARDLESS OF THE TYPE OF CORONARY HEART DISEASE AND TYPE AND SETTING OF CR. INDIVIDUALIZED CR PROGRAMS SHOULD BE CONSIDERED TOGETHER WITH VARIOUS FACTORS, INCLUDING DIFFERENCES IN HEART FUNCTION AND LIFESTYLE, AND DOING SO WILL BOOST PARTICIPATION AND ADHERENCE WITH THE CR PROGRAM, ULTIMATELY MEETING THE FINAL GOALS OF THE PROGRAM, NAMELY REDUCING THE RECURRENCE OF MYOCARDIAL INFARCTION AND MORTALITY RATES. COPYRIGHT © 2019. THE KOREAN SOCIETY OF CARDIOLOGY.","ACUTE CORONARY SYNDROME; CARDIAC REHABILITATION; CLINICAL PRACTICE GUIDELINE; MORTALITY; SECONDARY PREVENTION","ANTIOXIDANT; POLYCOSANOL; UNCLASSIFIED DRUG; ACUTE CORONARY SYNDROME; AEROBIC EXERCISE; CARDIOLOGIST; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DIETARY SUPPLEMENT; DIETITIAN; EXERCISE; GERIATRIC PATIENT; HEALTH CARE UTILIZATION; HEART FUNCTION; HEART INFARCTION; HEART REHABILITATION; HOME CARE; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; NURSE; PATIENT EDUCATION; PATIENT SAFETY; PHYSICAL ACTIVITY; PHYSIOTHERAPIST; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PSYCHOLOGIC ASSESSMENT; RESISTANCE TRAINING; REVIEW; SECONDARY PREVENTION; SIX MINUTE WALK TEST; SMOKING CESSATION; SPORTS MEDICINE; THORACIC SURGEON","DEPARTMENT OF FOOD AND NUTRITION; DEPARTMENT OF SPORTS MEDICINE CENTER; HALLYM UNIVERSITY COLLEGE OF MEDICINE; HEALTH AND MEDICAL TECHNOLOGY RESEARCH AND DEVELOPMENT; SAMSUNG; KYUNG HEE UNIVERSITY; UNIVERSITY OF SEOUL, UOS; EWHA WOMANS UNIVERSITY, EWHA; INJE UNIVERSITY, INJE; KONKUK UNIVERSITY, KU; SUNGKYUNKWAN UNIVERSITY, SKKU; MINISTRY OF HEALTH AND WELFARE, MOHW; KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE, KHIDI, (HC17C0063); KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE, KHIDI; COLLEGE OF MEDICINE, KOREA UNIVERSITY","THIS STUDY WAS FUNDED BY THE MINISTRY OF HEALTH AND WELFARE (MOHW) AS PART OF THE HEALTH AND MEDICAL TECHNOLOGY RESEARCH AND DEVELOPMENT PROJECT OF THE KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE (KHIDI) (PROJECT NUMBER: HC17C0063, STUDY PERIOD: NOVEMBER 1,2018 TO OCTOBER 31, 2018). THERE HAS NOT BEEN ANY INFLUENCE FROM THE KHIDI AND NATIONAL EVIDENCE-BASED HEALTHCARE COLLABORATING AGENCY THROUGHOUT THE ENTIRE PROCESS OF THE CPGS DEVELOPMENT, AND NO FUNDING HAS BEEN RECEIVED FROM OTHER ACADEMIC SOCIETIES, ORGANIZATIONS, AND INTEREST GROUPS. THE AUTHORS EXPRESS THEIR GRATITUDE TO KYUNG PYO HONG, SAMSUNG MEDICAL CENTER, YUN-HEE KIM, DEPARTMENT OF PHYSICAL AND REHABILITATION MEDICINE, SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE, SUNG-BO SIM, DEPARTMENT OF THORACIC AND CARDIOVASCULAR SURGERY, THE CATHOLIC UNIVERSITY OF KOREA COLLEGE OF MEDICINE, WON-HAH PARK, DEPARTMENT OF SPORTS MEDICINE CENTER, SAMSUNG MEDICAL CENTER, SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE, KUN-SEI LEE, DEPARTMENT OF PREVENTIVE MEDICINE, SCHOOL OF MEDICINE, KONKUK UNIVERSITY, SOO YOUNG KIM, DEPARTMENT OF FAMILY MEDICINE, KANGDONG SACRED HEART HOSPITAL, HALLYM UNIVERSITY COLLEGE OF MEDICINE, WOONG JU, SCHOOL OF MEDICINE, EWHA WOMANS UNIVERSITY, SAE YOUNG JAE, DEPARTMENT OF SPORT SCIENCE, GRADUATE SCHOOL OF URBAN PUBLIC HEALTH, UNIVERSITY OF SEOUL, MI JA JANG, SAMSUNG MEDICAL CENTER, HYE JEONG KIM, INJE UNIVERSITY SANGGYE PAIK HOSPITAL, JUNG-HO YOUN, MEDIPLEX SEJONG HOSPITAL, SONG MI LEE, SEVERANCE HOSPITAL, SEUNGMIN LEE, DEPARTMENT OF FOOD AND NUTRITION, SUNGSHIN WOMEN'S UNIVERSITY, JEONG JU LEE, KYUNGHEE UNIVERSITY HOSPITAL AT GANGDONG FOR THEIR EFFORT IN EXPERT'S ADVICES. ALL RESEARCHERS INVOLVED IN THE DEVELOPMENT OF THESE CPGS DECLARE NO CONFLICT OF INTEREST WHILE PARTICIPATING IN THE DEVELOPMENT PROCESS.","SHIN H.Y., LEE J.Y., SONG J., ET AL., CAUSE-OF-DEATH STATISTICS IN THE REPUBLIC OF KOREA, 2014, J KOREAN MED ASSOC, 59, PP. 221-232, (2016); LEE S.W., KIM H.C., LEE H.S., SUH I., THIRTY-YEAR TRENDS IN MORTALITY FROM CARDIOVASCULAR DISEASES IN KOREA, KOREAN CIRC J, 45, PP. 202-209, (2015); CAUSE OF DEATH STATISTICS, (2016); CANADIAN GUIDELINES FOR CARDIAC REHABILITATION AND CARDIOVASCULAR DISEASE PREVENTION: TRANSLATING KNOWLEDGE INTO ACTION, (2009); CARDIAC REHABILITATION: A NATIONAL CLINICAL GUIDELINE, (2017); MYOCARDIAL INFARCTION: CARDIAC REHABILITATION AND PREVENTION OF FURTHER CARDIOVASCULAR DISEASE (CG172), (2013); SMITH S.C., BENJAMIN E.J., BONOW R.O., ET AL., AHA/ACCF SECONDARY PREVENTION AND RISK REDUCTION THERAPY FOR PATIENTS WITH CORONARY AND OTHER ATHEROSCLEROTIC VASCULAR DISEASE: 2011 UPDATE: A GUIDELINE FROM THE AMERICAN HEART ASSOCIATION AND AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ENDORSED BY THE WORLD HEART FEDERATION AND THE PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION, CIRCULATION, 124, PP. 2458-2473, (2011); GUIDELINES FOR REHABILITATION IN PATIENTS WITH CARDIOVASCULAR DISEASE (JCS 2012), CIR J, 78, PP. 2022-2093, (2014); PIEPOLI M.F., HOES A.W., AGEWALL S., ET AL., 2016 EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: THE SIXTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUR HEART J, 37, PP. 2315-2381, (2016); KOREAN APPRAISAL OF GUIDELINES FOR RESEARCH & EVALUATION II, (2010); CARDIAC REHABILITATION GUIDELINE PANEL, AM FAM PHYSICIAN, 52, PP. 2257-2264, (1995); BALADY G.J., ADES P.A., BITTNER V.A., ET AL., REFERRAL, ENROLLMENT, AND DELIVERY OF CARDIAC REHABILITATION/SECONDARY PREVENTION PROGRAMS AT CLINICAL CENTERS AND BEYOND: A PRESIDENTIAL ADVISORY FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 124, PP. 2951-2960, (2011); PERK J., DE BACKER G., GOHLKE H., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (VERSION 2012). THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR HEART J, 33, PP. 1635-1701, (2012); ANDERSON L., OLDRIDGE N., THOMPSON D.R., ET AL., EXERCISE-BASED CARDIAC REHABILITATION FOR CORONARY HEART DISEASE: COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS, J AM COLL CARDIOL, 67, PP. 1-12, (2016); SUMNER J., HARRISON A., DOHERTY P., THE EFFECTIVENESS OF MODERN CARDIAC REHABILITATION: A SYSTEMATIC REVIEW OF RECENT OBSERVATIONAL STUDIES IN NON-ATTENDERS VERSUS ATTENDERS, PLOS ONE, 12, (2017); GOODWIN L., OSTUZZI G., KHAN N., HOTOPF M.H., MOSS-MORRIS R., CAN WE IDENTIFY THE ACTIVE INGREDIENTS OF BEHAVIOUR CHANGE INTERVENTIONS FOR CORONARY HEART DISEASE PATIENTS? A SYSTEMATIC REVIEW AND META-ANALYSIS, PLOS ONE, 11, (2016); KIM C., KIM D.Y., MOON C.J., PROGNOSTIC INFLUENCES OF CARDIAC REHABILITATION IN KOREAN ACUTE MYOCARDIAL INFARCTION PATIENTS, ANN REHABIL MED, 35, PP. 375-380, (2011); ANDERSON L., TAYLOR R.S., CARDIAC REHABILITATION FOR PEOPLE WITH HEART DISEASE: AN OVERVIEW OF COCHRANE SYSTEMATIC REVIEWS, COCHRANE DATABASE SYST REV, (2014); SHEPHERD C.W., WHILE A.E., CARDIAC REHABILITATION AND QUALITY OF LIFE: A SYSTEMATIC REVIEW, INT J NURS STUD, 49, PP. 755-771, (2012); ABELL B., GLASZIOU P., HOFFMANN T., THE CONTRIBUTION OF INDIVIDUAL EXERCISE TRAINING COMPONENTS TO CLINICAL OUTCOMES IN RANDOMISED CONTROLLED TRIALS OF CARDIAC REHABILITATION: A SYSTEMATIC REVIEW AND META-REGRESSION, SPORTS MED OPEN, 3, (2017); VAN HALEWIJN G., DECKERS J., TAY H.Y., VAN DOMBURG R., KOTSEVA K., WOOD D., LESSONS FROM CONTEMPORARY TRIALS OF CARDIOVASCULAR PREVENTION AND REHABILITATION: A SYSTEMATIC REVIEW AND META-ANALYSIS, INT J CARDIOL, 232, PP. 294-303, (2017); CHAN E., GIALLAURIA F., VIGORITO C., SMART N.A., EXERCISE TRAINING IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS, MONALDI ARCH CHEST DIS, 86, (2016); PANDEY A., PARASHAR A., KUMBHANI D., ET AL., EXERCISE TRAINING IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: META-ANALYSIS OF RANDOMIZED CONTROL TRIALS, CIRC HEART FAIL, 8, PP. 33-40, (2015); HAYKOWSKY M., SCOTT J., ESCH B., ET AL., A META-ANALYSIS OF THE EFFECTS OF EXERCISE TRAINING ON LEFT VENTRICULAR REMODELING FOLLOWING MYOCARDIAL INFARCTION: START EARLY AND GO LONGER FOR GREATEST EXERCISE BENEFITS ON REMODELING, TRIALS, 12, (2011); ZHANG Y.M., LU Y., TANG Y., ET AL., THE EFFECTS OF DIFFERENT INITIATION TIME OF EXERCISE TRAINING ON LEFT VENTRICULAR REMODELING AND CARDIOPULMONARY REHABILITATION IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION, DISABIL REHABIL, 38, PP. 268-276, (2016); OLDRIDGE N., EXERCISE-BASED CARDIAC REHABILITATION IN PATIENTS WITH CORONARY HEART DISEASE: META-ANALYSIS OUTCOMES REVISITED, FUTURE CARDIOL, 8, PP. 729-751, (2012); KIM C., BANG H.J., KIM J.H., ET AL., RECOMMENDATIONS FOR ESTABLISHING CARDIAC REHABILITATION PROGRAMS; FACILITY, EQUIPMENT AND STAFF: THE KOREAN SOCIETY OF CARDIAC REHABILITATION (KSCR) POSITION STATEMENT, ANN REHABIL MED, 34, PP. 491-497, (2010); THE BACPR STANDARDS AND CORE COMPONENTS FOR CARDIOVASCULAR PREVENTION AND REHABILITATION 2012, (2012); CLARK A.M., CATTO S., BOWMAN G., MACINTYRE P.D., DESIGN MATTERS IN SECONDARY PREVENTION: INDIVIDUALIZATION AND SUPERVISED EXERCISE IMPROVES THE EFFECTIVENESS OF CARDIAC REHABILITATION, EUR J CARDIOVASC PREV REHABIL, 18, PP. 761-769, (2011); COULTER A., ENTWISTLE V.A., ECCLES A., RYAN S., SHEPPERD S., PERERA R., PERSONALISED CARE PLANNING FOR ADULTS WITH CHRONIC OR LONG-TERM HEALTH CONDITIONS, COCHRANE DATABASE SYST REV, (2015); HILL K., WALWYN R., CAMIDGE D., ET AL., A RANDOMIZED FEASIBILITY TRIAL OF A NEW LIFESTYLE REFERRAL ASSESSMENT VERSUS USUAL ASSESSMENT IN AN ACUTE CARDIOLOGY SETTING, J CARDIOVASC NURS, 31, PP. 507-516, (2016); WEIBEL L., MASSAROTTO P., HEDIGER H., MAHRER-IMHOF R., EARLY EDUCATION AND COUNSELLING OF PATIENTS WITH ACUTE CORONARY SYNDROME. A PILOT STUDY FOR A RANDOMIZED CONTROLLED TRIAL, EUR J CARDIOVASC NURS, 15, PP. 213-222, (2016); FORS A., SWEDBERG K., ULIN K., WOLF A., EKMAN I., EFFECTS OF PERSON-CENTRED CARE AFTER AN EVENT OF ACUTE CORONARY SYNDROME: TWO-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL, INT J CARDIOL, 249, PP. 42-47, (2017); LESPERANCE F., FRASURE-SMITH N., DEPRESSION IN PATIENTS WITH CARDIAC DISEASE: A PRACTICAL REVIEW, J PSYCHOSOM RES, 48, PP. 379-391, (2000); CARNEY R.M., FREEDLAND K.E., DEPRESSION, MORTALITY, AND MEDICAL MORBIDITY IN PATIENTS WITH CORONARY HEART DISEASE, BIOL PSYCHIATRY, 54, PP. 241-247, (2003); FRASURE-SMITH N., LESPERANCE F., RECENT EVIDENCE LINKING CORONARY HEART DISEASE AND DEPRESSION, CAN J PSYCHIATRY, 51, PP. 730-737, (2006); GEHI A., HAAS D., PIPKIN S., WHOOLEY M.A., DEPRESSION AND MEDICATION ADHERENCE IN OUTPATIENTS WITH CORONARY HEART DISEASE: FINDINGS FROM THE HEART AND SOUL STUDY, ARCH INTERN MED, 165, PP. 2508-2513, (2005); ADES P.A., WALDMANN M.L., MCCANN W.J., WEAVER S.O., PREDICTORS OF CARDIAC REHABILITATION PARTICIPATION IN OLDER CORONARY PATIENTS, ARCH INTERN MED, 152, PP. 1033-1035, (1992); GLAZER K.M., EMERY C.F., FRID D.J., BANYASZ R.E., PSYCHOLOGICAL PREDICTORS OF ADHERENCE AND OUTCOMES AMONG PATIENTS IN CARDIAC REHABILITATION, J CARDIOPULM REHABIL, 22, PP. 40-46, (2002); FRASURE-SMITH N., LESPERANCE F., GRAVEL G., ET AL., DEPRESSION AND HEALTH-CARE COSTS DURING THE FIRST YEAR FOLLOWING MYOCARDIAL INFARCTION, J PSYCHOSOM RES, 48, PP. 471-478, (2000); SHIBESHI W.A., YOUNG-XU Y., BLATT C.M., ANXIETY WORSENS PROGNOSIS IN PATIENTS WITH CORONARY ARTERY DISEASE, J AM COLL CARDIOL, 49, PP. 2021-2027, (2007); MURPHY B.M., HIGGINS R.O., JACKSON A.C., ANXIETY, DEPRESSION, AND PSYCHOLOGICAL ADJUSTMENT AFTER AN ACUTE CARDIAC EVENT: HANDBOOK OF PSYCHOCARDIOLOGY, (2015); RICHARDS S.H., ANDERSON L., JENKINSON C.E., ET AL., PSYCHOLOGICAL INTERVENTIONS FOR CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, 4, (2017); KLAININ-YOBAS P., NG S.H., STEPHEN P.D., LAU Y., EFFICACY OF PSYCHOSOCIAL INTERVENTIONS ON PSYCHOLOGICAL OUTCOMES AMONG PEOPLE WITH CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS, PATIENT EDUC COUNS, 99, PP. 512-521, (2016); VON KANEL R., BARTH J., PRINCIP M., ET AL., EARLY PSYCHOLOGICAL COUNSELING FOR THE PREVENTION OF POSTTRAUMATIC STRESS INDUCED BY ACUTE CORONARY SYNDROME: THE MI-SPRINT RANDOMIZED CONTROLLED TRIAL, PSYCHOTHER PSYCHOSOM, 87, PP. 75-84, (2018); ACSM'S GUIDELINES FOR EXERCISE TESTING AND PRESCRIPTION., (2013); GUIDELINES FOR CARDIA REHABILITATION AND SECONDARY PREVENTION PROGRAMS., (2013); BALADY G., LEITSCHUH M.L., JACOBS A.K., MERRELL D., WEINER D.A., RYAN T.J., SAFETY AND CLINICAL USE OF EXERCISE TESTING ONE TO THREE DAYS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, AM J CARDIOL, 69, PP. 1259-1264, (1992); HORGAN J., BETHELL H., CARSON P., ET AL., WORKING PARTY REPORT ON CARDIAC REHABILITATION, BR HEART J, 67, PP. 412-418, (1992); GOBLE A.J., WORCESTER M.C., BEST PRACTICE GUIDELINES FOR CARDIAC REHABILITATION AND SECONDARY PREVENTION, (1999); WRIGHT D.J., KHAN K.M., GOSSAGE E.M., SALTISSI S., ASSESSMENT OF A LOW-INTENSITY CARDIAC REHABILITATION PROGRAMME USING THE SIX-MINUTE WALK TEST, CLIN REHABIL, 15, PP. 119-124, (2001); TALLAJ J.A., SANDERSON B., BRELAND J., ADAMS C., SCHUMANN C., BITTNER V., ASSESSMENT OF FUNCTIONAL OUTCOMES USING THE 6-MINUTE WALK TEST IN CARDIAC REHABILITATION: COMPARISON OF PATIENTS WITH AND WITHOUT LEFT VENTRICULAR DYSFUNCTION, J CARDIOPULM REHABIL, 21, PP. 221-224, (2001); VERRILL D.E., BARTON C., BEASLEY W., LIPPARD M., KING C.N., SIX-MINUTE WALK PERFORMANCE AND QUALITY OF LIFE COMPARISONS IN NORTH CAROLINA CARDIAC REHABILITATION PROGRAMS, HEART LUNG, 32, PP. 41-51, (2003); BELLET R.N., ADAMS L., MORRIS N.R., THE 6-MINUTE WALK TEST IN OUTPATIENT CARDIAC REHABILITATION: VALIDITY, RELIABILITY AND RESPONSIVENESS - A SYSTEMATIC REVIEW, PHYSIOTHERAPY, 98, PP. 277-286, (2012); NOGUEIRA P.A., LEAL A.C., PULZ C., NOGUEIRA I.D., FILHO J.A., CLINICAL RELIABILITY OF THE 6 MINUTE CORRIDOR WALK TEST PERFORMED WITHIN A WEEK OF A MYOCARDIAL INFARCTION, INT HEART J, 47, PP. 533-540, (2006); HANSON L.C., MCBURNEY H., TAYLOR N.F., THE RETEST RELIABILITY OF THE SIX-MINUTE WALK TEST IN PATIENTS REFERRED TO A CARDIAC REHABILITATION PROGRAMME, PHYSIOTHER RES INT, 17, PP. 55-61, (2012); HARRIS K.M., ANDERSON D.R., LANDERS J.D., EMERY C.F., UTILITY OF WALK TESTS IN EVALUATING FUNCTIONAL STATUS AMONG PARTICIPANTS IN AN OUTPATIENT CARDIAC REHABILITATION PROGRAM, J CARDIOPULM REHABIL PREV, 37, PP. 329-333, (2017); GOTO Y., CURRENT STATE OF CARDIAC REHABILITATION IN JAPAN, PROG CARDIOVASC DIS, 56, PP. 557-562, (2014); IM H.W., BAEK S., JEE S., AHN J.M., PARK M.W., KIM W.S., BARRIERS TO OUTPATIENT HOSPITAL-BASED CARDIAC REHABILITATION IN KOREAN PATIENTS WITH ACUTE CORONARY SYNDROME, ANN REHABIL MED, 42, PP. 154-165, (2018); ADES P.A., KETEYIAN S.J., WRIGHT J.S., ET AL., INCREASING CARDIAC REHABILITATION PARTICIPATION FROM 20% TO 70%: A ROAD MAP FROM THE MILLION HEARTS CARDIAC REHABILITATION COLLABORATIVE, MAYO CLIN PROC, 92, PP. 234-242, (2017); KARMALI K.N., DAVIES P., TAYLOR F., BESWICK A., MARTIN N., EBRAHIM S., PROMOTING PATIENT UPTAKE AND ADHERENCE IN CARDIAC REHABILITATION, COCHRANE DATABASE SYST REV, (2014); COSSETTE S., FRASURE-SMITH N., DUPUIS J., JUNEAU M., GUERTIN M.C., RANDOMIZED CONTROLLED TRIAL OF TAILORED NURSING INTERVENTIONS TO IMPROVE CARDIAC REHABILITATION ENROLLMENT, NURS RES, 61, PP. 111-120, (2012); HILLEBRAND T., FRODERMANN H., LEHR D., WIRTH A., INCREASED PARTICIPATION IN CORONARY GROUPS BY MEANS OF AN OUTPATIENT CARE PROGRAM, HERZ KREISLAUF, 27, PP. 346-349, (1995); JOLLY K., BRADLEY F., SHARP S., ET AL., RANDOMISED CONTROLLED TRIAL OF FOLLOW UP CARE IN GENERAL PRACTICE OF PATIENTS WITH MYOCARDIAL INFARCTION AND ANGINA: FINAL RESULTS OF THE SOUTHAMPTON HEART INTEGRATED CARE PROJECT (SHIP). THE SHIP COLLABORATIVE GROUP, BMJ, 318, PP. 706-711, (1999); PRICE J.A.D., A PILOT TRIAL OF A COACHING INTERVENTION DESIGNED TO INCREASE WOMEN'S ATTENDANCE AT CARDIAC REHABILITATION INTAKE, (2012); PACK Q.R., MANSOUR M., BARBOZA J.S., ET AL., AN EARLY APPOINTMENT TO OUTPATIENT CARDIAC REHABILITATION AT HOSPITAL DISCHARGE IMPROVES ATTENDANCE AT ORIENTATION: A RANDOMIZED, SINGLE-BLIND, CONTROLLED TRIAL, CIRCULATION, 127, PP. 349-355, (2013); WYER S., EARLL L., JOSEPH S., HARRISON J., GILES M., JOHNSTON M., INCREASING ATTENDANCE AT A CARDIAC REHABILITATION PROGRAMME: AN INTERVENTION STUDY USING THE THEORY OF PLANNED BEHAVIOUR, CORON HEALTH CARE, 5, PP. 154-159, (2001); ARRIGO I., BRUNNER-LAROCCA H., LEFKOVITS M., PFISTERER M., HOFFMANN A., COMPARATIVE OUTCOME ONE YEAR AFTER FORMAL CARDIAC REHABILITATION: THE EFFECTS OF A RANDOMIZED INTERVENTION TO IMPROVE EXERCISE ADHERENCE, EUR J CARDIOVASC PREV REHABIL, 15, PP. 306-311, (2008); DUNCAN K.A., POZEHL B., STAYING ON COURSE: THE EFFECTS OF AN ADHERENCE FACILITATION INTERVENTION ON HOME EXERCISE PARTICIPATION, PROG CARDIOVASC NURS, 17, PP. 59-65, (2002); SNIEHOTTA F.F., SCHOLZ U., SCHWARZER R., ACTION PLANS AND COPING PLANS FOR PHYSICAL EXERCISE: A LONGITUDINAL INTERVENTION STUDY IN CARDIAC REHABILITATION, BR J HEALTH PSYCHOL, 11, PP. 23-37, (2006); REID R.D., MORRIN L.I., HIGGINSON L.A., ET AL., MOTIVATIONAL COUNSELLING FOR PHYSICAL ACTIVITY IN PATIENTS WITH CORONARY ARTERY DISEASE NOT PARTICIPATING IN CARDIAC REHABILITATION, EUR J PREV CARDIOL, 19, PP. 161-166, (2012); GRACE S.L., MIDENCE L., OH P., ET AL., CARDIAC REHABILITATION PROGRAM ADHERENCE AND FUNCTIONAL CAPACITY AMONG WOMEN: A RANDOMIZED CONTROLLED TRIAL, MAYO CLIN PROC, 91, PP. 140-148, (2016); LYNGGAARD V., NIELSEN C.V., ZWISLER A.D., TAYLOR R.S., MAY O., THE PATIENT EDUCATION - LEARNING AND COPING STRATEGIES - IMPROVES ADHERENCE IN CARDIAC REHABILITATION (LC-REHAB): A RANDOMISED CONTROLLED TRIAL, INT J CARDIOL, 236, PP. 65-70, (2017); GRACE S.L., CHESSEX C., ARTHUR H., ET AL., SYSTEMATIZING INPATIENT REFERRAL TO CARDIAC REHABILITATION 2010: CANADIAN ASSOCIATION OF CARDIAC REHABILITATION AND CANADIAN CARDIOVASCULAR SOCIETY JOINT POSITION PAPER ENDORSED BY THE CARDIAC CARE NETWORK OF ONTARIO, CAN J CARDIOL, 27, PP. 192-199, (2011); TAYLOR R.S., BROWN A., EBRAHIM S., ET AL., EXERCISE-BASED REHABILITATION FOR PATIENTS WITH CORONARY HEART DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 116, PP. 682-692, (2004); VAN DEN BERG-EMONS R.J., BUSSMANN J.B., BALK A.H., STAM H.J., FACTORS ASSOCIATED WITH THE LEVEL OF MOVEMENT-RELATED EVERYDAY ACTIVITY AND QUALITY OF LIFE IN PEOPLE WITH CHRONIC HEART FAILURE, PHYS THER, 85, PP. 1340-1348, (2005); TER HOEVE N., HUISSTEDE B.M., STAM H.J., VAN DOMBURG R.T., SUNAMURA M., VAN DEN BERG-EMONS R.J., DOES CARDIAC REHABILITATION AFTER AN ACUTE CARDIAC SYNDROME LEAD TO CHANGES IN PHYSICAL ACTIVITY HABITS? SYSTEMATIC REVIEW, PHYS THER, 95, PP. 167-179, (2015); CHA S., PARK J.J., KIM S., ET AL., NEED FOR SYSTEMATIC EFFORTS TO MODIFY HEALTH-RELATED BEHAVIORS AFTER ACUTE MYOCARDIAL INFARCTION IN KOREA, CIRC J, 82, PP. 2523-2529, (2018); ALDCROFT S.A., TAYLOR N.F., BLACKSTOCK F.C., O'HALLORAN P.D., PSYCHOEDUCATIONAL REHABILITATION FOR HEALTH BEHAVIOR CHANGE IN CORONARY ARTERY DISEASE: A SYSTEMATIC REVIEW OF CONTROLLED TRIALS, J CARDIOPULM REHABIL PREV, 31, PP. 273-281, (2011); TINGSTROM P.R., KAMWENDO K., BERGDAHL B., EFFECTS OF A PROBLEM-BASED LEARNING REHABILITATION PROGRAMME ON QUALITY OF LIFE IN PATIENTS WITH CORONARY ARTERY DISEASE, EUR J CARDIOVASC NURS, 4, PP. 324-330, (2005); CARLSON J.J., JOHNSON J.A., FRANKLIN B.A., VANDERLAAN R.L., PROGRAM PARTICIPATION, EXERCISE ADHERENCE, CARDIOVASCULAR OUTCOMES, AND PROGRAM COST OF TRADITIONAL VERSUS MODIFIED CARDIAC REHABILITATION, AM J CARDIOL, 86, PP. 17-23, (2000); IZAWA K.P., WATANABE S., OMIYA K., ET AL., EFFECT OF THE SELF-MONITORING APPROACH ON EXERCISE MAINTENANCE DURING CARDIAC REHABILITATION: A RANDOMIZED, CONTROLLED TRIAL, AM J PHYS MED REHABIL, 84, PP. 313-321, (2005); FOURNIER M., RADEL R., BAILLY L., ET AL., AS DU COEUR"" STUDY: A RANDOMIZED CONTROLLED TRIAL ON PHYSICAL ACTIVITY MAINTENANCE IN CARDIOVASCULAR PATIENTS, BMC CARDIOVASC DISORD, 18, (2018); TER HOEVE N., SUNAMURA M., STAM H.J., ET AL., EFFECTS OF TWO BEHAVIORAL CARDIAC REHABILITATION INTERVENTIONS ON PHYSICAL ACTIVITY: A RANDOMIZED CONTROLLED TRIAL, INT J CARDIOL, 255, PP. 221-228, (2018); KULIK A., RUEL M., JNEID H., ET AL., SECONDARY PREVENTION AFTER CORONARY ARTERY BYPASS GRAFT SURGERY: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 131, PP. 927-964, (2015); HANSEN D., DENDALE P., LEENDERS M., ET AL., REDUCTION OF CARDIOVASCULAR EVENT RATE: DIFFERENT EFFECTS OF CARDIAC REHABILITATION IN CABG AND PCI PATIENTS, ACTA CARDIOL, 64, PP. 639-644, (2009); HEDBACK B., PERK J., HORNBLAD M., OHLSSON U., CARDIAC REHABILITATION AFTER CORONARY ARTERY BYPASS SURGERY: 10-YEAR RESULTS ON MORTALITY, MORBIDITY AND READMISSIONS TO HOSPITAL, J CARDIOVASC RISK, 8, PP. 153-158, (2001); ALDAHASH R., AL DERA H.S., PHYSICAL THERAPY PROGRAM IMPROVES THE PHYSIOLOGICAL IMPACT TOWARDS BETTER QUALITY OF LIFE AND LOW CARDIAC RISK FACTORS IN PATIENTS FOLLOWING CORONARY ARTERY BYPASS GRAFTING. SYSTEMATIC REVIEW, ACTA MED INT, 3, PP. 185-195, (2016); KIM S.Y., OH J.K., YOUN J.H., KIM Y.J., THE EFFECT OF CARDIAC REHABILITATION I PHASE PROGRAM ON PHYSICAL CAPACITY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY, KOREAN J SPORTS MED, 30, PP. 85-91, (2012); HAMM L.F., SANDERSON B.K., ADES P.A., ET AL., CORE COMPETENCIES FOR CARDIAC REHABILITATION/SECONDARY PREVENTION PROFESSIONALS: 2010 UPDATE: POSITION STATEMENT OF THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION, J CARDIOPULM REHABIL PREV, 31, PP. 2-10, (2011); ANDERSON L., THOMPSON D.R., OLDRIDGE N., ET AL., EXERCISE-BASED CARDIAC REHABILITATION FOR CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, (2016); BROWN A., TAYLOR R., NOORANI H., STONE J., SKIDMORE B., EXERCISE-BASED CARDIAC REHABILITATION PROGRAMS FOR CORONARY ARTERY DISEASE: A SYSTEMATIC CLINICAL AND ECONOMIC REVIEW, (2003); CHEN Y.C., TSAI J.C., LIOU Y.M., CHAN P., EFFECTIVENESS OF ENDURANCE EXERCISE TRAINING IN PATIENTS WITH CORONARY ARTERY DISEASE: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, EUR J CARDIOVASC NURS, 16, PP. 397-408, (2017); LIOU K., HO S., FILDES J., OOI S.Y., HIGH INTENSITY INTERVAL VERSUS MODERATE INTENSITY CONTINUOUS TRAINING IN PATIENTS WITH CORONARY ARTERY DISEASE: A META-ANALYSIS OF PHYSIOLOGICAL AND CLINICAL PARAMETERS, HEART LUNG CIRC, 25, PP. 166-174, (2016); CHOI H.Y., HAN H.J., CHOI J.W., JUNG H.Y., JOA K.L., SUPERIOR EFFECTS OF HIGH-INTENSITY INTERVAL TRAINING COMPARED TO CONVENTIONAL THERAPY ON CARDIOVASCULAR AND PSYCHOLOGICAL ASPECTS IN MYOCARDIAL INFARCTION, ANN REHABIL MED, 42, PP. 145-153, (2018); KIM C., CHOI H.E., LIM M.H., EFFECT OF HIGH INTERVAL TRAINING IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH DRUG-ELUTING STENT, AM J PHYS MED REHABIL, 94, PP. 879-886, (2015); WILLIAMS M.A., HASKELL W.L., ADES P.A., ET AL., RESISTANCE EXERCISE IN INDIVIDUALS WITH AND WITHOUT CARDIOVASCULAR DISEASE: 2007 UPDATE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION COUNCIL ON CLINICAL CARDIOLOGY AND COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM, CIRCULATION, 116, PP. 572-584, (2007); HOLLINGS M., MAVROS Y., FREESTON J., FIATARONE SINGH M., THE EFFECT OF PROGRESSIVE RESISTANCE TRAINING ON AEROBIC FITNESS AND STRENGTH IN ADULTS WITH CORONARY HEART DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, EUR J PREV CARDIOL, 24, PP. 1242-1259, (2017); KARAGIANNIS C., SAVVA C., MAMAIS I., EFSTATHIOU M., MONTICONE M., XANTHOS T., ECCENTRIC EXERCISE IN ISCHEMIC CARDIAC PATIENTS AND FUNCTIONAL CAPACITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ANN PHYS REHABIL MED, 60, PP. 58-64, (2017); XANTHOS P.D., GORDON B.A., KINGSLEY M.I., IMPLEMENTING RESISTANCE TRAINING IN THE REHABILITATION OF CORONARY HEART DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, INT J CARDIOL, 230, PP. 493-508, (2017); KAVANAGH T., MERTENS D.J., HAMM L.F., ET AL., PREDICTION OF LONG-TERM PROGNOSIS IN 12 169 MEN REFERRED FOR CARDIAC REHABILITATION, CIRCULATION, 106, PP. 666-671, (2002); KAVANAGH T., MERTENS D.J., HAMM L.F., ET AL., PEAK OXYGEN INTAKE AND CARDIAC MORTALITY IN WOMEN REFERRED FOR CARDIAC REHABILITATION, J AM COLL CARDIOL, 42, PP. 2139-2143, (2003); MARK D.B., HLATKY M.A., HARRELL F.E., LEE K.L., CALIFF R.M., PRYOR D.B., EXERCISE TREADMILL SCORE FOR PREDICTING PROGNOSIS IN CORONARY ARTERY DISEASE, ANN INTERN MED, 106, PP. 793-800, (1987); MARK D.B., SHAW L., HARRELL F.E., ET AL., PROGNOSTIC VALUE OF A TREADMILL EXERCISE SCORE IN OUTPATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE, N ENGL J MED, 325, PP. 849-853, (1991); VANHEES L., FAGARD R., THIJS L., STAESSEN J., AMERY A., PROGNOSTIC SIGNIFICANCE OF PEAK EXERCISE CAPACITY IN PATIENTS WITH CORONARY ARTERY DISEASE, J AM COLL CARDIOL, 23, PP. 358-363, (1994); KOKKINOS P., MYERS J., KOKKINOS J.P., ET AL., EXERCISE CAPACITY AND MORTALITY IN BLACK AND WHITE MEN, CIRCULATION, 117, PP. 614-622, (2008); FLETCHER G.F., BALADY G.J., AMSTERDAM E.A., ET AL., EXERCISE STANDARDS FOR TESTING AND TRAINING: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 104, PP. 1694-1740, (2001); KIM C., MOON C.J., LIM M.H., SAFETY OF MONITORING EXERCISE FOR EARLY HOSPITAL-BASED CARDIAC REHABILITATION, ANN REHABIL MED, 36, PP. 262-267, (2012); CLAES J., BUYS R., BUDTS W., SMART N., CORNELISSEN V.A., LONGER-TERM EFFECTS OF HOME-BASED EXERCISE INTERVENTIONS ON EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN CORONARY ARTERY DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR J PREV CARDIOL, 24, PP. 244-256, (2017); ANDERSON L., SHARP G.A., NORTON R.J., ET AL., HOME-BASED VERSUS CENTRE-BASED CARDIAC REHABILITATION, COCHRANE DATABASE SYST REV, 6, (2017); HUANG K., LIU W., HE D., ET AL., TELEHEALTH INTERVENTIONS VERSUS CENTER-BASED CARDIAC REHABILITATION OF CORONARY ARTERY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR J PREV CARDIOL, 22, PP. 959-971, (2015); MCCLURE T., HAYKOWSKY M.J., SCHOPFLOCHER D., HSU Z.Y., CLARK A.M., HOME-BASED SECONDARY PREVENTION PROGRAMS FOR PATIENTS WITH CORONARY ARTERY DISEASE: A META-ANALYSIS OF EFFECTS ON ANXIETY, J CARDIOPULM REHABIL PREV, 33, PP. 59-67, (2013); HERON N., KEE F., DONNELLY M., CARDWELL C., TULLY M.A., CUPPLES M.E., BEHAVIOUR CHANGE TECHNIQUES IN HOME-BASED CARDIAC REHABILITATION: A SYSTEMATIC REVIEW, BR J GEN PRACT, 66, PP. E747-E757, (2016); LEE Y.H., HUR S.H., SOHN J., ET AL., IMPACT OF HOME-BASED EXERCISE TRAINING WITH WIRELESS MONITORING ON PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION, J KOREAN MED SCI, 28, PP. 564-568, (2013); CHUNG H., KO H., THAP T., ET AL., SMARTPHONE-BASED CARDIAC REHABILITATION PROGRAM: FEASIBILITY STUDY, PLOS ONE, 11, (2016); LEE H., CHUNG H., KO H., ET AL., DEDICATED CARDIAC REHABILITATION WEARABLE SENSOR AND ITS CLINICAL POTENTIAL, PLOS ONE, 12, (2017); RICH M.W., BOSNER M.S., CHUNG M.K., SHEN J., MCKENZIE J.P., IS AGE AN INDEPENDENT PREDICTOR OF EARLY AND LATE MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION?, AM J MED, 92, PP. 7-13, (1992); ADES P.A., SAVAGE P.D., TISCHLER M.D., POEHLMAN E.T., DEE J., NIGGEL J., DETERMINANTS OF DISABILITY IN OLDER CORONARY PATIENTS, AM HEART J, 143, PP. 151-156, (2002); PASQUALI S.K., ALEXANDER K.P., PETERSON E.D., CARDIAC REHABILITATION IN THE ELDERLY, AM HEART J, 142, PP. 748-755, (2001); AUDELIN M.C., SAVAGE P.D., ADES P.A., EXERCISE-BASED CARDIAC REHABILITATION FOR VERY OLD PATIENTS (> OR =75 YEARS): FOCUS ON PHYSICAL FUNCTION, J CARDIOPULM REHABIL PREV, 28, PP. 163-173, (2008); YAMAMOTO S., HOTTA K., OTA E., MORI R., MATSUNAGA A., EFFECTS OF RESISTANCE TRAINING ON MUSCLE STRENGTH, EXERCISE CAPACITY, AND MOBILITY IN MIDDLE-AGED AND ELDERLY PATIENTS WITH CORONARY ARTERY DISEASE: A META-ANALYSIS, J CARDIOL, 68, PP. 125-134, (2016); KIM J.H., EFFECTS OF CARDIAC REHABILITATION IN ELDERLY PATIENTS AFTER MYOCARDIAL INFARCTION, J KOREA ACAD IND COOP SOC, 17, PP. 464-471, (2016); THE BACPR STANDARDS AND CORE COMPONENTS FOR CARDIOVASCULAR DISEASE PREVENTION AND REHABILITATION 2017, (2017); FERRIER S., BLANCHARD C.M., VALLIS M., GIACOMANTONIO N., BEHAVIOURAL INTERVENTIONS TO INCREASE THE PHYSICAL ACTIVITY OF CARDIAC PATIENTS: A REVIEW, EUR J CARDIOVASC PREV REHABIL, 18, PP. 15-32, (2011); TIERNEY S., MAMAS M., SKELTON D., ET AL., WHAT CAN WE LEARN FROM PATIENTS WITH HEART FAILURE ABOUT EXERCISE ADHERENCE? A SYSTEMATIC REVIEW OF QUALITATIVE PAPERS, HEALTH PSYCHOL, 30, PP. 401-410, (2011); ANDERSON L., BROWN J.P., CLARK A.M., ET AL., PATIENT EDUCATION IN THE MANAGEMENT OF CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, 6, (2017); NIEUWLAAT R., WILCZYNSKI N., NAVARRO T., ET AL., INTERVENTIONS FOR ENHANCING MEDICATION ADHERENCE, COCHRANE DATABASE SYST REV, (2014); CHASE J.A., BOGENER J.L., RUPPAR T.M., CONN V.S., THE EFFECTIVENESS OF MEDICATION ADHERENCE INTERVENTIONS AMONG PATIENTS WITH CORONARY ARTERY DISEASE: A META-ANALYSIS, THE JOURNAL OF CARDIOVASCULAR NURSING., 31, PP. 357-366, (2016); ADLER A.J., MARTIN N., MARIANI J., ET AL., MOBILE PHONE TEXT MESSAGING TO IMPROVE MEDICATION ADHERENCE IN SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 4, (2017); GANDAPUR Y., KIANOUSH S., KELLI H.M., ET AL., THE ROLE OF MHEALTH FOR IMPROVING MEDICATION ADHERENCE IN PATIENTS WITH CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW, EUR HEART J QUAL CARE CLIN OUTCOMES, 2, PP. 237-244, (2016); GANDHI S., CHEN S., HONG L., ET AL., EFFECT OF MOBILE HEALTH INTERVENTIONS ON THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS, CAN J CARDIOL, 33, PP. 219-231, (2017); ZULLIG L.L., RAMOS K., BOSWORTH H.B., IMPROVING MEDICATION ADHERENCE IN CORONARY HEART DISEASE, CURR CARDIOL REP, 19, (2017); BARTH J., JACOB T., DAHA I., CRITCHLEY J.A., PSYCHOSOCIAL INTERVENTIONS FOR SMOKING CESSATION IN PATIENTS WITH CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, (2015); KOTB A., HSIEH S., WELLS G.A., THE EFFECT OF TELEPHONE SUPPORT INTERVENTIONS ON CORONARY ARTERY DISEASE (CAD) PATIENT OUTCOMES DURING CARDIAC REHABILITATION: A SYSTEMATIC REVIEW AND META-ANALYSIS, PLOS ONE, 9, (2014); RIGOTTI N.A., CLAIR C., MUNAFO M.R., STEAD L.F., INTERVENTIONS FOR SMOKING CESSATION IN HOSPITALISED PATIENTS, COCHRANE DATABASE SYST REV, (2012); RICE V.H., HARTMANN-BOYCE J., STEAD L.F., NURSING INTERVENTIONS FOR SMOKING CESSATION, COCHRANE DATABASE SYST REV, (2013); STEAD L.F., KOILPILLAI P., LANCASTER T., ADDITIONAL BEHAVIOURAL SUPPORT AS AN ADJUNCT TO PHARMACOTHERAPY FOR SMOKING CESSATION, COCHRANE DATABASE SYST REV, (2015); FRANCK C., FILION K.B., EISENBERG M.J., SMOKING CESSATION IN PATIENTS WITH ACUTE CORONARY SYNDROME, AM J CARDIOL, 121, PP. 1105-1111, (2018); ECKEL R.H., JAKICIC J.M., ARD J.D., ET AL., 2013 AHA/ACC GUIDELINE ON LIFESTYLE MANAGEMENT TO REDUCE CARDIOVASCULAR RISK: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, PP. S76-S99, (2014); REDUCING RISK IN HEART DISEASE: AN EXPERT GUIDE TO CLINICAL PRACTICE FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE, (2012); KOREAN GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA, (2018); EVIDENCE-BASED RECOMMENDATIONS FOR HYPERTENSION IN PRIMARY CARE, (2018); SOFI F., ABBATE R., GENSINI G.F., CASINI A., ACCRUING EVIDENCE ON BENEFITS OF ADHERENCE TO THE MEDITERRANEAN DIET ON HEALTH: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 92, PP. 1189-1196, (2010); ESTRUCH R., ROS E., SALAS-SALVADO J., ET AL., PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE WITH A MEDITERRANEAN DIET SUPPLEMENTED WITH EXTRA-VIRGIN OLIVE OIL OR NUTS, N ENGL J MED, 378, (2018); SINGH R.B., DUBNOV G., NIAZ M.A., ET AL., EFFECT OF AN INDO-MEDITERRANEAN DIET ON PROGRESSION OF CORONARY ARTERY DISEASE IN HIGH RISK PATIENTS (INDO-MEDITERRANEAN DIET HEART STUDY): A RANDOMISED SINGLE-BLIND TRIAL, LANCET, 360, PP. 1455-1461, (2002); DE LORGERIL M., SALEN P., MARTIN J.L., MONJAUD I., DELAYE J., MAMELLE N., MEDITERRANEAN DIET, TRADITIONAL RISK FACTORS, AND THE RATE OF CARDIOVASCULAR COMPLICATIONS AFTER MYOCARDIAL INFARCTION: FINAL REPORT OF THE LYON DIET HEART STUDY, CIRCULATION, 99, PP. 779-785, (1999); SINGH R.B., RASTOGI S.S., VERMA R., ET AL., RANDOMISED CONTROLLED TRIAL OF CARDIOPROTECTIVE DIET IN PATIENTS WITH RECENT ACUTE MYOCARDIAL INFARCTION: RESULTS OF ONE YEAR FOLLOW UP, BMJ, 304, PP. 1015-1019, (1992); MCGOWAN M.P., PROULX S., NUTRITIONAL SUPPLEMENTS AND SERUM LIPIDS: DOES ANYTHING WORK?, CURR ATHEROSCLER REP, 11, PP. 470-476, (2009); ABDELHAMID A.S., BROWN T.J., BRAINARD J.S., ET AL., OMEGA-3 FATTY ACIDS FOR THE PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 7, (2018); KOTWAL S., JUN M., SULLIVAN D., PERKOVIC V., NEAL B., OMEGA 3 FATTY ACIDS AND CARDIOVASCULAR OUTCOMES: SYSTEMATIC REVIEW AND META-ANALYSIS, CIRC CARDIOVASC QUAL OUTCOMES, 5, PP. 808-818, (2012); RIZOS E.C., ELISAF M.S., DOES SUPPLEMENTATION WITH OMEGA-3 PUFAS ADD TO THE PREVENTION OF CARDIOVASCULAR DISEASE?, CURR CARDIOL REP, 19, (2017); ENNS J.E., YEGANEH A., ZARYCHANSKI R., ET AL., THE IMPACT OF OMEGA-3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION ON THE INCIDENCE OF CARDIOVASCULAR EVENTS AND COMPLICATIONS IN PERIPHERAL ARTERIAL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, BMC CARDIOVASC DISORD, 14, (2014); GONG J., QIN X., YUAN F., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL NUTR FOOD RES, 62, (2018); MARAZZI G., CAMPOLONGO G., PELLICCIA F., ET AL., COMPARISON OF LOW-DOSE STATIN VERSUS LOW-DOSE STATIN + ARMOLIPID PLUS IN HIGH-INTENSITY STATIN-INTOLERANT PATIENTS WITH A PREVIOUS CORONARY EVENT AND PERCUTANEOUS CORONARY INTERVENTION (ADHERENCE TRIAL), AM J CARDIOL, 120, PP. 893-897, (2017); XU K., LIU X., LI Y., ET AL., SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ON-TREATMENT PLATELET REACTIVITY AFTER DRUG-ELUTING STENT IMPLANTATION: TWO-YEAR FOLLOW-UP RESULTS, CARDIOVASC THER, 34, PP. 337-342, (2016); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); YE Y., LI J., YUAN Z., EFFECT OF ANTIOXIDANT VITAMIN SUPPLEMENTATION ON CARDIOVASCULAR OUTCOMES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLOS ONE, 8, (2013); LEE I.M., COOK N.R., GAZIANO J.M., ET AL., VITAMIN E IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER: THE WOMEN'S HEALTH STUDY: A RANDOMIZED CONTROLLED TRIAL, JAMA, 294, PP. 56-65, (2005); LEE I.M., COOK N.R., MANSON J.E., BURING J.E., HENNEKENS C.H., BETA-CAROTENE SUPPLEMENTATION AND INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE: THE WOMEN'S HEALTH STUDY, J NATL CANCER INST, 91, PP. 2102-2106, (1999); LOFFREDO L., PERRI L., DI CASTELNUOVO A., IACOVIELLO L., DE GAETANO G., VIOLI F., SUPPLEMENTATION WITH VITAMIN E ALONE IS ASSOCIATED WITH REDUCED MYOCARDIAL INFARCTION: A META-ANALYSIS, NUTR METAB CARDIOVASC DIS, 25, PP. 354-363, (2015); MYUNG S.K., JU W., CHO B., ET AL., EFFICACY OF VITAMIN AND ANTIOXIDANT SUPPLEMENTS IN PREVENTION OF CARDIOVASCULAR DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 346, (2013); MHEALTH: NEW HORIZONS FOR HEALTH THROUGH MOBILE TECHNOLOGIES: BASED ON THE FINDINGS OF THE SECOND GLOBAL SURVEY ON EHEALTH (GLOBAL OBSERVATORY FOR EHEALTH SERIES, VOLUME 3), (2011); POUSHTER J., SMARTPHONE OWNERSHIP AND INTERNET USAGE CONTINUES TO CLIMB IN EMERGING ECONOMIES, (2016); CLEMENT J., MOBILE INTERNET - STATISTICS & FACTS, (2018); MIKULIC M., NUMBER OF MHEALTH APP DOWNLOADS WORLDWIDE FROM 2013 TO 2017, (2017); CLARK R.A., CONWAY A., POULSEN V., KEECH W., TIRIMACCO R., TIDEMAN P., ALTERNATIVE MODELS OF CARDIAC REHABILITATION: A SYSTEMATIC REVIEW, EUR J PREV CARDIOL, 22, PP. 35-74, (2015); MADDISON R., PFAEFFLI L., WHITTAKER R., ET AL., A MOBILE PHONE INTERVENTION INCREASES PHYSICAL ACTIVITY IN PEOPLE WITH CARDIOVASCULAR DISEASE: RESULTS FROM THE HEART RANDOMIZED CONTROLLED TRIAL, EUR J PREV CARDIOL, 22, PP. 701-709, (2015); BUTLER L., FURBER S., PHONGSAVAN P., MARK A., BAUMAN A., EFFECTS OF A PEDOMETER-BASED INTERVENTION ON PHYSICAL ACTIVITY LEVELS AFTER CARDIAC REHABILITATION: A RANDOMIZED CONTROLLED TRIAL, J CARDIOPULM REHABIL PREV, 29, PP. 105-114, (2009)","G.J. LEE; DEPARTMENT OF REHABILITATION MEDICINE, CHUNGBUK NATIONAL UNIVERSITY HOSPITAL, CHUNGBUK REGIONAL CARDIOCEREBROVASCULAR CENTER, CHUNGBUK NATIONAL UNIVERSITY COLLEGE OF MEDICINE, CHEONGJU, 776, 1SHUNHWAN-RO, 28644, SOUTH KOREA; EMAIL: RMDR29@CBNUH.OR.KR","KOREAN SOCIETY OF CARDIOLOGY","ENGLISH","KOREAN CIRC. J.","REVIEW","ISI","2-S2.0-85076792198","KOREAN CIRC J","INJE UNIVERSITY SCHOOL OF MEDICINE;SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE-HEART VASCULAR STROKE INSTITUTE;DONG-A UNIVERSITY COLLEGE OF MEDICINE-REGIONAL CARDIOCEREBROVASCULAR CENTER;SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL;CHUNGBUK NATIONAL UNIVERSITY HOSPITAL;CHUNGNAM NATIONAL UNIVERSITY COLLEGE OF MEDICINE;CHUNGNAM NATIONAL UNIVERSITY COLLEGE OF MEDICINE;AJOU UNIVERSITY SCHOOL OF MEDICINE;INJE UNIVERSITY SCHOOL OF MEDICINE;UNIVERSITY OF ULSAN COLLEGE OF MEDICINE;DONGGUK UNIVERSITY SCHOOL OF MEDICINE;KYUNG HEE UNIVERSITY COLLEGE OF MEDICINE;CHUNGBUK NATIONAL UNIVERSITY HOSPITAL;SEOUL NATIONAL UNIVERSITY CHILDREN'S HOSPITAL;YONSEI UNIVERSITY COLLEGE OF MEDICINE;NATIONAL TRAFFIC INJURY REHABILITATION HOSPITAL;KOREA UNIVERSITY GURO HOSPITAL;NAMDARUN REHABILITATION CLINIC;INJE UNIVERSITY SCHOOL OF MEDICINE;KOREA UNIVERSITY MEDICAL CENTER;SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE;CHONNAM NATIONAL UNIVERSITY MEDICAL SCHOOL AND HOSPITAL;JEJU NATIONAL UNIVERSITY HOSPITAL;RESEARCH INSTITUTE OF CLINICAL MEDICINE OF CHONBUK NATIONAL UNIVERSITY;CHUNGNAM NATIONAL UNIVERSITY HOSPITAL;KANGWON NATIONAL UNIVERSITY SCHOOL OF MEDICINE;INHA UNIVERSITY HOSPITAL;CATHOLIC UNIVERSITY OF KOREA;KYUNGPOOK NATIONAL UNIVERSITY SCHOOL OF MEDICINE;JEJU NATIONAL UNIVERSITY HOSPITAL;WONKWANG UNIVERSITY SCHOOL OF MEDICINE;INJE UNIVERSITY HAEUNDAE PAIK HOSPITAL;PUSAN NATIONAL UNIVERSITY HOSPITAL;EWHA WOMAN'S UNIVERSITY","NOTREPORTED;CHUNGBUK NATIONAL UNIVERSITY HOSPITAL;NOTREPORTED",NA,"KIM C, 2019, KOREAN CIRC J","KIM C, 2019, KOREAN CIRC J"
"AZIZOVA D;MAVLYANOV I;SABIROVA R;KULMANOVA M;SOLIEV A;ZHARYLKASYNOVA G","AZIZOVA, DILZODA M. (57214590328); MAVLYANOV, ISKANDAR R. (6505781882); SABIROVA, RIKHSI A. (57214603041); KULMANOVA, MUNOZHAT U. (57219285867); SOLIEV, A'ZAMZHON B. (57219280128); ZHARYLKASYNOVA, GAUKHAR ZH. (57219278844)","DEVELOPING NEW APPROACHES TO HYPERLIPIDEMIA CORRECTION TAKING INTO ACCOUNT CHANGES IN FATTY ACIDS STRUCTURE OF BLOOD SERUM",2020,"HEALTH RISK ANALYSIS","2020","11",0,"10.21668/health.risk/2020.2.17.eng","MEDICAL AND BIOLOGICAL CHEMISTRY DEPARTMENT, TASHKENT MEDICAL ACADEMY, 2 FAROBI STR, TASHKENT, 100109, UZBEKISTAN;CLINICAL PHARMACOLOGY DEPARTMENT, REPUBLICAN SCIENTIFIC AND PRACTICAL CENTER FOR SPORT MEDICINE, NATIONAL OLYMPIC COMMITTEE OF UZBEKISTAN, 6 ALMAZAR STR, TASHKENT, 100027, UZBEKISTAN;MEDICAL AND BIOLOGICAL CHEMISTRY DEPARTMENT, TASHKENT MEDICAL ACADEMY, 2 FAROBI STR, TASHKENT, 100109, UZBEKISTAN;MEDICAL AND BIOLOGICAL CHEMISTRY DEPARTMENT, TASHKENT MEDICAL ACADEMY, 2 FAROBI STR, TASHKENT, 100109, UZBEKISTAN;REPUBLICAN SCIENTIFIC AND PRACTICAL CENTER FOR SPORT MEDICINE, NATIONAL OLYMPIC COMMITTEE OF UZBEKISTAN, 6 ALMAZAR STR, TASHKENT, 100027, UZBEKISTAN;DEPARTMENT FOR SKILLS DEVELOPMENT FOR GENERAL PRACTITIONERS, SKILLS DEVELOPMENT FACULTY, BUKHARA STATE MEDICAL INSTITUTE NAMED AFTER ABU ALI IBN SINO, 1 NAVOI AVE, BUKHARA, 200118, UZBEKISTAN","IT IS STILL A PRESSING ISSUE IN CONTEMPORARY MEDICINE TO EXAMINE PATHOGENESIS MECHANISMS AND UPDATE PROCEDURES AIMED AT TREATING ATHEROSCLEROSIS. DEVELOPMENTS BY DOMESTIC AND FOREIGN RESEARCHERS REVEALED THAT COMPLEX MOLECULAR AND CELLULAR STUDIES ON A MECHANISM OF IMPACTS EXERTED BY VEGETATIVE-BASED MEDICATIONS, PRODUCED BOTH DOMESTICALLY AND ABROAD AND USED TO TREAT ATHEROSCLEROSIS, WERE OF PRIMARY IMPORTANCE IN PRACTICAL MEDICINE IN TERMS OF EDUCING POPULATION HEALTH RISKS. IT IS ASSUMED THAT DISORDERS IN FORMATION AND TRANSFER OF NON-ESTERIFIED FATTY ACIDS (NEFA) IN BLOOD PLASMA ARE A MAJOR REASON FOR HYPERTRIGLYCERIDEMIA OCCURRENCE. THE ARTICLE CONTAINS RESEARCH DATA ON LIPID METABOLISM PARAMETERS TAKEN IN DYNAMICS OF EXPERIMENTAL HYPERCHOLESTEROLEMIA DEVELOPMENT. PERFORMED RESEARCH ALLOWED REVEALING HYPOLIPIDEMIC EFFECTS PRODUCED BY A BIOLOGICALLY ACTIVE ADDITIVE CALLED BIOMAYS. WE DEVELOPED THEORETICAL GROUNDS FOR RECOMMENDATIONS THAT SHOULD BE GIVEN TO PATIENTS SUFFERING FROM HYPERLIPIDEMIA AND NOT GETTING PROPER THERAPEUTIC EFFECTS FORM TREATMENT WITH STATINS. WE RECOMMEND A COMPLEX APPROACH WHICH INCLUDES A BAA (BIOLOGICALLY ACTIVE ADDITIVE) BIOMAYS MADE OF DRIED WHEAT SPROUTS IN ORDER TO REDUCE RISKS CAUSED BY COMPLICATIONS RELATED TO TREATMENT WITH STATINS. OUR RESEARCH GOAL WAS TO DEVELOP NEW APPROACHES TO CORRECTING HYPERLIPIDEMIA BASING ON CHANGES IN FATTY ACIDS STRUCTURE OF BLOOD SERUM. THE EXPERIMENTS WERE PERFORMED ON 30 MALE RABBITS BELONGING TO CHINCHILLA BREED WITH INITIAL BODY MASS EQUAL TO 2,500-3,00 GRAMS; ANIMALS WERE DIVIDED INTO 5 GROUPS, 6 ANIMALS IN EACH, DEPENDING ON A RESEARCH GOAL AND TREATMENT PROCEDURES. WE STARTED A 30-DAY TREATMENT OF EXPERIMENTAL ANIMALS WITH ULTROX AND BIOMAYS IN DOSES EQUAL TO 0.6 MG/KG AND 142 MG/KG ACCORDINGLY AFTER THEY HAD BEEN GIVEN CHOLESTEROL FOR 2 MONTHS. WE DETERMINED FATTY ACIDS STRUCTURE OF BLOOD SERUM WITH A TRIPLE QUADRUPOLE CHROMATO-MASS-SPECTROMETER WITH GAS CHROMATOGRAPHER (GC-MS/MS) TRACE 1310 TSQ 8000 AND AUTOMATED AUTOSAMPLER CTC TRIPLUS RSH PRODUCED BY THERMO FISHER SCIENTIFIC (THE USA).COMBINED APPLICATION OF ULTROX AND BIOMAYS LED TO MORE SIGNIFICANT HYPOLIPIDEMIC EFFECTS. USE OF STATINS AND WHEAT SPROUTS HAD A DISTINCT POSITIVE EFFECT ON CONTENTS OF SATURATED AND POLY-UNSATURATED FATTY ACIDS N BLOOD SUCH AS LINOLEIC ACID AND LINOLENIC ACID. © AZIZOVA D.M., MAVLYANOV I.R., SABIROVA R.A., KULMANOVA M.U., SOLIEV A.B., ZHARYLKASYNOVA G.ZH., 2020.","BIOMAYS BIOLOGICALLY ACTIVE ADDITIVE; FATTY ACIDS; GAS CHROMATOGRAPHY; HYPERLIPIDEMIA; MASS-SPECTROMETRY; POLICOSANOL; WATER-SOLUBLE VITAMINS","","","","OGANOV R.G., PROFILAKTIKA SERDECHNO-SOSUDISTYKH ZABOLEVANII VRACHA OBSHCHEI PRAKTIKI, KARDIOLOGIYA UZBEKISTANA, 1, PP. 17-20, (2006); GRAHAM I., ATAR D., BORCH-JOHNSEN K., BOYSEN G., BURELL G., CIFKOVA R., DALLONGEVILLE J., DE BACKER G., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE:EXECUTIVE SUMMARY: FOURTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR. HEART. J., 28, 19, PP. 2375-2414, (2007); GRUNDY S.M., CLEEMAN J.I., MERZ C.N., BREWER H.B., CLARK L.T., HUNNINGHAKE D.B., PASTERNAK R.C., SMITH S.C., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, 2, PP. 227-239, (2004); INNIS S.M., GREEN T.J., HALSEY T.K., VARIABILITY IN THE TRANS FATTY ACID CONTENT OF FOODS WITHIN A FOOD CATEGORY: IMPLICATIONS FOR ESTIMATION OF DIETARY TRANS FATTY ACID INTAKES, J. AM. COLL. NUTR., 18, PP. 255-260, (1999); KAVANAGH K., JONES K.L., SAWYER J., KELLEY K., CARR J.J., WAGNER J.D., RUDEL L.L., TRANS FAT DIET INDUCES ABDOMINAL OBESITY AND CHANGES IN INSULIN SENSITIVITY IN MONKEYS, OBESITY (SILVER SPRING), 15, 7, PP. 1675-1684, (2007); TITOV V.N., PHYLOGENETICALLY THEORY OF GENERAL PATHOLOGY, NUTRITIVE DISTURBANCE IS THE BASIS OF METABOLIC SYNDROME PATHOGENESIS, OVEREATING SYNDROME. LEPTIN AND ADIPONECTIN ROLE, EUR. J. MED., 1, 1, PP. 48-60, (2013); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, 19, PP. 2486-2497, (2001); VAN TOL A., ZOCK P.L., VAN GENT T., SCHEEK L.M., KATAN M.B., DIETARY TRANS FATTY ACIDS INCREASE SERUM CHOLESTERYLESTER TRANSFER PROTEIN ACTIVITY IN MAN, ATHEROSCLEROSIS, 115, 1, PP. 129-134, (1995); ZARODYSH PSHENITSY, MIRAGRO; ERKKILA A.T., LICHTENSTEIN A.H., MOZAFFARIAN D., HERRINGTON D.M., FISH INTAKE IS ASSOCIATED WITH A REDUCED PROGRESSION OF SORONARY ARTERY ATHEROSCLEROSIS IN POSTMENOPAUSAL WOMEN WITH CORONARY ARTERY DISEASE, AM. J. CLIN. NUTR., 80, 3, PP. 626-632, (2004); TITOV V.N., LISITSYN D.M., PLASMA CONTENT OF CHOLESTEROL AND GLYCEROL ALCOHOLS DEPENDS ON THE NUMBER OF FATTY ACID DOUBLE BONDS IN LIPOPROTEIN LIPID POOL, BULL. EXP. BIOL. MED., 142, 5, PP. 577-580, (2006); GUSEVA D.A., PROZOROVSKAYA N.N., SHIRONIN A.V., ANTIOKSIDANTNAYA AKTIVNOST' RASTITEL'NYKH MASEL S RAZNYM SOOTNOSHENIEM OMEGA-6 I OMEGA-3 ZHIRNYKH KISLOT, BIOMEDITSINSKAYA KHIMIYA, 3, PP. 342-350, (2010); KURBANOV R.D., PERSPEKTIVY RAZVITIYA KARDIOLOGII V UZBEKISTANE, MEDITSINSKII ZHURNAL UZBEKISTANA, 3, 2, PP. 10-12, (2002); MAKAROV V.I., BELYAKOV N.A., PRODUKTY PITANIYA FUNKTSIONAL'NOGO NAZNACHENIYA. METODY LECHENIYA FUNCTIONAL FOOD PRODUCTS. TREATMENT PROCEDURES, (2013); ISSLEDOVANIE EFFEKTIVNOSTI MASLA ZARODYSHEI PSHENITSY RESEARCH ON EFFICIENCY OF WHEAT GERM OIL, (2004); DASHTI N., FENG Q., FREEMAN M.R., GANDHI M., FRANKLIN F.A., TRANS POLYUNSATURATED FATTY ACIDS HAVE MORE ADVERSE EFFECTS THAN SATURATED FATTY ACIDS ON THE CONCENTRATION AND COMPOSITION OF LIPOPROTEINS SECRETED BY HUMAN HEPATOMA HEPG2 CELLS, J. NUTR., 132, 9, PP. 2651-2659, (2002); MARISCALCO G., SARZI BRAGA S., BANACH M., BORSANI P., BRUNO V.D., NAPOLEONE M., VITALE C., PIFFARETTI G., ET AL., PREOPERATIVE N-3 POLYUNSATURED FATTY ACIDS ARE ASSOCIATED WITH A DECREASE IN THE INCIDENCE OF EARLY ATRIAL FIBRILLATION FOLLOWING CARDIAC SURGERY, ANGIOLOGY, 61, 7, PP. 643-650, (2010); CHAZOV E.I., PROBLEMYPERVICHNOIIVTORICHNOIPROFILAKTIKISERDECHNO-SOSUDISTYKHZABOLEVANII V ROSSIII SNG, KARDIOLOGIYA UZBEKISTANA, 1, PP. 15-17, (2006); ARRUZAZABALA M., CARBAJAL D., MOLINA V., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE AZ. PROSTAGLANDINS, LEUKO. ESSENT. FATTY ACIDS, 49, 3, PP. 695-697, (2012); ARRUZAZABALA M., VALDES S., MAS R., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE IN PLATELET AGGREGATION HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, 5-6, PP. 181-185, (2013); RAGINO Y.I., VAVILIN V.A., SALAKHUTDINOV N.F., MAKAROVA S.I., STAKHNEVA E.M., SAFRONOVA O.G., IZUCHENIE ANTIATEROGENNYKH EFFEKTOV SIMVAGLI NA MODELI GIPERKHOLESTERINEMII U KROLIKOV, ATEROSKLEROZ, 6, 1, PP. 5-11; LEE H.Y., WOO J., CHEN Z.Y., LEUNG S.F., PENG X.H., SERUM FATTY ACID, LIPID PROFILE AND DIETARY INTAKE OF HONG KONG CHINESE OMNIVORES AND VEGETARIANS, EUR. J. CLIN. NUTR., 54, 10, PP. 768-773, (2000); ARIEL A., SERHAN C., RESOLVINS AND PROTECTINS IN THE TERMINATION PROGRAM OF ACUTE INFLAMMATION, TRENDS IMMUNOL, 28, 4, PP. 176-183, (2011); ARRUZAZABALA M., CARBAJAL D., MAS R., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES, 36, 4, PP. 293-297, (2010); ANICHKOV N.N., KHALATOV S.S., NOVYE DANNYE PO VOPROSU O PATOLOGII I ETIOLOGII ATEROSKLEROZA, RUSSKII VRACH, 8, PP. 184-186, (1913); AZIZOVA D.M., SABIROVA R.A., KULMANOVA M.U., EFFECTS OF BIOMAISE ON ATEROGENIC PLASMA INDEX DURING THE DEVELOPMENT OF EXPERIMENTAL HYPERHOLESTERYNEMIA, MEDITSINSKIE NOVOSTI, 7, PP. 78-80, (2019); LANKIN V.Z., TIKHAZE A.K., KUKHARCHUK V.V., ANTIOKSIDANTY V PROFILAKTIKE I KOMPLEKSNOI TERAPII ATEROSKLEROZA, FUNDAMENTAL'NYE ISSLEDOVANIYA I PROGRESS KARDIOLOGII: SBORNIK TRUDOV NAUCHNOI SESSII, PP. 141-146, (2002); BROCHOT A., GUINOT M., AUCHERE D., EFFECTS OF ALPHA-LINOLENIC ACID VS. DOCOSAHEXAENOIC ACID SUPPLY ON THE DISTRIBUTION OF FATTY ACIDS AMONG THE RAT CARDIAC SUBCELLULAR MEMBRANES AFTER A SHORT-OR LONG-TERM DIETARY EXPOSURE, NUTR. METAB. (LOND), 10, 3, PP. 115-119, (2013); LEFEVRE M., CHAMPAGNE C.M., TULLEY R.T., ROOD J.C., MOST M.M., INDIVIDUAL VARIABILITY IN CARDIOVASCULAR DISEASE RISK FACTOR RESPONSES TO LOW-FAT AND LOW-SATURATED-FAT DIETS IN MEN: BODY MASS INDEX, ADIPOSITY, AND INSULIN RESISTANCE PREDICT CHANGES IN LDL CHOLESTEROL, AM. J. CLIN. NUTR., 82, 5, PP. 957-963, (2005); HIPPISLEY-COX J., COUPLAND C., UNINTENDED EFFECTS OF STATINS IN MEN AND WOMEN IN ENGLAND AND WALES: POPULATION BASED COHORT STUDY USING THE Q RESEARCH DATABASE, BMJ, 340, (2010); MOZAFFARIAN D., CAO H., KING I.B., LEMAITRE R.N., SONG X., SISCOVICK D.S., HOTAMISLIGIL G.S., TRANS-PALMITOLEIC ACID, METABOLIC RISK FACTORS, AND NEW-ONSET DIABETES IN U.S. ADULTS: A COHORT STUDY, ANN. INTERN. MED., 153, 12, PP. 790-799, (2010); KON' I.Y., ISPOL'ZOVANIE POLINENASYSHCHENNYKH ZHIRNYKH KISLOT V PITANII ZDOROVYKH DETEI, LECHASHCHII VRACH, 1, PP. 42-47, (2011); GAPPAROV M.G., FUNKTSIONAL'NYE PRODUKTY PITANIYA, PISHCHEVAYA PROMYSHLENNOST', 3, PP. 11-12, (2013); TITOV V.N., AMELYUSHKINA V.A., ROZHKOVA T.A., THE CONFORMATION OF APOB-100 IN PHYLOGENETICALLY AND FUNCTIONALLY DIFFERENT LIPOPROTEINS OF LOW AND VERY LOW DENSITY: ALGORITHM OF FORMATION OF PHENOTYPES OF HYPER LIPOPROTEINIMIA (A LECTURE), KLINICHESKAYA LABORATORNAYA DIAGNOSTIKA, 1, PP. 27-38, (2014); MAZIDI M., GAO H.K., VATANPARAST H., KENGNE A.P., IMPACT OF THE DIETARY FATTY ACID INTAKE ON C-REACTIVE PROTEIN LEVELS IN US ADULTS, MEDICINE (BALTIMORE), 96, 7, (2017); MOZAFFARIAN D., DE OLIVEIRA OTTO M.C., LEMAITRE R.N., FRETTS A.M., HOTAMISLIGIL G., TSAI M.Y., SISCOVICK D.S., NETTLETON J.A., TRANS-PALMITOLEIC ACID, OTHER DAIRY FAT BIOMARKERS, AND INCIDENT DIABETES:THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), AM. J. CLIN. NUTR., 97, 4, PP. 854-861, (2013); MAZIDI M., MICHOS E.D., BANACH M., THE ASSOCIATION OF TELOMERE LENGTH AND SERUM 25-HYDROXYVITAMIN D LEVELS IN US ADULTS: THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, ARCH. MED. SCI., 13, 1, PP. 61-65, (2017); MENSINK R.P., ZOCK P.L., KESTER A.D., KATAN M.B., EFFECTS OF DIETARY FATTY ACIDS AND CARBOHYDRATES ON THE RATIO OF SERUM TOTAL TO HDL CHOLESTEROL AND ON SERUM LIPIDS AND APOLIPOPROTEINS:A META-ANALYSIS OF 60 CONTROLLED TRIALS, AM. J. CLIN. NUTR., 77, 5, PP. 1146-1155, (2003); KLEIN-PLATAT C., DRAI J., OUJAA M., SCHLIENGER J.L., SIMON C., PLASMA FATTY ACID COMPOSITION IS ASSOCIATED WITH THE METABOLIC SYNDROME AND LOW-GRADE INFLAMMATION IN OVERWEIGHT ADOLESCENTS, AM. J. CLIN. NUTR., 82, 6, PP. 1178-1184, (2005); ARRUZAZABALA M., CARBAJAL D., MOLINA V., EFFECT OF POLICOSANOL ON CEREBRAL ISCHCMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE AZ, PROSTAGLANDINS LEUKOT & ESSENT. FATTY ACIDS, 49, PP. 695-697, (2012); MICHA R., MOZAFFARIAN D., TRANS FATTY ACIDS: EFFECTS ON METABOLIC SYNDROME, HEART DISEASE AND DIABETES, NAT. REV. ENDOCRINOL., 5, 6, PP. 335-344, (2009); VEGA-LOPEZ S., AUSMAN L.M., JALBERT S.M., ERKKILA A.T., LICHTENSTEIN A.H., PALM AND PARTIALLY HYDROGENATED SOYBEAN OILS ADVERSELY ALTER LIPOPROTEIN PROFILES COMPARED WITH SOYBEAN AND CANOLA OILS IN MODERATELY HYPERLIPIDEMIC SUBJECTS, AM J. CLIN. NUTR., 84, 1, PP. 54-62, (2006); VON SCHACKY C., ANGERER P., KOTHNY W., MUDRA H., THE EFFECT OF DIETARY OMEGA-3 FATTY ACIDS ON CORONARY ATHEROSCLEROSIS. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ANN. INTERN. MED., 130, 7, PP. 554-622, (1999); CHAJES V., THIEBAUT A.C., ROTIVAL M., GAUTHIER E., MAILLARD V., BOUTRON-RUAULT M.-C., JOULIN V., LENOIR G.M., CLAVEL-CHAPELON F., ASSOCIATION BETWEEN SERUM TRANS-MONOUNSATURATED FATTY ACIDS AND BREAST CANCER RISK IN THE E3N-EPIC STUDY, AM. J. EPIDEMIOL., 167, PP. 1312-1320, (2008); IMAMURA F., MICHA R., WU J.H., DE OLIVEIRA OTTO M.C., OTITE F.O., ABIOYE A.I., MOZAFFARIAN D., EFFECTS OF SATURATED FAT, POLYUNSATURATED FAT, MONOUNSATURATED FAT, AND CARBOHYDRATE ON GLUCOSE-INSULIN HOMEOSTASIS: A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMISED CONTROLLED FEEDING TRIALS, PLOS MED, 13, 7, (2016); MAZIDI M., KENGNE A.P., BANACH M., MINERAL AND VITAMINS CONSUMPTION IS ASSOCIATED WITH LONGER TELOMERES AMONG US ADULTS, POL. ARCH. MED. WEWN., 127, 2, PP. 87-90, (2017)","","FEDERAL SCIENTIFIC CENTER FOR MEDICAL AND PREVENTIVE HEALTH RISK MANAGEMENT TECHNOLOGIES","ENGLISH","HEALTH RISK ANAL.","ARTICLE","ISI","2-S2.0-85092052684","HEALTH RISK ANAL",NA,"NOTREPORTED",NA,"AZIZOVA DM, 2020, HEALTH RISK ANAL","AZIZOVA DM, 2020, HEALTH RISK ANAL"
"KIM S;YADAV D;PARK H;KIM J;CHO K","KIM, SUK-JEONG (57193310178); YADAV, DHANANJAY (55779022200); PARK, HYE-JEONG (57201722508); KIM, JAE-RYONG (7601360934); CHO, KYUNG-HYUN (7403956966)","LONGTERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES LIPID PROFILE WITH ENHANCEMENT OF LIPOPROTEIN PROPERTIES IN HEALTHY KOREAN PARTICIPANTS",2018,"FRONTIERS IN PHYSIOLOGY","9","",25,"10.3389/fphys.2018.00412","DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, SMART-AGING CONVERGENCE RESEARCH CENTER, COLLEGE OF MEDICINE, YEUNGNAM UNIVERSITY, DAEGU, SOUTH KOREA;DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, LIPOLAB, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA","METABOLIC SYNDROME IS CLOSELY ASSOCIATED WITH HIGHER RISK OF HYPERTENSION, CARDIOVASCULAR DISEASE (CVD), DIABETES AND STROKE. THE AIM OF THE PRESENT STUDY WAS TO INVESTIGATE THE LONG-TERM EFFECTS OF POLICOSANOL SUPPLEMENTATION ON BLOOD PRESSURE (BP) AND THE LIPID PROFILE IN HEALTHY KOREAN PARTICIPANTS WITH PRE-HYPERTENSION (SYSTOLIC 120-139 MMHG, DIASTOLIC 85-89 MMHG). THIS RANDOMIZED, DOUBLE-BLINDED, AND PLACEBO-CONTROLLED TRIAL INCLUDED 84 HEALTHY PARTICIPANTS WHO WERE RANDOMLY ASSIGNED TO THREE GROUPS RECEIVING 10 MG OF POLICOSANOL, 20 MG OF POLICOSANOL, OR PLACEBO FOR 24 WEEKS. THE BP, LIPID PROFILE, AND ANTHROPOMETRIC FACTORS WERE MEASURED PRE- AND POST-INTERVENTION AND THEN COMPARED. BASED ON AN AVERAGE OF THREE MEASUREMENTS OF BRACHIAL BP, THE POLICOSANOL 20 MG GROUP SHOWED THE MOST SIGNIFICANT REDUCTION IN AVERAGE SYSTOLIC BP (SBP) FROM 140 ± 12 MMHG AT WEEK 0 TO 126 ± 13 MMHG AT WEEK 24 (P < 0.0001). THE POLICOSANOL 20 MG GROUP ALSO SHOWED SIGNIFICANT REDUCTIONS IN AORTIC SBP AND DBP UP TO 9% (P = 0.00057) AND 8% (P = 0.004), RESPECTIVELY COMPARED WITH WEEK 0. ADDITIONALLY, BLOOD RENIN AND ALDOSTERONE LEVELS WERE SIGNIFICANTLY REDUCED IN THE POLICOSANOL 20 MG GROUP UP TO 63% (P < 0.01) AND 42% (P < 0.05), RESPECTIVELY, AT WEEK 24. FOR THE BLOOD LIPID PROFILE, THE POLICOSANOL 10 MG AND 20 MG GROUPS SHOWED SIGNIFICANT REDUCTIONS IN TOTAL CHOLESTEROL (TC) OF AROUND 8% (P = 0.029) AND 13% (P = 0.0004), RESPECTIVELY, AT WEEK 24 COMPARED WITH WEEK 0. SERUM HDL-C LEVEL SIGNIFICANTLY INCREASED UP TO 16% AND 12% IN THE POLICOSANOL 10 MG (P = 0.002) AND 20 MG (P = 0.035) GROUP, RESPECTIVELY. THE STUDY RESULTS SUGGEST THAT LONG-TERM POLICOSANOL CONSUMPTION SIMULTANEOUSLY REDUCES PERIPHERAL BP AS WELL AS AORTIC BP ACCOMPANIED BY ELEVATION OF HDL-C AND % HDL-C IN TC IN A DOSE-DEPENDENT MANNER. © 2018 KIM, YADAV, PARK, KIM AND CHO.","APOLIPOPROTEIN A-I; BLOOD PRESSURE; GLYCATION; LIPOPROTEINS; POLICOSANOL","ALDOSTERONE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; POLICOSANOL; RENIN; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; AORTIC PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG USE; FEMALE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; KOREAN (PEOPLE); LIPID COMPOSITION; LIPID OXIDATION; LONG TERM EXPOSURE; LONGITUDINAL STUDY; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PREHYPERTENSION; PROTEIN GLYCOSYLATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TOTAL CHOLESTEROL LEVEL","MEDICAL RESEARCH CENTER, (2015R1A5A2009124); NATIONAL RESEARCH FOUNDATION; NATIONAL RESEARCH FOUNDATION, NRF; MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING, MSIP","THIS WORK WAS SUPPORTED BY A GRANT FROM THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF), FUNDED BY THE MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING OF KOREA.","ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES, 33, PP. 835-840, (2000); ATLAS S.A., THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM: PATHOPHYSIOLOGICAL ROLE AND PHARMACOLOGIC INHIBITION, J. MANAG. CARE PHARM, 13, PP. 9-20, (2007); BLOIS M.S., ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R. D, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CUR. THER. RES, 60, PP. 379-391, (1999); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM. HEART J, 152, (2006); DHAKAM Z., MCENIERY C.M., YASMIN COCKCROFT J.R., BROWN M.J., WILKINSON I.B., ATENOLOL AND EPROSARTAN: DIFFERENTIAL EFFECTS ON CENTRAL BLOOD PRESSURE AND AORTIC PULSE WAVE VELOCITY, AM. J. HYPERTENS, 19, PP. 214-219, (2006); EREN E., YILMAZ N., AYDIN O., HIGH DENSITY LIPOPROTEIN AND IT'S DYSFUNCTION, OPEN BIOCHEM. J, 6, PP. 78-93, (2012); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT. THER. MED, 16, PP. 61-65, (2008); GONG J., QIN X., YUAN F., HU M., CHEN G., FANG K., ET AL., EFFICACY AND SAFETY OF SUGARCANE POLICOSANOL ON DYSLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MOL. NUTR. FOOD RES, 62, (2018); HALPERIN R.O., SESSO H.D., MA J., BURING J.E., STAMPFER M.J., GAZIANO J.M., DYSLIPIDEMIA AND THE RISK OF INCIDENT HYPERTENSION IN MEN, HYPERTENSION, 47, PP. 45-50, (2006); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J. CLIN. INVEST, 34, (1955); HIRANO M., NAKANISHI S., KUBOTA M., MAEDA S., YONEDA M., YAMANE K., ET AL., LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IS A SIGNIFICANT RISK FACTOR FOR DEVELOPMENT OF TYPE 2 DIABETES: DATA FROM THE HAWAII-LOS ANGELES-HIROSHIMA STUDY, J. DIABETES INVESTIG, 5, PP. 501-506, (2014); HOLVOET P., DE KEYZER D., JACOBS D.R., OXIDIZED LDL AND THE METABOLIC SYNDROME, FUTURE LIPIDOL, 3, PP. 637-649, (2008); HSU C.H., CHANG J.B., LIU I.C., LAU S.C., YU S.M., HSIEH C.H., ET AL., MEAN ARTERIAL PRESSURE IS BETTER AT PREDICTING FUTURE METABOLIC SYNDROME IN THE NORMOTENSIVE ELDERLY: A PROSPECTIVE COHORT STUDY IN TAIWAN, PREV. MED, 72, PP. 76-82, (2015); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE? (POLICOSANOL), ALTERN. MED. REV, 7, PP. 203-218, (2002); KASHYAP S.R., OSME A., ILCHENKO S., GOLIZEH M., LEE K., WANG S., ET AL., GLYCATION REDUCES THE STABILITY OF APOAI AND INCREASES HDL DYSFUNCTION IN DIET-CONTROLLED TYPE 2 DIABETES, J. CLIN. ENDOCRINOL. METAB, 103, PP. 388-396, (2017); KIM J.Y., KIM S.M., KIM S.J., LEE E.Y., KIM J.R., CHO K.H., CONSUMPTION OF POLICOSANOL ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLE-AGED SUBJECTS, INT. J. MOL. MED, 39, PP. 889-899, (2017); KIM Y., LEE S., PREVALENCE AND RISK FACTORS ASSOCIATED WITH PREHYPERTENSION BY GENDER AND AGE IN A KOREAN POPULATION IN THE KNHANES 2010-2012, IRAN. J. PUBLIC HEALTH, 44, PP. 1594-1602, (2015); LEE E.Y., YOO J.A., LIM S.M., CHO K.H., ANTI-AGING AND TISSUE REGENERATION ABILITY OF POLICOSANOL ALONG WITH LIPID-LOWERING EFFECT IN HYPERLIPIDEMIC ZEBRAFISH VIA ENHANCEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, REJUVENATION RES, 19, PP. 149-158, (2016); LEE J.S., CHANG P.Y., ZHANG Y., KIZER J.R., BEST L.G., HOWARD B.V., TRIGLYCERIDE AND HDL-C DYSLIPIDEMIA AND RISKS OF CORONARY HEART DISEASE AND ISCHEMIC STROKE BY GLYCEMIC DYSREGULATION STATUS: THE STRONG HEART STUDY, DIABETES CARE, 40, PP. 529-537, (2017); LI W.Y., WANG X.H., LU L.C., LI H., DISCREPANCY OF BLOOD PRESSURE BETWEEN THE BRACHIAL ARTERY AND RADIAL ARTERY, WORLD J. EMERG. MED, 4, PP. 294-297, (2013); LONDON G.M., ASMAR R.G., O'ROURKE M.F., SAFAR M.E., INVESTIGATORS R.P., MECHANISM (S) OF SELECTIVE SYSTOLIC BLOOD PRESSURE REDUCTION AFTER A LOW-DOSE COMBINATION OF PERINDOPRIL/INDAPAMIDE IN HYPERTENSIVE SUBJECTS: COMPARISON WITH ATENOLOL, J. AM. COLL. CARDIOL, 43, PP. 92-99, (2004); MACKENZIE I.S., MCENIERY C.M., DHAKAM Z., BROWN M.J., COCKCROFT J.R., WILKINSON I.B., COMPARISON OF THE EFFECTS OF ANTIHYPERTENSIVE AGENTS ON CENTRAL BLOOD PRESSURE AND ARTERIAL STIFFNESS IN ISOLATED SYSTOLIC HYPERTENSION, HYPERTENSION, 54, PP. 409-413, (2009); MARKWELL M.A., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM, 87, PP. 206-210, (1978); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); MCENIERY C.M., COCKCROFT J.R., ROMAN M.J., FRANKLIN S.S., WILKINSON I.B., CENTRAL BLOOD PRESSURE: CURRENT EVIDENCE AND CLINICAL IMPORTANCE, EUR. HEART J, 35, PP. 1719-1725, (2014); MCGROWDER D., RILEY C., MORRISON E.Y.S.A., GORDON L., THE ROLE OF HIGH-DENSITY LIPOPROTEINS IN REDUCING THE RISK OF VASCULAR DISEASES, NEUROGENERATIVE DISORDERS, AND CANCER, CHOLESTEROL, 2011, (2010); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); MITCHELL G.F., LACOURCIERE Y., OUELLET J.P., IZZO J.L., NEUTEL J., KERWIN L.J., ET AL., DETERMINANTS OF ELEVATED PULSE PRESSURE IN MIDDLE-AGED AND OLDER SUBJECTS WITH UNCOMPLICATED SYSTOLIC HYPERTENSION, CIRCULATION, 108, PP. 1592-1598, (2003); MORGAN T., LAURI J., BERTRAM D., ANDERSON A., EFFECT OF DIFFERENT ANTIHYPERTENSIVE DRUG CLASSES ON CENTRAL AORTIC PRESSURE, AM. J. HYPERTENS, 17, PP. 118-123, (2004); NAWALE R.B., MOURYA V.K., BHISE S.B., NON-ENZYMATIC GLYCATION OF PROTEINS: A CAUSE FOR COMPLICATIONS IN DIABETES, INDIAN J. BIOCHEM. BIOPHYS, 43, PP. 337-344, (2006); NELSON R.H., HYPERLIPIDEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE, PRIM. CARE, 40, PP. 195-211, (2013); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J. PHARM. PHARMACOL, 47, PP. 289-291, (1995); NOA M., DE LA ROSA M., MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J. PHARM. PHARMACOL, 48, PP. 306-309, (1996); PARK K.H., JANG W., KIM K.Y., KIM J.R., CHO K.H., FRUCTATED APOLIPOPROTEIN A-I SHOWED SEVERE STRUCTURAL MODIFICATION AND LOSS OF BENEFICIAL FUNCTIONS IN LIPID-FREE AND LIPID-BOUND STATE WITH ACCELERATION OF ATHEROSCLEROSIS AND SENESCENCE, BIOCHEM. BIOPHYS. RES. COMMUN, 392, PP. 295-300, (2010); PERTICONE F., CERAVOLO R., PUJIA A., VENTURA G., IACOPINO S., SCOZZAFAVA A., ET AL., PROGNOSTIC SIGNIFICANCE OF ENDOTHELIAL DYSFUNCTION IN HYPERTENSIVE PATIENTS, CIRCULATION, 104, PP. 191-196, (2001); REITZ C., TANG M.X., SCHUPF N., MANLY J.J., MAYEUX R., LUCHSINGER J.A., ASSOCIATION OF HIGHER LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ELDERLY INDIVIDUALS AND LOWER RISK OF LATE-ONSET ALZHEIMER DISEASE, ARCH. NEUROL, 67, PP. 1491-1497, (2010); ROHATGI A., KHERA A., BERRY J.D., GIVENS E.G., AYERS C.R., WEDIN K.E., ET AL., HDL CHOLESTEROL EFFLUX CAPACITY AND INCIDENT CARDIOVASCULAR EVENTS, NEW ENGL. J. MED, 371, PP. 2383-2393, (2014); SAHEBKAR A., SERBAN M.C., GLUBA-BRZOZKA A., MIKHAILIDIS D.P., CICERO A.F., RYSZ J., ET AL., LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH, NUTRITION, 32, PP. 1179-1192, (2016); SESSO H.D., STAMPFER M.J., ROSNER B., HENNEKENS C.H., GAZIANO J.M., MANSON J.E., ET AL., SYSTOLIC AND DIASTOLIC BLOOD PRESSURE, PULSE PRESSURE, AND MEAN ARTERIAL PRESSURE AS PREDICTORS OF CARDIOVASCULAR DISEASE RISK IN MEN, HYPERTENSION, 36, PP. 801-807, (2000); SHARMAN J.E., MARWICK T.H., GILROY D., OTAHAL P., ABHAYARATNA W.P., STOWASSER M., RANDOMIZED TRIAL OF GUIDING HYPERTENSION MANAGEMENT USING CENTRAL AORTIC BLOOD PRESSURE COMPAREDWITH BEST-PRACTICE CARE: PRINCIPAL FINDINGS OF THE BP GUIDE STUDY, HYPERTENSION, 62, PP. 1138-1145, (2013); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); TOMASCHITZ A., MAERZ W., PILZ S., RITZ E., SCHARNAGL H., RENNER W., ET AL., ALDOSTERONE/RENIN RATIO DETERMINES PERIPHERAL AND CENTRAL BLOOD PRESSURE VALUES OVER A BROAD RANGE, J. AM. COLL. CARDIOL, 55, PP. 2171-2180, (2010); TOMASCHITZ A., PILZ S., RITZ E., OBERMAYER-PIETSCH B., PIEBER T.R., ALDOSTERONE AND ARTERIAL HYPERTENSION, NAT. REV. ENDOCRINOL, 6, PP. 83-93, (2010); VLACHOPOULOS C., AZNAOURIDIS K., O'ROURKE M.F., SAFAR M.E., BAOU K., STEFANADIS C., PREDICTION OF CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY WITH CENTRAL HAEMODYNAMICS: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR. HEART J, 31, PP. 1865-1871, (2010); WANG Y., CHEN S., YAO T., LI D., WANG Y., LI Y., ET AL., HOMOCYSTEINE AS A RISK FACTOR FOR HYPERTENSION: A 2-YEAR FOLLOW-UP STUDY, PLOS ONE, 9, (2014); WILLIAMS B., LACY P.S., THOM S.M., CRUICKSHANK K., STANTON A., COLLIER D., ET AL., DIFFERENTIAL IMPACT OF BLOOD PRESSURE-LOWERING DRUGS ON CENTRAL AORTIC PRESSURE AND CLINICAL OUTCOMES: PRINCIPAL RESULTS OF THE CONDUIT ARTERY FUNCTION EVALUATION (CAFE) STUDY, CIRCULATION, 113, PP. 1213-1225, (2006); YADAV D., HYUN D.S., AHN S.V., KOH S.B., KIM J.Y., A PROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN TOTAL SLEEP DURATION AND INCIDENT HYPERTENSION, J. CLIN. HYPERTENS, 19, PP. 550-557, (2017); YADAV D., KIM S.J., KIM J.R., CHO K.H., CORRELATION AMONG LIPID PARAMETERS, PULSE WAVE VELOCITY AND CENTRAL BLOOD PRESSURE IN YOUNG KOREAN POPULATION, CLIN. EXP. HYPERTENS, (2018); YANG B., FAN S., ZHI X., HE J., MA P., YU L., ET AL., INTERACTIONS OF HOMOCYSTEINE AND CONVENTIONAL PREDISPOSING FACTORS ON HYPERTENSION IN CHINESE ADULTS, J. CLIN. HYPERTENS, 19, PP. 1162-1170, (2017); ZACHARIEVA S., KIRILOV G., ORBETZOVA M., ELENKOVA A., SHIGARMINOVA R., LOZANOV V., ET AL., HOMOCYSTEINE, RENIN AND ALDOSTERONE IN PATIENTS WITH CUSHING'S SYNDROME, METHODS FIND. EXP. CLIN. PHARMACOL, 30, PP. 221-224, (2008)","K.-H. CHO; DEPARTMENT OF MEDICAL BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","FRONTIERS MEDIA S.A.","ENGLISH","FRONT. PHYSIOL.","ARTICLE","ISI","2-S2.0-85045936600","FRONT PHYSIOL","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"KIM S-J, 2018, FRONT PHYSIOL","KIM S-J, 2018, FRONT PHYSIOL"
"PIRRO M;MANNARINO M;BIANCONI V;SIMENTAL-MENDÍA L;BAGAGLIA F;MANNARINO E;SAHEBKAR A","PIRRO, MATTEO (22036502300); MANNARINO, MASSIMO RAFFAELE (26643162800); BIANCONI, VANESSA (57188676466); SIMENTAL-MENDÍA, LUIS E. (56013552700); BAGAGLIA, FRANCESCO (6507029663); MANNARINO, ELMO (26643283400); SAHEBKAR, AMIRHOSSEIN (26639699900)","THE EFFECTS OF A NUTRACEUTICAL COMBINATION ON PLASMA LIPIDS AND GLUCOSE A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2016,"PHARMACOLOGICAL RESEARCH","110","12",86,"10.1016/j.phrs.2016.04.021","UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;BIOMEDICAL RESEARCH UNIT, MEXICAN SOCIAL SECURITY INSTITUTE, DURANGO, MEXICO;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;BIOTECHNOLOGY RESEARCH CENTER, MASHHAD UNIVERSITY OF MEDICAL SCIENCES, MASHHAD, 917794856, IRAN, METABOLIC RESEARCH CENTRE, ROYAL PERTH HOSPITAL, SCHOOL OF MEDICINE AND PHARMACOLOGY, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA","DYSLIPIDEMIA AND HYPERGLYCEMIA ARE ASSOCIATED WITH AN INCREASED RISK OF ISCHEMIC CARDIOVASCULAR DISEASE. POSITIVE EFFECTS OF A NUTRACEUTICAL COMBINATION COMPRISING RED YEAST RICE, BERBERINE, POLICOSANOL, ASTAXANTHIN, COENZYME Q10 AND FOLIC ACID (NCOMB) ON PLASMA LIPID AND GLUCOSE LEVELS HAVE BEEN REPORTED IN SOME BUT NOT ALL CLINICAL TRIALS. TO ADDRESS THIS INCONSISTENCY, WE TRIED TO ESTIMATE THE SIZE OF LIPID- AND GLUCOSE-LOWERING EFFECTS OF NCOMB THROUGH A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. A SYSTEMATIC LITERATURE SEARCH IN PUBMED-MEDLINE, SCOPUS AND GOOGLE SCHOLAR DATABASES WAS CONDUCTED TO IDENTIFY RANDOMIZED CONTROLLED TRIALS INVESTIGATING THE EFFECTS OF NCOMB ON PLASMA LIPIDS AND GLUCOSE LEVELS. INVERSE VARIANCE-WEIGHTED MEAN DIFFERENCES (WMDS) AND 95% CONFIDENCE INTERVALS (CIS) WERE CALCULATED FOR NET CHANGES IN LIPID AND GLUCOSE LEVELS USING A RANDOM-EFFECTS MODEL. RANDOM-EFFECTS META-REGRESSION WAS PERFORMED TO ASSESS THE EFFECT OF PUTATIVE CONFOUNDERS ON PLASMA LIPID AND GLUCOSE LEVELS. FOURTEEN TRIALS (1670 SUBJECTS IN THE NCOMB ARM AND 1489 SUBJECTS IN THE CONTROL ARM) MET THE ELIGIBILITY CRITERIA FOR LIPID ANALYSIS AND 10 TRIALS (1014 SUBJECTS IN THE NCOMB ARM AND 962 SUBJECTS IN THE CONTROL ARM) FOR GLUCOSE ANALYSIS. OVERALL, WMDS WERE SIGNIFICANT FOR THE IMPACT OF NCOMB SUPPLEMENTATION ON PLASMA LEVELS OF TOTAL CHOLESTEROL (-26.15 MG/DL, P < 0.001), LDL-CHOLESTEROL (-23.85 MG/DL, P < 0.001), HDL-CHOLESTEROL (2.53 MG/DL, P < 0.001), TRIGLYCERIDES (-13.83 MG/DL, P < 0.001) AND GLUCOSE (-2.59 MG/DL, P = 0.010). NCOMB-INDUCED AMELIORATION OF LIPID PROFILE WAS NOT AFFECTED BY DURATION OF SUPPLEMENTATION NOR BY BASELINE LIPID LEVELS; CONVERSELY, A GREATER GLUCOSE-LOWERING EFFECT OF NCOMB WAS FOUND WITH HIGHER BASELINE GLUCOSE LEVELS AND LONGER DURATIONS OF SUPPLEMENTATION. IN CONCLUSION, THE PRESENT RESULTS SUGGEST THAT NCOMB SUPPLEMENTATION IS ASSOCIATED WITH IMPROVEMENT OF LIPID AND GLUCOSE PROFILE. SHORT-TERM BENEFICIAL EFFECTS OF NCOMB SUPPLEMENTATION APPEAR TO BE MAINTAINED IN THE LONG TERM. © 2016 ELSEVIER LTD. ALL RIGHTS RESERVED.","BERBERINE; CHOLESTEROL; GLUCOSE; LIPID; NUTRACEUTICAL; RED YEAST RICE","ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD GLUCOSE; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; ASTAXANTHIN; BERBERINE; CHOLESTEROL; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; XUEZHIKANG; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LIPID; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SUPPLEMENTATION; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; AGED; BLOOD; DIETARY SUPPLEMENT; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY","","","MCQUEEN M.J., HAWKEN S., WANG X., OUNPUU S., SNIDERMAN A., PROBSTFIELD J., STEYN K., SANDERSON J.E., HASANI M., VOLKOVA E., KAZMI K., YUSUF S., LIPIDS, LIPOPROTEINS, AND APOLIPOPROTEINS AS RISK MARKERS OF MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): A CASE-CONTROL STUDY, LANCET, 372, 9634, PP. 224-233, (2008); COUTINHO M., GERSTEIN H.C., WANG Y., YUSUF S., THE RELATIONSHIP BETWEEN GLUCOSE AND INCIDENT CARDIOVASCULAR EVENTS. A METAREGRESSION ANALYSIS OF PUBLISHED DATA FROM 20 STUDIES OF 95,783 INDIVIDUALS FOLLOWED FOR 12.4 YEARS, DIABETES CARE, 22, 2, PP. 233-240, (1999); CASTELLI W.P., CHOLESTEROL AND LIPIDS IN THE RISK OF CORONARY ARTERY DISEASE - THE FRAMINGHAM HEART STUDY, CAN. J. CARDIOL., 4, PP. 5A-10A, (1988); NORDESTGAARD B.G., VARBO A., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE, LANCET, 384, 9943, PP. 626-635, (2014); PIRRO M., DEL GIORNO R., LUPATTELLI G., MANNARINO M.R., ROSCINI A.R., COVELLI D., SCHILLACI G., PASQUALINI L., BAGAGLIA F., SIEPI D., MANNARINO E., CARDIOVASCULAR RISK FACTORS AND RECOMMENDED LIPID GOALS ATTAINMENT AMONG PATIENTS REFERRED IN A TERTIARY CARE LIPID CLINIC, EUR. J. INTERN. MED., 22, 4, PP. 412-417, (2011); STAMLER J., VACCARO O., NEATON J.D., WENTWORTH D., DIABETES, OTHER RISK FACTORS, AND 12-YR CARDIOVASCULAR MORTALITY FOR MEN SCREENED IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL, DIABETES CARE, 16, 2, PP. 434-444, (1993); LAWES C.M., PARAG V., BENNETT D.A., SUH I., LAM T.H., WHITLOCK G., BARZI F., WOODWARD M., BLOOD GLUCOSE AND RISK OF CARDIOVASCULAR DISEASE IN THE ASIA PACIFIC REGION, DIABETES CARE, 27, 12, PP. 2836-2842, (2004); SPERLING L.S., MECHANICK J.I., NEELAND I.J., HERRICK C.J., DESPRES J.P., NDUMELE C.E., VIJAYARAGHAVAN K., HANDELSMAN Y., PUCKREIN G.A., ARANETA M.R., BLUM Q.K., COLLINS K.K., COOK S., DHURANDHAR N.V., DIXON D.L., EGAN B.M., FERDINAND D.P., HERMAN L.M., HESSEN S.E., JACOBSON T.A., PATE R.R., RATNER R.E., BRINTON E.A., FORKER A.D., RITZENTHALER L.L., GRUNDY S.M., THE CARDIOMETABOLIC HEALTH ALLIANCE: WORKING TOWARD A NEW CARE MODEL FOR THE METABOLIC SYNDROME, J. AM. COLL. CARDIOL., 66, 9, PP. 1050-1067, (2015); LAKKA H.M., LAAKSONEN D.E., LAKKA T.A., NISKANEN L.K., KUMPUSALO E., TUOMILEHTO J., SALONEN J.T., THE METABOLIC SYNDROME AND TOTAL AND CARDIOVASCULAR DISEASE MORTALITY IN MIDDLE-AGED MEN, JAMA, 288, 21, PP. 2709-2716, (2002); LORENZO C., WILLIAMS K., HUNT K.J., HAFFNER S.M., THE NATIONAL CHOLESTEROL EDUCATION PROGRAM - ADULT TREATMENT PANEL III INTERNATIONAL DIABETES FEDERATION, AND WORLD HEALTH ORGANIZATION DEFINITIONS OF THE METABOLIC SYNDROME AS PREDICTORS OF INCIDENT CARDIOVASCULAR DISEASE AND DIABETES, DIABETES CARE, 30, 1, PP. 8-13, (2007); HORTON J.D., COHEN J.C., HOBBS H.H., PCSK9: A CONVERTASE THAT COORDINATES LDL CATABOLISM, J. LIPID RES., 50, PP. S172-S177, (2009); RISK FACTORS COLLABORATION E., DI ANGELANTONIO E., GAO P., KHAN H., BUTTERWORTH A.S., WORMSER D., KAPTOGE S., KONDAPALLY SESHASAI S.R., THOMPSON A., SARWAR N., WILLEIT P., RIDKER P.M., BARR E.L., KHAW K.T., PSATY B.M., BRENNER H., BALKAU B., DEKKER J.M., LAWLOR D.A., DAIMON M., WILLEIT J., NJOLSTAD I., NISSINEN A., BRUNNER E.J., KULLER L.H., PRICE J.F., SUNDSTROM J., KNUIMAN M.W., FESKENS E.J., VERSCHUREN W.M., WALD N., BAKKER S.J., WHINCUP P.H., FORD I., GOLDBOURT U., GOMEZ-DE-LA-CAMARA A., GALLACHER J., SIMONS L.A., ROSENGREN A., SUTHERLAND S.E., BJORKELUND C., BLAZER D.G., WASSERTHEIL-SMOLLER S., ONAT A., MARIN IBANEZ A., CASIGLIA E., JUKEMA J.W., SIMPSON L.M., GIAMPAOLI S., NORDESTGAARD B.G., SELMER R., WENNBERG P., KAUHANEN J., SALONEN J.T., DANKNER R., BARRETT-CONNOR E., KAVOUSI M., GUDNASON V., EVANS D., WALLACE R.B., CUSHMAN M., D'AGOSTINO R.B., UMANS J.G., KIYOHARA Y., NAKAGAWA H., SATO S., GILLUM R.F., FOLSOM A.R., VAN DER SCHOUW Y.T., MOONS K.G., GRIFFIN S.J., SATTAR N., WAREHAM N.J., SELVIN E., THOMPSON S.G., DANESH J., GLYCATED HEMOGLOBIN MEASUREMENT AND PREDICTION OF CARDIOVASCULAR DISEASE, JAMA, 311, 12, PP. 1225-1233, (2014); ROBINSON J.G., STARTING PRIMARY PREVENTION EARLIER WITH STATINS, AM. J. CARDIOL., 114, 9, PP. 1437-1442, (2014); PISTROSCH F., NATALI A., HANEFELD M., IS HYPERGLYCEMIA A CARDIOVASCULAR RISK FACTOR?, DIABETES CARE, 34, PP. S128-S131, (2011); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR. J. INTERN. MED., 25, 7, PP. 592-599, (2014); LI Y., JIANG L., JIA Z., XIN W., YANG S., YANG Q., WANG L., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, 6, (2014); LAN J., ZHAO Y., DONG F., YAN Z., ZHENG W., FAN J., SUN G., META-ANALYSIS OF THE EFFECT AND SAFETY OF BERBERINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, HYPERLIPEMIA AND HYPERTENSION, J. ETHNOPHARMACOL., 161, PP. 69-81, (2015); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR., 50, 3, PP. 259-267, (2010); CHOI H.D., YOUN Y.K., SHIN W.G., POSITIVE EFFECTS OF ASTAXANTHIN ON LIPID PROFILES AND OXIDATIVE STRESS IN OVERWEIGHT SUBJECTS, PLANT FOODS HUM. NUTR., 66, 4, PP. 363-369, (2011); URSONIU S., SAHEBKAR A., SERBAN M.C., BANACH M., LIPID PROFILE AND GLUCOSE CHANGES AFTER SUPPLEMENTATION WITH ASTAXANTHIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCH. MED. SCI., 11, 2, PP. 253-266, (2015); SAHEBKAR A., SIMENTAL-MENDIA L.E., STEFANUTTI C., PIRRO M., SUPPLEMENTATION WITH COENZYME Q10 REDUCES PLASMA LIPOPROTEIN(A) CONCENTRATIONS BUT NOT OTHER LIPID INDICES: A SYSTEMATIC REVIEW AND META-ANALYSIS, PHARMACOL. RES., 105, PP. 198-209, (2016); FLOWERS N., HARTLEY L., TODKILL D., STRANGES S., REES K., CO-ENZYME Q10 SUPPLEMENTATION FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV., 12, (2014); SUKSOMBOON N., POOLSUP N., JUANAK N., EFFECTS OF COENZYME Q10 SUPPLEMENTATION ON METABOLIC PROFILE IN DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS, J. CLIN. PHARM. THER., 40, 4, PP. 413-418, (2015); CICERO A.F.G., COLLETTI A., COMBINATIONS OF PHYTOMEDICINES WITH DIFFERENT LIPID LOWERING ACTIVITY FOR DYSLIPIDEMIA MANAGEMENT: THE AVAILABLE CLINICAL DATA, PHYTOMEDICINE, (2015); CICERO A.F.G., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR. METAB. CARDIOVASC. DIS., 20, 9, PP. 656-661, (2010); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., TRIMARCO B., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J. HYPERTENS., 28, 7, PP. 1482-1487, (2010); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV. THER., 28, 12, PP. 1105-1113, (2011); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED. J. NUTR. METAB., 4, 2, PP. 133-139, (2011); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., GRIECO F., FAZIO S., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J. CARDIOL., 4, 3, PP. 77-83, (2012); CICERO A.F.G., DE SANDO V., BENEDETTO D., CEVENINI M., GRANDI E., BORGHI C., LONG-TERM EFFICACY AND TOLERABILITY OF A MULTICOMPONENT LIPID-LOWERING NUTRACEUTICAL IN OVERWEIGHT AND NORMOWEIGHT PATIENTS, NUTRAFOODS, 11, PP. 55-61, (2012); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS., 11, (2012); PIRRO M., LUPATTELLI G., DEL GIORNO R., SCHILLACI G., BERISHA S., MANNARINO M.R., BAGAGLIA F., MELIS F., MANNARINO E., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, PHARMANUTRITION, 1, PP. 73-77, (2013); RUSCICA M., GOMARASCHI M., MOMBELLI G., MACCHI C., BOSISIO R., PAZZUCCONI F., PAVANELLO C., CALABRESI L., ARNOLDI A., SIRTORI C.R., MAGNI P., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J. CLIN. LIPIDOL., 8, 1, PP. 61-68, (2014); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR. THER. RES. CLIN. EXP., 77, PP. 1-6, (2014); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., MORINA D., VILLAR J., MILLAN J., ANGUERA A., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, 8, (2014); MARAZZI G., PELLICCIA F., CAMPOLONGO G., QUATTRINO S., CACCIOTTI L., VOLTERRANI M., GAUDIO C., ROSANO G., USEFULNESS OF NUTRACEUTICALS (ARMOLIPID PLUS) VERSUS EZETIMIBE AND COMBINATION IN STATIN-INTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE, AM. J. CARDIOL., 116, 12, PP. 1798-1801, (2015); GENTILE M., CALCATERRA I., STRAZZULLO A., PAGANO C., PACIONI D., SPERANZA E., RUBBA P., MAROTTA G., EFFECTS OF ARMOLIPID PLUS ON SMALL DENSE LDL PARTICLES IN A SAMPLE OF PATIENTS AFFECTED BY FAMILIAL COMBINED HYPERLIPIDEMIA, CLIN. LIPIDOL., 10, PP. 475-480, (2015); MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., PRISMA GROUP: PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES: THE PRISMA STATEMENT, BMJ, 339, (2009); HIGGINS J.P.T., GREEN S., COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS. VERSION 5.0.2., (2009); BORENSTEIN M., HEDGES L., HIGGINS J., ROTHSTEIN H., COMPREHENSIVE META-ANALYSIS VERSION 2, (2005); WAN X., WANG W., LIU J., TONG T., ESTIMATING THE SAMPLE MEAN AND STANDARD DEVIATION FROM THE SAMPLE SIZE, MEDIAN, RANGE AND/OR INTERQUARTILE RANGE, BMC MED. RES. METHODOL., 14, (2014); SUTTON A.J., ABRAMS K.R., JONES D.R., ET AL., METHODS FOR META-ANALYSIS IN MEDICAL RESEARCH, (2000); BANACH M., SERBAN C., URSONIU S., RYSZ J., MUNTNER P., TOTH P.P., JONES S.R., RIZZO M., GLASSER S.P., WATTS G.F., BLUMENTHAL R.S., LIP G.Y., MIKHAILIDIS D.P., SAHEBKAR A., STATIN THERAPY AND PLASMA COENZYME Q10 CONCENTRATIONS - A SYSTEMATIC REVIEW AND META-ANALYSIS OF PLACEBO-CONTROLLED TRIALS, PHARMACOL. RES., 99, PP. 329-336, (2015); FERRETTI G., BACCHETTI T., SAHEBKAR A., EFFECT OF STATIN THERAPY ON PARAOXONASE-1 STATUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 25 CLINICAL TRIALS, PROG. LIPID RES., 60, PP. 50-73, (2015); DUVAL S., TWEEDIE R., TRIM AND FILL: A SIMPLE FUNNEL-PLOT-BASED METHOD OF TESTING AND ADJUSTING FOR PUBLICATION BIAS IN META-ANALYSIS, BIOMETRICS, 56, PP. 455-463, (2000); RIDKER P.M., LDL CHOLESTEROL: CONTROVERSIES AND FUTURE THERAPEUTIC DIRECTIONS, LANCET, 384, 9943, PP. 607-617, (2014); SCHEEN A.J., CHARBONNEL B., EFFECTS OF GLUCOSE-LOWERING AGENTS ON VASCULAR OUTCOMES IN TYPE 2 DIABETES: A CRITICAL REAPPRAISAL, DIABETES METAB., 40, 3, PP. 176-185, (2014); CHAPMAN K., CAN PEOPLE MAKE HEALTHY CHANGES TO THEIR DIET AND MAINTAIN THEM IN THE LONG TERM? A REVIEW OF THE EVIDENCE, APPETITE, 54, 3, PP. 433-441, (2010); ROUMEN C., BLAAK E.E., CORPELEIJN E., LIFESTYLE INTERVENTION FOR PREVENTION OF DIABETES: DETERMINANTS OF SUCCESS FOR FUTURE IMPLEMENTATION, NUTR. REV., 67, 3, PP. 132-146, (2009); DE VERA M.A., BHOLE V., BURNS L.C., LACAILLE D., IMPACT OF STATIN ADHERENCE ON CARDIOVASCULAR DISEASE AND MORTALITY OUTCOMES: A SYSTEMATIC REVIEW, BR. J. CLIN. PHARMACOL., 78, 4, PP. 684-698, (2014); BROWN M.T., BUSSELL J.K., MEDICATION ADHERENCE: WHO CARES?, MAYO CLIN. PROC., 86, 4, PP. 304-314, (2011); DAVI G., SANTILLI F., PATRONO C., NUTRACEUTICALS IN DIABETES AND METABOLIC SYNDROME, CARDIOVASC. THER., 28, 4, PP. 216-226, (2010); GEIL P., SHANE-MCWHORTER L., DIETARY SUPPLEMENTS IN THE MANAGEMENT OF DIABETES: POTENTIAL RISKS AND BENEFITS, J. AM. DIET. ASSOC., 108, 4, PP. S59-S65, (2008); CANNON C.P., BLAZING M.A., GIUGLIANO R.P., MCCAGG A., WHITE J.A., THEROUX P., DARIUS H., LEWIS B.S., OPHUIS T.O., JUKEMA J.W., DE FERRARI G.M., RUZYLLO W., DE LUCCA P., IM K., BOHULA E.A., REIST C., WIVIOTT S.D., TERSHAKOVEC A.M., MUSLINER T.A., BRAUNWALD E., CALIFF R.M., EZETIMIBE ADDED TO STATIN THERAPY AFTER ACUTE CORONARY SYNDROMES, N. ENGL. J. MED., 372, 25, PP. 2387-2397, (2015); BURKE F.M., RED YEAST RICE FOR THE TREATMENT OF DYSLIPIDEMIA, CURR. ATHEROSCLER. REP., 17, 4, (2015); PIRILLO A., CATAPANO A.L., BERBERINE, A PLANT ALKALOID WITH LIPID- AND GLUCOSE-LOWERING PROPERTIES: FROM IN VITRO EVIDENCE TO CLINICAL STUDIES, ATHEROSCLEROSIS, 243, 2, PP. 449-461, (2015); CHAIT A., ECKEL R.H., LIPIDS LIPOPROTEINS, AND CARDIOVASCULAR DISEASE: CLINICAL PHARMACOLOGY NOW AND IN THE FUTURE, J. CLIN. ENDOCRINOL. METAB., 101, 3, PP. 804-814, (2016); BARTER P.J., RYE K.A., TARGETING HIGH-DENSITY LIPOPROTEINS TO REDUCE CARDIOVASCULAR RISK: WHAT IS THE EVIDENCE?, CLIN. THER., 37, 12, PP. 2716-2731, (2015); YOSHIDA H., YANAI H., ITO K., TOMONO Y., KOIKEDA T., TSUKAHARA H., TADA N., ADMINISTRATION OF NATURAL ASTAXANTHIN INCREASES SERUM HDL-CHOLESTEROL AND ADIPONECTIN IN SUBJECTS WITH MILD HYPERLIPIDEMIA, ATHEROSCLEROSIS, 209, 2, PP. 520-523, (2010); TIGHE P., WARD M., MCNULTY H., FINNEGAN O., DUNNE A., STRAIN J., MOLLOY A.M., DUFFY M., PENTIEVA K., SCOTT J.M., A DOSE-FINDING TRIAL OF THE EFFECT OF LONG-TERM FOLIC ACID INTERVENTION: IMPLICATIONS FOR FOOD FORTIFICATION POLICY, AM. J. CLIN. NUTR., 93, 1, PP. 11-18, (2011); ALBERT C.M., COOK N.R., GAZIANO J.M., ZAHARRIS E., MACFADYEN J., DANIELSON E., BURING J.E., MANSON J.E., EFFECT OF FOLIC ACID AND B VITAMINS ON RISK OF CARDIOVASCULAR EVENTS AND TOTAL MORTALITY AMONG WOMEN AT HIGH RISK FOR CARDIOVASCULAR DISEASE: A RANDOMIZED TRIAL, JAMA, 299, 17, PP. 2027-2036, (2008); VERHOEF P., KATAN M.B., A HEALTHY LIFESTYLE LOWERS HOMOCYSTEINE, BUT SHOULD WE CARE?, AM. J. CLIN. NUTR., 79, 5, PP. 713-714, (2004)","M. PIRRO; UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY; EMAIL: MATTEO.PIRRO@UNIPG.IT","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","REVIEW","ISI","2-S2.0-84969869877","PHARMACOL RES","UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;MEXICAN SOCIAL SECURITY INSTITUTE;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;MASHHAD UNIVERSITY OF MEDICAL SCIENCES","NOTREPORTED;UNIVERSITY OF PERUGIA;NOTREPORTED",NA,"PIRRO M, 2016, PHARMACOL RES","PIRRO M, 2016, PHARMACOL RES"
"PATTI A;TOTH P;GIGLIO R;BANACH M;NOTO M;NIKOLIC D;MONTALTO G;RIZZO M","PATTI, ANGELO M. (16432525100); TOTH, PETER P. (7102285226); GIGLIO, ROSARIA V. (55645572700); BANACH, MACIEJ (22936699500); NOTO, MARCELLO (56042511400); NIKOLIC, DRAGANA (48061331700); MONTALTO, GIUSEPPE (7102692251); RIZZO, MANFREDI (7202023733)","NUTRACEUTICALS AS AN IMPORTANT PART OF COMBINATION THERAPY IN DYSLIPIDAEMIA",2017,"CURRENT PHARMACEUTICAL DESIGN","23","7",35,"10.2174/1381612823666170317145851","BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, ITALY, EURO-MEDITERRANEAN INSTITUTE OF SCIENCE AND TECHNOLOGY, PALERMO, ITALY;CGH MEDICAL CENTER, STERLING, IL, UNITED STATES, SCHOOL OF MEDICINE, UNIVERSITY OF ILLINOIS, PEORIA, IL, UNITED STATES, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, BALTIMORE, MD, UNITED STATES;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, ITALY, EURO-MEDITERRANEAN INSTITUTE OF SCIENCE AND TECHNOLOGY, PALERMO, ITALY;DEPARTMENT OF HYPERTENSION, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, ITALY;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, ITALY, EURO-MEDITERRANEAN INSTITUTE OF SCIENCE AND TECHNOLOGY, PALERMO, ITALY;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, ITALY;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, ITALY, EURO-MEDITERRANEAN INSTITUTE OF SCIENCE AND TECHNOLOGY, PALERMO, ITALY","SEVERAL RISK FACTORS SUCH AS ABNORMALITY OF LIPID METABOLISM (E.G. HIGH LEVELS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), ELEVATED TRIGLYCERIDES AND LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C)) PLAY A CENTRAL ROLE IN THE AETIOLOGY OF CARDIOVASCULAR DISEASE (CVD). NUTRACEUTICAL COMBINATION TOGETHER WITH A CHOLESTEROL-LOWERING ACTION, WHEN ASSOCIATED WITH SUITABLE LIFESTYLE, SHOULD FURNISH AN ALTERNATIVE TO PHARMACOTHERAPY IN PATIENTS REPORTING STATIN-INTOLERANCE AND IN SUBJECTS AT LOW CARDIOVASCULAR RISK. THE PRESENT REVIEW IS FOCUSED ON NUTRACEUTICALS AND THEIR SYNERGETIC COMBINATIONS DEMONSTRATING A BENEFICIAL EFFECT IN THE MANAGEMENT OF DYSLIPIDAEMIA. SEVERAL NUTRACEUTICALS HAVE BEEN SHOWN TO POSITIVELY MODULATE LIPID METABOLISM HAVING DIFFERENT FUNCTIONS. PLANT STEROLS AND SOLUBLE FIBRES CAN, FOR EXAMPLE, DECREASE THE INTESTINAL ASSIMILATION OF LIPIDS AND INCREASE THEIR ELIMINATION. FURTHERMORE, BERBERINE AND SOYBEAN PROTEINS IMPROVE THE CHOLESTEROL UPTAKE IN THE LIVER. POLICOSANOLS, MONACOLINS AND BERGAMOT INHIBIT HYDROXY-METHYL-GLUTARYL COENZYME A REDUCTASE (HMGCOA REDUCTASE) ENZYME ACTION DETERMINING THE CHOLESTEROL HEPATIC SYNTHESIS. MOREOVER, POMEGRANATE CAN DECREASE LDL OXIDATION AND POSITIVELY AFFECT SUBCLINICAL ATHEROSCLEROSIS; RED YEAST RICE AND BERBERINE PLAY, INSTEAD, AN IMPORTANT ROLE ON ENDOTHELIAL DYSFUNCTION AND PSYLLIUM, PLANT STEROLS AND BERGAMOT HAVE POSITIVE EFFECTS ON LDL SUBCLASSES. TO THE BEST OF OUR KNOWLEDGE, THERE ARE NO LONG-TERM LARGE-SCALE STUDIES ON THE ANTI-ATHEROGENIC EFFECT OF THE NUTRACEUTICALS THAT ARE AVAILABLE ON THE MARKET. THUS, FURTHER CLINICAL STUDIES SHOULD INVESTIGATE IN ORDER TO ACHIEVE LONG TERM TOLERABILITY AND SAFETY AND TO PROVIDE A BETTER NUTRACEUTICAL COMBINATION TAILORED TO THE PATIENT NEEDS. © 2017 BENTHAM SCIENCE PUBLISHERS.","CARDIOVASCULAR RISK; CAROTID; DYSLIPIDAEMIA; ENDOTHELIAL DYSFUNCTION; INTIMA MEDIA THICKNESS; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICALS","DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; LIPIDS; ALPHA TOCOTRIENOL; BERBERINE; BERGAMOT OIL; CASEIN; CHLOROGENIC ACID; CHOLESTIN; CITRININ; DAIDZEIN; FISH OIL; GENISTEIN; GLYCITEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOFLAVONE DERIVATIVE; ISPAGULA; LOW DENSITY LIPOPROTEIN RECEPTOR; MANNAN; MEVINOLIN; MONACOLIN L; NUTRACEUTICAL; PECTIN; PHYTOSTEROL; PLACEBO; PLANT PROTEIN; POLICOSANOL; POLYPHENOL; POMEGRANATE EXTRACT; PRAVASTATIN; SILYMARIN; SOYBEAN PROTEIN; UNINDEXED DRUG; LIPID; ABDOMINAL DISTENSION; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONSTIPATION; DIARRHEA; DIETARY FIBER; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID OXIDATION; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PLANT FIBER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; BLOOD; COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; DYSLIPIDEMIA","","","D'AGOSTINO R.B., GRUNDY S., SULLIVAN L.M., ET AL., VALIDATION OF THE FRAMINGHAM CORONARY HEART DISEASE PREDICTION SCORES: RESULTS OF A MULTIPLE ETHNIC GROUPS INVESTIGATION, JAMA, 286, PP. 180-187, (2001); KANNEL W.B., CASTELLI W.P., GORDON T., ET AL., SERUM CHOLESTEROL, LIPOPROTEINS, AND THE RISK OF CORONARY HEART DISEASE. THE FRAMINGHAM STUDY, ANN INTERN MED, 74, PP. 1-12, (1971); CATAPANO A.L., REINER Z., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), ATHEROSCLEROSIS, 217, PP. 3-46, (2011); BAIGENT C., BLACKWELL L., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); BANACH M., RIZZO M., TOTH P.P., ET AL., STATIN INTOLERANCE-AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015); STROES E.S., THOMPSON P.D., CORSINI A., ET AL., EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL. STATIN-ASSOCIATED MUSCLE SYMPTOMS: IMPACT ON STATIN THERAPY-EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL STATEMENT ON ASSESSMENT, AETIOLOGY AND MANAGEMENT, EUR HEART J, 36, PP. 1012-1022, (2015); RIMM E.B., ASCHERIO A., GIOVANNUCCI E., ET AL., VEGETABLE, FRUIT, AND CEREAL FIBER INTAKE AND RISK OF CORONARY HEART DISEASE AMONG MEN, JAMA, 275, PP. 447-451, (1996); JACOBS D.R., PEREIRA M.A., MEYER K.A., ET AL., FIBER FROM WHOLE GRAINS, BUT NOT REFINED GRAINS, IS INVERSELY ASSOCIATED WITH ALL-CAUSE MORTALITY IN OLDER WOMEN: THE IOWA WOMEN'S HEALTH STUDY, J AM COLL NUTR, 19, 3, PP. S326-S330, (2000); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., ET AL., PREDIMED STUDY INVESTIGATORS. EFFECTS OF DIETARY FIBRE INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK, J EPIDEMIOL COMMUNITY HEALTH, 63, PP. 582-588, (2009); PATTI A.M., KATSIKI N., NIKOLIC D., ET AL., NUTRACEUTICALS IN LIPIDLOWERING TREATMENT: A NARRATIVE REVIEW ON THE ROLE OF CHITOSAN, ANGIOLOGY, 66, PP. 416-421, (2015); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROLLOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); O'NEILL F.H., SANDERS T.A., THOMPSON G.R., COMPARISON OF EFFICACY OF PLANT STANOL ESTER AND STEROL ESTER: SHORT-TERM AND LONGER-TERM STUDIES, AM J CARDIOL, 96, PP. 29D-36D, (2005); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., THE EFFECT OF COMBINING PLANT STEROLS, SOY PROTEIN, VISCOUS FIBERS, AND ALMONDS IN TREATING HYPERCHOLESTEROLEMIA, METABOLISM, 52, PP. 1478-1483, (2003); VUKSAN V., SIEVENPIPER J.L., XU Z., ET AL., KONJAC-MANNAN AND AMERICAN GINSENG: EMERGING ALTERNATIVE THERAPIES FOR TYPE 2 DIABETES MELLITUS, J AM COLL NUTR, 20, 5, PP. S370-S380, (2001); YOSHIDA M., VANSTONE C.A., PARSONS W.D., ET AL., EFFECT OF PLANT STEROLS AND GLUCOMANNAN ON LIPIDS IN INDIVIDUALS WITH AND WITHOUT TYPE II DIABETES, EUR J CLIN NUTR, 60, PP. 529-537, (2006); SIRTORI C.R., TRIOLO M., BOSISIO R., ET AL., HYPOCHOLESTEROLAEMIC EFFECTS OF LUPIN PROTEIN AND PEA PROTEIN/FIBRE COMBINATIONS IN MODERATELY HYPERCHOLESTEROLAEMIC INDIVIDUALS, BR J NUTR, 107, PP. 1176-1183, (2012); SIRTORI C.R., GALLI C., ERSON J.W., ET AL., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); ANDERSON J.W., STORY L., SIELING B., ET AL., HYPOCHOLESTEROLEMIC EFFECTS OF OAT-BRAN OR BEAN INTAKE FOR HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 40, PP. 1146-1155, (1984); ANDERSON J.W., GUSTAFSON N.J., SPENCER D.B., ET AL., SERUM LIPID RESPONSE OF HYPERCHOLESTEROLEMIC MEN TO SINGLE AND DIVIDED DOSES OF CANNED BEANS, AM J CLIN NUTR, 51, PP. 1013-1019, (1990); LING W.H., JONES P.J., DIETARY PHYTOSTEROLS: A REVIEW OF METABOLISM, BENEFITS AND SIDE EFFECTS, LIFE SCI, 57, PP. 195-206, (1995); BADIMON L., VILAHUR G., PADRO T., NUTRACEUTICALS AND ATHEROSCLEROSIS: HUMAN TRIALS, CARDIOVASC THER, 28, PP. 202-215, (2010); MANNARINO E., PIRRO M., CORTESE C., ET AL., EFFECTS OF A PHYTOSTEROLENRICHED DAIRY PRODUCT ON LIPIDS, STEROLS AND 8-ISOPROSTANE IN HYPERCHOLESTEROLEMIC PATIENTS: A MULTICENTER ITALIAN STUDY, NUTR METAB CARDIOVASC DIS, 19, PP. 84-90, (2009); HALLIKAINEN M.A., UUSITUPA M.I., EFFECTS OF 2 LOW-FAT STANOL ESTERCONTAINING MARGARINES ON SERUM CHOLESTEROL CONCENTRATIONS AS PART OF A LOW-FAT DIET IN HYPERCHOLESTEROLEMIC SUBJECTS, AM J CLIN NUTR, 69, PP. 403-410, (1999); AMIR SHAGHAGHI M., ABUMWEIS S.S., JONES P.J., CHOLESTEROL-LOWERING EFFICACY OF PLANT STEROLS/STANOLS PROVIDED IN CAPSULE AND TABLET FORMATS: RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS, J ACAD NUTR DIET, 113, PP. 1494-1503, (2013); MIKSICEK R.J., ESTROGENIC FLAVONOIDS: STRUCTURAL REQUIREMENTS FOR BIOLOGICAL ACTIVITY, PROC SOC EXP BIOL MED, 208, PP. 44-50, (1995); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); SACKS F.M., LICHTENSTEIN A., VAN HORN L., ET AL., SOY PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH: AN AMERICAN HEART ASSOCIATION SCIENCE ADVISORY FOR PROFESSIONALS FROM THE NUTRITION COMMITTEE, CIRCULATION, 113, PP. 1034-1044, (2006); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS VS. LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, JAMA, 290, PP. 502-510, (2003); KOKUBO Y., ISO H., ISHIHARA J., ET AL., ASSOCIATION OF DIETARY INTAKE OF SOY, BEANS, AND ISOFLAVONES WITH RISK OF CEREBRAL AND MYOCARDIAL INFARCTIONS IN JAPANESE POPULATIONS: THE JAPAN PUBLIC HEALTH CENTERBASED (JPHC) STUDY COHORT I, CIRCULATION, 116, PP. 2553-2562, (2007); CICERO A.F., FIORITO A., PANOURGIA M.P., ET AL., EFFECTS OF A NEW SOY/BETA-SITOSTEROL SUPPLEMENT ON PLASMA LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS, J AM DIET ASSOC, 102, PP. 1807-1811, (2002); FEUERSTEIN J.S., BJERKE W.S., POWDERED RED YEAST RICE AND PLANT STANOLS AND STEROLS TO LOWER CHOLESTEROL, J DIET, 9, PP. 110-115, (2012); OGIER N., AMIOT M.J., GEORGE S., ET AL., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR J NUTR, 52, PP. 547-557, (2013); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTRITION METAB, 4, PP. 133-139, (2011); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, PP. 61-68, (2014); CICERO A.F., ROSTICCI M., PARINI A., ET AL., SHORT-TERM EFFECTS OF A COMBINED NUTRACEUTICAL OF INSULIN-SENSITIVITY, LIPID LEVEL AND INDEXES OF LIVER STEATOSIS: A DOUBLE-BLIND, RANDOMIZED, CROSS-OVER CLINICAL TRIAL, NUTR J, 14, (2015); VASANTHI H.R., PARAMESWARI R.P., DAS D.K., MULTIFACETED ROLE OF TOCOTRIENOLS IN CARDIOPROTECTION SUPPORTS THEIR STRUCTURE: FUNCTION RELATION, GENES NUTR, 7, PP. 19-28, (2012); DEROSA G., BONAVENTURA A., BIANCHI L., ET AL., A RANDOMIZED, PLACEBOCONTROLLED STUDY ON THE EFFECTS OF A NUTRACEUTICAL COMBINATION OF RED YEAST RICE, SILYBUM MARIANUM AND OCTASANOL ON LIPID PROFILE, ENDOTHELIAL AND INFLAMMATORY PARAMETERS, J BIOL REGUL HOMEOST AGENTS, 28, PP. 317-324, (2014); DEROSA G., BONAVENTURA A., BIANCHI L., ET AL., BERBERIS ARISTATA/ SILYBUM MARIANUM FIXED COMBINATION ON LIPID PROFILE AND INSULIN SECRETION IN DYSLIPIDEMIC PATIENTS, EXPERT OPIN BIOL THER, 13, PP. 1495-1506, (2013); BAUR J.A., SINCLAIR D.A., THERAPEUTIC POTENTIAL OF RESVERATROL: THE IN VIVO EVIDENCE, NAT REV DRUG DISCOV, 5, PP. 493-506, (2006); BURNS J., YOKOTA T., ASHIHARA H., LEAN M.E., CROZIER A., PLANT FOODS AND HERBAL SOURCES OF RESVERATROL, J AGRIC FOOD CHEM, 50, PP. 3337-3340, (2002); SAHEBKAR A., SERBAN C., URSONIU S., ET AL., LIPID AND BLOOD PRESSURE META-ANALYSIS COLLABORATION GROUP. LACK OF EFFICACY OF RESVERATROL ON C-REACTIVE PROTEIN AND SELECTED CARDIOVASCULAR RISK FACTORS--RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, INT J CARDIOL, 189, PP. 47-55, (2015); CICERO A.F., BRANCALEONI M., LAGHI L., ET AL., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENT THER MED, 13, PP. 273-278, (2005); BANERJEE S.K., MAULIK S.K., EFFECT OF GARLIC ON CARDIOVASCULAR DISORDERS: A REVIEW, NUTR J, 1, (2002); HARRIS W.S., FISH OILS AND PLASMA LIPID AND LIPOPROTEIN METABOLISM IN HUMANS: A CRITICAL REVIEW, J LIPID RES, 30, PP. 785-807, (1989); ADLER A.J., HOLUB B.J., EFFECT OF GARLIC AND FISH-OIL SUPPLEMENTATION ON SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS IN HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 65, PP. 445-450, (1997); CICERO A.F., GADDI A., RICE BRAN OIL AND GAMMA-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHER RES, 15, PP. 277-289, (2001); SCAVARIELLO E.M., ARELLANO D.B., GAMMA-ORYZANOL: AN IMPORTANT COMPONENT IN RICE BRAIN OIL, ARCH LATINOAM NUTR, 48, PP. 7-12, (1998); BERGER A., REIN D., SCHAFER A., ET AL., SIMILAR CHOLESTEROL-LOWERING PROPERTIES OF RICE BRAN OIL, WITH VARIED GAMMA-ORYZANOL, IN MILDLY HYPERCHOLESTEROLEMIC MEN, EUR J NUTR, 44, PP. 163-173, (2005); GIGLIO R.V., PATTI A.M., NIKOLIC D., ET AL., THE EFFECT OF BERGAMOT ON DYSLIPIDEMIA, PHYTOMEDICINE, 23, PP. 1175-1181, (2016); TOTH P.P., PATTI A.M., NIKOLIC D., ET AL., BERGAMOT REDUCES PLASMA LIPIDS, ATHEROGENIC SMALL DENSE LDL, AND SUBCLINICAL ATHEROSCLEROSIS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA: A 6 MONTHS PROSPECTIVE STUDY, FRONT PHARMACOL, 6, (2016); JEYAM M., SYED ABUTHAKIR M., RAVIKUMAR P., ILANAGAI M., IDENTIFICATION OF HMG COA REDUCTASE INHIBITOR FROM NUTRACEUTICALS FOR ATHEROSCLEROSIS, INDIAN RES J PHARMACY SCI, 1, PP. 99-107, (2014); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); DEROSA G., MAFFIOLI P., CICERO A.F., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPIN BIOL THER, 12, PP. 1113-1124, (2012); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J CLIN HYPERTENS (GREENWICH), 14, PP. 121-132, (2012); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., ET AL., COMPARATIVE LIPIDLOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., ET AL., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); MCCARTY M.F., GLUCOMANNAN MINIMIZES THE POSTPRANDIAL INSULIN SURGE: A POTENTIAL ADJUVANT FOR HEPATOTHERMIC THERAPY, MED HYPOTHESES, 58, PP. 487-490, (2002); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., ET AL., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); SOLA R., FITO M., ESTRUCH R., ET AL., EFFECT OF A TRADITIONAL MEDITERRANEAN DIET ON APOLIPOPROTEINS B, A-I, AND THEIR RATIO: A RANDOMIZED, CONTROLLED TRIAL, ATHEROSCLEROSIS, 218, PP. 174-180, (2011); BROWN L., ROSNER B., WILLETT W.W., ET AL., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J NUTR, 125, 3, PP. S606-S611, (1995); HO S.S., PAL S., MARGARINE PHYTOSTEROLS DECREASE THE SECRETION OF ATHEROGENIC LIPOPROTEINS FROM HEPG2 LIVER AND CACO2 INTESTINAL CELLS, ATHEROSCLEROSIS, 182, PP. 29-36, (2005); SABEVA N.S., MCPHAUL C.M., LI X., ET AL., PHYTOSTEROLS DIFFERENTIALLY INFLUENCE ABC TRANSPORTER EXPRESSION, CHOLESTEROL EFFLUX AND INFLAMMATORY CYTOKINE SECRETION IN MACROPHAGE FOAM CELLS, J NUTR BIOCHEM, 22, PP. 777-783, (2011); SCICHILONE N., RIZZO M., BENFANTE A., ET AL., SERUM LOW DENSITY LIPOPROTEIN SUBCLASSES IN ASTHMA, RESPIR MED, 107, PP. 1866-1872, (2013); RIZZO M., GIGLIO R.V., NIKOLIC D., ET AL., EFFECTS OF CHITOSAN ON PLASMA LIPIDS AND LIPOPROTEINS: A 4-MONTH PROSPECTIVE PILOT STUDY, ANGIOLOGY, 65, PP. 538-542, (2014); BERNEIS K., RIZZO M., BERTHOLD H.K., ET AL., EZETIMIBE ALONE OR IN COMBINATION WITH SIMVASTATIN INCREASES SMALL DENSE LOW-DENSITY LIPOPROTEINS IN HEALTHY MEN: A RANDOMIZED TRIAL, EUR HEART J, 31, PP. 1633-1639, (2010); MIKHAILIDIS D.P., ELISAF M., RIZZO M., ET AL., EUROPEAN PANEL ON LOW DENSITY LIPOPROTEIN (LDL) SUBCLASSES"": A STATEMENT ON THE PATHOPHYSIOLOGY, ATHEROGENICITY AND CLINICAL SIGNIFICANCE OF LDL SUBCLASSES: EXECUTIVE SUMMARY, CURR VASC PHARMACOL, 9, PP. 531-532, (2011); MIKHAILIDIS D.P., ELISAF M., RIZZO M., ET AL., EUROPEAN PANEL ON LOW DENSITY LIPOPROTEIN (LDL) SUBCLASSES"": A STATEMENT ON THE PATHOPHYSIOLOGY, ATHEROGENICITY AND CLINICAL SIGNIFICANCE OF LDL SUBCLASSES, CURR VASC PHARMACOL, 9, PP. 533-571, (2011); RIZZO M., BERNEIS K., LOW-DENSITY LIPOPROTEIN SIZE AND CARDIOVASCULAR RISK ASSESSMENT, QJM, 99, PP. 1-14, (2006); RIZZO M., BERNEIS K., SHOULD WE MEASURE ROUTINELY THE LDL PEAK PARTICLE SIZE?, INT J CARDIOL, 107, PP. 166-170, (2006); BJORKBACKA H., KUNJATHOOR V.V., MOORE K.J., ET AL., REDUCED ATHEROSCLEROSIS IN MYD88-NULL MICE LINKS ELEVATED SERUM CHOLESTEROL LEVELS TO ACTIVATION OF INNATE IMMUNITY SIGNALING PATHWAYS, NAT MED, 10, PP. 416-421, (2004); SHRESTHA S., VOLEK J.S., UDANI J., ET AL., A COMBINATION THERAPY INCLUDING PSYLLIUM AND PLANT STEROLS LOWERS LDL CHOLESTEROL BY MODIFYING LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC INDIVIDUALS, J NUTR, 136, PP. 2492-2497, (2006); SHRESTHA S., FREAKE H.C., MCGRANE M.M., ET AL., A COMBINATION OF PSYLLIUM AND PLANT STEROLS ALTERS LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC SUBJECTS BY MODIFYING THE INTRAVASCULAR PROCESSING OF LIPOPROTEINS AND INCREASING LDL UPTAKE, J NUTR, 137, PP. 1165-1170, (2007); LERMAN R.H., MINICH D.M., DARLAND G., ET AL., SUBJECTS WITH ELEVATED LDL CHOLESTEROL AND METABOLIC SYNDROME BENEFIT FROM SUPPLEMENTATION WITH SOY PROTEIN, PHYTOSTEROLS, HOPS RHO ISO-ALPHA ACIDS, AND ACACIA NILOTICA PROANTHOCYANIDINS, J CLIN LIPIDOL, 4, PP. 59-68, (2010); MOLLACE V., SACCO I., JANDA E., ET AL., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, PP. 309-316, (2011); GLIOZZI M., CARRESI C., MUSOLINO V., ET AL., THE EFFECT OF BERGAMOTDERIVED POLYPHENOLIC FRACTION ON LDL SMALL DENSE PARTICLES AND NON ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME, ADV BIOL CHEM, 4, PP. 129-137, (2014); GLIOZZI M., WALKER R., MUSCOLI S., ET AL., BERGAMOT POLYPHENOLIC FRACTION ENHANCES ROSUVASTATIN-INDUCED EFFECT ON LDL-CHOLESTEROL, LOX-1 EXPRESSION AND PROTEIN KINASE B PHOSPHORYLATION IN PATIENTS WITH HYPERLIPIDEMIA, INT J CARDIOL, 170, PP. 140-145, (2013); O'LEARY D.H., POLAK J.F., KRONMAL R.A., ET AL., CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS. CARDIOVASCULAR HEALTH STUDY COLLABORATIVE RESEARCH GROUP, N ENGL J MED, 340, PP. 14-22, (1999); MANCIA G., DE BACKER G., DOMINICZAK A., ET AL., THE TASK FORCE FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION (ESH) AND OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC), EUR HEART J, 28, PP. 1462-1536, (2007); GRAHAM I., ATAR D., BORCH-JOHNSEN K., ET AL., EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION AND REHABILITATION (EACPR). EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: EXECUTIVE SUMMARY, EUR J CARDIOVASC PREV REHABIL, 14, PP. 1-40, (2007); VASAN R.S., BIOMARKERS OF CARDIOVASCULAR DISEASE: MOLECULAR BASIS AND PRACTICAL CONSIDERATIONS, CIRCULATION, 113, PP. 2335-2362, (2006); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); SOFI F., ABBATE R., GENSINI G.F., ET AL., ACCRUING EVIDENCE ON BENEFITS OF ADHERENCE TO THE MEDITERRANEAN DIET ON HEALTH: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 92, PP. 1189-1196, (2010); MURIE-FERNANDEZ M., IRIMIA P., TOLEDO E., ET AL., CAROTID INTIMAMEDIA THICKNESS CHANGES WITH MEDITERRANEAN DIET: A RANDOMIZED TRIAL (PREDIMED-NAVARRA), ATHEROSCLEROSIS, 219, PP. 158-162, (2011); MOZAFFARIAN D., WILSON P., KANNEL W.B., BEYOND ESTABLISHED AND NOVEL RISK FACTORS LIFESTYLE RISK FACTORS FOR CARDIOVASCULAR DISEASE, CIRCULATION, 117, PP. 3031-3038, (2008); NETTLETON J.A., SCHULZE M.B., JIANG R., ET AL., A PRIORI-DEFINED DIETARY PATTERNS AND MARKERS OF CARDIOVASCULAR DISEASE RISK IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), AM J CLIN NUTR, 88, PP. 185-194, (2008); AGEWALL S., FAGERBERG B., BERGLUND G., ET AL., RISK FACTOR INTERVENTION STUDY GROUP, SWEDEN MULTIPLE RISK INTERVENTION TRIAL IN HIGH RISK HYPERTENSIVE MEN: COMPARISON OF ULTRASOUND INTIMA-MEDIA THICKNESS AND CLINICAL OUTCOME DURING 6 YEARS OF FOLLOW-UP, J INTERN MED, 249, PP. 305-314, (2001); ACCINNI R., ROSINA M., BAMONTI F., ET AL., EFFECTS OF COMBINED DIETARY SUPPLEMENTATION ON OXIDATIVE AND INFLAMMATORY STATUS IN DYSLIPIDEMIC SUBJECTS, NUTR METAB CARDIOVASC DIS, 16, PP. 121-127, (2006); GYLLING H., PLAT J., TURLEY S., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, PP. 346-360, (2014); WANG P., CHEN Y.M., HE L.P., ET AL., ASSOCIATION OF NATURAL INTAKE OF DIETARY PLANT STEROLS WITH CAROTID INTIMA-MEDIA THICKNESS AND BLOOD LIPIDS IN CHINESE ADULTS: A CROSS SECTION STUDY, PLOS ONE, 7, (2012); RAITAKARI O.T., SALO P., GYLLING H., ET AL., PLANT STANOL ESTER CONSUMPTION AND ARTERIAL ELASTICITY AND ENDOTHELIAL FUNCTION, BR J NUTR, 100, PP. 603-608, (2008); RAITAKARI O.T., SALO P., AHOTUPA M., CAROTID ARTERY COMPLIANCE IN USERS OF PLANT STANOL ESTER MARGARINE, EUR J CLIN NUTR, 62, PP. 218-224, (2008); AVIRAM M., ROSENBLAT M., GAITINI D., ET AL., POMEGRANATE JUICE CONSUMPTION FOR 3 YEARS BY PATIENTS WITH CAROTID ARTERY STENOSIS REDUCES COMMON CAROTID INTIMA-MEDIA THICKNESS, BLOOD PRESSURE AND LDL OXIDATION, CLIN NUTR, 23, PP. 423-433, (2004); GIL M.I., TOMAS-BARBERAN F.A., HESS-PIERCE B., ET AL., ANTIOXIDANT ACTIVITY OF POMEGRANATE JUICE AND ITS RELATIONSHIP WITH PHENOLIC COMPOSITION AND PROCESSING, J AGRIC FOOD CHEM, 10, PP. 4581-4589, (2000); AVIRAM M., DORNFELD L., ROSENBLAT M., ET AL., POMEGRANATE JUICE CONSUMPTION REDUCES OXIDATIVE STRESS, ATHEROGENIC MODIFICATIONS OF LDL, AND PLATELET AGGREGATION: STUDIES IN HUMANS AND IN ATHEROSCLEROTIC APOLIPOPROTEIN E-DEFICIENT MICE, AM J CLIN NUTR, 71, PP. 1062-1076, (2000); AVIRAM M., ROSENBLAT M., BILLECKE S., ET AL., HUMAN SERUM PARAOXONASE (PON1) IS INACTIVATED BY OXIDIZED LOW DENSITY LIPOPROTEIN AND PRESERVED BY ANTIOXIDANTS, FREE RADIC BIOL MED, 26, PP. 892-904, (1999); GIANETTI J., PEDRINELLI R., PETRUCCI R., ET AL., INVERSE ASSOCIATION BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND THE ANTIOXIDANT LYCOPENE IN ATHEROSCLEROSIS, AM HEART J, 143, PP. 467-474, (2002); DAVIDSON M.H., MAKI K.C., DICKLIN M.R., ET AL., EFFECTS OF CONSUMPTION OF POMEGRANATE JUICE ON CAROTID INTIMA-MEDIA THICKNESS IN MEN AND WOMEN AT MODERATE RISK FOR CORONARY HEART DISEASE, AM J CARDIOL, 104, PP. 936-942, (2009); HODIS H.N., MACK W.J., LABREE L., ET AL., ALPHA-TOCOPHEROL SUPPLEMENTATION IN HEALTHY INDIVIDUALS REDUCES LOW-DENSITY LIPOPROTEIN OXIDATION BUT NOT ATHEROSCLEROSIS: THE VITAMIN E ATHEROSCLEROSIS PREVENTION STUDY (VEAPS), CIRCULATION, 106, PP. 1453-1459, (2002); KATSIKI N., MANES C., IS THERE A ROLE FOR SUPPLEMENTED ANTIOXIDANTS IN THE PREVENTION OF ATHEROSCLEROSIS?, CLIN NUTR, 28, PP. 3-9, (2009); OZKANLAR S., AKCAY F., ANTIOXIDANT VITAMINS IN ATHEROSCLEROSIS— ANIMAL EXPERIMENTS AND CLINICAL STUDIES, ADV CLIN EXP MED, 21, PP. 115-123, (2012); DEBRECENI B., DEBRECENI L., WHY DO HOMOCYSTEINE-LOWERING B VITAMIN AND ANTIOXIDANT E VITAMIN SUPPLEMENTATIONS APPEAR TO BE INEFFECTIVE IN THE PREVENTION OF CARDIOVASCULAR DISEASES?, CARDIOVASC THER, 30, PP. 227-233, (2012); SALONEN R.M., NYYSSONEN K., KAIKKONEN J., ET AL., SIX-YEAR EFFECT OF COMBINED VITAMIN C AND E SUPPLEMENTATION ON ATHEROSCLEROTIC PROGRESSION: THE ANTIOXIDANT SUPPLEMENTATION IN ATHEROSCLEROSIS PREVENTION (ASAP) STUDY, CIRCULATION, 107, PP. 947-953, (2003); PLAT J., MENSINK R.P., VEGETABLE OIL BASED VERSUS WOOD BASED STANOL ESTER MIXTURES: EFFECTS ON SERUM LIPIDS AND HEMOSTATIC FACTORS IN NON-HYPERCHOLESTEROLEMIC SUBJECTS, ATHEROSCLEROSIS, 148, PP. 101-112, (2000); GLADE M.J., FOOD, NUTRITION, AND THE PREVENTION OF CANCER: A GLOBAL PERSPECTIVE. AMERICAN INSTITUTE FOR CANCER RESEARCH/WORLD CANCER RESEARCH FUND, AMERICAN INSTITUTE FOR CANCER RESEARCH, 1997, NUTRITION, 15, PP. 523-526, (1999); HEBER D., LEMBERTAS A., LU Q.Y., ET AL., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, PP. 133-139, (2001); BENNETT J.W., KLICH M., MYCOTOXINS. CLIN MICROBIOL REV, 16, PP. 497-516, (2003); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); DONG H., ZHAO Y., ZHAO L., ET AL., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROLLOWERING AGENTS. A SINGLE BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007)","M. RIZZO; BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND MEDICAL SPECIALTIES, UNIVERSITY OF PALERMO, PALERMO, VIA DEL VESPRO, 141, 90127, ITALY; EMAIL: MANFREDI.RIZZO@UNIPA.IT","BENTHAM SCIENCE PUBLISHERS B.V.","ENGLISH","CURR. PHARM. DES.","REVIEW","ISI","2-S2.0-85016826285","CURR PHARM DES","UNIVERSITY OF PALERMO;UNIVERSITY OF ILLINOIS;UNIVERSITY OF PALERMO;MEDICAL UNIVERSITY OF LODZ;UNIVERSITY OF PALERMO;UNIVERSITY OF PALERMO;UNIVERSITY OF PALERMO;UNIVERSITY OF PALERMO","NOTREPORTED;UNIVERSITY OF PALERMO;NOTREPORTED",NA,"PATTI AM, 2017, CURR PHARM DES","PATTI AM, 2017, CURR PHARM DES"
"PASHA I;SAEED F;WAQAS K;ANJUM F;ARSHAD M","PASHA, IMRAN (20434614500); SAEED, FARHAN (37662112200); WAQAS, KHALID (55513841900); ANJUM, FAQIR MUHAMMAD (7003436069); ARSHAD, MUHAMMAD UMAIR (57215062998)","NUTRACEUTICAL AND FUNCTIONAL SCENARIO OF WHEAT STRAW",2013,"CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION","53","8",14,"10.1080/10408398.2010.528080","NATIONAL INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF AGRICULTURE, FAISALABAD, PAKISTAN;NATIONAL INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF AGRICULTURE, FAISALABAD, PAKISTAN;NATIONAL INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF AGRICULTURE, FAISALABAD, PAKISTAN;NATIONAL INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF AGRICULTURE, FAISALABAD, PAKISTAN;NATIONAL INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF AGRICULTURE, FAISALABAD, PAKISTAN","IN THE ERA OF NUTRITION, MUCH FOCUS HAS BEEN REMUNERATED TO FUNCTIONAL AND NUTRACEUTICAL FOODSTUFFS. THE HEALTH ENDORSING POTENTIAL OF SUCH PROVISIONS IS ATTRIBUTED TO AFFLUENT PHYTOCHEMISTRY. THESE DYNAMIC CONSTITUENTS HAVE FUNCTIONAL POSSESSIONS THAT ARE IMPERATIVE FOR CEREAL INDUSTRY. THE FUNCTIONAL AND NUTRACEUTICAL SIGNIFICANCE OF VARIETY OF FOODS IS OFTEN ACCREDITED TO THEIR BIOACTIVE MOLECULES. NUMEROUS COMPONENTS HAVE BEEN CONSIDERED BUT WHEAT STRAW AND ITS DIVERSE COMPONENTS ARE OF PRIME CONSIDERATION. IN THIS COMPREHENSIVE DISSERTATION, EFFORTS ARE DIRECTED TO ELABORATE THE FUNCTIONAL AND NUTRACEUTICAL IMPORTANCE OF WHEAT STRAW. WHEAT STRAW IS LIGNOCELLULOSIC MATERIALS INCLUDING CELLULOSE, HEMICELLULOSE AND LIGNIN. IT HOLD VARIOUS BIOACTIVE COMPOUNDS SUCH AS POLICOSANOLS, PHYTOSTEROLS, PHENOLICS, AND TRITERPENOIDS, HAVING ENORMOUS NUTRACEUTICAL PROPERTIES LIKE ANTI-ALLERGENIC, ANTI-ARTHEROGENIC, ANTI-INFLAMMATORY, ANTI-MICROBIAL, ANTIOXIDANT, ANTI-THROMBOTIC, CARDIOPROTECTIVE AND VASODILATORY EFFECTS, ANTIVIRAL, AND ANTICANCER. THESE COMPOUNDS ARE PROTECTING AGAINST VARIOUS AILMENTS LIKE HYPERCHOLESTEROLEMIA, INTERMITTENT CLAUDICATION, BENIGN PROSTATIC HYPERPLASIA AND CARDIOVASCULAR DISEASES. ADDITIONALLY, WHEAT STRAW HAS DEMONSTRATED SUCCESSFULLY, LOW COST, RENEWABLE, VERSATILE, WIDELY DISTRIBUTED, EASILY AVAILABLE SOURCE FOR THE PRODUCTION OF BIOGAS, BIOETHANOL, AND BIOHYDROGEN IN BIOREFINERIES TO ENHANCE THE OVERALL EFFECTIVENESS OF BIOMASS CONSUMPTION IN PROTECTED AND ECO-FRIENDLY ENVIRONMENT. FURTHERMORE, ITS ROLE IN ENHANCING THE QUALITY AND EXTENDING THE SHELF LIFE OF BAKERY PRODUCTS THROUGH REDUCING THE PROGRESSION OF STALING AND RETROGRADATION IS LIMELIGHT OF THE ARTICLE. © 2013 COPYRIGHT TAYLOR AND FRANCIS GROUP, LLC.","NUTRACEUTICAL; PHENOLIC ACIDS; PHYTOSTEROL; POLICOSANOL; WHEAT; WHEAT STRAW","LIGNOCELLULOSE; PHYTOSTEROLS; WHEAT; WHEAT STRAW; BIOFUELS; BIOMASS; CELLULOSE; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FOOD HANDLING; LIGNIN; PHENOLS; PHYTOSTEROLS; PLANT STEMS; POLYSACCHARIDES; TRITERPENES; TRITICUM; TRITICUM AESTIVUM; BIOGAS; CELLULOSE; ETHANOL; NUTRITION; ORGANIC ACIDS; BAKERY PRODUCTS; CELLULOSE; NUTRITION; STRAW; BIOFUEL; CELLULOSE; FATTY ALCOHOL; HEMICELLULOSE; LIGNIN; PHENOL DERIVATIVE; PHYTOSTEROL; POLICOSANOL; POLYSACCHARIDE; TRITERPENE; NUTRACEUTICALS; PHENOLIC ACIDS; PHYTOSTEROL; POLICOSANOL; WHEAT; WHEAT STRAWS; NUTRACEUTICALS; PHENOLIC ACIDS; PHYTOSTEROL; POLICOSANOL; WHEAT; WHEAT STRAWS; BIOMASS; CHEMISTRY; DIET SUPPLEMENTATION; FOOD HANDLING; METHODOLOGY; PLANT STEM; REVIEW; WHEAT; PHENOLS; FUNCTIONAL FOOD","","","STROKE NEWS 12/28/2000. DEATHS FROM HEART DISEASE AND STROKE DOWN, BUT NOT ENOUGH, (2006); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES., 33, PP. 835-840, (2000); ARRUZAZABALA M.L., VALDES S., MAS R., COMPARATIVE STUDY OF POLICOSANOL, AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, PP. 293-297, (1997); ATCHISON J.E., DATA ON NON-WOOD PLANT FIBERS, PULP AND PAPER MANUFACTURE, PP. 157-169, (1997); CAUSES OF DEATH (3303.0), (2009); AUTIO K., EFFECTS OF CELL WALL COMPONENTS ON THE FUNCTIONALITY OF WHEAT GLUTEN, BIOTECHNOL. ADV., 24, 6, PP. 633-635, (2006); AWARD A.B., FINK C.S., PHYTOSTEROLS AS ANTICANCER DIETARY COMPONENTS: EVIDENCE AND MECHANISM OF ACTION, J. NUTR., 130, PP. 2127-2130, (2000); BALASUNDRAM N., AI T.Y., SAMBANTHAMURTHI R., SUNDRAM K., SAMMAN S., ANTIOXIDANT PROPERTIES OF PALM FRUIT EXTRACTS, ASIA PAC. J. CLIN. NUTR., 4, 4, PP. 319-324, (2006); BARTSCH G., RITTMASTER R.S., KLOCKER H., DIHYDROTESTOSTERONE AND THE CONCEPT OF 5A-REDUCTASE INHIBITION IN HUMAN BENIGN PROSTATIC HYPERPLASIA, WORLD J. URO., 19, PP. 413-425, (2002); BARZI F., PATEL A., WOODWARD M., A COMPARISON OF LIPID VARIABLES AS PREDICTORS OF CARDIOVASCULAR DISEASE IN THE ASIA PACIFIC REGION, ANN. EPIDEMIOL., 15, PP. 405-413, (2005); BENOIT I., NAVARRO D., MARNET N., RAKOTOMANOMANA N., JOHNSON I.T., DIETARY FIBER: PHYSIOLOGICAL EFFECTS ON ABSORPTION, ENCYCLOPEDIA OF HUMAN NUTRITION. SECOND EDITION, PP. 572-578, (2005); BERGER A., JONES P.J., ABUMWEIS S.S., PLANT STEROLS: FACTORS AFFECTING THEIR EFFICACY AND SAFETY AS FUNCTIONAL FOOD INGREDIENTS, LIPIDS HEALTH DIS., 3, (2004); BHATTACHARYYA A.K., CONNOR W.E., BETA-SITOSTEROLEMIA AND XANTHOMATOSIS A NEWLY DESCRIBED LIPID STORAGE DISEASE IN TWO SISTERS, J. CLIN. INVEST., 53, PP. 1033-1043, (1974); BHATTACHARYYA K.G., SARMA A., ADSORPTION CHARACTERISTICS OF THE DYE, BRILLIANT GREEN, ON NEEM LEAF POWDER, DYES PIGMENTS., 57, PP. 211-222, (2003); BILIADERIS C.G., IZYDORCZYK M.S., RATTAN O., EFFECT OF ARABINOXYLANS ON BREAD-MAKING QUALITY OF WHEAT FLOURS, FOOD CHEM., 5, PP. 165-171, (1995); BINDER A., PELLONI L., FIECHTER A., DELIGNIFICATION OF STRAW WITH OZONE TO ENHANCE BIODEGRADABILITY, EUR. J. APPL. MICROBIOL. BIOTECHNOL., 11, PP. 1-5, (1980); CASTANO G., MAS R., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R. D., 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ L., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT. J. CLIN. PHARMACOL. RES., 21, PP. 43-57, (2001); CASTANO G., MAS R., ROCA J., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, 50, PP. 123-130, (1999); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP. CLIN. RES., 31, PP. 31-44, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING., 20, 2, PP. 153-163, (2003); CHINWETKITVANICH S., TUNTOOLVEST M., PANSWAD T., ANAEROBIC DECOLORIZATION OF REACTIVE DYE BATH EFFLUENTS BY A TWO-STAGE UASB SYSTEM WITH TAPIOCA AS A COSUBSTRATE, WATER RES., 34, PP. 222-232, (2000); CHRISTOPHER P.F.M., PETER J.H.J., AMIRA N.K., MICHAEL N.A.E., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD. SCI., 50, 3, PP. 259-267, (2010); CHU B., LEE H., GENETIC IMPROVEMENT OF SACCHAROMYCES CEREVISIAE FOR XYLOSE FERMENTATION, BIOTECHNOL. ADV., 25, 5, PP. 425-441, (2007); CURLING S., HILL C., FOWLER P., TIMBER RESIDUE AS A SOURCE FOR HEMICELLULOSE PROCESS CHEMICALS, (2005); DANG V.B.H., DOAN H.D., DANG-VUC T., LOHI A., EQUILIBRIUM AND KINETICS OF BIOSORPTION OF CADMIUM(II) AND COPPER(II) IONS BY WHEAT STRAW, BIORESOUR. TECHNOL., 100, PP. 211-219, (2009); DAVIS P.J., POZNANSKY M.J., MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE BY CHANGES IN MICROSOMAL CHOLESTEROL CONTENT OR PHOSPHOLIPID COMPOSITION, PROC. NATL. ACAD. SCI. U.S.A., 84, 1, PP. 118-121, (1987); DELCOUR J.A., VAN-WIN H., GROBET P.J., DISTRIBUTION AND STRUCTURAL VARIATION OF ARABINOXYLANS IN COMMON WHEAT MILL STREAMS, J. AGRIC. FOOD CHEM., 47, PP. 271-275, (1999); DENKE M.A., LACK OF EFFICACY OF LOW-DOSE SITOSTANOL THERAPY AS AN ADJUNCT TO A CHOLESTEROL-LOWERING DIET IN MEN WITH MODERATE HYPERCHOLESTEROLEMIA, AM. J. CLIN. NUTR., 61, PP. 392-396, (1995); DILLARD C.J., GERMAN J.B., PHYTOCHEMICALS: NUTRACEUTICALS AND HUMAN HEALTH, J. SCI. FOOD AGRIC., 80, PP. 1744-1756, (2000); DU C., CAMPBELL G.M., MISAILIDISA N., MATEOS-SALVADORA F., SADHUKHANB J., MUSTAFAB M., WEIGHTMAN R.M., EVALUATING THE FEASIBILITY OF COMMERCIAL ARABINOXYLAN PRODUCTION IN THE CONTEXT OF A WHEAT BIOREFINERY PRINCIPALLY PRODUCING ETHANOL. PART 1. EXPERIMENTAL STUDIES OF ARABINOXYLAN EXTRACTION FROM WHEAT BRAN, CHEM. ENG. RES. DES., 87, PP. 1232-1238, (2009); DUNFORD N.T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOUR. TECHNOL., 101, PP. 422-425, (2010); EBRINGEROVA A., HROMADKOVA Z., BERTH G., STRUCTURAL AND MOLECULAR PROPERTIES OF A WATER-SOLUBLE ARABINOXYLAN-PROTEIN COMPLEX ISOLATED FROM RYE BRAN, CARBOHYDR. RES., 264, PP. 97-109, (1994); ELKIND M.S., INFLAMMATION, ATHEROSCLEROSIS, AND STROKE, 12, 3, PP. 140-148, (2006); FAN Y., ZHANG Y., ZHANG S., HOU H., REN B., EFFICIENT CONVERSION OF WHEAT STRAW WASTES INTO BIOHYDROGEN GAS BY COW DUNG COMPOST, BIORESOUR. TECHNOL., 97, PP. 500-505, (2006); FOOD AND AGRICULTURAL ORGANIZATION. FAOSTAT. DATABASE, (2003); FOOD AND AGRICULTURAL ORGANIZATION. FAOSTAT. DATABASE, (2007); FENGEL D., WEGENER G., WOOD CHEMISTRY, ULTRASTRUCTURE, REACTIONS, (1989); FINNIE S.M., BETTGE A.D., MORRIS C.F., INFLUENCE OF CULTIVAR AND ENVIRONMENT ON WATER-SOLUBLE AND WATER-INSOLUBLE ARABINOXYLANS IN SOFT WHEAT, CEREAL CHEM., 83, 6, PP. 617-623, (2006); FOCHER B., PALMA M.T., CANETTI M., TORRI G., COSENTINO C., GASTALDI G., STRUCTURAL DIFFERENCES BETWEEN NON-WOOD PLANT CELLULOSES: EVIDENCE FROM SOLID STATE NMR, VIBRATIONAL SPECTROSCOPY AND X-RAY DIFFRACTOMETRY, IND. CROPS PROD., 13, PP. 193-208, (2001); GALLETI G.C., PICCAGLIA R., CHIAVARI G., CONCIALINI V., BUTA J.G., HPLC CHARACTERIZATION OF PHENOLICS IN LIGNOCELLULOSIC MATERIALS, CHROMATOGRAPHIA., 26, PP. 191-196, (1988); GARCIA A., OTTO B., REICH S.C., WEICKERT M.O., STEINIGER J., MACHOWETZ A., RUDOVICH N.N., MOHLIG M., KATZ N., SPETH M., MEUSER F., DOERFER J., ZUNFT H.J.F., PFEIFFER A.H.F., KOEBNICK C., ARABINOXYLAN CONSUMPTION DECREASES POSTPRANDIAL SERUM GLUCOSE, SERUM INSULIN AND PLASMA TOTAL GHRELIN RESPONSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE, EUR. J. CLIN. NUTR., 61, PP. 334-341, (2007); GHOLAM M., NASSERI S., ALIZADEHFARD M.R., MESDAGHINIA A., TEXTILE DYE REMOVAL BY MEMBRANE TECHNOLOGY AND BIOLOGICAL OXIDATION, WATER QUAL. RES. J. CAN., 38, PP. 379-391, (2003); GIREK T., KOZLOWSKI C.A., KOZIOL J.J., WALKOWIAK W.I., KORUS, POLYMERISATION OF BETA-CYCLODEXTRIN WITH SUCCINIC ANHYDRIDE. SYNTHESIS, CHARACTERIZATION, AND ION FLOTATION OF TRANSITION METALS, CARBOHYDR. POLYM., 59, PP. 211-215, (2005); GONG R.M., DING Y., LI M., YANG C., LIU H.J., SUN Y.Z., UTILIZATION OF POWDERED PEANUT HULL AS BIOSORBENT FOR REMOVAL OF ANIONIC DYES FROM AQUEOUS SOLUTION, DYES PIGMENTS., 64, PP. 187-192, (2005); ECONOMIC SURVEY OF PAKISTAN, (2008); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, 2, PP. 356-365, (2002); GUO Y., ZHAO J., ZHANG H., YANG S., QI J., WANG Z., USE OF RICE HUSK BASED POROUS CARBON FOR ADSORPTION OF RHODAMINE B FROM AQUEOUS SOLUTIONS, DYES PIGMENTS., 66, PP. 123-128, (2005); GUPTA V.K., JAIN R., VARSHNEY S., REMOVALS OF REACT FIX GOLDEN YELLOW 3 RFN FROM AQUEOUS SOLUTION USING WHEAT HUSK-AN AGRICULTURAL WASTE, J. HAZARD. MATER., 142, PP. 443-448, (2007); GUPTA V.K., MITTAL A., KRISHNAN L., MITTAL J., ADSORPTION TREATMENT AND RECOVERY OF THE HAZARDOUS DYE, BRILLIANT BLUE FCF, OVER BOTTOM ASH AND DE-OILED SOYA, J. COLLOID INTERFACE SCI., 293, PP. 16-26, (2006); GUYTON A.C., HALL J.E., HEMOSTASIS AND BLOOD COAGULATION, TEXTBOOK OF MEDICAL PHYSIOLOGY, PP. 463-473, (1996); HAGGLUND P., MANNAN-HYDROLYSIS BY HEMICELLULASES. (ENZYMEPOLYSACCHARIDE INTERACTION OF A MODULAR-MANNANASE), (2002); HAN R.P., DING D.D., XU Y.F., ZOU W.H., WANG Y.F., LI Y.F., USE OF RICE HUSK FOR THE ADSORPTION OF CONGO RED FROM AQUEOUS SOLUTION IN COLUMN MODE, BIORESOUR. TECHNOL., 99, PP. 2938-2946, (2008); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP. BIOL. MED., 229, 3, PP. 215-226, (2004); HARPER S.H., LYNCH J.M., THE CHEMICAL COMPONENTS AND DECOMPOSITION OF WHEAT STRAW LEAVES, INTERNODES AND NODES, J. SCI. FOOD AGRIC., 32, PP. 1057-1062, (1981); HJERSTED J.L., HENSON M.A., OPTIMIZATION OF FED-BATCH SACCHAROMYCES CEREVISIAE FERMENTATION USING DYNAMIC FLUX BALANCE MODELS, BIOTECHNOL. PROG., 22, PP. 1239-1248, (2006); HORACE G.C., STEPHEN J.C., BIOLOGICALLY ACTIVE NATURAL PRODUCTS: AGROCHEMICALS, (1999); HOSKINSON R.L., HESS J.R., FOUST T.D., MCKEAN W.T., LEWIS M.S., FRACTIONATION OF HIGHER VALUE CROP RESIDUE COMPONENTS FOR CONVERSION INTO BIOENERGY AND INDUSTRIAL PRODUCTS, (2001); IRANMAHBOOB J., NADIM F., MONEMI S., OPTIMIZING ACIDHYDROLYSIS: A CRITICAL STEP FOR PRODUCTION OF ETHANOL FROM MIXED WOOD CHIPS, BIOMASS BIOENERGY., 22, PP. 401-404, (2002); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD. CHEM., 53, PP. 5583-5586, (2005); KALMAN G., RECZEY K., POSSIBLE WAYS OF BIO-REFINING AND UTILIZING THE RESIDUAL LIGNOCELLULOSES OF CORN GROWING AND PROCESSING. PERIOD, POLYTECH. CHEM., 51, 2, PP. 29-36, (2007); KAPARAJU P., SERRANO M., THOMSEN A.B., KONGJAN P., ANGELIDAKI I., BIOETHANOL, BIOHYDROGEN AND BIOGAS PRODUCTION FROM WHEAT STRAW IN A BIOREFINERY CONCEPT, BIORESOUR. TECHNOL., 100, PP. 2562-2568, (2009); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO. CLIN. PROC., 78, PP. 965-978, (2003); KHAN K., SHEWRY P.R., CARBOHYDRATES, WHEAT CHEMISTRY AND TECHNOLOGY, PP. 319-336, (2009); KLINKE H.B., AHRING B.K., SCHMIDT A.S., THOMSEN A.B., BIORESOUR. TECHNOL., 82, PP. 15-26, (2002); KRIS-ETHERTON P.M., HECKER K.D., BONANOME A., COVAL S.M., BINKOSKI A.E., HILPERT K., GRIEL A.E., ETHERTON T.D., BIOACTIVE COMPOUNDS IN FOODS: THEIR ROLE IN THE PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER, AM. J. MED., 113, PP. 71-88, (2002); LAIRON D., NUTRITIONAL QUALITY AND SAFETY OF ORGANIC FOOD. A REVIEW. AGRONOMY FOR SUSTAINABLE DEVELOPMENT, (2009); LAWTHER J.M., SUN R.C., BANKS W.B., EXTRACTION, FRACTIONATION, AND CHARACTERIZATION OF STRUCTURAL POLYSACCHARIDES FROM WHEAT STRAW, J. AGRIC. FOOD CHEM., 43, PP. 667-675, (1995); LEON E., PISTON F., AOUNI R., SHEWRY P.R., CRISTINA M., ROSELL C.M., MARTIN A., BARRO F., PASTING PROPERTIES OF TRANSGENIC LINES OF A COMMERCIAL BREAD WHEAT EXPRESSING COMBINATIONS OF HMW GLUTENIN SUBUNIT GENES, J. CEREAL SCI., 51, PP. 344-349, (2010); LICHTENSTEIN A.H., DECKELBAUM R.J., STANOL/STEROL ESTER-CONTAINING FOODS AND BLOOD CHOLESTEROL LEVELS. A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE NUTRITION COMMITTEE OF THE COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM OF THE AMICAN HEART ASSOCIATION, CIRCULATION, 103, PP. 1177-1179, (2002); LINDE M., JAKOBSSON E., GALBE M., ZACCHI G., STEAM PRETREATMENT OF DILUTE H2SO4-IMPREGNATED WHEAT STRAW AND SSF WITH LOW YEAST AND ENZYME LOADINGS FOR BIOETHANOL PRODUCTION, BIOMASS BIOENERGY., 32, PP. 326-332, (2007); LIU J., SHIMIZU K., KONISHI F., NODA K., KUMAMOTO S., KURASHIKI K., KONDO R., ANTI-ANDROGENIC ACTIVITIES OF THE TRITERPENOIDS FRACTION OF GANODERMA LUCIDUM, FOOD CHEM., 100, PP. 1691-1696, (2007); LIU R., YU H., HUANG Y., STRUCTURE AND MORPHOLOGY OF CELLULOSE IN WHEAT STRAW, CELLULOSE, 12, 1, PP. 25-34, (2005); LOPEZ A., BENBELKACEM H., PIC J.S., DEBELLEFONTAINE H., OXIDATION PATHWAYS FOR OZONATION OF AZO DYES IN A SEMI-BATCH REACTOR: A KINETIC PARAMETERS APPROACH, ENVIRON. TECHNOL., 25, PP. 311-321, (2004); LU Z.X., WALKER K.Z., MUIR J.G., O'DEA K., ARABINOXYLAN FIBER IMPROVES METABOLIC CONTROL IN PEOPLE WITH TYPE II DIABETES, EUR. J. CLIN. NUTR., 58, PP. 621-628, (2004); LU Z.X., WALKER K.Z., MUIR J.G., MASCARA T., O'DEA K., ARABINOXYLAN FIBER, A BY PRODUCT OF WHEAT FLOUR PROCESSING REDUCES THE POSTPRANDIAL GLUCOSE RESPONSE IN NORMOGLYCEMIC SUBJECTS, AM. J. CLIN. NUTR., 71, PP. 1123-1128, (2000); LUNDQVIST J., TELEMAN A., JUNEL L., ZACCHI G., DAHLMAN O., TJERNELD F., STALBRAND H., ISOLATION AND CHARACTERIZATION OF GALACTOGLUCOMANNAN FROM SPRUCE (PICEA ABIES), CARBOHYDR. POLYM., 48, 1, PP. 29-39, (2002); MACIAS F.A., SIMONET A.M., GALINDO J.C.G., NATURAL PRODUCTS AS ALLELOCHEMICALS. BIOACTIVE STEROIDS AND TRITERPENES FROM MELILOTUS MESSANENSIS AND THEIR ALLELOPATHIC POTENTIAL, (1995); MAHATO S.B., SEN S., ADVANCES IN TRITERPENOID RESEARCH, PHYTOCHEM., 44, PP. 1185-1236, (1997); MALL I.D., SRIVASTAVA V.C., AGARWAL N.K., REMOVAL OF ORANGE-G AND METHYL VIOLET DYES BY ADSORPTION ONTO BAGASSE FLY ASH-KINETIC STUDY AND EQUILIBRIUM ISOTHERM ANALYSES, DYES PIGMENTS., 69, PP. 210-223, (2006); MANACH C., MAZUR A., SCALBERT A., POLYPHENOLS AND PREVENTION OF CARDIOVASCULAR DISEASES, CURR. OPIN. LIPIDOL., 16, PP. 2305-2425, (2005); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMSAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); MAYA J.J., THOMAS S., BIOFIBERS BIOCOMPOSITES, CARBOHYD. POLYM., 71, PP. 343-364, (2008); MCKENDRY P., ENERGY PRODUCTION FROM BIOMASS (PART 1): OVERVIEW OF BIOMASS, BIORESOUR. TECHNOL., 83, PP. 37-46, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); MENENDEZ R., FERNANDEZ S.I., DEL R.A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MIDDLETON E., KANDASWAMI C., THEOHARIDES T.C., THE EFFECTS OF PLANT FLAVONOIDS ON MAMMALIAN CELLS: IMPLICATIONS FOR INFLAMMATION, HEART DISEASE, AND CANCER, PHARMACOL. REV., 52, PP. 673-751, (2000); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., FUSTER A., LASTRETO E., YANEZ M., IRICO G., MCCOOK B., FARRE A., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, 1, PP. 31-41, (2001); NEUKOM H., MARKWALDER H.U., OXIDATIVE GELATION OF WHEAT FLOUR PENTOSANS: A NEW WAY OF CROSS LINKING POLYMERS, CEREAL FOODS WORLD., 23, PP. 374-376, (1978); NINO-MEDINA G., CARVAJAL-MILLAN E., LIZARDI J., RASCON-CHU A., MARQUEZ-ESCALANTE J.A., GARDEA A., MARTINEZ-LOPEZ A.L., GUERRERO V., MAIZE PROCESSING WASTE WATER ARABINOXYLANS: GELLING CAPABILITY AND CROSS-LINKING CONTENT, FOOD CHEM., 115, PP. 1286-1290, (2009); NOA M., MAS R., MESA R., COMPARATIVE STUDY OF POLICOSANOL VS. LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL. RES., 43, PP. 31-37, (2001); OLIVIER L.M., KRISANS S.K., PEROXISOMAL PROTEIN TARGETING AND IDENTIFICATION OF PEROXISOMAL TARGETING SIGNALS IN CHOLESTEROL BIOSYNTHETIC ENZYMES, BIOCHIM. BIOPHYS. ACTA., 1529, 1-3, PP. 89-102, (2000); ORLANDO U.S., BAES A.U., NISHIJIMA W., PREPARATION OF AGRICULTURAL RESIDUE ANION EXCHANGERS AND ITS NITRATE MAXIMUM EXCHANGE CAPACITY, CHEMOSPHERE, 48, PP. 1041-1046, (2002); OSTLUND R.E., RACETTE S.B., STENSON W.F., INHIBITION OF CHOLESTEROL ABSORPTION BY PYTOSTEROL-REPLETE WHEAT GERM COMPARED WITH PHYTOSTEROL-DEPLETED WHEAT GERM, AM. J. CLIN. NUTR., 77, 6, PP. 1385-1589, (2002); PALMQVIST E., HAHN-HAGERDAL B., FERMENTATION OF LIGNOCELLULOSIC HYDROLYSATES. II. INHIBITORS AND MECHANISMS OF INHIBITION, BIORESOUR. TECHNOL., 74, PP. 25-33, (2000); PARR A.J., BOLWELL G.P., PHENOLS IN PLANT AND IN MAN. THE POTENTIAL FOR POSSIBLE NUTRITIONAL ENHANCEMENT OF THE DIET BY MODIFYING THE PHENOLS CONTENT OR PROFILE, J. SCI. FOOD AGRIC., 80, PP. 985-1012, (2000); PETRUCCI R.S., WILLIAM S., HARWOOD F., HERRING G., GENERAL CHEMISTRY: PRINCIPLES AND MODERN APPLICATIONS, (2002); PETZOLD G., SCHWARZ S., MENDE M., JAEGER W., DYE FLOCCULATION USING POLYAMPHOLYTES AND POLYELECTROLYTE-SURFACTANT NANOPARTICLES, J. APPL. POLYM. SCI., 104, PP. 1342-1349, (2007); PLANTE M., CRAFTS C., BAILEY B., GAMACHE P., WARASKA J., ACWORTH I., SIMPLE AND DIRECT ANALYSIS OF PHYTOSTEROLS BY REVERSED-PHASE HPLC AND CHARGED AEROSOL DETECTION. ESA-A DIONEX COMPANY, (2010); PRACHAYASITTIKUL S., SARABAN1 P., CHERDTRAKULKIAT R., RUCHIRAWAT S., PRACHAYASITTIKUL V., NEW BIOACTIVE TRITERPENOIDS AND ANTIMALARIAL ACTIVITY OF DIOSPYROS RUBRA LEC, EXCLI J., 9, PP. 1-10, (2010); PUTNAM A.R., WEED ALLELOPATHY, WEED PHYSIOLOGY, PP. 131-155, (1985); PUUPPONEN-PIMIA R., AURA A.M., OKSMAN-CALDENTEY K.M., MYLLAERINEN P., SAARELA M., MAILA-SANDHOLM T., POUTANEN K., DEVELOPMENT OF FUNCTIONAL INGREDIENTS FOR GUT HEALTH, TRENDS FOOD. SCI. TECHNOL., 13, PP. 3-11, (2002); RANDHIR R., LIN Y.T., SHETTY K., PHENOLICS, THEIR ANTIOXIDANT AND ANTIMICROBIAL ACTIVITY IN DARK GERMINATED FENUGREEK SPROUTS IN RESPONSE TO PEPTIDE AND PHYTOCHEMICAL ELICITORS, ASIA PAC. J. CLIN. NUTR., 13, PP. 295-307, (2004); REVANAPPA S.B., NANDINI C.D., SALIMATH P.V., STRUCTURAL CHARACTERIZATION OF PENTOSANS FROM HEMICELLULOSE B OF WHEAT VARIETIES WITH VARYING CHAPATTI MAKING QUALITY, FOOD CHEM., 119, PP. 27-33, (2010); RICE E.L., ALLELOPATHY, (1984); ROBINSON T., CHANDRAN P., NIGAM P., REMOVAL OF DYES FROM A SYNTHETIC TEXTILE DYE EFFLUENT BY BIOSORPTION ON APPLE POMACE AND WHEAT STRAW, WATER RES., 36, PP. 2824-2830, (2002); ROGERS P.L., JEON Y.J., LEE K.J., LAWFORD H.G., ZYMOMONAS MOBILIS FOR FUEL ETHANOL AND HIGHER VALUE PRODUCTS, ADV. BIOCHEM. ENG. BIOTECHNOL., 108, PP. 263-288, (2007); ROLLER M., CLUNE Y., COLLINS K., RECHKEMMER G., WATZL B., CONSUMPTION OF PREBIOTIC INULIN ENRICHED WITH OLIGOFRUCTOSE IN COMBINATION WITH THE PROBIOTICS LACTOBACILLUS RHAMNOSUS AND BIFIDOBACTERIUM LACTIS HAS MINOR EFFECTS ON SELECTED IMMUNE PARAMETERS IN POLYPECTOMISED AND COLON CANCER PATIENTS, BR. J. NUTR., 97, PP. 676-684, (2007); ROWELL R.M., SPELTER H., NOVEL USES FOR WHEAT BY-PRODUCTS, PROCEEDINGS OF THE INTERNATIONAL WHEAT QUALITY CONFERENCE, PP. 417-423, (2003); RUSSELL D.W., WILSON J.D., STEROID 5A-REDUCTASE: TWO GENES/TWO ENZYMES, ANN. REV. CLIN. BIOCHEM., 63, PP. 25-61, (1994); SAHA B.C., ITEN L.B., COTTA M.A., WU Y.V., DILUTEACIDPRETREATMENT, ENZYMATIC SACCHARIFICATION AND FERMENTATION OF WHEAT STRAW TO ETHANOL, PROCESS BIOCHEM., 40, PP. 3693-3700, (2005); SAHA B.D., HEMICELLULOSE BIOCONVERSION (2003), J. IND. MICROBIOL. BIOTECHNOL., 30, PP. 279-291, (2003); SANADI A.R., NATURAL FIBERS AS FILLERS/REINFORCEMENTS IN THERMOPLASTICS, INTRODUCTION TO LOW ENVIRONMENTAL IMPACT POLYMERS, PP. 105-140, (2004); SASAKI T., KAORU K., TAKESHI Y., EFFECT OF WATER-SOLUBLE AND INSOLUBLE NONSTARCH POLYSACCHARIDES ISOLATED FROM WHEAT FLOUR ON THE RHEOLOGICAL PROPERTIES OF WHEAT STARCH GEL, CARBOHYDR. POLYMER., 57, PP. 451-458, (2004); SASAKI T., YASUI T., KIRIBUCHI-OTOBE C., YANAGISAWA T., FUJITA M., KOHYAMA K., RHEOLOGICAL PROPERTIES OF STARCH GELS FROM WHEAT MUTANTS WITH REDUCE AMYLOSE CONTENT, CEREAL CHEM., 84, PP. 102-107, (2007); SUN R.C., SUN X.F., IDENTIFICATION AND QUANTITATION OF LIPOPHILIC EXTRACTIVES FROM WHEAT STRAW, IND. CROPS PROD., 14, PP. 51-64, (2001); SUN R.C., SALISBURY D., TOMKINSON J., CHEMICAL COMPOSITION OF LIPOPHILIC EXTRACTIVES RELEASED DURING THE HOT WATER TREATMENT OF WHEAT STRAW, BIORESOUR. TECHNOL., 88, PP. 95-101, (2003); SUN R., LAWTHER J.M., BANKS W.B., ISOLATION AND CHARACTERIZATION OF HEMICELLULOSE B AND CELLULOSE FROM PRESSURE REFINED WHEAT STRAW, IND. CROPS PROD., 7, PP. 121-128, (1998); THEANDER O., REVIEW OF STRAW CARBOHYDRATE RESEARCH, PROG. BIOTECHNOL., 1, (1985); MONOGRAPH. POLICOSANOL, ALTERN. MED. REV., 9, 3, PP. 312-317, (2004); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE., 18, 3, PP. 393-397, (1995); TSANG D.C.W., HU J., LIU M.Y., ZHANG W.H., LAI K.C.K., LO I.M.C., ACTIVATED CARBON PRODUCED FROM WASTE WOOD PALLETS: ADSORPTION OF THREE CLASSES OF DYES, WATER AIR SOIL POLLUT., 184, PP. 141-155, (2007); VOLPE R., NIITTYNEN L., KORPELA R., SIRTORI C., BUCCI A., FRAONE N., PAZZUCCONI F., EFFECTS OF YOGHURT ENRICHED WITH PLANT STEROLS ON SERUM LIPIDS IN PATIENTS WITH MODERATE HYPERCHOLESTEROLAEMIA, BR. J. NUTR., 86, PP. 233-239, (2001); WALKER J.R.L., THE BIOLOGY OF PLANT PHENOLICS, PP. 1-57, (1975); WANG M., HAM R.J., VLIET T.V., OUDGENOEG G., INTERACTION OF WATER EXTRACTABLE PENTOSANS WITH GLUTEN PROTEIN: EFFECT ON DOUGH PROPERTIES AND GLUTEN QUALITY, J. CEREAL SCI., 36, PP. 25-37, (2002); WANG Y., GAO B.Y., YUE W.W., YUE Q.Y., ADSORPTION KINETICS OF NITRATE FROM AQUEOUS SOLUTIONS ONTO MODIFIED WHEAT RESIDUE, COLLOIDS SURF., 308, PP. 1-5, (2007); WASSER S.P., WEIS A.L., THERAPEUTIC EFFECTS OF SUBSTANCES OCCURRING IN HIGHER BASIDIOMYCETES MUSHROOMS: A MODERN PERSPECTIVE, CRIT. REV. IMMUNOL., 19, PP. 65-96, (1999); WIESENBERG G.L.B., LEHNDORFF E., SCHWARK L., THERMAL DEGRADATION OF RYE AND MAIZE STRAW: LIPID PATTERN CHANGES AS A FUNCTION OF TEMPERATURE, ORG. GEOCHEM., 40, PP. 167-174, (2009); XU X., GAO B.Y., WANG W.Y., YUE Q.Y., WANG Y., NI S.Q., ADSORPTION OF PHOSPHATE FROM AQUEOUS SOLUTIONS ONTO MODIFIED WHEAT RESIDUE: CHARACTERISTICS, KINETIC AND COLUMN STUDIES, COLLOIDS SURF., 70, PP. 46-52, (2009); ZHANG X., PATEL A., HORIBE H., CHOLESTEROL, CORONARY HEART DISEASE, AND STROKE IN THE ASIA PACIFIC REGION, INT. J. EPIDEMIOL., 32, PP. 563-572, (2003); ZHANG Y., REVIVING THE CARBOHYDRATE ECONOMY VIA MULTI-PRODUCT LIGNOCELLULOSE BIOREFINERIES, J. IND. MICROBIOL. BIOTECHNOL., 35, PP. 367-375, (2008); ZUNFT H.J., LUEDER W., KOEBNICK C., IMHOF D., REDUCTION OF POSTPRANDIAL GLUCOSE AND INSULIN RESPONSE IN SERUM OF HEALTHY SUBJECTS BY AN ARABINOXYLAN CONCENTRATE ISOLATED FROM WHEAT STARCH PLANT PROCESS WATER, ASIA PAC. J. CLIN. NUTR., 13, PP. 147-150, (2004)","F. SAEED; NATIONAL INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF AGRICULTURE, FAISALABAD, PAKISTAN; EMAIL: FAR1552@YAHOO.COM","","ENGLISH","CRIT. REV. FOOD SCI. NUTR.","ARTICLE","ISI","2-S2.0-84870654595","CRIT REV FOOD SCI NUTR","UNIVERSITY OF AGRICULTURE;UNIVERSITY OF AGRICULTURE;UNIVERSITY OF AGRICULTURE;UNIVERSITY OF AGRICULTURE;UNIVERSITY OF AGRICULTURE","NOTREPORTED;UNIVERSITY OF AGRICULTURE;NOTREPORTED",NA,"PASHA I, 2013, CRIT REV FOOD SCI NUTR","PASHA I, 2013, CRIT REV FOOD SCI NUTR"
"HOKSRUD A;TORGALSEN T;HARSTAD H;HAUGEN S;ANDERSEN T;RISBERG M;BAHR R","HOKSRUD, AASNE (8533868300); TORGALSEN, THOMAS (55070850300); HARSTAD, HERLOF (15071337300); HAUGEN, SIMEN (15071550000); ANDERSEN, THOR EINAR (7201524414); RISBERG, MAY ARNA (6603553600); BAHR, ROALD (7102647460)","ULTRASOUNDGUIDED SCLEROSIS OF NEOVESSELS IN PATELLAR TENDINOPATHY A PROSPECTIVE STUDY OF 101 PATIENTS",2012,"AMERICAN JOURNAL OF SPORTS MEDICINE","40","5",54,"10.1177/0363546511433012","OSLO SPORTS TRAUMA RESEARCH CENTER, DEPARTMENT OF SPORTS MEDICINE, NORWEGIAN SCHOOL OF SPORT SCIENCES, 0806 OSLO, PO BOX 4014 ULLEVAAL STADION, NORWAY;HJELP24 NIMI, OSLO, NORWAY;SYKEHUSET VESTFOLD, STAVERN, NORWAY;SYKEHUSET VESTFOLD, STAVERN, NORWAY;OSLO SPORTS TRAUMA RESEARCH CENTER, DEPARTMENT OF SPORTS MEDICINE, NORWEGIAN SCHOOL OF SPORT SCIENCES, 0806 OSLO, PO BOX 4014 ULLEVAAL STADION, NORWAY;HJELP24 NIMI, OSLO, NORWAY, NAR, OSLO, NORWAY;OSLO SPORTS TRAUMA RESEARCH CENTER, DEPARTMENT OF SPORTS MEDICINE, NORWEGIAN SCHOOL OF SPORT SCIENCES, 0806 OSLO, PO BOX 4014 ULLEVAAL STADION, NORWAY","BACKGROUND: A RANDOMIZED CONTROLLED STUDY HAS SHOWN PROMISING CLINICAL RESULTS AFTER TREATMENT WITH SCLEROSING INJECTIONS IN A GROUP OF PATIENTS WITH PATELLAR TENDINOPATHY, BUT NO STUDY HAS INVESTIGATED MEDIUM- OR LONG-TERM OUTCOME IN A LARGE AND UNSELECTED GROUP OF PATIENTS. PURPOSE: TO INVESTIGATE IF SCLEROSING TREATMENT WOULD AFFECT THE LEVEL OF PATELLAR TENDON PAIN AND KNEE FUNCTION AFTER 24 MONTHS IN A LARGE GROUP OF PATIENTS WITH PATELLAR TENDINOPATHY. STUDY DESIGN: CASE SERIES; LEVEL OF EVIDENCE, 4. METHODS: THIS PROSPECTIVE STUDY RECRUITED PATIENTS WITH A CLINICAL DIAGNOSIS OF JUMPER'S KNEE AND VISIBLE NEOVASCULARIZATION CORRESPONDING TO THE PAINFUL AREA ON POWER DOPPLER ULTRASOUND. THEY RECEIVED UP TO A MAXIMUM OF 5 ULTRASOUND-GUIDED SCLEROSING INJECTIONS USING POLIDOCANOL AT 4- TO 6-WEEK INTERVALS. KNEE PAIN AND FUNCTION WERE RECORDED USING THE VICTORIAN INSTITUTE OF SPORT ASSESSMENT-PATELLA (VISA-P) SCORE BEFORE TREATMENT AND 6, 12, AND 24 MONTHS AFTER THE FIRST INJECTION.RESULTS: IN TOTAL, 101 PATIENTS (15 WOMEN AND 86 MEN) WITH 120 TENDONS WERE INCLUDED AND GIVEN FROM 1 TO 5 SCLEROSING INJECTIONS (MEAN [SD], 2.5 [0.9]). THE PATIENTS REPORTED A SIGNIFICANTLY IMPROVED VISA-P SCORE FROM BASELINE (MEAN, 39; 95% CONFIDENCE INTERVAL [CI], 36-42) TO THE 24-MONTH FOLLOW-UP (MEAN, 65; 95% CI, 60-70) (RANGE, 21-100; P <.001, PAIRED T TEST). HOWEVER, A VISA-P SCORE OF >95 POINTS WAS REPORTED IN ONLY 22 CASES (20%), WHEREAS 37 CASES (36%) REPORTED A VISA-P SCORE OF <50 AT 24 MONTHS. CONCLUSION: SCLEROSING TREATMENT WITH POLIDOCANOL RESULTED IN A MODERATE IMPROVEMENT IN KNEE FUNCTION AND REDUCED PAIN IN A HETEROGENEOUS GROUP OF PATIENTS WITH PATELLAR TENDINOPATHY. NEVERTHELESS, FEW OF THE PATIENTS WERE CURED, AND THE MAJORITY STILL HAD REDUCED FUNCTION AND SUBSTANTIAL PAIN AFTER 24 MONTHS OF FOLLOW-UP. © 2012 AMERICAN ORTHOPAEDIC SOCIETY FOR SPORTS MEDICINE.","JUMPER'S KNEE; NEOVASCULARIZATION; POLIDOCANOL; SCLEROSING TREATMENT","ADOLESCENT; ADULT; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PAIN; PAIN MANAGEMENT; PATELLAR LIGAMENT; SCLEROSING SOLUTIONS; SCLEROTHERAPY; TENDINOPATHY; TREATMENT OUTCOME; YOUNG ADULT; FATTY ALCOHOL; POLICOSANOL; SCLEROSING AGENT; ADOLESCENT; ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; ECHOGRAPHY; FEMALE; HUMAN; INJURY; MALE; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PAIN; PATELLA LIGAMENT; SCLEROTHERAPY; TENDINITIS; TREATMENT OUTCOME","","","ALFREDSON H., HARSTAD H., HAUGEN S., OHBERG L., SCLEROSING POLIDOCANOL INJECTIONS TO TREAT CHRONIC PAINFUL SHOULDER IMPINGEMENT SYNDROME-RESULTS OF A TWO-CENTRE COLLABORATIVE PILOT STUDY, KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 14, 12, PP. 1321-1326, (2006); ALFREDSON H., OHBERG L., NEOVASCULARISATION IN CHRONIC PAINFUL PATELLAR TENDINOSIS - PROMISING RESULTS AFTER SCLEROSING NEOVESSELS OUTSIDE THE TENDON CHALLENGE THE NEED FOR SURGERY, KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 13, 2, PP. 74-80, (2005); ALFREDSON H., OHBERG L., SCLEROSING INJECTIONS TO AREAS OF NEO-VASCULARISATION REDUCE PAIN IN CHRONIC ACHILLES TENDINOPATHY: A DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL, KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 13, 4, PP. 338-344, (2005); ALFREDSON H., OHBERG L., ZEISIG E., LORENTZON R., TREATMENT OF MIDPORTION ACHILLES TENDINOSIS: SIMILAR CLINICAL RESULTS WITH US AND CD-GUIDED SURGERY OUTSIDE THE TENDON AND SCLEROSING POLIDOCANOL INJECTIONS, KNEE SURG SPORTS TRAUMATOL ARTHROSC, 15, PP. 1504-1509, (2007); ALMEKINDERS L.C., TEMPLE J.D., ETIOLOGY, DIAGNOSIS, AND TREATMENT OF TENDONITIS: AN ANALYSIS OF THE LITERATURE, MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 30, 8, PP. 1183-1190, (1998); BAHR R., FOSSAN B., LOKEN S., ENGEBRETSEN L., SURGICAL TREATMENT COMPARED WITH ECCENTRIC TRAINING FOR PATELLAR TENDINOPATHY (JUMPER'S KNEE): A RANDOMIZED, CONTROLLED TRIAL, JOURNAL OF BONE AND JOINT SURGERY - SERIES A, 88, 8, PP. 1689-1698, (2006); CLEMENTSON M., LOREN I., DAHLBERG L., ASTROM M., SCLEROSING INJECTIONS IN MIDPORTION ACHILLES TENDINOPATHY: A RETROSPECTIVE STUDY OF 25 PATIENTS, KNEE SURG SPORTS TRAUMATOL ARTHROSC, 16, PP. 887-890, (2008); COLEMAN B.D., KHAN K.M., MAFFULLI N., COOK J.L., WARK J.D., STUDIES OF SURGICAL OUTCOME AFTER PATELLAR TENDINOPATHY: CLINICAL SIGNIFICANCE OF METHODOLOGICAL DEFICIENCIES AND GUIDELINES FOR FUTURE STUDIES. VICTORIAN INSTITUTE OF SPORT TENDON STUDY GROUP, SCAND J MED SCI SPORTS, 10, PP. 2-11, (2000); COOK J.L., KHAN K.M., HARCOURT P.R., GRANT M., YOUNG D.A., BONAR S.F., A CROSS SECTIONAL STUDY OF 100 ATHLETES WITH JUMPER'S KNEE MANAGED CONSERVATIVELY AND SURGICALLY. THE VICTORIAN INSTITUTE OF SPORT TENDON STUDY GROUP, BR J SPORTS MED, 31, PP. 332-336, (1997); FREDBERG U., BOLVIG L., JUMPER'S KNEE: REVIEW OF THE LITERATURE, SCAND J MED SCI SPORTS, 9, PP. 66-73, (1999); HOKSRUD A., OHBERG L., ALFREDSON H., BAHR R., ULTRASOUND-GUIDED SCLEROSIS OF NEOVESSELS IN PAINFUL CHRONIC PATELLAR TENDINOPATHY: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF SPORTS MEDICINE, 34, 11, PP. 1738-1746, (2006); HOKSRUD A.F., BAHR R., INJECTABLE AGENTS DERIVED FROM OR TARGETING VASCULARITY: HAS CLINICAL ACCEPTANCE IN MANAGING TENDON DISORDERS SUPERSEDED SCIENTIFIC EVIDENCE?, J MUSCULOSKELET NEURONAL INTERACT, 11, PP. 174-184, (2011); LIAN O., HOLEN K.J., ENGEBRETSEN L., BAHR R., RELATIONSHIP BETWEEN SYMPTOMS OF JUMPER'S KNEE AND THE ULTRASOUND CHARACTERISTICS OF THE PATELLAR TENDON AMONG HIGH LEVEL MALE VOLLEYBALL PLAYERS, SCANDINAVIAN JOURNAL OF MEDICINE AND SCIENCE IN SPORTS, 6, 5, PP. 291-296, (1996); LIND B., OHBERG L., ALFREDSON H., SCLEROSING POLIDOCANOL INJECTIONS IN MID-PORTION ACHILLES TENDINOSIS: REMAINING GOOD CLINICAL RESULTS AND DECREASED TENDON THICKNESS AT 2-YEAR FOLLOW-UP, KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 14, 12, PP. 1327-1332, (2006); MAFFULLI N., LONGO U.G., DENARO V., NOVEL APPROACHES FOR THE MANAGEMENT OF TENDINOPATHY, J BONE JOINT SURG AM, 92, PP. 2604-2613, (2010); MAGNUSSEN R.A., DUNN W.R., THOMSON A.B., NONOPERATIVE TREATMENT OF MIDPORTION ACHILLES TENDINOPATHY: A SYSTEMATIC REVIEW, CLIN J SPORT MED, 19, PP. 54-64, (2009); OHBERG L., ALFREDSON H., SCLEROSING THERAPY IN CHRONIC ACHILLES TENDON INSERTIONAL PAIN-RESULTS OF A PILOT STUDY, KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 11, 5, PP. 339-343, (2003); OHBERG L., ALFREDSON H., KHAN K., ULTRASOUND GUIDED SCLEROSIS OF NEOVESSELS IN PAINFUL CHRONIC ACHILLES TENDINOSIS: PILOT STUDY OF A NEW TREATMENT, BR J SPORTS MED, 36, PP. 173-177, (2002); RABAGO D., BEST T.M., ZGIERSKA A.E., ZEISIG E., RYAN M., CRANE D., A SYSTEMATIC REVIEW OF FOUR INJECTION THERAPIES FOR LATERAL EPICONDYLOSIS: PROLOTHERAPY, POLIDOCANOL, WHOLE BLOOD AND PLATELET-RICH PLASMA, BR J SPORTS MED, 43, PP. 471-481, (2009); VAN STERKENBURG M.N., DE JONGE M.C., SIEREVELT I.N., VAN DIJK C.N., LESS PROMISING RESULTS WITH SCLEROSING ETHOXYSCLEROL INJECTIONS FOR MIDPORTION ACHILLES TENDINOPATHY: A RETROSPECTIVE STUDY, AM J SPORTS MED, 38, PP. 2226-2232, (2010); VISENTINI P.J., KHAN K.M., COOK J.L., KISS Z.S., HARCOURT P.R., WARK J.D., THE VISA SCORE: AN INDEX OF SEVERITY OF SYMPTOMS IN PATIENTS WITH JUMPER'S KNEE (PATELLAR TENDINOSIS). VICTORIAN INSTITUTE OF SPORT TENDON STUDY GROUP, J SCI MED SPORT, 1, PP. 22-28, (1998); VISNES H., BAHR R., THE EVOLUTION OF ECCENTRIC TRAINING AS TREATMENT FOR PATELLAR TENDINOPATHY (JUMPER'S KNEE): A CRITICAL REVIEW OF EXERCISE PROGRAMMES, BRITISH JOURNAL OF SPORTS MEDICINE, 41, 4, PP. 217-223, (2007); VISNES H., HOKSRUD A., COOK J., BAHR R., NO EFFECT OF ECCENTRIC TRAINING ON JUMPER'S KNEE IN VOLLEYBALL PLAYERS DURING THE COMPETITIVE SEASON: A RANDOMIZED CLINICAL TRIAL, CLIN J SPORT MED, 15, PP. 227-234, (2005); WILLBERG L., SUNDING K., OHBERG L., FORSSBLAD M., FAHLSTROM M., ALFREDSON H., SCLEROSING INJECTIONS TO TREAT MIDPORTION ACHILLES TENDINOSIS: A RANDOMISED CONTROLLED STUDY EVALUATING TWO DIFFERENT CONCENTRATIONS OF POLIDOCANOL, KNEE SURG SPORTS TRAUMATOL ARTHROSC, 16, PP. 859-864, (2008); ZEISIG E., FAHLSTROM M., OHBERG L., ALFREDSON H., PAIN RELIEF AFTER INTRATENDINOUS INJECTIONS IN PATIENTS WITH TENNIS ELBOW: RESULTS OF A RANDOMISED STUDY, BRITISH JOURNAL OF SPORTS MEDICINE, 42, 4, PP. 267-271, (2008); ZEISIG E., OHBERG L., ALFREDSON H., SCLEROSING POLIDOCANOL INJECTIONS IN CHRONIC PAINFUL TENNIS ELBOW-PROMISING RESULTS IN A PILOT STUDY, KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 14, 11, PP. 1218-1224, (2006)","A. HOKSRUD; OSLO SPORTS TRAUMA RESEARCH CENTER, DEPARTMENT OF SPORTS MEDICINE, NORWEGIAN SCHOOL OF SPORT SCIENCES, 0806 OSLO, PO BOX 4014 ULLEVAAL STADION, NORWAY; EMAIL: AASNE.HOKSRUD@NIH.NO","","ENGLISH","AM. J. SPORTS MED.","REVIEW","ISI","2-S2.0-84857986849","AM J SPORTS MED","NORWEGIAN SCHOOL OF SPORT SCIENCES;NORWEGIAN SCHOOL OF SPORT SCIENCES;NORWEGIAN SCHOOL OF SPORT SCIENCES","NOTREPORTED;NORWEGIAN SCHOOL OF SPORT SCIENCES;NOTREPORTED",NA,"HOKSRUD A, 2012, AM J SPORTS MED","HOKSRUD A, 2012, AM J SPORTS MED"
"MAZZA A;LENTI S;SCHIAVON L;ZUIN M;D'AVINO M;RAMAZZINA E;CASIGLIA E","MAZZA, ALBERTO (7006213924); LENTI, SALVATORE (24376483800); SCHIAVON, LAURA (6603432402); ZUIN, MARCO (37032368300); D’AVINO, MARIA (56602860200); RAMAZZINA, EMILIO (6603459917); CASIGLIA, EDOARDO (7005951169)","NUTRACEUTICALS FOR SERUM LIPID AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE AND HYPERCHOLESTEROLEMIC SUBJECTS AT LOW CARDIOVASCULAR RISK",2015,"ADVANCES IN THERAPY","32","10",23,"10.1007/s12325-015-0229-x","HYPERTENSION CENTRE AND DEPARTMENT OF INTERNAL MEDICINE, SANTA MARIA DELLA MISERICORDIA GENERAL HOSPITAL, AULSS 18, ROVIGO, ITALY;HYPERTENSION CENTRE AND INTERNAL MEDICINE AND GERIATRICS, SAN DONATO HOSPITAL, USL 8, AREZZO, ITALY;DEPARTMENT OF INTERNAL MEDICINE, SANTA MARIA DELLA MISERICORDIA GENERAL HOSPITAL, AULSS 18, ROVIGO, ITALY;FACULTY OF MEDICINE, UNIVERSITY OF FERRARA, FERRARA, ITALY;UNIT OF INTERNAL MEDICINE, AORN A. CARDARELLI, NAPLES, ITALY;DEPARTMENT OF INTERNAL MEDICINE, SANTA MARIA DELLA MISERICORDIA GENERAL HOSPITAL, AULSS 18, ROVIGO, ITALY;DEPARTMENT OF MEDICINE, LABORATORY OF EPIDEMIOLOGY, UNIVERSITY OF PADUA, PADUA, ITALY","INTRODUCTION: PRIMARY CARDIOVASCULAR (CV) PREVENTION MAY BE ACHIEVED BY LIFESTYLE/NUTRITION CHANGES, ALTHOUGH A RELEVANT ROLE IS NOW EMERGING FOR SPECIFIC, FUNCTIONAL FOODS AND NUTRACEUTICAL COMPOUNDS (NCS). THE AIM OF THIS STUDY WAS TO INVESTIGATE THE EFFICACY AND SAFETY OF NCS IN LOWERING BLOOD PRESSURE (BP) AND IMPROVING LIPID PROFILE, WHEN ADDED TO DIET AND LIFESTYLE MANAGEMENT VERSUS DIET ALONE IN A GROUP OF PATIENTS WITH HYPERTENSION (HT) AND HYPERCHOLESTEROLEMIA (HCH) WITH LOW CV RISK. METHODS: SIXTY-SIX PATIENTS WITH HT AND HCH WITH GRADE 1 ESSENTIAL HT (MEAN AGE 56.0 ± 4.6 YEARS) WITHOUT HISTORY OF CV DISEASES OR ORGAN DAMAGE WERE ANALYZED. THESE SUBJECTS WERE STARTED ON ONE TABLET OF AN NC-CONTAINING RED YEAST RICE, POLICOSANOL, BERBERINE, FOLIC ACID AND COENZYME Q10 ONCE DAILY FOR 6 MONTHS AND WERE AGE AND GENDER MATCHED WITH SUBJECTS FOLLOWING A DIET PROGRAM. DIFFERENCES IN CLINIC BP, 24-H AMBULATORY BP (24 H-ABPM), SERUM TOTAL CHOLESTEROL, LOW-DENSITY AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C AND HDL-C) AND TRIGLYCERIDE VALUES WERE COMPARED BY ANALYSIS OF VARIANCE. RESULTS: IN THE TREATMENT GROUP, A SIGNIFICANT REDUCTION OF SYSTOLIC 24 H-ABPM (141.6 ± 6.4 VS. 136.2 ± 4.8 MMHG; P < 0.05) AND PULSE PRESSURE 24 H-ABPM (52.6 ± 7.2 VS. 47.3 ± 5.4 MMHG; P < 0.05) WAS FOUND AT THE END OF FOLLOW-UP. A REDUCTION OF TOTAL CHOLESTEROL (−19.2%), LDL-C (−17.4%) AND TRIGLYCERIDES (−16.3%) WAS OBSERVED (P < 0.001 FOR ALL); HDL-C REMAINED UNCHANGED. NO DIFFERENCE WAS FOUND IN THE CONTROL GROUP. CONCLUSIONS: THE TESTED NCS WAS FOUND TO BE SAFE, WELL TOLERATED AND EFFECTIVE IN REDUCING MEAN 24-H SYSTOLIC AND 24-H PULSE PRESSURE AND IN IMPROVING LIPID PATTERN. © 2015, SPRINGER HEALTHCARE.","BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL; DIET; LIPIDS; NUTRACEUTICAL COMPOUNDS","BERBERINE; BIOLOGICAL PRODUCTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FEMALE; FOLIC ACID; HEALTH BEHAVIOR; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; UBIQUINONE; BERBERINE; CHOLESTIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; BERBERINE; BIOLOGICAL PRODUCT; FATTY ALCOHOL; FOLIC ACID; LIPID; UBIQUINONE; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DIET; DIET SUPPLEMENTATION; DRUG EFFECTS; HEALTH BEHAVIOR; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; RISK FACTOR","","","LEWINGTON S., CLARKE R., QIZILBASH N., ET AL., AGE-SPECIFIC RELEVANCE OF USUAL BLOOD PRESSURE TO VASCULAR MORTALITY: A META-ANALYSIS OF INDIVIDUAL DATA FOR ONE MILLION ADULTS IN 61 PROSPECTIVE STUDIES, LANCET, 360, PP. 1903-1913, (2002); GAZIANO T.A., BITTON A., ANAND S., WEINSTEIN M.C., INTERNATIONAL SOCIETY OF HYPERTENSION. THE GLOBAL COST OF NON-OPTIMAL BLOOD PRESSURE, J HYPERTENS, 27, PP. 1472-1477, (2009); PRACTICE GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION (ESH) AND THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC): ESH/ESC TASK FORCE FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION, J HYPERTENS, 2013, 31, PP. 1925-1938, (2013); FILIPPIDIS F.T., GEROVASILI V., MAJEED A., ASSOCIATION BETWEEN CARDIOVASCULAR RISK FACTORS AND MEASUREMENTS OF BLOOD PRESSURE AND CHOLESTEROL IN 27 EUROPEAN COUNTRIES IN 2009, PREV MED, 67, PP. 71-74, (2014); KIM M.K., AHN C.W., KANG S., ET AL., ASSOCIATION BETWEEN APOLIPOPROTEIN B/APOLIPOPROTEIN A-1 AND ARTERIAL STIFFNESS IN METABOLIC SYNDROME, CLIN CHIM ACTA, 437, PP. 115-119, (2014); REINER Z., CATAPANO A.L., ET AL., ESC COMMITTEE FOR PRACTICE GUIDELINES (CPG) 2008–2010 AND 2010–2012 COMMITTEES. ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); ELMER P.J., OBARZANEK E., VOLLMER W.M., ET AL., EFFECTS OF COMPREHENSIVE LIFESTYLE MODIFICATION ON DIET, WEIGHT, PHYSICAL FITNESS, AND BLOOD PRESSURE CONTROL: 18-MONTH RESULTS OF A RANDOMIZED TRIAL, ANN INTERN MED, 144, PP. 485-495, (2006); OSTERBERG L., BLASCHKE T., ADHERENCE TO MEDICATION, N ENGL J MED, 353, PP. 487-497, (2005); LI Y., JIANG L., JIA Z., ET AL., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS, 9, (2014); CICERO A.F., TARTAGNI E., ERTEK S., NUTRACEUTICALS FOR METABOLIC SYNDROME MANAGEMENT: FROM LABORATORY TO BENCHSIDE, CURR VASC PHARMACOL, 12, PP. 565-571, (2014); CICERO A.F., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN DRUG SAF, 11, PP. 753-766, (2012); TRIMARCO V., CIMMINO C.S., SANTORO M., ET AL., NUTRACEUTICALS FOR BLOOD PRESSURE CONTROL IN PATIENTS WITH HIGH-NORMAL OR GRADE 1 HYPERTENSION, HIGH BLOOD PRESS CARDIOVASC PREV, 19, PP. 117-122, (2012); HOUSTON M.C., THE ROLE OF NUTRITION, NUTRACEUTICALS, VITAMINS, ANTIOXIDANTS, AND MINERALS IN THE PREVENTION AND TREATMENT OF HYPERTENSION, ALTERN THER HEALTH MED, 19, PP. 32-49, (2013); PALATINI P., FRIGO G., BERTOLO O., ROMAN E., DA CORTA R., WINNICKI M., VALIDATION OF THE A&D TM-2430 DEVICE FOR AMBULATORY BLOOD PRESSURE MONITORING AND EVALUATION OF PERFORMANCE ACCORDING TO SUBJECTS’ CHARACTERISTICS, BLOOD PRESS MONIT, 3, PP. 255-260, (1998); ESTRUCH R., ROS E., MARTINEZ-GONZALEZ M.A., MEDITERRANEAN DIET FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, N ENGL J MED, 69, PP. 676-677, (2013); TARONE R.E., A MODIFIED BONFERRONI METHOD FOR DISCRETE DATA, BIOMETRICS, 46, PP. 515-522, (1990); MCHUGH M.L., MULTIPLE COMPARISON ANALYSIS TESTING IN ANOVA, BIOCHEM MED (ZAGREB), 21, PP. 203-209, (2011); SAFAR M.E., BOUDIER H.S., VASCULAR DEVELOPMENT: PULSE PRESSURE, AND THE MECHANISMS OF HYPERTENSION, HYPERTENSION, 46, PP. 205-209, (2005); MAZZA A., PESSINA A.C., TIKHONOFF V., PAVEI A., PRIVATO G., CASIGLIA E., PULSE PRESSURE: AN INDEPENDENT PREDICTOR OF CORONARY AND STROKE MORTALITY IN ELDERLY FEMALES FROM THE GENERAL POPULATION, BLOOD PRESS, 10, PP. 205-211, (2001); HONG Y., HUI S.S., CHAN B.T., HOU J., EFFECT OF BERBERINE ON CATECHOLAMINE LEVELS IN RATS WITH EXPERIMENTAL CARDIAC HYPERTROPHY, LIFE SCI, 72, PP. 2499-2507, (2003); BANACH M., SERBAN C., SAHEBKAR A., ET AL., EFFECTS OF COENZYME Q10 ON STATIN-INDUCED MYOPATHY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, MAYO CLIN PROC, 90, PP. 24-34, (2015); HO M.J., BELLUSCI A., WRIGHT J.M., BLOOD PRESSURE LOWERING EFFICACY OF COENZYME Q10 FOR PRIMARY HYPERTENSION, COCHRANE DATABASE SYST REV, 4, (2009); PATTI A.M., KATSIKI N., NIKOLIC D., ET AL., NUTRACEUTICALS IN LIPID-LOWERING TREATMENT: A NARRATIVE REVIEW ON THE ROLE OF CHITOSAN, ANGIOLOGY, 66, PP. 416-421, (2015); RIZZO M., GIGLIO R.V., NIKOLIC D., ET AL., EFFECTS OF CHITOSAN ON PLASMA LIPIDS AND LIPOPROTEINS: A 4-MONTH PROSPECTIVE PILOT STUDY, ANGIOLOGY, 65, PP. 538-542, (2014); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTR METAB, 4, PP. 133-139, (2011); CICERO A.F.G., DEROSA G., BOVE M., ET AL., LONG TERM EFFECTIVENESS AND SAFETY OF A NATRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUTH METABOLIC SYNDROME, CURR TOPICS NUTR RES, 7, (2009); ARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS AND BERBERINE) IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS: A DOUBLE-BLIND, PLACEBO CONTROLLED STUDY, CURR THER RES, 77, PP. 1-6, (2015); PIRRO M., LUPATTELLI G., GIORNO D., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, PHARMA NUTR, 1, PP. 73-77, (2013); MARK A.L., WEIGHT REDUCTION FOR TREATMENT OF OBESITY-ASSOCIATED HYPERTENSION: NUANCES AND CHALLENGES, CURR HYPERTENS REP, 9, PP. 368-372, (2007); TANG J.L., ARMITAGE J.M., LANCASTER T., SILAGY C.A., FOWLER G.H., NEIL H.A., SYSTEMATIC REVIEW OF DIETARY INTERVENTION TRIALS TO LOWER BLOOD TOTAL CHOLESTEROL IN FREE-LIVING SUBJECTS, BMJ, 316, PP. 1213-1220, (1998); WILLETT W.C., THE MEDITERRANEAN DIET: SCIENCE AND PRACTICE, PUBLIC HEALTH NUTR, 9, PP. 105-110, (2006)","A. MAZZA; HYPERTENSION CENTRE AND DEPARTMENT OF INTERNAL MEDICINE, SANTA MARIA DELLA MISERICORDIA GENERAL HOSPITAL, ROVIGO, AULSS 18, ITALY; EMAIL: MAZZA.ALBERTO@AZISANROVIGO.IT","SPRINGER HEALTHCARE","ENGLISH","ADV. THER.","ARTICLE","ISI","2-S2.0-84938414356","ADV THER","HYPERTENSION CENTRE AND DEPARTMENT OF INTERNAL MEDICINE;HYPERTENSION CENTRE AND INTERNAL MEDICINE AND GERIATRICS;SANTA MARIA DELLA MISERICORDIA GENERAL HOSPITAL;UNIVERSITY OF FERRARA;SANTA MARIA DELLA MISERICORDIA GENERAL HOSPITAL;UNIVERSITY OF PADUA","NOTREPORTED;HYPERTENSION CENTRE AND DEPARTMENT OF INTERNAL MEDICINE;NOTREPORTED",NA,"MAZZA A, 2015, ADV THER","MAZZA A, 2015, ADV THER"
"GUO Y;XU R;ZHU C;WU N;CUI Z;LI J","GUO, YUAN-LIN (12799448200); XU, RUI-XIA (55303585500); ZHU, CHENG-GANG (55671542400); WU, NA-QIONG (26435613100); CUI, ZHI-PING (56437172500); LI, JIAN-JUN (57211730901)","POLICOSANOL ATTENUATES STATININDUCED INCREASES IN SERUM PROPROTEIN CONVERTASE SUBTILISINKEXIN TYPE 9 WHEN COMBINED WITH ATORVASTATIN",2014,"EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE","2014","",16,"10.1155/2014/926087","DIVISION OF DYSLIPIDEMIA, FU WAI HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES, BEILISHI ROAD 167, BEIJING, 100037, CHINA;DIVISION OF DYSLIPIDEMIA, FU WAI HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES, BEILISHI ROAD 167, BEIJING, 100037, CHINA;DIVISION OF DYSLIPIDEMIA, FU WAI HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES, BEILISHI ROAD 167, BEIJING, 100037, CHINA;DIVISION OF DYSLIPIDEMIA, FU WAI HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES, BEILISHI ROAD 167, BEIJING, 100037, CHINA;KENLI COUNTY HOSPITAL, SHANDONG, 257500, CHINA;DIVISION OF DYSLIPIDEMIA, FU WAI HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES, BEILISHI ROAD 167, BEIJING, 100037, CHINA","OBJECTIVE. STATIN TREATMENT ALONE HAS BEEN DEMONSTRATED TO SIGNIFICANTLY INCREASE PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) LEVELS. THE EFFECT OF POLICOSANOL COMBINED WITH STATIN ON PCSK9 IS UNKNOWN. METHODS. PROTOCOL I: 26 PATIENTS WITH ATHEROSCLEROSIS WERE RANDOMLY ASSIGNED TO RECEIVE EITHER ATORVASTATIN 20 MG/D OR POLICOSANOL 20 MG/D + ATORVASTATIN 20 MG/D FOR 8 WEEKS. PROTOCOL II: 15 HEALTHY VOLUNTEERS WERE RANDOMLY ASSIGNED TO EITHER POLICOSANOL 20 MG/D OR A CONTROL GROUP FOR 12 WEEKS. SERUM LEVELS OF PCSK9 WERE DETERMINED AT DAY 0 AND THE END OF EACH PROTOCOL. RESULTS. PROTOCOL I: ATORVASTATIN 20 MG/D SIGNIFICANTLY INCREASED SERUM PCSK9 LEVEL BY 39.4% (256 ± 84 NG/ML VERSUS 357 ± 101 NG/ML, P = 0.002). HOWEVER, POLICOSANOL 20 MG/D + ATORVASTATIN 20 MG/D INCREASED SERUM PCSK9 LEVEL BY ONLY 17.4% WITHOUT STATISTICAL SIGNIFICANCE (264 ± 60 NG/ML VERSUS 310 ± 86 NG/ML, P = 0.184). PROTOCOL II: THERE WAS A TREND TOWARD DECREASING SERUM PCSK9 LEVELS IN THE POLICOSANOL GROUP (289 ± 71 NG/ML VERSUS 235 ± 46 NG/ML, P = 0.069). CONCLUSION. POLICOSANOL COMBINED WITH STATIN ATTENUATED THE STATIN-INDUCED INCREASE IN SERUM PCSK9 LEVELS. THIS FINDING INDICATES THAT POLICOSANOL MIGHT HAVE A MODEST EFFECT OF LOWERING SERUM PCSK9 LEVELS. © 2014 YUAN-LIN GUO ET AL.","","ATORVASTATIN; KEXIN; PLACEBO; POLICOSANOL; SUBTILISIN; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; YOUNG ADULT","","","MOUSAVI S.A., BERGE K.E., LEREN T.P., THE UNIQUE ROLE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 IN CHOLESTEROL HOMEOSTASIS, JOURNAL OF INTERNAL MEDICINE, 266, 6, PP. 507-519, (2009); KHERA A., STATINS, PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 CONCENTRATIONS, AND LDL LOWERING, CLINICAL CHEMISTRY, 58, 1, PP. 6-7, (2012); CARESKEY H.E., DAVIS R.A., ALBORN W.E., TROUTT J.S., CAO G., KONRAD R.J., ATORVASTATIN INCREASES HUMAN SERUM LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, JOURNAL OF LIPID RESEARCH, 49, 2, PP. 394-398, (2008); WELDER G., ZINEH I., PACANOWSKI M.A., TROUTT J.S., CAO G., KONRAD R.J., HIGH-DOSE ATORVASTATIN CAUSES A RAPID SUSTAINED INCREASE IN HUMAN SERUM PCSK9 AND DISRUPTS ITS CORRELATION WITH LDL CHOLESTEROL, THE JOURNAL OF LIPID RESEARCH, 51, 9, PP. 2714-2721, (2010); DONG B., WU M., LI H., KRAEMER F.B., ADELI K., SEIDAH N.G., PARK S.W., LIU J., STRONG INDUCTION OF PCSK9 GENE EXPRESSION THROUGH HNF1 Α AND SREBP2: MECHANISM FOR THE RESISTANCE TO LDL-CHOLESTEROL LOWERING EFFECT OF STATINS IN DYSLIPIDEMIC HAMSTERS, JOURNAL OF LIPID RESEARCH, 51, 6, PP. 1486-1495, (2010); KONRAD R.J., TROUTT J.S., CAO G., EFFECTS OF CURRENTLY PRESCRIBED LDL-C-LOWERING DRUGS ON PCSK9 AND IMPLICATIONS FOR THE NEXT GENERATION OF LDL-C-LOWERING AGENTS, LIPIDS IN HEALTH AND DISEASE, 1038, (2011); GUO Y.-L., LIU J., LI J.-J., ZHU C.-G., QING P., JIA Y.-J., WU N.-Q., NIE S.-P., LI Z.-C., ZENG H.-S., YANG P., A MULTI-CENTER SURVEY OF ACHIEVING RECOMMENDED LIPID GOALS IN CHINESE PATIENTS WITH CORONARY ARTERY DISEASE IN REAL WORLD CARDIOVASCULAR PRACTICE, INTERNATIONAL JOURNAL OF CARDIOLOGY, 153, 2, PP. 211-212, (2011); DUBUC G., TREMBLAY M., PARE G., JACQUES H., HAMELIN J., BENJANNET S., BOULET L., GENEST J., BERNIER L., SEIDAH N.G., DAVIGNON J., A NEW METHOD FOR MEASUREMENT OF TOTAL PLASMA PCSK9: CLINICAL APPLICATIONS, JOURNAL OF LIPID RESEARCH, 51, 1, PP. 140-149, (2010); AWAN Z., SEIDAH N.G., MACFADYEN J.G., BENJANNET S., CHASMAN D.I., RIDKER P.M., GENEST J., ROSUVASTATIN, PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 CONCENTRATIONS, AND LDL CHOLESTEROL RESPONSE: THE JUPITER TRIAL, CLINICAL CHEMISTRY, 58, 1, PP. 183-189, (2012); HUIJGEN R., BOEKHOLDT S.M., ARSENAULT B.J., BAO W., DAVAINE J.-M., TABET F., PETRIDES F., RYE K.-A., DEMICCO D.A., BARTER P.J., KASTELEIN J.J.P., LAMBERT G., PLASMA PCSK9 LEVELS AND CLINICAL OUTCOMES IN THE TNT (TREATING TO NEW TARGETS) TRIAL: A NESTED CASE-CONTROL STUDY, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 59, 20, PP. 1778-1784, (2012); CARIOU B., LE MAY C., COSTET P., CLINICAL ASPECTS OF PCSK9, ATHEROSCLEROSIS, 216, 2, PP. 258-265, (2011); RASHID S., CURTIS D.E., GARUTI R., ANDERSON N.H., BASHMAKOV Y., HO Y.K., HAMMER R.E., MOON Y.-A., HORTON J.D., DECREASED PLASMA CHOLESTEROL AND HYPERSENSITIVITY TO STATINS IN MICE LACKING PCSK9, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102, 15, PP. 5374-5379, (2005); STEIN E.A., GIPE D., BERGERON J., EFFECT OF A MONOCLONAL ANTIBODY TO PCSK9, REGN727/SAR236553, TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA ON STABLE STATIN DOSE WITH OR WITHOUT EZETIMIBE THERAPY: A PHASE 2 RANDOMISED CONTROLLED TRIAL, THE LANCET, 380, 9836, PP. 29-36, (2012); VOGEL R.A., PCSK9 INHIBITION: THE NEXT STATIN?, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 59, 25, PP. 2354-2355, (2012); COSTET P., HOFFMANN M.M., CARIOU B., DELASALLE B.G., KONRAD T., WINKLER K., PLASMA PCSK9 IS INCREASED BY FENOFIBRATE AND ATORVASTATIN IN A NON-ADDITIVE FASHION IN DIABETIC PATIENTS, ATHEROSCLEROSIS, 212, 1, PP. 246-251, (2010); MAYNE J., DEWPURA T., RAYMOND A., PLASMA PCSK9 LEVELS ARE SIGNIFICANTLY MODIFIED BY STATINS AND FIBRATES IN HUMANS, LIPIDS IN HEALTH AND DISEASE, 722, (2008); DAVIGNON J., DUBUC G., STATINS AND EZETIMIBE MODULATE PLASMA PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) LEVELS, TRANSACTIONS OF THE AMERICAN CLINICAL AND CLIMATOLOGICAL ASSOCIATION, 120, PP. 163-173, (2009); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERNATIVE MEDICINE REVIEW, 7, 3, PP. 203-217, (2002); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AND AGING, 20, 2, PP. 153-163, (2003); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLINICAL DRUG INVESTIGATION, 25, 11, PP. 701-707, (2005); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1543-1548, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, 10, PP. 923-929, (2011); MARTINO F., PUDDU P.E., PANNARALE G., LOW DOSE CHROMIUM-POLYNICOTINATE OR POLICOSANOL IS EFFECTIVE IN HYPERCHOLESTEROLEMIC CHILDREN ONLY IN COMBINATION WITH GLUCOMANNAN, ATHEROSCLEROSIS, 228, 1, PP. 198-202, (2013); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADVANCES IN THERAPY, 28, 12, PP. 1105-1113, (2011); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES, 20, 9, PP. 656-661, (2010); CICERO A.F.G., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS: A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 57, 1, PP. 26-30, (2007); MCCARTY M.F., AN EZETIMIBE-POLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTS, MEDICAL HYPOTHESES, 64, 3, PP. 636-645, (2005); NEW POLICOSANOL PRODUCT COMBINES NATURAL CHOLESTEROL LOWERING WITH OMEGA-3 FATTY ACIDS TO LOWER CV RISK, CARDIOVASCULAR JOURNAL OF SOUTH AFRICA, 17, 2, (2006); FONTANI G., LODI L., MIGLIORINI S., CORRADESCHI F., EFFECT OF OMEGA-3 AND POLICOSANOL SUPPLEMENTATION ON ATTENTION AND REACTIVITY IN ATHLETES, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 28, 4, PP. 473S-481S, (2009); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERREIRO R.M., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, 3, PP. 393-397, (1995); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., DIAZ E., FERNANDEZ L., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL, 57, 7, PP. 568-577, (1996)","","HINDAWI PUBLISHING CORPORATION","ENGLISH","EVID.-BASED COMPLEMENT. ALTERN. MED.","ARTICLE","ISI","2-S2.0-84914703154","EVID-BASED COMPLEMENT ALTERN MED",NA,"NOTREPORTED",NA,"GUO Y-L, 2014, EVID-BASED COMPLEMENT ALTERN MED","GUO Y-L, 2014, EVID-BASED COMPLEMENT ALTERN MED"
"HSU C;SHIH H;CHANG Y;HUANG Z;TSAI M;CHIA Y;CHEN C;LAI Y;WENG C","HSU, C.Y. (57191538448); SHIH, H.Y. (55811244900); CHANG, Y.C. (56580702600); HUANG, Z.L. (56580725000); TSAI, M.J. (7403551533); CHIA, Y.C. (7006358195); CHEN, C. (9632675500); LAI, Y.K. (7401512434); WENG, C.F. (7102126581)","THE BENEFICIAL EFFECTS OF TETRACOSANOL ON INSULINRESISTANCE BY INSULIN RECEPTOR KINASE SENSIBILISATION",2015,"JOURNAL OF FUNCTIONAL FOODS","14","8",9,"10.1016/j.jff.2015.01.033","INSTITUTE OF BIOTECHNOLOGY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN, INSTITUTE OF BIOTECHNOLOGY, NATIONAL TSING HUA UNIVERSITY, HSINCHU, 30013, TAIWAN;INSTITUTE OF BIOTECHNOLOGY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN;INSTITUTE OF BIOTECHNOLOGY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN;INSTITUTE OF BIOTECHNOLOGY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN;NEURAL REGENERATION LABORATORY, NEUROLOGICAL INSTITUTE, TAIPEI VETERANS GENERAL HOSPITAL, TAIPEI, 112, TAIWAN;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, TAJEN UNIVERSITY, PING TUNG HSIEN, TAIWAN;DEPARTMENT OF CHEMISTRY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN;INSTITUTE OF BIOTECHNOLOGY, NATIONAL TSING HUA UNIVERSITY, HSINCHU, 30013, TAIWAN;INSTITUTE OF BIOTECHNOLOGY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN","IN THIS STUDY, WE INVESTIGATED WHETHER TETRACOSANOL, AN ALIPHATIC ALCOHOL ISOLATED FROM SACCHARUM SINENSE, ENHANCES INSULIN RECEPTOR KINASE ACTIVITY TO EXHIBIT AN INSULIN SYNERGISTIC EFFECT IN VITRO AND IN VIVO. THE INSULIN PLUS TETRACOSANOL ENHANCED INSULIN RECEPTOR KINASE SHOWED THAT AKT ACTIVITY WAS DOWN-REGULATED BY S961 IN DIFFERENTIATED L6 MYOTUBES. MEANWHILE, INSULIN PLUS TETRACOSANOL RESTORED THE ABILITY OF GLUCOSE TRANSPORTER TRANSLOCATION AND GLUCOSE UPTAKE IN DIFFERENTIATED MYOTUBES WITH S961-INDUCED INSULIN RESISTANCE IN VITRO. THE MODIFICATION OF CARBON CHAIN LENGTHS AND THE HYDROXYL GROUP OF TETRACOSANOL SHOWED THAT IT SERVED AS A CRITICAL CHEMICAL STRUCTURE FOR THE GLUCOSTASIS EFFECT IN VIVO. THIS STUDY PROVIDES NEW EVIDENCE TO SHOW THAT TETRACOSANOL CAN IMPROVE GLYCAEMIC CONTROL VIA INSULIN RECEPTOR KINASE ACTIVITY INDUCED AND LEADS TO THE ENHANCEMENT OF GLUCOSE TRANSPORTER TRANSLOCATION TO IMPROVE GLUCOSE UPTAKE. THE HYDROXYL GROUP OF TETRACOSANOL PLAYS A CRITICAL ROLE FOR INSULIN RECEPTOR KINASE ACTIVITY. © 2015 ELSEVIER LTD.","DIABETES MELLITUS; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR KINASE; INSULIN RESISTANCE; POLICOSANOL; TETRACOSANOL","SACCHARUM SINENSE","","","ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 176-182, (1995); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 33, PP. 835-840, (2000); AVOGARO A., TREATING DIABETES TODAY WITH GLICLAZIDE MR: A MATTER OF NUMBERS, DIABETES, OBESITY AND METABOLISM, 14, PP. 14-19, (2012); DUNAIF A., XIA J., BOOK C.B., SCHENKER E., TANG Z., EXCESSIVE INSULIN RECEPTOR SERINE PHOSPHORYLATION IN CULTURED FIBROBLASTS AND IN SKELETAL MUSCLE. A POTENTIAL MECHANISM FOR INSULIN RESISTANCE IN THE POLYCYSTIC OVARY SYNDROME, JOURNAL OF CLINICAL INVESTIGATION, 96, PP. 801-810, (1995); ELLIS L., CLAUSER E., MORGAN D.O., EDERY M., ROTH R.A., RUTTER W.J., REPLACEMENT OF INSULIN RECEPTOR TYROSINE RESIDUES 1162 AND 1163 COMPROMISES INSULIN-STIMULATED KINASE ACTIVITY AND UPTAKE OF 2-DEOXYGLUCOSE, CELL, 45, PP. 721-732, (1986); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 20, PP. 155-162, (2009); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANTHYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 16, PP. 61-65, (2008); HSU C.Y., SHIH H.Y., CHIA Y.C., LEE C.H., ASHIDA H., LAI Y.K., WENG C.F., RUTIN POTENTIATES INSULIN RECEPTOR KINASE TO ENHANCE INSULIN-DEPENDENT GLUCOSE TRANSPORTER 4 TRANSLOCATION, MOLECULAR NUTRITION & FOOD RESEARCH, 58, 6, PP. 1168-1176, (2014); HUANG S., CZECH M.P., THE GLUT4 GLUCOSE TRANSPORTER, CELL METABOLISM, 5, PP. 237-252, (2007); HUBBARD S., WEI L., ELLIS L., HENDRICKSON W., CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR, NATURE, 372, (1994); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 5583-5586, (2005); JONES P.J.H., KASSIS A.N., MARINANGELI C.P.F., POLICOSANOLS LOSE THEIR LUSTRE AS CHOLESTEROL-LOWERING AGENTS, JOURNAL OF FUNCTIONAL FOODS, 1, PP. 236-239, (2009); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, JOURNAL OF FOOD SCIENCE, 76, PP. C891-C899, (2011); KNUDSEN L., HANSEN B.F., JENSEN P., PEDERSEN T.A., VESTERGAARD K., SCHAFFER L., BLAGOEV B., OLEKSIEWICZ M.B., KISELYOV V.V., DE MEYTS P., AGONISM AND ANTAGONISM AT THE INSULIN RECEPTOR, PLOS ONE, 7, (2012); KOBAYASHI M., IWANISHI M., EGAWA K., SHIGETA Y., PIOGLITAZONE INCREASES INSULIN SENSITIVITY BY ACTIVATING INSULIN RECEPTOR KINASE, DIABETES, 41, PP. 476-483, (1992); KUMAR N., DEY C.S., METFORMIN ENHANCES INSULIN SIGNALLING IN INSULIN-DEPENDENT AND-INDEPENDENT PATHWAYS IN INSULIN RESISTANT MUSCLE CELLS, BRITISH JOURNAL OF PHARMACOLOGY, 137, PP. 329-336, (2002); MATSUDA H., TOKUNAGA M., IWAHASHI H., NARUTO S., YAGI H., MASUKO T., KUBO M., STUDIES ON PALAUAN MEDICINAL HERBS. II. ACTIVATION OF MOUSE MACROPHAGES RAW 264.7 BY ONGAEL, LEAVES OF PHALERIA CUMINGII (MEISN.) F. VILL. AND ITS ACYLGLUCOSYLSTEROLS, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 28, PP. 929-933, (2005); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, PP. 8-12, (2001); MOLLER D.E., NEW DRUG TARGETS FOR TYPE 2 DIABETES AND THE METABOLIC SYNDROME, NATURE, 414, PP. 821-827, (2001); MONTSERRAT-DE LA PAZ S., GARCIA-GIMENEZ M.D., ANGEL-MARTIN M., PEREZ-CAMINO M.C., FERNANDEZ ARCHE A., LONG-CHAIN FATTY ALCOHOLS FROM EVENING PRIMROSE OIL INHIBIT THE INFLAMMATORY RESPONSE IN MURINE PERITONEAL MACROPHAGES, JOURNAL OF ETHNOPHARMACOLOGY, 151, PP. 131-136, (2014); NATARAJAN V., SCHMID H.H., 1-DOCOSANOL AND OTHER LONG CHAIN PRIMARY ALCOHOLS IN DEVELOPING RAT BRAIN, LIPIDS, 12, PP. 128-130, (1977); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 6289-6293, (2005); ROSEN O.M., HERRERA R., OLOWE Y., PETRUZZELLI L.M., COBB M.H., PHOSPHORYLATION ACTIVATES THE INSULIN RECEPTOR TYROSINE PROTEIN KINASE, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 80, PP. 3237-3240, (1983); SARKHEL S., DESIRAJU G.R., N-H...O, O-H...O, AND C-H...O HYDROGEN BONDS IN PROTEIN-LIGAND COMPLEXES: STRONG AND WEAK INTERACTIONS IN MOLECULAR RECOGNITION, PROTEINS, 54, PP. 247-259, (2004); SHAW J.E., SICREE R.A., ZIMMET P.Z., GLOBAL ESTIMATES OF THE PREVALENCE OF DIABETES FOR 2010 AND 2030, DIABETES RESEARCH AND CLINICAL PRACTICE, 87, PP. 4-14, (2010); SHISHEVA A., PHOSPHOINOSITIDES IN INSULIN ACTION ON GLUT4 DYNAMICS: NOT JUST PTDINS(3,4,5)P3, AMERICAN JOURNAL OF PHYSIOLOGY. ENDOCRINOLOGY AND METABOLISM, 295, PP. E536-E544, (2008); SON N.H., PARK T.S., YAMASHITA H., YOKOYAMA M., HUGGINS L.A., OKAJIMA K., HOMMA S., SZABOLCS M.J., HUANG L.S., GOLDBERG I.J., CARDIOMYOCYTE EXPRESSION OF PPARGAMMA LEADS TO CARDIAC DYSFUNCTION IN MICE, JOURNAL OF CLINICAL INVESTIGATION, 117, PP. 2791-2801, (2007); TAKAHASHI M., KONNO C., HIKINO H., ISOLATION AND HYPOGLYCEMIC ACTIVITY OF SACCHARANS A, B, C, D, E AND F, GLYCANS OF SACCHARUM OFFICINARUM STALKS1, PLANTA MEDICA, 51, PP. 258-260, (1985); TAKAYAMA S., WHITE M.F., KAHN C.R., PHORBOL ESTER-INDUCED SERINE PHOSPHORYLATION OF THE INSULIN RECEPTOR DECREASES ITS TYROSINE KINASE ACTIVITY, JOURNAL OF BIOLOGICAL CHEMISTRY, 263, PP. 3440-3447, (1988); TOWLER M.C., HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE IN METABOLIC CONTROL AND INSULIN SIGNALING, CIRCULATION RESEARCH, 100, PP. 328-341, (2007); WHITING D.R., GUARIGUATA L., WEIL C., SHAW J., IDF DIABETES ATLAS: GLOBAL ESTIMATES OF THE PREVALENCE OF DIABETES FOR 2011 AND 2030, DIABETES RESEARCH AND CLINICAL PRACTICE, 94, PP. 311-321, (2011); YAMAMOTO N., KAWASAKI K., KAWABATA K., ASHIDA H., AN ENZYMATIC FLUORIMETRIC ASSAY TO QUANTITATE 2-DEOXYGLUCOSE AND 2-DEOXYGLUCOSE-6-PHOSPHATE FOR IN VITRO AND IN VIVO USE, ANALYTICAL BIOCHEMISTRY, 404, PP. 238-240, (2010)","C.F. WENG; INSTITUTE OF BIOTECHNOLOGY, NATIONAL DONG-HWA UNIVERSITY, HUALIEN, 974, TAIWAN; EMAIL: CFWENG@MAIL.NDHU.EDU.TW","ELSEVIER LTD","ENGLISH","J. FUNCT. FOODS","ARTICLE","ISI","2-S2.0-84926336631","J FUNCT FOODS","NATIONAL DONG-HWA UNIVERSITY;NATIONAL DONG-HWA UNIVERSITY;NATIONAL DONG-HWA UNIVERSITY;NATIONAL DONG-HWA UNIVERSITY;NEUROLOGICAL INSTITUTE;TAJEN UNIVERSITY;NATIONAL DONG-HWA UNIVERSITY;NATIONAL TSING HUA UNIVERSITY;NATIONAL DONG-HWA UNIVERSITY","NOTREPORTED;NATIONAL DONG-HWA UNIVERSITY;NOTREPORTED",NA,"HSU CY, 2015, J FUNCT FOODS","HSU CY, 2015, J FUNCT FOODS"
"HOBBS T;CASO R;MCMAHON D;NYMARK M","HOBBS, THOMAS (56560843800); CASO, RICHARD (56560870600); MCMAHON, DAVID (56560688900); NYMARK, MARIA (36475364800)","A NOVEL MULTIINGREDIENT SUPPLEMENT TO MANAGE ELEVATED BLOOD LIPIDS IN PATIENTS WITH NO EVIDENCE OF CARDIOVASCULAR DISEASE A PILOT STUDY",2014,"ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE","20","5",9,"","POWER MED, SAINT LOUIS, MO, UNITED STATES;ORANGE COUNTY HEART CENTER, ALISO VIEJO, CA, UNITED STATES;SOLANA HEALTH, INC, SAN DIEGO, CA, UNITED STATES;BIOBUTLERS, SAN DIEGO, CA, UNITED STATES","CONTEXT • RECENT CHANGES IN USAGE GUIDELINES HAVE CREATED THE POTENTIAL FOR MILLIONS MORE AMERICANS TO BE PRESCRIBED STATIN MEDICATIONS. CAUTION SHOULD BE ADVISED BECAUSE THE RISK OF ADVERSE EFFECTS OF STATINS MAY OUTWEIGH THEIR BENEFITS AND PRECLUDE THEIR PREVENTIVE USE FOR PATIENTS WITHOUT CONFIRMED CARDIOVASCULAR DISEASE (CVD) WHO PRESENT WITH ELEVATED BLOOD LIPIDS. HOWEVER, STATINS HAVE SHOWN SOME BENEFIT IN PRIMARY CVD PREVENTION. RED YEAST RICE (RYR) IS A DIETARY SUPPLEMENT THAT HAS BEEN DEMONSTRATED TO REDUCE LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL LEVELS IN BLOOD AND OMEGA-3 POLYUNSATURATED FATTY ACIDS HAVE BEEN SHOWN TO REDUCE BLOOD LEVELS OF TRIGLYCERIDES (TGS). ALTHOUGH EFFECTIVE, QUALITY CONTROL ISSUES AGGRAVATE RISK OF ADVERSE EFFECTS FOR BOTH OF THESE SUPPLEMENTS. FURTHERMORE, LOW DOSAGES PER CAPSULE, WHICH REQUIRE PATIENTS TO MANAGE AND CONSUME MANY CAPSULES PER DAY, ALSO MAY REDUCE PATIENT COMPLIANCE TO SUPPLEMENTATION REGIMENS. OBJECTIVES • THE AUTHORS’ OBJECTIVE WAS TO DETERMINE THE EFFECTS OF A MULTI-INGREDIENT SUPPLEMENT (MIS) FEATURING RYR FOR PRIMARY SUPPORT OF CARDIOVASCULAR (CV) HEALTH IN PATIENTS WHO PRESENT NO CVD HISTORY OR SYMPTOMS OTHER THAN ELEVATED BLOOD LIPIDS. THE MIS WAS FORMULATED INTENTIONALLY WITH A LOWER DOSAGE OF RYR THAN THAT USED IN PRIOR STUDIES IN ORDER TO REDUCE THE OCCURRENCE OF ADVERSE EFFECTS. SECONDARY TO THE OBJECTIVE OF MANAGING BLOOD LIPIDS, THE AUTHORS WERE INTERESTED IN DETERMINING THE EFFECTS OF THE MIS IN COMBINATION WITH A HIGH-POTENCY OMEGA-3 POLYUNSATURATED FATTY ACID SUPPLEMENT AND ITS EFFECT ON TG LEVELS AND OBSERVING WHETHER ADVERSE EFFECTS WOULD INHIBIT PATIENT COMPLIANCE. DESIGN • THE RESEARCH TEAM DESIGNED AN OPEN-LABEL PILOT STUDY FOLLOWING A PRE-POST PRAGMATIC DESIGN. SETTING • THE STUDY TOOK PLACE AT 2 PRIMARY CARE SETTINGS. PARTICIPANTS • NINETEEN PATIENTS WITH HYPERCHOLESTEROLEMIA WERE PARTICIPANTS IN THE STUDY. ALL PARTICIPANTS WERE REQUIRED TO CONFIRM THAT THEY HAD NOT TAKEN ANY OTHER PHARMACEUTICAL OR SUPPLEMENT THERAPY TO TREAT CHOLESTEROL FOR AT LEAST 30 D PRIOR TO BASELINE, ESTABLISHING A WASHOUT PERIOD. AT COMPLETION OF THE INTERVENTION, 3 PARTICIPANTS WERE EXCLUDED FOR NONCOMPLIANCE WITH THE PROTOCOL, ALTHOUGH THEY HAD TAKEN THE SUPPLEMENTS AS DIRECTED. INTERVENTION(S) • THE RECOMMENDED SERVING OF THE MIS SUPPLEMENT CONSISTED OF 1 SOFTGEL THAT CONTAINED 9 INGREDIENTS: A PROPRIETARY BLEND OF RYR, BIOFLAVONOIDS, POLYCOSANOL, 525 MG OMEGA-3 FATTY ACIDS IN THE NATURAL TG FORM (294 MG EICOSAPENTAENOIC ACID [EPA], 147 MG DOCOSAHEXAENOIC ACID [DHA]) AS WELL AS OTHER SUPPORTING INGREDIENTS, RESVERATROL, COENZYME Q10 (COQ10), FOLIC ACID VITAMIN B3 (NIACIN), B6, B12, AND BLACK PEPPER. EACH SERVING OF THE OMEGA-3 SUPPLEMENT CONTAINED 834 MG OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN THE NATURAL TG FORM (484 MG EPA, 234 MG DHA) AND 33 IU VITAMIN E, (D-Α-TOCOPHEROL). THE STUDYS PARTICIPANTS WERE ASSIGNED TO A GROUP BASED ON THEIR INITIAL TG LEVELS. PARTICIPANTS WITH TG LEVELS <140 MG/DL TOOK THE MIS ONLY, AND PARTICIPANTS WHOSE INITIAL TG LEVELS EXCEEDED 140 MG/DL WERE ASSIGNED TO TAKE BOTH THE MIS AND THE OMEGA-3 SUPPLEMENT, RECEIVING 1384 MG OF OMEGA-3 DAILY (778 MG EPA, 381 MG DHA). ALL PARTICIPANTS CONFIRMED BY POSTSTUDY SURVEY THAT THEY TOOK THE RECOMMENDED SERVING OF 1 SOFTGEL/D OF THE ASSIGNED SUPPLEMENT(S) FOR A MINIMUM OF 30 D. OUTCOME MEASURE(S) • AT BASELINE AND FOLLOW-UP, STANDARD VENOUS BLOOD LABS WERE DRAWN AND PROCESSED AT NATIONALLY ACCREDITED LABS. ALTHOUGH NOT STANDARDIZED, ALL REPORTS CONTAINED: TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN (HDL), LDL, AND TG LEVELS. THE RESEARCH TEAM ACKNOWLEDGES THAT THIS LACK OF STANDARDIZATION AND ADDITIONAL LIPID DATA, SUCH AS VERY LOW-DENSITY LIPOPROTEIN, IS A LIMITATION OF THE STUDY. RESULTS • TOTAL CHOLESTEROL AND LDL DECREASED SIGNIFICANTLY, BY 12.0% (P =.0004) AND 17.3% (P =.0001), RESPECTIVELY, FOR THE 16 PARTICIPANTS TAKING THE MIS SUPPLEMENT. PARTICIPANTS WITH AN LDL AT BASELINE GREATER THAN 145 MG/DL (N = 7) BENEFITED EVEN MORE, WITH TOTAL CHOLESTEROL AND LDL DECREASING SIGNIFICANTLY BY 17.1% (P =.01) AND 24.5% (P =.0014), RESPECTIVELY. ALTHOUGH THE RESULTS WERE NOT SIGNIFICANT, ADDING THE OMEGA-3 SUPPLEMENT TO THE PROTOCOL RESULTED IN A DECREASE IN THE TGS OF THE SUBGROUP TAKING BOTH SUPPLEMENTS (N = 8), WITH THAT MEASURE DECREASING BY 13.1% (P =.27) FROM BASELINE COMPARED WITH A DECREASE OF 2% (P =.95) FOR ALL PARTICIPANTS. THE SUBGROUP TAKING BOTH THE MIS AND OMEGA-3 SUPPLEMENTS EXPERIENCED SIMILAR DECREASES IN TOTAL CHOLESTEROL AND LDL AS PARTICIPANTS TAKING ONLY THE MIS. NO SIDE EFFECTS WERE REPORTED BY PARTICIPANTS, AND ALL PARTICIPANTS COMPLETED THE ASSIGNED PROTOCOL. CONCLUSIONS • THE MIS SUPPLEMENT DECREASED TOTAL CHOLESTEROL AND LDL SIGNIFICANTLY AND OFFERS A PROMISING THERAPY FOR THE MANAGEMENT OF CHOLESTEROL THAT MAY ENABLE BETTER PATIENT COMPLIANCE. THE ADDITION OF AN OMEGA-3 SUPPLEMENT ALSO DECREASED TGS IN THE SUBGROUP THAT RECEIVED BOTH THERAPIES, ALTHOUGH THIS DECREASE WAS NOT SIGNIFICANT, POTENTIALLY BECAUSE OF THE UNDERPOWERED SIZE OF THE SUBGROUP. THE RESEARCH TEAM PLANS FUTURE STUDIES WITH MORE ROBUST LIPID TESTING AND LARGER NUMBERS OF PARTICIPANTS TO SUPPORT THE FINDINGS OF THE CURRENT STUDY. © 2014, INNOVISION COMMUNICATIONS. ALL RIGHTS RESERVED.","","ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FATTY ACIDS, OMEGA-3; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; UNITED STATES; YOUNG ADULT; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PILOT STUDY; UNITED STATES; VERY ELDERLY; YOUNG ADULT","","","STONE N.J., ROBINSON J., LICHTENSTEIN A.H., ET AL., ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, 63, 25, PP. 2889-2934, (2013); GOLOMB B.A., EVANS M.A., STATIN ADVERSE EFFECTS: A REVIEW OF THE LITERATURE AND EVIDENCE FOR A MITOCHONDRIAL MECHANISM, AM J CARDIOVASC DRUGS, 8, 6, PP. 373-418, (2008); COLLINS R., ARMITAGE J., PARISH S., ET AL., MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL-LOWERING WITH SIMVASTATIN IN 5963 PEOPLE WITH DIABETES: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 361, 9374, PP. 2005-2016, (2003); LOWE G., RUMLEY A., NORRIE J., ET AL., BLOOD RHEOLOGY, CARDIOVASCULAR RISK FACTORS, AND CARDIOVASCULAR DISEASE: THE WEST OF SCOTLAND CORONARY PREVENTION STUDY, THROMB HAEMOST, 84, 4, PP. 553-558, (2000); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, 2, PP. 198-204, (2010); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA, A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. CHIN MED, 1, (2006); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, 12, PP. 1689-1693, (2008); BECKER D.J., GORDON R.Y., MORRIS P.B., ET AL., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN PROC, 83, 7, PP. 758-764, (2008); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, 2, PP. 231-236, (1999); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, 5, PP. 679-686, (2005); MILLER M., STONE N.J., BALLANTYNE C., ET AL., TRIGLYCERIDES AND CARDIOVASCULAR DISEASE: A SCIENTIFIC STATEMENT FROM THE AMER I CAN HEART ASSOC IAT ION, CIRCULATION, 123, 20, PP. 2292-2333, (2011); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMIZED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, 9567, PP. 1090-1098, (2007); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, 9177, PP. 447-455, (1999); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLYCOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPD PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, 4, PP. 207-219, (2005); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTSBUYER BEWARE!, ARCH INTERN MED, 70, 19, PP. 1722-1727, (2010); RED YEAST RICE, (2013); FISH OIL SAFETY; HUANG J., FROHLICH J., IGNASZEWSKI A.P., THE IMPACT OF DIETARY CHANGES AND DIETARY SUPPLEMENTS ON LIPID PROFILE, CAN J CARDIOL, 27, 4, PP. 488-505, (2011); POLYCHLORINATED BIPHENYLS (PCBS), (2013); DAVIGNON J., CARDIOPROTECTIVE AND OTHER EMERGING EFFECTS OF STATINS, INT J CLIN PRACT SUPPL, 143, PP. 49-57, (2004)","D. MCMAHON; SOLANA HEALTH, INC, SAN DIEGO, UNITED STATES; EMAIL: INFO@SOLANAHEALTH.COM","INNOVISION COMMUNICATIONS","ENGLISH","ALTERN. THER. HEALTH MED.","ARTICLE","ISI","2-S2.0-84925223619","ALTERN THER HEALTH MED","ORANGE COUNTY HEART CENTER;SOLANA HEALTH","NOTREPORTED;SOLANA HEALTH;EMAIL: INFO@SOLANAHEALTH.COM",NA,"HOBBS T, 2014, ALTERN THER HEALTH MED","HOBBS T, 2014, ALTERN THER HEALTH MED"
"ASIKIN Y;TAKAHASHI M;HIROSE N;HOU D;TAKARA K;WADA K","ASIKIN, YONATHAN (35092077000); TAKAHASHI, MAKOTO (56287823400); HIROSE, NAOTO (24474914200); HOU, DE-XING (7103150875); TAKARA, KENSAKU (7005621893); WADA, KOJI (7401668452)","WAX POLICOSANOL AND LONGCHAIN ALDEHYDES OF DIFFERENT SUGARCANE SACCHARUM OFFICINARUM L CULTIVARS",2012,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","114","8",50,"10.1002/ejlt.201100300","UNITED GRADUATE SCHOOL OF AGRICULTURAL SCIENCE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN;FACULTY OF AGRICULTURE, DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, UNIVERSITY OF THE RYUKYUS, OKINAWA, JAPAN;OKINAWA PREFECTURAL AGRICULTURAL RESEARCH CENTER, OKINAWA, JAPAN;UNITED GRADUATE SCHOOL OF AGRICULTURAL SCIENCE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN, FACULTY OF AGRICULTURE, DEPARTMENT OF BIOCHEMICAL SCIENCE AND TECHNOLOGY, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN;UNITED GRADUATE SCHOOL OF AGRICULTURAL SCIENCE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN, FACULTY OF AGRICULTURE, DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, UNIVERSITY OF THE RYUKYUS, OKINAWA, JAPAN;UNITED GRADUATE SCHOOL OF AGRICULTURAL SCIENCE, KAGOSHIMA UNIVERSITY, KAGOSHIMA, JAPAN, FACULTY OF AGRICULTURE, DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, UNIVERSITY OF THE RYUKYUS, OKINAWA, JAPAN","SUGARCANE (SACCHARUM OFFICINARUM L.) WAX THAT CONTAINS POLICOSANOL (A MIXTURE OF LONG-CHAIN ALCOHOLS), IS WIDELY KNOWN TO HAVE BENEFICIAL EFFECTS ON HUMAN HEALTH. IN ORDER TO INVESTIGATE DIFFERENCES IN THE COMPOSITION AND CONTENT OF SUGARCANE WAX IN DIFFERENT SUGARCANE CULTIVARS, THE WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDE COMPOSITION OF EIGHT SUGARCANE CULTIVARS WERE EXAMINED. THE WAX COMPOSITION OF SUGARCANE WAS ANALYZED USING HPLC COUPLED WITH AN EVAPORATIVE LIGHT SCATTERING DETECTOR (ELSD). SUGARCANE WAXES WERE COMPRISED OF 55-60% ALDEHYDE AND STEROL ESTERS, 32-40% ALCOHOL, AND SMALL AMOUNTS OF TAG, ACID, AND PLANT STEROLS. ADDITIONALLY, THE COMPOSITION OF POLICOSANOL AND LONG-CHAIN ALDEHYDES WAS DETERMINED USING GC-FID AND THEIR MASS FRAGMENT COMPOUNDS WERE IDENTIFIED USING GC-MS. THE HIGHEST CONTENT OF POLICOSANOL AND LONG-CHAIN ALDEHYDE COMPOUNDS (500MG AND 600MG/100G RIND, RESPECTIVELY), WAS FOUND IN THE HAND-PEELED RIND OF THE NI 22 SUGARCANE CULTIVAR. THE CONTENT OF THESE COMPOUNDS INCREASED UP TO 72% DURING SUGARCANE MATURATION FROM OCTOBER TO JANUARY. THIS STUDY INDICATED THAT THE COMPOSITION AND CONTENT OF WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES MAY VARY DEPENDING ON THE CULTIVAR OF THE SUGARCANE AND THE SPECIFIC PART OF THE SUGARCANE ANALYZED, AS WELL AS ON THE DEGREE OF SUGARCANE MATURITY. © 2012 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.","DEGREE OF MATURITY; LONG-CHAIN ALDEHYDE; POLICOSANOL; SUGARCANE CULTIVARS; WAX COMPOSITION","SACCHARUM OFFICINARUM","JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE, JSPS, (23500932)","","NUISSIER G., BOURGEOIS P., GRIGNON-DUBOIS M., PARDON P., LESCURE M.H., COMPOSITION OF SUGARCANE WAXES IN RUM FACTORY WASTES, PHYTOCHEMISTRY, 61, PP. 721-726, (2002); PHUKAN A.C., BORUAH R.K., EXTRACTION AND EVALUATION OF MICROCRYSTALLINE WAX FROM PRESS MUD WASTE OF THE SUGAR INDUSTRY, SEP. PURIF. TECHNOL., 17, PP. 189-194, (1999); TAMAKI H., MAN S.L., OHTA Y., KATSUYAMA N., CHINEN I., INHIBITION OF OSTEOPOROSIS IN RATS FED WITH SUGAR CANE WAX, BIOSCI. BIOTECHNOL. BIOCHEM., 67, PP. 423-425, (2003); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. P, 29, PP. 891-897, (2002); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH. MED. RES., 36, PP. 441-447, (2005); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER., 318, PP. 1020-1026, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., ET AL., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM. HEART J., 152, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER. RES., 22, PP. 318-322, (2008); WANG L., WELLER C.L., SCHLEGEL V.L., CARR T.P., CUPPETT S.L., COMPARISON OF SUPERCRITICAL CO<SUB>2</SUB> AND HEXANE EXTRACTION OF LIPIDS FROM SORGHUM DISTILLERS GRAINS, EUR. J. LIPID SCI. TECHNOL., 109, PP. 567-574, (2007); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR. J. LIPID SCI. TECHNOL., 106, PP. 147-151, (2004); CHEN Y., DUNFORD N.T., EDWARDS J., CARVER B., GOAD C., POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, J. SCI. FOOD AGRIC., 89, PP. 310-314, (2009); CHERIF A.O., MESSAOUDA M.B., KAABI B., BOUKHCHINA S., ET AL., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), J. AGRIC. FOOD CHEM., 58, PP. 12143-12148, (2010); DE LUCAS A., GARCIA A., ALVAREZ A., GRACIA I., SUPERCRITICAL EXTRACTION OF LONG CHAIN N-ALCOHOLS FROM SUGAR CANE CRUDE WAX, J. SUPERCRIT. FLUIDS, 41, PP. 267-271, (2007); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., CHANGES IN COMPOSITION AND THERMAL TRANSITION TEMPERATURES OF GRAIN SORGHUM WAX DURING STORAGE, IND. CROP PROD., 19, PP. 125-132, (2004); JANSEN B., NIEROP K.G.J., HAGEMAN J.A., CLEEF A.M., VERSTRATEN J.M., THE STRAIGHT-CHAIN LIPID BIOMARKER COMPOSITION OF PLANT SPECIES RESPONSIBLE FOR THE DOMINANT BIOMASS PRODUCTION ALONG TWO ALTITUDINAL TRANSECTS IN THE ECUADORIAN ANDES, ORG. GEOCHEM., 37, PP. 1514-1536, (2006); HANSJAKOB A., BISCHOF S., BRINGMANN G., RIEDERER M., HILDEBRANDT U., VERY-LONG-CHAIN ALDEHYDES PROMOTE IN VITRO PREPENETRATION PROCESSES OF BLUMERIA GRAMINIS IN A DOSE- AND CHAIN LENGTH-DEPENDENT MANNER, NEW PHYTOL., 188, PP. 1039-1054, (2010); TAKAGI H., SATO M., MATSUOKA M., (2005); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J. AM. OIL CHEM. SOC., 79, PP. 529-533, (2002); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J. AGRIC. FOOD CHEM., 54, PP. 5359-5362, (2006); PEREZ-CAMINO M.C., MOREDA W., MATEOS R., CERT A., SIMULTANEOUS DETERMINATION OF LONG-CHAIN ALIPHATIC ALDEHYDE AND WAXES IN OLIVE OILS, J. CHROMATOGR., A, 983, PP. 283-288, (2003); ASIKIN Y., CHINEN T., TAKARA K., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI. TECHNOL. RES., 14, PP. 583-588, (2008); PURCELL D.E., LEONARD G.J., O'SHEA M.G., KOKOT S., A CHEMOMETRICS INVESTIGATION OF SUGARCANE PLANT PROPERTIES BASED ON THE MOLECULAR COMPOSITION OF EPICUTICULAR WAX, CHEMOMETR. INTELL. LAB., 76, PP. 135-147, (2005); GEORGES P., SYLVESTRE M., RUEGGER H., BOURGEOIS P., KETOSTEROIDS AND HYDROXYKETOSTEROIDS, MINOR METABOLITES OF SUGARCANE WAX, STEROIDS, 71, PP. 647-652, (2006); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); DOMINGUEZ E., HEREDIA A., WAXES A., A FORGOTTEN TOPIC IN LIPID TEACHING, BIOCHEM. EDUC., 26, PP. 315-316, (1998); KOCH K., HARTMANN K.D., SCHREIBER L., BARTHLOTT W., NEINHUIS C., INFLUENCES OF AIR HUMIDITY DURING THE CULTIVATION OF PLANTS ON WAX CHEMICAL COMPOSITION, MORPHOLOGY AND LEAF SURFACE WETTABILITY, ENVIRON. EXP. BOT., 56, PP. 1-9, (2006); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUR. J. LIPID SCI. TECHNOL., 112, PP. 373-379, (2010); MARRISON III W.B., HOLSER R., AKIN D.E., CUTICULAR WAX FROM FLAX PROCESSING WASTE WITH HEXANE AND SUPER CRITICAL CARBON DIOXIDE EXTRACTIONS, IND. CROP PROD., 24, PP. 119-122, (2006); REISIGE K., GORZELANNY C., DANIELS U., MOERSCHBACHER B.M., THE C28 ALDEHYDE OCTACOSANAL IS A MORPHOGENETICALLY ACTIVE COMPONENT INVOLVED IN HOST PLANT RECOGNITION AND INFECTION STRUCTURE DIFFERENTIATION IN THE WHEAT STEM RUST FUNGUS, PHYSIOL. MOL. PLANT M., 68, PP. 33-40, (2006); RUTHERFORD R.S., VAN STADEN J., TOWARDS A RAPID NEAR-INFRARED TECHNIQUE FOR PREDICTION OF RESISTANCE TO SUGARCANE BORER ELDANA SACCHARINA WALKER (LEPIDOPTERA: PYRALIDAE) USING STALK SURFACE WAX, J. CHEM. ECOL., 22, PP. 681-694, (1996); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM., 115, PP. 918-923, (2009); RAVINDRANATH S.V., UPPUGUNDLA N., LAY J.O., CLAUSEN E.C., ET AL., POLICOSANOL, Α-TOCOPHEROL, AND MOISTURE CONTENT AS A FUNCTION OF TIMING OF HARVEST OF SWITCHGRASS (PANICUM VIRGATUM L.), J. AGRIC. FOOD CHEM., 57, PP. 3500-3505, (2009)","K. WADA; FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, OKINAWA 903-0213, 1 SENBARU, JAPAN; EMAIL: KOJIWADA@AGR.U-RYUKYU.AC.JP","","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-84861136024","EUR J LIPID SCI TECHNOL","KAGOSHIMA UNIVERSITY;UNIVERSITY OF THE RYUKYUS;OKINAWA PREFECTURAL AGRICULTURAL RESEARCH CENTER;KAGOSHIMA UNIVERSITY;KAGOSHIMA UNIVERSITY;KAGOSHIMA UNIVERSITY","NOTREPORTED;UNIVERSITY OF THE RYUKYUS;NOTREPORTED",NA,"ASIKIN Y, 2012, EUR J LIPID SCI TECHNOL","ASIKIN Y, 2012, EUR J LIPID SCI TECHNOL"
"HOUSTON M","HOUSTON, MARK (7103236355)","THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA",2012,"JOURNAL OF CLINICAL HYPERTENSION","14","11",42,"10.1111/j.1751-7176.2011.00576.x","DEPARTMENT OF MEDICINE, VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, UNITED STATES, THE SAINT THOMAS MEDICAL GROUP, SAINT THOMAS HOSPITAL, NASHVILLE, TN, UNITED STATES","THE COMBINATION OF A LIPID-LOWERING DIET AND SCIENTIFICALLY PROVEN NUTRACEUTICAL SUPPLEMENTS HAS THE ABILITY TO SIGNIFICANTLY REDUCE LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL, INCREASE LDL PARTICLE SIZE, DECREASE LDL PARTICLE NUMBER, LOWER TRIGYLCERIDES AND VERY LDL LEVELS, AND INCREASE TOTAL AND HIGH-DENSITY LIPOPROTEIN 2B CHOLESTEROL. IN ADDITION, INFLAMMATION, OXIDATIVE STRESS, AND IMMUNE RESPONSES ARE DECREASED. IN SEVERAL PROSPECTIVE CLINICAL TRIALS, CORONARY HEART DISEASE AND CARDIOVASCULAR DISEASE HAVE BEEN REDUCED WITH MANY NUTRACEUTICAL SUPPLEMENTS. THIS NUTRITIONAL AND NUTRACEUTICAL SUPPLEMENT TREATMENT IS A VALID ALTERNATIVE FOR PATIENTS WHO ARE INTOLERANT TO STATINS, CANNOT TAKE OTHER DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA, OR PREFER ALTERNATIVE TREATMENTS. THIS NEW APPROACH TO LIPID MANAGEMENT TO DECREASE VASCULAR DISEASE UTILIZES A FUNCTIONAL MEDICINE APPROACH WITH A BROADER TREATMENT PROGRAM THAT WILL ADDRESS THE MULTITUDE OF STEPS INVOLVED IN LIPID-INDUCED VASCULAR DAMAGE. © 2012 WILEY PERIODICALS, INC.","","ATHEROSCLEROSIS; DIETARY FATS; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, VLDL; OXIDATIVE STRESS; PANTETHEINE; STILBENES; TOCOTRIENOLS; TRIGLYCERIDES; VASCULAR DISEASES; VASODILATOR AGENTS; ACETYLSALICYLIC ACID; ALLICIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTIN; CURCUMIN; GAMMA TOCOTRIENOL; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HISTIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAEMPFEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYCOPENE; MONOCYTE CHEMOTACTIC PROTEIN 1; MORIN; MYRICETIN; NICOTINIC ACID; NUTRACEUTICAL; OLEIC ACID; PANTETHINE; PHYTOSTEROL; POLICOSANOL; POLYPHENOL; POMEGRANATE EXTRACT; RUTOSIDE; TRIACYLGLYCEROL; UBIDECARENONE; UNINDEXED DRUG; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; EXERCISE; FLUSHING; GASTRITIS; GENE EXPRESSION; GOUT; HEART PALPITATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERPIGMENTATION; HYPERURICEMIA; IMMUNE RESPONSE; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; TACHYCARDIA; ULCER; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION","","","KANNEL W.B., CASTELLI W.D., GORDON T., ET AL., SERUM CHOLESTEROL, LIPOPROTEINS AND RISK OF CORONARY ARTERY DISEASE. THE FRAMINGHAM STUDY, ANN INTERN MED, 74, PP. 1-12, (1971); HOUSTON M.C., NUTRITION AND NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF HYPERTENSION, EXPERT REV CARDIOVASC THER, 8, PP. 821-833, (2010); TIAN N., PENMAN A.D., MAWSON A.R., ET AL., ASSOCIATION BETWEEN CIRCULATING SPECIFIC LEUKOCYTE TYPES AND BLOOD PRESSURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY, J AM SOC HYPERTENS, 4, PP. 272-283, (2010); UNGVARI Z., KALEY G., DE CABO R., ET AL., MECHANISMS OF VASCULAR AGING: NEW PERSPECTIVES, J GERONTOL A BIOL SCI MED SCI, 65, PP. 1028-1041, (2010); HOUSTON M.C., FAZIO S., CHILTON F.H., ET AL., NON PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA, PROG CARDIOVASC DIS, 52, PP. 61-94, (2009); PLOURDE M., VOHL M.C., VANDAL M., ET AL., PLASMA N-3 FATTY ACID SUPPLEMENT IS MODULATED BY APOE EPSILON 4 BUT NOT BY THE COMMON PPAR-ALPHA L162 POLYMORPHISM IN MEN, BR J NUTR, 102, PP. 1121-1124, (2009); NEIMINEN T., KAHONEN M., VIIRI L.E., ET AL., PHARMACOGENETICS OF APOLIPROPROTEIN E GENE DURING LIPID-LOWERING THERAPY: LIPID LEVELS AND PREVENTION OF CORONARY HEART DISEASE, PHARMACOGENOMICS, 9, PP. 1475-1486, (2008); SHIH D.M., LUSIS A.J., THEROLES OF PON 1 AND PON 2 IN CARDIOVASCULAR DISEASE AND INNATE IMMUNITY, CURR OPIN LIPIDOL, 20, PP. 288-292, (2009); CALKIN A.C., TONTONOZ P., GENOME-WIDE ASSOCIATION STUDIES IDENTIFY NEW TARGETS IN CARDIOVASCULAR DISEASE, SCI TRANSL MED, 2, (2010); DJOUSSE L., CAZIANO J.M., DIETARY CHOLESTEROL AND CORONARY ARTERY DISEASE: A SYSTEMATIC REVIEW, CURR ATHEROSCLER REP, 11, PP. 418-422, (2009); WERKO L., END OF THE ROAD FOR THE DIET-HEART THEORY?, SCAND CARDIOVASC J, 42, PP. 250-255, (2008); ERKKILA A., DE MELLO V.D., RISERUS U., LAAKSONEN D.E., DIETARY FATTY ACIDS AND CARDIOVASCULAR DISEASE: AN EPIDEMIOLOGICAL APPROACH, PROG LIPID RES, 47, PP. 172-187, (2008); WEINBERG S.L., THE DIET-HEART HYPOTHESIS: A CRITIQUE, J AM COLL CARDIOL, 43, PP. 731-733, (2004); MOZAFFARIAN D., WILLET W.C., TRANS FATTY ACIDS AND CARDIOVASCULAR RISK: A UNIQUE CARDIOMETABOLIC IMPRINT, CURR ATHEROSCLER REP, 9, PP. 486-493, (2007); CHEN C.L., TETRI L.H., NEUSCHWANDER-TETRI B.A., ET AL., A MECHANISM BY WHICH DIETARY TRANS FATS CAUSE ATHEROSCLEROSIS, J NUTR BIOCHEM, 22, PP. 649-655, (2011); SIRI-TARINO P.W., SUN Q., HU F.B., KRAUSS R.M., SATURATED FAT, CARBOHYDRATE AND CARDIOVASCULAR DISEASE, AM J CLIN NUTR, 91, PP. 502-509, (2010); OTVOS J.D., MORA S., SHALAUROVA I., ET AL., CLINICAL IMPLICATIONS OF DISCORDANCE BETWEEN LOW DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, J CLIN LIPIDOL, 5, PP. 105-113, (2011); HODGE A.M., JENKINS A.J., ENGLISH D.R., ET AL., NMR DETERMINED LIPOPROTEIN SUBCLASS PROFILE IS ASSOCIATED WITH DIETARY COMPOSITION AND BODY SIZE, NUTR METAB CARDIOVASC DIS, 21, PP. 603-609, (2011); ASZTALOS B.F., TANI M., SCHAEFER E., METABOLIC AND FUNCTIONAL OF HDL SUBSPECIES, CURR OPIN LIPIDOL, 22, PP. 176-185, (2011); KHERA A.V., CUCHEL M., DE LA LLERA-MOYA M., ET AL., CHOLESTEROL EFFLUX CAPACITY, HIGH-DENSITY LIPOPROTEIN FUNCTION, AND ATHEROSCLEROSIS, N ENGL J MED, 364, PP. 127-135, (2011); KARAKAS M., KOENIG W., ZIERER A., ET AL., MYELOPEROXIDASE IS ASSOCIATED WITH INCIDENT CORONARY HEART DISEASE INDEPENDENTLY OF TRADITIONAL RISK FACTORS: RESULTS FORM THE MONICA/KORA AUGSBURG STUDY, J INTERN MED, 271, PP. 43-50, (2011); LAMARCHE B., TCHERNOF A., MOORIANI S., ET AL., SMALL, DENSE LOW-DENSITY LIPOPROTEIN PARTICLES AS A PREDICTOR OF THE RISK OF ISCHEMIC HEART DISEASE IN MEN. PROSPECTIVE RESULTS FROM THE QUEBEC CARDIOVASCULAR STUDY, CIRCULATION, 95, PP. 69-75, (1997); KRUTH H.S., RECEPTOR-INDEPENDENT FLUID-PHASE PINOCYTOSIS MECHANISMS FOR INDUCTION OF FOAM CELL FORMATION WITH NATIVE LOW DENSITY LIPOPROTEIN PARTICLES, CURR OPIN LIPIDOL, 22, PP. 386-393, (2011); ZHAO Z.W., ZHU X.L., LUO Y.K., ET AL., CIRCULATING SOLUBLE LECTIN-LIKE OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR-1 LEVELS ARE ASSOCIATED WITH ANGIOGRAPHIC CORONARY LESION COMPLEXITY IN PATIENTS WITH CORONARY ARTERY DISEASE, CLIN CARDIOL, 34, PP. 172-177, (2011); EHARA S., UEDA M., NARUKO T., ET AL., ELEVATED LEVELS OF OXIDIZED LOW DENSITY LIPOPROTEIN SHOW A POSITIVE RELATIONSHIP WITH THE SEVERITY OF ACUTE CORONARY SYNDROMES, CIRCULATION, 103, PP. 1955-1960, (2001); HANSSON G.K., INFLAMMATION, ATHEROSCLEROSIS, AND CORONARY ARTERY DISEASE, N ENGL J MED, 352, PP. 1685-1695, (2005); HARPER C.R., JACOBSON T.A., USING APOLIPOPROTEIN B TO MANAGE DYSLIPIDEMIC PATIENTS: TIME FOR A CHANGE?, MAYO CLIN PROC, 85, PP. 440-445, (2010); CURTISS L.K., REVERSING ATHEROSCLEROSIS?, N ENGL J MED, 360, PP. 1144-1146, (2009); SHEN G.X., IMPACT AND MECHANISM FOR OXIDIZED AND GLYCATED LIPOPROTEINS ON GENERATION OF FIBRINOLYTIC REGULATORS FROM VASCULAR ENDOTHELIAL CELLS, MOL CELL BIOCHEM, 246, PP. 69-74, (2003); RIDKER P.M., DANIELSON E., FONSECA F.A., ET AL., ROSUVASTATIN TO PREVENT VASCULAR EVENTS IN MEN AND WOMEN WITH ELEVATED C-REACTIVE PROTEIN, N ENGL J MED, 359, PP. 2195-2207, (2008); KRISHNAN G.M., THOMPSON P.D., THE EFFECTS OF STATINS ON SKELETAL MUSCLE STRENGTH AND EXERCISE PERFORMANCE, CURR OPIN LIPIDOL, 21, PP. 324-328, (2010); MILLS E.J., WU P., CHONG G., ET AL., EFFICACY AND SAFETY OF STATIN TREATMENT FOR CARDIOVASCULAR DISEASE: A NETWORK META-ANALYSIS OF 170,255 PATIENTS FROM 76 RANDOMIZED TRIALS, QJM, 104, PP. 109-124, (2011); MAMMEN A.L., AMATO A.A., STATIN MYOPATHY: A REVIEW OF RECENT PROGRESS, CURR OPIN RHEUMATOL, 22, PP. 544-550, (2010); RUSSO M.W., SCOBEV M., BONKOVSKY H.L., DRUG-INDUCED LIVER INJURY ASSOCIATED WITH STATINS, SEMIN LIVER DIS, 29, PP. 412-422, (2009); MOOSMANN B., BEHL C., SELENOPROTEINS, CHOLESTEROL-LOWERING DRUGS, AND THE CONSEQUENCES: REVISITING OF THE MEVALONATE PATHWAY, TRENDS CARDIOVASC MED, 14, PP. 273-281, (2004); LIU C.S., LII C.K., CHANG L.L., ET AL., ATORVASTATIN INCREASES BLOOD RATIOS OF VITAMIN E/LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND COENZYME Q10/LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS, NUTR RES, 30, PP. 118-124, (2010); WYMAN M., LEONARD M., MORLEDGE T., COENZYME Q 10: A THERAPY FOR HYPERTENSION AND STATIN-INDUCED MYALGIA?, CLEV CLIN J MED, 77, PP. 435-442, (2010); MORTENSEN S.A., LOW COENZYME Q LEVELS AND THE OUTCOME OF STATIN TREATMENT IN HEART FAILURE, J AM COLL CARDIOL, 57, (2011); SHOJAEI M., DJALALI M., KHATAMI M., ET AL., EFFECTS OF CARNITINE AND COENZYME Q 10 ON LIPID PROFILE AND SERUM LEVELS OF LIPOPROTEIN (A) IN MAINTENANCE HEMODIALYSIS PATIENTS ON STATIN THERAPY, IRAN J KIDNEY DIS, 5, PP. 114-118, (2011); GUPTA A., THOMPSON P.D., THE RELATIONSHIP OF VITAMIN D DEFICIENCY TO STATIN MYOPATHY, ATHEROSCLEROSIS, 215, PP. 23-29, (2011); AVIS H.J., HARGREAVES I.P., RUITER J.P., ET AL., ROSUVASTATIN LOWERS COENZYME Q 10 LEVELS, BUT NOT MITOCHONDRIAL ADENOSINE TRIPHOSPHATE SYNTHESIS, IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, J PEDIATR, 158, PP. 458-462, (2011); KIERNAN T.J., ROCHFORD M., MCDERMOTT J.H., SIMVASTATIN INDUCED RHABDOMYLOYSIS AND AN IMPORTANT CLINICAL LINK WITH HYPOTHYROIDISM, INT J CARDIOL, 119, PP. 374-376, (2007); NIJJAR P.S., BURKE F.M., BIOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, J CLIN LIPIDOL, 4, PP. 248-258, (2010); HOUSTON M.C., JUICE POWDER CONCENTRATE AND SYSTEMIC BLOOD PRESSURE, PROGRESSION OF CORONARY ARTERY CALCIUM AND ANTIOXIDANT STATUS IN HYPERTENSIVE SUBJECTS: A PILOT STUDY EVIDENCE BASED COMPLEMENTARY, ALTERNAT MED, 4, PP. 455-462, (2007); BUDOFF M.J., AHMADI N., GUL K.M., ET AL., AGED GARLIC EXTRACT SUPPLEMENTED WITH B VITAMINS, FOLIC ACID AND L-ARGININE RETARDS PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS: A RANDOMIZED CLINICAL TRIAL, PREV MED, 49, PP. 101-107, (2009); RUPARELIA N., DIGBY J.E., CHOUDHURY R.P., EFFECTS OF NIACIN ON ATHEROSCLEROSIS AND VASCULAR FUNCTION, CURR OPIN CARDIOL, (2010); AL-MOHISSEN M.A., PUN S.C., FROHLICH J.J., NIACIN: FROM MECHANISMS OF ACTION TO THERAPEUTIC USES, MINI REV MED CHEM, 10, PP. 204-217, (2010); CLOFIBRATE AND NIACIN IN CORONARY HEART DISEASE, JAMA, 231, PP. 360-381, (1975); TAYLOR A.J., LEE H.J., SULLENBERGER L.E.; LEE J.M., ROBSON M.D., YU L.M., ET AL., EFFECTS OF HIGH DOSE MODIFIED RELEASE NICOTINIC ACID ON ATHEROSCLEROSIS AND VASCULAR FUNCTION: A RANDOMIZED, PLACEBO CONTROLLED, MAGNETIC RESONANCE IMAGING STUDY, J AM COLL CARDIOL, 54, PP. 1787-1794, (2009); TAYLOR A.J., VILLINES T.C., STANEK E.J., ET AL., EXTENDED RELEASE NIACIN OR EZETIMIBE AND CAROTID INTIMA MEDIA THICKNESS, N ENGL J MED, 361, PP. 2113-2122, (2009); IMPACT ON GLOBAL HEALTH OUTCOMES (AIM-HIGH) TRIAL, AM HEART J, 161, PP. 538-543, (2011); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., GORDON M., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., ET AL., CONTINUOUS DOSE RESPONSE RELATIONSHIP OF THE LDL CHOLESTEROL LOWERING EFFECT OF PHYTOSTEROL INTAKE, J NUTR, 139, PP. 271-284, (2009); OTHMAN R.A., MOGHADASIAN M.H., BEYOND CHOLESTEROL LOWERING EFFECTS OF PLANT STEROLS: CLINICAL AND EXPERIMENTAL EVIDENCE OF ANTI-INFLAMMATORY PROPERTIES, NUTR REV, 69, PP. 371-382, (2011); SABEVA N.S., MCPHAUL C.M., LI X., ET AL., PHYTOSTEROLS DIFFERENTLY INFLUENCE ABC TRANSPORTER EXPRESSION, CHOLESTEROL EFFLUX AND INFLAMMATORY CYTOKINE SECRETION IN MACROPHAGE FOAM CELLS, J NUTR BIOCHEM, 22, PP. 777-783, (2011); SACKS F.M., LICHTENSTEIN A., VAN HORN L., ET AL., AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 113, PP. 1034-1044, (2006); HARLAND J.I., HAFFNER T.A., SYSTEMIC REVIEW, META-ANALYSIS AND REGRESSION OF RANDOMIZED CONTROLLED TRIALS REPORTING AN ASSOCIATION BETWEEN AN INTAKE OF CIRCA 25G SOYA PROTEIN PER DAY AND BLOOD CHOLESTEROL, ATHEROSCLEROSIS, 200, PP. 13-27, (2008); SINGH D.K., BANERJEE S., PORTER T.D., GREEN AND BLACK TEA EXTRACTS INHIBIT HMG-COA REDUCTASE AND ACTIVATE AMP KINASE TO DECREASE CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS, J NUTR BIOCHEM, 20, PP. 816-822, (2009); TINAHONES F.J., RUBIO M.A., GARRIDO-SANCHEZ L., ET AL., GREEN TEA REDUCES LDL OXIDABILITY AND IMPROVES VASCULAR FUNCTION, J AM COLL NUTR, 27, PP. 209-213, (2008); BROWN A.L., LANE J., HOLYOAK C., ET AL., HEALTH EFFECTS OF GREEN TEA CATECHINS IN OVERWEIGHT AND OBESE MEN: A RANDOMIZED CONTROLLED CROSS-OVER TRIAL, BR J NUT, 7, PP. 1-10, (2011); ZHENG X.X., XU Y.L., LI S.H., ET AL., GREEN TEA INTAKE LOWERS FASTING SERUM TOTAL AND LDL CHOLESTEROL IN ADULTS: A META-ANALYSIS OF 14 RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 94, PP. 601-610, (2011); SAREMI A., ARORA R., THE UTILITY OF OMEGA-3 FATTY ACIDS IN CARDIOVASCULAR DISEASE, AM J THER, 16, PP. 421-436, (2009); RISSANEN T., VOUTILAINEN S., NYYSSONEN K., ET AL., FISH OIL-DERIVED FATTY ACIDS, DOCOSAHEXAENOIC ACID AND DOCOSAPENTAENOIC ACID AND THE RISK OF ACUTE CORONARY EVENTS: THE KUOPIO ISCHAEMIC HEART DISEASE RISK FACTOR STUDY, CIRCULATION, 102, PP. 2677-2679, (2000); DAVIS W., ROCKWAY S., KWASNY M., EFFECT OF A COMBINED THERAPEUTIC APPROACH OF INTENSIVE LIPID MANAGEMENT, OMEGA 3 FATTY ACID SUPPLEMENTATION, AND INCREASED SERUM 25(OH) D ON CORONARY CALCIUM SCORES IN ASYMPTOMATIC ADULTS, AM J THER, 16, PP. 326-332, (2009); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., JAPAN EPA LIPID INTERVENTION STUDY (JELIS) INVESTIGATORS, LANCET, 369, PP. 1090-1098, (2007); RYAN A.S., KESKE M.A., HOFFMAN J.P., NELSON E.B., CLINICAL OVERVIEW OF ALGAL-DOCOSAHEXAENOIC ACID: EFFECTS ON TRIGLYCERIDE LEVELS AND OTHER CARDIOVASCULAR RISK FACTORS, AM J THER, 16, PP. 183-192, (2009); KELLEY D.S., SIEGAL D., VEMURI M., ET AL., DOCOSAHEXAENOIC ACID SUPPLEMENTATION DECREASES REMNANT-LIKE PARTICLE CHOLESTEROL AND INCREASES THE (N-3) INDEX IN HYPERTRIGLYCERIDEMIC MEN, J NUTR, 138, PP. 30-35, (2008); MAKI K.C., DICKLIN M.R., DAVIDSON M.H., ET AL., COMBINATION OF PRESCRIPTION OMEGA-3 WITH SIMVASTATIN (COMBOS) INVESTIGATORS, AM J CARDIOL, 105, PP. 1409-1412, (2010); MICALLEF M.A., GARG M.L., THE LIPID-LOWERING EFFECTS OF PHYTOSTEROLS AND (N-3) POLYUNSATURATED FATTY ACIDS ARE SYNERGISTIC AND COMPLEMENTARY IN HYPERLIPIDEMIC MEN AND WOMEN, J NUTR, 138, PP. 1085-1090, (2008); MORI T.A., BURKE V., PUDDEY I.B., ET AL., PURIFIED EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS HAVE DIFFERENTIAL EFFECTS ON SERUM LIPIDS AND LIPOPROTEINS, LDL PARTICLE SIZE, GLUCOSE AND INSULIN IN MILDLY HYPERLIPIDEMIC MEN, AM J CLIN NUTR, 71, PP. 1085-1094, (2000); PRASAD K., FLAXSEED AND CARDIOVASCULAR HEALTH, J CARDIOVASC PHARMACOL, 54, PP. 369-377, (2009); BIOEDON L.T., BALKAI S., CHITTAMS J., ET AL., FLAXSEED AND CARDIOVASCULAR RISK FACTORS: RESULTS FROM A DOUBLE-BLIND, RANDOMIZED CONTROLLED CLINICAL TRIAL, J AM COLL NUTR, 27, PP. 65-74, (2008); MANDASESCU S., MOCANU V., DASCALITA A.M., ET AL., FLAXSEED SUPPLEMENTATION IN HYPERLIPIDEMIC PATIENTS, REV MED CHIR SOC MED NAT LASI, 109, PP. 502-506, (2005); BESTER D., ESTERHUYSE A.J., TRUTER E.J., VAN ROOVEN J., CARDIOVASCULAR EFFECTS OF EDIBLE OILS: A COMPARISON BETWEEN FOUR POPULAR EDIBLE OILS, NUTR RES REV, 23, PP. 334-348, (2010); BROWN J.M., SHELNESS G.S., RUDEL L.L., MONOUNSATURATED FATTY ACIDS AND ATHEROSCLEROSIS: OPPOSING VIEWS FROM EPIDEMIOLOGY AND EXPERIMENTAL ANIMAL MODELS, CURR ATHEROSCLER REP, 9, PP. 494-500, (2007); BOGANI P., GALI C., VILLA M., VISIOLI F., POSTPRANDIAL ANTI-INFLAMMATORY AND ANTIOXIDANT EFFECTS OF EXTRA VIRGIN OLIVE OIL, ATHEROSCLEROSIS, 190, PP. 181-186, (2007); COVAS M.I., OLIVE OIL AND THE CARDIOVASCULAR SYSTEM, PHARMACOL RES, 55, PP. 175-186, (2007); WU W.H., KANG Y.P., WANG N.H., ET AL., SESAME INGESTION AFFECTS SEX HORMONES, ANTIOXIDANT STATUS AND BLOOD LIPIDS IN POSTMENOPAUSAL WOMEN, J NUTR, 136, PP. 1270-1275, (2006); NAMIKI M., NUTRACEUTICAL FUNCTIONS OF SESAME: A REVIEW, CRIT REV FOOD SCI NUTR, 47, PP. 651-673, (2007); QURESHI A.A., SAMI S.A., SALSER W.A., KHAN F.A., SYNERGISTIC EFFECT OF TOCOTRIENOL-RICH FRACTION (TRF 25) OF RICE BRAN AND LOVASTATIN ON LIPID PARAMETERS IN HYPERCHOLESTEROLEMIC HUMANS, J NUTR BIOCHEM, 12, PP. 318-329, (2001); SONG B.L., DEBOSE-BOYD R.A., INSIG-DEPENDENT UBIQUITINATION AND DEGRADATION OF 3-HYDROXY-3 METHYLGLUTARYL COENZYME A REDUCTASE STIMULATED BY DELTA-AND GAMMA-TOCOTRIENOLS, J BIOL CHEM, 281, PP. 54-61, (2006); PRASAD K., TOCOTRIENOLS AND CARDIOVASCULAR HEALTH, CURR PHARM DES, 17, PP. 2147-2154, (2011); MCRAE M.P., TREATMENT OF HYPERLIPOPROTEINEMIA WITH PANTETHINE A REVIEW AND ANALYSIS OF EFFICACY AND TOLERABILITY, NUTR RES, 25, PP. 319-333, (2005); KELLY G., PANTETHINE: A REVIEW OF ITS BIOCHEMISTRY AND THERAPEUTIC APPLICATIONS, ALTERN MED REV, 2, PP. 365-377, (1997); HORVATH Z., VECSEI L., CURRENT MEDICAL ASPECTS OF PANTETHINE, IDEGGYOGY SZ, 8, PP. 220-229, (2009); PINS L.L., KEENAN J.M., DIETARY AND NUTRACEUTICAL OPTIONS FOR MANAGING THE HYPERTRIGLYCERIDEMIC PATIENT, PROG CARDIOVASC NURS, 21, PP. 89-93, (2006); PANTETHINE MONOGRAPH, ALTERN MED REV, 15, PP. 279-282, (2010); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); ULBRICHT C., BASCH E., SZAPARY P., ET AL., GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENT THER MED, 13, PP. 279-290, (2005); NOHR L.A., RASMUSSEN L.B., STRAAND J., RESIN FROM THE MUKUL MYRRH TREE, GUGGUL, CAN IT BE USED FOR TREATING HYPERCHOLESTEROLEMIA: A RANDOMIZED, CONTROLLED STUDY, COMPLEMENT THER MED, 17, PP. 16-22, (2009); GARDNER C.D., LAWSON L.D., BLOCK E., ET AL., EFFECT OF RAW GARLIC VS COMMERCIAL GARLIC SUPPLEMENTS ON PLASMA LIPID CONCENTRATION IN ADULTS WITH MODERATE HYPERCHOLESTEROLEMIA: A RANDOMIZED CLINICAL TRIAL, ARCH INTERN MED, 167, PP. 346-353, (2007); SONI K.B., KUTTAN R., EFFECT OF ORAL CURCUMIN ADMINISTRATION ON SERUM PEROXIDES AND CHOLESTEROL LEVELS IN HUMAN VOLUNTEERS, INDIAN J PHYSIOL PHARMACOL, 36, PP. 273-275, (1992); AVIRAM M., ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS - OXIDATIVE STRESS AND PARAOXONASES REGULATE ATHEROGENESIS, CURR OPIN LIPIDOL, 21, PP. 163-164, (2010); FUHRMAN B., VOLKOVA N., AVIRAM M., POMEGRANATE JUICE POLYPHENOLS INCREASE RECOMBINANT PAROXONASE-1 BINDING TO HIGH DENSITY LIPOPROTEIN: STUDIES IN VITRO AND IN DIABETIC PATIENTS, NUTRITION, 26, PP. 359-366, (2010); AVAIRAM M., ROSENBLAT M., GAITINE D., ET AL., POMEGRANATE JUICE CONSUMPTION FOR 3YEARS BY PATIENTS WITH CAROTID ARTERY STENOSIS REDUCES COMMON CAROTID INTIMA-MEDIA THICKNESS, BLOOD PRESSURE AND LDL OXIDATION, CLIN NUTR, 23, PP. 423-433, (2004); MATTIELLO T., TRIFIRO E., JOTTI G.S., PULCINELLI F.M., EFFECTS OF POMEGRANATE JUICE AND EXTRACT POLYPYENOLS ON PLATELET FUNCTION, J MED FOOD, 12, PP. 334-339, (2009); AVIRAM M., DORNFELD L., ROSENBLAT M., ET AL., POMEGRANATE JUICE CONSUMPTION REDUCES OXIDATIVE STRESS, ATHEROGENIC MODIFICATIONS TO LDL, AND PLATELET AGGREGATION: STUDIES IN HUMANS AND IN ATHEROSCLEROTIC APOLIPOPROTEIN E-DEFICIENT MICE, AM J CLIN NUTR, 71, PP. 1062-1076, (2000); DAVIDSON M.H., MAKI K.C., DICKLIN M.R., ET AL., EFFECTS OF CONSUMPTION OF POMEGRANATE JUICE ON CAROTID INTIMA-MEDIA THICKNESS IN MEN AND WOMEN AT MODERATE RISK FOR CORONARY HEART DISEASE, AM J CARDIOL, 104, PP. 936-942, (2009); CESAR T.B., APTEKMAN N.P., ARAUJO M.P., ET AL., ORANGE JUICE DECREASES LOW DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC SUBJECTS AND IMPROVES LIPID TRANSFER TO HIGH DENSITY LIPOPROTEIN IN NORMAL AND HYPERCHOLESTEROLEMIC SUBJECTS, NUTR RES, 30, PP. 689-694, (2010); DI DONNA L., DE LUCA G., MAZZOTTI F., ET AL., STATIN-LIKE PRINCIPLES OF BERGAMOT FRUIT (CITRUS BERGAMIA): ISOLATION OF 3 HYDROXYMETHYLGLUTARYL FLAVONOID GLYCOSIDES, J NAT PROD, 72, PP. 1352-1354, (2009); MOLLACE V., SACCO I., JANDA E., ET AL., HYPOLIPIDEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTHERAPIA, 82, PP. 309-316, (2011); MCRAE M.P., VITAMIN C SUPPLEMENTATION LOWERS SERUM LOW-DENSITY CHOLESTEROL AND TRIGLYCERIDES: A META-ANALYSIS OF 13 RANDOMIZED CONTROLLED TRIALS, J CHIROPR MED, 7, PP. 48-58, (2008); MCRAE M.P., THE EFFICACY OF VITAMIN C SUPPLEMENTATION ON REDUCING TOTAL SERUM CHOLESTEROL IN HUMAN SUBJECTS: A REVIEW OF 51 EXPERIMENTAL TRIALS, J CHIROPR MED, 5, PP. 2-12, (2006); PALOZZA P., SIMONE R., GATALANO A., ET AL., LYCOPENE REGULATION OF CHOLESTEROL SYNTHESIS AND EFFLUX IN HUMAN MACROPHAGES, J NUTR BIOCHEM, 22, PP. 971-978, (2011); HOUSTON M., SPARKS W., EFFECT OF COMBINATION PANTETHINE, PLANT STEROLS, GREEN TEA EXTRACT, DELTA-TOCOTRIENOL AND PHYTOLENS ON LIPID PROFILES IN PATIENTS WITH HYPERLIPIDEMIA, JANA, 13, PP. 15-20, (2010); STUDER M., BRIEL M., LEIMENSTOLL B., ET AL., EFFECT OF DIFFERENT ANTI-LIPIDEMIC AGENTS AND DIETS ON MORTALITY: A SYSTEMIC REVIEW, ARCH INT MED, 165, PP. 725-730, (2005)","M. HOUSTON; HYPERTENSION INSTITUTE, SAINT THOMAS MEDICAL GROUP, SAINT THOMAS HOSPITAL, NASHVILLE, TN, 4230 HARDING ROAD, SUITE 400, UNITED STATES; EMAIL: MHOUSTONHISTH@YAHOO.COM","","ENGLISH","J. CLIN. HYPERTENS.","REVIEW","ISI","2-S2.0-84856237816","J CLIN HYPERTENS","VANDERBILT UNIVERSITY SCHOOL OF MEDICINE","NOTREPORTED;HYPERTENSION INSTITUTE;NOTREPORTED",NA,"HOUSTON M, 2012, J CLIN HYPERTENS","HOUSTON M, 2012, J CLIN HYPERTENS"
"KIM J;PARK S;JUNG J;HA S;LIM S;LEE S;WOO H;PARK S;SUH S","KIM, JAE KWANG (57193343343); PARK, SOO-YUN (45661697500); JUNG, JI YUN (55263201000); HA, SUN-HWA (7202501231); LIM, SUN-HYUNG (7404081419); LEE, SI MYUNG (8107878500); WOO, HEE-JONG (48061583100); PARK, SANG UN (57783497100); SUH, SEOK-CHEOL (8969541000)","POLICOSANOL CONTENT AND COMPOSITION OF KOREAN RICE ORYZA SATIVA L CULTIVARS",2012,"CEREAL CHEMISTRY","89","3",5,"10.1094/CCHEM-09-11-0113","NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;DEPARTMENT OF CROP SCIENCE, CHUNGNAM NATIONAL UNIVERSITY, DAEJEON, 305-764, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA","POLICOSANOLS (PCS) ARE A GROUP OF LONG-CHAIN ALCOHOLS THAT HAVE BEEN REPORTED TO HAVE MANY BENEFICIAL PHYSIOLOGICAL ACTIVITIES. IN THIS STUDY, THE TOTAL CONTENT AND COMPOSITION OF PCS IN 15 RICE (ORYZA SATIVA L.) CULTIVARS FROM KOREA WERE CHARACTERIZED BY GAS CHROMATOGRAPHY-TIME-OF-FLIGHT MASS SPECTROMETRY. THIS METHOD PROVED TO BE SUFFICIENTLY PRECISE AND ACCURATE WITH RESPECT TO THE DEGREE OF ENDOGENOUS BIOLOGICAL VARIABILITY FOUND IN THE RICE SAMPLES. OCTACOSANOL (C28) AND TRIACONTANOL (C30) WERE THE MAJOR COMPONENTS OF PCS IN ALL CULTIVARS. IN ADDITION, THERE WERE POSITIVE CORRELATIONS AMONG THE DETERMINED PC CONTENTS. GIVEN ITS HIGH PC CONTENT, THE HEUGHYANGBYEO CULTIVAR MAY APPEAR TO BE A GOOD CANDIDATE FOR FUTURE BREEDING PROGRAMS. © 2012 AACC INTERNATIONAL, INC.","","ORYZA SATIVA; MASS SPECTROMETRY; MICROCOMPUTERS; BIOLOGICAL VARIABILITY; KOREAN RICE; LONG CHAIN ALCOHOLS; OCTACOSANOL; PHYSIOLOGICAL ACTIVITY; POLICOSANOLS; RICE (ORYZA SATIVA L.); RICE SAMPLES; TIME OF FLIGHT MASS SPECTROMETRY; TOTAL CONTENT; GAS CHROMATOGRAPHY","","","ADHIKARI P., KEUM T.H., JAE N.P., CHOONG K.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, 15, PP. 5359-5362, (2006); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, 3, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, 10, PP. 891-897, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 58, 1, PP. 61-64, (1998); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL, 57, 9, PP. 691-699, (1996); CHERIF A.O., MESSAOUDA B.M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), J. AGRIC. FOOD CHEM., 58, PP. 12143-12148, (2010); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEMISTRY, 81, 3, PP. 345-349, (2004); KEUM T.H., JI E.K., WELLER C.L., POLICOSANOL CONTENTS AND COMPOSITIONS IN WAX-LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN, CEREAL CHEMISTRY, 82, 3, PP. 242-245, (2005); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 14, PP. 5583-5586, (2005); KIM J.K., PARK S.-Y., HA S.-H., LEE S.M., LIM S.H., YU C.Y., SUH S.-C., KWEON S.J., STABLE ISOTOPE DILUTION GAS CHROMATOGRAPHY-TIME-OF-FLIGHT MASS SPECTROMETRY METHOD FOR DETERMINING NIACIN IN RICE, CEREAL CHEM., 88, PP. 397-399, (2011); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM: CLINICAL AND EXPERIMENTAL, 53, 10, PP. 1309-1314, (2004); CHI H.N., KA Y.L., HUANG Y., ZHEN Y.C., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 16, PP. 6289-6293, (2005); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 36, 9, PP. 469-473, (1998); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); WANG M.-F., LIAN H.-Z., MAO L., ZHOU J.-P., GONG H.-J., QIAN B.-Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 14, PP. 5552-5558, (2007)","J.K. KIM; NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA; EMAIL: KJKPJ@KOREA.KR","AMERICAN ASSOCIATION OF CEREAL CHEMISTS","ENGLISH","CEREAL CHEM.","ARTICLE","ISI","2-S2.0-84862881923","CEREAL CHEM","NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;CHUNGNAM NATIONAL UNIVERSITY;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE","NOTREPORTED;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NOTREPORTED",NA,"KIM JK, 2012, CEREAL CHEM","KIM JK, 2012, CEREAL CHEM"
"LUPI F;GABRIELE D;GRECO V;BALDINO N;SETA L;DE C B","LUPI, F.R. (24768180600); GABRIELE, D. (6507587673); GRECO, V. (57190121462); BALDINO, N. (24767432700); SETA, L. (36140452900); DE CINDIO, B. (6602864175)","A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OILFATTY ALCOHOLS ORGANOGEL",2013,"FOOD RESEARCH INTERNATIONAL","51","7",72,"10.1016/j.foodres.2013.01.013","UNIVERSITY OF CALABRIA, DEPARTMENT OF ENGINEERING MODELLING, I-87036 RENDE (CS), VIA P. BUCCI - CUBO 39C, ITALY;UNIVERSITY OF CALABRIA, DEPARTMENT OF ENGINEERING MODELLING, I-87036 RENDE (CS), VIA P. BUCCI - CUBO 39C, ITALY;UNIVERSITY OF CALABRIA, DEPARTMENT OF ENGINEERING MODELLING, I-87036 RENDE (CS), VIA P. BUCCI - CUBO 39C, ITALY;UNIVERSITY OF CALABRIA, DEPARTMENT OF ENGINEERING MODELLING, I-87036 RENDE (CS), VIA P. BUCCI - CUBO 39C, ITALY;UNIVERSITY OF CALABRIA, DEPARTMENT OF ENGINEERING MODELLING, I-87036 RENDE (CS), VIA P. BUCCI - CUBO 39C, ITALY;UNIVERSITY OF CALABRIA, DEPARTMENT OF ENGINEERING MODELLING, I-87036 RENDE (CS), VIA P. BUCCI - CUBO 39C, ITALY","POLICOSANOL IS A MIXTURE OF FATTY ALCOHOLS WELL KNOWN FOR ITS NUTRACEUTICAL EFFECTS ON CONSUMERS' HEALTH. IN THE PRESENT PAPER, THE POTENTIAL ABILITY OF THIS FOOD-GRADE ADDITIVE TO ORGANOGEL VEGETABLE OILS HAS BEEN INVESTIGATED BY PREPARING SAMPLES BASED ON VIRGIN OLIVE OIL AT DIFFERENT POLICOSANOL CONCENTRATIONS. THE ONSET OF CRYSTALLISATION TEMPERATURE (TCO) AND THE GELATION TEMPERATURE (TG) WERE EVALUATED BY CARRYING OUT DYNAMIC TEMPERATURE RAMP TESTS, WHEREAS THE RHEOLOGICAL CHARACTERISTICS OF SAMPLES AT TEMPERATURES LOWER THAN THE CRYSTALLISATION ONSET WERE STUDIED WITH FREQUENCY SWEEP TESTS AT 25 °C. EXPERIMENTAL DATA HAVE SHOWN THAT CRYSTALLISATION OCCURS FOR POLICOSANOL CONCENTRATION LARGER THAN 0.1% W/W WHEREAS GELATION (I.E. THE FORMATION OF A STRUCTURED 3D NETWORK) CAN BE OBSERVED ONLY FOR CONCENTRATIONS LARGER THAN A CRITICAL VALUE RANGING BETWEEN 0.3% AND 0.5% W/W. THE ONSET OF CRYSTALLISATION TEMPERATURE INCREASES NONLINEARLY WITH ORGANOGELATOR AMOUNT EVEN IF AN ASYMPTOTIC TREND SEEMS TO BE PRESENT FOR CONCENTRATIONS LARGER THAN 50% W/W. A FRACTAL MODEL WAS USED TO FIT EXPERIMENTAL STORAGE MODULUS DATA, G', AS A FUNCTION OF POLICOSANOL AMOUNT, AND A FRACTAL DIMENSION EQUAL TO 2.75, IN AGREEMENT WITH LITERATURE VALUES, WAS FOUND. FINALLY, A PHENOMENOLOGICAL EQUATION BASED ON A MODIFIED FRACTAL MODEL, WAS PROPOSED TO FIT, WITH A GOOD AGREEMENT, THE EXPERIMENTAL TCO VALUES AS A FUNCTION OF THE POLICOSANOL FRACTION. © 2013 ELSEVIER LTD.","CRYSTALLISATION; OLEOGEL; OLIVE OIL; ORGANOGEL; POLICOSANOL; RHEOLOGY","ALCOHOLS; CRYSTALLIZATION; FRACTAL DIMENSION; GELATION; OLIVE OIL; RHEOLOGY; 3D NETWORKS; CRITICAL VALUE; EXPERIMENTAL DATUM; FATTY ALCOHOLS; FOOD GRADE; FRACTAL MODEL; FREQUENCY SWEEP; GELATION TEMPERATURE; NUTRACEUTICALS; OLEOGEL; ORGANO-GELATOR; ORGANOGELS; PHENOMENOLOGICAL EQUATIONS; POLICOSANOL; POTENTIAL ABILITY; RHEOLOGICAL CHARACTERISTICS; TEMPERATURE INCREASE; TEMPERATURE RAMP; VIRGIN OLIVE OIL; OILS AND FATS","","","AMBROSONE L., MOSCA M., CEGLIE A., OXIDATION OF WATER EMULSIFIED OLIVE OILS, FOOD HYDROCOLLOIDS, 20, PP. 1080-1086, (2006); BLANCO MUNOZ M.A., OLIVE OIL IN FOOD SPREADS, GRASAS Y ACEITES, 55, PP. 92-94, (2004); BOT A., DEN ADEL R., ROIJERS E.C., REGKOS C., NON-TRIGLYCERIDE STRUCTURING OF EDIBLE OILS: TUBULES IN STEROL+Γ-ORYZANOL-BASED ORGANOGELS, PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON FOOD RHEOLOGY AND STRUCTURE, PP. 224-227, (2009); CALLIGARIS S., DA PIEVE S., ARRIGHETTI G., BARBA L., EFFECT OF THE STRUCTURE OF MONOGLYCERIDE-OIL-WATER GELS ON AROMA PARTITION, FOOD RESEARCH INTERNATIONAL, 43, PP. 671-677, (2010); CO D.E., MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 89, PP. 749-780, (2012); DA PIEVE S., CALLIGARIS S., CO D.E., NICOLI M.C., MARANGONI A.G., SHEAR NANOSTRUCTURING OF MONOGLYCERIDE ORGANOGELS, FOOD BIOPHYSICS, 5, PP. 211-217, (2010); DASSANAYAKE L.S.K., KODAL D.R., UENO S., FORMATION OF OLEOGELS BASED ON EDIBLE LIPID MATERIALS, CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 16, PP. 432-439, (2011); DE LUCAS A., GARCIA A., ALVAREZ A., GRACIA I., SUPERCRITICAL EXTRACTION OF LONG CHAIN N-ALCOHOLS FROM SUGAR CANE CRUDE WAX, JOURNAL OF SUPERCRITICAL FLUIDS, 41, PP. 267-271, (2007); DUFFY N., BLONK H.C.G., BEINDORFF C.M., CAZADE M., BOT A., DUCHATEAU G.S.M.J.E., ORGANOGEL-BASED EMULSION SYSTEMS, MICRO-STRUCTURAL FEATURES AND IMPACT ON IN VITRO DIGESTION, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 86, PP. 733-741, (2009); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 16, PP. 61-65, (2008); GANDOLFO F.G., BOT A., FLOTER E., STRUCTURING OF EDIBLE OILS BY LONG-CHAIN FA, FATTY ALCOHOLS, AND THEIR MIXTURES, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 81, PP. 1-6, (2004); GHOTRA B.S., DYAL S.D., NARINE S.S., LIPID SHORTENINGS: A REVIEW, FOOD RESEARCH INTERNATIONAL, 35, PP. 1015-1048, (2002); GRONWALD O., SNIP E., SHINKAI S., GELATORS FOR ORGANIC LIQUIDS BASED ON SELF-ASSEMBLY: A NEW FACET OF SUPRAMOLECULAR AND COMBINATORIAL CHEMISTRY, CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 7, PP. 148-156, (2002); HUGHES N.E., MARANGONI A.G., WRIGHT A.J., ROGERS M.A., RUSH J.W.E., POTENTIAL FOOD APPLICATIONS OF EDIBLE OIL ORGANOGELS, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 20, PP. 470-480, (2009); HWANG H.-S., KIM S., SINGH M., WINKLER-MOSER J.K., LIU S.X., ORGANOGEL FORMATION OF SOYBEAN OIL WITH WAXES, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 89, PP. 639-647, (2012); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); KIM T.H., KIM D.G., LEE M., LEE T.S., SYNTHESIS OF REVERSIBLE FLUORESCENT ORGANOGEL CONTAINING 2-(2'-HYDROXYPHENYL) BENZOXAZOLE: FLUORESCENCE ENHANCEMENT UPON GELATION AND DETECTING PROPERTY FOR NERVE GAS STIMULANT, TETRAHEDRON, 66, PP. 1667-1672, (2010); LAREDO T., BARBUT S., MARANGONI A.G., MOLECULAR INTERACTIONS OF POLYMER OLEOGELATION, SOFT MATTER, 7, PP. 2734-2743, (2011); LUPI F.R., GABRIELE D., BALDINO N., SETA L., DE CINDIO B., DE ROSE C., STABILISATION OF MEAT SUSPENSIONS BY ORGANOGELATION: A RHEOLOGICAL APPROACH, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, PP. 1381-1389, (2012); LUPI F.R., GABRIELE D., DE CINDIO B., EFFECT OF SHEAR RATE ON CRYSTALLISATION PHENOMENA IN OLIVE OIL BASED ORGANOGELS, FOOD AND BIOPROCESS TECHNOLOGY, 5, PP. 2880-2888, (2012); LUPI F.R., GABRIELE D., DE CINDIO B., SANCHEZ M.C., GALLEGOS C., A RHEOLOGICAL ANALYSIS OF STRUCTURED WATER-IN-OLIVE OIL EMULSIONS, JOURNAL OF FOOD ENGINEERING, 107, PP. 296-303, (2011); LUPI F.R., GABRIELE D., FACCIOLO D., BALDINO N., SETA L., DE CINDIO B., EFFECT OF ORGANOGELATOR AND FAT SOURCE ON RHEOLOGICAL PROPERTIES OF OLIVE OIL-BASED ORGANOGELS, FOOD RESEARCH INTERNATIONAL, 46, PP. 177-184, (2012); MARANGONI A.G., NOVEL STRATEGIES FOR NANOSTRUCTURING LIQUID OILS INTO FUNCTIONAL FATS, PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON FOOD RHEOLOGY AND STRUCTURE, PP. 38-44, (2009); MARANGONI A.G., GARTI N., EDIBLE OLEOGELS: STRUCTURE AND HEALTH IMPLICATIONS, (2011); MARANGONI A.G., IDZIAK S.H.J., VEGA C., BATTE H., OLLIVON M., JANTZI P.S., ET AL., ENCAPSULATION-STRUCTURING OF EDIBLE OIL ATTENUATES ACUTE ELEVATION OF BLOOD LIPIDS AND INSULIN IN HUMANS, SOFT MATTER, 3, PP. 183-187, (2007); MOSCA M., CEGLIE A., AMBROSONE L., ANTIOXIDANT DISPERSIONS IN EMULSIFIED OLIVE OILS, FOOD RESEARCH INTERNATIONAL, 41, PP. 201-207, (2008); OJIJO N.K.O., NEEMAN I., EGER S., SHIMONI E., EFFECTS OF MONOGLYCERIDE CONTENT, COOLING RATE AND SHEAR ON THE RHEOLOGICAL PROPERTIES OF OLIVE OIL/MONOGLYCERIDE GEL NETWORKS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 84, PP. 1585-1593, (2004); PERNETTI M., VAN MALSSEN K.F., FLOTER E., BOT A., STRUCTURING OF EDIBLE OILS BY ALTERNATIVES TO CRYSTALLINE FAT, CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 12, PP. 221-231, (2007); PERNETTI M., VAN MALSSEN K., KALNIN D., FLOTER E., STRUCTURING EDIBLE OIL WITH LECITHIN AND SORBITAN TRI-STEARATE, FOOD HYDROCOLLOIDS, 21, PP. 855-861, (2007); PRISTOURI G., BADEKA A., KONTOMINAS M.G., EFFECT OF PACKAGING MATERIAL HEADSPACE, OXYGEN AND LIGHT TRANSMISSION, TEMPERATURE AND STORAGE TIME ON QUALITY CHARACTERISTICS OF EXTRA VIRGIN OLIVE OIL, FOOD CONTROL, 21, PP. 412-418, (2010); RAO M.A., RHEOLOGY OF FLUID AND SEMISOLID FOODS-PRINCIPLES AND APPLICATIONS, (1999); ROGERS M.A., WRIGHT A.J., MARANGONI A.G., CRYSTALLINE STABILITY OF SELF-ASSEMBLED FIBRILLAR NETWORKS OF 12-HYDROXYSTEARIC ACID IN EDIBLE OILS, FOOD RESEARCH INTERNATIONAL, 41, PP. 1026-1034, (2008); ROGERS M.A., WRIGHT A.J., MARANGONI A.G., OIL ORGANOGELS: THE FAT OF THE FUTURE?, SOFT MATTER, 5, PP. 1594-1596, (2009); RONHOLT S., KIRKENSGAARD J.J.K., PEDERSEN T.B., MORTENSEN K., KNUDSEN J.C., POLYMORPHISM, MICROSTRUCTURE AND RHEOLOGY OF BUTTER. EFFECTS OF CREAM HEAT TREATMENT, FOOD CHEMISTRY, 135, PP. 1730-1739, (2012); SCHAINK H.M., VAN MALSSEN K.F., MORGADO-ALVES S., KALNIN D., VAN DER LINDEN E., CRYSTAL NETWORK FOR EDIBLE OIL ORGANOGELS: POSSIBILITIES AND LIMITATIONS OF THE FATTY ACID AND FATTY ALCOHOL SYSTEMS, FOOD RESEARCH INTERNATIONAL, 40, PP. 1185-1193, (2007); SHAPIRO Y.E., STRUCTURE AND DYNAMICS OF HYDROGELS AND ORGANOGELS: AN NMR SPECTROSCOPY APPROACH, PROGRESS IN POLYMER SCIENCE, 36, PP. 1184-1253, (2011); SHCHIPUNOV Y.A., LECITHIN ORGANOGEL-A MICELLAR SYSTEM WITH UNIQUE PROPERTIES, COLLOIDS AND SURFACES A: PHYSICOCHEMICAL AND ENGINEERING ASPECTS, PP. 541-554, (2001); SINGH D., REZAC M.E., PFROMM P.H., PARTIAL HYDROGENATION OF SOYBEAN OIL WITH MINIMAL TRANS-FAT PRODUCTION USING A PT-DECORATED POLYMERIC MEMBRANE REACTOR, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 86, PP. 93-101, (2009); TANG D., MARANGONI A.G., MODELING THE RHEOLOGICAL PROPERTIES AND STRUCTURE OF COLLOIDAL FAT CRYSTAL NETWORKS, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 18, PP. 474-483, (2007); TANG D., MARANGONI A.G., MODIFIED FRACTAL MODEL AND RHEOLOGICAL PROPERTIES OF COLLOIDAL NETWORKS, JOURNAL OF COLLOID AND INTERFACE SCIENCE, 318, PP. 202-209, (2008); TORO-VAZQUEZ J.F., MORALES-RUEDA J., AJAY MALLIA V., WEISS R.G., RELATIONSHIP BETWEEN MOLECULAR STRUCTURE AND THERMO-MECHANICAL PROPERTIES OF CANDELILLA WAX AND AMIDES DERIVED FROM (R)-12-HYDROXYSTEARIC ACID AS GELATORS OF SAFFLOWER OIL, FOOD BIOPHYSICS, 5, PP. 193-202, (2010); TORO-VAZQUEZ J.F., MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M., ALONZO-MACIAS M., GONZALEZ-CHAVEZ M.M., THERMAL AND TEXTURAL PROPERTIES OF ORGANOGELS DEVELOPED BY CANDELILLA WAX IN SAFFLOWER OIL, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 84, PP. 989-1000, (2007); VAISEY-GENSER M., MARGARINE/TYPES AND PROPERTIES, ENCYCLOPAEDIA OF FOOD SCIENCE AND NUTRITION, PP. 3704-3709, (2003); VITHANAGE C.R., GRIMSON M.J., SMITH B.G., THE EFFECT OF TEMPERATURE ON THE RHEOLOGY OF BUTTER, A SPREADABLE BLEND AND SPREADS, JOURNAL OF TEXTURE STUDIES, 40, PP. 346-369, (2009); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, NUTRITION RESEARCH, 27, PP. 212-217, (2007); ZETZL A.K., MARANGONI A.G., BARBUT S., MECHANICAL PROPERTIES OF ETHYLCELLULOSE OLEOGELS AND THEIR POTENTIAL FOR SATURATED FAT REDUCTION IN FRANKFURTERS, FOOD AND FUNCTION, 3, PP. 327-337, (2012)","F.R. LUPI; DEPARTMENT OF ENGINEERING MODELLING, UNIVERSITY OF CALABRIA, I 87030 RENDE (CS), VIA P. BUCCI CUBO 39C, ITALY; EMAIL: DOMENICO.GABRIELE@UNICAL.IT","","ENGLISH","FOOD RES. INT.","ARTICLE","ISI","2-S2.0-84873909846","FOOD RES INT","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA","NOTREPORTED;UNIVERSITY OF CALABRIA;NOTREPORTED",NA,"LUPI FR, 2013, FOOD RES INT","LUPI FR, 2013, FOOD RES INT"
"HAIM D;VALENZUELA A;BRAÑES M;FUENZALIDA M;VIDELA L","HAIM, D. (26649453600); VALENZUELA, A. (7103344850); BRAÑES, M.C. (6603076028); FUENZALIDA, M. (58339545200); VIDELA, L.A. (7005959174)","THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS",2012,"GRASAS Y ACEITES","63","9",11,"10.3989/gya.010612","MOLECULAR AND CLINICAL PHARMACOLOGY PROGRAM, INSTITUTE OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, UNIVERSITY OF CHILE, SANTIAGO, CHILE, FACULTY OF MEDICINE, UNIVERSITY OF THE ANDES, SANTIAGO, CHILE;LABORATORY OF LIPIDS AND ANTIOXIDANTS, INSTITUTE OF NUTRITION AND FOOD TECHNOLOGY, UNIVERSITY OF CHILE, SANTIAGO, CHILE, FACULTY OF MEDICINE, UNIVERSITY OF THE ANDES, SANTIAGO, CHILE;SANTIAGO, CHILE;SANTIAGO, CHILE;MOLECULAR AND CLINICAL PHARMACOLOGY PROGRAM, INSTITUTE OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, UNIVERSITY OF CHILE, SANTIAGO, CHILE","POLICOSANOL COMPRISES A MIXTURE OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM SUGARCANE WAX. MORE THAN 50 STUDIES INDICATE THAT POLICOSANOL DECREASES SERUM CHOLESTEROL, WHILE OTHERS FAILED TO REPRODUCE THIS EFFECT. THE OBJECTIVE OF THIS INVESTIGATION WAS TO ASSESS THE BIOAVAILABILITY OF ESTERIFIED POLICOSANOL AND NON-ESTERIFIED POLICOSANOL (NEP), IN RELATION TO THEIR HYPOCHOLESTEROLEMIC EFFECTS. SPRAGUE DAWLEY RATS WERE GIVEN A DAILY ORAL DOSE OF 100 MG/KG OF NEP, 117 MG KG-1 OF BUTYRIC ACID ESTERIFIED POLICOSANOL (BAEP), OR 164 MG KG-1 OF OLEIC ACID ESTERIFIED POLICOSANOL (OAEP). POLICOSANOL ABSORPTION WAS EVALUATED IN PLASMA BETWEEN 0 AND 3 HOURS AFTER INGESTION. TO ASSESS CHANGES IN TOTAL CHOLESTEROL, LDL-CHOLESTEROL, HDLCHOLESTEROL AND TRIACYLGLYCEROLS IN PLASMA AND LIVER 3-HYDROXY- 3-METHYLGLUTARYL COENZYME A REDUCTASE (HMG- COA RED) PHOSPHORYLATION, THE RATS WERE SUPPLEMENTED WITH NONESTERIFIED OR ESTERIFIED POLICOSANOL FOR 5 WEEKS. THE RESULTS INDICATE THAT POLICOSANOL ABSORPTION WAS SIGNIFICANTLY GREATER IN OAEP-TREATED RATS THAN IN THOSE SUBJECTED TO NEP OR BAEP ADMINISTRATION. OAEP SIGNIFICANTLY REDUCED PLASMA TOTAL AND LDL-CHOLESTEROL IN RATS, IN ADDITION TO A 5.6-FOLD INCREASE (P < 0.05) IN THE HEPATIC CONTENT OF PHOSPHORYLATED HMG-COA RED OVER THE CONTROL VALUES. IN CONCLUSION, ESTERIFICATION OF POLICOSANOL WITH OLEIC ACID ENHANCES POLICOSANOL BIOAVAILABILITY, AND SIGNIFICANTLY IMPROVES THE SERUM LIPID PROFILE IN NORMOCHOLESTEROLEMIC RATS IN ASSOCIATION WITH THE INACTIVATION OF HMG-COA RED CONTROLLING CHOLESTEROGENESIS.","BIOAVAILABILITY; CHOLESTEROL LOWERING EFFECT; OCTACOSANOL; POLICOSANOL; POLICOSANOL ABSORPTION; RATS; TRIACONTANOL","RATTUS; BIOCHEMISTRY; BODY FLUIDS; CHOLESTEROL; ESTERS; OLEIC ACID; PHOSPHORYLATION; PLASMAS; BIOAVAILABILITY; CHOLESTEROL-LOWERING EFFECTS; OCTACOSANOL; POLICOSANOL; TRIACONTANOL; RATS","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES., 33, PP. 835-840, (2000); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT. J. CLIN. PHARMACOL. THER., 34, PP. 134-137, (1996); BERTHOLD H., UNVERDOEBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF LIPIDS POLICOSANOL ON LIPID LEVELS AMONG WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA, 295, PP. 2262-2269, (2006); BROCKERHOFF H., SUBSTRATE SPECIFICITY OF PANCREATIC LIPASE: INFLUENCE OF THE STRUCTURE OF FATTY ACIDS ON THE REACTIVITY OF ESTERS, BIOCHIM. BIOPHYS. ACTA., 212, PP. 92-101, (1970); BUHMAN K.K., ACCAD M., NOVAK S., CHOI R.S., WONG J.S., HAMILTON R.L., TURLEY S., FARESE JR. R.V., RESISTANCE TO DIET-INDUCED HYPERCHOLESTEROLEMIA AND GALLSTONE FORMATION IN ACAT2-DEFICIENT MICE, NAT. MED., 6, PP. 1341-1347, (2000); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., MOLINA V., MENENDEZ A., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT. J. CLIN. PHARMACOL. RES., 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., LOPEZ E., GAMEZ R., MENDOZA S., FERNANDEZ J., MESA M., EFFECTS OF D-003 ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A PHASE II CLINICAL STUDY, CLIN. DRUG INVESTIG., 23, PP. 789-802, (2003); CHOUDHURY N., TAN L., TRUSWELL A.S., COMPARISON OF PALMOLEIN AND OLIVE OIL: EFFECTS ON PLASMA LIPIDS AND VITAMIN E IN YOUNG ADULTS, AM. J. CLIN. NUTR., 61, PP. 1043-1051, (1995); CLIFTON P., LOWERING CHOLESTEROL - A REVIEW ON THE ROLE OF PLANT STEROLS, AUST. FAM. PHYSICIAN, 38, PP. 218-221, (2009); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 29, PP. 117-127, (1999); DULIN M., HATCHER L., SASSE H., BARRINGER T., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED, AM. J. CLIN. NUTR., 84, PP. 1543-1548, (2006); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT THER. MED., 16, PP. 61-65, (2008); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER. RES., 22, PP. 318-322, (2008); GONZALEZ-BRAVO L., MAGRANER-HERNANDEZ J., ACOSTA- GONZALEZ P.C., PEREZ-SOUTO N., ANALYTICAL PROCEDURE FOR THE DETERMINATION OF 1-OCTACOSANOL IN PLASMA BY SOLVENT EXTRACTION AND CAPILLARY GAS CHROMATOGRAPHY, J. CHROMATOGR. B BIOMED. APPL., 682, PP. 359-363, (1996); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); GREYLING A., DEWITT C., OOSTHUIZEN W., JERLING J., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS, BR. J. NUTR, 95, PP. 968-975, (2006); HAIM D., BERRIOS M., VALENZUELA A., VIDELA L., TRACE QUANTIFICATION OF 1-OCTACOSANOL AND 1-TRIACONTANOL AND THEIR MAIN METABOLITES IN PLASMA BY LIQUID-LIQUID EXTRACTION COUPLED WITH GAS CHROMATOGRAPHY MASS SPECTROMETRY, J. CHROMATOGR. B. BIOMED. APPL., 887, PP. 4154-4158, (2009); HAIM D., VIDELA L., POLICOSANOLS, PROTECTIVE NATURAL COMPOUNDS IN CARDIOVASCULAR DISEASE, AGRO FOOD INDUSTRY HI-TECH., 19, PP. 60-63, (2008); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP. BIOL. MED., 229, PP. 215-226, (2004); HAYES K.C., KHOSLA P., DIETARY FATTY ACID THRESHOLDS AND CHOLESTEROLEMIA, FASEB, J6, PP. 2600-2607, (1992); HERNANDEZ F., ILLNAIT J., MAS R., EFFECT OF POLICOSANOL ON SERUM LIPID AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES. CLIN. EXP., 51, PP. 568-575, (1992); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN. MED. REV., 7, PP. 203-217, (2002); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB., 37, PP. 33-38, (1993); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM. J. CLIN. NUTR., 84, PP. 1003-1008, (2006); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); KELLER S., GIMMLER F., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS., 43, PP. 109-115, (2008); LAEMMLI U.K., CLEAVAGE OF STRUCTURAL PROTEINS DURING THE ASSEMBLY OF THE HEAD OF BACTERIOPHAGE T4, NATURE., 227, PP. 680-685, (1970); MARRERO D., GONZALEZ-BRAVO L., TRACE DETERMINATION OF 1-OCTACOSANOL IN RAT PLASMA BY SOLID-PHASE EXTRACTION WITH TENAX GC AND CAPILLARY GAS CHROMATOGRAPHY, J. CHROMATOGR B. BIOMED. APPL., 762, PP. 43-49, (2001); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA R., MESA M.S., ARMAS M., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR. THER. RES., 62, PP. 209-220, (2001); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL. RES., 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 31, PP. 8-12, (2001); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH. MED. RES., 36, PP. 113-119, (2005); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, J. AM. COLL. NUTR., 27, PP. 476-484, (2008); NG T.K., HAYES K.C., DEWITT G.F., JEGATHESAN M., SATGUNASINGAM N., ONG A.S., TAN D., DIETARY PALMITIC ACID AND OLEIC ACID EXERT SIMILAR EFFECTS ON SERUM CHOLESTEROL AND LIPOPROTEIN PROFILES IN NORMOCHOLESTEROLEMIC MEN AND WOMEN, J. AM. COLL. NUTR., 11, PP. 383-390, (1992); NG CHI H., LEUNG KA Y., HUAN Y., CEHN ZHEN Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOWDENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J. AGRIC. FOOD CHEM., 53, PP. 6289-6293, (2005); NISSINEN M.J., GYLLING H., MIETTINEN T.A., EFFECTS OF PLANT STANOL ESTERS SUPPLIED IN A FAT FREE MILIEU BY PASTILLES ON CHOLESTEROL METABOLISM IN COLECTOMIZED HUMAN SUBJECTS, NUTR. METAB. CARDIOVASC. DIS., 16, PP. 426-435, (2006); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMG-COA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS., 44, PP. 907-916, (2009); PLACE A.R., COMPARATIVE ASPECTS OF LIPID DIGESTION AND ABSORPTION: PHYSIOLOGICAL CORRELATES OF WAX ESTER DIGESTION, AM. J. PHYSIOL, 263, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES. CLIN. EXP., 52, PP. 507-513, (1992); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV. MED. CHILE, 127, PP. 286-294, (1999); SANCHEZ-MUNIZ F.J., CRUZ-MERINERO M., RODRIGUEZ-GIL S., ORDOVAS J.M., RODENAS S., CUESTA C., DIETARY FAT SATURATION AFFECTS APOLIPOPROTEIN AII LEVELS AND HDL COMPOSITION IN POSTMENOPAUSAL WOMEN, J. NUTR, 132, PP. 50-54, (2002); SINGH B.K., MEHTA J.L., MANAGEMENT OF DYSLIPIDEMIA IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE, CURR. OPIN. CARDIOL., 17, PP. 503-511, (2002); SINGH D., LI L., PORTER T., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP KINASE, J. PHARM. EXP. THERAP., 318, PP. 1020-1026, (2006); TORRES O., AGRAMONTE A.J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE., 18, PP. 393-397, (1995); TOWBIN H., STAEHELIN T., GORDON J., ELECTROPHORETIC TRANSFER OF PROTEINS FROM POLYACRYLAMIDE GELS TO NITROCELLULOSE SHEETS: PROCEDURE AND SOME APPLICATIONS, PROC. NATL. ACAD. SCI. USA, 76, PP. 4350-4354, (1979); WONG A.K., HOWIE J., PETRIE J.R., LANG C.C., AMPACTIVATED PROTEIN KINASE PATHWAY: A POTENTIAL THERAPEUTIC TARGET IN CARDIOMETABOLIC DISEASE, CLIN. SCI., 16, PP. 607-620, (2009); WU T., FU J., YANG Y., ZHANG L., HAN J., THE EFFECTS OF PHYTOSTEROLS/STANOLS ON BLOOD LIPID PROFILES: A SYSTEMATIC REVIEW WITH META-ANALYSIS, ASIA PAC. J. CLIN. NUTR., 18, PP. 179-186, (2009)","D. HAIM; MOLECULAR AND CLINICAL PHARMACOLOGY PROGRAM, INSTITUTE OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, UNIVERSITY OF CHILE, SANTIAGO, CHILE; EMAIL: DNHAIM@MIUANDES.CL","","ENGLISH","GRASAS ACEITES","ARTICLE","ISI","2-S2.0-84870772221","GRASAS ACEITES","UNIVERSITY OF CHILE;UNIVERSITY OF CHILE;UNIVERSITY OF CHILE","NOTREPORTED;UNIVERSITY OF CHILE;NOTREPORTED",NA,"HAIM D, 2012, GRASAS ACEITES","HAIM D, 2012, GRASAS ACEITES"
"CICERO A;TARTAGNI E;BORGHI C","CICERO, ARRIGO F.G. (7003403707); TARTAGNI, ELISA (55245795500); BORGHI, CLAUDIO (7102731762)","NUTRACEUTICALS WITH LIPIDLOWERING ACTIVITY DO THEY HAVE ANY EFFECT BEYOND CHOLESTEROL REDUCTION",2012,"CLINICAL LIPIDOLOGY","7","10",6,"10.2217/clp.12.55","MEDICAL AND SURGICAL SCIENCES DEPARTMENT, S ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY;MEDICAL AND SURGICAL SCIENCES DEPARTMENT, S ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY;MEDICAL AND SURGICAL SCIENCES DEPARTMENT, S ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY","A LARGE NUMBER OF NUTRACEUTICALS WITH LIPID-LOWERING ACTIVITY ARE CURRENTLY AVAILABLE ON THE MARKET, HOWEVER, FOR MOST OF THEM, IT IS NOT KNOWN WHETHER THE LIPID-LOWERING ACTIVITY IS ASSOCIATED WITH A CONCRETE REDUCTION IN CARDIOVASCULAR DISEASE RISK. THE AIM OF THIS REVIEW IS TO EVALUATE WHETHER THE MOST COMMONLY USED LIPID-LOWERING NUTRACEUTICALS (I.E., SOLUBLE FIBERS, PHYTOSTEROLS, GARLIC, SOY PROTEINS, MONACOLINS, POLICOSANOLS, BERBERINE AND N-3 FATTY ACIDS) ALSO HAVE SOME POSITIVE EFFECTS ON OTHER CARDIOVASCULAR DISEASE RISK FACTORS, ON INSTRUMENTAL BIOMARKERS OF CARDIOVASCULAR DISEASE RISK OR THE RISK OF CARDIOVASCULAR EVENTS. BEYOND RED YEAST RICE AND N-3 FATTY ACIDS, WHOSE USE WAS RELATED TO A SIGNIFICANT AND RELIABLE DECREASE IN CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY, NO EVIDENCE IS AVAILABLE THAT DEMONSTRATES A PREVENTIVE EFFECT OF LIPID-LOWERING NUTRACEUTICALS ON HARD CARDIOVASCULAR OUTCOMES. HOWEVER, FOR BERBERINE AND SOLUBLE FIBERS, THE EVIDENCE OF A POSITIVE MULTIMETABOLIC EFFECT IS GROWING, CONTRIBUTING TO A BETTER CONTROL OF BOTH GLUCOSE AND LIPIDS VALUES THAT CONSEQUENTLY COULD BE USEFUL IN THE MANAGEMENT OF METABOLIC SYNDROME. © 2012 FUTURE MEDICINE LTD.","LIPIDS; MORBIDITY; MORTALITY; NUTRACEUTICALS; PLEIOTROPIC EFFECTS","ALLIUM SATIVUM; ACETYLSALICYLIC ACID; ALPHA TOCOTRIENOL; BERBERINE; BETA GLUCAN; BIOLOGICAL MARKER; CHOLESTEROL; CHOLESTIN; FLAVONOID; GARLIC EXTRACT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INULIN; ISPAGULA; LIPID; LYCOPENE; MONOUNSATURATED FATTY ACID; NUTRACEUTICAL; OLIGOSACCHARIDE; OMEGA 3 FATTY ACID; PECTIN; PHYTOSTEROL; PLACEBO; POLICOSANOL; POLYPHENOL; RESVERATROL; SOYBEAN PROTEIN; THIOPENTAL; UNINDEXED DRUG; WARFARIN; XUEZHIKANG; ACUTE CORONARY SYNDROME; ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSTIPATION; CORONARY ARTERY DISEASE; DIETARY FIBER; DRUG ACTIVITY; DRUG MEGADOSE; DYSPNEA; FISHY AFTERTASTE; FLU LIKE SYNDROME; GARLIC; GASTROINTESTINAL SYMPTOM; HEART INJURY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID LOWERING ACTIVITY; LOW DRUG DOSE; MARKET; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SMELLING AND TASTE; UNSPECIFIED SIDE EFFECT","","","BANEGAS J.R., LOPEZ-GARCIA E., DALLONGEVILLE J., ET AL., ACHIEVEMENT OF TREATMENT GOALS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE ACROSS EUROPE: THE EURIKA STUDY, EUR. HEART J., 32, PP. 2143-2152, (2011); SAHA S., GERDTHAM U.G., JOHANSSON P., ECONOMIC EVALUATION OF LIFESTYLE INTERVENTIONS FOR PREVENTING DIABETES AND CARDIOVASCULAR DISEASES, INT. J. ENVIRON. RES. PUBLIC HEALTH, 7, PP. 3150-3195, (2010); KING D.E., MAINOUS III A.G., MATHESON E.M., ET AL., IMPACT OF HEALTHY LIFESTYLE ON MORTALITY IN PEOPLE WITH NORMAL BLOOD PRESSURE LDL CHOLESTEROL, AND C-REACTIVE PROTEIN, EUR. J. CARDIOVASC. PREV. REHABIL., (2011); CICERO A.F.G., DEROSA G., D'ANGELO A., ET AL., GENDER-SPECIFIC HAEMODYNAMIC AND METABOLIC EFFECTS OF A SEQUENTIAL TRAINING PROGRAMME ON OVERWEIGHT-OBESE HYPERTENSIVES, BLOOD PRESS., 18, PP. 111-116, (2009); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); CATAPANO A.L., REINER Z., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), ATHEROSCLEROSIS, 217, 1, PP. 3-46, (2011); HASANI-RANJBAR S., NAYEBI N., MORADI L., ET AL., THE EFFICACY AND SAFETY OF HERBAL MEDICINES USED IN THE TREATMENT OF HYPERLIPIDEMIA: A SYSTEMATIC REVIEW, CURR. PHARM. RES., 16, PP. 2935-2947, (2010); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J. CLIN. HYPERTENS., 14, 2, PP. 121-132, (2012); GUNNESS P., GIDLEY M.J., MECHANISMS UNDERLYING THE CHOLESTEROL-LOWERING PROPERTIES OF SOLUBLE DIETARY FIBRE POLYSACCHARIDES, FOOD FUNCT., 1, 2, PP. 149-155, (2010); WEI Z.H., WANG H., CHEN X.Y., ET AL., TIME- AND DOSE-DEPENDENT EFFECT OF PSYLLIUM ON SERUM LIPIDS IN MILD-TO-MODERATE HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, EUR. J. CLIN. NUTR., 63, PP. 821-827, (2009); FINKS S.W., AIREE A., CHOW S.L., ET AL., KEY ARTICLES OF DIETARY INTERVENTIONS THAT INFLUENCE CARDIOVASCULAR MORTALITY, PHARMACOTHERAPY, 32, 4, (2012); CICERO A.F.G., DEROSA G., MANCA M., BOVE M., BORGHI C., GADDI A.V., DIFFERENT EFFECT OF PSYLLIUM AND GUAR DIETARY SUPPLEMENTATION ON BLOOD PRESSURE CONTROL IN HYPERTENSIVE OVERWEIGHT PATIENTS: A SIX-MONTH, RANDOMIZED CLINICAL TRIAL, CLINICAL AND EXPERIMENTAL HYPERTENSION, 29, 6, PP. 383-394, (2007); PAL S., KHOSSOUSI A., BINNS C., ET AL., THE EFFECTS OF 12-WEEK PSYLLIUMFIBRE SUPPLEMENTATION OR HEALTHY DIET ON BLOOD PRESSURE AND ARTERIAL STIFFNESS IN OVERWEIGHT AND OBESE INDIVIDUALS, BR. J. NUTR., 107, PP. 725-734, (2012); LATTIMER J.M., HAUB M.D., EFFECTS OF DIETARY FIBER AND ITS COMPONENTS ON METABOLIC HEALTH, NUTRIENTS, 2, 12, PP. 1266-1289, (2010); MELLO V.D., LAAKSONEN D.E., DIETARY FIBERS: CURRENT TRENDS AND HEALTH BENEFITS IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES, ARQ. BRAS ENDOCRINOL. METABOL., 53, PP. 509-518, (2009); MA Y., HEBERT J.R., LI W., ET AL., ASSOCIATION BETWEEN DIETARY FIBER AND MARKERS OF SYSTEMIC INFLAMMATION IN THE WOMEN'S HEALTH INITIATIVE OBSERVATIONAL STUDY, NUTRITION, 24, 10, PP. 941-949, (2008); CICERO A.F., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN. DRUG SAF., 11, 5, PP. 753-766, (2012); MECHANICK J.I., BRETT E.M., CHAUSMER A.B., ET AL., AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR THE CLINICAL USE OF DIETARY SUPPLEMENTS AND NUTRACEUTICALS, ENDOCR. PRACT., 9, PP. 417-470, (2003); MACKAY D.S., JONES P.J., PLASMA NONCHOLESTEROL STEROLS: CURRENT USES, POTENTIAL AND NEED FOR STANDARDIZATION, CURR. OPIN. LIPIDOL., 23, 3, PP. 241-247, (2012); MENSINK R.P., DE JONG A., LUTJOHANN D., ET AL., PLANT STENOLS DOSE DEPENDENTLY DECREASE LDL CHOLESTEROL CONCENTRATIONS BUT NOT CHOLESTEROL STANDARDIZED FAT SOLUBLE ANTIOXIDANT CONCENTRATIONS, AT INTAKES UP TO 9G/D, AM. J. CLIN. NUTR., 92, PP. 24-33, (2010); MORUISI K.G., OOSTHUIZEN W., OPPERMAN A.M., PHYTOSTEROLS/STANOLS LOWER CHOLESTEROL CONCENTRATIONS IN FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS: A SYSTEMATIC REVIEW WITH META-ANALYSIS, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 25, 1, PP. 41-48, (2006); PLANT STANOL ESTER CONSUMPTION AND ARTERIAL ELASTICITY AND ENDOTHELIAL FUNCTION, BR. J. NUTR., 100, PP. 603-608, (2008); GENSER B., SILBERNAGEL G., DE BACKER G., ET AL., PLANT STEROLS AND CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS, EUR. HEART J., 33, PP. 444-451, (2012); CHEN Q., GRUBER H., SWIST E., ET AL., DIETARY PHYTOSTEROLS AND PHYTOSTANOLS DECREASE CHOLESTEROL LEVELS BUT INCREASE BLOOD PRESSURE IN WKY INBRED RATS IN THE ABSENCE OF SALTLOADING, NUTR. METAB., 7, 11, (2010); LOTTENBERG A.M., BOMBO R.P., ILHA A., ET AL., DO CLINICAL AND EXPERIMENTAL INVESTIGATIONS SUPPORT AN ANTIATHEROGENIC ROLE FOR DIETARY PHYTOSTEROLS/STANOLS?, IUBMB LIFE, 64, 4, PP. 296-306, (2012); OTHMAN R.A., MOGHADASIAN M.H., BEYOND CHOLESTEROL-LOWERING EFFECTS OF PLANT STEROLS: CLINICAL AND EXPERIMENTAL EVIDENCE OF ANTI-INFLAMMATORY PROPERTIES, NUTR. REV., 69, PP. 371-382, (2011); DERDEMEZIS C.S., FILIPPATOS T.D., MIKHAILIDIS D.P., ET AL., REVIEW ARTICLE: EFFECTS OF PLANT STEROLS AND STANOLS BEYOND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING, J. CARDIOVASC. PHARMACOL. THER., 15, PP. 120-134, (2010); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., PRIMARY HYPERLIPIDEMIAS IN CHILDREN: EFFECT OF PLANT STEROL SUPPLEMENTATION ON PLASMA LIPIDS AND MARKERS OF CHOLESTEROL SYNTHESIS AND ABSORPTION, ACTA DIABETOL., 48, PP. 127-133, (2011); MOGHADASIAN M.H., DIETARY PHYTOSTEROLS REDUCE CYCLOSPORINE-INDUCED HYPERCHOLESTEROLEMIA IN APOLIPOPROTEIN E-KNOCKOUT MICE, TRANSPLANTATION, 81, PP. 207-213, (2006); PLAT J., MENSINK R.P., PLANT STANOL AND STEROL ESTERS IN THE CONTROL OF BLOOD CHOLESTEROL LEVELS: MECHANISM AND SAFETY ASPECTS, AMERICAN JOURNAL OF CARDIOLOGY, 96, 1 SUPPL., (2005); GYLLING H., HALLIKAINEN M., NISSINEN M.J., ET AL., THE EFFECT OF A VERY HIGH DAILY PLANT STANOL ESTER INTAKE ON SERUM LIPIDS, CAROTENOIDS, AND FAT SOLUBLE VITAMINS, CLIN. NUTR., 29, PP. 112-118, (2010); REINHART K.M., TALATI R., WHITE C.M., ET AL., THE IMPACT OF GARLIC ON LIPID PARAMETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR. RES. REV., 22, PP. 39-48, (2009); RAHMAN K., LOWE G.M., GARLIC AND CARDIOVASCULAR DISEASE: A CRITICAL REVIEW, JOURNAL OF NUTRITION, 136, 3, (2006); RIED K., FRANK O.R., STOCKS N.P., AGED GARLIC EXTRACT LOWERS BLOOD PRESSURE IN PATIENTS WITH TREATED BUT UNCONTROLLED HYPERTENSION: A RANDOMIZED CONTROLLED TRIAL, MATURITAS, 67, PP. 144-150, (2010); SIMONS S., WOLLERSHEIM H., THIEN T., A SYSTEMATIC REVIEW ON THE INFLUENCE OF TRIAL QUALITY ON THE EFFECT OF GARLIC ON BLOOD PRESSURE, NETH. J. MED., 67, PP. 212-219, (2009); WILLIAMS M.J.A., SUTHERLAND W.H.F., MCCORMICK M.P., YEOMAN D.J., DE JONG S.A., AGED GARLIC EXTRACT IMPROVES ENDOTHELIAL FUNCTION IN MEN WITH CORONARY ARTERY DISEASE, PHYTOTHERAPY RESEARCH, 19, 4, PP. 314-319, (2005); BUDOFF M.J., AHMADI N., GUL K.M., ET AL., AGED GARLIC EXTRACT SUPPLEMENTED WITH B VITAMINS, FOLIC ACID AND L-ARGININE RETARDS THE PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS: A RANDOMISED CLINICAL TRIAL, PREV. MED., 49, PP. 101-107, (2009); VAN DOORN M.B.A., ESPIRITO SANTO S.M., MEIJER P., KAMERLING I.M., SCHOEMAKER R.C., DIRSCH V., VOLLMAR A., HAFFNER T., GEBHARDT R., COHEN A.F., PRINCEN H.M., BURGGRAAF J., EFFECT OF GARLIC POWDER ON C-REACTIVE PROTEIN AND PLASMA LIPIDS IN OVERWEIGHT AND SMOKING SUBJECTS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1324-1329, (2006); MACAN H., UYKIMPANG R., ALCONCEL M., TAKASU J., RAZON R., AMAGASE H., NIIHARA Y., AGED GARLIC EXTRACT MAY BE SAFE FOR PATIENTS ON WARFARIN THERAPY, JOURNAL OF NUTRITION, 136, 3, (2006); BERGINC K., MILISAV I., KRISTL A., GARLIC FLAVONOIDS AND ORGANOSULFUR COMPOUNDS: IMPACT ON THE HEPATIC PHARMACOKINETICS OF SAQUINAVIR AND DARUNAVIR, DRUG METAB. PHARMACOKINET., 25, PP. 521-530, (2010); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J. NUTR., 125, (1995); TORRES N., TORRE-VILLALVAZO I., TOVAR A.R., REGULATION OF LIPID METABOLISM BY SOY PROTEIN AND ITS IMPLICATION IN DISEASES MEDIATED BY LIPID DISORDERS, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 17, 6, PP. 365-373, (2006); MULLEN E., BROWN R.M., OSBORNE T.F., SHAY N.F., SOY ISOFLAVONES AFFECT STEROL REGULATORY ELEMENT BINDING PROTEINS (SREBPS) AND SREBP-REGULATED GENES IN HEPG2 CELLS, JOURNAL OF NUTRITION, 134, 11, PP. 2942-2947, (2004); ANDERSON J.W., BUSH H.M., SOY PROTEIN EFFECTS ON SERUM LIPOPROTEINS: A QUALITY ASSESSMENT AND META-ANALYSIS OF RANDOMIZED, CONTROLLED STUDIES, J. AM. COLL. NUTR., 30, PP. 79-91, (2011); PASE M.P., GRIMA N.A., SARRIS J., THE EFFECTS OF DIETARY AND NUTRIENT INTERVENTIONS ON ARTERIAL STIFFNESS: A SYSTEMATIC REVIEW, AM. J. CLIN. NUTR., 93, PP. 446-454, (2011); ADLERCREUTZ H., EPIDEMIOLOGY OF PHYTOESTROGENS, BAILLIERE'S CLINICAL ENDOCRINOLOGY AND METABOLISM, 12, 4, PP. 605-623, (1998); ORGAARD A., JENSEN L., THE EFFECTS OF SOY ISOFLAVONES ON OBESITY, EXP. BIOL. MED., 233, PP. 1066-1080, (2008); WEGHUBER D., WIDHALM K., EFFECT OF 3 MONTH TREATMENT OF CHILDREN AND ADOLESCENTS WITH FAMILIAL AND POLYGENIC HYPERCHOLESTEROLEMIA WITH A SOY-SUBSTITUTED DIET, BR. J. NUTR., 99, PP. 281-286, (2008); CHEN S.T., FERNG S.H., YANG C.S., ET AL., VARIABLE EFFECTS OF SOY PROTEIN ON PLASMA LIPIDS IN HYPERLIPIDEMIC AND NORMOLIPIDEMIC HEMODIALYSIS PATIENTS, AM. J. KIDNEY DIS, 46, PP. 1099-1106, (2005); HUTCHINS A.M., MCIVER I.E., JOHNSTON C.S., HYPERTENSIVE CRISIS ASSOCIATED WITH HIGH DOSE SOY ISOFLOVANE SUPPLEMENTATION IN A POST-MENOPAUSAL WOMAN; A CASE REPORT, BMC WOMEN'S HEALTH, 5, (2005); CAMBRIA-KIELY J.A., EFFECT OF SOY MILK ON WARFARIN, ANN. PHARMACOTHER., 36, PP. 1893-1896, (2002); ANDERSON G.D., ROSITO G., MOHUSTSY M.A., ELMER G.W., DRUG INTERACTION POTENTIAL OF SOY EXTRACT AND PANAX GINSENG, JOURNAL OF CLINICAL PHARMACOLOGY, 43, 6, PP. 643-648, (2003); MONASCUS PURPUREUS (RED YEAST RICE), ALTERN. MED. REV., 9, PP. 208-210, (2004); CICERO A.F.G., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 13, 4, PP. 273-278, (2005); KEITHLEY J.K., SWANSON B., SHA B.E., ZELLER J.M., KESSLER H.A., SMITH K.Y., A PILOT STUDY OF THE SAFETY AND EFFICACY OF CHOLESTIN IN TREATING HIV-RELATED DYSLIPIDEMIA, NUTRITION, 18, 2, PP. 201-204, (2002); GHEIT O., SHEASHAA H., ABDELSALAM M., ET AL., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH SECONDARY HYPERLIPIDEMIA, EUR. J. INTERN. MED., 20, (2009); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN. MEDICINE, 1, (2006); ZHAO S.P., LIU L., CHENG Y.C., SHISHEHBOR M.H., LIU M.H., PENG D.Q., LI Y.L., XUEZHIKANG, AN EXTRACT OF CHOLESTIN, PROTECTS ENDOTHELIAL FUNCTION THROUGH ANTIINFLAMMATORY AND LIPID-LOWERING MECHANISMS IN PATIENTS WITH CORONARY HEART DISEASE, CIRCULATION, 110, 8, PP. 915-920, (2004); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM. J. CARDIOL., 101, PP. 1689-1693, (2008); YE P., LU Z.-L., DU B.-M., CHEN Z., WU Y.-F., YU X.-H., ZHAO Y.-C., EFFECT OF XUEZHIKANG ON CARDIOVASCULAR EVENTS AND MORTALITY IN ELDERLY PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION: A SUBGROUP ANALYSIS OF ELDERLY SUBJECTS FROM THE CHINA CORONARY SECONDARY PREVENTION STUDY, JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 55, 7, PP. 1015-1022, (2007); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AND AGING, 20, 2, PP. 153-163, (2003); NOA M., MAS R., LARIOT C., PROTECTIVE EFFECT OF POLICOSANOL ON ENDOTHELIUM AND INTIMAL THICKNESS INDUCED BY FORCEPS IN RABBITS, JOURNAL OF MEDICINAL FOOD, 10, 3, PP. 452-459, (2007); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, 4, PP. 361-371, (2004); SIRTORI C.R., GALLI C., ANDERSON J.W., SIRTORI E., ARNOLDI A., FUNCTIONAL FOODS FOR DYSLIPIDAEMIA AND CARDIOVASCULAR RISK PREVENTION, NUTR RES. REV., 22, 2, PP. 244-261, (2009); MARINANGELI C.P., JONES P.J., KASSIS A.N., ET AL., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR., 50, PP. 259-267, (2010); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS, 21, PP. 424-429, (2011); ABDUL M.I., JIANG X., WILLIAMS K.M., ET AL., PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS OF ECHINACEA AND POLICOSANOL WITH WARFARIN IN HEALTHY SUBJECTS, BR. J. CLIN. PHARMACOL., 69, PP. 508-515, (2010); IMANSHAHIDI M., HOSSEINZADEH H., PHARMACOLOGICAL AND THERAPEUTIC EFFECTS OF BERBERIS VULGARIS AND ITS ACTIVE CONSTITUENT, BERBERINE, PHYTOTHER. RES., 22, 8, PP. 999-1012, (2008); CICERO A.F., TARTAGNI E., ANTIDIABETIC PROPERTIES OF BERBERINE: FROM CELLULAR PHARMACOLOGY TO CLINICAL EFFECTS, HOSP. PRACT., 40, PP. 56-63, (2012); MENG S., WANG L.S., HUANG Z.Q., ET AL., BERBERINE AMELIORATES INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION, CLIN. EXP. PHARMACOL. PHYSIOL., 39, PP. 406-411, (2012); CHENG F., WANG Y., LI J., ET AL., BERBERINE IMPROVES ENDOTHELIAL FUNCTION BY REDUCING ENDOTHELIAL MICROPARTICLES-MEDIATED OXIDATIVE STRESS IN HUMANS, INT. J. CARDIOL., (2012); XU M.-G., WANG J.-M., CHEN L., WANG Y., YANG Z., TAO J., BERBERINE-INDUCED MOBILIZATION OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IMPROVES HUMAN SMALL ARTERY ELASTICITY, JOURNAL OF HUMAN HYPERTENSION, 22, 6, PP. 389-393, (2008); CICERO A.F., TARTAGNI E., FERRONI A., ET AL., COMBINED NUTRACEUTICAL APPROACH TO POSTMENOPAUSAL SYNDROME AND VASCULAR REMODELING BIOMARKERS, J. ALT. COMPL. MED., (2012); CHAN E., DISPLACEMENT OF BILIRUBIN FROM ALBUMIN BY BERBERINE, BIOLOGY OF THE NEONATE, 63, 4, PP. 201-208, (1993); TAN Y.Z., WU A.C., TAN B.Y., ET AL., STUDY ON THE INTERACTIONS OF BERBERINE DISPLACE OTHER DRUG FROM THEIR PLASMA PROTEINS BINDING SITES, CHIN. PHARMACOL. BULL., 18, PP. 576-578, (2002); XIN H.W., WU X.C., LI Q., ET AL., THE EFFECTS OF BERBERINE ON THE PHARMACOKINETICS OF CYCLOSPORINE A IN HEALTHY VOLUNTEERS, METHODS FIND. EXP. CLIN. PHARMACOL., 28, PP. 25-29, (2006); MOZAFFARIAN D., WU J.H., OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE: EFFECTS ON RISK FACTORS, MOLECULAR PATHWAYS, AND CLINICAL EVENTS, J. AM. COLL. CARDIOL., 58, 20, PP. 2047-2067, (2011); CAMPBELL F., DICKINSON H.O., CRITCHLEY J.A., ET AL., A SYSTEMATIC REVIEW OF FISH-OIL SUPPLEMENTS FOR THE PREVENTION AND TREATMENT OF HYPERTENSION, EUR. J. PREV. CARDIOL., (2012); PASE M.P., GRIMA N.A., SARRIS J., DO LONG-CHAIN N-3 FATTY ACIDS REDUCE ARTERIAL STIFFNESS? A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BR. J. NUTR., 106, PP. 974-980, (2011); THIES F., GARRY J.M.C., YAQOOB P., RERKASEM K., WILLIAMS J., SHEARMAN C.P., GALLAGHER P.J., CALDER P.C., GRIMBLE R.F., ASSOCIATION OF N-3 POLYUNSATURATED FATTY ACIDS WITH STABILITY OF ATHEROSCLEROTIC PLAQUES: A RANDOMISED CONTROLLED TRIAL, LANCET, 361, 9356, PP. 477-485, (2003); CICERO A.F., ERTEK S., BORGHI C., OMEGA-3 POLYUNSATURATED FATTY ACIDS: THEIR POTENTIAL ROLE IN BLOOD PRESSURE PREVENTION AND MANAGEMENT, CURR. VASC. PHARMACOL., 7, PP. 330-337, (2009); VALAGUSSA F., FRANZOSI M.G., GERACI E., ET AL., DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); DELGADO-LISTA J., PEREZ-MARTINEZ P., LOPEZ-MIRANDA J., PEREZ-JIMENEZ F., LONG CHAIN OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW, BR. J. NUTR., 107, SUPPL. 2, (2012); CICERO A.F., DE SANDO V., PARINI A., ET AL., POLYUNSATURATED FATTY ACIDS APPLICATION IN INTERNAL MEDICINE: BEYOND THE ESTABLISHED CARDIOVASCULAR EFFECTS, ARCH. MED. SCI., (2012); HOOPER L., THOMPSON R.L., HARRISON R.A., ET AL., RISKS AND BENEFITS OF OMEGA 3 FATS FOR MORTALITY, CARDIOVASCULAR DISEASE, AND CANCER: SYSTEMATIC REVIEW, BRIT. MED. J., 332, PP. 752-760, (2006); HARRIS W.S., EXPERT OPINION: OMEGA-3 FATTY ACIDS AND BLEEDING-CAUSE FOR CONCERN?, AM. J CARDIOL., 99, (2007); BHUPATHIRAJU S.N., TUCKER K.L., CORONARY HEART DISEASE PREVENTION: NUTRIENTS, FOODS, AND DIETARY PATTERNS, CLIN. CHIM. ACTA, 412, 17-18, PP. 1493-1514, (2011); RAMPRASATH V.R., JONES P.J., ANTI-ATHEROGENIC EFFECTS OF RESVERATROL, EUR. J. CLIN. NUTR., 64, 7, PP. 660-668, (2010); TOME-CARNEIRO J., GONZALVEZ M., LARROSA M., ET AL., CONSUMPTION OF A GRAPE EXTRACT SUPPLEMENT CONTAINING RESVERATROL DECREASES OXIDIZED LDL AND APOB IN PATIENTS UNDERGOING PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A TRIPLE-BLIND, 6-MONTH FOLLOW-UP, PLACEBO-CONTROLLED, RANDOMIZED TRIAL, MOL. NUTR. FOOD RES., 56, 5, PP. 810-821, (2011); MOLLACE V., SACCO I., JANDA E., ET AL., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, 3, PP. 309-316, (2011); CESAR T.B., APTEKMANN N.P., ARAUJO M.P., VINAGRE C.C., MARANHAO R.C., ORANGE JUICE DECREASES LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC SUBJECTS AND IMPROVES LIPID TRANSFER TO HIGH-DENSITY LIPOPROTEIN IN NORMAL AND HYPERCHOLESTEROLEMIC SUBJECTS, NUTR. RES., 30, 10, PP. 689-694, (2010); GORINSTEIN S., CASPI A., LIBMAN I., KATRICH E., LERNER H.T., TRAKHTENBERG S., FRESH ISRAELI JAFFA SWEETIE JUICE CONSUMPTION IMPROVES LIPID METABOLISM AND INCREASES ANTIOXIDANT CAPACITY IN HYPERCHOLESTEROLEMIC PATIENTS SUFFERING FROM CORONARY ARTERY DISEASE: STUDIES IN VITRO AND IN HUMANS AND POSITIVE CHANGES IN ALBUMIN AND FIBRINOGEN FRACTIONS, J. AGRIC. FOOD CHEM., 52, 16, PP. 5215-5222, (2004); DEMONTY I., LIN Y., ZEBREGS Y.E., ET AL., THE CITRUS FLAVONOIDS HESPERIDIN AND NARINGIN DO NOT AFFECT SERUM CHOLESTEROL IN MODERATELY HYPERCHOLESTEROLEMIC MEN AND WOMEN, J. NUTR., 140, 9, PP. 1615-1620, (2010); AVIRAM M., ROSENBLAT M., GAITINI D., NITECKI S., HOFFMAN A., DORNFELD L., VOLKOVA N., PRESSER D., ATTIAS J., LIKER H., HAYEK T., POMEGRANATE JUICE CONSUMPTION FOR 3 YEARS BY PATIENTS WITH CAROTID ARTERY STENOSIS REDUCES COMMON CAROTID INTIMA-MEDIA THICKNESS, BLOOD PRESSURE AND LDL OXIDATION, CLINICAL NUTRITION, 23, 3, PP. 423-433, (2004); DAVIDSON M.H., MAKI K.C., DICKLIN M.R., ET AL., EFFECTS OF CONSUMPTION OF POMEGRANATE JUICE ON CAROTID INTIMA-MEDIA THICKNESS IN MEN AND WOMEN AT MODERATE RISK FOR CORONARY HEART DISEASE, AM. J. CARDIOL., 104, 7, PP. 936-942, (2009); PRASAD K., TOCOTRIENOLS AND CARDIOVASCULAR HEALTH, CURR. PHARM. DES., 17, 21, PP. 2147-2154, (2011); BALIARSINGH S., BEG Z.H., AHMAD J., THE THERAPEUTIC IMPACTS OF TOCOTRIENOLS IN TYPE 2 DIABETIC PATIENTS WITH HYPERLIPIDEMIA, ATHEROSCLEROSIS, 182, 2, PP. 367-374, (2005); CHIN S.F., IBAHIM J., MAKPOL S., ET AL., TOCOTRIENOL RICH FRACTION SUPPLEMENTATION IMPROVED LIPID PROFILE AND OXIDATIVE STATUS IN HEALTHY OLDER ADULTS: A RANDOMIZED CONTROLLED STUDY, NUTR. METAB., 8, 1, (2011); RIED K., FAKLER P., PROTECTIVE EFFECT OF LYCOPENE ON SERUM CHOLESTEROL AND BLOOD PRESSURE: META-ANALYSES OF INTERVENTION TRIALS, MATURITAS, 68, 4, PP. 299-310, (2011); MCENENY J., WADE L., YOUNG I.S., ET AL., LYCOPENE INTERVENTION REDUCES INFLAMMATION AND IMPROVES HDL FUNCTIONALITY IN MODERATELY OVERWEIGHT MIDDLE-AGED INDIVIDUALS, J. NUTR. BIOCHEM., (2012); XAPLANTERIS P., VLACHOPOULOS C., PIETRI P., ET AL., TOMATO PASTE SUPPLEMENTATION IMPROVES ENDOTHELIAL DYNAMICS AND REDUCES PLASMA TOTAL OXIDATIVE STATUS IN HEALTHY SUBJECTS, NUTR. RES., 32, 5, PP. 390-394, (2012); SLEVIN M., AHMED N., WANG Q., MCDOWELL G., BADIMON L., UNIQUE VASCULAR PROTECTIVE PROPERTIES OF NATURAL PRODUCTS: SUPPLEMENTS OR FUTURE MAIN-LINE DRUGS WITH SIGNIFICANT ANTI-ATHEROSCLEROTIC POTENTIAL? VASC, CELL, 4, 1, (2012); HOUSTON M.C., FAZIO S., CHILTON F.H., ET AL., NONPHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA, PROG. CARDIOVASC. DIS., 52, PP. 61-94, (2009); ROS E., HEALTH BENEFITS OF NUT CONSUMPTION, NUTRIENTS, 2, 7, PP. 652-682, (2010); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED. J. NUTR. METAB., 4, PP. 133-140, (2011); CICERO A.F.G., DE SANDO V., IZZO R., ET AL., EFFECT OF A COMBINED NUTRACEUTICAL CONTAINING ORTHOSIPHON STAMINEUS EFFECT ON BLOOD PRESSURE AND METABOLIC SYNDROME COMPONENTS IN HYPERTENSIVE DYSLIPIDAEMIC PATIENTS: A RANDOMIZED CLINICAL TRIAL, COMPLEMENT. THER. CLIN. PRACT., 18, 3, PP. 190-194, (2012); AFFUSO F., MERCURIO V., RUVOLO A., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J. CARDIOL., 4, PP. 77-83, (2012); PIRRO M., DEL GIORNO R., LUPATTELLI G., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNES IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, NUTR. RES., (2012); YOKOYAMA M., ORIGASA H., MATSUZAKI M., MATSUZAWA Y., SAITO Y., ISHIKAWA Y., OIKAWA S., SASAKI J., HISHIDA H., ITAKURA H., KITA T., KITABATAKE A., NAKAYA N., SAKATA T., SHIMADA K., SHIRATO K., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, 9567, PP. 1090-1098, (2007); LIN X., RACETTE S.B., LEFEVRE M., ET AL., COMBINED EFFECTS OF EZETIMIBE AND PHYTOSTEROLS ON CHOLESTEROL METABOLISM: A RANDOMIZED, CONTROLLED FEEDING STUDY IN HUMANS, CIRCULATION, 124, 5, PP. 596-601, (2011); EUSSEN S.R., ROMPELBERG C.J., KLUNGEL O.H., VAN EIJKEREN J.C., MODELLING APPROACH TO SIMULATE REDUCTIONS IN LDL CHOLESTEROL LEVELS AFTER COMBINED INTAKE OF STATINS AND PHYTOSTEROLS/-STANOLS IN HUMANS, LIPIDS HEALTH DIS., 10, 187, (2011)","A.F.G. CICERO; MEDICAL AND SURGICAL SCIENCES DEPARTMENT, S ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY; EMAIL: ARRIGO.CICERO@UNIBO.IT","","ENGLISH","CLINICAL LIPIDOLOGY","REVIEW","ISI","2-S2.0-84869465455","CLINICAL LIPIDOLOGY","MEDICAL AND SURGICAL SCIENCES DEPARTMENT;MEDICAL AND SURGICAL SCIENCES DEPARTMENT;MEDICAL AND SURGICAL SCIENCES DEPARTMENT","NOTREPORTED;MEDICAL AND SURGICAL SCIENCES DEPARTMENT;NOTREPORTED",NA,"CICERO AFG, 2012, CLINICAL LIPIDOLOGY","CICERO AFG, 2012, CLINICAL LIPIDOLOGY"
"MOLINA V;RAVELO Y;NOA M;MAS R;PÉREZ Y;OYARZÁBAL A;MENDOZA N;VALLE M;JIMÉNEZ S;SÁNCHEZ J","MOLINA, V. (7006062814); RAVELO, Y. (26030104500); NOA, M. (7003318964); MAS, R. (7007164570); PÉREZ, Y. (23995375700); OYARZÁBAL, A. (24399409700); MENDOZA, N. (7006243358); VALLE, M. (22936513700); JIMÉNEZ, S. (19735040200); SÁNCHEZ, J. (57210524556)","THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIAREPERFUSION INJURY IN GERBILS",2013,"INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES","75","6",14,"","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA","STROKE IS THE THIRD CAUSE OF DEATH AND THE FIRST OF PERMANENT ADULT DISABILITY. PRETREATMENT WITH POLICOSANOL AND ATORVASTATIN HAS BEEN EFFECTIVE IN EXPERIMENTAL MODELS OF CEREBRAL ISCHAEMIA IN RODENTS. THE OBJECTIVE WAS TO COMPARE THE THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN IN A MODEL OF GLOBAL CEREBRAL ISCHAEMIA IN GERBILS. GERBILS WERE DISTRIBUTED INTO SEVEN GROUPS, A NEGATIVE CONTROL AND SIX WITH ISCHAEMIA-REPERFUSION-INDUCED GLOBAL CEREBRAL ISCHEMIA (ONE VEHICLE POSITIVE CONTROL, TWO POLICOSANOL (100 AND 200 MG/KG), TWO ATORVASTATIN (10 AND 20 MG/KG) AND ONE ASPIRIN (60 MG/KG) GROUP). TREATMENTS WERE GIVEN 4 H AFTER ISCHAEMIA INDUCTION. EFFECTS ON ISCHEMIA-REPERFUSION-INDUCED SYMPTOMS, HYPERLOCOMOTION, DAMAGE OF PYRAMIDAL HIPOCCAMPAL NEURONS AND INCREASED PLASMA OXIDATIVE MARKERS WERE INVESTIGATED. POSITIVE, NOT NEGATIVE CONTROLS, EXHIBITED CLINICAL SYMPTOMS, HYPERLOCOMOTION, NEURONAL DAMAGE AND INCREASED PLASMA OXIDATIVE MARKERS. POLICOSANOL (100 AND 200 MG/KG) REDUCED SIGNIFICANTLY ISCHEMIA-REPERFUSION-INDUCED SYMPTOMS, THE FREQUENCY OF SYMPTOMATIC ANIMALS, HISTOLOGICAL SCORES OF NEURONAL DAMAGE AND PLASMA OXIDATIVE MARKERS AS COMPARED WITH THE POSITIVE CONTROL GROUP. ATORVASTATIN (10 AND 20 MG/KG) DECREASED SIGNIFICANTLY THE SYMPTOMS AND HISTOLOGICAL SCORES, BUT UNCHANGED THE FREQUENCY OF SYMPTOMATIC GERBILS AND OXIDATIVE VARIABLES. ONLY THE HIGHEST DOSE OF POLICOSANOL (200 MG/KG) AND ATORVASTATIN (20 MG/KG) REDUCED SIGNIFICANTLY ISCHEMIA REPERFUSION-INDUCED HYPERLOCOMOTION, POLICOSANOL BEING THE MOST EFFECTIVE. ASPIRIN 60 MG/KG LOWERED SIGNIFICANTLY SYMPTOM SCORE, THE RATE OF SYMPTOMATIC GERBILS AND HYPERLOCOMOTION VERSUS THE POSITIVE CONTROLS, BUT FAILED TO MODIFY OXIDATIVE PARAMETERS. IN CONCLUSION, POSTREPERFUSION TREATMENT WITH POLICOSANOL AND ATORVASTATIN WAS EFFECTIVE FOR AMELIORATING SYMPTOMS, HYPERLOCOMOTION AND NEUROLOGICAL DAMAGE OF HIPPOCAMPAL CA1 NEURONS IN GERBILS WITH ISCHEMIA-REPERFUSION-INDUCED GLOBAL CEREBRAL ISCHEMIA, BUT ONLY POLICOSANOL REDUCED INCREASED PLASMA OXIDATIVE VARIABLES.","ATORVASTATIN; CEREBRAL ISCHAEMIA; GERBILS; POLICOSANOL; STATINS","ACETYLSALICYLIC ACID; ATORVASTATIN; POLICOSANOL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL LOSS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EXPERIMENTAL HYPERACTIVITY; HIPPOCAMPAL CA1 REGION; HISTOLOGY; LIPID PEROXIDATION; LOCOMOTION; MALE; MERIONES UNGUICULATUS; NERVE CELL LESION; NEUROPROTECTION; NISSL SUBSTANCE; NONHUMAN; OXIDATIVE STRESS; PYRAMIDAL NERVE CELL; REPERFUSION INJURY; SINGLE DRUG DOSE; SYMPTOM; THERAPY EFFECT","","","BAKER W.L., MARRS J.C., DAVIS L.E., NUTESCU E.A., ROWE A.S., RYAN M., ET AL., KEY ARTICLES AND GUIDELINES IN THE PRIMARY PREVENTION OF ISCHEMIC STROKE, PHARMACOTHERAPY, 33, (2013); BAKER W.L., MARRS J.C., DAVIS L.E., NUTESCU E.A., ROWE A.S., RYAN M., ET AL., KEY ARTICLES AND GUIDELINES IN THE ACUTE MANAGEMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE, PHARMACOTHERAPY, 33, (2013); RIVERA-NAVA S.C., MIRANDA-MEDRANO L.I., PEREZ-ROJAS J.E., DE JESUS FLORES J., RIVERA-GARCIA B.E., DEL PILAR TORRES-ARREOLA L., CLINICAL GUIDELINE FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ISCHEMIC CEREBRAL DISEASE, REV MED INST MEX SEGURO SOC, 50, PP. 335-346, (2012); MONTANER J., MENDIOROZ M., DELGADO P., GARCIA-BERROCOSO T., GIRALT D., MERINO C., ET AL., DIFFERENTIATING ISCHEMIC FROM HEMORRHAGIC STROKE USING PLASMA BIOMARKERS: THE S100B/RAGE PATHWAY, J PROTEOMICS, 75, PP. 4758-4765, (2012); LUCKE-WOLD B.P., TURNER R.C., LUCKE-WOLD A.N., ROSEN C.L., HUBER J.D., AGE AND THE METABOLIC SYNDROME AS RISK FACTORS FOR ISCHEMIC STROKE: IMPROVING PRECLINICAL MODELS OF ISCHEMIC STROKE, YALE J BIOL MED, 85, PP. 523-539, (2012); AMARENCO P., BOGOUSSLAVSKY J., CAPLAN L.R., DONNAN G.A., HENNERICI M.G., CLASSIFICATION OF STROKE SUBTYPES, CEREBROVASC DIS, 27, PP. 493-501, (2009); MADDEN J.A., ROLE OF THE VASCULAR ENDOTHELIUM AND PLAQUE IN ACUTE ISCHEMIC STROKE, NEUROLOGY, 79, SUPPL. 13, (2012); CANAL CASTRO C., PAGNUSSAT A.S., ORLANDI L., WORM P., MOURA N., ETGEN A.M., ET AL., COUMESTROL HAS NEUROPROTECTIVE EFFECTS BEFORE AND AFTER GLOBAL CEREBRAL ISCHEMIA IN FEMALE RATS, BRAIN RES, 1474, PP. 82-90, (2012); ZHU H., YOSHIMOTO T., IMAJO-OHMI S., DAZORTSAVA M., MATHIVANAN A., YAMASHIMA T., WHY ARE HIPPOCAMPAL CA1 NEURONS VULNERABLE BUT MOTOR CORTEX NEURONS RESISTANT TO TRANSIENT ISCHEMIA?, J NEUROCHEM, 120, PP. 574-585, (2012); AMANTEA D., NAPPI G., BERNARDI G., BAGETTA G., CORASANITI M.T., POSTISCHEMIC BRAIN DAMAGE: PATHOPHYSIOLOGY AND ROLE OF INFLAMMATORY MEDIATORS, FEBS J, 276, PP. 13-26, (2009); MANSOORALI K.P., PRAKASH T., KOTRESHA D., PRABHU K., RAMA RAO N., CEREBROPROTECTIVE EFFECT OF ECLIPTA ALBA AGAINST GLOBAL MODEL OF CEREBRAL ISCHEMIA INDUCED OXIDATIVE STRESS IN RATS, PHYTOMEDICINE, 19, PP. 1108-1116, (2012); PRADEEP H., DIYA J.B., SHASHIKUMAR S., RAJANIKANT G.K., OXIDATIVE STRESS-ASSASSIN BEHIND THE ISCHEMIC STROKE, FOLIA NEUROPATHOL, 50, PP. 219-230, (2012); PHILLIS J.W., HORROCKS L.A., FAROOQUI A.A., CYCLOOXYGENASES, LIPOOXYGENASES AND EPOXYGENASES IN CNS: THEIR ROLE AND INVOLVEMENT IN NEUROLOGICAL DISORDERS, BRAIN RES REV, 52, PP. 201-243, (2006); WANG Q., TANG X.N., YENARI M.A., THE INFLAMMATORY RESPONSE IN STROKE, J NEUROIMMUNOL, 184, PP. 53-68, (2007); DUSZCZYK M., ZIEMBOWICZ A., GADAMSKI R., WIERONSKA J.M., SMIALOWSKA M., LAZAREWICZ J.W., CHANGES IN THE IMMUNOREACTIVITY IN GERBIL HIPPOCAMPUS AFTER HYPOXIC AND ISCHEMIC PRECONDITIONING, NEUROPEPTIDES, 43, PP. 31-39, (2009); SOMOVA L.I., GREGORY M.A., NXUMALO E.N., MONGOLIAN GERBIL (MERIONES UNGUICULATUS) AS A MODEL OF CEREBRAL INFARCTION FOR TESTING NEW THERAPEUTIC AGENTS, METHODS FIND EXP CLIN PHARMACOL, 22, PP. 203-210, (2000); FANG K.M., CHENG F.C., HUANG Y.L., CHUNG S.Y., JIAN Z.Y., LIN M.C., TRACE ELEMENT, ANTIOXIDANT ACTIVITY, AND LIPID PEROXIDATION LEVELS IN BRAIN CORTEX OF GERBILS AFTER CEREBRAL ISCHEMIC INJURY, BIOL TRACE ELEM RES, 152, PP. 66-74, (2013); MOLLACE V., IANNONE M., MUSCOLI C., PALMA E., GRANATO T., MODESTI A., ET AL., THE PROTECTIVE EFFECT OF M40401, A SUPEROXIDE DISMUTASE MIMETIC, ON POST-ISCHEMIC BRAIN DAMAGE IN MONGOLIAN GERBILS, BMC PHARMACOL, 3, (2003); DEKANSKI D., SELAKOVI V., PIPERSKI V., RADULOVI Z., KORENI A., RADENOVI L., PROTECTIVE EFFECT OF OLIVE LEAF EXTRACT ON HIPPOCAMPAL INJURY INDUCED BY TRANSIENT GLOBAL CEREBRAL ISCHEMIA AND REPERFUSION IN MONGOLIAN GERBILS, PHYTOMEDICINE, 18, PP. 1137-1143, (2011); GOLDSTEIN L.B., STATINS AND ISCHEMIC STROKE SEVERITY: CYTOPROTECTION, CURR ATHEROSCLER REP, 11, PP. 296-300, (2009); ELEWA H.F., KOZAK A., EL-REMESSY A.B., FRYE R.F., JOHNSON M.H., ERGUL A., ET AL., EARLY ATORVASTATIN REDUCES HEMORRHAGE AFTER ACUTE CEREBRAL ISCHEMIA IN DIABETIC RATS, J PHARMACOL EXP THER, 330, PP. 532-540, (2009); PIGNATELLI P., CARNEVALE R., PASTORI D., CANGEMI R., NAPOLEONE L., BARTIMOCCIA S., ET AL., IMMEDIATE ANTIOXIDANT AND ANTIPLATELET EFFECT OF ATORVASTATIN VIA INHIBITION OF NOX2, CIRCULATION, 126, PP. 92-103, (2012); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); MOLINA V., CARBAJAL D., ARRUZAZABALA M.L., RAVELO Y., MAS R., COMPARATIVE STUDY OF POLICOSANOL AND GRAPE SEED EXTRACT ON PLATELET AGGREGATION IN RATS, REV CIENC BIOL, 42, PP. 3-6, (2011); PEREZ Y., MAS R., GONZALEZ R.M., JIMENEZ S., MOLINA V., EFFECTS OF D-003 AND POLICOSANOL ON IN VIVO LIPID PEROXIDATION IN RATS, ARZNEIMITTELFORSCHUNG, 58, PP. 126-130, (2008); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., VALLE M., PEREZ Y., ET AL., EFFECTS OF POLICOSANOL AND GRAPE SEED EXTRACT AGAINST GLOBAL BRAIN ISCHEMIAREPERFUSION INJURY IN GERBILS, LAT. AM J PHARM, 32, PP. 113-119, (2013); QIU L.Y., DU B., LI Y., FAN H.B., YANG Z.Y., ANTIAPOPTOTIC EFFECTS OF ASPIRIN FOLLOWING CEREBRAL ISCHEMIA-REPERFUSION INJURY IN RATS, NEURAL REGENER RES, 3, PP. 979-984, (2008); MCGRAW C.P., EXPERIMENTAL CEREBRAL INFARCTION EFFECTS OF PENTOBARBITAL IN MONGOLIAN GERBILS, ARCH NEUROL, 34, PP. 334-336, (1977); BARTUS R.T., DEAN R.L., MENNERICK S., EVELETH E., LYBCH G., TEMPORAL ORDERING OF PATHOGENIC EVENTS FOLLOWING TRANSIENT GLOBAL ISCHEMIA, BRAIN RES, 790, PP. 1-13, (1998); MARXWELL M.A., HAAS S.M., BEIBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-209, (1987); OHKAWA H., OHISHI N., YAGI K., ASSAY FOR LIPID PEROXIDES IN ANIMAL TISSUES BY THIOBARBITURIC ACID REACTION, ANAL BIOCHEM, 95, PP. 351-358, (1979); MIAO-LIN H., MEASUREMENT OF PROTEIN THIOLE GROUPS AND GLUTATIONE IN PLASMA, METHODS ENZYMOL, 233, PP. 380-382, (1994); RAMOS-ZUNIGA R., GOMEZ P.U., NAVARRO A., DE LUQUIN A.S., GARCIA-ESTRADA J., LOCOMOTOR ACTIVITY IS A PREDICTIVE TEST AFTER GLOBAL ISCHEMIA-REPERFUSION IN MONGOLIAN GERBILS, MINIM INVASIVE NEUROSURG, 51, PP. 87-90, (2008); KATSUMATA N., KUROIWA T., ISHIBASHI S., LI S., ENDO S., OHNO K., HETEROGENEOUS HYPERACTIVITY AND DISTRIBUTION OF ISCHEMIC LESIONS AFTER FOCAL CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, NEUROPATHOLOGY, 26, PP. 283-292, (2006); WANG D., CORBETT D., CEREBRAL ISCHEMIA, LOCOMOTOR ACTIVITY AND SPATIAL MAPPING, BRAIN RES, 533, PP. 78-82, (1990); KATSUTA K., UMEMURA K., UEYAMA N., MATSUOKA N., PHARMACOLOGICAL EVIDENCE FOR A CORRELATION BETWEEN HIPPOCAMPAL CA1 CELL DAMAGE AND HYPERLOCOMOTION FOLLOWING GLOBAL CEREBRAL ISCHEMIA IN GERBILS, EUR J PHARMACOL, 467, PP. 103-109, (2003); JANAC B., RADENOVIC L., SELAKOVIC V., PROLIC Z., TIME COURSE OF MOTOR BEHAVIOR CHANGES IN MONGOLIAN GERBILS SUBMITTED TO DIFFERENT DURATIONS OF CEREBRAL ISCHEMIA, BEHAV BRAIN RES, 175, PP. 362-373, (2006); WANG Q., TOMPKINS K.D., SIMONYI A., KORTHUIS R.J., SUN A.Y., SUN Y., APOCYNIN PROTECTS AGAINST GLOBAL CEREBRAL ISCHEMIA-REPERFUSION-INDUCED OXIDATIVE STRESS AND INJURY IN THE GERBIL HIPPOCAMPUS, BRAIN RES, 23, PP. 182-189, (2006); YASUI H., ASANUMA T., WATANABE Y., WAKI K., INANAMI O., KUWABARA M., ORAL ADMINISTRATION OF ANTIOXIDANT BIOFACTOR (AOBTRADE MARK) AMELIORATES ISCHEMIA/REPERFUSION-INDUCED NEURONAL DEATH IN THE GERBIL, BIOFACTORS, 29, PP. 113-121, (2007); GUPTA S., SHARMA S.S., NEUROPROTECTIVE EFFECTS OF TROLOX IN GLOBAL CEREBRAL ISCHEMIA IN GERBILS, BIOL PHARM BULL, 29, PP. 957-961, (2006); WASSMANN S., LAUFS U., MULLER K., KONKOL C., AHLBORY K., BAUMER A.T., ET AL., CELLULAR ANTIOXIDANT EFFECTS OF ATORVASTATIN IN VITRO AND IN VIVO, ARTERIOSCLER THROMB VASC BIOL, 22, PP. 300-305, (2002); HADI N.R., ABDELHUSSEIN M.A., ALHAMAMI O.M., MUHAMMAD RUDHA A.R., SABAH E., ANTIOXIDANT EFFECT OF ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS, PHARMACOL PHARM, 1, PP. 53-59, (2010); RAJESH P., RAJASEKHAR P., CHRONOTHERAPY STUDIES OF ATORVASTATIN ON ANTIOXIDANT MARKERS IN CHOLESTEROL FED RABBIT MODELS, INT J PHARM IND RES, 1, PP. 251-260, (2011); INZITARI D., PICCARDI B., SARTI C., A CRITICAL REVIEW OF ASPIRIN IN THE SECONDARY PREVENTION OF NONCARDIOEMBOLIC ISCHAEMIC STROKE, INT J STROKE, 5, PP. 306-318, (2010)","V. MOLINA; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA; EMAIL: VIVIAN.MOLINA@CNIC.EDU.CU","","ENGLISH","INDIAN J. PHARM. SCI.","ARTICLE","ISI","2-S2.0-84892709608","INDIAN J PHARM SCI","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"MOLINA V, 2013, INDIAN J PHARM SCI","MOLINA V, 2013, INDIAN J PHARM SCI"
"AL-OBAIDI L;DUNFORD N;GOAD C","AL-OBAIDI, L. (55972463600); DUNFORD, NURHAN T. (6603296815); GOAD, C. (7004431837)","MECHANICAL EXTRACTION OF WHEAT GERM OIL",2013,"TRANSACTIONS OF THE ASABE","56","5",6,"10.13031/trans.56.10270","DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES;DEPARTMENT OF STATISTICS, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES","WHEAT GERM OIL (WGO) IS ONE OF THE RICHEST NATURAL SOURCES OF VITAMIN E AND CONTAINS A NUMBER OF OTHER HEALTH-BENEFICIAL BIOACTIVE COMPOUNDS, INCLUDING POLYUNSATURATED FATTY ACIDS, POLICOSANOL, AND PHYTOSTEROLS. THE CONVENTIONAL WGO EXTRACTION TECHNIQUE USES HEXANE, WHICH MAY CAUSE ENVIRONMENTAL AND HUMAN HEALTH RISKS. THE OBJECTIVE OF THIS STUDY WAS TO OPTIMIZE A SOLVENTLESS WGO EXTRACTION PROCESS THAT PRODUCES GOOD-QUALITY OIL. TO ACHIEVE THIS GOAL, A MECHANICAL EXTRACTION PROCESS WAS EXAMINED. WGO WAS EXPRESSED USING A HEAVY-DUTY SCREW PRESS. THE SCREW PRESS SHAFT SPEED, CAGE TEMPERATURE, BACKPRESSURE AT THE MEAL DISCHARGE END, SHAFT ARRANGEMENT, AND GERM PRETREATMENT CONDITIONS WERE OPTIMIZED FOR MAXIMUM OIL YIELD. THE FREE FATTY ACIDS, PEROXIDE VALUE, AND P-ANISIDINE VALUE OF OIL OBTAINED BY MECHANICAL PRESSING WERE LOWER THAN THOSE FOR COMMERCIALLY HEXANE-EXTRACTED OIL, BUT THE MECHANICALLY PRESSED WGO WAS RICH IN ESSENTIAL FATTY ACIDS AND TOCOPHEROLS. MECHANICAL PRESSING IS AN ENVIRONMENTALLY BENIGN ALTERNATIVE TO HEXANE EXTRACTION, SPECIFICALLY FOR SPECIALTY OILS SUCH AS WGO. SOLVENT-FREE OIL AND CAKE FROM MECHANICAL EXTRACTION CAN BE USED IN FUNCTIONAL FOODS AND NUTRACEUTICAL FORMULATIONS AND CAN ADD VALUE TO THE WHEAT MILLING BYPRODUCT WHEAT GERM. © 2013 AMERICAN SOCIETY OF AGRICULTURAL AND BIOLOGICAL ENGINEERS.","EXTRACTION; MECHANICAL PRESS; PROCESS OPTIMIZATION; WHEAT GERM; WHEAT GERM OIL","EXTRACTION; FATTY ACIDS; HEXANE; OPTIMIZATION; PLANTS (BOTANY); POLYUNSATURATED FATTY ACIDS; SCREWS; VEGETABLE OILS; ENVIRONMENTALLY BENIGN; ESSENTIAL FATTY ACIDS; EXTRACTION TECHNIQUES; MECHANICAL EXTRACTION; MECHANICAL PRESS; PRETREATMENT CONDITIONS; WHEAT GERM; WHEAT GERM OIL; BIOCHEMICAL COMPOSITION; BIOMECHANICS; BIOTECHNOLOGY; EXTRACTION METHOD; HEALTH RISK; OPTIMIZATION; VEGETABLE OIL; VITAMIN; PRESSES (MACHINE TOOLS)","","","AMERICAN ASSOCIATION OF CEREAL CHEMISTS APPROVED METHODS, (1995); ADEEKO K., AJIBOLA O., PROCESSING FACTORS AFFECTING YIELD AND QUALITY OF MECHANICALLY EXPRESSED GROUNDNUT OIL, J. AGRIC. ENG. RES., 45, PP. 31-43, (1990); AJIBOLA O.O., ENIYEMO S.E., FASINA O.O., ADEEKO K.A., MECHANICAL EXPRESSION OF OIL FROM MELON SEEDS, J. AGRIC. ENG. RES., 45, PP. 45-53, (1990); OFFICIAL METHODS OF ANALYSIS, (2005); OFFICIAL METHODS AND RECOMMENDED PRACTICES, (2004); BARYEH E.A., EFFECTS OF PALM OIL PROCESSING PARAMETERS ON YIELD, J. FOOD ENG., 48, 1, PP. 1-6, (2001); DELI S., FARAH MASTURAH M., TAJUL ARIS Y., WAN NADIAH W.A., THE EFFECTS OF PHYSICAL PARAMETERS OF THE SCREW PRESS OIL EXPELLER ON OIL YIELD FROM NIGELLA SATIVA L. SEEDS, INTL. FOOD RES. J., 18, 4, PP. 1367-1373, (2011); DUNFORD N.T., GERM OILS FROM VARIOUS SOURCES, BAILEY'S INDUSTRIAL OIL AND FAT PRODUCTS, PP. 195-231, (2005); DUNFORD N.T., WHEAT GERM OIL, GOURMET AND HEALTH-PROMOTING SPECIALTY OILS, PP. 359-376, (2009); EISENMENGER M., DUNFORD N.T., BIOACTIVE COMPONENTS OF COMMERCIAL AND SUPERCRITICAL CARBON DIOXIDE PROCESSED WHEAT GERM OIL, J. AMERICAN OIL CHEM. SOC., 85, 1, PP. 55-61, (2008); EISENMENGER M., DUNFORD N.T., ELLER F., TAYLOR S., MARTINEZ J., PILOT-SCALE SUPERCRITICAL CARBON DIOXIDE EXTRACTION AND FRACTIONATION OF WHEAT GERM OIL, J. AMERICAN CHEM. SOC., 10, 2, PP. 863-868, (2006); EVANGELISTA R.L., OIL EXTRACTION FROM LESQUERELLA SEEDS BY DRY EXTRUSION AND EXPELLING, IND. CROPS PROD., 2, 1, PP. 189-196, (2009); KARAJ S., MULLER J., OPTIMIZING MECHANICAL OIL EXTRACTION OF JATROPHA CURCAS L. SEEDS WITH RESPECT TO PRESS CAPACITY, OIL RECOVERY, AND ENERGY EFFICIENCY, IND. CROPS PROD., 34, 1, PP. 1010-1016, (2011); KATSANIDIS E., ADDIS P.B., NOVEL HPLC ANALYSIS OF TOCOPHEROLS, TOCOTRIENOLS, AND CHOLESTEROL IN TISSUE, FREE RAD. BIOL. MED., 27, 11-12, PP. 1137-1140, (1999); KHAN L.M., HANNA M.A., EXPRESSION OF OIL FROM OILSEEDS: A REVIEW, J. AGRIC. ENG. RES., 28, 6, PP. 495-503, (1983); LOWRY R.R., TINSLEY I.J., RAPID COLORIMETRIC DETERMINATION OF FREE FATTY ACIDS, J. AMERICAN OIL CHEM. SOC., 53, 4, PP. 470-472, (1976); MOREAU R.A., JOHNSTON D.B., HICKS K.B., THE INFLUENCE OF MOISTURE CONTENT AND COOKING ON THE SCREW PRESSING AND PREPRESSING OF CORN OIL FROM CORN GERM, J. AMERICAN OIL CHEM. SOC., 82, 11, PP. 851-854, (2005); MWITHIGA G., MORIASI L., A STUDY OF YIELD CHARACTERISTICS DURING MECHANICAL OIL EXTRACTION OF PREHEATED AND GROUND SOYBEANS, J. APPL. SCI. RES., 3, 10, PP. 1146-1151, (2007); OYINLOLA A., OJO A., ADEKOYA L.O., DEVELOPMENT OF A LABORATORY MODEL SCREW PRESS FOR PEANUT OIL EXPRESSION, J. FOOD ENG., 64, 2, PP. 221-227, (2004); TACORONTE L.C., PUTTING THE PRESS TO THE TEST: EFFECTS OF TEMPERATURE ON SHEA NUT OIL OUTPUT, (2010); TKACHUK R., NITROGEN-TO-PROTEIN CONVERSION FACTORS FOR CEREALS AND OILSEED MEALS, CEREAL CHEM., 46, 4, PP. 419-423, (1969); VADKE V., SOSULSKI F., MECHANICS OF OIL EXPRESSION FROM CANOLA, J. AMERICAN OIL CHEM. SOC., 65, 7, PP. 1169-1176, (1988); WANG T., JOHNSON L.A., REFINING HIGH FREE FATTY ACID WHEAT GERM OIL, J. AMERICAN OIL CHEM. SOC., 78, 1, PP. 71-76, (2001); WARD J., PROCESSING HIGH OIL CONTENT SEEDS IN CONTINUOUS SCREW PRESSES, J. AMERICAN OIL CHEM. SOC., 53, 6, PP. 261-264, (1976); XIE M., DUNFORD N.T., GOAD C., ENZYMATIC EXTRACTION OF WHEAT GERM OIL, J. AMERICAN OIL CHEM. SOC., 88, 12, PP. 2015-2021, (2011); XIE M., DUNFORD N.T., GOAD C., AQUEOUS EXTRACTION OF WHEAT GERM OIL, BIOL. ENG. TRANS., 5, 2, PP. 99-106, (2012)","N.T. DUNFORD; FAPC, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","TRANS. ASABE","ARTICLE","ISI","2-S2.0-84890820520","TRANS ASABE","OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY","NOTREPORTED;OKLAHOMA STATE UNIVERSITY;NOTREPORTED",NA,"AL-OBAIDI L, 2013, TRANS ASABE","AL-OBAIDI L, 2013, TRANS ASABE"
"ESTIASIH T;AHMADI K;WIDYANINGSIH T;MALIGAN J;MUBAROK A;ZUBAIDAH E;MUKHLISIYYAH J;PUSPITASARI R","ESTIASIH, TETI (55622661500); AHMADI, KGS. (55622638800); WIDYANINGSIH, TRI DEWANTI (55900709900); MALIGAN, JAYA MAHAR (55900593300); MUBAROK, AHMAD ZAKI (57194546694); ZUBAIDAH, ELOK (55874719600); MUKHLISIYYAH, JHAUHAROTUL (55875732600); PUSPITASARI, RISMA (55875051500)","BIOACTIVE COMPOUNDS OF PALM FATTY ACID DISTILLATE PFAD FROM SEVERAL PALM OIL REFINERIES",2013,"ADVANCE JOURNAL OF FOOD SCIENCE AND TECHNOLOGY","5","6",20,"10.19026/ajfst.5.3074","DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA;DEPARTMENT OF AGROINDUSTRY TECHNOLOGY, FACULTY OF AGRICULTURE, TRIBHUWANA TUNGGADEWI UNIVERSITY, MALANG, JAWA TIMUR, 6514, JL. TELAGA WARNA, TLOGOMAS, INDONESIA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BRAWIJAYA UNIVERSITY, MALANG, JAWA TIMUR, 65145, JL. VETERAN, INDONESIA","THIS RESEARCH STUDIED THE CHARACTERISTICS OF PALM FATTY ACIDS DISTILLATES (PFADS) FROM SEVERAL PALM OIL REFINERIES. IT WAS AIMED TO KNOW THE POTENCY OF PFAD AS BIOACTIVE COMPOUNDS SOURCE, INCLUDING VITAMIN E (MAINLY TOCOTRIENOLS), PHYTOSTEROLS, SQUALENE AND POSSIBLY CO-ENZYME Q10 AND POLYCOSANOL. SAMPLING WAS CONDUCTED AT 6 PALM OIL REFINERIES. THE RESULTS SHOWED THAT PFAD WAS DOMINATED BY FREE FATTY ACIDS OF 85-95% WITH LOW OXIDATION LEVEL INDICATED BY PEROXIDE VALUE OF 1-10 MEQ/KG AND ANISIDIN VALUE OF 6-31. BIOACTIVE COMPOUNDS FOUND WERE VITAMIN E 60-200 PPM, PHYTOSTEROLS 400-7500 PPM AND SQUALENE 400-2800 PPM, MEANWHILE POLYCOSANOL AND CO-ENZYME Q10 WERE NOT FOUND. VITAMIN E WAS DOMINATED BY TOCOTRIENOLS AND ? TOCOTRIENOL WAS THE MAJOR VITAMIN E, FOLLOWED BY A AND D TOCOTRIENOLS. PHYTOSTEROLS IN PFADS FROM SEVERAL PALM OIL REFINERIES HAD VARIETY IN QUANTITY AND COMPOSITION. GENERALLY IT WAS DOMINATED BY ß SITOSTEROL, FOLLOWED BY STIGMASTEROL AND CAMPESTEROL.","CO-ENZYME Q10; PALM FATTY ACID DISTILLATE; PALM OIL REFINERY; PHYTOSTEROL; SQUALENE; TOCOPHEROL; TOCOTRIENOL","ALCOHOLS; ENZYMES; FATTY ACIDS; OIL SHALE; PETROLEUM REFINERIES; OIL REFINERIES; PALM FATTY ACID DISTILLATE; PHYTOSTEROL; SQUALENE; TOCOPHEROL; TOCOTRIENOLS; PALM OIL","","","AFFANDI M.S.Y., REFINING AND DOWNSTREAMING PROCESSING OF PALM AND PALM KERNEL OILS: PROCESSING OF PALM AND PALM KERNEL OILS, IN SELECTED READINGS ON PALM OIL AND ITS USES EDITED BY TECHNICAL COMMITEE OF 1995 PALM OIL FAMILIARIZATION PROGRAMME, PP. 35-59, (1994); OFFICIAL METHODS AND RECOMMENDED PRACTICES OF THE AMERICAN OIL CHEMISTRY SOCIETY. 4TH (ED.), (1990); AWAD A.B., FINK C.S., PHYTOSTEROL AS ANTICANCER DIETARY COMPONENT: EVIDENCE AND MECHANISM OF ACTION, J. NUTR., 130, PP. 2127-2130, (2000); AWIKA J.M., ROONEY L.W., SORGHUM PHYTOCHEMICALS AND THEIR POTENTIAL IMPACT ON HUMAN HEALTH, PHYTOCHEMISTRY, 65, PP. 1199-1221, (2004); BALL G.F.M., FAT-SOLUBLE VITAMIN ASSAYS IN FOOD ANALYSIS (A COMPREHENSIVE REVIEW), (1988); BENITES C.I., CHONCA V.O.C., REIS S.M.P.M., DE OLIVEIRRA O.C., PHYSIOCHEMICAL CHARACTERIZATION OF SOYBEAN OIL DEODORIZER DISTILLATE, CHEM. ENG.TRANS., 17, PP. 903-908, (2009); BONDIOLI P., MARIANI C., LANZANI A., FEDELI E., MULLER A., SQUALENE RECOVERY FROM OLIVE OIL DEODORIZER DISTILLATES, J. AM. OIL CHEM. SOC., 70, 8, (1993); CARR T.P., ASH M.M., BROWN A.W., CHOLESTEROL-LOWERING PHYTOSTEROLS: FACTORS AFFECTING THEIR USE AND EFFICACY, NUT. DIETARY SUPPL., 2, PP. 59-72, (2010); CERIANI R., MEIRELLES A.J.A., SIMULATION OF CONTINUOUS DEODORIZER: EFFECTS ON PRODUCT STREAMS, J. AM. OIL CHEM. SOC., 81, 11, PP. 1059-1069, (2004); CHEAH K.Y., TOH T.S., KOH P.M., PALM FATTY ACID DISTILLATE BIODIESEL: NEXT GENERATION PALM BIODIESEL, (2010); CHU B.S., QUEK S.Y., BAHARIN B.S., OPTIMISATION OF ENZYMATIC HYDROLYSIS FOR CONCENTRATION OF VITAMIN E IN PALM FATTY ACID DISTILLATE, J. FOOD CHEM., 80, 3, PP. 295-302, (2003); ESTIASIH T., CHOLIS M.N., HEPATOPROTECTIVE EFFECT OF TOCOTRIENOL RICH FRACTION FROM PALM FATTY ACID DISTILLATE ON HIGHLY OXIDIZED FRYING OIL INDUCED PEROXIDATION RATS, (2012); GAPOOR A., HASSAN W.H.W., SULONG M., PHYTOCHEMICAL FOR NUTRACEUTICAL FROM THE BY PRODUCT OF PALM OIL REFINING, PALM OIL DEVELOP., 36, PP. 13-19, (2002); GOH S.H., GEE P.T., NONCAROTENOIDS HYDROCARBON IN PALM OIL AND PALM FATTY ACID DISTILLATE, J. AM. OIL CHEM. SOC., 63, 2, PP. 226-230, (1985); HEINONEN M., PIIRONEN V., THE TOCOTRIENOL AND VITAMIN E CONTENT OF THE AVERAGE FINNISH DIET, INT. J. VITAM. NUTR. RES., 61, 1, PP. 27-32, (1991); HILLS G., THIEL C.C., THE FRRIC THYOCYANATE METHOD OF ESTIMATING PEROXIDE IN THE FAT OF BUTTER, MILK AND DRIED MILK, J. DAIRY RES., 14, 3, PP. 340-353, (1946); ANIMAL AND VEGETABLE FATS AND OILS-DETERMINATION OF ANISIDINE VALUE., (2006); JAIN R., JINDAL K.C., PATIL C.S., PHARMACEUTICAL COMPOSITIONS CONTAINING LONG CHAIN FATTY ACIDS AS EXCIPIENTS AS WELL AS PROCESS FOR MANUFACTURING THE SAME, (2007); KASSIS A.N., EVALUATION OF CHOLESTEROL-LOWERING AND ANTIOXIDANT PROPERTIES OF SUGAR CANE POLICOSANOLS IN HAMSTERS AND HUMANS, (2008); KHATOON S., RAJA R.G.R., KRISHNA A.G.G., PHYSICOCHEMICAL CHARACTERISTICS AND COMPOSITION OF INDIAN SOYBEAN OIL DEODORIZER DISTILLATE AND THE RECOVERY OF PHYTOSTEROLS, J. AM. OIL CHEM. SOC., 87, 3, PP. 321-326, (2010); LEWIS J., PROCESS FOR THE PRODUCTION OF TOCOTRIENOL, (2001); LIU D., SHI J., POSADA L.R., KAKUDA Y., XUE S.J., SEPARATING TOCOTRIENOL FROM PALM OIL BY MOLECULAR DISTILLATION, FOOD REV. INT., 24, 4, PP. 376-391, (2008); LOGANATHAN R., SELVADURAY K.R., RADHAKRISHNAN A., NESARETNAM K., PALM OIL RICH IN HEALTH PROMOTING PHYTONUTRIENTS, PALM OIL DEVELOP., 50, PP. 16-25, (2009); MAHENDRA K., MURTHY Y.L.N., RAO C.V.N., KRISHNA B.M., DETERMINATION OF UBIQUINONE Q10 (COENZYME Q10) AND ITS SYNTHESIS RELATED IMPURITIES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) AND MASS SPECTROMETRY (MS), INT. J. PHARMA TECH. RES., 3, 3, PP. 1467-1477, (2011); MENDEZ E., BLANCO M., LAGUNA A., GARCIA E., ISOLATION AND CHARACTERIZATION OF A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS OF HIGH MOLECULAR WEIGHT FROM HENEQUEN (AGAVE FURCROYDES L.) WAX, REVISTA CENIC CIENCIAS QUÍMICAS, 34, 1, PP. 35-38, (2003); NANDI S., SARBANI G., GOSH S., LIPASE CATALYZED SYNTHESIS OF NEUTRAL GLYSERIDES RICH IN MICRONUTRIENTS FROM RICE BRAN OIL FATTY ACIDS DISTILLATE, J. OLEO SCI., 57, 11, PP. 599-603, (2008); NANG H.L.L., WAFTI N.S.A., MAY C.Y., PALM FATTY ACID DISTILLATE, (2009); NEWMARK H.L., SQUALENE, OLIVE OIL AND CANCER RISK: A REVIEW AND HYPOTHESIS, CANCER EPIDEMIOL. BIOMARKER PREV., 6, 12, PP. 1101-1103, (1997); NG M.H., CHAO Y.M., MA A.H., CHOAH C.H., HASHIM M.A., SEPARATION VITAMIN E (TOCOPHEROL, TOCOTRIENOL AND TOCOMONOENAL) IN PALM OIL, LIPIDS, 39, PP. 1031-1035, (2004); PACKER L., WEBER S.U., RIMBACH G., MOLECULAR ASPECTS OF A-TOCOTRIENOL ANTIOXIDANT ACTION AND CELL SIGNALLING, J. NUTR., 131, 2, (2001); PIIRON V., LINDSAY D.G., MIEYYINEN T.A., TOIVO J., LAMPI A.M., PLANT STEROL: BIOSYNTHESIS, BIOLOGICAL FUNCTION AND THEIR IMPORTANCE TO HUMAN NUTRITION, J. SCI. FOOD AGRIC., 80, 7, PP. 939-966, (2000); POSADA L.R., SHI J., KAKUDA Y., XUE S.J., EXTRACTION OF TOCOTRIENOLS FROM PALM FATTY ACID DISTILLATES USING MOLECULAR DISTILLATION, J. SEPAR. PURIF. TECHNOL., 57, 2, PP. 220-229, (2007); PRAKASH I., DUBOIS G.E., HIGH SWEETENER COMPOSITION WITH LONG-CHAIN PRIMARY ALIPHATIC SATURATED ALCOHOL AND COMPOSITIONS SWEETENED THEREWITH, (2007); PUAH C.W., MAY C.Y., AHNGAN M., HOCK C.C., DEGUMMING AND BLEACHING: EFFECT ON SELECTED CONSTITUENTS OF PALM OIL, J.OIL PALM RES., 16, PP. 57-63, (2004); RAKMI A.R., HERAWAN T., PROPERTIES OF BIOSURFACTANT ENZYMATICALLY PREPARED FROM FRUCTOSE AND PALM FATTY ACID, J. OIL PALM RES., 12, 1, PP. 117-122, (2000); SERBINOVA E.A., PACKER L., ANTIOXIDANT PROPERTIES OF Α- TOCOPHEROL AND Α-TOCOTRIENOL, METHODS ENZYMOL., 234, PP. 354-366, (1994); SOMAIYA S.S., SRIVASTAVA S., GHAH S., MULIK N., A METHOD OF OBTAINING POLICOSANOLS FROM NATURAL MATERIAL, WORLD INT. PROPERTY ORGNIZ., (2010); TASAN M., BILGIN B., GECGEL U., DEMIRCI A.S., PHYTOSTEROLS AS FUNCTIONAL FOOD INGREDIENTS, J. TEKIRDAG AGRIC. FACULTY, 3, 2, PP. 153-159, (2006); THERIAULT A., CHAO J.T., WANG Q., GAPOR A., ADELI K., TOCOTRIENOL: A REVIEW OF ITS THERAPEUTIC POTENTIAL, CLIN. BIOCHEM., 32, 5, PP. 309-319, (1999); WAN J., ZHANG W., JIANG B., GUO Y., HU C., SEPARATION OF INDIVIDUAL TO COPHEROLS FROM SOYBEAN DISTILLATE BY LOW PRESSURE COLUMN CHROMATOGRAPHY, J. AM. OIL CHEM. SOC., 85, 4, PP. 331-338, (2008); WINKLE-MOSER J.K., VAUGHN S.F., ANTIOXIDANT ACTIVITY OF PHYTOCHEMICLAS FROM DITILLERS DRIED GRAIN OILS, J. AM. OIL CHEM. SOC., 86, 11, PP. 1073-1082, (2009)","","MAXWELL SCIENCE PUBLICATIONS","ENGLISH","ADV. J. FOOD SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-84885145875","ADV J FOOD SCI TECHNOL",NA,"NOTREPORTED",NA,"ESTIASIH T, 2013, ADV J FOOD SCI TECHNOL","ESTIASIH T, 2013, ADV J FOOD SCI TECHNOL"
"KIM J;PARK S;NA J;SEONG E;YU C","KIM, JAE KWANG (57193343343); PARK, SOO-YUN (45661697500); NA, JONG-KUK (57208176245); SEONG, EUN SOO (15844270500); YU, CHANG YEON (57218570487)","METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA PERILLA FRUTESCENS CULTIVARS",2012,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","60","6",41,"10.1021/jf204977x","NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;COLLEGE OF AGRICULTURE AND LIFE SCIENCE, KANGWON NATIONAL UNIVERSITY, CHUNCHON 200-701, SOUTH KOREA;COLLEGE OF AGRICULTURE AND LIFE SCIENCE, KANGWON NATIONAL UNIVERSITY, CHUNCHON 200-701, SOUTH KOREA","LIPOPHILIC COMPOUNDS FROM KOREAN PERILLA (PERILLA FRUTESCENS) SEEDS WERE CHARACTERIZED TO DETERMINE THE DIVERSITY AMONG THEIR PHYTOCHEMICALS AND TO ANALYZE RELATIONSHIPS BETWEEN THEIR CONTENTS. TWENTY-FOUR METABOLITES CONSISTING OF POLICOSANOL, PHYTOSTEROL, TOCOPHEROL, AND FATTY ACIDS WERE IDENTIFIED. THE METABOLITE PROFILES WERE SUBJECTED TO DATA MINING PROCESSES, INCLUDING PRINCIPAL COMPONENT ANALYSIS (PCA), PARTIAL LEAST-SQUARES DISCRIMINATE ANALYSIS (PLS-DA), AND PEARSON'S CORRELATION ANALYSIS. PLS-DA COULD DISTINGUISH BETWEEN ALL CULTIVARS EXCEPT BETWEEN DAESIL AND DAEYEUP CULTIVARS. LINOLENIC ACID CONTENTS WERE POSITIVELY CORRELATED WITH Β-SITOSTEROL (R = 0.8367, P < 0.0001) AND Γ-TOCOPHEROL CONTENTS (R = 0. 7201, P < 0.001) AMONG ALL PERILLA GRAINS. THE DAESIL AND DAEYEUP CULTIVARS APPEAR TO BE GOOD CANDIDATES FOR FUTURE BREEDING PROGRAMS BECAUSE THEY HAVE SIMULTANEOUSLY HIGH LINOLENIC ACID, PHYTOSTEROL, AND TOCOPHEROL LEVELS. THESE RESULTS DEMONSTRATE THE USE OF METABOLITE PROFILING AS A TOOL FOR ASSESSING THE QUALITY OF FOOD. © 2012 AMERICAN CHEMICAL SOCIETY.","FATTY ACID; METABOLITE PROFILING; PERILLA; PHYTOSTEROL; POLICOSANOL; PRINCIPAL COMPONENT ANALYSIS; TOCOPHEROL","ANTICHOLESTEREMIC AGENTS; FATTY ACIDS; FATTY ALCOHOLS; METABOLOME; PERILLA FRUTESCENS; PHYTOSTEROLS; SEEDS; TOCOPHEROLS; PERILLA; PERILLA FRUTESCENS; CORRELATION METHODS; FATTY ACIDS; METABOLITES; PRINCIPAL COMPONENT ANALYSIS; FATTY ACID; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; PHYTOSTEROL; POLICOSANOL; TOCOPHEROL; METABOLITE PROFILING; PERILLA; PHYTOSTEROL; POLICOSANOL; TOCOPHEROL; ARTICLE; CHEMISTRY; METABOLISM; METABOLOME; PERILLA FRUTESCENS; PLANT SEED; BIOMOLECULES","","","KAMAL-ELDIN A., ANDERSSON R., A MULTIVARIATE STUDY OF THE CORRELATION BETWEEN TOCOPHEROL CONTENT AND FATTY ACID COMPOSITION IN VEGETABLE OILS, JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 74, 4, PP. 375-380, (1997); TATEMATSU K., HIROSE N., ICHIKAWA Y., FUJII Y., TAKAMI A., OKUYAMA H., NUTRITIONAL EVALUATION OF AN INTER-ESTERIFIED PERILLA OIL AND LARD IN COMPARISON WITH BUTTER AND MARGARINE BASED ON THE SURVIVAL OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE (SHRSP) RATS, JOURNAL OF HEALTH SCIENCE, 50, 1, PP. 108-111, (2004); ADHIKARI P., KEUM T.H., JAE N.P., CHOONG K.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, 15, PP. 5359-5362, (2006); HAFFNER S.M., CLINICAL RELEVANCE OF THE OXIDATIVE STRESS CONCEPT, METABOLISM: CLINICAL AND EXPERIMENTAL, 49, 2 SUPPL. 1, PP. 30-34, (2000); ALLARD J.P., AGHDASSI E., CHAU J., TAM C., KOVACS C.M., SALIT I.E., WALMSLEY S.L., EFFECTS OF VITAMIN E AND C SUPPLEMENTATION ON OXIDATIVE STRESS AND VIRAL LOAD IN HIV-INFECTED SUBJECTS, AIDS, 12, 13, PP. 1653-1659, (1998); KRAMER-STICKLAND K., KROL E.S., LIEBLER D.C., UV-B-INDUCED PHOTOOXIDATION OF VITAMIN E IN MOUSE SKIN, CHEMICAL RESEARCH IN TOXICOLOGY, 12, 2, PP. 187-191, (1999); FAHN S., A PILOT TRIAL OF HIGH-DOSE Α-TOCOPHEROL AND ASCORBATE IN EARLY PARKINSON'S DISEASE, ANN. NEUROL, 32, PP. 128-132, (1992); HALLIKAINEN M.A., SARKKINEN E.S., UUSITUPA M.I.J., PLANT STANOL ESTERS AFFECT SERUM CHOLESTEROL CONCENTRATIONS OF HYPERCHOLESTEROLEMIC MEN AND WOMEN IN A DOSE-DEPENDENT MANNER, JOURNAL OF NUTRITION, 130, 4, PP. 767-776, (2000); JONES P.J., RAEINI-SARJAZ M., NTANIOS F.Y., VANSTONE C.A., FENG J.Y., PARSONS W.E., MODULATION OF PLASMA LIPID LEVELS AND CHOLESTEROL KINETICS BY PHYTOSTEROL VERSUS PHYTOSTANOL ESTERS, JOURNAL OF LIPID RESEARCH, 41, 5, PP. 697-705, (2000); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, 10, PP. 891-897, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); LONGVAH T., DEOSTHALE Y.G., UDAY KUMAR P., NUTRITIONAL AND SHORT TERM TOXICOLOGICAL EVALUATION OF PERILLA SEED OIL, FOOD CHEMISTRY, 70, 1, PP. 13-16, (2000); SHIN H.-S., KIM S.-W., LIPID COMPOSITION OF PERILLA SEED, J. AM. OIL CHEM. SOC, 71, PP. 619-622, (1994); RAMADAN Z., JACOBS D., GRIGOROV M., KOCHHAR S., METABOLIC PROFILING USING PRINCIPAL COMPONENT ANALYSIS, DISCRIMINANT PARTIAL LEAST SQUARES, AND GENETIC ALGORITHMS, TALANTA, 68, 5, PP. 1683-1691, (2006); TIANNIAM S., TARACHIWIN L., BAMBA T., KOBAYASHI A., FUKUSAKI E., METABOLIC PROFILING OF ANGELICA ACUTILOBA ROOTS UTILIZING GAS CHROMATOGRAPHY-TIME-OF-FLIGHT-MASS SPECTROMETRY FOR QUALITY ASSESSMENT BASED ON CULTIVATION AREA AND CULTIVAR VIA MULTIVARIATE PATTERN RECOGNITION, JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 105, 6, PP. 655-659, (2008); KIM J.K., HA S.-H., PARK S.-Y., LEE S.M., KIM H.J., LIM S.H., SUH S.-C., KIM D.H., CHO H.S., DETERMINATION OF LIPOPHILIC COMPOUNDS IN GENETICALLY MODIFIED RICE USING GAS CHROMATOGRAPHY- TIME-OF-FLIGHT MASS SPECTROMETRY, J. FOOD COMPOS. ANAL, 25, PP. 31-38, (2012); FATTY ACID COMPOSITION BY GAS CHROMATOGRAPHY, OFFICIAL METHODS AND RECOMMENDED PRACTICES OF THE AMERICAN OIL CHEMISTS, PP. 1-62, (1997); SCHUMMER C., DELHOMME O., APPENZELLER B.M.R., WENNIG R., MILLET M., COMPARISON OF MTBSTFA AND BSTFA IN DERIVATIZATION REACTIONS OF POLAR COMPOUNDS PRIOR TO GC/MS ANALYSIS, TALANTA, 77, PP. 1473-1482, (2009); VAN PELT C.K., HAGGARTY P., BRENNA J.T., QUANTITATIVE SUBFEMTOMOLE ANALYSIS OF Α-TOCOPHEROL AND DEUTERATED ISOTOPOMERS IN PLASMA USING TABLETOP GC/MS/MS, J. AGRIC. FOOD CHEM, 70, PP. 4369-4375, (1998); KIM J.K., LEE S.Y., CHU S.M., LIM S.H., SUH S.-C., LEE Y.-T., CHO H.S., HA S.-H., VARIATION AND CORRELATION ANALYSIS OF FLAVONOIDS AND CAROTENOIDS IN KOREAN PIGMENTED RICE (ORYZA SATIVA L.) CULTIVARS, J. AGRIC. FOOD CHEM, 58, PP. 12804-12809, (2010); PHILLIPS K.M., TARRAGO-TRANI M.T., STEWART K.K., PHYTOSTEROL CONTENT OF EXPERIMENTAL DIETS DIFFERING IN FATTY ACID COMPOSITION, FOOD CHEMISTRY, 64, 3, PP. 415-422, (1999)","J.K. KIM; NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA; EMAIL: KJKPJ@KOREA.KR","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-84859751640","J AGRIC FOOD CHEM","NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;KANGWON NATIONAL UNIVERSITY;KANGWON NATIONAL UNIVERSITY","NOTREPORTED;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NOTREPORTED",NA,"KIM JK, 2012, J AGRIC FOOD CHEM","KIM JK, 2012, J AGRIC FOOD CHEM"
"CICERO A;FERRONI A;ERTEK S","CICERO, ARRIGO F.G. (7003403707); FERRONI, ALIENOR (55318158100); ERTEK, SIBEL (15135521900)","TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPIDLOWERING EFFECTS",2012,"EXPERT OPINION ON DRUG SAFETY","11","13",63,"10.1517/14740338.2012.705827","INTERNAL MEDICINE, AGING AND KIDNEY DISEASES DEPARTMENT, UNIVERSITY OF BOLOGNA, S. ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY;INTERNAL MEDICINE, AGING AND KIDNEY DISEASES DEPARTMENT, UNIVERSITY OF BOLOGNA, S. ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY;TURKISH MINISTRY OF HEALTH-ŞANLIURFA EDUCATION AND RESEARCH HOSPITAL, ENDOCRINOLOGY AND METABOLIC DISEASES DEPARTMENT, ŞANLIURFA, TURKEY","CARDIOVASCULAR DISEASES ARE ONE OF THE HIGHEST CAUSES OF DEATH AND DISABILITY IN INDUSTRIALIZED COUNTRIES, WHEREAS A LARGE PORTION OF PATIENTS IN PRIMARY PREVENTION HAVE CARDIOVASCULAR DISEASE RISK FACTORS THAT REMAIN UNCONTROLLED. LIFESTYLE INTERVENTIONS, INCLUDING DIETARY SUPPLEMENTATION WITH NATURAL COMPOUNDS POSSESSING KNOWN LIPID-LOWERING EFFECTS, ARE STRONGLY SUPPORTED BY THE INTERNATIONAL GUIDELINES FOR CARDIOVASCULAR DISEASE PREVENTION. AREAS COVERED: THIS REVIEW PROVIDES INSIGHTS ON ISSUES CONCERNING THE SAFETY OF THE MOST COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH DEMONSTRATED LIPID-LOWERING ACTIONS. SOLUBLE FIBERS, PHYTOSTEROLS, SOY PROTEINS, OMEGA 3 POLYUNSATURATED FATTY ACIDS, MONAKOLINES, POLICOSANOLS, BERBERINE AND GARLIC EXTRACTS ARE ALL DISCUSSED AND A SPECIFIC FOCUS HAS BEEN PLACED ON THEIR PHARMACOLOGICAL INTERACTIONS. EXPERT OPINION: A RELATIVELY LARGE AMOUNT OF PRECLINICAL, EPIDEMIOLOGICAL AND CLINICAL EVIDENCE HAS DEMONSTRATED THE TOLERABILITY AND SAFETY OF THE MOST COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH DEMONSTRATED LIPID-LOWERING ACTION. HOWEVER, FOR MOST SUPPLEMENTS AND NUTRACEUTICALS, NO EVIDENCE IS CURRENTLY AVAILABLE FROM LONG-TERM TRIALS ON MORBIDITY AND MORTALITY. DETAILED KNOWLEDGE OF SPECIFIC HEALTH RISKS AND PHARMACOLOGICAL INTERACTIONS FOR EACH INDIVIDUAL COMPOUND IS NEEDED FOR THE MANAGEMENT OF FRAIL PATIENTS, SUCH AS CHILDREN, THE ELDERLY, PATIENTS WITH LIVER OR RENAL FAILURE, HIGH-RISK PATIENTS, AND PATIENTS CONSUMING NUMEROUS DRUGS. © 2012 INFORMA UK, LTD.","ADVERSE EFFECTS; DYSLIPIDEMIA; HYPERLIPIDEMIA; NUTRACEUTICALS; SAFETY; TOLERABILITY","ANIMALS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; HYPOLIPIDEMIC AGENTS; META-ANALYSIS AS TOPIC; RISK FACTORS; ALPHA TOCOPHEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTILIPEMIC AGENT; BERBERINE; CARBAMAZEPINE; CHOLESTEROL 7ALPHA MONOOXYGENASE; DARUNAVIR; DIGOXIN; GARLIC EXTRACT; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; ISPAGULA; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; MONACOLINE; NUTRACEUTICAL; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PHYTOSTEROL; POLICOSANOL; PROBIOTIC AGENT; SAQUINAVIR; SOYBEAN PROTEIN; STEROID; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ANTICOAGULATION; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; COMMIPHORA; DIET SUPPLEMENTATION; DIETARY FIBER; DISEASE EXACERBATION; DIVERTICULITIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GARLIC; GENE EXPRESSION; HALITOSIS; HUMAN; INTESTINE FLORA; LD 50; META ANALYSIS (TOPIC); MONASCUS PURPUREUS; NONHUMAN; PATIENT COMPLIANCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SIDE EFFECT; STOMACH DISCOMFORT; TEA; TRIACYLGLYCEROL BLOOD LEVEL","","","BANEGAS J.R., LOPEZ-GARCIA E., DALLONGEVILLE J., ET AL., ACHIEVEMENT OF TREATMENT GOALS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE ACROSS EUROPE: THE EURIKA STUDY, EUR HEART J, 32, PP. 2143-2152, (2011); SAHA S., GERDTHAM U.G., JOHANSSON P., ECONOMIC EVALUATION OF LIFESTYLE INTERVENTIONS FOR PREVENTING DIABETES AND CARDIOVASCULAR DISEASES, INT J ENVIRON RES PUBLIC HEALTH, 7, PP. 3150-3195, (2010); KING D.E., MAINOUS III A.G., MATHESON E.M., EVERETT C.J., IMPACT OF HEALTHY LIFESTYLE ON MORTALITY IN PEOPLE WITH NORMAL BLOOD PRESSURE, LDL CHOLESTEROL, AND C-REACTIVE PROTEIN, EUR J CARDIOVASC PREV REHABIL, (2011); CICERO A.F.G., DEROSA G., D'ANGELO A., ET AL., GENDER-SPECIFIC HAEMODYNAMIC AND METABOLIC EFFECTS OF A SEQUENTIAL TRAINING PROGRAMME ON OVERWEIGHT-OBESE HYPERTENSIVES, BLOOD PRESS, 18, PP. 111-116, (2009); CICERO A.F.G., ERTEK S., NATURAL SOURCES OF ANTIDYSLIPIDAEMIC AGENTS: IS THERE AN EVIDENCE-BASED APPROACH FOR THEIR PRESCRIPTION?, MED J NUTR METAB, 1, 2, PP. 85-93, (2008); EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) (ADULT TREATMENT PANEL III), J AM MED ASSOC, 285, PP. 2486-2497, (2001); CATAPANO A.L., REINER Z., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), ATHEROSCLEROSIS, 217, PP. 3-46, (2011); HASANI-RANJBAR S., NAYEBI N., MORADI L., ET AL., THE EFFICACY AND SAFETY OF HERBAL MEDICINES USED IN THE TREATMENT OF HYPERLIPIDEMIA: A SYSTEMATIC REVIEW, CURR PHARM RES, 16, PP. 2935-2947, (2010); MCGOWAN M.P., PROULX S., NUTRITIONAL SUPPLEMENTS AND SERUM LIPIDS: DOEAS ANYTHING WORK?, CURR ATHEROSCLER REP, 11, PP. 470-476, (2009); KIM J.Y., KWON O., CULINARY PLANTS AND THEIR POTENTIAL IMPACT ON METABOLIC OVERLOAD, ANN NY ACAD SCI, 1229, PP. 133-139, (2011); VERGARA-JIMENEZ M., CONDE K., ERICKSON S.K., FERNANDEZ M.L., HYPOLIPIDEMIC MECHANISMS OF PECTIN AND PSYLLIUM IN GUINEA PIGS FED HIGH FAT-SUCROSE DIETS: ALTERATIONS ON HEPATIC CHOLESTEROL METABOLISM, JOURNAL OF LIPID RESEARCH, 39, 7, PP. 1455-1465, (1998); WEI Z.H., WANG H., CHEN X.Y., ET AL., TIME- AND DOSE-DEPENDENT EFFECT OF PSYLIUM ON SERUM LIPIDS IN MILD-TO-MODERATE HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF CONTROLLED TRIALS, EUR J CLIN NUTR, 63, PP. 821-827, (2009); MACIEJKO J.J., BRAZG R., SHAH A., ET AL., PSYLLIUM FOR THE REDUCTION OF CHOLESTYRAMINE-ASSOCIATED GASTROINTESTINAL SYMPTOMS IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, ARCH FAM MED, 3, PP. 955-960, (1994); SHRESTHA S., FREAKE H.C., MCGRANE M.M., VOLEK J.S., FERNANDEZ M.L., A COMBINATION OF PSYLLIUM AND PLANT STEROLS ALTERS LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC SUBJECTS BY MODIFYING THE INTRAVASCULAR PROCESSING OF LIPOPROTEINS AND INCREASING LDL UPTAKE, JOURNAL OF NUTRITION, 137, 5, PP. 1165-1170, (2007); MOREYRA A.E., WILSON A.C., KORAYM A., EFFECT OF COMBINING PSYLLIUM FIBER WITH SIMVASTATIN IN LOWERING CHOLESTEROL, ARCHIVES OF INTERNAL MEDICINE, 165, 10, PP. 1161-1166, (2005); MECHANICK J.I., BRETT E.M., CHAUSMER A.B., ET AL., AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR THE CLINICAL USE OF DIETARY SUPPLEMENTS AND NUTRACEUTICALS, ENDOCR PRACT, 9, PP. 417-470, (2003); KEITHLEY J., SWANSON B., GLUCOMANNAN AND OBESITY: A CRITICAL REVIEW, ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 11, 6, PP. 30-34, (2005); YOSHIDA M., VANSTONE C.A., PARSONS W.D., ET AL., EFFECT OF PLANT STEROLS AND GLUCOMANNAN ON LIPIDS IN INDIVIDUALS WITH AND WITHOUT TYPE 2 DIABETES, EUR J CLIN NUTR, 60, PP. 529-537, (2006); MORGAN L.M., TREDGER J.A., WRIGHT J., MARKS V., THE EFFECT OF SOLUBLE- AND INSOLUBLE-FIBRE SUPPLEMENTATION ON POST-PRANDIAL GLUCOSE TOLERANCE, INSULIN AND GASTRIC INHIBITORY POLYPEPTIDE SECRETION IN HEALTHY SUBJECTS, BRITISH JOURNAL OF NUTRITION, 64, 1, PP. 103-110, (1990); VUKSAN V., SIEVENPIPER J.L., XU Z., WONG E.Y.Y., JENKINS A.L., BELJAN-ZDRAVKOVIC U., LEITER L.A., JOSSE R.G., STAVRO M.P., KONJAC-MANNAN AND AMERICAN GINSENG: EMERGING ALTERNATIVE THERAPIES FOR TYPE 2 DIABETES MELLITUS, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 20, 5 SUPPL., (2001); MCCARTY M.F., GLUCOMANNAN MINIMIZES THE POSTPRANDIAL INSULIN SURGE: A POTENTIAL ADJUVANT FOR HEPATOTHERMIC THERAPY, MED HYPOTHESES, 58, 6, PP. 487-490, (2002); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 88, 4, PP. 1167-1175, (2008); MARTINO F., MARTINO E., MORRONE F., CARNEVALI E., FORCONE R., NIGLIO T., EFFECT OF DIETARY SUPPLEMENTATION WITH GLUCOMANNAN ON PLASMA TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC CHILDREN, NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES, 15, 3, PP. 174-180, (2005); VEGA-LOPEZ S., FREAKE H.C., FERNANDEZ M.L., SEX AND HORMONAL STATUS MODULATE THE EFFECTS OF PSYLLIUM ON PLASMA LIPIDS AND MONOCYTE GENE EXPRESSION IN HUMANS, JOURNAL OF NUTRITION, 133, 1, PP. 67-70, (2003); CHUA M., BALDWIN T.C., HOCKING T.J., CHAN K., TRADITIONAL USES AND POTENTIAL HEALTH BENEFITS OF AMORPHOPHALLUS KONJAC K. KOCH EX N.E., BR. J ETHNOPHARMACOL, 128, PP. 268-278, (2010); VILLAVERDE A.F., BENLLOCH S., BERENGUER M., MIGUEL RAYON J., PINA R., BERENGUER J., ACUTE HEPATITIS OF CHOLESTATIC TYPE POSSIBLY ASSOCIATED WITH THE USE OF GLUCOMANNAN (AMORPHOPHALUS KONJAC) 1, JOURNAL OF HEPATOLOGY, 41, 6, PP. 1061-1062, (2004); VANDERBEEK P.B., FASANO C., O'MALLEY G., HORNSTEIN J., ESOPHAGEAL OBSTRUCTION FROM A HYGROSCOPIC PHARMACOBEZOAR CONTAINING GLUCOMANNAN, CLIN TOXICOL, 45, PP. 80-82, (2007); MOGHADASIAN M.H., MCMANUS B.M., GODIN D.V., RODRIGUES B., FROHLICH J.J., PROATHEROGENIC AND ANTIATHEROGENIC EFFECTS OF PROBUCOL AND PHYTOSTEROLS IN APOLIPOPROTEIN E-DEFICIENT MICE: POSSIBLE MECHANISMS OF ACTION, CIRCULATION, 99, 13, PP. 1733-1739, (1999); GRUNDY S.M., STANOL ESTERS AS A COMPONENT OF MAXIMAL DIETARY THERAPY IN THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III REPORT, AMERICAN JOURNAL OF CARDIOLOGY, 96, 1 SUPPL., (2005); MENSINK R.P., DE JONG A., LUTJOHANN D., ET AL., PLANT STENOLS DOSE DEPENDENTLY DECREASE LDL CHOLESTEROL CONCENTRATIONS BUT NOT CHOLESTEROL STANDARDIZED FAT SOLUBLE ANTIOXIDANT CONCENTRATIONS, AT INTAKES UP TO 9 G/D, AM J CLIN NUTR, 92, PP. 24-33, (2010); MORUISI K.G., OOSTHUIZEN W., OPPERMAN A.M., PHYTOSTEROLS/STANOLS LOWER CHOLESTEROL CONCENTRATIONS IN FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS: A SYSTEMATIC REVIEW WITH META-ANALYSIS, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 25, 1, PP. 41-48, (2006); SCHOLLE J.M., BAKER W.L., TALATI R., COLEMAN C.I., THE EFFECT OF ADDING PLANT STEROLS OR STANOLS TO STATIN THERAPY IN HYPERCHOLESTEROLEMIC PATIENTS: SYSTEMATIC REVIEW AND META-ANALYSIS, J AM COLL NUTR, 28, PP. 517-524, (2009); YU L., THE STRUCTURE AND FUNCTION OF NIEMANN-PICK C1-LIKE 1 PROTEIN, CURRENT OPINION IN LIPIDOLOGY, 19, 3, PP. 263-269, (2008); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., PRIMARY HYPERLIPIDEMIAS IN CHILDREN: EFFECT OF PLANT STEROL SUPPLEMENTATION ON PLASMA LIPIDS AND MARKERS OF CHOLESTEROL SYNTHESIS AND ABSORPTION, ACTA DIABETOL, 48, PP. 127-133, (2011); WEINGARTNER O., LUTJOHANN D., JI S., WEISSHOFF N., LIST F., SUDHOP T., VON BERGMANN K., GERTZ K., KONIG J., SCHAFERS H.-J., ENDRES M., BOHM M., LAUFS U., VASCULAR EFFECTS OF DIET SUPPLEMENTATION WITH PLANT STEROLS, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 51, 16, PP. 1553-1561, (2008); WEINGARTNER O., BOHM M., LAUFS U., CONTROVERSIAL ROLE OF PLANT STEROL ESTERS IN THE MANAGEMENT OF HYPERCHOLESTEROLAEMIA, EUR HEART J, 30, 4, PP. 404-409, (2009); WEINGARTNER O., ULRICH C., LUTJOHANN D., ET AL., DIFFERENTIAL EFFECTS ON INHIBITION OF CHOLESTEROL ABSORPTION BY PLANT STANOL AND PLANT STEROL ESTERS IN APOE-/-MICE, CARDIOVASC RES, 90, 3, PP. 484-492, (2011); GYLLING H., HALLIKAINEN M., NISSINEN M.J., MIETTINEN T.A., THE EFFECT OF A VERY HIGH DAILY PLANT STANOL ESTER INTAKE ON SERUM LIPIDS, CAROTENOIDS, AND FAT SOLUBLE VITAMINS, CLIN NUTR, 29, PP. 112-118, (2010); GUO Z., LIU X.M., ZHANG Q.X., ET AL., INFLUENCE OF CONSUMPTION OF PROBIOTICS ON THE PLASMA LIPID PROFILE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, NUTR METAB CARDIOVASC DIS, 21, PP. 844-850, (2011); BURCELIN R., LUCHE E., SERINO M., AMAR J., THE GUT MICROBIOTA ECOLOGY: NEW OPPORTUNITY FOR THE TREATMENT OF METABOLIC DISEASES?, FRONT BIOSCI, 14, PP. 5107-5117, (2009); KLAVER F.A., VAN DER MEER V., THE ASSUMED ASSIMILATION OF CHOLESTEROL BY LACTOBACILLI AND BIFIDOBACTERIUM BIFIDUM IS DUE TO THEIR BILE SALT-DECONJUGATING ACTIVITY, APPL ENVIRON MICROBIOL, 59, PP. 1120-1124, (1999); GRILL J.P., CAYUELA C., ANTOINE J.M., SCHNEIDER F., EFFECTS OF LACTOBACILLUS AMYLOVORUS AND BIFIDOBACTERIUM BREVE ON CHOLESTEROL, LETTERS IN APPLIED MICROBIOLOGY, 31, 2, PP. 154-156, (2000); BRASHEARS M.M., GILLILAND S.E., BUCK L.M., BILE SALT DECONJUGATION AND CHOLESTEROL REMOVAL FROM MEDIA BY LACTOBACILLUS CASEI, JOURNAL OF DAIRY SCIENCE, 81, 8, PP. 2103-2110, (1998); KUMAR M., NAGPAL R., KUMAR R., ET AL., CHOLESTEROL-LOWERING PROBIOTICS AS POTENTIAL BIOTHERAPEUTICS FOR METABOLIC DISEASES, EXP DIABETES RES, 2012, PP. 902-917, (2012); CANI P.D., POSSEMIERS S., VAN DE WIELE T., ET AL., CHANGES IN GUT MICROBIOTA CONTROL INFLAMMATION IN OBESE MICE THROUGH A MECHANISM INVOLVING GLP-2-DRIVEN IMPROVEMENT OF GUT PERMEABILITY, GUT, 58, 8, PP. 1091-1103, (2009); LIU Z.L., LIU J.P., ZHANG A.L., ET AL., CHINESE HERBAL MEDICINES FOR HYPERCHOLESTEROLEMIA, COCHRANE DATABASE SYST REV, 7, (2011); CICERO A.F.G., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 13, 4, PP. 273-278, (2005); KEITHLEY J.K., SWANSON B., SHA B.E., ZELLER J.M., KESSLER H.A., SMITH K.Y., A PILOT STUDY OF THE SAFETY AND EFFICACY OF CHOLESTIN IN TREATING HIV-RELATED DYSLIPIDEMIA, NUTRITION, 18, 2, PP. 201-204, (2002); GHEIT O., SHEASHAA H., ABDELSALAM M., ET AL., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH SECONDARY HYPERLIPIDEMIA, EUR J INTERN MED, 20, (2009); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, 2, PP. 198-204, (2010); NIJJAR P.S., BURKE F.M., BLOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, J CLIN LIPIDOL, 4, 4, PP. 248-258, (2010); GRIECO A., MIELE L., POMPILI M., ET AL., A CUTE HEPATITIS CAUSED BY A NATURAL LIPID-LOWERING PRODUCT: WHEN ""ALTERNATIVE"" MEDICINE IS NO ""ALTERNATIVE"" AT ALL, J HEPATOL, 50, PP. 1273-1277, (2009); WIGGER-ALBERTI W., BAUER A., HIPLER U.-C., ELSNER P., ANAPHYLAXIS DUE TO MONASCUS PURPUREUS-FERMENTED RICE (RED YEAST RICE), ALLERGY: EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 54, 12, PP. 1330-1331, (1999); IN Y.L., WANG T.H., LEE M.H., SU N.W., BIOLOGICALLY ACTIVE COMPONENTS AND NUTRACEUTICALS IN MONASCUS-FERMENTED RICE: A REVIEW, APPL MICROBIOL BIOTECHNOL, 77, PP. 965-973, (2008); EISENBRAND G., TOXICOLOGICAL EVALUATION OF RED MOULD RICE, MOL NUTR FOOD RES, 50, PP. 322-327, (2006); GORDON R.Y., BECKER D.J., THE ROLE OF RED YEAST RICE FOR THE PHYSICIAN, CURR ATHEROSCLER REP, 13, PP. 73-80, (2011); MONOGRAPH, MONASCUS PURPUREUS (RED YEAST RICE), ALTERN MED REV, 9, PP. 208-210, (2004); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, PP. 259-267, (2010); CHI H.N., KA Y.L., HUANG Y., ZHEN Y.C., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 16, PP. 6289-6293, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AND AGING, 20, 2, PP. 153-163, (2003); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, 3, PP. 1020-1026, (2006); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); ACKERMANN R.T., MULROW C.D., RAMIREZ G., GARDNER C.D., MORBIDONI L., LAWRENCE V.A., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCHIVES OF INTERNAL MEDICINE, 161, 6, PP. 813-824, (2001); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN INTERN MED, 133, PP. 420-429, (2000); MACAN H., UYKIMPANG R., ALCONCEL M., TAKASU J., RAZON R., AMAGASE H., NIIHARA Y., AGED GARLIC EXTRACT MAY BE SAFE FOR PATIENTS ON WARFARIN THERAPY, JOURNAL OF NUTRITION, 136, 3, (2006); IZZO A.A., ERNST E., INTERACTIONS BETWEEN HERBAL MEDICINES AND PRESCRIBED DRUGS: A SYSTEMATIC REVIEW, DRUGS, 61, 15, PP. 2163-2175, (2001); BERGINC K., MILISAV I., KRISTL A., GARLIC FLAVONOIDS AND ORGANOSULFUR COMPOUNDS: IMPACT ON THE HEPATIC PHARMACOKINETICS OF SAQUINAVIR AND DARUNAVIR, DRUG METAB PHARMACOKINET, 25, 6, PP. 521-530, (2010); POTTER S.M., OVERVIEW OF PROPOSED MECHANISMS FOR THE HYPOCHOLESTEROLEMIC EFFECT OF SOY, J NUTR, 125, 3 SUPPL., (1995); TORRES N., TORRE-VILLALVAZO I., TOVAR A.R., REGULATION OF LIPID METABOLISM BY SOY PROTEIN AND ITS IMPLICATION IN DISEASES MEDIATED BY LIPID DISORDERS, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 17, 6, PP. 365-373, (2006); MULLEN E., BROWN R.M., OSBORNE T.F., SHAY N.F., SOY ISOFLAVONES AFFECT STEROL REGULATORY ELEMENT BINDING PROTEINS (SREBPS) AND SREBP-REGULATED GENES IN HEPG2 CELLS, JOURNAL OF NUTRITION, 134, 11, PP. 2942-2947, (2004); SIRTORI C.R., LOVATI M.R., SOY PROTEINS AND CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 3, PP. 47-53, (2001); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); LENZ T.L., THERAPEUTIC LIFESTYLE CHANGES AND PHARMACEUTICAL CARE IN THE TREATMENT OF DYSLIPIDEMIAS IN ADULTS, J AM PHARM ASSOC, 45, 4, PP. 492-499, (2005); HARLAND J.I., HAFFNER T.A., SYSTEMATIC REVIEW, META-ANALYSIS AND REGRESSION OF RANDOMIZED CONTROLLED TRIALS REPORTING AN ASSOCIATION BETWEEN AN INTAKE OF CIRCA 25 G SOYA PROTEIN PER DAY AND BLOOD CHOLESTEROL, ATHEROSCLEROSIS, 200, PP. 13-27, (2008); WEGHUBER D., WIDHALM K., EFFECT OF 3 MONTH TREATMENT OF CHILDREN AND ADOLESCENTS WITH FAMILIAL AND POLYGENIC HYPERCHOLESTEROLEMIA WITH A SOY-SUBSTITUTED DIET, BR J NUTR, 99, PP. 281-286, (2008); CHEN S.T., FERNG S.H., YANG C.S., ET AL., VARIABLE EFFECTS OF SOY PROTEIN ON PLASMA LIPIDS IN HYPERLIPIDEMIC AND NORMOLIPIDEMIC HEMODIALYSIS PATIENTS, AM J KIDNEY DIS, 46, PP. 1099-1106, (2005); HUTCHINS A.M., MCIVER I.E., JOHNSTON C.S., HYPERTENSIVE CRISIS ASSOCIATED WITH HIGH DOSE SOY ISOFLOVANE SUPPLEMENTATION IN A POST-MENOPAUSAL WOMAN; A CASE REPORT, BMC WOMENS HEALTH, 5, (2005); CAMBRIA-KIELY J.A., EFFECT OF SOY MILK ON WARFARIN, ANN PHARMACOTHER, 36, PP. 1893-1896, (2002); ANDERSON G.D., ROSITO G., MOHUSTSY M.A., ELMER G.W., DRUG INTERACTION POTENTIAL OF SOY EXTRACT AND PANAX GINSENG, JOURNAL OF CLINICAL PHARMACOLOGY, 43, 6, PP. 643-648, (2003); CICERO A.F.G., ERTEK S., BERBERINE: METABOLIC AND CARDIOVASCULAR EFFECTS IN PRECLINICAL AND CLINICAL TRIALS, NUTR DIET SUPPL, 1, PP. 1-10, (2009); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.-D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NATURE MEDICINE, 10, 12, PP. 1344-1351, (2004); YIN J., XING H., YE J., EFFICACY OF BERBERINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, METABOLISM: CLINICAL AND EXPERIMENTAL, 57, 5, PP. 712-717, (2008); CICERO A.F.G., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS: A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 57, 1, PP. 26-30, (2007); SABIR M., BHIDE N.K., STUDY OF SOME PHARMACOLOGICAL ACTIONS OF BERBERINE, INDIAN J PHYSIOL PHARMACOL, 15, PP. 111-132, (1971); KUPELI E., KOSAR M., YESILADA E., BASER K.H.C., BASER C., A COMPARATIVE STUDY ON THE ANTI-INFLAMMATORY, ANTINOCICEPTIVE AND ANTIPYRETIC EFFECTS OF ISOQUINOLINE ALKALOIDS FROM THE ROOTS OF TURKISH BERBERIS SPECIES, LIFE SCIENCES, 72, 6, PP. 645-657, (2002); AFFUSO F., MERCURIO V., FAZIO V., FAZIO S., CARDIOVASCULAR AND METABOLIC EFFECTS OF BERBERINE, WORLD J CARDIOL, 2, 4, PP. 71-77, (2010); CHAN E., DISPLACEMENT OF BILIRUBIN FROM ALBUMIN BY BERBERINE, BIOLOGY OF THE NEONATE, 63, 4, PP. 201-208, (1993); XIN H.W., WU X.C., LI Q., ET AL., THE EFFECTS OF BERBERINE ON THE PHARMACOKINETICS OF CYCLOSPORINE A IN HEALTHY VOLUNTEERS, METHODS FIND EXP CLIN PHARMACOL, 28, PP. 25-29, (2006); LIN H.L., LIU T.Y., WU C.W., CHI C.W., BERBERINE MODULATES EXPRESSION OF MDR1 GENE PRODUCT AND THE RESPONSES OF THE DIGESTIVE TRACT CANCERS TO PACLITAXEL, BR J CANCER, 81, PP. 416-422, (1999); VRZAL R., ZDARILOVA A., ULRICHOVA J., BLAHA L., GIESY J.P., DVORAK Z., ACTIVATION OF THE ARYL HYDROCARBON RECEPTOR BY BERBERINE IN HEPG2 AND H4IIE CELLS: BIPHASIC EFFECT ON CYP1A1, BIOCHEMICAL PHARMACOLOGY, 70, 6, PP. 925-936, (2005); DENG R., THERAPEUTIC EFFECTS OF GUGGUL AND ITS CONSTITUENT GUGGULSTERONE: CARDIOVASCULAR BENEFITS, CARDIOVASCULAR DRUG REVIEWS, 25, 4, PP. 375-390, (2007); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., CUCCHIARA A.J., DERMARDEROSIAN A.H., CIRIGLIANO M.D., RADER D.J., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA. A RANDOMIZED, CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 290, 6, PP. 765-772, (2003); ULBRICHT C., BASCH E., SZAPARY P., HAMMERNESS P., AXENTSEV S., BOON H., KROLL D., GARRAWAY L., VORA M., WOODS J., GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENTARY THERAPIES IN MEDICINE, 13, 4, PP. 279-290, (2005); DALVI S.S., NAYAK V.K., POHUJANI S.M., ET AL., EFFECT OF GUGULIPID ON BIOAVAILABILITY OF DILTIAZEM AND PROPRANOLOL, J ASSOC PHYSICIANS INDIA, 42, PP. 454-455, (1994); MENON V.P., SUDHEER A.R., ANTI-OXIDANT AND ANTI-INFLAMMATORY PROPERTIES OF CURCUMIN, ADV EXP MED BIOL, 595, PP. 105-125, (2007); AGGARVAL B.B., SUNDARAM C., MALANI N., ICHIKAWA H., CURCUMIN: THE INDIAN SOLID GOLD, ADV EXP MED BIOL, 595, PP. 1-75, (2007); KANG Q., CHEN A., CURCUMIN SUPPRESSES EXPRESSION OF LOW-DENSITY LIPOPROTEIN RECEPTOR, LEADING TO THE INHIBITION OF LDL-INDUCED ACTIVATION OF HEPATIC STELLATE CELLS, BR J PHARMACOL, 157, PP. 1354-1367, (2009); FENG D., OHLSSON L., DUAN R.D., CURCUMIN INHIBITS CHOLESTEROL UPTAKE IN CACO-2 CELLS BY DOWN-REGULATION OF NPC1L1 EXPRESSION, LIPIDS HEALTH DIS, 9, (2010); AGGARWAL B.B., TARGETTING INFLAMMATION-INDUCED OBESITY AND METABOLIC DISEASES BY CURCUMIN AND OTHER NUTRACEUTICALS, ANNU REV NUTR, 30, PP. 173-199, (2010); SPECIALE A., CHIRAFISI J., SAIJA A., CIMINO F., NUTRITIONAL ANTIOXIDANTS AND ADAPTIVE CELL RESPONSES: AN UPDATE, CURR MOL MED, 11, 9, PP. 770-789, (2011); LI G., LIN W., ARAYA J.J., ET AL., A TEA CATECHIN, EPIGALLOCATECHIN-3-GALLATE, IS A UNIQUE MODULATOR OF THE FARNESOID X RECEPTOR, TOXICOL APPL PHARMACOL, 258, 2, PP. 268-274, (2012); TOKUNAGA S., WHITE I.R., FROST C., TANAKA K., KONO S., TOKUDOME S., AKAMATSU T., MORIYAMA T., ZAKOUJI H., GREEN TEA CONSUMPTION AND SERUM LIPIDS AND LIPOPROTEINS IN A POPULATION OF HEALTHY WORKERS IN JAPAN, ANNALS OF EPIDEMIOLOGY, 12, 3, PP. 157-165, (2002); KIM A., CHIU A., BARONE M.K., ET AL., GREEN TEA CATECHINS DECREASE TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A SYSTEMATIC REVIEW AND META-ANALYSIS, J AM DIET ASSOC, 111, PP. 1720-1729, (2011); ZHENG X.X., XU Y.L., LI S.H., ET AL., GREEN TEA INTAKE LOWERS FASTING SERUM TOTAL AND LDL CHOLESTEROL IN ADULTS: A META-ANALYSIS OF 14 RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 94, PP. 601-610, (2011); SAMMAN S., SANDSTROM B., TOFT M.B., BUKHAVE K., JENSEN M., SORENSEN S.S., HANSEN M., GREEN TEA OR ROSEMARY EXTRACT ADDED TO FOODS REDUCES NONHEME-IRON ABSORPTION, AMERICAN JOURNAL OF CLINICAL NUTRITION, 73, 3, PP. 607-612, (2001); SHIRASHI M., HARUNA M., MATSUZAKI M., ET AL., ASSOCIATION BETWEEN SERUM FOLATE LEVELS AND TEA CONSUMPTION DURING PREGNANCY, BIOSCI TRENDS, 4, PP. 225-230, (2010); RUBENFIRE M., BROOKE R.D., ROSENSON R.S., TREATING MIXED HYPERLIPIDEMIA AND THE ATHEROGENIC LIPID PHENOTYPE FOR PREVENTION OF CARDIOVASCULAR EVENTS, AM J MED, 123, PP. 892-898, (2010); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE: NEW RECOMMENDATIONS FROM THE AMERICAN HEART ASSOCIATION, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 23, 2, PP. 151-152, (2003); CICERO A.F.G., DE SANDO V., PARINI A., BORGHI C., POLYUNSATURATED FATTY ACIDS APPLICATION IN INTERNAL MEDICINE: BEYOND THE ESTABLISHED CARDIOVASCULAR EFFECTS, ARCH MED SCI, (2012); DJOUSSE L., GAZIANO J.M., BURING J.E., LEE I.M., DIETARY OMEGA-3 FATTY ACIDS AND FISH CONSUMPTION AND RISK OF TYPE 2 DIABETES, AM J CLIN NUTR, 93, PP. 143-150, (2011); NETTLETON J.A., KATZ R., N-3 LONG-CHAIN POLYUNSATURATED FATTY ACIDS IN TYPE 2 DIABETES: A REVIEW, JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 105, 3, PP. 428-440, (2005); HOOPER L., THOMPSON R.L., HARRISON R.A., ET AL., RISKS AND BENEFITS OF OMEGA 3 FATS FOR MORTALITY, CARDIOVASCULAR DISEASE, AND CANCER: SYSTEMATIC REVIEW, BR MED J, 332, PP. 752-760, (2006); HARRIS W.S., EXPERT OPINION: OMEGA-3 FATTY ACIDS AND BLEEDING-CAUSE FOR CONCERN?, AM J CARDIOL, 99, 6 A, (2007); GUALLAR E., SANZ-GALLARDO M.I., VAN'T VEER P., BODE P., ARO A., GOMEZ-ARACENA J., KARK J.D., RIEMERSMA R.A., MARTIN-MORENO J.M., KOK F.J., MERCURY, FISH OILS, AND THE RISK OF MYOCARDIAL INFARCTION, NEW ENGLAND JOURNAL OF MEDICINE, 347, 22, PP. 1747-1754, (2002); ELIAT-ADAR S., GOLDBOURT U., NUTRITIONAL RECOMMENDATIONS FOR PREVENTING CORONARY HEART DISEASE IN WOMEN: EVIDENCE CONCERNING WHOLE FOODS AND SUPPLEMENTS, NUTR METAB CARDIOVASC DIS, 20, PP. 459-466, (2010); COHEN J.T., BELLINGER D.C., CONNOR W.E., KRIS-ETHERTON P.M., LAWRENCE R.S., SAVITZ D.A., SHAYWITZ B.A., TEUTSCH S.M., GRAY G.M., A QUANTITATIVE RISK-BENEFIT ANALYSIS OF CHANGES IN POPULATION FISH CONSUMPTION, AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 29, 4, PP. 325-334, (2005); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTR METAB, 4, 2, PP. 133-139, (2011); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010)","A.F.G. CICERO; INTERNAL MEDICINE, AGING AND KIDNEY DISEASES DEPARTMENT, UNIVERSITY OF BOLOGNA, S. ORSOLA-MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA ALBERTONI, 15, ITALY; EMAIL: AFGCICERO@CARDIONET.IT","","ENGLISH","EXPERT OPIN. DRUG SAF.","REVIEW","ISI","2-S2.0-84865482955","EXPERT OPIN DRUG SAF","UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA;TURKISH MINISTRY OF HEALTH-ŞANLIURFA EDUCATION AND RESEARCH HOSPITAL","NOTREPORTED;UNIVERSITY OF BOLOGNA;NOTREPORTED",NA,"CICERO AFG, 2012, EXPERT OPIN DRUG SAF","CICERO AFG, 2012, EXPERT OPIN DRUG SAF"
"LIM S;YOO J;LEE E;CHO K","LIM, SO-MANG (56443072000); YOO, JEONG-AH (56949637200); LEE, EUN-YOUNG (57204082360); CHO, KYUNG-HYUN (7403956966)","ENHANCEMENT OF HIGHDENSITY LIPOPROTEIN CHOLESTEROL FUNCTIONS BY ENCAPSULATION OF POLICOSANOL EXERTS ANTISENESCENCE AND TISSUE REGENERATION EFFECTS VIA IMPROVEMENT OF ANTIGLYCATION ANTIAPOPTOSIS AND CHOLESTERYL ESTER TRANSFER INHIBITION",2016,"REJUVENATION RESEARCH","19","11",22,"10.1089/rej.2015.1712","SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, CHOK@YU.AC.KR, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, CHOK@YU.AC.KR, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, CHOK@YU.AC.KR, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA;SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, CHOK@YU.AC.KR, SOUTH KOREA, RESEARCH INSTITUTE OF PROTEIN SENSOR, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA, BK21PLUS PROGRAM SERUM BIOMEDICAL RESEARCH AND EDUCATION TEAM, YEUNGNAM UNIVERSITY, GYEONGSAN, SOUTH KOREA","CONSUMPTION OF POLICOSANOL (PCO), A REFINED MIXTURE OF SUGAR CANE WAX ALCOHOLS, CAN ELEVATE SERUM LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), ALTHOUGH THE MOLECULAR MECHANISM IS STILL UNKNOWN. TO INVESTIGATE THE MECHANISM OF ACTION RESPONSIBLE FOR THE ANTI-SENESCENCE EFFECTS OF PCO ON LIPOPROTEIN METABOLISM AND HDL FUNCTIONALITY, WE SYNTHESIZED RECONSTITUTED HDL (RHDL) CONTAINING PCO. ENCAPSULATION OF PCO BY RHDL (PCO-RHDL) ENHANCED ANTI-OXIDANT ACTIVITY AGAINST CUPRIC ION-MEDIATED LOW-DENSITY LIPOPROTEIN (LDL) OXIDATION. PCO-RHDL (FINAL CONCENTRATION, 9 ΜM PCO) SHOWED MORE POTENT ANTI-OXIDANT ACTIVITY THAN VITAMIN C TREATMENT (FINAL CONCENTRATION, 100 ΜM). PCO-RHDL INHIBITED FRUCTOSE-MEDIATED GLYCATION, WHICH IS A MAJOR PATHOLOGICAL MECHANISM OF DIABETIC COMPLICATIONS, IN A DOSE-DEPENDENT MANNER. PCO ALSO SHOWED CYTOPROTECTIVE EFFECTS IN MONOCYTES AND MACROPHAGES WITH LESS TRIGGERING OF APOPTOTIC PROCESSES AND REACTIVE OXYGEN SPECIES (ROS) PRODUCTION IN THE PRESENCE OF HYDROGEN PEROXIDE (H2O2). PCO-RHDL STRONGLY INHIBITED UPTAKE OF ACETYLATED LDL INTO MACROPHAGES, WHICH IS AN INITIAL ATHEROSCLEROTIC PROCESS. SURPRISINGLY, PCO-RHDL INHIBITED HUMAN SERUM CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY BY UP TO 47% (FINAL CONCENTRATION, 10 ΜM PCO). SUBCUTANEOUS INJECTION OF PCO-RHDL DOSE-DEPENDENTLY ENHANCED TISSUE REGENERATION ACTIVITY BY 2.4-FOLD AND 3.6-FOLD COMPARED TO THAT OF THE PHOSPHATE-BUFFERED SALINE (PBS) CONTROL. IN CONCLUSION, PCO IN HDL SHOWED POTENT ANTI-OXIDANT, ANTI-GLYCATION, AND CETP INHIBITORY ACTIVITIES ALONG WITH TISSUE REGENERATIVE ACTIVITY, ESPECIALLY UPON INCORPORATION INTO HDL. THESE RESULTS SUGGEST THAT PCO CAN ENHANCE FUNCTIONALITY OF HDL IN SERUM TO EXERT ANTI-SENESCENCE AND LONGEVITY EFFECTS. © COPYRIGHT 2016, MARY ANN LIEBERT, INC. 2016.","","AGING; ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; APOPTOSIS; CELL AGING; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CYTOPROTECTION; DERMIS; FATTY ALCOHOLS; GLYCOSYLATION; HUMANS; LIPOPROTEINS, LDL; OXIDATIVE STRESS; REGENERATION; ZEBRAFISH; ACETYL LOW DENSITY LIPOPROTEIN; ASCORBIC ACID; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CUPRIC ION; FRUCTOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN; PHOSPHATE BUFFERED SALINE; POLICOSANOL; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; APOLIPOPROTEIN A1; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; POLICOSANOL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL AGING; CELL ENCAPSULATION; CELL PROTECTION; CHOLESTEROL SYNTHESIS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; ENZYME MECHANISM; GLYCATION; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATION KINETICS; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; SENESCENCE; TISSUE REGENERATION; AGING; ANIMAL; APOPTOSIS; CELL AGING; DERMIS; DRUG EFFECTS; GLYCOSYLATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; REGENERATION; ZEBRA FISH","","","GOTTO A.M., MILLER N.E., OLIVER M.F., HIGH DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS, (1978); MAZZOTTI D.R., GUINDALINI C., MORAES W.A., ANDERSEN M.L., CENDOROGLO M.S., RAMOS L.R., TUFIK S., HUMAN LONGEVITY IS ASSOCIATED WITH REGULAR SLEEP PATTERNS, MAINTENANCE OF SLOW WAVE SLEEP, AND FAVORABLE LIPID PROFILE, FRONT AGING NEUROSCI, 24, (2014); MILMAN S., ATZMON G., CRANDALL J., BARZILAI N., PHENOTYPES AND GENOTYPES OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN EXCEPTIONAL LONGEVITY, CURR VASC PHARMACOL, 12, PP. 690-697, (2014); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPIDLOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CHO K.H., BIOMEDICINAL IMPLICATIONS OF HIGH-DENSITY LIPOPROTEIN: ITS COMPOSITION, STRUCTURE, FUNCTIONS, AND CLINICAL APPLICATIONS, BMB REP, 42, PP. 393-400, (2009); PARK K.H., SHIN D.G., CHO K.H., DYSFUNCTIONAL LIPOPROTEINS FROM YOUNG SMOKERS EXACERBATE CELLULAR SENESCENCE AND ATHEROGENESIS WITH SMALLER PARTICLE SIZE AND SEVERE OXIDATION AND GLYCATION, TOXICOL SCI, 140, PP. 16-25, (2014); KHALIL A., JAY-GERIN J.P., FULOP T., AGE-RELATED INCREASED SUSCEPTIBILITY OF HIGH-DENSITY LIPOPROTEINS (HDL) TO IN VITRO OXIDATION INDUCED BY GAMMA-RADIOLYSIS OF WATER, FEBS LETT, 435, PP. 153-158, (1998); SERES I., PARAGH G., DESCHENE E., FULOP T., KHALIL A., STUDY OF FACTORS INFLUENCING THE DECREASED HDL ASSOCIATED PON 1 ACTIVITY WITH AGING, EXP GERONTOL, 39, PP. 59-66, (2004); PARK K.H., JANG W., KIM K.Y., KIM J.R., CHO K.H., FRUCTATED APOLIPOPROTEIN A-I SHOWED SEVERE STRUCTURAL MODIFICATION AND LOSS OF BENEFICIAL FUNCTIONS IN LIPID-FREE AND LIPID-BOUND STATE WITH ACCELERATION OF ATHEROSCLEROSIS AND SENESCENCE, BIOCHEM BIOPHYS RES COMMUN, 392, PP. 295-300, (2010); PARK K.H., SHIN G.D., KIM J.R., CHO K.H., SENESCENCE-RELATED TRUNCATION AND MULTIMERIZATION OF APOLIPOPROTEIN A-I IN HIGH-DENSITY LIPOPROTEIN WITH AN ELEVATED LEVEL OF ADVANCED GLYCATED END PRODUCTS AND CHOLESTERYL ESTER TRANSFER ACTIVITY, J GERONTOL A BIOL SCI MED SCI, 65, PP. 600-610, (2010); CHO K.H., SYNTHESIS OF RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) CONTAINING APOA-I AND APOCIII: THE FUNCTIONAL ROLE OF APOC-III IN RHDL, MOL CELLS, 27, PP. 291-297, (2009); CHEN Y.H., YANG J.T., MARTINEZ H.M., DETERMINATION OF THE SECONDARY STRUCTURES OF PROTEINS BY CIRCULAR DICHROISMAND OPTICAL ROTATORY DISPERSION, BIOCHEMISTRY, 11, PP. 4120-4131, (1972); KIM S.M., KIM J.M., SHIN D.G., KIM J.R., CHO K.H., RELATION OF ATRIAL FIBRILLATION (AF) AND CHANGE OF LIPOPROTEINS: MALE PATIENTS WITH AF EXHIBITED SEVERE PRO-INFLAMMATORY AND PRO-ATHEROGENIC PROPERTIES IN LIPOPROTEINS, CLIN BIOCHEM, 47, PP. 869-875, (2014); HAVEL R.J., EDER H.A., BRAGDON J.H., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, J CLIN INVEST, 34, PP. 1345-1353, (1955); PONGOR S., ULRICH P.C., BENCSATH F.A., CERAMI A., AGING OF PROTEINS: ISOLATION AND IDENTIFICATION OF A FLUORESCENT CHROMOPHORE FROM THE REACTION OF POLYPEPTIDES WITH GLUCOSE, PROC NATL ACAD SCI USA, 81, PP. 2684-2688, (1984); MCPHERSON J.D., SHILTON B.H., WALTON D.J., ROLE OF FRUCTOSE IN GLYCATION AND CROSS-LINKING OF PROTEINS, BIOCHEMISTRY, 27, PP. 1901-1907, (1988); PARK K.H., CHO K.H., HIGH-DENSITY LIPOPROTEIN (HDL) FROM ELDERLY AND RECONSTITUTED HDL CONTAINING GLYCATED APOLIPOPROTEINS A-I SHARE PROATHEROSCLEROTIC AND PROSENESCENT PROPERTIES WITH INCREASED CHOLESTEROL INFLUX, J GERONTOL A BIOL SCI MED SCI, 66, PP. 511-520, (2011); CHO K.H., LEE J.Y., CHOI M.S., CHO J.M., LIM J.S., PARK Y.B., A PEPTIDE FROM HOG PLASMA THAT INHIBITS HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN, BIOCHIM BIOPHYS ACTA, 1391, PP. 133-144, (1998); ESTERBAUER H., STRIEGL G., PUHL H., ROTHENEDER M., CONTINUOUS MONITORING OF IN VITRO OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN, FREE RADIC RES COMMUN, 6, PP. 67-75, (1989); KIM S.M., BAEK J.M., LIM S.M., KIM J.Y., KIM J., CHOI I., CHO K.H., MODIFIED LIPOPROTEINS BY ACRYLAMIDE SHOWED MORE ATHEROGENIC PROPERTIES AND EXPOSURE OF ACRYLAMIDE INDUCES ACUTE HYPERLIPIDEMIA AND FATTY LIVER CHANGES IN ZEBRAFISH, CARDIOVASC TOXICOL, PP. 1-9, (2014); FRAENKEL-CONRAT H., METHODS FOR INVESTIGATING THE ESSENTIAL GROUPS FOR ENZYME ACTIVITY, METHODS ENZYMOL, 4, PP. 247-269, (1957); CHO K.H., ENHANCED DELIVERY OF RAPAMYCIN BY V156K-APOA-I HIGH-DENSITY LIPOPROTEIN INHIBITS CELLULAR PRO-ATHEROGENIC EFFECTS AND SENESCENCE AND PROMOTES TISSUE REGENERATION, J GERONTOL A BIOL SCI MED SCI, 66, PP. 1274-1285, (2011); ITAHANA K., CAMPISI J., DIMRI G.P., METHODS TO DETECT BIOMARKERS OF CELLULAR SENESCENCE: THE SENESCENCE-ASSOCIATED BETAGALACTOSIDASE ASSAY, METHODS MOL BIOL, 371, PP. 21-31, (2007); NUSSLEIN-VOLHARD C., DAHM R., ZEBRAFISH: A PRACTICAL APPROACH, (2002); OWUSU-ANSAH E., DISTINCT MITOCHONDRIAL RETROGRADE SIGNALS CONTROL THE G1-S CELL CYCLE CHECKPOINT, NAT GENET, 4, PP. 356-361, (2008); YOON J.H., CHO K.H., A POINT MUTANT OF APOLIPOPROTEIN A-I (V156K) SHOWED ENHANCEMENT OF CELLULAR INSULIN SECRETION AND POTENT ACTIVITY OF FACULTATIVE REGENERATION IN ZEBRAFISH, REJUVENATION RES, 15, PP. 313-321, (2012); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPIDLOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); JOSEPH P., ALTERNATIVE THERAPIES, AM J HEALTH-SYST PHARM, 60, PP. 1112-1114, (2003); ROBERTO M., ROSA M., ANA-MA A., ROSA-MA G., JULIO C.F., IDANIA R., MIRTA Z., SONIA J., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); DULLENS S.P., MENSINK R.P., BRAGT M.C., KIES A.K., PLAT J., EFFECTS OF EMULSIFIED POLICOSANOLS WITH DIFFERENT CHAIN LENGTHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTORDEFICIENT MICE, J LIPID RES, 4, PP. 790-796, (2008); CHO K.H., SHIN D.G., BAEK S.H., KIM J.R., MYOCARDIAL INFARCTION PATIENTS SHOWED ALTERED LIPOPROTEIN PROPERTIES AND FUNCTIONS WHEN COMPARED WITH STABLE ANGINA PECTORIS PATIENTS, EXP MOL MED, 41, PP. 67-76, (2009); GUTSTEIN D.E., KRISHNA R., JOHNS D., SURKS H.K., DANSKY H.M., SHAH S., MITCHEL Y.B., ARENA J., WAGNER J.A., ANACETRAPIB, A NOVEL CETP INHIBITOR: PURSUING A NEW APPROACH TO CARDIOVASCULAR RISK REDUCTION, CLIN PHARMACOL THER, 91, PP. 109-122, (2012); KASTELEIN J.J., BESSELING J., SHAH S., BERGERON J., LANGSLET G., HOVINGH G.K., AL-SAADY N., KOEIJVOETS M., HUNTER J., JOHNSON-LEVONAS A.O., FABLE J., SAPRE A., MITCHEL Y., ANACETRAPIB AS LIPID-MODIFYING THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (REALIZE): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY, LANCET, 385, PP. 2153-2161, (2015); KRAUSS R.M., PINTO C.A., LIU Y., JOHNSON-LEVONAS A.O., DANSKY H.M., CHANGES IN LDL PARTICLE CONCENTRATIONS AFTER TREATMENT WITH ESTER TRANSFER PROTEIN INHIBITOR ANACETRAPIB ALONE OR IN COMBINATION WITH ATORVASTATIN, J CLIN LIPIDOL, 9, PP. 93-102, (2015); BARZILAI N., ATZMON G., SCHECHTER C., SCHAEFER E.J., CUPPLES A.L., LIPTON R., CHENG S., SHULDINER A.R., UNIQUE LIPOPROTEIN PHENOTYPE AND GENOTYPE ASSOCIATED WITH EXCEPTIONAL LONGEVITY, JAMA, 15, PP. 2030-2040, (2003); KARADAG A.S., TUTAL E., ERTUGRUL D.T., INSULIN RESISTANCE IS INCREASED IN PATIENTS WITH VITILIGO, ACTA DERM VENEREOL, 91, PP. 541-544, (2011); MCMAHON M., GROSSMAN J., FITZGERALD J., DAHLIN-LEE E., WALLACE D.J., THONG B.Y., BADSHA H., KALUNIAN K., CHARLES C., NAVAB M., FOGELMAN A.M., HAHN B.H., PROINFLAMMATORY HIGHDENSITY LIPOPROTEIN AS A BIOMARKER FOR ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS, ARTHRITIS RHEUM, 54, PP. 2541-2549, (2006); RANALLETTA M., BIERILO K.K., CHEN Y., MILOT D., CHEN Q., TUNG E., HOUDE C., ELOWE N.H., GARCIA-CALVO M., PORTER G., EVELAND S., FRANTZ-WATTLEY B., KAVANA M., ADDONA G., SINCLAIR P., SPARROW C., O'NEILL E.A., KOBLAN K.S., SITLANI A., HUBBARD B., FISHER T.S., BIOCHEMICAL CHARACTERIZATION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, J LIPID RES, 51, PP. 2739-2752, (2010); GARCIA-GONZALEZ V., GUTIERREZ-QUINTANAR N., MENDOZA-ESPINOSA P., BROCOS P., PINEIRO A., MAS-OLIVA J., KEY STRUCTURAL ARRANGEMENTS AT THE C-TERMINUS DOMAIN OF CETP SUGGEST A POTENTIAL MECHANISM FOR LIPID-TRANSFER ACTIVITY, J STRUCT BIOL, 186, PP. 19-27, (2014); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006)","K.-H. CHO; SCHOOL OF BIOTECHNOLOGY, YEUNGNAM UNIVERSITY, GYEONGSAN, CHOK@YU.AC.KR, SOUTH KOREA; EMAIL: CHOK@YU.AC.KR","MARY ANN LIEBERT INC.","ENGLISH","REJUVENATION RES.","ARTICLE","ISI","2-S2.0-84959018334","REJUVENATION RES","YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY;YEUNGNAM UNIVERSITY","NOTREPORTED;YEUNGNAM UNIVERSITY;NOTREPORTED",NA,"LIM S-M, 2016, REJUVENATION RES","LIM S-M, 2016, REJUVENATION RES"
"KIM J;HA S;PARK S;LEE S;KIM H;LIM S;SUH S;KIM D;CHO H","KIM, JAE KWANG (57193343343); HA, SUN-HWA (7202501231); PARK, SOO-YUN (45661697500); LEE, SI MYUNG (8107878500); KIM, HYO JIN (57200179359); LIM, SUN HYUNG (7404081419); SUH, SEOK-CHEOL (8969541000); KIM, DONG HERN (57198636923); CHO, HYUN SUK (55912519700)","DETERMINATION OF LIPOPHILIC COMPOUNDS IN GENETICALLY MODIFIED RICE USING GAS CHROMATOGRAPHYTIMEOFFLIGHT MASS SPECTROMETRY",2012,"JOURNAL OF FOOD COMPOSITION AND ANALYSIS","25","7",36,"10.1016/j.jfca.2011.06.002","NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA","AN ACCURATE AND SENSITIVE METHOD FOR DETERMINING 14 LIPOPHILIC COMPOUNDS, INCLUDING TOCOPHEROLS, TOCOTRIENOLS, STEROLS AND POLICOSANOLS FROM RICE (ORYZA SATIVA L.) GRAIN WAS DEVELOPED USING GAS CHROMATOGRAPHY (GC) COUPLED TO TIME-OF-FLIGHT MASS SPECTROMETRY (TOFMS). THE METHOD IS FAST, REQUIRING ONLY 13. MIN FOR THE GC-TOFMS RUN. DURING THE VALIDATION PROCEDURE, THE METHOD PROVED TO BE SUFFICIENTLY PRECISE AND ACCURATE WITH RESPECT TO THE DEGREE OF ENDOGENOUS BIOLOGICAL VARIABILITY FOUND IN RICE SAMPLES. THE PROFILES OF THE 14 LIPOPHILIC COMPOUNDS OF PIGMENTED RICE, AS WELL AS GENETICALLY MODIFIED (GM) RICE TO IMPROVE Β-CAROTENE, WERE SUBJECTED TO PRINCIPAL COMPONENT ANALYSIS (PCA) TO EVALUATE THE DIFFERENCES AMONG CULTIVARS. PCA COULD FULLY DISTINGUISH PIGMENTED RICE FROM NON-PIGMENTED RICE. HOWEVER, GM RICE COULD NOT BE SEPARATED FROM ITS NON-TRANSGENIC COUNTERPART (NAKDONGBYEO). THIS PROTOCOL PROVIDES A RAPID AND FEASIBLE METHOD FOR MONITORING THE BIOACTIVE COMPOUNDS OF RICE. © 2011 ELSEVIER INC.","Β-CAROTENE; FOOD ANALYSIS; FOOD COMPOSITION; GAS CHROMATOGRAPHY; POLICOSANOL; RICE; STEROL; TIME-OF-FLIGHT MASS SPECTROMETRY; TOCOPHEROL","ORYZA SATIVA","RURAL DEVELOPMENT ADMINISTRATION, RDA; NATIONAL ACADEMY OF AGRICULTURAL SCIENCES, NAS, (PJ0068342011, PJ0068352011, PJ0081842011); NATIONAL ACADEMY OF AGRICULTURAL SCIENCES, NAS","THIS STUDY WAS SUPPORTED BY THE NATIONAL ACADEMY OF AGRICULTURAL SCIENCE (CODE PJ0068352011 , PJ0068342011 AND PJ0081842011 ), THE RURAL DEVELOPMENT ADMINISTRATION , AND REPUBLIC OF KOREA . THE AUTHORS ARE GRATEFUL TO THE NATIONAL INSTITUTE OF CROP SCIENCE FOR THE RICE SEEDS USED IN THIS STUDY.","ABIDI S.L., CHROMATOGRAPHIC ANALYSIS OF TOCOL-DERIVED LIPID ANTIOXIDANTS, JOURNAL OF CHROMATOGRAPHY A, 881, PP. 197-216, (2000); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 5359-5362, (2006); AMES S.R., DETERMINATION OF VITAMIN E IN FOODS AND FEEDS-A COLLABORATIVE STUDY, JOURNAL ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, 54, PP. 1-12, (1971); ARIIZUMI T., KISHITANI S., INATSUGI R., NISHIDA I., MURATA N., TORIYAMA K., AN INCREASE IN UNSATURATION OF FATTY ACIDS IN PHOSPHATIDYLGLYCEROL FROM LEAVES IMPROVES THE RATES OF PHOTOSYNTHESIS AND GROWTH AT LOW TEMPERATURES IN TRANSGENIC RICE SEEDLINGS, PLANT AND CELL PHYSIOLOGY, 43, PP. 751-758, (2002); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, PP. 891-897, (2002); CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, PP. 12143-12148, (2010); DE GREYT W.F., PETRAUSKAITE V., KELLENS M.J., HUYGHEBAERT A.D., ANALYSIS OF TOCOPHEROLS BY GAS-LIQUID AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY: A COMPARATIVE STUDY, FETT/LIPID, 100, PP. 503-507, (1998); DU M., AHN D.U., SIMULTANEOUS ANALYSIS OF TOCOPHEROLS, CHOLESTEROL, AND PHYTOSTEROLS USING GAS CHROMATOGRAPHY, JOURNAL OF FOOD SCIENCE, 67, PP. 1696-1700, (2002); SAFETY ASPECTS OF GENETICALLY MODIFIED FOODS OF PLANT ORIGIN, (2000); HAFFNER S.M., CLINICAL RELEVANCE OF THE OXIDATIVE STRESS CONCEPT, METABOLISM, 49, PP. 30-34, (2000); HA S.-H., LIANG Y.S., JUNG H., AHN M.-J., SUH S.-C., KWEON S.-J., KIM D.-H., KIM Y.-M., KIM J.-K., APPLICATION OF TWO BICISTRONIC SYSTEMS INVOLVING 2A AND IRES SEQUENCES TO THE BIOSYNTHESIS OF CAROTENOIDS IN RICE ENDOSPERM, PLANT BIOTECHNOLOGY JOURNAL, 8, PP. 928-938, (2010); HA T.-Y., KO S.-N., LEE S.-M., KIM H.-R., CHUNG S.-H., KIM S.-R., YOON H.-H., KIM I.-H., CHANGES IN NUTRACEUTICAL LIPID COMPONENTS OF RICE AT DIFFERENT DEGREES OF MILLING, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 108, PP. 175-181, (2006); JIANG Y., WANG T., PHYTOSTEROLS IN CEREAL BY-PRODUCTS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 82, PP. 439-444, (2005); JIAO Z., SI X.X., LI G.K., ZHANG Z.M., XU X.P., UNINTENDED COMPOSITIONAL CHANGES IN TRANSGENIC RICE SEEDS (ORYZA SATIVA L.) STUDIED BY SPECTRAL AND CHROMATOGRAPHIC ANALYSIS COUPLED WITH CHEMOMETRICS METHODS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, PP. 1746-1754, (2010); KIM J.K., CHU S.M., KIM S.J., LEE D.J., LEE S.Y., LIM S.H., HA S.-H., KWEON S.J., CHO H.S., VARIATION OF GLUCOSINOLATES IN VEGETABLE CROPS OF BRASSICA RAPA L. SSP. PEKINENSI, FOOD CHEMISTRY, 119, PP. 423-428, (2010); KIM J.K., LEE S.Y., CHU S.M., LIM S.H., SUH S.-C., LEE Y.-T., CHO H.S., HA S.-H., VARIATION AND CORRELATION ANALYSIS OF FLAVONOIDS AND CAROTENOIDS IN KOREAN PIGMENTED RICE (ORYZA SATIVA L.) CULTIVARS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, PP. 12804-12809, (2010); KIM J.K., RYU T.H., SOHN S.I., KIM J.H., CHU S.M., YU C.Y., BAEK H.J., METABOLIC FINGERPRINTING STUDY ON THE SUBSTANTIAL EQUIVALENCE OF GENETICALLY MODIFIED (GM) CHINESE CABBAGE TO NON-GM CABBAGE, JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY, 52, PP. 186-192, (2009); KURILICH A.C., JUVIK J.A., SIMULTANEOUS QUANTIFICATION OF CAROTENOIDS AND TOCOPHEROLS IN CORN KERNEL EXTRACTS BY HPLC, JOURNAL OF LIQUID CHROMATOGRAPHY AND RELATED TECHNOLOGIES, 22, PP. 2925-2934, (1999); LANDRUM J.T., BONE R.A., LUTEIN, ZEAXANTHIN, AND THE MACULAR PIGMENT, ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 385, PP. 28-40, (2001); LECHNER M., REITER B., LORBEER E., DETERMINATION OF TOCOPHEROLS AND STEROLS IN VEGETABLE OILS BY SOLID-PHASE EXTRACTION AND SUBSEQUENT CAPILLARY GAS CHROMATOGRAPHIC ANALYSIS, JOURNAL OF CHROMATOGRAPHY A, 857, PP. 231-238, (1999); LYTOVCHENKO A., BELEGGIA R., SCHAUER N., ISAACSON T., LEUENDORF J.E., HELLMANN H., ROSE J.K.C., FERNIE A.R., APPLICATION OF GC-MS FOR THE DETECTION OF LIPOPHILIC COMPOUNDS IN DIVERSE PLANT TISSUES, PLANT METHODS, 5, (2009); OBERDOERFER R.B., SHILLITO R.D., DE BEUCKELEER M., MITTEN D.H., RICE (ORYZA SATIVA L.) CONTAINING THE BAR GENE IS COMPOSITIONALLY EQUIVALENT TO THE NONTRANSGENIC COUNTERPART, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 1457-1465, (2005); SAFETY EVALUATION OF FOODS DERIVED BY MODERN BIOTECHNOLOGY: CONCEPT AND PRINCIPLES, (1993); PAINE J.A., SHIPTON C.A., CHAGGAR S., HOWELLS R.M., KENNEDY M.J., VERNON G., WRIGHT S.Y., HINCHLIFFE E., ADAMS J.L., SILVERSTONE A.L., DRAKE R., IMPROVING THE NUTRITIONAL VALUE OF GOLDEN RICE THROUGH INCREASED PRO-VITAMIN A CONTENT, NATURE BIOTECHNOLOGY, 23, PP. 482-487, (2005); PERERA C.O., YEN G.M., FUNCTIONAL PROPERTIES OF CAROTENOIDS IN HUMAN HEALTH, INTERNATIONAL JOURNAL OF FOOD PROPERTIES, 10, PP. 201-230, (2007); PIIRONEN V., TOIVO J., LAMPI A.-M., PLANT STEROLS IN CEREALS AND CEREAL PRODUCTS, CEREAL CHEMISTRY, 79, PP. 148-154, (2002); RISCHER H., OKSMAN-CALDENTEY K.M., UNINTENDED EFFECTS IN GENETICALLY MODIFIED CROPS: REVEALED BY METABOLOMICS?, TRENDS IN BIOTECHNOLOGY, 24, PP. 102-104, (2006); SCHUMMER C., DELHOMME O., APPENZELLER B.M.R., WENNIG R., MILLET M., COMPARISON OF MTBSTFA AND BSTFA IN DERIVATIZATION REACTIONS OF POLAR COMPOUNDS PRIOR TO GC/MS ANALYSIS, TALANTA, 77, PP. 1473-1482, (2009); SHEPHERD T., DOBSON G., VERRALL S.R., CONNER S., GRIFFITHS D.W., MCNICOL J.W., DAVIES H.V., STEWART D., POTATO METABOLOMICS BY GC-MS: WHAT ARE THE LIMITING FACTORS?, METABOLOMICS, 3, PP. 475-488, (2007); SNYDER J.M., TAYLOR S.L., KING J.W., ANALYSIS OF TOCOPHEROLS BY CAPILLARY SUPERCRITICAL FLUID CHROMATOGRAPHY AND MASS SPECTROMETRY, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 70, PP. 349-354, (1993); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); VAN PELT C.K., HAGGARTY P., BRENNA J.T., QUANTITATIVE SUBFEMTOMOLE ANALYSIS OF Α-TOCOPHEROL AND DEUTERATED ISOTOPOMERS IN PLASMA USING TABLETOP GC/MS/MS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 70, PP. 4369-4375, (1998); VILLEN J., BLANCH G.P., DEL CASTILLO M.L.R., HERRAIZ M., RAPID AND SIMULTANEOUS ANALYSIS OF FREE STEROLS, TOCOPHEROLS, AND SQUALENE IN EDIBLE OILS BY COUPLED REVERSED-PHASE LIQUID CHROMATOGRAPHY-GAS CHROMATOGRAPHY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 1419-1422, (1998)","H.S. CHO; NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON 441-707, SOUTH KOREA; EMAIL: HSCHO@KOREA.KR","","ENGLISH","J. FOOD COMPOS. ANAL.","ARTICLE","ISI","2-S2.0-84855572101","J FOOD COMPOS ANAL","NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE","NOTREPORTED;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE;EMAIL: HSCHO@KOREA.KR",NA,"KIM JK, 2012, J FOOD COMPOS ANAL","KIM JK, 2012, J FOOD COMPOS ANAL"
"GUERRA Y;YERA A;FERREIRO R;DESPAIGNE S;CUEVAS V","GUERRA, YOHANI PÉREZ (23995375700); YERA, AMBAR OYARZÁBAL (36020873200); FERREIRO, ROSA MAS (6602148780); DESPAIGNE, SONIA JIMÉNEZ (36096505400); CUEVAS, VIVIAN MOLINA (7006062814)","IN VITRO EFFECTS OF POLICOSANOL SACCHARUM OFFICINARUM L WAX ALCOHOLS ON THE 5LIPOOXYGENASE ENZYME EFECTO IN VITRO DEL POLICOSANOL ALCOHOLES DE LA CERA DE SACCHARUM OFFICINARUM L SOBRE LA ENZIMA 5LIPOOXIGENASA",2014,"REVISTA CUBANA DE FARMACIA","48","6",1,"","CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA","INTRODUCTION: POLICOSANOL, A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ALCOHOLS PURIFIED FROM SUGARCANE WITH OCTACOSANOL AS THE MAIN COMPONENT, SHOWS CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS IN ADDITION TO AN INHIBITORY EFFECT ON TYPE I CICLOXYGENASE.; OBJECTIVE: TO DETERMINE WHETHER POLICOSANOL MAY INHIBIT 5-LOX ENZYME ACTIVITY IN VITRO.; METHODS: EFFECTS ON 5-LOX ENZYME ACTIVITIES WERE ASSESSED IN RAT BLOOD POLYMORPHONUCLEAR LEUKOCYTES. VEHICLE OR POLICOSANOL SUSPENSIONS (0.6 TO 6 000 ΜG/ML) WERE ADDED TO TUBES CONTAINING THE REACTION MIX AND THEN ABSORBANCE CHANGES AT 234 NM WERE MEASURED.; CONCLUSIONS: POLICOSANOL DID NOT SIGNIFICANTLY INHIBIT 5-LOX ENZYME ACTIVITY IN RAT PMNL PREPARATIONS, SO THAT IT DOES NOT SEEM TO BE A DUAL INHIBITOR OF COX AND-LOX ENZYMES. THIS RESULT DIFFERS FROM THAT FOUND FOR BEESWAX ALCOHOLS AND UNDERLINES THE DIFFERENT EFFECTS OF THE MIXTURES OF LONG-CHAIN FATTY ALCOHOLS PURIFIED FROM THE SUGARCANE AND THE BEESWAX.; RESULTS: ADDED POLICOSANOL INHIBITED IN VITRO 5-LOX ACTIVITY BY 30 %, WHICH WAS NOT A SIGNIFICANT FIGURE BUT DEPENDED ON THE CONCENTRATION (R= 0.992; P< 0.05); IT WAS 1 250 ΜG/ML. © 2014 1999, EDITORIAL CIENCIAS MÉDICAS.","5-LOX; LIPOXYGENASES; POLICOSANOL; SACCHARUM OFFICINARUM L; SUGARCANE WAX ALCOHOLS","LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; POLICOSANOL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GAS CHROMATOGRAPHY; MALE; NEUTROPHIL; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SUGARCANE; ULTRAVIOLET SPECTROPHOTOMETRY","","","POLICOSANOL M.R., DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); MAS R., D-002. DRUGS OF THE FUTURE, 26, PP. 731-744, (2001); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., ACOSTA P., ALFONSO J., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL THER, 318, PP. 1020-1025, (2006); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, 4, PP. 311-321, (2011); MENENDEZ R., ARRUZAZABALA M.L., MAS R., CARBAJAL D., MOLINA V., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CICLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, INT J PHARM SCI REV RES, 19, 2, PP. 18-23, (2013); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMBO HEMOST, 9, PP. 58-62, (1996); BOYUM A., IN IODINATED DENSITY GRADIENT MEDIA, A PRACTICAL APPROACH, PP. 147-170, (1983); TATESON J.E., RANDALL R.W., REYNOLDS C.H., JACKSON W.P., BHATTACHERJEE P., SALMON J.A., SELECTIVE INHIBITION OF ARACHIDONATE 5-LIPOXYGENASE BY A NOVEL ACETOHYDROXAMIC ACIDS: BIOCHEMICAL ASSESSMENT IN VITRO AND EX VIVO, BR J PHARMACOL, 94, PP. 528-529, (1988); PEREZ Y., OYARZABAL A., RAVELO Y., MAS R., JIMENEZ S., MOLINA V., INHIBITION OF COX AND 5-LOX ENZYMES BY D-002 (BEESWAX ALCOHOLS), CURRENT TOP NUTR RES. (FORTHCOMING), (2012); GONZALEZ V.L., MAGRANER J., LAGUNA A., VELAZQUEZ C., LORENZO M., METODOLOGÍA ANALÍTICA POR CROMATOGRAFÍA GASEOSA PARA LA DETERMINACIÓN DE LOS ALCOHOLES ALIFÁTICOS SUPERIORES QUE COMPONEN EL POLICOSANOL, REV CENIC CIEN QUIM, 29, PP. 123-126, (1998); MARQUES DE OLIVEIRA A., CONSERVA L.M., DE SOUZA FERRO N., DE ALMEIDA F., ROSANGELA P., LEMOS L., ET AL., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INT J MOL SCI, 13, PP. 1598-1611, (2012); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., ET AL., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, PP. 155-162, (2009); WANG Y., KUANMAN K.E., WANG L., HIA L., JIAO Y., ZHAO X., ET AL., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); LAMARQUE D., PATHOGENESIS OF GASTRODUODENAL LESIONS INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, GASTROENTEROL CLIN BIOL, 28, PP. C18-C26, (2004); HUDSON N., BALSITIS M., EVERITT S., HAWKEY C.J., ENHANCED GASTRIC MUCOSAL LEUKOTRIENE B4 SYNTHESIS IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, GUT, 34, PP. 742-747, (1993); MENENDEZ R., FRAGA V., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEH, 67, PP. 1-7, (1999); MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., INHIBITION OF RAT MICROSOMAL LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-002, BRAZIL J MED BIOL RES, 33, PP. 85-90, (2000); MENENDEZ R., MAS R., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000)","","EDITORIAL CIENCIAS MEDICAS","SPANISH","REV. CUBA. FARM.","ARTICLE","ISI","2-S2.0-84907285150","REV CUBA FARM",NA,"NOTREPORTED",NA,"GUERRA YP, 2014, REV CUBA FARM","GUERRA YP, 2014, REV CUBA FARM"
"OGIER N;AMIOT M;GEORGÉ S;MAILLOT M;MALLMANN C;MARANINCHI M;MORANGE S;LESCUYER J;PELTIER S;CARDINAULT N","OGIER, NICOLAS (22980892200); AMIOT, MARIE-JOSÈPHE (7006947353); GEORGÉ, STÉPHANE (7401960180); MAILLOT, MATTHIEU (9737614300); MALLMANN, CÉCILIA (57196967631); MARANINCHI, MARIE (6505967817); MORANGE, SOPHIE (6603329045); LESCUYER, JEAN-FRANÇOIS (54796767200); PELTIER, SÉBASTIEN L. (23390396700); CARDINAULT, NICOLAS (6506246808)","LDLCHOLESTEROLLOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA",2013,"EUROPEAN JOURNAL OF NUTRITION","52","10",41,"10.1007/s00394-012-0357-x","LABORATOIRE LESCUYER, DEPARTMENT OF RESEARCH ZAC BELLE-AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE;INRA, UMR1260, AIX MARSEILLE UNIVERSITÉ NUTRITION, OBESITY AND THROMBOTIC RISK HEALTH CAMPUS LA TIMONE, 13385 MARSEILLE, CEDEX 5, 27 BOULEVARD JEAN MOULIN, FRANCE;BIOCHEMISTRY DEPARTMENT, CENTRE TECHNIQUE DE CONSERVATION DES PRODUITS AGRICOLES (CTCPA), SITE AGROPARC, 84911 AVIGNON, CEDEX 9, FRANCE;INRA, UMR1260, AIX MARSEILLE UNIVERSITÉ NUTRITION, OBESITY AND THROMBOTIC RISK HEALTH CAMPUS LA TIMONE, 13385 MARSEILLE, CEDEX 5, 27 BOULEVARD JEAN MOULIN, FRANCE;CENTRE D'INVESTIGATION CLINIQUE (CIC), INSERM-APHM, HÔPITAL DE LA CONCEPTION, 13385 MARSEILLE, 147 BD BAILLE, FRANCE;INRA, UMR1260, AIX MARSEILLE UNIVERSITÉ NUTRITION, OBESITY AND THROMBOTIC RISK HEALTH CAMPUS LA TIMONE, 13385 MARSEILLE, CEDEX 5, 27 BOULEVARD JEAN MOULIN, FRANCE;CENTRE D'INVESTIGATION CLINIQUE (CIC), INSERM-APHM, HÔPITAL DE LA CONCEPTION, 13385 MARSEILLE, 147 BD BAILLE, FRANCE;LABORATOIRE LESCUYER, DEPARTMENT OF RESEARCH ZAC BELLE-AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE;LABORATOIRE LESCUYER, DEPARTMENT OF RESEARCH ZAC BELLE-AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE;LABORATOIRE LESCUYER, DEPARTMENT OF RESEARCH ZAC BELLE-AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE","PURPOSE: RED YEAST RICE (RYR), SUGAR CANE-DERIVED POLICOSANOLS (SCDP) AND ARTICHOKE LEAF EXTRACTS (ALES) ARE CURRENTLY INCORPORATED ALONE OR IN COMBINATION INTO DIETARY SUPPLEMENTS FOR THEIR POTENTIAL LOW-DENSITY-LIPOPROTEIN CHOLESTEROL (LDL-CHOLESTEROL)-LOWERING EFFECTS. YET, THERE IS NO INFORMATION SUPPORTING THE EFFICACY OF THIS ASSOCIATION ON THE REDUCTION IN LDL-CHOLESTEROL. THE MAIN OBJECTIVE OF THIS STUDY WAS TO INVESTIGATE THE EFFECTS OF A NEW DIETARY SUPPLEMENT (DS) WITH RYR, SCDP AND ALES ON LDL-CHOLESTEROL. METHODS: IN A DOUBLE-BLIND, RANDOMIZED, PARALLEL CONTROLLED STUDY, 39 SUBJECTS FROM 21 TO 55 YEARS WITH MODERATE HYPERCHOLESTEROLEMIA WITHOUT DRUG TREATMENT WERE ASSIGNED TO 2 GROUPS AND THEN CONSUMED EITHER A DS CONTAINING RYR, SCDP AND ALES OR A PLACEBO OVER A 16-WEEK PERIOD. PLASMA CONCENTRATIONS OF LIPIDS [LDL-CHOLESTEROL, TOTAL CHOLESTEROL (TC), HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL (HDL-CHOLESTEROL), TRIACYLGLYCEROLS (TG)] AND PLASMA LEVELS OF VITAMINS C AND E, TOTAL POLYPHENOLS AND MALONDIALDEHYDE WERE DETERMINED AT BASELINE AND AFTER 4, 8, 12 AND 16 WEEKS. RESULTS: LDL-CHOLESTEROL AND TC WERE REDUCED BY, RESPECTIVELY, 21.4 % (95 % CI, -13.3 TO -24.9 %, P < 0.001) AND 14.1 % (95 % CI, -10.1 TO -18.0 %, P < 0.001) AT WEEK 16 IN THE DS GROUP COMPARED WITH BASELINE. SIMILAR RESULTS WERE OBTAINED AT WEEKS 4, 8 AND 12. TG DECREASED BY 12.2 % AFTER 16 WEEKS IN THE DS GROUP (95 % CI: -24.4 TO -0.1 %, P < 0.05). FOR THE VITAMIN E/TC RATIO, A DIFFERENCE WAS OBSERVED BETWEEN GROUPS AT WEEK 16 (P < 0.05). OTHER PARAMETERS WERE NOT MODIFIED. CONCLUSIONS: DAILY CONSUMPTION OF THIS NEW DS DECREASED LDL-CHOLESTEROL AND TC AND IS THEREFORE AN INTERESTING, CONVENIENT AID IN MANAGING MILD TO MODERATE HYPERCHOLESTEROLEMIA. © 2012 SPRINGER-VERLAG.","DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA; LIPID-LOWERING PLANT EXTRACTS; LOW-DENSITY-LIPOPROTEIN CHOLESTEROL; POLICOSANOLS; RED YEAST RICE","ADULT; ANTICHOLESTEREMIC AGENTS; ASCORBIC ACID; BIOLOGICAL AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYNARA SCOLYMUS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MALONDIALDEHYDE; MIDDLE AGED; PLANT EXTRACTS; PLANT LEAVES; POLYPHENOLS; TRIGLYCERIDES; VITAMIN E; YOUNG ADULT; CYNARA SCOLYMUS; SACCHARUM; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ARTICHOKE LEAF EXTRACT; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLACEBO; PLANT EXTRACT; POLYPHENOL; SUGAR CANE EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG; ABSENCE OF SIDE EFFECTS; ADULT; ARTICHOKE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL","LABORATOIRE LESCUYER","ACKNOWLEDGMENTS WE WOULD LIKE TO THANK MARION NOWICKI AND ROMAIN BOTT FOR THEIR EXPERT TECHNICAL ASSISTANCE. THIS WORK WAS FINANCED BY LABORATOIRE LESCUYER.","WILSON P.W., CASTELLI W.P., KANNEL W.B., CORONARY RISK PREDICTION IN ADULTS (THE FRAMINGHAM HEART STUDY), AM J CARDIOL, 59, (1987); ROBINSON J.G., SMITH B., MAHESHWARI N., SCHROTT H., PLEIOTROPIC EFFECTS OF STATINS: BENEFIT BEYOND CHOLESTEROL REDUCTION? A META-REGRESSION ANALYSIS, J AM COLL CARDIOL, 46, PP. 1855-1862, (2005); BAIGENT C., KEECH A., KEARNEY P.M., BLACKWELL L., BUCK G., POLLICINO C., KIRBY A., SOURJINA T., PETO R., COLLINS R., SIMES R., EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); VONDRAKOVA D., OSTADAL P., KRUGER A., IMMEDIATE EFFECT OF INTENSIVE ATORVASTATIN THERAPY ON LIPID PARAMETERS IN PATIENTS WITH ACUTE CORONARY SYNDROME, LIPIDS HEALTH DIS, 9, (2010); KELLY J.P., KAUFMAN D.W., KELLEY K., ROSENBERG L., ANDERSON T.E., MITCHELL A.A., RECENT TRENDS IN USE OF HERBAL AND OTHER NATURAL PRODUCTS, ARCH INTERN MED, 165, PP. 281-286, (2005); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); NIJJAR P.S., BURKE F.M., BLOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, J CLIN LIPIDOL, 4, PP. 248-258, (2010); BOGSRUD M.P., OSE L., LANGSLET G., OTTESTAD I., STROM E.C., HAGVE T.A., RETTERSTOL K., HYPOCOL (RED YEAST RICE) LOWERS PLASMA CHOLESTEROL: A RANDOMIZED PLACEBO CONTROLLED STUDY, SCAND CARDIOVASC J, 44, PP. 197-200, (2010); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); HUANG C.F., LI T.C., LIN C.C., LIU C.S., SHIH H.C., LAI M.M., EFFICACY OF MONASCUS PURPUREUS WENT RICE ON LOWERING LIPID RATIOS IN HYPERCHOLESTEROLEMIC PATIENTS, EUR J CARDIOVASC PREV REHABIL, 14, PP. 438-440, (2007); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, PP. 133-139, (2001); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); WIDER B., PITTLER M.H., THOMPSON-COON J., ERNST E., ARTICHOKE LEAF EXTRACT FOR TREATING HYPERCHOLESTEROLAEMIA, COCHRANE DATABASE SYST REV, (2009); KAPLAN M., AVIRAM M., OXIDIZED LOW DENSITY LIPOPROTEIN: ATHEROGENIC AND PROINFLAMMATORY CHARACTERISTICS DURING MACROPHAGE FOAM CELL FORMATION. AN INHIBITORY ROLE FOR NUTRITIONAL ANTIOXIDANTS AND SERUM PARAOXONASE, CLIN CHEM LAB MED, 37, PP. 777-787, (1999); TOSHIMA S., HASEGAWA A., KURABAYASHI M., ITABE H., TAKANO T., SUGANO J., SHIMAMURA K., KIMURA J., MICHISHITA I., SUZUKI T., NAGAI R., CIRCULATING OXIDIZED LOW DENSITY LIPOPROTEIN LEVELS. A BIOCHEMICAL RISK MARKER FOR CORONARY HEART DISEASE, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 2243-2247, (2000); BOWEN P.E., BORTHAKUR G., POSTPRANDIAL LIPID OXIDATION AND CARDIOVASCULAR DISEASE RISK, CURR ATHEROSCLER REP, 6, PP. 477-484, (2004); ROMERO F.J., BOSCH-MORELL F., ROMERO M.J., JARENO E.J., ROMERO B., MARIN N., ROMA J., LIPID PEROXIDATION PRODUCTS AND ANTIOXIDANTS IN HUMAN DISEASE, ENVIRON HEALTH PERSPECT, 106, SUPPL. 5, PP. 1229-1234, (1998); LOSONCZY K.G., HARRIS T.B., HAVLIK R.J., VITAMIN E AND VITAMIN C SUPPLEMENT USE AND RISK OF ALL-CAUSE AND CORONARY HEART DISEASE MORTALITY IN OLDER PERSONS: THE ESTABLISHED POPULATIONS FOR EPIDEMIOLOGIC STUDIES OF THE ELDERLY, AM J CLIN NUTR, 64, PP. 190-196, (1996); RIMM E.B., STAMPFER M.J., ASCHERIO A., GIOVANNUCCI E., COLDITZ G.A., WILLETT W.C., VITAMIN E CONSUMPTION AND THE RISK OF CORONARY HEART DISEASE IN MEN, N ENGL J MED, 328, PP. 1450-1456, (1993); STAMPFER M.J., HENNEKENS C.H., MANSON J.E., COLDITZ G.A., ROSNER B., WILLETT W.C., VITAMIN E CONSUMPTION AND THE RISK OF CORONARY DISEASE IN WOMEN, N ENGL J MED, 328, PP. 1444-1449, (1993); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); HU F.B., WILLETT W.C., OPTIMAL DIETS FOR PREVENTION OF CORONARY HEART DISEASE, JAMA, 288, PP. 2569-2578, (2002); MENTE A., DE KONING L., SHANNON H.S., ANAND S.S., A SYSTEMATIC REVIEW OF THE EVIDENCE SUPPORTING A CAUSAL LINK BETWEEN DIETARY FACTORS AND CORONARY HEART DISEASE, ARCH INTERN MED, 169, PP. 659-669, (2009); REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., AGEWALL S., ALEGRIA E., CHAPMAN M.J., DURRINGTON P., ERDINE S., HALCOX J., HOBBS R., KJEKSHUS J., FILARDI P.P., RICCARDI G., STOREY R.F., WOOD D., BAX J., VAHANIAN A., AURICCHIO A., BAUMGARTNER H., CECONI C., DEAN V., DEATON C., FAGARD R., FILIPPATOS G., FUNCK-BRENTANO C., HASDAI D., HOES A., KEARNEY P., KNUUTI J., KOLH P., MCDONAGH T., MOULIN C., POLDERMANS D., POPESCU B.A., SECHTEM U., SIRNES P.A., TENDERA M., TORBICKI A., VARDAS P., WIDIMSKY P., WINDECKER S., BERKENBOOM G., DE GRAAF J., DESCAMPS O., GOTCHEVA N., GRIFFITH K., GUIDA G.F., GULEC S., HENKIN Y., HUBER K., KESANIEMI Y.A., LEKAKIS J., MANOLIS A.J., MARQUES-VIDAL P., MASANA L., MCMURRAY J., MENDES M., PAGAVA Z., PEDERSEN T., PRESCOTT E., RATO Q., ROSANO G., SANS S., STALENHOEF A., TOKGOZOGLU L., VIIGIMAA M., WITTEKOEK M.E., ZAMORANO J.L., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); ENDO A., MONACOLIN K, A NEW HYPOCHOLESTEROLEMIC AGENT PRODUCED BY A MONASCUS SPECIES, J ANTIBIOT (TOKYO), 32, PP. 852-854, (1979); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); JOURNOUD M., JONES P.J., RED YEAST RICE: A NEW HYPOLIPIDEMIC DRUG, LIFE SCI, 74, PP. 2675-2683, (2004); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVESTIG, 25, PP. 701-707, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVESTIG, 23, PP. 639-650, (2003); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT THER MED, 16, PP. 61-65, (2008); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 982, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); GEBHARDT R., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN PRIMARY CULTURED RAT HEPATOCYTES BY ARTICHOKE (CYNARA SCOLYMUS L.) EXTRACTS, J PHARMACOL EXP THER, 286, PP. 1122-1128, (1998); BUNDY R., WALKER A.F., MIDDLETON R.W., WALLIS C., SIMPSON H.C., ARTICHOKE LEAF EXTRACT (CYNARA SCOLYMUS) REDUCES PLASMA CHOLESTEROL IN OTHERWISE HEALTHY HYPERCHOLESTEROLEMIC ADULTS: A RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL, PHYTOMEDICINE, 15, PP. 668-675, (2008); ENGLISCH W., BECKERS C., UNKAUF M., RUEPP M., ZINSERLING V., EFFICACY OF ARTICHOKE DRY EXTRACT IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ARZNEIMITTELFORSCHUNG, 50, PP. 260-265, (2000); GLASS C.K., WITZTUM J.L., ATHEROSCLEROSIS. THE ROAD AHEAD, CELL, 104, PP. 503-516, (2001); BAZZANO L.A., SERDULA M.K., LIU S., DIETARY INTAKE OF FRUITS AND VEGETABLES AND RISK OF CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 5, PP. 492-499, (2003); HUNG H.C., JOSHIPURA K.J., JIANG R., HU F.B., HUNTER D., SMITH-WARNER S.A., COLDITZ G.A., ROSNER B., SPIEGELMAN D., WILLETT W.C., FRUIT AND VEGETABLE INTAKE AND RISK OF MAJOR CHRONIC DISEASE, J NATL CANCER INST, 96, PP. 1577-1584, (2004); ETUDE INDIVIDUELLE NATIONALE DES CONSOMMATIONS ALIMENTATION: INCA2, (2009); NAGILA A., PERMPONGPAIBOON T., TANTRARONGROJ S., PORAPAKKHAM P., CHINWATTANA K., DEAKIN S., PORNTADAVITY S., EFFECT OF ATORVASTATIN ON PARAOXONASE 1 (PON1) AND OXIDATIVE STATUS, PHARMACOL REP, 61, PP. 892-898, (2009); MEAGHER E.A., BARRY O.P., LAWSON J.A., ROKACH J., FITZGERALD G.A., EFFECTS OF VITAMIN E ON LIPID PEROXIDATION IN HEALTHY PERSONS, JAMA, 285, PP. 1178-1182, (2001)","S.L. PELTIER; LABORATOIRE LESCUYER, DEPARTMENT OF RESEARCH ZAC BELLE-AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE; EMAIL: SEBASTIEN.PELTIER@LABORATOIRE-LESCUYER.COM","","ENGLISH","EUR. J. NUTR.","ARTICLE","ISI","2-S2.0-84878714194","EUR J NUTR","LABORATOIRE LESCUYER;OBESITY AND THROMBOTIC RISK HEALTH CAMPUS LA TIMONE;CENTRE TECHNIQUE DE CONSERVATION DES PRODUITS AGRICOLES (CTCPA);OBESITY AND THROMBOTIC RISK HEALTH CAMPUS LA TIMONE;CENTRE D'INVESTIGATION CLINIQUE (CIC);OBESITY AND THROMBOTIC RISK HEALTH CAMPUS LA TIMONE;CENTRE D'INVESTIGATION CLINIQUE (CIC);LABORATOIRE LESCUYER;LABORATOIRE LESCUYER;LABORATOIRE LESCUYER","NOTREPORTED;LABORATOIRE LESCUYER;EMAIL: SEBASTIEN.PELTIER@LABORATOIRE-LESCUYER.COM",NA,"OGIER N, 2013, EUR J NUTR","OGIER N, 2013, EUR J NUTR"
"PAN'KIV V","PAN'KIV, V.I. (6603629203)","NEW POSSIBILITIES OF CORRECTION OF HYPERCHOLESTEROLEMIA IN PATIENTS WITH DIABETES MELLITUS",2014,"LIKARS'KA SPRAVA / MINISTERSTVO OKHORONY ZDOROV'IA UKRAÏNY","","11",1,"","","THIS ARTICLE PRESENTS SCIENTIFIC DATA TO PROVE EFFECT OF STATINS ON CARBOHYDRATE METABOLISM AND THE NEED TO OPTIMIZE HYPOLIPIDEMIC THERAPY IN PATIENTS WITH DIABETES. SYSTEMATIZED THE AVAILABLE SCIENTIFIC DATA ON THE MECHANISM OF ACTION, PARAMETERS OF HYPOLIPIDEMIC ACTIVITY AND THE POSSIBILITY OF USING POLICOSANOL. AUTHOR IS GIVING US HIS OWN CLINICAL EXPERIENCE WITH HERBAL DRUG FITOSTATIN (POLICOSANOL) IN PATIENTS WITH DIABETES BASED ON 6-MONTH FOLLOW-UP.","","CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; FATTY ALCOHOLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LOVASTATIN; PRAVASTATIN; PREGNANCY; SIMVASTATIN; TRIGLYCERIDES; ANTILIPEMIC AGENT; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLICOSANOL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; PATHOPHYSIOLOGY; PREGNANCY","","","","","","RUSSIAN","LIK. SPRAVA","REVIEW","ISI","2-S2.0-84929023700","LIK SPRAVA",NA,"NOTREPORTED",NA,"PAN'KIV VI, 2014, LIK SPRAVA","PAN'KIV VI, 2014, LIK SPRAVA"
"TRIMARCO V;CIMMINO C;SANTORO M;PAGNANO G;MANZI M;PIGLIA A;GIUDICE C;DE L N;IZZO R","TRIMARCO, VALENTINA (6602355473); CIMMINO, CLAUDIA SARA (36705618500); SANTORO, MARIO (57192204546); PAGNANO, GIANPIERO (55332406800); MANZI, MARIA VIRGINIA (55484916200); PIGLIA, ANNA (55364666000); GIUDICE, CATERINA ANNA (7003414425); DE LUCA, NICOLA (7006357146); IZZO, RAFFAELE (7004640234)","NUTRACEUTICALS FOR BLOOD PRESSURE CONTROL IN PATIENTS WITH HIGHNORMAL OR GRADE 1 HYPERTENSION",2012,"HIGH BLOOD PRESSURE AND CARDIOVASCULAR PREVENTION","19","5",28,"10.2165/11632160-000000000-00000","DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, 80131 NAPLES, VIA S. PANSINI 5, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, 80131 NAPLES, VIA S. PANSINI 5, ITALY, DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY","BACKGROUND: CURRENT HYPERTENSION MANAGEMENT GUIDELINES DO NOT RECOMMEND DRUG TREATMENT IN SUBJECTS WITH BLOOD PRESSURE (BP) IN THE HIGH-NORMAL RANGE DUE TO THE RISK OF SIDE EFFECTS OF THE CURRENTLY AVAILABLE ANTIHYPERTENSIVE AGENTS THAT OVERCOMES THE POSSIBLE BENEFIT. NUTRACEUTICALS ARE FREE FROM RELEVANT SIDE EFFECTS AND COULD BE A VALUABLE STRATEGY FOR THE TREATMENT OF THESE PATIENTS. AIM: THE OBJECTIVE OF THIS STUDY WAS TO COMPARE THE EFFICACY OF TWO NUTRACEUTICAL COMPOSITIONS GIVEN BY THE COMBINATION OF POLICOSANOL, RED YEAST RICE EXTRACT, BERBERINE, FOLIC ACID AND COENZYME Q10 WITH OR WITHOUT ORTHOSIPHON STAMINEUS IN LOWERING THE BP AND LIPID PROFILE. METHODS: THIRTY PATIENTS WITH GRADE 1 ESSENTIAL HYPERTENSION AND LOW CARDIOVASCULAR RISK WERE ANALYSED. AT THE END OF A RUN-IN PERIOD, PATIENTS WERE DIVIDED INTO TWO STUDY ARMS AND ASSIGNED TO RECEIVE THE NUTRACEUTICAL COMBINATION WITH AND WITHOUT ORTHOSIPHON STAMINEUS. ALL PARTICIPANTS UNDERWENT 24-HOUR AMBULATORY BP MONITORING AT THE END OF THE RUN-IN PERIOD AND OF THE 4-WEEK TREATMENT WITH EACH OF THE TWO DIFFERENT NUTRACEUTICAL COMBINATIONS. RESULTS: IN PATIENTS TREATED WITH ORTHOSIPHON STAMINEUS A SIGNIFICANT REDUCTION OF MEAN 24-HOUR SYSTOLIC AND DIASTOLIC BP LEVELS COMPARED WITH BASELINE VALUES WAS REGISTERED AND THE SMOOTHNESS INDEX CALCULATED FOR SYSTOLIC AND DIASTOLIC BP SHOWED A MORE RELIABLE AND HOMOGENEOUS EFFECT ON BP OVER 24 HOURS. IN CONTRAST, NUTRACEUTICAL TREATMENT WITHOUT ORTHOSIPHON STAMINEUS WAS NOT ASSOCIATED WITH A SIGNIFICANT REDUCTION OF BP. CONCLUSIONS: OUR RESULTS SHOW THAT THE ADDITION OF ORTHOSIPHON STAMINEUS TO THE COMBINATION OF NUTRACEUTICALS CONFERS AN ANTIHYPERTENSIVE EFFECT THAT ALLOWS A SURPRISINGLY EFFECTIVE 24-HOUR BP CONTROL IN HYPERTENSIVE PATIENTS. ADIS © 2012 SPRINGER INTERNATIONAL PUBLISHING AG. ALL RIGHTS RESERVED.","BLOOD PRESSURE CONTROL; NUTRACEUTICALS","ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AGENTS; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; ORTHOSIPHON; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UBIQUINONE; BERBERINE; FOLIC ACID; NUTRACEUTICAL; POLICOSANOL; UBIDECARENONE; XUEZHIKANG; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; ORTHOSIPHON STAMINEUS; PARALLEL DESIGN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE","","","MANCIA G., DE BACKER G., DOMINICZAK A., ET AL., 2007 GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: THE TASK FORCE FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION (ESH) AND OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC), J HYPERTENS, 25, 6, PP. 1105-1187, (2007); MANCIA G., LAURENT S., AGABITI-ROSEI E., ET AL., REAPPRAISAL OF EUROPEAN GUIDELINES ON HYPERTENSION MANAGEMENT: A EUROPEAN SOCIETY OF HYPERTENSION TASK FORCE DOCUMENT, J HYPERTENS, 27, 11, PP. 2121-2158, (2009); DEVEREUX R.B., DE SIMONE G., KOREN M.J., ET AL., LEFT VENTRICULAR MASS AS A PREDICTOR OF DEVELOPMENT OF HYPERTENSION, AM J HYPERTENS, 4, 11, (1991); IZZO R., DE SIMONE G., GIUDICE R., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, 7, PP. 1482-1487, (2010); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS: A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); TRIMARCO B., BENVENUTI C., CONTROLLED CLINICAL STUDY ON A NEW DIETARY SUPPLEMENT ACTIVE ON CHOLESTEROL AND TRIGLYCERIDES IN CV RISK AND METABOLIC SYNDROME CONTROL ABSTRACT NO. 950109, XV INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, (2009); ROZZA F., DE SIMONE G., IZZO R., ET AL., NUTRACEUTICALS FOR TREATMENT OF HIGH BLOOD PRESSURE VALUES IN PATIENTS WITH METABOLIC SYNDROME, HIGH BLOOD PRESS CARDIOVASC PREV, 16, 4, PP. 177-182, (2009); CHOBANIAN A.V., BAKRIS G.L., BLACK H.R., ET AL., SEVENTH REPORT OF THE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE, HYPERTENSION, 42, 6, PP. 1206-1252, (2003); PARATI G., OMBONI S., PALATINI P., ET AL., ITALIAN SOCIETY OF HYPERTENSION GUIDELINES FOR CONVENTIONAL AND AUTOMATED BLOOD PRESSURE MEASUREMENT IN THE OFFICE, AT HOME AND OVER 24 HOURS, HIGH BLOOD PRESS CARDIOVASC PREV, 15, 4, PP. 283-310, (2008); PARATI G., OMBONI S., RIZZONI D., ET AL., THE SMOOTHNESS INDEX: A NEW, REPRODUCIBLE AND CLINICALLY RELEVANT MEASURE OF THE HOMOGENEITY OF THE BLOOD PRESSURE REDUCTION WITH TREATMENT FOR HYPERTENSION, J HYPERTENS, 16, 11, PP. 1685-1691, (1998); LEWINGTON S., CLARKE R., QIZILBASH N., ET AL., AGE-SPECIFIC RELEVANCE OF USUAL BLOOD PRESSURE TO VASCULAR MORTALITY: A META-ANALYSIS OF INDIVIDUAL DATA FOR ONE MILLION ADULTS IN 61 PROSPECTIVE STUDIES, LANCET, 360, 9349, PP. 1903-1913, (2002); VERDECCHIA P., STAESSEN J.A., ANGELI F., ET AL., USUAL VERSUS TIGHT CONTROL OF SYSTOLIC BLOOD PRESSURE IN NON-DIABETIC PATIENTS WITH HYPERTENSION (CARDIO-SIS): AN OPEN-LABEL RANDOMISED TRIAL, LANCET, 374, 9689, PP. 525-533, (2009); GIANNATTASIO C., CATTANEO B.M., MANGONI A.A., ET AL., CARDIAC AND VASCULAR STRUCTURAL CHANGES IN NORMOTENSIVE SUBJECTS WITH PARENTAL HYPERTENSION, J HYPERTENS, 13, 2, PP. 259-264, (1995); ELMER P.J., OBARZANEK E., VOLLMER W.M., ET AL., EFFECTS OF COMPREHENSIVE LIFESTYLE MODIFICATION ON DIET, WEIGHT, PHYSICAL FITNESS, AND BLOOD PRESSURE CONTROL: 18-MONTH RESULTS OF A RANDOMIZED TRIAL, ANN INTERN MED, 144, 7, PP. 485-495, (2006); HOUSTON M.C., NUTRACEUTICALS, VITAMINS, ANTIOXIDANTS, AND MINERALS IN THE PREVENTION AND TREATMENT OF HYPERTENSION, PROG CARDIOVASC DIS, 47, 6, PP. 396-449, (2005); COOK N.R., CUTLER J.A., OBARZANEK E., ET AL., LONG TERM EFFECTS OF DIETARY SODIUM REDUCTION ON CARDIOVASCULAR DISEASE OUTCOMES: OBSERVATIONAL FOLLOW-UP OF THE TRIALS OF HYPERTENSION PREVENTION (TOHP), BMJ, 334, 7599, PP. 885-888, (2007); RIZZONI D., MUIESAN M.L., SALVETTI M., ET AL., THE SMOOTHNESS INDEX, BUT NOT THE TROUGH-TO-PEAK RATIO PREDICTS CHANGES IN CAROTID ARTERY WALL THICKNESS DURING ANTIHYPERTENSIVE TREATMENT, J HYPERTENS, 19, 4, PP. 703-711, (2001); PARATI G., BLOOD PRESSURE VARIABILITY: ITS MEASUREMENT AND SIGNIFICANCE IN HYPERTENSION, J HYPERTENS SUPPL, 23, 1, (2005); WIDMAN L., WESTER P.O., STEGMAYR B.K., ET AL., THE DOSE-DEPENDENT REDUCTION IN BLOOD PRESSURE THROUGH ADMINISTRATION OF MAGNESIUM: A DOUBLE BLIND PLACEBO CONTROLLED CROSS-OVER STUDY, AM J HYPERTENS, 6, 1, PP. 41-45, (1993); SIANI A., PAGANO E., IACONE R., ET AL., BLOOD PRESSURE AND METABOLIC CHANGES DURING DIETARY L-ARGININE SUPPLEMENTATION IN HUMANS, AM J HYPERTENS, 13, 5 PART 1, PP. 547-551, (2000); HE K., LIU K., DAVIGLUS M.L., ET AL., MAGNESIUM INTAKE AND INCIDENCE OF METABOLIC SYNDROME AMONG YOUNG ADULTS, CIRCULATION, 113, 13, PP. 1675-1682, (2006); DICKINSON H.O., NICOLSON D.J., CAMPBELL F., ET AL., MAGNESIUM SUPPLEMENTATION FOR THE MANAGEMENT OF ESSENTIAL HYPERTENSION IN ADULTS, COCHRANE DATABASE SYST REV, 3, (2006); STAMLER J., BROWN I.J., DAVIGLUS M.L., ET AL., GLUTAMIC ACID, THE MAIN DIETARY AMINO ACID, AND BLOOD PRESSURE: THE INTERMAP STUDY (INTERNATIONAL COLLABORATIVE STUDY OF MACRONUTRIENTS, MICRONUTRIENTS AND BLOOD PRESSURE), CIRCULATION, 120, 3, PP. 221-228, (2009)","N. DE LUCA; DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY HOSPITAL, 80131 NAPLES, VIA S. PANSINI 5, ITALY; EMAIL: NICOLA.DELUCA@UNINA.IT","","ENGLISH","HIGH BLOOD PRESS. CARDIOVASC. PREV.","ARTICLE","ISI","2-S2.0-84866620458","HIGH BLOOD PRESS CARDIOVASC PREV","FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY HOSPITAL;FEDERICO II UNIVERSITY","NOTREPORTED;FEDERICO II UNIVERSITY HOSPITAL;NOTREPORTED",NA,"TRIMARCO V, 2012, HIGH BLOOD PRESS CARDIOVASC PREV","TRIMARCO V, 2012, HIGH BLOOD PRESS CARDIOVASC PREV"
"KIM T;LEE K;BAEK S;CHOI J;HA S;LIM S;PARK S;YEO Y;PARK S;KIM J","KIM, TAE JIN (57202388112); LEE, KYOUNG BOK (56962992100); BAEK, SEUNG-A (56963292500); CHOI, JAEHYUK (55722494200); HA, SUN-HWA (7202501231); LIM, SUN-HYUNG (7404081419); PARK, SOO-YUN (45661697500); YEO, YUNSOO (15735489400); PARK, SANG UN (7501831941); KIM, JAE KWANG (56892616700)","DETERMINATION OF LIPOPHILIC METABOLITES FOR SPECIES DISCRIMINATION AND QUALITY ASSESSMENT OF NINE LEAFY VEGETABLES",2015,"JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY","58","9",26,"10.1007/s13765-015-0119-6","DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 406-772, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 406-772, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 406-772, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 406-772, SOUTH KOREA;GRADUATE SCHOOL OF BIOTECHNOLOGY, CROP BIOTECH INSTITUTE, KYUNG HEE UNIVERSITY, YOUNGIN, 446-701, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, WANJU-GUN, 565-851, JEOLLABUK-DO, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, WANJU-GUN, 565-851, JEOLLABUK-DO, SOUTH KOREA;NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, WANJU-GUN, 565-851, JEOLLABUK-DO, SOUTH KOREA;DEPARTMENT OF CROP SCIENCE, CHUNGNAM NATIONAL UNIVERSITY, DAEJEON, 305-764, SOUTH KOREA;DIVISION OF LIFE SCIENCES, COLLEGE OF LIFE SCIENCES AND BIOENGINEERING, INCHEON NATIONAL UNIVERSITY, INCHEON, 406-772, SOUTH KOREA","THE LIPOPHILIC COMPOUNDS IN NINE VEGETABLES CONSUMED IN KOREA WERE CHARACTERIZED FOR DIVERSITY IN PHYTOCHEMICAL CONTENT. WE ALSO ANALYZED THE RELATIONSHIPS AMONG THESE COMPOUNDS IN TERMS OF THEIR CONTENTS. THE PROFILES OF 18 LIPOPHILIC COMPOUNDS IN THE LEAVES WERE SUBJECTED TO DATA-MINING PROCESSES, INCLUDING PRINCIPAL COMPONENT ANALYSIS (PCA), PEARSON’S CORRELATION ANALYSIS, HIERARCHICAL CLUSTERING ANALYSIS (HCA), AND PARTIAL LEAST SQUARES DISCRIMINANT ANALYSIS (PLS-DA). THESE SPECIES COULD BE DISTINGUISHED BY MEANS OF THE PCA RESULTS. HCA OF THESE PHYTOCHEMICALS RESULTED IN CLUSTERS DERIVED FROM CLOSELY RELATED BIOCHEMICAL PATHWAYS. PLS-DA SHOWED SIGNIFICANT SEPARATION AMONG EXTRACTS FROM THE FOLLOWING FOUR FAMILIES: AMARANTHACEAE, ASTERACEAE, BRASSICACEAE, AND MALVACEAE. THE MAJOR METABOLITES THAT FACILITATED DIFFERENTIATION IN THE PLS-DA MODEL WERE CAMPESTEROL, Β-SITOSTEROL, Β-AMYRIN, STIGMASTEROL, CHOLESTEROL, OCTACOSANOL (C28), Α-AMYRIN, AND HEXACOSANOL (C26). CHARD CONTAINED HIGH LEVELS OF TRIACONTANOL (C30), WHICH WAS POSITIVELY CORRELATED WITH THE C28 CONTENT (R = 0.746, P < 0.0001). STIGMASTEROL, Α-AMYRIN, AND Β-AMYRIN CONTENTS WERE HIGHER IN ASTERACEAE SPECIES INCLUDING CHICON, LETTUCE, AND OAK THAN OTHER PLANT FAMILIES. THESE RESULTS DEMONSTRATE THE UTILITY OF METABOLIC PROFILING, COMBINED WITH MULTIVARIATE ANALYSIS, FOR DISCRIMINATION OF VEGETABLE SPECIES AS WELL AS EVALUATION OF FOOD QUALITY. © 2015, THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY.","MULTIVARIATE ANALYSIS; PHYTOSTEROL; POLICOSANOL; TOCOPHEROL; VEGETABLE","","","","ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, PP. 5359-5362, (2006); AGREN J.J., TVRZICKA E., NENONEN M.T., HELVE T., HANNINEN O., DIVERGENT CHANGES IN SERUM STEROLS DURING A STRICT UNCOOKED VEGAN DIET IN PATIENTS WITH RHEUMATOID ARTHRITIS, BR J NUTR, 85, PP. 137-139, (2001); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); BAI S., EFFECTS OF OCTACOSANOL IN FOOD PHYSIOLOGICAL PARAMETERS IN TAIL-SUSPENDED RATS, SPACE MED MED ENG, 10, PP. 450-452, (1997); ERIKSSON L., JOHANSSON E., KETTANEH-WOLD N., WOLD S., MULTI- AND MEGAVARIATE DATA ANALYSIS PRINCIPLES AND APPLICATIONS, (2001); GOODACRE R., ROBERTS L., ELLIS D.I., THOROGOOD D., READER S.M., OUGHAM H., KING I., FROM PHENOTYPE TO GENOTYPE: WHOLE TISSUE PROFILING FOR PLANT BREEDING, METABOLOMICS, 3, PP. 489-501, (2007); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HAFFNER S.M., CLINICAL RELEVANCE OF THE OXIDATIVE STRESS CONCEPT, METABOLISM, 49, PP. 30-34, (2000); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEM, 81, PP. 345-349, (2004); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); KIM H.E., CHOI Y.H., CHOI K.H., PARK J.S., KIM H.S., JEON J.H., HEU M.S., SHIN D.S., LEE J.H., METABOLIC CLASSIFICATION OF HERB PLANTS BY NMR-BASED METABOLOMICS, J KOREAN MAGN RESON SOC, 16, PP. 91-102, (2012); KIM J.K., HA S.H., PARK S.Y., LEE S.M., KIM H.J., LIM S.H., SUH S.C., KIM D.H., CHO H.S., DETERMINATION OF LIPOPHILIC COMPOUNDS IN GENETICALLY MODIFIED RICE USING GAS CHROMATOGRAPHY TIME-OF-FLIGHT-MASS SPECTROMETRY, J FOOD COMPOS ANAL, 25, PP. 31-38, (2012); KIM J.K., PARK S.Y., JUNG J.Y., HA S.H., LIM S.H., LEE S.M., WOO H.J., PARK S.U., SUH S.C., THE POLICOSANOL CONTENT AND COMPOSITION OF KOREAN RICE (ORYZA SATIVA L.) CULTIVARS, CEREAL CHEM, 89, PP. 151-154, (2012); KIM J.K., PARK S.Y., NA J.K., SEONG E.S., YU C.Y., METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA (PERILLA FRUTESCENS) CULTIVARS, J AGRIC FOOD CHEM, 60, PP. 2257-2263, (2012); KIM Y.B., PARK S.Y., THWE A.A., SEO J.M., SUZUKI T., KIM S.J., KIM J.K., PARK S.U., METABOLOMIC ANALYSIS AND DIFFERENTIAL EXPRESSION OF ANTHOCYANIN BIOSYNTHETIC GENES IN WHITE- AND RED-FLOWERED BUCKWHEAT CULTIVARS (FAGOPYRUM ESCULENTUM), J AGRIC FOOD CHEM, 61, PP. 10525-10533, (2013); LECHNER M., REITER B., LORBEER E., DETERMINATION OF TOCOPHEROLS AND STEROLS IN VEGETABLE OILS BY SOLID-PHASE EXTRACTION AND SUBSEQUENT CAPILLARY GAS CHROMATOGRAPHIC ANALYSIS, J CHROMATOGR A, 857, PP. 231-238, (1999); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); PAN O., DAI Y., NURINGTYAS T.R., RIANIKA R.M., SCHULTE A.E., VERPOORTE R., CHOI Y.H., INVESTIGATION OF THE CHEMOMARKERS CORRELATED WITH FLOWER COLOR IN DIFFERENT ORGANS OF CATHARANTHUS ROSEUS USING NMR-BASED METABOLOMICS, PHYTOCHEM, 25, PP. 66-74, (2012); PARK S.Y., CHOI S.R., LIM S.H., YEO Y., KWEON S.J., BAE Y.S., KIM K.W., IM K.H., AHN S.K., HA S.H., PARK S.U., KIM J.K., IDENTIFICATION AND QUANTIFICATION OF CAROTENOIDS IN PAPRIKA FRUITS AND CABBAGE, KALE, AND LETTUCE LEAVES, J KOREAN SOC APPL BIOL CHEM, 57, PP. 355-358, (2014); PIIRONEN V., LINDSAY D.G., MIETTINEN T.A., TOIVO J., LAMPI A.M., PLANT STEROLS: BIOSYNTHESIS, BIOLOGICAL FUNCTION AND THEIR IMPORTANCE TO HUMAN NUTRITION, J AGRIC FOOD CHEM, 80, PP. 939-966, (2000); PONGSUWAN W., FUKUSAKI E., BAMBA T., YONETANI T., YAMAHARA T., KOBAYASHI A., PREDICTION OF JAPANESE GREEN TEA RANKING BY GAS CHROMATOGRAPHY/MASS SPECTROMETRY-BASED HYDROPHILIC METABOLITE FINGERPRINTING, J AGRIC FOOD CHEM, 55, PP. 231-236, (2007); RUSAK D.A., BROWN L.M., MARTIN S.D., CLASSIFICATION OF VEGETABLE OILS BY PRINCIPAL COMPONENT ANALYSIS OF FTIR SPECTRA, J CHEM EDUC, 80, PP. 541-543, (2003); SCHUMMER C., DELHOMME O., APPENZELLER B.M.R., WENNIG R., MILLET M., COMPARISON OF MTBSTFA AND BSTFA IN DERIVATIZATION REACTIONS OF POLAR COMPOUNDS PRIOR TO GC/MS ANALYSIS, TALANTA, 77, PP. 1473-1482, (2009); SHEPHERD T., DOBSON G., VERRALL S.R., CONNER S., GRIFFITHS D.W., MCNICOL J.W., DAVIES H.V., STEWART D., POTATO METABOLOMICS BY GC–MS: WHAT ARE THE LIMITING FACTORS?, METABOLOMICS, 3, PP. 475-488, (2007); STEUER R., KURTHS J., FIEHN O., WECKWERTH W., INTERPRETING CORRELATIONS IN METABOLOMIC NETWORKS, BIOCHEM SOC TRANS, 31, PP. 1476-1478, (2003); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); VAN PELT C.K., HAGGARTY P., BRENNA T., QUANTITATIVE SUBFEMTOMOLE ANALYSIS OF Α-TOCOPHEROL AND DEUTERATED ISOTOPOMERS IN PLASMA USING TABLETOP GC/MS/MS, J AGRIC FOOD CHEM, 70, PP. 4369-4375, (1998)","","KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY","ENGLISH","J. KOREAN SOC. APPL. BIOL. CHEM.","ARTICLE","ISI","2-S2.0-84947245568","J KOREAN SOC APPL BIOL CHEM",NA,"NOTREPORTED",NA,"KIM TJ, 2015, J KOREAN SOC APPL BIOL CHEM","KIM TJ, 2015, J KOREAN SOC APPL BIOL CHEM"
"JUNG D;YOON S;JUNG M","JUNG, DONG MIN (48461336000); YOON, SUK HOO (57024282100); JUNG, MUN YHUNG (35336963900)","CHEMICAL PROPERTIES AND OXIDATIVE STABILITY OF PERILLA OILS OBTAINED FROM ROASTED PERILLA SEEDS AS AFFECTED BY EXTRACTION METHODS",2012,"JOURNAL OF FOOD SCIENCE","77","6",30,"10.1111/j.1750-3841.2012.02965.x","WANJU-KUN, JEONBUK PROVINCE 565-701, SAMREA-UP, SOUTH KOREA;BUNDANG-KU, KYONGGI-DO, SOUTH KOREA;WANJU-KUN, JEONBUK PROVINCE 565-701, SAMREA-UP, SOUTH KOREA","THE CHEMICAL PROPERTIES AND OXIDATIVE STABILITY OF PERILLA OILS OBTAINED FROM ROASTED PERILLA SEEDS AS AFFECTED BY EXTRACTION METHODS (SUPERCRITICAL CARBON DIOXIDE [SC-CO2], MECHANICAL PRESS, AND SOLVENT EXTRACTION) WERE STUDIED. THE SC-CO2 EXTRACTION AT 420 BAR AND 50 °C AND HEXANE EXTRACTION SHOWED SIGNIFICANTLY HIGHER OIL YIELD THAN MECHANICAL PRESS EXTRACTION (P < 0.05). THE FATTY ACID COMPOSITIONS IN THE OILS WERE VIRTUALLY IDENTICAL REGARDLESS OF THE EXTRACTION METHODS. THE CONTENTS OF TOCOPHEROL, STEROL, POLICOSANOL, AND PHOSPHORUS IN THE PERILLA OILS GREATLY VARIED WITH THE EXTRACTION METHODS. THE SC-CO2-EXTRACTED PERILLA OILS CONTAINED SIGNIFICANTLY HIGHER CONTENTS OF TOCOPHEROLS, STEROLS, AND POLICOSANOLS THAN THE MECHANICAL PRESS-EXTRACTED AND HEXANE-EXTRACTED OILS (P < 0.05). THE SC-CO2-EXTRACTED OIL SHOWED THE GREATLY LOWER OXIDATIVE STABILITY THAN PRESS-EXTRACTED AND HEXANE-EXTRACTED OILS DURING THE STORAGE IN THE OVEN UNDER DARK AT 60 °C. HOWEVER, THE PHOTOOXIDATIVE STABILITIES OF THE OILS WERE NOT CONSIDERABLY DIFFERENT WITH EXTRACTION METHODS. © 2012 INSTITUTE OF FOOD TECHNOLOGISTS®.","CHEMICAL PROPERTIES; EXTRACTION METHODS; OXIDATIVE STABILITY; PERILLA OIL","ALPHA-LINOLENIC ACID; CHROMATOGRAPHY, GAS; FATTY ALCOHOLS; HEXANES; MASS SPECTROMETRY; OXIDATION-REDUCTION; PERILLA; PHOSPHORUS; PLANT OILS; SEEDS; STEROLS; TOCOPHEROLS; PERILLA; FATTY ALCOHOL; HEXANE; LINOLENIC ACID; N-HEXANE; PERILLA SEED OIL; PHOSPHORUS; POLICOSANOL; STEROL; TOCOPHEROL; VEGETABLE OIL; ARTICLE; CHEMISTRY; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; OXIDATION REDUCTION REACTION; PERILLA; PLANT SEED","","","OFFICIAL METHOD AND RECOMMENDED PRACTICE OF THE AMERICAN OIL CHEMISTS' SOCIETY, (1990); CALVO L., COCERO M.J., DIEZ J.M., OXIDATIVE STABILITY OF SUNFLOWER OIL EXTRACTED WITH SUPERCRITICAL CARBON DIOXIDE, J AM OIL CHEM SOC, 71, PP. 1251-1254, (1994); CARDENIA V., WARAHO T., RODRIGUEZ-ESTRADA M.T., MCCLEMENTS D.J., DECKER E.A., ANTIOXIDANT AND PROOXIDANT ACTIVITY BEHAVIOR OF PHOSPHOLIPIDS IN STRIPPED SOYBEAN OIL-IN-WATER EMULSIONS, J AM OIL CHEM SOC, 88, PP. 1409-1416, (2011); CARPENTER A.P., DETERMINATION OF TOCOPHEROLS IN VEGETABLE OILS, J AM OIL CHEM SOC, 56, PP. 668-671, (1979); CROWE T.D., WHITE P.J., OXIDATIVE STABILITY OF WALNUT OILS EXTRACTED WITH SUPERCRITICAL CARBON DIOXIDE, J AM OIL CHEM SOC, 80, PP. 575-578, (2003); EISENMENGER M., DUNFORD N.T., BIOACTIVE COMPONENTS OF COMMERCIAL AND SUPERCRITICAL CARBON DIOXIDE PROCESSED WHEAT GERM OIL, J AM OIL CHEM SOC, 85, PP. 55-61, (2008); EZAKI O., TAKAHASHI M., SHIGEMATSU T., SHIMAMURA K., KIMURA J., EZAKI H., GOTOH T., LONG-TERM EFFECTS OF DIETARY ALPHA-LINOLENIC ACID FROM PERILLA OIL ON SERUM FATTY ACIDS COMPOSITION AND ON THE RISK FACTORS OF CORONARY HEART DISEASE IN JAPANESE ELDERLY SUBJECTS, J NUTR SCI VITAMINOL, 45, PP. 759-772, (1999); JUNG M.Y., BOCK J.Y., BACK S.O., LEE J.H., LEE T.K., EFFECTS OF ROASTING ON THE PYRAZINE CONTENTS AND OXIDATIVE STABILITY OF RED PEPPER SEED OIL PRIOR TO EXTRACTION, J AGRIC FOOD CHEM., 47, PP. 1700-1704, (1999); JUNG M.Y., CHOI N.J., OH C.H., SHIN H.K., YOON S.H., SELECTIVELY HYDROGENATED SOYBEAN OIL EXERTS STRONG ANTI-PROSTATE CANCER ACTIVITY, LIPIDS, 46, PP. 287-295, (2011); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J FOOD SCI, 76, (2011); KIM I.H., KIM M.H., KIM Y.E., LEE C.Y., OXIDATIVE STABILITY AND EXTRACTION OF PERILLA SEED OIL WITH SUPERCRITICAL CARBON DIOXIDE. FOOD SCI, BIOTECH., 7, PP. 177-180, (1998); KIM S.G., LEE W.Y., YEO S.D., CHOI Y.H., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF PERILLA SEED OIL, FOOD SCI BIOTECHNOL, 5, PP. 300-304, (1996); KING R.E., MIN D.B., MIN S.C., STUDY OF Α,Γ,Δ-TOCOPHEROLS IN THE OXIDATIVE STABILITY OF LARD, FOOD SCI BIOTECHNOL, 20, PP. 817-822, (2011); MARTINEZ M.L., MATTEA M.A., MAESTRI D.M., PRESSING AND SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF WALNUT OIL, J FOOD ENGR, 88, PP. 399-403, (2008); MITRA K., LEE J.H., LEE K.T., KIM S.I., PRODUCTION TACTIC AND PHYSIOCHEMICAL PROPERTIES OF LOW Ω6/Ω3 RATIO STRUCTURED LIPID SYNTHESISED FROM PERILLA AND SOYBEAN OIL, INT J FOOD SCI TECHNOL, 45, 7, PP. 1321-1329, (2010); OKUYAMA H., YAMADA K., MIYAZAWA D., YASUI Y., OHARA N., DIETARY LIPIDS IMPACTS ON HEALTHY AGEING, LIPIDS, 42, PP. 821-825, (2007); OLIVEIRA R., RODRIGUEZ M.F., BERNARDO-GIL M.A., CHARACTERIZATION AND SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF WALNUT OIL, J AM OIL CHEM SOC, 79, PP. 225-230, (2002); TOMPKINS C., PERKINS E.G., THE EVALUATION OF FRYING OILS WITH THE P-ANISIDINE VALUE, J AM OIL CHEM SOC, 76, PP. 945-947, (1999); WATANABE N., KIMURA F., KOJIMA F., ENDO Y., FUJIMOTO K., KIKUCHI Y., EFFECT OF STEROLS IN DIETARY FATS ON WHOLE BLOOD VISCOSITY OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS (SHRSP), J OLEO SCI, 54, PP. 1-6, (2005); WATANABE S., SAKAI N., YASUI Y., KIMURA Y., KOBAYASHI T., MIZUTANI T., OKUYAMA H., A HIGH ALPHA-LINOLENATE DIET SUPPRESSES ANTIGEN-INDUCED IMMUNOGLOBULIN E RESPONSE AND ANAPHYLACTIC SHOCK IN MICE, J NUTR, 124, PP. 1566-1573, (1994); WANG S., HWANG H., YOON S.H., CHOE E., TEMPERATURE DEPENDENCE OF AUTOXIDATION OF PERILLA OIL AND TOCOPHEROL DEGRADATION, J FOOD SCI, 75, PP. 498-505, (2010); XU Z., GODBER J.S., COMPARISON OF SUPERCRITICAL FLUID AND SOLVENT EXTRACTION METHODS IN EXTRACTING G-ORYZANOL FROM RICE BRAN, J AM OIL CHEM SOC, 77, PP. 547-551, (2000); YAMAMOTO N., SAITOH M., MORIUCHI A., NOMURA M., OKUYAMA H., EFFECT OF DIETARY ALPHA-LINOLENATE/LINOLEATE BALANCE ON BRAIN LIPID COMPOSITIONS AND LEARNING ABILITY OF RATS, J LIPID RES, 28, PP. 144-151, (1987)","M.Y. JUNG; KOREA FOOD RESEARCH INST., BUNDANG-KU, KYONGGI-DO, SOUTH KOREA; EMAIL: MUNJUNG@WOOSUK.AC.KR","","ENGLISH","J. FOOD. SCI.","ARTICLE","ISI","2-S2.0-84871223905","J FOOD SCI","NOTREPORTED","NOTREPORTED;KOREA FOOD RESEARCH INST.;NOTREPORTED",NA,"JUNG DM, 2012, J FOOD SCI","JUNG DM, 2012, J FOOD SCI"
"ABDALLAH I;TLILI N;MARTINEZ-FORCE E;RUBIO A;PEREZ-CAMINO M;ALBOUCHI A;BOUKHCHINA S","ABDALLAH, IKRAM BOU (56000656100); TLILI, NIZAR (55953950900); MARTINEZ-FORCE, ENRIQUE (6602077828); RUBIO, ANA GRACIA PÉREZ (56412445000); PEREZ-CAMINO, MARIA CARMEN (6603929113); ALBOUCHI, ALI (6507054148); BOUKHCHINA, SADOK (6507257738)","CONTENT OF CAROTENOIDS TOCOPHEROLS STEROLS TRITERPENIC AND ALIPHATIC ALCOHOLS AND VOLATILE COMPOUNDS IN SIX WALNUTS JUGLANS REGIA L VARIETIES",2015,"FOOD CHEMISTRY","173","6",152,"10.1016/j.foodchem.2014.10.095","LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, UNIVERSITÉ DE TUNIS EL MANAR, TUNIS, 2092, TUNISIA;LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, UNIVERSITÉ DE TUNIS EL MANAR, TUNIS, 2092, TUNISIA;INSTITUTO DE LA GRASA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), SEVILLA, 41012, SPAIN;INSTITUTO DE LA GRASA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), SEVILLA, 41012, SPAIN;INSTITUTO DE LA GRASA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), SEVILLA, 41012, SPAIN;INSTITUT NATIONAL DE RECHERCHES EN GÉNIE RURAL, EAUX ET FORÊTS (INRGREF), TUNIS, TUNISIA;LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, UNIVERSITÉ DE TUNIS EL MANAR, TUNIS, 2092, TUNISIA","THE AIM OF THIS WORK WAS TO STUDY THE CONTENT OF TOCOPHEROLS, STEROLS, TRITERPENIC AND ALIPHATIC ALCOHOLS, CAROTENOIDS, AND VOLATILE COMPOUNDS IN THE KERNEL OILS FROM SIX WALNUT (JUGLANS REGIA L.) VARIETIES. THE LEVELS OF Β-CAROTENE RANGED BETWEEN 0.22 AND 0.62 MG/KG, FOLLOWED BY LUTEIN (0.01-0.06 MG/KG). THE TOTAL CONTENT OF TOCOPHEROL RANGED FROM 186.5 TO 436.2 MG/KG OF THE EXTRACTED OIL AND THE MAJOR ISOFORM IN ALL SAMPLES WAS Γ-TOCOPHEROL. THE MOST ABUNDANT PHYTOSTEROL WAS Β-SITOSTEROL (974-1494 MG/KG) FOLLOWED BY CAMPESTEROL THEN Δ-5-AVENASTEROL. THE MAJOR TRITERPENIC ALCOHOL WAS CYCLOARTENOL (226.4-532.1 MG/KG). HEXACOSANOL (9.71-28.15 MG/KG) WAS THE MAJOR ALIPHATIC ALCOHOL. THE DETECTED VOLATILE COMPOUNDS WERE PENTANAL, HEXANAL, NONANAL, 2-DECENAL AND HEXANOL. THE STATISTICAL ANALYSIS SHOWED SIGNIFICANT DIFFERENCES BETWEEN VARIETIES, WHICH ARE PROBABLY DUE TO GENETIC FACTORS. © 2014 ELSEVIER LTD. ALL RIGHTS RESERVED.","CAROTENOIDS; JUGLANS REGIA L.; PHYTOSTEROL; TOCOPHEROL; TRITERPENIC AND ALIPHATIC ALCOHOLS; VOLATILE COMPOUNDS","BETA CAROTENE; CAROTENOIDS; JUGLANS; STEROLS; TOCOPHEROLS; VITAMIN E; VOLATILE ORGANIC COMPOUNDS; ALCOHOLS; LIPIDS; OIL SHALE; PIGMENTS; ALKANOL; BETA CAROTENE; CAMPESTANOL; CAMPESTEROL; CAROTENOID; CYCLOARTENOL; GAMMA TOCOPHEROL; HEXACOSANOL; HEXANAL; LIPID; PHYTOSTEROL; PIGMENT; POLICOSANOL; SITOSTANOL; SITOSTEROL; STEROL; TOCOPHEROL; TRITERPENE DERIVATIVE; VEGETABLE OIL; VOLATILE AGENT; XANTHOPHYLL; ALPHA TOCOPHEROL; BETA CAROTENE; CAROTENOID; STEROL; TOCOPHEROL; VOLATILE ORGANIC COMPOUND; ALIPHATIC ALCOHOL; CAROTENOIDS; JUGLANS REGIA L; PHYTOSTEROL; TOCOPHEROL; VOLATILE COMPOUNDS; ARTICLE; EXTRACTION; FLAVOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JUGLANS REGIA; PLANTING DENSITY; STEROL ANALYSIS; VARIETAS; CHEMISTRY; WALNUT; VOLATILE ORGANIC COMPOUNDS","MINISTRY OF HIGHER EDUCATION AND SCIENTIFIC RESEARCH, MHE&SR","THIS WORK HAS BEEN DONE AS A PART OF A NATIONAL RESEARCH PROJECT. WE THANK THE MINISTRY OF HIGHER EDUCATION AND SCIENTIFIC RESEARCH OF TUNISIA FOR FINANCIALLY SUPPORTING THIS INVESTIGATION. WE THANK ALSO DR. MOUNAWER BADRI FOR HIS CONSTRUCTIVE ADVICES. PART OF THIS WORK WAS CARRIED OUT AT “INSTITUTO DE LA GRASA”, CONSEJO SUPERIOR DE INVESTIGACIÓNES CIENTÍFICAS (CSIC), 41012 SEVILLA, SPAIN.  ","ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 5359-5362, (2006); AGER D.J., SCHROEDER S.A., STABILIZATION OF CAROTENOID COLORANTS AND USES IN LOW-FAT FOOD SYSTEMS, SCIENCE FOR THE FOOD INDUSTRY OF THE 21ST CENTURY, (1993); AKIHISA T., YASUKAWA K., YAMAURA M., UKIYA M., KIMURA Y., SHIMIZU N., ET AL., TRITERPENE ALCOHOL AND STEROL FERULATES FROM RICE BRAN AND THEIR ANTI-INFLAMMATORY EFFECTS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 48, PP. 2313-2319, (2000); ALTISENT R., ECHEVERRIA G., LARA I., LOPEZ M.L., GRAELL J., SHELF-LIFE OF 'GOLDEN REINDERS' APPLES AFTER ULTRA LOW OXYGEN STORAGE: EFFECT ON AROMA VOLATILE COMPOUNDS, STANDARD QUALITY, SENSORY ATTRIBUTES AND ACCEPTABILITY, FOOD SCIENCE AND TECHNOLOGY INTERNATIONAL, 15, PP. 481-493, (2009); ANGEROSA F., BASTI C., OLIVE OIL VOLATILE COMPOUNDS FROM THE LIPOXYGENASE PATHWAY IN RELATION TO FRUIT RIPENESS, ITALIAN JOURNAL OF FOOD SCIENCE, 13, 4, PP. 421-428, (2001); AZADMARD-DAMIRCHI S., DUTTA P.C., NOVEL SOLID-PHASE EXTRACTION METHOD TO SEPARATE 4-DESMETHYL-, 4-MONOMETHYL-, AND 4,4-DIMETHYLSTEROLS IN VEGETABLE OILS, JOURNAL OF CHROMATOGRAPHY A, 1108, PP. 183-187, (2006); BANEL D.K., HU F.B., EFFECTS OF WALNUT CONSUMPTION ON BLOOD LIPIDS AND OTHER CARDIOVASCULAR RISK FACTORS: A META-ANALYSIS AND SYSTEMATIC REVIEW, AMERICAN JOURNAL OF CLINICAL NUTRITION, 90, PP. 56-63, (2009); BOUABDALLAH I., BOUALI I., MARTINEZ-FORCE E., ALBOUCHI A., PEREZ CAMINO M.C., BOUKHCHINA S., COMPOSITION OF FATTY ACIDS, TRIACYLGLYCEROLS AND POLAR COMPOUNDS OF DIFFERENT WALNUT VARIETIES (JUGLANS REGIA L.) FROM TUNISIA, NATURAL PRODUCT RESEARCH, 28, PP. 1826-1833, (2014); CALPE-BERDIEL L., ESCOL-GIL J.C., BLANCO-VACA F., NEW INSIGHTS INTO THE MOLECULAR ACTIONS OF PLANT STEROLS AND STANOLS IN CHOLESTEROL METABOLISM, ATHEROSCLEROSIS, 203, PP. 18-31, (2009); CARDELLO A.V., CONSUMER EXPECTATIONS AND THEIR ROLE IN FOOD ACCEPTANCE, MEASUREMENT OF FOOD PREFERENCES, (1994); CHOE E.D., MIN B., CHEMISTRY AND REACTIONS OF REACTIVE OXYGEN SPECIES IN FOODS, JOURNAL OF FOOD SCIENCE, 70, PP. 142-159, (2005); CRIADO M.N., COMPARATIVE STUDY OF THE EFFECT OF THE MATURATION PROCESS OF THE OLIVE FRUIT ON THE CHLOROPHYLL AND CAROTENOID FRACTIONS OF DRUPES AND VIRGIN OILS FROM ARBEQUINA AND FARGA CULTIVARS, FOOD CHEMISTRY, 100, PP. 748-755, (2007); DOGAN S.F., SAHIN S., SUMMU G., EFFECTS OF BATTERS CONTAINING DIFFERENT PROTEIN TYPES ON THE QUALITY OF DEEP-FAT-FRIED CHICKEN NUGGETS, EUROPEAN FOOD RESEARCH AND TECHNOLOGY, 220, PP. 502-508, (2005); FERNANDES P., CABRAL J.M.S., PHYTOSTEROLS: APPLICATIONS AND RECOVERY METHODS, BIORESOURCE TECHNOLOGY, 98, PP. 2335-2350, (2007); GHARIBZAHEDI S.M.T., MOUSAVI S.M., HAMEDI M., REZAEI K., KHODAIYAN F., EVALUATION OF PHYSICOCHEMICAL PROPERTIES AND ANTIOXIDANT ACTIVITIES OF PERSIAN WALNUT OIL OBTAINED BY SEVERAL EXTRACTION METHODS, INDUSTRIAL CROPS AND PRODUCTS, 45, PP. 133-140, (2013); GIMENO E., CALERO E., CASTELLOTE A.I., LAMUELA-RAVENTOS R.M., DE LA TORRE M.C., LOPEZ-SABATER M.C., SIMULTANEOUS DETERMINATION OF Α-TOCOPHEROL AND Β-CAROTENE IN OLIVE OIL BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, JOURNAL OF CHROMATOGRAPHY A, 881, PP. 255-259, (2000); GUTIERREZ F., ALBI M.A., PALMA R., RIOS J.J., OLI AS J.M., BITTER TASTE OF VIRGIN OLIVE OIL: CORRELATION OF SENSORY EVALUATION AND INSTRUMENTAL HPLC ANALYSIS, JOURNAL OF FOOD SCIENCE, 54, PP. 68-70, (1989); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITIONS OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEMISTRY, 81, PP. 345-349, (2004); IRMAK S., JONNALA R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES. LINES, THE JOURNAL OF CEREAL SCIENCE, 48, PP. 20-26, (2008); INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY (IUPAC), STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS AND DERIVATIVES, (1992); JACKSON M.A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYZED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, JOURNAL OF SUPERCRITICAL FLUIDS, 37, PP. 173-177, (2006); JIA M., KIM H.J., MIN D.B., EFFECTS OF SOYBEAN OIL AND OXIDIZED SOYBEAN OIL ON THE STABILITY OF Β-CAROTENE, FOOD CHEMISTRY, 103, PP. 695-700, (2007); JUDDE A., VILLENEUVE P., ROSSIGNOL-CASTERA A., LE GUILLOU A., ANTIOXIDANT EFFECT OF SOY LECITHINS ON VEGETABLE OIL STABILITY AND THEIR SYNERGISM WITH TOCOPHEROLS, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 80, PP. 1209-1215, (2003); KALUA C.M., ALLEN M.S., BEDGOOD D.R., BISHOP A.G., PRENZLER P.D., ROBARDS K., OLIVE OIL VOLATILE COMPOUNDS, FLAVOUR DEVELOPMENT AND QUALITY: A CRITICAL REVIEW, FOOD CHEMISTRY, 100, PP. 273-286, (2007); KENDALL C.W.C., ESFAHANI A., JOSSE A.R., AUGUSTIN L.S.A., VIDGEN E., JENKINS D.J.A., THE GLYCEMIC EFFECT OF NUT-ENRICHED MEALS IN HEALTHY AND DIABETIC SUBJECTS. NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES, 21, PP. 34-39, (2011); KIRITSAKIS A.K., CHRISTIE W.W., ANALYSIS OF EDIBLE OILS, HANDBOOK OF OLIVE OIL, ANALYSIS AND PROPERTIES, PP. 129-158, (2000); KORNSTEINER M., KARL-HEINZ W., IBRAHIM E., TOCOPHEROLS AND PHENOLICS IN 10 DIFFERENT NUT TYPES, FOOD CHEMISTRY, 98, PP. 381-387, (2006); LI D., SALDEEN T., ROMEO F., MEHTA J.L., RELATIVE EFFECTS OF ALPHA- AND GAMMA-TOCOPHEROL ON LOW-DENSITY LIPOPROTEIN OXIDATION AND SUPEROXIDE DISMUTASE AND NITRIC OXIDE SYNTHASE ACTIVITY AND PROTEIN EXPRESSION IN RATS, THE JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 4, PP. 219-226, (1999); LI L., TSAO R., YANG R., KARMER J.K., HERNANDEZ M., FATTY ACID PROFILES, TOCOPHEROL CONTENTS, AND ANTIOXIDANT ACTIVITIES OF HEARTNUT (JUGLANS AILANTHIFOLIA VAR. CORDIFORMIS) AND PERSIAN WALNUT (JUGLANS REGIA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, PP. 1164-1169, (2007); LORENZO I.M., PAVON J.L., LAESPADA M.E., PINTO C.G., CORDERO B.M., HENRIQUES L.R., ET AL., APPLICATION OF HEADSPACE-MASS SPECTROMETRY FOR DIFFERENTIATING SOURCES OF OLIVE OIL, ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 374, PP. 1205-1211, (2002); MADAWALA S.R.P., KOCHHAR S.P., DUTTA P.C., LIPID COMPONENTS AND OXIDATIVE STATUS OF SELECTED SPECIALTY OILS, GRASAS Y ACEITES, 63, 2, PP. 143-151, (2012); MAESTRI D., MERILES J.M., GUZMAN C.A., CORRELATION OF MATURITY GROUPS WITH SEED COMPOSITION IN SOYBEANS, AS INFLUENCED BY GENOTYPIC VARIATION, GRSSAS Y ACEITES, 49, PP. 395-399, (1998); MARCOS L.I., PEREZ P.J.L., FERNANDEZ L.M.E., GARCIA P.C., MORENO C.B., DETECTION OF ADULTERANTS IN OLIVE OIL BY HEADSPACE-MASS SPECTROMETRY, JOURNAL OF CHROMATOGRAPHY A, 945, PP. 221-230, (2002); MARTINEZ M.L., LABUCKAS D.O., LAMARQUE A.L., MAESTRI D.M., WALNUT (JUGLANS REGIA L.): GENETIC RESOURCES, CHEMISTRY, BY-PRODUCTS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 12, PP. 1959-1967, (2010); MARTINEZ M.L., MATTEA M.A., MAESTRI D.M., PRESSING AND SUPER-CRITICAL CARBON DIOXIDE EXTRACTION OF WALNUT OIL, JOURNAL OF FOOD ENGINEERING, 88, PP. 399-404, (2008); MINGUEZ-MOSQUERA M.I., GARRIDO-FERNANDEZ J., CHLOROPHYLL AND CAROTENOID PRESENCE IN OLIVE FRUIT (OLEA EUROPAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 37, PP. 1-7, (1989); MIRALIAKBARI H., SHAHIDI F., ANTIOXIDANT ACTIVITY OF MINOR COMPONENTS OF TREE NUTS OIL, FOOD CHEMISTRY, 111, PP. 421-427, (2008); MISAWA N., PATHWAY ENGINEERING OF PLANTS TOWARD ASTAXANTHIN PRODUCTION, PLANT BIOTECHNOLOGY, 26, PP. 93-99, (2009); MORALES M.T., RIOS J.J., APARICIO R., CHANGES IN THE VOLATILE COMPOSITION OF VIRGIN OLIVE OIL DURING OXIDATION: FLAVORS AND OFF-FLAVORS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 45, PP. 2666-2673, (1997); MUKUDDEM-PETERSEN J., OOSTHUIZEN W., JERLING J.C., A SYSTEMATIC REVIEW OF THE EFFECTS OF NUTS ON BLOOD LIPID PROFILES IN HUMANS, JOURNAL OF NUTRITION, 135, PP. 2082-2089, (2005); NASRI N., FADY B., TRIKI S., QUANTIFICATION OF STEROLS AND ALIPHATIC ALCOHOLS IN MEDITERRANEAN STONE PINE (PINUS PINEA L.) POPULATIONS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, PP. 2251-2255, (2007); NIE L.C., SUN J.S., HUANG R.H., THE BIOSYNTHESIS AND AFFECTING FACTORS OF AROMA IN SOME FRUITS, CHINESE BULLETIN OF BOTANY, 21, PP. 631-637, (2004); NORMEN L., ELLEGARD L., JANSSEN H.G., STREENBERGEN H., TRAUTWEIN E., ANDERSSON H., PHYTOSTEROL AND PHYTOSTANOLS ESTERS ARE EFFECTIVELY HYDROLYSED IN THE GUT AND DO NOT AFFECT FAT DIGESTION IN ILEOSTOMY SUBJECTS, EUROPEAN JOURNAL OF NUTRITION, 45, PP. 165-170, (2006); PARK S.K., PAGE G.P., KIM K., ALLISON D.B., MEYDANI M., WEINDRUCH R., ET AL., ALPHA- AND GAMMA-TOCOPHEROL PREVENT AGE-RELATED TRANSCRIPTIONAL ALTERATIONS IN THE HEART AND BRAIN OF MICE, JOURNAL OF NUTRITION, 138, PP. 1010-1018, (2008); RABRENOVIC B., PICURIC-JOVANOVIC K., SOBAJIC S., PHYSICOCHEMICAL PROPERTIES AND FATTY ACID COMPOSITION OF JUGLANS REGIA CULTIVARS GROWN IN SERBIA, CHEMISTRY OF NATURAL COMPOUNDS, 44, PP. 151-154, (2008); REINERS J., GROSCH W., ODORANTS OF VIRGIN OLIVE OILS WITH DIFFERENT FLAVOR PROFILES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 2754-2763, (1998); RICHARDSON D.G., THE HEALTH BENEFIT OF EATING HAZELNUTS: IMPLICATIONS FOR BLOOD LIPID PROFILES, CORONARY HEART DISEASE AND CANCER RISKS, ACTA HORTICULTURAE, 445, PP. 295-300, (1996); SAKOUHI F., ABSALON C., SEBEI K., FOUQUET E., BOUKHCHINA S., KALLEL H., GAS CHROMATOGRAPHIC-MASS SPECTROMETRIC CHARACTERISATION OF TRITERPENE ALCOHOLS AND MONOMETHYLSTEROLS IN DEVELOPING OLEA EUROPAEA L. FRUITS, FOOD CHEMISTRY, 116, PP. 345-350, (2009); SCHWARTZ H., OLLILAINEN V., PIIRONEN V., LAMPI A.M., TOCOPHEROL, TOCOTRIENOL AND PLANT STEROL CONTENTS OF VEGETABLE OILS AND INDUSTRIAL FATS, JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 21, PP. 152-161, (2008); SERANI A., PIACENTI D., SISTEMA ANALITICO PER L'IDENTIFICAZIONE DI OLI DEODORATI IN OLI VERGINI DI OLIVA. NOTA 1- ANALISI DEI PIGMENTI CLOROFILLIANI IN OLI VERGINI DI OLIVE, RIVISTA ITALIANA DELLE SOSTANZE GRASSE, 78, PP. 459-463, (2001); TAY B.Y.P., CHOO Y.M., VALUABLE MINOR CONSTITUENTS OF COMMERCIAL RED PAL OLEIN: CAROTENOIDS, VITAMIN E, UBIQUINONE AND STEROLS, JOURNAL OF OIL PALM RESEARCH, 13, 2, PP. 14-24, (2000); THOMAS H., CHLOROPHYLL: A SYMPTOM AND A REGULATOR OF PLASTID DEVELOPMENT, NEW PHYTOLOGIST, 136, PP. 163-181, (1997); WAGNER K.H., ELMADFA I., EFFECTS OF TOCOPHEROLS AND THEIR MIXTURES ON THE OXIDATIVE STABILITY OF OLIVE OIL AND LINSEED OIL UNDER HEATING, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 102, PP. 624-629, (2000); WANAKHACHORNKRAI P., LERTSIRI S., COMPARISON OF DETERMINATION METHOD FOR VOLATILE COMPOUNDS IN THAI SOY SAUCE, FOOD CHEMISTRY, 83, PP. 619-629, (2003)","","ELSEVIER LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-84909998887","FOOD CHEM",NA,"NOTREPORTED",NA,"ABDALLAH IB, 2015, FOOD CHEM","ABDALLAH IB, 2015, FOOD CHEM"
"TRIMARCO V;IZZO R;STABILE E;ROZZA F;SANTORO M;MANZI M;SERINO F;GIACOMO S G;ESPOSITO G;TRIMARCO B","TRIMARCO, VALENTINA (6602355473); IZZO, RAFFAELE (7004640234); STABILE, EUGENIO (6701371251); ROZZA, FRANCESCO (23498918300); SANTORO, MARIO (57192204546); MANZI, MARIA VIRGINIA (55484916200); SERINO, FEDERICA (55253875200); GIACOMO SCHIATTARELLA, GABRIELE (16029615600); ESPOSITO, GIOVANNI (55482395100); TRIMARCO, BRUNO (57210773404)","EFFECTS OF A NEW COMBINATION OF NUTRACEUTICALS WITH MORUS ALBA ON LIPID PROFILE INSULIN SENSITIVITY AND ENDOTELIAL FUNCTION IN DYSLIPIDEMIC SUBJECTS A CROSSOVER RANDOMIZED DOUBLEBLIND TRIAL",2015,"HIGH BLOOD PRESSURE AND CARDIOVASCULAR PREVENTION","22","5",38,"10.1007/s40292-015-0087-2","DEPARTMENT OF NEUROSCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY, HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY;HYPERTENSION RESEARCH CENTER, FEDERICO II UNIVERSITY, NAPLES, ITALY, DEPARTMENT OF ADVANCED BIOMEDICAL SCIENCES, FEDERICO II UNIVERSITY, NAPLES, ITALY","INTRODUCTION: NUTRACEUTICALS (NUT) ARE FORMS OF COMPOUNDS WITH BIOLOGICAL ACTIVITY COMMONLY USED TO IMPROVE HEALTH IN DOSAGE LARGELY EXCEEDING THOSE OBTAINABLE IN FOOD. AIM: WE COMPARED, IN A DOUBLE BLIND RANDOMIZED CROSS-OVER TRIAL, THE EFFECTS OF TWO NUT COMBINATIONS ON THE CONTROL OF GLICO-LIPIDIC METABOLISM IN PATIENTS WITH HYPERCHOLESTEROLEMIA NOT ON STATINS. METHODS: AT STUDY START PATIENTS WERE GIVEN DIETARY COUNSELING AND RECEIVED PLACEBO FOR 2 WEEKS. AFTER THIS RUN-IN PERIOD, PATIENTS WERE RANDOMIZED: (1) COMBINATION A [POLICOSANOL, RED YEAST RICE (MONAKOLIN K 3 MG), BERBERINE 500 MG, ASTAXANTINE, FOLIC ACID AND COENZYME Q10] FOR 4 WEEKS FOLLOWED BY 4 WEEKS OF COMBINATION B [RED YEAST RICE (MONAKOLIN K 3.3 MG), BERBERINE 531.25 MG AND LEAF EXTRACT OF MORUS ALBA]; (2) COMBINATION B FOR 4 WEEKS FOLLOWED BY 4 WEEKS OF COMBINATION A. RESULTS: COMBINATION B REDUCED LDL CHOLESTEROL BELOW 130 MG/DL IN 56.5 % OF THE PATIENTS, AND CAMBINATION A ONLY IN 21.7 % OF THEM (P ≤ 0.027). BOTH TREATMENTS REDUCED PLASMA LEVELS OF TRIGLYCERIDES, TOTAL AND LDL CHOLESTEROL AND INCREASED HDL CHOLESTEROL (ALL P < 0.03). TOTAL AND LDL CHOLESTEROL REDUCTION WAS MORE PRONOUNCED IN PATIENTS TAKING COMBINATION B (P < 0.005). COMBINATION B REDUCED ALSO GLYCATED HEMOGLOBIN, FASTING GLUCOSE AND INSULIN PLASMA LEVELS AS WELL AS HOMA INDEX (P < 0.005). CONCLUSIONS: AN INCREASED CONTENT OF BERBERIN AND MONACOLIN K AND THE ADDITION OF MORUS ALBA EXTRACT IMPROVES THE EFFECT ON PLASMA CHOLESTEROL AND ON GLUCOSE METABOLISM OF THE NUT COMBINATION. THESE EFFECTS MAY ALLOW THE SPECULATION OF A MORE MARKED IMPROVEMENT IN CARDIOVASCULAR PROGNOSIS. © 2015, THE AUTHOR(S).","HYPERCHOLESTEROLEMIA; INSULIN SENSITIVITY; NUTRACEUTICALS","AGED; BERBERINE; BIOMARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ITALY; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; MORUS; PLANT EXTRACTS; PLANT LEAVES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; ASTAXANTINE PLUS BERBERINE PLUS COENZYME Q10 PLUS FOLIC ACID PLUS POLICOSANOL PLUS MONACOLIN K PLUS RED YEAST RICE; BERBERINE PLUS MONACOLIN K PLUS MORUS ALBA LEAF EXTRACT PLUS RED YEAST RICE POWDER; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULBERRY EXTRACT; NUTRACEUTICAL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BERBERINE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; MEVINOLIN; PLANT EXTRACT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MORUS ALBA; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; AGED; BLOOD; DIETARY SUPPLEMENT; DRUG EFFECTS; DYSLIPIDEMIAS; INSULIN RESISTANCE; ITALY; METABOLISM; MIDDLE AGED; MORUS; PATHOPHYSIOLOGY; PLANT LEAF; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION","","","REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J., 32, 14, PP. 1769-1818, (2011); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS., 28, 7, PP. 1482-1487, (2010); LIBBY P., THE FORGOTTEN MAJORITY: UNFINISHED BUSINESS IN CARDIOVASCULAR RISK REDUCTION, J AM COLL CARDIOL., 46, 7, PP. 1225-1228, (2005); KHAW K.T., WAREHAM N., BINGHAM S., LUBEN R., WELCH A., DAY N., ASSOCIATION OF HEMOGLOBIN A1C WITH CARDIOVASCULAR DISEASE AND MORTALITY IN ADULTS: THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER IN NORFOLK, ANN INTERN MED., 141, 6, PP. 413-420, (2004); GAST K.B., TJEERDEMA N., STIJNEN T., SMIT J.W., DEKKERS O.M., INSULIN RESISTANCE AND RISK OF INCIDENT CARDIOVASCULAR EVENTS IN ADULTS WITHOUT DIABETES: META-ANALYSIS, PLOS ONE., 7, 12, (2012); WANG Y., XIANG L., WANG C., TANG C., HE X., ANTIDIABETIC AND ANTIOXIDANT EFFECTS AND PHYTOCHEMICALS OF MULBERRY FRUIT (MORUS ALBA L.) POLYPHENOL ENHANCED EXTRACT, PLOS ONE., 8, 7, (2013); MANCIA G., FAGARD R., NARKIEWICZ K., REDON J., ZANCHETTI A., BOHM M., ET AL., 2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: THE TASK FORCE FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION (ESH) AND OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC), EUR HEART J., 34, 28, PP. 2159-2219, (2013); GARGIULO P., MARCIANO C., SAVARESE G., D'AMORE C., PAOLILLO S., ESPOSITO G., ET AL., ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH NORMAL CORONARY ARTERIES: A DIGITAL REACTIVE HYPEREMIA STUDY, INT J CARDIOL., 165, 1, PP. 67-71, (2013); JULIOUS S.A., SAMPLE SIZES FOR CLINICAL TRIALS WITH NORMAL DATA, STAT MED., 23, 12, PP. 1921-1986, (2004); MATTHEWS D.R., HOSKER J.P., RUDENSKI A.S., NAYLOR B.A., TREACHER D.F., TURNER R.C., HOMEOSTASIS MODEL ASSESSMENT: INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA GLUCOSE AND INSULIN CONCENTRATIONS IN MAN, DIABETOLOGIA., 28, 7, PP. 412-419, (1985); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, 9, PP. 656-661, (2010); YANG X., YANG L., ZHENG H., HYPOLIPIDEMIC AND ANTIOXIDANT EFFECTS OF MULBERRY (MORUS ALBA L.) FRUIT IN HYPERLIPIDAEMIA RATS, FOOD CHEM TOXICOL, 48, 8-9, PP. 2374-2379, (2010); NATHAN D.M., KUENEN J., BORG R., ZHENG H., SCHOENFELD D., HEINE R.J., ET AL., TRANSLATING THE A1C ASSAY INTO ESTIMATED AVERAGE GLUCOSE VALUES, DIABETES CARE., 31, 8, PP. 1473-1478, (2008); MARCIANO C., GALDERISI M., GARGIULO P., ACAMPA W., D'AMORE C., ESPOSITO R., ET AL., EFFECTS OF TYPE 2 DIABETES MELLITUS ON CORONARY MICROVASCULAR FUNCTION AND MYOCARDIAL PERFUSION IN PATIENTS WITHOUT OBSTRUCTIVE CORONARY ARTERY DISEASE, EUR J NUCL MED MOL IMAGING., 39, 7, PP. 1199-1206, (2012); DEROSA G., ROMANO D., D'ANGELO A., MAFFIOLI P., BERBERIS ARISTATA COMBINED WITH SILYBUM MARIANUM ON LIPID PROFILE IN PATIENTS NOT TOLERATING STATINS AT HIGH DOSES, ATHEROSCLEROSIS., 239, 1, PP. 87-92, (2015); DI PIERRO F., PUTIGNANO P., VILLANOVA N., MONTESI L., MOSCATIELLO S., MARCHESINI G., PRELIMINARY STUDY ABOUT THE POSSIBLE GLYCEMIC CLINICAL ADVANTAGE IN USING A FIXED COMBINATION OF BERBERIS ARISTATA AND SILYBUM MARIANUM STANDARDIZED EXTRACTS VERSUS ONLY BERBERIS ARISTATA IN PATIENTS WITH TYPE 2 DIABETES, CLIN PHARMACOL, 5, PP. 167-174, (2013)","","SPRINGER INTERNATIONAL PUBLISHING","ENGLISH","HIGH BLOOD PRESS. CARDIOVASC. PREV.","ARTICLE","ISI","2-S2.0-84930938641","HIGH BLOOD PRESS CARDIOVASC PREV",NA,"NOTREPORTED",NA,"TRIMARCO V, 2015, HIGH BLOOD PRESS CARDIOVASC PREV","TRIMARCO V, 2015, HIGH BLOOD PRESS CARDIOVASC PREV"
"KIM J;LEE J;JEONG D;JANG D;SEO T;LIM S","KIM, JONG-YEA (35211003900); LEE, JU HUN (58807077500); JEONG, DU-YUN (57225713930); JANG, DONG-KYUN (56478161400); SEO, TAE-RANG (37084041900); LIM, SEUNG-TAIK (7404081168)","PREPARATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF DEXTRIN AND POLICOSANOL COMPOSITES",2015,"CARBOHYDRATE POLYMERS","121","6",11,"10.1016/j.carbpol.2014.12.050","DEPARTMENT OF FOOD SCIENCE AND BIOTECHNOLOGY, KANGWON NATIONAL UNIVERSITY, CHUNCHEON, 200-701, SOUTH KOREA;SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, 5-1, ANAM-DONG, SUNGBUK-KU, SEOUL, 136-701, SOUTH KOREA;SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, 5-1, ANAM-DONG, SUNGBUK-KU, SEOUL, 136-701, SOUTH KOREA;SAMYANG GENEX CO. RANDD CENTER, DAEJEON, 305-707, SOUTH KOREA;SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, 5-1, ANAM-DONG, SUNGBUK-KU, SEOUL, 136-701, SOUTH KOREA;SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, 5-1, ANAM-DONG, SUNGBUK-KU, SEOUL, 136-701, SOUTH KOREA","POLICOSANOL (50-100 MG) WAS DISPERSED IN AN AQUEOUS SOLUTION (0.5-2.0% SOLIDS, W/V, 50 ML) OF AN AMYLOMAIZE STARCH DEXTRIN AT 90 °C UNDER DIFFERENT CONDITIONS. THE DISPERSION OF THE MIXTURE WAS OPAQUE BUT REMAINED HOMOGENOUS FOR UP TO 7 DAYS AT AN AMBIENT TEMPERATURE. THE PRECIPITATES OBTAINED BY CENTRIFUGING THE DISPERSION (5000 × G, 30 MIN) CONTAINED CRYSTALLINE V-AMYLOSE COMPLEX OF POLICOSANOL. THE SUPERNATANT ALSO CONTAINED POLICOSANOL BUT NOT IN THE COMPLEX FORM. STEPWISE ADDITION OF POLICOSANOL AND LONGER TIME COMPLEX FORMATION INCREASED THE DISPERSIBLE POLICOSANOL: ABOUT 95% BY 30 MIN INTERVAL, 1.0% DEXTRIN SOLUTION AND 12 H COMPLEX FORMATION TIME. AMONG THE DISPERSIBLE POLICOSANOL (95%), 70% POLICOSANOL RESIDED IN THE PRECIPITATES AND 25% WAS IN THE SUPERNATANT, INDICATING THE DEXTRIN BEHAVED AS A STABILIZER FOR THE DISPERSED POLICOSANOL AS WELL AS A COMPLEX FORMING AGENT WITH POLICOSANOL. THE POLICOSANOL DISPERSION WAS SONICATED UP TO 30 S TO EVALUATE PHYSICAL STABILITY. AROUND 70% POLICOSANOL IN THE DISPERSION REMAINED STABLE AGAINST THE SONICATION TREATMENT. © 2015 ELSEVIER LTD.","AQUEOUS DISPERSION; DEXTRIN; INCLUSION COMPLEX; POLICOSANOL; V-AMYLOSE","DEXTRINS; FATTY ALCOHOLS; SONICATION; STARCH; TEMPERATURE; TIME FACTORS; WATER; CYCLODEXTRINS; CALOREEN; DEXTRIN; FATTY ALCOHOL; POLICOSANOL; STARCH; WATER; AQUEOUS DISPERSIONS; DEXTRIN; INCLUSION COMPLEX; POLICOSANOL; V-AMYLOSE; CHEMISTRY; TEMPERATURE; TIME; ULTRASOUND; DISPERSIONS","KOREA INSTITUTE OF PLANNING AND EVALUATION FOR TECHNOLOGY IN FOOD, AGRICULTURE, FORESTRY AND FISHERIES, IPET; MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, MIFAFF","THIS STUDY WAS FINANCIALLY SUPPORTED BY THE IPET (KOREA INSTITUTE OF PLANNING AND EVALUATION FOR TECHNOLOGY IN FOOD, AGRICULTURE, FORESTRY AND FISHERIES) , MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, REPUBLIC OF KOREA .","ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, 3, PP. 321-327, (1993); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 58, 1, PP. 61-64, (1998); CHERIF A.O., BEN MESSAOUDA M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 58, 23, PP. 12143-12148, (2010); DE VOS P., FAAS M.M., SPASOJEVIC M., SIKKEMA J., ENCAPSULATION FOR PRESERVATION OF FUNCTIONALITY AND TARGETED DELIVERY OF BIOACTIVE FOOD COMPONENTS, INTERNATIONAL DAIRY JOURNAL, 20, 4, PP. 292-302, (2010); DUBOIS M., GILLES K.A., HAMILTON J.K., REBERS P.A., SMITH F., COLORIMETRIC METHOD FOR DETERMINATION OF SUGARS AND RELATED SUBSTANCES, ANALYTICAL CHEMISTRY, 28, 3, PP. 350-356, (1956); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM AND BRAN, FOOD CHEMISTRY, 119, 3, PP. 1246-1249, (2010); ELIASSON A.C., STARCH IN FOOD: STRUCTURE, FUNCTION AND APPLICATIONS, (2004); GELDERS G.G., VANDERSTUKKEN T.C., GOESAERT H., DELCOUR J.A., AMYLOSE-LIPID COMPLEXATION: A NEW FRACTIONATION METHOD, CARBOHYDRATE POLYMERS, 56, 4, PP. 447-458, (2004); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); HEINEMANN C., ZINSLI M., RENGGLI A., ESCHER F., CONDE-PETIT B., INFLUENCE OF AMYLOSE-FLAVOR COMPLEXATION ON BUILD-UP AND BREAKDOWN OF STARCH STRUCTURES IN AQUEOUS FOOD MODEL SYSTEMS, LWT - FOOD SCIENCE AND TECHNOLOGY, 38, 8, PP. 885-894, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); JANE J.-L., ROBYT J.F., STRUCTURE STUDIES OF AMYLOSE-V COMPLEXES AND RETRO-GRADED AMYLOSE BY ACTION OF Α-AMYLASES, AND A NEW METHOD FOR PREPARING AMYLODEXTRINS, CARBOHYDRATE RESEARCH, 132, 1, PP. 105-118, (1984); JOUQUAND C., DUCRUET V., LE BAIL P., FORMATION OF AMYLOSE COMPLEXES WITH C<SUB>6</SUB>-AROMA COMPOUNDS IN STARCH DISPERSIONS AND ITS IMPACT ON RETENTION, FOOD CHEMISTRY, 96, 3, PP. 461-470, (2006); JOVANOVICH G., ANON M.C., AMYLOSE-LIPID COMPLEX, PHYSICOCHEMICAL PROPERTIES AND THE EFFECTS OF DIFFERENT VARIABLES, LEBENSMITTEL-WISSENSCHAFT UND-TECHNOLOGIE, 32, 2, PP. 95-101, (1999); KIM E.-A., KIM J.-Y., CHUNG H.-J., LIM S.-T., PREPARATION OF AQUEOUS DISPERSIONS OF COENZYME Q10 NANOPARTICLES WITH AMYLOMAIZE STARCH AND ITS DEXTRIN, LWT - FOOD SCIENCE AND TECHNOLOGY, 47, 2, PP. 493-499, (2012); KIM J.-Y., SEO T.-R., LIM S.-T., PREPARATION OF AQUEOUS DISPERSION OF Β-CAROTENE NANO-COMPOSITES THROUGH COMPLEX FORMATION WITH STARCH DEXTRIN, FOOD HYDROCOLLOIDS, 33, 2, PP. 256-263, (2013); KIM J.-Y., YOON J.-W., LIM S.-T., FORMATION AND ISOLATION OF NANOCRYSTAL COMPLEXES BETWEEN DEXTRINS AND N-BUTANOL, CARBOHYDRATE POLYMERS, 78, 3, PP. 626-632, (2009); LALUSH I., BAR H., ZAKARIA I., EICHLER S., SHIMONI E., UTILIZATION OF AMYLOSE-LIPID COMPLEXES AS MOLECULAR NANOCAPSULES FOR CONJUGATED LINOLEIC ACID, BIOMACROMOLECULES, 6, 1, PP. 121-130, (2004); LEE J.H., HAN J.-A., LIM S.-T., EFFECT OF PH ON AQUEOUS STRUCTURE OF MAIZE STARCHES ANALYZED BY HPSEC-MALLS-RI SYSTEM, FOOD HYDROCOLLOIDS, 23, 7, PP. 1935-1939, (2009); LESMES U., COHEN S.H., SHENER Y., SHIMONI E., EFFECTS OF LONG CHAIN FATTY ACID UNSATURATION ON THE STRUCTURE AND CONTROLLED RELEASE PROPERTIES OF AMYLOSE COMPLEXES, FOOD HYDROCOLLOIDS, 23, 3, PP. 667-675, (2009); MADHAVI D.L., KAGAN D.I., WATER DISPERSIBLE POLICOSANOL CYCLODEXTRIN COMPLEX AND METHOD OF ITS PRODUCTION, (2013); MARTINEZ L., URIBARRI E., LAGUNA A., CHARACTERIZATION AND COMPATIBILITY STUDIES BETWEEN POLICOSANOL, A NEW HYPOCHOLESTEROLEMIC DRUG, AND TABLET EXCIPIENTS USING DIFFERENTIAL SCANNING CALORIMETRY (DSC), ARCHIV DER PHARMAZIE, 332, 12, PP. 439-441, (1999); MASWAL M., DAR A.A., FORMULATION CHALLENGES IN ENCAPSULATION AND DELIVERY OF CITRAL FOR IMPROVED FOOD QUALITY, FOOD HYDROCOLLOIDS, 37, 0, PP. 182-195, (2014); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOLOGY & BEHAVIOR, 67, 1, PP. 1-7, (1999); MENENDEZ R., FERNANDEZ S., DEL RIO A., GONZALEZ R., FRAGA V., AMOR A., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOLOGICAL RESEARCH, 27, PP. 199-203, (1994); ROUSSEAU D., FAT CRYSTALS AND EMULSION STABILITY - A REVIEW, FOOD RESEARCH INTERNATIONAL, 33, 1, PP. 3-14, (2000); SOMOGYI M., NOTES ON SUGAR DETERMINATION, JOURNAL OF BIOLOGICAL CHEMISTRY, 195, 1, PP. 19-23, (1952); TOMASIK P., SCHILLING C.H., COMPLEXES OF STARCH WITH INORGANIC GUESTS, ADVANCES IN CARBOHYDRATE CHEMISTRY AND BIOCHEMISTRY, 53, PP. 263-343, (1998); TOMASIK P., SCHILLING C.H., COMPLEXES OF STARCH WITH ORGANIC GUESTS, ADVANCES IN CARBOHYDRATE CHEMISTRY AND BIOCHEMISTRY, 53, PP. 345-426, (1998); TUFVESSON F., ELIASSON A.C., FORMATION AND CRYSTALLIZATION OF AMYLOSE-MONOGLYCERIDE COMPLEX IN A STARCH MATRIX, CARBOHYDRATE POLYMERS, 43, 4, PP. 359-365, (2000); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, 11, PP. 376-383, (2003); WHISTLER R.L., BEMILLER J.N., INDUSTRIAL GUMS: POLYSACCHARIDES AND THEIR DERIVATIVES, (1993); WU C., WANG Z., ZHI Z., JIANG T., ZHANG J., WANG S., DEVELOPMENT OF BIODEGRADABLE POROUS STARCH FOAM FOR IMPROVING ORAL DELIVERY OF POORLY WATER SOLUBLE DRUGS, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 403, 1-2, PP. 162-169, (2011); WULFF G., AVGENAKI G., GUZMANN M.S.P., MOLECULAR ENCAPSULATION OF FLAVOURS AS HELICAL INCLUSION COMPLEXES OF AMYLOSE, JOURNAL OF CEREAL SCIENCE, 41, 3, PP. 239-249, (2005); YAMAMOTO K., ZHANG Z.Z., KOBAYASHI S., CYCLOAMYLOSE (CYCLODEXTRIN) GLUCANOTRANSFERASE DEGRADES INTACT GRANULES OF POTATO RAW STARCH, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 48, 3, PP. 962-966, (2000)","","ELSEVIER LTD","ENGLISH","CARBOHYDR POLYM","ARTICLE","ISI","2-S2.0-84920863701","CARBOHYDR POLYM",NA,"NOTREPORTED",NA,"KIM J-Y, 2015, CARBOHYDR POLYM","KIM J-Y, 2015, CARBOHYDR POLYM"
"SOLA R;VALLS R;PUZO J;CALABUIG J;BREA A;PEDRET A;MORINÃ D;VILLAR J;MILLÁN J;ANGUERA A","SOLA, ROSA (56242966500); VALLS, ROSA-M. (7003369627); PUZO, JOSÉ (57211538770); CALABUIG, JOSÉ-RAḾON (55743695300); BREA, ANGEL (6701857932); PEDRET, ANNA (55123256900); MORINÃ, DAVID (37012685600); VILLAR, JOSÉ (59121473100); MILLÁN, JESÚS (55177496800); ANGUERA, ANNA (6603274608)","EFFECTS OF POLYBIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK A MULTICENTER RANDOMIZED TRIAL",2014,"PLOS ONE","9","",50,"10.1371/journal.pone.0101978","CIBERDEM, HOSPITAL UNIVERSITARI DE SAN JOAN, UNIVERSITAT ROVIRA I VIRGILI, REUS, SPAIN;CIBERDEM, HOSPITAL UNIVERSITARI DE SAN JOAN, UNIVERSITAT ROVIRA I VIRGILI, REUS, SPAIN;UNIDAD DE LÍPIDOS Y LABORATORIO DE BIOQUÍMICA, HOSPITAL UNIVERSITARIO SAN JORGE, HUESCA, SPAIN;DEPARTAMENTO DE MEDICINA INTERNA, HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE, VALENCIA, SPAIN;UNIDAD DE LÍPIDOS, SERVICIO DE MEDICINA INTERNA, HOSPITAL UNIVERSITARIO SAN PEDRO, LOGROÑO, SPAIN;CIBERDEM, HOSPITAL UNIVERSITARI DE SAN JOAN, UNIVERSITAT ROVIRA I VIRGILI, REUS, SPAIN;CENTRE TECNOLÒGIC DE NUTRICIÓ I SALUT, REUS, SPAIN;UNIDAD DE HIPERTENSIÓN Y LÍPIDOS, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLA, SPAIN;SERVICIO DE MEDICINA INTERNA, HOSPITAL UNIVERSITARIO GREGORIO MARAÑÓN, MADRID, SPAIN;MEDICAL DEPARTMENT, ROTTAPHARM S.L, BARCELONA, SPAIN","A DIETARY SUPPLEMENT (AP, ARMOLIPID PLUS) THAT COMBINES RED YEAST RICE EXTRACT, POLICOSANOL, BERBERINE, FOLIC ACID, COENZYME Q10 AND ASTHAXANTINE CAN HAVE BENEFICIAL EFFECTS ON CARDIOVASCULAR DISEASE (CVD) BIOMARKERS. THE AIM OF THIS STUDY WAS TO ASSESS WHETHER THE INTAKE OF AP, IN COMBINATION WITH DIETARY RECOMMENDATIONS, REDUCES SERUM LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) CONCENTRATIONS AND OTHER CVD BIOMARKERS IN PATIENTS WITH HYPERCHOLESTEROLEMIA. ELIGIBLE PATIENTS WERE RECRUITED FROM THE OUTPATIENT CLINICS OF SIX SPANISH HOSPITALS HOSPITAL VIRGEN DEL ROĆO (SEVILLA); HOSPITAL SAN JORGE (HUESCA); HOSPITAL SAN PEDRO (LOGROÑO); HOSPITAL GREGORIO MARAÑÓN (MADRID), HOSPITAL LA FE (VALENCIA) AND HOSPITAL UNIVERSITARI SANT JOAN (REUS) AS RECRUITING AND COORDINATING CENTER. 102 PARTICIPANTS (MEAN AGE ± SD; 50.91±11.61; 32 MEN) WITH LOW CVD, WITH MILD-TO-MODERATELY ELEVATED LDL-C (BETWEEN 3.35 MMOL/L AND 4.88 MMOL/L) WITHOUT HYPOLIPEMIC THERAPY WERE RANDOMIZED IN A DOUBLE-BLIND, PARALLEL, CONTROLLED, MULTICENTER TRIAL COMMENCING JANUARY 2012 AND ENDING DECEMBER 2012. AMONG THE EXCLUSION CRITERIA WERE ANY CONCOMITANT CHRONIC DISEASE, TRIGLYCERIDES (TG) >3.97 MMOL/L, PREGNANT OR LACTATING, AND HISTORY OF CVD. AT 12 WEEKS, COMPARED TO PLACEBO, AP REDUCED LDL-C BY -6.9%, APOLIPOPROTEIN (APO) B-100 BY -6.6% AND TOTAL CHOLESTEROL/HDL-C RATIO BY -5.5%, THE APOB/APOA1 RATIO BY -8.6%, WHILE INCREASING APOA1 BY +2.5% (P<0.05). AP CONSUMPTION WAS ASSOCIATED WITH MODEST MEAN WEIGHT LOSS OF -0.93 KG (95%CI: -1.74 TO -0.12; P = 0.02) COMPARED WITH CONTROL GROUP WHILE DIETARY COMPOSITION REMAINED UNCHANGED IN THE AP GROUP. THE AP PRODUCT WAS WELL TOLERATED. IN CONCLUSION, AP, COMBINED WITH DIETARY RECOMMENDATIONS, REDUCED LDL-C LEVELS AS WELL AS TOTAL CHOLESTEROL/HDL-C AND APOB/APOA1 RATIOS, WHILE INCREASING APO A1, ALL OF WHICH ARE IMPROVEMENTS IN CVD RISK INDICATORS. AP IS A PRODUCT WHICH COULD BENEFIT PATIENTS HAVING MODERATE HYPERLIPIDEMIA AND EXCESS BODY WEIGHT. © 2014 SOLÀ ET AL.","","ADULT; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; FEMALE; GLUCOSE; HUMANS; HYPERCHOLESTEROLEMIA; INSULIN; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; TREATMENT OUTCOME; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ARMOLIPID PLUS; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; GLUCOSE; INSULIN; LIPID; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FOOD COMPOSITION; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN METABOLISM; LACTATION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PARALLEL DESIGN; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL; SPAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; BLOOD; BODY WEIGHT; CLINICAL TRIAL; DIET; DIET SUPPLEMENTATION; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME","","","CARDIOVASCULAR DISEASES (CVDS), (2012); REDBERG R.F., BENJAMIN E.J., BITTNER V., BRAUN L.T., GOFF JR. D.C., ET AL., AHA/ACCF CORRECTED 2009 PERFORMANCE MEASURES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION/AMERICAN HEART ASSOCIATION TASK FORCE ON PERFORMANCE MEASURES, CIRCULATION, 120, 13, PP. 1296-1336, (2009); ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS, EUROPEAN HEART JOURNAL, 2, PP. 1769-1818, (2011); EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUROPEAN HEART JOURNAL, 33, PP. 1635-1701, (2012); CLEEMAN J.I., EXECUTIVE SUMMARY OF THE TRIAL REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); STONE N.J., ROBINSON J., LICHTENSTEIN A.H., BAIREY MERZ C.N., LLOYD-JONES D.M., ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, (2013); NEEDHAM M., MASTAGLIA F.L., STATIN MYOTOXICITY: A REVIEW OF GENETIC SUSCEPTIBILITY FACTORS, NEUROMUSCUL DISORD, (2013); ENGELFRIET P., HOEKSTRA J., HOOGENVEEN R., BUCHNER F., VAN ROSSUM C., ET AL., FOOD AND VESSELS: THE IMPORTANCE OF A HEALTHY DIET TO PREVENT CARDIOVASCULAR DISEASE, EUR J CARDIOV PREV REHABIL, 17, 1, PP. 50-55, (2010); DIETARY SUPPLEMENTS, (2010); CICERO A.F.G., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENTARY THERAPIES IN MEDICINE, 13, 4, PP. 273-278, (2005); CICERO A.F.G., BENVENUTI C., EFFICACY OF A RED YEAST RICE BASED NUTRACEUTICAL IN LARGE SUBGROUPS OF HYPERCHOLESTEROLEMIC SUBJECTS IN EVERY DAY CLINICAL PRACTICE, MED J NUTR METAB, 3, PP. 239-246, (2010); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTRITION METAB, 4, 2, PP. 133-139, (2011); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1543-1548, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); CICERO A.F.G., DEROSA G., PARINI A., MAFFIOLI P., D'ADDATO S., ET AL., RED YEAST RICE IMPROVES LIPID PATTERN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND VASCULAR REMODELING PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC ITALIAN SUBJECTS, NUTR RES, 33, 8, PP. 622-628, (2013); YANG C.W., MOUSA S.A., THE EFFECT OF RED YEAST RICE (MONASCUS PURPUREUS) IN DYSLIPIDEMIA AND OTHER DISORDERS, COMPLEMENT THER MED, 20, 6, PP. 466-474, (2012); KIDD P., ASTAXANTHIN, CELL MEMBRANE NUTRIENT WITH DIVERSE CLINICAL BENEFITS AND ANTI-AGING POTENTIAL, ALTERN MED REV, 16, 4, PP. 355-364, (2011); DOSE-DEPENDENT EFFECTS OF FOLIC ACID ON BLOOD CONCENTRATIONS OF HOMOCYSTEINE: A META-ANALYSIS OF THE RANDOMIZED TRIALS, AM J CLIN NUT82, 4, PP. 806-812, (2005); HU Y., EHLI E.A., KITTELSRUD J., RONAN P.J., MUNGER K., ET AL., LIPID-LOWERING EFFECT OF BERBERINE IN HUMAN SUBJECTS AND RATS, PHYTOMEDICINE, 19, 10, PP. 861-867, (2012); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, 3, PP. 77-83, (2012); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, 7, PP. 1482-1487, (2010); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, 6, PP. 424-429, (2011); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGATION, CLIN CHEM, 18, PP. 499-502, (1972); MATTHEWS D.R., HOSKER J.P., RUDENSKI A.S., HOMEOSTASIS MODEL ASSESSMENT: INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA GLUCOSE AND INSULIN CONCENTRATIONS IN MAN, DIABETOLOGIA, 28, 7, PP. 412-419, (1985); HARLAND J.I., FOOD COMBINATIONS FOR CHOLESTEROL LOWERING, NUTR RES REV, 25, 2, PP. 249-266, (2012); LEE Y.S., KIM W.S., KIM K.H., YOON M.J., CHO H.J., ET AL., BERBERINE, A NATURAL PLANT PRODUCT, ACTIVATES AMP-ACTIVATED PROTEIN KINASE WITH BENEFICIAL METABOLIC EFFECTS IN DIABETIC AND INSULIN-RESISTANT STATES, DIABETES, 55, 8, PP. 2256-2256, (2006); XIE W., GU D., LI J., CUI K., ZHANG Y., EFFECTS AND ACTION MECHANISMS OF BERBERINE AND RHIZOMA COPTIDIS ON GUT MICROBES AND OBESITY IN HIGH-FAT DIET-FED C57BL/6J MICE, PLOS ONE, 6, 9, (2011); CICERO A.F.G., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS: A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 57, 1, PP. 26-30, (2007); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, 12, PP. 1105-1113, (2011); CASTELLI W.P., GARRISON R.J., WILSON P.W.F., INCIDENCE OF CORONARY HEART DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS. THE FRAMINGHAM STUDY, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 256, 20, PP. 2835-2838, (1986); RIDKER P.M., RIFAI N., COOK N.R., BRADWIN G., BURING J.E., NON-HDL CHOLESTEROL, APOLIPOPROTEINS A-I AND B<SUB>100</SUB>, STANDARD LIPID MEASURES, LIPID RATIOS, AND CRP AS RISK FACTORS FOR CARDIOVASCULAR DISEASE IN WOMEN, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 294, 3, PP. 326-333, (2005); (2013); MCQUEEN M.J., HAWKEN S., WANG X., OUNPUU S., SNIDERMAN A., PROBSTFIELD J., STEYN K., SANDERSON J.E., HASANI M., VOLKOVA E., KAZMI K., YUSUF S., LIPIDS, LIPOPROTEINS, AND APOLIPOPROTEINS AS RISK MARKERS OF MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): A CASE-CONTROL STUDY, THE LANCET, 372, 9634, PP. 224-233, (2008); PARISH S., PETO R., PALMER A., CLARKE R., LEWINGTON S., ET AL., THE JOINT EFFECTS OF APOLIPOPROTEIN B, APOLIPOPROTEIN A1, LDL CHOLESTEROL, AND HDL CHOLESTEROL ON RISK: 3510 CASES OF ACUTE MYOCARDIAL INFARCTION AND 9805 CONTROLS, EUR HEART J, 30, 17, PP. 2137-2146, (2009); WALLDIUS G., AASTVEIT A.H., JUNGNER I., STROKE MORTALITY AND THE APOB/APOAI RATIO: RESULTS OF THE AMORIS PROSPECTIVE STUDY, J INTERN MED, 259, PP. 259-266, (2006); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., DIAZ E., CASTANO G., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 15, 4, PP. 159-165, (1995); LI Y.-G., ZHANG F., WANG Z.-T., HU Z.-B., IDENTIFICATION AND CHEMICAL PROFILING OF MONACOLINS IN RED YEAST RICE USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH PHOTODIODE ARRAY DETECTOR AND MASS SPECTROMETRY, JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 35, 5, PP. 1101-1112, (2004); WANG T.H., LIN T.F., MONASCUS RICE PRODUCTS, ADV FOOD NUTR RES, 53, PP. 123-159, (2007); LU Z., KOU W., DU B., WU Y., ZHAO S., LI S., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, 12, PP. 1689-1693, (2008); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.-D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NATURE MEDICINE, 10, 12, PP. 1344-1351, (2004); SNIDERMAN A.D., WILLIAMS K., CONTOIS J.H., MONROE H.M., MCQUEEN M.J., ET AL., A META-ANALYSIS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL, NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, AND APOLIPOPROTEIN B AS MARKERS OF CARDIOVASCULAR RISK, CIRC CARDIOVASC QUAL OUTCOMES, 4, 3, PP. 337-345, (2011)","","PUBLIC LIBRARY OF SCIENCE","ENGLISH","PLOS ONE","ARTICLE","ISI","2-S2.0-84905402529","PLOS ONE",NA,"NOTREPORTED",NA,"SOLA R, 2014, PLOS ONE","SOLA R, 2014, PLOS ONE"
"MONTSERRAT-DE L P S;FERNÁNDEZ-ARCHE M;ÁNGEL-MARTÍN M;GARCÍA-GIMÉNEZ M","MONTSERRAT-DE LA PAZ, S. (57210725095); FERNÁNDEZ-ARCHE, M.A. (12244901200); ÁNGEL-MARTÍN, M. (55314617900); GARCÍA-GIMÉNEZ, M.D. (7404278083)","PHYTOCHEMICAL CHARACTERIZATION OF POTENTIAL NUTRACEUTICAL INGREDIENTS FROM EVENING PRIMROSE OIL OENOTHERA BIENNIS L",2014,"PHYTOCHEMISTRY LETTERS","8","4",50,"10.1016/j.phytol.2013.08.008","DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/ PROFESOR GARCÍA GONZÁLEZ, 2, SPAIN;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/ PROFESOR GARCÍA GONZÁLEZ, 2, SPAIN;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/ PROFESOR GARCÍA GONZÁLEZ, 2, SPAIN;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/ PROFESOR GARCÍA GONZÁLEZ, 2, SPAIN","EVENING PRIMROSE OIL (EPO) IS A NATURAL PRODUCT EXTRACTED BY COLD-PRESSED FROM OENOTHERA BIENNIS L. SEEDS. EPO IS WIDELY USED AS A DIETARY SUPPLEMENT FROM WHICH BENEFICIAL EFFECTS HAVE BEEN REPORTED IN RHEUMATIC AND ARTHRITIC CONDITIONS, ATOPIC DERMATITIS, PSORIASIS, PREMENSTRUAL AND MENOPAUSAL SYNDROME, AND DIABETIC NEUROPATHY. THE BENEFICIAL EFFECTS OF EPO ARE THOUGHT TO BE DUE TO ITS Γ-LINOLENIC ACID CONTENT; IN CONTRAST, LITTLE EFFORT HAS BEEN EXPENDED TO CHARACTERIZE THE NON-TRIGLYCERIDIC CONSTITUENTS OF EPO. IN ORDER TO EVALUATE ITS POTENTIAL AS SOURCE OF FUNCTIONAL FOOD INGREDIENTS OUR AIM IN THIS WORK HAS BEEN IDENTIFIED AND QUANTIFIED THE DIFFERENT COMPONENTS OF EPO BY DIFFERENT TECHNIQUES (GC-MS AND HPLC). THE LIPID PROFILE SHOWED THAT OLEIC (7%), LINOLEIC (74%) AND Γ-LINOLENIC (9%) WERE THE MOST ABUNDANCE FATTY ACIDS. UNSAPONIFIABLE MATTER AND SUBFRACTIONS WERE OBTAINED BY CEE/2568/91. SEPARATION OF THE COMPOUNDS UNDER STUDY WAS ACHIEVED GIVING A REASONABLE ANALYSIS TIME AND GOOD RESOLUTION. A YIELD (1.82-1.95%) OF UNSAPONIFIABLE MATTER WAS OBTAINED AND LEVELS OF SATURATED HYDROCARBONS (0.291.97 ± 14.85 MG) WERE NOTICED. Β-SITOSTEROL (7952.00 ± 342.25 MG/KG OIL) AND CAMPESTEROL (883.32 ± 0.45 MG/KG OIL) WERE PREDOMINANT IN PHYTOSTEROL FRACTION (9573 MG/KG OIL), WHILE TETRACOSANOL (236.93 ± 2.32 MG/KG OIL) AND HEXACOSANOL (289.92 ± 3.41 MG/KG OIL) IN LINEAR ALIPHATIC ALCOHOL FRACTION (798.04 ± 5.66 MG/KG OIL). IN THE PHENOLIC FRACTION (55.49 ± 2.76 MG/KG OIL), FERULIC ACID (25.23 ± 2.64 MG/KG OIL) WAS THE MAJOR COMPONENT. FROM THE RESULTS OBTAINED, IT CAN BE SUGGESTED THAT THE EVENING PRIMROSE OIL CAN BE CONSIDERED AN INTERESTING ALIMENTARY SOURCE OF SUBSTANCES OF NUTRACEUTICAL VALUE. © 2013 PHYTOCHEMICAL SOCIETY OF EUROPE.","EVENING PRIMROSE; FUNCTIONAL FOOD; OIL; PHYTOSTEROLS; POLICOSANOL; UNSAPONIFIABLE","OENOTHERA; OENOTHERA BIENNIS; ALKANOL; CAMPESTEROL; FATTY ACID; FATTY ACID ESTER; FERULIC ACID; GAMMA LINOLENIC ACID; HEXACOSANOL; HYDROCARBON; LINOLEIC ACID; OLEIC ACID; PHYTOSTEROL; PLANT MEDICINAL PRODUCT; PRIMROSE OIL; SITOSTEROL; TETRACOSANOL; UNCLASSIFIED DRUG; ARTICLE; EVENING PRIMROSE; FUNCTIONAL FOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID COMPOSITION; MASS FRAGMENTOGRAPHY; NONHUMAN; PRIORITY JOURNAL","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 33, 7, PP. 835-840, (2000); BELCH J.J.F., HILL A., EVENING PRIMROSE OIL AND BORAGE OIL IN RHEUMATOLOGIC CONDITIONS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 71, 1 SUPPL., (2000); CERT A., MOREDA W., GARCIA-MORENO J., DETERMINACIÓN DE ESTEROLES Y DIALCOHOLES TRITERPÉNICOS EN ACEITE DE OLIVA MEDIANTE SEPARACIÓN DE LA FRACCIÓN POR CROMATOGRAFÍA DE ALTA EFICACIA Y ANÁLISIS POR CROMATOGRAFÍA DE GASES. ESTANDARIZACIÓN DEL MÉTODO ANALÍTICO, GRASAS Y ACEITES, 48, PP. 207-218, (1997); CERT A., MOREDA W., PEREZ-CAMINO M.C., METHODS OF PREPARATION OF FATTY ACID METHYL ESTERS (FAME). STATISTICAL ASSESSMENT OF THE PRECISION CHARACTERISTICS FROM A COLLABORATIVE TRIAL, GRASAS Y ACEITES, 51, 6, PP. 447-456, (2000); CERT A., MOREDA W., PEREZ-CAMINO M.C., CHROMATOGRAPHIC ANALYSIS OF MINOR CONSTITUENTS IN VEGETABLE OILS, JOURNAL OF CHROMATOGRAPHY A, 881, 1-2, PP. 131-148, (2000); DEVARAJ S., JIALAL I., THE ROLE OF DIETARY SUPPLEMENTATION WITH PLANT STEROLS AND STANOLS IN THE PREVENTION OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 64, 7, PP. 348-354, (2006); FAN Y.-Y., CHAPKIN R.S., IMPORTANCE OF DIETARY Γ,-LINOLENIC ACID IN HUMAN HEALTH AND NUTRITION, JOURNAL OF NUTRITION, 128, 9, PP. 1411-1414, (1998); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA-VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J. NUTR. BIOCHEM., 20, PP. 155-162, (2009); HUDSON B.J.F., EVENING PRIMROSE (OENOTHERA SPP. ) OIL AND SEED, JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 61, 3, PP. 540-543, (1984); KIM H.K., JEONG T.-S., LEE M.-K., PARK Y.B., CHOI M.-S., LIPID-LOWERING EFFICACY OF HESPERETIN METABOLITES IN HIGH-CHOLESTEROL FED RATS, CLINICA CHIMICA ACTA, 327, 1-2, PP. 129-137, (2003); KLEIJNEN J., EVENING PRIMROSE OIL, BRITISH MEDICAL JOURNAL, 309, 6958, PP. 824-825, (1994); MAHADY G.B., FONG H.H.S., FARNSWORTH N.R., BOTANICAL DIETARY SUPPLEMENTS: QUALITY, SAFETY AND EFFICACY, PP. 75-85, (2001); MATEOS R., ESPARTERO J.L., TRUJILLO M., RIOS J.J., LEON-CAMACHO M., ALCUDIA F., CERT A., DETERMINATION OF PHENOLS, FLAVONES, AND LIGNANS IN VIRGIN OLIVE OILS BY SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH DIODE ARRAY ULTRAVIOLET DETECTION, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, 5, PP. 2185-2192, (2001); MEDINA E., BRENES M., ROMERO C., GARCIA A., DE CASTRO A., MAIN ANTIMICROBIAL COMPOUNDS IN TABLE OLIVES, J. AGRIC. FOOD. CHEM., 55, PP. 9817-9823, (2007); MONTSERRAT-DE LA PAZ S., FERNANDEZ-ARCHE M.A., ANGEL-MARTIN M., GARCIA-GIMENEZ M.D., THE STEROLS ISOLATED FROM EVENING PRIMROSE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, PHYTOMEDICINE, 19, PP. 1072-1076, (2012); OSTLUND JR. R.E., RACETTE S.B., STENSON W.F., EFFECTS OF TRACE COMPONENTS OF DIETARY FAT ON CHOLESTEROL METABOLISM: PHYTOSTEROLS, OXYSTEROLS, AND SQUALENE, NUTRITION REVIEWS, 60, 11, PP. 349-359, (2002); PAQUOT C., DETERMINATION OF THE UNSAPONIFIABLE MATTER. METHOD 2401, IUPAC STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS AND SERIVATIVES, (1992); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, 3, PP. 1020-1026, (2006); WEIHRAUCH J.L., GARDNER J.M., STEROL CONTENT OF FOODS OF PLANT ORIGIN, J. AM. DIET. ASSOC., 73, PP. 39-47, (1978)","S. MONTSERRAT-DE LA PAZ; DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/ PROFESOR GARCÍA GONZÁLEZ, 2, SPAIN; EMAIL: DELAPAZ@US.ES","ELSEVIER BV","ENGLISH","PHYTOCHEM. LETT.","ARTICLE","ISI","2-S2.0-84899915691","PHYTOCHEM LETT","UNIVERSITY OF SEVILLE;UNIVERSITY OF SEVILLE;UNIVERSITY OF SEVILLE;UNIVERSITY OF SEVILLE","NOTREPORTED;UNIVERSITY OF SEVILLE;NOTREPORTED",NA,"MONTSERRAT-DE LA PAZ S, 2014, PHYTOCHEM LETT","MONTSERRAT-DE LA PAZ S, 2014, PHYTOCHEM LETT"
"BARBAGALLO C;CEFALÙ A;NOTO D;AVERNA M","BARBAGALLO, CARLO M. (7006280963); CEFALÙ, ANGELO BALDASSARE (35599640600); NOTO, DAVIDE (6701558266); AVERNA, MAURIZIO R. (7005411173)","ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY",2015,"FRONTIERS IN CARDIOVASCULAR MEDICINE","2","",25,"10.3389/fcvm.2015.00022","BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS (DIBIMIS), UNIVERSITY OF PALERMO, PALERMO, ITALY;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS (DIBIMIS), UNIVERSITY OF PALERMO, PALERMO, ITALY;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS (DIBIMIS), UNIVERSITY OF PALERMO, PALERMO, ITALY;BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS (DIBIMIS), UNIVERSITY OF PALERMO, PALERMO, ITALY","NUTRACEUTICALS ARE FOOD COMPONENTS OR ACTIVE INGREDIENTS PRESENT IN FOODS AND USED IN THERAPY. THIS ARTICLE ANALYZES THE CHARACTERISTICS OF THE MOLECULES WITH A LIPID-LOWERING EFFECT. THE DIFFERENT NUTRACEUTICALS MAY HAVE DIFFERENT MECHANISMS OF ACTION: INHIBITION OF CHOLESTEROL SYNTHESIS PRIMARILY THROUGH ACTION ON THE ENZYME HMG-COA REDUCTASE (POLICOSANOL, POLYPHENOLS, GARLIC AND, ABOVE ALL, RED YEAST RICE), INCREASE IN LDL RECEPTOR ACTIVITY (BERBERINE), REDUCTION OF INTESTINAL CHOLESTEROL ABSORPTION (GARLIC, PLANT STEROLS, PROBIOTICS), AND ALSO THE ABILITY TO INTERFERE WITH BILE METABOLISM (PROBIOTICS, GUGGUL). BASED ON THE DIFFERENT MECHANISMS OF ACTION, SOME NUTRACEUTICALS ARE THEN ABLE TO ENHANCE THE ACTION OF STATINS. NUTRACEUTICALS ARE OFTEN USED WITHOUT RELEVANT EVIDENCE: MECHANISMS OF ACTION ARE NOT CLEARLY CONFIRMED; MOST OF CLINICAL DATA ARE DERIVED FROM SMALL, UNCONTROLLED STUDIES, AND FINALLY, EXCEPT FOR FERMENTED RED RICE, THERE ARE NO CLINICAL TRIALS WHICH MAY DOCUMENT THE RELATIONSHIP BETWEEN THESE INTERVENTIONS AND THE REDUCTION OF CLINICAL EVENTS. THEREFORE, AMONG ALL NUTRACEUTICALS, IT IS NECESSARY TO EXTRAPOLATE THOSE HAVING A REALLY DOCUMENTABLE EFFICACY. HOWEVER, THESE KINDS OF TREATMENTS ARE USUALLY WELL-TOLERATED BY PATIENTS. OVERALL, SUBJECTS WITH A MIDDLE OR LOW CARDIOVASCULAR RISK ARE THE BEST INDICATION OF NUTRACEUTICALS, BUT THEY MAY ALSO BE USEFUL FOR PATIENTS EXPERIENCING SIDE EFFECTS DURING CLASSICAL THERAPIES. FINALLY, IN CONSIDERATION OF THE ADDITIVE EFFECT OF SOME NUTRACEUTICALS, A COMBINATION THERAPY WITH CLASSICAL DRUGS MAY IMPROVE THE ACHIEVEMENT OF CLINICAL TARGETS. THUS, NUTRACEUTICALS MAY BE A HELPFUL ALTERNATIVE IN HYPOLIPIDEMIC TREATMENT AND, IF PROPERLY USED, MIGHT REPRESENT A VALID STRATEGY OF CARDIOVASCULAR PREVENTION. © COPYRIGHT © 2015 BARBAGALLO, CEFALÙ, NOTO AND AVERNA.","CARDIOVASCULAR PREVENTION; HYPOLIPIDEMIC THERAPY; LDL-CHOLESTEROL; LIPIDS; NUTRACEUTICALS","","","","DAS L., BHAUMIK E., RAYCHAUDHURI U., CHAKRABORTY R., ROLE OF NUTRACEUTICALS IN HUMAN HEALTH, J FOOD SCI TECHNOL, 49, PP. 173-183, (2012); COPPENS P., DA SILVA M.F., PETTMAN S., EUROPEAN REGULATIONS ON NUTRACEUTICALS, DIETARY SUPPLEMENTS AND FUNCTIONAL FOODS: A FRAMEWORK BASED ON SAFETY, TOXICOLOGY, 221, PP. 59-74, (2006); NIJJAR P.S., BURKE F.M., BLOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, J CLIN LIPIDOL, 4, PP. 248-258, (2010); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, PP. 469-473, (1998); CASTANO G., MAS R., ROCA J., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, PP. 259-267, (2010); ZERN T.L., FERNANDEZ M.L., CARDIOPROTECTIVE EFFECTS OF DIETARY POLYPHENOLS, J NUTR, 135, PP. 2291-2294, (2005); DAVALOS A., FERNANDEZ-HERNANDO C., CERRATO F., MARTINEZ-BOTAS J., GOMEZ-CORONADO D., GOMEZ-CORDOVES C., ET AL., RED GRAPE JUICE POLYPHENOLS ALTER CHOLESTEROL HOMEOSTASIS AND INCREASE LDL-RECEPTOR ACTIVITY IN HUMAN CELLS IN VITRO, J NUTR, 136, PP. 1766-1773, (2006); MOLLACE V., SACCO I., JANDA E., MALARA C., VENTRICE D., COLICA C., ET AL., HYPOLIPEMIC AND HYPOGLYCAEMIC ACTIVITY OF BERGAMOT POLYPHENOLS: FROM ANIMAL MODELS TO HUMAN STUDIES, FITOTERAPIA, 82, PP. 309-316, (2011); DEMONTY I., LIN Y., ZEBREGS Y.E., VERMEER M.A., VAN DER KNAAP H.C., JAKEL M., ET AL., THE CITRUS FLAVONOIDS HESPERIDIN AND NARINGIN DO NOT AFFECT SERUM CHOLESTEROL IN MODERATELY HYPERCHOLESTEROLEMIC MEN AND WOMEN, J NUTR, 140, PP. 1615-1620, (2010); BOREK C., GARLIC REDUCES DEMENTIA AND HEART-DISEASE RISK, J NUTR, 136, PP. 810S-812, (2006); SILAGY C., NEIL A., GARLIC AS A LIPID LOWERING AGENT: A META-ANALYSIS, J R COLL PHYSICIANS LOND, 28, PP. 39-45, (1994); GARDNER C.D., LAWSON L.D., BLOCK E., CHATTERJEE L.M., KIAZAND A., BALISE R.R., ET AL., EFFECT OF RAW GARLIC VS COMMERCIAL GARLIC SUPPLEMENTS ON PLASMA LIPID CONCENTRATIONS IN ADULTS WITH MODERATE HYPERCHOLESTEROLEMIA: A RANDOMIZED CLINICAL TRIAL, ARCH INTERN MED, 167, PP. 346-353, (2007); ERNST E., CARDIOVASCULAR EFFECTS OF GARLIC (ALLIUM SATIVUM): A REVIEW, PHARMATHERAPEUTICA, 5, PP. 83-89, (1987); KUMAR M., NAGPAL R., KUMAR R., HEMALATHA R., VERMA V., KUMAR A., ET AL., CHOLESTEROL-LOWERING PROBIOTICS AS POTENTIAL BIOTHERAPEUTICS FOR METABOLIC DISEASES, EXP DIABETES RES, 2012, PP. 902-917, (2012); TARANTO M.P., MEDICI M., PERDIGON G., RUIZ HOLGADO A.P., VALDEZ G.F., EVIDENCE FOR HYPOCHOLESTEROLEMIC EFFECT OF LACTOBACILLUS REUTERI IN HYPERCHOLESTEROLEMICMICE, J DAIRY SCI, 81, PP. 2336-2340, (1998); KUMAR R., GROVER S., BATISH V.K., HYPOCHOLESTEROLAEMIC EFFECT OF DIETARY INCLUSION OF TWO PUTATIVE PROBIOTIC BILE SALT HYDROLASE-PRODUCING LACTOBACILLUS PLANTARUM STRAINS IN SPRAGUE-DAWLEY RATS, BR J NUTR, 12, PP. 1-12, (2010); ABD EL-GAWAD A., EL-SAYED E.M., HAFEZ S.A., EL-ZEINI H.M., SALEH F.A., THE HYPOCHOLESTEROLAEMIC EFFECT OF MILK YOGHURT AND SOY-YOGHURT CONTAINING BIFIDOBACTERIA IN RATS FED ON A CHOLESTEROL-ENRICHED DIET, INT DAIRY J, 15, PP. 37-44, (2005); LIONG M.T., SHAH N.P., BILE SALT DECONJUGATION ABILITY, BILE SALT HYDROLASE ACTIVITY AND CHOLESTEROL CO-PRECIPITATION ABILITY OF LACTOBACILLI STRAINS, INT DAIRY J, 15, PP. 391-398, (2005); NITYANAND S., KAPOOR N.K., CHOLESTEROL LOWERING ACTIVITY OF THE VARIOUS FRACTIONS OF THE GUGGUL, INDIAN J EXP BIOL, 11, PP. 395-396, (1973); URIZAR N.L., LIVERMAN A.B., DODDS D.T., SILVA F.V., ORDENTLICH P., YAN Y., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, PP. 1703-1706, (2002); ULBRICHT C., BASCH E., SZAPARY P., HAMMERNESS P., AXENTSEV S., BOON H., ET AL., NATURAL STANDARD RESEARCH COLLABORATION. GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENT THER MED, 13, PP. 279-290, (2005); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., CUCCHIARA A.J., DERMARDEROSIAN A.H., CIRIGLIANO M.D., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., GORDON M., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); JONES P.J., RAEINI-SARJAZ M., NTANIOS F.Y., VANSTONE C.A., FENG J.Y., PARSONS W.E., MODULATION OF PLASMA LIPID LEVELS AND CHOLESTEROL KINETICS BY PHYTOSTEROL VERSUS PHYTOSTANOL ESTERS, J LIPID RES, 41, PP. 697-705, (2000); VON BERGMANN K., SUDHOP T., LUTJOHANN D., CHOLESTEROL AND PLANT STEROL ABSORPTION: RECENT INSIGHTS, AM J CARDIOL, 96, PP. 10D-14, (2005); HALLIKAINEN M.A., SARKKINEN E.S., GYLLING H., ERKKILA A.T., UUSITUPA M.I., COMPARISON OF THE EFFECTS OF PLANT STEROL ESTER AND PLANT STANOL ESTERENRICHED MARGARINES IN LOWERING SERUM CHOLESTEROL CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC SUBJECTS ON A LOW-FAT DIET, EUR J CLIN NUTR, 54, PP. 715-725, (2000); DAVIDSON M.H., MAKI K.C., UMPOROWICZ D.M., INGRAM K.A., DICKLIN M.R., SCHAEFER E., ET AL., SAFETY AND TOLERABILITY OF ESTERIFIED PHYTOSTEROLS ADMINISTERED IN REDUCED-FAT SPREAD AND SALAD DRESSING TO HEALTHY ADULT MEN AND WOMEN, J AM COLL NUTR, 20, PP. 307-319, (2001); DEVARAJ S., JIALAL I., VEGA-LOPEZ S., PLANT STEROL-FORTIFIED ORANGE JUICE EFFECTIVELY LOWERS CHOLESTEROL LEVELS IN MILDLY HYPERCHOLESTEROLEMIC HEALTHY INDIVIDUALS, ARTERIOSCLER THROMB VASC BIOL, 24, PP. 25-28, (2004); VOLPE R., NIITTYNEN L., KORPELA R., SIRTORI C., BUCCI A., FRAONE N., ET AL., EFFECTS OF YOGHURT ENRICHED WITH PLANT STEROLS ON SERUM LIPIDS IN PATIENTS WITH MODERATE HYPERCHOLESTEROLAEMIA, BR J NUTR, 86, PP. 233-239, (2001); MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N ENGL J MED, 333, PP. 1308-1312, (1995); HALLIKAINEN M.A., SARKKINEN E.S., UUSITUPA M.I., PLANT STANOL ESTERS AFFECT SERUM CHOLESTEROL CONCENTRATIONS OF HYPERCHOLESTEROLEMIC MEN AND WOMEN IN A DOSE-DEPENDENT MANNER, J NUTR, 130, PP. 767-776, (2000); VANSTONE C.A., RAEINI-SARJAZ M., PARSONS W.E., JONES P.J., UNESTERIFIED PLANT STEROLS AND STANOLS LOWER LDL-CHOLESTEROL CONCENTRATIONS EQUIVALENTLY IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 76, PP. 1272-1278, (2002); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., DUCHATEAU G.S., MEIJER L., ZOCK P.L., ET AL., CONTINUOUS DOSERESPONSE RELATIONSHIP OF THE LDL-CHOLESTEROL-LOWERING EFFECT OF PHYTOSTEROL INTAKE, J NUTR, 139, PP. 271-284, (2009); LAITINEN K., GYLLING H., DOSE-DEPENDENT LDL-CHOLESTEROL LOWERING EFFECT BY PLANT STANOL ESTER CONSUMPTION: CLINICAL EVIDENCE, LIPIDS HEALTH DIS, 11, (2012); MANNARINO E., PIRRO M., CORTESE C., LUPATTELLI G., SIEPI D., MEZZETTI A., ET AL., EFFECTS OF A PHYTOSTEROL-ENRICHED DAIRY PRODUCT ON LIPIDS, STEROLS AND 8-ISOPROSTANE IN HYPERCHOLESTEROLEMIC PATIENTS: A MULTICENTER ITALIAN STUDY, NUTR METAB CARDIOVASC DIS, 19, PP. 84-90, (2009); GOLDBERG A.C., OSTLUND R.E., BATEMAN J.H., SCHIMMOELLER L., MCPHERSON T.B., SPILBURG C.A., EFFECT OF PLANT STANOL TABLETS ON LOWDENSITY LIPOPROTEIN CHOLESTEROL LOWERING IN PATIENTS ON STATIN DRUGS, AM J CARDIOL, 97, PP. 376-379, (2006); MIETTINEN T.A., STRANDBERG T.E., GYLLING H., NONCHOLESTEROL STEROLS AND CHOLESTEROL LOWERING BY LONG-TERM SIMVASTATIN TREATMENT IN CORONARY PATIENTS: RELATION TO BASAL SERUM CHOLESTANOL, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 1340-1346, (2000); ROCHA M., BANULS C., BELLOD L., JOVER A., VICTOR V.M., HERNANDEZ-MIJARES A., A REVIEW ON THE ROLE OF PHYTOSTEROLS: NEW INSIGHTS INTO CARDIOVASCULAR RISK, CURR PHARM DES, 17, PP. 4061-4075, (2011); SILBERNAGEL G., CHAPMAN M.J., GENSER B., KLEBER M.E., FAULER G., SCHARNAGL H., ET AL., HIGH INTESTINAL CHOLESTEROL ABSORPTION IS ASSOCIATED WITH CARDIOVASCULAR DISEASE AND RISK ALLELES IN ABCG8 AND ABO: EVIDENCE FROM THE LURIC AND YFS COHORTS AND FROM A META-ANALYSIS, J AM COLL CARDIOL, 62, PP. 291-299, (2013); LAU C.W., YAO X.Q., CHEN Z.Y., KO W.H., HUANG Y., CARDIOVASCULAR ACTIONS OF BERBERINE, CARDIOVASC DRUG REV, 19, PP. 234-244, (2001); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); KONG W.J., WEI J., ZUO Z.Y., WANG Y.M., SONG D.Q., YOU X.F., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFICACY, METABOLISM, 57, PP. 1029-1037, (2008); URBAN D., POSS J., BOHM M., LAUFS U., TARGETING THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FOR THE TREATMENT OF DYSLIPIDEMIA AND ATHEROSCLEROSIS, J AM COLL CARDIOL, 62, PP. 1401-1408, (2013); DADU R.T., BALLANTYNE C.M., LIPID LOWERING WITH PCSK9 INHIBITORS, NAT REV CARDIOL, 11, PP. 563-575, (2014); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); DEROSA G., MAFFIOLI P., CICERO A.F., BERBERINE ON METABOLIC AND CARDIOVASCULAR RISK FACTORS: AN ANALYSIS FROM PRECLINICAL EVIDENCES TO CLINICAL TRIALS, EXPERT OPIN BIOL THER, 12, PP. 1113-1124, (2012); ENDO A., MONACOLIN K, A NEW HYPOCHOLESTEROLEMIC AGENT PRODUCED BY A MONASCUS SPECIES, J ANTIBIOT, 32, PP. 852-854, (1979); CHENA C.-H., YANGB J.-C., UANGC Y.-U., LINA C.-J., IMPROVED DISSOLUTION RATE AND ORAL BIOAVAILABILITY OF LOVASTATIN IN RED YEAST RICE PRODUCTS, INT J PHARM, 444, PP. 18-24, (2013); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META- ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); HALBERT S.C., FRENCH B., GORDON R.Y., FARRAR J.T., SCHMITZ K., MORRIS P.B., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); ARMITAGE J., THE SAFETY OF STATINS IN CLINICAL PRACTICE, LANCET, 370, PP. 1781-1790, (2007); VAKLAVAS C., CHATZIZISIS Y.S., ZIAKAS A., ZAMBOULIS C., GIANNOGLOU G.D., MOLECULAR BASIS OF STATIN-ASSOCIATED MYOPATHY, ATHEROSCLEROSIS, 202, PP. 18-28, (2009); BARBAGALLO C.M., LONGO F., NOTO D., CEFALU A.B., GANCI A., CUSUMANO G., ET AL., REDUCTION OF CHOLESTEROL WITH NUTRACEUTICALS: RESULT OF A DOUBLE-BLIND STUDY, INT J CARDIOVASC DIS, (2015); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); NASRI H., BARADARAN A., SHIRZAD H., RAFIEIAN-KOPAEI M., NEW CONCEPTS IN NUTRACEUTICALS AS ALTERNATIVE FOR PHARMACEUTICALS, INT J PREV MED, 5, PP. 1487-1499, (2014); LAPLACE J.P., HEALTH AND NUTRITION CLAIMS MADE ON FOOD: WHAT FUTURE?, BULL ACAD NATL MED, 190, PP. 1663-1680, (2006)","C.M. BARBAGALLO; BIOMEDICAL DEPARTMENT OF INTERNAL MEDICINE AND SPECIALISTICS (DIBIMIS), UNIVERSITY OF PALERMO, PALERMO, ITALY; EMAIL: CARLO.BARBAGALLO@UNIPA.IT","FRONTIERS MEDIA S.A.","ENGLISH","FRONT. CARDIOVASC. MED.","ARTICLE","ISI","2-S2.0-84974529397","FRONT CARDIOVASC MED","UNIVERSITY OF PALERMO;UNIVERSITY OF PALERMO;UNIVERSITY OF PALERMO;UNIVERSITY OF PALERMO","NOTREPORTED;UNIVERSITY OF PALERMO;NOTREPORTED",NA,"BARBAGALLO CM, 2015, FRONT CARDIOVASC MED","BARBAGALLO CM, 2015, FRONT CARDIOVASC MED"
"MURUGASAN T;RANGAN P;ALAGUMUTHU T","MURUGASAN, THILAGAM (56260715500); RANGAN, PANDIAN (57188754416); ALAGUMUTHU, TAMILSELVI (57188754690)","EXTRACTION AND CHARACTERIZATION OF WAX FROM SACCHARUM SPONTANEUM L",2016,"DER PHARMACIA LETTRE","8","5",1,"","DEPARTMENT OF PLANT BIOLOGY AND PLANT BIOTECHNOLOGY, PRESIDENCY COLLEGE, CHENNAI, INDIA;DIRECTORATE OF HIGHER EDUCATION, TIRUNELVELI, TAMILNADU, INDIA;CHORD, CSIR-CLRI, CHENNAI, INDIA","SACCHARUM SPONTANEUM L. (WILD SUGARCANE, KANS GRASS) IS A WEED NATIVE TO SOUTH ASIA AND GROWS THROUGHOUT INDIA. SACCHARUM OFFICINARUM (SUGARCANE) IS A COMMERCIAL SOURCE OF WAX. ITS CONTAINS ESTERS, POLICOSANOL AND LONG CHAIN FATTY ACIDS. IN THE PRESENT INVESTIGATION AN ATTEMPT WAS MADE TO EXTRACT THE CRUDE WAX FROM WILD CANE PEEL AND ITS CHARACTERIZATION WAS STUDIED. THE COLOUR OF PURIFIED WAX WAS PALE YELLOW AND ITS YIELD WAS 5.5%. THE ACID VALUE, SAPONIFICATION VALUE AND IODINE VALUE WAS FOUND TO BE 57.1, 112.2 AND 5.076 MG/G RESPECTIVELY. MELTING POINT OF CRUDE WAX OBSERVED AT 85 - 90°C. THIN LAYER CHROMATOGRAPHY SHOWED THE PRESENCE OF ALCOHOL AND HYDROCARBON FRACTIONS. IN FTIR ANALYSIS PROMINENT PEAKS INDICATED ALCOHOL, ALDEHYDE, ALKANES, KETONES AND CARBOXYLIC ACID GROUPS. GC-MS ANALYSIS REVEALED THE PRESENCE OF PROPANOIC ACID, PENTADECENOIC ACID, HEPTADECENOIC ACID, OCTADECENOIC ACID AND DOCASANEDIOIC ACID RESPECTIVELY. APART FROM THE MAJOR COMPONENTS CARBOXYLIC AND BENZOIC ACIDS WERE ALSO PRESENT. THESE ACIDS PLAY A SIGNIFICANT ROLE IN HUMAN NUTRITION, LIPID PEROXIDATION, ANTIPLATELET AND CHOLESTROL LOWERING EFFECTS.","CHARACTERIZATION; EXTRACTION; PHYSIOCHEMICAL ANALYSIS; SACCHARUM SPONTANEUM; WAX","ALCOHOL DERIVATIVE; ALDEHYDE DERIVATIVE; ALKANE DERIVATIVE; BENZOIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DOCASANEDIOIC ACID; HEPTADECENOIC ACID; HYDROCARBON; IODINE; KETONE DERIVATIVE; OCTADECENOIC ACID; PENTADECENOIC ACID; PLANT MEDICINAL PRODUCT; PROPIONIC ACID; UNCLASSIFIED DRUG; WAX; ARTICLE; COLOR; DRUG ISOLATION; DRUG PURIFICATION; DRUG SCREENING; INFRARED SPECTROSCOPY; MASS FRAGMENTOGRAPHY; MELTING POINT; NONHUMAN; QUANTUM YIELD; SACCHARUM SPONTANEUM; SAPONIFICATION; THIN LAYER CHROMATOGRAPHY; WILD SPECIES","","","BERNARD, JOUBES J., PROG. LIPID RES., 52, PP. 110-129, (2013); LAWRENCE J.F., IYENGAR J.R., PAGE B.D., CONACHER H.B.S., J. CHROMATOGRAPHY, 236, PP. 403-409, (1982); CHERIF A.O., BEN M., KAABI B., BOUKHCHINA S., PEPE C., KALLEL H., J. AGRI. FOOD. CHEM., 58, PP. 12143-12148, (2010); CERMAK S.C., ISBELL T.A., IND CROPS PROD, 16, PP. 119-127, (2002); OU S., ZHAO J., WANG Y., TIAN Y., WANG J., J. FOOD SCI. TECHNOL., 45, PP. 295-298, (2012); REZANKA T., SIGLER K., PHYTOCHEMISTRY, 67, PP. 916-923, (2006); METHOD 930.15, OFFICIAL METHODS OF ANALYSES OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, (1990); PHUKAN A.C., BORUAH R.K., SEPARATION AND PURIFICATION TECHNOLOGY, 17, (1999); MANGESH I.S., LELE S., ISRN AGRONOMY, 2012, PP. 1-6, (2012); KARDASH E., TURYAN Y., ACID VALUE DETERMINATION IN VEGETABLE OILS BY DIRECT TITRATION IN AQUEOUS ALCOHOL MEDIA, NATIONAL PHYSICAL LABORATORY OF ISRAEL, (2005); POCKLINGTON W.D., PURE AND APPL.CHEM, 62, PP. 2339-2343, (1990); BHOSALE CHONDE P.R., SONAL G., RAUT P.D., ENVIRONMENTAL RESEARCH AND DEVELOPMENT, 6, PP. 715-720, (2012); (2010); KNUUTINEN U., NORRMAN A.A., WORLD CONFERENCE ON NONDESTRUCTIVE TESTING, (2000); HOLLOWAY P.J., CHALLEN S.B., JOURNAL OF CHROMATOGRAPHY, 25, PP. 336-346, (1966); RAINER K., TIM S., HEINRICH L., URSULA M., RUDOLF R., ALEXANDER S., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 72, PP. 1373-1379, (2006); IRMAK S., DUNFORD N.T., MILLIGAN J., J. FOOD CHEM, 95, PP. 312-318; SINDHU KANYA T.C., JAGANMOHAN RAO L., SHAMANTHAKA SASTRY M.C., J. FOOD CHEMISTRY., 101, PP. 1552-1557, (2007)","","SCHOLARS RESEARCH LIBRARY","ENGLISH","DER PHARM. LETT.","ARTICLE","ISI","2-S2.0-84962844428","DER PHARM LETT",NA,"NOTREPORTED",NA,"MURUGASAN T, 2016, DER PHARM LETT","MURUGASAN T, 2016, DER PHARM LETT"
"MARAZZI G;PELLICCIA F;CAMPOLONGO G;QUATTRINO S;CACCIOTTI L;VOLTERRANI M;GAUDIO C;ROSANO G","MARAZZI, GIUSEPPE (6602583977); PELLICCIA, FRANCESCO (7005360685); CAMPOLONGO, GIUSEPPE (8575747900); QUATTRINO, SILVIA (53881852900); CACCIOTTI, LUCA (6506023158); VOLTERRANI, MAURIZIO (7004062259); GAUDIO, CARLO (7003692781); ROSANO, GIUSEPPE (7007131876)","USEFULNESS OF NUTRACEUTICALS ARMOLIPID PLUS VERSUS EZETIMIBE AND COMBINATION IN STATININTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE",2015,"AMERICAN JOURNAL OF CARDIOLOGY","116","3",39,"10.1016/j.amjcard.2015.09.023","ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;DEPARTMENT OF CARDIOVASCULAR SCIENCES, SAPIENZA UNIVERSITY, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;INSTITUTE OF CARDIOLOGY, MADRE GIUSEPPINA VANNINI HOSPITAL, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY;DEPARTMENT OF CARDIOVASCULAR SCIENCES, SAPIENZA UNIVERSITY, ROME, ITALY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY","STATINS ARE EXTENSIVELY USED TO TREAT DYSLIPIDEMIA, BUT, BECAUSE OF THEIR LOW TOLERABILITY PROFILE, THEY ARE DISCONTINUED IN A SIGNIFICANT PROPORTION OF PATIENTS. EZETIMIBE AND NUTRACEUTICALS HAVE BEEN INTRODUCED AS ALTERNATIVE THERAPIES AND HAVE PROVED TO BE EFFECTIVE AND WELL TOLERATED. A SINGLE-BLIND, SINGLE-CENTER, RANDOMIZED, PROSPECTIVE, AND PARALLEL GROUP TRIAL COMPARING A COMBINATION OF NUTRACEUTICALS (RED YEAST RICE, POLICOSANOL, BERBERINE, FOLIC ACID, COENZYME Q10 AND ASTAXANTHIN), CALLED ARMOLIPID PLUS, AND EZETIMIBE FOR 3 MONTHS IN TERMS OF EFFICACY AND TOLERABILITY. PATIENTS WHO DID NOT ACHIEVE THEIR THERAPEUTIC TARGET (LOW-DENSITY LIPOPROTEIN CHOLESTEROL <100 MG/DL) COULD ADD THE ALTERNATIVE TREATMENT ON TOP OF RANDOMIZED TREATMENT FOR ANOTHER 12 MONTHS: 100 PATIENTS WHO ARE DYSLIPIDEMIC WITH ISCHEMIC HEART DISEASE TREATED WITH PERCUTANEOUS CORONARY INTERVENTION WERE ENROLLED (EZETIMIBE N = 50, NUTRACEUTICAL N = 50). EFFICACY (LIPID PROFILE) AND TOLERABILITY (ADVERSE EVENTS, TRANSAMINASES, AND CREATINE KINASE) WERE ASSESSED AFTER 3 AND 12 MONTHS. AFTER 3 MONTHS, 14 PATIENTS IN THE NUTRACEUTICAL GROUP ACHIEVED THEIR THERAPEUTIC TARGET, WHEREAS NONE OF THE PATIENTS IN THE EZETIMIBE GROUP DID. AT 1-YEAR FOLLOW-UP, 58 PATIENTS (72.5%) OF THE COMBINED THERAPY GROUP (N = 86) AND 14 (100%) OF THE NUTRACEUTICAL GROUP REACHED THE THERAPEUTIC GOAL. NO PATIENTS EXPERIENCED IMPORTANT UNDESIRABLE EFFECTS. IN CONCLUSION, NUTRACEUTICALS ALONE OR IN COMBINATION WITH EZETIMIBE ARE WELL TOLERATED AND IMPROVE THE LIPID PROFILE IN STATIN-INTOLERANT PATIENTS WITH CORONARY HEART DISEASE. FURTHER STUDIES ARE NEEDED TO ASSESS LONG-TERM EFFECTS OF NUTRACEUTICALS ON MORTALITY. © 2015 ELSEVIER INC. ALL RIGHTS RESERVED.","","CHOLESTEROL; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EZETIMIBE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; ALANINE AMINOTRANSFERASE; ARMOLIPID PLUS; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; BERBERINE; CHOLESTIN; CREATINE KINASE; EZETIMIBE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG COMBINATION; DYSLIPIDEMIAS; MIDDLE AGED; TREATMENT OUTCOME","","","KALRA E.K., NUTRACEUTICAL-DEFINITION AND INTRODUCTION, AAPS PHARM SCI, 5, (2003); ENDO A., THE ORIGIN OF THE STATINS. 2004, ATHEROSCLER SUPPL, 5, PP. 125-130, (2004); HALBERT S.C., FRENCH B., GORDON R.Y., FARRAR J.T., SCHMITZ K., MORRIS P.B., THOMPSON P.D., RADER D.J., BECKER D.J., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); KARL M., RUBENSTEIN M., RUDNICK C., BREJDA J., A MULTICENTER STUDY OF NUTRACEUTICAL DRINKS FOR CHOLESTEROL (EVALUATING EFFECTIVENESS AND TOLERABILITY), J CLIN LIPIDOL, 6, PP. 150-158, (2012); CICERO A.F., DEROSA G., PARINI A., MAFFIOLI P., D'ADDATO S., REGGI A., GIOVANNINI M., BORGHI C., RED YEAST RICE IMPROVES LIPID PATTERN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND VASCULAR REMODELING PARAMETERS IN MODERATELY HYPERCHOLESTEROLEMIC ITALIAN SUBJECTS, NUTR RES, 33, PP. 622-628, (2013); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); BOGSRUD M.P., OSE L., LANGSLET G., OTTESTAD I., STROM E.C., HAGVE T.A., RETTERSTOL K., HYPOCOL (RED YEAST RICE) LOWERS PLASMA CHOLESTEROL- A RANDOMIZED PLACEBO CONTROLLED STUDY, SCAND CARDIOVASC J, 44, PP. 197-200, (2010); AFFUSO F., MERCURIO V., FAZIO V., FAZIO S., CARDIOVASCULAR AND METABOLIC EFFECTS OF BERBERINE, WORLD J CARDIOL, 2, PP. 71-77, (2010); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); RUSCICA M., GOMARASCHI M., MOMBELLI G., MACCHI C., BOSISIO R., PAZZUCCONI F., PAVANELLO C., CALABRESI L., ARNOLDI A., SIRTORI C.R., MAGNI P., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J CLIN LIPIDOL, 8, PP. 61-68, (2014); BARRAT E., ZAIR Y., OGIER N., HOUSEZ B., VERGARA C., MAUDET C., LESCUYER J.F., BARD J.M., CARPENTIER Y.A., CAZAUBIEL M., PELTIER S.L., A COMBINED NATURAL SUPPLEMENT LOWERS LDL CHOLESTEROL IN SUBJECTS WITH MODERATE UNTREATED HYPERCHOLESTEROLEMIA: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, INT J FOOD SCI NUTR, 64, PP. 882-889, (2013); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDICTIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); LEVEY A.S., CORESH J., GREENE T., STEVENS L.A., ZHANG Y.L., HENDRIKSEN S., KUSEK J.W., VAN LENTE F., USING STANDARDIZED SERUM CREATININE VALUES IN THE MODIFICATION OF DIET IN RENAL DISEASE STUDY EQUATION FOR ESTIMATING GLOMERULAR FILTRATION RATE, ANN INTERN MED, 45, PP. 247-254, (2006); ENDO A., CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS, KLIN WOCHENSCHR, 66, PP. 421-427, (1988); MAN R.Y., LYNN E.G., CHEUNG F., TSANG P.S., CHOLESTIN INHIBITS CHOLESTEROL SYNTHESIS AND SECRETION IN HEPATIC CELLS (HEPG2), MOL CELL BIOCHEM, 233, PP. 153-158, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); PANDOR A., ARA R.M., TUMUR I., WILKINSON A.J., PAISLEY S., DUENAS A., DURRINGTON P.N., CHILCOTT J., EZETIMIBE MONOTHERAPY FOR CHOLESTEROL LOWERING IN 2722 PEOPLE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J INTERN MED, 265, PP. 568-580, (2009); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); CICERO A.F., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN DRUG SAF, 11, PP. 753-766, (2012); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., GRIECO F., FAZIO S., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., MORINA D., VILLAR J., MILLAN J., ANGUERA A., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); BANACH M., RIZZO M., TOTH P.P., FARNIER M., DAVIDSON M.H., AL-RASADI K., ARONOW W.S., ATHYROS V., DJURIC D.M., EZHOV M.V., GREENFIELD R.S., HOVINGH G.K., KOSTNER K., SERBAN C., LIGHEZAN D., FRAS Z., MORIARTY P.M., MUNTNER P., GOUDEV A., CESKA R., NICHOLLS S.J., BRONCEL M., NIKOLIC D., PELLA D., PURI R., RYSZ J., WONG N.D., BAJNOK L., JONES S.R., RAY K.K., MIKHAILIDIS D.P., STATIN INTOLERANCE- AN ATTEMPT AT A UNIFIED DEFINITION. POSITION PAPER FROM AN INTERNATIONAL LIPID EXPERT PANEL, ARCH MED SCI, 11, PP. 1-23, (2015)","G. MARAZZI; ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA, ROME, ITALY; EMAIL: GIUSEPPE.MARAZZI@SANRAFFAELE.IT","ELSEVIER INC.","ENGLISH","AM. J. CARDIOL.","ARTICLE","ISI","2-S2.0-84951842352","AM J CARDIOL","ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;SAPIENZA UNIVERSITY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;INSTITUTE OF CARDIOLOGY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;SAPIENZA UNIVERSITY;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA","NOTREPORTED;ISTITUTO DI RICERCA A CARATTERE SCIENTIFICO (IRCCS) SAN RAFFAELE PISANA;NOTREPORTED",NA,"MARAZZI G, 2015, AM J CARDIOL","MARAZZI G, 2015, AM J CARDIOL"
"DUNN A;BOURGEOIS F;MURTHY S;MANDL K;DAY R;COIERA E","DUNN, A.G. (17342099000); BOURGEOIS, F.T. (7006196289); MURTHY, S. (36247670800); MANDL, K.D. (7003721828); DAY, R.O. (56962776900); COIERA, E. (7003453209)","THE ROLE AND IMPACT OF RESEARCH AGENDAS ON THE COMPARATIVEEFFECTIVENESS RESEARCH AMONG ANTIHYPERLIPIDEMICS",2012,"CLINICAL PHARMACOLOGY AND THERAPEUTICS","91","6",10,"10.1038/clpt.2011.279","CENTRE FOR HEALTH INFORMATICS, AUSTRALIAN INSTITUTE OF HEALTH INNOVATION, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, NSW, AUSTRALIA;CHILDREN'S HOSPITAL INFORMATICS PROGRAM, HARVARD-MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY, CHILDREN'S HOSPITAL BOSTON, BOSTON, MA, UNITED STATES, DEPARTMENT OF PEDIATRICS, CHILDREN'S HOSPITAL BOSTON, BOSTON, MA, UNITED STATES;DIVISION OF INFECTIOUS DISEASES, HOSPITAL FOR SICK CHILDREN, UNIVERSITY OF TORONTO, TORONTO, ON, CANADA, DIVISION OF CRITICAL CARE, HOSPITAL FOR SICK CHILDREN, UNIVERSITY OF TORONTO, TORONTO, ON, CANADA;CHILDREN'S HOSPITAL INFORMATICS PROGRAM, HARVARD-MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY, CHILDREN'S HOSPITAL BOSTON, BOSTON, MA, UNITED STATES, DEPARTMENT OF PEDIATRICS, CHILDREN'S HOSPITAL BOSTON, BOSTON, MA, UNITED STATES;DEPARTMENT OF CLINICAL PHARMACOLOGY, ST VINCENT'S HOSPITAL, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, NSW, AUSTRALIA;CENTRE FOR HEALTH INFORMATICS, AUSTRALIAN INSTITUTE OF HEALTH INNOVATION, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, NSW, AUSTRALIA","ALTHOUGH IT IS WELL ESTABLISHED THAT FUNDING SOURCE INFLUENCES THE PUBLICATION OF CLINICAL TRIALS, RELATIVELY LITTLE IS KNOWN ABOUT HOW FUNDING INFLUENCES TRIAL DESIGN. WE EXAMINED A PUBLIC TRIAL REGISTRY TO DETERMINE HOW FUNDING SOURCE SHAPES TRIAL DESIGN AMONG TRIALS INVOLVING ANTIHYPERLIPIDEMICS. WE USED AN AUTOMATED PROCESS TO IDENTIFY AND ANALYZE 809 TRIALS FROM A SET OF 72,564. THREE NETWORKS REPRESENTING INDUSTRY-, COLLABORATIVELY, AND NON-INDUSTRY-FUNDED TRIALS WERE CONSTRUCTED. EACH NETWORK COMPRISED 18 DRUGS AS NODES CONNECTED ACCORDING TO THE NUMBER OF COMPARISONS MADE BETWEEN THEM. THE RESULTS INDICATED THAT INDUSTRY-FUNDED TRIALS WERE MORE LIKELY TO COMPARE ACROSS DRUGS AND EXAMINE DYSLIPIDEMIA AS A CONDITION, AND LESS LIKELY TO REGISTER SAFETY OUTCOMES. THE SOURCE OF FUNDING FOR CLINICAL TRIALS HAD A MEASURABLE EFFECT ON TRIAL DESIGN, WHICH HELPS QUANTIFY DIFFERENCES IN RESEARCH AGENDAS. IMPROVED MONITORING OF CURRENT CLINICAL TRIALS MAY BE USED TO MORE CLOSELY ALIGN RESEARCH AGENDAS TO CLINICAL NEEDS. © 2012 AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS.","","CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; HYPOLIPIDEMIC AGENTS; RANDOM ALLOCATION; REGISTRIES; RESEARCH DESIGN; ACIPIMOX; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; COLESEVELAM; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FENOFIBRATE PLUS PRAVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PITAVASTATIN; PLACEBO; POLICOSANOL; PROBUCOL; ROSUVASTATIN; SIMVASTATIN; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME","U.S. NATIONAL LIBRARY OF MEDICINE, NLM, (G08LM009778); U.S. NATIONAL LIBRARY OF MEDICINE, NLM","","HOCHMAN M., MCCORMICK D., CHARACTERISTICS OF PUBLISHED COMPARATIVE EFFECTIVENESS STUDIES OF MEDICATIONS, JAMA, 303, PP. 951-958, (2010); O'CONNOR A.B., BUILDING COMPARATIVE EFFICACY AND TOLERABILITY INTO THE FDA APPROVAL PROCESS, JAMA, 303, PP. 979-980, (2010); NAIK A.D., PETERSEN L.A., THE NEGLECTED PURPOSE OF COMPARATIVEEFFECTIVENESS RESEARCH, N. ENGL. J. MED., 360, PP. 1929-1931, (2009); FRASER A.G., DUNSTAN F.D., ON THE IMPOSSIBILITY OF BEING EXPERT, BMJ, 341, (2010); BASTIAN H., GLASZIOU P., CHALMERS I., SEVENTY-FIVE TRIALS AND ELEVEN SYSTEMATIC REVIEWS A DAY: HOW WILL WE EVER KEEP UP?, PLOS MED., 7, (2010); SHANEYFELT T.M., CENTOR R.M., REASSESSMENT OF CLINICAL PRACTICE GUIDELINES: GO GENTLY INTO THAT GOOD NIGHT, JAMA, 301, PP. 868-869, (2009); TRICOCI P., ALLEN J.M., KRAMER J.M., CALIFF R.M., SMITH JR. S.C., SCIENTIFIC EVIDENCE UNDERLYING THE ACC/AHA CLINICAL PRACTICE GUIDELINES, JAMA, 301, PP. 831-841, (2009); LEE D.H., VIELEMEYER O., ANALYSIS OF OVERALL LEVEL OF EVIDENCE BEHIND INFECTIOUS DISEASES SOCIETY OF AMERICA PRACTICE GUIDELINES, ARCH. INTERN. MED., 171, PP. 18-22, (2011); MCALISTER F.A., VAN DIEPEN S., PADWAL R.S., JOHNSON J.A., MAJUMDAR S.R., HOW EVIDENCE-BASED ARE THE RECOMMENDATIONS IN EVIDENCE-BASED GUIDELINES?, PLOS MED., 4, (2007); CHALMERS I., GLASZIOU P., AVOIDABLE WASTE IN THE PRODUCTION AND REPORTING OF RESEARCH EVIDENCE, LANCET, 374, PP. 86-89, (2009); LESKO L.J., ZINEH I., HUANG S.M., WHAT IS CLINICAL UTILITY AND WHY SHOULD WE CARE?, CLIN. PHARMACOL. THER., 88, PP. 729-733, (2010); UMSCHEID C.A., MAXIMIZING THE CLINICAL UTILITY OF COMPARATIVE EFFECTIVENESS RESEARCH, CLIN. PHARMACOL. THER., 88, PP. 876-879, (2010); ALS-NIELSEN B., CHEN W., GLUUD C., KJAERGARD L.L., ASSOCIATION OF FUNDING AND CONCLUSIONS IN RANDOMIZED DRUG TRIALS: A REFLECTION OF TREATMENT EFFECT OR ADVERSE EVENTS?, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 290, 7, PP. 921-928, (2003); RASMUSSEN N., LEE K., BERO L., ASSOCIATION OF TRIAL REGISTRATION WITH THE RESULTS AND CONCLUSIONS OF PUBLISHED TRIALS OF NEW ONCOLOGY DRUGS, TRIALS, 10, (2009); MATHIEU S., BOUTRON I., MOHER D., ALTMAN D.G., RAVAUD P., COMPARISON OF REGISTERED AND PUBLISHED PRIMARY OUTCOMES IN RANDOMIZED CONTROLLED TRIALS, JAMA, 302, PP. 977-984, (2009); BOURGEOIS F.T., MURTHY S., MANDL K.D., OUTCOME REPORTING AMONG DRUG TRIALS REGISTERED IN CLINICALTRIALS.GOV, ANN. INTERN. MED., 153, PP. 158-166, (2010); LATHYRIS D.N., PATSOPOULOS N.A., SALANTI G., IOANNIDIS J.P., INDUSTRY SPONSORSHIP AND SELECTION OF COMPARATORS IN RANDOMIZED CLINICAL TRIALS, EUR. J. CLIN. INVEST., 40, PP. 172-182, (2010); ROSS J.S., MULVEY G.K., HINES E.M., NISSEN S.E., KRUMHOLZ H.M., TRIAL PUBLICATION AFTER REGISTRATION IN CLINICALTRIALS.GOV: A CROSS-SECTIONAL ANALYSIS, PLOS MED., 6, (2009); BUTTS C.T., REVISITING THE FOUNDATIONS OF NETWORK ANALYSIS, SCIENCE, 325, PP. 414-416, (2009); BARABASI A.L., SCALE-FREE NETWORKS: A DECADE AND BEYOND, SCIENCE, 325, PP. 412-413, (2009); BORGATTI S.P., MEHRA A., BRASS D.J., LABIANCA G., NETWORK ANALYSIS IN THE SOCIAL SCIENCES, SCIENCE, 323, PP. 892-895, (2009); GREENBERG S.A., HOW CITATION DISTORTIONS CREATE UNFOUNDED AUTHORITY: ANALYSIS OF A CITATION NETWORK, BMJ, 339, (2009); CHEN P., REDNER S., COMMUNITY STRUCTURE OF THE PHYSICAL REVIEW CITATION NETWORK, JOURNAL OF INFORMETRICS, 4, PP. 278-290, (2010); MOODY J., THE STRUCTURE OF A SOCIAL SCIENCE COLLABORATION NETWORK: DISCIPLINARY COHESION FROM 1963 TO 1999, AMERICAN SOCIOLOGICAL REVIEW, 69, 2, PP. 213-238, (2004); RIZOS E.C., SALANTI G., KONTOYIANNIS D.P., IOANNIDIS J.P., HOMOPHILY AND CO-OCCURRENCE PATTERNS SHAPE RANDOMIZED TRIALS AGENDAS: ILLUSTRATION IN ANTIFUNGAL AGENTS, J. CLIN. EPIDEMIOL., 64, PP. 830-842, (2011); BHAVNANI S.K., CARINI S., ROSS J., SIM I., NETWORK ANALYSIS OF CLINICAL TRIALS ON DEPRESSION: IMPLICATIONS FOR COMPARATIVE EFFECTIVENESS RESEARCH, AMIA ANNUAL SYMPOSIUM, PP. 51-55, (2010); ZARIN D.A., TSE T., WILLIAMS R.J., CALIFF R.M., IDE N.C., THE CLINICALTRIALS.GOV RESULTS DATABASE-UPDATE AND KEY ISSUES, N. ENGL. J. MED., 364, PP. 852-860, (2011); STAFFORD R.S., WAGNER T.H., LAVORI P.W., NEW BUT NOT IMPROVED? INCORPORATING COMPARATIVE-EFFECTIVENESS INFORMATION INTO FDA LABELING, N. ENGL. J. MED., 361, PP. 1230-1233, (2009); GAGNE J.J., CHOUDHRY N.K., HOW MANY ""ME-TOO"" DRUGS IS TOO MANY?, JAMA, 305, PP. 711-712, (2011); LEE K., BACCHETTI P., SIM I., PUBLICATION OF CLINICAL TRIALS SUPPORTING SUCCESSFUL NEW DRUG APPLICATIONS: A LITERATURE ANALYSIS, PLOS MED., 5, (2008); RISING K., BACCHETTI P., BERO L., REPORTING BIAS IN DRUG TRIALS SUBMITTED TO THE FOOD AND DRUG ADMINISTRATION: REVIEW OF PUBLICATION AND PRESENTATION, PLOS MED., 5, (2008); BRODY H., LIGHT D.W., THE INVERSE BENEFIT LAW: HOW DRUG MARKETING UNDERMINES PATIENT SAFETY AND PUBLIC HEALTH, AM. J. PUBLIC HEALTH, 101, PP. 399-404, (2011); MOYNIHAN R., AUSTRALIAN GOVERNMENT SAYS HEALTHY UNDER 5S SHOULD NOT BE GIVEN SEASONAL FLU JAB, BMJ, 340, (2010); MAJOR LIPIDS, APOLIPOPROTEINS, AND RISK OF VASCULAR DISEASE, JAMA, 302, PP. 1993-2000, (2009); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); KASTELEIN J.J.P., AKDIM F., STROES E.S.G., ZWINDERMAN A.H., BOTS M.L., STALENHOEF A.F.H., VISSEREN F.L.J., SIJBRANDS E.J.G., TRIP M.D., STEIN E.A., GAUDET D., DUIVENVOORDEN R., VELTRI E.P., MARAIS A.D., DE GROOT E., SIMVASTATIN WITH OR WITHOUT EZETIMIBE IN FAMILIAL HYPERCHOLESTEROLEMIA, NEW ENGLAND JOURNAL OF MEDICINE, 358, 14, PP. 1431-1443, (2008); BARTER P.J., CAULFIELD M., ERIKSSON M., GRUNDY S.M., KASTELEIN J.J.P., KOMAJDA M., LOPEZ-SENDON J., MOSCA L., TARDIF J.-C., WATERS D.D., SHEAR C.L., REVKIN J.H., BUHR K.A., FISHER M.R., TALL A.R., BREWER B., EFFECTS OF TORCETRAPIB IN PATIENTS AT HIGH RISK FOR CORONARY EVENTS, NEW ENGLAND JOURNAL OF MEDICINE, 357, 21, PP. 2109-2122, (2007); BRASS E.P., THE GAP BETWEEN CLINICAL TRIALS AND CLINICAL PRACTICE: THE USE OF PRAGMATIC CLINICAL TRIALS TO INFORM REGULATORY DECISION MAKING, CLIN. PHARMACOL. THER., 87, PP. 351-355, (2010); RAWLINS M., DE TESTIMONIO: ON THE EVIDENCE FOR DECISIONS ABOUT THE USE OF THERAPEUTIC INTERVENTIONS, LANCET, 372, PP. 2152-2161, (2008); ANDERSON B.S., BUTTS C., CARLEY K., THE INTERACTION OF SIZE AND DENSITY WITH GRAPH-LEVEL INDICES, SOCIAL NETWORKS, 21, PP. 239-267, (1999); DUNN A.G., WESTBROOK J.I., INTERPRETING SOCIAL NETWORK METRICS IN HEALTHCARE ORGANISATIONS: A REVIEW AND GUIDE TO VALIDATING SMALL NETWORKS, SOC. SCI. MED., 72, PP. 1064-1068, (2011); STINGL KIRCHHEINER J.C., BROCKMOLLER J., WHY WHEN, AND HOW SHOULD PHARMACOGENETICS BE APPLIED IN CLINICAL STUDIES?: CURRENT AND FUTURE APPROACHES TO STUDY DESIGNS, CLIN. PHARMACOL. THER., 89, PP. 198-209, (2011); TATONETTI N.P., ET AL., DETECTING DRUG INTERACTIONS FROM ADVERSE-EVENT REPORTS: INTERACTION BETWEEN PAROXETINE AND PRAVASTATIN INCREASES BLOOD GLUCOSE LEVELS, CLIN. PHARMACOL. THER., 90, PP. 133-142, (2011); CLEMENT F.M., HARRIS A., LI J.J., YONG K., LEE K.M., MANNS B.J., USING EFFECTIVENESS AND COST-EFFECTIVENESS TO MAKE DRUG COVERAGE DECISIONS: A COMPARISON OF BRITAIN AUSTRALIA, AND CANADA, JAMA, 302, PP. 1437-1443, (2009); SHANNON P., MARKIEL A., OZIER O., BALIGA N.S., WANG J.T., RAMAGE D., AMIN N., SCHWIKOWSKI B., IDEKER T., CYTOSCAPE: A SOFTWARE ENVIRONMENT FOR INTEGRATED MODELS OF BIOMOLECULAR INTERACTION NETWORKS, GENOME RESEARCH, 13, 11, PP. 2498-2504, (2003)","A.G. DUNN; CENTRE FOR HEALTH INFORMATICS, AUSTRALIAN INSTITUTE OF HEALTH INNOVATION, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, NSW, AUSTRALIA; EMAIL: A.DUNN@UNSW.EDU.AU","","ENGLISH","CLIN. PHARMACOL. THER.","ARTICLE","ISI","2-S2.0-84858794885","CLIN PHARMACOL THER","UNIVERSITY OF NEW SOUTH WALES;HARVARD-MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY;UNIVERSITY OF TORONTO;HARVARD-MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY;UNIVERSITY OF NEW SOUTH WALES;UNIVERSITY OF NEW SOUTH WALES","NOTREPORTED;UNIVERSITY OF NEW SOUTH WALES;NOTREPORTED",NA,"DUNN AG, 2012, CLIN PHARMACOL THER","DUNN AG, 2012, CLIN PHARMACOL THER"
"MUJICA-MOTA M;BEZDJIAN A;SALEHI P;SCHERMBRUCKER J;DANIEL S","MUJICA-MOTA, MARIO A. (53984553100); BEZDJIAN, AREN (56293363500); SALEHI, PEZHMAN (55337603400); SCHERMBRUCKER, JONAH (56460309900); DANIEL, SAM J. (7201730733)","ASSESSMENT OF OTOTOXICITY OF INTRATYMPANIC ADMINISTRATION OF AURALGAN IN A CHINCHILLA ANIMAL MODEL",2015,"LARYNGOSCOPE","125","4",4,"10.1002/lary.25080","MCGILL AUDITORY SCIENCES LABORATORY, MCGILL UNIVERSITY HEALTH CENTRE, 2300 TUPPER STREET, MONTREAL, H3H1P3, QC, CANADA;MCGILL AUDITORY SCIENCES LABORATORY, MCGILL UNIVERSITY HEALTH CENTRE, 2300 TUPPER STREET, MONTREAL, H3H1P3, QC, CANADA;MCGILL AUDITORY SCIENCES LABORATORY, MCGILL UNIVERSITY HEALTH CENTRE, 2300 TUPPER STREET, MONTREAL, H3H1P3, QC, CANADA;MCGILL AUDITORY SCIENCES LABORATORY, MCGILL UNIVERSITY HEALTH CENTRE, 2300 TUPPER STREET, MONTREAL, H3H1P3, QC, CANADA;MCGILL AUDITORY SCIENCES LABORATORY, MCGILL UNIVERSITY HEALTH CENTRE, 2300 TUPPER STREET, MONTREAL, H3H1P3, QC, CANADA, DEPARTMENT OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY, MONTREAL CHILDREN'S HOSPITAL, MONTREAL, QC, CANADA","OBJECTIVES/HYPOTHESIS AURALGAN (BENZOCAINE AND ANTIPYRINE) IS AN OVER-THE-COUNTER OTIC DRUG COMMONLY USED FOR OTALGIA. NEVERTHELESS, THERE IS LIMITED EVIDENCE ABOUT THE EFFECTS OF THE DRUG ON HEARING FUNCTION AND COCHLEAR MORPHOLOGY IN THE PRESENCE OF A TYMPANIC MEMBRANE PERFORATION. THE AIM OF THE PRESENT STUDY WAS TO ASSESS THE CYTOTOXICITY OF AURALGAN USING CULTURED AUDITORY CELLS (HEI-OC1) AND TO EXAMINE ITS EFFECTS ON HEARING FUNCTION AND COCHLEAR MORPHOLOGY AFTER INTRATYMPANIC ADMINISTRATION IN A CHINCHILLA MODEL. STUDY DESIGN ANIMAL EXPERIMENT. METHODS CELL VIABILITY AND DNA LABELING ASSAYS WERE CONDUCTED TO INVESTIGATE THE CYTOTOXIC EFFECT OF THE DRUG ON CULTURED AUDITORY CELLS (HEI-OC1). TO EXAMINE THE POSSIBLE DRUG OTOTOXIC EFFECT IN VIVO, CHINCHILLAS RECEIVED INTRATYMPANIC INJECTION OF AURALGAN IN ONE EAR, WHEREAS THE CONTRALATERAL CONTROL EAR RECEIVED SALINE. OUTCOME MEASURES INCLUDED AUDITORY BRAINSTEM RESPONSE AND POSTMORTEM COCHLEAR MORPHOLOGY. RESULTS A DOSE-DEPENDENT TOXIC EFFECT OF AURALGAN WAS NOTED ON CULTURED CELLS. ANIMAL EXPERIMENTS SHOWED AN INFLAMMATORY REACTION IN THE EXPERIMENTAL EARS AND FACIAL PARALYSIS IN 80% OF THE ANIMALS ON THE SIDE RECEIVING TRANSTYMPANIC INJECTION OF AURALGAN (P-‰<-‰.05). AUDITORY BRAINSTEM RESPONSE TESTING DEMONSTRATED A 30- TO 50-DB HEARING THRESHOLD SHIFT ACROSS ALL FREQUENCIES TESTED (P-‰<-‰.05). CONTROL EARS SHOWED NO INFLAMMATION OR SIGNIFICANT THRESHOLD SHIFT. MICROSCOPY SHOWED DAMAGE TO THE HAIR CELLS AND STRIA VASCULARIS WITH BLEEDING IN THE PERILYMPHATIC SPACE IN THE EXPERIMENTAL EARS AND DAMAGE TO THE HAIR CELLS. CONCLUSIONS AURALGAN WAS CYTOTOXIC TO CULTURED AUDITORY CELLS. IT PROMOTED AN INFLAMMATORY REACTION AND SEEMED TO BE OTOTOXIC WHEN GIVEN VIA TRANSTYMPANIC INJECTION IN AN ANIMAL MODEL. © 2014 THE AMERICAN LARYNGOLOGICAL, RHINOLOGICAL AND OTOLOGICAL SOCIETY, INC.","ANTIPYRINE; BENZOCAINE; CHINCHILLA; HEI-OC1; OTOTOXICITY","ANIMALS; ANTIPYRINE; AUDITORY THRESHOLD; BENZOCAINE; CELLS, CULTURED; CHINCHILLA; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; EAR, INNER; FEMALE; OTITIS MEDIA; AURALGAN; ACETIC ACID, ANTIPYRINE, BENZOCAINE, GLYCEROL, POLYCOSANOL DRUG COMBINATION; BENZOCAINE; DRUG COMBINATION; PHENAZONE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; AUDITORY RESPONSE; AUDITORY THRESHOLD SHIFT; BACTERIAL GROWTH; BRAIN STEM RESPONSE; CELL COUNT; CELL CULTURE; CELL DEATH; CELL LOSS; CELL VIABILITY; CHINCHILLA MODEL; COCHLEA ATROPHY; COCHLEA INFLAMMATION; COCHLEA INJURY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; FACIAL NERVE PARALYSIS; FEMALE; HEARING; IN VIVO STUDY; INFLAMMATION; INNER EAR DISEASE; MORPHOLOGY; NONHUMAN; OTORRHEA; OTOTOXICITY; OUTCOME ASSESSMENT; PASTEURELLA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRIA VASCULARIS BLEEDING; VISUAL FIELD; ANIMAL; AUDITORY THRESHOLD; CHINCHILLA; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; INNER EAR; OTITIS MEDIA","","","HAYDEN G.F., SCHWARTZ R.H., CHARACTERISTICS OF EARACHE AMONG CHILDREN WITH ACUTE OTITIS MEDIA, AM J DIS CHILD, 139, PP. 721-723, (1985); GLASZIOU P.P., DEL MAR C.B., SANDERS S.L., HAYEM M., ANTIBIOTICS FOR ACUTE OTITIS MEDIA IN CHILDREN, COCHRANE DATABASE SYST REV, 1, (2004); HOBERMAN A., PARADISE J.L., REYNOLDS E.A., URKIN J., EFFICACY OF AURALGAN FOR TREATING EAR PAIN IN CHILDREN WITH ACUTE OTITIS MEDIA, ARCH PEDIATR ADOLESC MED, 151, PP. 675-678, (1997); LIESE J.G., SILFVERDAL S.A., GIAQUINTO C., ET AL., INCIDENCE AND CLINICAL PRESENTATION OF ACUTE OTITIS MEDIA IN CHILDREN AGED <6 YEARS IN EUROPEAN MEDICAL PRACTICES, EPIDEMIOL INFECT, 142, PP. 1778-1788, (2014); MAROM T., TAN A., WILKINSON G.S., PIERSON K.S., FREEMAN J.L., CHONMAITREE T., TRENDS IN OTITIS MEDIA-RELATED HEALTH CARE USE IN THE UNITED STATES, 2001-2011, JAMA PEDIATR, 168, PP. 68-75, (2014); DIMMITT P., CERUMEN REMOVAL PRODUCTS, J PEDIATR HEALTH CARE, 19, PP. 332-336, (2005); ANTIPYRINE AND BENZOCAINE EAR DROPS; VERLEYE M., HEULARD I., GILLARDIN J.M., PHENAZONE POTENTIATES THE LOCAL ANAESTHETIC EFFECT OF LIDOCAINE IN MICE, PHARMACOL RES, 41, PP. 539-542, (2000); ZIMMERMAN L., PETERSON A.M., OTITIS MEDIA AND OTITIS EXTERNA, PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE. A PRACTICAL APPROACH, 188, (2011); LOGAN B.K., GORDON A.M., DEATH OF AN INFANT INVOLVING BENZOCAINE, J FORENSIC SCI, 50, PP. 1486-1488, (2005); WOOD D.N., NAKAS N., GREGORY C.W., CLINICAL TRIALS ASSESSING OTOTOPICAL AGENTS IN THE TREATMENT OF PAIN ASSOCIATED WITH ACUTE OTITIS MEDIA IN CHILDREN, INT J PEDIATR OTORHINOLARYNGOL, 76, PP. 1229-1235, (2012); MCGOWAN E.M., ALLING N., JACKSON E.A., ET AL., EVALUATION OF CELL CYCLE ARREST IN ESTROGEN RESPONSIVE MCF-7 BREAST CANCER CELLS: PITFALLS OF THE MTS ASSAY, PLOS ONE, 6, (2011); ROLAND P.S., RYBAK L., HANNLEY M., ET AL., ANIMAL OTOTOXICITY OF TOPICAL ANTIBIOTICS AND THE RELEVANCE TO CLINICAL TREATMENT OF HUMAN SUBJECTS, OTOLARYNGOL HEAD NECK SURG, 130, PP. S57-S78, (2004); DANIEL S.J., DUVAL M., SAHMKOW S., AKACHE F., OTOTOXICITY OF TOPICAL MOXIFLOXACIN IN A CHINCHILLA ANIMAL MODEL, LARYNGOSCOPE, 117, PP. 2201-2205, (2007); MILLER J.D., AUDIBILITY CURVE OF THE CHINCHILLA, J ACOUST SOC AM, 48, PP. 513-523, (1970); WALL E.C., AJDUKIEWICZ K.M., HEYDERMAN R.S., GARNER P., OSMOTIC THERAPIES ADDED TO ANTIBIOTICS FOR ACUTE BACTERIAL MENINGITIS, COCHRANE DATABASE SYST REV, 3, (2013)","","JOHN WILEY AND SONS INC","ENGLISH","LARYNGOSCOPE","ARTICLE","ISI","2-S2.0-84929702188","LARYNGOSCOPE",NA,"NOTREPORTED",NA,"MUJICA-MOTA MA, 2015, LARYNGOSCOPE","MUJICA-MOTA MA, 2015, LARYNGOSCOPE"
"LEE B;CARR T;WELLER C;CUPPETT S;DWEIKAT I;SCHLEGEL V","LEE, BO HYUN (55993946200); CARR, TIMOTHY P. (7103305648); WELLER, CURTIS L. (57204340168); CUPPETT, SUSAN (7003349552); DWEIKAT, ISMAIL M. (6602486245); SCHLEGEL, VICKI (7003881781)","GRAIN SORGHUM WHOLE KERNEL OIL LOWERS PLASMA AND LIVER CHOLESTEROL IN MALE HAMSTERS WITH MINIMAL WAX INVOLVEMENT",2014,"JOURNAL OF FUNCTIONAL FOODS","7","9",15,"10.1016/j.jff.2013.12.014","DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, LINCOLN, NE, UNITED STATES;DEPARTMENT OF NUTRITION AND HEALTH SCIENCE, UNIVERSITY OF NEBRASKA, LINCOLN, NE, UNITED STATES;DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, LINCOLN, NE, UNITED STATES;DEPARTMENT OF AGRONOMY AND HORTICULTURE, UNIVERSITY OF NEBRASKA, LINCOLN, NE, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, LINCOLN, NE, UNITED STATES","THE LIPID FRACTION OF THE GRAIN SORGHUM WHOLE KERNEL (GS-WK) (I.E., PHYTOSTEROL RICH OIL OR POLICOSANOL RICH WAX) RESPONSIBLE FOR LOWERING CHOLESTEROL IN HAMSTERS FED THE CRUDE LIPID (WAX. +. OIL) WAS DETERMINED. AS EXPECTED, HAMSTERS FED AN ATHEROGENIC DIET FOR A FOUR WEEK PERIOD PRESENTED WITH HIGHER PLASMA NON-HDL PLASMA AND LIVER ESTERIFIED CHOLESTEROL THAN THOSE ON THE LOW FAT DIET. HOWEVER, THE ATHEROGENIC DIET CONTAINING 5% (W/W) OIL SIGNIFICANTLY LOWERED NON-HDL PLASMA AND LIVER CHOLESTEROL. ALTHOUGH THE 5% WAX SUPPLEMENT DID NOT AFFECT EITHER PLASMA OR LIVER CHOLESTEROL, EXCRETED NEUTRAL STEROL AND BILE ACID WERE SLIGHTLY HIGHER THAN PRODUCED BY THE ATHEROGENIC DIET. STILL, CHOLESTEROL EXCRETION NEGATIVELY CORRELATED WITH LIVER CHOLESTEROL CONCENTRATION ( R= -0.681, P<. 0.001) ACROSS DIETS WITH THE OIL FRACTION PRODUCING THE GREATEST IMPACT. THESE COMBINED RESULTS INDICATE THAT OIL PLAYS THE MOST SIGNIFICANT ROLE IN MODULATING CHOLESTEROL, MOST LIKELY BY INHIBITING ABSORPTION, BUT SUBTLE INTERACTIONS BY THE WAX MAY BE INVOLVED. HOWEVER, THE SORGHUM OIL WOULD BE THE MOST POTENT COMPONENT TO SERVE AS A POSSIBLE HEART HEALTH INGREDIENT IN FUNCTIONAL FOODS. © 2013 ELSEVIER LTD.","CHOLESTEROL; GRAIN SORGHUM; PHYTOSTEROLS; POLICOSANOLS; WHOLE KERNELS","CRICETINAE; SORGHUM BICOLOR BICOLOR","UNITED SORGHUM CHECK OFF PROGRAM, (R0027-10); UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION; U.S. DEPARTMENT OF AGRICULTURE, USDA","A CONTRIBUTION OF THE UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION, SUPPORTED IN PART BY FUNDS PROVIDED THROUGH THE HATCH ACT, USDA. ADDITIONAL SUPPORT WAS PROVIDED BY THE UNITED SORGHUM CHECK OFF PROGRAM (GRANT PROJECT NUMBER R0027-10 ). MENTION OF A TRADE NAME, PROPRIETARY PRODUCTS, OR COMPANY NAME IS FOR PRESENTATION CLARITY AND DOES NOT IMPLY ENDORSEMENT BY THE AUTHORS OR THE UNIVERSITY OF NEBRASKA. THE AUTHORS RECOGNIZE THE VALUABLE SUPPORT PROVIDED BY MARK ASH AND KATE WOLFORD IN ANIMAL CARE.  ","BATTA A.K., XU G., HONDA A., MIYAZAKI T., SALEN G., STIGMASTEROL REDUCES PLASMA CHOLESTEROL LEVELS AND INHIBITS HEPATIC SYNTHESIS AND INTESTINAL ABSORPTION IN THE RAT, METABOLISM: CLINICAL AND CXPERIMENTAL, 55, PP. 292-299, (2006); BRAVO E., CANTAFORA A., CALCABRINI A., ORTU G., WHY PREFER THE GOLDEN SYRIAN HAMSTER (MESOCRICETUS AURATUS) TO THE WISTAR RAT IN EXPERIMENTAL STUDIES ON PLASMA LIPOPROTEIN METABOLISM?, COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY PART B: COMPARATIVE BIOCHEMISTRY, 107, PP. 347-355, (1994); BROUSSEAU M.E., SCHAEFER E.J., DIET AND CORONARY HEART DISEASE: CLINICAL TRIALS, CURRENT ATHEROSCLEROSIS REPORTS, 2, PP. 487-493, (2000); BURSILL C.A., ROACH P.D., A GREEN TEA CATECHIN EXTRACT UPREGULATES THE HEPATIC LOW-DENSITY LIPOPROTEIN RECEPTOR IN RATS, LIPIDS, 42, PP. 621-627, (2007); BUTLER L.M., WANG R., KOH W.P., STERN M.C., YUAN J.M., YU M.C., MARINE N-3 AND SATURATED FATTY ACIDS IN RELATION TO RISK OF COLORECTAL CANCER IN SINGAPORE CHINESE: A PROSPECTIVE STUDY, INTERNATIONAL JOURNAL OF CANCER, 124, PP. 678-686, (2009); CAI G., CARR T.P., BILIARY CHOLESTEROL AND BILE ACID EXCRETION DO NOT INCREASE IN HAMSTERS FED CEREAL-BASED DIETS CONTAINING CHOLESTEROL, METABOLISM, 48, PP. 400-405, (1999); CALPE-BERDIEL L., ESCOLA-GIL J.C., RIBAS V., NAVARRO-SASTRE A., GARCES-GARCES J., BLANCO-VACA F., CHANGES IN INTESTINAL AND LIVER GLOBAL GENE EXPRESSION IN RESPONSE TO A PHYTOSTEROL-ENRICHED DIET, ATHEROSCLEROSIS, 181, PP. 75-85, (2005); CARR T.P., ANDRESEN C.J., RUDEL L.L., ENZYMATIC DETERMINATION OF TRIGLYCERIDE, FREE CHOLESTEROL, AND TOTAL CHOLESTEROL IN TISSUE LIPID EXTRACTS, CLINICAL BIOCHEMISTRY, 26, PP. 39-42, (1993); CARR T.P., ASH M.M., BROWN A.W., CHOLESTEROL-LOWERING PHYTOSTEROLS: FACTORS AFFECTING THEIR USE AND EFFICACY, JOURNAL OF NUTRITION AND DIETARY SUPPLEMENTS, 2, PP. 59-72, (2010); CARR T.P., CAI G., LEE J.Y., SCHNEIDER C.L., CHOLESTERYL ESTER ENRICHMENT OF PLASMA LOW-DENSITY LIPOPROTEINS IN HAMSTERS FED CEREAL-BASED DIETS CONTAINING CHOLESTEROL, PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 223, PP. 96-101, (2000); CARR T.P., WELLER C.L., SCHLEGEL V.L., CUPPETT S.L., GUDERIAN D.M., JOHNSON K.R., GRAIN SORGHUM LIPID EXTRACT REDUCES CHOLESTEROL ABSORPTION AND PLASMA NON-HDL CHOLESTEROL CONCENTRATION IN HAMSTERS, THE JOURNAL OF NUTRITION, 135, PP. 2236-2240, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 31, PP. 31-44, (2005); CASTILLA P., ECHARRI R., DAVALOS A., CERRATO F., ORTEGA H., TERUEL J.L., LUCAS M.F., GOMEZ-CORONADO D., ORTUNO J., LASUNCION M.A., CONCENTRATED RED GRAPE JUICE EXERTS ANTIOXIDANT, HYPOLIPIDEMIC, AND ANTIINFLAMMATORY EFFECTS IN BOTH HEMODIALYSIS PATIENTS AND HEALTHY SUBJECTS, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, PP. 252-262, (2006); CHARACH G., RABINOVICH A., ARGOV O., WEINTRAUB M., RABINOVICH P., THE ROLE OF BILE ACID EXCRETION IN ATHEROSCLEROTIC CORONARY ARTERY DISEASE, INTERNATIONAL JOURNAL OF VASCULAR MEDICINE, (2012); CHEEMA S., CORNISH M., BIO F1B HAMSTER: A UNIQUE ANIMAL MODEL WITH REDUCED LIPOPROTEIN LIPASE ACTIVITY TO INVESTIGATE NUTRIENT MEDIATED REGULATION OF LIPOPROTEIN METABOLISM, NUTRITION & METABOLISM, 4, (2007); CHEN Z.-Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 56, PP. 8761-8773, (2008); CHO E., SPIEGELMAN D., HUNTER D.J., CHEN W.Y., STAMPFER M.J., COLDITZ G.A., WILLETT W.C., PREMENOPAUSAL FAT INTAKE AND RISK OF BREAST CANCER, JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95, PP. 1079-1085, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INTERNATIONL JOURNAL ON CLINICAL PHARMACOLOGY RESEARCH, 19, PP. 117-128, (1999); DAVIS H.R., ZHU L., HOOS L.M., TETZLOFF G., MAGUIRE M., LIU J., YAO X., IYER S.P.N., LAM M.H., LUND E.G., NIEMANN-PICK C1 LIKE 1 (NPC1L1) IS THE INTESTINAL PHYTOSTEROL AND CHOLESTEROL TRANSPORTER AND A KEY MODULATOR OF WHOLE-BODY CHOLESTEROL HOMEOSTASIS, JOURNAL OF BIOLOGICAL CHEMISTRY, 279, PP. 33586-33592, (2004); ERKKILA A.T., LICHTENSTEIN A.H., FIBER AND CARDIOVASCULAR DISEASE RISK: HOW STRONG IS THE EVIDENCE?, JOURNAL OF CARDIOVASCULAR NURSING, 21, PP. 3-8, (2006); FERNANDEZ M.L., WEBB D., THE LDL TO HDL CHOLESTEROL RATIO AS A VALUABLE TOOL TO EVALUATE CORONARY HEART DISEASE RISK, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 27, PP. 1-5, (2008); FIELD F.J., BORN E., MATHUR S.N., STANOL ESTERS DECREASE PLASMA CHOLESTEROL INDEPENDENTLY OF INTESTINAL ABC STEROL TRANSPORTERS AND NIEMANN-PICK C1-LIKE 1 PROTEIN GENE EXPRESSION, JOURNAL OF LIPID RESEARCH, 45, PP. 2252-2259, (2004); FOLCH J., LEES M., SLOANE-STANLEY G.H., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDS FROM ANIMAL TISSUES, JOURNAL OF BIOLOGICAL CHEMISTRY, 224, PP. 497-509, (1957); FREMEAUX A.E., HOSKING J., METCALF B.S., JEFFERY A.N., VOSS L.D., WILKIN T.J., CONSISTENCY OF CHILDREN'S DIETARY CHOICES: ANNUAL REPEAT MEASURES FROM 5 TO 13YEARS (EARLYBIRD 49), THE BRITISH JOURNAL OF NUTRITION, 106, PP. 725-731, (2011); GAMEZ R., MAZ R., ARRUZAZABALA M., MENDOZA S., CASTANO G., EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS, DRUGS IN RESEARCH AND DEVELOPMENT, 6, PP. 11-19, (2005); HAYES K.C., LIVINGSTON A., TRAUTWEIN E.A., DIETARY IMPACT ON BILIARY LIPIDS AND GALLSTONES, ANNUAL REVIEW IN NUTRITION, 12, PP. 299-326, (1992); HEGELE R.A., POLLEX R.L., HYPERTRIGLYCERIDEMIA: PHENOMICS AND GENOMICS, MOLECULAR AND CELLULAR BIOCHEMISTRY, 326, PP. 35-43, (2009); HEIDENREICH P.A., TROGDON J.G., KHAVJOU O.A., BUTLER J., DRACUP K., EZEKOWITZ M.D., FINKELSTEIN E.A., HONG Y., JOHNSTON S.C., KHERA A., FORECASTING THE FUTURE OF CARDIOVASCULAR CISEASE IN THE UNITED STATES: A POLICY STATEMENT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, PP. 933-944, (2011); HOI J.T., WELLER C.L., SCHLEGEL V.L., CUPPETT S.L., LEE J.-Y., CARR T.P., SORGHUM DISTILLERS DRIED GRAIN LIPID EXTRACT INCREASES CHOLESTEROL EXCRETION AND DECREASES PLASMA AND LIVER CHOLESTEROL CONCENTRATION IN HAMSTERS, JOURNAL OF FUNCTIONAL FOODS, 1, PP. 381-386, (2009); JAKOBSEN M.U., O'REILLY E.J., HEITMANN B.L., PEREIRA M.A., BALTER K., FRASER G.E., GOLDBOURT U., HALLMANS G., KNEKT P., LIU S., MAJOR TYPES OF DIETARY FAT AND RISK OF CORONARY HEART DISEASE: A POOLED ANALYSIS OF 11 COHORT STUDIES, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 89, PP. 1425-1432, (2009); JONES P.J.H., DASSIS A.N., MARINANGELI C.P.F., POLICOSANOLS LOSE THEIR LUSTRE AS CHOLESTRO-LOWERING AGENTS, JOURNAL OF FUNCTIONAL FOODS, 1, PP. 236-239, (2009); JUNIO H.A., SY-CORDERO A.A., ETTEFAGH K.A., BURNS J.T., MICKO K.T., GRAF T.N., RCHTER S.J., CANNON R.E., OBERLIES N.H., CECH N.B., SYNERGY-DIRECTED FRACTIONATION OF BOTANICAL MEDICINES: A CASE STUDY WITH GOLDENSEAL; (HYDRASTOS CAMADEMSIS), JOURNAL OF NATURAL PRODUCTS, (2011); KASSIS A.N., JONES P., EVALUATION OF POLICOSANOLS AS FUNCTIONAL FOODS FOR CHOLESTEROL-LOWEREING, THE FASEB JOURNAL, 20, (2006); KASSIS A.N., MARINANGELI C.P.F., JAIN D., EBINE N., JONES P.J.H., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); KOWALA M., NUNNARI J., DURHAM S., NICOLOSI R., DOXAZOSIN AND CHOLESTYRAMINE SIMILARLY DECREASE FATTY STREAK FORMATION IN THE AORTIC ARCH OF HYPERLIPIDEMIC HAMSTERS, ATHEROSLCEROSIS, 91, PP. 35-49, (1991); KWAPE L., CRILLY M., KYLE J., SARWAR N., MASSON L., MCNEILL G., IS SATURATED FAT INTAKE ASSOCIATED WITH CVD RISK, ARTERIAL STIFFNESS OR DISEASE SEVERITY IN PATIENTS WITH RHEUMATOID ARTHRITIS?, PROCEEDINGS OF THE NUTRITION SOCIETY, 69, (2010); LEE B.-H., WELLER C.L., CUPPETT S.L., CARR T.P., WALTER J., MARTINEZ I., SCHLEGEL V.L., GRAIN SORGHUM LIPIDS: EXTRACTION, CHARACTERIZATION, AND HEALTH POTENTIAL, ADVANCES IN CEREAL SCIENCE: IMPLICATION TO FOOD PROCESSING AND HEALTH PROMOTION, PP. 140-170, (2010); LEGUIZAMON C., WELLER C., SCHLEGEL V., CARR T., PLANT STEROL AND POLICOSANOL CHARACTERIZATION OF HEXANE EXTRACTS FROM GRAIN SORGHUM, CORN AND THEIR DDGS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 86, PP. 707-716, (2009); LINDSTROM J., ILANNE-PARIKKA P., PELTONEN M., AUNOLA S., ERIKSSON J.G., HEMIO K., HAMALAINEN H., HARKONEN P., KEINANEN-KIUKAANNIEMI S., LAAKSO M., SUSTAINED REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES BY LIFESTYLE INTERVENTION: FOLLOW-UP OF THE FINNISH DIABETES PREVENTION STUDY, THE LANCET, 368, PP. 1673-1679, (2006); MEISSNER M., LOMBARDO E., HAVINGA R., TIETGE U.J.F., KUIPERS F., GROEN A.K., VOLUNTARY WHEEL RUNNING INCREASES BILE ACID AS WELL AS CHOLESTEROL EXCRETION AND DECREASES ATHEROSCLEROSIS IN HYPERCHOLESTEROLEMIC MICE, ATHEROSCLEROSIS, 218, PP. 323-329, (2011); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, PP. 8-12, (2001); NEWGARD C.B., AN J., BAIN J.R., MUEHLBAUER M.J., STEVENS R.D., LIEN L.F., HAQQ A.M., SHAH S.H., ARLOTTO M., SLENTZ C.A., ROCHON J., GALLUP D., ILKAYEVA O., WENNER B.R., YANCY W.S., EISENSON H., MUSANTE G., SURWIT R.S., MILLINGTON D.S., BUTLER M.D., SVETKEY L.P., A BRANCHED-CHAIN AMINO ACID-RELATED METABOLIC SIGNATURE THAT DIFFERENTIATES OBESE AND LEAN HUMANS AND CONTRIBUTES TO INSULIN RESISTANCE, CELL METABOLISM, 9, PP. 311-326, (2009); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 6289-6293, (2005); NOTHLINGS U., WILKENS L.R., MURPHY S.P., HANKIN J.H., HENDERSON B.E., KOLONEL L.N., MEAT AND FAT INTAKE AS RISK FACTORS FOR PANCREATIC CANCER: THE MULTIETHNIC COHORT STUDY, JOURNAL OF THE NATIONAL CANCER INSTITUTE, 97, PP. 1458-1465, (2005); OSTLUND R.E., PHYTOSTEROLS, CHOLESTEROL ABSORPTION AND HEALTHY DIETS, LIPIDS, 42, PP. 41-45, (2007); PIPE E.A., GOBERT C.P., CAPES S.E., DARLINGTON G.A., LAMPE J.W., DUNCAN A.M., SOY PROTEIN REDUCES SERUM LDL CHOLESTEROL AND THE LDL CHOLESTEROL HDL CHOLESTEROL AND APOLIPOPROTEIN B: APOLIPOPROTEIN A-I RATIONS IN ADULTS WITH TYPE 2 DIABETES, JOURNAL OF NUTRITION, 139, PP. 1700-1706, (2009); PLOSCH T., KRUIT J.K., BLOKS V.W., HUIJKMAN N.C.A., HAVINGA R., DUCHATEAU G.S., LIN Y., KUIPERS F., REDUCTION OF CHOLESTEROL ABSORPTION BY DIETARY PLANT STEROLS AND STANOLS IN MICE IS INDEPENDENT OF THE ABCG5/8 TRANSPORTER, THE JOURNAL OF NUTRITION, 136, PP. 2135-2140, (2006); RACETTE S.B., LIN X., LEFEVRE M., SPEARIE C.A., MOST M.M., MA L., OSTLUND R.E., DOSE EFFECTS OF DIETARY PHYTOSTEROLS ON CHOLESTEROL METABOLISM: A CONTROLLED FEEDING STUDY, THE AMERICAN JOURNAL OF CLINICAL NUTRITION, 91, PP. 32-38, (2010); SCHNEIDER C.L., COWLES R.L., STUEFER-POWELL C.L., CARR T.P., DIETARY STEARIC ACID REDUCES CHOLESTEROL ABSORPTION AND INCREASES ENDOGENOUS CHOLESTEROL EXCRETION IN HAMSTERS FED CEREAL-BASED DIETS, THE JOURNAL OF NUTRITION, 130, PP. 1232-1238, (2000); SIRI-TARINO P.W., SUN Q., HU F.B., KRAUSS R.M., SATURATED FATTY ACIDS AND RISK OF CORONARY HEART DISEASE MODULATION BY REPLACEMENT NUTRIENTS, CURRENT AHTEROSCLOROSIS REPORTS, 12, 6, PP. 384-390, (2010); TRAUTWEIN E.A., JINGSHENG L., HAYES K.C., PLASMA LIPOPROTEINS, BILIARY LIPIDS AND BILE ACID PROFILE DIFFER IN VARIOUS STRAINS OF SYRIAN HAMSTERS MESOCRICETUS AURATUS, COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY PART A: PHYSIOLOGY, 104, PP. 829-835, (1993); VALSTA L.M., JAUHIAINEN M., ARO A., KATAN M.B., MUTANEN M., EFFECTS OF A MONOUNSATURATED RAPESEED OIL AND A POLYUNSATURATED SUNFLOWER OIL DIET ON LIPOPROTEIN LEVELS IN HUMANS, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 12, PP. 50-57, (1992); VANSTONE C.A., RAEINI-SARJAZ M., JONES P.J.H., INJECTED PHYTOSTEROLS/STANOLS SUPPRESS PLASMA CHOLESTEROL LEVELS IN HAMSTERS, THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 12, PP. 565-574, (2001); VERLEYEN T., VERHE R., GARCIA L., DEWETTINCK K., HUYGHEBAERT A., DE GREYT W., GAS CHROMATOGRAPHIC CHARACTERIZATION OF VEGETABLE OIL DEODORIZATION DISTILLATE, JOURNAL OF CHROMATOGRAPHY A, 921, PP. 277-285, (2001); WAGNER H., ULRICH-MERZENICH G., SYNERGY RESEARCH: APPROACHING A NEW GENERATION OF PHYTOPHARMACEUTICALS, PHYTOMEDICINE, 16, PP. 97-110, (2009); WANG Y., CASTORENO A.B., STOCKINGER W., NOHTURFFT A., MODULATION OF ENDOSOMAL CHOLESTERYL ESTER METABOLISM BY MEMBRANE CHOLESTEROL, JOURNAL OF BIOLOGICAL CHEMISTRY, 280, PP. 11876-11886, (2005); WANG Y., JONES P.J.H., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); WANG L., WELLER C.L., HWANG K.T., EXTRACTION OF LIPIDS FROM GRAIN SORGHUM DDG, TRANSACTIONS OF THE ASAE, 48, PP. 1883-1888, (2005); XU Z., LE K., MOGHADASIAN M.H., LONG-TERM PHYTOSTEROL TREATMENT ALTERS GENE EXPRESSION IN THE LIVER OF APO E-DEFICIENT MICE, THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 19, PP. 545-554, (2008)","V. SCHLEGEL; DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA-LINCOLN, LINCOLN, NE 68583-0919, 143 FILLEY HALL, UNITED STATES; EMAIL: VSCHLEGEL3@UNL.EDU","ELSEVIER LTD","ENGLISH","J. FUNCT. FOODS","ARTICLE","ISI","2-S2.0-84898038899","J FUNCT FOODS","UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA","V. SCHLEGEL;UNIVERSITY OF NEBRASKA-LINCOLN;NOTDECLARED",NA,"LEE BH, 2014, J FUNCT FOODS","LEE BH, 2014, J FUNCT FOODS"
"JIMÉNEZ F;ALMENDROS M;SACRISTÁN A;TABERNERO J;LLOPIS B;BARRERA V;GALLINARI H;RUBIO P;SÁNCHEZ E","JIMÉNEZ, FRANCISCO MARÍN (57194145437); ALMENDROS, MIGUEL MARTÍN (57194153755); SACRISTÁN, ALBERTO (56269508400); TABERNERO, JUAN CARLOS OCAÑA (57194143475); LLOPIS, BEGOÑA (57194143256); BARRERA, VALLE FERNÁNDEZ (57194149105); GALLINARI, HUGO JUAN (57194151611); RUBIO, PILAR SÁNCHEZ (57194151256); SÁNCHEZ, ESMERALDA BUENDÍA (57191629247)","CHOLESTEROL LOWERING EFFECT OF A COMBINATION OF RED YEAST RICE AND POLYCOSANOL EFEITO DE REDUÇÃO DO COLESTEROL DE UMA COMBINAÇÃO DE ARROZ VERMELHO FERMENTADO E POLICOSANOL EFECTO REDUCTOR DEL COLESTEROL DE UNA COMBINACIÓN DE LEVADURA ROJA DE ARROZ Y POLICOSANOL",2016,"REVISTA DE FITOTERAPIA","16","9",0,"","GRUPO DE TRABAJO EN FITOTERAPIA SEMERGEN, SPAIN;GRUPO DE TRABAJO EN FITOTERAPIA SEMERGEN, SPAIN;GRUPO DE TRABAJO EN FITOTERAPIA SEMERGEN, SPAIN;GRUPO DE TRABAJO EN FITOTERAPIA SEMERGEN, SPAIN;GRUPO DE TRABAJO EN FITOTERAPIA SEMERGEN, SPAIN;GRUPO DE TRABAJO EN FITOTERAPIA SEMERGEN, SPAIN;MÉDICO DE FAMILIA, CENTRO DE ATENCIÓN PRIMARIA PANADERAS, MADRID, SPAIN;FRANCE;FRANCE","IT IS WIDELY KNOWN THAT HIGH CHOLESTEROL LEVELS ARE ASSOCIATED WITH CARDIOVASCULAR RISK. RED YEAST RICE OR RED RICE YEAST IS A PRODUCT OBTAINED FROM A YEAST (MONASCUS PURPUREUS WENT.), WHICH GROWS ON RICE. AMONG ITS CONSTITUENTS, IT STAND OUT MONACOLIN K, ALSO KNOWN AS LOVASTATIN, COMPOUND RELATED TO THE CHOLESTEROL LOWERING EFFECT THROUGH THE INHIBITION OF THE HMG-COA REDUCTASE. POLYCOSANOL IS A MIXTURE OF LONG CHAIN ALIPHATIC ALCOHOLS OBTAINED FROM SUGAR CANE (SACCHARUM OFFICINARUM L.). IN ADDITION OF MODULATING THAT ENZYME, IT INCREASES THE ACTIVITY OF LDL RECEPTORS AND HAS ANTIOXIDANT AND ANTIPLATELET EFFECT. IN THE PRESENT WORK, RESULTS IN 65 PATIENTS TREATED FOR 2 MOUNTS WITH A PRODUCT COMBINING RED YEAST RICE (PROVIDING 10 MG/DAY OF MONACOLIN K) AND POLICOSANOL FROM SUGAR CANE (14 MG/DAY). AN AVERAGE DECREASE, STATISTICALLY SIGNIFICANT, OF BLOOD CHOLESTEROL (22% OF TOTAL CHOLESTEROL AND 29% OF LDL) AND TRIGLYCERIDES (22%) HAS BEEN OBSERVED. THE COMBINATION OF MONACOLIN K AND POLYCOSANOL IS CONSIDERED AN OPTION FOR PATIENTS WITH LOW OR MODERATE CARDIOVASCULAR RISK. © 2016 REVISTA DE FITOTERAPIA. ALL RIGHTS RESERVED.","CARDIOVASCULAR PREVENTION; CHOLESTEROL; DYSLIPIDEMIA; MONACOLIN K; MONASCUS PURPUREUS; POLICOSANOL; RED YEAST RICE; SACCHARUM OFFICINARUM; TRIGLYCERIDES","CHOLESTEROL; CHOLESTIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; POLICOSANOL; TRIACYLGLYCEROL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; HYPOCHOLESTEROLEMIA; MAJOR CLINICAL STUDY","","","BADIMAN L., VILAHURY G., PADRO T., LIPOPROTEINAS, PLAQUETAS Y ATEROTROMBOSIS, REV ESP CARDIOL, 62, 10, PP. 1161-1178, (2009); ENFERMEDADES CARDIOVASCULARES, (2015); BAENA-DIEZ J.M., GRAU M., SANCHEZ-PEREZ R., ALTES-VAQUES E., SALAS-GAETJENS L.H., HERNANDEZ-IBANEZ M.R., THE REGICOR-CALIBRATED FUNCTION PROVIDES A BETTER CLASSIFICATION OF HIGH-RISK PATIENTS ON STATIN TREATMENT IN THE SPANISH POPULATION THAN THE FRAMINGHAM OR SCORE CLASSIFICATIONS, REV ESP CARDIOL, 62, 10, PP. 1134-1140, (2009); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEASTRICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LACHENMEIER D.W., MONAKHOVA Y.B., KUBALLA T., LOBELL-BEHRENDS S., MAIXNER S., KOHL-HIMMELSEHER M., ET AL., NMR EVALUATION OF TOTAL STATIN CONTENT AND HMG-COA REDUCTASE INHIBITION IN RED YEAST RICE (MONASCUS SPP.) FOOD SUPPLEMENTS, CHINESE MEDICINE, 7, (2012); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, 1, PP. 8-12, (2011); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, 10, PP. 907-916, (2009); GUO Y.-L., XU R.-X., ZHU C.-G., WU N.-Q., CUI Z.-P., LI J.-J., POLICOSANOL ATTENUATES STATIN-INDUCED INCREASES IN SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WHEN COMBINED WITH ATORVASTATIN, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, (2014); CASTANO G., MAS R., ROCA J., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., SELMAN E., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, 2, PP. 123-130, (1999); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, 4, PP. 119-124, (1998); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, 4, PP. 293-297, (1997); BARBAGALLO C.M., CEFALU A.B., NOTO D., AVERNA M.R., ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY, FRONTIERS IN CARDIOVASCULAR MEDICINE, 2, (2015); LAW M.R., WALD N.J., RUDNICKA A.R., QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS, BRITISH MEDICAL JOURNAL (BMJ), (2003); JIANPING L., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONERBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHINESE MEDICINE, 1, (2006); LI Y., JIANG L., JIA Z., XIN W., YANG S., YANG Q., WANG L., METAANALYSIS OF RED YEAST RICE: EFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, 6, (2014); BECKER D.J., GORDON R.Y., HALBERT S.C., FENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS. A RANDOMIZED TRIAL, ANN INTERN MED, 150, 12, PP. 830-839, (2009); TRIMARCO B., BENVENITI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTRITION METAB, 4, 2, PP. 133-139, (2011); BARRAT E., ZAIR Y., OGIER N., HOUSEZ B., VERGARA C., MAUDET C., ET AL., A COMBINED NATURAL SUPPLEMENT LOWERS LDL CHOLESTEROL IN SUBJECTS WITH MODERATE UNTREATED HYPERCHOLESTEROLEMIA: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, INT J FOOD SCI NUTR, 64, 7, PP. 882-889, (2013); MORIARTY P.M., ROTH E.M., KARNS A., YE P., ZHAO S.P., LIAO Y., ET AL., EFFECTS OF XUEZHIKANG IN PATIENTS WITH DYSLIPIDEMIA: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY, JOURNAL OF CLINICAL LIPIDOLOGY, 8, PP. 568-575, (2014); VERHOEVEN V., VAN DER AUWERA A., VAN GAAL L., REMMEN R., APERS S.M., ET AL., CAN RED YEAST RICE AND OLIVE EXTRACT IMPROVE LIPID PROFILE AND CARDIOVASCULAR RISK IN METABOLIC SYNDROME?: A DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED TRIAL, BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 15, (2015); GONNELLI S., CAFFARELLI C., STOLAKIS K., CUDA C., GIORDANO N., NUTI R., EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION (RED YEAST RICE, POLICOSANOLS, AND BERBERINE) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURRENT THERAPEUTIC RESEARCH, CLINICAL AND EXPERIMENTAL, 77, PP. 1-6, (2015); CICERO A.F., MORBINI M., PARINI A., URSO R., ROSTICCI M., GRANDI E., BORGHI C., EFFECT OF RED YEAST RICE COMBINED WITH ANTIOXIDANTS ON LIPID PATTERN, HS-CRP LEVEL, AND ENDOTHELIAL FUNCTION IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS; MARTINEZ ALVAREZ J.R., LA LEVADURA ROJA DE ARROZ EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA, NUT. CLÍN. DIET. HOSP, 32, 2, PP. 106-109, (2012); OPINION OF THE FRENCH AGENCY FOR FOOD, ENVIRONMENTAL AND OCCUPATIONAL HEALTH & SAFETY (ANSES) ON THE RISKS ASSOCIATED WITH THE PRESENCE OF “RED YEAST RICE” IN FOOD SUPPLEMENTS; BARRAT E., ZAIR Y., SIRVENT P., CHAUVEAU P., MAUDET C., HOUSEZ B., DERBORD E., ET AL., EFFECT ON LDL-CHOLESTEROL OF A LARGE DOSE OF 1 A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH UNTREATED MODERATE HYPERCHOLESTEROLEMIA: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EUR J NUTR, 52, 8, PP. 1843-1852, (2013); CARRETERO M., ORTEGA T., LEVADURA ROJA DE ARROZ, PANORAMA ACTUAL MED, 37, 368, PP. 1112-1116, (2013); BIANCHI A., LOS EXTRACTOS DE MONASCUS PURPUREUS EN LA PREVENCIÓN Y TRATAMIENTO DE LA ARTERIOSCLEROSIS, REVISTA DE FITOTERAPIA, 4, 2, PP. 117-127, (2004); REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIAS THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUROPEAN HEART JOURNAL, 32, PP. 1769-1818, (2011)","M.M. ALMENDROS; MOTRIL, C/ RÍO TAJO, Nº 5, BAJO, 18600, SPAIN; EMAIL: NATURALIA1@GMAIL.COM","CITA PUBLICACIONES Y DOCUMENTACION","SPANISH","REV. FITOTERAPIA","ARTICLE","ISI","2-S2.0-85018860968","REV FITOTERAPIA","CENTRO DE ATENCIÓN PRIMARIA PANADERAS","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"JIMÉNEZ FM, 2016, REV FITOTERAPIA","JIMÉNEZ FM, 2016, REV FITOTERAPIA"
"TRABELSI H;RENAUD J;HERCHI W;BOUKHCHINA S;MAYER P","TRABELSI, HAJER (38362398500); RENAUD, JUSTIN (27268054600); HERCHI, WAHID (22934042600); BOUKHCHINA, SADOK (6507257738); MAYER, PAUL (7203028266)","TRIACYLGLYCEROLS AND ALIPHATIC ALCOHOLS FROM FRUITS OF THREE TUNISIAN PISTACIA LENTISCUS POPULATIONS",2015,"JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE","95","4",9,"10.1002/jsfa.6915","UNIVERSITÉ DE TUNIS EL MANAR, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS LABORATOIRE DE BIOCHIMIE DES LIPIDES, 2092 EL MANAR II, TUNIS, TUNISIA;LABORATORY OF MASS SPECTROMETRY, CHEMISTRY DEPARTMENT, UNIVERSITY OF OTTAWA, OTTAWA, K1N 6 N5, ON, CANADA;UNIVERSITÉ DE TUNIS EL MANAR, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS LABORATOIRE DE BIOCHIMIE DES LIPIDES, 2092 EL MANAR II, TUNIS, TUNISIA;UNIVERSITÉ DE TUNIS EL MANAR, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS LABORATOIRE DE BIOCHIMIE DES LIPIDES, 2092 EL MANAR II, TUNIS, TUNISIA;LABORATORY OF MASS SPECTROMETRY, CHEMISTRY DEPARTMENT, UNIVERSITY OF OTTAWA, OTTAWA, K1N 6 N5, ON, CANADA","BACKGROUND: THE SEARCH FOR OTHER SOURCES OF VEGETABLE OILS BY THE EXPLOITATION AND THE ENHANCEMENT OF OTHER OIL PLANTS WILL BE NEEDED TO MEET THE DEMANDS OF THE INTERNATIONAL MARKET. THIS STUDY AIMS TO DETERMINE THE TRIACYLGLYCEROL (TAG) MOLECULAR SPECIES AND ALIPHATIC ALCOHOL COMPOSITIONS OF UNEXPLOITED FRUITS OF THREE TUNISIAN PISTACIA LENTISCUS (LENTISC) POPULATIONS FROM THE KORBOUS, TEBABA AND RIMEL AREAS OF TUNISIA. RESULTS: RESULTS SHOW THAT THE CONTENT OF TOTAL TAG VARIES FROM 738.32 MG G-1 OF TOTAL LIPID IN THE TEBABA POPULATION TO 981.15 MG G-1 OF TOTAL LIPID IN THE KORBOUS POPULATION. FURTHERMORE, 14 SPECIES OF TAG WERE DETECTED IN THE THREE STUDIED POPULATIONS. IN ADDITION, 13 ALIPHATIC COMPOUNDS WERE IDENTIFIED AND CLASSIFIED INTO TWO GROUPS: (1) ALIPHATIC ALCOHOLS WITH FEWER THAN 20 CARBON ATOMS (HEXADECANOL, HEPTADECANOL, (Z)-OCTADEC-9-EN-1-OL, OCTADECANOL AND NONADÉCANOL); AND (2) THE POLICOSANOL GROUP (EICOSENOL, DOCOSENOL, DOCOSANOL TETRACOSANOL, HEXACOSANOL OCTACOSANOL AND TRIACONTANOL). THE TEBABA POPULATION SHOWED A DISTINCT COMPOSITION COMPARED TO KORBOUS AND RIMEL WHERE HEPTADECANOL IS THE MAJOR COMPOUND. CONCLUSION: QUANTITATIVELY, THE MOST ABUNDANT TAG SPECIES ARE THOSE CONSTITUTED BY PALMITIC, OLEIC AND/OR LINOLEIC ACID. FURTHERMORE, THE SIGNIFICANT DIFFERENCE OBSERVED AT THE OIL COMPOSITION IS ASSOCIATED WITH A REMARKABLE STATION EFFECT. © 2014 SOCIETY OF CHEMICAL INDUSTRY.","ALIPHATIC ALCOHOL; FRUIT COMPOSITION; PISTACIA LENTISCUS; POLICOSANOL; TRIACYLGLYCEROL","ALCOHOLS; FOOD ANALYSIS; FRUIT; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; PISTACIA; PLANT OILS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIGLYCERIDES; TUNISIA; PISTACIA LENTISCUS; ALCOHOL DERIVATIVE; TRIACYLGLYCEROL; VEGETABLE OIL; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; FOOD ANALYSIS; FRUIT; MASS FRAGMENTOGRAPHY; PISTACIA; TUNISIA","","","APARICIO R., FERREIRO L., ALONSO V., EFFECT OF CLIMATE ON THE CHEMICAL COMPOSITION OF VIRGIN OLIVE OIL, ANAL CHIM ACTA, 292, PP. 235-241, (1994); TRABELSI H., SAKOUHI F., RENAUD J., VILLENEUVE P., KHOUJA M.L., MAYER P., ET AL., FATTY ACIDS, 4-DESMETHYLSTEROLS AND TRITERPENE ALCOHOLS FROM TUNISIAN LENTISC (PISTACIA LENTISCUS) FRUITS, EUR J LIPID SCI TECHNOL, 114, PP. 968-973, (2012); SEIGUE A., LA FORÊT CIRCUMMÉDITERRANÉENNE ET SES PROBLÈMES, PP. 137-139, (1985); SAKOUHI F., ABSALON C., KALLEL H., BOUKHCHINA S., COMPARATIVE ANALYSIS OF TRIACYLGLYCEROLS FROM OLEA EUROPAEA L. FRUITS USING HPLC AND MALDI-TOFMS, EUR J LIPID SCI TECHNOL, 112, PP. 574-579, (2010); QIANG H., MILTON S., ERIC J., MARIA G., MATTHEW P., MICHAEL S., ET AL., MICROALGAL TRIACYLGLYCEROLS AS FEEDSTOCKS FOR BIOFUEL PRODUCTION: PERSPECTIVES AND ADVANCES, THEN PLANT J, 54, PP. 621-639, (2008); SPADY D.K., DIETSCHY J.M., DIETARY SATURATED TRIACYLGLYCEROLS SUPPRESS HEPATIC LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY IN THE HAMSTER, PROC NAT ACAD SCI U S A, 82, PP. 4526-4530, (1985); TAKEUCHI H., KASAI M., TAGUCHI N., TSUJI H., SUZUKI M., EFFECT OF TRIACYLGLYCEROLS CONTAINING MEDIUM- AND LONG-CHAIN FATTY ACIDS ON SERUM TRIACYLGLYCEROL LEVELS AND BODY FAT IN COLLEGE ATHLETES, J NUTR SCI VITAMINOL, 48, PP. 109-114, (2002); QUALITY AND STANDARDS AUTHORITY OF ETHIOPIA, OLIVE OILS AND OLIVE-POMACE OILS DETERMINATION OF ALIPHATIC ALCOHOLS CONTENT BY CAPILLARY GAS CHROMATOGRAPHY, (2012); TRADE STANDARD APPLYING TO OLIVE OILS AND OLIVE-POMACE OILS, (2009); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, PP. 259-267, (2010); TLILI N., TRABELSI H., RENAUD J., KHALDI A., MAYER P.M., TRIKI S., TRIACYLGLYCEROLS AND PHOSPHOLIPIDS COMPOSITION OF CAPER CAPPARIS SPINOSA, J AM OIL CHEM SOC, 88, PP. 1787-1793, (2011); YOUSFI M., NADJEMI B., BELAL R., BOMBARDA I., GAYDOU E.M., TRIACYLGLYCEROL COMPOSITION OF OIL FROM PISTACIA ATLANTICA FRUIT GROWING IN ALGERIA, J AM OIL CHEM SOC, 82, PP. 93-96, (2005); CHERIF A., SEBEI K., BOUKHCHINA S., KALLEL H., BELKACEMI K., ARUL J., KERNEL FATTY ACID AND TRIACYLGLYCEROL COMPOSITION FOR THREE ALMOND CULTIVARS DURING MATURATION, J AM OIL CHEM SOC, 81, PP. 901-905, (2004); SAKOUHI F., ABSALON C., KALLEL H., BOUKHCHINA S., COMPARATIVE ANALYSIS OF TRIACYLGLYCEROLS FROM OLEA EUROPAEA FRUITS USING HPLC AND MALDI-TOFMS, EUR J LIPID SCI TECHNOL, 112, PP. 574-579, (2010); NASRI N., TLILI N., BEN AMMAR K., KHALDI A., BRUNO F., TRIKI S., HIGH TOCOPHEROL AND TRIACYLGLYCEROL CONTENTS IN PINUS PINEA L. SEEDS, INTER J FOOD SCI NUTR, 60, PP. 161-169, (2009); CHAREF M., YOUSFI M., SAIDI M., DETERMINATION OF FATTY ACID COMPOSITION OF ACORN (QUERCUS), PISTACIA LENTISCUS SEEDS GROWING IN ALGERIA, J AM OIL CHEM SOC, 85, PP. 921-924, (2008); SOULIER P., FARINES M., SOULIER J., TRITERPENE ALCOHOLS, 4-METHYLSTEROLS AND 4-DESMETHYLSTEROLS OF SAL AND ILLIPE BUTTERS, J AM OIL CHEM SOC, 67, PP. 388-399, (1990); TLILI N., GUIZANI T., NASRI N., KHALDI A., TRIKI S., PROTEIN, LIPID, ALIPHATIC AND TRITERPENIC ALCOHOL CONTENT OF CAPER SEEDS CAPPARIS SPINOSA, J AM OIL CHEM SOC, 8, PP. 265-270, (2011); NASRI N., FADY B., TRIKI S., QUANTIFICATION OF STEROLS AND ALIPHATIC ALCOHOLS IN MEDITERRANEAN STONE PINE (PINUS PINEA L.) POPULATIONS, J AGRIC FOOD CHEM, 55, PP. 2251-2255, (2007); LEON CAMACHO M., ALCAIDEA I.V., VICARIO I.M., ACORN (QUERCUS SPP.) FRUIT LIPIDS: SAPONIFIABLE AND UNSAPONIFIABLE FRACTIONS: A DETAILED STUDY, J AM OIL CHEM SOC, 81, PP. 447-453, (2004); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUR J LIPID SCI TECHNOL, 112, PP. 373-379, (2010); LEHMLER H.J., BUMMER P.M., BEHAVIOR OF 10-(PERFLUOROHEXYL)-DECANOL, A PARTIALLY FLUORINATED ANALOG OF HEXADECANOL, AT THE AIR-WATER INTERFACE, J FLUORINE CHEM, 28, PP. 17-22, (2002); LINY R.M., WIELEN R.P., TRAUTWEIN E.A., MCNEIL G., SIERKSMA A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATION, METABOLISM, 53, PP. 1309-1314, (2004); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOASONOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); HARRABI S., BOUKHCHINA S., MAYER P., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009)","","JOHN WILEY AND SONS LTD","ENGLISH","J. SCI. FOOD AGRIC.","ARTICLE","ISI","2-S2.0-84930621582","J SCI FOOD AGRIC",NA,"NOTREPORTED",NA,"TRABELSI H, 2015, J SCI FOOD AGRIC","TRABELSI H, 2015, J SCI FOOD AGRIC"
"CHEN Y;DUNFORD N;GOAD C","CHEN, YONGFEN (55046220700); DUNFORD, NURHAN TURGUT (6603296815); GOAD, CARLA (7004431837)","TANGENTIAL ABRASIVE DEHULLING OF WHEAT GRAIN TO OBTAIN POLICOSANOL AND PHYTOSTEROL ENRICHED FRACTIONS",2013,"JOURNAL OF CEREAL SCIENCE","57","2",5,"10.1016/j.jcs.2012.12.002","DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, OKLAHOMA STATE UNIVERSITY, UNITED STATES;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, OKLAHOMA STATE UNIVERSITY, UNITED STATES, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, UNITED STATES;DEPARTMENT OF STATISTICS, OKLAHOMA STATE UNIVERSITY, UNITED STATES","[NO ABSTRACT AVAILABLE]","PHYTOSTEROL; POLICOSANOL; TANGENTIAL ABRASIVE DEHULLING; WHEAT","TRITICUM AESTIVUM","","","BRUFAU G., CANELA M.A., RAFECAS M., PHYTOSTEROLS: PHYSIOLOGIC AND METABOLIC ASPECTS RELATED TO CHOLESTEROL-LOWERING PROPERTIES, NUTRITION RESEARCH, 28, 4, PP. 217-225, (2008); CHEN Y., EFFICIENCY OF ABRASIVE DEHULLING TO PRODUCE WHEAT GRAIN FRACTIONS ENRICHED IN ANTIOXIDANTS, DISSERTATION THESIS, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, (2011); CHEN Y., DUNFORD N.T., EDWARDS J., CARVER B., GOAD C., GENOTYPE AND ENVIRONMENT AFFECT PHYTOSTEROL CONTENT AND COMPOSITION OF WHEAT, CEREAL CHEMISTRY, 86, 1, PP. 96-99, (2009); CHEN Y., DUNFORD N.T., EDWARDS J., CARVER B., GOAD C., POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 89, 2, PP. 310-314, (2009); CHEN Y., DUNFORD N.T., GOAD C., EVALUATION OF WHEAT BRAN OBTAINED BY TANGENTIAL ABRASIVE DEHULLING DEVICE, FOOD AND BIOPROCESS TECHNOLOGY, (2012); DUNFORD N.T., EDWARDS J., NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT, BIORESOURCE TECHNOLOGY, 101, 1, PP. 422-425, (2010); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, 2, PP. 356-365, (2002); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 14, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); JIANG Y., WANG T., PHYTOSTEROLS IN CEREAL BY-PRODUCTS, JOURNAL OF AMERICAN OIL CHEMISTS SOCIETY, 82, 6, PP. 439-444, (2005); KRITCHEVSKY D., CHEN S.C., PHYTOSTEROLS-HEALTH BENEFITS AND POTENTIAL CONCERNS: A REVIEW, NUTRITION RESEARCH, 25, 5, PP. 413-428, (2005); MIETTINEN T., VURISTO M., NISSINEN M., JARVINEN H., GYLLING H., SERUM, BILLARY, AND FECAL CHOLESTEROL AND PLANT STEROLS IN COLECTOMIZED PATIENTS BEFORE AND DURING CONSUMPTION OF STANOL ESTER MARGARINE, AMERICAN JOURNAL CLINICAL NUTRITION, 71, PP. 1095-1102, (2000); NYSTROM L., PAASONEN A., LAMPI A.-M., PIIRONEN V., TOTAL PLANT STEROLS, STERYL FERULATES AND STERYL GLYCOSIDES IN MILLING FRACTIONS OF WHEAT AND RYE, JOURNAL OF CEREAL SCIENCE, 45, 1, PP. 106-115, (2007); PIIRONEN V., TOIVO J., LAMPI A.M., PLANT STEROLS IN CEREALS AND CEREAL PRODUCTS, CEREAL CHEMISTRY, 79, 1, PP. 148-154, (2002); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, 11, (2003)","N.T. DUNFORD; DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, FAPC, STILLWATER, OK 74078 6055, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","J. CEREAL SCI.","ARTICLE","ISI","2-S2.0-84877130731","J CEREAL SCI","OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY","NOTREPORTED;ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER;NOTREPORTED",NA,"CHEN Y, 2013, J CEREAL SCI","CHEN Y, 2013, J CEREAL SCI"
"CICERO A;PARINI A;ROSTICCI M","CICERO, ARRIGO F.G. (7003403707); PARINI, ANGELO (56343808900); ROSTICCI, MARTINA (37054598600)","NUTRACEUTICALS AND CHOLESTEROLLOWERING ACTION",2015,"IJC METABOLIC AND ENDOCRINE","6","3",18,"10.1016/j.ijcme.2014.10.009","ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, ITALY;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, ITALY;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA, ITALY","NUTRACEUTICALS PLAY AN IMPORTANT ROLE IN CARDIOVASCULAR PREVENTION IN PATIENTS WITH DYSLIPIDEMIA. MANY SCIENTIFIC STUDIES SUPPORT THE USE OF THESE SUBSTANCES ALONE OR ASSOCIATED WITH OTHER DRUGS IN CLINICAL PRACTICE. SPECIFICALLY, MONACOLINES, BERBERINE, POLICOSANOL AND GAMMA-ORYZANOL COULD SIGNIFICANTLY REDUCE CHOLESTEROLEMIA. HOWEVER, THERE IS STILL AN INSUFFICIENT NUMBER OF STUDIES DEMONSTRATING MORBIDITY AND MORTALITY OUTCOMES OF NUTRACEUTICALS, NOR ARE SUFFICIENT DATA REGARDING THE USE OF NUTRACEUTICALS IN DIFFERENT TYPES OF PATIENTS, ON TOLERABILITY, SAFETY, TARGET POPULATION, MODALITY AND DURATION OF USE PRESENT IN THE LITERATURE. © 2014.","BERBERINE; CHOLESTEROL REDUCTION; GAMMA-ORYZANOL; MONACOLIN; NUTRACEUTICALS; POLYCOSANOL","BERBERINE; CYTOCHROME P450 3A4; GAMMA ORYZANOL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONACOLIN L; NUTRACEUTICAL; POLICOSANOL; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; HYPOCHOLESTEROLEMIA; LIPID METABOLISM; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME","","","DAHLOF B., CARDIOVASCULAR DISEASE RISK FACTORS: EPIDEMIOLOGY AND RISK ASSESSMENT, AM J CARDIOL, 105, 1, PP. 3A-9A, (2010); GOULD A.L., DAVIES G.M., ALEMAO E., ET AL., CHOLESTEROL REDUCTION YIELDS CLINICAL BENEFITS: META-ANALYSIS INCLUDING RECENT TRIALS, CLIN THER, 29, 5, PP. 778-794, (2007); GUARNERI M., MERCADO N., SUHAR C., INTEGRATIVE APPROACHES FOR CARDIOVASCULAR DISEASE, NUTR CLIN PRACT, 24, 6, PP. 701-708, (2009); CICERO A.F.G., TARTAGNI E., ERTEK S., NUTRACEUTICALS FOR METABOLIC SYNDROME MANAGEMENT: FROM LABORATORY TO BENCHSIDE, CURR VASC PHARMACOL, 12, 4, PP. 565-571, (2014); JOURNOUD M., JONES P.J., RED YEAST RICE: A NEW HYPOLIPIDEMIC DRUG, LIFE SCI, 74, 22, PP. 2675-2683, (2004); LI J.J., LU Z.L., KOU W.R., ET AL., CHINESE CORONARY SECONDARY PREVENTION STUDY GROUP. IMPACT OF XUEZHIKANG ON CORONARY EVENTS IN HYPERTENSIVE PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION FROM THE CHINA CORONARY SECONDARY PREVENTION STUDY (CCSPS), ANN MED, 42, 3, PP. 231-240, (2010); CICERO A.F.G., DEROSA G., BORGHI C., RED YEAST RICE AND STATIN-INTOLERANT PATIENTS, AM J CARDIOL, 105, 10, (2010); CICERO A.F.G., ERTEK S., BERBERINE: METABOLIC AND CARDIOVASCULAR EFFECTS IN PRECLINICAL AND CLINICAL TRIALS, NUTR DIET SUPPL, 1, PP. 1-10, (2009); CICERO A.F.G., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN LIPIDOL, 4, 5, PP. 553-563, (2009); YIN J., XING H., YE J., EFFICACY OF BERBERINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, METABOLISM, 57, 5, PP. 712-717, (2008); WANG J.M., YANG Z., XU M.G., ET AL., BERBERINE-INDUCED DECLINE IN CIRCULATING CD31+/CD42-MICROPARTICLES IS ASSOCIATED WITH IMPROVEMENT OF ENDOTHELIAL FUNCTION IN HUMANS, EUR J PHARMACOL, 614, 1-3, PP. 77-83, (2009); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, 3, PP. 1020-1026, (2006); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, 3, PP. 259-267, (2010); CICERO A.F., GADDI A., RICE BRAN OIL AND GAMMA-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHER RES, 15, 4, PP. 277-289, (2001); BERGER A., REIN D., SCHAFER A., ET AL., SIMILAR CHOLESTEROL-LOWERING PROPERTIES OF RICE BRAN OIL, WITH VARIED GAMMA-ORYZANOL, IN MILDLY HYPERCHOLESTEROLEMIC MEN, EUR J NUTR, 44, 3, PP. 163-173, (2005); GLIOZZI M., WALKER R., MUSCOLI S., VITALE C., GRATTERI S., CARRESI C., ET AL., BERGAMOT POLYPHENOLIC FRACTION ENHANCES ROSUVASTATIN-INDUCED EFFECT ON LDL-CHOLESTEROL, LOX-1 EXPRESSION AND PROTEIN KINASE B PHOSPHORYLATION IN PATIENTS WITH HYPERLIPIDEMIA, INT J CARDIOL, 170, 2, PP. 140-145, (2013); CICERO A.F.G., BRANCALEONI M., LAGHI L., ET AL., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMEMT THER MED, 13, PP. 273-278, (2005); CICERO A.F.G., BENVENUTI C., ARMOWEB STUDY GROUP. EFFICACY OF A RED YEAST RICE BASED NUTRACEUTICAL IN LARGE SUBGROUPS OF HYPERCHOLESTEROLEMIC SUBJECTS IN EVERY DAY CLINICAL PRACTICE, MED J NUTR METAB, 3, PP. 239-246, (2010); CICERO A.F.G., DEROSA G., BOVE M., ET AL., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOP NUTRACEUTICALS RES, 7, 3-4, PP. 121-126, (2009); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, 9, PP. 656-661, (2010); CICERO A.F.G., FERRONI A., ERTEK S., TOLERABILITY AND SAFETY OF COMMONLY USED DIETARY SUPPLEMENTS AND NUTRACEUTICALS WITH LIPID-LOWERING EFFECTS, EXPERT OPIN DRUG SAF, 11, 5, PP. 753-766, (2012)","A.F.G. CICERO; S. ORSOLA-MALPIGHI UNIVERSITY HOSPITAL, BOLOGNA, VIA ALBERTONI, 15, 41038, ITALY; EMAIL: ARRIGO.CICERO@UNIBO.IT","ELSEVIER IRELAND LTD","ENGLISH","IJC METAB. ENDOCR.","ARTICLE","ISI","2-S2.0-84926016824","IJC METAB ENDOCR","ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA;ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA","NOTREPORTED;S. ORSOLA-MALPIGHI UNIVERSITY HOSPITAL;NOTREPORTED",NA,"CICERO AFG, 2015, IJC METAB ENDOCR","CICERO AFG, 2015, IJC METAB ENDOCR"
"SOLOMENCHUK T;VOSUKH V;BEDZAY A;KOVAL V;CHEPKA I;TROTSKO V","SOLOMENCHUK, T.M. (6506172564); VOSUKH, V. (57190865722); BEDZAY, A. (57190863638); KOVAL, V.G. (57190858677); CHEPKA, I.M. (57190856314); TROTSKO, V.V. (57190860723)","EFFICIENCY OF CONCOMITANT USE OF POLICOSANOL AND ROSUVASTATIN IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND MODERATE HEPATIC DYSFUNCTION",2015,"LIKARS'KA SPRAVA / MINISTERSTVO OKHORONY ZDOROV'IA UKRAÏNY","","8",1,"","","THE ARTICLE PRESENTS THE RESULTS FOR THE STUDY OF LIPID CORRECTION CAPACITY AND SAFETY OF CONCOMITANT USE OF POLICOSANOL AND ROSUVASTATIN COMPARED WITH ROSUVASTATIN MONOTHERAPY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND MODERATE HEPATIC DYSFUNCTION. FIFTY-SEVEN SUBJECTS AGED 37 TO 72 YEARS (MEAN AGE 54.4 YEARS +/- 6.5 YEARS) HAVE BEEN ENROLLED INTO THE STUDY WITH THE FOLLOWING INCLUSION CRITERIA: THERAPY WITH STATINS FOR MORE THAN 8 WEEKS, FAILURE TO ACHIEVE TARGET LDL CHOLESTEROL LEVELS AND MODERATELY ELEVATED LIVER ENZYMES. THE FOLLOWING LABORATORY TESTS WERE PERFORMED AT BASELINE AND AFTER 12 WEEKS OF FOLLOW-UP: BLOOD LIPID PROFILE (TOTAL CHOLESTEROL (TC), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL (VLDL-C), HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND TRIGLYCERIDES (TG), LIPID PEROXIDATION (MA- IONIC DIALDEHYDE (MDA), GLYCOSYLATED HEMOGLOBIN HBALC (%) AND LIVER FUNCTION TESTS (GAMMA-GLUTAMYL TRANSPEPTIDASE-GAMMA-GTP) AND ALANINE AMINOTRANSFERASE (ALT). CONCOMITANT USE OF POLICOSANOL WITH ROSUVASTATIN WAS SUPERIOR TO ROSUVASTATIN MONOTHERAPY IN TERMS OF REDUCTION OF PRO-ATEROGENICITY OF LIPID METABOLISM BY DECREASING SERUM TC, LDL-C AND TG, INCREASING SERUM HDL-C AND DECREASING THE PRO-OXIDATIVE ACTIVITY (MDA) WITH SIMULTANEOUS SUBSTANTIAL IMPROVEMENT OF HEPATIC FUNCTION. CONCOMITANT USE OF POLICOSANOL AT THE DOSE OF 20 MG/DAY AND ROSUVASTATIN AT 10-20 MG/DAY WAS FAVORABLY TOLERATED. NONE OF THE SUBJECTS HAD ANY DISCONTINUATIONS OF THERAPY DUE TO ADVERSE EVENTS.","","ADULT; AGED; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CORONARY ARTERY DISEASE; DRUG COMBINATIONS; FATTY ALCOHOLS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEMOGLOBIN A, GLYCOSYLATED; HEPATIC INSUFFICIENCY; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; TRIGLYCERIDES; ALANINE AMINOTRANSFERASE; DRUG COMBINATION; FATTY ALCOHOL; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; POLICOSANOL; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; AGED; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; DRUG COMBINATION; FEMALE; HEPATIC INSUFFICIENCY; HUMAN; LIPID PEROXIDATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME","","","","","","UKRAINIAN","LIK. SPRAVA","ARTICLE","ISI","2-S2.0-84983503422","LIK SPRAVA",NA,"NOTREPORTED",NA,"SOLOMENCHUK TM, 2015, LIK SPRAVA","SOLOMENCHUK TM, 2015, LIK SPRAVA"
"MONTSERRAT-DE L P S;GARCÍA-GIMÉNEZ M;ÁNGEL-MARTÍN M;PÉREZ-CAMINO M;FERNÁNDEZ A A","MONTSERRAT-DE LA PAZ, S. (57210725095); GARCÍA-GIMÉNEZ, M.D. (7404278083); ÁNGEL-MARTÍN, M. (55314617900); PÉREZ-CAMINO, M.C. (6603929113); FERNÁNDEZ ARCHE, A. (12244901200)","LONGCHAIN FATTY ALCOHOLS FROM EVENING PRIMROSE OIL INHIBIT THE INFLAMMATORY RESPONSE IN MURINE PERITONEAL MACROPHAGES",2014,"JOURNAL OF ETHNOPHARMACOLOGY","151","5",52,"10.1016/j.jep.2013.10.012","DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/PROFESOR GARCÍA GONZÁLEZ NO. 2, SPAIN;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/PROFESOR GARCÍA GONZÁLEZ NO. 2, SPAIN;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/PROFESOR GARCÍA GONZÁLEZ NO. 2, SPAIN;DEPARTMENT OF CHARACTERIZATION AND FOOD QUALITY, INSTITUTO DE LA GRASA (CSIC), 41012 SEVILLE, AVENIDA PADRE GARCÍA TEJERO NO. 4, SPAIN;DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/PROFESOR GARCÍA GONZÁLEZ NO. 2, SPAIN","ETHNOPHARMACOLOGICAL RELEVANCE EVENING PRIMROSE (OENOTHERA BIENNIS L., ONAGRACEAE) IS A WILD MEDICINAL PLANT OF CENTRAL AMERICAN ORIGIN THAT IS NOW ONE OF THE MOST WIDELY USED HERBAL MEDICINES IN DIFFERENT PARTS OF THE WORLD. OIL EXTRACTED FROM IT SEEDS IS TRADITIONALLY USED IN THE TREATMENT OF ECZEMA, ASTHMA, RHEUMATOID ARTHRITIS, BREAST PROBLEM, PREMENSTRUAL AND MENOPAUSAL SYNDROME, ALL THEY HAVE AN INFLAMMATORY COMPONENT. THE PRESENT STUDY DEMONSTRATES THE IN VITRO ANTI-INFLAMMATORY EFFECT OF LONG-CHAIN FATTY ALCOHOLS, MINOR COMPOUNDS ISOLATED FROM EVENING PRIMROSE OIL (EPO). MATERIAL AND METHODS A MIXTURE OF LONG CHAIN FATTY ALCOHOLS (LCFAS) WAS ISOLATED FROM THE NON-TRIACYLGLYCEROL FRACTION OF THE EPO. HEXACOSANOL (C26OH: 38.65%), TETRACOSANOL (C24OH: 31.59%), DOCOSANOL (C22OH: 11.36%) AND OCTOCOSANOL (C28OH: 7.64%), WERE THE MAJOR CONSTITUENTS, IDENTIFIED AND QUANTIFIED BY GC AND GC-MS. LCFA WAS TESTED WITH LPS STIMULATED MURINE PERITONEAL MACROPHAGE. THIS FRACTION, SIGNIFICANTLY AND DOSE-DEPENDENTLY DECREASED NITRIC OXIDE PRODUCTION INDUCED BY LPS (P<0.001) AND THE INHIBITORY EFFECT SEEMS TO BE CONSEQUENCE OF AN ACTION AT THE LEVEL OF THE INDUCIBLE NITRIC-OXIDE SYNTHETHASE (INOS) GENE ENZYME EXPRESSION RATHER THAN TO A DIRECT INHIBITORY ACTION ON ENZYME ACTIVITY. THE RELEASE OF PLA2 AND TXB2 ALSO WAS SIGNIFICANTLY INHIBITED BY LCFAS (P<0.001) ALTHOUGH LCFAS DID NOT AFFECT TO PGE2 GENERATION, HOWEVER THE WESTERN BLOT ASSAY SHOWED THAT LCFAS REDUCED CYCLOOXYGENASE-2 ENZYME GENE EXPRESSION AT ALL DOSES ASSAYED. IN THE SAME WAY, THE SECRETION OF INFLAMMATORY CYTOKINES INTERLEUKIN 1Β (IL-1Β) AND TUMOUR NECROSIS FACTOR Α (TNF-Α) FROM LPS-STIMULATED MURINE MACROPHAGE, WERE ALSO SIGNIFICANTLY REDUCED (P<0.001). CONCLUSION THESE RESULTS DEMONSTRATES THE ANTI-INFLAMMATORY ACTIVITY OF LCFAS, PROVIDING AN ADDITIONAL VALUE ABOUT THE ROLE OF BIOACTIVE MINOR COMPOUNDS IN THE BENEFICIAL EFFECT OF EPO AND SUPPORTS ITS TRADITIONAL USES IN INFLAMMATORY PROCESSES MANAGEMENT. © 2013 ELSEVIER IRELAND LTD.","ANTI-INFLAMMATORY ACTIVITY; EVENING PRIMROSE; LONG CHAIN FATTY ALCOHOL; OIL; POLICOSANOL","ANIMALS; CELL SURVIVAL; DINOPROSTONE; FATTY ALCOHOLS; GAMMA-LINOLENIC ACID; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-1BETA; LINOLEIC ACIDS; MACROPHAGES, PERITONEAL; MICE; NITRITES; PHOSPHOLIPASES A2, SECRETORY; PLANT OILS; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA; MURINAE; OENOTHERA; OENOTHERA BIENNIS; ONAGRACEAE; 3-(4,5-DIMETHYLTHIAZOL-2YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; ANTI-INFLAMMATORY ACTIVITY; COX(2); CYCLOOXYGENASE 2; DIMETHYL SULFOXIDEM; DMSO; EIA; ELISA; ENZIMOINMUNOANALISIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPO; EVENING PRIMROSE; EVENING PRIMROSE OIL; FBS; FETAL BOVINE SERUM; GAS CHROMATOGRAPHY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GC; GC-MS; IL-1Β; INDUCIBLE NITRIC OXIDE; INOS; INTERLEUKIN-1Β; LCFAS; LIPOPOLYSACCHARIDE; LONG CHAIN FATTY ALCOHOL; LONG CHAIN FATTY ALCOHOLS; LPS; MTT; NF-ΚB; NITRIC OXIDE; NO; NUCLEAR FACTOR KAPPA B; OIL; PGE(2); PHOSPHOLIPASE A(2); PLA(2); POLICOSANOL; PROSTAGLANDINE E(2); SECRETORY PHOSPHOLIPASE A(2); SNP; SODIUM NITROPRUSSIDE; SPLA(2); THROMBAXANE E(2); TNF-Α; TUMOR NECROSIS FACTOR ALPHA; TXB(2); ALKANOL; ANTIINFLAMMATORY AGENT; BEHENYL ALCOHOL; CYCLOOXYGENASE 2; DEXAMETHASONE; FATTY ALCOHOL; HEXACOSANOL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LONG CHAIN FATTY ALCOHOL; MARNYS; NITRIC OXIDE; PRIMROSE OIL; PROSTAGLANDIN E2; SECRETORY PHOSPHOLIPASE A2; TETRACOSANOL; THROMBOXANE B2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; ENZYME ACTIVITY; EVENING PRIMROSE; FEMALE; IN VITRO STUDY; MASS FRAGMENTOGRAPHY; MOUSE; MURINE MODEL; NONHUMAN; PERITONEUM MACROPHAGE; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; WESTERN BLOTTING","","","AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., GRIECO F., FAZIO S., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J. CARDIOL., 4, PP. 77-83, (2012); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARVAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. PHYSIOL., 29, PP. 891-897, (2002); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARVAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES., 33, PP. 835-840, (2000); BOWDISH D.M., LOFFREDO M.S., MUKHOPADHYAY S., MANTOVANI A., GORDON S., MACROPHAGE RECEPTORS IMPLICATED IN THE ""ADAPTATIVE"" FORM OF INNATE IMMUNITY, MICROBES INFECT., 9, PP. 1680-1687, (2007); BRADFORD M.M., RAPID AND SENSITIVE METHOD FOR THE QUANTITATION OF MICROGRAM QUANTITIES OF PROTEINS UTILIZING THE PRINCIPLE OF PROTEIN-DYE BINDING, ANN. BIOCHEM., 72, PP. 248-254, (1976); BROWNLI R.P., BROWNRIGG H.M., BUTCHER R., GARCIA R., JESSUP V.J., LEE S., TUNSTALL M.G., ZD1542, A POTENT THROMBOXANE A<SUB>2</SUB> SYNTHASE INHIBITOR AND RECEPTOR ANTAGONIST IN VITRO, BR. J. PHARMACOL., 110, PP. 1600-1606, (1993); CERT A., MOREDA W., GARCIA-MORENO J., DETERMINACIÓN DE ESTEROLES Y DIALCOHOLES TRITERPÉNICOS EN ACEITE DE OLIVA MEDIANTE SEPARACIÓN DE LA FRACCIÓN POR CROMATOGRAFÍA DE ALTA EFICACIA Y ANÁLISIS POR CROMATOGRAFÍA DE GASES. ESTANDARIZACIÓN DEL MÉTODO ANALÍTICO, GRASAS ACEITES, 48, PP. 207-218, (1997); CHOI C.Y., KIM J.Y., CHUNG Y., HAHM K.S., JEONG H.G., AQUEOUS EXTRACT ISOLATED FROM PLATYCODON GRANDIFLORUM ELICITS THE RELEASE OF NITRIC OXIDE AND TUMOR NECROSIS FACTOR-ALPHA FROM MURINE MACROPHAGES, INT. IMMUNOPHARMACOL., 1, PP. 1141-1151, (2001); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J. NUTR. BIOCHEM., 20, PP. 155-162, (2009); GARCIA-JIMENEZ M.D., GARCIA-PRADO E., SAENZ-RODRIGUEZ T., FERNANDEZ-ARCHE A., DE LA PUERTA-VAZQUEZ R., CYTOTOXIC EFFECT OF THE PENTACUCLIC OXINDOLE ALKALOID MITRAPHYLLINE ISOLATED FROM UNCARIA TOMENTOSA BARK ON HUMAN EWING'S SARCOMA AND BREAST CANCER CELL LINES, PLANTA MED., 76, PP. 133-136, (2010); GOMEZ P.F., PILLINGER M.H., ATTUR M., MARJANOVIC N., DAVE M., PARK J., BINGHAM III C.O., AL-MUSSAWIR H., ABRAMSON S.B., RESOLUTION OF INFLAMMATION: PROSTAGLANDIN E<SUB>2</SUB> DISSOCIATES NUCLEAR TRAFFICKING OF INDIVIDUAL NF-KAPPAB SUBUNITS (P65, P50) IN STIMULATED RHEUMATOID SYNOVIAL FIBROBLASTS, J. IMMUNOL., 175, PP. 6924-6930, (2005); GREEN L.C., WANGE R.D.A., GLOGOWSKI J., SKIPPER P.L., WISHNOK J.S., TANNENBAUM S.R., ANALYSIS OF NITRATE, NITRITE, AND <SUP>15</SUP>N NITRATE IN BIOLOGICAL FLUIDS, ANN. BIOCHEM., 126, PP. 131-138, (1982); HUANG K.C., CHEN C.W., CHEN J.C., LIN W.W., HMG-COA REDUCTASE INHIBITORS INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE GENE EXPRESSION IN MACROPHAGES, J. BIOMED. SCI., 10, PP. 396-405, (2003); KANG R.I., FREIRE-MOAR J., SIGAL E., CHU C.Q., EXPRESSION OF CYCLOOXIGENASE-2 IN HUMAN AND ANIMAL MODEL OF RHEUMATOID ARTHRITIS, BR. J. RHEUMATOL., 35, PP. 711-718, (1996); KNORR R., HAMBURGER M., QUANTITATIVE ANALYSIS OF ANTI-INFLAMMATORY AND RADICAL SCAVENGING TRITERPENOID ESTERS IN EVENING PRIMROSE OIL, J. AGRIC. FOOD. CHEM., 52, PP. 3319-3324, (2004); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRIECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) INELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV. THER., 28, PP. 1105-1113, (2011); MARCOCCI L., MAGUIRE J.J., DROY-LEFAIX M.T., PACKER L., THE NITRIC OXIDE SCAVENGING PROPERTIES OF GINKGO BILOBA EXTRACT EGB 761, BIOCHEM. BIOPHYS. RES. COMMUN., 201, PP. 748-755, (1994); MARQUEZ-MARTIN A., DE LA PUERTA-VAZQUEZ R., FERNANDEZ-ARCHE A., RUIZ-GUTIERREZ V., SUPRESSIVE EFFECT OF MASLINIC ACID FROMPOMACE OLIVE OIL ON OXIDATIVE STRESS AND CYTOKINE PRODUCTION IN STIMULATED MURINE MACROPHAGES, FREE RADICAL RES., 40, PP. 295-302, (2006); MONTSERRAT-DE LA PAZ S., FERNANDEZ-ARCHE M.A., ANGEL- MARTIN M., GARCIA-GIMENEZ M.D., PHYTOCHEMICAL CHARACTERIZATION OF POTENTIAL NUTRACEUTICAL INGREDIENTS OF EVENING PRIMROSE OIL (OENOTHERA BIENNIS L.), PHYTOCHEM. LETT., (2013); MONTSERRAT-DE LA PAZ S., ANGEL-MARTIN M., GARCIA-GIMENEZ M.D., MARIN-AGUILAR F., FERNANDEZ-ARCHE M.A., DIETARY SUPPLEMENTATION EVENING PRIMROSE OIL IMPROVE SYMPTOMS OF FIBROMYALGIA SYNDROME, J. FUNCT. FOODS, 5, PP. 1279-1287, (2013); MONTSERRAT-DE LA PAZ S., FERNANDEZ-ARCHE M.A., ANGEL-MARTIN M., GARCIA-GIMENEZ M.D., THE STEROLS ISOLATED FROM EVENING PRIMROSE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, PHYTOMEDICINE, 19, PP. 1072-1076, (2012); MOSMANN T., RAPID COLORIMETRIC ASSAY FOR CELLULAR GROWTH AND SURVIVAL: APPLICATION TO PROLIFERATION AND CITOTOXICITY ASSAYS, J. IMMUNOL. METHODS, 65, PP. 55-63, (1983); MULLER T., GRANDBARBE L., MORGA E., HEUSCHLING P., LUU B., TOCOPHEROL LONG CHAIN FATTY ALCOHOLS DECREASE THE PRODUCTION OF TNF-ALPHA AND NO RADICALS BY ACTIVATED MICROGIAL CELLS, BIOORG. MED. CHEM. LETT., 14, PP. 6023-6026, (2004); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROSIS PLAQUE ON AORTAS IN MONKEYS, ARCH. MED. RES., 36, PP. 441-447, (2005); OLA M., OMRAN M.D., HISTOPATHOLOGICAL STUDY OF EVENING PRIMROSE OIL EFFECTS ON EXPERIMENTAL DIABETIC NEUROPATHY, ULTRASTRUCT. PATHOL., 36, PP. 222-227, (2012); PAQUOT C., DETERMINATION OF THE UNSAPONIFIABLE MATTER. METHOD 2401, IUPAC STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS AND DERIVATIVES, (1992); PUERTA R., MARQUEZ-MARTIN A., FERNANDEZ-ARCHE A., RUIZ-GUTIERREZ V., INFLUENCE OF DIETARY FAT ON OXIDATIVE STRESS AND INFLAMMATION IN MURINE MACROPHAGE, NUTRITION, 25, PP. 548-554, (2009); RODGERS A., LEWANDOSKI S., ALLIE-HAMDULAY S., PINNOCK D., BARETTA G., GAMBARO G., EVENING PRIMROSE OIL SUPPLEMENTATION INCREASES CITRATURIA AND DECREASES OTHER URINARY RISK FACTORS FOR CALCIUM OXALATE UROLITHIASIS, J. UROL., 182, PP. 2957-2963, (2009); SHINBORI C., SAITO M., KINOSHITA Y., SATOH I., KONO T., HANADA T., NANBA E., ADACHI K., SUZUKI H., YAMADA M., SATOH K., CYCLOHEXENONIC LONG-CHAIN FATTY ALCOHOL HAS THERAPEUTIC EFFECTS ON DIABETES-INDUCED ANGIOPATHY IN THE RAT AORTA, EUR. BR. J. PHARMACOL., 567, PP. 139-144, (2007); TRIGGIANI M., GRANATA F., GIANNATTASIO G., MARONE G., SECRETORY PHOSPHOLIPASE A2 IN INFLAMMATORY AND ALLERGIC DISEASES: NOT JUST ENZYMES, J. ALLERGY CLIN. IMMUNOL., 12, PP. 903-923, (2005); WETTASINGHE M., SHAHIDI F., AMAROWICZ R., IDENTIFICATION AND QUANTIFICATION OF LOW MOLECULAR WEIGHT PHENOLIC ANTIOXIDANTS IN SEEDS OF EVENING PRIMROSE (OENOTHERA BIENNIS L.), J. AGRIC. FOOD. CHEM., 50, PP. 1267-1271, (2002); ZAUGG J., POTTERAT O., PLESCHER A., HONERMEIER B., HAMBURGER M., QUANTITATIVE ANALYSIS OF ANTI-INFLAMMTORY AND RADICAL SCAVENGING TRITERPENOID ESTERS IN EVENING PRIMROSE SEEDS, J. AGRIC. FOOD. CHEM., 54, PP. 6623-6628, (2006)","A. FERNÁNDEZ ARCHE; DEPARTMENT OF PHARMACOLOGY, SCHOOL OF PHARMACY, UNIVERSITY OF SEVILLE, 41012 SEVILLE, C/PROFESOR GARCÍA GONZÁLEZ NO. 2, SPAIN; EMAIL: ARCHE@US.ES","","ENGLISH","J. ETHNOPHARMACOL.","ARTICLE","ISI","2-S2.0-84891491673","J ETHNOPHARMACOL","UNIVERSITY OF SEVILLE;UNIVERSITY OF SEVILLE;UNIVERSITY OF SEVILLE;INSTITUTO DE LA GRASA (CSIC);UNIVERSITY OF SEVILLE","A. FERNÁNDEZ ARCHE;UNIVERSITY OF SEVILLE;EMAIL: ARCHE@US.ES",NA,"MONTSERRAT-DE LA PAZ S, 2014, J ETHNOPHARMACOL","MONTSERRAT-DE LA PAZ S, 2014, J ETHNOPHARMACOL"
"MOLINA V;RAVELO Y;NOA M;MAS R;VALLE M;PÉREZ Y;OYARZÁBAL A;MENDOZA N;JIMÉNEZ S;SÁNCHEZ J","MOLINA, VIVIAN (7006062814); RAVELO, YAZMIN (26030104500); NOA, MIRIAM (7003318964); MAS, ROSA (7007164570); VALLE, MAIKEL (22936513700); PÉREZ, YOHANI (23995375700); OYARZÁBAL, AMBAR (24399409700); MENDOZA, NILDA (7006243358); JIMÉNEZ, SONIA (19735040200); SÁNCHEZ, JAVIER (57210524556)","EFFECTS OF POLICOSANOL AND GRAPE SEED EXTRACT AGAINST GLOBAL BRAIN ISCHEMIAREPERFUSION INJURY IN GERBILS",2013,"LATIN AMERICAN JOURNAL OF PHARMACY","32","6",2,"","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","SUMMARY. STROKE IS THE THIRD CAUSE OF DEATH AND THE FIRST OF PERMANENT ADULT DISABILITY. OXIDATIVE DAM- AGE PLAYS A KEY ROLE IN STROKE. GRAPE SEED EXTRACT (GSE) AND POLICOSANOL PRODUCE ANTIOXIDANT AND ANTI-IS- CHEMIC EFFECTS. IN THIS STUDY GSE AND POLICOSANOL EFFECTS ON A GERBIL GLOBAL CEREBRAL ISCHEMIA MODEL (GCI) WERE COMPARED. GERBILS WERE DISTRIBUTED IN SIX GROUPS: A NEGATIVE CONTROL AND FIVE WITH GCI: A POSITIVE CONTROL (VEHICLE), TWO WITH GSE AND TWO WITH POLICOSANOL (100 AND 200 MG/KG). POLICOSANOL AND GSE 100 AND 200 MG/KG SIGNIFICANTLY DECREASED THE HISTOLOGICAL SCORES OF NEURONAL INJURY AND PLASMA MDA AND SHG LEVELS, WHILE ONLY AT 200 MG/KG SIGNIFICANTLY ATTENUATED HYPERLOCOMOTION AS COMPARED TO POSITIVE CON- TROL GROUP. ALTHOUGH BOTH THERAPIES WERE SIMILARLY EFFECTIVE ON MOST PARAMETERS, THE ANTIOXIDANT EFFECT OF THE LOW DOSE OF GSE WAS GREATER THAN THAT OF POLICOSANOL. IN CONCLUSION, GSE AND POLICOSANOL SIMILARLY PROTECTED AGAINST GCI INDUCED IN GERBILS.","CEREBRAL ISCHEMIA; GERBILS; GRAPE SEED EXTRACT; POLICOSANOL","GRAPE SEED EXTRACT; MALONALDEHYDE; POLICOSANOL; THIOL GROUP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GERBIL; HIPPOCAMPUS; HISTOPATHOLOGY; HYPERLOCOMOTION; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; MOTOR DYSFUNCTION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; SINGLE DRUG DOSE","","","HEART DIS- EASE AND STROKE STATISTICS -, (2005); DONNAN G.A., FISHER M., MACLEOD M., DAVIS S.M., LANCET, 371, PP. 1612-1623, (2008); AMARENCO P., BOGOUSSLAVSKY J., CAPLAN L.R., DONNAN G.A., HENNERICI M.G., CERE-BROVASC. DIS, 27, PP. 493-501, (2009); WANG Q., XU J., ROTTINGHAUS G.E., SIMONYI A., LUBAHN D., SUN G.Y., ET AL., BRAIN RES, 958, PP. 439-447, (2002); LIM C., ALEXANDER M.P., LAFLECHE G., SCHNYER D.M., VERFAELLIE M., NEUROLOGY, 63, PP. 1774-1778, (2004); KIRINO T., NEUROPATHOLOGY, 20, SUPPL, PP. 95-97, (2000); HARA A., MORI H., NIWA M., STROKE, 31, PP. 236-238, (2000); MEHTA S.L., MANHAS N., RAGHUBIR R., BRAIN RES. REV, 54, PP. 34-66, (2007); AMANTEA D., NAPPI G., BERNARDI G., BAGET-TA G., CORASANITI M.T., FEBS J, 276, PP. 13-26, (2009); PHILLIS J.W., HORROCKS L.A., FAROOQUI A.A., BRAIN RES. REV, 52, PP. 201-243, (2006); WANG Q., TANG X.N., YENARI M.A., J. NEUROIMMUNOL, 184, PP. 53-68, (2007); GRAHAM S.H., CHEN J., J. CEREB. BLOOD FLOW METAB, 21, PP. 99-109, (2001); CHAN P.H., J. CEREB. BLOOD FLOW METAB, 21, PP. 2-14, (2001); SIMONYI A., WANG Q., MILLER R.L., YUSOF M., SHELAT P.B., SUN A.Y., ET AL., MOL. NEURO- BIOL, 31, PP. 135-147, (2005); WANG Q., SIMONYI A., LI W., SISK B.A., MILLER R.L., MACDONALD R.S., ET AL., MOL. NUTR. FOOD RES, 49, PP. 443-451, (2005); VITSEVA O., VARGHESE S., CHAKRABARTI S., FOLTS J.D., FREEDMAN J.E., J. CARDIOVASC. PHARMACOL, 46, PP. 445-451, (2005); FENG Y., LIU Y.M., FRATKINS J.D., LEBLANC M.H., BRAIN RES. BULL, 66, PP. 120-127, (2005); FENG Y., LIU Y.M., LEBLANC M.H., BHATT A.J., RHODES P.G., PEDIATR. RES, 61, PP. 295-300, (2007); HWANG I.K., YOO K.Y., KIM D.S., JEONG Y.K., KIM J.D., SHINK H.K., ET AL., LIFE SCI, 75, PP. 1989-2001, (2004); WANG Q., SUN A.Y., SIMONYI A., MILLER D.K., SMITH R.E., LUCHTEFELD R.G., ET AL., J. NUTR. BIOCHEM, 20, PP. 369-377, (2009); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., THROMB. RES. 69: 321-, (1993); PEREZ Y., MAS R., GONZALEZ R.M., JIMENEZ S., MOLINA V., ARZN.-FORSCH. DRUG RES, 58, PP. 126-130, (2008); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., PROSTAGL. LEUKOTR. ES- SENT, FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., ET AL., BRAZ. J. MED. BIOL. RES, 32, PP. 1269-1276, (1999); OHTA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., J CLIN. BIOCHEM. NUTR, 42, PP. 118-125, (2008); WANG T., LIU Y.Y., WANG X., YANG N., ZHU H.B., ZUO P.P., ACTA PHARMACOL. SIN, 31, PP. 765-774, (2010); BARTUS R.T., DEAN R.L., MENNERICK S., EVELETH D., LYBCH G., BRAIN RES, 790, PP. 1-13, (1998); MARXWELL M.A., HAAS S.M., BEIBER L.L., TOLBERT N.E., ANAL. BIOCHEM, 87, PP. 206-209, (1987); OHKAWA H., OHISHI N., YAGI K., ANAL. BIOCHEM, 95, PP. 351-358, (1979); MIAO-LIN H., METHODS IN ENZIMOLOGY, 233, PP. 380-382, (1994); GINSBERG M.D., BUSTO R., STROKE, 20, PP. 1627-1642, (1989); WANG Q., TOMPKINS K.D., SIMONYI A., KO-RTHUIS R.J., SUN A.Y., SUN G.Y., BRAIN RES, 23, PP. 182-189, (2006); YASUI H., ASANUMA T., WATANABE Y., WAKI K., INANAMI O., KUWABARA M., BIOFACTORS, 29, PP. 113-121, (2007); WANG D., CORBETT D., BRAIN RES, 533, PP. 78-82, (1990); KATSUTA K., UMEMURA K., UEYAMA N., MAT-SUOKA N., EUR. J. PHARMACOL, 467, PP. 103-109, (2003); JANAC B., RADENOVIC L., SELAKOVIC V., PRO-LIC Z., BEHAV. BRAIN RES, 175, PP. 362-373, (2006); RAMOS Z.R., GAMEZ P.U., NAVARRO R., LUQUAN A.S., GARCIA-ESTRADA J., MINIM. IN- VASIVE NEUROSURG, 51, PP. 87-90, (2008); KATSUMATA N., KUROIWA T., ISHIBASHI S., LI S., ENDO S., OHNO K., NEUROPATHOLOGY, 26, PP. 283-292, (2006); HOU S.T., MACMANUS J.P., INT. REV. CY-TOL, 221, PP. 93-148, (2002); GUPTA S., SHARMA S.S., BIOL. PHARM. BULL, 29, PP. 957-961, (2006); MOLINA V., CARBAJAL D., ARRUZAZABALA M.L., RAVELO Y., MAS R., REV CNIC CIENCIAS BIOL, 42, PP. 3-6, (2010)","V. MOLINA; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA; EMAIL: VIVIAN.MOLINA@CNIC.EDU.CU","","ENGLISH","LAT. AM. J. PHARM.","ARTICLE","ISI","2-S2.0-84876008210","LAT AM J PHARM","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"MOLINA V, 2013, LAT AM J PHARM","MOLINA V, 2013, LAT AM J PHARM"
"CARBAJAL Q D;MOLINA C V;RAVELO C Y;ZAMORA R Z;MAS F R","CARBAJAL QUINTANA, DAISY (55821592400); MOLINA CUEVAS, VIVIAN (7006062814); RAVELO CALZADO, YAZMIN (34976285600); ZAMORA RODRÍGUEZ, ZULLYT (6507399878); MAS FERREIRO, ROSA (6602148780)","EFFECTS OF POLICOSANOL ON GASTROPROTECTIVE ACTION OF D002 EFECTOS DEL POLICOSANOL EN LA ACCIÓN GASTROPROTECTORA DEL D002",2014,"REVISTA CUBANA DE FARMACIA","48","8",0,"","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","INTRODUCTION: POLICOSANOL, A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX, IS USED TO TREAT HYPERCHOLESTEROLEMIA. D-002 (ABEXOL), A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS FROM BEESWAX, IS AN ANTIOXIDANT SUPPLEMENT WITH GASTROPROTECTIVE EFFECTS. THEN, CONCOMITANT INTAKE OF D-002 AND POLICOSANOL MAY OCCUR IN ROUTINE PRACTICE, SO POTENTIAL PHARMACOLOGICAL INTERACTIONS BETWEEN THEM SHOULD BE RESEARCHED ON. OBJECTIVE: TO FIND OUT THE INFLUENCE OF POLICOSANOL ON THE GASTROPROTECTIVE EFFECT OF D-002 ON THE ETHANOL-INDUCED GASTRIC ULCER MODEL. METHODS: RATS WERE RANDOMIZED INTO EIGHT GROUPS: ONE TREATED WITH THE VEHICLE (CONTROL), TWO WITH D-002 (25 AND 200 MG/KG), TWO WITH POLICOSANOL (25 AND 200 MG/KG), TWO WITH THE SAME DOSES OF D-002 + POLICOSANOL AND OTHER WITH SUCRALFATE (100 MG/KG). TREATMENTS WERE GIVEN AS SINGLE ORAL DOSES. ONE HOUR AFTER TREATMENT, RATS RECEIVED 60% ETHANOL ORALLY AND ONE HOUR LATER THEY WERE KILLED AND THEIR STOMACHS EXPOSED. EFFECTS ON ULCER INDEXES (UI) WERE ASSESSED. RESULTS: ACUTE ORAL ADMINISTRATION OF D-002 (25 AND 200 MG/KG) SIGNIFICANTLY REDUCED THE ULCER INDEXES BY 40% AND 68%, RESPECTIVELY, AS COMPARED TO THE CONTROL GROUP, AND POLICOSANOL BY 26% AND 47%, RESPECTIVELY. THE CONCOMITANT ADMINISTRATION OF THE SAME DOSES OF D-002 AND POLICOSANOL SIGNIFICANTLY DECREASED ULCER INDEXES BY 64% (BOTH GIVEN AT 25 MG/KG) AND BY 92% (BOTH GIVEN AT 200 MG/KG) AS COMPARED TO THE RESPECTIVE MONOTHERAPIES. SUCRALFATE (100 MG/KG) SIGNIFICANTLY REDUCED ( 99%) ULCER INDEXES COMPARED TO THE CONTROL GROUP. CONCLUSIONS: THE CONCOMITANT ORAL ADMINISTRATION OF POLICOSANOL WITH D-00 2 GIVES GREATER GASTROPROTECTION THAN D-002 MONOTHERAPY, SO BOTH PRODUCTS CAN BE TAKEN TOGETHER. © 2014, EDITORIAL CIENCIAS MEDICAS. ALL RIGHTS RESERVED.","BEES WAX ALCOHOLS; COMBINED THERAPY; ETHANOL-INDUCED ULCERS; GASTRIC ULCERS; POLICOSANOL","ABEXOL; ANTIOXIDANT; POLICOSANOL; SUCRALFATE; UNCLASSIFIED DRUG; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIULCER ACTIVITY; ARTICLE; CONTROLLED STUDY; MALE; MONOTHERAPY; NONHUMAN; RAT; SINGLE DRUG DOSE; STOMACH ULCER","","","ZAPATA-COLINDRES J.C., ZEPEDA-GOMEZ S., MONTANO-LOZA A., VAZQUEZ-BALLESTEROS E., VILLALOBOS J.J., VALDOVINOS-ANDRACA F., THE ASSOCIATION OF HELICOBACTER PYLORI INFECTION AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN PEPTIC ULCER DISEASE, CAN J GASTROENTEROL, 20, PP. 277-280, (2006); SUNG J.Y., TOSI K.F., MA T.K., YUNG M.Y., LAU Y.W., CHIU W.Y., CAUSES OF MORTALITY IN PATIENTS WITH PEPTIC ULCER BLEEDING: A PROSPECTIVE COHORT STUDY OF 10 428 CASES, AM J GASTROENTEROL, 105, PP. 84-89, (2010); ZULLO A., HASSAN C., CAMPO S.M., MORINI S., BLEEDING PEPTIC ULCER IN THE ELDERLY: RISK FACTORS AND PREVENTION STRATEGIES, DRUGS AGING, 24, PP. 815-828, (2007); SHIOTANI A., MANABE N., KAMADA T., FUJIMURA Y., SAKAKIBARA T., HARUMA K., RISK AND PREVENTIVE FACTORS OF LOW-DOSE ASPIRIN-INDUCED GASTRODUODENAL INJURIES: A COMPREHENSIVE REVIEW, GASTROENTEROL HEPATOL, 27, 3, PP. 8-12, (2012); IWAMOTO J., SAITO Y., HONDA A., MATSUZAKI Y., CLINICAL FEATURES OF GASTRODUODENAL INJURY ASSOCIATED WITH LONG-TERM LOW-DOSE ASPIRIN THERAPY, WORLD J GASTROENTEROL, 19, PP. 1673-1682, (2013); ANUARIO ESTADÍSTICO DE SALUD, (2012); ALLEN A., FLEMSTROM G., GASTRODUODENAL MUCUS BICARBONATE BARRIER: PROTECTION AGAINST ACID AND PEPSIN, AM J PHYSIOL CELL PHYSIOL, 288, PP. CC1-C19, (2005); PHILLIPSON M., JOHANSSON M.E., HENRIKSNAS J., PETERSSON J., GENDLER S.J., SANDLER S., ET AL., THE GASTRIC MUCUS LAYERS: CONSTITUENTS AND REGULATION OF ACCUMULATION, AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, 295, PP. 806-812, (2008); PALILEO C., KAUNITZ J.D., GASTROINTESTINAL DEFENSE MECHANISMS, CURR OPIN GASTROENTEROL, 27, PP. 543-548, (2011); LAMARQUE D., PATHOGENESIS OF GASTRODUODENAL LESIONS INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, GASTROENTEROL CLIN BIOL, 28, PP. C18-C26, (2004); YOSHIKAWA T., NAITO Y., PATHOGENESIS OF NSAIDS-INDUCED GASTROINTESTINAL ULCERS, NIHON RINSHO, 69, PP. 995-1002, (2011); TAKEUCHI K., PATHOGENESIS OF NSAID-INDUCED GASTRIC DAMAGE: IMPORTANCE OF CYCLOOXYGENASE INHIBITION AND GASTRIC HYPERMOTILITY, WORLD J GASTROENTEROL, 18, PP. 2147-2160, (2012); MURESAN A., SUCIU S., MITREA D.R., ALB C., LOGIN C., CRISAN D., DAICOVICIU D., OXIDATIVE STRESS IMPLICATIONS IN EXPERIMENTAL GASTRIC ULCER INDUCED BY INDOMETHACIN. BULLETIN UASVM, VETERINARY MEDICINE, 65, 1, PP. 119-125, (2008); PARIKH N., HOWDEN C.W., THE SAFETY OF DRUGS USED IN ACID-RELATED DISORDERS AND FUNCTIONAL GASTROINTESTINAL DISORDERS, GASTROENTEROL CLIN NORTH AM, 39, PP. 529-542, (2010); FUJIKAWA Y., WATANABE T., TOMINAGA K., FUJIWARA Y., SATO H., ARAKAWA T., EFFICACY OF PROSTAGLANDIN DERIVATIVES AND MUCOPROTECTIVE DRUGS IN TREATMENT AND PREVENTION FOR NSAIDS-INDUCED ULCER, NIHON RINSHO, 69, PP. 1039-1043, (2011); HEIDELBAUGH J.J., METZ D.C., YANG Y.X., PROTON PUMP INHIBITORS: ARE THEY OVER UTILISED IN CLINICAL PRACTICE AND DO THEY POSE SIGNIFICANT RISK?, INT J CLIN PRACT, 66, PP. 582-591, (2012); DESILETS A.R., ASAL N.J., DUNICAN K.C., CONSIDERATIONS FOR THE USE OF PROTON-PUMP INHIBITORS IN OLDER ADULTS, CONSULT PHARM, 27, PP. 114-210, (2012); ROULET L., VERNAZ N., GIOSTRA E., GASCHE Y., DESMEULES J., ADVERSE EFFECTS OF PROTON PUMP INHIBITORS: SHOULD WE WORRY ABOUT LONG-TERM EXPOSURE?, REV MED INTERNE, 33, 8, PP. 439-445, (2012); MAS R., D-002: A PRODUCT OBTAINED FROM BEESWAX, DRUGS OF THE FUTURE, 26, 8, PP. 731-744, (2001); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA M.L., MAS R., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J PHARM PHARMACOL, 47, PP. 731-733, (1995); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA M.L., RODEIRO I., MAS R., ET AL., POSSIBLE CYTOPROTECTIVE MECHANISM IN RATS OF D-002 AN ANTI-ULCEROGENIC PRODUCT ISOLATED FROM BEESWAX, J PHARM PHARMACOL, 48, PP. 858-860, (1996); CARBAJAL D., MOLINA V., NOA M., VALDES S., ARRUZAZABALA M.L., AGUIAR A., ET AL., EFFECTS OF D-002 ON GASTRIC MUCUS COMPOSITION IN ETHANOL-INDUCED ULCER, PHARMACOL RES, 42, 4, PP. 329-332, (2000); MOLINA V., VALDES S., CARBAJAL D., ARRUZAZABALA M.L., MENENDEZ R., MAS R., ANTIOXIDANT EFFECTS OF D-002 ON GASTRIC MUCOSA OF RATS WITH EXPERIMENTALLY-INDUCED INJURY, J MED FOOD, 4, PP. 79-83, (2001); PEREZ Y., OYARZABAL A., MAS R., MOLINA V., JIMENEZ S., PROTECTIVE EFFECT OF D-002, A MIXTURE OF BEESWAX ALCOHOLS, AGAINST INDOMETHACIN-INDUCED GASTRIC ULCERS AND MECHANISM OF ACTION, INT J NAT MED, 67, 1, PP. 182-189, (2013); HANO O., ILLNAIT J., MAS R., FERNANDEZ L., PINOL F., FERNANDEZ J., EFFECTS OF D-002, A PRODUCT ISOLATED FROM BEESWAX, ON DUODENAL ULCER: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES, 62, PP. 394-407, (2001); ILLNAIT J., TERRY H., MAS R., FERNANDEZ L., CARBAJAL D., EFFECTS OF D-002, A PRODUCT ISOLATED FROM BEESWAX, ON GASTRIC SYMPTOMS OF PATIENTS WITH OSTEOARTHRITIS TREATED WITH PIROXICAM: A PILOT STUDY, J MED FOOD, 8, 1, PP. 63-68, (2005); ILLNAIT J., RODRIGUEZ I., MOLINA V., MENDOZA S., MAS R., FERNANDEZ L., ET AL., EFFECTS OF D-002 (BEESWAX ALCOHOLS) ON GASTROINTESTINAL SYMPTOMS AND OXIDATIVE MARKERS IN MIDDLE-AGED AND OLDER SUBJECTS, LAT AM J PHARM, 32, PP. 166-174, (2013); CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., MAS R., MESA M., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH BORDERLINE TO MILDLY INCREASED SERUM CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY, CURR THER RES CLIN AND EXP, 142, 7, PP. 277-284, (2003); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.C., GONZALEZ R.M., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDÍATED LIPID PEROXIDATION, CURR THER RES, 61, PP. 609-620, (2000); NOA M., MAS R., EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE COMPOSITION ON AORTAS OF MACACA ARCTOIDES MONKEYS, ARCH MED RES, 36, PP. 441-447, (2005); GONZALEZ V., MARRERO D., SIERRA R., VELAZQUEZ C., VICENTE R., NUEVO MÉTODO POR CROMATOGRAFÍA GASEOSA CAPILAR PARA EL ANÁLISIS DEL INGREDIENTE ACTIVO D-002, REV CENIC CIENCIAS QUÍMICAS, 9, PP. 123-125, (2008); MARRERO D., GONZALEZ V., SIERRA R., VELAZQUEZ C., VALIDACIÓN DE UN NUEVO MÉTODO ANALÍTICO POR CG CON COLUMNA CAPILAR PARA LA DETERMINACIÓN DE ALCOHOLES ALIFÁTICOS DE ALTO PESO MOLECULAR EN EL POLICOSANOL INGREDIENTE ACTIVO, REV COLOMBIANA DE CIENCIAS QUIM FARM, 37, 1, PP. 62-68, (2008); ZENGIL H., ONUK E., ERCAN Z.S., TURKER R.K., PROTECTIVE EFFECT OF ILOPROST AND UK 38 485 AGAINST GASTRIC MUCOSAL DAMAGE INDUCED BY VARIOUS STIMULI, PROSTAGL LEUKOTR MED, 30, PP. 61-67, (1987); OHARA A., SUGIYAMA S., HOSHINO H., HAMAJIMA E., GOTO H., TSUKAMOTO Y., REDUCTION OF ADVERSE EFFECTS OF INDOMETHACIN BY ANTI-ALLERGIC DRUGS IN RAT STOMACHS, ARZNEIM-FORSCH DRUG RES, 42, PP. 1115-1118, (1992); MUHAMMED ASHRAF V.K., THAMOTHARAN G., SENGOTTUVELU S., HAJA SHERIEF S., SIVAKUMAR T., EVALUATION OF ANTI ULCER ACTIVITY OF FICUS PUMILA L. LEAF EXTRACT IN ALBINO RATS, GJRMI, 1, 8, PP. 340-351, (2012); PEREZ Y., OYARZABAL A., RAVELO Y., MAS R., JIMENEZ S., MOLINA V., INHIBITION OF COX AND 5-LOX ENZYMES BY D-002 (BEESWAX ALCOHOLS), CURR TOP NUTR RES (FORTHCOMING), (2012); PEREZ Y., OYARZABAL A., JIMENEZ S., MOLINA V., MAS R., EFECTO SECUESTRADOR DEL D- 002 SOBRE RADICALES HIDROXILO EN MUCOSA GÁSTRICA, REV CUBANA FARM, 46, 1, PP. 87-96, (2012); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAM TROMB HEMOST, 5, PP. 17-20, (1992); OYARZABAL A., MOLINA V., JIMENEZ S., CURVECO D., MAS R., EFECTOS DEL POLICOSANOL, EL EXTRACTO DE SEMILLAS DE UVA Y SU TERAPIA COMBINADA SOBRE MARCADORES OXIDATIVOS EN RATAS, REV CUBANA FARM, 45, 1, PP. 87-96, (2010)","","EDITORIAL CIENCIAS MEDICAS","SPANISH","REV. CUBA. FARM.","ARTICLE","ISI","2-S2.0-84925342036","REV CUBA FARM",NA,"NOTREPORTED",NA,"CARBAJAL QUINTANA D, 2014, REV CUBA FARM","CARBAJAL QUINTANA D, 2014, REV CUBA FARM"
"SÁNCHEZ J;ILLNAIT J;MAS R;MENDOZA S;VEGA H;FERNÁNDEZ L;MESA M;FERNÁNDEZ J;REYES P;RUIZ D","SÁNCHEZ, JAVIER (57210524556); ILLNAIT, JOSÉ (8631465800); MAS, ROSA (7007164570); MENDOZA, SARAHÍ (7102759819); VEGA, HERMYS (57188666109); FERNÁNDEZ, LILIA (7202848319); MESA, MEILIS (36880545700); FERNÁNDEZ, JULIO (9432805500); REYES, PABLO (57196910548); RUIZ, DALMER (26425153000)","POLICOSANOL VERSUS ATORVASTATIN ON THE FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE",2016,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH","37","7",5,"","INSTITUTE OF NEUROLOGY AND NEUROSURGERY, HAVANA, CUBA;SURGICAL MEDICAL RESEARCH CENTRE, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA, CUBA;SURGICAL MEDICAL RESEARCH CENTRE, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA, CUBA;SURGICAL MEDICAL RESEARCH CENTRE, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA, CUBA;DATABASE BRANCH, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;DATABASE BRANCH, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","STROKE IS AMONG THE LEADING CAUSES OF MORTALITY AND DISABILITY. STATIN MAY IMPROVE STROKE FUNCTIONAL OUTCOME. POLICOSANOL ADDED TO ASPIRIN (AS) THERAPY IMPROVES STROKE OUTCOME COMPARED TO PLACEBO + AS. THE OBJECTIVE IS TO COMPARE THE EFFICACY OF POLICOSANOL AND ATORVASTATIN ON THE FUNCTIONAL STROKE IN PATIENTS WHO HAD HAD A RECENT ISCHEMIC STROKE. PATIENTS WHO HAD SUFFERED A RECENT (≤ 30 DAYS EVOLUTION) STROKE AND HAD MODIFIED RANKIN SCALE SCORES (MRSS) BETWEEN 2 AND 4 WERE DOUBLE-BLINDLY RANDOMIZED TO POLICOSANOL (20 MG/DAY) OR ATORVASTATIN (20 MG/DAY) FOR 12 WEEKS. THE PRIMARY OUTCOME WAS THE REDUCTION OF MRSS AT 12 WEEKS AFTER RANDOMIZATION, AND THE SECONDARY OUTCOME THE INCREASE OF THE BARTHEL INDEX (BI). SIXTY PATIENTS (MEAN AGE: 68 YEARS) WERE RANDOMIZED, AND ALL COMPLETED THE STUDY. AFTER 4 WEEKS ON THERAPY, BOTH TREATMENTS DECREASED SIGNIFICANTLY (P<0.001) MEAN MRSS VERSUS BASELINE. THIS EFFECT IMPROVED THEREAFTER, ACHIEVING DECREASES OF 56.5% (POLICOSANOL) AND 52.2% (ATORVASTATIN), RESPECTIVELY, AT STUDY COMPLETION. NO SIGNIFICANT DIFFERENCES BETWEEN GROUPS WERE SEEN. BI INCREASED SIGNIFICANTLY (P<0.00001) IN BOTH GROUPS AT WEEK 4 AND SUCH EFFECT WAS ENHANCED THEREAFTER. THE INCREASE WITH POLICOSANOL WAS HIGHER (P<0.01) THAN WITH ATORVASTATIN. LOWDENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) AND TOTAL CHOLESTEROL (TC) DECREASED SIGNIFICANTLY WITH BOTH TREATMENTS, BUT MORE (P<0.05 AND P<0.01, RESPECTIVELY) WITH ATORVASTATIN. HDL-C INCREASED SIGNIFICANTLY (P<0.01) WITH POLICOSANOL, NOT WITH ATORVASTATIN. TRIGLYCERIDES REMAINED UNCHANGED IN BOTH GROUPS. POLICOSANOL (20 MG/DAY) AND ATORVASTATIN (20 MG/DAY), ADMINISTERED FOR 12 WEEKS WITHIN THE NEXT 30 DAYS AFTER STROKE ONSET, WERE SIMILARLY EFFECTIVE FOR IMPROVING THE FUNCTIONAL OUTCOME IN ISCHEMIC STROKE PATIENTS TREATED WITH AS. © 2016, GLOBAL RESEARCH ONLINE. ALL RIGHTS RESERVED.","ASPIRIN; ATORVASTATIN; BARTHEL INDEX; ISCHEMIC STROKE; POLICOSANOL; RANKIN-MODIFIED SCALE","ATORVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BARTHEL INDEX; BLOOD SAMPLING; BRAIN ISCHEMIA; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL RECOVERY; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STOMACH PAIN","","","AMARENCO P., BOGOUSSLAVSKY J., CAPLAN L.R., DONNAN G.A., HENNERICI M.G., CLASSIFICATION OF STROKE SUBTYPES, CEREBROVASC DIS, 27, PP. 493-501, (2009); AMANTEA D., NAPPI G., BERNARDI G., BAGETTA G., CORASANITI M.T., POST-ISCHEMIC BRAIN DAMAGE: PATHOPHYSIOLOGY AND ROLE OF INFLAMMATORY MEDIATORS, FEBS J, 276, PP. 13-26, (2009); DI CARLO A., HUMAN AND ECONOMIC BURDEN OF STROKE, AGE AGEING, 38, PP. 4-5, (2009); ROGER V.L., GO A.S., LLOYD-JONES D.M., BENJAMIN E.J., BERRY J.D., BORDEN W.B., HEART DISEASE AND STROKE STATISTICS—2012 UPDATE, CIRCULATION, 125, PP. E2-E220, (2012); COUILLARD P., POPPE A.Y., COUTTS S.B., PREDICTING RECURRENT STROKE AFTER MINOR STROKE AND TRANSIENT ISCHEMIC ATTACK, EXPERT REV CARDIOVASC THER, 7, PP. 1273-1281, (2009); ARBOIX A., CARDIOVASCULAR RISK FACTORS FOR ACUTE STROKE: RISK PROFILES IN THE DIFFERENT SUBTYPES OF ISCHEMIC STROKE, WORLD J CLIN CASES, 3, PP. 418-429, (2015); AMARENCO P., LABREUCHE J., LIPID MANAGEMENT IN THE PREVENTION OF STROKE: REVIEW AND UPDATED META-ANALYSIS OF STATINS FOR STROKE PREVENTION, LANCET NEUROL, 8, PP. 453-463, (2009); OREGAN C., WU P., ARORA P., PERRI D., MILLS E.J., STATIN THERAPY IN STROKE PREVENTION: A META-ANALYSIS INVOLVING 121,000 PATIENTS, AM J MED, 121, PP. 24-33, (2008); FILALO J., DUQUE G., STEELE R., JUKEMA W., DE CRAEN A.J., EISENBERG M.J., STATINS FOR SECONDARY PREVENTION IN ELDERLY PATIENTS: A HIERARCHICAL BAYESIAN META-ANALYSIS, J AM COLL CARDIOL, 51, PP. 37-45, (2008); KEARNEY P.M., BLACKWELL L., COLLINS R., KEECH A., SIMES J., PETO R., EFFICACY OF CHOLESTEROL-LOWERING THERAPY IN 18,686 PEOPLE WITH DIABETES IN 14 RANDOMISED TRIALS OF STATINS: A METAANALYSIS, LANCET, 371, PP. 117-125, (2008); RUGTS J.J., YETGIN T., HOEKS S.E., GOTTO A.M., SHEPHERD J., WESTENDORP R.G., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS: META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 338, (2009); NACI H., BRUGTS J.J., FLEURENCE R., ADES A.E., COMPARATIVE EFFECTS OF STATINS ON MAJOR CEREBROVASCULAR EVENTS: A MULTIPLE-TREATMENTS META-ANALYSIS OF PLACEBO-CONTROLLED AND ACTIVE-COMPARATOR TRIALS, QJM, 106, PP. 299-306, (2013); GUAN W., KOZAK A., FAGAN S.C., DRUG REPURPOSING FOR VASCULAR PROTECTION AFTER ACUTE ISCHEMIC STROKE, ACTA NEUROCHIR SUPPL, 111, PP. 295-298, (2011); LAKHAN S.E., BAGCHI S., HOFER M., STATINS AND CLINICAL OUTCOME OF ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW, INT ARCH MED, 3, 3, (2010); HJALMARSSON C., BOKEMARK L., MANHEM K., MEHLIG K., ERSSON B., THE EFFECT OF STATINS ON ACUTE AND LONG-TERM OUTCOME AFTER ISCHEMIC STROKE IN THE ELDERLY, AM J GERIATR PHARMACOTHER, 10, PP. 313-322, (2012); SONG B., WANG Y., ZHAO X., LIU L., WANG C., WANG A., ASSOCIATION BETWEEN STATIN USE AND SHORT-TERM OUTCOME BASED ON SEVERITY OF ISCHEMIC STROKE: A COHORT STUDY, PLOS ONE, 9, (2014); ASDAGHI N., COULTER J.I., MODI J., CAMDEN M.C., QAZI A., GOYAL M., STATIN THERAPY DOES NOT AFFECT THE RADIOGRAPHIC AND CLINICAL PROFILE OF PATIENTS WITH TIA AND MINOR STROKE, AM J NEURORADIOL, (2015); CHROININ N., ASPLUND K., ASBERG S., CALLALY E., CUADRADO E., DIEZ E., STATIN THERAPY AND OUTCOME AFTER ISCHEMIC STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES AND RANDOMIZED TRIALS, STROKE, 44, PP. 448-456, (2013); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAG, LEUK AND ESS FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZIL J MED BIOL RES, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J PHARM SCI, 75, PP. 635-641, (2013); ORTEGA L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE. A PILOT OPEN STUDY, J MED FOOD, 9, PP. 378-385, (2006); SANCHEZ J., MAS R., MENDOZA S., FERNANDEZ J., RUIZ D., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE WITH PREVIOUS TRANSIENT ISCHEMIC ATTACK: A LONG-TERM FOLLOW-UP, REV CENIC CIEN BIOL, 41, 41, PP. 23-29, (2010); SANCHEZ J., FERNANDEZ L., ILLNAIT J., ARRUZAZABALA M.L., MOLINA V., MAS R., EFFECTS OF POLICOSANOL ON THE RECOVERY OF ISCHEMIC STROKE: A RANDOMIZED CONTROLLED STUDY, IOSR JOURNAL OF PHARMACY, 2, PP. 14-24, (2012); SANCHEZ J., FERNANDEZ L., ILLNAIT J., ARRUZAZABALA M.L., MOLINA V., MAS R., EFFECTS OF POLICOSANOL ON THE RECOVERY OF ISCHEMIC STROKE: A RANDOMIZED CONTROLLED STUDY, IOSR JOURNAL OF PHARMACY, 4, PP. 31-40, (2013); RANKIN J., CEREBRAL VASCULAR ACCIDENTS IN PATIENTS OVER THE AGE OF 60. II. PROGNOSIS, SCOTT MED J, 2, PP. 200-215, (1957); COLLABORATIVE METAANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE IN HIGH/RISK PATIENTS, BMJ, 324, PP. 71-86, (2000); LEVI M., THROMBOPROPHYLAXIS FOR CEREBROVASCULAR DISORDERS: ACETYLSALICYLIC ACID REMAINS THE CORNERSTONE, NED TIJDSCHR GENEESKD, 152, PP. 423-425, (2008); LIKOSKY D.J., LEE K., BROWN D.M., AMIN A., DRESSLER D.D., KRAKOW D., EVIDENCE-BASED MEDICINE: REVIEW OF GUIDELINES AND TRIALS IN THE PREVENTION OF SECONDARY STROKE, J HOSP MED, 3, PP. SS6-S19, (2008); MAHONEY F.I., BARTHEL D.W., FUNCTIONAL EVALUATION: THE BARTHEL INDEX, MD MED J, 14, PP. 61-65, (1965); QUINN T.J., LANGHORNE P., STOTT D.J., BARTHEL INDEX FOR STROKE TRIALS: DEVELOPMENT, PROPERTIES, AND APPLICATION, STROKE, 42, PP. 1146-1151, (2011); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); MIEDEMA I., UYTTENBOOGAART M., KOOPMAN K., DE KEYSER J., LUIJCKX G.J., STATIN USE AND FUNCTIONAL OUTCOME AFTER TISSUE PLASMINOGEN ACTIVATOR TREATMENT IN ACUTE ISCHAEMIC STROKE, CEREBROVASC DIS, 29, PP. 263-267, (2010); FISHER M., MOONIS M., NEUROPROTECTIVE EFFECTS OF STATINS: EVIDENCE FROM PRECLINICAL AND CLINICAL STUDIES, CURR TREAT OPTIONS CARDIOVASC MED, 14, PP. 252-259, (2012); GHANDEHARI K., CHALLENGING COMPARISON OF STROKE SCALES, J RES MED SCI, 18, PP. 906-910, (2013); THE NATIONAL INSTITUTE FOR NEUROLOGICAL DESORDERS AND STROKE RT-PA STROKE STUDY GROUP, N ENGL J MED, 333, PP. 1581-1587, (1995); LEE Y.C., CHEN S.S., KOH C.L., HSUEH I.P., YAO K.P., HSIEH C.L., DEVELOPMENT OF TWO BARTHEL INDEX-BASED SUPPLEMENTARY SCALES FOR PATIENTS WITH STROKE, PLOS ONE, 9, (2014); MAR J., MASJUAN J., OLIVA J., GONZALEZ N., BECERRA V., CASADO M., OUTCOMES MEASURED BY MORTALITY RATES, QUALITY OF LIFE AND DEGREE OF AUTONOMY IN THE FIRST YEAR IN STROKE UNITS IN SPAIN, HEALTH QUAL LIFE OUTCOMES, 13, (2015); BERTHOLD H.K., UNVERDOBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); FRANCINI F., BELTRAMOLLI D., DALL´ACQUA S, BROCADELLO F, EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-494, (1999); NIKITIN I.P., SLEPCHENKO N.V., GRATSIANSKII N.A., NECHAEV A.S., SYRKIN A.L., POLTAVSKAIA M.G., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC POLICOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); WANG Y., KUANMAN K.E., WANG HIA L., JIAO Y., ZHAO X., SUN N., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); LIU S., TAN M.Y., ZHAO S.P., RONG H., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND HEME OXYGENASE-1 IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 40, PP. 840-843, (2012); TANG M., WU S.Z., GONG X., EFFECTS OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 4, PP. 488-492, (2013)","S. MENDOZA; CENTER OF NATURAL PRODUCTS, HAVANA, CUBA; EMAIL: SARAHI.MENDOZA@CNIC.EDU.CU","GLOBAL RESEARCH ONLINE","ENGLISH","INT. J. PHARM. SCI. REV. RES.","ARTICLE","ISI","2-S2.0-84962159705","INT J PHARM SCI REV RES","INSTITUTE OF NEUROLOGY AND NEUROSURGERY;SURGICAL MEDICAL RESEARCH CENTRE;CENTER OF NATURAL PRODUCTS;CENTER OF NATURAL PRODUCTS;SURGICAL MEDICAL RESEARCH CENTRE;CENTER OF NATURAL PRODUCTS;SURGICAL MEDICAL RESEARCH CENTRE;CENTER OF NATURAL PRODUCTS;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;CENTER OF NATURAL PRODUCTS;NOTREPORTED",NA,"SÁNCHEZ J, 2016, INT J PHARM SCI REV RES","SÁNCHEZ J, 2016, INT J PHARM SCI REV RES"
"WANG C;FAN A;ZHU X;LU Y;DENG S;GAO W;ZHANG W;LIU Q;CHEN X","WANG, CHUNFENG (55782820200); FAN, ALI (56179667800); ZHU, XIAOJIE (56442871000); LU, YANG (57157492200); DENG, SHUHUA (56754550200); GAO, WENCHAO (55849711900); ZHANG, WEI (56442954700); LIU, QI (56183806100); CHEN, XIJING (12766222800)","TRACE QUANTIFICATION OF 1TRIACONTANOL IN BEAGLE PLASMA BY GCMSMS AND ITS APPLICATION TO A PHARMACOKINETIC STUDY",2015,"BIOMEDICAL CHROMATOGRAPHY","29","6",4,"10.1002/bmc.3351","CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;DIVISION OF PHARMACOTHERAPY AND EXPERIMENTAL THERAPEUTICS, ESHELMAN SCHOOL OF PHARMACY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, CHAPEL HILL, 27599, NC, UNITED STATES;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA;CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA","1-TRIACONTANOL (TA), A MEMBER OF LONG CHAIN FATTY ALCOHOL, HAS RECENTLY BEEN RECEIVED GREAT ATTENTION OWING TO ITS ANTITUMOR ACTIVITY. IN THIS STUDY, AN ACCURATE, SENSITIVE AND SELECTIVE GAS CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD WAS DEVELOPED AND VALIDATED FOR THE QUANTIFICATION OF TA IN BEAGLE PLASMA USING 1-OCTACOSANAL AS THE INTERNAL STANDARD (IS) FOR THE FIRST TIME. WITH TEMPERATURE PROGRAMMING, CHROMATOGRAPHIC SEPARATION WAS CARRIED OUT ON AN HP-5MS COLUMN, USING HELIUM AS CARRIER GAS AND ARGON AS COLLISION GAS, BOTH AT A FLOW RATE OF 1ML/MIN. TA WAS ANALYZED USING POSITIVE ION ELECTROSPRAY IONIZATION IN MULTIPLE-REACTION MONITORING MODE, WITH THE PRECURSOR TO PRODUCT ION TRANSITIONS OF M/Z 495.6→97.0 AND M/Z 467.5→97.0 FOR TA AND THE IS, RESPECTIVELY. THE LOWER LIMIT OF QUANTITATION, LINEARITY, INTRA- AND INTERDAY PRECISION, ACCURACY, STABILITY, EXTRACTION RECOVERY AND MATRIX EFFECT OF TA WERE WITHIN THE ACCEPTABLE LIMITS. THE VALIDATED METHOD WAS SUCCESSFULLY APPLIED TO A PHARMACOKINETIC STUDY OF TA IN BEAGLES. © 2014 JOHN WILEY & SONS, LTD.","1-TRIACONTANOL; GC-MS/MS; PHARMACOKINETICS","ANIMALS; DOGS; FATTY ALCOHOLS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; TANDEM MASS SPECTROMETRY; ALCOHOLS; ELECTROSPRAY IONIZATION; GAS CHROMATOGRAPHY; IONIZATION OF GASES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POSITIVE IONS; 1 TRIACONTANOL; POLICOSANOL; UNCLASSIFIED DRUG; 1-TRIACONTANOL; FATTY ALCOHOL; 1-TRIACONTANOL; ANTITUMOUR ACTIVITY; FATTY ALCOHOLS; GAS CHROMATOGRAPHY/TANDEM MASS SPECTROMETRIES; GC/MS/MS; INTERNAL STANDARDS; ITS APPLICATIONS; LONG CHAINS; PHARMACOKINETIC STUDIES; TEMPERATURE-PROGRAMMING; ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; GAS CHROMATOGRAPHY; LIMIT OF QUANTITATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; POSITIVE ION ELECTROSPRAY; QUALITY CONTROL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD; DOG; EVALUATION STUDY; FEMALE; MALE; MASS FRAGMENTOGRAPHY; PROCEDURES; TANDEM MASS SPECTROMETRY; PHARMACOKINETICS","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, PP. 205-208, (1994); CASTANO G., MAS R., FERNANDEZ J.C., ALVAREZ E., LEZSCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL, 61, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOLOGICAL ENDOCRINOLOGY, 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, JOURNAL OF GERONTOLOGY, 56, PP. M186-M192, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUG AGING, 20, PP. 153-163, (2003); DULLENS S.P., MENSINK R.P., BRAGT M.C., EFFECTS OF EMULSIFIED POLICOSANOLS WITH DIFFERENT CHAIN LENGTHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTOR-DEFICIENT MICE, JOURNAL OF LIPID RESEARCH, 49, PP. 790-796, (2008); FAN X.E., ZHANG R.W., CHENG H.J., USE OF TRIACONTANOL IN PREPARATION OF MEDICAMENTS FOR TREATMENT OF CANCERS., (2011); HAIM D., BERRIOS M., VALENZUELA A., VIDELA L.A., TRACE QUANTIFICATION OF 1-OCTACOSANOL AND TA AND THEIR MAIN METABOLITES IN PLASMA BY LIQUID-LIQUID EXTRACTION COUPLED WITH GAS CHROMATOGRAPHY-MASS SPECTROMETRY, JOURNAL OF CHROMATOGRAPHY B, 877, PP. 4154-4158, (2009); HERNANDEZ J., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 51, PP. 568-575, (1992); MAS R., POLICOSANOL-HYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSIS, DRUG FUTURE, 25, PP. 569-586, (2000); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLINICAL PHARMACOLOGY & THERAPEUTICS, 65, PP. 439-447, (1998); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLINICAL DRUG INVESTIGATION, 21, PP. 485-497, (2001); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLES-TEROLEMIC BEAGLES, BIOLOGICAL RESEARCH, 29, PP. 253-257, (1996); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLES DOGS: ONE-YEAR STUDY, TOXICOLOGY LETTERS, 73, PP. 81-90, (1994); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN BEAGLES, JOURNAL OF PHARMACY AND PHARMACOLOGY, 47, PP. 289-291, (1995); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 14, PP. 27-33, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD AND CHEMICAL TOXICOLOGY, 32, PP. 565-575, (1994); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); GUIDANCE FOR INDUSTRY: BIOANALYTICAL METHOD VALIDATION, (2001); ZHANG R.W., CHENG H.J., FAN X.E., THE APPLICATION OF 1-TRIACONTANOL IN THE PREPARATION OF ANTI-CANCER DRUGS., (2008)","X. CHEN; CENTER OF DRUG METABOLISM AND PHARMACOKINETICS, CHINA PHARMACEUTICAL UNIVERSITY, NANJING, 210009, CHINA; EMAIL: CHENXJ-LAB@HOTMAIL.COM","JOHN WILEY AND SONS LTD","ENGLISH","BIOMED. CHROMATOGR.","ARTICLE","ISI","2-S2.0-84927757384","BIOMED CHROMATOGR","CHINA PHARMACEUTICAL UNIVERSITY;CHINA PHARMACEUTICAL UNIVERSITY;CHINA PHARMACEUTICAL UNIVERSITY;THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL;CHINA PHARMACEUTICAL UNIVERSITY;CHINA PHARMACEUTICAL UNIVERSITY;CHINA PHARMACEUTICAL UNIVERSITY;CHINA PHARMACEUTICAL UNIVERSITY;CHINA PHARMACEUTICAL UNIVERSITY","NOTREPORTED;CHINA PHARMACEUTICAL UNIVERSITY;EMAIL: CHENXJ-LAB@HOTMAIL.COM",NA,"WANG C, 2015, BIOMED CHROMATOGR","WANG C, 2015, BIOMED CHROMATOGR"
"KIM N;KWAK J;BAIK J;YOON M;LEE J;YOON S;KIM I","KIM, NAM HO (56654656500); KWAK, JIEUN (56577248000); BAIK, JI YEON (56075692300); YOON, MI-RA (36912827800); LEE, JEOM-SIG (55454693700); YOON, SUNG WON (55780418300); KIM, IN-HWAN (47161438300)","CHANGES IN LIPID SUBSTANCES IN RICE DURING GRAIN DEVELOPMENT",2015,"PHYTOCHEMISTRY","116","9",33,"10.1016/j.phytochem.2015.05.004","DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, 145 ANAM-RO, SEONGBUK-GU, SEOUL, 136-701, SOUTH KOREA, DEPARTMENT OF PUBLIC HEALTH SCIENCES, GRADUATE SCHOOL, KOREA UNIVERSITY, SEOUL, 136 703, SOUTH KOREA;NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON, GYUNGGI-DO, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, 145 ANAM-RO, SEONGBUK-GU, SEOUL, 136-701, SOUTH KOREA, DEPARTMENT OF PUBLIC HEALTH SCIENCES, GRADUATE SCHOOL, KOREA UNIVERSITY, SEOUL, 136 703, SOUTH KOREA;NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON, GYUNGGI-DO, SOUTH KOREA;NATIONAL INSTITUTE OF CROP SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, SUWON, GYUNGGI-DO, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, 145 ANAM-RO, SEONGBUK-GU, SEOUL, 136-701, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, 145 ANAM-RO, SEONGBUK-GU, SEOUL, 136-701, SOUTH KOREA, DEPARTMENT OF PUBLIC HEALTH SCIENCES, GRADUATE SCHOOL, KOREA UNIVERSITY, SEOUL, 136 703, SOUTH KOREA","LIPID SUBSTANCES, SUCH AS FATTY ACIDS, Γ-ORYZANOL, POLICOSANOLS, AND TOCOL (TOCOPHEROL + TOCOTRIENOL), WERE INVESTIGATED IN TWO RICE CULTIVARS, ILPUM AND DASAN, DURING RICE DEVELOPMENT. IN BOTH CULTIVARS, THE LIPID EXTRACT LEVEL DECREASED STEADILY AFTER IT REACHED ITS MAXIMUM LEVEL. ADDITIONALLY, THERE WERE DIFFERENCES IN THE FATTY ACID COMPOSITION, DEPENDING ON THE RICE DEVELOPMENTAL STAGE, BETWEEN THE TWO CULTIVARS. THE Γ-ORYZANOL LEVEL INCREASED DURING RICE DEVELOPMENT, AND THERE WERE DIFFERENCES IN THE COMPOSITION OF Γ-ORYZANOL BETWEEN THE TWO CULTIVARS. THE LEVELS OF POLICOSANOLS DRASTICALLY DECREASED DURING THE EARLY STAGE OF RICE DEVELOPMENT IN THE TWO CULTIVARS. THE TOTAL TOCOL LEVEL SHOWED A DOWNWARD TREND DURING RICE DEVELOPMENT. THE PREDOMINANT TOCOL ISOMER IN ILPUM WAS Α-TOCOPHEROL DURING RICE DEVELOPMENT. IN DASAN, THE PREDOMINANT TOCOL ISOMER WAS Α-TOCOPHEROL AT THE EARLY STAGE, BUT Γ-TOCOTRIENOL AT THE LATER STAGE. THIS STUDY PROVIDED INFORMATION ON THE LEVELS AND COMPOSITION OF LIPID SUBSTANCES, SUCH AS FATTY ACIDS, Γ-ORYZANOL, POLICOSANOLS, AND TOCOL DURING RICE DEVELOPMENT. © 2015 ELSEVIER LTD. ALL RIGHTS RESERVED.","C-ORYZANOL; FATTY ACID; GRAIN DEVELOPMENT; GRAMINEAE; POLICOSANOL; RICE (ORYZA SATIVA L.); TOCOPHEROL; TOCOTRIENOL","CHROMANS; EDIBLE GRAIN; LIPID METABOLISM; ORYZA; PHENYLPROPIONATES; SEEDS; TOCOPHEROLS; TOCOTRIENOLS; VITAMIN E; ORYZA SATIVA; POACEAE; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; CHROMAN DERIVATIVE; GAMMA-ORYZANOL; PHENYLPROPIONIC ACID DERIVATIVE; PLASTOCHROMANOL 8; TOCOL; TOCOPHEROL; ANALOGS AND DERIVATIVES; CEREAL; CHEMISTRY; LIPID METABOLISM; ORYZA; PLANT SEED","","","ABDUL-HAMID A., LUAN Y.S., FUNCTIONAL PROPERTIES OF DIETARY FIBRE PREPARED FROM DEFATTED RICE BRAN, FOOD CHEM, 68, PP. 15-19, (2000); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J. AGRIC. FOOD CHEM, 54, PP. 5359-5362, (2006); ASAOKA M., OKUNO K., SUGIMOTO Y., KAWAKAMI J., FUWA H., EFFECT OF ENVIRONMENTAL TEMPERATURE DURING DEVELOPMENT OF RICE PLANTS ON SOME PROPERTIES OF ENDOSPERM STARCH, STARCH/STÄRKE, 36, PP. 189-193, (1984); BERGMAN C., XU Z., GENOTYPE AND ENVIRONMENT EFFECTS ON TOCOPHEROL, TOCOTRIENOL, AND Γ-ORYZANOL CONTENTS OF SOUTHERN US RICE, CEREAL CHEM, 80, PP. 446-449, (2003); BRITZ S.J., PRASAD P., MOREAU R.A., ALLEN L.H., KREMER D.F., BOOTE K.J., INFLUENCE OF GROWTH TEMPERATURE ON THE AMOUNTS OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL IN BROWN RICE, J. AGRIC. FOOD CHEM, 55, PP. 7559-7565, (2007); CHOUDHURY N.H., JULIANO B.O., LIPIDS IN DEVELOPING AND MATURE RICE GRAIN, PHYTOCHEMISTRY, 19, PP. 1063-1069, (1980); DOLDE D., VLAHAKIS C., HAZEBROEK J., TOCOPHEROLS IN BREEDING LINES AND EFFECTS OF PLANTING LOCATION, FATTY ACID COMPOSITION, AND TEMPERATURE DURING DEVELOPMENT, J. AM. OIL CHEM. SOC, 76, PP. 349-355, (1999); FALK J., KRAHNSTOVER A., VAN DER KOOIJ T.A., SCHLENSOG M., KRUPINSKA K., TOCOPHEROL AND TOCOTRIENOL ACCUMULATION DURING DEVELOPMENT OF CARYOPSES FROM BARLEY (HORDEUM VULGARE L.), PHYTOCHEMISTRY, 65, PP. 2977-2985, (2004); GOFFMAN F.D., PINSON S., BERGMAN C., GENETIC DIVERSITY FOR LIPID CONTENT AND FATTY ACID PROFILE IN RICE BRAN, J. AM. OIL CHEM. SOC, 80, PP. 485-490, (2003); HA T.Y., KO S.N., LEE S.M., KIM H.R., CHUNG S.H., KIM S.R., YOON H.H., KIM I.H., CHANGES IN NUTRACEUTICAL LIPID COMPONENTS OF RICE AT DIFFERENT DEGREES OF MILLING, EUR. J. LIPID SCI. TECHNOL, 108, PP. 175-181, (2006); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP. BIOL. MED. (MAYWOOD), 229, PP. 215-226, (2004); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); HEINEMANN R.J., XU Z., GODBER J.S., LANFER-MARQUEZ U.M., TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL CONTENTS IN JAPONICA AND INDICA SUBSPECIES OF RICE (ORYZA SATIVA L.) CULTIVATED IN BRAZIL, CEREAL CHEM, 85, PP. 243-247, (2008); HORVATH G., WESSJOHANN L., BIGIRIMANA J., MONICA H., JANSEN M., GUISEZ Y., CAUBERGS R., HOREMANS N., ACCUMULATION OF TOCOPHEROLS AND TOCOTRIENOLS DURING SEED DEVELOPMENT OF GRAPE (VITIS VINIFERA L. CV. ALBERT LAVALLEE), PLANT PHYSIOL. BIOCHEM, 44, PP. 724-731, (2006); HUANG S.H., NG L.T., QUANTIFICATION OF TOCOPHEROLS, TOCOTRIENOLS, AND CORYZANOL CONTENTS AND THEIR DISTRIBUTION IN SOME COMMERCIAL RICE VARIETIES IN TAIWAN, J. AGRIC. FOOD CHEM, 59, PP. 11150-11159, (2011); HWANG K.T., KIM J.E., WELLER C.L., POLICOSANOL CONTENTS AND COMPOSITIONS IN WAX-LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN, CEREAL CHEM, 82, PP. 242-245, (2005); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); KHATOON S., GOPALAKRISHNA A., FAT-SOLUBLE NUTRACEUTICALS AND FATTY ACID COMPOSITION OF SELECTED INDIAN RICE VARIETIES, J. AM. OIL CHEM. SOC, 81, PP. 939-943, (2004); KO S.N., KIM C.J., KIM H., KIM C.T., CHUNG S.H., TAE B.S., KIM I.H., TOCOL LEVELS IN MILLING FRACTIONS OF SOME CEREAL GRAINS AND SOYBEAN, J. AM. OIL CHEM. SOC, 80, PP. 585-589, (2003); LEE Y.R., KIM J.Y., WOO K.S., HWANG I.G., KIM K.H., KIM K.J., KIM J.H., JEONG H.S., CHANGES IN THE CHEMICAL AND FUNCTIONAL COMPONENTS OF KOREAN ROUGH RICE BEFORE AND AFTER GERMINATION, FOOD SCI. BIOTECHNOL, 16, PP. 1006-1010, (2007); LERMA-GARCIA M.J., HERRERO-MARTINEZ J.M., SIMO ALFONSO E.F., MENDONCA C.R.B., RAMIS-RAMOS G., COMPOSITION, INDUSTRIAL PROCESSING AND APPLICATIONS OF RICE BRAN Γ-ORYZANOL, FOOD CHEM, 115, PP. 389-404, (2009); LIN P.-Y., LAI H.-M., BIOACTIVE COMPOUNDS IN RICE DURING GRAIN DEVELOPMENT, FOOD CHEM, 127, PP. 86-93, (2011); MARTINEZ-FORCE E., ALVAREZ-ORTEGA R., CANTISAN S., GARCES R., FATTY ACID COMPOSITION IN DEVELOPING HIGH SATURATED SUNFLOWER (HELIANTHUS ANNUUS) SEEDS: MATURATION CHANGES AND TEMPERATURE EFFECT, J. AGRIC. FOOD CHEM, 46, PP. 3577-3582, (1998); MATSUZUKA K., KIMURA E., NAKAGAWA K., MURATA K., KIMURA T., MIYAZAWA T., INVESTIGATION OF TOCOTRIENOL BIOSYNTHESIS IN RICE (ORYZA SATIVA L.), FOOD CHEM, 140, PP. 91-98, (2013); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH. MED. RES, 36, PP. 113-119, (2005); MILLER A., ENGEL K.-H., CONTENT OF Γ-ORYZANOL AND COMPOSITION OF STERYL FERULATES IN BROWN RICE (ORYZA SATIVA L.) OF EUROPEAN ORIGIN, J. AGRIC. FOOD CHEM, 54, PP. 8127-8133, (2006); MURPHY D.J., CUMMINS I., BIOSYNTHESIS OF SEED STORAGE PRODUCTS DURING EMBRYOGENESIS IN RAPESEED, BRASSICA NAPUS, J. PLANT PHYSIOL, 135, PP. 63-69, (1989); NAGENDRA PRASAD M.N., KHATOKAR M.S., COMPOSITIONAL CHANGES IN DEVELOPING RAPE SEED (BRASSICA NAPUS L.), J. NUTR. FOOD SCI, 1, (2011); NORTON G., HARRIS J., HEALTH BENEFITS OF RICE BRAN-A REVIEW, PLANTA, 123, PP. 163-174, (1975); PATEL M., NAIK S., GAMMA-ORYZANOL FROM RICE BRAN OIL: A REVIEW, J. SCI. IND. RES, 63, PP. 569-578, (2004); PERRY H.J., HARWOOD J.L., CHANGES IN THE LIPID CONTENT OF DEVELOPING SEEDS OF BRASSICA NAPUS, PHYTOCHEMISTRY, 32, PP. 1411-1415, (1993); RAKOW G., MCGREGOR D., OIL, FATTY ACID AND CHLOROPHYLL ACCUMULATION IN DEVELOPING SEEDS OF TWO "" LINOLENIC ACID LINES"" OF LOW ERUCIC ACID RAPESEED, CAN. J. PLANT SCI, 55, PP. 197-203, (1975); RAMANARAYAN K., BHAT A., SHRIPATHI V., SWAMY G.S., RAO K.S., TRIACONTANOL INHIBITS BOTH ENZYMATIC AND NONENZYMATIC LIPID PEROXIDATION, PHYTOCHEMISTRY, 55, PP. 59-66, (2000); RAMEZANZADEH F.M., RAO R.M., PRINYAWIWATKUL W., MARSHALL W.E., WINDHAUSER M., EFFECTS OF MICROWAVE HEAT, PACKAGING, AND STORAGE TEMPERATURE ON FATTY ACID AND PROXIMATE COMPOSITIONS IN RICE BRAN, J. AGRIC. FOOD CHEM, 48, PP. 464-467, (2000); REINER Z., TEDESCHI-REINER E., Z R., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN. DRUG INVEST, 25, PP. 701-707, (2005); SCHRAMM R., ABADIE A., HUA N., XU Z., LIMA M., FRACTIONATION OF THE RICE BRAN LAYER AND QUANTIFICATION OF VITAMIN E, ORYZANOL, PROTEIN, AND RICE BRAN SACCHARIDE, J. BIOL. ENG, 1, PP. 1-9, (2007); SHIN T.S., GODBER J.S., MARTIN D.E., WELLS J.H., HYDROLYTIC STABILITY AND CHANGES IN E VITAMERS AND ORYZANOL OF EXTRUDED RICE BRAN DURING STORAGE, J. FOOD SCI, 62, PP. 704-728, (1997); SLAVIN J., WHOLE GRAINS AND HUMAN HEALTH, NUTR. RES. REV, 17, PP. 99-110, (2004); TAIRA H., CHANG W.L., LIPID CONTENT AND FATTY ACID COMPOSITION OF INDICA AND JAPONICA TYPES OF NONGLUTINOUS BROWN RICE, J. AGRIC. FOOD CHEM, 34, PP. 542-545, (1986); TAIRA H., NAKAGAHRA M., NAGAMINE T., FATTY ACID COMPOSITION OF INDICA, SINICA, JAVANICA, JAPONICA GROUPS OF NONGLUTINOUS BROWN RICE, J. AGRIC. FOOD CHEM, 36, PP. 45-47, (1988); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); TIWARI U., CUMMINS E., NUTRITIONAL IMPORTANCE AND EFFECT OF PROCESSING ON TOCOLS IN CEREALS, TRENDS FOOD SCI. TECHNOL, 20, PP. 511-520, (2009); WANG X., SONG Y.E., LI J.Y., HIGH EXPRESSION OF TOCOCHROMANOL BIOSYNTHESIS GENES INCREASES THE VITAMIN E LEVEL IN A NEW LINE OF GIANT EMBRYO RICE, J. AGRIC. FOOD CHEM, 61, PP. 5860-5869, (2013); XU Z., HUA N., GODBER J.S., ANTIOXIDANT ACTIVITY OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL COMPONENTS FROM RICE BRAN AGAINST CHOLESTEROL OXIDATION ACCELERATED BY 2, 20-AZOBIS (2-METHYLPROPIONAMIDINE) DIHYDROCHLORIDE, J. AGRIC. FOOD CHEM, 49, PP. 2077-2081, (2001); YASUMATSU K., MORITAKA S., FATTY ACID COMPOSITIONS OF RICE LIPID AND THEIR CHANGES DURING STORAGE, AGRIC. BIOL. CHEM, 28, PP. 257-264, (1964); YOON S.W., LEE J., PYO Y.G., OH S.K., LEE J.S., KIM I.H., NUTRACEUTICAL LIPID SUBSTANCES IN KOREAN RICE CULTIVARS, J. FOOD NUTR. RES, 2, PP. 40-46, (2014); ZHOU Z., ROBARDS K., HELLIWELL S., BLANCHARD C., COMPOSITION AND FUNCTIONAL PROPERTIES OF RICE, INT. J. FOOD SCI. TECHNOL, 37, PP. 849-868, (2002); ZHOU Z., BLANCHARD C., HELLIWELL S., ROBARDS K., FATTY ACID COMPOSITION OF THREE RICE VARIETIES FOLLOWING STORAGE, J. CEREAL SCI, 37, PP. 327-335, (2003)","","ELSEVIER LTD","ENGLISH","PHYTOCHEMISTRY","ARTICLE","ISI","2-S2.0-84934920974","PHYTOCHEMISTRY",NA,"NOTREPORTED",NA,"KIM NH, 2015, PHYTOCHEMISTRY","KIM NH, 2015, PHYTOCHEMISTRY"
"TANG M;WU S;GONG X","TANG, MIN (55823442600); WU, SAI-ZHU (7407183656); GONG, XUN (55823893300)","EFFECTS OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA",2013,"CHINESE JOURNAL OF CARDIOLOGY","41","4",4,"10.3760/cma.j.issn.0253-3758.2013.06.011","DEPARTMENT OF CARDIOLOGY, NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, GUANGZHOU 510515, CHINA;DEPARTMENT OF CARDIOLOGY, NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, GUANGZHOU 510515, CHINA;DEPARTMENT OF CARDIOLOGY, NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, GUANGZHOU 510515, CHINA","OBJECTIVE: TO EVALUATE THE EFFECTS AND SAFETY OF POLICOSANOL COMBINED WITH SIMVASTATIN ON SERUM LIPIDS AND SEX HORMONES IN MALE PATIENTS WITH HYPERLIPIDEMIA. METHODS: THIS RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED STUDY INCLUDED 120 MALE PATIENTS WITH HYPERLIPIDEMIA. PATIENTS WERE DEVIDED RANDOMLY INTO TREATMENT GROUP (N = 60) AND CONTROL GROUP (N = 60). PATIENTS IN THE TREATMENT GROUP WERE ADMINISTRATED WITH SIMVASTATIN (40 MG/D) PLUS POLICOSANOL (20 MG/D), AND THOSE IN THE CONTROL GROUP WERE TREATED WITH SIMVASTATIN (40 MG/D) PLUS PLACEBO (20 MG/D). THE VALUES OF TOTAL CHOLESTEROL (TC), TRIGLYCERIDE (TG), HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), TESTOSTERONE (T) AND ESTRADIOL (E2) WERE ASSESSED BEFORE AND AFTER 16 WEEKS TREATMENT. DRUG-INDUCED ADVERSE EFFECTS WERE OBSERVED. RESULTS: BASELINE CHARACTERISTICS WERE SIMILAR BETWEEN GROUPS. TC, TG, LDL-C WERE (5.74 ± 0.99), (1.62 ± 0.69), (3.60 ± 0.56) MMOL/L IN THE TREATMENT GROUP AT BASELINE AND SIGNIFICANTLY REDUCED AFTER 16 WEEKS TREATMENT (4.57 ± 0.58), (1.54 ± 0.55), (2.68 ± 0.38) MMOL/L (ALL P < 0.05). TC, LDL-C WERE (5.99 ± 0.93), (3.76 ± 0.42) MMOL/L IN THE CONTROL GROUP AT BASELINE AND SIGNIFICANTLY REDUCED AFTER 16 WEEKS TREATMENT (5.03 ± 0.59), (2.98 ± 0.28) MMOL/L (ALL P < 0.05) WHILE TG REMAINED UNCHANGED POST 16 WEEKS THERAPY IN THE CONTROL GROUP. SIMVASTATIN PLUS POLICOSANOL ACHIEVED A SIGNIFICANTLY GREATER REDUCTION IN LDL-C AND TC THAN SIMVASTATIN PLUS PLACEBO (P < 0.05). HDL-C, T AND E2 WERE SIMILAR BEFORE AND AFTER 16 WEEKS TREATMENTS IN BOTH GROUPS (P ≤ 0.05). THE ADVERSE REACTIONS WERE SIMILAR BETWEEN THE TWO GROUPS, MOST OF THEM WERE MILD AND HAPPENED AT THE BEGINNING OF DRUG THERAPY AND COULD HE WELL TOLERATED. CONCLUSION: SIMVASTATIN/POLICOSANOL PRODUCES GREATER DECREASES IN TC, LDL-C THAN SIMVASTATIN/PLACEBO WITHOUT RESULTING MORE SIDE EFFECTS AND CHANGES ON SEX HORMONES. COPYRIGHT © 2013 BY THE CHINESE MEDICAL ASSOCIATION.","ANTILIPEMIC AGENTS; GONADAL STEROID HORMONES; HYPERLIPIDEMIA","ADULT; AGED; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; GONADAL STEROID HORMONES; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; SIMVASTATIN; SINGLE-BLIND METHOD; CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; SIMVASTATIN; SYNAPSIN I; TESTOSTERONE; TRIACYLGLYCEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; UNSPECIFIED SIDE EFFECT","","","BRUGTS J.J., YETGIN T., HOEKS S.E., ET AL., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS: META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BM J, 338, (2009); ARMITAGE J., THE SAFETY OF STATINS IN CLINICAL PRACTICE, LANCET, 370, PP. 1781-1790, (2007); REINER Z., CATAPANO A.L., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); JONES P., KAFONEK S., LAURORA I., ET AL., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN, AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM J CARDIOL, 81, PP. 582-587, (1998); BALLANTYNE C.M., ANDREWS T.C., HSIA J.A., ET AL., CORRELATION OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH APOLIPOPROTEIN B: EFFECT OF 5 HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS ON NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, AM J CARDIOL, 88, PP. 265-269, (2001); EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A METAANALYSIS OF DATA FROM 170000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); KIM H.S., WU Y., LIN S.J., ET AL., CURRENT STATUS OF CHOLESTEROL GOAL ATTAINMENT AFTER STATIN THERAPY AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN ASIAN COUNTRIES AND REGION: THE RETURN ON EXPENDITURE ACHIEVED FOR LIPID THERAPY IN ASIA (REALITY-ASIA) STUDY, CURR MED RES OPIN, 24, PP. 1951-1963, (2008); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CUBEDDU L.X., CUBEDDU R.J., HEIMOWILZ T., ET AL., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 982, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., ET AL., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); VAN POTTELBERGH L., BRACEEKMAN L., DE BACQUER D., ET AL., DIFFERENTIAL CONTRIBUTION OF TESTOSTERONE AND ESTRADIOL IN THE DETEMINATION OF CHOLESTEROL AND LIPEPROTEIN PROFILE IN HEALTH MIDDLE-AGED MEN, THEROSELEROSIS, 166, PP. 95-102, (2003); JONES T.H., SAAD F., THE EFFECTS OF TESTOSTERONE ON RISK FACTORS FOR AND THE MÉDIATORS OF THE ATHEROSCLEROTIC PROCESS, ATHEROSCLEROSIS, 207, PP. 318-327, (2009); DOBS A.S., SCHROTT H., DAVIDSON M.H., ET AL., EFFECTS OF HIGH-DOSE SIMVASTATIN ON ADRENAL AND GONADAL STEROIDOGENESIS IN MEN WITH HYPERCHOLESTEROLEMIA, METABOLISM, 49, PP. 1234-1238, (2000); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); CASTANO G., MAS R., FERNANDEZ L., ET AL., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, SUPPL., (2005); MAS R., CASTANO G., FERNANDEZ J., ET AL., LONG-TERM EFFECTS OF PELICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005)","S.-Z. WU; DEPARTMENT OF CARDIOLOGY, NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, GUANGZHOU 510515, CHINA; EMAIL: WUSAIZHU@FIMMU.COM","","CHINESE","CHIN. J. CARDIOL.","ARTICLE","ISI","2-S2.0-84881638809","CHIN J CARDIOL","SOUTHERN MEDICAL UNIVERSITY;SOUTHERN MEDICAL UNIVERSITY;SOUTHERN MEDICAL UNIVERSITY","NOTREPORTED;SOUTHERN MEDICAL UNIVERSITY;NOTREPORTED",NA,"TANG M, 2013, CHIN J CARDIOL","TANG M, 2013, CHIN J CARDIOL"
"LIU S;TAN M;ZHAO S;RONG H","LIU, SHUN (55485169700); TAN, MING-YUE (7401464927); ZHAO, SHUI-PING (7403578038); RONG, HUI (55259721600)","EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND HEME OXYGENASE1 IN PATIENTS WITH HYPERLIPIDEMIA",2012,"CHINESE JOURNAL OF CARDIOLOGY","40","3",12,"10.3760/cma.j.issn.0253-3758.2012.10.008","DEPARTMENT OF CARDIOLOGY, XIANGYA SECOND HOSPITAL, CENTRAL SOUTH UNIVERSITY, CHANGSHA 410011, CHINA;DEPARTMENT OF CARDIOLOGY, XIANGYA SECOND HOSPITAL, CENTRAL SOUTH UNIVERSITY, CHANGSHA 410011, CHINA;DEPARTMENT OF CARDIOLOGY, XIANGYA SECOND HOSPITAL, CENTRAL SOUTH UNIVERSITY, CHANGSHA 410011, CHINA;DEPARTMENT OF CARDIOLOGY, XIANGYA SECOND HOSPITAL, CENTRAL SOUTH UNIVERSITY, CHANGSHA 410011, CHINA","OBJECTIVE: TO EVALUATE THE EFFECTS OF POLICOSANOL ON SERUM LIPID AND HEME OXYGENASE-1 (HO-1) IN PATIENTS WITH HYPERLIPIDEMIA. METHODS: THIS RANDOMIZED, OPEN STUDY INCLUDED 72 PATIENTS WITH HYPERLIPIDEMIA. THE PATIENTS WERE RANDOMLY ASSIGNED TO TREATMENT GROUP (POLICOSANOL, 20 MG/D, N = 36) OR PLACEBO GROUP (PLACEBO, TWO TABLETS/D, N =36). THE LEVELS OF SERUM LIPIDS, HYPERSENSITIVE C-REACTIVE PROTEIN (HS-CRP), HO-1 WERE ASSESSED BEFORE AND AFTER 16 WEEKS TREATMENT. DRUG-INDUCED ADVERSE EFFECTS AND EVENTS WERE RECORDED DURING THE OBSERVATION PERIOD. THE SERUM HO-1 WAS MEASURED BY ELISA. RESULTS: (1) AFTER 16 WEEKS, ALL PARAMETERS REMAINED UNCHANGED IN THE PLACEBO GROUP; THE LEVEL OF TC DECREASED FROM (7.01 ± 1.03) MMOL/L TO (5.66 ± 0.83) MMOL/L (-19.4%, P < 0.01), THE LEVEL OF LDL-C DECREASED FROM (4.78 ± 0.72) MMOL/L TO (3.70 ± 0.69) MMOL/L (-22.5%, P < 0.01) IN THE TREATMENT GROUP. TG AND HDL-C LEVELS REMAINED UNCHANGED (P > 0.05) WHILE THE LEVEL OF HO-1 SIGNIFICANTLY DECREASED FROM (1.82 ± 1.08) ΜG/L TO (1.45 ± 0.81) ΜG/L (P < 0.01) AND THE LEVEL OF HS-CRP DECREASED FROM (3.40 ± 3.64) MG/L TO (1.86 ± 2.02) MG/L (P < 0.01) IN THE TREATMENT GROUP. (2) SAFETY INDEX WAS SIMILAR BETWEEN PLACEBO AND TREATMENT GROUPS (P > 0.05) AND THERE WAS NO ADVERSE EVENTS INCLUDING ALLERGIC REACTION, MUSCLE PAIN IN ALL SUBJECTS DURING THE OBSERVATION PERIOD. CONCLUSION: THE SHORT-TERM DATA OBTAINED FROM THIS SMALL HYPERLIPIDEMIA PATIENT COHORT SUGGEST THAT POLICOSANOL IS A SAFE LIPID-LOWERING AND ANTI-INFLAMMATORY AGENT FOR HYPERLIPIDEMIA PATIENTS. COPYRIGHT © 2012 BY THE CHINESE MEDICAL ASSOCIATION.","HEME OXYGENASE (DECYCLIZING); HYPERLIPIDEMIA; POLICOSANOL","ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; FEMALE; HEME OXYGENASE-1; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; C REACTIVE PROTEIN; HEME OXYGENASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MYALGIA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION","","","29, PP. 17-19, (2009); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D.K., LI L., PORTER T.D., ET AL., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVESTIG, 23, PP. 639-650, (2003); CASTANO G., MAS R., GAMEZ R., ET AL., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2004); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, SUPPL., PP. 31-44, (2005); CHENG P.Y., LEE Y.M., SHIH N.L., ET AL., HEME OXYGENASE-1 CONTRIBUTES TO THE CYTOPROTECTION OF ALPHA-LIPOIC ACID VIA ACTIVATION OF P44/42 MITOGEN-ACTIVATED PROTEIN KINASE IN VASCULAR SMOOTH MUSCLE CELLS, FREE RADIC BIOL MED, 40, PP. 1313-1322, (2006); FERNANDEZ S., MAS R., GAMEZ R., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, PP. 219-229, (2004); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011)","M.-Y. TAN; DEPARTMENT OF CARDIOLOGY, XIANGYA SECOND HOSPITAL, CENTRAL SOUTH UNIVERSITY, CHANGSHA 410011, CHINA; EMAIL: TANMINGYUE2003@YAHOO.COM.CN","","CHINESE","CHIN. J. CARDIOL.","ARTICLE","ISI","2-S2.0-84869131619","CHIN J CARDIOL","CENTRAL SOUTH UNIVERSITY;CENTRAL SOUTH UNIVERSITY;CENTRAL SOUTH UNIVERSITY;CENTRAL SOUTH UNIVERSITY","NOTREPORTED;CENTRAL SOUTH UNIVERSITY;NOTREPORTED",NA,"LIU S, 2012, CHIN J CARDIOL","LIU S, 2012, CHIN J CARDIOL"
"AL-OKBI S;AMMAR N;MOHAMED D;HAMED I;DESOKY A;EL B H;HELAL A","AL-OKBI, S.Y. (6506387258); AMMAR, N.M. (6701309755); MOHAMED, D.A. (8685446400); HAMED, I.M. (23566646800); DESOKY, A.H. (55893175300); EL BAKRY, H.F. (57204595788); HELAL, A.M. (7006266267)","EGYPTIAN RICE BRAN OIL CHEMICAL ANALYSIS OF THE MAIN PHYTOCHEMICALS",2014,"RIVISTA ITALIANA DELLE SOSTANZE GRASSE","91","11",12,"","FOOD SCIENCES AND NUTRITION DEPARTMENT, NATIONAL RESEARCH CENTRE, EL-DOKKI, 12622, CAIRO, EGYPT;PHARMACOGNOSY DEPARTMENT, NATIONAL RESEARCH CENTRE, CAIRO, EGYPT;FOOD SCIENCES AND NUTRITION DEPARTMENT, NATIONAL RESEARCH CENTRE, EL-DOKKI, 12622, CAIRO, EGYPT;FOOD SCIENCES AND NUTRITION DEPARTMENT, NATIONAL RESEARCH CENTRE, EL-DOKKI, 12622, CAIRO, EGYPT;PHARMACOGNOSY DEPARTMENT, NATIONAL RESEARCH CENTRE, CAIRO, EGYPT;FOOD SCIENCES AND NUTRITION DEPARTMENT, NATIONAL RESEARCH CENTRE, EL-DOKKI, 12622, CAIRO, EGYPT;INTERNATIONAL TRADE AND MARKETING, EGYPT","IN THE PRESENT WORK, RICE BRAN OIL (RBO) WAS EXTRACTED BY N-HEXANE AND BY SUPERCRITICAL CO2 EXTRACTION UNDER SPECIFIC CONDITIONS. OIL EXTRACTED BY HEXANE WAS PURIFIED AND THE PERCENTAGE WAX WAS ESTIMATED. GAMMA ORYZANOL, TOCOPHEROLS AND TOCOTRIENOLS WERE DETERMINED IN THE PREPARED OILS USING HPLC. POLICOSANOLS AND PHYTOSTEROLS WERE ASSESSED BY GLC. BETA-CAROTENE CONTENTS OF THE WHOLE RICE BRAN AND DIFFERENT PREPARED OILS WERE DETERMINED COLORIMETRY. ACID VALUE, % FREE FATTY ACIDS, PEROXIDE VALUE AND IODINE VALUE OF THE OILS WERE ASSESSED. RESULTS SHOWED THAT WAX WAS 5.12% OF THE CRUDE OIL EXTRACTED BY N-HEXANE. IDENTIFIED STEROLS WERE CAMPESTEROL, STIGMASTEROL AND Β-SITOSTEROL. TOTAL STEROLS CONTENT OF RICE BRAN OIL EXTRACTED BY HEXANE (12.04%) WAS HIGHER THAN THAT EXTRACTED BY SUPERCRITICAL CO2 (7.6%). THE CONTENT OF BETA CAROTENE IN THE OIL EXTRACTED BY SUPERCRITICAL CO2 WAS HIGHER THAN THAT EXTRACTED BY HEXANE AND THE PURIFIED OIL (263, 225 AND 49.6 ΜG/100G, RESPECTIVELY). GAMMA ORYZANOL CONCENTRATION IN THE OIL EXTRACTED BY N-HEXANE WAS 3.33% WHILE IT WAS 2.25% IN THE PURIFIED OIL AND 1.54% IN THE OIL EXTRACTED BY SUPERCRITICAL CO2. TOTAL TOCOTRIENOLS WERE 310.24, 398.70 AND 395.00 WHILE TOTAL TOCOPHEROL WAS 907, 857.3 AND 434.9 ΜG/G RICE BRAN OIL EXTRACTED BY HEXANE; RICE BRAN OIL EXTRACTED BY SUPERCRITICAL CO2 AND PURIFIED OIL RESPECTIVELY. TOTAL IDENTIFIED POLICOSANOL CONCENTRATION IN THE OIL EXTRACTED BY N-HEXANE, SUPERCRITICAL CO2 AND WAX WAS 69.62, 48.63 AND 590.89 MG/100G, RESPECTIVELY. IN CONCLUSION; BETA CAROTENE AND TOCOTRIENOLS CONTENT OF OIL EXTRACTED BY SUPERCRITICAL CO2 WERE HIGHER THAN THAT EXTRACTED BY N-HEXANE WHILE GAMMA ORYZANOL, TOTAL STEROL, TOCOPHEROL AND POLICOSANOL WERE HIGHER IN OIL EXTRACTED BY HEXANE. THE PURIFIED OIL SHOWED THE LEAST LEVEL OF BETA-CAROTENE AND TOCOPHEROLS.","","","","","CICERO A.F., GADDI A., RICE BRAN OIL AND GAMMAORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHER. RES., 15, 4, PP. 277-289, (2001); EADY S., WALLACE A., WILLIS J., SCOTT R., FRAMPTON C., CONSUMPTION OF A PLANT STEROL-BASED SPREAD DERIVED FROM RICE BRAN OIL IS EFFECTIVE AT REDUCING PLASMA LIPID LEVELS IN MILDLY HYPERCHOLESTEROLAEMIC INDIVIDUALS, BR. J. NUTR., 15, PP. 1-12, (2011); MOLDENHAUER K.A., CHAMPAGNE E.T., MC-CASKILL D.R., GURAYA H., FUNCTIONAL PRODUCTS FROM RICE, PP. 71-89, (2003); SUGANO M., TSUJI E., RICE BRAN OIL AND CHOLESTEROL METABOLISM, J. NUTR., 127, (1997); RYAN E.P., BIOACTIVE FOOD COMPONENTS AND HEALTH PROPERTIES OF RICE BRAN, J. AM. VET. MED. ASSOC., 238, 5, PP. 593-600, (2011); STOGGL W., HUCK C., WONGYAI S., SCHERZ H., BONN G., SIMULTANEOUS DETERMINATION OF CAROTENOIDS, TOCOPHEROLS, AND GAMMA-ORYZANOL IN CRUDE RICE BRAN OIL BY LIQUID CHROMATOGRAPHY COUPLED TO DIODE ARRAY AND MASS SPECTROMETRIC DETECTION EMPLOYING SILICA C30 STATIONARY PHASES, J. SEP. SCI., 28, 14, PP. 1712-1718, (2005); DIACK M., SAKSKA M., SEPARATION OF VITAMIN E AND ORYZANOLS FROM RICE BRAN BY NORMAL-PHASE CHROMATOGRAPHY, J. AM. OIL CHEM. SOC., 71, PP. 1211-1217, (1994); RONG N., AUSMAN L.M., NICOLOSI R.J., ORYZANOL DECREASES CHOLESTEROL ABSORPTION AND AORTIC FATTY STEAKS IN HAMSTERS, LIPIDS, 32, PP. 303-309, (1997); RUKMINI C., RAGHURAM T.C., NUTRITIONAL AND BIOCHEMICAL ASPECTS OF THE HYPOLIPIDEMIC ACTION OF RICE BRAN OIL: A REVIEW, J. AM. COLL. NUTR., 10, PP. 593-601, (1991); RUKMANI C., NUTRITIONAL SIGNIFICANE OF RICE BRAN OIL, INDIAN J. MED. RES., 102, PP. 241-244, (1995); WILSON T.A., NICOLOSI R.J., WOOLFREY B., KRITCHEVSKY D., RICE BRAN OIL AND ORYZANOL REDUCE PLASMA LIPID AND LIPOPROTEIN CHOLESTEROL CONCENTRATIONS AND AORTIC CHOLESTEROL ESTER ACCUMULATION TO A GREATER EXTENT THAN FERULIC ACID IN HYPERCHOLESTEROLEMIC HAMSTERS, J. NUTR. BIOCHEM., 18, PP. 105-112, (2007); SEETHARAMIAH G.S., CHANDRASEKHRA N., STUDIES ON HYPOCHOLESTEROLEMIC ACTIVITY OF RICE BRAN OIL, ATHEROSCLEROSIS, 78, PP. 219-223, (1989); JARIWALLA R.J., RICE-BRAN PRODUCTS: PHYTONUTRIENTS WITH POTENTIAL APPLICATIONS IN PREVENTIVE AND CLINICAL MEDICINE, DRUGS. EXP. CLIN. RES., 27, 1, PP. 17-26, (2001); VISSERS M.N., ZOCK P.L., MEIJER G.W., KATAN M.B., EFFECT OF PLANT STEROLS FROMRICE BRAN OIL AND TRITERPENE ALCOHOLS FROM SHEANUT OIL ON SERUM LIPOPROTEIN CONCENTRATIONS IN HUMAN, AM. J. CLIN. NUTR., 72, 6, PP. 1510-1515, (2000); LING W.H., JONES P.J., MINI-REVIEW OF DIETARY PHYTOSTEROLS: A REVIEW OF METABOLISM, BENEFITS AND SIDE EFFECTS, LIFE SCI., 57, PP. 195-206, (1995); WESTSTRATE J.A., MEIJER G.W., PLANT STEROL-ENRICHED MARGARINES AND REDUCTION OF PLASMA TOTALAND LDL-CHOLESTEOL CONCENTRATIONS IN NORMOCHOLESTEROLAEMIC AND MILDLY HYPERCHOLESTEROLAEMIC SUBJECTS, EUR. J. CLIN. NUTR., 52, PP. 334-343, (1998); PEERS K.E., THE NON-GLYCERIDE SAPONIFIABLES OF SHEA BUTTER, J. SCI. FOOD AGRIC., 28, PP. 1000-1009, (1977); HUANG Z.R., LIN Y.K., FANG J.Y., BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES OF SQUALENE AND RELATED COMPOUNDS: POTENTIAL USES IN COSMETIC DERMATOLOGY, MOLECULES., 14, 1, PP. 540-554, (2009); PEARCE B.C., PARKER R.A., DEASON M.E., QURESHI A.A., WRIGHT J.J., HYPOCHOLESTEROLEMIC ACTIVITY OF SYNTHETIC AND NATURAL TOCOTRIENOLS, J. MED. CHEM., 35, PP. 3595-3606, (1992); PEARCE B.C., PARKER R.A., DEASON M.E., DISCHINO D.D., GILLESPIE E., QURESHI A.A., VOLK K., WRIGHT J.J., INHIBITORS OF CHOLESTEROL BIOSYNTHESIS: HYPOCHOLESTEROLEMIC AND ANTIOXIDANT ACTIVITIES OF BENZOPYRAN AND TETRAHYDRONAPHTHALENE ANALOGUES OF THE TOCOTRIENOLS, J. MED. CHEM., 37, PP. 526-541, (1994); KERCKHOFFS D.A., BROUNS F., HORNSTRA G., MENSINK R.P., EFFECTS ON THE HUMAN SERUM LIPOPROTEIN PROFILE OF BETA-GLUCAN, SOY PROTEIN AND ISOFLAVONES, PLANT STEROLS AND STANOLS, GARLIC AND TOCOTRIENOLS, J. NUTR., 132, 9, PP. 2494-2505, (2002); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM., 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENT OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2005); HWANG K.T., KIM J.E., WELLER C.L., POLICOSANOL CONTENT AND COMPOSITIONS IN WAX LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN, CEREAL CHEM., 82, PP. 242-245, (2005); ARRUZAZABALA M.L., CARBAJAL D., MAS P., GARCIA M., FRAGA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOTRIENS ESS. FATTY ACIDS, 58, PP. 61-64, (1998); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8- 14C)- OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTRITION METAB., 39, PP. 279-284, (1995); STUSSER R., BATISTA J., PARDON R., SOSA F., PEREZTOL O., LONG TERM THERAPY WITH OCTACOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT. J. CLIN. PHARMACOL. THER., 36, PP. 469-473, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECT OF POLICOSANOL (20 AND 40 MG/ DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDEMIC PATIENTS, CLIN.EXP. PHARMACOL. PHYS., 29, PP. 891-897, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J. AGRIC. FOOD CHEM., 54, PP. 5359-5362, (2006); KAIMAL T.N.B., RAMJAN VALI S.K., RAO B.V.S.K., CHAKRABARTI P.P., LAKSHMI P.V., KALE V., RANI N.P.K., RAJAMMA O., BHASKAR P.S., RAO T.C., ORIGIN OF PROBLEM ENCOUNTERED IN RICE BRAN OIL PROCESSING, EUR. J. LIPID SCI. TECHNOL., 104, PP. 203-211, (2002); (2000); (1998); IMSANGUAN P., ROAYSUBTAWEE A., BORIRAK R., PONGAMPHAI S., DOUGLAS S., DOUGLAS P.L., EXTRACTION OF Α-TOCOPHEROL AND Γ-ORYZANOL FROM RICE BRAN, LWT-FOOD SCIENCE AND TECHNOLOGY, 41, PP. 1417-1424, (2008); AMARAL J.S., CASAL S., TORRES D., SEABRA R.M., OLIVEIRA B.P.P., SIMULTANEOUS DETERMINATION OF TOCOPHEROLS AND TOCOTRIENOLS IN HAZELNUTS BY A NORMAL PHASE LIQUID CHROMATOGRAPHIC METHOD, ANALYTICAL SCIENCES, 21, PP. 1545-1548, (2005); 41.1.16 AOAC OFFICIAL METHOD 965.33, PEROXIDE VALUE OF OILS AND FATS, (2002); OFFICIAL METHODS OF ANALYSIS, PP. 801-805, (1990); NARWAR W.W., LIPIDS, FOOD CHEMISTRY, PP. 225-319, (1996); ORTHOEFER F.T., RICE BRAN OIL: HEALTHY LIPID SOURCE, FOOD TECHNOLOGY, 62, (1996); XU Z., HUA N., GODBER J.S., ANTIOXIDANT ACTIVITY OF TOCOPHEROLS, TOCOTRIENOLS, AND ORYZANOL COMPONENTS FROM RICE BRAN AGAINST CHOLESTEROL OXIDATION ACCELERATED BY 2, 2'-AZOBIS (2-METHYLPROPIONAMIDINE) DIHYDROCHOLORIDE, J. AGRIC. FOOD CHEM., 49, PP. 2077-2081, (2001); HAKALA P., LAMPI A.M., OLLILAINEN V., WERNER U., MURKOVIC M., WAHALA K., KARKOLA S., PIIRONEN V., STERYL PHENOLIC ACID ESTERS IN CEREALS AND THEIR MILLING FRACTIONS, J. AGRIC. FOOD CHEM., 50, PP. 5300-5307, (2002); QURESHI A.A., SALSER W.A., PARMAR P., EMESON E.E., NOVEL TOCOTRIENOLS OF RICE BRAN INHIBIT ATHEROSCLEROTIC LESIONS IN C57BL/6 APOE-DEFICIENT MICE, J.NUTR., 131, (2001); STOGGL W., HUCK C., WONGYAI S., SCHERZ H., BONN G., SIMULTANEOUS DETERMINATION OF CAROTENOIDS, TOCOPHEROLS, AND GAMMA-ORYZANOL IN CRUDE RICE BRAN OIL BY LIQUID CHROMATOGRAPHY COUPLED TO DIODE ARRAY AND MASS SPECTROMETRIC DETECTION EMPLOYING SILICA C30 STATIONARY PHASES, J. SEP. SCI., 28, 14, PP. 1712-1718, (2005); LAMBERTS L., DELCOUR J.A., CAROTENOIDS IN RAW AND PARBOILED BROWN AND MILLED RICE, J. AGRIC. FOOD CHEM. 24, 56, 24, PP. 11914-11919, (2008); FANG N., YU S., BADGER T.M., CHARACTERIZATION OF TRITERPENE ALCOHOL AND STEROL FERULATES IN RICE BRAN USING LC-MS/MS, J AGRIC FOOD CHEM. 21, 51, 11, PP. 3260-3267, (2003); XU Z., GODBER J.S., PURIFICATION AND IDENTIFICATION OF COMPONENTS OF Γ-ORYZANOL IN RICE BRAN OIL, J. AGRIC. FOOD CHEM., 47, PP. 2724-2728, (1999); SCAVARIELLO E.M., ARELLANO D.B., GAMMA-ORYZANOL: AN IMPORTANT COMPONENT IN RICE BRAIN OIL, ARCH LATINOAM NUTR., 48, 1, PP. 7-12, (1998); CHEN M.H., BERGMAN C.J., A RAPID PROCEDURE FOR ANALYZING RICE BRAN TOCOPHEROL, TOCOTRIENOL AND Γ-ORYZANOL CONTENTS, J. FOOD COMPOSITION AND ANALYSIS, 18, PP. 139-151, (2005); DAI Z., FECAL STEROID EXCRETION OF RATS FED RICE BRAN OIL AND ORYZANOL, MASTER OF SCIENCE, (2004); ZULLAIKAH S., MELWITA E., JU Y.H., ISOLATION OF ORYZANOL FROM CRUDE RICE BRAN OIL, BIORESOUR TECHNOL., 100, 1, PP. 299-302, (2009); BALACHANDRAN C., MAYAMOL P.N., THOMAS S., SUKUMAR D., SUNDARESAN A., ARUMUGHAN C., AN ECOFRIENDLY APPROACH TO PROCESS RICE BRAN FOR HIGH QUALITY RICE BRAN OIL USING SUPERCRITICAL CARBON DIOXIDE FOR NUTRACEUTICAL APPLICATIONS, BIORESOUR TECHNOL., 99, 8, PP. 2905-2912, (2008); TSAKNIS J., CHARACTERIZATION OF MORINGA PEREGRINE ARABIAN SEED OIL, GRASAS Y ACEITES, 49, PP. 170-176, (1998); ROSSELL J.B., ANALYSIS AND PROPERTIES OF OILSEEDS, ANALYSIS OF OILSEEDS, FATS AND FATTY FOODS, PP. 80-98, (1991); ANWAR F., ANWER T., MAHMOOD Z., METHODICAL CHARACTERIZATION OF RICE (ORYZA SATIVA) BRAN OIL FROM PAKISTAN, GRASAS Y ACEITES 56. FASC., 2, PP. 125-134, (2005); SOOKWONG P., NAKAGWA K., MURATA K., KOJIMA Y., MIYAZAWA T., QUANTITATION OF TOCOTRIENOL AND TOCOPHEROL IN VARIOUS RICE BRANS, J. AGRIC. FOOD CHEM., 55, PP. 461-466, (2007); MALEKIAN F., RAO R.M., PRINYAWIWATKUL W., MARSHALL W.E., WINDHAUSER M., AHMEDNA M., LIPASE AND LIPOXYGENASE ACTIVITY, FUNCTIONALITY, AND NUTRIENT LOSSES IN RICE BRAN DURING STORAGE, PP. 1-68, (2000); LLOYD B.J., SIEBENMORGEN T.J., BEERS K.W., EFFECTS OF COMMERCIAL PROCESSING ON ANTIOXIDANT, S IN RICE BRAN, CEREAL CHEM., 77, 5, PP. 551-555, (2000); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM., 55, PP. 5552-5558, (2007); ITO S., SUZUKI T., FUJINO Y., WAX LIPID IN RICE BRAN, CEREAL CHEM., 60, PP. 252-253, (1983); SUNDERS R.M., RICE BRAN: COMPOSITION AND POTENTIAL FOOD SOURCES, FOOD REV. INT., 1, PP. 465-495, (1985); ARUMUGHAN C., SKHARIYA R., ARORA R., RICE BRAN OIL: AN UNTAPPED HEALTH FOOD, INFORM, 15, PP. 706-707, (2004); ROSSELL J.B., VEGETABLE OIL AND FATS, ANALYSIS OF OILSEEDS, FATS AND FATTY FOODS, PP. 261-328, (1991); KHALAFY H.M.E., FADEL H.M., STUDIES ON THE FATTY ACID COMPOSITION OF EGYPTIAN RICE BRAN OILS, SEIFEN-OLE-FETTE-WACHSE, 115, PP. 8-10, (1989); SHARMA H.K., KAUR B., SARKAR B.C., SINGH C., THERMAL BEHAVIOR OF PURE RICE BRAN OIL, SUNFLOWER OIL AND THEIR MODEL BLENDS DURING DEEP FAT FRYING, GRASAS Y ACEITES, 57, 4, PP. 376-381, (2006); PEROXIDE VALUE IN OIL AND FATS/PEARSONS COMPOSITION AND ANALYSIS OF FOODS, (2000); TAO J., RAO R.M., LUIZZO J.A., THERMAL EFFICIENCIES OF CONVENTIONAL AND MICROWAVE HEAT STABILIZATION OF RICE BRAN, LOUISIANA AGRICULTURE, 36, (1993); CHERUVANKY R., WHAT IS RICE BRAN (A WEB ARTICLE ON RICE BRAN), (2002)","S.Y. AL-OKBI; FOOD SCIENCES AND NUTRITION DEPARTMENT, NATIONAL RESEARCH CENTRE, EL-DOKKI, 12622, CAIRO, EGYPT; EMAIL: S_Y_ALOKBI@HOTMAIL.COM","STAZIONE SPERIMENTALE PER LE INDUSTRIE","ENGLISH","RIV. ITAL. SOSTANZE GRASSE","ARTICLE","ISI","2-S2.0-84905252059","RIV ITAL SOSTANZE GRASSE","FOOD SCIENCES AND NUTRITION DEPARTMENT;NATIONAL RESEARCH CENTRE;FOOD SCIENCES AND NUTRITION DEPARTMENT;FOOD SCIENCES AND NUTRITION DEPARTMENT;NATIONAL RESEARCH CENTRE;FOOD SCIENCES AND NUTRITION DEPARTMENT","NOTREPORTED;FOOD SCIENCES AND NUTRITION DEPARTMENT;NOTREPORTED",NA,"AL-OKBI SY, 2014, RIV ITAL SOSTANZE GRASSE","AL-OKBI SY, 2014, RIV ITAL SOSTANZE GRASSE"
"ABE A;KAYE A;GRITSENKO K;URMAN R;KAYE A","ABE, ANDREW (56191083300); KAYE, ALAN DAVID (34975085700); GRITSENKO, KARINA (55013499700); URMAN, RICHARD D. (6507054376); KAYE, ADAM MARC (36572032700)","PERIOPERATIVE ANALGESIA AND THE EFFECTS OF DIETARY SUPPLEMENTS",2014,"BEST PRACTICE AND RESEARCH: CLINICAL ANAESTHESIOLOGY","28","6",18,"10.1016/j.bpa.2014.04.002","UNIVERSITY OF KANSAS, LAWRENCE, KS, UNITED STATES;DEPARTMENT OF ANESTHESIOLOGY, LSU SCHOOL OF MEDICINE, NEW ORLEANS, LA, UNITED STATES, DEPARTMENT OF PHARMACOLOGY, LSU SCHOOL OF MEDICINE, NEW ORLEANS, LA, UNITED STATES;DEPARTMENT OF ANESTHESIOLOGY, PAIN MEDICINE, REGIONAL ANESTHESIOLOGY, MONTEFIORE MEDICAL CENTER, ALBERT EINSTEIN COLLEGE OF MEDICINE, NEW YORK, NY, UNITED STATES;DEPARTMENT OF ANESTHESIOLOGY, PERIOPERATIVE AND PAIN MEDICINE, BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA 02115, UNITED STATES;DEPARTMENT OF PHARMACY PRACTICE, THOMAS J. LONG SCHOOL OF PHARMACY AND HEALTH SCIENCES, UNIVERSITY OF THE PACIFIC, STOCKTON, CA, UNITED STATES","WITH OVER 50,000 DIETARY SUPPLEMENTS AVAILABLE, RESURGENCE IN CONSUMER INTEREST OVER THE PAST FEW DECADES HAS RESULTED IN AN EXPLOSION OF USE OF THESE AGENTS WORLDWIDE. DISILLUSIONMENT WITH CURRENT MEDICATIONS AND BELIEF IN ""NATURAL MEDICINES"" HAS RESULTED IN A MULTIBILLION DOLLAR INDUSTRY. ACTIVE INGREDIENTS IN A NUMBER OF HERBS ARE BEING TESTED FOR THERAPEUTIC POTENTIAL, AND SOME ARE EFFICACIOUS, SO HERBAL MEDICINES CANNOT BE DISMISSED. THE PREVALENCE OF HERBOLOGY IS FURTHER ENCOURAGED BY A RELATIVELY RELAXED POLICY OF THE FDA REGARDING THESE COMPOUNDS, WHICH THEY CONSIDER FOODS. AS HERBAL PRODUCTS ARE INCLUDED IN THE ""SUPPLEMENT"" CATEGORY, THERE IS NO EXISTING PROTOCOL FOR STANDARDIZATION OF THESE PRODUCTS. THERE ARE NUMEROUS EXAMPLES OF HERBALS THAT CAN ADVERSELY AFFECT PATIENT RECOVERY AND OUTCOMES IN ANESTHESIA. THE PRUDENT ANESTHESIA PROVIDER WILL MAKE SURE TO OBTAIN CORRECT INFORMATION AS TO ACCURATE HERBAL USAGE OF EACH PATIENT AND ATTEMPT TO DISCONTINUE THESE PRODUCTS TWO TO THREE WEEKS PRIOR TO THE DELIVERY OF AN ANESTHETIC. POSTOPERATIVE ANALGESIA, BLEEDING, AND LEVEL OF SEDATION CAN BE NEGATIVELY IMPACTED RELATED TO HERBAL PRODUCTS AND HERBAL-DRUG INTERACTIONS. OVER 90 HERBAL PRODUCTS ARE ASSOCIATED WITH BLEEDING AND THIS CAN BE A SPECIFIC PROBLEM INTRAOPERATIVELY OR WHEN CONSIDERING PLACEMENT OF A REGIONAL ANESTHETIC FOR POSTOPERATIVE PAIN MANAGEMENT. © 2014 ELSEVIER LTD. ALL RIGHTS RESERVED.","ANESTHESIA; BLEEDING; DIETARY SUPPLEMENTS; KAVA KAVA; MESH INDEX: HERBALS; OVER THE COUNTER AGENTS; ST. JOHN'S WORT; VALERIAN","ANALGESIA; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; HUMANS; PERIOPERATIVE CARE; 3 INDOLEMETHANOL; ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CHAMOMILE; CHONDROITIN; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ENFLURANE; FISH OIL; GLUCOSAMINE; HALOTHANE; IMMUNOSUPPRESSIVE AGENT; IPRIFLAVONE; PETHIDINE; POLICOSANOL; QUERCETIN; RESVERATROL; TURMERIC; UNINDEXED DRUG; VALERIAN; ACT; AESCULUS HIPPOCASTANUM; ANALGESIA; ANDROGRAPHIS; ANGELICA SINENSIS; ARTICLE; BLEEDING; DIET SUPPLEMENTATION; DRUG METABOLISM; ELEUTHEROCOCCUS SENTICOSUS; ENZYME INDUCTION; ENZYME INHIBITION; EVODIA; FOOD AND DRUG ADMINISTRATION; GARLIC; GINGER; GINKGO BILOBA; GRAPEFRUIT; GUARANA; HEALTH CARE POLICY; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYDRASTIS; HYPERICUM PERFORATUM; PERIOPERATIVE PERIOD; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RED CLOVER; REGIONAL ANESTHESIA; SABAL; SALVIA MILTIORRHIZA; SEDATION; STANDARDIZATION; TANACETUM PARTHENIUM; TEA; ANALGESIA; DRUG INTERACTION; PERIOPERATIVE PERIOD; PROCEDURES","","","DANGEROUS SUPPLEMENTS: WHAT YOU DON'T KNOW ABOUT THESE 12 INGREDIENTS COULD HURT YOU; EXPLORING THE SCIENCE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE; WU C.H., WANG C.C., KENNEDY J., CHANGES IN HERB AND DIETARY SUPPLEMENT USE IN THE US ADULT POPULATION: A COMPARISON OF THE 2002 AND 2007 NATIONAL HEALTH INTERVIEW SURVEYS, CLIN THER, 33, 11, PP. 1749-1758, (2011); BARNES P.M., BLOOM B., COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG ADULTS AND CHILDREN: UNITED STATES, 2007, NATL HEALTH STAT REP, 12, PP. 1-23, (2008); SIGNIFICANT AMENDMENTS TO THE FD&C ACT: DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT OF 1994; BAILEY R.L., GAHCHE J.J., MILLER P.E., ET AL., WHY US ADULTS USE DIETARY SUPPLEMENTS, JAMA INTERN MED, 173, 5, PP. 355-361, (2013); EXPANDING HORIZONS OF HEALTH CARE; KAYE A.D., BALUCH A., KAYE A.J., FRASS M., HOFBAUER R., PHARMACOLOGY OF HERBALS AND THEIR IMPACT IN ANESTHESIA, CURRENT OPINION IN ANAESTHESIOLOGY, 20, 4, PP. 294-299, (2007); KAYE A.D., SABAR R., VIG S., ET AL., NUTRACEUTICALS - CURRENT CONCEPTS AND THE ROLE OF THE ANESTHESIOLOGIST. PART 1. ECHINACEA, GARLIC, GINGER, GINGKO, AND ST. JOHN'S WORT, AM J ANESTHESIOL, 27, 7, PP. 405-407, (2000); KAYE A.D., SABAR R., VIG S., ET AL., NUTRACEUTICALS - CURRENT CONCEPTS AND THE ROLE OF THE ANESTHESIOLOGIST. PART 2. PANAX GINSENG, KAVA KAVA, FEVERFEW, AND MA HUANG, AM J ANESTHESIOL, 27, 8, PP. 467-471, (2000); KAYE A.D., CLARKE R., SABAR R., ET AL., HERBAL MEDICATIONS SURVEY, J CLIN ANESTH, 12, PP. 468-471, (2000); SOUSA M., POZNIAK A., BOFFITO M., PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUG INTERACTIONS INVOLVING RIFAMPICIN, RIFABUTIN AND ANTIMALARIAL DRUGS, J ANTIMICROB CHEMOTHER, 62, 5, PP. 872-878, (2008); JELLIN J.M., GREGORY P.J., NATURAL MEDICINES COMPREHENSIVE DATABASE, (2013); BAUER S., STORMER E., JOHNE A., KRUGER H., BUDDE K., NEUMAYER H.-H., ROOTS I., MAI I., ALTERATIONS IN CYCLOSPORIN A PHARMACOKINETICS AND METABOLISM DURING TREATMENT WITH ST JOHN'S WORT IN RENAL TRANSPLANT PATIENTS, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 55, 2, PP. 203-211, (2003); VOLPI ABADIE J., KAYE A.M., KAYE A.D., SEROTONIN SYNDROME, OCHSNER J., 13, 4, PP. 533-540, (2013); EICH-HOCHLI D., OPPLIGER R., GOLAY K.P., BAUMANN P., EAP C.B., METHADONE MAINTENANCE TREATMENT AND ST. JOHN'S WORT: A CASE REPORT, PHARMACOPSYCHIATRY, 36, 1, PP. 35-37, (2003); GURLEY B.J., GARDNER S.F., HUBBARD M.A., ET AL., CYTOCHROME P450 PHENOTYPIC RATIOS FOR PREDICTING HERB-DRUG INTERACTIONS IN HUMANS, CLIN PHARMACOL THER, 72, PP. 276-287, (2002); PISCITELLI S.C., BURSTEIN A.H., WELDEN N., GALLICANO K.D., FALLOON J., THE EFFECT OF GARLIC SUPPLEMENTS ON THE PHARMACOKINETICS OF SAQUINAVIR, CLINICAL INFECTIOUS DISEASES, 34, 2, PP. 234-238, (2002); THOMSON A., INTRODUCTION TO CLINICAL PHARMACOKINETICS, PAEDIATR PERINAT DRUG THER, 4, 1, (2000); GURLEY B.J., GARDNER S.F., HUBBARD M.A., WILLIAMS D.K., GENTRY W.B., KHAN I.A., SHAH A., IN VIVO EFFECTS OF GOLDENSEAL, KAVA KAVA, BLACK COHOSH, AND VALERIAN ON HUMAN CYTOCHROME P450 1A2, 2D6, 2E1, AND 3A4/5 PHENOTYPES, CLINICAL PHARMACOLOGY AND THERAPEUTICS, 77, 5, PP. 415-426, (2005); KAYE A.D., KUCERA I., SABAR R., PERIOPERATIVE ANESTHESIA CLINICAL CONSIDERATIONS OF ALTERNATIVE MEDICINES, ANESTHESIOLOGY CLINICS OF NORTH AMERICA, 22, 1, PP. 125-139, (2004); ANG-LEE M.K., MOSS J., YUAN C.-S., HERBAL MEDICINES AND PERIOPERATIVE CARE, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 286, 2, PP. 208-216, (2001)","A.D. KAYE; DEPARTMENT OF ANESTHESIOLOGY, LSU SCHOOL OF MEDICINE, NEW ORLEANS, LA, UNITED STATES; EMAIL: ALANKAYE44@HOTMAIL.COM","BAILLIERE TINDALL LTD","ENGLISH","BEST PRACT. RES. CLIN. ANAESTHESIOL.","REVIEW","ISI","2-S2.0-84903726687","BEST PRACT RES CLIN ANAESTHESIOL","UNIVERSITY OF KANSAS;LSU SCHOOL OF MEDICINE;ALBERT EINSTEIN COLLEGE OF MEDICINE;BRIGHAM AND WOMEN'S HOSPITAL;UNIVERSITY OF THE PACIFIC","NOTREPORTED;LSU SCHOOL OF MEDICINE;NOTREPORTED",NA,"ABE A, 2014, BEST PRACT RES CLIN ANAESTHESIOL","ABE A, 2014, BEST PRACT RES CLIN ANAESTHESIOL"
"KAUP R;KHAYYAL M;VERSPOHL E","KAUP, REBECCA M. (24366467600); KHAYYAL, MOHAMED T. (57198366646); VERSPOHL, EUGEN J. (7005611319)","ANTIDIABETIC EFFECTS OF A STANDARDIZED EGYPTIAN RICE BRAN EXTRACT",2013,"PHYTOTHERAPY RESEARCH","27","7",32,"10.1002/ptr.4705","DEPARTMENT OF PHARMACOLOGY, INSTITUTE OF MEDICINAL CHEMISTRY, UNIVERSITY OF MUENSTER, 48149 MÜNSTER, HITTORFSTR. 58-62, GERMANY;DEPARTMENT OF PHARMACOLOGY, FACULTY OF PHARMACY, CAIRO UNIVERSITY, CAIRO, EGYPT;DEPARTMENT OF PHARMACOLOGY, INSTITUTE OF MEDICINAL CHEMISTRY, UNIVERSITY OF MUENSTER, 48149 MÜNSTER, HITTORFSTR. 58-62, GERMANY","AN EXTRACT WAS PREPARED FROM EGYPTIAN STABILIZED RICE BRAN AND STANDARDIZED TO CONTAIN 2% Γ-ORYZANOL IN ADDITION TO ITS CONTENT OF OTHER BIOACTIVES, NOTABLY TOCOTRIENOL AND POLICOSANOL. THE STANDARDIZED EXTRACT WAS FOUND TO HAVE A CONCENTRATION-DEPENDENT EFFECT ON INSULIN RELEASE IN VITRO, WHICH, HOWEVER, IS NOT MEDIATED BY Γ-TOCOTRIENOL IN RICE BRAN (DETECTED BY HPLC) AS COULD HAVE BEEN EXPECTED. POLICOSANOL AND Γ-ORYZANOL HAVE INSULINOTROPIC EFFECTS. THE IN VITRO DATA OF RICE BRAN DIRECTLY TRANSLATE INTO IN VIVO DATA OF RATS BY USING A GLUCOSE TOLERANCE TEST (INCREASE IN PLASMA INSULIN). TOCOTRIENOLS ARE WELL KNOWN FOR THEIR APOPTOTIC EFFECT ON TUMOR CELLS; NEVERTHELESS, AN ATTEMPT WAS MADE TO STUDY GLUCOSE UPTAKE IN HEP-G2 CELLS, WHICH NEEDS TO INDUCE AN INSULIN-RESISTANT STATE BY TNF-Α. THE EGYPTIAN RICE BRAN EXTRACT HAS AN ANTIDIABETIC EFFECT. Γ-ORYZANOL, WHICH IS A POSSIBLE PRECURSOR OF THE INSULINOTROPIC COMPOUND FERULIC ACID, IS A CANDIDATE FOR THIS EFFECT. THEREFORE, IT IS REASONABLE TO ASSUME THAT THE PREVALENCE OF DIABETES OR AT LEAST A PREDIABETIC (TYPE 2) SITUATION CAN BE AMELIORATED BY THE INVESTIGATED RICE BRAN EXTRACT. THE POTENTIAL USEFULNESS OF THE EXTRACT AS A NUTRACEUTICAL IS CURRENTLY UNDERGOING MORE THOROUGH INVESTIGATIONS. COPYRIGHT © 2012 JOHN WILEY & SONS, LTD.","Γ-ORYZANOL; DIABETES; POLICOSANOL; RICE BRAN; TOCOTRIENOL","ANIMALS; BLOOD GLUCOSE; CHROMANS; COUMARIC ACIDS; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FEMALE; GLUCOSE TOLERANCE TEST; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; ORYZA SATIVA; PHENYLPROPIONATES; PLANT EXTRACTS; RATS; TOCOTRIENOLS; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN E; RATTUS; ALPHA TOCOTRIENOL; ANTIDIABETIC AGENT; FERULIC ACID; GAMMA ORYZANOL; GAMMA TOCOTRIENOL; GLIBENCLAMIDE; GLUCOSE; INSULIN; PLANT EXTRACT; POLICOSANOL; RICE BRAN EXTRACT; TOCOPHEROL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; EGYPT; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NONHUMAN; PROTEIN DETERMINATION; RAT; RICE BRAN; TUMOR CELL","","","ADEN D.P., FOGEL A., PLOTKIN S., DAMJANOV I., KNOWLES B.B., CONTROLLED SYNTHESIS OF HBSAG IN A DIFFERENTIATED HUMAN LIVER CARCINOMA-DERIVED CELL LINE, NATURE, 282, 5739, PP. 615-616, (1979); ADISAKWATTANA S., MOONSAN P., YIBCHOK-ANUN S., INSULIN-RELEASING PROPERTIES OF A SERIES OF CINNAMIC ACID DERIVATIVES IN VITRO AND IN VIVO, J AGRIC FOOD CHEM, 56, PP. 7838-7844, (2008); ASFARI M., JANJIC D., MEDA P., LI G., HALBAN P.A., WOLLHEIM C.B., ESTABLISHMENT OF 2-MERCAPTOETHANOL-DEPENDENT DIFFERENTIAL INSULIN SECRETING CELL LINES, ENDOCRINOLOGY, 130, PP. 167-178, (1992); BALIARSINGH S., THE THERAPEUTIC IMPACTS OF TOCOTRIENOLS IN TYPE 2 DIABETIC PATIENTS WITH HYPERLIPIDEMIA, ATHERIOSCLEROSIS, 182, PP. 367-374, (2005); BALZ M., SCHULTE E., THIER H.P., ET AL., TRENNUNG VON TOCOPHEROLEN UND TOCOTRIENOLEN DURCH HPLC, FAT SCI TECHNOL, 94, PP. 209-213, (1992); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); CHEN C.W., CHENG H.H., A RICE BRAN OIL DIET INCREASES LDL-RECEPTOR AND HMG-COA REDUCTASE MRNA EXPRESSIONS AND INSULIN SENSITIVITY OF RATS WITH STREPTOZOTOCIN/NICOTINAMIDE- INDUCED TYPE 2 DIABETES, J NUTR, 136, PP. 1472-1476, (2006); CHENG H.H., HUANG H.Y., CHEN Y.Y., ET AL., AMELIORATIVE EFFECTS OF STABILIZED RICE BRAN ON TYPE 2 DIABETES PATIENTS, ANN NUTR METAB, 56, PP. 45-51, (2010); CHENG H.H., MA C.Y., CHOU T.W., CHEN Y.Y., LAI M.H., GAMMA-ORYZANOL AMELIORATES INSULIN RESISTANCE AND HYPERLIPIDEMIA IN RATS WITH STREPTOZOTOCIN/NICOTINAMIDE-INDUCED TYPE 2 DIABETES, INT J VITAM NUTR RES, 80, PP. 45-53, (2010); CHOU T.W., MA C.Y., CHENG H.H., CHEN Y.Y., LAI M.H., A RICE BRAN OIL DIET IMPROVES LIPID ABNORMALITIES AND SUPPRESS HYPERINSULINEMIC RESPONSES IN RATS WITH STREPTOZOCINNICOTINAMIDE-INDUCED TYPE 2 DIABETES, J CLIN BIOCHEM NUTR, 45, PP. 29-36, (2009); CICERO A.F.G., GADDI A., RICE BRAN OIL AND Γ-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHER RES, 15, PP. 277-289, (2001); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); DEUTSCHLANDER M.S., LALL N., VAN DE VENTER M., HUSSEIN A.A., HYPOGLYCEMIC EVALUATION OF A NEW TRITERPENE AND OTHER COMPOUNDS ISOLATED FROM EUCLEA UNDULATA THUNB. VAR. MYRTINA (EBENACEAE) ROOT BARK, J ETHNOPHARMACOL, 133, PP. 1091-1095, (2011); FANG F., KANG Z., WONG C., VITAMIN E TOCOTRIENOLS IMPROVE INSULIN SENSITIVITY THROUGH ACTIVATING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS, MOL NUTR FOOD RES, 54, PP. 345-352, (2010); FREDE W., TASCHENBUCH FÜR LEBENSMITTELCHEMIKER, (2006); HERNANDEZ R., TERUEL T., DE ALVARO C., LORENZO M., ROSIGLITAZONE AMELIORATES INSULIN RESISTANCE IN BROWN ADIPOCYTES OF WISTAR RATS BY IMPAIRING TNF-Α INDUCTION OF P38 AND P42/P44 MITOGEN-ACTIVATED PROTEIN KINASES, DIABETOLOGIA, 47, PP. 1615-1624, (2004); IQBAL J., MINHAJUDDIN M., BEG Z.H., SUPPRESSION OF 7,12-DIMETHYLBENZALPHAANTHRACENE-INDUCED CARCINOGENESIS AND HYPERCHOLESTEROLAEMIA IN RATS BY TOCOTRIENOL-RICH FRACTION ISOLATED FROM RICE BRAN OIL, EUR J CANCER PREV, 12, PP. 447-453, (2003); JUN H.G., LEE G.S., LEE S.H., ORYZANOL FOR LOWERING BLOOD GLUCOSE LEVEL, (2004); JUNG E.H., KIM S.R., HWANG I.K., HA T.Y., HYPOGLYCEMIC EFFECTS OF A PHENOLIC ACID FRACTION OF RICE BRAN AND FERULIC ACID IN C57BL/KSJ-DB/DB-MICE, J AGRIC FOOD CHEM, 55, PP. 9800-9804, (2007); KANNAN A., HETTIARACHCHY N., JOHNSON M.G., NANNAPANENI R., HUMAN COLON AND LIVER CANCER CELL PROLIFERATION INHIBITION BY PEPTIDE HYDROLYSATES DERIVED FROM HEAT STABILIZED DEFATTED RICE BRAN, J AGRIC FOOD CHEM, 56, PP. 11643-11647, (2008); LAI K.K., LORCA G.L., GONZALEZ C.F., BIOCHEMICAL PROPERTIES OF TO CINNAMOYL ESTERASES PURIFIED FROM A LACTOBACILLUS JOHNSONII STRAIN ISOLATED FROM STOOL SAMPLES OF DIABETES-RESISTANT RATS, APPL ENVIRONM MICROBIOLOGY, 75, PP. 5018-5024, (2009); LEE S.-H., CHUN H.-K., CHANG S.-O., LEE Y.-S., EFFECT OF Γ-ORYZANOL ON BLOOD GLUCOSE IN DIABETIC KK MICE, HANGUK SIK YONG KWAHAK HOECHI, 33, PP. 827-831, (2004); MAKYNEN K., CHITCHUMROONCHOKCHAI C., ADISAKWATTANA S., FAILLA M., ARIYAPITIPUN T., EFFECT OF GAMMA-ORYZANOL ON THE BIOACCESSIBILITY AND SYNTHESIS OF CHOLESTEROL, EUR REV MED PHARMACOL SCI, 16, PP. 49-56, (2012); MANDAL S., BARIK B., MALLICK C., DE D., GHOSH D., THERAPEUTIC EFFECT OF FERULIC ACID, AN ETHEREAL FRACTION OF ETHANOLIC EXTRACT OF SEED OF SYZYGIUM CUMINI AGAINST STREPTOZOTOCIN-INDUCED DIABETES IN MALE RAT, METHODS FIND EXP CLIN PHARMACOL, 30, PP. 121-128, (2008); NAGASAKA R., HORI M., NEW BIOACTIVE FUNCTIONS AND APPLICATIONS OF Γ-ORYZANOL, A COMPONENT OF RICE BRAN. PREVENTIVE AND THERAPEUTIC EFFECTS VIA NF-ΚB-INHIBITORY ACTION OF DIABETES, ULCERATIVE COLITIS ETC. ARE EXPECTED, KAGAKU TO SEIBUTSU, 47, PP. 816-818, (2009); NAM S.H., CHOI S.P., KANG M.Y., KOZUKUE N., FRIEDMAN M., ANTIOXIDATIVE, ANTIMUTAGENIC AND ANTICARCINOGENIC ACTIVITIES OF RICE BRAN EXTRACTS IN CHEMICAL AND CELL ASSAYS, J AGRIC FOOD CHEM, 53, PP. 816-822, (2005); NOMURA E., KASHIWADA A., HOSODA A., ET AL., SYNTHESIS OF AMIDE COMPOUNDS OF FERULIC ACID AND THEIR STIMULATORY EFFECTS ON INSULIN SECRETION IN VITRO, BIOORG MED CHEM, 11, PP. 3807-3813, (2003); OHNISHI M., MATUO T., TSUNO T., ET AL., ANTIOXIDANT ACTIVITY AND HYPOGLYCEMIC EFFECT OF FERULIC ACID IN STZ-INDUCED DIABETIC MICE AND KK-AY MICE, BIOFACTORS, 21, PP. 315-319, (2004); INTERACTION OF CINNAMIC ACID DERIVATIVES WITH COMMERCIAL HYPOGLYCEMIC DRUGS ON 2-DEOXYGLUCOSE UPTAKE IN 3T3-L1 ADIPOCYTES, J AGRIC FOOD CHEM, 59, PP. 9835-9844, (2011); QURESHI A.A., MO H., PACKER L., PETERSON D.M., ISOLATION AND IDENTIFICATION OF NOVEL TOCOTRIENOLS FROM RICE BRAN WITH HYPOCHOLESTEROLEMIC, ANTIOXIDANT AND ANTITUMOR PROPERTIES, J AGRIC FOOD CHEM, 48, PP. 3130-3140, (2000); QURESHI A.A., SAMI S.A., KHAN F.A., EFFECTS OF STABILIZED RICE BRAN, ITS SOLUBLE AND FIBER FRACTIONS ON BLOOD GLUCOSE LEVELS AND SERUM LIPID PARAMETERS IN HUMANS WITH DIABETES MELLITUS TYPES I AND II, J NUTR BIOCHEM, 13, PP. 175-187, (2002); QURESHI A.A., SAMI S.A., SALSER W.A., KHAN F.A., DOSE-DEPENDENT SUPPRESSION OF SERUM CHOLESTEROL BY TOCOTRIENOL-RICH FRACTION (TRF25) OF RICE BRAN IN HYPERCHOLESTEROLEMIC HUMANS, ATHEROSCLEROSIS, 161, PP. 199-207, (2002); RAGHAVAN P.R., POLICOSANOL NANOPARTICLES FOR TREATMENT OF VARIOUS DISORDERS INCLUDING DIABETES, PCT INT. APPL., (2010); SCHULTE E., BALZ M., THIER H.P., ET AL., SCHNELLE HERSTELLUNG DER FETTSÄUREMETHYLESTER AUS FETTEN MIT TRIMETHYLSULFONIUMHYDROXID ODER NATRIUMMETHYLAT, FAT SCI TECHNOL, 5, PP. 181-183, (1989); SIDDIQUI S., RASHID KHAN M., SIDDIQUI W.A., COMPARATIVE HYPOGLYCEMIC AND NEPHROPROTECTIVE EFFECTS OF TOCOTRIENOL RICH FRACTION (TRF) FROM PALM OIL AND RICE BRAN OIL AGAINST HYPERGLYCEMIA INDUCED NEPHROPATHY IN TYPE 1 DIABETIC RATS, CHEM BIOL INTERACT, 188, PP. 651-658, (2010); SON M.J., RICO C.W., NAM S.H., KANG M.Y., EFFECT OF ORYZANOL AND FERULIC ACID ON THE GLUCOSE METABOLISM OF MICE FED WITH A HIGH-FAT DIET, J FOOD SCI, 76, (2011); TAKUMI M., TANAKA T., TAKAMURA Y., WATANABE N., AGENT FOR AMELIORATING TYPE-2 DIABETES CONTAINING KOALIANG-DERIVED WAX MIXTURE, AND FOOD OR BEVERAGE CONTAINING SAME, PCT INT. APPL., (2011); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERREIRO R.M., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-398, (1995); VERSPOHL E.J., RECOMMENDED TESTING IN DIABETES RESEARCH, PLANTA MED, 68, PP. 581-590, (2002); WAN NAZAIMOON W.M., KHALID B.A., TOCOTRIENOL-RICH DIET DECREASES ADVANCED GLYCOSYLATION END-PRODUCTS IN NONDIABETIC RATS AND IMPROVES GLYCAEMIC CONTROL IN STREPTOZOTOCIN-INDUCED DIABETIC RATS, MALAYS J PATHOL, 24, PP. 77-82, (2002); WILD S., ROGLIC G., GREEN A., SICREE R., KING H., GLOBAL PREVALENCE OF DIABETES, DIABETES CARE, 27, PP. 1047-1053, (2004); YAP S.P., YUEN K.H., WONG J.W., PHARMACOKINETICS AND BIOAVAILABILITY OF ALPHA-, GAMMA- AND DELTA-TOCOTRIENOLS UNDER DIFFERENT FOOD STATUS, J PHARM PHARMACOL, 53, PP. 67-71, (2001); YOSHIOKA K., TAKAHASHI T., HOMMA T., ET AL., A NOVEL FLUORESCENT DERIVATIVE OF GLUCOSE APPLICABLE TO THE ASSESSMENT OF GLUCOSE UPTAKE ACTIVITY OF ESCHERICHIA COLI, BIOCHIM BIOPHYS ACTA, 1289, PP. 5-9, (1996); ZIMMET P., ALBERTI K., SHAW J., GLOBAL AND SOCIETAL IMPLICATIONS OF THE DIABETES EPIDEMIC, NATURE, 414, PP. 782-787, (2001); ZOU C., WANG Y., SHEN Z., 2-NBDG AS A FLUORESCENT INDICATOR FOR DIRECT GLUCOSE UPTAKE MEASUREMENT, J BIOCHEM BIOPHYS METHODS, 64, PP. 207-215, (2005)","E.J. VERSPOHL; DEPARTMENT OF PHARMACOLOGY, INSTITUTE OF MEDICINAL CHEMISTRY, UNIVERSITY OF MUENSTER, 48149 MÜNSTER, HITTORFSTR. 58-62, GERMANY; EMAIL: VERSPOH@UNI-MUENSTER.DE","","ENGLISH","PHYTOTHER. RES.","ARTICLE","ISI","2-S2.0-84873414467","PHYTOTHER RES","UNIVERSITY OF MUENSTER;CAIRO UNIVERSITY;UNIVERSITY OF MUENSTER","NOTREPORTED;UNIVERSITY OF MUENSTER;NOTREPORTED",NA,"KAUP RM, 2013, PHYTOTHER RES","KAUP RM, 2013, PHYTOTHER RES"
"LUPI F;GABRIELE D;SETA L;BALDINO N;DE C B","LUPI, FRANCESCA R. (24768180600); GABRIELE, DOMENICO (6507587673); SETA, LUCIA (36140452900); BALDINO, NOEMI (24767432700); DE CINDIO, BRUNO (6602864175)","RHEOLOGICAL DESIGN OF STABILIZED MEAT SAUCES FOR INDUSTRIAL USES",2014,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","116","10",25,"10.1002/ejlt.201400286","DEPARTMENT OF INFORMATICS, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, UNIVERSITY OF CALABRIA, RENDE (CS), ITALY;DEPARTMENT OF INFORMATICS, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, UNIVERSITY OF CALABRIA, RENDE (CS), ITALY;DODARO SALUMI, CASTROLIBERO (CS), ITALY;DEPARTMENT OF INFORMATICS, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, UNIVERSITY OF CALABRIA, RENDE (CS), ITALY;DEPARTMENT OF INFORMATICS, MODELING, ELECTRONICS AND SYSTEM ENGINEERING, UNIVERSITY OF CALABRIA, RENDE (CS), ITALY","IN THE PRESENT WORK A RHEOLOGICAL ANALYSIS WAS CARRIED OUT ON SAUCES PRODUCED WITH A SPREADABLE SPICY SAUSAGE, TYPICAL OF THE ITALIAN DIETARY CULTURE, AND MODIFIED BY ORGANOGELATOR ADDITION IN ORDER TO CHANGE THEIR MECHANICAL PROPERTIES AND TO SOLVE POTENTIAL STABILITY ISSUES. FROM A MICROSTRUCTURAL POINT OF VIEW, THE INVESTIGATED SAUCES ARE SUSPENSIONS OF HARD FAT/MEAT PHASE IN A LIQUID OIL SOLVENT BASED ON A MIXTURE OF SUNFLOWER AND OLIVE OIL. THE STABILIZATION OF THESE HETEROGENEOUS SYSTEMS WAS CARRIED OUT BY AN ORGANOGELATION TECHNIQUE, THANKS TO WHICH THE SOLVENT WAS STABILIZED BY A NETWORK LINKING THE SOLID PARTICLES. MONOGLYCERIDES OF FATTY ACIDS AND POLICOSANOL, A FATTY ALCOHOL MIXTURE, WERE USED AS ORGANOGELATORS AT TWO DIFFERENT FRACTIONS (0.1 AND 0.5% W/W). SMALL AMPLITUDE OSCILLATION TESTS AND FLOW TESTS WERE CARRIED OUT, BOTH ON FRESH SAMPLES AND ON SAMPLES DESTABILIZED BY CENTRIFUGATION; POLICOSANOL WAS FOUND TO BE MORE EFFICIENT, EVEN AT LOW CONCENTRATION, IN STABILIZING THE SYSTEM, GUARANTEEING RHEOLOGICAL PROPERTIES SIMILAR TO THOSE OF A BENCHMARK UNSTABLE SAMPLE, AND, IN THE MEANTIME, GIVING A GOOD STABILITY TO THE SYSTEM SUBJECTED TO SHEAR STRESSES (LIKE THOSE ARISING DURING MECHANICAL MANIPULATIONS). PRACTICAL APPLICATIONS: OIL SUSPENSION STABILIZATION IS A RELEVANT CHALLENGE IN FOOD INDUSTRY OWING TO THE DIFFICULTIES IN STRUCTURING AN OIL PHASE. ORGANOGELATION IS A POTENTIAL SOLUTION TO THESE STABILITY ISSUES BECAUSE ORGANOGELATORS CAN STRUCTURE THE OIL PHASE ENTRAPPING THE DISPERSED PARTICLE IN A SEMI-SOLID GEL NETWORK THAT PREVENTS OR DELAYS THE SEPARATION PHENOMENA. IN THE PRESENT WORK TWO DIFFERENT EDIBLE ORGANOGELATORS WERE ADOPTED TO STABILIZE MEAT SUSPENSIONS IN A VEGETABLE OIL MIXTURE, AND THEIR EFFECTS ON BOTH QUIESCENT STABILITY AND RESISTANCE TO MECHANICAL STRESSES WERE INVESTIGATED BY USING RHEOLOGICAL TESTS. IT WAS SHOWN THAT ORGANOGELATION CAN SIGNIFICANTLY REDUCE THE SEPARATION PHENOMENA BETWEEN TWO PHASES, AND IT CAN INCREASE THE CAPACITY OF MATERIALS TO BEAR MECHANICAL LOADS WITHOUT AFFECTING THE DESIRED CONSISTENCY. THE PROPOSED RHEOLOGICAL APPROACH AND THE ADOPTED ORGANOGELATORS CAN BE USED TO STABILIZE ALSO DIFFERENT FOOD SUSPENSIONS BASED ON LIQUID OILS. © 2014 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.","FATTY ALCOHOLS; MEAT SUSPENSIONS; MONOGLYCERIDES OF FATTY ACIDS; ORGANOGEL; POLICOSANOL; RHEOLOGY","HELIANTHUS","","","CHOJNICKA A., SALA G., DE KRUIF C.G., VAN DE VELDE F., THE INTERACTIONS BETWEEN OIL DROPLETS AND GEL MATRIX AFFECT THE LUBRICATION PROPERTIES OF SHEARED EMULSION-FILLED GELS, FOOD HYDROCOLLOIDS, 23, PP. 1038-1104, (2009); LORENZO G., ZARITZKY N., CALIFANO A., RHEOLOGICAL ANALYSIS OF EMULSION-FILLED GELS BASED ON HIGH ACYL GELLAN GUM, FOOD HYDROCOLLOIDS, 30, PP. 672-680, (2013); HOUZE G., CASES E., COLAS B., CAYOT P., VISCOELASTIC PROPERTIES OF ACID MILK GEL AS AFFECTED BY FAT NATURE AT LOW LEVEL, INT. DAIRY J., 15, PP. 1006-1016, (2005); KOKINI J., VAN AKEN G., DISCUSSION SESSION ON FOOD EMULSIONS AND FOAMS, FOOD HYDROCOLLOIDS, 20, PP. 438-445, (2006); LUPI F.R., GABRIELE D., DE CINDIO B., SANCHEZ M.C., GALLEGOS C., A RHEOLOGICAL ANALYSIS OF STRUCTURED WATER-IN-OLIVE OIL EMULSIONS, J. FOOD ENG., 107, PP. 296-303, (2011); LUPI F.R., GABRIELE D., BALDINO N., SETA L., ET AL., STABILIZATION OF MEAT SUSPENSIONS BY ORGANOGELATION: A RHEOLOGICAL APPROACH, EUR. J. LIPID SCI. TECHNOL., 114, PP. 1381-1389, (2012); YOON H.-K., SEO T.-R., LIM S.-T., STABILIZATION OF AQUEOUS DISPERSION OF COQ10 NANOPARTICLES USING MAIZE STARCHES, FOOD HYDROCOLLOIDS, 35, PP. 144-149, (2014); RAY M., ROUSSEAU D., STABILIZATION OF OIL-IN-WATER EMULSIONS USING MIXTURES OF DENATURED SOY WHEY PROTEINS AND SOLUBLE SOYBEAN POLYSACCHARIDES, FOOD RES. INT., 52, PP. 298-307, (2013); SETA L., BALDINO N., GABRIELE D., LUPI F.R., DE CINDIO B., THE INFLUENCE OF CARRAGEENAN ON INTERFACIAL PROPERTIES AND SHORT-TERM STABILITY OF MILK WHEY PROTEINS EMULSIONS, FOOD HYDROCOLLOIDS, 32, PP. 373-382, (2013); VAN VLIET T., RHEOLOGICAL PROPERTIES OF FILLED GELS. INFLUENCE OF FILLER MATRIX INTERACTION, COLLOID POLYM. SCI., 266, PP. 518-524, (1988); SALA G., VAN DE VELDE F., COHEN STUART M.A., VAN AKEN G., OIL DROPLET RELEASE FROM EMULSION-FILLED GELS IN RELATION TO SENSORY PERCEPTION, FOOD HYDROCOLLOIDS, 21, PP. 977-985, (2007); CO E.D., MARANGONI A.G., ORGANOGELS: AN ALTERNATIVE EDIBLE OIL-STRUCTURING METHOD, J. AM. OIL CHEM. SOC., 89, PP. 749-780, (2012); LUPI F.R., GABRIELE D., DE CINDIO B., EFFECT OF SHEAR RATE ON CRYSTALLISATION PHENOMENA IN OLIVE OIL-BASED ORGANOGELS, FOOD BIOPROCESS TECHNOL., 5, PP. 2880-2888, (2012); LUPI F.R., GABRIELE D., FACCIOLO D., BALDINO N., ET AL., EFFECT OF ORGANOGELATOR AND FAT SOURCE ON RHEOLOGICAL PROPERTIES OF OLIVE OIL-BASED ORGANOGELS, FOOD RES. INT., 46, PP. 177-184, (2012); LUPI F.R., GABRIELE D., GRECO V., BALDINO N., ET AL., A RHEOLOGICAL CHARACTERISATION OF AN OLIVE OIL/FATTY ALCOHOLS ORGANOGEL, FOOD RES. INT., 51, PP. 510-517, (2013); TORO-VAZQUEZ J.F., MAURICIO-PEREZ R., GONZALEZ-CHAVEZ M.M., SANCHEZ-BECERRIL M., ET AL., PHYSICAL PROPERTIES OF ORGANOGELS AND WATER IN OIL EMULSIONS STRUCTURED BY MIXTURES OF CANDELILLA WAX AND MONOGLYCERIDES, FOOD RES. INT., 54, PP. 1360-1368, (2013); LUPI F.R., GABRIELE D., BALDINO N., MIJOVIC P., ET AL., OLIVE OIL/POLICOSANOL ORGANOGELS FOR NUTRACEUTICAL AND DRUG DELIVERY PURPOSES, FOOD FUNCT., 4, PP. 1512-1520, (2013); KHELIFI H., PERROT A., LECOMPTE T., RANGEARD D., AUSIAS G., PREDICTION OF EXTRUSION LOAD AND LIQUID PHASE FILTRATION DURING RAM EXTRUSION OF HIGH SOLID VOLUME FRACTION PASTES, POWDER TECHNOL., 249, PP. 258-268, (2013); ZETZL A.K., MARANGONI A., BARBUT S., MECHANICAL PROPERTIES OF ETHYLCELLULOSE OLEOGELS AND THEIR POTENTIAL FOR SATURATED FAT REDUCTION IN FRANKFURTERS, FOOD FUNCT., 3, PP. 327-337, (2012); SOMBOONPANYAKUL P., BARBUT S., JANTAWAT P., CHINPRAHAST N., TEXTURAL AND SENSORY QUALITY OF POULTRY MEAT BATTER CONTAINING MALVA NUT GUM, SALT AND PHOSPHATE, LWT - FOOD SCI. TECHNOL., 40, PP. 498-505, (2007); RUIZ-CAPILLAS C., CARMONA P., JIMENEZ-COLMENERO F., HERRERO A.M., OIL BULKING AGENTS BASED ON POLYSACCHARIDE GELS IN MEAT BATTERS: A RAMAN SPECTROSCOPIC STUDY, FOOD CHEM., 141, PP. 3688-3694, (2013); FLORES M., GINER E., FISZMAN S.M., SALVADOR A.J.F., EFFECT OF A NEW EMULSIFIER CONTAINING SODIUM STEAROYL-2-LACTYLATE AND CARRAGEENAN ON THE FUNCTIONALITY OF MEAT EMULSION SYSTEMS, MEAT SCI., 76, PP. 9-18, (2007); OJIJO N.K.O., NEEMAN I., EGER S., SHIMONI E., EFFECTS OF MONOGLYCERIDE CONTENT, COOLING RATE AND SHEAR ON THE RHEOLOGICAL PROPERTIES OF OLIVE OIL/MONOGLYCERIDE GEL NETWORKS, J. SCI. FOOD AGRIC., 84, PP. 1585-1593, (2004); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, NUTR. RES., 27, PP. 212-217, (2007); BARNES H.A., A HANDBOOK OF ELEMENTARY RHEOLOGY, (2000); MACOSKO C.W., RHEOLOGY, PRINCIPLES, MEASUREMENTS AND APPLICATIONS, (1994); BARNES H.A., THE YIELD STRESS - A REVIEW OR ΠΑΝΤΑ ΡΕ{LUNATE}Ι - EVERYTHING FLOWS, J. NON-NEWTONIAN FLUID MECH., 81, PP. 133-178, (1999); COPPOLA L., GABRIELE D., NICOTERA I., OLIVIERO C., MRI EXPERIMENTS AS A TOOL TO STUDY ASYMPTOTIC-SHEAR FLOW BEHAVIOUR OF A WORM-LIKE REVERSE MICELLAR PHASE, APPL. RHEOL., 16, PP. 190-197, (2006); DAPCEVIC T., DOKIC P., HADNADEV M., POJIC M., DETERMINING THE YIELD STRESS OF FOOD PRODUCTS - IMPORTANCE AND SHORTCOMINGS, FOOD FEED RES., 35, PP. 143-149, (2008); ROBERTS G.P., BARNES H.A., CAREW P., MODELLING THE FLOW BEHAVIOUR OF VERY SHEAR-THINNING LIQUIDS, CHEM. ENG. SCI., 56, PP. 5617-5623, (2001); GABRIELE D., DE CINDIO B., D'ANTONA P., A WEAK GEL MODEL FOR FOODS, RHEOL. ACTA., 40, PP. 120-127, (2001); RAO M.A., RHEOLOGY OF FLUID AND SEMISOLID FOODS PRINCIPLES AND APPLICATIONS, (1999); DORA M., KUMAR M., VAN GOUBERGEN D., MOLNAR A., GELLYNCK X., FOOD QUALITY MANAGEMENT SYSTEM: REVIEWING ASSESSMENT STRATEGIES AND A FEASIBILITY STUDY FOR EUROPEAN FOOD SMALL AND MEDIUM-SIZED ENTERPRISES, FOOD CONTROL, 31, PP. 607-616, (2013); SORLAND G.H., LARSEN P.M., LUNDBY F., RUDI A.-P., GUIHENEUF T., DETERMINATION OF TOTAL FAT AND MOISTURE CONTENT IN MEAT USING LOW FIELD NMR, MEAT SCI., 66, PP. 543-550, (2004)","","WILEY-VCH VERLAG","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-84919692341","EUR J LIPID SCI TECHNOL",NA,"NOTREPORTED",NA,"LUPI FR, 2014, EUR J LIPID SCI TECHNOL","LUPI FR, 2014, EUR J LIPID SCI TECHNOL"
"WANG Z;HWANG S;LIM S","WANG, ZHIQIANG (56511735800); HWANG, SEUNG HWAN (55627351600); LIM, SOON SUNG (7404081703)","CHEMOENZYMATICALLY SYNTHESIZED POLICOSANYL PHENOLATES AS AUTOXIDATION INHIBITORS",2015,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","117","10",5,"10.1002/ejlt.201400296","DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA, INSTITUTE OF NATURAL MEDICINE, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA, INSTITUTE OF NATURAL MEDICINE, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA, DEPARTMENT OF CENTER FOR AGING AND HEALTH CARE, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA","IN THIS STUDY, TEN POLICOSANYL PHENOLATES WERE SYNTHESIZED VIA A TWO-STEP CHEMOENZYMATIC ROUTE. THE INTERMEDIATE VINYL ESTERS WERE FIRST CHEMICALLY PRODUCED AND SUBSEQUENTLY ESTERIFIED WITH POLICOSANOLS CATALYZED BY NOVOZYME 435 (CANDIDA ANTARCTICA LIPASE B). THE CONVERSION YIELDS OF THE POLICOSANYL PHENOLATES WERE IN THE RANGE OF 4.20-37.14%. THEIR ANTIOXIDANT ACTIVITIES WERE EVALUATED. RESULTS SHOWED THAT, COMPARED WITH THE CORRESPONDING PHENOLIC ACIDS, ALL SYNTHESIZED POLICOSANYL PHENOLATES HAD BETTER ACTIVITIES FOR PEROXIDE VALUE, BUT WORSE FOR 2,2'-AZINOBIS(3-ETHYLBENZOTHIAZOLINE-6-SULFONIC ACID) ASSAY; POLICOSANYL P-COUMARATE AND POLICOSANYL 5-PHENYLVALERATE SHOWED A MODERATE AND DURABLE INHIBITION EFFECT ON LIPID OXIDATION BOTH IN A LINOLEIC ACID SYSTEM AND A COOKED PORK SYSTEM. PRACTICAL APPLICATIONS: IT IS IMPORTANT TO DEVELOP ANTIOXIDANTS FROM NATURAL SOURCES. THE LIPOPHILIZATION OF PHENOLIC ACIDS WITH FATTY ALCOHOLS CAN IMPROVE THE HYDROPHOBICITY AND CHANGE THE ANTIOXIDANT CAPACITY OF PHENOLS. THIS STUDY FOCUSES ON POLICOSANOL, WHICH IS A FOOD-GRADE MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ALCOHOLS, HAVING DEVELOPMENT AND APPLICATION POTENTIAL AS A COST-EFFECTIVE FOOD ADDITIVE. ACCORDING TO OUR RESULTS, POLICOSANYL PHENOLATES, WHICH ARE A NEW RANGE OF AMPHIPHILIC ANTIOXIDANT MOLECULES, HAVE THE POTENTIAL FOR USE AS ALTERNATIVE FOOD ANTIOXIDANTS IN THE FOOD INDUSTRY. © 2015 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.","ANTIOXIDANT; AUTOXIDATION; CHEMOENZYMATIC SYNTHESIS; LIPASE; POLICOSANYL PHENOLATES","CANDIDA ANTARCTICA","","","BONDET V., BRAND-WILLIAMS W., BERSET C., KINETICS AND MECHANISMS OF ANTIOXIDANT ACTIVITY USING THE DPPH FREE RADICAL METHOD, LWT-FOOD SCI. TECHNOL., 30, PP. 609-615, (1997); BRAND-WILLIAMS W., CUVELIER M.E., BERSET C., USE OF A FREE RADICAL METHOD TO EVALUATE ANTIOXIDANT ACTIVITY, LWT-FOOD SCI. TECHNOL., 28, PP. 25-30, (1995); FARKAS J., OXIDATION IN FOODS AND BEVERAGES AND ANTIOXIDANT APPLICATIONS. VOLS 1 & 2, ACTA ALIMENT. HUNG., 40, PP. 415-416, (2011); MATALANIS A., DECKER E.A., MCCLEMENTS D.J., INHIBITION OF LIPID OXIDATION BY ENCAPSULATION OF EMULSION DROPLETS WITHIN HYDROGEL MICROSPHERES, FOOD CHEM., 132, PP. 766-772, (2012); BRANEN A.L., TOXICOLOGY AND BIOCHEMISTRY OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE, J. AM. OIL CHEM. SOC., 52, PP. 59-63, (1975); ITO N., HIROSE M., FUKUSHIMA S., TSUDA H., ET AL., STUDIES ON ANTIOXIDANTS: THEIR CARCINOGENIC AND MODIFYING EFFECTS ON CHEMICAL CARCINOGENESIS, FOOD CHEM. TOXICOL., 24, PP. 1071-1082, (1986); MADHAVI D., DESHPANDE S., SALUNKHE D.K., FOOD ANTIOXIDANTS: TECHNOLOGICAL: TOXICOLOGICAL AND HEALTH PERSPECTIVES, (1995); GUYOT B., GUEULE D., PINA M., GRAILLE J., ET AL., ENZYMATIC SYNTHESIS OF FATTY ESTERS IN 5-CAFFEOYL QUINIC ACID, EUR. J. LIPID SCI. TECHNOL., 102, PP. 93-95, (2000); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); SHRIPATHI V., SWAMY G.S., EFFECT OF TRIACONTANOL ON THE LIPID COMPOSITION OF COTTON (GOSSYPIUM HIRSUTUM L.) LEAVES AND ITS INTERACTION WITH INDOLE-3-ACETIC ACID AND BENZYLADENINE, PLANT GROWTH REGUL., 14, PP. 45-50, (1994); SHRIPATHI V., SWAMY G.S., CHANDRASEKHAR K.S., MICROVISCOSITY OF CUCUMBER (CUCUMIS SATIVUS L.) FRUIT PROTOPLAST MEMBRANES IS ALTERED BY TRIACONTANOL AND ABSCISIC ACID, BIOCHIM. BIOPHYS. ACTA., 1323, PP. 263-271, (1997); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, NUTR. RES., 27, PP. 212-217, (2007); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONROLLED TRIAL, J. AM. MED. ASSOC., 295, PP. 2262-2269, (2014); VIDELA CABRERA L.A., HAIM D., VALENZUELA A., BRANES M.C., FUENZALIDA M., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASA ACEITES., 63, PP. 345-354, (2012); ZHAO T., HA T.-Y., LEE J., KIM B.H., KIM I.-H., MODELING AND OPTIMIZATION OF LIPASE-CATALYZED ESTERIFICATION OF POLICOSANOLS WITH CONJUGATED LINOLEIC ACID BY RESPONSE SURFACE METHODOLOGY, BIOCATAL. BIOTRANSFOR., 31, PP. 114-122, (2013); HILLS G., INDUSTRIAL USE OF LIPASES TO PRODUCE FATTY ACID ESTERS, EUR. J. LIPID SCI. TECHNOL., 105, PP. 601-607, (2003); VILLENEUVE P., MUDERHWA J.M., GRAILLE J., HAAS M.J., CUSTOMIZING LIPASES FOR BIOCATALYSIS: A SURVEY OF CHEMICAL, PHYSICAL AND MOLECULAR BIOLOGICAL APPROACHES, J. MOL. CATAL. B- ENZYM., 9, PP. 113-148, (2000); VISKUPICOVA J., ONDREJOVIC M., MALIAR T., ENZYME-MEDIATED PREPARATION OF FLAVONOID ESTERS AND THEIR APPLICATIONS. IN: BIOCHEMISTRY, (2012); YANG Z., GUO Z., XU X., ENZYMATIC LIPOPHILISATION OF PHENOLIC ACIDS THROUGH ESTERIFICATION WITH FATTY ALCOHOLS IN ORGANIC SOLVENTS, FOOD CHEM., 132, PP. 1311-1315, (2012); MONDAL M., VAN DER MEER R., GERMAN A.L., HEIKENS D., A NOVEL SYNTHESIS OF VINYL ESTERS FROM VINYLVERSATATE-10, TETRAHEDRON, 30, PP. 4205-4207, (1974); TORRES P., REYES-DUARTE D., LOPEZ-CORTES N., FERRER M., ET AL., ACETYLATION OF VITAMIN E BY CANDIDA ANTARCTICA LIPASE B IMMOBILIZED ON DIFFERENT CARRIERS, PROCESS BIOCHEM., 43, PP. 145-153, (2008); RE R., PELLEGRINI N., PROTEGGENTE A., PANNALA A., ET AL., ANTIOXIDANT ACTIVITY APPLYING AN IMPROVED ABTS RADICAL CATION DECOLORIZATION ASSAY, FREE RADICAL BIO. MED., 26, PP. 1231-1237, (1999); SAKANAKA S., TACHIBANA Y., ISHIHARA N., RAJ JUNEJA L., ANTIOXIDANT ACTIVITY OF EGG-YOLK PROTEIN HYDROLYSATES IN A LINOLEIC ACID OXIDATION SYSTEM, FOOD CHEM., 86, PP. 99-103, (2004); LIPS A., CHAPMAN R.A., MCFARLANE W.D., THE APPLICATION OF THE FERRIC THIOCYANATE METHOD TO THE DETERMINATION OF INCIPIENT RANCIDITY IN FATS AND OILS, OIL & SOAP, 20, PP. 240-243, (1943); PAQUOT B., HAUTFENNE A., STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS, AND DERIVATIVES, (1987); SHAHIDI F., ZHONG Y., LIPID OXIDATION: MEASUREMENT METHODS, BAILEY'S INDUSTRIAL OIL AND FAT PRODUCTS, (2005); SHAHIDI F., ALEXANDER D.M., GREEN TEA CATECHINS AS INHIBITORS OF OXIDATION OF MEAT LIPIDS, J. FOOD LIPIDS, 5, PP. 125-133, (1998); SHAHIDI F., PEGG R.B., HEXANAL AS AN INDICATOR OF MEAT FLAVOR DETERIORATION, J. FOOD LIPIDS, 1, PP. 177-186, (1994); GUYOT B., BOSQUETTE B., PINA M., GRAILLE J., ESTERIFICATION OF PHENOLIC ACIDS FROM GREEN COFFEE WITH AN IMMOBILIZED LIPASE FROM CANDIDA ANTARCTICA IN SOLVENT-FREE MEDIUM, BIOTECHNOL. LETT., 19, PP. 529-532, (1997); KWON H.C., SHIN D.Y., LEE J.H., KIM S.W., KANG J.W., MOLECULAR MODELING AND ITS EXPERIMENTAL VERIFICATION FOR THE CATALYTIC MECHANISM OF CANDIDA ANTARCTICA LIPASE B, J. MICROBIOL. BIOTECHN., 17, PP. 1098-1105, (2007); TAN Z., SHAHIDI F., CHEMOENZYMATIC SYNTHESIS OF PHYTOSTERYL FERULATES AND EVALUATION OF THEIR ANTIOXIDANT ACITIVITY, J. AGR. FOOD CHEM., 59, PP. 12375-12383, (2011); CHIGORIMBO-MUREFU N.T.L., RIVA S., BURTON S.G., LIPASE-CATALYSED SYNTHESIS OF ESTERS OF FERULIC ACID WITH NATURAL COMPOUNDS AND EVALUATION OF THEIR ANTIOXIDANT PROPERTIES, J. MOL. CATAL. B- ENZYM., 56, PP. 277-282, (2009); CELIZ G., DAZ M., BIOCATALYTIC PREPARATION OF ALKYL ESTERS OF CITRUS FLAVANONE GLUCOSIDE PRUNIN IN ORGANIC MEDIA, PROCESS BIOCHEM., 46, PP. 94-100, (2011); PRIYA K., CHADHA A., SYNTHESIS OF HYDROCINNAMIC ESTERS BY PSEUDOMONAS CEPACIA LIPASE, ENZYME MICROB. TECH., 32, PP. 485-490, (2003); SEBRAO D., SA M.M., NASCIMENTO M.G., REGIOSELECTIVE ACYLATION OF D-RIBONO-1, 4-LACTONE CATALYZED BY LIPASES, PROCESS BIOCHEM., 46, PP. 551-556, (2011); BUETTNER G.R., THE PECKING ORDER OF FREE RADICALS AND ANTIOXIDANTS: LIPID PEROXIDATION, Á-TOCOPHEROL, AND ASCORBATE, ARCH. BIOCHEM. BIOPHYS., 300, PP. 535-543, (1993); NATELLA F., NARDINI M., DI FELICE M., SCACCINI C., BENZOIC AND CINNAMIC ACID DERIVATIVES AS ANTIOXIDANTS: STRUCTURE-ACTIVITY RELATION, J. AGR. FOOD CHEM., 47, PP. 1453-1459, (1999); SANCHEZ-MORENO C., LARRAURI J.A., SAURA-CALIXTO F., FREE RADICAL SCAVENGING CAPACITY AND INHIBITION OF LIPID OXIDATION OF WINES, GRAPE JUICES AND RELATED POLYPHENOLIC CONSTITUENTS, FOOD RES. INT., 32, PP. 407-412, (1999); BORG D.C., SCHAICH K.M., IRON AND HYDROXYL RADICALS IN LIPID OXIDATION: FENTON REACTIONS IN LIPID AND NUCLEIC ACIDS CO-OXIDIZED WITH LIPID, (1987); GUTTERIDGE J., HALLIWELL B., THE MEASUREMENT AND MECHANISM OF LIPID PEROXIDATION IN BIOLOGICAL SYSTEMS, TRENDS BIOCHEM. SCI., 15, PP. 129-135, (1990); FARMER E.H., BLOOMFIELD G.F., SUNDRALINGAM A., SUTTON D.A., THE COURSE AND MECHANISM OF AUTOXIDATION REACTIONS IN OLEFINIC AND POLYOLEFINIC SUBSTANCES, INCLUDING RUBBER, TRANS. FARADAY SOC., 38, PP. 348-356, (1942); FRANKEL E., VOLATILE LIPID OXIDATION PRODUCTS, PROG. LIPID RES., 22, PP. 1-33, (1983)","S.S. LIM; HALLYM UNIVERSITY, CHUNCHEON, 1 HALLYMDEAHAK-GIL, 200-702, SOUTH KOREA; EMAIL: LIMSS@HALLYM.AC.KR","WILEY-VCH VERLAG","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-84924196474","EUR J LIPID SCI TECHNOL","HALLYM UNIVERSITY;HALLYM UNIVERSITY;HALLYM UNIVERSITY","NOTREPORTED;HALLYM UNIVERSITY;NOTREPORTED",NA,"WANG Z, 2015, EUR J LIPID SCI TECHNOL","WANG Z, 2015, EUR J LIPID SCI TECHNOL"
"GIUFFRÈ A;CAPOCASALE M","GIUFFRÈ, ANGELO MARIA (9279506500); CAPOCASALE, MARCO (56664492000)","POLICOSANOL IN TOMATO SOLANUM LYCOPERSICUM L SEED OIL THE EFFECT OF CULTIVAR",2015,"JOURNAL OF OLEO SCIENCE","64","6",37,"10.5650/jos.ess15002","UNIVERSITÀ DEGLI STUDI ‘MEDITERRANEA’ DI REGGIO CALABRIA (ITALY), DIPARTIMENTO AGRARIA, ITALY;UNIVERSITÀ DEGLI STUDI ‘MEDITERRANEA’ DI REGGIO CALABRIA (ITALY), DIPARTIMENTO AGRARIA, ITALY","SOXHLET-PETROLEUM ETHER EXTRACTION WAS USED TO OBTAIN OIL FROM TOMATO SEEDS. THREE TOMATO CULTIVARS FROM SOUTH ITALY (PRINCIPE BORGHESE, REBELION F1 AND SAN MARZANO) WERE STUDIED. POLICOSANOL IS A MIXTURE OF LONG CHAIN LINEAR FATTY ALCOHOLS (N-ALKANOLS), ITS CONTENT AND COMPOSITION WAS FOUND TO BE HIGHLY SIGNIFICANTLY INFLUENCED BY CULTIVAR. SEVEN FATTY ALCOHOLS WERE DETECTED: DOCOSANOL (C22-OL), TRICOSANOL (C23-OL), TETRACOSANOL (C24-OL), PENTACOSANOL (C25-OL), HEXACOSANOL (C26-OL), HEPTACOSANOL (C27-OL) AND OCTACOSANOL (C28-OL). THE HIGHEST POLICOSANOL CONTENT WAS FOUND IN PRINCIPE BORGHESE 71.88 MG/KG. OCTACOSANOL WAS THE LINEAR ALCOHOL PRESENT IN HIGHEST QUANTITY, I.E. 38-42% OF THE TOTAL LINEAR ALCOHOLS DETECTED IN TOMATO SEED OILS (TSO). CHEMOMETRICS WAS APPLIED TO STUDY THE DIFFERENCES AMONG CULTIVARS. THE SUM OF EVEN LONG CHAINED FATTY ALCOHOLS WAS ALWAYS MORE THAN 95% OF THE TOTAL POLICOSANOL CONTENT. ONEWAY ANOVA AND PRINCIPAL COMPONENT ANALYSIS WELL DIFFERENTIATED THE THREE CULTIVARS. © 2015 BY JAPAN OIL CHEMISTS’ SOCIETY.","LINEAR FATTY ALCOHOLS; MINOR COMPONENTS; N-ALKANOLS; UNSAPONIFIABLE; VEGETABLE EDIBLE OIL","FATTY ALCOHOLS; LIQUID-LIQUID EXTRACTION; LYCOPERSICON ESCULENTUM; PLANT OILS; SEEDS; SPECIES SPECIFICITY; ALCOHOLS; FRUITS; OILS AND FATS; PLANTS (BOTANY); 1-OCTACOSANOL; FATTY ALCOHOL; POLICOSANOL; VEGETABLE OIL; EDIBLE OIL; FATTY ALCOHOLS; MINOR COMPONENTS; N-ALKANOLS; UNSAPONIFIABLE; CHEMISTRY; ISOLATION AND PURIFICATION; LIQUID LIQUID EXTRACTION; PLANT SEED; PROCEDURES; SPECIES DIFFERENCE; TOMATO; PRINCIPAL COMPONENT ANALYSIS","","","IRMARK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); KUNST L., SAMUELS L., PLANT CUTICLES SHINE: ADVANCES IN WAX BIOSYNTHESIS AND EXPORT, CURRENT OPIN. PLANT BIOL., 12, PP. 721-727, (2009); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (2005); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROTOINFLAMMATORY MEDIATOR, S. J. NUTR. BIOCHEM, 20, PP. 155-162, (2009); GROB K., GIUFFRE A.M., LEUZZI U., MINCIONE B., RECOGNITION OF ADULTERATED OILS BY DIRECT ANALYSIS OF THE MINOR COMPONENTS, FAT SCIENCE TECHNOL, 96, PP. 286-290, (1994); MARCELLETTI J.F., SYNERGISTIC INHIBITION OF HERPESVIRUS REPLICATION BY DOCOSANOL AND ANTIVIRAL NUCLEOSIDE ANALOGS, ANTIVIR. RES, 56, PP. 153-166, (2002); EL-GIBALY I., ABDEL-GHAFFAR S.K., EFFECT OF HEXACOSANOL ON THE CHARACTERISTICS OF NOVEL SUSTAINED-RELEASE ALLOPURINOL SOLID LIPOSPHERES (SLS): FACTORIAL DESIGN APPLICATION AND PRODUCT EVALUATION, INT. J. PHARM, 294, PP. 33-51, (2005); THIPPESWAMY G., SHEELA M.L., SALIMATH B.P., OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-BKAPPANB AND ITS DNA BINDING ACTIVITY, EUR. J. PHARMACOL, 588, PP. 141-150, (2008); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS, 43, PP. 109-115, (2008); TANTOS A., MESZAROS A., KISSIMON J., HORVATH G., FARKAS T., THE EFFECT OF TRIACONTANOL ON MICROPROPAGATION OF BALM, MELISSA OFFICINALIS L, PLANT CELL REP, 19, PP. 88-91, (1999); MUTHUCHELIAN K., BERTAMINI M., NEDUNCHEZHIAN N., TRIACONTANOL CAN PROTECT ERYTHRINA VARIEGATA FROM CADMIUM TOXICITY, J. PLANT PHYSIOL, 158, PP. 1487-1490, (2001); BAUMLER E.R., CRAPISTE G.H., CARELLI A.A., SUNFLOWER- OIL WAX REDUCTION BY SEED SOLVENT WASHING, J. AMER. OIL CHEM. SOC, 84, PP. 603-608, (2007); VICHI S., CORTES-FRANCISCO N., ROMERO A., CAIXACH J., DIRECT CHEMICAL PROFILING OF OLIVE (OLEA EUROPAEA)FRUIT EPICUTICULAR WAXES BY DIRECT ELECTROSPRAY-ULTRAHIGH RESOLUTION MASS SPECTROMETRY, J. MASS SPECTROM, (2015); KIM K.S., PARK S.H., JENKS M.A., CHANGES IN LEAF CUTICULAR WAXES OF SESAME (SESAMUM INDICUM L.)PLANTS EXPOSED TO WATER DEFICIT, J. PLANT PHYSIOL, 164, PP. 1134-1143, (2007); SHEPHERD T., ROBERTSON G.W., GRIFFITHS D.W., BIRCH A., EPICUTICULAR WAX ESTER AND TRIACYLGLYCEROL COMPOSITION IN RELATION TO APHID INFESTATION AND RESISTANCE IN RED RASPBERRY (RUBUS IDAEUS L.), PHYTOCHEMISTRY, 52, PP. 1255-1267, (1999); XIE S., CHEN F., WANG Z., WANG H., GU Y., HUANG Y., LIPID DISTRIBUTIONS IN LOESS-PALEOSOL SEQUENCES FROM NORTHWEST CHINA, ORG. GEOCHEM, 34, PP. 1071-1079, (2003); CINQUANTA L., ALBANESE D., FRATIANNI A., LA FIANZA G., DI MATTEO M., ANTIOXIDANT ACTIVITY AND SENSORY ATTRIBUTES OF TOMATOES DEHYDRATED BY COMBINATION OF MICROWAVE AND CONVECTIVE HEATING, AGRO FOOD IND. HI- TECH, 24, PP. 35-38, (2014); ALBANESE D., ADILETTA G., D'ACUNTO M., CINQUANTA L., DI MATTEO M., TOMATO PEEL DRYING AND CAROTENOIDS STABILITY OF THE EXTRACTS, INT. J. FOOD SCI. TECH, 49, PP. 2458-2463, (2014); RIGGI E., PATANE C., RUBERTO G., CONTENT OF CAROTENOIDS AT DIFFERENT RIPENING STAGES IN PROCESSING TOMATO IN RELATION TO SOIL WATER AVAILABILITY. AUSTR, J. AGRIC. RES, 59, PP. 348-353, (2008); ISLAM M.Z., KIM Y.S., HONG S.K., BAEK J.P., KIM I.S., KANG H.M., EFFECTS OF CULTURAL METHODS ON QUALITY AND POSTHARVEST PHYSIOLOGY OF CHERRY TOMATO, J. AGRIC. LIFE ENVIRON. SCI., 25, PP. 15-19, (2013); ALONSO A., GARCIA-ALIAGA R., GARCIA-MARTINEZ S., RUIZ J.J., CARBONELL-BARRACHINA A., A. CHARACTERIZATION OF SPANISH TOMATOES USING AROMA COMPOSITION AND DISCRIMINANT ANALYSIS, FOOD SCI. TECHNOL. INT, 15, PP. 47-55, (2009); SPAGNA G., TODARO A., PELUSO O., CATALANO A.E., BARABAGALLO R.N., EFFETTI DELL’ESSICCAMENTO SULL’ATTIVITÀ POLIFENOLOSSIDASICA E PATTERN ANTIOSSIDANTE DI POMODORO CILIEGINO, INDUSTRIE ALIMENTARI, 59, PP. 25-29, (2010); GIUFFR A., SICARI V., CAPOCASALE M., ZAPPIA C., PELLICANO T.M., POIANA M., PHYSICO-CHEMICAL PROPERTIES OF TOMATO SEED OI (L SOLANUM LYCOPERSICUM L.)FOR BIODIESEL PRODUCTION, ACTA HORT; GIUFFRE A.M., LOUADJ L., POIANA M., MACARIO A., COMPOSITION EN STÉROLS DES HUILES EXTRAITES D’OLIVES DE CULTIVARS DE LA PROVINCE DE REGGIO CALABRIA (SUD D’ITALIE), RIV. ITAL. SOSTANZE GRASSE, 89, PP. 177-183, (2012); GIUFFRE A.M., LOUADJ L., INFLUENCE OF CROP SEASON AND CULTIVAR ON STEROL COMPOSITION OF MONOVARIETAL OLIVE OILS IN REGGIO CALABRIA (ITALY). CZECH, J. FOOD SCI, 31, PP. 256-263, (2013); GIUFFRE A.M., ALCOLI ALIFATICI E TERPENICI IN OLIO DI OLIVA ESTRATTO DA CULTIVAR ALLEVATE IN CALABRIA, INDUSTRIE ALIMENTARI, 52, PP. 28-35, (2013); GIUFFRE A.M., EVOLUTION OF FATTY ALCOHOLS IN OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY)DURING FRUIT RIPENING, J. OLEO SCI, 63, PP. 486-496, (2014); GIUFFRE A.M., THE EFFECTS OF CULTIVAR AND HARVEST YEAR ON FATTY ALCOHOL COMPOSITION OF OLIVE OILS FROM SOUTH WEST CALABRIA (ITALY), GRASAS ACEITES, 65, (2014); GIUFFRE A.M., WAX ESTER VARIATION IN OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY)DURING OLIVE RIPENING, J. AM. OIL CHEM. SOC, 91, PP. 1355-1366, (2014); GIUFFRE A.M., INFLUENCE OF HARVEST YEAR AND CULTIVAR ON WAX COMPOSITION OF OLIVE OILS, EUR. J. LIPID SCI. TECHNOL, 115, PP. 549-555, (2013); GIUFFRE A.M., INFLUENCE OF CULTIVAR AND HARVEST YEAR ON TRIGLYCERIDE COMPOSITION OF OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY), EUR. J. LIPID SCI. TECHNOL, 115, PP. 928-934, (2013); GIUFFRE A.M., VARIATION IN TRIACYLGLYCEROLS OF OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY)DURING OLIVE RIP ENING, RIV. ITAL. SOSTANZE GRASSE; LAZOS E.S., TSAKNIS J., LALAS S., CHARACTERISTICS AND COMPOSITION OF TOMATO SEED OIL, GRASAS ACEITES, 9, PP. 440-445, (1998); BOTINESTEAN C., HADARUGA N.G., HADARUGA D.I., JIANU I., FATTY ACIDS COMPOSITION BY GAS CHROMATOGRAPHYMASS SPECTROMETRY (GC-MS)AND MOST IMPORTANT PHYSICAL- CHEMICALS PARAMETERS OF TOMATO SEED OIL, J. AGRO. PROC. TECHNOL, 18, PP. 89-94, (2012); POPE L.E., MARCELLETTI J.F., KATZ L.R., LIN J.Y., KATZ D.H., PARISH M.L., SPEAR P.G., THE ANTI-HERPES SIMPLEX VIRUS ACTIVITY OF N-DOCOSANOL INCLUDES INHIBITION OF THE VIRAL ENTRY PROCESS. ANTIVIR, RES, 40, PP. 85-94, (1998); GIUFFRE A.M., CHEMICAL COMPOSITION OF PURPLE PASSION FRUIT (PASSIFLORA EDULIS SIMS VAR. EDULIS)SEED OIL, RIV. ITAL. SOSTANZE GRASSE, 84, PP. 87-93, (2007); GARCIA-GONZALES D.L., TENA N., APARICIO R., DESCRIBING THE CHEMICAL SINGULARITY OF THE SPANISH PROTECTED DESIGNATIONS OF ORIGIN FOR VIRGIN OLIVE OILS IN RELATION TO OILS FROM NEIGHBOURING AREAS, GRASAS ACEITES, 63, PP. 26-34, (2012); KRICHENE D., ALLALOUT A., SALVADOR M.D., FREGAPANE G., ZARROUK M., FATTY ACIDS, VOLATILES, STEROLS AND TRITERPENIC ALCOHOLS OF SIX MONOVARIETAL TUNISIAN VIRGIN OLIVE OIL, EUR. J. LIPID SCI. TECHNOL, 112, PP. 400-409, (2010); ANASTASI U., SANTONOCETO C., GIUFFRE A.M., SORTINO M., GRESTA F., ABBATE V., YIELD PERFORMANCE AND GRAIN LIPID COMPOSITION OF STANDARD AND OLEIC SUNFLOWER AS AFFECTED BY WATER SUPPLY, FIELD CROP. RES, 119, PP. 145-153, (2010); SAITO M., KINOSHITA Y., SATOH I., SHINBORI C., KONO T., HANADA T., UEMASU J., SUZUKI H., YAMADA M., SATOH K., N-HEXACOSANOL AMELIORATES STREPTOZOTOCIN-INDUCED DIABETIC RAT NEPHROPATHY, EUR. J. PHARMACOL, 544, PP. 132-137, (2006); LAZZEZ A., PERRI E., CARAVITA M.A., KHLIF M., COSSENTINI M., INFLUENCE OF OLIVE MATURITY STAGE AND GEOGRAPHICAL ORIGIN ON SOME MINOR COMPONENTS IN VIRGIN OLIVE OIL OF THE CHEMLALI VARIETY, J. AGRIC. FOOD CHEM., 56, PP. 982-988, (2008); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOASONOL IN HUMAN HEALTH, NUTRITON, 9, PP. 192-195, (2003); EL ANTARI A., HILAL A., BOULOUHA B., EL MOUDNI A., INFLUENCE OF VARIETY, ENVIRONMENTAL AND CULTURAL TECHNIQUES ON THE CHARACTERISTICS OF OLIVE FRUITS AND THE CHEMICAL COMPOSITION OF EXTRA VIRGIN OLIVE OIL IN MOROCCO, OLIVAE, 80, PP. 29-36, (2000)","A.M. GIUFFRÈ; UNIVERSITÀ DEGLI STUDI ‘MEDITERRANEA’ DI REGGIO CALABRIA (ITALY), DIPARTIMENTO AGRARIA, ITALY; EMAIL: AMGIUFFRE@UNIRC.IT","JAPAN OIL CHEMISTS SOCIETY","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","2-S2.0-84930247470","J OLEO SCI","UNIVERSITÀ DEGLI STUDI ‘MEDITERRANEA’ DI REGGIO CALABRIA (ITALY);UNIVERSITÀ DEGLI STUDI ‘MEDITERRANEA’ DI REGGIO CALABRIA (ITALY)","NOTREPORTED;UNIVERSITÀ DEGLI STUDI ‘MEDITERRANEA’ DI REGGIO CALABRIA (ITALY);NOTREPORTED",NA,"GIUFFRÈ AM, 2015, J OLEO SCI","GIUFFRÈ AM, 2015, J OLEO SCI"
"ZHAO T;HA T;LEE J;KIM B;KIM I","ZHAO, TINGTING (55262017500); HA, TAE-YEOUL (12794595100); LEE, JUNSOO (36910863400); KIM, BYUNG HEE (55542498400); KIM, IN-HWAN (47161438300)","MODELING AND OPTIMIZATION OF LIPASECATALYZED ESTERIFICATION OF POLICOSANOLS WITH CONJUGATED LINOLEIC ACID BY RESPONSE SURFACE METHODOLOGY",2013,"BIOCATALYSIS AND BIOTRANSFORMATION","31","8",3,"10.3109/10242422.2013.777434","DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, JEONGNEUNG-DONG, SEONGBUK-GU, SEOUL, 136-703, SOUTH KOREA;KOREA FOOD RESEARCH INSTITUTE, SUNGNAM, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, CHUNGBUK NATIONAL UNIVERSITY, CHEONGJU, CHUNGBUK, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, CHUNG-ANG UNIVERSITY, ANSEONG, 456-756, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, JEONGNEUNG-DONG, SEONGBUK-GU, SEOUL, 136-703, SOUTH KOREA","THE AIM OF THIS STUDY WAS TO MODEL THE LIPASE-CATALYZED ESTERIFICATION OF POLICOSANOLS WITH CONJUGATED LINOLEIC ACID (CLA) IN A SOLVENT-FREE SYSTEM TO PRODUCE WAX ESTERS WHICH HAD A LOWER MELTING POINT THAN THAT OF THEIR CORRESPONDING POLICOSANOL FORMS AND TO OPTIMIZE THE REACTION CONDITIONS BY RESPONSE SURFACE METHODOLOGY (RSM). NOVOZYM 435 WAS SELECTED AS A SUITABLE BIOCATALYST FOR THE REACTION. THE MOLAR RATIO OF SUBSTRATES (POLICOSANOLS TO CLA) WAS 1:2. A WELL-FITTING QUADRATIC POLYNOMIAL REGRESSION MODEL FOR THE DEGREE OF ESTERIFICATION (DE) OF POLICOSANOLS WITH CLA WAS ESTABLISHED WITH REGARD TO TEMPERATURE (35-65°C), ENZYME LOADING (1-5% OF WEIGHT OF TOTAL SUBSTRATES), AND REACTION TIME (10-50 MIN). OPTIMAL REACTION CONDITIONS WERE 61.3°C FOR TEMPERATURE, 3.7% FOR ENZYME LOADING, AND 34.1 MIN FOR REACTION TIME, AND THE DE WAS ̃ 95 MOL% UNDER THESE CONDITIONS. THE POLICOSANOLS AND WAX ESTERS SYNTHESIZED UNDER OPTIMAL CONDITIONS HAD MELTING POINTS OF 79°C AND 57°C, RESPECTIVELY. © 2013 INFORMA UK, LTD.","CONJUGATED LINOLEIC ACID; NOVOZYM 435; POLICOSANOLS; RESPONSE SURFACE METHODOLOGY; WAX ESTER","ENZYMES; ESTERIFICATION; ESTERS; LOADING; MELTING POINT; OPTIMIZATION; REGRESSION ANALYSIS; SURFACE PROPERTIES; LINOLEIC ACID; POLICOSANOL; TRIACYLGLYCEROL LIPASE; CONJUGATED LINOLEIC ACID; NOVOZYM435; POLICOSANOLS; RESPONSE SURFACE METHODOLOGY; WAX ESTERS; ARTICLE; CATALYSIS; ESTERIFICATION; MELTING POINT; REACTION TIME; TEMPERATURE SENSITIVITY; LINOLEIC ACID","TECHNOLOGY DEVELOPMENT PROGRAM FOR AGRICULTURE AND FORESTRY MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, REPUBLIC OF KOREA","THIS WORK WAS SUPPORTED BY TECHNOLOGY DEVELOPMENT PROGRAM FOR AGRICULTURE AND FORESTRY MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, REPUBLIC OF KOREA.","ADHIKARI P., KEUM T.H., JAE N.P., CHOONG K.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, 15, PP. 5359-5362, (2006); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, 10, PP. 891-897, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); BLANKSON H., STAKKESTAD J.A., FAGERTUN H., THOM E., WADSTEIN J., GUDMUNDSEN O., CONJUGATED LINOLEIC ACID REDUCES BODY FAT MASS IN OVERWEIGHT AND OBESE HUMANS, JOURNAL OF NUTRITION, 130, 12, PP. 2943-2948, (2000); BOCCA C., BOZZO F., CANNITO S., COLOMBATTO S., MIGLIETTA A., CLA REDUCES BREAST CANCER CELL GROWTH AND INVASION THROUGH ERALPHA AND PI3K/AKT PATHWAYS, CHEM-BIOL INTERACT, 183, PP. 187-193, (2010); KIM B.H., AKOH C.C., MODELING AND OPTIMIZATION OF LIPASE-CATALYZED SYNTHESIS OF PHYTOSTERYL ESTERS OF OLEIC ACID BY RESPONSE SURFACE METHODOLOGY, FOOD CHEMISTRY, 102, 1, PP. 336-342, (2007); ERBELDINGER M., NI X., HALLING P.J., ENZYMATIC SYNTHESIS WITH MAINLY UNDISSOLVED SUBSTRATES AT VERY HIGH CONCENTRATIONS, ENZYME AND MICROBIAL TECHNOLOGY, 23, 1-2, PP. 141-148, (1998); FLINTOFF-DYE N.L., OMAYE S.T., ANTIOXIDANT EFFECTS OF CONJUGATED LINOLEIC ACID ISOMERS IN ISOLATED HUMAN LOW-DENSITY LIPOPROTEINS, NUTRITION RESEARCH, 25, 1, PP. 1-12, (2005); GARCIA H.S., KEOUGH K.J., ARCOS J.A., HILL JR. C.G., CONTINUOUS INTERESTERIFICATION OF BUTTEROIL AND CONJUGATED LINOLEIC ACID IN A TUBULAR REACTOR PACKED WITH AN IMMOBILIZED LIPASE, BIOTECHNOLOGY TECHNIQUES, 13, 6, PP. 369-373, (1999); GORRETA F., BERNASCONI R., GALLIANI G., SALMONA M., TACCONI M.T., BIANCHI R., WAX ESTERS OF N-3 POLYUNSATURATED FATTY ACIDS: A NEW STABLE FORMULATION AS A POTENTIAL FOOD SUPPLEMENT. 1-DIGESTION AND ABSORPTION IN RATS. LW T, FOOD SCI TECH, 35, PP. 458-465, (2002); GUNAWAN S., VALI S.R., JU Y.-H., PURIFICATION AND IDENTIFICATION OF RICE BRAN OIL FATTY ACID STERYL AND WAX ESTERS, JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 83, 5, PP. 449-456, (2006); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); HANSEN I.A., MEAD J.F., THE FATE OF DIETARY WAX ESTERS IN THE RAT, PROC SOC EXP BIOL MED, 120, PP. 527-532, (1965); KEUM T.H., JI E.K., WELLER C.L., POLICOSANOL CONTENTS AND COMPOSITIONS IN WAX-LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN, CEREAL CHEMISTRY, 82, 3, PP. 242-245, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, NUTR METAB, 39, PP. 279-284, (1995); KELLY G.S., CONJUGATED LINOLEIC ACID: A REVIEW, ALTERNATIVE MEDICINE REVIEW, 6, 4, PP. 367-382, (2001); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 36, 9, PP. 469-473, (1998); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); VALI S.R., JU Y.-H., KAIMAL T.N.B., CHERN Y.-T., A PROCESS FOR THE PREPARATION OF FOOD-GRADE RICE BRAN WAX AND THE DETERMINATION OF ITS COMPOSITION, JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 82, 1, PP. 57-64, (2005); VERSCHUREN P.M., NUGTEREN D.H., EVALUATION OF JOJOBA OIL AS A LOW-ENERGY FAT. 2. INTESTINAL TRANSIT TIME, STOMACH EMPTYING AND DIGESTIBILITY IN SHORT-TERM FEEDING STUDIES IN RATS, FOOD AND CHEMICAL TOXICOLOGY, 27, 1, PP. 45-48, (1989); WAHLE K.W.J., HEYS S.D., ROTONDO D., CONJUGATED LINOLEIC ACIDS: ARE THEY BENEFICIAL OR DETRIMENTAL TO HEALTH?, PROGRESS IN LIPID RESEARCH, 43, 6, PP. 553-587, (2004); YARON A., SAMOILOFF V., BENZIONI A., ABSORPTION AND DISTRIBUTION OF ORALLY ADMINISTERED JOJOBA WAX IN MICE, LIPIDS, 17, PP. 169-171, (1982)","I.-H. KIM; DEPARTMENT OF FOOD AND NUTRITION, KOREA UNIVERSITY, JEONGNEUNG-DONG, SEONGBUK-GU, SEOUL, 136-703, SOUTH KOREA; EMAIL: K610IN@KOREA.AC.KR","","ENGLISH","BIOCATAL. BIOTRANSFORM.","ARTICLE","ISI","2-S2.0-84876354362","BIOCATAL BIOTRANSFORM","KOREA UNIVERSITY;KOREA FOOD RESEARCH INSTITUTE;CHUNGBUK NATIONAL UNIVERSITY;CHUNG-ANG UNIVERSITY;KOREA UNIVERSITY","NOTREPORTED;KOREA UNIVERSITY;NOTREPORTED",NA,"ZHAO T, 2013, BIOCATAL BIOTRANSFORM","ZHAO T, 2013, BIOCATAL BIOTRANSFORM"
"ATTARD T;MCELROY C;REZENDE C;POLIKARPOV I;CLARK J;HUNT A","ATTARD, THOMAS M. (56149399500); MCELROY, C.ROB (56084371800); REZENDE, CAMILA A. (57039798100); POLIKARPOV, IGOR (7006220351); CLARK, JAMES H. (57218227445); HUNT, ANDREW J. (57219415406)","SUGARCANE WASTE AS A VALUABLE SOURCE OF LIPOPHILIC MOLECULES",2015,"INDUSTRIAL CROPS AND PRODUCTS","76","8",61,"10.1016/j.indcrop.2015.05.077","DEPARTMENT OF CHEMISTRY, UNIVERSITY OF YORK, HESLINGTON, YORK, YO10 5DD, UNITED KINGDOM;DEPARTMENT OF CHEMISTRY, UNIVERSITY OF YORK, HESLINGTON, YORK, YO10 5DD, UNITED KINGDOM;UNIVERSIDADE ESTADUAL DE CAMPINAS (UNICAMP), INSTITUTO DE QUÍMICA, PO BOX 6154, CAMPINAS, SP 13083-970, BRAZIL;TRABALHADOR SÃOCARLENSE, SÃO CARLOS, SP 400 13566-590, BRAZIL;DEPARTMENT OF CHEMISTRY, UNIVERSITY OF YORK, HESLINGTON, YORK, YO10 5DD, UNITED KINGDOM;DEPARTMENT OF CHEMISTRY, UNIVERSITY OF YORK, HESLINGTON, YORK, YO10 5DD, UNITED KINGDOM","EXTRACTION OF HIGH-VALUE PRODUCTS FROM AGRO-INDUSTRIAL WASTE IS AN IMPORTANT COMPONENT FOR THE DEVELOPMENT OF A SUSTAINABLE BIOECONOMY. IN THIS WORK, NATURAL WAX EXTRACTION WAS CARRIED OUT ON DIFFERENT TYPES OF SUGARCANE WASTE (RIND, LEAF AND BAGASSE) USING SUPERCRITICAL CO2 (SCCO2). SUBSTANTIAL QUANTITIES OF LONG-CHAIN ALDEHYDES AND N-POLICOSANOLS (NUTRACEUTICAL COMPOUNDS) WERE FOUND IN THE RIND (83% OF TOTAL COMPOSITION). INTERESTINGLY, THE WAX OBTAINED FROM THE LEAF RESIDUES VARIED FROM OTHER TYPES OF WAXES FROM SUGARCANE WASTE, WITH LOW ALDEHYDE AND N-POLICOSANOL CONTENTS (NORMALLY FOUND IN HIGH QUANTITIES) AND CONSIDERABLE AMOUNTS OF HIGH-VALUE TRITERPENOIDS (169±6MG/G WAX), WHICH HAVE WELL-KNOWN MEDICINAL PROPERTIES. THE USE OF SUGARCANE LEAF RESIDUES FOR THE EXTRACTION OF WAXES HAS NOT BEEN PREVIOUSLY CONSIDERED, THOUGH THE AMOUNT OF THESE RESIDUES INCREASED SIGNIFICANTLY AFTER THE SWITCH TO GREEN HARVESTING. SUGARCANE BAGASSE WAX SHOWED THE HIGHEST ESTER COMPOSITION (37±1.5MG/G OF WAX), WHICH CAN BE USEFUL IN A HOST OF APPLICATIONS, RANGING FROM COSMETICS TO HARD WAX POLISHES, LUBRICANTS, COATINGS AND PLASTICISERS. © 2015.","CARBON DIOXIDE; EXTRACTION; SUGARCANE; SUPERCRITICAL; WAX","","SEVENTH FRAMEWORK PROGRAMME, FP7, (251132); EUROPEAN COMMISSION, EC","WE GRATEFULLY ACKNOWLEDGE FUNDING THROUGH THE EUROPEAN COMMISSION’S DIRECTORATE-GENERAL FOR RESEARCH WITHIN THE 7TH FRAMEWORK PROGRAM (FP7/2007–2013) UNDER THE GRANT AGREEMENT NO. 251132 (SUNLIBB). ","AHRENS JUN E., INSULL JUN W., BLOMSTRAND R., HIRSCH J., TSALTAS T., PETERSON M., THE INFLUENCE OF DIETARY FATS ON SERUM-LIPID LEVELS IN MAN, LANCET, 269, PP. 943-953, (1957); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.-X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR. J. LIPID SCI. TECHNOL., 114, PP. 583-591, (2012); ATTARD T.M., THEEUWES E., GOMEZ L.D., JOHANSSON E., DIMITRIOU I., WRIGHT P.C., CLARK J.H., MCQUEEN-MASON S.J., HUNT A.J., SUPERCRITICAL EXTRACTION AS AN EFFECTIVE FIRST-STEP IN A MAIZE STOVER BIOREFINERY, RSC ADV., 5, PP. 43831-43838, (2015); AZMIR J., ZAIDUL I.S.M., RAHMAN M.M., SHARIF K.M., MOHAMED A., SAHENA F., JAHURUL M.H.A., GHAFOOR K., NORULAINI N.A.N., OMAR A.K.M., TECHNIQUES FOR EXTRACTION OF BIOACTIVE COMPOUNDS FROM PLANT MATERIALS: A REVIEW, J. FOOD ENG., 117, PP. 426-436, (2013); BAUDEL H.M., ZAROR C., DE ABREU C.A.M., IMPROVING THE VALUE OF SUGARCANE BAGASSE WASTES VIA INTEGRATED CHEMICAL PRODUCTION SYSTEMS: AN ENVIRONMENTALLY FRIENDLY APPROACH, IND. CROPS PROD., 21, PP. 309-315, (2005); BENJAMIN Y., CHENG H., GORGENS J.F., EVALUATION OF BAGASSE FROM DIFFERENT VARIETIES OF SUGARCANE BY DILUTE ACID PRETREATMENT AND ENZYMATIC HYDROLYSIS, IND. CROPS PROD., 51, PP. 7-18, (2013); BERGES R.R., WINDELER J., TRAMPISCH H.J., SENGE T., Β-SITOSTEROL STUDY, G., 1995. RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL OF Β-SITOSTEROL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, LANCET, 345, PP. 1529-1532, (1995); BERNARDO-GIL M.G., GRENHA J., SANTOS J., CARDOSO P., SUPERCRITICAL FLUID EXTRACTION AND CHARACTERISATION OF OIL FROM HAZELNUT, EUR. J. LIPID SCI. TECHNOL., 104, PP. 402-409, (2002); BRAAM L.A.J.L.M., KNAPEN M.H.J., GEUSENS P., BROUNS F., HAMULYAK K., GERICHHAUSEN M.J.W., VERMEER C., VITAMIN K1 SUPPLEMENTATION RETARDS BONE LOSS IN POSTMENOPAUSAL WOMEN BETWEEN 50 AND 60 YEARS OF AGE, CALCIF. TISSUE INT., 73, PP. 21-26, (2003); BRADFORD P.G., AWAD A.B., PHYTOSTEROLS AS ANTICANCER COMPOUNDS, MOL. NUTR. FOOD RES., 51, PP. 161-170, (2007); BRYCE T.A., MARTIN-SMITH M., OSSKE G., SCHREIBER K., SUBRAMANIAN G., STEROLS AND TRITERPENOIDS-XI: ISOLATION OF ARUNDOIN AND SAWAMILLETIN FROM CUBAN SUGAR CANE WAX, TETRAHEDRON, 23, PP. 1283-1296, (1967); CASTOLA V., MARONGIU B., BIGHELLI A., FLORIS C., LA A., CASANOVA J., EXTRACTIVES OF CORK (QUERCUS SUBER L.): CHEMICAL COMPOSITION OF DICHLOROMETHANE AND SUPERCRITICAL CO<SUB>2</SUB> EXTRACTS, IND. CROPS PROD., 21, PP. 65-69, (2005); CHINEN I., COMPOSITION CONTAINING HIGHER FATTY ACID DERIVATIVE AND FOODS AND DRINKS, (2006); DE LORGERIL M., RENAUD S., SALEN P., MONJAUD I., MAMELLE N., MARTIN J.L., GUIDOLLET J., TOUBOUL P., DELAYE J., MEDITERRANEAN ALPHA-LINOLENIC ACID-RICH DIET IN SECONDARY PREVENTION OF CORONARY HEART DISEASE, LANCET, 343, PP. 1454-1459, (1994); DE STEFANI E., BOFFETTA P., RONCO A.L., BRENNAN P., DENEO-PELLEGRINI H., CARZOGLIO J.C., MENDILAHARSU M., PLANT STEROLS AND RISK OF STOMACH CANCER: A CASE-CONTROL STUDY IN URUGUAY, NUTR. CANCER, 37, PP. 140-144, (2000); DESIMONE J.M., PRACTICAL APPROACHES TO GREEN SOLVENTS, SCIENCE, 297, PP. 799-803, (2002); DESWARTE F.E.I., CLARK J.H., HARDY J.J.E., ROSE P.M., THE FRACTIONATION OF VALUABLE WAX PRODUCTS FROM WHEAT STRAW USING CO2, GREEN CHEM., 8, PP. 39-42, (2006); DOBBS J.M., WONG J.M., LAHIERE R.J., JOHNSTON K.P., MODIFICATION OF SUPERCRITICAL FLUID PHASE BEHAVIOR USING POLAR COSOLVENTS, IND. ENG. CHEM. RES., 26, PP. 56-65, (1987); EGGLESTON G., KLICH M., ANTOINE A., BELTZ S., VIATOR R., BROWN AND GREEN SUGARCANE LEAVES AS POTENTIAL BIOMASS: HOW THEY DETERIORATE UNDER DRY AND WET STORAGE CONDITIONS, IND. CROPS PROD., 57, PP. 69-81, (2014); FRAME A., ANTI-BACTERIAL PLANT COMPOSITIONS, GOOGLE PATENTS, (2003); GILL I., VALIVETY R., POLYUNSATURATED FATTY ACIDS, PART 1: OCCURRENCE, BIOLOGICAL ACTIVITIES AND APPLICATIONS, TRENDS BIOTECHNOL., 15, PP. 401-409, (1997); GUNAWAN E.R., BASRI M., RAHMAN M.B.A., SALLEH A.B., RAHMAN R.N.Z.A., STUDY ON RESPONSE SURFACE METHODOLOGY (RSM) OF LIPASE-CATALYZED SYNTHESIS OF PALM-BASED WAX ESTER, ENZYME MICROB. TECHNOL., 37, PP. 739-744, (2005); HILL K., FATS AND OILS AS OLEOCHEMICAL RAW MATERIALS, PURE APPL. CHEM., 72, PP. 1255-1264, (2000); HORROBIN D.F., HUANG Y.S., THE ROLE OF LINOLEIC ACID AND ITS METABOLITES IN THE LOWERING OF PLASMA CHOLESTEROL AND THE PREVENTION OF CARDIOVASCULAR DISEASE, INT. J. CARDIOL., 17, PP. 241-255, (1987); KLINE GLOBAL WAX INDUSTRY 2010 : MARKET ANALYSIS AND OPPORTUNITIES, (2011); KLIPPEL K.F., HILTL D.M., SCHIPP B., A MULTICENTRIC, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL OF BETA-SITOSTEROL (PHYTOSTEROL) FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. GERMAN BPH-PHYTO STUDY GROUP, BR. J. UROL., 80, PP. 427-432, (1997); KUNST L., SAMUELS A.L., BIOSYNTHESIS AND SECRETION OF PLANT CUTICULAR WAX, PROG. LIPID RES., 42, PP. 51-80, (2003); LAMBERTON J., REDCLIFFE A., THE CHEMISTRY OF SUGAR-CANE WAX. I. THE NATURE OF SUGAR-CANE WAX, AUST. J. CHEM., 13, PP. 261-268, (1960); LAVARACK B.P., GRIFFIN G.J., RODMAN D., MEASURED KINETICS OF THE ACID-CATALYSED HYDROLYSIS OF SUGAR CANE BAGASSE TO PRODUCE XYLOSE, CATAL. TODAY, 63, PP. 257-265, (2000); MAJEED M., GANGADHARAN G.K., PRAKASH S., COMPOSITIONS AND METHODS CONTAINING HIGH PURITY FATTY ALCOHOL C24 TO C36 FOR COSMETIC APPLICATIONS, GOOGLE PATENTS, (2007); MARINANGELI C.P.F., JONES P.J.H., KASSIS A.N., ESKIN M.N.A., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR., 50, PP. 259-267, (2010); MCCANN S.E., FREUDENHEIM J.L., MARSHALL J.R., GRAHAM S., RISK OF HUMAN OVARIAN CANCER IS RELATED TO DIETARY INTAKE OF SELECTED NUTRIENTS, PHYTOCHEMICALS AND FOOD GROUPS, J. NUTR., 133, PP. 1937-1942, (2003); MCGINTY D., LETIZIA C.S., API A.M., FRAGRANCE MATERIAL REVIEW ON PHYTOL. FOOD AND CHEMICAL TOXICOLOGY 48, SUPPLEMENT, 3, PP. S59-S63, (2010); MOGHADASIAN M.H., FROHLICH J.J., EFFECTS OF DIETARY PHYTOSTEROLS ON CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS: CLINICAL AND EXPERIMENTAL EVIDENCE, AM. J. MED., 107, PP. 588-594, (1999); MOITEIRO C., JUSTINO F., TAVARES R., MARCELO-CURTO M.J., FLORENCIO M.H., NASCIMENTO M.S.J., PEDRO M., CERQUEIRA F., PINTO M.M.M., SYNTHETIC SECOFRIEDELANE AND FRIEDELANE DERIVATIVES AS INHIBITORS OF HUMAN LYMPHOCYTE PROLIFERATION AND GROWTH OF HUMAN CANCER CELL LINES IN VITRO, J. NAT. PROD., 64, PP. 1273-1277, (2001); MOITEIRO C., MANTA C., JUSTINO F., TAVARES R., CURTO M.J.M., PEDRO M., NASCIMENTO M.S.J., PINTO M., HEMISYNTHETIC SECOFRIEDELANE TRITERPENES WITH INHIBITORY ACTIVITY AGAINST THE GROWTH OF HUMAN TUMOR CELL LINES IN VITRO, J. NAT. PROD., 67, PP. 1193-1196, (2004); NAKAMURA M., NAKASUMI T., YOSHIZAWA T., MINAGAWA Y., ANALGESIC ANTI-INFLAMMATORY DRUG, GOOGLE PATENTS., (1997); NUISSIER G., BOURGEOIS P., GRIGNON-DUBOIS M., PARDON P., LESCURE M.H., COMPOSITION OF SUGARCANE WAXES IN RUM FACTORY WASTES, PHYTOCHEMISTRY, 61, PP. 721-726, (2002); PANDEY A., SOCCOL C.R., NIGAM P., SOCCOL V.T., BIOTECHNOLOGICAL POTENTIAL OF AGRO-INDUSTRIAL RESIDUES. I: SUGARCANE BAGASSE, BIORESOUR. TECHNOL., 74, PP. 69-80, (2000); PIMENTA M.D.A., FROLLINI E., LIGNIN: UTILIZATION AS A MACROMONOMER IN THE SYNTHESIS OF PHENOLIC TYPE RESINS, ANAIS ASSOCIAÇO BRASILEIRA DE QUÍMICA, 46, PP. 43-49, (1997); PIRES R.A.R., DA SILVA ESTIMA MARTINS S.P.A., DAS CHAGAS J.A.M., DOS REIS R.L.G., EXTRACTION AND PURIFICATION OF FRIEDELIN, GOOGLE PATENTS., (2009); PURCELL D.E., LEONARD G.J., O'SHEA M.G., KOKOT S., A CHEMOMETRICS INVESTIGATION OF SUGARCANE PLANT PROPERTIES BASED ON THE MOLECULAR COMPOSITION OF EPICUTICULAR WAX, CHEMOM. INTELL. LAB. SYST., 76, PP. 135-147, (2005); RITTER B., SCHULTE J., SCHULTE E., THIER H.-P., DETECTION OF COATING WAXES ON APPLES BY DIFFERENTIAL SCANNING CALORIMETRY, EUR. FOOD RES. TECHNOL., 212, PP. 603-607, (2001); ROCHA G.J.M., GONCALVES A.R., OLIVEIRA B.R., OLIVARES E.G., ROSSELL C.E.V., STEAM EXPLOSION PRETREATMENT REPRODUCTION AND ALKALINE DELIGNIFICATION REACTIONS PERFORMED ON A PILOT SCALE WITH SUGARCANE BAGASSE FOR BIOETHANOL PRODUCTION, IND. CROPS PROD., 35, PP. 274-279, (2012); RUTHERFORD R.S., VAN STADEN J., TOWARDS A RAPID NEAR-INFRARED TECHNIQUE FOR PREDICTION OF RESISTANCE TO SUGARCANE BORERELDANA SACCHARINA WALKER (LEPIDOPTERA: PYRALIDAE) USING STALK SURFACE WAX, J. CHEM. ECOL., 22, PP. 681-694, (1996); SCHAUMBURG H.H., SPENCER P.S., DEGENERATION IN CENTRAL AND PERIPHERAL NERVOUS SYSTEMS PRODUCED BY PURE N-HEXANE: AN EXPERIMENTAL STUDY, BRAIN: J. NEUROL., 99, PP. 183-192, (1976); SHEPHERD J., PACKARD C.J., PATSCH J.R., GOTTO A.M., TAUNTON O.D., EFFECTS OF DIETARY POLYUNSATURATED AND SATURATED FAT ON THE PROPERTIES OF HIGH DENSITY LIPOPROTEINS AND THE METABOLISM OF APOLIPOPROTEIN AI, J. CLIN. INVEST., 61, (1978); SHIMIZU H., ROSS R., BERNSTEIN L., YATANI R., HENDERSON B., MACK T., CANCERS OF THE PROSTATE AND BREAST AMONG JAPANESE AND WHITE IMMIGRANTS IN LOS ANGELES COUNTY, BR. J. CANCER, 63, PP. 963-966, (1991); SIN E.H.K., MARRIOTT R., HUNT A.J., CLARK J.H., IDENTIFICATION, QUANTIFICATION AND CHRASTIL MODELLING OF WHEAT STRAW WAX EXTRACTION USING SUPERCRITICAL CARBON DIOXIDE, C. R. CHIM., 17, PP. 293-300, (2014); SMITH R.M., MARTIN-SMITH M., TRITERPENE METHYL ETHERS IN LEAF WAXES OF SACCHARUM AND RELATED GENERA, PHYTOCHEMISTRY, 17, PP. 1307-1312, (1978); SUBRAMANIAM B., RAJEWSKI R.A., SNAVELY K., PHARMACEUTICAL PROCESSING WITH SUPERCRITICAL CARBON DIOXIDE, J. PHARM. SCI., 86, PP. 885-890, (1997); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR. REV., 61, PP. 376-383, (2003); WANG L., WELLER C.L., SCHLEGEL V.L., CARR T.P., CUPPETT S.L., COMPARISON OF SUPERCRITICAL CO2 AND HEXANE EXTRACTION OF LIPIDS FROM SORGHUM DISTILLERS GRAINS, EUR. J. LIPID SCI. TECHNOL., 109, PP. 567-574, (2007); ZHANG Y., WU X., YU Z., ZHU Y.L., CHEN L., LOU S., COMPOSITION CONTAINING TOTAL TRITERPENOID SAPONINS EXTRACTED FROM BAMBOO, AND THE PREPARATION METHOD AND USE THEREOF, GOOGLE PATENTS, (2006); ZUURBIER P., VAN DE VOOREN J., SUGARCANE ETHANOL: CONTRIBUTIONS TO CLIMATE CHANGE MITIGATION AND THE ENVIRONMENT, (2008)","","ELSEVIER","ENGLISH","IND. CROPS PROD.","ARTICLE","ISI","2-S2.0-84934289458","IND CROPS PROD",NA,"NOTREPORTED",NA,"ATTARD TM, 2015, IND CROPS PROD","ATTARD TM, 2015, IND CROPS PROD"
"MARTINO F;PUDDU P;PANNARALE G;COLANTONI C;MARTINO E;NIGLIO T;ZANONI C;BARILLÀ F","MARTINO, FRANCESCO (7006704655); PUDDU, PAOLO EMILIO (7101784080); PANNARALE, GIUSEPPE (7004145547); COLANTONI, CHIARA (55503589800); MARTINO, ELIANA (7102176844); NIGLIO, TARCISIO (8932659400); ZANONI, CRISTINA (24781396500); BARILLÀ, FRANCESCO (7003852030)","LOW DOSE CHROMIUMPOLYNICOTINATE OR POLICOSANOL IS EFFECTIVE IN HYPERCHOLESTEROLEMIC CHILDREN ONLY IN COMBINATION WITH GLUCOMANNAN",2013,"ATHEROSCLEROSIS","228","4",27,"10.1016/j.atherosclerosis.2013.02.005","LIPID RESEARCH, DIPARTIMENTO DI PEDIATRIA E NEUROPSICHIATRIA INFANTILE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;LIPID RESEARCH, DIPARTIMENTO DI PEDIATRIA E NEUROPSICHIATRIA INFANTILE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;LIPID RESEARCH, DIPARTIMENTO DI PEDIATRIA E NEUROPSICHIATRIA INFANTILE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;ISTITUTO SUPERIORE DI SANITÀ, ROME, ITALY;LIPID RESEARCH, DIPARTIMENTO DI PEDIATRIA E NEUROPSICHIATRIA INFANTILE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY","OBJECTIVE: A LOW-FAT, FIBER-RICH DIET IS THE FIRST STEP IN THE MANAGEMENT FOR HYPERCHOLESTEROLEMIC CHILDREN. GLUCOMANNAN (GM) IS A NATURAL FIBER THAT HAS BEEN DEMONSTRATED TO LOWER TOTAL AND LDL-CHOLESTEROL. THE USE OF HIGH-DOSE CHROMIUM-POLYNICOTINATE (CP) AND POLICOSANOL (PC) HAS ALSO SHOWN CHOLESTEROL-LOWERING BENEFITS. WE AIMED AT INVESTIGATING THE EFFECTS OF LOW-DOSE CP OR PC AND THEIR GM COMBINATION IN HYPERCHOLESTEROLEMIC CHILDREN. METHODS: A DOUBLE-BLIND TRIAL WAS CONDUCTED IN 120 CHILDREN (60 M, 60 F, 9 ± 4 YEARS, MEDIAN 9.6 YEARS, RANGE: 3-16 YEARS) RANDOMLY ASSIGNED TO 5 NEUTRACEUTICAL AND 1 PLACEBO (ONLY RESISTANT STARCH) 8-WEEK TREATMENT GROUPS. FASTING BLOOD GLUCOSE (FBG), TOTAL CHOLESTEROL (CHOLT), TRIGLYCERIDES (TG), HDL AND LDL CHOLESTEROL WERE CONSIDERED. RESULTS: GM COMBINATION OF LOW-DOSE CP OR PC REDUCED CHOLT AND LDL WITHOUT CHANGING HDL, TG AND FBG. THE HIGHEST POST-TREATMENT CHANGES WERE SEEN AFTER GM COMBINATION WITH CP (CHOLT 85 ± 3% AND LDL 85 ± 5%, OF PRETREATMENT) WHICH WAS SIGNIFICANTLY (P < 0.01) LESS THAN WITH LOW-DOSE CP OR PC AND STARCH. WHEN GM WAS ASSOCIATED WITH STARCH, THERE WAS NO LIPID LOWERING EFFECT, WHICH WAS AN UNEXPECTED FINDING AS COMPARED TO PREVIOUS DATA WITH GM AND NO STARCH. NO ADVERSE EFFECTS WERE REPORTED. CONCLUSION: THIS IS THE FIRST REPORT TO SHOW THE CHOLESTEROL-LOWERING EFFICACY OF GM COMBINED TREATMENT WITH LOW-DOSE CP OR PC. FURTHER STUDIES ARE NEEDED TO INVESTIGATE THE BEST COMBINATIONS AND DOSES OF NUTRACEUTICS TO BE ADDED TO THE STANDARD GM TREATMENT. THE POTENTIAL NEGATIVE ASSOCIATION OF GM AND NUTRACEUTICS WITH STARCH IS CLEARLY SHOWN. © 2013 ELSEVIER IRELAND LTD.","CHILDREN; CHOLESTEROL; CHROMIUM-POLINICOTINATE; GLUCOMANNAN; LIPIDS; POLICOSANOL","ADOLESCENT; ATHEROSCLEROSIS; BLOOD GLUCOSE; CATHARTICS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MANNANS; NICOTINIC ACIDS; TRIGLYCERIDES; CHOLESTEROL; CHROMIUM DERIVATIVE; CHROMIUM POLYNICOTINATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD","","","STARY H.C., CHANDLER A.B., DINSMORE R.E., ET AL., A DEFINITION OF ADVANCED TYPES OF ATHEROSCLEROTIC LESIONS AND A HISTOLOGICAL CLASSIFICATION OF ATHEROSCLEROSIS. A REPORT FROM THE COMMITTEE ON VASCULAR LESIONS OF THE COUNCIL ON ARTERIOSCLEROSIS, AMERICAN HEART ASSOCIATION, CIRCULATION, 92, PP. 1355-1374, (1995); FRONTINI M.G., SRINIVASAN S.R., XU J., TANG R., BOND M.G., BERENSON G.S., USEFULNESS OF CHILDHOOD NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS VERSUS OTHER LIPOPROTEIN MEASURES IN PREDICTING ADULT SUBCLINICAL ATHEROSCLEROSIS: THE BOGALUSA HEART STUDY, PEDIATRICS, 121, PP. 924-929, (2008); JOUNALA M., VIIKARI J.S.A., RONNEMAA T., ET AL., ASSOCIATIONS OF DYSLIPIDEMIAS FROM CHILDHOOD TO ADULTHOOD WITH CAROTID INTIMA-MEDIA THICKNESS, ELASTICITY, AND BRACHIAL FLOW-MEDIATED DILATATION IN ADULTHOOD: THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY, ARTERIOSCLER THROMB VASC BIOL, 28, PP. 1012-1017, (2008); MARTINO F., LOFFREDO L., CARNEVALE R., ET AL., OXIDATIVE STRESS IS ASSOCIATED WITH ARTERIAL DYSFUNCTION AND ENHANCED INTIMA-MEDIA THICKNESS IN CHILDREN WITH HYPERCHOLESTEROLEMIA: THE POTENTIAL ROLE OF NICOTINAMIDE-ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE, PEDIATRICS, 122, (2008); MCNEAL C.J., DAJANI T., WILSON D., CASSIDY-BUSHROW A.E., DICKERSON B., HYPERCHOLESTEROLEMIA IN YOUTH: OPPORTUNITIES AND OBSTACLES TO PREVENT PREMATURE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 12, PP. 20-28, (2010); DANIELS S.R., GREER F.R., LIPID SCREENING AND CARDIOVASCULAR HEALTH IN CHILDHOOD, PEDIATRICS, 122, PP. 198-208, (2008); MARTINO F., PUDDU P.E., PANNARALE G., ET AL., ARTERIAL BLOOD PRESSURE AND SERUM LIPIDS IN A POPULATION OF CHILDREN AND ADOLESCENTS FROM SOUTHERN ITALY: THE CALABRIAN SIERRAS COMMUNITY STUDY (CSCS), INT J CARDIOL, (2012); CHOLESTEROL IN CHILDHOOD, (2011); HASKELL W.L., SPILLER G.A., JENSEN C.D., ELLIS B.K., GATES J.E., ROLE OF WATER-SOLUBLE DIETARY FIBER IN THE MANAGEMENT OF ELEVATED PLASMA CHOLESTEROL IN HEALTHY SUBJECTS, AM J CARDIOL, 69, (1992); JENKINS D.J.A., KENDALL C.W.C., VUKSAN V., VISCOUS FIBERS, HEALTH CLAIMS, AND STRATEGIES TO REDUCE CARDIOVASCULAR DISEASE RISK, AM J CLIN NUTR, 71, (2000); ARVILL A., BODIN L., EFFECT OF SHORT-TERM INGESTION OF KONJAC GLUCOMANNAN ON SERUM CHOLESTEROL IN HEALTHY MEN, AM J CLIN NUTR, 61, PP. 585-659, (1995); CHEN H.L., SHEU W.H., TAI T.S., LIAW Y.P., CHEN Y.C., KONJAC SUPPLEMENT ALLEVIATED HYPERCHOLESTEROLEMIA AND HYPERGLYCEMIA IN TYPE 2 DIABETIC SUBJECTS - A RANDOMIZED DOUBLE-BLIND TRIAL, J AM COLL NUTR, 22, PP. 36-42, (2003); MARTINO F., MARTINO E., MORRONE F., CARNEVALI E., FORCONE R., NIGLIO T., EFFECT OF DIETARY SUPPLEMENTATION WITH GLUCOMANNAN ON PLASMA TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC CHILDREN, NUTR METAB CARDIOVASC DIS, 15, PP. 174-180, (2005); SOOD N., BAKER W.L., COLEMAN C.I., EFFECT OF GLUCOMANNAN ON PLASMA LIPID AND GLUCOSE CONCENTRATIONS, BODY WEIGHT, AND BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 88, PP. 1167-1175, (2008); VIOLI F., INTRODUCTION TO NUTRACEUTICALS SPECIAL ISSUE, CARDIOVASC THER, 128, PP. 185-186, (2010); VUKSAN V., SIEVENPIPER J.L., OWEN R., ET AL., BENEFICIAL EFFECTS OF VISCOUS DIETARY FIBER FROM KONJAC-MANNAN IN SUBJECTS WITH THE INSULIN RESISTANCE SYNDROME, DIABETES CARE, 23, (2000); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); PREUSS H.G., WALLERSTEDT D., TALPUR N., ET AL., EFFECTS OF NIACIN-BOUND CHROMIUM AND GRAPE SEED PROANTHOCYANIDIN EXTRACT ON THE LIPID PROFILE OF HYPERCHOLESTEROLEMIC SUBJECTS: A PILOT STUDY, J MED, 31, PP. 227-246, (2000); STEARNS D.M., WISE J.P., PATIERNO S.R., WETTERHAHN K.E., CHROMIUM (III) PICOLINATE PRODUCES CHROMOSOME DAMAGE IN CHINESE HAMSTER OVARY CELLS, FASEB J, 9, PP. 1643-1648, (1995); CERULLI J., GRABE D.W., GAUTHIER I., MALONE M., MCGOLDRICK M.D., CHROMIUM PICOLINATE TOXICITY, ANN PHARMACOTHER, 32, PP. 428-431, (1998); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); BROWN W.H., POON T., INTRODUCTION TO ORGANIC CHEMISTRY, (2005); ROBERTSON M.D., WRIGHT J.W., LOIZON E., ET AL., INSULIN-SENSITIZING EFFECTS ON MUSCLE AND ADIPOSE TISSUE AFTER DIETARY FIBER INTAKE IN MEN AND WOMEN WITH METABOLIC SYNDROME, J CLIN ENDOCRINOL METAB, 97, PP. 3326-3332, (2012); PACIFICO L., ANANIA C., MARTINO F., ET AL., MANAGEMENT OF METABOLIC SYNDROME IN CHILDREN AND ADOLESCENTS, NUTR METAB CARDIOVASC DIS, 21, PP. 455-466, (2011); DAVIDSON M.H., A SYSTEMATIC REVIEW OF BILE ACID SEQUESTRANT THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, J CLIN LIPIDOL, 5, PP. 76-81, (2011); AMUNDSEN A.L., NTANIOS F., PUT N., OSE L., LONG-TERM COMPLIANCE AND CHANGES IN PLASMA LIPIDS, PLANT STEROLS AND CAROTENOIDS IN CHILDREN AND PARENTS WITH FH CONSUMING PLANT STEROL ESTER-ENRICHED SPREAD, EUR J CLIN NUTR, 58, PP. 1612-1620, (2004); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF RED YEAST RICE EXTRACT PLUS POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); CARNEVALE R., LOFFREDO L., PIGNATELLI P., ET AL., DARK CHOCOLATE INHIBITS PLATELET ISOPROSTANES VIA NOX2 DOWN-REGULATION IN SMOKERS, J THROMB HAEMOST, 10, PP. 125-132, (2012)","P.E. PUDDU; LABORATORY OF BIOTECHNOLOGIES APPLIED TO CARDIOVASCULAR MEDICINE, DEPARTMENT OF CARDIOVASCULAR, RESPIRATORY, NEPHROLOGICAL, ANESTHESIOLOGICAL AND GERIATRICAL SCIENCES, SAPIENZA, UNIVERSITY OF ROME, ROMA 00161, VIALE DEL POLICLINICO 155, ITALY; EMAIL: PAOLOEMILIO.PUDDU@UNIROMA1.IT","","ENGLISH","ATHEROSCLEROSIS","ARTICLE","ISI","2-S2.0-84876801187","ATHEROSCLEROSIS","SAPIENZA UNIVERSITÀ DI ROMA;SAPIENZA UNIVERSITÀ DI ROMA;SAPIENZA UNIVERSITÀ DI ROMA;SAPIENZA UNIVERSITÀ DI ROMA;SAPIENZA UNIVERSITÀ DI ROMA;ISTITUTO SUPERIORE DI SANITÀ;SAPIENZA UNIVERSITÀ DI ROMA;SAPIENZA UNIVERSITÀ DI ROMA","NOTREPORTED;UNIVERSITY OF ROME;NOTREPORTED",NA,"MARTINO F, 2013, ATHEROSCLEROSIS","MARTINO F, 2013, ATHEROSCLEROSIS"
"GENTILE M;CALCATERRA I;STRAZZULLO A;PAGANO C;PACIONI D;SPERANZA E;RUBBA P;MAROTTA G","GENTILE, MARCO (7101638352); CALCATERRA, ILENIA (56586261800); STRAZZULLO, ALFONSO (36062073800); PAGANO, CARMEN (57006380400); PACIONI, DELIA (57200871268); SPERANZA, ENZA (55295587400); RUBBA, PAOLO (7006211983); MAROTTA, GENNARO (7005943638)","EFFECTS OF ARMOLIPID PLUS ON SMALL DENSE LDL PARTICLES IN A SAMPLE OF PATIENTS AFFECTED BY FAMILIAL COMBINED HYPERLIPIDEMIA",2015,"CLINICAL LIPIDOLOGY","10","5",14,"10.2217/clp.15.37","DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY;DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY","AIM: THE AIM OF THIS STUDY WAS TO TEST SMALL DENSE LDL CHANGES WITH ARMOLIPID PLUS TREATMENT IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA (FCHL). METHODS: AFTER 4 WEEKS, 30 PATIENTS WITH FCHL WERE INCLUDED IN AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY AND WERE TAKING, IN ADDITION TO THE STANDARD DIET, EITHER PLACEBO OR ARMOLIPID PLUS. RESULTS: THE PLACEBO GROUP SHOWED NO STATISTICALLY SIGNIFICANT DIFFERENCES IN THE STUDIED PARAMETERS; INSTEAD, IN THE ARMOLIPID PLUS GROUP, STATISTICALLY SIGNIFICANT REDUCTION DIFFERENCES WERE DETECTED IN BMI (P = 0.010), LDL SCORE (P = 0.035) AND AN INCREASE IN MEAN LDL PARTICLE DIAMETER (P = 0.040). CONCLUSION: THE COMBINATION OF A STANDARD DIET WITH ARMOLIPID PLUS IS ABLE TO REDUCE LDL SCORE AND INCREASE LDL PARTICLE DIAMETER IN A GROUP OF FCHL AFTER 8 WEEKS OF TREATMENT. © 2015 FUTURE MEDICINE LTD.","ARMOLIPID PLUS; FAMILIAL COMBINED HYPERLIPIDEMIA; SMALL DENSE LDL","ANTILIPEMIC AGENT; ASTAXANTHIN; BERBERINE; FOLIC ACID; LOW DENSITY LIPOPROTEIN; NUTRACEUTICAL; PLACEBO; POLICOSANOL; SMALL DENSE LOW DENSITY LIPOPROTEIN; UBIDECARENONE; UNCLASSIFIED DRUG; XUEZHIKANG; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; LOW DENSITY LIPOPROTEIN SCORE; MALE; MEAN LOW DENSITY LIPOPROTEIN PARTICLE DIAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE","","","VAN GREEVENBROEK M.M., STALENHOEF A.F., DE GRAAF J., BROUWERS M.C., FAMILIAL COMBINED HYPERLIPIDEMIA: FROM MOLECULAR INSIGHTS TO TAILORED THERAPY, CURR. OPIN. LIPIDOL., 25, PP. 176-182, (2014); HOPKINS P.N., HEISS G., ELLISON R.C., ET AL., CORONARY ARTERY DISEASE RISK IN FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA: A CASE-CONTROL COMPARISON FROM THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE FAMILY HEART ST UDY, CIRCULATION, 108, PP. 519-523, (2003); PAUCIULLO P., GENTILE M., MAROTTA G., ET AL., SMALL DENSE LOW-DENSITY LIPOPROTEIN IN FAMILIAL COMBINED HYPERLIPIDEMIA: INDEPENDENT OF METABOLIC SYNDROME AND RELATED TO HISTORY OF CARDIOVASCULAR EVENTS, ATHEROSCLEROSIS, 203, PP. 320-324, (2009); MYKKANEN L., KUUSISTO J., HAFFNER S.M., LAAKSO M., AUSTIN M.A., LDL SIZE AND RISK OF CORONARY HEART DISEASE IN ELDERLY MEN AND WOMEN, ARTERIOSCLER. THROMB. VASC. BIOL., 19, PP. 2742-2748, (1999); AUSTIN M.A., BRESLOW J.L., HENNEKENS C.H., BURING J.E., WILLETT W.C., KRAUSS R.M., LOW-DENSITY LIPOPROTEIN SUBCLASS PATTERNS AND RISK OF MYOCARDIAL INFARCTION, JAMA, 260, PP. 1917-1921, (1988); AUSTIN M.A., KING M.C., VRANIZAN K.M., KRAUSS R.M., ATHEROGENIC LIPOPROTEIN PHENOTYPE. A PROPOSED GENETIC MARKER FOR CORONARY HEART DISEASE RISK, CIRCULATION, 82, PP. 495-506, (1990); WAHRBURG U., ASSMANN G., PROPERTIES OF OLIVE OIL, LANCET, 357, (2001); DAVIDSON M.H., KONG J.C., DRENNAN K.B., STORY K., ANDERSON G.H., EFFCACY OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP I DIET. A RANDOMIZED TRIAL INCORPORATING QUICK-SERVICE FOODS, ARCH. ITERN. MED., 156, PP. 305-312, (1996); RUSCICA M., GOMARASCHI M., MOMBELLI G., ET AL., NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK: RESULTS OF A RANDOMIZED, DOUBLE-BLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS, J. CLIN. LIPIDOL., 8, PP. 61-68, (2014); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFCANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART. J., 143, PP. 356-365, (2002); GADDI A., GALETTI C., PAUCIULLO P., ARCA M., FAMILIAL COMBINED HYPERLIPOPROTEINEMIA: EXPERTS PANEL POSITION ON DIAGNOSTIC CRITERIA FOR CLINICAL PRACTICE, NUTR. METAB. CARDIOVASC. DIS., 9, PP. 304-311, (1999); SIEDEL J., SCHLUMBERGER H., KLOSE S., ZIEGENHORN J., WAHLEFELD A.W., IMPROVED REAGENT FOR ENZYMATIC DETERMINATION OF SERUM CHOLESTEROL, J. CLIN. CHEM. BIOCHEM., 19, PP. 838-839, (1981); WAHLEFELD A.W., TRIGLYCERIDE DETERMINATION AFTER ENZYMATIC HYDROLYSIS, METHODS OF ENZYMATIC ANALYSIS, VOLUME 4 (2ND EDITION), (1974); LOPES-VIRELLA M.F., STONE P., ELLIS S., COLWELL J.A., CHOLESTEROL DETERMINATION IN HIGH-DENSITY LIPOPROTEINS SEPARATED BY THREE DIFFERENT METHODS, CLIN. CHEM., 23, PP. 882-884, (1977); HOEFNER D.M., HODEL S.D., O'BRIEN J.F., ET AL., DEVELOPMENT OF A RAPID, QUANTITATIVE METHOD FOR LDL SUBFRACTIONATION WITH USE OF THE QUANTIMETRIX LIPOPRINT LDL SYSTEM, CLIN. CHEM., 47, PP. 266-274, (2001); GENTILE M., PANICO S., MATTIELLO A., ET AL., ASSOCIATION BETWEEN SMALL DENSE LDL AND EARLY ATHEROSCLEROSIS IN A SAMPLE OF MENOPAUSAL WOMEN, CLIN. CHIM. ACTA, 426, PP. 1-5, (2013); KRAUSS R.M., BURKE D.J., IDENTIFCATION OF MULTIPLE SUBCLASSES OF PLASMA LOW-DENSITY LIPOPROTEINS IN NORMAL HUMANS, J. LIPID RES., 23, PP. 97-104, (1982); AUSTIN M.A., HOKANSON J.E., BRUNZELL J.D., CHARACTERIZATION OF LOW-DENSITY LIPOPROTEIN SUBCLASSES: METHODOLOGIC APPROACHES AND CLINICAL RELEVANCE, CURR. OPIN. LIPIDOL., 5, PP. 395-403, (1994); GARDNER C.D., FORTMANN S.P., KRAUSS R.M., ASSOCIATION OF SMALL LOW-DENSITY LIPOPROTEIN PARTICLES WITH THE INCIDENCE OF CORONARY ARTERY DISEASE IN MEN AND WOMEN, JAMA, 276, PP. 875-881, (1996); CAMPOS H., BLIJLEVENS E., MCNAMARA J.R., ET AL., LDL PARTICLE SIZE DISTRIBUTION RESULTS FROM THE FRAMINGHAM OFFSPRING STUDY, ARTERIOSCLER. THROMB., 12, PP. 1410-1419, (1992); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST RICE DIETARY SUPPLEMENT, AM. J. CLIN. NUTR., 69, PP. 231-236, (1999); LEE S., LIM H.J., PARK J.H., LEE K.S., JANG Y., PARK H.Y., BERBERINE INDUCED LDLR UPREGULATION INVOLVES JNK PATHWAY, BIOCHEM. BIOPHYS. RES. COMMUN., 362, PP. 853-857, (2007); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROLLOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT. MED., 10, PP. 1344-1351, (2004); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN. MED. REV., 7, PP. 203-217, (2002); MANNARINO M.R., MINISTRINI S., PIRRO M., NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, EUR. J. INTERN. MED., 25, PP. 592-599, (2014); TAPPIA P.S., XU Y.J., DHALLA N.S., REDUCTION OF CHOLESTEROL AND OTHER CARDIOVASCULAR DISEASE RISK FACTORS BY ALTERNATIVE THERAPIES, CLIN. LIPIDOL., 8, PP. 345-359, (2013); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYP ERCHOLESTEROLE MIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-L OWE RING TREATMENT, LIPIDS HEALTH DIS., 11, (2012); LEE Y.S., KIM W.S., KIM K.H., ET AL., BERBERINE, A NATURAL PLANT PRODUCT, ACTIVATES AMP-ACTIVATED PROTEIN KINASE WITH BENEFCIAL METABOLIC EFFECTS IN DIABETIC AND INSULIN-RESISTANT STATES, DIABETES, 55, PP. 2256-2256, (2006)","M. GENTILE; DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA, UNIVERSITÀ FEDERICO II DI NAPOLI, NAPOLI, ITALY; EMAIL: MARGENTI@UNINA.IT","FUTURE MEDICINE LTD.","ENGLISH","CLINICAL LIPIDOLOGY","ARTICLE","ISI","2-S2.0-84950141466","CLINICAL LIPIDOLOGY","UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI;UNIVERSITÀ FEDERICO II DI NAPOLI","NOTREPORTED;UNIVERSITÀ FEDERICO II DI NAPOLI;NOTREPORTED",NA,"GENTILE M, 2015, CLINICAL LIPIDOLOGY","GENTILE M, 2015, CLINICAL LIPIDOLOGY"
"WYSOCKA A;CYBULSKI M;BERBEĆ H;WYSOKIŃSKI A;STAZKA J;ZAPOLSKI T","WYSOCKA, ANNA (55582161200); CYBULSKI, MAREK (6701685189); BERBEĆ, HENRYK (6603708493); WYSOKIŃSKI, ANDRZEJ (7006717063); STAZKA, JANUSZ (6601966995); ZAPOLSKI, TOMASZ (6701915682)","PROGNOSTIC VALUE OF PARAOXONASE 1 IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY",2014,"MEDICAL SCIENCE MONITOR","20","6",14,"10.12659/MSM.890025","DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND;DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND;DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND;DEPARTMENT OF CARDIOSURGERY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND;DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND","BACKGROUND: THE AIM OF THIS STUDY WAS TO EVALUATE WHETHER -108C/T POLYMORPHISM OF THE PARAOXONASE 1 (PON1) GENE AND THE PLASMA ENZYME ACTIVITY ARE RISK FACTORS FOR ADVERSE CARDIAC EVENTS AFTER CORONARY ARTERY BYPASS GRAFTING (CABG). MATERIAL/METHODS: SEVENTY-ONE PATIENTS WITH CORONARY HEART DISEASE (CHD) UNDERGOING CABG WERE ENROLLED IN THE STUDY. GENOMIC DNA WAS EXTRACTED FROM THE VENOUS BLOOD USING THE GEN ELUTE™ BLOOD GENOMIC DNA KIT (SIGMA) ACCORDING TO THE MANUFACTURER'S INSTRUCTIONS. PON1 ACTIVITY WAS MEASURED IN 50 MM GLYCINE/NAOH BUFFER (PH 10.5) CONTAINING 1.0 MM PARAOXON, AND 1.0MM CACL2. RESULTS: THE MEAN PON1 ACTIVITY TOWARD PARAOXON AND TOWARD PHENYL ACETATE WAS EQUAL (166.5±86.9 U/ML AND 96.0±47.2 U/ML, RESPECTIVELY) IN PATIENTS WITH CHD. THE -108C/T POLYMORPHISM OF PON1 GENE WAS TESTED. IN CABG PATIENTS, PON1 ACTIVITIES IN DEPENDENCE ON GENOTYPES WERE SIGNIFICANTLY DIFFERENT AND EQUALLED 266.2±117.9 U/ML FOR CC, 178.8±64.7 U/ML FOR CT, AND 98.9±59.2 U/ML FOR TT GENOTYPE. PATIENTS WITH PON1 ACTIVITY LOWER THAN 193.5 U/ML EXHIBITED SIGNIFICANTLY INCREASED RISK OF A SERIOUS CARDIAC EVENT IN COMPARISON WITH PATIENTS WITH PON1 ACTIVITY HIGHER OR EQUAL TO THIS VALUE (P=0.03). ADDITIONALLY, TT GENOTYPE WAS SIGNIFICANTLY ASSOCIATED WITH SHORTER TIME OF EVENT-FREE SURVIVAL IN COMPARISON WITH CT AND CC GENOTYPES (P=0.009). CONCLUSIONS: THE PON1 POLYMORPHISM AND ENZYME PLASMA ACTIVITY ARE ASSOCIATED WITH CHD OCCURRENCE. HIGH PON1 ACTIVITY CONNECTED WITH THE PRESENCE OF CC AND CT GENOTYPES DECREASES THE RECURRENCE OF SYMPTOMS OF CORONARY HEART DISEASE AND IMPROVE PROGNOSIS AFTER CABG. © MED SCI MONIT, 2014.","ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE","ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY BYPASS; CORONARY DISEASE; DEMOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROMOTER REGIONS, GENETIC; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PHENYLACETIC ACID; TRIACYLGLYCEROL; BERBERINE; CYTOCHROME P450 3A4; GAMMA ORYZANOL; LIVER ENZYME; MONACOLIN L; NUTRACEUTICAL; POLICOSANOL; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CORONARY ARTERY BYPASS SURGERY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION SYSTEM; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HYPOCHOLESTEROLEMIA; LIPID METABOLISM; MORTALITY; TREATMENT OUTCOME","","","HAREL M., AHARONI A., GAIDUKOV L., ET AL., STRUCTURE AND EVOLUTION OF THE SERUM PARAOXONASE FAMILY OF DETOXIFYING AND ANTI-ATHEROSCLEROTIC ENZYMES, NAT STRUCT MOL BIOL, 11, PP. 412-419, (2004); SHIH D.M., GU L., XIA Y.R., ET AL., MICE LACKING SERUM PARAOXONASE ARE SUSCEPTIBLE TO ORGANOPHOSPHATE TOXICITY AND ATHEROSCLEROSIS, NATURE, 394, PP. 284-287, (1998); MACKNESS M., MACKNESS B., PARAOXONASE 1 AND ATHEROSCLEROSIS: IS THE GENE OR THE PROTEIN MORE IMPORTANT?, FREE RADIC BIOL MED, 37, PP. 1317-1323, (2004); SANGHERA D.K., ASTON C.E., SAHA N., KAMBOH M.I., DNA POLYMORPHISMS IN TWO PARAOXONASE GENES (PON1 AND PON2) ARE ASSOCIATED WITH THE RISK OF CORONARY HEART DISEASE, AM J HUM GENET, 62, PP. 36-44, (1998); AGRAWAL S., TRIPATHI G., PRAJNYA R., ET AL., PARAOXONASE 1 GENE POLYMORPHISMS CONTRIBUTE TO CORONARY ARTERY DISAESE RISK AMONG NORTH INDIANS, INDIAN J MED SCI, 63, PP. 335-344, (2009); GLUBA A., PIETRUCHA T., BANACH M., ET AL., THE ROLE OF POLYMORPHISMS WITHIN PARAOXONASES (192 GLN/ARG IN PON1 AND 311 SER/CYS IN PON2) IN THE MODULATION OF CARDIOVASCULAR RISK: A PILOT STUDY, ANGIOLOGY, 61, PP. 157-165, (2010); DEAKIN S., LEVIEV I., MEYNET B.M.C., JAMES R.W., PARAOXONASE-1 PROMOTER HAPLOTYPES AND SERUM PARAOXONASE: A PREDOMINANT ROLE IN VIVO FOR POLYMORPHIC POSITION - 107 IMPLICATING THE TRANSCRIPTIONFACTOR SP 1, BIOCHEM J, 372, PP. 643-649, (2003); POKROVSKY S.N., EZHOV M.V., ILINA L.N., ET AL., ASSOCIATION OF LIPOPROTEIN (A) EXCESS WITH EARLY VEIN GRAFT OCCLUSIONS IN MIDDLE AGED MEN UNDERGOING CORONARY ARTERY BYPASS SURGERY, J THORAC CARDIOVASC SURG, 126, PP. 1071-1075, (2003); CAMPEAU L., LETTER. GRADING OF ANGINA PECTORIS, CIRCULATION, 54, PP. 522-523, (1976); BRAUNWALD E., UNSTABLE ANGINA: A CLASSIFICATION, CIRCULATION, 80, PP. 410-414, (1989); ECKERSON H., ROMSON W.J., WYTE C., LA DU B., THE HUMAN SERUM PARAOXONASE POLYMORPHISM: IDENTIFICATION OF PHENOTYPES BY THEIR RESPONSE TO SALTS, AM J HUM GENET, 35, PP. 214-227, (1983); BROPHY V.H., JAMPSA R.L., CLENDENNING J.B., ET AL., EFFECTS OF 5' REGULATORY-REGION POLYMORPHISMS ON PARAOXONASE-GENE (PON1) EXPRESSION, AM J HUM GENET, 68, PP. 1428-1436, (2001); FRIEDWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); WANG M., LANG X., ZOU L., ET AL., FOUR GENETIC POLYMORPHISMS OF PARAOXONASE GENE AND RISK OF CORONARY HEART DISEASE: A META-ANALYSIS BASED ON 88 CASECONTROL STUDIES, ATHEROSCLEROSIS, 214, PP. 377-385, (2011); WHEELER J.G., KEAVNEY B.D., WATKINS H., ET AL., FOUR PARAOXONASE GENE POLYMORPHISMS IN 11212 CASES OF CORONARY HEART DISEASE AND 12786 CONTROLS: META- ANALYSIS OF 43 STUDIES, LANCET, 363, PP. 689-695, (2004); MACKNESS B., DURRINGTON P., MCELDUFF P., ET AL., LOW PARAOXONASE ACTIVITY PREDICTS CORONARY EVENTS IN THE CAERPHILLY PROSPECTIVE STUDY, CIRCULATION, 107, PP. 2775-2779, (2003); KURBAN S., MEHMETOGLU I., EGE E., EFFECTS OF PREOPERATIVE ATORVASTATIN THERAPY ON PARAOXONASE ACTIVITY AND OXIDATIVE STRESS AFTER CORONARY ARTERY BYPASS GRAFTING, PERFUSION, 24, PP. 271-276, (2009); LINDEN T., TADDEI-PETERS W., WILHELMSEN L., ET AL., SERUM LIPIDS, LIPOPROTEIN (A) AND APO (A) ISOFORMS IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE AND THEIR RELATION TO DISEASE AND PROGNOSIS AFTER CORONARY BYPASS SURGERY, ATHEROSCLEROSIS, 137, PP. 175-186, (1998); DE RIJKE Y., VERWEY H.F., VOGELEZANG C.J., ET AL., ENHANCED SUSCEPTIBILITY OF LOWDENSITY LIPOPROTEINS TO OXIDATION IN CORONARY BYPASS PATIENTS WITH PROGRESSION OF ATHEROSCEROSIS, CLIN CHEM ACTA, 243, PP. 137-149, (1995); KUMON Y., SUEHIRO T., IKEDA Y., HASHIMOTO K., 73, PP. 2807-2815, (2003); LUYTEN C.R., VAN OVERVELD F.J., DE BACKER L.A., ET AL., ANTIOXIDANT DEFENCE DURING CARDIOPULMONARY BYPASS SURGERY, EUR J CARDIOTHORAC SURG, 27, PP. 611-616, (2005)","T. ZAPOLSKI; DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND; EMAIL: ZAPOLIA@WP.PL","INTERNATIONAL SCIENTIFIC LITERATURE INC.","ENGLISH","MED. SCI. MONIT.","ARTICLE","ISI","2-S2.0-84898403128","MED SCI MONIT","MEDICAL UNIVERSITY OF LUBLIN;MEDICAL UNIVERSITY OF LUBLIN;MEDICAL UNIVERSITY OF LUBLIN;MEDICAL UNIVERSITY OF LUBLIN;MEDICAL UNIVERSITY OF LUBLIN;MEDICAL UNIVERSITY OF LUBLIN","NOTREPORTED;MEDICAL UNIVERSITY OF LUBLIN;NOTREPORTED",NA,"WYSOCKA A, 2014, MED SCI MONIT","WYSOCKA A, 2014, MED SCI MONIT"
"CARBAJAL Q D;MOLINA C V;RAVELO C Y;PÉREZ G Y;OYARZABAL Y A;MAS F R","CARBAJAL QUINTANA, DAISY (55821592400); MOLINA CUEVAS, VIVIAN (7006062814); RAVELO CALZADO, YAZMIN (34976285600); PÉREZ GUERRA, YOHANIS (56070325000); OYARZABAL YERA, AMBAR (36020873200); MAS FERREIRO, ROSA (6602148780)","EFFECTS OF POLICOSANOL ON CARRAGEENANINDUCED PLEURISY AND COTTON PELLET GRANULOMA MODELS EFECTOS DEL POLICOSANOL EN LOS MODELOS DE PLEURESÍA INDUCIDA POR CARRAGENINA Y GRANULOMA POR ALGODÓN",2013,"REVISTA CUBANA DE FARMACIA","47","9",0,"","CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CUBA","INTRODUCTION: POLICOSANOL, A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS PURIFIED FROM SUGARCANE WAX, INHIBITS CYCLOOXYGENASE-1 (COX-1) ACTIVITY IN VITRO, AN EFFECT THAT COULD SUPPORT ITS ANTI-PLATELET ACTION. ITS PUTATIVE EFFECTS ON EXPERIMENTAL MODELS OF INFLAMMATION HAD NOT BEEN YET INVESTIGATED. OBJECTIVE: TO DETERMINE THE IN VIVO EFFECT OF POLICOSANOL ON ACUTE (CARRAGEENANINDUCED PLEURISY) AND CHRONIC INFLAMMATION (COTTON-PELLET GRANULOMA) IN VIVO MODELS. METHODS: IN THE ACUTE MODEL, RATS WERE RANDOMLY DISTRIBUTED INTO SEVEN GROUPS: A NEGATIVE VEHICLE CONTROL, AND SIX WITH CARRAGEENAN-INDUCED PLEURISY: A POSITIVE CONTROL (VEHICLE), FOUR TREATED WITH POLICOSANOL (50-800 MG/KG) AND ONE WITH ASPIRIN (100 MG/KG). FIVE HOURS LATER, VOLUME OF PLEURAL EXUDATE, PROTEIN CONCENTRATION AND MYELOPEROXIDASE ACTIVITY WERE QUANTIFIED. FOR THE CHRONIC MODEL, RATS WERE DISTRIBUTED INTO SIX GROUPS: A CONTROL (VEHICLE), FOUR TREATED WITH POLICOSANOL (50-800 MG/KG) AND ONE GROUP WITH ASPIRIN (100 MG/KG). THE COTTON PELLET WAS IMPLANTED AND SIX DAYS AFTER TREATMENT, IT WAS EXTRACTED TO DETERMINE THE DRY AND THE WET WEIGHTS. RESULTS: SINGLE ORAL DOSES OF POLICOSANOL (200, 400 AND 800 MG/KG) REDUCED SIGNIFICANTLY AND MODERATELY THE VOLUME (≈ 20 %), THE MYELOPEROXIDASE ACTIVITY (≈ 12 %) AND THE PROTEIN CONCENTRATION (≈ 20 %) IN PLEURAL EXUDATES, WHEREAS ASPIRIN 100 MG/KG DECREASED SIGNIFICANTLY THESE INDICATORS BY 35.3, 19.9 AND 19.1 %, RESPECTIVELY. ORAL ADMINISTRATION OF POLICOSANOL (400 AND 800 MG/KG) FOR 6 DAYS REDUCED SIGNIFICANTLY AND MODERATELY THE WET (16.4 AND 16.2 %, RESPECTIVELY) AND DRY (28.4 AND 34.4 %, RESPECTIVELY) GRANULOMA WEIGHTS. TREATMENT WITH 100 MG/KG ASPIRIN REDUCED THESE VARIABLES BY 18.5 % (WET WEIGHT) AND 34.4 % (DRY WEIGHT), RESPECTIVELY. BOTH TREATMENTS REDUCED THE DRY MORE THAN THE WET GRANULOMA WEIGHT. CONCLUSION: ORAL ADMINISTRATION OF POLICOSANOL PRODUCED A MODERATE ANTI-INFLAMMATORY EFFECT IN VIVO ON MODELS OF ACUTE AND CHRONIC INFLAMMATION.","CARRAGEENAN; GRANULOMA; MYELOPEROXIDASE; PLEURISY; POLICOSANOL","ACETYLSALICYLIC ACID; MYELOPEROXIDASE; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARRAGEENAN-INDUCED PLEURISY; CONTROLLED STUDY; GRANULOMA; INFLAMMATION; NONHUMAN; PLEURA FLUID; SINGLE DRUG DOSE","","","MAS R., POLICOSANOL, DRUGS FUTURE., 25, 6, PP. 569-586, (2000); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, CURR TOP NUTRACEUT RES., (2012); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., ACOSTA P., ALFONSO J., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES., 32, PP. 8-12, (2001); DEV K., SINGH L.L., TODD D., PORTER POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JPET., 318, PP. 1020-1026, (2006); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., ET AL., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS., 44, PP. 907-916, (2009); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL 20 AND 40 MG/D IN HEALTHY VOLUNTEERS AND DYSLIPIDEMIC PATIENTS, CLIN EXP. PHARMACOL. PHYSIOL, 29, 10, PP. 891-897, (2002); CASTANO G., ARRUZAZABALA L., FERNANDEZ L., MAS R., CARBAJAL D., MOLINA V., ET AL., EFFECTS OF COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON PLATELET AGGREGATION. A RANDOMIZED DOUBLE-BLIND CLINICAL STUDY, CUR THERAPEUTIC RES., 67, 3, PP. 174-192, (2006); MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.C., GONZALEZ R.M., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION, CURR THER RES., 61, PP. 609-620, (2000); OYARZABAL A., MOLINA V., JIMENEZ S., CURVECO D., MAS R., EFECTOS DEL POLICOSANOL, EL EXTRACTO DE SEMILLAS DE UVA Y SU TERAPIA COMBINADA SOBRE MARCADORES OXIDATIVOS EN RATAS, REV CUBANA FARM., 45, 1, PP. 87-96, (2010); NOA M., MAS R., EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE COMPOSITION ON AORTAS OF MACACA ARCTOIDES MONKEYS, ARCH MED RES., 36, PP. 441-447, (2005); FERRERO-MILIANI L., NIELSEN O.H., ANDERSEN P.S., GIRARDIN S.E., CHRONIC INFLAMMATION: IMPORTANCE OF NOD2 AND NALP3 IN INTERLEUKIN-1BETA GENERATION, CLIN EXP IMMUNOL., 147, PP. 227-235, (2007); GOUWY M., STRUYF S., PROOST P., VAN DAMME J., SYNERGY IN CYTOKINE AND CHEMOKINE NETWORK AMPLIFIES THE INFLAMMATORY RESPONSE, CYTOKINE GROWTH FACTOR REV., 16, PP. 561-580, (2005); WELLEN K.E., HOTAMISLIGIL G.S., INFLAMMATION, STRESS AND DIABETES, J CLIN INVEST., 115, PP. 1111-1119, (2005); ROSS R., HARKER L., HYPERLIPIDEMIA AND ATHEROSCLEROSIS, SCIENCE., 193, (1976); DAVID J., LEFERSTATINS AS POTENT ANTIINFLAMMATORY DRUGS, CIRCULATION., 106, PP. 2041-2042, (2002); QUIST-PAULSEN P., STATINS AND INFLAMMATION: AN UPDATE, CURR OPIN CARDIOL., 25, 4, PP. 399-405, (2010); MOORE A.R., PLEURAL MODELS OF INFLAMMATION: IMMUNE AND NONIMMUNE, METHODS MOL BIOL, 225, PP. 123-128, (2003); SWINGLE K.F., SHIDEMAN F.E., PHASES OF THE INFLAMMATORY RESPONSE TO SUBCUTANEOUS IMPLANTATION OF A COTTON PELLET AND THEIR MODIFICATION BY CERTAIN ANTI-INFLAMMATORY AGENTS, J PHARMACOL EXP THER, 183, PP. 226-234, (1972); BAILEY P.J., STURM A., LOPEZ-RAMOS B., A BIOCHEMICAL STUDY OF THE COTTON PELLET GRANULOMA IN THE RAT. EFFECTS OF DEXAMETHASONE AND INDOMETHACIN, BIOCHEM PHARMACOL., 31, 7, PP. 1213-1218, (1982); WORTHINGTON ENZYME MANUAL., PP. 43-45, (1972); MARXWELL M.A., HAAS S.M., BEIBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE LIPOPROTEIN SAMPLES, ANALYTICAL BIOCHEMISTRY., 87, PP. 206-209, (1987); ZAKARIA N.M., ISLAM M.W., RADHAKRISHNANA R., CHEN H.B., KAMIL M., AL-GIFRIAN A.N., ET AL., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY PROPERTIES OF CARALLUMA ARABICA, J ETHNOPHARMACOL., 76, PP. 155-158, (2001); VAN DER VEEN B.S., DE WINTHER M.P., HEERINGA P., AUGUSTO O., CHEN J.W., DAVIES M., ET AL., MYELOPEROXIDASE: MOLECULAR MECHANISMS OFACTION AND THEIR RELEVANCE TO HUMAN HEALTH AND DISEASE, ANTIOXID REDOX SIGNAL., 11, PP. 2899-2937, (2009); DI PAOLA R., DI MARCO R., MAZZON E., GENOVESE T., BENDTZEN K., MACRI B., NICOLETTI F., CUZZOCREA S., PREVENTION OF CARRAGEENAN-INDUCED PLEURISY IN MICE BY ANTI-CD30 LIGAND MONOCLONAL ANTIBODY, CLIN IMMUNOL., 113, PP. 64-73, (2004); CORSINI E., DI PAOLA R., VIVIANI B., GENOVESE T., MAZZO E., LUCCHI L., ET AL., INCREASED CARRAGEENAN-INDUCED ACUTE LUNG INFLAMMATION IN OLD RATS, IMMUNOLOGY., 115, 2, PP. 253-261, (2005); FARIAS J.A., FERRO J.N., SILVA J.P., AGRA I.K., OLIVEIRA F.M., CANDEA A.L., ET AL., MODULATION OF INFLAMMATORY PROCESSES BY LEAVES EXTRACT FROM CLUSIA NEMOROSA BOTH IN VITRO AND IN VIVO ANIMAL MODELS, INFLAMMATION., 5, 2, PP. 764-771, (2011); MOORE A.R., PLEURAL MODELS OF INFLAMMATION: IMMUNE AND NONIMMUNE, METHODS MOL BIOL., 225, PP. 123-132, (2003); OLAJIDE O.A., AWE S.O., MAKINDE J.M., EKHELAR A.I., OLUSOLA A., STUDIES ON THE ANTIINFLAMMATORY, ANTIPYRETIC AND ANALGESIC PROPERTIES OF ALSTONIA BOONEI STEM BARK, J ETHNOPHARMACOL., 71, PP. 179-186, (2000); RAJESWARI R., THEJOMOORTHY P., MATHURAM L.N., NARAYANA RAJU K.V.S., ANTI-INFLAMMATORY ACTIVITY OF CASSIA FISTULA LINN. BARK EXTRACTS IN SUB-ACUTE MODELS OF INFLAMMATION IN RATS, TAMILNADU J VETERINARY & ANIMAL SCI., 2, 5, PP. 193-199, (2006); RAMAKRISHNAN G., JOSHUA J.A., GOUDAR K., AMIT A., COMPARATIVE EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF DIFFERENT EXTRACTS OF BOSWELLIA SERRATA IN WISTAR ALBINO RATS, INTERN J PHARM TECH RES., 3, PP. 261-267, (2011); NAKANO M., DENDA N., MATSUMOTO M., KAWAMURA M., KAWAKUBO Y., HATANAKA K., ET AL., INTERACTION BETWEEN CYCLOOXYGENASE (COX)-1-AND COX-2-PRODUCTS MODULATES COX-2 EXPRESSION IN THE LATE PHASE OF ACUTE INFLAMMATION, EUR J PHARMACOL., 22, PP. 210-218, (2007); DE OLIVEIRA MARQUES A., CONSERVA L.M., DE SOUZA FERRO J.N., DE ALMEIDA BRITO F., LYRA LEMOS R.P., BARRETO E., ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR. GRISEA IN MICE, INT J MOL SCI., 13, 2, PP. 1598-1611, (2012)","D. CARBAJAL QUINTANA; CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), LA HABANA, CAL 198 ENTRE 19 Y 21, ATA, MUNICI PLAYA, APA P6414, CUBA; EMAIL: CPN.SUP@CNIC.EDU.CU","EDITORIAL CIENCIAS MEDICAS","ENGLISH","REV. CUBA. FARM.","ARTICLE","ISI","2-S2.0-84896268801","REV CUBA FARM","CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES","NOTREPORTED;CENTRO DE PRODUCTOS NATURALES;NOTREPORTED",NA,"CARBAJAL QUINTANA D, 2013, REV CUBA FARM","CARBAJAL QUINTANA D, 2013, REV CUBA FARM"
"HERCEG D;HERCEG G","HERCEG, DAVORIN (25642320200); HERCEG, GORDANA HORVATIĆ (26633842800)","TARGETED THERAPY IN PATIENTS WITH RADIOIODINEREFRACTORY DIFFERENTIATED THYROID CANCER DTC",2014,"PERIODICUM BIOLOGORUM","116","8",1,"","DEPARTMENT OF ONCOLOGY, UNIVERSITY HOSPITAL ZAGREB, ZAGREB, CROATIA;CLINICAL DEPARTMENT OF NUCLEAR MEDICINE AND RADIATION PROTECTION, UNIVERSITY HOSPITAL ZAGREB, ZAGREB, CROATIA","PAPILLARY (PTC) AND FOLLICULAR (FTC) THYROID CANCER (TC) BELONG TO DIFFERENTIATED THYROID CANCER (DTC). THE INITIAL TREATMENT OF DTC IS SURGERY FOLLOWED BY RADIOIODINE REMNANT ABLATION. ALTHOUGH THE PROGNOSIS OF DTC IS GENERALLY GOOD, APPROXIMATELY 10-15% OF DTC PATIENTS WILL DEVOLP ADVANCED DISEASE AND THEIR DISEASE WILL BECOME RADIOIODINE REFRACTORY. EVEN IN RADIOIODINE REFRACTORY PATIENTS THE NATURAL HISTORY OF DISEASE CAN BE SLOWLY PROGRESSIVE OR INDOLENT.THE EXPANDED KNOWLEDGE OF THE THE BIOLOGICAL BASIS OF DTC HAS OPENED NEW OPPORTUNITIES IN THERAPY – TARGETED THERAPY, AIMED AT INHIBITING SPECIFIC MOLECULAR TARGETS AND PATHWAYS IN TUMOR PROLIFERATION, SURVIVAL AND PROGRESSION. WE REWIEVED DIFFERENT TAGETED THERAPIES IN DTC. SORAFENIB WAS THE FIRST AND ONLY TARGETED DRUG APPROVED BY FDA FOR PROGRESSIVE AND RADIODINE-REFRACTORY DTC. ALSO, LENVATINIB HAD PROMISING EFFICACY RESULTS IN PHASE III TRIAL, PROBABLY EVEN BETTER THAN SORAFENIB, BUT WITH MORE TREATMENT-RELATED DEATHS. THE TIMING OF TARGETED THERAPY FOR DTC IS OF DECISIVE IMPORTANCE. THE POTENTIAL BENEFIT SHOULD BE BALANCED WITH POTENTIAL TOXICITY OF TARGETED THERAPIES. © 2014, CROATIAN SOCIETY OF NATURAL SCIENCES. ALL RIGHTS RESEVED.","","BERBERINE; CYTOCHROME P450 3A4; GAMMA ORYZANOL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONACOLIN L; NUTRACEUTICAL; POLICOSANOL; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; HYPOCHOLESTEROLEMIA; LIPID METABOLISM; MORTALITY; TREATMENT OUTCOME","","","SIEGELL R., MA J., ZOU Z., JEMAL A., CANCER STATISTICS, 2014, CACANCER J CLIN, 64, PP. 9-29, (2014); (2013); DAVIES L., WELCH H.G., INCREASING INCIDENCE OF THYROID CANCER IN THE UNITED STATES, 1973-2002, JAMA 295, PP. 2164-2167, (2006); HOWLADER N., NOONE A.M., KRAPCHO M., SEER CANCER STATISTICS REVIEW, (2013); YU X.M., WAN Y., SIPPEL R.S., CHEN H., SHOULD ALL PAPILLARY THYROID MICROCARCINOMAS BE AGRESSIVELY TREATED? AN ANALYSIS OF 18,445 CASES, ANN SURG, 254, PP. 653-660, (2011); DEAN D.S., HAY I.D., PROGNOSTIC INDICATORS IN DIFFERENTIATED THYROID CARCINOMA, CANCER CONTROL, 7, PP. 229-239, (2007); PODNOSY D., SMITH D., WAGMAN L.D., ELLENHORN J.D., THE IMPLICATION OF LYMPH NODE METASTASIS ON SURVIVAL IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER, ANN SURG, 71, PP. 731-734, (2005); PATELK N., SHAHA A.R., POORLY DIFFERENTIATED AND ANAPLASTIC THYROID CANCER, CANCER CONTROL, 13, PP. 119-128, (2006); SSCLUMBERGERM J., PAPILLARY AND FOLLICULAR THYROID CARCINOMA, N ENGL J MED, 338, PP. 297-306, (1998); CHEN H., NICOL T.L., ZEIGER M.A., DOOLEY W.C., LADESON P.W., COOPER D.S., RINGEL M., PARKERSON S., ALLO M., UDELSMAN R., HÜRTHLE CELL NEOPLASMS OF THE THYROID GLAND: ARE THERE FACTORS PREDICTIVE FOR MALIGNANCY?, ANN SURG, 227, PP. 542-546, (1988); XING M., BRAF MUTATION IN THYROID CANCER, ENDOCR RELAT CANCER, 12, PP. 245-262, (2005); SCHNEIDERD F., CHEN H., NEW DEVELOPMENTS IN THE DIAGNOSIS AND TREATMENT OF THYROID CANCER, CA CANCER J CLIN, 63, PP. 374-394, (2013); GERMSENJAGER E., PERREN A., SEIFERTT B., SCHULER G., SSCHWEIZER I., HEIZ P.U., LYMPH NODE SURGERY IN PAPILLARY THYROID CANCER, J AM COLL SURG, 197, PP. 182-560, (2003); BARDET S., MELVILLE E., RAME J.P., BABIN E., SAMAMA G., DE RAUCOURT D., MICHELS J.J., REZNIK Y., HENRY-AMAR M., MACROSCOPIC LYMPH NODE INVOLMENT AND NECK DISSECTION PREDICT LYMPH-NODE RECCURENCE IN PAPILLARY THYROID CARCINOMA, EUR J ENDOCRINOL, 158, PP. 551-560, (2008); ROH J.L., PARK J.Y., PARK C.L., TOTAL THYROIDECTOMY PLUS NECK DISSECTION IN DIFFERENTIATED PAPILLARY THYROID CARCINOMA PATIENTS: PATTERNS OD NODAL METASTASIS, MORBIDITY, RECCURENCE, AND POSTOPERATIVE LEVELS OF SERUM PARATHYROID HORMNONE, ANN SURG, 245, PP. 04-610, (2007); BROWNA P., CHEN J., HITCHCOCK Y.J., SZABO A., SHRIEVE D.C., TWAD J.D., THE RISK OF SECOND PRIMARY MALIGNANCIES UP TO THREE DECADES AFTER THE TREATMENT OF DIFFERENTIATED THYROID CANCER, J CLIN ENDOCRINOL METAB, 93, PP. 504-515, (2008); SCHLUMBERGER M., CATARGI B., BORGET I., DEANDREIS D., ZERDOUD S., BRIDJI B., BARDET S., LEENHARDT L., BASTIE D., SCHVARTZ C., VERA P., MOREL O., BENISVY D., BOURNARD C., BONICHON F., DEJAX C., TOUBERT M.-E., LEBOLLEAUX S., RICARD M., BENHAMOU E., TUMEURS DE LA THYROIDE REFARACTARIES NETWORK FOR THE ESSAI STIMULATION ABLATION EQUIVALALENCE TRIAL. STRATEGIES FOR IODINE ABLATION IN PATIENTS WITH LOW-RISK THYROID CANCER, N ENGL J MED, 366, PP. 1663-1673, (2012); MALLICK U., HARMER C., YAP B., WADSLEY J., MOSS L., NICOL A., CLARK P.M., FARNELL K., MCCREADY R., SMELLIE J., FRANKLY J.A., JOHN R., NUTTING C.M., NEWBOLD K., LEMON C., GERRARD G., ABDEL-HAMID A., HARDMAN J., MACIAS E., ROQUES T., WHITAKER S., VIJAYAN R., ALVAREZ P., BEARE S., FORSYTH S., KADALAYIL L., HACKSHOW A., ABLATION WITH LOW-DOSE RADIOIODINE AND THYROTROPIN ALFA IN THYROID CANCER, N ENGL J MED, 366, PP. 1674-1685, (2012); CHENG W., MA C., FU H., LI J., CHEN S., WU S., WANG H., LOW- OR HIGH-DOSE RADIOIODINE REMNANT ABLATION FOR DIFFERENTIATED THYROID CARCINOMA: A META-ANALYSIS, J CLIN ENDOCRINOL METAB, 98, PP. 1353-1360, (2013); HAUGENB R., KANE M.A., APPROACH TO THE THYROID CANCER PATIENT WITH EXTRACERVICAL METASTASES, J CLIN ENDOCRINOL METAB, 95, PP. 987-993, (2010); SHERMANS I., CYTOTOXIC CHEMOTHERAPY FOR DIFFERENTIATED THYROID CANCER, CLIN ONCOL (RCOLL RADIOL), 22, PP. 464-468, (2010); XING M., HAUGEN B.R., SCHLUMBERGER M.L., PROGRESS IN MOLECULAR-BASED MANAGEMENT OF DIFFERENTIATED THYROID CANCER, LANCET, 381, PP. 1058-1069, (2013); DURANTE C., HADDY N., BAUDIN E., LEBOLLEAUX S., HARTL J.P., TRAVAGLI B., CAILLOU B., RICARD M., LUMBROSO J.D., DE VATHAIRE F., SCHLUMBERGER M., LONG-TERM OUTCOME OF 444 PATIENTS WITH DISTANT METASTASES FROM PAPILLARY AND FOLLICULAR THYROID CARCINOMA: BENEFITS AND LIMITS OF RADIOIODINE THERAPY, J CLIN ENDOCRINOL METAB, 91, PP. 2892-2899, (2006); GUPTA-ABRAMSON V., TROXEL A.B., NELLORE P., REDLINGER M., RANSONE K., FLAHERTY K.T., MANDEL, LOEVNER S.J., O'DWAYER L.A.P.J., BROSE M.S., A PHASE II TRIAL OF SORAFENIB IN ADVANCED THYROID CANCER, J CLIN ONCOL, 26, PP. 4714-4719, (2008); BROSE M., TROXEL A., REDINGER M., EFFECT OF BRAF V600E ON RESPONSE TO SORAFENIB IN ADVANCED THYROID CANCER PATIENTS, J CLIN ONCOL 23: ABSTR, (2009); KLOSS R.T., RINGEL M.D., KNOPP M.V., PHASE II TRIAL OF SORAFENIB IN METASTATIC THYROID CANCER, J CLIN ONCOL, 27, PP. 1675-1684, (2009); HOFIJZER H., HEMSTRA K.A., MORREAU H., STOKEL M.P., CORSSMITH E.P., GELDERBLOM H., WEIJERS K., PEREIRA A.M., HUJIBERTS M., KAPITEIJN E., ROMIJN J.A., SMIT J.W., BENEFICIAL EFFECTS OF SORAFENIB ON TUMOR PROGRESSION, BUT NOT ON RADIOIODINE UPTAKE IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA, EUR J ENDOCRINOL, 161, PP. 923-931, (2009); AHMED M., BARBACHANO Y., RIDELL A., HICKEY J., NEWBOLD K.L., VIROS A., HARRINGTON K.J., MARAIS R., NUTTING C.M., ANALYSIS OF THE EFFICACY AND TOXICITY OF SORAFENIB IN THYROID CANCER: A PHASE II STUDY IN A UK BASED POPULATION, EUR J ENDOCRINOL, 185, PP. 315-322, (2011); CAPDEVILLA J., IGLESIAS L., HALPERIN I., SORAFENIB IN PATIENTS (PTS) WITH ADVANCED THYROID CARCINOMA (TC): A COMPASSIONATE USE PROGRAM, J CLIN ONCOL 28: ABSTRACT, (2010); KEEFES M., TROXEL S., RHEE S., PUTTASWAMY K., O'DWYER P.J., MANDEL S.J., LOEVNER L.A., MANDEL S.J., BROSE M.S., PHASE II TRIAL OF SORAFENIB IN PATIENTS WITH ADVANCED THYROID CANCER, J CLIN ONCOL 29: ABSTR, (2011); SCHNEIDERT C., ABDULRAHMAN R.M., CORSSMIT E.P., MORREAU H., SMITH J., KAPITEJIN E., LONG TERM ANALYSIS OF THE EFFICACY AND TOLERABILITY OF SORAFENIB IN ADVANCED RADIO-IODINE REFRACTORY DIFFERENTIATED THYROID CARCINOMA: FINAL RESULTS OF A PHASE II TRIAL, EUR J ENDOCRINOL, 167, PP. 643-650, (2012); ADILI A., CHASEN R.J.B., DADU R., OUTCOMES OF PATIENTS WITH POORLY DIFFERENTIATED THYROID CANCER OF FOLLICULAR ORIGIN TREATED WITH FIRST LINE SORAFENIB (ABSTRACT ORAL 96), (2013); MAROTTA V., RAMUNDO V., CAMERA L., DEL PRETE M., FONTI R., ESPOSITO R., PALMIERI G., SALVATORE M., VITALE M., COLAO A., FAGGIANO A., SORAFENIB IN ADVANCED IODINE REFRACTORY DIFFERENTIATED THYROID CANCER: EFFICACY, SAFETY AND EXPLORATORY ANALYSIS OF ROLE OF SERUM THYROGLOBULIN AND FDG-PET, CLIN ENDOCRINOL (OXF), 78, PP. 760-767, (2013); DE LA F., MASSICOTTE M.H., BORGET I., SEQUENTIAL TKI TREATMENTS FOR IODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMAS (ABSTRACT5586), J CLIN ONCOL, 31, (2013); CHENL S., LOU Q., YU Y., LU H., ZHU R., RESPONSE TO SORAFENIB AT A LOW DOSE IN PATIENTS WITH RADIOIODINE-REFRACTORY PULMORARY METASTASES FROM PAPILLARY CARCINOMA, THYROID 21: 119-, (2011); CABANILLAS M., WAQUESPACK S., BRONSTEIN Y., WILLIAMS M.D., FENG L., HERNANDEZ M., LOPEZ A., SHERMAN S.I., BUSAIDY M.L., TREATMENT WITH THYROSINE KINASE INHIHITORS FOR PATIENTS WITH DIFFERENTIATED THYROID CANCER; THE MD ANDERSON EXPERIENCE, J CLIN ENDOCRINOL METAB, 95, PP. 2588-2595, (2010); BROSEM S., NUTTING C.M., JARZAB B., ELISEI R., SALVATORE S., BASTHOLT L., DE LA FOUCHARDIERE C., PACINI F., PASCHKE R., SHONG J.K., SHERMAN S.I., SMIT J., CHUNG J.W., SIEDENTROP H., MOLNAR I., SCHLUMBERGER M., SORAFENIB IN RADIOACTIVE IODINE-REFRACTORY, LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL, LANCET, 384, PP. 319-328, (2014); NEMUNAITIS J.J., SENZER N.N., KURZROCK R., NG C.S., DAS A., ATIENZA R.S., ZANG E.A., JANSEN E., ASWORTH S., HONG D.A., PHASE I DOSE-ESCALATION STUDY OF E7080, A MULTIKINASE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, J CLIN ONCOL 26: ABSTRACT, (2008); SHERMANS I., JARZAB B., CABANILLAS L., PACINI F., MARTINS R., ROBINSON B., BALL D., MCCAFFREY J., SHAH M.H., BODENNER D., ALLISON R., NEWBOLD K., ELISEI R., O'BRIEN J.P., SCHLUMBERGER M., A PHASE II TRIAL OF THE MULTI-TARGETED KINASE INHIBITOR, LENVATINIB (E7080), IN ADVANCED RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC), J CLIN ONCOL 29: ABSTRACT, (2011); SCHLUMBERGER M., TAHARA M., WIRTH L.J., ROBINSON B., BROSE M.S., ELISEI R., DUTCUS C.E., DE LAS HERAS B., ZHU J., HABRA M.A., NEWBOLD K., SHAH M.H., HOFF A.O., GIANOUKAKIS A.G., KIYOTA N., TAYLOR M.H., KIM S.-B., KRZYZANOWSKA M., SHERMAN S.I., A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF LENVATINIB (E7080) IN PATIENTS WITH 131I-REFRACTORY DIFFERENTIATED THYROID CANCER (SELECT), J CLIN ONCOL 32: ABSTRACT LBA6008, (2014); THORNTON K., KIM G., MAHLER V.E., CHATTOPADHYAY S., TANG S., MOON Y.J., SONG P., MARATHE A., BALAKRISHNAN S., ZHU H., GARNETT C., LIU Q., BOOTH B., GEHRKE B., DORSAM R., VERBOIS L., GHOSH D., WILSON W., DUAN J., SARKER H., MIKSINSKI S.P., SKARUPA L., IBRAHIM A., JUSTICE R., MURGO A., PAZDUR R., VANDETANIB FOR THE TREATMENT OF SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE. US FOOD AND DRUG ADMINISTRATION DRUG APPROVAL SUMMARY, CLIN CANCER RES, 18, PP. 722-3730, (2012); LEBOULLEUX S., BASTHOLT L., KRAUSE T., DE LA FOUCHARDIERE C., TENNVALL J., AWADA A., GOMEZ J.M., BONICHON F., LENNHARDT L., SOUFFLET C., LICOUR M., SCHLUMBERGER M.J., VANDETANIB IN LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER: A RANDOMISED DOUBLEBLIND PHASE 2, LANCET ONCOL, 3, PP. 897-905, (2012); SHERMANS I., WIRTH L.J., DROZ H., BASTHOLT L., MARTINS R.G., LICITRA L., ESCHENBERG M.J., SUN Y.N., JUAN T., STEPAN D.E., SCHLUMBERGER M.J., MOTESANIB THYROID CANCER STUDY GROUP. MOTESANIB DIPHOSPHATE IN PROGRESSIVE DIFFERENTIATED THYROID CANCER, N ENGL J MED, 359, PP. 31-42, (2008); COHENE E., ROSEN L.S., VOKES E.E., KIES M.S., FORASTIERE A.A., WORDEN F.P., KANE M.A., SHERMAN E., KIM S., BYCOTT P., TORTORICI M., SHALINSKY D.R., LIAU K.F., COHEN R.B., AXITINIB IS AN ACTIVE TREATMENT FOR ALL HISTOLOGIC SUBTYPES OF ADVANCED THYROID CANCER: RESULTS FROM A PHASE II STUDY, J CLIN ONCOL, 26, PP. 4708-4713, (2008); COHENE E., NEEDLES K.J., CULLEN K.J., WONG S.J., WADE J.L., IVY S.P., VILLAFLOR V.M., SEIWERT T.Y., NICHOLS K., VOKES E.E., PHASE 2 STUDY OF SUNITINIB IN REFRACTORY THYROID CANCER, J CLIN ONCOL, 26, (2008); CARRL L., MANKOFF D.A., GOULART B.H., EATON K.D., CAPELL P.T., KELL E.M., BAUMAN J.E., MARTINS R.G., PHASE II STUDY OF DAILY SUNITINIB IN FDG-PET POSITIVE, IODINEREFRACTORY DIFFERENTIATED THYROID CANCER AND METASTATIC MEDULLARY CARCINOMA OF THYROID WITH FUNCTIONAL IMAGING CORRELATION, CLIN CANC RES, 16, PP. 5260-5268, (2010); SCHOFFSKI P., ELISEI R., MULLER S., MARCIA S., BROSE M.S., SHAH M.H., LICITRA L.F., JARZAB B., MEDVEDEV V., KREISSL M., NIEDERLE B., COHEN E., WIRTH L.J., ALI H.Y., HESSEL C., YARON Y., BALL D.W., NELKIN B., SHERMAN S.I., SCHLUMBERGER M., AN INTERNATIONAL, DOUBLEBLIND, PLACEBO-CONTROLLED PHASE III TRIAL (EXAM) OF CABOZATINIB (XL184) IN MEDULLARY THYROID CANCER (MTC) PATIENTS (PTS) WITH DOCUMENTED RECIST PROGRESSION AT BASELINE, J CLIN ONCOL, 30, (2012); CABANILLASM E., BROSE M.S., RAMIES D.A., YIHUA L., MILES D., SHERMAN S.I., ANTITUMOR ACTIVITY OF CABOZATINIB (XL184) IN A COHORT OF PATIENTS (PTS) WITH DIFFERENTIATED THYROID CANCER (DTC), J CLIN ONCOL, 30, (2012); BIBLEK C., SUMAN V.J., MOLINA J.R., SMALLRIDGE R.C., MAPLES W.J., MENEFEE M.E., RUBIN J., SIDERAS K., MORRIS J.C., MCIVER B., BURTON J.K., WEBSTER K.P., BIEBER C., TRAYNOR A.M., FLYNN P.J., GOH B.C., TANG H., IVY S.P., ERLICHMAN C., EFFICACY OF PAZOPANIB IN PROGRESSIVE, RADIODINE- REFRACTORY, METASTATIC DIFFERENTIATED THYROID CANCERS: RESULTS OF A PHASE 2 CONSORTIUM STUDY, LANCET ONCOLO, 11, PP. 962-972, (2010); BROSEM S., CABANILLAS M.E., COHEN E., WIRTH L., SHERMAN S.I., RIEHL T., YUE H., SHERMAN E., AN OPEN-LABEL, MULTI-CENTER PHASE 2 STUDY OF THE BRAF INHIBITOR VEMURAFENIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE PAPILLARY THYROID CANCER (PTC) POSITIVE FOR THE BRAF V600 MUTATION AND RESISTANT TO RADIOACTIVE IODINE, PRESENTED AT: EUROPEAN CANCER CONGRESS 2013, (2013); FALCOOK G.S., LONG G.V., KURZROCK R., NAING A., PIHAPAUL S., WAGUESPACK S.G., CABANILLAS M.E., SHERMAN S.I., MA B., CURTIS M., GOODMAN V., KURZROCK R., DABRAFENIB IN PATIENTS WITH MELANOMA, UNTREATED BRAIN METASTASES, AND OTHER SOLID TUMORS: A PHASE I DOSE-ESCALATION TRIAL, LANCET, 379, PP. 1893-1901, (2012); HONG D.S., CABANILLAS M.E., WHELER N., TSIMBERIDOU A.M., YE L., WAGUES-PACK S.G., HERNANDEZ M., EL NAGGAR A.K., BIDYASAR S., WRIGHT J., SHERMAN S.I., KURZRROCK R., INHIBITION OF THE RAS/RAF/MEK/ERK AND RET KINASE PATHWAYS WITH THE COMBINATION OF THE MULTIKINASE INHIBITOR SORAFENIB AND THE FARNESYTRANSFERASE INHIBITOR TIPIFARNIB IN MEDULLARY AND DIFFERENTIATED THYROID MALIGNANCIES, J CLIN ENDOCRINOL METAB, 96, PP. 997-1005, (2001); SHERMANE J., HO A.L., FURY M.G., BAXI S.S., HAQUE S., KORTE S.H., SMITH-MARRONE S., XIAO H., GHOSSEIN R.A., FAGIN J.A., PFISTER D.G., A PHASE II STUDY OF TEMSIROLIMUS/ SORAFENIB IN PATIENTS WITH RADIOACTIVE IODINE (RAI)-REFRACTORY THYROID CARCINOMA, J CLIN ONCOL, 29, (2012); SHERMANE J., HO A.L., FURY M.G., BAXI S.S., HAQUE S., LIPSON B.L., KURZ S., FAGIN J.A., PFISTER D.G., PHASE II OF EVEROLIMUS AND SORAFENIB FOR THE TREATMENT OF METASTATIC THYROID CANCER, J CLIN ONCOL, 31, (2013)","","CROATIAN SOCIETY OF NATURAL SCIENCES","ENGLISH","PERIOD. BIOL.","ARTICLE","ISI","2-S2.0-84930003853","PERIOD BIOL",NA,"NOTREPORTED",NA,"HERCEG D, 2014, PERIOD BIOL","HERCEG D, 2014, PERIOD BIOL"
"GONNELLI S;CAFFARELLI C;STOLAKIS K;CUDA C;GIORDANO N;NUTI R","GONNELLI, STEFANO (7005809020); CAFFARELLI, CARLA (57189021821); STOLAKIS, KOSTANTINOS (57225239783); CUDA, CLAUDIA (56462724900); GIORDANO, NICOLA (57204354095); NUTI, RANUCCIO (7006273080)","EFFICACY AND TOLERABILITY OF A NUTRACEUTICAL COMBINATION RED YEAST RICE POLICOSANOLS AND BERBERINE IN PATIENTS WITH LOWMODERATE RISK HYPERCHOLESTEROLEMIA A DOUBLEBLIND PLACEBOCONTROLLED STUDY",2015,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","77","5",42,"10.1016/j.curtheres.2014.07.003","DEPARTMENT OF MEDICINE, SURGERY, AND NEUROSCIENCE, UNIVERSITY OF SIENA, ITALY;DEPARTMENT OF MEDICINE, SURGERY, AND NEUROSCIENCE, UNIVERSITY OF SIENA, ITALY;DEPARTMENT OF MEDICINE, SURGERY, AND NEUROSCIENCE, UNIVERSITY OF SIENA, ITALY;DEPARTMENT OF MEDICINE, SURGERY, AND NEUROSCIENCE, UNIVERSITY OF SIENA, ITALY;DEPARTMENT OF MEDICINE, SURGERY, AND NEUROSCIENCE, UNIVERSITY OF SIENA, ITALY;DEPARTMENT OF MEDICINE, SURGERY, AND NEUROSCIENCE, UNIVERSITY OF SIENA, ITALY","BACKGROUND: STATINS ARE AT THE FOREFRONT OF STRATEGIES TO MANAGE HYPERCHOLESTEROLEMIA. HOWEVER 10% TO 15% OF PATIENTS ARE INTOLERANT TO ANY STATIN DRUGS, EVEN AT LOW DAILY DOSES AND ALMOST ONE-THIRD OF STATIN USERS DISCONTINUE THERAPY WITHIN 1 YEAR. SOME NUTRACEUTICALS ARE PRESCRIBED AS LIPID-LOWERING SUBSTANCES, BUT DOUBTS REMAIN ABOUT THEIR EFFICACY AND TOLERABILITY. OBJECTIVES: WE AIMED TO INVESTIGATE THE EFFICACY AND THE SAFETY OF A NUTRACEUTICAL COMBINATION CONSISTING MAINLY OF 200 MG RED YEAST RICE EXTRACT (EQUIVALENT TO 3 MG MONACOLINS), 500 MG BERBERINE, AND 10 MG POLICOSANOLS (MBP-NC) IN PATIENTS WITH LOW-MODERATE RISK HYPERCHOLESTEROLEMIA. METHODS: IN THIS SINGLE CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 60 CONSECUTIVE OUTPATIENTS (29 MEN AND 31 WOMEN; AGE RANGE = 18-60 YEARS), WITH NEWLY DIAGNOSED PRIMARY HYPERCHOLESTEROLEMIA NOT PREVIOUSLY TREATED, AFTER A RUN-IN PERIOD OF 3 WEEKS ON A STABLE HYPOLIPIDIC DIET, WERE RANDOMIZED TO RECEIVE A PILL OF MBP-NC (N = 30) OR PLACEBO (N = 30) ONCE A DAY AFTER DINNER, IN ADDITION TO THE HYPOLIPIDIC DIET. THE EFFICACY AND THE TOLERABILITY OF THE PROPOSED NUTRACEUTICAL TREATMENT WERE FULLY ASSESSED AFTER 4, 12, AND 24 WEEKS OF TREATMENT. RESULTS: IN THE MBP-NC GROUP BOTH TOTAL CHOLESTEROL AND LDL-C ALREADY SHOWED A SIGNIFICANT REDUCTION AT WEEK 4 (-30.3% ± 33.9% AND -29.4% ± 35.3%, RESPECTIVELY) THAT REMAINED SUBSTANTIALLY UNCHANGED AT WEEK 12 (-26.7% ± 33.1% AND -25.6% ± 31.5%, RESPECTIVELY) AND AT WEEK 24 (-24.6% ± 32.1% AND -23.7% ± 32.6%, RESPECTIVELY). THE BETWEEN-GROUPS DIFFERENCES WERE SIGNIFICANT AT ALL TIME POINTS FOR BOTH TOTAL CHOLESTEROL AND LDL-C. THERE WERE NO SIGNIFICANT CHANGES IN HDL-C, FASTING GLUCOSE, AND TRIGLYCERIDE SERUM LEVELS IN EITHER GROUP. MBP-NC WAS ALSO SAFE AND WELL TOLERATED. CONCLUSIONS: IN PATIENTS WITH LOW- TO MODERATE-RISK HYPERCHOLESTEROLEMIA A NUTRACEUTICAL COMBINATION IN ASSOCIATION WITH A HYPOLIPIDIC DIET SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL AND LDL-C LEVELS AND MAY FAVOR THE REACHING THE RECOMMENDED CHOLESTEROL TARGETS. CLINICALTRIALS.GOV IDENTIFIER: NCT02078167. © 2014 THE AUTHORS.","BERBERINE; HYPERCHOLESTEROLEMIA; MONACOLIN; POLICOSANOLS; RED YEAST RICE; TOLERABILITY","ASTAXANTHIN; BERBERINE; CHOLESTEROL; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; XUEZHIKANG; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPIDIC DIET; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION","","","EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); LEWINGTON S., WHITLOCK G., CLARKE R., ET AL., BLOOD CHOLESTEROL AND VASCULAR MORTALITY BY AGE, SEX, AND BLOOD PRESSURE: A META-ANALYSIS OF INDIVIDUAL DATA FROM 61 PROSPECTIVE STUDIES WITH 55,000 VASCULAR DEATHS, LANCET, 370, PP. 1829-1839, (2007); BAIGENT C., BLACKWELL L., EMBERSON J., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); CATAPANO A.L., REINER Z., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) ATHEROSCLEROSIS, 217, PP. S1-S44, (2011); JACKEVICIUS C.A., MAMDANI M., TU J.V., ADHERENCE WITH STATIN THERAPY IN ELDERLY PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROMES, JAMA, 288, PP. 462-467, (2002); NIJJAR P.S., BURKE F.M., BLOESH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, J CLIN LIPIDOL, 4, PP. 248-258, (2010); TRIMARCO B., BENVENUTI C., ROZZA F., ET AL., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTRITION METAB, 4, PP. 133-139, (2011); CICERO A.F.G., DEROSA G., BOVE M., ET AL., LONG-TERM EFFECTIVENESS AND SAFETY OF A NATRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOPICS NUTRAC RES, 7, PP. 121-126, (2009); IZZO R., DE SIMONE G., GIUDICE R., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS, 28, PP. 1482-1487, (2010); CICERO A.F.G., DE SANDO V., BENEDETTO D., ET AL., LONG-TERM EFFICACY AND TOLERABILITY OF A MULTICOMPONENT LIPID-LOWERING NUTRACEUTICAL IN OVERWEIGHT AND NORMOWEIGHT PATIENTS, NUTRAFOOD, 11, PP. 55-61, (2012); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); PIRRO M., LUPATTELLI G., DEL GIORNO R., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, PHARMANUTRITION, 1, PP. 73-77, (2013); AFFUSO F., MERCURIO V., RUVOLO A., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL, 4, PP. 77-83, (2012); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 23, PP. 1-4, (2006); LU Z., KOU W., DU B., ET AL., LI S. EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CICERO A.F.G., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN LIPIDOL, 4, PP. 553-563, (2009); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); ZHANG Y., LI X., ZOU D., ET AL., TREATMENT OF TYPE 2 DIABETES AND DYSLIPIDEMIA WITH THE NATURAL PLANT ALKALOID BERBERINE, J CLIN ENDOCRINOL METAB, 93, PP. 2559-2565, (2008); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 22, 11, (2012)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-84919910593","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"GONNELLI S, 2015, CURR THER RES CLIN EXP","GONNELLI S, 2015, CURR THER RES CLIN EXP"
"GIUFFRÈ A","GIUFFRÈ, ANGELO M. (9279506500)","EVOLUTION OF FATTY ALCOHOLS IN OLIVE OILS PRODUCED IN CALABRIA SOUTHERN ITALY DURING FRUIT RIPENING",2014,"JOURNAL OF OLEO SCIENCE","63","11",36,"10.5650/jos.ess13212","UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, DIPARTIMENTO AGRARIA, ITALY","A STUDY WAS CONDUCTED ON OLIVE OILS EXTRACTED FROM OLIVES COLLECTED IN SOUTH WEST CALABRIA (SOUTHERN ITALY) OVER THREE HARVEST YEARS 2010-2011-2012. THREE AUTOCHTHONOUS CULTIVARS WERE CONSIDERED: CASSANESE, OTTOBRATICA AND SINOPOLESE AND SEVEN ALLOCHTONOUS CULTIVARS: CORATINA, ITRANA, LECCINO, NOCELLARA MESSINESE, NOCIARA, PENDOLINO AND PICHOLINE. THIN LAYER CHROMATOGRAPHY - GAS CHROMATOGRAPH (TLC-GC) TECHNIQUE PERMITTED THE SEPARATION AND ANALYSIS OF THE FATTY ALCOHOL COMPOUNDS. A GENERAL DECLINE IN FATTY ALCOHOL CONTENT WAS FOUND DURING THE THREE MONTHS OF SAMPLING, MOST EVIDENT IN HEXACOSANOL. PENDOLINO SHOWED THE GREATEST DECLINE. A LESS EVIDENT DECREASE WAS MEASURED IN THE ODD CHAINED FATTY ALCOHOLS, MAINLY IN HEPTACOSANOL. BOTH HARVEST DATE AND CULTIVAR SIGNIFICANTLY INFLUENCED THE FATTY ALCOHOL CONTENT. THIS IS THE FIRST REPORT ABOUT THE FATTY ALCOHOL VARIATION DURING RIPENING IN OLIVE OIL PRODUCED IN SOUTH WEST CALABRIA (SOUTHERN ITALY). ©2014 BY JAPAN OIL CHEMISTS' SOCIETY.","ANOVA; FATTY ALCOHOLS; MINOR COMPONENTS; POLICOSANOLS; UNSAPONIFIABLE","ANTICHOLESTEREMIC AGENTS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, THIN LAYER; FATTY ALCOHOLS; FRUIT; ITALY; OLEA; PLANT OILS; PLATELET AGGREGATION INHIBITORS; TIME FACTORS; ANALYSIS OF VARIANCE (ANOVA); OLIVE OIL; THIN LAYER CHROMATOGRAPHY; ANTITHROMBOCYTIC AGENT; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; OLIVE OIL; POLICOSANOL; VEGETABLE OIL; CALABRIA; FATTY ALCOHOLS; FRUIT RIPENING; GAS CHROMATOGRAPHS; MINOR COMPONENTS; POLICOSANOLS; SOUTHERN ITALY; UNSAPONIFIABLE; ARTICLE; CHEMISTRY; CLASSIFICATION; FRUIT; GAS CHROMATOGRAPHY; ISOLATION AND PURIFICATION; ITALY; METHODOLOGY; OLIVE TREE; PHYSIOLOGY; THIN LAYER CHROMATOGRAPHY; TIME; ALCOHOLS","","","GIUFFRE A.M., L'OLIO DI OLIVA CALABRESE: ASPETTI PRODUT-TIVI E TECNOLOGICI, INDUSTRIE ALIMENTARI, 42, PP. 20-25, (2003); GUILLAUME C., RAVETTI L., RAY D.L., JOHNSON J., TECHNOLOGICAL FACTORS AFFECTING STEROLS IN AUSTRALIAN OLIVE OILS, J. AM. OIL CHEM. SOC, 89, PP. 29-39, (2012); GIUFFRE A.M., LOUADJ L., INFLUENCE OF CROP SEASON AND CULTIVAR ON STEROL COMPOSITION OF MONOVARIETAL OLIVE OILS IN REGGIO CALABRIA (ITALY), CZECH J. FOOD SCI, 31, PP. 256-263, (2013); BIEDERMANN M., HAASE-ASCHOFF P., GROB K., WAX ESTER FRACTION OF EDIBLE OILS: ANALYSIS BY ON-LINE LC-GC-MS AND GCXGC-FID, EUR. J. LIPID SCI. TECHNOL, 110, PP. 1084-1094, (2008); GIUFFRE A.M., INFLUENCE OF HARVEST YEAR AND CULTIVAR ON WAX COMPOSITION OF OLIVE OILS, EUR. J. LIPID SCI. TECHNOL, 115, PP. 549-555, (2013); VICHI S., LAZZEZ A., GRATI KAMOUN N., LOPEZ-TAMA-MES E., BUXADERAS S., EVOLUTION OF SESQUITERPENE HYDROCARBONS IN VIRGIN OLIVE OIL DURING FRUIT RIPENING, J. AGRIC. FOOD CHEM, 58, PP. 6972-6976, (2010); JERMAN KLEN T., MOZETICCVODOPIVEC B., THE FATE OF OLIVE FRUIT PHENOLS DURING COMMERCIAL OLIVE OIL PROCESSING: TRADITIONAL PRESS VERSUS CONTINUOUS TWO- AND THREE-PHASE CENTRIFUGE, LWT - FOOD SCI. TECHNOL, 49, PP. 267-274, (2012); GARGOURI B., AMMAR S., ZRIBI A., BEN MANSOUR A., BOUAZIZ M., EFFECT OF GROWING REGION ON QUALITY CHARACTERISTICS AND PHENOLIC COMPOUNDS OF CHEMLALI EXTRA-VIRGIN OLIVE OILS, ACTA PHYSIOL PLANT, 35, PP. 2801-2812, (2013); MIGLIORINI M., CHERUBINI C., CHECCHI L., ZANONI B., DEGRADAZIONE DEI COMPOSTI FENOLICI DURANTE LA CONSER-VAZIONE DELL'OLIO EXTRA VERGINE DI OLIVA, RIV. ITAL. SOS-TANZE GRASSE, 90, PP. 71-79, (2013); CRIADO M.N., RAMON MORELLO J., MOTILVA M.J., PAZ ROMERO M., EFFECT OF GROWING AREA ON PIGMENT AND PHENOLIC FRACTIONS OF VIRGIN OLIVE OILS OF THE ARBEQUINA VARIETY IN SPAIN, J. AM. OIL CHEM. SOC, 81, PP. 633-640, (2004); RIGANE G., BOUAZIZ M., SAYADI S., BEN SALEM M., EFFECT OF STORAGE ON REFINED OIL COMPOSITION: STABILIZATION BY ADDITION OF CHLOROPHYLL PIGMENTS AND SQUALENE, J. OLEO SCI, 62, PP. 981-987, (2013); DABBOU S., DABBOU S., SELVAGGINI R., URBANI S., TAT-ICCHI A., SERVILI M., HAMMAMI M., COMPARISON OF THE CHEMICAL COMPOSITION AND THE ORGANOLEPTIC PROFILE OF VIRGIN OLIVE OIL FROM TWO WILD AND TWO CULTIVATED TUNI-SIAN OLEA EUROPAEA, CHEM. BIODIVERS, 8, PP. 189-202, (2011); CONDE C., DELROT S., GEROS H., PHYSIOLOGICAL, BIOCHEMICAL AND MOLECULAR CHANGES OCCURRING DURING OLIVE DEVELOPMENT AND RIPENING, J. PLANT PHYSIOL, 165, PP. 1545-1562, (2008); GUERFEL M., BENMANSOUR M., OUNI Y., GUIDO F., BOUJ-NAH D., ZARROUK M., TRIACYLGLYCEROLS COMPOSITION AND VOLATILE COMPOUNDS OF VIRGIN OLIVE OIL FROM CHEMLALI CULTIVAR: COMPARISON AMONG DIFFERENT PLANTING DENSITIES, SCIENTIFICWORLDJOURNAL, 2012, PP. 1-6, (2012); MUDGE S.M., BELANGER S.E., NIELSEN A.M., FATTY ALCOHOLS - ANTHROPOGENIC AND NATURAL OCCURRENCE IN THE ENVIRONMENT, (2008); COMMISSION IMPLEMENTING REGULATION (EU), (2013); TRADE STANDARD APPLYING TO OLIVE OILS AND OLIVE-POMACE OILS, (2013); GROB K., LANFRANCHI M., MARIANI C., EVALUATION OF OLIVE OILS THROUGH THE FATTY ALCOHOLS, THE STEROLS AND THEIR ESTERS BY COUPLED LC-GC, J. AM. OIL CHEM. SOC, 67, (1990); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT. J. CLIN PHARMACOL. THER, 36, PP. 469-473, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. P, 29, PP. 891-897, (2002); TUBAILEH R.M., GARRIDO-FERNANDEZ A., RUIZ-MENDEZ M.V., LEON-CAMACHO M., GRACIANI-CONSTANTE E., EFFECTS OF PHYSICAL REFINING ON CONTENTS OF WAXES AND FATTY ALCOHOLS OF REFINED OLIVE OIL, J. AM. OIL CHEM. SOC, 79, PP. 101-104, (2002); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DELA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROTOINFLAM-MATORY MEDIATORS, J. NUTR. BIOCHEM, 20, PP. 155-162, (2009); GIUFFRE A.M., THE EFFECTS OF CULTIVAR AND HARVEST YEAR ON FATTY ALCOHOL COMPOSITION OF OLIVE OILS FROM SOUTH WEST CALABRIA (ITALY); GIUFFRE A.M., PISCOPO A., SICARI V., POIANA M., THE EFFECTS OF HARVESTING ON PHENOLIC COMPOUNDS AND FATTY ACIDS CONTENT IN VIRGIN OLIVE OIL (CV ROGGIANELLA), RIV. ITAL. SOSTANZE GRASSE, 87, PP. 14-23, (2010); SICARI V., GIUFFRE A.M., PISCOPO A., POIANA M., EFFECT OF THE OTTOBRATICA VARIETY RIPENING STAGE ON THE PHENOLIC PROFILE OF THE OBTAINED OIL, RIV. ITAL. SOSTANZE GRASSE, 86, PP. 215-219, (2009); GIUFFRE A.M., LOUADJ L., POIANA M., MACARIO A., COMPOSITION EN STEROLS DES HUILES EXTRAITES D' OLIVES DE CUL-TIVARS DE LA PROVINCE DE REGGIO CALABRIA(SUD D'ITALIE), RIV. ITAL. SOSTANZE GRASSE, 89, PP. 177-183, (2012); GIUFFRE A.M., VARIATION IN TRIACYLGLYCEROLS OF OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY) DURING OLIVE RIPENING, RIV. ITAL. SOSTANZE GRASSE; CONSLEG: 1991R2568 - 01/11/ 2003, ON THE CHARACTERISTICS OF OLIVE OIL AND OLIVE-RESIDUE OIL AND ON THE RELEVANT METHODS OF ANALYSIS; LAZZEZ A., PERRI E., CARAVITA M.A., KHLIF M., COSSEN-TINI M., INFLUENCE OF OLIVE MATURITY STAGE AND GEOGRAPHICAL ORIGIN ON SOME MINOR COMPONENTS IN VIRGIN OLIVE OIL OF THE CHEMLALI VARIETY, J. AGRIC. FOOD CHEM, 56, PP. 982-988, (2008); RANALLI A., POLLASTRI L., CONTENTO S., DI LORETO G., IANNUCCI E., LUCERA L., RUSSI F., STEROL AND ALCOHOL COMPONENTS OF SEED, PULP AND WHOLE OLIVE FRUIT OILS. THEIR USE TO CHARACTERISE OLIVE FRUIT VARIETY BY MULTIVARIATES, J. SCI. FOOD AGRIC, 82, PP. 854-859, (2002); KRICHENE D., ALLALOUT A., SALVADOR M.D., FREGAPANE G., ZARROUK M., FATTY ACIDS, VOLATILES, STEROLS AND TRIT-ERPENIC ALCOHOLS OF SIX MONOVARIETAL TUNISIAN VIRGIN OLIVE OIL, EUR. J. LIPID SCI. TECHNOL, 112, PP. 400-409, (2010); GARCIA-GONZALES D.L., TENA N., APARICIO R., DESCRIBING THE CHEMICAL SINGULARITY OF THE SPANISH PROTECTED DESIGNATIONS OF ORIGIN FOR VIRGIN OLIVE OILS IN RELATION TO OILS FROM NEIGHBOURING AREAS, GRASAS ACEITES, 63, PP. 26-34, (2012); STRABBIOLI R., BOCCI F., FREGA N.G., QUALITÀ E STABILITÀ DELL' OLIO ESTRATTO DALLE OLIVE DELLE VARIETÀ MARCHIGIANE PIANTONE DI MOGLIANO E RAGGIA A CONFRONTO CON LA CV LECCINO, RIV. ITAL. SOSTANZE GRASSE, 84, PP. 125-132, (2007); EL ANTARI A., HILAL A., BOULOUHA B., EL MOUDNI A., INFLUENCE OF VARIETY, ENVIRONMENTAL AND CULTURAL TECHNIQUES ON THE CHARACTERISTICS OF OLIVE FRUITS AND THE CHEMICAL COMPOSITION OF EXTRA VIRGIN OLIVE OIL IN MOROCCO, OLIVAE, 80, PP. 29-36, (2000); SIFI S., BEN AMMAR K., CHEKIR S., AMAMOU T., ETUDE DE COMPOSÉ MINEURS LIBRE ET ESTERIFIÉS DANS LA FRACTION INSAPONIFIABLE DES HUILES D'OLIVES TUNISIENNES, RIV. ITAL. SOSTANZE GRASSE, 80, PP. 229-231, (2003); RANALLI A., MODESTI G., PATUMI M., FONTANAZZA G., THE COMPOSITIONAL QUALITY AND SENSORY PROPERTIES OF VIRGIN OLIVE OIL FROM A NEW OLIVE CULTIVAR - I-77, FOOD CHEM, 69, PP. 37-46, (2000); APARICIO R., LUNA G., CHARACTERISATION OF MONOVARIETAL VIRGIN OLIVE OILS, EUR. J. LIPID SCI. TECHNOL, 104, PP. 614-627, (2002); RIVERA DEL ALAMO R.M., FREGAPANE G., ARANDA F., GOMEZ-ALONSO S., SALVADOR M.D., STEROL AND ALCOHOL COMPOSITION OF CORNICABRA VIRGIN OLIVE OIL: THE CAMPES-TEROL CONTENT EXCEEDS THE UPPER LIMIT OF 4% ESTABLISHED BY EU REGULATIONS, FOOD CHEM, 84, PP. 533-537, (2004); SAKOUHI F., BOUKHCHINA S., ABSALO C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUR. J. LIPID SCI. TECHNOL, 112, PP. 373-379, (2010)","A. M. GIUFFRÈ; UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, DIPARTIMENTO AGRARIA, ITALY; EMAIL: AMGIUFFRE@UNIRC.IT","JAPAN OIL CHEMISTS SOCIETY","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","2-S2.0-84899415437","J OLEO SCI","UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA","NOTREPORTED;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;NOTREPORTED",NA,"GIUFFRÈ AM, 2014, J OLEO SCI","GIUFFRÈ AM, 2014, J OLEO SCI"
"ILLNAIT J;LÓPEZ E;FERNÁNDEZ L;MAS R;GÁMEZ R;MESA M;MENDOZA S;FERNÁNDEZ J","ILLNAIT, JOSÉ (8631465800); LÓPEZ, ERNESTO (57198355062); FERNÁNDEZ, LILIA (7202848319); MAS, ROSA (7007164570); GÁMEZ, RAFAEL (7003605346); MESA, MEILIS (36880545700); MENDOZA, SARAHI (7102759819); FERNÁNDEZ, JULIO CÉSAR (9432805500)","EFFECTS OF POLICOSANOL 5 AND 10 MGDAY IN ADULTS WITH SERUM CHOLESTEROL LEVELS 59 MMOLL",2013,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH","22","6",4,"","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA","HYPERCHOLESTEROLEMIA IS A CORONARY RISK FACTOR. LOWERING SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) BENEFITS INDIVIDUALS WITH A BROAD RANGE OF SERUM TOTAL CHOLESTEROL (TC) VALUES. THEN, SUBJECTS ARE ENCOURAGED TO DECREASE LDL-C TO TARGETS ACCORDING TO THEIR INDIVIDUAL CORONARY RISKS. POLICOSANOL, PURIFIED FROM SUGAR CANE WAX, HAS BEEN SHOWN TO LOWER LDL-C IN SUBJECTS WITH ""NORMAL TO MILDLY ELEVATED TC"", BUT NEW EVIDENCES ON THIS POPULATION ARE REQUIRED. OBJECTIVE OF THE PRESENT STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF POLICOSANOL 5 AND 10 MG/DAY IN SUBJECTS WITH SERUM TC ≤ 5.9 MMOL/L. AFTER A 4 WEEK DIET-ONLY PERIOD, 90 SUBJECTS OF BOTH SEXES (MEAN AGE: 57 YEARS) WERE DOUBLE-BLINDED TO PLACEBO, POLICOSANOL 5 MG/DAY OR POLICOSANOL 10 MG/DAY FOR 12 WEEKS. LIPID PROFILE, SAFETY INDICATORS, ADVERSE EVENTS (AE) AND COMPLIANCE WITH STUDY TREATMENTS WERE ASSESSED. POLICOSANOL (5 AND 10 MG/DAY) SIGNIFICANTLY (P< 0.00001) LOWERED LDL-C (17.6% AND 19.7%, RESPECTIVELY) AND TC (13.1% AND 17.4%), RAISED (P<0.00001) HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) (11.3% AND 14.8%), AND UNCHANGED TRIGLYCERIDES. LIPID PROFILE UNCHANGED IN PLACEBO. THE FREQUENCY OF POLICOSANOL-TREATED SUBJECTS WHO REACHED LDL-C TARGETS (54/70, 5 MG/DAY) (60/70, 10 MG/DAY) WAS GREATER (P < 0.001) THAN IN PLACEBO (4/70). POLICOSANOL WAS WELL TOLERATED. SEVEN SUBJECTS (4 PLACEBO, 2 POLICOSANOL-5MG, 1 POLICOSANOL-10MG) DISCONTINUED THE TRIAL, TWO (PLACEBO) DUE TO AE (DIZZINESS, DIARRHOEA). THIS STUDY DEMONSTRATES THAT POLICOSANOL (5 AND 10 MG/DAY) FOR 12 WEEKS LOWERED SERUM LDL-C AND TC, AND RAISED HDL-C IN SUBJECTS WITH SERUM TC ≤ 5.9 MMOL/L, BEING WELL TOLERATED.","BORDERLINE CHOLESTEROL; CHOLESTEROL LOWERING; LDL-C; POLICOSANOL","HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGE DISTRIBUTION; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; EVENING DOSAGE; FEMALE; HEADACHE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; PARESTHESIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO; WEIGHT REDUCTION","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOY L.A., ET AL., FOR THE CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A., AYLWARD P., COLQHOUN D., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, NEW ENG J MED, 339, PP. 1349-1357, (1998); DOWNS J.R., CLEARFIELD M., WEISS S., FOR THE AFCAPS/TEXCAPS RESEARCH GROUP. PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GRUNDY S.M., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, PP. 227-239, (2004); TERAMOTO T., SASAKI J., UESHIMA H., EXECUTIVE SUMMARY OF JAPAN ATHEROSCLEROSIS SOCIETY (JAS) GUIDELINE FOR DIAGNOSIS AND PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES FOR JAPANESE, J ATHEROSCLER THROMB, 14, PP. 45-50, (2007); SHERBET D.P., GARG P., BRILAKIS E.S., BANERJEE S., LOW-DENSITY LIPOPROTEIN CHOLESTEROL: HOW LOW CAN WE GO?, AM J CARDIOVASC DRUGS, (2013); BROWN T.M., TANNER R.M., CARSON A.P., YUN H., ROSENSON R.S., FARKOUH M.E., WOOLLEY J.M., THACKER E.L., GLASSER S.P., SAFFORD M.M., MUNTNER P., AWARENESS, TREATMENT, AND CONTROL OF LDL CHOLESTEROL ARE LOWER AMONG UNITED STATES ADULTS WITH UNDIAGNOSED DIABETES VERSUS DIAGNOSED DIABETES, DIABETES CARE, (2013); GAO F., ZHOU Y.J., DA HU Y., ZHAO Y.X., LIU Y.Y., WANG Z.J., YANG S.W., LIU X.L., CONTEMPORARY MANAGEMENT AND ATTAINMENT OF CHOLESTEROL TARGETS FOR PATIENTS WITH DYSLIPIDEMIA IN CHINA, PLOS ONE, 8; TAKAHASHI E., MORIYAMA K., YAMAKADO M., STATUS OF DYSLIPIDEMIA TREATMENT IN JAPANESE ADULTS: AN ANALYSIS OF THE 2009 JAPAN SOCIETY OF NINGEN DOCK DATABASE, INTERN MED, 52, PP. 295-301, (2013); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., ACOSTA P., ALFONSO J., MAS R., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL THER, 318, PP. 1020-1025, (2006); ROSSO S.O., CALCIO E., MANTEGNA S., REGUALTION OF HMGCOA REDUCTASE BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, (2009); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, (2011); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT J NUTR, 77, PP. 923-932, (1997); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL MED SCI, 56, (2001); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); NIKITIN I.P., SLEPCHENKO N.V., GRATSIANSKII N.A., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC POLICOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS & AGING, 20, PP. 153-163, (2002); WANG Y., KUANMAN K.E., HIA L.W., JIAO Y., ZHAO X., SUN N., YANG X., SUN R., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); LIU S., TAN M.Y., ZHAO S.P., RONG H., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND HEME OXYGENASE-1 IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 40, PP. 840-843, (2012); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., FERNANDEZ L., MAS R., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2000); HERNANDEZ F., ILLNAIT J., MAS R., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); MENENDEZ R., MAS R., AMOR A.M., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT J CLIN PHARMACOL, 50, PP. 255-262, (2000); CASTANO G., MAS R., FERNANDEZ J., EFFECTS OF POLICOSANOL ON PATIENTS WITH BORDERLINE TO MILDLY INCREASED SERUM CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLINDED PLACEBOCONTROLLED STUDY, CURR THER RES CLIN & EXP, 64, PP. 522-536, (2003); LOPEZ E., ILLNAIT J., FERNANDEZ J.C., FERNANDEZ L., GAMEZ R., MESA M., MENDOZA S., MAS R., RUIZ D., JARDINES Y., EFFECTS OF SUGARCANE WAX ALCOHOLS IN SUBJECTS WITH NORMAL OR BORDERLINE SERUM CHOLESTEROL LEVELS, REV CENIC CIEN BIOL, 41, PP. 31-37, (2010); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., GORDON M., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); NARANJO C.A., BUSTO U., SELLERS E.M., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN PHARMACOL THER, 30, PP. 239-245, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); AMBEGAONKAR B., CHIROVSKY D., TSE H.F., LAU Y.K., TOMLINSON B., LI S.K., YUE C.S., WONG T.H., CHOI M.C., TUNGGAL P., SAZONOV V., ATTAINMENT OF NORMAL LIPID LEVELS AMONG PATIENTS ON LIPIDMODIFYING THERAPY IN HONG KONG, ADV THER, 29, PP. 427-441, (2012); LEE J.A., SUNWOO S., KIM Y.S., OH H.J., KANG H.C., PARK K.C., SIN D.H., LEE S.Y., YANG Y.J., YU B.Y., KIM C.M., ACHIEVING RECOMMENDED LOW DENSITY LIPOPROTEIN CHOLESTEROL GOALS AND THE FACTORS ASSOCIATED WITH TARGET ACHIEVEMENT OF HYPERCHOLESTEROLEMIA PATIENTS WITH ROSUVASTATIN IN PRIMARY CARE, CURR MED RES OPIN, 29, PP. 751-760, (2013); FERNANDEZ L., MAS R., ILLNAIT J., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); FERNANDEZ S., MAS R., GAMEZ R., A PHARMACOLOGICAL SURVEILLANCE OF POLICOSANOL TOLERABILITY IN THE ELDERLY, AM J GER PHARMACOTHERAPY, 2, PP. 219-229, (2004)","S. MENDOZA; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC), HAVANA CITY, CUBA; EMAIL: SARAHI.MENDOZA@CNIC.EDU.CU","","ENGLISH","INTL. J. PHARM. SCI. REV. RES.","ARTICLE","ISI","2-S2.0-84884925387","INTL J PHARM SCI REV RES","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC);MEDICAL SURGICAL RESEARCH CENTRE;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC);NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC);NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC);MEDICAL SURGICAL RESEARCH CENTRE;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC);NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC)","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH RESEARCH (CNIC);NOTREPORTED",NA,"ILLNAIT J, 2013, INTL J PHARM SCI REV RES","ILLNAIT J, 2013, INTL J PHARM SCI REV RES"
"MANNARINO M;MINISTRINI S;PIRRO M","MANNARINO, MASSIMO R. (26643162800); MINISTRINI, STEFANO (56235852300); PIRRO, MATTEO (22036502300)","NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA",2014,"EUROPEAN JOURNAL OF INTERNAL MEDICINE","25","7",70,"10.1016/j.ejim.2014.06.008","UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, UNIVERSITY OF PERUGIA, HOSPITAL SANTA MARIA DELLA MISERICORDIA, 1-06129, PERUGIA, PIAZZALE MENGHINI, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, UNIVERSITY OF PERUGIA, HOSPITAL SANTA MARIA DELLA MISERICORDIA, 1-06129, PERUGIA, PIAZZALE MENGHINI, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, UNIVERSITY OF PERUGIA, HOSPITAL SANTA MARIA DELLA MISERICORDIA, 1-06129, PERUGIA, PIAZZALE MENGHINI, ITALY","HYPERCHOLESTEROLEMIA IS A WELL-ESTABLISHED MODIFIABLE CARDIOVASCULAR RISK FACTOR AND ITS TREATMENT IS AN ESSENTIAL AIM IN PREVENTING CARDIOVASCULAR DISEASE. CURRENT GUIDELINES HIGHLIGHT LIFESTYLE INTERVENTION AS A PRIMARY ISSUE IN THE TREATMENT OF THE PATIENT WITH HYPERCHOLESTEROLEMIA. THERAPEUTIC LIFESTYLE CHANGES ARE OFTEN INSUFFICIENT TO ACHIEVE DESIRABLE CHOLESTEROL LEVELS. THIS IS PARTICULARLY TRUE FOR HIGH RISK PATIENTS; HOWEVER, ALSO LOW RISK PATIENTS, WHOSE CHOLESTEROL LEVELS ARE NOT NECESSARILY FAR FROM RECOMMENDED TARGETS, HAVE EITHER SUB-OPTIMAL OR EVEN SIGNIFICANTLY INCREASED LIPID LEVELS. NUTRACEUTICALS ARE BORDERLINE DEVICES BETWEEN NUTRIENTS AND DRUGS PROVIDING A SUPPLEMENTATION OF PARTICULAR NUTRIENTS WITH BENEFICIAL EFFECTS ON HEALTH. SEVERAL NUTRACEUTICALS HAVE BEEN SUGGESTED TO IMPROVE PLASMA LIPID PROFILE. THE LITERATURE COUNTED OVER 40 NUTRACEUTICAL SUBSTANCES WITH A SUPPOSED BENEFICIAL EFFECT ON LIPID METABOLISM; FOR SOME OF THEM A NUMBER OF CLINICAL TRIALS HIGHLIGHTED A CHOLESTEROL LOWERING EFFECT AND A POSSIBLE POSITIVE INFLUENCE ON CARDIOVASCULAR PROGNOSIS. THE AIM OF THIS ARTICLE IS TO REVIEW THE MAIN EVIDENCES SUPPORTING OR DENYING THE EFFICACY AND SAFETY OF SOME OF THE MOST COMMONLY USED NUTRACEUTICALS WITH SUPPOSED CHOLESTEROL LOWERING ACTIVITY. © 2014 EUROPEAN FEDERATION OF INTERNAL MEDICINE.","BERBERINE; HYPERCHOLESTEROLEMIA; NUTRACEUTICALS; PHYTOSTEROLS; RED YEAST RICE","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DIETARY SUPPLEMENTS; HUMANS; HYPERCHOLESTEROLEMIA; BERBERINE; CHOLESTEROL; CHOLESTIN; DAIDZIN; EZETIMIBE; GENISTEIN; GLYCITIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; PHYTOSTEROL; POLICOSANOL; SIMVASTATIN; SOYBEAN PROTEIN; STANOZOLOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; BERBERINE; CHOLESTIN; HYPOCHOLESTEROLEMIC AGENT; NUTRACEUTICAL; PHYTOSTEROL; POLICOSANOL; SOY DERIVATIVE; STANOZOLOL; CHOLESTEROL BLOOD LEVEL; DIETARY FIBER; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LOW RISK PATIENT; NUTRIENT; PROGNOSIS; REVIEW; BLOOD; DIET SUPPLEMENTATION; HYPERCHOLESTEROLEMIA; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC)","","","ALLENDER S., SCARBOROUGH P., PETO V., RAYNER M., LEAL J., LUENGO-FERNANDEZ R., ET AL., EUROPEAN CARDIOVASCULAR DISEASE STATISTICS, 2008 EDITION INTERNET, (2008); BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., BHALA N., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170000 PARTICIPANTS IN 26 RANDOMIZED TRIALS, LANCET, 376, 9753, PP. 1670-1681, (2010); STONE N.J., ROBINSON J., LICHTENSTEIN A.H., BAIREY MERZ C.N., LLOYD-JONES D.M., BLUM C.B., ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES INTERNET, CIRCULATION, (2013); CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., AGEWALL E., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); NEATON J.D., BLACKBURN H., JACOBS D., KULLER L., LEE D.J., SHERWIN R., ET AL., SERUM CHOLESTEROL LEVEL AND MORTALITY FINDINGS FOR MEN SCREENED IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL. MULTIPLE RISK FACTOR INTERVENTION TRIAL RESEARCH GROUP, ARCH INTERN MED, 152, 7, PP. 1490-1500, (1992); PIRRO M., DEL GIORNO R., LUPATTELLI G., MANNARINO M.R., ROSCINI A.R., COVELLI D., ET AL., CARDIOVASCULAR RISK FACTORS AND RECOMMENDED LIPID GOALS ATTAINMENT AMONG PATIENTS REFERRED IN A TERTIARY CARE LIPID CLINIC, EUR J INT MED, 22, 4, PP. 412-417, (2011); SHAY C.M., NING H., ALLEN N.B., CARNETHON M.R., CHIUVE S.E., GREENLUND K.J., ET AL., STATUS OF CARDIOVASCULAR HEALTH IN US ADULTS: PREVALENCE ESTIMATES FROM THE NATIONAL HEALTH AND NUTRITION SURVEYS (NHANES) 2003-2008, CIRCULATION, 125, 1, PP. 45-56, (2012); ARCA M., PIGNA G., TREATING STATIN-INTOLERANT PATIENTS, DIABETES METAB SYNDR OBES, 4, PP. 155-166, (2011); ABD T.T., JACOBSON T.A., STATIN-INDUCED MYOPATHY: A REVIEW AND UPDATE, EXPERT OPIN DRUG SAF, 10, PP. 373-387, (2011); BLAHA M.J., NASIR K., BLUMENTHAL R.S., STATIN THERAPY FOR HEALTHY MEN IDENTIFIED AS ""INCREASED RISK, JAMA, 307, 14, PP. 1489-1490, (2012); REDBERG R.F., KATZ M.H., HEALTHY MEN SHOULD NOT TAKE STATINS, JAMA, 307, 14, PP. 1491-1492, (2012); HOWARD B.V., VAN HORN L., HSIA J., MANSON J.E., STEFANICK M.L., WASSERTHEIL-SMOLLER S., ET AL., LOW-FAT DIETARY PATTERN AND RISK OF CARDIOVASCULAR DISEASE: THE WOMEN'S HEALTH INITIATIVE RANDOMIZED CONTROLLED DIETARY MODIFICATION TRIAL, JAMA, 295, PP. 655-666, (2006); CHAUHAN B., KUMAL G., KALAM N., ANSARI S.H., CURRENT CONCEPTS AND PROSPECTS OF HERBAL NUTRACEUTICAL: A REVIEW, J ADV PHARM TECHNOL RES, 4, 1, PP. 4-8, (2013); ZEISEL S.H., REGULATION OF ""NUTRACEUTICALS, SCIENCE, 285, PP. 1853-1855, (1999); SILVER SPRING: U.S. FOOD AND DRUG ADMINISTRATION; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; IMPLEMENTING RULES FOR APPLICATIONS FOR AUTHORIZATION OF HEALTH CLAIMS AS PROVIDED FOR IN ARTICLE 15 OF REGULATION NO 1924/2006 OF THE EUROPEAN PARLIAMENT AND THE COUNCIL, COMMISSION REGULATION NO 353/2008 OF 18 APRIL 2008, (2008); HOUSTON M., THE ROLE OF NUTRACEUTICAL SUPPLEMENTS IN THE TREATMENT OF DYSLIPIDEMIA, J CLIN HYPERTENS, 14, PP. 121-132, (2012); HOUSTON M.C., FAZIO S., CHILTON F.H., WISE D.E., JONES K.B., BARRINGER T.A., ET AL., NON PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA, PROG CARDIOVASC DIS, 52, PP. 61-94, (2009); MIKSICEK R.J., ESTROGENIC FLAVONOIDS: STRUCTURAL REQUIREMENTS FOR BIOLOGICAL ACTIVITY, PROC SOC EXP BIOL MED, 208, PP. 44-50, (1995); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); SACKS F.M., LICHTENSTEIN A., VAN HORN L., HARRIS W., KRIS-ETHERTON P., WINSTON M., SOY PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH. A SUMMARY OF A STATEMENT FOR PROFESSIONALS FROM THE AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, ARTERIOSCLER THROMB VASC BIOL, 26, PP. 1689-1692, (2006); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); JENKINS D.J., KENDALL C.W., MARCHIE A., FAULKNER D.A., WONG J.M., DE SOUZA R., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL LOWERING FOODS VS LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, J AM MED ASSOC, 290, PP. 502-510, (2003); KOKUBO Y., ISO H., ISHIHARA J., OKADA K., INOUE M., TSUGANE S., ASSOCIATION OF DIETARY INTAKE OF SOY, BEANS, AND ISOFLAVONES WITH RISK OF CEREBRAL AND MYOCARDIAL INFARCTIONS IN JAPANESE POPULATIONS. THE JAPAN PUBLIC HEALTH CENTER-BASED (JPHC) STUDY COHORT I, CIRCULATION, 116, PP. 2553-2562, (2007); EASTWOOD M.A., PASSMORE R., DIETARY FIBRE, LANCET, 2, PP. 202-206, (1983); KEYS A., GRANDE F., ANDERSON J.T., FIBRE AND PECTIN IN THE DIET AND SERUM CHOLESTEROL CONCENTRATION IN MAN, PROC SOC EXP BIOL, 106, PP. 555-558, (1961); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); GLORE S.R., VAN TREECK D., KNEHANS A.W., GUILD M., SOLUBLE FIBER AND SERUM LIPIDS: A LITERATURE REVIEW, J AM DIET ASSOC, 94, PP. 425-436, (1994); KRIS-ETHERTON P.M., KRUMMEL D., RUSSELL M.E., DREON D., MACKEY S., BORCHERS J., ET AL., THE EFFECT OF DIET ON PLASMA LIPIDS, LIPOPROTEINS, AND CORONARY HEART DISEASE, J AM DIET ASSOC, 88, PP. 1373-1400, (1988); LIU S., BURING J.E., SESSO H.D., RIMM E.B., WILLETT W.C., MANSON J.E., A PROSPECTIVE STUDY OF DIETARY FIBER INTAKE AND RISK OF CARDIOVASCULAR DISEASE AMONG WOMEN, J AM COLL CARDIOL, 39, PP. 49-56, (2002); JACOBS D.R., PEREIRA M.A., MEYER K.A., KUSHI L.H., FIBER FROM WHOLE GRAINS, BUT NOT REFINED GRAINS, IS INVERSELY ASSOCIATED WITH ALL-CAUSE MORTALITY IN OLDER WOMEN: THE IOWA WOMEN'S HEALTH STUDY, J AM COLL NUTR, 19, (2000); PEREIRA M.A., O'REILLY E., AUGUSTSSON K., FRASER G.E., GOLDBOURT U., HEITMANN B.L., ET AL., DIETARY FIBER AND RISK OF CORONARY HEART DISEASE: A POOLED ANALYSIS OF COHORT STUDIES, ARCH INTERN MED, 164, PP. 370-376, (2004); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., BASORA-GALLISA J., RUIZ-GUTIERREZ V., COVAS M.I., ET AL., EFFECTS OF DIETARY FIBRE INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK, J EPIDEMIOL COMMUNITY HEALTH, 63, PP. 582-588, (2009); RESEARCH COUNCIL N., DIETARY REFERENCE INTAKES FOR ENERGY, CARBOHYDRATE, FIBER, FAT, FATTY ACIDS, CHOLESTEROL, PROTEIN, AND AMINO ACIDS (MACRONUTRIENTS), (2005); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ALTRINGER L.A., JERDACK G.R., HENGEHOLD D.A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, 2, PP. 472-479, (2000); HEINEMANN T., AXTMANN G., VON BERGMANN K., COMPARISON OF INTESTINAL ABSORPTION OF CHOLESTEROL WITH DIFFERENT PLANT STEROLS IN MAN, EUR J CLIN INVEST, 23, PP. 827-831, (1993); VON BERGMANN K., PRANGE W., LUTJOHANN D., METABOLISM AND MECHANISM OF ACTION OF PLANT STEROLS, EUR HEART J, 1, SUPPL. N, (1999); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., GORDON M., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); HO S.S., PAL S., MARGARINE PHYTOSTEROLS DECREASE THE SECRETION OF ATHEROGENIC LIPOPROTEINS FROM HEPG2 LIVER AND CACO2 INTESTINAL CELLS, ATHEROSCLEROSIS, 182, 1, PP. 29-36, (2005); SABEVA N.S., MCPHAUL C.M., LI X., CORY T.J., FEOLA D.J., GRAF G.A., PHYTOSTEROLS DIFFERENTLY INFLUENCE ABC TRANSPORTER EXPRESSION, CHOLESTEROL EFFLUX AND INFLAMMATORY CYTOKINE SECRETION IN MACROPHAGE FOAM CELLS, J NUTR BIOCHEM, 22, PP. 777-783, (2011); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., ET AL., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, PP. 965-978, (2003); MATTSON F.H., VOLPENHEIN R.A., ERICKSON B.A., EFFECT OF PLANT STEROL ESTERS ON THE ABSORPTION OF DIETARY CHOLESTEROL, J NUTR, 107, PP. 139-1146, (1977); MANNARINO E., PIRRO M., CORTESE C., LUPATTELLI G., SIEPI D., MEZZETTI A., ET AL., EFFECTS OF A PHYTOSTEROL-ENRICHED DAIRY PRODUCT ON LIPIDS, STEROLS AND 8-ISOPROSTANE IN HYPERCHOLESTEROLEMIC PATIENTS: A MULTICENTER ITALIAN STUDY, NUTR METAB CARDIOVASC DIS, 19, 2, PP. 84-90, (2009); HALLIKAINEN M.A., UUSITUPA M.I., EFFECTS OF 2 LOW-FAT STANOL ESTER-CONTAINING MARGARINES ON SERUM CHOLESTEROL CONCENTRATIONS AS PART OF A LOW-FAT DIET IN HYPERCHOLESTEROLEMIC SUBJECTS, AM J CLIN NUTR, 69, PP. 403-410, (1999); AMIR SHAGHAGHI M., ABUMWEIS S.S., JONES P.J., CHOLESTEROL-LOWERING EFFICACY OF PLANT STEROLS/STANOLS PROVIDED IN CAPSULE AND TABLET FORMATS: RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS, J ACAD NUTR DIET, 113, 11, PP. 1494-1503, (2013); GUARDAMAGNA O., ABELLO F., BARACCO V., ET AL., PRIMARY HYPERLIPIDEMIAS IN CHILDREN: EFFECT OF PLANT STEROL SUPPLEMENTATION ON PLASMA LIPIDS AND MARKERS OF CHOLESTEROL SYNTHESIS AND ABSORPTION, ACTA DIABETOL, 48, PP. 127-133, (2011); BECKER M., STAAB D., VON BERGMANN K., TREATMENT OF SEVERE FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDHOOD WITH SITOSTEROL AND SITOSTANOL, J PEDIATR, 122, PP. 292-296, (1993); GYLLING H., PLAT J., TURLEY S., GINSBERG H.N., ELLEGARD L., JESSUP W., ET AL., PLANT STEROLS AND PLANT STANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 232, 2, PP. 346-360, (2014); BLAIR S.N., CAPUZZI D.M., GOTTLIEB S.O., NGUYEN T., MORGAN J.M., CATER N.B., INCREMENTAL REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH THE ADDITION OF PLANT STANOL ESTER-CONTAINING SPREAD TO STATIN THERAPY, AM J CARDIOL, 86, PP. 46-52, (2000); VUORIO A.F., GYLLING H., TURTOLA H., KONTULA K., KETONEN P., MIETTINEN T.A., STANOL ESTER MARGARINE ALONE AND WITH SIMVASTATIN LOWERS SERUM CHOLESTEROL IN FAMILIES WITH FAMILIAL HYPERCHOLESTEROLEMIA CAUSED BY THE FH-NORTH KARELIA MUTATION, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 500-506, (2000); GYLLING H., MIETTINEN T.A., EFFECTS OF INHIBITING CHOLESTEROL ABSORPTION AND SYNTHESIS ON CHOLESTEROL AND LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC NON-INSULIN-DEPENDENT DIABETIC MEN, J LIPID RES, 37, PP. 1776-1785, (1996); WANG P., CHEN Y.M., HE L.P., CHEN C.G., ZHANG B., XUE W.Q., ET AL., ASSOCIATION OF NATURAL INTAKE OF DIETARY PLANT STEROLS WITH CAROTID INTIMA-MEDIA THICKNESS AND BLOOD LIPIDS IN CHINESE ADULTS: A CROSS SECTION STUDY, PLOS ONE, 7, 3, (2012); RAITAKARI O.T., SALO P., GYLLING H., MIETTINEN T.A., PLANT STANOL ESTER CONSUMPTION AND ARTERIAL ELASTICITY AND ENDOTHELIAL FUNCTION, BR J NUTR, 100, PP. 603-608, (2008); RAITAKARI O.T., SALO P., AHOTUPA M., CAROTID ARTERY COMPLIANCE IN USERS OF PLANT STANOL ESTER MARGARINE, EUR J CLIN NUTR, 62, PP. 218-224, (2008); PLAT J., MENSINK R.P., VEGETABLE OIL BASED VERSUS WOOD BASED STANOL ESTER MIXTURES: EFFECTS ON SERUM LIPIDS AND HEMOSTATIC FACTORS IN NON-HYPERCHOLESTEROLEMIC SUBJECTS, ATHEROSCLEROSIS, 148, PP. 101-112, (2000); EXPERT PANEL OF THE DIET AND CANCER PROJECT, FOOD, NUTRITION AND THE PREVENTION OF CANCER: A GLOBAL PERSPECTIVE, PP. 412-413, (1997); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); DULIN M.F., HATCHER L.F., SASSER H., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); MA J., LI Y., YE Q., LI J., HUA Y., JU D., ET AL., CONSTITUENTS OF RED YEAST RICE, A TRADITIONAL CHINESE FOOD AND MEDICINE, J AGRIC FOOD CHEM, 48, PP. 5220-5225, (2000); WENT F.A., MONASCUS PURPUREUS LE CHAMPIGNON DE L'ANGQUAC UNE NOUVELLE THELOBOLEE, ANN SOC NAT BOT, 8, PP. 1-17, (1895); ENDO A., MONACOLIN K., A NEW HYPOCHOLESTEROLEMIC AGENT PRODUCED BY A MONASCUS SPECIES, J ANTIBIOT (TOKYO), 32, PP. 852-854, (1979); LIN C.C., LI T.C., LAI M.M., WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LI J.J., LU Z.L., KOU W.R., CHEN Z., WU Y.F., YU X.H., ET AL., BENEFICIAL IMPACT OF XUEZHIKANG ON CARDIOVASCULAR EVENTS AND MORTALITY IN ELDERLY HYPERTENSIVE PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION FROM THE CHINA CORONARY SECONDARY PREVENTION STUDY (CCSPS), J CLIN PHARMACOL, 49, 8, PP. 947-956, (2009); YANG C.W., MOUSA S.A., THE EFFECT OF RED YEAST RICE (MONASCUS PURPUREUS) IN DYSLIPIDEMIA AND OTHER DISORDERS, COMPLEMENT THER MED, 20, PP. 466-474, (2012); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, 830, (2009); HANSEN K.E., HILDEBRAND J.P., FERGUSON E.E., STEIN J.H., OUTCOMES IN 45 PATIENTS WITH STATIN-ASSOCIATED MYOPATHY, ARCH INTERN MED, 165, PP. 2671-2676, (2005); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS, ARCH INTERN MED, 170, PP. 1722-1727, (2010); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, 2, PP. 133-139, (2001); BENNETT J.W., KLICH M., MYCOTOXINS, CLIN MICROBIOL REV, 16, 3, PP. 497-516, (2003); YIN J., ZHANG H., YE J., TRADITIONAL CHINESE MEDICINE IN TREATMENT OF METABOLIC SYNDROME, ENDOCRINOL METAB IMMUNE DISORD DRUG TARGETS, 8, 2, PP. 99-111, (2008); LEE S., LIM H.J., PARK J.H., LEE K.S., JANG Y., PARK H.Y., BERBERINE INDUCED LDLR UP-REGULATION INVOLVES JNK PATHWAY, BIOCHEM BIOPHYS RES COMMUN, 362, PP. 853-857, (2007); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASE PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); BRUSQ J.M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINTILLAN Y., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); DONG H., ZHAO Y., ZHAO L., FUER L., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); KONG W.J., WEI J., ZUO Z.Y., WANG Y.M., SONG D.Q., YOU X.F., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFECT, METABOLISM, 57, PP. 1029-1037, (2008); GUO Y., CHEN Y., TAN Z.R., KLAASSEN C.D., ZHOU H.H., REPEATED ADMINISTRATION OF BERBERINE INHIBITS CYTOCHROMES P450 MRNA EXPRESSION AND ACTIVITIES IN MICE, J ETHNOPHARMACOL, 138, PP. 111-118, (2011); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); PIRRO M., LUPATTELLI G., DEL GIORNO R., SCHILLACI G., BERISHA S., MANNARINO M.R., ET AL., NUTRACEUTICAL COMBINATION (RED YEAST RICE, BERBERINE AND POLICOSANOLS) IMPROVES AORTIC STIFFNESS IN LOW-MODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS, PHARMA NUTR, 1, PP. 73-77, (2013); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, PP. 424-429, (2011); BECKER D.J., GORDON R.Y., MORRIS P.B., YORKO J., GORDON J.Y., LI M., ET AL., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN PROC, 83, PP. 758-764, (2008); BECKER D.J., FRENCH B., MORRIS P.B., SILVENT E., GORDON R.Y., PHYTOSTEROLS, RED YEAST RICE, AND LIFESTYLE CHANGES INSTEAD OF STATINS: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL, AM HEART J, 166, PP. 187-196, (2013); AGOSTONI C., BRESSON J.L., FAIRWEATHER-TAIT S., FLYNN A., GOLLY I., KORHONEN H., ET AL., SCIENTIFIC OPINION ON THE SUBSTANTIATION OF A HEALTH CLAIM RELATED TO ISOLATED SOY PROTEIN AND REDUCTION OF BLOOD LDL-CHOLESTEROL CONCENTRATIONS PURSUANT TO ARTICLE 14 OF REGULATION (EC) NO 1924/2006, EFSA J, 10, 2, (2012); HEALTH CLAIMS: SOY PROTEIN AND RISK OF CORONARY HEART DISEASE (CHD), (1999); AGOSTONI C., BRESSON J.L., FAIRWEATHER-TAIT S., FLYNN A., GOLLY I., KORHONEN H., ET AL., SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO DIETARY FIBRE (ID 744, 745, 746, 748, 749, 753, 803, 810, 855, 1415, 1416, 4308, 4330) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 8, 10, (2010); HEALTH CLAIMS: SOLUBLE FIBER FROM CERTAIN FOODS AND RISK OF CORONARY HEART DISEASE (CHD), (2008); AGOSTONI C., BRESSON J.L., FAIRWEATHER-TAIT S., FLYNN A., GOLLY I., KORHONEN H., ET AL., SCIENTIFIC OPINION ON THE SUBSTANTIATION OF A HEALTH CLAIM RELATED TO 3 G/DAY PLANT STEROLS/STANOLS AND LOWERING BLOOD LDL-CHOLESTEROL AND REDUCED RISK OF (CORONARY) HEART DISEASE PURSUANT TO ARTICLE 19 OF REGULATION (EC) NO 1924/2006, EFSA J, 10, 5, (2012); HEALTH CLAIMS: PLANT STEROL/STANOL ESTERS AND RISK OF CORONARY HEART DISEASE (CHD), (2005); AGOSTONI C., BRESSON J.L., FAIRWEATHER-TAIT S., FLYNN A., GOLLY I., KORHONEN H., ET AL., SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO POLICOSANOLS FROM SUGAR CANE WAX AND MAINTENANCE OF NORMAL BLOOD LDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) AND MAINTENANCE OF NORMAL BLOOD HDL-CHOLESTEROL CONCENTRATIONS (ID 1747, 1748, 1864, 1951, 1954, 4693) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, 6, (2011); FULFILLMENT OF REPORTING OBLIGATION UNDER 21 U.S.C. 343(R) AND 21 C.F.R. 101.93; AGOSTONI C., BRESSON J.L., FAIRWEATHER-TAIT S., FLYNN A., GOLLY I., KORHONEN H., ET AL., SCIENTIFIC OPINION ON THE SUBSTANTIATION OF HEALTH CLAIMS RELATED TO MONACOLIN K FROM RED YEAST RICE AND MAINTENANCE OF NORMAL BLOOD LDL CHOLESTEROL CONCENTRATIONS (ID 1648, 1700) PURSUANT TO ARTICLE 13(1) OF REGULATION (EC) NO 1924/2006, EFSA J, 9, 7, (2011)","M.R. MANNARINO; UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, UNIVERSITY OF PERUGIA, HOSPITAL SANTA MARIA DELLA MISERICORDIA, 1-06129, PERUGIA, PIAZZALE MENGHINI, ITALY; EMAIL: MASSIMO.MANNARINO@UNIPG.IT","ELSEVIER B.V.","ENGLISH","EUR. J. INTERN. MED.","REVIEW","ISI","2-S2.0-84906933528","EUR J INTERN MED","UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA","NOTREPORTED;UNIVERSITY OF PERUGIA;NOTREPORTED",NA,"MANNARINO MR, 2014, EUR J INTERN MED","MANNARINO MR, 2014, EUR J INTERN MED"
"GUERRA Y;CUEVAS V;FERREIRO R;YERA A;DESPAIGNEV S","GUERRA, YOHANI PÉREZ (23995375700); CUEVAS, VIVIAN MOLINA (7006062814); FERREIRO, ROSA MAS (6602148780); YERA, AMBAR OYÁRZABAL (36020873200); DESPAIGNEV, SONIA JIMÉNEZ (56659492700)","EFFECTS OF POLICOSANOL PRETREATMENT ON BLOODBRAIN BARRIER DAMAGE INDUCED BY ISCHEMIAREPERFUSION IN RATS",2015,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH","32","5",3,"","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BLOOD-BRAIN BARRIER (BBB) DISRUPTION FOLLOWING ISCHEMIA-REPERFUSION (I/R) IS ASSOCIATED WITH POOR OUTCOMES IN STROKE PATIENTS. POLICOSANOL, A MIXTURE OF SUGARCANE WAX ALCOHOLS, HAS BEEN SHOWN TO PROTECT AGAINST CEREBRAL FUNCTIONAL AND HISTOLOGICAL DISTURBANCES INDUCED BY I/R IN GERBILS. NEVERTHELESS, THE EFFECTS OF POLICOSANOL ON EXPERIMENTALLY INDUCED BBB DISRUPTION HAVE NOT BEEN EXPLORED. THE OBJECTIVE OF THIS STUDY WAS TO INVESTIGATE THE EFFECTS OF POLICOSANOL ON BBB DISRUPTION FOLLOWING THE INDUCTION OF CEREBRAL I/R IN RATS. RATS WERE RANDOMIZED INTO A NEGATIVE VEHICLE CONTROL AND FIVE I/R GROUPS: A POSITIVE VEHICLE CONTROL, THREE POLICOSANOL (50, 200 AND 400 MG/KG), ONE ASPIRIN (150 MG/KG). TREATMENTS WERE GIVEN ORALLY 1 H BEFORE ISCHEMIA INDUCTION. BRAIN ISCHEMIA WAS INDUCED BY 30 MIN BILATERAL OCCLUSION OF CAROTID ARTERIES, FOLLOWED BY 24 H REPERFUSION. BBB PERMEABILITY WAS EVALUATED ACCORDING TO EVANS BLUE (EB) DYE EXTRAVASATION. ALSO, MYELOPEROXIDASE (MPO) ACTIVITY IN BRAIN HOMOGENATES WAS MEASURED. EB CONCENTRATION AND MPO VALUES AFTER 24 H OF REPERFUSION WERE SIGNIFICANTLY INCREASED IN POSITIVE CONTROLS WHEN COMPARED WITH THE NEGATIVE CONTROLS. ORAL PRE-TREATMENT WITH POLICOSANOL (50 - 400 MG/KG) SIGNIFICANTLY DECREASED EB EXTRAVASATION (60.4% - 71.7%) AS COMPARED TO THE POSITIVE CONTROLS. ASPIRIN REDUCED SIGNIFICANTLY BBB LEAKAGE BY 92.5%. ALSO, THE I/R-INDUCED INCREASES OF MPO ACTIVITIES WERE LOWERED SIGNIFICANTLY WITH POLICOSANOL (50 - 400 MG/KG) (46.3% - 65.3) AND ASPIRIN (68.4%). IN CONCLUSION, ORAL POLICOSANOL PRE-TREATMENT (50 – 400 MG/KG) PROTECTED AGAINST BBB DAMAGE INDUCED BY CEREBRAL I/R IN RATS, AND ATTENUATED THE INCREASE OF MPO, A MARKER OF INFLAMMATION, IN THE BRAIN TISSUE. © 2015, GLOBAL RESEARCH ONLINE. ALL RIGHTS RESERVED.","ASPIRIN; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; MYELOPEROXIDASE; POLICOSANOL","ACETYLSALICYLIC ACID; MYELOPEROXIDASE; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOLOGY; MALE; NONHUMAN; OUTCOME ASSESSMENT; RAT; REPERFUSION INJURY","","","BAKER W.L., MARRS J.C., DAVIS L.E., NUTESCU E.A., ROWE S.A., RYAN M., SPLINTER M.Y., VARDENY O., FAGAN S.C., PHARMACOTHERAPY, (2013); BAKER W.L., MARRS J.C., DAVIS L.E., NUTESCU E.A., ROWE A.S., RYAN M., SPLINTER M.Y., VARDENY O., FAGAN S.C., KEY ARTICLES AND GUIDELINES IN THE ACUTE MANAGEMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE, PHARMACOTHERAPY, (2013); MONTANER J., MENDIOROZ M., DELGADO P., GARCIA-BERROCOSO T., GIRALT D., MERINO C., RIBO M., ROSELL A., PENALBA A., FERNANDEZ- CADENAS I., ROMERO F., MOLINA C., ALVAREZ-SABIN J., HERNANDEZ-GUILLAMON M., RIBO M., ROSELL A., PENALBA A., FERNANDEZ-CADENAS I., ROMERO F., MOLINA C., ALVAREZ-SABIN J., HERNANDEZ-GUILLAMON M., DIFFERENTIATING ISCHEMIC FROM HEMORRHAGIC STROKE USING PLASMA BIOMARKERS: THE S100B/RAGE PATHWAY, J PROTEOMICS, 75, PP. 4758-4765, (2012); AMARENCO P., BOGOUSSLAVSKY J., CAPLAN L.R., DONNAN G.A., HENNERICI M.G., CLASSIFICATION OF STROKE SUBTYPES, CEREBROVASC DIS, 27, PP. 493-501, (2009); MADDEN J.A., ROLE OF THE VASCULAR ENDOTHELIUM AND PLAQUE IN ACUTE ISCHEMIC STROKE, NEUROLOGY, 79, PP. S58-S62, (2012); WANG Q., TANG X.N., YENARI M.A., THE INFLAMMATORY RESPONSE IN STROKE, J NEUROIMMUNOL, 184, PP. 53-68, (2007); RANSOHOFF R.M., KIVISAKK P., KIDD G., THREE OR MORE ROUTES FOR LEUKOCYTE MIGRATION INTO THE CENTRAL NERVOUS SYSTEM, NAT REV IMMUNOL, 3, PP. 569-581, (2003); BAKE S., SELVAMANI A., CHERRY J., SOHRABJI F., BLOOD BRAIN BARRIER AND NEUROINFLAMMATION ARE CRITICAL TARGETS OF IGF-1- MEDIATED NEUROPROTECTION IN STROKE FOR MIDDLE-AGED FEMALE RRATS, PLOS ONE, 9-11, 3, (2014); WARACH S., LATOUR L.L., EVIDENCE OF REPERFUSION INJURY, EXACERBATED BY THROMBOLYTIC THERAPY, IN HUMAN FOCAL BRAIN ISCHEMIA USING A NOVEL IMAGING MARKER OF EARLY BLOOD-BRAIN BARRIER DISRUPTION, 35, STROKE, PP. 2659-2661, (2004); LATOUR L.L., KANG D.W., EZZEDDINE M.A., CHALELA J.A., WARACH S., EARLY BLOOD-BRAIN BARRIER DISRUPTION IN HUMAN FOCAL BRAIN ISCHEMIA, ANN NEUROL, 56, PP. 468-477, (2004); AMANTEA D., NAPPI G., BERNARDI G., BAGETTA G., CORASANITI M.T., POST-ISCHEMIC BRAIN DAMAGE: PATHOPHYSIOLOGY AND ROLE OF INFLAMMATORY MEDIATORS, FEBS, J., 276, PP. 13-26, (2009); BACIGALUPPI M., COMI G., HERMANN D.A., ANIMAL MODELS OF ISCHEMIC STROKE, PART ONE: MODELING RISK FACTORS, OPEN NEUROL J, 4, PP. 26-33, (2010); GARCIA-BONILLA L., ROSELL A., TORREGROSA G., SALOM J.B., ALBORCH E., GUTIERREZ M., DIEZ-TEJEDOR E., MARTINEZ-MURILLO R., AGULLA J., RAMOS-CABRER P., CASTILLO J., GASULL T., MONTANER J., RECOMMENDATIONS GUIDE FOR EXPERIMENTAL ANIMAL MODELS IN STROKE RESEARCH, NEUROLOGIA, 26, PP. 105-110, (2011); NEUMANN-HAEFELIN T., KASTRUP A., DE CRESPIGNY A., YENARI M.A., RINGER T., SUN G.H., MOSELEY M.E., SERIAL MRI AFTER TRANSIENT FOCAL CEREBRAL ISCHEMIA IN RATS: DYNAMICS OF TISSUE INJURY, BLOOD-BRAIN BARRIER DAMAGE, AND EDEMA FORMATION, STROKE, 31, PP. 1965-1973, (2000); PILLAI D.R., DITTMAR M.S., BALDARANOV D., HEIDEMANN R.M., HENNING E.C., SCHUIERER G., BOGDAHN U., SCHLACHETZKI F., CEREBRAL ISCHEMIA-REPERFUSION INJURY IN RATS--A 3 T MRI STUDY ON BIPHASIC BLOOD-BRAIN BARRIER OPENING AND THE DYNAMICS OF EDEMA FORMATION, J CEREB BLOOD FLOW METAB, 29, PP. 1846-1855, (2009); DURUKAN A., MARINKOVIC I., STRBIAN D., PITKONEN M., PEDRONO E., SOINNE L., ABO-RAMADAN U., TATLISUMAK T., POST-ISCHEMIC BLOOD-BRAIN BARRIER LEAKAGE IN RATS: ONE-WEEK FOLLOW-UP BY MRI, BRAIN RES, 1280, PP. 158-165, (2009); SINGH D.P., CHOPRA K., VERAPAMIL AUGMENTS THE NEUROPROTECTANT ACTION OF BERBERINE IN RAT MODEL OF TRANSIENT GLOBAL CEREBRAL ISCHEMIA, EUR J PHARMACOL, 720, PP. 98-106, (2013); CHANDRASHEKHAR V.M., GANAPATY S., RAMKISHAN A., NARSU M.L., NEUROPROTECTIVE ACTIVITY OF GOSSYPIN FROM HIBISCUS VITIFOLIUS AGAINST GLOBAL CEREBRAL ISCHEMIA MODEL IN RATS, INDIAN J PHARMACOL, 45, PP. 575-580, (2013); TU Q., WANG R., DING B., ZHONG W., CAO H., PROTECTIVE AND ANTIOXIDANT EFFECT OF DANSHEN POLYSACCHARIDES ON CEREBRAL ISCHEMIA/REPERFUSION INJURY IN RATS, INT J BIOL MACROMOL, 60, PP. 268-271, (2013); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAMER TROMB HEMOST, 5, PP. 17-20, (1992); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGL LEUKOTR ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., FRAGA V., MENENDEZ R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZILIAN J MED BIOL RES, 32, PP. 1269-1276, (1999); MOLINA V., RAVELO Y., NOA M., MAS R., VALLE M., PEREZ Y., OYARZABAL A., MENDOZA N., JIMENEZ S., SANCHEZ J., EFFECTS OF POLICOSANOL AND GRAPE SEED EXTRACT AGAINST GLOBAL BRAIN ISCHEMIA-REPERFUSION INJURY IN GERBILS, LAT AM J PHARM, 32, PP. 113-119, (2013); MOLINA V., RAVELO Y., NOA M., MAS R., PEREZ Y., OYARZABAL A., MENDOZA N., VALLE M., JIMENEZ S., SANCHEZ J., THERAPEUTIC EFFECTS OF POLICOSANOL AND ATORVASTATIN AGAINST GLOBAL BRAIN ISCHAEMIA-REPERFUSION INJURY IN GERBILS, INDIAN J PHARM SCI, 75, PP. 635-641, (2013); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, INT. J. PHARM. SCI. REV. RES, 19, PP. 18-23, (2013); KALSOTRA A., ZHAO J., ANAK S., DASH P.K., STROBEL H.W., BRAIN TRAUMA LEADS TO ENHANCED LUNG INFLAMMATION AND INJURY: EVIDENCE FOR ROLE OF P4504FS IN RESOLUTION, J CEREB B F & METAB, 27, PP. 963-974, (2007); WORTHINGTON ENZYME MANUAL, PP. 43-45, (1972); CHO J.Y., KIM I.S., JANG Y.H., KIM A.R., LEE S.R., PROTECTIVE EFFECT OF QUERCETIN, A NATURAL FLAVONOID AGAINST NEURONAL DAMAGE AFTER TRANSIENT GLOBAL CEREBRAL ISCHEMIA, NEUROSCI. LETT, 404, PP. 330-335, (2006); KHAN M., DHAMMU T.S., SAKAKIMA H., SHUNMUGAVEL A., GILG A.G., SINGH A.K., SINGH I., THE INHIBITORY EFFECT OF S-NITROSOGLUTATHIONE ON BLOOD-BRAIN BARRIER DISRUPTION AND PEROXYNITRITE FORMATION IN A RAT MODEL OF EXPERIMENTAL STROKE, J NEUROCHEMISTRY, 123, PP. 86-97, (2012); GOLD S.M., SASIDHAR M.V., MORALES L.B., DU S., SICOTTE N.L., TIWARI-WOODRUFF S.K., VOSKUHL R.R., ESTROGEN TREATMENT DECREASES MATRIX METALLOPROTEINASE (MMP)-9 IN AUTOIMMUNE DEMYELINATING DISEASE THROUGH ESTROGEN RECEPTOR ALPHA (ERΑ), LABORATORY INVESTIGATION, 89, PP. 1076-1083, (2009); WANG T., FU F.H., HAN B., ZHU M., YU X., ZHANG L.M., ASPIRIN ATTENUATES CEREBRAL ISCHEMIC INJURY IN DIABETIC RATS, EXP CLIN ENDOCRINOL DIABETES, 117, PP. 181-185, (2009); BHATT L.K., ADEPALLI B., POTENTIATION OF ASPIRIN-INDUCED CEREBROPROTECTION BY MINOCYCLINE: A THERAPEUTIC APPROACH TO ATTENUATE EXACERBATION OF TRANSIENT FOCAL CEREBRAL ISCHEMIA, DIAB VASC DIS RES, 9, PP. 25-34, (2012); ISHIZUKA T., NIWA A., TABUCHI M., OOSHIMA K., HIGASHINO H., ACETYLSALICYLIC ACID PROVIDES CEREBROVASCULAR PROTECTION FROM OXIDANT DAMAGE IN SALT-LOADED STROKE-PRONE RATS, LIFE SCI, 82, PP. 806-815, (2008); FERNANDEZ A., MARQUEZ A., VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, PP. 155-162, (2009); WESTON R.M., JONES N.M., JARROTT B., CALLAWAY J.K., INFLAMMATORY CELL INFILTRATION AFTER ENDOTHELIN-1-INDUCED CEREBRAL ISCHEMIA: HISTOCHEMICAL AND MYELOPEROXIDASE CORRELATION WITH TEMPORAL CHANGES IN BRAIN INJURY, J CEREB BLOOD FLOW METAB, 10, PP. 100-114, (2007); FISHER M., FEUERSTEIN G., HOWELLS D.W., HURN P.D., KENT T.A., SAVITZ S.I., STAIR GROUP UPDATE OF THE STROKE THERAPY ACADEMIC INDUSTRY ROUNDTABLE PRECLINICAL RECOMMENDATIONS, STROKE, 10, PP. 2244-2250, (2009); SANCHEZ J., ILLNAIT J., MAS R., PEREZ Y., MENDOZA S., CABRERA L., FERNANDEZ L., MESA M., FERNANDEZ J.C., OYARZABAL A., MOLINA V., JIMENEZ S., REYES P., EFFECTS OF POLICOSANOL PLUS ASPIRIN THERAPY ON THE NEUROLOGICAL RECOVERY AND PLASMA OXIDATIVE MARKERS OF PATIENTS WITH ISCHEMIC STROKE, IOSR JOURNAL OF PHARMACY, 3, PP. 31-40, (2013); SANCHEZ J., FERNANDEZ L., ILLNAIT J., ARRUZAZABALA M.L., MOLINA V., MAS R., MENDOZA S., CARBAJAL D., MESA M., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON THE RECOVERY OF ISCHEMIC STROKE: A RANDOMIZED CONTROLLED STUDY, IOSR JOURNAL OF PHARMACY, 2, PP. 14-24, (2012); SANCHEZ J., MAS R., MENDOZA S., FERNANDEZ J., RUIZ D., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE WITH PREVIOUS TRANSIENT ISCHEMIC ATTACK: A LONG-TERM FOLLOW-UP, REV CENIC CIEN BIOL, 41, PP. 23-29, (2010)","V.M. CUEVAS; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA; EMAIL: VIVIAN.MOLINA@CNIC.EDU.CU","GLOBAL RESEARCH ONLINE","ENGLISH","INT. J. PHARM. SCI. REV. RES.","ARTICLE","ISI","2-S2.0-84930014518","INT J PHARM SCI REV RES","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"GUERRA YP, 2015, INT J PHARM SCI REV RES","GUERRA YP, 2015, INT J PHARM SCI REV RES"
"WHAYNE T;JR ;MAULIK N","WHAYNE, THOMAS F. (57204791430); MAULIK, NILANJANA (7005372154)","NUTRITION AND THE HEALTHY HEART WITH AN EXERCISE BOOST",2012,"CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY","90","9",16,"10.1139/Y2012-074","GILL HEART INSTITUTE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0200, 326 WETHINGTON BUILDING, 900 SOUTH LIMESTONE STREET, UNITED STATES;MOLECULAR CARDIOLOGY AND ANGIOGENESIS LABORATORY, UNIVERSITY OF CONNECTICUT, SCHOOL OF MEDICINE, FARMINGTON, CT 06030-1110, 263 FARMINGTON AVENUE, UNITED STATES","IN THIS ERA OF POTENT MEDICATIONS AND MAJOR CARDIOVASCULAR (CV) PROCEDURES, THE VALUE OF NUTRITION CAN BE FORGOTTEN. A HEALTHY DIET IS ESSENTIAL, REGARDLESS OF CV RISK. CALORIC BALANCE IS INHERENT TO A GOOD DIET. DESPITE PATIENTS WHO SAY THEY EAT LITTLE, IDEAL WEIGHT CAN BE MAINTAINED IF CALORIES ARE BURNED. COMPOSITION IS ANOTHER COMPONENT OF A HEALTHY DIET. THE DIETARY APPROACHES TO STOP HYPERTENSION (DASH) AND MEDITERRANEAN DIETS PROVIDE PROOF OF CV BENEFIT FROM THEIR SPECIFIC CONTENT. METABOLIC SYNDROME (MS) IS ASSOCIATED WITH POOR DIET AND OBESITY. A HEALTHY DIET WITH GOOD NUTRITION BENEFITS THE MS PATIENT AND ASSOCIATED CONDITIONS SUCH AS OBESITY AND DIABETES. EXERCISE, IN CONJUNCTION WITH A HEALTHY DIET AND GOOD NUTRITION, HELPS MAINTAIN OPTIMAL WEIGHT AND PROVIDES CV BENEFIT SUCH AS DECREASED INFLAMMATION AND INCREASED VASODILATATION. WHETHER VITAMINS OR OTHER NUTRITIONAL SUPPLEMENTS ARE IMPORTANT IN A HEALTHY DIET IS UNPROVEN. NEVERTHELESS, THE MOST PROMISING DATA OF ADDED BENEFIT TO A HEALTHY DIET IS WITH VITAMIN D. SOME DIETARY SUPPLEMENTS ALSO HAVE PROMISE. ALCOHOL, IN MODERATION, ESPECIALLY RED WINE, HAS NUTRITIONAL AND HEART PROTECTIVE BENEFITS. ANTIOXIDANTS, ENDOGENOUS OR EXOGENOUS, HAVE RECEIVED INCREASED INTEREST AND APPEAR TO PLAY A FAVORABLE NUTRITIONAL ROLE. CV HEALTH STARTS WITH GOOD NUTRITION.","ANTIOXIDANTS; CALORIES; CORONARY HEART DISEASE; DIET; EXERCISE; LIPOPROTEINS; METABOLIC SYNDROME; NUTRITION; VITAMINS","ALCOHOL; ALPHA TOCOPHEROL; ANTHOCYANIN; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BETA CAROTENE; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTIN; FATTY ACID; FLAVONOID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; POLYPHENOL DERIVATIVE; RESVERATROL; RETINOL; SOYBEAN PROTEIN; STANOZOLOL; TRIACYLGLYCEROL; UBIDECARENONE; UNINDEXED DRUG; VITAMIN D; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR RISK; DAIRY PRODUCT; DIABETES MELLITUS; DIET SUPPLEMENTATION; EXERCISE; FOOD COMPOSITION; FRUIT; GRAIN; HEART FUNCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE; MEDITERRANEAN DIET; METABOLIC SYNDROME X; MYOPATHY; NONHUMAN; NUT; NUTRITION; NUTRITIONAL SUPPORT; NUTRITIONAL VALUE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RED WINE; REVIEW; VASODILATATION; VEGETABLE; VITAMIN SUPPLEMENTATION","","","ABBEY M., NOAKES M., BELLING G.B., NESTEL P.J., PARTIAL REPLACEMENT OF SATURATED FATTY ACIDS WITH ALMONDS OR WALNUTS LOWERS TOTAL PLASMA CHOLESTEROL AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL, AM. J. CLIN. NUTR, 59, 5, PP. 995-999, (1994); AHMED W., KHAN N., GLUECK C.J., PANDEY S., WANG P., GOLDENBERG N., ET AL., LOW SERUM 25 (OH) VITAMIN D LEVELS (<32 NG/ML) ARE ASSOCIATED WITH REVERSIBLE MYOSITIS-MYALGIA IN STATIN-TREATED PATIENTS, TRANSL. RES, 153, 1, PP. 11-16, (2009); ANDRE D., WOLF D.L., RECENT ADVANCES IN FREE-LIVING PHYSICAL ACTIVITY MONITORING: A REVIEW, J. DIABETES SCI. TECHNOL, 1, 5, PP. 760-767, (2007); ARAD Y., SPADARO L.A., ROTH M., NEWSTEIN D., GUERCI A.D., TREATMENT OF ASYMPTOMATIC ADULTS WITH ELEVATED CORONARY CALCIUM SCORES WITH ATORVASTATIN, VITAMIN C, AND VITAMIN E: THE ST. FRANCIS HEART STUDY RANDOMIZED CLINICAL TRIAL, J. AM. COLL. CARDIOL, 46, 1, PP. 166-172, (2005); AUTIER P., GANDINI S., VITAMIN D SUPPLEMENTATION AND TOTAL MORTALITY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCH. INTERN. MED, 167, 16, PP. 1730-1737, (2007); BAUR J.A., SINCLAIR D.A., THERAPEUTIC POTENTIAL OF RESVERATROL: THE IN VIVO EVIDENCE, NAT. REV. DRUG DISCOV, 5, 6, PP. 493-506, (2006); BERGER M.M., CAN OXIDATIVE DAMAGE BE TREATED NUTRITIONALLY?, CLIN. NUTR, 24, 2, PP. 172-183, (2005); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); BIJNEN F.C., CASPERSEN C.J., FESKENS E.J., SARIS W.H., MOSTERD W.L., KROMHOUT D., PHYSICAL ACTIVITY AND 10-YEAR MORTALITY FROM CARDIOVASCULAR DISEASES AND ALL CAUSES: THE ZUTPHEN ELDERLY STUDY, ARCH. INTERN. MED, 158, 14, PP. 1499-1505, (1998); BJELAKOVIC G., NIKOLOVA D., GLUUD L.L., SIMONETTI R.G., GLUUD C., MORTALITY IN RANDOMIZED TRIALS OF ANTIOXIDANT SUPPLEMENTS FOR PRIMARY AND SECONDARY PREVENTION: SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 297, 8, PP. 842-857, (2007); CASO G., KELLY P., MCNURLAN M.A., LAWSON W.E., EFFECT OF COENZYME Q10 ON MYOPATHIC SYMPTOMS IN PATIENTS TREATED WITH STATINS, AM. J. CARDIOL, 99, 10, PP. 1409-1412, (2007); COOMBES R., TRANS FATS: CHASING A GLOBAL BAN, BMJ, 343, 1, (2011); COOPER-DEHOFF R.M., PEPINE C.J., METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE: CHALLENGES AND OPPORTUNITIES, CLIN. CARDIOL, 30, 12, PP. 593-597, (2007); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., SALAS-SALVADO J., RUIZ-GUTIERREZ V., COVAS M.I., ET AL., EFFECTS OF A MEDITERRANEAN-STYLE DIET ON CARDIOVASCULAR RISK FACTORS: A RANDOMIZED TRIAL, ANN. INTERN. MED, 145, 1, PP. 1-11, (2006); FITO M., GUXENS M., CORELLA D., SAEZ G., ESTRUCH R., DE LA TORRE R., ET AL., EFFECT OF A TRADITIONAL MEDITERRANEAN DIET ON LIPOPROTEIN OXIDATION: A RANDOMIZED CONTROLLED TRIAL, ARCH. INTERN. MED, 167, 11, PP. 1195-1203, (2007); FLORES-MATEO G., CARRILLO-SANTISTEVE P., ELOSUA R., GUALLAR E., MARRUGAT J., BLEYS J., COVAS M.-I., ANTIOXIDANT ENZYME ACTIVITY AND CORONARY HEART DISEASE: META-ANALYSES OF OBSERVATIONAL STUDIES, AM. J. EPIDEMIOL, 170, 2, PP. 135-147, (2009); FRANCO O.H., DE LAET C., PEETERS A., JONKER J., MACKENBACH J., NUSSELDER W., EFFECTS OF PHYSICAL ACTIVITY ON LIFE EXPECTANCY WITH CARDIOVASCULAR DISEASE, ARCH. INTERN. MED, 165, 20, PP. 2355-2360, (2005); GERMAN J.B., DILLARD C.J., SATURATED FATS: WHAT DIETARY INTAKE?, AM. J. CLIN. NUTR, 80, 3, PP. 550-559, (2004); GRUNDY S.M., CLEEMAN J.I., MERZ C.N., BREWER JR. H.B., CLARK L.T., HUNNINGHAKE D.B., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, 2, PP. 227-239, (2004); GRUNDY S.M., CLEEMAN J.I., DANIELS S.R., DONATO K.A., ECKEL R.H., FRANKLIN B.A., ET AL., DIAGNOSIS AND MANAGEMENT OF THE METABOLIC SYNDROME: AN AMERICAN HEART ASSOCIATION/NATIONAL HEART, LUNG, AND BLOOD INSTITUTE SCIENTIFIC STATEMENT, CIRCULATION, 112, 17, PP. 2735-2752, (2005); HAKIM A.A., CURB J.D., PETROVITCH H., RODRIGUEZ B.L., YANO K., ROSS G.W., ET AL., EFFECTS OF WALKING ON CORONARY HEART DISEASE IN ELDERLY MEN: THE HONOLULU HEART PROGRAM, CIRCULATION, 100, 1, PP. 9-13, (1999); HATHCOCK J.N., SHAO A., VIETH R., HEANEY R., RISK ASSESSMENT FOR VITAMIN D, AM. J. CLIN. NUTR, 85, 1, PP. 6-18, (2007); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, 9326, PP. 7-22, (2002); HELLENIUS M.L., DE FAIRE U., BERGLUND B., HAMSTEN A., KRAKAU I., DIET AND EXERCISE ARE EQUALLY EFFECTIVE IN REDUCING RISK FOR CARDIOVASCULAR DISEASE. RESULTS OF A RANDOMIZED CONTROLLED STUDY IN MEN WITH SLIGHTLY TO MODERATELY RAISED CARDIOVASCULAR RISK FACTORS, ATHEROSCLEROSIS, 103, 1, PP. 81-91, (1993); HERCBERG S., BERTRAIS S., CZERNICHOW S., NOISETTE N., GALAN P., JAOUEN A., ET AL., ALTERATIONS OF THE LIPID PROFILE AFTER 7.5 YEARS OF LOW-DOSE ANTIOXIDANT SUPPLEMENTATION IN THE SU. VI, MAX STUDY. LIPIDS, 40, 4, PP. 335-342, (2005); HERNANDEZ F., ILLNAIT J., MAS R., FERNANDEZ G.G., GONZALEZ L., CORDOVI M., FERNANDEZ JC N., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES, 51, PP. 568-575, (1992); HOLICK M.F., VITAMIN D DEFICIENCY, N. ENGL. J. MED, 357, 3, PP. 266-281, (2007); HOWARD A.A., ARNSTEN J.H., GOUREVITCH M.N., EFFECT OF ALCOHOL CONSUMPTION ON DIABETES MELLITUS: A SYSTEMATIC REVIEW, ANN. INTERN. MED, 140, 3, PP. 211-219, (2004); IANNITTI T., PALMIERI B., ANTIOXIDANT THERAPY EFFECTIVENESS: AN UP TO DATE, EUR. REV. MED. PHARMACOL. SCI, 13, 4, PP. 245-278, (2009); JELLIN J.M., GREGORY P.J., PHARMACIST'S LETTER/PRESCRIBER'S LETTER NATURAL MEDICINES COMPREHENSIVE DATABASE, (2008); JENNINGS G., NELSON L., NESTEL P., ESLER M., KORNER P., BURTON D., BAZELMANS J., THE EFFECTS OF CHANGES IN PHYSICAL ACTIVITY ON MAJOR CARDIOVASCULAR RISK FACTORS, HEMODYNAMICS, SYMPATHETIC FUNCTION, AND GLUCOSE UTILIZATION IN MAN: A CONTROLLED STUDY OF FOUR LEVELS OF ACTIVITY, CIRCULATION, 73, 1, PP. 30-40, (1986); KASTORINI C.M., MILIONIS H.J., ESPOSITO K., GIUGLIANO D., GOUDEVENOS J.A., PANAGIOTAKOS D.B., THE EFFECT OF MEDITERRANEAN DIET ON METABOLIC SYNDROME AND ITS COMPONENTS: A META-ANALYSIS OF 50 STUDIES AND 534,906 INDIVIDUALS, J. AM. COLL. CARDIOL, 57, 11, PP. 1299-1313, (2011); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN. PROC, 78, 8, PP. 965-978, (2003); KUJALA U.M., KAPRIO J., SARNA S., KOSKENVUO M., RELATIONSHIP OF LEISURE-TIME PHYSICAL ACTIVITY AND MORTALITY: THE FINNISH TWIN COHORT, JAMA, 279, 6, PP. 440-444, (1998); LAKKA T.A., LAKKA H.M., RANKINEN T., LEON A.S., RAO D.C., SKINNER J.S., ET AL., EFFECT OF EXERCISE TRAINING ON PLASMA LEVELS OF C-REACTIVE PROTEIN IN HEALTHY ADULTS: THE HERITAGE FAMILY STUDY, EUR. HEART J, 26, 19, PP. 2018-2025, (2005); LEE J.H., O'KEEFE J.H., BELL D., HENSRUD D.D., HOLICK M.F., VITAMIN D DEFICIENCY AN IMPORTANT, COMMON, AND EASILY TREATABLE CARDIOVASCULAR RISK FACTOR?, J. AM. COLL. CARDIOL, 52, 24, PP. 1949-1956, (2008); LEITZMANN M.F., PARK Y., BLAIR A., BALLARD-BARBASH R., MOUW T., HOLLENBECK A.R., SCHATZKIN A., PHYSICAL ACTIVITY RECOMMENDATIONS AND DECREASED RISK OF MORTALITY, ARCH. INTERN. MED, 167, 22, PP. 2453-2460, (2007); LIND L., HANNI A., LITHELL H., HVARFNER A., SORENSEN O.H., LJUNGHALL S., VITAMIN D IS RELATED TO BLOOD PRESSURE AND OTHER CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED MEN, AM. J. HYPERTENS, 8, 9, PP. 894-901, (1995); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN. MED, 1, 1, (2006); MARCOFF L., THOMPSON P.D., THE ROLE OF COENZYME Q10 IN STATIN-ASSOCIATED MYOPATHY: A SYSTEMATIC REVIEW, J. AM. COLL. CARDIOL, 49, 23, PP. 2231-2237, (2007); MARIE J., THE BEST SOURCES OF RESVERATROL, (2011); MARON D.J., FLAVONOIDS FOR REDUCTION OF ATHEROSCLEROTIC RISK, CURR. ATHEROSCLER. REP, 6, 1, PP. 73-78, (2004); MARTINS D., WOLF M., PAN D., ZADSHIR A., TAREEN N., THADHANI R., ET AL., PREVALENCE OF CARDIOVASCULAR RISK FACTORS AND THE SERUM LEVELS OF 25-HYDROXYVITAMIN D IN THE UNITED STATES: DATA FROM THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, ARCH. INTERN. MED, 167, 11, PP. 1159-1165, (2007); MELANSON JR. E.L., FREEDSON P.S., BLAIR S., PHYSICAL ACTIVITY ASSESSMENT: A REVIEW OF METHODS, CRIT. REV. FOOD SCI. NUTR, 36, 5, PP. 385-396, (1996); MICHA R., MOZAFFARIAN D., SATURATED FAT AND CARDIOMETABOLIC RISK FACTORS, CORONARY HEART DISEASE, STROKE, AND DIABETES: A FRESH LOOK AT THE EVIDENCE, LIPIDS, 45, 10, PP. 893-905, (2010); MISH F., MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY, (2003); MOZAFFARIAN D., ARO A., WILLETT W.C., HEALTH EFFECTS OF TRANS-FATTY ACIDS: EXPERIMENTAL AND OBSERVATIONAL EVIDENCE, EUR. J. CLIN. NUTR, 63, SUPPL. 2, (2009); NEMEROVSKI C.W., DORSCH M.P., SIMPSON R.U., BONE H.G., AARONSON K.D., BLESKE B.E., VITAMIN D AND CARDIOVASCULAR DISEASE, PHARMACOTHERAPY, 29, 6, PP. 691-708, (2009); NOJIRI S., DAIDA H., INABA Y., ANTIOXIDANTS AND CARDIOVASCULAR DISEASE: STILL A TOPIC OF INTEREST, ENVIRON. HEALTH PREV. MED, 9, 5, PP. 200-213, (2004); PEDERSEN T.R., RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, 8934, PP. 1383-1389, (1994); REAVEN G.M., BANTING LECTURE 1988. ROLE OF INSULIN RESISTANCE IN HUMAN DISEASE, NUTRITION, 13, 1, (1997); SABATE J., FRASER G.E., BURKE K., KNUTSEN S.F., BENNETT H., LINDSTED K.D., EFFECTS OF WALNUTS ON SERUM LIPID LEVELS AND BLOOD PRESSURE IN NORMAL MEN, N. ENGL. J. MED, 328, 9, PP. 603-607, (1993); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N. ENGL. J. MED, 335, 14, PP. 1001-1009, (1996); SACKS F.M., SVETKEY L.P., VOLLMER W.M., APPEL L.J., BRAY G.A., HARSHA D., ET AL., EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION (DASH) DIET. DASHSODIUM COLLABORATIVE RESEARCH GROUP, N. ENGL. J. MED, 344, 1, PP. 3-10, (2001); SACKS F.M., LICHTENSTEIN A., VAN HORN L., HARRIS W., KRIS-ETHERTON P., WINSTON M., SOY PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH: AN AMERICAN HEART ASSOCIATION SCIENCE ADVISORY FOR PROFESSIONALS FROM THE NUTRITION COMMITTEE, CIRCULATION, 113, 7, PP. 1034-1044, (2006); SCHAUSS A.G., ACAI: AN EXTRAORDINARY ANTIOXIDANT-RICH PALM FRUIT FROM THE AMAZON, (2009); SCHLEITHOFF S.S., ZITTERMANN A., TENDERICH G., BERTHOLD H.K., STEHLE P., KOERFER R., VITAMIN D SUPPLEMENTATION IMPROVES CYTOKINE PROFILES IN PATIENTS WITH CONGESTIVE HEART FAILURE: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, AM. J. CLIN. NUTR, 83, 4, PP. 754-759, (2006); SEGURA R., JAVIERRE C., LIZARRAGA M.A., ROS E., OTHER RELEVANT COMPONENTS OF NUTS: PHYTOSTEROLS, FOLATE AND MINERALS, BR. J. NUTR, 96, SUPPL. 2, (2006); SHEPHERD J., COBBE S.M., FORD I., ISLES C.G., LORIMER A.R., MACFARLANE P.W., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA. WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, N. ENGL. J. MED, 333, 20, PP. 1301-1308, (1995); SUGDEN J.A., DAVIES J.I., WITHAM M.D., MORRIS A.D., STRUTHERS A.D., VITAMIN D IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND LOW VITAMIN D LEVELS, DIABET. MED, 25, 3, PP. 320-325, (2008); SULLIVAN S., SAMUEL S., EFFECT OF SHORT-TERM PRITIKIN DIET THERAPY ON THE METABOLIC SYNDROME, J. CARDIOMETAB. SYNDR, 1, 5, PP. 308-312, (2006); TANAKA K., ISHIKAWA Y., YOKOYAMA M., ORIGASA H., MATSUZAKI M., SAITO Y., ET AL., REDUCTION IN THE RECURRENCE OF STROKE BY EICOSAPENTAENOIC ACID FOR HYPERCHOLESTEROLEMIC PATIENTS: SUBANALYSIS OF THE JELIS TRIAL, STROKE, 39, 7, PP. 2052-2058, (2008); THOMPSON P.D., BUCHNER D., PINA I.L., BALADY G.J., WILLIAMS M.A., MARCUS B.H., ET AL., EXERCISE AND PHYSICAL ACTIVITY IN THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A STATEMENT FROM THE COUNCIL ON CLINICAL CARDIOLOGY (SUBCOMMITTEE ON EXERCISE, REHABILITATION, AND PREVENTION) AND THE COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM (SUBCOMMITTEE ON PHYSICAL ACTIVITY), CIRCULATION, 107, 24, PP. 3109-3116, (2003); TONKIN A., ALYWARD P., COLQUHOUN D., GLASZIOU P., HARRIS P., HUNT D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS. THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP, N. ENGL. J. MED, 339, 19, PP. 1349-1357, (1998); VACEK J.L., VANGA S.R., GOOD M., LAI S.M., LAKKIREDDY D., HOWARD P.A., VITAMIN D DEFICIENCY AND SUPPLEMENTATION AND RELATION TO CARDIOVASCULAR HEALTH, AM. J. CARDIOL, 109, 3, PP. 359-363, (2012); VIITALA P., NEWHOUSE I.J., VITAMIN E SUPPLEMENTATION, EXERCISE AND LIPID PEROXIDATION IN HUMAN PARTICIPANTS, EUR. J. APPL. PHYSIOL, 93, 1-2, PP. 108-115, (2004); VISIOLI F., GALLI C., BIOLOGICAL PROPERTIES OF OLIVE OIL PHYTOCHEMICALS, CRIT. REV. FOOD SCI. NUTR, 42, 3, PP. 209-221, (2002); VISIOLI F., POLI A., GALL C., ANTIOXIDANT AND OTHER BIOLOGICAL ACTIVITIES OF PHENOLS FROM OLIVES AND OLIVE OIL, MED. RES. REV, 22, 1, PP. 65-75, (2002); WALLERATH T., POLEO D., LI H., FORSTERMANN U., RED WINE INCREASES THE EXPRESSION OF HUMAN ENDOTHELIAL NITRIC OXIDE SYNTHASE: A MECHANISM THAT MAY CONTRIBUTE TO ITS BENEFICIAL CARDIOVASCULAR EFFECTS, J. AM. COLL. CARDIOL, 41, 3, PP. 471-478, (2003); WANG J., RUOTSALAINEN S., MOILANEN L., LEPISTO P., LAAKSO M., KUUSISTO J., THE METABOLIC SYNDROME PREDICTS INCIDENT STROKE: A 14-YEAR FOLLOW-UP STUDY IN ELDERLY PEOPLE IN FINLAND, STROKE, 39, 4, PP. 1078-1083, (2008); WANG T.J., PENCINA M.J., BOOTH S.L., JACQUES P.F., INGELSSON E., LANIER K., ET AL., VITAMIN D DEFICIENCY AND RISK OF CARDIOVASCULAR DISEASE, CIRCULATION, 117, 4, PP. 503-511, (2008); WHAYNE JR. T.F., IN DEFENSE OF THE METABOLIC SYNDROME, J. CLIN. LIPIDOL, 3, 4, PP. 247-249, (2009); WHAYNE JR. T.F., VITAMIN D: POPULAR CARDIOVASCULAR SUPPLEMENT BUT BENEFIT MUST BE EVALUATED, INT. J. ANGIOL, 20, 2, PP. 63-71, (2011); WRIGHT J.D., WANG C., KENNEDY-STEPHENSON J., ERVIN R.B., DIETARY INTAKE OF TEN KEY NUTRIENTS FOR PUBLIC HEALTH, UNITED STATES: 1999-2000, ADVANCE DATA FROM VITAL AND HEALTH STATISTICS, (2003); WRIGHT C., ZIELKE J., WHAYNE JR. T., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE: USE IN PATIENTS INTOLERANT OF OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INT. J. ANGIOL, 13, 4, PP. 173-175, (2004); YOKOYAMA M., ORIGASA H., MATSUZAKI M., MATSUZAWA Y., SAITO Y., ISHIKAWA Y., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, 9567, PP. 1090-1098, (2007); ZAMBON D., SABATE J., MUNOZ S., CAMPERO B., CASALS E., MERLOS M., ET AL., SUBSTITUTING WALNUTS FOR MONOUNSATURATED FAT IMPROVES THE SERUM LIPID PROFILE OF HYPERCHOLESTEROLEMIC MEN AND WOMEN. A RANDOMIZED CROSSOVER TRIAL, ANN. INTERN. MED, 132, 7, PP. 538-546, (2000); ZHANG H., ZHANG J., UNGVARI Z., ZHANG C., RESVERATROL IMPROVES ENDOTHELIAL FUNCTION: ROLE OF TNFA AND VASCULAR OXIDATIVE STRESS, ARTERIOSCLER. THROMB. VASC. BIOL, 29, 8, PP. 1164-1171, (2009)","T. F. WHAYNE; GILL HEART INSTITUTE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0200, 326 WETHINGTON BUILDING, 900 SOUTH LIMESTONE STREET, UNITED STATES; EMAIL: TWHAYN0@UKY.EDU","CANADIAN SCIENCE PUBLISHING","ENGLISH","CAN. J. PHYSIOL. PHARMACOL.","REVIEW","ISI","2-S2.0-84864245697","CAN J PHYSIOL PHARMACOL","UNIVERSITY OF KENTUCKY;UNIVERSITY OF CONNECTICUT","NOTREPORTED;UNIVERSITY OF KENTUCKY;NOTREPORTED",NA,"WHAYNE TF, 2012, CAN J PHYSIOL PHARMACOL","WHAYNE TF, 2012, CAN J PHYSIOL PHARMACOL"
"MARTÍNEZ-SÁNCHEZ G;DELGADO-ROCHE L;DÍAZ-BATISTA A;PÉREZ-DAVISON G;RE L","MARTÍNEZ-SÁNCHEZ, GREGORIO (6603422480); DELGADO-ROCHE, LIVAN (26647327300); DÍAZ-BATISTA, ARQUÍMIDES (54971850500); PÉREZ-DAVISON, GEMA (8704857700); RE, LAMBERTO (7003874125)","EFFECTS OF OZONE THERAPY ON HAEMOSTATIC AND OXIDATIVE STRESS INDEX IN CORONARY ARTERY DISEASE",2012,"EUROPEAN JOURNAL OF PHARMACOLOGY","691","6",36,"10.1016/j.ejphar.2012.07.010","MEDINAT SRL CLINIC, 60021 CAMERANO, VIA FAZIOLI 22, ITALY;CENTER OF STUDIES FOR RESEARCH AND BIOLOGICAL EVALUATIONS, PHARMACY AND FOOD SCIENCES COLLEGE, UNIVERSITY OF HAVANA, HAVANA, CUBA;NATIONAL INSTITUTE OF ANGIOLOGY AND VASCULAR SURGERY, HAVANA, CUBA;UNIVERSITY OF ANCONA, ANCONA, ITALY;UNIVERSITY OF ANCONA, ANCONA, ITALY","CORONARY ARTERY DISEASE (CAD) IS THE MOST COMMON CAUSE OF SUDDEN DEATH, AND DEATH OF PEOPLE OVER 20 YEARS OF AGE. BECAUSE OZONE THERAPY CAN ACTIVATE THE ANTIOXIDANT SYSTEM AND IMPROVE BLOOD CIRCULATION AND OXYGEN DELIVERY TO TISSUE, THE AIM OF THIS STUDY WAS TO INVESTIGATE THE THERAPEUTIC EFFICACY OF OZONE IN PATIENTS WITH CAD, TREATED WITH ANTITHROMBOTIC THERAPY, ASPIRIN® AND POLICOSANOL. A RANDOMIZED CONTROLLED CLINICAL TRIAL WAS PERFORMED WITH 53 PATIENTS DIVIDED INTO TWO GROUPS: ONE (N=27) TREATED WITH ANTITHROMBOTIC THERAPY AND OTHER (N=26) TREATED WITH ANTITHROMBOTIC THERAPY PLUS RECTAL INSUFFLATION OF O3. A PARALLEL GROUP (N=50) AGE AND GENDER MATCHED WAS USED AS REFERENCE FOR THE EXPERIMENTAL VARIABLES. THE EFFICACY OF THE TREATMENTS WAS EVALUATED BY COMPARING HEMOSTATIC INDEXES AND BIOCHEMICAL MARKERS OF OXIDATIVE STRESS IN BOTH GROUPS AFTER 20 DAY OF TREATMENT. OZONE TREATMENT SIGNIFICANTLY (P<0.001) IMPROVED PROTHROMBIN TIME WHEN COMPARED TO THE ANTITHROMBOTIC THERAPY ONLY GROUP, WITHOUT MODIFYING BLEEDING TIME. COMBINATION ANTITHROMBOTIC THERAPYO3 IMPROVED THE ANTIOXIDANT STATUS OF PATIENTS REDUCING BIOMARKERS OF PROTEIN AND LIPID OXIDATION, ENHANCING TOTAL ANTIOXIDANT STATUS AND MODULATING THE LEVEL OF SUPEROXIDE DISMUTASE AND CATALASE WITH A 57% AND 32% REDUCTION IN SUPEROXIDE DISMUTASE AND CATALASE ACTIVITIES RESPECTIVELY, MOVING THE REDOX ENVIRONMENT TO A STATUS OF LOW PRODUCTION OF O2 •- WITH AN INCREASE IN H2O2 DETOXIFICATION. NO SIDE EFFECTS WERE OBSERVED. THESE RESULTS SHOW THAT MEDICAL OZONE TREATMENT COULD BE A COMPLEMENTARY THERAPY IN THE TREATMENT OF CAD AND ITS COMPLICATIONS. © 2012 ELSEVIER B.V. ALL RIGHTS RESERVED.","ASPIRIN; CORONARY ARTERY DISEASES; OXIDATIVE STRESS; OZONE; POLICOSANOL","AGED; AGED, 80 AND OVER; ANTIOXIDANTS; ASPIRIN; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FATTY ALCOHOLS; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; OZONE; REACTIVE OXYGEN SPECIES; ACETYLSALICYLIC ACID; CAPTOPRIL; CATALASE; HYDROGEN PEROXIDE; NIFEDIPINE; OXYGEN; OZONE; PENTAERYTHRITYL TETRANITRATE; POLICOSANOL; SUPEROXIDE DISMUTASE; ABSENCE OF SIDE EFFECTS; ADULT; AERATION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BIOCHEMISTRY; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DETOXIFICATION; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HEMOSTASIS; HUMAN; HYPERTENSION; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OZONE THERAPY; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE","","","ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOLOGICAL RESEARCH, 36, 4, PP. 293-297, (1997); BALTAZAR M.T., DINIS-OLIVEIRA R.J., DUARTE J.A., BASTOS M.L., CARVALHO F., ANTIOXIDANT PROPERTIES AND ASSOCIATED MECHANISMS OF SALICYLATES, CURR. MED. CHEM., 18, PP. 3252-3264, (2011); BENZIE I.F., STRAIN J.J., THE FERRIC REDUCING ABILITY OF PLASMA (FRAP) AS A MEASURE OF ANTIOXIDANT POWER: THE FRAP ASSAY, ANAL. BIOCHEM., 239, PP. 70-76, (1996); BIEDUNKIEWICZ B., LIZAKOWSKI S., TYLICKI L., SKIBOESKA A., NIEWEGLOWSKI T., CHAMIENIA A., DEBSKA-SLIZIEN A., RUTKOWSKI B., BLOOD COAGULATION UNAFFECTED BY OZONATED AUTOHEMOTHERAPY IN PATIENTS ON MAINTENANCE HEMODIALYSIS, ARCHIVES OF MEDICAL RESEARCH, 37, 8, PP. 1034-1037, (2006); BOCCI V., TRAVAGLI V., ZANARDI I., MAY OXYGEN-OZONE THERAPY IMPROVES CARDIOVASCULAR DISORDERS?, CARDIOVASC. HEMATOL. DISORD. DRUG TARGETS, 9, PP. 78-85, (2009); BOCCI V.A., ZANARDI I., TRAVAGLI V., OZONE ACTING ON HUMAN BLOOD YIELDS A HORMETIC DOSE-RESPONSE RELATIONSHIP, J. TRANSL. MED., 9, (2011); CALUNGA J., PAZ Y., MENENDEZ S., MARTINEZ A., HERNANDEZ A., RECTAL OZONE THERAPY FOR PATIENTS WITH PULMONARY EMPHYSEMA, REV. MED. CHILE, 139, PP. 439-447, (2011); CAMPBELL C.L., SMYTH S., MONTALESCOT G., STEINHUBL S.R., ASPIRIN DOSE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 297, 18, PP. 2018-2024, (2007); CARDILE V., JIANG X., RUSSO A., CASELLA F., RENIS M., BINDONI M., EFFECTS OF OZONE ON SOME BIOLOGICAL ACTIVITIES OF CELLS IN VITRO, CELL BIOL. TOXICOL., 11, PP. 11-21, (1995); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 22, 3-4, PP. 89-99, (2002); CHEN H., XING B., LIU X., ZHAN B., ZHOU J., ZHU H., CHEN Z., OZONE OXIDATIVE PRECONDITIONING INHIBITS INFLAMMATION AND APOPTOSIS IN A RAT MODEL OF RENAL ISCHEMIA/REPERFUSION INJURY, EUR. J. PHARMACOL., 581, PP. 306-314, (2008); COLLABORATION A.T., COLLABORATIVE META-ANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION, AND STROKE IN HIGH RISK PATIENTS, BR. MED. J., 324, PP. 71-86, (2002); COLOMBO R., D'ANGELO F., ARZINI A., ABBRITTI F., BOCCALON L., ARTERIOPATIE OBLITERANTI CRONICHE DEGLI ARTI INFERIORI: TERAPIA FARMACOLOGICA ED OZONO TERAPIA, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 159, 2, PP. 53-57, (2000); DELGADO-ROCHE L., MARTINEZ-SANCHEZ G., DIAZ-BATISTA A., RE L., EFFECTS OF OZONE THERAPY ON OXIDATIVE STRESS BIOMARKERS IN CORONARY ARTERY DISEASE PATIENTS, INT. J. OZONE RES., 10, PP. 99-104, (2011); DIAZ-LLERA S., GONZALEZ-HERNANDEZ Y., MESA J.E.G., MARTINEZ-SANCHEZ G., RE L., INDUCTION OF DNA PRIMARY DAMAGE IN PERIPHERAL BLOOD LEUKOCYTES AND EXFOLIATED COLORECTAL EPITHELIAL CELLS IN RATS TREATED WITH O<SUB>3</SUB>/O <SUB>2</SUB> MIX, INT. J. OZONE THER., 8, PP. 217-221, (2009); ESTERBAUER H., CHEESEMAN K.H., DETERMINATION OF ALDEHYDIC LIPID PEROXIDATION PRODUCTS: MALONALDEHYDE AND 4-HYDROXYNONENAL, METHODS IN ENZYMOLOGY, 186, PP. 407-421, (1990); FAUL F., ERDFELDER E., LANG A.G., BUCHNER A., GPOWER 3: A FLEXIBLE STATISTICAL POWER ANALYSIS PROGRAM FOR THE SOCIAL, BEHAVIORAL, AND BIOMEDICAL SCIENCES, BEHAV. RES. METHODS, 39, PP. 175-191, (2007); FLORES-MATEO G., CARRILLO-SANTISTEVE P., ELOSUA R., GUALLAR E., MARRUGAT J., BLEYS J., COVAS M.I., ANTIOXIDANT ENZYME ACTIVITY AND CORONARY HEART DISEASE: META-ANALYSES OF OBSERVATIONAL STUDIES, AM. J. EPIDEMIOL., 170, PP. 135-147, (2009); FRANCO M., COOPER R.S., BILAL U., FUSTER V., CHALLENGES AND OPPORTUNITIES FOR CARDIOVASCULAR DISEASE PREVENTION, AM. J. MED., 124, PP. 95-102, (2011); GIUNTA R., COPPOLA A., LUONGO C., SAMMARTINO A., GUASTAFIERRO S., GRASSIA A., GIUNTA L., MASCOLO L., TIRELLI A., COPPOLA L., OZONIZED AUTOHEMOTRANSFUSION IMPROVES HEMORHEOLOGICAL PARAMETERS AND OXYGEN DELIVERY TO TISSUES IN PATIENTS WITH PERIPHERAL OCCLUSIVE ARTERIAL DISEASE, ANNALS OF HEMATOLOGY, 80, 12, PP. 745-748, (2001); GONZALEZ R., BORREGO A., ZAMORA Z., ROMAY C., HERNANDEZ F., MENENDEZ S., MONTERO T., ROJAS E., REVERSION BY OZONE TREATMENT OF ACUTE NEPHROTOXICITY INDUCED BY CISPLATIN IN RATS, MEDIATORS OF INFLAMMATION, 13, 5-6, PP. 307-312, (2004); GRAHAM I., ATAR D., BORCH-JOHNSEN K., BOYSEN G., BURELL G., CIFKOVA R., DALLONGEVILLE J., DE BACKER G., EBRAHIM S., GJELSVIK B., HERRMANN-LINGEN C., HOES A., HUMPHRIES S., KNAPTON M., PERK J., PRIORI S.G., PYORALA K., REINER Z., RUILOPE L., SANS-MENENDEZ S., SCHOLTE OP REIMER W., WEISSBERG P., WOOD D., YARNELL J., ZAMORANO J.L., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: EXECUTIVE SUMMARY - FOURTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUROPEAN HEART JOURNAL, 28, 19, PP. 2375-2414, (2007); GUANCHE D., ZAMORA Z., HERNANDEZ F., MENA K., ALONSO Y., RODA M., GONZALES M., GONZALES R., EFFECT OF OZONE/OXYGEN MIXTURE ON SYSTEMIC OXIDATIVE STRESS AND ORGANIC DAMAGE, TOXICOL. MECH. METHODS, 20, PP. 25-30, (2010); GUPTA R., JOSHI P., MOHAN V., REDDY K.S., YUSUF S., EPIDEMIOLOGY AND CAUSATION OF CORONARY HEART DISEASE AND STROKE IN INDIA, HEART, 94, PP. 16-26, (2008); HAINING J.L., LEGAN J.S., IMPROVED ASSAY FOR CATALASE BASED UPON STEADY-STATE SUBSTRATE CONCENTRATION, ANAL. BIOCHEM., 45, PP. 469-479, (1972); HERNANDEZ ROSALES F.A., CALUNGA FERNANDEZ J.L., FIGUERAS J.T., CEPERO S.M., PERDOMO A.M., OZONE THERAPY EFFECTS ON BIOMARKERS AND LUNG FUNCTION IN ASTHMA, ARCHIVES OF MEDICAL RESEARCH, 36, 5, PP. 549-554, (2005); HUANG D., BOXIN O.U., PRIOR R.L., THE CHEMISTRY BEHIND ANTIOXIDANT CAPACITY ASSAYS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 6, PP. 1841-1856, (2005); JOHNSTON-COX H.A., RAVID K., ADENOSINE AND BLOOD PLATELETS, PURINERGIC SIGNAL, 7, PP. 357-365, (2011); KOWALCZYK E., KOPFF A., BLASZCZYK J., FIJALKOWSKI P., KOPFF M., WPŁYW WYBRANYCH NIESTEROIDOWYCH LEKÓW PRZECIWZAPALNYCH NA AKTYWNOŚĆ ENZYMÓW ANTYOKSYDACYJNYCH, POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 115, 2, PP. 112-117, (2006); LEON FERNANDEZ O.S., AJAMIEH H.H., BERLANGA J., MENENDEZ S., VIEBAHN-HANSLER R., RE L., CARMONA A.M., OZONE OXIDATIVE PRECONDITIONING IS MEDIATED BY A<SUB>1</SUB> ADENOSINE RECEPTORS IN A RAT MODEL OF LIVER ISCHEMIA/ REPERFUSION, TRANSPLANT INTERNATIONAL, 21, 1, PP. 39-48, (2008); MARTINEZ-SANCHEZ G., AL-DALAIN S.M., MENENDEZ S., RE L., GIULIANI A., CANDELARIO-JALIL E., ALVAREZ H., FERNANDEZ-MONTEQUIN J.I., LEON O.S., THERAPEUTIC EFFICACY OF OZONE IN PATIENTS WITH DIABETIC FOOT, EUROPEAN JOURNAL OF PHARMACOLOGY, 523, 1-3, PP. 151-161, (2005); MARTINEZ-SANCHEZ G., GIULIANI A., PEREZ-DAVISON G., LEON-FERNANDEZ O.S., OXIDIZED PROTEINS AND THEIR CONTRIBUTION TO REDOX HOMEOSTASIS, REDOX REPORT, 10, 4, PP. 175-185, (2005); MASON R.P., OPTIMAL THERAPEUTIC STRATEGY FOR TREATING PATIENTS WITH HYPERTENSION AND ATHEROSCLEROSIS: FOCUS ON OLMESARTAN MEDOXOMIL, VASC. HEALTH RISK MANAGE., 7, PP. 405-416, (2011); MILLER J.D., CHU Y., BROOKS R.M., RICHENBACHER W.E., PENA-SILVA R., HEISTAD D.D., DYSREGULATION OF ANTIOXIDANT MECHANISMS CONTRIBUTES TO INCREASED OXIDATIVE STRESS IN CALCIFIC AORTIC VALVULAR STENOSIS IN HUMANS, J. AM. COLL. CARDIOL., 52, PP. 843-850, (2008); NOA M., MAS R., LARIOT C., PROTECTIVE EFFECT OF POLICOSANOL ON ENDOTHELIUM AND INTIMAL THICKNESS INDUCED BY FORCEPS IN RABBITS, JOURNAL OF MEDICINAL FOOD, 10, 3, PP. 452-459, (2007); OZDEMIRLER G., MEHMETCIK G., OZTEZCAN S., TOKER G., SIVAS A., UYSAL M., PEROXIDATION POTENTIAL AND ANTIOXIDANT ACTIVITY OF SERUM IN PATIENTS WITH DIABETES MELLITUS AND MYOCARD INFARCTION, HORM. METAB. RES., 27, PP. 194-196, (1995); RAO V., KIRAN R., EVALUATION OF CORRELATION BETWEEN OXIDATIVE STRESS AND ABNORMAL LIPID PROFILE IN CORONARY ARTERY DISEASE, J. CARDIOVASC. DIS. RES., 2, PP. 57-60, (2011); RE L., MAWSOUF M.N., MENENDEZ S., LEON O.S., SANCHEZ G.M., HERNANDEZ F., OZONE THERAPY: CLINICAL AND BASIC EVIDENCE OF ITS THERAPEUTIC POTENTIAL, ARCHIVES OF MEDICAL RESEARCH, 39, 1, PP. 17-26, (2008); RODRIGUEZ Z.Z., GUANCHE D., ALVAREZ R.G., ROSALES F.H., ALONSO Y., SCHULZ S., PRECONDITIONING WITH OZONE/OXYGEN MIXTURE INDUCES REVERSION OF SOME INDICATORS OF OXIDATIVE STRESS AND PREVENTS ORGANIC DAMAGE IN RATS WITH FECAL PERITONITIS, INFLAMM. RES, (2009); ROGER V.L., GO A.S., LLOYD-JONES D.M., ADAMS R.J., BERRY J.D., BROWN T.M., CARNETHON M.R., DAI S., DE SIMONE G., FORD E.S., FOX C.S., FULLERTON H.J., GILLESPIE C., GREENLUND K.J., HAILPERN S.M., HEIT J.A., HO P.M., HOWARD V.J., KISSELA B.M., KITTNER S.J., LACKLAND D.T., LICHTMAN J.H., LISABETH L.D., MAKUC D.M., MARCUS G.M., MARELLI A., MATCHAR D.B., MCDERMOTT M.M., MEIGS J.B., MOY C.S., MOZAFFARIAN D., MUSSOLINO M.E., NICHOL G., PAYNTER N.P., ROSAMOND W.D., SORLIE P.D., STAFFORD R.S., TURAN T.N., TURNER M.B., WONG N.D., WYLIE-ROSETT J., HEART DISEASE AND STROKE STATISTICS - 2011 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 123, (2011); ROMERO VALDES A., BLANCO GONZALEZ R., MENENDEZ CEPERO S., GOMEZ MORALEDA M., LEY POZO J., ARTERIOSCLEROSIS OBLITERANS AND OZONE THERAPY. ITS ADMINISTRATION BY DIFFERENT ROUTES, ANGIOLOGIA, 45, PP. 177-179, (1993); SCHMAIER A.H., (2008); SCHWARTZ A., MARTINEZ-SANCHEZ G., RE L., GUIA PARA EL USO MÉDICO DEL OZONO, (2011); SCOTT J., THE PATHOGENESIS OF ATHEROSCLEROSIS AND NEW OPPORTUNITIES FOR TREATMENT AND PREVENTION, JOURNAL OF NEURAL TRANSMISSION, SUPPLEMENT, 63, PP. 1-17, (2002); SEDA ARTIS A., AYDOGAN S., GOKHAN SAHIN M., THE EFFECTS OF COLORECTALLY INSUFFLATED OXYGEN-OZONE ON RED BLOOD CELL RHEOLOGY IN RABBITS, CLIN. HEMORHEOL. MICROCIRC., 45, PP. 329-336, (2010); SEDLAK J., LINDSAY R.H., ESTIMATION OF TOTAL, PROTEIN-BOUND, AND NONPROTEIN SULFHYDRYL GROUPS IN TISSUE WITH ELLMAN'S REAGENT, ANAL. BIOCHEM., 25, PP. 192-205, (1968); STADLBAUER T.H.W., EISELE A., HEIDT M.C., TILLMANNS H.H., SCHULZ S., PRECONDITIONING WITH OZONE ABROGATES ACUTE REJECTION AND PROLONGS CARDIAC ALLOGRAFT SURVIVAL IN RATS, TRANSPLANTATION PROCEEDINGS, 40, 4, PP. 974-977, (2008); STEPPAN J., MEADERS T., MUTO M., MURPHY K.J., A METAANALYSIS OF THE EFFECTIVENESS AND SAFETY OF OZONE TREATMENTS FOR HERNIATED LUMBAR DISCS, J. VASC. INTERV. RADIOL., 21, PP. 534-548, (2010); TURCZYNSKI B., SROCZYNSKI J., ANTOSZEWSKI Z., MATYSZCZYK B., KRUPA G., MLYNARSKI J., STRUGALA M., OZONE THERAPY AND VISCOSITY OF BLOOD AND PLASMA, DISTANCE OF INTERMITTENT CLAUDICATION AND CERTAIN BIOCHEMICAL COMPONENTS IN PATIENTS WITH DIABETES TYPE II AND ISCHEMIA OF THE LOWER EXTREMITIES, POL. TYG. LEK., 46, PP. 708-710, (1991); UNO K., NICHOLLS S.J., BIOMARKERS OF INFLAMMATION AND OXIDATIVE STRESS IN ATHEROSCLEROSIS, BIOMARK MED., 4, PP. 361-373, (2010); VERRAZZO G., COPPOLA L., LUONGO C., SAMMARTINO A., GIUNTA R., GRASSIA A., RAGONE R., TIRELLI A., HYPERBARIC OXYGEN, OXYGEN-OZONE THERAPY, AND RHEOLOGIC PARAMETERS OF BLOOD IN PATIENTS WITH PERIPHERAL OCCLUSIVE ARTERIAL DISEASE, UNDERSEA HYPERB. MED., 22, PP. 17-22, (1995); WITKO-SARSAT V., FRIEDLANDER M., KHOA T.N., CAPEILLERE-BLANDIN C., NGUYEN A.T., CANTELOUP S., DAYER J.-M., JUNGERS P., DRUCKE T., DESCAMPS-LATSCHA B., ADVANCED OXIDATION PROTEIN PRODUCTS AS NOVEL MEDIATORS OF INFLAMMATION AND MONOCYTE ACTIVATION IN CHRONIC RENAL FAILURE, JOURNAL OF IMMUNOLOGY, 161, 5, PP. 2524-2532, (1998); WITKO-SARSAT V., NGUYEN-KHOA T., JUNGERS P., DRUEKE T.B., DESCAMPS-LATSCHA B., ADVANCED OXIDATION PROTEIN PRODUCTS AS A NOVEL MOLECULAR BASIS OF OXIDATIVE STRESS IN URAEMIA, NEPHROLOGY DIALYSIS TRANSPLANTATION, 14, SUPPL. 1, PP. 76-78, (1999); ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS, J. INT. BIOETHIQUE, PP. 124-129, (2004); YANG H., ROBERTS L.J., MING J.S., LI C.Z., BALLARD B.R., RICHARDSON A., ZHONG M.G., RETARDATION OF ATHEROSCLEROSIS BY OVEREXPRESSION OF CATALASE OR BOTH CU/ZN-SUPEROXIDE DISMUTASE AND CATALASE IN MICE LACKING APOLIPOPROTEIN E, CIRCULATION RESEARCH, 95, 11, PP. 1075-1081, (2004); YUSUF P.S., HAWKEN S., OUNPUU S., DANS T., AVEZUM A., LANAS F., MCQUEEN M., BUDAJ A., PAIS P., VARIGOS J., LISHENG L., EFFECT OF POTENTIALLY MODIFIABLE RISK FACTORS ASSOCIATED WITH MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): CASE-CONTROL STUDY, LANCET, 364, 9438, PP. 937-952, (2004); ZAKY S., FOUAD E., HI H.K., THE EFFECT OF RECTAL OZONE ON THE PORTAL VEIN OXYGENATION AND PHARMACOKINETICS OF PROPRANOLOL IN LIVER CIRRHOSIS (A PRELIMINARY HUMAN STUDY), BR. J. CLIN. PHARMACOL., 71, PP. 411-415, (2011); ZAKY S., KAMEL S.E., HASSAN M.S., SALLAM N.A., SHAHATA M.A., HELAL S.R., MAHMOUD H., PRELIMINARY RESULTS OF OZONE THERAPY AS A POSSIBLE TREATMENT FOR PATIENTS WITH CHRONIC HEPATITIS C, J. ALTERN. COMPLEMENT. MED., 17, PP. 259-263, (2011)","G. MARTÍNEZ-SÁNCHEZ; MEDINAT SRL CLINIC, 60021 CAMERANO, VIA FAZIOLI 22, ITALY; EMAIL: GREGORCUBA@YAHOO.IT","","ENGLISH","EUR. J. PHARMACOL.","ARTICLE","ISI","2-S2.0-84865001031","EUR J PHARMACOL","MEDINAT SRL CLINIC;UNIVERSITY OF HAVANA;NATIONAL INSTITUTE OF ANGIOLOGY AND VASCULAR SURGERY;UNIVERSITY OF ANCONA;UNIVERSITY OF ANCONA","NOTREPORTED;MEDINAT SRL CLINIC;NOTREPORTED",NA,"MARTÍNEZ-SÁNCHEZ G, 2012, EUR J PHARMACOL","MARTÍNEZ-SÁNCHEZ G, 2012, EUR J PHARMACOL"
"PISCIOTTA L;BELLOCCHIO A;BERTOLINI S","PISCIOTTA, LIVIA (6602289161); BELLOCCHIO, ANTONELLA (6603322896); BERTOLINI, STEFANO (7004305389)","NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROLLOWERING TREATMENT",2012,"LIPIDS IN HEALTH AND DISEASE","11","",67,"10.1186/1476-511X-11-123","DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF GENOA, 16132, GENOA, VIALE BENEDETTO XV N. 6, ITALY;DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF GENOA, 16132, GENOA, VIALE BENEDETTO XV N. 6, ITALY;DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF GENOA, 16132, GENOA, VIALE BENEDETTO XV N. 6, ITALY","ABSTRACT. BACKGROUND: ALTHOUGH STATINS (STS) ARE DRUGS OF FIRST CHOICE IN HYPERCHOLESTEROLEMIC PATIENTS, ESPECIALLY IN THOSE AT HIGH CARDIOVASCULAR RISK, SOME OF THEM ARE INTOLERANT TO STS OR REFUSE TREATMENT WITH THESE DRUGS. IN VIEW OF THIS, WE HAVE EVALUATED THE LIPID-LOWERING EFFECT OF A NUTRACEUTICAL PILL CONTAINING BERBERINE (BBR) AND OF EZETIMIBE, AS ALTERNATIVE TREATMENTS, IN MONOTHERAPY OR IN COMBINATION, IN 228 SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HCH), WITH HISTORY OF STS INTOLERANCE OR REFUSING STS TREATMENT. IN ADDITION, SINCE PCSK9 WAS FOUND UP-REGULATED BY STS DAMPENING THEIR EFFECT THROUGH AN LDL RECEPTORS (LDLRS) DEGRADATION, AND BBR SUPPRESSED PCSK9 EXPRESSION IN CELLULAR STUDIES, WE SUPPLEMENTED THE STABLE LIPID-LOWERING THERAPY OF 30 GENOTYPE-CONFIRMED FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES (HEFH) WITH BBR, SEARCHING FOR A FURTHER PLASMA CHOLESTEROL REDUCTION. PLASMA LIPID PATTERN WAS EVALUATED AT BASELINE AND DURING TREATMENTS. RESULTS: IN HCH SUBJECTS THE NUTRACEUTICAL PILL RESULTED MORE EFFECTIVE THAN EZE IN LOWERING LDL CHOLESTEROL (31.7% VS 25.4%, P<0.001) AND BETTER TOLERATED. ON TREATMENT, LDL-C LEVEL BELOW 3.36MMOL/L (130 MG/DL) WAS OBSERVED IN 28.9% OF SUBJECTS TREATED WITH THE NUTRACEUTICAL PILL AND 11.8% OF THOSE TREATED WITH EZE (P <0.007). IN THE GROUP TREATED WITH EZE THE SUBJECTS CARRYING THE G ALLELE OF THE G.1679 C > G SILENT POLYMORPHISM OF NPC1L1 GENE SHOWED A HIGHER RESPONSE TO EZE THAN HOMOZYGOUS FOR THE COMMON ALLELE (GG + CG: LDL-C 29.45.0%, CC 23.66.5%, P <0.001). COMBINED TREATMENT WITH THESE DRUGS WAS AS EFFECTIVE AS STS IN MODERATE DOSES (LDL CHOLESTEROL 37%, TRIGLYCERIDES 23%). IN HEFH PATIENTS THE ADDITION OF BBR RESULTED IN LDL CHOLESTEROL REDUCTIONS INVERSELY RELATED TO THOSE INDUCED BY THE STABLE THERAPY (R=0.617, P <0.0001), WITH MEAN 10.5% FURTHER DECREASE. CONCLUSIONS: THE ALTERNATIVE TREATMENTS TESTED IN OUR HCH SUBJECTS WERE RATHER EFFECTIVE AND SAFE. THE FINDINGS IN HEFH PATIENTS SUGGEST THAT BBR MIGHT ACT IN VIVO INCREASING EXPRESSION AND STABILITY OF LDLRS AND/OR SUPPRESSING PCSK9 EXPRESSION. © 2012 PISCIOTTA ET AL.; LICENSEE BIOMED CENTRAL LTD.","BERBERINE; EZETIMIBE; FAMILIAL HYPERCHOLESTEROLEMIA; PCSK9; PRIMARY POLYGENIC HYPERCHOLESTEROLEMIA","AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BERBERINE; BIOLOGICAL AGENTS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; MUTATION; RECEPTORS, LDL; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES; BERBERINE; CHOLESTIN; EZETIMIBE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NUTRACEUTICAL; POLICOSANOL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MALE; MEDICAL HISTORY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIMARY POLYGENIC HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT REFUSAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION","UNIVERSITÀ DEGLI STUDI DI GENOVA","THIS WORK WAS SUPPORTED BY A GRANT FROM THE UNIVERSITY OF GENOVA (TO SB).","CLEEMAN J.I., EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); CATAPANO A.L., REINER Z., DE BACKER G., GRAHAN I., TASKINEN M.-R., WIKLUND O., AGEWALL S., ALEGRIA E., CHAPMAN M.J., DURRINGTON P., ERDINE S., HALCOX J., HOBBS R., KJEKSHUS J., PERRONE FILARDI P., RICCARDI G., STOREY R., WOOD D., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), ATHEROSCLEROSIS, 217, (2011); LEWIS S.J., LIPID-LOWERING THERAPY: WHO CAN BENEFIT?, VASC HEALTH RISK MANAG, 7, PP. 525-534, (2011); EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170 000 PARTICIPANTS IN 26 RANDOMIZED TRIAL, LANCET, 376, PP. 1670-1681, (2010); MILLS E.J., OREGAN C., EYAWO O., WU P., MILLS F., BERWANGER O., BRIEL M., INTENSIVE STATIN THERAPY COMPARED WITH MODERATE DOSING FOR PREVENTION OF CARDIOVASCULAR EVENTS: A META-ANALYSIS OF >40 000 PATIENTS, EUR HEART J, 32, PP. 1409-1415, (2011); ABD T.T., JACOBSON T.A., STATIN-INDUCED MYOPATHY: A REVIEW AND UPDATE, EXPERT OPIN DRUG SAF, 10, PP. 373-387, (2011); ARCA M., PIGNA G., TREATING STATIN-INTOLERANT PATIENTS, DIABETES METAB SYNDR OBES, 4, PP. 155-166, (2011); COSTET P., MOLECULAR PATHWAYS AND AGENTS FOR LOWERING LDL-CHOLESTEROL IN ADDITION TO STATINS, PHARMACOL THER, 126, PP. 263-278, (2010); ADOURIDIS A., FILIPPATOS T.D., TSIMIHODIMOS V., ELISAF M.S., COMBINATIONS OF EZETIMIBE WITH NONSTATIN DRUG REGIMENS AFFECTING LIPID METABOLISM, EXPERT REV CARDIOVASC THER, 9, PP. 355-366, (2011); CARIOU B., LE MAY C., COSTET P., CLINICAL ASPECTS OF PCSK9, ATHEROSCLEROSIS, 216, PP. 258-265, (2011); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASE PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-273, (2008); BERTOLINI S., CANTAFORA A., AVERNA M., CORTESE C., MOTTI C., MARTINI S., PES G., POSTIGLIONE A., STEFANUTTI C., BLOTTA I., PISCIOTTA L., ROLLERI M., LANGHEIM S., GHIBELLINI M., RABBONE I., CALANDRA S., CLINICAL EXPRESSION OF FAMILIAL HYPERCHOLESTEROLEMIA IN CLUSTERS OF MUTATIONS OF THE LDL RECEPTOR GENE THAT CAUSE A RECEPTOR-DEFECTIVE OR RECEPTOR-NEGATIVE PHENOTYPE, ARTERIOSCLER THROMB VASC BIOL, 20, (2000); SIMON J.S., KARNOUB M.C., DEVLIN D.J., ARREAZA M.G., QIU P., MONKS S.A., SEVERINO M.E., DEUTSCH P., PALMISANO J., SACHS A.B., BAYNE M.L., PLUMP A.S., SCHADT E.E., SEQUENCE VARIATION IN NPC1L1 AND ASSOCIATION WITH IMPROVED LDL-CHOLESTEROL LOWERING IN RESPONSE TO EZETIMIBE TREATMENT, GENOMICS, 86, PP. 648-656, (2005); PISCIOTTA L., FASANO T., BELLOCCHIO A., BOCCHI L., SALLO R., FRESA R., COL ANGELI I., CANTAFORA A., CALANDRA S., BERTOLINI S., EFFECT OF EZETIMIBE COADMINISTERED WITH STATINS IN GENOTYPE-CONFIRMED HETEROZYGOUS FH PATIENTS, ATHEROSCLEROSIS, 194, (2007); CICERO A.F.G., ROVATI L., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS IN HUMANS, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); AFFUSO F., RUVOLO A., MICILLO F., SACC L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., SPOSATO B., MASSARO R., GRECO F., ROSANO G., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, PP. 1105-1113, (2011); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MEDITERR J NUTR METAB, 4, PP. 133-139, (2011); HUANG J., FROHLICH J., IGNASZEWSKI A.P., THE IMPACT OF DIETARY CHANGES AND DIETARY SUPPLEMENTS ON LIPID PROFILE, CAN J CARDIOL, 27, PP. 488-505, (2011); HALBERT S.C., FRENCH B., GORDON R.Y., FARRAR J.T., SCHMITZ K., MORRIS P.B., THOMPSON P.D., RADER D.J., BECKER D.J., TOLERABILITY OF RED YEAST RICE (2,400MG TWICE DAILY) VERSUS PRAVASTATIN (20MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); VENERO C.V., VENERO J.V., WORTHAM D.C., THOMPSON P.D., LIPID-LOWERING EFFICACY OF RED YEAST RICE IN A POPULATION INTOLERANT TO STATINS, AM J CARDIOL, 105, PP. 664-666, (2010); GORDON R.Y., COOPERMAN T., OBERMEYER W., BECKER D.J., MARKED VARIABILITY OF MONACOLIN LEVELS IN COMMERCIAL RED YEAST RICE PRODUCTS, ARCH INTERN MED, 170, PP. 1722-1727, (2010); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA, 295, PP. 2262-2269, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.-D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); LI H., CHEN W., ZHOU Y., ABIDI P., SHARPE O., ROBINSON W.H., KRAEMER F.B., LIU J., IDENTIFICATION OF MRNA BINDING PROTEINS THAT REGULATE THE STABILITY OF LDL RECEPTOR MRNA THROUGH AU-RICH ELEMENTS, J LIPID RES, 50, PP. 820-831, (2009); LEE S., LIM H.J., PARK J.H., LEE K.S., JANG Y., PARK H.Y., BERBERINE INDUCED LDLR UP-REGULATION INVOLVES JNK PATHWAY, BIOCHEM BIOPHYS RES COMMUN, 362, PP. 853-857, (2007); BRUSQ J.M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINTILLAN Y., ISSANDOU M., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); PHAN B.A.P., DAYSPRING T.D., TOTH P.P., EZETIMIBE THERAPY: MECHANISM OF ACTION AND CLINICAL UPDATE, VASC HEALTH RISK MANAG, 8, PP. 415-427, (2012); TREMBLAY A.J., LAMARCHE B., COHN J.S., HOGUE J.C., COUTURE P., EFFECT OF EZETIMIBE ON THE IN VIVO KINETICS OF APOB-48 AND APOB-100 IN MEN WITH PRIMARY HYPERCHOLESTEROLEMIA, ARTERIOSCLER THROMB VASC BIOL, 26, PP. 1101-1106, (2006); DESCAMPS O.S., DE SUTTER J., GUILLAUME M., MISSAULT L., WHERE DOES THE INTERPLAY BETWEEN CHOLESTEROL ABSORPTION AND SYNTHESIS IN THE CONTEXT OF STATIN AND/OR EZETIMIBE TREATMENT STAND TODAY?, ATHEROSCLEROSIS, 217, PP. 308-321, (2011); MIKHAILIDIS D.P., LAWSON R.W., MCCORMICK A.L., SIBBRING G.C., TERSHAKOVEC A.M., DAVIES G.M., TUNCELI K., COMPARATIVE EFFICACY OF THE ADDITION OF EZETIMIBE TO STATIN VS STATIN TITRATION IN PATIENTS WITH HYPERCHOLESTEROLEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS, CURR MED RES OPIN, 27, PP. 1191-1210, (2011); PANDOR A., ARA R.M., TUMUR I., WILKINSON A.J., PAISLEY S., DUENAS A., DURRINGTON P.N., CHILCOTT J., EZETIMIBE MONOTHERAPY FOR CHOLESTEROL LOWERING IN 2,722 PEOPLE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, J INTERN MED, 265, PP. 568-580, (2009); DERDEMEZIS C.S., FILIPPATOS T.D., TSELEPIS A.D., MIKHAILIDIS D.P., ELISAF M.S., EFFECT OF EZETIMIBE, EITHER ALONE OR IN COMBINATION WITH ATORVASTATIN, ON SERUM VISTATIN LEVELS: A PILOT STUDY, EXPERT OPIN PHARMACOTHER, 9, PP. 1829-1837, (2008); WENG T.C., YANG Y.H.K., LIN S.-J., TAI S.H., A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE THERAPEUTIC EQUIVALENCE OF STATINS, J CLIN PHARM THER, 35, PP. 139-151, (2010); HORTON J.D., COHEN J.C., HOBBS H.H., PCSK9: A CONVERTASE THAT COORDINATES LDL CATABOLISM, J LIPID RES, 50, (2009); LI H., DONG B., PARK S.W., LEE H.S., CHEN W., LIU J., HEPATOCYTE NUCLEAR FACTOR 1 PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINA, J BIOL CHEM, 42, PP. 28885-28895, (2009); DUBUC G., CHAMBERLAND A., WASSEF H., DAVIGNON J., SEIDAH N.G., BERNIER L., PRAT A., STATINS UPREGULATE PCSK9, THE GENE ENCODING THE PROPROTEIN CONVERTASE NEURAL APOPTOSIS-REGULATED CONVERTASE-1 IMPLICATED IN FAMILIAL HYPERCHOLESTEROLEMIA, ARTERIOSCLER THROMB VASC BIOL, 24, PP. 1454-1459, (2004); DUBUC G., TREMBLAY M., PARE G., JACQUES H., HAMELIN J., BENJANNET S., BOULET L., GENEST J., BERNIER L., SEIDAH N.G., DAVIGNON J., A NEW METHOD FOR MEASUREMENT OF TOTAL PLASMA PCSK9: CLINICAL APPLICATIONS, J LIPID RES, 51, PP. 140-149, (2010); KONRAD R.J., TROUTT J.S., CAO G., EFFECTS OF CURRENTLY PRESCRIBED LDL-C LOWERING DRUGS ON PCSK9 AND IMPLICATIONS FOR THE NEXT GENERATION OF LDL-C LOWERING AGENTS, LIPIDS HEALTH DIS, 10, (2011); RASHID S., CURTIS D.E., GARUTI R., ANDERSON N.N., BASHMAKOV Y., HO Y.K., HAMMER R.E., MOON Y.A., HORTON J.D., DECREASED PLASMA CHOLESTEROL AND HYPERSENSITIVITY TO STATINS IN MICE LACKING PCSK9, PROC NATL ACAD SCI USA, 102, PP. 5374-5379, (2005); BERGE K.E., OSE L., LEREN T.P., MISSENSE MUTATIONS IN THE PCSK9 GENE ARE ASSOCIATED WITH HYPOCHOLESTEROLEMIA AND POSSIBLY INCREASED RESPONSE TO STATIN THERAPY, ARTERIOSCLER THROMB VASC BIOL, 26, PP. 1094-1100, (2006); TIBOLLA G., NORATA G.D., ARTALI R., MENEGHETTI F., CATALANO A.L., PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9): FROM STRUCTURE-FUNCTION RELATION TO THERAPEUTIC INHIBITION, NUTR METAB CARDIOVASC DIS, 21, PP. 835-843, (2011); DONG B., WU M., LI H., KRAEMER F.B., ADELI K., SEIDAH N.G., PARK S.W., LIU J., STRONG INDUCTION OF PCSK9 GENE EXPRESSION THROUGH HNF1 AND SREBP2: MECHANISM FOR THE RESISTANCE TO LDL-CHOLESTEROL LOWERING EFFECT OF STATINS IN DYSLIPIDEMIC HAMSTER, J LIPID RES, 51, PP. 1486-1495, (2010); KONG W.J., WEI J., ZUO Z.Y., WANG Y.M., SONG D.Q., YOU X.F., ZHAO L.X., PAN H.N., JIANG J.D., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFECT, METABOLISM, 57, PP. 1029-1037, (2008); AWAN Z., SEIDAH N.G., MACFADYEN J.G., BENJANNET S., CHASMAN D.I., RIDKER P.M., GENEST J., ROSUVASTATIN, PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 CONCENTRATIONS, AND LDL CHOLESTEROL RESPONSE: THE JUPITER TRIAL, CLIN CHEM, 58, PP. 183-189, (2012)","S. BERTOLINI; DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF GENOA, 16132, GENOA, VIALE BENEDETTO XV N. 6, ITALY; EMAIL: STEFBERT@UNIGE.IT","","ENGLISH","LIPIDS HEALTH DIS.","ARTICLE","ISI","2-S2.0-84866495078","LIPIDS HEALTH DIS","UNIVERSITY OF GENOA;UNIVERSITY OF GENOA;UNIVERSITY OF GENOA","NOTREPORTED;UNIVERSITY OF GENOA;NOTREPORTED",NA,"PISCIOTTA L, 2012, LIPIDS HEALTH DIS","PISCIOTTA L, 2012, LIPIDS HEALTH DIS"
"ARDJOMAND-WOELKART K;BAUER R","ARDJOMAND-WOELKART, KARIN (36730711200); BAUER, RUDOLF (7401721175)","REVIEW AND ASSESSMENT OF MEDICINAL SAFETY DATA OF ORALLY USED ECHINACEA PREPARATIONS",2015,"PLANTA MEDICA","82","14",31,"10.1055/s-0035-1558096","INSTITUTE OF PHARMACEUTICAL SCIENCES, UNIVERSITY OF GRAZ, DEPARTMENT OF PHARMACOGNOSY, UNIVERSITAETSPLATZ 4/I, GRAZ, 8010, AUSTRIA;INSTITUTE OF PHARMACEUTICAL SCIENCES, UNIVERSITY OF GRAZ, DEPARTMENT OF PHARMACOGNOSY, UNIVERSITAETSPLATZ 4/I, GRAZ, 8010, AUSTRIA","ECHINACEA PURPUREA, ECHINACEA ANGUSTIFOLI AND ECHINACEA PALLIDA ARE FREQUENTLY USED AS MEDICINAL PLANTS. BESIDES ASKING FOR EVIDENCE ON THEIR EFFICACY, THERE IS AN INCREASING INTEREST FOR SAFETY DATA. THIS REVIEW SYSTEMATICALLY PRESENTS THE AVAILABLE LITERATURE ON DRUG INTERACTIONS, CONTRAINDICATIONS, ADVERSE EVENTS, DURATION OF USE, AND SAFETY OF USE IN PREGNANT AND NURSING WOMEN, AND ASSESSES THE SAFETY PROFILE OF CORRESPONDING ECHINACEA PREPARATIONS. IT IS NOTEWORTHY THAT ALL SAFETY DATA REPORTED ARE AS PRODUCT SPECIFIC AS THE PHARMACOLOGICAL OR EFFICACY DATA ARE. IN PHARMACOKINETIC HERB-DRUG INTERACTION STUDIES PERFORMED IN VIVO, NO SIGNIFICANT INHIBITIONS OF HUMAN CYP2D6 AND CYP3A4 ISOFORMS HAVE BEEN FOUND AFTER THE ADMINISTRATION OF STANDARDIZED E. PURPUREA PREPARATIONS. HOWEVER, CONTRADICTORY RESULTS EXIST IN STUDIES USING LIVER MICROSOMES. ADVERSE EVENTS REPORTED DURING CLINICAL TRIALS FOLLOWING ADMINISTRATION OF ECHINACEA SPP. MONO-PREPARATIONS WERE GENERALLY MILD AND MOSTLY WITHOUT CAUSALITY. DUE TO PUBLISHED LONG TERM STUDIES WITH CONTINUOUS INGESTION OF DIFFERENT ECHINACEA PREPARATIONS UP TO 6 MONTH WITH NO REPORTED TOXICOLOGICAL CONCERNS, ECHINACEA CAN BE RECOMMENDED ALSO FOR LONG-TERM USE. MOREOVER, THE CONTRAINDICATIONS IN CASES OF AUTOIMMUNE DISEASES AND IMMUNE-SUPPRESSION ARE QUESTIONABLE, SINCE LIPOPHILIC ECHINACEA PREPARATIONS CONTAINING ALKAMIDES SUPPRESS CELLULAR IMMUNE RESPONSES, AND BENEFICIAL EFFECTS IN AUTOIMMUNITY WERE REPORTED. THE SAME APPLIES FOR THE USE DURING PREGNANCY. ALTHOUGH THERE HAS BEEN SOME IMPACT REPORTED ON EMBRYONIC ANGIOGENESIS IN MICE, NO ASSOCIATION WITH AN INCREASED RISK FOR MAJOR OR MINOR MALFORMATIONS DURING ORGANOGENESIS WAS FOUND IN A LITERATURE REVIEW. ALTOGETHER, THE DIFFERENT EVALUATED ECHINACEA PREPARATIONS ARE WELL-TOLERATED HERBAL MEDICINES IN THE MANAGEMENT IN CHILDREN AND ADULTS ALIKE. © GEORG THIEME VERLAG KG STUTTGART · NEW YORK.","ASTERACEAE; ECHINACEA SPP.; SAFETY","ANIMALS; CONSUMER PRODUCT SAFETY; ECHINACEA; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PREGNANCY; CISPLATIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARUNAVIR; DEXTROMETHORPHAN; ECHINACEA ANGUSTIFOLIA EXTRACT; ECHINACEA EXTRACT; ECHINACEA PALLIDA EXTRACT; ECHINACEA PURPUREA EXTRACT; ETOPOSIDE; ETRAVIRINE; FEXOFENADINE; LEVAMISOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MELATONIN; MIDAZOLAM; PHENYTOIN; POLICOSANOL; RITONAVIR; THEOPHYLLINE; TOLBUTAMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; WARFARIN; PLANT EXTRACT; ACUTE CHOLESTATIC AUTOIMMUNE HEPATITIS; ANGIOGENESIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CHOLESTASIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TRANSFORMATION; ECHINACEA ANGUSTIFOLIA; ECHINACEA PALLIDA; ECHINACEA PURPUREA; EOSINOPHILIA; ERYTHEMA NODOSUM; HERB DRUG INTERACTION; HUMAN; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORGANOGENESIS; PHAGOCYTOSIS; RASH; REPRODUCTION; REVIEW; SJOEGREN SYNDROME; THROMBOCYTOPENIA; TREATMENT DURATION; ADVERSE EFFECTS; ANIMAL; ECHINACEA; FEMALE; HERB DRUG INTERACTION; PHYTOTHERAPY; PREGNANCY; PRODUCT SAFETY","","","BARNES J., ANDERSON L.A., GIBBONS S., PHILLIPSON J.D., ECHINACEA SPECIES (ECHINACEA ANGUSTIFOLIA (DC.) HELL., ECHINACEA PALLIDA (NUTT.) NUTT., ECHINACEA PURPUREA (L.) MOENCH): A REVIEW OF THEIR CHEMISTRY, PHARMACOLOGY AND CLINICAL PROPERTIES, J PHARM PHARMACOL, 57, PP. 929-954, (2005); WOELKART K., BAUER R., THE ROLE OF ALKAMIDES AS AN ACTIVE PRINCIPLE OF ECHINACEA, PLANTA MED, 73, PP. 615-623, (2007); ASSESSMENT REPORT ON ECHINACEA PURPUREA (L.) MOENCH, HERBA RECENS. EMA/HMPC/557979/2013, (2015); EUROPEAN UNION HERBAL MONOGRAPH ON ECHINACEA PURPUREA (L.) MOENCH., HERBA RECENS. EMA/HMPC/48704/2014, (2015); COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX. EMA/HMPC/332350/2008, (2009); COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PURPUREA (L.) MOENCH., RADIX. EMA/HMPC/577784/2008, (2011); COMMUNITY LIST ENTRY ON ECHINACEA PURPUREA (L.) MOENCH., HERBA RECENS. EMA/HMPC/189629/2007, (2007); MATTHIAS A., BANBURY L.K., STEVENSON L.M., BONE K.M., LEACH D.N., LEHMANN R.P., ALKYLAMIDES FROM ECHINACEA MODULATE INDUCED IMMUNE RESPONSES IN MACROPHAGES, IMMUNOL INVEST, 36, PP. 117-130, (2007); CURRIER N.L., MILLER S.C., ECHINACEA PURPUREA AND MELATONIN AUGMENT NATURAL-KILLER CELLS IN LEUKEMIC MICE AND PROLONG LIFE SPAN, J ALTERN COMPLEMENT MED, 7, PP. 241-251, (2001); CURRIER N.L., SICOTTE M., MILLER S.C., DELETERIOUS EFFECTS OF ECHINACEA PURPUREA AND MELATONIN ON MYELOID CELLS IN MOUSE SPLEEN AND BONE MARROW, J LEUKOC BIOL, 70, PP. 274-276, (2001); KHAKSARY MAHABADY M., RANJBAR R., ARZI A., PAPAHN A.A., NAJAFZADEH H., A COMPARISON STUDY OF EFFECTS OF ECHINACEA EXTRACT AND LEVAMISOLE ON PHENYTOIN-INDUCED CLEFT PALATE IN MICE, REGUL TOXICOL PHARMACOL, 6, PP. 163-166, (2006); MOHAMMED ABDUL M.I., JIANG X., WILLIAMS K.M., DAY R., ROUFOGALIS B.D., LIAUW W.S., XU H., MATTHIAS A., LEHMANN R.P., MCLACHLAN A.J., PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS OF ECHINACEA AND POLICOSANOL WITH WARFARIN IN HEALTHY SUBJECTS, BR J CLIN PHARMACOL, 69, PP. 508-515, (2010); BOSSAER J.B., ODLE B.L., PROBABLE ETOPOSIDE INTERACTION WITH ECHINACEA, J DIET SUPPL, 9, PP. 90-95, (2012); BUDZINSKI J.W., FOSTER B.C., VANDENHOEK S., ARNASON J.T., AN IN VITRO EVALUATION OF HUMAN CYTOCHROME P450 3A4 INHIBITION BY SELECTED COMMERCIAL HERBAL EXTRACTS AND TINCTURES, PHYTOMEDICINE, 7, PP. 273-282, (2000); GORSKI J.C., HUANG S., PINTO A.G., HAMMAN M.A., HILLIGOSS J.K., ZAHEER N.A., DESAI M.P., MILLER M.A., HALL S.D., THE EFFECT OF ECHINACEA (ECHINACEA PURPUREA ROOT) ON CYTOCHROME P450 ACTIVITY IN VIVO, CLIN PHARMACOL THER, 75, PP. 89-100, (2004); GURLEY B.J., GARDNER S.F., HUBBARD M.A., WILLIAMS D.K., GENTRY W.B., CARRIER J.C., KHAN I.A., EDWARDS D.J., SHAH A.K., IN VIVO ASSESSMENT OF BOTANICAL SUPPLEMENTATION ON HUMAN CYTOCHROME P450 PHENOTYPES: CITRUS AURANTIUM, ECHINACEA PURPUREA, MILK THISTLE, AND SAW PALMETTO, CLIN PHARMACOL THER, 76, PP. 428-440, (2004); YALE S.H., GLURICH I.E., ANALYSIS OF THE INHIBITORY POTENTIAL OF GINKGO BILOBA, ECHINACEA PURPUREA, AND SERENOA REPENS ON THE METABOLIC ACTIVITY OF CYTOCHROME P450 3A4, 2D6, AND 2C9, J ALTERN COMPLEMENT MED, 11, PP. 433-439, (2005); GURLEY B.J., SWAIN A., HUBBARD M.A., WILLIAMS D.K., BARONE G.W., HARTSFIELD F., TONG Y., CARRIER D.J., CHEBOYINA S., BATTU S.K., CLINICAL ASSESSMENT OF CYP2D6-MEDIATED HERB-DRUG INTERACTIONS IN HUMANS: EFFECTS OF MILK THISTLE, BLACK COHOSH, GOLDENSEAL, KAVA KAVA, ST. JOHNS WORT, AND ECHINACEA, MOL NUTR FOOD RES, 52, PP. 755-763, (2008); MOLTO J.M., VALLE M., MIRANDA C., CEDENO S., NEGREDO E., BARBANOJ M.J., CLOTET B., HERB-DRUG INTERACTION BETWEEN ECHINACEA PURPUREA AND DARUNAVIR-RITONAVIR IN HIV-INFECTED PATIENTS, ANTIMICROB AGENTS CHEMOTHER, 55, PP. 326-330, (2011); MOLTO J.M., VALLE M., MIRANDA C., CEDENO S., NEGREDO E., CLOTET B., HERB-DRUG INTERACTION BETWEEN ECHINACEA PURPUREA AND ETRAVIRINE IN HIV-INFECTED PATIENTS, ANTIMICROB AGENTS CHEMOTHER, 56, PP. 5328-5331, (2012); PENZAK S.R., ROBERTSON S.M., HUNT J.D., CHAIREZ C.L., MALATI C.Y., ALFARO R.M., STEVENSON J.G., KOVACS J.A., ECHINACEA PURPUREA SIGNIFICANTLY INDUCES CYTOCHROME P450 3 A ACTIVITY BUT DOES NOT ALTER LOPINAVIR-RITONAVIR EXPOSURE IN HEALTHY SUBJECTS, PHARMACOTHERAPY, 30, PP. 797-805, (2010); HELLUM B.H., HU Z., NILSEN O.G., THE INDUCTION OF CYP1A2, CYP2D6 AND CYP3A4 BY SIX TRADE HERBAL PRODUCTS IN CULTURED PRIMARY HUMAN HEPATOCYTES, BASIC CLIN PHARMACOL TOXICOL, 100, PP. 23-30, (2007); HELLUM B.H., NILSEN O.G., IN VITRO INHIBITION OF CYP3A4 METABOLISM AND P-GLYCOPROTEIN-MEDIATED TRANSPORT BY TRADE HERBAL PRODUCTS, BASIC CLIN PHARMACOL TOXICOL, 102, PP. 466-475, (2008); MODARAI M., GERTSCH J.U., SUTER A., HEINRICH M.M., KORTENKAMP A., CYTOCHROME P450 INHIBITORY ACTION OF ECHINACEA PREPARATIONS DIFFERS WIDELY AND CO-VARIES WITH ALKYLAMIDE CONTENT, J PHARM PHARMACOL, 59, PP. 567-573, (2007); MODARAI M., YANG M., SUTER A., KORTENKAMP A., HEINRICH M.M., METABOLOMIC PROFILING OF LIQUID ECHINACEA MEDICINAL PRODUCTS WITH IN VITRO INHIBITORY EFFECTS ON CYTOCHROME P450 3A4 (CYP3A4), PLANTA MED, 76, PP. 378-385, (2010); MROZIKIEWICZ P.M., BOGACZ A., KARASIEWICZ M., MIKOLAJCZAK P.L., OZAROWSKI M., SEREMAK-MROZIKIEWICZ A., CZERNY B., BOBKIEWICZ-KOZLOWSKA T., GRZESKOWIAK E., THE EFFECT OF STANDARDIZED ECHINACEA PURPUREA EXTRACT ON RAT CYTOCHROME P450 EXPRESSION LEVEL, PHYTOMEDICINE, 17, PP. 830-833, (2010); RANER G.M., CORNELIOUS S., MOULICK K., WANG Y., MORTENSON A.M., CECH N.B., EFFECTS OF HERBAL PRODUCTS AND THEIR CONSTITUENTS ON HUMAN CYTOCHROME P4502E1 ACTIVITY, FOOD CHEM TOXICOL, 45, PP. 2359-2365, (2007); HANSEN T.S., NILSEN O.G., IN VITRO CYP3A4 METABOLISM: INHIBITION BY ECHINACEA PURPUREA AND CHOICE OF SUBSTRATE FOR THE EVALUATION OF HERBAL INHIBITION, BASIC CLIN PHARMACOL TOXICOL, 103, PP. 445-449, (2008); KORTENKAMP A., MODARAI M., SILVA E., SUTER A., HEINRICH M.M., SAFETY OF HERBAL MEDICINAL PRODUCTS: ECHINACEA AND SELECTED ALKYLAMIDES DO NOT INDUCE CYP3A4 MRNA EXPRESSION, EVID BASED COMPLEMENT ALTERNAT MED, 2011, (2011); ARDJOMAND-WOELKART K., KOLLROSER M., LI L., DERENDORF H., BUTTERWECK V., BAUER R., DEVELOPMENT AND VALIDATION OF A LC-MS/MS METHOD BASED ON A NEW 96-WELL HYBRID-SPE™-PRECIPITATION TECHNIQUE FOR QUANTIFICATION OF CYP450 SUBSTRATES/METABOLITES IN RAT PLASMA, ANAL BIOANAL CHEM, 400, PP. 2371-2381, (2011); ARDJOMAND-WOELKART K., KOLLROSER M., DERENDORF H., BAUER R., BUTTERWECK V., HERB-DRUG INTERACTIONS: EFFECTS OF ECHINACEA PREPARATIONS ON CYTOCHROME P450 ACTIVITIES IN RATS, PLANTA MED, 78, (2012); GERTSCH J., IMMUNOMODULATORY LIPIDS IN PLANTS: PLANT FATTY ACID AMIDES AND THE HUMAN ENDOCANNABINOID SYSTEM, PLANTA MED, 74, PP. 638-650, (2008); GERTSCH J., SCHOOP R., KUENZLE U., SUTER A., ECHINACEA ALKYLAMIDES MODULATE TNF-ALPHA GENE EXPRESSION VIA CANNABINOID RECEPTOR CB2 AND MULTIPLE SIGNAL TRANSDUCTION PATHWAYS, FEBS LETT, 77, PP. 563-569, (2004); RADUNER S., MAJEWSKA A., CHEN J.Z., XIE X.Q., HAMON J., FALLER B., ALTMANN K.H., GERTSCH J., ALKYLAMIDES FROM ECHINACEA ARE A NEW CLASS OF CANNABINOMIMETICS: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS, J BIOL CHEM, 281, PP. 14192-14206, (2006); HINZ B., WOELKART K., BAUER R., ALKAMIDES FROM ECHINACEA INHIBIT CYCLOOXYGENASE-2 ACTIVITY IN HUMAN NEUROGLIOMA CELLS, BIOCHEM BIOPHYS RES COMMUN, 360, PP. 441-446, (2007); SASAGAWA M., CECH N.B., GRAY D.E., ELMER G.W., WENNER C.A., ECHINACEA ALKYLAMIDES INHIBIT INTERLEUKIN-2 PRODUCTION BY JURKAT T CELLS, INT IMMUNOPHARMACOL, 6, PP. 1214-1221, (2006); WOELKART K., MARTH E., SUTER A., SCHOOP R., RAGGAM R.B., KOIDL C., KLEINHAPPL B., BAUER R., BIOAVAILABILITY AND PHARMACOKINETICS OF ECHINACEA PURPUREA PREPARATIONS AND THEIR INTERACTION WITH THE IMMUNE SYSTEM, INT J CLIN PHARMACOL THER, 44, PP. 401-408, (2006); BAUER R., ECHINACEA CONTAINING DRUGS: EFFECTS AND ACTIVE CONSTITUENTS, Z ARZTL FORTBILD (JENA), 90, PP. 111-115, (1996); BAUER R., PLANT IMMUNOSTIMULATING AGENTS IN SELF MEDICATION, PHARM UNSERER ZEIT, 27, PP. 144-157, (1998); BAUER V.R., JURCIC K., PUHLMANN J., WAGNER H., IMMUNOLOGICAL IN VIVO AND IN VITRO EXAMINATIONS OF ECHINACEA EXTRACTS, ARZNEIMITTELFORSCHUNG, 38, PP. 276-281, (1988); GOEL V., CHANG C., SLAMA J.V., BARTON R., BAUER R., GAHLER R., BASU T.K., ALKYLAMIDES OF ECHINACEA PURPUREA STIMULATE ALVEOLAR MACROPHAGE FUNCTION IN NORMAL RATS, INT IMMUNOPHARMACOL, 2, PP. 381-387, (2002); GOEL V., CHANG C., SLAMA J.V., BARTON R., BAUER R., GAHLER R., BASU T.K., ECHINACEA STIMULATES MACROPHAGE FUNCTION IN THE LUNG AND SPLEEN OF NORMAL RATS, J NUTR BIOCHEM, 13, PP. 487-492, (2002); BODINET C., WILLIGMANN I., BEUSCHER N., HOST-RESISTANCE INCREASING ACTIVITY OF ROOT EXTRACTS FROM ECHINACEA SPECIES, PLANTA MED, 59, PP. A672-A673, (1993); RITCHIE M.R., GERTSCH J.U., KLEIN P.M., SCHOOP R., EFFECTS OF ECHINAFORCE ® TREATMENT ON EX VIVO-STIMULATED BLOOD CELLS, PHYTOMEDICINE, 18, PP. 826-831, (2011); HUNTLEY A.L., COON J.T., ERNST E.E., THE SAFETY OF HERBAL MEDICINAL PRODUCTS DERIVED FROM ECHINACEA SPECIES: A SYSTEMATIC REVIEW, DRUG SAF, 28, PP. 387-400, (2005); MILLER L.G., HERBAL MEDICINALS: SELECTED CLINICAL CONSIDERATIONS FOCUSING ON KNOWN OR POTENTIAL DRUG-HERB INTERACTIONS, ARCH INTERN MED, 158, PP. 2200-2211, (1998); ELLINGWOOD F., AMERICAN MATERIA MEDICA, THERAPEUTICS AND PHARMACOGNOSY: ELLINGWOODS THERAPEUTIST, (1919); LEE A.N., WERTH V.P., ACTIVATION OF AUTOIMMUNITY FOLLOWING USE OF IMMUNOSTIMULATORY HERBAL SUPPLEMENTS, ARCH DERMATOL, 140, PP. 723-727, (2004); LOGAN J.L., AHMED J., CRITICAL HYPOKALEMIC RENAL TUBULAR ACIDOSIS DUE TO SJÖGRENS SYNDROME: ASSOCIATION WITH THE PURPORTED IMMUNE STIMULANT ECHINACEA 3, CLIN RHEUMATOL, 22, PP. 158-159, (2003); CHRISTENSEN K.B., MINET A.D., SVENSTRUP H., GREVSEN K., ZHANG H., SCHRADER E.M., RIMBACH G.H., WEIN S., WOLFFRAM S.J., KRISTIANSEN K., CHRISTENSEN L.P., IDENTIFICATION OF PLANT EXTRACTS WITH POTENTIAL ANTIDIABETIC PROPERTIES: EFFECT ON HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR), ADIPOCYTE DIFFERENTIATION AND INSULIN-STIMULATED GLUCOSE UPTAKE, PHYTOTHER RES, 23, PP. 1316-1325, (2009); CHRISTENSEN K.B., PETERSEN R.K., PETERSEN S., KRISTIANSEN K., CHRISTENSEN L.P., ACTIVATION OF PPARΓ BY METABOLITES FROM THE FLOWERS OF PURPLE CONEFLOWER (ECHINACEA PURPUREA), J NAT PROD, 72, PP. 933-937, (2009); BONE K., ECHINACEA: QUALITY, USES, AND IMMUNOMODULATING ACTIVITY FROM A PHYTOTHERAPISTS PERSPECTIVE, PP. 203-213, (2004); SEE D., BROUMAND N., SAHL L., TILLES J.G., IN VITRO EFFECTS OF ECHINACEA AND GINSENG ON NATURAL KILLER AND ANTIBODY-DEPENDENT CELL CYTOTOXICITY IN HEALTHY SUBJECTS AND CHRONIC FATIGUE SYNDROME OR ACQUIRED IMMUNODEFICIENCY SYNDROME PATIENTS, IMMUNOPHARMACOLOGY, 35, PP. 229-235, (1997); SEE D., CIMOCH P.J., CHOU S., CHANG J., TILLES J.G., THE IN VITRO IMMUNOMODULATORY EFFECTS OF GLYCONUTRIENTS ON PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH CHRONIC FATIGUE SYNDROME, INTEGR PHYSIOL BEHAV SCI, 33, PP. 280-287, (1998); BIELORY L., ADVERSE REACTIONS TO COMPLEMENTARY AND ALTERNATIVE MEDICINE: RAGWEEDS COUSIN, THE CONEFLOWER (ECHINACEA), IS A PROBLEM MORE THAN A SNEEZE, ANN ALLERGY ASTHMA IMMUNOL, 88, PP. 7-9, (2002); ERNST E., THE RISK-BENEFIT PROFILE OF COMMONLY USED HERBAL THERAPIES: GINKGO, ST. JOHNS WORT, GINSENG, ECHINACEA, SAW PALMETTO, AND KAVA, ANN INTERN MED, 136, PP. 42-53, (2002); MULLINS R.J., ECHINACEA-ASSOCIATED ANAPHYLAXIS, MED J AUST, 168, PP. 170-171, (1998); JESCHKE E., OSTERMANN T., LUKE C., TABALI M., KROZ M., BOCKELBRINK A., WITT C.M., WILLICH S.N., MATTHES H., REMEDIES CONTAINING ASTERACEAE EXTRACTS: A PROSPECTIVE OBSERVATIONAL STUDY OF PRESCRIBING PATTERNS AND ADVERSE DRUG REACTIONS IN GERMAN PRIMARY CARE, DRUG SAF, 32, PP. 691-706, (2009); LIATSOS G.D., ELEFSINIOTIS I.S., TODOROVA R., MOULAKAKIS A.M., ERRATUM: SEVERE THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) INDUCED OR EXACERBATED BY THE IMMUNOSTIMULATORY HERB ECHINACEA, AM J HEMATOL, 81, (2006); KEMP D.E., FRANCO K.N., POSSIBLE LEUKOPENIA ASSOCIATED WITH LONG-TERM USE OF ECHINACEA, J AM BOARD FAM PRACT, 15, PP. 417-419, (2002); GOEL V., LOVLIN R.E., BARTON R., LYON M.R., BAUER R., LEE T., BASU T.K., EFFICACY OF A STANDARDIZED ECHINACEA PREPARATION (ECHINILIN™) FOR THE TREATMENT OF THE COMMON COLD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, J CLIN PHARM THER, 29, PP. 75-83, (2004); MASKATIA Z.K., BAKER K., HYPEREOSINOPHILIA ASSOCIATED WITH ECHINACEA USE, SOUTH MED J, 103, PP. 1173-1174, (2010); LEE SOON S., CRAWFORD R.I., RECURRENT ERYTHEMA NODOSUM ASSOCIATED WITH ECHINACEA HERBAL THERAPY, J AM ACAD DERMATOL, 44, PP. 298-299, (2001); JACOBSSON I., JONSSON A.K., GERDEN B., HAGG S., SPONTANEOUSLY REPORTED ADVERSE REACTIONS IN ASSOCIATION WITH COMPLEMENTARY AND ALTERNATIVE MEDICINE SUBSTANCES IN SWEDEN, PHARMACOEPIDEMIOL DRUG SAF, 18, PP. 1039-1047, (2009); KOCAMAN O., HULAGU S., SENTURK O., ECHINACEA-INDUCED SEVERE ACUTE HEPATITIS WITH FEATURES OF CHOLESTATIC AUTOIMMUNE HEPATITIS, EUR J INTERN MED, 19, (2008); BARSKI L., RABAEV E., SZTARKIER I., DELGADO J., PORATH A., JOTKOWITZ A.B., AUTOIMMUNE HEPATITIS AND HYPERGAMMAGLOBULINEMIC PURPURA ASSOCIATED WITH HERBAL MEDICINE USE, ISR MED ASSOC J, 10, PP. 390-391, (2008); RUSU M.A., TAMAS M., PUICA C.D., ROMAN I.C., SABADAS M., THE HEPATOPROTECTIVE ACTION OF TEN HERBAL EXTRACTS IN CCL4 INTOXICATED LIVER, PHYTOTHER RES, 19, PP. 744-749, (2005); MENGS U., CLARE C.B., POILEY J.A., TOXICITY OF ECHINACEA PURPUREA. ACUTE, SUBACUTE AND GENOTOXICITY STUDIES, ARZNEIMITTELFORSCHUNG, 41, PP. 1076-1081, (1991); ONDRIZEK R.R., CHAN P., PATTON W.C., KING A., AN ALTERNATIVE MEDICINE STUDY OF HERBAL EFFECTS ON THE PENETRATION OF ZONA-FREE HAMSTER OOCYTES AND THE INTEGRITY OF SPERM DEOXYRIBONUCLEIC ACID, FERTIL STERIL, 71, PP. 517-522, (1999); ONDRIZEK R.R., CHAN P., PATTON W.C., KING A., INHIBITION OF HUMAN SPERM MOTILITY BY SPECIFIC HERBS USED IN ALTERNATIVE MEDICINE, J ASSIST REPROD GENET, 16, PP. 87-91, (1999); BARCZ E., SOMMER E., NARTOWSKA J., BALAN B.J., CHOROSTOWSKA-WYNIMKO J., SKOPINSKA-ROZEWSKA E.W., INFLUENCE OF ECHINACEA PURPUREA INTAKE DURING PREGNANCY ON FETAL GROWTH AND TISSUE ANGIOGENIC ACTIVITY, FOLIA HISTOCHEM CYTOBIOL, 45, PP. 35-39, (2007); SKOPINSKA-ROZEWSKA E.W., MAKUCH K., USE OF DIET SUPPLEMENTS, SYNTHETIC DRUGS AND HERBAL REMEDIES WITH IMMUNOTROPIC ACTIVITY DURING PREGNANCY. I. ECHINACEA, CENTR EUR J IMMUNOL, 35, PP. 183-185, (2010); WASIUTYNSKI A.J., BALAN B.J., SKOPINSKA-ROZEWSKA E.W., SIWICKI A.K., SKURZAK H.M., CHOROSTOWSKA-WYNIMKO J., SOMMER E., MAZURKIEWICZ M.X., THE EFFECT OF ECHINACEA PURPUREA ON THE MORPHOLOGY, ANGIOGENIC ACTIVITY AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) CONCENTRATION OF MURINE L-1 SARCOMA TUMORS, CENTR EUR J IMMUNOL, 34, PP. 38-41, (2009); PERRI D., DUGOUA J.J., MILLS E.J., KOREN G., SAFETY AND EFFICACY OF ECHINACEA (ECHINACEA AUGUSTAFOLIA, E. PURPUREA AND E. PALLIDA) DURING PREGNANCY AND LACTATION, CAN J CLIN PHARMACOL, 13, PP. E262-E267, (2006); GALLO M., KOREN G., CAN HERBAL PRODUCTS BE USED SAFELY DURING PREGNANCY? FOCUS ON ECHINACEA, CAN FAM PHYSICIAN, 47, PP. 1727-1728, (2001); GALLO M., SARKAR M., AU W., PIETRZAK K., COMAS B., SMITH M., JAEGER T.V., EINARSON A., KOREN G., PREGNANCY OUTCOME FOLLOWING GESTATIONAL EXPOSURE TO ECHINACEA: A PROSPECTIVE CONTROLLED STUDY, ARCH INTERN MED, 160, PP. 3141-3143, (2000); NORDENG H.M., HAVNEN G.C., USE OF HERBAL DRUGS IN PREGNANCY. A SURVEY AMONG 400 NORWEGIAN WOMEN, PHARMACOEPIDEMIOL DRUG SAF, 13, PP. 371-380, (2004); GOTTE K., ROSCHKE I., A SUPPORTIVE MEASURE IN THE TREATMENT OF ACUTE INFECTIONS OF THE RESPIRATORY TRACT IN CHILDREN WITH RECURRING INFECTIONS OF THE UPPER RESPIRATORY TRACT, PÄD PRAKTISCHE PÄDIATRIE, 7, PP. 1-7, (2001); DU Y., WOLF I.K., ZHUANG W., BODEMANN S., KNO W., KNOPF H., USE OF HERBAL MEDICINAL PRODUCTS AMONG CHILDREN AND ADOLESCENTS IN GERMANY, BMC COMPLEMENT ALTERN MED, 14, (2014); TAYLOR J.A., WEBER W.J., STANDISH L.J., QUINN H.C., GOESLING J., MCGANN M., CALABRESE C., EFFICACY AND SAFETY OF ECHINACEA IN TREATING UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 2824-2830, (2003); WEBER W.J., TAYLOR J.A., VANDER STOEP A.V., WEISS N., STANDISH L.J., CALABRESE C., ECHINACEA PURPUREA FOR PREVENTION OF UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN, J ALTERN COMPLEMENT MED, 11, PP. 1021-1026, (2005); SAUNDERS P.R., SMITH F., SCHUSKY R.W., ECHINACEA PURPUREA L. IN CHILDREN: SAFETY, TOLERABILITY, COMPLIANCE, AND CLINICAL EFFECTIVENESS IN UPPER RESPIRATORY TRACT INFECTIONS, CAN J PHYSIOL PHARMACOL, 85, PP. 1195-1199, (2007); THE SCIENTIFIC FOUNDATION FOR HERBAL MEDICINAL PRODUCTS, 2, (2003); MILLS S., BONE K., THE ESSENTIAL GUIDE TO HERBAL SAFETY, (2005); COEUGNIET E.G., KUHNAST R., RECURRENT CANDIDIASIS. ADJUVANT IMMUNOTHERAPY WITH SEVERAL ECHINACIN FORMULATIONS REZIDIVIERENDE CANDIDIASIS. ADJUVANTE IMMUNTHERAPIE MIT VERSCHIEDENEN ECHINACIN®-DARREICHUNGSFORMEN, THERAPIEWOCHE, 36, PP. 3352-3358, (1986); MELCHART D.V., WALTHER E., LINDE K., BRANDMAIER R., LERSCH C., ECHINACEA ROOT EXTRACTS FOR THE PREVENTION OF UPPER RESPIRATORY TRACT INFECTIONS: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL, ARCH FAM MED, 7, PP. 541-545, (1998); VONAU B.U., CHARD S., MANDALIA S., WILKINSON D.M., BARTON S.E., DOES THE EXTRACT OF THE PLANT ECHINACEA PURPUREA INFLUENCE THE CLINICAL COURSE OF RECURRENT GENITAL HERPES?, INT J STD AIDS, 12, PP. 154-158, (2001); PARNHAM M.J., BENEFIT-RISK ASSESSMENT OF THE SQUEEZED SAP OF THE PURPLE CONEFLOWER (ECHINACEA PURPUREA) FOR LONG-TERM ORAL IMMUNOSTIMULATION, PHYTOMEDICINE, 3, PP. 95-102, (1996); JAWAD M.S., SCHOOP R., SUTER A., KLEIN P.M., ECCLES R., SAFETY AND EFFICACY PROFILE OF ECHINACEA PURPUREA TO PREVENT COMMON COLD EPISODES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVID BASED COMPLEMENT ALTERN MED, (2012); SCHAPOWAL A.G., EFFICACY AND SAFETY OF ECHINAFORCE® IN RESPIRATORY TRACT INFECTIONS, WIEN MED WOCHENSCHR, 163, PP. 102-105, (2013); CHICCA A., PELLATI F., ADINOLFI B., MATTHIAS A., MASSARELLI I., BENVENUTI S., MARTINOTTI E., BIANUCCI A.M., BONE K., LEHMANN R., NIERI P., CYTOTOXIC ACTIVITY OF POLYACETYLENES AND POLYENES ISOLATED FROM ROOTS OF ECHINACEA PALLIDA, BR J PHARMACOL, 153, PP. 879-885, (2008); ERNST E., HERBAL MEDICINAL PRODUCTS, BR J GEN PRACT, 52, (2002); CHOW G., JOHNS T.A., MILLER S.C., DIETARY ECHINACEA PURPUREA DURING MURINE PREGNANCY: EFFECT ON MATERNAL HEMOPOIESIS AND FETAL GROWTH, BIOL NEONATE, 89, PP. 133-138, (2006); CURRIER N.L., MILLER S.C., THE EFFECT OF IMMUNIZATION WITH KILLED TUMOR CELLS, WITH/WITHOUT FEEDING OF ECHINACEA PURPUREA IN AN ERYTHROLEUKEMIC MOUSE MODEL, J ALTERN COMPLEMENT MED, 8, PP. 49-58, (2002); SUN L.Z., CURRIER N.L., MILLER S.C., THE AMERICAN CONEFLOWER: A PROPHYLACTIC ROLE INVOLVING NONSPECIFIC IMMUNITY, J ALTERN COMPLEMENT MED, 5, PP. 437-446, (1999); CROY B.A., GAMBEL P., ROSSANT J., WEGMANN T.G., CHARACTERIZATION OF MURINE DECIDUAL NATURAL KILLER (NK) CELLS AND THEIR RELEVANCE TO THE SUCCESS OF PREGNANCY, CELL IMMUNOL, 93, PP. 315-326, (1985); DE FOUGEROLLES A.R., BAINES M.G., MODULATION OF THE NATURAL KILLER CELL ACTIVITY IN PREGNANT MICE ALTERS THE SPONTANEOUS ABORTION RATE, J REPROD IMMUNOL, 11, PP. 147-153, (1987); GENDRON R.L., BAINES M.G., INFILTRATING DECIDUAL NATURAL KILLER CELLS ARE ASSOCIATED WITH SPONTANEOUS ABORTION IN MICE, CELL IMMUNOL, 113, PP. 261-267, (1988); LALA P.K., SCODRAS J.M., GRAHAM C.H., LYSIAK J.J., PARHAR R.S., ACTIVATION OF MATERNAL KILLER CELLS IN THE PREGNANT UTERUS WITH CHRONIC INDOMETHACIN THERAPY, IL-2 THERAPY, OR A COMBINATION THERAPY IS ASSOCIATED WITH EMBRYONIC DEMISE, CELL IMMUNOL, 127, PP. 368-381, (1990); HOLST L., HAVNEN G.C., NORDENG H.M., ECHINACEA AND ELDERBERRY-SHOULD THEY BE USED AGAINST UPPER RESPIRATORY TRACT INFECTIONS DURING PREGNANCY?, FRONT PHARMACOL, 5, (2014); MORAZZONI P., CRISTONI A., DI PIERRO F., AVANZINI C., RAVARINO D., STORNELLO S.L., ZUCCA M., MUSSO T., IN VITRO AND IN VIVO IMMUNE STIMULATING EFFECTS OF A NEW STANDARDIZED ECHINACEA ANGUSTIFOLIA ROOT EXTRACT (POLINACEA™), FITOTERAPIA, 76, PP. 401-411, (2005); GUIDELINE ON THE INVESTIGATION OF DRUG INTERACTIONS, (2012); DRUG INTERACTION STUDIES - STUDY DESIGN, DATA ANALYSIS IMPLICATIONS FOR DOSING, AND LABELING RECOMMENDATIONS, (2012); SCHAPOWAL A.G., BERGER D.S., KLEIN P.M., SUTER A., ECHINACEA/SAGE OR CHLORHEXIDINE/LIDOCAINE FOR TREATING ACUTE SORE THROATS: A RANDOMIZED DOUBLE-BLIND TRIAL, EUR J MED RES, 14, PP. 406-412, (2009); HILL L.L., FOOTE J.C., ERICKSON B.D., CERNIGLIA C.E., DENNY G.S., ECHINACEA PURPUREA SUPPLEMENTATION STIMULATES SELECT GROUPS OF HUMAN GASTROINTESTINAL TRACT MICROBIOTA, J CLIN PHARM THER, 31, PP. 599-604, (2006); SEE D., BERMAN S., JUSTIS J., BROUMAND N., CHOU S., CHANG J., TILLES J., A PHASE I STUDY ON THE SAFETY OF ECHINACEA ANGUTIFOLIA AND ITS EFFECT ON VIRAL LOAD IN HIV INFECTED INDIVIDUALS, J AM NUTR ASSOC (JANA), 1, PP. 14-17, (1998); GRIMM W., MULLER H.H., A RANDOMIZED CONTROLLED TRIAL OF THE EFFECT OF FLUID EXTRACT OF ECHINACEA PURPUREA ON THE INCIDENCE AND SEVERITY OF COLDS AND RESPIRATORY INFECTIONS, AM J MED, 106, PP. 138-143, (1999); BRINKEBORN R.M., SHAH D.V., DEGENRING F.H., ECHINAFORCE® AND OTHER ECHINACEA FRESH PLANT PREPARATIONS IN THE TREATMENT OF THE COMMON COLD: A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL, PHYTOMEDICINE, 6, PP. 1-6, (1999); GALLO M.A., SARKAR M., AU W., PIETRZAK K., COMAS B., SMITH M.J., JAEGER T.V., EINARSON A.R., KOREN G., PREGNANCY OUTCOME FOLLOWING GESTATIONAL EXPOSURE TO ECHINACEA: A PROSPECTIVE CONTROLLED STUDY, ARCH INTERN MED, 160, PP. 3141-3143, (2000); SCHULTEN B., BULITTA M., BALLERING-BRUHL B., KOSTER U., SCHAFER M., EFFICACY OF ECHINACEA PURPUREA IN PATIENTS WITH A COMMON COLD: A PLACEBO-CONTROLLED, RANDOMISED, DOUBLE-BLIND CLINICAL TRIAL, ARZNEIMITTELFORSCHUNG, 51, PP. 563-568, (2001); ROSTOCK M., MUMM A., UNGER C., APPLICATION OF MEDICINAL PLANTS IN ONCOLOGY DIE ANWENDUNG VON ARZNEIPFLANZEN IN DER ONKOLOGIE, Z ALLGEMEINMED, 74, PP. 1163-1168, (1998); KIM L., WATERS R.F., BURKHOLDER P.M., IMMUNOLOGICAL ACTIVITY OF LARCH ARABINOGALACTAN AND ECHINACEA: A PRELIMINARY, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ALTERN MED REV, 7, PP. 138-149, (2002); BARRETT B.P., BROWN R.L., LOCKEN K., MABERRY R., BOBULA J.A., DALESSIO D.J., TREATMENT OF THE COMMON COLD WITH UNREFINED ECHINACEA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ANN INTERN MED, 137, PP. 939-946, (2002); LINDENMUTH G.F., LINDENMUTH E.B., THE EFFICACY OF ECHINACEA COMPOUND HERBAL TEA PREPARATION ON THE SEVERITY AND DURATION OF UPPER RESPIRATORY AND FLU SYMPTOMS: A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY, J ALTERN COMPLEMENT MED, 6, PP. 327-334, (2000); TURNER R.B., RIKER D.K., GANGEMI J.D., INEFFECTIVENESS OF ECHINACEA FOR PREVENTION OF EXPERIMENTAL RHINOVIRUS COLDS, ANTIMICROB AGENTS CHEMOTHER, 44, PP. 1708-1709, (2000); SPERBER S.J., SHAH L.P., GILBERT R.D., RITCHEY T.W., MONTO A.S., ECHINACEA PURPUREA FOR PREVENTION OF EXPERIMENTAL RHINOVIRUS COLDS, CLIN INFECT DIS, 38, PP. 1367-1371, (2004); YALE S.H., LIU K., ECHINACEA PURPUREA THERAPY FOR THE TREATMENT OF THE COMMON COLD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, ARCH INTERN MED, 164, PP. 1237-1241, (2004); GOEL V., LOVLIN R.E., CHANG C., SLAMA J.Y., BARTON R., GAHLER R.J., BAUER R., GOONEWARDENE L.A., BASU T.K., A PROPRIETARY EXTRACT FROM THE ECHINACEA PLANT (ECHINACEA PURPUREA) ENHANCES SYSTEMIC IMMUNE RESPONSE DURING A COMMON COLD, PHYTOTHER RES, 19, PP. 689-694, (2005); TURNER R.B., BAUER R., WOELKART K., HULSEY T.C., GANGEMI J.D., AN EVALUATION OF ECHINACEA ANGUSTIFOLIA IN EXPERIMENTAL RHINOVIRUS INFECTIONS, N ENGL J MED, 353, PP. 341-348, (2005); HALL H.L., FAHLMAN M.M., ENGELS H.J., ECHINACEA PURPUREA AND MUCOSAL IMMUNITY, INT J SPORTS MED, 28, PP. 792-797, (2007); ONEIL J., HUGHES S.M., LOURIE A., ZWEIFLER J.A., EFFECTS OF ECHINACEA ON THE FREQUENCY OF UPPER RESPIRATORY TRACT SYMPTOMS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ANN ALLERGY ASTHMA IMMUNOL, 100, PP. 384-388, (2008); BARRETT B.P., BROWN R.L., RAKEL D.P., RABAGO D.P., MARCHAND L.R., SCHEDER J., MUNDT M.P., THOMAS G.R., BARLOW S.K., PLACEBO EFFECTS AND THE COMMON COLD: A RANDOMIZED CONTROLLED TRIAL, ANN FAM MED, 9, PP. 312-322, (2011); TIRALONGO E., LEA R.A., WEE S., HANNA M., GRIFFITHS L.R., RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF ECHINACEA SUPPLEMENTATION IN AIR TRAVELLERS, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012)","R. BAUER; INSTITUTE OF PHARMACEUTICAL SCIENCES, UNIVERSITY OF GRAZ, DEPARTMENT OF PHARMACOGNOSY, GRAZ, UNIVERSITAETSPLATZ 4/I, 8010, AUSTRIA; EMAIL: RUDOLF.BAUER@UNI-GRAZ.AT","GEORG THIEME VERLAG","ENGLISH","PLANTA MED.","REVIEW","ISI","2-S2.0-84954092069","PLANTA MED","UNIVERSITY OF GRAZ;UNIVERSITY OF GRAZ","NOTREPORTED;UNIVERSITY OF GRAZ;NOTREPORTED",NA,"ARDJOMAND-WOELKART K, 2015, PLANTA MED","ARDJOMAND-WOELKART K, 2015, PLANTA MED"
"SINGH A;LAL U;MUKHTAR H;SINGH P;SHAH G;DHAWAN R","SINGH, AMANDEEP (58688349700); LAL, UMA RANJAN (57216707445); MUKHTAR, HAYAT MUHAMMAD (7101959318); SINGH, PRABH SIMRAN (55789088200); SHAH, GAGAN (36703182500); DHAWAN, RAVI KUMAR (46061872500)","PHYTOCHEMICAL PROFILE OF SUGARCANE AND ITS POTENTIAL HEALTH ASPECTS",2015,"PHARMACOGNOSY REVIEWS","9","9",124,"10.4103/0973-7847.156340","DEPARTMENT OF PHARMACOGNOSY, KHALSA COLLEGE OF PHARMACY, AMRITSAR, PUNJAB, INDIA;DEPARTMENT OF PHARMACEUTICAL SCIENCES, BIRLA INSTITUTE OF TECHNOLOGY, RANCHI, JHARKHAND, INDIA;DEPARTMENT OF PHARMACOGNOSY, SHAHEED BHAGAT SINGH COLLEGE OF PHARMACY, PATTI, PUNJAB, INDIA;DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, KHALSA COLLEGE OF PHARMACY, AMRITSAR, INDIA;DEPARTMENT OF PHARMACOGNOSY, KHALSA COLLEGE OF PHARMACY, AMRITSAR, PUNJAB, INDIA;DEPARTMENT OF PHARMACOLOGY, KHALSA COLLEGE OF PHARMACY, AMRITSAR, INDIA","SUGARCANE (SACCHARUM OFFICINARUM LINN.) IS AN IMPORTANT PERENNIAL GRASS OF POACEAE FAMILY, INDIGENOUS TO TROPICAL SOUTH ASIA AND SOUTHEAST ASIA. IT IS CULTIVATED WORLDWIDE DUE TO THE ECONOMICAL AND MEDICINAL VALUE OF ITS HIGH YIELDING PRODUCTS. SUGARCANE JUICE IS WELL KNOWN AS A RAW MATERIAL FOR THE PRODUCTION OF REFINED SUGAR AND ITS WAX IS CONSIDERED AS A POTENTIAL SUBSTITUTE FOR THE EXPENSIVE CARNAUBA WAX, WHICH IS OF COSMETIC AND PHARMACEUTICAL INTEREST. REFINED SUGAR IS THE PRIMARY PRODUCT OF SUGARCANE JUICE, BUT DURING ITS PROCESSING, VARIOUS OTHER VALUABLE PRODUCTS ARE ALSO OBTAINED IN AN UNREFINED FORM, SUCH AS, BROWN SUGAR, MOLASSES, AND JAGGERY. SUGARCANE JUICE IS WIDELY USED IN INDIA IN THE TREATMENT OF JAUNDICE, HEMORRHAGE, DYSURIA, ANURIA, AND OTHER URINARY DISEASES. HEREIN, WE HAVE SUMMARIZED THE DIFFERENT PHYTOCONSTITUENTS AND HEALTH BENEFITS OF SUGARCANE AND ITS VALUABLE PRODUCTS. THE PHYTOCHEMISTRY OF SUGARCANE WAX (OBTAINED FROM THE LEAVES AND STALKS OF SUGARCANE), LEAVES, JUICE, AND ITS PRODUCTS HAS REVEALED THE PRESENCE OF VARIOUS FATTY ACID, ALCOHOL, PHYTOSTEROLS, HIGHER TERPENOIDS, FLAVONOIDS, -O- AND -C-GLYCOSIDES, AND PHENOLIC ACIDS. THE FUTURE PROSPECTIVE OF SOME OF THE SUGARCANE PRODUCTS HAS BEEN DISCUSSED, WHICH NEEDS A PHYTOPHARMACOLOGICAL STUDY AND HAS A GREAT POTENTIAL TO BE A VALUABLE MEDICINAL PRODUCT. © 2015, MEDKNOW. ALL RIGHTS RESERVED.","FATTY ACID; PHENOLIC ACIDS; PHYTOCHEMISTRY; SACCHARUM OFFICINARUM","POACEAE; SACCHARUM OFFICINARUM; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; APIGENIN; CAFFEIC ACID; CHLOROGENIC ACID; CINNAMIC ACID; COUMARIC ACID; D 003; DEHYDROCONIFERYLALCOHOL 9' O BETA DEXTRO GLUCOPYRANOSIDE; DIURETIC AGENT; HERBACEOUS AGENT; HYPOCHOLESTEROLEMIC AGENT; ISOORIENTIN 7,3' O DIMETHYL ETHER; LIVER PROTECTIVE AGENT; LUTEOLIN; OCTACOSANOL; ORIENTIN 7, 3' DIMETHYL ETHER; PLANT EXTRACT; POLICOSANOL; SINAPIC ACID; SUGARCANE WAX; TRICIN7 (2' RHAMNOSYL)ALPHA GALACTURONIDE; UNCLASSIFIED DRUG; WAX; ACETYLCHOLINE RELEASE; ANALGESIC ACTIVITY; ANTICOAGULATION; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; DIURETIC ACTIVITY; LIVER PROTECTION; LIVER TOXICITY; NEUROMUSCULAR SYNAPSE; NONHUMAN; PHYTOCHEMISTRY; PLANT LEAF; PLANT PRODUCT; REVIEW; SUGARCANE; SUGARCANE JUICE; SYRUP","","","JAMES G., SUGARCANE. 2<SUP>ND</SUP> ED., PP. 152-157, (2004); KOH H.L., CHUA T.K., TAN C.H., A GUIDE TO MEDICINAL PLANTS: AN ILLUSTRATED SCIENTIFIC AND MEDICAL APPROACH, (2009); ANIS M., IQBAL M., ANTIPYRETIC UTILITY OF SOME INDIAN PLANTS IN TRADITIONAL MEDICINE, FILOTERPIA, 57, PP. 52-55, (1986); VEDAVTHY S., RAO K.N., RAJIAH M., NAGARAJUN N., FOLKLORE INFORMATION FROM RYSALASENNA REGION, ANDHRA PRADESH FOR FAMILY PLANNING AND BIRTH CONTROL, INT J PHARMACOGNOSY, 29, PP. 113-116, (1991); KARTHIKEYAN J., SIMIPILLAI S.S., SUGARCANE IN THERAPEUTICS, J HERB MED TOXICOL, 4, PP. 9-14, (2010); CACERES A., GIRON L.M., ALVARADO S.R., TORRES M.F., SCREENING OF ANTIMICROBIAL ACTIVITY OF PLANTS POPULARLY USED IN GUATEMALA FOR THE TREATMENT OF DERMATOMUCOSAL DISEASES, J ETHNOPHARMACOL, 20, PP. 223-237, (1987); KHARE C.P., INDIAN MEDICINAL PLANTS: AN ILLUSTRATED DICTIONARY, (2007); XU F., SUN R.C., SUN J.X., LIU C.F., HE B.H., FAN J.S., DETERMINATION OF CELL WALL FERULIC AND P-COUMARIC ACIDS IN SUGARCANE BAGASSE, ANALYTICA CHIMICA ACTA, 552, PP. 207-217, (2005); HARISH NAYAKA M.A., SATHISHA U.V., MANOHAR M.P., CHANDRASHEKAR K.B., DHARMESH M.S., CYTOPROTECTIVE AND ANTIOXIDANT ACTIVITY STUDIES OF JAGGERY SUGAR, FOOD CHEM, 115, PP. 113-118, (2009); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, PP. 8761-8773, (2008); SACCHARUM OFFICINARUM, PP. 9-21, (2012); THE BIOLOGY AND ECOLOGY OF SUGARCANE (SACCHARUM SPP. HYBRIDS) IN AUSTRALIA, (2004); HOEPFNER S.W., BOTHA F.C., PURIFICATION AND CHARACTERISATION OF FRUCTOKINASE FROM THE CULM OF SUGARCANE, PLANT SCI, 167, PP. 645-654, (2004); TAYLOR A.K., FROM RAW SUGAR TO RAW MATERIALS, CHEM INNOV, 30, PP. 45-48, (2000); LAGUNA GRANJA A., HERNANDEZ J.M., QUINTANA D.C., VALMANA L.A., FERREIRO R.M., MESA M.G., MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACEUTICAL USES, (1999); AWIKA J.M., ROONEY L.W., SORGHUM PHYTOCHEMICALS AND THEIR POTENTIAL IMPACT ON HUMAN HEALTH, PHYTOCHEMISTRY, 65, PP. 1199-1221, (2004); MAS R., D-003: A NEW SUBSTANCE WITH PROMISING LIPID MODIFYING AND PLEIOTROPIC EFFECTS FOR ATHEROSCLEROSIS MANAGEMENT, DRUGS FUTURE, 29, PP. 773-786, (2004); GUITA B.K., GUPTA G.K., ATAL C.K., SUGARCANE PRESS MUD: A POTENTIAL SOURCE OF PHYTOSTEROLS, FATTY ALCOHOLS, FATTY ACID AND HARD WAX, RES IND, 30, PP. 95-101, (1985); LAMBERTON J.A., REDCLIFFE A.H., THE CHEMISTRY OF SUGAR-CANE WAX. I. NATURE OF SUGAR-CANE WAX, AUST J CHEM, 13, PP. 261-268, (1960); WARTH A.H., THE CHEMISTRY AND TECHNOLOGY OF WAXES, (1956); DESHMANE S.S., DEV S., HIGHER ISOPRENOIDS-II: TRITERPENOIDS AND STEROIDS OF SACCHARUM OFFICINARUM LINN, TETRAHEDRON, 27, PP. 1109-1118, (1971); GOSWAMI P.C., SINGH H.D., BAREUH J.N., ISOLATION OF PHYTOSTEROLS FROM SUGARCANE PRESS MUD AND MICROBIAL CONVERSION OF THE PHYTOSTEROLS TO 17- KETOSTEROIDS, CURR SCI, 53, PP. 917-919, (1984); GEORGES P., SYLVESTRE M., RUEGGER H., BOURGEOIS P., KETOSTEROIDS AND HYDROXYKETOSTEROIDS, MINOR METABOLITES OF SUGARCANE WAX, STEROIDS, 71, PP. 647-652, (2006); BRYCE T.A., MARTIN-SMITH M., OSSKE G., SCHREIBER K., SUBRAMANIAN G., STEROLS AND TRITERPENOIDS-XI. ISOLATION OF ARUNDOIN AND SAWAMMILLETIN FROM CUBAN SUGAR CANE WAX, TETRAHEDRON, 23, PP. 1283-1296, (1967); FARBER L., CARPENTER F.G., MCDONALD E.J., SEPARATION OF COLORANTS FROM CANE SUGAR, INT SUGAR J, 69, PP. 323-328, (1971); SMITH P., PATON N.H., SUGARCANE FLAVONOIDS, SUGAR TECHNOL REV, 12, PP. 117-142, (1985); MCGHIE T.K., ANALYSIS OF SUGAR CANE FLAVONOIDS BY CAPILLARY ZONE ELECTROPHORESIS, J CHROMATOGR, 634, PP. 107-112, (1993); DE ARMAS R., MARTINEZ M., VINCENTE C., LEGAZ M.E., FREE AND CONJUGATED POLYAMINES AND PHENOLS IN RAW AND ALKALINE-CLARIFIED SUGARCANE JUICE, J AGRIC FOOD CHEM, 47, PP. 3086-3092, (1999); MAURICIO DUARTE-ALMEIDA J., NOVOA A.V., LINARES A.F., LAJOLO F.M., INES GENOVESE M., ANTIOXIDANT ACTIVITY OF PHENOLIC COMPOUNDS FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) JUICE, PLANT FOODS HUM NUTR, 61, PP. 187-192, (2006); VILA F.C., COLOMBO R., DE LIRA T.O., YARIWAKE J.H., HPLC MICROFRACTIONATION OF FLAVONES AND ANTIOXIDANT (RADICAL SCAVENGING) ACTIVITY OF SACCHARUM OFFICINARUM L, J BRAZ CHEM SOC, 19, PP. 903-908, (2008); COLOMBO R., YARIWAKE J.H., QUEROZ E.F., NDJOKO K., HOSTETTMANN K., ON-LINE IDENTIFICATION OF MINOR FLAVONES FROM SUGARCANE JUICE BY LC/UV/MS AND POST-COLUMN DERIVATIZATION, J BRAZ CHEM SOC, 20, PP. 1574-1579, (2009); DUARTE-ALMEIDA J.M., NEGRI G., SALATINO A., DE CARVALHO J.E., LAJOLO F.M., ANTIPROLIFERATIVE AND ANTIOXIDANT ACTIVITIES OF A TRICIN ACYLATED GLYCOSIDE FROM SUGARCANE (SACCHARUM OFFICINARUM) JUICE, PHYTOCHEMISTRY, 68, PP. 1165-1171, (2007); BALASUNDRAM N., SUNDRAM K., SAMMAN S., PHENOLIC COMPOUNDS IN PLANTS AND AGRI-INDUSTRIAL BY-PRODUCTS: ANTIOXIDANT ACTIVITY, OCCURRENCE, AND POTENTIAL USES, FOOD CHEM, 99, PP. 191-203, (2006); MABRY T.M., LIU Y.L., PEARCE J., DELLAMONICA G., CHOPIN J., MARKHAM K.R., ET AL., NEW FLAVONOIDS FROM SUGARCANE (SACCHARUM), J NAT PROD, 47, PP. 127-130, (1984); TAKARA K., USHIJIMA K., WADA K., IWASAKI H., YAMASHITA M., PHENOLIC COMPOUNDS FROM SUGARCANE MOLASSES POSSESSING ANTIBACTERIAL ACTIVITY AGAINST CARCINOGENIC BACTERIA, J OLEO SCI, 56, PP. 611-614, (2007); PAYET B., SHUM CHEONG SING A., SMADJA J., ASSESSMENT OF ANTIOXIDANT ACTIVITY OF CANE BROWN SUGARS BY ABTS AND DPPH RADICAL SCAVENGING ASSAYS: DETERMINATION OF THEIR POLYPHENOLIC AND VOLATILE CONSTITUENTS, J AGRI FOOD CHEM, 53, PP. 10074-10079, (2005); GODSHELL M.A., ROBERTS E.J., PHENOLICS IN SUGAR PRODUCTS: THEIR ROLE IN FLAVOUR AND COLOR PRODUCTION, PROCEEDINGS OF THE 1982 SUGAR PROCESSING RESEARCH CONFERENCE, PP. 47-72, (1982); PAYET B., SHUM CHEONG SING A., SMADJA J., COMPARISON OF THE CONCENTRATIONS OF PHENOLIC CONSTITUENTS IN CANE SUGAR MANUFACTURING PRODUCTS WITH THEIR ANTIOXIDANT ACTIVITIES, J AGRIC FOOD CHEM, 54, PP. 7270-7276, (2006); COSTA M., DI STASI L.C., KIRIZAWA M., MENDACOLLI S.L., GOMES C., TROLIN G., SCREENING IN MICE OF SOME MEDICINAL PLANTS USED FOR ANALGESIC PURPOSES IN THE STATE OF SÃO PAULO, J ETHNOPHARMACOL, 27, PP. 25-33, (1989); JIN Y.F., LIANG H.Z., CAO C.Y., WANG Z.W., SHU R.S., LI X.Y., IMMUNOLOGICAL ACTIVITY OF BAGASSE POLYSACCHARIDES (AUTHOR'S TRANSL), ZHONGGUO YAO LI XUE BAO, 2, PP. 269-275, (1981); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); TAKAHASHI M., KONNO C., HIKINO H., ISOLATION AND HYPOGLYCEMIC ACTIVITY OF SACCHARIN A, B, C, D, E AND F GLYCANS OF SACCHARUM OFFICINARUM STALKS, PLANTA MED, 3, PP. 258-260, (1985); RIBEIRO RDE A., FIUZA DE MELO M.M., DE BARROS F., GOMES C., TROLIN G., ACUTE ANTIHYPERTENSIVE EFFECT IN CONSCIOUS RATS PRODUCED BY SOME MEDICINAL PLANTS USED IN THE STATE OF SÃO PAULO, J ETHNOPHARMACOL, 15, PP. 261-269, (1986); CACERES A., GIRON L.M., ALVARADO S.R., TORRES M.F., SCREENING OF ANTIMICROBIAL ACTIVITY OF PLANTS POPULARLY USED IN THE GUATEMALA FOR THE TREATMENT OF DERMATOMUCOSAL DISEASES, J ETHNOPHARMACOL, 20, PP. 223-237, (1987); RE L., BAROCCI S., CAPITAINI C., VIVANI C., RICCI M., RINALDI L., ET AL., EFFECTS OF SOME NATURAL EXTRACTS ON THE ACETYLCHOLINE RELEASE AT THE MOUSE NEUROMUSCULAR JUNCTION, PHARMACOL RES, 39, PP. 239-245, (1999); LEDON N., CASACO A., RODRIGUEZ V., CRUZ J., GONZALEZ R., TOLON Z., ET AL., ANTI-INFLAMMATORY AND ANALGESIC EFFECTS OF A MIXTURE OF FATTY ACIDS ISOLATED AND PURIFIED FROM SUGARCANE WAX OIL, PLANTA MED, 69, PP. 367-369, (2003); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., D-003, A POTENTIAL ANTITHROMBOTIC COMPOUND ISOLATED FROM SUGAR CANE WAX WITH EFFECTS ON ARACHIDONIC ACID METABOLITES, PROSTAGLANDINS LEUKO ESSENT FATTY ACIDS, 67, PP. 19-24, (2002); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., VALDES S., ANTIPLATELET AND ANTITHROMBOTIC EFFECT OF D-003, PHARMACOL RES, 42, PP. 137-143, (2000); SILVIA A.V., NATALI G.S., MILTON B.N., POLYCYCLIC AROMATIC HYDROCARBONS IN SUGARCANE JUICE, FOOD CHEM, 116, PP. 391-394, (2009)","","MEDKNOW PUBLICATIONS","ENGLISH","PHARMACOGN. REV.","REVIEW","ISI","2-S2.0-84929411145","PHARMACOGN REV",NA,"NOTREPORTED",NA,"SINGH A, 2015, PHARMACOGN REV","SINGH A, 2015, PHARMACOGN REV"
"LOPEZ E;FERNANDEZ L;MAS R;ILLNAIT J;MENDOZA S;RAMIREZ Y;FERNÁNDEZ J;RUIZ D","LOPEZ, ERNESTO (57198355062); FERNANDEZ, LILIA (7202848319); MAS, ROSA (7007164570); ILLNAIT, JOSE (8631465800); MENDOZA, SARAHÍ (7102759819); RAMIREZ, YOANDI (24776602400); FERNÁNDEZ, JULIO C. (9432805500); RUIZ, DALMER (26425153000)","A COMPARISON OF THE LONGTERM 1 YEAR LIPID MODIFYING EFFECTS OF D003 SUGARCANE WAX ACIDS AND POLICOSANOL A RANDOMIZED DOUBLEBLIND STUDY",2015,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH","33","7",1,"","MEDICAL SURGICAL RESEARCH CENTRE, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, HAVANA, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;SOFTWARE AND DATABASE GROUP, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THE MAIN GOAL OF DYSLIPIDEMIA MANAGEMENT IS TO LOWER SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C). D-003 IS A MIXTURE OF SUGARCANE WAX ACIDS WITH CHOLESTEROL-LOWERING AND BONE PROTECTIVE EFFECTS. POLICOSANOL, A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS PURIFIED FROM THE SAME SOURCE, IS A CHOLESTEROL-LOWERING AGENT. D-003 ADMINISTERED FOR SHORT-TERM (8 WEEKS) WAS MORE EFFECTIVE THAN POLICOSANOL (BOTH AT 5 AND 10 MG/DAY) FOR LOWERING LDL-C, TOTAL CHOLESTEROL (TC), AND FOR INCREASING HIGH-DENSITY LIPOPROTEINCHOLESTEROL (HDL-C). TO COMPARE THE LONG-TERM (1 YEAR) EFFICACY, SAFETY AND TOLERABILITY OF D-003 AND POLICOSANOL (TITRATED FROM 5 TO 20 MG/DAY) IN HYPERCHOLESTEROLEMIC PATIENTS. AFTER A 5-WEEK BASELINE PERIOD, 165 PATIENTS WERE DOUBLE-BLIND RANDOMIZED TO D-003 OR POLICOSANOL 5 MG/DAY FOR 3 MONTHS. THE DOSE WAS DOUBLED IN SUBJECTS WITH LDL-C REDUCTIONS = 15% AND THE SAME WAS REPEATED AT 6 MONTHS. LDL-C REDUCTION WAS THE MAIN EFFICACY OUTCOME. DATA WERE ANALYZED ACCORDING TO INTENTION TO TREAT. D-003 AND POLICOSANOL (5 MG/DAY FOR 3 MONTHS) REDUCED (P <0.0001) SIMILARLY LDL-C BY 19.7% AND 19.6%, RESPECTIVELY. THESE EFFECTS DID NOT WEAR OFF, EVEN ENHANCED, WITH LONG-TERM TREATMENT AND DOSE INCREASES. AT STUDY COMPLETION D-003 REDUCED LDL-C (34.3%, P <0.0001 VERSUS BASELINE) MORE (P<0.05) THAN POLICOSANOL (30.0%). THE FREQUENCY OF DOSE TITRATION WITH POLICOSANOL (66/83, 79.5%) WAS HIGHER (P<0.01) THAN WITH D-003 (47/82, 57.3%). THE MEAN ESTIMATED DOSES (MG/DAY) AT 12 MONTHS WERE 10.2 (D-003) AND 13.9 (POLICOSANOL). THE FREQUENCY OF LDL-C REDUCTIONS = 15% WITH D-003 (72/82, 87.8%) WAS HIGHER (P<0.01) THAN WITH POLICOSANOL (66/82, 79.5%). D-003 AND POLICOSANOL DECREASED (P<0.0001) TC (21.7% AND 19.5%, RESPECTIVELY) AND INCREASED HDL-C (12.0% AND 7.4%, RESPECTIVELY), D-003 BEING MORE EFFECTIVE FOR INCREASING HDL-C (P<0.01). D-003 REDUCED LDL-C/HDL-C AND TC/HDL-C RATIOS (P<0.0001) TO 38.8% AND 27.7%, RESPECTIVELY, AND POLICOSANOL TO 30.0% AND 20.4%, RESPECTIVELY. D-003 WAS THE MOST EFFECTIVE FOR LOWERING BOTH RATIOS (P<0.05). TREATMENTS UNCHANGED TRIGLYCERIDES. BOTH TREATMENTS WERE SAFE AND WELL TOLERATED. LONG-TERM ADMINISTRATION (1 YEAR) OF D-003 (MEAN DOSE 10.2 MG/DAY) PERSISTENTLY EXHIBITED LONG-TERM CHOLESTEROL-LOWERING EFFICACY, AND WAS MORE EFFECTIVE THAN POLICOSANOL (MEAN DOSE 13.9 MG/DAY) FOR LOWERING LDL-C, BOTH RATIOS, AND FOR INCREASING HDL-C. BOTH TREATMENTS WERE SAFE AND WELL TOLERATED. © 2015, GLOBAL RESEARCH ONLINE. ALL RIGHTS RESERVED.","D-003; HYPERCHOLESTEROLEMIA; LIPID MODIFYING; LONG-TERM; POLICOSANOL; SUGARCANE WAX ACIDS","D 003; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEURALGIA; PNEUMONIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STOMACH ULCER","","","LOZANO R., NAGHAVI M., FOREMAN K., LIM S., SHIBUYA K., ABOYANS V., GLOBAL AND REGIONAL MORTALITY FROM 235 CAUSES OF DEATH FOR 20 AGE GROUPS IN 1990 AND 2010: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2010, LANCET, 380, PP. 2095-2128, (2012); CATAPANO AL, DE BACKER G, GRAHAM I, TASKINEN MR, WIKLUND O, ET AL, ESC COMMITTEE FOR PRACTICE GUIDELINES (CPG) 2008-2010 AND 2010-2012 COMMITTEES. ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); PERK J., DE BACKER G., GOHLKE H., GRAHAM I., REINER Z., VERSCHUREN M., THE FIFTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF NINE SOCIETIES AND BY INVITED EXPERTS), EUR HEART J, 33, 2012, PP. 1635-1701, (2012); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., BAIREY-MERZ C.N., BLUM C.B., ECKEL RH, 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, CIRCULATION, 129, 25, PP. S1-S45, (2014); ALLA V.M., AGRAWAL V., DENAZARETH A., MOHIUDDIN S., RAVILLA S., RENDELL M., A REAPPRAISAL OF THE RISKS AND BENEFITS OF TREATING TO TARGET WITH CHOLESTEROL LOWERING DRUGS, 73, PP. 1025-1054, (2013); LIM T.H., ORIJA I.B., PEARLMAN B.L., AMERICAN COLLEGE OF CARDIOLOGY. AMERICAN COLLEGE OF CARDIOLOGY. THE NEW CHOLESTEROL TREATMENT GUIDELINES FROM THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION, 2013: WHAT CLINICIANS NEED TO KNOW, POSTGRAD MED, 126, PP. 35-44, (2014); ANTHONY D., GEORGE P., EATON C.B., AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION. EIGHTH JOINT NATIONAL COMMITTEE. CARDIAC RISK FACTORS: NEW CHOLESTEROL AND BLOOD PRESSURE MANAGEMENT GUIDELINES, FP ESSENT, 421, 2014, PP. 28-43, (2013); WILKINSON M.J., LAFFIN L.J., DAVIDSON M.H., OVERCOMING TOXICITY AND SIDE-EFFECTS OF LIPID-LOWERING THERAPIES, BEST PRACT RES CLIN ENDOCRINOL METAB, 28, PP. 439-452, (2014); LOZZI A., OVERVIEW ON PHARMACOLOGICAL AND NUTRACEUTICAL STRATEGIES FOR TREATMENT OF BORDERLINE DYSLIPIDEMIA, MINERVA CARDIOANGIOL, 62, PP. 277-282, (2014); MAHVAN T.D., HILAIRE M.L., VIGIL A., MLODINOW S., CONSULT PHARM, 30, PP. 68-76, (2015); CORRAL P., GUIDELINES ACC/AHA CARDIOVASCULAR RISK. INCOMPLETE EVIDENCE AND FAILED ATTEMPT AT SIMPLIFICATION, CLIN INVESTIG ARTERIOSCLER, 27, 2015, PP. 74-79, (2013); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT J NUTR, 77, PP. 923-932, (1997); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, (1999); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, , BRIT J CLIN PHARMACOL, 50, (2000); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-494, (1999); NIKITIN I.P., SLEPCHENKO N.V., GRATSIANSKII N.A., NECHAEV A.S., SYRKIN A.L., POLTAVSKAIA M.G., SUMAROKOV A.V., REVAZOV A.V., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC POLICOSANOL IN RUSSIA, TER ARKH, 72, (2000); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., MESA M., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLINDED PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, (2003); WANG Y., KUANMAN K.E., WANG L., JIAO Y., ZHAO X., SUN N., YANG X., SUN R., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); LOPEZ E., ILLNAIT J., FERNANDEZ J.C., FERNANDEZ L., GAMEZ R., MESA M., MENDOZA S., MAS R., RUIZ D., JARDINES Y., EFFECTS OF SUGARCANE WAX ALCOHOLS IN SUBJECTS WITH NORMAL OR BORDERLINE SERUM CHOLESTEROL LEVELS, REV CENIC CIEN BIOL, 41, PP. 31-37, (2010); LIU S., TAN M.Y., ZHAO S.P., RONG H., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND HEME OXYGENASE-1 IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 40, PP. 840-843, (2012); BERTHOLD H.K., UNVERDOBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYOPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 2006, JAMA, 295, PP. 2262-2269, (2006); FRANCINI PESENTI F., BELTRAMOLLI D., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, (2008); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., ACOSTA P., ALFONSO J., MAS R., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D.K., LI L.I., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL THER, 318, PP. 1020-1025, (2006); OLIARO-BOSSO S., CALCIO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, 10, PP. 907-916, (2009); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 46, 4, PP. 311-321, (2011); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, 3, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); PEREZ Y., MAS R., GONZALEZ R.M., JIMENEZ S., MOLINA V., EFFECTS OF D-003 AND POLICOSANOL ON IN VIVO LIPID PEROXIDATION IN RATS, ARZN-FORSCH DRUG RES, 58, PP. 126-130, (2008); GAMEZ R., MENDOZA S., MAS R., DOSE-DEPENDENT CHOLESTEROLLOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES, 61, PP. 460-468, (2000); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA R., MESA M., DE ARMAS M., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES, 62, PP. 209-220, (2001); MENENDEZ R., MAS R., AMOR A.M., RODEIRO I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); MENENDEZ R., MAS R., PEREZ J., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CANADIAN J PHYSIOL PHARMACOL, 82, PP. 22-29, (2004); CASTANO G., MENENDEZ R., MAS R., LEDON N., FERNANDEZ J.C., PEREZ J.L., GONZALEZ R.M., LESCAY M., EFFECTS OF D-003: A NEW HYPOCHOLESTEROLAEMIC AND ANTIPLATELET COMPOUND ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY VOLUNTEERS, CLIN DRUG INVEST, 23, PP. 193-203, (2003); PEREZ Y., MENENDEZ R., MAS R., GONZALEZ R., FERNANDEZ L., FERNANDEZ J., ILLNAIT J., MENDOZA S., EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT ACIDS FROM SUGARCANE WAX, ON LIPID PEROXIDATION (LP) MARKERS OF OLDER INDIVIDUALS, CURR THER RES, 69, PP. 36-48, (2008); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., MENDOZA S., GAMEZ R., MESA M., LOPEZ E., ALVAREZ E., EFFECTS OF D-003 ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A PHASE II CLINICAL STUDY, CLIN DRUG INVEST, 23, PP. 789-802, (2003); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLEBLINDED STUDY, DRUGS EXP CLIN RES, 31, PP. 31-44, (2005); PEREZ P., ILLNAIT J., FERNÁNDEZ, EFFECTS OF D-003 (SUGAR CANE ALCOHOLS) ON THE PHYSICAL EXERCISE ON STATIC BICYCLE TEST, LAT AM J PHARM, 29, PP. 263-270, (2010); CEBALLOS A., MAS R., CASTANO G., FERNANDEZ L., MENDOZA S., MENENDEZ R., GONZALEZ J., ILLNAIT J., GAMEZ R., MESA M., FERNANDEZ J., THE EFFECT OF D-003 (10 MG/DAY) ON BIOCHEMICAL PARAMETERS OF BONE REMODELLING IN POSTMENOPAUSAL WOMEN: A RANDOMIZED DOUBLE-BLIND STUDY, INT J CLIN PHARM RES, 25, PP. 175-186, (2005); CEBALLOS A., CASTANO G., MENDOZA S., GONZALEZ J., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., GAMEZ R., FERNANDEZ J.C., TELLES R., MARRERO D., GOMEZ M., RUIZ D., JARDINES Y., EFFECT OF D-003 (10 MG/DAY) ON THE BONE MINERAL DENSITY OF THE LUMBAR SPINE AND FEMORAL NECK IN POSTMENOPAUSAL WOMEN: A RANDOMIZED, DOUBLE-BLINDED STUDY, KOREAN J INTERN MED, 26, PP. 168-178, (2011); CEBALLOS A., MENDOZA S., MAS R., ILLNAIT J., FERNANDEZ J., FERNANDEZ L., MESA M., GAMEZ R., CRUZ Y., RUIZ D., EFFECTS OF D-003 (SUGARCANE WAX ACIDS) (10 MG/DAY) ON THE QUALITY OF LIFE OF POSTMENOPAUSAL WOMEN: A RANDOMIZED, DOUBLE-BLINDED STUDY, IJPSRR, 26, PP. 168-178, (2011); CEBALLOS A., MENDOZA S., MAS R L., AIT R., NDE F., FERNANDE R., MENENDEZ R., MAS R., AMOR A.M., RODEIRO I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); MENENDEZ R., MAS R., PEREZ Y., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, CAN J PHYSIOL PHARMACOL, 80, PP. 13-21, (2002); PEREZ Y., MOLINA V., MAS R., GONZALEZ R.M., JIMENEZ S., A COMPARISON OF IN VIVO EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT SUGARCANE WAX ACIDS, AND GRAPE SEED EXTRACT ON LIPID PEROXIDATION MARKERS IN RATS, LAT AM J PHARM, 27, PP. 498-504, (2008); PEREZ Y., MAS R., GONZALEZ R.M., JIMENEZ S., MOLINA V., EFFECTS OF D-003 AND POLICOSANOL ON IN VIVO LIPID PEROXIDATION IN RATS, ARZN-FORSCH.DRUG RES, 58, PP. 126-130, (2008); MENDOZA S., NOA M., MAS R., MENDOZA N., COMPARISON OF THE EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ACIDS FROM SUGARCANE WAX, AND PRAVASTATIN ON BONES AND OSTEOCLAST APOPTOSIS OF OVARIECTOMIZED RATS, DRUGS EXPTL CLIN RES, 31, PP. 181-191, (2005); MENDOZA S., NOA M., MAS R., MENDOZA N., EFFECTS OF D-003 (5200 MG/KG), A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ACIDS FROM SUGARCANE WAX, ON BONES AND BONE CELL APOPTOSIS IN OVARIECTOMIZED RATS, INT J TISSUE REACT, 26, PP. 213-222, (2005); NOA M., MENDOZA S., MAS R., MENDOZA N., GOICOCHEA E., LONG TERM EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT ACIDS FROM SUGARCANE WAX, ON BONES OF OVARIECTOMIZED RATS: A ONE YEAR STUDY, PHARMAZIE, 63, PP. 486-488, (2008); FRIEDEWALD W.T., LEVY I.R., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); NARANJO C.A., BUSTO U., SELLERS E.M., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN PHARMACOL THER, 30, PP. 239-245, (1981); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981)","","GLOBAL RESEARCH ONLINE","ENGLISH","INT. J. PHARM. SCI. REV. RES.","ARTICLE","ISI","2-S2.0-84937895241","INT J PHARM SCI REV RES",NA,"NOTREPORTED",NA,"LOPEZ E, 2015, INT J PHARM SCI REV RES","LOPEZ E, 2015, INT J PHARM SCI REV RES"
"PÉREZ Y;MAS R;OYARZÁBAL A;JIMÉNEZ S;MOLINA V","PÉREZ, YOHANI (23995375700); MAS, ROSA (7007164570); OYARZÁBAL, ÁMBAR (24399409700); JIMÉNEZ, SONIA (19735040200); MOLINA, VIVIAN (7006062814)","EFFECTS OF POLICOSANOL SUGAR CANE WAX ALCOHOLS AND D003 SUGARCANE WAX ACIDS ON CYCLOOXYGENASE COX ENZYME ACTIVITY IN VITRO",2013,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH","19","5",11,"","PHARMACOLOGY DEPARTMENT, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, THE HAVANA, CUBA;PHARMACOLOGY DEPARTMENT, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, THE HAVANA, CUBA;PHARMACOLOGY DEPARTMENT, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, THE HAVANA, CUBA;PHARMACOLOGY DEPARTMENT, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, THE HAVANA, CUBA;PHARMACOLOGY DEPARTMENT, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, THE HAVANA, CUBA","BOTH POLICOSANOL AND D-003 ARE MIXTURES OF HIGHER ALIPHATIC ALCOHOLS AND ACIDS, RESPECTIVELY, PURIFIED FROM SUGARCANE WAX, WHOSE MAIN COMPONENTS ARE OCTACOSANOL AND OCTACOSANOIC ACID (AN ACTIVE METABOLITE OF OCTACOSANOL), RESPECTIVELY. BOTH SUBSTANCES SHARE SOME, NOT ALL, PHARMACOLOGICAL EFFECTS, LIKE CHOLESTEROL-LOWERING, ANTIPLATELET AND ANTIOXIDANT EFFECTS. THE MECHANISMS WHEREBY THEY EXHIBIT CHOLESTEROL-LOWERING HAVE BEEN INVESTIGATED, BUT THOSE SUPPORTING THEIR ANTIPLATELET EFFECTS REMAIN UNKNOWN. WE HYPOTHESIZED THAT THESE SUBSTANCES COULD INHIBIT CYCLOOXYGENASE (COX) ACTIVITY. THE AIM OF THIS STUDY WAS TO INVESTIGATE WHETHER POLICOSANOL AND D-003 MAY INHIBIT COX-1 AND COX-2 ENZYME ACTIVITIES, EFFECTS ASSESSED IN CYTOSOLIC MICROSOMES FROM RAT PLATELETS AND SEMINAL VESICLES, RESPECTIVELY. VEHICLE, POLICOSANOL OR D-003 SUSPENSIONS (0.6 TO 6000 ΜG/ML) WERE ADDED TO TUBES CONTAINING A MIXTURE OF REACTIONS AND ABSORBANCE CHANGES AT 480 NM WERE MEASURED. BOTH POLICOSANOL AND D-003 INHIBITED SIGNIFICANTLY (MAXIMAL INHIBITION ≅ 80%) AND DOSE-DEPENDENTLY COX-1 ENZYME ACTIVITY (IC50 = 312.5 ΜG/ML AND 14.84 ΜG/ML, RESPECTIVELY) BY MODIFYING BOTH KINETIC PARAMETERS, SO THAT THE INHIBITION WAS UNCOMPETITIVE. D-003, NOT POLICOSANOL, ALSO INHIBITED SIGNIFICANTLY AND DOSE DEPENDENTLY, BUT MODERATELY (MAXIMAL INHIBITION ≅ 54%), COX-2 ACTIVITY. CONCLUDING, POLICOSANOL AND D-003 PRODUCE MARKED AND COMPARABLE IN VITRO INHIBITIONS OF COX-1 ACTIVITY IN RAT PLATELET MICROSOMES, D-003 BEING THE MOST POTENT. D-003, NOT POLICOSANOL, ALSO INHIBITS MODERATELY COX-2 ACTIVITY IN RAT SEMINAL VESICLES.","CICLOXYGENASES; COX-1; COX-2; D-003; POLICOSANOL; SUGARCANE WAX ACIDS","CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; D 003; POLICOSANOL; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; MALE; MICROSOME; NONHUMAN; RAT; SEMINAL VESICLE; THROMBOCYTE","","","MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., MARRERO D., MAS R., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCHIVE MEDICAL RESEARCH, 36, PP. 113-119, (2005); MAS R., D-003: A NEW SUBSTANCE WITH PROMISING LIPID MODIFYING AND PLEIOTROPIC EFFECTS FOR ATHEROSCLEROSIS MANAGEMENT, DRUGS OF THE FUTURE, 29, PP. 773-786, (2004); MENENDEZ R., ARRUZAZABALA M.L., MAS R., GONZALEZ R.M., AMOR A.M., JIMENEZ S., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRITISH JOURNAL NUTRACEUTICAL, 77, PP. 923-932, (1997); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTEL FORSCHUNG, 55, PP. 312-317, (2005); MENENDEZ R., MAS R., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRITISH JOURNAL CLINICAL PHARMACOLOGY, 50, PP. 255-262, (2000); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., RODEIRO I., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLINICAL PHARMACOLOGY THERAPEUTIC, 65, PP. 439-447, (1999); NIKITIN I.P., SLEPCHENKO N.V., GRATSIANSKII N.A., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC POLICOSANOL IN RUSSIA, TERAPEVTICHESKY ARKHIV, 72, PP. 7-10, (2000); WANG Y., KUANMAN K.E., WANG H.L., JIAO Y., ZHAO X., SUN N., YANG X., SUN R., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, JOURNAL NEW DRUGS CLINICAL RESEARCH, 2, PP. 124-129, (2008); GAMEZ R., MENDOZA S., MAS R., MESA R., CASTANO G., RODRIGUEZ B., GARCIA A., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURRENT THERAPEUTIC RESEARCH CLINICAL & EXPERIMENTAL, 61, PP. 8-16, (2000); CASTANO G., MAS R., FERNANDEZ M.L., ILLNAIT J., FERNANDEZ J.C., MENDOZA S., ASSESSMENT OF THE EFFECTS OF D-003, A NEW ANTIPLATELET AND LIPID-LOWERING COMPOUND IN HEALTHY VOLUNTEERS: A PHASE I CLINICAL STUDY, DRUGS R & D, 3, PP. 337-348, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., MENDOZA S., EFFECTS OF D-003 (5-40 MG/DAY) ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A PHASE II CLINICAL STUDY, CLINICAL DRUG INVESTIGATION, 23, PP. 789-802, (2003); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., MENDOZA S., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/D) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXPERIMENTAL CLINICAL RESEARCH, 31, PP. 31-44, (2005); ARRUZAZABALA M.L., LOPEZ E., MOLINA V., ILLNAIT J., CARBAJAL D., FERNANDEZ J.C., MAS R., EFECTOS DEL D-003, MEZCLA DE ÁCIDOS GRADOS DE LA CAÑA DE AZÚCAR, SOBRE EL PERFIL LIPÍDICO Y LA AGREGACIÓN PLAQUETARIA DE PACIENTES CON DIABETES TIPO 2. UN ENSAYO CONTROLADO CON PLACEBO, ACTA BIOQUÍMICA CLÍNICA LATINOAMERICANA, 44, PP. 15-24, (2010); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., JIMENEZ S., MAS R., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVE MEDICINE RESEARCH, 32, PP. 8-12, (2001); SINGH D.K., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL PHARMACOLOGY THERAPEUTIC, 318, PP. 1020-1025, (2006); OLIARO S., CALCIO E., MANTEGNA S., REGUALTION OF HMGCOA REDUCTASE BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 10, PP. 33-38, (2009); BANERJEE S., GHOSHAL S., PORTER T.D., ACTIVATION OF AMP-KINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM, LIPIDS, 27, PP. 24-30, (2011); MENENDEZ R., MAS R., AMOR A.M., RODEIRO I., GONZALEZ R.M., JIMENEZ S., MAS R., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOLOGY RESEARCH, 44, PP. 299-304, (2001); MENENDEZ R., MAS R., PEREZ J., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CANADIAN JOURNAL PHYSIOLOGY PHARMACOLOGY, 82, PP. 22-29, (2004); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOXANO RESEARCH, 69, PP. 321-327, (1993); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REVISTA IBEROAMERICANA TROMBO HEMOSTASIA, 9, PP. 58-62, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., MOLINA V., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOLOGY RESEARCH, 36, PP. 293-297, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDIN LEUKOTRIEN ESSENTIAL FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., EFFECTS OF D-003, A NEW COMPOUND PURIFIED FROM SUGAR CANE WAX, ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS. A RANDOMISED DOUBLE-BLIND CLINICAL STUDY, CLINICAL DRUG INVESTIGATION, 23, PP. 107-118, (2003); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., MAS R., A RANDOMISED, DOUBLE-BLINDED CLINICAL STUDY OF THE EFFECTS OF D-003, A NEW SUBSTANCE PURIFIED FROM SUGAR CANE WAX, ON PLATELET AGGREGATION AND PLASMA LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, INTERNATIONAL JOURNAL PHARMACOLOGY RESEARCH, 24, PP. 55-63, (2004); ARRUZAZABALA M.L., MOLINA V., LOPEZ E., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., MAS R., EFFECTS OF D-003, A MIXTURE OF SUGARCANE WAX ACIDS, ON PLATELET AGGREGATION IN HYPERCHOLESTEROLEMIC PATIENTS: A DOSE-TITRATION, RANDOMISED, PLACEBO-CONTROLLED TRIAL, ARZNEIMITTEL FORSCHUNG DRUG RESEARCH, 58, PP. 376-384, (2008); GONZALEZ V.L., MAGRANER J., LAGUNA A., VELAZQUEZ C., LORENZO M., METODOLOGÍA ANALÍTICA POR CROMATOGRAFÍA GASEOSA PARA LA DETERMINACIÓN DE LOS ALCOHOLES ALIFÁTICOS SUPERIORES QUE COMPONEN EL POLICOSANOL, REVISTA CENIC CIENCIAS QUÍMICAS, 29, PP. 123-126, (1998); MENDEZ E., MARRERO D., GONZALEZ V., LAGUNA A., GC DETERMINATION OF LONG CHAIN FATTY ACIDS THAT COMPORSE D003 IN 5 MG FILM COATED TABLETS, JOURNAL PHARMACOLOGY AND BIMOLECULAR ANALYSIS, 31, PP. 613-620, (2003); BOYUM A., IN IODINATED DENSITY GRADIENT MEDIA, A PRACTICAL APPROACH, PP. 147-170, (1983); ABAD M.J., BERMEJO P., VALVERDE S., VILLAR A., ANTIINFLAMMATORY ACTIVITY OF HYDROXYACHILLIN A SESQUUITERPENE LACTONE FROM TANACETUM MICROPHYLLUM, PLANTA MEDICINALS, 60, PP. 228-323, (1994); FITZPATRICK F.A., ENNIS M.D., BAZE M.E., WYNALDA M.A., MCGEE J.E., LIGGETT W.F., INHIBITION OF CYCLOOXYGENASE ACTIVITY AND PLATELET AGGREGATION BY EPOXYEICOSATRIENOIC ACIDS, INFLUENCE OF STEREOCHEMISTRY, JOURNAL BIOLOGICAL CHEMISTRY, 261, PP. 15334-15338, (1986); DE OLIVEIRA A.M., CONSERVA L.M., SOUZA N., ALMEIDA F., ROSANGELA P., LEMOS L., BARRETO E., ANTINOCICEPTIVE AND ANTIINFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF SABICEA GRISEA VAR GRISEA IN MICE, INTERNATIONAL JOURNAL MOLECULAR SCIENCE, 13, PP. 1598-1611, (2012); FERNANDEZ A., MARQUEZ A., DE LA PUERTA R., PERONA J.S., TERENCIO C., PEREZ C., RUIZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, JOURNAL NUTRACEUTICAL BIOCHEMISTRY, 20, PP. 155-162, (2009); RAVELO Y., MOLINA V., CARBAJAL D., FERNANDEZ L., FERNANDEZ J.C., ARRUZAZABALA M.L., MAS R., EVALUATION OF ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECTS OF D-002 (BEESWAX ALCOHOLS), JOURNAL NATURE MEDICINE, 65, PP. 330-335, (2011)","PHARMACOLOGY DEPARTMENT, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, THE HAVANA, CUBA; EMAIL: YOHANI.PEREZ@CNIC.EDU.CU","","ENGLISH","INTL. J. PHARM. SCI. REV. RES.","ARTICLE","ISI","2-S2.0-84876228694","INTL J PHARM SCI REV RES","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"PÉREZ Y, 2013, INTL J PHARM SCI REV RES","PÉREZ Y, 2013, INTL J PHARM SCI REV RES"
"SEO W;YUK H;CURTIS-LONG M;JANG K;LEE J;HAN S;KANG H;NAM M;LEE S;LEE J;PARK K","SEO, WOO DUCK (8921329600); YUK, HEUNG JOO (36969874600); CURTIS-LONG, MARCUS J. (9036261900); JANG, KI CHANG (24070893400); LEE, JIN HWAN (36062793300); HAN, SANG-IK (7405942341); KANG, HANG WON (35223338200); NAM, MIN HEE (9245082100); LEE, SUNG-JOON (23065729100); LEE, JI HAE (56046902700); PARK, KI HUN (37081917200)","EFFECT OF THE GROWTH STAGE AND CULTIVAR ON POLICOSANOL PROFILES OF BARLEY SPROUTS AND THEIR ADENOSINE 5MONOPHOSPHATEACTIVATED PROTEIN KINASE ACTIVATION",2013,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","61","6",44,"10.1021/jf3041879","DEPARTMENT OF FUNCTIONAL CROP, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RURAL DEVELOPMENT ADMINISTRATION (RDA), MIRYANG 627-803, SOUTH KOREA;DIVISION OF APPLIED LIFE SCIENCE (BK21 PROGRAM), INSTITUTE OF AGRICULTURE AND LIFE SCIENCES (IALS), GYEONGSANG NATIONAL UNIVERSITY, JINJU 660-701, SOUTH KOREA;GRADUATE PROGRAM IN BIOCHEMISTRY AND BIOPHYSICS, BRANDEIS UNIVERSITY, WOLTHAM, MA 02453, 415 SOUTH STREET, UNITED STATES;DEPARTMENT OF FUNCTIONAL CROP, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RURAL DEVELOPMENT ADMINISTRATION (RDA), MIRYANG 627-803, SOUTH KOREA;NAKDONG RIVER BASIN ENVIRONMENTAL OFFICE, MINISTRY OF ENVIRONMENT, CHANGWON 641-722, SOUTH KOREA;DEPARTMENT OF FUNCTIONAL CROP, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RURAL DEVELOPMENT ADMINISTRATION (RDA), MIRYANG 627-803, SOUTH KOREA;DEPARTMENT OF FUNCTIONAL CROP, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RURAL DEVELOPMENT ADMINISTRATION (RDA), MIRYANG 627-803, SOUTH KOREA;DEPARTMENT OF FUNCTIONAL CROP, NATIONAL INSTITUTE OF CROP SCIENCE (NICS), RURAL DEVELOPMENT ADMINISTRATION (RDA), MIRYANG 627-803, SOUTH KOREA;DIVISION OF FOOD BIOSCIENCE AND TECHNOLOGY, COLLEGE OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, SEOUL 136-713, SOUTH KOREA;DIVISION OF FOOD BIOSCIENCE AND TECHNOLOGY, COLLEGE OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, SEOUL 136-713, SOUTH KOREA;DIVISION OF APPLIED LIFE SCIENCE (BK21 PROGRAM), INSTITUTE OF AGRICULTURE AND LIFE SCIENCES (IALS), GYEONGSANG NATIONAL UNIVERSITY, JINJU 660-701, SOUTH KOREA","ADENOSINE 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) IS AN INTRACELLULAR SENSOR THAT CAN REGULATE GLUCOSE LEVELS WITHIN THE CELL. FOR THIS REASON, IT IS WELL-KNOWN TO BE A TARGET FOR DRUGS AGAINST DIABETES AND OBESITY. AMPK WAS ACTIVATED SIGNIFICANTLY BY THE HEXANE EXTRACT OF BARLEY SPROUTS. THIS AMPK ACTIVATION EMERGES ACROSS THE GROWTH STAGES OF THE SPROUT, BECOMING MOST SIGNIFICANT (3 TIMES ABOVE THE INITIAL STAGES) 10 DAYS AFTER SPROUTING. AFTER THIS TIME, THE ACTIVATION DECREASED BETWEEN 13 AND 20 DAYS POST-SPROUTING. ANALYSIS OF THE HEXANE EXTRACTS BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY SHOWED THAT THE AMOUNTS OF POLICOSANOLS (PCS, WHICH ARE LINEAR, PRIMARY ALIPHATIC ALCOHOLS WITH 20-30 CARBONS) IN THE PLANT DRAMATICALLY INCREASED BETWEEN 5 DAYS (109.7 MG/100 G) AND 10 DAYS (343.7 MG/100 G) POST-SPROUTING AND THEN LEVELS FELL BACK DOWN, REACHING 76.4 MG/100 G AT 20 DAYS POST-SPROUTING. THIS TREND IS CONSISTENT WITH PCS BEING THE ACTIVE INGREDIENT IN THE BARLEY PLANTS. WE VALIDATE THIS BY SHOWING THAT HEXACOSANOL IS AN ACTIVATOR OF AMPK. THE RICHEST CULTIVAR FOR PCS WAS FOUND TO BE THE DAEJIN CULTIVAR. CULTIVARS HAD A SIGNIFICANT EFFECT ON THE TOTAL PC CONTENT (113.2-183.5 MG/100 G) WITHIN THE PLANT UP TO 5 DAYS POST-SPROUTING. HOWEVER THIS DEPENDENCE UPON THE CULTIVAR WAS NOT SO APPARENT AT PEAK STAGES OF PC PRODUCTION (10 DAYS POST-SPROUTING). THE MOST ABUNDANT PC IN BARLEY SPROUT, HEXACOSANOL, CONTRIBUTED 62-80% OF THE TOTAL PC CONTENT AT EVERY STAGE. THESE RESULTS ARE VALUABLE TO DETERMINE THE OPTIMAL TIMES OF HARVEST TO OBTAIN THE HIGHEST YIELD OF PCS. © 2013 AMERICAN CHEMICAL SOCIETY.","AMPK; BARLEY SPROUT; HEXACOSANOL; POLICOSANOL","AMP-ACTIVATED PROTEIN KINASES; CELL SURVIVAL; FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEP G2 CELLS; HORDEUM; HUMANS; IMMUNOBLOTTING; PHOSPHORYLATION; PLANT EXTRACTS; PLANT LEAVES; HORDEUM; CHEMICAL ACTIVATION; ENZYME ACTIVITY; GAS CHROMATOGRAPHY; GLUCOSE; HEXANE; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PLANT EXTRACT; POLICOSANOL; ACTIVE INGREDIENTS; ALIPHATIC ALCOHOL; AMPK; BARLEY SPROUT; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOSE LEVEL; GROWTH STAGES; HEXACOSANOL; INITIAL STAGES; INTRACELLULAR SENSOR; POLICOSANOL; POLICOSANOLS; PROTEIN KINASE; ARTICLE; CELL STRAIN HEPG2; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; HORDEUM; HUMAN; IMMUNOBLOTTING; MASS FRAGMENTOGRAPHY; METABOLISM; PHOSPHORYLATION; PLANT LEAF; MICROCOMPUTERS","","","DUH P.D., YEN G.C., YEN W.J., CHANG L.W., ANTIOXIDANT EFFECTS OF WATER EXTRACTS FROM BARLEY (HORDEUM VULGARE L.) PREPARED UNDER DIFFERENT ROASTING TEMPERATURES, J. AGRIC. FOOD CHEM., 49, PP. 1455-1463, (2001); KAMIYAMA M., SHIBAMOTO T., FLAVONOIDS WITH POTENT ANTIOXIDANT ACTIVITY FOUND IN YOUNG GREEN BARLEY LEAVES, J. AGRIC. FOOD CHEM., 60, PP. 6260-6267, (2012); YU Y.M., WU C.H., TSENG Y.H., TSAI C.E., CHANG W.C., ANTIOXIDATIVE AND HYPOLIPIDEMIC EFFECTS OF BARLEY LEAF ESSENCE IN A RABBIT MODEL OF ATHEROSCLEROSIS, JPN. J. PHARMACOL., 89, PP. 142-148, (2002); FERRERES F., KRSKOVA Z., GONCALVES R.F., VALENTAO P., PEREIRA J.A., DUSEK J., MARTIN J., ANDRADE P.B., FREE WATER-SOLUBLE PHENOLICS PROFILING IN BARLEY (HORDEUM VULGARE L.), J. AGRIC. FOOD CHEM., 57, PP. 2405-2409, (2009); BENEDET J.A., UMEDA H., SHIBAMOTO T., ANTIOXIDANT ACTIVITY OF FLAVONOIDS ISOLATED FROM YOUNG GREEN BARLEY LEAVES TOWARD BIOLOGICAL LIPID SAMPLES, J. AGRIC. FOOD CHEM., 55, PP. 5499-5504, (2007); JEYABALAN J., SHAH M., VIOLLET B., CHENU C., AMP-ACTIVATED PROTEIN KINASE PATHWAY AND BONE METABOLISM, J. ENDOCRINOL., 212, PP. 277-290, (2012); HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE: A CELLULAR ENERGY SENSOR WITH A KEY ROLE IN METABOLIC DISORDERS AND IN CANCER, BIOCHEM. SOC. TRANS., 39, PP. 1-13, (2011); KIM M.S., HUR H.J., KWON D.Y., HWANG J.T., TANGERETIN STIMULATES GLUCOSE UPTAKE VIA REGULATION OF AMPK SIGNALING PATHWAYS IN C2C12 MYOTUBES AND IMPROVES GLUCOSE TOLERANCE IN HIGH-FAT DIET-INDUCED OBESE MICE, MOL. CELL. ENDOCRINOL., 358, PP. 127-134, (2012); ZHANG W., ZHANG X., WANG H., GUO X., LI H., WANG Y., XU X., TAN L., MASHEK M.T., ZHANG C., CHEN Y., MASHEK D.G., FORETZ M., ZHU C., ZHOU H., LIU X., VIOLLET B., WU C., HUO Y., AMP-ACTIVATED PROTEIN KINASE Α1 PROTECTS AGAINST DIET-INDUCED INSULIN RESISTANCE AND OBESITY, DIABETES, 61, PP. 3114-3125, (2012); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MEDITERR. J. NUTR. METAB., 1, PP. 77-83, (2008); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUE E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUR. J. LIPID SCI. TECHNOL., 112, PP. 373-379, (2010); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHARMACOL. EXP. THER., 318, PP. 1020-1026, (2006); YAO H., WEI C., SONG H., GUO R., QUALITY EVALUATION OF POLICOSANOL FILM-COATED TABLETS BY SIMULTANEOUS DETERMINATION OF EIGHT INGREDIENTS USING GC-FID AND GC-MS, J. ANAL. SCI. METH. INSTRUM., 2, PP. 24-28, (2012); GUO H., LIU G., ZHONG R., WANG Y., WANG D., XIA M., CYANIDIN-3- O -Β-GLUCOSIDE REGULATES FATTY ACID METABOLISM VIA AN AMP-ACTIVATED PROTEIN KINASE-DEPENDENT SIGNALING PATHWAY IN HUMAN HEPG2 CELLS, LIPIDS HEALTH DIS., 11, PP. 1-13, (2012); BRADFORD M.M., A RAPID AND SENSITIVE METHOD FOR THE QUANTITATION OF MICROGRAM QUANTITIES OF PROTEIN UTILIZING THE PRINCIPLE OF PROTEIN-DYE BINDING, ANAL. BIOCHEM., 72, PP. 248-254, (1976); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J. FOOD SCI., 76, PP. 891-899, (2011); RICHARDSON A., FRANKE R., KERSTIENS G., JARVIS M., SCHREIBER L., FRICKE W., CUTICULAR WAX DEPOSITION IN GROWING BARLEY (HORDEUM VULGARE) LEAVES COMMENCES IN RELATION TO THE POINT OF EMERGENCE OF EPIDERMAL CELLS FROM THE SHEATHS OF OLDER LEAVES, PLANTA, 222, PP. 472-483, (2005); ZANG M., XU S., MAITLAND-TOOLAN K.A., ZUCCOLLO A., HOU X., JIANG B., WIERZBICKI M., VERBEUREN T.J., COHEN R.A., POLYPHENOLS STIMULATE AMP-ACTIVATED PROTEIN KINASE, LOWER LIPIDS, AND INHIBIT ACCELERATED ATHEROSCLEROSIS IN DIABETIC LDL RECEPTOR-DEFICIENT MICE, DIABETES, 55, PP. 2180-2191, (2006); SAMARI H.R., MOLLER M.T., HOLDEN L., ASMYHR T., SEGLEN P.O., STIMULATION OF HEPATOCYTIC AMP-ACTIVATED PROTEIN KINASE BY OKADAIC ACID AND OTHER AUTOPHAGY-SUPPRESSIVE TOXINS, BIOCHEM. J., 386, PP. 237-244, (2005); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009)","K.H. PARK; DIVISION OF APPLIED LIFE SCIENCE (BK21 PROGRAM), INSTITUTE OF AGRICULTURE AND LIFE SCIENCES (IALS), GYEONGSANG NATIONAL UNIVERSITY, JINJU 660-701, SOUTH KOREA; EMAIL: KHPARK@GNU.AC.KR","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-84873390190","J AGRIC FOOD CHEM","NATIONAL INSTITUTE OF CROP SCIENCE (NICS);SOUTH KOREA;BRANDEIS UNIVERSITY;NATIONAL INSTITUTE OF CROP SCIENCE (NICS);NAKDONG RIVER BASIN ENVIRONMENTAL OFFICE;NATIONAL INSTITUTE OF CROP SCIENCE (NICS);NATIONAL INSTITUTE OF CROP SCIENCE (NICS);NATIONAL INSTITUTE OF CROP SCIENCE (NICS);KOREA UNIVERSITY;KOREA UNIVERSITY;SOUTH KOREA","NOTREPORTED;GYEONGSANG NATIONAL UNIVERSITY;NOTREPORTED",NA,"SEO WD, 2013, J AGRIC FOOD CHEM","SEO WD, 2013, J AGRIC FOOD CHEM"
"ARUL G R","ARUL GNANARAJ, R. (55208119400)","APPLICATIONS OF SUGARCANE WAX AND ITS PRODUCTS A REVIEW",2012,"INTERNATIONAL JOURNAL OF CHEMTECH RESEARCH","4","7",3,"","SCHOOL OF CHEMICAL AND BIOTECHNOLOGY, SASTRA UNIVERSITY, TIRUMALAISAMUDRAM THANJAVUR, TAMILNADU, 613 401, INDIA","SUGARCANE WAX IS A PRODUCT EXTRACTED FROM PRESS MUD, A SUGAR MILL WASTE. SUBSEQUENTLY, D-003ACIDS, POLICOSANOL AND OCTACOSANOL CAN BE DERIVED FROM THE EXTRACTED SUGAR CANE WAX. THESE COMPOUNDS EXHIBIT LIPID LOWERING EFFECT IN ANIMALS AND HUMANS. MOREOVER, THEY ARE NON-TOXIC AND NON-CARCINOGENIC. THE PRESENT ARTICLE DISCUSSES THE VARIOUS APPLICATIONS OF POLICOSANOL AND PRESENTS THE COMPILATION OF THE STUDIES CONDUCTED TO ASSESS THE HEALTH EFFECTS OF POLICOSANOL.","LIPID LOWERING; OCTASANOL; POLCOSANOL; SUGARCANE WAX","ACETYLSALICYLIC ACID; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; D 003; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OCTACOSANOL; PLANT MEDICINAL PRODUCT; POLICOSANOL; PRAVASTATIN; SIMVASTATIN; SUGARCANE WAX OIL; THROMBOXANE B2; UNCLASSIFIED DRUG; WARFARIN; ABSENCE OF SIDE EFFECTS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY THROMBOSIS; ARTHRITIS; ARTICLE; BLEEDING TIME; BRAIN ISCHEMIA; CARCINOGENICITY; CHOLESTEROL SYNTHESIS; DEVELOPMENTAL TOXICITY; DIET SUPPLEMENTATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; EMBRYOTOXICITY; EXTRACTION; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; LOW FAT DIET; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PSORIASIS; REPRODUCTIVE TOXICITY; SAPONIFICATION; SINGLE DRUG DOSE; SPINAL CORD INJURY; SUGARCANE; TERATOGENICITY; THROMBOCYTE AGGREGATION; THROMBOSIS","","","REZANKA T., SIGLER K., IDENTIFICATION OF VERY LONG CHAIN FATTY ACIDS FROM SUGAR CANE WAX BY ATMOSPHERIC PRESSURE CHEMICAL IONIZATION LIQUID CHROMATOGRAPHY-MASS SPECTROSCOPY, PHYTOCHEMISTRY, 67, PP. 916-923, (2006); PEREZ Y., MENENDEZ R., FERRER J.I., LOPEZ E., CASTANO G., FERNANDEZ J., FERREIRO R.M., FERNANDEZ L., MENDOZA S., GONZALEZ R., ME M., EFFECTS OF D-003, A MIXTURE OF HIGH-MOLECULARWEIGHT SUGAR CANE WAX ACIDS, ON LIPID PEROXIDATION MARKERS IN OLDER INDIVIDUALS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR. THER. RES., 69, PP. 36-48, (2008); LEDON N., CASACO A., REMIREZ D., GONZALEZ A., CRUZ J., GONZALEZ R., CAPOTE A., TOLON Z., ROJAS E., RODRIGUEZ V.J., MERINO N., RODRIGUEZ S., ANCHETA O., CANO M.C., EFFECTS OF A MIXTURE OF FATTY ACIDS FROM SUGAR CANE (SACCHARUM OFFICINARUM L) WAX OIL IN TWO MODELS OF INFLAMMATION: ZYMOSAN-INDUCED ARTHRITIS AND MICE TAIL TEST OF PSORIASIS, PHYTOMEDICINE, 14, PP. 690-695, (2007); PHUKAN A.C., BORUAH R.K., EXTRACTION AND EVALUATION OF MICROCRYSTALLINE WAX FROM PRESS MUD WASTE OF THE SUGAR INDUSTRY, SEP. PURIF. TECHNOL., 17, PP. 189-194, (1999); SMITH R.M., SMITH M.M., HYDROCARBONS IN LEAF WAXES OF SACCHARUM AND RELATED GENERA, PHYTOCHEMISTRY, 17, PP. 1293-1296, (1978); GAMEZ R., NOA M., MAS R., MENDOZA N., PARDO B., MENENDEZ R., PEREZ Y., GONZALEZ R.M., GUTIERREZ A., MARRERO G., GOICOCHEA E., GARCIA H., CURVECO D., LONG-TERM CARCINOGENICITY OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT ACIDS FROM SUGARCANE WAX, IN SPRAGUE DAWLEY RATS: A 24 MONTHS STUDY, FOOD CHEM. TOXICOL., 45, PP. 2352-2358, (2007); NOA M., GAMEZ R., MAS R., GUTIERREZ A., MENDOZA N., PARDO B., MARRERO G., CURVECO D., GOICOCHEA E., GARCIA H., PEREZ Y., GONZALEZ R.M., STUDY OF THE LONG-TERM CARCINOGENICITY POTENTIAL OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT SUGARCANE WAX ACIDS, IN MICE, FOOD CHEM. TOXICOL., 47, PP. 687-692, (2009); RODRIGUEZ M.D., GAMEZ R., GONZALEZ J.E., GARCIA H., ACOSTA C.P., GOICOCHEA E., LACK OF DEVELOPMENTAL TOXICITY OF D-003: A MIXTURE OF LONG-CHAIN FATTY ACIDS IN RATS, FOOD CHEM. TOXICOL., 41, PP. 89-93, (2003); RODRIGUEZ M.D., GONZALEZ J.E., ALEMAN C., RODEIRO I., ARANGO E., GAMEZ R., VALDES S., GARCIA H., GOICOCHEA E., ACOSTA C.P., EVALUATION OF THE REPRODUCTIVE AND DEVELOPMENTAL TOXICITY OF THE D-003, A MIXTURE OF LONG-CHAIN FATTY ACIDS, IN RATS AND RABBITS, FOOD CHEM. TOXICOL., 42, PP. 1977-1985, (2004); CARBAJAL D., ARRUZAZABALA M.L., NOA M., MOLINA V., MAS R., ARANGO E., VALDES S., GONZALEZ J.E., PROTECTIVE EFFECT OF D-003 ON EXPERIMENTAL SPINAL CORD ISCHEMIA IN RABBITS, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 70, PP. 1-6, (2004); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL, AM. HEART. J., 152, (2006); FERNANDEZ S., ROSA M., GAMEZ R., DIAZ A., FERNANDEZ J., ORTA S.D., ILLNAIT J., CASTANO G., MENDOZA S., VALDES F., ALVAREZ E., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION, AM. J. GERIATR. PHARMACOTHER., 2, PP. 219-229, (2004); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM. TOXICOL., 33, PP. 573-578, (1995); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., FERNANDEZ J.C., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR. THER. RES., 62, PP. 194-208, (2001); PONS P., ILLNAIT J., MAS R., RODRIGUEZ M., ALEMAN C., FERNAANDEZ J.C., FERNANDEZ L., MARTIN M., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 26-35, (1997); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 50, PP. 249-251, (1994); MCCARTY M.F., AN EZETIMIBE-POLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTS, MED. HYPOTHESES, 64, PP. 636-645, (2005); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH. MED. RES., 36, PP. 441-447, (2005); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL. BEHAV., 67, PP. 1-7, (1999); CANETTI M.M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR. THER. RES., 58, PP. 868-875, (1997); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULINDEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, PP. 44-51, (1997); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, PP. 379-391, (1999); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR. THER. RES., 59, PP. 717-722, (1998); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 859-867, (1997); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR. THER. RES., 61, PP. 346-357, (2000); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR. THER. RES., 61, PP. 137-146, (2000); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, PP. 293-297, (1997); ORTENSI G., JULIO J., HECTOR V., PEDRO A.T., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 390-401, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS D., INTERACTION POLICOSANOL-WARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS, PHARMACOL. RES., 38, PP. 89-91, (1998); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); BATISTA J., STUSSER R., PENICHET M., UGUET E., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR. THER. RES., 56, PP. 906-914, (1995); CASTANO G., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., MOLINA V., ILLNAIT J., MENDOZA S., GAMEZ R., MESA M., FERNANDEZ J., EFFECTS OF COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON PLATELET AGGREGATION: A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY, CURR. THER. RES., 67, PP. 174-192, (2006); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., DIAZ E., FERNANDEZ L., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, PP. 568-577, (1996); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, PP. 507-513, (1992); ECHENIQUE C.R., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR. THER. RES., 54, PP. 304-312, (1993); BERTHOLD I.G., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART. J., 143, PP. 356-365, (2002); JONES P.J.H., KASSIS A.N., MARINANGELI C.P.F., POLICOSANOLS LOSE THEIR LUSTRE AS CHOLESTEROLLOWERING AGENTS, JOURNAL OF FUNCTIONAL FOODS, 1, PP. 236-239, (2009); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BERTHOLD I.G., TH-P16:328 POLICOSANOL DOES NOT LOWER CHOLESTEROL IN CAUCASIAN PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA-AN RCT WITH USUAL AND HIGH DOSES, ATHEROSCLEROSIS SUPP., 7, PP. 565-566, (2006); MAS R., CASTANO G., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 144, SUPPL. 1, (1999); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR. METAB. CARDIOVASC. DIS., 21, PP. 424-429, (2011); AND ITS COSMETIC APPLICATION FOR SKIN HAIR AND NAILS.; OU S., ZHAO J., WANG Y., TIAN Y., WANG J., PREPARATION OF OCTACOSANOL FROM FILTER MUD PRODUCED AFTER SUGARCANE JUICE CLARIFICATION, LWT-FOOD SCI. TECHNOL., 45, PP. 295-298, (2012)","R. ARUL GNANARAJ; SCHOOL OF CHEMICAL AND BIOTECHNOLOGY, SASTRA UNIVERSITY, TIRUMALAISAMUDRAM THANJAVUR, TAMILNADU, 613 401, INDIA; EMAIL: RAARUL@CHEM.SASTRA.EDU","","ENGLISH","INT. J. CHEMTECH RES.","ARTICLE","ISI","2-S2.0-84860604062","INT J CHEMTECH RES","SASTRA UNIVERSITY","NOTREPORTED;SASTRA UNIVERSITY;NOTREPORTED",NA,"ARUL GNANARAJ R, 2012, INT J CHEMTECH RES","ARUL GNANARAJ R, 2012, INT J CHEMTECH RES"
"AFINISHA D L;ARUMUGHAN C","AFINISHA DEEPAM, L.S. (23011480500); ARUMUGHAN, C. (6601970250)","EFFECT OF SAPONIFI CATION ON COMPOSITION OF UNSAPONIFI ABLE MATTER IN RICE BRAN OIL",2012,"JOURNAL OF OLEO SCIENCE","61","6",16,"10.5650/jos.61.241","NATIONAL INSTITUTE FOR INTERDISCIPLINARY SCIENCE AND TECHNOLOGY (CSIR) THIRUVANANTHAPURAM, KERALA, PIN 695019, INDIA;NATIONAL INSTITUTE FOR INTERDISCIPLINARY SCIENCE AND TECHNOLOGY (CSIR) THIRUVANANTHAPURAM, KERALA, PIN 695019, INDIA","RICE BRAN OIL CONTAINS A VARIETY OF UNSAPONIFIABLE CONSTITUENTS (USC) THAT ARE PRESUMED TO CONTRIBUTE TO THE HIGH VALUE OF UNSAPONIFABLE MATTER (USM). THE OBJECTIVES OF THE PRESENT STUDY WERE TO IDENTIFY AND QUANTIFY THE CONSTITUENTS IN USM. THE CHANGES THAT THE UNSAPONIFIABLES UNDERGO DURING SAPONIFI CATION WERE ALSO QUANTITATIVELY INVESTIGATED. WHILE ANALYZING THE PERCENTAGE OF ALL CONSTITUENTS, THE PERCENTAGE OF STEROL GET INCREASED FROM 22.46 TO 23.77 IN USM OF CRUDE RICE BRAN OIL (CRBO) AND 33.42 TO 36.79 IN USM OF REFI NED RICE BRAN OIL (RRBO). ORYZANOL THAT COMPRISED 34% OF THE UNSAPONIFI ABLE IN THE CRUDE OIL BY DIRECT ESTIMATION WAS ALMOST ELIMINATED IN USM AND SAME IN REFINED OIL. THE RESULTS ALSO REVEALED THE PRESENCE OF FOUR ADDITIONAL CLASSES OF COMPOUNDS THAT WERE QUANTIFI ED IN USM (POLICOSANOL, FATTY ALDEHYDES, TRITERPENE ALCOHOLS AND POTASSIUM SALT OF ORYZANOLS). AMONG THE FOUR CLASSES OF COMPOUNDS, POLICOSANOL CONTRIBUTED HIGH PERCENTAGE IN USM, (43.39% IN CRBO AND 28.46% IN RRBO). FATTY ALDEHYDES, TRITERPENE ALCOHOLS AND POTASSIUM SALT OF ORYZANOLS TOGETHER CONTRIBUTED 27.68% AND 25.13% OF USM FROM CRBO AND RRBO RESPECTIVELY. THE HPTLC METHOD EMPLOYED HERE THUS, ACCOUNTED FOR 96.75% BY WT OF THE USM OF CRBO AND 92.00% BY WT OF THE USM OF RRBO. © 2012 BY JAPAN OIL CHEMISTS' SOCIETY.","FATTY ALDEHYDES; HPTLC; POLICOSANOL; RICE BRAN OIL; UNSAPONIFI ABLE MATTER","ALCOHOLS; ALDEHYDES; CHROMATOGRAPHY, THIN LAYER; FATTY ALCOHOLS; PHENYLPROPIONATES; PLANT OILS; SAPONINS; TRITERPENES; ALDEHYDES; CRUDE OIL; PETROLEUM REFINING; POSITIVE IONS; SALTS; ALCOHOL DERIVATIVE; ALDEHYDE; FATTY ALCOHOL; GAMMA ORYZANOL; GAMMA-ORYZANOL; PHENYLPROPIONIC ACID DERIVATIVE; POLICOSANOL; RICE BRAN OIL; SAPONIN; TRITERPENE; VEGETABLE OIL; CRUDE RICE BRAN OIL; HPTLC; ORYZANOL; POLICOSANOL; POTASSIUM SALTS; RICE BRAN OIL; TRITERPENES; UNSAPONIFI ABLE MATTER; ARTICLE; CHEMISTRY; ISOLATION AND PURIFICATION; THIN LAYER CHROMATOGRAPHY; FURFURAL","","","SHARMA R.D., RUKMINI C., RICE BRAN OIL AND HYPOCHOLESTEROLEMIA IN RATS, LIPIDS, 21, PP. 715-717, (1986); DEVI R.R., ARUMUGHAN C., PHYTOCHEMICAL CHARACTERIZATION OF DEFATTED RICE BRAN AND OPTIMIZATION OF A PROCESS FOR THEIR EXTRACTION AND ENRICHMENT, BIORESOUR. TECHNOL., 98, PP. 3037-3043, (2007); KRISHNA A.G.G., SAKINA K., SHIELA P.M., SARMANDAL C.V., INDIRA T.N., ARVIND M., EFFECT OF REFINING OF CRUDE RICE BRAN OIL ON THE RETENTION OF ORYZANOL IN THE REFINED OIL, J. AM. OIL CHEM. SOC., 78, (2001); MEZOUARI S., EICHNER K., COMPARATIVE STUDY ON THE STABILITY OF CRUDE AND REFINED RICE BRAN OIL DURING LONGTERM STORAGE AT ROOM TEMPERATURE, EUR. J. LIPID SCI. TECHNOL. ECHNOL., 109, PP. 198-205, (2007); HOED V., DEPAEMELAERE G., AYALA J.V., SANTIWATTANA P., VERHE R., GREYT D., INFLUENCE OF CHEMICAL REFINING ON THE MAJOR AND MINOR COMPONENTS OF RICE BRAN OIL, J. AM. OIL CHEM. SOC., 83, PP. 315-321, (2006); PRASAD R.B.N., REFINING OF RICE BRAN OIL, LIPID TECHNOL, 18, PP. 275-279, (2006); RAJAM L., KUMAR D.R.S., SUNDARESAN A., ARUMUGHAN C., A NOVEL PROCESS FOR PHYSICALLY REFINING RICE BRAN OIL THROUGH SIMULTANEOUS DEGUMMING AND DEWAXING, J. AM. OIL CHEM. SOC., 82, PP. 213-220, (2005); THE PREVENTION OF FOOD ADULTERATION ACT, (1954); CODEX ALIMENTARIUS STANDARD FOR NAMED VEGETABLE OILS REF, (2005); MARINI F., BALESTRIERI F., BUCCI R., MAGR A.L., MARINI D., SUPERVISED PATTERN RECOGNITION TO DISCRIMINATE THE GEOGRAPHICAL ORIGIN OF RICE BRAN OILS: A FIRST STUDY, MICROCHEM. J., 74, PP. 239-242, (2003); XU Z., GODBER J.S., PURIFICATION AND IDENTIFICATION OF COMPONENTS Γ-ORYZANOL IN RICE BRAN OIL, J. AGRIC. FOOD CHEM., 47, PP. 2724-2728, (1999); ZIGONEANU I.G., WILLIAMS L., XU Z., SABLIOV C.M., DETERMINATION OF ANTIOXIDANT COMPONENTS IN RICE BRAN OIL EXTRACTED BY MICROWAVE-ASSISTED METHOD, BIORESOUR. TECHNOL., 99, PP. 4910-4918, (2008); (1997); KRISHNA A.G.G., PRASHANTH P.A., PRAGASAM A., RAGHAVENDRA K.V., KHATOON S., UNSAPONIFIABLE MATTER AND OXIDATIVE STABILITY OF COMMERCIALLY PRODUCED INDIAN RICE BRAN OILS, J. FOOD LIPIDS., 10, PP. 329-340, (2003); DEEPAM L.S.A., KUMAR D.R.S., SUNDARESAN A., ARUMUGHAN C., A NEW METHOD FOR SIMULTANEOUS ESTIMATION OF USCS OF RICE BRAN OIL USING HPTLC, J. SEP. SCI., 30, PP. 2786-2793, (2007); GALLO M.L., SELDES A.M., CABRERA G.M., ANTIBIOTIC LONG-CHAIN AND Α, Β-UNSATURATED ALDEHYDES FROM THE CULTURE OF THE MARINE FUNGUS CLADOSPORIUM SP, BIOCHEM. SYST. ECOL., 32, PP. 545-551, (2004); HAMILL F.A., APIO S., MUBIRU N.K., MOSANGO M., BUKENYA-ZIRABA R., MAGANYI O.W., SOEJARTO D.D., TRADITIONAL HERBAL DRUGS OF SOUTHERN UGANDA PART III: ISOLATION AND METHODS FOR PHYSICAL CHARACTERIZATION OF BIOACTIVE ALKANOLS FROM RUBUS APETALUS, J. ETHNOPHARMACOL., 87, PP. 15-19, (2003); YUASA Y., TSURUTA H., CONVENIENT SYNTHESES OF ISOMETHYL-BRANCHED LONG-CHAIN ALIPHATIC ALDEHYDES, KNOWN TO CONTRIBUTE SIGNIFICANTLY TO MEAT FLAVOUR, FLAVOR FRAG. J., 19, PP. 199-204, (2004); DEEPAM L.S.A., ARUMUGHAN C., CHARACTERIZATION OF SN-2 ALK-1'-ENYL ETHERS OF GLYCEROL FROM RICE BRAN OIL, J OLEO SCI., 59, PP. 521-526, (2010); OFFICIAL METHODS OF ANALYSIS OF AOAC INTERNATIONAL, (2000); BIANCHI G., LUPOTTO E., RUSSO S., COMPOSITION OF EPICUTICULAR WAX OF RICE, ORYZA SATIVA, EXPERIENTIA., 35, PP. 1417-1540, (1979); WANG M., LIAN H., MAO L., ZHOU J., GONG H., QIAN B., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM., 55, PP. 5552-5558, (2007); TAYLOR J.C., RAPPORT L., WOOD G.B.L., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); SUBRAHMANYAM C.V., RAO M.V., BALASUBRAHMANYAM V., BHOWMICK N., MEMBRANE DEGUMMING OF CRUDE RICE BRAN OIL PILOT PLANT STUDY, EUR. J. LIPID SCI. TECHNOL., 108, PP. 746-752, (2006); CHRISTIANNE E.C., PEDRO R., FILHO A.P., ANTONIO J.A.M., PHASE EQUILIBRIUM FOR THE SYSTEM RICE BRAN OIL+FATTY ACIDS+ETHANOL+WATER+Γ-ORYZANOL+TOCOLS, FLUID PHASE EQUILIB., 216, PP. 271-283, (2004)","L. S. AFINISHA DEEPAM; NATIONAL INSTITUTE FOR INTERDISCIPLINARY SCIENCE AND TECHNOLOGY (CSIR) THIRUVANANTHAPURAM, KERALA, PIN 695019, INDIA; EMAIL: AFINISHADPM@GMAIL.COM","","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","2-S2.0-84860183018","J OLEO SCI","NATIONAL INSTITUTE FOR INTERDISCIPLINARY SCIENCE AND TECHNOLOGY (CSIR) THIRUVANANTHAPURAM;NATIONAL INSTITUTE FOR INTERDISCIPLINARY SCIENCE AND TECHNOLOGY (CSIR) THIRUVANANTHAPURAM","NOTREPORTED;NATIONAL INSTITUTE FOR INTERDISCIPLINARY SCIENCE AND TECHNOLOGY (CSIR) THIRUVANANTHAPURAM;NOTREPORTED",NA,"AFINISHA DEEPAM LS, 2012, J OLEO SCI","AFINISHA DEEPAM LS, 2012, J OLEO SCI"
"GUERRA Y;FERREIRO R;YERA Á;DESPAIGNE S;CUEVAS V","GUERRA, YOHANI PÉREZ (23995375700); FERREIRO, ROSA MAS (6602148780); YERA, ÁMBAR OYARZÁBAL (36020873200); DESPAIGNE, SONIA JIMÉNEZ (36096505400); CUEVAS, VIVIAN MOLINA (7006062814)","EFFECTS OF OCTACOSANOL AND TRIACONTANOL ALCOHOLS ON CICLOOXYGENASE AND 5LIPOXYGENASE ENZYME ACTIVITIES IN VITRO EFECTO SOBRE LA ACTIVIDAD IN VITRO DE LAS ENZIMAS CICLOXIGENASA Y 5LIPOXIGENASA DE LOS ALCOHOLES OCTACOSANOL Y EL TRIACONTANOL",2015,"REVISTA CUBANA DE FARMACIA","49","",1,"","CENTRO DE PRODUCTOS NATURALES, (CNIC), CUBA;CENTRO DE PRODUCTOS NATURALES, (CNIC), CUBA;CENTRO DE PRODUCTOS NATURALES, (CNIC), CUBA;CENTRO DE PRODUCTOS NATURALES, (CNIC), CUBA;CENTRO DE PRODUCTOS NATURALES, (CNIC), CUBA","INTRODUCTION: POLICOSANOL, A MIXTURE OF EIGHT PRIMARY ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX, CONTAINS OCTACOSANOL AS MAJOR COMPONENT. D-002, A MIXTURE OF SIX PRIMARY ALIPHATIC ALCOHOLS PURIFIED FROM BEESWAX, PRESENTS TRIACONTANOL AS THE MAIN COMPONENT. ALTHOUGH BOTH SUBSTANCES ARE HIGH MOLECULAR WEIGHT ALCOHOL MIXTURES, THEY HAVE DIFFERENT COMPOSITIONS AND PHARMACOLOGICAL EFFECTS SUCH AS THEIR DISTINCT EFFECTS ON ARACHIDONIC ACID METABOLISM ENZYMES; WHEREAS POLICOSANOL INHIBITS CYCLOOXYGENASE (COX)-1, D-002 INHIBITS COX AND 5-LIPOXYGENASE (5-LOX) ACTIVITIES. OBJECTIVE: TO STUDY THE EFFECTS OF OCTACOSANOL AND TRIACONTANOL, WHICH ARE MAIN COMPONENTS OF POLICOSANOL AND D-002, RESPECTIVELY ON THE COX AND THE 5-LOX ENZYME IN VITRO ACTIVITIES. METHODS: TRIACONTANOL AND OCTACOSANOL WERE SUSPENDED IN A TWEEN-20/H2O (2 %) (0.6-5000 G/ML) VEHICLE. THE EFFECTS OF ADDING THESE ALCOHOLS ON COX-1, COX-2 AND 5-LOX ENZYMES ACTIVITIES WERE ASSESSED IN RAT PLATELET MICROSOMES, RAT SEMINAL VESICLE MICROSOMES AND RAT POLYMORPHONUCLEAR (PMN) PREPARATIONS, RESPECTIVELY. INDOMETHACIN (0.4ΜG/ML) WAS USED AS REFERENCE INHIBITOR OF COX-1 AND COX-2, AND LYPRINOL AS 5-LOX INHIBITOR. RESULTS: OCTACOSANOL SHOWED SIGNIFICANT, MARKED (70% WITH HIGHEST CONCENTRATION) (IC50=143.54 G/ML) AND DOSE-DEPENDENT (R=0.991, P <0.001) INHIBITORY ACTION ON COX-1 ACTIVITY. HOWEVER, TRIACONTANOL DID NOT AFFECT COX-1, BUT INHIBITED SIGNIFICANTLY, DEPENDING ON DOSE (R=0.985, P <0.001) THE COX-2 ACTIVITY TO 50 % WITH 1250 G/ML. IN CONTRAST, OCTACOSANOL DID NOT CHANGE COX-2 ACTIVITY. INDOMETHACIN INHIBITED BOTH COX-1 AND COX-2 BY 83 %. OCTACOSANOL ADDITION WAS INEFFECTIVE WHEREAS TRIACONTANOL HAD SIGNIFICANT, DOSE-DEPENDENT (R=0.978, P<0.001) AND MARKED EFFECT (79 %) ON THE 5-LOX ACTIVITY (IC50=58.74 G/ML). LYPRINOL INHIBITED 5-LOX BY 89 %. THE INHIBITIONS INDUCED BY OCTACOSANOL AND TRIACONTANOL WERE COMPETITIVE. CONCLUSIONS: IN VITRO ADDITION OF OCTACOSANOL AND TRIACONTANOL CAUSED DIFFERENTIAL EFFECTS ON COX-1, COX-2 AND 5-LOX ENZYME ACTIVITIES. WHEREAS OCTACOSANOL MARKEDLY INHIBITED COX-1 ACTIVITY AND DID NOT CHANGE THOSE OF COX-2 AND 5-LO, TRIACONTANOL MARKEDLY INHIBITED 5-LOX ACTIVITY, BUT HAD MODERATE EFFECT ON COX-2 AND DID NOT CHANGE COX-1 ACTIVITY. © 2015, EDITORIAL CIENCIAS MEDICAS. ALL RIGHTS RESERVED.","CICLOOXYGENASES; D-002; LIPOOXYGENASES; OCTACOSANOL; POLICOSANOL; TRIACONTANOL","ALKANOL; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; LYPRINOL; OCTACOSANOL; PROSTAGLANDIN SYNTHASE; TRIACONTANOL; UNCLASSIFIED DRUG; ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; IC50; IN VITRO STUDY; MICROSOME; NONHUMAN","","","MAS R., POLICOSANOL. DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); MAS R., D-002. DRUGS OF THE FUTURE, 26, 8, PP. 731-744, (2001); MENENDEZ R., ARRUZAZABALA M.L., MAS R., GONZALEZ R.M., AMOR A., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT J NUTR, 77, PP. 923-932, (1997); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTELFORSCHUNG RES, 55, PP. 312-317, (2005); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); WANG Y., KUANMAN K.E., WANG HIA L., JIAO Y., ZHAO X., SUN N., ET AL., EFFICACY AND SAFETY OF POLICOSANOL AND PRAVASTATIN IN TREATMENT OF HYPERLIPIDEMIA IN CHINESE PATIENTS, J NEW DRUGS CLIN RES, 2, PP. 124-129, (2008); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMBO HEMOST, 9, PP. 58-62, (1996); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., ALEMAN C., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, 2-3, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RESS, 34, 5-6, PP. 181-185, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., MOLINA V., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL 20 AND 40 MG/D IN HEALTHY VOLUNTEERS AND DYSLIPIDEMIC PATIENTS, CLIN EXP. PHARMACOL. PHYSIOL, 29, 10, PP. 891-897, (2002); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA M.L., MAS R., POSSIBLE CYTOPROTECTIVE MECHANISM IN RATS OF D-002 AN ANTI-ULCEROGENIC PRODUCT ISOLATED FROM BEESWAX, J PHARM. PHARMACOL, 48, PP. 858-860, (1996); CARBAJAL D., MOLINA V., NOA M., VALDES S., ARRUZAZABALA M.L., AGUILAR A., ET AL., EFFECTS OF D-002 ON GASTRIC MUCUS COMPOSITION IN ETHANOL INDUCED ULCER, PHARMACOL RES, 42, PP. 329-332, (2000); PEREZ Y., OYARZABAL A., MAS R., MOLINA V., JIMENEZ S., PROTECTIVE EFFECT OF D-002, A MIXTURE OF BEESWAX ALCOHOLS, AGAINST INDOMETHACIN-INDUCED GASTRIC ULCERS AND MECHANISM OF ACTION, J NAT MEDICINE, 32, 1, PP. 113-117, (2013); RODRIGUEZ I., ILLNAIT J., TERRY H., MAS R., FERNANDEZ L., FERNANDEZ J.C., ET AL., EFECTOS DEL ABEXOL ® (ALCOHOLES DE LA CERA DE ABEJA) SOBRE SÍNTOMAS GASTROINTESTINALES EN SUJETOS DE EDAD MEDIA Y AVANZADA, REV CENIC CIEN BIOL, 40, 3, PP. 147-154, (2009); ILLNAIT J., TERRY H., MAS R., FERNANDEZ L., CARBAJAL D., ET AL., EFFECTS OF D-002, A PRODUCT ISOLATED FROM BEESWAX, ON GASTRIC SYMPTOMS OF PATIENTS WITH OSTEOARTHRITIS TREATED WITH PIROXICAM: A PILOT STUDY, J MED FOOD, 8, 1, PP. 63-68, (2005); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA M.L., MAS R., ANTI-INFLAMMATORY ACTIVITY OF D-002: AN ACTIVE PRODUCT ISOLATED FROM BEESWAX. PROSTAGL. LEUKOTR. ESSENT, FATTY ACIDS, 59, PP. 235-238, (1998); RAVELO Y., MOLINA V., CARBAJAL D., ARRUZAZABALA M.L., MAS R., OYARZABAL A., ET AL., EFFECTS OF SINGLE ORAL AND TOPICAL ADMINISTRATION OF D-002 (BEESWAX ALCOHOLS) ON XYLENE-INDUCED EAR OEDEMA IN MICE, LAJP, 29, PP. 1451-1454, (2010); RAVELO Y., MOLINA V., CARBAJAL D., FERNANDEZ L., FERNANDEZ J.C., ARRUZAZABALA M.L., ET AL., EVALUATION OF ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECTS OF D-002 (BEESWAX ALCOHOLS), J NAT MED, 65, PP. 330-335, (2011); RAVELO Y., MOLINA V., PEREZ Y., OYARZABAL A., JIMENEZ S., MAS R., ANTI-OEDEMA EFFECTS OF D-002 AND LYPRINOL ON THE CARRAGEENAN-INDUCED PLEURISY IN RATS, INT J PHARM SCIENC REVIEW RES, 23, 1, PP. 24-28, (2013); RAVELO Y., MOLINA V., OYARZABAL A., PEREZ Y., NOA M., MAS R., JIMENEZ S., MENDOZA N. EFFECTS OF D-002 (BEESWAX ALCOHOLS) ON LUNG LEUKOCYTE INFILTRATION AND LIPID PEROXIDATION IN RATS WITH CARRAGEENAN-INDUCED PLEURISY, INT J PHARM SCIENC REVIEW RES, (2014); MENENDEZ R., FRAGA V., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEH, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., AMOR A.M., GONZALEZ R.M., MAS R., PEREZ Y., JIMENEZ S., INHIBITION OF RAT MICROSOMAL LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-002, BRAZIL J MED BIOL RES, 33, PP. 85-90, (2000); RODRIGUEZ I., ILLNAIT J., FERNANDEZ L., MENDOSA S., MAS R., FERNANDEZ J.C., ET AL., COMPARATIVE ANTIOXIDANT EFFECTS OF BEESWAX ALCOHOLS AND GRAPE SEED EXTRACT IN HEALTHY PERSONS, LAJP, 29, PP. 255-262, (2010); PEREZ Y., MAS R., OYARZABAL A., JIMENEZ S., MOLINA V., EFFECTS OF POLICOSANOL (SUGAR CANE WAX ALCOHOLS) AND D-003 (SUGARCANE WAX ACIDS) ON CYCLOOXYGENASE (COX) ENZYME ACTIVITY IN VITRO, IJPSRR, 19, 2, PP. 18-23, (2013); PEREZ Y., OYARZABAL A., MAS R., JIMENEZ S., MOLINA V., PEREZ GUERRA Y., ET AL., IN VITRO EFFECTS OF POLICOSANOL (SACCHARUM OFFICINARUM L WAX ALCOHOLS) ON THE 5-LIPOOXYGENASE ENZYME, REV CUBANA FARM, 48, 1, PP. 139-145, (2014); PEREZ Y., OYARZABAL A., RAVELO Y., MAS R., JIMENEZ S., MOLINA V., INHIBITION OF CICLOOXYGENASE AND 5-LIPOOXYGENASE ENZYMES BY D-002 (BEESWAX ALCOHOLS), CURRENT TOP NUTRA RES, (2014); BOYUM A., IN IODINATED DENSITY GRADIENT MEDIA, A PRACTICAL APPROACH, PP. 147-170, (1983); NEERAJA S., RAMAKRISHNA B., SREENATH A.S., REDDY G.V., REDDY P., REDDANNA P., NOVEL FUNCTIONAL ASSOCIATION OF RAT TESTICULAR MEMBRANE-ASSOCIATED CYTOSOLIC GLUTATHIONE S TRANSFERASES AND CYCLOOXYGENASE IN VITRO, ASIAN J ANDROL, 7, 2, PP. 171-178, (2005); ABAD M.J., BERMEJO P., VALVERDE S., VILLAR A., ANTI-INFLAMMATORY ACTIVITY OF HYDROXYACHILLIN A ESQUUITERPENE LACTONE FROM TANACETUM MICROPHYLLUM, PLANTA MED, 60, PP. 228-230, (1994); TATESON J.E., RANDALL R.W., REYNOLDS C.H., JACKSON WP, BHATTACHERJEE P, SALMON JA, ET AL. SELECTIVE INHIBITION OF ARACHIDONATE 5 –LIPOXYGENASE BY A NOVEL ACETOHYDROXAMIC ACIDS: BIOCHEMICAL ASSESSMENT IN VITRO AND EX VIVO, BR J PHARMACOL, 94, PP. 528-539, (1988); MARXWELL M.A., HAAS S.M., BEIBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-209, (1987); BLANCO F.J., GUITIAN R., MORENO J., DE TORO F.J., GALDO F., EFFECT OF ANTIINFLAMMATORY DRUGS ON COX-1 AND COX-2 ACTIVITY IN HUMAN ARTICULAR CHONDROCYTES, J RHEUMATOL, 26, 6, PP. 1366-1373, (1999); DUGAS B., LYPRINOL INHIBITS LTB4 PRODUCTION BY HUMAN MONOCYTES, ALLERG IMMUNOL (PARIS), 32, 7, PP. 284-289, (2000); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, 3, PP. 155-162, (2009); OHTA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, J CLIN BIOCHEM NUTR, 42, 2, PP. 118-125, (2008); WARREN R.P., BURGER R.A., SIDWELL R.W., CLARK L.L., EFFECT OF TRIACONTANOL ON NUMBERS AND FUNCTIONS OF CELLS INVOLVED IN INFLAMMATORY RESPONSES, PROC SOC EXP BIOL MED, 200, 3, PP. 349-352, (1992)","Y.P. GUERRA; PLAYA, C. HABANA, CALLE 198 E/ 19 Y 21 ATABEY, CUBA; EMAIL: YOHANI.PEREZ@CNIC.EDU.CU","EDITORIAL CIENCIAS MEDICAS","ENGLISH","REV. CUBA. FARM.","ARTICLE","ISI","2-S2.0-84954528628","REV CUBA FARM","CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"GUERRA YP, 2015, REV CUBA FARM","GUERRA YP, 2015, REV CUBA FARM"
"ZANARDI M;QUIRICO E;BENVENUTI C;PEZZANA A","ZANARDI, M. (56437471400); QUIRICO, E. (47561826600); BENVENUTI, C. (7101839008); PEZZANA, A. (6603942398)","USE OF A LIPIDLOWERING FOOD SUPPLEMENT IN PATIENTS ON HORMONE THERAPY FOLLOWING BREAST CANCER",2012,"MINERVA GINECOLOGICA","64","4",10,"","S.O.S.D. DIETETICA E NUTRIZIONE CLINICA, PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO, TURIN, ITALY;S.O.S.D. DIETETICA E NUTRIZIONE CLINICA, PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO, TURIN, ITALY;MEDICAL DEPARTMENT, ROTTAPHARM/MADAUS, MONZA, ITALY;S.O.S.D. DIETETICA E NUTRIZIONE CLINICA, PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO, TURIN, ITALY","AIM. THE AIM OF THIS PAPER WAS TO DETERMINE THE ACTIVITY OF A NATURAL NUTRACEUTICALS COMBINATION (AP=BERBERINE+RED YEAST RICE) ON DYSLIPIDEMIA WHICH FREQUENTLY PERSISTS AFTER LIFE STYLE CHANGES IN PATIENTS ON HORMONE-THERAPY FOLLOWING BREAST CANCER (HT-BC). METHODS. TWENTY-ONE HT-BC PATIENTS, FREE OF TUMOR, MEAN AGE 59.9 YEARS, BMI 28,9 KG/M2, WAIST CIRCUMFERENCE 95.9 CM, WITH ALTERED LIPID PROFILE (TOTAL CHOLESTEROL 269.0 MG/DL, HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL 54.9 MG/DL, LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL 184.0 MG/DL, AND TRIGLYCERIDES 263.3 MG/DL) WERE RECRUITED. THEY WERE RECOMMENDED A 3-MONTH PERIOD OF DIET FOLLOWED BY A 3-MONTH PERIOD OF TREATMENT WITH AP 1 TABLET/DAY. AP TABLETS CONTAIN BERBERINE 500 MG, RED YEAST RICE EXTRACT 200 MG (EQUIVALENT TO 3 MG MONACOLINS), POLICOSANOL 10 MG, FOLIC ACID 0.2 MG, COENZYME Q10 2 MG, AND ASTHAXANTIN 0.5 MG. RESULTS. THE LIPID PROFILE WAS SIGNIFICANTLY IMPROVED BY AP VS. DIET: 1.8% DECREASE IN TOTAL CHOLESTEROL ON DIET AND A FURTHER 15.3% DECREASE WITH AP VS. DIET (P<0.001); A 3.1% DECREASE IN LDL CHOLESTEROL AFTER DIET AND AN 18.9% DECREASE AFTER AP TREATMENT VS DIET ALONE (P<0.01); A 2.3% DECREASE IN TRIGLYCERIDES AFTER DIET ALONE AND A 36.5% DECREASE AFTER AP VS. DIET (P<0.05). CONCLUSION. ADEQUATE LIFE STYLE THERAPY IS EFFECTIVE IN REDUCING, BUT NOT IN NORMALIZING, THE LIPID PROFILE IN PATIENTS ON HORMONE-THERAPY FOLLOWING BREAST CANCER. THE USE OF NATURAL NUTRACEUTICALS AS AP, COMBINED WITH DIET, LEADS TO A GOOD THERAPEUTIC RESPONSE AND OPTIMAL ACCEPTANCE BY THE PATIENTS.","BERBERINE; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; HORMONES","ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BERBERINE; BIOLOGICAL AGENTS; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MIDDLE AGED; PILOT PROJECTS; TAMOXIFEN; ARMOLIPID PLUS; ASTAXANTHIN; BERBERINE; CHOLESTEROL; CHOLESTIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONACOLIN J; NUTRACEUTICAL; POLICOSANOL; TAMOXIFEN; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DYSLIPIDEMIA; FEMALE; HORMONAL THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; PHYSICAL ACTIVITY; PILOT STUDY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE","","","ALIEV D.A., AZIZOV V.A., SADYGOVA T.A., ZEINALOV R.S., MUSEV I.N., LIPID METABOLISM DISORDERS AT THE BREAST CANCER PATIENTS RECEIVING HORMONOTHERAPY, GEORGIAN MED NEWS, 168, PP. 44-47, (2009); PEREZ E.A., SAFETY PROFILES OF TAMOXIFENE AND THE AROMATASE INHIBITORS IN ADJUVANT THERAPY OF HORMONE-RESPONSIVE EARLY BREAST CANCER, ANN ONCOL, 18, SUPPL. 8, (2007); CICERO A.F.G., BENVENUTI C., ARMOWEB STUDY GROUP EFFICACY OF A RED YEAST RICE BASED NUTRACEUTICAL IN LARGE SUBGROUPS OF HYPERCHOLESTEROLEMIC SUBJECTS IN EVERY DAY CLINICAL PRACTICE, MEDITERR J NUTR METAB, 3, PP. 239-246, (2010); CICERO A.F.G., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIM-FORSCH (DRUG RESEARCH), 57, PP. 26-30, (2007); GUIDELINES FOR CANCER PREVENTION, (2007); COLOMBO C., MUTI P., PALA V., CAVALLERI A., VENTURELLI E., LOCARDI M., ET AL., PLANT-BASED DIET, SERUM FATTY ACID PROFILE, AND FREE RADICALS IN POSTMENOPAUSAL WOMEN: THE DIET AND ANDROGENS (DIANA) RANDOMIZED TRIAL, INT J BIOL MARKERS, 20, PP. 169-176, (2005); AGNOLI C., BERRINO F., ABAGNATO C.A., MUTI P., PANICO S., CROSIGNANI P., ET AL., METABOLIC SYNDROME AND POSTMENOPAUSAL BREAST CANCER IN THE ORDET COHORT: A NESTED CASE-CONTROL STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 41-48, (2010); CLEARY M.P., GROSSMANN M.E., RAY A., EFFECT OF OBESITY ON BREAST CANCER DEVELOPMENT, VET PATHOL, 47, PP. 202-213, (2010); JONES L.W., HAYKOWSKY M.J., SWARTZ J.J., DOUGLAS P.S., MACKEY J.R., EARLY BREAST CANCER THERAPY AND CARDIOVASCULAR INJURY, J AM COLL CARDIOL, 50, PP. 1435-1441, (2007); IRWIN M.L., CRUMLEY D., MCTIERNAN A., BERNSTEIN L., BAUMGARTNER R., GILLILAND F.D., ET AL., PHYSICAL ACTIVITY LEVELS BEFORE AND AFTER A DIAGNOSIS OF BREAST CARCINOMA: THE HEALTH, EATING, ACTIVITY AND LIFESTYLE (HEAL) STUDY, CANCER, 97, PP. 1746-1757, (2003); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN SUBJECTS WITH DYSLIPIDEMIA, J HYPERTENSION, 28, PP. 1482-1487, (2010); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, (2010); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MEDITER J NUTR METABOL, 4, PP. 13-19, (2011); CICERO A.F.G., DEROSA G., BOVE M., BORGHI C., GADDI A.V., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOPICS NUTRAC RES, 7, PP. 121-126, (2009)","M. ZANARDI; S.O.S.D. DIETETICA E NUTRIZIONE CLINICA, PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO, TURIN, ITALY; EMAIL: MICHELA.ZANARDI@ASLTO2NORD.IT","","ENGLISH","MINERVA GINECOL.","ARTICLE","ISI","2-S2.0-84869204891","MINERVA GINECOL","PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO;PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO;PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO","NOTREPORTED;PRESIDIO OSPEDALIERO TORINO NORD EMERGENZA SAN GIOVANNI BOSCO;NOTREPORTED",NA,"ZANARDI M, 2012, MINERVA GINECOL","ZANARDI M, 2012, MINERVA GINECOL"
"ZOU X;SI Q","ZOU, XIAO (56011159200); SI, QUAN-JIN (8629813000)","IS COMBINED LIPIDREGULATING THERAPY SAFE AND FEASIBLE FOR THE VERY OLD PATIENTS WITH MIXED DYSLIPIDEMIA",2013,"JOURNAL OF GERIATRIC CARDIOLOGY","10","5",4,"10.3969/j.issn.1671-5411.2013.04.014","FIRST DEPARTMENT OF THE GERIATRIC CARDIOLOGY, CHINESE PLA GENERAL HOSPITAL, BEIJING 100853, NO. 28, FUXING ROAD, CHINA;FIRST DEPARTMENT OF THE GERIATRIC CARDIOLOGY, CHINESE PLA GENERAL HOSPITAL, BEIJING 100853, NO. 28, FUXING ROAD, CHINA","OBJECTIVES: TO DETECT THE EFFICACY AND SAFETY OF COMBINED LIPID-REGULATING THERAPIES IN THE VERY OLD PATIENTS WITH MIXED DYSLIPIDEMIA AND DETERMINE AN APPROPRIATE THERAPY FOR THEM. METHODS: FOUR HUNDRED AND FIFTY PATIENTS AGED OVER 75 WITH MIXED DYSLIPIDEMIA WERE DIVIDED INTO FIVE GROUPS ACCORDING TO DIFFERENT COMBINATION THERAPIES. LIPID LEVELS AND DRUG RELATED ADVERSE EVENTS WERE TESTED DURING THE STUDY. RESULTS: TOTAL CHOLESTEROL (TC) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS WERE REDUCED IN EVERY GROUP COMPARED TO BASELINE: STATIN + EZETIMIBE: -30.0% AND -55.5%; STATIN + POLICOSANOL: -31.1% AND -51.2%; STATIN + FIBRATES: -23.7% AND -44.6%; STATIN + NIACIN: -25.2% AND -43.0%; AND NIACIN + FIBRATES: -11.3% AND -23.5%. THE TARGET ACHIEVEMENT RATES OF LDL-C ALL EXCEEDED 50%, EXCEPT IN NIACIN + FIBRATES (42.0%); STATIN + EZETIMIBE: 57.0%; STATIN + POLICOSANOL: 56.0%; STATIN + NIACIN: 52.0%; AND STATIN + FIBRATES: 50.0%. HOWEVER, OVERALL, THE NIACIN + FIBRATES GROUP WAS THE MOST EFFECTIVE IN DECREASING TRIGLYCERIDE (TG) AND INCREASING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AS FOLLOWS: NIACIN + FIBRATES: -39.3% AND 28.6%; STATIN + FIBRATES: -29.3% AND 18.4%; STATIN + NIACIN: -18.5% AND 16.7%; STATIN + EZETIMIBE: -17.1% AND 7.1%; AND STATIN + POLICOSANOL: -15.6% AND 9.5%. THE ACHIEVEMENT RATES OF TG AND HDL-C LEVELS IN NIACIN + FIBRATES (58.0% AND 39.0%) WERE BETTER THAN THE OTHER FOUR GROUPS: STATIN + NIACIN (34.0% AND 34.0%), STATIN + FIBRATES (43.0% AND 28.0%), STATIN + POLICOSANOL (30.0% AND 24.0%) AND STATIN + EZETIMIBE (28.0% AND 25.0%). PATIENTS IN ALL FIVE GROUPS EXPERIENCING DRUG ADVERSE EVENTS WERE ONLY 2% AND NO SEVERE ADVERSE EVENTS OCCURRED. CONCLUSIONS: STATIN + EZETIMIBE WAS THE MOST EFFECTIVE GROUP IN LOWERING TC AND LDL-C LEVELS, WHILE NIACIN + FIBRATES WAS THE MOST EFFECTIVE IN DECREASING TG AND INCREASING HDL-C LEVELS. THE COMMONLY USED COMBINED LIPID-REGULATING THERAPIES WITH COMMON DOSAGES IN THIS STUDY WERE ALL QUITE SAFE AND FEASIBLE FOR THE VERY OLD PATIENTS WITH MIXED HYPERLIPIDEMIA. © 2013 JGC ALL RIGHTS RESERVED.","COMBINATION THERAPIES; ELDERLY PATIENTS; MIXED DYSLIPIDEMIA; SAFETY","ACIPIMOX; AGENTS AFFECTING LIPID METABOLISM; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; POLICOSANOL; TRIACYLGLYCEROL; ABDOMINAL PAIN; AGED; ARTICLE; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPNEA; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYOPATHY; RHABDOMYOLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VERY ELDERLY","","","NATARAJAN P., RAY K.K., CANNON C.P., HIGH DENSITY LIPOPROTEIN AND CORONARY HEART DISEASE: CURRENT AND FUTURE THERAPIES, J AM COLL CARDIOL, 55, PP. 1283-1299, (2010); CHAPMAN M.J., REDFERN J.S., MCGOVERN M.E., ET AL., NIACIN AND FIBRATES IN ATHEROGENIC DYSLIPIDEMIA: PHARMACOTHERAPY TO REDUCE CARDIOVASCULAR RISK, PHARMACOL THER, 126, PP. 314-345, (2010); DASKALOPOULOU S.S., MIKHAILIDIS D.P., REACHING GOAL IN HYPERCHOLESTEROLAEMIA: DUAL INHIBITION OF CHOLESTEROL SYNTHESIS AND ABSORPTION WITH SIMVASTATIN PLUS EZETIMIBE, CURR MED RES OPIN, 22, PP. 511-528, (2006); STEIN E.A., MANAGING DYSLIPIDEMIA IN THE HIGH-RISK PATIENT, AM J CARDIOL, 89, 5 A, (2002); JOINT COMMITTEE FOR DEVELOPING CHINESE GUIDELINES ON PREVENTION AND TREATMENT OF DYSLIPIDEMIA IN ADULTS. CHINESE GUIDELINES ON PREVENTION AND TREATMENT OF DYSLIPIDEMIA IN ADULTS, CHIN J CARDIOL, 35, PP. 390-419, (2007); WU Y.F., LIU X.Q., LI X., ET AL., USA-PRC COLLABORATIVE STUDY OF CARDIOVASCULAR AND CARDIOPULMONARY EPIDEMIOLOGY RESEARCH GROUP; CHINA MULTICENTER COLLABORATIVE STUDY OF CARDIOVASCULAR EPIDEMIOLOGY RESEARCH GROUP. ESTIMATION OF TEN-YEAR RISK OF FATAL AND NON-FATAL ISEHEMIC CARDIOVASCULAR DISEASES IN CHINESE, CIRCULATION, 114, PP. 2217-2225, (2006); LA ROSA J.C., PEDERSEN T.R., SOMARATNE R., ET AL., SAFETY AND EFFECT OF VERY LOW LEVELS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON CARDIOVASCULAR EVENTS, AM J CARDIOL, 111, PP. 1221-1229, (2013); KASHANI A., PHILLIPS C.O., FOODY J.M., ET AL., RISKS ASSOCIATED WITH STATIN THERAPY: A SYSTEMATIC OVERVIEW OF RANDOMIZED CLINICAL TRIALS, CIRCULATION, 114, PP. 2788-2797, (2006); SILVA M., MATTHEWS M.L., JARVIS C., ET AL., META-ANALYSIS OF DRUG-INDUCED ADVERSE EVENTS ASSOCIATED WITH INTENSIVEDOSE STATIN THERAPY, CLIN THER, 29, PP. 253-260, (2007); KASHANI A., SALLAM T., BHEEMREDDY S., ET AL., REVIEW OF SIDEEFFECT PROFILE OF COMBINATION EZETIMIBE AND STATIN THERAPY IN RANDOMIZED CLINICAL TRIALS, AM J CARDIOL, 101, PP. 1606-1613, (2008); HAUSENLOY D.J., YELLON D.M., ENHANCING CARDIOVASCULAR DISEASE RISK REDUCTION: RAISING HIGH-DENSITY LIPOPROTEIN LEVELS, CURR OPIN CARDIOL, 24, PP. 473-482, (2009); SPRECHER D.L., RAISING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH NIACIN AND FIBRATES: A COMPARATIVE REVIEW, AM J CARDIOL, 86, (2000); MUREDDU G.F., BRANDIMARTE F., DE LUCA L., HIGH-DENSITY LIPOPROTEIN LEVELS AND RISK OF CARDIOVASCULAR EVENTS: A REVIEW, J CARDIOVASC MED (HAGERSTOWN), 13, PP. 575-586, (2012); TAYLOR A.J., EVIDENCE TO SUPPORT AGGRESSIVE MANAGEMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: IMPLICATIONS OF RECENTIMAGING TRIALS, AM J CARDIOL, 101, (2008); HU D.-Y., ADVANCE IN DYSLIPIDEMIA TREATMENT IN 2010, CHIN J NEW DRUGS, 20, PP. 1358-1361, (2011); MCKENNEY J.M., COMBINATION TREATMENT WITH ATORVASTATIN PLUS NIACIN PROVIDES EFFECTIVE CONTROL OF COMPLEX DYSLIPIDEMIAS: A LITERATURE REVIEW, POSTGRAD MED, 124, PP. 7-20, (2012); MOHIUDDIN S.M., THAKKER K.M., SETZE C.M., ET AL., EVALUATING OPTIMAL LIPID LEVELS IN PATIENTS WITH MIXED DYSLIPIDEMIA FOLLOWING SHORT- AND LONG-TERM TREATMENT WITH FENOFIBRIC ACID AND STATIN COMBINATION THERAPY: A POST HOC ANALYSIS, CURR MED RES OPIN, 27, PP. 1067-1078, (2011); BAYS H.E., OSE L., FRASER N., ET AL., A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FACTORIAL DESIGN STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND SAFETY PROFILE OF THE EZETIMIBE/SIMVASTATIN TABLET COMPARED WITH EZETIMIBE AND SIMVASTATIN MONOTHERAPY IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CLIN THER, 26, PP. 1758-1773, (2004); BACKES J.M., GIBSON C.A., RUISINGER J.F., ET AL., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); REINER Z., COMBINED THERAPY IN THE TREATMENT OF DYSLIPIDEMIA, FUNDAM CLIN PHARMACOL, 24, PP. 19-28, (2010); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., ET AL., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); WATTS G.F., KARPE F., REPUBLISHED REVIEW: TRIGLYCERIDES AND ATHEROGENIC DYSLIPIDAEMIA: EXTENDING TREATMENT BEYOND STATINS IN THE HIGH-RISK CARDIOVASCULAR PATIENT, POSTGRAD MED J, 87, PP. 776-782, (2011); UEMURA Y., WATARAI M., ISHII H., ET AL., ATORVASTATIN 10 MG PLUS EZETIMIBE 10 MG COMPARED WITH ATORVASTATIN 20 MG: IMPACT ON THE LIPID PROFILE IN JAPANESE PATIENTS WITH ABNORMAL GLUCOSE TOLERANCE AND CORONARY ARTERY DISEASE, J CARDIOL, 59, PP. 50-56, (2012); EFRATI S., AVERBUKH M., DISHY V., ET AL., THE EFFECT OF SIMVASTATIN, EZETIMIBE AND THEIR COMBINATION ON THE LIPID PROFILE, ARTERIAL STIFFNESS AND INFLAMMATORY MARKERS, EUR J CLIN PHARMACOL, 63, PP. 113-121, (2007); LEE Y.H., KIM M.J., CHOI C.I., ET AL., RETROSPECTIVE STUDY ON ANTIHYPERLIPIDEMIC EFFICACY AND SAFETY OF SIMVASTATIN, EZETIMIBE AND THEIR COMBINATION IN KOREAN ADULTS, ARCH PHARM RES, 34, PP. 1331-1337, (2011); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); DAVIDSON M.H., MACCUBBIN D., STEPANAVAGE M., ET AL., STRIATED MUSCLE SAFETY OF EZETIMIBE/SIMVASTATIN (VYTORIN), AM J CARDIOL, 97, PP. 223-228, (2006)","Q.-J. SI; FIRST DEPARTMENT OF THE GERIATRIC CARDIOLOGY, CHINESE PLA GENERAL HOSPITAL, BEIJING 100853, NO. 28, FUXING ROAD, CHINA; EMAIL: QUANJIN2004@SOHU.COM","","ENGLISH","J. GERIATR. CARDIOL.","ARTICLE","ISI","2-S2.0-84892728979","J GERIATR CARDIOL","CHINESE PLA GENERAL HOSPITAL;CHINESE PLA GENERAL HOSPITAL","NOTREPORTED;CHINESE PLA GENERAL HOSPITAL;NOTREPORTED",NA,"ZOU X, 2013, J GERIATR CARDIOL","ZOU X, 2013, J GERIATR CARDIOL"
"BARRAT E;ZAÏR Y;SIRVENT P;CHAUVEAU P;MAUDET C;HOUSEZ B;DERBORD E;LESCUYER J;BARD J;CAZAUBIEL M;PELTIER S","BARRAT, EMMANUEL (24597059800); ZAÏR, YASSINE (6602320134); SIRVENT, PASCAL (9242425900); CHAUVEAU, PATRICE (55533807900); MAUDET, CORINNE (55533406200); HOUSEZ, BÉATRICE (39261486200); DERBORD, ELODIE (55533923100); LESCUYER, JEAN-FRANÇOIS (54796767200); BARD, JEAN-MARIE (7202839766); CAZAUBIEL, MURIELLE (25421045100); PELTIER, SÉBASTIEN L. (23390396700)","EFFECT ON LDLCHOLESTEROL OF A LARGE DOSE OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH UNTREATED MODERATE HYPERCHOLESTEROLAEMIA A RANDOMISED DOUBLEBLIND PLACEBOCONTROLLED STUDY",2013,"EUROPEAN JOURNAL OF NUTRITION","52","9",26,"10.1007/s00394-012-0486-2","DEPARTMENT OF RESEARCH, LABORATOIRE LESCUYER, 17442 AYTRÉ CEDEX, BP 33, FRANCE;DEPARTMENT OF ENDOCRINOLOGY, L'INSTITUT DU THORAX, NANTES UNIVERSITY HOSPITAL, 44007 NANTES CEDEX 1, BP 70721, FRANCE;EA 3533, LABORATOIRE DES ADAPTATIONS METABOLIQUES A L'EXERCICE EN CONDITIONS PHYSIOLOGIQUES ET PATHOLOGIQUES, UNIVERSITÉ BLAISE PASCAL, 63000 CLERMONT-FERRAND, BP 10448, FRANCE;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, 44800 SAINT-HERBLAIN, 3 ROUTE DE LA CHATTERIE, FRANCE;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, 44800 SAINT-HERBLAIN, 3 ROUTE DE LA CHATTERIE, FRANCE;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, 44800 SAINT-HERBLAIN, 3 ROUTE DE LA CHATTERIE, FRANCE;DEPARTMENT OF RESEARCH, LABORATOIRE LESCUYER, 17442 AYTRÉ CEDEX, BP 33, FRANCE;DEPARTMENT OF RESEARCH, LABORATOIRE LESCUYER, 17442 AYTRÉ CEDEX, BP 33, FRANCE;LUNAM, EA2160 NANTES ET INSTITUT DE CANCÉROLOGIE DE L'OUEST, 44800 SAINT-HERBLAIN, FRANCE;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, 44800 SAINT-HERBLAIN, 3 ROUTE DE LA CHATTERIE, FRANCE;DEPARTMENT OF RESEARCH, LABORATOIRE LESCUYER, 17442 AYTRÉ CEDEX, BP 33, FRANCE","PURPOSE: TO DETERMINE THE EFFECT OF 4 WEEKS OF SUPPLEMENTATION, THEN, WITHDRAWAL OF A DIETARY SUPPLEMENT (DS) CONTAINING RED YEAST RICE EXTRACT, POLICOSANOL AND ARTICHOKE LEAF EXTRACT AT TWICE THE RECOMMENDED DAILY DOSE (6 TABLETS, 6-TAB) COMPARED TO THE USUAL DOSE (3-TAB) OR TO A PLACEBO (PLA), ON BLOOD LIPID PROFILES AND SAFETY BIOMARKERS. METHODS: FORTY-FIVE HEALTHY SUBJECTS (15 PER GROUP), WITH UNTREATED HYPERCHOLESTEROLAEMIA, WERE INCLUDED IN THIS RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL. RESULTS: AFTER 4 WEEKS OF SUPPLEMENTATION, LDL-C WAS SIGNIFICANTLY LOWER IN 6-TAB (-0.21 G/L; 95 % CI -0.38 TO -0.03 G/L; P = 0.0217) AND 3-TAB (-0.25 G/L; 95 % CI -0.42 TO -0.07 G/L; P = 0.0071) COMPARED TO PLA, ALTHOUGH NO DIFFERENCE IN LDL-CHOLESTEROL WAS OBSERVED BETWEEN THE TWO GROUPS, WHILE NO EFFECT WAS SEEN ON TRIACYLGLYCEROL AND HDL-CHOLESTEROL. FOUR WEEKS AFTER THE END OF SUPPLEMENTATION, NO DIFFERENCE IN LDL-C WAS SEEN BETWEEN THE PLA GROUP AND THE DS-TREATED GROUPS. THE MUSCLE BREAKDOWN BIOMARKERS, AS WELL AS BIOMARKERS OF LIVER AND RENAL FUNCTION, WERE ALTERED BY NEITHER DOSE OF THE DS. ACUTE APPLICATION OF THE DS ON PERMEABILISED SKELETAL MUSCLE FIBRES OF RATS DID NOT INDUCE DELETERIOUS EFFECTS ON MITOCHONDRIAL FUNCTION. CONCLUSIONS: SUPPLEMENTATION WITH TWICE THE RECOMMENDED DOSE OF THE DS WAS EFFECTIVE IN REDUCING LDL-CHOLESTEROL AND APPEARED SAFE, BUT ACCORDING TO THE PRESENT RESULTS, NO ADDITIONAL BENEFIT COULD BE ACHIEVED COMPARED TO THE RECOMMENDED DOSE. © 2012 SPRINGER-VERLAG BERLIN HEIDELBERG.","ARTICHOKE LEAF EXTRACT; MUSCLE BREAKDOWN; POLICOSANOLS; RED YEAST RICE; WITHDRAWAL","ADOLESCENT; ADULT; AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYNARA SCOLYMUS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; MIDDLE AGED; MITOCHONDRIA; MUSCLE, SKELETAL; PLANT EXTRACTS; PLANT LEAVES; RATS; RATS, WISTAR; RECOMMENDED DIETARY ALLOWANCES; TRIGLYCERIDES; YOUNG ADULT; CYNARA SCOLYMUS; RATTUS; ARTICHOKE LEAF EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLANT EXTRACT; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG; ADULT; ANIMAL CELL; ARTICHOKE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PATIENT SAFETY; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT","","","REINER Z., CATAPANO A.L., DE BACKER G., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, 14, PP. 1769-1818, (2011); SMITH JR.S.C., BENJAMIN E.J., BONOW R.O., ET AL., AHA/ACCF SECONDARY PREVENTION AND RISK REDUCTION THERAPY FOR PATIENTS WITH CORONARY AND OTHER ATHEROSCLEROTIC VASCULAR DISEASE: 2011 UPDATE: A GUIDELINE FROM THE AMERICAN HEART ASSOCIATION AND AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION, CIRCULATION, 124, 22, PP. 2458-2473, (2011); MANCINI G.B., BAKER S., BERGERON J., ET AL., DIAGNOSIS, PREVENTION, AND MANAGEMENT OF STATIN ADVERSE EFFECTS AND INTOLERANCE: PROCEEDINGS OF A CANADIAN WORKING GROUP CONSENSUS CONFERENCE, CAN J CARDIOL, 27, 5, PP. 635-662, (2011); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, 12, PP. 1689-1693, (2008); KLIMEK M., WANG S., OGUNKANMI A., SAFETY AND EFFICACY OF RED YEAST RICE (MONASCUS PURPUREUS) AS AN ALTERNATIVE THERAPY FOR HYPERLIPIDEMIA, PHARM THER, 34, 6, PP. 313-327, (2009); WIDER B., PITTLER M.H., THOMPSON-COON J., ET AL., ARTICHOKE LEAF EXTRACT FOR TREATING HYPERCHOLESTEROLAEMIA, COCHRANE DATABASE SYST REV, 4, (2009); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); OGIER N., AMIOT M.J., GEORGE S., ET AL., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR J NUTR, (2012); SIRVENT P., MERCIER J., LACAMPAGNE A., NEW INSIGHTS INTO MECHANISMS OF STATIN-ASSOCIATED MYOTOXICITY, CURR OPIN PHARMACOL, 8, 3, PP. 333-338, (2008); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, 6, PP. 499-502, (1972); SIRVENT P., BORDENAVE S., VERMAELEN M., ET AL., SIMVASTATIN INDUCES IMPAIRMENT IN SKELETAL MUSCLE WHILE HEART IS PROTECTED, BIOCHEM BIOPHYS RES COMMUN, 338, 3, PP. 1426-1434, (2005); SAKS V.A., VEKSLER V.I., KUZNETSOV A.V., ET AL., PERMEABILIZED CELL AND SKINNED FIBER TECHNIQUES IN STUDIES OF MITOCHONDRIAL FUNCTION IN VIVO, MOL CELL BIOCHEM, 184, 1-2, PP. 81-100, (1998); JIANG F.Y., SUN L.P., YANG J., EFFECTS OF XUEZHIKANG AT DIFFERENT DOSES ON PATIENTS SUFFERING FROM ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, 31, 12, PP. 1607-1610, (2011); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, 1, PP. 27-33, (1994); CROUSE III J.R., LUKACSKO P., NIECESTRO R., ET AL., DOSE RESPONSE, SAFETY, AND EFFICACY OF AN EXTENDED-RELEASE FORMULATION OF LOVASTATIN IN ADULTS WITH HYPERCHOLESTEROLEMIA, AM J CARDIOL, 89, 2, PP. 226-229, (2002); HUNNINGHAKE D.B., KNOPP R.H., SCHONFELD G., ET AL., EFFICACY AND SAFETY OF PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. I. A DOSE-RESPONSE STUDY, ATHEROSCLEROSIS, 85, 1, PP. 81-89, (1990); JACOTOT B., BANGA J.D., PFISTER P., ET AL., EFFICACY OF A LOW DOSE-RANGE OF FLUVASTATIN (XU 62-320) IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA. A DOSE-RESPONSE STUDY IN 431 PATIENTS. THE FRENCH-DUTCH FLUVASTATIN STUDY GROUP, BR J CLIN PHARMACOL, 38, 3, PP. 257-263, (1994); SAITO Y., GOTO Y., DANE A., ET AL., RANDOMIZED DOSE-RESPONSE STUDY OF ROSUVASTATIN IN JAPANESE PATIENTS WITH HYPERCHOLESTEROLEMIA, J ATHEROSCLER THROMB, 10, 6, PP. 329-336, (2003); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, 2, PP. 231-236, (1999); ENGLISCH W., BECKERS C., UNKAUF M., ET AL., EFFICACY OF ARTICHOKE DRY EXTRACT IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ARZNEIMITTELFORSCHUNG, 50, 3, PP. 260-265, (2000); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, 2, PP. 55-66, (2002); CHEN H., REN J.Y., XING Y., ET AL., SHORT-TERM WITHDRAWAL OF SIMVASTATIN INDUCES ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE: A DOSE-RESPONSE EFFECT DEPENDENT ON ENDOTHELIAL NITRIC OXIDE SYNTHASE, INT J CARDIOL, 131, 3, PP. 313-320, (2009); TOMASZEWSKI M., STEPIEN K.M., TOMASZEWSKA J., ET AL., STATIN-INDUCED MYOPATHIES, PHARMACOL REP, 63, 4, PP. 859-866, (2011); KAUFMANN P., TOROK M., ZAHNO A., ET AL., TOXICITY OF STATINS ON RAT SKELETAL MUSCLE MITOCHONDRIA, CELL MOL LIFE SCI, 63, 19-20, PP. 2415-2425, (2006); KWAK H.B., THALACKER-MERCER A., ANDERSON E.J., ET AL., SIMVASTATIN IMPAIRS ADP-STIMULATED RESPIRATION AND INCREASES MITOCHONDRIAL OXIDATIVE STRESS IN PRIMARY HUMAN SKELETAL MYOTUBES, FREE RADICAL BIOL MED, 52, 1, PP. 198-207, (2012); SIRVENT P., FABRE O., BORDENAVE S., ET AL., MUSCLE MITOCHONDRIAL METABOLISM AND CALCIUM SIGNALING IMPAIRMENT IN PATIENTS TREATED WITH STATINS, TOXICOL APPL PHARMACOL, 259, 2, PP. 263-268, (2012); BOUITBIR J., CHARLES A.L., RASSENEUR L., ET AL., ATORVASTATIN TREATMENT REDUCES EXERCISE CAPACITIES IN RATS: INVOLVEMENT OF MITOCHONDRIAL IMPAIRMENTS AND OXIDATIVE STRESS, J APPL PHYSIOL, 111, 5, PP. 1477-1483, (2011)","S.L. PELTIER; DEPARTMENT OF RESEARCH, LABORATOIRE LESCUYER, 17442 AYTRÉ CEDEX, BP 33, FRANCE; EMAIL: SEBASTIEN.PELTIER@LABORATOIRE-LESCUYER.COM","","ENGLISH","EUR. J. NUTR.","ARTICLE","ISI","2-S2.0-84890565328","EUR J NUTR","LABORATOIRE LESCUYER;NANTES UNIVERSITY HOSPITAL;FRANCE;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;LABORATOIRE LESCUYER;LABORATOIRE LESCUYER;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;LABORATOIRE LESCUYER","NOTREPORTED;LABORATOIRE LESCUYER;EMAIL: SEBASTIEN.PELTIER@LABORATOIRE-LESCUYER.COM",NA,"BARRAT E, 2013, EUR J NUTR","BARRAT E, 2013, EUR J NUTR"
"LOMBARDO F;LUNGHI R;PALLOTTI F;PALUMBO A;SENOFONTE G;CEFALONI A;GANDINI L;LENZI A","LOMBARDO, F. (7101849996); LUNGHI, R. (54582493400); PALLOTTI, F. (57200572266); PALUMBO, A. (57197261862); SENOFONTE, G. (55847218300); CEFALONI, A.C. (55846782900); GANDINI, L. (7005038071); LENZI, A. (7005446458)","EFFECTS OF A DIETARY SUPPLEMENT ON CHOLESTEROL IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA",2013,"CLINICA TERAPEUTICA","164","3",6,"10.7417/CT.2013.1556","DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY;DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, UNIVERSITY SAPIENZA, ROME, ITALY","BACKGROUND AND AIMS: PROSPECTIVE STUDIES HAVE DEMONSTRATED THAT THE RISK OF DEATH DUE TO ISCHAEMIC HEART DISEASE IS STRONGLY CORRELATED WITH BLOOD CHOLESTEROL (TC) LEVELS. DIET IS THE BASIC TREATMENT FOR ALL DYSLIPIDAEMIA. IF DIET ALONE PROVES INADEQUATE, SUPPLEMENTS CAN BE USED TO TRY TO REDUCE CHOLESTEROL LEVELS. THESE SUBSTANCES ARE INDICATED IN MODERATE DYSLIPIDAEMIA, AS THEY ARE ABLE TO INDUCE A MODERATE REDUCTION IN BLOOD CHOLESTEROL. THE OBJECTIVE OF OUR STUDY WAS TO INVESTIGATE THE EFFECTS OF A DIETARY SUPPLEMENT CONTAINING OMEGA-3, POLICOSANOL, RESVERATROL, L-CARNITINE, MONASCUS PURPUREUS, COENZYME Q10, VITAMIN B6 AND VITAMIN B12 ON TC (PRIMARY END POINT) AND LDL, TRIGLYCERIDES AND HDL (SECONDARY ENDPOINTS). PATIENTS AND METHODS: THE STUDY INVOLVED 40 MEN AND 40 WOMEN RECRUITED FROM THE OUTPATIENT SECTION OF OUR DEPARTMENT RANDOMLY ASSIGNED TO THE TREATMENT GROUP (A) OR THE CONTROL GROUP (B). RESULTS: THERE WAS A STATISTICALLY SIGNIFICANT REDUCTION IN TC 6 MONTHS AFTER THE END OF TREATMENT IN BOTH GROUPS. IN GROUP A, THERE WAS ALSO A STATISTICALLY SIGNIFICANT CHANGE IN HDL, LDL AND TG, WHILE IN GROUP B, THERE WAS NO STATISTICALLY SIGNIFICANT CHANGE IN HDL, LDL OR TG. CONCLUSIONS:S THE DIETARY SUPPLEMENT USED IN OUR STUDY, IN COMBINATION WITH A BALANCED DIET AND PHYSICAL EXERCISE, WAS FOUND TO INDUCE A SIGNIFICANT REDUCTION IN TC AND LDL-C AND AN IMPROVEMENT IN HDL-C. IN CONTRAST, WHILE A BALANCED DIET TOGETHER WITH PHYSICAL EXERCISE BUT WITHOUT THE DIETARY SUPPLEMENT PRODUCED A SIGNIFICANT REDUCTION IN TC, IT HAD NO SIGNIFICANT EFFECT ON THE OTHER LIPID PARAMETERS TESTED. © SOCIETÀ EDITRICE UNIVERSO (SEU).","CHOLESTEROL; DIETARY SUPPLEMENT; NUTRACEUTICAL","CHOLESTEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; CARNITINE; CHOLESTEROL; CYANOCOBALAMIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; POLICOSANOL; PYRIDOXINE; RESVERATROL; TRIACYLGLYCEROL; UBIDECARENONE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONASCUS PURPUREUS","","","WOLF P.A., CONTRIBUTIONS OF THE FRAMINGHAM HEART STUDY TO STROKE AND DEMENTIA EPIDEMIOLOGIC RESEARCH AT 60 YEARS, ARCH NEUROL 2012, 69, 5, PP. 567-571; RELATIONSHIP OF BLOOD PRESSURE, SERUM CHOLESTEROL, SMOKING HABIT, RELATIVE WEIGHT AND ECG ABNORMALITIES TO INCIDENCE OF MAJOR CORONARY EVENTS: FINAL REPORT OF THE POOLING PROJECT, J CHRONIC DIS, 31, 4, PP. 201-306, (1978); STAMLER J., NEATON D., THE MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT) - IMPORTANCE THEN AND NOW, JAMA, 300, 11, PP. 1343-1345, (2008); HUTCHESON R., ROCIC P., THE METABOLIC SYNDROME, OXIDATIVE STRESS, ENVIRONMENT, AND CARDIOVASCULAR DISEASE: THE GREAT EXPLORATION, EXP DIABETES RES, 2012, (2012); HOOPER L., SUMMERBELL C.D., THOMPSON R., ET AL., REDUCED OR MODIFIED DIETARY FAT FOR PREVENTING CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 5, (2012); ESPOSITO K., KASTORINI C.M., PANAGIOTAKOS D.B., ET AL., MEDITERRANEAN DIET AND WEIGHT LOSS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, METAB SYNDR RELAT DISORD, 9, 1, PP. 1-12, (2011); HUANG J., FROHLICH J., IGNASZEWSKI A.P., THE IMPACT OF DIETARY CHANGES AND DIETARY SUPPLEMENTS ON LIPID PROFILE, CAN J CARDIOL, 27, 4, PP. 488-505, (2011); WILLETT W.C., DIETARY FATS AND CORONARY HEART DISEASE, J INTERN MED, 272, 1, PP. 13-24, (2012); CASCIO G., SCHIERA G., DI LIEGRO I., DIETARY FATTY ACIDS IN METABOLIC SYNDROME, DIABETES AND CARDIOVASCULAR DISEASES, CURR DIABETES REV, 8, 1, PP. 2-17, (2012); DE LORGERIL M., SALEN P., MEDITERRANEAN DIET IN SECONDARY PREVENTION OF CHD, PUBLIC HEALTH NUTR, 14, 12 A, PP. 2333-2337, (2011); LABRUNEE M., PATHAK A., LOSCOS M., ET AL., THERAPEUTIC EDUCATION IN CARDIOVASCULAR DISEASES: STATE OF THE ART AND PERSPECTIVES, ANN PHYS REHABIL MED, 55, 5, PP. 322-341, (2012); NIJJAR P.S., BURKE F.M., BLOESCH A., ET AL., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW J CLIN LIPIDOL, 4, PP. 248-258, (2010); ENDO A., HASUMI K., HMG-COA REDUCTASE INHIBITORS, NAT PROD REP, 10, 6, PP. 541-550, (1993); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, 2, PP. 231-236, (1999); JOURNOUD M., JONES P.J., RED YEAST RICE: A NEW HYPOLIPIDEMIC DRUG, LIFE SCI, 74, 22, PP. 2675-2683, (2004); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); YANG C.W., MOUSA S.A., THE EFFECT OF RED YEAST RICE (MONASCUS PURPUREUS) IN DYSLIPIDEMIA AND OTHER DISORDERS, COMPLEMENT THER MED, 20, 6, PP. 466-474, (2012); MARAZZI G., CACCIOTTI L., PELLICCIA F., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADV THER, 28, 12, PP. 1105-1113, (2011); MARINANGELI C.P., JONES P.J., KASSIS A.N., ET AL., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, 3, PP. 259-267, (2010); VOLOSHYNA I., HUSSAINI S.M., REISS A.B., RESVERATROL IN CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS J MED FOOD, 15, 9, PP. 763-773, (2012); VANG O., AHMAD N., BAILE C.A., ET AL., SYSTEMATIC REVIEW AND RECOMMENDATIONS ON THE USE OF RESVERATROL. PLOS ONE, 6, 6, (2011); BRASNYO P., MOLNAR G.A., MOHAS M., ET AL., RESVERATROL IMPROVES INSULIN SENSITIVITY, REDUCES OXIDATIVE STRESS AND ACTIVATES THE AKT PATHWAY IN TYPE 2 DIABETIC PATIENTS, BR J NUTR, 106, 3, PP. 383-389, (2011); TOME-CARNEIRO J., GONZALVEZ M., LARROSA M., ET AL., CONSUMPTION OF A GRAPE EXTRACT SUPPLEMENT CONTAINING RESVERATROL DECREASES OXIDIZED LDL AND APOB IN PATIENTS UNDERGOING PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A TRIPLE-BLIND, 6-MONTH FOLLOW-UP, PLACEBO-CONTROLLED, RANDOMIZED TRIAL, MOL NUTR FOOD RES, 56, 5, PP. 810-821, (2012); PREGNOLATO P., MARANESI M., MARCHETTI M., ET AL., INTERACTION AMONG DIETARY VITAMIN B6, PROTEINS AND LIPIDS: EFFECTS ON LIVER LIPIDS IN RATS, INT J VITAM NUTR RES, 64, 4, PP. 263-269, (1994); HLAIS S., RESLAN D.R., SARIEDDINE H.K., ET AL., EFFECT OF LYSINE, VITAMIN B6, AND CARNITINE SUPPLEMENTATION ON THE LIPID PROFILE OF MALE PATIENTS WITH HYPERTRIGLYCERIDEMIA: A 12-WEEK, OPEN-LABEL, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. CLIN THER, 34, 8, PP. 1674-1682, (2012); KARANTH J., JEEVARATNAM K., EFFECT OF CARNITINE SUPPLEMENTATION ON MITOCHONDRIAL ENZYMES IN LIVER AND SKELETAL MUSCLE OF RAT AFTER DIETARY LIPID MANIPULATION AND PHYSICAL ACTIVITY, INDIAN J EXP BIOL, 48, 5, PP. 503-510, (2010); MASSY Z.A., MA J.Z., LOUIS T.A., ET AL., LIPID-LOWERING THERAPY IN PATIENTS WITH RENAL DISEASE, KIDNEY INT, 48, 1, PP. 188-198, (1995); HUROT J.M., CUCHERAT M., HAUGH M., ET AL., EFFECTS OF L-CARNITINE SUPPLEMENTATION IN MAINTENANCE HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW, J AM SOC NEPHROL, 13, 3, PP. 708-714, (2002)","F. LOMBARDO; DEPARTMENT OF EXPERIMENTAL MEDICINE, POLICLINICO UMBERTO I, SAPIENZA UNIVERSITY OF ROME, 00161 ROME, ITALY; EMAIL: FRANCESCO.LOMBARDO@UNIROMA1.IT","","ENGLISH","CLIN. TER.","ARTICLE","ISI","2-S2.0-84883590125","CLIN TER","UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA;UNIVERSITY SAPIENZA","NOTREPORTED;SAPIENZA UNIVERSITY OF ROME;NOTREPORTED",NA,"LOMBARDO F, 2013, CLIN TER","LOMBARDO F, 2013, CLIN TER"
"ISHAKA A;IMAM M;MAHAMUD R;ZUKI A;MAZNAH I","ISHAKA, AMINU (55944603100); IMAM, MUSTAPHA UMAR (57469476100); MAHAMUD, ROZI (56157797300); ZUKI, ABU BAKAR ZAKARIA (9737771600); MAZNAH, ISMAIL (57191087465)","CHARACTERIZATION OF RICE BRAN WAX POLICOSANOL AND ITS NANOEMULSION FORMULATION",2014,"INTERNATIONAL JOURNAL OF NANOMEDICINE","9","8",40,"10.2147/IJN.S56999","LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, SELANGOR, MALAYSIA, DEPARTMENT OF MEDICAL BIOCHEMISTRY, COLLEGE OF HEALTH SCIENCES, USMANU DANFODIYO UNIVERSITY, SOKOTO, NIGERIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, SELANGOR, MALAYSIA;HEALTH SCIENCES, SERDANG, SELANGOR, MALAYSIA;UNIVERSITY PUTRA MALAYSIA, SERDANG, SELANGOR, MALAYSIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, SELANGOR, MALAYSIA","POLICOSANOL, A MIXTURE OF LONG-CHAIN ALCOHOLS FOUND IN ANIMAL AND PLANT WAXES, HAS SEVERAL BIOLOGICAL EFFECTS; HOWEVER, IT HAS A BIOAVAILABILITY OF LESS THAN 10%. THEREFORE, THERE IS A NEED TO IMPROVE ITS BIOAVAILABILITY, AND ONE OF THE WAYS OF DOING THIS IS BY NANOEMULSION FORMULATION. DIFFERENT DROPLET SIZE DISTRIBUTIONS ARE USUALLY ACHIEVED WHEN EMULSIONS ARE FORMED, WHICH SOLELY DEPENDS ON THE PREPARATION METHOD USED. MOSTLY, EMULSIONS ARE INTENDED FOR BETTER DELIVERY WITH MAINTENANCE OF THE CHARACTERISTICS AND PROPERTIES OF THE LEADING COMPONENTS. IN THIS STUDY, POLICOSANOL WAS EXTRACTED FROM RICE BRAN WAX, ITS COMPOSITION WAS DETERMINED BY GAS CHROMATOGRAPHY MASS SPECTROPHOTOMETRY, NANOEMULSION WAS MADE, AND THE PHYSICAL STABILITY CHARACTERISTICS WERE DETERMINED. THE RESULTS SHOWED THAT POLICOSANOL NANOEMULSION HAS A NANOSIZE PARTICLE DISTRIBUTION BELOW 100 NM (92.56-94.52 NM), WITH OPTIMUM CHARGE DISTRIBUTION (-55.8 TO -45.12 MV), PH (6.79-6.92) AND REFRACTIVE INDEX (1.50); THESE WERE MONITORED AND FOUND TO BE STABLE FOR 8 WEEKS. THE STABILITY OF POLICOSANOL NANOEMULSION CONFERS THE POTENTIAL TO WITHSTAND LONG STORAGE TIMES. © 2014 ISHAKA ET AL.","CHARACTERIZATION; NANOEMULSION; POLICOSANOL; RICE BRAN WAX","DRUG STABILITY; DRUG STORAGE; EMULSIONS; FATTY ALCOHOLS; MATERIALS TESTING; NANOPARTICLES; PARTICLE SIZE; PLANT EXTRACTS; PLANT OILS; WAXES; POLICOSANOL; WAX; EMULSION; FATTY ALCOHOL; NANOPARTICLE; PLANT EXTRACT; POLICOSANOL; RICE BRAN OIL; VEGETABLE OIL; WAX; ARTICLE; BIOCHEMICAL COMPOSITION; CHEMICAL ANALYSIS; CHEMICAL PARAMETERS; CONTROLLED STUDY; DRUG FORMULATION; DRUG ISOLATION; DRUG STORAGE; MASS FRAGMENTOGRAPHY; MONITORING; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL PARAMETERS; REFRACTION INDEX; RICE BRAN; SHELF LIFE; CHEMISTRY; DRUG STABILITY; EMULSION; ISOLATION AND PURIFICATION; MATERIALS TESTING; SYNTHESIS; ULTRASTRUCTURE","","","TEMPLE N.J., ANTIOXIDANTS AND DISEASE: MORE QUESTIONS THAN ANSWERS, NUTR RES, 20, 3, PP. 449-459, (2000); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA. A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN INTERN MED, 133, 6, PP. 420-429, (2000); FRANK N., ANDREWS F.M., ELLIOTT S.B., LEW J., BOSTON R.C., EFFECTS OF RICE BRAN OIL ON PLASMA LIPID CONCENTRATIONS, LIPOPROTEIN COMPOSITION, AND GLUCOSE DYNAMICS IN MARES, J ANIM SCI, 83, 11, PP. 2509-2518, (2005); TAI-SUN S., GODBER J.S., ISOLATION OF FOUR TOCOPHEROLS AND FOUR TOCOTRIENOLS FROM A VARIETY OF NATURAL SOURCES BY SEMI-PREPARATIVE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, J CHROMATOGRAPHY A, 678, 1, PP. 49-58, (1994); AKIHISA T., YASUKAWA K., YAMAURA M., ET AL., TRITERPENE ALCOHOL AND STEROL FERULATES FROM RICE BRAN AND THEIR ANTI-INFLAMMATORY EFFECTS, J AGRIC FOOD CHEM, 48, 6, PP. 2313-2319, (2000); XU Z., GODBER J.S., PURIFICATION AND IDENTIFICATION OF COMPONENTS OF GAMMA-ORYZANOL IN RICE BRAN OIL, J AGRIC FOOD CHEM, 47, 7, PP. 2724-2728, (1999); HU W., WELLS J.H., SHIN T.-S., GODBER J.S., COMPARISON OF ISOPROPANOL AND HEXANE FOR EXTRACTION OF VITAMIN, E AND ORYZANOLS FROM STABILIZED RICE BRAN. J AM OIL CHEMISTS' SOC, 73, 12, PP. 1653-1656, (1996); CONSULTATIVE GROUP ON INTERNATIONAL AGRICULTURAL RESEARCH ANNUAL REPORT 2007; VAGI E., SIMANDI B., DAOOD H.G., DEAK A., SAWINSKY J., RECOVERY OF PIGMENTS FROM ORIGANUM MAJORANA L. BY EXTRACTION WITH SUPERCRITICAL CARBON DIOXIDE, J AGRIC FOOD CHEM, 50, 8, PP. 2297-2301, (2002); JOHNSON L.A., LUSAS E., COMPARISON OF ALTERNATIVE SOLVENTS FOR OILS EXTRACTION, J AM OIL CHEMISTS' SOC, 60, 2, PP. 229-242, (1983); LAKKAKULA N.R., LIMA M., WALKER T., RICE BRAN STABILIZATION AND RICE BRAN OIL EXTRACTION USING OHMIC HEATING, BIORESOUR TECHNOL, 92, 2, PP. 157-161, (2004); LEIBOVITZ Z., RUCKENSTEIN C., WINTERIZATION OF SUNFLOWER OIL, J AM OIL CHEMISTS' SOC, 61, 5, PP. 870-872, (1984); RAMASWAMY K.G., GOPALAKRISHNA A.G., SEN D.P., REFINING OF RICE BRAN OIL, J OIL TECHNOLOGISTS ASSOC INDIA, 12, 1, PP. 16-19, (1980); TAYLOR R.J., MCCORMACK A.J., STUDY OF SOLVENT AND CATALYTIC LUBE OIL DEWAXING BY ANALYSIS OF FEEDSTOCKS AND PRODUCTS, IND ENG CHEM RES, 31, 7, PP. 1731-1738, (1992); SCHARNAGL H., MARZ W., NEW LIPID-LOWERING AGENTS ACTING ON LDL RECEPTORS, CURR TOP MED CHEM, 3, PP. 233-242, (2005); ARRUZAZABALA M.L., NOA M., MENENDEZ R., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, 7, PP. 835-840, (2000); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, 3-4, PP. 205-208, (1993); KATO S., KARINO K., HASEGAWA S., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR J NUTR, 73, 3, PP. 433-441, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, 7, PP. 568-577, (1996); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVESTIG, 25, 11, PP. 701-707, (2005); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, 5-6, PP. 181-185, (1996); POPE L.E., MARCELLETTI J.F., KATZ L.R., ET AL., THE ANTI-HERPES SIMPLEX VIRUS ACTIVITY OF N-DOCOSANOL INCLUDES INHIBITION OF THE VIRAL ENTRY PROCESS, ANTIVIRAL RES, 40, 1-2, PP. 85-94, (1998); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, 4, PP. 361-371, (2004); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, 10, PP. 923-929, (2011); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 5, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, 6, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, 5, PP. 968-975, (2006); SWANSON B., KEITHLEY J.K., SHA B.E., ET AL., POLICOSANOL FOR MANAGING HUMAN IMMUNODEFICIENCY VIRUS-RELATED DYSLIPIDEMIA IN A MEDICALLY UNDERSERVED POPULATION: A RANDOMIZED, CONTROLLED CLINICAL TRIAL, ALTERN THER HEALTH MED, 17, 2, PP. 30-35, (2011); SWANSON B., KEITHLEY J., POLICOSANOL TO MANAGE DYSLIPIDEMIA IN OLDER ADULTS, COMPLEMENTARY AND ALTERNATIVE THERAPIES AND THE AGING POPULATION: AN EVIDENCE-BASED APPROACH, (2011); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, 1, PP. 33-38, (1993); RAGHAVAN P.R., POLICOSANOL NANOPARTICLES, (2013); COOPER E., KLINE L., LIVERSIDGE G., RYDE N.P., NANOPARTICULATE POLYCOSANOL FORMULATIONS AND NOVEL POLYCOSANOL COMBINATIONS, (2003); GUGLIELMINI G., NANOSTRUCTURED NOVEL CARRIER FOR TOPICAL APPLICATION, CLIN DERMATOL, 26, 4, PP. 341-346, (2008); SOLANS C., IZQUIERDO P., NOLLA J., AZEMAR N., GARCIA-CELMA M.J., NANO-EMULSIONS, CURR OPIN COLLOID INTERFACE SCI, 10, 3, PP. 102-110, (2005); MASON T.G., WILKING J.N., MELESON K., CHANG C.B., GRAVES S.M., NANOEMULSIONS: FORMATION, STRUCTURE, AND PHYSICAL PROPERTIES, J PHYSICS CONDENSED MATTER, 18, 41, (2006); ISMAIL M., AL-NAQEEB G., MAMAT W.A., AHMAD Z., GAMMA-ORYZANOL RICH FRACTION REGULATES THE EXPRESSION OF ANTIOXIDANT AND OXIDATIVE STRESS RELATED GENES IN STRESSED RAT'S LIVER, NUTR METAB (LOND), 7, (2010); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR J LIPID SCI TECHNOL, 106, 3, PP. 147-151, (2004); DUNFORD N.T., IRMAK S., JONNALA R., PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW, GERM AND BRAN, FOOD CHEMISTRY, 119, 3, PP. 1246-1249, (2010); AL-QUBAISI M.S., RASEDEE A., FLAIFEL M.H., ET AL., CYTOTOXICITY OF NICKEL ZINC FERRITE NANOPARTICLES ON CANCER CELLS OF EPITHELIAL ORIGIN, INT J NANOMEDICINE, PP. 2497-2508, (2013); BELAVADI V.K., BHOWMICK D.N., AN INVESTIGATION OF RICE BRAN OIL TANK SETTLING, J AM OIL CHEMISTS' SOC, 65, 2, PP. 241-245, (1988); YOON S.H., RHEE J.S., COMPOSITION OF WAXES FROM CRUDE RICE BRAN OIL, J AM OIL CHEMISTS' SOC, 59, 12, PP. 561-563, (1982); REDDI P.B.V., MURTI K.S., FEUGE R.O., RICE BRAIN OIL. I. OIL OBTAINED BY SOLVENT EXTRACTION, J AM OIL CHEMISTS' SOC, 25, 6, PP. 206-211, (1948); COUSINS E.R., FORE S.P., JANSSEN H.J., FEUGE R.O., RICE BRAN OIL. VIII. TANK SETTLINGS FROM CRUDE RICE BRAN OIL AS A SOURCE OF WAX, J AM OIL CHEMISTS' SOC, 30, 1, PP. 9-14, (1953); SAUNDERS R., RICE BRAN: COMPOSITION AND POTENTIAL FOOD USES, FOOD REV INTERN, 1, 3, PP. 465-495, (1985); LIU Y., YU J., WANG X., EXTRACTION OF POLICOSANOLS FROM HYDROLYSED RICE BRAN WAX BY HIGH-INTENSITY ULTRASOUND, INTERN J FOOD SCI TECHNOL, 43, 5, PP. 763-769, (2008); WANG M.-F., LIAN H.-Z., MAO L., ET AL., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J AGRIC FOOD CHEM, 55, 14, PP. 5552-5558, (2007); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUM OFFICINARUM L.) CULTIVARS, EUR J LIPID SCI TECHNOL, 114, 5, PP. 583-591, (2012); TAGNE J.B., KAKUMANU S., NICOLOSI R.J., NANOEMULSION PREPARATIONS OF THE ANTICANCER DRUG DACARBAZINE SIGNIFICANTLY INCREASE ITS EFFICACY IN A XENOGRAFT MOUSE MELANOMA MODEL, MOL PHARM, 5, 6, PP. 1055-1063, (2008); KONG M., PARK H.J., STABILITY INVESTIGATION OF HYALURONIC ACID BASED NANOEMULSION AND ITS POTENTIAL AS TRANSDERMAL CARRIER, CARBOHYD POLYM, 83, 3, PP. 1303-1310, (2011); LOVELYN C., ATTAMA A.A., CURRENT STATE OF NANOEMULSIONS IN DRUG DELIVERY, J BIOMATER NANOBIOTECHNOL, 2, 5 A, PP. 626-639, (2011); REN W., TIAN G., JIAN S., ET AL., TWEEN COATED NAYF4:YB, ER/NAYF4 CORE/SHELL UPCONVERSION NANOPARTICLES FOR BIOIMAGING AND DRUG DELIVERY, RSC ADV, 2, 18, PP. 7037-7041, (2012); LIN-VIEN D., COLTHUP N.B., FATELEY W.G., GRASSELLI J.G., THE HANDBOOK OF INFRARED AND RAMAN CHARACTERISTIC FREQUENCIES OF ORGANIC MOLECULES, (1991); COATES J., INTERPRETATION OF INFRARED SPECTRA, A PRACTICAL APPROACH, ENCYCLOPEDIA ANALYT CHEM, (2006); CAROLEI L., GUTZ I.G., SIMULTANEOUS DETERMINATION OF THREE SURFACTANTS AND WATER IN SHAMPOO AND LIQUID SOAP BY ATR-FTIR, TALANTA, 66, 1, PP. 118-124, (2005); LINDNER J., CRINGUS D., PSHENICHNIKOV M.S., VOHRINGER P., ANHARMONIC BEND-STRETCH COUPLING IN NEAT LIQUID WATER, CHEM PHYS, 341, 1, PP. 326-335, (2007); SMITH B.C., INFRARED SPECTRAL INTERPRETATION: A SYSTEMATIC APPROACH, (1998); SOCRATES G., INFRARED AND RAMAN CHARACTERISTIC GROUP FREQUENCIES: TABLES AND CHARTS, (2001)","A. ISHAKA; LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITY PUTRA MALAYSIA, SERDANG, SELANGOR, MALAYSIA; EMAIL: MYHOME.E@GMAIL.COM","DOVE MEDICAL PRESS LTD.","ENGLISH","INT. J. NANOMED.","ARTICLE","ISI","2-S2.0-84900443040","INT J NANOMED","UNIVERSITY PUTRA MALAYSIA;UNIVERSITY PUTRA MALAYSIA;HEALTH SCIENCES;UNIVERSITY PUTRA MALAYSIA;UNIVERSITY PUTRA MALAYSIA","NOTREPORTED;UNIVERSITY PUTRA MALAYSIA;NOTREPORTED",NA,"ISHAKA A, 2014, INT J NANOMED","ISHAKA A, 2014, INT J NANOMED"
"LUO X;LI N;LIANG Y","LUO, XIAN-YANG (41461625300); LI, NA-NA (55833726500); LIANG, YUE-RONG (55804944600)","EFFECTS OF ILEX LATIFOLIA AND CAMELLIA SINENSIS ON CHOLESTEROL AND CIRCULATING IMMUNE COMPLEXES IN RATS FED WITH A HIGHCHOLESTEROL DIET",2013,"PHYTOTHERAPY RESEARCH","27","3",10,"10.1002/ptr.4693","TEA RESEARCH INSTITUTE, ZHEJIANG UNIVERSITY, HANGZHOU 310058, CHINA, TEA RESEARCH INSTITUTE, AGRICULTURAL ACADEMY OF GUIZHOU, GUIYANG 550006, CHINA;TEA RESEARCH INSTITUTE, ZHEJIANG UNIVERSITY, HANGZHOU 310058, CHINA;TEA RESEARCH INSTITUTE, ZHEJIANG UNIVERSITY, HANGZHOU 310058, CHINA","HYPERCHOLESTEROLAEMIA IS ONE OF THE RISK FACTORS FOR ATHEROSCLEROSIS AND SUBSEQUENT CARDIOVASCULAR DISEASE. HERE, WE INVESTIGATED THE EFFECTS OF DIETARY SUPPLEMENTATION WITH ILEX LATIFOLIA OR GREEN TEA (CAMELLIA SINENSIS) ON THE LEVELS OF PLASMA TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CIRCULATING IMMUNE COMPLEXES IN SPRAGUE DAWLEY RATS FED WITH A HIGH-CHOLESTEROL DIET. WE DEMONSTRATED THAT DAILY ADMINISTRATION BY GAVAGE OF I. LATIFOLIA OR C. SINENSIS AT DOSES OF 1.0 OR 2.0 G/KG BODY WEIGHT FOR 30 DAYS RESULTED IN A SIGNIFICANT DECREASE IN PLASMA TOTAL CHOLESTEROL LEVELS AND CIRCULATING IMMUNE COMPLEXES AND AN INCREASE IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN RATS FED WITH A HIGH-CHOLESTEROL DIET COMPARED WITH LEVELS IN THE HIGH-CHOLESTEROL DIET CONTROL GROUP. C. SINENSIS WAS MORE EFFECTIVE THAN I. LATIFOLIA. I. LATIFOLIA AND C. SINENSIS COULD BE USED AS FOOD SUPPLEMENTS TO PROTECT AGAINST THE DEVELOPMENT OF HYPERCHOLESTEROLAEMIA. COPYRIGHT © 2012 JOHN WILEY & SONS, LTD.","CAMELLIA SINENSIS; CHOLESTEROL; CIRCULATING IMMUNE COMPLEX; HYPERCHOLESTEROLAEMIA; ILEX LATIFOLIA; RAT","ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BODY WEIGHT; CAMELLIA SINENSIS; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; DIETARY SUPPLEMENTS; FEMALE; ILEX; MALE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; TEA; CAMELLIA SINENSIS; ILEX LATIFOLIA; RATTUS; ASCORBIC ACID; CATECHIN; CATECHOL METHYLTRANSFERASE; CHOLESTEROL; FLAVONOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE CONTROL; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HYPERCHOLESTEROLEMIA; ILEX LATIFOLIA; MALE; MEDICINAL PLANT; NONHUMAN; OUTCOME ASSESSMENT; RAT; TEA; THERAPY EFFECT; WEIGHT GAIN","","","ASSY N., KAITA K., MYMIN D., LEVY C., ROSSER B., MINUK G., FATTY INFILTRATION OF LIVER IN HYPERLIPIDEMIC PATIENTS, DIGEST DIS SCI, 45, PP. 1929-1934, (2000); BROWN A.L., LANE J., HOLYOAK C., NICOL B., MAYES A.E., DADD T., HEALTH EFFECTS OF GREEN TEA CATECHINS IN OVERWEIGHT AND OBESE MEN: A RANDOMISED CONTROLLED CROSS-OVER TRIAL, BRIT J NUTRIT, 106, PP. 1880-1889, (2011); CAI Y., LUO Q., SUN M., HAROLD C., ANTIOXIDANT ACTIVITY AND PHENOLIC COMPOUNDS OF 112 TRADITIONAL CHINESE MEDICINAL PLANTS ASSOCIATED WITH ANTICANCER, LIFE SCI, 74, PP. 2157-2184, (2004); DIGEON M., LAVER M., RIZA J., BACH J.F., DETECTION OF CIRCULATING IMMUNE COMPLEXES IN HUMAN SERA BY SIMPLIFIED ASSAYS WITH POLYETHYLENE GLYCOL, J IMMUNOL METH, 16, PP. 165-183, (1977); HURSEL R., VIECHTBAUER W., WESTERTERP-PLANTENGA M.S., THE EFFECTS OF GREEN TEA ON WEIGHT LOSS AND WEIGHT MAINTENANCE: A META-ANALYSIS, INT J OBES, 33, PP. 956-961, (2009); KLAUS S., PULTZ S., THONE-REINEKE C., WOLFRAM S., EPIGALLOCATECHIN GALLATE ATTENUATES DIET-INDUCED OBESITY IN MICE BY DECREASING ENERGY ABSORPTION AND INCREASING FAT OXIDATION, INT J OBESITY, 29, PP. 615-623, (2005); LIANG Y.R., MA S.C., LUO X.Y., ET AL., EFFECTS OF GREEN TEA ON BLOOD PRESSURE AND HYPERTENSION-INDUCED CARDIOVASCULAR DAMAGE IN SPONTANEOUSLY HYPERTENSIVE RAT, FOOD SCI BIOTECHNOL, 20, PP. 93-98, (2011); LIANG Y.R., MA W.Y., LU J.L., WU Y., COMPARISON OF CHEMICAL COMPOSITIONS OF ILEX LATIFOLIA THUMB AND CAMELLIA SINENSIS L, FOOD CHEM, 75, PP. 339-343, (2001); LIANG Y.R., XU J.Y., LUO X.Y., ET AL., EFFECT OF GREEN TEA ON ANGIOTENSIN II LEVEL AND MYOCARDIAL MICROSTRUCTURE IN SPONTANEOUS HYPERTENSIVE RATS, J MED PLANTS RES, 4, PP. 1843-1846, (2010); LU T.M., LEE C.C., MAU J.L., LIN S.D., QUALITY AND ANTIOXIDANT PROPERTY OF GREEN TEA SPONGE CAKE, FOOD CHEM, 119, PP. 1090-1095, (2010); MOLAN A.L., LIU Z.J., TIWARI R., THE ABILITY OF GREEN TEA TO POSITIVELY MODULATE KEY MARKERS OF GASTROINTESTINAL FUNCTION IN RATS, PHYTOTHER RES, 24, PP. 1614-1619, (2010); MURASE T., MISAWA K., HARAMIZU S., HASE T., CATECHIN-INDUCED ACTIVATION OF THE LKB1/AMP-ACTIVATED PROTEIN KINASE PATHWAY, BIOCHEM PHARMACOL, 78, PP. 78-84, (2009); STEINBERG D., ATHEROGENESIS IN PERSPECTIVE: HYPERCHOLESTEROLEMIA AND INFLAMMATION AS PARTNERS IN CRIME, NAT MED, 8, PP. 1211-1217, (2002); VIJAYAKUMAR R.S., NALINI N., LIPID-LOWERING EFFICACY OF PIPERINE FROM PIPER NIGRUM L. IN HIGH-FAT DIET AND ANTITHYROID DRUG-INDUCED HYPERCHOLESTEROLEMIC RATS, J FOOD BIOCHEM, 30, PP. 405-421, (2006); WISSLER R.W., THEORIES AND NEW HORIZONS IN THE PATHOGENESIS OF ATHEROSCLEROSIS AND THE MECHANISMS OF CLINICAL EFFECTS, ARCH PATHOL LAB MED, 116, PP. 1281-1291, (1992); WU L.Y., ZHENG X.Q., LU J.L., LIANG Y.R., PROTECTIVE EFFECT OF GREEN TEA POLYPHENOLS AGAINST ULTRAVIOLET B-INDUCED DAMAGE TO HACAT CELLS, HUM CELL, 22, PP. 18-24, (2009); XU J.Y., WU L.Y., ZHENG X.Q., LU J.L., WU M.Y., LIANG Y.R., GREEN TEA POLYPHENOLS ATTENUATING ULTRAVIOLET B-INDUCED DAMAGE TO HUMAN RETINAL PIGMENT EPITHELIAL CELLS IN VITRO, INVEST OPHTH VIS SCI, 51, PP. 6665-6670, (2010); YOKOZAWA T., DONG E., NAKAGAWA T., KIM D.W., HATTORI M., NAKAGAWA H., EFFECTS OF JAPANESE BLACK TEA ON ATHEROSCLEROTIC DISORDERS, BIOSCI BIOTECH BIOCHEM, 62, PP. 44-48, (1998)","Y.-R. LIANG; TEA RESEARCH INSTITUTE, ZHEJIANG UNIVERSITY, HANGZHOU 310058, CHINA; EMAIL: YRLIANG@ZJU.EDU.CN","","ENGLISH","PHYTOTHER. RES.","ARTICLE","ISI","2-S2.0-84872060832","PHYTOTHER RES","ZHEJIANG UNIVERSITY;ZHEJIANG UNIVERSITY;ZHEJIANG UNIVERSITY","NOTREPORTED;ZHEJIANG UNIVERSITY;NOTREPORTED",NA,"LUO X-Y, 2013, PHYTOTHER RES","LUO X-Y, 2013, PHYTOTHER RES"
"KIM S;CHUNG H;LIM S","KIM, SUNG-MIN (57196227232); CHUNG, HYUN-JUNG (7404006790); LIM, SEUNG-TAIK (7404081168)","EFFECT OF VARIOUS HEAT TREATMENTS ON RANCIDITY AND SOME BIOACTIVE COMPOUNDS OF RICE BRAN",2014,"JOURNAL OF CEREAL SCIENCE","60","5",101,"10.1016/j.jcs.2014.04.001","SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, SUNGBUK-KU, SEOUL 136-701, 5-1 ANAM-DONG, SOUTH KOREA;DEPARTMENT OF FOOD AND NUTRITION, CHONNAM NATIONAL UNIVERSITY, BUK-GU, GWANGJU 500-757, 77 YONGBONG-RO, SOUTH KOREA;SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, SUNGBUK-KU, SEOUL 136-701, 5-1 ANAM-DONG, SOUTH KOREA","RICE BRAN CONTAINS NATURAL PHYTOCHEMICALS BUT UNSTABLE AGAINST HYDROLYTIC AND OXIDATIVE RANCIDITY. VARIOUS HEAT TREATMENTS, SUCH AS DRY-HEATING (DH), FREEZE-DRYING FOLLOWED BY DRY-HEATING (FDDH), MICROWAVE HEATING (MH), AUTOCLAVING (AC), AND ETHANOL VAPOR (EV) TREATMENT WERE APPLIED TO RICE BRAN AND THEIR EFFECTS ON THE STORAGE STABILITY AT ROOM TEMPERATURE WERE EVALUATED. THE FREE FATTY ACID (FFA) CONTENT OF UNTREATED RICE BRAN GRADUALLY INCREASED FROM 2.14 TO 19.81% DURING 24 WEEKS, WHEREAS THOSE OF THE TREATED RICE BRANS WERE NOT OR MARGINALLY CHANGED. THE FFA CONTENT IN DH SAMPLES WAS GREATER THAN THAT IN FDDH SAMPLES, INDICATING THE POSITIVE EFFECT OF FREEZE-DRYING PRIOR TO DH. AMONG THE TREATMENTS, AUTOCLAVING WAS MOST EFFECTIVE IN RETARDING THE FFA FORMATION. THE TOCOL CONTENT IN THE RICE BRANS VARIED WITH THE TREATMENTS, RANGING FROM 181.4MG/KG (EV) TO 310.6MG/KG (AC), WHEREAS THAT IN UNTREATED RICE BRAN WAS 216.3MG/KG. AMOUNTS OF OTHER BIO-FUNCTIONAL COMPONENTS SUCH AS PHYTOSTEROLS AND POLICOSANOLS WERE EITHER UNCHANGED OR INCREASED BY THE TREATMENTS. POLICOSANOL LEVEL WAS INCREASED BY ALL THE HEAT TREATMENTS, BUT NOT AFFECTED BY EV TREATMENT, INDICATING THAT THE THERMAL TREATMENTS INDUCED THE RELEASE OF FREE POLICOSANOLS. © 2014 ELSEVIER LTD.","HEAT TREATMENT; POLICOSANOLS; RICE BRAN; STORAGE STABILITY","","KOREA INSTITUTE OF PLANNING AND EVALUATION FOR TECHNOLOGY IN FOOD, AGRICULTURE, FORESTRY AND FISHERIES, IPET, (610009-03-2-WT241); MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, MIFAFF; KOREA INSTITUTE OF PLANNING AND EVALUATION FOR TECHNOLOGY IN FOOD, AGRICULTURE AND FORESTRY, IPET","THIS RESEARCH WAS FINANCIALLY SUPPORTED BY IPET (KOREA INSTITUTE 356 OF PLANNING AND EVALUATION FOR TECHNOLOGY IN FOOD, AGRICULTURE, FORESTRY AND FISHERIES , UNDER GRANT NO: 610009-03-2-WT241 ), MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, REPUBLIC OF KOREA .  ","ALIVA I., SILVA C.L.M., MODELING KINETICS OF THERMAL DEGRADATION OF COLOUR IN PEACH PUREE, J.FOOD ENG., 39, PP. 161-166, (1999); AMARASINGHE B.M.W.P., KUMARASIRI M.P.M., GANGODAVILAGE N.C., EFFECT OF METHOD OF STABILIZATION ON AQUEOUS EXTRACTION OF RICE BRAN OIL, FOOD BIOPROD. PROCESS., 87, PP. 108-114, (2009); OFFICIAL METHODS AND RECOMMENDED PRACTICES, (1989); AZADMARD-DAMIRCHI S., HABIBI-NODEH F., HESARI F., NEMATI M., ACHACHLOUEI B.F., EFFECT OF PRETREATMENT WITH MICROWAVES ON OXIDATIVE STABILITY AND NUTRACEUTICALS CONTENT OF OIL FROM RAPESEED, FOOD CHEM., 121, PP. 1211-1215, (2010); BRYNGELSSON S., DIMBERG L.H., KAMAL-ELDIN A., EFFECTS OF COMMERCIAL PROCESSING ON LEVELS OF ANTIOXIDANTS IN OATS (AVENA SATIVA L.), J.AGRIC. FOOD CHEM., 50, PP. 1890-1896, (2002); CHAMPAGNE E.T., HORN R.J., ABRAHAM G., STABILIZING BROWN RICE TO LIPOLYTIC HYDROLYSIS BY ETHANOL VAPORS, CEREAL CHEM., 69, PP. 152-156, (1992); CICERO A.F.G., DEROSA G., RICE BRAN AND ITS MAIN COMPONENTS: POTENTIAL ROLE IN THE MANAGEMENT OF CORONARY RISK FACTORS, CURR. TOP. NUTRACEUTICAL RES., 3, PP. 29-46, (2005); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR. J. LIPID SCI. TECHNOL., 106, PP. 147-151, (2004); HA T.Y., KO S.N., LEE S.M., KIM H.R., CHUNG S.H., KIM S.R., KIM I.H., CHANGES IN NUTRACEUTICAL LIPID COMPONENTS OF RICE AT DIFFERENT DEGREE OF MILLING, EUR. J. LIPID SCI. TECHNOL., 108, PP. 175-181, (2006); JAYARAMAN P., KALYANASUNDARAM I., CHANGES IN MOISTURE CONTENT, MYCOFLORA AND AFLATOXIN CONTENT OF RICE BRAN DURING STORAGE, MYCOPATHOLOGIA, 126, PP. 115-120, (1994); KATO S., KARINO K.I., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., HAMATANI K., TAKAHASHI M., OGASAWARA J., MASUSHIGE S., HASEGAWA T., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR. J. NUTR., 73, PP. 433-441, (1995); KWON Y.J., LEE K.T., YUM T.M., CHOI S.W., EFFECT OF HEAT PRETREATMENT ON THE FUNCTIONAL CONSTITUENTS OF RICE GERM, J.FOOD SCI. NUTRITION, 9, PP. 330-335, (2004); LANE R.H., QUERESHI A.A., SALSER W.A., TOCOTRIENOLS AND TOCOTRIENOLS-LIKE COMPOUNDS AND METHODS FOR THEIR USE., (1997); LLOYD B.J., SIEBENMORGEN T.J., BEERS K.W., EFFECTS OF COMMERCIAL PROCESSING ON ANTIOXIDANTS IN RICE BRAN, CEREAL CHEM., 77, PP. 551-555, (2000); LOYPIMAI P., MOONGGARM A., CHOTTANOM P., EFFECTS OF OHMIC HEATING ON LIPASE ACTIVITY, BIOACTIVE COMPOUNDS AND ANTIOXIDANT ACTIVITY OF RICE BRAN, AUST. J. BASIC APPL. SCI., 3, PP. 3642-3652, (2009); MOREAU R.A., HICKS K.B., POWELL M.J., EFFECTS OF HEAT PRETREATMENT ON THE YIELD AND COMPOSITION OF OIL EXTRACTED FROM CORN FIBER, J.AGRIC. FOOD CHEM., 47, PP. 2867-2871, (1999); MUJAHID A., HAQ I., ASIF M., GILANI A.H., EFFECT OF VARIOUS PROCESSING TECHNIQUES AND DIFFERENT LEVELS OF ANTIOXIDANT ON STABILITY OF RICE BRAN DURING STORAGE, J.SCI. FOOD AGRIC., 85, PP. 847-852, (2005); POURALI O., ASGHARI F.S., YOSHIDA H., SIMULTANEOUS RICE BRAN OIL STABILIZATION AND EXTRACTION USING SUB-CRITICAL WATER MEDIUM, J.FOOD ENG., 95, PP. 510-516, (2009); PRAKASH J., RICE BRAN PROTEINS: PROPERTIES AND FOOD USES, CRIT. REV. FOOD SCI. NUTR., 36, PP. 537-552, (1996); QURESHI A.A., BRADLOW B.A., SALSER W.A., BRACE L.D., NOVEL TOCOTRIENOLS OF RICE BRAN MODULATE CARDIOVASCULAR DISEASE RISK PARAMETERS OF HYPERCHOLESTEROLEMIC HUMANS, J.NUTR. BIOCHEM., 8, PP. 290-298, (1997); RAMARATHNAM N., OSAWA T., NAMIKI M., KAWAKISHI N., STUDIES ON CHANGES IN FATTY ACID COMPOSITION AND CONTENT OF ENDOGENOUS ANTIOXIDANT DURING GAMMA-IRRADIATION OF RICE SEEDS, J.AM. OIL CHEM. SOC., 66, PP. 105-108, (1989); RAMEZANZADEH F.M., RAO R.M., WINDHAUSER M., PRINYAWIWATKUL W., TULLEY R., MARSHALL W.E., PREVENTION OF HYDROLYTIC RANCIDITY IN RICE BRAN DURING STORAGE, J.AGRIC. FOOD CHEM., 47, PP. 3050-3052, (1999); SHARMA H.R., CHAUHAN G.S., AGRAWAL K., PHYSICO-CHEMICAL CHARACTERISTICS OF RICE BRAN PROCESSED BY DRY HEATING AND EXTRUSION COOKING, INT. J. FOOD PROP., 7, PP. 603-614, (2004); SHIRAKAWA H., KOSEKI T., OHINATA K., HAZHIZUME K., KOMAI M., RICE BRAN FRACTIONS IMPROVE BLOOD PRESSURE, LIPID PROFILE, AND GLUCOSE METABOLISM IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS, J.AGRIC. FOOD CHEM., 54, PP. 1914-1920, (2006); SINGH V., JOHNSTON D.B., MOREAU R.A., HICKS K.B., DIEN B.S., BOTHAST R.J., PRETREATMENT OF WET-MILLED CORN FIBER TO IMPROVE RECOVERY OF CORN FIBER OIL AND PHYTOSTEROLS, CEREAL CHEM., 80, PP. 118-122, (2003); TAO J., RAO R.M., LIUZZO J.A., THERMAL EFFICIENCIES OF CONVENTIONAL AND MICROWAVE HEAT STABILIZATION OF RICE BRAN, LA. AGRIC., 36, (1993); UQUICHE E., JEREZ M., ORTIZ J., EFFECT OF PRETREATMENT WITH MICROWAVES ON MECHANICAL EXTRACTION YIELD AND QUALITY OF VEGETABLE OIL FROM CHILEAN HAZELNUTS (GEVUINA AVELLANA MOL), INNOV. FOOD SCI. EMERG. TECHNOL., 9, PP. 495-500, (2008); VANSTONE C.A., SARJAZ M.R., JONES P.J.H., INJECTED PHYTOSTEROL/STANOLS SUPPRESS PLASMA CHOLESTEROL LEVELS IN HAMSTERS, J.NUTR. BIOCHEM., 12, PP. 565-574, (2001); YUEH J.Y., DIXON PHILLIPS R., RESURRECCION A.V.A., HUNG Y.C., PHYSICOCHEMICAL AND SENSORY CHARACTERISTIC CHANGES IN FORTIFIED PEANUT SPREADS AFTER 3 MONTHS OF STORAGE AT DIFFERENT TEMPERATURES, J.AGRIC. FOOD CHEM., 50, PP. 2377-2384, (2002)","S.-T. LIM; SCHOOL OF LIFE SCIENCES AND BIOTECHNOLOGY, KOREA UNIVERSITY, SUNGBUK-KU, SEOUL 136-701, 5-1 ANAM-DONG, SOUTH KOREA; EMAIL: LIMST@KOREA.AC.KR","ACADEMIC PRESS","ENGLISH","J. CEREAL SCI.","ARTICLE","ISI","2-S2.0-84901926470","J CEREAL SCI","KOREA UNIVERSITY;CHONNAM NATIONAL UNIVERSITY;KOREA UNIVERSITY","NOTREPORTED;KOREA UNIVERSITY;NOTREPORTED",NA,"KIM S-M, 2014, J CEREAL SCI","KIM S-M, 2014, J CEREAL SCI"
"RODIONOVA N;ISAEV V;VISHNYAKOV A;POPOV E;SAFONOVA N;SRORUBLYOVTSEV S","RODIONOVA, N.S. (36537734600); ISAEV, V.A. (57193696370); VISHNYAKOV, A.B. (57193692378); POPOV, E.S. (57190418952); SAFONOVA, N.V. (57193689721); SRORUBLYOVTSEV, S.A. (57193700647)","INVESTIGATION OF THE EFFECT OF OIL AND FLOUR FROM WHEAT GERM MEAL ON LIPID METABOLISM OF STUDENTS AND TEACHERS OF THE UNIVERSITY",2016,"VOPROSY PITANIIA","85","6",6,"","VORONEZH STATE UNIVERSITY OF ENGINEERING TECHNOLOGIES, 394036, RUSSIAN FEDERATION;LLC SCIENTIFIC-MANUFACTURING ENTERPRISE TRINITA, MOSCOW, RUSSIAN FEDERATION;LLC PULAT, KOROLEV, MICRODISTRICT YUBILEYNYY, MOSCOW REGION, RUSSIAN FEDERATION;VORONEZH STATE UNIVERSITY OF ENGINEERING TECHNOLOGIES, 394036, RUSSIAN FEDERATION;VORONEZH STATE UNIVERSITY OF ENGINEERING TECHNOLOGIES, 394036, RUSSIAN FEDERATION;VORONEZH STATE UNIVERSITY OF ENGINEERING TECHNOLOGIES, 394036, RUSSIAN FEDERATION","THE RESULTS OF INVESTIGATION OF ALIMENTARY CORRECTION OF LIPID METABOLISM UNDER THE ADMIN-ISTRATION OF PROCESSED PRODUCTS FROM WHEAT GERM - OIL (WITH THE CONTENT OF POLICOSANOL AT LEAST 1.5-8.0 MG/100 G, VITAMIN E - 180-200 MG/100 G, PUFA - 60-65%) AND CAKE FLOUR (WITH THE CONTENT OF PROTEIN - 30-35%, OIL WITH ANALOGUE COMPOSITION - 5-7%, DIGESTIBLE CARBOHYDRATES - 45-47%, FIBER - 18-26%, VITAMINS B, B3, B6, B9, E, PP, MINERALS AND TRACE ELEMENTS - ZN, MN, K, FE, SE, P) ARE PRESENTED. VOLUNTEERS AMONG TEACHERS AND STUDENTS OF THE UNIVERSITY AGED 16 TO 65 YEARS DAILY CONSUMED WHEAT GERM OIL OBTAINED BY COLD PRESSING IN AN AMOUNT OF 3.5 G, REGARDLESS OF THE MEAL WITHIN 30 DAYS. THEN A PART OF THEM (30 PERSONS) CONSUMED DAILY 50GOF OIL CAKE OBTAINED AFTER PRESSING OIL, WHICH PROVIDED THE INTAKE OF THE SAME AMOUNT OF OIL (3.5 G). LIPID METABOLISM PARAM-ETERS WERE MONITORED IN EXPERIMENT PARTICIPANTS BEFORE RECEIVING THE PROCESSED PRODUCTS OF WHEAT GERM, AFTER GERM MEAL INTAKE AND BEYOND 30 AND 60 DAYS AFTER CONSUMPTION OF WHEAT GERM. DATA ANALYSIS WAS CARRIED OUT ON THREE AGE GROUPS: 16-24, 25-44 AND 45-65 YEARS. ALL PARTICIPANTS OF THE EXPERIMENT SHOWED A REDUCTION IN TOTAL CHOLESTEROL LEVEL BY 6-8%, INCREASING THE CONCENTRATION OF HDL CHOLESTEROL BY 3-24%, LOWERING LDL CHOLESTEROL CONCENTRATIONS BY 4-21%, REDUCTION OF TRIGLYCERIDE CONCENTRATION BY 12-24%, A POSITIVE CORRECTION OF ATHEROGENIC FACTOR VALUES BY FOR 10-25%. PROLONGED ACTION OF THE INVESTIGATED FOODS WAS ESTABLISHED: LIPID METABOLISM PARAMETERS IN THE TESTED GROUP WERE BETTER THAN IN THE CONTROL GROUP AFTER 30 DAYS OF INTAKE DISCONTINUATION OF OIL OR WHEAT GERM FLOUR, THE POSITIVE ADJUSTMENT EFFECT DISAPPEARED 60 DAYS AFTER CONSUMING THE PRODUCTS. THE FINDINGS DEMONSTRATE A POSITIVE EFFECT ON THE NORMALIZATION OF LIPID METABOLISM WHEN CAKE FLOUR OF WHEAT GERM WAS ADMINISTERED IN DAILY FOOD RATION, SIMILAR TO THE EFFECT OF OIL INTAKE, WHICH IS IMPORTANT FOR THE PREVENTION OF CARDIOVASCULAR DISEASES AND ATHEROSCLEROSIS. GIVEN THE SIGNIFICANT PRODUCTION OF CAKE FLOUR OF WHEAT GERM (UP TO 90-95% OF THE RAW MATERIAL) AND ITS NOT HIGH COST AS A SECONDARY BIOLOGICAL RESOURCE, THIS PRODUCT CAN BE RECOMMENDED TO THE INTRODUCTION IN THE DIET OF ORGANIZED GROUPS, INCLUDING SOCIALLY VULNERABLE GROUPS.","FLOUR CAKE WHEAT GERM; LIPID METABOLISM; NUTRITIONAL STATUS; POLICOSANOL; WHEAT GERM OIL","ADOLESCENT; ADULT; AGED; FEMALE; FLOUR; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; PLANT OILS; SCHOOL TEACHERS; STUDENTS; TRITICUM; VEGETABLE OIL; ADOLESCENT; ADULT; AGED; DRUG EFFECTS; FEMALE; FLOUR; HUMAN; LIPID METABOLISM; MALE; MIDDLE AGED; SCHOOL TEACHER; STUDENT; WHEAT","","","NOA M., MAS R., ROSA M.C., EFFECT OF POLICOSANOLON LIPOFUNDIN INDUCED LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., ROSA M.C., MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMA-TION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, 11, PP. 125-132, (1998); SHPAGINA L.A., MODERN ASPECTS OF FUNCTIONAL FOODS, CLINICAL EFFICACY OF WHEAT GERM OIL, 2, PP. 44-48, (2008); POPOV E.S., RODIONOVA N.S., SOKOLOVA O.A., MAZURENKO N.YU., ASSESSMENT OF THE PROSPECTS FOR THE PRODUCTION OF A BALANCED POLYUNSATURATED FATTY ACIDS PRODUCTS FROM DOMESTIC VEGETABLE RAW MATERIALS, GIGIENA I SANITARIYA, 1, PP. 79-84, (2016); RODIONOVA N.S., SOKOLOVA O.A., EFFECT OF HEAT TREATMENT ON THE BIOLOGICAL VALUE OF THE PROTEIN WHEAT GERM FLOUR. SOVREMENNYE PROBLEMY NAUKI I OBRAZOVANIYA, 4, (2015); RODIONOVA N.S., ALEKSEEVA T.V., THEORETICAL ASPECTS OF TECHNOLOGY DEVELOPMENT AND COMPONENT COMPOSITION OF PLANT FOOD COMPLEX SYSTEMS BASED ON DEEP PROCESSING OF RAW PRODUCTS NIZKOMASLICH- NOGO, (2014); ARABIDZE G.G., TEBLOEV K.I., ATHEROSCLEROSIS AND RISK FACTORS, (2008); OGANOV R.G., DYSLIPIDEMIA AND ATHEROSCLEROSIS, (2009); TOT P.P., MEKI K.K., DISORDERS OF LIPID METABOLISM, (2010); ROITMAN A.P., LABORATORY DIAGNOSIS AND MONITORING OF PATIENTS WITH DISORDERS OF LIPID METABOLISM PROTOCOLS, LABORATORIYA, 2, PP. 12-13, (2003); GRACHEV YU.P., PLAKSIN YU.M., MATHEMATICAL METHODS FOR DESIGN OF EXPERIMENTS, (2005); CASTANO G., MAS R., FERNANDEZ J.C., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ L., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 95-97, (2000); CASTANO G., CANETTI M., MOREIRA M., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 19-28, (1995); ORTENSI G., GLADSTEIN J., VALLI H., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997)","","NUTRITEC","RUSSIAN","VOPR. PITAN.","ARTICLE","ISI","2-S2.0-85015862345","VOPR PITAN",NA,"NOTREPORTED",NA,"RODIONOVA NS, 2016, VOPR PITAN","RODIONOVA NS, 2016, VOPR PITAN"
"LUKIĆ M;LUKIĆ I;SLADONJA B;PILIŽOTA V","LUKIĆ, MARINA (36181149200); LUKIĆ, IGOR (9941727900); SLADONJA, BARBARA (9939334900); PILIŽOTA, VLASTA (6603031825)","POLICOSANOL VARIATION IN OLIVE OIL AS A RESULT OF VARIETY RIPENING AND STORAGE",2015,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","117","12",5,"10.1002/ejlt.201400483","INSTITUTE OF AGRICULTURE AND TOURISM, POREČ, CROATIA;INSTITUTE OF AGRICULTURE AND TOURISM, POREČ, CROATIA;INSTITUTE OF AGRICULTURE AND TOURISM, POREČ, CROATIA;FACULTY OF FOOD TECHNOLOGY, JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK, OSIJEK, CROATIA","DESPITE THEIR IMPORTANCE AS BIOACTIVE COMPOUNDS AND AUTHENTICATION PARAMETERS IN OLIVE OIL, THE RESPONSE OF POLICOSANOL ALIPHATIC ALCOHOLS TO EVEN THE MOST INFLUENTIAL SOURCES OF VARIABILITY IS PRACTICALLY UNKNOWN. TO INVESTIGATE POLICOSANOL VARIATION IN OLIVE OIL AS A RESULT OF VARIETY, RIPENING, AND OIL STORAGE TEMPERATURE, 36 SAMPLES WERE SUBJECTED TO GAS CHROMATOGRAPHIC (GC-FID) AND MASS SPECTROMETRIC (GC-MS) ANALYSIS, AND RESULTS WERE PROCESSED BY UNIVARIATE (ANOVA) AND MULTIVARIATE (SLDA) STATISTICS. THE CONCENTRATION (MG/100G) AND RELATIVE AMOUNT (%) OF PENTACOSANOL ACCOUNTED FOR THE MOST VARIATION DUE TO VARIETY. THE LARGEST INFLUENCE OF RIPENING WAS OBSERVED FOR PENTACOSANOL (%) AND DOCOSANOL (%). DOCOSANOL, TRICOSANOL, AND TETRACOSANOL AMOUNTS MOSTLY INCREASED DURING RIPENING, WHEREAS THOSE OF PENTACOSANOL, HEXACOSANOL, HEPTACOSANOL, AND OCTACOSANOL DECREASED IN ČRNA AND ROSINJOLA OILS, WHEREAS BUŽA SHOWED DIFFERENT PATTERNS IN SOME CASES. VARIATIONS AS A RESULT OF STORAGE WERE LOWER AND INCONSISTENT. RESULTS SUGGEST THAT THE INVESTIGATED OLIVE OILS RETAINED THE BULK OF THEIR HEALTH BENEFICIAL FEATURES OF POLICOSANOL ORIGIN THROUGHOUT SHELF-LIFE. RELATIVELY SUCCESSFUL DIFFERENTIATION OF OILS ACHIEVED BY MULTIVARIATE MODELS POINTED TO THE POTENTIAL USE OF POLICOSANOL ALCOHOLS AS CHEMICAL INDICATORS OF VARIETAL ORIGIN WHICH ARE INDEPENDENT ON RIPENING DEGREE, AND VICE VERSA, APPLICABLE BOTH FOR FRESH AND STORED OILS. © 2015 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.","OLIVE OIL; POLICOSANOL; RIPENING DEGREE; STORAGE; VARIETY","","","","CHERIF A.O., MESSAOUDA M.B., KAABI B., BOUKHCHINA S., ET AL., COMPARISON OF THE CONCENTRATIONS OF LONG-CHAIN ALCOHOLS (POLICOSANOL) IN THREE TUNISIAN PEANUT VARIETIES (ARACHIS HYPOGAEA L.), J. AGRIC. FOOD CHEM., 58, PP. 12143-12148, (2010); JUNG D.M., LEE M.J., YOON S.H., JUNG M.Y., A GAS CHROMATOGRAPHY-TANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS, J. FOOD SCI., 76, PP. C891-C899, (2011); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., DE LA PUERTA VAZQUEZ R., PERONA J.S., ET AL., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J. NUTR. BIOCHEM., 20, PP. 155-162, (2009); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40ÁMG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. P., 29, PP. 891-897, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT. THER. MED., 16, PP. 61-65, (2008); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAG. LEUKOTR. ESS, 58, PP. 61-64, (1998); COMMISSION IMPLEMENTING REGULATION NO 1348/2013 OF 16 DECEMBER 2013 AMENDING REGULATION (EEC) NO 2568/91 ON THE CHARACTERISTICS OF OLIVE OIL AND OLIVE-RESIDUE OIL AND ON THE RELEVANT METHODS OF ANALYSIS, OJEU, L338, PP. 31-67, (2013); TRADE STANDARDS APPLYING TO OLIVE OILS AND OLIVE-POMACE OILS, 7, (2013); CECI L.N., CARELLI A.A., CHARACTERIZATION OF MONOVARIETAL ARGENTINIAN OLIVE OILS FROM NEW PRODUCTIVE ZONES, J. AM. OIL CHEM. SOC., 84, PP. 1125-1136, (2007); VOLPE M.G., DE CUNZO F., SIANO F., PAOLUCCI M., ET AL., INFLUENCE OF EXTRACTION TECHNIQUES ON PHYSICAL-CHEMICAL CHARACTERISTICS AND VOLATILE COMPOUNDS OF EXTRA VIRGIN OLIVE OIL, J. OLEO SCI., 63, PP. 875-883, (2014); CECI L.N., CARELLI A.A., RELATION BETWEEN OXIDATIVE STABILITY AND COMPOSITION IN ARGENTINIAN OLIVE OILS, J. AM. OIL CHEM. SOC., 87, PP. 1189-1197, (2010); GIUFFRE A.M., LOUADJ L., POIANA M., MACARIO A., COMPOSITION EN STEROLS DES HUILES EXTRAITES D'OLIVES DE CULTIVARS DE LA PROVINCE DE REGGIO CALABRIA (SUD D'ITALIE), RIV. ITAL. SOSTANZE GR., 89, PP. 177-183, (2012); GIUFFRE A.M., LOUADJ L., INFLUENCE OF CROP SEASON AND CULTIVAR ON STEROL COMPOSITION OF MONOVARIETAL OLIVE OILS IN REGGIO CALABRIA (ITALY), CZECH J. FOOD SCI., 31, PP. 256-263, (2013); GIUFFRE A.M., INFLUENCE OF CULTIVAR AND HARVEST YEAR ON TRIGLYCERIDE COMPOSITION OF OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY), EUR. J. LIPID SCI. TECHNOL., 115, PP. 928-934, (2013); GIUFFRE A.M., INFLUENCE OF HARVEST YEAR AND CULTIVAR ON WAX COMPOSITION OF OLIVE OILS, EUR. J. LIPID SCI. TECHNOL, 115, PP. 549-555, (2013); GIUFFRE A.M., WAX ESTER VARIATION IN OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY) DURING OLIVE RIPENING, J. AM. OIL CHEM. SOC., 91, PP. 1355-1366, (2014); LAZZEZ A., PERRI E., CARAVITA M.A., KHLIF M., COSSENTINI M., INFLUENCE OF OLIVE MATURITY STAGE AND GEOGRAPHICAL ORIGIN ON SOME MINOR COMPONENTS IN VIRGIN OLIVE OIL OF THE CHEMLALI VARIETY, J. AGRIC. FOOD CHEM., 56, PP. 982-988, (2008); APARICIO R., LUNA G., CHARACTERISATION OF MONOVARIETAL VIRGIN OLIVE OILS, EUR. J. LIPID SCI. TECHNOL., 104, PP. 614-627, (2002); STEFANOUDAKI E., KOTSIFAKI F., KOUTSAFTAKIS A., SENSORY AND CHEMICAL PROFILES OF THREE EUROPEAN OLIVE VARIETIES (OLEA EUROPEA L); AN APPROACH FOR THE CHARACTERISATION AND AUTHENTICATION OF THE EXTRACTED OILS, J. SCI. FOOD AGRIC., 80, PP. 381-389, (2000); SAKOUHI F., ABSALON C., FLAMINI G., CIONI P.L., ET AL., LIPID COMPONENTS OF OLIVE OIL FROM TUNISIAN CV. SAYALI: CHARACTERIZATION AND AUTHENTICITY, C. R. BIOL., 333, PP. 642-648, (2010); KRICHENE D., ALLALOUT A., SALVADOR M.D., FREGAPANE G., ZARROUK M., FATTY ACIDS, VOLATILES, STEROLS AND TRITERPENIC ALCOHOLS OF SIX MONOVARIETAL TUNISIAN VIRGIN OLIVE OIL, EUR. J. LIPID SCI. TECHNOL., 112, PP. 400-409, (2010); GIUFFRE A.M., ALCOLI ALIFATICI E TERPENICI IN OLIO DI OLIVA ESTRATTO DA CULTIVAR ALLEVATE IN CALABRIA, IND. ALIMENT., 52, PP. 28-35, (2013); GIUFFRE A.M., EVOLUTION OF FATTY ALCOHOLS IN OLIVE OILS PRODUCED IN CALABRIA (SOUTHERN ITALY) DURING FRUIT RIPENING, J. OLEO SCI., 63, PP. 486-496, (2014); GIUFFRE A.M., THE EFFECTS OF CULTIVAR AND HARVEST YEAR ON FATTY ALCOHOL COMPOSITION OF OLIVE OILS FROM SOUTH WEST CALABRIA (ITALY), GRASAS ACEITES, 65, (2014); CAMERA L., ANGEROSA F., THE HIGHER ALCOHOLS OF OLIVE OIL. THEIR DEVELOPMENT WITH THE PROGRESSIVE RIPENING OF THE OLIVES, RIV. ITAL. SOSTANZE GR., 55, PP. 138-146, (1978); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L. FRUITS, EUR. J. LIPID SCI. TECHNOL., 112, PP. 373-379, (2010); OROZCO-SOLANO M., RUIZ-JIMENEZ J., LUQUE DE CASTRO M.D., CHARACTERIZATION OF FATTY ALCOHOL AND STEROL FRACTIONS IN OLIVE TREE, J. AGRIC. FOOD CHEM., 58, PP. 7539-7546, (2010); BIANCHI G., GIANSANTE L., SHAW A., KELL D.B., CHEMOMETRIC CRITERIA FOR THE CHARACTERISATION OF ITALIAN PROTECTED DENOMINATION OF ORIGIN (DOP) OLIVE OILS FROM THEIR METABOLIC PROFILES, EUR. J. LIPID SCI. TECHNOL., 103, PP. 141-150, (2001); RANALLI A., POLLASTRI L., CONTENTO S., DI LORETO G., ET AL., STEROL AND ALCOHOL COMPONENTS OF SEEDS, PULP, AND WHOLE OLIVE FRUIT OILS. THEIR USE TO CHARACTERISE OLIVE FRUIT VARIETY BY MULTIVARIATES, J. SCI. FOOD AGRIC., 82, PP. 854-859, (2002); RIVERA DEL ALAMO R.M., FREGAPANE G., ARANDA F., GOMEZ-ALONSO S., SALVADOR M.D., STEROL AND ALCOHOL COMPOSITION OF CORNICABRA VIRGIN OLIVE OIL: THE CAMPESTEROL CONTENT EXCEEDS THE UPPER LIMIT OF 4% ESTABLISHED BY EU REGULATIONS, FOOD CHEM., 84, PP. 533-537, (2004); LERMA-GARCIA M.J., RAMIS-RAMOS G., HERRERO-MARTINEZ J.M., GIMENO-ADELANTADO J.V., SIMO-ALFONSO E.F., CHARACTERIZATION OF THE ALCOHOLIC FRACTION OF VEGETABLE OILS BY DERIVATIZATION WITH DIPHENIC ANHYDRIDE FOLLOWED BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH SPECTROPHOTOMETRIC AND MASS SPECTROMETRIC DETECTION, J. CHROMATOGR. A, 1216, PP. 230-236, (2009); MULINACCI N., IERI F., IGNESTI G., ROMANI A., ET AL., THE FREEZING PROCESS HELPS TO PRESERVE THE QUALITY OF EXTRA VIRGIN OLIVE OIL OVER TIME: A CASE STUDY UP TO 18 MONTHS, FOOD RES. INT., 54, PP. 2008-2015, (2013); BELTRAN G., DEL RIO C., SANCHEZ S., MARTINEZ L., SEASONAL CHANGES IN OLIVE FRUIT CHARACTERISTICS AND OIL ACCUMULATION DURING RIPENING PROCESS, J. SCI. FOOD AGRIC., 84, PP. 1783-1790, (2004); SOKAL R.R., ROHLF F.J., BIOMETRY, (1981); EL ANTARI A., HILAL A., BOULOUHA B., EL MOUDNI A., ETUDE DE L'INFLUENCE DE LA VARIÉTÉ, DE L'ENVIRONMENT ET DES TECHNIQUES CULTURALES SUR LES CARACTÉRISTIQUES DES FRUITS ET LA COMPOSITION CHIMIQUE DE L'HULLE D'OLIVE VIERGE EXTRA AU MAROC, OLIVAE, 80, PP. 29-36, (2000); GROB K., LANFRANCHI M., MARIANI C., EVALUATION OF OLIVE OILS THROUGH THE FATTY ALCOHOLS, THE STEROLS AND THEIR ESTERS BY COUPLED LC-GC, J. AM. OIL CHEM. SOC., 67, PP. 626-634, (1990); TUBAILEH R.M., GARRIDO-FERNANDEZ A., RUIZ-MENDEZ M.V., LEON-CAMACHO M., GRACIANI-CONSTANTE E., EFFECTS OF PHYSICAL REFINING ON CONTENTS OF WAXES AND FATTY ALCOHOLS OF REFINED OLIVE OIL, J. AM. OIL CHEM. SOC., 79, PP. 101-104, (2002); OROZCO-SOLANO M., RUIZ-JIMENEZ J., LUQUE DE CASTRO M.D., ULTRASOUND-ASSISTED EXTRACTION AND DERIVATIZATION OF STEROLS AND FATTY ALCOHOLS FROM OLIVE LEAVES AND DRUPES PRIOR TO DETERMINATION BY GAS CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, J. CHROMATOGR. A, 1217, PP. 1227-1235, (2010); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM., 115, PP. 918-923, (2009); LEGUIZAMON C., WELLER C.L., SCHLEGEL V.L., CARR T.P., PLANT STEROL AND POLICOSANOL CHARACTERIZATION OF HEXANE EXTRACTS FROM GRAIN SORGHUM, CORN, AND THEIR DDGS, J. AM. OIL CHEM. SOC., 86, PP. 707-716, (2009); ANASTASI U., SANTONOCETO C., GIUFFRE A.M., SORTINO M., ET AL., YIELD PERFORMANCE AND GRAIN LIPID COMPOSITION OF STANDARD AND OLEIC SUNFLOWER AS AFFECTED BY WATER SUPPLY, FIELD CROP. RES., 119, PP. 145-153, (2010); LOPEZ-LOPEZ A., MONTANO A., RUIZ-MENDEZ M.V., GARRIDO-FERNANDEZ A., STEROLS, FATTY ALCOHOL AND TRITERPENIC ALCOHOLS IN COMMERCIAL TABLE OLIVES, J. AM. OIL CHEM. SOC., 85, PP. 253-262, (2008); RANALLI A., TOMBESI A., FERRANTE M., DE MATTIA G., RESPIRATORY RATE OF OLIVE DRUPES DURING THEIR RIPENING CYCLE AND QUALITY OF OIL EXTRACTED, J. SCI. FOOD AGRIC., 77, PP. 359-367, (1998); GARCIA-GONZALES D.L., TENA N., APARICIO R., DESCRIBING THE CHEMICAL SINGULARITY OF THE SPANISH PROTECTED DESIGNATIONS OF ORIGIN FOR VIRGIN OLIVE OILS IN RELATION TO OILS FROM NEIGHBOURING AREAS, GRASAS ACEITES, 63, PP. 26-34, (2012); SAMUELS L., KUNST L., JETTER R., SEALING PLANT SURFACES: CUTICULAR WAX FORMATION BY EPIDERMAL CELLS, ANNU. REV. PLANT BIOL., 59, PP. 683-707, (2008); SALAS J.J., WILLIAMS M., HARWOOD J.L., SANCHEZ J., LIPOXYGENASE ACTIVITY IN OLIVE (OLEA EUROPAEA) FRUIT, J. AM. OIL CHEM. SOC., 76, PP. 1163-1168, (1999); CARADEC S., GROSSI V., GILBERT F., GUIGUE C., GOUTX M., INFLUENCE OF VARIOUS REDOX CONDITIONS ON THE DEGRADATION OF MICROALGAL TRIACYLGLYCEROLS AND FATTY ACIDS IN MARINE SEDIMENTS, ORG. GEOCHEM., 35, PP. 277-287, (2004)","M. LUKIĆ; INSTITUTE OF AGRICULTURE AND TOURISM, POREČ, KARLA HUGUESA 8, 52440, CROATIA; EMAIL: MARINA@IPTPO.HR","WILEY-VCH VERLAG","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-84938744683","EUR J LIPID SCI TECHNOL","INSTITUTE OF AGRICULTURE AND TOURISM;INSTITUTE OF AGRICULTURE AND TOURISM;INSTITUTE OF AGRICULTURE AND TOURISM;JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK","NOTREPORTED;INSTITUTE OF AGRICULTURE AND TOURISM;NOTREPORTED",NA,"LUKIĆ M, 2015, EUR J LIPID SCI TECHNOL","LUKIĆ M, 2015, EUR J LIPID SCI TECHNOL"
"BARRAT E;ZAÏR Y;OGIER N;HOUSEZ B;VERGARA C;MAUDET C;LESCUYER J;BARD J;CARPENTIER Y;CAZAUBIEL M;PELTIER S","BARRAT, EMMANUEL (24597059800); ZAÏR, YASSINE (6602320134); OGIER, NICOLAS (22980892200); HOUSEZ, BÉATRICE (39261486200); VERGARA, CORALIE (55240030300); MAUDET, CORINNE (55533406200); LESCUYER, JEAN-FRANÇOIS (54796767200); BARD, JEAN-MARIE (7202839766); CARPENTIER, YVON A. (7005938168); CAZAUBIEL, MURIELLE (25421045100); PELTIER, SÉBASTIEN L. (23390396700)","A COMBINED NATURAL SUPPLEMENT LOWERS LDL CHOLESTEROL IN SUBJECTS WITH MODERATE UNTREATED HYPERCHOLESTEROLEMIA A RANDOMIZED PLACEBOCONTROLLED TRIAL",2013,"INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION","64","7",29,"10.3109/09637486.2013.809405","DEPARTMENT OF RESEARCH AND DEVELOPMENT, LABORATOIRE LESCUYER, ZAC DE BELLE AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE;DEPARTMENT OF ENDOCRINOLOGY, L'INSTITUT DU THORAX, NANTES UNIVERSITY HOSPITAL, NANTES, FRANCE;DEPARTMENT OF RESEARCH AND DEVELOPMENT, LABORATOIRE LESCUYER, ZAC DE BELLE AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE;DEPARTMENT BIOFORTIS CLINICAL, BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, SAINT-HERBLAIN, FRANCE;DEPARTMENT BIOFORTIS CLINICAL, BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, SAINT-HERBLAIN, FRANCE;DEPARTMENT BIOFORTIS CLINICAL, BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, SAINT-HERBLAIN, FRANCE;DEPARTMENT OF RESEARCH AND DEVELOPMENT, LABORATOIRE LESCUYER, ZAC DE BELLE AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE;DEPARTMENT MER, MOLÉCULES, SANTÉ, LUNAM, UNIVERSITÉ DE NANTES EA2160, NANTES, FRANCE, DEPARTMENT OF BIOPATHOLOGY, INSTITUT DE CANCÉROLOGIE DE L'OUEST, SAINT-HERBLAIN, FRANCE;UNIVERSITÉ LIBRE DE BRUXELLES, BRUSSELS, BELGIUM;DEPARTMENT BIOFORTIS CLINICAL, BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY, SAINT-HERBLAIN, FRANCE;DEPARTMENT OF RESEARCH AND DEVELOPMENT, LABORATOIRE LESCUYER, ZAC DE BELLE AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE","OBJECTIVE: TO INVESTIGATE THE EFFECT OF A NATURAL CHOLESTEROL-LOWERING SUPPLEMENT (NCLS) CONTAINING RED YEAST RICE, POLICOSANOLS AND ARTICHOKE LEAF EXTRACTS ON BLOOD LIPID CONCENTRATIONS AS WELL AS ON SAFETY PARAMETERS WHEN GIVEN OVER 16 WEEKS IN 100 VOLUNTEERS WITH UNTREATED MODERATE HYPERCHOLESTEROLEMIA, IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. RESULTS: REDUCTION OF PRIMARY OUTCOME LOW-DENSITY LIPOPROTEIN CHOLESTEROL [-0.22 G/L (95% CONFIDENCE INTERVAL, CI:-0.31 TO-0.12) CORRESPONDING TO-14.3% FROM BASELINE (95% CI:-21.5 TO-7.2) COMPARED TO PLACEBO], AS WELL AS TOTAL CHOLESTEROL, APOLIPOPROTEIN B100 AND APOLIPOPROTEIN B100/APOLIPOPROTEIN A-I RATIO, WERE OBSERVED AFTER 16 WEEKS OF SUPPLEMENTATION WITH NCLS. THESE EFFECTS WERE ALREADY OBSERVED AT WEEK 4 AND 10 OF SUPPLEMENTATION. NO SIGNIFICANT CHANGES WERE OBSERVED IN HIGH-DENSITY LIPOPROTEIN, TRIACYLGLYCEROL, CREATINE KINASE, LACTATE DEHYDROGENASE AND COENZYME Q10 LEVELS, AS WELL AS IN MARKERS OF LIVER AND RENAL FUNCTION. CONCLUSIONS: THE NCLS WAS EFFECTIVE IN REDUCING LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN B100 IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA, WITHOUT MODIFYING SAFETY PARAMETERS. © 2013 INFORMA UK LTD. ALL RIGHTS RESERVED.","ARTICHOKE; CHOLESTEROL; COENZYME Q10; CREATINE KINASE; POLICOSANOLS; RED YEAST RICE","ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; BIOLOGICAL PRODUCTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYNARA SCOLYMUS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TRIGLYCERIDES; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICHOKE; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL","","","ANDERSON T.J., GREGOIRE J., HEGELE R.A., COUTURE P., MANCINI G.B., MCPHERSON R., FRANCIS G.A., ET AL., 2012 UPDATE OF THE CANADIAN CARDIOVASCULAR SOCIETY GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIA FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE ADULT, CAN J CARDIOL, 29, PP. 151-167, (2013); APPELKVIST E.L., EDLUND C., LOW P., SCHEDIN S., KALEN A., DALLNER G., EFFECTS OF INHIBITORS OF HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE ON COENZYME Q AND DOLICHOL BIOSYNTHESIS, CLIN INVESTIG, 71, (1993); BARRAT E., ZAIR Y., SIRVENT P., CHAUVEAU P., MAUDET C., HOUSEZ B., DERBORD E., ET AL., EFFECT ON LDL-CHOLESTEROL OF A LARGE DOSE OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH UNTREATED MODERATE HYPERCHOLESTEROLAEMIA: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EUR J NUTR, (2013); BAUMGARTNER S., MENSINK R.P., PLAT J., PLANT STEROLS AND STANOLS IN THE TREATMENT OF DYSLIPIDEMIA: NEW INSIGHTS INTO TARGETS AND MECHANISMS RELATED TO CARDIOVASCULAR RISK, CURR PHARM DES, 17, PP. 922-932, (2011); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); MIHAYLOVA B., EMBERSON J., BLACKWELL L., KEECH A., SIMES J., BARNES E.H., ET AL., THE EFFECTS OF LOWERING LDL CHOLESTEROL WITH STATIN THERAPY IN PEOPLE AT LOW RISK OF VASCULAR DISEASE: META-ANALYSIS OF INDIVIDUAL DATA FROM 27 RANDOMISED TRIALS, LANCET, 380, PP. 581-590, (2012); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); EGAN A., COLMAN E., WEIGHING THE BENEFITS OF HIGH-DOSE SIMVASTATIN AGAINST THE RISK OF MYOPATHY, N ENGL J MED, 365, PP. 285-287, (2011); ENDO A., MONACOLIN K, A NEW HYPOCHOLESTEROLEMIC AGENT PRODUCED BY A MONASCUS SPECIES, J ANTIBIOT, 32, PP. 852-854, (1979); FOOD LABELING: HEALTH CLAIMS; PLANT STEROL/STANOL ESTERS AND CORONARY HEART DISEASE. FOOD AND DRUG ADMINISTRATION, HHS. INTERIM FINAL RULE, FED REGIST, 65, PP. 54686-54739, (2000); NUTS & HEART DISEASE, (2003); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GAUTHIER A.P., LARIVIERE M., YOUNG N., PSYCHOMETRIC PROPERTIES OF THE IPAQ: A VALIDATION STUDY IN A SAMPLE OF NORTHERN FRANCO-ONTARIANS, J PHYS ACT HEALTH, 6, (2009); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLES-TEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, PP. 133-139, (2001); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); HU F.B., WILLETT W.C., OPTIMAL DIETS FOR PREVENTION OF CORONARY HEART DISEASE, JAMA, 288, PP. 2569-2578, (2002); HUANG C.F., LI T.C., LIN C.C., LIU C.S., SHIH H.C., LAI M.M., EFFICACY OF MONASCUS PURPUREUS WENT RICE ON LOWERING LIPID RATIOS IN HYPERCH-OLESTEROLEMIC PATIENTS, EUR J CARDIOVASC PREV REHABIL, 14, PP. 438-440, (2007); JENKINS D.J., JONES P.J., LAMARCHE B., KENDALL C.W., FAULKNER D., CERMAKOVA L., GIGLEUX I., ET AL., EFFECT OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS GIVEN AT 2 LEVELS OF INTENSITY OF DIETARY ADVICE ON SERUM LIPIDS IN HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 306, PP. 831-839, (2011); JENKINS D.J., KENDALL C.W., MARCHIE A., FAULKNER D.A., WONG J.M., DE SOUZA R., EMAM A., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS VS LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, JAMA, 290, PP. 502-510, (2003); JENKINS D.J., KENDALL C.W., VUKSAN V., VIDGEN E., PARKER T., FAULKNER D., MEHLING C.C., ET AL., SOLUBLE FIBER INTAKE AT A DOSE APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR A CLAIM OF HEALTH BENEFITS: SERUM LIPID RISK FACTORS FOR CARDIOVASCULAR DISEASE ASSESSED IN A RANDOMIZED CONTROLLED CROSSOVER TRIAL, AM J CLIN NUTR, 75, PP. 834-839, (2002); JENKINS D.J., MIRRAHIMI A., SRICHAIKUL K., BERRYMAN C.E., WANG L., CARLETON A., ABDULNOUR S., ET AL., SOY PROTEIN REDUCES SERUM CHOLESTEROL BY BOTH INTRINSIC AND FOOD DISPLACEMENT MECHANISMS, J NUTR, 140, (2010); KLIMEK M., WANG S., OGUNKANMI A., SAFETY AND EFFICACY OF RED YEAST RICE (MONASCUS PURPUREUS) AS AN ALTERNATIVE THERAPY FOR HYPERLIPID-EMIA. P & T, 34, PP. 313-327, (2009); LIU C.S., LII C.K., CHANG L.L., KUO C.L., CHENG W.L., SU S.L., TSAI C.W., CHEN H.W., ATORVASTATIN INCREASES BLOOD RATIOS OF VITAMIN E/LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND COENZYME Q10/LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS, NUTR RES, 30, PP. 118-124, (2010); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); MENTE A., DE KONING L., SHANNON H.S., ANAND S.S., A SYSTEMATIC REVIEW OF THE EVIDENCE SUPPORTING A CAUSAL LINK BETWEEN DIETARY FACTORS AND CORONARY HEART DISEASE, ARCH INTERN MED, 169, PP. 659-669, (2009); MILLS S., BONE K., PRINCIPLES AND PRACTICE OF PHYTOTHERAPY, (1999); OGIER N., AMIOT M.J., GEORGE S., MAILLOT M., MALLMANN C., MARANINCHI M., MORANGE S., ET AL., LDL-CHOLESTEROL-LOWERING EFFECT OF A DIETARY SUPPLEMENT WITH PLANT EXTRACTS IN SUBJECTS WITH MODERATE HYPERCHOL-ESTEROLEMIA, EUR J NUTR, 52, PP. 547-557, (2013); PALOMAKI A., MALMINIEMI K., SOLAKIVI T., MALMINIEMI O., UBIQUINONE SUPPLEMENTATION DURING LOVASTATIN TREATMENT: EFFECT ON LDL OXIDATION EX VIVO, J LIPID RES, 39, PP. 1430-1437, (1998); REINER Z., CATAPANO A.L., DE BACKER G., GRAHAM I., TASKINEN M.R., WIKLUND O., AGEWALL S., ET AL., ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS: THE TASK FORCE FOR THE MANAGEMENT OF DYSLIPIDAEMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), EUR HEART J, 32, PP. 1769-1818, (2011); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); SIRVENT P., FABRE O., BORDENAVE S., HILLAIRE-BUYS D., RAYNAUD DE MAUVERGER E., LACAMPAGNE A., MERCIER J., MUSCLE MITOCHONDRIAL METABOLISM AND CALCIUM SIGNALING IMPAIRMENT IN PATIENTS TREATED WITH STATINS, TOXICOL APPL PHARMACOL, 259, PP. 263-268, (2012); SMITH JR. S.C., BENJAMIN E.J., BONOW R.O., BRAUN L.T., CREAGER M.A., FRANKLIN B.A., GIBBONS R.J., ET AL., CIRCULATION, 124, PP. 2458-2473, (2011); STOCKER R., BOWRY V.W., FREI B., UBIQUINOL-10 PROTECTS HUMAN LOW DENSITY LIPOPROTEIN MORE EFFICIENTLY AGAINST LIPID PEROXIDATION THAN DOES ALPHA-TOCOPHEROL, PROC NATL ACAD SCI USA, 88, PP. 1646-1650, (1991); WARNICK G.R., WOOD P.D., NATIONAL CHOLESTEROL EDUCATION PROGRAM RECOMMENDATIONS FOR MEASUREMENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: EXECUTIVE SUMMARY. THE NATIONAL CHOLESTEROL EDUCATION PROGRAM WORKING GROUP ON LIPOPROTEIN MEASUREMENT, CLIN CHEM, 41, PP. 1427-1433, (1995); WIDER B., PITTLER M.H., THOMPSON-COON J., ERNST E., ARTICHOKE LEAF EXTRACT FOR TREATING HYPERCHOLESTEROLAEMIA, COCHRANE DATABASE SYST REV, 3, (2013); YAMASHITA S., YAMAMOTO Y., SIMULTANEOUS DETECTION OF UBIQUINOL AND UBIQUINONE IN HUMAN PLASMA AS A MARKER OF OXIDATIVE STRESS, ANAL BIOCHEM, 250, PP. 66-73, (1997); YANG H.T., LIN S.H., HUANG S.Y., CHOU H.J., ACUTE ADMINISTRATION OF RED YEAST RICE (MONASCUS PURPUREUS) DEPLETES TISSUE COENZYME Q(10) LEVELS IN ICR MICE, BR J NUTR, 93, PP. 131-135, (2005); ZHAO S.P., LIU L., CHENG Y.C., SHISHEHBOR M.H., LIU M.H., PENG D.Q., LI Y.L., XUEZHIKANG, AN EXTRACT OF CHOLESTIN, PROTECTS ENDOTHELIAL FUNCTION THROUGH ANTIINFLAMMATORY AND LIPID-LOWERING MECHANISMS IN PATIENTS WITH CORONARY HEART DISEASE, CIRCULATION, 110, PP. 915-920, (2004)","S.L. PELTIER; DEPARTMENT OF RESEARCH AND DEVELOPMENT, LABORATOIRE LESCUYER, ZAC DE BELLE AIRE NORD, 17440 AYTRÉ, 15 RUE LE CORBUSIER, FRANCE; EMAIL: SEBASTIEN.PELTIER@LABORATOIRE-LESCUYER.COM","","ENGLISH","INT. J. FOOD SCI. NUTR.","ARTICLE","ISI","2-S2.0-84885397137","INT J FOOD SCI NUTR","LABORATOIRE LESCUYER;NANTES UNIVERSITY HOSPITAL;LABORATOIRE LESCUYER;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;LABORATOIRE LESCUYER;SAINT-HERBLAIN;UNIVERSITÉ LIBRE DE BRUXELLES;BIOFORTIS-MÉRIEUX NUTRISCIENCES COMPANY;LABORATOIRE LESCUYER","NOTREPORTED;LABORATOIRE LESCUYER;EMAIL: SEBASTIEN.PELTIER@LABORATOIRE-LESCUYER.COM",NA,"BARRAT E, 2013, INT J FOOD SCI NUTR","BARRAT E, 2013, INT J FOOD SCI NUTR"
"STANGER M;THOMPSON L;YOUNG A;LIEBERMAN H","STANGER, MICHAEL J. (54947863900); THOMPSON, LAUREN A. (55419120500); YOUNG, ANDREW J. (7403881844); LIEBERMAN, HARRIS R. (7101773970)","ANTICOAGULANT ACTIVITY OF SELECT DIETARY SUPPLEMENTS",2012,"NUTRITION REVIEWS","70","10",66,"10.1111/j.1753-4887.2011.00444.x","MILITARY NUTRITION DIVISION, US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE, NATICK, MA, UNITED STATES;MILITARY NUTRITION DIVISION, US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE, NATICK, MA, UNITED STATES;MILITARY NUTRITION DIVISION, US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE, NATICK, MA, UNITED STATES;MILITARY NUTRITION DIVISION, US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE, NATICK, MA, UNITED STATES","THIS REVIEW CONSIDERS THE POTENTIAL OF CERTAIN DIETARY SUPPLEMENTS, INCLUDING GARLIC, GINKGO BILOBA, GINGER, GINSENG, FISH OIL, AND VITAMIN E, TO INTERFERE WITH HEMOSTASIS. DIETARY SUPPLEMENTS ARE COMMON COMPONENTS OF THE DIET IN THE UNITED STATES, WITH ABOUT HALF THE US ADULT POPULATION TAKING SOME TYPE OF DIETARY SUPPLEMENT REGULARLY. IT HAS BEEN SUGGESTED THAT SOME SUPPLEMENTS COULD ADVERSELY AFFECT COAGULATION WHEN TAKEN ALONE OR IN COMBINATION WITH ANTIPLATELET MEDICATIONS. SUPPLEMENTS COULD ALTER HEMOSTASIS BY A VARIETY OF MECHANISMS, SUCH AS REDUCING PLATELET AGGREGATION OR INHIBITING ARACHIDONIC ACID, A CELLULAR SIGNALING MESSENGER AND INFLAMMATORY INTERMEDIATE. TO CONDUCT THIS REVIEW, MULTIPLE DATABASES WERE SEARCHED USING A VARIETY OF SEARCH TERMS TO ENSURE RELEVANT PAPERS WERE LOCATED. MODERATE TO SEVERE ADVERSE EVENTS, SUCH AS SPINAL EPIDURAL HEMATOMA, SPONTANEOUS INTRACEREBRAL HEMORRHAGE, RETROBULBAR HEMORRHAGE, SUBARACHNOID HEMORRHAGE, SPONTANEOUS HYPHEMA, AND POSTOPERATIVE BLEEDING, HAVE OCCASIONALLY BEEN ANECDOTALLY ASSOCIATED WITH CONSUMPTION OF DIETARY SUPPLEMENTS. HOWEVER, THE NUMBER OF CONTROLLED STUDIES IN THE LITERATURE IS TOO LIMITED TO DEMONSTRATE CONSISTENT ANTICOAGULANT EFFECTS OF DIETARY SUPPLEMENTS ALONE OR IN COMBINATION WITH DRUG THERAPY. © 2012 INTERNATIONAL LIFE SCIENCES INSTITUTE.","ADVERSE EVENTS; ANTIPLATELET; HEMORRHAGE; HEMOSTASIS; SUPPLEMENTS","ANTICOAGULANTS; DIETARY SUPPLEMENTS; HEMORRHAGE; HERB-DRUG INTERACTIONS; HOMEOSTASIS; HUMANS; PLATELET AGGREGATION INHIBITORS; ALLIUM SATIVUM; GINKGO BILOBA; PANAX GINSENG; ZINGIBER OFFICINALE; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; ARGININE; CILOSTAZOL; FISH OIL; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUCOSAMINE; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; POLICOSANOL; SIGNAL PEPTIDE; TANACETUM PARTHENIUM EXTRACT; TAURINE; UBIDECARENONE; WARFARIN; ANGELICA SINENSIS; ANTICOAGULATION; ARTHRITIS; BLEEDING; BRAIN HEMORRHAGE; DATA BASE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; GARLIC; GINGER; GINKGO BILOBA; GINSENG; HEMOSTASIS; HUMAN; INFLAMMATION; MEDLINE; NAUSEA; NONHUMAN; PERIPHERAL VASCULAR DISEASE; RETROBULBAR HEMORRHAGE; REVIEW; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TANACETUM PARTHENIUM; UNITED STATES; VERTIGO","","","RADIMER K., BINDEWALD B., HUGHES J., ET AL., DIETARY SUPPLEMENT USE BY ADULTS: DATA FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 1999-2000, AM J EPID., 160, PP. 339-349, (2004); RAGHAVAN S.A.V., DIKSHIT M., RECENT ADVANCES IN THE STATUS AND TARGETS OF ANTITHROMBOTIC AGENTS, DRUGS FUTURE., 27, PP. 669-683, (2002); CAVALIERE C., REA P., BLUMENTHAL M., HERBAL SUPPLEMENT SALES IN THE UNITED STATES SHOW GROWTH IN ALL CHANNELS, HERBAL GRAM., 78, PP. 60-63, (2008); TATTELMAN E., HEALTH EFFECTS OF GARLIC, AM FAM PHYSICIAN., 72, PP. 13-106, (2005); AMAGASE H., PETESCH B.L., MATSUURA H., ET AL., INTAKE OF GARLIC AND ITS BIOACTIVE COMPONENTS, J NUTR., 131, SUPPL., (2001); MAKHEJA A.N., BAILEY J.M., ANTIPLATELET CONSTITUENTS OF GARLIC AND ONION, AGENTS ACTIONS., 29, PP. 360-363, (1990); EL-SABBAN F., GARLIC AS AN ANTITHROMBOTIC AND ANTIPLATELET AGGREGATION AGENT, J CHIN CLIN MED., 4, PP. 288-294, (2009); RAHMAN K., BILLINGTON D., DIETARY SUPPLEMENTATION WITH AGED GARLIC EXTRACT INHIBITS ADP-INDUCED PLATELET AGGREGATION IN HUMANS, J NUTR., 130, PP. 2662-2665, (2000); STEINER M., LI W., AGED GARLIC EXTRACT, A MODULATOR OF CARDIOVASCULAR RISK FACTORS: A DOSE-FINDING STUDY ON THE EFFECTS OF AGE ON PLATELET FUNCTIONS, J NUTR., 131, SUPPL., (2001); GADKARI J.V., JOSHI V.D., EFFECT OF INGESTION OF RAW GARLIC ON SERUM CHOLESTEROL LEVEL, CLOTTING TIME AND FIBRINOLYTIC ACTIVITY IN NORMAL SUBJECTS, POSTGRAD MED J., 37, PP. 128-131, (1991); PIERRE S., CROSBIE L., DUTTAROY A.K., INHIBITORY EFFECT OF AQUEOUS EXTRACTS OF SOME HERBS ON HUMAN PLATELET AGGREGATION IN VITRO, PLATELETS., 16, PP. 469-473, (2005); SRIVASTAVA K.C., EVIDENCE FOR THE MECHANISM BY WHICH GARLIC INHIBITS PLATELET AGGREGATION, PROSTAGLANDINS LEUKOT MED., 22, PP. 313-321, (1986); ALLISON G.L., LOWE G.M., RAHMAN K., AGED GARLIC EXTRACT MAY INHIBIT AGGREGATION IN HUMAN PLATELETS BY SUPPRESSING CALCIUM MOBILIZATION, J NUTR., 136, SUPPL., (2006); ROSE K.D., CROISSANT P.D., PARLIAMENT C.F., ET AL., SPONTANEOUS SPINAL EPIDURAL HEMATOMA WITH ASSOCIATED PLATELET DYSFUNCTION FROM EXCESSIVE GARLIC INGESTION: A CASE REPORT, NEUROSURGERY., 26, PP. 880-882, (1990); ROSE K.D., CROISSANT P.D., PARLIAMENT C.F., ET AL., SPONTANEOUS SPINAL EPIDURAL HEMATOMA WITH ASSOCIATED PLATELET DYSFUNCTION FROM EXCESSIVE GARLIC INGESTION: A CASE REPORT, NEUROSURGERY., 26, PP. 880-882, (1990); ROWIN J., LEWIS S.L., SPONTANEOUS BILATERAL SUBDURAL HEMATOMAS ASSOCIATED WITH CHRONIC GINKGO BILOBA INGESTION, NEUROLOGY., 46, PP. 1775-1776, (1996); GERMAN K., KUMAR U., BLACKFORD H.N., GARLIC AND THE RISK OF TURP BLEEDING, BR J UROL., 76, (1995); BORRELLI F., CAPASSO R., IZZO A.A., GARLIC (ALLIUM SATIUUM L.): ADVERSE EFFECTS AND DRUG INTERACTIONS IN HUMANS, MOL NUTR FOOD RES., 51, PP. 1386-1397, (2007); SAW J.T., BAHARI M.B., ANG H.H., ET AL., POTENTIAL DRUG-HERB INTERACTION WITH ANTIPLATELET/ANTICOAGULANT DRUGS, COMPLEMENT THER CLIN PRACT., 12, PP. 236-241, (2006); WOJCIKOWSKI K., MYERS S., BROOKS L., EFFECTS OF GARLIC OIL ON PLATELET AGGREGATION: A DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER STUDY, PLATELETS., 18, PP. 29-34, (2007); HARENBERG J., GIESE C., ZIMMERMANN R., EFFECT OF DRIED GARLIC ON BLOOD COAGULATION, FIBRINOLYSIS, PLATELET AGGREGATION AND SERUM CHOLESTEROL LEVELS IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ATHEROSCLEROSIS., 74, PP. 247-249, (1988); BECKERT B.W., CONCANNON M.J., HENRY S.L., ET AL., THE EFFECT OF HERBAL MEDICINES ON PLATELET FUNCTION: AN IN VIVO EXPERIMENT AND REVIEW OF THE LITERATURE, PLAST RECONSTR SURG., 120, PP. 2044-2050, (2007); ABEBE W., HERBAL MEDICATIONS: POTENTIAL FOR ADVERSE INTERACTIONS WITH ANALGESIC DRUGS, J CLIN PHARM THER., 27, PP. 391-401, (2002); YOSKIKAWA T., NAITO Y., KONDO M., GINKGO BILOBA LEAF EXTRACT: REVIEW OF BIOLOGICAL ACTIONS AND CLINICAL APPLICATION, ANTIOXID REDOX SIGNAL., 1, PP. 469-480, (1999); SIERPINA V.S., WOLLSCHLAGER B., BLUMENTHAL M., GINKGO BILOBA, AM FAM PHYSICIAN., 68, PP. 923-926, (2003); BENJAMIN J., MUIR T., BRIGGS K., ET AL., A CASE OF CEREBRAL HAEMORRHAGE-CAN GINKGO BILOBA BE IMPLICATED?, POSTGRAD MED J., 77, PP. 112-113, (2001); FONG K.C.S., KINNEAR P.E., RETROBULBAR HAEMORRHAGE ASSOCIATED WITH CHRONIC GINKGO BILOBA INGESTION, POSTGRAD MED J., 79, PP. 531-532, (2003); FRIEDMAN J.A., TAYLOR S.A., MCDERMOTT W., ET AL., MULTIFOCAL AND RECURRENT SUBARACHNOID HEMORRHAGE DUE TO AN HERBAL SUPPLEMENT CONTAINING NATURAL COUMARINS, NEUROCRIT CARE., 7, PP. 76-80, (2007); ROSENBLATT M., MINDEL J., SPONTANEOUS HYPHEMA ASSOCIATED WITH INGESTION OF GINKGO BILOBA EXTRACT, N ENGL J MED., 336, (1997); VALE S., SUBARACHNOID HAEMORRHAGE ASSOCIATED WITH GINKGO BILOBA, LANCET., 352, (1998); GILBERT G.J., GINKGO BILOBA, NEUROLOGY., 48, (1997); BENT S., GOLDBERG H., PADULA A., ET AL., SPONTANEOUS BLEEDING ASSOCIATED WITH GINKGO BILOBA: A CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE, J GEN INTERN MED., 20, PP. 657-661, (2005); JIANG X., WILLIAMS K.M., LIAUW W.S., ET AL., EFFECT OF GINKGO AND GINGER ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN IN HEALTHY SUBJECTS, BR J CLIN PHARMACOL., 59, PP. 425-432, (2005); KOEHLER S., FUNK P., KIESER M., INFLUENCE OF A 7-DAY TREATMENT WITH GINKGO BILOBA SPECIAL EXTRACT EGB 761 ON BLEEDING TIME AND COAGULATION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS, BLOOD COAGUL FIBRINOLYSIS., 15, PP. 303-309, (2004); KOCH E., INHIBITION OF PLATELET ACTIVATING FACTOR (PAF)-INDUCED AGGREGATION OF HUMAN THROMBOCYTES BY GINKGOLIDES: CONSIDERATIONS ON POSSIBLE BLEEDING COMPLICATIONS AFTER ORAL INTAKE OF GINKGO BILOBA EXTRACTS, PHYTOMEDICINE., 12, PP. 10-16, (2005); RYU K.H., HAN H.Y., LEE S.Y., ET AL., GINKGO BILOBA EXTRACT ENHANCES ANTIPLATELET AND ANTITHROMBOTIC EFFECTS OF CILOSTAZOL WITHOUT PROLONGATION OF BLEEDING TIME, THROMB RES., 124, PP. 328-334, (2009); LE BARS P.L., KATZ M.M., BERMAN N., ET AL., A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF AN EXTRACT OF GINKGO BILOBA FOR DEMENTIA. NORTH AMERICAN EGB STUDY GROUP, JAMA., 278, PP. 1327-1332, (1997); COON J.T., ERNST E., PANAX GINSENG: A SYSTEMATIC REVIEW OF ADVERSE EFFECTS AND DRUG INTERACTIONS, DRUG SAF., 25, PP. 323-344, (2002); VOGLER B.K., PITTLER M.H., ERNST E., THE EFFICACY OF GINSENG: A SYSTEMATIC REVIEW OF RANDOMIZED CLINICAL TRIALS, EUR J CLIN PHARMACOL., 55, PP. 567-575, (1999); KIEFER D., PANTUSO T., PANAX GINSENG, AM FAM PHYSICIAN., 68, PP. 1539-1542, (2003); HOPKINS M.P., ANDROFF L., BENNINGHOFF A.S., GINSENG FACE CREAM AND UNEXPLAINED VAGINAL BLEEDING, AM J OBSTET GYNECOL., 159, PP. 1121-1122, (1988); JANETZKY K., MORREALE A.P., PROBABLE INTERACTION BETWEEN WARFARIN AND GINSENG, AM J HEALTH SYST PHARM., 54, PP. 692-693, (1997); PAOLETTI A., GALLO E., BENEMEI S., ET AL., INTERACTIONS BETWEEN NATURAL HEALTH PRODUCTS AND ORAL ANTICOAGULANTS: SPONTANEOUS REPORTS IN THE ITALIAN SURVEILLANCE SYSTEM OF NATURAL HEALTH PRODUCTS, EVID BASED COMPLEMENT ALTERNAT MED., 2011, PP. 1-5, (2011); TENG C.M., KUO S.C., KO F.N., ET AL., ANTIPLATELET ACTIONS OF PANAXYNOL AND GINSENOSIDES ISOLATED FROM GINSENG, BIOCHIM BIOPHYS ACTA., 990, PP. 315-320, (1989); THOMSON M., AL-QATTAN K.K., AL-SAWAN S.M., ET AL., THE USE OF GINGER (ZINGIBER OFFICINALE ROSC.) AS A POTENTIAL ANTI-INFLAMMATORY AND ANTITHROMBOTIC AGENT, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS., 67, PP. 475-478, (2002); VERMA S.K., SINGH J., KHAMESRA R., ET AL., EFFECT OF GINGER ON PLATELET AGGREGATION IN MAN, INDIAN J MED RES., 98, PP. 240-242, (1993); SRIVASTAVA K.C., AQUEOUS EXTRACTS OF ONION, GARLIC AND GINGER INHIBIT PLATELET AGGREGATION AND ALTER ARACHIDONIC ACID METABOLISM, BIOMED BIOCHIM ACTA., 43, SUPPL., (1984); KOO K.L., AMMIT A.J., TRAN V.H., ET AL., GINGEROLS AND RELATED ANALOGUES INHIBIT ARACHIDONIC ACID-INDUCED HUMAN PLATELET SEROTONIN RELEASE AND AGGREGATION, THROMB RES., 103, PP. 387-397, (2001); LUMB A.B., EFFECT OF DRIED GINGER ON HUMAN PLATELET FUNCTION, THROMB HAEMOST., 71, PP. 110-111, (1994); DYERBERG J., BANG H.O., HEMOSTATIC FUNCTION AND PLATELET POLYUNSATURATED FATTY ACIDS IN ESKIMOS, LANCET., 1, PP. 433-435, (1979); PHILLIPSON B.E., ROTHROCK D.W., CONNOR W.E., ET AL., REDUCTION OF PLASMA LIPIDS, LIPOPROTEINS, AND APOPROTEINS BY DIETARY FISH OILS IN PATIENTS WITH HYPERTRIGLYCERIDEMIA, N ENGL J MED., 312, PP. 1210-1216, (1985); MUELLER B.A., TALBERT R.L., BIOLOGICAL MECHANISMS AND CARDIOVASCULAR EFFECTS OF OMEGA-3 FATTY ACIDS, CLIN PHARM., 7, PP. 795-807, (1988); VANSCHOONBEEK K., FEIJGE M.A., PAQUAY M., ET AL., VARIABLE HYPOCOAGULANT EFFECT OF FISH OIL INTAKE IN HUMANS: MODULATION OF FIBRINOGEN LEVEL AND THROMBIN GENERATION, ARTERIOSCLER THROMB VASC BIOL., 24, PP. 1734-1740, (2004); AGREN J.J., VAISANEN S., HANNINEN O., ET AL., HEMOSTATIC FACTORS AND PLATELET AGGREGATION AFTER A FISH-ENRICHED DIET OR FISH OIL OR DOCOSAHEXAENOIC ACID SUPPLEMENTATION, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS., 57, PP. 419-421, (1997); COBIAC L., CLIFTON P.M., ABBEY M., ET AL., LIPID, LIPOPROTEIN, AND HEMOSTATIC EFFECTS OF FISH VS FISH-OIL N-3 FATTY ACIDS IN MILDLY HYPERLIPIDEMIC MALES, AM J CLIN NUTR., 53, PP. 1210-1216, (1991); BLONK M.C., BILO H.J., NAUTA J.J., ET AL., DOSE-RESPONSE EFFECTS OF FISH-OIL SUPPLEMENTATION IN HEALTHY VOLUNTEERS, AM J CLIN NUTR., 52, PP. 120-127, (1990); BAYS H.E., SAFETY CONSIDERATIONS WITH OMEGA-3 FATTY ACID THERAPY, AM J CARDIOL., 99, (2007); KNAPP H.R., DIETARY FATTY ACIDS IN HUMAN THROMBOSIS AND HEMOSTASIS, AM J CLIN NUTR., 65, SUPPL., (1997); LEAF A., JORGENSEN M.B., JACOBS A.K., ET AL., DO FISH OILS PREVENT RESTENOSIS AFTER CORONARY ANGIOPLASTY?, CIRCULATION., 90, PP. 2248-2257, (1994); BAIRATI I., ROY L., MEYER F., DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL OF FISH OIL SUPPLEMENTS IN PREVENTION OF RECURRENCE OF STENOSIS AFTER CORONARY ANGIOPLASTY, CIRCULATION., 85, PP. 950-956, (1992); DECATERINA R., GIANNESSI D., MAZZONE A., ET AL., VASCULAR PROSTACYCLIN IS INCREASED IN PATIENTS INGESTING OMEGA-3 POLYUNSATURATED FATTY ACIDS BEFORE CORONARY ARTERY BYPASS GRAFT SURGERY, CIRCULATION., 82, PP. 428-438, (1990); ROGERS S., JAMES K.S., BUTLAND B.K., ET AL., EFFECTS OF A FISH OIL SUPPLEMENT ON SERUM LIPIDS, BLOOD PRESSURE, BLEEDING TIME, HAEMOSTATIC AND RHEOLOGICAL VARIABLES. A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL IN HEALTHY VOLUNTEERS, ATHEROSCLEROSIS., 63, PP. 137-143, (1987); KAUL N., KREML R., AUSTRIA J.A., ET AL., A COMPARISON OF FISH OIL, FLAXSEED OIL AND HEMPSEED OIL SUPPLEMENTATION ON SELECTED PARAMETERS OF CARDIOVASCULAR HEALTH IN HEALTHY VOLUNTEERS, J AM COLL NUTR., 27, PP. 51-58, (2008); MUELLER B.A., TALBERT R.L., TEGELER C.H., ET AL., THE BLEEDING TIME EFFECTS OF A SINGLE DOSE OF ASPIRIN IN SUBJECTS RECEIVING OMEGA-3 FATTY ACID DIETARY SUPPLEMENTATION, J CLIN PHARMACOL., 31, PP. 185-190, (1991); HARRIS W.S., SILVEIRA S., DUJOVNE C.A., THE COMBINED EFFECTS OF N-3 FATTY ACIDS AND ASPIRIN ON HEMOSTATIC PARAMETERS IN MAN, THROMB RES., 57, PP. 517-526, (1990); SVANEBORG N., KRISTENSEN S.D., HANSEN L.M., ET AL., THE ACUTE AND SHORT-TIME EFFECT OF SUPPLEMENTATION WITH THE COMBINATION OF N-3 FATTY ACIDS AND ACETYLSALICYLIC ACID ON PLATELET FUNCTION AND PLASMA LIPIDS, THROMB RES., 105, PP. 311-316, (2002); HARKER L.A., KELLY A.B., HANSON S.R., ET AL., INTERRUPTION OF VASCULART THROMBUS FORMATION AND VASCULAR LESION FORMATION BY DIETARY N-3 FATTY ACIDS IN FISH OIL IN NONHUMAN PRIMATES, CIRCULATION., 87, PP. 1017-1029, (1993); DIETARY REFERENCE INTAKES: VITAMIN C, VITAMIN E, SELENIUM, AND CAROTENOIDS, PP. 186-263, (2000); TRABER M.G., VITAMIN E REGULATORY MECHANISMS, ANNU REV NUTR., 27, PP. 347-362, (2007); STAMPFER M.J., JAKUBOWSKI J.A., FAIGEL D., ET AL., VITAMIN E SUPPLEMENTATION EFFECT ON HUMAN PLATELET FUNCTION, ARACHIDONIC ACID METABOLISM, AND PLASMA PROSTACYCLIN LEVELS, AM J CLIN NUTR., 47, PP. 700-706, (1988); LEPPALA J.M., VIRTAMO J., FOGELHOLM R., ET AL., VITAMIN E AND BETA CAROTENE SUPPLEMENTATION IN HIGH RISK FOR STROKE: A SUBGROUP ANALYSIS OF THE ALPHA-TOCOPHEROL, BETA-CAROTENE CANCER PREVENTION STUDY, ARCH NEUROL., 57, PP. 1503-1509, (2000); DERESKA N.H., MCLEMORE E.C., TESSIER D.J., ET AL., SHORT-TERM, MODERATE DOSAGE VITAMIN E SUPPLEMENTATION MAY HAVE NO EFFECT ON PLATELET AGGREGATION, COAGULATION PROFILE, AND BLEEDING TIME IN HEALTHY INDIVIDUALS, J SURG RES., 132, PP. 121-129, (2006); LIU M., WALLMON A., OLSSON-MORTLOCK C., ET AL., MIXED TOCOPHEROLS INHIBIT PLATELET AGGREGATION IN HUMANS: POTENTIAL MECHANISMS, AM J CLIN NUTR., 77, PP. 700-706, (2003); STEINER M., INFLUENCE OF VITAMIN E ON PLATELET FUNCTION IN HUMANS, J AM COLL NUTR., 10, PP. 466-473, (1991); SZUWART T., BRZOSKA T., LUGER T.A., ET AL., VITAMIN E REDUCES PLATELET ADHESION TO HUMAN ENDOTHELIAL CELLS IN VITRO, AM J HEMATOL., 65, PP. 1-4, (2000); STEINER M., GLANTZ M., LEKOS A., VITAMIN E PLUS ASPIRIN COMPARED WITH ASPIRIN ALONE IN PATIENTS WITH TRANSIENT ISCHEMIC ATTACKS, AM J CLIN NUTR., 62, SUPPL., (1995); FREEDMAN J.E., FARHAT J.H., LOSCALZO J., ET AL., Α-TOCOPHEROL INHIBITS AGGREGATION OF HUMAN PLATELETS BY A PROTEIN KINASE C-DEPENDENT MECHANISM, CIRCULATION., 94, PP. 2434-2440, (1996); MABILE L., BRUCKDORFER K.R., RICE-EVANS C., MODERATE SUPPLEMENTATION WITH NATURAL ALPHA-TOCOPHEROL DECREASES PLATELET AGGREGATION AND LOW-DENSITY LIPOPROTEIN OXIDATION, ATHEROSCLEROSIS, 147, PP. 177-185, (1999); BAKALTCHEVA I., GYIMAH D., REID T., EFFECTS OF ALPHA-TOCOPHEROL ON PLATELETS AND THE COAGULATION SYSTEM, PLATELETS., 12, PP. 389-394, (2001); KAUFMAN D.W., KELLY J.P., ROSENBERG L., ET AL., RECENT PATTERNS OF MEDICATION USE IN THE AMBULATORY ADULT POPULATION OF THE UNITED STATES: THE SLONE SURVEY, JAMA., 287, PP. 337-344, (2002); LIEBERMAN H.R., STAVINOHA T.B., MCGRAW S.M., ET AL., USE OF DIETARY SUPPLEMENTS AMONG ACTIVE-DUTY US ARMY SOLDIERS, AM J CLIN NUTR., 92, PP. 985-995, (2010); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER., 318, PP. 1020-1026, (2006); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES., 16, PP. 67-72, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS., 58, PP. 61-64, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES., 19, PP. 105-116, (1999); ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL., 29, PP. 891-897, (2002); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES., 36, PP. 293-297, (1997); WESTER P.O., MAGNESIUM, AM J CLIN NUTR., 45, PP. 1305-1312, (1987); GAWAZ M., OTT I., REININGER A.J., ET AL., EFFECTS OF MAGNESIUM ON PLATELET AGGREGATION AND ADHESION. MAGNESIUM MODULATES SURFACE EXPRESSION OF GLYCOPROTEINS ON PLATELETS IN VITRO AND EX VIVO, THROMB HAEMOST., 72, PP. 912-918, (1994); RAVN H.B., VISSINGER H., KRISTENSEN S.D., ET AL., MAGNESIUM INHIBITS PLATELET ACTIVITY-AN INFUSION STUDY IN HEALTHY VOLUNTEERS, THROMB HAEMOST., 75, PP. 939-944, (1996); RAVN H.B., KRISTENSEN S.D., VISSINGER H., ET AL., MAGNESIUM INHIBITS HUMAN PLATELETS, BLOOD COAGUL FIBRINOLYSIS., 7, PP. 241-244, (1996); SHECHTER M., MERZ C.N., PAUL-LABRADOR M., ET AL., ORAL MAGNESIUM SUPPLEMENTATION INHIBITS PLATELET-DEPENDENT THROMBOSIS IN PATIENTS WITH CORONARY ARTERY DISEASE, AM J CARDIOL., 84, PP. 152-156, (1999); LOESHE W., MAZUROV A.V., HEPTINSTALL S., ET AL., AN EXTRACT OF FEVERFEW INHIBITS INTERACTIONS OF HUMAN PLATELETS WITH COLLAGEN SUBSTRATES, THROM RES., 48, PP. 511-518, (1987); GROENEWEGEN W.A., HEPTINSTALL S., A COMPARISON OF THE EFFECTS OF AN EXTRACT OF FEVERFEW AND PARTHENOLIDE, A COMPONENT OF FEVERFEW, ON HUMAN PLATELET ACTIVITY IN-VITRO, J PHARM PHARMACOL., 42, PP. 553-557, (1990); MAKHEJA A.N., BAILEY J.M., A PLATELET PHOSPHOLIPASE INHIBITOR FROM THE MEDICINAL HERB FEVERFEW (TANACETUM PARTHENIUM), PROSTAGLANDINS LEUKOT MED., 8, PP. 653-660, (1982); HEPTINSTALL S., WHITE A., WILLIAMSON L., ET AL., EXTRACTS OF FEVERFEW INHIBIT GRANULE SECRETION IN BLOOD PLATELETS AND POLYMORPHONUCLEAR LEUCOCYTES, LANCET., 1, PP. 1071-1074, (1985); HEPTINSTALL S., GROENEWEGEN W.A., SPANGENBERG P., ET AL., EXTRACTS OF FEVERFEW MAY INHIBIT PLATELET BEHAVIOUR VIA NEUTRALIZATION OF SULPHYDRYL GROUPS, J PHARM PHARMACOL., 39, PP. 459-465, (1987); ZHU D.P., DONG QUAI, AM J CHIN MED., 15, PP. 117-125, (1987); PAGE R.L., LAWRENCE J.D., POTENTIATION OF WARFARIN BY DONG QUAI, PHARMACOTHERAPY., 19, PP. 870-876, (1999); NORRED C.L., BRINKER F., POTENTIAL COAGULATION EFFECTS OF PREOPERATIVE COMPLEMENTARY AND ALTERNATIVE MEDICINES, ALTERN THER HEALTH MED., 7, PP. 58-67, (2001); HECK A.M., DEWITT B.A., LUKES A.L., POTENTIAL INTERACTIONS BETWEEN ALTERNATIVE THERAPIES AND WARFARIN, AM J HEALTH SYST PHARM., 57, PP. 1221-1227, (2000); ERNSTER L., DALLNER G., BIOCHEMICAL, PHYSIOLOGICAL AND MEDICAL ASPECTS OF UBIQUINONE FUNCTION, BIOCHIM BIOPHYS ACTA., 1271, PP. 195-204, (1995); SEREBRUANY V.L., ORDONEZ J.V., HERZOG W.R., ET AL., DIETARY COENZYME Q10 SUPPLEMENTATION ALTERS PLATELET SIZE AND INHIBITS HUMAN VITRONECTIN (CD51/CD61) RECEPTOR EXPRESSION, J CARDIOVASC PHARMACOL., 29, PP. 16-22, (1997); ENGELSEN J., NIELSEN J.D., WINTHER K., EFFECT OF COENZYME Q10 AND GINKGO BILOBA ON WARFARIN DOSAGE IN STABLE, LONG-TERM WARFARIN TREATED OUTPATIENTS. A RANDOMISED, DOUBLE BLIND, PLACEBO-CROSSOVER TRIAL, THROMB HAEMOST., 87, PP. 1075-1076, (2002); HUA J., SUGURO S., IWABUCHI K., ET AL., GLUCOSAMINE, A NATURALLY OCCURRING AMINO MONOSACCHARIDE, SUPPRESSES THE ADP-MEDIATED PLATELET ACTIVATION IN HUMANS, INFLAMM RES., 53, PP. 680-688, (2004); LU-SUGURO J.F., HUA J., SAKAMOTO K., ET AL., INHIBITORY ACTION OF GLUCOSAMINE ON PLATELET ACTIVATION IN GUINEA PIGS, INFLAMM RES., 54, PP. 493-499, (2005); KNUDSEN J.F., SOKOL G.H., POTENTIAL GLUCOSAMINE-WARFARIN INTERACTION RESULTING IN INCREASED INTERNATIONAL NORMALIZED RATIO: CASE REPORT AND REVIEW OF THE LITERATURE AND MEDWATCH DATABASE, PHARMACOTHERAPY., 28, PP. 540-548, (2008); HSIAO G., WANG Y., TZU N.H., ET AL., INHIBITORY EFFECTS OF LYCOPENE ON IN VITRO PLATELET ACTIVATION AND IN VIVO PREVENTION OF THROMBUS FORMATION, J LAB CLIN MED., 146, PP. 216-226, (2005); ANFOSSI G., RUSSO I., MASSUCCO P., ET AL., L-ARGININE MODULATES AGGREGATION AND INTRACELLULAR CYCLIC 3,5-GUANOSINE MONOPHOSPHATE LEVELS IN HUMAN PLATELETS: DIRECT EFFECT AND INTERPLAY WITH ANTIOXIDATIVE THIOL AGENT, THROMB RES., 94, PP. 307-316, (1999); HAYES K.C., PRONCZUK A., ADDESA A.E., ET AL., TAURINE MODULATES PLATELET AGGREGATION IN CATS AND HUMANS, AM J CLIN NUTR., 49, PP. 1211-1216, (1989); MIGLIS M., WILDER D., REID T., ET AL., EFFECT OF TAURINE ON PLATELETS AND THE PLASMA COAGULATION SYSTEM, PLATELETS., 13, PP. 5-10, (2002); PERONA G., SCHIAVON R., GUIDI G.C., ET AL., SELENIUM DEPENDENT GLUTATHIONE PEROXIDASE: A PHYSIOLOGICAL REGULATORY SYSTEM FOR PLATELET FUNCTION, THROM HAEM., 64, PP. 312-318, (1990); DAVILA J.C., EDDS G.T., OSUNA O., ET AL., MODIFICATION OF THE EFFECTS OF AFLATOXIN B1 AND WARFARIN IN YOUNG PIGS GIVEN SELENIUM, AM J VET RES., 44, PP. 1877-1883, (1983); AOYAGI N., KIMURA R., MURATA T., STUDIES ON PASSIFLORA INCARNATA DRY EXTRACT. I. ISOLATION OF MALTOL AND PHARMACOLOGICAL ACTION OF MALTOL AND ETHYL MALTOL, CHEM PHARM BULL (TOKYO)., 22, PP. 1008-1013, (1974); SEGAL R., PILOTE L., WARFARIN INTERACTION WITH MATRICARIA CHAMOMILLA, CMAJ., 174, PP. 1281-1282, (2006)","H.R. LIEBERMAN; MILITARY NUTRITION DIVISION, US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE, NATICK, MA 01760-5007, UNITED STATES; EMAIL: HARRIS.LIEBERMAN@US.ARMY.MIL","","ENGLISH","NUTR. REV.","REVIEW","ISI","2-S2.0-84856510176","NUTR REV","US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE;US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE;US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE;US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE","NOTREPORTED;US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE;NOTREPORTED",NA,"STANGER MJ, 2012, NUTR REV","STANGER MJ, 2012, NUTR REV"
"RUSCICA M;GOMARASCHI M;MOMBELLI G;MACCHI C;BOSISIO R;PAZZUCCONI F;PAVANELLO C;CALABRESI L;ARNOLDI A;SIRTORI C;MAGNI P","RUSCICA, MASSIMILIANO (6506814092); GOMARASCHI, MONICA (7801539816); MOMBELLI, GIULIANA (23480174800); MACCHI, CHIARA (55735408000); BOSISIO, RAFFAELLA (8205982600); PAZZUCCONI, FRANCO (7003294375); PAVANELLO, CHIARA (55938335300); CALABRESI, LAURA (7004515442); ARNOLDI, ANNA (7004093133); SIRTORI, CESARE R. (57203252370); MAGNI, PAOLO (55255644800)","NUTRACEUTICAL APPROACH TO MODERATE CARDIOMETABOLIC RISK RESULTS OF A RANDOMIZED DOUBLEBLIND AND CROSSOVER STUDY WITH ARMOLIPID PLUS",2014,"JOURNAL OF CLINICAL LIPIDOLOGY","8","7",79,"10.1016/j.jacl.2013.11.003","CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY;DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACEUTICHE, UNIVERSITÀ DEGLI STUDI DI MILANO, MILANO, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY;CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY, DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI, UNIVERSITÀ DEGLI STUDI DI MILANO, 20133 MILANO, VIA BALZARETTI 9, ITALY","BACKGROUND PRIMARY CARDIOVASCULAR PREVENTION MAY BE ACHIEVED BY LIFESTYLE/NUTRITION IMPROVEMENTS AND SPECIFIC DRUGS, ALTHOUGH A RELEVANT ROLE IS NOW EMERGING FOR SPECIFIC FUNCTIONAL FOODS AND NUTRACEUTICALS. OBJECTIVES THE AIM OF THIS STUDY WAS TO EVALUATE THE USEFULNESS OF A NUTRACEUTICAL MULTITARGET APPROACH IN SUBJECTS WITH MODERATE CARDIOVASCULAR RISK AND TO COMPARE IT WITH PRAVASTATIN TREATMENT. SUBJECTS THIRTY PATIENTS WITH MODERATE DYSLIPIDEMIA AND METABOLIC SYNDROME (ACCORDING TO THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS) WERE INCLUDED IN AN 8-WEEK RANDOMIZED, DOUBLE-BLIND CROSSOVER STUDY AND TOOK EITHER PLACEBO OR A NUTRACEUTICAL COMBINATION THAT CONTAINED RED YEAST RICE EXTRACT, BERBERINE, POLICOSANOL, ASTAXANTHIN, COENZYME Q10, AND FOLIC ACID (ARMOLIPID PLUS). SUBSEQUENTLY, THEY WERE SUBJECTED TO ANOTHER 8-WEEK TREATMENT WITH PRAVASTATIN 10 MG/D. THIS DOSAGE WAS SELECTED ON THE BASIS OF ITS EXPECTED -20% EFFICACY IN REDUCING LOW-DENSITY LIPOPROTEIN-CHOLESTEROL. RESULTS TREATMENT WITH ARMOLIPID PLUS LED TO A SIGNIFICANT REDUCTION OF TOTAL CHOLESTEROL (-12.8%) AND LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (-21.1%), SIMILAR TO PRAVASTATIN (-16% AND -22.6%, RESPECTIVELY), AND AN INCREASE OF HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (4.8%). ARMOLIPID PLUS IMPROVED THE LEPTIN-TO-ADIPONECTIN RATIO, WHEREAS ADIPONECTIN LEVELS WERE UNCHANGED. CONCLUSIONS THESE RESULTS INDICATE THAT THIS NUTRACEUTICAL APPROACH SHOWS A LIPID-LOWERING ACTIVITY COMPARABLE TO PRAVASTATIN TREATMENT. HENCE, IT MAY BE A SAFE AND USEFUL OPTION, ESPECIALLY IN CONDITIONS OF MODERATE CARDIOVASCULAR RISK, IN WHICH A PHARMACOLOGIC INTERVENTION MAY NOT BE APPROPRIATE. © 2014 NATIONAL LIPID ASSOCIATION. ALL RIGHTS RESERVED.","BERBERINE; CARDIOVASCULAR RISK; HDL-CHOLESTEROL; LDL-CHOLESTEROL; MONACOLIN K","BERBERINE; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FATTY ALCOHOLS; FEMALE; FOLIC ACID; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PRAVASTATIN; TIME FACTORS; UBIQUINONE; XANTHOPHYLLS; BERBERINE; CARDIOVASCULAR RISK; HDL-CHOLESTEROL; LDL-CHOLESTEROL; MONACOLIN K","ROTTAPHARM S.P.A.","THE STUDY WAS SUPPORTED BY AN UNRESTRICTED GRANT TO CENTRO DISLIPIDEMIE (A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY) FROM ROTTAPHARM S.P.A. (MONZA, ITALY) . THE EXPERT STATISTICAL CONTRIBUTION OF DR. FABRIZIO VEGLIA IS GRATEFULLY ACKNOWLEDGED. ALL AUTHORS HAVE SEEN AND HAVE APPROVED THE PRESENT STUDY. NO AUTHORS HAVE ANY CONFLICT OF INTEREST.","ALBERTI K.G., ZIMMET P., THE METABOLIC SYNDROME: TIME TO REFLECT, CURR DIAB REP, 6, PP. 259-261, (2006); ALBERTI K.G., ECKEL R.H., GRUNDY S.M., ET AL., HARMONIZING THE METABOLIC SYNDROME: A JOINT INTERIM STATEMENT OF THE INTERNATIONAL DIABETES FEDERATION TASK FORCE ON EPIDEMIOLOGY AND PREVENTION; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; AMERICAN HEART ASSOCIATION; WORLD HEART FEDERATION; INTERNATIONAL ATHEROSCLEROSIS SOCIETY; AND INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY, CIRCULATION, 120, PP. 1640-1645, (2009); KAITIN K.I., DECONSTRUCTING THE DRUG DEVELOPMENT PROCESS: THE NEW FACE OF INNOVATION, CLIN PHARMACOL THER, 87, PP. 356-361, (2010); LEE I.T., LEE W.J., TSAI C.M., SU I.J., YEN H.T., SHEU W.H., COMBINED EXTRACTIVES OF RED YEAST RICE, BITTER GOURD, CHLORELLA, SOY PROTEIN, AND LICORICE IMPROVE TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDE IN SUBJECTS WITH METABOLIC SYNDROME, NUTR RES, 32, PP. 85-92, (2012); SIRTORI C.R., MOMBELLI G., TRIOLO M., LAAKSONEN R., CLINICAL RESPONSE TO STATINS: MECHANISM(S) OF VARIABLE ACTIVITY AND ADVERSE EFFECTS, ANN MED, 44, PP. 419-432, (2012); GORDON R.Y., BECKER D.J., THE ROLE OF RED YEAST RICE FOR THE PHYSICIAN, CURR ATHEROSCLER REP, 13, PP. 73-80, (2011); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204, (2010); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); KONG W.J., WEI J., ZUO Z.Y., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFICACY, METABOLISM, 57, PP. 1029-1037, (2008); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS, 201, PP. 266-373, (2008); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BACKES J.M., GIBSON C.A., RUISINGER J.F., MORIARTY P.M., MODIFIED-POLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY, LIPIDS, 46, PP. 923-929, (2011); YOSHIDA H., YANAI H., ITO K., ET AL., ADMINISTRATION OF NATURAL ASTAXANTHIN INCREASES SERUM HDL-CHOLESTEROL AND ADIPONECTIN IN SUBJECTS WITH MILD HYPERLIPIDEMIA, ATHEROSCLEROSIS, 209, PP. 520-523, (2010); LAW M.R., WALD N.J., RUDNICKA A.R., QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS, BMJ, 326, (2003); GRIGORE L., RASELLI S., GARLASCHELLI K., ET AL., EFFECT OF TREATMENT WITH PRAVASTATIN OR EZETIMIBE ON ENDOTHELIAL FUNCTION IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, EUR J CLIN PHARMACOL, 69, PP. 341-346, (2013); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); LI J.J., LU Z.L., KOU W.R., ET AL., BENEFICIAL IMPACT OF XUEZHIKANG ON CARDIOVASCULAR EVENTS AND MORTALITY IN ELDERLY HYPERTENSIVE PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION FROM THE CHINA CORONARY SECONDARY PREVENTION STUDY (CCSPS), J CLIN PHARMACOL, 49, PP. 947-956, (2009); DONG H., ZHAO Y., ZHAO L., LU F., THE EFFECTS OF BERBERINE ON BLOOD LIPIDS: A SYSTEMIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, PLANTA MED, 79, PP. 437-446, (2013); PISCHON T., GIRMAN C.J., HOTAMISLIGIL G.S., RIFAI N., HU F.B., RIMM E.B., PLASMA ADIPONECTIN LEVELS AND RISK OF MYOCARDIAL INFARCTION IN MEN, JAMA, 291, PP. 1730-1737, (2004); NORATA G.D., RASELLI S., GRIGORE L., ET AL., LEPTIN:ADIPONECTIN RATIO IS AN INDEPENDENT PREDICTOR OF INTIMA MEDIA THICKNESS OF THE COMMON CAROTID ARTERY, STROKE, 38, PP. 2844-2846, (2007); CICERO A.F., MAGNI P., MORE M., RUSCICA M., BORGHI C., STROLLO F., METABOLIC SYNDROME, ADIPOKINES AND HORMONAL FACTORS IN PHARMACOLOGICALLY UNTREATED ADULT ELDERLY SUBJECTS FROM THE BRISIGHELLA HEART STUDY HISTORICAL COHORT, OBES FACTS, 5, PP. 319-326, (2012); KAPPELLE P.J., DULLAART R.P., VAN BEEK A.P., HILLEGE H.L., WOLFFENBUTTEL B.H., THE PLASMA LEPTIN/ADIPONECTIN RATIO PREDICTS FIRST CARDIOVASCULAR EVENT IN MEN: A PROSPECTIVE NESTED CASE-CONTROL STUDY, EUR J INTERN MED, 23, PP. 755-759, (2012); JEON T., HWANG S.G., HIRAI S., ET AL., RED YEAST RICE EXTRACTS SUPPRESS ADIPOGENESIS BY DOWN-REGULATING ADIPOGENIC TRANSCRIPTION FACTORS AND GENE EXPRESSION IN 3T3-L1 CELLS, LIFE SCI, 75, PP. 3195-3203, (2004); FUJIMOTO M., TSUNEYAMA K., CHEN S.Y., ET AL., STUDY OF THE EFFECTS OF MONACOLIN K AND OTHER CONSTITUENTS OF RED YEAST RICE ON OBESITY, INSULIN-RESISTANCE, HYPERLIPIDEMIA, AND NONALCOHOLIC STEATOHEPATITIS USING A MOUSE MODEL OF METABOLIC SYNDROME, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012); LEE C.Y., JAN M.S., YU M.C., LIN C.C., WEI J.C., SHIH H.C., RELATIONSHIP BETWEEN ADIPONECTIN AND LEPTIN, AND BLOOD LIPIDS IN HYPERLIPIDEMIA PATIENTS TREATED WITH RED YEAST RICE, FORSCH KOMPLEMENTMED, 20, PP. 197-203, (2013); YANG J., YIN J., GAO H., XU L., WANG Y., LI M., BERBERINE IMPROVES INSULIN SENSITIVITY BY INHIBITING FAT STORE AND ADJUSTING ADIPOKINES PROFILE IN HUMAN PREADIPOCYTES AND METABOLIC SYNDROME PATIENTS, EVID BASED COMPLEMENT ALTERNAT MED, 2012, (2012); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS, 11, (2012); KOH K.K., QUON M.J., SAKUMA I., ET AL., DIFFERENTIAL METABOLIC EFFECTS OF ROSUVASTATIN AND PRAVASTATIN IN HYPERCHOLESTEROLEMIC PATIENTS, INT J CARDIOL, 166, PP. 509-515, (2011); KIM J.H., LEE M.R., SHIN J.A., ET AL., EFFECTS OF PRAVASTATIN ON SERUM ADIPONECTIN LEVELS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS, ATHEROSCLEROSIS, 227, PP. 355-359, (2013)","C.R. SIRTORI; CENTRO DISLIPIDEMIE, A. O. OSPEDALE NIGUARDA CÀ GRANDA, MILANO, ITALY; EMAIL: CESARE.SIRTORI@UNIMI.IT","","ENGLISH","J. CLIN. LIPIDOLOGY","ARTICLE","ISI","2-S2.0-84893982496","J CLIN LIPIDOLOGY","UNIVERSITÀ DEGLI STUDI DI MILANO;UNIVERSITÀ DEGLI STUDI DI MILANO;CENTRO DISLIPIDEMIE;UNIVERSITÀ DEGLI STUDI DI MILANO;CENTRO DISLIPIDEMIE;UNIVERSITÀ DEGLI STUDI DI MILANO;CENTRO DISLIPIDEMIE;UNIVERSITÀ DEGLI STUDI DI MILANO;UNIVERSITÀ DEGLI STUDI DI MILANO;UNIVERSITÀ DEGLI STUDI DI MILANO;UNIVERSITÀ DEGLI STUDI DI MILANO","NOTREPORTED;CENTRO DISLIPIDEMIE;NOTREPORTED",NA,"RUSCICA M, 2014, J CLIN LIPIDOLOGY","RUSCICA M, 2014, J CLIN LIPIDOLOGY"
"LUPI F;GABRIELE D;BALDINO N;MIJOVIC P;PARISI O;PUOCI F","LUPI, FRANCESCA R. (24768180600); GABRIELE, DOMENICO (6507587673); BALDINO, NOEMI (24767432700); MIJOVIC, PAVLE (55851325700); PARISI, ORTENSIA I. (23571174200); PUOCI, FRANCESCO (9734761900)","OLIVE OILPOLICOSANOL ORGANOGELS FOR NUTRACEUTICAL AND DRUG DELIVERY PURPOSES",2013,"FOOD AND FUNCTION","4","8",49,"10.1039/c3fo60259a","DEPARTMENT OF INFORMATION, MODELING, ELECTRONIC AND SYSTEM ENGINEERING (D.I.M.E.S), UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), VIA P. BUCCI CUBO 39C, ITALY;DEPARTMENT OF CHEMISTRY AND CHEMICAL TECHNOLOGIES, UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), VIA P. BUCCI CUBO 39C, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONIC AND SYSTEM ENGINEERING (D.I.M.E.S), UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), VIA P. BUCCI CUBO 39C, ITALY;DEPARTMENT OF INFORMATION, MODELING, ELECTRONIC AND SYSTEM ENGINEERING (D.I.M.E.S), UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), VIA P. BUCCI CUBO 39C, ITALY, DEPARTMENT OF PRODUCTION AND INDUSTRIAL ENGINEERING, UNIVERSITY OF KRAGUJEVAC, 34000 KRAGUJEVAC, SESTRE JANJIC BB, SERBIA;DEPARTMENT OF PHARMACY, HEALTH AND NUTRITIONAL SCIENCES, UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), ITALY;DEPARTMENT OF PHARMACY, HEALTH AND NUTRITIONAL SCIENCES, UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), ITALY","LOW MOLECULAR WEIGHT ORGANOGELS ARE SEMISOLID SYSTEMS STRUCTURED BY THE ASSEMBLY OF MOLECULES THAT CRYSTALLISE UNDER SUITABLE PROCESS CONDITIONS. THE INNER MICROSTRUCTURE OF ORGANOGELS IS MADE UP OF A 3-D NETWORK, IN WHICH BOTH AN ORGANIC LIQUID SOLVENT AND OTHER DISPERSED PARTICLES CAN BE ENTRAPPED. IN THIS WORK, OLIVE OIL ORGANOGELS, STRUCTURED FROM POLICOSANOL (A NUTRACEUTICAL MIXTURE OF FATTY ALCOHOLS), WERE STUDIED IN ORDER TO OBTAIN THE BEST FORMULATION FOR PRODUCING A SUPPORT FOR DELIVERY OF LIPOPHILIC AGENTS (NAMELY FERULIC ACID) VIA ORAL ADMINISTRATION. A RHEOLOGICAL OPTIMISATION OF THE OLIVE OIL-POLICOSANOL ORGANOGEL WAS FIRST OF ALL PERFORMED WITH STEP SHEAR RATE TEMPERATURE RAMP TESTS. THIS PROVIDED IMPORTANT INFORMATION ON THE POLICOSANOL FRACTION TO BE ADDED TO THE SYSTEM AND ON THE ONSET OF CRYSTALLISATION TEMPERATURE, AN INDIRECT MEASUREMENT OF THE SYSTEM MELTING POINT. IT WAS FOUND THAT A POLICOSANOL WEIGHT PERCENTAGE OF 0.03 WAS SUITABLE TO OBTAIN CONTEMPORARY SEMISOLID ORGANOGELS, CONSISTENT ENOUGH AND THERMALLY STABLE FOR HUMAN INGESTION. IN VITRO TESTS ON ORGANOGELS LOADED WITH FERULIC ACID WERE ALSO CARRIED OUT IN ORDER TO SIMULATE THE ORAL INTAKE OF THE NUTRACEUTICAL COMPOUND. THIS EVIDENCED A RELEASE MECHANISM DETERMINED BY BOTH EROSION AND DIFFUSION; A GOOD PERFORMANCE OF GELS AND THEIR ABILITY TO CONTROL THE RELEASE RATE THROUGH THE DEGREE OF STRUCTURATION WERE ALSO OBSERVED. © 2013 THE ROYAL SOCIETY OF CHEMISTRY.","","COUMARIC ACIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FATTY ALCOHOLS; GELS; HUMANS; KINETICS; MOLECULAR WEIGHT; PLANT OILS; RHEOLOGY; ALCOHOLS; DRUG DELIVERY; COUMARIC ACID; DRUG CARRIER; FATTY ALCOHOL; FERULIC ACID; OLIVE OIL; POLICOSANOL; VEGETABLE OIL; COUMARIC ACID; DRUG CARRIER; FATTY ALCOHOL; GEL; VEGETABLE OIL; DISPERSED PARTICLE; INDIRECT MEASUREMENTS; LOW MOLECULAR WEIGHT ORGANOGELS; NUTRACEUTICAL COMPOUNDS; ORAL ADMINISTRATION; RELEASE MECHANISM; SEMI-SOLID SYSTEM; WEIGHT PERCENTAGES; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; EQUIPMENT; FLOW KINETICS; GEL; HUMAN; KINETICS; MOLECULAR WEIGHT; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; GEL; OLIVE OIL","","","CO D.E., MARANGONI A.G., J. AM. OIL CHEM. SOC., 89, (2012); LUPI F.R., GABRIELE D., FACCIOLO D., BALDINO N., SETA L., DE CINDIO B., FOOD RES. INT., 46, (2012); LUPI F.R., GABRIELE D., DE CINDIO B., FOOD BIOPROCESS TECHNOL., 5, (2012); LUPI F.R., GABRIELE D., BALDINO N., SETA L., DE CINDIO B., DE ROSE C., EUR. J. LIPID SCI. TECHNOL., 114, PP. 1381-1389, (2012); LUPI F.R., GABRIELE D., BALDINO N., SETA L., DE CINDIO B., FOOD RES. INT., 51, (2013); KABIRI K., AZIZI A., ZOHURIAAN-MEHR M.J., MARANDI G.B., BOUHENDI H., J. APPL. POLYM. SCI., 120, (2011); SHAPIRO Y.E., PROG. POLYM. SCI., 36, (2011); TANG D., MARANGONI A.G., TRENDS FOOD SCI. TECHNOL., 18, (2007); MARANGONI A.G., GARTI N., EDIBLE OLEOGELS: STRUCTURE AND HEALTH IMPLICATIONS, (2011); MARANGONI A.G., IDZIAK S.H.J., VEGA C., BATTE H., OLLIVON M., JANTZI P.S., RUSH J.W.E., SOFT MATTER, 3, (2007); MARANGONI A.G., PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON FOOD RHEOLOGY AND STRUCTURE, (2009); ROGERS M.A., WRIGHT A.J., MARANGONI A.G., SOFT MATTER, 5, (2009); DUFFY N., BLONK H.C.G., BEINDORFF C.M., CAZADE M., BOT A., DUCHATEAU G.S.M.J.E., J. AM. OIL CHEM. SOC., 86, (2009); LUPI F.R., GABRIELE D., DE CINDIO B., SANCHEZ M.C., GALLEGOS C., J. FOOD ENG., 107, (2011); ZETZL A.K., MARANGONI A.G., BARBUT S., FOOD FUNCT., 3, (2012); STORTZ T.A., ZETZL A.K., BARBUT S., CATTARUZZA A., MARANGONI A.G., LIPID TECHNOL., 24, (2012); HUGHES N.E., MARANGONI A.G., WRIGHT A.J., ROGERS M.A., RUSH J.W.E., TRENDS FOOD SCI. TECHNOL., 20, (2009); TORO-VAZQUEZ J.F., MORALES-RUEDA J.A., DIBILDOX-ALVARADO E., CHARO-ALONSO M., ALONZO-MACIAS M., GONZALEZ-CHAVEZ M.M., J. AM. OIL CHEM. SOC., 84, (2007); SAHOO S., KUMAR N., BHATTACHARYA C., SAGIRI S.S., JAIN K., PAL K., RAY S.S., NAYAK B., DES. MONOMERS POLYM., 14, (2011); MCCLEMENTS D.J., DECKER D.E., PARK Y., WEISS J., CRIT. REV. FOOD SCI. NUTR., 49, (2009); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., NUTR. RES., 27, (2007); FERREIRA P., DIEZ N., FAULDS C.B., SOLIVERI J., COPA-PATINO J.L., BIORESOUR. TECHNOL., 98, (2007); ZHAO Z., MOGHADASIAN M.H., FOOD CHEM., 109, (2008); ZHANG L.-W., AL-SUWAYEH S.A., HSIEH P.-W., FANG J.-Y., INT. J. PHARMACOL., 399, (2010); KOH P.-O., NEUROSCI. LETT., 507, (2012); STAPLES M., DANIEL K., CIMA M.J., LANGER R., PHARM. RES., 23, (2006); NAVARRA G., CANNAS M., D'AMICO M., GIACOMAZZA D., MILITELLO V., VACCARO L., LEONE M., FOOD CHEM., 126, (2011); GRAVELLE A.J., BARBUT S., MARANGONI A.G., FOOD RES. INT., 48, (2012); AMBROSONE L., MOSCA M., CEGLIE A., FOOD HYDROCOLLOIDS, 20, (2006); MOSCA M., CEGLIE A., AMBROSONE L., FOOD RES. INT., 41, (2008); BOLLINGER D.W., TSUNODA A., LEDOUX D.R., ELLERSIECK M.R., VEUM T.L., J. AGRIC. FOOD CHEM., 53, (2005); TARABUKINA E., JEGO F., HAUDIN J.M., NAVARD P., PEUVREL-DISDIER E., J. FOOD SCI., 74, (2009); OJIJO N.K.O., NEEMAN I., EGER S., SHIMONI E., J. SCI. FOOD AGRIC., 84, (2004); FREDENBERG S., WAHLGREN M., RESLOW M., AXELSSON A., INT. J. PHARM., 415, (2011); SIEPMANN J., GOPFERICH A., ADV. DRUG DELIVERY REV., 48, (2001); IWANAGA K., SUMIZAWA T., MIYAZAKI M., KAKEMI M., INT. J. PHARM., 388, (2010); NAYAK A.K., PAL D., INT. J. BIOL. MACROMOL., 49, (2011); KAJJARI P.B., MANJESHWAR L.S., AMINABHAVI T.M., J. IND. ENG. CHEM., (2013)","D. GABRIELE; DEPARTMENT OF CHEMISTRY AND CHEMICAL TECHNOLOGIES, UNIVERSITY OF CALABRIA, I-87036 RENDE (CS), VIA P. BUCCI CUBO 39C, ITALY; EMAIL: DOMENICO.GABRIELE@UNICAL.IT","","ENGLISH","FOOD. FUNCT.","ARTICLE","ISI","2-S2.0-84884808029","FOOD FUNCT","UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA;UNIVERSITY OF CALABRIA","NOTREPORTED;UNIVERSITY OF CALABRIA;NOTREPORTED",NA,"LUPI FR, 2013, FOOD FUNCT","LUPI FR, 2013, FOOD FUNCT"
"CHOI J;JEON M;MOON W;MOON J;CHEON E;KIM J;JUNG S;JI Y;SON S;KIM M","CHOI, JAE-SUK (35104615200); JEON, MIN-HEE (55841541700); MOON, WOI-SOOK (55815465000); MOON, JIN-NAM (55841372200); CHEON, EUN JIN (56338490500); KIM, JOO-WAN (35867349300); JUNG, SUNG KYU (59109312400); JI, YI-HWA (42561186100); SON, SANG WOOK (7202529945); KIM, MI-RYUNG (7406090824)","IN VIVO HAIR GROWTHPROMOTING EFFECT OF RICE BRAN EXTRACT PREPARED BY SUPERCRITICAL CARBON DIOXIDE FLUID",2014,"BIOLOGICAL AND PHARMACEUTICAL BULLETIN","37","9",40,"10.1248/bpb.b13-00528","RIS CENTER, IACF, SILLA UNIVERSITY, SASANG-GU, BUSAN 617-736, SOUTH KOREA;LTD, NAM-GU, BUSAN 608-736, SOUTH KOREA;LTD, NAM-GU, BUSAN 608-736, SOUTH KOREA;LTD, NAM-GU, BUSAN 608-736, SOUTH KOREA;DEPARTMENT OF BIO-FOOD MATERIALS, SILLA UNIVERSITY, SASANG-GU, BUSAN 617-736, SOUTH KOREA;DEPARTMENT OF VETERINARY MEDICINE, KYUNGPOOK NATIONAL UNIVERSITY, BUK-GU, DAEGU 702-701, SOUTH KOREA;DEPARTMENT OF DERMATOLOGY, KOREA UNIVERSITY ANSAN HOSPITAL, ANSAN 425-701, SOUTH KOREA;DEPARTMENT OF DERMATOLOGY, KOREA UNIVERSITY ANSAN HOSPITAL, ANSAN 425-701, SOUTH KOREA;DEPARTMENT OF DERMATOLOGY, KOREA UNIVERSITY ANSAN HOSPITAL, ANSAN 425-701, SOUTH KOREA;DEPARTMENT OF BIO-FOOD MATERIALS, SILLA UNIVERSITY, SASANG-GU, BUSAN 617-736, SOUTH KOREA","[NO ABSTRACT AVAILABLE]","HAIR GROWTH-PROMOTING ACTIVITY; IN VIVO; RICE BRAN SUPERCRITICAL CO<SUB>2</SUB> EXTRACT","ALOPECIA; ANIMALS; FIBROBLAST GROWTH FACTOR 7; HAIR; HAIR FOLLICLE; LINOLEIC ACID; MICE; MICE, INBRED C57BL; ORYZA SATIVA; PHENYLPROPIONATES; PHYTOTHERAPY; PLANT EXTRACTS; RNA, MESSENGER; SEEDS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; CARBON DIOXIDE; GAMMA ORYZANOL; GAMMA TOCOTRIENOL; KERATINOCYTE GROWTH FACTOR; LINOLEIC ACID; MESSENGER RNA; MINOXIDIL; NATURAL PRODUCT; POLICOSANOL; RICE BRAN EXTRACT; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG ISOLATION; EXPERIMENTAL MOUSE; FEMALE; HAIR FOLLICLE; HAIR GROWTH; HISTOLOGY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RICE BRAN; SUPERCRITICAL FLUID EXTRACTION; UPREGULATION","","","OLSEN E.A., ANDROGENETIC ALOPECIA, DISORDERS OF HAIR GROWTH: DIAGNOSIS AND TREATMENT (OLSEN EA ED.), PP. 257-283, (1994); SAWAYA M.E., PRICE V.H., DIFFERENT LEVELS OF 5Α-REDUCTASE TYPE I AND II, AROMATASE, AND ANDROGEN RECEPTOR IN HAIR FOLLICLES OF WOMEN AND MEN WITH ANDROGENETIC ALOPECIA, J. INVEST. DERMATOL., 109, PP. 296-300, (1997); SAWAYA M.E., SHAPIRO J., ALOPECIA: UNAPPROVED TREATMENTS OR INDICATIONS, CLIN. DERMATOL., 18, PP. 177-186, (2000); TRUEB R.M., MOLECULAR MECHANISMS OF ANDROGENETIC ALOPECIA, EXP. GERONTOL., 37, PP. 981-990, (2002); DE VILLEZ R.L., THE THERAPEUTIC USE OF TOPICAL MINOXIDIL, DERMATOL. CLIN., 8, PP. 367-375, (1990); SHAPIRO J., PRICE V.H., HAIR REGROWTH: THERAPEUTIC AGENTS, DERMATOL. CLIN., 16, PP. 341-356, (1998); WILSON C., WALKDEN V., POWELL S., SHAW S., WILKINSON J., DAWBER R.P.R., CONTACT DERMATITIS IN REACTION TO 2% TOPICAL MINOXIDIL SOLUTION, J. AM. ACAD. DERMATOL., 24, PP. 661-662, (1991); FRIEDMAN E.S., FRIEDMAN P.M., COHEN D.E., WASHENIK K., ALLERGIC CONTACT DERMATITIS TO TOPICAL MINOXIDIL SOLUTION: ETIOLOGY AND TREATMENT, J. AM. ACAD. DERMATOL., 46, PP. 309-312, (2002); MCCLELLAN K.J., MARKHAM A., FINESTERIDE. A REVIEW OF ITS USE IN MALE PATTERN HAIR LOSS, DRUGS, 57, PP. 111-126, (1999); TOSTI A., PIRACCINI B.M., SOLI M., EVALUATION OF SEXUAL FUNCTION IN SUBJECTS TAKING FINASTERIDE FOR THE TREATMENT OF ANDROGENETIC ALOPECIA, J. EUR. ACAD. DERMATOL. VENEREOL., 15, PP. 418-421, (2001); SAWAYA M.E., NOVEL AGENTS FOR THE TREATMENT OF ALOPECIA, SEMIN. CUTAN. MED. SURG., 17, PP. 276-283, (1998); ROH S.-S., KIM C.D., LEE M.-H., HWANG S.-L., RANG M.-J., YOON Y.-K., THE HAIR GROWTH PROMOTING EFFECT OF SOPHORA FLAVESCENS EXTRACT AND ITS MOLECULAR REGULATION, J. DERMATOL. SCI., 30, PP. 43-49, (2002); RHO S.-S., PARK S.-J., HWANG S.-L., LEE M.-H., KIM C.D., LEE I.-H., CHANG S.-Y., RANG M.-J., THE HAIR GROWTH PROMOTING EFFECT OF ASIASARI RADIX EXTRACT AND ITS MOLECULAR REGULATION, J. DERMATOL. SCI., 38, PP. 89-97, (2005); DATTA K., SINGH A.T., MUKHERJEE A., BHAT B., RAMESH B., BURMAN A.C., ECLIPTA ALBA EXTRACT WITH POTENTIAL FOR HAIR GROWTH PROMOTING ACTIVITY, J. ETHNOPHARMACOL., 124, PP. 450-456, (2009); LEE G.-S., HONG E.-J., GWAK K.-S., PARK M.-J., CHOI K.-C., CHOI I.-G., JANG J.-W., JEUNG E.-B., THE ESSENTIAL OILS OF CHAMAECYPARIS OBTUSE PROMOTE HAIR GROWTH THROUGH THE INDUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR GENE, FITOTERAPIA, 81, PP. 17-24, (2010); YOON J.I., AL-REZA S.M., KANG S.C., HAIR GROWTH PROMOTING EFFECT OF ZIZYPHUS JUJUBE ESSENTIAL OIL, FOOD CHEM. TOXICOL., 48, PP. 1350-1354, (2010); BHATTACHARJEE P., SINGHAL R.S., KULKARNI P.R., BASMATI RICE: A REVIEW, INT. J. FOOD SCI. TECH., 37, PP. 1-12, (2002); WATCHARARUJI K., GOTO M., SASAKI M., SHOTIPRUK A., VALUE-ADDED SUBCRITICAL WATER HYDROLYSATE FROM RICE BRAN AND SOYBEAN MEAL, BIORESOUR. TECHNOL., 99, PP. 6207-6213, (2008); MANOSROI A., RUKSIRIWANICH W., ABE M., SAKAI H., MANOSROI W., MANOSROI J., BIOLOGICAL ACTIVITIES OF THE RICE BRAN EXTRACT AND PHYSICAL CHARACTERISTICS OF ITS ENTRAPMENT IN NIOSOMES BY SUPERCRITICAL CARBON DIOXIDE FLUID, J. SUPERCRIT. FLUID., 54, PP. 137-144, (2010); LI S.C., CHOU T.C., SHIH C.K., EFFECTS OF BROWN RICE, RICE BRAN, AND POLISHED RICE ON COLON CARCINOGENESIS IN RATS, FOOD RES. INT., 44, PP. 209-216, (2011); JARIWALLA R.J., RICE-BRAN PRODUCTS: PHYTONUTRIENTS WITH POTENTIAL APPLICATIONS IN PREVENTIVE AND CLINICAL MEDICINE, DRUGS EXP. CLIN. RES., 27, PP. 17-26, (2001); RUKSIRIWANICH W., MANOSROI J., ABE M., MANOSROI W., MANOSROI A., 5Α-REDUCTASE TYPE 1 INHIBITION OF ORYZA SATIVA BRAN EXTRACT PREPARED BY SUPERCRITICAL CARBON DIOXIDE FLUID, J. SUPERCRIT. FLUID., 59, PP. 61-71, (2011); XU Z., GODBER J.S., COMPARISON OF SUPERCRITICAL FLUID AND SOLVENT EXTRACTION METHODS IN EXTRACTING Γ-ORYZANOL FROM RICE BRAN, J. AM. OIL CHEM. SOC., 77, PP. 547-551, (2000); YEDDES N., CHERIF J.K., JRAD A., BARTH D., TRABELSI-AYADI M., SUPERCRITICAL SC-CO<SUB>2</SUB> AND SOXHLET N-HEXANE EXTRACT OF TUNISIAN OPUNTIA FICUS INDICA SEEDS AND FATTY ACIDS ANALYSIS, J. LIPIDS, 2012, (2012); SAHENA F., ZAIDUL I.S.M., JINAP S., KARIM A.A., ABBAS K.A., NORULAINI N.A.N., OMAR A.K.M., APPLICATION OF SUPERCRITICAL CO<SUB>2</SUB> IN LIPID EXTRACTION - A REVIEW, J. FOOD ENG., 95, PP. 240-253, (2009); ROH M.-K., JEON M.-H., MOON W.-S., MOON J.-N., CHEON E.-J., CHOI J.-S., KIM M.-R., CHARACTERISTICS OF EXTRACTION AND FATTY ACID COMPOSITION FOR RICE BRAN OIL BY SUPERCRITICAL CARBON DIOXIDE, J. SUPERCRIT. FLUID.; METHOD 2.411 IDENTIFICATION AND DETERMINATION OF TOCOPHEROLS. STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS AND DERIVATIVES., (1987); AMERICAN OIL CHEMISTS, (1998); KIM I.H., KIM C.J., SEPARATION OF ORYZANOL FROM THE REFINING BYPRODUCT OF RICE BRAN OIL, KOREAN J. FOOD SCI TECHNOL., 23, PP. 76-89, (1991); MOFFAT G.H., THE GROWTH OF HAIR FOLLICLES AND ITS RELATION TO THE ADJACENT DERMAL STRUCTURES, J. ANAT., 102, PP. 527-540, (1968); OGAWA H., HATTORI M., REGULATION MECHANISMS OF HAIR GROWTH, CURR. PROBL. DERMATOL., 11, PP. 159-170, (1983); FUJIE T., KATOH S., OURA H., URANO Y., ARASE S., THE CHEMOTACTIC EFFECT OF A DERMAL PAPILLA CELL-DERIVED FACTOR ON OUTER ROOT SHEATH CELLS, J. DERMATOL. SCI., 25, PP. 206-212, (2001); DANILENKO D.M., RING B.D., PIERCE G.F., GROWTH FACTORS AND CYTOKINES IN HAIR FOLLICLE DEVELOPMENT AND CYCLING: RECENT INSIGHTS FROM ANIMAL MODELS AND THE POTENTIALS FOR CLINICAL THERAPY, MOL. MED. TODAY, 2, PP. 460-467, (1996); MESSENGER A.G., RUNDEGREN J., MINOXIDIL: MECHANISMS OF ACTION ON HAIR GROWTH, BR. J. DERMATOL., 150, PP. 186-194, (2004); WEGER N., SCHLAKE T., IGF-I SIGNALLING CONTROLS THE HAIR GROWTH CYCLE AND THE DIFFERENTIATION OF HAIR SHAFTS, J. INVEST. DERMATOL., 125, PP. 873-882, (2005); WERNER S., SMOLA H., PARACRINE REGULATION OF KERATINOCYTE PROLIFERATION AND DIFFERENTIATION, TRENDS CELL BIOL., 11, PP. 143-146, (2001); LI J., FOITZIK K., CALAUTTI E., BADEN H., DOETSCHMAN T., DOTTO G.P., TGF-Β3, BUT NOT TGF-Β1, PROTECTS KERATINOCYTES AGAINST 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED CELL DEATH IN VITRO AND IN VIVO, J. BIOL. CHEM., 274, PP. 4213-4219, (1999); OTOMO S., HAIR GROWTH EFFECT OF MINOXIDIL, NIHON YAKURIGAKU ZASSHI, 119, PP. 167-174, (2002); YOSHIDA H., TANIGAWA T., YOSHIDA N., KURIYAMA I., TOMIYAMA Y., MIZUSHINA Y., LIPID COMPONENTS, FATTY ACID DISTRIBUTIONS OF TRIACYLGLYCEROLS AND PHOSPHOLIPIDS IN RICE BRANS, FOOD CHEM., 129, PP. 479-484, (2011); CHEN M.H., BERGMAN C.J., A RAPID PROCEDURE FOR ANALYSING RICE BRAN TOCOPHEROL TOCOTRIENOL AND Γ-ORYZANOL CONTENTS, J. FOOD COMPOS. ANAL., 18, PP. 319-331, (2005); XU Z., GODBER J.S., PURIFICATION AND IDENTIFICATION OF COMPONENTS OF GAMMA-ORYZANOL IN RICE BRAN OIL, J. AGRIC. FOOD CHEM., 47, PP. 2724-2728, (1999); LIANG T., LIAO S., INHIBITION OF STEROID 5 ALPHA-REDUCTASE BY SPECIFIC ALIPHATIC UNSATURATED FATTY ACIDS, BIOCHEM. J., 285, PP. 557-562, (1992); PASCUAL C.S.C.I., MASSARETTO I.L., KAWASSAKI F., BARROS R.M.C., NOLDIN J.A., MARQUEZ U.M.L., EFFECTS OF PARBOILING, STORAGE AND COOKING ON THE LEVELS OF TOCOPHEROLS, TOCOTRIENOLS AND Γ-ORYZANOL IN BROWN RICE (ORYZA SATIVA L.), FOOD RES. INT., 50, PP. 676-681, (2013); HAIM D., VALENZUELA A., BRANES M.C., FUENZALIDA M., VIDELA L.A., THE OLEIC ACID ESTERIFICATION OF POLICOSANOL INCREASES ITS BIOAVAILABILITY AND HYPOCHOLESTEROLEMIC ACTION IN RATS, GRASAS ACEITES, 63, PP. 345-354, (2012); LIM A.B., WONG J.W., YUEN K.H., EFFECTS OF TOCOTRIENOL SUPPLEMENTATION ON HAIR GROWTH IN HUMAN VOLUNTEERS, TROP. LIFE SCI. RES., 21, PP. 91-99, (2010)","S.W. SON; DEPARTMENT OF DERMATOLOGY, KOREA UNIVERSITY ANSAN HOSPITAL, ANSAN 425-701, SOUTH KOREA; EMAIL: SKIN4U@KOREA.AC.KR","","ENGLISH","BIOL. PHARM. BULL.","ARTICLE","ISI","2-S2.0-84892586115","BIOL PHARM BULL","SILLA UNIVERSITY;SILLA UNIVERSITY;KYUNGPOOK NATIONAL UNIVERSITY;KOREA UNIVERSITY ANSAN HOSPITAL;KOREA UNIVERSITY ANSAN HOSPITAL;KOREA UNIVERSITY ANSAN HOSPITAL;SILLA UNIVERSITY","NOTREPORTED;KOREA UNIVERSITY ANSAN HOSPITAL;NOTREPORTED",NA,"CHOI J-S, 2014, BIOL PHARM BULL","CHOI J-S, 2014, BIOL PHARM BULL"
"DE C I;SOLÀ R;VALLS R;BREA A;MOZAS P;PUZO J;POCOVÍ M","DE CASTRO-ORÓS, ISABEL (36503761500); SOLÀ, ROSA (56242966500); VALLS, ROSA MARÍA (7003369627); BREA, ANGEL (6701857932); MOZAS, PILAR (6602253032); PUZO, JOSE (57211538770); POCOVÍ, MIGUEL (7005256919)","GENETIC VARIANTS OF LDLR AND PCSK9 ASSOCIATED WITH VARIATIONS IN RESPONSE TO ANTIHYPERCHOLESTEROLEMIC EFFECTS OF ARMOLIPID PLUS WITH BERBERINE",2016,"PLOS ONE","11","",22,"10.1371/journal.pone.0150785","DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR Y CELULAR, UNIVERSIDAD DE ZARAGOZA, INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN (IIS ARAGÓN), ZARAGOZA, SPAIN;UNIDAD DE LÍPIDOS, SERVICIO DE MEDICINA INTERNA, HOSPITAL UNIVERSITARIO SAN PEDRO, LOGROÑO, SPAIN;UNITAT DE RECERCA DE LIPIDS I ARTERIOSCLEROSI, CIBERDEM, SERVEI DE MEDICINA INTERNA, HOSPITAL UNIVERSITARI SAN JOAN, IISPV FACULTAT DE MEDICINA, UNIVERSITAT ROVIRA I VIRGILI, REUS, SPAIN;UNIDAD DE LÍPIDOS, SERVICIO DE MEDICINA INTERNA, HOSPITAL UNIVERSITARIO SAN PEDRO, LOGROÑO, SPAIN;DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR Y CELULAR, UNIVERSIDAD DE ZARAGOZA, INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN (IIS ARAGÓN), ZARAGOZA, SPAIN;SERVICIO DE BIOQUÍMICA CLÍNICA, HOSPITAL UNIVERSITARIO MIGUEL SERVET, ZARAGOZA, SPAIN;DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR Y CELULAR, UNIVERSIDAD DE ZARAGOZA, INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN (IIS ARAGÓN), ZARAGOZA, SPAIN","BACKGROUND: ARMOLIPID PLUS (AP) IS A NUTRACEUTICAL THAT CONTAINS POLICOSANOL, FERMENTED RICE WITH RED YEAST, BERBERINE, COENZYME Q10, FOLIC ACID, AND ASTAXANTHIN. IT HAS BEEN SHOWN TO BE EFFECTIVE IN REDUCING PLASMA LDL CHOLESTEROL (LDLC) LEVELS. IN THE MULTICENTER RANDOMIZED TRIAL NCT01562080, THERE WAS LARGE INTERINDIVIDUAL VARIABILITY IN THE PLASMA LDLC RESPONSE TO AP SUPPLEMENTATION. WE HYPOTHESIZED THAT THE VARIABILITY IN LDLC RESPONSE TO AP SUPPLEMENTATION MAY BE LINKED TO LDLR AND PCSK9 POLYMORPHISMS. MATERIAL AND METHODS: WE SEQUENCED THE LDLR 30 AND 50 UNTRANSLATED REGIONS (UTR) AND THE PCSK9 50 UTR OF 102 PARTICIPANTS WITH MODERATE HYPERCHOLESTEROLEMIA IN TRIAL NCT01562080. IN THIS TRIAL, 50 INDIVIDUALS WERE TREATED WITH AP SUPPLEMENTATION AND THE REST WITH PLACEBO. RESULTS: MULTIPLE LINEAR REGRESSION ANALYSIS, USING THE RESPONSE OF LDLC LEVELS TO AP AS THE DEPENDENT VARIABLE, REVEALED THAT POLYMORPHISMS RS2149041 (C.-3383C>G) IN THE PCSK9 50 UTR AND RS14158 (C.∗52G>A) IN THE LDLR 30 UTR EXPLAINED 14.1%AND 6.4%, RESPECTIVELY, OF THE VARIABILITY AFTER ADJUSTING FOR GENDER, AGE, AND BMI OF INDIVIDUALS. COMBINING POLYMORPHISMS RS2149041 AND RS14158 EXPLAINED 20.5%OF THIS VARIABILITY (P < 0.004). CONCLUSIONS: THREE POLYMORPHISMS IN THE 30 UTR REGION OF LDLR, C.∗52G>A, C.∗504G>A, AND C. ∗773A>G, AND TWO AT THE 50 UTR REGION OF PCSK9, C.-3383C>G AND C.-2063A>G, WERE ASSOCIATED WITH RESPONSE TO AP. THESE RESULTS COULD EXPLAIN THE VARIABILITY OBSERVED IN THE RESPONSE TO BERBERINE AMONG PEOPLE WITH MODERATE HYPERCHOLESTEROLEMIA, AND THEY MAY BE USEFUL IN IDENTIFYING PATIENTS WHO COULD POTENTIALLY BENEFIT FROM SUPPLEMENTATION WITH AP. © 2016 DE CASTRO-ORÓS ET AL. THIS IS AN OPEN-ACCESS ARTICLE DISTRIBUTED UNDER THE TERMS OF THE CREATIVE COMMONS ATTRIBUTION LICENSE, WHICH PERMITS UNRESTRICTED USE, DISTRIBUTION, AND REPRODUCTION IN ANY MEDIUM, PROVIDED THE ORIGINAL AUTHOR AND SOURCE ARE CREDITED.","","ADULT; AGED; ALLELES; BERBERINE; CHOLESTEROL, LDL; FATTY ALCOHOLS; FEMALE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; XANTHOPHYLLS; ADENINE; ASTHAXANTINE; BERBERINE; CYTOSINE; FOLIC ACID; GUANINE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; NUTRACEUTICAL; PLACEBO; POLICOSANOL; UBIDECARENONE; UNCLASSIFIED DRUG; XUEZHIKANG; ASTAXANTHIN; BERBERINE; FATTY ALCOHOL; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; POLICOSANOL; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE; XANTHOPHYLL; 3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGE; ANTIHYPERCHOLESTEROLEMIC EFFECT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENDER; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; LDLR GENE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PCSK9 GENE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; AGED; ALLELE; FEMALE; GENETICS; HETEROZYGOTE; MALE; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA., 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N ENGL J MED., 335, PP. 1001-1009, (1996); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20, 536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); LEE I.T., LEE W.J., TSAI C.M., SU I.J., YEN H.T., SHEU W.H., COMBINED EXTRACTIVES OF RED YEAST RICE, BITTER GOURD, CHLORELLA, SOY PROTEIN, AND LICORICE IMPROVE TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDE IN SUBJECTS WITH METABOLIC SYNDROME, NUTR RES., 32, PP. 85-92, (2012); TIWARI A., BANSAL V., CHUGH A., MOOKHTIAR K., STATINS AND MYOTOXICITY: A THERAPEUTIC LIMITATION, EXPERT OPIN DRUG SAF., 5, PP. 651-666, (2006); SIRTORI C.R., MOMBELLI G., TRIOLO M., LAAKSONEN R., CLINICAL RESPONSE TO STATINS: MECHANISM (S) OF VARIABLE ACTIVITY AND ADVERSE EFFECTS, ANN MED., 44, PP. 419-432, (2012); THE NATIONAL LIPID ASSOCIATION STATIN INTOLERANCE PANEL, GUYTON J.R., BAYS H.E., GRUNDY S.M., JACOBSON T.A., AN ASSESSMENT BY THE STATIN INTOLERANCE PANEL: 2014 UPDATE, J CLIN LIPIDOL., 8, PP. S72-S81, (2014); AFFUSO F., MERCURIO V., RUVOLO A., PIROZZI C., MICILLO F., CARLOMAGNO G., ET AL., A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME, WORLD J CARDIOL., 4, PP. 77-83, (2012); PISCIOTTA L., BELLOCCHIO A., BERTOLINI S., NUTRACEUTICAL PILL CONTAINING BERBERINE VERSUS EZETIMIBE ON PLASMA LIPID PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS AND ITS ADDITIVE EFFECT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE CHOLESTEROL-LOWERING TREATMENT, LIPIDS HEALTH DIS., 11, (2012); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., ET AL., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN INDIVIDUALS WITH DYSLIPIDEMIA, J HYPERTENS., 28, PP. 1482-1487, (2010); TRIMARCO B., BENVENUTI C., ROZZA F., CIMMINO C.S., GIUDICE R., CRISPO S., CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET, MED J NUTRITION METAB., 4, PP. 133-139, (2011); SOLA R., VALLS R.M., PUZO J., CALABUIG J.R., BREA A., PEDRET A., ET AL., EFFECTS OF POLY-BIOACTIVE COMPOUNDS ON LIPID PROFILE AND BODY WEIGHT IN A MODERATELY HYPERCHOLESTEROLEMIC POPULATION WITH LOW CARDIOVASCULAR DISEASE RISK: A MULTICENTER RANDOMIZED TRIAL, PLOS ONE, 9, (2014); LIU J., ZHANG J., SHI J., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED., 23, PP. 1-4, (2006); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES., 32, PP. 8-12, (2001); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER., 318, PP. 1020-1026, (2006); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED., 10, PP. 1344-1351, (2004); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS, ATHEROSCLEROSIS., 201, PP. 266-273, (2008); LI H., DONG B., PARK S.W., LEE H.S., CHEN W., LIU J., HEPATOCYTE NUCLEAR FACTOR 1ALPHA PLAYS A CRITICAL ROLE IN PCSK9 GENE TRANSCRIPTION AND REGULATION BY THE NATURAL HYPOCHOLESTEROLEMIC COMPOUND BERBERINE, J BIOL CHEM., 284, PP. 28885-28895, (2009); DE CASTRO-OROS I., PAMPIN S., BOLADO-CARRANCIO A., DE CUBAS A., PALACIOS L., PLANA N., ET AL., FUNCTIONAL ANALYSIS OF LDLR PROMOTER AND 5' UTR MUTATIONS IN SUBJECTS WITH CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA, HUM MUTAT., 32, PP. 868-872, (2011); JACOBS D.R., ANDERSON J.T., HANNAN P., KEYS A., BLACKBURN H., VARIABILITY IN INDIVIDUAL SERUM CHOLESTEROL RESPONSE TO CHANGE IN DIET, ARTERIOSCLEROSIS., 3, PP. 349-356, (1983); BEYNEN A.C., KATAN M.B., REPRODUCIBILITY OF THE VARIATIONS BETWEEN HUMANS IN THE RESPONSE OF SERUM CHOLESTEROL TO CESSATION OF EGG CONSUMPTION, ATHEROSCLEROSIS., 57, PP. 19-31, (1985); BEYNEN A.C., KATAN M.B., VAN ZUTPHEN L.F., HYPO- AND HYPERRESPONDERS: INDIVIDUAL DIFFERENCES IN THE RESPONSE OF SERUM CHOLESTEROL CONCENTRATION TO CHANGES IN DIET, ADV LIPID RES., 22, PP. 115-171, (1987); KATAN M.B., BEYNEN A.C., DE VRIES J.H., NOBELS A., EXISTENCE OF CONSISTENT HYPO- AND HYPERRESPONDERS TO DIETARY CHOLESTEROL IN MAN, AM J EPIDEMIOL., 123, PP. 221-234, (1986); GERARDS M.C., TERLOU R.J., YU H., KOKS C.H., GERDES V.E., TRADITIONAL CHINESE LIPID-LOWERING AGENT RED YEAST RICE RESULTS IN SIGNIFICANT LDL REDUCTION BUT SAFETY IS UNCERTAIN-A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS., 240, PP. 415-423, (2015); WILSON G.M., VASA M.Z., DEELEY R.G., STABILIZATION AND CYTOSKELETAL-ASSOCIATION OF LDL RECEPTOR MRNA ARE MEDIATED BY DISTINCT DOMAINS IN ITS 3' UNTRANSLATED REGION, J LIPID RES., 39, PP. 1025-1032, (1998); CHEN W., WANG S., MA Y., ZHOU Y., LIU H., STRNAD P., ET AL., ANALYSIS OF POLYMORPHISMS IN THE 3' UNTRANSLATED REGION OF THE LDL RECEPTOR GENE AND THEIR EFFECT ON PLASMA CHOLESTEROL LEVELS AND DRUG RESPONSE, INT J MOL MED., 21, PP. 345-353, (2008); SINGH A.B., LI H., KAN C.F., DONG B., NICOLLS M.R., LIU J., THE CRITICAL ROLE OF MRNA DESTABILIZING PROTEIN HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D IN 3' UNTRANSLATED REGION-MEDIATED DECAY OF LOW-DENSITY LIPOPROTEIN RECEPTOR MRNA IN LIVER TISSUE, ARTERIOSCLER THROMB VASC BIOL., 34, PP. 8-16, (2014); DONG B., LI H., SINGH A.B., CAO A., LIU J., INHIBITION OF PCSK9 TRANSCRIPTION BY BERBERINE INVOLVES DOWN-REGULATION OF HEPATIC HNF1Α PROTEIN EXPRESSION THROUGH THE UBIQUITIN-PROTEASOME DEGRADATION PATHWAY, J BIOL CHEM., 290, PP. 4047-4058, (2015)","","PUBLIC LIBRARY OF SCIENCE","ENGLISH","PLOS ONE","ARTICLE","ISI","2-S2.0-84962159229","PLOS ONE",NA,"NOTREPORTED",NA,"DE CASTRO-ORÓS I, 2016, PLOS ONE","DE CASTRO-ORÓS I, 2016, PLOS ONE"
"PIRRO M;LUPATTELLI G;DEL G R;SCHILLACI G;BERISHA S;MANNARINO M;BAGAGLIA F;MELIS F;MANNARINO E","PIRRO, MATTEO (22036502300); LUPATTELLI, GRAZIANA (56248572700); DEL GIORNO, ROSARIA (35147488700); SCHILLACI, GIUSEPPE (7005176634); BERISHA, SOKOL (55688377800); MANNARINO, MASSIMO R. (26643162800); BAGAGLIA, FRANCESCO (6507029663); MELIS, FRANCESCO (54179744800); MANNARINO, ELMO (26643283400)","NUTRACEUTICAL COMBINATION RED YEAST RICE BERBERINE AND POLICOSANOLS IMPROVES AORTIC STIFFNESS IN LOWMODERATE RISK HYPERCHOLESTEROLEMIC PATIENTS",2013,"PHARMANUTRITION","1","4",22,"10.1016/j.phanu.2013.02.003","UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY;UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS DISEASES, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY OF PERUGIA, PERUGIA, ITALY","HYPERCHOLESTEROLEMIA IS IMPORTANT IN THE PATHOGENESIS OF ARTERIAL STIFFNESS. TREATMENT WITH A COMBINATION OF RED YEAST RICE, BERBERINE AND POLICOSANOLS REDUCED CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS. WE INVESTIGATED WHETHER THIS NUTRACEUTICAL COMBINATION WOULD IMPROVE AORTIC STIFFNESS IN HYPERCHOLESTEROLEMIA.SEVENTY HYPERCHOLESTEROLEMIC PATIENTS WERE ASSIGNED TO ORAL NUTRACEUTICAL COMBINATION (NC, RED YEAST RICE 200. MG, BERBERINE 500. MG AND POLICOSANOLS 10. MG) OR NO ACTIVE TREATMENT (NONC). LIPID LEVELS AND AORTIC PULSE WAVE VELOCITY (APWV) WERE ASSESSED BEFORE AND AFTER TREATMENT.NC REDUCED LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL BY 20%. MORE THAN 65% PATIENTS REACHED THE RECOMMENDED LDL CHOLESTEROL TARGET. A SIGNIFICANT DIFFERENCE IN THE RESPONSE OF APWV TO TREATMENTS (NC VS NONC) WAS FOUND (. P=. 0.005): NC WAS ASSOCIATED WITH A REDUCTION IN APWV (FROM 9.1. ±. 2.0 TO 8.3. ±. 1.7. M/S, P<. 0.001), WHEREAS NO CHANGE WAS OBSERVED IN THE NONC ARM. LDL CHOLESTEROL REDUCTION WAS ASSOCIATED WITH IMPROVEMENT IN APWV (. R=. 0.30, P=. 0.01). IN REGRESSION ANALYSES, NC WAS ASSOCIATED WITH THE PRESENCE OF APWV AMELIORATION (OR AND 95% CI, 4.2, 1.4-12.5) AND THE DEGREE OF APWV REDUCTION (. Β=. 0.33, P=. 0.007).IN CONCLUSION, IN PATIENTS WITH HYPERCHOLESTEROLEMIA, THE NUTRACEUTICAL COMBINATION REDUCED CHOLESTEROL LEVELS AND IMPROVED APWV. AN ASSOCIATION BETWEEN CHOLESTEROL REDUCTION AND AORTIC STIFFNESS WAS FOUND. © 2013 .","AORTIC STIFFNESS; BERBERINE; HYPERCHOLESTEROLEMIA; POLICOSANOLS; RED YEAST RICE","BERBERINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; XUEZHIKANG; ADULT; AORTIC PULSE WAVE VELOCITY; ARTERIAL STIFFNESS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR","","","NIJJAR P.S., BURKE F.M., BLOESCH A., RADER D.J., ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL: A REVIEW, JOURNAL OF CLINICAL LIPIDOLOGY, 4, PP. 248-258, (2010); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHINESE MEDICAL, 1, (2006); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AMERICAN JOURNAL OF CARDIOLOGY, 101, PP. 1689-1693, (2008); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NATURE MEDICINE, 10, PP. 1344-1351, (2004); MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 50, PP. 259-267, (2010); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, PP. 1543-1548, (2006); WEI W., LI C., WANG Y., SU H., ZHU J., KRITCHEVSKY D., HYPOLIPIDEMIC AND ANTI-ATHEROGENIC EFFECTS OF LONG-TERM CHOLESTIN (MONASCUS PURPUREUS-FERMENTED RICE, RED YEAST RICE) IN CHOLESTEROL FED RABBITS, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 4, PP. 314-318, (2003); LEE T.S., PAN C.C., PENG C.C., KOU Y.R., CHEN C.Y., CHING L.C., ET AL., ANTI-ATHEROGENIC EFFECT OF BERBERINE ON LXRALPHA-ABCA1-DEPENDENT CHOLESTEROL EFFLUX IN MACROPHAGES, JOURNAL OF CELLULAR BIOCHEMISTRY, 111, PP. 104-110, (2010); NOA M., MAS R., LARIOT C., PROTECTIVE EFFECT OF POLICOSANOL ON ENDOTHELIUM AND INTIMAL THICKNESS INDUCED BY FORCEPS IN RABBITS, JOURNAL OF MEDICINAL FOOD, 10, PP. 452-459, (2007); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTEL-FORSCHUNG, 55, PP. 312-317, (2005); AFFUSO F., RUVOLO A., MICILLO F., SACCA L., FAZIO S., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 20, PP. 656-661, (2010); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 21, PP. 424-429, (2011); MARAZZI G., CACCIOTTI L., PELLICCIA F., IAIA L., VOLTERRANI M., CAMINITI G., ET AL., LONG-TERM EFFECTS OF NUTRACEUTICALS (BERBERINE, RED YEAST RICE, POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, ADVANCES IN THERAPY, 28, PP. 1105-1113, (2011); VLACHOPOULOS C., AZNAOURIDIS K., STEFANADIS C., PREDICTION OF CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY WITH ARTERIAL STIFFNESS: A SYSTEMATIC REVIEW AND META-ANALYSIS, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 55, PP. 1318-1327, (2010); WILKINSON I.B., PRASAD K., HALL I.R., THOMAS A., MACCALLUM H., WEBB D.J., ET AL., INCREASED CENTRAL PULSE PRESSURE AND AUGMENTATION INDEX IN SUBJECTS WITH HYPERCHOLESTEROLEMIA, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, PP. 1005-1011, (2002); PIRRO M., SCHILLACI G., SAVARESE G., GEMELLI F., VAUDO G., SIEPI D., ET AL., LOW-GRADE SYSTEMIC INFLAMMATION IMPAIRS ARTERIAL STIFFNESS IN NEWLY DIAGNOSED HYPERCHOLESTEROLAEMIA, EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 4, PP. 335-341, (2004); PIRRO M., SCHILLACI G., PALTRICCIA R., BAGAGLIA F., MENECALI C., MANNARINO M.R., ET AL., INCREASED RATIO OF CD31<SUP>+</SUP>/CD42<SUP>-</SUP> MICROPARTICLES TO ENDOTHELIAL PROGENITORS AS A NOVEL MARKER OF ATHEROSCLEROSIS IN HYPERCHOLESTEROLEMIA, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 26, PP. 2530-2535, (2006); PIRRO M., SCHILLACI G., MANNARINO M.R., SAVARESE G., VAUDO G., SIEPI D., ET AL., EFFECTS OF ROSUVASTATIN ON 3-NITROTYROSINE AND AORTIC STIFFNESS IN HYPERCHOLESTEROLEMIA, NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 7, PP. 436-441, (2007); PIRRO M., SCHILLACI G., SAVARESE G., GEMELLI F., MANNARINO M.R., SIEPI D., ET AL., ATTENUATION OF INFLAMMATION WITH SHORT-TERM DIETARY INTERVENTION IS ASSOCIATED WITH A REDUCTION OF ARTERIAL STIFFNESS IN SUBJECTS WITH HYPERCHOLESTEROLAEMIA, EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION AND REHABILITATION, 11, PP. 497-502, (2004); EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); RIZOS E.C., AGOURIDIS A.P., ELISAF M.S., THE EFFECT OF STATIN THERAPY ON ARTERIAL STIFFNESS BY MEASURING PULSE WAVE VELOCITY: A SYSTEMATIC REVIEW, CURRENT VASCULAR PHARMACOLOGY, 8, PP. 638-644, (2010); LIN C.P., LIN Y.L., HUANG P.H., TSAI H.S., CHEN Y.H., INHIBITION OF ENDOTHELIAL ADHESION MOLECULE EXPRESSION BY MONASCUS PURPUREUS-FERMENTED RICE METABOLITES, MONACOLIN K, ANKAFLAVIN, AND MONASCIN, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 91, PP. 1751-1758, (2011); MENG S., WANG L.S., HUANG Z.Q., ZHOU Q., SUN Y.G., CAO J.T., ET AL., BERBERINE AMELIORATES INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 39, PP. 406-411, (2012); THIPPESWAMY G., SHEELA M.L., SALIMATH B.P., OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-<KAPPA>B AND ITS DNA BINDING ACTIVITY, EUROPEAN JOURNAL OF PHARMACOLOGY, 588, PP. 141-150, (2008); NIKLOWITZ P., SONNENSCHEIN A., JANETZKY B., ANDLER W., MENKE T., ENRICHMENT OF COENZYME Q10 IN PLASMA AND BLOOD CELLS: DEFENSE AGAINST OXIDATIVE DAMAGE, INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 3, PP. 257-262, (2007); LEE Y.J., CHO W.J., KIM J.K., LEE D.C., EFFECTS OF COENZYME Q10 ON ARTERIAL STIFFNESS, METABOLIC PARAMETERS, AND FATIGUE IN OBESE SUBJECTS: A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY, JOURNAL OF MEDICINAL FOOD, 14, PP. 386-390, (2011); XU M.G., WANG J.M., CHEN L., WANG Y., YANG Z., TAO J., BERBERINE-INDUCED MOBILIZATION OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IMPROVES HUMAN SMALL ARTERY ELASTICITY, JOURNAL OF HUMAN HYPERTENSION, 22, PP. 389-393, (2008); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); BORGHI C., DORMI A., VERONESI M., SANGIORGI Z., GADDI A., BRISIGHELLA HEART STUDY WORKING PARTY. ASSOCIATION BETWEEN DIFFERENT LIPID-LOWERING TREATMENT STRATEGIES AND BLOOD PRESSURE CONTROL IN THE BRISIGHELLA HEART STUDY, AMERICAN HEART JOURNAL, 148, PP. 285-292, (2004)","M. PIRRO; UNIT OF INTERNAL MEDICINE, ANGIOLOGY AND ARTERIOSCLEROSIS, UNIVERSITY OF PERUGIA, HOSPITAL SANTA MARIA DELLA MISERICORDIA, PIAZZALE MENGHINI, 1-06156 PERUGIA, ITALY; EMAIL: MPIRRO@UNIPG.IT","","ENGLISH","PHARMANUTRITION","ARTICLE","ISI","2-S2.0-84877115304","PHARMANUTRITION","UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA;UNIVERSITY OF PERUGIA","NOTREPORTED;UNIVERSITY OF PERUGIA;NOTREPORTED",NA,"PIRRO M, 2013, PHARMANUTRITION","PIRRO M, 2013, PHARMANUTRITION"
"DE F S","DE FERRANTI, SARAH D. (57195454443)","FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN AND ADOLESCENTS A CLINICAL PERSPECTIVE",2015,"JOURNAL OF CLINICAL LIPIDOLOGY","9","8",19,"10.1016/j.jacl.2015.04.009","DEPARTMENT OF CARDIOLOGY, BOSTON CHILDREN'S HOSPITAL, 300 LONGWOOD AVENUE, FA607, BOSTON, 02115, MA, UNITED STATES","FAMILIAL HYPERCHOLESTEROLEMIA (FH) IS AN AUTOSOMAL DOMINANT DISORDER OF LOW-DENSITY LIPOPROTEIN (LDL) METABOLISM LEADING TO HIGH LDL CHOLESTEROL (LDL-C) AND ACCELERATED ATHEROSCLEROSIS. THE RARE HOMOZYGOUS FORM IS ASSOCIATED WITH PHYSICAL EXAMINATION FINDINGS AND CORONARY HEART DISEASE DURING CHILDHOOD. THE MORE COMMON HETEROZYGOUS FORM (HETFH) IS ASYMPTOMATIC UNTIL ADULTHOOD, WHEN THOSE AFFECTED DEVELOP PREMATURE CARDIOVASCULAR DISEASE (CVD) EVENTS, OFTEN IN EARLY ADULTHOOD. IDENTIFICATION OF HETFH IS KEY BECAUSE OF THE RELATIVELY HIGH PREVALENCE, 1 IN 200 TO 500, AND THE OPPORTUNITY TO LOWER LDL-C AND REDUCE CVD OUTCOMES. SELECTIVE SCREENING BASED ON FAMILY HISTORY CAN IDENTIFY AFFECTED INDIVIDUALS, BUT MANY WITH HETFH ARE MISSED BY RELYING ON THIS STRATEGY AND GO UNDIAGNOSED DURING CHILDHOOD, LEADING TO THE RECOMMENDATION BY THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE EXPERT PANEL FOR UNIVERSAL LIPID SCREENING BETWEEN AGES 9 AND 11 Y AND AGAIN AT AGES 17 TO 21 Y. DIAGNOSIS SHOULD LEAD TO TREATMENT WITH LIFESTYLE MODIFICATION AND PHARMACOTHERAPY WHEN APPROPRIATE BECAUSE LOWERING LDL-C IN YOUTH HAS BENEFICIAL EFFECTS ON SUBCLINICAL ATHEROSCLEROSIS AND LIKELY REDUCES PREMATURE CVD EVENTS. THIS ARTICLE REVIEWS WHAT IS KNOWN ABOUT THE EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF FH AS IT RELATES TO THE CARE OF CHILDREN AND ADOLESCENTS. APPROACHES TO IDENTIFICATION AND TREATMENT OF FH DURING CHILDHOOD ARE PRESENTED, INCLUDING BOTH RECOMMENDATIONS FROM PUBLISHED GUIDELINES AND CLINICAL EXPERIENCE. A CLINICAL CASE IS USED TO ILLUSTRATE VARIOUS POINTS. © 2015 NATIONAL LIPID ASSOCIATION.","ADOLESCENT; CHILD; CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; PREVALENCE; SCREENING; TREATMENT","ADOLESCENT; CHILD; DIETARY SUPPLEMENTS; GENETIC TESTING; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; APOLIPOPROTEIN B; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; POLICOSANOL; PRAVASTATIN; STANOL ESTER; STANOZOLOL; TRIACYLGLYCEROL; XUEZHIKANG; ADOLESCENT; ANTISENSE THERAPY; APOB GENE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHILD; CHILD CARE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE; GENETIC SCREENING; HUMAN; ISCHEMIC HEART DISEASE; LDLR GENE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PCSK9 GENE; PHYSICAL EXAMINATION; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; DIETARY SUPPLEMENT; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; PATHOPHYSIOLOGY","","","BENN M., WATTS G.F., TYBJAERG-HANSEN A., NORDESTGAARD B.G., FAMILIAL HYPERCHOLESTEROLEMIA IN THE DANISH GENERAL POPULATION: PREVALENCE, CORONARY ARTERY DISEASE, AND CHOLESTEROL-LOWERING MEDICATION, J CLIN ENDOCRINOL METAB, 97, 11, PP. 3956-3964, (2012); WATTS G.F., GIDDING S., WIERZBICKI A.S., ET AL., INTEGRATED GUIDANCE ON THE CARE OF FAMILIAL HYPERCHOLESTEROLEMIA FROM THE INTERNATIONAL FH FOUNDATION, J CLIN LIPIDOL, 8, 2, PP. 148-172, (2014); GOLDSTEIN J.L., SCHROTT H.G., HAZZARD W.R., BIERMAN E.L., MOTULSKY A.G., HYPERLIPIDEMIA IN CORONARY HEART DISEASE. II. GENETIC ANALYSIS OF LIPID LEVELS IN 176 FAMILIES AND DELINEATION OF A NEW INHERITED DISORDER, COMBINED HYPERLIPIDEMIA, J CLIN INVEST, 52, 7, PP. 1544-1568, (1973); NEIL A., COOPER J., BETTERIDGE J., ET AL., REDUCTIONS IN ALL-CAUSE, CANCER, AND CORONARY MORTALITY IN STATIN-TREATED PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: A PROSPECTIVE REGISTRY STUDY, EUR HEART J, 29, 21, PP. 2625-2633, (2008); VERSMISSEN J., OOSTERVEER D.M., YAZDANPANAH M., ET AL., EFFICACY OF STATINS IN FAMILIAL HYPERCHOLESTEROLAEMIA: A LONG TERM COHORT STUDY, BMJ, 337, (2008); HOPKINS P.N., TOTH P.P., BALLANTYNE C.M., RADER D.J., FAMILIAL HYPERCHOLESTEROLEMIAS: PREVALENCE, GENETICS, DIAGNOSIS AND SCREENING RECOMMENDATIONS FROM THE NATIONAL LIPID ASSOCIATION EXPERT PANEL ON FAMILIAL HYPERCHOLESTEROLEMIA, J CLIN LIPIDOL, 5, 3, PP. S9-S17, (2011); GOLDBERG A.C., HOPKINS P.N., TOTH P.P., ET AL., FAMILIAL HYPERCHOLESTEROLEMIA: SCREENING, DIAGNOSIS AND MANAGEMENT OF PEDIATRIC AND ADULT PATIENTS: CLINICAL GUIDANCE FROM THE NATIONAL LIPID ASSOCIATION EXPERT PANEL ON FAMILIAL HYPERCHOLESTEROLEMIA, J CLIN LIPIDOL, 5, 3, PP. S1-S8, (2011); PAUCIULLO P., IANNUZZI A., SARTORIO R., ET AL., INCREASED INTIMA-MEDIA THICKNESS OF THE COMMON CAROTID ARTERY IN HYPERCHOLESTEROLEMIC CHILDREN, ARTERIOSCLER THROMB, 14, 7, PP. 1075-1079, (1994); TONSTAD S., JOAKIMSEN O., STENSLAND-BUGGE E., ET AL., RISK FACTORS RELATED TO CAROTID INTIMA-MEDIA THICKNESS AND PLAQUE IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA AND CONTROL SUBJECTS, ARTERIOSCLER THROMB VASC BIOL, 16, 8, PP. 984-991, (1996); WIEGMAN A., DE GROOT E., HUTTEN B.A., ET AL., ARTERIAL INTIMA-MEDIA THICKNESS IN CHILDREN HETEROZYGOUS FOR FAMILIAL HYPERCHOLESTEROLAEMIA, LANCET, 363, 9406, PP. 369-370, (2004); KUSTERS D.M., WIEGMAN A., KASTELEIN J.J., HUTTEN B.A., CAROTID INTIMA-MEDIA THICKNESS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, CIRC RES, 114, 2, PP. 307-310, (2014); WIEGMAN A., HUTTEN B.A., DE GROOT E., ET AL., EFFICACY AND SAFETY OF STATIN THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 292, 3, PP. 331-337, (2004); RODENBURG J., VISSERS M.N., WIEGMAN A., ET AL., STATIN TREATMENT IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA: THE YOUNGER, THE BETTER, CIRCULATION, 116, 6, PP. 664-668, (2007); KUSTERS D.M., AVIS H.J., DE GROOT E., ET AL., TEN-YEAR FOLLOW-UP AFTER INITIATION OF STATIN THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, JAMA, 312, 10, PP. 1055-1057, (2014); BRAAMSKAMP M.J., KUSTERS D.M., AVIS H.J., ET AL., PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA WHO INITIATED STATIN TREATMENT IN CHILDHOOD ARE AT LOWER RISK FOR CHD THEN THEIR AFFECTED PARENTS, CIRCULATION, 128, (2013); RIGGIO S., MANDRAFFINO G., SARDO M.A., ET AL., PULSE WAVE VELOCITY AND AUGMENTATION INDEX, BUT NOT INTIMA-MEDIA THICKNESS, ARE EARLY INDICATORS OF VASCULAR DAMAGE IN HYPERCHOLESTEROLEMIC CHILDREN, EUR J CLIN INVEST, 40, 3, PP. 250-257, (2010); DE JONGH S., LILIEN M.R., OP'T ROODT J., STROES E.S., BAKKER H.D., KASTELEIN J.J., EARLY STATIN THERAPY RESTORES ENDOTHELIAL FUNCTION IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, J AM COLL CARDIOL, 40, 12, PP. 2117-2121, (2002); VLAHOS A.P., NAKA K.K., BECHLIOULIS A., ET AL., ENDOTHELIAL DYSFUNCTION, BUT NOT STRUCTURAL ATHEROSCLEROSIS, IS EVIDENT EARLY IN CHILDREN WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, PEDIATR CARDIOL, 35, 1, PP. 63-70, (2014); GOLDSTEIN J.L., BROWN M.S., EXPRESSION OF THE FAMILIAL HYPERCHOLESTEROLEMIA GENE IN HETEROZYGOTES: MODEL FOR A DOMINANT DISORDER IN MAN, TRANS ASSOC AM PHYSICIANS, 87, PP. 120-131, (1974); WILLIAMS R.R., HUNT S.C., SCHUMACHER M.C., ET AL., DIAGNOSING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING NEW PRACTICAL CRITERIA VALIDATED BY MOLECULAR GENETICS, AM J CARDIOL, 72, 2, PP. 171-176, (1993); FAMILIAL HYPERCHOLESTEROLEMIA (FH): REPORT OF A SECOND WHO CONSULTATION, (1999); NORDESTGAARD B.G., CHAPMAN M.J., HUMPHRIES S.E., ET AL., FAMILIAL HYPERCHOLESTEROLAEMIA IS UNDERDIAGNOSED AND UNDERTREATED IN THE GENERAL POPULATION: GUIDANCE FOR CLINICIANS TO PREVENT CORONARY HEART DISEASE: CONSENSUS STATEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY, EUR HEART J, 34, 45, PP. 3478A-3490A, (2013); GOLDBERG A.C., HOPKINS P.N., TOTH P.P., ET AL., FAMILIAL HYPERCHOLESTEROLEMIA: SCREENING, DIAGNOSIS AND MANAGEMENT OF PEDIATRIC AND ADULT PATIENTS: CLINICAL GUIDANCE FROM THE NATIONAL LIPID ASSOCIATION EXPERT PANEL ON FAMILIAL HYPERCHOLESTEROLEMIA, J CLIN LIPIDOL, 5, 3, PP. 133-140, (2011); GILLMAN M.W., DANIELS S.R., IS UNIVERSAL PEDIATRIC LIPID SCREENING JUSTIFIED?, JAMA, 307, 3, PP. 259-260, (2012); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP): HIGHLIGHTS OF THE REPORT OF THE EXPERT PANEL ON BLOOD CHOLESTEROL LEVELS IN CHILDREN AND ADOLESCENTS, PEDIATRICS, 89, 3, PP. 495-501, (1992); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, 19, PP. 2486-2497, (2001); DANIELS S.R., GREER F.R., LIPID SCREENING AND CARDIOVASCULAR HEALTH IN CHILDHOOD, PEDIATRICS, 122, 1, PP. 198-208, (2008); DENNISON B.A., JENKINS P.L., PEARSON T.A., CHALLENGES TO IMPLEMENTING THE CURRENT PEDIATRIC CHOLESTEROL SCREENING GUIDELINES INTO PRACTICE, PEDIATRICS, 94, 3, PP. 296-302, (1994); O'LOUGHLIN J., LAUZON B., PARADIS G., ET AL., USEFULNESS OF THE AMERICAN ACADEMY OF PEDIATRICS RECOMMENDATIONS FOR IDENTIFYING YOUTHS WITH HYPERCHOLESTEROLEMIA, PEDIATRICS, 113, 6, PP. 1723-1727, (2004); RIFAI N., NEUFELD E., AHLSTROM P., RIMM E., D'ANGELO L., HICKS J.M., FAILURE OF CURRENT GUIDELINES FOR CHOLESTEROL SCREENING IN URBAN AFRICAN-AMERICAN ADOLESCENTS, PEDIATRICS, 98, 3, PP. 383-388, (1996); SHEA S., BASCH C.E., IRIGOYEN M., ET AL., FAILURE OF FAMILY HISTORY TO PREDICT HIGH BLOOD CHOLESTEROL AMONG HISPANIC PRESCHOOL CHILDREN, PREV MED, 19, 4, PP. 443-455, (1990); EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS: SUMMARY REPORT, PEDIATRICS, 128, PP. S213-S256, (2011); UMANS-ECKENHAUSEN M.A., DEFESCHE J.C., SIJBRANDS E.J., SCHEERDER R.L., KASTELEIN J.J., REVIEW OF FIRST 5 YEARS OF SCREENING FOR FAMILIAL HYPERCHOLESTEROLAEMIA IN THE NETHERLANDS, LANCET, 357, 9251, PP. 165-168, (2001); ADEMI Z., WATTS G.F., PANG J., ET AL., CASCADE SCREENING BASED ON GENETIC TESTING IS COST-EFFECTIVE: EVIDENCE FOR THE IMPLEMENTATION OF MODELS OF CARE FOR FAMILIAL HYPERCHOLESTEROLEMIA, J CLIN LIPIDOL, 8, 4, PP. 390-400, (2014); MARANG-VAN DE MHEEN P.J., TEN ASBROEK A.H., BONNEUX L., BONSEL G.J., KLAZINGA N.S., COST-EFFECTIVENESS OF A FAMILY AND DNA BASED SCREENING PROGRAMME ON FAMILIAL HYPERCHOLESTEROLAEMIA IN THE NETHERLANDS, EUR HEART J, 23, 24, PP. 1922-1930, (2002); MORRISON J.A., GLUECK C.J., WANG P., THE CHILD AS PROBAND FOR FUTURE PARENTAL CARDIOMETABOLIC DISEASE: THE 26-YEAR PROSPECTIVE PRINCETON LIPID RESEARCH CLINICS FOLLOW-UP STUDY, J PEDIATR, 160, 4, PP. 590.E3-597.E3, (2012); EFFICACY AND SAFETY OF LOWERING DIETARY INTAKE OF FAT AND CHOLESTEROL IN CHILDREN WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL. THE DIETARY INTERVENTION STUDY IN CHILDREN (DISC). THE WRITING GROUP FOR THE DISC COLLABORATIVE RESEARCH GROUP, JAMA, 273, 18, PP. 1429-1435, (1995); NIINIKOSKI H., LAGSTROM H., JOKINEN E., ET AL., IMPACT OF REPEATED DIETARY COUNSELING BETWEEN INFANCY AND 14 YEARS OF AGE ON DIETARY INTAKES AND SERUM LIPIDS AND LIPOPROTEINS. THE STRIP STUDY, CIRCULATION, 116, PP. 1032-1040, (2007); HO M., GARNETT S.P., BAUR L., ET AL., EFFECTIVENESS OF LIFESTYLE INTERVENTIONS IN CHILD OBESITY: SYSTEMATIC REVIEW WITH META-ANALYSIS, PEDIATRICS, 130, 6, PP. E1647-E1671, (2012); BROEKHUIZEN K., VAN POPPEL M.N., KOPPES L.L., KINDT I., BRUG J., VAN MECHELEN W., NO SIGNIFICANT IMPROVEMENT OF CARDIOVASCULAR DISEASE RISK INDICATORS BY A LIFESTYLE INTERVENTION IN PEOPLE WITH FAMILIAL HYPERCHOLESTEROLEMIA COMPARED TO USUAL CARE: RESULTS OF A RANDOMISED CONTROLLED TRIAL, BMC RES NOTES, 5, (2012); MUSA-VELOSO K., POON T.H., ELLIOT J.A., CHUNG C., A COMPARISON OF THE LDL-CHOLESTEROL LOWERING EFFICACY OF PLANT STANOLS AND PLANT STEROLS OVER A CONTINUOUS DOSE RANGE: RESULTS OF A META-ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 85, 1, PP. 9-28, (2011); LI Y., JIANG L., JIA Z., ET AL., A META-ANALYSIS OF RED YEAST RICE: AN EFFECTIVE AND RELATIVELY SAFE ALTERNATIVE APPROACH FOR DYSLIPIDEMIA, PLOS ONE, 9, 6, (2014); TAMMI A., RONNEMAA T., GYLLING H., ET AL., PLANT STANOL ESTER MARGARINE LOWERS SERUM TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATIONS OF HEALTHY CHILDREN: THE STRIP PROJECT. SPECIAL TURKU CORONARY RISK FACTORS INTERVENTION PROJECT, J PEDIATR, 136, 4, PP. 503-510, (2000); GUARDAMAGNA O., ABELLO F., BARACCO V., STASIOWSKA B., MARTINO F., THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN: EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS, NUTR METAB CARDIOVASC DIS, 21, 6, PP. 424-429, (2011); KWITEROVICH P.O., THE ROLE OF FIBER IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CHILDREN AND ADOLESCENTS, PEDIATRICS, 96, 5, PP. 1005-1009, (1995); DENNISON B.A., LEVINE D.M., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-PERIOD CROSSOVER CLINICAL TRIAL OF PSYLLIUM FIBER IN CHILDREN WITH HYPERCHOLESTEROLEMIA, J PEDIATR, 123, 1, PP. 24-29, (1993); BAIGENT C., KEECH A., KEARNEY P.M., ET AL., EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, 9493, PP. 1267-1278, (2005); BAIGENT C., BLACKWELL L., EMBERSON J., HOLLAND L.E., REITH C., ET AL., EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170,000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, 9753, PP. 1670-1681, (2010); VUORIO A., KUOPPALA J., KOVANEN P.T., ET AL., STATINS FOR CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, COCHRANE DATABASE SYST REV, 7, (2014); BRAAMSKAMP M.J., KUSTERS D.M., AVIS H.J., ET AL., LONG-TERM STATIN TREATMENT IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA: MORE INSIGHT INTO TOLERABILITY AND ADHERENCE, PAEDIATR DRUGS, 17, 2, PP. 159-166, (2015); TONSTAD S., KNUDTZON J., SIVERTSEN M., REFSUM H., OSE L., EFFICACY AND SAFETY OF CHOLESTYRAMINE THERAPY IN PERIPUBERTAL AND PREPUBERTAL CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, J PEDIATR, 129, 1, PP. 42-49, (1996); LIACOURAS C.A., COATES P.M., GALLAGHER P.R., CORTNER J.A., USE OF CHOLESTYRAMINE IN THE TREATMENT OF CHILDREN WITH FAMILIAL COMBINED HYPERLIPIDEMIA, J PEDIATR, 122, 3, PP. 477-482, (1993); MCCRINDLE B.W., O'NEILL M.B., CULLEN-DEAN G., HELDEN E., ACCEPTABILITY AND COMPLIANCE WITH TWO FORMS OF CHOLESTYRAMINE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CHILDREN: A RANDOMIZED, CROSSOVER TRIAL, J PEDIATR, 130, 2, PP. 266-273, (1997); STONE N.J., ROBINSON J.G., LICHTENSTEIN A.H., ET AL., 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES, J AM COLL CARDIOL, 63, 25, PP. 2889-2934, (2014); BESSELING J., KASTELEIN J.J., DEFESCHE J.C., HUTTEN B.A., HOVINGH G.K., ASSOCIATION BETWEEN FAMILIAL HYPERCHOLESTEROLEMIA AND PREVALENCE OF TYPE 2 DIABETES MELLITUS, JAMA, 313, 10, PP. 1029-1036, (2015); HUDGINS L.C., KLEINMAN B., SCHEUER A., WHITE S., GORDON B.R., LONG-TERM SAFETY AND EFFICACY OF LOW-DENSITY LIPOPROTEIN APHERESIS IN CHILDHOOD FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, AM J CARDIOL, 102, 9, PP. 1199-1204, (2008); BRUCKERT E., RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: OVERVIEW OF A NEW EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS STATEMENT, ATHEROSCLER SUPPL, 15, 2, PP. 26-32, (2014); LEFORT B., SAHEB S., BRUCKERT E., GIRAUD C., HEQUET O., HANKARD R., IMPACT OF LDL APHERESIS ON AORTIC ROOT ATHEROMA IN CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 239, 1, PP. 158-162, (2015)","S.D. DE FERRANTI; DEPARTMENT OF CARDIOLOGY, BOSTON CHILDREN'S HOSPITAL, BOSTON, 300 LONGWOOD AVENUE, FA607, 02115, UNITED STATES; EMAIL: SARAH.DEFERRANTI@CARDIO.CHBOSTON.ORG","ELSEVIER LTD","ENGLISH","J. CLIN. LIPIDOLOGY","REVIEW","ISI","2-S2.0-84940933549","J CLIN LIPIDOLOGY","BOSTON CHILDREN'S HOSPITAL","NOTREPORTED;BOSTON CHILDREN'S HOSPITAL;NOTREPORTED",NA,"DE FERRANTI SD, 2015, J CLIN LIPIDOLOGY","DE FERRANTI SD, 2015, J CLIN LIPIDOLOGY"
"MAZZA A;FRUCI B;GARINIS G;GIULIANO S;MALAGUARNERA R;BELFIORE A","MAZZA, ANGELA (57536873000); FRUCI, BARBARA (37033893300); GARINIS, GIORGIA ANNA (36862448500); GIULIANO, STEFANIA (26767718200); MALAGUARNERA, ROBERTA (10039134800); BELFIORE, ANTONINO (57200902495)","THE ROLE OF METFORMIN IN THE MANAGEMENT OF NAFLD",2012,"EXPERIMENTAL DIABETES RESEARCH","2012","",152,"10.1155/2012/716404","ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY;ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY;ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY;ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY;ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY;ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY","NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS THE MOST COMMON LIVER DISORDER WORLDWIDE. ITS PREVALENCE RANGES 10-24% IN THE GENERAL POPULATION, REACHING 60-95% AND 28-55% IN OBESE AND DIABETIC PATIENTS, RESPECTIVELY. ALTHOUGH THE ETIOLOGY OF NAFLD IS STILL UNCLEAR, SEVERAL LINES OF EVIDENCES HAVE INDICATED A PATHOGENETIC ROLE OF INSULIN RESISTANCE IN THIS DISORDER. THIS CONCEPT HAS STIMULATED SEVERAL CLINICAL STUDIES WHERE ANTIDIABETIC DRUGS, SUCH AS INSULIN SENSITIZERS INCLUDING METFORMIN, HAVE BEEN EVALUATED IN INSULIN-RESISTANT, NAFLD PATIENTS. THESE STUDIES INDICATE THAT METFORMIN MIGHT BE OF BENEFIT IN THE TREATMENT OF NAFLD, ALSO IN NONDIABETIC PATIENTS, WHEN ASSOCIATED TO HYPOCALORIC DIET AND WEIGHT CONTROL. HOWEVER, THE HETEROGENEITY OF THESE STUDIES STILL PREVENTS US FROM REACHING FIRM CONCLUSIONS ABOUT TREATMENT GUIDELINES. MOREOVER, METFORMIN COULD HAVE BENEFICIAL TISSUE-SPECIFIC EFFECTS IN NAFLD PATIENTS IRRESPECTIVE OF ITS EFFECTS AS INSULIN SENSITIZER. © 2012 ANGELA MAZZA ET AL.","","FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYL COENZYME A CARBOXYLASE; ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; METFORMIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PIOGLITAZONE; POLICOSANOL; ROSIGLITAZONE; SATURATED FATTY ACID; SILYMARIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; METFORMIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BODY MASS; DIET; ENDOPLASMIC RETICULUM; EXERCISE; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LOW CALORY DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STEATOSIS; VULVA DISEASE; WEIGHT CONTROL; FATTY LIVER; INSULIN RESISTANCE","","","FESTI D., COLECCHIA A., SACCO T., BONDI M., RODA E., MARCHESINI G., HEPATIC STEATOSIS IN OBESE PATIENTS: CLINICAL ASPECTS AND PROGNOSTIC SIGNIFICANCE, OBESITY REVIEWS, 5, 1, PP. 27-42, (2004); MARCHESINI G., BUGIANESI E., FORLANI G., CERRELLI F., LENZI M., MANINI R., NATALE S., VANNI E., VILLANOVA N., MELCHIONDA N., RIZZETTO M., NONALCOHOLIC FATTY LIVER, STEATOHEPATITIS, AND THE METABOLIC SYNDROME, HEPATOLOGY, 37, 4, PP. 917-923, (2003); LORIA P., LONARDO A., BELLENTANI S., DAY C.P., MARCHESINI G., CARULLI N., NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CARDIOVASCULAR DISEASE: AN OPEN QUESTION, NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES, 17, 9, PP. 684-698, (2007); DE ALWIS N.M.W., DAY C.P., NON-ALCOHOLIC FATTY LIVER DISEASE: THE MIST GRADUALLY CLEARS, JOURNAL OF HEPATOLOGY, 48, SUPPL. 1, (2008); SOCHA P., HORVATH A., VAJRO P., DZIECHCIARZ P., DHAWAN A., SZAJEWSKA H., PHARMACOLOGICAL INTERVENTIONS FOR NONALCOHOLIC FATTY LIVER DISEASE IN ADULTS AND IN CHILDREN: A SYSTEMATIC REVIEW, JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 48, 5, PP. 587-596, (2009); SCHWIMMER J.B., KHORRAM O., CHIU V., SCHWIMMER W.B., ABNORMAL AMINOTRANSFERASE ACTIVITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, FERTILITY AND STERILITY, 83, 2, PP. 494-497, (2005); SETJI T.L., HOLLAND N.D., SANDERS L.L., PEREIRA K.C., DIEHL A.M., BROWN A.J., NONALCOHOLIC STEATOHEPATITIS AND NONALCOHOLIC FATTY LIVER DISEASE IN YOUNG WOMEN WITH POLYCYSTIC OVARY SYNDROME, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 91, 5, PP. 1741-1747, (2006); ANGULO P., MEDICAL PROGRESS: NONALCOHOLIC FATTY LIVER DISEASE, NEW ENGLAND JOURNAL OF MEDICINE, 346, 16, PP. 1221-1231, (2002); DAY C.P., JAMES O.F.W., STEATOHEPATITIS: A TALE OF TWO 'HITS'?, GASTROENTEROLOGY, 114, I4, PP. 842-845, (1998); MATSUZAWA N., TAKAMURA T., KURITA S., MISU H., OTA T., ANDO H., YOKOYAMA M., HONDA M., ZEN Y., NAKANUMA Y., MIYAMOTO K.-I., KANEKO S., LIPID-INDUCED OXIDATIVE STRESS CAUSES STEATOHEPATITIS IN MICE FED AN ATHEROGENIC DIET, HEPATOLOGY, 46, 5, PP. 1392-1403, (2007); GENTILE C.L., PAGLIASSOTTI M.J., THE ROLE OF FATTY ACIDS IN THE DEVELOPMENT AND PROGRESSION OF NONALCOHOLIC FATTY LIVER DISEASE, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 19, 9, PP. 567-576, (2008); STEFAN N., HRING H.-U., THE METABOLICALLY BENIGN AND MALIGNANT FATTY LIVER, DIABETES, 60, 8, PP. 2011-2017, (2011); MOFRAD P., CONTOS M.J., HAQUE M., SARGEANT C., FISHER R.A., LUKETIC V.A., STERLING R.K., SHIFFMAN M.L., STRAVITZ R.T., SANYAL A.J., CLINICAL AND HISTOLOGIC SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE ASSOCIATED WITH NORMAL ALT VALUES, HEPATOLOGY, 37, 6, PP. 1286-1292, (2003); STEFAN N., KANTARTZIS K., MACHANN J., SCHICK F., THAMER C., RITTIG K., BALLETSHOFER B., MACHICAO F., FRITSCHE A., HRING H.U., IDENTIFICATION AND CHARACTERIZATION OF METABOLICALLY BENIGN OBESITY IN HUMANS, ARCHIVES OF INTERNAL MEDICINE, 168, 15, PP. 1609-1616, (2008); FABBRINI E., MAGKOS F., MOHAMMED B.S., PIETKA T., ABUMRAD N.A., PATTERSON B.W., OKUNADE A., KLEIN S., INTRAHEPATIC FAT, NOT VISCERAL FAT, IS LINKED WITH METABOLIC COMPLICATIONS OF OBESITY, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106, 36, PP. 15430-15435, (2009); AKBAR D.H., KAWTHER A.H., NON-ALCOHOLIC FATTY LIVER DISEASE AND METABOLIC SYNDROME: WHAT WE KNOW AND WHAT WE DON'T KNOW, MEDICAL SCIENCE MONITOR, 12, 1, (2006); BROWNING J.D., SZCZEPANIAK L.S., DOBBINS R., NUREMBERG P., HORTON J.D., COHEN J.C., GRUNDY S.M., HOBBS H.H., PREVALENCE OF HEPATIC STEATOSIS IN AN URBAN POPULATION IN THE UNITED STATES: IMPACT OF ETHNICITY, HEPATOLOGY, 40, 6, PP. 1387-1395, (2004); KOTRONEN A., WESTERBACKA J., BERGHOLM R., PIETILAINEN K.H., YKI-JARVINEN H., LIVER FAT IN THE METABOLIC SYNDROME, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 92, 9, PP. 3490-3497, (2007); WIECKOWSKA A., MCCULLOUGH A.J., FELDSTEIN A.E., NONINVASIVE DIAGNOSIS AND MONITORING OF NONALCOHOLIC STEATOHEPATITIS: PRESENT AND FUTURE, HEPATOLOGY, 46, 2, PP. 582-589, (2007); HAMAGUCHI M., KOJIMA T., TAKEDA N., NAKAGAWA T., TANIGUCHI H., FUJII K., OMATSU T., NAKAJIMA T., SARUI H., SHIMAZAKI M., KATO T., OKUDA J., IDA K., THE METABOLIC SYNDROME AS A PREDICTOR OF NONALCOHOLIC FATTY LIVER DISEASE, ANNALS OF INTERNAL MEDICINE, 143, 10, PP. 722-728, (2005); TOBARI M., HASHIMOTO E., YATSUJI S., TORII N., SHIRATORI K., IMAGING OF NONALCOHOLIC STEATOHEPATITIS: ADVANTAGES AND PITFALLS OF ULTRASONOGRAPHY AND COMPUTED TOMOGRAPHY, INTERNAL MEDICINE, 48, 10, PP. 739-746, (2009); DASARATHY S., DASARATHY J., KHIYAMI A., JOSEPH R., LOPEZ R., MCCULLOUGH A.J., VALIDITY OF REAL TIME ULTRASOUND IN THE DIAGNOSIS OF HEPATIC STEATOSIS: A PROSPECTIVE STUDY, JOURNAL OF HEPATOLOGY, 51, 6, PP. 1061-1067, (2009); VUPPALANCHI R., CHALASANI N., NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS: SELECTED PRACTICAL ISSUES IN THEIR EVALUATION AND MANAGEMENT, HEPATOLOGY, 49, 1, PP. 306-317, (2009); YAMAUCHI T., KAMON J., MINOKOSHI Y., ITO Y., WAKI H., UCHIDA S., YAMASHITA S., NODA M., KITA S., UEKI K., ETO K., AKANUMA Y., FROGUEL P., FOUFELLE F., FERRE P., CARLING D., KIMURA S., NAGAI R., KAHN B.B., KADOWAKI T., ADIPONECTIN STIMULATES GLUCOSE UTILIZATION AND FATTY-ACID OXIDATION BY ACTIVATING AMP-ACTIVATED PROTEIN KINASE, NATURE MEDICINE, 8, 11, PP. 1288-1295, (2002); TSOCHATZIS E.A., PAPATHEODORIDIS G.V., ARCHIMANDRITIS A.J., ADIPOKINES IN NONALCOHOLIC STEATOHEPATITIS: FROM PATHOGENESIS TO IMPLICATIONS IN DIAGNOSIS AND THERAPY, MEDIATORS OF INFLAMMATION, 2009, (2009); TINIAKOS D.G., VOS M.B., BRUNT E.M., NONALCOHOLIC FATTY LIVER DISEASE: PATHOLOGY AND PATHOGENESIS, ANNUAL REVIEW OF PATHOLOGY, 5, PP. 145-171, (2010); YONEDA M., FUJITA K., INAMORI M., NAKAJIMA A., YONEDA M., TAMANO M., HIRAISHI H., TRANSIENT ELASTOGRAPHY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 14, GUT, 56, 9, PP. 1330-1331, (2007); ANGULO P., HUI J.M., MARCHESINI G., BUGIANESI E., GEORGE J., FARRELL G.C., ENDERS F., SAKSENA S., BURT A.D., BIDA J.P., LINDOR K., SANDERSON S.O., LENZI M., ADAMS L.A., KENCH J., THERNEAU T.M., DAY C.P., THE NAFLD FIBROSIS SCORE: A NONINVASIVE SYSTEM THAT IDENTIFIES LIVER FIBROSIS IN PATIENTS WITH NAFLD, HEPATOLOGY, 45, 4, PP. 846-854, (2007); RATZIU V., GIRAL P., CHARLOTTE F., BRUCKERT E., THIBAULT V., THEODOROU I., KHALIL L., TURPIN G., OPOLON P., POYNARD T., LIVER FIBROSIS IN OVERWEIGHT PATIENTS, GASTROENTEROLOGY, 118, 6, PP. 1117-1123, (2000); DIXON J.B., BHATHAL P.S., O'BRIEN P.E., NONALCOHOLIC FATTY LIVER DISEASE: PREDICTORS OF NONALCOHOLIC STEATOHEPATITIS AND LIVER FIBROSIS IN THE SEVERELY OBESE, GASTROENTEROLOGY, 121, 1, PP. 91-100, (2001); HUANG M.A., GREENSON J.K., CHAO C., ANDERSON L., PETERMAN D., JACOBSON J., EMICK D., LOK A.S., CONJEEVARAM H.S., ONE-YEAR INTENSE NUTRITIONAL COUNSELING RESULTS IN HISTOLOGICAL IMPROVEMENT IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: A PILOT STUDY, AMERICAN JOURNAL OF GASTROENTEROLOGY, 100, 5, PP. 1072-1081, (2005); PALMER M., SCHAFFNER F., EFFECT OF WEIGHT REDUCTION ON HEPATIC ABNORMALITIES IN OVERWEIGHT PATIENTS, GASTROENTEROLOGY, 99, 5, PP. 1408-1413, (1990); WANG R.T., KORETZ R.L., YEE JR. H.F., IS WEIGHT REDUCTION AN EFFECTIVE THERAPY FOR NONALCOHOLIC FATTY LIVER? A SYSTEMATIC REVIEW, AMERICAN JOURNAL OF MEDICINE, 115, 7, PP. 554-559, (2003); KADAYIFCI A., MERRIMAN R.B., BASS N.M., MEDICAL TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, CLINICS IN LIVER DISEASE, 11, 1, PP. 119-140, (2007); GARINIS G.A., FRUCI B., MAZZA A., DE SIENA M., ABENAVOLI S., GULLETTA E., VENTURA V., GRECO M., ABENAVOLI L., BELFIORE A., METFORMIN VERSUS DIETARY TREATMENT IN NONALCOHOLIC HEPATIC STEATOSIS: A RANDOMIZED STUDY, INTERNATIONAL JOURNAL OF OBESITY, 34, 8, PP. 1255-1264, (2010); MARLATT G.A., LARIMER M.E., MAIL P.D., HAWKINS E.H., CUMMINS L.H., BLUME A.W., LONCZAK H.S., BURNS K.M., CHAN K.K., CRONCE J.M., LA MARR C.J., RADIN S., FORQUERA R., GONZALES R., TETRICK C., GALLION S., JOURNEYS OF THE CIRCLE: A CULTURALLY CONGRUENT LIFE SKILLS INTERVENTION FOR ADOLESCENT INDIAN DRINKING, ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 27, 8, PP. 1327-1329, (2003); TIIKKAINEN M., HAKKINEN A.-M., KORSHENINNIKOVA E., NYMAN T., MAKIMATTILA S., YKI-JARVINEN H., EFFECTS OF ROSIGLITAZONE AND METFORMIN ON LIVER FAT CONTENT, HEPATIC INSULIN RESISTANCE, INSULIN CLEARANCE, AND GENE EXPRESSION IN ADIPOSE TISSUE IN PATIENTS WITH TYPE 2 DIABETES, DIABETES, 53, 8, PP. 2169-2176, (2004); RATZIU V., GIRAL P., JACQUEMINET S., CHARLOTTE F., HARTEMANN-HEURTIER A., SERFATY L., PODEVIN P., LACORTE J., BERNHARDT C., BRUCKERT E., GRIMALDI A., POYNARD T., ROSIGLITAZONE FOR NONALCOHOLIC STEATOHEPATITIS: ONE-YEAR RESULTS OF THE RANDOMIZED PLACEBO-CONTROLLED FATTY LIVER IMPROVEMENT WITH ROSIGLITAZONE THERAPY (FLIRT) TRIAL, GASTROENTEROLOGY, 135, 1, PP. 100-110, (2008); SANYAL A.J., MOFRAD P.S., CONTOS M.J., SARGEANT C., LUKETIC V.A., STERLING R.K., STRAVITZ R.T., SHIFFMAN M.L., CLORE J., MILLS A.S., A PILOT STUDY OF VITAMIN E VERSUS VITAMIN E AND PIOGLITAZONE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2, 12, PP. 1107-1115, (2004); BELFORT R., HARRISON S.A., BROWN K., DARLAND C., FINCH J., HARDIES J., BALAS B., GASTALDELLI A., TIO F., PULCINI J., BERRIA R., MA J.Z., DWIVEDI S., HAVRANEK R., FINCKE C., DEFRONZO R., BANNAYAN G.A., SCHENKER S., CUSI K., A PLACEBO-CONTROLLED TRIAL OF PIOGLITAZONE IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS, NEW ENGLAND JOURNAL OF MEDICINE, 355, 22, PP. 2297-2307, (2006); AITHAL G.P., THOMAS J.A., KAYE P.V., LAWSON A., RYDER S.D., SPENDLOVE I., AUSTIN A.S., FREEMAN J.G., MORGAN L., WEBBER J., RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PIOGLITAZONE IN NONDIABETIC SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS, GASTROENTEROLOGY, 135, 4, PP. 1176-1184, (2008); PROMRAT K., KLEINER D.E., NIEMEIER H.M., JACKVONY E., KEARNS M., WANDS J.R., FAVA J.L., WING R.R., RANDOMIZED CONTROLLED TRIAL TESTING THE EFFECTS OF WEIGHT LOSS ON NONALCOHOLIC STEATOHEPATITIS, HEPATOLOGY, 51, 1, PP. 121-129, (2010); SANYAL A.J., CHALASANI N., KOWDLEY K.V., MCCULLOUGH A., DIEHL A.M., BASS N.M., NEUSCHWANDER-TETRI B.A., LAVINE J.E., TONASCIA J., UNALP A., VAN NATTA M., CLARK J., BRUNT E.M., KLEINER D.E., HOOFNAGLE J.H., ROBUCK P.R., PIOGLITAZONE, VITAMIN E, OR PLACEBO FOR NONALCOHOLIC STEATOHEPATITIS, THE NEW ENGLAND JOURNAL OF MEDICINE, 362, 18, PP. 1675-1685, (2010); CHAFFER C.L., THOMAS D.M., THOMPSON E.W., WILLIAMS E.D., PPAR -INDEPENDENT INDUCTION OF GROWTH ARREST AND APOPTOSIS IN PROSTATE AND BLADDER CARCINOMA, BMC CANCER, 653, (2006); HE L., SABET A., DJEDJOS S., MILLER R., SUN X., HUSSAIN M.A., RADOVICK S., WONDISFORD F.E., METFORMIN AND INSULIN SUPPRESS HEPATIC GLUCONEOGENESIS THROUGH PHOSPHORYLATION OF CREB BINDING PROTEIN, CELL, 137, 4, PP. 635-646, (2009); STUMVOLL M., NURJHAN N., PERRIELLO G., DAILEY G., GERICH J.E., METABOLIC EFFECTS OF METFORMIN IN NON-INSULIN-DEPENDENT DIABETES MELLITUS, THE NEW ENGLAND JOURNAL OF MEDICINE, 333, 9, PP. 550-554, (1995); LOOMBA R., LUTCHMAN G., KLEINER D.E., RICKS M., FELD J.J., BORG B.B., MODI A., NAGABHYRU P., SUMNER A.E., LIANG T.J., HOOFNAGLE J.H., CLINICAL TRIAL: PILOT STUDY OF METFORMIN FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, 29, 2, PP. 172-182, (2009); KOHJIMA M., HIGUCHI N., KATO M., KOTOH K., YOSHIMOTO T., FUJINO T., YADA M., YADA R., HARADA N., ENJOJI M., TAKAYANAGI R., NAKAMUTA M., SREBP-1C, REGULATED BY THE INSULIN AND AMPK SIGNALING PATHWAYS, PLAYS A ROLE IN NONALCOHOLIC FATTY LIVER DISEASE, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 21, 4, PP. 507-511, (2008); HUYPENS P., QUARTIER E., PIPELEERS D., VAN DE CASTEELE M., METFORMIN REDUCES ADIPONECTIN PROTEIN EXPRESSION AND RELEASE IN 3T3-L1 ADIPOCYTES INVOLVING ACTIVATION OF AMP ACTIVATED PROTEIN KINASE, EUROPEAN JOURNAL OF PHARMACOLOGY, 518, 2-3, PP. 90-95, (2005); LIN H.Z., YANG S.Q., CHUCKAREE C., KUHAJDA F., RONNET G., DIEHL A.M., METFORMIN REVERSES FATTY LIVER DISEASE IN OBESE, LEPTIN-DEFICIENT MICE, NATURE MEDICINE, 6, 9, PP. 998-1003, (2000); ZHANG S., LIU X., BRICKMAN W.J., CHRISTOFFEL K.K., ZIMMERMAN D., TSAI H.J., WANG G., WANG B., LI Z., TANG G., LIU X., YANG J., XU X., WANG X., ASSOCIATION OF PLASMA LEPTIN CONCENTRATIONS WITH ADIPOSITY MEASUREMENTS IN RURAL CHINESE ADOLESCENTS, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 94, 9, PP. 3497-3504, (2009); MARCHESINI G., BRIZI M., BIANCHI G., TOMASSETTI S., ZOLI M., MELCHIONDA N., METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS, LANCET, 358, 9285, PP. 893-894, (2001); NAIR S., DIEHL A.M., WISEMAN M., FARR JR. G.H., PERRILLO R.P., METFORMIN IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS: A PILOT OPEN LABEL TRIAL, ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, 20, 1, PP. 23-28, (2004); UYGUN A., KADAYIFCI A., ISIK A.T., OZGURTAS T., DEVECI S., TUZUN A., YESILOVA Z., GULSEN M., DAGALP K., METFORMIN IN THE TREATMENT OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS, ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, 19, 5, PP. 537-544, (2004); BUGIANESI E., GENTILCORE E., MANINI R., NATALE S., VANNI E., VILLANOVA N., DAVID E., RIZZETTO M., MARCHESINI G., A RANDOMIZED CONTROLLED TRIAL OF METFORMIN VERSUS VITAMIN E OR PRESCRIPTIVE DIET IN NONALCOHOLIC FATTY LIVER DISEASE, AMERICAN JOURNAL OF GASTROENTEROLOGY, 100, 5, PP. 1082-1090, (2005); DUSEJA A., DAS A., DHIMAN R.K., CHAWLA Y.K., THUMBURU K.K., BHADADA S., BHANSALI A., METFORMIN IS EFFECTIVE IN ACHIEVING BIOCHEMICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) NOT RESPONDING TO LIFESTYLE INTERVENTIONS, ANNALS OF HEPATOLOGY, 6, 4, PP. 222-226, (2007); DE OLIVEIRA C.P.M.S., STEFANO J.T., DE SIQUEIRA E.R.F., SILVA L.S., DE CAMPOS MAZO D.F., LIMA V.M.R., FURUYA C.K., MELLO E.S., SOUZA F.G., RABELLO F., SANTOS T.E., NOGUEIRA M.A., CALDWELL S.H., ALVES V.A.F., CARRILHO F.J., COMBINATION OF N-ACETYLCYSTEINE AND METFORMIN IMPROVES HISTOLOGICAL STEATOSIS AND FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS, HEPATOLOGY RESEARCH, 38, 2, PP. 159-165, (2008); IDILMAN R., MIZRAK D., CORAPCIOGLU D., BEKTAS M., DOGANAY B., SAYKI M., COBAN S., ERDEN E., SOYKAN I., EMRAL R., UYSAL A.R., OZDEN A., CLINICAL TRIAL: INSULIN-SENSITIZING AGENTS MAY REDUCE CONSEQUENCES OF INSULIN RESISTANCE IN INDIVIDUALS WITH NON-ALCOHOLIC STEATOHEPATITIS, ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, 28, 2, PP. 200-208, (2008); HAUKELAND J.W., KONOPSKI Z., EGGESB H.B., METFORMIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, CONTROLLED TRIAL, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 44, 7, PP. 853-860, (2009); JANIEC D.J., JACOBSON E.R., FREETH A., SPAULDING L., BLASZYK H., HISTOLOGIC VARIATION OF GRADE AND STAGE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN LIVER BIOPSIES, OBESITY SURGERY, 15, 4, PP. 497-501, (2005); OMER Z., CETINKALP S., AKYILDIZ M., YILMAZ F., BATUR Y., YILMAZ C., AKARCA U., EFFICACY OF INSULIN-SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 22, 1, PP. 18-23, (2010); NAR A., GEDIK O., THE EFFECT OF METFORMIN ON LEPTIN IN OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NONALCOHOLIC FATTY LIVER DISEASE, ACTA DIABETOLOGICA, 46, 2, PP. 113-118, (2009); SCHWIMMER J.B., BEHLING C., NEWBURY R., DEUTSCH R., NIEVERGELT C., SCHORK N.J., LAVINE J.E., HISTOPATHOLOGY OF PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE, HEPATOLOGY, 42, 3, PP. 641-649, (2005); NADEAU K.J., EHLERS L.B., ZEITLER P.S., LOVE-OSBORNE K., TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE WITH METFORMIN VERSUS LIFESTYLE INTERVENTION IN INSULIN-RESISTANT ADOLESCENTS, PEDIATRIC DIABETES, 10, 1, PP. 5-13, (2009); NOBILI V., MARCELLINI M., DEVITO R., CIAMPALINI P., PIEMONTE F., COMPARCOLA D., SARTORELLI M.R., ANGULO P., NAFLD IN CHILDREN: A PROSPECTIVE CLINICAL-PATHOLOGICAL STUDY AND EFFECT OF LIFESTYLE ADVICE, HEPATOLOGY, 44, 2, PP. 458-465, (2006); LAVINE J.E., SCHWIMMER J.B., MOLLESTON J.P., SCHEIMANN A.O., MURRAY K.F., ABRAMS S.H., ROSENTHAL P., SANYAL A.J., ROBUCK P.R., BRUNT E.M., NALP A., TONASCIA J., TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN: TONIC TRIAL DESIGN, CONTEMPORARY CLINICAL TRIALS, 31, 1, PP. 62-70, (2010); KIRPICHNIKOV D., MCFARLANE S.I., SOWERS J.R., METFORMIN: AN UPDATE, ANNALS OF INTERNAL MEDICINE, 137, 1, PP. 25-33, (2002); LANDIN K., TENGBORN L., SMITH U., TREATING INSULIN RESISTANCE INHYPERTENSION WITH METFORMIN REDUCES BOTH BLOOD PRESSURE AND METABOLIC RISK FACTORS, JOURNAL OF INTERNAL MEDICINE, 229, 2, PP. 181-187, (1991); PETERSEN J.S., DIBONA G.F., ACUTE SYMPATHOINHIBITORY ACTIONS OF METFORMIN IN SPONTANEOUSLY HYPERTENSIVE RATS, HYPERTENSION, 27, II3, PP. 619-625, (1996); MORROW V.A., FOUFELLE F., CONNELL J.M.C., PETRIE J.R., GOULD G.W., SALT I.P., DIRECT ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE STIMULATES NITRIC-OXIDE SYNTHESIS IN HUMAN AORTIC ENDOTHELIAL CELLS, JOURNAL OF BIOLOGICAL CHEMISTRY, 278, 34, PP. 31629-31639, (2003); FABBRINI E., SULLIVAN S., KLEIN S., OBESITY AND NONALCOHOLIC FATTY LIVER DISEASE: BIOCHEMICAL, METABOLIC, AND CLINICAL IMPLICATIONS, HEPATOLOGY, 51, 2, PP. 679-689, (2010); JOHANSEN K., EFFICACY OF METFORMIN IN THE TREATMENT OF NIDDM: META-ANALYSIS, DIABETES CARE, 22, 1, PP. 33-37, (1999); HAUPT E., KNICK B., KOSCHINSKY T., LIEBERMEISTER H., SCHNEIDER J., HIRCHE H., ORAL ANTIDIABETIC COMBINATION THERAPY WITH SULPHONYLUREAS AND METFORMIN, DIABETE ET METABOLISME, 17, 1, PP. 224-231, (1991); PASQUALI R., GAMBINERI A., BISCOTTI D., VICENNATI V., GAGLIARDI L., COLITTA D., FIORINI S., COGNIGNI G.E., FILICORI M., MORSELLI-LABATE A.M., EFFECT OF LONG-TERM TREATMENT WITH METFORMIN ADDED TO HYPOCALORIC DIET ON BODY COMPOSITION, FAT DISTRIBUTION, AND ANDROGEN AND INSULIN LEVELS IN ABDOMINALLY OBESE WOMEN WITH AND WITHOUT THE POLYCYSTIC OVARY SYNDROME, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 85, 8, PP. 2767-2774, (2000); GLUECK C.J., WANG P., FONTAINE R., TRACY T., SIEVE-SMITH L., METFORMIN-INDUCED RESUMPTION OF NORMAL MENSES IN 39 OF 43 (91%) PREVIOUSLY AMENORRHEIC WOMEN WITH THE POLYCYSTIC OVARY SYNDROME, METABOLISM: CLINICAL AND EXPERIMENTAL, 48, 4, PP. 511-519, (1999); YKI-JRVINEN H., NIKKIL K., MKIMATTILA S., METFORMIN PREVENTS WEIGHT GAIN BY REDUCING DIETARY INTAKE DURING INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, DRUGS, 58, SUPPL. 1, PP. 53-54, (1999); SOWERS J.R., OBESITY AND CARDIOVASCULAR DISEASE, CLINICAL CHEMISTRY, 44, II8, PP. 1821-1825, (1998); EFFECTS OF WITHDRAWAL FROM METFORMIN ON THE DEVELOPMENT OF DIABETES IN THE DIABETES PREVENTION PROGRAM, DIABETES CARE, 26, 4, PP. 977-980, (2003); MCFARLANE S.I., BANERJI M., SOWERS J.R., INSULIN RESISTANCE AND CARDIOVASCULAR DISEASE, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 86, 2, PP. 713-718, (2001); HICKMAN I.J., JONSSON J.R., PRINS J.B., ASH S., PURDIE D.M., CLOUSTON A.D., POWELL E.E., MODEST WEIGHT LOSS AND PHYSICAL ACTIVITY IN OVERWEIGHT PATIENTS WITH CHRONIC LIVER DISEASE RESULTS IN SUSTAINED IMPROVEMENTS IN ALANINE AMINOTRANSFERASE, FASTING INSULIN, AND QUALITY OF LIFE, GUT, 53, 3, PP. 413-419, (2004); LARSON-MEYER D.E., NEWCOMER B.R., HEILBRONN L.K., VOLAUFOVA J., SMITH S.R., ALFONSO A.J., LEFEVRE M., ROOD J.C., WILLIAMSON D.A., RAVUSSIN E., DELANY J., DE JONGE L., NGUYEN T., MARTIN C.K., MOST M.M., GREENWAY F.L., YORK-CROW E., ANTON S., CHAMPAGNE C., DAHMER B., DEUTSCH A., GEISELMAN P., HOWARD J., IHRIG J., MARQUIS D., MURLA C., OWENS S., STEWART A., TARVER V., EFFECT OF 6-MONTH CALORIE RESTRICTION AND EXERCISE ON SERUM AND LIVER LIPIDS AND MARKERS OF LIVER FUNCTION, OBESITY, 16, 6, PP. 1355-1362, (2008); KRAKOFF J., CLARK J.M., CRANDALL J.P., WILSON C., MOLITCH M.E., BRANCATI F.L., EDELSTEIN S.L., KNOWLER W.C., EFFECTS OF METFORMIN AND WEIGHT LOSS ON SERUM ALANINE AMINOTRANSFERASE ACTIVITY IN THE DIABETES PREVENTION PROGRAM, OBESITY, 18, 9, PP. 1762-1767, (2010); KNOWLER W.C., BARRETT-CONNOR E., FOWLER S.E., HAMMAN R.F., LACHIN J.M., WALKER E.A., NATHAN D.M., REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR METFORMIN, NEW ENGLAND JOURNAL OF MEDICINE, 346, 6, PP. 393-403, (2002); DIAMANTI-KANDARAKIS E., POLYCYSTIC OVARIAN SYNDROME: PATHOPHYSIOLOGY, MOLECULAR ASPECTS AND CLINICAL IMPLICATIONS, EXPERT REVIEWS IN MOLECULAR MEDICINE, 10, 3, PP. 1-21, (2008); GUTIERREZ-GROBE Y., PONCIANO-RODRGUEZ G., RAMOS M.H., URIBE M., MENDEZ-SNCHEZ N., PREVALENCE OF NON ALCOHOLIC FATTY LIVER DISEASE IN PREMENOPAUSAL, POSMENOPAUSAL AND POLYCYSTIC OVARY SYNDROME WOMEN. THE ROLE OF ESTROGENS, ANNALS OF HEPATOLOGY, 9, 4, PP. 402-409, (2010); CHODICK G., HEYMANN A.D., ROSENMANN L., GREEN M.S., FLASH S., PORATH A., KOKIA E., SHALEV V., DIABETES AND RISK OF INCIDENT CANCER: A LARGE POPULATION-BASED COHORT STUDY IN ISRAEL, CANCER CAUSES AND CONTROL, 21, 6, PP. 879-887, (2010); VIGNERI P., FRASCA F., SCIACCA L., FRITTITTA L., VIGNERI R., OBESITY AND CANCER, NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES, 16, 1, PP. 1-7, (2006); STRICKLER H.D., WYLIE-ROSETT J., ROHAN T., HOOVER D.R., SMOLLER S., BURK R.D., YU H., THE RELATION OF TYPE 2 DIABETES AND CANCER, DIABETES TECHNOLOGY AND THERAPEUTICS, 3, 2, PP. 263-274, (2001); COUGHLIN S.S., CALLE E.E., TERAS L.R., PETRELLI J., THUN M.J., DIABETES MELLITUS AS A PREDICTOR OF CANCER MORTALITY IN A LARGE COHORT OF US ADULTS, AMERICAN JOURNAL OF EPIDEMIOLOGY, 159, 12, PP. 1160-1167, (2004); RENEHAN A.G., TYSON M., EGGER M., HELLER R.F., ZWAHLEN M., BODY-MASS INDEX AND INCIDENCE OF CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDIES, THE LANCET, 371, 9612, PP. 569-578, (2008); CANTRELL L.A., ZHOU C., MENDIVIL A., MALLOY K.M., GEHRIG P.A., BAE-JUMP V.L., METFORMIN IS A POTENT INHIBITOR OF ENDOMETRIAL CANCER CELL PROLIFERATION-IMPLICATIONS FOR A NOVEL TREATMENT STRATEGY, GYNECOLOGIC ONCOLOGY, 116, 1, PP. 92-98, (2010); VAINIO H., KAAKS R., BIANCHINI F., WEIGHT CONTROL AND PHYSICAL ACTIVITY IN CANCER PREVENTION: INTERNATIONAL EVALUATION OF THE EVIDENCE, EUROPEAN JOURNAL OF CANCER PREVENTION, 11, SUPPL. 2, (2002); BELFIORE A., FRASCA F., IGF AND INSULIN RECEPTOR SIGNALING IN BREAST CANCER, JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 13, 4, PP. 381-406, (2008); SIEGEL A.B., ZHU A.X., METABOLIC SYNDROME AND HEPATOCELLULAR CARCINOMA: TWO GROWING EPIDEMICS WITH A POTENTIAL LINK, CANCER, 115, 24, PP. 5651-5661, (2009); GUZMAN G., BRUNT E.M., PETROVIC L.M., CHEJFEC G., LAYDEN T.J., COTLER S.J., DOES NONALCOHOLIC FATTY LIVER DISEASE PREDISPOSE PATIENTS TO HEPATOCELLULAR CARCINOMA IN THE ABSENCE OF CIRRHOSIS?, ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, 132, 11, PP. 1761-1766, (2008); ZAKIKHANI M., DOWLING R., FANTUS I.G., SONENBERG N., POLLAK M., METFORMIN IS AN AMP KINASE-DEPENDENT GROWTH INHIBITOR FOR BREAST CANCER CELLS, CANCER RESEARCH, 66, 21, PP. 10269-10273, (2006); EVANS J.M.M., DONNELLY L.A., EMSLIE-SMITH A.M., ALESSI D.R., MORRIS A.D., METFORMIN AND REDUCED RISK OF CANCER IN DIABETIC PATIENTS, BRITISH MEDICAL JOURNAL, 330, 7503, PP. 1304-1305, (2005); BOWKER S.L., MAJUMDAR S.R., VEUGELERS P., JOHNSON J.A., INCREASED CANCER-RELATED MORTALITY FOR PATIENTS WITH TYPE 2 DIABETES WHO USE SULFONYLUREAS OR INSULIN, DIABETES CARE, 29, 2, PP. 254-258, (2006); ZHUANG Y., MISKIMINS W.K., CELL CYCLE ARREST IN METFORMIN TREATED BREAST CANCER CELLS INVOLVES ACTIVATION OF AMPK, DOWNREGULATION OF CYCLIN D1, AND REQUIRES P27KIP1 OR P21CIP1, JOURNAL OF MOLECULAR SIGNALING, 318, (2008); DONADON V., BALBI M., GHERSETTI M., GRAZIOLI S., PERCIACCANTE A., DELLA VALENTINA G., GARDENAL R., DAL MAS M., CASARIN P., ZANETTE G., MIRANDA C., ANTIDIABETIC THERAPY AND INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE, WORLD JOURNAL OF GASTROENTEROLOGY, 15, 20, PP. 2506-2511, (2009); VERLATO G., ZOPPINI G., BONORA E., MUGGEO M., MORTALITY FROM SITE-SPECIFIC MALIGNANCIES IN TYPE 2 DIABETIC PATIENTS FROM VERONA, DIABETES CARE, 26, 4, PP. 1047-1051, (2003); BALKAU B., KAHN H.S., COURBON D., ESCHWEGE E., DUCIMETIERE P., HYPERINSULINEMIA PREDICTS FATAL LIVER CANCER BUT IS INVERSELY ASSOCIATED WITH FATAL CANCER AT SOME OTHER SITES: THE PARIS PROSPECTIVE STUDY, DIABETES CARE, 24, 5, PP. 843-849, (2001); GAIDOS J.K.J., HILLNER B.E., SANYAL A.J., A DECISION ANALYSIS STUDY OF THE VALUE OF A LIVER BIOPSY IN NONALCOHOLIC STEATOHEPATITIS, LIVER INTERNATIONAL, 28, 5, PP. 650-658, (2008); JIN X., YE Y.F., CHEN S.H., YU C.H., LIU J., LI Y.M., MICRORNA EXPRESSION PATTERN IN DIFFERENT STAGES OF NONALCOHOLIC FATTY LIVER DISEASE, DIGESTIVE AND LIVER DISEASE, 41, 4, PP. 289-297, (2009); CHEUNG O., PURI P., EICKEN C., CONTOS M.J., MIRSHAHI F., MAHER J.W., KELLUM J.M., MIN H., LUKETIC V.A., SANYAL A.J., NONALCOHOLIC STEATOHEPATITIS IS ASSOCIATED WITH ALTERED HEPATIC MICRORNA EXPRESSION, HEPATOLOGY, 48, 6, PP. 1810-1820, (2008); MUSSO G., GAMBINO R., CASSADER M., EMERGING MOLECULAR TARGETS FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE, ANNUAL REVIEW OF MEDICINE, 61, PP. 375-392, (2010); KRTZFELDT J., RAJEWSKY N., BRAICH R., RAJEEV K.G., TUSCHL T., MANOHARAN M., STOFFEL M., SILENCING OF MICRORNAS IN VIVO WITH ANTAGOMIRS, NATURE, 438, 7068, PP. 685-689, (2005); ELMEN J., LINDOW M., SCHUTZ S., LAWRENCE M., PETRI A., OBAD S., LINDHOLM M., HEDTJARN M., HANSEN H.F., BERGER U., GULLANS S., KEARNEY P., SARNOW P., STRAARUP E.M., KAUPPINEN S., LNA-MEDIATED MICRORNA SILENCING IN NON-HUMAN PRIMATES, NATURE, 452, 7189, PP. 896-899, (2008); BERGERON R., PREVIS S.F., CLINE G.W., PERRET P., RUSSELL III R.R., YOUNG L.H., SHULMAN G.I., EFFECT OF 5-AMINOIMIDAZOLE-4-CARBOXAMIDE-1-Β-D-RIBOFURANOSIDE INFUSION ON IN VIVO GLUCOSE AND LIPID METABOLISM IN LEAN AND OBESE ZUCKER RATS, DIABETES, 50, 5, PP. 1076-1082, (2001); PARK K.G., MIN A.K., KOH E.H., KIM H.S., KIM M.O., PARK H.S., KIM Y.D., YOO T.S., JANG B.K., HWANG J.S., KIM J.B., CHOI H.S., PARK J.Y., LEE I.K., LEE K.U., ALPHA-LIPOIC ACID DECREASES HEPATIC LIPOGENESIS THROUGH ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK)-DEPENDENT AND AMPK-INDEPENDENT PATHWAYS, HEPATOLOGY, 48, 5, PP. 1477-1486, (2008); LEWIS J.R., MOHANTY S.R., NONALCOHOLIC FATTY LIVER DISEASE: A REVIEW AND UPDATE, DIGESTIVE DISEASES AND SCIENCES, 55, 3, PP. 560-578, (2010); DING X., SAXENA N.K., LIN S., GUPTA N., ANANIA F.A., EXENDIN-4, A GLUCAGON-LIKE PROTEIN-1 (GLP-1) RECEPTOR AGONIST, REVERSES HEPATIC STEATOSIS IN OB/OB MICE, HEPATOLOGY, 43, 1, PP. 173-181, (2006); TUSHUIZEN M.E., BUNCK M.C., POUWELS P.J., VAN WAESBERGHE J.H.T., DIAMANT M., HEINE R.J., INCRETIN MIMETICS AS A NOVEL THERAPEUTIC OPTION FOR HEPATIC STEATOSIS, LIVER INTERNATIONAL, 26, 8, PP. 1015-1017, (2006)","A. BELFIORE; ENDOCRINOLOGY UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, UNIVERSITY MAGNA GRAECIA OF CATANZARO, 88100 CATANZARO, LOCALITÀ GERMANETO, VIALE EUROPA, ITALY; EMAIL: BELFIORE@UNICZ.IT","","ENGLISH","EXP. DIA. RES.","REVIEW","ISI","2-S2.0-84855572961","EXP DIA RES","UNIVERSITY MAGNA GRAECIA OF CATANZARO;UNIVERSITY MAGNA GRAECIA OF CATANZARO;UNIVERSITY MAGNA GRAECIA OF CATANZARO;UNIVERSITY MAGNA GRAECIA OF CATANZARO;UNIVERSITY MAGNA GRAECIA OF CATANZARO;UNIVERSITY MAGNA GRAECIA OF CATANZARO","NOTREPORTED;UNIVERSITY MAGNA GRAECIA OF CATANZARO;NOTREPORTED",NA,"MAZZA A, 2012, EXP DIA RES","MAZZA A, 2012, EXP DIA RES"
"WANG Z;HWANG S;LIM S","WANG, ZHIQIANG (56511735800); HWANG, SEUNG HWAN (55627351600); LIM, SOON SUNG (7404081703)","EFFECT OF NOVEL SYNTHESISED POLICOSANYL PHENOLATES ON LIPID OXIDATION",2016,"CZECH JOURNAL OF FOOD SCIENCES","34","7",1,"10.17221/530/2015-CJFS","DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, 1 HALLYMDEAHAK-GIL, CHUNCHEON, GANGWON-DO, 24252, SOUTH KOREA, INSTITUTE OF KOREA NUTRITION RESEARCH, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, 1 HALLYMDEAHAK-GIL, CHUNCHEON, GANGWON-DO, 24252, SOUTH KOREA, INSTITUTE OF KOREA NUTRITION RESEARCH, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, 1 HALLYMDEAHAK-GIL, CHUNCHEON, GANGWON-DO, 24252, SOUTH KOREA, INSTITUTE OF NATURAL MEDICINE, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA, INSTITUTE OF KOREA NUTRITION RESEARCH, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, SOUTH KOREA","LIPOPHILIC DERIVATISATION OF PHENOLIC ACIDS COULD GREATLY IMPROVE THEIR ANTIOXIDANT ACTIVITIES AND SOLUBILITY IN HYDROPHOBIC ENVIRONMENTS, BROADENING THEIR APPLICATIONS IN FOOD, PHARMACEUTICAL, AND COSMETIC INDUSTRIES. IN THIS STUDY, WE CONDUCTED ENZYMATIC LIPOPHILISATION OF EIGHT PHENOLATES WITH POLICOSANOLS. VINYL PHENOLATES WERE USED AS INTERMEDIATES TO IMPROVE THE EFFICIENCY OF ENZYMATIC LIPOPHILISATION; AND THE YIELDS OF POLICOSANYL PHENOLATES WERE IN THE RANGE OF 1.32-20.58%. THE ANTIOXIDANT ACTIVITIES OF THE RESULTING PHENOLIPIDS WERE COMPARED USING 2,2′-AZINOBIS( 3-ETHYLBENZOTHIAZOLINE-6-SULPHONIC ACID) (ABTS) ASSAY AND LINOLEIC ACID PEROXIDATION FERRIC THIOCYANATE ASSAY. THE SYNTHESISED POLICOSANYL PHENOLATES SHOWED LOWER ABTS RADICAL SCAVENGING CAPACITIES (IC50S > 15 MM); WHEREAS THEY SHOWED HIGH LIPID PEROXIDATION INHIBITORY ACTIVITIES (IC50S OF PEROXIDATION VALUE < 0.25 MM). THE LIPID OXIDATION INHIBITORY ACTIVITIES OF POLICOSANOL PHENOLATES WERE FURTHER EVALUATED USING THE TOTAL OXIDATION VALUE IN A LINOLEIC ACID MODEL SYSTEM AND THE THIOBARBITURIC ACID REACTIVE SUBSTANCES VALUE IN A COOKED PORK MODEL SYSTEM. FINALLY, POLICOSANYL 4-HYDROXYBENZOATE, POLICOSANYL SYRINGATE, AND POLICOSANYL 4-HYDROXYPHENYLACETATE SHOWED THE HIGHEST INHIBITION EFFECTS ON LIPID OXIDATION AND A POTENTIAL FOR USE AS LIPID ANTIOXIDANTS.","ANTIOXIDANT; LIPOPHILISATION; NOVOZYME 435; PHENOLIC ACIDS; POLICOSANOLS","ANTIOXIDANTS; FATTY ACIDS; INTEGRATED CIRCUITS; ORGANIC ACIDS; OXIDATION; HYDROPHOBIC ENVIRONMENT; LINOLEIC ACID PEROXIDATION; LIPOPHILISATION; NOVOZYME 435; PHENOLIC ACIDS; POLICOSANOLS; RADICAL SCAVENGING CAPACITIES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; LINOLEIC ACID","HALLYM UNIVERSITY, HALLYM, (HRF-201609-007); MINISTRY OF EDUCATION, MOE, (NRF-2012R1A1A2008842); NATIONAL RESEARCH FOUNDATION OF KOREA, NRF; MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY, MEST, (NRF-2009-0094071)","SUPPORTED BY BASIC SCIENCE RESEARCH PROGRAM THROUGH THE NATIONAL RESEARCH FOUNDATION OF KOREA (NRF) FUNDED BY THE MINISTRY OF EDUCATION (NRF-2012R1A1A2008842) AND PRIORITY RESEARCH CENTERS PROGRAM THROUGH THE NATIONAL RESEARCH FOUNDATION OF KOREA (NRF) FUNDED BY THE MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY (NRF-2009-0094071), HALLYM UNIVERSITY RESEARCH FUND (HRF-201609-007).","BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, PP. 2262-2269, (2006); BUETTNER G.R., THE PECKING ORDER OF FREE RADICALS AND ANTIOXIDANTS: LIPID PEROXIDATION, Α-TOCOPHEROL, AND ASCORBATE, ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 300, PP. 535-543, (1993); CHAIYASIT C., ELIAS R.J., MCCLEMENTS D.J., DECKER E.A., ROLE OF PHYSICAL STRUCTURES IN BULK OILS ON LIPID OXIDATION, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 47, PP. 299-317, (2007); CHIGORIMBO-MUREFU N.T., RIVA S., BURTON S.G., LIPASE-CATALYSED SYNTHESIS OF ESTERS OF FERULIC ACID WITH NATURAL COMPOUNDS AND EVALUATION OF THEIR ANTIOXIDANT PROPERTIES, JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC, 56, PP. 277-282, (2009); DECKER E.A., STRATEGIES FOR MANIPULATING THE PROOXIDATIVE/ ANTIOXIDATIVE BALANCE OF FOODS TO MAXIMIZE OXIDATIVE STABILITY, TRENDS IN FOOD SCIENCE & TECHNOLOGY, 9, PP. 241-248, (1998); DECKER E., ELIAS R., MCCLEMENTS D.J., OXIDATION IN FOODS AND BEVERAGES AND ANTIOXIDANT APPLICATIONS, 1-2, (2010); FIGUEROA-ESPINOZA M.C., VILLENEUVE P., PHENOLIC ACIDS ENZYMATIC LIPOPHILIZATION, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 2779-2787, (2005); FU Y., ZHANG Y., HU H., CHEN Y., WANG R., LI D., LIU S., DESIGN AND STRAIGHTFORWARD SYNTHESIS OF NOVEL GALLOYL PHYTOSTEROLS WITH EXCELLENT ANTIOXIDANT ACTIVITY, FOOD CHEMISTRY, 163, PP. 171-177, (2014); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); ITO N., HIROSE M., FUKUSHIMA S., TSUDA H., SHIRAI T., TATEMATSU M., STUDIES ON ANTIOXIDANTS: THEIR CARCINOGENIC AND MODIFYING EFFECTS ON CHEMICAL CARCINOGENESIS, FOOD AND CHEMICAL TOXICOLOGY, 24, PP. 1071-1082, (1986); KWON H., SHIN D.Y., LEE J.H., KIM S.W., KANG J.W., MOLECULAR MODELING AND ITS EXPERIMENTAL VERIFICATION FOR THE CATALYTIC MECHANISM OF CANDIDA ANTARCTICA LIPASE B, JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 17, PP. 1098-1105, (2007); PAQUOT C., STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS AND DERIVATIVES, (1979); RE R., PELLEGRINI N., PROTEGGENTE A., PANNALA A., YANG M., RICE-EVANS C., ANTIOXIDANT ACTIVITY APPLYING AN IMPROVED ABTS RADICAL CATION DECOLORIZATION ASSAY, FREE RADICAL BIOLOGY AND MEDICINE, 26, PP. 1231-1237, (1999); SAKANAKA S., TACHIBANA Y., ISHIHARA N., JUNEJA L.R., ANTIOXIDANT ACTIVITY OF EGG-YOLK PROTEIN HYDROLYSATES IN A LINOLEIC ACID OXIDATION SYSTEM, FOOD CHEMISTRY, 86, PP. 99-103, (2004); SHERWIN E., OXIDATION AND ANTIOXIDANTS IN FAT AND OIL PROCESSING, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 55, PP. 809-814, (1978); SOOBRATTEE M.A., NEERGHEEN V.S., LUXIMON-RAMMA A., ARUOMA O.I., BAHORUN T., PHENOLICS AS POTENTIAL ANTIOXIDANT THERAPEUTIC AGENTS: MECHANISM AND ACTIONS, MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 579, PP. 200-213, (2005); SORENSEN A.D.M., NIELSEN N.S., YANG Z., XU X., JACOBSEN C., LIPOPHILIZATION OF DIHYDROCAFFEIC ACID AFFECTS ITS ANTIOXIDATIVE PROPERTIES IN FISH-OIL-ENRICHED EMULSIONS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, PP. 134-145, (2012); SUN Y.E., WANG W.D., CHEN H.W., LI C., AUTOXIDATION OF UNSATURATED LIPIDS IN FOOD EMULSION, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 51, PP. 453-466, (2011); TAN Z., SHAHIDI F., CHEMOENZYMATIC SYNTHESIS OF PHYTOSTERYL FERULATES AND EVALUATION OF THEIR ANTIOXIDANT ACTIVITY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 59, PP. 12375-12383, (2011); TAN Z., SHAHIDI F., A NOVEL CHEMOENZYMATIC SYNTHESIS OF PHYTOSTERYL CAFFEATES AND ASSESSMENT OF THEIR ANTIOXIDANT ACTIVITY, FOOD CHEMISTRY, 133, PP. 1427-1434, (2012); TAN Z., SHAHIDI F., PHYTOSTERYL SINAPATES AND VANILLATES: CHEMOENZYMATIC SYNTHESIS AND ANTIOXIDANT CAPACITY ASSESSMENT, FOOD CHEMISTRY, 138, PP. 1438-1447, (2013); WANG T., HICKS K.B., MOREAU R., ANTIOXIDANT ACTIVITY OF PHYTOSTEROLS, ORYZANOL, AND OTHER PHYTOSTEROL CONJUGATES, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 79, PP. 1201-1206, (2002); WANG Z., HWANG S.H., LIM S.S., LIPOPHILIZATION OF PHENOLIC ACIDS WITH PHYTOSTEROLS BY A CHEMOENZYMATIC METHOD TO IMPROVE THEIR ANTIOXIDANT ACTIVITIES, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 117, PP. 1037-1048, (2015); WANG Z., HWANG S.H., LIM S.S., CHEMOENZYMATICALLY SYNTHESIZED POLICOSANYL PHENOLATES AS AUTOXIDATION INHIBITORS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 117, PP. 300-310, (2015); WHITAKER B.D., SCHMIDT W.F., KIRK M.C., BARNES S., NOVEL FATTY ACID ESTERS OF P-COUMARYL ALCOHOL IN EPICUTICULAR WAX OF APPLE FRUIT, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 3787-3792, (2001)","S.S. LIM; DEPARTMENT OF FOOD SCIENCE AND NUTRITION, HALLYM UNIVERSITY, CHUNCHEON, GANGWON-DO, 1 HALLYMDEAHAK-GIL, 24252, SOUTH KOREA; EMAIL: LIMSS@HALLYM.AC.KR","CZECH ACADEMY OF AGRICULTURAL SCIENCES","ENGLISH","CZECH J. FOOD SCI.","ARTICLE","ISI","2-S2.0-84994613526","CZECH J FOOD SCI","HALLYM UNIVERSITY;HALLYM UNIVERSITY;HALLYM UNIVERSITY","NOTREPORTED;HALLYM UNIVERSITY;NOTREPORTED",NA,"WANG Z, 2016, CZECH J FOOD SCI","WANG Z, 2016, CZECH J FOOD SCI"
"WONG W;ISMAIL M;TOHIT E;ABDULLAH R;ZHANG Y","WONG, WAI-TENG (56991885100); ISMAIL, MAZNAH (57191087465); TOHIT, EUSNI RAHAYU MOHD (8256080100); ABDULLAH, RASEDEE (35291214300); ZHANG, YI-DA (57190386931)","ATTENUATION OF THROMBOSIS BY CRUDE RICE ORYZA SATIVA BRAN POLICOSANOL EXTRACT EX VIVO PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES",2016,"EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE","2016","",18,"10.1155/2016/7343942","LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA, DEPARTMENT OF NUTRITION AND DIETETICS, FACULTY OF MEDICINE AND HEALTH SCIENCES, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA;DEPARTMENT OF PATHOLOGY, FACULTY OF MEDICINE AND HEALTH SCIENCES, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA;DEPARTMENT OF VETERINARY LABORATORY DIAGNOSTICS, FACULTY OF VETERINARY MEDICINE, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA;LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA, CARDIOLOGY DEPARTMENT, AFFILIATED HOSPITAL OF CHENGDE MEDICAL UNIVERSITY, CHENGDE, HEBEI, 067000, CHINA","BACKGROUND. VASCULAR OCCLUSION OR THROMBOSIS WAS OFTEN ATTRIBUTED TO UNCONTROLLED PLATELET ACTIVATION. INFLUENCE OF SUGARCANE POLICOSANOL EXTRACT ON PLATELET WAS REPORTED BUT LITTLE WAS KNOWN OF RICE BRAN POLICOSANOL, PARTICULARLY ITS MECHANISMS OF ACTIONS ON PLATELET ACTIVITIES. OBJECTIVE. ANTIPLATELET MECHANISMS OF RICE BRAN POLICOSANOL EXTRACT (RBE) WERE STUDIED USING HYPERLIPIDEMIC SPRAGUE DAWLEY RATS. EX VIVO PLATELET AGGREGATION, PLATELET COUNT (PC), BLEEDING TIME (BT), AND COAGULATION TIME WERE ASSAYED. SERUM EICOSANOIDS AND OTHER AGGREGATION-RELATED METABOLITES LEVELS WERE QUANTIFIED. DESIGN. RATS WERE DIVIDED INTO 6 GROUPS FOR COMPARISONS (VEHICLE CONTROL TWEEN 20/H2O, HIGH DOSE POLICOSANOL 500 MG/KG, MIDDLE DOSE POLICOSANOL 250 MG/KG, LOW DOSE POLICOSANOL 100 MG/KG, AND POSITIVE CONTROL ASPIRIN 30 MG/KG). RESULTS. LOW DOSE 100 MG/KG OF RBE INHIBITED AGGREGATION BY 42.32 ± 4.31 % AND THIS WAS COMPARABLE WITH THE EFFECT OF 30 MG/KG ASPIRIN, 43.91 ± 5.27 %. RESULTS SHOWED THAT THERE WERE NO SIGNIFICANT DIFFERENCES IN PC, BT, AND COAGULATION TIME AMONG VARIOUS GROUPS AFTER RBE TREATMENT. SERUM THROMBOXANE A2 WAS ATTENUATED WHILE PROSTACYCLIN LEVEL INCREASED UPON RBE TREATMENT. CONCLUSIONS. RBE REDUCED EX VIVO ADP-INDUCED PLATELET AGGREGATION WITHOUT GIVING ADVERSE EFFECTS. NO CHANGES IN FULL BLOOD COUNT SUGGESTED THAT RICE BRAN POLICOSANOL DID NOT DISTURB BIOLOGICAL BLOOD CELL PRODUCTION AND DESTRUCTION YET IT REDUCED AGGREGATION THROUGH DIFFERENT MECHANISMS. © 2016 WAI-TENG WONG ET AL.","","ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; POLICOSANOL; POLYSORBATE 20; PROSTACYCLIN; THROMBOXANE A2; THROMBOXANE B2; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; WATER; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; EX VIVO STUDY; FATTY ACID BLOOD LEVEL; HYPERLIPIDEMIA; LIPID DIET; LOW DRUG DOSE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLATELET REACTIVITY; PROTHROMBIN TIME; RAT; RICE BRAN; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL","","","WHAYNE T.F., CORONARY ATHEROSCLEROSIS, LOW-DENSITY LIPOPROTEINS AND MARKERS OF THROMBOSIS, INFLAMMATION AND ENDOTHELIAL DYSFUNCTION, THE INTERNATIONAL JOURNAL OFANGIOLOGY, 16, 1, PP. 12-16, (2007); DIAZ M.N., FREI B., VITA J.A., KEANEY J.F., ANTIOXIDANTS AND ATHEROSCLEROTIC HEART DISEASE, THE NEW ENGLAND JOURNAL OF MEDICINE, 337, 6, PP. 408-416, (1997); MAY A.E., SEIZER P., GAWAZ M., PLATELETS: INFLAMMATORY FIREBUGS OF VASCULAR WALLS, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 28, 3, PP. 5-10, (2008); MOSA R.A., VITRO ANTI-PLATELET AGGREGATION ACTIVITY OF THE EXTRACTS OF PROTORHUS LONGIFOLIA, (2011); JOHNSON S., KNOWN KNOWNS AND KNOWN UNKNOWNS: RISKS ASSOCIATED WITH COMBINATION ANTITHROMBOTIC THERAPY, THROMBOSIS RESEARCH, 123, 1, PP. S7-S11, (2008); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE ANDWHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); RODRGUEZ M.D., SANCHEZ M., GARCA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOLOGY LETTERS, 90, 2-3, PP. 97-106, (1997); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE, ALTERNATIVE MEDICINE REVIEW, 7, 3, PP. 203-217, (2002); ASIKIN Y., TAKAHASHI M., HIROSE N., HOU D.-X., TAKARA K., WADA K., WAX, POLICOSANOL, AND LONG-CHAIN ALDEHYDES OF DIFFERENT SUGARCANE (SACCHARUMOFFICINARUML.) CULTIVARS, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 114, 5, PP. 583-591, (2012); LEVIN B.E., HOGAN S., SULLIVAN A.C., INITIATION AND PERPETUATION OF OBESITY AND OBESITY RESISTANCE IN RATS, AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 256, 3, PP. R766-R771, (1989); IMAM M.U., ISMAIL M., EFFECTS OF BROWN RICE AND WHITE RICE ON EXPRESSION OF XENOBIOTICMETABOLISMGENES IN TYPE 2 DIABETIC RATS, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 13, 7, PP. 8597-8608, (2012); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 32, 10, PP. 1269-1276, (1999); VAIYAPURI S., GIBBINS J.M., MINIATURISED PLATELET AGGREGATION ASSAYS USING NOVOSTAR MICROPLATE READER, BMG LABTECH APPLICATION NOTE, (2011); WANG Y.-Y., TANG Z.-Y., DONG M., LIU X.-Y., PENG S.-Q., INHIBITION OF PLATELET AGGREGATION BY POLYASPARTOYL L-ARGININE AND ITS MECHANISM, ACTA PHARMACOLOGICA SINICA, 25, 4, PP. 469-473, (2004); GREGG D., GOLDSCHMIDT-CLERMONT P.J., PLATELETS AND CARDIOVASCULAR DISEASE, CIRCULATION, 108, 13, PP. 88-90, (2003); AOKI R., IKARUGI H., NAEMURA A., IJIRI Y., YAMASHITA T., YAMAMOTO J., ENDOTHELIAL DYSFUNCTION PRECEDES ATHEROSCLEROTIC LESIONS AND PLATELET ACTIVATION IN HIGH FAT DIET-INDUCED PROTHROMBOTIC STATE, THROMBOSIS RESEARCH, 117, 5, PP. 529-535, (2006); GADI D., BNOUHAM M., AZIZ M., ET AL., PARSLEY EXTRACT INHIBITS IN VITRO AND EX VIVO PLATELET AGGREGATION AND PROLONGS BLEEDING TIME IN RATS, JOURNAL OF ETHNOPHARMACOLOGY, 125, 1, PP. 170-174, (2009); MICHELSON A.D., FURMAN M.I., LABORATORY MARKERS OF PLATELET ACTIVATION AND THEIR CLINICAL SIGNIFICANCE, CURRENT OPINION IN HEMATOLOGY, 6, 5, PP. 342-348, (1999); BOUKERCHE H., RUCHAUD-SPARAGANO M.-H., ROUEN C., BROCHIER J., KAPLAN C., MCGRECOR J.L., A MONOCLONAL ANTIBODY DIRECTED AGAINST A GRANULE MEMBRANE GLYCOPROTEIN(GMP-140/PADGEM, P-SELECTIN, CD62P) INHIBITS RISTOCETININDUCED PLATELET AGGREGATION, BRITISH JOURNAL OF HAEMATOLOGY, 92, 2, PP. 442-451, (1996); RINDER H.M., BONAN J.L., RINDER C.S., AULT K.A., SMITH B.R., DYNAMICS OF LEUKOCYTE-PLATELET ADHESION IN WHOLE BLOOD, BLOOD, 78, 7, PP. 1730-1737, (1991); HOLMES M.B., SOBEL B.E., HOWARD D.B., SCHNEIDER D.J., DIFFERENCES BETWEEN ACTIVATION THRESHOLDS FOR PLATELET PSELECTIN AND GLYCOPROTEIN IIB-IIIA EXPRESSION AND THEIR CLINICAL IMPLICATIONS, THROMBOSIS RESEARCH, 95, 2, PP. 75-82, (1999); PERUMAL R., RAJENDRAN M., KRISHNAMURTHY M., GANJI K.K., PENDOR S.D., MODULATION OF P-SELECTION AND PLATELET AGGREGATION IN CHRONIC PERIODONTITIS: A CLINICAL STUDY, JOURNAL OF INDIAN SOCIETY OF PERIODONTOLOGY, 18, 3, PP. 293-300, (2014); PRAGA C., CORTELLARO M., POGLIANI E., STANDARDIZED BLEEDING TIME IN THE STUDY OF DRUG INTERFERING WITH PLATELET FUNCTION, ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, 34, PP. 146-158, (1972); RYU K.H., HAN H.Y., LEE S.Y., ET AL., GINKGO BILOBA EXTRACT ENHANCES ANTIPLATELET AND ANTITHROMBOTIC EFFECTS OF CILOSTAZOL WITHOUT PROLONGATION OF BLEEDING TIME, THROMBOSIS RESEARCH, 124, 3, PP. 328-334, (2009); TIAN Z., GAO N., LI L., YU J., LUO X., EFFECT OF TWO EXTRACTED FRACTION FROMLYCOPUS LUCIDUS ON COAGULATION FUNCTION, JOURNAL OF CHINESEMEDICINALMATERIALS, 24, 7, PP. 507-508, (2001); WILLOUGHBY S., HOLMES A., LOSCALZO J., PLATELETS ANDCARDIOVASCULAR DISEASE, EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 1, 4, PP. 273-288, (2002); CICERO A.F.G., GADDI A., RICE BRAN OIL AND-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHERAPY RESEARCH, 15, 4, PP. 277-289, (2001); KIM H., LEE D., HONG J.H., ET AL., INHIBITORY EFFECTS OF RICE BRAN WATER EXTRACT FERMENTED LACTOBACILLUS PLANTARUM DUE TO CAMP-DEPENDENT PHOSPHORYLATION OFVASP (SER157) ON HUMAN PLATELET AGGREGATION, BIOMEDICAL SCIENCE LETTERS, 21, 2, PP. 103-114, (2015); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, 3, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 50, 5, PP. 249-251, (1994); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., SYNERGISTIC EFFECT OF D-003 AND ASPIRIN ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 68, 5, PP. 305-310, (2003); JIN J., QUINTON T.M., ZHANG J., RITTENHOUSE S.E., KUNAPULI S.P., ADENOSINE DIPHOSPHATE (ADP)-INDUCED THROMBOXANE A2 GENERATION IN HUMAN PLATELETS REQUIRES COORDINATED SIGNALING THROUGH INTEGRIN II/ 3 AND ADP RECEPTORS, BLOOD, 99, 1, PP. 193-198, (2002); KIM H., HONG J.H., INGKASUPART P., LEE D., PARK H., INHIBITORY EFFECTS OF WATER EXTRACT FROMRICE BRAN DUE TO CAMPDEPENDENT PHOSPHORYLATION OF VASP (SER 157) ON ADP-INDUCED PLATELET AGGREGATION, BIOMEDICAL SCIENCE LETTERS, 20, 3, PP. 129-138, (2014); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCHIVES OF MEDICAL RESEARCH, 28, 3, PP. 355-360, (1997); ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 29, 10, PP. 891-897, (2002); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 22, 3-4, PP. 89-99, (2002); VARADY K.A., WANG Y., JONES P.J.H., ROLEOFPOLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, 11, PP. 376-383, (2003)","W.-T. WONG; LABORATORY OF MOLECULAR BIOMEDICINE, INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA, SERDANG, SELANGOR, 43400, MALAYSIA; EMAIL: W0049@HOTMAIL.COM","HINDAWI LIMITED","ENGLISH","EVID.-BASED COMPLEMENT. ALTERN. MED.","ARTICLE","ISI","2-S2.0-84992223373","EVID-BASED COMPLEMENT ALTERN MED","UNIVERSITI PUTRA MALAYSIA;UNIVERSITI PUTRA MALAYSIA;UNIVERSITI PUTRA MALAYSIA;UNIVERSITI PUTRA MALAYSIA;UNIVERSITI PUTRA MALAYSIA","NOTREPORTED;UNIVERSITI PUTRA MALAYSIA;NOTREPORTED",NA,"WONG W-T, 2016, EVID-BASED COMPLEMENT ALTERN MED","WONG W-T, 2016, EVID-BASED COMPLEMENT ALTERN MED"
"LANDIS E;DAVIS S;FELDMAN S;TAYLOR S","LANDIS, ERIN T. (55314917200); DAVIS, SCOTT A. (45661042800); FELDMAN, STEVEN R. (55446806200); TAYLOR, SARAH (57045132000)","COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN DERMATOLOGY IN THE UNITED STATES",2014,"JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE","20","6",25,"10.1089/acm.2013.0327","CENTER FOR DERMATOLOGY RESEARCH, DEPARTMENT OF DERMATOLOGY, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES;CENTER FOR DERMATOLOGY RESEARCH, DEPARTMENT OF DERMATOLOGY, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES;CENTER FOR DERMATOLOGY RESEARCH, DEPARTMENT OF DERMATOLOGY, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES, DEPARTMENT OF PATHOLOGY, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES, DEPARTMENT OF PUBLIC HEALTH, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES;CENTER FOR DERMATOLOGY RESEARCH, DEPARTMENT OF DERMATOLOGY, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES","BACKGROUND: COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) HAS AN INCREASING PRESENCE IN DERMATOLOGY. COMPLEMENTARY THERAPIES HAVE BEEN STUDIED IN MANY SKIN DISEASES, INCLUDING ATOPIC DERMATITIS AND PSORIASIS. OBJECTIVES: THIS STUDY SOUGHT TO ASSESS ORAL CAM USE IN DERMATOLOGY RELATIVE TO MEDICINE AS A WHOLE IN THE UNITED STATES, USING THE NATIONAL AMBULATORY MEDICAL CARE SURVEY. DESIGN: VARIABLES STUDIED INCLUDE PATIENT DEMOGRAPHIC CHARACTERISTICS, DIAGNOSES, AND CAM DOCUMENTED AT THE VISITS. A BRIEF LITERATURE REVIEW OF THE TOP 5 CAM TREATMENTS UNIQUE TO DERMATOLOGY VISITS WAS PERFORMED. RESULTS: MOST CAM USERS IN BOTH DERMATOLOGY AND MEDICINE AS A WHOLE WERE FEMALE AND WHITE AND WERE INSURED WITH PRIVATE INSURANCE OR MEDICARE. FISH OIL, GLUCOSAMINE, GLUCOSAMINE CHONDROITIN, AND OMEGA-3 WERE THE MOST COMMON COMPLEMENTARY SUPPLEMENTS USED IN BOTH SAMPLES. CONCLUSIONS: CAM USE IN DERMATOLOGY APPEARS TO BE PART OF A LARGER TREND IN MEDICINE. KNOWLEDGE OF COMMON COMPLEMENTARY THERAPIES CAN HELP DERMATOLOGISTS NAVIGATE THIS EXPANDING FIELD. © MARY ANN LIEBERT, INC. 2014.","","COMPLEMENTARY THERAPIES; DERMATOLOGY; HUMANS; UNITED STATES; ACUNOL; ALIGN; CARNITINE; CHOLESTIN; CHONDROITIN SULFATE; CIMICIFUGA RACEMOSA EXTRACT; FISH OIL; GARLIC OIL; GINSENG EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; HERBAVISION; HYPERICUM PERFORATUM EXTRACT; LACTINEX; LINSEED OIL; MELATONIN; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OSTEO BI FLEX; POLICOSANOL; PRIMROSE OIL; PROBIOTICA; PSORIZIDE; SABAL EXTRACT; UBIDECARENONE; UNCLASSIFIED DRUG; XANTHOPHYLL; ADOLESCENT; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CHILD; FEMALE; HEALTH SURVEY; HUMAN; INFANT; LACTOBACILLUS ACIDOPHILUS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICARE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; TREATMENT INDICATION; UNITED STATES; VITAMIN SUPPLEMENTATION; ALTERNATIVE MEDICINE; DERMATOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION","","","WHAT IS COMPLEMENTARY AND ALTERNATIVE MEDICINE, (2013); STRAUS S.E., HERBAL MEDICINES-WHAT'S IN THE BOTTLE?, N ENGL J MED, 19, 347, PP. 1997-1998, (2002); ERNST E., THE USAGE OF COMPLEMENTARY THERAPIES BY DERMATOLOGICAL PATIENTS: A SYSTEMATIC REVIEW, BR J DERMATOL, 142, PP. 857-861, (2000); FLEISCHER JR. A.B., FELDMAN S.R., BRADHAM D.D., OFFICEBASED PHYSICIAN SERVICES PROVIDED BY DERMATOLOGISTS IN THE UNITED STATES IN 1990, J INVEST DERMATOL, 102, PP. 93-97, (1994); FLEISCHER JR. A.B., FELDMAN S.R., WHITE R.E., LESHIN B., BYINGTON R., PROCEDURES FOR SKIN DISEASES PERFORMED BY PHYSICIANS IN 1993 AND 1994: ANALYSIS OF DATA FROM THE NATIONAL AMBULATORY MEDICAL CARE SURVEY, J AM ACAD DERMATOL, 37, 5 PART 1, PP. 719-724, (1997); PSORIZIDE FORTE HOMEPAGE ON INTERNET., (2013); PSORIZIDE FORTE HOMEPAGE ON INTERNET, (2013); SMITH S.A., YOUNG T.R., WINSJANSEN E., BAKER A.E., WILLIAMS JR. J.H., IMPROVEMENT OF PSORIASIS VULGARIS WITH ORAL NICKEL DIBROMIDE, ARCH DERMATOL, 133, PP. 661-663, (1997); SMITH S.A., BAKER A.E., WILLIAMS J.H., EFFECTIVE TREATMENT OF SEBORRHEIC DERMATITIS USING A LOW DOSE, ORAL HOMEOPATHIC MEDICATION CONSISTING OF POTASSIUM BROMIDE, SODIUM BROMIDE, NICKEL SULFATE, AND SODIUM CHLORIDE IN A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, ALTERN MED REV, 7, PP. 59-67, (2002); RICCIARDI L., CARNI A., LOSCHIAVO G., ET AL., SYSTEMIC NICKEL ALLERGY: ORAL DESENSITIZATION AND POSSIBLE ROLE OF CYTOKINES INTERLEUKINS 2 AND 10, INT J IMMUNOPATHOL PHARMACOL, 26, PP. 251-257, (2013); HENDERSON R.G., CAPPELLINI D., SEILKOP S.K., BATES H.K., OLLER A.R., ORAL BIOACCESSIBILITY TESTING AND READ-ACROSS HAZARD ASSESSMENT OF NICKEL COMPOUNDS, REGUL TOXICOL PHARMACOL, 63, PP. 20-28, (2012); ANTTILA A., PUKKALA E., AITIO A., RANTANEN T., KARJALAINEN S., UPDATE OF CANCER INCIDENCE AMONG WORKERS AT A COPPER/ NICKEL SMELTER AND NICKEL REFINERY, INT ARCH OCCUP ENVIRON HEALTH, 71, PP. 245-250, (1998); DIETER M.P., JAMESON C.W., TUCKER A.N., ET AL., EVALUATION OF TISSUE DISPOSITION, MYELOPOIETIC, AND IMMUNOLOGIC RESPONSES IN MICE AFTER LONG-TERM EXPOSURE TO NICKEL SULFATE IN THE DRINKING WATER, J TOXICOL ENVIRON HEALTH, 24, PP. 357-372, (1988); ANZAI S., FUJIWARA S., INUZUKA M., BROMODERMA, INT J DERMATOL, 42, PP. 370-371, (2003); HANSON J., GILLE A., OFFERMANNS S., ROLE OF HCA(2) (GPR109A) IN NICOTINIC ACID AND FUMARIC ACID ESTER-INDUCED EFFECTS ON THE SKIN, PHARMACOL THER, 136, PP. 1-7, (2012); TANKANOW R.M., ROSS M.B., ERTEL I.J., DICKINSON D.G., MCCORMICK L.S., GARFINKEL J.F., A DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF THE EFFICACY OF LACTINEX IN THE PROPHYLAXIS OF AMOXICILLIN-INDUCED DIARRHEA, DICP, 24, PP. 382-384, (1990); DRAGO L., IEMOLI E., RODIGHIERO V., NICOLA L., DE V.E., PICONI S., EFFECTS OF LACTOBACILLUS SALIVARIUS LS01 (DSM 22775) TREATMENT ON ADULT ATOPIC DERMATITIS: A RANDOMIZED PLACEBOCONTROLLED STUDY, INT J IMMUNOPATHOL PHARMACOL, 24, PP. 1037-1048, (2011); PASSERON T., LACOUR J.P., FONTAS E., ORTONNE J.P., PREBIOTICS AND SYNBIOTICS: TWO PROMISING APPROACHES FOR THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN ABOVE 2 YEARS, ALLERGY, 61, PP. 431-437, (2006); KAUR M., CONDE J., WILLARD J.D., ET AL., A RANDOMIZED, DOUBLEBLIND CLINICAL TRIAL OF A PROBIOTIC NUTRITIONAL INTERVENTION IN THE TREATMENT OF MILD TO MODERATE NON-SCALP PSORIASIS, PSORIASIS FORUM, 13, PP. 12-15, (2007); BOWE W.P., LOGAN A.C., ACNE VULGARIS PROBIOTICS AND THE GUT-BRAIN-SKIN AXIS-BACK TO THE FUTURE?, GUT PATHOG, 3, PP. 1-3, (2011); HEMPEL S., NEWBERRY S.J., MAHER A.R., ET AL., PROBIOTICS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-ASSOCIATED DIARRHEA: A SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 307, PP. 1959-1969, (2012); HERBAVISION WITH LUTEIN AND BILBERRY HOMEPAGE ON INTERNET, (2013); VACCINIUM MYRTILLUS (BILBERRY), ALTERN MED REV, 6, PP. 500-504, (2001); SVOBODOVA A., RAMBOUSKOVA J., WALTEROVA D., VOSTALOVA J., BILBERRY EXTRACT REDUCES UVA-INDUCED OXIDATIVE STRESS IN HACAT KERATINOCYTES: A PILOT STUDY, BIOFACTORS, 33, PP. 249-266, (2008); HEINRICH U., TRONNIER H., STAHL W., BEJOT M., MAURETTE J.M., ANTIOXIDANT SUPPLEMENTS IMPROVE PARAMETERS RELATED TO SKIN STRUCTURE IN HUMANS, SKIN PHARMACOL PHYSIOL, 19, PP. 224-231, (2006); MAROON J.C., BOST J.W., OMEGA-3 FATTY ACIDS (FISH OIL) AS AN ANTI-INFLAMMATORY: AN ALTERNATIVE TO NONSTEROIDAL ANTIINFLAMMATORY DRUGS FOR DISCOGENIC PAIN, SURG NEUROL, 65, PP. 326-331, (2006); VAN GOOL C.J., ZEEGERS M.P., THIJS C., ORAL ESSENTIAL FATTY ACID SUPPLEMENTATION IN ATOPIC DERMATITIS-A META-ANALYSIS OF PLACEBO-CONTROLLED TRIALS, BR J DERMATOL, 150, PP. 728-740, (2004); FOSTER R.H., HARDY G., ALANY R.G., BORAGE OIL IN THE TREATMENT OF ATOPIC DERMATITIS, NUTRITION, 26, PP. 708-718, (2010); MOUGIOS V., MATSAKAS A., PETRIDOU A., ET AL., EFFECT OF SUPPLEMENTATION WITH CONJUGATED LINOLEIC ACID ON HUMAN SERUM LIPIDS AND BODY FAT, J NUTR BIOCHEM, 12, PP. 585-594, (2001); RISERUS U., ARNER P., BRISMAR K., VESSBY B., TREATMENT WITH DIETARY TRANS10CIS12 CONJUGATED LINOLEIC ACID CAUSES ISOMER-SPECIFIC INSULIN RESISTANCE IN OBESE MEN WITH THE METABOLIC SYNDROME, DIABETES CARE, 25, PP. 1516-1521, (2002)","S.R. FELDMAN; DEPARTMENT OF PUBLIC HEALTH, WAKE FOREST SCHOOL OF MEDICINE, WINSTON-SALEM, NC, UNITED STATES; EMAIL: SFELDMAN@WAKEHEALTH.EDU","MARY ANN LIEBERT INC.","ENGLISH","J. ALTERN. COMPLEMENT. MED.","ARTICLE","ISI","2-S2.0-84900022264","J ALTERN COMPLEMENT MED","WAKE FOREST SCHOOL OF MEDICINE;WAKE FOREST SCHOOL OF MEDICINE;WAKE FOREST SCHOOL OF MEDICINE;WAKE FOREST SCHOOL OF MEDICINE","NOTREPORTED;WAKE FOREST SCHOOL OF MEDICINE;EMAIL: SFELDMAN@WAKEHEALTH.EDU",NA,"LANDIS ET, 2014, J ALTERN COMPLEMENT MED","LANDIS ET, 2014, J ALTERN COMPLEMENT MED"
"LI K;ZHENG H;ZHANG H;ZHANG W","LI, KUN (57188983355); ZHENG, HUA (55303225100); ZHANG, HONG (55070241500); ZHANG, WEN-WEN (55072382600)","SIMULATED OXIDATION OF INSECT WAX UNDER UVLIGHT AND HEATING CATALYTIC CONDITIONS AND ANALYSIS OF THE OXIDATIVES",2014,"JOURNAL OF CHEMICAL AND PHARMACEUTICAL RESEARCH","6","9",1,"","RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA, KEY LABORATORY OF CULTIVATION AND UTILIZATION OF RESOURCE INSECTS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA, RESEARCH CENTER OF ENGINEERING AND TECHNOLOGY ON FOREST RESOURCES WITH CHARACTERISTICS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA, KEY LABORATORY OF CULTIVATION AND UTILIZATION OF RESOURCE INSECTS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA, RESEARCH CENTER OF ENGINEERING AND TECHNOLOGY ON FOREST RESOURCES WITH CHARACTERISTICS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA, KEY LABORATORY OF CULTIVATION AND UTILIZATION OF RESOURCE INSECTS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA, RESEARCH CENTER OF ENGINEERING AND TECHNOLOGY ON FOREST RESOURCES WITH CHARACTERISTICS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA;RESEARCH INSTITUTE OF RESOURCES INSECTS, CHINESE ACADEMY OF FORESTRY, KUNMING, YUNNAN, CHINA, KEY LABORATORY OF CULTIVATION AND UTILIZATION OF RESOURCE INSECTS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA, RESEARCH CENTER OF ENGINEERING AND TECHNOLOGY ON FOREST RESOURCES WITH CHARACTERISTICS, STATE FORESTRY ADMINISTRATION, KUNMING, YUNNAN, CHINA","THE AIM OF THIS STUDY WAS TO EXPLORE THE ROLE OF ENVIRONMENTAL CONDITIONS TO INSECT WAX DURING ITS STORAGE AND APPLICATION, AND DETERMINE THE TYPES AND COMPOSITIONS OF THE OXIDATIVES. OXIDATION OF INSECT WAX WITH UV-LIGHT OR HEATING CATALYZING WERE SIMULATED IN THIS PAPER, AND PHYSICOCHEMICAL PARAMETERS, THERMOGRAVIMETRIC (TG), INFRARED SPECTRUM (IR), GAS CHROMATOGRAPHY-MASS SPECTROMETRY(GC-MS) OF THE OXIDATIVES WERE ANALYZED, RESPECTIVELY. TO SOME EXTENT, IT WAS REVEALED THAT UV-LIGHT AND HEATING MAY ACCELERATE THE OXIDATION. THE CHARACTERISTICS AND THE TYPES OF THE OXIDATIVES WERE ANALYZED AND SUMMARIZED. THE RESULTS SHOWED THAT THE EFFECT OF IRRADIATION OF 300NM UV-LIGHT WAS APPROXIMATELY EQUAL TO THAT OF 50° THERMAL CATALYSIS. THE WAX WAS OXIDIZED MORE SEVERE AT 100°. ITS ACID VALUE REACHED TO 69.62MG KOH/G AND SAPONIFICATION VALUE REACHED TO 208.36 MG KOH/G. THE WHOLE PROCESS CONTAINED TWO STAGES, INCLUDING DEGRADATION AND OXIDATION. THE LONG CARBON CHAINS OF SENIOR ALKYL ACID AND POLICOSANOL SHORTENED DURING THE DEGRADATION PROCESS, MANIFESTED AS LOWER MELTING PEAK, INCREASING OF THE LOW-MELTING POINT COMPONENTS, ALTIUDINAL SUCCESSION OF CARBON NUMBER OF SENIOR ALKYL ACID AND BALANCED DISTRIBUTION OF RELATIVE CONTENT. DURING THE OXIDATIVE DEGRADATION, FREE ALKANE, POLICOSANOL, SENIOR ALKYL ACID CONTINUED TO OXIDIZE, CHARACTERIZED BY THE INCREASE OF ACID VALUE AND SAPONIFICATION VALUE, MEANWHILE THE ENHANCEMENT AND SPLIT OF CHARACTERISTIC ABSORPTION PEAK OF CARBONYL IN IR SPECTRUM OF OXIDATION PRODUCTS.","CATALYZE; INSECT WAX; OXIDATIVE; SIMULATED OXIDATION","CARBON; CATALYTIC OXIDATION; GAS CHROMATOGRAPHY; HYDROLYSIS; ALKANE; BEHENIC ACID; HEXACOSANOIC ACID; HEXACOSANOL; HEXADECANOL; LIGNOCERIC ACID; MYRISTIC ACID; OCTACOSANIC ACID; OCTACOSANOL; OCTADECANOL; PALMITIC ACID; POLICOSANOL; STEARIC ACID; TETRACOSANOL; UNCLASSIFIED DRUG; CATALYZE; CHARACTERISTIC ABSORPTION; ENVIRONMENTAL CONDITIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRIES (GC-MS); INSECT WAXES; OXIDATIVE; OXIDATIVE DEGRADATION; PHYSICOCHEMICAL PARAMETERS; ACCELERATION; ACID VALUE; ANIMAL PRODUCT; ARTICLE; CATALYSIS; DEGRADATION; HEATING; INFRARED SPECTROMETRY; INSECT; INSECT WAX; IODINE VALUE; MASS FRAGMENTOGRAPHY; MELTING POINT; NONHUMAN; OXIDATION; PHOTOSTIMULATION; PHYSICAL PARAMETERS; SAPONIFICATION; THERMOGRAVIMETRY; ULTRAVIOLET RADIATION; OXIDATION","","","CHEN X.M., FENG Y., PP. 29-30, (2009); MA L.Y., WANG Y.Q., ZHANG Z.Q., ET AL., CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, 27, PP. 29-32, (2007); YANG P., ZHU J.Y., GONG Z.J., ET AL., AFRICAN JOURNAL OF MICROBIOLOGY RESEARCH, 5, 10, PP. 1246-1248, (2011); ZHANG R.G., ZHENG H., ZHANG H., ET AL., PROCEDIA ENGINEERING, 18, PP. 101-106, (2011); YANG P., XU D.L., CHEN X.M., ET AL., CHINESE JOURNAL OF CELL BIOLOGY, 34, 7, PP. 695-703, (2012); YANG P., ZHU J.Y., GONG Z.J., ET AL., PLOS ONE, 7, 4, (2012); SHEN Y.D., XU X.R., CHINA LEATHER, 21, PP. 19-21, (1992); HOU X.Y., CAO M.Y., GONG J., ET AL., JOURNAL OF ANHUI AGRICULTURAL SCIENCE, 39, 5, PP. 2817-2818, (2011); WANG R.L., CHINA JOURNAL OF CHINESE MATERIA MEDICA, 15, 11, PP. 36-37, (1990); LI Q.F., ZHOU W., ZHANG B., JIANGXI CHEMICAL INDUSTRY, 4, PP. 5-8, (2008); WANG Y.Q., DUAN Q.F., SUN L., ET AL., CHEMICAL REAGENTS, 27, 2, PP. 124-125, (2005); CHEN X.P., JOURNAL OF SICHUAN FORESTRY SCIENCE AND TECHNOLOGY, 28, 2, PP. 50-55, (2007); QU X.P., CHEN L.F., HONG L., ET AL., CHINA PHARMACEUTICALS, 16, 12, (2007); WANG Y.Q., DUAN Q.F., SUN L., ET AL., CHINESE JOURNAL OF SYNTHETIC CHEMISTRY, 13, 4, PP. 403-405, (2005); RIOS T., PEREZ C.S., JOURNAL OF THE CHEMICAL SOCIETY D: CHEMICAL COMMUNICATIONS, 5, PP. 214-215, (1969); CALDERON J.S., QUIJANO L., RIOS T., CELLULAR AND MOLECULAR LIFE SCIENCE, 34, 4, PP. 421-422, (1978); ZHANG H., ZHENG H., CHEN J., ET AL., APPLIED MECHANICS AND MATERIALS, 161, PP. 94-99, (2012)","","JOURNAL OF CHEMICAL AND PHARMACEUTICAL RESEARCH","ENGLISH","J. CHEM. PHARM. RES.","ARTICLE","ISI","2-S2.0-84899846416","J CHEM PHARM RES",NA,"NOTREPORTED",NA,"LI K, 2014, J CHEM PHARM RES","LI K, 2014, J CHEM PHARM RES"
"FRANCINI-PESENTI F;BELTRAMOLLI D;DALL'ACQUA S;BROCADELLO F","FRANCINI-PESENTI, F. (23392494300); BELTRAMOLLI, D. (23391933800); DALL'ACQUA, S. (57202642839); BROCADELLO, F. (15755353400)","EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA",2008,"PHYTOTHERAPY RESEARCH","22","4",33,"10.1002/ptr.2315","CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, PADUA, ITALY, CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY;CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, PADUA, ITALY;DEPARTMENT OF PHARMACEUTICAL SCIENCES, UNIVERSITY OF PADUA, ITALY;CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, PADUA, ITALY","POLICOSANOL, A MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ALCOHOLS, IS USED AS A CHOLESTEROL-LOWERING SUPPLEMENTS. THE EFFECTIVENESS OF POLICOSANOL IS STILL QUESTIONABLE. TO DETERMINE THE LIPOPROTEIN-LOWERING EFFECTS OF CUBAN SUGAR CANE-DERIVED POLICOSANOL A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL WAS PERFORMED. SIXTY-EIGHT PRIMARY HYPERCHOLESTEROLEMIC SUBJECTS WERE ENROLLED AND RANDOMLY ASSIGNED TO THE TREATMENT OR TO THE CONTROL GROUP. THE FIRST GROUP RECEIVED SUGAR CANE POLICOSANOL 20 MG DAILY FOR 8 WEEKS, WHILE THE CONTROL GROUP WAS TREATED WITH PLACEBO. ALL SUBJECTS FOLLOWED A NORMOCALORIC DIET. THE CONTENT OF POLICOSANOL IN THE SUPPLEMENT TABLETS WAS ASSESSED BY GAS CHROMATOGRAPHY. A TOTAL OF 32 SUBJECTS IN THE POLICOSANOL GROUP AND 31 SUBJECTS IN THE CONTROL GROUP COMPLETED THE STUDY. BODY MASS INDEX, TOTAL CHOLESTEROL, HDL-CHOLESTEROL, LDL-CHOLESTEROL AND TRIGLYCERIDE PLASMA LEVELS DID NOT CHANGE SIGNIFICANTLY IN EITHER GROUP. IN CONCLUSION, SUGAR CANE POLICOSANOL AT DOSES OF 20 MG DAILY SHOWED NO LIPID LOWERING EFFECTS IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA. COPYRIGHT © 2007 JOHN WILEY & SONS, LTD.","CLINICAL TRIAL; HYPERCHOLESTEROLEMIA; SUGAR CANE POLICOSANOL","ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; CHOLESTEROL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; SACCHARUM; TRIGLYCERIDES; SACCHARUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; TRIACYLGLYCEROL BLOOD LEVEL","","","ALEMAN C.L., MAS R., HERNANDEZ, ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); ALEMAN C., RODEIRO I., NOA M., ET AL., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J APPL TOXICOL, 21, PP. 179-184, (2001); ARRUZAZABALA M.L., NOA M., MENENDEZ R., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA, 295, PP. 2262-2269, (2006); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVESTIG, 21, PP. 103-113, (2001); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-65, (2001); GONZALEZ V.L., HERNANDEZ J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOL THAT COMPOSE POLICOSANOL IN FIVE-MILLIGRAM FILM-COATED TABLETS, AOAC INT, 82, PP. 834-839, (1999); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); HOWARD B.V., HANNAH J.S., HEISER C.C., JABLONSKI K.A., EFFECTS OF SEX AND ETHNICITY ON RESPONSES TO A LOW-FAT DIET: A STUDY OF AFRICAN AMERICANS AND WHITES, AM J CLIN NUTR, 62, (1995); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); MARIANGELI C.P.F., KASSIS A.K., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.H., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR J NUTR, 97, PP. 381-388, (2007); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, (2004); PEARSON T.A., DENKE M.A., MCBRIDE P.E., BATTISTI W.P., BRADY W.E., PALMISANO J., A COMMUNITY-BASED, RANDOMIZED TRIAL OF EZETIMIBE ADDED TO STATIN THERAPY TO ATTAIN NCEP ATP III GOALS FOR LDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS: THE EZETIMIBE ADD-ON TO STATIN FOR EFFECTIVENESS (EASE) TRIAL, MAYO CLIN PROC, 80, PP. 587-595, (2005); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); TAN C.E., LOH L.M., TAI E.S., DO SINGAPORE PATIENTS REQUIRE LOWER DOSES OF STATINS? THE SGH LIPID CLINIC EXPERIENCE, SINGAPORE MED J, 44, PP. 635-638, (2003); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003)","F. FRANCINI-PESENTI; CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY; EMAIL: FRANCESCOFRANCINI@YAHOO.IT","","ENGLISH","PHYTOTHER. RES.","ARTICLE","ISI","2-S2.0-40849094376","PHYTOTHER RES","CLINICAL NUTRITION UNIT;CLINICAL NUTRITION UNIT;UNIVERSITY OF PADUA;CLINICAL NUTRITION UNIT","NOTREPORTED;CLINICAL NUTRITION UNIT;NOTREPORTED",NA,"FRANCINI-PESENTI F, 2008, PHYTOTHER RES","FRANCINI-PESENTI F, 2008, PHYTOTHER RES"
"FUNG M;HILL J;COOK D;FROHLICH J","FUNG, MICHELLE (7101955087); HILL, JOHN (23070651800); COOK, DONALD (8432276000); FROHLICH, JIRI (7101929228)","CASE SERIES OF TYPE III HYPERLIPOPROTEINEMIA IN CHILDREN",2011,"BMJ CASE REPORTS","","",17,"10.1136/bcr.02.2011.3895","UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, BC, CANADA;HEALTHY HEART PROGRAM, ST. PAUL'S HOSPITAL, VANCOUVER, BC, CANADA;DEPARTMENT OF GENERAL INTERNAL MEDICINE, ROCKYVIEW GENERAL HOSPITAL, CALGARY, AB, CANADA;DEPARTMENT OF PATHOLOGY, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, BC, CANADA","TYPE III HYPERLIPOPROTEINEMIA (TYPE III HLP) RARELY MANIFESTS IN CHILDHOOD. LONG-TERM FOLLOW-UP (37 YEARS) OF THE FIRST PATIENT REVEALED HYPOTHYROIDISM AT DIAGNOSIS REQUIRING THYROXINE REPLACEMENT, PALMAR XANTHOMAS REQUIRING SURGICAL REMOVAL, SPLENOMEGALY REQUIRING SPLENECTOMY, 18 EPISODES OF PANCREATITIS AND PREMATURE CORONARY ARTERY DISEASE. INVESTIGATION REVEALED AN APOLIPOPROTEIN E PHENOTYPE OF E2/E2 AND PARTIAL LIPOPROTEIN LIPASE DEFICIENCY. INVESTIGATION OF THE SECOND PATIENT REVEALED A COMBINATION OF APOE2/E2 PHENOTYPE AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA. THE THIRD PATIENT HAD A COMPLETE DEFICIENCY OF LIPOPROTEIN LIPASE ACTIVITY, AN ABNORMAL THYROID STIMULATING HORMONE ON DIAGNOSIS (WITH SUBSEQUENT NORMALISATION WITHOUT TREATMENT), AND APOE2/E2 PHENOTYPE. TYPE III HLP IS A SERIOUS DISORDER WITH LIFELONG CONSEQUENCES OF PREMATURE VASCULAR DISEASE AND RECURRENT PANCREATITIS. EARLY PRESENTATION OF DISEASE IN OUR PATIENTS WAS ASSOCIATED WITH ADDITIONAL PRECIPITATING FACTORS. DRUG TREATMENT OF PAEDIATRIC TYPE III HLP IS INDICATED IF DIETARY MODIFICATIONS ALONE ARE INSUFFICIENT IN MANAGING THE DYSLIPIDAEMIA. COPYRIGHT 2011 BMJ PUBLISHING GROUP. ALL RIGHTS RESERVED.","","APOLIPOPROTEIN E2; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LIPOPROTEIN LIPASE; NICOTINIC ACID; POLICOSANOL; ROSUVASTATIN; SALMON OIL; SIMVASTATIN; THYROTROPIN; UNCLASSIFIED DRUG; ADULT; ARTICLE; CASE REPORT; CHILD; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG DOSE INCREASE; DYSLIPIDEMIA; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART SURGERY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; MALE; METABOLIC SYNDROME X; PANCREATITIS; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; SPLENECTOMY; SPLENOMEGALY; STABLE ANGINA PECTORIS; XANTHOMA","","","MAHLEY R.W., HUANG Y., RALL JR. S.C., PATHOGENESIS OF TYPE III HYPERLIPOPROTEINEMIA (DYSBETALIPOPROTEINEMIA): QUESTIONS, QUANDARIES, AND PARADOXES, JOURNAL OF LIPID RESEARCH, 40, 11, PP. 1933-1949, (1999); WALDEN C.C., HEGELE R.A., APOLIPOPROTEIN E IN HYPERLIPIDEMIA, ANNALS OF INTERNAL MEDICINE, 120, 12, PP. 1026-1036, (1994); GODOLPHIN W.J., CONRADI G., CAMPBELL D.J., TYPE-3 HYPERLIPOPROTEINAEMIA IN A CHILD, LANCET, 1, PP. 209-210, (1972); PIMSTONE S.N., GAGNE S.E., GAGNE C., ET AL., MUTATIONS IN THE GENE FOR LIPOPROTEIN LIPASE. A CAUSE FOR LOW HDL CHOLESTEROL LEVELS IN INDIVIDUALS HETEROZYGOUS FOR FAMILIAL HYPERCHOLESTEROLEMIA, ARTERIOSCLER THROMB VASC BIOL, 15, PP. 1704-1712, (1995); CARR M.C., BRUNZELL J.D., DEEB S.S., ETHNIC DIFFERENCES IN HEPATIC LIPASE AND HDL IN JAPANESE, BLACK, AND WHITE AMERICANS: ROLE OF CENTRAL OBESITY AND LIPC POLYRNORPHISMS, JOURNAL OF LIPID RESEARCH, 45, 3, PP. 466-473, (2004); KOBAYASHI J., YAMAZAKI K., TASHIRO J., MURANO S., SAITO Y., MORISAKI N., TYPE III HYPERLIPIDAEMIA WITH PRIMARY HYPOTHYROIDISM: A UNIQUE CLINICAL COURSE OF HYPERLIPIDAEMIA DURING REPLACEMENT THERAPY OF THYROID HORMONE, CLINICAL ENDOCRINOLOGY, 46, 5, PP. 627-630, (1997); LINDNER M.A., ILLINGWORTH D.R., EXPRESSION OF TYPE III HYPERLIPOPROTEINEMIA IN AN ADOLESCENT PATIENT WITH HYPOTHYROIDISM, J PEDIATR, 113, PP. 86-89, (1988); FEUSSNER G., ZIEGLER R., EXPRESSION OF TYPE III HYPERLIPOPROTEINAEMIA IN A SUBJECT WITH SECONDARY HYPOTHYROIDISM BEARING THE APOLIPOPROTEIN E2/2 PHENOTYPE, J INTERN MED, 230, PP. 183-186, (1991); KRSEK M., CESKA R., HORINEK A., HOREJSI B., WEISS V., TYPE III HYPERLIPOPROTEINAEMIA AND PRIMARY AMENORRHOEA ASSOCIATED WITH SEVERE HYPOTHYROIDISM, ACTA PAEDIATRICA, INTERNATIONAL JOURNAL OF PAEDIATRICS, 89, 8, PP. 1023-1024, (2000); KASHYAP A.S., SHARMA H.S., KUMAR P., DENTAL ANOMALIES IN WILLIAMS SYNDROME, POSTGRAD MED J, 76, (2000); CROOK M.A., MUKHERJEE A., MARSHALL K., UNUSUAL PRESENTATIONS TO A LIPID CLINIC, POSTGRADUATE MEDICAL JOURNAL, 75, 888, PP. 633-634, (1999); KASHYAP A.S., ANAND K.P., PRIMARY AMENORRHOEA AND XANTHOMATOSIS, LANCET, 363, 9409, (2004); STONE N.J., SECONDARY CAUSES OF HYPERLIPIDEMIA, MEDICAL CLINICS OF NORTH AMERICA, 78, 1, PP. 117-141, (1994); CARMENA R., ROY M., ROEDERER G., ET AL., COEXISTING DYSBETALIPOPROTEINEMIA AND FAMILIAL HYPERCHOLESTEROLEMIA. CLINICAL AND LABORATORY OBSERVATIONS, ATHEROSCLEROSIS, 148, PP. 113-124, (2000); FEUSSNER G., DOBMEYER J., NISSEN H., ET AL., UNUSUAL XANTHOMAS IN A YOUNG PATIENT WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND TYPE III HYPERLIPOPROTEINEMIA, AM J MED GENET, 65, PP. 149-154, (1996); SAKUMA N., IWATA S., IKEUCHI R., ET AL., COEXISTING TYPE III HYPERLIPOPROTEINEMIA AND FAMILIAL HYPERCHOLESTEROLEMIA: A CASE REPORT, METAB CLIN EXP, 44, PP. 460-465, (1995); HOPKINS P.N., WU L.L., SCHUMACHER M.C., ET AL., TYPE III DYSLIPOPROTEINEMIA IN PATIENTS HETEROZYGOUS FOR FAMILIAL HYPERCHOLESTEROLEMIA AND APOLIPOPROTEIN E2. EVIDENCE FOR A GENE-GENE INTERACTION, ARTERIOSCLER THROMB, 11, PP. 1137-1146, (1991); FUNG M., BEBB R., FROHLICH J., FOLLOW-UP OF TYPE III HYPERLIPOPROTEINAEMIA IN A CHILD 6, LANCET, 358, 9299, (2001); MANN W.A., MEYER N., BERG D., GRETEN H., BEISIEGEL U., LIPOPROTEIN LIPASE COMPENSATES FOR THE DEFECTIVE FUNCTION OF APO E VARIANTS IN VITRO BY INTERACTING WITH PROTEOGLYCANS AND LIPOPROTEIN RECEPTORS, ATHEROSCLEROSIS, 145, 1, PP. 61-69, (1999); DOBIASOVA M., ADLER L., OHTA T., ET AL., EFFECT OF LABELING OF PLASMA LIPOPROTEINS WITH (3)H CHOLESTEROL ON VALUES OF ESTERIFICATION RATE OF CHOLESTEROL IN APOLIPOPROTEIN B-DEPLETED PLASMA, J LIPID RES, 41, PP. 1356-1357, (2000); DOBIASOVA M., FROHLICH J., MEASUREMENT OF FRACTIONAL ESTERIFICATION RATE OF CHOLESTEROL IN PLASMA DEPLETED OF APOPROTEIN B CONTAINING LIPOPROTEIN: METHODS AND NORMAL VALUES, PHYSIOLOGICAL RESEARCH, 45, 1, PP. 65-73, (1996); KIMURA W., MOSSNER J., ROLE OF HYPERTRIGLYCERIDEMIA IN THE PATHOGENESIS OF EXPERIMENTAL ACUTE PANCREATITIS IN RATS, INTERNATIONAL JOURNAL OF PANCREATOLOGY, 20, 3, PP. 177-184, (1996); TOSKES P.P., HYPERLIPIDEMIC PANCREATITIS, GASTROENTEROL CLIN NORTH AM, 19, PP. 783-791, (1990); DIRISAMER A., HACHEMIAN N., BUCEK R.A., WOLF F., REITER M., WIDHALM K., THE EFFECT OF LOW-DOSE SIMVASTATIN IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA: A 1-YEAR OBSERVATION, EUROPEAN JOURNAL OF PEDIATRICS, 162, 6, PP. 421-425, (2003); DE JONGH S., LILIEN M.R., OP'T R.J., STROES E.S.G., BAKKER H.D., KASTELEIN J.J.P., EARLY STATIN THERAPY RESTORES ENDOTHELIAL FUNCTION IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 40, 12, PP. 2117-2121, (2002); DE JONGH S., OSE L., SZAMOSI T., GAGNE C., LAMBERT M., SCOTT R., PERRON P., DOBBELAERE D., SABORIO M., TUOHY M.B., STEPANAVAGE M., SAPRE A., GUMBINER B., MERCURI M., VAN TROTSENBURG A.S.P., BAKKER H.D., KASTELEIN J.J.P., EFFICACY AND SAFETY OF STATIN THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH SIMVASTATIN, CIRCULATION, 106, 17, PP. 2231-2237, (2002); VOHL M.-C., SZOTS F., LELIEVRE M., LUPIEN P., BERGERON J., GAGNE C., COUTURE P., INFLUENCE OF LDL RECEPTOR GENE MUTATION AND APO E POLYMORPHISM ON LIPOPROTEIN RESPONSE TO SIMVASTATIN TREATMENT AMONG ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 160, 2, PP. 361-368, (2002); LAMBERT M., LUPIEN P.-J., GAGNE C., LEVY E., BLAICHMAN S., LANGLOIS S., HAYDEN M., ROSE V., CLARKE J.T.R., WOLFE B.M.J., CLARSON C., PARSONS H., STEPHURE D.K., POTVIN D., LAMBERT J., TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN AND ADOLESCENTS: EFFECT OF LOVASTATIN, PEDIATRICS, 97, 5, PP. 619-628, (1996)","M. FUNG; UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, BC, CANADA; EMAIL: MICHELLE.FUNG@VCH.CA","BMJ PUBLISHING GROUP","ENGLISH","BMJ CASE REP.","ARTICLE","ISI","2-S2.0-79959306352","BMJ CASE REP","UNIVERSITY OF BRITISH COLUMBIA;ST. PAUL'S HOSPITAL;ROCKYVIEW GENERAL HOSPITAL;UNIVERSITY OF BRITISH COLUMBIA","NOTREPORTED;UNIVERSITY OF BRITISH COLUMBIA;NOTREPORTED",NA,"FUNG M, 2011, BMJ CASE REP","FUNG M, 2011, BMJ CASE REP"
"JONES A;HARAMIZU S;RANCHORDAS M;BURKE L;STEAR S;CASTELL L","JONES, ANDREW M (7407101756); HARAMIZU, SATOSHI (6505978584); RANCHORDAS, MAYUR (39062073400); BURKE, LOUISE (7102048294); STEAR, SAMANTHA (6602335278); CASTELL, LINDA M (35554567000)","AZ OF NUTRITIONAL SUPPLEMENTS DIETARY SUPPLEMENTS SPORTS NUTRITION FOODS AND ERGOGENIC AIDS FOR HEALTH AND PERFORMANCEPART 27",2011,"BRITISH JOURNAL OF SPORTS MEDICINE","45","2",13,"10.1136/bjsports-2011-090669","SCHOOL OF SPORT AND HEALTH SCIENCES, UNIVERSITY OF EXETER, EXETER, UNITED KINGDOM;BIOLOGICAL SCIENCE LABORATORIES, KAO CORPORATION, HAGA-GUN, JAPAN;DEPARTMENT OF SPORT, SHEFFI ELD HALLAM UNIVERSITY, SHEFFIELD, UNITED KINGDOM;AUSTRALIAN INSTITUTE OF SPORT, CANBERRA, ACT, AUSTRALIA;PERFORMANCE INFLUENCERS LIMITED, LONDON, UNITED KINGDOM;UNIVERSITY OF OXFORD, GREEN TEMPLETON COLLEGE, OXFORD OX2 6HG, UNITED KINGDOM","WELCOME TO PART 27, WHERE WE FI NISH 'N' WITH NITRATES AND NOOTKATONE AND MOVE ONTO 'O' STARTING WITH OCTACOSANOL. THE FI RST REVIEW FOCUSES ON WHAT HAS BECOME QUITE A HOT TOPIC IN SPORT NUTRITION IN THE RECENT YEARS WITH THE BBC LEADING WITH A HEADLINE IN AUGUST 2009 THAT 'BEETROOT JUICE BOOSTS STAMINA'. THE BBC WAS DESCRIBING A STUDY FROM PROFESSOR ANDY JONES' GROUP: IN HIS BRIEF REVIEW FOR PART 27, HE DESCRIBES THE LINK BETWEEN SUPPLEMENTING THE DIET WITH NITRATE-RICH BEETROOT JUICE TO ENHANCE NO AVAILABILITY AND THE CONSEQUENTIAL PROPOSED MECHANISMS THAT COULD LEAD TO AN IMPROVEMENT IN EXERCISE PERFORMANCE. THE OTHER TWO REVIEWS DEAL WITH SUBSTANCES THAT ARE GENERALLY FOUND AS PLANT EXTRACTS: NOOTKATONE, A CHEMICAL FOUND IN THE ESSENTIAL OIL OF GRAPEFRUIT AND OTHER PLANTS INCLUDING CEDARS, WHICH IS USED PREDOMINANTLY AS A FL AVOURING COMPOUND BUT ALSO AS A NATURAL INSECTICIDE; AND POLICOSANOL, A WHEAT-GERM EXTRACT WHOSE MAIN COMPONENT IS OCTACOSANOL.","","ATHLETIC PERFORMANCE; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; HUMANS; NITRATES; PHYSICAL ENDURANCE; SESQUITERPENES; 1 OCTACOSANOL; 1-OCTACOSANOL; FATTY ALCOHOL; NITRATE; NOOTKATONE; POLICOSANOL; SESQUITERPENE; ATHLETIC PERFORMANCE; DIET SUPPLEMENTATION; ENDURANCE; HUMAN; REVIEW","","","STAMLER J.S., MEISSNER G., PHYSIOLOGY OF NITRIC OXIDE IN SKELETAL MUSCLE, PHYSIOLOGICAL REVIEWS, 81, 1, PP. 209-237, (2001); MONCADA S., HIGGS A., THE L-ARGININE-NITRIC OXIDE PATHWAY, NEW ENGLAND JOURNAL OF MEDICINE, 329, 27, PP. 2002-2012, (1993); DUNCAN C., DOUGALL H., JOHNSTON P., ET AL., CHEMICAL GENERATION OF NITRIC OXIDE IN THE MOUTH FROM THE ENTEROSALIVARY CIRCULATION OF DIETARY NITRATE, NAT MED, 1, PP. 546-51, (1995); LUNDBERG J.O., GOVONI M., INORGANIC NITRATE IS A POSSIBLE SOURCE FOR SYSTEMIC GENERATION OF NITRIC OXIDE, FREE RADICAL BIOLOGY AND MEDICINE, 37, 3, PP. 395-400, (2004); LARSEN F.J., WEITZBERG E., LUNDBERG J.O., EKBLOM B., EFFECTS OF DIETARY NITRATE ON OXYGEN COST DURING EXERCISE, ACTA PHYSIOLOGICA, 191, 1, PP. 59-66, (2007); BAILEY S.J., WINYARD P., VANHATALO A., ET AL., DIETARY NITRATE SUPPLEMENTATION REDUCES THE O2 COST OF LOW-INTENSITY EXERCISE AND ENHANCES TOLERANCE TO HIGHINTENSITY EXERCISE IN HUMANS, J APPL PHYSIOL, 107, PP. 1144-55, (2009); BAILEY S.J., FULFORD J., VANHATALO A., ET AL., DIETARY NITRATE SUPPLEMENTATION ENHANCES MUSCLE CONTRACTILE EFFICIENCY DURING KNEE-EXTENSOR EXERCISE IN HUMANS, J APPL PHYSIOL, 109, PP. 135-48, (2010); VANHATALO A., BAILEY S.J., BLACKWELL J.R., ET AL., ACUTE AND CHRONIC EFFECTS OF DIETARY NITRATE SUPPLEMENTATION ON BLOOD PRESSURE AND THE PHYSIOLOGICAL RESPONSES TO MODERATE-INTENSITY AND INCREMENTAL EXERCISE, AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, 299, (2010); LANSLEY K.E., WINYARD P.G., FULFORD J., ET AL., DIETARY NITRATE SUPPLEMENTATION REDUCES THE O2 COST OF WALKING AND RUNNING: A PLACEBO-CONTROLLED STUDY, J APPL PHYSIOL, 110, PP. 591-600, (2011); LANSLEY K.E., WINYARD P.G., BAILEY S.J., ET AL., ACUTE DIETARY NITRATE SUPPLEMENTATION IMPROVES CYCLING TIME TRIAL PERFORMANCE, MED SCI SPORTS EXERC, 43, PP. 1125-31, (2011); FERREIRA L.F., BEHNKE B.J., A TOAST TO HEALTH AND PERFORMANCE! BEETROOT JUICE LOWERS BLOOD PRESSURE AND THE O2 COST OF EXERCISE, J APPL PHYSIOL, 110, PP. 585-6, (2011); LARSEN F.J., SCHIFFER T.A., BORNIQUEL S., ET AL., DIETARY INORGANIC NITRATE IMPROVES MITOCHONDRIAL EFFICIENCY IN HUMANS, CELL METAB, 13, PP. 149-59, (2011); KENJALE A.A., HAM K.L., STABLER T., ET AL., DIETARY NITRATE SUPPLEMENTATION ENHANCES EXERCISE PERFORMANCE IN PERIPHERAL ARTERIAL DISEASE, J APPL PHYSIOL, 110, PP. 1582-91, (2011); LITTLE D.P., EVOLUTION AND CIRCUMSCRIPTION OF THE TRUE CYPRESSES (CUPRESSACEAE: CUPRESSUS), HANDBOOK OF ENVIRONMENTAL CHEMISTRY, VOLUME 5: WATER POLLUTION, 31, 3, PP. 461-480, (2006); MURASE T., MISAWA K., HARAMIZU S., ET AL., NOOTKATONE, A CHARACTERISTIC CONSTITUENT OF GRAPEFRUIT, STIMULATES ENERGY METABOLISM AND PREVENTS DIET-INDUCED OBESITY BY ACTIVATING AMPK, AM J PHYSIOL ENDOCRINOL METAB, 299, (2010); FUJIOKA K., GREENWAY F., SHEARD J., YING Y., THE EFFECTS OF GRAPEFRUIT ON WEIGHT AND INSULIN RESISTANCE: RELATIONSHIP TO THE METABOLIC SYNDROME, JOURNAL OF MEDICINAL FOOD, 9, 1, PP. 49-54, (2006); SINGH B.K., MEHTA J.L., MANAGEMENT OF DYSLIPIDEMIA IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE, CURRENT OPINION IN CARDIOLOGY, 17, 5, PP. 503-511, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); KATO S., KARINO K., HASEGAWA S., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR J NUTR, 73, PP. 433-41, (1995); SAINT-JOHN M., MCNAUGHTON L., OCTASANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME AND CHEST GRIP STRENGTH, INT CLIN NUTR REV, 6, (1986); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-79, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BRITISH JOURNAL OF NUTRITION, 95, 5, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); COCKERILL D.L., BUCCI L.R., INCREASES IN MUSCLE GIRTH AND DECREASES IN BODY FAT ASSOCIATED WITH A NUTRITIONAL SUPPLEMENT PROGRAM, CHIROPRACT SPORTS MED, 1, (1987); CALDER P.C., LINDLEY M.R., BURKE L.M., ET AL., A-Z OF NUTRITIONAL SUPPLEMENTS: DIETARY SUPPLEMENTS, SPORTS NUTRITION FOODS AND ERGOGENIC AIDS FOR HEALTH AND PERFORMANCE PART 14, BR J SPORTS MED, 44, PP. 1065-7, (2010); RANCHORDAS M.K., BLOMSTRAND E., CALDER P.C., ET AL., A-Z OF NUTRITIONAL SUPPLEMENTS: DIETARY SUPPLEMENTS, SPORTS NUTRITION FOODS AND ERGOGENIC AIDS FOR HEALTH AND PERFORMANCE-PART 23, BR J SPORTS MED, 45, PP. 830-1, (2011); LUNDBERG J.O., LARSEN F.J., WEITZBERG E., SUPPLEMENTATION WITH NITRATE AND NITRITE SALTS IN EXERCISE: A WORD OF CAUTION, J APPL PHYSIOL, 111, PP. 616-17, (2011)","L.M. CASTELL; UNIVERSITY OF OXFORD, GREEN TEMPLETON COLLEGE, OXFORD OX2 6HG, UNITED KINGDOM; EMAIL: LINDY.CASTELL@GTC.OX.AC.UK","","ENGLISH","BR. J. SPORTS MED.","ARTICLE","ISI","2-S2.0-81055131769","BR J SPORTS MED","UNIVERSITY OF EXETER;BIOLOGICAL SCIENCE LABORATORIES;SHEFFI ELD HALLAM UNIVERSITY;AUSTRALIAN INSTITUTE OF SPORT;UNIVERSITY OF OXFORD","NOTREPORTED;UNIVERSITY OF OXFORD;NOTREPORTED",NA,"JONES AM, 2011, BR J SPORTS MED","JONES AM, 2011, BR J SPORTS MED"
"ROZZA F;DE S G;IZZO R;DE L N;TRIMARCO B","ROZZA, FRANCESCO (23498918300); DE SIMONE, GIOVANNI (55515626600); IZZO, RAFFAELE (7004640234); DE LUCA, NICOLA (7006357146); TRIMARCO, BRUNO (57210773404)","NUTRACEUTICALS FOR TREATMENT OF HIGH BLOOD PRESSURE VALUES IN PATIENTS WITH METABOLIC SYNDROME",2009,"HIGH BLOOD PRESSURE AND CARDIOVASCULAR PREVENTION","16","5",8,"10.2165/11530420-000000000-00000","DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, FEDERICO II UNIVERSITY, NAPLES, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY","AIM: TO ASSESS WHETHER THE ASSOCIATION OF A DIETARY SUPPLEMENT WITH A CORRECT DIET CAN DECREASE THE INCIDENCE OF METABOLIC SYNDROME. IN PARTICULAR, WE STUDIED THE EFFECT OF A COMBINATION OF ORTOSIPHON STAMINENSIS, WHICH IN RATS EXERTS A DIURETIC EFFECT, WITH POLICOSANOL, RED YEAST RICE EXTRACT, BERBERINE, FOLIC ACID AND COENZYME Q10 ON THE DETERMINANTS OF METABOLIC SYNDROME DIAGNOSIS. METHODS: THE ANALYSED SAMPLE CONSISTED OF 21 MALES AND 9 FEMALES, WHO WERE COMPARABLE IN AGE, IN ORDER TO OBTAIN AN ADEQUATE COMPARISON BETWEEN GROUPS WITH SIMILAR DEMOGRAPHIC CHARACTERISTICS. THIRTY PATIENTS WITH METABOLIC SYNDROME WERE DIVIDED INTO TWO STUDY ARMS. BOTH GROUPS RECEIVED THE USUAL DIET RECOMMENDED BY THE DOCTOR ACCORDING TO THEIR CLINICAL CONDITIONS AND PLACEBO FOR 2 WEEKS BEFORE THE BEGINNING OF THE STUDY, AND THEN THEY WERE RANDOMLY ASSIGNED TO TWO DIFFERENT DRUG REGIMENS: PLACEBO OR THE COMBINATION OF NUTRACEUTICALS PREVIOUSLY DESCRIBED, AND WERE FOLLOWED-UP FOR 6 WEEKS. RESULTS: AT BASELINE, THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN THE STUDY AND CONTROL GROUPS FOR AGE, SEX DISTRIBUTION, WAIST MEASUREMENT, BODY MASS INDEX, SYSTOLIC AND DIASTOLIC BLOOD PRESSURE, FAMILIARITY FOR CARDIOVASCULAR EVENTS, SMOKING HABIT, FASTING GLUCOSE AND LIPID PROFILE. AT THE END OF THE FOLLOW-UP, ONLY IN THE STUDY GROUP WAS THERE A SIGNIFICANT REDUCTION IN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE (-19.6 ± 9.7 VS -3.6 ± 8.1MMHG AND -13.6 ± 5.5 VS -2.3 ± 5.3MMHG; ALL P < 0.0001) ASSOCIATED WITH AMARKED DECREASE IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDE PLASMA LEVELS. CONSEQUENTLY, 10 OF 15 PATIENTS IN THIS GROUP NO LONGER SATISFIED THE CRITERIA FOR METABOLIC SYNDROME, WHILE IN THE CONTROL GROUP THE RATIO WAS OF 2 OF 15. CONCLUSIONS: THE ADDITION OF ORTOSIPHON STAMINENSIS TO THE COMBINATION OF POLICOSANOL, RED YEAST RICE EXTRACT, BERBERINE, FOLIC ACID AND COENZYMEQ 10 PROVIDES AN ANTIHYPERTENSIVE EFFECT, WHICH ALLOWS AN EFFECTIVE CONTROL OF BLOOD PRESSURE IN PATIENTS WITH METABOLIC SYNDROME. © 2009 ADIS DATA INFORMATION BV. ALL RIGHTS RESERVED.","ANTIHYPERTENSIVE THERAPY; DYSLIPIDAEMIA","ARMOLIPID PREV; BERBERINE; FOLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; PLACEBO; POLICOSANOL; UBIDECARENONE; UNCLASSIFIED DRUG; XUEZHIKANG; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DIET THERAPY; DIURETIC ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; ORTHOSIPHON; ORTHOSIPHON STAMINENSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE","","","GRUNDY S.M., CLEEMAN J.I., DANIELS S.R., ET AL., DIAGNOSIS AND MANAGEMENT OF THE METABOLIC SYNDROME: AN AMERICAN HEART ASSOCIATION/NATIONAL HEART LUNG AND BLOOD INSTITUTE SCIENTIFIC STATEMENT, CIRCULATION, 112, 17, PP. 2735-2752, (2005); MANCIA G., DE BACKER G., DOMINICZAK A., CIFKOVA R., FAGARD R., GERMANO G., GRASSI G., HEAGERTY A.M., KJELDSEN S.E., LAURENT S., NARKIEWICZ K., RUILOPE L., RYNKIEWICZ A., SCHMIEDER R.E., BOUDIER H.A.J.S., ZANCHETTI A., 2007 GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: THE TASK FORCE FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION (ESH) AND OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC), JOURNAL OF HYPERTENSION, 25, 6, PP. 1105-1187, (2007); AZADBAKHT L., MIRMIRAN P., ESMAILLZADEH A., ET AL., BENEFICIAL EFFECTS OF ADIETARY APPROACHES TO STOP HYPERTENSION EATING PLAN ON FEATURES OF THE METABOLIC SYNDROME, DIABETES CARE, 28, 12, PP. 2823-2831, (2005); FORD E.S., PREVALENCE OF THE METABOLIC SYNDROME DEFINED BY THE INTERNATIONAL DIABETES FEDERATION AMONG ADULTS IN THE US, DIABETES CARE, 28, 11, PP. 2745-2749, (2005); MATTAR M., OBEID O., FISH OIL AND THE MANAGEMENT OF HYPERTRIGLYCERIDEMIA, NUTR HEALTH, 20, 1, PP. 41-49, (2009); CICERO A.F.G., ROVATI L., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); SENIN P., SETNIKAR I., ROVATI A.L., FORMULATION FOR ORAL ADMINISTRATION HAVING A HEALTH-PROMOTING EFFECT ON THE CARDIOVASCULAR SYSTEM, (2008); TRIMARCO B., BENVENUTI C., CONTROLLED CLINICAL STUDY ON A NEW DIETARY SUPPLEMENT ACTIVE ON CHOLESTEROL AND TRIGLYCERIDES IN CV RISK AND METABOLIC SYNDROME CONTROL ABSTRACT NO. 950109, XV INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, PP. 14-18, (2009); ADAMY SOMCHIT M.N., SULAIMAN M.R., ET AL., DIURETIC PROPERTIES OF ORTHOSIPHON STAMINEUS BENTH, J ETHNOPHARMACOL, 124, 1, PP. 154-158, (2009); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, 19, PP. 2486-2497, (2001); APPEL L.J., MOORE T.J., OBARZANEK E., ET AL., A CLINICAL TRIAL OF THE EFFECTS OF DIETARY PATTERNS ON BLOOD PRESSURE, N ENGL J MED, 336, PP. 1117-1124, (1997); DICKINSON H.O., NICOLSON D.J., CAMPBELL F., ET AL., MAGNESIUM SUPPLEMENTATION FOR THE MANAGEMENT OF ESSENTIAL HYPERTENSION IN ADULTS, COCHRANE DATABASE SYST REV, 3, (2006); STAMLER J., BROWN I.J., DAVIGLUS M.L., ET AL., GLUTAMIC ACID, THE MAIN DIETARY AMINO ACID, AND BLOOD PRESSURE. THE INTERMAP STUDY (INTERNATIONAL COLLABORATIVE STUDY OF MACRONUTRIENTS, MICRONUTRIENTS AND BLOOD PRESSURE), CIRCULATION, 120, 3, PP. 221-228, (2009)","B. TRIMARCO; DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY; EMAIL: TRIMARCO@UNINA.IT","","ENGLISH","HIGH BLOOD PRESS. CARDIOVASC. PREV.","ARTICLE","ISI","2-S2.0-76249112797","HIGH BLOOD PRESS CARDIOVASC PREV","FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY","NOTREPORTED;FEDERICO II UNIVERSITY;NOTREPORTED",NA,"ROZZA F, 2009, HIGH BLOOD PRESS CARDIOVASC PREV","ROZZA F, 2009, HIGH BLOOD PRESS CARDIOVASC PREV"
"BAKER S;SAMJOO I","BAKER, STEVEN K. (7403307787); SAMJOO, IMTIAZ A. (6505980655)","A NEUROMUSCULAR APPROACH TO STATINRELATED MYOTOXICITY",2008,"CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES","35","13",36,"10.1017/S0317167100007514","DEPARTMENT OF MEDICINE, NEUROMUSCULAR DISEASE CLINIC, MCMASTER UNIVERSITY, HAMILTON, ON, CANADA, DEPARTMENT OF MEDICINE, NEUROMUSCULAR DISEASE CLINIC, MCMASTER UNIVERSITY, HAMILTON, ON L8N 3Z5, CANADA;DEPARTMENT OF MEDICINE, NEUROMUSCULAR DISEASE CLINIC, MCMASTER UNIVERSITY, HAMILTON, ON, CANADA","APPROXIMATELY 95% OF STATIN-TREATED PATIENTS TOLERATE THIS FORM OF CHOLESTEROL MANAGEMENT WITHOUT ANY ADVERSE EFFECTS. HOWEVER, GIVEN THEIR EFFICACY IN REDUCING LOW DENSITY LIPOPROTEINS AND CARDIOVASCULAR EVENTS LARGE NUMBERS OF PATIENTS ARE SELECTED FOR STATIN THERAPY. THEREFORE MUSCLE COMPLICATIONS ARE, IN FACT, QUITE COMMON. LIMITED UNDERSTANDING OF THE UNDERLYING PATHOPHYSIOLOGY HAS HAMPERED PHYSICIANS' ABILITY TO IDENTIFY PATIENTS AT RISK FOR DEVELOPING STATIN MYOTOXICITY. A GROWING NUMBER OF PUBLISHED CASE REPORTS/SERIES HAVE IMPLICATED STATINS IN THE EXACERBATION OF BOTH ACQUIRED AND GENETIC MYOPATHIES. A CLINICAL MANAGEMENT ALGORITHM IS PRESENTED WHICH OUTLINES A VARIETY OF CO-MORBIDITIES WHICH CAN POTENTIATE THE ADVERSE EFFECTS OF STATINS ON MUSCLE. IN ADDITION, A RATIONAL APPROACH TO THE SELECTION OF THOSE PATIENTS MOST LIKELY TO BENEFIT FROM SKELETAL MUSCLE BIOPSY IS DISCUSSED. ONGOING WORK WILL DEFINE THE EXTENT TO WHICH STATIN-INTOLERANT PATIENTS REPRESENT CARRIERS OF RECESSIVE METABOLIC MYOPATHIES OR PRE-SYMPTOMATIC ACQUIRED MYOPATHIES. THE EXPANDING IMPORTANCE OF PHARMACOGENOMICS WILL UNDOUBTEDLY BE REALIZED IN THE FIELD OF STATIN MYOPATHY RESEARCH WITHIN THE NEXT FEW YEARS. SUCH CRITICAL INFORMATION IS NEEDED TO ESTABLISH MORE DEFINITIVE MANAGEMENT AND DIAGNOSTIC STRATEGIES.","","ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; CLOFIBRATE; COLCHICINE; COLESTYRAMINE; COLSEVELAM; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; METHOTREXATE; MEVINOLIN; NEUROLEPTIC AGENT; NICOTINIC ACID; PLACEBO; POLICOSANOL; PRAVASTATIN; PREDNISONE; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN D; ABSENCE OF SIDE EFFECTS; ALGORITHM; AMYOTROPHIC LATERAL SCLEROSIS; ANAMNESIS; CARNITINE PALMITOYL TRANSFERASE DEFICIENCY; CHOLESTEROL METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; ELECTROMYOGRAM; ETHNICITY; FATIGUE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GLUCAN 1,4 ALPHA GLUCOSIDASE DEFICIENCY; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTHYROIDISM; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; KENNEDY DISEASE; LABORATORY TEST; LIMB WEAKNESS; MALIGNANT HYPERTHERMIA; MITOCHONDRIAL MYOPATHY; MONOTHERAPY; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE STIFFNESS; MUSCLE TIGHTNESS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYASTHENIA GRAVIS; MYOPATHY; MYOSITIS; MYOTONIA; MYOTONIC DYSTROPHY TYPE 1; NEUROMUSCULAR DISEASE; NEUROPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHARMACOGENOMICS; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; POLYMYOSITIS; PRIORITY JOURNAL; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; RIPPLING MUSCLE DISEASE; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE","","","EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); MITKA M., EXPANDING STATIN USE TO HELP MORE AT-RISK PATIENTS IS CAUSING FINANCIAL HEARTBURN, JAMA, 290, PP. 2243-2245, (2003); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N ENGL J MED, 335, PP. 1001-1009, (1996); SHEPHERD J., COBBE S.M., FORD I., ISLES C.G., LORIMER A.R., MACFARLANE P.W., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP. N ENGL J MED, 333, PP. 1301-1307, (1995); NISSEN S.E., NICHOLLS S.J., SIPAHI I., LIBBY P., RAICHLEN J.S., BALLANTYNE C.M., ET AL., EFFECT OF VERY HIGH-INTENSITY STATIN THERAPY ON REGRESSION OF CORONARY ATHEROSCLEROSIS: THE ASTEROID TRIAL, JAMA, 295, PP. 1556-1565, (2006); AMARENCO P., BOGOUSSLAVSKY J., CALLAHAN 3RD A., GOLDSTEIN L.B., HENNERICI M., RUDOLPH A.E., ET AL., HIGH-DOSE ATORVASTATIN AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK, N ENGL J MED, 355, PP. 549-559, (2006); RASHID S., SHOULD CHOLESTEROL-LOWERING MEDICATIONS BE AVAILABLE IN CANADA WITHOUT A PRESCRIPTION?, CAN J CARDIOL, 23, PP. 189-193, (2007); VLADUTIU G.D., SIMMONS Z., ISACKSON P.J., TARNOPOLSKY M., PELTIER W.L., BARBOI A.C., ET AL., GENETIC RISK FACTORS ASSOCIATED WITH LIPID-LOWERING DRUG-INDUCED MYOPATHIES, MUSCLE NERVE, 34, PP. 153-162, (2006); CORSINI A., MAGGI F.M., CATAPANO A.L., PHARMACOLOGY OF COMPETITIVE INHIBITORS OF HMG-COA REDUCTASE, PHARMACOL RES, 31, PP. 9-27, (1995); SABIA H., PRASAD P., SMITH H.T., STOLTZ R.R., ROTHENBERG P., SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AN EXTENDED-RELEASE FORMULATION OF FLUVASTATIN ADMINISTERED ONCE DAILY TO PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, J CARDIOVASC PHARMACOL, 37, PP. 502-511, (2001); CORSINI A., BELLOSTA S., BAETTA R., FUMAGALLI R., PAOLETTI R., BERNINI F., NEW INSIGHTS INTO THE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF STATINS, PHARMACOL THER, 84, PP. 413-428, (1999); KITAZAWA E., TAMURA N., IWABUCHI H., UCHIYAMA M., MURAMATSU S., TAKAHAGI H., ET AL., BIOTRANSFORMATION OF PRAVASTATIN SODIUM (I). MECHANISMS OF ENZYMIC TRANSFORMATION AND EPIMERIZATION OF AN ALLYLIC HYDROXY GROUP OF PRAVASTATIN SODIUM, BIOCHEM BIOPHYS RES COMMUN, 192, PP. 597-602, (1993); WHITE C.M., A REVIEW OF THE PHARMACOLOGIC AND PHARMACOKINETIC ASPECTS OF ROSUVASTATIN, J CLIN PHARMACOL, 42, PP. 963-970, (2002); EJENDAL K.F., HRYCYNA C.A., DIFFERENTIAL SENSITIVITIES OF THE HUMAN ATP-BINDING CASSETTE TRANSPORTERS ABCG2 AND P-GLYCOPROTEIN TO CYCLOSPORIN A, MOL PHARMACOL, 67, PP. 902-911, (2005); KAJOSAARI L.I., NIEMI M., NEUVONEN M., LAITILA J., NEUVONEN P.J., BACKMAN J.T., CYCLOSPORINE MARKEDLY RAISES THE PLASMA CONCENTRATIONS OF REPAGLINIDE, CLIN PHARMACOL THER, 78, PP. 388-399, (2005); SHITARA Y., ITOH T., SATO H., LI A.P., SUGIYAMA Y., INHIBITION OF TRANSPORTER-MEDIATED HEPATIC UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN CERIVASTATIN AND CYCLOSPORIN A, J PHARMACOL EXP THER, 304, PP. 610-616, (2003); HSIANG B., ZHU Y., WANG Z., WU Y., SASSEVILLE V., YANG W.P., ET AL., A NOVEL HUMAN HEPATIC ORGANIC ANION TRANSPORTING POLYPEPTIDE (OATP2). IDENTIFICATION OF A LIVER-SPECIFIC HUMAN ORGANIC ANION TRANSPORTING POLYPEPTIDE AND IDENTIFICATION OF RAT AND HUMAN HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR TRANSPORTERS, J BIOL CHEM, 274, PP. 37161-37168, (1999); BROWN C.D., WINDASS A.S., BLEASBY K., LAUFFART B., ROSUVASTATIN IS A HIGH AFFINITY SUBSTRATE OF HEPATIC ORGANIC ANION TRANSPORTER OATP-C ABSTR, ATHEROSCLER SUPPL, 2, (2001); JACOBSON T.A., COMPARATIVE PHARMACOKINETIC INTERACTION PROFILES OF PRAVASTATIN, SIMVASTATIN, AND ATORVASTATIN WHEN COADMINISTERED WITH CYTOCHROME P450 INHIBITORS, AM J CARDIOL, 94, PP. 1140-1146, (2004); BAKER S.K., GOODWIN S., SUR M., TARNOPOLSKY M.A., CYTOSKELETAL MYOTOXICITY FROM SIMVASTATIN AND COLCHICINE, MUSCLE NERVE, 30, PP. 799-802, (2004); ZUCCARO P., MOMBELLI G., CALABRESI L., BALDASSARRE D., PALMI I., SIRTORI C.R., TOLERABILITY OF STATINS IS NOT LINKED TO CYP450 POLYMORPHISMS, BUT REDUCED CYP2D6 METABOLISM IMPROVES CHOLESTERAEMIC RESPONSE TO SIMVASTATIN AND FLUVASTATIN, PHARMACOL RES, (2007); STAFFA J.A., CHANG J., GREEN L., CERIVASTATIN AND REPORTS OF FATAL RHABDOMYOLYSIS, N ENGL J MED, 346, PP. 539-540, (2002); CHANG J.T., STAFFA J.A., PARKS M., GREEN L., RHABDOMYOLYSIS WITH HMG-COA REDUCTASE INHIBITORS AND GEMFIBROZIL COMBINATION THERAPY, PHARMACOEPIDEMIOL DRUG SAF, 13, PP. 417-426, (2004); BACKMAN J.T., KYRKLUND C., KIVISTO K.T., WANG J.S., NEUVONEN P.J., PLASMA CONCENTRATIONS OF ACTIVE SIMVASTATIN ACID ARE INCREASED BY GEMFIBROZIL, CLIN PHARMACOL THER, 68, PP. 122-129, (2000); BERGMAN A.J., MURPHY G., BURKE J., ZHAO J.J., VALESKY R., LIU L., ET AL., SIMVASTATIN DOES NOT HAVE A CLINICALLY SIGNIFICANT PHARMACOKINETIC INTERACTION WITH FENOFIBRATE IN HUMANS, J CLIN PHARMACOL, 44, PP. 1054-1062, (2004); MARTIN P.D., DANE A.L., SCHNECK D.W., WARWICK M.J., AN OPEN-LABEL, RANDOMIZED, THREE-WAY CROSSOVER TRIAL OF THE EFFECTS OF COADMINISTRATION OF ROSUVASTATIN AND FENOFIBRATE ON THE PHARMACOKINETIC PROPERTIES OF ROSUVASTATIN AND FENOFIBRIC ACID IN HEALTHY MALE VOLUNTEERS, CLIN THER, 25, PP. 459-471, (2003); GRAHAM D.J., STAFFA J.A., SHATIN D., ANDRADE S.E., SCHECH S.D., LA GRENADE L., ET AL., INCIDENCE OF HOSPITALIZED RHABDOMYOLYSIS IN PATIENTS TREATED WITH LIPID-LOWERING DRUGS, JAMA, 292, PP. 2585-2590, (2004); JACOB S.S., JACOB S., WILLIAMS C., DEEG M.A., SIMVASTATIN, FENOFIBRATE, AND RHABDOMYOLYSIS, DIABETES CARE, 28, (2005); JONES P.H., DAVIDSON M.H., REPORTING RATE OF RHABDOMYOLYSIS WITH FENOFIBRATE + STATIN VERSUS GEMFIBROZIL + ANY STATIN, AM J CARDIOL, 95, PP. 120-122, (2005); MELLI G., CHAUDHRY V., CORNBLATH D.R., RHABDOMYOLYSIS: AN EVALUATION OF 475 HOSPITALIZED PATIENTS, MEDICINE (BALTIMORE), 84, PP. 377-385, (2005); TOKINAGA K., OEDA T., SUZUKI Y., MATSUSHIMA Y., HMG-COA REDUCTASE INHIBITORS (STATINS) MIGHT CAUSE HIGH ELEVATIONS OF CREATINE PHOSPHOKINASE (CK) IN PATIENTS WITH UNNOTICED HYPOTHYROIDISM, ENDOCR J, 53, PP. 401-405, (2006); SHEK A., FERRILL M.J., STATIN-FIBRATE COMBINATION THERAPY, ANN PHARMACOTHER, 35, PP. 908-917, (2001); CHOI J.W., CHOI H.S., THE REGULATORY EFFECTS OF THYROID HORMONE ON THE ACTIVITY OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE, ENDOCR RES, 26, PP. 1-21, (2000); HEKIMSOY Z., OKTEM I.K., SERUM CREATINE KINASE LEVELS IN OVERT AND SUBCLINICAL HYPOTHYROIDISM, ENDOCR RES, 31, PP. 171-175, (2005); KISCH E., SEGALL H.S., INTERACTION BETWEEN SIMVASTATIN AND L-THYROXINE, ANN INTERN MED, 143, (2005); SINCLAIR C., GILCHRIST J.M., HENNESSEY J.V., KANDULA M., MUSCLE CARNITINE IN HYPO- AND HYPERTHYROIDISM, MUSCLE NERVE, 32, PP. 357-359, (2005); GALLAND S., GEORGES B., LE BORGNE F., CONDUCTIER G., DIAS J.V., DEMARQUOY J., THYROID HORMONE CONTROLS CARNITINE STATUS THROUGH MODIFICATIONS OF GAMMA-BUTYROBETAINE HYDROXYLASE ACTIVITY AND GENE EXPRESSION, CELL MOL LIFE SCI, 59, PP. 540-545, (2002); THOMPSON P.D., ZMUDA J.M., DOMALIK L.J., ZIMET R.J., STAGGERS J., GUYTON J.R., LOVASTATIN INCREASES EXERCISE-INDUCED SKELETAL MUSCLE INJURY, METABOLISM, 46, PP. 1206-1210, (1997); SINZINGER H., O'GRADY J., PROFESSIONAL ATHLETES SUFFERING FROM FAMILIAL HYPERCHOLESTEROLAEMIA RARELY TOLERATE STATIN TREATMENT BECAUSE OF MUSCULAR PROBLEMS, BR J CLIN PHARMACOL, 57, PP. 525-528, (2004); CLARKSON P.M., KEARNS A.K., ROUZIER P., RUBIN R., THOMPSON P.D., SERUM CREATINE KINASE LEVELS AND RENAL FUNCTION MEASURES IN EXERTIONAL MUSCLE DAMAGE, MED SCI SPORTS EXERC, 38, PP. 623-627, (2006); GRAVES J.E., CLARKSON P.M., LITCHFIELD P., KIRWAN J.P., NORTON J.P., SERUM CREATINE KINASE ACTIVITY FOLLOWING REPEATED BOUTS OF ISOMETRIC EXERCISE WITH DIFFERENT MUSCLE GROUPS, EUR J APPL PHYSIOL OCCUP PHYSIOL, 56, PP. 657-661, (1987); CLARKSON P.M., BYRNES W.C., GILLISSON E., HARPER E., ADAPTATION TO EXERCISE-INDUCED MUSCLE DAMAGE, CLIN SCI (LOND), 73, PP. 383-386, (1987); SKENDERI K.P., KAVOURAS S.A., ANASTASIOU C.A., YIANNAKOURIS N., MATALAS A.L., EXERTIONAL RHABDOMYOLYSIS DURING A 246-KM CONTINUOUS RUNNING RACE, MED SCI SPORTS EXERC, 38, PP. 1054-1057, (2006); NEUMAYR G., PFISTER R., HOERTNAGL H., MITTERBAUER G., GETZNER W., ULMER H., ET AL., THE EFFECT OF MARATHON CYCLING ON RENAL FUNCTION, INT J SPORTS MED, 24, PP. 131-137, (2003); ARMSTRONG R.B., MUSCLE DAMAGE AND ENDURANCE EVENTS, SPORTS MED, 3, PP. 370-381, (1986); SCHWANE J.A., BUCKLEY R.T., DIPAOLO D.P., ATKINSON M.A., SHEPHERD J.R., PLASMA CREATINE KINASE RESPONSES OF 18- TO 30-YR-OLD AFRICAN-AMERICAN MEN TO ECCENTRIC EXERCISE, MED SCI SPORTS EXERC, 32, PP. 370-378, (2000); STREICHENBERGER N., MEYRONET D., FIERE V., PELLISSIER J.F., PETIOT P., FOCAL MYOSITIS ASSOCIATED WITH S-1 RADICULOPATHY: REPORT OF TWO CASES, MUSCLE NERVE, 29, PP. 443-446, (2004); LIMA A.F., EVANGELISTA T., DE CARVALHO M., INCREASED CREATINE KINASE AND SPONTANEOUS ACTIVITY ON ELECTROMYOGRAPHY, IN AMYOTROPHIC LATERAL SCLEROSIS, ELECTROMYOGR CLIN NEUROPHYSIOL, 43, PP. 189-192, (2003); LEE E., RYAN S., BIRMINGHAM B., ZALIKOWSKI J., MARCH R., AMBROSE H., ET AL., ROSUVASTATIN PHARMACOKINETICS AND PHARMACOGENETICS IN WHITE AND ASIAN SUBJECTS RESIDING IN THE SAME ENVIRONMENT, CLIN PHARMACOL THER, 78, PP. 330-341, (2005); FERNANDEZ C., DE PAULA A.M., FIGARELLA-BRANGER D., KRAHN M., GIORGI R., CHABROL B., ET AL., DIAGNOSTIC EVALUATION OF CLINICALLY NORMAL SUBJECTS WITH CHRONIC HYPERCKEMIA, NEUROLOGY, 66, PP. 1585-1587, (2006); FINSTERER J., NEUHUBER W., MITTENDORFER B., RECONSIDERING IDIOPATHIC CK-ELEVATION, INT J NEUROSCI, 114, PP. 1333-1342, (2004); PRELLE A., TANCREDI L., SCIACCO M., CHIVERI L., COMI G.P., BATTISTEL A., ET AL., RETROSPECTIVE STUDY OF A LARGE POPULATION OF PATIENTS WITH ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC RAISED SERUM CREATINE KINASE LEVELS, J NEUROL, 249, PP. 305-311, (2002); SIMMONS Z., PETERLIN B.L., BOYER P.J., TOWFIGHI J., MUSCLE BIOPSY IN THE EVALUATION OF PATIENTS WITH MODESTLY ELEVATED CREATINE KINASE LEVELS, MUSCLE NERVE, 27, PP. 242-244, (2003); CAPASSO M., DE ANGELIS M.V., DI MUZIO A., SCARCIOLLA O., PACE M., STUPPIA L., ET AL., FAMILIAL IDIOPATHIC HYPER-CK-EMIA: AN UNDERRECOGNIZED CONDITION, MUSCLE NERVE, 33, PP. 760-765, (2006); PHILLIPS P.S., HAAS R.H., BANNYKH S., HATHAWAY S., GRAY N.L., KIMURA B.J., ET AL., STATIN-ASSOCIATED MYOPATHY WITH NORMAL CREATINE KINASE LEVELS, ANN INTERN MED, 137, PP. 581-585, (2002); TROSEID M., HENRIKSEN O.A., LINDAL S., STATIN-ASSOCIATED MYOPATHY WITH NORMAL CREATINE KINASE LEVELS. CASE REPORT FROM A NORWEGIAN FAMILY, APMIS, 113, PP. 635-637, (2005); THOMPSON P.D., CLARKSON P.M., ROSENSON R.S., AN ASSESSMENT OF STATIN SAFETY BY MUSCLE EXPERTS, AM J CARDIOL, 97, (2006); BAKRIS G.L., WEIR M.R., ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-ASSOCIATED ELEVATIONS IN SERUM CREATININE: IS THIS A CAUSE FOR CONCERN?, ARCH INTERN MED, 160, PP. 685-693, (2000); CHAZERAIN P., HAYEM G., HAMZA S., BEST C., ZIZA J.M., FOUR CASES OF TENDINOPATHY IN PATIENTS ON STATIN THERAPY, JOINT BONE SPINE, 68, PP. 430-433, (2001); BEATTIE M.S., LANE N.E., HUNG Y.Y., NEVITT M.C., ASSOCIATION OF STATIN USE AND DEVELOPMENT AND PROGRESSION OF HIP OSTEOARTHRITIS IN ELDERLY WOMEN, J RHEUMATOL, 32, PP. 106-110, (2005); HARADA K., TSURUOKA S., FUJIMURA A., SHOULDER STIFFNESS: A COMMON ADVERSE EFFECT OF HMG-COA REDUCTASE INHIBITORS IN WOMEN?, INTERN MED, 40, PP. 817-818, (2001); NOEL B., PANIZZON R.G., LUPUS-LIKE SYNDROME ASSOCIATED WITH STATIN THERAPY, DERMATOLOGY, 208, PP. 276-277, (2004); GRAZIADEI I.W., OBERMOSER G.E., SEPP N.T., ERHART K.H., VOGEL W., DRUG-INDUCED LUPUS-LIKE SYNDROME ASSOCIATED WITH SEVERE AUTOIMMUNE HEPATITIS, LUPUS, 12, PP. 409-412, (2003); HANSON J., BOSSINGHAM D., LUPUS-LIKE SYNDROME ASSOCIATED WITH SIMVASTATIN, LANCET, 352, (1998); CHONG P.H., BOSKOVICH A., STEVKOVIC N., BARTT R.E., STATIN-ASSOCIATED PERIPHERAL NEUROPATHY: REVIEW OF THE LITERATURE, PHARMACOTHERAPY, 24, PP. 1194-1203, (2004); LO Y.L., LEOH T.H., LOH L.M., TAN C.E., STATIN THERAPY AND SMALL FIBRE NEUROPATHY: A SERIAL ELECTROPHYSIOLOGICAL STUDY, J NEUROL SCI, 208, PP. 105-108, (2003); VAUGHAN T.B., BELL D.S., STATIN NEUROPATHY MASQUERADING AS DIABETIC AUTOIMMUNE POLYNEUROPATHY, DIABETES CARE, 28, (2005); MCPHERSON R., FROHLICH J., FODOR G., GENEST J., CANADIAN CARDIOVASCULAR SOCIETY POSITION STATEMENT-RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE, CAN J CARDIOL, 22, PP. 913-927, (2006); GENEST J., FROHLICH J., FODOR G., MCPHERSON R., RECOMMENDATIONS FOR THE MANAGEMENT OF DYSLIPIDEMIA AND THE PREVENTION OF CARDIOVASCULAR DISEASE: SUMMARY OF THE 2003 UPDATE, CMAJ, 169, PP. 921-924, (2003); GOLOMB B.A., IMPLICATIONS OF STATIN ADVERSE EFFECTS IN THE ELDERLY, EXPERT OPIN DRUG SAF, 4, PP. 389-397, (2005); GOLOMB G., YANG E., DENENBERG J., CRIQUI M., STATIN-ASSOCIATED ADVERSE EFFECTS, CIRCULATION, 107, (2003); GARCIA-CALVO M., LISNOCK J., BULL H.G., HAWES B.E., BURNETT D.A., BRAUN M.P., ET AL., THE TARGET OF EZETIMIBE IS NIEMANN-PICK C1-LIKE 1 (NPC1L1), PROC NATL ACAD SCI USA, 102, PP. 8132-8137, (2005); ALTMANN S.W., DAVIS JR. H.R., ZHU L.J., YAO X., HOOS L.M., TETZLOFF G., ET AL., NIEMANN-PICK C1 LIKE 1 PROTEIN IS CRITICAL FOR INTESTINAL CHOLESTEROL ABSORPTION, SCIENCE, 303, PP. 1201-1204, (2004); DAVIS JR. H.R., ZHU L.J., HOOS L.M., TETZLOFF G., MAGUIRE M., LIU J., ET AL., NIEMANN-PICK C1 LIKE 1 (NPC1L1) IS THE INTESTINAL PHYTOSTEROL AND CHOLESTEROL TRANSPORTER AND A KEY MODULATOR OF WHOLE-BODY CHOLESTEROL HOMEOSTASIS, J BIOL CHEM, 279, PP. 33586-33592, (2004); DAVIDSON M.H., MACCUBBIN D., STEPANAVAGE M., STRONY J., MUSLINER T., STRIATED MUSCLE SAFETY OF EZETIMIBE/SIMVASTATIN (VYTORIN), AM J CARDIOL, 97, PP. 223-228, (2006); FUX R., MORIKE K., GUNDEL U.F., HARTMANN R., GLEITER C.H., EZETIMIBE AND STATIN-ASSOCIATED MYOPATHY, ANN INTERN MED, 140, PP. 671-672, (2004); PHILLIPS P.S., EZETIMIBE AND STATIN-ASSOCIATED MYOPATHY, ANN INTERN MED, 141, (2004); PEREZ-CALVO J., CIVEIRA-MURILLO F., CABELLO A., WORSENING MYOPATHY ASSOCIATED WITH EZETIMIBE IN A PATIENT WITH MCARDLE DISEASE, Q J MED, 98, PP. 461-462, (2005); CZIRAKY M.J., WILLEY V.J., MCKENNEY J.M., KAMAT S.A., FISHER M.D., GUYTON J.R., ET AL., STATIN SAFETY: AN ASSESSMENT USING AN ADMINISTRATIVE CLAIMS DATABASE, AM J CARDIOL, 97, (2006); FRANC S., BRUCKERT E., GIRAL P., TURPIN G., RHABDOMYOLYSIS IN PATIENTS WITH PREEXISTING MYOPATHY, TREATED WITH ANTILIPEMIC AGENTS, PRESSE MED, 26, PP. 1855-1858, (1997); PHILLIPS P., GRAY N., MCDONALD F., BLASZCAK M., WOLFSON T., SULLIVAN M., COLESEVELAM HCL IS SAFE AND EFFECTIVE IN PATIENTS WITH STATIN MYOTOXICITY, ATHEROSCLER THROMB VASC BIOL ONLINE JOURNAL, 25, (2005); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, PP. 207-219, (2005); MAS R., CASTANO G., FERNANDEZ J., GAMEZ R., ILLNAIT J., FERNANDEZ L., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA PAC J CLIN NUTR, 13, (2004); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNIBERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); DAVIDSON M.H., DUGAN L.D., BURNS J.H., BOVA J., STORY K., DRENNAN K.B., THE HYPOCHOLESTEROLEMIC EFFECTS OF BETA-GLUCAN IN OATMEAL AND OAT BRAN. A DOSE-CONTROLLED STUDY, JAMA, 265, PP. 1833-1839, (1991); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); LAAKSONEN R., JOKELAINEN K., LAAKSO J., SAHI T., HARKONEN M., TIKKANEN M.J., ET AL., THE EFFECT OF SIMVASTATIN TREATMENT ON NATURAL ANTIOXIDANTS IN LOW-DENSITY LIPOPROTEINS AND HIGH-ENERGY PHOSPHATES AND UBIQUINONE IN SKELETAL MUSCLE, AM J CARDIOL, 77, PP. 851-854, (1996); CHARIOT P., ABADIA R., AGNUS D., DANAN C., CHARPENTIER C., GHERARDI R.K., SIMVASTATIN-INDUCED RHABDOMYOLYSIS FOLLOWED BY A MELAS SYNDROME, AM J MED, 94, PP. 109-110, (1993); DE PINIEUX G., CHARIOT P., AMMI-SAID M., LOUARN F., LEJONC J.L., ASTIER A., ET AL., LIPID-LOWERING DRUGS AND MITOCHONDRIAL FUNCTION: EFFECTS OF HMG-COA REDUCTASE INHIBITORS ON SERUM UBIQUINONE AND BLOOD LACTATE/PYRUVATE RATIO, BR J CLIN PHARMACOL, 42, PP. 333-337, (1996); ELMBERGER P.G., KALEN A., LUND E., REIHNER E., ERIKSSON M., BERGLUND L., ET AL., EFFECTS OF PRAVASTATIN AND CHOLESTYRAMINE ON PRODUCTS OF THE MEVALONATE PATHWAY IN FAMILIAL HYPERCHOLESTEROLEMIA, J LIPID RES, 32, PP. 935-940, (1991); FOLKERS K., LANGSJOEN P., WILLIS R., RICHARDSON P., XIA L.J., YE C.Q., ET AL., LOVASTATIN DECREASES COENZYME Q LEVELS IN HUMANS, PROC NATL ACAD SCI USA, 87, PP. 8931-8934, (1990); WILLIS R.A., FOLKERS K., TUCKER J.L., YE C.Q., XIA L.J., TAMAGAWA H., LOVASTATIN DECREASES COENZYME Q LEVELS IN RATS, PROC NATL ACAD SCI USA, 87, PP. 8928-8930, (1990); GHIRLANDA G., ORADEI A., MANTO A., LIPPA S., UCCIOLI L., CAPUTO S., ET AL., EVIDENCE OF PLASMA COQ10-LOWERING EFFECT BY HMG-COA REDUCTASE INHIBITORS: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, J CLIN PHARMACOL, 33, PP. 226-229, (1993); LAAKSONEN R., JOKELAINEN K., SAHI T., TIKKANEN M.J., HIMBERG J.J., DECREASES IN SERUM UBIQUINONE CONCENTRATIONS DO NOT RESULT IN REDUCED LEVELS IN MUSCLE TISSUE DURING SHORT-TERM SIMVASTATIN TREATMENT IN HUMANS, CLIN PHARMACOL THER, 57, PP. 62-66, (1995); SCHAEFER W.H., LAWRENCE J.W., LOUGHLIN A.F., STOFFREGEN D.A., MIXSON L.A., DEAN D.C., ET AL., EVALUATION OF UBIQUINONE CONCENTRATION AND MITOCHONDRIAL FUNCTION RELATIVE TO CERIVASTATIN-INDUCED SKELETAL MYOPATHY IN RATS, TOXICOL APPL PHARMACOL, 194, PP. 10-23, (2004); WALRAVENS P.A., GREENE C., FRERMAN F.E., LOVASTATIN, ISOPRENES, AND MYOPATHY, LANCET, 2, PP. 1097-1098, (1989); STREY C.H., YOUNG J.M., MOLYNEUX S.L., GEORGE P.M., FLORKOWSKI C.M., SCOTT R.S., ET AL., ENDOTHELIUM-AMELIORATING EFFECTS OF STATIN THERAPY AND COENZYME Q10 REDUCTIONS IN CHRONIC HEART FAILURE, ATHEROSCLEROSIS, 179, PP. 201-206, (2005); STOCKER R., POLLICINO C., GAY C.A., NESTEL P., COLQUHOUN D., WHITING M., ET AL., NEITHER PLASMA COENZYME Q10 CONCENTRATION, NOR ITS DECLINE DURING PRAVASTATIN THERAPY, IS LINKED TO RECURRENT CARDIOVASCULAR DISEASE EVENTS: A PROSPECTIVE CASE-CONTROL STUDY FROM THE LIPID STUDY, ATHEROSCLEROSIS, 187, PP. 198-204, (2006); BERTHOLD H.K., NAINI A., DI MAURO S., HALLIKAINEN M., GYLLING H., KRONE W., ET AL., EFFECT OF EZETIMIBE AND/OR SIMVASTATIN ON COENZYME Q10 LEVELS IN PLASMA : A RANDOMISED TRIAL, DRUG SAF, 29, PP. 703-712, (2006); MABUCHI H., HIGASHIKATA T., KAWASHIRI M., KATSUDA S., MIZUNO M., NOHARA A., ET AL., REDUCTION OF SERUM UBIQUINOL-10 AND UBIQUINONE-10 LEVELS BY ATORVASTATIN IN HYPERCHOLESTEROLEMIC PATIENTS, J ATHEROSCLER THROMB, 12, PP. 111-119, (2005); LAMPERTI C., NAINI A.B., LUCCHINI V., PRELLE A., BRESOLIN N., MOGGIO M., ET AL., MUSCLE COENZYME Q10 LEVEL IN STATIN-RELATED MYOPATHY, ARCH NEUROL, 62, PP. 1709-1712, (2005); COLQUHOUN D.M., JACKSON R., WALTERS M., HICKS B.J., GOLDSMITH J., YOUNG P., ET AL., EFFECTS OF SIMVASTATIN ON BLOOD LIPIDS, VITAMIN E, COENZYME Q10 LEVELS AND LEFT VENTRICULAR FUNCTION IN HUMANS, EUR J CLIN INVEST, 35, PP. 251-258, (2005); MABUCHI H., HABA T., TATAMI R., MIYAMOTO S., SAKAI Y., WAKASUGI T., ET AL., EFFECTS OF AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ON SERUM LIPOPROTEINS AND UBIQUINONE-10 LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA. 1981, ATHEROSCLER SUPPL, 5, PP. 51-55, (2004); RUNDEK T., NAINI A., SACCO R., COATES K., DIMAURO S., ATORVASTATIN DECREASES THE COENZYME Q10 LEVEL IN THE BLOOD OF PATIENTS AT RISK FOR CARDIOVASCULAR DISEASE AND STROKE, ARCH NEUROL, 61, PP. 889-892, (2004); PAIVA H., THELEN K.M., VAN COSTER R., SMET J., DE PAEPE B., MATTILA K.M., ET AL., HIGH-DOSE STATINS AND SKELETAL MUSCLE METABOLISM IN HUMANS: A RANDOMIZED, CONTROLLED TRIAL, CLIN PHARMACOL THER, 78, PP. 60-68, (2005); KELLY P., VASO S., GELATO M., MCNURLAN M., LAWSON W., COENZYME Q10 IMPROVES MYOPATHIC PAIN IN STATIN TREATED PATIENTS ABSTRACT, J AM COLL CARDIOL, 45, 3 SUPPL. A, (2005); INUI D., FUKUTA Y., OTO J., MIKI T., SUZUE A., KAWAHITO S., ET AL., SIX CASES OF RHABDOMYOLYSIS INDUCED BY DEHYDRATION, MASUI, 54, PP. 1024-1026, (2005); KODAMA K., IKEDA K., KAWAMURA S., OYAMA T., FUJITA S., KOBAYASHI Y., A CASE OF SEVERE DEHYDRATION WITH MARKED RHABDOMYOLYSIS, JPN J MED, 24, PP. 150-154, (1985); BAKER S.K., TARNOPOLSKY M.A., SPORADIC RIPPLING MUSCLE DISEASE UNMASKED BY SIMVASTATIN, MUSCLE NERVE, 34, 4, PP. 387-390, (2006); KRIVOSIC-HORBER R., DEPRET T., WAGNER J.M., MAURAGE C.A., MALIGNANT HYPERTHERMIA SUSCEPTIBILITY REVEALED BY INCREASED SERUM CREATINE KINASE CONCENTRATIONS DURING STATIN TREATMENT, EUR J ANAESTHESIOL, 21, PP. 572-574, (2004); PARMAR B., FRANCIS P.J., RAGGE N.K., STATINS, FIBRATES, AND OCULAR MYASTHENIA, LANCET, 360, (2002); CARTWRIGHT M.S., JEFFERY D.R., NUSS G.R., DONOFRIO P.D., STATIN-ASSOCIATED EXACERBATION OF MYASTHENIA GRAVIS, NEUROLOGY, 63, (2004); GUIS S., BENDAHAN D., KOZAK-RIBBENS G., FIGARELLA-BRANGER D., MATTEI J.P., PELLISSIER J.F., ET AL., RHABDOMYOLYSIS AND MYALGIA ASSOCIATED WITH ANTICHOLESTEROLEMIC TREATMENT AS POTENTIAL SIGNS OF MALIGNANT HYPERTHERMIA SUSCEPTIBILITY, ARTHRITIS RHEUM, 49, PP. 237-238, (2003); DELGADO-LOPEZ F., BAUTISTA-LORITE J., VILLAMIL-FERNANDEZ F., WORSENING FOR USING STATIN IN CARNITINE PALMITYOL TRANSFERASE DEFICIENCY MYOPATHY, REV NEUROL, 38, (2004); LIVINGSTONE C., AL RIYAMI S., WILKINS P., FERNS G.A., MCARDLE'S DISEASE DIAGNOSED FOLLOWING STATIN-INDUCED MYOSITIS, ANN CLIN BIOCHEM, 41, PP. 338-340, (2004); BAKER S.K., VLADUTIU G.D., TARNOPOLSKY M.A., MCARDLE DISEASE UNMASKED BY STATIN EXPOSURE, MUSCLE NERVE, (2003); VASCONCELOS O.M., CAMPBELL W.W., DERMATOMYOSITIS-LIKE SYNDROME AND HMG-COA REDUCTASE INHIBITOR (STATIN) INTAKE, MUSCLE NERVE, 30, PP. 803-807, (2004); HUYNH T., CORDATO D., YANG F., CHOY T., JOHNSTONE K., BAGNALL F., ET AL., HMG COA REDUCTASE-INHIBITOR-RELATED MYOPATHY AND THE INFLUENCE OF DRUG INTERACTIONS, INTERN MED J, 32, PP. 486-490, (2002); GIORDANO N., SENESI M., MATTII G., BATTISTI E., VILLANOVA M., GENNARI C., POLYMYOSITIS ASSOCIATED WITH SIMVASTATIN, LANCET, 349, PP. 1600-1601, (1997); HILL C., ZEITZ C., KIRKHAM B., DERMATOMYOSITIS WITH LUNG INVOLVEMENT IN A PATIENT TREATED WITH SIMVASTATIN, AUST N Z J MED, 25, PP. 745-746, (1995); KHATTAK F.H., MORRIS I.M., BRANFORD W.A., SIMVASTATIN-ASSOCIATED DERMATOMYOSITIS, BR J RHEUMATOL, 33, (1994); RODRIGUEZ-GARCIA J.L., SERRANO COMMINO M., LOVASTATIN-ASSOCIATED DERMATOMYOSITIS, POSTGRAD MED J, 72, (1996); VOERMANS N.C., LAMMENS M., WEVERS R.A., HERMUS A.R., VAN ENGELEN B.G., STATIN-DISCLOSED ACID MALTASE DEFICIENCY, J INTERN MED, 258, PP. 196-197, (2005); TSIVGOULIS G., SPENGOS K., KARANDREAS N., PANAS M., KLADI A., MANTA P., PRESYMPTOMATIC NEUROMUSCULAR DISORDERS DISCLOSED FOLLOWING STATIN TREATMENT, ARCH INTERN MED, 166, PP. 1519-1524, (2006); EDWARDS I.R., STAR K., KIURU A., STATINS, NEUROMUSCULAR DEGENERATIVE DISEASE AND AN AMYOTROPHIC LATERAL SCLEROSIS-LIKE SYNDROME: AN ANALYSIS OF INDIVIDUAL CASE SAFETY REPORTS FROM VIGIBASE, DRUG SAF, PP. 515-525, (2007); DALAKAS M.C., THERAPEUTIC APPROACHES IN PATIENTS WITH INFLAMMATORY MYOPATHIES, SEMIN NEUROL, 23, PP. 199-206, (2003); DALAKAS M.C., MOLECULAR PATHOGENESIS OF INFLAMMATORY MYOPATHIES AND FUTURE THERAPEUTIC STRATEGIES, SUPPL CLIN NEUROPHYSIOL, 57, PP. 288-303, (2004); DALAKAS M.C., INFLAMMATORY DISORDERS OF MUSCLE: PROGRESS IN POLYMYOSITIS, DERMATOMYOSITIS AND INCLUSION BODY MYOSITIS, CURR OPIN NEUROL, 17, PP. 561-567, (2004); DALAKAS M.C., UPDATE ON THE MOLECULAR PATHOGENESIS OF INFLAMMATORY MYOPATHIES, AUTOIMMUN REV, 3, SUPPL. 1, (2004); GRIGGS R.C., MENDELL J.R., BROOKE M.H., FENICHEL G.M., MILLER J.P., PROVINCE M., ET AL., CLINICAL INVESTIGATION IN DUCHENNE DYSTROPHY: V. USE OF CREATINE KINASE AND PYRUVATE KINASE IN CARRIER DETECTION, MUSCLE NERVE, 8, PP. 60-67, (1985); YOUSSEF S., STUVE O., PATARROYO J.C., RUIZ P.J., RADOSEVICH J.L., HUR E.M., ET AL., THE HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, PROMOTES A TH2 BIAS AND REVERSES PARALYSIS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNE DISEASE, NATURE, 420, PP. 78-84, (2002); KRENDEL D.A., SANDERS D.B., MASSEY J.M., SINGLE FIBER ELECTROMYOGRAPHY IN CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, MUSCLE NERVE, 10, PP. 299-302, (1987); DAI Z., LUO X., XIE H., PENG H.B., THE ACTIN-DRIVEN MOVEMENT AND FORMATION OF ACETYLCHOLINE RECEPTOR CLUSTERS, J CELL BIOL, 150, PP. 1321-1334, (2000); BLOCH R.J., ACETYLCHOLINE RECEPTOR CLUSTERING IN RAT MYOTUBES: REQUIREMENT FOR CA2+ AND EFFECTS OF DRUGS WHICH DEPOLYMERIZE MICROTUBULES, J NEUROSCI, 3, PP. 2670-2680, (1983); BIFULCO M., LAEZZA C., ALOJ S.M., GARBI C., MEVALONATE CONTROLS CYTOSKELETON ORGANIZATION AND CELL MORPHOLOGY IN THYROID EPITHELIAL CELLS, J CELL PHYSIOL, 155, PP. 340-348, (1993); THOMAS J.E., LEE N., THOMPSON P.D., STATINS PROVOKING MELAS SYNDROME. A CASE REPORT, EUR NEUROL, 57, PP. 232-235, (2007); ESTORNELL E., FATO R., CASTELLUCCIO C., CAVAZZONI M., PARENTI CASTELLI G., LENAZ G., SATURATION KINETICS OF COENZYME Q IN NADH AND SUCCINATE OXIDATION IN BEEF HEART MITOCHONDRIA, FEBS LETT, 311, PP. 107-109, (1992); OH J., BAN M.R., MISKIE B.A., POLLEX R.L., HEGELE R.A., GENETIC DETERMINANTS OF STATIN INTOLERANCE, LIPIDS HEALTH DIS, 6, (2007); BHUIYAN J., SECCOMBE D.W., THE EFFECTS OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITION ON TISSUE LEVELS OF CARNITINE AND CARNITINE ACYLTRANSFERASE ACTIVITY IN THE RABBIT, LIPIDS, 31, PP. 867-870, (1996); KAUFMANN P., TOROK M., ZAHNO A., WALDHAUSER K.M., BRECHT K., KRAHENBUHL S., TOXICITY OF STATINS ON RAT SKELETAL MUSCLE MITOCHONDRIA, CELL MOL LIFE SCI, 63, PP. 2415-2425, (2006); SIRVENT P., MERCIER J., VASSORT G., LACAMPAGNE A., SIMVASTATIN TRIGGERS MITOCHONDRIA-INDUCED CA2+ SIGNALING ALTERATION IN SKELETAL MUSCLE, BIOCHEM BIOPHYS RES COMMUN, 329, PP. 1067-1075, (2005); GUIS S., FIGARELLA-BRANGER D., MATTEI J.P., NICOLI F., LE FUR Y., KOZAK-RIBBENS G., ET AL., IN VIVO AND IN VITRO CHARACTERIZATION OF SKELETAL MUSCLE METABOLISM IN PATIENTS WITH STATIN-INDUCED ADVERSE EFFECTS, ARTHRITIS RHEUM, 55, PP. 551-557, (2006); LAMB G.D., RIPPLING MUSCLE DISEASE MAY BE CAUSED BY ""SILENT"" ACTION POTENTIALS IN THE TUBULAR SYSTEM OF SKELETAL MUSCLE FIBERS, MUSCLE NERVE, 31, PP. 652-658, (2005); MINETTI C., SOTGIA F., BRUNO C., SCARTEZZINI P., BRODA P., BADO M., ET AL., MUTATIONS IN THE CAVEOLIN-3 GENE CAUSE AUTOSOMAL DOMINANT LIMB-GIRDLE MUSCULAR DYSTROPHY, NAT GENET, 18, PP. 365-368, (1998); POL A., MARTIN S., FERNANDEZ M.A., INGELMO-TORRES M., FERGUSON C., ENRICH C., ET AL., CHOLESTEROL AND FATTY ACIDS REGULATE DYNAMIC CAVEOLIN TRAFFICKING THROUGH THE GOLGI COMPLEX AND BETWEEN THE CELL SURFACE AND LIPID BODIES, MOL BIOL CELL, 16, PP. 2091-2105, (2005); WEIS M., HEESCHEN C., GLASSFORD A.J., COOKE J.P., STATINS HAVE BIPHASIC EFFECTS ON ANGIOGENESIS, CIRCULATION, 105, PP. 739-745, (2002); TSAO C.Y., MENDELL J.R., COMBINED PARTIAL DEFICIENCIES OF CARNITINE PALMITOYLTRANSFERASE II AND MITOCHONDRIAL COMPLEX I PRESENTING AS INCREASED SERUM CREATINE KINASE LEVEL, J CHILD NEUROL, 17, PP. 304-306, (2002); AGUILERA I., GARCIA-LOZANO J.R., MUNOZ A., ARENAS J., CAMPOS Y., CHINCHON I., ET AL., MITOCHONDRIAL DNA POINT MUTATION IN THE COI GENE IN A PATIENT WITH MCARDLE'S DISEASE, J NEUROL SCI, 192, PP. 81-84, (2001); BAKER S.K., TARNOPOLSKY M.A., STATIN MYOPATHIES: PATHOPHYSIOLOGIC AND CLINICAL PERSPECTIVES, CLIN INVEST MED, 24, PP. 258-272, (2001); MAZZUCA M., LESAGE F., LAZDUNSKI M., ION CHANNELS AND EPILEPSY, EPILEPTIC DISORD, 8, SUPPL. 1, PP. 1-16, (2006); SHERER Y., LIVNEH A., LEVY Y., SHOENFELD Y., LANGEVITZ P., DERMATOMYOSITIS AND POLYMYOSITIS ASSOCIATED WITH THE ANTIPHOSPHOLIPID SYNDROME-A NOVEL OVERLAP SYNDROME, LUPUS, 9, PP. 42-46, (2000); SONODA Y., GOTOW T., KURIYAMA M., NAKAHARA K., ARIMURA K., OSAME M., ELECTRICAL MYOTONIA OF RABBIT SKELETAL MUSCLES BY HMG-COA REDUCTASE INHIBITORS, MUSCLE NERVE, 17, PP. 891-897, (1994); PIERNO S., DE LUCA A., TRICARICO D., FERRANNINI E., CONTE T., D'ALO G., ET AL., EXPERIMENTAL EVALUATION OF THE EFFECTS OF PRAVASTATIN ON ELECTROPHYSIOLOGICAL PARAMETERS OF RAT SKELETAL MUSCLE, PHARMACOL TOXICOL, 71, PP. 325-329, (1992); PIERNO S., DE LUCA A., TRICARICO D., ROSELLI A., NATUZZI F., FERRANNINI E., ET AL., POTENTIAL RISK OF MYOPATHY BY HMG-COA REDUCTASE INHIBITORS: A COMPARISON OF PRAVASTATIN AND SIMVASTATIN EFFECTS ON MEMBRANE ELECTRICAL PROPERTIES OF RAT SKELETAL MUSCLE FIBERS, J PHARMACOL EXP THER, 275, PP. 1490-1496, (1995); NAKAHARA K., KURIYAMA M., SONODA Y., YOSHIDOME H., NAKAGAWA H., FUJIYAMA J., ET AL., MYOPATHY INDUCED BY HMG-COA REDUCTASE INHIBITORS IN RABBITS: A PATHOLOGICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL STUDY, TOXICOL APPL PHARMACOL, 152, PP. 99-106, (1998); RIGGS J.E., SCHOCHET JR. S.S., MYOTONIA ASSOCIATED WITH SARCOIDOSIS: MARKED EXACERBATION WITH PRAVASTATIN, CLIN NEUROPHARMACOL, 22, PP. 180-181, (1999); CAMPBELL W.W., STATIN MYOPATHY: THE ICEBERG OR ITS TIP?, MUSCLE NERVE, 34, PP. 387-390, (2006); DIRKS A.J., JONES K.M., STATIN-INDUCED APOPTOSIS AND SKELETAL MYOPATHY, AM J PHYSIOL CELL PHYSIOL, 291, (2006); HOLTZMAN C.W., WIGGINS B.S., SPINLER S.A., ROLE OF P-GLYCOPROTEIN IN STATIN DRUG INTERACTIONS, PHARMACOTHERAPY, 26, PP. 1601-1607, (2006); BELLOSTA S., PAOLETTI R., CORSINI A., SAFETY OF STATINS: FOCUS ON CLINICAL PHARMACOKINETICS AND DRUG INTERACTIONS, CIRCULATION, 109, (2004); REIJNEVELD J.C., NOTERMANS N.C., LINSSEN W.H., BAR P.R., WOKKE J.H., HYPER-CK-AEMIA REVISITED, NEUROMUSCUL DISORD, 11, PP. 163-164, (2001); FEE D.B., SO Y.T., BARRAZA C., FIGUEROA K.P., PULST S.M., PHENOTYPIC VARIABILITY ASSOCIATED WITH ARG26GLN MUTATION IN CAVEOLIN3, MUSCLE NERVE, 30, PP. 375-378, (2004); GALASSI G., ROWLAND L.P., HAYS A.P., HOPKINS L.C., DIMAURO S., HIGH SERUM LEVELS OF CREATINE KINASE: ASYMPTOMATIC PRELUDE TO DISTAL MYOPATHY, MUSCLE NERVE, 10, PP. 346-350, (1987); MERLINI L., SABATELLI P., COLUMBARO M., BONIFAZI E., PISANI V., MASSA R., ET AL., HYPER-CK-EMIA AS THE SOLE MANIFESTATION OF MYOTONIC DYSTROPHY TYPE 2, MUSCLE NERVE, 31, PP. 764-767, (2005); NEVINS M.A., SARAN M., BRIGHT M., LYON L.J., PITFALLS IN INTERPRETING SERUM CREATINE PHOSPHOKINASE ACTIVITY, JAMA, 224, PP. 1382-1387, (1973); MONSIEURS K.G., VAN BROECKHOVEN C., MARTIN J.J., VAN HOOF V.O., HEYTENS L., GLY341ARG MUTATION INDICATING MALIGNANT HYPERTHERMIA SUSCEPTIBILITY: SPECIFIC CAUSE OF CHRONICALLY ELEVATED SERUM CREATINE KINASE ACTIVITY, J NEUROL SCI, 154, PP. 62-65, (1998); SUNOHARA N., TAKAGI A., NONAKA I., SUGITA H., SATOYOSHI E., IDIOPATHIC HYPERCKEMIA, NEUROLOGY, 34, PP. 544-547, (1984); WEGLINSKI M.R., WEDEL D.J., ENGEL A.G., MALIGNANT HYPERTHERMIA TESTING IN PATIENTS WITH PERSISTENTLY INCREASED SERUM CREATINE KINASE LEVELS, ANESTH ANALG, 84, PP. 1038-1041, (1997); BREWSTER L.M., DE VISSER M., PERSISTENT HYPERCKEMIA: FOURTEEN PATIENTS STUDIED IN RETROSPECT, ACTA NEUROL SCAND, 77, PP. 60-63, (1988); SHANE E., MCCLANE K.A., OLARTE M.R., BILEZIKIAN J.P., HYPOPARATHYROIDISM AND ELEVATED MUSCLE ENZYMES, NEUROLOGY, 30, PP. 192-195, (1980); OSBORN L.A., ROSSUM A., STANDEFER J., JACKSON J., SKIPPER B., BEESON C., ET AL., EVALUATION OF CK AND CK-MB IN ALCOHOL ABUSE SUBJECTS WITH RECENT HEAVY CONSUMPTION, CARDIOLOGY, 86, PP. 130-134, (1995); PRELLE A., RIGOLETTO C., MOGGIO M., SCIACCO M., COMI G.P., CISCATO P., ET AL., ASYMPTOMATIC FAMILIAL HYPERCKEMIA ASSOCIATED WITH DESMIN ACCUMULATION IN SKELETAL MUSCLE, J NEUROL SCI, 140, PP. 132-136, (1996)","","CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES","ENGLISH","CAN. J. NEUROL. SCI.","REVIEW","ISI","2-S2.0-42049083130","CAN J NEUROL SCI",NA,"NOTREPORTED",NA,"BAKER SK, 2008, CAN J NEUROL SCI","BAKER SK, 2008, CAN J NEUROL SCI"
"HOUSTON M;FAZIO S;CHILTON F;WISE D;JONES K;BARRINGER T;BRAMLET D","HOUSTON, MARK C. (7103236355); FAZIO, SERGIO (7103305966); CHILTON, FLOYD H. (7005377008); WISE, DAN E. (55421684500); JONES, KATHRYN B. (55471855200); BARRINGER, THOMAS A. (6603697078); BRAMLET, DEAN A. (6603533270)","NONPHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA",2009,"PROGRESS IN CARDIOVASCULAR DISEASES","52","33",71,"10.1016/j.pcad.2009.02.002","VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES, WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC, UNITED STATES, PRESBYTERIAN CENTER FOR PREVENTIVE CARDIOLOGY, CHARLOTTE, NC, UNITED STATES, UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC, UNITED STATES, DUKE UNIVERSITY SCHOOL OF MEDICINE, DURHAM, NC, UNITED STATES","THE FOUNDATION FOR THE TREATMENT OF DYSLIPIDEMIA IS OPTIMAL NUTRITION, DIET, AND IDEAL BODY WEIGHT COMBINED WITH AN AEROBIC AND RESISTANCE EXERCISE PROGRAM IN ALL PATIENTS. DEPENDING ON DEGREE OF CV RISK, NUTRITIONAL SUPPLEMENTS OR DRUG THERAPY IS THE NEXT STEP. FOR THE LOW- TO MODERATE-RISK PATIENT, NUTRITIONAL SUPPLEMENTS ARE THE SECOND CORNERSTONE OF THERAPY. IN THE HIGH- AND VERY HIGH-RISK PATIENTS, PHARMACOLOGIC AGENTS ARE NEEDED AND SHOULD BE USED IN CONJUNCTION WITH DIET, NUTRITION, EXERCISE, WEIGHT LOSS, AND SCIENTIFICALLY PROVEN NUTRITIONAL SUPPLEMENTS. CLINICAL STUDIES SUPPORT THE ABILITY TO REDUCE SERUM CHOLESTEROL, LDL, AND TGS BY 30% TO 40% WITH THE COMBINATION OF DIET, LIFESTYLE MODIFICATIONS, AND NUTRITIONAL SUPPLEMENTS IN MOST PATIENTS. DETAILS OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM, PORTFOLIO, DIETARY APPROACHES TO STOP HYPERTENSION (DASH), AND MEDITERRANEAN DIETS ARE DISCUSSED IN DETAIL IN THIS ARTICLE, AS WELL AS THE TYPE AND DURATION OF EXERCISE REQUIRED TO ACHIEVE SIGNIFICANT AND CLINICALLY RELEVANT REDUCTIONS IN SERUM LIPIDS. NUTRITIONAL SUPPLEMENTS PROVIDE ADDITIONAL THERAPEUTIC INTERVENTIONS FOR LIPID-LOWERING. THOSE SUPPLEMENTS THAT HAVE THE BEST CLINICAL DATA IN HUMANS FOR IMPROVING THE LIPID PROFILE INCLUDE NIACIN, Ω-3 FAS, RICE BRAN OIL, Γ-/Δ-TOCOTRIENOLS, PANTETHINE, RED YEAST RICE, PLANT STEROLS, SOLUBLE FIBERS, PROBIOTICS, SOY, AND MIXED NUTS WITH MUFA AND PUFA SUCH AS ALMONDS. AGENTS THAT DO NOT APPEAR TO HAVE SIGNIFICANT EFFECTS ON LIPIDS BASED ON RECENT RANDOMIZED CONTROL CLINICAL TRIAL (RCCT) ARE GUGGULIPID, POLICOSANOL, GARLIC, IHN, GINSENG, FENJUSEEK, COENZYME Q-10, AND CHROMIUM. ADDITIONAL STUDIES ARE NEEDED TO EVALUATE THE ROLE OF GREEN TEA (EGCG) AND CURCUMIN (TURMERIC) AS EFFECTIVE LIPID-LOWERING AGENTS IN HUMANS. IN ADDITION TO CHOLESTEROL AND LDL REDUCTIONS, SEVERAL NUTRITIONAL SUPPLEMENTS HAVE OTHER ANTIATHEROGENIC EFFECTS. REDUCED OXIDATION OF LDL-C IS DOCUMENTED WITH NIACIN, EGCG, PANTETHINE, RESVERATROL, GARLIC, POLICOSANOL, RICE BRAN OIL (RBO), CO-Q-10, Γ-/Δ-TOCOTRIENOLS, VITAMIN E, MUFA, POLYPHENOLS, AND CURCUMIN. NIACIN, Ω-3 FAS, PLANT STEROLS, AND PSYLLIUM CONVERT TYPE B DENSE LDL TO THE LARGER TYPE A LDL, WHICH IS NOT ATHEROGENIC. INTESTINAL CHOLESTEROL ABSORPTION IS REDUCED WITH PLANT STEROLS, SOY, EGCG, SESAME AND FIBER. INHIBITION OF THE HMG-COA REDUCTASE IS SEEN IN THE PRESENCE OF PANTETHINE, Γ-/Δ-TOCOTRIENOLS, RED YEAST RICE, AND SESAME. TRIGLYCERIDES ARE ESPECIALLY LOWERED WITH NIACIN, Ω-3 FAS, AND PANTETHINE AND, TO A LESSER EXTENT, WITH RED YEAST RICE AND SOY. HIGH-DENSITY LIPOPROTEIN IS INCREASED IN SIZE FROM HDL-3 TO HDL-2 BY NIACIN, Ω-3 FAS, PANTETHINE, AND SOY. THE BEST CLINICAL DATA FOR REDUCTION IN CV EVENTS WITH NUTRITIONAL SUPPLEMENTS IS WITH Ω-3 FAS, ALPHA LINOLENIC ACID (ALA), AND TO A LESSER EXTENT, WITH NIACIN AND FIBER. THIS INCLUDES CHD, MI, AND OVERALL CV EVENTS FOR EACH OF THESE, AS WELL AS REDUCTIONS IN CVA AND SUDDEN DEATH FOR Ω-3 FAS AND DECREASE IN PAD WITH FIBER. © 2009 ELSEVIER INC. ALL RIGHTS RESERVED.","","ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; AQUACULTURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET; DYSLIPIDEMIAS; EICOSANOIDS; EXERCISE; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; FISHES; HERBAL MEDICINE; HUMANS; LIFE STYLE; NIACIN; NUTRITION THERAPY; OXYGEN CONSUMPTION; SEAFOOD; SOYBEAN PROTEINS; TOCOTRIENOLS; ALPHA TOCOTRIENOL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; CHROMIUM; CURCUMIN; EPIGALLOCATECHIN GALLATE; FENOFIBRATE; GALACTOMANNAN; GEMFIBROZIL; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSANOID; INOSITOL NICOTINATE; LIPID; METHYLMERCURY; NICOTINIC ACID; OMEGA 3 FATTY ACID; ORGANIC COMPOUND; PANTETHINE; PHYTOSTEROL; PLACEBO; PLANT MEDICINAL PRODUCT; POLICOSANOL; POLYBROMINATED BIPHENYL; PROBIOTIC AGENT; SESAME SEED OIL; UBIDECARENONE; UNINDEXED DRUG; AEROBIC EXERCISE; ARTICLE; BODY COMPOSITION; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MEMBRANE FLUIDITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; FAT INTAKE; FENUGREEK; FISH; FOOD AVAILABILITY; FOOD COMPOSITION; FOOD CONTAMINATION; FOOD SAFETY; FRUIT; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GINSENG; GLYCEMIC CONTROL; HEART PROTECTION; HICCUP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LIPOGENESIS; MENTAL DEVELOPMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL VALUE; OBESITY; PATIENT COMPLIANCE; PATIENT SAFETY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PROTEIN INTAKE; RISK REDUCTION; SESAME; SOCIAL SUPPORT; STRESS MANAGEMENT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEGETABLE; WEIGHT REDUCTION","CENTER OF NATURAL PRODUCTS; DALMER LABORATORIES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CNRS","POLICOSANOL IS THE COMMONLY USED NAME FOR A MIXTURE OF LONG-CHAIN ALIPHATIC ALCOHOLS ORIGINALLY DERIVED FROM PURIFIED SUGARCANE WAX. 317 THE PURPORTED ABILITY OF THIS DRUG TO LOWER CHOLESTEROL WITHOUT SIGNIFICANT SIDE EFFECTS HAS MADE IT ONE OF THE FASTEST GROWING OVER-THE-COUNTER SUPPLEMENTS IN THE UNITED STATES. 318 POLICOSANOL HAS BEEN USED IN CUBA SINCE 1991, AND UNTIL 2004, VIRTUALLY ALL OF THE PUBLISHED MEDICAL LITERATURE ON POLICOSANOL HAD BEEN AUTHORIZED BY ONE RESEARCH GROUP BASED IN HAVANA. 319-333 FUNDING FOR THE CUBAN STUDIES WAS PROVIDED BY DALMER LABORATORIES, A COMMERCIAL ENTERPRISE FOUNDED BY THE CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, LA HABANA, CUBA, TO MARKET POLICOSANOL. THEIR STUDIES HAVE UNIFORMLY REPORTED THAT SUGARCANE-DERIVED POLICOSANOL HAS SIMILAR EFFICACY TO STATINS IN ITS ABILITY TO LOWER TOTAL AND LDL-C, AND EVEN GREATER EFFICACY IN RAISING HDL-C WITHOUT ANY SIGNIFICANT SIDE EFFECTS. 334 THE CHOLESTEROL-LOWERING RESPONSE HAS BEEN REPORTED TO BE DOSE-DEPENDANT WITHIN THE RANGE OF 2 TO 40 MG. 335 THE UNDERLYING MECHANISM OF ACTION OF POLICOSANOL TO LOWER CHOLESTEROL HAS NOT BEEN DEFINITIVELY ELUCIDATED BUT IS PROPOSED TO INCLUDE INHIBITION OF CHOLESTEROL SYNTHESIS BY DOWN-REGULATING THE CELLULAR EXPRESSION OF HMG-COA REDUCTASE. 336,337 ","NATIONAL CENTER FOR HEALTH STATISTICS, AMERICAN HEART ASSOCIATION, FACTS ABOUT CARDIOVASCULAR DISEASE, CIRCULATION, 85, (1992); KANNEL W.B., CASTELLI W.D., GORDON T., ET AL., SERUM CHOLESTEROL, LIPOPROTEINS, AND RISK OF CORONARY ARTERY DISEASE. THE FRAMINGHAM STUDY, ANN INTERN MED, 74, PP. 1-12, (1971); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); BYINGTON R.P., JUKEMA J.W., SALONEN J.T., ET AL., REDUCTION IN CARDIOVASCULAR EVENTS DURING PRAVASTATIN THERAPY: POOLED ANALYSIS OF CLINICAL EVENTS OF THE PRAVASTATIN ATHEROSCLEROSIS INTERVENTION PROGRAM, CIRCULATION, 92, PP. 2419-2425, (1995); KUSHI L.H., LEW R.A., STARE F.J., ET AL., DIET AND 20-YEAR MORTALITY FROM CORONARY HEART DISEASE: THE IRELAND-BOSTON DIET-HEART STUDY, N ENGL J MED, 312, PP. 811-818, (1985); BURR M.L., FEHILY A.M., GILBERT J.F., ET AL., EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART), LANCET, 2, PP. 757-761, (1989); SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION. EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), CIRCULATION, 106, PP. 3143-3421, (2002); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, PP. 2001-2007, (1998); PISCHKE C.R., WEIDNER G., ELLIOTT-ELLER M., ET AL., COMPARISON OF CORONARY RISK FACTORS AND QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTS WITH VERSUS WITHOUT DIABETES MELLITUS, AM J CARDIOL, 97, PP. 1267-1273, (2006); PI-SUNYER X., BLACKBURN G., BRANCATI F.L., ET AL., REDUCTION IN WEIGHT AND CARDIOVASCULAR DISEASE RISK FACTORS IN INDIVIDUALS WITH TYPE 2 DIABETES: ONE-YEAR RESULTS OF THE LOOK AHEAD TRIAL, DIABETES CARE, 30, PP. 1374-1383, (2007); YANCY JR. W.S., OLSEN M.K., GUYTON J.R., ET AL., A LOW-CARBOHYDRATE, KETOGENIC DIET VERSUS A LOW-FAT DIET TO TREAT OBESITY AND HYPERLIPIDEMIA: A RANDOMIZED, CONTROLLED TRIAL, ANN INTERN MED, 140, PP. 769-777, (2004); CROMWELL W.C., OTVOS J.D., LOW-DENSITY LIPOPROTEIN PARTICLE NUMBER AND RISK FOR CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 6, PP. 381-387, (2004); BLAKE G.J., OTVOS J.D., RIFAI N., ET AL., LOW-DENSITY LIPOPROTEIN PARTICLE CONCENTRATION AND SIZE AS DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AS PREDICTORS OF CARDIOVASCULAR DISEASE IN WOMEN, CIRCULATION, 106, PP. 1930-1937, (2002); GARVEY W.T., KWON S., ZHENG D., ET AL., EFFECTS OF INSULIN RESISTANCE AND TYPE 2 DIABETES ON LIPOPROTEIN SUBCLASS PARTICLE SIZE AND CONCENTRATION DETERMINED BY NUCLEAR MAGNETIC RESONANCE, DIABETES, 52, PP. 453-462, (2003); KULLER L., ARNOLD A., TRACY R., ET AL., NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY OF LIPOPROTEINS AND RISK OF CORONARY HEART DISEASE IN THE CARDIOVASCULAR HEALTH STUDY, ARTERIOSCLER THROMB VASC BIOL, 22, PP. 1175-1180, (2002); WESTMAN E.C., YANCY JR. W.S., OLSEN M.K., ET AL., EFFECT OF A LOW-CARBOHYDRATE, KETOGENIC DIET PROGRAM COMPARED TO A LOW-FAT DIET ON FASTING LIPOPROTEIN SUBCLASSES, INT J CARDIOL, 110, PP. 212-216, (2006); FOSTER G.D., WYATT H.R., HILL J.O., ET AL., A RANDOMIZED TRIAL OF A LOW-CARBOHYDRATE DIET FOR OBESITY, N ENGL J MED, 348, PP. 2082-2090, (2003); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., DIRECT COMPARISON OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS WITH A STATIN IN HYPERCHOLESTEROLEMIC PARTICIPANTS, AM J CLIN NUTR, 81, PP. 380-387, (2005); KEYS A., PARLIN R.W., SERUM CHOLESTEROL RESPONSE TO CHANGES IN DIETARY LIPIDS, AM J CLIN NUTR, 19, PP. 175-181, (1966); HEGSTED D.M., MCGANDY R.B., MYERS M.L., ET AL., QUANTITATIVE EFFECTS OF DIETARY FAT ON SERUM CHOLESTEROL IN MAN, AM J CLIN NUTR, 17, PP. 281-295, (1965); YU S., DERR J., ETHERTON T.D., ET AL., PLASMA CHOLESTEROL-PREDICTIVE EQUATIONS DEMONSTRATE THAT STEARIC ACID IS NEUTRAL AND MONOUNSATURATED FATTY ACIDS ARE HYPOCHOLESTEROLEMIC, AM J CLIN NUTR, 61, PP. 1129-1139, (1995); SALMERON J., HU F.B., MANSON J.E., ET AL., DIETARY FAT INTAKE AND RISK OF TYPE 2 DIABETES IN WOMEN, AM J CLIN NUTR, 73, PP. 1019-1026, (2001); MENSINK R.P., KATAN M.B., EFFECT OF DIETARY TRANS FATTY ACIDS ON HIGH-DENSITY AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN HEALTHY SUBJECTS, N ENGL J MED, 323, PP. 439-445, (1990); KATAN M.B., ZOCK P.L., MENSINK R.P., TRANS FATTY ACIDS AND THEIR EFFECTS ON LIPOPROTEINS IN HUMANS, ANNU REV NUTR, 15, PP. 473-493, (1995); NESTEL P., NOAKES M., BELLING B., ET AL., PLASMA LIPOPROTEIN LIPID AND LPA CHANGES WITH SUBSTITUTION OF ELAIDIC ACID FOR OLEIC ACID IN THE DIET, J LIPID RES, 33, PP. 1029-1036, (1992); DE ROOS N.M., BOTS M.L., SIEBELINK E., ET AL., FLOW-MEDIATED VASODILATION IS NOT IMPAIRED WHEN HDL-CHOLESTEROL IS LOWERED BY SUBSTITUTING CARBOHYDRATES FOR MONOUNSATURATED FAT, BR J NUTR, 86, PP. 181-188, (2001); DE LORGERIL M., SALEN P., MARTIN J.L., ET AL., MEDITERRANEAN DIET, TRADITIONAL RISK FACTORS, AND THE RATE OF CARDIOVASCULAR COMPLICATIONS AFTER MYOCARDIAL INFARCTION: FINAL REPORT OF THE LYON DIET HEART STUDY, CIRCULATION, 99, PP. 779-785, (1999); THIES F., GARRY J.M., YAQOOB P., ET AL., ASSOCIATION OF N-3 POLYUNSATURATED FATTY ACIDS WITH STABILITY OF ATHEROSCLEROTIC PLAQUES: A RANDOMISED CONTROLLED TRIAL, LANCET, 361, PP. 477-485, (2003); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); JOSHIPURA K.J., HU F.B., MANSON J.E., ET AL., THE EFFECT OF FRUIT AND VEGETABLE INTAKE ON RISK FOR CORONARY HEART DISEASE, ANN INTERN MED, 134, PP. 1106-1114, (2001); JACOBS JR. D.R., MEYER K.A., KUSHI L.H., ET AL., WHOLE-GRAIN INTAKE MAY REDUCE THE RISK OF ISCHEMIC HEART DISEASE DEATH IN POSTMENOPAUSAL WOMEN: THE IOWA WOMEN'S HEALTH STUDY, AM J CLIN NUTR, 68, PP. 248-257, (1998); LIU S., STAMPFER M.J., HU F.B., ET AL., WHOLE-GRAIN CONSUMPTION AND RISK OF CORONARY HEART DISEASE: RESULTS FROM THE NURSES' HEALTH STUDY, AM J CLIN NUTR, 70, PP. 412-419, (1999); JENKINS D.J., WOLEVER T.M., TAYLOR R.H., ET AL., GLYCEMIC INDEX OF FOODS: A PHYSIOLOGICAL BASIS FOR CARBOHYDRATE EXCHANGE, AM J CLIN NUTR, 34, PP. 362-366, (1981); JENKINS D.J., KENDALL C.W., AUGUSTIN M.J., ET AL., GLYCEMIC INDEX: OVERVIEW OF IMPLICATIONS IN HEALTH AND DISEASE, AM J CLIN NUTR, 76, (2002); HU F.B., STAMPFER M.J., MANSON J.E., ET AL., FREQUENT NUT CONSUMPTION AND RISK OF CORONARY HEART DISEASE IN WOMEN: PROSPECTIVE COHORT STUDY, BMJ, 317, PP. 1341-1345, (1998); ALBERT C.M., GAZIANO J.M., WILLETT W.C., ET AL., NUT CONSUMPTION AND DECREASED RISK OF SUDDEN CARDIAC DEATH IN THE PHYSICIANS' HEALTH STUDY, ARCH INTERN MED, 162, PP. 1382-1387, (2002); KRIS-ETHERTON P.M., ZHAO G., BINKOSKI A.E., ET AL., THE EFFECTS OF NUTS ON CORONARY HEART DISEASE RISK, NUTR REV, 59, PP. 103-111, (2001); SINGH R.B., RASTOGI S.S., VERMA R., ET AL., RANDOMISED CONTROLLED TRIAL OF CARDIOPROTECTIVE DIET IN PATIENTS WITH RECENT ACUTE MYOCARDIAL INFARCTION: RESULTS OF ONE YEAR FOLLOW UP, BMJ, 304, PP. 1015-1019, (1992); MARCHIOLI R., BARZI F., BOMBA E., ET AL., EARLY PROTECTION AGAINST SUDDEN DEATH BY N-3 POLYUNSATURATED FATTY ACIDS AFTER MYOCARDIAL INFARCTION: TIME-COURSE ANALYSIS OF THE RESULTS OF THE GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO (GISSI)-PREVENZIONE, CIRCULATION, 105, PP. 1897-1903, (2002); MARON B.J., CHAITMAN B.R., ACKERMAN M.J., ET AL., RECOMMENDATIONS FOR PHYSICAL ACTIVITY AND RECREATIONAL SPORTS PARTICIPATION FOR YOUNG PATIENTS WITH GENETIC CARDIOVASCULAR DISEASES, CIRCULATION, 109, PP. 2807-2816, (2004); AMERICAN HEART ASSOCIATION, HEART DISEASE AND STROKE STATISTICS-2005; FRANCO O.H., DE LAET C., PEETERS A., ET AL., EFFECTS OF PHYSICAL ACTIVITY ON LIFE EXPECTANCY WITH CARDIOVASCULAR DISEASE, ARCH INTERN MED, 165, PP. 2355-2360, (2005); KLEM M.L., WING R.R., MCGUIRE M.T., ET AL., A DESCRIPTIVE STUDY OF INDIVIDUALS SUCCESSFUL AT LONG-TERM MAINTENANCE OF SUBSTANTIAL WEIGHT LOSS, AM J CLIN NUTR, 66, PP. 239-246, (1997); KNOWLER W.C., BARRETT-CONNOR E., FOWLER S.E., ET AL., REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR METFORMIN, N ENGL J MED, 346, PP. 393-403, (2002); JOLLIFFE J.A., REES K., TAYLOR R.S., ET AL., EXERCISE-BASED REHABILITATION FOR CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, (2001); FAGARD R.H., EXERCISE CHARACTERISTICS AND THE BLOOD PRESSURE RESPONSE TO DYNAMIC PHYSICAL TRAINING, MED SCI SPORTS EXERC, 33, (2001); LEON A.S., SANCHEZ O.A., RESPONSE OF BLOOD LIPIDS TO EXERCISE TRAINING ALONE OR COMBINED WITH DIETARY INTERVENTION, MED SCI SPORTS EXERC, 33, (2001); SLENTZ C.A., DUSCHA B.D., JOHNSON J.L., ET AL., EFFECTS OF THE AMOUNT OF EXERCISE ON BODY WEIGHT, BODY COMPOSITION, AND MEASURES OF CENTRAL OBESITY: STRRIDE-A RANDOMIZED CONTROLLED STUDY, ARCH INTERN MED, 164, PP. 31-39, (2004); HASKELL W.L., LEE I.M., PATE R.R., ET AL., PHYSICAL ACTIVITY AND PUBLIC HEALTH: UPDATED RECOMMENDATION FOR ADULTS FROM THE AMERICAN COLLEGE OF SPORTS MEDICINE AND THE AMERICAN HEART ASSOCIATION, CIRCULATION, 116, PP. 1081-1093, (2007); SWAIN D.P., FRANKLIN B.A., COMPARISON OF CARDIOPROTECTIVE BENEFITS OF VIGOROUS VERSUS MODERATE INTENSITY AEROBIC EXERCISE, AM J CARDIOL, 97, PP. 141-147, (2006); NELSON M.E., REJESKI W.J., BLAIR S.N., ET AL., PHYSICAL ACTIVITY AND PUBLIC HEALTH IN OLDER ADULTS: RECOMMENDATION FROM THE AMERICAN COLLEGE OF SPORTS MEDICINE AND THE AMERICAN HEART ASSOCIATION, CIRCULATION, 116, PP. 1094-1105, (2007); SERVINOVA E., KAGAN V., HAN D., ET AL., FREE RADICAL RECYCLING AND INTRAMEMBRANE MOBILITY IN THE ANTIOXIDANT PROPERTIES OF ALPHA-TOCOPHEROL AND ALPHA-TOCOTRIENOL, FREE RADIC BIOL MED, 10, PP. 263-275, (1991); KHOR H.T., CHIENG D.Y., ONG K.K., TOCOTRIENOLS INHIBIT LIVER HMG-COA REDUCTASE ACTIVITY IN THE GUINEA PIG, NUTR RES, 15, PP. 537-544, (1995); QURESHI A.A., PEARCE B.C., NOR R.M., ET AL., DIETARY ALPHA-TOCOPHEROL ATTENUATES THE IMPACT OF GAMMA-TOCOTRIENOL ON 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY IN CHICKENS, J NUTR, 126, PP. 389-394, (1996); QURESHI A.A., BURGER W.C., PETERSON D.M., ET AL., THE STRUCTURE OF AN INHIBITOR OF CHOLESTEROL BIOSYNTHESIS ISOLATED FROM BARLEY, J BIOL CHEM, 261, PP. 10544-10550, (1986); HOSOMI A., ARITA M., SATO Y., ET AL., AFFINITY FOR ALPHA-TOCOPHEROL TRANSFER PROTEIN AS A DETERMINANT OF THE BIOLOGICAL ACTIVITIES OF VITAMIN E ANALOGS, FEBS LETT, 409, PP. 105-108, (1997); SONG B.L., DEBOSE-BOYD R.A., INSIG-DEPENDENT UBIQUITINATION AND DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE STIMULATED BY DELTA- AND GAMMA-TOCOTRIENOLS, J BIOL CHEM, 281, PP. 25054-25061, (2006); O'BYRNE D., GRUNDY S., PACKER L., ET AL., STUDIES OF LDL OXIDATION FOLLOWING ALPHA-, GAMMA-, OR DELTA-TOCOTRIENYL ACETATE SUPPLEMENTATION OF HYPERCHOLESTEROLEMIC HUMANS, FREE RADIC BIOL MED, 29, PP. 834-845, (2000); QURESHI A.A., SAMI S.A., SALSER W.A., ET AL., DOSE-DEPENDENT SUPPRESSION OF SERUM CHOLESTEROL BY TOCOTRIENOL-RICH FRACTION (TRF25) OF RICE BRAN IN HYPERCHOLESTEROLEMIC HUMANS, ATHEROSCLEROSIS, 161, PP. 199-207, (2002); PARKER R.A., PEARCE B.C., CLARK R.W., ET AL., TOCOTRIENOLS REGULATE CHOLESTEROL PRODUCTION IN MAMMALIAN CELLS BY POST-TRANSCRIPTIONAL SUPPRESSION OF 3-HYDROXY-3-METHYL-GLUTARYL-COENZYME A REDUCTASE, J BIOL CHEM, 268, PP. 11230-11238, (1993); CORRELL C.C., NG L., EDWARDS P.A., IDENTIFICATION OF FARNESOL AS THE NON-STEROL DERIVATIVE OF MEVALONIC ACID REQUIRED FOR THE ACCELERATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, J BIOL CHEM, 269, PP. 17390-17393, (1994); PEARCE B.C., PARKER R.A., DEASON M.E., ET AL., HYPOCHOLESTEROLEMIC ACTIVITY OF SYNTHETIC AND NATURAL TOCOTRIENOLS, J MED CHEM, 35, PP. 3595-3606, (1992); PEARCE B.C., PARKER R.A., DEASON M.E., ET AL., INHIBITORS OF CHOLESTEROL BIOSYNTHESIS. 2. HYPOCHOLESTEROLEMIC AND ANTIOXIDANT ACTIVITIES OF BENZOPYRAN AND TETRAHYDRONAPHTHALENE ANALOGUES OF THE TOCOTRIENOLS, J MED CHEM, 37, PP. 526-541, (1994); QURESHI A.A., PETERSON D.M., ELSON C.E., ET AL., STIMULATION OF AVIAN CHOLESTEROL METABOLISM BY ALPHA-TOCOPHEROL, NUTR REP INT, 40, PP. 993-1001, (1989); YAP S.P., YUEN K.H., WONG J.W., PHARMACOKINETICS AND BIOAVAILABILITY OF ALPHA-, GAMMA-, AND DELTA-TOCOTRIENOLS UNDER DIFFERENT FOOD STATUS, J PHARM PHARMACOL, 53, PP. 67-71, (2001); YU S.G., THOMAS A.M., GAPOR A., ET AL., DOSE-RESPONSE IMPACT OF VARIOUS TOCOTRIENOLS ON SERUM LIPID PARAMETERS IN 5-WEEK-OLD FEMALE CHICKENS, LIPIDS, 41, PP. 453-461, (2006); MINHAJUDDIN M., BEG Z.H., IQBAL J., HYPOLIPIDEMIC AND ANTIOXIDANT PROPERTIES OF TOCOTRIENOL RICH FRACTION ISOLATED FROM RICE BRAN OIL IN EXPERIMENTALLY INDUCED HYPERLIPIDEMIC RATS, FOOD CHEM TOXICOL, 43, PP. 747-753, (2005); IQBAL J., MINHAJUDDIN M., BEG Z.H., SUPPRESSION OF 7,12-DIMETHYLBENZALPHAANTHRACENE-INDUCED CARCINOGENESIS AND HYPERCHOLESTEROLAEMIA IN RATS BY TOCOTRIENOL-RICH FRACTION ISOLATED FROM RICE BRAN OIL, EUR J CANCER PREV, 12, PP. 447-453, (2003); QURESHI A.A., PETERSON D.M., HASLER-RAPACZ J.O., ET AL., NOVEL TOCOTRIENOLS OF RICE BRAN SUPPRESS CHOLESTEROGENESIS IN HEREDITARY HYPERCHOLESTEROLEMIC SWINE, J NUTR, 131, PP. 223-230, (2001); TEOH M.K., CHONG J.M., MOHAMED J., ET AL., PROTECTION BY TOCOTRIENOLS AGAINST HYPERCHOLESTEROLAEMIA AND ATHEROMA, MED J MALAYSIA, 49, PP. 255-262, (1994); QURESHI A.A., QURESHI N., HASLER-RAPACZ J.O., ET AL., DIETARY TOCOTRIENOLS REDUCE CONCENTRATIONS OF PLASMA CHOLESTEROL, APOLIPOPROTEIN B, THROMBOXANE B2, AND PLATELET FACTOR 4 IN PIGS WITH INHERITED HYPERLIPIDEMIAS, AM J CLIN NUTR, 53, (1991); QURESHI A.A., QURESHI N., WRIGHT J.J., ET AL., LOWERING OF SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC HUMANS BY TOCOTRIENOLS (PALMVITEE), AM J CLIN NUTR, 53, PP. 1021-1026, (1991); QURESHI A.A., BRADLOW B.A., BRACE L., ET AL., RESPONSE OF HYPERCHOLESTEROLEMIC SUBJECTS TO ADMINISTRATION OF TOCOTRIENOLS, LIPIDS, 30, PP. 1171-1177, (1995); TOMEO A.C., GELLER M., WATKINS T.R., ET AL., ANTIOXIDANT EFFECTS OF TOCOTRIENOLS IN PATIENTS WITH HYPERLIPIDEMIA AND CAROTID STENOSIS, LIPIDS, 30, PP. 1179-1183, (1995); MENSINK R.P., VAN HOUWELINGEN A.C., KROMHOUT D., ET AL., A VITAMIN E CONCENTRATE RICH IN TOCOTRIENOLS HAD NO EFFECT ON SERUM LIPIDS, LIPOPROTEINS, OR PLATELET FUNCTION IN MEN WITH MILDLY ELEVATED SERUM LIPID CONCENTRATIONS, AM J CLIN NUTR, 69, PP. 213-219, (1999); MUSTAD V.A., SMITH C.A., RUEY P.P., ET AL., SUPPLEMENTATION WITH 3 COMPOSITIONALLY DIFFERENT TOCOTRIENOL SUPPLEMENTS DOES NOT IMPROVE CARDIOVASCULAR DISEASE RISK FACTORS IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 76, PP. 1237-1243, (2002); BALIARSINGH S., BEG Z.H., AHMAD J., THE THERAPEUTIC IMPACTS OF TOCOTRIENOLS IN TYPE 2 DIABETIC PATIENTS WITH HYPERLIPIDEMIA, ATHEROSCLEROSIS, 182, PP. 367-374, (2005); WAHLQVIST M.L., KRIVOKUCA-BOGETIC Z., LO C.S., ET AL., DIFFERENTIAL SERUM RESPONSES OF TOCOPHEROLS AND TOCOTRIENOLS DURING VITAMIN SUPPLEMENTATION IN HYPERCHOLESTEROLAEMIC INDIVIDUALS WITHOUT CHANGE IN CORONARY RISK FACTORS, NUTR RES, 12, (1992); WILSON T.A., NICOLOSI R.J., WOOLFREY B., ET AL., RICE BRAN OIL AND ORYZANOL REDUCE PLASMA LIPID AND LIPOPROTEIN CHOLESTEROL CONCENTRATIONS AND AORTIC CHOLESTEROL ESTER ACCUMULATION TO A GREAT EXTENT THAN FERULIC ACID IN HYPERCHOLESTEROLEMIC HAMSTERS, J NUTR BIOCHEM, 18, PP. 105-112, (2007); KURIYAN R., GOPINATH N., VAZ M., ET AL., USE OF RICE BRAN OIL IN PATIENTS WITH HYPERLIPIDAEMIA, NATL MED J INDIA, 18, PP. 292-296, (2005); AUSMAN L.M., RONG N., NICOLOSI R.J., HYPERCHOLESTEROLEMIC EFFECT OF PHYSICALLY REFINED RICE BRAN OIL: STUDIES OF CHOLESTEROL METABOLISM AND EARLY ATHEROSCLEROSIS IN HYPERCHOLESTEROLEMIC HAMSTERS, J NUTR BIOCHEM, 16, PP. 521-529, (2005); MOST M.M., TULLEY R., MORALES S., ET AL., RICE BRAN OIL, NOT FIBER, LOWERS CHOLESTEROL IN HUMANS, AM J CLIN NUTR, 81, PP. 64-68, (2005); NAGAO K., SATO M., TAKENAKA M., ET AL., FEEDING UNSAPONIFIABLE COMPOUNDS FROM RICE BRAN OIL DOES NOT ALTER HEPATIC MRNA ABUNDANCE FOR CHOLESTEROL METABOLISM-RELATED PROTEINS IN HYPERCHOLESTEROLEMIC RATS, BIOSCI BIOTECHNOL BIOCHEM, 65, PP. 371-377, (2001); GERHARDT A.L., GALLO N.B., FULL-FAT RICE BRAN AND OAT BRAN SIMILARLY REDUCE HYPERCHOLESTEROLEMIA IN HUMANS, J NUTR, 128, PP. 865-869, (1998); LICHTENSTEIN A.H., AUSMAN L.M., CARRASCO W., ET AL., RICE BRAN OIL CONSUMPTION AND PLASMA LIPID LEVELS IN MODERATELY HYPERCHOLESTEROLEMIC HUMANS, ARTERIOSCLER THROMB, 14, PP. 549-556, (1994); CICERO A.F., GADDI A., RICE BRAN OIL AND GAMMA-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIAS AND OTHER CONDITIONS, PHYTOTHER RES, 15, PP. 277-289, (2001); RUSSELL K.R., MORRISON E.Y., RAGOOBIRSINGH D., THE EFFECT OF ANNATTO ON INSULIN BINDING PROPERTIES IN THE DOG, PHYTOTHER RES, 19, PP. 433-436, (2005); JUNIOR A.C., ASAD L.M., OLIVEIRA E.B., ET AL., ANTIGENOTOXIC AND ANTIMUTAGENIC POTENTIAL OF AN ANNATTO PIGMENT (NORBIXIN) AGAINST OXIDATIVE STRESS, GENET MOL RES, 31, PP. 94-99, (2005); MCRAE M.P., TREATMENT OF HYPERLIPOPROTEINEMIA WITH PANTETHINE: A REVIEW AND ANALYSIS OF EFFICACY AND TOLERABILITY, NUTR RES, 25, PP. 319-333, (2005); KEENAN J., TREATMENT OF PATIENTS WITH LIPID DISORDERS IN THE PRIMARY CARE SETTING: NEW TREATMENT GUIDELINES AND THEIR IMPLICATIONS, SOUTH MED J, 96, PP. 266-275, (2003); KELLY G., PANTETHINE: A REVIEW OF ITS BIOCHEMISTRY AND THERAPEUTIC APPLICATIONS, ALTERN MED REV, 2, PP. 365-377, (1997); WITTWER C., GRAVES C., PETERSON M., ET AL., PANTETHINE LIPOMODULATION: EVIDENCE FOR CYSTEAMINE MEDIATION IN VITRO AND IN VIVO, ATHEROSCLEROSIS, 68, PP. 41-49, (1987); CIGHETTI G., DELPUPPO M., PARONI R., ET AL., PANTETHINE INHIBITS CHOLESTEROL AND FATTY ACID SYNTHESIS AND STIMULATES CARBON DIOXIDE FORMATION IN ISOLATED RAT HEPATOCYTES, J LIPID RES, 28, PP. 152-161, (1987); RANGANATHAN S., JACKSON R., HARMONY J., EFFECT OF PANTETHINE ON THE BIOSYNTHESIS OF CHOLESTEROL IN HUMAN SKIN FIBROBLASTS, ATHEROSCLEROSIS, 44, PP. 261-273, (1982); TOMIKAWA M., NAKAYASU T., TAWARA K., ET AL., EFFECT OF PANTETHINE ON LIPOPROTEIN PROFILES AND HDL SUBFRACTIONS IN EXPERIMENTALLY HYPERCHOLESTEROLEMIC RABBITS, ATHEROSCLEROSIS, 41, PP. 267-277, (1982); SHINOMIYA M., MATSUOKA N., SHIRAI K., ET AL., EFFECT OF PANTETHINE ON CHOLESTEROL ESTER METABOLISM IN RAT ARTERIAL WALL, ATHEROSCLEROSIS, 36, PP. 75-80, (1980); CARRARA P., MATTURRI L., GALBUSSERA M., ET AL., PANTETHINE REDUCES PLASMA CHOLESTEROL AND THE SEVERITY OF ARTERIAL LESIONS IN EXPERIMENTAL HYPERCHOLESTEROLEMIC RABBITS, ATHEROSCLEROSIS, 53, PP. 255-264, (1984); BON G., CAZZOLATO G., ZAGO S., ET AL., EFFECTS OF PANTETHINE ON IN-VITRO PEROXIDATION OF LOW DENSITY LIPOPROTEINS, ATHEROSCLEROSIS, 57, PP. 99-106, (1985); CORONEL F., TORNERO F., TORRENTE J., ET AL., TREATMENT OF HYPERLIPIDEMIA IN DIABETIC PATIENTS ON DIALYSIS WITH A PHYSIOLOGICAL SUBSTANCE, AM J NEPHROL, 11, PP. 32-36, (1991); TONUTTI L., TABOGA C., NOACCO C., CONFRONTO DELL'EFFICACIA DI PANTETINA, ACIPIMOX E BEZAFIBATO SUI LIPIDI PLASMATICI ED INDICE DI RISCHIO CARDIOVASCOLARE IN DIABETICI DISLIPIDEMICI, MINERVA MED, 82, PP. 657-663, (1991); BINAGHI P., CELLINA G., LOCICERO G., ET AL., EVALUATION OF THE HYPOCHOLESTEROLEMIC ACTIVITY OF PANTETHINE IN PERIMENOPAUSAL WOMEN, MINERVA MED, 81, PP. 475-479, (1990); LU Z., A DOUBLE-BLIND CLINICAL TRIAL: THE EFFECTS OF PANTETHINE ON SERUM LIPIDS IN PATIENTS WITH HYPERLIPIDEMIA, ZHONGHUA XIN XUE GUAN BING ZA ZHI, 17, PP. 221-223, (1989); ETO M., WATANABE K., CHONAN N., ET AL., LOWERING EFFECT OF PANTETHINE ON PLASMA BETA-THROMBOGLOBULIN AND LIPIDS IN DIABETES MELLITUS, ARTERY, 15, PP. 1-12, (1987); PRISCO D., ROGASI P., MATUCCI M., ET AL., EFFECT OF ORAL TREATMENT WITH PANTETHINE ON PLATELET AND PLASMA PHOSPHOLIPIDS IN TYPE IIA HYPERLIPOPROTEINEMIA, J VASC DIS, 38, PP. 241-247, (1987); BELLANI F., COLNAGO R., MEREGALLI M., ET AL., TREATMENT OF HYPERLIPIDEMIAS COMPLICATED BY CARDIOVASCULAR DISEASE IN THE ELDERLY: RESULTS OF AN OPEN SHORT-TERM STUDY WITH PANTETHINE, CURR THER RES, 40, PP. 912-916, (1986); BERTOLINI S., DONATI C., ELICIO N., ET AL., LIPOPROTEIN CHANGES INDUCED BY PANTETHINE IN HYPERLIPOPROTEINEMIC PATIENTS: ADULTS AND CHILDREN, INT J CLIN PHARMACOL THER TOXICOL, 24, PP. 630-637, (1986); DONATI C., BARBI G., CAIRO G., ET AL., PANTETHINE IMPROVES THE LIPID ABNORMALITIES OF CHRONIC HEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTER CLINICAL TRIAL, CLIN NEPHROL, 25, PP. 70-74, (1986); ARSENIO L., BODRIA P., MAGNATI G., ET AL., EFFECTIVENESS OF LONG-TERM TREATMENT WITH PANTETHINE IN PATIENTS WITH DYSLIPIDEMIA, CLIN THER, 8, PP. 537-545, (1986); GIANNINI S., FORTI N., DIRIENZO F., ET AL., EFEITOS DA PANTETINA SOBRELIPIDES SANGINEOS, ARQ BRAS CARDIOL, 46, PP. 283-289, (1986); BERGESIO F., CIUTI R., INNOCENTI D., ET AL., IMPIEGO DELLA PANTETINA NELLA DISLIPIDEMIA DELL'UREMICO CRONICO IN TRATTAMENTO DIALITICO, G CLIN MED, 66, PP. 433-440, (1985); GENSINI G.F., PRISCO D., ROGASI P.G., ET AL., CHANGES IN FATTY ACID COMPOSITION OF THE SINGLE PLATELET PHOSPHOLIPIDS INDUCED BY PANTETHINE TREATMENT, INT J CLIN PHARMACOL RES, 5, PP. 309-318, (1985); CATTIN L., DACOL P., FONDA M., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA WITH PANTETHINE AND FENOFIBRATE: AN OPEN RANDOMIZED STUDY ON 43 SUBJECTS, CURR THER RES, 38, PP. 386-395, (1985); POSTIGLIONE A., RUBBA P., CICERANO U., ET AL., PANTETHINE VERSUS FENOFIBRATE IN THE TREATMENT OF TYPE II HYPERLIPOPROTEINEMIA, MONOGR ATHEROSCLER, 13, PP. 145-148, (1985); SEGHIERI G., MAFFUCCI G., TOSCANO G., ET AL., EFFETTO DELLA TERAPIA CON PANTETINA IN UREMICI CRONICI EMODIALIZZATI CON IPERLIPOPROTEINEMIA DI TIPO IV, G CLIN MED, 66, PP. 187-192, (1985); ARSENIO L., CARONNA S., LATEANA M., ET AL., IPERLIPIDEMIA DIABETE ED ATEROSCLEROSI: EFFICACIA DEL TRATTAMENTO CON PANTETINA, ACTA BIOMED ATENEO PARMENSE, 55, PP. 25-42, (1984); BOSELLO O., COMINACINI L., GARRBIN U, ET AL. CHANGES IN THE VERY LOW DENSITY LIPOPROTEIN DISTRIBUTION OF APOLIPOPROTEINS C-III2, CIII1, C-III0, C-II AND APOLIPOPROTEIN E AFTER PANTETHINE ADMINISTRATION, ACTA THER, 10, PP. 421-430, (1984); DA COL P., CATTIN L., FONDA M., ET AL., PANTETHINE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED DOUBLE-BLIND TRIAL VERSUS TIADENOL, CURR THER RES, 36, PP. 314-321, (1984); GADDI A., DESCOVICH G.C., NOSEDA G., ET AL., CONTROLLED EVALUATION OF PANTETHINE, A NATURAL HYPOLIPIDEMIC COMPOUND, IN PATIENTS WITH DIFFERENT FORMS OF HYPERLIPOPROTEINEMIA, ATHEROSCLEROSIS, 50, PP. 73-83, (1984); MICCOLI R., MARCHETTI P., SAMPIETRO T., ET AL., EFFECTS OF PANTETHINE ON LIPIDS AND APOLIPOPROTEINS IN HYPERCHOLESTEROLEMIC DIABETIC AND NON-DIABETIC PATIENTS, CURR THER RES, 36, PP. 545-549, (1984); MAIOLI M., PACIFICO A., CHERCHI G., EFFECT OF PANTETHINE ON THE SUBFRACTIONS OF HDL IN DYSLIPIDEMIC PATIENTS, CURR THER RES, 35, PP. 307-311, (1984); RANIERI G., CHIARAPPA R., BALESTRAZZI M., ET AL., EFFECT OF PANTETHINE ON LIPIDS AND LIPOPROTEINS IN MAN, ACTA THER, 10, PP. 219-227, (1984); GALEONE F., SCALABRINO A., GIUNTOLI F., ET AL., THE LIPID LOWERING EFFECT OF PANTETHINE IN HYPERLIPIDEMIC PATIENTS: A CLINICAL INVESTIGATION, CURR THER RES, 34, PP. 383-390, (1983); MURAI A., MIYAHARA T., TANAKA T., ET AL., THE EFFECTS OF PANTETHINE ON LIPID AND LIPOPROTEIN ABNORMALITIES IN SURVIVORS OF CEREBRAL INFARCTION, ARTERY, 12, PP. 234-243, (1983); AVOGARO P., BITTOLO G., FUSELLO M., EFFECT OF PANTETHINE ON LIPIDS, LIPOPROTEINS AND APOLIPOPROTEINS IN MAN, CURR THER RES, 33, PP. 488-493, (1983); MAGGI G., DONATI C., CRISCUOLI G., PANTETHINE: A PHYSIOLOGICAL LIPOMODULATING AGENT IN THE TREATMENT OF HYPERLIPIDEMIA, CURR THER RES, 32, PP. 380-386, (1982); HIRAMATSU K., NOZAKI H., ARIMORI S., INFLUENCE OF PANTETHINE ON PLATELET VOLUME, MICROVISCOSITY, LIPID COMPOSITION AND FUNCTIONS IN DIABETES MELLITUS WITH HYPERLIPIDEMIA, TOKAI J EXP CLIN MED, 6, PP. 49-57, (1981); DYERBERG J., BANG H.O., HJORNE N., PLASMA CHOLESTEROL CONCENTRATION IN CAUCASIAN DANES AND GREENLAND WEST-COAST ESKIMOS, DAN MED BULL, 24, PP. 52-55, (1977); BANG H.O., DYERBERG J., HJOORNE N., THE COMPOSITION OF FOOD CONSUMED BY GREENLAND ESKIMOS, ACTA MED SCAND, 200, PP. 69-73, (1976); BANG H.O., DYERBERG J., PLASMA LIPIDS AND LIPOPROTEINS IN GREENLANDIC WEST COAST ESKIMOS, ACTA MED SCAND, 192, PP. 85-94, (1972); BANG H.O., DYERBERG J., NIELSEN A.B., PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS, LANCET, 1, PP. 1143-1145, (1971); DYERBERG J., BANG H.O., HJORNE N., FATTY ACID COMPOSITION OF THE PLASMA LIPIDS IN GREENLAND ESKIMOS, AM J CLIN NUTR, 28, PP. 958-966, (1975); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO, LANCET, 354, PP. 447-455, (1999); HU F.B., BRONNER L., WILLETT W.C., ET AL., FISH AND OMEGA-3 FATTY ACID INTAKE AND RISK OF CORONARY HEART DISEASE IN WOMEN, JAMA, 287, PP. 1815-1821, (2002); ALBERT C.M., CAMPOS H., STAMPFER M.J., ET AL., BLOOD LEVELS OF LONG-CHAIN N-3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH, N ENGL J MED, 346, PP. 1113-1118, (2002); HE K., SONG Y., DAVIGLUS M.L., ET AL., ACCUMULATED EVIDENCE ON FISH CONSUMPTION AND CORONARY HEART DISEASE MORTALITY: A META-ANALYSIS OF COHORT STUDIES, CIRCULATION, 109, PP. 2705-2711, (2004); KROMHOUT D., BOSSCHIETER E.B., DE LEZENNE C.C., THE INVERSE RELATION BETWEEN FISH CONSUMPTION AND 20-YEAR MORTALITY FROM CORONARY HEART DISEASE, N ENGL J MED, 312, PP. 1205-1209, (1985); OOMEN C.M., FESKENS E.J., RASANEN L., ET AL., FISH CONSUMPTION AND CORONARY HEART DISEASE MORTALITY IN FINLAND, ITALY, AND THE NETHERLANDS, AM J EPIDEMIOL, 151, PP. 999-1006, (2000); ISO H., KOBAYASHI M., ISHIHARA J., ET AL., INTAKE OF FISH AND N3 FATTY ACIDS AND RISK OF CORONARY HEART DISEASE AMONG JAPANESE: THE JAPAN PUBLIC HEALTH CENTER-BASED (JPHC) STUDY COHORT I, CIRCULATION, 113, PP. 195-202, (2006); DOLECEK T.A., GRANDITIS G., DIETARY POLYUNSATURATED FATTY ACIDS AND MORTALITY IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT), WORLD REV NUTR DIET, 66, PP. 205-216, (1991); KROMHOUT D., FESKENS E.J., BOWLES C.H., THE PROTECTIVE EFFECT OF A SMALL AMOUNT OF FISH ON CORONARY HEART DISEASE MORTALITY IN AN ELDERLY POPULATION, INT J EPIDEMIOL, 24, PP. 340-345, (1995); DAVIGLUS M.L., STAMLER J., ORENCIA A.J., ET AL., FISH CONSUMPTION AND THE 30-YEAR RISK OF FATAL MYOCARDIAL INFARCTION, N ENGL J MED, 336, PP. 1046-1053, (1997); ALBERT C.M., HENNEKENS C.H., O'DONNELL C.J., ET AL., FISH CONSUMPTION AND RISK OF SUDDEN CARDIAC DEATH, JAMA, 279, PP. 23-28, (1998); YUAN J.M., ROSS R.K., GAO Y.T., ET AL., FISH AND SHELLFISH CONSUMPTION IN RELATION TO DEATH FROM MYOCARDIAL INFARCTION AMONG MEN IN SHANGHAI, CHINA, AM J EPIDEMIOL, 154, PP. 809-816, (2001); LEMAITRE R.N., KING I.B., MOZAFFARIAN D., ET AL., SISCOVICK DS. N-3 POLYUNSATURATED FATTY ACIDS, FATAL ISCHEMIC HEART DISEASE, AND NONFATAL MYOCARDIAL INFARCTION IN OLDER ADULTS: THE CARDIOVASCULAR HEALTH STUDY, AM J CLIN NUTR, 77, PP. 319-325, (2003); MOZAFFARIAN D., LEMAITRE R.N., KULLER L.H., ET AL., CARDIAC BENEFITS OF FISH CONSUMPTION MAY DEPEND ON THE TYPE OF FISH MEAL CONSUMED: THE CARDIOVASCULAR HEALTH STUDY, CIRCULATION, 107, PP. 1372-1377, (2003); MOZAFFARIAN D., ASCHERIO A., HU F.B., ET AL., INTERPLAY BETWEEN DIFFERENT POLYUNSATURATED FATTY ACIDS AND RISK OF CORONARY HEART DISEASE IN MEN, CIRCULATION, 111, PP. 157-164, (2005); FRASER G.E., SABATE J., BEESON W.L., ET AL., A POSSIBLE PROTECTIVE EFFECT OF NUT CONSUMPTION ON RISK OF CORONARY HEART DISEASE. THE ADVENTIST HEALTH STUDY, ARCH INTERN MED, 152, PP. 1416-1424, (1992); MANN J.I., APPLEBY P.N., KEY T.J., ET AL., DIETARY DETERMINANTS OF ISCHAEMIC HEART DISEASE IN HEALTH CONSCIOUS INDIVIDUALS, HEART, 78, PP. 450-455, (1997); OSLER M., ANDREASEN A.H., HOIDRUP S., NO INVERSE ASSOCIATION BETWEEN FISH CONSUMPTION AND RISK OF DEATH FROM ALL-CAUSES, AND INCIDENCE OF CORONARY HEART DISEASE IN MIDDLE-AGED, DANISH ADULTS, J CLIN EPIDEMIOL, 56, PP. 274-279, (2003); FOLSOM A.R., DEMISSIE Z., FISH INTAKE, MARINE OMEGA-3 FATTY ACIDS, AND MORTALITY IN A COHORT OF POSTMENOPAUSAL WOMEN, AM J EPIDEMIOL, 160, PP. 1005-1010, (2004); NAKAMURA Y., UESHIMA H., OKAMURA T., ET AL., ASSOCIATION BETWEEN FISH CONSUMPTION AND ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY IN JAPAN: NIPPON DATA80, 1980-99, AM J MED, 118, PP. 239-245, (2005); BURR M.L., ASHFIELD-WATT P.A., DUNSTAN F.D., ET AL., LACK OF BENEFIT OF DIETARY ADVICE TO MEN WITH ANGINA: RESULTS OF A CONTROLLED TRIAL, EUR J CLIN NUTR, 57, PP. 193-200, (2003); SISCOVICK D.S., LEMAITRE R.N., MOZAFFARIAN D., THE FISH STORY: A DIET-HEART HYPOTHESIS WITH CLINICAL IMPLICATIONS: N-3 POLYUNSATURATED FATTY ACIDS, MYOCARDIAL VULNERABILITY, AND SUDDEN DEATH, CIRCULATION, 107, PP. 2632-2634, (2003); LUCAS M., HARRIS W.S., RISKS AND BENEFITS OF FISH INTAKE, JAMA, 297, (2007); TRIGGIANI M., CONNELL T.R., CHILTON F.H., EVIDENCE THAT INCREASING THE CELLULAR CONTENT OF EICOSAPENTAENOIC ACID DOES NOT REDUCE THE BIOSYNTHESIS OF PLATELET-ACTIVATING FACTOR, J IMMUNOL, 145, PP. 2241-2248, (1990); LICHTENSTEIN A.H., APPEL L.J., BRANDS M., ET AL., DIET AND LIFESTYLE RECOMMENDATIONS REVISION 2006: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 114, PP. 82-96, (2006); HARRIS W.S., VON SCHACKY C., THE OMEGA-3 INDEX: A NEW RISK FACTOR FOR DEATH FROM CORONARY HEART DISEASE?, PREV MED, 39, PP. 212-220, (2004); RAITT M.H., CONNOR W.E., MORRIS C., ET AL., FISH OIL SUPPLEMENTATION AND RISK OF VENTRICULAR TACHYCARDIA AND VENTRICULAR FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEFIBRILLATORS: A RANDOMIZED CONTROLLED STUDY, JAMA, 293, PP. 2884-2891, (2005); LEAF A., ALBERT C.M., JOSEPHSON M., ET AL., PREVENTION OF FATAL ARRHYTHMIAS IN HIGH-RISK SUBJECTS BY FISH OIL N-3 FATTY ACID INTAKE, CIRCULATION, 112, PP. 2762-2768, (2005); BROUWER I.A., ZOCK P.L., CAMM A.J., ET AL., EFFECT OF FISH OIL ON VENTRICULAR TACHYARRHYTHMIA AND DEATH IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFRIBILLATORS: THE STUDY ON OMEGA-3 FATTY ACIDS AND VENTRICULAR ARRHYTHMIA (SOFA) RANDOMIZED TRIAL, JAMA, 295, PP. 2613-2619, (2006); KONIG A., BOUZAN C., COHEN J.T., ET AL., A QUANTITATIVE ANALYSIS OF FISH CONSUMPTION AND CORONARY HEART DISEASE MORTALITY, AM J PREV MED, 29, PP. 335-346, (2005); BOUZAN C., COHEN J.T., CONNOR W.E., ET AL., A QUANTITATIVE ANALYSIS OF FISH CONSUMPTION AND STROKE RISK, AM J PREV MED, 29, PP. 347-352, (2005); COHEN J.T., BELLINGER D.C., CONNOR W.E., ET AL., A QUANTITATIVE ANALYSIS OF PRENATAL INTAKE OF N-3 POLYUNSATURATED FATTY ACIDS AND COGNITIVE DEVELOPMENT, AM J PREV MED, 29, PP. 366-374, (2005); COHEN J.T., BELLINGER D.C., SHAYWITZ B.A., A QUANTITATIVE ANALYSIS OF PRENATAL METHYL MERCURY EXPOSURE AND COGNITIVE DEVELOPMENT, AM J PREV MED, 29, PP. 353-365, (2005); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEINS: HUMAN STUDIES, AM J CLIN NUTR, 65, (1997); MCLENNAN P.L., MYOCARDIAL MEMBRANE FATTY ACIDS AND THE ANTIARRHYTHMIC ACTIONS OF DIETARY FISH OIL IN ANIMAL MODELS, LIPIDS, 36, (2001); LEAF A., KANG J.X., XIAO Y.F., ET AL., CLINICAL PREVENTION OF SUDDEN CARDIAC DEATH BY N-3 POLYUNSATURATED FATTY ACIDS AND MECHANISM OF PREVENTION OF ARRHYTHMIAS BY N-3 FISH OILS, CIRCULATION, 107, PP. 2646-2652, (2003); MORI T.A., BEILIN L.J., OMEGA-3 FATTY ACIDS AND INFLAMMATION, CURR ATHEROSCLER REP, 6, PP. 461-467, (2004); MOZAFFARIAN D., PSATY B.M., RIMM E.B., ET AL., FISH INTAKE AND RISK OF INCIDENT ATRIAL FIBRILLATION, CIRCULATION, 110, PP. 368-373, (2004); FROST L., VESTERGAARD P., N-3 FATTY ACIDS CONSUMED FROM FISH AND RISK OF ATRIAL FIBRILLATION OR FLUTTER: THE DANISH DIET, CANCER, AND HEALTH STUDY, AM J CLIN NUTR, 81, PP. 50-54, (2005); CALO L., BIANCONI L., COLIVICCHI F., ET AL., N-3 FATTY ACIDS FOR THE PREVENTION OF ATRIAL FIBRILLATION AFTER CORONARY ARTERY BYPASS SURGERY: A RANDOMIZED, CONTROLLED TRIAL, J AM COLL CARDIOL, 45, PP. 1723-1728, (2005); MOZAFFARIAN D., BRYSON C.L., LEMAITRE R.N., ET AL., FISH INTAKE AND RISK OF INCIDENT HEART FAILURE, J AM COLL CARDIOL, 45, PP. 2015-2021, (2005); CHARNOCK J.S., MCLENNAN P.L., ABEYWARDENA M.Y., DIETARY MODULATION OF LIPID METABOLISM AND MECHANICAL PERFORMANCE OF THE HEART, MOL CELL BIOCHEM, 116, PP. 19-25, (1992); KENNY D., WARLTIER D.C., PLEUSS J.A., ET AL., EFFECT OF OMEGA-3 FATTY ACIDS ON THE VASCULAR RESPONSE TO ANGIOTENSIN IN NORMOTENSIVE MEN, AM J CARDIOL, 70, PP. 1347-1352, (1992); CHIN J.P., GUST A.P., NESTEL P.J., ET AL., MARINE OILS DOSE-DEPENDENTLY INHIBIT VASOCONSTRICTION OF FOREARM RESISTANCE VESSELS IN HUMANS, HYPERTENSION, 21, PP. 22-28, (1993)","M.C. HOUSTON; VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, NASHVILLE, TN, UNITED STATES; EMAIL: BOOHOUSTON@COMCAST.NET","","ENGLISH","PROG. CARDIOVASC. DIS.","ARTICLE","ISI","2-S2.0-69349095428","PROG CARDIOVASC DIS","VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE","NOTREPORTED;VANDERBILT UNIVERSITY SCHOOL OF MEDICINE;NOTREPORTED",NA,"HOUSTON MC, 2009, PROG CARDIOVASC DIS","HOUSTON MC, 2009, PROG CARDIOVASC DIS"
"GONZÁLEZ V;MARRERO D;SIERRA R;VELÁZQUEZ C","GONZÁLEZ, VÍCTOR L. (7102097566); MARRERO, DAVID (36485087800); SIERRA, ROXANA (7006854525); VELÁZQUEZ, CARIDAD (7004670124)","CAPILLARY GAS CHROMATOGRAPHY OF THE FATTY ALCOHOLS C24C 34 COMPOSING POLICOSANOL IN FILMCOATED TABLETS",2007,"LATIN AMERICAN JOURNAL OF PHARMACY","26","3",0,"","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, AVE 25 AND 158, CUBA","POLICOSANOL IS A DRUG SUBSTANCE CONSISTING OF A MIXTURE OF VERY LONG CHAIN ALCOHOLS (C24-C34) EXTRACTED AND PURIFIED FROM SUGAR CANE WAX. A GAS CHROMATOGRAPHIC METHOD USING A WIDE-BORE CAPILLARY COLUMN, AND 1-EICOSANOL AS INTERNAL STANDARD WAS DEVELOPED AND VALIDATED FOR DETERMINING POLICOSANOL IN 5 AND 10 MG FILM-COATED TABLETS. THE ALCOHOLS WERE ANALYZED AS TRIMETHYLSILYL DERIVATIVES. THE METHOD CAN DETECT DEGRADATION PRODUCTS WITH HIGH RETENTION TIMES, WITHOUT INTERFERING WITH THE PEAKS OF THE ACTIVE INGREDIENT. GOOD LINEARITY (CORRELATION COEFFICIENT = 0.9991) AND ACCURACY (MEAN RECOVERY = 99.63%) WERE PROVEN OVER A RANGE OF 50-150% OF THE NOMINAL CONCENTRATION. REPEATABILITY AND INTERLABORATORY PRECISION AT THE NOMINAL 100% VALUE MET THE ACCEPTANCE CRITERIA (<2%). THE METHOD IS 0.7 TIMES FASTER AND SHOWED SUPERIOR EFFICIENCY THAN PREVIOUS DEVELOPED METHODS, BEING SUITABLE FOR QUALITY CONTROL PROCESS AND STABILITY STUDIES OF POLICOSANOL IN THESE FINISHED FORMS.","GAS CHROMATOGRAPHY; POLICOSANOL; TABLET; VALIDATION","ALCOHOL DERIVATIVE; FATTY ALCOHOL; POLICOSANOL; SILANE DERIVATIVE; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CORRELATION COEFFICIENT; DRUG COATING; QUALITY CONTROL","","","MAS R., DRUG FUTURE, 25, PP. 569-586, (2000); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., MESA M., FERNANDEZ J.C., CLIN. DRUG INVEST, 23, PP. 639-650, (2003); FERNANDEZ S., MAS R., GAMEZ R., DIAZ A., FERNANDEZ J.C., ORTA S., ILLNAIT J., CASTANO G., MENDOZA S., VALDES F., ALVAREZ E., AM. J. GERIATR. PHARMACOTHER, 2, PP. 219-229, (2004); GONZALEZ V., MAGRANER J., J. AOAC INT, 82, PP. 834-839, (1999); SIERRA R., GONZALEZ V., MAGRANER J., J. AOAC INT, 85, PP. 563-566, (2002); SIERRA R., GONZALEZ V., TEJEDA Y., CAMPANA H., MILIAN V., ACTA FARM. BONAERENSE, 24, PP. 99-103, (2005)","D. MARRERO; CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, AVE 25 AND 158, CUBA; EMAIL: DAVID.MARRERO@CNIC.EDU.CU","","ENGLISH","LAT. AM. J. PHARM.","ARTICLE","ISI","2-S2.0-39849087101","LAT AM J PHARM","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"GONZÁLEZ VL, 2007, LAT AM J PHARM","GONZÁLEZ VL, 2007, LAT AM J PHARM"
"SWANSON B;KEITHLEY J;SHA B;FOGG L;NERAD J;NOVAK R;ADEYEMI O;SPEAR G","SWANSON, BARBARA (7102031502); KEITHLEY, JOYCE K. (7003912536); SHA, BEVERLY E. (7005779955); FOGG, LOUIS (7003418034); NERAD, JUDITH (7004370775); NOVAK, RICHARD M. (9041839000); ADEYEMI, OLUWATOYIN (55395671200); SPEAR, GREGORY T. (7006814568)","POLICOSANOL FOR MANAGING HUMAN IMMUNODEFICIENCY VIRUSRELATED DYSLIPIDEMIA IN A MEDICALLY UNDERSERVED POPULATION A RANDOMIZED CONTROLLED CLINICAL TRIAL",2011,"ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE","17","5",11,"","ADULT HEALTH AND GERONTOLOGICAL NURSING, RUSH UNIVERSITY COLLEGE OF NURSING, UNITED STATES;ADULT HEALTH AND GERONTOLOGICAL NURSING, RUSH UNIVERSITY COLLEGE OF NURSING, UNITED STATES;RUSH UNIVERSITY MEDICAL CENTER, UNITED STATES;COMMUNITY AND MENTAL HEALTH NURSING, RUSH UNIVERSITY COLLEGE OF NURSING, CHICAGO, IL, UNITED STATES;COOK COUNTY BUREAU OF HEALTH, CHICAGO, UNITED STATES;UNIVERSITY OF ILLINOIS, CHICAGO, UNITED STATES;COOK COUNTY BUREAU OF HEALTH, CHICAGO, UNITED STATES;DEPARTMENT OF IMMUNOLOGY AND MICROBIOLOGY, RUSH UNIVERSITY MEDICAL CENTER, UNITED STATES","BACKGROUND HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IS ASSOCIATED WITH DYSLIPIDEMIA AND INCREASED RISK FOR CARDIOVASCULAR EVENTS; HOWEVER, THE USE OF STATINS IN HIV-INFECTED PEOPLE IS COMPLICATED BY PHARMACOKINETIC INTERACTIONS AND OVERLAPPING TOXICITIES WITH ANTIRETROVIRAL MEDICATIONS. POLICOSANOL IS A DIETARY SUPPLEMENT DERIVED FROM SUGAR CANE THAT IS WIDELY USED AS A STATIN ALTERNATIVE IN LATIN AMERICA. PRIMARY STUDY OBJECTIVE TO COLLECT FEASIBILITY DATA ON SUGAR CANE-DERIVED POLICOSANOL TO NORMALIZE DYSLIPIDEMIC PROFILES IN A SAMPLE OF MEDICALLY UNDERSERVED HIV-INFECTED PEOPLE. METHODS/DESIGN RANDOMIZED, CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL. SETTING TWO INFECTIOUS DISEASE OUTPATIENT CLINICS LOCATED IN A HEALTH RESOURCES SERVICE ADMINISTRATION-DESIGNATED MEDICALLY UNDERSERVED NEIGHBORHOOD IN CHICAGO, ILLINOIS. PARTICIPANTS FIFTY-FOUR CLINICALLY STABLE HIV-INFECTED PEOPLE (91% BLACK) WITH AT LEAST ONE LIPID ABNORMALITY THAT WARRANTED DIETARY MODIFICATIONS AND/OR DRUG THERAPY. INTERVENTION PARTICIPANTS RECEIVED EITHER 20 MG/DAY OF POLI COSANOL OR PLACEBO FOR 12 WEEKS, FOLLOWED BY A 4-WEEK WASHOUT AND CROSSOVER TO THE OTHER ARM. PRIMARY OUTCOME MEASURES EFFICACY MEASURES INCLUDED THE STANDARD LIPID PANEL (LOW-DENSITY LIPOPROTEIN CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TRIGLYCERIDES) AND NUCLEAR MAGNETIC RESONANCE (NMR)-DERIVED LIPOPROTEIN PARTICLE PROFILES. SAFETY MEASURES INCLUDED CD4+ T LYMPHOCYTE COUNTS, PLASMA HIV RIBONUCLEIC ACID LEVELS, SERUM CREATININE, AND LIVER FUNCTION TESTS. RESULTS POLICOSANOL SUPPLEMENTATION WAS NOT ASSOCIATED WITH NORMALIZATION OF ANY DYSLIPIDEMIC PARAMETERS AS MEASURED BY THE STANDARD LIPID PANEL OR NMR SPECTROSCOPY-MEASURED LIPOPROTEIN SIZE OR CONCENTRATION. THE SUPPLEMENT WAS WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY CHANGES IN PARAMETERS OF HIV DISEASE PROGRESSION. CONCLUSIONS OUR FINDINGS CORROBORATE RECENT STUDIES CONDUCTED OUTSIDE CUBA THAT HAVE FAILED TO FIND ANY LIPID MODULATORY EFFECTS FOR POLICOSANOL.","","ADULT; ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FATTY ALCOHOLS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TRIGLYCERIDES; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE","NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH, NCCIH, (R21AT003077)","","PALELLA JR. F.J., DELANEY K.M., MOORMAN A.C., ET AL., DECLINING MORBIDITY AND MORTALITY AMONG PATIENTS WITH ADVANCED HUMAN IMMUNODEFICIENCY VIRUS INFECTION, N ENGL J MED, 338, 13, PP. 853-860, (1998); FONTAS E., VAN LETH F., SABIN C.A., ET AL., LIPID PROFILES IN HIV-INFECTED PATIENTS RECEIVING COMBINATION ANTIRETROVIRAL THERAPY: ARE DIFFERENT ANTIRETROVIRAL DRUGS ASSOCIATED WITH DIFFERENT LIPID PROFILES?, J INFECT DIS, 189, 6, PP. 1056-1074, (2004); FRIIS-MOLLER N., WEBER R., REISS P., ET AL., CARDIOVASCULAR DISEASE RISK FACTORS IN HIV PATIENTS-ASSOCIATION WITH ANTIRETROVIRAL THERAPY. RESULTS FROM THE DAD STUDY, AIDS, 17, 8, PP. 1179-1193, (2003); MULLIGAN K., GRUNFELD C., TAI V.W., ET AL., HYPERLIPIDEMIA AND INSULIN RESISTANCE ARE INDUCED BY PROTEASE INHIBITORS INDEPENDENT OF CHANGES IN BODY COMPOSITION IN PATIENTS WITH HIV INFECTION, J ACQUIR IMMUNE DEFIC SYNDR, 23, 1, PP. 35-43, (2000); RIDDLER S.A., SMIT E., COLE S.R., ET AL., IMPACT OF HIV INFECTION AND HAART ON SERUM LIPIDS IN MEN, JAMA, 289, 22, PP. 2978-2982, (2003); EL-SADR W.M., MULLIN C.M., CARR A., ET AL., EFFECTS OF HIV DISEASE ON LIPID, GLUCOSE AND INSULIN LEVELS: RESULTS FROM A LARGE ANTIRETROVIRAL NAIVE COHORT, HIV MED, 6, 2, PP. 1-7, (2005); EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, JAMA, 285, 19, PP. 2486-2497, (2001); COLL B., PARRA S., ALONSO-VILLAVERDE C., ET AL., THE ROLE OF IMMUNITY AND INFLAMMATION IN THE PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH HIV INFECTION, STROKE, 38, 9, PP. 2477-2484, (2007); HSUE P.Y., LO J.C., FRANKLIN A., ET AL., PROGRESSION OF ATHEROSCLEROSIS AS ASSESSED BY CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH HIV INFECTION, CIRCULATION, 109, 13, PP. 1603-1608, (2004); TRIANT V.A., LEE H., HADIGAN C., GRINSPOON S.K., INCREASED ACUTE MYOCARDIAL INFARCTION RATES AND CARDIOVASCULAR RISK FACTORS AMONG PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS DISEASE, J CLIN ENDOCRINOL METAB, 92, 7, PP. 2506-2512, (2007); SMITH C., ASSOCIATION BETWEEN MODIFIABLE AND NON-MODIFIABLE RISK FACTORS AND SPECIFIC CAUSES OF DEATH IN THE HAART ERA: THE DATA COLLECTION ON ADVERSE EVENTS OF ANTI-HIV DRUG STUDY, PAPER PRESENTED AT: 16TH CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, (2009); MOCROFT A., REISS P., GASIOROWSKI J., ET AL., SERIOUS FATAL AND NON-FATAL NON-AIDS-DEFINING ILLNESSES IN EUROPE, PAPER PRESENTED AT: 16TH CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, (2009); MCCARTY M.F., IATROGENIC LIPODYSTROPHY IN HIV PATIENTS-THE NEED FOR VERY-LOW-FAT DIETS, MED HYPOTHESES, 61, 5-6, PP. 561-566, (2003); BARRIOS A., BLANCO F., GARCIA-BENAYAS T., ET AL., EFFECT OF DIETARY INTERVENTION ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY-RELATED DYSLIPEMIA, AIDS, 16, 15, PP. 2079-2081, (2002); RAY G.M., ANTIRETROVIRAL AND STATIN DRUG-DRUG INTERACTIONS, CARDIOL REV, 17, 1, PP. 44-47, (2009); NARAYAN S., HAWLEY N., GIGUERE P., BADLEY A.D., ATTENTUATED T-LYMPHOCYTE RESPONSE TO HIV THERAPY IN INDIVIDUALS RECEIVING HMG-COA REDUCTASE INHIBITORS, HIV CLIN TRIALS, 4, 3, PP. 164-169, (2003); RODRIGUEZ B., VALDEZ H., MIJCH A., ET AL., STATINS BLUNT HAART-INDUCED CD4+ T-CELL GAINS BUT HAVE NO LONG-TERM EFFECT ON VIROLOGIC RESPONSE TO HAART, J INT ASSOC PHYSICIANS AIDS CARE (CHICILL), 6, 3, PP. 198-202, (2007); WOHL D.A., TIEN H.C., BUSBY M., ET AL., RANDOMIZED STUDY OF THE SAFETY AND EFFICACY OF FISH OIL (OMEGA-3 FATTY ACID) SUPPLEMENTATION WITH DIETARY AND EXERCISE COUNSELING FOR THE TREATMENT OF ANTIRETROVIRAL THERAPY-ASSOCIATED HYPERTRIGLYCERIDEMIA, CLIN INFECT DIS, 41, 10, PP. 1498-1504, (2005); GERBER J.G., KITCH D.W., FICHTENBAUM C.J., ET AL., FISH OIL AND FENOFIBRATE FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA IN HIV-INFECTED SUBJECTS ON ANTIRETROVIRAL THERAPY: RESULTS OF ACTG A5186, J ACQUIR IMMUNE DEFIC SYNDR, 47, 4, PP. 459-466, (2008); KEITHLEY J., SWANSON B., SHA B.E., ZELLER J.M., KESSLER H.A., SMITH K.Y., A PILOT STUDY OF THE SAFETY AND EFFICACY OF CHOLESTIN IN TREATING HIV-RELATED DYSLIPIDEMIA, NUTRITION, 18, 2, PP. 201-204, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); MCGOWAN M.P., PROULX S., NUTRITIONAL SUPPLEMENTS AND SERUM LIPIDS: DOES ANYTHING WORK?, CURR ATHEROSCLER REP, 11, 6, PP. 470-476, (2009); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, 1, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, 6, PP. 923-932, (1997); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, 3, PP. 255-262, (2000); KASSIS A.N., KUBOW S., JONES P.J., SUGAR CANE POLICOSANOLS DO NOT REDUCE LDL OXIDATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS, LIPIDS, 44, 5, PP. 391-396, (2009); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PEOPLE, AM J CLIN NUTR, 84, 5, PP. 1003-1008, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, 3, PP. 318-322, (2008); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, 1, PP. 27-33, (1994); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, 2, PP. 176-182, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, 3, PP. 187-195, (2000); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, 4, PP. 117-127, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, 4, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); ORTENSI G., JULIO G., HECTOR V., PEDRO A.T., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 819-828, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, 4, PP. 105-116, (1999); THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, 25, PP. 3143-3421, (2002); RUBIN D.B., MULTIPLE IMPUTATIONS FOR NONRESPONSES IN SURVEYS, (1987); COHEN J., STATISTICAL POWER ANALYSIS FOR THE BEHAVIORAL SCIENCES, (1988); SWANSON B., KEITHLEY J., POLICOSANOL TO MANAGE DYSLIPIDEMIA IN OLDER ADULTS, COMPLEMENTARY AND ALTERNATIVE THERAPIES AND THE AGING POPULATION: AN EVIDENCE-BASED APPROACH, PP. 117-134, (2009); SINGH D.K., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, 3, PP. 1020-1026, (2006); NIKITIN IU P., SLEPCHENKO N.V., GRATSIANSKII N.A., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC DRUG POLICOSANOL IN RUSSIA ARTICLE IN RUSSIAN, TER ARKHIV, 72, 12, PP. 7-10, (2000); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-GOA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA ARTICLE IN SPANISH, REV MED CHIL, 127, 3, PP. 286-294, (1999); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 5, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, 6, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, 5, PP. 968-975, (2006); PRODUCT REVIEW: REVIEW OF CHOLESTEROL-LOWERING SUPPLEMENTS (PLANT STEROLS AND POLICOSANOL)","S. BARBARA; ADULT HEALTH AND GERONTOLOGICAL NURSING, RUSH UNIVERSITY COLLEGE OF NURSING, CHICAGO, IL, UNITED STATES; EMAIL: BARBARA_A_SWANSON@RUSH.EDU","INNOVISION COMMUNICATIONS","ENGLISH","ALTERN. THER. HEALTH MED.","ARTICLE","ISI","2-S2.0-80051948404","ALTERN THER HEALTH MED","RUSH UNIVERSITY COLLEGE OF NURSING;RUSH UNIVERSITY COLLEGE OF NURSING;RUSH UNIVERSITY MEDICAL CENTER;RUSH UNIVERSITY COLLEGE OF NURSING;COOK COUNTY BUREAU OF HEALTH;UNIVERSITY OF ILLINOIS;COOK COUNTY BUREAU OF HEALTH;RUSH UNIVERSITY MEDICAL CENTER","NOTREPORTED;RUSH UNIVERSITY COLLEGE OF NURSING;NOTREPORTED",NA,"SWANSON B, 2011, ALTERN THER HEALTH MED","SWANSON B, 2011, ALTERN THER HEALTH MED"
"OGBAC F;QUIMPO R;HILADO J;SY R;LUZ V;TANKEH-TORRES S","OGBAC, FREDERICK (54411139900); QUIMPO, ROLANDO (54783330800); HILADO, JAIME ENRIQUE (54410701700); SY, ROSA ALLYN (57208431777); LUZ, VIMAR (48461414100); TANKEH-TORRES, SANDRA (14039739200)","A METAANALYSIS ON SUGAR CANE POLICOSANOL AS TREATMENT FOR HYPERCHOLESTEROLEMIA",2010,"PHILLIPPINE JOURNAL OF INTERNAL MEDICINE","48","6",0,"","DEPARTMENT OF INTERNAL MEDICINE, OSPITAL NG MAKATI, PHILIPPINES;DEPARTMENT OF INTERNAL MEDICINE, OSPITAL NG MAKATI, PHILIPPINES;DEPARTMENT OF INTERNAL MEDICINE, OSPITAL NG MAKATI, PHILIPPINES;DEPARTMENT CHAIR AND SECTION HEAD, SECTION OF ENDOCRINOLOGY, DEPARTMENT OF INTERNAL MEDICINE, OSPITAL NG MAKATI, PHILIPPINES;SECTION OF NEPHROLOGY, DEPARTMENT OF INTERNAL MEDICINE, OSPITAL NG MAKATI, PHILIPPINES;SECTION OF RHEUMATOLOGY, DEPARTMENT OF INTERNAL MEDICINE, OSPITAL NG MAKATI, PHILIPPINES","BACKGROUND: SUGAR CANE POLICOSANOL IS COMPOSED OF EIGHT HIGH MOLECULAR MASS ALIPHATIC ALCOHOLS THAT CLAIMED TO HAVE A CHOLESTEROL LOWERING EFFECT. IT WAS FIRST INTRODUCED IN CUBA AND WAS EXTRACTED FROM LOCAL SUGAR CANE. ANIMAL TRIALS AND EARLIER HUMAN TRIALS HAVE SHOWN IT TO HAVE A CHOLESTEROL LOWERING EFFECTS.HOWEVER, RECENT HUMAN TRIALS SHOWED CONTRADICTING RESULTS. OBJECTIVE: THE OBJECTIVE OF THIS RESEARCH IS TO COMPARE THE EFFECTS OF SUGAR CANE POLICOSANOL WITH PLACEBO OR NON-TREATMENT ON THE LEVEL OF TOTAL CHOLESTEROL AND LDL AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA. MATERIALS AND METHODS: MEDLINE SEARCH WAS DONE USING ""SUGAR CANE POLICOSANOL (MESH OR FREE TEXT) AND HYPERCHOLESTEROLEMIA (MESH OR FREE TEXT)"" LIMITED TO HUMAN SUBJECTS, MALE AND FEMALE GENDER, ALL ADULT 19+ YEARS, META-ANALYSIS, CLINICAL TRIALS, PRACTICE GUIDELINES, AND RANDOMI ZED CONTROLLED TRIALS. TRIALS INCLUDED WERE RANDOMIZED CONTROLLED TRIAL COMPARING SUGAR CANE POLICOSANOL AND PLACEBO IN PATIENTS WITH HYPERCHOLESTEROLEMIA. THREE INDEPENDENT REVIEWERS ASSESSED AND GRADED THE STUDIES USING THE COCHRANE COLLABORATION TOOL. REVIEW MANAGER 5 WAS UTILIZED FOR CALCULATIONS USING MEAN DIFFERENCE FOR CONTINUOUS VARIABLES. A SUBGROUP ANALYSIS ON THE AMOUNT OF POLICOSANOL USED WAS DONE. RESULTS: A TOTAL OF 16 STUDIES WERE IDENTIFIED AND THREE FULFILLED THE CRITERIA. ONE STUDY WAS A CROSSOVER STUDY, WHILE THE OTHER TWO WERE PARALLEL STUDIES. THERE WAS NO STATISTICALLY SIGNIFICANT DIFFERENCE IN THE MEAN END POINT LEVEL OF TOTAL CHOLESTEROL BETWEEN THE PLACEBO GROUP AND SUGAR CANE POLICOSANOL GROUP (0.19 [0.08, 0.30]). THERE WAS ALSO NO STATISTICALLY SIGNIFICANT DIFFERENCE IN THE MEAN END POINT LEVEL OF LDL (0.09 [-0.01, 0.19]). THE SUBGROUP GROUP ANALYSIS ON BOTH 10MG AND 20MG POLICOSANOL WAS ALSO CONSISTENT IN SHOWING NO STATISTICALLY SIGNIFICANT DIFFERENCE IN THE MEAN END POINT LEVELS OF TOTAL CHOLESTEROL, (0.18 [0.05, 0.30]) AND (0.39 [0.06, 0.72]) RESPECTIVELY. THE SUBGROUP ANALYSIS ON LDL USING 10MG AND 20MG ALSO SHOWED NO STATISTICALLY SIGNIFICANT DIFFERENCE IN THE MEAN END POINT LEVELS, (0.09 [-0.02, 0.20]) AND (0.12 [-0.13, 0.037]) RESPECTIVELY. CONCLUSION: IN CONCLUSION, SUGAR CANE POLICOSANOL DID NOT DEMONSTRATE ANY SIGNIFICANT DIFFERENCE IN THE MEAN END POINT LEVELS OF BOTH TOTAL CHOLESTEROL AND LDL AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA COMPARED TO PLACEBO.","","ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLACEBO; POLICOSANOL; SIMVASTATIN; CHOLESTEROL BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUGARCANE; SYSTEMATIC REVIEW","","","FINAL REPORT OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL PROGRAM EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), PP. 02-5215, (2002); FORD E.S., MOKDAD A.H., GILES H.W., ET AL., SERUM TOTAL CHOLESTEROL CONCENTRATIONS AND AWARENESS, TREATMENT, AND CONTROL OF HYPERCHOLESTEROLEMIA AMONG US ADULTS: FINDINGS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 1999 TO 2000, CIR, 107, PP. 2185-2189, (2003); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, 6, PP. 923-932, (1997); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, 3, PP. 203-217, (2002); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POST MARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURRENT THERAPEUTIC RESEARCH OCTOBER, 59, 10, PP. 717-722, (1998); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, 1, PP. 8-12, (2001); SHO H., CHINEN I., FUKUDA N., EFFECTS OF OKINAWAN SUGAR CANE WAX AND FATTY ALCOHOL ON SERUM AND LIVER LIPIDS IN THE RAT, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY (TOKYO), 30, 6, PP. 553-559, (1984); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, 3-4, PP. 205-208, (1994); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOLOGICAL RESEARCH, 27, 3-4, PP. 199-203, (1994); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECT OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REVISTA MEDICA DE CHILE, 123, 3, PP. 286-294, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, 3, PP. 187-195, (2000); GREYLING A., DE WITT C., OOSTHUIZEN W., ET AL., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROL A EMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., ET AL., POLICOSANOL IN INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, 6, PP. 154-348, (2006); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOILESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, 5, PP. 1003-1008, (2006); MIRKIN A., MAS R., MARINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROILEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, 1, PP. 31-41, (2001); CASTANO G., MAS R., FERNANDAEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT CLIN PHARMACOL RES, 21, 1, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); FERNANDEZ S., MAS R., GAMEZ R., ET AL., A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN ELDERLY POPULATION, AM J GERIATR PHARMACOTHER, 2, 4, PP. 219-229, (2004); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS R D, 6, 4, PP. 207-219, (2005); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., ET AL., COMPARATIVE LIPID LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 5, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., ET AL., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, 3, PP. 318-322, (2008); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., ET AL., SUGAR CANE POLICOSANOL FAILED TO LOWER CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT THER MED, 16, 2, PP. 61-65, (2008); KASSIS A.N., KUBOW S., JONES P.J., SUGAR CANE POLICOSANOL DO NOT REDUCE LDL OXIDATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS, LIPIDS, 22, 5, PP. 391-396, (2009)","","","ENGLISH","PHILIPP. J. INTERN. MED.","REVIEW","ISI","2-S2.0-82355163473","PHILIPP J INTERN MED",NA,"NOTREPORTED",NA,"OGBAC F, 2010, PHILIPP J INTERN MED","OGBAC F, 2010, PHILIPP J INTERN MED"
"FARDET A","FARDET, ANTHONY (23466878500)","NEW HYPOTHESES FOR THE HEALTHPROTECTIVE MECHANISMS OF WHOLEGRAIN CEREALS WHAT IS BEYOND FIBRE",2010,"NUTRITION RESEARCH REVIEWS","23","69",814,"10.1017/S0954422410000041","INRA, UMR 1019 NUTRITION HUMAINE, F-63122 SAINT-GENÈS-CHAMPANELLE, FRANCE, CLERMONT UNIVERSITÉ, UFR MÉDECINE, UMR 1019 NUTRITION HUMAINE, F-63000 CLERMONT-FERRAND, FRANCE","EPIDEMIOLOGICAL STUDIES HAVE CLEARLY SHOWN THAT WHOLE-GRAIN CEREALS CAN PROTECT AGAINST OBESITY, DIABETES, CVD AND CANCERS. THE SPECIFIC EFFECTS OF FOOD STRUCTURE (INCREASED SATIETY, REDUCED TRANSIT TIME AND GLYCAEMIC RESPONSE), FIBRE (IMPROVED FAECAL BULKING AND SATIETY, VISCOSITY AND SCFA PRODUCTION, AND/OR REDUCED GLYCAEMIC RESPONSE) AND MG (BETTER GLYCAEMIC HOMEOSTASIS THROUGH INCREASED INSULIN SECRETION), TOGETHER WITH THE ANTIOXIDANT AND ANTI-CARCINOGENIC PROPERTIES OF NUMEROUS BIOACTIVE COMPOUNDS, ESPECIALLY THOSE IN THE BRAN AND GERM (MINERALS, TRACE ELEMENTS, VITAMINS, CAROTENOIDS, POLYPHENOLS AND ALKYLRESORCINOLS), ARE TODAY WELL-RECOGNISED MECHANISMS IN THIS PROTECTION. RECENT FINDINGS, THE EXHAUSTIVE LISTING OF BIOACTIVE COMPOUNDS FOUND IN WHOLE-GRAIN WHEAT, THEIR CONTENT IN WHOLE-GRAIN, BRAN AND GERM FRACTIONS AND THEIR ESTIMATED BIOAVAILABILITY, HAVE LED TO NEW HYPOTHESES. THE INVOLVEMENT OF POLYPHENOLS IN CELL SIGNALLING AND GENE REGULATION, AND OF SULFUR COMPOUNDS, LIGNIN AND PHYTIC ACID SHOULD BE CONSIDERED IN ANTIOXIDANT PROTECTION. WHOLE-GRAIN WHEAT IS ALSO A RICH SOURCE OF METHYL DONORS AND LIPOTROPES (METHIONINE, BETAINE, CHOLINE, INOSITOL AND FOLATES) THAT MAY BE INVOLVED IN CARDIOVASCULAR AND/OR HEPATIC PROTECTION, LIPID METABOLISM AND DNA METHYLATION. POTENTIAL PROTECTIVE EFFECTS OF BOUND PHENOLIC ACIDS WITHIN THE COLON, OF THE B-COMPLEX VITAMINS ON THE NERVOUS SYSTEM AND MENTAL HEALTH, OF OLIGOSACCHARIDES AS PREBIOTICS, OF COMPOUNDS ASSOCIATED WITH SKELETON HEALTH, AND OF OTHER COMPOUNDS SUCH AS -LINOLENIC ACID, POLICOSANOL, MELATONIN, PHYTOSTEROLS AND PARA-AMINOBENZOIC ACID ALSO DESERVE TO BE STUDIED IN MORE DEPTH. FINALLY, BENEFITS OF NUTRIGENOMICS TO STUDY COMPLEX PHYSIOLOGICAL EFFECTS OF THE WHOLE-GRAIN PACKAGE, AND THE MOST PROMISING WAYS FOR IMPROVING THE NUTRITIONAL QUALITY OF CEREAL PRODUCTS ARE DISCUSSED. © 2010 THE AUTHOR.","BIOACTIVE COMPOUNDS; HEALTH; PHYSIOLOGICAL MECHANISMS; WHOLE-GRAIN WHEAT","ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; BUTYRIC ACID; CARDIOVASCULAR DISEASES; CEREALS; DIABETES MELLITUS; DIETARY FIBER; FLAVONOIDS; GASTROINTESTINAL MOTILITY; HEALTH PROMOTION; HUMANS; LIGNIN; NEOPLASMS; OBESITY; PHENOLS; PHYTIC ACID; SATIATION; SULFUR COMPOUNDS; TRITICUM AESTIVUM; 4 AMINOBENZOIC ACID; ALPHA TOCOPHEROL; BETAINE; CAROTENOID; CHOLINE; CYSTINE; FLAVONOID; FOLIC ACID; GLUTATHIONE; INOSITOL; INSULIN; LIGNAN; LIGNIN; LINOLENIC ACID; MAGNESIUM; MELATONIN; METHIONINE; MINERAL; MONOSACCHARIDE; OLIGOSACCHARIDE; PHYTIC ACID; PHYTOSTEROL; POLICOSANOL; POLYPHENOL; RESORCINOL; SULFUR; TRACE ELEMENT; UNINDEXED DRUG; VITAMIN; VITAMIN B COMPLEX; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BUTYRIC ACID; PHENOL DERIVATIVE; POLYPHENOLS; SULFUR DERIVATIVE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; BRAN; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CEREAL; DIETARY FIBER; DNA METHYLATION; FERMENTATION; FOOD COMPOSITION; GENE CONTROL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAIN; HEART PROTECTION; HUMAN; HYDROLYSIS; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE TRANSIT TIME; INTRACELLULAR SIGNALING; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER PROTECTION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIGENOMICS; OBESITY; SATIETY; WHEAT GERM; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GASTROINTESTINAL MOTILITY; GLUCOSE BLOOD LEVEL; HEALTH PROMOTION; METABOLISM; NEOPLASM; OBESITY; REVIEW","","","KOH-BANERJEE P., RIMM E.B., WHOLE GRAIN CONSUMPTION AND WEIGHT GAIN: A REVIEW OF THE EPIDEMIOLOGICAL EVIDENCE, POTENTIAL MECHANISMS AND OPPORTUNITIES FOR FUTURE RESEARCH, PROCEEDINGS OF THE NUTRITION SOCIETY, 62, 1, PP. 25-29, (2003); VAN DE VIJVER LPL, VAN DEN BOSCH LMC, VAN DEN BRANDT P.A., ET AL., WHOLE-GRAIN CONSUMPTION, DIETARY FIBRE INTAKE AND BODY MASS INDEX IN THE NETHERLANDS COHORT STUDY, EUR J CLIN NUTR, 63, PP. 31-38, (2009); ESMAILLZADEH A., MIRMIRAN P., AZIZI F., WHOLE-GRAIN CONSUMPTION AND THE METABOLIC SYNDROME: A FAVORABLE ASSOCIATION IN TEHRANIAN ADULTS, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 59, 3, PP. 353-362, (2005); SAHYOUN N.R., JACQUES P.F., ZHANG X.L., ET AL., WHOLEGRAIN INTAKE IS INVERSELY ASSOCIATED WITH THE METABOLIC SYNDROME AND MORTALITY IN OLDER ADULTS, AM J CLIN NUTR, 83, PP. 124-131, (2006); DE MUNTER J.S.L., HU F.B., SPIEGELMAN D., FRANZ M., VAN DAM R.M., WHOLE GRAIN, BRAN, AND GERM INTAKE AND RISK OF TYPE 2 DIABETES: A PROSPECTIVE COHORT STUDY AND SYSTEMATIC REVIEW, PLOS MEDICINE, 4, 8, PP. 1385-1395, (2007); MURTAUGH M.A., JACOBS JR. D.R., JACOB B., STEFFEN L.M., MARQUART L., EPIDEMIOLOGICAL SUPPORT FOR THE PROTECTION OF WHOLE GRAINS AGAINST DIABETES, PROCEEDINGS OF THE NUTRITION SOCIETY, 62, 1, PP. 143-149, (2003); MELLEN P.B., WALSH T.F., HERRINGTON D.M., WHOLE GRAIN INTAKE AND CARDIOVASCULAR DISEASE: A META-ANALYSIS, NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES, 18, 4, PP. 283-290, (2008); CHAN J.M., WANG F., HOLLY E.A., WHOLE GRAINS AND RISK OF PANCREATIC CANCER IN A LARGE POPULATION-BASED CASE-CONTROL STUDY IN THE SAN FRANCISCO BAY AREA, CALIFORNIA, AMERICAN JOURNAL OF EPIDEMIOLOGY, 166, 10, PP. 1174-1185, (2007); CHATENOUD L., TAVANI A., LA VECCHIA C., JACOBS JR. D.R., NEGRI E., LEVI F., FRANCESCHI S., WHOLE GRAIN FOOD INTAKE AND CANCER RISK, INTERNATIONAL JOURNAL OF CANCER, 77, 1, PP. 24-28, (1998); JACOBS JR. D.R., MARQUART L., SLAVIN J., KUSHI L.H., WHOLE-GRAIN INTAKE AND CANCER: AN EXPANDED REVIEW AND META-ANALYSIS, NUTRITION AND CANCER, 30, 2, PP. 85-96, (1998); LARSSON S.C., GIOVANNUCCI E., BERGKVIST L., WOLK A., WHOLE GRAIN CONSUMPTION AND RISK OF COLORECTAL CANCER: A POPULATION-BASED COHORT OF 60 000 WOMEN, BRITISH JOURNAL OF CANCER, 92, 9, PP. 1803-1807, (2005); SCHATZKIN A., PARK Y., LEITZMANN M.F., ET AL., PROSPECTIVE STUDY OF DIETARY FIBER, WHOLE GRAIN FOODS, AND SMALL INTESTINAL CANCER, GASTROENTEROLOGY, 135, PP. 1163-1167, (2008); JACOBS JR. D.R., ANDERSEN L.F., BLOMHOFF R., WHOLE-GRAIN CONSUMPTION IS ASSOCIATED WITH A REDUCED RISK OF NONCARDIOVASCULAR, NONCANCER DEATH ATTRIBUTED TO INFLAMMATORY DISEASES IN THE IOWA WOMEN'S HEALTH STUDY, AMERICAN JOURNAL OF CLINICAL NUTRITION, 85, 6, PP. 1606-1614, (2007); ADOM K.K., SORRELLS M.E., LIU R.H., PHYTOCHEMICAL PROFILES AND ANTIOXIDANT ACTIVITY OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 51, PP. 7825-7834, (2003); JACOBS D.R., MEYER H.E., SOLVOLL K., REDUCEDMORTALITY AMONG WHOLE GRAIN BREAD EATERS IN MEN AND WOMEN IN THE NORWEGIAN COUNTY STUDY, EUR J CLIN NUTR, 55, PP. 137-143, (2001); CHATENOUD L., LA VECCHIA C., FRANCESCHI S., ET AL., REFINED-CEREAL INTAKE AND RISK OF SELECTED CANCERS IN ITALY, AM J CLIN NUTR, 70, PP. 1107-1110, (1999); JENSEN M.K., KOH-BANERJEE P., FRANZ M., SAMPSON L., GRONBAEK M., RIMM E.B., WHOLE GRAINS, BRAN, AND GERM IN RELATION TO HOMOCYSTEINE AND MARKERS OF GLYCEMIC CONTROL, LIPIDS, AND INFLAMMATION, AMERICAN JOURNAL OF CLINICAL NUTRITION, 83, 2, PP. 275-283, (2006); LIU R.H., WHOLE GRAIN PHYTOCHEMICALS AND HEALTH, J CEREAL SCI, 46, PP. 207-219, (2007); TRUSWELL A.S., CEREAL GRAINS AND CORONARY HEART DISEASE, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 56, 1, PP. 1-14, (2002); DEFINITION OF WHOLE GRAIN, (1999); (2010); DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF: WHOLE GRAIN LABEL STATEMENTS, (2006); AACC INTERNATIONAL COMMENTS ON PART III OF THE DRAFT GUIDANCE ON WHOLE GRAIN LABEL STATEMENTS, (2006); JONES J.M., WHOLE GRAINS - ISSUES AND DELIBERATIONS FROM THE WHOLE GRAIN TASK FORCE, CEREAL FOODS WORLD, 53, PP. 260-264, (2008); SRIVASTAVA A.K., SUDHA M.L., BASKARAN V., LEELAVATHI K., STUDIES ON HEAT STABILIZED WHEAT GERM AND ITS INFLUENCE ON RHEOLOGICAL CHARACTERISTICS OF DOUGH, EUROPEAN FOOD RESEARCH AND TECHNOLOGY, 224, 3, PP. 365-372, (2007); HEALTH CLAIM NOTIFICATION FOR WHOLE GRAIN FOODS, (1999); JACOBS JR. D.R., MEYER K.A., KUSHI L.H., ET AL., WHOLEGRAIN INTAKE MAY REDUCE THE RISK OF ISCHEMIC HEART DISEASE DEATH IN POSTMENOPAUSAL WOMEN: THE IOWA WOMENS HEALTH STUDY, AM J CLIN NUTR, 68, PP. 248-257, (1998); LIU S.M., MANSON J.E., STAMPFER M.J., ET AL., WHOLE GRAIN CONSUMPTION AND RISK OF ISCHEMIC STROKE IN WOMEN - A PROSPECTIVE STUDY, JAMA, 284, PP. 1534-1540, (2000); THANE C.W., JONES A.R., STEPHEN A.M., ET AL., WHOLEGRAIN INTAKE OF BRITISH YOUNG PEOPLE AGED 4-18 YEARS, BR J NUTR, 94, PP. 825-831, (2005); THANE C.W., STEPHEN A.M., JEBB S.A., WHOLE GRAINS AND ADIPOSITY: LITTLE ASSOCIATION AMONG BRITISH ADULTS, EUR J CLIN NUTR, 63, PP. 229-237, (2009); CLEVELAND L.E., MOSHFEGH A.J., ALBERTSON A.M., ET AL., DIETARY INTAKE OF WHOLE GRAINS, J AM COLL NUTR, 19, (2000); LANG R., JEBB S.A., WHO CONSUMES WHOLE GRAINS, AND HOW MUCH?, PROCEEDINGS OF THE NUTRITION SOCIETY, 62, 1, PP. 123-127, (2003); WELSH S., SHAW A., DAVIS C., ACHIEVING DIETARY RECOMMENDATIONS - WHOLE-GRAIN FOODS IN THE FOOD GUIDE PYRAMID, CRIT REV FOOD SCI NUTR, 34, PP. 441-451, (1994); ALBERTSON A.M., TOBELMANN R.C., CONSUMPTION OF GRAIN AND WHOLE-GRAIN FOODS BY AN AMERICAN POPULATION DURING THE YEARS 1990 TO 1992, JAMDIET ASSOC, 95, PP. 703-704, (1995); DEVELOPMENT OF THE NORWEGIAN DIET, (1998); PRATTALA R., HELASOJA V., MYKKANEN H., THE CONSUMPTION OF RYE BREAD AND WHITE BREAD AS DIMENSIONS OF HEALTH LIFESTYLES IN FINLAND, PUBLIC HEALTH NUTR, 4, PP. 813-819, (2007); ADAMS J.F., ENGSTROM A., HELPING CONSUMERS ACHIEVE RECOMMENDED INTAKES OF WHOLE GRAIN FOODS, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 19, 3 SUPPL., (2000); JENKINS D.J., WESSON V., WOLEVER T.M., ET AL., WHOLEMEAL VERSUS WHOLEGRAIN BREADS: PROPORTION OF WHOLE OR CRACKED GRAIN AND THE GLYCAEMIC RESPONSE, BMJ, 297, PP. 958-960, (1988); JACOBS JR. D.R., PEREIRA M.A., STUMPF K., PINS J.J., ADLERCREUTZ H., WHOLE GRAIN FOOD INTAKE ELEVATES SERUM ENTEROLACTONE, BRITISH JOURNAL OF NUTRITION, 88, 2, PP. 111-116, (2002); LUTSEY P.L., JACOBS JR. D.R., KORI S., MAYER-DAVIS E., SHEA S., STEFFEN L.M., SZKLO M., TRACY R., WHOLE GRAIN INTAKE AND ITS CROSS-SECTIONAL ASSOCIATION WITH OBESITY, INSULIN RESISTANCE, INFLAMMATION, DIABETES AND SUBCLINICAL CVD: THE MESA STUDY, BRITISH JOURNAL OF NUTRITION, 98, 2, PP. 397-405, (2007); MCKEOWN N.M., MEIGS J.B., LIU S., WILSON P.W.F., JACQUES P.F., WHOLE-GRAIN INTAKE IS FAVORABLY ASSOCIATED WITH METABOLIC RISK FACTORS FOR TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE IN THE FRAMINGHAM OFFSPRING STUDY, AMERICAN JOURNAL OF CLINICAL NUTRITION, 76, 2, PP. 390-398, (2002); NEWBY P.K., MARAS J., BAKUN P., MULLER D., FERRUCCI L., TUCKER K.L., INTAKE OF WHOLE GRAINS, REFINED GRAINS, AND CEREAL FIBER MEASURED WITH 7-D DIET RECORDS AND ASSOCIATIONS WITH RISK FACTORS FOR CHRONIC DISEASE, AMERICAN JOURNAL OF CLINICAL NUTRITION, 86, 6, PP. 1745-1753, (2007); VANHARANTA M., VOUTILAINEN S., LAKKA T.A., VAN DER LEE M., ADLERCREUTZ H., SALONEN J.T., RISK OF ACUTE CORONARY EVENTS ACCORDING TO SERUM CONCENTRATIONS OF ENTEROLACTONE: A PROSPECTIVE POPULATION-BASED CASE-CONTROL STUDY, LANCET, 354, 9196, PP. 2112-2115, (1999); LEVI F., PASCHE C., LUCCHINI F., CHATENOUD L., JACOBS JR. D.R., LA VECCHIA C., REFINED AND WHOLE GRAIN CEREALS AND THE RISK OF ORAL, OESOPHAGEAL AND LARYNGEAL CANCER, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 54, 6, PP. 487-489, (2000); SLAVIN J.L., MECHANISMS FOR THE IMPACT OF WHOLE GRAIN FOODS ON CANCER RISK, J AM COLL NUTR, 19, (2000); SLAVIN J.L., MARTINI M.C., JACOBS JR. D.R., ET AL., PLAUSIBLE MECHANISMS FOR THE PROTECTIVENESS OF WHOLE GRAINS, AM J CLIN NUTR, 70, (1999); HABER G.B., HEATON K.W., MURPHY D., ET AL., DEPLETION AND DISRUPTION OF DIETARY FIBRE, EFFECTS ON SATIETY, PLASMAGLUCOSE, AND SERUM-INSULIN. LANCET, 2, PP. 679-682, (1977); READ N.W., WELCH I.M., AUSTEN C.J., ET AL., SWALLOWING FOOD WITHOUT CHEWING; A SIMPLE WAY TO REDUCE POSTPRANDIAL GLYCAEMIA, BR J NUTR, 55, PP. 43-47, (1986); FARDET A., LEENHARDT F., LIOGER D., SCALBERT A., REMESY C., PARAMETERS CONTROLLING THE GLYCAEMIC RESPONSE TO BREADS, NUTRITION RESEARCH REVIEWS, 19, 1, PP. 18-25, (2006); GRANFELDT Y., HAGANDER B., BJORCK I., METABOLIC RESPONSES TO STARCH IN OAT AND WHEAT PRODUCTS. ON THE IMPORTANCE OF FOOD STRUCTURE, INCOMPLETE GELATINIZATION OR PRESENCE OF VISCOUS DIETARY FIBRE, EUR J CLIN NUTR, 49, PP. 189-199, (1995); LILJEBERG H., GRANFELDT Y., BJORCK I., METABOLIC RESPONSES TO STARCH IN BREAD CONTAINING INTACT KERNELS VS MILLED FLOUR, AMERICAN JOURNAL OF CLINICAL NUTRITION, 59, 3 SUPPL., (1994); NILSSON A.C., OSTMAN E.M., GRANFELDT Y., BJORCK I.M.E., EFFECT OF CEREAL TEST BREAKFASTS DIFFERING IN GLYCEMIC INDEX AND CONTENT OF INDIGESTIBLE CARBOHYDRATES ON DAYLONG GLUCOSE TOLERANCE IN HEALTHY SUBJECTS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 87, 3, PP. 645-654, (2008); THE DEFINITION OF DIETARY FIBER, CEREAL FOODS WORLD, 46, 3, PP. 112-129, (2001); NILSSON A.C., OSTMAN E.M., HOLST J.J., ET AL., INCLUDING INDIGESTIBLE CARBOHYDRATES IN THE EVENING MEAL OF HEALTHY SUBJECTS IMPROVES GLUCOSE TOLERANCE, LOWERS INFLAMMATORY MARKERS, AND INCREASES SATIETY AFTER A SUBSEQUENT STANDARDIZED BREAKFAST, J NUTR, 138, PP. 732-739, (2008); TOPPING D., CEREAL COMPLEX CARBOHYDRATES AND THEIR CONTRIBUTION TO HUMAN HEALTH, JOURNAL OF CEREAL SCIENCE, 46, 3, PP. 220-229, (2007); WOOD P.J., CEREAL B-GLUCANS IN DIET AND HEALTH, J CEREAL SCI, 46, PP. 230-238, (2007); KOH-BANERJEE P., FRANZ M., SAMPSON L., LIU S., JACOBS JR. D.R., SPIEGELMAN D., WILLETT W., RIMM E., CHANGES IN WHOLE-GRAIN, BRAN, AND CEREAL FIBER CONSUMPTION IN RELATION TO 8-Y WEIGHT GAIN AMONG MEN, AMERICAN JOURNAL OF CLINICAL NUTRITION, 80, 5, PP. 1237-1245, (2004); SLAVIN J.L., DIETARY FIBER AND BODY WEIGHT, NUTRITION, 21, PP. 411-418, (2005); JENKINS A.L., JENKINS D.J.A., ZDRAVKOVIC U., WURSCH P., VUKSAN V., DEPRESSION OF THE GLYCEMIC INDEX BY HIGH LEVELS OF Β-GLUCAN FIBER IN TWO FUNCTIONAL FOODS TESTED IN TYPE 2 DIABETES, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 56, 7, PP. 622-628, (2002); ZHANG J.X., HALLMANS G., ANDERSSON H., ET AL., EFFECT OF OAT BRAN ON PLASMA CHOLESTEROL AND BILE ACID EXCRETION IN NINE SUBJECTS WITH ILEOSTOMIES, AM J CLIN NUTR, 56, PP. 99-105, (1992); LIA A., HALLMANS G., SANDBERG A.S., ET AL., OAT BGLUCAN INCREASES BILE ACID EXCRETION AND A FIBER-RICH BARLEY FRACTION INCREASES CHOLESTEROL EXCRETION IN ILEOSTOMY SUBJECTS, AM J CLIN NUTR, 62, PP. 1245-1251, (1995); SCHEPPACH W., BARTRAM H.P., RICHTER F., ROLE OF SHORT-CHAIN FATTY ACIDS IN THE PREVENTION OF COLORECTAL CANCER, EUR J CANCER, 31, PP. 1077-1080, (1995); SLAVIN J., WHY WHOLE GRAINS ARE PROTECTIVE: BIOLOGICAL MECHANISMS, PROCEEDINGS OF THE NUTRITION SOCIETY, 62, 1, PP. 129-134, (2003); COSTABILE A., KLINDER A., FAVA F., NAPOLITANO A., FOGLIANO V., LEONARD C., GIBSON G.R., TUOHY K.M., WHOLE-GRAIN WHEAT BREAKFAST CEREAL HAS A PREBIOTIC EFFECT ON THE HUMAN GUT MICROBIOTA: A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY, BRITISH JOURNAL OF NUTRITION, 99, 1, PP. 110-120, (2008); BROUNS F., KETTLITZ B., ARRIGONI E., RESISTANT STARCH AND THE BUTYRATE REVOLUTION, TRENDS FOOD SCI TECHNOL, 13, PP. 251-261, (2002); BOFFA L.C., LUPTON J.R., MARIANI M.R., ET AL., MODULATION OF COLONIC EPITHELIAL CELL PROLIFERATION, HISTONE ACETYLATION, AND LUMINAL SHORT CHAIN FATTY ACIDS BY VARIATION OF DIETARY FIBER (WHEAT BRAN) IN RATS, CANCER RES, 52, PP. 5906-5912, (1992); HIGGINS J., THE ROLE OF RESISTANT STARCH CONSUMPTION IN WEIGHT LOSS, AGRO FOOD INDUSTRY HI-TECH, 15, 1, PP. 45-47, (2004); MCINTOSH G.H., NOAKES M., ROYLE P.J., ET AL., WHOLEGRAIN RYE AND WHEAT FOODS AND MARKERS OF BOWEL HEALTH IN OVERWEIGHT MIDDLE-AGED MEN, AM J CLIN NUTR, 77, PP. 967-974, (2003); FERGUSON L.R., HARRIS P.J., PROTECTION AGAINST CANCER BY WHEAT BRAN: ROLE OF DIETARY FIBRE AND PHYTOCHEMICALS, EUR J CANCER PREV, 8, PP. 17-25, (1999); LOPEZ H.W., COUDRAY C., BELLANGER J., LEVRAT-VERNY M.-A., DEMIGNE C., RAYSSIGUIER Y., REMESY C., RESISTANT STARCH IMPROVES MINERAL ASSIMILATION IN RATS ADAPTED TO A WHEAT BRAN DIET, NUTRITION RESEARCH, 20, 1, PP. 141-155, (2000); LOPEZ H.W., LEVRAT-VERNY M.-A., COUDRAY C., BESSON C., KRESPINE V., MESSAGER A., DEMIGNE C., REMESY C., CLASS 2 RESISTANT STARCHES LOWER PLASMA AND LIVER LIPIDS AND IMPROVE MINERAL RETENTION IN RATS, JOURNAL OF NUTRITION, 131, 4, PP. 1283-1289, (2001); COUDRAY C., BELLANGER J., CASTIGLIA-DELAVAUD C., REMESY C., VERMOREL M., RAYSSIGNUIER Y., EFFECT OF SOLUBLE OR PARTLY SOLUBLE DIETARY FIBRES SUPPLEMENTATION ON ABSORPTION AND BALANCE OF CALCIUM, MAGNESIUM, IRON AND ZINC IN HEALTHY YOUNG MEN, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 51, 6, PP. 375-380, (1997); LOPEZ H.W., COUDRAY C., LEVRAT-VERNY M.A., ET AL., FRUCTOOLIGOSACCHARIDES ENHANCE MINERAL APPARENT ABSORPTION AND COUNTERACT THE DELETERIOUS EFFECTS OF PHYTIC ACID ON MINERAL HOMEOSTASIS IN RATS, J NUTR BIOCHEM, 11, PP. 500-508, (2000); REDDY B.S., HAMID R., RAO C.V., EFFECT OF DIETARY OLIGOFRUCTOSE AND INULIN ON COLONIC PRENEOPLASTIC ABERRANT CRYPT FOCI INHIBITION, CARCINOGENESIS, 18, 7, PP. 1371-1374, (1997); MCINTYRE A., GIBSON P.R., YOUNG G.P., BUTYRATE PRODUCTION FROM DIETARY FIBRE AND PROTECTION AGAINST LARGE BOWEL CANCER IN A RAT MODEL, GUT, 34, 3, PP. 386-391, (1993); HEERDT B.G., HOUSTON M.A., ANTHONY G.M., ET AL., INITIATION OF GROWTH ARREST AND APOPTOSIS OF MCF-7 MAMMARY CARCINOMA CELLS BY TRIBUTYRIN, A TRIGLYCERIDE ANALOGUE OF THE SHORT-CHAIN FATTY ACID BUTYRATE, IS ASSOCIATED WITH MITOCHONDRIAL ACTIVITY, CANCER RES, 59, PP. 1584-1591, (1999); ELLERHORST J., NGUYEN T., DNW C., ET AL., INDUCTION OF DIFFERENTIATION AND APOPTOSIS IN THE PROSTATE CANCER CELL LINE LNCAP BY SODIUM BUTYRATE AND GALECTIN-1, INT J ONCOL, 14, PP. 225-232, (1999); BIRD A.R., VUARAN M.S., KING R.A., ET AL., WHOLEGRAIN FOODS MADE FROM A NOVEL HIGH-AMYLOSE BARLEY VARIETY (HIMALAYA 292) IMPROVE INDICES OF BOWEL HEALTH IN HUMAN SUBJECTS, BR J NUTR, 99, PP. 1032-1040, (2008); LILJEBERG H., BJORCK I., BIOAVAILABILITY OF STARCH IN BREAD PRODUCTS. POSTPRANDIAL GLUCOSE AND INSULIN RESPONSES IN HEALTHY SUBJECTS AND IN VITRO RESISTANT STARCH CONTENT, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 48, 3, PP. 151-163, (1994); HARA H., HAGA S., AOYAMA Y., KIRIYAMA S., SHORT-CHAIN FATTY ACIDS SUPPRESS CHOLESTEROL SYNTHESIS IN RAT LIVER AND INTESTINE, JOURNAL OF NUTRITION, 129, 5, PP. 942-948, (1999); JENKINS D.J.A., WOLEVER T.M.S., NINEHAM R., IMPROVED GLUCOSE TOLERANCE FOUR HOURS AFTER TAKING GUAR WITH GLUCOSE, DIABETOLOGIA, 19, 1, PP. 21-24, (1980); JENKINS D., WOLEVER T., TAYLOR R., ET AL., SLOW RELEASE DIETARY CARBOHYDRATE IMPROVES SECOND MEAL TOLERANCE, AM J CLIN NUTR, 35, PP. 1339-1346, (1982); NILSSON A., GRANFELDT Y., OSTMAN E., PRESTON T., BJORCK I., EFFECTS OF GI AND CONTENT OF INDIGESTIBLE CARBOHYDRATES OF CEREAL-BASED EVENING MEALS ON GLUCOSE TOLERANCE AT A SUBSEQUENT STANDARDISED BREAKFAST, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 60, 9, PP. 1092-1099, (2006); CHERBUT C., MOTOR EFFECTS OF SHORT-CHAIN FATTY ACIDS AND LACTATE IN THE GASTROINTESTINAL TRACT, PROCEEDINGS OF THE NUTRITION SOCIETY, 62, 1, PP. 95-99, (2003); WOLEVER T.M.S., SPADAFORA P., ESHUIS H., INTERACTION BETWEEN COLONIC ACETATE AND PROPIONATE IN HUMANS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 53, 3, PP. 681-687, (1991); HOMKO C.J., CHEUNG P., BODEN G., EFFECTS OF FREE FATTY ACIDS ON GLUCOSE UPTAKE AND UTILIZATION IN HEALTHY WOMEN, DIABETES, 52, 2, PP. 487-491, (2003); ANDERSON J.W., BRIDGES S.R., SHORT-CHAIN FATTY ACID FERMENTATION PRODUCTS OF PLANT FIBER AFFECT GLUCOSE METABOLISM OF ISOLATED RAT HEPATOCYTES, PROC SOC EXP BIOL MED, 177, PP. 372-376, (1984); LIU R.H., POTENTIAL SYNERGY OF PHYTOCHEMICALS IN CANCER PREVENTION: MECHANISM OF ACTION, J NUTR, 134, (2004); REDDY B.S., HIROSE Y., COHEN L.A., ET AL., PREVENTIVE POTENTIAL OF WHEAT BRAN FRACTIONS AGAINST EXPERIMENTAL COLON CARCINOGENESIS: IMPLICATIONS FOR HUMAN COLON CANCER PREVENTION, CANCER RES, 60, PP. 4792-4797, (2000); SANG S.M., JU J.Y., LAMBERT J.D., ET AL., WHEAT BRAN OIL AND ITS FRACTIONS INHIBIT HUMAN COLON CANCER CELL GROWTH AND INTESTINAL TUMORIGENESIS IN APC(MIN/) MICE, J AGRIC FOOD CHEM, 54, PP. 9792-9797, (2006); BARTSCH H., NAIR J., CHRONIC INFLAMMATION AND OXIDATIVE STRESS IN THE GENESIS AND PERPETUATION OF CANCER: ROLE OF LIPID PEROXIDATION, DNA DAMAGE, AND REPAIR, LANGENBECK'S ARCHIVES OF SURGERY, 391, 5, PP. 499-510, (2006); GRAF E., EATON J.W., DIETARY SUPPRESSION OF COLONIC CANCER;, FIBER OR PHYTATE? CANCER, 56, PP. 717-718, (1985); KOHLMEIER L., SIMONSEN N., MOTTUS K., DIETARY MODIFIERS OF CARCINOGENESIS, ENVIRONMENTAL HEALTH PERSPECTIVES, 103, SUPPL. 8, PP. 177-184, (1995); NESARETNAM K., WONG W.Y., WAHID M.B., TOCOTRIENOLS AND CANCER: BEYOND ANTIOXIDANT ACTIVITY, EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 109, 4, PP. 445-452, (2007); SHAMSUDDIN A.M., ANTI-CANCER FUNCTION OF PHYTIC ACID, INT J FOOD SCI TECHNOL, 37, PP. 769-782, (2002); ADLERCREUTZ H., PHYTO-OESTROGENS AND CANCER, LANCET ONCOLOGY, 3, 6, PP. 364-373, (2002); ADLERCREUTZ H., MOUSAVI Y., CLARK J., ET AL., DIETARY PHYTOESTROGENS AND CANCER: IN VITRO AND IN VIVO STUDIES, J STEROID BIOCHEM MOLEC BIOL, 41, PP. 331-337, (1992); MARKAVERICH B.M., WEBB B., DENSMORE C.L., ET AL., EFFECTS OF COUMESTROL ON ESTROGEN RECEPTOR FUNCTION AND UTERINE GROWTH IN OVARIECTOMIZED RATS, ENVIRON HEALTH PERSPECT, 103, PP. 574-581, (1995); REDDY B.S., PREVENTION OF COLON CARCINOGENESIS BY COMPONENTS OF DIETARY FIBER, ANTICANCER RES, 19, PP. 3681-3683, (1999); ULLAH A., SHAMSUDDIN A.M., DOSE-DEPENDENT INHIBITION OF LARGE INTESTINAL CANCER BY INOSITOL HEXAPHOSPHATE IN F344 RATS, CARCINOGENESIS, 11, PP. 2219-2222, (1990); VUCENIK I., YANG G.-Y., SHAMSUDDIN A.M., COMPARISON OF PURE INOSITOL HEXAPHOSPHATE AND HIGH-BRAN DIET IN THE PREVENTION OF DMBA-INDUCED RAT MAMMARY CARCINOGENESIS, NUTRITION AND CANCER, 28, 1, PP. 7-13, (1997); HOLLMAN P.C.H., KATAN M.B., ABSORPTION, METABOLISM AND HEALTH EFFECTS OF DIETARY FLAVONOIDS IN MAN, BIOMEDICINE AND PHARMACOTHERAPY, 51, 8, PP. 305-310, (1997); EDENHARDER R., RAUSCHER R., PLATT K.L., THE INHIBITION BY FLAVONOIDS OF 2-AMINO-3-METHYLIMIDAZO4,5-FQUINOLINE METABOLIC ACTIVATION TO A MUTAGEN: A STRUCTURE-ACTIVITY RELATIONSHIP STUDY, MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 379, 1, PP. 21-32, (1997); BARONE E., CALABRESE V., MANCUSO C., FERULIC ACID AND ITS THERAPEUTIC POTENTIAL AS A HORMETIN FOR AGE-RELATED DISEASES, BIOGERONTOLOGY, 10, PP. 97-108, (2009); KAWABATA K., YAMAMOTO T., HARA A., SHIMIZU M., YAMADA Y., MATSUNAGA K., TANAKA T., MORI H., MODIFYING EFFECTS OF FERULIC ACID ON AZOXYMETHANE-INDUCED COLON CARCINOGENESIS IN F344 RATS, CANCER LETTERS, 157, 1, PP. 15-21, (2000); ALABASTER O., TANG Z., SHIVAPURKAR N., DIETARY FIBER AND THE CHEMOPREVENTIVE MODELATION OF COLON CARCINOGENESIS, MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 350, 1, PP. 185-197, (1996); EASTWOOD M.A., GIRDWOOD R.H., LIGNIN: A BILE-SALT SEQUESTRATING AGENT, LANCET, 2, PP. 1170-1172, (1968); EASTWOOD M.A., HAMILTON D., STUDIES ON THE ADSORPTION OF BILE SALTS TO NON-ABSORBED COMPONENTS OF DIET, BIOCHIM BIOPHYS ACTA, 152, PP. 165-173, (1968); LABAJ J., SLAMENOVA D., LAZAROVA M., ET AL., LIGNINSTIMULATED REDUCTION OF OXIDATIVE DNA LESIONS IN TESTICULAR CELLS AND LYMPHOCYTES OF SPRAGUE-DAWLEY RATS IN VITRO AND EX VIVO, NUTR CANCER, 50, PP. 198-205, (2004); WATTENBERG L.W., CHEMOPREVENTION OF CANCER, CANCER RES, 45, PP. 1-8, (1985); JABLONSKA E., SOBALAW G.J., ET AL., JOINT EFFECT OF GPX1 POLYMORPHISM AND SELENIUM STATUS ON LUNG CANCER RISK, EUR J CANCER SUPPL, 6, (2008); STAVRIC B., ANTIMUTAGENS AND ANTICARCINOGENS IN FOODS, FOOD AND CHEMICAL TOXICOLOGY, 32, 1, PP. 79-90, (1994); HARRIS P.J., FERGUSON L.R., DIETARY FIBER - ITS COMPOSITION AND ROLE IN PROTECTION AGAINST COLORECTAL CANCER, MUTAT RES, 290, PP. 97-110, (1993); HARRIS P.J., ROBERTON A.M., WATSON M.E., ET AL., THE EFFECTS OF SOLUBLE-FIBER POLYSACCHARIDES ON THE ADSORPTION OF A HYDROPHOBIC CARCINOGEN TO AN INSOLUBLE DIETARY FIBER, NUTR CANCER, 19, PP. 43-54, (1993); MORITA T., TANABE H., SUGIYAMA K., KASAOKA S., KIRIYAMA S., DIETARY RESISTANT STARCH ALTERS THE CHARACTERISTICS OF COLONIC MUCOSA AND EXERTS A PROTECTIVE EFFECT ON TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS IN RATS, BIOSCIENCE, BIOTECHNOLOGY AND BIOCHEMISTRY, 68, 10, PP. 2155-2164, (2004); TODEN S., BIRD A.R., TOPPING D.L., CONLON M.A., DOSE-DEPENDENT REDUCTION OF DIETARY PROTEIN-INDUCED COLONOCYTE DNA DAMAGE BY RESISTANT STARCH IN RATS CORRELATES MORE HIGHLY WITH CAECAL BUTYRATE THAN WITH OTHER SHORT CHAIN FATTY ACIDS, CANCER BIOLOGY AND THERAPY, 6, 2, PP. 253-258, (2007); STORY J.A., KRITCHEVSKY D., DENIS PARSONS BURKITT 1911-1993, J NUTR, 124, PP. 1551-1554, (1994); BAUER-MARINOVIC M., FLORIAN S., MULLER-SCHMEHL K., GLATT H., JACOBASCH G., DIETARY RESISTANT STARCH TYPE 3 PREVENTS TUMOR INDUCTION BY 1,2-DIMETHYLHYDRAZINE AND ALTERS PROLIFERATION, APOPTOSIS AND DEDIFFERENTIATION IN RAT COLON, CARCINOGENESIS, 27, 9, PP. 1849-1859, (2006); BINGHAM S.A., MECHANISMS AND EXPERIMENTAL AND EPIDEMIOLOGICAL EVIDENCE RELATING DIETARY FIBRE (NON-STARCH POLYSACCHARIDES) AND STARCH TO PROTECTION AGAINST LARGE BOWEL CANCER, PROC NUTR SOC, 49, PP. 153-171, (2007); SJD O., KIDD M., ESPITALIER-NOEL G., ET AL., RARITY OF COLON CANCER IN AFRICANS IS ASSOCIATED WITH LOW ANIMAL PRODUCT CONSUMPTION, NOT FIBER, AM J GASTROENTEROL, 94, PP. 1373-1380, (1999); CHO E., WILLETT W.C., COLDITZ G.A., FUCHS C.S., WU K., CHAN A.T., ZEISEL S.H., GIOVANNUCCI E.L., DIETARY CHOLINE AND BETAINE AND THE RISK OF DISTAL COLORECTAL ADENOMA IN WOMEN, JOURNAL OF THE NATIONAL CANCER INSTITUTE, 99, 16, PP. 1224-1231, (2007); KLAUNIG J.E., XU Y., ISENBERG J.S., BACHOWSKI S., KOLAJA K.L., JIANG J., STEVENSON D.E., WALBORG JR. E.F., THE ROLE OF OXIDATIVE STRESS IN CHEMICAL CARCINOGENESIS, ENVIRONMENTAL HEALTH PERSPECTIVES, 106, SUPPL. 1, PP. 289-295, (1998); HARRIS P.J., FERGUSON L.R., DIETARY FIBRES MAY PROTECT OR ENHANCE CARCINOGENESIS, MUTAT RES, 443, PP. 95-110, (1999); FORD E.S., MOKDAD A.H., GILES W.H., BROWN D.W., THE METABOLIC SYNDROME AND ANTIOXIDANT CONCENTRATIONS: FINDINGS FROM THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, DIABETES, 52, 9, PP. 2346-2352, (2003); HIGDON J.V., FREI B., OBESITY AND OXIDATIVE STRESS: A DIRECT LINK TO CVD?, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 23, 3, PP. 365-367, (2003); KEANEY J.F., LARSON M.G., VASAN R.S., ET AL., OBESITY AS A SOURCE OF SYSTEMIC OXIDATIVE STRESS: CLINICAL CORRELATES OF OXIDATIVE STRESS IN THE FRAMINGHAM STUDY, CIRCULATION, 106, (2002); EVANS J.L., GOLDFINE I.D., MADDUX B.A., ET AL., OXIDATIVE STRESS AND STRESS-ACTIVATED SIGNALING PATHWAYS: A UNIFYING HYPOTHESIS OF TYPE 2 DIABETES, ENDOCR REV, 23, PP. 599-622, (2002); MAIESE K., MORHAN S.D., ZHAO Z.C., OXIDATIVE STRESS BIOLOGY AND CELL INJURY DURING TYPE 1 AND TYPE 2 DIABETES MELLITUS, CURRENT NEUROVASCULAR RESEARCH, 4, 1, PP. 63-71, (2007); CAI H., HARRISON D.G., ENDOTHELIAL DYSFUNCTION IN CARDIOVASCULAR DISEASES: THE ROLE OF OXIDANT STRESS, CIRC RES, 87, PP. 840-844, (2000); CASTELAO J.E., GAGO-DOMINGUEZ M., RISK FACTORS FOR CARDIOVASCULAR DISEASE IN WOMEN: RELATIONSHIP TO LIPID PEROXIDATION AND OXIDATIVE STRESS, MEDICAL HYPOTHESES, 71, 1, PP. 39-44, (2008); MARTINEZ-TOME M., MURCIA M.A., FREGA N., ET AL., EVALUATION OF ANTIOXIDANT CAPACITY OF CEREAL BRANS, J AGRIC FOOD CHEM, 52, PP. 4690-4699, (2004); MILLER H.E., RIGELHOF F., MARQUART L., PRAKASH A., KANTER M., ANTIOXIDANT CONTENT OF WHOLE GRAIN BREAKFAST CEREALS, FRUITS AND VEGETABLES, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 19, 3 SUPPL., (2000); PEREZ-JIMENEZ J., SAURA-CALIXTO F., LITERATURE DATA MAY UNDERESTIMATE THE ACTUAL ANTIOXIDANT CAPACITY OF CEREALS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 12, PP. 5036-5040, (2005); SERPEN A., GOKMEN V., PELLEGRINI N., ET AL., DIRECT MEASUREMENT OF THE TOTAL ANTIOXIDANT CAPACITY OF CEREAL PRODUCTS, J CEREAL SCI, 48, PP. 816-820, (2008); ZIELINSKI H., KOZLOWSKA H., ANTIOXIDANT ACTIVITY AND TOTAL PHENOLICS IN SELECTED CEREAL GRAINS AND THEIR DIFFERENT MORPHOLOGICAL FRACTIONS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 48, 6, PP. 2008-2016, (2000); FARDET A., ROCK E., REMESY C., IS THE IN VITRO ANTIOXIDANT POTENTIAL OF WHOLE-GRAIN CEREALS AND CEREAL PRODUCTS WELL REFLECTED IN VIVO?, J CEREAL SCI, 48, PP. 258-276, (2008); ANDERSSON A., TENGBLAD S., KARLSTROM B., KAMAL-ELDIN A., LANDBERG R., BASU S., AMAN P., VESSBY B., WHOLE-GRAIN FOODS DO NOT AFFECT INSULIN SENSITIVITY OR MARKERS OF LIPID PEROXIDATION AND INFLAMMATION IN HEALTHY, MODERATELY OVERWEIGHT SUBJECTS, JOURNAL OF NUTRITION, 137, 6, PP. 1401-1407, (2007); BEATTIE R.K., LEE A.M., STRAIN J.J., ET AL., EVALUATION OF THE IN VIVO ANTIOXIDANT ACTIVITY OF WHEAT BRAN IN HUMAN SUBJECTS, PROC NUTR SOC, 62, (2003); BRUCE B., SPILLER G.A., KLEVAY L.M., GALLAGHER S.K., A DIET HIGH IN WHOLE AND UNREFINED FOODS FAVORABLY ALTERS LIPIDS, ANTIOXIDANT DEFENSES, AND COLON FUNCTION, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 19, 1, PP. 61-67, (2000); CYO C., MILBURY P.E., COLLINS F.W., ET AL., AVENANTHRAMIDES ARE BIOAVAILABLE AND HAVE ANTIOXIDANT ACTIVITY IN HUMANS AFTER ACUTE CONSUMPTION OF AN ENRICHED MIXTURE FROM OATS, J NUTR, 137, PP. 1375-1382, (2007); HAMILL L.L., KEAVENEY E.M., PRICE R.K., ET AL., ASSESSMENT OF ANTIOXIDANT BIOMARKERS IN HUMAN PLASMA AND URINE AFTER CONSUMPTION OF WHEAT BRAN AND ALEURONE FRACTIONS, PROC NUTR SOC, 66, (2007); JANG Y., JONG H.L., OH Y.K., HYUN Y.P., SANG Y.L., CONSUMPTION OF WHOLE GRAIN AND LEGUME POWDER REDUCES INSULIN DEMAND, LIPID PEROXIDATION, AND PLASMA HOMOCYSTEINE CONCENTRATIONS IN PATIENTS WITH CORONARY ARTERY DISEASE: RANDOMIZED CONTROLLED CLINICAL TRIAL, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 21, 12, PP. 2065-2071, (2001); KIM J.Y., KIM J.H., LEE D.H., ET AL., MEAL REPLACEMENT WITH MIXED RICE IS MORE EFFECTIVE THAN WHITE RICE IN WEIGHT CONTROL, WHILE IMPROVING ANTIOXIDANT ENZYME ACTIVITY IN OBESE WOMEN, NUTR RES, 28, PP. 66-71, (2008); LEWIS S., BOLTON C., HEATON K., LACK OF INFLUENCE OF INTESTINAL TRANSIT ON OXIDATIVE STATUS IN PREMENOPAUSAL WOMEN, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 50, 8, PP. 565-568, (1996); MAKI K.C., GALANT R., SAMUEL P., TESSER J., WITCHGER M.S., RIBAYA-MERCADO J.D., BLUMBERG J.B., GEOHAS J., EFFECTS OF CONSUMING FOODS CONTAINING OAT Β-GLUCAN ON BLOOD PRESSURE, CARBOHYDRATE METABOLISM AND BIOMARKERS OF OXIDATIVE STRESS IN MEN AND WOMEN WITH ELEVATED BLOOD PRESSURE, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 61, 6, PP. 786-795, (2007); PRICE R.K., WELCH R.W., LEE-MANION A.M., ET AL., TOTAL PHENOLICS AND ANTIOXIDANT POTENTIAL IN PLASMA AND URINE OF HUMANS AFTER CONSUMPTION OF WHEAT BRAN, CEREAL CHEM, 85, PP. 152-157, (2008); WANG Q., HAN P., ZHANG M., XIA M., ZHU H., MA J., HOU M., TANG Z., LING W., SUPPLEMENTATION OF BLACK RICE PIGMENT FRACTION IMPROVES ANTIOXIDANT AND ANTI-INFLAMMATORY STATUS IN PATIENTS WITH CORONARY HEART DISEASE, ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 16, SUPPL.1, PP. 295-301, (2007); GRAF E., EMPSON K.L., EATON J.W., PHYTIC ACID. A NATURAL ANTIOXIDANT, J BIOL CHEM, 262, PP. 11647-11650, (1987); DIZHBITE T., TELYSHEVA G., JURKJANE V., VIESTURS U., CHARACTERIZATION OF THE RADICAL SCAVENGING ACTIVITY OF LIGNINS - NATURAL ANTIOXIDANTS, BIORESOURCE TECHNOLOGY, 95, 3, PP. 309-317, (2004); VITAGLIONE P., NAPOLITANO A., FOGLIANO V., CEREAL DIETARY FIBRE: A NATURAL FUNCTIONAL INGREDIENT TO DELIVER PHENOLIC COMPOUNDS INTO THE GUT, TRENDS IN FOOD SCIENCE AND TECHNOLOGY, 19, 9, PP. 451-463, (2008); BABBS C.F., FREE RADICALS AND THE ETIOLOGY OF COLON CANCER, FREE RADICAL BIOLOGY AND MEDICINE, 8, 2, PP. 191-200, (1990); ADAM A., CRESPY V., LEVRAT-VERNY M.-A., LEENHARDT F., LEUILLET M., DEMIGNE C., REMESY C., THE BIOAVAILABILITY OF FERULIC ACID IS GOVERNED PRIMARILY BY THE FOOD MATRIX RATHER THAN ITS METABOLISM IN INTESTINE AND LIVER IN RATS, JOURNAL OF NUTRITION, 132, 7, PP. 1962-1968, (2002); MATEO ANSON N., VAN DEN BERG R., HAVENAAR R., ET AL., BIOAVAILABILITY OF FERULIC ACID IS DETERMINED BY ITS BIOACCESSIBILITY, J CEREAL SCI, 49, PP. 296-300, (2009); RONDINI L., PEYRAT-MAILLARD M.N., MARSSET-BAGLIERI A., ET AL., BOUND FERULIC ACID FROM BRAN IS MORE BIOAVAILABLE THAN THE FREE COMPOUND IN RAT, J AGRIC FOOD CHEM, 52, PP. 4338-4343, (2004); PELLEGRINI N., SERAFINI M., SALVATORE S., DEL RIO D., BIANCHI M., BRIGHENTI F., TOTAL ANTIOXIDANT CAPACITY OF SPICES, DRIED FRUITS, NUTS, PULSES, CEREALS AND SWEETS CONSUMED IN ITALY ASSESSED BY THREE DIFFERENT IN VITRO ASSAYS, MOLECULAR NUTRITION AND FOOD RESEARCH, 50, 11, PP. 1030-1038, (2006); MCCARTY M.F., MAGNESIUM MAY MEDIATE THE FAVORABLE IMPACT OF WHOLE GRAINS ON INSULIN SENSITIVITY BY ACTING AS A MILD CALCIUM ANTAGONIST, MED HYPOTHESES, 64, PP. 619-627, (2005); DURLACH J., COLLERY P., MAGNESIUM AND POTASSIUM IN DIABETES AND CARBOHYDRATE METABOLISM, REVIEW OF THE PRESENT STATUS AND RECENT RESULTS. MAGNESIUM, 3, PP. 315-323, (1984); PAOLISSO G., SGAMBATO S., GAMBARDELLA A., ET AL., DAILY MAGNESIUM SUPPLEMENTS IMPROVE GLUCOSE HANDLING IN ELDERLY SUBJECTS, AM J CLIN NUTR, 55, PP. 1161-1167, (1992); PAOLISSO G., SGAMBATO S., PIZZA G., PASSARIELLO N., VARRICCHIO M., D'ONOFRIO F., IMPROVED INSULIN RESPONSE AND ACTION BY CHRONIC MAGNESIUM ADMINISTRATION IN AGED NIDDM SUBJECTS, DIABETES CARE, 12, 4, PP. 265-269, (1989); PEREIRA M.A., JACOBS JR. D.R., PINS J.J., ET AL., EFFECT OF WHOLE GRAINS ON INSULIN SENSITIVITY IN OVERWEIGHT HYPERINSULINEMIC ADULTS, AM J CLIN NUTR, 75, PP. 848-855, (2002); BALON T.W., JASMAN A., SCOTT S., MEEHAN W.P., RUDE R.K., NADLER J.L., DIETARY MAGNESIUM PREVENTS FRUCTOSE-INDUCED INSULIN INSENSITIVITY IN RATS, HYPERTENSION, 23, 6, PP. 1036-1039, (1994); BALON T.W., GU J.L., TOKUYAMA Y., ET AL., MAGNESIUM SUPPLEMENTATION REDUCES DEVELOPMENT OF DIABETES IN A RAT MODEL OF SPONTANEOUS NIDDM, AM J PHYSIOL ENDOCRINOL METAB, 269, (1995); GOULD M.K., CHAUDRY I.H., THE ACTION OF INSULIN ON GLUCOSE UPTAKE BY ISOLATED RAT SOLEUS MUSCLE. 1. EFFECTS OF CATIONS, BIOCHIM BIOPHYS ACTA, 215, PP. 249-257, (1970); WEGLICKI W.B., MAK I.T., KRAMER J.H., DICKENS B.F., CASSIDY M.M., STAFFORD R.E., PHILLIPS T.M., ROLE OF FREE RADICALS AND SUBSTANCE P IN MAGNESIUM DEFICIENCY, CARDIOVASCULAR RESEARCH, 31, 5, PP. 677-682, (1996); CERIELLO A., BORTOLOTTI N., CRESCENTINI A., MOTZ E., LIZZIO S., RUSSO A., EZSOL Z., TONUTTI L., TABOGA C., ANTIOXIDANT DEFENCES ARE REDUCED DURING THE ORAL GLUCOSE TOLERANCE TEST IN NORMAL AND NON-INSULIN-DEPENDENT DIABETIC SUBJECTS, EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 28, 4, PP. 329-333, (1998); PEREIRA E.C., FERDERBAR S., BERTOLAMI M.C., ET AL., BIOMARKERS OF OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN GLUCOSE INTOLERANCE AND DIABETES MELLITUS, CLIN BIOCHEM, 41, PP. 1454-1460, (2008); ISERI L.T., FRENCH J.H., MAGNESIUM - NATURES PHYSIOLOGIC CALCIUM BLOCKER, AM HEART J, 108, PP. 188-193, (1984); RESNICK L.M., CELLULAR CALCIUM AND MAGNESIUM METABOLISM IN THE PATHOPHYSIOLOGY AND TREATMENT OF HYPERTENSION AND RELATED METABOLIC DISORDERS, AM J MED, 93, (1992); LIAO F., FOLSOM A.R., BRANCATI F.L., IS LOW MAGNESIUM CONCENTRATION A RISK FACTOR FOR CORONARY HEART DISEASE? THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY, AMERICAN HEART JOURNAL, 136, 3, PP. 480-490, (1998); SHECHTER M., MERZ C.N.B., PAUL-LABRADOR M., MEISEL S.R., RUDE R.K., MOLLOY M.D., DWYER J.H., SHAH P.K., KAUL S., ORAL MAGNESIUM SUPPLEMENTATION INHIBITS PLATELET-DEPENDENT THROMBOSIS IN PATIENTS WITH CORONARY ARTERY DISEASE, AMERICAN JOURNAL OF CARDIOLOGY, 84, 2, PP. 152-156, (1999); KAWANO Y., MATSUOKA H., TAKISHITA S., OMAE T., EFFECTS OF MAGNESIUM SUPPLEMENTATION IN HYPERTENSIVE PATIENTS: ASSESSMENT BY OFFICE, HOME, AND AMBULATORY BLOOD PRESSURES, HYPERTENSION, 32, 2, PP. 260-265, (1998); AL-MAMARY M., MOLHAM A.-H., ABDULWALI A.-A., AL-OBEIDI A., IN VIVO EFFECTS OF DIETARY SORGHUM TANNINS ON RABBIT DIGESTIVE ENZYMES AND MINERAL ABSORPTION, NUTRITION RESEARCH, 21, 10, PP. 1393-1401, (2001); THOMPSON L.U., POTENTIAL HEALTH BENEFITS AND PROBLEMS ASSOCIATED WITH ANTINUTRIENTS IN FOODS, FOOD RES INT, 26, PP. 131-149, (1993); GILLOOLY M., BOTHWELL T.H., CHARLTON R.W., FACTORS AFFECTING THE ABSORPTION OF IRON FROM CEREALS, BRITISH JOURNAL OF NUTRITION, 51, 1, PP. 37-46, (1984); TATALA S., SVANBERG U., MDUMA B., LOW DIETARY IRON AVAILABILITY IS A MAJOR CAUSE OF ANEMIA: A NUTRITION SURVEY IN THE LINDI DISTRICT OF TANZANIA, AMERICAN JOURNAL OF CLINICAL NUTRITION, 68, 1, PP. 171-178, (1998)","A. FARDET; INRA, UMR 1019 NUTRITION HUMAINE, F-63122 SAINT-GENÈS-CHAMPANELLE, FRANCE; EMAIL: ANTHONY.FARDET@CLERMONT.INRA.FR","","ENGLISH","NUT. RES. REV.","ARTICLE","ISI","2-S2.0-77957271871","NUT RES REV","FRANCE","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"FARDET A, 2010, NUT RES REV","FARDET A, 2010, NUT RES REV"
"ILLNAIT J;CASTAÑO G;ALVAREZ E;FERNÁNDEZ L;MAS R;MENDOZA S;GAMEZ R","ILLNAIT, JOSÉ (8631465800); CASTAÑO, GLADYS (56232967100); ALVAREZ, ERNESTO (57197027849); FERNÁNDEZ, LILIA (7202848319); MAS, ROSA (7007164572); MENDOZA, SARAHÍ (7102759819); GAMEZ, RAFAEL (7003605346)","EFFECTS OF POLICOSANOL 10 MGD VERSUS ASPIRIN 100 MGD IN PATIENTS WITH INTERMITTENT CLAUDICATION A 10WEEK RANDOMIZED COMPARATIVE STUDY",2008,"ANGIOLOGY","59","8",2,"10.1177/0003319707306963","MEDICAL SURGICAL RESEARCH CENTRE, HAVANA CITY, CUBA, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTRE, HAVANA CITY, CUBA","ANTIPLATELET THERAPY, INCLUDING ASPIRIN, IS RECOMMENDED TO LOWER THE VASCULAR RISK IN PATIENTS WITH INTERMITTENT CLAUDICATION. POLICOSANOL HAS INCREASED WALKING DISTANCES IN THESE PATIENTS, PROBABLY BECAUSE OF ITS ANTIPLATELET EFFECTS, BUT THE EFFECT OF SHORTER TREATMENT HAS NOT BEEN STUDIED. THIS DOUBLE-BLIND STUDY COMPARED THE EFFECTS OF POLICOSANOL 10 MG/D AND ASPIRIN 100 MG/D FOR 10 WEEKS ON WALKING DISTANCES IN CLAUDICANTS. THIRTY-NINE PATIENTS WERE RANDOMIZED TO POLICOSANOL OR ASPIRIN. WALKING DISTANCES ON A TREADMILL WERE ASSESSED BEFORE AND AFTER TREATMENT. POLICOSANOL SIGNIFICANTLY INCREASED THE INITIAL AND ABSOLUTE CLAUDICATION DISTANCES, WHILE ASPIRIN CHANGED NEITHER VARIABLE. POLICOSANOL, NOT ASPIRIN, SIGNIFICANTLY LOWERED SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL AND TOTAL CHOLESTEROL WHILE RAISING HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL. IN CONCLUSION, TREATMENTS OF POLICOSANOL, NOT ASPIRIN, FOR 10 WEEKS SIGNIFICANTLY INCREASED WALKING DISTANCES, BUT MODESTLY, IN CONTRAST WITH PREVIOUS RESULTS. THEREFORE, THE DURATION OF TREATMENTS AT THE DOSES TESTED WAS TOO SHORT FOR MEANINGFUL EFFECTS ON THE TREADMILL TEST. © 2008 SAGE PUBLICATIONS.","ASPIRIN; INTERMITTENT CLAUDICATION; POLICOSANOL; WALKING DISTANCES","ADULT; AGED; ASPIRIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FATTY ALCOHOLS; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LIPIDS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECOVERY OF FUNCTION; TREATMENT OUTCOME; WALKING; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; POLICOSANOL; ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BULIMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEARTBURN; HUMAN; INTERMITTENT CLAUDICATION; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREADMILL; WALKING SPEED","","","HIRSCH A.T., CRIQUI M.H., TREAT-JACOBSON D., PERIPHERAL ARTERIAL DISEASE DETECTION, AWARENESS, AND TREATMENT IN PRIMARY CARE, JAMA, 286, PP. 1317-1324, (2001); HIATT W.R., MEDICAL TREATMENT OF PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, N ENGL J MED, 344, PP. 1608-1621, (2001); HANKEY G.J., NORMAN P.E., EIKELBOOM J.W., MEDICAL TREATMENT OF PERIPHERAL ARTERIAL DISEASE, JAMA, 295, PP. 547-553, (2006); CRIQUI M.H., FRONEK A., BARRETT-CONNOR E., THE PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN A DEFINED POPULATION, CIRCULATION, 71, PP. 510-515, (1985); BALKAN B., VRAY M., ESCHWEGP E., EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE, J CARDIOVASC PHARMACOL, 23, 3, PP. 8-16, (1994); MA H., COLGAN M.P., SEEGER R.W., RELATIONSHIP OF SEVERITY OF LOWER LIMB PERIPHERAL VASCULAR DISEASE TO MORTALITY AND MORBIDITY: A SIX-YEAR FOLLOW-UP STUDY, J VASC SURG, 9, PP. 691-697, (1989); OGREN M., HEDBLAD B., ISACSSON S.O., NON-INVASIVELY DETECTED CAROTID STENOSIS AND ISCHAEMIC HEART DISEASE IN MEN WITH LEG ARTERIOSCLEROSIS, LANCET, 342, PP. 1138-1141, (1993); CRIQUI M.H., DENENBERG J.O., LANGER R.D., THE EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE: IMPORTANCE OF IDENTIFYING THE POPULATION AT RISK, VASC MED, 2, PP. 221-226, (1997); MURABITO J.M., EVANS J.C., NIETO K., PREVALENCE AND CLINICAL CORRELATES OF PERIPHERAL ARTERIAL DISEASE IN THE FRAMINGHAM OFFSPRING STUDY, AM HEART J, 143, PP. 961-965, (2002); AB N., SISCOVICK D.S., MANOLIO T.A., ANKLE-ARM INDEX AS A MARKER OF ATHEROSCLEROSIS IN THE CARDIOVASCULAR HEALTH STUDY, CIRCULATION, 88, PP. 837-845, (1993); FGR F., LENG G.C., LEE A.J., THE ANKLE ARM INDEX AS A PREDICTOR OF CARDIOVASCULAR EVENTS AND DEATH IN GENERAL POPULATION. ABSTRACTS OF THE 4TH INTERNATIONAL CONFERENCE ON PREVENTIVE CARDIOLOGY. CAN J CARDIOL, (1997); BOWLIN S.J., MEDALIE J.H., FLOCKE S.A., EPIDEMIOLOGY OF INTERMITTENT CLAUDICATION IN MIDDLE-AGED MEN, AM J EPIDEMIOL, 140, PP. 418-430, (1994); DORMANDY J.A., RUTHERFORD R.B., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD): TASC WORKING GROUP, J VASC SURG, 31, (2000); FGR F., HOUSLEY E., RIEMERSMA R.A., SMOKING, LIPIDS, GLUCOSE INTOLERANCE AND BLOOD PRESSURE AS RISK FACTORS FOR PERIPHERAL ATHEROSCLEROSIS COMPARED WITH ISCHEMIC HEART DISEASE IN THE EDINBURGH ARTERY STUDY, AM J EPIDEMIOL, 135, PP. 331-340, (1992); GDO L., FGR F., DAWES J., BLOOD VISCOSITY, FIBRINOGEN AND ACTIVATION OF COAGULATION AND LEUCOCYTES IN PERIPHERAL ARTERIAL DISEASE AND THE NORMAL POPULATION IN THE EDINBURGH ARTERY STUDY, CIRCULATION, 87, PP. 1915-1920, (1993); RIDKER P.M., STAMPFER M.J., RIFAI N., NOVEL RISK FACTORS FOR SYSTEMIC ATHEROSCLEROSIS: A COMPARISON OF C-REACTIVE PROTEIN, FIBRINOGEN, HOMOCYSTEINE, LIPOPROTEIN(A) AND STANDARD CHOLESTEROL SCREENING AS PREDICTORS OF PERIPHERAL ARTERIAL DISEASE, JAMA, 285, PP. 2481-2485, (2001); HIATT W.R., PHARMACOLOGIC THERAPY FOR PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, J VASC SURG, 36, PP. 1283-1291, (2002); HIATT W.R., KRANTZ M.J., MASTERCLASS SERIES IN PERIPHERAL ARTERIAL DISEASE. ANTIPLATELET THERAPY FOR PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, VASC MED, 11, PP. 55-60, (2006); CLAGETT G.P., SOBEL M., JACKSON M.R., ANTITHROMBOTIC THERAPY IN PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, THE SEVENTH ACCP CONFERENCE ON ANTITHROMBOTIC AND THROMBOLYTIC THERAPY; TRIALISTS A., COLLABORATION. COLLABORATIVE META-ANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION, AND STROKE IN HIGH RISK PATIENTS, BMJ, 324, PP. 71-86, (2002); BEEBE H.G., DAWSON D.L., CUTLER B.S., A NEW PHARMACOLOGIC TREATMENT FOR INTERMITTENT CLAUDICATION: RESULTS OF A RANDOMIZED, MULTICENTER TRIAL, ARCH INTERN MED, 159, PP. 2041-2050, (1999); DAWSON D.L., CUTLER B.S., HIATT W.R., A COMPARISON OF CILOSTAZOL AND PENTOXIFYLLINE FOR TREATING INTERMITTENT CLAUDICATION, AM J MED, 109, PP. 523-530, (2000); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); MOHLER E.R., HIATT W.R., MA C., FOR THE STUDY INVESTIGATORS. CHOLESTEROL REDUCTION WITH ATORVASTATIN IMPROVES WALKING DISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 108, (2003); MONDILLO S., BALLO P., BARBATI R., EFFECTS OF SIMVASTATIN ON WALKING PERFORMANCE AND SYMPTOMS OF INTERMITTENT CLAUDICATION IN HYPERCHOLESTEROLEMIC PATIENTS WITH PERIPHERAL VASCULAR DISEASE, AM J MED, 114, PP. 359-364, (2003); ARONOW W.S., NAYAK D., WOODWORTH S., AHN C., EFFECT OF SIMVASTATIN VERSUS PLACEBO ON TREADMILL EXERCISE TIME UNTIL THE ONSET OF INTERMITTENT CLAUDICATION IN OLDER PATIENTS WITH PERIPHERAL ARTERIAL DISEASE AT SIX MONTHS AND AT ONE YEAR AFTER TREATMENT, AM J CARDIOL, 92, PP. 711-712, (2003); MCDERMOTT M., GURALNIK J., GREENLAND P., STATIN USE AND LEG FUNCTIONING IN PATIENTS WITH AND WITHOUT LOWER-EXTREMITY PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 107, (2003); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); PONS P., RODRIGUEZ M., ROBAINA C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); TORRES O., AGRAMONTE A.J., ILLNAIT J., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CAMPILONGO R., SANDINI P., FELDMAN R., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, LA PRENSA MÉDICA ARGENTINA, 83, PP. 665-672, (1996); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); PRAT H., ROMAN O., PINO E., EFECTO COMPARATIVO DEL POLICOSANOL CON DOS INHIBIDORES DE LA HMGCOA REDUCTASA EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA TIPO II, REV MED CHILE, 127, PP. 286-294, (1999); ALCOCER A., FERNANDEZ L., CAMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 57-64, (1999); NIKITIN I.P., STEPCHENKO N.V., GRATSIANSKI N.A., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC DRUG POLYCOSANOL IN RUSSIA, TTER ARKH, 72, PP. 7-10, (2000); MIRKIN A., MAS R., MARTINTO M., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-42, (2001); FIGUERA S.R., SOTO I., LARA A., ESTUDIO COMPARATIVO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL EN PACIENTES CON HIPERCOLESTEROLEMIA TIPO II, ARCH VENEZOL FARMACOL TERAP, 20, PP. 88-91, (2001); MORENO F.L., LAGOMASINO A.L., RAMIREZ M., UTILIDAD DEL POLICOSANOL EN PACIENTES OBESOS SOMETIDOS A REVASCULARIZACIÓN MIOCÁRDICA QUIRÚRGICA, CONGRESS OF CARDIOLOGY, (2005); CANETTI M., MORERA M., ILLNAIT J., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); BATISTA J.F., STUSSER R.J., PADRON R., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTH OF LIPID-LOWERING THERAPY WITH POLICOSANOL, ADV THER, 13, PP. 137-148, (1996); CASTANO G., MAS R., FERNANDEZ J., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLEMIA, DRUGS R D, 3, PP. 159-172, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAM TROMB HEMOST, 5, PP. 17-20, (1992); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMB HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAG LEUK ESS FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., ANTIPLATELET EFFECTS OF POLICOSANOL 20 AND 40 MG/D IN HEALTHY VOLUNTEERS AND DYSLIPIDEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); CASTANO G., FERNANDEZ L., MAS R., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); CASTANO G., MAS R., FERNANDEZ L., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ J., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., FERNANDEZ L., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2004); HEIDRICH H., ALLENBERG J., CACHOVAN M., GUIDELINES FOR THERAPEUTIC STUDIES ON PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN FONTAINE STAGES II-IV, VASA, 21, PP. 339-343, (1992); CIOCON J.O., GALINDO-CIOCON D., GALINDO D.J., A COMPARISON BETWEEN ASPIRIN AND PENTOXIFYLLINE IN RELIEVING CLAUDICATION DUE TO PERIPHERAL VASCULAR DISEASE IN THE ELDERLY, ANGIOLOGY, 48, PP. 237-240, (1997); GOTTO A., ASSMANN G., CARMENA R., THE INTERNATIONAL LIPID INFORMATION BUREAU (ILIB): LIPID HANDBOOK FOR CLINICAL PRACTICE, BLOOD LIPIDS AND CORONARY HEART DISEASE, (2000); TOFLER G.H., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH, N ENGL J MED, 316, PP. 1514-1518, (1987); SEIGLER L., WU T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGUE, CLIN CHEM, 18, PP. 499-502, (1972); NARANJO C.A., BUSTO U., SELLERS E.M., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN PHARMACOL THER, 30, PP. 239-245, (1981); COMEROTA A.J., EFFECT ON PLATELET FUNCTION OF CILOSTAZOL, CLOPIDOGREL, AND ASPIRIN, EACH ALONE OR IN COMBINATION, ATHEROSCLER SUPPL, 6, PP. 13-19, (2005); ALLEGRA C., POLLARI G., CARIOTI B., SARDINA M., THROMBIN AND PLATELET INHIBITION WITH LOW-DOSE CALCIUM-HEPARIN IN COMPARISON WITH ASA IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE AT LERICHE-FONTAINE IIB CLASS, INT J CLIN PHARMACOL THER, 32, PP. 646-651, (1994); PEDERSEN T.R., KJEKSHUS J., PYORALA K., EFFECT OF SIMVASTATIN ON ISCHEMIC SIGNS AND SYMPTOMS IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), AM J CARDIOL, 81, PP. 333-335, (1998); BLANKENHORN D.H., AZEN S.P., CRAWFORD D.W., EFFECTS OF COLESTIPOL-NIACIN THERAPY ON HUMAN FEMORAL ATHEROSCLEROSIS, CIRCULATION, 83, PP. 438-447, (1991); CHEN J.T., WESLEY R., SHAMBUREK R.D., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLIN J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEAEMIC AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDOBEN S., DEGENHARDT R., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED-TRIAL, JAMA, 295, PP. 2262-2269, (2006); CUBBEDU L.X., CUBBEDU R.J., HEIMOWITZ T., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, PP. 982-985, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCOLESTEROLEMIA: A RANDOMIZED, CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); WRIGHT C.M., ZIEIKE J.C., WHAYNE T.F., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE. USE IN PATIENTS INTOLERANT OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INT J ANGIOL, 13, PP. 173-175, (2004); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASES, J PHARMACOL EXP THER, 106, PP. 107-144, (2006); KRUSIUS T., HIRVONEN J., VAHTERA E., KALA R., SHORT-TERM ASPIRIN TREATMENT DOES NOT REDUCE PLASMA FIBRINOGEN CONCENTRATION IN YOUNG HEALTHY ADULTS, THROMB RES, 75, PP. 653-656, (1994); HAMPTON K.K., CERLETTI C., LOIZOU L.A., COAGULATION, FIBRINOLYTIC AND PLATELET FUNCTION IN PATIENTS ON LONG-TERM THERAPY WITH ASPIRIN 300 MG OR 1,200 MG DAILY COMPARED WITH PLACEBO, THROMB HAEMOST, 64, PP. 17-20, (1990); WOODWARD M., GDO L., LMAMA F., FOR THE CADET STUDY INVESTIGATORS. A RANDOMIZED COMPARISON OF THE EFFECTS OF ASPIRIN AND CLOPIDOGREL ON THROMBOTIC RISK FACTORS AND C-REACTIVE PROTEIN FOLLOWING MYOCARDIAL INFARCTION: THE CADET TRIAL, J THROMB HAEMOST, 2, PP. 1934-1940, (2004)","J. ILLNAIT; NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA, HAVANA CITY, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","ANGIOLOGY","ARTICLE","ISI","2-S2.0-44849085353","ANGIOLOGY","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTRE;MEDICAL SURGICAL RESEARCH CENTRE;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTRE","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"ILLNAIT J, 2008, ANGIOLOGY","ILLNAIT J, 2008, ANGIOLOGY"
"LYDIC M;JUTURU V","LYDIC, MICHAEL (6508334873); JUTURU, VIJAYA (57193640539)","DIETARY APPROACHES AND ALTERNATIVE THERAPIES FOR POLYCYSTIC OVARY SYNDROME",2008,"CURRENT NUTRITION AND FOOD SCIENCE","4","16",3,"10.2174/157340108786263711","SUNY-STONY BROOK, DEPT. OB-GYN, DIVISION OF REPRODUCTIVE ENDOCRINOLOGY, PURCHASE, NY, UNITED STATES;PURCHASE, NY 10577, 4 MANHATTANVILLE ROAD, UNITED STATES","POLYCYSTIC OVARIAN SYNDROME (PCOS) IS A COMMON ENDOCRINE DISORDER IN REPRODUCTIVE AGE WOMEN. PCOS IS CHARACTERIZED BY THE ABSENCE OF MENSTRUATION OR IRREGULAR AND ABNORMAL MENSTRUATION, EXCESSIVE AMOUNTS OF BODY HAIR, EXCESSIVE BODY WEIGHT, AND INFERTILITY. WOMEN WITH PCOS OFTEN HAVE MULTIPLE OVARIAN CYSTS, HIGH LEVELS OF ANDROGEN HORMONES, INSULIN RESISTANCE AND METABOLIC SYNDROME. THIS REVIEW IS FOCUSED ON THE DIETARY APPROACHES AND ALTERNATIVE THERAPIES WHICH HAVE BEEN PROVED TO PLAY MAJOR ROLES IN THE TREATMENT OF PCOS. THE IDEAL DIET FOR PCOS IS ONE THAT PROMOTES WEIGHT LOSS AND THEN WEIGHT MAINTENANCE. IN ADDITION, SOME OF THE ESSENTIAL NUTRIENTS MAY IMPROVE ASSOCIATED RISK FACTORS OF PCOS. AMONG THEM ARE CHROMIUM, OMEGA 3 FATTYACIDS, ANTIOXIDANTS, PHYTOSTEROLS, MAGNESIUM, CALCIUM, POTASSIUM AND OTHER ESSENTIAL VITAMINS AND MINERALS. THE MOST IMPORTANT ASPECT OF TREATMENT IS MANAGING CARDIOVASCULAR RISKS, SUCH AS OBESITY, HIGH BLOOD CHOLESTEROL, DIABETES AND HIGH BLOOD PRESSURE. EARLY RECOGNITION AND AGGRESSIVE LIFESTYLE INTERVENTIONS ARE THE CORNERSTONES OF PCOS TREATMENT. TREATING INDIVIDUAL RISK FACTORS MIGHT HELP TO REDUCE OVERALL RISK OF PCOS. SOME OF THE PCOS RISK FACTORS ARE MODIFIABLE. AGGRESSIVE MEDICAL NUTRITIONAL THERAPY MAY BE APPROPRIATE IN EARLY CONDITIONS THAN ADVANCED STAGES. © 2008 BENTHAM SCIENCE PUBLISHERS LTD.","","ACETYLCYSTEINE; ANTIOXIDANT; CALCIUM; CHOLESTEROL; CHROMIUM; CHROMIUM PICOLINATE; CLOMIFENE CITRATE; DEXTRO CHIRO INOSITOL; GENISTEIN; INOSITOL; MAGNESIUM; METFORMIN; MINERAL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; VITAMIN; VITAMIN B GROUP; VITAMIN D; ACANTHOSIS NIGRICANS; ACNE; ALTERNATIVE MEDICINE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIARRHEA; DIETARY INTAKE; EXERCISE; FEMALE; FEMALE INFERTILITY; HIRSUTISM; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; NAUSEA; NUTRIENT; NUTRITIONAL SUPPORT; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VOMITING; WEIGHT REDUCTION","","","BERRINO F., BELLATI C., SECRETO G., ET AL., REDUCING BIOAVAILABLE SEX HORMONES THROUGH A COMPREHENSIVE CHANGE IN DIET: THE DIET AND ANDROGENS (DIANA) RANDOMIZED TRIAL, CANCER EPIDEMIOL BIOMARKERS PREV, 10, 1, PP. 25-33, (2001); SLABBER M., BARNARD H.C., KUYL J.M., DANNHAUSER A., SCHALL R., EFFECTS OF A LOW-INSULIN-RESPONSE, ENERGY-RESTRICTED DIET ON WEIGHT LOSS AND PLASMA INSULIN CONCENTRATIONS IN HYPERINSULINEMIC OBESE FEMALES, AM J CLIN NUTR, 60, 1, PP. 48-53, (1994); LUDWIG D.S., DIETARY GLYCEMIC INDEX AND OBESITY, J NUTR, 130, SUPPL. 2, (2000); AUGUSTIN L.S., DAL MASO L., LA VECCHIA C., ET AL., DIETARY GLYCEMIC INDEX AND GLYCEMIC LOAD, AND BREAST CANCER RISK: A CASE-CONTROL STUDY, ANN ONCOL, 12, 11, PP. 1533-1538, (2001); KNOCHENHAUER E.S., KEY T.J., KAHSAR-MILLER M., WAGGONER W., BOOTS L.R., AZZIZ R., PREVALENCE OF THE POLYCYSTIC OVARY SYNDROME IN UNSELECTED BLACK AND WHITE WOMEN OF THE SOUTHEASTERN UNITED STATES: A PROSPECTIVE STUDY, J CLIN ENDOCRINOL METAB, 83, PP. 3078-3082, (1998); APRIDONIDZE T., ESSAH P.A., IUORNO M.J., NESTLER J.E., PREVALENCE AND CHARACTERISTICS OF THE METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, J CLIN ENDOCRINOL METAB, 90, 4, PP. 1929-1935, (2005); ORIO F., VUOLO L., PALOMBA S., LOMBARDI G., COLAO A., METABOLIC AND CARDIOVASCULAR CONSEQUENCES OF POLYCYSTIC OVARY SYNDROME, MINERVA GINECOL, 60, 1, PP. 39-51, (2008); CHO L.W., ATKIN S.L., CARDIOVASCULAR RISK IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, MINERVA ENDOCRINOL, 32, 4, PP. 263-273, (2007); KENT S.C., GNATUK C.L., KUNSELMAN A.R., DEMERS L.M., LEE P.A., LEGRO R.S., HYPERANDROGENISM AND HYPERINSULINISM IN CHILDREN OF WOMEN WITH PCOS: A CONTROLLED STUDY, J CLIN ENDOCRINOL METAB, 180, 5, PP. 2876-2885, (2008); DIAMANTI-KANDARAKIS E., PAPAVASSILIOU A.G., KANDARAKIS S.A., CHROUSOS G.P., PATHOPHYSIOLOGY AND TYPES OF DYSLIPIDEMIA IN PCOS, TRENDS ENDOCRINOL METAB, 18, 7, PP. 280-285, (2007); CHO L.W., RANDEVA H.S., ATKIN S.L., CARDIOMETABOLIC ASPECTS OF POLYCYSTIC OVARIAN SYNDROME, VASC HEALTH RISK MANAG, 3, 1, PP. 55-63, (2007); GUZELMERIC K., ALKAN N., PIRIMOGLU M., UNAL O., TURAN C., CHRONIC INFLAMMATION AND ELEVATED HOMOCYSTEINE LEVELS ARE ASSOCIATED WITH INCREASED BODY MASS INDEX IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, GYNECOL ENDOCRINOL, 23, 9, PP. 505-510, (2007); COULAM C.B., ANNEGERS J.F., KRANZ J.S., CHRONIC AN OVULATION SYNDROME AND ASSOCIATED NEOPLASIA, OBSTET GYNECOL, 61, 4, PP. 403-407, (1983); FURBERG A.S., THUNE I., METABOLIC ABNORMALITIES (HYPERTENSION, HYPERGLYCEMIA AND OVERWEIGHT), LIFESTYLE (HIGH ENERGY INTAKE AND PHYSICAL INACTIVITY) AND ENDOMETRIAL CANCER RISK IN A NORWEGIAN COHORT, INT J CANCER, 104, 6, PP. 669-676, (2003); DOUGLAS C.C., NORRIS L.E., OSTER R.A., DARNELL B.E., AZZIZ R., GOWER B.A., DIFFERENCE IN DIETARY INTAKE BETWEEN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND HEALTHY CONTROLS, FERTIL STERIL, 86, 2, PP. 411-417, (2006); MUNEYYIRCI-DELALE O., NACHARAJU V.L., DALLOUL M., ET AL., DIVALENT CATIONS IN WOMEN WITH PCOS: IMPLICATIONS FOR CARDIOVASCULAR DISEASE, GYNECOL ENDOCRINOL, 15, 3, PP. 198-201, (2001); SALEH A.M., KHALIL H.S., REVIEW OF NON-SURGICAL AND SURGICAL TREATMENT AND THE ROLE OF INSULIN-SENSITIZING AGENTS IN THE MANAGEMENT OF INFERTILE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME, ACTA OBSTET GYNECOL SCAND, 83, 7, PP. 614-621, (2004); CHAVARRO J.E., RICH-EDWARDS J.W., ROSNER B.A., WILLETT W.C., IRON INTAKE AND RISK OF OVULATORY INFERTILITY, OBSTET GYNECOL, 108, 5, PP. 1145-1152, (2006); CHAVARRO J.E., RICH-EDWARDS J.W., ROSNER B., WILLETT W.C., A PROSPECTIVE STUDY OF DAIRY FOODS INTAKE AND ANOVULATORY INFERTILITY, HUM REPROD, 22, 5, PP. 1340-1347, (2007); PAPALEO E., UNFER V., BAILLARGEON J.P., ET AL., MYO-INOSITOL IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME: A NOVEL METHOD FOR OVULATION INDUCTION, GYNECOL ENDOCRINOL, 23, 12, PP. 700-703, (2007); MCINTOSH E.N., TREATMENT OF WOMEN WITH THE GALACTORRHEA-AMENORRHEA SYNDROME WITH PYRIDOXINE (VITAMIN B6), J CLIN ENDOCRINOL METAB, 42, PP. 1192-1195, (1976); VESCOVI P.P., GERRA G., RASTELLI G., CERESINI G., MOCCIA G., PYRIDOXINE (VIT. B6) DECREASES OPIOIDS-INDUCED HYPERPROLACTINEMIA, HORM METABOL RES, 17, PP. 46-47, (1985); BENDER D.A., GHARTEY-SAM K., SINGH A., EFFECTS OF VITAMIN B6 DEFICIENCY AND REPLETION ON THE UPTAKE OF STEROID HORMONES INTO UTERUS SLICES AND ISOLATED LIVER CELLS OF RATS, BR J NUTR, 61, PP. 619-628, (1989); LEVIN R.M., A SCIENTIFIC BASIS FOR THE THERAPEUTIC EFFECTS OF PYGEUM AFRICANUM AND SERENOA REPENS, UROL RES, 28, PP. 201-209, (2000); KRZESKI T., KAZON M., BORKOWSKI A., WITESKA A., KUCZERA J., COMBINED EXTRACTS OF URTICA DIOICA AND PYGEUM AFRICANUM IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: DOUBLE-BLIND COMPARISON OF TWO DOSES, CLIN THER, 15, PP. 1011-1020, (1993); KOCH E., EXTRACTS FROM FRUITS OF SAW PALMETTO (SABAL SERRULATA) AND ROOTS OF STINGING NETTLE (URTICA DIOICA): VIABLE ALTERNATIVES IN THE MEDICAL TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND ASSOCIATED LOWER URINARY TRACT SYMPTOMS, PLANTA MED, 67, PP. 489-500, (2001); MARSHALL K., POLYCYSTIC OVARY SYNDROME: CLINICAL CONSIDERATIONS, ALTERN MED REV, 6, PP. 272-292, (2001); DOCHERTY J.P., SACK D.A., ROFFMAN M., FINCH M., KOMOROWSKI J.R., A DOUBLE-BLIND, PLACEBO-CONTROLLED, EXPLORATORY TRIAL OF CHROMIUM PICOLINATE IN ATYPICAL DEPRESSION: EFFECT ON CARBOHYDRATE CRAVING, J PSYCHIATR PRACT, 11, PP. 302-314, (2005); CEFALU W.T., HU F.B., ROLE OF CHROMIUM IN HUMAN HEALTH AND IN DIABETES, DIABETES CARE, 27, PP. 2741-2751, (2004); MARTIN J., WANG Z.Q., ZHANG X.H., ET AL., CHROMIUM PICOLINATE SUPPLEMENTATION ATTENUATES BODY WEIGHT GAIN AND INCREASES INSULIN SENSITIVITY IN SUBJECTS WITH TYPE 2 DIABETES, DIABETES CARE, 29, PP. 1826-1832, (2006); INANC N., UYANIK F., SAHIN H., YAMAN H., ERDEM O., EFFECTS OF CHROMIUM SUPPLEMENTATION ON BODY COMPOSITION, LEPTIN, GHRELIN LEVELS AND SELECTED BIOCHEMICAL PARAMETERS IN OBESE WOMEN, TRACE ELEM ELECTROLYTES, 23, PP. 128-133, (2006); PITTLER M.H., STEVINSON C., ERNST E., CHROMIUM PICOLINATE FOR REDUCING BODY WEIGHT: META-ANALYSIS OF RANDOMIZED TRIALS, INT J OBES RELAT METAB DISORD, 27, PP. 522-529, (2003); DOUGLAS C.C., NORRIS L.E., OSTER R.A., DARNELL B.E., AZZIZ R., GOWER B.A., DIFFERENCE IN DIETARY INTAKE BETWEEN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND HEALTHY CONTROLS, FERTIL STERIL, 86, PP. 411-417, (2006); STAMETS K., TAYLOR D.S., KUNSELMAN A., DEMERS L.M., PELKMAN C.L., LEGRO R.S., A RANDOMIZED TRIAL OF THE EFFECTS OF TWO TYPES OF SHORT-TERM HYPOCALORIC DIETS ON WEIGHT LOSS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, FERTIL STERIL, 81, PP. 630-637, (2004); GARG A., HIGH-MONOUNSATURATED-FAT DIETS FOR PATIENTS WITH DIABETES MELLITUS: A META-ANALYSIS, AM J CLIN NUTR, 67, 3 SUPPL., (1998); EFFECT OF DIETARY FAT ON INSULIN SENSITIVITY AND INSULIN SECRETION. THE KANWU STUDY, DIABETOLOGIA, 42, SUPPL. 1, (1999); PARKER B., NOAKES M., LUSCOMBE N., CLIFTON P., EFFECT OF A HIGH-PROTEIN, HIGH-MONOUNSATURATED FAT WEIGHT LOSS DIET ON GLYCEMIC CONTROL AND LIPID LEVELS IN TYPE 2 DIABETES, DIABETES CARE, 25, PP. 425-430, (2002); FARNSWORTH E., LUSCOMBE N.D., NOAKES M., WITTERT G., ARGYIOU E., CLIFTON P.M., EFFECT OF A HIGH-PROTEIN, ENERGY-RESTRICTED DIET ON BODY COMPOSITION, GLYCEMIC CONTROL, AND LIPID CONCENTRATIONS IN OVERWEIGHT AND OBESE HYPERINSULINEMIC MEN AND WOMEN, AM J CLIN NUTR, 78, PP. 31-39, (2003); MORAN L.J., NOAKES M., CLIFTON P.M., TOMLINSON L., GALLETLY C., NORMAN R.J., DIETARY COMPOSITION IN RESTORING REPRODUCTIVE AND METABOLIC PHYSIOLOGY IN OVERWEIGHT WOMEN WITH POLYCYSTIC OVARY SYNDROME, J CLIN ENDOCRINOL METAB, 88, PP. 812-819, (2003); STERN L., IQBAL N., SESHADRI P., ET AL., THE EFFECTS OF LOW-CARBOHYDRATE VERSUS CONVENTIONAL WEIGHT LOSS DIETS IN SEVERELY OBESE ADULTS: ONE-YEAR FOLLOW-UP OF A RANDOMIZED TRIAL, ANN INTERN MED, 140, PP. 778-785, (2004); MORAN L.J., NOAKES M., CLIFTON P.M., ET AL., GHRELIN AND MEASURES OF SATIETY ARE ALTERED IN POLYCYSTIC OVARY SYNDROME BUT NOT DIFFERENTIALLY AFFECTED BY DIET COMPOSITION, J CLIN ENDOCRINOL METAB, 89, PP. 3337-3344, (2004); SWINBURN B.A., METCALF P.A., LEY S.J., LONG-TERM (5-YEAR) EFFECTS OF A REDUCED-FAT DIET INTERVENTION IN INDIVIDUALS WITH GLUCOSE INTOLERANCE, DIABETES CARE, 24, PP. 619-624, (2001); WOLEVER T.M., MEHLING C., HIGH-CARBOHYDRATE-LOW-GLYCAEMIC INDEX DIETARY ADVICE IMPROVES GLUCOSE DISPOSITION INDEX IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE, BR J NUTR, 87, PP. 477-487, (2002); SALMERON J., MANSON J.E., STAMPFER M.J., COLDITZ G.A., WING A.L., WILLETT W.C., DIETARY FIBER, GLYCEMIC LOAD, AND RISK OF NON-INSULIN-DEPENDENT DIABETES MELLITUS IN WOMEN, JAMA, 277, PP. 472-477, (1997); MEYER K.A., KUSHI L.H., JACOBS JR D.R., SLAVIN J., SELLERS T.A., FOLSOM A.R., CARBOHYDRATES, DIETARY FIBER, AND INCIDENT TYPE 2 DIABETES IN OLDER WOMEN, AM J CLIN NUTR, 71, PP. 921-930, (2000); MONTONEN J., KNEKT P., JARVINEN R., AROMAA A., REUNANEN A., WHOLE-GRAIN AND FIBER INTAKE AND THE INCIDENCE OF TYPE 2 DIABETES, AM J CLIN NUTR, 77, PP. 622-629, (2003); IUORNO M.J., JAKUBOWICZ D.J., BAILLARGEON J.P., ET AL., EFFECTS OF D-CHIROINOSITOL IN LEAN WOMEN WITH THE POLYCYSTIC OVARY SYNDROME, ENDOCR PRACT, 8, PP. 417-423, (2002); FULGHESU A.M., CIAMPELLI M., MUZJ G., ET AL., N-ACETYL-CYSTEINE TREATMENT IMPROVES INSULIN SENSITIVITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, FERTIL STERIL, 77, PP. 1128-1135, (2002); RIZK A.Y., BEDAIWY M.A., AL-INANY H.G., N-ACETYL-CYSTEINE IS A NOVEL ADJUVANT TO CLOMIPHENE CITRATE IN CLOMIPHENE CITRATE-RESISTANT PATIENTS WITH POLYCYSTIC OVARY SYNDROME, FERTIL STERIL, 83, PP. 367-370, (2005); WANG H., KRUSZEWSKI A., BRAUTIGAN D.L., CELLULAR CHROMIUM ENHANCES ACTIVATION OF INSULIN RECEPTOR KINASE, BIOCHEMISTRY, 44, PP. 8167-8175, (2005); CEFALU W.T., WANG Z.Q., ZHANG X.H., BALDOR L.C., RUSSELL J.C., ORAL CHROMIUM PICOLINATE IMPROVES CARBOHYDRATE AND LIPID METABOLISM AND ENHANCES SKELETAL MUSCLE GLUT-4 TRANSLOCATION IN OBESE, HYPERINSULINEMIC (JCR-LA CORPULENT) RATS, J NUTR, 132, PP. 1107-1114, (2002); PATTAR G.R., TACKETT L., LIU P., ELMENDORF J.S., CHROMIUM PICOLINATE POSITIVELY INFLUENCES THE GLUCOSE TRANSPORTER SYSTEM VIA AFFECTING CHOLESTEROL HOMEOSTASIS IN ADIPOCYTES CULTURED UNDER HYPERGLYCEMIC DIABETIC CONDITIONS, MUTAT RES, 610, PP. 93-100, (2006); CHEN G., LIU P., PATTAR G.R., ET AL., CHROMIUM ACTIVATES GLUCOSE TRANSPORTER 4 TRAFFICKING AND ENHANCES INSULIN-STIMULATED GLUCOSE TRANSPORT IN 3T3-L1 ADIPOCYTES VIA A CHOLESTEROL-DEPENDENT MECHANISM, MOL ENDOCRINOL, 20, PP. 857-870, (2006); LUCIDI R.S., THYER A.C., EASTON C.A., HOLDEN A.E., SCHENKEN R.S., BRZYSKI R.G., EFFECT OF CHROMIUM SUPPLEMENTATION ON INSULIN RESISTANCE AND OVARIAN AND MENSTRUAL CYCLICITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, FERTIL STERIL, 84, PP. 1755-1757, (2005); LYDIC M.L., MCNURLAN M., BEMBO S., MITCHELL L., KOMAROFF E., GELATO M., CHROMIUM PICOLINATE IMPROVES INSULIN SENSITIVITY IN OBESE SUBJECTS WITH POLYCYSTIC OVARY SYNDROME, FERTIL STERIL, 86, PP. 243-246, (2006); HAHN S., HASELHORST U., TAN S., ET AL., LOW SERUM 25-HYDROXYVITAMIN D CONCENTRATIONS ARE ASSOCIATED WITH INSULIN RESISTANCE AND OBESITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME, EXP CLIN ENDOCRINOL DIABETES, 114, PP. 577-583, (2006); SHANKAR S.S., MIRZAMOHAMMADI B., WALSH J.P., STEINBERG H.O., L-CARNITINE MAY ATTENUATE FREE FATTY ACID-INDUCED ENDOTHELIAL DYSFUNCTION, ANN N Y ACAD SCI, 1033, PP. 189-197, (2004); JUTURU V., GORMLEY J., NUTRITIONAL SUPPLEMENTS MODULATING METABOLIC SYNDROME RISK FACTORS AND THE PREVENTION OF CARDIOVASCULAR DISEASE, CURR NUTR FOOD SCI, 1, PP. 1-11, (2005); FENKCI V., DECREASED TOTAL ANTIOXIDANT STATUS AND INCREASED OXIDATIVE STRESS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME MAY CONTRIBUTE TO THE RISK OF CARDIOVASCULAR DISEASE, FERTIL STERIL, 80, PP. 123-127, (2003); ZAWADZKI J.K., DUNAIF A., DIAGNOSTIC CRITERIA FOR POLYCYSTIC OVARY SYNDROME: TOWARDS A RATIONAL APPROACH, POLYCYSTIC OVARY SYNDROME, PP. 377-384, (1992); YAMADA Y., KATO K., HIBINO T., ET AL., PREDICTION OF GENETIC RISK FOR METABOLIC SYNDROME, ATHEROSCLEROSIS, 191, 2, PP. 298-304, (2007)","V. JUTURU; NUTRITION 21 INC., PURCHASE, NY 10577, 4 MANHATTANVILLE ROAD, UNITED STATES; EMAIL: VJUTURU@GMAIL.COM","","ENGLISH","CURR. NUTR. FOOD SCI.","REVIEW","ISI","2-S2.0-68549128908","CURR NUTR FOOD SCI","NOTREPORTED","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"LYDIC M, 2008, CURR NUTR FOOD SCI","LYDIC M, 2008, CURR NUTR FOOD SCI"
"SPAR M","SPAR, MYLES (21934791400)","INTEGRATIVE MENS NUTRITION",2010,"EXPLORE: THE JOURNAL OF SCIENCE AND HEALING","6","4",0,"10.1016/j.explore.2009.11.001","","[NO ABSTRACT AVAILABLE]","","CARDIOVASCULAR DISEASES; COLONIC NEOPLASMS; DIET; HUMANS; HYPOGONADISM; MALE; NUTRIGENOMICS; OSTEOPOROSIS; PROSTATIC DISEASES; RISK FACTORS; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA CAROTENE; C REACTIVE PROTEIN; CHOLESTIN; COLECALCIFEROL; DOCOSAHEXAENOIC ACID; FISH OIL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; LYCOPENE; MAGNESIUM; NICOTINIC ACID; POLICOSANOL; POMEGRANATE EXTRACT; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SELENIUM; UBIDECARENONE; ALCOHOL ABUSE; ARTICLE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COLON CANCER; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DRUG MECHANISM; FLUSHING; GENETIC RISK; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPOGONADISM; LUNG CANCER; MALE; MEN'S HEALTH; NAUSEA; NUTRIGENOMICS; NUTRITIONAL HEALTH; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PRURITUS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY","","","MEN'S HEALTH; LICHTENSTEIN A., APPEL L., BRANDS M., ET AL., DIET AND LIFESTYLE RECOMMENDATIONS REVISION 2006: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 114, PP. 82-96, (2006); FITO M., GUXENS M., CORELLA D., ET AL., EFFECT OF A TRADITIONAL MEDITERRANEAN DIET ON LIPOPROTEIN OXIDATION, ARCH INT MED, 167, PP. 1195-1203, (2007); PANAGIOTAKOS D., MEDITERRANEAN DIET LOWERS C-REACTIVE PROTEIN LEVELS, ABSTRACT PRESENTED AT AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS, (2003); HU F.B., WILLETT W.C., OPTIMAL DIETS FOR PREVENTION OF CORONARY HEART DISEASE, JAMA, 288, PP. 2569-2578, (2002); O'KEEFE J.H., GHEEWALA N.M., O'KEEFE J.O., DIETARY STRATEGIES FOR IMPROVING POST-PRANIDAL GLUCOSE, LIPIDS, INFLAMMATION AND CARDIOVASCULAR HEALTH, J AM COLL CARDIOL, 51, PP. 249-255, (2008); MENTE A., DE KONING L., SHANNON H.S., ANAND S.S., A SYTEMATIC REVIEW OF THE EVIDENCE SUPPORTING A CAUSAL LINK BETWEEN DIETARY FACTORS AND CORONARY HEART DISEASE, ARCH INTERN MED, 169, PP. 659-669, (2009); DANSINGER M.L., GLEASON J.A., GRIFFITH J.L., SELKER H.P., SCHAEFER E.J., COMPARISON OF THE ATKINS, ORNISH, WEIGHT WATCHERS, AND ZONE DIETS FOR WEIGHT LOSS AND HEART DISEASE RISK REDUCTION: A RANDOMIZED TRIAL, JAMA, 293, PP. 43-53, (2005); PSOTA T., GEBAUER S., KRIS-ETHERTON P., DIETARY OMEGA-3 FATTY ACID INTAKE AND CARDIOVASCULAR RISK, AM J CARDIOL, 8, PP. 3-18, (2006); DIETARY SUPPLEMENTATION WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); HARPER C.R., JACOBSON T.A., THE FATS OF LIFE: THE ROLE OF OMEGA-3 FATTY ACIDS IN THE PREVENTION OF CORONARY HEART DISEASE, ARCH INTERN MED, 161, PP. 2185-2192, (2001); GOUNI-BERTHOLD I., KRONE W., BERTHOLD H.K., VITAMIN D AND CARDIOVASCULAR DISEASE, CURR VASC PHARMACOL, 7, PP. 414-422, (2009); LEE J.H., O'KEEFE J.H., BELL D., HENSRUD D.D., HOLICK M.F., VITAMIN D DEFICIENCY AN IMPORTANT, COMMON, AND EASILY TREATABLE CARDIOVASCULAR RISK FACTOR?, J AM COLL CARDIOL, 52, PP. 1949-1956, (2008); OHIRA T., PEACOCK J.M., ISO H., ET AL., SERUM AND DIETARY MAGNESIUM AND RISK OF ISCHEMIC STROKE-THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. A PROSPECTIVE STUDY OF TOTAL AND IONIZED SERUM CALCIUM AND FATAL PROSTATE CANCER, AM JNL EPI, 12, PP. 1437-1444, (2009); HOMOSYSTEINE, DIET AND CARDIOVASCULAR DISEASES, CIRCULATION, 99, PP. 178-182, (1999); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS VS LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, JAMA, 290, PP. 502-510, (2003); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N ENGL J MED, 333, PP. 1308-1312, (1995); ILLINGWORTH D.R., STEIN E.A., MITCHEL Y.B., ET AL., COMPARATIVE EFFECTS OF LOVASTATIN AND NIACIN IN PRIMARY HYPERCHOLESTEROLEMIA. A PROSPECTIVE TRIAL, ARCH INTERN MED, 154, PP. 1586-1595, (1994); ANDERSSON S.O., WOLK A., BERGSTROM R., ET AL., BODY SIZE AND PROSTATE CANCER: A 20-YEAR FOLLOW-UP STUDY AMONG 135,006 SWEDISH CONSTRUCTION WORKERS, J NATL CANCER INST, 89, PP. 385-389, (1997); AZIZ N.M., HARTMAN T., BARRETT M., ET AL., WEIGHT AND PROSTATE CANCER IN THE ALPHA-TOCOPHEROL BETA-CAROTENE CANCER PREVENTION (ATBC) TRIAL, ASCO ANNUAL MEETING, 19, (2000); KING I.B., KRISTAL A.R., SCHAFFER S., THORNQUIST M., GOODMAN G.E., SERUM TRANS-FATTY ACIDS ARE ASSOCIATED WITH RISK OF PROSTATE CANCER IN BETA-CAROTENE AND RETINOL EFFICACY TRIAL, CANCER EPIDEMIOL BIOMARKERS PREV, 14, PP. 988-992, (2005); PROSTATE CANCER PREVENTION (PDQ); LIPMAN S.A., KLEIN E.A., GOODMAN P.J., ET AL., EFFECT OF SELENIUM AND VITAMIN E ON RISK OF PROSTATE CANCER AND OTHER CANCERS: THE SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT), JAMA, 301, PP. 39-51, (2009); COHEN J.H., KRISTAL A.R., STANFORD J.L., FRUIT AND VEGETABLE INTAKES AND PROSTATE CANCER RISK, J NATL CANCER INST, 92, PP. 61-68, (2000); PANTUCK A.J., LEPPERT J.T., ZOMORODIAN N., ET AL., PHASE II STUDY OF POMEGRANATE JUICE FOR MEN WITH RISING PROSTATE-SPECIFIC ANTIGEN FOLLOWING SURGERY OR RADIATION FOR PROSTATE CANCER, CLIN CANCER RES, 12, PP. 4018-4026, (2006); GIOVANNUCCI E., RIMM E.B., WOLK A., A PROSPECTIVE STUDY OF CALCIUM INTAKE AND INCIDENT AND FATAL PROSTATE CANCER, CANCER EPIDEMIOL BIOMARKERS PREV, 15, PP. 203-210, (2006); SKINNER H.G., SCHWARTZ G.G., CANCER EPIDEMIOL BIOMARKERS PREV, 18, PP. 575-578, (2009); GAO X., LAVALLEY M.P., TUCKER K.L., PROSPECTIVE STUDIES OF DAIRY PRODUCT AND CALCIUM INTAKES AND PROSTATE CANCER RISK: A META-ANALYSIS, J NATL CANCER INST, 97, PP. 1768-1777, (2005); SIMON J.A., CHEN Y.-H., BENT S., ET AL., THE RELATION OF ALPHA-LINOLENIC ACID TO THE RISK OF PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS, AM J CLIN NUTR, 89, (2009); BOEHM K., BORRELLI F., ERNST E., ET AL., GREEN TEA (CAMELLIA SINENSIS) FOR THE PREVENTION OF CANCER, COCHRANE DATABASE SYST REV, 3, (2009); HUSSAIN M., BANERJEE M., SARKAR F.H., ET AL., SOY ISOFLAVONES IN THE TREATMENT OF PROSTATE CANCER, NUTR CANCER, 47, PP. 111-117, (2003); MESSINA M.J., PERSKY V., SETCHELL K.D., SOY INTAKE AND CANCER RISK: A REVIEW OF THE IN VITRO AND IN VIVO DATA, NUTR CANCER, 21, PP. 113-131, (1994); BERRY S.J., COFFEY D.S., WALSH P.C., ET AL., THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE, J UROL, 132, (1984); BOYLE P., ROBERTSON C., LOWE F., ROEHRBORN C., META-ANALYSIS OF CLINICAL TRIALS OF PERMIXON IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA, UROLOGY, 55, PP. 533-539, (2000); KRISTAL A.R., ARNOLD K.B., SCHENK J.M., ET AL., DIETARY PATTERNS, SUPPLEMENT USE AND THE RISK OF SYMPTOMATIC BPH: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIAL, AM J EPIDEMIOL, 167, PP. 925-934, (2008); WILT T., ISHANI A., PGEUM AFRICANUM FOR BENIGN PROSTATIC HYPERPLASIA, COCHRANE DATABASE SYST REV, 1, (2002); NORAT T., BINGHAM S., FERRARI P., MEAT, FISH, AND COLORECTAL CANCER RISK: THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION, J NATL CANCER INST, 97, PP. 906-916, (2005); BINGHAM S.A., DAY N.E., LUBEN R., ET AL., DIETARY FIBRE IN FOOD AND PROTECTION AGAINST COLORECTAL CANCER IN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC): AN OBSERVATIONAL STUDY, LANCET, 361, PP. 1496-1501, (2003); FLEISCHAUER A.T., ARAB L., GARLIC AND CANCER: A CRITICAL REVIEW OF THE EPIDEMIOLOGIC LITERATURE, J NUTR, 131, 3 S, (2001); NGO S.N.T., WILLIAMS D.B., COBIAC L., HEAD R.J., DOES GARLIC REDUCE RISK OF COLORECTAL CANCER?"". A SYSTEMATIC REVIEW, J NUTR, 137, PP. 2264-2269, (2007); INTEGRATIVE ONCOLOGY, (2009); NG K., MEYERHARDT J.A., WU K., ET AL., CIRCULATING 25-HYDROXYVITAMIN D LEVELS AND SURVIVAL IN PATIENTS WITH COLORECTAL CANCER, J CLIN ONCOL, 26, PP. 2984-2991, (2008); PRASAD A.S., MANTZOROS C.S., BECK F.W., ET AL., ZINC STATUS AND SERUM TESTOSTERONE LEVELS OF HEALTHY ADULTS, NUTRITION, 12, PP. 344-348, (1996); RIMBACH G., MINIHANE A.M., NUTRIGENETICS AND PERSONALISED NUTRITION: HOW FAR HAVE WE PROGRESSED AND ARE WE LIKELY TO GET THERE?, PROC NUTR SOC, 68, PP. 162-172, (2009)","","","ENGLISH","EXPLOR. J. SCI. HEAL.","ARTICLE","ISI","2-S2.0-72949100576","EXPLOR J SCI HEAL",NA,"NOTREPORTED",NA,"SPAR M, 2010, EXPLOR J SCI HEAL","SPAR M, 2010, EXPLOR J SCI HEAL"
"FEHER G;ILLES Z","FEHER, GERGELY (8375800900); ILLES, ZSOLT (6701865395)","GENE PATENTS IN THE PRIMARY PREVENTION OF VASCULAR DISEASES",2008,"RECENT PATENTS ON DNA AND GENE SEQUENCES","2","7",3,"10.2174/187221508786241693","DEPARTMENT OF NEUROLOGY, UNIVERSITY OF PECS, SCHOOL OF MEDICINE, PECS H-7623, RET U. 2, HUNGARY;DEPARTMENT OF NEUROLOGY, UNIVERSITY OF PECS, SCHOOL OF MEDICINE, PECS H-7623, RET U. 2, HUNGARY","ATHEROSCLEROSIS IS THE LEADING CAUSE OF DEATH AND DISABILITY IN THE DEVELOPED WORLD. DESPITE THE USE OF AGGRESSIVE THERAPIES, A HIGH MORBIDITY AND MORTALITY WITH VASCULAR ORIGIN PERSISTS. IT IS NECESSARY TO FIND NEW THERAPEUTIC TARGETS COMPLEMENTING THE EXISTING ONES TO SOLVE THIS SANITARY PROBLEM. BASIC AND CLINICAL INVESTIGATION INTO MANY OF THE DIVERSE ASPECTS OF CARDIOVASCULAR DRUG DISCOVERY EMPLOYS VARIED APPROACHES AIMED AT DETERMINING PHYSIOLOGIC AND PATHOPHYSIOLOGIC EFFICACY OF CANDIDATE AGENTS FOR THERAPEUTIC UTILITY WITH THE ULTIMATE HOPE OF IDENTIFYING THOSE AGENTS CAPABLE OF EXERTING SALUTARY INFLUENCE UPON CARDIAC AND VASCULAR TISSUES. WE COLLECTED THE ARTICLES PUBLISHED BASED ON GENE PATENTING IN THE PRIMARY PREVENTION OF VASCULAR DISEASES. PROMISING COMPOUNDS MAY THEN BE USED FOR PROPHYLACTIC CARDIOVASCULAR PROTECTION AND FOR THE TREATMENT OF VARIOUS DISORDERS INCLUDING ENDOTHELIAL DYSFUNCTION, INFLAMMATION, HYPERTENSION AND DYSLIPIDAEMIA. © 2008 BENTHAM SCIENCE PUBLISHERS LTD.","ATHEROSCLEROSIS; DYSLIPIDAEMIA; ENDOTHELIAL DYSFUNCTION; GENE PATENTS; HYPERTENSION; VASCULAR DISEASE","ATHEROSCLEROSIS; DYSLIPIDEMIAS; HYPERTENSION; PATENTS AS TOPIC; VASCULAR DISEASES; 1 CYCLOHEXYL 3 DODECYLUREA; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLICOSANOL; TELMISARTAN; THROMBOXANE A2; UNCLASSIFIED DRUG; ANGIONEUROTIC EDEMA; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; COUGHING; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; KIDNEY INJURY; LIPID ABSORPTION; MEMBRANE MICROPARTICLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW","","","BACHETTI T., ENDOTHELIAL DYSFUNCTION IN CHRONIC HEART FAILURE: SOME NEW BASIC MECHANISMS, ITAL HEART J, 1, PP. 656-661, (2000); GANZ P., VITA J.A., TESTING ENDOTHELIAL VASOMOTOR FUNCTION. NITRIC OXIDE, A MULTIPOTENT MOLECULE, CIRCULATION, 108, PP. 2049-2053, (2003); LANDMESSER U., HORNIG B., DREXLER H., ENDOTHELIAL FUNCTION: A CRITICAL DETERMINANT IN ATHEROSCLEROSIS?, CIRCULATION, 109, SUPPL. II, (2004); TULIS D.A., METHODS FOR IDENTIFYING CARDIOVASCULAR AGENTS: A REVIEW, RECENT PATENTS CARDIOVASC DRUG DISCOV, 1, PP. 47-56, (2006); CAPDEVILA J.H., FALCK J.R., HARRIS R.C., CYTOCHROME P450 AND ARACHIDONIC ACID BIOACTIVATION. MOLECULAR AND FUNCTIONAL PROPERTIES OF THE ARACHIDONATE MONOOXYGENASE, J LIPID RES, 41, PP. 163-181, (2000); ZELDIN D.C., EPOXYGENASE PATHWAYS OF ARACHIDONIC ACID METABOLISM, J BIOL CHEM, 276, PP. 36059-36062, (2001); SPECTOR A.A., FANG X., SNYDER G.D., WEINTRAUB N.L., EPOXYEICOSATRIENOIC ACIDS (EETS): METABOLISM AND BIOCHEMICAL FUNCTION, PROG LIPID RES, 43, PP. 55-90, (2004); KROETZ D.L., ZELDIN D.C., HAMMOCK B.D., MORISSEAU C., (2003); HAMMOCK B.D., MOGHADDAM M.F., CHEEK J.M., BORHAN B., FERGUSSON J., GRANT D.F., GREENE J.F., MATOBA K., ZHENG J., SISEMORE M.F., (2001); HAMMOCK B.D., KIM I.H., MORISSEAU C., WATANABE T., NEWMAN J.W.; INGRAHAM R.H., PROUDFOOT J.R., (2004); SEUBERT J.M., XU F., GRAVES J.P., ET AL., DIFFERENTIAL RENAL GENE EXPRESSION IN PRE-HYPERTENSIVE AND HYPERTENSIVE SPONTANEOUSLY HYPERTENSIVE RATS, AM J PHYSIOL RENAL PHYSIOL, 289, 3, (2005); IMIG J.D., ZHAO X., CAPDEVILA J.H., MORISSEAU C., HAMMOCK B.D., SOLUBLE EPOXIDE HYDROLASE INHIBITION LOWERS ARTERIAL BLOOD PRESSURE IN ANGIOTENSIN II HYPERTENSION, HYPERTENSION, 39, 2 PART 2, PP. 690-694, (2002); ZHAO X., YAMAMOTO T., NEWMAN J.W., ET AL., SOLUBLE EPOXIDE HYDROLASE INHIBITION PROTECTS THE KIDNEY FROM HYPERTENSION-INDUCED DAMAGE, J AM SOC NEPHROL, 15, PP. 1244-1253, (2004); YU Z., XU F., HUSE L.M., ET AL., SOLUBLE EPOXIDE HYDROLASE REGULATES HYDROLYSIS OF VASOACTIVE EPOXYEICOSATRIENOIC ACIDS, CIRC RES, 87, PP. 992-998, (2000); CATELLA F., LAWSON J.A., FITZGERALD D.J., FITZGERALD G.A., ENDOGENOUS BIOSYNTHESIS OF ARACHIDONIC ACID EPOXIDES IN HUMANS: INCREASED FORMATION IN PREGNANCY-INDUCED HYPERTENSION, PROC NATL ACAD SCI USA, 87, PP. 5893-5897, (1990); SINAL C.J., MIYATA M., TOHKIN M., NAGATA K., BEND J.R., GONZALEZ F.J., TARGETED DISRUPTION OF SOLUBLE EPOXIDE HYDROLASE REVEALS A ROLE IN BLOOD PRESSURE REGULATION, J BIOL CHEM, 275, PP. 40504-40510, (2000); JUNG O., BRANDES R.P., KIM I.H., ET AL., SOLUBLE EPOXIDE HYDROLASE IS A MAIN EFFECTOR OF ANGIOTENSIN II-INDUCED HYPERTENSION, HYPERTENSION, 45, PP. 759-765, (2005); LOCH D., HAMMOCK B., BROWN L., SOLUBLE EPOXIDE HYDROLASE INHIBITION IN DOCA-SALT HYPERTENSIVE RATS PREVENTS VASCULAR REMODELING AND DYSFUNCTION, CARDIOVASC J S AFR, 15, 4 SUPPL. 1, (2004); SELLERS K.W., SUN C., DIEZ-FREIRE C., ET AL., NOVEL MECHANISM OF BRAIN SOLUBLE EPOXIDE HYDROLASE-MEDIATED BLOOD PRESSURE REGULATION IN THE SPONTANEOUSLY HYPERTENSIVE RAT, FASEB J, 19, PP. 626-628, (2005); FANG X., SOLUBLE EPOXIDE HYDROLASE: A NOVEL TARGET FOR THE TREATMENT OF HYPERTENSION, RECENT PATENTS CARDIOVASC DRUG DISCOV, 1, PP. 67-72, (2006); IGNARRO L.J., KADOWITZ P.J., THE PHARMACOLOGICAL AND PHYSIOLOGICAL ROLE OF CYCLIC GMP IN VASCULAR SMOOTH MUSCLE RELAXATION, ANNU REV PHARMACOL TOXICOL, 25, PP. 171-191, (1985); VANHOUTTE P.M., VASCULAR BIOLOGY. OLD-TIMER MAKES A COMEBACK, NATURE, 396, 6708, PP. 213-216, (1998); GAUTHIER K.M., DEETER C., KRISHNA U.M., ET AL., 14, 15-EPOXYEICOSA-5Z-ENOIC ACID: A SELECTIVE EPOXYEICOSATRIENOIC ACID ANTAGONIST THAT INHIBITS ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION AND RELAXATION IN CORONARY ARTERIES, CIRC RES, 90, 9, PP. 1028-1036, (2002); POLLOCK D.M., OPGENORTH T.J., EVIDENCE FOR METALLOPROTEASE INVOLVEMENT IN THE IN VIVO EFFECTS OF BIG ENDOTHELIN 1, AM J PHYSIOL, 261, 1 PART 2, (1991); GRANGER J.P., ENDOTHELIN, AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, 285, 2, (2003); YANAGISAWA M., KURIHARA H., KIMURA S., ET AL., A NOVEL POTENT VASOCONSTRICTOR PEPTIDE PRODUCED BY VASCULAR ENDOTHELIAL CELLS, NATURE, 332, 6163, PP. 411-415, (1988); RUBANYI G.M., POLOKOFF M.A., ENDOTHELINS: MOLECULAR BIOLOGY, BIOCHEMISTRY, PHARMACOLOGY, PHYSIOLOGY, AND PATHOPHYSIOLOGY, PHARMACOL REV, 46, 3, PP. 325-415, (1994); KONISHI F., OKADA Y., TAKAOKA M., GARIEPY C.E., YANAGISAWA M., MATSUMURA Y., ROLE OF ENDOTHELIN ETB RECEPTORS IN THE RENAL HEMODYNAMIC AND EXCRETORY RESPONSES TO BIG ENDOTHELIN-1, EUR J PHARMACOL, 451, 2, PP. 177-184, (2002); KEDZIERSKI R.M., YANAGISAWA M., ENDOTHELIN SYSTEM: THE DOUBLEEDGED SWORD IN HEALTH AND DISEASE, ANNU REV PHARMACOL TOXICOL, 41, PP. 851-876, (2001); HYNYNEN M.M., KHALIL R.A., THE VASCULAR ENDOTHELIN SYSTEM IN HYPERTENSION - RECENT PATENTS AND DISCOVERIES, RECENT PATENTS CARDIOVASC DRUG DISCOV, 1, PP. 95-108, (2006); SCHIFFRIN E.L., ROLE OF ENDOTHELIN-1 IN HYPERTENSION AND VASCULAR DISEASE, AM J HYPERTENS, 14, 6 PART 2, (2001); BURNIER M., BRUNNER H.R., ANGIOTENSIN II RECEPTOR ANTAGONISTS, LANCET, 355, PP. 637-645, (2000); DE GASPARO M., CATT K.J., INAGAMI T., WRIGHT J.W., UNGER T., INTERNATIONAL UNION OF PHARMACOLOGY, XXIII. THE ANGIOTENSIN II RECEPTORS, PHARMACOL REV, 52, PP. 415-472, (2000); STOLL M., UNGER T., ANGIOTENSIN AND ITS AT2 RECEPTOR: NEW INSIGHTS INTO AN OLD SYSTEM, REGUL PEPT, 99, PP. 175-182, (2001); SIRAGY H.M., ANGIOTENSIN RECEPTOR BLOCKERS: HOW IMPORTANT IS SELECTIVITY?, AM J HYPERTENS, 15, PP. 1006-1014, (2002); PYLYPCHUK G.B., ACE INHIBITOR- VERSUS ANGIOTENSIN II BLOCKER INDUCED COUGH AND ANGIOEDEMA, ANN PHARMACOTHER, 32, PP. 1060-1060, (1998); YAMAGISHI S., NAKAMURA K., TELMISARTAN ITS POTENTIAL THERAPEUTIC IMPLICATIONS IN CARDIOMETABOLIC DISORDERS, RECENT PATENTS CARDIOVASC DRUG DISCOV, 1, PP. 79-83, (2006); SUZUKI N., MATSUMOTO H., (1993); REYNOLDS M., POLAKIS P., (2005); LUM P.Y., TAN Y., DAI H., MUISE E.S., BERGER J.P., THOMPSON J.R., (2005); YORIO T., PRASANNA G., DIBAS A., STOKELY M.E., (2003); DORSCH D., OSSWALD M., MEDERSKI W., DORSCH D., OSSWALD M., MEDERSKI W., WILM C., CHRISTADLER M., SCHMITGES C.J., (2000); BUNKER A.M., CHENG X., DOHERTY A.M., EDMUNDS J.J., KANTER G.D., LEE C., REPINE J.T., SKEEAN R.W., (2002); MURUGESAN N., (1995); RAWSON D.J., DACK K.N., DICKINSON R.P., JAMES K., (2002); CHENG X., DOHERTY A.M., HURLEY T.R., LOVDAHL M.J., PATT W.C., REPINE J.T., (2000); BAGLEY S.W., BROTEN T.P., CHAKRAVARTY P.K., DHANOA D.S., FITCH K.J., GREENLEE W.J., KEVIN N.J., PETTIBONE D.J., RIVERO R.A., WALSH T.F., WILLIAMS JR. D.L., TOUPENCE R.B., MATTHEWS J.M., (1996); UENO R., (2001); DORSCH D., OSSWALD M., MEDERSKI W., WILM C., SCHMITGES C.J., CHRISTADLER M., (1999); ELLIOTT J.D., LEBER J.D., (2000); BANKS B.J., CHUBB N.A.L., ESHELBY J.J., PACEY M.S., SCHULZ D.J., (2002); MURUGESAN N., HUNT J.T., (2000); CHENG X., MASSA M.A., PATT W.C., (1999); ELLIOTT J.D., GAO A., (2000); OHWAKI T., SAKAI H., (1995); LEBWOHL D.E., (2003); WHITTLE B.A., (2005); LAWRENCE III J.H., DONAHUE J.K., (2005); DORSCH D., OSSWALD M., MEDERSKI W., WILM C., CHRISTADLER M., SCHMITGES C.J., (2001); ELLIOTT J.D., FRANZ R.G., LAGO M.A., GAO A., (1999); COUSINS R.D., ELLIOTT J.D., LAGO M.A., LEBER J.D., PEISHOFF C.E., (2002); ELLIOTT J.D., WEINSTOCK J., XIANG J., (2003); ELLIOTT J.D., LUENGO J.I., XIANG J., (2001); BERRYMAN K.A., CHENG X., DOHERTY A.M., EDMUNDS J.J., KLUTCHKO S., (1997); LUENGO J.I., ELLIOTT J.D., XIANG J., (2003); HIRATA M., DEUSHI T., TAKAHASHI Y., TAMURA M., OHSHIMA T., ODA T., ISHIKAWA T., SONOKI H., SHIRATSUCHI M., (1999); AMBERG W., JANSEN R., KLINGE D., (2001); WU C., BLOK N., HOLLAND G.W., (2004); VERNER E.J., (2000); AHN K., CHENG X., DOHERTY A.M., ELSLAGER E.F., KORNBERG B., LEE C., LEONARD D., NIKAM S., WERBEL L.M., (1998); RUILOPE L.M., SEGURA J., LOSARTAN AND OTHER ANGIOTENSIN II ANTAGONISTS FOR NEPHROPATHY IN TYPE 2 DIABETES MELLITUS: A REVIEW OF THE CLINICAL TRIAL EVIDENCE, CLIN THER, 25, PP. 3044-3064, (2003); SILVERSTEIN R.L., FENVES A.Z., RAM C.V., ARBS AND TARGET ORGAN PROTECTION. EXPLORING BENEFITS BEYOND THEIR ANTIHYPERTENSIVE EFFECTS, POSTGRAD MED, 116, PP. 31-38, (2004); BALL S.G., BENEFITS OF BLOOD PRESSURE REDUCTION IN DIABETIC PATIENTS, J HYPERTENS, 21, (2003); STRAZZULLO P., GALLETTI F., IMPACT OF THE RENIN-ANGIOTENSIN SYSTEM ON LIPID AND CARBOHYDRATE METABOLISM, CURR OPIN NEPH HYPERT, 13, PP. 325-332, (2004); ANDERSON S., ROLE OF LOCAL AND SYSTEMIC ANGIOTENSIN IN DIABETIC RENAL DISEASE, KIDNEY INT SUPPL, 63, (1997); YAMAGISHI S., AMANO S., INAGAKI Y., ET AL., ANGIOTENSIN II-TYPE 1 RECEPTOR INTERACTION UPREGULATES VASCULAR ENDOTHELIAL GROWTH FACTOR MESSENGER RNA LEVELS IN RETINAL PERICYTES THROUGH INTRACELLULAR REACTIVE OXYGEN SPECIES GENERATION, DRUGS EXP CLIN RES, 29, PP. 75-80, (2003); AMANO S., YAMAGISHI S., INAGAKI Y., OKAMOTO T., ANGIOTENSIN II STIMULATES PLATELET-DERIVED GROWTH FACTOR-B GENE EXPRESSION IN CULTURED RETINAL PERICYTES THROUGH INTRACELLULAR REACTIVE OXYGEN SPECIES GENERATION, INT J TISSUE REACT, 25, PP. 51-55, (2003); BROWNLEE M., CERAMI A., VLASSARA H., ADVANCED GLYCOSYLATION END PRODUCTS IN TISSUE AND THE BIOCHEMICAL BASIS OF DIABETIC COMPLICATIONS, N ENGL J MED, 318, PP. 1315-1321, (1988); DYER D.G., BLACKLEDGE J.A., THORPE S.R., BAYNES J.W., FORMATION OF PENTOSIDINE DURING NONENZYMATIC BROWNING OF PROTEINS BY GLUCOSE. IDENTIFICATION OF GLUCOSE AND OTHER CARBOHYDRATES AS POSSIBLE PRECURSORS OF PENTOSIDINE IN VIVO, J BIOL CHEM, 266, PP. 11654-11660, (1991); GRANDHEE S.K., MONNIER V.M., MECHANISM OF FORMATION OF THE MAILLARD PROTEIN CROSS-LINK PENTOSIDINE. GLUCOSE, FRUCTOSE, AND ASCORBATE AS PENTOSIDINE PRECURSORS, J BIOL CHEM, 266, PP. 11649-11653, (1991); YAMAGISHI S., TAKEUCHI M., MATSUI T., NAKAMURA K., IMAIZUMI T., INOUE H., ANGIOTENSIN II AUGMENTS ADVANCED GLYCATION END PRODUCT-INDUCED PERICYTE APOPTOSIS THROUGH RAGE OVEREXPRESSION, FEBS LETT, 579, 20, PP. 4265-4270, (2005); PEPINE C.J., CLINICAL IMPLICATIONS OF ENDOTHELIAL DYSFUNCTION, CLIN CARDIOL, 21, PP. 795-799, (1998); MARTINEZ M.C., TESSE A., ZOBAIRI F., ANDRIANTSITOHAINA R., SHED MEMBRANE MICROPARTICLES FROM CIRCULATING AND VASCULAR CELLS IN REGULATING VASCULAR FUNCTION, AM J PHYSIOL HEART CIRC PHYSIOL, 288, (2005); AZEVEDO C.P., PEDROC A.M., LAURINDOC R.M., CIRCULATING MICROPARTICLES AS THERAPEUTIC TARGETS IN CARDIOVASCULAR DISEASES. RECENT; STEELE R.E.; SKULTETYOVA D., FILIPOVA S., RIECANSKY I., SKULTETY J., THE ROLE OF ANGIOTENSIN TYPE 1 RECEPTOR IN INFLAMMATION AND ENDOTHELIAL DYSFUNCTION. RECENT; KRIS-ETHERTON P.M., TAYLOR D.S., YU-POTH S., ET AL., POLYUNSATURATED FATTY ACIDS IN THE FOOD CHAIN IN THE UNITED STATES, AM J CLIN NUTR, 71, (2000); BANG H.O., DYERBERG J., HJOORNE T., THE COMPOSITION OF FOOD CONSUMED BY GREENLAND ESKIMOS, ACTA MED SCAND, 200, PP. 69-73, (1976); BANG H.O., DYERBERG J., SINCLAIR H.M., THE COMPOSITION OF THE ESKIMO FOOD IN NORTH WESTERN GREENLAND, AM J CLIN NUTR, 33, PP. 2657-2661, (1980); MIDDAUGH J.P., CARDIOVASCULAR DEATHS AMONG ALASKAN NATIVES, 1980-86, AM J PUBLIC HEALTH, 80, PP. 282-285, (1990); NEWMAN W.P., MIDDAUGH J.P., PROPST M.T., ROGER D.R., ATHEROSCLEROSIS IN ALASKA NATIVES AND NON-NATIVES, LANCET, 341, PP. 1056-1057, (1993); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE. AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 106, PP. 2747-2757, (2002); VAN DE WERF F., ARDISSINO D., BETRIU A., ET AL., MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH ST-SEGMENT ELEVATION, EUR HEART J, 24, PP. 28-66, (2003); LIBBY P., INFLAMMATION IN ATHEROSCLEROSIS, NATURE, 420, PP. 868-874, (2002); SERHAN C.N., CLISH C.B., (2006); BERLIN R.; MENDELSOHN M.E., KARAS R.H., (2004); GENSINI G.F., COMEGLIO M., CORELLA A., CLASSICAL RISK FACTORS AND EMERGING ELEMENTS IN THE RISK PROFILE FOR CORONARY ARTERY DISEASE, EUR HEART J, 19, SUPPL. A, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY ARTERY DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLAEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); WOOD D., DE BACKER G., FAERGEMAN O., ET AL., PREVENTION OF CORONARY ARTERY DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUR HEART J, 19, PP. 1434-1503, (1998); EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); PEARSON T.A., LAURORA I., CHU H., KAFONK S., THE LIPID TREATMENT ASSESSMENT PROJECT (L-TAP), ARCH INTERN MED, 160, PP. 459-465, (2000); VAN HEEK M., FARLEY C., COMPTON D.S., ET AL., COMPARISON OF THE ACTIVITY AND DISPOSITION OF THE NOVEL CHOLESTEROL ABSORPTION INHIBITOR, SCH58235, AND ITS GLUCURONIDE, SCH60663, BR J PHARMACOLOGY, 129, PP. 1748-1754, (2000); VAN HEEK M., FARLEY C., COMPTON D.S., ET AL., EZETIMIDE SELECTIVELY INHIBITS INTESTINAL CHOLESTEROL ABSORPTION IN RODENTS IN THE PRESENCE AND ABSENCE OF EXOCRINE PANCREATIC FUNCTION, BR J PHARMACOL, 21, SUPPL., PP. 636-640, (2001); SUDHOP T., LUTJOHANN K.A., ET AL., INHIBITION OF INTESTINAL CHOLESTEROL ABSORPTION BY EZETIMIBE IN HUMANS, CIRCULATION, 106, PP. 1943-1948, (2002); BJORKHEM I., MIETTINEN T., REIHNER E., ET AL., CORRELATION BETWEEN SERUM LEVELS OF SOME CHOLESTEROL PRECURSORS AND ACTIVITY OF HMGCOA REDUCTASE IN HUMAN LIVER, J LIPID RES, 28, PP. 1137-1143, (1987); KEMPEN H.J., GLATZ J.F., GEVERS LEUVEN J.A., ET AL., SERUM LATHOSTEROL CONCENTRATION IS AN INDICATOR OF WHOLE-BODY CHOLESTEROL SYNTHESIS IN HUMANS, J LIPID RES, 29, PP. 1149-1155, (1988); CHRYSOHOOU C., SINGH S., COMBINATION OF A STEROL ABSORPTION INHIBITOR AND CARDIOVASCULAR AGENTS FOR THE TREATMENT OF DYSLIPIDEMIA. RECENT; MILLER M., GINSBERG H.N., SCHAEFER E.J., RELATIVE ATHEROGENICITY AND PREDICTIVE VALUE OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL FOR CORONARY HEART DISEASE, AM J CARDIOL, 101, 7, PP. 1003-1008, (2008)","Z. ILLES; DEPARTMENT OF NEUROLOGY, UNIVERSITY OF PECS, SCHOOL OF MEDICINE, PECS H-7623, RET U. 2, HUNGARY; EMAIL: ZSOLT.ILLES@AOK.PTE.HU","BENTHAM SCIENCE PUBLISHERS B.V.","ENGLISH","RECENT PAT. DNA GENE  SEQUENCES","REVIEW","ISI","2-S2.0-70350233326","RECENT PAT DNA GENE  SEQUENCES","UNIVERSITY OF PECS;UNIVERSITY OF PECS","NOTREPORTED;UNIVERSITY OF PECS;NOTREPORTED",NA,"FEHER G, 2008, RECENT PAT DNA GENE SEQUENCES","FEHER G, 2008, RECENT PAT DNA GENE SEQUENCES"
"LI Q;THOMSON A;CLANDININ M","LI, QUN (57191697841); THOMSON, ALAN B. R. (14326427800); CLANDININ, MICHAEL T. (35569902000)","CHOLESTEROL ESTER AND FREE FATTY ACIDS ARE MODULATED BY POLICOSANOL IN CACO2 INTESTINAL CELLS",2011,"JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION","30","8",4,"10.1080/07315724.2011.10719961","DEPARTMENT OF AGRICULTURAL, FOOD AND NUTRITIONAL SCIENCE, ALBERTA INSTITUTE FOR HUMAN NUTRITION, UNIVERSITY OF ALBERTA, EDMONTON, AB, CANADA;DEPARTMENT OF MEDICINE, ALBERTA INSTITUTE FOR HUMAN NUTRITION, UNIVERSITY OF ALBERTA, EDMONTON, AB, CANADA;DEPARTMENT OF AGRICULTURAL, FOOD AND NUTRITIONAL SCIENCE, ALBERTA INSTITUTE FOR HUMAN NUTRITION, UNIVERSITY OF ALBERTA, EDMONTON, AB, CANADA, DEPARTMENT OF MEDICINE, ALBERTA INSTITUTE FOR HUMAN NUTRITION, UNIVERSITY OF ALBERTA, EDMONTON, AB, CANADA","OBJECTIVE: TO INVESTIGATE POLICOSANOL ABSORPTION BY BRUSH BORDER MEMBRANE (BBM), METABOLISM IN CACO-2 ENTEROCYTES, AND TRANSPORT OF POLICOSANOL METABOLITES ACROSS THE BASOLATERAL MEMBRANE (BLM). IT WAS HYPOTHESIZED THAT POLICOSANOL IS PARTIALLY OXIDIZED INTO FATTY ACIDS AND THEN IS INCORPORATED INTO OTHER LIPIDS. METHODS: POLICOSANOL WAS EMULSIFIED WITH PHOSPHATIDYLCHOLINE IN THE CULTURE MEDIUM. THE VIABILITY OF CELLS WAS ASSESSED VIA AN MTT (3-[4,5]DIMETHYLTHIAZOL-2-YL-2,5-DIPHENYLTETRAZOLIM) ASSAY. CONTROL CELLS RECEIVED ONLY THE SAME AMOUNT OF “VEHICLE” (PHOSPHATIDYLCHOLINE) WITHOUT POLICOSANOL. CACO-2 CELL MONOLAYER AND MEDIUM WERE COLLECTED; LIPID WAS EXTRACTED AND ANALYZED BY THIN-LAYER CHROMATOGRAPHY (TLC) AND GAS LIQUID CHROMATOGRAPHY (GLC). RESULTS: EIGHTY-SIX PERCENT OF POLICOSANOL ADDED TO THE CELL CULTURE MEDIUM WAS ABSORBED AFTER 48 HOURS' INCUBATION. THE AMOUNT OF CHOLESTEROL ESTER FATTY ACID WAS SIGNIFICANTLY INCREASED BOTH IN THE CELLS AND IN THE BASOLATERAL MEDIUM, AND WAS REDUCED IN THE APICAL MEDIUM. POLICOSANOL INCREASED THE QUANTITY OF FREE FATTY ACIDS IN THE BASOLATERAL MEDIUM AND REDUCED THE FREE FATTY ACID CONTENT OF CACO-2 CELLS. FURTHER EVALUATION OF LIPID PROFILES INDICATED THAT POLICOSANOL MODULATED THE FATTY ACID PROFILE OF CHOLESTEROL ESTER IN THE BASOLATERAL MEDIUM. CONCLUSION: IT WAS CONCLUDED THAT POLICOSANOL OR POLICOSANOL METABOLITES MAY MODULATE LIPID METABOLISM AND/OR TRANSPORT FOLLOWING ABSORPTION BY THE BBM, PARTIAL OXIDATION BY THE INTESTINAL EPITHELIUM, AND TRANSPORT OF POLICOSANOL METABOLITES ACROSS THE BLM. © 2011 AMERICAN COLLEGE OF NUTRITION.","ABSORPTION; CACO-2 CELL; ENTEROCYTE; LIPID; METABOLISM; OCTACOSANOL; POLICOSANOL; TRANSPORT","ABSORPTION; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL SURVIVAL; CHOLESTEROL ESTERS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, THIN LAYER; FATTY ACIDS, NONESTERIFIED; FATTY ALCOHOLS; HUMANS; INTESTINES; LIPID METABOLISM; PHOSPHATIDYLCHOLINES; CHOLESTEROL ESTER; FATTY ACID; LIPID; PHOSPHATIDYLCHOLINE; POLICOSANOL; ARTICLE; BASOLATERAL MEMBRANE; BRUSH BORDER; CELL METABOLISM; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; GAS LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE CELL; LIPID METABOLISM; LIPID TRANSPORT; OXIDATION; THIN LAYER CHROMATOGRAPHY","","","VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MEDITERR J NUTR METAB, 1, PP. 77-83, (2008); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, J AM COLL NUTR, 27, PP. 476-484, (2008); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR J NUTR, 97, PP. 381-388, (2007); RIZZO W.B., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS: EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); RIZZO W.B., INHERITED DISORDERS OF FATTY ALCOHOL METABOLISM, MOL GEN METAB, 65, PP. 63-73, (1998); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); CHANTRET I., BARBAT A., DUSSAULX E., BRATTAIN M.G., ZWEIBAUM A., EPITHELIAL POLARITY, VILLIN EXPRESSION, AND ENTEROCYTIC DIFFERENTIATION OF CULTURED HUMAN COLON CARCINOMA CELLS: A SURVEY OF TWENTY CELL LINES, CANCER RES, 48, PP. 1936-1942, (1988); COSTA C., HUNEAU J.F., TOME D., CHARACTERISTICS OF L-GLUTAMINE TRANSPORT DURING CACO-2 CELL DIFFERENTIATION, BIOCHEM BIOPHYS ACTA, 1509, PP. 95-102, (2000); NICKLIN P.L., IRWIN W.J., HASSAN I.F., MACKAY M., DIXON H., THE TRANSPORT OF ACIDIC AMINO ACIDS AND THEIR ANALOGUES ACROSS MONOLAYERS OF HUMAN INTESTINAL ABSORPTIVE (CACO-2) CELLS IN VITRO, BIOCHEM BIOPHYS ACTA, 1269, PP. 176-186, (1995); RANHEIM T., GEDDE-DAHL A., RUSTAN A.C., DREVON C.A., FATTY ACID UPTAKE AND METABOLISM IN CACO-2 CELLS: EICOSAPENTAENOIC ACID (20:5(N-3)) AND OLEIC ACID (18:1(N-9)) PRESENTED IN ASSOCIATION WITH MICELLES OR ALBUMIN, BIOCHIM BIOPHYS ACTA, 1212, PP. 295-304, (1994); GLAHN R.P., CHENG Z., WELCH R.M., GREGORIO G.B., COMPARISON OF IRON BIOAVAILABILITY FROM 15 RICE GENOTYPES: STUDIES USING AN IN VITRO DIGESTION/CACO-2 CELL CULTURE MODEL, J AGRIC FOOD CHEM, 50, PP. 3586-3591, (2002); AU A.P., REDDY M.B., CACO-2 CELLS CAN BE USED TO ASSESS HUMAN IRON BIOAVAILABILITY FROM A SEMIPURIFIED MEAL, J NUTR, 130, PP. 1329-1334, (2000); GONZALEZ CANAVACIOLO V.L., MAGRANER HERNANDEZ J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN FIVE-MILLIGRAM FILM-COATED TABLETS, J AOAC INT, 82, PP. 834-839, (1999); NAPOLITANO M., RAINALDI G., BRAVO E., RIVABENE R., INFLUENCE OF THIOL BALANCE ON MICELLAR CHOLESTEROL HANDLING BY POLARIZED CACO-2 INTESTINAL CELLS, FEBS LETT, 551, PP. 165-170, (2003); RAMSOONDAR J., CHRISTOPHERSON R.J., GUILBERT L.J., WEGMANN T.G., A PORCINE TROPHOBLAST CELL LINE THAT SECRETES GROWTH FACTORS WHICH STIMULATE PORCINE MACROPHAGES, BIOL REPROD, 49, PP. 681-694, (1993); HIDALGO I., RAUB T., BORCHARDT R., CHARACTERIZATION OF THE HUMAN COLON CARCINOMA CELL LINE (CACO-2) AS A MODEL SYSTEM FOR INTESTINAL EPITHELIAL PERMEABILITY, GASTROENTEROLOGY, 96, PP. 736-749, (1989); MEHRAN M., LEVY E., BENDAYAN M., SEIDMAN E., LIPID, APOLIPOPROTEIN, AND LIPOPROTEIN SYNTHESIS AND SECRETION DURING CELLULAR DIFFERENTIATION IN CACO-2 CELLS, VITRO CELL DEV BIOL ANIM, 33, PP. 118-128, (1997); FOLCH J., LEES M., STANLEY G., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDS FROM ANIMAL TISSUES, J BIOL CHEM, 226, PP. 497-509, (1957); STEEL R., TORRIE J.H., ''PRINCIPLES AND PROCEDURES OF STATISTICS: A BIOMETRICAL APPROACH.'', (1980); MENENDEZ R., MAS R., AMOR A., GONZALEZ R., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); THIPPESWAMY G., SHEELA M., SALIMATH B.P., OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-B AND ITS DNA BINDING ACTIVITY, EUR J PHARMACOL, 588, PP. 141-150, (2008); MARCIL V., DELVIN E., GAROFALO C., LEVY E., BUTYRATE IMPAIRS LIPID TRANSPORT BY INHIBITING MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN CACO-2 CELLS, J NUTR, 133, PP. 2180-2183, (2003); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); KIM E.J., HOLTHUIZEN P.E., PARK H.S., HA Y.L., JUNG K.C., PARK J.H., TRANS-10, CIS-12-CONJUGATED LINOLEIC ACID INHIBITS CACO-2 COLON CANCER CELL GROWTH, AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, 283, PP. G357-G367, (2002); KIM E.J., KIM W.Y., KANG Y.H., HA Y.L., BACH L.A., PARK J., INHIBITION OF CACO-2 CELL PROLIFERATION BY (N-3) FATTY ACIDS: POSSIBLE MEDIATION BY INCREASED SECRETION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-6, NUTR RES, 20, PP. 1409-1421, (2000); LEVY E., MEHRAN M., SEIDMAN E., CACO-2 CELLS AS A MODEL FOR INTESTINAL LIPOPROTEIN SYNTHESIS AND SECRETION, FASEB J, 9, PP. 626-635, (1995); DROVER V.A., NGUYEN D.V., BASTIE C.C., DARLINGTON Y.F., ABUMRAD N.A., PESSIN J.E., LONDON E., SAHOO D., PHILLIPS M.C., CD36 MEDIATES BOTH CELLULAR UPTAKE OF VERY LONG CHAIN FATTY ACIDS AND THEIR INTESTINAL ABSORPTION IN MICE, J BIOL CHEM, 283, PP. 13108-13115, (2008); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS, 43, PP. 109-115, (2008); MANSBACH C., PARTHASARATHY S., A RE-EXAMINATION OF THE FATE OF GLYCERIDE-GLYCEROL IN NEUTRAL LIPID ABSORPTION AND TRANSPORT, J LIPID RES, 23, PP. 1009-1019, (1982); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., MESA M., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, PP. 522-537, (2003); VAN GREEVENBROEK M., ERKELENS D.W., DE BRUIN T., CACO-2 CELLS SECRETE TWO INDEPENDENT CLASSES OF LIPOPROTEINS WITH DISTINCT DENSITY: EFFECT OF THE RATIO OF UNSATURATED TO SATURATED FATTY ACID, ATHEROSCLEROSIS, 149, PP. 25-31, (2000); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009)","M.T. CLANDININ; ALBERTA INSTITUTE FOR HUMAN NUTRITION, UNIVERSITY OF ALBERTA, EDMONTON, AB, T6G 2R1, 4-002C LI KA SHING, CANADA; EMAIL: TCLANDIN@PROFESSORPUFA.COM","","ENGLISH","J. AM. COLL. NUTR.","ARTICLE","ISI","2-S2.0-80052614269","J AM COLL NUTR","UNIVERSITY OF ALBERTA;UNIVERSITY OF ALBERTA;UNIVERSITY OF ALBERTA","NOTREPORTED;UNIVERSITY OF ALBERTA;NOTREPORTED",NA,"LI Q, 2011, J AM COLL NUTR","LI Q, 2011, J AM COLL NUTR"
"REMIREZ D;PÉREZ J;LÓPEZ G;JACOBO O;O'BRIEN P","REMIREZ, DIADELIS (6602074384); PÉREZ, JENNY AVILA (14627571100); LÓPEZ, GISET JIMÉNEZ (36192983400); JACOBO, OLGA L. (36192937200); O'BRIEN, PETER J. (8978240400)","INTERACTIONS BETWEEN HERBAL REMEDIES AND MEDICINAL DRUGS CONSIDERATIONS ABOUT CUBA",2009,"DRUG METABOLISM AND DRUG INTERACTIONS","24","11",6,"10.1515/DMDI.2009.24.2-4.183","NATIONAL CENTER FOR STATE QUALITY CONTROL OF DRUGS (CECMED), HAVANA, CUBA;CENTER FOR DEVELOPMENT OF PHARMACOEPIDEMIOLOGY (CDF), HAVANA, CUBA;CENTER FOR DEVELOPMENT OF PHARMACOEPIDEMIOLOGY (CDF), HAVANA, CUBA;NATIONAL CENTER FOR STATE QUALITY CONTROL OF DRUGS (CECMED), HAVANA, CUBA;FACULTY OF PHARMACY, UNIVERSITY OF TORONTO, CANADA","THE USE OF HERBAL PRODUCTS TO TREAT A WIDE RANGE OF CONDITIONS IS RAPIDLY LEADING TO INCREASED INTAKE OF PHYTOCHEMICALS. THIS IS ONE OF THE MAIN REASONS FOR REINFORCING THE SURVEILLANCE OF THE SAFETY, EFFICACY AND QUALITY CONTROL OF TRADITIONAL AND COMPLEMENTARY MEDICINES. HERBAL PREPARATIONS CAN INTERACT WITH A DRUG AT PHARMACOKINETIC, PHARMACODYNAMIC AND PHARMACOGENETIC LEVELS. IN THIS ARTICLE INTERACTIONS BETWEEN HERBAL PRODUCTS AND CONVENTIONAL MEDICINES ARE REVIEWED. REPORTS ABOUT SIDE EFFECTS OF TRADITIONAL MEDICINES AND MAIN INTERACTIONS BETWEEN HERBAL MEDICINES AND CONVENTIONAL DRUGS IN CUBA ARE ALSO INCLUDED. HERBAL PRODUCTS ARE CURRENTLY NOT SUBJECT TO THE RIGOROUS TESTING INDISPENSABLE FOR CONVENTIONAL DRUGS. HOWEVER, IF POTENTIAL DRUG INTERACTIONS ARE TO BE PREDICTED, IT IS ESSENTIAL THAT THE ABILITY OF HERBAL PRODUCTS TO INTERFERE WITH DRUG-METABOLIZING ENZYME SYSTEMS IS FULLY ESTABLISHED. ©FREUND PUBLISHING HOUSE LTD., 2009.","CUBA; DRUG INTERACTIONS; HERBAL-DRUG INTERACTION; PHARMACOVIGILANCE","ACETYLSALICYLIC ACID; AMITRIPTYLINE; CAPTOPRIL; CARBAMAZEPINE; CLOMIPRAMINE; CYCLOSPORIN; DIAZEPAM; DIGOXIN; DRUG METABOLIZING ENZYME; ENALAPRIL; ERYTHROMYCIN; FLUNITRAZEPAM; IMIPRAMINE; ISOSORBIDE DINITRATE; KANAMYCIN; KAVA; LANSOPRAZOLE; MORPHINE; NELFINAVIR; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PHENELZINE; PLANT MEDICINAL PRODUCT; POLICOSANOL; SALBUTAMOL; SAQUINAVIR; TAMOXIFEN; UNINDEXED DRUG; VALERIAN; ALLOPATHY; ALOE VERA; COMPETITIVE INHIBITION; CUBA; CYMBOPOGON CITRATUS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; ENZYME SUBSTRATE; EPIGASTRIC DISCOMFORT; FOOD DRUG INTERACTION; GARLIC; GENETIC POLYMORPHISM; GINKGO BILOBA; GINSENG; GRAFT REJECTION; GUAVA; HERB DRUG INTERACTION; HERBAL MEDICINE; HORMONAL THERAPY; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LARYNX EDEMA; MANGO; MANGROVE; MANIA; MARIGOLD; MORINDA CITRIFOLIA; NAUSEA; NONHUMAN; PARESTHESIA; PHARMACOGENETICS; RASH; REVIEW; SKIN BRUISING; SKIN REDNESS; TEA; TRADITIONAL MEDICINE","","","EISENBERG D.M., DAVIS R.B., ETNER S.L., TRENDS IN ALTERNATIVE MEDICINE USE IN THE UNITED STATES, 1990-1997, RESULTS OF A FOLLOW-UP NATIONAL SURVEY, JAMA, 280, PP. 1569-1575, (1998); GOLDBECK-WOOD S., DOROZYNSKI A., LIE L.G., COMPLEMENTARY MEDICINE IS BLOOMING WORLDWIDE, BMJ, 313, PP. 131-133, (1996); TOMLINSON B., CHAN T.Y., CHAN J.C., CRITCHLEY J.A., BUTT P.P., TOXICITY OF COMPLEMENTARY THERAPIES: AN EASTERN PERSPECTIVE, J CLIN PHARMACOL, 40, PP. 451-456, (2000); SPARBER A., WOOTTON J.C., BAUER L., CURT G., ET AL., USE OF COMPLEMENTARY MEDICINE BY ADULT PATIENTS PARTICIPATING IN HIV/AIDS CLINICAL TRIALS, J ALTERN COMPLEMENT MED, 6, PP. 415-422, (2000); CHAVEZ M.L., JORDAN M.A., CHAVEZ P.I., EVIDENCE-BASED DRUG-HERBAL INTERACTIONS, LIFE SCI, 78, PP. 2146-2157, (2006); BARNES J., PHARMACOVIGILANCE OF HERBAL MEDICINE. A UK PERSPECTIVE, DRUG SAF, 26, PP. 829-851, (2003); THOMAS K.J., NICHOLL J.P., COLEMAN P., USE AND EXPENDITURE ON COMPLEMENTARY MEDICINE IN ENGLAND: A POPULATION BASED SURVEY, COMPLEMENTARY THERAPIES IN MEDICINE, 9, 1, PP. 2-11, (2001); LIU E.H., TURNER L.M., LIN S.X., KLAUS L., CHOI L.Y., WHITWORTH J., TING W., OZ M.C., USE OF ALTERNATIVE MEDICINE BY PATIENTS UNDERGOING CARDIAC SURGERY, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 120, 2, PP. 335-341, (2000); HERBAL MEDICINALS: A CLINICIAN'S GUIDE, (1998); BARNES J., PHILLIPSON J.D., ANDERSON L.A., HERBAL MEDICINES, (2002); ANG-LEE M.K., MOSS J., YAUN C., HERBAL MEDICINES AND PERIOPERATIVE CARE, JAMA, 286, PP. 208-216, (2001); FUGH-BERMAN A., ERNST E., HERB-DRUG INTERACTIONS: REVIEW AND ASSESSMENT OF REPORT RELIABILITY, BR J CLIN PHARM, 52, PP. 587-595, (2002); ZHOU S., GAO Y., JIANG W., HUANG M., XU A., PAXTON J.W., INTERACTIONS OF HERBS WITH CYTOCHROME P450, DRUG METABOL REV, 35, PP. 35-98, (2003); AHMAD N., KATIYAR S.K., MUKHTAR H., CANCER CHEMOPREVENTION BY TEA POLYPHENOLS, NUTRITION AND CHEMICAL TOXICITY, PP. 301-343, (1998); VALDES M., GARRIDO G., TRENDS IN RESEARCHING AND REPORTING ON HERBAL-DRUG INTERACTIONS, LATINAMERICAN AND CARIBBEAN BULLETIN OF MEDICINAL AND AROMATIC PLANTS (BLACPMA), 7, PP. 345-358, (2008); DELGODA R., WESTLAKE A.C.G., HERBAL INTERACTIONS INVOLVING CYTOCHROME P450 ENZYMES: A MINI REVIEW, TOXICOLOGICAL REVIEWS, 23, 4, PP. 239-249, (2004); GUENGERICH F.P., ROLE OF CYTOCHROME P450 ENZYMES IN DRUG-DRUG INTERACTIONS, DRUG-DRUG INTERACTIONS, PP. 7-35, (1997); HU Z., YANG X., HO P.C., CHAN S.Y., ET AL., HERB-DRUG INTERACTIONS: A LITERATURE REVIEW, DRUGS, 65, PP. 1239-1282, (2005); PRIOR T.I., CHUE P.S., TIBBO P., ET AL., DRUG METABOLISM AND ATYPICAL ANTIPSYCHOTICS, EUR NEUROSYCHOPHARMACOL, 9, PP. 301-309, (1999); HO R.H., KIM R.B., TRANSPORTERS AND DRUG THERAPY: IMPLICATIONS FOR DRUG DISPOSITION AND DISEASE, CLIN PHARMACOL THER, 78, PP. 260-277, (2005); ZHANG L., STRONG J.M., QIU W., LESKO L.J., HUANG S.-M., SCIENTIFIC PERSPECTIVES ON DRUG TRANSPORTERS AND THEIR ROLE IN DRUG INTERACTION, MOLECULAR PHARMACEUTICS, 3, 1, PP. 62-69, (2006); FOSTER B.C., FOSTER M.S., VANDENHOEK S., KRANTIS A., BUDZINSKI J.W., ARNASON J.T., GALLICANO K.D., CHOUDRI S., AN IN VITRO EVALUATION OF HUMAN CYTOCHROME P450 3A4 AND P-GLYCOPROTEIN INHIBITION BY GARLIC, J PHARM PHARM SCI, 4, PP. 176-184, (2000); SPINELLA M., HERBAL MEDICINES AND EPILEPSY: THE POTENTIAL FOR BENEFIT AND ADVERSE EFFECTS, EPILEPSY AND BEHAVIOR, 2, 6, PP. 524-532, (2001); SHINOZUKA K., UMEGAKI K., KUBOTA Y., TANAKA N., MIZUNO H., YAMAUCHI J., NAKAMURA K., KUNITOMO M., FEEDING OF GINKGO BILOBA EXTRACT (GBE) ENHANCES GENE EXPRESSION OF HEPATIC CYTOCHROME P-450 AND ATTENUATES THE HYPOTENSIVE EFFECT OF NICARDIPINE IN RATS, LIFE SCIENCES, 70, 23, PP. 2783-2792, (2002); SORENSEN J.M., HERB-DRUG, FOOD-DRUG, NUTRIENT-DRUG AND DRUG-DRUG INTERACTIONS: MECHANISMS INVOLVED AND THEIR MEDICAL IMPLICATIONS, J ALTERN COMPLEMENT MED, 8, PP. 293-308, (2002); SHAH R.S., CAN PHARMACOGENETICS HELP RESCUE DRUGS WITHDRAWN FROM THE MARKET?, PHARMACOGENOMICS, 7, PP. 889-908, (2006); EICHELBAUM M., INGELMAN-SUNDBERG M., EVANS W.E., PHARMACOGENOMICS AND INDIVIDUALIZED DRUG THERAPY, ANNU REV MED, 57, PP. 119-137, (2006); PHILIPS K.A., VAN BEBBER S.L., MEASURING THE VALUE OF PHARMACOGENOMICS, NAT REV DRUG DISCOV, 4, PP. 500-509, (2005); TOMLLISON B., HU M., LEE V.W.Y., IN VIVO ASSESSMENT OF HERB-DRUG INTERACTIONS: POSSIBLE UTILITY OF A PHARMACOGENETIC APPROACH?, MOL NUTR FOOD RES, 52, PP. 799-809, (2008); FUNG-BERMAN A., ERNST E., HERB-DRUG INTERACTIONS. REVIEW AND ASSESSMENT OF REPORT RELIABILITY, BR J CLIN PHARMACOL, 52, PP. 587-595, (2001); YIN O.Q.P., TOMLINSON B., WAYE M.M.Y., CHOW A.H.L., CHOW M.S.S., PHARMACOGENETICS AND HERB-DRUG INTERACTIONS: EXPERIENCE WITH GINKGO BILOBA AND OMEPRAZOLE, PHARMACOGENETICS, 14, 12, PP. 841-850, (2004); GONZALEZ M., REMIREZ D., JACOBO O.L., ANTECEDENTS AND CURRENT SITUATION OF THE REGULATION OF HERBAL MEDICINES IN CUBA, LATINAMERICAN BULLETIN OF MEDICINAL PLANTS (BLACPMA), 6, PP. 118-124, (2007); THE IMPORTANCE OF PHARMACOVIGILANCE. SAFETY MONITORING OF MEDICINAL PRODUCTS, PP. 15-23, (2002); GARCIA M., CACERES A., LEGISLACIÓN EN IBEROAMÉRICA SOBRE FITOFÁRMACOS Y PRODUCTOS NATURALES, (2000); NUNEZ-SELLES A.J., DELGADO-HERNANDEZ R., GARRIDO-GARRIDO G., GARCIA-RIVERA D., GUEVARA-GARCIA M., PARDO-ANDREU G.L., THE PARADOX OF NATURAL PRODUCTS AS PHARMACEUTICALS. EXPERIMENTAL EVIDENCE OF A MANGO STEM BARK EXTRACT, PHARMACOL RES, 55, PP. 351-358, (2007); DE ARMAS E., SARRACENT Y., MARRERO E., FERNANDEZ O., BRANFORD-WHITE C., EFFICACY OF RHIZOPHORA MANGLE AQUEOUS BARK EXTRACT (RMABE) IN THE TREATMENT OF APHTHOUS ULCERS: A PILOT STUDY, CURRENT MEDICAL RESEARCH AND OPINION, 21, 11, PP. 1711-1715, (2005); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 58, 1, PP. 61-64, (1998); WHO GUIDELINES ON SAFETY MONITORING AND PHARMACOVIGILANCE OF HERBAL MEDICINES, (2003); REMIREZ D., LESCAY M., GONZALEZ M., REGULATORY STATUS OF HERBAL MEDICINE, PHARMACOLOGY ONLINE, 3, PP. 107-110, (2006); REQUIREMENTS FOR APPLYING INSCRIPTION OF REGISTRATION OF HERBAL MEDICINES IN CUBA. GUIDELINES, PP. 28-2002; REPORTS OF PHARMACOVIGILANCE IN CUBA, (2007); LAPORTE J.R., TOGNONI G., PRINCIPIOS DE EPIDEMIOLOGÍA DEL MEDICAMENTO, (1993); FARMACOVIGILANCE, (2007); GARCIA B.L., GARCIA L.V., ET AL., PLANTS WITH ANTIOXIDANT PROPERTIES, CUBAN PLANT MEDICAL, 9, (2004)","D. REMIREZ; NATIONAL CENTER FOR STATE QUALITY CONTROL OF DRUGS (CECMED), HAVANA, CUBA; EMAIL: DIADE.REMIREZ@INFOMED.SLD.CU","WALTER DE GRUYTER GMBH","ENGLISH","DRUG METAB. DRUG INTERACT.","REVIEW","ISI","2-S2.0-77950608257","DRUG METAB DRUG INTERACT","NATIONAL CENTER FOR STATE QUALITY CONTROL OF DRUGS (CECMED);CENTER FOR DEVELOPMENT OF PHARMACOEPIDEMIOLOGY (CDF);CENTER FOR DEVELOPMENT OF PHARMACOEPIDEMIOLOGY (CDF);NATIONAL CENTER FOR STATE QUALITY CONTROL OF DRUGS (CECMED);UNIVERSITY OF TORONTO","NOTREPORTED;NATIONAL CENTER FOR STATE QUALITY CONTROL OF DRUGS (CECMED);NOTREPORTED",NA,"REMIREZ D, 2009, DRUG METAB DRUG INTERACT","REMIREZ D, 2009, DRUG METAB DRUG INTERACT"
"OKABE T;TODA T;INAFUKU M;WADA K;IWASAKI H;OKU H","OKABE, TAKAFUMI (23571175300); TODA, TAKAYOSHI (57203440548); INAFUKU, MASASHI (10043967000); WADA, KOJI (7401668452); IWASAKI, HIRONORI (7403250867); OKU, HIROSUKE (7102887181)","ANTIATHEROSCLEROTIC FUNCTION OF KOKUTO OKINAWAN NONCENTRIFUGAL CANE SUGAR",2009,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","57","6",21,"10.1021/jf802796m","UNITED GRADUATE SCHOOL OF AGRICULTURAL SCIENCES, KAGOSHIMA UNIVERSITY, KAGOSHIMA 890-0065, KORIMOTO 1-21-24, JAPAN, DIVISION OF MOLECULAR BIOTECHNOLOGY, CENTER OF MOLECULAR BIOSCIENCE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, OKINAWA 903-0213, SENBARU 1, JAPAN;DEPARTMENT OF CLINICAL LABORATORY MEDICINE, SCHOOL OF MEDICINE, UNIVERSITY OF THE RYUKYUS HOSPITAL, NISHIHARA, OKINAWA 903-0215, UEHARA 207, JAPAN;DEPARTMENT OF CELL BIOLOGY AND MOLECULAR MEDICINE, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, NEW JERSEY MEDICAL SCHOOL, NEWARK, NJ 07103, 185 SOUTH ORANGE AVENUE, UNITED STATES;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, OKINAWA 903-0213, SENBARU 1, JAPAN;DIVISION OF MOLECULAR BIOTECHNOLOGY, CENTER OF MOLECULAR BIOSCIENCE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, OKINAWA 903-0213, SENBARU 1, JAPAN;DIVISION OF MOLECULAR BIOTECHNOLOGY, CENTER OF MOLECULAR BIOSCIENCE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, OKINAWA 903-0213, SENBARU 1, JAPAN","IN THE PRESENT STUDY, WE INVESTIGATED THE EFFECT OF PHENOLIC COMPOUNDS (PCS) AND POLICOSANOL OF KOKUTO, OKINAWAN NONCENTRIFUGAL CANE SUGAR, ON THE DEVELOPMENT OF ATHEROSCLEROSIS. A TOTAL OF 67 MALE JAPANESE QUAIL WERE DIVIDED INTO EIGHT DIETARY GROUPS IN TRIAL 1. THE DIETARY GROUPS WERE FED THE ATHEROSCLEROTIC DIET (AD) CONTAINING 5% CORN OIL, 2% CHOLESTEROL, AND 30% SUCROSE OR SEVEN DIFFERENT TYPES OF KOKUTO. DIETARY INTAKES OF KOKUTO NOTABLY PREVENTED THE DEVELOPMENT OF ATHEROSCLEROSIS. FURTHERMORE, THERE WAS A SIGNIFICANT NEGATIVE CORRELATION BETWEEN THE SERUM RADICAL SCAVENGING ACTIVITY AND THE DEGREE OF ATHEROSCLEROSIS IN THE DIETARY GROUPS. IN TRIAL 2, A TOTAL OF 63 JAPANESE QUAIL WERE FED AD WITH SUCROSE, KOKUTO, PC EXTRACTS FROM KOKUTO, WAX EXTRACTS FROM SUGAR CANE, OCTACOSANOL, VITAMIN C, AND VITAMIN E. AS A RESULT, THE SUPPLEMENTATION OF THE DIET WITH KOKUTO AND PCS SIGNIFICANTLY REDUCED THE DEVELOPMENT OF ATHEROSCLEROSIS AS COMPARED WITH THE INGESTION OF AD WITH SUCROSE. IN CONCLUSION, THESE FINDINGS SUGGEST THAT, AMONG VARIOUS COMPONENTS OF KOKUTO, PCS PLAY A CENTRAL ROLE FOR THE PREVENTION OF EXPERIMENTAL ATHEROSCLEROSIS IN JAPANESE QUAIL. © 2009 AMERICAN CHEMICAL SOCIETY.","ATHEROSCLEROSIS; JAPANESE QUAIL; KOKUTO; OCTACOSANOL; PHENOLIC COMPOUNDS; RADICAL SCAVENGING ACTIVITY; WAX","ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL, DIETARY; COTURNIX; DIET, ATHEROGENIC; DIETARY SUCROSE; FATTY ALCOHOLS; JAPAN; LIPIDS; LIVER; MALE; PHENOLS; PLANT EXTRACTS; SACCHARUM; COTURNIX JAPONICA; PHASIANIDAE; SACCHARUM; ZEA MAYS; ANTIOXIDANT; FATTY ALCOHOL; LIPID; PHENOL DERIVATIVE; PLANT EXTRACT; POLICOSANOL; ANIMAL; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; BLOOD; BODY WEIGHT; CHEMISTRY; CHOLESTEROL INTAKE; COTURNIX; GROWTH, DEVELOPMENT AND AGING; JAPAN; LIVER; MALE; SUGAR INTAKE; SUGARCANE","","","AUSTIN M.A., HOKANSON J.E., EDWARDS K.L., HYPERTRIGLYCERIDEMIA AS A CARDIOVASCULAR RISK FACTOR, AM. J. CARDIOL, 81, (1998); LIBBY P., AIKAWA M., SCHONBECK U., CHOLESTEROL AND ATHEROSCLEROSIS, BIOCHIM. BIOPHYS. ACTA, 1529, PP. 299-309, (2000); KITA T., KUME N., MINAMI M., HAYASHIDA K., MURAYAMA T., SANO H., MORIWAKI H., KATAOKA H., NISHI E., HORIUCHI H., ARAI H., YOKODE M., ROLE OF OXIDIZED LDL IN ATHEROSCLEROSIS, ANN. N. Y. ACAD. SCI, 947, PP. 199-206, (2001); STAPRANS I., PAN X.M., RAPP J.H., FEINGOLD K.R., THE ROLE OF DIETARY OXIDIZED CHOLESTEROL AND OXIDIZED FATTY ACIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS, MOL. NUTR. FOOD RES, 49, PP. 1075-1082, (2005); KUROSAWA T., ITOH F., NOZAKI A., NAKANO Y., KATSUDA S., OSAKABE N., TSUBONE H., KONDO K., ITAKURA H., SUPPRESSIVE EFFECTS OF CACAO LIQUOR POLYPHENOLS (CLP) ON LDL OXIDATION AND THE DEVELOPMENT OF ATHEROSCLEROSIS IN KUROSAWA AND KUSANAGI-HYPERCHOLESTEROLEMIC RABBITS, ATHEROSCLEROSIS, 179, PP. 237-246, (2005); ANTER E., THOMAS S.R., SCHULZ E., SHAPIRA O.M., VITA J.A., KEANEY JR. J.F., ACTIVATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE BY THE P38 MAPK IN RESPONSE TO BLACK TEA POLYPHENOLS, J. BIOL. CHEM, 279, PP. 46637-46643, (2004); LEIKERT J.F., RATHEL T.R., WOHLFART P., CHEYNIER V., VOLLMAR A.M., DIRSCH V.M., RED WINE POLYPHENOLS ENHANCE ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION AND SUBSEQUENT NITRIC OXIDE RELEASE FROM ENDOTHELIAL CELLS, CIRCULATION, 106, PP. 1614-1617, (2002); DELLI'AGLI M., BUSCIALA A., BOSISIO E., VASCULAR EFFECTS OF WINE POLYPHENOLS, CARDIOVASC. RES, 63, PP. 593-602, (2004); HAYEK T., FUHRMAN B., VAYA J., ROSENBLAT M., BELINKY P., COLEMAN R., ELIS A., AVIRAM M., REDUCED PROGRESSION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE FOLLOWING CONSUMPTION OF RED WINE, OR ITS POLYPHENOLS QUERCETIN OR CATECHIN, IS ASSOCIATED WITH REDUCED SUSCEPTIBILITY OF LDL TO OXIDATION AND AGGREGATION, ARTERIOSCLER., THROMB., VASC. BIOL, 17, PP. 2744-2752, (1997); NAKASONE Y., TAKARA K., WADA K., TANAKA J., YOGI S., NAKATANI N., ANTIOXIDATIVE COMPOUNDS ISOLATED FROM KOKUTO, NON-CENTRIFUGAL CANE SUGAR, BIOSCI., BIOTECHNOL., BIOCHEM, 60, PP. 1714-1716, (1996); TAKARA K., MATSUI D., WADA K., ICHIBA T., NAKASONE Y., NEW ANTIOXIDATIVE PHENOLIC GLYCOSIDES ISOLATED FROM KOKUTO NON-CENTRIFUGED CANE SUGAR, BIOSCI., BIOTECHNOL., BIOCHEM, 66, PP. 29-35, (2002); TAKARA K., MATSUI D., WADA K., ICHIBA T., CHINEN I., NAKASONE Y., NEW PHENOLIC COMPOUNDS FROM KOKUTO, NON-CENTRIFUGED CANE SUGAR, BIOSCI., BIOTECHNOL., BIOCHEM, 67, PP. 376-379, (2003); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR, 77, PP. 923-932, (1997); SHO H., CHINEN I., FUKUDA N., EFFECT OF OKINAWAN SUGAR CANE WAX AND FATTY ALCOHOL ON SERUM AND LIVER LIPIDS IN THE RAT, J. NUTR. SCI. VITAMINOL. (TOKYO), 30, PP. 553-539, (1984); FUKUDA N., SATO M., OKU H., SHO H., CHINEN I., EFFECT OF SUGAR CANE WAX ON SERUM AND LIVER LIPIDS OF RATS, NIPPON NOGEIKAGAKU KAISHI, 60, PP. 1023-1025, (1986); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J. AGRIC. FOOD. CHEM, 53, PP. 6289-6293, (2005); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT. J. CARDIOL, 67, PP. 125-132, (1998); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ. J. MED. BIOL. RES, 33, PP. 835-840, (2000); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH. MED. RES, 36, PP. 441-447, (2005); INAFUKU M., TODA T., OKABE T., WADA K., TAKARA K., IWASAKI H., OKU H., EFFECT OF KOKUTO, A NON-CENTRIFUGAL CANE SUGAR, ON THE DEVELOPMENT OF EXPERIMENTAL ATHEROSCLEROSIS IN JAPANESE QUAIL AND APOLIPOPROTEIN E DEFICIENT MICE, FOOD SCI. TECHNOL. RES, 13, PP. 61-66, (2007); TODA T., KUMMEROW F.A., NISHIMORI I., SYMPOSIUM I., ANIMAL MODEL OF ATHEROSCLEROSIS, EXPERIMENTAL ATHEROSCLEROSIS IN THE CHICKEN ANIMAL MODEL, JPN. ATHEROSCLER. SOC, 11, PP. 755-761, (1976); INAFUKU M., TODA T., OKABE T., SHINJO A., IWASAKI H., OKU H., EXPRESSION OF CELL-CYCLE-REGULATING GENES IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN JAPANESE QUAIL (COTURNIX JAPONICA), POULT. SCI, 86, PP. 1166-1173, (2007); TAKARA K., OTSUKA K., WADA K., IWASAKI H., YAMASHITA M., PHENOLIC COMPOUNDS FROM SUGARCANE MOLASSES POSSESSING ANTIBACTERIAL ACTIVITY AGAINST CARIOGENIC BACTERIA, J. OLEO SCI, 56, PP. 611-614, (2007); ASIKIN Y., CHINEN T., TAKARA K., WADA K., DETERMINATION OF LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NON-CENTRIFUGED CANE SUGAR KOKUTO, FOOD SCI. TECHNOL. RES, 14, PP. 583-588, (2008); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J. AGRIC. FOOD. CHEM, 54, PP. 5359-5362, (2006); TATEYAMA C., HOMMA N., NAMIKI K., UCHIYAMA T., POLYPHENOL CONTENT AND ANTIOXIDANT ACTIVITY OF VARIOUS FLOWER PETALS, NIPPON SHOKUHIN KAGAKU KOKAKU KAISHI, 44, PP. 290-299, (1997); OKI T., MASUDA M., KOBAYASHI M., NISHIBA Y., FURUTA S., SUDA I., SATO T., RADICAL SCAVENGING ACTIVITY OF FRIED CHIPS MADE FROM PURPLE-FLESHED SWEET POTATO, NIPPON SHOKUHIN KAGAKU KOGAKU KAISHI, 48, PP. 926-932, (2001); FOLCH J., LEES M., SLOANE STANLEY G.H., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES, J. BIOL. CHEM, 226, PP. 497-509, (1957); SPERRY W.M., WEBB M.J., A REVISION OF THE SHOENHEIMER-SPERRY METHOD FOR CHOLESTEROL DETERMINATION, J. BIOL. CHEM, 187, PP. 97-106, (1950); FLETCHER M.J., A COLORIMETRIC METHOD FOR ESTIMATING SERUM TRIGLYCERIDES, CLIN. CHIM. ACTA, 22, PP. 393-397, (1986); RE R., PELLEGRINI N., PROTEGGENTE A., PANNALA A., YANG M., RICE-EVANS C., ANTIOXIDANT ACTIVITY APPLYING AN IMPROVED ABTS RADICAL CATION DECOLORIZATION ASSAY, FREE. RADICAL BIOL. MED, 26, PP. 1231-1237, (1999); ZERN T.L., WOOD R.J., GREENE C., WEST K.L., LIU Y., AGGARWAL D., SHACHTER N.S., FERNANDEZ M.L., GRAPE POLYPHENOLS EXERT A CARDIOPROTECTIVE EFFECT IN PRE- AND POSTMENOPAUSAL WOMEN BY LOWERING PLASMA LIPIDS AND REDUCING OXIDATIVE STRESS, J. NUTR, 135, PP. 1911-1917, (2005); SUGIYAMA H., AKAZOME Y., SHOJI T., YAMAGUCHI A., YASUE M., KANDA T., OHTAKE Y., OLIGOMERIC PROCYANIDINS IN APPLE POLYPHENOL ARE MAIN ACTIVE COMPONENTS FOR INHIBITION OF PANCREATIC LIPASE AND TRIGLYCERIDE ABSORPTION, J. AGRIC. FOOD CHEM, 55, PP. 4604-4609, (2007); KIMURA Y., OKUDA H., ARICHI S., EFFECT OF NON-SUGAR FRACTION IN BLACK SUGAR ON LIPID AND CARBOHYDRATE METABOLISM; PART I, PLANTA MED, 50, PP. 465-468, (1984); SHO H., CHINEN I., UCHIHARA K., FUKUDA N., EFFECT OF OKINAWAN SUGAR CANE RIND ON SERUM AND LIVER CHOLESTEROL AND TRIGLYCERIDE LEVEL IN THE RAT, J. NUTR. SCI. VITAMINOL. (TOKYO), 27, PP. 463-470, (1981); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL, 50, PP. 255-262, (2000); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR, 84, PP. 1543-1548, (2006); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); KATO S., KARINO K., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., HAMATANI K., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR. J. NUTR, 73, PP. 433-441, (1995); FUHRMAN B., VOLKOVA N., COLEMAN R., AVIRAM M., GRAPE POWDER POLYPHENOLS ATTENUATE ATHEROSCLEROSIS DEVELOPMENT IN APOLIPOPROTEIN E DEFICIENT (E0) MICE AND REDUCE MACROPHAGE ATHEROGENICITY, J. NUTR, 135, PP. 722-728, (2005); MARTIN A., FREI B., BOTH INTRACELLULAR AND EXTRACELLULAR VITAMIN C INHIBIT ATHEROGENIC MODIFICATION OF LDL BY HUMAN VASCULAR ENDOTHELIAL CELLS, ARTERIOSCLER., THROMB., VASC. BIOL, 17, PP. 1583-1590, (1997); DAS S., RAY R., SNEHLATA D.N., SRIVASTAVA L.M., EFFECT OF ASCORBIC ACID ON PREVENTION OF HYPERCHOLESTEROLEMIA INDUCED ATHEROSCLEROSIS, MOL. CELL. BIOCHEM, 285, PP. 143-147, (2006); RAINWATER D.L., MAHANEY M.C., VANDEBERG J.L., WANG X.L., VITAMIN, E. DIETARY SUPPLEMENTATION SIGNIFICANTLY AFFECTS MULTIPLE RISK FACTORS FOR CARDIOVASCULAR DISEASE IN BABOONS, AM. J. CLIN. NUTR, 86, PP. 597-603, (2007); TERASAWA Y., LADHA Z., LEONARD S.W., MORROW J.D., NEWLAND D., SANAN D., PACKER L., TRABER M.G., FARESE JR. R.V., INCREASED ATHEROSCLEROSIS IN HYPERLIPIDEMIC MICE DEFICIENT IN ALPHA-TOCOPHEROL TRANSFER PROTEIN AND VITAMIN E, PROC. NATL. ACAD. SCI. U.S.A, 97, PP. 13830-13834, (2000); KERCKHOFFS D.A., BROUNS F., HORNSTRA G., MENSINK R.P., EFFECTS ON THE HUMAN SERUM LIPOPROTEIN PROFILE OF BETA-GLUCAN, SOY PROTEIN AND ISOFLAVONES, PLANT STEROLS AND STANDS, GARLIC AND TOCOTRIENOLS, J. NUTR, 132, PP. 2494-2505, (2002)","H. OKU; DIVISION OF MOLECULAR BIOTECHNOLOGY, CENTER OF MOLECULAR BIOSCIENCE, UNIVERSITY OF THE RYUKYUS, NISHIHARA, OKINAWA 903-0213, SENBARU 1, JAPAN; EMAIL: OKUHIROS@COMB.U-RYUKYU.AC.JP","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-59849087365","J AGRIC FOOD CHEM","KAGOSHIMA UNIVERSITY;UNIVERSITY OF THE RYUKYUS HOSPITAL;UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS;UNIVERSITY OF THE RYUKYUS","NOTREPORTED;UNIVERSITY OF THE RYUKYUS;NOTREPORTED",NA,"OKABE T, 2009, J AGRIC FOOD CHEM","OKABE T, 2009, J AGRIC FOOD CHEM"
"VUDDANDA P;CHAKRABORTY S;SINGH S","VUDDANDA, PARAMESWARA RAO (36344407200); CHAKRABORTY, SUBHASHIS (7201528168); SINGH, SANJAY (58843051800)","BERBERINE A POTENTIAL PHYTOCHEMICAL WITH MULTISPECTRUM THERAPEUTIC ACTIVITIES",2010,"EXPERT OPINION ON INVESTIGATIONAL DRUGS","19","10",277,"10.1517/13543784.2010.517745","BANARAS HINDU UNIVERSITY, INSTITUTE OF TECHNOLOGY, DEPARTMENT OF PHARMACEUTICS, VARANASI 221005, INDIA;BANARAS HINDU UNIVERSITY, INSTITUTE OF TECHNOLOGY, DEPARTMENT OF PHARMACEUTICS, VARANASI 221005, INDIA;BANARAS HINDU UNIVERSITY, INSTITUTE OF TECHNOLOGY, DEPARTMENT OF PHARMACEUTICS, VARANASI 221005, INDIA","IMPORTANCE OF THE FIELD: THE USE OF TRADITIONAL MEDICINES OF NATURAL ORIGIN IS BEING ENCOURAGED FOR THE TREATMENT OF CHRONIC DISORDERS, AS SYNTHETIC DRUGS IN SUCH CASES MAY CAUSE UNPREDICTABLE ADVERSE EFFECTS. BERBERINE, A TRADITIONAL PLANT ALKALOID, IS USED IN AYURVEDIC AND CHINESE MEDICINE FOR ITS ANTIMICROBIAL AND ANTIPROTOZOAL PROPERTIES. INTERESTINGLY, CURRENT CLINICAL RESEARCH ON BERBERINE HAS REVEALED ITS VARIOUS PHARMACOLOGICAL PROPERTIES AND MULTI-SPECTRUM THERAPEUTIC APPLICATIONS. AREAS COVERED IN THIS REVIEW: AN EXTENSIVE SEARCH IN THREE ELECTRONIC DATABASES (UNBOUND MEDLINE, PUBMED AND SCIENCEDIRECT) AND INTERNET SEARCH ENGINES (SCIRUS AND GOOGLE SCHOLAR) WERE USED TO IDENTIFY THE CLINICAL STUDIES ON BERBERINE, WITHOUT ANY TIME CONSTRAINTS. THIS REVIEW ELABORATES THE RECENT STUDIES WHICH REVEAL THAT WITH TIME, THE DRUG HAS EVOLVED WITH SUPERIOR THERAPEUTIC ACTIVITIES. IN ADDITION, THIS REVIEW WILL ALSO ATTRACT THE ATTENTION OF FORMULATION SCIENTISTS TOWARDS THE ISSUES AND CHALLENGES ASSOCIATED IN ITS DRUG DELIVERY AND THE PROBABLE APPROACHES THAT MAY BE EXPLORED TO HELP PATIENTS REAP THE MAXIMUM BENEFIT OF THIS POTENTIALLY USEFUL DRUG. WHAT THE READER WILL GAIN: A RELATIVELY LARGE NUMBER OF STUDIES DISCUSSED HERE HAVE REVEALED THE POSSIBLE AREAS WHERE THIS PHYTOCHEMICAL CONSTITUENT CAN EXHIBIT ITS THERAPEUTIC ACTIVITIES IN THE TREATMENT OF CHRONIC AILMENTS OR DISEASES INCLUDING DIABETES, CANCER, DEPRESSION, HYPERTENSION AND HYPERCHOLESTEROLEMIA. TAKE HOME MESSAGE: THE POTENTIAL OF THE DRUG REMAINS TO BE HARVESTED BY DESIGNING A SUITABLE FORMULATION THAT COULD OVERCOME ITS INHERENT LOW BIOAVAILABILITY. © 2010 INFORMA UK, LTD.","BERBERINE; LIPIDS; MULTIDRUG RESISTANCE; P-GP; P-GP INHIBITORS; POLYMERS","BERBERINE; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; ASTAXANTHIN; BERBERINE; COTRIMOXAZOLE; DESIPRAMINE; FENOFIBRATE; FLUOXETINE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MAPROTILINE; METFORMIN; MIANSERIN; MOCLOBEMIDE; PHENYLEPHRINE; POLICOSANOL; PRAZOSIN; PROSTAGLANDIN E2; ROSIGLITAZONE; SEROTONIN ANTAGONIST; TETRACYCLINE; TRAZODONE; TRIACYLGLYCEROL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CANCER CELL CULTURE; CANDIDA; CELL PROLIFERATION; CELL PROTECTION; CHOLERA; CLINICAL TRIAL; CLOSTRIDIUM; CRYPTOCOCCUS; DIABETES MELLITUS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENTAMOEBA; ESCHERICHIA COLI; FORCED SWIMMING TEST; GASTROINTESTINAL SYMPTOM; GIARDIA; GIARDIA LAMBLIA; HEART FAILURE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERLIPIDEMIA; INTERNET; KIDNEY INJURY; KLEBSIELLA; LEISHMANIA DONOVANI; MALARIA; MEDLINE; NEISSERIA MENINGITIDIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYTOCHEMISTRY; PROSTATE CANCER; PSEUDOMONAS; SALMONELLA; SHIGELLA; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; TASK PERFORMANCE; TRICHOMONAS VAGINALIS; VIBRIO","","","GENERAL GUIDELINES FOR METHODOLOGIES ON RESEARCH AND EVALUATION OF TRADITIONAL MEDICINE, PP. 1-73, (2000); PATWARDHAN B., HOPPER M.L., AYURVEDA AND FUTURE DRUG DEVELOPMENT, J ALTERN COMPLEMENT MED, 3, PP. 9-11, (1992); ARAYNE M.S., SULTANA N., BAHADUR S.S., ET AL., THE BERBERIS STORY: BERBERIS VULGARIS IN THERAPEUTICS, PAK J PHARM SCI, 20, PP. 83-92, (2007); IMANSHAHIDI M., HOSSEINZADEH H., PHARMACOLOGICAL AND THERAPEUTIC EFFECTS OF BERBERIS VULGARIS AND ITS ACTIVE CONSTITUENT, BERBERINE, PHYTOTHER RES, 22, PP. 999-1012, (2008); CERNAKOVA M., KOSTALOVA D., ANTIMICROBIAL ACTIVITY OF BERBERINE - A CONSTITUENT OF MAHONIA AQUIFOLIUM, FOLIA MICROBIOL (PRAHA), 47, PP. 375-378, (2002); BENSKY D., GAMBLE A., KAPCHUK T., CHINESE HERBAL MEDICINE: MATERIA MEDICA, (1993); SACK R.B., FROEHLICH J.L., BERBERINE-ONE HERB IN MANY WAYS, ALTERN MED REV, 5, PP. 175-177, (2000); KANEDA Y., TORII M., TANAKA T., ET AL., IN VITRO EFFECTS OF BERBERINE SULPHATE ON THE GROWTH AND STRUCTURE OF ENTAMOEBA HISTOLYTICA, GIARDIA LAMBLIA AND TRICHOMONAS VAGINALIS, ANN TROP MED PARASITOL, 85, PP. 417-425, (1991); GHOSH A.K., BHATTACHARYYA F.K., GHOSH D.K., LEISHMANIA DONOVANI: AMASTIGOTE INHIBITION AND MODE OF ACTION OF BERBERINE, EXP PARASITOL, 60, PP. 404-413, (1985); KANEDA Y., TANAKA T., SAW T., EFFECTS OF BERBERINE, A PLANT ALKALOID, ON THE GROWTH OF ANAEROBIC PROTOZOA IN AXENIC CULTURE, TOKAI J EXP CLIN MED, 15, PP. 417-423, (1990); NAIR K.P., GIARDIASIS IN CHILDREN, PEDIATR CLIN INDIA, 5, (1970); CHOUDHRY V.P., SABIR M., BHIDE V.N., BERBERINE IN GIARDIASIS, INDIAN PEDIATR, 9, PP. 143-146, (1972); SHENG W.D., JIDDAWI M.S., HONG X.Q., ET AL., TREATMENT OF CHLOROQUINE-RESISTANT MALARIA USING PYRIMETHAMINE IN COMBINATION WITH BERBERINE, TETRACYCLINE OR COTRIMOXAZOLE, EAST AFR MED J, 74, PP. 283-284, (1997); SWABB E.A., TAI Y.H., JORDAN L., REVERSAL OF CHOLERA TOXIN-INDUCED SECRETION IN RAT ILEUM BY LUMINAL BERBERINE, AM J PHYSIOL, 241, (1981); SACK R.B., FROEHLICH J.L., BERBERINE INHIBITS INTESTINAL SECRETORY RESPONSE OF VIBRIO CHOLERAE AND ESCHERICHIA COLI ENTEROTOXINS, INFECT IMMUN, 35, PP. 471-475, (1982); YUAN J., SHEN X.Z., ZHU X.S., EFFECT OF BERBERINE ON TRANSIT TIME OF HUMAN SMALL INTESTINE, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, 14, PP. 718-720, (1994); SUN D., ABRAHAM S.N., BEACHEY E.H., INFLUENCE OF BERBERINE SULFATE ON SYNTHESIS AND EXPRESSION OF PAP FIMBRIAL ADHESIN IN UROPATHOGENIC ESCHERICHIA COLI, ANTIMICROB AGENTS CHEMOTHER, 32, PP. 1274-1277, (1988); HOSTETTMANN K., MARSTON A., MAILLARD M., ET AL., PHYTOCHEMISTRY OF PLANTS USED IN TRADITIONAL MEDICINE, (1995); SZETO S., CMN Y., FUNG K.W., CHARACTERIZATION OF BERBERINE ON HUMAN CANCER CELLS IN CULTURE, TURK J MED SCI, 32, PP. 363-368, (2002); LIN T.H., KUO H.C., CHOU F.P., ET AL., BERBERINE ENHANCES INHIBITION OF GLIOMA TUMOR CELL MIGRATION AND INVASIVENESS MEDIATED BY ARSENIC TRIOXIDE, BMC CANCER, 8, (2008); MANTENA S.K., SHARMA S.D., KATIYAR S.K., BERBERINE, A NATURAL PRODUCT, INDUCES G1-PHASE CELL CYCLE ARREST AND CASPASE-3-DEPENDENT APOPTOSIS IN HUMAN PROSTATE CARCINOMA CELLS, MOL CANCER THER, 5, PP. 296-308, (2006); SUN Y., XUN K., WANG Y., ET AL., A SYSTEMATIC REVIEW OF THE ANTI CANCER PROPERTIES OF BERBERINE, A NATURAL PRODUCT FROM CHINESE HERBS, ANTICANCER DRUGS, 20, PP. 757-769, (2009); KONG W.J., ZHANG H., SONG D.Q., ET AL., BERBERINE REDUCES INSULIN RESISTANCE THROUGH PROTEIN KINASE C-DEPENDENT UP-REGULATION OF INSULIN RECEPTOR EXPRESSION, METABOLISM, 58, PP. 109-119, (2009); ZHOU J., ZHOU S., TANG J., ET AL., PROTECTIVE EFFECT OF BERBERINE ON BETA CELLS IN STREPTOZOTOCIN-AND HIGH-CARBOHYDRATE/HIGH-FAT DIET-INDUCED DIABETIC RATS, EUR J PHARMACOL, 606, PP. 262-268, (2009); YIN J., XING H., YE J., EFFICACY OF BERBERINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, METABOLISM, 57, PP. 712-717, (2008); KULKARNI S.K., DHIR A., POSSIBLE INVOLVEMENT OF L-ARGININE-NITRIC OXIDE (NO)-CYCLIC GUANOSINE MONOPHOSPHATE (CGMP) SIGNALING PATHWAY IN THE ANTIDEPRESSANT ACTIVITY OF BERBERINE CHLORIDE, EUR J PHARMACOL, 569, PP. 77-83, (2007); KULKARNI S.K., DHIR A., ON THE MECHANISM OF ANTIDEPRESSANT-LIKE ACTION OF BERBERINE CHLORIDE, EUR J PHARMACOL, 589, PP. 163-172, (2008); PENG W.H., LO K.L., LEE Y.H., ET AL., BERBERINE PRODUCES ANTIDEPRESSANT-LIKE EFFECTS IN THE FORCED SWIM TEST AND IN THE TAIL SUSPENSION TEST IN MICE, LIFE SCI, 81, PP. 933-938, (2007); ABIDI P., ZHOU Y., JIANG J.D., LIU J., EXTRA CELLULAR SIGNAL REGULATED KINASE-DEPENDENT STABILIZATION OF HEPATIC LOW DENSITY LIPOPROTEIN RECEPTOR MRNA BY HERBAL MEDICINE BERBERINE, ARTERIOSCLER THROMB VASC BIOL, 25, PP. 2170-2176, (2005); LEE S., LIM H.J., PARK J.H., ET AL., BERBERINE-INDUCED LDLR UP-REGULATION INVOLVES JNK PATHWAY, BIOCHEM BIOPHYS RES COMMUN, 362, PP. 853-857, (2007); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); FATEHI-HASSANABAD Z., ZAFARZADEH M., TARHINI A., ET AL., THE ANTI HYPERTENSIVE AND VASODILATOR EFFECTS OF AQUEOUS EXTRACT FROM BERBERIS VULGARIS FRUIT ON HYPERTENSIVE RAT, PHYSIOTHER RES, 19, PP. 222-225, (2005); CHUN Y.T., YIP T.T., LAU K.L., ET AL., A BIOCHEMICAL STUDY ON THE HYPOTENSIVE EFFECT OF BERBERINE IN RATS, GEN PHARMACOL, 10, PP. 177-182, (1979); WONG K.K., MECHANISM OF THE AORTIC RELAXATION INDUCED BY LOW CONCENTRATIONS OF BERBERINE, PLANTA MED, 64, PP. 756-757, (1998); KANG D.G., SOHN E.J., KWON E.K., ET AL., EFFECTS OF BERBERINE ON ANGIOTENSIN-CONVERTING ENZYME AND NO/CGMP SYSTEM IN VESSELS, VASCUL PHARMACOL, 39, PP. 281-286, (2002); OLMEZ E., ILHAN M., EVALUATION OF ALPHA-ADRENORECEPTOR ANTAGONISTIC ACTION OF BERBERINE IN ISOLATED ORGANS, ARZNEIMITTELFORSCHUNG, 42, PP. 1095-1097, (1992); CHIOU W.F., YEN M.H., CHEN C.F., MECHANISM OF VASODILATORY EFFECT OF BERBERINE IN RAT MESENTERIC ARTERY, EUR J PHARMACOL, 204, PP. 35-40, (1991); BIN C., WEI-XING Y., DA-CHAO F., ET AL., CARDIOVASCULAR ASPECTS OF PHARMACOLOGY OF BERBERINE: I. ALPHA-ADRENORECEPTOR BLOCKING ACTION OF BERBERINE IN ISOLATED RAT ANOCOCCYGEUS MUSCLE AND RABBIT AORTIC STRIP, J TONGJI MED UNIV, 7, PP. 239-241, (1987); LAU C.W., YAO X.Q., CHEN Z.Y., ET AL., CARDIOVASCULAR ACTIONS OF BERBERINE, CARDIOVASC DRUG REV, 19, PP. 234-244, (2001); KUO C.L., CHI C.W., LIU T.Y., THE ANTI-INFLAMMATORY POTENTIAL OF BERBERINE IN VITRO AND IN VIVO, CANCER LETT, 203, PP. 127-137, (2004); THE AYURVEDIC PHARMACOPOEIA OF INDIA, PART-I, VOLUME-II; A BERBERINE A DAY MAY KEEP THE DOCTOR AT BAY (MODERN TRANSPORTATION AND THE HUMAN HEART); KIM R.B., TRANSPORTERS AND DRUG DISCOVERY: WHY, WHEN, AND HOW, MOL PHARM, 3, PP. 26-32, (2006); KUNTA J.R., SINKO P.J., INTESTINAL DRUG TRANSPORTERS: IN VIVO FUNCTION AND CLINICAL IMPORTANCE, CURR DRUG METAB, 5, PP. 109-124, (2004); AYRTON A., MORGAN P., ROLE OF TRANSPORT PROTEINS IN DRUG ABSORPTION, DISTRIBUTION AND EXCRETION, XENOBIOTICA, 31, PP. 469-497, (2001); ZHANG L., STRONG J.M., QIU W., ET AL., SCIENTIFIC PERSPECTIVES ON DRUG TRANSPORTERS AND THEIR ROLE IN DRUG INTERACTIONS, MOL PHARM, 3, PP. 62-69, (2006); FARDEL O., LECUREUR V., GUILLOUZO A., THE P-GLYCOPROTEIN MULTIDRUG TRANSPORTER, GEN PHARMACOL, 27, PP. 1283-1291, (1996); AMBUDKAR S.V., KIM I.W., SAUNA Z.E., THE POWER OF THE PUMP: MECHANISMS OF ACTION OF P-GLYCOPROTEIN (ABCB1), EUR J PHARM SCI, 27, PP. 392-400, (2006); LOO T.W., CLARKE D.M., RECENT PROGRESS IN UNDERSTANDING THE MECHANISM OF P-GLYCOPROTEIN-MEDIATED DRUG EFFLUX, J MEMBR BIOL, 206, PP. 173-185, (2005); VARMA M.V., PERUMAL O.P., PANCHAGNULA R., FUNCTIONAL ROLE OF P-GLYCOPROTEIN IN LIMITING PERORAL DRUG ABSORPTION: OPTIMIZING DRUG DELIVERY, CURR OPIN CHEM BIOL, 10, PP. 367-373, (2006); FROMM M.F., IMPORTANCE OF P-GLYCOPROTEIN AT BLOOD-TISSUE BARRIERS, TRENDS PHARMACOL SCI, 25, PP. 423-429, (2004); THIEBAUT F., SURUO T.T., HAMADA H., ET AL., CELLULAR LOCALIZATION OF THE MULTI DRUG RESISTENCE GENE PRODUCT P-GLYCOPROTEIN IN NORMAL HUMAN TISSUES, PROC NATL ACAD SCI USA, 84, PP. 7735-7738, (1987); MOULY S., PAINE M.F., P-GLYCOPROTEIN INCREASES FROM PROXIMAL TO DISTAL REGIONS OF HUMAN SMALL INTESTINE, PHARM RES, 20, PP. 1595-1599, (2003); VARMA M.V., SATEESH K., PANCHAGNULA R., FUNCTIONAL ROLE OF P-GLYCOPROTEIN IN LIMITING INTESTINAL ABSORPTION OF DRUGS: CONTRIBUTION OF PASSIVE PERMEABILITY TO P-GLYCOPROTEIN MEDIATED EFFLUX TRANSPORT, MOL PHARM, 2, PP. 12-21, (2005); VARMA M.V., ASHOKRAJ Y., DEY C.S., ET AL., P-GLYCOPROTEIN INHIBITORS AND THEIR SCREENING: A PERSPECTIVE FROM BIOAVAILABILITY ENHANCEMENT, PHARMACOL RES, 48, PP. 347-359, (2003); CHIOU W.L., CHUNG S.M., WU T.C., ET AL., A COMPREHENSIVE ACCOUNT ON THE ROLE OF EFFLUX TRANSPORTERS IN THE GASTROINTESTINAL ABSORPTION OF 13 COMMONLY USED SUBSTRATE DRUGS IN HUMANS, INT J CLIN PHARMACOL THER, 39, PP. 93-101, (2001); BREEDVELD P., BEIJNEN J.H., SCHELLENS J.H., USE OF P-GLYCOPROTEIN AND BCRP INHIBITORS TO IMPROVE ORAL BIOAVAILABILITY AND CNS PENETRATION OF ANTICANCER DRUGS, TRENDS PHARMACOL SCI, 27, PP. 17-24, (2006); VARMA M.V., PANCHAGNULA R., PREDICTION OF IN VIVO INTESTINAL ABSORPTION ENHANCEMENT ON P-GLYCOPROTEIN INHIBITION, FROM RAT IN SITU PERMEABILITY, J PHARM SCI, 94, PP. 1694-1704, (2005); PAN G.Y., WANG G.J., LIU X.D., ET AL., THE INVOLVEMENT OF P-GLYCOPROTEIN IN BERBERINE ABSORPTION, PHARMACOL TOXICOL, 91, PP. 193-197, (2002); BANSAL T., JAGGI M., KHAR R.K., ET AL., EMERGING SIGNIFICANCE OF FLAVONOIDS AS P-GLYCOPROTEIN INHIBITORS IN CANCER CHEMOTHERAPY, J PHARM PHARM SCI, 12, PP. 46-78, (2009); BANSAL T., AKHTAR N., JAGGI M., ET AL., NOVEL FORMULATION APPROACHES FOR OPTIMISING DELIVERY OF ANTICANCER DRUGS BASED ON P-GLYCOPROTEIN MODULATION, DRUG DISCOV TODAY, 14, PP. 1067-1074, (2009); LO Y.L., RELATIONSHIP BETWEEN THE HYDROPHILIC-LIPOPHILIC BALANCE VALUES OF PHARMACEUTICAL EXCIPIENTS S AND MULTI DRUG RESISTANCE MODULATING EFFECT IN CACO-2 CELLS AND RAT INTESTINE, J CONTROL RELEASE, 90, PP. 37-48, (2003); BATRAKOVA E.V., KABANOV A.V., PLURONIC BLOCK CO POLYMERS: EVOLUTION OF DRUG DELIVERY CONCEPT FROM INERT NANOCARRIERS TO BIOLOGICAL RESPONSE MODIFIERS, J CONTROL RELEASE, 130, PP. 98-106, (2008); CORNAIRE G., WOODLEY J., HERMANN P., ET AL., IMPACT OF EXCIPIENTS ON THE ABSORPTION OF P-GLYCOPROTEIN SUBSTRATES IN VITRO AND IN VIVO, INT J PHARM, 278, PP. 119-131, (2004); BERNKOP-SCHNURCH, GRABOVAC V., POLYMERIC EFFLUX PUMP INHIBITORS IN ORAL DRUG DELIVERY, AM J DRUG DELIV, 4, PP. 263-272, (2006); SHEN Q., LIN Y., HANDA T., ET AL., MODULATION OF INTESTINAL P-GLYCOPROTEIN FUNCTION BY POLYETHYLENE GLYCOLS AND THEIR DERIVATIVES BY IN VITRO TRANSPORT AND IN SITU ABSORPTION STUDIES, INT J PHARM, 313, PP. 49-56, (2006); SACHS-BARRABLE K., THAMBOO A., LEE S.D., ET AL., LIPID EXCIPIENTS PECEOL AND GELUCIRE 44/14 DECREASE P-GLYCOPROTEIN MEDIATED EFFLUX OF RHODAMINE 123 PARTIALLY DUE TO MODIFYING P-GLYCOPROTEIN PROTEIN EXPRESSION WITHIN CACO-2 CELLS, J PHARM PHARM SCI, 10, PP. 319-331, (2007); TSAI P., TSAI T.H., SIMULTANEOUS DETERMINATION OF BERBERINE IN RAT BLOOD, LIVER AND BILE USING MICRODIALYSIS COUPLED TO HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, J CHROMATOGR A, 961, PP. 125-130, (2002); DELIE F., BLANCO-PRIETO M.J., POLYMERIC PARTICULATES TO IMPROVE ORAL BIOAVAILABILITY OF PEPTIDE DRUGS, MOLECULES, 10, PP. 65-80, (2005); CHAKRABORTY S., SHUKLA D., MISHRA B., SINGH S., LIPID-AN EMERGING PLATFORM FOR ORAL DELIVERY OF DRUGS WITH POOR BIOAVAILABILITY, EUR J PHARM BIOPHARM, 73, PP. 1-15, (2009); LAI J., LU Y., YIN Z., ET AL., PHARMACOKINETICS AND ENHANCED ORAL BIOAVAILABILITY IN BEAGLE DOGS OF CYCLOSPORINE A ENCAPSULATED IN GLYCERYL MONOOLEATE/POLOXAMER 407 CUBIC NANOPARTICLES, INT J NANOMEDICINE, 5, PP. 13-23, (2010); XIN H.W., WU X.C., LI Q., ET AL., EFFECTS OF COADMINISTRATION OF BERBERINE CHLORIDE WITH CYCLOSPORINE ON LIVER MICROSOMAL CYTOCHROME P450 ISOENZYME AND MDR1 IN RATS, CHIN PHARMACOL BULL, 18, PP. 397-401, (2002); GUI S.Y., WU L., PENG D.Y., ET AL., PREPARATION AND EVALUATION OF A MICROEMULSION FOR ORAL DELIVERY OF BERBERINE, PHARMAZIE, 63, PP. 516-519, (2008); NASSAR T., ROM A., NYSKA A., ET AL., NOVEL DOUBLE COATED NANOCAPSULES FOR INTESTINAL DELIVERY AND ENHANCED ORAL BIOAVAILABILITY OF TACROLIMUS, A P-GP SUBSTRATE DRUG, J CONTROL RELEASE, 133, PP. 77-84, (2009)","S. SINGH; BANARAS HINDU UNIVERSITY, INSTITUTE OF TECHNOLOGY, DEPARTMENT OF PHARMACEUTICS, VARANASI 221005, INDIA; EMAIL: DRSANJAYSINGH@REDIFFMAIL.COM","","ENGLISH","EXPERT OPIN. INVEST. DRUGS","ARTICLE","ISI","2-S2.0-77956589652","EXPERT OPIN INVEST DRUGS","BANARAS HINDU UNIVERSITY;BANARAS HINDU UNIVERSITY;BANARAS HINDU UNIVERSITY","NOTREPORTED;BANARAS HINDU UNIVERSITY;NOTREPORTED",NA,"VUDDANDA PR, 2010, EXPERT OPIN INVEST DRUGS","VUDDANDA PR, 2010, EXPERT OPIN INVEST DRUGS"
"KASSIS A;KUBOW S;JONES P","KASSIS, AMIRA N. (12800588300); KUBOW, STAN (7003998822); JONES, PETER J. H. (36078426500)","SUGAR CANE POLICOSANOLS DO NOT REDUCE LDL OXIDATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS",2009,"LIPIDS","44","5",11,"10.1007/s11745-009-3295-5","SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTREAL, QC, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTREAL, QC, CANADA;RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, UNIVERSITY OF MANITOBA, SMART PARK, WINNIPEG, MB R3T 6C5, 196 INNOVATION DRIVE, CANADA","SUGAR CANE POLICOSANOLS (SCP) HAVE BEEN SHOWN TO EXERT ANTIOXIDANT PROPERTIES IN VARIOUS STUDIES CONDUCTED IN CUBA. INDEPENDENT STUDIES HAVE SINCE REPORTED NO SIGNIFICANT EFFECT OF SCP CONSUMPTION ON OXIDIZED LDL LEVELS. THE OBJECTIVE OF THE PRESENT STUDY WAS TO CONFIRM THE EFFECTS OF CUBAN SCP ON LDL OXIDATION USING A HIGH-PRECISION CAPTURE ELISA PROCEDURE IN HYPERCHOLESTEROLEMIC INDIVIDUALS. TWENTY-ONE OTHERWISE HEALTHY HYPERCHOLESTEROLEMIC MEN AND POST-MENOPAUSAL WOMEN PARTICIPATED IN A RANDOMIZED DOUBLE BLIND CROSSOVER STUDY WHERE THEY RECEIVED 10 MG/DAY OF POLICOSANOL OR A PLACEBO INCORPORATED IN MARGARINE AS AN EVENING SNACK FOR A PERIOD OF 28 DAYS. SUBJECTS MAINTAINED THEIR USUAL DIETARY AND EXERCISE HABITS THROUGHOUT THE DURATION OF THE STUDY. BLOOD WAS COLLECTED ON THE FIRST AS WELL AS THE LAST 2 DAYS OF THE TRIAL. LDL OXIDATION WAS MEASURED FROM PLASMA USING A SOLID PHASE TWO-SITE ENZYME IMMUNOASSAY. A LACK OF EFFECT OF SCP WAS OBSERVED ON LDL CHOLESTEROL LEVELS, AS WELL AS NO DIFFERENCE IN LDL OXIDATION BETWEEN THE SCP TREATMENT AND PLACEBO AT THE END OF THE INTERVENTION PERIOD. SUBJECT BODY WEIGHTS REMAINED STABLE THROUGHOUT THE STUDY AND SHOWED NO SIGNIFICANT CORRELATION WITH LDL OXIDATION LEVELS. ABSOLUTE LEVELS OF PLASMA LDL CHOLESTEROL WERE SIGNIFICANTLY (P < 0.05) CORRELATED WITH PLASMA CONCENTRATIONS OF OXIDIZED LDL. THE FINDINGS OF THE PRESENT STUDY SUGGEST THAT SCP DO NOT SIGNIFICANTLY AFFECT LDL OXIDATION. OUR RESULTS ALIGN WITH RESULTS OF RECENT POLICOSANOL RESEARCH QUESTIONING THE EFFICACY OF THESE NATURAL EXTRACTS AS CARDIO-PROTECTIVE AGENTS. © 2009 AOCS.","ELISA; HYPERCHOLESTEROLEMIA; LOW-DENSITY LIPOPROTEIN; OXIDATION; SUGAR CANE POLICOSANOL","ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SACCHARUM; SACCHARUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; POLICOSANOL; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENING DOSAGE; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE","ADVANCED FOODS AND MATERIALS NETWORK—NETWORKS OF CENTRES OF EXCELLENCE","ACKNOWLEDGMENTS THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE ADVANCED FOODS AND MATERIALS NETWORK—NETWORKS OF CENTRES OF EXCELLENCE.","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 33, 7, PP. 835-840, (2000); AVIRAM M., MODIFIED FORMS OF LOW DENSITY LIPOPROTEIN AND ATHEROSCLEROSIS, ATHEROSCLEROSIS, 98, 1, PP. 1-9, (1993); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); BONANOME A., PAGNAN A., BIFFANTI S., OPPORTUNO A., SORGATO F., DORELLA M., MAIORINO M., URSINI F., EFFECT OF DIETARY MONOUNSATURATED AND POLYUNSATURATED FATTY ACIDS ON THE SUSCEPTIBILITY OF PLASMA LOW DENSITY LIPOPROTEINS TO OXIDATIVE MODIFICATION, ARTERIOSCLER THROMB, 12, PP. 529-533, (1992); CARRU C., ZINELLU A., GALISTU F., BARCA M., PASCIU V., LUMBAU F., SANNA B., TADOLINI B., DEIANA L., THE EVALUATION OF THE OXIDATIVE STATE OF NATIVE-LDL: THREE METHODS COMPARED, JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 61, 3, PP. 271-281, (2004); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 22, 3-4, PP. 89-99, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AMERICAN HEART JOURNAL, 152, 5, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); HOLVOET P., MERTENS A., VERHAMME P., BOGAERTS K., BEYENS G., VERHAEGHE R., COLLEN D., MULS E., VAN DE WERF F., CIRCULATING OXIDIZED LDL IS A USEFUL MARKER FOR IDENTIFYING PATIENTS WITH CORONARY ARTERY DISEASE, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 21, 5, PP. 844-848, (2001); HULTHE J., FAGERBERG B., CIRCULATING OXIDIZED LDL IS ASSOCIATED WITH INCREASED LEVELS OF CELL-ADHESION MOLECULES IN CLINICALLY HEALTHY 58-YEAR OLD MEN (AIR STUDY), MEDICAL SCIENCE MONITOR, 8, 3, (2002); JONES P.J.H., PENCHARZ P.B., CLANDININ M.T., ABSORPTION OF <SUP>13</SUP>C-LABELED STEARIC, OLEIC, AND LINOLEIC ACIDS IN HUMANS: APPLICATION TO BREATH TESTS, JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 105, 6, PP. 647-652, (1985); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); KASSIS A.N., MARINANGELI C.P.F., JAIN D., EBINE N., JONES P.J.H., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, 1, PP. 153-158, (2007); LAPENNA D., CIOFANI G., PIERDOMENICO S.D., GIAMBERARDINO M.A., CUCCURULLO F., REACTION CONDITIONS AFFECTING THE RELATIONSHIP BETWEEN THIOBARBITURIC ACID REACTIVITY AND LIPID PEROXIDES IN HUMAN PLASMA, FREE RADICAL BIOLOGY AND MEDICINE, 31, 3, PP. 331-335, (2001); LEFKOWITZ R.J., WILLERSON J.T., PROSPECTS FOR CARDIOVASCULAR RESEARCH, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 285, 5, PP. 581-587, (2001); MARINANGELI C.P.F., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.H., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BRITISH JOURNAL OF NUTRITION, 97, 2, PP. 381-388, (2007); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., CLINICAL USE-EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVESTIG, 21, PP. 485-499, (2001); DEL VALLE R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., INHIBITION OF RAT MICROSOMAL LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D002, BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 33, 1, PP. 85-90, (2000); MENENDEZ R., FRAGA V., AMOR A.MA., GONZALEZ R.MA., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOLOGY AND BEHAVIOR, 67, 1, PP. 1-7, (1999); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCHIVES OF MEDICAL RESEARCH, 36, 2, PP. 113-119, (2005); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ J., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 80, 1, PP. 13-21, (2002); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, J AM COLL NUTR, 27, PP. 476-484, (2008); MURRAY C.J.L., LOPEZ A.D., GLOBAL MORTALITY, DISABILITY, AND THE CONTRIBUTION OF RISK FACTORS: GLOBAL BURDEN OF DISEASE STUDY, LANCET, 349, 9063, PP. 1436-1442, (1997); MURRAY C.J.L., LOPEZ A.D., MORTALITY BY CAUSE FOR EIGHT REGIONS OF THE WORLD: GLOBAL BURDEN OF DISEASE STUDY, LANCET, 349, 9061, PP. 1269-1276, (1997); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); PARTHASARATHY S., KHOO J.C., MILLER E., BARNETT J., WITZTUM J.L., STEINBERG D., LOW DENSITY LIPOPROTEIN RICH IN OLEIC ACID IS PROTECTED AGAIINST OXIDATIVE MODIFICATION: IMPLICATIONS FOR DIETARY PREVENTION OF ATHEROSCLEROSIS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 87, 10, PP. 3894-3898, (1990); PERMAN J., FAGERLUND C., HULTHE J., METHODOLOGICAL ASPECTS OF MEASURING OXIDIZED LOW DENSITY LIPOPROTEINS IN HUMAN SERUM AND PLASMA, SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, 64, 8, PP. 753-755, (2004); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, 11, PP. 376-383, (2003); VISTISEN B., MU H., HOY C.-E., THE RECOVERY OF <SUP>13</SUP>C-LABELED OLEIC ACID IN RAT LYMPH AFTER ADMINISTRATION OF LONG CHAIN TRIACYLGLYCEROLS OR SPECIFIC STRUCTURED TRIACYLGLYCEROLS, EUROPEAN JOURNAL OF NUTRITION, 45, 6, PP. 363-368, (2006); WILLIAMS K.J., TABAS I., THE RESPONSE-TO-RETENTION HYPOTHESIS OF EARLY ATHEROGENESIS, ARTERIOSCLER THROMB VASC BIOL, 15, PP. 551-561, (1995)","P. J. H. JONES; RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, UNIVERSITY OF MANITOBA, SMART PARK, WINNIPEG, MB R3T 6C5, 196 INNOVATION DRIVE, CANADA; EMAIL: PETER_JONES@UMANITOBA.CA","","ENGLISH","LIPIDS","ARTICLE","ISI","2-S2.0-67349220077","LIPIDS","MCGILL UNIVERSITY;MCGILL UNIVERSITY;UNIVERSITY OF MANITOBA","NOTREPORTED;UNIVERSITY OF MANITOBA;NOTREPORTED",NA,"KASSIS AN, 2009, LIPIDS","KASSIS AN, 2009, LIPIDS"
"WANG L;WELLER C;SCHLEGEL V;CARR T;CUPPETT S","WANG, LIJUN (37105248800); WELLER, CURTIS L. (7102722517); SCHLEGEL, VICKI L. (7003881781); CARR, TIMOTHY P. (7103305648); CUPPETT, SUSAN L. (7003349552)","SUPERCRITICAL CO2 EXTRACTION OF LIPIDS FROM GRAIN SORGHUM DRIED DISTILLERS GRAINS WITH SOLUBLES",2008,"BIORESOURCE TECHNOLOGY","99","9",59,"10.1016/j.biortech.2007.01.055","DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0726, UNITED STATES;DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0726, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0919, UNITED STATES;DEPARTMENT OF NUTRITION AND HEALTH SCIENCE, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0806, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0919, UNITED STATES","EXPERIMENTS WERE CARRIED OUT ON A LAB SUPERCRITICAL CO2 EXTRACTION SYSTEM TO DETERMINE THE EFFECTS OF EXTRACTION CONDITIONS, INCLUDING MASS RATIO OF CO2 CONSUMED TO DISTILLERS DRY GRAIN WITH SOLUBLES (DDGS) EXTRACTED, EXTRACTION PRESSURE, EXTRACTION TEMPERATURE AND TIME, ON YIELD AND COMPOSITION OF EXTRACTED LIPIDS. A MAXIMUM LIPID YIELD OF 150 G/KG DDGS WAS ACHIEVED WITH A MASS RATIO ∼45, AN EXTRACTION PRESSURE AT 27.5 MPA, AN EXTRACTION TEMPERATURE AT 70 °C AND AN EXTRACTION TIME OF 4 H. UNDER THESE EXTRACTION CONDITIONS, THE CONTENTS OF TOCOLS, PHYTOSTEROLS, POLICOSANOLS AND FREE FATTY ACIDS WERE 0.44, 15.6, 31.2 AND 155.3 MG/G IN THE EXTRACT. EXPERIMENTAL RESULTS INDICATED THAT SHORTER EXTRACTION TIME AND HIGHER FLOW RATE OF CO2 CAN ACHIEVE HIGHER CONTENTS OF TOCOLS, PHYTOSTEROLS AND POLICOSANOLS BUT LOWER CONTENT OF FREE FATTY ACIDS IN THE LIPID EXTRACT. EXTRACTION CONDITIONS HAD NO OBSERVED EFFECTS ON THE COMPOSITION OF FREE FATTY ACIDS IN THE EXTRACT. PALMITIC, OLEIC AND LINOLEIC ACIDS WERE THREE MAIN FREE FATTY ACIDS EXTRACTED AND CONSTITUTED ABOUT 94% OF ALL FREE FATTY ACIDS. © 2007 ELSEVIER LTD. ALL RIGHTS RESERVED.","DDGS; NUTRACEUTICALS; PHYTOSTEROLS; POLICOSANOLS; SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION","CARBON DIOXIDE; CEREALS; CHROMATOGRAPHY, THIN LAYER; LIPIDS; SORGHUM; TEMPERATURE; CARBON DIOXIDE; EXTRACTION; LIPIDS; PRESSURE EFFECTS; SUPERCRITICAL FLUID EXTRACTION; SORGHUM BICOLOR BICOLOR; CARBON DIOXIDE; EXTRACTION; PRESSURE EFFECTS; SUPERCRITICAL FLUID EXTRACTION; CARBON DIOXIDE; FATTY ACID; LINOLEIC ACID; LIPID; OLEIC ACID; PALMITIC ACID; PHYTOSTEROL; POLICOSANOL; TOCOL; CARBON DIOXIDE; EXPERIMENTAL STUDY; FOOD SUPPLEMENTATION; LABORATORY METHOD; LIPID; SORGHUM; STEROL; TEMPERATURE PROFILE; ARTICLE; EXTRACTION; GRAIN; PRIORITY JOURNAL; SORGHUM; TEMPERATURE; TIME; CEREAL; CHEMISTRY; THIN LAYER CHROMATOGRAPHY; DDGS; NUTRACEUTICALS; PHYTOSTEROLS; POLICOSANOLS; LIPIDS","USDA-CSREES-NATIONAL, (2004-35503-14824); UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION; U.S. DEPARTMENT OF AGRICULTURE, USDA","A CONTRIBUTION OF THE UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION, SUPPORTED IN PART BY FUNDS PROVIDED THROUGH THE HATCH ACT, USDA. ADDITIONAL SUPPORT WAS PROVIDED BY THE USDA-CSREES-NATIONAL RESEARCH INITIATIVE COMPETITIVE GRANTS PROGRAM (GRANT NO.: 2004-35503-14824). MENTION OF A TRADE NAME, PROPRIETARY PRODUCTS, OR COMPANY NAME IS FOR PRESENTATION CLARITY AND DOES NOT IMPLY ENDORSEMENT BY THE AUTHORS OR THE UNIVERSITY OF NEBRASKA. THE AUTHORS THANK TAMMY GRIES AND RICHARD ZBASNIK FOR THEIR EXCELLENT TECHNICAL ASSISTANCE.","BERNARDO-GIL M.G., GRENHA J., SANTOS J., CARDOSO P., SUPERCRITICAL FLUID EXTRACTION AND CHARACTERIZATION OF OIL FROM HAZELNUT, EUR. J. LIPID SCI. TECHNOL., 104, PP. 402-409, (2002); BRUNI R., GUERRINI A., SCALIA S., ROMAGNOLI C., SACCHETTI G., RAPID TECHNIQUES FOR THE EXTRACTION OF VITAMIN E ISOMERS FROM AMARANTHUS CAUDATUS SEEDS: ULTRASONIC AND SUPERCRITICAL FLUID EXTRACTION, PHYTOCHEM. ANAL., 13, PP. 257-261, (2002); CARR T.P., WELLER C.L., SCHLEGEL V.L., CUPPETT S.L., GUDERIAN JR. D.M., JOHNSON K.R., GRAIN SORGHUM LIPID EXTRACT REDUCES CHOLESTEROL ABSORPTION AND PLASMA NON-HDL CHOLESTEROL CONCENTRATION IN HAMSTERS, J. NUTR., 135, PP. 2236-2240, (2005); CHOI Y.H., KIM J., NOH M.J., CHOI E.S., YOO K.P., COMPARISON OF SUPERCRITICAL CARBON DIOXIDE EXTRACTION WITH SOLVENT OF NONACOSAN-10-OL, Α-AMYRIN ACETATE, SQUALENE AND STIGMASTEROL FROM MEDICINAL PLANTS, PHYTOCHEM. ANAL., 8, PP. 233-237, (1997); COELHO J.A.P., PEREIRA A.P., MENDES R.L., PALAVRA A.M.F., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF FOENICULUM VULGARE VOLATILE OIL, FLAVOR FRAGRANCE J., 18, PP. 316-319, (2003); DEAN J.R., LIU B., SUPERCRITICAL FLUID EXTRACTION OF CHINESE HERBAL MEDICINES: INVESTIGATION OF EXTRACTION KINETICS, PHYTOCHEM. ANAL., 11, PP. 1-6, (2000); ELLINGTON E., BASTIDA J., VILADOMAT F., CODINA C., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF COLCHICINES AND RELATED ALKALOIDS FROM SEEDS OF COLCHICUM AUTUMNALE L, PHYTOCHEM. ANAL., 14, PP. 164-169, (2003); FRONING G.W., FIEMAN F., WEHLING R.L., CUPPETT S.L., NIEMANN L., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF LIPIDS AND CHOLESTEROL FROM DEHYDRATED CHICKEN MEAT, POULTRY SCI., 73, 4, PP. 571-575, (1994); GIANNUZZO A.N., BOGGETTI H.J., NAZARENO M.A., MISHIMA H.T., SUPERCRITICAL FLUID EXTRACTION OF NARINGIN FROM THE PEEL OF CITRUS PARADISE, PHYTOCHEM. ANAL., 14, PP. 221-223, (2003); HAMBURGER M., BAUMANN D., ADLER S., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF SELECTED MEDICINAL PLANTS - EFFECTS OF HIGH PRESSURE AND ADDED ETHANOL ON YIELD OF EXTRACTED SUBSTANCES, PHYTOCHEM. ANAL., 15, PP. 46-54, (2004); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., PROPERTIES, COMPOSITION, AND ANALYSIS OF GRAIN SORGHUM WAX, J. AM. OIL CHEM. SOC., 79, PP. 521-527, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPARATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, J. SEP. SCI., 25, PP. 619-623, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J. AM. OIL CHEM. SOC., 79, PP. 529-533, (2002); LANG Q., WAI C.M., SUPERCRITICAL FLUID EXTRACTION IN HERBAL AND NATURAL PRODUCT STUDIES - A PRACTICAL REVIEW, TALANTA, 53, PP. 771-782, (2001); MARONGIU B., PORCEDDA S., CAREDDA A., DE GIOANNIS B., VARGIU L., LA COLLA P., EXTRACTION OF JUNIPERUS OXYCEDRUS SSP. OXYCEDRUS ESSENTIAL OIL BY SUPERCRITICAL CARBON DIOXIDE: INFLUENCE OF SOME PROCESS PARAMETERS AND BIOLOGICAL ACTIVITY, FLAVOR FRAGRANCE J., 18, PP. 390-397, (2003); MAS R., POLICOSANOL-HYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSIS, DRUG FUTURE, 25, PP. 569-586, (2000); MEIRELES A., ANGELA M., SUPERCRITICAL EXTRACTION FROM SOLID: PROCESS DESIGN DATA (2001-2003), CURR. OPIN. SOLID STATE MATER. SCI., 7, PP. 321-330, (2003); ROY B.C., GOTO M., KODAMA A., HIROSE T., SUPERCRITICAL CO<SUB>2</SUB> EXTRACTION OF ESSENTIAL OILS AND CUTICULAR WAXES FROM PEPPERMINT LEAVES, J. CHEM. TECH. BIOTECHNOL., 67, PP. 21-26, (1996); SASS-KISS A., SIMANDI B., GAO Y., BOROSS F., VAMOS-FALUSI Z., STUDY ON THE PILOT-SCALE EXTRACTION OF ONION OLEORESIN USING SUPERCRITICAL CO<SUB>2</SUB>, J. SCI. FOOD AGRIC., 76, PP. 320-326, (1998); SINGH V., MOREAU R.A., HICKS K.B., YIELD AND PHYTOSTEROL COMPOSITION OF OIL EXTRACTED FROM GRAIN SORGHUM AND ITS WET-MILLED FRACTIONS, CEREAL CHEM., 80, PP. 126-129, (2003); WANG L.J., WELLER C.L., RECENT ADVANCES IN EXTRACTION OF NATURAL PRODUCTS FROM PLANTS, TRENDS FOOD SCI. TECHNOL., 17, PP. 300-312, (2006); WANG L.J., WELLER C.L., HWANG K.T., EXTRACTION OF LIPIDS FROM GRAIN SORGHUM DDG, TRANS. ASAE., 48, PP. 1883-1888, (2005)","C.L. WELLER; DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0726, UNITED STATES; EMAIL: CWELLER1@UNL.EDU","","ENGLISH","BIORESOUR. TECHNOL.","ARTICLE","ISI","2-S2.0-37049003943","BIORESOUR TECHNOL","UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA","NOTREPORTED;UNIVERSITY OF NEBRASKA;NOTREPORTED",NA,"WANG L, 2008, BIORESOUR TECHNOL","WANG L, 2008, BIORESOUR TECHNOL"
"BRONCEL M;KOZIRÓG M;CHOJNOWSKA-JEZIERSKA J","BRONCEL, MARLENA (6507507565); KOZIRÓG, MARZENA (14043789900); CHOJNOWSKA-JEZIERSKA, JULITA (7003403754)","LIPID LOWERING AGENTS INFLAMMATION AND ATHEROSCLEROSIS",2008,"ANTI-INFLAMMATORY AND ANTI-ALLERGY AGENTS IN MEDICINAL CHEMISTRY","7","10",0,"10.2174/187152308785699254","DEPARTMENT OF INTERNAL DISEASES WITH CLINICAL PHARMACOLOGY AND THERAPY MONITORING UNIT, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND, KLINIKA CHORÓB WEWNETRZNYCH Z ODDZIALEM FARMAKOLOGII KLINICZNEJ I TERAPII MONITOROWANEJ, LODZ 91-347, UL. KNIAZIEWICZA 1/5, POLAND;DEPARTMENT OF INTERNAL DISEASES WITH CLINICAL PHARMACOLOGY AND THERAPY MONITORING UNIT, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND;DEPARTMENT OF INTERNAL DISEASES WITH CLINICAL PHARMACOLOGY AND THERAPY MONITORING UNIT, MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND","ATHEROSCLEROSIS HAS BEEN RECOGNIZED AS AN INFLAMMATORY DISEASE. THE INNATE AND ADAPTIVE IMMUNITY MECHANISMS ARE INVOLVED IN ATHEROGENESIS. LOW-GRADE INFLAMMATION IS ASSOCIATED WITH INNATE IMMUNITY ACTIVATION. THE CRP HAS BEEN PROPOSED AS THE BEST INDICATOR OF LOW-GRADE INFLAMMATION AND A PREDICTOR OF CARDIOVASCULAR EVENTS. A TRIUMVIRATE OF TARGETS IN THE PREVENTION OF CVD ARE: LDL-C AGGRESSIVE LOWERING, HDL-C INCREASING AND CRP LOWERING. THE STATINS' ROLE IN LIPIDS AND CRP LOWERING IS WELL ESTABLISHED. MOREOVER, STATINS MAY BE BENEFICIAL IN MANY OTHER INFLAMMATORY IMMUNE CONDITIONS. AMONG PPAR-Α AGONISTS, ANTI-INFLAMMATORY PROPERTIES OF FENOFIBRATE ARE THE BEST DEMONSTRATED. PPAR-Γ AGONISTS (THIAZOLIDINEDIONES) PLEIOTROPIC EFFECTS ARE ALSO PROMISING. PPAR Α/Γ AGONISTS HAVE BEEN PROVED TO CAUSE SEVERE SIDE EFFECTS. EZETIMIBE EXERTS BENEFICIAL ANTI-INFLAMMATORY ACTIONS WHEN ADMINISTERED WITH STATINS. COLESEVELAM, A NOVEL BILEACID SEQUESTRANT HAS BENEFICIAL LIPID-LOWERING AND ANTI-INFLAMMATORY ACTIONS. CETP AND ACAT INHIBITORS ACTIONS CALL FOR FURTHER STUDIES. INHIBITION OF CRP, CRP-TARGETED ANTISENSES, HDL-PARTICLE MODIFICATION AND IMMUNOMODULATION OF ATHEROSCLEROSIS ARE POSSIBLE NOVEL APPROACHES IN ATHEROSCLEROSIS TREATMENT AND PREVENTION. © 2008 BENTHAM SCIENCE PUBLISHER LTD.","ATHEROSCLEROSIS; CRP; FIBRATES; IMMUNE SYSTEM; INFLAMMATION; STATINS","2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; C REACTIVE PROTEIN; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PACTIMIBE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; POLICOSANOL; PRAVASTATIN; RALOXIFENE; RIMONABANT; ROSUVASTATIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; UNINDEXED DRUG; ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL IRRITATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MENTAL DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SPINAL CORD INJURY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT","","","ROSS R., N. ENGL. J. MED, 340, (1999); WATANABE T., FAN J., INT. J. CARDIOL, 66, SUPPL. 1, (1998); SMITH R.E., HOGABOAM C.M., STRIETER R.M., LUKACS N.W., KUNKEL S.L., J. LEUKOC. BIOL, 62, (1997); PERRETTI M., TRENDS PHARMACOL. SCI, 18, (1997); RECKLESS J., RUBIN E.M., VERSTUYFT J.B., METCALFE J.C., GRAINGER D.J., CIRCULATION, 99, (1999); KUNJATHOOR V.V., FEBBRAIO M., PODREZ E.A., MOORE K.J., ANDERSSON L., KOEHN S., RHEE J.S., SILVERSTEIN R., HOFF H.F., FREEMAN M.W., J. BIOL. CHEM, 277, (2002); YOSHIDA H., KONDRATENKO N., GREEN S., STEINBERG D., QUEHENBERGER O., BIOCHEM. J, 334, (1998); BINDER C.J., CHANG M., SHAW P.X., MILLER Y.I., HARTVIGSEN K., DEWAN A., WITZTUM J.L., NAT. MED, 8, (2002); EDFELDT K., SWEDENBORG J., HANSSON G.K., YAN Z.Q., CIRCULATION, 105, (2002); KIECHL S., LORENZ E., REINDL M., WIEDERMANN C.J., OBERHOLLENZER F., BONORA E., WILLEIT J., SCHWARTZ D.A., N. ENGL. J. MED, 347, (2002); VLAICU R., NICULESCU F., RUS H.G., CRISTEA A., ATHEROSCLEROSIS, 57, (1985); MILLONIG G., SCHWENTNER C., MUELLER P., MAYERL C., WICK G., CURR. OPIN. LIPIDOL, 12, (2001); MEHRA V.C., RAMGOLAM V.S., BENDER J.R., J. LEUCOCYTE BIOL, 78, (2005); PINDERSKI L.J., FISCHBEIN M.P., SUBBANAGOUNDER G., FISHBEIN M.C., KUBO N., CHEROUTRE H., CURTISS L.K., BERLINER J.A., BOISVERT W.A., CIRC. RES, 90, (2002); DANESH J., WHEELER J.G., HIRSCHFIELD G.M., EDA S., EIRIKSDOTTIR G., RUMLEY A., LOWE G.D., PEPYS M.B., GUDANSON P., N. ENGL. J. MED, 350, (2004); IKONOMIDIS I., STAMATELOPOULOS K., LEKAKIS J., KREMASTINOS D.T., CURR. CARDIOL. REV, 2, (2006); PASCERI V., CHENG J.S., WILLERSON J.T., YEH E.T., CIRCULATION, 103, (2001); PASCERI V., WILLERSON J.T., YEH E.T., CIRCULATION, 102, (2000); VENUGOPAL S.K., DEVARAJ S., YUHANNA I., SHAUL P., JIALAL I., CIRCULATION, 106, (2002); ZWAKA T.P., HOMBACH V., TORZEWSKI J., CIRCULATION, 103, (2001); CERMAK J., KEY N.S., BACH R.R., BALLA J., JACOB H.S., VERCELLOTTI G.M., BLOOD, 82, (1993); DEVARAJ S., KUMARESAN P.R., JIALAL I., J. MOL. CELL. CARDIOL, 36, (2004); VERMA S., LI S.H., BADIWALA M.V., WEISEL R.D., FEDAK P.W., LI R.K., DHILLON B., MICKLE D.A., CIRCULATION, 105, (2002); WILLIAMS T.N., ZHANG C.X., GAME B.A., HE L., HUANG Y., ARTERIOSCLER. THROMB. VASC. BIOL, 24, (2004); CHANG M.K., BINDER C.J., TORZEWSKI M., WITZTUM J.L., PROC. NATL. ACAD. SCI. USA, 99, (2002); RIDKER P.M., RIFAI N., ROSE L., BURING J.E., COOK N.R., N. ENGL. J. MED, 347, (2002); RIDKER P.M., CIRCULATION, 107, (2003); RIDKER P.M., BURING J.E., COOK N.R., RIFAI N., CIRCULATION, 107, (2003); MATZINGER P., SCIENCE, 296, (2002); TSIRPANLIS G., KIDNEY BLOOD PRESS. RES, 28, (2005); CHANG M.K., BINDER C.J., TORZEWSKI M., WITZTUM J.L., PROC. NATL. ACAD. SCI USA, 99, (2002); RIDKER P.M., N. ENGL. J. MED, 336, (1997); LIBBY P., AIKAWA M., NAT. MED, 8, (2002); FALK E., SHAH P.K., FUSTER V., CIRCULATION, 92, (1995); KHOT U.N., KHOT M.B., BAJZER C.T., SAPP S.K., OHMAN E.M., BRENER S.J., ELLIS S.G., LINCOFF A.M., TOPOL E.J., JAMA, 290, (2003); LANGE L.A., CARLSON C.S., HINDORFF L.A., LANGE E.M., WALSTON J., DURDA J.P., CUSHMAN M., BIS J.C., ZENG D., LIN D., KULLER L.H., NICKERSON D.A., PSATY B.M., TRACY R.P., REINER A.P., JAMA, 296, (2006); WALSTON J.D., FALLIN M., CUSHMAN M., LANGE L., PSATY B., JENNY N., BROWNER W., TRACY R., DURDA P., REINER A., HUM. GENET, 122, (2007); ZIESKE A.W., TRACY R.P., MCMAHAN C.A., HERDERICK E.E., HOMMA S., MALCOM G.T., MCGILL H.C., STRONG J.P., ARTERIOSCLER. THROMB. VASC. BIOL, 25, (2005); RIDKER P.M., HENNEKENS C.H., BURING J.E., RIFAI N., N. ENGL. J. MED, 296, (2006); PACKARD C., ATHEROSCLEROSIS, SUPPL. 7, (2005); ALBERT M.A., DANIELSON E., RIFAI N., RIDKER P.M., JAMA, 286, (2001); DOWNS J.R., CLEARFIELD M., WEIS S., WHITNEY E., SHAPIRO D.R., BEERE P.A., LANGENDORFER A., STEIN E.A., KRUYER W., GOTTO A.M., JAMA, 279, (1998); KINLAY S., SCHWARTZ G.G., OLSSON A.G., RIFAI N., LESLIE S.J., SASIELA W.J., SZAREK M., LIBBY P., GANZ P., CIRCULATION, 108, (2003); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., AM. J. CARDIOL, 81, (1998); NISSEN S.E., AM. J. MED, SUPPL. 118, (2005); SERGIENKO I.V., SAMOILENKO E.I., MASENKO V.P., EZHOV M.V., SUMAROKOV A.B., TKACHEV G.A., POGORELOVA O.A., BALAKHONOVA T.V., NAUMOV V.G., KARDIOLOGIIA, 46, (2006); BETTERIDGE D.J., GIBSON J.M., SAGER P.T., AM. J. CARDIOL, 100, (2007); BRUNETTI N.D., MAULUCCI G., CASAVECCHIA G.P., DISTASO C., DE GENNARO L., LUIGI PELLEGRINO P., DI BIASE M., J. INTERVENT. CARDIOL, 20, (2007); VERMA A., RANGANNA K.M., REDDY R.S., VERMA M., GORDON N.F., AM. J. CARDIOL, 96, (2005); ROSENSON R.S., TANGNEY C.C., SCHAEFER E.J., ATHEROSCLEROSIS, 155, (2001); OKOPIEN B., KRYSIAK R., KOWALSKI J., MADEJ A., BELOWSKI D., ZIELINSKI M., HERMAN Z.S., J. CARDIOVASC. PHARMACOL, 46, (2005); YANG J., LI X.P., ZHAO S.P., LI J., LI J.D., XIE X.M., CLIN. CHIM. ACTA, 368, (2006); MARKETOU M.E., ZACHARIS E.A., NIKITOVIC D., GANOTAKIS E.S., PARTHENAKIS F.I., MALIARAKI N., VARDAS P.E., ANGIOLOGY, 57, (2006); ARNAUD C., VEILLARD N.R., MACH F., CURR. DRUG TARG. - CARDIOVAS. HAEMATOL. DISORD, 5, (2005); KLEEMANN R., KOOISTRA T., CURR. DRUG TARG. - CARDIOVAS. HAEMATOL. DISORD, 5, (2005); JAIN M., RIDKER P.M., NAT. REV. DRUG DISCOV, 4, (2005); SAKAMOTO T., KOJIMA S., OGAWA H., SHIMOMURA H., KIMURA K., OGATA Y., SAKAINO N., KITAGAWA A., AM. J. CARDIOL, 97, (2006); WRIGHT R.S., BYBEE K., MILLER W.L., LAUDON D.A., MURPHY J.G., JAFFE A.S., INT. J. CARDIOL, 108, (2006); MOZAFFARIAN D., NYE R., LEVY W.C., AM. J. CARDIOL, 93, (2004); SCIRICA B.M., MORROW D.A., CANNON C.P., RAY K.K., SABATINE M.S., JAROLIM P., SHUI A., MCCABE C.H., BRAUNWALD E., J. AM. COLL. CARDIOL, 47, (2006); KHUSH K.K., WATERS D.D., BITTNER V., DEEDWANIA P.C., KASTELEIN J.J., LEWIS S.J., WENGER N.K., CIRCULATION, 115, (2007); ANKER S.D., CLARK A.L., WINKLER R., ZUGCK C., CICOIRA M., PONIKOWSKI P., DAVOS C.H., BANASIAK W., ZARDINI P., HAASS M., SENGES J., COATS A.J.S., POOLE-WILSON P.A., PITT B., INT. J.CARDIOL, 112, (2006); FOLKERINGA R.J., VAN KRAAIJ D.J., TIELEMAN R.G., NIEMAN F.H., PINTO Y.M., CRIJNS H.J., J CARD FAIL, 12, (2006); HUAN L.P., WINDRAM J.D., TIN L., REDDY P., VELAVAN P., RIGBY A.S., ATKIN P., NIKITIN N.P., CLARK A.L., CLELAND J.G., AM. HEART J, 153, (2007); FOODY J.M., SHAH R., GALUSHA D., MASOUDI F.A., HAVRANEK E.P., KRUMHOLZ H.M., CIRCULATION, 113, (2006); GO A.S., LEE W.Y., YANG J., LO J.C., GURWITZ J.H., JAMA, 296, (2006); SOLA S., MIR M.Q., RAJAGOPALAN S., HELMY T., TANDON N., KHAN B.V., J. CARD. FAIL, 11, (2005); SOLA S., MIR M.Q.S., LERAKIS S., TANDON N., KHAN B.V., J. AM. COLL. CARDIOL, 47, (2006); KUZNAR W., GERIATRICS, 63, (2008); FAROOQUI A.A., ONG W.Y., HORROCKS L.A., CHEN P., FAROOQUI T., BRAIN RES. REV, 56, (2007); AMARENCO P., LAVALLEE P., TOUBOUL P.J., LANCET NEUROLOGY, 3, (2004); WATERS D.D., SCHWARTZ G.G., OLSSON A.G., ZEIHER A., OLIVER M.F., GANZ P., EZEKOWITZ M., CHAITMAN B.R., LESLIE S.J., STERN T., CIRCULATION, 106, (2002); BALLANTYNE C.M., HOOGEVEEN R.C., HEEJUNG B., CORESH J., FOLSOM A.R., CHAMBLESS L.E., MYERSON M., WU K.K., SHARRETT A.R., BOERWINKLE E., ARCH. INT. MED, 165, (2005); CALLAHAN A., WELCH K.M., AMARENCO P., SZAREK M., RUDOLPH A.E., GOLDSTEIN L.B., HENNERICI M., SILLESEN H., ZIVIN J.A., DIABETES, SUPPL. 1, 56, (2007); VOLLMER T., KEY L., DURALSKI V., TYOR W., CORBOY J., MARKOVIC-PLESE S., PREININGEROVA J., RIZZO M., SINGH I., LANCET, 363, (2004); MENGE T., HARTUNG H.P., STUVE O., NAT. REV. NEUROSCI, 6, PP. 325-331, (2005); JICK H., ZORNBERG G.L., JICK S.S., SESHADRI S., DRACHMAN D.A., LANCET, 356, (2000); SHEPHERD J., BLAUW G.J., MURPHY M.B., BOLLEN E.L., BUCKLEY B.M., COBBE S.M., FORD I., GAW A., HYLAND M., JUKEMA J.W., KAMPER A.M., MACFARLANE P.W., MEINDERS A.E., NORRIE J., PACKARD C.J., PERRY I.J., STOTT D.J., SWEENEY B.J., TWOMEY C., WESTENDORP R.G., LANCET, 360, (2002); SPARKS D.L., CONNOR D.J., SABBAGH M.N., PETERSEN R.B., LOPEZ J., BROWNE P., ACTA NEUROLOGICA SCANDINAVICA, SUPPL. 185, (2006); STANKOVIC G., SPARKS D.L., NEUROL. RES, 28, (2006); TONELLI M., ISLES C., CRAVEN T., TONKIN A., PFEFFER M.A., SHEPHERD J., SACKS F.M., FURBERG C., COBBE S.M., SIMES J., WEST M., PACKARD C., CURHAN G.C., CIRCULATION, 112, (2005); COLLINS R., ARMITAGE J., PARISH S., SLEIGH P., PETO R., LANCET, 2003, (2005); BIANCHI S., BIGAZZI R., CAIAZZA A., CAMPESE V.M., AM. J. KIDNEY DIS, 41, (2003); OKAMOTO H., KOIZUMI K., KAMITSUJI S., INOUE E., HARA M., TOMATSU T., KAMATANI N., YAMANAKA H., J. RHEUMATOL, 34, (2007); KANDA H., YOKOTA K., KOHNO C., SAWADA T., SATO K., YAMAGUCHI M., KOMAGATA Y., SHIMADA K., YAMAMOTO K., MIMURA T., MOD. RHEUMATOL, 17, (2007); SCHOEMAN C., KHANNA D., FURST D.E., MCMAHON M., REDDY S.T., FOGELMAN A.M., PAULUS H.E., PARK G.S., GONG T., ANSELL B.J., J. RHEUMATOL, 34, (2007); HOTHERSALL E., MCSHARRY C., THOMSON N.C., THORAX, 61, (2006); GOUNI-BERTHOLD I., KRONE W., CURR. DRUG TARG. - CARDIOVAS. HAEMATOL. DISORD, 5, (2005); ZANDBERGEN F., PLUTZKY J., BIOCHIM. BIOPHYS. ACTA, 1771, (2007); TENENBAUM A., MOTRO M., FISMAN E.Z., CARDIOVASC. DIABETOL, 54, (2005); KLEEMANN R., VERSCHUREN L., DE ROOIJ B.J., LINDEMAN J., DE MAAT M.M., SZALAI A.J., PRINCEN H.M., KOOISTRA T., BLOOD, 103, (2004); MAISON P., MENNEN L., SAPINHO D., BALKAU B., SIGALAS J., CHESNIER M.C., ESCHWEGE E., ATHEROSCLEROSIS, 160, (2002); GERVOIS P., KLEEMANN R., PILON A., PERCEVAULT F., KOENIG W., STAELS B., KOOISTRA T., J. BIOL. CHEM, 279, (2004); ALVAREZ DE SOTOMAYOR M., MINGORANCE C., ANDRIANTSITOHAINA R., ATHEROSCLEROSIS, 193, (2007); VANDEN BERGHE W., VERMEULEN L., DELERIVE P., DE BOSSCHER K., STAELS B., HAEGEMAN G., ADV. EXP. MED. BIOL, 544, (2003); UNDAS A., CELINSKA-LOWENHOFF M., DOMAGALA T.B., IWANIEC T., DROPINSKI J., LOWENHOFF T., SZCZEKLIK A., THROMB. HAEMOST, 94, (2005); COBAN E., SARI R., ENDOCR. RES, 30, (2004); WANG T.D., CHEN W.J., LIN J.W., CHENG C.C., CHEN M.F., LEE Y.T., ATHEROSCLEROSIS, 170, (2003); YESILBURSA D., SERDAR A., SALTAN Y., SERDAR Z., HEPER Y., GUCLU S., CORDAN J., KARDIOL POL, 62, (2005); MELENOVSKY V., MALIK J., WICHTERLE D., SIMEK J., PISARIKOVA A., SKRHA J., POLE, NE R., STAVEK P., CESKA R., AM. HEART J, 144, (2002); KIM C., J. CARDIOVASC. PHARMACOL, 47, (2006); ATHYROS V.G., MIKHAILIDIS D.P., PAPAGEORGIOU A.A., DIDANGELOS T.P., PELETIDOU A., KLETA D., KARAGIANNIS A., KAKAFIKA A.I., TZIOMALOS K., ELISAF M., METABOLISM, 54, (2005); STEINMETZ A., SCHWARTZ T., HEHNKE U., KAFFARNIK H., J. CARDIOVASC. PHARMACOL, 27, (1996); FROST R.J.A., OTTO C., GEISS H.C., SCHWANDT P., PARHOFER K.G., AM. J. CARDIOL, 87, (2001); KOWALSKI J., OKOPIEN B., MADEJ A., ZIELINSKI M., BELOWSKI D., KALINA Z., HERMAN Z.S., EUR. J. CLIN. PHARMACOL, 59, (2003); OKOPIEN B., KRYSIAK R., KOWALSKI J., MADEJ A., BELOWSKI D., ZIELINSKI M., LABUZEK K., HERMAN Z.S., ATHEROSCLEROSIS, 176, (2004); MADEJ A., OKOPIEN B., KOWALSKI J., ZIELINSKI M., WYSOCKI J., SZYGULA B., KALINA Z., HERMAN Z.S., INT. J. CLIN. PHARMACOL. THER, 36, (1998); KOH K.K., AHN J.Y., SEUNG H.H., DONG K.J., HYUNG S.K., KYUNG C.L., EAK K.S., ICHIRO S., ATHEROSCLEROSIS, 174, PP. 379-383, (2004); LANCET, 366, (2005); RUBINS H.B., ROBINS S.J., COLLINS D., FYE C.L., ANDERSON J.W., ELAM M.B., FAAS F.H., LINARES E., SCHAEFER E.J., SCHECTMAN G., WILT T.J., WITTES, J. N. ENGL. J. MED, 341, (1999); MUHLESTEIN J.B., MAY H.T., JENSEN J.R., HORNE B.D., LANMAN R.B., LAVASANI F., WOLFERT R.L., PEARSON R.R., YANNICELLI H.D., ANDERSON J.L., J. AM. COLL. CARDIOL, 48, (2006); BUSE J.B., AM. J. CARDIOL, (2007); HAFFNER S.M., GREENBERG A.S., WESTON W.M., CHEN H., WILLIAMS K., FREED M.I., CIRCULATION, 106, (2002); MOHANTY P., ALJADA A., GHANIM H., HOFMEYER D., TRIPATHY D., SYED T., AL-HADDAD W., DHINDSA S., DANDONA P., J CLIN ENDOCRINOL METAB, 89, (2004); PFUTZNER A., MARX N., LUBBEN G., LANGENFELD M., WALCHER D., KONRAD T., FORST T., J. AM. COLL. CARDIOL, 45, (2005); HANEFELD M., MARX N., PFUTZNER A., BAURECHT W., LUBBEN G., KARAGIANNIS E., STIER U., FORST T., J. AM. COLL. CARDIOL, 49, (2007); PITCHAI B., MADHANKUMAR R., SUBRAHMANYA G.S., PAWAN K., MANJEET S., PHARMACOL. RES, 56, (2007); MIYACHI H., CURR. MED. CHEM, 14, (2007); KASUGA J., YAMASAKI D., OGURA K., SHIMIZU M., SATO M., MAKISHIMA M., DOI T., HASHIMOTO Y., MIYACHI H., BIOORG. MED. CHEM. LETT, 18, (2008); MIYACHI H., YAKUGAKU Z., YAKUGAKU ZASSHI, 124, (2004); VAN HEEK M., FARLEY C.F., COMPTON D.S., HOOS L., ALTON K.B., SYBERTZ E.J., DAVIS H.R., BR. J. PHARMACOL, 129, (2000); EFRATI S., AVERBUKH M., DISHY V., FAYGENZO M., FRIEDENSOHN L., GOLIK A., EUR. J. CLIN. PHARMACOL, 63, (2007); BALLANTYNE C.M., CIRCULATION, 107, (2003); SAGER P.T., MELANI L., LIPKA L., STRONY J., YANG B., SURESH R., VELTRI E., AM. J. CARDIOL, 92, (2003); BAYS H.E., OSE L., FRASER N., TRIBBLE D.L., QUINTO K., REYES R., JOHNSON-LEVONAS A.O., SAPRE A., DONAHUE S.R., CLIN. THERAP, 26, (2004); BALLANTYNE C.M., DAVIDSON M.H., CATAPANO A.L., XU X., ROSENBERG E., TERSHAKOVEC A.M., ATHEROSCLEROSIS, SUPPL. 7, (2006); KINLAY S., J. AM. COLL. CARDIOL, 2007, (2003); MAKI-PETAJA K.M., BOOTH A.D., HALL F.C., WALLACE S.M.L., BROWN J., MCENIERY C.M., WILKINSON I.B., J. AM. COLL. CARDIOL, 50, (2007); BARTER P.J., CAULFIELD M., ERIKSSON M., GRUNDY S.M., KASTELEIN J.J., KOMAJDA M., LOPEZ-SENDON J., MOSCA L., TARDIF J.C., WATERS D.D., SHEAR C.L., REVKIN J.H., BUHR K.A., FISHER M.R., TALL A.R., BREWER B., N. ENGL. J. MED, 357, (2007); KRISHNA R., ANDERSON M.S., BERGMAN A.J., JIN B., FALLON M., COTE J., ROSKO K., CHAVEZ-ENG C., LUTZ R., BLOOMFIELD D., GUTIERREZ M., DOHERTY J., BIEBERDORF F., CHODAKEWITZ J., GOTTESDIENER K.M., WAGNER J.A., LANCET, 370, (2007); ARAGANE K., KOJAMI K., FUJINAMI K., KAMEI J., KUSUNOKI J., ATHEROSCLEROSIS, 158, (2001); INSULL W., KOREN M., DAVIGNON J., SPRECHER D., SCHROTT H., KEILSON L.M., BROWN A.S., DUJOVNE C.A., DAVIDSON M.H., MCLAIN R., HEINONEN T., ATHEROSCLEROSIS, 157, (2001); RAAL F.J., MARAIS A.D., KLEPACK E., LOVALVO J., MCLAIN R., HEINONEN T., ATHEROSCLEROSIS, 171, (2003); TARDIF J.C., GREGOIRE J., L'ALLIER P.L., ANDERSON T.J., BERTRAND O., REEVES F., TITLE L.M., ALFONSO F., SCHAMPAERT E., HASSAN A., MCLAIN R., PRESSLER M.L., IBRAHIM R., LESPERANCE J., BLUE J., HEINONEN T., RODES-CABAU J., CIRCULATION, 110, (2004); N. ENGL. J. MED, 354, (2006); TAYLOR A.J., SULLENBERGER L.E., LEE H.J., LEE J.K., GRACE K.A., CIRCULATION, 110, (2004); WESTPHAL S., BORUCKI K., TANEVA E., MAKAROVA R., LULEY C., ATHEROSCLEROSIS, 193, (2007); TAVINTHARAN S., SIVAKUMAR M., LIM S.C., SUM C.F., CLIN. CHIM. ACTA, 376, (2007); ANSELL B.J., WATSON K.E., FOGELMAN A.M., NAVAB M., FONAROW G.C., J. AM. COLL. CARDIOL, 46, (2005); FOGELMAN A.M., NAT. MED, 10, (2004); FOGELMAN A.M., CELL. METAB, 2, (2005); ANSELL B.J., AM. J. CARDIOL, 100, SUPPL., (2007); NAVAB M., ANANTHARAMAIAH G.M., REDDY S.T., VAN LENTEN B.J., DATTA G., GARBER D., FOGELMAN A.M., CURR. OPIN. LIPIDOL, 17, (2006); MADSEN T., CHRISTENSEN J.H., BLOM M., SCHMIDT E.B., BR. J. NUTR, 89, (2003); CHAN D.C., WATTS G.F., BARRET P.H., BEILIN L.J., MORI T.A., CLIN. CHEM, 48, (2002); BURNS T., MACIEJEWSKI S.R., HAMILTON W.R., ZHENG M., MOOSS A.N., HILLEMAN D.E., PHARMACOTHERAPY, 27, (2007); GEELEN A., BROUWER I.A., SCHOUTEN E.G., KLUFT C., KATAN M.B., ZOCK P.L., EUR. J. CLIN. NUTR, 58, (2004); FUJIOKA S., HAMAZAKI K., ITOMURA M., HUAN M., NISHIZAWA H., SAWAZAKI S., KITAJIMA I., HAMAZAKI T., J. NUTR. SCI. VITAMINOL. (TOKYO), 52, (2006); MEZZANO D., LEIGHTON F., MARTINEZ C., MARSHALL G., CUEVAS A., CASTILLO O., PANES O., MUNOZ B., PEREZ D.D., ROZOWSKI J., SAN MARTIN A., PEREIRA J., EUR. J. CLIN. NUTR, 55, (2001); JUNKER R., KRATZ M., NEUFELD M., ERREN M., NOFER J.R., SCHULTE H., NOWAK-GOTTL U., ASSMANN G., WAHRBURG U., THROMB. HAEMOST, 85, (2001); MADSEN T., CHRISTENSEN J.H., SCHMIDT E.B., EUR. J. NUTR, 46, (2007); MORI T.A., BEILIN L.J., CURR ATHEROSCLER REP, 6, (2004); MEHRA M.R., LAVIE C.J., VENTURA H.O., MILANI R.V., J. HEART LUNG TRANSPLANT, 25, (2006); INSULL W., TOTH P., MULLICAN W., HUNNINGHAKE D., BURKE S., DONOVAN J.M., DAVIDSON M.H., MAYO. CLIN. PROC, 76, (2001); DEVARAJ S., AUTRET B., JIALAL I., AM. J. CARDIOL, 98, (2006); GOUNI-BERTHOLD I., BERTHOLD H.K., AM. HEART J, 143, (2002); REINER Z., TEDESCHI-REINER E., ROMIC Z., CLIN. DRUG INVEST, 25, (2005); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., AM. HEART J, 152, 982, (2006); DESPRES J.P., N. ENGL. J. MED, 353, (2005); VAN GAAL L.F., LANCET, 365, (2005); PI-SUNYER F.X., JAMA, 295, (2006); GARY-BOBO M., ELACHOURI G., SCATTON B., LE FUR G., OURY-DONAT F., BENSAID M., MOL. PHARMACOL, 63, (2003); CHRISTENSEN R., KRISTENSEN P.K., BARTELS E.M., BLIDDAL H., ASTRUP A., LANCET, 370, (2007); JAMA, 288, (2002); CHRISTODOULAKOS G.E., LAMBRINOUDAKI I.V., BOTSIS D.C., ANN. N.Y. ACAD. SCI, 1092, (2006); SAARTO T., BLOMQVIST C., EHNHOLM C., TASKINEN M.R., ELOMAA I., J. CLIN. ONCOL, 14, (1996); WALSH B.W., KULLER L.H., WILD R.A., PAUL S., FARMER M., LAWRENCE J.B., SHAH A.S., ANDERSON P.W., JAMA, 279, (1998); KOMI J., LANKINEN K.S., HARKONEN P., DEGREGORIO M.W., VOIPIO S., KIVINEN S., TUIMALA R., VIHTAMAKI T., VIHKO K., YLIKORKALA O., ERKKOLA R., MENOPAUSE, 12, (2005); LAKOSKI S.G., HERRINGTON D.M., CLIMACTERIC, 8, (2005); HERRINGTON D.M., BROSNIHAN K.B., PUSSER B.E., SEELY E.W., RIDKER P.M., RIFAI N., MACLEAN D.B., J. CLIN. ENDOCRINOL. METAB, 86, (2001); WALSH B.W., COX D.A., SASHEGYI A., AM. J. CARDIOL, 88, (2001); CHRISTODOULAKOS G.E., PANOULIS C.P., LAMBRINOUDAKI I.V., BOTSIS D.S., DENDRINOS S.G., ECONOMOU E., CREATSAS G.C., MENOPAUSE, 11, (2004); PEPYS M.B., HIRSCHFIELD G.M., TENNENT G.A., GALLIMORE J.R., KAHAN M.C., BELLOTTI V., HAWKINS P.N., MYERS R.M., SMITH M.D., POLARA A., COBB A.J.A., LEY S.V., AQUILINA J.A., ROBINSON C.V., SHARIF I., GRAY G.A., SABIN C.A., JENVEY M.C., KOLSTOE S.E., THOMPSON D., NATURE, 440, (2006); NILSSON J., HANSSON G.K., SHAH P.K., ARTERIOSCLER. THROMB. VASC. BIOL, 25, (2005)","M. BRONCEL; KLINIKA CHORÓB WEWNETRZNYCH Z ODDZIALEM FARMAKOLOGII KLINICZNEJ I TERAPII MONITOROWANEJ, LODZ 91-347, UL. KNIAZIEWICZA 1/5, POLAND; EMAIL: TTM@TTM.ORG.PL","BENTHAM SCIENCE PUBLISHERS B.V.","ENGLISH","ANTI-INFLAMMATORY ANTI-ALLERGY AGENTS MED. CHEM.","ARTICLE","ISI","2-S2.0-54349085064","ANTI-INFLAMMATORY ANTI-ALLERGY AGENTS MED CHEM","MEDICAL UNIVERSITY OF LODZ;MEDICAL UNIVERSITY OF LODZ;MEDICAL UNIVERSITY OF LODZ","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"BRONCEL M, 2008, ANTI-INFLAMMATORY ANTI-ALLERGY AGENTS MED CHEM","BRONCEL M, 2008, ANTI-INFLAMMATORY ANTI-ALLERGY AGENTS MED CHEM"
"TUNG C;CHANG Y;LEE S;CHU Y","TUNG, CHIH-HONG (23502516700); CHANG, YUN-PING (55511080900); LEE, SHIN-MEI (7601403859); CHU, YAN-HWA (7403050985)","EXTRACTION OF FUNCTIONAL COMPOUNDS FROM SORGHUM DISTILLERY RESIDUES",2010,"TAIWANESE JOURNAL OF AGRICULTURAL CHEMISTRY AND FOOD SCIENCE","48","5",0,"","FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE, HSINCHU, TAIWAN;FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE, HSINCHU, TAIWAN;DEPARTMENT OF FOOD SCIENCE, NATIONAL KINMEN INSTITUTE OF TECHNOLOGY, TAIWAN;FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE, HSINCHU, TAIWAN","SOLVENT AND SUPERCRITICAL CARBON DIOXIDE WERE USED TO EXTRACT THE FUNCTIONAL COMPOUNDS, INCLUDING POLYCOSANOLS, PHYTOSTEROLS, TOTAL PHENOLIC COMPOUNDS AND TANNINS, FROM SORGHUM DISTILLERY RESIDUES (SDR), RESPECTIVELY. RESULTS SHOWED THAT USING ETHANOL, ETHYL ACETATE AND N-HEXANE AS EXTRACTION SOLVENTS, THE EXTRACTION YIELDS OF POLICOSANOLS WERE 348, 322 AND 275 MG/KG SDR, AND THOSE OF PHYTOSTEROLS WERE 317, 311 AND 323 MG/KG SDR. USING 50% ETHANOL AS EXTRACTION SOLVENT, EXTRACTION YIELDS OF TOTAL PHENOLIC COMPOUNDS (TPC) AND TANNINS WERE THE HIGHEST AMONG ALL EXTRACTION, AND THE DPPH SCAVENGING ABILITY OF THE EXTRACT WAS ALSO HIGHER THAN THOSE OBTAINED BY USING OTHER SOLVENTS. BY USING SUPERCRITICAL CARBON DIOXIDE TO EXTRACT SDR, AN INCREASE IN TEMPERATURE WOULD RESULT IN A HIGHER YIELDS OF POLICOSANOLS, PHYTOSTEROLS, TOTAL PHENOLIC COMPOUNDS AND TANNINS, BUT THIS EFFECT WAS LEVELED OFF WHEN THE TEMPERATURE IS HIGHER THAN 65°C. THE POLICOSANOLS AND PHYTOSTEROLS EXTRACTION YIELDS COULD REACH 273 MG AND 516 MG, RESPECTIVELY, AT THE CONDITION OF 65°C/379 BAR SUPERCRITICAL CARBON DIOXIDE EXTRACTION FOR 3 H. AFTER SEPARATION, THE POLICOSANOLS CONTENT OF THE EXTRACT WAS 2.16% HIGHER THAN THAT OF N-HEXANE SOLVENT EXTRACT WITH 0.94% OF POLICOSANOLS CONTENT.","POLICOSANOL; SORGHUM DISTILLERY RESIDUES; SUPERCRITICAL CARBON DIOXIDE EXTRACTION","","","","WANG L., WELLER C.L., SCHLEGEL V.L., CARR T.P., CUPPETT S.L., SUPERCRITICAL CO2 EXTRACTION OF LIPIDS FROM GRAIN SORGHUM DRIED DISTILLERS GRAINS WITH SOLUBLES, BIORESOUR. TECHNOL., 99, PP. 1373-1382, (2008); AWIKA J.M., ROONEY L.W., SORGHUM PHYTOCHEMICALS AND THEIR POTENTIAL IMPACT ON HUMAN HEALTH, PHYTOCHEM., 65, PP. 1199-1221, (2004); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN. PROC., 78, PP. 965-978, (2003); TAYLOR J.R.N., SCHOBER T.J., BEAN S.R., NOVEL FOOD AND NON-FOOD USES FOR SORGHUM AND MILLETS, J. CEREAL SCI., 44, PP. 252-271, (2006); BERNARDO-GIL M.G., GRENHA J., SANTOS J., CARDOSO P., SUPERCRITICAL FUID EXTRACTION AND CHARACTERIZATION OF OIL FROM HAZELNUT, EUR. J. LIPID SCI. TECHNOL., 104, PP. 402-409, (2002); COELHO J.A.P., PEREIRA A.P., MENDES R.L., PALAVRA A.M.F., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF FOENICULUM VULGARE VOLATILE OIL, FLAVOR FRAGRANCE J., 18, PP. 316-319, (2003); MARONGIU B., PORCEDDA S., CAREDDA A.D., GIOANNIS B., VARGIU L., COLLA P., EXTRACTION OF JUNIPERUS OXYCEDRUS SSP. OXYCEDRUS ESSENTIAL OIL BY SUPERCRITICAL CARBON DIOXIDE: INFLUENCE OF SOME PROCESS PARAMETERS AND BIOLOGICAL ACTIVITY, FLAVOR FRAGRANCE J., 18, PP. 390-397, (2003); GIANNUZZO A.N., BOGGETTI H.J., NAZARENO M.A., MISHIMA H.T., SUPERCRITICAL FUID EXTRACTION OF NARINGIN FROM THE PEEL OF CITRUS PARADISE, PHYTOCHEM. ANAL., 14, PP. 221-223, (2003); ELLINGTON E., BASTIDA J., VILADOMAT F., CODINA C., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF COLCHICINES AND RELATED ALKALOIDS FROM SEEDS OF COLCHICUM AUTUMNALE L, PHYTOCHEM. ANAL., 14, PP. 164-169, (2003); HAMBURGER M., BAUMANN D., ADLER S., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF SELECTED MEDICINAL PLANTSEFFECTS OF HIGH PRESSURE AND ADDED ETHANOL ON YIELD OF EXTRACTED SUBSTANCES, PHYTOCHEM. ANAL., 15, PP. 46-54, (2004); HOI J.T., WELLER C.L., SCHLEGEL V.L., CUPPETT S.L., LEE J.Y., CARR T.P., SORGHUM DISTILLERS DRIED GRAIN LIPID EXTRACT INCREASES CHOLESTEROL EXCRETION AND DECREASES PLASMA AND LIVER CHOLESTEROL CONCENTRATION IN HAMSTERS, J. FUNCT. FOODS, 1, PP. 381-386, (2009); CHEN F., WANG Z.F., ZHAO G.H., LIAO X.J., CAI T.Y., GUO L.Y., HU X.S., PURIFICATION PROCESS OF OCTACOSANOL EXTRACTS FROM RICE BRAN WAX BY MOLECULAR DISTILLATION, J. FOOD ENG., 79, PP. 63-68, (2007); KAHKONEN M.P., HOPIA A.I., VUORELA H.J., RAUHA J., PIHLAJA P.K., KUJALA T.S., HEINONEN M., ANTIOXIDANT ACTIVITY OF PLANT EXTRACTS CONTAINING PHENOLIC COMPOUNDS, J. AGRIC. FOOD CHEM., 47, PP. 3954-3962, (1999); PRICE M.L., VAN SCOYOCAND S., BULTER L., A CRITICAL EVALUATION OF THE VANILLIN REACTION AS AN ASSAY FOR TANNIN IN SORGHUM GRAIN, J. AGRIC. FOOD CHEM., 26, PP. 1214-1218, (1978); SHIMADA K., FUJIKAWA K., YAHARA K., NAKAMURA T., ANTIOXIDATIVE PROPERTIES OF XANTHAN ON THE AUTOXIDATION OF SOYBEAN OIL IN CYCLODEXTRIN EMULSION, J. AGRIC. FOOD CHEM., 40, PP. 945-948, (1992); HOLSER R.A., AKIN D.E., EXTRACTION OF LIPIDS FROM FLAX PROCESSING WASTE USING HOT ETHANOL, IND. CROPS PROD., 27, PP. 236-240, (2008); XI J., SHEN D.J., ZHAO S., LU B.B., LI Y., ZHANG R., CHARACTERIZATION OF POLYPHENOLS FROM GREEN TEA LEAVES USING A HIGH HYDROSTATIC PRESSURE EXTRACTION, INT. J. PHARM., 382, PP. 139-143, (2009); MARKOM M., HASAN M., RAMLI W., DAUD W., SINGH H., JAHIM J.M., EXTRACTION OF HYDROLYSABLE TANNINS FROM PHYLLANTHUS NIRURI LINN.: EFFECTS OF SOLVENTS AND EXTRACTION METHODS, SEP. PURIF. TECHNOL., 52, PP. 487-496, (2007); THOMAS J.B., JAMES F.E., SUPERCRITICAL FLUID TECHNOLOGY: REVIEW IN MODERN THEORY AND APPLICATIONS, (1991); MORRISON W.H., HOLSER R., AKIN D.E., CUTICULAR WAX FROM FAX PROCESSING WASTE WITH HEXANE AND SUPER CRITICAL CARBON DIOXIDE EXTRACTIONS, IND. CROPS PROD., 24, PP. 119-122, (2006)","C.-H. TUNG; FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE, HSINCHU, TAIWAN; EMAIL: DJH@FRDI.ORG.TW","","CHINESE","TAIWANESE J. AGRIC. CHEM. FOOD SCI.","ARTICLE","ISI","2-S2.0-84870504541","TAIWANESE J AGRIC CHEM FOOD SCI","FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE;FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE;NATIONAL KINMEN INSTITUTE OF TECHNOLOGY;FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE","NOTREPORTED;FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE;NOTREPORTED",NA,"TUNG C-H, 2010, TAIWANESE J AGRIC CHEM FOOD SCI","TUNG C-H, 2010, TAIWANESE J AGRIC CHEM FOOD SCI"
"YAGHMAEI P;AMRAEI M;KOOHI M;NASIM H","YAGHMAEI, PARICHEHR (25639203600); AMRAEI, MANSOUR (54584857600); KOOHI, MOHAMMAD KAZEM (57172656600); NASIM, HAYATI R. (55255194000)","EFFECTS OF POLICOSANOL ON CHOLESTEROL LIPOPROTEINS AND ATHROM PLAQUES IN MALE RABBITS",2011,"SCIENTIFIC JOURNAL OF KURDISTAN UNIVERSITY OF MEDICAL SCIENCES","16","7",2,"","BIOLOGY DEPT, FACULTY OF BASIC SCIENCES, SCIENCE AND RESEARCH BRANCH, ISLAMIC AZAD UNIVERSITY, TEHRAN, IRAN;SCIENCE AND RESEARCH BRANCH, ISLAMIC AZAD UNIVERSITY, TEHRAN, IRAN;BASIC SCIENCES DEPT, FACULTY OF VETERINARY MEDICINE, TEHRAN UNIVERSITY, TEHRAN, IRAN;BIOLOGY DEPT, FACULTY OF BASIC SCIENCES, SCIENCE AND RESEARCH BRANCH, ISLAMIC AZAD UNIVERSITY, TEHRAN, IRAN","BACKGROUND AND AIM: POLICOSANOL IS A COMPONENT FROM MAIN ALCOHOL GROUPS WITH LONG-CHAIN WHICH IS EXTRACTED FROM CANE SUGAR. IN THE PRESENT STUDY, WE INVESTIGATED THE EFFECT OF POLICOSANOL ON ATHEROSCLEROSIS SOME OF ITS BIOCHEMICAL RISK FACTORS IN HYPERCHOLESTEROLEMIC RABBITS. MATERIALS AND METHODS: 24 MALE RABBITS OF NEW ZEALAND RACE WITH AVERAGE WEIGHT OF 1750GR WERE DIVIDED IN TO 4 GROUP: CONTROL GROUP(N=6) HAD NORMAL DIET, SHAM AND EXPERIMENTAL GROUP NO.1 AND NO.2(N=6) HAD HIGH CHOLESTEROL (2%) DIET, AND THEY RECEIVED PLACEBO AND POLICOSANOL WITH DOSES OF 0.25 AND 0.5MG RESPECTIVELY, EVERY DAY. AFTER 4 WEEKS OF TREATMENT, BLOOD SAMPLES WERE OBTAINED AND CHOLESTEROL, TRIGLYCERIDE, LDL-C AND HDL-C WERE MEASURED. FOR HISTOLOGICAL STUDIES PART OF AORTA WAS DISSECTED AND FIXED IN FORMALIN %10. DATA WERE INTRODUCED INTO SPSS SOFTWARE AND ANALYZED BY VARIANCE ANALYSIS. RESULT: THE RESULTS SHOWED THAT IN EXPERIMENTAL GROUP NO.1 THERE WAS SIGNIFICANT DECREASE IN THE RATE OF CHOLESTEROL, LDL-C AND TRIGLYCERIDE (P<0.05), AND SIGNIFICANT INCREASE IN HDL-C (P<0.05) COMPARED WITH THOSE OF CONTROL GROUP. ALSO IN EXPERIMENTAL GROUP NO.2 THERE WAS A SIGNIFICANT DECREASE IN CHOLESTEROL, LDL-C AND TRIGLYCERIDE (P<0.01) IN THE RATE OF CHOLESTEROL, LDL-C AND TRIGLYCERIDE, AND SIGNIFICANT INCREASE (P<0.01), AND SIGNIFICANT INCREASE IN HDL-C (P<0.01) COMPARED WITH THOSE OF CONTROL GROUP. HISTOLOGICAL INVESTIGATIONS SHOWED TREATMENT BY POLICOSANOL IN EXPERIMENTAL GROUP NO.1 AND NO.2 COULD PREVENT ATHEROMA PLAQUE FORMATION. CONCLUSION: POLICOSANOL CAN BE AN EFFECTIVE COMPONENT IN DECREASING CHOLESTEROL, LDL-C AND TRIGLYCERIDE AND INCREASING HDL-C, LEADING TO PREVENTION OF ATHEROMA PLAQUE FORMATION.","ATHEROSCLEROSIS; HDL-C; LDL-C; POLICOSANAL","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOLOGY; MALE; NONHUMAN; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL","","","HANSSON G.K., IMMUNO RESPONSES IN ATHEROSCLEROSIS, IMMUNO FUNCTIONS OF THE VASEL WELL, PP. 322-324, (1996); BAND W.S., HYPERCHOLESTEROLEMIA: CURRENT THERAPY AND DRUG OF FUTURE, DRUG NEWS LETTER (FACT AND COMPARISON), 10, PP. 65-76, (1997); BULLOCK B., HENZE R.H., NORMAL AND A LATHERED CELLUAR FUNCTION FOCUS ON PATHOPHYSIOLOGY, PHILADELPHIA, (2000); FRANK J.S., WATSON A.D., EDWARDS P.A., PATHOGENESIS OF ATHEROSCLEROSIS, AM J CARDIOL, 76, PP. 18-23, (1995); HO N.C., LEUNG K., CHEN Z., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); ZILVERSMIT D.B., ATHEROSCLEROSIS: A POSTPRANDIAL PHENOMEN, CIRCULATION, 60, PP. 473-485, (1997); DULIN M., HATCHER L., SASSER H., BARRINGER T., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, J CLINICAL NUTRITION, 84, PP. 1543-1548, (2006); BAYTAN S.H., ALKANAT M., OZERN M., EKINCI M., AKGUN A., FLUVASTATIN ALTERS PSYCHOMOTOR PERFORMANCE AND DAILY ACTIVITY BUT NOT THE SPATIAL MEMORY IN RATS, J EXP MED, 209, PP. 311-320, (2006); ALAWI A., THOMAS A., DAVID M., RICHARD H., STATIN, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND RISK FACTOR OF CANCER, JAM CELL CARDIOL, 52, PP. 1141-1147, (2008); GEY K.F., STAHELIN H.B., EICHHOLZER M., POOR PLASMA STATUS OF CAROTENE AND VITAMIN C ASSOCIATED WITH HIGHER MORTALITY FROM ISCHEMIC HEART DISEASE AAND STROKE. BASEL PROSPECTIVE STUDY, CLIN INVEST, 71, PP. 3-6, (1993); HERTOG M.G.L., KROMHOUT D., ARAVANIS C., BLACKBURN H., BUZINA R., FIDANZA F., ET AL., FLAVONOID INTAKE AND LONG-TERM RISK OF CORONARY HEART DISEASE AND CANCER IN THE SEVEN COUNTRIES STUDY, ARCH INTERN MED, 27, PP. 381-386, (1995); MOREL I., LESCOAT G., COGREL P., ANTIOXIDANT AND IRON CHELATING ACTIVITIES OF FLAVONOIDS OF THE CATECHIN, QUERCETIN AND DIOSMETIN ON IRONLOADED RAT HEPATOCYTE CULTURES, BIOCHEM PHARMACOL, 1, PP. 13-19, (1993); PARTIFF V.J., RUBBA P., BOLTON C., MAROTTA G., COMPARISON OF ANTIOXIDANT STATUS AND FREE RADICAL PROXIDATION OF PLASMA LIPOPROTEINS IN HEALTHY YOUNG PERSONS FROM NAPLES AND BRISTOL, EUR HEART J, 15, PP. 871-876, (1994); SING D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); SING H., DERWAS N., POULOS A., VERY LONG CHAIN FATTY ACID BETA-OXIDATION BY RAT LIVER MITOCHONDRIA AND PEROXISOMA, ARCH BIOCHEM BIOPHYS, 310, PP. 382-390, (1987); NOA M., MAS R., LARIOT C., PROTECTIVE EFFECT OF POLICOSANOL ON ENDOTHELIUM AND INTIMAL THICKNESS INDUCED BY FORCEPS IN RABBITS, J MED FOOD, 10, PP. 452-459, (2007); KASSIS A., KUBOW S., CHEN Z., SUGER CANE POLICOSONALS DO NOT REDUCE LDL OXIDATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS, J LIPIDS, 44, PP. 391-396, (2009); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES, 32, PP. 8-12, (2001); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECT OF POLICOSANOL AND PHYTOSTEROLS ON LIPID LEVELS CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); DULLENS S., MENSIK R., BRAGT M., KIES A., PLAT J., EFFECTS OF EMULSIFIED POLICOSANOL WITH DIFFERENT CHAIN LENGHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTOR-DEFICIENT MICE, J LIPID RES, 49, PP. 790-796, (2008); MCCARTY M.F., POLICOSANOL SAFELY DOW-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED, 59, PP. 268-279, (2002); CARLING D., ZAMMIT V.A., HARDIE D.J., A COMMON BICYCLIC PROTEIN KINASE CASCADE IN ACTIVATES THE REGULATORY ENZYMES OF FATTY ACID AND CHOLESTEROL BIOSYNTHESIS, FEBS LETT, 223, PP. 217-222, (1987); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, J CLIN PHARMACOL, 50, PP. 255-262, (2000); MATRISIAN L.M., THE MATRIX DEGRADING METALLOPROTEINASES, BIOESSAYS, 14, PP. 455-463, (1992); ZAMAN A., HELFT G., WORTHLEY S., BADIMON J., THE ROLE OF PLAQUE RUPTURE AND THROMBOSIS IN CORONARY ARTERY DISEASE, ATTEROSCLEROSIS, 49, PP. 251-266, (2000); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998)","P. YAGHMAEI; BIOLOGY DEPT, FACULTY OF BASIC SCIENCES, SCIENCE AND RESEARCH BRANCH, ISLAMIC AZAD UNIVERSITY, TEHRAN, IRAN; EMAIL: YAGHMAEI_P@YAHOO.COM","","ENGLISH","SCI. J. KURDISTAN UNIV. MED. SCI.","ARTICLE","ISI","2-S2.0-83255189442","SCI J KURDISTAN UNIV MED SCI","ISLAMIC AZAD UNIVERSITY;ISLAMIC AZAD UNIVERSITY;TEHRAN UNIVERSITY;ISLAMIC AZAD UNIVERSITY","NOTREPORTED;ISLAMIC AZAD UNIVERSITY;NOTREPORTED",NA,"YAGHMAEI P, 2011, SCI J KURDISTAN UNIV MED SCI","YAGHMAEI P, 2011, SCI J KURDISTAN UNIV MED SCI"
"KASSIS A;MARINANGELI C;JAIN D;EBINE N;JONES P","KASSIS, AMIRA N. (12800588300); MARINANGELI, CHRISTOPHER P.F. (12787919400); JAIN, DEEPAK (56206778500); EBINE, NAOYUKI (6602098156); JONES, PETER J.H. (36078426500)","LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS",2007,"ATHEROSCLEROSIS","194","5",24,"10.1016/j.atherosclerosis.2006.10.008","SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QUE. H9X 3V9, 21, 111 LAKESHORE ROAD, STE-ANNE-DE-BELLEVUE, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QUE. H9X 3V9, 21, 111 LAKESHORE ROAD, STE-ANNE-DE-BELLEVUE, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QUE. H9X 3V9, 21, 111 LAKESHORE ROAD, STE-ANNE-DE-BELLEVUE, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QUE. H9X 3V9, 21, 111 LAKESHORE ROAD, STE-ANNE-DE-BELLEVUE, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QUE. H9X 3V9, 21, 111 LAKESHORE ROAD, STE-ANNE-DE-BELLEVUE, CANADA","POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS SHOWN TO HAVE BENEFICIAL EFFECTS ON PLASMA LIPID LEVELS IN ANIMALS AND HUMANS. OVER 50 STUDIES HAVE REPORTED SIGNIFICANT REDUCTIONS IN PLASMA CHOLESTEROL USING POLICOSANOL OBTAINED FROM CUBAN SUGAR CANE (DALMER, LA HAVANA, CUBA). HOWEVER, OTHER RESEARCH GROUPS USING POLICOSANOL FROM ALTERNATIVE SOURCES HAVE FAILED TO REPRODUCE THE EFFICACY OF THESE ALCOHOLS OBSERVED IN EARLIER STUDIES. THEREFORE, THE OBJECTIVE OF THE PRESENT STUDY WAS TO COMPARE THE CHOLESTEROL-LOWERING EFFECT OF THE DALMER SUGAR CANE POLICOSANOL (SCP) PRODUCT VERSUS AN ALTERNATIVE MIXTURE OF SIMILAR POLICOSANOL COMPOSITION. FORTY-EIGHT MALE GOLDEN SYRIAN HAMSTERS WERE RANDOMLY ASSIGNED TO FOUR GROUPS AND FED EXPERIMENTAL DIETS AD LIBITUM FOR A PERIOD OF 4 WEEKS: (I) NON-CHOLESTEROL CONTROL, (II) 0.1% CHOLESTEROL CONTROL, (III) 0.1% CHOLESTEROL DIET SUPPLEMENTED WITH 275 MG/KG DIET OF DALMER CUBAN SUGAR CANE POLICOSANOL AND (IV) 0.1% CHOLESTEROL DIET SUPPLEMENTED WITH 275 MG/KG DIET OF ALTERNATIVE SUGAR CANE POLICOSANOL. HAMSTERS WERE SACRIFICED AND BLOOD WAS COLLECTED AT THE END OF THE FEEDING PERIOD. BODY WEIGHTS AND FOOD INTAKES WERE SIMILAR ACROSS STUDY GROUPS. NEITHER OF THE TWO POLICOSANOL TREATMENTS HAD ANY SIGNIFICANT EFFECT ON PLASMA LIPID LEVELS, AS COMPARED TO CHOLESTEROL CONTROL. THE OUTCOME OF THE PRESENT STUDY QUESTIONS THE CLINICAL USEFULNESS OF POLICOSANOL MIXTURES AS CHOLESTEROL-LOWERING NUTRACEUTICALS. © 2006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.","CHOLESTEROL LOWERING; HAMSTERS; LOW-DENSITY LIPOPROTEIN; OCTACOSANOL; POLICOSANOL; VERY LONG CHAIN FATTY ALCOHOLS","ANIMAL FEED; ANIMALS; ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CRICETINAE; EATING; FATTY ALCOHOLS; HYPERCHOLESTEROLEMIA; MALE; MESOCRICETUS; SACCHARUM; TRIGLYCERIDES; CHOLESTEROL; LIPID; NUTRACEUTICAL; POLICOSANOL; ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CUBA; FOOD INTAKE; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; SUGARCANE; SYRIAN HAMSTER","ADVANCED FOODS AND MATERIALS NETWORK, AFMNET","THIS STUDY WAS SUPPORTED BY THE ADVANCED FOODS AND MATERIALS NETWORK—NETWORKS OF CENTRES OF EXCELLENCE.","MAS R., MONOGRAPHS-POLICOSANOL: HYPOLIPIDEMIC, ANTIOXIDANT, TREATMENT OF ATHEROSCLEROSIS, DRUGS FUTURE, 25, PP. 569-586, (2000); ARRUZAZABALA M.L.C.D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, 2, PP. 81-90, (1994); RODRIGUEZ-ECHENIQUE C.M.R., MAS R., NOA M., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, 2, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, 6, PP. 923-932, (1997); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, 3, PP. 255-262, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, 1, PP. 43-57, (2001); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, 1, PP. 31-41, (2001); CASTANO G.M.R., FERNANDEZ L., ILLNAIT J., ET AL., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 63, PP. 286-303, (2002); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, 2, PP. 165-170, (2003); MURPHY K.J.S.D., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, (2004); LIN Y.R.M., VAN DER WIELEN R.P., TRAUTWEIN E.A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); REINER Z.T.-R.E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 5, PP. 701-707, (2005); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA. A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2263-2269, (2006); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); REEVES P.G., COMPONENTS OF THE AIN-93 DIETS AS IMPROVEMENTS IN THE AIN-76A DIET, J NUTR, 127, 5 SUPPL, (1997); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, 11, PP. 376-383, (2003); KRIS-ETHERTON P.M., DIETSCHY J., DESIGN CRITERIA FOR STUDIES EXAMINING INDIVIDUAL FATTY ACID EFFECTS ON CARDIOVASCULAR DISEASE RISK FACTORS: HUMAN AND ANIMAL STUDIES, AM J CLIN NUTR, 65, 5 SUPPL, (1997); SPADY D.K., DIETSCHY J.M., INTERACTION OF DIETARY CHOLESTEROL AND TRIGLYCERIDES IN THE REGULATION OF HEPATIC LOW DENSITY LIPOPROTEIN TRANSPORT IN THE HAMSTER, J CLIN INVEST, 81, 2, PP. 300-309, (1988); OTTO J., ORDOVAS J.M., SMITH D., ET AL., LOVASTATIN INHIBITS DIET INDUCED ATHEROSCLEROSIS IN F1B GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 114, 1, PP. 19-28, (1995); FIELD F.J., BORN E., MATHUR S.N., STANOL ESTERS DECREASE PLASMA CHOLESTEROL INDEPENDENTLY OF INTESTINAL ABC STEROL TRANSPORTERS AND NIEMANN-PICK C1-LIKE 1 PROTEIN GENE EXPRESSION, J LIPID RES, 45, 12, PP. 2252-2259, (2004); EBINE N., JIA X., DEMONTY I., WANG Y., JONES P.J., EFFECTS OF A WATER-SOLUBLE PHYTOSTANOL ESTER ON PLASMA CHOLESTEROL LEVELS AND RED BLOOD CELL FRAGILITY IN HAMSTERS, LIPIDS, 40, 2, PP. 175-180, (2005); DOGGRELL S.A., BERBERINE-A NOVEL APPROACH TO CHOLESTEROL LOWERING, EXP OPIN INVEST DRUGS, 14, 5, PP. 683-685, (2005); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, 3-4, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, 1, PP. 8-12, (2001); KOBAYASHI M., ISHIDA F., TAKAHASHI T., ET AL., PREVENTIVE EFFECT OF MK-733 (SIMVASTATIN), AN INHIBITOR OF HMG-COA REDUCTASE, ON HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS INDUCED BY CHOLESTEROL FEEDING IN RABBITS, JPN J PHARMACOL, 49, 1, PP. 125-133, (1989); JONES P.J., PAPPU A.S., HATCHER L., ET AL., DIETARY CHOLESTEROL FEEDING SUPPRESSES HUMAN CHOLESTEROL SYNTHESIS MEASURED BY DEUTERIUM INCORPORATION AND URINARY MEVALONIC ACID LEVELS, ARTERIOSCLER THROMB VASC BIOL, 16, 10, PP. 1222-1228, (1996); SINGH D.V., LI L.T.P.P., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION O AMP-KINASE, J PHARMACOL EXP THER, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 5, PP. 701-707, (2005); TEDESCHI-REINER E., REINER Z., ROMIC Z., IVANKOVIC D., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTILIPEMIC EFFICACY AND TOLERABILITY OF FOOD SUPPLEMENT POLICOSANOL IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, LIJEC VJESN, 127, PP. 273-279, (2005); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, 2, PP. 55-66, (2002)","P.J.H. JONES; SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QUE. H9X 3V9, 21, 111 LAKESHORE ROAD, STE-ANNE-DE-BELLEVUE, CANADA; EMAIL: PETER.JONES@MCGILL.CA","","ENGLISH","ATHEROSCLEROSIS","ARTICLE","ISI","2-S2.0-34748872135","ATHEROSCLEROSIS","MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY","NOTREPORTED;MCGILL UNIVERSITY;NOTREPORTED",NA,"KASSIS AN, 2007, ATHEROSCLEROSIS","KASSIS AN, 2007, ATHEROSCLEROSIS"
"NOA M;MÁS R;LARIOT C","NOA, MIRÍAM (7003318964); MÁS, ROSA (7007164572); LARIOT, CARLOS (6506302000)","PROTECTIVE EFFECT OF POLICOSANOL ON ENDOTHELIUM AND INTIMAL THICKNESS INDUCED BY FORCEPS IN RABBITS",2007,"JOURNAL OF MEDICINAL FOOD","10","7",9,"10.1089/jmf.2006.232","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, POST BOX 6990, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;ELECTRONIC MICROSCOPY, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG ISOLATED FROM SUGAR CANE WAX WITH CONCOMITANT ANTIPLATELET EFFECTS THAT PREVENTS LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RABBITS AND RATS, INCLUDING FOAM CELL FORMATION, AND ALSO REDUCES FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, WHILE IT INHIBITS PROLIFERATION OF SMOOTH MUSCLE CELLS INDUCED IN RABBIT CUFFED ARTERY. THIS STUDY WAS UNDERTAKEN TO DETERMINE WHETHER POLICOSANOL PREVENTS ENDOTHELIUM DAMAGE AND INCREASE IN ARTERIAL WALL THICKNESS IN RABBITS WITH ARTERIAL WALLS DAMAGED WITH A FORCEPS. ARTERY FORCEPS WERE PLACED OVER THE CENTRAL ARTERY OF THE RIGHT EAR OF ALL RABBITS, AND EACH ARTERY WAS INJURED EIGHT TIMES. ANIMALS WERE RANDOMLY DISTRIBUTED INTO FOUR GROUPS: A POSITIVE CONTROL GROUP TREATED WITH TWEEN 20/H2O VEHICLE, TWO GROUPS TREATED WITH POLICOSANOL (5 AND 25 MG/KG, RESPECTIVELY), AND A GROUP TREATED WITH ASPIRIN (8 MG/KG). TREATMENTS WERE GIVEN FOR 30 DAYS. DAMAGED ARTERIES WERE EXAMINED BY LIGHT AND ELECTRON (TRANSMISSION AND SCANNING) MICROSCOPY. TO EVALUATE INTIMAL THICKENING, AREAS OF INTIMA WERE MEASURED, AND A SIGNIFICANT REDUCTION IN POLICOSANOL-TREATED ANIMALS WAS OBSERVED. THE ENDOTHELIAL SURFACE, STUDIED WITH SCANNING ELECTRON MICROSCOPY, REVEALED SEVERAL TYPES OF DAMAGE. IN CONTROL GROUP, THE ENDOTHELIAL SURFACE WAS SEVERELY DAMAGED. DEENDOTHELIALIZED AREAS WERE REDUCED IN POLICOSANOL-TREATED ANIMALS. PLATELET ADHESION TO SUBENDOTHELIUM WAS SEEN IN ALL ANIMALS OF THE CONTROL GROUP, WHEREAS POLICOSANOL-TREATED GROUPS EXHIBITED SIGNIFICANTLY REDUCED PLATELET ADHESION. POLICOSANOL ALSO REDUCED, DOSE-DEPENDENTLY, THE PLATELET SEQUESTRATION INDUCED IN THE DAMAGED VESSEL WALL, PARTIALLY PREVENTING THE REDUCTION IN PLATELET COUNT. IT IS CONCLUDED THAT POLICOSANOL PREVENTS ENDOTHELIUM INJURY AND REDUCES SIGNIFICANTLY INTIMAL THICKNESS OF RABBIT ARTERIES DAMAGED WITH FORCEPS. © MARY ANN LIEBERT, INC. AND KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION.","ENDOTHELIUM; INTIMAL THICKNESS; POLICOSANOL; RABBIT","ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIES; ATHEROSCLEROSIS; BLOOD PLATELETS; EAR; ENDOTHELIUM, VASCULAR; FATTY ALCOHOLS; MALE; MICROSCOPY, ELECTRON; MICROSCOPY, ELECTRON, SCANNING; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; RABBITS; SURGICAL INSTRUMENTS; TUNICA INTIMA; ANIMALIA; ORYCTOLAGUS CUNICULUS; RATTUS; SACCHARUM; ACETYLSALICYLIC ACID; POLICOSANOL; POLYSORBATE 20; WATER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY INJURY; ARTERY INTIMA; ARTERY WALL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EAR; ENDOTHELIUM INJURY; FORCEPS; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; TRANSMISSION ELECTRON MICROSCOPY","","","MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A, 56, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED TO TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, DRUGS AGING, 20, PP. 155-163, (2003); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLAST, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D., LI L., PORTER T., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); NOA M., MAGRANER J., MAS R., EFECTO DEL ATEROMIXOL EN LAS LESIONES AORTICAS INDUCIDAS POR LIPOFUNDIN EN CONEJOS, PROG CIEN MED (VENEZUELA), 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); RODRIGUEZ C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FUND CHEM TOXICOL, 32, PP. 565-575, (1994); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH MED RES, 36, PP. 441-447, (2005); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-699, (1993); NOA M., MAS R., BRINIS F., MESA R., EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS, J PHARM PHARMACOL, 49, PP. 999-1003, (1997); SCHWARTZ C.J., KELLEY J.L., NEREM R.M., SPRAGUE E.A., ROSCK M., VALENTE A., PATHOPHYSIOLOGY OF THE ATHEROGENIC PROCESS, AM J CARDIOL, 64, PP. 236-306, (1989); IP J., FUSTER V., BADIMON L., BADIMON J., TAUBMAN M., CHESEBRO J., SYNDROMES OF ACCELERATED ATHEROSCLEROSIS: ROLE OF VASCULAR INJURY AND SMOOTH MUSCLE CELL PROLIFERATION, J AM COLL CARDIOL, 15, PP. 1667-1687, (1990); GUYTON J.R., MOAKE J.L., THROMBOTIC PROCESSES IN ATHEROGENESIS, BLOOD VESSEL WALL AND THROMBOSIS, 2, PP. 1-23, (1988); FANELLI C., ARONOFF R., RESTENOSIS FOLLOWING CORONARY ANGIOPLASTY, AM HEART J, 119, PP. 357-368, (1990); SILVER M.J., INGERMAN-WOJENSKI C.M., SEDAR A.W., SMITH M., MODEL SYSTEM TO STUDY INTERACTION OF PLATELETS WITH DAMAGED ARTERIAL WALL. I. INHIBITION OF PLATELET ADHESION TO SUBENDOTHELIUM BY ASPIRIN AND DIPYRIDAMOLE, EXP MOL PATHOL, 41, PP. 141-152, (1984); INGERMAN-WOJENSKI C.M., SILVER M.J., MODEL SYSTEM TO STUDY INTERACTION OF PLATELETS WITH DAMAGED ARTERIAL WALL. II. INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION BY DIPYRIDAMOLE AND AH-P719, EXP MOL PATHOL, 48, PP. 116-134, (1988); HAUST M.D., DERIVATION AND PROGRESSION OF ATHEROSCLEROTIC PLAQUE, INTERNATIONAL SYMPOSIUM OF ATHEROSCLEROSIS, PP. 25-28, (1983); CADROY Y., HARKER L., PLATELETS, THROMBOSIS AND ANTITHROMBOTIC THERAPIES, CARDIOVASCULAR PHARMACOLOGY, PP. 18-24, (1990); HLADOVEC J., ANTITHROMBOTIC DRUGS IN THROMBOSIS MODELS, (1989); ATKINSON D., HOOVER R., BERRY K., SWILT L., CHOLESTEROL-FED HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDEMIC RABBITS: A NEW MODEL FOR ATHEROSCLEROSIS, ATHEROSCLEROSIS, 79, PP. 123-136, (1989); DE CLERCK F., LOOTS W., SOMERS Y., VAN GORP L., VERHEYEN A., WOUTERS L., THROMBOXANE A<SUB>2</SUB>-INDUCED VASCULAR ENDOTHELIAL CELL DAMAGE AND RESPIRATORY SMOOTH MUSCLE CELL CONTRACTION: INHIBITION BY FLUNARIZINE, A CA-OVERLOAD BLOCKER, ARCH INT PHARMACODYN THER, 274, PP. 4-23, (1985); ZAMAN A., HELFT G., WORTHLEY S., BADIMON J., THE ROLE OF PLAQUE RUPTURE AND THROMBOSIS IN CORONARY ARTERY DISEASE, ATHEROSCLEROSIS, 49, PP. 251-266, (2000); ARRUZAZABALA M.L., CARBAJAL D., GARCIA M., LEVAMISOL: UN INHIBIDOR DE LA ENZIMA TROMBOXANO SINTETASA, REV LATINOAM TROMB HEMOST, 111, PP. 19-21, (1990); CARBAJAL D., GONZALEZ R., EFECTO DEL CNIC-4 (LOBENZARIT) COMO ANTAGONISTA DEL TX A<SUB>2</SUB>, REV CENIC CIEN BIOL, 21, PP. 2-3, (1990); ROTH G., CALVERLEY D., ASPIRIN, PLATELETS AND THROMBOSIS: THEORY AND PRACTICE, BLOOD, 83, PP. 885-898, (1994); HLADOVEC J., DE CLERCK F., PROTECTION BY FLUNARIZINE AGAINST ENDOTHELIAL CELL INJURY IN VIVO, ANGIOLOGY, 32, PP. 448-462, (1981); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARM RES, 16, PP. 67-72, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., M-S R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); SOMA M., CORSINI A., PAOLETTI R., CHOLESTEROL AND MEVALONIC ACID MODULATION IN CELL METABOLISM AND MULTIPLICATION, TOXICOL LETT, (1992); SOMA M., BAETTA R., DONNETTI E., PAOLETTI R., FUMAGALLI R., MODULATION OF THE MEVALONATE PATHWAY IN ATHEROSCLEROSIS AND TUMORS ABSTRACT, INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (1995); POMERANTZ K.B., HAJJAR D.P., EICOSANOIDS IN REGULATION OF ARTERIAL SMOOTH MUSCLE CELL PHENOTYPE, PROLIFERATIVE, CAPACITY AND CHOLESTEROL METABOLISM, ARTERIOSCLEROSIS, 9, PP. 413-429, (1989); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MATRISIAN L.M., THE MATRIX DEGRADING METALLOPROTEINASES, BIOESSAYS, 14, PP. 455-463, (1992); BENNETT M., EVAN G., SCHWARTZ S., APOPTOSIS OF HUMAN VASCULAR SMOOTH MUSCLE CELLS DERIVED FROM NORMAL VESSELS AND CORONARY ATHEROSCLEROTIC PLAQUES, J CLIN INVEST, 95, PP. 2266-2274, (1995); ANGELINI A., VISONA A., PETTENAZZO E., CALABRESE F., YACOUB A., PROLIFERATION AND CELLULAR DEATH (APOPTOSIS) IN AN ANIMAL MODEL OF ACCELERATED ATHEROSCLEROSIS, ATHEROSCLEROSIS, 134, PP. 267-276, (1997); BAR P.R., APOPTOSIS - THE CELL'S SILENT EXIT, LIFE SCI, 59, PP. 369-378, (1996); GHAVAMI S., BARCZYCK K., MADDIKA S., ET AL., MONITORING OF PROGRAMMED CELL DEATH IN VIVO AND IN VITRO - NEW AND OLD METHODS OF CANCER THERAPY ASSESSMENT, APOPTOTIC PATHWAYS AS TARGETS FOR NOVEL THERAPIES IN CANCER AND OTHER DISEASES, PP. 323-341, (2005); HARDWICK S.J., HEGYI L., CLARE K., APOPTOSIS IN HUMAN MONOCYTE-MACROPHAGES EXPOSED TO OXIDIZED LOW DENSITY LIPOPROTEIN, J PATHOL, 179, PP. 294-302, (1996)","M. NOA; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, HAVANA CITY, POST BOX 6990, CUBA; EMAIL: MIRIAM.NOA@CNIC.EDU.CU","","ENGLISH","J. MED. FOOD","ARTICLE","ISI","2-S2.0-34848911663","J MED FOOD","NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;ELECTRONIC MICROSCOPY","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"NOA M, 2007, J MED FOOD","NOA M, 2007, J MED FOOD"
"FONTANI G;LODI L;MIGLIORINI S;CORRADESCHI F","FONTANI, GIULIANO (7003337518); LODI, LEDA (7004903156); MIGLIORINI, SILVIA (23392970400); CORRADESCHI, FAUSTO (6603849315)","EFFECT OF OMEGA3 AND POLICOSANOL SUPPLEMENTATION ON ATTENTION AND REACTIVITY IN ATHLETES",2009,"JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION","28","8",29,"10.1080/07315724.2009.10718114","DEPARTMENT OF PHYSIOLOGY, UNIVERSITY OF SIENA, SIENA, ITALY;DEPARTMENT OF PHYSIOLOGY, UNIVERSITY OF SIENA, SIENA, ITALY;DEPARTMENT OF PHYSIOLOGY, UNIVERSITY OF SIENA, SIENA, ITALY;DEPARTMENT OF PHYSIOLOGY, UNIVERSITY OF SIENA, SIENA, ITALY","OBJECTIVE: THE PURPOSE OF THIS STUDY WAS TO DETERMINE THE EFFECT OF OMEGA-3 FATTY ACIDS AND POLICOSANOL SUPPLEMENTATION ON THE COGNITIVE PROCESSES INVOLVED IN THE CONTROL OF REACTIVITY IN KARATEKA ENGAGED IN ATTENTION TESTS. METHODS: EIGHTEEN KARATEKA WERE RANDOMLY ASSIGNED TO 2 GROUPS. ONE GROUP (10 SUBJECTS) TOOK THE SUPPLEMENT OF OMEGA-3 FATTY ACIDS (2.25 G) PLUS POLICOSANOL (10 MG) (O3 + P) FOR 21 DAYS, AND THE OTHER GROUP WAS SUPPLEMENTED WITH PLACEBO (OLEIC SUNFLOWER OIL). SUBJECTS WERE TESTED AT THE BEGINNING OF THE EXPERIMENT (TEST 1), AFTER 21 DAYS (TEST 2), AND AFTER 42 DAYS (TEST 3). THE EXPERIMENTAL PROCEDURE CONSISTED OF AN ALERT AND A SUSTAINED ATTENTION (SA) REACTION TIME TEST: THE SUBJECT HAD TO REACT BY PRESSING A KEY OF A COMPUTER KEYBOARD IN ALERT AND A SEQUENCE OF 3 KEYS IN SA IN RESPONSE TO STIMULI, ACTIVATING A COMPLEX GO/NO-GO PARADIGM. FOR EACH TEST, WE RECORDED THE REACTION TIME AND THE EVENT-RELATED POTENTIALS BY ELECTROENCEPHALOGRAM AND ELECTROMYOGRAPHY (EMG) OF THE FOREFINGER FLEXOR MUSCLE. THE PROFILE OF MOOD STATES (POMS) TEST WAS ALSO ADMINISTERED. RESULTS: AFTER 21 DAYS OF SUPPLEMENTATION, SUBJECTS WHO RECEIVED O3 + P SHOWED A REDUCED REACTION TIME AND INCREASED VIGOR SENSATION ASSOCIATED WITH A REDUCTION OF THE NEGATIVE STATES MEASURED WITH THE POMS TEST. ANALYSIS OF THE EVENT-RELATED BRAIN POTENTIALS SHOWED A REDUCED LATENCY OF THE MOVEMENT-RELATED BRAIN MACROPOTENTIALS. IN PARTICULAR, THE POTENTIALS RECORDED IN THE PREMOTOR PERIOD AND MOTOR PERIOD OCCURRED EARLIER AND THE LATENCY OF EMG ACTIVATION WAS REDUCED. IN THE THIRD TEST, 21 DAYS AFTER THE LAST O3 + P SUPPLEMENTATION, THE POSITIVE EFFECTS ON THE MOOD STATE PERSISTED, WHILE THE REACTION TIME, EMG, AND BRAIN POTENTIAL LATENCIES INCREASED, ALTHOUGH THEIR VALUES REMAINED LOWER THAN IN THE FIRST TEST. THE PLACEBO GROUP DID NOT SHOW ANY SIGNIFICANT DIFFERENCES IN TESTS 2 AND 3 COMPARED TO TEST 1 FOR EITHER POMS OR REACTIVITY AND BRAIN POTENTIALS. CONCLUSIONS: SUPPLEMENTATION WITH O3 + P MAY BE EFFECTIVE IN IMPROVING MOOD STATE AND REACTIVITY. THE REACTION TIME REDUCTION APPEARS TO BE DUE TO A CENTRAL NERVOUS SYSTEM EFFECT, AS SHOWN BY THE REDUCED LATENCY OF MOVEMENT-RELATED BRAIN MACROPOTENTIALS AND EMG ACTIVATION. THESE RESULTS ARE IN LINE WITH PREVIOUS EXPERIMENTS. © 2009 AMERICAN COLLEGE OF NUTRITION.","ATTENTION; MOVEMENT-RELATED BRAIN MACROPOTENTIALS; OMEGA-3; POLICOSANOL; REACTIVITY","ADULT; AFFECT; ATHLETES; ATTENTION; BRAIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EVOKED POTENTIALS; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT; MUSCLE, SKELETAL; NEUROTRANSMITTER AGENTS; PATTERN RECOGNITION, VISUAL; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SPORTS; YOUNG ADULT; HELIANTHUS; OLEIC ACID; OMEGA 3 FATTY ACID; POLICOSANOL; SUNFLOWER OIL; ADULT; ALERTNESS; ARTICLE; ATHLETE; ATTENTION; COGNITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EVENT RELATED POTENTIAL; EVOKED MUSCLE RESPONSE; FEMALE; FLEXOR MUSCLE; HAND MUSCLE; HUMAN; HUMAN EXPERIMENT; KEYBOARD; LATENT PERIOD; MALE; MOOD; NORMAL HUMAN; PROFILE OF MOOD STATES; RESPONSE TIME; SENSATION; SPORTS MEDICINE; STIMULUS RESPONSE","","","JHO D.H., COLE S.M., LEE E.M., ESPAT N.J., ROLE OF OMEGA-3 FATTY ACID SUPPLEMENTATION IN INFLAMMATION AND MALIGNANCY, INTEGR CANCER THER, 3, PP. 98-111, (2004); LARSSON S.C., KUMLIN M., SUNDBERG M.I., WOLK A., DIETARY LONG-CHAIN OMEGA-3 FATTY ACIDS FOR THE PREVENTION OF CANCER: A REVIEW OF POTENTIAL MECHANISMS, AM J CLIN NUTR, 79, PP. 935-945, (2004); LOPEZ P.M., ORTEGA R.M., OMEGA-3 FATTY ACIDS IN THE PREVENTION AND CONTROL OF CARDIOVASCULAR DISEASE, EUR J CLIN NUTR, 57, PP. 22-25, (2003); YEHUDA S., RABINOVITZ S., CRASSO R.L., MOSTOFSKY D.I., THE ROLE OF POLYUNSATURATED FATTY ACIDS IN RESTORING THE AGING NEURONAL MEMBRANE, NEUROBIOL AGING, 23, PP. 843-853, (2002); HAAG M., ESSENTIAL FATTY ACIDS AND THE BRAIN, CAN J PSYCHIATRY, 48, PP. 195-203, (2003); PIOMELLI D., EICOSANOIDS IN SYNAPTIC TRANSMISSION, CRIT REV NEUROBIOL, 8, PP. 65-83, (1994); PIOMELLI D., PILON C., GIROS B., SOKOLOFF P., MARTRES M.P., SCHWARTZ Y.C., DOPAMINE ACTIVATION OF THE ARACHIDONIC ACID CASCADE AS A BASIS FOR D1/D2 RECEPTOR SYNERGISM, NATURE, 353, PP. 164-167, (1991); MARTIN R.E., BAZAN N.G., CHANGING FATTY ACID CONTENT OF GROWTH CONE LIPIDS PRIOR TO SYNAPTOGENESIS, J NEUROCHEM, 59, PP. 318-325, (1992); JONES C.R., ARAI T., RAPOPORT S.I., EVIDENCE FOR THE INVOLVEMENT OF DOCOSAHEXANOIC ACID IN CHOLINERGIC STIMULATED SIGNAL TRANSDUCTION AT THE SYNAPSE, NEUROCHEM RES, 22, PP. 663-670, (1997); WAINWRIGHT P.E., DIETARY ESSENTIAL FATTY ACIDS AND BRAIN FUNCTION: A DEVELOPMENTAL PERSPECTIVE ON MECHANISM, PROC NUTR SOC, 61, PP. 61-69, (2002); TAKEUCHI T., FUKUMOTOY, HARADA E: INFLUENCE OF A DIETARY OMEGA-3 FATTY ACID DEFICIENCY ON THE CEREBRAL CATECHOLAMINE CONTENTS, EEG AND LEARNING ABILITY IN RAT, BEHAV BRAIN RES, 131, PP. 193-203, (2002); YOSHIDA S., YASUDA A., KAWAZATO H., SAKAI K., SHIMADA T., TAKESHITA M., YUASA S., KOBAYASHI T., WATANABE S., OKUYAMA H., SYNAPTIC VESICLE ULTRASTRUCTURAL CHANGES IN THE RAT HIPPOCAMPUS INDUCED BY A COMBINATION OF ALPHA-LINOLENATE DEFICIENCY AND LEARNING TASK, J NEUROCHEM, 68, PP. 1261-1268, (1997); KALMIJN S., VAN BOXTEL M., OCKE M., VERSCHUREN W., KROMHOUT D., LAURNER L.J., DIETARY INTAKE OF FATTY ACIDS AND FISH IN RELATION TO COGNITIVE PERFORMANCE AT MIDDLE AGE, NEUROLOGY, 62, PP. 275-280, (2004); FABRIGOULE C., ROUCH I., TABERLY A., LETENNEUR L., COMMENGES D., MAXAUS J.M., ORGOGOZO J.M., DARTIGUES J.F., COGNITIVE PROCESS IN PRECLINICAL PHASE OF DEMENTIA, BRAIN, 121, PP. 135-141, (1998); FREEMAN M.P., OMEGA-3 FATTY ACIDS IN PSYCHIATRY: A REVIEW, ANN CLIN PSYCHIATRY, 12, PP. 159-165, (2000); ZIMMERMANN P., FIMM B., BATTERY OF TESTS FOR THE STUDY OF ATTENTION (TAP), WU˝RSELEN, GERMANY: PSYTEST, PP. 1-73, (1992); STOLL A.L., SEVERUS W.E., FREEMAN M.P., RUETER S., ZBOYAN H.A., DIAMOND E., CRESS K.K., MARANGELL L.B., OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER: A PRELIMINARY DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ARCH GEN PSYCHIATRY, 56, PP. 407-412, (1999); SILVERS K.M., SCOTT K.M., FISH CONSUMPTION AND SELF PHYSICAL AND MENTAL HEALTH STATUS, PUBLIC HEALTH NUTR, 5, PP. 427-431, (2002); FONTANI G., CORRADESCHI F., FELICI A., ALFATTI F., MIGLIORINI S., LODI L., COGNITIVE AND PHYSIOLOGICAL EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION IN HEALTHY SUBJECTS, EUR J CLIN INVEST, 35, PP. 691-699, (2005); MENENDEZ R., ARRUZZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); FONTANI G., MAFFEI D., LODI L., POLICOSANOL, REACTION TIME AND EVENTRELATED POTENTIALS, NEUROPSYCHOBIOLOGY, 41, PP. 158-165, (2000); KORNHUBER H.H., DEECKE L., HIMPOTENTIALANDERUNGEN BEI WILLKÜRBEWEGUNGEN UND PASSIVEN BEWEGUNGEN DES MENSCHEN: BEREITSCHAFTSPOTENTIAL UND REAFFERENTE POTENTIAL, PFLÜGERS ARCHIV, 284, PP. 1-17, (1965); SHIBASAKI H., BARRET G., HALLIDAY E., HALLIDAY A.M., COMPONENTS OF THE MOVEMENT-RELATED CORTICAL POTENTIALS AND THEIR SCALP TOPOGRAPHY, ELECTROENCEPH CLIN NEUROPHYSIOL, 49, PP. 213-226, (1980); CHIARENZA G.A., A CRITICAL REVIEW OF PHYSIOLOGICAL AND CLINICAL ASPECTS OF MOVEMENT-RELATED BRAIN MACROPOTENTIALS IN HUMANS, ITAL J NEUROL SCI, 12, PP. 17-30, (1991); CHIARENZA G.A., PAPAKOSTOPOULOS D., GIORDANA F., GUARESCHI CAZZULLO A., MOVEMENT-RELATED BRAIN MACROPOTENTIALS DURING SKILLED PERFORMANCES: A DEVELOPMENTAL STUDY, ELECTROENCEPH CLIN NEUROPHYSIOL, 56, PP. 373-383, (1983); CHIARENZA G.A., ELECTROPHYSIOLOGY OF SKILLED PERFORMANCES IN CHILDREN, ITAL J NEUROL SCI, 5, PP. 155-162, (1986); FONTANI G., MIGLIORINI S., BENOCCI R., FACCHINI A., CASINI M., CORRADESCHI F., EFFECT OF MENTAL IMAGERY ON THE DEVELOPMENT OF SKILLED MOTOR ACTIONS, PERCEPT MOTOR SKILLS, 105, PP. 803-826, (2007); MCNAIR D.M., LORR M., DROPPLEMAN L.F., MANUAL OF THE PROFILE OF THE MOOD STATES., (1981); FONTANI G., MAFFEI D., CAMELI S., POLIDORI F., REACTIVITY AND EVENTRELATED POTENTIALS DURING ATTENTIONAL TESTS IN ATHLETES, EUR J APPL PHYSIOL, 80, PP. 308-317, (1999); FONTANI G., LODI L., FELICI A., CORRADESCHI F., LUPO C., ATTENTIONAL, EMOTIONAL AND HORMONAL DATA IN SUBJECTS OF DIFFERENT AGES, EUR J APPL PHYSIOL, 92, PP. 452-461, (2004); FATTAPPOSTA F., AMABILE G., CORDISCHI M.V., DI VENEZIO D., FOTI A., PIERELLI F., D'ALESSIO C., PIGOZZI F., PARISI A., MORROCUTTI C., LONGTERM PRACTICE EFFECTS ON A NEW SKILLED MOTOR LEARNING: AN ELECTROPHYSIOLOGICAL STUDY, ELECTROENCEPH CLIN NEUROPHYSIOL, 99, PP. 495-507, (1996); RANGANATHAN V., SIEMIONOW V., LIU Z., SAHGAL V., YUE G., FROM MENTAL POWER TO MUSCLE POWER—GAINING STRENGTH BY USING THE MIND, NEUROPSYCHOLOGIA, 42, PP. 944-956, (2004); WASSERMAN L., ALL OF NONPARAMETRIC STATISTICS., (2006); FONTANI G., CORRADESCHI F., FELICI A., ALFATTI F., BUGARINI R., FIASCHI A.I., CERRETANI D., MONTORFANO G., RIZZO A.M., BERRA B., BLOOD PROFILES, BODY FAT AND MOOD STATE IN HEALTHY SUBJECTS ON DIFFERENT DIETS SUPPLEMENTED WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS, EUR J CLIN INVEST, 35, PP. 499-507, (2005); DI RUSSO F., PITZALIS S., APRILE T., SPINELLI D., EFFECT OF PRACTICE ON BRAIN ACTIVITY: AN INVESTIGATION IN TOP-LEVEL RIFLE SHOOTERS, MED SCI SPORTS EXERC, 37, PP. 1586-1593, (2005); DEECKE L., SCHEID P., KORNHUBER H.H., DISTRIBUTION OF READINESS POTENTIAL, PRE-MOTION POSITIVITY, AND MOTOR POTENTIAL OF THE HUMAN CEREBRAL CORTEX PRECEDING VOLUNTARY FINGER MOVEMENTS, EXP BRAIN RES, 7, PP. 158-168, (1969); PAPAKOSTOPOULOS D., STAMLER R., NEWTON P., MOVEMENT-RELATED BRAIN MACROPOTENTIALS DURING SELF-PACED SKILLED PERFORMANCE WITH AND WITHOUT KNOWLEDGE OF RESULTS, CEREBRAL PSYCHOPHYSIOLOGY: STUDIES IN EVENT-RELATED POTENTIALS, PP. 261-262, (1986); RYBACK R., BIOELECTRICAL MODULATORS AND THE CELL MEMBRANE IN PSYCHIATRIC MEDICINE, PSYCOPHARMACOL BULL, 35, PP. 5-44, (2001); CURETON T.K., THE PHYSIOLOGICAL EFFECTS OF WHEAT GERM OIL ON HUMANS IN EXERCISE., (1972); FONTANI G., LODI L., FELICI A., MIGLIORINI S., CORRADESCHI F., ATTENTION IN ATHLETES OF HIGH AND LOW EXPERIENCE ENGAGED IN DIFFERENT OPEN SKILL SPORTS, PERCEPT MOTOR SKILLS, 102, PP. 791-805, (2006)","G. FONTANI; DEPARTMENT OF PHYSIOLOGY, UNIVERSITY OF SIENA, SIENA, I-53100, VIA A. MORO 2, ITALY; EMAIL: FONTANIG@UNISI.IT","","ENGLISH","J. AM. COLL. NUTR.","ARTICLE","ISI","2-S2.0-77951610298","J AM COLL NUTR","UNIVERSITY OF SIENA;UNIVERSITY OF SIENA;UNIVERSITY OF SIENA;UNIVERSITY OF SIENA","NOTREPORTED;UNIVERSITY OF SIENA;NOTREPORTED",NA,"FONTANI G, 2009, J AM COLL NUTR","FONTANI G, 2009, J AM COLL NUTR"
"REINER Ž;CATAPANO A;DE B G;GRAHAM I;TASKINEN M;WIKLUND O;AGEWALL S;ALEGRIA E;CHAPMAN M;DURRINGTON P;ERDINE S;HALCOX J;HOBBS R;KJEKSHUS J;FILARDI P;RICCARDI G;STOREY R;WOOD D","REINER, ŽELJKO (55411641000); CATAPANO, ALBERICO L. (7006246941); DE BACKER, GUY (24288352300); GRAHAM, IAN (35373661800); TASKINEN, MARJA-RIITTA (57193256111); WIKLUND, OLOV (7005459783); AGEWALL, STEFAN (7006435302); ALEGRIA, EDUARDO (7005803441); CHAPMAN, M. JOHN (7401435980); DURRINGTON, PAUL (7101726771); ERDINE, SERAP (56235521000); HALCOX, JULIAN (6603008454); HOBBS, RICHARD (7005778918); KJEKSHUS, JOHN (7103357258); FILARDI, PASQUALE PERRONE (56830643800); RICCARDI, GABRIELE (7102385746); STOREY, ROBERT F. (7101733693); WOOD, DAVID (14627040300)","ESCEAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS",2011,"EUROPEAN HEART JOURNAL","32","49",2638,"10.1093/eurheartj/ehr158","UNIVERSITY HOSPITAL CENTER ZAGREB, SCHOOL OF MEDICINE, UNIVERSITY OF ZAGREB, 10 000 ZAGREB, SALATA 2, CROATIA; CATAPANO A.L.; DE BACKER G.; GRAHAM I.; TASKINEN M.-R.; WIKLUND O.; AGEWALL S.; ALEGRIA E.; CHAPMAN M.J.; DURRINGTON P.; ERDINE S.; HALCOX J.; HOBBS R.; KJEKSHUS J.; FILARDI P.P.; RICCARDI G.; STOREY R.F.; WOOD D.","[NO ABSTRACT AVAILABLE]","CARDIOVASCULAR DISEASES; CHOLESTEROL; DYSLIPIDAEMIA; GUIDELINES; TREATMENT; TRIGLYCERIDES","ADULT; CARDIOVASCULAR DISEASES; CHILD; DIET; DIETARY FATS; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; EARLY DIAGNOSIS; ENERGY INTAKE; EXERCISE; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; LIFE STYLE; LIPID METABOLISM; MALE; PATIENT COMPLIANCE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SPECIMEN HANDLING; TRANSPLANTATION; WEIGHT LOSS; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CHOLESTIN; CIPROFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PITAVASTATIN; PLACEBO; POLICOSANOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SOYBEAN PROTEIN; SWEETENING AGENT; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; ABDOMINAL AORTA ANEURYSM; ACANTHOSIS NIGRICANS; ACUTE CORONARY SYNDROME; ACUTE PANCREATITIS; ALCOHOL ABSTINENCE; ALZHEIMER DISEASE; ANTIPHOSPHOLIPID SYNDROME; AORTA STENOSIS; APHERESIS; BLEEDING; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREAL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; COOKING; CORONARY ARTERY DISEASE; DAIRY PRODUCT; DIABETES MELLITUS; DIET RESTRICTION; DIETARY FIBER; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; EGG; FISH MEAT; FLATULENCE; FRUIT; GENOTYPE; HEART FAILURE; HIGH FIBER DIET; HIGH RISK PATIENT; HORMONAL THERAPY; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEGUME; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID METABOLISM; LIVER TOXICITY; LOW FAT DIET; MEDICAL SOCIETY; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; MYALGIA; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUT; PARTICLE SIZE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; RETINA ARTERY OCCLUSION; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VEGETABLE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION","EUROPEAN SOCIETY OF CARDIOLOGY, ESC","THE EXPERTS OF THE WRITING AND REVIEWING PANELS FILLED IN DECLARATIONS OF INTEREST FORMS OF ALL RELATIONSHIPS WHICH MIGHT BE PERCEIVED AS REAL OR POTENTIAL SOURCES OF CONFLICTS OF INTEREST. THESE FORMS WERE COMPILED INTO ONE FILE AND CAN BE FOUND ON THE ESC WEBSITE (HTTP://WWW.ESCARDIO.ORG/GUIDELINES). ANY CHANGES IN DECLARATIONS OF INTEREST THAT ARISE DURING THE WRITING PERIOD MUST BE NOTIFIED TO THE ESC AND UPDATED. THE TASK FORCE RECEIVED ITS ENTIRE FINANCIAL SUPPORT FROM THE ESC WITHOUT ANY INVOLVEMENT FROM THE HEALTHCARE INDUSTRY.","ALLENDER S., SCARBOROUGH P., PETO V., RAYNER M., LEAL J., LUENGO-FERNANDEZ R., GRAY A., EUROPEAN CARDIOVASCULAR DISEASE STATISTICS 2008, EUROPEAN HEART NETWORK, (2008); PYORALA K., DE BACKER G., GRAHAM I., POOLE-WILSON P., WOOD D., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY EUROPEAN ATHEROSCLEROSIS SOCIETY EUROPEAN SOCIETY OF HYPERTENSION, ATHEROSCLEROSIS, 110, PP. 121-161, (1994); WOOD D., DE BACKER G., FAERGEMAN O., GRAHAM I., MANCIA G., PYORALA K., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUROPEAN HEART JOURNAL, 19, 10, PP. 1434-1503, (1998); DE BACKER G., AMBROSIONI E., BORCH-JOHNSEN K., BROTONS C., CIFKOVA R., DALLONGEVILLE J., EBRAHIM S., FAERGEMAN O., GRAHAM I., MANCIA G., CATS V.M., ORTH-GOMER K., PERK J., PYORALA K., RODICIO J.L., SANS S., SANSOY V., SECHTEM U., SILBER S., THOMSEN T., WOOD D., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: THIRD JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF EIGHT SOCIETIES AND BY INVITED EXPERTS), EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION AND REHABILITATION, 10, SUPPL. 1, (2003); GRAHAM I., ATAR D., BORCH-JOHNSEN K., BOYSEN G., BURELL G., CIFKOVA R., DALLONGEVILLE J., DE BACKER G., EBRAHIM S., GJELSVIK B., HERRMANN-LINGEN C., HOES A., HUMPHRIES S., KNAPTON M., PERK J., PRIORI S.G., PYORALA K., REINER Z., RUILOPE L., SANS-MENENDEZ S., OP REIMER W.S., WEISSBERG P., WOOD D., YARNELL J., ZAMORANO J.L., WALMA E., FITZGERALD T., COONEY M.T., DUDINA A., VAHANIAN A., CAMM J., DE CATERINA R., DEAN V., DICKSTEIN K., FUNCK-BRENTANO C., FILIPPATOS G., HELLEMANS I., KRISTENSEN S.D., MCGREGOR K., SECHTEM U., SILBER S., TENDERA M., WIDIMSKY P., ZAMORANO J.L., ALTINER A., BONORA E., DURRINGTON P.N., FAGARD R., GIAMPAOLI S., HEMINGWAY H., HAKANSSON J., KJELDSEN S.E., LARSEN L., MANCIA G., MANOLIS A.J., ORTH-GOMER K., PEDERSEN T., RAYNER M., RYDEN L., SAMMUT M., SCHNEIDERMAN N., STALENHOEF A.F., TOKGOZOGLU L., WIKLUND O., ZAMPELAS A., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: FOURTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES, EUR. J. CARDIOVASC. PREV. REHABIL., 14, 2, (2007); COONEY M.T., DUDINA A.L., GRAHAM I.M., VALUE AND LIMITATIONS OF EXISTING SCORES FOR THE ASSESSMENT OF CARDIOVASCULAR RISK A REVIEW FOR CLINICIANS, J. AM. COLL. CARDIOL., 54, PP. 1209-1227, (2009); COONEY M.T., DUDINA A., D'AGOSTINO R., GRAHAM I.M., CARDIOVASCULAR RISK ESTIMATION SYSTEMS IN PRIMARY PREVENTION DO THEY DIFFER DO THEY MAKE A DIFFERENCE CAN WE SEE THE FUTURE, CIRCULATION, 122, PP. 300-310, (2010); CONROY R.M., PYORALA K., FITZGERALD A.P., SANS S., MENOTTI A., DE BACKER G., DE BACQUER D., DUCIMETIERE P., JOUSILAHTI P., KEIL U., NJOLSTAD I., OGANOV R.G., THOMSEN T., TUNSTALL-PEDOE H., TVERDAL A., WEDEL H., WHINCUP P., WITHEIMSEN L., GRAHAM I.M., ESTIMATION OF TEN-YEAR RISK OF FATAL CARDIOVASCULAR DISEASE IN EUROPE: THE SCORE PROJECT, EUROPEAN HEART JOURNAL, 24, 11, PP. 987-1003, (2003); D'AGOSTINO SR. R.B., VASAN R.S., PENCINA M.J., WOLF P.A., COBAIN M., MASSARO J.M., KANNEL W.B., GENERAL CARDIOVASCULAR RISK PROFILE FOR USE IN PRIMARY CARE: THE FRAMINGHAM HEART STUDY, CIRCULATION, 117, 6, PP. 743-753, (2008); COONEY M., DUDINA A., BACQUER D.D., FITZGERALD A., CONROY R., SANS S., MENOTTI A., BACKER G.D., JOUSILAHTI P., KEIL U., THOMSEN T., WHINCUP P., GRAHAM I., HOW MUCH DOES HDL CHOLESTEROL ADD TO RISK ESTIMATION A REPORT FROM THE SCORE INVESTIGATORS, EUR. J. CARDIOVASC. PREV. REHABIL., 16, PP. 304-314, (2009); COONEY M.T., DUDINA A., DE BACQUER D., WILHELMSEN L., SANS S., MENOTTI A., DE BACKER G., JOUSILAHTI P., KEIL U., THOMSEN T., WHINCUP P., GRAHAM I M., HDL CHOLESTEROL PROTECTS AGAINST CARDIOVASCULAR DISEASE IN BOTH GENDERS AT ALL AGES AND AT ALL LEVELS OF RISK, ATHEROSCLEROSIS, 206, PP. 611-616, (2009); BANSAL S., BURING J.E., RIFAI N., MORA S., SACKS F.M., RIDKER P.M., FASTING COMPARED WITH NONFASTING TRIGLYCERIDES AND RISK OF CARDIOVASCULAR EVENTS IN WOMEN, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 298, 3, PP. 309-316, (2007); BASSAND J.P., HAMM C.W., ARDISSINO D., BOERSMA E., BUDAJ A., FERNANDEZ-AVILES F., FOX K.A., HASDAI D., OHMAN E.M., WALLENTIN L., WIJNS W., GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES, EUR. HEART J., 28, PP. 1598-1660, (2007); VAN DE WERF F., BAX J., BETRIU A., BLOMSTROM-LUNDQVIST C., CREA F., FALK V., FILIPPATOS G., FOX K., HUBER K., KASTRATI A., ROSENGREN A., STEG P.G., TUBARO M., VERHEUGT F., WEIDINGER F., WEIS M., MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION: THE TASK FORCE ON THE MANAGEMENT OF ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUR. HEART J., 29, PP. 2909-2945, (2008); COLLABORATION EFFICACY AND SAFETY OF MORE INTENSIVE LOWERING OF LDL CHOLESTEROL: A META-ANALYSIS OF DATA FROM 170000 PARTICIPANTS IN 26 RANDOMISED TRIALS, LANCET, 376, PP. 1670-1681, (2010); BRUGTS J.J., YETGIN T., HOEKS S.E., GOTTO A.M., SHEPHERD J., WESTENDORP R.G., DE CRAENA.J., KNOPP R.H., NAKAMURA H., RIDKER P., VAN DOMBURG R., DECKERS J.W., THE BENEFITS OF STATINS IN PEOPLE WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE BUT WITH CARDIOVASCULAR RISK FACTORS: META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, BMJ, 338, (2009); MILLS E.J., RACHLIS B., WU P., DEVEREAUX P.J., ARORA P., PERRI D., PRIMARY PREVENTION OF CARDIOVASCULAR MORTALITY AND EVENTS WITH STATIN TREATMENTS A NETWORK META-ANALYSIS INVOLVING MORE THAN 65000 PATIENTS, J. AM. COLL. CARDIOL., 52, PP. 1769-1781, (2008); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY 4S, LANCET, 344, PP. 1383-1389, (1994); SHEPHERD J., COBBE S.M., FORD I., ISLES C.G., LORIMER A.R., MACFARLANE P.W., MCKILLOP J.H., PACKARD C.J., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); LEWIS S.J., MOYE L.A., SACKS F.M., JOHNSTONE D.E., TIMMIS G., MITCHELL J., LIMACHER M., KELL S., GLASSER S.P., GRANT J., DAVIS B.R., PFEFFER M.A., BRAUNWALD E., EFFECT OF PRAVASTATIN ON CARDIOVASCULAR EVENTS IN OLDER PATIENTS WITH MYOCARDIAL INFARCTION AND CHOLESTEROL LEVELS IN THE AVERAGE RANGE: RESULTS OF THE CHOLESTEROL AND RECURRENT EVENTS (CARE) TRIAL, ANNALS OF INTERNAL MEDICINE, 129, 9, PP. 681-689, (1998); DOWNS J.R., CLEARFIELD M., WEIS S., WHITNEY E., SHAPIRO D.R., BEERE P.A., LANGENDORFER A., STEIN E.A., KRUYER W., GOTTO JR. A.M., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 279, 20, PP. 1615-1622, (1998); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, PP. 1349-1357, (1998); SCHWARTZ G.G., OLSSON A.G., EZEKOWITZ M.D., GANZ P., OLIVER M.F., WATERS D., ZEIHER A., CHAITMAN B.R., LESLIE S., STERN T., EFFECTS OF ATORVASTATIN ON EARLY RECURRENT ISCHEMIC EVENTS IN ACUTE CORONARY SYNDROMES THE MIRACL STUDY: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 285, 13, PP. 1711-1718, (2001); SERRUYS P.W.J.C., DE FEYTER P., MACAYA C., KOKOTT N., PUEL J., VROLIX M., BRANZI A., BERTOLAMI M.C., JACKSON G., STRAUSS B., MEIER B., FLUVASTATIN FOR PREVENTION OF CARDIAC EVENTS FOLLOWING SUCCESSFUL FIRST PERCUTANEOUS CORONARY INTERVENTION: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 287, 24, PP. 3215-3222, (2002); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20 536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., BOLLEN E.L.E.M., BUCKLEY B.M., COBBE S.M., FORD I., GAW A., HYLAND M., JUKEMA J.W., KAMPER A.M., MACFARLANE P.W., MEINDERS A.E., NORRIE J., PACKARD C.J., PERRY I.J., STOTT D.J., SWEENEY B.J., TWOMEY C., WESTENDORP R.G.J., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED TRIAL, LANCET, 360, 9346, PP. 1623-1630, (2002); HOLDAAS H., FELLSTROM B., JARDINE A.G., HOLME I., NYBERG G., FAUCHALD P., GRONHAGEN-RISKA C., MADSEN S., NEUMAYER H.-H., COLE E., MAES B., AMBUHL P., OLSSON A.G., HARTMANN A., SOLBU D.O., PEDERSEN T.R., EFFECT OF FLUVASTATIN ON CARDIAC OUTCOMES IN RENAL TRANSPLANT RECIPIENTS: A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED TRIAL, LANCET, 361, 9374, PP. 2024-2031, (2003); SEVER P.S., DAHLOF B., POULTER N.R., WEDEL H., BEEVERS G., CAULFIELD M., COLLINS R., KJELDSEN S.E., KRISTINSSON A., MCINNES G.T., MEHLSEN J., NIEMINEN M., O'BRIEN E., OSTERGREN J., PREVENTION OF CORONARY AND STROKE EVENTS WITH ATORVASTATIN IN HYPERTENSIVE PATIENTS WHO HAVE AVERAGE OR LOWER-THAN-AVERAGE CHOLESTEROL CONCENTRATIONS, IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL - LIPID LOWERING ARM (ASCOT-LLA): A MULTICENTRE RANDOMISED CONTROLLED TRIAL, LANCET, 361, 9364, PP. 1149-1158, (2003); COLHOUN H.M., BETTERIDGE D.J., DURRINGTON P.N., HITMAN G.A., NEIL H.A.W., LIVINGSTONE S.J., THOMASON M.J., MACKNESS M.I., CHARLTON-MENYS V., FULLER J.H., PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE WITH ATORVASTATIN IN TYPE 2 DIABETES IN THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS): MULTICENTRE RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 364, 9435, PP. 685-696, (2004); DE LEMOS J.A., BLAZING M.A., WIVIOTT S.D., LEWIS E.F., FOX K.A.A., WHITE H.D., ROULEAU J.-L., PEDERSEN T.R., GARDNER L.H., MUKHERJEE R., RAMSEY K.E., PALMISANO J., BILHEIMER D.W., PFEFFER M.A., CALIFF R.M., BRAUNWALD E., EARLY INTENSIVE VS A DELAYED CONSERVATIVE SIMVASTATIN STRATEGY IN PATIENTS WITH ACUTE CORONARY SYNDROMES: PHASE Z OF THE A TO Z TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 292, 11, PP. 1307-1316, (2004); WANNER C., KRANE V., MARZ W., OLSCHEWSKI M., MANN J.F.E., RUF G., RITZ E., ATORVASTATIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNDERGOING HEMODIALYSIS, NEW ENGLAND JOURNAL OF MEDICINE, 353, 3, PP. 238-248, (2005); PEDERSEN T.R., FAERGEMAN O., KASTELEIN J.J.P., OLSSON A.G., TIKKANEN M.J., HOLME I., LARSEN M.L., BENDIKSEN F.S., LINDAHL C., SZAREK M., TSAI J., HIGH-DOSE ATORVASTATIN VS USUAL-DOSE SIMVASTATIN FOR SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION: THE IDEAL STUDY: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 294, 19, PP. 2437-2445, (2005); LAROSA J.C., GRUNDY S.M., WATERS D.D., SHEAR C., BARTER P., FRUCHART J.-C., GOTTO A.M., GRETEN H., KASTELEIN J.J.P., SHEPHERD J., WENGER N.K., INTENSIVE LIPID LOWERING WITH ATORVASTATIN IN PATIENTS WITH STABLE CORONARY DISEASE, NEW ENGLAND JOURNAL OF MEDICINE, 352, 14, PP. 1425-1435, (2005); AMARENCO P., BOGOUSSLAVSKY J., CALLAHAN III A., GOLDSTEIN L.B., HENNERICI M., RUDOLPH A.E., SILLESEN H., SIMUNOVIC L., SZAREK M., WELCH K.M.A., ZIVIN J.A., HIGH-DOSE ATORVASTATIN AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK, NEW ENGLAND JOURNAL OF MEDICINE, 355, 6, PP. 549-559, (2006); RAY K.K., CANNON C.P., MCCABE C.H., CAIRNS R., TONKIN A.M., SACKS F.M., JACKSON G., BRAUNWALD E., EARLY AND LATE BENEFITS OF HIGH-DOSE ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PROVE IT-TIMI 22 TRIAL, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 46, 8, PP. 1405-1410, (2005); KJEKSHUS J., APETREI E., BARRIOS V., BOHM M., CLELAND J.G.F., CORNEL J.H., DUNSELMAN P., FONSECA C., GOUDEV A., GRANDE P., GULLESTAD L., HJALMARSON A., HRADEC J., JANOSI A., KAMENSKY G., KOMAJDA M., KOREWICKI J., KUUSI T., MACH F., MAREEV V., MCMURRAY J.J.V., RANJITH N., SCHAUFELBERGER M., VANHAECKE J., VAN VELDHUISEN D.J., WAAGSTEIN F., WEDEL H., WIKSTRAND J., ROSUVASTATIN IN OLDER PATIENTS WITH SYSTOLIC HEART FAILURE, NEW ENGLAND JOURNAL OF MEDICINE, 357, 22, PP. 2248-2261, (2007); RIDKER P.M., DANIELSON E., FONSECA F.A., GENEST J., GOTTO JR. A.M., KASTELEIN J.J., KOENIG W., LIBBY P., LORENZATTI A.J., MACFADYEN J.G., NORDESTGAARD B.G., SHEPHERD J., WILLERSON J.T., GLYNN R.J., ROSUVASTATIN TO PREVENT VASCULAR EVENTS IN MEN AND WOMEN WITH ELEVATED C-REACTIVE PROTEIN, N. ENGL. J. MED., 359, PP. 2195-2207, (2008); ROSSEBO A.B., PEDERSEN T.R., BOMAN K., BRUDI P., CHAMBERS J.B., EGSTRUP K., GERDTS E., GOHLKE-BARWOLF C., HOLME I., KESANIEMI Y.A., MALBECQ W., NIENABER C.A., RAY S., SKJAERPE T., WACHTELL K., WILLENHEIMER R., INTENSIVE LIPID LOWERING WITH SIMVASTATIN AND EZETIMIBE IN AORTIC STENOSIS, N. ENGL. J. MED., 359, PP. 1343-1356, (2008); TAVAZZI L., MAGGIONI A.P., MARCHIOLI R., BARLERA S., FRANZOSI M.G., LATINI R., LUCCI D., NICOLOSI G.L., PORCU M., TOGNONI G., EFFECT OF ROSUVASTATIN IN PATIENTS WITH CHRONIC HEART FAILURE THE GISSI-HF TRIAL: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL, LANCET, 372, PP. 1231-1239, (2008); FELLSTROM B.C., JARDINE A.G., SCHMIEDER R.E., HOLDAAS H., BANNISTER K., BEUTLER J., CHAE D.W., CHEVAILE A., COBBE S.M., GRONHAGEN-RISKA C., DE LIMA J.J., LINS R., MAYER G., MCMAHON A.W., PARVING H.H., REMUZZI G., SAMUELSSON O., SONKODI S., SCI D., SULEYMANLAR G., TSAKIRIS D., TESAR V., TODOROV V., WIECEK A., WUTHRICH R.P., GOTTLOW M., JOHNSSON E., ZANNAD F., ROSUVASTATIN AND CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING HEMODIALYSIS, N. ENGL. J. MED., 360, PP. 1395-1407, (2009); TAYLOR F., WARD K., MOORE T.H., BURKE M., DAVEY SMITH G., CASAS J.P., EBRAHIM S., STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST. REV., 1, (2011); MAJOR LIPIDS APOLIPOPROTEINS AND RISK OF VASCULAR DISEASE, JAMA, 302, PP. 1993-2000, (2009); LANGSTED A., FREIBERG J.J., NORDESTGAARD B.G., FASTING AND NONFASTING LIPID LEVELS: INFLUENCE OF NORMAL FOOD INTAKE ON LIPIDS LIPOPROTEINS APOLIPOPROTEINS AND CARDIOVASCULAR RISK PREDICTION, CIRCULATION, 118, PP. 2047-2056, (2008); ROBINSON J.G., WANG S., SMITH B.J., JACOBSON T.A., META-ANALYSIS OF THE RELATIONSHIP BETWEEN NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND CORONARY HEART DISEASE RISK, J. AM. COLL. CARDIOL., 53, PP. 316-322, (2009); NORDESTGAARD B.G., BENN M., SCHNOHR P., TYBJAERG-HANSEN A., NONFASTING TRIGLYCERIDES AND RISK OF MYOCARDIAL INFARCTION, ISCHEMIC HEART DISEASE, AND DEATH IN MEN AND WOMEN, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 298, 3, PP. 299-308, (2007); CHARLTON-MENYS V., BETTERIDGE D.J., COLHOUN H., FULLER J., FRANCE M., HITMAN G.A., LIVINGSTONE S.J., NEIL H.A., NEWMAN C.B., SZAREK M., DEMICCO D.A., DURRINGTON P.N., TARGETS OF STATIN THERAPY: LDL CHOLESTEROL NON-HDL CHOLESTEROL AND APOLIPOPROTEIN B IN TYPE 2 DIABETES IN THE COLLABORATIVE ATORVASTATIN DIABETES STUDY CARDS, CLIN. CHEM., 55, PP. 473-480, (2009); TASKINEN M.R., BARTER P.J., EHNHOLM C., SULLIVAN D.R., MANN K., SIMES J., BEST J.D., HAMWOOD S., ABILITY OF TRADITIONAL LIPID RATIOS AND APOLIPOPROTEIN RATIOS TO PREDICT CARDIOVASCULAR RISK IN PEOPLE WITH TYPE 2 DIABETES, DIABETOLOGIA, 53, PP. 1846-1855, (2010); SNIDERMAN A.D., WILLIAMS K., CONTOIS J.H., MONROE H.M., MCQUEEN M.J., DE GRAAF J., FURBERG C.D., META-ANALYSIS OF LDL-C NON-HDL-C AND APO B AS MARKERS OF CARDIOVASCULAR RISK, CIRCULATION; ERQOU S., KAPTOGE S., PERRY P.L., DI ANGELANTONIO E., THOMPSON A., WHITE I.R., MARCOVINA S.M., COLLINS R., THOMPSON S.G., DANESH J., LIPOPROTEIN A CONCENTRATION AND THE RISK OF CORONARY HEART DISEASE STROKE AND NONVASCULAR MORTALITY, JAMA, 302, PP. 412-423, (2009); MARCOVINA S.M., KOSCHINSKY M.L., ALBERS J.J., SKARLATOS S., REPORT OF THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE WORKSHOP ON LIPOPROTEIN(A) AND CARDIOVASCULAR DISEASE: RECENT ADVANCES AND FUTURE DIRECTIONS, CLINICAL CHEMISTRY, 49, 11, PP. 1785-1796, (2003); NORDESTGAARD B.G., CHAPMAN J., RAY K., BOREN J., ANDREOTTI F., WATTS G.F., GINSBERG H., AMARENCO P., CATAPANO A., DESCAMPS O.S., FISHER E., KOVANEN P.T., KUIVENHOVEN J.A., LESNIK P., MASANA L., REINER Z., TASKINEN M.R., TOKGOZOGLU L., TYBJAERG-HANSEN A., LIPOPROTEIN A AS A CARDIOVASCULAR RISK FACTOR: CURRENT STATUS, EUR. HEART J., 31, PP. 2844-2853, (2010); JUN M., FOOTE C., LU J., PATEL A., NICHOLLS S.J., GROBBEE D.E., CASS A., CHALMERS J., PERKOVIC V., EFFECTS OF FIBRATES ON CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS, LANCET, 375, PP. 1875-1884, (2010); HOLME I., CATER N.B., FAERGEMAN O., KASTELEIN J.J.P., OLSSON A.G., TIKKANEN M.J., LARSEN M.L., LINDAHL C., PEDERSEN T., LIPOPROTEIN PREDICTORS OF CARDIOVASCULAR EVENTS IN STATIN-TREATED PATIENTS WITH CORONARY HEART DISEASE INSIGHTS FROM THE INCREMENTAL DECREASE IN END-POINTS THROUGH AGGRESSIVE LIPID-LOWERING TRIAL IDEAL, ANN. MED., 40, PP. 456-464, (2008); PACKARD C.J., SMALL DENSE LOW-DENSITY LIPOPROTEIN AND ITS ROLE AS AN INDEPENDENT PREDICTOR OF CARDIOVASCULAR DISEASE, CURRENT OPINION IN LIPIDOLOGY, 17, 4, PP. 412-417, (2006); MORA S., SZKLO M., OTVOS J.D., GREENLAND P., PSATY B.M., GOFF JR. D.C., O'LEARY D.H., SAAD M.F., TSAI M.Y., SHARRETT A.R., LDL PARTICLE SUBCLASSES, LDL PARTICLE SIZE, AND CAROTID ATHEROSCLEROSIS IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), ATHEROSCLEROSIS, 192, 1, PP. 211-217, (2007); DRENOS F., WHITTAKER J.C., HUMPHRIES S.E., THE USE OF META-ANALYSIS RISK ESTIMATES FOR CANDIDATE GENES IN COMBINATION TO PREDICT CORONARY HEART DISEASE RISK, ANNALS OF HUMAN GENETICS, 71, 5, PP. 611-619, (2007); WIERZBICKI A.S., HUMPHRIES S.E., MINHAS R., FAMILIAL HYPERCHOLESTEROLAEMIA: SUMMARY OF NICE GUIDANCE, BMJ, 337, (2008); MURPHY S.A., CANNON C.P., WIVIOTT S.D., DE LEMOS J.A., BLAZING M.A., MCCABE C.H., CALIFF R.M., BRAUNWALD E., EFFECT OF INTENSIVE LIPID-LOWERING THERAPY ON MORTALITY AFTER ACUTE CORONARY SYNDROME (A PATIENT-LEVEL ANALYSIS OF THE AGGRASTAT TO ZOCOR AND PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY-THROMBOLYSIS IN MYOCARDIAL INFARCTION 22 TRIALS), AMERICAN JOURNAL OF CARDIOLOGY, 100, 7, PP. 1047-1051, (2007); RIDKER P.M., DANIELSON E., FONSECA F.A.H., GENEST J., GOTTO A.M., KASTELEIN J.J.P., KOENIG W., LIBBY P., LORENZATTI A.J., MACFADYEN J.G., NORDESTGAARD B.G., SHEPHERD J., WILLERSON J.T., GLYNN R.J., REDUCTION IN C-REACTIVE PROTEIN AND LDL-CHOLESTEROL AND CARDIOVASCULAR EVENT RATES AFTER INTITIATION OF ROSUVASTATIN: A PROSPECTIVE STUDY OF THE JUPITER TRIAL, LANCET, 373, PP. 1175-1182, (2009); HU F.B., WILLETT W.C., OPTIMAL DIETS FOR PREVENTION OF CORONARY HEART DISEASE, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 288, 20, PP. 2569-2578, (2002); GRUNDY S.M., LIPIDS NUTRITION AND CORONARY HEART DISEASE, ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE, (1996); MENTE A., DE KONING L., SHANNON H.S., ANAND S.S., A SYSTEMATIC REVIEW OF THE EVIDENCE SUPPORTING A CAUSAL LINK BETWEEN DIETARY FACTORS AND CORONARY HEART DISEASES, ARCH. INTERN. MED., 169, PP. 659-669, (2009); MENSINK R.P., ZOCK P.L., KESTER A.D.M., KATAN M.B., EFFECTS OF DIETARY FATTY ACIDS AND CARBOHYDRATES ON THE RATIO OF SERUM TOTAL TO HDL CHOLESTEROL AND ON SERUM LIPIDS AND APOLIPOPROTEINS: A META-ANALYSIS OF 60 CONTROLLED TRIALS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 77, 5, PP. 1146-1155, (2003); MOZAFFARIAN D., ARO A., WILLETT W.C., HEALTH EFFECTS OF TRANS-FATTY ACIDS: EXPERIMENTAL AND OBSERVATIONAL EVIDENCE, EUR. J. CLIN. NUTR., 63, (2009); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 69, 1, PP. 30-42, (1999); KEYS A., SERUM CHOLESTEROL RESPONSE TO DIETARY CHOLESTEROL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 40, 2, PP. 351-359, (1984); ABUMWEIS S.S., BARAKE R., JONES P.J., PLANT STEROLS/STANOLS AS CHOLESTEROL LOWERING AGENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, FOOD NUTR. RES., 52, (2008); DATTILO A.M., KRIS-ETHERTON P.M., EFFECTS OF WEIGHT REDUCTION ON BLOOD LIPIDS AND LIPOPROTEINS: A META-ANALYSIS, AM. J. CLIN. NUTR., 56, PP. 320-328, (1992); SIRTORI C.R., GALLI C., ANDERSON J.W., ARNOLDI A., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); SHAW K., GENNAT H., O'ROURKE P., DEL MAR C., EXERCISE FOR OVERWEIGHT OR OBESITY, COCHRANE DATABASE SYST. REV., 4, (2006); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN. INTERN. MED., 150, PP. 830-839, (2009); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., MORGAN J.M., CAPUZZI D.M., LI S., EFFECT OF XUEZHIKANG AN EXTRACT FROM RED YEAST CHINESE RICE ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM. J. CARDIOL., 101, PP. 1689-1693, (2008); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); RIMM E.B., WILLIAMS P., FOSHER K., CRIQUI M., STAMPFER M.J., MODERATE ALCOHOL INTAKE AND LOWER RISK OF CORONARY HEART DISEASE: META-ANALYSIS OF EFFECTS ON LIPIDS AND HAEMOSTATIC FACTORS, BMJ, 319, PP. 1523-1528, (1999); BANTLE J.P., RAATZ S.K., THOMAS W., GEORGOPOULOS A., EFFECTS OF DIETARY FRUCTOSE ON PLASMA LIPIDS IN HEALTHY SUBJECTS, AM. J. CLIN. NUTR., 72, PP. 1128-1134, (2000); STANHOPE K.L., SCHWARZ J.M., KEIM N.L., GRIFFEN S.C., BREMER A.A., GRAHAM J.L., HATCHER B., COX C.L., DYACHENKO A., ZHANG W., MCGAHAN J.P., SEIBERT A., KRAUSS R.M., CHIU S., SCHAEFER E.J., AI M., OTOKOZAWA S., NAKAJIMA K., NAKANO T., BEYSEN C., HELLERSTEIN M.K., BERGLUND L., HAVEL P.J., CONSUMING FRUCTOSE-SWEETENED NOT GLUCOSE-SWEETENED BEVERAGES INCREASES VISCERAL ADIPOSITY AND LIPIDS AND DECREASES INSULIN SENSITIVITY IN OVERWEIGHT/OBESE HUMANS, J. CLIN. INVEST., 119, PP. 1322-1334, (2009); KRAUS W.E., HOUMARD J.A., DUSCHA B.D., KNETZGER K.J., WHARTON M.B., MCCARTNEY J.S., BALES C.W., HENES S., SAMSA G.P., OTVOS J.D., KULKARNI K.R., SLENTZ C.A., EFFECTS OF THE AMOUNT AND INTENSITY OF EXERCISE ON PLASMA LIPOPROTEINS, NEW ENGLAND JOURNAL OF MEDICINE, 347, 19, PP. 1483-1492, (2002); NORDMANN A.J., NORDMANN A., BRIEL M., KELLER U., YANCY JR. W.S., BREHM B.J., BUCHER H.C., EFFECTS OF LOW-CARBOHYDRATE VS LOW-FAT DIETS ON WEIGHT LOSS AND CARDIOVASCULAR RISK FACTORS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCHIVES OF INTERNAL MEDICINE, 166, 3, PP. 285-293, (2006); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEINS: HUMAN STUDIES, AM. J. CLIN. NUTR., 65, 5, (1997); BEULENS J.W.J., RIMM E.B., ASCHERIO A., SPIEGELMAN D., HENDRIKS H.F.J., MUKAMAL K.J., ALCOHOL CONSUMPTION AND RISK FOR CORONARY HEART DISEASE AMONG MEN WITH HYPERTENSION, ANNALS OF INTERNAL MEDICINE, 146, 1, PP. 10-19, (2007); RABKIN S.W., EFFECT OF CIGARETTE SMOKING CESSATION ON RISK FACTORS FOR CORONARY ATHEROSCLEROSIS. A CONTROL CLINICAL TRIAL, ATHEROSCLEROSIS, 53, 2, PP. 173-184, (1984); ORDOVAS J.M., GENETIC INFLUENCES ON BLOOD LIPIDS AND CARDIOVASCULAR DISEASE RISK: TOOLS FOR PRIMARY PREVENTION, AM. J. CLIN. NUTR., 89, (2009); NCEP EXPERT PANEL ON DETECTION EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM NCEP EXPERT PANEL ON DETECTION EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS ADULT TREATMENT PANEL III, JAMA, 285, PP. 2486-2497, (2001); MATTAR M., OBEID O., FISH OIL AND THE MANAGEMENT OF HYPERTRIGLYCERIDEMIA, NUTR. HEALTH, 20, PP. 41-49, (2009); LIU S., MANSON J.E., STAMPFER M.J., HOLMES M.D., HU F.B., HANKINSON S.E., WILLETT W.C., DIETARY GLYCEMIC LOAD ASSESSED BY FOOD-FREQUENCY QUESTIONNAIRE IN RELATION TO PLASMA HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND FASTING PLASMA TRIACYLGLYCEROLS IN POSTMENOPAUSAL WOMEN, AMERICAN JOURNAL OF CLINICAL NUTRITION, 73, 3, PP. 560-566, (2001); MOORADIAN A.D., HAAS M.J., WONG N.C.W., THE EFFECT OF SELECT NUTRIENTS ON SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN A-I LEVELS, ENDOCRINE REVIEWS, 27, 1, PP. 2-16, (2006); KELLY S., FROST G., WHITTAKER V., SUMMERBELL C., LOW GLYCAEMIC INDEX DIETS FOR CORONARY HEART DISEASE, COCHRANE DATABASE SYST. REV., 4, (2004); PROCESS FOR THE ASSESSMENT OF SCIENTIFIC SUPPORT FOR CLAIMS ON FOODS: CONSENSUS ON CRITERIA, EUR. J. NUTR., 44, (2005); LEA L.J., HEPBURN P.A., SAFETY EVALUATION OF PHYTOSTEROL-ESTERS PART 9: RESULTS OF A EUROPEAN POST-LAUNCH MONITORING PROGRAMME, FOOD CHEM. TOXICOL., 44, PP. 1213-1222, (2006); DEWELL A., HOLLENBECK P.L.W., HOLLENBECK C.B., CLINICAL REVIEW: A CRITICAL EVALUATION OF THE ROLE OF SOY PROTEIN AND ISOFLAVONE SUPPLEMENTATION IN THE CONTROL OF PLASMA CHOLESTEROL CONCENTRATIONS, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 91, 3, PP. 772-780, (2006); RIDEOUT T.C., HARDING S.V., JONES P.J., FAN M.Z., GUAR GUM AND SIMILAR SOLUBLE FIBERS IN THE REGULATION OF CHOLESTEROL METABOLISM: CURRENT UNDERSTANDINGS AND FUTURE RESEARCH PRIORITIES, VASC. HEALTH RISK MANAG., 4, PP. 1023-1033, (2008); KROMHOUT D., GILTAY E.J., GELEIJNSE J.M., N-3 FATTY ACIDS AND CARDIOVASCULAR EVENTS AFTER MYOCARDIAL INFARCTION, N. ENGL. J. MED., 363, PP. 2015-2026, (2010); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLINICAL PHARMACOLOGY AND THERAPEUTICS, 65, 4, PP. 439-447, (1999); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLINICAL DRUG INVESTIGATION, 25, 11, PP. 701-707, (2005); ALBERTI K.G., ECKEL R.H., GRUNDY S.M., ZIMMET P.Z., CLEEMAN J.I., DOANTO K.A., FRUCHART J.-C., JAMES P.T., LORIA C.M., SMITH S.C., HARMONIZING THE METABOLIC SYNDROME: A JOINT INTERIM STATEMENT OF THE INTERNATIONAL DIABETES FEDERATION TASK FORCE ON EPIDEMIOLOGY AND PREVENTION NATIONAL HEART LUNG AND BLOOD INSTITUTE, CIRCULATION, 120, PP. 1640-1645, (2009); SWAIN J.F., MCCARRON P.B., HAMILTON E.F., SACKS F.M., APPEL L.J., CHARACTERISTICS OF THE DIET PATTERNS TESTED IN THE OPTIMAL MACRONUTRIENT INTAKE TRIAL TO PREVENT HEART DISEASE (OMNIHEART): OPTIONS FOR A HEART-HEALTHY DIET, JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 108, 2, PP. 257-265, (2008); HOWARD B.V., VAN HORN L., HSIA J., MANSON J.E., STEFANICK M.L., WASSERTHEIL-SMOLLER S., KULLER L.H., LACROIX A.Z., LANGER R.D., LASSER N.L., LEWIS C.E., LIMACHER M.C., MARGOLIS K.L., MYSIW W.J., OCKENE J.K., PARKER L.M., PERRI M.G., PHILLIPS L., PRENTICE R.L., ROBBINS J., ROSSOUW J.E., SARTO G.E., SCHATZ I.J., SNETSELAAR L.G., STEVENS V.J., TINKER L.F., TREVISAN M., VITOLINS M.Z., ANDERSON G.L., ASSAF A.R., BASSFORD T., BERESFORD S.A.A., BLACK H.R., BRUNNER R.L., BRZYSKI R.G., CAAN B., CHLEBOWSKI R.T., GASS M., GRANEK I., GREENLAND P., HAYS J., HEBER D., HEISS G., HENDRIX S.L., HUBBELL F.A., JOHNSON K.C., KOTCHEN J.M., LOW-FAT DIETARY PATTERN AND RISK OF CARDIOVASCULAR DISEASE: THE WOMEN'S HEALTH INITIATIVE RANDOMIZED CONTROLLED DIETARY MODIFICATION TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 6, PP. 655-666, (2006); HARRIS W.S., MOZAFFARIAN D., RIMM E., KRIS-ETHERTON P., RUDEL L.L., APPEL L.J., ENGLER M.M., ENGLER M.B., SACKS F., OMEGA-6 FATTY ACIDS AND RISK FOR CARDIOVASCULAR DISEASE: A SCIENCE ADVISORY FROM THE AMERICAN HEART ASSOCIATION NUTRITION SUBCOMMITTE OF THE COUNCIL ON NUTRITION PHYSICAL ACTIVITY AND METABOLISM COUNCIL ON CARDIOVASCULAR NURSING AND COUNCIL ON EPIDEMIOLOGY AND PREVENTION, CIRCULATION, 119, PP. 902-907, (2009); POLI A., MARANGONI F., PAOLETTI R., MANNARINO E., LUPATTELLI G., NOTARBARTOLO A., AURELI P., BERNINI F., CICERO A., GADDI A., CATAPANO A., CRICELLI C., GATTONE M., MARROCCO W., PORRINI M., STELLA R., VANOTTI A., VOLPE M., VOLPE R., CANNELLA C., PINTO A., DEL TOMA E., LA VECCHIA C., TAVANI A., MANZATO E., RICCARDI G., IRTORI C., ZAMBON A., NON-PHARMACOLOGICAL CONTROL OF PLASMA CHOLESTEROL LEVELS, NUTR. METAB. CARDIOVASC. DIS., 18, (2008); CATAPANO A.L., PERSPECTIVES ON LOW-DENSITY-LIPOPROTEIN CHOLESTEROL GOAL ACHIEVEMENT, CURR. MED. RES. OPIN., 25, PP. 431-447, (2009); SATTAR N., PREISS D., MURRAY H.M., WELSH P., BUCKLEY B.M., DE CRAEN A.J., SESHASAI S.R., MCMURRAY J.J., FREEMAN D.J., JUKEMA J.W., MACFARLANE P.W., PACKARD C.J., STOTT D.J., WESTENDORP R.G., SHEPHERD J., DAVIS B.R., PRESSEL S.L., MARCHIOLI R., MARFISI R.M., MAGGIONI A.P., TAVAZZI L., TOGNONI G., KJEKSHUS J., PEDERSEN T.R., COOK T.J., GOTTO A.M., CLEARFIELD M.B., DOWNS J.R., NAKAMURA H., OHASHI Y., MIZUNO K., RAY K.K., FORD I., STATINS AND RISK OF INCIDENT DIABETES: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED STATIN TRIALS, LANCET, 375, PP. 735-742, (2010); HIPPISLEY-COX J., COUPLAND C., UNINTENDED EFFECTS OF STATINS IN MEN AND WOMEN IN ENGLAND AND WALES: POPULATION-BASED COHORT STUDY USING THE QRESEARCH DATABASE, BMJ, 340, (2010); GARCIA-RODRIGUEZ L.A., MASSO-GONZALEZ E.L., WALLANDER M.A., JOHANSSON S., THE SAFETY OF ROSUVASTATIN IN COMPARISON WITH OTHER STATINS IN OVER 100,000 STATIN USERS IN UK PRIMARY CARE, PHARMACOEPIDEMIOL. DRUG SAF., 17, PP. 943-952, (2008); HOLOSHITZ N., ALSHEIKH-ALI A.A., KARAS R.H., RELATIVE SAFETY OF GEMFIBROZIL AND FENOFIBRATE IN THE ABSENCE OF CONCOMITANT CERIVASTATIN USE, AM. J. CARDIOL., 101, PP. 95-97, (2008); FRANSSEN R., VERGEER M., STROES E.S., KASTELEIN J.J., COMBINATION STATIN-FIBRATE THERAPY: SAFETY ASPECTS, DIABETES OBES. METAB., 11, PP. 89-94, (2009); GUYTON J.R., BAYS H.E., SAFETY CONSIDERATIONS WITH NIACIN THERAPY, AM. J. CARDIOL., 99, (2007); CZIRAKY M.J., WILLEY V.J., MCKENNEY J.M., KARNAT S.A., FISHER M.D., GUYTON J.R., JACOBSON T.A., DAVIDSON M.H., STATIN SAFETY: AN ASSESSMENT USING AN ADMINISTRATIVE CLAIMS DATABASE, AM. J. CARDIOL., 97, (2006); TYROLER H.A., CHOLESTEROL AND CARDIOVASCULAR DISEASE. AN OVERVIEW OF LIPID RESEARCH CLINICS (LRC) EPIDEMIOLOGIC STUDIES AS BACKGROUND FOR THE LRC CORONARY PRIMARY PREVENTION TRIAL, AMERICAN JOURNAL OF CARDIOLOGY, 54, 5, (1984); LEVY P., REVIEW OF STUDIES ON THE EFFECT OF BILE ACID SEQUESTRANTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, METAB. SYNDR. RELAT. DISORD., 8, 1, (2010); FONSECA V.A., HANDELSMAN Y., STAELS B., COLESEVELAM LOWERS GLUCOSE AND LIPID LEVELS IN TYPE 2 DIABETES: THE CLINICAL EVIDENCE, DIABETES OBES. METAB., 12, PP. 384-392, (2010); STUDY OF HEART AND RENAL PROTECTION SHARP: RANDOMIZED TRIAL TO ASSESS THE EFFECTS OF LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL AMONG 9438 PATIENTS WITH CHRONIC KIDNEY DISEASE, AM. HEART J., 160, PP. 785-794, (2010); CHAPMAN M.J., REDFERN J.S., MCGOVERN M.E., GIRAL P., NIACIN AND FIBRATES IN ATHEROGENIC DYSLIPIDEMIA: PHARMACOTHERAPY TO REDUCE CARDIOVASCULAR RISK, PHARMACOL. THER., 126, PP. 314-345, (2010); REINER Z., COMBINED THERAPY IN THE TREATMENT OF DYSLIPIDEMIA, FUNDAM CLIN. PHARMACOL., 24, PP. 19-28, (2010); ZHAO X.Q., KRASUSKI R.A., BAER J., WHITNEY E.J., NERADILEK B., CHAIT A., MARCOVINA S., ALBERS J.J., BROWN G., EFFECTS OF COMBINATION LIPID THERAPY ON CORONARY STENOSIS PROGRESSION AND CLINICAL CARDIOVASCULAR EVENTS IN CORONARY DISEASE PATIENTS WITH METABOLIC SYNDROME: A COMBINED ANALYSIS OF THE FAMILIAL ATHEROSCLEROSIS TREATMENT STUDY FATS THE HDL-ATHEROSCLEROSIS TREATMENT STUDY HATS AND THE ARMED FORCES REGRESSION STUDY AFREGS, AM. J. CARDIOL., 104, PP. 1457-1464, (2009); HUIJGEN R., ABBINK E.J., BRUCKERT E., STALENHOEF A.F., IMHOLZ B.P., DURRINGTON P.N., TRIP M.D., ERIKSSON M., VISSEREN F.L., SCHAEFER J.R., KASTELEIN J.J., COLESEVELAM ADDED TO COMBINATION THERAPY WITH A STATIN AND EZETIMIBE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: A 12-WEEK MULTICENTER RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL, CLIN. THER., 32, PP. 615-625, (2010); BALLANTYNE C.M., WEISS R., MOCCETTI T., VOGT A., EBER B., SOSEF F., DUFFIELD E., EFFICACY AND SAFETY OF ROSUVASTATIN 40 MG ALONE OR IN COMBINATION WITH EZETIMIBE IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE RESULTS FROM THE EXPLORER STUDY, AM. J. CARDIOL., 99, PP. 673-680, (2007); CUCHEL M., BLOEDON L.T., SZAPARY P.O., KOLANSKY D.M., WOLFE M.L., SARKIS A., MILLAR J.S., IKEWAKI K., SIEGELMAN E.S., GREGG R.E., RADER D.J., INHIBITION OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN FAMILIAL HYPERCHOLESTEROLEMIA, NEW ENGLAND JOURNAL OF MEDICINE, 356, 2, PP. 148-156, (2007); LADENSON P.W., KRISTENSEN J.D., RIDGWAY E.C., OLSSON A.G., CARLSSON B., KLEIN I., BAXTER J.D., ANGELIN B., USE OF THE THYROID HORMONE ANALOGUE EPROTIROME IN STATINTREATED DYSLIPIDAEMIA, N. ENGL. J. MED., 362, PP. 906-916, (2010)","Ž. REINER; UNIVERSITY HOSPITAL CENTER ZAGREB, SCHOOL OF MEDICINE, UNIVERSITY OF ZAGREB, 10 000 ZAGREB, SALATA 2, CROATIA; EMAIL: ZREINER@KBC-ZAGREB.HR","","ENGLISH","EUR. HEART J.","REVIEW","ISI","2-S2.0-79960539641","EUR HEART J","UNIVERSITY HOSPITAL CENTER ZAGREB","NOTREPORTED;UNIVERSITY HOSPITAL CENTER ZAGREB;NOTREPORTED",NA,"REINER Ž, 2011, EUR HEART J","REINER Ž, 2011, EUR HEART J"
"LOCKWOOD G","LOCKWOOD, G. BRIAN (7102722685)","THE QUALITY OF COMMERCIALLY AVAILABLE NUTRACEUTICAL SUPPLEMENTS AND FOOD SOURCES",2011,"JOURNAL OF PHARMACY AND PHARMACOLOGY","63","7",33,"10.1111/j.2042-7158.2010.01159.x","SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES, UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PT, OXFORD ROAD, UNITED KINGDOM","OBJECTIVES: NUTRACEUTICALS ARE COMPONENTS OF DIETARY ORIGIN, WITH CLAIMED BENEFICIAL THERAPEUTIC ACTIVITIES. THE QUALITY OF NUTRACEUTICALS IS PARAMOUNT FOR EFFICACY AND SAFETY, AND IT INCLUDES QUALITY OF RAW MATERIALS, DIFFERENT AVAILABLE CHEMICAL FORMS, COMPLEX PRODUCTS, LACK OF SUBSTITUTION OF INAPPROPRIATE MATERIALS, AND THE ABSENCE OF CONTAMINANTS. THE AIM OF THIS REVIEW IS TO INVESTIGATE THE EXTENT OF SUBSTANDARD FORMULATED AND RAW MATERIAL NUTRACEUTICALS, AND TO HIGHLIGHT ANY CONSEQUENT HEALTH CONCERN. KEY FINDINGS REPORTS OF THE QUALITY OF RAW MATERIALS HAVE REVEALED WIDE VARIATIONS, OFTEN AS A RESULT OF LACK OF CLEAR REGULATORY DEFINITIONS WITH RESPECT TO SIZE OF POLYMERIC ENTITIES AND ALSO PRESENCE OF GLYCOSIDIC AND SALT FORMS. PUBLISHED EVALUATIONS OF OVER 70 FORMULATIONS OF 25 DIFFERENT NUTRACEUTICALS REVEALED VARIABLE QUALITY; NO NUTRACEUTICAL SHOWED CONSISTENT HIGH QUALITY, BUT A NUMBER REVEALED CONSISTENT LOW QUALITY, THEREBY MAKING THE CASE FOR CLOSER REGULATION OF MANUFACTURERS. WHOLE FOOD SOURCES HAVE ALSO BEEN SHOWN TO BE WIDELY VARIABLE IN CONSTITUENT LEVELS. THE EFFECT OF DIFFERENT FORMULATIONS REQUIRES CONSIDERATION, AS THE DIFFERENT TYPES HAVE BEEN SHOWN TO HAVE MARKED EFFECTS ON BIOAVAILABILITY. SUMMARY THE POOR QUALITY OF COMMERCIALLY AVAILABLE NUTRACEUTICALS HAS BEEN HIGHLIGHTED. IN ADDITION, INCIDENCES OF SIDE EFFECTS AND DRUG INTERACTIONS ARE INCREASING, AS CONSUMPTION OF NUTRACEUTICALS RISES. PHARMACISTS AND HEALTH PRACTITIONERS NEED TO BE AWARE OF THE SCIENTIFIC LITERATURE TO ADVISE ACCORDINGLY. © 2010 ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN.","NUTRACEUTICAL SUPPLEMENTS; QUALITY EVALUATIONS","ANIMALS; BIOLOGICAL AVAILABILITY; DIETARY SUPPLEMENTS; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; LEGISLATION, FOOD; ALPHA TOCOPHEROL; BETA CAROTENE; BRANCHED CHAIN AMINO ACID; CARNITINE; CHONDROITIN; CREATINE; DOCOSAHEXAENOIC ACID; GAMMA LINOLENIC ACID; GLUCOSAMINE; GREEN TEA EXTRACT; ICOSAPENTAENOIC ACID; LYCOPENE; MELATONIN; NUTRACEUTICAL; OXYRESVERATROL; POLICOSANOL; PRASTERONE; PROANTHOCYANIDIN; RESVERATROL; STEROL; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN; AREA UNDER THE CURVE; ARTICLE; DIET SUPPLEMENTATION; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; FOOD QUALITY; MAXIMUM PLASMA CONCENTRATION","","","LOCKWOOD G.B., NUTRACEUTICALS: A BALANCED VIEW FOR HEALTHCARE PROFESSIONALS, (2007); GUNTHER S., ET AL., DEMOGRAPHIC AND HEALTH-RELATED CORRELATES OF HERBAL AND SPECIALTY SUPPLEMENT USE, J AM DIET ASSOC, 104, PP. 27-34, (2004); LOCKWOOD G.B., THE HYPE SURROUNDING NUTRACEUTICAL SUPPLEMENTS: DO CONSUMERS GET WHAT THEY DESERVE?, NUTRITION, 23, PP. 771-772, (2007); SURVEY OF DIOXINS AND DIOXIN-LIKE PCBS IN FISH OIL SUPPLEMENTS, (2010); JAKSCH F., ET AL., HANDBOOK OF ANALYTICAL METHODS FOR DIETARY SUPPLEMENTS, (2005); UNITED STATES PHARMACOPEIA/NATIONAL FORMULARY, (2007); WECHSLER J., STANDARDS FOR SUPPLEMENTS, PHARM TECHNOL EUR, PP. 18-20, (2003); DIETARY SUPPLEMENTS METHODS, (2009); SIM J.-S., ET AL., QUANTITATIVE ANALYSIS OF CHONDROITIN SULFATE IN RAW MATERIALS, OPHTHALMIC SOLUTIONS, SOFT CAPSULES, AND LIQUID PREPARATIONS, J CHROMATOGR B, 818, PP. 133-139, (2005); LIANG Z., ET AL., DETERMINATION OF THE NUTRACEUTICAL, GLUCOSAMINE HYDROCHLORIDE, IN RAW MATERIALS, DOSAGE FORMS AND PLASMA USING PRE-COLUMN DERIVATIZATION WITH ULTRAVIOLET HPLC, J PHARM BIOMED ANAL, 20, PP. 807-814, (1999); GREEN R., THE LABORATORY NOTEBOOK, NUTRACEUTICALS WORLD, PP. 24-25, (2004); RUSSELL A.S., ET AL., ACTIVE INGREDIENT CONSISTENCY OF COMMERCIALLY AVAILABLE GLUCOSAMINE SULFATE PRODUCTS, J RHEUMATOL, 29, PP. 2407-2409, (2002); CAVAZZA A., ET AL., RAPID ANALYSIS OF ESSENTIAL AND BRANCHED -CHAIN AMINO ACIDS IN NUTRACEUTICAL PRODUCTS BY MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY, J AGRIC FOOD CHEM, 48, PP. 3324-3329, (2000); PROKORATOVA V., ET AL., CAPILLARY ELECTROPHORESIS DETERMINATION OF CARNITINE IN FOOD SUPPLEMENTS, J CHROMATOGR A, 1081, PP. 60-64, (2005); KAKOU A., ET AL., DETERMINATION OF L-CARNITINE IN FOOD SUPPLEMENT FORMULATIONS USING ION-PAIR CHROMATOGRAPHY WITH INDIRECT CONDUCTIMETRIC DETECTION, J CHROMATOGR A, 1069, PP. 209-215, (2005); AMAN R., ET AL., DETERMINATION OF CAROTENOID STEREOISOMERS IN COMMERCIAL DIETARY SUPPLEMENTS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, J AGRIC FOOD CHEM, 52, PP. 6086-6090, (2004); HUMAYOUN M., BRYAN M., EXTRACTION AND QUANTIFICATION OF MAJOR CAROTENOIDS IN PROCESSED FOODS AND SUPPLEMENTS BY LIQUID CHROMATOGRAPHY, FOOD CHEM, 111, PP. 255-261, (2008); NISHII S., ET AL., QUALITY TEST OF COMMERCIAL UBIDECARENONE TABLETS, BYOIN YAKUGAKU, 9, PP. 14-18, (1983); MOLYNEUX S., ET AL., THE BIOAVAILABILITY OF COENZYME Q10 SUPPLEMENTS AVAILABLE IN NEW ZEALAND DIFFERS MARKEDLY, N Z MED J, 117, (2004); JOHNSON C., ET AL., ANALYSIS OF COQ10 IN NUTRACEUTICALS, 229TH ACS NATIONAL MEETING, (2005); TANG P.H., DETERMINATION OF COENZYME Q10 IN OVER-THE-COUNTER DIETARY SUPPLEMENTS BY HIGH - PERFORMANCE LIQUID CHROMATOGRAPHY WITH COULOMETRIC DETECTION, J AOAC INT, 89, PP. 35-39, (2006); KETTAWAN A., ET AL., THE QUALITY CONTROL ASSESSMENT OF COMMERCIALLY AVAILABLE COENZYME Q10-CONTAINING DIETARY AND HEALTH SUPPLEMENTS IN JAPAN, J CLIN BIOCHEM NUTR, 41, PP. 124-131, (2007); WAGNER S.D., ET AL., QUANTIFICATION OF CREATINE IN NUTRITION SUPPLEMENTS BY THIN LAYER CHROMATOGRAPHY-DENSITOMETRY WITH THERMOCHEMICAL ACTIVATION OF FLUORESCENCE QUENCHING, J LIQUID CHROMATOGR REL TECHNOL, 24, PP. 2525-2530, (2001); DASH A.K., SAWHNEY A., A SIMPLE LC METHOD WITH UV DETECTION FOR THE ANALYSIS OF CREATINE AND CREATININE AND ITS APPLICATION TO SEVERAL CREATINE FORMULATIONS, J PHARM BIOMED ANAL, 29, PP. 939-945, (2002); PERSKY A.M., ET AL., VALIDATION OF A SIMPLE LIQUID CHROMATOGRAPHY ASSAY FOR CREATINE SUITABLE FOR PHARMACOKINETIC APPLICATIONS, DETERMINATION OF PLASMA PROTEIN BINDING AND VERIFICATION OF PERCENT LABELLED CLAIM OF VARIOUS CREATINE PRODUCTS, J CHROMATOGR B, 794, PP. 157-165, (2003); PARASRAMPURIA J., ET AL., QUALITY CONTROL OF DEHYDROEPIANDROSTERONE DIETARY SUPPLEMENT PRODUCTS, J AM MED ASSOC, 280, (1998); THOMPSON R.D., CARLSON M., LIQUID CHROMATOGRAPHIC DETERMINATION OF DEHYDROEPIANDROSTERONE (DHEA) IN DIETARY SUPPLEMENT PRODUCTS, J AOAC INT, 83, PP. 847-857, (2000); CHEE K.M., ET AL., FATTY ACID CONTENT OF MARINE OIL CAPSULES, LIPIDS, 25, PP. 523-528, (1990); IHRIG M., BLUME H., PREPARATIONS OF EVENING PRIMROSE OIL: A QUALITY COMPARISON, PHARMAZEUTISCHE ZEIT, 139, PP. 39-42, (1994); GIBSON R.A., ET AL., Î-LINOLENIC ACID (GLA) CONTENT OF ENCAPSULATED EVENING PRIMROSE OIL PRODUCTS, LIPIDS, 27, PP. 82-84, (1992); SITTON A., ET AL., DETERMINATION OF LIPOIC ACID IN DIETARY SUPPLEMENT PREPARATIONS BY CAPILLARY ELECTROPHORESIS, J BIOCHEM BIOPHYS METHODS, 61, PP. 119-124, (2004); DURRANI A.I., ET AL., ALPHA-LIPOIC ACID IN DIETARY SUPPLEMENTS: DEVELOPMENT AND COMPARISON OF HPLC - CEAD AND HPLC -ESI-MS METHODS, J PHARM BIOMED ANAL, 45, PP. 694-699, (2007); SECHRIST J., ET AL., QUANTIFICATION OF LUTEIN IN DIETARY SUPPLEMENTS BY REVERSED-PHASE HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY WITH VISIBLE-MODE DENSITOMETRY, ACTA CHROMATOGR, 12, PP. 151-158, (2002); BREITHAUPT D.E., SCHLATTERER J., LUTEIN AND ZEAXANTHIN IN NEW DIETARY SUPPLEMENTS -ANALYSIS AND QUANTIFICATION, EUR FOOD RES TECHNOL, 220, PP. 648-652, (2005); FEIFER A.H., ET AL., ANALYTICAL ACCURACY AND RELIABILITY OF COMMONLY USED NUTRITIONAL SUPPLEMENTS IN PROSTATE DISEASE, J UROL, 168, PP. 150-154, (2002); COSTANTINI A., PAOLI F., MELATONIN: QUANTITATIVE ANALYSIS IN PHARMACEUTICAL ORAL DOSAGE FORMS USING THIN-LAYER CHROMATOGRAPHY (TLC) DENSITOMETRY, IL FARMACO, 53, PP. 443-447, (1998); BERTRAM R.M., ET AL., HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ANALYSIS: APPLICATIONS TO NUTRACEUTICAL CONTENT AND URINARY DISPOSITION OF OXYRESVERATROL IN RATS, BIOMED CHROMATOGR, 24, PP. 516-521, (2010); IRMAK S., ET AL., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); NAKAMURA Y., ET AL., ANALYSIS OF PROANTHOCYANINS IN GRAPE SEED EXTRACTS, HEALTH FOODS AND GRAPE SEED OILS, J HEALTH SCI, 49, PP. 45-54, (2003); BABU S.K., ET AL., ESTIMATION OF TRANS-RESVERATROL IN HERBAL EXTRACTS AND DOSAGE FORMS BY HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY, CHEM PHARM BULL, 53, PP. 691-693, (2005); EMOTIONAL ASPIRIN. CONSUMER REPORTS, PP. 60-62, (2000); SETCHELL K.D.R., ET AL., BIOAVAILABILITY OF SUPPLEMENTS, J NUTR, 131, (2001); HOWES J.B., HOWES L.G., CONTENT OF ISOFLAVONE-CONTAINING PREPARATIONS, MED J AUST, 176, PP. 135-136, (2002); NURMI T., ET AL., ISOFLAVONE CONTENT OF THE SOY BASED SUPPLEMENTS, J PHARM BIOMED ANAL, 28, PP. 1-11, (2002); PENALVO J.L., ET AL., PLANT LIGNANS IN SOY-BASED HEALTH SUPPLEMENTS, J AGRIC FOOD CHEM, 52, PP. 4133-4138, (2004); CHUA R., ET AL., QUALITY, LABELING ACCURACY, AND COST COMPARISON OF PURIFIED SOY ISOFLAVONOID PRODUCTS, J ALTERN COMPLEMENT MED, 10, PP. 1053-1060, (2004); KRENN L., POETSCH V., AN EFFICIENT HPLC METHOD FOR THE QUANTIFICATION OF ISOFLAVONES IN SOY EXTRACT AND SOY DIETARY SUPPLEMENTS IN ROUTINE QUALITY CONTROL, PHARMAZIE, 61, PP. 582-585, (2006); STURTZ M., ET AL., QUANTITATIVE DETERMINATION OF ISOFLAVONES IN SOY BASED NUTRITIONAL SUPPLEMENTS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, J VERBRAUCHERSCHUTZ LEBENSMITTELSICHERHEIT, 3, PP. 127-136, (2008); CLARKE D.B., ET AL., DETERMINATION OF PHYTOESTROGENS IN DIETARY SUPPLEMENTS BY LC - MS / MS, FOOD ADDIT CONTAM PART A CHEM ANAL CONTROL EXPO RISK ASSESS, 25, PP. 534-547, (2008); NAIR V.D.P., ET AL., DETERMINATION OF STIGMASTEROL, Β-SITOSTEROL AND STIGMASTANOL IN ORAL DOSAGE FORMS USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH EVAPORATIVE LIGHT SCATTERING DETECTION, J PHARM BIOMED ANAL, 41, PP. 731-737, (2006); HALKINA T., SHERMA J., DETERMINATION OF STEROLS AND FATTY ACIDS IN PROSTATE HEALTH DIETARY SUPPLEMENTS BY SILICA GEL HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY WITH VISIBLE MODE DENSITOMETRY, J LIQUID CHROMATOGR REL TECHNOL, 30, PP. 2329-2335, (2007); MANNING J., ROBERTS J.C., ANALYSIS OF CATECHIN CONTENT OF COMMERCIAL GREEN TEA PRODUCTS, J HERB PHARMACOTHER, 3, PP. 19-32, (2003); WEISS D.J., ET AL., ANALYSIS OF GREEN TEA EXTRACT DIETARY SUPPLEMENTS BY MICELLAR ELECTROKINETIC CHROMATOGRAPHY, J CHROMATOGR A, 1117, PP. 103-108, (2006); REMSBERG C.M., ET AL., INGREDIENT CONSISTENCY OF COMMERCIALLY AVAILABLE POLYPHENOL AND TOCOPHEROL NUTRACEUTICALS, PHARMACEUTICS, 2, PP. 50-60, (2010); ADEBOWALE A., ET AL., NUTRACEUTICALS, A CALL FOR QUALITY CONTROL OF DELIVERY SYSTEMS: A CASE STUDY WITH CHONDROITIN SULFATE AND GLUCOSAMINE, J NUTRACEUTICALS FUNCT MED FOOD, 2, PP. 15-30, (1999); CONSUMER REPORTS, PP. 18-21, (2002); EDDINGTON N.D., DESIGN AND RESULTS OF A STUDY TO ANALYZE THE CONTENTS OF GLUCOSAMINE AND CHONDROITIN SULPHATE CONTENT IN MARKETED PRODUCTS: UPDATE AND THE NEED FOR INDUSTRY STANDARDS, EXAMINING THE SCIENCE BEHIND NUTRACEUTICALS, PP. 228-239, (2005); SIM J.-S., ET AL., EVALUATION OF CHONDROITIN SULFATE IN SHARK CARTILAGE POWDER AS A DIETARY SUPPLEMENT: RAW MATERIALS AND FINISHED PRODUCTS, FOOD CHEM, 101, PP. 532-539, (2007); WAY W.K., ET AL., DETERMINATION OF GLUCOSAMINE IN NUTRITIONAL SUPPLEMENTS BY REVERSED-PHASE ION-PAIRING HPLC, J LIQUID CHROMATOGR REL TECHNOL, 23, PP. 2861-2871, (2000); SHAO Y., ET AL., A STABILITY-INDICATING HPLC METHOD FOR THE DETERMINATION OF GLUCOSAMINE IN PHARMACEUTICAL FORMULATIONS, J PHARM BIOMED ANAL, 35, PP. 625-631, (2004); SULLIVAN C., SHERMA J., DEVELOPMENT AND VALIDATION OF AN HPTLC - DENSITOMETRY METHOD FOR ASSAY OF GLUCOSAMINE OF DIFFERENT FORMS IN DIETARY SUPPLEMENT TABLETS AND CAPSULES, ACTA CHROMATOGR, 15, PP. 119-130, (2005); NEMATI M., ET AL., DEVELOPMENT OF A SIMPLE AND SENSITIVE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR DETERMINATION OF GLUCOSAMINE IN PHARMACEUTICAL FORMULATIONS, J AOAC INT, 90, PP. 354-357, (2007); VOLPI N., CAPILLARY ELECTROPHORESIS DETERMINATION OF GLUCOSAMINE IN NUTRACEUTICAL FORMULATIONS AFTER LABELING WITH ANTHRANILIC ACID AND UV DETECTION, J PHARM BIOMED ANAL, 49, PP. 868-871, (2009); DENTITH S., LOCKWOOD B., DEVELOPMENT OF TECHNIQUES FOR THE ANALYSIS OF ISOFLAVONES IN SOY FOODS AND NUTRACEUTICALS, CURR OPIN CLIN NUTR METAB CARE, 11, PP. 242-247, (2008); KIRRANE M., LOCKWOOD B., DEVELOPMENTS IN THE ANALYSIS OF TEA, NUTRAFOODS, 7, PP. 11-20, (2008); ADAMS J., LOCKWOOD B., DEVELOPMENT OF TECHNIQUES FOR ANALYSIS OF NUTRACEUTICALS WITH PARTICULAR REFERENCE TO GLUCOSAMINE AND COENZYME Q10, HANDBOOK OF NUTRACEUTICALS, 1, PP. 132-148, (2009); VOLPI N., ANALYTICAL ASPECTS OF PHARMACEUTICAL GRADE CHONDROITIN SULFATES, J PHARM SCI, 96, PP. 3168-3180, (2007); SAKAI S., ET AL., IDENTIFICATION OF THE ORIGIN OF CHONDROITIN SULFATE IN 'HEALTH FOODS, CHEM PHARM BULL, 55, PP. 299-303, (2007); SAAD O.M., ET AL., ANALYSIS OF HYALURONAN CONTENT IN CHONDROITIN SULFATE PREPARATIONS BY USING SELECTIVE ENZYMATIC DIGESTION AND ELECTROSPRAY IONIZATION MASS SPECTROMETRY, ANAL BIOCHEM, 344, PP. 232-239, (2005); VOLPI N., QUALITY OF DIFFERENT CHONDROITIN SULPHATE PREPARATIONS IN RELATION TO THEIR THERAPEUTIC ACTIVITY, J PHARM PHARMACOL, 61, PP. 1271-1280, (2009); SPENCE J.D., ET AL., THE EFFECT OF FLAX SEED CULTIVARS WITH DIFFERING CONTENT OF ALPHA-LINOLENIC ACID AND LIGNANS ON RESPONSES TO MENTAL STRESS, J AM COLL NUTR, 22, PP. 494-501, (2003); CHEN Z., ET AL., DEGRADATION OF GREEN TEA CATECHINS IN TEA DRINKS, J AGRIC FOOD CHEM, 49, PP. 477-482, (2001); CHEN C.-N., ET AL., CAPILLARY ELECTROPHORETIC DETERMINATION OF THEANINE, CAFFEINE, AND CATECHINS IN FRESH TEA LEAVES AND OOLONG TEA AND THEIR EFFECTS ON RAT NEUROSPHERE ADHESION AND MIGRATION, J AGRIC FOOD CHEM, 51, PP. 7495-7503, (2003); PRABHAKARAN M.P., ET AL., EVALUATION OF THE COMPOSITION AND CONCENTRATION OF ISOFLAVONES IN SOY BASED SUPPLEMENTS, HEALTH PRODUCTS AND INFANT FORMULAS, FOOD RES INT, 39, PP. 730-738, (2006); PREINERSTORFER B., SONTAG G., DETERMINATION OF ISOFLAVONES IN COMMERCIAL SOY PRODUCTS BY HPLC AND COULOMETRIC ELECTRODE ARRAY DETECTION, EUR FOOD RES TECHNOL, 219, PP. 305-310, (2004); NIKFARDJAM M.P., ET AL., INVESTIGATION OF PURE GRAPE JUICES ON THEIR CONTENT OF RESVERATROLS, DEUTSCHE LEBENSMITTEL-RUNDSCHAU, 96, PP. 319-324, (2000); YU L., ET AL., COMPARISON OF COMMERCIAL SUPPLEMENTS CONTAINING CONJUGATED LINOLEIC ACIDS, J FOOD COMPOSIT ANAL, 16, PP. 419-428, (2003); MONAGAS M., ET AL., QUALITY ASSESSMENT OF COMMERCIAL DIETARY ANTIOXIDANT PRODUCTS FROM VITIS VINIFERA L. GRAPE SEEDS, NUTR CANCER, 53, PP. 244-254, (2005); MONAGAS M., ET AL., COMMERCIAL DIETARY INGREDIENTS FROM VITIS VINIFERA L. LEAVES AND GRAPE SKINS: ANTIOXIDANT AND CHEMICAL CHARACTERIZATION, J AGRIC FOOD CHEM, 54, PP. 319-327, (2006); MILES M.V., ET AL., BIOEQUIVALENCE OF COENZYME Q10 FROM OVER-THE-COUNTER SUPPLEMENTS, NUTR RES, 22, PP. 919-929, (2002); PERSKY A.M., ET AL., PHARMACOKINETICS OF THE DIETARY SUPPLEMENT CREATINE, CLIN PHARMACOKINET, 42, PP. 557-574, (2003); WEIS M., ET AL., BIOAVAILABILITY OF FOUR ORAL COENZYME Q10 FORMULATIONS IN HEALTHY VOLUNTEERS, MOL ASPECTS MED, 15, (1994); DAVIES E., ET AL., ADVERSE EFFECTS AND TOXICITY OF NUTRACEUTICALS, REVIEWS IN FOOD AND NUTRITION TOXICITY, 3, PP. 165-195, (2005)","G. B. LOCKWOOD; SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES, UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PT, OXFORD ROAD, UNITED KINGDOM; EMAIL: BRIAN.LOCKWOOD@MANCHESTER.AC.UK","","ENGLISH","J. PHARM. PHARMACOL.","ARTICLE","ISI","2-S2.0-78650361123","J PHARM PHARMACOL","UNIVERSITY OF MANCHESTER","NOTREPORTED;UNIVERSITY OF MANCHESTER;NOTREPORTED",NA,"LOCKWOOD GB, 2011, J PHARM PHARMACOL","LOCKWOOD GB, 2011, J PHARM PHARMACOL"
"REINER Ž;TEDESCHI-REINER E","REINER, ŽEJKO (55411641000); TEDESCHI-REINER, EUGENIA (6603094621)","RICE POLICOSANOL DOES NOT HAVE ANY EFFECTS ON BLOOD COAGULATION FACTORS IN HYPERCHOLESTEROLEMIC PATIENTS",2007,"COLLEGIUM ANTROPOLOGICUM","31","3",7,"","DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY HOSPITAL CENTRE ZAGREB, ZAGREB, CROATIA, DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY HOSPITAL CENTER ZAGREB, 10000 ZAGREB, KIŠPATIĆEVA 12, CROATIA;DEPARTMENT OF OPHTHALMOLOGY, UNIVERSITY HOSPITAL SESTRE MILOSRDNICE, ZAGREB, CROATIA","POLICOSANOL IS AN AGENT THAT INCLUDES MIXTURES OF ALIPHATIC PRIMARY ALCOHOLS EXTRACTED PRIMARILY FROM SUGERCANE WAX. POLICOSANOL HAS BEEN SHOWN TO LOWER TOTAL AND LDL CHOLESTEROL IN ANIMAL MODELS, HEALTHY VOLUNTEERS AND HYPERCHOLESTEROLEMIC PATIENTS. HOWEVER, THESE FINDINGS HAVE BEEN CHALLANGED RECENTLY. UP TO NOW, THERE HAS BEEN NO STUDY INVESTIGATING THE EFFECTS OF POLICOSANOL ON BLOOD COAGULATION FACTORS. THIS STUDY INVESTIGATED THE EFFECTS OF RICE POLICOSANOL (ORYZA SP.) 10 MG/DAY ON BLOOD COAGULATION FACTORS IN 66 HYPERCHOLESTEROLEMIC PATIENTS OF BOTH SEXES AGED 20 TO 78 YEARS IN A SINGLE CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL. AFTER AN 8-WEEK RUN-IN PERIOD IN WHICH PATIENTS WERE PLACED ON THERAPEUTIC LIFESTYLE CHANGES, IN PARTICULAR A CHOLESTEROL-LOWERING DIET, THEY WERE RANDOMLY ASSIGNED TO RECEIVE RICE POLICOSANOL 10 MG TABLETS OR PLACEBO TABLETS ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. DURING NEXT 8 WEEKS THOSE RECEIVING POLICOSANOL DURING THE FIRST 8 WEEKS, RECEIVED PLACEBO AND THOSE TAKING PLACEBO DURING THE FIRST 8 WEEKS, RECEIVED POLICOSANOL. PLASMA FIBRINOGEN, FACTORS VII, VIII, XII AND XIII WERE MEASURED BEFORE AND AFTER THE TREATMENT. RICE POLICOSANOL TREATMENT DID NOT CHANGE SIGNIFICANTLY NEITHER FIBRINOGEN NOR FACTORS VII, VIII, XII AND XIII.","FACTOR VII; FACTOR VIII; FACTOR XII; FACTOR XIII; FIBRINOGEN; HYPERCHOLESTEROLEMIA; POLICOSANOL","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD COAGULATION FACTORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; ORYZA SATIVA; BLOOD CLOTTING FACTOR; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RICE","","","GOUNI-BERTHOLD I., BERTHOLD H.K., AM HEART J, 143, (2002); HERNANDEZ F., ILLNAIT J., MAS R., CURR THER RES, 51, (1992); CASTANO G., MAS R., FERNANDEZ J., CURR THER RES, 64, (2003); MAS R., CASTANO G., ILLNAIT J., CLIN PHARMACOL THER, 65, (1999); CASTANO G., MAS R., FERNANDEZ L., GYNECOL ENDOCRINOL, 13, (2000); CASTANO G., MAS R., FERNANDEZ L., CURR THER RES, 62, (2001); CASTANO G., MAS R., FERNANDEZ L., DRUGS AGING, 20, (2003); CASTANO G., MAS R., FERNANDEZ L., CURR THER RES, 63, (2002); CRESPO N., ALVAREZ R., MAS R., CURR THER RES, 58, (1997); CASTANO G., MAS R., FERNANDEZ J.C., CURR THER RES, 60, (1999); ORTENSI G., GLADSTEIN J., VAILI H., CURR THER RES, 58, (1997); BENITEZ M., ROMERO C., MAS R., CURR THER RES, 58, (1997); CASTANO G., MAS R., FERNANDEZ J., ANGIOLOGY, 54, (2003); REINER Z., TEDESCHI-REINER E., ROMIC Z., CLIN DRUG INVEST, 25, (2005); BURSTEIN M., SCHOLNICK H.R., MORFIN R., J LIPID RES, 11, (1970); CLAUSS A., ACTA HAEMATOL, 17, (1957); DORDRECHT N., 141, (1999); FICKENSCHER K., AAB A., STUBER W., THROMB HAEMOSTAS, 65, (1991); BERTHOLD H.K., UNVEDRDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., JAMA, 295, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARINGER T.A., AM J CLIN NUTR, 84, (2006); KASSIS A.N., JONES P.J., AM J CLIN NUTR, 84, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., BR J NUTR, 95, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., METABOLISM, 53, (2004); CASTANO G., MAS F.R., FERNANDEZ J., ANGIOLOGY, 52, (2001); CASTANO G., MAS R., FERNANDEZ J., ILLNAIT J., ANGIOLOGY, 55, (2004); VASSE M., PAYSANT J., SORIA J., COLLET J.P., VANNIER J.P., SORIA C., HAEMOSTASIA, 26, (1996); FOLSOM A., THROMB HAEMOST, 86, (2001); SMITH A., PATTERSON C., YARNELL J., RUMLEY A., BEN-SHLOMO Y., LOWE G., CIRCULATION, 112, (2005); RUDNICKA A.R., MT-ISA S., MEADE T.W., J THROMB HAEMOST, 4, (2006); DE STAVOLA B.L., MEADE T.W., J THROMB HAEMOST, 5, (2007); EKSTROM M., SILVEIRA A., BENNERMO M., ERIKSSON P., TORNVALL P., BLOOD COAGUL FIBRINOLYSIS, 18, (2007); TZOULAKI I., MURRAY G.D., LEE A.J., RUMLEY A., LOWE G.D., FOWKES F.G., EUR HEART J, 28, (2007); ZHU Y.C., CUI L.Y., HUA B.L., PAN J.Q., CLIN MED, SCI J, 21, (2006); JUNKER R., HEINRICH J., SCHULTE H., VAN DE LOO J., ASSMANN G., ARTERIOSCLER THROMB VASC BIOL, 17, (1997); HEYWOOD D.M., OSSEI-GERNING N., GRANT P.J., THROMB HAEMOST, 76, (1996); GOROQ D.A., RAKHIT R., PARUNES D., LAFFAN M., DAVIES G.J., HEART, 80, (1998); TRACY R.P., ARNOLD A.M., ETTINGER W., FRIED L., MEILAHN E., SAVAGE P., ARTERIOSCLER THROMB VASC BIOL, 19, (1999); MARTINELLI I., SEMIN HEMATOL, 42, (2005); RICE G.I., GRANT P.J., THROMB HAEMOST, 80, (1998); GRUNDT H., NILSEN D.W., HETLAND O., VALENTE E., FAQUERTUM H.E., AM HEART J, 147, (2004); ZITO F., DRUMMOND F., BUJAC S., ESNOUF M.P., MORRISSEY J.H., HUMPHRIES S.E., MILLER G.J., CIRCULATION, 102, (2000); LOWE G.D., RUMLEY A., MCMAHON A.D., FORD I.D., O'REILLY D.S., PACKARD C.J., ARTERIOSCLER THROMB VASC BIOL, 24, (2004); O'CALLAGHAN P.A., FITZGERALD A., FOGARTY J., GAFFNEY P., HANBRIDGE M., BORAN G., ENRIGHT H., MURPHY J., MCCARTHY B., GRAHAM I.M., EUR J CARDIOVASC PREV REHABIL, 12, (2005); ZITO F., LOWE G.D., RUMLEYA M.M.A.H.O.N., AD H.S., ATHEROSCLEROSIS, 165, (2002); BERECZKY Z., BALOGH E., KATONA E., CZURIGA I., EDES I., MUSZBEK L., HAEMATOLOGICA, 92, (2007); FRANCIS C.W., CONNAGHAN D.G., SCOTT W.L., MARDER V.J., CIRCULATION, 6, (1987); VOKO Z., BERECZKY Z., KATONA E., ADANY R., MUSZBEK L., THROMB HEAMOST, 97, (2007)","","","ENGLISH","COLL. ANTROPOL.","ARTICLE","ISI","2-S2.0-38049120451","COLL ANTROPOL",NA,"NOTREPORTED",NA,"REINER Ž, 2007, COLL ANTROPOL","REINER Ž, 2007, COLL ANTROPOL"
"MOMSEN A;JENSEN M;NORAGER C;MADSEN M;VESTERSGAARD-ANDERSEN T;LINDHOLT J","MOMSEN, A.H. (36499864600); JENSEN, M.B. (9437261100); NORAGER, C.B. (9436917100); MADSEN, M.R. (57202652596); VESTERSGAARD-ANDERSEN, T. (6508252775); LINDHOLT, J.S. (7005442384)","DRUG THERAPY FOR IMPROVING WALKING DISTANCE IN INTERMITTENT CLAUDICATION A SYSTEMATIC REVIEW AND METAANALYSIS OF ROBUST RANDOMISED CONTROLLED STUDIES",2009,"EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY","38","11",133,"10.1016/j.ejvs.2009.06.002","SURGICAL RESEARCH UNIT, DEPARTMENT OF SURGERY, REGIONAL HOSPITAL HERNING, DENMARK;SURGICAL RESEARCH UNIT, DEPARTMENT OF SURGERY P, UNIVERSITY HOSPITAL OF AARHUS, DENMARK;SURGICAL RESEARCH UNIT, DEPARTMENT OF SURGERY, REGIONAL HOSPITAL HERNING, DENMARK;SURGICAL RESEARCH UNIT, DEPARTMENT OF SURGERY, REGIONAL HOSPITAL HERNING, DENMARK;VASCULAR SURGICAL RESEARCH UNIT, DEPARTMENT OF VASCULAR SURGERY, REGIONAL HOSPITAL VIBORG, DENMARK;VASCULAR SURGICAL RESEARCH UNIT, DEPARTMENT OF VASCULAR SURGERY, REGIONAL HOSPITAL VIBORG, DENMARK","OBJECTIVES: TO EVALUATE THE EFFICACY OF PHARMACOLOGICAL INTERVENTIONS IN IMPROVING WALKING CAPACITY AND HEALTH-RELATED QUALITY OF LIFE FOR PEOPLE WITH INTERMITTENT CLAUDICATION. DATASOURCES: WE SEARCHED MEDLINE, EMBASE, COCHRANE LIBRARY AND RELEVANT WEBSITES FOR STUDIES PUBLISHED FROM THE START OF THE DATABASES TO FEBRUARY 2009. IN ADDITION, REFERENCE LISTS WERE MANUALLY SEARCHED. REVIEW METHODS: BASED UPON A POWER CALCULATION, ONLY ROBUST (N > 56), PEER-REVIEWED, DOUBLE-BLINDED, RANDOMISED AND PLACEBO-CONTROLLED TRIALS WERE INCLUDED. THE MAIN OUTCOMES EVALUATED WERE MAXIMAL WALKING DISTANCE (MWD) AND PAIN-FREE WALKING DISTANCE ON A TREADMILL. RANDOM MODELS WERE USED IN THE STATISTICAL ANALYSIS, AND CHI-SQUARE TEST WERE USED TO TEST FOR HETEROGENEITY. RESULTS: AMONG 220 TRIALS, ONLY 43 TRIALS FULFILLED THE QUALITY CRITERIA. TREATMENT PERIODS, FOLLOW-UP AND TREADMILL PROTOCOLS VARIED SUBSTANTIALLY. VASODILATOR AGENTS AND PHOSPHODIESTERASE INHIBITORS SHOW ROBUST SIGNIFICANT RESULTS COMPARED TO PLACEBO, BUT THE IMPROVEMENTS IN MWD ARE MODEST. THE HIGHEST BENEFIT WAS CAUSED BY LIPID-LOWERING AGENTS, WHICH IN MEAN GAINED ABOVE 160 M IN MWD, WHILE THE OTHER AGENTS ONLY IMPROVED MWD ABOUT 50 M. CONCLUSION: SEVERAL DRUGS HAVE SHOWN TO IMPROVE MWD, BUT WITH LIMITED BENEFITS. STATINS SEEM TO BE THE MOST EFFICIENT DRUG AT THE MOMENT. © 2009 EUROPEAN SOCIETY FOR VASCULAR SURGERY.","DRUG THERAPY; INTERMITTENT CLAUDICATION; MOBILITY LIMITATION; RANDOMISED CONTROLLED TRIALS","CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; EXERCISE TEST; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ATORVASTATIN; AVASIMIBE; BUFLOMEDIL; CILOSTAZOL; CLORICROMEN; DEFIBROTIDE; EDETIC ACID; GARLIC EXTRACT; HEPARAN SULFATE; HEPARIN CALCIUM; ILOPROST; INDOBUFEN; INOSITOL NICOTINATE; MESOGLYCAN; NAFTIDROFURYL; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POLICOSANOL; PROSTACYCLIN; PROSTANOID; SEROTONIN; SIMVASTATIN; SULODEXIDE; TICLOPIDINE; UNINDEXED DRUG; VASODILATOR AGENT; CHI SQUARE TEST; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; FOLLOW UP; HUMAN; INTERMITTENT CLAUDICATION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREADMILL EXERCISE; WALKING","REGIONAL HOSPITAL HERNING AND REGIONAL HOSPITAL VIBORG","THIS STUDY WAS SUPPORTED BY REGIONAL HOSPITAL HERNING AND REGIONAL HOSPITAL VIBORG. ","NORGREN L., HIATT W.R., DORMANDY J.A., NEHLER M.R., HARRIS K.A., FOWKES F.G., INTER-SOCIETY CONSENSUS FOR THE MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (TASC II), J VASC SURG, 45, SUPPL. S, (2007); STEG P.G., BHATT D.L., WILSON P.W., D'AGOSTINO SR. R., OHMAN E.M., ROTHER J., ET AL., ONE-YEAR CARDIOVASCULAR EVENT RATES IN OUTPATIENTS WITH ATHEROTHROMBOSIS, JAMA, 297, PP. 1197-1206, (2007); REGENSTEINER J.G., WARE JR. J.E., MCCARTHY W.J., ZHANG P., FORBES W.P., HECKMAN J., ET AL., EFFECT OF CILOSTAZOL ON TREADMILL WALKING, COMMUNITY-BASED WALKING ABILITY, AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH INTERMITTENT CLAUDICATION DUE TO PERIPHERAL ARTERIAL DISEASE: META-ANALYSIS OF SIX RANDOMIZED CONTROLLED TRIALS, J AM GERIATR SOC, 50, PP. 1939-1946, (2002); REGENSTEINER J.G., CURRENT MEDICAL THERAPIES FOR PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: A CRITICAL REVIEW, AM J MED, 112, PP. 49-57, (2002); HIATT W.R., MEDICAL TREATMENT OF THE PATIENT WITH INTERMITTENT CLAUDICATION, J VASC TECHNOL, 18, PP. 311-315, (1994); WATSON L., ELLIS B., LENG G.C., EXERCISE FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, (2008); AUNG P.P., MAXWELL H.G., JEPSON R.G., PRICE J.F., LENG G.C., LIPID-LOWERING FOR PERIPHERAL ARTERIAL DISEASE OF THE LOWER LIMB, COCHRANE DATABASE SYST REV, (2007); KLEIJNEN J., MACKERRAS D., VITAMIN E FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, (2000); SOMMERFIELD T., HIATT W.R., OMEGA-3 FATTY ACIDS FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, (2004); JEPSON R.G., KLEIJNEN J., LENG G.C., GARLIC FOR PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, COCHRANE DATABASE SYST REV, (2000); PRICE J.F., LENG G.C., STEROID SEX HORMONES FOR LOWER LIMB ATHEROSCLEROSIS, COCHRANE DATABASE SYST REV, (2002); BERGLUND B., EKLUND B., REPRODUCIBILITY OF TREADMILL EXERCISE IN PATIENTS WITH INTERMITTENT CLAUDICATION, CLIN PHYSIOL, 1, PP. 253-256, (1981); PERAKYLA T., TIKKANEN H., VON K.J., LEPANTALO M., POOR REPRODUCIBILITY OF EXERCISE TEST IN ASSESSMENT OF CLAUDICATION, CLIN PHYSIOL, 18, PP. 187-193, (1998); ALTSTAEDT H.O., BERZEWSKI B., BREDDIN H.K., BROCKHAUS W., BRUHN H.D., CACHOVAN M., ET AL., TREATMENT OF PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE FONTAINE STAGE IV WITH INTRAVENOUS ILOPROST AND PGE1: A RANDOMIZED OPEN CONTROLLED STUDY, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 573-578, (1993); JADAD A.R., MOORE R.A., CARROLL D., JENKINSON C., REYNOLDS D.J., GAVAGHAN D.J., ET AL., ASSESSING THE QUALITY OF REPORTS OF RANDOMIZED CLINICAL TRIALS: IS BLINDING NECESSARY?, CONTROL CLIN TRIALS, 17, PP. 1-12, (1996); TONNESEN K.H., ALBUQUERQUE P., BAITSCH G., GOMEZ A.A., IBANEZ F., KESTER R.C., ET AL., DOUBLE-BLIND, CONTROLLED, MULTICENTER STUDY OF INDOBUFEN VERSUS PLACEBO IN PATIENTS WITH INTERMITTENT CLAUDICATION, INT ANGIOL, 12, PP. 371-377, (1993); GULDAGER B., JELNES R., JORGENSEN S.J., NIELSEN J.S., KLAERKE A., MOGENSEN K., ET AL., EDTA TREATMENT OF INTERMITTENT CLAUDICATION-A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, J INTERN MED, 231, PP. 261-267, (1992); HIATT W.R., HIRSCH A.T., COOKE J.P., OLIN J.W., BRATER D.C., CREAGER M.A., RANDOMIZED TRIAL OF AT-1015 FOR TREATMENT OF INTERMITTENT CLAUDICATION. A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST WITH NO EVIDENCE OF EFFICACY, VASC MED, 9, PP. 18-25, (2004); MOHLER III E.R., HIATT W.R., CREAGER M.A., CHOLESTEROL REDUCTION WITH ATORVASTATIN IMPROVES WALKING DISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 108, PP. 1481-1486, (2003); ARONOW W.S., LIPID-LOWERING THERAPY IN HIGH-RISK PERSONS, COMPR THER, 32, PP. 68-73, (2006); MONDILLO S., BALLO P., BARBATI R., GUERRINI F., AMMATURO T., AGRICOLA E., ET AL., EFFECTS OF SIMVASTATIN ON WALKING PERFORMANCE AND SYMPTOMS OF INTERMITTENT CLAUDICATION IN HYPERCHOLESTEROLEMIC PATIENTS WITH PERIPHERAL VASCULAR DISEASE, AM J MED, 114, PP. 359-364, (2003); CASTANO G., MAS F.R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); STRANDNESS JR. D.E., DALMAN R.L., PANIAN S., RENDELL M.S., COMP P.C., ZHANG P., ET AL., EFFECT OF CILOSTAZOL IN PATIENTS WITH INTERMITTENT CLAUDICATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, VASC ENDOVASC SURG, 36, PP. 83-91, (2002); FARKOUH M.E., FUSTER V., META-ANALYSIS OF SMALL TRIALS: PROCEED WITH CAUTION, NAT CLIN PRACT NEPHROL, 4, (2008); MOHER D., PHAM B., AUSEJO M., SAENZ A., HOOD S., BARBER G.G., PHARMACOLOGICAL MANAGEMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMISED TRIALS, DRUGS, 59, PP. 1057-1070, (2000); GOLDSMITH D.R., WELLINGTON K., NAFTIDROFURYL: A REVIEW OF ITS USE IN THE TREATMENT OF INTERMITTENT CLAUDICATION, DRUGS AGING, 22, PP. 967-977, (2005); MOHLER III E.R., BEEBE H.G., SALLES-CUHNA S., ZIMET R., ZHANG P., HECKMAN J., ET AL., EFFECTS OF CILOSTAZOL ON RESTING ANKLE PRESSURES AND EXERCISE-INDUCED ISCHEMIA IN PATIENTS WITH INTERMITTENT CLAUDICATION, VASC MED, 6, PP. 151-156, (2001); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); MANNAVA K., CURRENT MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE: A REVIEW OF PHARMACOLOGIC AGENTS AND OTHER INTERVENTIONS, AM J CARDIOVASC DRUGS, 7, PP. 59-66, (2007); ROWLANDS T.E., DONNELLY R., MEDICAL THERAPY FOR INTERMITTENT CLAUDICATION, EUR J VASC ENDOVASC SURG, 34, PP. 314-321, (2007); DE BACKER T.L., BOGAERT M., VANDER S.R., BUFLOMEDIL FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, (2008); DE-BACKER T.L., VANDER-STICHELE R.H., WARIE H.H., BOGAERT M.G., ORAL VASOACTIVE MEDICATION IN INTERMITTENT CLAUDICATION: UTILE OR FUTILE?, EUR J CLIN PHARMACOL, 56, PP. 199-206, (2000); LEIZOROVICZ A., BECKER F., ORAL BUFLOMEDIL IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, 4-YEAR STUDY, CIRCULATION, 117, PP. 816-822, (2008); CREAGER M.A., PANDE R.L., HIATT W.R., A RANDOMIZED TRIAL OF ILOPROST IN PATIENTS WITH INTERMITTENT CLAUDICATION, VASC MED, 13, PP. 5-13, (2008); AMENDT K., PGE1 AND OTHER PROSTAGLANDINS IN THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS, ANGIOLOGY, 56, PP. 409-415, (2005); ROBLESS P., MIKHAILIDIS D.P., STANSBY G.P., CILOSTAZOL FOR PERIPHERAL ARTERIAL DISEASE, COCHRANE DATABASE SYST REV, (2008); HIATT W.R., KRANTZ M.J., MASTERCLASS SERIES IN PERIPHERAL ARTERIAL DISEASE. ANTIPLATELET THERAPY FOR PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, VASC MED, 11, PP. 55-60, (2006); LABS K.H., NEHLER M.R., ROESSNER M., JAEGER K.A., HIATT W.R., RELIABILITY OF TREADMILL TESTING IN PERIPHERAL ARTERIAL DISEASE: A COMPARISON OF A CONSTANT LOAD WITH A GRADED LOAD TREADMILL PROTOCOL, VASC MED, 4, PP. 239-246, (1999); MONEY S.R., HERD J.A., ISAACSOHN J.L., DAVIDSON M., CUTLER B., HECKMAN J., ET AL., EFFECT OF CILOSTAZOL ON WALKING DISTANCES IN PATIENTS WITH INTERMITTENT CLAUDICATION CAUSED BY PERIPHERAL VASCULAR DISEASE, J VASC SURG, 27, PP. 267-274, (1998); HOOD S.C., MANAGEMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CAN MED ASSOC J, 155, PP. 1053-1059, (1996); DUPREZ D.A., PHARMACOLOGICAL INTERVENTIONS FOR PERIPHERAL ARTERY DISEASE, EXPERT OPIN PHARMACOTHER, 8, PP. 1465-1477, (2007); GIROLAMI B., BERNARDI E., PRINS M.H., TEN CATE J.W., HETTIARACHCHI R., PRANDONI P., ET AL., TREATMENT OF INTERMITTENT CLAUDICATION WITH PHYSICAL TRAINING, SMOKING CESSATION, PENTOXIFYLLINE, OR NAFRONYL: A META-ANALYSIS, ARCH INTERN MED, 159, PP. 337-345, (1999); DE BACKER T.L., VANDER S.R., LEHERT P., VAN B.L., NAFTIDROFURYL FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, (2008)","A.H. MOMSEN; SURGICAL RESEARCH UNIT, DEPARTMENT OF SURGERY, REGIONAL HOSPITAL HERNING, DENMARK; EMAIL: ANMOM@RINGAMT.DK","","ENGLISH","EUR. J. VASC. ENDOVASC. SURG.","REVIEW","ISI","2-S2.0-69949098158","EUR J VASC ENDOVASC SURG","REGIONAL HOSPITAL HERNING;UNIVERSITY HOSPITAL OF AARHUS;REGIONAL HOSPITAL HERNING;REGIONAL HOSPITAL HERNING;REGIONAL HOSPITAL VIBORG;REGIONAL HOSPITAL VIBORG","NOTREPORTED;REGIONAL HOSPITAL HERNING;NOTREPORTED",NA,"MOMSEN AH, 2009, EUR J VASC ENDOVASC SURG","MOMSEN AH, 2009, EUR J VASC ENDOVASC SURG"
"FRANCINI-PESENTI F;BROCADELLO F;BELTRAMOLLI D;NARDI M;CAREGARO L","FRANCINI-PESENTI, F. (23392494300); BROCADELLO, F. (15755353400); BELTRAMOLLI, D. (23391933800); NARDI, M. (57196081477); CAREGARO, L. (7004023424)","SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE DIETRESISTANT HYPERCHOLESTEROLAEMIA A DOUBLE BLIND CONTROLLED STUDY",2008,"COMPLEMENTARY THERAPIES IN MEDICINE","16","4",24,"10.1016/j.ctim.2007.08.003","CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY;CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY;CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY;CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY;CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY","PREVIOUS CLINICAL STUDIES HAVE SHOWN THAT ORAL ADMINISTRATION OF SUGAR CANE POLICOSANOL (SCP) REDUCES PLASMA TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS. A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL WAS PERFORMED IN HYPERCHOLESTEROLAEMIC, DIET-RESISTANT PATIENTS. SEVENTY PATIENTS MEETING THE SELECTION CRITERIA WERE ENROLLED. EACH SUBJECT WAS TREATED WITH POLICOSANOL 10 MG/D IN ADDITION TO A DIETETIC REGIMEN FOR 8 WEEKS. AT THE START AND AT THE END OF THE STUDY BODY WEIGHT, BODY MASS INDEX (BMI), TOTAL CHOLESTEROL, HDL-CHOLESTEROL, LDL-CHOLESTEROL AND TRIGLYCERIDES (TG) PLASMA LEVELS WERE MEASURED. THIRTY-THREE SUBJECTS IN THE POLICOSANOL AND THIRTY-ONE SUBJECTS IN THE CONTROL GROUP COMPLETED THE STUDY. DURING THE STUDY BODY MASS INDEX, TOTAL CHOLESTEROL, HDL-CHOLESTEROL, LDL-CHOLESTEROL AND TRIGLYCERIDES PLASMA LEVELS DID NOT CHANGE SIGNIFICANTLY WITHIN AND BETWEEN GROUPS. IN CONCLUSION, SUGAR CANE POLICOSANOL AT A DOSE OF 10 MG/D SHOWED NO LIPID LOWERING EFFECTS IN SUBJECTS WITH PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA. © 2007 ELSEVIER LTD. ALL RIGHTS RESERVED.","HYPERCHOLESTEROLAEMIA; LONG-CHAIN ALIPHATIC PRIMARY ALCOHOLS; POLICOSANOL; SUGAR CANE WAX","ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; COMPLEMENTARY THERAPIES; DIET; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SACCHARUM; TRIGLYCERIDES; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; TRIACYLGLYCEROL BLOOD LEVEL","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); ALEMAN C., RODEIRO I., NOA M., MENENDEZ R., GAMEZ R., HERNANDEZ C., ET AL., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J APPL TOXICOL, 21, PP. 179-184, (2001); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); FERNANDEZ J.C., MAS R., CASTANO G., MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVESTIG, 21, PP. 103-113, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-65, (2001); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA, 295, PP. 2262-2269, (2006); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); JANIKULA M., CANDIDATE N.D., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, (2004); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); HOWARD B.V., HANNAH J.S., HEISER C.C., JABLONSKI K.A., EFFECTS OF SEX AND ETHNICITY ON RESPONSES TO A LOW-FAT DIET: A STUDY OF AFRICAN AMERICANS AND WHITES, AM J CLIN NUTR, 62, (1995); TAN C.E., LOH L.M., TAI E.S., DO SINGAPORE PATIENTS REQUIRE LOWER DOSES OF STATINS? THE SGH LIPID CLINIC EXPERIENCE, SINGAPORE MED J, 44, PP. 635-638, (2003); PEARSON T.A., DENKE M.A., MCBRIDE P.E., BATTISTI W.P., BRADY W.E., PALMISANO J., A COMMUNITY-BASED, RANDOMIZED TRIAL OF EZETIMIBE ADDED TO STATIN THERAPY TO ATTAIN NCEP ATP III GOALS FOR LDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS: THE EZETIMIBE ADD-ON TO STATIN FOR EFFECTIVENESS (EASE) TRIAL, MAYO CLIN PROC, 80, PP. 587-595, (2005)","F. FRANCINI-PESENTI; CLINICAL NUTRITION UNIT, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, AZIENDA OSPEDALIERA, 35100 PADUA, VIA GIUSTINIANI 2, ITALY; EMAIL: FRANCESCOFRANCINI@YAHOO.IT","","ENGLISH","COMPLEMENT. THER. MED.","ARTICLE","ISI","2-S2.0-44349151865","COMPLEMENT THER MED","CLINICAL NUTRITION UNIT;CLINICAL NUTRITION UNIT;CLINICAL NUTRITION UNIT;CLINICAL NUTRITION UNIT;CLINICAL NUTRITION UNIT","NOTREPORTED;CLINICAL NUTRITION UNIT;NOTREPORTED",NA,"FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED","FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED"
"COHEN P;ERNST E","COHEN, PIETER A. (55142014600); ERNST, E. (36040636300)","SAFETY OF HERBAL SUPPLEMENTS A GUIDE FOR CARDIOLOGISTS",2010,"CARDIOVASCULAR THERAPEUTICS","28","7",103,"10.1111/j.1755-5922.2010.00193.x","HARVARD MEDICAL SCHOOL, CAMBRIDGE HEALTH ALLIANCE, SOMERVILLE, MA, UNITED STATES;COMPLEMENTARY MEDICINE, PENINSULA MEDICAL SCHOOL, UNIVERSITIES OF EXETER AND PLYMOUTH, EXETER, UNITED KINGDOM","MANY PATIENTS USE HERBAL SUPPLEMENTS TO TREAT CHRONIC CARDIOVASCULAR CONDITIONS AND OFTEN COMBINE HERBAL INGREDIENTS WITH CARDIOVASCULAR MEDICATIONS. HOWEVER, PHYSICIANS DO NOT RELIABLY ELICIT A HISTORY OF HERBAL USE FROM THEIR PATIENTS AND MAY OVERLOOK HERBAL SUPPLEMENTS' ADVERSE EFFECTS. ALTHOUGH OFTEN CONSIDERED HARMLESS BY PATIENTS, HERBAL SUPPLEMENTS MAY CAUSE ADVERSE CARDIOVASCULAR EFFECTS FROM AN HERBAL INGREDIENT, A CONTAMINANT, OR AN HERB-DRUG INTERACTION. HERBAL STIMULANTS, INCLUDING BITTER ORANGE, EPHEDRA, CAFFEINE, GUARANA, MATÉ, KOLA, ARECA, LOBELIA, KHAT, AND OTHERS ARE THE MOST COMMON CATEGORY OF HERBAL THERAPIES TO CAUSE CARDIOVASCULAR EFFECTS. HOWEVER, DOZENS OF OTHER HERBAL INGREDIENTS HAVE ALSO BEEN LINKED TO ADVERSE CARDIOVASCULAR EVENTS. IN ADDITION TO LISTED INGREDIENTS, HERBAL SUPPLEMENTS MAY BECOME CONTAMINATED AT A NUMBER OF STAGES DURING PRODUCTION. PESTICIDES, HEAVY METALS, BACTERIA, AND PHARMACEUTICAL AGENTS HAVE BEEN DETECTED IN HERBAL SUPPLEMENTS. SUPPOSEDLY ""HERBAL"" PRODUCTS THAT ARE ADULTERATED WITH PRESCRIPTION ANORECTICS, ANTIDEPRESSANTS, DIURETICS, PHOSPHODIESTERASE-5 INHIBITORS ALONG WITH OTHER MEDICATIONS HAVE BEEN IDENTIFIED THROUGHOUT EUROPE, NORTH AMERICA, AND ASIA. ALL OF THESE ADULTERANTS HAVE POTENTIAL CARDIOVASCULAR EFFECTS. HERBAL INTERACTIONS WITH A VARIETY OF CARDIOVASCULAR MEDICATIONS MAY ALSO LEAD TO ADVERSE EVENTS. HERBAL INGREDIENTS MAY CAUSE PHARMACOKINETIC AS WELL AS PHARMACODYNAMIC HERB-DRUG INTERACTIONS. WE REVIEW CLINICALLY RELEVANT PATTERNS OF ADVERSE CARDIOVASCULAR REACTIONS TO HERBAL SUPPLEMENTS, AND WE PROVIDE RESOURCES AND RECOMMENDATIONS FOR PRACTICING CARDIOLOGISTS EVALUATING PATIENTS WITH SUSPECTED HERBAL ADVERSE EFFECTS. © 2010 BLACKWELL PUBLISHING LTD.","ADULTERATION; ADVERSE EFFECTS; HERB-DRUG INTERACTIONS; HERBAL SUPPLEMENTS","CARDIOVASCULAR AGENTS; COMMUNICATION; DIETARY SUPPLEMENTS; DRUG CONTAMINATION; EVIDENCE-BASED MEDICINE; HERB-DRUG INTERACTIONS; HUMANS; PHYSICIAN-PATIENT RELATIONS; PLANT PREPARATIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; AESCULUS HIPPOCASTANUM EXTRACT; ALOE VERA EXTRACT; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; CAFFEINE; CATHA EDULIS EXTRACT; DIURETIC AGENT; EPHEDRA EXTRACT; FENUGREEK EXTRACT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; GREEN TEA EXTRACT; GUAR GUM; GUGGULSTERONE; HEAVY METAL; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; ILEX PARAGUARIENSIS EXTRACT; ISPAGULA; MANNAN; PESTICIDE; PHOSPHODIESTERASE V INHIBITOR; POLICOSANOL; POMEGRANATE EXTRACT; SOUR ORANGE EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; XUEZHIKANG; CARDIOVASCULAR AGENT; PLANT MEDICINAL PRODUCT; ANGIONEUROTIC EDEMA; ASIA; BETEL NUT; BLEEDING; CARDIOLOGIST; CARDIOVASCULAR DISEASE; COLA; DEATH; DIARRHEA; DRUG CONTAMINATION; DRUG SAFETY; EPHEDRA; ESOPHAGUS OBSTRUCTION; EUROPE; FOOD DRUG INTERACTION; GASTROINTESTINAL OBSTRUCTION; GUARANA; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART RATE; HERB; HERB DRUG INTERACTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; ILEX PARAGUARIENSIS; INSOMNIA; LOBELIA; MYOPATHY; NAUSEA; NONHUMAN; NORTH AMERICA; POTASSIUM DEPLETION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SIDE EFFECT; SOUR ORANGE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; DIET SUPPLEMENTATION; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; INTERPERSONAL COMMUNICATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME","","","ARTZ M.B., HARNACK L.J., DUVAL S.J., ET AL., USE OF NONPRESCRIPTION MEDICATIONS FOR PERCEIVED CARDIOVASCULAR HEALTH, AM J PREV MED, 30, PP. 78-81, (2006); GARDINER P., GRAHAM R.E., LEGEDZA A.T., EISENBERG D.M., PHILLIPS R.S., FACTORS ASSOCIATED WITH DIETARY SUPPLEMENT USE AMONG PRESCRIPTION MEDICATION USERS, ARCH INTERN MED, 166, PP. 1968-1974, (2006); QATO D.M., ALEXANDER G.C., CONTI R.M., ET AL., USE OF PRESCRIPTION AND OVER-THE-COUNTER MEDICATIONS AND DIETARY SUPPLEMENTS AMONG OLDER ADULTS IN THE UNITED STATES, JAMA, 300, PP. 2867-2878, (2008); ERNST E., PITTLER M.H., WIDER B., BODDY K., THE DESKTOP GUIDE TO COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2ND ED; ERNST E., PITTLER M.H., WIDER B., BODDY K., COMPLEMENTARY THERAPIES FOR PAIN MANAGEMENT., (2007); HEMODYNAMIC EFFECTS OF EPHEDRA-FREE WEIGHT-LOSS SUPPLEMENTS IN HUMANS, AM J MED, 118, PP. 998-1003, (2009); JACK S., DESJARLAIS-RENAUD T., PILON K., BITTER ORANGE OR SYNEPHRINE: UPDATE ON CARDIOVASCULAR ADVERSE REACTIONS, CAN ADV REACT NEWSLTR, 17, PP. 2-3, (2007); DASGUPTA A., HERBAL SUPPLEMENTS AND THERAPEUTIC DRUG MONITORING: FOCUS ON DIGOXIN IMMUNOASSAYS AND INTERACTIONS WITH ST JOHN'S WORT, THER DRUG MONIT, 30, PP. 212-217, (2008); SCHEINOST M.E., DIGOXIN TOXICITY IN A 26-YEAR OLD WOMAN TAKING A HERBAL DIETARY SUPPLEMENT, J AM OSTEOP ASS, 101, PP. 444-446, (2001); PATEL S., ROBINSON R., BURK M., LETTER TO THE EDITOR: HYPERTENSIVE CRISIS ASSOCIATED WITH ST JOHN'S WORT, AM J MED, 112, PP. 507-508, (2002); HERBAL DIETARY SUPPLEMENTS: EXAMPLES OF DECEPTIVE OR QUESTIONABLE MARKETING PRACTICES AND POTENTIALLY DANGEROUS ADVICE, J HEPATOLOGY, 50, PP. 111-117, (2009); TOURNAS V.H., KATSOUDAS E., MIRACCO E.J., MOULDS, YEASTS AND AEROBIC PLATE COUNTS IN GINSENG SUPPLEMENTS, INTERNL J FOOD MICRO, 108, PP. 178-181, (2006); COHEN P.A., AMERICAN ROULETTE - CONTAMINATED DIETARY SUPPLEMENTS, N ENG J MED, 361, PP. 1523-1525, (2009); FDA NEWS RELEASE: FDA UNCOVERS ADDITIONAL TAINTED WEIGHT LOSS PRODUCTS. FOOD AND DRUG ADMINISTRATION DOCUMENTS AND PUBLICATIONS, (2009); HIDDEN RISKS OF ERECTILE DYSFUNCTION ""TREATMENTS"" SOLD ONLINE, J GEN INTERN MED, 24, PP. 430-433, (2009); POON W.T., LAM Y.H., LAI C.K., CHAN A.Y., MAK T.W., ANALOGUES OF ERECTILE DYSFUNCTION DRUGS: AN UNDER-RECOGNISED THREAT, HONG KONG MED J, 13, PP. 359-363, (2007); BUSH T.M., RAYBURN K.S., HOLLOWAY S.W., ET AL., ADVERSE INTERACTIONS BETWEEN HERBAL AND DIETARY SUBSTANCES AND PRESCRIPTION MEDICATIONS: A CLINICAL SURVEY, ALTERNAT THER HEALTH MED, 13, PP. 30-35, (2007); ERNST E., HERB-DRUG INTERACTIONS - AN UPDATE, PERFUSION, 16, PP. 175-194, (2003); SCOTT G.N., ELMER G.W., UPDATE ON NATURAL PRODUCT-DRUG INTERACTIONS, AM J HEALTH-SYST PHARM, 59, PP. 339-347, (2002); BARNES J., MILLS S.Y., ABBOT N.C., WILLOUGHBY M., ERNST E., DIFFERENT STANDARDS FOR REPORTING ADRS TO HERBAL REMEDIES AND CONVENTIONAL OTC MEDICINES FACE-TO-FACE INTERVIEWS WITH 515 USERS OF HERBAL REMEDIES, BR J CLIN PHARMACOL, 45, PP. 496-500, (1998); IZZO A.A., ERNST E., INTERACTIONS BETWEEN HERBAL MEDICINES AND PRESCRIBED DRUGS: A SYSTEMATIC REVIEW, DRUGS, 69, PP. 1777-1798, (2009); RUSCHITZKA F., MEIER P.J., TURINA M., LUSCHER T.F., NOLL G., ACUTE HEART TRANSPLANT REJECTION DUE TO SAINT JOHN'S WORT, LANCET, 355, PP. 548-549, (2000); YUAN C.-S., WIE G., DEY L., ET AL., BRIEF COMMUNICATION: AMERICAN GINSENG REDUCES WARFARIN'S EFFECT IN HEALTHY PATIENTS, ANN INTERN MED, 141, PP. 23-27, (2004); ROSADO M.F., THROMBOSIS OF A PROSTHETIC AORTIC VALVE DISCLOSING A HAZARDOUS INTERACTION BETWEEN WARFARIN AND A COMMERCIAL GINSENG PRODUCT, CARDIOLOGY, 99, (2003); GOLDSTEIN L.H., ELIAS M., RON-AVRAHAM G., ET AL., CONSUMPTION OF HERBAL REMEDIES AND DIETARY SUPPLEMENTS AMONGST PATIENTS HOSPITALIZED IN MEDICAL WARDS, BR J CLIN PHARMACOL, 64, PP. 373-380, (2007); YOUNG L.A., FAUROT K.R., GAYLORD S.A., USE OF AND COMMUNICATION ABOUT DIETARY SUPPLEMENTS AMONG HOSPITALIZED PATIENTS, J GEN INTERN MED, 24, PP. 366-369, (2008); HENSRUD D.D., ENGLE D.D., SCHEITEL S.M., UNDERREPORTING THE USE OF DIETARY SUPPLEMENTS AND NONPRESCRIPTION MEDICATIONS AMONG PATEITNS UNDERGOING A PERIODIC HEALTH EXAMINATION, MAYO CLIN PROC, 74, PP. 443-447, (1999); VOGEL J.H.K., BOLLING S.F., COSTELLO R.B., ET AL., INTEGRATING COMPLEMENTARY MEDICINE INTO CARDIOVASCULAR MEDICINE-ONLINE APPENDICES: A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION TASK FORCE ON CLINICAL EXPERT CONSENSUS DOCUMENTS (WRITING COMMITTEE TO DEVELOP AN EXPERT CONSENSUS DOCUMENT ON COMPLEMENTARY AND INTEGRATIVE MEDICINE), J AM COLL CARDIOL, 46, PP. 184-221, (2005)","P. A. COHEN; CAMBRIDGE HEALTH ALLIANCE, SOMERVILLE, MA 02143, 26 CENTRAL STREET, UNITED STATES; EMAIL: PCOHEN@CHALLIANCE.ORG","BLACKWELL PUBLISHING LTD","ENGLISH","CARDIOVASC. THER.","REVIEW","ISI","2-S2.0-77954359970","CARDIOVASC THER","HARVARD MEDICAL SCHOOL;UNIVERSITIES OF EXETER AND PLYMOUTH","NOTREPORTED;CAMBRIDGE HEALTH ALLIANCE;NOTREPORTED",NA,"COHEN PA, 2010, CARDIOVASC THER","COHEN PA, 2010, CARDIOVASC THER"
"MUSTO D;MARTORELLI L;RUSSO M;ESPOSITO G;AMATO M;ESPOSITO P;RIEGLER G","MUSTO, D. (36504645600); MARTORELLI, L. (36151163600); RUSSO, M. (35554900500); ESPOSITO, G. (56921393100); AMATO, M.R. (55871123294); ESPOSITO, P. (7006089107); RIEGLER, G. (55404015700)","THE EFFICACY OF POLICOSANOLS IN THE TREATMENT OF ASSOCIATED HYPERLIPIDEMIA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE LA STEATOSI EPATICA NON ALCOLICA IL RUOLO DEI POLICOSANOLI NELLE IPERLIPEMIE ASSOCIATE",2010,"MINERVA GASTROENTEROLOGICA E DIETOLOGICA","56","6",3,"","D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY;D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY;D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY;D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY;D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY;D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY;D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY","AIM. THE PURPOSE OF THIS STUDY WAS TO EVALUATE THE EFFICACY OF POLICOSANOLS IN THE TREATMENT OF ASSOCIATED HYPERLIPIDEMIA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). METHODS. WE CONDUCTED A RETROSPECTIVE STUDY ON 52 PATIENTS WITH NAFLD. PRETREATMENT PATIENTS' DATA (TOTAL CHOLESTEROL, LDL CHOLESTEROL, TRIGLYCERIDES, ALT, AND AST) WERE COLLECTED AND ANALYZED. FURTHERMORE, BASED ON WEIGHT AND HEIGHT, WE CALCULATED THE BODY MASS INDEX (BMI) AND, BASED ON BLOOD GLUCOSE AND INSULIN LEVELS, WE ESTIMATED THE HUMAN OMEOSTATIC ASSESMENT INDEX (HOMA). AFTER THAT, ALL PATIENTS WERE TREATED WITH A POLICOSANOLS' SUPPLEMENT (FRLLIPID®) AND A HYPOCALORIC BALANCED DIET, AND THEN FOLLOWED OVER TIME WITH QUARTERLY INSPECTIONS. WE COLLECTED AND ANALYZED DATA ON THREE SUBSEQUENT QUARTERLY MONITORING DURING TREATMENT. RESULTS. THE COLLECTED AND ANALYZED DATA SHOWED A SIGNIFICANT REDUCTION IN TOTAL CHOLESTEROL, LDL CHOLESTEROL AND HOMA INDEX (P<0.002). IT WAS ALSO FOUND A TREND NOT STATISTICALLY SIGNIFICANT FOR A MARKED REDUCTION IN ALT, AST, TRIGLYCERIDES, AND BMI. CONCLUSION. THE USE OF POLICOSANOLS IS SHOWN EFFECTIVE IN THE TREATMENT OF ASSOCIATED HYPERLIPIDEMIA AND INSULIN RESISTANCE IN PATIENTS WITH FATTY LIVER DISEASE.","FATTY LIVER, ALCOHOLIC; HYPERLIPIDEMIAS; INSULIN RESISTANCE; POLICOSANOL","AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; FATTY ALCOHOLS; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TRIGLYCERIDES; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SCREENING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN OMEOSTATIC ASSESSMENT INDEX; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; LOW CALORY DIET; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PATIENT MONITORING; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL","","","MARCHESINI G., BRIZI M., MORSELLI-LABATE A.M., BIANCHI G., BUGIANESI E., MCCULLOUGH A.J., FORLANI G., MELCHIONDA N., ASSOCIATION OF NONALCOHOLIC FATTY LIVER DISEASE WITH INSULIN RESISTANCE, AMERICAN JOURNAL OF MEDICINE, 107, 5, PP. 450-455, (1999); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES E., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALES R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALES R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS IN NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL R.A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRITISH JOURNAL OF NUTRITION, 77, 6, PP. 923-932, (1997); MENENDEZ R., MAS R., AMOR A.M., GONZALES R.M., FERNANDEZ J.C., RODEIRO I., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, 1, PP. 8-12, (2001); PARKER R.A., PEARCE B.C., CLARK R.W., GORDON D.A., WRIGHT J.J.K., TOCOTRIENOLS REGULATE CHOLESTEROL PRODUCTION IN MAMMALIAN CELLS BY POST- TRANSCRIPTIONAL SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, JOURNAL OF BIOLOGICAL CHEMISTRY, 268, 15, PP. 11230-11238, (1993); KLEINVELD H.A., DEMACKER P.N.M., DE H.A.F.J., STALENHOEF A.F.H., DECREASED IN VITRO OXIDIZABILITY OF LOW-DENSITY LIPOPROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS TREATED WITH 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS, EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 23, 5, PP. 289-295, (1993); BERTRAM S.R., VENTER I., STEWART R.I., WEIGHT LOSS IN OBESE WOMEN - EXERCISE V. DIETARY EDUCATION, SOUTH AFRICAN MEDICAL JOURNAL, 78, 1, PP. 15-18, (1990); JONES N.L., KILLIAN K.J., EXERCISE LIMITATION IN HEALTH AND DISEASE, N ENGL J MED, 343, PP. 632-641, (2000)","D. MUSTO; D.A.I. DI MEDICINA INTERNA E SPECIALISTICA, UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA E ENDOSCOPIA DIGESTIVA, SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI, 80135 NAPOLI, PIAZZA MIRAGLIA 1, ITALY; EMAIL: DARIO.MUSTO@ALICE.IT","","ITALIAN","MINERVA GASTROENTEROL. DIETOL.","ARTICLE","ISI","2-S2.0-79952267154","MINERVA GASTROENTEROL DIETOL","SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI","NOTREPORTED;SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI;NOTREPORTED",NA,"MUSTO D, 2010, MINERVA GASTROENTEROL DIETOL","MUSTO D, 2010, MINERVA GASTROENTEROL DIETOL"
"WHAYNE J T","WHAYNE JR., THOMAS F. (57204791430)","WHAT SHOULD MEDICAL PRACTITIONERS KNOW ABOUT THE ROLE OF ALTERNATIVE MEDICINES IN CARDIOVASCULAR DISEASE MANAGEMENT",2010,"CARDIOVASCULAR THERAPEUTICS","28","17",8,"10.1111/j.1755-5922.2009.00101.x","DEPARTMENT OF MEDICINE, GILL HEART INSTITUTE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES","ALTERNATIVE MEDICATIONS AS A TERM CALL UP MANY DIFFERENT MEANINGS, SIGNIFICANCE, AND PERCEPTIONS TO VARIOUS MEDICAL PRACTITIONERS. SOME ARE GOOD; OTHERS ARE BAD. A WIDE RANGE OF ALTERNATIVE MEDICATIONS WITH RELEVANCE OR CONNECTION TO CARDIOVASCULAR (CV) DISEASE HAVE BEEN CONSIDERED. WHILE MANY ARE WORTHLESS, OTHERS HAVE DEFINITE BENEFIT, AND AT LEAST ONE, CHELATION THERAPY, IS ASSOCIATED WITH DEFINITE HARM, SIGNIFICANT RISK, NO BENEFIT, AND ENRICHMENT OF THE PRACTITIONERS WHO PRESCRIBE IT. THE ISSUES CONCERNING ALTERNATIVE THERAPIES WILL LIKELY NEVER BE STUDIED WITH RANDOMIZED CLINICAL TRIALS DUE TO THE LACK OF A PROFIT MOTIVE ON THE PART OF PHARMACEUTICAL COMPANIES - ONLY RARELY DO OTHER INSTITUTIONS, SUCH AS THE NATIONAL INSTITUTES OF HEALTH, SUPPORT MEDICINAL STUDIES. BASIC KNOWLEDGE OF ALTERNATIVE THERAPIES IS ESSENTIAL FOR THE CV SPECIALIST AND OTHER PRACTICING PHYSICIANS AND OTHER PRACTITIONERS, SINCE AT LEAST A FEW OF THEIR PATIENTS WILL TAKE THESE MEDICATIONS REGARDLESS OF MEDICAL ADVICE. THE RESULT IS THAT A NUMBER OF THESE ALTERNATIVE MEDICATIONS WILL THEN INTERACT WITH CONVENTIONAL CV MEDICATIONS, MANY TIMES UNFAVORABLY. © 2010 BLACKWELL PUBLISHING LTD.","ALTERNATIVE MEDICINES; ANTIOXIDANTS; CARDIOVASCULAR DISEASE; CHELATION; RED WINE; VITAMINS","ATTITUDE OF HEALTH PERSONNEL; CARDIOLOGY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CHOLESTIN; CINNAMON EXTRACT; CORDYCEPS SINENSIS EXTRACT; CORDYMAX; CYANOCOBALAMIN; DIGOXIN; EDETIC ACID; FISH OIL; FOLIC ACID; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GUGGULSTERONE; HERBACEOUS AGENT; HOMOCYSTEINE; HYPERICUM PERFORATUM EXTRACT; ICOSAPENTAENOIC ACID; KAVA EXTRACT; LINSEED OIL; OLIVE OIL; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE; PLACEBO; POLICOSANOL; PYRIDOXINE; RETINOL; SOYBEAN PROTEIN; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ACUTE CORONARY SYNDROME; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AYURVEDA; BERRY; CARDIOVASCULAR DISEASE; CHELATION THERAPY; CLINICAL TRIAL; CORDYCEPS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEMENTIA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; GARLIC; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GINKGO BILOBA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MEDICAL SPECIALIST; MEDITERRANEAN DIET; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUT; PERIPHERAL VASCULAR DISEASE; PHYSICIAN; PRIORITY JOURNAL; RED WINE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE","","","SOOD A., SOOD R., BRINKER F.J., MANN R., LOEHRER L.L., WAHNER-ROEDLER D.L., POTENTIAL FOR INTERACTIONS BETWEEN DIETARY SUPPLEMENTS AND PRESCRIPTION MEDICATIONS, AM J MED, 121, PP. 207-211, (2008); PENG C.C., GLASSMAN P.A., TRILLI L.E., HAYES-HUNTER J., GOOD C.B., INCIDENCE AND SEVERITY OF POTENTIAL DRUG-DIETARY SUPPLEMENT INTERACTIONS IN PRIMARY CARE PATIENTS: AN EXPLORATORY STUDY OF 2 OUTPATIENT PRACTICES, ARCH INTERN MED, 164, PP. 630-636, (2004); EISENBERG D.M., DAVIS R.B., ETTNER S.L., ET AL., TRENDS IN ALTERNATIVE MEDICINE USE IN THE UNITED STATES, 1990-1997: RESULTS OF A FOLLOW-UP NATIONAL SURVEY, JAMA, 280, PP. 1569-1575, (1998); ED., (2008); ED., (2003); NATURAL MEDICINES: COMPREHENSIVE DATABASE, (2007); ACAI BERRY AN EXTRAORDINARY ANTIOXIDANT-RICH PALM FRUIT FROM AMAZON RAIN FOREST; COLLINS R., ARMITAGE J., PARISH S., SLEIGHT P., PETO R., MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20 536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, 9326, PP. 7-22, (2002); COLLINS R., ARMITAGE J., PARISH S., ET AL., MRC/BHF HEART PROTECTION STUDY OF ANTIOXIDANT VITAMIN SUPPLEMENTATION IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 25-33, (2002); YUSUF S., SLEIGHT P., POGUE J., BOSCH J., DAVIES R., DAGENAIS G., EFFECTS OF AN ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR, RAMIPRIL, ON CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, N ENGL J MED, 342, PP. 145-153, (2000); YUSUF S., DAGENAIS G., POGUE J., BOSCH J., SLEIGHT P., VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, N ENGL J MED, 342, PP. 154-160, (2000); HODIS H.N., MACK W.J., LABREE L., MAHRER P.R., SEVANIAN A., LIU C.R., ET AL., ALPHA-TOCOPHEROL SUPPLEMENTATION IN HEALTHY INDIVIDUALS REDUCES LOW-DENSITY LIPOPROTEIN OXIDATION BUT NOT ATHEROSCLEROSIS: THE VITAMIN E ATHEROSCLEROSIS PREVENTION STUDY (VEAPS), CIRCULATION, 106, PP. 1453-1459, (2002); BJELAKOVIC G., NIKOLOVA D., GLUUD L.L., SIMONETTI R.G., GLUUD C., MORTALITY IN RANDOMIZED TRIALS OF ANTIOXIDANT SUPPLEMENTS FOR PRIMARY AND SECONDARY PREVENTION: SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 297, PP. 842-857, (2007); MILLER III E.R., PASTOR-BARRIUSO R., DALAL D., RIEMERSMA R.A., APPEL L.J., GUALLAR E., META-ANALYSIS: HIGH-DOSAGE VITAMIN E SUPPLEMENTATION MAY INCREASE ALL-CAUSE MORTALITY, ANN INTERN MED, 142, PP. 37-46, (2005); COOK N.R., ALBERT C.M., GAZIANO J.M., ET AL., A RANDOMIZED FACTORIAL TRIAL OF VITAMINS C AND E AND BETA CAROTENE IN THE SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN WOMEN: RESULTS FROM THE WOMEN'S ANTIOXIDANT CARDIOVASCULAR STUDY, ARCH INTERN MED, 167, PP. 1610-1618, (2007); LEE I.M., COOK N.R., GAZIANO J.M., ET AL., VITAMIN E IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER. THE WOMEN'S HEALTH STUDY: A RANDOMIZED CONTROLLED TRIAL, JAMA, 294, PP. 56-65, (2005); SALONEN R.M., NYYSSONEN K., KAIKKONEN J., ET AL., SIX-YEAR EFFECT OF COMBINED VITAMIN C AND E SUPPLEMENTATION ON ATHEROSCLEROTIC PROGRESSION: THE ANTIOXIDANT SUPPLEMENTATION IN ATHEROSCLEROSIS PREVENTION (ASAP) STUDY, CIRCULATION, 107, PP. 947-953, (2003); SESSO H.D., BURING J.E., CHRISTEN W.G., ET AL., VITAMINS E AND C IN THE PREVENTION OF CARDIOVASCULAR DISEASE IN MEN: THE PHYSICIANS' HEALTH STUDY II RANDOMIZED CONTROLLED TRIAL, JAMA, 300, PP. 2123-2133, (2008); KULLER L.H., A TIME TO STOP PRESCRIBING ANTIOXIDANT VITAMINS TO PREVENT AND TREAT HEART DISEASE?, ARTERIOSCLER THROMB VASC BIOL, 21, (2001); CHEUNG M.C., ZHAO X.Q., CHAIT A., ALBERS J.J., BROWN B.G., ANTIOXIDANT SUPPLEMENTS BLOCK THE RESPONSE OF HDL TO SIMVASTATIN-NIACIN THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE AND LOW HDL, ARTERIOSCLER THROMB VASC BIOL, 21, PP. 1320-1326, (2001); BROWN B.G., CHEUNG M.C., LEE A.C., ZHAO X.Q., CHAIT A., ANTIOXIDANT VITAMINS AND LIPID THERAPY: END OF A LONG ROMANCE?, ARTERIOSCLER THROMB VASC BIOL, 22, PP. 1535-1546, (2002); VAN LEEUWEN R., BOEKHOORN S., VINGERLING J.R., ET AL., DIETARY INTAKE OF ANTIOXIDANTS AND RISK OF AGE-RELATED MACULAR DEGENERATION, JAMA, 294, PP. 3101-3107, (2005); AYURVEDA, (2008); SAPER R.B., PHILLIPS R.S., SEHGAL A., ET AL., LEAD, MERCURY, AND ARSENIC IN US- AND INDIAN-MANUFACTURED AYURVEDIC MEDICINES SOLD VIA THE INTERNET, JAMA, 300, PP. 915-923, (2008); LONN E., YUSUF S., ARNOLD M.J., ET AL., HOMOCYSTEINE LOWERING WITH FOLIC ACID AND B VITAMINS IN VASCULAR DISEASE, N ENGL J MED, 354, PP. 1567-1577, (2006); BAZZANO L.A., REYNOLDS K., HOLDER K.N., HE J., EFFECT OF FOLIC ACID SUPPLEMENTATION ON RISK OF CARDIOVASCULAR DISEASES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, JAMA, 296, PP. 2720-2726, (2006); BONAA K.H., NJOLSTAD I., UELAND P.M., ET AL., HOMOCYSTEINE LOWERING AND CARDIOVASCULAR EVENTS AFTER ACUTE MYOCARDIAL INFARCTION, N ENGL J MED, 354, PP. 1578-1588, (2006); ALBERT C.M., COOK N.R., GAZIANO J.M., ZAHARRIS E., MACFADYEN J., DANIELSON E., ET AL., EFFECT OF FOLIC ACID AND B VITAMINS ON RISK OF CARDIOVASCULAR EVENTS AND TOTAL MORTALITY AMONG WOMEN AT HIGH RISK FOR CARDIOVASCULAR DISEASE: A RANDOMIZED TRIAL, JAMA, 299, PP. 2027-2036, (2008); LOSCALZO J., HOMOCYSTEINE TRIALS - CLEAR OUTCOMES FOR COMPLEX REASONS, N ENGL J MED, 354, PP. 1629-1632, (2006); SEARCH: FOLIC ACID AND B12 SUPPLEMENTATION FOR HOMOCYSTEINE LOWERING DID NOT LOWER CARDIOVASCULAR EVENTS; KNUDTSON M.L., WYSE D.G., GALBRAITH P.D., ET AL., CHELATION THERAPY FOR ISCHEMIC HEART DISEASE: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, PP. 481-486, (2002); ANDERSON T.J., HUBACEK J., WYSE D.G., KNUDTSON M.L., EFFECT OF CHELATION THERAPY ON ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE: PATCH SUBSTUDY, J AM COLL CARDIOL, 41, PP. 420-425, (2003); QUESTIONS AND ANSWERS ABOUT CHELATION THERAPY, (2008); TRIAL TO ASSESS CHELATION THERAPY (TACT): NCT00044213 (CLINICAL TRIALS.GOV IDENTIFIER); MANG B., WOLTERS M., SCHMITT B., ET AL., EFFECTS OF A CINNAMON EXTRACT ON PLASMA GLUCOSE, HBA, AND SERUM LIPIDS IN DIABETES MELLITUS TYPE 2, EUR J CLIN INVEST, 36, PP. 340-344, (2006); DUGOUA J.J., SEELY D., PERRI D., ET AL., FROM TYPE 2 DIABETES TO ANTIOXIDANT ACTIVITY: A SYSTEMATIC REVIEW OF THE SAFETY AND EFFICACY OF COMMON AND CASSIA CINNAMON BARK, CAN J PHYSIOL PHARMACOL, 85, PP. 837-847, (2007); CASO G., KELLY P., MCNURLAN M.A., LAWSON W.E., EFFECT OF COENZYME Q10 ON MYOPATHIC SYMPTOMS IN PATIENTS TREATED WITH STATINS, AM J CARDIOL, 99, PP. 1409-1412, (2007); MARCOFF L., THOMPSON P.D., THE ROLE OF COENZYME Q10 IN STATIN-ASSOCIATED MYOPATHY: A SYSTEMATIC REVIEW, J AM COLL CARDIOL, 49, PP. 2231-2237, (2007); PRUEKSARITANONT T., TANG C., QIU Y., MU L., SUBRAMANIAN R., LIN J.H., EFFECTS OF FIBRATES ON METABOLISM OF STATINS IN HUMAN HEPATOCYTES, DRUG METAB DISPOS, 30, PP. 1280-1287, (2002); PARCELL A.C., SMITH J.M., SCHULTHIES S.S., MYRER J.W., FELLINGHAM G., CORDYCEPS SINENSIS (CORDYMAX CS-4) SUPPLEMENTATION DOES NOT IMPROVE ENDURANCE EXERCISE PERFORMANCE, INT J SPORT NUTR EXERC METAB, 14, PP. 236-242, (2004); COLSON S.N., WYATT F.B., JOHNSTON D.L., AUTREY L.D., FITZGERALD Y.L., EARNEST C.P., CORDYCEPS SINENSIS- AND RHODIOLA ROSEA-BASED SUPPLEMENTATION IN MALE CYCLISTS AND ITS EFFECT ON MUSCLE TISSUE OXYGEN SATURATION, J STRENGTH COND RES / NATIONAL STRENGTH AND CONDITIONING ASSOCIATION, 19, PP. 358-363, (2005); GARDNER C.D., LAWSON L.D., BLOCK E., ET AL., EFFECT OF RAW GARLIC VERSUS COMMERCIAL GARLIC SUPPLEMENTS ON PLASMA LIPID CONCENTRATIONS IN ADULTS WITH MODERATE HYPERCHOLESTEROLEMIA: A RANDOMIZED CLINICAL TRIAL, ARCH INTER MED, 167, PP. 346-353, (2007); KANOWSKI S., HOERR R., GINKGO BILOBA EXTRACT EGB 761 IN DEMENTIA: INTENT-TO-TREAT ANALYSES OF A 24-WEEK, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL, PHARMACOPSYCHIATRY, 36, PP. 297-303, (2003); PETERS H., KIESER M., HOLSCHER U., DEMONSTRATION OF THE EFFICACY OF GINKGO BILOBA SPECIAL EXTRACT EGB 761® ON INTERMITTENT CLAUDICATION - A PLACEBO-CONTROLLED, DOUBLE-BLIND MULTICENTER TRIAL, VASA - JOURNAL OF VASCULAR DISEASES, 27, 2, PP. 106-110, (1998); GERTSCH J.H., SETO T.B., MOR J., ONOPA J., GINKGO BILOBA FOR THE PREVENTION OF SEVERE ACUTE MOUNTAIN SICKNESS (AMS) STARTING ONE DAY BEFORE RAPID ASCENT, HIGH ALTITUDE MED BIOL, 3, PP. 29-37, (2002); DEKOSKY S.T., WILLIAMSON J.D., FITZPATRICK A.L., ET AL., GINKGO BILOBA FOR PREVENTION OF DEMENTIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 300, PP. 2253-2262, (2008); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); ULBRICHT C., BASCH E., SZAPARY P., HAMMERNESS P., AXENTSEV S., BOON H., KROLL D., GARRAWAY L., VORA M., WOODS J., GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENTARY THERAPIES IN MEDICINE, 13, 4, PP. 279-290, (2005); THOMPSON R., RUCH W., HASENOHRL R.U., ENHANCED COGNITIVE PERFORMANCE AND CHEERFUL MOOD BY STANDARDIZED EXTRACTS OF PIPER METHYSTICUM (KAVA-KAVA), HUM PSYCHOPHARMACOL, 19, PP. 243-250, (2004); LEHRL S., CLINICAL EFFICACY OF KAVA EXTRACT WS 1490 IN SLEEP DISTURBANCES ASSOCIATED WITH ANXIETY DISORDERS. RESULTS OF A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL, J AFFECT DISORD, 78, PP. 101-110, (2004); CONNOR K.M., PAYNE V., DAVIDSON J.R., KAVA IN GENERALIZED ANXIETY DISORDER: THREE PLACEBO-CONTROLLED TRIALS, INT CLIN PSYCHOPHARMACOL, 21, PP. 249-253, (2006); GURLEY B.J., SWAIN A., HUBBARD M.A., ET AL., SUPPLEMENTATION WITH GOLDENSEAL (HYDRASTIS CANADENSIS), BUT NOT KAVA KAVA (PIPER METHYSTICUM), INHIBITS HUMAN CYP3A ACTIVITY IN VIVO, CLIN PHARMACOL THER, 83, PP. 61-69, (2008); WATKINS L.L., CONNOR K.M., DAVIDSON J.R., EFFECT OF KAVA EXTRACT ON VAGAL CARDIAC CONTROL IN GENERALIZED ANXIETY DISORDER: PRELIMINARY FINDINGS, J PSYCHOPHARMACOL (OXFORD, ENGLAND), 15, PP. 283-286, (2001); GURLEY B.J., SWAIN A., BARONE G.W., ET AL., EFFECT OF GOLDENSEAL (HYDRASTIS CANADENSIS) AND KAVA KAVA (PIPER METHYSTICUM) SUPPLEMENTATION ON DIGOXIN PHARMACOKINETICS IN HUMANS, DRUG METAB DISPOS, 35, PP. 240-245, (2007); OOSTHUIZEN W., VORSTER H.H., VERMAAK W.J., ET AL., LECITHIN HAS NO EFFECT ON SERUM LIPOPROTEIN, PLASMA FIBRINOGEN AND MACRO MOLECULAR PROTEIN COMPLEX LEVELS IN HYPERLIPIDAEMIC MEN IN A DOUBLE-BLIND CONTROLLED STUDY, EUR J CLIN NUTR, 52, PP. 419-424, (1998); SIMONS L.A., HICKIE J.B., RUYS J., TREATMENT OF HYPERCHOLESTEROLAEMIA WITH ORAL LECITHIN, AUST NZ J MED, 7, PP. 262-266, (1977); SPILBURG C.A., GOLDBERG A.C., MCGILL J.B., ET AL., FAT-FREE FOODS SUPPLEMENTED WITH SOY STANOL-LECITHIN POWDER REDUCE CHOLESTEROL ABSORPTION AND LDL CHOLESTEROL, J AM DIET ASSOC, 103, PP. 577-581, (2003); OSTLUND JR. R.E., SPILBURG C.A., STENSON W.F., SITOSTANOL ADMINISTERED IN LECITHIN MICELLES POTENTLY REDUCES CHOLESTEROL ABSORPTION IN HUMANS, AM J CLIN NUTR, 70, PP. 826-831, (1999); HEYMAN A., SCHMECHEL D., WILKINSON W., ET AL., FAILURE OF LONG TERM HIGH-DOSE LECITHIN TO RETARD PROGRESSION OF EARLY-ONSET ALZHEIMER'S DISEASE, J NEURAL TRANSM, 24, PP. 279-286, (1987); COHEN M.B., FITTEN L.J., LAKE R.R., PERRYMAN K.M., GRAHAM L.S., SEVRIN R., SPECT BRAIN IMAGING IN ALZHEIMER'S DISEASE DURING TREATMENT WITH ORAL TETRAHYDROAMINOACRIDINE AND LECITHIN, CLIN NUCL MED, 17, PP. 312-315, (1992); ABBEY M., NOAKES M., BELLING G.B., NESTEL P.J., PARTIAL REPLACEMENT OF SATURATED FATTY ACIDS WITH ALMONDS OR WALNUTS LOWERS TOTAL PLASMA CHOLESTEROL AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL, AM J CLIN NUTR, 59, PP. 995-999, (1994); SABATE J., FRASER G.E., BURKE K., KNUTSEN S.F., BENNETT H., LINDSTED K.D., EFFECTS OF WALNUTS ON SERUM LIPID LEVELS AND BLOOD PRESSURE IN NORMAL MEN, N ENGL J MED, 328, PP. 603-607, (1993); ZAMBON D., SABATE J., MUNOZ S., ET AL., SUBSTITUTING WALNUTS FOR MONOUNSATURATED FAT IMPROVES THE SERUM LIPID PROFILE OF HYPERCHOLESTEROLEMIC MEN AND WOMEN. A RANDOMIZED CROSSOVER TRIAL, ANN INTERN MED, 132, PP. 538-546, (2000); SEGURA R., JAVIERRE C., LIZARRAGA M.A., ROS E., OTHER RELEVANT COMPONENTS OF NUTS: PHYTOSTEROLS, FOLATE AND MINERALS, BR J NUTR, 96, SUPPL. 2, (2006); VISIOLI F., GALLI C., BIOLOGICAL PROPERTIES OF OLIVE OIL PHYTOCHEMICALS, CRIT REV FOOD SCI NUTR, 42, PP. 209-221, (2002); VISIOLI F., POLI A., GALL C., ANTIOXIDANT AND OTHER BIOLOGICAL ACTIVITIES OF PHENOLS FROM OLIVES AND OLIVE OIL, MEDICINAL RESEARCH REVIEWS, 22, 1, PP. 65-75, (2002); RUANO J., LOPEZ-MIRANDA J., FUENTES F., ET AL., PHENOLIC CONTENT OF VIRGIN OLIVE OIL IMPROVES ISCHEMIC REACTIVE HYPEREMIA IN HYPERCHOLESTEROLEMIC PATIENTS, JAM COLL CARDIOL, 46, PP. 1864-1868, (2005); KONTOGIANNI M.D., PANAGIOTAKOS D.B., CHRYSOHOOU C., PITSAVOS C., ZAMPELAS A., STEFANADIS C., THE IMPACT OF OLIVE OIL CONSUMPTION PATTERN ON THE RISK OF ACUTE CORONARY SYNDROMES: THE CARDIO2000 CASE-CONTROL STUDY, CLIN CARDIOL, 30, PP. 125-129, (2007); HANSEN S.N., HARRIS W.S., NEW EVIDENCE FOR THE CARDIOVASCULAR BENEFITS OF LONG CHAIN OMEGA-3 FATTY ACIDS, CURR ATHEROSCLER REP, 9, PP. 434-440, (2007); TANAKA K., ISHIKAWA Y., YOKOYAMA M., ET AL., REDUCTION IN THE RECURRENCE OF STROKE BY EICOSAPENTAENOIC ACID FOR HYPERCHOLESTEROLEMIC PATIENTS: SUBANALYSIS OF THE JELIS TRIAL, STROKE, 39, PP. 2052-2058, (2008); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); YAMAGISHI K., ISO H., DATE C., ET AL., FISH, OMEGA-3 POLYUNSATURATED FATTY ACIDS, AND MORTALITY FROM CARDIOVASCULAR DISEASES IN A NATIONWIDE COMMUNITY-BASED COHORT OF JAPANESE MEN AND WOMEN THE JACC (JAPAN COLLABORATIVE COHORT STUDY FOR EVALUATION OF CANCER RISK) STUDY, J AM COLL CARDIOL, 52, PP. 988-996, (2008); HARRIS W.S., VON SCHACKY C., THE OMEGA-3 INDEX: A NEW RISK FACTOR FOR DEATH FROM CORONARY HEART DISEASE?, PREV MED, 39, PP. 212-220, (2004); ERKKILA A.T., LICHTENSTEIN A.H., MOZAFFARIAN D., HERRINGTON D.M., FISH INTAKE IS ASSOCIATED WITH A REDUCED PROGRESSION OF CORONARY ARTERY ATHEROSCLEROSIS IN POSTMENOPAUSAL WOMEN WITH CORONARY ARTERY DISEASE, AM J CLIN NUTR, 80, PP. 626-632, (2004); PATADE A., DEVAREDDY L., LUCAS E.A., KORLAGUNTA K., DAGGY B.P., ARJMANDI B.H., FLAXSEED REDUCES TOTAL AND LDL CHOLESTEROL CONCENTRATIONS IN NATIVE AMERICAN POSTMENOPAUSAL WOMEN, J WOMEN HEALTH, 17, PP. 355-366, (2008); BLOEDON L.T., BALIKAI S., CHITTAMS J., ET AL., FLAXSEED AND CARDIOVASCULAR RISK FACTORS: RESULTS FROM A DOUBLE BLIND, RANDOMIZED, CONTROLLED CLINICAL TRIAL, J AM COLL NUTR, 27, PP. 65-74, (2008); MCKENNEY J.M., SICA D., PRESCRIPTION OMEGA-3 FATTY ACIDS FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA, AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 64, 6, PP. 595-605, (2007); VERBOOM C.N., HIGHLY PURIFIED OMEGA-3 POLYUNSATURATED FATTY ACIDS ARE EFFECTIVE AS ADJUNCT THERAPY FOR SECONDARY PREVENTION OF MYOCARDIAL INFARCTION, HERZ, 31, SUPPL. 3, PP. 49-59, (2006); PATEL J.V., LEE K.W., TOMSON J., DUBB K., HUGHES E.A., LIP G.Y., EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON METABOLICALLY ACTIVE HORMONES IN PATIENTS POST-MYOCARDIAL INFARCTION, INT J CARDIOL, 115, PP. 42-45, (2007); DAVIDSON M.H., STEIN E.A., BAYS H.E., ET AL., EFFICACY AND TOLERABILITY OF ADDING PRESCRIPTION OMEGA-3 FATTY ACIDS 4 G/D TO SIMVASTATIN 40 MG/D IN HYPERTRIGLYCERIDEMIC PATIENTS: AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CLIN THER, 29, PP. 1354-1367, (2007); MITA T., WATADA H., OGIHARA T., ET AL., EICOSAPENTAENOIC ACID REDUCES THE PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH TYPE 2 DIABETES, ATHEROSCLEROSIS, 191, PP. 162-167, (2007); HJERKINN E.M., ABDELNOOR M., BREIVIK L., ET AL., EFFECT OF DIET OR VERY LONG CHAIN OMEGA-3 FATTY ACIDS ON PROGRESSION OF ATHEROSCLEROSIS, EVALUATED BY CAROTID PLAQUES, INTIMA-MEDIA THICKNESS AND BY PULSE WAVE PROPAGATION IN ELDERLY MEN WITH HYPERCHOLESTEROLAEMIA, EUR J CARDIOVASC PREV REHABIL, 13, PP. 325-333, (2006); SCHIANO V., LAURENZANO E., BREVETTI G., ET AL., OMEGA-3 POLYUNSATURATED FATTY ACID IN PERIPHERAL ARTERIAL DISEASE: EFFECT ON LIPID PATTERN, DISEASE SEVERITY, INFLAMMATION PROFILE, AND ENDOTHELIAL FUNCTION, CLIN NUTR (EDINBURGH, SCOTLAND), 27, PP. 241-247, (2008); MADSEN T., CHRISTENSEN J.H., SCHMIDT E.B., C-REACTIVE PROTEIN AND N-3 FATTY ACIDS IN PATIENTS WITH A PREVIOUS MYOCARDIAL INFARCTION: A PLACEBO-CONTROLLED RANDOMIZED STUDY, EUR J NUTR, 46, PP. 428-430, (2007); MEHRA M.R., LAVIE C.J., VENTURA H.O., MILANI R.V., FISH OILS PRODUCE ANTI-INFLAMMATORY EFFECTS AND IMPROVE BODY WEIGHT IN SEVERE HEART FAILURE, J HEART LUNG TRANSPLANT, 25, PP. 834-838, (2006); DOKHOLYAN R.S., ALBERT C.M., APPEL L.J., COOK N.R., WHELTON P., HENNEKENS C.H., A TRIAL OF OMEGA-3 FATTY ACIDS FOR PREVENTION OF HYPERTENSION, AM J CARDIOL, 93, PP. 1041-1043, (2004); RASMUSSEN B.M., VESSBY B., UUSITUPA M., ET AL., EFFECTS OF DIETARY SATURATED, MONOUNSATURATED, AND N-3 FATTY ACIDS ON BLOOD PRESSURE IN HEALTHY SUBJECTS, AM J CLIN NUTR, 83, PP. 221-226, (2006); KELLEY D.S., SIEGEL D., VEMURI M., CHUNG G.H., MACKEY B.E., DOCOSAHEXAENOIC ACID SUPPLEMENTATION DECREASES REMNANT-LIKE PARTICLE-CHOLESTEROL AND INCREASES THE (N-3) INDEX IN HYPERTRIGLYCERIDEMIC MEN, J NUTR, 138, PP. 30-35, (2008); BROUWER I.A., ZOCK P.L., CAMM A.J., ET AL., EFFECT OF FISH OIL ON VENTRICULAR TACHYARRHYTHMIA AND DEATH IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS: THE STUDY ON OMEGA-3 FATTY ACIDS AND VENTRICULAR ARRHYTHMIA (SOFA) RANDOMIZED TRIAL, JAMA, 295, PP. 2613-2619, (2006); LEAF A., ALBERT C.M., JOSEPHSON M., STEINHAUS D., KLUGER J., KANG J.X., COX B., ZHANG H., SCHOENFELD D., PREVENTION OF FATAL ARRHYTHMIAS IN HIGH-RISK SUBJECTS BY FISH OIL N-3 FATTY ACID INTAKE, CIRCULATION, 112, 18, PP. 2762-2768, (2005); CALO L., BIANCONI L., COLIVICCHI F., ET AL., N-3 FATTY ACIDS FOR THE PREVENTION OF ATRIAL FIBRILLATION AFTER CORONARY ARTERY BYPASS SURGERY: A RANDOMIZED, CONTROLLED TRIAL, J AM COLL CARDIOL, 45, PP. 1723-1728, (2005); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); WRIGHT C., ZIELKE J., WHAYNE T.F., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE: USE IN PATIENTS INTOLERANT OF OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INT J ANGIOL, 13, PP. 173-175, (2005); FERNANDEZ J., EFICACIA Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II, REVISTA CNIC CIENC BIOL, 30, PP. 127-132, (1999); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 21, 1, PP. 43-57, (2001); HOWARD A.A., ARNSTEN J.H., GOUREVITCH M.N., EFFECT OF ALCOHOL CONSUMPTION ON DIABETES MELLITUS: A SYSTEMATIC REVIEW, ANN INTERN MED, 140, PP. 211-219, (2004); WALLERATH T., POLEO D., LI H., FORSTERMANN U., RED WINE INCREASES THE EXPRESSION OF HUMAN ENDOTHELIAL NITRIC OXIDE SYNTHASE: A MECHANISM THAT MAY CONTRIBUTE TO ITS BENEFICIAL CARDIOVASCULAR EFFECTS, J AM COLL CARDIOL, 41, PP. 471-478, (2003); MARON D.J., FLAVONOIDS FOR REDUCTION OF ATHEROSCLEROTIC RISK, CURR ATHEROSCLER REP, 6, PP. 73-78, (2004); DE LORGERIL M., SALEN P., MARTIN J.L., BOUCHER F., DE LEIRIS J., INTERACTIONS OF WINE DRINKING WITH OMEGA-3 FATTY ACIDS IN PATIENTS WITH CORONARY HEART DISEASE: A FISH-LIKE EFFECT OF MODERATE WINE DRINKING, AM HEART J, 155, PP. 175-181, (2008); BAUR J.A., SINCLAIR D.A., THERAPEUTIC POTENTIAL OF RESVERATROL: THE IN VIVO EVIDENCE, NAT REV, 5, PP. 493-506, (2006); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); KIMPEL P., CHOLESTIN: NATURAL OR NOT?; SNOW W., BLURRY LINE BETWEEN SUPPLEMENTS AND DRUGS; CHOLESTEROL HEALTH; LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); ANDERSON R.G., JOE GOLDSTEIN AND MIKE BROWN: FROM CHOLESTEROL HOMEOSTASIS TO NEW PARADIGMS IN MEMBRANE BIOLOGY, TRENDS CELL BIOL, 13, PP. 534-539, (2003); GOLDSTEIN J.L., BROWN M.S., BINDING AND DEGRADATION OF LOW DENSITY LIPOPROTEINS BY CULTURED HUMAN FIBROBLASTS. COMPARISON OF CELLS FROM A NORMAL SUBJECT AND FROM A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, J BIOL CHEM, 249, PP. 5153-5162, (1974); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED (NEW YORK, NY), 7, PP. 133-139, (2001); POLSANI V., JONES P.H., BALLANTYNE C.M., NAMBI V., A CASE REPORT OF MYOPATHY FROM CONSUMPTION OF RED YEAST, J CLIN LIPIDOL, 2, PP. 60-62, (2008); BECKER D., GORDON R.Y., MORRIS P.B., YORKO J., GORDON Y.J., LI M., IQBAL N., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN PROC, 83, PP. 758-764, (2008); SACKS F.M., LICHTENSTEIN A., VAN HORN L., HARRIS W., KRIS-ETHERTON P., WINSTON M., SOY PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH: AN AMERICAN HEART ASSOCIATION SCIENCE ADVISORY FOR PROFESSIONALS FROM THE NUTRITION COMMITTEE, CIRCULATION, 113, 7, PP. 1034-1044, (2006); LECRUBIER Y., CLERC G., DIDI R., KIESER M., EFFICACY OF ST. JOHN'S WORT EXTRACT WS 5570 IN MAJOR DEPRESSION: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM J PSYCHIATRY, 159, PP. 1361-1366, (2002); SUGIMOTO K., OHMORI M., TSURUOKA S., ET AL., DIFFERENT EFFECTS OF ST JOHN'S WORT ON THE PHARMACOKINETICS OF SIMVASTATIN AND PRAVASTATIN, CLIN PHARMACOL THER, 70, PP. 518-524, (2001); MUKHERJEE D., KLINE-ROGERS E., FANG J., MUNIR K., EAGLE K.A., LACK OF CLOPIDOGREL-CYP3A4 STATIN INTERACTION IN PATIENTS WITH ACUTE CORONARY SYNDROME, HEART, 91, 1, PP. 23-26, (2005); FARID N.A., PAYNE C.D., SMALL D.S., WINTERS K.J., ERNEST II C.S., BRANDT J.T., ET AL., CYTOCHROME P450 3A INHIBITION BY KETOCONAZOLE AFFECTS PRASUGREL AND CLOPIDOGREL PHARMACOKINETICS AND PHARMACODYNAMICS DIFFERENTLY, CLIN PHARMACOL THER, 81, PP. 735-741, (2007); ZHOU S.F., LAI X., AN UPDATE ON CLINICAL DRUG INTERACTIONS WITH THE HERBAL ANTIDEPRESSANT ST. JOHN'S WORT, CURR DRUG METAB, 9, PP. 394-409, (2008); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, PP. 965-978, (2003); ARAD Y., SPADARO L.A., ROTH M., NEWSTEIN D., GUERCI A.D., TREATMENT OF ASYMPTOMATIC ADULTS WITH ELEVATED CORONARY CALCIUM SCORES WITH ATORVASTATIN, VITAMIN C, AND VITAMIN E: THE ST. FRANCIS HEART STUDY RANDOMIZED CLINICAL TRIAL, J AM COLL OF CARDIOL, 46, PP. 166-172, (2005); HERCBERG S., BERTRAIS S., CZERNICHOW S., ET AL., ALTERATIONS OF THE LIPID PROFILE AFTER 7.5 YEARS OF LOW-DOSE ANTIOXIDANT SUPPLEMENTATION IN THE SU.VI.MAX STUDY, LIPIDS, 40, PP. 335-342, (2005); SASAZUKI S., SASAKI S., TSUBONO Y., OKUBO S., HAYASHI M., TSUGANE S., EFFECT OF VITAMIN C ON COMMON COLD: RANDOMIZED CONTROLLED TRIAL, EUR J CLIN NUTR, 60, PP. 9-17, (2006)","T. F. WHAYNE JR.; 326 WETHINGTON BUILDING, LEXINGTON, KY 40536-0200, 900 SOUTH LIMESTONE ST., UNITED STATES; EMAIL: TWHAYN0@UKY.EDU","","ENGLISH","CARDIOVASC. THER.","REVIEW","ISI","2-S2.0-77749286361","CARDIOVASC THER","UNIVERSITY OF KENTUCKY","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"WHAYNE JR TF, 2010, CARDIOVASC THER","WHAYNE JR TF, 2010, CARDIOVASC THER"
"RAVINDRANATH S;UPPUGUNDLA N;LAY J;CLAUSEN E;WILKINS M;INGRAHAM R;WEST C;WU Y;CARRIER D","RAVINDRANATH, SATHYA VANDHANA (26635946200); UPPUGUNDLA, NIRMAL (26636093300); LAY, JACKSON O. (35554369200); CLAUSEN, EDGAR C. (7006676797); WILKINS, MARK (56492323200); INGRAHAM, ROBERT G. (26635349600); WEST, CHARLES (7402187763); WU, YANQI (8227098600); CARRIER, DANIELLE JULIE (55663971400)","POLICOSANOL RTOCOPHEROL AND MOISTURE CONTENT AS A FUNCTION OF TIMING OF HARVEST OF SWITCHGRASS PANICUM VIRGATUM L",2009,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","57","5",11,"10.1021/jf803846e","DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING, UNITED STATES;DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING, UNITED STATES;DEPARTMENT OF CHEMISTRY;RALPH E. MARTIN DEPARTMENT OF CHEMICAL ENGINEERING, UNITED STATES;DEPARTMENT OF CROP, SOIL, AND ENVIRONMENTAL SCIENCES, UNIVERSITY OF ARKANSAS, FAYETTEVILLE, AR 72701, UNITED STATES;DEPARTMENT OF CROP, SOIL, AND ENVIRONMENTAL SCIENCES, UNIVERSITY OF ARKANSAS, FAYETTEVILLE, AR 72701, UNITED STATES;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING;DEPARTMENT OF PLANT, SOIL SCIENCES AND OKLAHOMA STATE UNIVERSITY, STILLWATER, OK 74078, UNITED STATES;DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING, UNITED STATES","USING SWITCHGRASS (PANICUM VIRGATUM L.) AS A CELLULOSIC FEEDSTOCK FOR THE PRODUCTION OF ETHANOL COULD LEAD TO THE EXTRACTION OF CO-PRODUCTS PRIOR TO THE PRETREATMENT STEP, THEREBY ADDING VALUE TO THE ETHANOL CONVERSION PROCESS. POLICOSANOLS, REGISTERED AS 142583-61-7, ARE PRESENT IN POACEAE AND ARE A MIXTURE OF LONG-CHAINED PRIMARY ALCOHOLS. POLICOSANOLS ARE COMPOSED MAINLY OF DOCOSANOL (C 22), TETRACOSANOL (C 24), HEXACOSANOL (C 26), OCTACOSANOL (C 28), TRIACONTANOL (C 30), AND DOTRIACONTANOL (C 32). THIS STUDY DETERMINED CHANGES IN MOISTURE, POLICOSANOL, AND R-TOCOPHEROL CONCENTRATIONS OF CAVE-IN- ROCK AND BLACKWELL SWITCHGRASS CULTIVARS DURING MATURATION FROM JULY TO DECEMBER IN ARKANSAS AND OKLAHOMA. MOISTURE CONTENT ON A DRY WEIGHT BASIS DECLINED FROM 150 TO 50% WITH PROGRESSIVE HARVESTS. THE TOTAL POLICOSANOL CONCENTRATION RANGED BETWEEN 89 MG/KG FOR JULY HARVESTED CAVE-IN-ROCK SWITCHGRASS FROM ARKANSAS AND 182 MG/KG FOR AUGUST HARVESTED CAVE-IN-ROCK SWITCHGRASS FOR OKLAHOMA, AND THESE VALUES REMAINED RELATIVELY CONSTANT THROUGHOUT THE SEASON. THIS IS THE FIRST REPORT ON THE PRESENCE OF POLICOSANOLS IN SWITCHGRASS. TOTAL SWITCHGRASS POLICOSANOL CONCENTRATIONS WERE LOWER THAN THOSE TYPICALLY REPORTED FOR SORGHUM GRAINS; HOWEVER, SWITCHGRASS-EXTRACTED POLICOSANOLS CONTAINED DIFFERENT POLICOSANOL RATIOS, WHEREIN C 30 AND C 32 ALCOHOL RANGES WERE 36-41 AND 43-50%, RESPECTIVELY. Α-TOCOPHEROL EXTRACTED FROM BOTH SWITCHGRASS CULTIVARS VARIED BETWEEN 320 AND 400 MG/KG BUT DECREASED IN THE OCTOBER HARVEST AFTER FROST. © 2009 AMERICAN CHEMICAL SOCIETY.","MOISTURE CONTENT; PANICUM VIRGATUM; POLICOSANOL; R-TOCOPHEROL; SWITCHGRASS","ALPHA-TOCOPHEROL; FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; PANICUM; SEASONS; TIME FACTORS; WATER; PANICUM VIRGATUM; POACEAE; ALPHA TOCOPHEROL; FATTY ALCOHOL; POLICOSANOL; WATER; ARTICLE; CHEMISTRY; GROWTH, DEVELOPMENT AND AGING; MASS FRAGMENTOGRAPHY; MILLET; SEASON; TIME","","","SCHMER M., VOGEL K., MITCHELL R., PERRIN R., NET ENERGY OF CELLULOSIC ETHANOL FROM SWITCHGRASS, PROC. NATL. ACAD. SCI. U.S. A, 105, (2008); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEM, 81, PP. 345-349, (2004); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J. AGRIC. FOOD CHEM, 54, Z2006, PP. 5359-5362; TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTR, 19, PP. 192-195, (2003); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP. BIOL. MED, 229, PP. 215-226, (2004); ALDERSON J.S., SHARP W.C., HANSON A.A., GRASS VARIETIES IN THE UNITED STATES, (1995); CASLER M., VOGEL K., TALIAFERRO C., EHLKE N., BERDAHL J., BRUMMER E., KALLENBACH R., WEST C., MITCHELL R., LATITUDINAL AND LONGITUDINAL ADAPTATION OF SWITCHGRASS POPULATIONS, CROP SCI, 47, (2007); METHOD OFDETERMINING AND EXPRESSING OF FINENESS OF FEEDMATERIAL BY SIEVING, STANDARD S319, (2002); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); MUNNE-BOSCH S., THE ROLE OF R-TOCOPHEROL IN PLANT STRESS TOLERANCE, J. PLANT PHYSIOL, 162, PP. 743-748, (2005); MOCK H.P., TOCOPHEROL COMPOSITION OF PLANTS AND THEIR REGULATION, THE ENCYCLOPEDIA OF VITAMIN E, PP. 112-121, (2007)","D. J. CARRIER; DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING, UNITED STATES; EMAIL: CARRIER@UARK.EDU","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-66149137313","J AGRIC FOOD CHEM","DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING;DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING;UNIVERSITY OF ARKANSAS;UNIVERSITY OF ARKANSAS;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING;SOIL SCIENCES AND OKLAHOMA STATE UNIVERSITY;DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING","NOTREPORTED;DEPARTMENT OF BIOLOGICAL AND AGRICULTURAL ENGINEERING;NOTREPORTED",NA,"RAVINDRANATH SV, 2009, J AGRIC FOOD CHEM","RAVINDRANATH SV, 2009, J AGRIC FOOD CHEM"
"OLIARO-BOSSO S;CALCIO G E;MANTEGNA S;GIRAUDO E;MEDA C;VIOLA F;CRAVOTTO G","OLIARO-BOSSO, SIMONETTA (8953497300); CALCIO GAUDINO, EMANUELA (23488197200); MANTEGNA, STEFANO (22135571000); GIRAUDO, ENRICO (6701669477); MEDA, CLAUDIA (35100680300); VIOLA, FRANCA (7006847900); CRAVOTTO, GIANCARLO (7003394420)","REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL",2009,"LIPIDS","44","9",63,"10.1007/s11745-009-3338-y","DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TORINO, TORINO 10125, VIA GIURIA 9, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TORINO, TORINO 10125, VIA GIURIA 9, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TORINO, TORINO 10125, VIA GIURIA 9, ITALY;DEPARTMENT OF ONCOLOGICAL SCIENCES, SCHOOL OF MEDICINE, UNIVERSITY OF TORINO, CANDIOLO 10060, STR. PROVINCIALE 142, ITALY;DEPARTMENT OF ONCOLOGICAL SCIENCES, SCHOOL OF MEDICINE, UNIVERSITY OF TORINO, CANDIOLO 10060, STR. PROVINCIALE 142, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TORINO, TORINO 10125, VIA GIURIA 9, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TORINO, TORINO 10125, VIA GIURIA 9, ITALY","OCTACOSA-10,19-DIEN-1-OL IS A NEWLY SYNTHESIZED LONG-CHAIN ALCOHOL, AN UNSATURATED ANALOGUE OF 1-OCTACOSANOL, THE MAJOR COMPONENT OF POLICOSANOL, THE PURIFIED NATURAL MIXTURE OF DIFFERENT HIGHER ALIPHATIC ALCOHOLS OBTAINED FROM SUGARCANE WAX. OUR EFFICIENT SYNTHETIC PROTOCOL (FIVE STEPS WITH 50% OVERALL YIELD) IS WELL SUITED FOR GRAM SCALE PREPARATIONS AND A RAPID GENERATION OF ANALOGUES WITH DIFFERENT DEGREES OF UNSATURATION. BENEFICIAL EFFECTS OF POLICOSANOL IN THE PREVENTION OF ATHEROSCLEROSIS AND THROMBOEMBOLIC DISORDERS HAVE BEEN REPORTED AND RELATED TO THE INHIBITION OF STEROL BIOSYNTHESIS POSSIBLY BY THE REGULATION OF THE ACTIVITY OF HMGCOA REDUCTASE MEDIATED BY AMP-DEPENDENT KINASE AMPK. WE HAVE COMPARED THE EFFECT OF OCTACOSADIENOL AND POLICOSANOL ON THE REGULATION OF HMGCOA REDUCTASE IN HUVEC AND HEPG2 HUMAN HEPATOMA CELLS. OCTACOSADIENOL WAS AS EFFECTIVE AS POLICOSANOL IN INHIBITING THE UPREGULATION OF HMGCOA REDUCTASE, IN INDUCING THE PHOSPHORYLATION OF AMPK AND IN DOWNREGULATING THE HMGCOA REDUCTASE MRNA. © 2009 AOCS.","AMPK PHOSPHORYLATION; HMGCOA REDUCTASE; LONG-CHAIN ALCOHOLS SYNTHESIS; OCTACOSADIENOL; OCTACOSANOL; POLICOSANOL","CELL LINE, TUMOR; CELLS, CULTURED; DOWN-REGULATION; ENZYME ACTIVATION; FATTY ALCOHOLS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RNA, MESSENGER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OCTACOSADIENOL; OCTACOSANOL; POLICOSANOL; UNCLASSIFIED DRUG; ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; SUGARCANE; THROMBOEMBOLISM","UNIVERSITY OF TURIN; REGIONE PIEMONTE","ACKNOWLEDGMENTS THE UNIVERSITY OF TURIN AND THE REGIONAL GOVERNMENT (REGIONE PIEMONTE: SINAPSI AND RICERCA SANITARIA FINAL-IZZATA 2007–2008) ARE WARMLY ACKNOWLEDGED FOR THE FINANCIAL SUPPORT.","HOUTZ R.L., RIES S.K., TOLBERT N.E., EFFECT OF TRIACONTANOL ON CHLAMYDOMONAS. II. SPECIFIC ACTIVITY OF RIBULOSE-BISPHOSPHATE CARBOXYLASE/OXYGENASE, RIBULOSE-BISPHOSPHATE CONCENTRATION, AND CHARACTERISTICS OF PHOTORESPIRATION, PLANT PHYSIOL, 79, PP. 365-370, (1985); LESNIAK A.P., HAUG A., RIES S.K., STIMULATION OF ATPASE ACTIVITY IN BARLEY (HORDEUM VULGARE) ROOT PLASMA MEMBRANE AFTER TREATMENT OF INTACT TISSUES AND CELL FREE EXTRACTS WITH TRIACONTANOL, PHYSIOL PLANT, 68, PP. 20-26, (1986); MC BRIDE P.T., CLARK I., KRUEGER G.G., EVALUATION OF TRIACONTANOL-CONTAINING COMPOUNDS AS ANTI-INFLAMMATORY AGENTS USING GUINEA PIG MODELS, J INVEST DERMATOL, 89, PP. 380-383, (1987); SAINT-JOHN M., MCNAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME AND CHEST AND GRIP STRENGTH, INT CLIN NUTR REV, 6, PP. 81-87, (1986); OHIA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, J CLIN BIOCHEM NUTR, 42, PP. 118-125, (2008); SHO H., CHINEN I., FUKUDA N., EFFECT OF OKINAWAN SUGAR CANE WAX AND FATTY ALCOHOL ON SERUM AND LIVER LIPIDS IN THE RAT, J NUTR SCI VITAMINOL, 30, PP. 539-553, (1984); SHIMURA S., HASEGAWA T., TAKANO S., SUZUKI T., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTR REP INT, 36, PP. 1029-1038, (1987); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2005); KAZUKO K., KUMLKO A., YOHEL H., FREE PRIMARY ALCOHOLS IN OILS AND WAXES FROM GERMS, KERNELS AND OTHER COMPONENTS OF NUTS, SEEDS, FRUITS AND CEREALS, J AM OIL CHEM SOC, 68, PP. 869-872, (1991); PIATAK D.M., REIMANN K.A., ISOLATION OF 1-OCTACOSANOL FROM EUPHORBIA COROLLATA, PHYTOCHEMISTRY, 9, PP. 2585-2586, (1970); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW-DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRITISH JOURNAL OF NUTRITION, 77, 6, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); BERTHOLD I.G., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MEDITERR J NUTR METAB, 1, PP. 77-83, (2008); KASSIS A., JONES P.J.H., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOL IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, PP. 1003-1008, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, J AM MED ASSOC, 295, PP. 2262-2269, (2006); KASSIS A.N., KUBOW S., JONES P.J.H., SUGAR CANE POLICOSANOLS DO NOT REDUCE LDL OXIDATION IN HYPERCHOLESTEROLEMIC INDIVIDUALS, LIPIDS, 44, PP. 391-396, (2009); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS, 43, PP. 109-115, (2008); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, PP. 425-430, (1990); HARDIE D.G., CARLING D., CARLSON M., THE AMP-ACTIVATED/SNF1 PROTEIN KINASE SUBFAMILY: METABOLIC SENSORS OF THE EUKARYOTIC CELL?, ANNU REV BIOCHEM, 67, PP. 821-855, (1998); HARDIE D.G., THE AMP-ACTIVATED PROTEIN KINASE PATHWAY-NEW PLAYERS UPSTREAM AND DOWNSTREAM, J CELL SCI, 117, PP. 5479-5487, (2004); MOTOSHIMA H., GOLDSTEIN B.J., IGATA M., ARAKI E., AMPK AND CELL PROLIFERATION-AMPK AS A THERAPEUTIC TARGET FOR ATHEROSCLEROSIS AND CANCER, J PHYSIOL, 574, PP. 63-71, (2006); HADAD S.M., FLEMING S., THOMPSON A.M., TARGETING AMPK: A NEW THERAPEUTIC OPPORTUNITY IN BREAST CANCER, CRIT REV ONCOL HEMATOL, 67, PP. 1-7, (2008); TAKAHASHI H.K., NISHIBORI M., THE ANTITUMOUR ACTIVITIES OF STATINS, CURR ONCOL, 14, PP. 246-247, (2007); HO P.L., LIANG Y.C., HO H.S., CHEN C.T., LEE W.S., INHIBITION OF HUMAN VASCULAR ENDOTHELIAL CELLS PROLIFERATION BY TERBINAFINE, INT J CANCER, 111, PP. 51-59, (2004); CURTIS R., CHONG C.R., XU J., LU J., BHAT S., SULLIVAN JR.D.J., LIU J.O., INHIBITION OF ANGIOGENESIS BY THE ANTIFUNGAL DRUG ITRACONAZOLE, ACS CHEM BIOL, 2, PP. 263-270, (2007); THIPPESWAMY G., SHEELA M.I., SALIMATH B.P., OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NF-KAPPANB AND ITS DNA BINDING ACTIVITY, EUR J PHARMACOL, 588, PP. 141-150, (2008); BUSSOLINO F., DI RENZO M.F., ZICHE M., BOCCHIETTO E., OLIVERO M., NALDINI L., GAUDINO G., TAMAGNONE L., COFFER A., COMOGLIO P.M., HEPATOCYTE GROWTH FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL CELL MOTILITY AND GROWTH, J CELL BIOL, 119, PP. 629-641, (1992); CHAN B.E., KNOWLES B.R., A SOLVENT SYSTEM FOR DELIPIDATION OF PLASMA OR SERUM WITHOUT PROTEIN PRECIPITATION, J LIPID RES, 17, PP. 176-181, (1976); PETERSON G.L., A SIMPLIFICATION OF THE PROTEIN ASSAY METHOD OF LOWRY ET AL. WHICH IS MORE GENERALLY APPLICABLE, ANAL BIOCHEM, 83, PP. 346-356, (1977); ZANG M., ZUCCOLLO A., HOU X., NAGATA D., WALSH K., HERSCOVITZ H., BRECHER P., RUDERMAN N.B., COHEN R.A., AMP-ACTIVATED PROTEIN KINASE IS REQUIRED FOR THE LIPID-LOWERING EFFECT OF METFORMIN IN INSULIN-RESISTANT HUMAN HEPG2 CELLS, J BIOL CHEM, 279, PP. 47898-47905, (2004); AVIVA P., SABIN C., MEDICAL STATISTICS AT A GLANCE, (2000); CRAVOTTO G., A PROCESS FOR PREPARING LONG CHAIN SATURATED OR UNSATURATED OXYGENATED COMPOUNDS, (2003); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR J LIPID SCI TECHNOL, 106, PP. 147-151, (2004); ZHOU G., MYERS R., LI Y., CHEN Y., SHEN X., FENYK-MELODY J., WU M., VENTRE J., DOEBBER T., FUJII N., MUSI N., HIRSHMAN M.F., GOODYEAR L.J., MOLLER D.E., ROLE OF AMP-ACTIVATED PROTEIN KINASE IN MECHANISM OF METFORMIN ACTION, J CLIN INVEST, 108, PP. 1167-1174, (2001); LIVAK K.J., SCHMITTGEN T.D., ANALYSIS OF RELATIVE GENE EXPRESSION DATA USING REAL TIME QUANTITATIVE PCR AND THE 2<SUB>T</SUB>-DELTA DELTA C METHOD, METHODS, 25, PP. 402-408, (2001); GRAAF M.R., RICHEL D.J., VAN NOORDEN C.J.F., GUCHELAAR H.J., EFFECTS OF STATINS AND FARNESYLTRANSFERASE INHIBITORS ON THE DEVELOPMENT AND PROGRESSION OF CANCER, CANCER TREAT REV, 30, PP. 609-641, (2004); TANG C.H., CHIU Y.C., TAN T.W., YANG R.S., FU W.M., ADIPONECTIN ENHANCES IL-6 PRODUCTION IN HUMAN SYNOVIAL FIBROBLAST VIA AN ADIPOR1 RECEPTOR, AMPK, P38, AND NF-KB PATHWAY, J IMMUNOL, 179, PP. 5483-5492, (2007); ESCARCEGA R.O., FUENTES-ALEXANDRO S., GARCIA-CARRASCO M., GATICA A., ZAMORA A., THE TRANSCRIPTION FACTOR NUCLEAR FACTOR-KAPPA B AND CANCER, CLIN ONCOL, 19, PP. 154-161, (2007)","F. VIOLA; DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TORINO, TORINO 10125, VIA GIURIA 9, ITALY; EMAIL: FRANCA.VIOLA@UNITO.IT","","ENGLISH","LIPIDS","ARTICLE","ISI","2-S2.0-70350227283","LIPIDS","UNIVERSITY OF TORINO;UNIVERSITY OF TORINO;UNIVERSITY OF TORINO;UNIVERSITY OF TORINO;UNIVERSITY OF TORINO;UNIVERSITY OF TORINO;UNIVERSITY OF TORINO","NOTREPORTED;UNIVERSITY OF TORINO;NOTREPORTED",NA,"OLIARO-BOSSO S, 2009, LIPIDS","OLIARO-BOSSO S, 2009, LIPIDS"
"CICERO A;ERTEK S","CICERO, ARRIGO F.G. (7003403707); ERTEK, SIBEL (15135521900)","NATURAL SOURCES OF ANTIDYSLIPIDAEMIC AGENTS IS THERE AN EVIDENCEBASED APPROACH FOR THEIR PRESCRIPTION",2008,"MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM","1","8",15,"10.3233/s12349-008-0011-6","INTERNAL MEDICINE, AGING AND KIDNEY DISEASES DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY;DEPARTMENT OF ENDOCRINOLOGY AND METABOLIC DISEASES, UFUK UNIVERSITY FACULTY OF MEDICINE, ANKARA, TURKEY","NUMEROUS RANDOMIZED CLINICAL TRIALS, SYSTEMATIC REVIEWS AND META-ANALYSES HAVE CONFIRMED THE ANTIDYSLIPIDAEMIC ACTIVITY OF DIFFERENT DIETARY SUPPLEMENTS, NUTRACEUTICALS AND HERBAL REMEDIES. INTERNATIONAL GUIDELINES FOR CARDIOVASCULAR DISEASE PREVENTION HAVE BEGUN TO CONSIDER DIETARY SUPPLEMENTS AS AN EVIDENCE-BASED APPROACH TO IMPROVE PATIENTS’ PLASMA LIPID LEVELS. THEY ALREADY SUGGEST TO INCREASING OR SUPPLEMENTING THE DIETARY INTAKE OF SOLUBLE FIBRE (ESPECIALLY PSYLLIUM), SOY PROTEINS, PLANT STEROLS, NIACIN, AND FISH OIL. AMONG THE NUTRACEUTICALS, MEVACOLINE AND POLICOSANOL ARE BOTH ABLE TO REDUCE PLASMA LDL-C BY A MEAN OF 20%. A PRELIMINARY CLINICAL STUDY OF BERBERINE HAS SHOWN IT TO BE THE MOST POWERFUL ANTIHYPERLIPIDAEMIC NATURAL COMPOUND, REDUCING PLASMA LDL-C BY 25% AND TRIGLYCERIDES BY 35%. AMONG THE HERBAL REMEDIES, SEVERAL PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIALS HAVE CONFIRMED THE ANTIHYPERCHOLESTEROLAEMIC, AND ANTIHYPERTRIGLYCERIDAEMIC PROPERTIES OF AGED GARLIC POWDER, ARTICHOKE LEAF EXTRACTS, GUGGUL, AND FENUGREEK. SINGLE SMALL CLINICAL TRIALS HAVE ALSO SUGGESTED THAT KOREAN GINSENG, GREEN TEA, ONION, YARROW, HOLY BASIL AND ARJUN HAVE AN ANTIHYPERCHOLESTEROLAEMIC EFFECT. © 2008 SPRINGER-VERLAG 2008.","COMPLEMENTARY MEDICINE; DIETARY SUPPLEMENTS; DIETARY SUPPLEMENTS; DYSLIPIDAEMIA; EFFICACY; HERBAL; NUTRACEUTICALS; REMEDIES","","","","BEAN W.B., SIR WILLIAM OSLER: APHORISM FROM HIS BEDSIDE TEACHING AND WRITING, (1968); CAPASSO L., 5300 YEARS AGO, THE ICE MAN USED NATURAL LAXATIVES AND ANTIBIOTICS, LANCET, 352, (1998); GOLDMAN P., HERBAL MEDICINE TODAY AND THE ROOTS OF MODERN PHARMACOLOGY, ANN INTERN MED, 135, PP. 594-600, (2001); REES L., WEIL A., INTEGRATED MEDICINE, BMJ, 322, PP. 119-120, (2001); ASTIN J.A., WHY PATIENTS USE ALTERNATIVE MEDICINE, JAMA, 279, PP. 1548-1553, (1998); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROLLOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); SIERRA M., GARCIA J.J., FERNANDEZ N., ET AL., THERAPEUTIC EFFECTS OF PSYLLIUM IN TYPE 2 DIABETIC PATIENTS, EUR J CLIN NUTR, 56, PP. 830-842, (2002); WOLEVER T.M., JENKINS D.J., MUELLER S., ET AL., METHOD OF ADMINISTRATION INFLUENCES THE SERUM CHOLESTEROL-LOWERING EFFECT OF PSYLLIUM, AM J CLIN NUTR, 59, PP. 1055-1059, (1994); PETCHETTI L., FRISHMAN W.H., PETRILLO R., RAJU K., NUTRICEUTICALS IN CARDIOVASCULAR DISEASE: PSYLLIUM, CARDIOL REV, 15, PP. 116-122, (2007); MOREYRA A.E., WILSON A.C., KORAYM A., EFFECT OF COMBINING PSYLLIUM FIBER WITH SIMVASTATIN IN LOWERING CHOLESTEROL, ARCH INTERN MED, 165, PP. 1161-1166, (2005); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); BUCHER H.C., HENGSTLER P., SCHINDLER C., MEIER G., N-3 POLYUNSATURATED FATTY ACIDS IN CORONARY HEART DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 112, PP. 298-304, (2002); BORGHI C., CICERO A.F., BLOOD PRESSURE MODULATING PROPERTIES OF OMEGA-3 POLYUNSATURATED FATTY ACIDS (PUFA), ANOTHER PUFA HEART PROTECTIVE EFFECT? HIGH BLOOD PRESSURE CARDIOVASC PREVENT, 14, PP. 55-61, (2007); SIRTORI C.R., LOVATI M.R., SOY PROTEINS AND CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 3, PP. 47-53, (2001); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., METAANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); CICERO A.F., FIORITO A., PANOURGIA M.P., ET AL., EFFECTS OF A NEW SOY/BETA-SITOSTEROL SUPPLEMENT ON PLASMA LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS, J AM DIET ASSOC, 102, PP. 1807-1811, (2002); GRUNDY S.M., STANOL ESTERS AS A COMPONENT OF MAXIMAL DIETARY THERAPY IN THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III REPORT, AM J CARDIOL, 96, 1, PP. 47D-50, (2005); LAW M., PLANT STEROLS AND STANOLS MARGARINES AND HEATH, BMJ, 320, PP. 861-864, (2000); HALLIKAINEN M.A., SARKKINEN E.S., GYLLING H., ET AL., COMPARISON OF THE EFFECTS OF PLANT STEROL ESTER AND PLANT STANOL ESTER-ENRICHED MARGARINES IN LOWERING SERUM CHOLESTEROL CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC SUBJECTS ON A LOW-FAT DIET, EUR J CLIN NUTR, 54, PP. 715-725, (2000); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., GORDON M., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); PLAT J., MENSINK R.P., PLANT STANOL AND STEROL ESTERS IN THE CONTROL OF BLOOD CHOLESTEROL LEVELS: MECHANISM AND SAFETY ASPECTS, AM J CARDIOL, 96, 1, PP. 15D-22, (2005); EARNEST C.P., MIKUS C.R., LEMIEUX I., ET AL., EXAMINATION OF ENCAPSULATED PHYTOSTEROL ESTER SUPPLEMENTATION ON LIPID INDICES ASSOCIATED WITH CARDIOVASCULAR DISEASE, NUTRITION, 23, PP. 625-633, (2007); MCKENNEY J., NEW PERSPECTIVES ON THE USE OF NIACIN IN THE TREATMENT OF LIPID DISORDERS, ARCH INTERN MED, 164, PP. 697-705, (2004); LEVY D.R., PEARSON T.A., COMBINATION NIACIN AND STATIN THERAPY IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CLIN CARDIOL, 28, PP. 317-320, (2005); MCCORMACK P.L., KEATING G.M., PROLONGED-RELEASE NICOTINIC ACID: A REVIEW OF ITS USE IN THE TREATMENT OF DYSLIPIDAEMIA, DRUGS, 65, PP. 2719-2740, (2005); XU G., HUANG X., QIU L., ET AL., MECHANISM STUDY OF CHITOSAN ON LIPID METABOLISM IN HYPERLIPIDEMIC RATS, ASIA PAC J CLIN NUTR, 16, PP. 313-317, (2007); YLITALO R., LEHTINEN S., WUOLIJOKI E., ET AL., CHOLESTEROL-LOWERING PROPERTIES AND SAFETY OF CHITOSAN, ARZNEIMITTELFORSCHUNG, 52, PP. 1-7, (2002); LEHTIMAKI T., METSO S., YLITALO R., ET AL., MICROCRYSTALLINE CHITOSAN IS INEFFECTIVE TO DECREASE PLASMA LIPIDS IN BOTH APOPROTEIN E EPSILON 4 CARRIERS AND NON-CARRIERS: A LONG-TERM PLACEBO-CONTROLLED TRIAL IN HYPERCHOLESTEROLEMIC VOLUNTEERS, BASIC CLIN PHARMACOL TOXICOL, 97, PP. 98-103, (2005); RABINOVITZ H., FRIEDENSOHN A., LEIBOVITZ A., ET AL., EFFECT OF CHROMIUM SUPPLEMENTATION ON BLOOD GLUCOSE AND LIPID LEVELS IN TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS, INT J VITAM NUTR RES, 74, PP. 178-182, (2004); BROADHURST C.L., DOMENICO P., CLINICAL STUDIES ON CHROMIUM PICOLINATE SUPPLEMENTATION IN DIABETES MELLITUS-A REVIEW, DIABETES TECHNOL THER, 8, PP. 677-687, (2006); SIRTORI C.R., CALABRESI L., FERRARA S., ET AL., L-CARNITINE REDUCES PLASMA LIPOPROTEIN(A) LEVELS IN PATIENTS WITH HYPER LP(A), NUTR METAB CARDIOVASC DIS, 10, PP. 247-251, (2000); DEROSA G., CICERO A.F., GADDI A., ET AL., THE EFFECT OF L-CARNITINE ON PLASMA LIPOPROTEIN(A) LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS WITH TYPE 2 DIABETES MELLITUS, CLIN THER, 25, PP. 1429-1439, (2003); GUNES B., YALCIN S.S., KALKANOGLU H.S., ET AL., THE EFFECT OF ORAL CARNITINE SUPPLEMENTATION ON THE LIPID PROFILES OF HYPERLIPIDEMIC CHILDREN, ACTA PEDIATR, 9, PP. 711-716, (2005); MASON P., DIETARY SUPPLEMENTS, (2002); CICERO A.F., DEROSA G., MICONI A., ET AL., TREATMENT OF MASSI-VE HYPERTRIGLYCERIDEMIA RESISTANT TO PUFA AND FIBRATES: A POSSIBLE ROLE FOR THE COENZYME Q10?, BIOFACTORS, 23, PP. 7-14, (2005); LITTARRU G.P., LANGSJOEN P., COENZYME Q AND STATINS: BIOCHEMICAL AND CLINICAL IMPLICATIONS, MITOCHONDRION, 7, PP. S168-S174, (2007); CICERO A.F., BRANCALEONI M., LAGHI L., ET AL., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENT THER MED, 13, PP. 273-278, (2005); KEITHLEY J.K., SWANSON B., SHA B.E., ET AL., A PILOT STUDY OF THE SAFETY AND EFFICACY OF CHOLESTIN IN TREATING HIV-RELATED DYSLIPIDEMIA, NUTRITION, 18, PP. 201-204, (2002); GHEITH O., SHEASHAA H., ABDELSALAM M., ET AL., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH SECONDARY HYPERLIPIDEMIA, CLIN EXP NEPHROL, 12, PP. 189-194, (2008); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); CICERO A.F., DEROSA G., RICE BRAN AND ITS MAIN COMPONENTS: POTENTIAL ROLE IN THE MANAGEMENT OF CARDIOVASCULAR DISEASE RISK, CURR TOPICS NUTRACEUT RES, 3, PP. 29-46, (2005); CICERO A.F., MARTINI C., FIORITO A., GADDI A., CASE PROBLEM: DIETARY TREATMENT FOR CHILDREN WITH HYPERLIPIDEMIA, J AM DIET ASSOC, 101, PP. 693-696, (2001); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); DOGGRELL S.A., BERBERINE-A NOVEL APPROACH TO CHOLESTEROL LOWERING, EXPERT OPIN INVESTIG DRUGS, 14, PP. 683-685, (2005); CICERO A.F., ROVATI L., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS IN HUMANS, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); BOREK C., GARLIC REDUCES DEMENTIA AND HEART-DISEASE RISK, J NUTR, 136, PP. 810S-812, (2006); ACKERMANN R.T., MULROW C.D., RAMIREZ G., ET AL., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCH INTERN MED, 161, PP. 813-824, (2001); GARDNER C.D., LAWSON L.D., BLOCK E., ET AL., EFFECT OF RAW GARLIC VS COMMERCIAL GARLIC SUPPLEMENTS ON PLASMA LIPID CONCENTRATIONS IN ADULTS WITH MODERATE HYPERCHOLESTEROLEMIA: A RANDOMIZED CLINICAL TRIAL, ARCH INTERN MED, 26, 167, PP. 346-353, (2007); THOMPSON COON J.S., ERNST E., HERBS FOR SERUM CHOLESTEROL REDUCTION, A SYSTEMATIC REVIEW. J FAM PRACT, 52, PP. 468-478, (2003); TOKUNAGA S., WHITE I.R., FROST C., ET AL., GREEN TEA CONSUMPTION AND SERUM LIPIDS AND LIPOPROTEINS IN A POPULATION OF HEALTHY WORKERS IN JAPAN, ANN EPIDEMIOL, 12, PP. 157-165, (2002); ULBRICHT C., BASCH E., SZAPARY P., ET AL., GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENT THER MED, 13, PP. 279-290, (2005); BUETTNER C., YEH G.Y., PHILLIPS R.S., ET AL., SYSTEMATIC REVIEW OF THE EFFECTS OF GINSENG ON CARDIOVASCULAR RISK FACTOR, ANN PHARMACOTHER, 39, PP. 83-95, (2006); CICERO A.F., VITALE G., SAVINO G., ARLETTI R., NOTOGINSENOIDES EFFECTS ON FIBRINOGEN AND LIPID PLASMATIC LEVEL IN RAT SUBMITTED TO A NEW MODEL OF FAT DIET, PHYTOTHER RES, 17, PP. 174-178, (2003); ADAMS K.E., COHEN M.H., EISENBERG D., JONSEN A.R., ETHICAL CONSIDERATIONS OF COMPLEMENTARY AND ALTERNATIVE MEDICAL THERAPIES IN CONVENTIONAL MEDICAL SETTINGS, ANN INTERN MED, 137, PP. 660-664, (2002); GRAY C.M., TAN A.W., PRONK N.P., O'CONNOR P.J., COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG HEALTH PLAN MEMBERS, A CROSS-SECTIONAL SURVEY. EFF CLIN PRACT, 5, PP. 17-22, (2002); EISENBERG D.M., KESSLER R.C., VAN ROMPAY M.I., ET AL., PERCEPTIONS ABOUT COMPLEMENTARY THERAPIES RELATIVE TO CONVENTIONAL THERAPIES AMONG ADULTS WHO USE BOTH: RESULTS FROM A NATIONAL SURVEY, ANN INTERN MED, 135, PP. 344-351, (2001); OWEN D.K., LEWITH G., STEPHENS C.R., CAN DOCTORS RESPOND TO PATIENTS’ INCREASING INTEREST IN COMPLEMENTARY AND ALTERNATIVE MEDICINE?, BMJ, 322, PP. 154-158, (2001)","A.F.G. CICERO; INTERNAL MEDICINE, AGING AND KIDNEY DISEASES DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY; EMAIL: AFGCICERO@CARDIONET.IT","","ENGLISH","MEDITERR. J. NUTR. METAB.","ARTICLE","ISI","2-S2.0-77649113271","MEDITERR J NUTR METAB","UNIVERSITY OF BOLOGNA;UFUK UNIVERSITY FACULTY OF MEDICINE","NOTREPORTED;UNIVERSITY OF BOLOGNA;NOTREPORTED",NA,"CICERO AFG, 2008, MEDITERR J NUTR METAB","CICERO AFG, 2008, MEDITERR J NUTR METAB"
"AFFUSO F;RUVOLO A;MICILLO F;SACCÀ L;FAZIO S","AFFUSO, F. (22956768300); RUVOLO, A. (22958699100); MICILLO, F. (25031762500); SACCÀ, L. (36979922300); FAZIO, S. (56212339900)","EFFECTS OF A NUTRACEUTICAL COMBINATION BERBERINE RED YEAST RICE AND POLICOSANOLS ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY",2010,"NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES","20","5",114,"10.1016/j.numecd.2009.05.017","DEPARTMENT OF INTERNAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES, UNIVERSITY OF NAPLES FEDERICO II, 80131 NAPLES, VIA S. PANSINI 5, ITALY;DEPARTMENT OF INTERNAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES, UNIVERSITY OF NAPLES FEDERICO II, 80131 NAPLES, VIA S. PANSINI 5, ITALY;DEPARTMENT OF INTERNAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES, UNIVERSITY OF NAPLES FEDERICO II, 80131 NAPLES, VIA S. PANSINI 5, ITALY;DEPARTMENT OF INTERNAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES, UNIVERSITY OF NAPLES FEDERICO II, 80131 NAPLES, VIA S. PANSINI 5, ITALY;DEPARTMENT OF INTERNAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES, UNIVERSITY OF NAPLES FEDERICO II, 80131 NAPLES, VIA S. PANSINI 5, ITALY","BACKGROUND AND AIMS: SOME NUTRACEUTICALS ARE PRESCRIBED AS LIPID-LOWERING SUBSTANCES. HOWEVER, DOUBTS REMAIN ABOUT THEIR EFFICACY. WE EVALUATED THE EFFECTS OF A NUTRACEUTICAL COMBINATION (NC), CONSISTING OF 500. MG BERBERINE, 200. MG RED YEAST RICE AND 10. MG POLICOSANOLS, ON CHOLESTEROL LEVELS AND ENDOTHELIAL FUNCTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA. METHODS AND RESULTS: IN THIS SINGLE CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, 50 HYPERCHOLESTEROLEMIC PATIENTS (26 MALES AND 24 FEMALES, MEAN AGE 55 ± 7 YEARS, TOTAL CHOLESTEROL 6.55 ± 0.75. MMOL/L, BMI 28 ± 3.5) WERE RANDOMIZED TO 6 WEEKS OF TREATMENT WITH A DAILY ORAL DOSE OF NC (25 PATIENTS) OR PLACEBO (25 PATIENTS). IN A SUBSEQUENT OPEN-LABEL EXTENSION OF 4 WEEKS, THE WHOLE SAMPLE RECEIVED NC. THE MAIN OUTCOME MEASURE WAS DECREASE TOTAL CHOLESTEROL (C) LEVELS IN THE NC ARM. SECONDARY OUTCOME MEASURES WERE DECREASED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND TRIGLYCERIDE LEVELS, AND IMPROVED ENDOTHELIAL-DEPENDENT FLOW-MEDIATED DILATION (FMD) AND INSULIN SENSITIVITY IN RELATION TO NC. EVALUATION OF ABSOLUTE CHANGES FROM BASELINE SHOWED SIGNIFICANT REDUCTIONS IN NC VERSUS PLACEBO FOR C AND LDL-C (C: -1.14 ± 0.88 AND -0.03 ± 0.78. MMOL/L, P< 0.001; LDL-C: -1.06 ± 0.75 AND -00.4 ± 0.54. MMOL/L, P< 0.001), AND A SIGNIFICANT IMPROVEMENT OF FMD (3 ± 4% AND 0 ± 3% RESPECTIVELY, P< 0.05). AFTER THE EXTENSION PHASE, TRIGLYCERIDE LEVELS DECREASED SIGNIFICANTLY FROM 1.57 ± 0.77 TO 1.26 ± 0.63. MMOL/L, P< 0.05 AND INSULIN SENSITIVITY IMPROVED IN A PATIENT SUBGROUP WITH INSULIN RESISTANCE AT BASELINE (HOMA: FROM 3.3 ± 0.4 TO 2.5 ± 1.3, P< 0.05). NO ADVERSE EFFECT WAS REPORTED. CONCLUSIONS: THIS NC REDUCES CHOLESTEROL LEVELS. THE REDUCTION IS ASSOCIATED WITH IMPROVED ENDOTHELIAL FUNCTION AND INSULIN SENSITIVITY. © 2009 ELSEVIER B.V.","ENDOTHELIAL FUNCTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; NUTRACEUTICAL","ANTICHOLESTEREMIC AGENTS; BERBERINE; BIOLOGICAL PRODUCTS; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FATTY ALCOHOLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLACEBOS; TRIGLYCERIDES; BERBERINE; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM","ROTTAPHARM SPA","THIS STUDY WAS SUPPORTED BY ROTTAPHARM SPA (MONZA, ITALY) THAT SUPPLIED THE DRUG AND PLACEBO. WE ARE GRATEFUL TO JEAN ANN GILDER FOR TEXT EDITING.","ROSAMOND W., FLEGAL K., FURIE K., GO A., GREENLUND K., HAASE N., ET AL., AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE. HEART DISEASE AND STROKE STATISTICS 2008 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE, CIRCULATION, 117, (2008); ENDEMANN D.H., SCHIFFRIN E.L., ENDOTHELIAL DYSFUNCTION, J AM SOC NEPHROL, 15, PP. 1983-1992, (2004); HENRY P.D., CABELLO O.A., CHEN C.H., HYPERCHOLESTEROLEMIA AND ENDOTHELIAL DYSFUNCTION, CURR OPIN LIPIDOL, 6, PP. 190-195, (1995); MARTINEZ-GONZALEZ J., RAPOSO B., RODRIGUEZ C., BADIMON L., 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITION PREVENTS ENDOTHELIAL NO SYNTHASE DOWNREGULATION BY ATHEROGENIC LEVELS OF NATIVE LDLS: BALANCE BETWEEN TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION, ARTERIOSCLER THROMB VASC BIOL, 21, PP. 804-809, (2001); MONTAGNANI M., RAVICHANDRAN L.V., CHEN H., ESPOSITO D.L., QUON M.J., INSULIN RECEPTOR SUBSTRATE-1 AND PHOSPHOINOSITIDE-DEPENDENT KINASE-1 ARE REQUIRED FOR INSULIN-STIMULATED PRODUCTION OF NITRIC OXIDE IN ENDOTHELIAL CELLS, MOL ENDOCRINOL, 16, PP. 1931-1942, (2002); THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, PP. 3143-3421, (2002); NISSEN S.E., TUZCU E.M., SCHOENHAGEN P., CROWE T., SASIELA J.W., TSAI J., ET AL., REVERSAL OF ATHEROSCLEROSIS WITH AGGRESSIVE LIPID LOWERING (REVERSAL) INVESTIGATORS. STATIN THERAPY, LDL CHOLESTEROL, C-RACTIVE PROTEIN, AND CORONARY ARTERY DISEASE, N ENGL J MED, 352, PP. 29-38, (2005); KAMAL-BAHL S.J., BURKE T., WATSON D., WENTWORTH C., DISCONTINUATION OF LIPID MODIFYING DRUGS AMONG COMMERCIALLY INSURED UNITED STATES PATIENTS IN RECENT CLINICAL PRACTICE, AM J CARDIOL, 99, PP. 530-534, (2007); SCHULTZ J.S., O'DONNELL J.C., MCDONOUGH K.L., SASANE R., MEYER J., DETERMINANTS OF COMPLIANCE WITH STATIN THERAPY AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT IN A MANAGED CARE POPULATION, AM J MANAG CARE, 11, PP. 306-312, (2005); CASPARD H., CHAN A.K., WALKER A.M., COMPLIANCE WITH A STATIN TREATMENT IN A USUAL-CARE SETTING: RETROSPECTIVE DATABASE ANALYSIS OVER 3 YEARS AFTER TREATMENT INITIATION IN HEALTH MAINTENANCE ORGANIZATION ENROLLEES WITH DYSLIPIDEMIA, CLIN THER, 27, PP. 1639-1646, (2005); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); ZHANG Y., LI X., ZOU D., LIU W., YANG J., ZHU N., ET AL., TREATMENT OF TYPE 2 DIABETES AND DYSLIPIDEMIA WITH THE NATURAL PLANT ALKALOID BERBERINE, J CLIN ENDOCRINOL METAB, 93, 7, PP. 2559-2565, (2008); XU M.G., WANG J.M., CHEN L., WANG Y., YANG Z., TAO J., BERBERINE-INDUCED UPREGULATION OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IS RELATED TO NITRIC OXIDE PRODUCTION IN HEALTHY SUBJECTS, CARDIOLOGY, 112, PP. 279-286, (2008); LEE Y.S., KIM W.S., KIM K.H., YOON M.J., CHO H.J., SHEN Y., ET AL., BERBERINE, A NATURAL PLANT PRODUCT, ACTIVATES AMP-ACTIVATED PROTEIN KINASE WITH BENEFICIAL METABOLIC EFFECTS IN DIABETIC AND INSULIN-RESISTANT STATES, DIABETES, 55, PP. 2256-2264, (2006); CORRETTI M.C., ANDERSON T.J., BENJAMIN E.J., CELERMAJER D., CHARBONNEAU F., CREAGER M.A., ET AL., INTERNATIONAL BRACHIAL ARTERY REACTIVITY TASK FORCE. GUIDELINES FOR THE ULTRASOUND ASSESSMENT OF ENDOTHELIAL-DEPENDENT FLOW-MEDIATED VASODILATION OF THE BRACHIAL ARTERY: A REPORT OF THE INTERNATIONAL BRACHIAL ARTERY REACTIVITY TASK FORCE, J AM COLL CARDIOL, 39, PP. 257-265, (2002); MCAULEY K.A., WILLIAMS S.M., MANN J.I., WALKER R.J., LEWIS-BARNED N.J., TEMPLE L.A., ET AL., DIAGNOSING INSULIN RESISTANCE IN THE GENERAL POPULATION, DIABETES CARE, 24, 3, PP. 460-464, (2001); MATSUDA M., DEFRONZO M.R.A., INSULIN SENSITIVITY INDICES OBTAINED FROM ORAL GLUCOSE TOLERANCE TESTING: COMPARISON WITH THE EUGLICEMIC CLAMP, DIABETES CARE, 22, PP. 1462-1470, (1999); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENT. A SINGLE BLIND CLINICAL INVESTIGATION, ARZNEIMITTEL-FORSHUNG, 57, PP. 26-30, (2007); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); BRUSQ J.M., ANCELLIN N., GRONDIN P., GUILLARD P., MARTIN S., SAINTILLAN Y., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP-KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); JOURNOUD M., JONES P.J., RED YEAST RICE: A NEW HYPOLIPIDEMIC DRUG, LIFE SCI, 74, PP. 2675-2683, (2004); KONG W.J., ZHANG H., SONG D.Q., XUE R., ZHAO W., WEI J., ET AL., BERBERINE REDUCES INSULIN RESISTANCE THROUGH PROTEIN KINASE C-DEPENDENT UP-REGULATION OF INSULIN RECEPTOR EXPRESSION, METABOLISM, 58, PP. 109-119, (2009); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHINAS MED, 1, (2006); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, J AM MED ASSOC, 295, PP. 2262-2269, (2006); KASSIS A.N., JONES P.J., CHANGES IN CHOLESTEROL KINETICS FOLLOWING SUGAR CANE POLICOSANOL SUPPLEMENTATION: A RANDOMIZED CONTROL TRIAL, LIPIDS HEALTH DIS, 30, PP. 7-17, (2008)","S. FAZIO; DEPARTMENT OF INTERNAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES UNIV. FEDERICO II, 80131 NAPOLI, VIA S. PANSINI 5, ITALY; EMAIL: FAZIO@UNINA.IT","","ENGLISH","NUTR. METAB. CARDIOVASC. DIS.","ARTICLE","ISI","2-S2.0-78049406766","NUTR METAB CARDIOVASC DIS","UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF NAPLES FEDERICO II","NOTREPORTED;CARDIOVASCULAR AND IMMUNOLOGIC SCIENCES UNIV. FEDERICO II;NOTREPORTED",NA,"AFFUSO F, 2010, NUTR METAB CARDIOVASC DIS","AFFUSO F, 2010, NUTR METAB CARDIOVASC DIS"
"DULLENS S;MENSINK R;BRAGT M;KIES A;PLAT J","DULLENS, STEFAN P. J. (16834300000); MENSINK, RONALD P. (7006171830); BRAGT, MARJOLIJN C. E. (57194489830); KIES, ARIE K. (57204576901); PLAT, JOGCHUM (6604034517)","EFFECTS OF EMULSIFIED POLICOSANOLS WITH DIFFERENT CHAIN LENGTHS ON CHOLESTEROL METABOLISM IN HETEROZYGOUS LDL RECEPTORDEFICIENT MICE",2008,"JOURNAL OF LIPID RESEARCH","49","6",14,"10.1194/jlr.M700497-JLR200","DEPARTMENT OF HUMAN BIOLOGY, NUTRITION AND TOXICOLOGY, MAASTRICHT RESEARCH INSTITUTE, MAASTRICHT UNIVERSITY, MAASTRICHT, NETHERLANDS;DEPARTMENT OF HUMAN BIOLOGY, NUTRITION AND TOXICOLOGY, MAASTRICHT RESEARCH INSTITUTE, MAASTRICHT UNIVERSITY, MAASTRICHT, NETHERLANDS;DEPARTMENT OF HUMAN BIOLOGY, NUTRITION AND TOXICOLOGY, MAASTRICHT RESEARCH INSTITUTE, MAASTRICHT UNIVERSITY, MAASTRICHT, NETHERLANDS;DSM FOOD SPECIALTIES, RESEARCH AND DEVELOPMENT, BIOCHEMISTRY AND NUTRITION DEPARTMENT, DELFT, NETHERLANDS;DEPARTMENT OF HUMAN BIOLOGY, NUTRITION AND TOXICOLOGY, MAASTRICHT RESEARCH INSTITUTE, MAASTRICHT UNIVERSITY, MAASTRICHT, NETHERLANDS","POLICOSANOL IS A MIXTURE OF LONG-CHAIN PRIMARY ALIPHATIC SATURATED ALCOHOLS. PREVIOUS STUDIES IN HUMANS AND ANIMALS HAVE SHOWN THAT THESE COMPOUNDS IMPROVED LIPOPROTEIN PROFILES. HOWEVER, MORE-RECENT PLACEBO-CONTROLLED STUDIES COULD NOT CONFIRM THESE PROMISING EFFECTS. OCTACOSANOL (C28), THE MAIN COMPONENT OF SUGARCANE-DERIVED POLICOSANOL, IS ASSUMED TO BE THE BIOACTIVE COMPONENT. THIS HAS, HOWEVER, NEVER BEEN TESTED IN AN IN VIVO STUDY THAT COMPARED INDIVIDUAL POLICOSANOL COMPONENTS SIDE BY SIDE. HERE WE PRESENT THAT NEITHER THE INDIVIDUAL POLICOSANOL COMPONENTS (C24, C26, C28, OR C30) NOR THE NATURAL POLICOSANOL MIXTURE (ALL 30 MG/100 G DIET) LOWERED SERUM CHOLESTEROL CONCENTRATIONS IN LDL RECEPTOR KNOCK-OUT (LDLR+/- ) MICE. MOREOVER, THERE WAS NO EFFECT ON GENE EXPRESSION PROFILES OF LDLR, ABCA1, HMG-COA SYNTHASE 1, AND APOLIPOPROTEIN A-I (APOA-I) IN HEPATIC AND SMALL INTESTINAL TISSUE OF FEMALE LDLR+/- MICE AFTER THE 7 WEEK INTERVENTION PERIOD. FINALLY, NONE OF THE INDIVIDUAL POLICOSANOLS OR THEIR RESPECTIVE LONG- CHAIN FATTY ACIDS OR ALDEHYDES AFFECTED DE NOVO APOA-I PROTEIN PRODUCTION IN VITRO IN HEPG2 AND CACO-2 CELLS. COPYRIGHT © 2008 BY THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC.","CHD; HIGH DENSITY LIPOPROTEINS; LOW DENSITY LIPOPROTEINS; NUTRITION","ANIMALS; APOLIPOPROTEIN A-I; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHOLESTEROL; EMULSIONS; FATTY ALCOHOLS; FEMALE; GENE EXPRESSION REGULATION; HETEROZYGOTE; HUMANS; INTESTINE, SMALL; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; SOLUTIONS; ABC TRANSPORTER A1; ALDEHYDE DERIVATIVE; APOLIPOPROTEIN A1; CHOLESTEROL; HEXACOSANOL; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE 1; LESSTANOL; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN RECEPTOR; OCTACOSANOL; POLICOSANOL; TETRACOSANOL; TRIACONTANOL; UNCLASSIFIED DRUG; APOLIPOPROTEIN A1; CHOLESTEROL; FATTY ALCOHOL; LOW DENSITY LIPOPROTEIN RECEPTOR; POLICOSANOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CORONARY RISK; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SMALL INTESTINE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; CHEMISTRY; DRUG EFFECT; EMULSION; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; MOUSE MUTANT; SOLUTION AND SOLUBILITY; TUMOR CELL LINE","","","MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR. J. NUTR, 97, PP. 381-388, (2007); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM, 53, PP. 5583-5586, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J, 143, PP. 356-365, (2002); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLES- TEROLAEMIC SUBJECTS, BR. J. NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, J. AM. MED. ASSOC, 295, PP. 2262-2269, (2006); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM. J. CLIN. NUTR, 84, PP. 1003-1008, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR, 84, PP. 1543-1548, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID- LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM. HEART J, 152, 982, (2006); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPER- CHOLESTEROLEMIA, INT. J. CLIN. PHARMACOL. RES, 22, PP. 55-66, (2002); SINGH H., DERWAS N., POULOS A., VERY LONG CHAIN FATTY ACID BETA-OXIDATION BY RAT LIVER MITOCHONDRIA AND PEROXISOMES, ARCH. BIOCHEM. BIOPHYS, 259, PP. 382-390, (1987); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J. PHARM. PHARMACOL, 47, PP. 289-291, (1995); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR, 77, PP. 923-932, (1997); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH. MED. RES, 36, PP. 113-119, (2005); HARTLE D.K., HARGROVE J.L., GREENSPAN P., NUTRACEUTICAL USE OF GRAIN SORGHUM WAX LOWERS SERUM CHOLESTEROL IN HUMANS, FASEB J, 19, (2005); GHESQUIERE S.A., GIJBELS M.J., ANTHONSEN M., VAN GORP P.J., VAN DER MADE I., JOHANSEN B., HOFKER M.H., DE WINTHER M.P., MACROPHAGE-SPECIFIC OVEREXPRESSION OF GROUP IIA SPLA2 INCREASES ATHEROSCLEROSIS AND ENHANCES COLLAGEN DEPOSITION, J. LIPID RES, 46, PP. 201-210, (2005); PLAT J., MENSINK R.P., RELATIONSHIP OF GENETIC VARIATION IN GENES ENCODING APOLIPOPROTEIN A-IV, SCAVENGER RECEPTOR BI, HMG-COA REDUCTASE, CETP AND APOLIPOPROTEIN E WITH CHOLESTEROL METABOLISM AND THE RESPONSE TO PLANT STANOL ESTER CONSUMPTION, EUR. J. CLIN. INVEST, 32, PP. 242-250, (2002); LIVAK K.J., SCHMITTGEN T.D., ANALYSIS OF RELATIVE GENE EXPRESSION DATA USING REAL-TIME QUANTITATIVE PCR AND THE 2(-DELTA DELTA C(T)) METHOD, METHODS, 25, PP. 402-408, (2001); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OFAMP-KINASE, J. PHARMACOL. EXP. THER, 318, PP. 1020-1026, (2006); GILLER T., HENNES U., KEMPEN H.J., REGULATION OF HUMAN APOLIPOPROTEIN A-I EXPRESSION IN CACO-2 AND HEPG2 CELLS BY ALL-TRANS AND 9-CIS RETINOIC ACIDS, J. LIPID RES, 36, PP. 1021-1028, (1995); DULLENS S.P.J., MENSINK R.P., PLAT J., DIFFERENTIAL EFFECTS OF INDIVIDUAL FATTY ACIDS ON DE NOVO APOA-I PRODUCTION IN DIFFERENTIATED CACO-2 CELLS, ATHEROSCLER. SUPPL, 8, (2007); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); JONES P.J., PENCHARZ P.B., CLANDININ M.T., ABSORPTION OF 13C-LABELED STEARIC, OLEIC, AND LINOLEIC ACIDS IN HUMANS: APPLICATION TO BREATH TESTS, J. LAB. CLIN. MED, 105, PP. 647-652, (1985); SALLEE V.L., DIETSCHY J.M., DETERMINANTS OF INTESTINAL MUCOSAL UPTAKE OF SHORT- AND MEDIUM-CHAIN FATTY ACIDS AND ALCOHOLS, J. LIPID RES, 14, PP. 475-484, (1973); BERNARD A., CARLIER H., ABSORPTION AND INTESTINAL CATABOLISM OF FATTY ACIDS IN THE RAT: EFFECT OF CHAIN LENGTH AND UNSATURATION, EXP. PHYSIOL, 76, PP. 445-455, (1991)","J. PLAT; DEPARTMENT OF HUMAN BIOLOGY, NUTRITION AND TOXICOLOGY, MAASTRICHT RESEARCH INSTITUTE, MAASTRICHT UNIVERSITY, MAASTRICHT, NETHERLANDS; EMAIL: J.PLAT@HB.UNIMAAS.NL","","ENGLISH","J. LIPID RES.","ARTICLE","ISI","2-S2.0-44949087861","J LIPID RES","MAASTRICHT UNIVERSITY;MAASTRICHT UNIVERSITY;MAASTRICHT UNIVERSITY;RESEARCH AND DEVELOPMENT;MAASTRICHT UNIVERSITY","NOTREPORTED;MAASTRICHT UNIVERSITY;NOTREPORTED",NA,"DULLENS SPJ, 2008, J LIPID RES","DULLENS SPJ, 2008, J LIPID RES"
"WU T;CHARLES A;HUANG T","WU, TIEN-TSO (56302324600); CHARLES, ALBERT LINTON (7101891130); HUANG, TZOU-CHI (7404962191)","DETERMINATION OF THE CONTENTS OF THE MAIN BIOCHEMICAL COMPOUNDS OF ADLAY COXI LACHRYMALJOBI",2007,"FOOD CHEMISTRY","104","6",67,"10.1016/j.foodchem.2007.02.027","DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, TAJEN UNIVERSITY, PINGTUNG, 907, TAIWAN, DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY, PINGTUNG, 91207, TAIWAN;DEPARTMENT OF TROPICAL AGRICULTURE AND INTERNATIONAL COOPERATION, NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY, PINGTUNG, 91201, TAIWAN;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY, PINGTUNG, 91207, TAIWAN","ADLAY (COXI LACHRYMAL-JOBI), AN ANNUAL CROP, HAS LONG BEEN USED IN TRADITIONAL CHINESE MEDICINE FOR ITS BIOLOGICAL ACTIVITY AND AS A NOURISHING FOOD. ITS PHYTOCHEMICAL COMPOSITION HAS BEEN EXTENSIVELY STUDIED; HOWEVER, INFORMATION ON ITS POLICOSANOL (PC) AND PHYTOSTEROL CONTENT IS SCARCE. THE OBJECTIVE OF THIS STUDY WAS TO EXAMINE AND COMPARE THE PC, PHYTOSTEROL AND OLEAMIDE CONTENTS OF DIFFERENT FRACTIONS OF ADLAY COLLECTED FROM LAOS, THAILAND, VIETNAM AND TAIWAN. BIOCHEMICAL COMPOSITIONS OF THE SAMPLES WERE IDENTIFIED USING A GAS CHROMATOGRAPH COUPLED WITH A MASS SPECTROMETER (GC-MS). THE ADLAY BRAN HAD HIGHER CONTENTS OF POLICOSANOLS (246 MG/KG), PHYTOSTEROLS (4733 MG/KG) AND OLEAMIDE (45.8 MG/KG) THAN HAD HULLED AND POLISHED FRACTIONS. ALTHOUGH PLANT STEROLS REDUCE CHOLESTEROL ABSORPTION, POLICOSANOLS MAY INHIBIT ENDOGENOUS CHOLESTEROL SYNTHESIS. ALTHOUGH ADLAY CONTAINS BENEFICIAL PHYTOCHEMICALS THAT JUSTIFY ITS USE AS A FOOD INGREDIENT OR DIETARY SUPPLEMENT, RESEARCH IS STILL NEEDED TO CONFIRM ITS TRADITIONAL USE IN ASIAN MEDICINE. © 2007 ELSEVIER LTD. ALL RIGHTS RESERVED.","ADLAY; PHYTOCHEMICALS; PHYTOSTEROLS; POLICOSANOL","BEHENYL ALCOHOL; CAMPESTEROL; COXI LACHRYMAL JOBI EXTRACT; ERGOSTANOL; FRIEDELIN; HEXACOSANOL; OCTACOSANOL; OLEAMIDE; PHYTOSTEROL; PLANT EXTRACT; POLICOSANOL; SITOSTEROL; SQUALENE; STIGMATA 5,22 DIEN 3 OL; TETRACOSANOL; TOCOPHEROL; UNCLASSIFIED DRUG; ARTICLE; BIOCHEMICAL COMPOSITION; BRAN; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; COXI LACHRYMAL JOBI; DIET SUPPLEMENTATION; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; LAOS; MASS SPECTROMETER; NONHUMAN; PLANT; TAIWAN; THAILAND; VIET NAM","","","ANEIROS E., MAS R., CALDERON B., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 56, PP. 176-182, (1995); AVATO P., BIANCHI G., MURELLI C., ALIPHATIC AND CYCLIC LIPID COMPONENTS OF SORGHUM PLANT ORGANS, PHYTOCHEMISTRY, 29, PP. 1073-1078, (1990); BORG J., THE NEUROTROPHIC FACTOR, N-HEXACOSANOL, REDUCES THE NEURONAL DAMAGE INDUCED BY THE NEUROTOXIN, KAINIC ACID, JOURNAL OF NEUROSCIENCE RESEARCH, 26, PP. 62-67, (1991); BRADSHAW H.B., WALKER J.M., THE EXPANDING FIELD OF CANNABIMIMETIC AND RELATED LIPID MEDIATORS, BRITISH JOURNAL OF PHARMACOLOGY, 144, PP. 459-465, (2005); CHECK J.B., K'OMBUT F.O., THE EFFECT ON FIBRINOLYTIC SYSTEM OF BLOOD PLASMA OF WISTAR RATS AFTER FEEDING THEM WITH COIX MIXED DIET, EAST AFRICAN MEDICINE JOURNAL, 72, PP. 51-55, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., PERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PAITENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURRENT THERAPEUTIC RESEARCH, 58, PP. 44-51, (1997); DOUGALIS A., LEES G., GANELLIN C.R., THE SLEEP LIPID OLEAMIDE MAY REPRESENT AN ENDOGENOUS ANTICONVULSANT: AN IN VITRO COMPARATIVE STUDY IN THE 4-AMINOPYRIDINE RAT BRAIN-SLICE MODEL, NEUROPHARMACOLOGY, 46, PP. 541-554, (2004); FANG N., YU S., BADGER T., CHARACTERIZATION OF TRIPERPENE ALCOHOL AND STEROL FERULATES IN RICE BRAN USING LC-MS/MS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 3260-3267, (2003); GUILLEN M.D., MANZANOS M.J., STUDY OF THE COMPOSITION OF THE DIFFERENT PARTS OF A SPANISH THRUS VULGARIS L. PLANT, FOOD CHEMISTRY, 63, PP. 373-383, (1998); HANU L.O., FALES H.M., SPANDE T.F., BASILE A.S., A GAS CHROMATOGRAPHIC-MASS SPECTRAL ASSAY FOR THE QUANTITATIVE DETERMINATION OF OLEAMIDE IN BIOLOGICAL FLUIDS, ANALYTICAL BIOCHEMISTRY, 270, PP. 159-166, (1999); HUANG S.L., CHIANG W., COMPOSITION OF THE DIFFERENT FRACTIONS OF ADLAY SEED AND THE DEMUTAGENIC EFFECT OF THEIR HFD+ACETONE EXTRACT, FOOD SCIENCE, 26, PP. 121-130, (1999); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); KONDO Y., NAKAJIMA K., NAEOE S., SUZUKI S., ISOLATION OF OVULATORY-ACTIVE SUBSTANCES FROM CROPS OF JOB'S TEARS (COIX LACHRYMAL-JOBI L VAR. MA-YUENSTAPF), CHEMICAL AND PHARMACEUTICAL BULLETIN, 36, PP. 3147-3152, (1988); LEGGETT J.D., ASPLEY S., BECKETT S.R., D'ANTONA A.M., KENDALL D.A., OLEAMIDE IS A SELECTIVE ENDOGENOUS AGONIST OF RAT AND HUMAN CB1 CANNABINOID RECEPTORS, BRITISH JOURNAL OF PHARMACOLOGY, 141, PP. 253-262, (2004); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES IN MEDICAL RESEARCH, 32, PP. 8-12, (2001); NAGAO T., OTSUKA H., KOHDA H., SATO T., YAMASAKI K., BENZOXAZINONE FROM COIX LACHRYMAL-JOBI L VAR. MA-YUEN, PHYTOCHEMISTRY, 24, PP. 2959-2962, (1985); NORMEN L., SHAW C.A., FINK C.S., AWAD A.B., COMBINATION OF PHYTOSTEROLS AND OMEGA-3 FATTY ACIDS: A POTENTIAL STRATEGY TO PROMOTE CARDIOVASCULAR HEALTH, CURRENT MEDICAL CHEMISTRY: CARDIOVASCULAR AND HEMATOLOGICAL AGENTS, 2, PP. 1-12, (2004); OSTLUND R.E., PHYTOSTEROLS AND CHOLESTEROL METABOLISM, CURRENT OPINION IN LIPIDOLOGY, 15, PP. 37-41, (2004); PIIRONEN V., TOIVO J., LAMPI A.M., PLANT STEROLS IN CEREALS AND CEREAL PRODUCTS, CEREAL CHEMISTRY, 79, PP. 148-154, (2002); SHYU M.L., LIN B.F., CHIANG W., EFFECT OF DEHULLED ADLAY ON ALLERGIC RESPONSES OF SENSITIZED MICE, NUTRITIONAL SCIENCE JOURNAL, 23, PP. 161-170, (1998); SINGH V., MOREAU R.A., HICKS K.B., YIELD AND PHYTOSTEROL COMPOSITION OF OIL EXTRACTED FROM GRAIN SORGHUM AND ITS WET-MILLED FRACTIONS, CEREAL CHEMISTRY, 80, PP. 126-129, (2003); TAKAHASHI M., KONNO C., HIKINO H., ISOLATION AND HYPOGLYCEMIC ACTIVITY OF COIXAN A, B, C, GLYCANS OF COIX LACHRYMAL-JOBI VAR MA-YUEN SEEDS, PLANTA MEDICA, 52, PP. 64-75, (1986); TSAI C.E., YANG L.J., HSU H., INGESTION OF ADLAY MAY REDUCE LIVER FAT ACCUMULATION IN HAMSTERS FED HIGH FAT DIETS, FOOD SCIENCE, 26, PP. 265-276, (1999); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 16, PP. 67-72, (1996); WEIHRAUCH J.L., GARDNER J.M., STEROL CONTENT OF FOODS OF PLANT ORIGIN, JOURNAL OF AMERICAN DIET ASSOCIATION, 73, PP. 39-47, (1978); WETTSTEIN-KNOWLES P.V., GENETICS AND BIOSYNTHESIS OF PLANT EPICUTICULAR WAXES, ADVANCES IN THE BIOCHEMISTRY AND PHYSIOLOGY OF PLANT LIPIDS, PP. 1-26, (1979); YANG L.J., CHEN M.Y., HSU W.Y., PAI Y.H., YUH S.J., TSAI C.E., ET AL., EFFECTS OF ADLAY ON PLASMA LIPIDS AND GLUCOSE ON HYPERLIPIDEMIC PAITENTS, FOOD SCIENCE, 25, PP. 727-736, (1998); YOSHIDA Y., NIKI E., ANTIOXIDANT EFFECTS OF PHYTOSTEROL AND ITS COMPONENTS, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 49, PP. 277-280, (2003)","T.-C. HUANG; DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY, PINGTUNG, 91207, TAIWAN; EMAIL: TCHUANG@MAIL.NPUST.EDU.TW","","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-34249030292","FOOD CHEM","TAJEN UNIVERSITY;NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY;NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY","NOTREPORTED;NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY;NOTREPORTED",NA,"WU T-T, 2007, FOOD CHEM","WU T-T, 2007, FOOD CHEM"
"KRISHNAN G;THOMPSON P","KRISHNAN, GURU M. (36350799100); THOMPSON, PAUL D. (35392374400)","THE EFFECTS OF STATINS ON SKELETAL MUSCLE STRENGTH AND EXERCISE PERFORMANCE",2010,"CURRENT OPINION IN LIPIDOLOGY","21","4",52,"10.1097/MOL.0b013e32833c1edf","DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF CONNECTICUT, FARMINGTON, HARTFORD HOSPITAL, HARTFORD, CT, UNITED STATES;DIVISION OF CARDIOLOGY, HENRY LOW HEART CENTER, HARTFORD HOSPITAL, HARTFORD, CT, UNITED STATES","PURPOSE OF REVIEW: HMG-COA REDUCTASE INHIBITORS OR STATINS ARE ASSOCIATED WITH A VARIETY OF MUSCLE SIDE-EFFECTS BUT LITTLE IS KNOWN ABOUT THE EFFECT OF STATINS ON SKELETAL MUSCLE STRENGTH AND EXERCISE PERFORMANCE. WE PERFORMED A LITERATURE SEARCH TO EXAMINE THESE ISSUES. RECENT FINDINGS: WE IDENTIFIED SIX STUDIES EXAMINING THE EFFECT OF STATINS ON MUSCLE STRENGTH AND NINE STUDIES EXAMINING THEIR EFFECT ON EXERCISE TOLERANCE. IN GENERAL, STUDIES EXAMINING BOTH ISSUES WERE SMALL AND USED CRUDE MEASURES OF STRENGTH AND EXERCISE PERFORMANCE. SUMMARY: THERE IS INSUFFICIENT DATA TO DETERMINE IF STATINS AFFECT MUSCLE STRENGTH AND EXERCISE PERFORMANCE. THERE IS SUGGESTIVE EVIDENCE THAT THESE DRUGS MAY REDUCE MUSCLE STRENGTH IN OLDER PATIENTS AND ALTER ENERGY METABOLISM DURING AEROBIC EXERCISE, BOTH POSSIBILITIES REQUIRE FURTHER STUDY. © 2010 WOLTERS KLUWER HEALTH | LIPPINCOTT WILLIAMS & WILKINS.","AEROBIC CAPACITY; EXERCISE CAPACITY; MUSCLE STRENGTH; STATIN","EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE STRENGTH; MUSCLE, SKELETAL; ATORVASTATIN; AVASIMIBE; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; POLICOSANOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ABDUCTION; CLAUDICATION; CLINICAL TRIAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE TOLERANCE; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; GRIP STRENGTH; HAND GRIP; HEART FAILURE; HUMAN; MUSCLE STIFFNESS; MUSCLE STRENGTH; MYALGIA; MYOPATHY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; TREADMILL EXERCISE; DRUG EFFECTS; EXERCISE; MUSCLE STRENGTH; PHYSIOLOGY; SKELETAL MUSCLE","NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NHLBI, (R01HL081893)","","THOMPSON P.D., CLARKSON P., KARAS R.H., STATIN-ASSOCIATED MYOPATHY, JAMA, 289, PP. 1681-1690, (2003); OMAR M.A., WILSON J.P., COX T.S., RHABDOMYOLYSIS AND HMG-COA REDUCTASE INHIBITORS, ANN PHARMACOTHER, 35, PP. 1096-1107, (2001); PHILLIPS P.S., HAAS R.H., BANNYKH S., ET AL., STATIN-ASSOCIATED MYOPATHY WITH NORMAL CREATINE KINASE LEVELS, ANN INTERN MED, 137, PP. 581-585, (2002); BRUCKERT E., HAYEM G., DEJAGER S., ET AL., MILD TO MODERATE MUSCULAR SYMPTOMS WITH HIGH-DOSAGE STATIN THERAPY IN HYPERLIPIDEMIC PATIENTS-THE PRIMO STUDY, CARDIOVASC DRUGS THER, 19, PP. 403-414, (2005); AGOSTINI J.V., TINETTI M.E., HAN L., ET AL., EFFECTS OF STATIN USE ON MUSCLE STRENGTH, COGNITION, AND DEPRESSIVE SYMPTOMS IN OLDER ADULTS, J AM GERIATR SOC, 55, PP. 420-425, (2007); TRAUSTADOTTIR T., STOCK A.A., HARMAN S.M., HIGH-DOSE STATIN USE DOES NOT IMPAIR AEROBIC CAPACITY OR SKELETAL MUSCLE FUNCTION IN OLDER ADULTS, AGE (DORDR), 30, PP. 283-291, (2008); COEN P.M., FLYNN M.G., MARKOFSKI M.M., ET AL., ADDING EXERCISE TRAINING TO ROSUVASTATIN TREATMENT: INFLUENCE ON SERUM LIPIDS AND BIOMARKERS OF MUSCLE AND LIVER DAMAGE, METAB CLIN EXP, 58, PP. 1030-1038, (2009); SCOTT D., BLIZZARD L., FELL J., JONES G., STATIN THERAPY, MUSCLE FUNCTION AND FALLS RISK IN COMMUNITY-DWELLING OLDER ADULTS, QJM, 102, PP. 625-633, (2009); ASHFIELD T.A., SYDDALL H.E., MARTIN H.J., ET AL., GRIP STRENGTH AND CARDIOVASCULAR DRUG USE IN OLDER PEOPLE: FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY, AGE AGEING, (2009); BOHANNON R.W., HAND-GRIP DYNAMOMETRY PREDICTS FUTURE OUTCOMES IN AGING ADULTS, J GERIATR PHYS THER, 31, PP. 3-10, (2008); SIROLA J., RIKKONEN T., TUPPURAINEN M., ET AL., ASSOCIATION OF GRIP STRENGTH CHANGE WITH MENOPAUSAL BONE LOSS AND RELATED FRACTURES: A POPULATION-BASED FOLLOW-UP STUDY, CALCIF TISSUE INT, 78, PP. 218-226, (2006); SAYER A.A., SYDDALL H.E., DENNISON E.M., ET AL., GRIP STRENGTH AND THE METABOLIC SYNDROME: FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY, QJM, 100, PP. 707-713, (2007); PHILLIPS P., PHILLIPS C., SULLIVAN M., ET AL., STATIN MYOTOXICITY IS ASSOCIATED WITH CHANGES IN THE CARDIOPULMONARY FUNCTION, ATHEROSCLEROSIS, 177, PP. 183-188, (2004); SINZINGER H., O'GRADY J., PROFESSIONAL ATHLETES SUFFERING FROM FAMILIAL HYPER-CHOLESTEROLAEMIA RARELY TOLERATE STATIN TREATMENT BECAUSE OF MUSCULAR PROBLEMS, BR J CLIN PHARMACOL, 57, PP. 525-528, (2004); PAOLISSO G., BARBAGALLO M., PETRELLA G., ET AL., EFFECTS OF SIMVASTATIN AND ATORVASTATIN ADMINISTRATION ON INSULIN RESISTANCE AND RESPIRATORY QUOTIENT IN AGED DYSLIPIDEMIC NONINSULIN DEPENDENT DIABETIC PATIENTS, ATHEROSCLEROSIS, 150, PP. 121-127, (2000); CASTRO P.F., MIRANDA R., VERDEJO H.E., ET AL., PLEIOTROPIC EFFECTS OF ATORVASTATIN IN HEART FAILURE: ROLE IN OXIDATIVE STRESS, INFLAMMATION, ENDOTHELIAL FUNCTION, AND EXERCISE CAPACITY, J HEART LUNG TRANSPLANT, 27, PP. 435-441, (2008); MOHLER E.R., HIATT W.R., CREAGER M.A., CHOLESTEROL REDUCTION WITH ATORVASTATIN IMPROVES WALKING DISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 108, PP. 1481-1486, (2003); MONDILLO S., BALLO P., BARBATI R., ET AL., EFFECTS OF SIMVASTATIN ON WALKING PERFORMANCE AND SYMPTOMS OF INTERMITTENT CLAUDICATION IN HYPERCHOLESTEROLEMIC PATIENTS WITH PERIPHERAL VASCULAR DISEASE, AM J MED, 114, PP. 359-364, (2003); MOMSEN A.H., JENSEN M.B., NORAGER C.B., ET AL., DRUG THERAPY FOR IMPROVING WALKING DISTANCE IN INTERMITTENT CLAUDICATION: A SYSTEMATIC REVIEW AND META ANALYSIS OF ROBUST RANDOMISED CONTROLLED STUDIES, EUR J VASC ENDOVASC SURG, 38, PP. 463-474, (2009); KINLAY S., PLUTZKY J., EFFECT OF LIPID-LOWERING THERAPY ON VASOMOTION AND ENDOTHELIAL FUNCTION, CURR CARDIOL REP, 1, PP. 238-243, (1999); DRAEGER A., MONASTYRSKAYA K., MOHAUPT M., ET AL., STATIN THERAPY INDUCES ULTRASTRUCTURAL DAMAGE IN SKELETAL MUSCLE IN PATIENTS WITHOUT MYALGIA, J PATHOL, 210, PP. 94-102, (2006); MARCOFF L., THOMPSON P.D., THE ROLE OF COENZYME Q10 IN STATIN-ASSOCIATED MYOPATHY: A SYSTEMATIC REVIEW, J AM COLL CARDIOL, 49, PP. 2231-2237, (2007); PHILLIPS P.S., HAAS R.H., STATIN MYOPATHY AS A METABOLIC MUSCLE DISEASE, EXPERT REV CARDIOVASC THER, 6, PP. 971-978, (2008); YOKOYAMA M., PARKT S.T., ET AL., EFFECTS OF LIPOPROTEIN LIPASE AND STATINS ON CHOLESTEROL UPTAKE INTO HEART AND SKELETAL MUSCLE, J LIPID RES, 48, PP. 646-655, (2007); PAIVA H., THELEN K.M., VAN COSTER R., ET AL., HIGH-DOSE STATINS AND SKELETAL MUSCLE METABOLISM IN HUMANS: A RANDOMIZED, CONTROLLED TRIAL, CLIN PHARMACOL THER, 78, PP. 60-68, (2005); URSO M.L., CLARKSON P.M., HITTEL D., ET AL., CHANGES IN UBIQUITIN PROTEASOME PATHWAY GENE EXPRESSION IN SKELETAL MUSCLE WITH EXERCISE AND STATINS, ARTERIOSCLER THROMB VASC BIOL, 25, PP. 2560-2566, (2005); GUIS S., FIGARELLA-BRANGER D., MATTEI J.P., ET AL., IN VIVO AND IN VITRO CHARACTERIZATION OF SKELETAL MUSCLE METABOLISM IN PATIENTS WITH STATIN-INDUCED ADVERSE EFFECTS, ARTHRITIS RHEUM, 55, PP. 551-557, (2006); MOOSMANN B., BEHL C., SELENOPROTEIN SYNTHESIS AND SIDE-EFFECTS OF STATINS, LANCET, 363, PP. 892-894, (2004)","P. D. THOMPSON; CARDIOLOGY, HARTFORD HOSPITAL, HARTFORD, CT 06102, 80 SEYMOUR STREET, UNITED STATES; EMAIL: PTHOMPS@HARTHOSP.ORG","","ENGLISH","CURR. OPIN. LIPIDOLOGY","REVIEW","ISI","2-S2.0-77954957150","CURR OPIN LIPIDOLOGY","UNIVERSITY OF CONNECTICUT;HENRY LOW HEART CENTER","NOTREPORTED;HARTFORD HOSPITAL;EMAIL: PTHOMPS@HARTHOSP.ORG",NA,"KRISHNAN GM, 2010, CURR OPIN LIPIDOLOGY","KRISHNAN GM, 2010, CURR OPIN LIPIDOLOGY"
"HAIM D;BERRÍOS M;VALENZUELA A;VIDELA L","HAIM, DANIELA (26649453600); BERRÍOS, MIRIAM (35486548300); VALENZUELA, ALFONSO (7103344850); VIDELA, LUIS A. (7005959174)","TRACE QUANTIFICATION OF 1OCTACOSANOL AND 1TRIACONTANOL AND THEIR MAIN METABOLITES IN PLASMA BY LIQUIDLIQUID EXTRACTION COUPLED WITH GAS CHROMATOGRAPHYMASS SPECTROMETRY",2009,"JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES","877","4",15,"10.1016/j.jchromb.2009.10.034","MOLECULAR AND CLINICAL PHARMACOLOGY PROGRAM, INSTITUTE OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, SANTIAGO, 7, CHILE;SANTIAGO, CHILE;LABORATORY OF LIPIDS AND ANTIOXIDANTS, INSTITUTE OF NUTRITION AND FOOD TECHNOLOGY, UNIVERSITY OF CHILE, SANTIAGO, CHILE;MOLECULAR AND CLINICAL PHARMACOLOGY PROGRAM, INSTITUTE OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, SANTIAGO, 7, CHILE","A METHOD FOR THE SIMULTANEOUS DETERMINATION OF 1-OCTACOSANOL AND 1-TRIACONTANOL AND THEIR MAIN METABOLITES IN RAT PLASMA WAS DEVELOPED. THE PROCEDURE INVOLVED ETHANOLIC NAOH SAPONIFICATION OF THE SAMPLE, ACIDIFICATION, LIQUID-LIQUID EXTRACTION, AND DERIVATIZATION OF THE ANALYTES TO ITS TRIMETHYLSILYLETHER/ESTER, FOLLOWED ANALYSIS BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS) IN SELECTED ION MONITORING (SIM) MODE. QUANTIFICATION WAS PERFORMED BY THE INTERNAL STANDARD METHOD USING BETULIN. THE METHOD HAD A GOOD LINEARITY OVER THE RANGE 8.4-540 NG/ML (R ≥ 0.998) AND SHOWED AN EXCELLENT INTRA-DAY (R.S.D. = 0.59-3.06%) AND INTER-DAY (R.S.D. = 2.99-5.22%) PRECISION ACCORDING TO THE ACCEPTANCE CRITERIA. THE DETECTION LIMITS RANGED BETWEEN 1.32 AND 3.47 NG/ML. THE METHOD WAS APPLIED SUCCESSFULLY TO STUDY THE TOTAL PLASMATIC CONCENTRATION OF 1-OCTACOSANOL, OCTACOSANOIC ACID, 1-TRIACONTANOL, AND TRIACONTANOIC ACID, AFTER AN ORAL DOSE OF POLICOSANOLS MIXTURE, USING PLASMA SAMPLES OF 100 ΜL. © 2009 ELSEVIER B.V. ALL RIGHTS RESERVED.","1-OCTACOSANOL; 1-TRIACONTANOL; GC-MS","ANIMALS; CHEMICAL FRACTIONATION; FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LIMIT OF DETECTION; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATTUS; ACIDS; CHROMATOGRAPHIC ANALYSIS; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLISM; METABOLITES; PLASMA (HUMAN); SOLVENT EXTRACTION; 1 OCTACOSANOL; 1 TRIACONTANOL; ALCOHOL DERIVATIVE; BETULIN; ESTER; ETHER DERIVATIVE; OCTACOSANOIC ACID; OCTACOSANOL; POLICOSANOL DERIVATIVE; SODIUM HYDROXIDE; TRIACONTANOIC ACID; TRIMETHYLSILYLETHER; UNCLASSIFIED DRUG; ACCEPTANCE CRITERIA; ANALYTES; CONCENTRATION OF; DERIVATIZATION OF; DETECTION LIMITS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; INTERNAL STANDARD METHOD; LIQUID-LIQUID EXTRACTION; OCTACOSANOL; ORAL DOSE; PLASMA SAMPLES; POLICOSANOLS; RAT PLASMA; SELECTED ION MONITORING; SIMULTANEOUS DETERMINATIONS; ACCURACY; ARTICLE; ION MONITORING; LIQUID LIQUID EXTRACTION; MASS FRAGMENTOGRAPHY; NONHUMAN; PLANT PRODUCT; PRIORITY JOURNAL; RAT; GAS CHROMATOGRAPHY","","","JANIKULA M., ALTERN. MED. REV., 7, (2002); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., BRAZ. J. MED. BIOL. RES., 33, (2000); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., CURR. THER. RES. CLIN. EXP., 51, (1992); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., INT. J. CLIN. PHARMACOL. RES., 21, (2001); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., INT. J. CLIN. PHARMACOL. RES., 19, (1999); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., FUSTER A., LASTRETO E., YANEZ M., IRICO G., MCCOOK B., FARRE A., INT. J. CLIN. PHARMACOL. RES., 21, (2001); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., DIAZ E., FERNANDEZ L., CURR. THER. RES. CLIN. EXP., 57, (1996); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., AM. J. CLIN. NUTR., 84, (2006); BERTHOLD H.K., UNVERDOEBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., JAMA, 295, (2006); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., CURR. THER. RES., 59, (1998); HAIM D., VIDELA L.A., AGROFOOD IND. HI-TECH., 19, (2008); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., ARCH. MED. RES., 36, (2005); GONZALEZ-BRAVO L., MAGRANER-HERNANDEZ J., ACOSTA-GONZALEZ P.C., PEREZ-SOUTO N., J. CHROMATOGR. B, 682, (1996); MARRERO DELANGE D., GONZALEZ BRAVO L., J. CHROMATOGR. B, 762, (2001); PAIK M.J., YU J., HU M.B., KIM S.J., KIM K.R., AHN Y.H., CHOI S., LEE G., CLIN. CHIM. ACTA, 396, (2008); KARNES H.T., MARCH C., PHARM. RES., 10, (1993)","L.A. VIDELA; MOLECULAR AND CLINICAL PHARMACOLOGY PROGRAM, INSTITUTE OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, SANTIAGO, 7, CHILE; EMAIL: LVIDELA@MED.UCHILE.CL","","ENGLISH","J. CHROMATOGR. B ANAL. TECHNOL. BIOMED. LIFE SCI.","ARTICLE","ISI","2-S2.0-70649090272","J CHROMATOGR B ANAL TECHNOL BIOMED LIFE SCI","INSTITUTE OF BIOMEDICAL SCIENCES;UNIVERSITY OF CHILE;INSTITUTE OF BIOMEDICAL SCIENCES","NOTREPORTED;INSTITUTE OF BIOMEDICAL SCIENCES;NOTREPORTED",NA,"HAIM D, 2009, J CHROMATOGR B ANAL TECHNOL BIOMED LIFE SCI","HAIM D, 2009, J CHROMATOGR B ANAL TECHNOL BIOMED LIFE SCI"
"KENDALL C;ESFAHANI A;JENKINS D","KENDALL, CYRIL W. C. (34769951900); ESFAHANI, AMIN (25957564800); JENKINS, DAVID J. A. (34769634900)","INTRODUCTION BY GUEST EDITORS",2009,"JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION","28","0",0,"10.1080/07315724.2009.10718108","CANADA;CANADA;CANADA","[NO ABSTRACT AVAILABLE]","","DIET; GLYCEMIC INDEX; HUMANS; NUTRITIONAL SCIENCES; OMEGA 3 FATTY ACID; POLICOSANOL; POLYPHENOL; DIET; EDITORIAL; GLYCEMIC INDEX; HUMAN; NUTRITIONAL SCIENCE; AGING; ANTIOXIDANT ACTIVITY; CHRONIC DISEASE; GLYCEMIC LOAD; MEDICAL LITERATURE; MEDICAL RESEARCH; MOOD; NUTRITION; OBESITY; SPORTS MEDICINE; STRESS; TEA; WEIGHT REDUCTION","","","","","","ENGLISH","J. AM. COLL. NUTR.","ARTICLE","ISI","2-S2.0-85011165257","J AM COLL NUTR",NA,"NOTREPORTED",NA,"KENDALL CWC, 2009, J AM COLL NUTR","KENDALL CWC, 2009, J AM COLL NUTR"
"CHI J","CHI, JIA-MIN (7201908522)","DRUG THERAPY FOR DIABETES MELLITUS ACCOMPANIED BY DYSLIPIDEMIA",2011,"CHINESE JOURNAL OF NEW DRUGS","20","3",0,"","DEPARTMENT OF ENDOCRINOLOGY, BEIJING HOSPITAL, MINISTRY OF PUBLIC HEALTH, BEIJING 100730, CHINA","THE LIPID PROFILE OF TYPE 2 DIABETES MELLITUS ACCOMPANIED BY DYSLIPIDEMIA IS CHARACTERIZED BY INCREASED SERUM TRIGLYCERIDE (TG), SMALL DENSE LDL CHOLESTEROL (SLDL-C), AND DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C). TREATMENT OF DIABETES WITH DYSLIPIDEMIA INCLUDES CHANGES OF LIFE STYLE, MANAGEMENT OF HYPERGLYCEMIA AND DRUG TREATMENT OF DYSLIPIDEMIA. THE PRIMARY TARGET OF THERAPY IS TO REDUCE LDL-C. STATINS ARE CONSIDERED AS THE FIRST-LINE DRUGS TO ACHIEVE LDL TREATMENT GOALS, OTHER DRUGS AVAILABLE ARE EZETIMIBE, XUEZHIKANG, POLICOSANOL, BILE ACID SEQUESTRANTS AND PROBUCOL. IF THE PREDOMINANT LIPID ABNORMALITY WAS HYPERTRIGLYCERIDEMIA, OR WITH A SERUM TRIGLYCERIDE CONCENTRATION OVER 4.52 MMOL · L -1, TG-LOWERING DRUGS SUCH AS FIBRATE, NICOTINIC ACID AND ITS DERIVATIVES, AND OMEGA-3(Ω-3) FATTY ACIDS ARE CONSIDERED. FOR LOW HDL-C PATIENTS, NICOTINIC ACID IS CONSIDERED IN ADDITION TO LIFESTYLE INTERVENTION. FOR DIABETES COMBINED WITH MIXED HYPERLIPIDEMIA, OTHER LIPID MANAGEMENT DRUGS CAN BE USED IN COMBINATION WITH STAINS; HOWEVER, ADAPTATIONS SHOULD BE STRICTLY EVALUATED. FENOFIBRATE HAS ADVANTAGES OVER OTHER DRUGS IN TREATMENT OF THE MIXED DYSLIPIDEMIA.","CHOICE OF DRUGS; DIABETIC WITH DYSLIPIDEMIA; DRUG THERAPY; LIPID PROFILE","ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; POLICOSANOL; PROBUCOL; STATIN; TRIACYLGLYCEROL; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MEDICATION THERAPY MANAGEMENT; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL","","","35, 5, PP. 390-419, (2007); ADIELS M., BOREN J., MURIEL J., ET AL., OVERPRODUCTION OF VLDL1 DRIVEN BY HYPERGLYCEMIA IS A DOMINANT FEATURE OF DIABETIC DYSLIPIDEMIA, ARTERIOSCLR THROMB VASC BIOL, 25, 8, PP. 1697-1703, (2005); PP. 193-204, (2010); TURNER R.C., MILLNS H., RISK FACTORS FOR CORONARY ARTERY DISEASE IN NON-INSULIN DEPENDENT DIABETES MELLITUS; UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS: 23), BMJ, 316, PP. 823-828, (1998); COLHOUN H.M., BETTERIDGE D.J., DURRINGTON P.N., ET AL., PRIMARY PREVENTION OF CARDIOVASCULAR DISEAS WITH ATORVASTATIN IN TYPE 2 DIABETES IN THE COLLABORATIVE. ATORVASTATIN DIABETES STUDY(CARDS): MULTICENTRE RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 364, 9435, PP. 685-696, (2004); 9, 7, PP. 559-560, (2009); 37, 6, PP. 374-376, (1998); 9, 3, PP. 159-161, (2001); 2, 10, PP. 157-158, (2001); (2011); 11, 5, PP. 388-389, (2011); KEECH A., SIMES R.J., BARTER P., ET AL., FOR THE FIELD STUDY INVESTIGATORS. EFFECTS OF LONG-TERM FENOFIBRATE THERAPY ON CARDIOVASCULAR EVENTS IN 9795 PEOPLE WITH TYPE 2 DIABETES MELLITUS(THE FIELD STUDY): RANDOMIZED CONTROLLED TRIAL, LANCET, 366, 9500, PP. 1849-1861, (2005); KEECH A.C., MITCHELL P., SUMMANEN P.A., ET AL., EFFECT OF FENOFIBRATE ON THE NEED FOR LASER TREATMENT FOR DIABETIC RETINOPATHY (FIELD STUDY): A RANDOMISED CONTROLLED TRIAL, LANCET, 370, 9600, PP. 1687-1697, (2007); RAJAMANI K., COLMAN P.G., LI P.L., ET AL., EFFECT OF FENOFIBRATE ON AMPUTATION EVENTS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS (FIELD STUDY): A PRESPECIFIED ANALYSIS OF A RANDOMISED CONTROLLED TRIAL, LANCET, 373, 9677, PP. 1780-1788, (2007)","J.-M. CHI; DEPARTMENT OF ENDOCRINOLOGY, BEIJING HOSPITAL, MINISTRY OF PUBLIC HEALTH, BEIJING 100730, CHINA; EMAIL: CJM0223@YAHOO.COM.CN","","CHINESE","CHIN. J. NEW DRUGS","REVIEW","ISI","2-S2.0-84859492297","CHIN J NEW DRUGS","BEIJING HOSPITAL","NOTREPORTED;BEIJING HOSPITAL;NOTREPORTED",NA,"CHI J-M, 2011, CHIN J NEW DRUGS","CHI J-M, 2011, CHIN J NEW DRUGS"
"CAMPBELL A","CAMPBELL, AMY (8445748800)","NATURAL WAYS TO LOWER YOUR CHOLESTEROL",2010,"DIABETES SELF-MANAGEMENT","27","",2,"","JOSLIN DIABETES CENTER, BOSTON, MASSACHUSETTS, USA.","[NO ABSTRACT AVAILABLE]","","ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BIOLOGICAL PRODUCTS; COMMIPHORA; DIET; DIETARY FIBER; FATTY ALCOHOLS; GARLIC; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIFE STYLE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NIACIN; PHYTOSTEROLS; PLANT EXTRACTS; PLANT GUMS; TRIGLYCERIDES; ANTILIPEMIC AGENT; BIOLOGICAL PRODUCT; CHOLESTIN; FATTY ALCOHOL; GUGGULU EXTRACT; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PHYTOSTEROL; PLANT EXTRACT; PLANT GUM; POLICOSANOL; TRIACYLGLYCEROL; ARTICLE; BLOOD; COMMIPHORA; DIET; DIETARY FIBER; GARLIC; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE","","","","","","ENGLISH","DIABETES SELF MANAG","ARTICLE","ISI","2-S2.0-77955867232","DIABETES SELF MANAG",NA,"NOTREPORTED",NA,"CAMPBELL A, 2010, DIABETES SELF MANAG","CAMPBELL A, 2010, DIABETES SELF MANAG"
"BURILLO E;ANDRES E;MATEO-GALLEGO R;FIDDYMENT S;JARAUTA E;CENARRO A;CIVEIRA F","BURILLO, ELENA (26631813600); ANDRES, EVA MARIA (24334090700); MATEO-GALLEGO, ROCIO (25646291600); FIDDYMENT, SARAH (57194752066); JARAUTA, ESTIBALIZ (23472967000); CENARRO, ANA (7003538037); CIVEIRA, FERNANDO (35517335700)","HIGHDENSITY LIPOPROTEIN CHOLESTEROL INCREASE AND NONCARDIOVASCULAR MORTALITY A METAANALYSIS",2010,"HEART","96","6",17,"10.1136/hrt.2010.195396","LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN;UNIDAD DE INVESTIGACIÓN - EPIDEMIOLOGÍA CLÍNICA, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, CIBER DE EPIDEMIOLOGÍA Y SALUD PÚBLICA, MADRID, SPAIN;LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN;LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN;LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN;LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN;LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN","CONTEXT: MANY OBSERVATIONAL PROSPECTIVE STUDIES HAVE CONFIRMED THE INVERSE RELATIONSHIP BETWEEN HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL AND CORONARY HEART DISEASE. HOWEVER, THE POTENTIAL BENEFIT OF THE PHARMACOLOGICAL INCREASE IN HDL CHOLESTEROL HAS NOT BEEN CLEARLY DEMONSTRATED. MOREOVER, IN SOME INTERVENTIONS AN INCREASE IN TOTAL MORTALITY HAS BEEN REPORTED. OBJECTIVE: THE OBJECTIVE OF THIS META-ANALYSIS WAS TO DETERMINE THE RELATIONSHIP BETWEEN HDL CHOLESTEROL INCREASE AND NON-CARDIOVASCULAR MORTALITY IN RANDOMISED TRIALS. DATA SOURCES: AUTHORS SEARCHED MEDLINE UP TO DECEMBER 2008. STUDY SELECTION: FOUR REVIEWERS IDENTIFIED RANDOMISED TRIALS IN WHICH, THROUGH DIFFERENT TYPES OF INTERVENTIONS, HDL CHOLESTEROL INCREASE IN THE TREATMENT GROUP WAS >4% COMPARED TO CONTROL GROUP, BOTH GROUPS REPORTED SEPARATELY NON-CARDIOVASCULAR MORTALITY AND THE DURATION OF THE STUDY WAS, AT LEAST, ONE YEAR. DATA EXTRACTION: DATA OF HDL CHOLESTEROL CONCENTRATIONS AND DEATHS WERE COLLECTED AS THEY APPEARED IN THE ORIGINAL STUDIES. IF NECESSARY, REVIEWERS CALCULATED DATA BY USING TRIAL INFORMATION. RESULTS: META-REGRESSION ANALYSIS INCLUDED 44 ARTICLES CORRESPONDING TO 107 773 PARTICIPANTS. ANALYSIS SHOWED AN ASSOCIATION BETWEEN HDL CHOLESTEROL INCREASE AND NON-CARDIOVASCULAR MORTALITY (P=0.023), HOWEVER, THE CORRELATION DISAPPEARED WHEN WE EXCLUDED THE ILLUMINATE (INVESTIGATION OF LIPID LEVEL MANAGEMENT TO UNDERSTAND ITS IMPACT IN ATHEROSCLEROSIS EVENTS) TRIAL FROM THE ANALYSIS (P=0.972). CONCLUSIONS: META-REGRESSION ANALYSIS RESULTS SUGGEST THAT INCREASES IN HDL CHOLESTEROL UP TO 40% ARE NOT ASSOCIATED WITH HIGHER NON-CARDIOVASCULAR DEATH. THE INCREASE IN ADVERSE EVENTS OBSERVED IN SOME TRIALS WHERE HDL CHOLESTEROL WAS RAISED IN LARGE AMOUNTS COULD BE RELATED WITH THE DRUG MECHANISMS MORE THAN THE HDL CHOLESTEROL INCREASE ITSELF.","","CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; ATORVASTATIN; BEZAFIBRATE; CALCIUM; COLESTIPOL; COLESTYRAMINE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PLACEBO; POLICOSANOL; PRAVASTATIN; RIMONABANT; ROSUVASTATIN; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; TORCETRAPIB; XUEZHIKANG; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ATHEROSCLEROSIS; CLINICAL TRIAL; DEATH; DRUG MECHANISM; HORMONE SUBSTITUTION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR","","","ASSMANN G., SCHULTE H., THE PROSPECTIVE CARDIOVASCULAR MÜNSTER (PROCAM) STUDY: PREVALENCE OF HYPERLIPIDEMIA IN PERSONS WITH HYPERTENSION AND/OR DIABETES MELLITUS AND THE RELATIONSHIP TO CORONARY HEART DISEASE, AM HEART J, 116, PP. 1713-1724, (1988); GORDON T., CASTELLI W., HJORTLAND M., ET AL., HIGH DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART DISEASE. THE FRAMINGHAM STUDY, AM J MED, 62, PP. 707-714, (1977); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GRAHAM I., ATAR D., BORCH-JOHNSEN K., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: EXECUTIVE SUMMARY, EUR HEART J, 28, PP. 2375-2414, (2007); BARTER P., CAULFIELD M., ERIKSSON M., ET AL., EFFECTS OF TORCETRAPIB IN PATIENTS AT HIGH RISK FOR CORONARY EVENTS, N ENGL J MED, 357, PP. 2109-2122, (2007); COLHOUN H., AFTER FIELD: SHOULD FIBRATES BE USED TO PREVENT CARDIOVASCULAR DISEASE IN DIABETES?, LANCET, 366, PP. 1829-1831, (2005); BRIEL M., FERREIRA-GONZALEZ I., YOU J., ET AL., ASSOCIATION BETWEEN CHANGE IN HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY: SYSTEMATIC REVIEW AND META-REGRESSION ANALYSIS, BMJ, 338, (2009); TALL A., CHOLESTEROL EFFLUX PATHWAYS AND OTHER POTENTIAL MECHANISMS INVOLVED IN THE ATHERO-PROTECTIVE EFFECT OF HIGH DENSITY LIPOPROTEINS, J INTERN MED, 263, PP. 256-273, (2008); BREWER H.J., HDL METABOLISM AND THE ROLE OF HDL IN THE TREATMENT OF HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE, CURR CARDIOL REP, 9, PP. 486-492, (2007); FRICK M., ELO O., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); BOTS M., EVANS G., RILEY W., ET AL., THE EFFECT OF TIBOLONE AND CONTINUOUS COMBINED CONJUGATED EQUINE OESTROGENS PLUS MEDROXYPROGESTERONE ACETATE ON PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS: THE OSTEOPOROSIS PREVENTION AND ARTERIAL EFFECTS OF TIBOLONE (OPAL) STUDY, EUR HEART J, 27, PP. 746-755, (2006); EFFECTS OF OESTROGEN OR ESTROGEN/PROGESTIN REGIMENS ON HEART DISEASE RISK FACTORS IN POSTMENOPAUSAL WOMEN. THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL, JAMA, 273, PP. 199-208, (1995); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); SPEROFF L., ROWAN J., SYMONS J., ET AL., THE COMPARATIVE EFFECT ON BONE DENSITY, ENDOMETRIUM, AND LIPIDS OF CONTINUOUS HORMONES AS REPLACEMENT THERAPY (CHART STUDY). A RANDOMIZED CONTROLLED TRIAL, JAMA, 276, PP. 1397-1403, (1996); EFFECT OF FENOFIBRATE ON PROGRESSION OF CORONARY-ARTERY DISEASE IN TYPE 2 DIABETES: THE DIABETES ATHEROSCLEROSIS INTERVENTION STUDY, A RANDOMISED STUDY, LANCET, 357, PP. 905-1010, (2001); LEVY R., BRENSIKE J., EPSTEIN S., ET AL., THE INFLUENCE OF CHANGES IN LIPID VALUES INDUCED BY CHOLESTYRAMINE AND DIET ON PROGRESSION OF CORONARY ARTERY DISEASE: RESULTS OF NHLBI TYPE II CORONARY INTERVENTION STUDY, CIRCULATION, 69, PP. 325-337, (1984); HIGGINS J., THOMPSON S., QUANTIFYING HETEROGENEITY IN A META-ANALYSIS, STAT MED, 21, PP. 1539-1558, (2002); GREEN S., HIGGINGS J., COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS. 4.2.5. THE COCHRANE COLLABORATION, (2005); DEROSA G., MUGELLINI A., CICCARELLI L., ET AL., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED COMPARISON OF THE ACTION OF ORLISTAT, FLUVASTATIN, OR BOTH AN ANTHROPOMETRIC MEASUREMENTS, BLOOD PRESSURE, AND LIPID PROFILE IN OBESE PATIENTS WITH HYPERCHOLESTEROLEMIA PRESCRIBED A STANDARDIZED DIET, CLIN THER, 25, PP. 1107-1122, (2003); RUBINS H., ROBINS S., COLLINS D., ET AL., GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, N ENGL J MED, 341, PP. 410-418, (1999); ERICSSON C., HAMSTEN A., NILSSON J., ET AL., ANGIOGRAPHIC ASSESSMENT OF EFFECTS OF BEZAFIBRATE ON PROGRESSION OF CORONARY ARTERY DISEASE IN YOUNG MALE POSTINFARCTION PATIENTS, LANCET, 347, PP. 849-853, (1996); SECONDARY PREVENTION BY RAISING HDL CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CORONARY ARTERY DISEASE: THE BEZAFIBRATE INFARCTION PREVENTION (BIP) STUDY, CIRCULATION, 102, PP. 21-27, (2000); ELKELES R., DIAMOND J., POULTER C., ET AL., CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES. A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BEZAFIBRATE: THE ST. MARY'S, EALING, NORTHWICK PARK DIABETES CARDIOVASCULAR DISEASE PREVENTION (SENDCAP) STUDY, DIABETES CARE, 21, PP. 641-648, (1998); KEECH A., SIMES R., BARTER P., ET AL., EFFECTS OF LONG-TERM FENOFIBRATE THERAPY ON CARDIOVASCULAR EVENTS IN 9795 PEOPLE WITH TYPE 2 DIABETES MELLITUS (THE FIELD STUDY): RANDOMISED CONTROLLED TRIAL, LANCET, 366, PP. 1849-1861, (2005); PASTERNAK R., BROWN L., STONE P., ET AL., EFFECT OF COMBINATION THERAPY WITH LIPIDREDUCING DRUGS IN PATIENTS WITH CORONARY HEART DISEASE AND ""NORMAL"" CHOLESTEROL LEVELS. A RANDOMIZED, PLACEBO-CONTROLLED TRIAL, ANN INTERN MED, 125, PP. 529-540, (1996); TAYLOR A., SULLENBERGER L., LEE H., ET AL., ARTERIAL BIOLOGY FOR THE INVESTIGATION OF THE TREATMENT EFFECTS OF REDUCING CHOLESTEROL (ARBITER) 2: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EXTENDED-RELEASE NIACIN ON ATHEROSCLEROSIS PROGRESSION IN SECONDARY PREVENTION PATIENTS TREATED WITH STATINS, CIRCULATION, 110, PP. 3512-3517, (2004); BROWN B., ZHAO X., CHAIT A., ET AL., SIMVASTATIN AND NIACIN, ANTIOXIDANT VITAMINS, OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE, N ENGL J MED, 345, PP. 1583-1592, (2001); WHITNEY E., KRASUSKI R., PERSONIUS B., ET AL., A RANDOMIZED TRIAL OF A STRATEGY FOR INCREASING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: EFFECTS ON PROGRESSION OF CORONARY HEART DISEASE AND CLINICAL EVENTS, ANN INTERN MED, 142, PP. 95-104, (2005); BLANKENHORN D., NESSIM S., JOHNSON R., ET AL., BENEFICIAL EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS, JAMA, 257, PP. 3233-3240, (1987); BROWN G., ALBERS J., FISHER L., ET AL., REGRESSION OF CORONARY ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH LEVELS OF APOLIPOPROTEIN B, N ENGL J MED, 323, PP. 1289-1298, (1990); LINDHOLM L., EKBOM T., DASH C., ET AL., CHANGES IN CARDIOVASCULAR RISK FACTORS BY COMBINED PHARMACOLOGICAL AND NONPHARMACOLOGICAL STRATEGIES: THE MAIN RESULTS OF THE CELL STUDY, J INTERN MED, 240, PP. 13-22, (1996); VAN GAAL L., SCHEEN A., RISSANEN A., ET AL., LONG-TERM EFFECT OF CB1 BLOCKADE WITH RIMONABANT ON CARDIOMETABOLIC RISK FACTORS: TWO YEAR RESULTS FROM THE RIO-EUROPE STUDY, EUR HEART J, 29, PP. 1761-1771, (2008); PI-SUNYER F., ARONNE L., HESHMATI H., ET AL., EFFECT OF RIMONABANT, A CANNABINOID-1 RECEPTOR BLOCKER, ON WEIGHT AND CARDIOMETABOLIC RISK FACTORS IN OVERWEIGHT OR OBESE PATIENTS: RIO-NORTH AMERICA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 761-775, (2006); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); BERKOWITZ R., FUJIOKA K., DANIELS S., ET AL., EFFECTS OF SIBUTRAMINE TREATMENT IN OBESE ADOLESCENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 145, PP. 81-90, (2006); JAMES W., ASTRUP A., FINER N., ET AL., EFFECT OF SIBUTRAMINE ON WEIGHT MAINTENANCE AFTER WEIGHT LOSS: A RANDOMISED TRIAL. STORM STUDY GROUP. SIBUTRAMINE TRIAL OF OBESITY REDUCTION AND MAINTENANCE, LANCET, 356, PP. 2119-2125, (2000); REID I., MASON B., HORNE A., ET AL., EFFECTS OF CALCIUM SUPPLEMENTATION ON SERUM LIPID CONCENTRATIONS IN NORMAL OLDER WOMEN: A RANDOMIZED CONTROLLED TRIAL, AM J MED, 112, PP. 343-347, (2002); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); EFFECT OF SIMVASTATIN ON CORONARY ATHEROMA: THE MULTICENTRE ANTI-ATHEROMA STUDY (MAAS), LANCET, 344, PP. 633-638, (1994); TEO K., BURTON J., BULLER C., ET AL., LONG-TERM EFFECTS OF CHOLESTEROL LOWERING AND ANGIOTENSIN-CONVERTING ENZYME INHIBITION ON CORONARY ATHEROSCLEROSIS: THE SIMVASTATIN/ENALAPRIL CORONARY ATHEROSCLEROSIS TRIAL (SCAT), CIRCULATION, 102, PP. 1748-1754, (2000); SANTINGA J., ROSMAN H., RUBENFIRE M., ET AL., EFFICACY AND SAFETY OF PRAVASTATIN IN THE LONG-TERM TREATMENT OF ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, AM J MED, 96, PP. 509-515, (1994); SACKS F., PFEFFER M., MOYE L., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); PITT B., MANCINI G., ELLIS S., ET AL., PRAVASTATIN LIMITATION OF ATHEROSCLEROSIS IN THE CORONARY ARTERIES (PLAC I): REDUCTION IN ATHEROSCLEROSIS PROGRESSION AND CLINICAL EVENTS. PLAC I INVESTIGATION, J AM COLL CARDIOL, 26, PP. 1133-1139, (1995); SHEPHERD J., BLAUW G., MURPHY M., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED TRIAL, LANCET, 360, PP. 1623-1630, (2002); JUKEMA J., BRUSCHKE A., VAN BOVEN A., ET AL., EFFECTS OF LIPID LOWERING BY PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ARTERY DISEASE IN SYMPTOMATIC MEN WITH NORMAL TO MODERATELY ELEVATED SERUM CHOLESTEROL LEVELS. THE REGRESSION GROWTH EVALUATION STATIN STUDY (REGRESS), CIRCULATION, 91, PP. 2528-2540, (1995); DOWNS J., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS. AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); LAROSA J., APPLEGATE W., CROUSE III J.R., ET AL., CHOLESTEROL LOWERING IN THE ELDERLY. RESULTS OF THE CHOLESTEROL REDUCTION IN SENIORS PROGRAM (CRISP) PILOT STUDY, ARCH INTERN MED, 154, PP. 529-539, (1994); RIDKER P., DANIELSON E., FONSECA F., ET AL., ROSUVASTATIN TO PREVENT VASCULAR EVENTS IN MEN AND WOMEN WITH ELEVATED C-REACTIVE PROTEIN, N ENGL J MED, 359, PP. 2195-2207, (2008); HULLEY S., GRADY D., BUSH T., ET AL., RANDOMIZED TRIAL OF ESTROGEN PLUS PROGESTIN FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN, JAMA, 280, 7, PP. 605-613, (1998); HODIS H., MACK W., LOBO R., ET AL., ESTROGEN IN THE PREVENTION OF ATHEROSCLEROSIS. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ANN INTERN MED, 135, PP. 939-953, (2001); HERRINGTON D., REBOUSSIN D., BROSNIHAN K., ET AL., EFFECTS OF ESTROGEN REPLACEMENT ON THE PROGRESSION OF CORONARY-ARTERY ATHEROSCLEROSIS, N ENGL J MED, 343, PP. 522-529, (2000); ALAUPOVIC P., HODIS H., KNIGHT-GIBSON C., ET AL., EFFECTS OF LOVASTATIN ON APOA- AND APOB-CONTAINING LIPOPROTEINS. FAMILIES IN A SUBPOPULATION OF PATIENTS PARTICIPATING IN THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS), ARTERIOSCLER THROMB, 14, PP. 1906-1913, (1994)","E. BURILLO; LABORATORIO DE INVESTIGACIÓN MOLECULAR, HOSPITAL UNIVERSITARIO MIGUEL SERVET, INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD (I+CS), ZARAGOZA, SPAIN; EMAIL: EBURILLOI.IACS@ARAGON.ES","BMJ PUBLISHING GROUP","ENGLISH","HEART","REVIEW","ISI","2-S2.0-77956109178","HEART","HOSPITAL UNIVERSITARIO MIGUEL SERVET;HOSPITAL UNIVERSITARIO MIGUEL SERVET;HOSPITAL UNIVERSITARIO MIGUEL SERVET;HOSPITAL UNIVERSITARIO MIGUEL SERVET;HOSPITAL UNIVERSITARIO MIGUEL SERVET;HOSPITAL UNIVERSITARIO MIGUEL SERVET","NOTREPORTED;HOSPITAL UNIVERSITARIO MIGUEL SERVET;NOTREPORTED",NA,"BURILLO E, 2010, HEART","BURILLO E, 2010, HEART"
"DUNFORD N;EDWARDS J","DUNFORD, NURHAN T. (6603296815); EDWARDS, JEFF (26032065400)","NUTRITIONAL BIOACTIVE COMPONENTS OF WHEAT STRAW AS AFFECTED BY GENOTYPE AND ENVIRONMENT",2010,"BIORESOURCE TECHNOLOGY","101","3",21,"10.1016/j.biortech.2009.08.009","DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURE PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, FAPC ROOM 103, UNITED STATES;DEPARTMENT OF PLANT AND SOIL SCIENCES, OKLAHOMA STATE UNIVERSITY, UNITED STATES","POLICOSANOL (PC) AND PHYTOSTEROL (PS) ENRICHED DIETARY SUPPLEMENTS AND FUNCTIONAL FOODS ARE MARKETED FOR THEIR LOW DENSITY LIPOPROTEIN LOWERING PROPERTIES. THE PRESENCE OF PC AND PS IN WHEAT STRAW HAS BEEN REPORTED PREVIOUSLY. WHEAT STRAW CAN BE A POTENTIAL SOURCE FOR RECOVERY OF HIGH VALUE COMPONENTS. A FUNDAMENTAL UNDERSTANDING OF VARIATIONS IN CHEMICAL COMPOSITION OF FEEDSTOCK IS THE KEY FOR DESIGNING EFFICIENT PROCESSES FOR VALUE-ADDED PRODUCT DEVELOPMENT. INFORMATION ON VARIATIONS IN THE PC AND PS CONTENT AND COMPOSITION IN WHEAT STRAW IS LIMITED. THE OBJECTIVE OF THIS STUDY IS TO EXAMINE THE EFFECT OF GENOTYPE AND ENVIRONMENT ON PC AND PS CONTENTS AND COMPOSITIONS IN WHEAT STRAW. SAMPLES WERE COLLECTED FROM THREE VARIETIES, JAGGER, TREGO, AND INTRADA GROWN AT TWO LOCATIONS BALKO, AND GOODWELL, OK IN 2006. TOTAL PC AND PS CONTENTS AND COMPOSITIONS IN THE SAMPLES WERE DETERMINED BY USING A GAS CHROMATOGRAPHY SYSTEM. THIS STUDY SHOWED THAT WHEAT STRAW CONTAINS SIGNIFICANT AMOUNT OF PC (APPROXIMATELY 137-274 MG/KG) AND PS (APPROXIMATELY 834-1206 MG/KG). OCTACOSANOL, TETRACOSANOL, DOCOSANOL, HEXACOSANOL, AND TRICONTANOL WERE THE MAIN PC COMPONENTS. APPROXIMATELY 60-76% OF THE TOTAL PS CONSISTED OF Β-SITOSTEROL. GENOTYPE AND ENVIRONMENT HAD A SIGNIFICANT EFFECT ON PC AND PS CONTENTS IN WHEAT STRAW. THIS IS THE FIRST STUDY EXAMINING THE EFFECT OF ENVIRONMENT AND GENOTYPE ON WHEAT STRAW CHEMICAL COMPOSITION. A FUNDAMENTAL UNDERSTANDING OF VARIATIONS OF PC AND PS CONTENTS AND COMPOSITIONS IN WHEAT STRAW REQUIRES FURTHER RESEARCH INVOLVING SAMPLES COLLECTED OVER SEVERAL YEARS. © 2009 ELSEVIER LTD. ALL RIGHTS RESERVED.","PHYTOSTEROL; POLICOSANOL; WHEAT STRAW","FATTY ALCOHOLS; GENOTYPE; NUTRITIVE VALUE; PHYTOSTEROLS; PLANT COMPONENTS, AERIAL; SPECIES SPECIFICITY; TRITICUM; TRITICUM AESTIVUM; CHROMATOGRAPHIC ANALYSIS; PRODUCT DEVELOPMENT; PROJECT MANAGEMENT; BEHENYL ALCOHOL; HEXACOSANOL; OCTACOSANOL; PHYTOSTEROL; POLICOSANOL; SITOSTEROL; BIOACTIVE COMPONENTS; CHEMICAL COMPOSITIONS; DIETARY SUPPLEMENTS; EFFICIENT PROCESS; FUNCTIONAL FOODS; LOW DENSITY LIPOPROTEINS; OCTACOSANOL; PHYTOSTEROL; POLICOSANOL; POTENTIAL SOURCES; PS CONTENTS; VALUE ADDED PRODUCTS; WHEAT STRAW; WHEAT STRAWS; CHEMICAL COMPOSITION; ENVIRONMENTAL EFFECT; GENOTYPE; STRAW; WHEAT; ARTICLE; CONTROLLED STUDY; FOOD COMPOSITION; GAS CHROMATOGRAPHY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL VALUE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SEPARATION TECHNIQUE; VARIETAS; WHEAT; GAS CHROMATOGRAPHY","","","AHRING B.K., LICHT D., SCHMIDT A.S., SOMMER P., THOMSEN A.B., PRODUCTION OF ETHANOL FROM WET OXIDISED WHEAT STRAW BY THERMOANAEROBACTER MATHRANII, BIORESOURCE TECHNOLOGY, 68, PP. 3-9, (1999); CANTRILL R., PHYTOSTEROLS, PHYTOSTANOLS AND THEIR ESTERS, JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES (JECFA), PP. 1-13, (2003); CARVER B.F., KRENZER E.G., HUNGER R.M., MARTIN T.J., KLATT A.R., PORTER D.R., VERCHOT J., RAYAS-DUARTE P., GUENZI A.C., MARTIN B.C., BAI G., REGISTRATION OF 'INTRADA' WHEAT, CROP SCIENCE, 43, PP. 1135-1136, (2003); CHEN Y., EFFECT OF GENOTYPE AND ENVIRONMENT ON NUTRITIONAL AND HEALTH BENEFICIAL COMPOUNDS IN WHEAT GRAIN, (2007); CHEN Y., DUNFORD N.T., EDWARDS J., CARVER B., GOAD C., GENOTYPE AND ENVIRONMENT AFFECT PHYTOSTEROL CONTENT AND COMPOSITION OF WHEAT, CEREAL CHEMISTRY, 86, PP. 96-99, (2008); CHEN Y., DUNFORD N.T., EDWARDS J., CARVER B., GOAD C., POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 89, PP. 310-314, (2008); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); HARPER S.H., LYNCH J.M., THE CHEMICAL COMPONENTS AND DECOMPOSITION OF WHEAT STRAW LEAVES, INTERNODES AND NODES, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 32, PP. 1057-1062, (1981); HOSKINSON R.L., HESS J.R., FOUST T.D., MCKEAN W.T., LEWIS M.S., FRACTIONATION OF HIGHER VALUE CROP RESIDUE COMPONENTS FOR CONVERSION INTO BIOENERGY AND INDUSTRIAL PRODUCTS, (2001); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2005); KING J.W., DUNFORD N.T., PHYTOSTEROL-ENRICHED TRIGLYCERIDE FRACTIONS FROM VEGETABLE OIL DEODORIZER DISTILLATES UTILIZING SUPERCRITICAL FLUID FRACTIONATION TECHNOLOGY, SEPARATION SCIENCE AND TECHNOLOGY, 37, PP. 451-462, (2001); LAL R., WORLD CROP RESIDUES PRODUCTION AND IMPLICATIONS OF ITS USE AS A BIOFUEL, ENVIRONMENT INTERNATIONAL, 31, PP. 575-584, (2005); LEGUIZAMON C., WELLER C.L., CARR T.P., PLANT STEROL AND POLICOSANOL CHARACTERIZATION OF HEXANE EXTRACTS FROM GRAIN SORGHUM, CORN AND THEIR DDGS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 86, PP. 707-716, (2009); MARTIN T.J., SEARS R.G., SEIFERS D.L., HARVEY T.L., WITT M.D., SCHLEGEL A.J., MCCLUSKEY P.J., HATCHETT J.H., REGISTRATION OF 'TREGO' WHEAT, CROP SCIENCE, 41, (2001); SAHA B.C., ITEN L.B., COTTA M.A., WU Y.V., DILUTE ACID PRETREATMENT, ENZYMATIC SACCHARIFICATION AND FERMENTATION OF WHEAT STRAW TO ETHANOL, PROCESS BIOCHEMISTRY, 40, PP. 3693-3700, (2005); SEARS R.G., MOFFATT J.M., MARTIN T.J., COX T.S., BEQUETTE R.K., CURAN S.P., CHUNG O.K., HEER W.F., LONG J.H., WITT M.D., REGISTRATION OF 'JAGGER' WHEAT, CROP SCIENCE, 37, (1997); SMITH I.E., PROBERT S.D., STOKES R.E., HANSFORD R.J., THE BRIQUETTING OF WHEAT STRAW, JOURNAL OF AGRICULTURE AND ENGINEERING RESEARCH, 22, PP. 105-111, (1977); SRINIVASAN R., MOREAU R.A., RAUSCH K.D., TUMBLESON M.E., SINGH V., PHYTOSTEROL DISTRIBUTION IN FRACTIONS OBTAINED FROM PROCESSING OF DISTILLERS DRIED GRAINS WITH SOLUBLES USING SIEVING AND ELUTRIATION, CEREAL CHEMISTRY, 84, PP. 626-630, (2007); SUN R.C., SUN X.F., IDENTIFICATION AND QUANTITATION OF LIPOPHILIC EXTRACTIVES FROM WHEAT STRAW, INDUSTRIAL CROPS PRODUCTION, 14, PP. 51-64, (2001); SUN R.C., SALISBURY D., TOMKINSON J., CHEMICAL COMPOSITION OF LIPOPHILIC EXTRACTIVES RELEASED DURING THE HOT WATER TREATMENT OF WHEAT STRAW, BIORESOURCE TECHNOLOGY, 88, PP. 95-101, (2003); SUN X.F., XU F., SUN R.C., FOWLER P., BAIRD M.S., CHARACTERISTICS OF DEGRADED CELLULOSE OBTAINED FROM STEAM-EXPLODED WHEAT STRAW, CARBOHYDRATE RESEARCH, 340, PP. 97-106, (2005); TAYLOR J.C., PRAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003)","N.T. DUNFORD; DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURE PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, FAPC ROOM 103, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","BIORESOUR. TECHNOL.","ARTICLE","ISI","2-S2.0-70249112108","BIORESOUR TECHNOL","OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY","NOTREPORTED;OKLAHOMA STATE UNIVERSITY;NOTREPORTED",NA,"DUNFORD NT, 2010, BIORESOUR TECHNOL","DUNFORD NT, 2010, BIORESOUR TECHNOL"
"REINER Z","REINER, ŽELJKO (55411641000)","THE ROLE OF NUTRITION IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES ULOGA PREHRANE U PREVENCIJI I TERAPIJI KARDIOVASKULARNIH BOLESTI",2008,"MEDICUS","17","10",3,"","ZAVOD ZA BOLESTI METABOLIZMA, KLINIKA ZA UNUTRAŠNJE BOLESTI, SVEUČILIŠTA U ZAGREBU, 10000 ZAGREB, KIŠPATIĆEVA 12, CROATIA","HEALTHY NUTRITION HAS BEEN LONG ASSOCIATED WITH A LOWER RISK OF CARDIOVASCULAR DISEASES (CVD) DUE TO ATHEROSCLEROSIS, AND PARTICULARLY CORONARY HEART DISEASE AND MYOCARDIAL INFARCTION. OVER THE LAST DECADES THE INTEREST FOR THESE EFFECTS OF FOOD HAS INCREASED, AND THE LITERATURE TODAY PROVIDES A SERIES OF DATA ABOUT INGREDIENTS OF VARIOUS FOODSTUFFS AND BEVERAGES, AS WELL AS EPIDEMIOLOGICAL DATA ON THEIR POSSIBLE EFFECTS. HOWEVER, LARGE AND WELL-CONTROLLED CLINICAL TRIALS AND DIETARY INTERVENTION STUDIES USING WELL-DEFI NED SUBJECT POPULATIONS ARE RARE AND HAVE NOT PROVIDED A CLEAR EVIDENCE FOR MOST OF THE FOODS IN THE PREVENTION OF CVD, EXCEPT FOR FI SH OIL OMEGA-3 FATTY ACIDS AND THE MEDITERRANEAN DIET. ON THE CONTRARY, SOME STUDIES HAVE PRODUCED DISAPPOINTING RESULTS SUCH AS THOSE CONCERNING SUPPLEMENTATION WITH ANTIOXIDANT VITAMINS E, A AND C. HOWEVER, SINCE CONSUMPTION OF SOME FOODS SEEMS TO BE ACCOMPANIED BY BOTH BENEFI CIAL AND ADVERSE EFFECTS ON CVD RISK, THIS REVIEW SUMMARIZES OUR CURRENT KNOWLEDGE ABOUT THE EFFECTS OF DIFFERENT FATTY ACIDS, SOLUBLE DIETARY FI BER INCLUDING PSYLLIUM, BETA-GLUCAN, PECTIN AND GUAR GUM, LYCOPENE (A NATURAL TOMATO CAROTENOID), ANTIOXIDANT VITAMINS, GARLIC, NUTS AND PEANUTS, SOY PROTEINS AND PHYTOSTEROLS, POLICOSANOL, TEA, COCOA AND COFFEE, AS WELL AS OF ALCOHOL AND DIETARY SALT INTAKE. SPECIAL EMPHASIS HAS BEEN PLACED ON ANTIOXIDANT AND ANTIDYSLIPIDEMIC EFFECTS OF VARIOUS FOODSTUFFS IN TERMS OF IMPROVEMENT OF ENDOTHELIAL DYSFUNCTION AND EFFECTS ON BLOOD PRESSURE, AND THEIR CONSEQUENTIAL CONTRIBUTION TO THE PREVENTION OF CVD. PRACTICAL APPLICATIONS FOR CLINICIANS HAVE BEEN ALSO PROVIDED.","ANTIOXIDANT VITAMINS; CARDIOVASCULAR DISEASES; COCOA; COFFEE; DIET; DIETARY SALT; GARLIC; LYCOPENE; MEDITERRANEAN DIET; NUTRITION; NUTS; OMEGA-3 FATTY ACIDS; POLICOSANOL; SOLUBLE FIBER; TEA","","","","MINIERI M., DI NARDO P., NUTRIENTS: THE ENVIRONMENTAL REGULATION OF CARDIOVASCULAR GENE EXPRESSION, GENES NUTR, 2, 2, PP. 163-168, (2007); IACOVIELLO L., SANTIMONE I., LATELLA M.C., DE GAETANO G., DONATI M.B., NUTRIGENOMICS: A CASE FOR THE COMMON SOIL BETWEEN CARDIOVASCULAR DISEASE AND CANCER, GENES NUTR, 3, 1, PP. 19-24, (2008); RETELNY V.S., NEUENDORF A., ROTH J.L., NUTRITION PROTOCOLS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, NUTR CLIN PRACT, 23, 5, PP. 468-476, (2008); REINER Z., PROMJENA NAČINA ŽIVOTA-KLJUČNI ČIMBENIK U LIJEČENJU HIPERLIPIDEMIJA., MEDICUS, 9, PP. 49-58, (2000); WOUTERS K., VAN GORP P.J., BIEGHS V., DIETARY CHOLESTEROL, RATHER THAN LIVER STEATOSIS, LEADS TO HEPATIC INFL AMMATION IN HYPERLIPIDEMIC MOUSE MODELS OF NONALCOHOLIC STEATOHEPATITIS, HEPATOLOGY, 48, 2, PP. 474-486, (2008); REINER Z., UTJECAJ ALKOHOLA NA PRIJEVREMENI RAZVITAK ATEROSKLEROZE, PREVENCIJA ATEROSKLEROZE-MLADENAČKA DOB, PP. 37-46, (1998); ZOCK P.L., DE VRIES H., KATAN M.B., IMPACT OF MYRISTIC ACID VERSUS PALMITIC ACID ON SERUM LIPID AND LIPOPROTEIN LEVELS IN HEALTHY WOMEN AND MEN, ARTERIOSCL THROMB, 14, PP. 567-575, (1992); MENSINK R.P., KATAN M.B., EFFECTS OF DIETARY FATTY ACIDS ON SERUM LIPIDS AND LIPOPROTEINS: A META-ANALYSIS OF 27 TRIALS, ARTERIOSCL THROMB, 19, PP. 911-919, (1992); COVAS M.I., BIOACTIVE EFFECTS OF OLIVE OIL PHENOLIC COMPOUNDS IN HUMANS: REDUCTION OF HEART DISEASE FACTORS AND OXIDATIVE DAMAGE, INFL AMMOPHARMACOLOGY, (2008); SANCHEZ MUNIZ FJ B.S., VIEJO J.M., TERPSTRA A.H., SMALL SUPPLEMENTS OF N-3 FATTY ACIDS CHANGE SERUM LOW DENSITY LIPOPROTEIN COMPOSITION BY DECREASING PHOSPHOLIPID AND APOLIPOPROTEIN B CONCENTRATIONS IN YOUNG ADULT WOMEN, EUR J NUTR, 38, PP. 20-27, (1999); SOFI F., CESARI F., ABBATE R., GENSINI G.F., CASINI A., ADHERENCE TO MEDITERRANEAN DIET AND HEALTH STATUS: METAANALYSIS, BMJ, 337, (2008); ROMAN B., CARTA L., MARTINEZ-GONZALEZ M.A., SERRAMAJEM L., EFFECTIVENESS OF THE MEDITERRANEAN DIET IN THE ELDERLY, CLIN INTERV AGING, 3, 1, PP. 97-109, (2008); SERRA-MAJEM L., ROMAN B., ESTRUCH R., SCIENTIFI C EVIDENCE OF INTERVENTIONS USING THE MEDITERRANEAN DIET: A SYSTEMATIC REVIEW, NUTR REV, 64, (2006); MIURA K., STAMLER J., NAKAGAWA H., INTERNATIONAL STUDY OF MACRO-MICRONUTRIENTS AND BLOOD PRESSURE RESEARCH GROUP. RELATIONSHIP OF DIETARY LINOLEIC ACID TO BLOOD PRESSURE. THE INTERNATIONAL STUDY OF MACRO-MICRONUTRIENTS AND BLOOD PRESSURE STUDY, HYPERTENSION, 52, 2, PP. 408-414, (2008); ARO A., JAUHIANIEN M., PARTANEN R., SALMINEN I., MUTANEN M., STEARIC ACID, TRANS FATTY ACIDS, AND DAIRY FAT: EFFECTS ON SERUM AND LIPOPROTEIN LIPIDS, APOLIPOPROTEINS, LIPOPROTEIN(A), AND LIPID TRANSFER PROTEINS IN HEALTHY SUBJECTS, AM J CLIN NUTR, 65, PP. 1419-1426, (1997); WILLETT W.G., STAMPFER M.J., MANSON J.E., INTAKE OF TRANS FATTY ACIDS AND RISK OF CORONARY HEART DISEASE AMONG WOMEN, LANCET, 441, PP. 581-586, (1993); BANG H.O., DYEBERG J., PLASMA LIPIDS AND LIPOPROTEINS IN GREENLAND WESTCOAST ESKIMOS, ACTA MED SCAND, 192, PP. 85-94, (1972); MARCOVINA S.M., KENNEDY H., BITTOLO B.G., CAZZLATO G., GALLI C., CASIGLIA E., FISH INTAKE, INDEPENDENT OF APO(A) SIZE, ACCOUNTS FOR LOWER PLASMA LIPOPROTEIN(A) LEVELS IN BANTU FI SHERMEN OF TANZANIA: THE LUGALAWA STUDY, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 1250-1256, (1999); PREVENZIONE INVESTIGATORS. DIETARY SUPPLEMENTATION WITH N-3 POLY-UNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); MARCHIOLI R., BARZI F., BOMBA E., EARLY PROTECTION AGAINST SUDDEN DEATH BY N-3 POLYUNSATURATED FATTY ACIDS AFTER MYOCARDIAL INFARCTION: TIME-COURSE ANALYSES OF THE RESULTS OF THE GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO (GISSI)-PREVENZIONE, CIRCULATION, 105, PP. 1897-1903, (2002); STREPPEL M.T., OCKE M.C., BOSHUIZEN H.C., KOK F.J., KROMHOUT D., LONG-TERM FI SH CONSUMPTION AND N-3 FATTY ACID INTAKE IN RELATION TO (SUDDEN) CORONARY HEART DISEASE DEATH: THE ZUTPHEN STUDY, EUR HEART J, 29, 16, PP. 2024-2030, (2008); REINER Z., TEDESCHI-REINER E., STAJMINGER G., ULOGA OMEGA-3 MASNIH KISELINA IZ RIBA U PREVENCIJI KARDIOVASKULARNIH BOLESTI., LIJEČ VJESN, 129, PP. 350-355, (2007); ELVEVOLL E.O., EILERTSEN K.E., BROX J., SEAFOOD DIETS: HYPOLIPIDEMIC AND ANTIATHEROGENIC EFFECTS OF TAURINE AND N-3 FATTY ACIDS, ATHEROSCLEROSIS, 200, 2, PP. 396-402, (2008); EFFECT OF N-3 POLYUNSATURATED FATTY ACIDS IN PATIENTS WITH CHRONIC HEART FAILURE (THE GISSIHF TRIAL): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, LANCET, (2008); HARRIS W.S., KRIS-ETHERTON P.M., HARRIS K.A., INTAKES OF LONG-CHAIN OMEGA-3 FATTY ACID ASSOCIATED WITH REDUCED RISK FOR DEATH FROM CORONARY HEART DISEASE IN HEALTHY ADULTS, CURR ATHEROSCLER REP, 10, 6, PP. 503-509, (2008); REINER Z., TEDESCHI-REINER E., UČINCI BILJNIH STEROLA NA HIPERKOLESTEROLEMIJU., LIJEČ VJESN, 129, PP. 276-281, (2007); PIIRONEN V., TOIVO J., LAMPI A.-M., NATURAL SOURCES OF DIETARY PLANT STEROLS, J FOOD COMP ANAL, 13, PP. 619-624, (2000); DE VRIES J.H.M., JANSEN A., KROMHOUT D., THE FATTY ACID AND STEROL CONTENT OF FOOD COMPOSITES OF MIDDLE-AGED MEN IN SEVEN COUNTRIES, J FOOD COMP ANAL, 10, PP. 115-141, (1997); OSTLUND R.E., PLANT STEROLS AND STANOLS IN HUMAN NUTRITION, ANNU REV NUTR, 22, PP. 533-549, (2002); BAZZANO L.A., EFFECTS OF SOLUBLE DIETARY FI BER ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND CORONARY HEART DISEASE RISK, CURR ATHEROSCLER REP, 10, 6, PP. 473-477, (2008); QUEENAN K.M., STEWART M.L., SMITH K.N., THOMAS W., FULCHER R.G., SLAVIN J.L., CONCENTRATED OAT BETA-GLUCAN, A FERMENTABLE FI BER, LOWERS SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC ADULTS IN A RANDOMIZED CONTROLLED TRIAL, NUTR J, 6, (2007); OLSEN B.H., ANDERSON S.M., BECKER M.P., ANDERSON J.W., HUNNINGHAKE D.B., JENKINS D.J., PSYLLIUM-ENRICHED CEREALS LOWER BLOOD TOTAL CHOLESTEROL AND LDL CHOLESTEROL, BUT NOT HDL CHOLESTEROL, IN HYPERCHOLESTEROLEMIC ADULTS: RESULTS OF A META-ANALYSIS, J NUTR, 127, PP. 1973-1980, (1997); GANJI V., KUO J., SERUM LIPID RESPONSES TO PSYLLIUM FI BER: DIFFERENCES BETWEEN PRE-AND POST-MENOPAUSAL, HYPERCHOLESTEROLEMIC WOMEN, NUTR J, 7, (2008); GERHARDT A.L., GALLO N.B., FULL-FAT RICE BRAN AND OAT BRAN SIMILARLY REDUCE HYPERCHOLESTEROLEMIA IN HUMANS, J NUTR, 128, PP. 865-869, (1998); VUKSAN V., JENKINS D.J., SPADAFORA P., SIEVENPIPER J.L., OWEN R., VIDGEN E., KONJACMANNAN (GLUCOMANNAN) IMPROVED GLYCAEMIA AND OTHER ASSOCIATED RISK FACTORS FOR CORONARY HEART DISEASE IN TYPE 2 DIABETES. A RANDOMIZED CONTROLLED METABOLIC TRIAL, DIABETES CARE, 22, PP. 913-919, (1999); MACMAHON M., CARLESS J., ISPAGHULA HUSK IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA: A DOUBLE-BLIND CONTROLLED STUDY, J CARDIOVASC RISK, 5, PP. 167-172, (1998); NICOLOSI R., BELL S.J., BISTRIAN B.R., GREENBERG I., FORSE R.A., BLACKBURN G.L., PLASMA LIPID CHANGES AFTER SUPPLEMENTATION WITH BETA-GLUCAN FI BER FROM YEAST, AM J CLIN NUTR, 70, PP. 208-212, (1999); JENKINS D.J., KENDALL C.W., VIDGEN E., AGARWAL S., RAO A.F., ROSENBERG R.S., HEALTH ASPECTS OF PARTIALLY DEFATTED FL AXSEED, INCLUDING EFFECTS ON SERUM LIPIDS, OXIDATIVE MEASURES AND EX VIVO ANDROGEN AND PROGESTIN ACTIVITY: A CONTROLLED CROSSOVER TRIAL, AM J CLIN NUTR, 69, PP. 395-402, (1999); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); RAINES E.W., ROSS R., BIOLOGY OF ATHEROSCLEROTIC PLAQUE FORMATION: POSSIBLE ROLE OF GROWTH FRACTORS IN LESION DEVELOPMENT AND THE POTENTIAL IMPACT OF SOY, J NUTR, 125, SUPPL., PP. 624-630, (1995); HOOPER L., KROON P.A., RIMM E.B., FLAVONOIDS, FL AVONOID-RICH FOODS, AND CARDIOVASCULAR RISK: A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 88, 1, PP. 38-50, (2008); JENKINS D.J., KENDALL C.W., MEHLING C.C., PARKER T., RAO A.V., AGARWAL S., COMBINED EFFECT OF VEGETABLE PROTEIN (SOY) AND SOLUBLE FI BER ADDED TO A STANDARD CHOLESTEROLLOWERING DIET, METABOLISM, 48, PP. 809-816, (1999); REINER Z., OKSIDACIJA LIPOPROTEINA-KLJUČNO ZBIVANJE U RAZVOJU ATEROSKLEROZE., LIPIDI, 5, PP. 13-17, (1995); STEINBERG D., ANTIOXIDANT VITAMINS AND CORONARY HEART DISEASE, N ENGL J MED, 328, PP. 1587-1589, (1993); GAZIANO J.M., ANTIOXIDANTS IN CARDIOVASCULAR DISEASE: RANDOMIZED TRIALS, NUTRITION, 12, PP. 583-588, (1996); BOAZ M., SMETANA S., WEINSTEIN T., SECONDARY PREVENTION WITH ANTIOXIDANTS OF CARDIOVASCULAR DISEASE IN END-STAGE RENAL FAILURE (SPACE): A RANDOMIZED PLACEBOCONTROLLED TRIAL, LANCET, 356, PP. 1213-1218, (2000); STEPHENS N.G., PARSONS A., SCHOFIELD P.M., KELLY F., CHEESEMAN K., MITCHINSON M.J., RANDOMISED CONTROLLED TRIAL OF VITAMIN E IN PATIENTS WITH CORONARY DISEASE: CAMBRIDGE HEART ANTIOXIDANT STUDY (CHAOS), LANCET, 347, PP. 781-786, (1996); VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS, N ENGL J MED, 342, PP. 154-160, (2000); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); EFFECTS OD LONG-TERM VITAMIN E SUPPLEMENTATION ON CARDIOVASCULAR EVENTS AND CANCER: A RANDOMIZED CONTROLED TRIAL, JAMA, 293, PP. 1338-1347, (2005); RICCIONI G., MANCINI B., DI ILIO E., BUCCIARELLI T., D'ORAZIO N., PROTECTIVE EFFECT OF LYCOPENE IN CARDIOVASCULAR DISEASE, EUR REV MED PHARMACOL SCI, 12, 3, PP. 183-190, (2008); BLUM A., MEREI M., KAREM A., EFFECTS OF TOMATOES ON THE LIPID PROFI LE, CLIN INVEST MED, 29, 5, PP. 298-300, (2006); SILASTE M.L., ALFTHAN G., ARO A., KESANIEMI Y.A., HORKKO S., TOMATO JUICE DECREASES LDL CHOLESTEROL LEVELS AND INCREASES LDL RESISTANCE TO OXIDATION, BR J NUTR, 98, 6, PP. 1251-1258, (2007); HUNG C.F., HUANG T.F., CHEN B.H., SHIEH J.M., WU P.H., WU W.B., LYCOPENE INHIBITS TNF-ALPHA-INDUCED ENDOTHELIAL ICAM-1 EXPRESSION AND MONOCYTE-ENDOTHELIAL ADHESION, EUR J PHARMACOL, 586, 1-3, PP. 275-282, (2008); NAVARRO-ALARCON M., CABRERA-VIQUE C., SELENIUM IN FOOD AND THE HUMAN BODY: A REVIEW, SCI TOTAL ENVIRON, 400, 1-3, PP. 115-141, (2008); GEBHARDT R., MULTIPLE INHIBITORY EFFECTS OF GARLIC EXTRACTS ON CHOLESTEROL BIOSYNTHESIS IN HEPATOCYTES, LIPIDS, 28, PP. 613-619, (1993); GORINSTEIN S., JASTRZEBSKI Z., NAMIESNIK J., THE ATHEROSCLEROTIC HEART DISEASE AND PROTECTING PROPERTIES OF GARLIC: CONTEMPORARY DATA, MOL NUTR FOOD RES, 51, 11, PP. 1365-1381, (2007); RIED K., FRANK O.R., STOCKS N.P., EFFECT OF GARLIC ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS, BMC CARDIOVASC DISORD, 8, (2008); SUNGNOON R., KANLOP N., CHATTIPAKORN S.C., TAWAN R., CHATTIPAKORN N., EFFECTS OF GARLIC ON THE INDUCTION OF VENTRICULAR FI BRILLATION, NUTRITION, 24, 7-8, PP. 711-716, (2008); TERAO J., KAWAI Y., MUROTA K., VEGETABLE FL AVONOIDS AND CARDIOVASCULAR DISEASE, ASIA PAC J CLIN NUTR, 17, SUPPL. 1, PP. 291-293, (2008); KAWAI Y., NISHIKAWA T., SHIBA Y., MACROPHAGE AS A TARGET OF QUERCETIN GLUCURONIDES IN HUMAN ATHEROSCLEROTIC ARTERIES: IMPLICATION IN THE ANTI-ATHEROSCLEROTIC MECHANISM OF DIETARY FL AVONOIDS, J BIOL CHEM, 283, 14, PP. 9424-9434, (2008); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FI BRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 25, PP. 701-707, (2005); REINER Z., TEDESCHI-REINER E., RICE POLICOSANOL DOES NOT HAVE ANY EFFECTS ON BLOOD COAGULATION FACTORS IN HYPERCHOLESTEROLEMIC PATIENTS, COLL ANTROPOL, 31, PP. 315-319, (2007); LIN Y., RUDRUM M., VAN DER WIELEN R.P., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, 6, PP. 1543-1548, (2006); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFI CACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, 5, PP. 1003-1008, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CON-CENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, 5, PP. 968-975, (2006); ZOOCK P.I., KATAN M.E., MERKUS P., VAN DUSSELDORP M., HARRYVAN J.L., EFFECT OF LIPID-RICH FRACTION FROM BOILED COFFEE ON SERUM CHOLESTEROL, LANCET, 335, PP. 1235-1237, (1990); WEUSTEN-VAN D.W.M., KATAN M.B., VIANI R., IDENTITY OF THE CHOLESTEROL RAISING FACTOR FROM BOILED COFFE AND ITS EFFECTS ON LIVER FUNCTION ENZYMES, J LIPID RES, 35, PP. 721-733, (1994); BONITA J.S., MANDARANO M., SHUTA D., VINSON J., COFFEE AND CARDIOVASCULAR DISEASE: IN VITRO, CELLULAR, ANIMAL, AND HUMAN STUDIES, PHARMACOL RES. 2007, 55, 3, PP. 187-198, (2007); RODRIGUES I.M., KLEIN L.C., BOILED OR FI LTERED COFFEE? EFFECTS OF COFFEE AND CAFFEINE ON CHOLESTEROL, FI BRINOGEN AND C-REACTIVE PROTEIN, TOXICOL REV, 25, 1, PP. 55-69, (2006); CORNELIS M.C., EL-SOHEMY A., COFFEE, CAFFEINE, AND CORONARY HEART DISEASE, CURR OPIN CLIN NUTR METAB CARE, 10, 6, PP. 745-751, (2007); TVERDAL A., STENSVOLD I., SOLVOLL K., FOSS O.P., LUNDLARSEN P.G., BJARTVEIT K., COFFEE CONSUMPTION AND DEATH FROM CORONARY HEART DISEASE IN MIDDLE-AGED NORWEGIAN MEN AND WOMEN, BMJ, 300, PP. 566-569, (1990); GROBBEE D., RIMM E.B., GIOVANNUCCI E., COLDITZ G., STAMPFER M., WILETT W., COFFEE, CAFFEINE, AND CARDIOVASCULAR DISEASE IN MEN, N ENGL J MED, 323, PP. 1026-1032, (1990); SILLETTA M.G., MARFISI R., LEVANTESI G., GISSI-PREVENZIONE INVESTIGATORS. COFFEE CONSUMPTION AND RISK OF CARDIOVASCULAR EVENTS AFTER ACUTE MYOCARDIAL INFARCTION: RESULTS FROM THE GISSI (GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO)-PREVENZIONE TRIAL, CIRCULATION, 116, 25, PP. 2944-2951, (2007); VAN WOUDENBERGH G.J., VLIEGENTHART R., COFFEE CONSUMPTION AND CORONARY CALCIFI CATION: THE ROTTERDAM CORONARY CALCIFI CATION STUDY, ARTERIOSCLER THROMB VASC BIOL, 28, 5, PP. 1018-1023, (2008); LOPEZ-GARCIA E., VAN DAM R.M., LI T.Y., RODRIGUEZ-ARTALEJO F., HU F.B., THE RELATIONSHIP OF COFFEE CONSUMPTION WITH MORTALITY, ANN INTERN MED, 148, 12, PP. 904-914, (2008); NATELLA F., NARDINI M., BELELLI F., EFFECT OF COFFEE DRINKING ON PLATELETS: INHIBITION OF AGGREGATION AND PHENOLS INCORPORATION, BR J NUTR, 28, PP. 1-7, (2008); HERTOG M.G., FESKENS E.J., HOLLMAN P.C., KATAN M.B., KROMHOUT D., DIETARY ANTIOXIDANT FL AVONOIDS AND RISK OF CORONARY HEART DISEASE: THE ZUTPHEN ELDERLY STUDY, LANCET, 342, PP. 1007-1011, (1993); JOCHMANN N., LORENZ M., KROSIGK A., THE EFFI CACY OF BLACK TEA IN AMELIORATING ENDOTHELIAL FUNCTION IS EQUIVALENT TO THAT OF GREEN TEA, BR J NUTR, 99, 4, PP. 863-868, (2008); HEISS C., LAUER T., DEJAM A., PLASMA NITROSO COMPOUNDS ARE DECREASED IN PATIENTS WITH ENDOTHELIAL DYSFUNCTION, J AM COLL CARDIOL, 47, 3, PP. 573-579, (2006); FARIDI Z., NJIKE V.Y., DUTTA S., ALI A., KATZ D.L., ACUTE DARK CHOCOLATE AND COCOA INGESTION AND ENDOTHELIAL FUNCTION: A RANDOMIZED CONTROLLED CROSSOVER TRIAL, AM J CLIN NUTR, 88, 1, PP. 58-63, (2008); BABU P.V., LIU D., GREEN TEA CATECHINS AND CARDIOVASCULAR HEALTH: AN UPDATE, CURR MED CHEM, 15, 18, PP. 1840-1850, (2008); VLACHOPOULOS C., ALEXOPOULOS N., STEFANADIS C., EFFECT OF DARK CHOCOLATE ON ARTERIAL FUNCTION IN HEALTHY INDI-VIDUALS: COCOA INSTEAD OF AMBROSIA?, CURR HYPERTENS REP, 8, 3, PP. 205-211, (2006); VLACHOPOULOS C., ALEXOPOULOS N., DIMA I., AZNAOURIDIS K., ANDREADOU I., STEFANADIS C., ACUTE EFFECT OF BLACK AND GREEN TEA ON AORTIC STIFFNESS AND WAIVE REFL ECTIONS, J AM COLL NUTR, 25, PP. 216-223, (2006); STEPTOE A., GIBSON E.L., VUONONVIRTA R., THE EFFECTS OF CHRONIC TEA INTAKE ON PLATELET ACTIVATION AND INFL AMMATION: A DOUBLE-BLIND PLACEBO CONTROLLED TRIAL, ATHEROSCLEROSIS, 193, 2, PP. 277-282, (2007); GARDNER E.J., RUXTON C.H., LEEDS A.R., BLACK TEA-HELPFUL OR HARMFUL? A REVIEW OF THE EVIDENCE, EUR J CLIN NUTR. 2007, 61, 1, PP. 3-18, (2006); JOCHMANN N., BAUMANN G., STANGL V., GREEN TEA AND CARDIOVASCULAR DISEASE: FROM MOLECULAR TARGETS TOWARDS HUMAN HEALTH, CURR OPIN CLIN NUTR METAB CARE, 11, 6, PP. 758-765, (2008); ORALLO F., TRANS-RESVERATROL: A MAGICAL ELIXIR OF ETERNAL YOUTH?, CURR MED CHEM, 15, 19, PP. 1887-1898, (2008); GORINSTEIN S., CASPI A., LIBMAN I., BIOACTIVITY OF BEER AND ITS INFL UENCE ON HUMAN METABOLISM, INT J FOOD SCI NUTR, 58, 2, PP. 94-107, (2007); PLETCHER M.J., VAROSY P., KIEFE C.I., LEWIS C.E., SIDNEY S., HULLEY S.B., ALCOHOL CONSUMPTION, BINGE DRINKING, AND EARLY CORONARY CALCIFI CATION: FI NDINGS FROM THE CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY, AM J EPIDEMIOL, 161, 5, PP. 423-433, (2005); CARMONA-TORRE F.A., GARCIA-ARELLANO A., MARQUES-LOPES I., RELATIONSHIP OF ALCOHOLIC BEVERAGE CONSUMPTION TO FOOD HABITS IN A MEDITERRANEAN POPULATION, AM J HEALTH PROMOT, 23, 1, PP. 27-30, (2008); FRASER G.E., SABATE J., BEESON W.L., STRAHAN M., A POSSIBLE PROTECTIVE EFFECT OF NUT CONSUMPTION ON RISK OF CORONARY HEART DISEASE, ARCH INTERN MED, 152, PP. 1416-1424, (1992); SPILLER G.A., JENKINS D.J.A., CRAGEN L.N., EFFECTS OF A DIET HIGH IN MONOUNSATURATED FAT FROM ALMONDS ON PLASMA CHOLESTEROL AND LIPOPROTEINS, J AM COLL NUTR, 11, PP. 126-130, (1992); GEBAUER S.K., WEST S.G., KAY C.D., ALAUPOVIC P., BAGSHAW D., KRIS-ETHERTON P.M., EFFECTS OF PISTACHIOS ON CARDIOVASCULAR DISEASE RISK FACTORS AND POTENTIAL MECHANISMS OF ACTION: A DOSE-RESPONSE STUDY, AM J CLIN NUTR, 88, 3, PP. 651-659, (2008); KRIS-ETHERTON P.M., HU F.B., ROS E., SABATE J., THE ROLE OF TREE NUTS AND PEANUTS IN THE PREVENTION OF CORONARY HEART DISEASE: MULTIPLE POTENTIAL MECHANISMS, J NUTR, 38, 9, (2008); COOKE J.P., TSAO P., SINGER A., WANG B., KOSEK J., DREXLER H., ANTI-ATHEROGENIC EFFECT OF NUTS: IS THE ANSWER, ARCH INTERN MED, 153, PP. 896-899, (1993); UMESAWA M., ISO H., DATE C., JACC STUDY GROUP. RELATIONS BETWEEN DIETARY SODIUM AND POTASSIUM INTAKES AND MORTALITY FROM CARDIOVASCULAR DISEASE: THE JAPAN COLLABORATIVE COHORT STUDY FOR EVALUATION OF CANCER RISKS, AM J CLIN NUTR, 88, 1, PP. 195-202, (2008); REINER Z., NATIONAL PROGRAMME FOR THE REDUCTION OF SALT INTAKE IN CROATIA, KARDIOVASKULARNO ZDRAVLJE, AMZH, (2008); HOOPER L., BARTLETT C., DAVEY S.G., EBRAHIM S., ADVICE TO REDUCE DIETARY SALT FOR PREVENTION OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, 2004, 1; PENZ E.D., JOFFRES M.R., CAMPBELL N.R., REDUCING DIETARY SODIUM AND DECREASES IN CARDIOVASCULAR DISEASE IN CANADA, CAN J CARDIOL, 24, 6, PP. 497-501, (2008); HEIDEMANN C., SCHULZE M.B., FRANCO O.H., VAN DAM R.M., MANTZOROS C.S., HU F.B., DIETARY PATTERNS AND RISK OF MORTALITY FROM CARDIOVASCULAR DISEASE, CANCER, AND ALL CAUSES IN A PROSPECTIVE COHORT OF WOMEN, CIRCULATION, 118, 3, PP. 230-237, (2008)","Z. REINER; ZAVOD ZA BOLESTI METABOLIZMA, KLINIKA ZA UNUTRAŠNJE BOLESTI, SVEUČILIŠTA U ZAGREBU, 10000 ZAGREB, KIŠPATIĆEVA 12, CROATIA; EMAIL: ZREINER@KBC-ZAGREB.HR","","SERBIAN","MEDICUS","REVIEW","ISI","2-S2.0-68049148742","MEDICUS",NA,"NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"REINER Z, 2008, MEDICUS","REINER Z, 2008, MEDICUS"
"CICERO A;BENVENUTI C","CICERO, A.F.G. (7003403707); BENVENUTI, C. (7101839008)","EFFICACY OF A RED YEAST RICE BASED NUTRACEUTICAL IN LARGE SUBGROUPS OF HYPERCHOLESTEROLEMIC SUBJECTS IN EVERY DAY CLINICAL PRACTICE",2010,"MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM","3","7",11,"10.1007/s12349-010-0028-5","GC DESCOVICH ATHEROSCLEROSIS AND METABOLIC DISEASE STUDY CENTER, ALMA MATER STUDIORUM, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;MEDICAL DEPARTMENT, ROTTAPHARM MADAUS SPA, MONZA, ITALY","TO VERIFY THE EFFICACY OF A PATENTED PROPRIETARY COMBINATION OF NUTRACEUTICALS CONTAINING NATURAL HYPOCHOLESTEROLEMIC AND ANTIOXIDANT AGENTS AS RED YEAST RICE EXTRACT, POLICOSANOLS, COENZYME Q10, ASTAXANTHIN, AND FOLIC ACID IN THE FOLLOWING SUBGROUPS OF HYPERLIPIDEMIC SUBJECTS: FERTILE (F) VERSUS MENOPAUSE (M) WOMEN, ADULTS VERSUS ELDERLY (>65 YEARS), LUNCH VERSUS DINNER ADMINISTRATION TIME. A RANDOMISED, MULTICENTER STUDY IN 411 ITALIANS UNITS COMPARED ARMOLIPID-ROTTAPHARM|MADAUS (ARM) ONE TABLET/DAY PLUS DIET VERSUS DIET ALONE (D) FOR 16 WEEKS IN HYPERLIPIDEMIC PATIENTS [SERUM TOTAL CHOLESTEROL (TOT-C) >200 MG/DL OR LDL-CHOLESTEROL (LDL-C) >150 MG/DL AT ADMISSION]. EFFICACY PARAMETERS WERE MEASURED AT BASELINE AND EVERY 4 WEEKS. IN 2,408 ELIGIBLE SUBJECTS, 1,665 ADULTS AND 743 ELDERLY, TOTAL AND LDL-CHOLESTEROL WERE LIKEWISE REDUCED BY ARM + D IN BOTH AGE CLASSES AND SIGNIFICANTLY VERSUS D. IN 1,246 CASES, 302 F AND 946 M, TOT-C GRADUALLY AND SIGNIFICANTLY DECREASED UP TO 18.7 AND 16.8% IN F AND M TREATED GROUPS VERSUS 9% IN D GROUP. SIMILAR REDUCTION WAS OBSERVED IN LDL-C. IN 907 CASES, THE TIME OF ADMINISTRATION OF ARM WAS DETAILED: 733 RECEIVED ARM + D AT DINNER AND 174 AT LUNCH. CHOLESTEROLEMIA IMPROVED EQUALLY IN THE TWO GROUPS. THE ASSOCIATION OF ARM WITH AN APPROPRIATE DIET IS MORE EFFECTIVE THAN DIET ALONE IN REDUCING ABNORMAL CHOLESTEROLEMIA, INDEPENDENTLY FROM AGE CLASSES AND ADMINISTRATION TIME DURING THE DAY, SUPPORTING ITS POSITIVE USE FOR CONTROLLING HYPERCHOLESTEROLEMIA WITH A POSITIVE IMPACT ON CHD PREVENTION IN ALL CATEGORIES OF SUBJECTS. © 2010 SPRINGER-VERLAG.","ADMINISTRATION TIME; DIET; ELDERLY; LIPID-LOWERING AGENTS; MENOPAUSE; RED YEAST RICE","ASTAXANTHIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; UBIDECARENONE; XUEZHIKANG; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","PREISS D., SATTAR N., LIPIDS, LIPID MODIFYING AGENTS AND CARDIOVASCULAR RISK: A REVIEW OF THE EVIDENCE, CLIN ENDOCRINOL, 70, 6, PP. 815-828, (2009); RAZA J.A., BABB J.D., MOVAHED A., OPTIMAL MANAGEMENT OF HYPERLIPIDEMIA IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, INTERNATIONAL JOURNAL OF CARDIOLOGY, 97, 3, PP. 355-366, (2004); CICERO A.F.G., DEROSA G., BOVE M., BORGHI C., GADDI A.V., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOP NUTRACEUTICAL RES, 7, 34, PP. 121-126, (2009); CICERO A.F.G., ERTEK S., NATURAL SOURCES OF ANTIDYSLIPIDAEMIC AGENTS: IS THERE AN EVIDENCE-BASED APPROACH FOR THEIR PRESCRIPTION?, MED J NUTR METAB, 1, 2, PP. 85-93, (2008); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTELFORSCHUNG, 55, PP. 312-317, (2005); ENDO A., CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS, KLIN WOCHENSCHR, 66, PP. 421-427, (1988); MAN R.Y.K., LYNN E.G., CHEUNG F., TSANG P.S.Y., OAG K., CHOLESTIN INHIBITS CHOLESTEROL SYNTHESIS AND SECRETION IN HEPATIC CELLS (HEPG2), MOLECULAR AND CELLULAR BIOCHEMISTRY, 233, 1-2, PP. 153-158, (2002); HEBER D., YIP I., ASHELY J.M., ELASHOFF D.A., GO V.L.W., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); WANG J., LU Z., CHI J., WANG W., SU M., KOU W., YU P., YU L., CHEN L., ZHU J.-S., CHANG J., MULTICENTER CLINICAL TRIAL OF THE SERUM LIPID-LOWERING EFFECTS OF A MONASCUS PURPUREUS (RED YEAST) RICE PREPARATION FROM TRADITIONAL CHINESE MEDICINE, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL, 58, 12, PP. 964-978, (1997); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); LU Z., KOU W., DU B., WU Y., ZHAO S., BRUSCO O.A., MORGAN J.M., CAPUZZI D.M., CHINESE CORONARY SECONDARY PREVENTION STUDY GROUP, LI S EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, 12, PP. 1689-1693, (2008); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); GRIGORE L., RADAELLI L., MAGGI F.M., ROVATI L., CATAPANO A.L., ARMOLIPID, A NUTRITIONAL SUPPLEMENT, EFFECTIVELY REDUCES PLASMA TOTAL AND LDL CHOLESTEROL IN MODERATE HYPERCHOLESTEROLEMIA, ABSTRACTS OF XV INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM MEETING, (2004); CAPUTI A.P., BENVENUTI C., IMPROVING THE DIET EFFICACY IN HYPERCHOLESTEROLEMIC SUBJECTS WITH RED YEAST RICE PLUS POLICOSANOLS, L'INTERNISTA, 16, PP. 53-60, (2008); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, 19, PP. 2486-2497, (2001); CHEN Z.Y., JIAO R., MA K.Y., CHOLESTEROL-LOWERING NUTRACEUTICALS AND FUNCTIONAL FOODS, J AGRIC FOOD CHEM, 56, 19, PP. 8761-8773, (2008); KAJINAMI K., MASUYA H., HOSHIBA Y., TAKEDA K., SATO R., OKABAYASHI M., SCHAEFER E.J., STATIN RESPONSE AND PHARMACOKINETICS VARIANTS, EXPERT OPINION ON PHARMACOTHERAPY, 6, 8, PP. 1291-1297, (2005); PLAKOGIANNIS R., COHEN H., OPTIMAL LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING: MORNING VERSUS EVENING STATIN ADMINISTRATION, ANN PHARMACOTHER, 41, PP. 106-110, (2007)","A. F. G. CICERO; ATHEROSCLEROSIS AND METABOLIC DISEASES RESEARCH UNIT, AGING AND KIDNEY DISEASES DEPARTMENT, UNIVERSITY OF BOLOGNA, BOLOGNA 15-40138, POLIAMBULATORIO PAD. 2-VIA ALBERTONI, ITALY; EMAIL: AFGCICERO@CARDIONET.IT","","ENGLISH","MEDITERR. J. NUTR. METAB.","ARTICLE","ISI","2-S2.0-78649646297","MEDITERR J NUTR METAB","UNIVERSITY OF BOLOGNA","NOTREPORTED;UNIVERSITY OF BOLOGNA;NOTREPORTED",NA,"CICERO AFG, 2010, MEDITERR J NUTR METAB","CICERO AFG, 2010, MEDITERR J NUTR METAB"
"KELLER S;GIMMLER F;JAHREIS G","KELLER, SYLVIA (8587403200); GIMMLER, FRANZISKA (22957658400); JAHREIS, GERHARD (7007175896)","OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES",2008,"LIPIDS","43","6",23,"10.1007/s11745-007-3127-4","DEPARTMENT OF NUTRITIONAL PHYSIOLOGY, INSTITUTE OF NUTRITION, FRIEDRICH SCHILLER UNIVERSITY, 07743 JENA, DORNBURGER STREET 24, GERMANY;DEPARTMENT OF NUTRITIONAL PHYSIOLOGY, INSTITUTE OF NUTRITION, FRIEDRICH SCHILLER UNIVERSITY, 07743 JENA, DORNBURGER STREET 24, GERMANY;DEPARTMENT OF NUTRITIONAL PHYSIOLOGY, INSTITUTE OF NUTRITION, FRIEDRICH SCHILLER UNIVERSITY, 07743 JENA, DORNBURGER STREET 24, GERMANY","TO INVESTIGATE OCTACOSANOL (OC) METABOLISM IN HUMANS AND ITS INFLUENCE ON CHOLESTEROL METABOLISM, TWO STUDIES WERE CONDUCTED. IN THE FIRST STUDY TEN HEALTHY WOMEN RECEIVED DAILY 30 MG OC FOR A PERIOD OF 4 WEEKS. BLOOD AND FECES SAMPLES WERE COLLECTED AT BASELINE AND AFTER THE INTERVENTION. SERUM CONCENTRATIONS OF TOTAL CHOLESTEROL, LDL CHOLESTEROL, AND HDL CHOLESTEROL WERE NOT ALTERED FOLLOWING OC ADMINISTRATION. CONCENTRATIONS OF EXCRETED CHOLESTEROL END PRODUCTS DECREASED WITH THE INTERVENTION (NEUTRAL STEROLS: 24.6 ± 9.7 MG/G VS. 20.3 ± 7.5 MG/G DRY MATTER, P < 0.05; BILE ACIDS: 6.47 ± 3.89 MG/G VS. 4.03 ± 2.26 MG/G DRY MATTER, P < 0.05). OC WAS NOT DETECTED IN SERUM SAMPLES, BUT THE FECAL OC CONCENTRATION INCREASED AFTER THE INTERVENTION PERIOD (11 ± 7 ΜG/G VS. 817 ± 179 ΜG/G DRY MATTER, P < 0.05). IN THE SECOND KINETIC STUDY ON THREE PARTICIPANTS, OC WAS IDENTIFIED IN SERUMS AFTER ORAL APPLICATION OF 50 MG OC WITHIN 8 H. THE DECREASE IN THE CONCENTRATION OF FECAL CHOLESTEROL END PRODUCTS MAY UNDERLINE A SYSTEMIC EFFECT OF OC ON CHOLESTEROL METABOLISM, EVEN THOUGH THE SERUM CHOLESTEROL LEVELS WERE NOT INFLUENCED. © 2007 AOCS.","BILE ACID; CHOLESTEROL; LDL CHOLESTEROL; NEUTRAL STEROL; OCTACOSANOIC ACID; OCTACOSANOL; POLICOSANOL","ADULT; BILE ACIDS AND SALTS; CHOLESTEROL; FATTY ALCOHOLS; FECES; FEMALE; HUMANS; LIPID METABOLISM; BILE ACID; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LESSTANOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTACOSANOL; STEROL; UNCLASSIFIED DRUG; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; FECES LEVEL; FEMALE; HUMAN; NORMAL HUMAN","","","NIES L.K., CYMBALA A.A., KASTEN S.L., LAMPRECHT D.G., OLSON K.L., COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR THE MANAGEMENT OF DYSLIPIDEMIA, ANN PHARMACOTHER, 40, PP. 1984-1992, (2006); VARADY K.A., WANG Y., JONES P., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); FERNANDEZ J.C., MAS R., CASTANO G., MENENDEZ R., AMOR A., GONZALEZ R.M., ALVAREZ E., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVESTIG, 21, PP. 103-113, (2001); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-100, (2002); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA. A RANDOMIZED CONTROLLED TRIAL, J AM MED ASSOC, 295, PP. 2262-2269, (2006); RIZZO W.B., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); MAS R., POLICOSANOL. HYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSIS, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., MAS R., AMOR A.M., RODEIRO I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); CASTANO G., MAS R., FERNANDEZ L., LOPEZ E., GUTIERREZ J.A., ILLNAIT J., FERNANDEZ J.C., GAMEZ R., ALVAREZ E., ASSESSMENT OF THE EFFECTS OF D-003, A NEW ANTIPLATELET AND LIPID-LOWERING COMPOUND, IN HEALTHY VOLUNTEERS. A PHASE I CLINICAL STUDY, DRUGS R D, 3, PP. 337-348, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., LOPEZ E., GAMEZ R., MENDOZA S., FERNANDEZ J., MESA M., EFFECTS OF D-003 ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA. A PHASE II CLINICAL STUDY, CLIN DRUG INVESTIG, 23, PP. 789-802, (2003); MENENDEZ R., MAS R., PEREZ J., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN FATTY ACIDS PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CAN J PHYSIOL PHARMACOL, 82, PP. 22-29, (2004); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., SOTOLONGO V., FRAGA V., AMOR A.M., GONZALEZ R., DEL RIO A., JIMENEZ S., PEREZ N., MAS R., PLASMA LEVELS AND TOTAL RADIOACTIVITY EXCRETION IN HEALTHY VOLUNTEERS AFTER ORAL 3H-OCTACOSANOL ADMINISTRATION, REV CENIC CIEN BIOL, 27, PP. 32-35, (1996); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., DISTRIBUTION OF RADIOACTIVE OCTACOSANOL IN RESPONSE TO EXERCISE IN RATS, NAHRUNG, 38, PP. 373-377, (1994); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-<SUP>14</SUP>C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); MARINANGELI C.P.F., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.H., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOL, BR J NUTR, 97, PP. 381-388, (2007); DITSCHEID B., KELLER S., JAHREIS G., CHOLESTEROL METABOLISM IS AFFECTED BY CALCIUM PHOSPHATE SUPPLEMENTATION IN HUMANS, J NUTR, 135, PP. 1678-1682, (2005); KELLER S., JAHREIS G., DETERMINATION OF UNDERIVATISED STEROLS AND BILE ACID TRIMETHYL SILYL ETHER METHYL ESTERS BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY-SINGLE ION MONITORING IN FAECES, J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI, 813, PP. 199-207, (2004); KRAFT J., HANSKE L., MOCKEL P., ZIMMERMANN S., HARTL A., KRAMER J.K.G., JAHREIS G., THE CONVERSION EFFICIENCY OF TRANS-11 AND TRANS-12 18:1 BY Δ9-DESATURATION DIFFERS IN RATS, J NUTR, 136, PP. 1209-1214, (2006); WILKINS T.D., HACKMAN A.S., TWO PATTERNS OF NEUTRAL STEROID CONVERSION IN THE FECES OF NORMAL NORTH AMERICANS, CANCER RES, 34, PP. 2250-2254, (1974); PEPPING J., POLICOSANOL, AM J HEALTH SYST PHARM, 60, PP. 1112-1115, (2003); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNADEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES CLIN EXP, 51, PP. 568-575, (1992); SHEFER S., HAUSER S., LAPAR V., MOSBACH E.H., REGULATORY EFFECTS OF STEROLS AND BILE ACIDS ON HEPATIC 3-HYDROXY-3-METHYLGLUTARYL COA REDUCTASE AND CHOLESTEROL 7Α-HYDROXYLASE IN THE RAT, J LIPID RES, 14, PP. 573-580, (1973); WANG Y.W., JONES P.J.H., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005)","G. JAHREIS; DEPARTMENT OF NUTRITIONAL PHYSIOLOGY, INSTITUTE OF NUTRITION, FRIEDRICH SCHILLER UNIVERSITY, 07743 JENA, DORNBURGER STREET 24, GERMANY; EMAIL: B6JAGE@UNI-JENA.DE","","ENGLISH","LIPIDS","ARTICLE","ISI","2-S2.0-42549141348","LIPIDS","FRIEDRICH SCHILLER UNIVERSITY;FRIEDRICH SCHILLER UNIVERSITY;FRIEDRICH SCHILLER UNIVERSITY","NOTREPORTED;FRIEDRICH SCHILLER UNIVERSITY;NOTREPORTED",NA,"KELLER S, 2008, LIPIDS","KELLER S, 2008, LIPIDS"
"OGUNLESI M;OKIEI W;OSIBOTE E","OGUNLESI, MODUPE (6507330241); OKIEI, WESLEY (24434240800); OSIBOTE, ELIZABETH ADEJOKE (35741333300)","ANALYSIS OF THE ESSENTIAL OIL FROM THE LEAVES OF SESAMUM RADIATUM A POTENTIAL MEDICATION FOR MALE INFERTILITY FACTOR BY GAS CHROMATOGRAPHY MASS SPECTROMETRY",2010,"AFRICAN JOURNAL OF BIOTECHNOLOGY","9","7",32,"10.5897/ajb09.941","CHEMISTRY DEPARTMENT, UNIVERSITY OF LAGOS, AKOKA, LAGOS, NIGERIA;CHEMISTRY DEPARTMENT, UNIVERSITY OF LAGOS, AKOKA, LAGOS, NIGERIA;CHEMISTRY DEPARTMENT, UNIVERSITY OF LAGOS, AKOKA, LAGOS, NIGERIA","ESSENTIAL OIL WAS EXTRACTED FROM THE DRIED LEAVES OF SESAMUM RADIATUM BY HYDRO-DISTILLATION AND ANALYZED BY COMBINED GAS CHROMATOGRAPHY-MASS SPECTROMETRY. N-HEXADECANOIC ACID WAS FOUND TO BE THE MAJOR CONSTITUENT AND WITH THREE OTHER FATTY ACIDS NAMELY, 9,12,15-OCTADECANOIC ACID-(Z,Z,Z), DODECANOIC ACID AND TETRADECANOIC ACID CONSTITUTE 40.64% OF THE OIL. OTHER CONSTITUENTS INCLUDE HEPTATRIACONTANOL, ESTRA-1,3,5(10)-TRIEN-17Á-OL, 1-(+)-ASCORBIC ACID, 2,6-DIHEXADECANOATE, ETHYL ISOALLOCHOLATE, OLEIC ACID, 18,19-SECOYOHIMBAN-19-OIC ACID, 16,17,20,21-TETRAHYDRO-16-(HYDROXYMETHYL)-METHYL ESTER, (15Á, 16E)-TRANS-(2,3-DIPHENYLCYCLOPROPYL) METHYLPHENYL SULFOXIDE, 1,1-[2-METHYL-2-(PHENYLTHIO) CYCLOPROPYLIDENE]BIS-BENZENE AND PHENOLICS. THE PRESENCE OF SOME OF THESE CONSTITUENTS IN THE ESSENTIAL OIL PROVIDES THE SCIENTIFIC EVIDENCES FOR THE OBSERVED CARDIOVASCULAR AND ESTROGENIC ACTIVITY AS WELL AS CURATIVE PROPERTIES OF THE PLANT FOR MALE INFERTILITY FACTOR, CONSTIPATION, FUNGAL AND BACTERIAL INFECTIONS AND BRUISES. © 2010 ACADEMIC JOURNALS.","ESSENTIAL OIL; GC-MS; MALE INFERTILITY FACTOR; SESAMUM RADIATUM","BACTERIA (MICROORGANISMS); SESAMUM RADIATUM; (2,3 DIPHENYLCYCLOPROPYL)METHYLPHENYL SULFOXIDE; 16,17,20,21 TETRAHYDRO 16 (HYDROXYMETHYL)METHYLESTER; 16,17,20,21 TETRAHYDRO 16 HYDRO XYMETHYL)METHYL ESTER; 18,19 SECO YOHIMBAN 19 OIC ACID; 18,19 SECOYOHIMBAN 19 OIC ACID; 2 6 DIHEXADECANOATE; 2,4 BIS(1,1 DIMETHYLETHYL)PHENOL; 2,6 DIHEXADECANOATE; 9 HEXADECENOIC ACID; ANTIESTROGEN; ANTIINFECTIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; CARBOXYLIC ACID; CARDIOVASCULAR AGENT; CHEMICAL COMPOUND; ESSENTIAL OIL; ESTRA 1,3,5(10) TRIEN 17A OL; ETHYL ISOALLOCHOLATE; EUGENOL; HEPTATRIACONTANOL; LAURIC ACID; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; POLICOSANOL; SESAME SEED OIL; TERT HEXADECANETHIOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE; ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIAL INFECTION; CHEMICAL COMPOSITION; CONSTIPATION; CONTROLLED STUDY; DISTILLATION; DRUG ACTIVITY; DRUG ISOLATION; DYSLIPIDEMIA; ESTROGEN ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MALE INFERTILITY; MASS FRAGMENTOGRAPHY; MYCOSIS; NONHUMAN; PLANT LEAF; RAT; SESAME; SESAMUM RADIATUM","","","AKPAN-IWO G., IDOWU A.A., MISARI S.M., COLLECTION AND EVALUATION OF SESAME (SESAMUM SPP.) GERMPLASM IN NIGERIA, IGPR/FAO, 142, PP. 59-62, (2006); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES, 27, (1994); BENTEZ M., ROMERO C., MASS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES, 58, 11, PP. 859-867, (1997); BRUICE P.Y., ORGANIC CHEMISTRY, PP. 1054-1056, (1998); CASTANO G., MASS R., FERNANDEZ L., ILLNAIT J., HERNANDEZ E., FERNANDEZ J., GAMEZ R., GUTIERREZ C., ALVAREZ E., A RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THER. RES, 63, 4, PP. 286-303, (2002); COLLINS B.M., MCLACHLAN J.A., ARNOLD S., THE ESTROGENIC AND ANTIESTROGENIC ACTIVITIES OF PHYTOCHEMICALS WITH THE HUMAN RECEPTOR EXPRESSED IN YEAST, STEROIDS, 62, PP. 365-372, (1997); DAVIDSON W.S., SAXENA R.K., GUPTA R., THE FUNGISTATIC ACTION OF OLEIC ACID, CURR. SCI, 76, 8, PP. 1137-1139, (1999); DAWSON E.B., HARRIS W.A., TETER M.C., POWELL L.C., EFFECT OF ASCORBIC ACID SUPPLEMENTATION ON THE SPERM QUALITY OF SMOKERS, FERTIL. STERIL, 58, 5, PP. 1034-1039, (1992); DILIKA F., BREMNER P.D., MEYER J.J., ANTIBACTERIAL ACTIVITY OF LINOLEIC AND OLEIC ACIDS ISOLATED FROM HELICHRYSUM PEDUNCULATUM: A PLANT USED DURING CIRCUMCISION RITES, FITOTERAPIA, 71, PP. 450-452, (2000); GLENVILLE M., THE NUTRITIONAL APPROACH TO MALE FACTOR INFERTILITY, DRAGONS TALE, 18, PP. 4-5, (2008); HENAUER S.A., GILLESPIE H.K., HOLLISTER L.E., YOHIMBINE AND THE MODEL ANXIETY STATE, J. CLIN. PSYCHIATRY, 45, PP. 512-515, (1984); HUTCHINSON J., DALZIEL J.M., FLORA OF TROPICAL WESTERN AFRICA, 1, PART 1, (1954); KATO S., KARINO K.I., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., KAMATANI K., TAKAHASHI J., OGASAWARA S., MASUSHIGE S., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR. J. NUTR, 73, PP. 433-442, (1995); LI R.W., LEACH D.N., MYERS P., LEACH G.J., LIN G.D., BRUSHETT D.J., WATERMAN P.G., ANTI-INFLAMMATORY ACTIVITY, CYTOTOXICITY AND ACTIVE COMPOUNDS OF TINOSPORA SMILACINA BENTH, PHYTOTHER. RES, 18, PP. 78-83, (2004); MAIGNAN J., USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION, (1998); MCGRAW L.J., JAGER A.K., VAN STADEN J., ISOLATION OF ANTIBACTERIAL FATTY ACIDS FROM SCHOTIA BRACHYPETALA, FITOTERAPIA, 73, PP. 431-433, (2002); A TEXTBOOK OF MEDICINAL PLANTS FROM NIGERIA, (2008); OSHODI A.A., OGUNGBENLE H.N., OLADIMEJI M.O., CHEMICAL COMPOSITION; NUTRITIONALLY VALUABLE MINERALS AND FUNCTIONAL PROPERTIES OF BENNISEED SESAMUM RADIATUM, PEARL MILLET PENNISETUM TYPHOIDES AND QUINOA CHENOPODIUM QUIONA FLOURS.INT, J. FOOD. SCI. NUTR, 50, 5, PP. 325-331, (1999); PURSEGLOVE J.W., TROPICAL CROPS, DICOTYLEDONS, PP. 430-435, (1974); RUSSEL A.D., MECHANISMS OF BACTERIAL RESISTANCE OF NONANTIBIOTICS: FOOD ADDITIVES AND FOOD PHARMACEUTICAL PRESERVATIVES, J. APPL. BACTERIOL, 71, PP. 191-201, (1991); SELDEL V., TAYLOR P.W., IN-VITRO ACTIVITY OF EXTRACTS AND CONSTITUENTS OF PELAGONIUM AGAINST RAPIDLY GROWING MYCOBACTERIA, INT. J. ANTIMICROB. AGENT, 23, PP. 613-619, (2004); SOBOTKA J.J., AN EVALUATION OF AFRODEX TM IN THE MANAGEMENT OF MALE IMPOTENCY: A DOUBLE-BLIND CROSS-OVER STUDY, CURR. THER. RES, 2, PP. 87-94, (1969); TEMPLE WA, SMITH NA (1992). YOHIMBINE, PIM 567, (1992); XU C.J., LISNH Y.Z., CHAU F.T., IDENTIFICATION OF ESSENTIAL COMPONENTS OF HOUTTUYYNIA CORDATA BY GAS CHROMATOGRAPHY/MASS SPECTROMETRY AND THE INTEGRATED CHEMOMETRIC APPROACH, TALANTA, 68, PP. 108-115, (2005)","M. OGUNLESI; CHEMISTRY DEPARTMENT, UNIVERSITY OF LAGOS, AKOKA, LAGOS, NIGERIA; EMAIL: MAYOGUNLESI@YAHOO.COM","ACADEMIC JOURNALS","ENGLISH","AFR. J. BIOTECHNOL.","ARTICLE","ISI","2-S2.0-77249130355","AFR J BIOTECHNOL","UNIVERSITY OF LAGOS;UNIVERSITY OF LAGOS;UNIVERSITY OF LAGOS","NOTREPORTED;UNIVERSITY OF LAGOS;NOTREPORTED",NA,"OGUNLESI M, 2010, AFR J BIOTECHNOL","OGUNLESI M, 2010, AFR J BIOTECHNOL"
"PÉREZ Y;MÁS R;GONZÁLEZ R;JIMÉNEZ S;MOLINA V","PÉREZ, YOHANI (23995375700); MÁS, ROSA (7007164572); GONZÁLEZ, ROSA MARÍA (57191737509); JIMÉNEZ, SONIA (19735040200); MOLINA, VIVIAN (7006062814)","EFFECTS OF D003 A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS AND POLICOSANOL ON IN VIVO LIPID PEROXIDATION IN RATS",2008,"ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH","58","4",9,"10.1055/s-0031-1296481","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBANACÁN, HAVANA, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: D-003 AND POLICOSANOL (CAS 557-61-9), SPECIFIC AND DISTINCT MIXTURES OF HIGH MOLECULAR WEIGHT PRIMARY ALIPHATIC ACIDS AND ALCOHOLS, RESPECTIVELY, HAVE SHOWN TO INHIBIT LIPID PEROXIDATION IN VIVO, BUT COMPARATIVE STUDIES BETWEEN THEIR EFFECTS ON LIPID PEROXIDATION PROCESSES HAD NOT BEEN CONDUCTED BEFORE. OBJECTIVE: TO COMPARE THE EFFECTS OF D-003 AND POLICOSANOL ON MARKERS OF LIPID PEROXIDATION IN VIVO IN RATS. METHODS: MALE WISTAR RATS WERE DISTRIBUTED INTO 9 GROUPS: A CONTROL GROUP TREATED WITH ACACIA GUM/WATER VEHICLE, 4 WITH POLICOSANOL AND 4 WITH D-003, BOTH TREATMENTS AT 5, 25, 100 AND 250 MG/KG. TREATMENTS WERE ADMINISTERED DURING 4 WEEKS. RESULTS: BOTH TREATMENTS SIGNIFICANTLY AND DOSE-DEPENDENTLY REDUCED PLASMA MALONDYALDEHIDE (MDA) AND TOTAL PEROXIDES. NEVERTHELESS, WHILE D-003 WAS EFFECTIVE FROM 5 MG/KG, THE LOWEST EFFECTIVE DOSE OF POLICOSANOL WAS 25 MG/KG. THE MAXIMAL EFFECTS OF BOTH TREATMENTS WERE OBTAINED WITH 100 MG/KG, BUT GREATER IN D-003 THAN IN POLICOSANOL GROUP, AND THE SAME OCCURRED ACROSS ALL DOSES TESTED. MDA CONCENTRATIONS GENERATED WITH THE ENZYMATIC SYSTEM IN LIVER HOMOGENATES WERE ALSO SIGNIFICANTLY AND DOSE-DEPENDENTLY INHIBITED WITH BOTH TREATMENTS. THE LOWEST EFFECTIVE DOSES OF D-003 AND POLICOSANOL WERE 5 AND 100 MG/KG, RESPECTIVELY, AND THE HIGHEST INHIBITIONS OF ABOUT 80 % (D-003) AND 11 % (POLICOSANOL). D-003 WAS MORE EFFECTIVE THAN POLICOSANOL IN ALL COMPARISONS. D-003 WAS ALSO MORE EFFECTIVE THAN POLICOSANOL FOR LOWERING MDA CONCENTRATIONS GENERATED WITH THE NO ENZYMATIC SYSTEM, BUT IN THESE CONDITIONS POLICOSANOL WAS EFFECTIVE FROM 25 MG/KG AND PRODUCED AN INHIBITION SOMEWHAT GREATER (ABOUT 29 %) THAN ON MDA-GENERATED BY THE ENZYMATIC SYSTEM. BOTH POLICOSANOL AND D-003 DID NOT MODIFY THE ACTIVITY OF ENDOGENOUS ANTIOXIDANT ENZYMES COMPARED WITH THE CONTROLS. CONCLUSIONS: D-003 (5-250 MG/KG) ORALLY ADMINISTERED FOR 4 WEEKS WAS MORE EFFECTIVE THAN POLICOSANOL FOR LOWERING ALL THE LIPID PEROXIDATION MARKERS ASSESSED, LIKE PLASMA MDA AND TOTAL PEROXIDES, AND MDA CONCENTRATIONS GENERATED BY THE ENZYMATIC AND NON-ENZYMATIC OXIDANT SYSTEMS OF LIVER HOMOGENATES. THE INHIBITIONS WITH D-003 WERE MARKED AND DOSE-DEPENDENT. NEITHER D-003 NOR POLICOSANOL MODIFIED THE ACTIVITY OF ENZYMES INVOLVED IN THE ENDOGENIC ANTIOXIDANT DEFENSIVE SYSTEM. © ECV EDITIO CANTOR VERLAG.","ANTIOXIDANTS; CAS 557-61-9; D-003, EFFECT ON LIPID PEROXIDATION, RAT; FATTY ACIDS MIXTURE, VERY LONG CHAIN; LIPID PEROXIDATION; POLICOSANOL, EFFECT ON LIPID PEROXIDATION, RAT","ANTIOXIDANT; D 003; GUM ARABIC; MALONALDEHYDE; PEROXIDE; POLICOSANOL; SATURATED FATTY ACID; VERY LONG CHAIN FATTY ACID; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; IN VIVO STUDY; LIPID PEROXIDATION; LIVER HOMOGENATE; MALE; MORNING DOSAGE; NONHUMAN; RAT","","","CENTURY - A VISION OF ALL, WORLD HEALTH REPORT 1998, (1998); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., HEINONEN O.P., HEINSALMI P., HELO P., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); LUSCHER T.F., BIOLOGY OF THE ENDOTHELIUM, CLIN CARDIOL, (1997); MAS R., D-003: A NEW SUBSTANCE WITH PROMISING LIPID MODIFYING AND PLEIOTROPIC EFFECTS FOR ATHEROSCLEROSIS MANAGEMENT, DRUGS OF THE FUTURE, 29, PP. 773-786, (2004); MENENDEZ R., MAS R., PEREZ Y., AMOR A.M., LEDON N., GONZALEZ R.M., ET AL., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, CAN J PHYSIOL PHARMACOL, 80, PP. 13-17, (2002); CASTANO G., MENENDEZ R., MAS R., ILLNAIT J., FERNANDEZ J.C., PEREZ Y., ET AL., EFFECTS OF D-003 ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY VOLUNTEERS, CLIN DRUG INVEST, 23, PP. 193-203, (2003); POLICOSANOL M.R., DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); FRAGA V., MENENDEZ R., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEH, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CASTANO G., MENENDEZ R., MAS R., ILLNAIT J., FERNANDEZ J.C., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); MENENDEZ R., MARRERO D., MAS R., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); GAMEZ R., MENDOZA S., MAS R., MESA R., CASTANO G., RODRIGUEZ B., ET AL., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES CLIN EXP, 61, PP. 8-16, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., MENDOSA S., ET AL., EFFECTS OF D-003 (5-40 MG/DAY) ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A PHASE II CLINICAL STUDY, CLIN DRUG INVEST, 23, PP. 789-802, (2003); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., RODEIROS I., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); MENENDEZ R., MAS R., PEREZ Y., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CAN J PHYSIOL PHARMACOL, 82, PP. 22-29, (2003); MENENDEZ R., FERNANDEZ I., DEL RIO A., AMOR A.M., GONZALEZ R.M., FRAGA V., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., AMOR A.M., GONZALEZ R.M., CARVAJAL D., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); MENENDEZ R., AMOR A., RODEIRO I., MAS R., GONZALEZ R.M., GONZALEZ C.P., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASES, J PHARMACOL EXP THER, 106, PP. 107-144, (2006); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA R., ET AL., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES CLIN EXP, 62, PP. 209-220, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLAINT J., FERNANDEZ J., MENDOSA S., ET AL., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/D) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 30, SUPPL., PP. 31-44, (2005); JIANG Z.Y., HUNT J.V., WOLFF S.P., DETECTION OF LIPID HYDROPEROXIDES USING THE FOX METHOD, ANAL. BIOCHEM, 202, PP. 384-389, (1992); OHKAWA N., OHISH H., YAGI K., ASSAY OF LIPID PEROXIDES IN ANIMAL TISSUES BY THE THIOBARBITURIC ACID REACTION, ANAL BIOCHEM, 95, PP. 351-358, (1979); MARXWELL M.A., HAAS S.M., BEIBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-209, (1987); LAWRENCE R.A., BURK R.F., GLUTATHIONE PEROXYDASE ACTIVITY IN SELENIUM DEFICIENT RAT LIVER, BIOCHEM BIOPHYS RES COMM, 71, PP. 952-958, (1976); CALBERG I., MANNERVIK B., PURIFICATION AND CHARACTERIZATION OF THE FLAVOENZYME GLUTHATHIONE REDUCTASE FROM RAT LIVER, J BIOL CHEM, 250, PP. 5475-5479, (1975); SAZUKA Y., TANIZAWA H., TAKINO Y., EFFECT OF ADRIAMYCIN ON THE ACTIVITIES OF SUPEROXIDE DISMUTASE, GLUTATHIONE PEROXIDASE AND CATALASE IN TISSUES OF MICE, JPN J CANCER RES, 80, PP. 89-94, (1989); GAMEZ R., RODEIRO I., FERNANDEZ I., ACOSTA P., PRELIMINARY EVALUATION OF THE CYTOTOXIC AND GENOTOXIC POTENTIAL OF D-003: A MIXTURE OF VERY LONG CHAIN FATTY ACIDS, TERATOG CARCINOG MUTAGEN, 22, PP. 175-181, (2002); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); MENENDEZ R., MAS R., PEREZ Y., GONZALEZ R.M., JIMENEZ J., CINÉTICA DE LA RADIACTIVIDAD TOTAL (RT) TRAS LA ADMINISTRACIÓN ORAL Y ENDOVENOSA DE DOSIS ÚNICAS DE 3 H-OCTACOSANOICO A RATAS., ACTA FARM BONAERENSE, 24, PP. 48-60, (2005)","Y. PÉREZ; CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBANACÁN, HAVANA, AVE 25 AND 158, CUBA; EMAIL: YOHANI.PEREZ@CNIC.EDU.CU","EDITIO CANTOR VERLAG GMBH","ENGLISH","ARZNEIM.-FORSCH. DRUG RES.","ARTICLE","ISI","2-S2.0-41849126787","ARZNEIM-FORSCH DRUG RES","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC);NOTREPORTED",NA,"PÉREZ Y, 2008, ARZNEIM-FORSCH DRUG RES","PÉREZ Y, 2008, ARZNEIM-FORSCH DRUG RES"
"MURPHY K;HOWE P;SAINT D","MURPHY, KAREN J. (7402863771); HOWE, PETER R.C. (7102000298); SAINT, DAVID A. (57193363400)","LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS",2008,"JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION","27","8",8,"10.1080/07315724.2008.10719728","NUTRITIONAL PHYSIOLOGY RESEARCH CENTRE, SCHOOL OF HEALTH SCIENCES, UNIVERSITY OF SOUTH AUSTRALIA, AUSTRALIA;NUTRITIONAL PHYSIOLOGY RESEARCH CENTRE, SCHOOL OF HEALTH SCIENCES, UNIVERSITY OF SOUTH AUSTRALIA, AUSTRALIA;DISCIPLINE OF PHYSIOLOGY, SCHOOL OF MOLECULAR & BIOMEDICAL SCIENCE, UNIVERSITY OF ADELAIDE, ADELAIDE, SA, 5001, AUSTRALIA","OBJECTIVE: TO EVALUATE THE POTENTIAL FOR A MIXTURE OF POLICOSANOL EXTRACTED FROM SUNFLOWER OIL (SFP) TO LOWER BLOOD CHOLESTEROL LEVELS IN COMPARISON TO SUGAR CANE POLICOSANOL (SCP) IN RABBITS. DESIGN: TWENTY THREE SEMI-LOP RABBITS WERE BLOCKED INTO THREE GROUPS MATCHED ON FASTING PLASMA CHOLESTEROL LEVELS THEN RANDOMLY ASSIGNED TO ONE OF THREE PARALLEL TREATMENT ARMS: CONTROL (VEHICLE 28.6% SUNFLOWER OIL/70% WATER/1.4% EMULSIFIER) N = 7; SFP, 100 MG/KG IN VEHICLE, N = 8; SCP, 100 MG/KG IN VEHICLE, N = 8. RABBITS WERE GAVAGED ONCE EVERY TWO DAYS FOR FOUR WEEKS. BLOOD WAS COLLECTED AND ANALYSED FOR PLASMA LIPIDS. RESULTS: TOTAL CHOLESTEROL, NON-HDL AND HDL CHOLESTEROL INCREASED SIGNIFICANTLY FOLLOWING SCP SUPPLEMENTATION RELATIVE TO THE CONTROL. SFP SUPPLEMENTATION HAD NO EFFECT. TRIGLYCERIDE LEVELS DECREASED SIGNIFICANTLY FOLLOWING ALL DIETARY TREATMENTS (P < 0.05), POSSIBLY DUE TO THE EMULSIFIER. CONCLUSION: DIETARY SUPPLEMENTATION OF NORMOCHOLESTEROLEMIC RABBITS WITH POLICOSANOL FROM SUNFLOWER OIL DOES NOT APPEAR TO HAVE ANY CHOLESTEROL LOWERING EFFECT. A SIMILAR LACK OF EFFICACY OBSERVED WITH THE COMMERCIAL SCP PRODUCT WHICH WE EVALUATED RAISES DOUBTS ABOUT THE PURPORTED CHOLESTEROL-LOWERING EFFICACY OF THESE PRODUCTS, AS REFLECTED IN THE CURRENT LITERATURE. © 2008 AMERICAN COLLEGE OF NUTRITION.","HDL; LDL; POLICOSANOL; SUGAR CANE; SUNFLOWER SEED; TOTAL CHOLESTEROL","ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; FATTY ALCOHOLS; FEMALE; HYPERCHOLESTEROLEMIA; LIPIDS; PLANT OILS; RABBITS; RANDOM ALLOCATION; SACCHARUM; HELIANTHUS; ORYCTOLAGUS CUNICULUS; SACCHARUM; EMULSIFYING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LESSTANOL; LIPID; PLACEBO; POLICOSANOL; SUNFLOWER OIL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LIPID; POLICOSANOL; VEGETABLE OIL; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEEDING; FEMALE; HUMAN; LIPID BLOOD LEVEL; MEDICAL LITERATURE; NONHUMAN; PLANT SEED; RABBIT; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; SUNFLOWER; SUPPLEMENTATION; ANIMAL; BLOOD; HYPERCHOLESTEROLEMIA; RANDOMIZATION","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); MUSA R., YUNOKI K., KINOSHITA M., ODA Y., OHNISHI M., INCREASED LEVELS OF POLICOSANOL AND VERY LONG-CHAIN FATTY ACIDS IN POTATO PULP FERMENTED WITH RHIZOPUS ORYZAE, BIOSCI BIOTECHNOL BIOCHEM, 68, PP. 2401-2404, (2004); ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, PP. 5359-5362, (2006); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); WANG Y., EBINE N., JIA X., JONES P.J., FAIROW C., JAEGER R., VERY LONG CHAIN FATTY ACIDS (POLICOSANOLS) AND PHYTOSTEROLS AFFECT PLASMA LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, METABOLISM, 54, PP. 508-514, (2005); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); NOA M., MAS R., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS, ARCH MED RES, 36, PP. 441-447, (2005); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2004); MAS R., CASTANO G., FERNANDEZ J., GAMEZ R., ILLNAIT J., FERNANDEZ L., LOPEZ E., MESA M., ALVAREZ E., MENDOZA S., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA PAC J CLIN NUTR, 13, (2004); TEDESCHI-REINER E., REINER Z., ROMIC Z., IVANKOVIC D., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTILIPEMIC EFFICACY AND TOLERABILITY OF FOOD SUPPLEMENT POLICOSANOL IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, LIJEC VJESN, 127, PP. 273-279, (2005); ORTEGA L.L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., FERNANDEZ J.C., ILLNAIT J., ALVAREZ E., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE: A PILOT OPEN STUDY, J MED FOOD, 9, PP. 378-385, (2006); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL, AM HEART J, 152, 982, PP. E981-E985, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., INTERACTION POLICOSANOL-WARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS, PHARMACOL RES, 38, PP. 89-91, (1998); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, (2004); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); WILSON R., SMITH M., HUMAN STUDIES ON POLYGLYCEROL POLYRICINOLEATE (PGPR), FOOD CHEM TOXICOL, 36, PP. 743-745, (1998); HAILER S., WOLFRAM G., INFLUENCE OF ARTIFICIAL FAT EMULSIONS ON THE COMPOSITION OF SERUM LIPOPROTEINS IN HUMANS, AM J CLIN NUTR, 43, PP. 225-233, (1986); JONES D.B., HANCOCK J.D., HARMON D.L., WALKER C.E., EFFECTS OF EXOGENOUS EMULSIFIERS AND FAT SOURCES ON NUTRIENT DIGESTIBILITY, SERUM LIPIDS, AND GROWTH PERFORMANCE IN WEANLING PIGS, J ANIM SCI, 70, PP. 3473-3482, (1992); O'DOHERTY P., KUKIS A., ROLE OF LUMINAL LECITHIN IN INTESTINAL FAT ABSORPTION, LIPIDS, 8, (1972); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACOLOGICAL USES, (1997); HENON G., RECSEG K., KOVARI K., WAX ANALYSIS OF VEGETABLE OILS USING LIQUID CHROMATOGRAPHY ON A DOUBLE-ADSORBENT LAYER OF SILICA GEL AND SILVER NITRATE-IMPREGNATED SILICA GEL, JAOCS, 78, PP. 401-410, (2001); GAMEZ R., MAZ R., ARRUZAZABALA M.L., MENDOZA S., CASTANO G., EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS, DRUGS R D, 6, PP. 11-19, (2005); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA M.L., MAS R., MAGRANER J., ANTI-INFLAMMATORY ACTIVITY OF D-002: AN ACTIVE PRODUCT ISOLATED FROM BEESWAX, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 59, PP. 235-238, (1998); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, PP. 31-44, (2005); NIES L.K., CYMBALA A.A., KASTEN S.L., LAMPRECHT D.G., OLSON K.L., COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR THE MANAGEMENT OF DYSLIPIDEMIA, ANN PHARMACOTHER, 40, PP. 1984-1992, (2006); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002)","","","ENGLISH","J. AM. COLL. NUTR.","ARTICLE","ISI","2-S2.0-84950170741","J AM COLL NUTR",NA,"NOTREPORTED",NA,"MURPHY KJ, 2008, J AM COLL NUTR","MURPHY KJ, 2008, J AM COLL NUTR"
"TAMLER R;MECHANICK J","TAMLER, RONALD (8722061400); MECHANICK, JEFFREY I. (7003950866)","DIETARY SUPPLEMENTS AND NUTRACEUTICALS IN THE MANAGEMENT OF ANDROLOGIC DISORDERS",2007,"ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA","36","19",28,"10.1016/j.ecl.2007.03.005","DIVISION OF ENDOCRINOLOGY, DIABETES AND BONE DISEASE, MOUNT SINAI SCHOOL OF MEDICINE, NEW YORK, NY 10029, 1 GUSTAVE L. LEVY PLACE, UNITED STATES;DIVISION OF ENDOCRINOLOGY, DIABETES AND BONE DISEASE, MOUNT SINAI SCHOOL OF MEDICINE, NEW YORK, NY 10029, 1 GUSTAVE L. LEVY PLACE, UNITED STATES","DIETARY SUPPLEMENTS AND NUTRACEUTICALS ARE COMMONLY USED BY MEN WITH ERECTILE DYSFUNCTION, DECREASED LIBIDO, BPH, AND CONCERNS ABOUT DEVELOPING PROSTATE CANCER. MANY PREPARATIONS DO NOT CONTAIN THE ADVERTISED DOSAGES OF THE ACTIVE INGREDIENT OR ARE CONTAMINATED. DIETARY SUPPLEMENTS AND NUTRACEUTICALS, PARTICULARLY THOSE ADDRESSING ERECTILE DYSFUNCTION AND LIBIDO, NEED TO UNDERGO RIGOROUS TESTING BEFORE THEY CAN BE WHOLEHEARTEDLY RECOMMENDED. © 2007.","","ANTIOXIDANTS; ARGININE; CARNITINE; DEHYDROEPIANDROSTERONE; DIET; DIETARY SUPPLEMENTS; GINKGO BILOBA; HUMANS; IMPOTENCE; LIBIDO; MALE; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC DISEASES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; YOHIMBINE; 4 AMINOBUTYRIC ACID; AFLATOXIN; ANTIOXIDANT; ARGININE; ASPIDOSPERMINE; CHONDROITIN; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUCOSAMINE; GLYCYRRHIZA EXTRACT; LEVACECARNINE; LYCOPENE; METHIONINE; NUTRACEUTICAL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; POLICOSANOL; PRASTERONE; PROPIONYLCARNITINE; REHMANNIA GLUTINOSA EXTRACT; RETINOL; SABAL EXTRACT; SELENIUM; SILDENAFIL; TADALAFIL; TESTOSTERONE UNDECANOATE; TRAZODONE; UNINDEXED DRUG; URTICA DIOICA EXTRACT; YOHIMBINE; ANXIETY DISORDER; BLEEDING; DIET SUPPLEMENTATION; ERECTILE DYSFUNCTION; GINKGO BILOBA; GINSENG; HEART PALPITATION; HUMAN; HYPERTENSION; LIBIDO DISORDER; MALE GENITAL SYSTEM DISEASE; MOULD; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SABAL; SEIZURE; SIDE EFFECT; TREMOR; VASOCONSTRICTION; YEAST","","","SHAH J., ERECTILE DYSFUNCTION THROUGH THE AGES, BJU INT, 90, 4, PP. 433-441, (2002); EISENBERG D.M., ET AL., TRENDS IN ALTERNATIVE MEDICINE USE IN THE UNITED STATES, 1990-1997: RESULTS OF A FOLLOW-UP NATIONAL SURVEY, JAMA, 280, 18, PP. 1569-1575, (1998); SCALLY M.C., HODGE A., HEALTH SUPPLEMENT REGULATIONS AND CONSUMER PROTECTION RIGHTS, SOUTH MED J, 93, 12, PP. 1230-1232, (2000); SCALLY M.C., HODGE A., STREET C., PRESCRIPTION FOR CHANGE: HEALTH SUPPLEMENT REGULATIONS AND PROTECTING THE PUBLIC INTEREST, J NATL MED ASSOC, 93, 6, PP. 230-232, (2001); ZEISEL S.H., REGULATION OF ""NUTRACEUTICALS., SCIENCE, 285, 5435, PP. 1853-1855, (1999); GUNTHER S., ET AL., DEMOGRAPHIC AND HEALTH-RELATED CORRELATES OF HERBAL AND SPECIALTY SUPPLEMENT USE, J AM DIET ASSOC, 104, 1, PP. 27-34, (2004); BARQAWI A., ET AL., HERBAL AND VITAMIN SUPPLEMENT USE IN A PROSTATE CANCER SCREENING POPULATION, UROLOGY, 63, 2, PP. 288-292, (2004); AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR THE CLINICAL USE OF DIETARY SUPPLEMENTS AND NUTRACEUTICALS, ENDOCR PRACT, 9, 5, PP. 417-470, (2003); BETZ J.M., WHITE K.D., DER MARDEROSIAN A.H., GAS CHROMATOGRAPHIC DETERMINATION OF YOHIMBINE IN COMMERCIAL YOHIMBE PRODUCTS, J AOAC INT, 78, 5, PP. 1189-1194, (1995); PARASRAMPURIA J., SCHWARTZ K., PETESCH R., QUALITY CONTROL OF DEHYDROEPIANDROSTERONE DIETARY SUPPLEMENT PRODUCTS, JAMA, 280, 18, (1998); CHUA R., ET AL., QUALITY, LABELING ACCURACY, AND COST COMPARISON OF PURIFIED SOY ISOFLAVONOID PRODUCTS, J ALTERN COMPLEMENT MED, 10, 6, PP. 1053-1060, (2004); HARKEY M.R., ET AL., VARIABILITY IN COMMERCIAL GINSENG PRODUCTS: AN ANALYSIS OF 25 PREPARATIONS, AM J CLIN NUTR, 73, 6, PP. 1101-1106, (2001); ARLT V.M., SCHMEISER H.H., PFEIFER G.P., SEQUENCE-SPECIFIC DETECTION OF ARISTOLOCHIC ACID-DNA ADDUCTS IN THE HUMAN P53 GENE BY TERMINAL TRANSFERASE-DEPENDENT PCR, CARCINOGENESIS, 22, 1, PP. 133-140, (2001); GRATZ S.R., GAMBLE B.M., FLURER R.A., ACCURATE MASS MEASUREMENT USING FOURIER TRANSFORM ION CYCLOTRON RESONANCE MASS SPECTROMETRY FOR STRUCTURE ELUCIDATION OF DESIGNER DRUG ANALOGS OF TADALAFIL, VARDENAFIL AND SILDENAFIL IN HERBAL AND PHARMACEUTICAL MATRICES, RAPID COMMUN MASS SPECTROM, 20, 15, PP. 2317-2327, (2006); FLESHNER N., ET AL., EVIDENCE FOR CONTAMINATION OF HERBAL ERECTILE DYSFUNCTION PRODUCTS WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS, J UROL, 174, 2, PP. 636-641, (2005); D'OVIDIO K., ET AL., AFLATOXINS IN GINSENG ROOTS, FOOD ADDIT CONTAM, 23, 2, PP. 174-180, (2006); TRUCKSESS M., ET AL., DETERMINATION OF AFLATOXINS AND OCHRATOXIN A IN GINSENG AND OTHER BOTANICAL ROOTS BY IMMUNOAFFINITY COLUMN CLEANUP AND LIQUID CHROMATOGRAPHY WITH FLUORESCENCE DETECTION, J AOAC INT, 89, 3, PP. 624-630, (2006); TOURNAS V.H., KATSOUDAS E., MIRACCO E.J., MOULDS, YEASTS AND AEROBIC PLATE COUNTS IN GINSENG SUPPLEMENTS, INT J FOOD MICROBIOL, 108, 2, PP. 178-181, (2006); KUDO K., ET AL., A CASE OF POISONING IN A MAN WHO DRANK A NUTRITION SUPPLEMENT CONTAINING METHOMYL, A CARBAMATE PESTICIDE, FUKUOKA IGAKU ZASSHI, 96, 7, PP. 305-310, (2005); ROGAN W.J., ET AL., RECALL OF A LEAD-CONTAMINATED VITAMIN AND MINERAL SUPPLEMENT IN A CLINICAL TRIAL, PHARMACOEPIDEMIOL DRUG SAF, 8, 5, PP. 343-350, (1999); TSENG Y.L., KUO F.H., SUN K.H., QUANTIFICATION AND PROFILING OF 19-NORANDROSTERONE AND 19-NORETIOCHOLANOLONE IN HUMAN URINE AFTER CONSUMPTION OF A NUTRITIONAL SUPPLEMENT AND NORSTEROIDS, J ANAL TOXICOL, 29, 2, PP. 124-134, (2005); BAUME N., ET AL., RESEARCH OF STIMULANTS AND ANABOLIC STEROIDS IN DIETARY SUPPLEMENTS, SCAND J MED SCI SPORTS, 16, 1, PP. 41-48, (2006); MORRIS C.A., AVORN J., INTERNET MARKETING OF HERBAL PRODUCTS, JAMA, 290, 11, PP. 1505-1509, (2003); SRINIVASAN V.S., CHALLENGES AND SCIENTIFIC ISSUES IN THE STANDARDIZATION OF BOTANICALS AND THEIR PREPARATIONS. UNITED STATES PHARMACOPEIA'S DIETARY SUPPLEMENT VERIFICATION PROGRAM-A PUBLIC HEALTH PROGRAM, LIFE SCI, 78, 18, PP. 2039-2043, (2006); NIH CONSENSUS CONFERENCE, IMPOTENCE. NIH CONSENSUS DEVELOPMENT PANEL ON IMPOTENCE, JAMA, 270, 1, PP. 83-90, (1993); BENET A.E., MELMAN A., THE EPIDEMIOLOGY OF ERECTILE DYSFUNCTION, UROL CLIN NORTH AM, 22, 4, PP. 699-709, (1995); JOHANNES C.B., ET AL., INCIDENCE OF ERECTILE DYSFUNCTION IN MEN 40 TO 69 YEARS OLD: LONGITUDINAL RESULTS FROM THE MASSACHUSETTS MALE AGING STUDY, J UROL, 163, 2, PP. 460-463, (2000); MOYAD M.A., THE PLACEBO EFFECT AND RANDOMIZED TRIALS: ANALYSIS OF ALTERNATIVE MEDICINE, UROL CLIN NORTH AM, 29, 1, PP. 135-155, (2002); MOYAD M.A., ET AL., PREVENTION AND TREATMENT OF ERECTILE DYSFUNCTION USING LIFESTYLE CHANGES AND DIETARY SUPPLEMENTS: WHAT WORKS AND WHAT IS WORTHLESS, PART II, UROL CLIN NORTH AM, 31, 2, PP. 259-273, (2004); MONTORSI F., ET AL., EFFICACY AND SAFETY OF FIXED-DOSE ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION OF VARIOUS ETIOLOGIES, UROLOGY, 53, 5, PP. 1011-1018, (1999); DULA E., ET AL., EFFICACY AND SAFETY OF FIXED-DOSE AND DOSE-OPTIMIZATION REGIMENS OF SUBLINGUAL APOMORPHINE VERSUS PLACEBO IN MEN WITH ERECTILE DYSFUNCTION. THE APOMORPHINE STUDY GROUP, UROLOGY, 56, 1, PP. 130-135, (2000); THOMPSON I.M., ET AL., ERECTILE DYSFUNCTION AND SUBSEQUENT CARDIOVASCULAR DISEASE, JAMA, 294, 23, PP. 2996-3002, (2005); ARLT W., ET AL., BIOTRANSFORMATION OF ORAL DEHYDROEPIANDROSTERONE IN ELDERLY MEN: SIGNIFICANT INCREASE IN CIRCULATING ESTROGENS, J CLIN ENDOCRINOL METAB, 84, 6, PP. 2170-2176, (1999); PAWLIKOWSKI M., ADRENAL CORTEX-THE NEXT BIOLOGICAL CLOCK?, NEURO ENDOCRINOL LETT, 26, 3, PP. 193-195, (2005); OLECH E., MERRILL J.T., DHEA SUPPLEMENTATION: THE CLAIMS IN PERSPECTIVE, CLEVE CLIN J MED, 72, 11, PP. 965-966, (2005); BASAR M.M., ET AL., RELATIONSHIP BETWEEN SERUM SEX STEROIDS AND AGING MALE SYMPTOMS SCORE AND INTERNATIONAL INDEX OF ERECTILE FUNCTION, UROLOGY, 66, 3, PP. 597-601, (2005); REITER W.J., ET AL., SERUM DEHYDROEPIANDROSTERONE SULFATE CONCENTRATIONS IN MEN WITH ERECTILE DYSFUNCTION, UROLOGY, 55, 5, PP. 755-758, (2000); FELDMAN H.A., ET AL., IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES: RESULTS OF THE MASSACHUSETTS MALE AGING STUDY, J UROL, 151, 1, PP. 54-61, (1994); REITER W.J., ET AL., DEHYDROEPIANDROSTERONE IN THE TREATMENT OF ERECTILE DYSFUNCTION: A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, UROLOGY, 53, 3, PP. 590-594, (1999); REITER W.J., ET AL., DEHYDROEPIANDROSTERONE IN THE TREATMENT OF ERECTILE DYSFUNCTION IN PATIENTS WITH DIFFERENT ORGANIC ETIOLOGIES, UROL RES, 29, 4, PP. 278-281, (2001); GENAZZANI A.R., ET AL., LONG-TERM LOW-DOSE DEHYDROEPIANDROSTERONE REPLACEMENT THERAPY IN AGING MALES WITH PARTIAL ANDROGEN DEFICIENCY, AGING MALE, 7, 2, PP. 133-143, (2004); JONES J.A., ET AL., USE OF DHEA IN A PATIENT WITH ADVANCED PROSTATE CANCER: A CASE REPORT AND REVIEW, UROLOGY, 50, 5, PP. 784-788, (1997); MORALES A.J., ET AL., EFFECTS OF REPLACEMENT DOSE OF DEHYDROEPIANDROSTERONE IN MEN AND WOMEN OF ADVANCING AGE, J CLIN ENDOCRINOL METAB, 78, 6, PP. 1360-1367, (1994); ARAGHINIKNAM M., ET AL., ANTIOXIDANT ACTIVITY OF DIOSCOREA AND DEHYDROEPIANDROSTERONE (DHEA) IN OLDER HUMANS, LIFE SCI, 59, 11, (1996); ADIMOELJA A., PHYTOCHEMICALS AND THE BREAKTHROUGH OF TRADITIONAL HERBS IN THE MANAGEMENT OF SEXUAL DYSFUNCTIONS, INT J ANDROL, 23, SUPPL. 2, PP. 82-84, (2000); HORTON R., TAIT J.F., ANDROSTENEDIONE PRODUCTION AND INTERCONVERSION RATES MEASURED IN PERIPHERAL BLOOD AND STUDIES ON THE POSSIBLE SITE OF ITS CONVERSION TO TESTOSTERONE, J CLIN INVEST, 45, 3, PP. 301-313, (1966); BROWN G.A., ET AL., EFFECTS OF ANABOLIC PRECURSORS ON SERUM TESTOSTERONE CONCENTRATIONS AND ADAPTATIONS TO RESISTANCE TRAINING IN YOUNG MEN, INT J SPORT NUTR EXERC METAB, 10, 3, PP. 340-359, (2000); KING D.S., ET AL., EFFECT OF ORAL ANDROSTENEDIONE ON SERUM TESTOSTERONE AND ADAPTATIONS TO RESISTANCE TRAINING IN YOUNG MEN: A RANDOMIZED CONTROLLED TRIAL, JAMA, 281, 21, PP. 2020-2028, (1999); WALLACE M.B., ET AL., EFFECTS OF DEHYDROEPIANDROSTERONE VS ANDROSTENEDIONE SUPPLEMENTATION IN MEN, MED SCI SPORTS EXERC, 31, 12, PP. 1788-1792, (1999); RASMUSSEN B.B., ET AL., ANDROSTENEDIONE DOES NOT STIMULATE MUSCLE PROTEIN ANABOLISM IN YOUNG HEALTHY MEN, J CLIN ENDOCRINOL METAB, 85, 1, PP. 55-59, (2000); LEDER B.Z., ET AL., METABOLISM OF ORALLY ADMINISTERED ANDROSTENEDIONE IN YOUNG MEN, J CLIN ENDOCRINOL METAB, 86, 8, (2001); LEDER B.Z., ET AL., ORAL ANDROSTENEDIONE ADMINISTRATION AND SERUM TESTOSTERONE CONCENTRATIONS IN YOUNG MEN, JAMA, 283, 6, PP. 779-782, (2000); BROWN G.A., ET AL., ENDOCRINE RESPONSES TO CHRONIC ANDROSTENEDIONE INTAKE IN 30- TO 56-YEAR-OLD MEN, J CLIN ENDOCRINOL METAB, 85, 11, PP. 4074-4080, (2000); BROWN G.A., ET AL., EFFECTS OF ANDROSTENEDIONE-HERBAL SUPPLEMENTATION ON SERUM SEX HORMONE CONCENTRATIONS IN 30- TO 59-YEAR-OLD MEN, INT J VITAM NUTR RES, 71, 5, PP. 293-301, (2001); SIEGNER JR. A.W., THE FOOD AND DRUG ADMINISTRATION'S ACTIONS ON EPHEDRA AND ANDROSTENEDIONE: UNDERSTANDING THEIR POTENTIAL IMPACTS ON THE PROTECTIONS OF THE DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT, FOOD DRUG LAW J, 59, 4, PP. 617-628, (2004); BAHRKE M.S., YESALIS C.E., ABUSE OF ANABOLIC ANDROGENIC STEROIDS AND RELATED SUBSTANCES IN SPORT AND EXERCISE, CURR OPIN PHARMACOL, 4, 6, PP. 614-620, (2004); DESJARDINS M., SUPPLEMENT USE IN THE ADOLESCENT ATHLETE, CURR SPORTS MED REP, 1, 6, PP. 369-373, (2002); LUE T.F., LEE K.L., PHARMACOTHERAPY FOR ERECTILE DYSFUNCTION, CHIN MED J (ENGL), 113, 4, PP. 291-298, (2000); TODA N., AYAJIKI K., OKAMURA T., NITRIC OXIDE AND PENILE ERECTILE FUNCTION, PHARMACOL THER, 106, 2, PP. 233-266, (2005); ZORGNIOTTI A.W., LIZZA E.F., EFFECT OF LARGE DOSES OF THE NITRIC OXIDE PRECURSOR, L-ARGININE, ON ERECTILE DYSFUNCTION, INT J IMPOT RES, 6, 1, PP. 33-35, (1994); CHEN J., ET AL., EFFECT OF ORAL ADMINISTRATION OF HIGH-DOSE NITRIC OXIDE DONOR L-ARGININE IN MEN WITH ORGANIC ERECTILE DYSFUNCTION: RESULTS OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, BJU INT, 83, 3, PP. 269-273, (1999); KLOTZ T., ET AL., EFFECTIVENESS OF ORAL L-ARGININE IN FIRST-LINE TREATMENT OF ERECTILE DYSFUNCTION IN A CONTROLLED CROSSOVER STUDY, UROL INT, 63, 4, PP. 220-223, (1999); FITZPATRICK D.F., BING B., ROHDEWALD P., ENDOTHELIUM-DEPENDENT VASCULAR EFFECTS OF PYCNOGENOL, J CARDIOVASC PHARMACOL, 32, 4, PP. 509-515, (1998); STANISLAVOV R., NIKOLOVA V., TREATMENT OF ERECTILE DYSFUNCTION WITH PYCNOGENOL AND L-ARGININE, J SEX MARITAL THER, 29, 3, PP. 207-213, (2003); TAM S.W., WORCEL M., WYLLIE M., YOHIMBINE: A CLINICAL REVIEW, PHARMACOL THER, 91, 3, PP. 215-243, (2001); ERNST E., PITTLER M.H., YOHIMBINE FOR ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, J UROL, 159, 2, PP. 433-436, (1998); PITTLER M.H., ERNST E., TRIALS HAVE SHOWN YOHIMBINE IS EFFECTIVE FOR ERECTILE DYSFUNCTION, BMJ, 317, 7156, (1998); SUSSET J.G., ET AL., EFFECT OF YOHIMBINE HYDROCHLORIDE ON ERECTILE IMPOTENCE: A DOUBLE-BLIND STUDY, J UROL, 141, 6, PP. 1360-1363, (1989); GUAY A.T., ET AL., CLOMIPHENE INCREASES FREE TESTOSTERONE LEVELS IN MEN WITH BOTH SECONDARY HYPOGONADISM AND ERECTILE DYSFUNCTION: WHO DOES AND DOES NOT BENEFIT?, INT J IMPOT RES, 15, 3, PP. 156-165, (2003); KERNOHAN A.F., ET AL., AN ORAL YOHIMBINE/L-ARGININE COMBINATION (NMI 861) FOR THE TREATMENT OF MALE ERECTILE DYSFUNCTION: A PHARMACOKINETIC, PHARMACODYNAMIC AND INTERACTION STUDY WITH INTRAVENOUS NITROGLYCERINE IN HEALTHY MALE SUBJECTS, BR J CLIN PHARMACOL, 59, 1, PP. 85-93, (2005); LEBRET T., ET AL., EFFICACY AND SAFETY OF A NOVEL COMBINATION OF L-ARGININE GLUTAMATE AND YOHIMBINE HYDROCHLORIDE: A NEW ORAL THERAPY FOR ERECTILE DYSFUNCTION, EUR UROL, 41, 6, PP. 608-613, (2002); JOHNSON S., IAZZETTA J., DEWAR C., SEVERE RAYNAUD'S PHENOMENON WITH YOHIMBINE THERAPY FOR ERECTILE DYSFUNCTION, J RHEUMATOL, 30, 11, PP. 2503-2505, (2003); COHEN A.J., BARTLIK B., GINKGO BILOBA FOR ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION, J SEX MARITAL THER, 24, 2, PP. 139-143, (1998); BALON R., GINKGO BILOBA FOR ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION?, J SEX MARITAL THER, 25, 1, PP. 1-2, (1999); KANG B.J., ET AL., A PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF GINKGO BILOBA FOR ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION, HUM PSYCHOPHARMACOL, 17, 6, PP. 279-284, (2002); WHEATLEY D., TRIPLE-BLIND, PLACEBO-CONTROLLED TRIAL OF GINKGO BILOBA IN SEXUAL DYSFUNCTION DUE TO ANTIDEPRESSANT DRUGS, HUM PSYCHOPHARMACOL, 19, 8, PP. 545-548, (2004); WILLIAMSON E.M., INTERACTIONS BETWEEN HERBAL AND CONVENTIONAL MEDICINES, EXPERT OPIN DRUG SAF, 4, 2, PP. 355-378, (2005); IZZO A.A., ET AL., CARDIOVASCULAR PHARMACOTHERAPY AND HERBAL MEDICINES: THE RISK OF DRUG INTERACTION, INT J CARDIOL, 98, 1, PP. 1-14, (2005); KUPIEC T., RAJ V., FATAL SEIZURES DUE TO POTENTIAL HERB-DRUG INTERACTIONS WITH GINKGO BILOBA, J ANAL TOXICOL, 29, 7, PP. 755-758, (2005); RAMSAY N.A., ET AL., COMPLIMENTARY AND ALTERNATIVE MEDICINE USE AMONG PATIENTS STARTING WARFARIN, BR J HAEMATOL, 130, 5, PP. 777-780, (2005); KIM J.Y., ET AL., INDUCTION OF NITRIC OXIDE SYNTHASE BY SAPONINS OF HEAT-PROCESSED GINSENG, BIOSCI BIOTECHNOL BIOCHEM, 69, 5, PP. 891-895, (2005); CHOI Y.D., RHA K.H., CHOI H.K., IN VITRO AND IN VIVO EXPERIMENTAL EFFECT OF KOREAN RED GINSENG ON ERECTION, J UROL, 162, 4, PP. 1508-1511, (1999); CHOI Y.D., XIN Z.C., CHOI H.K., EFFECT OF KOREAN RED GINSENG ON THE RABBIT CORPUS CAVERNOSAL SMOOTH MUSCLE, INT J IMPOT RES, 10, 1, PP. 37-43, (1998); RYU J.K., ET AL., FREE RADICAL-SCAVENGING ACTIVITY OF KOREAN RED GINSENG FOR ERECTILE DYSFUNCTION IN NON-INSULIN-DEPENDENT DIABETES MELLITUS RATS, UROLOGY, 65, 3, PP. 611-615, (2005); KANG K.S., ET AL., STUDY ON THE NITRIC OXIDE SCAVENGING EFFECTS OF GINSENG AND ITS COMPOUNDS, J AGRIC FOOD CHEM, 54, 7, PP. 2558-2562, (2006); CHOI H.K., SEONG D.H., RHA K.H., CLINICAL EFFICACY OF KOREAN RED GINSENG FOR ERECTILE DYSFUNCTION, INT J IMPOT RES, 7, 3, PP. 181-186, (1995); HONG B., ET AL., A DOUBLE-BLIND CROSSOVER STUDY EVALUATING THE EFFICACY OF KOREAN RED GINSENG IN PATIENTS WITH ERECTILE DYSFUNCTION: A PRELIMINARY REPORT, J UROL, 168, 5, PP. 2070-2073, (2002); PRICE A., GAZEWOOD J., KOREAN RED GINSENG EFFECTIVE FOR TREATMENT OF ERECTILE DYSFUNCTION, J FAM PRACT, 52, 1, PP. 20-21, (2003); CIPOLLA M.J., ET AL., PROPIONYL-L-CARNITINE DILATES HUMAN SUBCUTANEOUS ARTERIES THROUGH AN ENDOTHELIUM-DEPENDENT MECHANISM, J VASC SURG, 29, 6, PP. 1097-1103, (1999); CAVALLINI G., ET AL., CARNITINE VERSUS ANDROGEN ADMINISTRATION IN THE TREATMENT OF SEXUAL DYSFUNCTION, DEPRESSED MOOD, AND FATIGUE ASSOCIATED WITH MALE AGING, UROLOGY, 63, 4, PP. 641-646, (2004); GENTILE V., ET AL., PRELIMINARY OBSERVATIONS ON THE USE OF PROPIONYL-L-CARNITINE IN COMBINATION WITH SILDENAFIL IN PATIENTS WITH ERECTILE DYSFUNCTION AND DIABETES, CURR MED RES OPIN, 20, 9, PP. 1377-1384, (2004); CAVALLINI G., ET AL., ACETYL-L-CARNITINE PLUS PROPIONYL-L-CARNITINE IMPROVE EFFICACY OF SILDENAFIL IN TREATMENT OF ERECTILE DYSFUNCTION AFTER BILATERAL NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY, UROLOGY, 66, 5, PP. 1080-1085, (2005); ENG J., ET AL., A POPULATION-BASED SURVEY OF COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN MEN RECENTLY DIAGNOSED WITH PROSTATE CANCER, INTEGR CANCER THER, 2, 3, PP. 212-216, (2003); CHAN J.M., ET AL., TOTAL AND SPECIFIC COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN A LARGE COHORT OF MEN WITH PROSTATE CANCER, UROLOGY, 66, 6, PP. 1223-1228, (2005); BARNES P.M., ET AL., COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG ADULTS: UNITED STATES, 2002, ADV DATA, 343, PP. 1-19, (2004); CARRARO J.C., ET AL., COMPARISON OF PHYTOTHERAPY (PERMIXON) WITH FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA: A RANDOMIZED INTERNATIONAL STUDY OF 1,098 PATIENTS, PROSTATE, 29, 4, PP. 231-240, (1996); BOYLE P., ET AL., UPDATED META-ANALYSIS OF CLINICAL TRIALS OF SERENOA REPENS EXTRACT IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA, BJU INT, 93, 6, PP. 751-756, (2004); GERBER G.S., ET AL., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SAW PALMETTO IN MEN WITH LOWER URINARY TRACT SYMPTOMS, UROLOGY, 58, 6, PP. 960-964, (2001); BECKMAN T.J., MYNDERSE L.A., EVALUATION AND MEDICAL MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA, MAYO CLIN PROC, 80, 10, PP. 1356-1362, (2005); BENT S., ET AL., SAW PALMETTO FOR BENIGN PROSTATIC HYPERPLASIA, N ENGL J MED, 354, 6, PP. 557-566, (2006); CHAN J.M., GANN P.H., GIOVANNUCCI E.L., ROLE OF DIET IN PROSTATE CANCER DEVELOPMENT AND PROGRESSION, J CLIN ONCOL, 23, 32, PP. 8152-8160, (2005); ANLASIK T., ET AL., DIETARY HABITS ARE MAJOR DETERMINANTS OF THE PLASMA ANTIOXIDANT STATUS IN HEALTHY ELDERLY SUBJECTS, BR J NUTR, 94, 5, PP. 639-642, (2005); SIES H., STAHL W., SEVANIAN A., NUTRITIONAL, DIETARY AND POSTPRANDIAL OXIDATIVE STRESS, J NUTR, 135, 5, PP. 969-972, (2005); DI MASCIO P., ET AL., CAROTENOIDS, TOCOPHEROLS AND THIOLS AS BIOLOGICAL SINGLET MOLECULAR OXYGEN QUENCHERS, BIOCHEM SOC TRANS, 18, 6, PP. 1054-1056, (1990); CLINTON S.K., ET AL., CIS-TRANS LYCOPENE ISOMERS, CAROTENOIDS, AND RETINOL IN THE HUMAN PROSTATE, CANCER EPIDEMIOL BIOMARKERS PREV, 5, 10, PP. 823-833, (1996); GIOVANNUCCI E., A REVIEW OF EPIDEMIOLOGIC STUDIES OF TOMATOES, LYCOPENE, AND PROSTATE CANCER, EXP BIOL MED (MAYWOOD), 227, 10, PP. 852-859, (2002); GIOVANNUCCI E., TOMATO PRODUCTS, LYCOPENE, AND PROSTATE CANCER: A REVIEW OF THE EPIDEMIOLOGICAL LITERATURE, J NUTR, 135, 8, (2005); GIOVANNUCCI E., ET AL., INTAKE OF CAROTENOIDS AND RETINOL IN RELATION TO RISK OF PROSTATE CANCER, J NATL CANCER INST, 87, 23, PP. 1767-1776, (1995); GIOVANNUCCI E., ET AL., A PROSPECTIVE STUDY OF TOMATO PRODUCTS, LYCOPENE, AND PROSTATE CANCER RISK, J NATL CANCER INST, 94, 5, PP. 391-398, (2002); WU K., ET AL., PLASMA AND DIETARY CAROTENOIDS, AND THE RISK OF PROSTATE CANCER: A NESTED CASE-CONTROL STUDY, CANCER EPIDEMIOL BIOMARKERS PREV, 13, 2, PP. 260-269, (2004); LU Q.Y., ET AL., INVERSE ASSOCIATIONS BETWEEN PLASMA LYCOPENE AND OTHER CAROTENOIDS AND PROSTATE CANCER, CANCER EPIDEMIOL BIOMARKERS PREV, 10, 7, PP. 749-756, (2001); VOGT T.M., ET AL., SERUM LYCOPENE, OTHER SERUM CAROTENOIDS, AND RISK OF PROSTATE CANCER IN US BLACKS AND WHITES, AM J EPIDEMIOL, 155, 11, PP. 1023-1032, (2002); ETMINAN M., TAKKOUCHE B., CAAMANO-ISORNA F., THE ROLE OF TOMATO PRODUCTS AND LYCOPENE IN THE PREVENTION OF PROSTATE CANCER: A META-ANALYSIS OF OBSERVATIONAL STUDIES, CANCER EPIDEMIOL BIOMARKERS PREV, 13, 3, PP. 340-345, (2004); COHEN J.H., KRISTAL A.R., STANFORD J.L., FRUIT AND VEGETABLE INTAKES AND PROSTATE CANCER RISK, J NATL CANCER INST, 92, 1, PP. 61-68, (2000); KOLONEL L.N., ET AL., VEGETABLES, FRUITS, LEGUMES AND PROSTATE CANCER: A MULTIETHNIC CASE-CONTROL STUDY, CANCER EPIDEMIOL BIOMARKERS PREV, 9, 8, PP. 795-804, (2000); LE MARCHAND L., ET AL., VEGETABLE AND FRUIT CONSUMPTION IN RELATION TO PROSTATE CANCER RISK IN HAWAII: A REEVALUATION OF THE EFFECT OF DIETARY BETA-CAROTENE, AM J EPIDEMIOL, 133, 3, PP. 215-219, (1991); HAYES R.B., ET AL., DIETARY FACTORS AND RISKS FOR PROSTATE CANCER AMONG BLACKS AND WHITES IN THE UNITED STATES, CANCER EPIDEMIOL BIOMARKERS PREV, 8, 1, PP. 25-34, (1999); KIRSH V.A., ET AL., A PROSPECTIVE STUDY OF LYCOPENE AND TOMATO PRODUCT INTAKE AND RISK OF PROSTATE CANCER, CANCER EPIDEMIOL BIOMARKERS PREV, 15, 1, PP. 92-98, (2006); COOK N.R., ET AL., BETA-CAROTENE SUPPLEMENTATION FOR PATIENTS WITH LOW BASELINE LEVELS AND DECREASED RISKS OF TOTAL AND PROSTATE CARCINOMA, CANCER, 86, 9, PP. 1783-1792, (1999); KIRSH V.A., ET AL., SUPPLEMENTAL AND DIETARY VITAMIN E, BETA-CAROTENE, AND VITAMIN C INTAKES AND PROSTATE CANCER RISK, J NATL CANCER INST, 98, 4, PP. 245-254, (2006); HEINONEN O.P., ET AL., PROSTATE CANCER AND SUPPLEMENTATION WITH ALPHA-TOCOPHEROL AND BETA-CAROTENE: INCIDENCE AND MORTALITY IN A CONTROLLED TRIAL, J NATL CANCER INST, 90, 6, PP. 440-446, (1998); GANN P.H., ET AL., LOWER PROSTATE CANCER RISK IN MEN WITH ELEVATED PLASMA LYCOPENE LEVELS: RESULTS OF A PROSPECTIVE ANALYSIS, CANCER RES, 59, 6, PP. 1225-1230, (1999); GOODMAN G.E., ET AL., THE ASSOCIATION BETWEEN LUNG AND PROSTATE CANCER RISK, AND SERUM MICRONUTRIENTS: RESULTS AND LESSONS LEARNED FROM BETA-CAROTENE AND RETINOL EFFICACY TRIAL, CANCER EPIDEMIOL BIOMARKERS PREV, 12, 6, PP. 518-526, (2003); EICHHOLZER M., ET AL., SMOKING, PLASMA VITAMINS C, E, RETINOL, AND CAROTENE, AND FATAL PROSTATE CANCER: SEVENTEEN-YEAR FOLLOW-UP OF THE PROSPECTIVE BASEL STUDY, PROSTATE, 38, 3, PP. 189-198, (1999); STAHELIN H.B., ET AL., PLASMA ANTIOXIDANT VITAMINS AND SUBSEQUENT CANCER MORTALITY IN THE 12-YEAR FOLLOW-UP OF THE PROSPECTIVE BASEL STUDY, AM J EPIDEMIOL, 133, 8, PP. 766-775, (1991); VLAJINAC H.D., ET AL., DIET AND PROSTATE CANCER: A CASE-CONTROL STUDY, EUR J CANCER, 33, 1, PP. 101-107, (1997); TZONOU A., ET AL., DIET AND CANCER OF THE PROSTATE: A CASE-CONTROL STUDY IN GREECE, INT J CANCER, 80, 5, PP. 704-708, (1999); DENEO-PELLEGRINI H., ET AL., FOODS, NUTRIENTS AND PROSTATE CANCER: A CASE-CONTROL STUDY IN URUGUAY, BR J CANCER, 80, 3-4, PP. 591-597, (1999); CHAN J.M., ET AL., SUPPLEMENTAL VITAMIN E INTAKE AND PROSTATE CANCER RISK IN A LARGE COHORT OF MEN IN THE UNITED STATES, CANCER EPIDEMIOL BIOMARKERS PREV, 8, 10, PP. 893-899, (1999); HARTMAN T.J., ET AL., THE ASSOCIATION BETWEEN BASELINE VITAMIN E, SELENIUM, AND PROSTATE CANCER IN THE ALPHA-TOCOPHEROL, BETA-CAROTENE CANCER PREVENTION STUDY, CANCER EPIDEMIOL BIOMARKERS PREV, 7, 4, PP. 335-340, (1998); RODRIGUEZ C., ET AL., VITAMIN E SUPPLEMENTS AND RISK OF PROSTATE CANCER IN U.S. MEN, CANCER EPIDEMIOL BIOMARKERS PREV, 13, 3, PP. 378-382, (2004); HSING A.W., ET AL., SEROLOGIC PRECURSORS OF CANCER. RETINOL, CAROTENOIDS, AND TOCOPHEROL AND RISK OF PROSTATE CANCER, J NATL CANCER INST, 82, 11, PP. 941-946, (1990); HAYES R.B., ET AL., SERUM RETINOL AND PROSTATE CANCER, CANCER, 62, 9, PP. 2021-2026, (1988); HERNAANDEZ J., ET AL., THE MODULATION OF PROSTATE CANCER RISK WITH ALPHA-TOCOPHEROL: A PILOT RANDOMIZED, CONTROLLED CLINICAL TRIAL, J UROL, 174, 2, PP. 519-522, (2005); HUANG H.Y., ET AL., PROSPECTIVE STUDY OF ANTIOXIDANT MICRONUTRIENTS IN THE BLOOD AND THE RISK OF DEVELOPING PROSTATE CANCER, AM J EPIDEMIOL, 157, 4, PP. 335-344, (2003); GIOVANNUCCI E., GAMMA-TOCOPHEROL: A NEW PLAYER IN PROSTATE CANCER PREVENTION?, J NATL CANCER INST, 92, 24, PP. 1966-1967, (2000); REDMAN C., ET AL., INVOLVEMENT OF POLYAMINES IN SELENOMETHIONINE INDUCED APOPTOSIS AND MITOTIC ALTERATIONS IN HUMAN TUMOR CELLS, CARCINOGENESIS, 18, 6, PP. 1195-1202, (1997); GRIFFIN A.C., ROLE OF SELENIUM IN THE CHEMOPREVENTION OF CANCER, ADV CANCER RES, 29, PP. 419-442, (1979); WATERS D.J., ET AL., EFFECTS OF DIETARY SELENIUM SUPPLEMENTATION ON DNA DAMAGE AND APOPTOSIS IN CANINE PROSTATE, J NATL CANCER INST, 95, 3, PP. 237-241, (2003); CHUN J.Y., ET AL., MECHANISMS OF SELENIUM DOWN-REGULATION OF ANDROGEN RECEPTOR SIGNALING IN PROSTATE CANCER, MOL CANCER THER, 5, 4, PP. 913-918, (2006); LEE S.O., ET AL., SELENIUM DISRUPTS ESTROGEN SIGNALING BY ALTERING ESTROGEN RECEPTOR EXPRESSION AND LIGAND BINDING IN HUMAN BREAST CANCER CELLS, CANCER RES, 65, 8, PP. 3487-3492, (2005); DONG Y., ET AL., PROSTATE SPECIFIC ANTIGEN EXPRESSION IS DOWN-REGULATED BY SELENIUM THROUGH DISRUPTION OF ANDROGEN RECEPTOR SIGNALING, CANCER RES, 64, 1, PP. 19-22, (2004); VAN DEN BRANDT P.A., ET AL., TOENAIL SELENIUM LEVELS AND THE SUBSEQUENT RISK OF PROSTATE CANCER: A PROSPECTIVE COHORT STUDY, CANCER EPIDEMIOL BIOMARKERS PREV, 12, 9, PP. 866-871, (2003); OZMEN H., ET AL., COMPARISON OF THE CONCENTRATION OF TRACE METALS (NI, ZN, CO, CU AND SE), FE, VITAMINS A, C AND E, AND LIPID PEROXIDATION IN PATIENTS WITH PROSTATE CANCER, CLIN CHEM LAB MED, 44, 2, PP. 175-179, (2006); LI H., ET AL., A PROSPECTIVE STUDY OF PLASMA SELENIUM LEVELS AND PROSTATE CANCER RISK, J NATL CANCER INST, 96, 9, PP. 696-703, (2004); NOMURA A.M., ET AL., SERUM SELENIUM AND SUBSEQUENT RISK OF PROSTATE CANCER, CANCER EPIDEMIOL BIOMARKERS PREV, 9, 9, PP. 883-887, (2000); YOSHIZAWA K., ET AL., STUDY OF PREDIAGNOSTIC SELENIUM LEVEL IN TOENAILS AND THE RISK OF ADVANCED PROSTATE CANCER, J NATL CANCER INST, 90, 16, PP. 1219-1224, (1998); LIPSKY K., ET AL., SELENIUM LEVELS OF PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER COMPARED WITH CONTROL GROUP, UROLOGY, 63, 5, PP. 912-916, (2004); NYMAN D.W., ET AL., SELENIUM AND SELENOMETHIONINE LEVELS IN PROSTATE CANCER PATIENTS, CANCER DETECT PREV, 28, 1, PP. 8-16, (2004); KUMAR N.B., ET AL., THE SPECIFIC ROLE OF ISOFLAVONES IN REDUCING PROSTATE CANCER RISK, PROSTATE, 59, 2, PP. 141-147, (2004); GHADIRIAN P., ET AL., A CASE-CONTROL STUDY OF TOENAIL SELENIUM AND CANCER OF THE BREAST, COLON, AND PROSTATE, CANCER DETECT PREV, 24, 4, PP. 305-313, (2000); DUFFIELD-LILLICO A.J., ET AL., SELENIUM SUPPLEMENTATION, BASELINE PLASMA SELENIUM STATUS AND INCIDENCE OF PROSTATE CANCER: AN ANALYSIS OF THE COMPLETE TREATMENT PERIOD OF THE NUTRITIONAL PREVENTION OF CANCER TRIAL, BJU INT, 91, 7, PP. 608-612, (2003); DUFFIELD-LILLICO A.J., ET AL., BASELINE CHARACTERISTICS AND THE EFFECT OF SELENIUM SUPPLEMENTATION ON CANCER INCIDENCE IN A RANDOMIZED CLINICAL TRIAL: A SUMMARY REPORT OF THE NUTRITIONAL PREVENTION OF CANCER TRIAL, CANCER EPIDEMIOL BIOMARKERS PREV, 11, 7, PP. 630-639, (2002); MEYER F., ET AL., ANTIOXIDANT VITAMIN AND MINERAL SUPPLEMENTATION AND PROSTATE CANCER PREVENTION IN THE SU.VI.MAX TRIAL, INT J CANCER, 116, 2, PP. 182-186, (2005); HOENJET K.M., ET AL., EFFECT OF A NUTRITIONAL SUPPLEMENT CONTAINING VITAMIN E, SELENIUM, VITAMIN C AND COENZYME Q10 ON SERUM PSA IN PATIENTS WITH HORMONALLY UNTREATED CARCINOMA OF THE PROSTATE: A RANDOMISED PLACEBO-CONTROLLED STUDY, EUR UROL, 47, 4, PP. 433-439, (2005); KLEIN E.A., SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL, ANN N Y ACAD SCI, 1031, PP. 234-241, (2004); LIPPMAN S.M., ET AL., DESIGNING THE SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT), J NATL CANCER INST, 97, 2, PP. 94-102, (2005); DRAKE E.N., CANCER CHEMOPREVENTION: SELENIUM AS A PROOXIDANT, NOT AN ANTIOXIDANT, MED HYPOTHESES, 67, 2, PP. 318-322, (2006); PLATZ E.A., ET AL., ALCOHOL INTAKE, DRINKING PATTERNS, AND RISK OF PROSTATE CANCER IN A LARGE PROSPECTIVE COHORT STUDY, AM J EPIDEMIOL, 159, 5, PP. 444-453, (2004); BARBA M., ET AL., LIFETIME TOTAL AND BEVERAGE SPECIFIC-ALCOHOL INTAKE AND PROSTATE CANCER RISK: A CASE-CONTROL STUDY, NUTR J, 3, (2004); SHARPE C.R., SIEMIATYCKI J., CASE-CONTROL STUDY OF ALCOHOL CONSUMPTION AND PROSTATE CANCER RISK IN MONTREAL, CANADA, CANCER CAUSES CONTROL, 12, 7, PP. 589-598, (2001); SCHOONEN W.M., ET AL., ALCOHOL CONSUMPTION AND RISK OF PROSTATE CANCER IN MIDDLE-AGED MEN, INT J CANCER, 113, 1, PP. 133-140, (2005); JAIN M.G., ET AL., ALCOHOL AND OTHER BEVERAGE USE AND PROSTATE CANCER RISK AMONG CANADIAN MEN, INT J CANCER, 78, 6, PP. 707-711, (1998); HEILBRUN L.K., NOMURA A., STEMMERMANN G.N., BLACK TEA CONSUMPTION AND CANCER RISK: A PROSPECTIVE STUDY, BR J CANCER, 54, 4, PP. 677-683, (1986); JIAN L., ET AL., PROTECTIVE EFFECT OF GREEN TEA AGAINST PROSTATE CANCER: A CASE-CONTROL STUDY IN SOUTHEAST CHINA, INT J CANCER, 108, 1, PP. 130-135, (2004); SONODA T., ET AL., A CASE-CONTROL STUDY OF DIET AND PROSTATE CANCER IN JAPAN: POSSIBLE PROTECTIVE EFFECT OF TRADITIONAL JAPANESE DIET, CANCER SCI, 95, 3, PP. 238-242, (2004); KINLEN L.J., ET AL., TEA CONSUMPTION AND CANCER, BR J CANCER, 58, 3, PP. 397-401, (1988); BETTUZZI S., ET AL., CHEMOPREVENTION OF HUMAN PROSTATE CANCER BY ORAL ADMINISTRATION OF GREEN TEA CATECHINS IN VOLUNTEERS WITH HIGH-GRADE PROSTATE INTRAEPITHELIAL NEOPLASIA: A PRELIMINARY REPORT FROM A ONE-YEAR PROOF-OF-PRINCIPLE STUDY, CANCER RES, 66, 2, PP. 1234-1240, (2006); GRAHAM H.N., GREEN TEA COMPOSITION, CONSUMPTION, AND POLYPHENOL CHEMISTRY, PREV MED, 21, 3, PP. 334-350, (1992); SHARPE C.R., SIEMIATYCKI J., CONSUMPTION OF NON-ALCOHOLIC BEVERAGES AND PROSTATE CANCER RISK, EUR J CANCER PREV, 11, 5, PP. 497-501, (2002); SLATTERY M.L., WEST D.W., SMOKING, ALCOHOL, COFFEE, TEA, CAFFEINE, AND THEOBROMINE: RISK OF PROSTATE CANCER IN UTAH (UNITED STATES), CANCER CAUSES CONTROL, 4, 6, PP. 559-563, (1993); ELLISON L.F., TEA AND OTHER BEVERAGE CONSUMPTION AND PROSTATE CANCER RISK: A CANADIAN RETROSPECTIVE COHORT STUDY, EUR J CANCER PREV, 9, 2, PP. 125-130, (2000); JATOI A., ET AL., A PHASE II TRIAL OF GREEN TEA IN THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT METASTATIC PROSTATE CARCINOMA, CANCER, 97, 6, PP. 1442-1446, (2003); LEE A.H., ET AL., PROTECTIVE EFFECTS OF GREEN TEA AGAINST PROSTATE CANCER, EXPERT REV ANTICANCER THER, 6, 4, PP. 507-513, (2006); ALBRECHT M., ET AL., POMEGRANATE EXTRACTS POTENTLY SUPPRESS PROLIFERATION, XENOGRAFT GROWTH, AND INVASION OF HUMAN PROSTATE CANCER CELLS, J MED FOOD, 7, 3, PP. 274-283, (2004); PANTUCK A.J., ET AL., PHASE II STUDY OF POMEGRANATE JUICE FOR MEN WITH RISING PROSTATE-SPECIFIC ANTIGEN FOLLOWING SURGERY OR RADIATION FOR PROSTATE CANCER, CLIN CANCER RES, 12, 13, PP. 4018-4026, (2006); HOLZBEIERLEIN J.M., MCINTOSH J., THRASHER J.B., THE ROLE OF SOY PHYTOESTROGENS IN PROSTATE CANCER, CURR OPIN UROL, 15, 1, PP. 17-22, (2005); LEE M.M., ET AL., SOY AND ISOFLAVONE CONSUMPTION IN RELATION TO PROSTATE CANCER RISK IN CHINA, CANCER EPIDEMIOL BIOMARKERS PREV, 12, 7, PP. 665-668, (2003); JACOBSEN B.K., KNUTSEN S.F., FRASER G.E., DOES HIGH SOY MILK INTAKE REDUCE PROSTATE CANCER INCIDENCE? THE ADVENTIST HEALTH STUDY (UNITED STATES), CANCER CAUSES CONTROL, 9, 6, PP. 553-557, (1998); HEBERT J.R., ET AL., NUTRITIONAL AND SOCIOECONOMIC FACTORS IN RELATION TO PROSTATE CANCER MORTALITY: A CROSS-NATIONAL STUDY, J NATL CANCER INST, 90, 21, PP. 1637-1647, (1998); NOMURA A.M., ET AL., COHORT STUDY OF TOFU INTAKE AND PROSTATE CANCER: NO APPARENT ASSOCIATION, CANCER EPIDEMIOL BIOMARKERS PREV, 13, 12, PP. 2277-2279, (2004); STROM S.S., ET AL., PHYTOESTROGEN INTAKE AND PROSTATE CANCER: A CASE-CONTROL STUDY USING A NEW DATABASE, NUTR CANCER, 33, 1, PP. 20-25, (1999); MASKARINEC G., ET AL., SERUM PROSTATE-SPECIFIC ANTIGEN BUT NOT TESTOSTERONE LEVELS DECREASE IN A RANDOMIZED SOY INTERVENTION AMONG MEN, EUR J CLIN NUTR, (2006); MCCARTY M.F., ISOFLAVONES MADE SIMPLE-GENISTEIN'S AGONIST ACTIVITY FOR THE BETA-TYPE ESTROGEN RECEPTOR MEDIATES THEIR HEALTH BENEFITS, MED HYPOTHESES, 66, 6, PP. 1093-1114, (2006); COSTELLO L.C., ET AL., ZINC AND PROSTATE CANCER: A CRITICAL SCIENTIFIC, MEDICAL, AND PUBLIC INTEREST ISSUE (UNITED STATES), CANCER CAUSES CONTROL, 16, 8, PP. 901-915, (2005); MOYAD M.A., LIFESTYLE/DIETARY SUPPLEMENT PARTIAL ANDROGEN SUPPRESSION AND/OR ESTROGEN MANIPULATION. A NOVEL PSA REDUCER AND PREVENTIVE/TREATMENT OPTION FOR PROSTATE CANCER?, UROL CLIN NORTH AM, 29, 1, PP. 115-124, (2002); DHAR N.K., ET AL., DISTRIBUTION AND CONCENTRATION OF ZINC IN THE SUBCELLULAR FRACTIONS OF BENIGN HYPERPLASTIC AND MALIGNANT NEOPLASTIC HUMAN PROSTATE, EXP MOL PATHOL, 19, 2, PP. 139-142, (1973); KRISTAL A.R., ET AL., VITAMIN AND MINERAL SUPPLEMENT USE IS ASSOCIATED WITH REDUCED RISK OF PROSTATE CANCER, CANCER EPIDEMIOL BIOMARKERS PREV, 8, 10, PP. 887-892, (1999); KEY T.J., ET AL., A CASE-CONTROL STUDY OF DIET AND PROSTATE CANCER, BR J CANCER, 76, 5, PP. 678-687, (1997); WEST D.W., ET AL., ADULT DIETARY INTAKE AND PROSTATE CANCER RISK IN UTAH: A CASE-CONTROL STUDY WITH SPECIAL EMPHASIS ON AGGRESSIVE TUMORS, CANCER CAUSES CONTROL, 2, 2, PP. 85-94, (1991); ANDERSSON S.O., ET AL., ENERGY, NUTRIENT INTAKE AND PROSTATE CANCER RISK: A POPULATION-BASED CASE-CONTROL STUDY IN SWEDEN, INT J CANCER, 68, 6, PP. 716-722, (1996); LEITZMANN M.F., ET AL., ZINC SUPPLEMENT USE AND RISK OF PROSTATE CANCER, J NATL CANCER INST, 95, 13, PP. 1004-1007, (2003); KOLONEL L.N., YOSHIZAWA C.N., HANKIN J.H., DIET AND PROSTATIC CANCER: A CASE-CONTROL STUDY IN HAWAII, AM J EPIDEMIOL, 127, 5, PP. 999-1012, (1988); SPERLING H., ET AL., AN EXTRACT FROM THE BARK OF ASPIDOSPERMA QUEBRACHO BLANCO BINDS TO HUMAN PENILE ALPHA-ADRENOCEPTORS, J UROL, 168, 1, PP. 160-163, (2002); CHOI J., ET AL., ANTINOCICEPTIVE ANTI-INFLAMMATORY EFFECT OF MONOTROPEIN ISOLATED FROM THE ROOT OF MORINDA OFFICINALIS, BIOL PHARM BULL, 28, 10, PP. 1915-1918, (2005); DI ROCCO A., ET AL., A PILOT STUDY OF L-METHIONINE FOR THE TREATMENT OF AIDS-ASSOCIATED MYELOPATHY, NEUROLOGY, 51, 1, PP. 266-268, (1998); JAMES J.S., FREQUENT URINATION, LEG CRAMPS, LEG WEAKNESS, ERECTION DIFFICULTIES: HIV MYELOPATHY AMINO ACID STUDY, AIDS TREAT NEWS, 344, PP. 3-4, (2000); HITIRIS N., BARRETT J.A., BRODIE M.J., ERECTILE DYSFUNCTION ASSOCIATED WITH PREGABALIN ADD-ON TREATMENT IN PATIENTS WITH PARTIAL SEIZURES: FIVE CASE REPORTS, EPILEPSY BEHAV, 8, 2, PP. 418-421, (2006); HONG J.H., ET AL., THE EFFECTS OF CURCUMIN ON THE INVASIVENESS OF PROSTATE CANCER IN VITRO AND IN VIVO, PROSTATE CANCER PROSTATIC DIS, 9, 2, PP. 147-152, (2006); ZAMBLE A., ET AL., PAULLINIA PINNATA EXTRACTS RICH IN POLYPHENOLS PROMOTE VASCULAR RELAXATION VIA ENDOTHELIUM-DEPENDENT MECHANISMS, J CARDIOVASC PHARMACOL, 47, 4, PP. 599-608, (2006)","R. TAMLER; DIVISION OF ENDOCRINOLOGY, DIABETES AND BONE DISEASE, MOUNT SINAI SCHOOL OF MEDICINE, NEW YORK, NY 10029, 1 GUSTAVE L. LEVY PLACE, UNITED STATES; EMAIL: RONALD.TAMLER@MSSM.EDU","","ENGLISH","ENDOCRINOL. METAB. CLIN. NORTH AM.","REVIEW","ISI","2-S2.0-34249313343","ENDOCRINOL METAB CLIN NORTH AM","MOUNT SINAI SCHOOL OF MEDICINE;MOUNT SINAI SCHOOL OF MEDICINE","NOTREPORTED;MOUNT SINAI SCHOOL OF MEDICINE;NOTREPORTED",NA,"TAMLER R, 2007, ENDOCRINOL METAB CLIN NORTH AM","TAMLER R, 2007, ENDOCRINOL METAB CLIN NORTH AM"
"ANTOLÍN E;CANAVACIOLO V;PÉREZ R","ANTOLÍN, ERNESTO J. MÉNDEZ (6603378103); CANAVACIOLO, VÍCTOR L. GONZÁLEZ (18433666300); PÉREZ, ROXANA SIERRA (55439804300)","GAS CHROMATOGRAPHIC DETERMINATION OF HIGH MOLECULAR WEIGHT ALCOHOLS FROM POLICOSANOL IN OMEGA3 FISH OIL BY ACYLATION WITH ACETYL CHLORIDE",2008,"JOURNAL OF AOAC INTERNATIONAL","91","6",2,"10.1093/jaoac/91.5.1013","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA, PO BOX 6414, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA, PO BOX 6414, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA, PO BOX 6414, HAVANA CITY, CUBA","A NEW VALIDATED GAS CHROMATOGRAPHIC (GC) METHOD USING ACETYL CHLORIDE AS A DERIVATIZING AGENT FOR DETERMINING POLICOSANOL'S HIGH MOLECULAR WEIGHT ALCOHOLS (POLICOSANOL'S FATTY ALCOHOLS; PFAS) IN FISH OIL (FO) IS DESCRIBED. BEFORE DERIVATIZING THE ALCOHOLS, FO WAS SUBJECTED TO A METHYLATION REACTION, AND THEN THE PFAS WERE ISOLATED IN A CHLOROFORM FRACTION BY SILICA GEL BY COLUMN LIQUID CHROMATOGRAPHY. GC ANALYSIS WAS PERFORMED USING A BPX-5 WIDE-BORE COLUMN AND 1-EICOSANOL AS AN INTERNAL STANDARD. VALIDATION ASSAYS APPLIED TO THE METHOD PROVED NONINTERFERENCE BY A VERY COMPLEX MIXTURE OF THE FO WITH PFAS, EVEN FOR SAMPLES SUBJECTED TO STRESS CONDITIONS. GOOD LINEARITY [CORRELATION COEFFICIENT >0.999, RELATIVE STANDARD DEVIATION (RSD) OF THE SLOPE <1.3%, AND RSD OF THE RESPONSE FACTORS <1.9% WITH NO BIAS] AND ACCURACY (AVERAGE RECOVERY FROM 100.6 TO 102.2%) OVER A RANGE OF 28-142% OF THE NOMINAL CONCENTRATION WERE OBTAINED. WITHIN-DAY AND INTERMEDIATE PRECISIONS AT THE NOMINAL DOSE (100%) WERE 1.7 AND 2.9%, RESPECTIVELY. THE METHOD WAS SUCCESSFULLY USED TO IDENTIFY AND QUANTITATE THE PFAS IN FO.","","ALCOHOLS; ALKYLATION; CHLORINE COMPOUNDS; COLUMN CHROMATOGRAPHY; FISH; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; SILICA; SILICA GEL; COLUMN LIQUID CHROMATOGRAPHY; CORRELATION COEFFICIENT; GAS-CHROMATOGRAPHIC DETERMINATION; HIGH MOLECULAR WEIGHT; INTERNAL STANDARDS; METHYLATION REACTION; RELATIVE STANDARD DEVIATIONS; STRESS CONDITION; GAS CHROMATOGRAPHY","","","RAPP J., CONNOR W., LIN D., PORTER D., J. ARTERIOSCLER. THMMB, 4, PP. 11-15, (1991); FAHRER H., CLIN. EXP. RHEUMATOL, 9, PP. 403-406, (1991); ANEIROS E., MAS R., CALDERON B., CURR. THER. RES, 56, PP. 176-182, (1995); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., CLIN. PHARMACOL. THER, 65, PP. 439-447, (1999); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., CLIN. DRUG INVEST, 21, PP. 485-497, (2001); ARRUZAZABALA M., MOLINA V., MAS R., CLIN. EXP. PHARMACOL. PHYSIOL, 29, PP. 891-897, (2002); CASTANO G., MAS R., FERNANDEZ L., J. CLIN. PHARMACOL. RES, 21, PP. 43-58, (2001); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARVAJAL D., ALEMAN C., MOLINA V., M. J. CLIN. PHARMACOL. RES, 26, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., PHARMACOL. RES, 36, PP. 293-297, (1997); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., INT. J. TISSUE REACT, 20, PP. 119-124, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., CLIN. EXP. PHARMACOL. PHYSIOL, 29, PP. 891-897, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., MESA M., FERNANDEZ J., CLIN. DRUG. INVEST, 23, PP. 639-650, (2003); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., PROSTAGL. LEUKOT. ESSENT, 50, PP. 249-251, (1994); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., PHARMACOL. RES, 38, PP. 89-91, (1998); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., MESA M., FERNANDEZ J., DRUGS RD, 6, PP. 207-219, (2005); GAMEZ R., MAS R., ARRUZAZABALA M.L., MENDOZA S., CASTANO G., DRUGS RD, 6, PP. 11-19, (2005); CASTANO G., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARVAJAL D., MOLINA V., ILLNAIT J., MENDOZA S., GAMEZ R., MESA M., FERNANDEZ J., CURR. THEN RES, 67, PP. 174-192, (2006); GONZALEZ V., MAGRANER J., J. AOACINT, 82, PP. 834-839, (1999); GONZALEZ V., MAGRANER J., LAGUNA A., VELASQUEZ C., LORENZO M., REV. CENIC CIEN. QUÍM, 29, PP. 123-126, (1998); PIERCE A., SILYLATION OF ORGANIC COMPOUNDS, (1968); MIYAZAKI H., ISHIBASHI M., ITOH M., NAMBARA T., BIOMED. MASS SPECTROM, 4, PP. 23-24, (1977); WATSON D.G., GAS CHROMATOGRAPHY: A PRACTICAL APPROACH, PP. 133-170, (1993); MORRISON R., BOYD R., ORGANIC CHEMISTRY, (1970); NOVAK J., QUANTITATIVE ANALYSIS BY GAS CHROMATOGRAPHY, PART 6, PP. 79-135, (1988); HORWITZ W., J. ASSOC. OFF. ANAL. CHEM, 65, PP. 525-530, (1982)","E. J. M. ANTOLÍN; CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA, PO BOX 6414, HAVANA CITY, CUBA; EMAIL: EJMANTOLIN@YAHOO.ES","AOAC INTERNATIONAL","ENGLISH","J AOAC INT","ARTICLE","ISI","2-S2.0-55549116347","J AOAC INT","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"ANTOLÍN EJM, 2008, J AOAC INT","ANTOLÍN EJM, 2008, J AOAC INT"
"VIOLA F;OLIARO S;BINELLO A;CRAVOTTO G","VIOLA, FRANCA (7006847900); OLIARO, SIMONA (57193398217); BINELLO, ARIANNA (6603442129); CRAVOTTO, GIANCARLO (7003394420)","POLICOSANOL UPDATING AND PERSPECTIVES",2008,"MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM","1","6",12,"10.3233/s12349-008-0019-y","DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TURIN, TURIN, VIA P. GIURIA 9, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TURIN, TURIN, VIA P. GIURIA 9, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TURIN, TURIN, VIA P. GIURIA 9, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TURIN, TURIN, VIA P. GIURIA 9, ITALY","DIFFERENT MIXTURES OF HIGHER ALIPHATIC ALCOHOLS ARE ON THE MARKET UNDER THE NAME ""POLICOSANOL"" CLAIMING, WITHOUT THE SUPPORT OF INDEPENDENT DATA, THE THERAPEUTIC EFFICACY AND TOLERABILITY THAT FORMER STUDIES HAD DEMONSTRATED FOR THE ORIGINAL POLICOSANOL. THIS NAME ORIGINALLY REFERRED TO A MIXTURE OF EIGHT HIGHER ALIPHATIC PRIMARY ALCOHOLS OBTAINED AT THE BEGINNING OF THE 1990S FROM SUGAR-CANE WAX, AND PATENTED BY CUBAN RESEARCHERS FOR ITS ABILITY TO LOWER BLOOD CHOLESTEROL, AND ITS ANTIPLATELET AND ANTIOXIDANT PROPERTIES. ANALYSIS BY GC-MS SHOWS QUALITATIVE/ QUANTITATIVE DIFFERENCES IN POLICOSANOL-LIKE PREPARATIONS FROM DIFFERENT PLANT SOURCES AND ORIGINS. THE ANTICHOLESTEROLAEMIC ACTIVITY AND SOME DESIRABLE PLEIOTROPIC EFFECTS (DECREASED PLATELET AGGREGATION, LDL OXIDATION, THROMBOXANE PRODUCTION AND FOAM-CELL PRODUCTION) OF THE ORIGINAL POLICOSANOL HAVE BEEN CONFIRMED BY MORE THAN 50 CLINICAL STUDIES. HOWEVER THESE RESULTS HAVE RECENTLY BEEN QUESTIONED BY A FEW AUTHORS WHO HAVE REPORTED A MODEST OR NEGLIGIBLE ACTIVITY OF POLICOSANOL, WHETHER FROM SUGAR CANE OR FROM OTHER PLANT SOURCES. A REVIEW OF THIS IMPORTANT ISSUE IS THEREFORE IN ORDER. ALTHOUGH THE MECHANISM INVOLVED IN THE ANTICHOLESTEROLAEMIC EFFECT HAS NOT BEEN FULLY ELUCIDATED, THERE IS CLEAR EVIDENCE THAT POLICOSANOL INDUCES AMP KINASE PHOSPHORYLATION AND INHIBITS HMG-COA REDUCTASE. © 2008 SPRINGER-VERLAG 2008.","CLINICAL STUDIES; HIGH MOLECULAR WEIGHT ALCOHOLS; HYPOCHOLESTEROLAEMIC; POLICOSANOL","","","","HOUTZ R.L., RIES S.K., TOLBERT N.E., EFFECT OF TRIACONTANOL ON CHLAMYDOMONAS: I STIMULATION OF GROWTH AND PHOTOSYNTHETIC CO<SUB>2</SUB> ASSIMILATION, PLANT PHYSIOL, 79, PP. 357-364, (1985); LESNIAK A.P., HAUG A., RIES S.K., STIMULATION OF ATPASE IN BARLEY (HORDEUM VULGARE) ROOT PLASMA MEMBRANE AFTER TREATMENT OF INTACT TISSUES AND CELL FREE EXTRACTS WITH TRIACONTANOL, PHYSIOL PLANT, 68, PP. 20-26, (1986); MCBRIDE P.T., CLARK I., KRUEGER G.G., EVALUATION OF TRIACONTANOL-CONTAINING COMPOUNDS AS ANTI-INFLAMMATORY AGENTS USING GUINEA-PIG MODELS, J INVEST DERMATOL, 89, PP. 380-383, (1987); SAINT-JOHN M., MCNAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME AND CHEST AND GRIP STRENGTH, INT CLIN NUTR REV, 6, PP. 81-87, (1986); NORRIS F.H., DENYS E.H., FALLAT R.J., TRIAL OF OCTACOSANOL IN AMYOTROPHIC LATERAL SCLEROSIS, NEUROLOGY, 36, PP. 1263-1264, (1986); SHO H., CHINEN I., FUKUDA N., EFFECTS OF OKINAWAN SUGAR CANE WAX AND FATTY ALCOHOL ON SERUM AND LIVER LIPIDS IN THE RAT, J NUTR SCI VITAMIN, 30, PP. 553-559, (1984); SHIMURA S., HASEGAWA T., TAKANO S., SUZUKI T., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTR REP INTERN, 36, PP. 1029-1036, (1987); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARM RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 187-195, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEARS STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II, INT J CLIN PHARM RES, 15, PP. 159-165, (1995); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARM RES, 19, PP. 117-127, (1999); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED TO TYPE 2 DIABETES MELLITUS, INT J CLIN PHARM RES, 22, PP. 89-100, (2002); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, 61, PP. 346-357, (2000); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL 20 AND 40 MG/D IN HEALTHY VOLUNTEERS AND DYSLIPIDEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISS REACT, 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROLLOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., GAMEZ R., ET AL., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2003); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACO-EPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); GONZALEZ CANAVACIOLO V.L., MAGRANER HERNANDEZ J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN FIVE-MILLIGRAM FILM-COATED TABLETS, J AOAC INT, 82, PP. 834-839, (1999); SIERRA R., GONZALEZ V., MAGRANER J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINATION OF FATTY ALCOHOLS IN 10 MG FILM-COATED TABLETS OF POLICOSANOL, J AOAC INT, 85, PP. 563-566, (2002); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMGCOA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); PEPPING J., POLICOSANOL, AM J HEALTH SYST PHARM, 60, PP. 1112-1115, (2003); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); STUART M.J., GERRARD J.M., WHITE J.G., EFFECT OF CHOLESTEROL ON PRODUCTION OF THROMBOXANE B2 BY PLATELETS IN VITRO, NEW ENGL J MED, 302, PP. 6-10, (1980); LACOSTE L., JULES Y.T., ET AL., HYPERLIPIDEMIA AND CORONARY DISEASE, CIRCULATION, 92, PP. 3172-3177, (1995); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLINL NUTR, 84, PP. 1003-1008, (2006); KASSIS A.N., MARINANGELI C.P., JAIN D., ET AL., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, A RANDOMIZED CONTROLLED TRIAL. JAMA, 295, PP. 2262-2269, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., ET AL., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 982, PP. 982.E1-982.E5, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, PP. 207-219, (2005); CASTANO G., MAS R., FERNANDEZ L., ET AL., A COMPARISON OF THE EFFECT OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, PP. 31-44, (2005); WRIGHT C.M., ZIELKE J.C., WHAYNE T.F., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE: USE IN PATIENTS INTOLERANT OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INT J ANGIOL, 13, PP. 173-175, (2004); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS, A SINGLE-BLIND CLINICAL INVESTIGATION. ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND CREACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVESTIG, 25, PP. 701-707, (2005); IRMAK S., TURGUT N., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); BORG J., THE NEUROTROPHIC FACTOR, N-HEXACOSANOL, REDUCES THE NEURONAL DAMAGE INDUCED BY THE NEUROTOXIN, KAINIC ACID, J NEUROSCI RES, 29, PP. 62-67, (1991); AZZOUZ M., KENNEL P.F., WARTER J.M., ET AL., ENHANCEMENT OF MOUSE SCIATIC NERVE REGENERATION BY THE LONG CHAIN FATTY ALCOHOL N-HEXACOSANOL, EXP NEUROL, 138, PP. 189-197, (1996); MAS R., D-002, DRUGS FUTURE, 26, PP. 731-744, (2001); CARBAJAL D., MOLINA V., VALDES S., ET AL., ANTI-INFLAMMATORY ACTIVITY OF D-002: AN ACTIVE PRODUCT ISOLATED FROM BEESWAX, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 59, PP. 235-238, (1998); CARBAJAL D., MOLINA V., VALDES S., ET AL., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J PHARM PHARMACOL, 47, PP. 731-733, (1995); CARBAJAL D., MOLINA V., VALDES S., ET AL., POSSIBLE CYTOPROTECTIVE MECHANISM IN RATS OF D-002 AN ANTI-ULCEROGENIC PRODUCT ISOLATED FROM BEESWAX, J PHARM PHARMACOL, 48, PP. 858-860, (1996); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., INHIBITION OF RAT MICROSOMAL LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-002, BRAZ J MED BIOL RES, 33, PP. 85-90, (2000); MOLINA V., VALDES S., CARBAJAL D., ET AL., ANTIOXIDANT EFFECTS OF D-002 ON GASTRIC MUCOSA OF RATS WITH INJURY INDUCED EXPERIMENTALLY, J MED FOOD, 4, PP. 79-83, (2001); MENENDEZ R., ET AL., ANTIOXIDANT EFFECTS OF D-002 ON HEALTHY VOLUNTEERS, (1998); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTELFORSCHUNG, 55, PP. 312-317, (2005); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); LUO C.-M., SHU X.-M., MECHANISM OF ACTION AND CLINICAL RESEARCH OF POLICOSANOL, ZHONGGUO YAOWU YU LINCHUANG, 6, PP. 607-611, (2006); MAJEED M., PRAKASH L., JAYARAM J., A DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF POLICOSANOL VS, ATORVASTATIN IN THE TREATMENT OF HYPERLIPIDEMIA. NUTRACOS, 6, PP. 16-19, (2007); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, PP. 425-430, (1990); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); FERRER A., CAELLES C., MASSOT N., HEGARDT F.G., ACTIVATION OF RAT LIVER CYTOSOLIC 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE KINASE BY ADENOSINE 5-MONOPHOSPHATE, BIOCHEM BIOPHYS RES COMMUN, 132, PP. 497-504, (1985)","G. CRAVOTTO; DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITY OF TURIN, TURIN, VIA P. GIURIA 9, ITALY; EMAIL: GIANCARLO.CRAVOTTO@UNITO.IT","","ENGLISH","MEDITERR. J. NUTR. METAB.","ARTICLE","ISI","2-S2.0-85013615580","MEDITERR J NUTR METAB","UNIVERSITY OF TURIN;UNIVERSITY OF TURIN;UNIVERSITY OF TURIN;UNIVERSITY OF TURIN","NOTREPORTED;UNIVERSITY OF TURIN;NOTREPORTED",NA,"VIOLA F, 2008, MEDITERR J NUTR METAB","VIOLA F, 2008, MEDITERR J NUTR METAB"
"HUANG J;FROHLICH J;IGNASZEWSKI A","HUANG, JINGBO (52263695800); FROHLICH, JIRI (7101929228); IGNASZEWSKI, ANDREW P. (7003838049)","THE IMPACT OF DIETARY CHANGES AND DIETARY SUPPLEMENTS ON LIPID PROFILE",2011,"CANADIAN JOURNAL OF CARDIOLOGY","27","17",50,"10.1016/j.cjca.2010.12.077","HEALTHY HEART PROGRAM, ST. PAUL'S HOSPITAL, VANCOUVER, BC, BURRARD BUILDING 180-1081, CANADA;HEALTHY HEART PROGRAM, ST. PAUL'S HOSPITAL, VANCOUVER, BC, BURRARD BUILDING 180-1081, CANADA, PATHOLOGY AND LABORATORY MEDICINE, ST. PAUL'S HOSPITAL, VANCOUVER, BC, BURRARD BUILDING 180-1081, CANADA;HEALTHY HEART PROGRAM, ST. PAUL'S HOSPITAL, VANCOUVER, BC, BURRARD BUILDING 180-1081, CANADA, DEPARTMENT OF CARDIOLOGY, ST. PAUL'S HOSPITAL, VANCOUVER, BC, BURRARD BUILDING 180-1081, CANADA","WITH A GROWING NUMBER OF DIETARY INTERVENTIONS THAT CLAIM TO IMPROVE LIPID PROFILE, IT IS IMPORTANT TO ENSURE THAT THESE CLAIMS ARE EVIDENCE BASED. THE OBJECTIVE OF THIS STUDY WAS TO MAKE RECOMMENDATIONS FOR DIETARY REGIMENS BY ANALYZING THEIR EFFECTIVENESS AND THE LEVEL OF EVIDENCE. WE SEARCHED MEDLINE AS WELL AS THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS FOR NUTRITIONAL STUDIES. META-ANALYSES AND RANDOMIZED CONTROLLED TRIALS PUBLISHED IN ENGLISH AND INCLUDING DATA ON THE EFFECT ON BLOOD LIPID LEVELS WERE USED. RANDOMIZED CONTROLLED TRIALS WERE INCLUDED IF THEY WERE AT LEAST 4 WEEKS IN DURATION AND HAD A MINIMUM OF 50 PARTICIPANTS. WE IDENTIFIED 22 DIFFERENT DIETARY INTERVENTIONS AND REVIEWED 136 STUDIES PUBLISHED BETWEEN JANUARY 1990 AND DECEMBER 2009 THAT MET OUR INCLUSION CRITERIA. OUR LITERATURE REVIEW SHOWED THAT TO IMPROVE LIPID PROFILE, THE FOLLOWING REGIMENS CAN BE RECOMMENDED FULLY: MEDITERRANEAN AND PORTFOLIO DIETS; LOW-FAT DIET; DIET HIGH IN SOY PROTEIN, FIBRE, OR PHYTOSTEROLS; WHOLE GRAIN FOODS, AND OMEGA-3 FATTY ACID SUPPLEMENTATION. THE CONSUMPTION OF NUTS, A DIET HIGH IN CARBOHYDRATES AND PROTEIN, GREEN TEA, AND RED WINE, AS WELL AS THE SUPPLEMENTATION WITH POLICOSANOL AND RED YEAST RICE EXTRACT, CAN BE CONSIDERED FOR IMPROVEMENT OF THE LIPID PROFILE, WHILE THE SUPPLEMENTS OF GUGGULIPID, GARLIC, CHROMIUM, VITAMIN C, MAGNESIUM-PYRIDOXAL-PHOSPHATE-GLUTAMATE, TOCOTRIENOLS, AND ABSORBITOL CANNOT BE RECOMMENDED. © 2011 CANADIAN CARDIOVASCULAR SOCIETY.","","DIET; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; ALPHA TOCOTRIENOL; ASCORBIC ACID; CARBOHYDRATE; CHROMIUM; GLUTAMIC ACID DERIVATIVE; GUGGULSTERONE; ISOFLAVONE; LIPID; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PROTEIN; PYRIDOXAL PHOSPHATE GLUTAMATE MAGNESIUM; SOYBEAN PROTEIN; UNCLASSIFIED DRUG; XUEZHIKANG; CARBOHYDRATE DIET; COCHRANE LIBRARY; DIET; DIET SUPPLEMENTATION; DIET THERAPY; FIBER; GARLIC; GRAIN; HIGH FIBER DIET; HUMAN; LIPID BLOOD LEVEL; LOW FAT DIET; MEDITERRANEAN DIET; MEDLINE; META ANALYSIS; NUT; NUTRITION; OAT; PORTFOLIO DIET; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED WINE; REVIEW; SYSTEMATIC REVIEW; TEA","","","PETRELLA R.J., MERIKLE E., A RETROSPECTIVE ANALYSIS OF THE PREVALENCE AND TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN SOUTHWESTERN ONTARIO, CANADA, CLIN THER, 30, PP. 1145-1154, (2008); RAINE K.D., ADDRESSING POOR NUTRITION TO PROMOTE HEART HEALTH: MOVING UPSTREAM, CAN J CARDIOL, 26, SUPPL. C, (2010); GOFF D.C., BERTONI A.G., KRAMER H., ET AL., DYSLIPIDEMIA PREVALENCE, TREATMENT, AND CONTROL IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA): GENDER, ETHNICITY, AND CORONARY ARTERY CALCIUM, CIRCULATION, 113, PP. 647-656, (2006); THOMPSON P.D., CLARKSON P., KARAS R.H., STATIN-ASSOCIATED MYOPATHY, JAMA, 289, PP. 1681-1690, (2003); BECKER D.J., GORDON R.Y., MORRIS P.B., ET AL., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN PROC, 83, PP. 758-764, (2008); LEOPOLDO A.S., SUGIZAKI M.M., LIMA-LEOPOLDO A.P., ET AL., CARDIAC REMODELING IN A RAT MODEL OF DIET-INDUCED OBESITY, CAN J CARDIOL, 26, PP. 423-429, (2010); SPENCE J.D., JENKINS D.J., DAVIGNON J., DIETARY CHOLESTEROL AND EGG YOLKS: NOT FOR PATIENTS AT RISK OF VASCULAR DISEASE, CAN J CARDIOL, 26, (2010); SQUADRITO F., ALTAVILLA D., MORABITO N., ET AL., THE EFFECT OF THE PHYTOESTROGEN GENISTEIN ON PLASMA NITRIC OXIDE CONCENTRATIONS, ENDOTHELIN-1 LEVELS AND ENDOTHELIUM DEPENDENT VASODILATION IN POSTMENOPAUSAL WOMEN, ATHEROSCLEROSIS, 163, PP. 339-347, (2002); HALE G., PAUL-LABRADOR M., DWYER J.H., MERZ C.N., ISOFLAVONE SUPPLEMENTATION AND ENDOTHELIAL FUNCTION IN MENOPAUSAL WOMEN, CLIN ENDOCRINOL (OXF), 56, PP. 693-701, (2002); LI S.H., LIU X.X., BAI Y.Y., ET AL., EFFECT OF ORAL ISOFLAVONE SUPPLEMENTATION ON VASCULAR ENDOTHELIAL FUNCTION IN POSTMENOPAUSAL WOMEN: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS, AM J CLIN NUTR, 91, PP. 480-486, (2010); BAUM J.A., TENG H., ERDMAN J.W., ET AL., LONG-TERM INTAKE OF SOY PROTEIN IMPROVES BLOOD LIPID PROFILES AND INCREASES MONONUCLEAR CELL LOW-DENSITY-LIPOPROTEIN RECEPTOR MESSENGER RNA IN HYPERCHOLESTEROLEMIC, POSTMENOPAUSAL WOMEN, AM J CLIN NUTR, 68, PP. 545-551, (1998); CROUSE J.R., MORGAN T., TERRY J.G., ELLIS J., VITOLINS M., BURKE G.L., A RANDOMIZED TRIAL COMPARING THE EFFECT OF CASEIN WITH THAT OF SOY PROTEIN CONTAINING VARYING AMOUNTS OF ISOFLAVONES ON PLASMA CONCENTRATIONS OF LIPIDS AND LIPOPROTEINS, ARCH INTERN MED, 159, PP. 2070-2076, (1999); DALAIS F.S., EBELING P.R., KOTSOPOULOS D., MCGRATH B.P., TEEDE H.J., THE EFFECTS OF SOY PROTEIN CONTAINING ISOFLAVONES ON LIPIDS AND INDICES OF BONE RESORPTION IN POSTMENOPAUSAL WOMEN, CLIN ENDOCRINOL (OXF), 58, PP. 704-709, (2003); GARDNER C.D., NEWELL K.A., CHERIN R., HASKELL W.L., THE EFFECT OF SOY PROTEIN WITH OR WITHOUT ISOFLAVONES RELATIVE TO MILK PROTEIN ON PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, AM J CLIN NUTR, 73, PP. 728-735, (2001); HOIE L.H., MORGENSTERN E.C., GRUENWALD J., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL COMPARES THE CHOLESTEROL-LOWERING EFFECTS OF TWO DIFFERENT SOY PROTEIN PREPARATIONS IN HYPERCHOLESTEROLEMIC SUBJECTS, EUR J NUTR, 44, PP. 65-71, (2005); NESTEL P., CEHUN M., CHRONOPOULOS A., DASILVA L., TEEDE H., MCGRATH B., A BIOCHANIN-ENRICHED ISOFLAVONE FROM RED CLOVER LOWERS LDL CHOLESTEROL IN MEN, EUR J CLIN NUTR, 58, PP. 403-408, (2004); PUSKA P., KORPELAINEN V., HOIE L.H., SKOVLUND E., SMERUD K.T., ISOLATED SOYA PROTEIN WITH STANDARDISED LEVELS OF ISOFLAVONES, COTYLEDON SOYA FIBRES AND SOYA PHOSPHOLIPIDS IMPROVES PLASMA LIPIDS IN HYPERCHOLESTEROLAEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A YOGHURT FORMULATION, BR J NUTR, 91, PP. 393-401, (2004); TEEDE H.J., DALAIS F.S., KOTSOPOULOS D., LIANG Y.L., DAVIS S., MCGRATH B.P., DIETARY SOY HAS BOTH BENEFICIAL AND POTENTIALLY ADVERSE CARDIOVASCULAR EFFECTS: A PLACEBO-CONTROLLED STUDY IN MEN AND POSTMENOPAUSAL WOMEN, J CLIN ENDOCRINOL METAB, 86, PP. 3053-3060, (2001); WASHBURN S., BURKE G.L., MORGAN T., ANTHONY M., EFFECT OF SOY PROTEIN SUPPLEMENTATION ON SERUM LIPOPROTEINS, BLOOD PRESSURE, AND MENOPAUSAL SYMPTOMS IN PERIMENOPAUSAL WOMEN, MENOPAUSE, 6, PP. 7-13, (1999); WELTY F.K., LEE K.S., LEW N.S., ZHOU J.R., EFFECT OF SOY NUTS ON BLOOD PRESSURE AND LIPID LEVELS IN HYPERTENSIVE, PREHYPERTENSIVE, AND NORMOTENSIVE POSTMENOPAUSAL WOMEN, ARCH INTERN MED, 167, PP. 1060-1067, (2007); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); REYNOLDS K., CHIN A., LEES K.A., NGUYEN A., BUJNOWSKI D., HE J., A META-ANALYSIS OF THE EFFECT OF SOY PROTEIN SUPPLEMENTATION ON SERUM LIPIDS, AM J CARDIOL, 98, PP. 633-640, (2006); TAKU K., UMEGAKI K., SATO Y., TAKI Y., ENDOH K., WATANABE S., SOY ISOFLAVONES LOWER SERUM TOTAL AND LDL CHOLESTEROL IN HUMANS: A META-ANALYSIS OF 11 RANDOMIZED CONTROLLED TRIALS, AM J CLIN NUTR, 85, PP. 1148-1156, (2007); CORONARY HEART DISEASE IN SEVEN COUNTRIES. SUMMARY, CIRCULATION, 41, SUPPL., PP. 186-195, (1970); HALL W.L., VAFEIADOU K., HALLUND J., ET AL., SOY-ISOFLAVONE-ENRICHED FOODS AND MARKERS OF LIPID AND GLUCOSE METABOLISM IN POSTMENOPAUSAL WOMEN: INTERACTIONS WITH GENOTYPE AND EQUOL PRODUCTION, AM J CLIN NUTR, 83, PP. 592-600, (2006); HERMANSEN K., HANSEN B., JACOBSEN R., ET AL., EFFECTS OF SOY SUPPLEMENTATION ON BLOOD LIPIDS AND ARTERIAL FUNCTION IN HYPERCHOLESTEROLAEMIC SUBJECTS, EUR J CLIN NUTR, 59, PP. 843-850, (2005); HODGSON J.M., PUDDEY I.B., BEILIN L.J., MORI T.A., CROFT K.D., SUPPLEMENTATION WITH ISOFLAVONOID PHYTOESTROGENS DOES NOT ALTER SERUM LIPID CONCENTRATIONS: A RANDOMIZED CONTROLLED TRIAL IN HUMANS, J NUTR, 128, PP. 728-732, (1998); HOIE L.H., GRAUBAUM H.J., HARDE A., GRUENWALD J., WERNECKE K.D., LIPID-LOWERING EFFECT OF 2 DOSAGES OF A SOY PROTEIN SUPPLEMENT IN HYPERCHOLESTEROLEMIA, ADV THER, 22, PP. 175-186, (2005); KREIJKAMP-KASPERS S., KOK L., GROBBEE D.E., ET AL., EFFECT OF SOY PROTEIN CONTAINING ISOFLAVONES ON COGNITIVE FUNCTION, BONE MINERAL DENSITY, AND PLASMA LIPIDS IN POSTMENOPAUSAL WOMEN: A RANDOMIZED CONTROLLED TRIAL, JAMA, 292, PP. 65-74, (2004); MA Y., CHIRIBOGA D., OLENDZKI B.C., NICOLOSI R., MERRIAM P.A., OCKENE I.S., EFFECT OF SOY PROTEIN CONTAINING ISOFLAVONES ON BLOOD LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS: A RANDOMIZED CONTROLLED TRIAL, J AM COLL NUTR, 24, PP. 275-285, (2005); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); OLSON B.H., ANDERSON S.M., BECKER M.P., ET AL., PSYLLIUM-ENRICHED CEREALS LOWER BLOOD TOTAL CHOLESTEROL AND LDL CHOLESTEROL, BUT NOT HDL CHOLESTEROL, IN HYPERCHOLESTEROLEMIC ADULTS: RESULTS OF A META-ANALYSIS, J NUTR, 127, PP. 1973-1980, (1997); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., ET AL., EFFECTS OF DIETARY FIBRE INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK, J EPIDEMIOL COMMUNITY HEALTH, 63, PP. 582-588, (2009); DAVIDSON M.H., MAKI K.C., KONG J.C., ET AL., LONG-TERM EFFECTS OF CONSUMING FOODS CONTAINING PSYLLIUM SEED HUSK ON SERUM LIPIDS IN SUBJECTS WITH HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 67, PP. 367-376, (1998); HASKELL W.L., SPILLER G.A., JENSEN C.D., ELLIS B.K., GATES J.E., ROLE OF WATER-SOLUBLE DIETARY FIBER IN THE MANAGEMENT OF ELEVATED PLASMA CHOLESTEROL IN HEALTHY SUBJECTS, AM J CARDIOL, 69, PP. 433-439, (1992); JENKINS D.J., KENDALL C.W., VUKSAN V., ET AL., SOLUBLE FIBER INTAKE AT A DOSE APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR A CLAIM OF HEALTH BENEFITS: SERUM LIPID RISK FACTORS FOR CARDIOVASCULAR DISEASE ASSESSED IN A RANDOMIZED CONTROLLED CROSSOVER TRIAL, AM J CLIN NUTR, 75, PP. 834-839, (2002); JENSEN C.D., HASKELL W., WHITTAM J.H., LONG-TERM EFFECTS OF WATER-SOLUBLE DIETARY FIBER IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA IN HEALTHY MEN AND WOMEN, AM J CARDIOL, 79, PP. 34-37, (1997); MACMAHON M., CARLESS J., ISPAGHULA HUSK IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA: A DOUBLE-BLIND CONTROLLED STUDY, J CARDIOVASC RISK, 5, PP. 167-172, (1998); RODRIGUEZ-MORAN M., GUERRERO-ROMERO F., LAZCANO-BURCIAGA G., LIPID- AND GLUCOSE-LOWERING EFFICACY OF PLANTAGO PSYLLIUM IN TYPE II DIABETES, J DIABETES COMPLICATIONS, 12, PP. 273-278, (1998); SALAS-SALVADO J., FARRES X., LUQUE X., ET AL., EFFECT OF TWO DOSES OF A MIXTURE OF SOLUBLE FIBRES ON BODY WEIGHT AND METABOLIC VARIABLES IN OVERWEIGHT OR OBESE PATIENTS: A RANDOMISED TRIAL, BR J NUTR, 99, PP. 1380-1387, (2008); SPRECHER D.L., HARRIS B.V., GOLDBERG A.C., ET AL., EFFICACY OF PSYLLIUM IN REDUCING SERUM CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS ON HIGH- OR LOW-FAT DIETS, ANN INTERN MED, 119, PP. 545-554, (1993); TAI E.S., FOK A.C., CHU R., TAN C.E., A STUDY TO ASSESS THE EFFECT OF DIETARY SUPPLEMENTATION WITH SOLUBLE FIBRE (MINOLEST) ON LIPID LEVELS IN NORMAL SUBJECTS WITH HYPERCHOLESTEROLAEMIA, ANN ACAD MED SINGAPORE, 28, PP. 209-213, (1999); ZUNFT H.J., LUDER W., HARDE A., ET AL., CAROB PULP PREPARATION RICH IN INSOLUBLE FIBRE LOWERS TOTAL AND LDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS, EUR J NUTR, 42, PP. 235-242, (2003); CHRISTIANSEN L.I., LAHTEENMAKI P.L., MANNELIN M.R., SEPPANEN-LAAKSO T.E., HILTUNEN R.V., YLIRUUSI J.K., CHOLESTEROL-LOWERING EFFECT OF SPREADS ENRICHED WITH MICROCRYSTALLINE PLANT STEROLS IN HYPERCHOLESTEROLEMIC SUBJECTS, EUR J NUTR, 40, PP. 66-73, (2001); EARNEST C.P., MIKUS C.R., LEMIEUX I., ARSENAULT B.J., CHURCH T.S., EXAMINATION OF ENCAPSULATED PHYTOSTEROL ESTER SUPPLEMENTATION ON LIPID INDICES ASSOCIATED WITH CARDIOVASCULAR DISEASE, NUTRITION, 23, PP. 625-633, (2007); KORPELA R., TUOMILEHTO J., HOGSTROM P., ET AL., SAFETY ASPECTS AND CHOLESTEROL-LOWERING EFFICACY OF LOW FAT DAIRY PRODUCTS CONTAINING PLANT STEROLS, EUR J CLIN NUTR, 60, PP. 633-642, (2006); MAKI K.C., DAVIDSON M.H., UMPOROWICZ D.M., ET AL., LIPID RESPONSES TO PLANT-STEROL-ENRICHED REDUCED-FAT SPREADS INCORPORATED INTO A NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP I DIET, AM J CLIN NUTR, 74, PP. 33-43, (2001); MAKI K.C., SHINNICK F., SEELEY M.A., ET AL., FOOD PRODUCTS CONTAINING FREE TALL OIL-BASED PHYTOSTEROLS AND OAT BETA-GLUCAN LOWER SERUM TOTAL AND LDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC ADULTS, J NUTR, 133, PP. 808-813, (2003); TIKKANEN M.J., HOGSTROM P., TUOMILEHTO J., KEINANEN-KIUKAANNIEMI S., SUNDVALL J., KARPPANEN H., EFFECT OF A DIET BASED ON LOW-FAT FOODS ENRICHED WITH NONESTERIFIED PLANT STEROLS AND MINERAL NUTRIENTS ON SERUM CHOLESTEROL, AM J CARDIOL, 88, PP. 1157-1162, (2001); WESTSTRATE J.A., MEIJER G.W., PLANT STEROL-ENRICHED MARGARINES AND REDUCTION OF PLASMA TOTAL- AND LDL-CHOLESTEROL CONCENTRATIONS IN NORMOCHOLESTEROLAEMIC AND MILDLY HYPERCHOLESTEROLAEMIC SUBJECTS, EUR J CLIN NUTR, 52, PP. 334-343, (1998); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., ET AL., CONTINUOUS DOSE-RESPONSE RELATIONSHIP OF THE LDL-CHOLESTEROL-LOWERING EFFECT OF PHYTOSTEROL INTAKE, J NUTR, 139, PP. 271-284, (2009); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); KELLY S.A., SUMMERBELL C.D., BRYNES A., WHITTAKER V., FROST G., WHOLEGRAIN CEREALS FOR CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, 2, (2007); KEENAN J.M., WENZ J.B., MYERS S., RIPSIN C., HUANG Z.Q., RANDOMIZED, CONTROLLED, CROSSOVER TRIAL OF OAT BRAN IN HYPERCHOLESTEROLEMIC SUBJECTS, J FAM PRACT, 33, PP. 600-608, (1991); ONNING G., WALLMARK A., PERSSON M., AKESSON B., ELMSTAHL S., OSTE R., CONSUMPTION OF OAT MILK FOR 5 WEEKS LOWERS SERUM CHOLESTEROL AND LDL CHOLESTEROL IN FREE-LIVING MEN WITH MODERATE HYPERCHOLESTEROLEMIA, ANN NUTR METAB, 43, PP. 301-309, (1999); WIEN M.A., SABATE J.M., IKLE D.N., COLE S.E., KANDEEL F.R., ALMONDS VS COMPLEX CARBOHYDRATES IN A WEIGHT REDUCTION PROGRAM, INT J OBES RELAT METAB DISORD, 27, PP. 1365-1372, (2003); ZAMBON D., SABATE J., MUNOZ S., ET AL., SUBSTITUTING WALNUTS FOR MONOUNSATURATED FAT IMPROVES THE SERUM LIPID PROFILE OF HYPERCHOLESTEROLEMIC MEN AND WOMEN: A RANDOMIZED CROSSOVER TRIAL, ANN INTERN MED, 132, PP. 538-546, (2000); HSU C.H., TSAI T.H., KAO Y.H., HWANG K.C., TSENG T.Y., CHOU P., EFFECT OF GREEN TEA EXTRACT ON OBESE WOMEN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, CLIN NUTR, 27, PP. 363-370, (2008); HANSEN A.S., MARCKMANN P., DRAGSTED L.O., FINNE NIELSEN I.L., NIELSEN S.E., GRONBAEK M., EFFECT OF RED WINE AND RED GRAPE EXTRACT ON BLOOD LIPIDS, HAEMOSTATIC FACTORS, AND OTHER RISK FACTORS FOR CARDIOVASCULAR DISEASE, EUR J CLIN NUTR, 59, PP. 449-455, (2005); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); HOWELL W.H., MCNAMARA D.J., TOSCA M.A., SMITH B.T., GAINES J.A., PLASMA LIPID AND LIPOPROTEIN RESPONSES TO DIETARY FAT AND CHOLESTEROL: A META-ANALYSIS, AM J CLIN NUTR, 65, PP. 1747-1764, (1997); TANG J.L., ARMITAGE J.M., LANCASTER T., SILAGY C.A., FOWLER G.H., NEIL H.A., SYSTEMATIC REVIEW OF DIETARY INTERVENTION TRIALS TO LOWER BLOOD TOTAL CHOLESTEROL IN FREE-LIVING SUBJECTS, BMJ, 316, PP. 1213-1220, (1998); YU-POTH S., ZHAO G., ETHERTON T., NAGLAK M., JONNALAGADDA S., KRIS-ETHERTON P.M., EFFECTS OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM'S STEP I AND STEP II DIETARY INTERVENTION PROGRAMS ON CARDIOVASCULAR DISEASE RISK FACTORS: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 632-646, (1999); ANDERSON J.W., DIET, LIPIDS AND CARDIOVASCULAR DISEASE IN WOMEN, J AM COLL NUTR, 12, PP. 433-437, (1993); AQUILANI R., TRAMARIN R., PEDRETTI R.F., ET AL., DESPITE GOOD COMPLIANCE, VERY LOW FAT DIET ALONE DOES NOT ACHIEVE RECOMMENDED CHOLESTEROL GOALS IN OUTPATIENTS WITH CORONARY HEART DISEASE, EUR HEART J, 20, PP. 1020-1029, (1999); DAVIDSON M.H., KONG J.C., DRENNAN K.B., STORY K., ANDERSON G.H., EFFICACY OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP I DIET: A RANDOMIZED TRIAL INCORPORATING QUICK-SERVICE FOODS, ARCH INTERN MED, 156, PP. 305-312, (1996); GARDNER C.D., COULSTON A., CHATTERJEE L., RIGBY A., SPILLER G., FARQUHAR J.W., THE EFFECT OF A PLANT-BASED DIET ON PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC ADULTS: A RANDOMIZED TRIAL, ANN INTERN MED, 142, PP. 725-733, (2005); GINSBERG H.N., KRIS-ETHERTON P., DENNIS B., ET AL., EFFECTS OF REDUCING DIETARY SATURATED FATTY ACIDS ON PLASMA LIPIDS AND LIPOPROTEINS IN HEALTHY SUBJECTS: THE DELTA STUDY, PROTOCOL 1, ARTERIOSCLER THROMB VASC BIOL, 18, PP. 441-449, (1998); HELLENIUS M.L., DE FAIRE U., BERGLUND B., HAMSTEN A., KRAKAU I., DIET AND EXERCISE ARE EQUALLY EFFECTIVE IN REDUCING RISK FOR CARDIOVASCULAR DISEASE: RESULTS OF A RANDOMIZED CONTROLLED STUDY IN MEN WITH SLIGHTLY TO MODERATELY RAISED CARDIOVASCULAR RISK FACTORS, ATHEROSCLEROSIS, 103, PP. 81-91, (1993); HUNNINGHAKE D.B., STEIN E.A., DUJOVNE C.A., ET AL., THE EFFICACY OF INTENSIVE DIETARY THERAPY ALONE OR COMBINED WITH LOVASTATIN IN OUTPATIENTS WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 328, PP. 1213-1219, (1993); INSULL W., SILVERS A., HICKS L., PROBSTFIELD J.L., PLASMA LIPID EFFECTS OF THREE COMMON VEGETABLE OILS IN REDUCED-FAT DIETS OF FREE-LIVING ADULTS, AM J CLIN NUTR, 60, PP. 195-202, (1994); KNOPP R.H., WALDEN C.E., RETZLAFF B.M., ET AL., LONG-TERM CHOLESTEROL-LOWERING EFFECTS OF 4 FAT-RESTRICTED DIETS IN HYPERCHOLESTEROLEMIC AND COMBINED HYPERLIPIDEMIC MEN: THE DIETARY ALTERNATIVES STUDY, JAMA, 278, PP. 1509-1515, (1997); MCCARRON D.A., OPARIL S., CHAIT A., ET AL., NUTRITIONAL MANAGEMENT OF CARDIOVASCULAR RISK FACTORS. A RANDOMIZED CLINICAL TRIAL, ARCH INTERN MED, 157, PP. 169-177, (1997); RETZLAFF B.M., WALDEN C.E., DOWDY A.A., MCCANN B.S., ANDERSON K.V., KNOPP R.H., CHANGES IN PLASMA TRIACYLGLYCEROL CONCENTRATIONS AMONG FREE-LIVING HYPERLIPIDEMIC MEN ADOPTING DIFFERENT CARBOHYDRATE INTAKES OVER 2 Y: THE DIETARY ALTERNATIVES STUDY, AM J CLIN NUTR, 62, PP. 988-995, (1995); SARKKINEN E.S., UUSITUPA M.I., PIETINEN P., ET AL., LONG-TERM EFFECTS OF THREE FAT-MODIFIED DIETS IN HYPERCHOLESTEROLEMIC SUBJECTS, ATHEROSCLEROSIS, 105, PP. 9-23, (1994); WALDEN C.E., RETZLAFF B.M., BUCK B.L., MCCANN B.S., KNOPP R.H., LIPOPROTEIN LIPID RESPONSE TO THE NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP II DIET BY HYPERCHOLESTEROLEMIC AND COMBINED HYPERLIPIDEMIC WOMEN AND MEN, ARTERIOSCLER THROMB VASC BIOL, 17, PP. 375-382, (1997); FARNSWORTH E., LUSCOMBE N.D., NOAKES M., WITTERT G., ARGYIOU E., CLIFTON P.M., EFFECT OF A HIGH-PROTEIN, ENERGY-RESTRICTED DIET ON BODY COMPOSITION, GLYCEMIC CONTROL, AND LIPID CONCENTRATIONS IN OVERWEIGHT AND OBESE HYPERINSULINEMIC MEN AND WOMEN, AM J CLIN NUTR, 78, PP. 31-39, (2003); SWAIN J.F., MCCARRON P.B., HAMILTON E.F., SACKS F.M., APPEL L.J., CHARACTERISTICS OF THE DIET PATTERNS TESTED IN THE OPTIMAL MACRONUTRIENT INTAKE TRIAL TO PREVENT HEART DISEASE (OMNIHEART): OPTIONS FOR A HEART-HEALTHY DIET, J AM DIET ASSOC, 108, PP. 257-265, (2008); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., ET AL., EFFECTS OF A MEDITERRANEAN-STYLE DIET ON CARDIOVASCULAR RISK FACTORS: A RANDOMIZED TRIAL, ANN INTERN MED, 145, PP. 1-11, (2006); ESPOSITO K., MARFELLA R., CIOTOLA M., ET AL., EFFECT OF A MEDITERRANEAN-STYLE DIET ON ENDOTHELIAL DYSFUNCTION AND MARKERS OF VASCULAR INFLAMMATION IN THE METABOLIC SYNDROME: A RANDOMIZED TRIAL, JAMA, 292, PP. 1440-1446, (2004); JULA A., MARNIEMI J., HUUPPONEN R., VIRTANEN A., RASTAS M., RONNEMAA T., EFFECTS OF DIET AND SIMVASTATIN ON SERUM LIPIDS, INSULIN, AND ANTIOXIDANTS IN HYPERCHOLESTEROLEMIC MEN: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, PP. 598-605, (2002); PEREZ-JIMENEZ F., LOPEZ-MIRANDA J., PINILLOS M.D., ET AL., A MEDITERRANEAN AND A HIGH-CARBOHYDRATE DIET IMPROVE GLUCOSE METABOLISM IN HEALTHY YOUNG PERSONS, DIABETOLOGIA, 44, PP. 2038-2043, (2001); VINCENT-BAUDRY S., DEFOORT C., GERBER M., ET AL., THE MEDI-RIVAGE STUDY: REDUCTION OF CARDIOVASCULAR DISEASE RISK FACTORS AFTER A 3-MO INTERVENTION WITH A MEDITERRANEAN-TYPE DIET OR A LOW-FAT DIET, AM J CLIN NUTR, 82, PP. 964-971, (2005); PAPADAKI A., SCOTT J.A., FOLLOW-UP OF A WEB-BASED TAILORED INTERVENTION PROMOTING THE MEDITERRANEAN DIET IN SCOTLAND, PATIENT EDUC COUNS, 73, PP. 256-263, (2008); SOFI F., ABBATE R., GENSINI G.F., CASINI A., EVIDENCES ON THE RELATIONSHIP BETWEEN MEDITERRANEAN DIET AND HEALTH STATUS, RECENTI PROG MED, 100, PP. 127-131, (2009); DE LORGERIL M., SALEN P., MARTIN J.L., MONJAUD I., DELAYE J., MAMELLE N., MEDITERRANEAN DIET, TRADITIONAL RISK FACTORS, AND THE RATE OF CARDIOVASCULAR COMPLICATIONS AFTER MYOCARDIAL INFARCTION: FINAL REPORT OF THE LYON DIET HEART STUDY, CIRCULATION, 99, PP. 779-785, (1999); JENKINS D.J., KENDALL C.W., FAULKNER D.A., ET AL., ASSESSMENT OF THE LONGER-TERM EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS IN HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 83, PP. 582-591, (2006); LUKACZER D., LISKA D.J., LERMAN R.H., ET AL., EFFECT OF A LOW GLYCEMIC INDEX DIET WITH SOY PROTEIN AND PHYTOSTEROLS ON CVD RISK FACTORS IN POSTMENOPAUSAL WOMEN, NUTRITION, 22, PP. 104-113, (2006); BUCHER H.C., HENGSTLER P., SCHINDLER C., MEIER G., N-3 POLYUNSATURATED FATTY ACIDS IN CORONARY HEART DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 112, PP. 298-304, (2002); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); DAVIDSON M.H., STEIN E.A., BAYS H.E., ET AL., EFFICACY AND TOLERABILITY OF ADDING PRESCRIPTION OMEGA-3 FATTY ACIDS 4 G/D TO SIMVASTATIN 40 MG/D IN HYPERTRIGLYCERIDEMIC PATIENTS: AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CLIN THER, 29, PP. 1354-1367, (2007); LARKIN T.A., ASTHEIMER L.B., PRICE W.E., DIETARY COMBINATION OF SOY WITH A PROBIOTIC OR PREBIOTIC FOOD SIGNIFICANTLY REDUCES TOTAL AND LDL CHOLESTEROL IN MILDLY HYPERCHOLESTEROLAEMIC SUBJECTS, EUR J CLIN NUTR, 63, PP. 238-245, (2009); LOVEGROVE J.A., LOVEGROVE S.S., LESAUVAGE S.V., ET AL., MODERATE FISH-OIL SUPPLEMENTATION REVERSES LOW-PLATELET, LONG-CHAIN N-3 POLYUNSATURATED FATTY ACID STATUS AND REDUCES PLASMA TRIACYLGLYCEROL CONCENTRATIONS IN BRITISH INDO-ASIANS, AM J CLIN NUTR, 79, PP. 974-982, (2004); NOONE E.J., ROCHE H.M., NUGENT A.P., GIBNEY M.J., THE EFFECT OF DIETARY SUPPLEMENTATION USING ISOMERIC BLENDS OF CONJUGATED LINOLEIC ACID ON LIPID METABOLISM IN HEALTHY HUMAN SUBJECTS, BR J NUTR, 88, PP. 243-251, (2002); SAITO Y., YOKOYAMA M., ORIGASA H., ET AL., EFFECTS OF EPA ON CORONARY ARTERY DISEASE IN HYPERCHOLESTEROLEMIC PATIENTS WITH MULTIPLE RISK FACTORS: SUB-ANALYSIS OF PRIMARY PREVENTION CASES FROM THE JAPAN EPA LIPID INTERVENTION STUDY (JELIS), ATHEROSCLEROSIS, 200, PP. 135-140, (2008); SINGH R.B., NIAZ M.A., SHARMA J.P., KUMAR R., RASTOGI V., MOSHIRI M., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF FISH OIL AND MUSTARD OIL IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL INFARCTION: THE INDIAN EXPERIMENT OF INFARCT SURVIVAL--4, CARDIOVASC DRUGS THER, 11, PP. 485-491, (1997); SVENSSON M., SCHMIDT E.B., JORGENSEN K.A., CHRISTENSEN J.H., THE EFFECT OF N-3 FATTY ACIDS ON LIPIDS AND LIPOPROTEINS IN PATIENTS TREATED WITH CHRONIC HAEMODIALYSIS: A RANDOMIZED PLACEBO-CONTROLLED INTERVENTION STUDY, NEPHROL DIAL TRANSPLANT, 23, PP. 2918-2924, (2008); TOFT I., BONAA K.H., INGEBRETSEN O.C., NORDOY A., JENSSEN T., EFFECTS OF N-3 POLYUNSATURATED FATTY ACIDS ON GLUCOSE HOMEOSTASIS AND BLOOD PRESSURE IN ESSENTIAL HYPERTENSION: A RANDOMIZED, CONTROLLED TRIAL, ANN INTERN MED, 123, PP. 911-918, (1995); WOODMAN R.J., MORI T.A., BURKE V., PUDDEY I.B., WATTS G.F., BEILIN L.J., EFFECTS OF PURIFIED EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS ON GLYCEMIC CONTROL, BLOOD PRESSURE, AND SERUM LIPIDS IN TYPE 2 DIABETIC PATIENTS WITH TREATED HYPERTENSION, AM J CLIN NUTR, 76, PP. 1007-1015, (2002); BEMELMANS W.J., BROER J., FESKENS E.J., ET AL., EFFECT OF AN INCREASED INTAKE OF ALPHA-LINOLENIC ACID AND GROUP NUTRITIONAL EDUCATION ON CARDIOVASCULAR RISK FACTORS: THE MEDITERRANEAN ALPHA-LINOLENIC ENRICHED GRONINGEN DIETARY INTERVENTION (MARGARIN) STUDY, AM J CLIN NUTR, 75, PP. 221-227, (2002); HARPER C.R., EDWARDS M.C., JACOBSON T.A., FLAXSEED OIL SUPPLEMENTATION DOES NOT AFFECT PLASMA LIPOPROTEIN CONCENTRATION OR PARTICLE SIZE IN HUMAN SUBJECTS, J NUTR, 136, PP. 2844-2848, (2006); KAUL N., KREML R., AUSTRIA J.A., ET AL., A COMPARISON OF FISH OIL, FLAXSEED OIL AND HEMPSEED OIL SUPPLEMENTATION ON SELECTED PARAMETERS OF CARDIOVASCULAR HEALTH IN HEALTHY VOLUNTEERS, J AM COLL NUTR, 27, PP. 51-58, (2008); VON SCHACKY C., ANGERER P., KOTHNY W., THEISEN K., MUDRA H., THE EFFECT OF DIETARY OMEGA-3 FATTY ACIDS ON CORONARY ATHEROSCLEROSIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ANN INTERN MED, 130, PP. 554-562, (1999); LEAF A., JORGENSEN M.B., JACOBS A.K., ET AL., DO FISH OILS PREVENT RESTENOSIS AFTER CORONARY ANGIOPLASTY?, CIRCULATION, 90, PP. 2248-2257, (1994); WANG C., HARRIS W.S., CHUNG M., ET AL., N-3 FATTY ACIDS FROM FISH OR FISH-OIL SUPPLEMENTS, BUT NOT ALPHA-LINOLENIC ACID, BENEFIT CARDIOVASCULAR DISEASE OUTCOMES IN PRIMARY- AND SECONDARY-PREVENTION STUDIES: A SYSTEMATIC REVIEW, AM J CLIN NUTR, 84, PP. 5-17, (2006); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); FERNANDEZ L., ILLNAIT J., FERNANDEZ J., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); SINGH R.B., NIAZ M.A., GHOSH S., HYPOLIPIDEMIC AND ANTIOXIDANT EFFECTS OF COMMIPHORA MUKUL AS AN ADJUNCT TO DIETARY THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CARDIOVASC DRUGS THER, 8, PP. 659-664, (1994); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); GARDNER C.D., CHATTERJEE L.M., CARLSON J.J., THE EFFECT OF A GARLIC PREPARATION ON PLASMA LIPID LEVELS IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS, ATHEROSCLEROSIS, 154, PP. 213-220, (2001); ISAACSOHN J.L., MOSER M., STEIN E.A., ET AL., GARLIC POWDER AND PLASMA LIPIDS AND LIPOPROTEINS: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, ARCH INTERN MED, 158, PP. 1189-1194, (1998); NEIL H.A., SILAGY C.A., LANCASTER T., ET AL., GARLIC POWDER IN THE TREATMENT OF MODERATE HYPERLIPIDAEMIA: A CONTROLLED TRIAL AND META-ANALYSIS, J R COLL PHYSICIANS LOND, 30, PP. 329-334, (1996); SATITVIPAWEE P., RAWDAREE P., INDRABHAKTI S., RATANASUWAN T., GETN-GERN P., VIWATWONGKASEM C., NO EFFECT OF GARLIC EXTRACT SUPPLEMENT ON SERUM LIPID LEVELS IN HYPERCHOLESTEROLEMIC SUBJECTS, J MED ASSOC THAI, 86, PP. 750-757, (2003); SUPERKO H.R., KRAUSS R.M., GARLIC POWDER, EFFECT ON PLASMA LIPIDS, POSTPRANDIAL LIPEMIA, LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, HIGH-DENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION AND LIPOPROTEIN(A), J AM COLL CARDIOL, 35, PP. 321-326, (2000); TANAMAI J., VEERAMANOMAI S., INDRAKOSAS N., THE EFFICACY OF CHOLESTEROL-LOWERING ACTION AND SIDE EFFECTS OF GARLIC ENTERIC COATED TABLETS IN MAN, J MED ASSOC THAI, 87, PP. 1156-1161, (2004); ZHANG L., GAIL M.H., WANG Y.Q., ET AL., A RANDOMIZED FACTORIAL STUDY OF THE EFFECTS OF LONG-TERM GARLIC AND MICRONUTRIENT SUPPLEMENTATION AND OF 2-WK ANTIBIOTIC TREATMENT FOR HELICOBACTER PYLORI INFECTION ON SERUM CHOLESTEROL AND LIPOPROTEINS, AM J CLIN NUTR, 84, PP. 912-919, (2006); REINHART K.M., TALATI R., WHITE C.M., COLEMAN C.I., THE IMPACT OF GARLIC ON LIPID PARAMETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR RES REV, 22, PP. 39-48, (2009); SILAGY C., NEIL A., GARLIC AS A LIPID LOWERING AGENT: A META-ANALYSIS, J R COLL PHYSICIANS LOND, 28, PP. 39-45, (1994); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN INTERN MED, 133, PP. 420-429, (2000); WARSHAFSKY S., KAMER R.S., SIVAK S.L., EFFECT OF GARLIC ON TOTAL SERUM CHOLESTEROL: A META-ANALYSIS, ANN INTERN MED, 119, PP. 599-605, (1993); ROEBACK J.R., HLA K.M., CHAMBLESS L.E., FLETCHER R.H., EFFECTS OF CHROMIUM SUPPLEMENTATION ON SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN MEN TAKING BETA-BLOCKERS: A RANDOMIZED, CONTROLLED TRIAL, ANN INTERN MED, 115, PP. 917-924, (1991); HAJJAR I.M., GEORGE V., SASSE E.A., KOCHAR M.S., A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF VITAMIN C IN THE MANAGEMENT OF HYPERTENSION AND LIPIDS, AM J THER, 9, PP. 289-293, (2002); KIM M.K., SASAKI S., SASAZUKI S., OKUBO S., HAYASHI M., TSUGANE S., LONG-TERM VITAMIN C SUPPLEMENTATION HAS NO MARKEDLY FAVOURABLE EFFECT ON SERUM LIPIDS IN MIDDLE-AGED JAPANESE SUBJECTS, BR J NUTR, 91, PP. 81-90, (2004); ENGLISCH W., BECKERS C., UNKAUF M., RUEPP M., ZINSERLING V., EFFICACY OF ARTICHOKE DRY EXTRACT IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ARZNEIMITTELFORSCHUNG, 50, PP. 260-265, (2000); SCHUITEMAKER G.E., VAN DER POL G.A., ARETZ C.P., DINANT G.J., A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMISED TRIAL OF MAGNESIUM-PYRIDOXAL-5'-PHOSPHATE-GLUTAMATE FOR HYPERCHOLESTEROLAEMIA AND OTHER CLINICAL-CHEMICAL RISK FACTORS OF CARDIOVASCULAR DISEASE IN A PRIMARY CARE SETTING, EUR J CLIN PHARMACOL, 56, PP. 857-863, (2001); MUSTAD V.A., SMITH C.A., RUEY P.P., EDENS N.K., DEMICHELE S.J., SUPPLEMENTATION WITH 3 COMPOSITIONALLY DIFFERENT TOCOTRIENOL SUPPLEMENTS DOES NOT IMPROVE CARDIOVASCULAR DISEASE RISK FACTORS IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 76, PP. 1237-1243, (2002); HO S.C., TAI E.S., ENG P.H., TAN C.E., FOK A.C., IN THE ABSENCE OF DIETARY SURVEILLANCE, CHITOSAN DOES NOT REDUCE PLASMA LIPIDS OR OBESITY IN HYPERCHOLESTEROLAEMIC OBESE ASIAN SUBJECTS, SINGAPORE MED J, 42, PP. 6-10, (2001); TRICOCI P., ALLEN J.M., KRAMER J.M., CALIFF R.M., SMITH S.C., SCIENTIFIC EVIDENCE UNDERLYING THE ACC/AHA CLINICAL PRACTICE GUIDELINES, JAMA, 301, PP. 831-841, (2009); KRIS-ETHERTON P., ECKEL R.H., HOWARD B.V., ST JEOR S., BAZZARRE T.L., AHA SCIENCE ADVISORY: LYON DIET HEART STUDY. BENEFITS OF A MEDITERRANEAN-STYLE, NATIONAL CHOLESTEROL EDUCATION PROGRAM/AMERICAN HEART ASSOCIATION STEP I DIETARY PATTERN ON CARDIOVASCULAR DISEASE, CIRCULATION, 103, PP. 1823-1825, (2001); JENKINS D.J., KENDALL C.W., AXELSEN M., AUGUSTIN L.S., VUKSAN V., VISCOUS AND NONVISCOUS FIBRES, NONABSORBABLE AND LOW GLYCAEMIC INDEX CARBOHYDRATES, BLOOD LIPIDS AND CORONARY HEART DISEASE, CURR OPIN LIPIDOL, 11, PP. 49-56, (2000); GARG A., HIGH-MONOUNSATURATED-FAT DIETS FOR PATIENTS WITH DIABETES MELLITUS: A META-ANALYSIS, AM J CLIN NUTR, 67, (1998); MICHALSEN A., LEHMANN N., PITHAN C., ET AL., MEDITERRANEAN DIET HAS NO EFFECT ON MARKERS OF INFLAMMATION AND METABOLIC RISK FACTORS IN PATIENTS WITH CORONARY ARTERY DISEASE, EUR J CLIN NUTR, 60, PP. 478-485, (2006); BOWDEN R.G., JITOMIR J., WILSON R.L., GENTILE M., EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON LIPID LEVELS IN ENDSTAGE RENAL DISEASE PATIENTS, J REN NUTR, 19, PP. 259-266, (2009); MAKI K.C., VAN ELSWYK M.E., MCCARTHY D., ET AL., LIPID RESPONSES TO A DIETARY DOCOSAHEXAENOIC ACID SUPPLEMENT IN MEN AND WOMEN WITH BELOW AVERAGE LEVELS OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL, J AM COLL NUTR, 24, PP. 189-199, (2005); DODIN S., LEMAY A., JACQUES H., LEGARE F., FOREST J.C., MASSE B., THE EFFECTS OF FLAXSEED DIETARY SUPPLEMENT ON LIPID PROFILE, BONE MINERAL DENSITY, AND SYMPTOMS IN MENOPAUSAL WOMEN: A RANDOMIZED, DOUBLE-BLIND, WHEAT GERM PLACEBO-CONTROLLED CLINICAL TRIAL, J CLIN ENDOCRINOL METAB, 90, PP. 1390-1397, (2005); RISERUS U., ARNER P., BRISMAR K., VESSBY B., TREATMENT WITH DIETARY TRANS10CIS12 CONJUGATED LINOLEIC ACID CAUSES ISOMER-SPECIFIC INSULIN RESISTANCE IN OBESE MEN WITH THE METABOLIC SYNDROME, DIABETES CARE, 25, PP. 1516-1521, (2002); JOHANSEN O., BREKKE M., SELJEFLOT I., ABDELNOOR M., ARNESEN H., N-3 FATTY ACIDS DO NOT PREVENT RESTENOSIS AFTER CORONARY ANGIOPLASTY: RESULTS FROM THE CART STUDY. CORONARY ANGIOPLASTY RESTENOSIS TRIAL, J AM COLL CARDIOL, 33, PP. 1619-1626, (1999); BAIRATI I., ROY L., MEYER F., DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL OF FISH OIL SUPPLEMENTS IN PREVENTION OF RECURRENCE OF STENOSIS AFTER CORONARY ANGIOPLASTY, CIRCULATION, 85, PP. 950-956, (1992)","A.P. IGNASZEWSKI; HEALTHY HEART PROGRAM, ST. PAUL'S HOSPITAL, VANCOUVER, BC V6Z 1Y6, BURRARD BUILDING 180-1081, CANADA; EMAIL: AIGNASZEWSKI@PROVIDENCEHEALTH.BC.CA","","ENGLISH","CAN. J. CARDIOL.","REVIEW","ISI","2-S2.0-80052183845","CAN J CARDIOL","ST. PAUL'S HOSPITAL;ST. PAUL'S HOSPITAL;ST. PAUL'S HOSPITAL","NOTREPORTED;ST. PAUL'S HOSPITAL;EMAIL: AIGNASZEWSKI@PROVIDENCEHEALTH.BC.CA",NA,"HUANG J, 2011, CAN J CARDIOL","HUANG J, 2011, CAN J CARDIOL"
"CICERO A;DEROSA G;BOVE M;GRANDI E;ULIASSI E;BORGHI C;GADDI A","CICERO, ARRIGO F.G. (7003403707); DEROSA, GIUSEPPE (7005336159); BOVE, MARILISA (22633562800); GRANDI, ELISA (57200427087); ULIASSI, ELISA (57195044659); BORGHI, CLAUDIO (7102731762); GADDI, ANTONIO V. (55257759400)","A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLAEMIA IN PATIENTS PREVIOUSLY INTOLERANT OF MORE THAN A STATIN A PILOT STUDY",2008,"MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM","1","3",4,"10.3233/s12349-008-0005-4","‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY;DEPARTMENT OF INTERNAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PAVIA, PAVIA, ITALY;‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY;‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY;‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY;‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY;‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY","THIS STUDY WAS AIMED AT EVALUATING THE TOLERABILITY OF A NUTRACEUTICAL COMBINATION WITH ANTICHOLESTEROLAEMIC ACTION IN PATIENTS INTOLERANT OF STATIN TREATMENT. A TOTAL OF 32 HYPERCHOLESTEROLAEMIC PATIENTS, ALL INTOLERANT TO AT LEAST TWO STATIN TREATMENTS, WERE ENROLLED IN THE AMBULATORY SERVICE. NONE OF THE ENROLLED PATIENTS WAS DIABETIC OR UNDERGOING SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE. PATIENTS CONSUMED ONE YOGHURT WITH 2 G OF ADDED PHYTOSTEROLS EACH MORNING (PRO-ACTIV, UNILEVER, MILAN, ITALY) AND ONE TABLET OF A REGISTERED COMBINED NUTRACEUTICAL (ARMOLIPID PLUS, ROTTAPHARM, MONZA, ITALY). WE TESTED THE EFFICACY OF THE TREATMENT AFTER 4 AND 6 MONTHS. ONE TABLET OF ARMOLIPID PLUS CONTAINS: BERBERINE 500 MG, MONACOLIN 3 MG, AND POLICOSANOL 10 MG. AFTER 3 MONTHS OF TREATMENT THE PATIENTS SHOWED A SIGNIFICANT DECREASE IN TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDES, AND A SIGNIFICANT INCREASE IN THE PLASMA LEVEL OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL. THESE RESULTS WERE MAINTAINED AFTER 6 MONTHS OF TREATMENT WITHOUT A SIGNIFICANT CHANGE IN THE MEAN VALUES. © 2008 SPRINGER-VERLAG 2008.","BERBERINE; HYPERCHOLESTEROLEMIA; NUTRACEUTICALS; PHYTOSTEROLS; STATIN INTOLERANCE","","","","THAVENDIRANATHAN P., BAGAI A., BROOKHART M.A., CHOUDHRY N.K., PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES WITH STATIN THERAPY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCH INTERN MED, 166, 21, PP. 2307-2313, (2006); SMITH JR S.C., ALLEN J., BLAIR S.N., BONOW R.O., BRASS L.M., FONAROW G.C., GRUNDY S.M., HIRATZKA L., JONES D., KRUMHOLZ H.M., MOSCA L., PASTERNAK R.C., PEARSON T., PFEFFER M.A., TAUBERT K.A., AHA/ACC GUIDELINES FOR SECONDARY PREVENTION FOR PATIENTS WITH CORONARY AND OTHER ATHEROSCLEROTIC VASCULAR DISEASE: 2006 UPDATE: ENDORSED BY THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, CIRCULATION, 113, PP. 2363-2372, (2006); POLUZZI E., STRAHINJA P., VACCHERI A., VARGIU A., SILVANI M.C., MOTOLA D., MARCHESINI G., DE PONTI F., MONTANARO N., ADHERENCE TO CHRONIC CARDIOVASCULAR THERAPIES: PERSISTENCE OVER THE YEARS AND DOSE COVERAGE, BR J CLIN PHARMACOL, 63, 3, PP. 346-355, (2007); MCKENNEY J.M., AN ASSESSMENT OF STATIN SAFETY, 12, PP. S310-S317, (2006); ANFOSSI G., MASSUCCO P., BONOMO K., TROVATI M., PRESCRIPTION OF STATINS TO DYSLIPIDEMIC PATIENTS AFFECTED BY LIVER DISEASES: A SUBTLE BALANCE BETWEEN RISKS AND BENEFITS, NUTR METAB CARDIOVASC DIS, 14, 4, PP. 215-224, (2004); VLADUTIU G.D., SIMMONS Z., ISACKSON P.J., TARNOPOLSKY M., PELTIER W.L., BARBOI A.C., SRIPATHI N., WORTMANN R.L., PHILLIPS P.S., GENETIC RISK FACTORS ASSOCIATED WITH LIPID-LOWERING DRUG-INDUCED MYOPATHIES, MUSCLE NERVE, 34, 2, PP. 153-162, (2006); DASKALOPOULOU S.S., MIKHAILIDIS D.P., REACHING GOAL IN HYPERCHOLESTEROLAEMIA: DUAL INHIBITION OF CHOLESTEROL SYNTHESIS AND ABSORPTION WITH SIMVASTATIN PLUS EZETIMIBE, CURR MED RES OPIN, 22, 3, PP. 511-528, (2006); KJEKSHUS J., APETREI E., BARRIOS V., BOHM M., CLELAND J.G., CORNEL J.H., DUNSELMAN P., FONSECA C., GOUDEV A., GRANDE P., GULLESTAD L., HJALMARSON A., HRADEC J., JANOSI A., KAMENSKY G., KOMAJDA M., KOREWICKI J., KUUSI T., MACH F., MAREEV V., MCMURRAY J.J., RANJITH N., SCHAUFELBERGER M., VANHAECKE J., VAN VELDHUISEN D.J., WAAGSTEIN F., WEDEL H., WIKSTRAND J., ROSUVASTATIN IN OLDER PATIENTS WITH SYSTOLIC HEART FAILURE, N ENGL J MED, 357, 22, PP. 2248-2261, (2007); IN BRIEF: ZETIA AND VYTORIN: THE ENHANCE STUDY, MED LETT DRUGS THER, 50, 1278, (2008); WANNER C., KRANE V., LESSONS LEARNT FROM THE 4D TRIAL, NEPHROL THER, 2, 1, PP. 3-7, (2006); CICERO A.F.G., DEROSA G., GADDI A., WHAT HERBALISTS SUGGEST TO OUR DIABETIC PATIENTS IN ORDER TO IMPROVE THEIR GLYCAEMIC CONTROL? EVALUATION OF SCIENTIFIC EVIDENCES AND POTENTIAL RISKS, ACTA DIABETOL, 41, 3, PP. 91-98, (2004); CICERO A.F.G., GADDI A.V., BORGHI C., COMPLEMENTARY MEDICINE FOR HYPERTENSION: WHAT EVIDENCE FOR HERBALISTS SUGGESTION? EVALUATION OF RISKS AND POTENTIAL APPLICATIONS, EVID BASED INTEGRATIVE MED, 2, 1, PP. 47-55, (2005); CICERO A.F.G., LINARELLO S., NASCETTI S., GADDI A., SCIENTIFIC LEVEL EVIDENCE OF SUGGESTIONS GIVEN BY 685 ITALIAN HERBALISTS FOR THE DYSLIPIDEMIAS TREATMENT BOOK OF ABSTRACTS. XVI CONGRESSO NAZIONALE SISA, NUTR METAB CARDIOVASC DIS, 12, 4, (2002); WARNICK G.R., BENDERSON J., ALBERS J.J., DEXTRAN SULFATE-MG2+ PRECIPITATION PROCEDURE FOR QUANTITATION OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL, CLIN CHEM, 28, PP. 1379-1388, (1982); A DESKTOP GUIDE TO TYPE 2 DIABETES MELLITUS, DIAB MED, 16, PP. 716-730, (1999); NORMAN G.R., STREINER D.L., BIOSTATISTICS: THE BARE ESSENTIALS, PP. 139-144, (2000); CARON M.F., WHITE C.M., EVALUATION OF THE ANTIHYPERLIPIDEMIC PROPERTIES OF DIETARY SUPPLEMENTS, PHARMACOTHERAPY, 21, 4, PP. 481-487, (2001); CICERO A.F.G., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEM THER MED, 13, PP. 273-278, (2005); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, 12, PP. 1344-1351, (2004); CICERO A.F.G., ROVATI L., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS IN HUMANS, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); PRASAD G.V., WONG T., MELITON G., BHALOO S., RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, 8, PP. 1200-1201, (2002); PACKARD C.J., EVOLUTION OF THE HMG COA REDUCTASE INHIBITORS (STATINS) IN CARDIOVASCULAR MEDICINE, BR J CARDIOL, 11, 2, PP. 129-136, (2004); EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90 056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005)","A.F.G. CICERO; ‘G.C. DESCOVICH’ ATHEROSCLEROSIS STUDY CENTER, ‘D. CAMPANACCI’ CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, S. ORSOLA-MALPIGHI HOSPITAL, UNIVERSITY OF BOLOGNA, BOLOGNA, 40138, VIA MASSARENTI 9, ITALY; EMAIL: AFGCICERO@CARDIONET.IT","","ENGLISH","MEDITERR. J. NUTR. METAB.","ARTICLE","ISI","2-S2.0-81255160815","MEDITERR J NUTR METAB","UNIVERSITY OF BOLOGNA;UNIVERSITY OF PAVIA;UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA;UNIVERSITY OF BOLOGNA","NOTREPORTED;UNIVERSITY OF BOLOGNA;NOTREPORTED",NA,"CICERO AFG, 2008, MEDITERR J NUTR METAB","CICERO AFG, 2008, MEDITERR J NUTR METAB-a"
"YERA A;CUEVAS V;DESPAIGNE S;SÁNCHEZ D;FERREIRO R","YERA, AMBAR OYARZÁBAL (36020873200); CUEVAS, VIVIAN MOLINA (7006062814); DESPAIGNE, SONIA JIMÉNEZ (36096505400); SÁNCHEZ, DAYISELL CURVECO (35216100700); FERREIRO, ROSA MAS (6602148780)","EFFECT OF POLYCOSANOL A GRAPE SEED EXTRACT AND ITS COMBINED THERAPY ON OXIDATION MARKERS IN RATS EFECTOS DEL POLICOSANOL EL EXTRACTO DE SEMILLAS DE UVA Y SU TERAPIA COMBINADA SOBRE MARCADORES OXIDATIVOS EN RATAS",2010,"REVISTA CUBANA DE FARMACIA","44","9",3,"","CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), ATABEY, MUNICIPIO PLAYA, LA HABANA, CALLE 198 ENTRE 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), ATABEY, MUNICIPIO PLAYA, LA HABANA, CALLE 198 ENTRE 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), ATABEY, MUNICIPIO PLAYA, LA HABANA, CALLE 198 ENTRE 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), ATABEY, MUNICIPIO PLAYA, LA HABANA, CALLE 198 ENTRE 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), ATABEY, MUNICIPIO PLAYA, LA HABANA, CALLE 198 ENTRE 19 Y 21, CUBA","THE POLYCOSANOL, A MIXTURE OF SUPERIOR PRIMARY ALIPHATIC ALCOHOLS OBTEINED FROM THE SUGARCANE WAX (SACHARUM OFFICINARUM, L.) AND THE GRAPE SEEDS EXTRACT (VITIS VINÍFERA, L.) PRODUCES ANTIOXIDANT EFFECTS EXPERIMENTALLY AND CLINICALLY DEMONSTRATED. THE AIM OF PRESENT PAPER WAS TO COMPARE THE EFFECTS OF POLYCOSANOL, THE GRAPE SEED EXTRACT, AND ITS COMBINED THERAPY ON OXIDATIVE MARKERS IN PLASMA AND LIVER OF RATS. THE RATS WERE DISTRIBUTED INTO 4 GROUPS: A CONTROL ONE AND THREE TREATED WITH POLYCOSANOL, GRAPE SEED EXTRACT AND ITS COMBINED THERAPY, RESPECTIVELY, USING A 25 MG/KG DOSE OVER 4 WEEKS. THE SINGLE-THERAPIES SIGNIFICANTLY REDUCED THE PLASMATIC CONCENTRATIONS OF MALONYLDIALDEHYDE AND OF PROETIN-ASSOCIATED CARBONYL GROUPS REGARDING THE CONTROL, SHOWING A SIMILAR EFFICACY. COMBINED THERAPY REDUCED IN A MORE EFFECTIVE WAY (P < 0,001) THE MALONYLDIALDEHYDE CONCENTRATIONS OF CARBONYL GROUPS, AND ALSO DECREASED (P < 0,01) THE CONCENTRATIONS OF CARBONYL GROUPS, BUT NO MORE THAN THE SINGLE-THERAPIES. EACH SINGLE-THERAPY REDUCED THE MALONYLDIALDEHYDE CONCENTRATIONS GENERATED BY SPONTANEOUS OXIDANT SYSTEM IN LIVER HOMOGENATE. THE EFFECT OF COMBINED THERAPY WAS HIGHER (P < 0,05) THAN THE GRAPE SEED EXTRACT, BUT NO MORE THAN THAT OF POLYCOSANOL. WE CONCLUDED THAT ORAL SINGLE-THERAPIES USING POLYCOSANOL AND GRAPE SEED EXTRACT, ADMINISTERED DURING 4 WEEKS, DECREASED IN A SIMILAR WAY, THE LIPID PEROXIDATION IN PLASMA AND LIVER OF RATS. COMBINED THERAPY WAS MORE EFFECTIVE TO INHIBITS THE LIPID PEROXIDATION IN PLASMA THAN EACH SINGLE-THERAPY, SEPARATELY.","ANTIOXIDANTS; CARBONYL GROUPS; GRAPE SEED EXTRACT; MALONYLDIALDEHYDE; POLICOSANOL","ALCOHOL DERIVATIVE; CARBONYL DERIVATIVE; GRAPE SEED EXTRACT; MALONALDEHYDE; POLYCOSANOL; UNCLASSIFIED DRUG; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; LIPID PEROXIDATION; LIVER HOMOGENATE; LIVER LEVEL; NONHUMAN; OXIDATION; RAT; SINGLE DRUG DOSE; SUGARCANE; TREATMENT DURATION","","","FINKEL T., KOLBROOK N.J., OXIDANTS, OXIDATIVE STRESS AND BIOLOGY OF AGEING, NATURE., 408, PP. 239-241, (2000); VAYA J., AVIRAM M., NUTRITIONAL ANTIOXIDANTS: MECHANISMS OF ACTION, ANALYSES OF ACTIVITIES AND MEDICAL APPLICATIONS, CURRENT MED CHEM, 1, PP. 99-117, (2001); YOUNG I.S., MC ENENY J., LIPOPROTEIN OXIDATION AND ATHEROSCLEROSIS, BIOCHEM SOC TRANSACTIONS, 29, PART 2, PP. 358-362, (2001); BIRUKOV K.G., OXIDIZED LIPIDS: THE TWO FACES OF VASCULAR INFLAMMATION, CURRENT ATHEROSCLEROSIS REPORTS, 8, PP. 222-231, (2006); BJELAKOVIC G., NIKOLOVA D., GLUUD L.L., SIMONETTI R.G., GLUUD C., JAMA, 297, PP. 842-857, (2007); BLEYS J., MILLER E.R., BARRIUSO P.R., APPEL L.J., GUALLAR E., AM J CLIN NUTR, 84, PP. 880-887, (2006); FRAGA V., MENENDEZ R., AMOR A.M., MAS R., GONZALEZ R.M., JIMENEZ S., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOLOGY AND BEHAVIOR, 67, 1, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT J CLIN PHARMACOL, 50, PP. 255-262, (2000); PEREZ Y., MAS R., GONZALEZ R.M., JIMENEZ S., MOLINA V., EFFECTS OF D-003 A MIXTURE OF VERY LONG CHAÍN SATURATED FATTY ACIDS AND POLICOSANOL ON IN VIVO LIPID PEROXIDATION IN RATS, ARZNEIM FORSCH DRUG RES, PP. 58126-58130, (2008); OHTA Y., OHASHI K., MATSURA T., TOKUNAGA K., KITAGAWA A., YAMADA K., OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE, J CLIN BIOCHEM NUTR, 42, PP. 118-125, (2008); SHI J., YU J., POHORLY J.E., KAKUDA Y., POLYPHENOLICS IN GRAPE SEEDS-BIOCHEMISTRY AND FUNCTIONALITY, J MED FOOD, 6, PP. 291-299, (2003); RABABAH T.M., HETTIARACHCHY N.S., HORAX R., TOTAL PHENOLICS AND ANTIOXIDANT ACTIVITIES OF FENUGREEK, GREEN TEA, BLACK TEA, GRAPE SEED, GINGER, ROSEMARY, GOTU KOLA, AND GINKGO EXTRACTS, VITAMIN E, AND TERT-BUTYLHYDROQUINONE, J AGRIC FOOD CHEM, 52, PP. 5183-5186, (2004); BUSSEROLLES J., GUEUX E., BALASINSKA B., PIRIOU Y., ROCK E., RAYSSIGUIER Y., ET AL., IN VIVO ANTIOXIDANT ACTIVITY OF PROCYANIDIN-RICH EXTRACTS FROM GRAPE SEED AND PINE (PINUS MARITIMA) BARK IN RATS, INT J VITAM NUTR RES, 76, PP. 22-27, (2006); BALU M., SANGEETHA P., MURALI G., PANNEERSELVAM C., AGE-RELATED OXIDATIVE PROTEIN DAMAGES IN CENTRAL NERVOUS SYSTEM OF RATS: MODULATORY ROLE OF GRAPE SEED EXTRACT, INT J DEV NEUROSCI, 23, PP. 501-507, (2005); DEVI A., JOLITHA A.B., ISHII N., GRAPE SEED PROANTHOCYANIDIN EXTRACT (GSPE) AND ANTIOXIDANT DEFENSE IN THE BRAIN OF ADULT RATS, MED SCI MONIT, 12, (2006); DU Y., GUO H., LOU H., GRAPE SEED POLYPHENOLS PROTECT CARDIAC CELLS FROM APOPTOSIS VIA INDUCTION OF ENDOGENOUS ANTIOXIDANT ENZYMES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 5, PP. 1695-1701, (2007); NUTTALL SL., KENDALL MJ., BOMBARDELLI E., MORAZZONI P., AN EVALUATION OF THE ANTIOXIDANT ACTIVITY OF A STANDARDIZED GRAPE SEED EXTRACT, LEUCOSELECT, J CLIN PHARM THER, 23, PP. 323-325, (1998); OHKAWA H., OHISHI N., YAGI K., ASSAY FOR LIPID PEROXIDES IN ANIMAL TISSUES BY THIOBARBITURIC ACID REACTION, ANALYTICAL BIOCHEMISTRY, 95, 2, PP. 351-358, (1979); REZNICK A.Z., PACKER L., OXIDATIVE DAMAGE TO PROTEINS: SPECTROPHOTOMETRIC METHOD FOR CARBONYL ASSAY, METHODS IN ENZYMOLOGY, (1994); MARXWELL M.A., HAAS S.M., BEIBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-209, (1987); RUSSO A., ACQUAVIVA R., CAMPISI A., SORRENTI V., DI GIACOMO C., VIRGATA G., BARCELLONA M.L., VANELLA A., BIOFLAVONOIDS AS ANTIRADICALS, ANTIOXIDANTS AND DNA CLEAVAGE PROTECTORS, CELL BIOLOGY AND TOXICOLOGY, 16, 2, PP. 91-98, (2000); FERRANDIZ M.L., ALCARAZ M.J., ANTI-INFLAMMATORY ACTIVITY AND INHIBITION OF ARACHIDONIC ACID METABOLISM BY FLAVONOIDS, AGENTS ACTIONS, 32, PP. 283-288, (1991); LINDAHL M., TAGESSON C., FLAVONOIDS AS PHOSPHOLIPASE A<SUB>2</SUB> INHIBITORS: IMPORTANCE OF THEIR STRUCTURE FOR SELECTIVE INHIBITION OF GROUP II PHOSPHOLIPASE A<SUB>2</SUB>, INFLAMMATION, 21, 3, PP. 347-356, (1997); SUDHEESH S., SANDHYA C., KOSHY A.S., VIJAYALAKSHMI N.R., ANTIOXIDANT ACTIVITY OF FLAVONOIDS FROM SOLANUM MELONGENA, PHYTOTHERAPY RESEARCH, 13, 5, PP. 393-396, (1999); PEREZ Y., MOLINA V., MAS R., GONZALEZ R.M., JIMENEZ S., A COMPARISON OF IN VIVO EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT SUGARCANE WAX ACIDS, AND GRAPE SEED EXTRACT ON LIPID PEROXIDATION MARKERS IN RATS, LAJP, 27, PP. 498-504, (2008)","A. O. YERA; CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS (CNIC), ATABEY, MUNICIPIO PLAYA, LA HABANA, CALLE 198 ENTRE 19 Y 21, CUBA; EMAIL: CPN@CNIC.EDU.CU","","SPANISH","REV. CUBA. FARM.","ARTICLE","ISI","2-S2.0-78650184967","REV CUBA FARM","CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES;CENTRO DE PRODUCTOS NATURALES","NOTREPORTED;CENTRO DE PRODUCTOS NATURALES;NOTREPORTED",NA,"YERA AO, 2010, REV CUBA FARM","YERA AO, 2010, REV CUBA FARM"
"KASSIS A;JONES P","KASSIS, AMIRA N. (12800588300); JONES, PETER J.H. (36078426500)","CHANGES IN CHOLESTEROL KINETICS FOLLOWING SUGAR CANE POLICOSANOL SUPPLEMENTATION A RANDOMIZED CONTROL TRIAL",2008,"LIPIDS IN HEALTH AND DISEASE","7","",11,"10.1186/1476-511X-7-17","SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, MONTRÉAL, QC H9X 3V9, CANADA;RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, UNIVERSITY OF MANITOBA, SMARTPARK, WINNIPEG, MB R3T 6C5, CANADA","BACKGROUND. SUGAR CANE POLICOSANOLS (SCP) HAVE BEEN SHOWN TO EXERT CHOLESTEROL-MODULATING PROPERTIES IN VARIOUS STUDIES CONDUCTED IN CUBA BY SUBSTANTIALLY REDUCING CHOLESTEROL SYNTHESIS. INDEPENDENT RESEARCH EXAMINING CHANGES IN CHOLESTEROL KINETICS IN RESPONSE TO SCP IS LIMITED TO FEW STUDIES, NONE OF WHICH WAS ABLE TO REPLICATE FINDINGS OF THE ORIGINAL RESEARCH. MOREOVER, NO DATA ARE AVAILABLE ON THE EFFECT OF SCP ON CHOLESTEROL ABSORPTION TO DATE. THE PRESENT STUDY WAS UNDERTAKEN TO DETERMINE EFFECTS ON CHOLESTEROL KINETICS, NAMELY SYNTHESIS AND ABSORPTION, WITHIN HYPERCHOLESTEROLEMIC INDIVIDUALS CONSUMING A SCP TREATMENT. TWENTY-ONE OTHERWISE HEALTHY HYPERCHOLESTEROLEMIC SUBJECTS PARTICIPATED IN A RANDOMIZED DOUBLE-BLIND CROSSOVER STUDY WHERE THEY RECEIVED 10 MG/DAY OF POLICOSANOLS OR A PLACEBO INCORPORATED IN MARGARINE AS AN EVENING SNACK FOR A PERIOD OF 28 DAYS. THE LAST WEEK OF THE STUDY PHASE, SUBJECTS WERE GIVEN 13C LABELLED CHOLESTEROL AND DEUTERATED WATER FOR THE MEASUREMENT OF CHOLESTEROL ABSORPTION AND SYNTHESIS RESPECTIVELY. BLOOD WAS COLLECTED ON THE FIRST TWO AND LAST FIVE DAYS OF THE TRIAL. CHOLESTEROL ABSORPTION AND SYNTHESIS WERE DETERMINED BY MEASURING RED CELL CHOLESTEROL 13C AND DEUTERIUM ENRICHMENT, RESPECTIVELY. RESULTS. THERE WAS NO SIGNIFICANT CHANGE IN LDL CHOLESTEROL LEVELS AS COMPARED TO CONTROL. IN ADDITION, THE AREA UNDER THE CURVE FOR RED CELL CHOLESTEROL 13C ENRICHMENT ACROSS 96 HOURS WAS NOT SIGNIFICANTLY DIFFERENT IN THE SCP GROUP AS COMPARED TO CONTROL. SIMILARLY, NO DIFFERENCE WAS OBSERVED IN THE FRACTIONAL RATE OF CHOLESTEROL SYNTHESIS OVER THE PERIOD OF 24 HOURS BETWEEN THE TWO TREATMENT GROUPS. CONCLUSION. THE FINDINGS OF THE PRESENT STUDY FAIL TO SUPPORT PREVIOUS RESEARCH CONCERNING EFFICACY AND MECHANISM OF ACTION FOR POLICOSANOLS. © 2008 KASSIS AND JONES; LICENSEE BIOMED CENTRAL LTD.","","ADULT; AGED; AGED, 80 AND OVER; CARBOHYDRATES; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ERYTHROCYTES; FATTY ALCOHOLS; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; PLACEBOS; SACCHARUM; CARBON 13; CHOLESTEROL; DEUTERIUM OXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; PLACEBO; POLICOSANOL; CARBOHYDRATE; CHOLESTEROL; FATTY ALCOHOL; POLICOSANOL; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ABSORPTION; MALE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; CHEMISTRY; ERYTHROCYTE; KINETICS; METABOLISM; MIDDLE AGED","","","","P. J. H. JONES; RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, UNIVERSITY OF MANITOBA, SMARTPARK, WINNIPEG, MB R3T 6C5, CANADA; EMAIL: PETER_JONES@UMANITOBA.CA","","ENGLISH","LIPIDS HEALTH DIS.","ARTICLE","ISI","2-S2.0-44049098057","LIPIDS HEALTH DIS","MCGILL UNIVERSITY;UNIVERSITY OF MANITOBA","NOTREPORTED;UNIVERSITY OF MANITOBA;NOTREPORTED",NA,"KASSIS AN, 2008, LIPIDS HEALTH DIS","KASSIS AN, 2008, LIPIDS HEALTH DIS"
"OHTA Y;OHASHI K;MATSURA T;TOKUNAGA K;KITAGAWA A;YAMADA K","OHTA, YOSHIJI (7403675651); OHASHI, KOJI (22958395200); MATSURA, TATSUYA (7004105754); TOKUNAGA, KENJI (57198247143); KITAGAWA, AKIRA (7101668860); YAMADA, KAZUO (57207381061)","OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE",2008,"JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION","42","7",51,"10.3164/jcbn.2008017","DEPARTMENT OF CHEMISTRY, FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE, TOYOAKE, AICHI 470-1192, JAPAN;DEPARTMENT OF CLINICAL BIOCHEMISTRY, SCHOOL OF HEALTH SCIENCES, FUJITA HEALTH UNIVERSITY, TOYOAKE, AICHI 470-1192, JAPAN;DIVISION OF MEDICAL BIOCHEMISTRY, DEPARTMENT OF PATHOPHYSIOLOGICAL AND THERAPEUTIC SCIENCE, TOTORRI UNIVERSITY FACULTY OF MEDICINE, YONAGO, TOTTORI 683-8503, JAPAN;DEPARTMENT OF CLINICAL MEDICAL TECHNOLOGY, KAGAWA PREFECTURAL COLLEGE OF HEALTH SCIENCE, MURE-CHO, KAGAWA 761-0123, JAPAN;DEPARTMENT OF NUTRITION, FACULTY OF WELLNESS, CHUKYO WOMEN'S UNIVERSITY, OHBU, AICHI 474-8651, JAPAN;DIVISION OF MEDICAL BIOCHEMISTRY, DEPARTMENT OF PATHOPHYSIOLOGICAL AND THERAPEUTIC SCIENCE, TOTORRI UNIVERSITY FACULTY OF MEDICINE, YONAGO, TOTTORI 683-8503, JAPAN","WE EXAMINED WHETHER OCTACOSANOL, THE MAIN COMPONENT OF POLICOSANOL, ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN RATS INTOXICATED WITH CARBON TETRACHLORIDE (CCL4). IN RATS INTOXICATED WITH CCL4 (1 ML/KG, I.P.). THE ACTIVITIES OF SERUM TRANSAMINASES INCREASED 6 H AFTER INTOXICATION AND FURTHER INCREASED AT 24 H. IN THE LIVER OF CCL4-INTOXICATED RATS, INCREASES IN LIPID PEROXIDE (LPO) CONCENTRATION AND MYELOPEROXIDASE ACTIVITY AND DECREASES IN SUPEROXIXDE DISMUTASE ACTIVITY AND REDUCED GLUTATHIONE (GSH) CONCENTRATION OCCURRED 6 H AFTER INTOXICATION AND THESE CHANGES WERE ENHANCED WITH AN INCREASE IN XANTHINE OXIDASE ACTIVITY AND A DECREASE IN CATALASE ACTIVITY AT 24 H. OCTACOSANOL (10, 50 OR 100 MG/KG) ADMINISTERED ORALLY TO CCL4- INTOXICATED RATS AT 6 H AFTER INTOXICATION ATTENUATED THE INCREASED ACTIVITIES OF SERUM TRANSAMINASES AND THE INCREASED HEPATIC MYELOPEROXIDASE AND XANTHINE OXIDASE ACTIVITIES AND LPO CONCENTRATION AND THE DECREASED HEPATIC SUPEROXIDE DISMUTASE AND CATALASE ACTIVITIES AND GSH CONCENTRATION FOUND AT 24 H AFTER INTOXICATION DOSE-DEPENDENTLY. OCTACOSANOL (50 OR 100 MG/KG) ADMINISTERED TO UNTREATED RATS DECREASED THE HEPATIC LPO CONCENTRATION AND INCREASED THE HEPATIC GSH CONCENTRATION. THESE RESULTS INDICATE THAT OCTACOSANOL ATTENUATES DISRUPTED HEPATIC REACTIVE OXYGEN SPECIES METABOLISM ASSOCIATED WITH ACUTE LIVER INJURY PROGRESSION IN CCL4-INTOXICATED RATS.","LIVER INJURY (RAT); OCTACOSANOL; OXIDATIVE STRESS","RATTUS; CARBON TETRACHLORIDE; CATALASE; GLUTATHIONE; LIPID PEROXIDE; MYELOPEROXIDASE; OCTACOSANOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; LIVER INJURY; LIVER LEVEL; LIVER METABOLISM; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; WISTAR RAT","","","FRAGA V., MENENDEZ R., AMOR A.N., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH. MED. RES, 28, PP. 355-360, (1997); MENEZDEN R., FRAGA V., AMOR A.N., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXDATION, PHYSIOL. BEHAV, 67, PP. 1-7, (1999); RECKNAGEL R.O., GLENDE JR. E.A., DOLAK J.A., WALLER R.L., MECHANISMS OF CARBON TETRACHLORIDE TOXICITY, PHARMACOL. THER, 43, PP. 139-154, (1989); WEBER L.W.D., BOLL M., STAMPFL A., HEPATOTOXICITY AND MECHANISM OF ACTION OF HALOALKANES: CARBON TETRACHLORIDE AS A TOXICOLOGICAL MODEL, CRIT. REV. TOXICOL, 33, PP. 105-136, (2003); MIYAZAWA T., SUZUKI T., FUJIMOTO K., KANEDA T., PHOSPHOLIPID HYDROPEROXIDE ACCUMULATION IN LIVER OF RATS INTOXICATED WITH CARBON TETRACHLORIDE AND ITS INHIBITION BY DIETARY A-TOCOPHEROL, J. BIOCHEM, 107, PP. 689-693, (1990); OHTA Y., SASAKI E., NISHIDA K., HAYASHI T., NAGATA M., ISHIGURO I., PREVENTIVE EFFECT OF DAI-SAIKO-TO (DA-CHAI-HU-TANG) EXTRACT ON DISRUPTED HEPATIC ACTIVE OXYGEN METABOLISM IN RATS WITH CARBON TETRACHLORIDE-INDUCED LIVER INJURY, AM. J. CHIN. MED, 23, PP. 53-64, (1995); OHTA Y., KONGO M., SASAKI E., NISHIDA K., ISHIGURO I., THERAPEUTIC EFFECT OF MELATONIN ON CARBON TETRACHLORIDE-INDUCED ACUTE LIVER INJURY IN RATS, J. PINEAL RES, 28, PP. 19-26, (2000); OHTA Y., KONGO-NISHIMURA M., MATSURA T., YAMADA K., KITAGAWA A., KISHIKAWA T., MELATONIN PREVENTS DISRUPTION OF HEPATIC REACTIVE OXYGEN SPECIES METABOLISM IN RATS TREATED WITH CARBON TETRACHLORIDE, J. PINEAL RES, 36, PP. 10-17, (2004); OHTA Y., KONGO-NISHIKAWA M., IMAI Y., KISHIKAWA T., CONTRIBUTION OF XANTHINE OXIDASE-DERIVED OXYGEN FREE RADICALS TO THE DEVELOPMENT OF CARBON TETRACHLORIDE-INDUCED ACUTE LIVER INJURY IN RATS, J. DIN. BIOCHEM. NUTR, 33, PP. 89-93, (2003); OHTA Y., IMAI Y., MATSURA T., KITAGAWA A., YAMADA K., PREVENTIVE EFFECT OF NEUTROPENIA ON CARBON TETRACHLORIDE-INDUCED HEPATOTOXICITY IN RATS, J. APPL. TOXICOL, 26, PP. 178-186, (2006); HARTELY D.P., KOLAJA K.L., REICHARD J., PETERSON D.R., 4-HYDROXYNONENAL AND MALONDIALDEHYDE HEPATIC PROTEIN ADDUCTS IN RATS TREATED WITH CARBON TETRACHLORIDE: IMMUNO-CHEMICAL DETECTION AND LOBULAR LOCALIZATION, TOXICOL. APPL. PHARMACOL, 161, PP. 23-33, (1999); SUN R., HAMAGAWA E., TSUTSUI C., ONO Y., OGIRI Y., KOJO S., EVALUATION OF OXIDATIVE STRESS DURING APOPTOSIS AND NECROSIS CAUSED BY CARBON TETRACHLORIDE IN RAT LIVER, BIOCHIM. BIOPHYS. ACTA, 1535, PP. 186-191, (2001); CAMPO G.M., AVENOSO A., CAMPO S., FERLAZZO A.M., MICALI C., ZANGHI L., CALATRONI A., HYALURONIC ACID AND CHONDROITIN-4-SULPHATE TREATMENT REDUCES DAMAGE IN CARBON TETRACHLORIDE-INDUCED ACUTE LIVER INJURY, LIFE SCI, 74, PP. 1289-1305, (2004); OHTA Y., SASAKI E., ISHIGURO I., EFFECT OF ORAL OCTACOSANOL ADMINISTRATION ON HEPATIC TRIGLYCERIDE ACCUMULATION IN RATS WITH CARBON TETRACHLORIDE-INDUCED ACUTE LIVER INJURY, MED. BIOL. (IGAKU TO SEIBUTSUGAKU), 134, PP. 185-189, (1997); DUVAL D.L., HOWARD D., MCCALDEN T.A., BILLINGS R.E., THE DETERMINATION OF MYELOPEROXIDASE ACTIVITY IN LIVER, LIFE SCI, 47, (1990); SCHIERWAGEN C., BYLUND-FELLENIUS A.-C., LUNDBERG C., IMPROVED METHOD FOR QUANTIFICATION OF TISSUE PMN ACCUMULATION MEASURED BY MYELOPEROXIDASE ACTIVITY, J. PHARMACOL. METHODS, 23, PP. 179-186, (1990); KOMATSU H., KOO A., GHADISHAH E., ZENG H., KUHLENKAMP J.E., INOUE M., GUTH P.H., KAPLOWITZ N., NEUTROPHIL ACCUMULATION IN ISCHEMIC REPRFUSED RAT LIVER: EVIDENCE FOR A ROLE FOR SUPEROXIDE FREE RADICAL, AM. J. PHYSIOL, 262, (1992); OHKAWA H., OHISHI N., YAGI K., ASSAY FOR LIPID PEROXIDES IN ANIMAL TISSUES WITH THIOBARBITURIC ACID REACTION, ANAL. BIOCHEM, 95, PP. 351-358, (1979); SEDLAK J., LINDSAY R.H., ESTIMATION OF TOTAL, PROTEIN-BOUND, AND NONPROTEIN SULFHYDRYL GROUPS IN TISSUE WITH ELLMAN'S REAGENT, ANAL. BIOCHEM, 25, PP. 192-205, (1968); OYANAGUI Y., REEVALUATION OF ASSAY METHODS AND ESTABLISHMENT OF KIT FOR SUPEROXIDE DISMUTASE ACTIVITY, ANAL. BICOHEM, 242, PP. 290-296, (1984); BERGMEYER H.U., ZUR MESUNG VON KATALASE-ACTIVITÄTEN., BIOCHEM. ZEIT, 327, PP. 255-258, (1955); HOCHSTEIN P.H., UTLEY H., HYDORGEN PEROXIDE DETOXICATION BY GLUTATHIONE PEROXIDASE AND CATALASE IN RAT LIVER HOMOGENATES, MOL. PHARMACOL, 4, PP. 574-579, (1968); HASHIMOTO S., A NEW SPECTROPHOTOMETRIC ASSAY METHOD OF XANTHINE OXIDASE IN CRUDE TISSUE HOMOGENATE, ANAL. BIOCHEM, 62, PP. 426-433, (1974); SUZUKI K., OTA H., SASAGAWA S., SAKATANI T., FUJIKURA T., ASSAY METHOD FOR MYELOPEROXIDASE IN HUMAN POLY-MORPHONUCLEAR LEUKOCYTES, ANAL. BIOCHEM, 132, PP. 345-353, (1983); LOWRY O.H., ROSEBROUGH N.H., FARR A.D., RANDALL R.J., PROTEIN MEASUREMENT WITH THE FOLIN REAGENT, J. BIOL. CHEM, 193, PP. 265-273, (1951); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J. AGRIC. FOOD CHEM, 53, PP. 6289-6293, (2005); FERNANDZ G., VILLARRUEL M.C., DE FERREYA E.C., DE FENOS O.M., CASTRO J.A., IMIPRAMINE PREVENTION OF CARBON TERRA CHLORIDE-INDUCED LIVER NECROSIS AT LATE STATES OF THE INTOXICATION PROCESS, J. APPL. TOXICOL, 6, PP. 413-418, (1986); VALLES F.G., DE CASTRO C.R., CASTRO J.A., N-ACECTYLCYSTEINE IS AN EARLY BUT ALSO LATE PREVENTIVE AGENT AGAINST CARBON TETRACHLORIDE-INDUCED LIVER NECROSIS, TOXICOL. LETT, 71, PP. 87-95, (1994); CORTE E.D., STIRPE F., THE REGULATION OF RAT LIVER XANTHINE OXIDASE. INVOLVEMENT OF THIOL GROUPS IN THE CONVERSION OF THE ENZYME ACTIVITY FROM DEHYDROGENASE (TYPE D) INTO OXIDASE (TYPE O) AND PURIFICATION OF THE ENZYME, BIOCHEM. J, 261, PP. 739-745, (1972); NISHINO T., TAMURA I., THE MECHANISM OF CONVERSION OF XANTHINE DEHYDROGENASE TO OXIDASE AND THE ROLE OF THE ENZYME IN REPURFUSION INJURY, ADV. EXP. MED. BIOL, 309 A, PP. 327-333, (1991); TRAVIS J., STRUCTURE, FUNCTION, AND CONTROL OF NEUTROPHIL PROTEASES, AM. J. MED, 84, PP. 37-43, (1988); TAKAHASHI R., EDASHIGE K., SATO E.F., INOUE M., MATSUNO T., USTUMI K., LUMINOL CHEMILUMINESCENCE AND ACTIVE OXYGEN GENERATED BY NEUTROPHILS, ARCH. BIOCHEM. BIOPHYS, 285, PP. 325-330, (1991); MENEZDEN R., MARREO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY ON OCTACOSANOL METABOLISM, ARCH. MED. RES, 36, PP. 113-119, (2005); NOA M., MENDOZA S., MAS R., MENDOZA N., EFFECT OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT PRIMARY ACIDS FROM SUGAR CANE WAX, ON CCL <SUB>4</SUB>-INDUCED LIVER ACUTE INJURY IN RATS, DRUGS EXP. CLIN. RES, 28, PP. 177-183, (2002); MENEZDEN R., MAS R., AMOR A.M., LODON N., PEREZ J., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXDIATION BY THE ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CAN. J. PHYSIOL. PHARMACOL, 80, PP. 12-21, (2002)","Y. OHTA; DEPARTMENT OF CHEMISTRY, FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE, TOYOAKE, AICHI 470-1192, JAPAN; EMAIL: YOHTA@FUJITA-HU.AC.JP","","ENGLISH","J. CLIN. BIOCHEM. NUTR.","ARTICLE","ISI","2-S2.0-46249096025","J CLIN BIOCHEM NUTR","FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE;FUJITA HEALTH UNIVERSITY;TOTORRI UNIVERSITY FACULTY OF MEDICINE;KAGAWA PREFECTURAL COLLEGE OF HEALTH SCIENCE;CHUKYO WOMEN'S UNIVERSITY;TOTORRI UNIVERSITY FACULTY OF MEDICINE","NOTREPORTED;FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE;NOTREPORTED",NA,"OHTA Y, 2008, J CLIN BIOCHEM NUTR","OHTA Y, 2008, J CLIN BIOCHEM NUTR"
"CICERO A;ERTEK S","CICERO, ARRIGO F. (7003403707); ERTEK, SIBEL (15135521900)","METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS",2009,"CLINICAL LIPIDOLOGY","4","10",45,"10.2217/clp.09.41","AGING AND KIDNEY DISEASES DEPARTMENT, UNIVERSITY OF BOLOGNA, MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA MASSARENTI, 9, ITALY;UFUK UNIVERSITY, ANKARA, TURKEY","BERBERINE IS A PLANT ALKALOID WITH VARIOUS BIOLOGICAL ACTIVITIES. A LARGE BODY OF LITERATURE SUPPORT DIFFERENT PHARMACOLOGICAL ACTIONS OF BERBERINE THAT COULD BE INTERESTING IN THE MANAGEMENT OF METABOLIC DISEASES ASSOCIATED WITH HIGH CARDIOVASCULAR DISEASE RISK, SUCH AS MIXED HYPERLIPIDEMIA, INSULIN RESISTANCE, METABOLIC SYNDROME AND TYPE 2 DIABETES. NUMEROUS PRECLINICAL IN VITRO AND IN VIVO STUDIES SUPPORT ALL THESE EFFECTS. MOREOVER, IT SEEMS THAT BERBERINE ALSO EXERTS ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE EFFECTS THAT COULD PLAY A ROLE IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND ITS CLINICAL CONSEQUENCES. RECENTLY, THE METABOLIC EFFECTS OF BERBERINE HAVE ALSO BEEN DEMONSTRATED IN HUMANS, OPENING NEW PERSPECTIVES FOR THE USE OF THIS MOLECULE IN PATIENT THERAPY. LARGER AND LONGER STUDIES NEED TO BE CARRIED OUT TO IMPLEMENT THE DEFINITION OF THE THERAPEUTIC ROLE OF BERBERINE IN HUMANS. © 2009 FUTURE MEDICINE LTD.","BERBERINE; CARDIOVASCULAR DISEASE; DIABETES; HYPERCHOLESTEROLEMIA","BERBERINE; CYCLOSPORIN A; GENISTEIN; GLIBENCLAMIDE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METFORMIN; MEVINOLIN; PACLITAXEL; POLICOSANOL; SIMVASTATIN; SULFONYLUREA; THIOPENTAL; TOLBUTAMIDE; WARFARIN; XUEZHIKANG; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSPORT; DYSPNEA; FATTY ACID METABOLISM; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART FAILURE; HEART INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT","","","MULLER-NORDHORN J., BINTING S., ROLL S., WILLICH S.N., AN UPDATE ON REGIONAL VARIATION IN CARDIOVASCULAR MORTALITY WITHIN EUROPE, EUR. HEART J., 29, 10, PP. 1316-1326, (2008); BAIGENT C., KEECH A., KEARNEY P.M., ET AL., CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS: EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, 9493, PP. 1267-1278, (2005); FRUCHART J.C., SACKS F., HERMANS M.P., ET AL., THE RESIDUAL RISK REDUCTION INITIATIVE: A CALL TO ACTION TO REDUCE RESIDUAL VASCULAR RISK IN PATIENTS WITH DYSLIPIDEMIA, AM. J. CARDIOL., 102, SUPPL. 10, (2008); SENECAL M., FODOR G., GAGNE C., ET AL., LIMITATIONS OF STATIN MONOTHERAPY FOR THE TREATMENT OF DYSLIPIDEMIA: A PROJECTION BASED ON THE CANADIAN LIPID STUDY - OBSERVATIONAL, CURR. MED. RES. OPIN., 25, 1, PP. 47-55, (2009); JACOBSON T.A., TOWARD 'PAIN-FREE' STATIN PRESCRIBING: CLINICAL ALGORITHM FOR DIAGNOSIS AND MANAGEMENT OF MYALGIA, MAYO CLIN. PROC., 83, 6, PP. 687-700, (2008); CICERO A.F.G., ERTEK S., NATURAL SOURCES OF ANTIDYSLIPIDAEMIC AGENTS: IS THERE AN EVIDENCE-BASED APPROACH FOR THEIR PRESCRIPTION?, MED. J. NUTR. METAB., 1, 2, PP. 85-93, (2008); BIRDSALL T.C., KELLY G.S., BERBERINE:THERAPEUTIC POTENTIAL OF AN ALKALOID FOUND IN SEVERAL MEDICINAL PLANTS, ALTERN. MED. REV., 2, PP. 94-103, (1997); ABIDI P., ZHOU Y., JIANG J.D., LIU J., EXTRACELLULAR SIGNAL REGULATED KINASE-DEPENDENT STABILIZATION OF HEPATIC LOW DENSITY LIPOPROTEIN RECEPTOR MRNA BY HERBAL MEDICINE BERBERINE, ARTERIOSCLER. THROMB. VASC. BIOL., 25, 10, PP. 2170-2176, (2005); LEE S., LIM H.J., PARK J.H., ET AL., BERBERINE INDUCED LDLR UP-REGULATION INVOLVES JNK PATHWAY, BIOCHEM. BIOPHY. RES. COMMUN., 362, 4, PP. 853-857, (2007); CAMERON J., RANHEIM T., KULSETH M.A., LEREN T.P., BERGE K.E., BERBERINE DECREASES PCSK9 EXPRESSION IN HEPG2 CELLS., ATHEROSCLEROSIS, 201, 2, PP. 266-273, (2008); LI H., CHEN W., ZHOU Y., ET AL., IDENTIFICATION OF MRNA BINDING PROTEINS THAT REGULATE THE STABILITY OF LDL RECEPTOR MRNA THROUGH AU-RICH ELEMENTS, J. LIPID RES., 50, PP. 820-831, (2009); CHOI B.H., AHN I.S., KIM Y.H., ET AL., BERBERINE REDUCES THE EXPRESSION OF ADIPOGENIC ENZYMES AND INFLAMMATORY MOLECULES OF 3T3-L1 ADIPOCYTE, EXP. MOL. MED., 38, 6, PP. 599-605, (2006); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J. LIPID RES., 47, 6, PP. 1281-1288, (2006); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT. MED., 10, 12, PP. 1344-1351, (2004); ZHANG Y., LI X., ZOU D., ET AL., TREATMENT OF TYPE 2 DIABETES AND DYSLIPIDEMIA WITH THE NATURAL PLANT ALKALOID BERBERINE, J. CLIN. ENDOCRINOL. METAB., 93, 7, PP. 2559-2565, (2008); YIN J., XING H., YE J., EFFICACY OF BERBERINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, METABOLISM, 57, 5, PP. 712-717, (2008); ZHAO W., XUE R., ZHOU Z.X., KONG W.J., JIANG J.D., REDUCTION OF BLOOD LIPID BY BERBERINE IN HYPERLIPIDEMIC PATIENTS WITH CHRONIC HEPATITIS OR LIVER CIRRHOSIS, BIOMED. PHARMACOTHER., 62, 10, PP. 730-731, (2008); CICERO A.F., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS. A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTELFORSCHUNG, 57, 1, PP. 26-30, (2007); KONG W.J., WEI J., ZUO Z.Y., ET AL., COMBINATION OF SIMVASTATIN WITH BERBERINE IMPROVES THE LIPID-LOWERING EFFICACY, METABOLISM, 57, 8, PP. 1029-1037, (2008); KONG W.J., ZHANG H., SONG D.Q., ET AL., BERBERINE REDUCES INSULIN RESISTANCE THROUGH PROTEIN KINASE C-DEPENDENT UP-REGULATION OF INSULIN RECEPTOR EXPRESSION, METABOLISM, 58, 1, PP. 109-119, (2009); KO B.S., CHOI S.B., PARK S.K., ET AL., INSULIN SENSITIZING AND INSULINOTROPIC ACTION OF BERBERINE FROM CORTIDIS RHIZOME, BIOL. PHARM. BULL., 28, 8, PP. 1431-1437, (2005); ZHANG W., XU Y.C., GUO F.J., MENG Y., LI M.L., ANTIDIABETIC EFFECTS OF CINNAMALDEHYDE AND BERBERINE AND THEIR IMPACTS ON RETINOL BINDING PROTEIN 4 EXPRESSION IN RATS WITH TYPE 2 DIABETES MELLITUS, CHIN. MED. J. (ENG.), 121, 21, PP. 2124-2128, (2008); YIN J., HU R., CHEN M., ET AL., EFFECTS OF BERBERINE ON GLUCOSE METABOLISM IN VITRO, METABOLISM, 51, 11, PP. 1439-1443, (2002); KIM S.H., SHIN E.J., KIM E.D., ET AL., BERBERINE ACTIVATED GLUT-1-MEDIATED GLUCOSE UPTAKE IN 3T3-L1 ADIPOCYTES, BIOL. PHARM. BULL., 30, 11, PP. 2120-2125, (2007); YIN J., GAO Z., LIU D., LIU Z., YE J., BERBERINE IMPROVES GLUCOSE METABOLISM THROUGH INDUCTION OF GLYCOLYSIS, AM. J. PHYSIOL. ENDOCRINOL. METAB., 294, 1, (2008); YI P., LU F.E., XU L.J., CHEN G., DONG H., WANG K.F., BERBERINE REVERSES FREE-FATTYACID- INDUCED INSULIN RESISTANCE IN 3T3-L1 ADIPOCYTES THROUGH TARGETING IKK BETA, WORLD J. GASTROENTEROL, 14, 6, PP. 876-883, (2008); ZHOU L., YANG Y., WANG X., ET AL., BERBERINE STIMULATES GLUCOSE TRANSPORT THROUGH A MECHANISM DISTINCT FROM INSULIN, METABOLISM, 56, 3, PP. 405-412, (2007); CHENG Z., PANG T., GU M., ET AL., BERBERINE STIMULATED GLUCOSE UPTAKE IN L6 MYOTUBES INCLUDES BOTH AMPK AND P 38 MAPK, BIOCHIM. BIOPHYS. ACTA, 1760, 11, PP. 1682-1689, (2006); HUANG C., ZHANG Y., GONG Z., ET AL., BERBERINE INHIBITS 3T3L1 ADIPOCYTE DIFFERENTIATION THROUGH THE PPAR ALPHA PATHWAY, BIOCHEM. BIOPHYS. RES. COMUN., 348, 2, PP. 571-578, (2006); WANG S.H., WANG W.J., WANG X.F., CHEN W., EFFECTS OF ASTRAGALUS POLYSACCHARIDES AND BERBERINE ON CARBOHYDRATE METABOLISM AND CELL DIFFERENTIATION IN 3T3-L1 ADIPOCYTES, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, 24, 10, PP. 926-928, (2004); LU S.S., YU Y.L., ZHU H.J., ET AL., BERBERINE PROMOTES GLUCAGONS-LIKE PEPTIDE-1 (7-36 AMIDE) SECRETION IN STREPTOZOCIN-INDUCED DIABETIC RATS, J. ENDOCRINOL., 200, 2, PP. 159-165, (2009); ZHOU J., ZHOU S., TANG J., ET AL., PROTECTIVE EFFECT OF BERBERINE ON CELLS IN STREPTOZOTOCIN- AND HIGH CARBOHYDRATE/ HIGH-FAT-DIET-INDUCED DIABETIC RATS, EUR. J. PHARMACOL., 606, 1-3, PP. 262-268, (2009); PAN G.Y., WANG G.J., LIU X.D., FAWCETT J.P., XIE Y.Y., THE INVOLVEMENT OF P-GLYCOPROTEIN IN BERBERINE ABSORPTION, PHARMACOL. TOXICOL, 91, 4, PP. 193-197, (2002); TURNER N., LI J.Y., GOSBY A., ET AL., BERBERINE AND ITS MORE BIOLOGICALLY AVAILABLE DERIVATIVE, DIHYDROBERBERINE, INHIBIT MITOCHONDRIAL RESPIRATORY COMPLEX I: A MECHANISM FOR THE ACTION OF BERBERINE TO ACTIVATE AMP-ACTIVATED PROTEIN KINASE AND IMPROVE INSULIN ACTION, DIABETES, 57, 5, PP. 1414-1418, (2008); YIN J., ZHANG H., YE J., TRADITIONAL CHINESE MEDICINE IN TREATMENT OF METABOLIC SYNDROME, ENDOCR. METAB. IMMUNE. DISORD. DRUG TARGETS, 8, 2, PP. 99-111, (2008); WANG Z.Q., LU F.E., LENG S.H., ET AL., FACILITATING EFFECTS OF BERBERINE ON RAT PANCREATIC ISLETS THROUGH MODULATING HEPATIC NUCLEAR FACTOR 4 ALPHA EXPRESSION AND GLUCOKINASE ACTIVITY, WORLD J. GASTROENTEROL., 14, 39, PP. 6004-6011, (2008); LENG S., LU F., XU L., THERAPEUTIC EFFECTS OF BERBERINE IN IMPAIRED GLUCOSE TOLERANCE RATS AND ITS INFLUENCE ON INSULIN SECRETION, ACTA PHARMACOL. SIN., 25, 4, PP. 496-502, (2004); LIU W.H., HEI Z.Q., NIE H., ET AL., BERBERINE AMELIORATES RENAL INJURY IN STREPTOZOCININDUCED DIABETIC RATS BY SUPPRESSION OF BOTH OXIDATIVE STRESS AND ALDOSE REDUCTASE, CHIN. MED. J., 121, 8, PP. 706-712, (2008); LIU W., TANG F., DENG Y., ET AL., BERBERINE REDUCES FIBRONECTIN AND COLLAGEN ACCUMULATION IN RAT GLOMERULAR MESANGIAL CELLS CULTURED UNDER HIGH GLUCOSE CONDITION, MOL. CELL. BIOCHEM., 325, 1-2, PP. 99-105, (2009); FATEHI-HASSANABAD Z., JAFARZADEH M., TARHINI A., FATEHI M., THE ANTIHYPERTENSIVE AND VASODILATOR EFFECTS OF AQUEOUS EXTRACT FROM BERBERIS VULGARIS FRUIT ON HYPERTENSIVE RATS, PHYTOTHER. RES., 19, 3, PP. 222-225, (2005); PEYCHEV L., PHARMACOLOGICAL INVESTIGATION ON THE CARDIOVASCULAR EFFECTS OF BERBERINE VULGARIS ON TESTED ANIMALS, PHARMACIA, 52, 1, PP. 118-121, (2005); CHUN Y.T., YIP T.T., LAU K.L., KONG Y.C., SANKAWA U., A BIOCHEMICAL STUDY ON HYPOTENSIVE EFFECTS OF BERBERINE IN RATS, GEN. PHARMACOL., 10, 3, PP. 177-182, (1979); WONG K.K., MECHANISM OF THE AORTIC RELAXATION INDUCED BY LOW CONCENTRATIONS OF BERBERINE, PLANTA MED., 64, 8, PP. 756-757, (1998); KO W.H., YAO X.Q., LAU C.W., ET AL., VASORELAXANT AND ANTIPROLIFERATIVE EFFECTS OF BERBERINE, EUR. J. PHARMACOL., 399, 2-3, PP. 187-196, (2000); KANG D.G., SOHN E.J., KWON E.K., ET AL., EFFECTS OF BERBERINE ON ANGIOTENSINCONVERTING ENZYME AND NO/CGMP SYSTEM IN VESSELS, VASCUL. PHARMACOL., 39, 6, PP. 281-286, (2002); OLMEZ E., ILHAN M., EVALUATION OF THE ALPHA-ADRENOCEPTOR ANTAGONISTIC ACTION OF BERBERINE IN ISOLATED ORGANS, ARZNEIMITTELFORSCHUNG, 42, 9, PP. 1095-1097, (1992); CHIOU W.E., YEN M.H., CHEN C.F., MECHANISM OF VASODILATORY EFFECT OF BERBERINE IN RAT MESENTERIC ARTERY, EUR. J. PHARMACOL., 204, 1, PP. 35-40, (1991); PAN L.R., TANG Q., FU Q., HU B.R., XIANG J.Z., QIAN J.Q., ROLES OF NITRIC OXIDE IN PROTECTIVE EFFECT OF BERBERINE IN ETHANOL-INDUCED GASTRIC ULCER MICE, ACTA PHARMACOL. SIN., 26, 11, PP. 1334-1338, (2005); LIANG K.W., YIN S.C., TING C.T., ET AL., BERBERINE INHIBITS PLATELET-DERIVED GROWTH FACTORINDUCED GROWTH AND MIGRATION PARTLY THROUGH AN AMPK-DEPENDENT PATHWAY IN VASCULAR SMOOTH MUSCLE CELLS, EUR. J. PHARMACOL., 590, 1-3, PP. 343-354, (2008); LIANG K.W., TING C.T., YIN S.C., ET AL., BERBERINE SUPPRESSES MEK/ERK-DEPENDENT EGR-1 SIGNALLING PATHWAY AND INHIBITS VASCULAR SMOOTH MUSCLE REGROWTH AFTER IN VITRO MECHANICAL INJURY, BIOCHEM. PHARMACOL., 71, 6, PP. 806-817, (2006); CHO B.J., IM E.K., KWON J.H., ET AL., BERBERINE INHIBITS THE PRODUCTION OF LYSOPHOSPHATIDYLCHOLINE-INDUCED REACTIVE OXYGEN SPECIES AND THE ERK1,2 PATHWAY IN SMOOTH MUSCLE CELLS., MOL. CELL, 20, 3, PP. 429-434, (2005); XU M.G., WANG J.M., CHEN L., ET AL., BERBERINEINDUCED UPREGULATION OF ENDOTHELIAL PROGENITOR CELLS IS RELATED TO NITRIC OXIDE PRODUCTION IN HEALTHY SUBJECTS, CARDIOLOGY, 112, 4, PP. 279-286, (2008); XU M.G., WANG J.M., CHEN L., WANG Y., YANG Z., TAO J., BERBERINE-INDUCED MOBILIZATION OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IMPROVES HUMAN SMALL ARTERY ELASTICITY, J. HUM. HYPERTENS., 22, 6, PP. 389-393, (2008); WANG J.M., YANG Z., XU M.G., ET AL., BERBERINE INDUCED DECLINE IN CIRCULATING CD31+/ CD42- MICROPARTICLES IS ASSOCIATED WITH IMPROVEMENT OF ENDOTHELIAL FUNCTION IN HUMANS, EUR. J. PHARMACOL., 614, 1-3, PP. 77-83, (2009); HONG Y., HUI S.S., CHAN B.T., HOU J., EFFECT OF BERBERINE ON CATECHOLAMINE LEVELS IN RATS WITH EXPERIMENTAL CARDIAC HYPERTROPHY, LIFE SCI., 72, 22, PP. 2499-2507, (2003); HONG Y., HUI S.C., CHAN T.Y., HOU J.Y., EFFECT OF BERBERINE ON REGRESSION OF PRESSURE OVERLOAD INDUCED CARDIAC HYPERTROPHY IN RATS, AM. J. CHIN. MED., 30, 4, PP. 589-599, (2002); HUANG W.M., YAN H., JIN J.M., YU C., ZHANG H., BENEFICIAL EFFECTS OF BERBERINE ON HEMODYNAMICS DURING ACUTE ISCHEMIC LEFT VENTRICULAR FAILURE IN DOGS, CHIN. MED. J., 105, 12, PP. 1014-1019, (1992); WANG Y.X., ZHENG Y.M., ZHOU X.B., INHIBITORY EFFECTS OF BERBERINE ON ATP-SENSITIVE K+ CHANNELS IN CARDIAC MYOCYTES, EUR. J. PHARMACOL., 316, 2-3, PP. 307-315, (1996); MARIN-NETO J.A., MACIEL B.C., SECCHES A.L., GALLO JR. L., CARDIOVASCULAR EFFECTS OF BERBERINE IN PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE, CLIN. CARDIOL., 11, 4, PP. 253-260, (1988); ZENG X.H., ZENG X.J., LI Y.Y., EFFICACY AND SAFETY OF BERBERINE FOR CONGESTIVE HEART FAILURE SECONDARY TO ISCHEMIC OR IDIOPATHIC DILATED CARDIOMYOPATHY, AM. J. CARDIOL., 92, 2, PP. 173-176, (2003); LAU C.W., YAO X.Q., CHEN Z.Y., KO W.H., HUANG Y., CARDIOVASCULAR ACTIONS OF BERBERINE. CARDIOVASC, DRUG REV., 19, 3, PP. 234-244, (2001); HUANG C.G., CHU Z.L., WEI S.J., JIANG H., JIAO B.H., EFFECTS OF BERBERINE ON ARACHIDONIC ACID METABOLISM IN RABBIT PLATELETS AND ENDOTHELIAL CELLS, THROMB. RES., 106, 4-5, PP. 223-227, (2002); HUANG C.G., CHU Z.L., YANG Z.M., THE PROGRESS IN PHARMACOLOGICAL RESEARCHES ON BERBERINE, COMUN. INFORM. PHARM., 9, 4, PP. 10-12, (1991); HOLY E.W., AKHMEDOV A., LUSCHER T.F., TANNER F.C., BERBERINE A NATURAL LIPID-LOWERING DRUG, EXERTS PROTHROMBIC EFFECTS ON VASCULAR CELLS, J. MOL. CELL. CARDIOL., 46, 2, PP. 234-240, (2009); GUO Y., WANG Q.Z., LI F.M., JIANG X., ZUO Y.F., WANG L., BIOCHEMICAL PATHWAYS IN THE ANTIATHEROSCLEROTIC EFFECT OF BERBERINE, CHIN. MED. J. (ENG.), 121, 13, PP. 1197-1203, (2008); PANDEY M.K., SUNG B., KUNNUMAKKARA A.B., ET AL., BERBERINE MODIFIES CYSTEINE 179 OF I KAPPA B BETA KINASE, SUPPRESSES NUCLEAR FACTOR KAPA?BETA-BREGULATED ANTIAPOPTOTIC GENE PRODUCTS, AND POTENTIATES APOPTOSIS, CANCER RES., 68, 13, PP. 5370-5379, (2008); HWANG J.M., WANG C.J., CHOU F.P., ET AL., INHIBITORY EFFECT OF BERBERINE ON TERT-BUTYLHYDROPEROXIDE- INDUCED OXIDATIVE DAMAGE IN RAT LIVER, ARCH. TOXICOL., 76, 11, PP. 664-670, (2002); LI B.X., ZHANG M.S., BAO L.H., STUDY OF PHARMACOKINETICS OF BERBERINE AFTER ORAL ADMINISTRATION IN HUMAN BEING, J. HAERBIN MED. UNIV., 29, PP. 382-385, (1995); YUAN J., SHEN X.Z., ZHU X.S., EFFECT OF BERBERINE ON TRANSIT TIME OF HUMAN SMALL INTESTINE, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, 14, 12, PP. 718-720, (1994); IMANSHAHIDI M., HOSSEINZADEH H., PHARMACOLOGICAL AND THERAPEUTIC EFFECTS OF BERBERIS VULGARIS AND ITS ACTIVE CONSTITUENT, BERBERINE, PHYTOTHER. RES., 22, 8, PP. 999-1012, (2008); HU Y.J., LIU Y., XIAO X.H., INVESTIGATION OF THE INTERACTION BETWEEN BERBERINE AND HUMAN SERUM ALBUMIN, BIOMACROMOLECULES, (2009); TAN Y.Z., WU A.C., TAN B.Y., ET AL., STUDY ON THE INTERACTIONS OF BERBERINE DISPLACE OTHER DRUG FROM THEIR PLASMA PROTEINS BINDING SITES, CHIN. PHARMACOL. BULL., 18, PP. 576-578, (2002); CHAN E., DISPLACEMENT OF BILIRUBIN FROM ALBUMIN BY BERBERINE, BIOL. NEONAT., 63, 4, PP. 201-208, (1993); TSAI P.L., TSAI T.H., HEPATOBILIARY EXCRETION OF BERBERINE, DRUG. METAB. DISPOS., 32, 4, PP. 405-412, (2003); ZUO F., NAKAMURA N., AKAO T., HATTORI M., PHARMACOKINETICS OF BERBERINE AND ITS MAIN METABOLITES IN CONVENTIONAL AND PSEUDO GERM-FREE RATS DETERMINED BY LIQUID CHROMATOGRAPHY/ION TRAP MASS SPECTROMETRY, DRUG METAB. DISPOS., 34, 12, PP. 2064-2072, (2006); CHEN C.M., CHANG H.C., DETERMINATION OF BERBERINE IN PLASMA, URINE AND BILE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, J. CHROMATOGR., 665, 1, PP. 117-123, (1995); PAN J.F., YU C., ZHU D.Y., ET AL., IDENTIFICATION OF THREE SULFATE-CONJUGATED METABOLITES OF BERBERINE CHLORIDE IN HEALTHY VOLUNTEERS' URINE AFTER ORAL ADMINISTRATION, ACTA PHARMACOL. SIN., 23, 1, PP. 77-82, (2002); RANER G.M., CORNELIUS S., MOULICK K., ET AL., EFFECTS OF HERBAL PRODUCTS ON HUMAN CYTOCHROME P450( 2E1) ACTIVITY, FOOD CHEM. TOX., 45, 12, PP. 2359-2365, (2007); ZHAO X., ZHANG J.J., WANG X., BU X.Y., LOU Y.Q., ZHANG G.L., EFFECT OF BERBERINE ON HEPATOCYTE PROLIFERATION INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION, CYROCHROME 450 2E1 AND 1A2 ACTIVITIES IN DIETHYLNITROSAMINE- AND PHENOBARBITAL-TREATED RATS, BIOMED. PHARMACOTHER., 62, 9, PP. 567-572, (2008); XIN H.W., WU X.C., LI Q., ET AL., THE EFFECTS OF BERBERINE ON THE PHARMACOKINETICS OF CYCLOSPORINE A IN HEALTHY VOLUNTEERS. METHODS FIND, EXP. CLIN. PHARMACOL., 28, 1, PP. 25-29, (2006); WU X., LI Q., XIN H., YU A., ZHONG M., EFFECTS OF BERBERINE ON THE BLOOD CONCENTRATION OF CYCLOSPORINE A IN RENAL TRANSPLANTED RECIPIENTS:CLINICAL AND PHARMACOKINETIC STUDY, EUR. J. CLIN. PHARMACOL., 61, 8, PP. 567-572, (2005); VRZAL R., ZDARILOVA A., ULRICHOVA J., ET AL., ACTIVATION OF THE ARYL HYDROCARBON RECEPTOR BY BERBERINE IN HEPG2 AND H4IIECELLS: BIPHASIC EFFECT ON CYP1A1, BIOCHEM. PHARMACOL., 70, 6, PP. 925-936, (2005); LIN H.L., LIU T.Y., WU C.W., CHI C.W., BERBERINE MODULATES EXPRESSION OF MDR1 GENE PRODUCT AND THE RESPONSES OF THE DIGESTIVE TRACT CANCERS TO PACLITAXEL, BR. J. CANCER., 81, 3, PP. 416-422, (1999); SABIR M., BHIDE N.K., STUDY OF SOME PHARMACOLOGICAL ACTIONS OF BERBERINE. INDIAN, J. PHYSIOL. PHARMACOL., 15, 3, PP. 111-132, (1971); PASQUAL M.S., LAUER C.P., MOYNA P., HENRIQUES J.A., GENOTOXICITY OF THE ISOQUINOLINE ALKALOID BERBERINE IN PROKARYOTIC AND EUKARYOTIC ORGANISMS, MUTAT. RES., 286, 2, PP. 243-252, (1993); GRYCOVA L., DOSTAL J., MAREK R., QUARTERNARY PROTOBERBERINE ALKALOIDS, PHYTOCHEMISTRY, 68, 2, PP. 150-175, (2007); HOLY E.W., AKHMEDOV A., LUSCHER T.F., TANNER F.C., BERBERINE, A NATURAL LIPIDLOWERING DRUG, EXERTS PROTHROMBOTIC EFFECTS ON VASCULAR CELLS, J. MOL. CELL. CARDIOL., 46, 2, PP. 234-240, (2009); CHU Z.L., HUANG C.G., XU Z.P., THE ANTI-PLATELET EFFECT OF BERBERINE AND ITS MECHANISM, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, 14, 8, PP. 510-512, (1994)","A. F. CICERO; AGING AND KIDNEY DISEASES DEPARTMENT, UNIVERSITY OF BOLOGNA, MALPIGHI HOSPITAL, 40138 BOLOGNA, VIA MASSARENTI, 9, ITALY; EMAIL: AFGCICERO@CARDIONET.IT","","ENGLISH","CLINICAL LIPIDOLOGY","REVIEW","ISI","2-S2.0-77649177283","CLINICAL LIPIDOLOGY","UNIVERSITY OF BOLOGNA;UFUK UNIVERSITY","NOTREPORTED;UNIVERSITY OF BOLOGNA;NOTREPORTED",NA,"CICERO AF, 2009, CLINICAL LIPIDOLOGY","CICERO AF, 2009, CLINICAL LIPIDOLOGY"
"GUARDAMAGNA O;ABELLO F;BARACCO V;STASIOWSKA B;MARTINO F","GUARDAMAGNA, O. (6701780640); ABELLO, F. (26655343000); BARACCO, V. (26655312000); STASIOWSKA, B. (6603327969); MARTINO, F. (7006704655)","THE TREATMENT OF HYPERCHOLESTEROLEMIC CHILDREN EFFICACY AND SAFETY OF A COMBINATION OF RED YEAST RICE EXTRACT AND POLICOSANOLS",2011,"NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES","21","5",64,"10.1016/j.numecd.2009.10.015","DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TURIN, I-10126 TURIN, PIAZZA POLONIA, 94, ITALY;DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TURIN, I-10126 TURIN, PIAZZA POLONIA, 94, ITALY;DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TURIN, I-10126 TURIN, PIAZZA POLONIA, 94, ITALY;DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TURIN, I-10126 TURIN, PIAZZA POLONIA, 94, ITALY;LIPID CLINIC RESEARCH, DEPARTMENT OF PEDIATRICS, UNIVERSITY OF ROME LA SAPIENZA, ITALY","BACKGROUND AND AIMS: THE PREVENTION OF CARDIOVASCULAR RISK, AS OCCURS IN LIPOPROTEIN DISORDERS, IS REQUIRED SINCE CHILDHOOD. AIM OF THE STUDY WAS TO EVALUATE, IN A GROUP OF CHILDREN AFFECTED BY PRIMARY DYSLIPIDEMIA, THE EFFICACY, TOLERABILITY AND SAFETY OF A SHORT-TERM TREATMENT WITH A DIETARY SUPPLEMENT CONTAINING RED YEAST RICE EXTRACT AND POLICOSANOLS. METHODS AND RESULTS: 40 CHILDREN AFFECTED BY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FH) (N= 24) AND FAMILIAL COMBINED HYPERLIPIDEMIA (FCH) (N= 16), AGED 8-16 YEARS, WERE ENROLLED IN A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER TRIAL. AFTER A 4-WEEK RUN-IN PERIOD WITH ONLY DIETARY ADVICE, CHILDREN RECEIVED A DIETARY SUPPLEMENT CONTAINING 200. MG RED YEAST RICE EXTRACT, CORRESPONDING TO 3. MG OF MONACOLINS, AND 10. MG POLICOSANOLS ONCE-DAILY AND PLACEBO FOR 8 WEEKS, SEPARATED BY A 4-WEEK WASHOUT PERIOD. LIPID PROFILE WAS ASSESSED AFTER EACH TREATMENT PERIOD.THE DIETARY SUPPLEMENT, COMPARED WITH THE PLACEBO, SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL BY 18.5% (P< 0.001), LDL-C LEVELS BY 25.1% (P< 0.001), AND APOLIPOPROTEIN B BY 25.3% (P< 0.001) WHEN PATIENTS WERE CONSIDERED AS A WHOLE GROUP. SIMILAR RESULTS WERE OBTAINED WHEN FH AND FCH WERE CONSIDERED SEPARATELY AND NO SIGNIFICANT DIFFERENCE BETWEEN GROUPS WAS DETECTED. NO SIGNIFICANT DIFFERENCES WERE OBSERVED IN HDL-C AND APOLIPOPROTEIN A-I LEVELS. NO ADVERSE EFFECTS WERE DETECTED WHEN LIVER AND MUSCULAR ENZYMES (AST, ALT, AND CK) WERE DETERMINED. CONCLUSIONS: THE TREATMENT WITH A DIETARY SUPPLEMENT CONTAINING RED YEAST RICE EXTRACT AND POLICOSANOLS HAS BEEN FOR THE FIRST TIME SUCCESSFULLY EMPLOYED IN HYPERCHOLESTEROLEMIC CHILDREN. RESULTS INDICATE THIS STRATEGY AS AN EFFECTIVE, SAFE AND WELL TOLERATED IN A SHORT-TERM TRIAL. © 2009.","CHILDREN; DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA; LIPID LOWERING TREATMENT; RED YEAST RICE EXTRACT","ADOLESCENT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL PRODUCTS; CHILD; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG EVALUATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL PRODUCT; CHOLESTIN; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ADOLESCENT; ARTICLE; BLOOD; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG SCREENING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL","UNIVERSITÀ DEGLI STUDI DI TORINO, UNITO","SUPPORTED BY GRANTS OF TURIN UNIVERSITY. ","BERENSON G.S., SRINIVASAN S.R., BAO W., NEWMAN W.P., TRACY R.E., WATTIGNEY W.A., ASSOCIATION BETWEEN MULTIPLE CARDIOVASCULAR RISK FACTORS AND ATHEROSCLEROSIS IN CHILDREN AND YOUNG ADULTS, N ENGL J MED, 338, PP. 1650-1656, (1998); LAUER R.M., LEE J., CLARKE W.R., FACTORS AFFECTING THE RELATIONSHIP BETWEEN CHILDHOOD AND ADULT CHOLESTEROL LEVELS: THE MUSCATINE STUDY, PEDIATRICS, 82, PP. 309-318, (1988); CHARAKIDA M., DEANFIELD J.E., HALCOX J.P.J., CHILDHOOD ORIGINS OF ARTERIAL DISEASE, CURR OPIN PEDIATR, 19, PP. 538-545, (2007); MCGILL H.C., MCMAHAN C.A., HERDERICK E.E., MALCOM G.T., TRACY R.E., STRONG J.P., ORIGIN OF ATHEROSCLEROSIS IN CHILDHOOD AND ADOLESCENCE, AM J CLIN NUTR, 72, (2000); DANIELS S.R., GREER F.R., LIPID SCREENING AND CARDIOVASCULAR HEALTH IN CHILDHOOD, PEDIATRICS, 122, PP. 198-208, (2008); MCCRINDLE B.W., CHAIR M.P.H., URBINA E.M., JACOBSON M.S., STEINBERGER J., ROCCHINI A.P., ET AL., DRUG THERAPY OF HIGH-RISK LIPID ABNORMALITIES IN CHILDREN AND ADOLESCENTS. A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION ATHEROSCLEROSIS, HYPERTENSION, AND OBESITY IN YOUTH COMMITTEE, COUNCIL OF CARDIOVASCULAR DISEASE IN THE YOUNG, WITH THE COUNCIL ON CARDIOVASCULAR NURSING, CIRCULATION, 115, PP. 1948-1967, (2007); KATAN M.B., GRUNDY S.M., JONES P., LA M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, PP. 965-978, (2003); BROWN L., ROSNER B., WILLET W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 965, PP. 439-447, (1999); JOURNOUD M., JONES P.J.H., RED YEAST RICE: A NEW HYPOLIPIDEMIC DRUG, LIFE SCI, 74, PP. 2675-2683, (2004); HEBER D., YIP I., ASHELY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); HUANG C.F., LI T.C., LIN C.C., LIU C.S., SHIH H.C., LAI M.M., EFFICACY OF MONASCUS PURPUREUS WENT RICE ON LOWERING LIPID RATIOS IN HYPERCHOLESTEROLEMIC PATIENTS, EUR J CARDIOVASC PREV REHABIL, 14, PP. 438-440, (2007); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); BERTOLINI S., CANTAFORA A., AVERNA M., CORTESE C., MOTTI C., MARTINI S., ET AL., CLINICAL EXPRESSION OF FAMILIAL HYPERCHOLESTEROLEMIA IN CLUSTERS OF MUTATIONS OF THE LDL RECEPTOR GENE THAT CAUSE A RECEPTOR-DEFECTIVE OR RECEPTOR-NEGATIVE PHENOTYPE, ARTERIOSCLER THROMB VASC BIOL, 20, (2000); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP): HIGHLIGHTS OF THE REPORT OF THE EXPERT PANEL ON BLOOD CHOLESTEROL LEVELS IN CHILDREN AND ADOLESCENTS. NCEP EXPERT PANEL ON BLOOD CHOLESTEROL LEVELS IN CHILDREN AND ADOLESCENTS, PEDIATRICS, 89, PP. 495-501, (1992); HILLS M., ARMITAGE P., THE TWO-PERIOD CROSS-OVER CLINICAL TRIAL, BR J CLIN PHARMACOL, 8, PP. 7-20, (1979); GIDDING S.S., DENNISON B.A., BIRCH L.L., DANIELS S.R., GILLMAN M.W., LICHTENSTEIN A.H., ET AL., DIETARY RECOMMENDATIONS FOR CHILDREN AND ADOLESCENTS: A GUIDE FOR PRACTITIONERS. AMERICAN HEART ASSOCIATION, PEDIATRICS, 117, PP. 544-559, (2006); WIDHALM K., BRAZDA G., SCHNEIDER B., KOHL S., EFFECT OF SOY PROTEIN DIET VERSUS STANDARD LOW FAT, LOW CHOLESTEROL DIET ON LIPID AND LIPOPROTEIN LEVELS IN CHILDREN WITH FAMILIAL OR POLYGENIC HYPERCHOLESTEROLEMIA, J PEDIATR, 123, PP. 30-34, (1993); RASK-NISSILA L., JOKINEN E., RONNEMAA T., VIIKARI J., TAMMI A., NIINIKOSKI H., ET AL., PROSPECTIVE, RANDOMIZED, INFANCY-ONSET TRIAL OF THE EFFECTS OF A LOW-SATURATED-FAT, LOW-CHOLESTEROL DIET ON SERUM LIPIDS AND LIPOPROTEINS BEFORE SCHOOL AGE: THE SPECIAL TURKU CORONARY RISK FACTOR INTERVENTION PROJECT (STRIP), CIRCULATION, 102, PP. 1477-1483, (2000); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); LAPI F., GALLO E., BERNASCONI S., VIETRI M., MENNITI-IPPOLITO F., RASCHETTI R., ET AL., MYOPATHIES ASSOCIATED WITH RED YEAST RICE AND LIQUORICE: SPONTANEOUS REPORTS FROM THE ITALIAN SURVEILLANCE SYSTEM OF NATURAL HEALTH PRODUCTS, BR J CLIN PHARMACOL, 66, PP. 572-574, (2008); PRASAD G.V.R., WONG T., MELITON G., BHALOO S., RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, PP. 1200-1201, (2002); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLEMIC PATIENTS, CLIN DRUG INVESTIG, 25, PP. 701-707, (2005); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BMJ, 95, PP. 968-975, (2006); AVIS H.J., VISSERS M.N., STEIN E.A., WIJBURG F.A., TRIP M.D., KASTELEIN J.J., ET AL., A SYSTEMATIC REVIEW AND META-ANALYSIS OF STATIN THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA, ARTERIOSCLER THROMB VASC BIOL, 27, PP. 1803-1810, (2007)","O. GUARDAMAGNA; DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TURIN, I-10126 TURIN, PIAZZA POLONIA, 94, ITALY; EMAIL: ORNELLA.GUARDAMAGNA@UNITO.IT","","ENGLISH","NUTR. METAB. CARDIOVASC. DIS.","ARTICLE","ISI","2-S2.0-79955972069","NUTR METAB CARDIOVASC DIS","UNIVERSITY OF TURIN;UNIVERSITY OF TURIN;UNIVERSITY OF TURIN;UNIVERSITY OF TURIN;UNIVERSITY OF ROME LA SAPIENZA","NOTREPORTED;UNIVERSITY OF TURIN;NOTREPORTED",NA,"GUARDAMAGNA O, 2011, NUTR METAB CARDIOVASC DIS","GUARDAMAGNA O, 2011, NUTR METAB CARDIOVASC DIS"
"CRAVOTTO G;CALCIO G E;BARGE A;BINELLO A;ALBERTINO A;AGHEMO C","CRAVOTTO, GIANCARLO (7003394420); CALCIO GAUDINO, EMANUELA (23488197200); BARGE, ALESSANDRO (7003400236); BINELLO, ARIANNA (6603442129); ALBERTINO, ANDREA (15838843300); AGHEMO, COSTANZA (36165375600)","SYNTHESIS OF 1OCTACOSANOL AND GCCIRMS DISCRIMINATION OF SAMPLES FROM DIFFERENT ORIGIN",2010,"NATURAL PRODUCT RESEARCH","24","11",14,"10.1080/14786410903194498","DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY;DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY;DIPARTIMENTO DI CHIMICA, IFM, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY;DIPARTIMENTO DI CHIMICA, IFM, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY","LATELY, LONG-CHAIN PRIMARY ALCOHOLS HAVE BEEN INVESTIGATED IN DEPTH ON ACCOUNT OF THEIR BIOLOGICAL ACTIVITIES. IN PARTICULAR, 1-OCTACOSANOL (C 28H57OH), THE MAIN COMPONENT OF POLICOSANOL, THE HYPOLIPIDAEMIC FATTY ALCOHOL MIXTURE OBTAINED FROM SUGAR CANE WAX, HAS BEEN THE SUBJECT OF A MULTITUDE OF PHARMACOLOGICAL STUDIES. THE AIM OF THIS WORK WAS TO SEARCH A CONVENIENT SYNTHETIC PROTOCOL FOR THE PREPARATION OF 1-OCTACOSANOL IN A GRAM SCALE. THE KEY STEP WAS A WITTIG REACTION BETWEEN THE OCTADECYLTRIPHENYLPHOSPHONIUM YLIDE AND THE METHYL 10-OXODECANOATE. SOME STEPS WERE FURTHER IMPROVED BY POWER ULTRASOUND AND MICROWAVE IRRADIATION, EITHER ALONE OR IN COMBINATION. OUR METHODOLOGY IS SUITABLE FOR A RAPID GENERATION OF HOMOLOGUES BY VARYING THE CHAIN LENGTH IN THE ALKYL HALIDE. DUE TO THE HIGH COMMERCIAL VALUE, A SERIES OF 1-OCTACOSANOL SAMPLES, EITHER ISOLATED FROM NATURAL SOURCES OR FROM SYNTHESIS (DIFFERENT ORIGIN AND SUPPLIERS), WERE ANALYSED BY GAS CHROMATOGRAPHY-COMBUSTION-ISOTOPIC RATIO MASS SPECTROMETRY (GC-C-IRMS) AND ACCORDING TO THE CARBON ISOTOPIC CONTENT, CLASSIFIED ON THE BASIS OF THEIR ORIGIN. © 2010 TAYLOR & FRANCIS.","GC-C-IRMS; MICROWAVES; OCTACOSANOL; SYNTHESIS; ULTRASOUND","FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MAGNETIC RESONANCE SPECTROSCOPY; MICROWAVES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SACCHARUM; 1 OCTACOSANOL; DECANOIC ACID DERIVATIVE; METHYL 10 OXODECANOATE; OCTACOSANOL; OCTADECYLTRIPHENYLPHOSPHONIUM YLIDE; UNCLASSIFIED DRUG; ARTICLE; COMBUSTION; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; MICROWAVE IRRADIATION; WITTIG REACTION","UNIVERSITÀ DEGLI STUDI DI TORINO, UNITO","FINANCIAL SUPPORT FROM THE UNIVERSITY OF TORINO IS GRATEFULLY ACKNOWLEDGED. WE ARE INDEBTED TO PROF. MARCO VINCENTI AND DR ALBERTO SALOMONE FOR THE IRMS ANALYSES AT THE CAD (ORBASSANO, TURIN).","AMARENGO W.L.F., PERRIN D.D., PURIFICATION OF LABORATORY CHEMICALS, (1998); BELTZ S.D., DOERING P.L., EFFICACY OF NUTRITIONAL SUPPLEMENTS USED BY ATHLETES, CLINICAL PHARMACOLOGY, 12, PP. 900-908, (1993); CHEN F., WANG Z., ZHAO G., LIAO X., CAI T., GUO L., ET AL., PURIFICATION PROCESS OF OCTACOSANOL EXTRACTS FROM RICE BRAN WAX BY MOLECULAR DISTILLATION, JOURNAL OF FOOD ENGINEERING, 79, PP. 63-68, (2007); COPLEN T.B., REPORTING OF STABLE HYDROGEN, CARBON, AND OXYGEN ISOTOPIC ABUNDANCES, PURE AND APPLIED CHEMISTRY, 66, PP. 273-276, (1994); COPLEN T.B., REPORTING OF STABLE HYDROGEN, CARBON, AND OXYGEN ISOTOPIC ABUNDANCES, GEOTHERMICS, 24, PP. 708-711, (1995); COPLEN T.B., BRAND W.A., GEHRE M., GRONING M., MEIJER H.A.J., TOMAN B., ET AL., AFTER TWO DECADES A SECOND ANCHOR FOR THE VPDB DELTA C-13 SCALE, RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 20, PP. 3165-3166, (2006); CRAVOTTO G., A PROCESS FOR PREPARING LONG CHAIN SATURATED OR UNSATURATED OXYGENATED COMPOUNDS, (2005); CRAVOTTO G., BOFFA L., MANTEGNA S., AVOGADRO M., PEREGO P., CINTAS P., IMPROVED EXTRACTION OF NATURAL MATRICES UNDER HIGH-INTENSITY ULTRASOUND AND MICROWAVE, ALONE OR COMBINED, ULTRASONIC SONOCHEMISTRY, 15, PP. 898-902, (2008); CRAVOTTO G., CINTAS P., THE COMBINED USE OF MICROWAVES AND ULTRASOUND: NEW TOOLS IN PROCESS CHEMISTRY AND ORGANIC SYNTHESIS, CHEMISTRY: A EUROPEAN JOURNAL, 13, PP. 1902-1909, (2007); HERNA NDEZ F., ILLNAIT J., MA S.R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 568-575, (1992); HOUTZ R.L., RIES S.K., TOLBERT N.E., EFFECT OF TRIACONTANOL ON CHLAMYDOMONAS: I. STIMULATION OF GROWTH AND PHOTOSYNTHETIC CO2 ASSIMILATION, PLANT PHYSIOLOGY, 79, PP. 357-364, (1985); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANNALS OF NUTRITIONAL AND METABOLISM, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., DISTRIBUTION OF RADIOACTIVE OCTACOSANOL IN RESPONSE TO EXERCISE IN RATS, NAHRUNG, 38, PP. 373-377, (1994); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANNALS OF NUTRITIONAL AND METABOLISM, 39, PP. 279-284, (1995); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NATURAL STEROL AND BILE ACID CONCENTRATION IN FAECES, LIPIDS, 43, PP. 109-115, (2008); MA S.R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., SOTOLONGO V., FRAGA V., AMOR A.M., GONZE LEZ R., DEL RIO A., ET AL., PLASMA LEVELS AND TOTAL RADIOACTIVITY EXCRETION IN HEALTHY VOLUNTEERS AFTER ORAL 3HOCTACOSANOL ADMINISTRATION, REVISTA CENIC CIENCIAS BIOLOGICAS, 27, PP. 32-35, (1996); NORRIS F.H., DENYS E.H., FALLAT R.J., TRIAL OF OCTACOSANOL IN AMYOTROPHIC LATERAL SCLEROSIS, NEUROLOGY, 36, PP. 1264-1264, (1986); PALMISANO G., TAGLIAPIETRA S., BARGE A., BINELLO A., BOFFA L., CRAVOTTO G., EFFICIENT REGIOSELECTIVE OPENING OF EPOXIDES BY NUCLEOPHILES IN WATER UNDER SIMULTANEOUS ULTRASOUND/MICROWAVE IRRADIATION, SYNLETT, 13, PP. 2041-2044, (2007); SAINT-JOHN M., MC NAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME AND CHEST AND GRIP STRENGTH, INTERNATIONAL CLINICAL NUTRITIONAL REVIEW, 6, PP. 81-87, (1986); SHIMURA S., HASEGAWA T., TAKANO S., SUZUKI T., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTRITIONAL REPORTS INTERNATIONAL, 36, PP. 1029-1036, (1987); SHO H., CHINEN I., FUKUDA N., EFFECTS OF OKINAWAN SUGAR CANE WAX AND FATTY ALCOHOL ON SERUM AND LIVER LIPIDS IN THE RAT, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 30, PP. 553-559, (1984); SIERRA R., GONZA LEZ V., MAGRANER J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN 10 MG FILM-COATED TABLETS, THE JOURNAL OF AOAC INTERNATIONAL, 85, PP. 563-566, (2002); SNIDER S.R., OCTACOSANOL IN PARKINSONISM, ANNALS OF NEUROLOGY, 16, PP. 723-723, (1984); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MEDITERRANEAN JOURNAL OF NUTRITIONAL AND METABOLISM, 1, PP. 77-83, (2008); VOY R., ILLICIT DRUGS AND THE ATHLETE, AMERICAN PHARMACY, 26, PP. 39-45, (1986); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, PP. 5552-5558, (2007); WOOLLEY B.H., THE LATEST FADS TO INCREASE MUSCLE MASS AND ENERGY: A LOOK AT WHAT SOME ATHLETES ARE USING, POSTGRADUATE MEDICINE, 89, PP. 195-205, (1991)","G. CRAVOTTO; DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, UNIVERSITÀ DI TORINO, 10125 TORINO, ITALY; EMAIL: GIANCARLO.CRAVOTTO@UNITO.IT","","ENGLISH","NAT. PROD. RES.","ARTICLE","ISI","2-S2.0-77950121134","NAT PROD RES","UNIVERSITÀ DI TORINO;UNIVERSITÀ DI TORINO;UNIVERSITÀ DI TORINO;UNIVERSITÀ DI TORINO;UNIVERSITÀ DI TORINO;UNIVERSITÀ DI TORINO","NOTREPORTED;UNIVERSITÀ DI TORINO;NOTREPORTED",NA,"CRAVOTTO G, 2010, NAT PROD RES","CRAVOTTO G, 2010, NAT PROD RES"
"NIJJAR P;BURKE F;BLOESCH A;RADER D","NIJJAR, PRABHJOT S. (16068917400); BURKE, FRANCES M. (23468557300); BLOESCH, ANNETTE (55947271500); RADER, DANIEL J. (7006990678)","ROLE OF DIETARY SUPPLEMENTS IN LOWERING LOWDENSITY LIPOPROTEIN CHOLESTEROL A REVIEW",2010,"JOURNAL OF CLINICAL LIPIDOLOGY","4","10",76,"10.1016/j.jacl.2010.07.001","INSTITUTE OF TRANSLATIONAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PENNSYLVANIA, SCHOOL OF MEDICINE, PHILADELPHIA, PA 19104-6160, 654 BRBII/III, UNITED STATES;INSTITUTE OF TRANSLATIONAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PENNSYLVANIA, SCHOOL OF MEDICINE, PHILADELPHIA, PA 19104-6160, 654 BRBII/III, UNITED STATES;ALBERT EINSTEIN MEDICAL CENTER, PHILADELPHIA, PA, UNITED STATES;INSTITUTE OF TRANSLATIONAL MEDICINE AND THERAPEUTICS, UNIVERSITY OF PENNSYLVANIA, SCHOOL OF MEDICINE, PHILADELPHIA, PA 19104-6160, 654 BRBII/III, UNITED STATES","CORONARY HEART DISEASE (CHD) REMAINS A MAJOR SOURCE OF MORBIDITY AND MORTALITY. AS THE EPIDEMIC OF OBESITY, DIABETES, AND HYPERTENSION CONTINUES TO GROW AMONG YOUNG ADULTS, THE POPULATION AT RISK FOR ATHEROSCLEROTIC CHD IS EVER INCREASING. MORE THAN A CENTURY OF LABORATORY AND HUMAN FINDINGS LINK CHOLESTEROL LEVELS WITH A PROPENSITY TO DEVELOP ATHEROSCLEROSIS. LOW-DENSITY LIPOPROTEIN (LDL) IS THE MAJOR ATHEROGENIC LIPOPROTEIN, AND NUMEROUS CLINICAL TRIALS HAVE SHOWN THE EFFICACY OF LOWERING LDLCHOLESTEROL (LDL-C) FOR REDUCING CHD RISK. NEW TRIAL DATA HAVE RESULTED IN LDL-C GOALS BEING LOWERED OVER TIME AND EXPANSION OF THE POPULATION OF PATIENTS THAT ARE CANDIDATES FOR LDL-LOWERING THERAPY TO DECREASE THEIR LIFETIME RISK OF CHD. ALTHOUGH STATINS ARE RELATIVELY SAFE AND WELL TOLERATED, THERE ARE STILL SIGNIFICANT NUMBERS OF PATIENTS WHO CANNOT TOLERATE THEM AND MANY OTHERS WHO ONLY REQUIRE MILD LDL-C REDUCTION AND PREFER NONPRESCRIPTION ALTERNATIVES TO STATIN THERAPY. A NUMBER OF DIETARY SUPPLEMENTS AND FUNCTIONAL FOODS HAVE BEEN SUGGESTED TO REDUCE LDL-C LEVELS, BUT ONLY A FEW HAVE WITHSTOOD THE RIGORS OF RANDOMIZED CONTROLLED TRIALS. HERE WE REVIEW THE EVIDENCE IN SUPPORT OF DIETARY SUPPLEMENTS AND THEIR LDL-C2LOWERING EFFECTS. WE ALSO REVIEW SUPPLEMENTS THAT, AFTER INITIAL EXCITEMENT ABOUT THEIR PURPORTED EFFECT, WERE NOT FOUND TO LOWER LDL-C SIGNIFICANTLY. © 2010 NATIONAL LIPID ASSOCIATION.","DIETARY SUPPLEMENT; LDL CHOLESTEROL; NUTRACEUTICAL; SUPPLEMENT","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DIETARY FIBER; DIETARY SUPPLEMENTS; HUMANS; PHYTOSTEROLS; SOYBEAN PROTEINS; CHOLESTIN; CYTELLIN; DAIDZIN; GENISTIN; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PHYTOSTEROL; POLICOSANOL; SIMVASTATIN; SOYBEAN PROTEIN; STANOZOLOL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; SOYBEAN PROTEIN; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GARLIC; HUMAN; NUT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIETARY FIBER; METABOLISM","","","MCNAMARA D.J., CHOLESTEROL AND ATHEROSCLEROSIS, BIOCHIM BIOPHYS ACTA, 1529, PP. 310-320, (2000); LAW M.R., WALD N.J., THOMPSON S.G., BY HOW MUCH AND HOW QUICKLY DOES REDUCTION IN SERUM CHOLESTEROL CONCENTRATION LOWER RISK OF ISCHAEMIC HEART DISEASE?, BMJ, 308, PP. 367-372, (1994); JAMA, 285, PP. 2486-2497, (2001); KELLY J.P., KAUFMAN D.W., KELLEY K., ROSENBERG L., ANDERSON T.E., MITCHELL A.A., RECENT TRENDS IN USE OF HERBAL AND OTHER NATURAL PRODUCTS, ARCH INTERN MED, 165, PP. 281-286, (2005); BARNES P.M., BLOOM B., NAHIN R.L., COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG ADULTS AND CHILDREN: UNITED STATES, 2007, NATL HEALTH STAT REP, PP. 1-23, (2008); LIU S., STAMPFER M.J., HU F.B., ET AL., WHOLE-GRAIN CONSUMPTION AND RISK OF CORONARY HEART DISEASE: RESULTS FROM THE NURSES' HEALTH STUDY, AM J CLIN NUTR, 70, PP. 412-419, (1999); BAZZANO L.A., HE J., OGDEN L.G., LORIA C.M., WHELTON P.K., DIETARY FIBER INTAKE AND REDUCED RISK OF CORONARY HEART DISEASE INUS MEN ANDWOMEN: THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY I EPIDEMIOLOGIC FOLLOW-UP STUDY, ARCH INTERN MED, 163, PP. 1897-1904, (2003); PEREIRA M.A., O'REILLY E., AUGUSTSSON K., ET AL., DIETARY FIBER AND RISK OF CORONARY HEART DISEASE: A POOLED ANALYSIS OF COHORT STUDIES, ARCH INTERN MED, 164, PP. 370-376, (2004); ANDERSON J.W., TIETYEN-CLARK J., DIETARY FIBER: HYPERLIPIDEMIA, HYPERTENSION, AND CORONARY HEART DISEASE, AM J GASTROENTEROL, 81, PP. 907-919, (1986); JENKINS D.J., JOSSE A.R., WONG J.M., ET AL., NUTRICEUTICALS AND FUNCTIONAL FOODS FOR CHOLESTEROL REDUCTION, CLINICAL LIPIDOLOGY: A COMPANION TO BRAUNWALD'S HEART DISEASE, (2009); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); LEINONEN K.S., POUTANEN K.S., MYKKANEN H.M., RYE BREAD DECREASES SERUM TOTAL AND LDL CHOLESTEROL IN MEN WITH MODERATELY ELEVATED SERUM CHOLESTEROL, J NUTR, 130, PP. 164-170, (2000); BLUNDELL J.E., BURLEY V.J., SATIATION, SATIETY AND THE ACTION OF FIBRE ON FOOD INTAKE, INT J OBES, 11, PP. 9-25, (1987); KRIS-ETHERTON P.M., KRUMMEL D., RUSSELL M.E., ET AL., THE EFFECT OF DIET ON PLASMA LIPIDS, LIPOPROTEINS, AND CORONARY HEART DISEASE, J AM DIET ASSOC, 88, PP. 1373-1400, (1988); RIPSIN C.M., KEENAN J.M., JACOBS JR. D.R., ET AL., OAT PRODUCTS AND LIPID LOWERING. A META-ANALYSIS, JAMA, 267, PP. 3317-3325, (1992); ARVILL A., BODIN L., EFFECT OF SHORT-TERM INGESTION OF KONJAC GLUCOMANNAN ON SERUM CHOLESTEROL IN HEALTHY MEN, AM J CLIN NUTR, 61, PP. 585-589, (1995); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); MOREYRA A.E., WILSON A.C., KORAYM A., EFFECT OF COMBINING PSYLLIUM FIBER WITH SIMVASTATIN IN LOWERING CHOLESTEROL, ARCH INTERN MED, 165, PP. 1161-1166, (2005); FERNANDEZ M.L., VEGA-LOPEZ S., EFFICACY AND SAFETY OF SITOSTEROL IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, CARDIOVASC DRUG REV, 23, PP. 57-70, (2005); POLLAK O.J., KRITCHEVSKY D., SITOSTEROL MONOGRAPHS ATHEROSCLEROSIS, 10, (1981); GENERAL VIEW OF THE SCIENTIFIC COMMITTEE ON FOOD ON THE LONG TERM EFFECTS OF THE INTAKE OF ELEVATED LEVELS OF PHYTOSTEROLS FROM MULTIPLE DIETARY SOURCES, SCIENTIFIC COMMITTEE ON FOOD, (2002); ITO T., TAMURA T., MATSUMOTO T., STEROL COMPOSITION OF 19 VEGETABLE OILS, J AM OIL CHEM SOC, 50, PP. 122-125, (1973); AMARAL J.S., CASAL S., PEREIRA J.A., SEABRA R.M., OLIVEIRA B.P., DETERMINATION OF STEROL AND FATTY ACID COMPOSITIONS, OXIDATIVE STABILITY, AND NUTRITIONAL VALUE OF SIX WALNUT (JUGLANS REGIA L.) CULTIVARS GROWN IN PORTUGAL, J AGRIC FOOD CHEM, 51, PP. 7698-7702, (2003); PATCH C.S., TAPSELL L.C., WILLIAMS P.G., GORDON M., PLANT STEROLS AS DIETARY ADJUVANTS IN THE REDUCTION OF CARDIOVASCULAR RISK: THEORY AND EVIDENCE, VASC HEALTH RISK MANAG, 2, PP. 157-162, (2006); JONES P.J., RAEINI-SARJAZ M., NTANIOS F.Y., VANSTONE C.A., FENG J.Y., PARSONS W.E., MODULATION OF PLASMA LIPID LEVELS AND CHOLESTEROL KINETICS BY PHYTOSTEROL VERSUS PHYTOSTANOL ESTERS, J LIPID RES, 41, PP. 697-705, (2000); BERGER A., JONES P.J., ABUMWEIS S.S., PLANT STEROLS: FACTORS AFFECTING THEIR EFFICACY AND SAFETY AS FUNCTIONAL FOOD INGREDIENTS, LIPIDS HEALTH DIS, 3, (2004); HALLIKAINEN M.A., SARKKINEN E.S., GYLLING H., ERKKILA A.T., UUSITUPA M.I., COMPARISON OF THE EFFECTS OF PLANT STEROL ESTER AND PLANT STANOL ESTERENRICHED MARGARINES IN LOWERING SERUM CHOLESTEROL CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC SUBJECTS ON A LOW-FAT DIET, EUR J CLIN NUTR, 54, PP. 715-725, (2000); WEINGARTNER O., BOHM M., LAUFS U., CONTROVERSIAL ROLE OF PLANT STEROL ESTERS IN THE MANAGEMENT OF HYPERCHOLESTEROLAEMIA, EUR HEART J, 30, PP. 404-409, (2009); MIETTINEN T.A., GYLLING H., PLANT STANOL AND STEROL ESTERS IN PREVENTION OF CARDIOVASCULAR DISEASES, ANN MED, 36, PP. 126-134, (2004); FRANSEN H.P., DE JONG N., WOLFS M., ET AL., CUSTOMARY USE OF PLANT STEROL AND PLANT STANOL ENRICHED MARGARINE IS ASSOCIATED WITH CHANGES IN SERUM PLANT STEROL AND STANOL CONCENTRATIONS IN HUMANS, J NUTR, 137, PP. 1301-1306, (2007); TALATI R., SOBIERAJ D.M., MAKANJI S.S., PHUNG O.J., COLEMAN C.I., THE COMPARATIVE EFFICACY OF PLANT STEROLS AND STANOLS ON SERUM LIPIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS, J AM DIET ASSOC, 110, PP. 719-726; MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N ENGL J MED, 333, PP. 1308-1312, (1995); HALLIKAINEN M.A., SARKKINEN E.S., UUSITUPA M.I., PLANT STANOL ESTERS AFFECT SERUM CHOLESTEROL CONCENTRATIONS OF HYPERCHOLESTEROLEMIC MEN AND WOMEN IN A DOSE-DEPENDENT MANNER, J NUTR, 130, PP. 767-776, (2000); VOLPE R., NIITTYNEN L., KORPELA R., ET AL., EFFECTS OF YOGHURT ENRICHED WITH PLANT STEROLS ON SERUM LIPIDS IN PATIENTS WITH MODERATE HYPERCHOLESTEROLAEMIA, BR J NUTR, 86, PP. 233-239, (2001); DAVIDSON M.H., MAKI K.C., UMPOROWICZ D.M., ET AL., SAFETY AND TOLERABILITY OF ESTERIFIED PHYTOSTEROLS ADMINISTERED IN REDUCED-FAT SPREAD AND SALAD DRESSING TO HEALTHY ADULT MEN AND WOMEN, J AM COLL NUTR, 20, PP. 307-319, (2001); VANSTONE C.A., RAEINI-SARJAZ M., PARSONS W.E., JONES P.J., UNESTERIFIED PLANT STEROLS AND STANOLS LOWER LDL-CHOLESTEROL CONCENTRATIONS EQUIVALENTLY IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 76, PP. 1272-1278, (2002); DEVARAJ S., JIALAL I., VEGA-LOPEZ S., PLANT STEROL-FORTIFIED ORANGE JUICE EFFECTIVELY LOWERS CHOLESTEROL LEVELS IN MILDLY HYPERCHOLESTEROLEMIC HEALTHY INDIVIDUALS, ARTERIOSCLER THROMB VASC BIOL, 24, (2004); GOLDBERG A.C., OSTLUND JR. R.E., BATEMAN J.H., SCHIMMOELLER L., MCPHERSON T.B., SPILBURG C.A., EFFECT OF PLANT STANOL TABLETS ON LOWDENSITY LIPOPROTEIN CHOLESTEROL LOWERING IN PATIENTS ON STATIN DRUGS, AM J CARDIOL, 97, PP. 376-379, (2006); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., ET AL., CONTINUOUS DOSERESPONSE RELATIONSHIP OF THE LDL-CHOLESTEROL-LOWERING EFFECT OF PHYTOSTEROL INTAKE, J NUTR, 139, PP. 271-284, (2009); MIETTINEN T.A., STRANDBERG T.E., GYLLING H., NONCHOLESTEROL STEROLS AND CHOLESTEROL LOWERING BY LONG-TERM SIMVASTATIN TREATMENT IN CORONARY PATIENTS: RELATION TO BASAL SERUM CHOLESTANOL, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 1340-1346, (2000); VANHANEN H., CHOLESTEROL MALABSORPTION CAUSED BY SITOSTANOL ESTER FEEDING AND NEOMYCIN IN PRAVASTATIN-TREATED HYPERCHOLESTEROLAEMIC PATIENTS, EUR J CLIN PHARMACOL, 47, PP. 169-176, (1994); GYLLING H., RADHAKRISHNAN R., MIETTINEN T.A., REDUCTION OF SERUM CHOLESTEROL IN POSTMENOPAUSAL WOMEN WITH PREVIOUS MYOCARDIAL INFARCTION AND CHOLESTEROL MALABSORPTION INDUCED BY DIETARY SITOSTANOL ESTER MARGARINE: WOMEN AND DIETARY SITOSTANOL, CIRCULATION, 96, PP. 4226-4231, (1997); NEIL H.A., MEIJER G.W., ROE L.S., RANDOMISED CONTROLLED TRIAL OF USE BY HYPERCHOLESTEROLAEMIC PATIENTS OF A VEGETABLE OIL STEROL-ENRICHED FAT SPREAD, ATHEROSCLEROSIS, 156, PP. 329-337, (2001); SIMONS L.A., ADDITIVE EFFECT OF PLANT STEROL-ESTER MARGARINE AND CERIVASTATIN IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 90, PP. 737-740, (2002); CLIFTON P.M., NOAKES M., SULLIVAN D., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PLANT STEROL ESTERS DIFFER IN MILK, YOGHURT, BREAD AND CEREAL, EUR J CLIN NUTR, 58, PP. 503-509, (2004); VAN HORN L., MCCOIN M., KRIS-ETHERTON P.M., ET AL., THE EVIDENCE FOR DIETARY PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, J AM DIET ASSOC, 108, PP. 287-331, (2008); BHATTACHARYYA A.K., CONNOR W.E., BETA-SITOSTEROLEMIA AND XANTHOMATOSIS. A NEWLY DESCRIBED LIPID STORAGE DISEASE IN TWO SISTERS, J CLIN INVEST, 53, PP. 1033-1043, (1974); LU K., LEE M.H., HAZARD S., ET AL., TWO GENES THAT MAP TO THE STSL LOCUS CAUSE SITOSTEROLEMIA: GENOMIC STRUCTURE AND SPECTRUM OF MUTATIONS INVOLVING STEROLIN-1 AND STEROLIN-2, ENCODED BY ABCG5 AND ABCG8, RESPECTIVELY, AM J HUM GENET, 69, PP. 278-290, (2001); SALEN G., SHEFER S., NGUYEN L., NESS G.C., TINT G.S., SHORE V., SITOSTEROLEMIA, J LIPID RES, 33, PP. 945-955, (1992); KWITEROVICH JR. P.O., CHEN S.C., VIRGIL D.G., SCHWEITZER A., ARNOLD D.R., KRATZ L.E., RESPONSE OF OBLIGATE HETEROZYGOTES FOR PHYTOSTEROLEMIA TO A LOW-FAT DIET AND TO A PLANT STEROL ESTER DIETARY CHALLENGE, J LIPID RES, 44, PP. 1143-1155, (2003); WILUND K.R., YU L., XU F., ET AL., NO ASSOCIATION BETWEEN PLASMA LEVELS OF PLANT STEROLS AND ATHEROSCLEROSIS IN MICE AND MEN, ARTERIOSCLER THROMB VASC BIOL, 24, PP. 2326-2332, (2004); MIETTINEN T.A., RAILO M., LEPANTALO M., GYLLING H., PLANT STEROLS IN SERUM AND IN ATHEROSCLEROTIC PLAQUES OF PATIENTS UNDERGOING CAROTID ENDARTERECTOMY, J AM COLL CARDIOL, 45, PP. 1794-1801, (2005); CLIFTON P.M., NOAKES M., ROSS D., FASSOULAKIS A., CEHUN M., NESTEL P., HIGH DIETARY INTAKE OF PHYTOSTEROL ESTERS DECREASES CAROTENOIDS AND INCREASES PLASMA PLANT STEROL LEVELS WITH NO ADDITIONAL CHOLESTEROL LOWERING, J LIPID RES, 45, PP. 1493-1499, (2004); NOAKES M., CLIFTON P., NTANIOS F., SHRAPNEL W., RECORD I., MCINERNEY J., AN INCREASE IN DIETARY CAROTENOIDS WHEN CONSUMING PLANT STEROLS OR STANOLS IS EFFECTIVE IN MAINTAINING PLASMA CAROTENOID CONCENTRATIONS, AM J CLIN NUTR, 75, PP. 79-86, (2002); HILLEBOE H.E., SOME EPIDEMIOLOGIC ASPECTS OF CORONARY ARTERY DISEASE, J CHRONIC DIS, 6, PP. 210-228, (1957); SACKS F.M., LICHTENSTEIN A., VAN HORN L., HARRIS W., KRIS-ETHERTON P., WINSTON M., SOY PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH: AN AMERICAN HEART ASSOCIATION SCIENCE ADVISORY FOR PROFESSIONALS FROM THE NUTRITION COMMITTEE, CIRCULATION, 113, PP. 1034-1044, (2006); IGNATOWSKI A.I., UEBER DIE WIRKUNG DER TIERSHEN EINWESSES AUF DER AORTA, VIRCHOW'S ARCH PATHOL ANAT, 198, (1909); SIRTORI C.R., AGRADI E., CONTI F., MANTERO O., GATTI E., SOYBEAN-PROTEIN DIET IN THE TREATMENT OF TYPE-II HYPERLIPOPROTEINAEMIA, LANCET, 1, PP. 275-277, (1977); CARROLL K.K., HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS: EFFECTS OF DIETARY PROTEIN, FED PROC, 41, PP. 2792-2796, (1982); CARROLL K.K., REVIEW OF CLINICAL STUDIES ON CHOLESTEROL-LOWERING RESPONSE TO SOY PROTEIN, J AM DIET ASSOC, 91, PP. 820-827, (1991); CASSIDY A., BINGHAM S., SETCHELL K., BIOLOGICAL EFFECTS OF ISOFLAVONES IN YOUNG WOMEN: IMPORTANCE OF THE CHEMICAL COMPOSITION OF SOYABEAN PRODUCTS, BR J NUTR, 74, PP. 587-601, (1995); CROUSE III J.R., MORGAN T., TERRY J.G., ELLIS J., VITOLINS M., BURKE G.L., A RANDOMIZED TRIAL COMPARING THE EFFECT OF CASEIN WITH THAT OF SOY PROTEIN CONTAINING VARYING AMOUNTS OF ISOFLAVONES ON PLASMA CONCENTRATIONS OF LIPIDS AND LIPOPROTEINS, ARCH INTERN MED, 159, PP. 2070-2076, (1999); LOVATI M.R., MANZONI C., GIANAZZA E., ET AL., SOY PROTEIN PEPTIDES REGULATE CHOLESTEROL HOMEOSTASIS IN HEP G2 CELLS, J NUTR, 130, PP. 2543-2549, (2000); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); HARLAND J.I., HAFFNER T.A., SYSTEMATIC REVIEW, META-ANALYSIS AND REGRESSION OF RANDOMISED CONTROLLED TRIALS REPORTING AN ASSOCIATION BETWEEN AN INTAKE OF CIRCA 25 G SOYA PROTEIN PER DAY AND BLOOD CHOLESTEROL, ATHEROSCLEROSIS, 200, PP. 13-27, (2008); REYNOLDS K., CHIN A., LEES K.A., NGUYEN A., BUJNOWSKI D., HE J., A META-ANALYSIS OF THE EFFECT OF SOY PROTEIN SUPPLEMENTATION ON SERUM LIPIDS, AM J CARDIOL, 98, PP. 633-640, (2006); APPEL L.J., SACKS F.M., CAREY V.J., ET AL., EFFECTS OF PROTEIN, MONOUNSATURATED FAT, AND CARBOHYDRATE INTAKE ON BLOOD PRESSURE AND SERUM LIPIDS: RESULTS OF THE OMNIHEART RANDOMIZED TRIAL, JAMA, 294, PP. 2455-2464, (2005); ALBERT C.M., GAZIANO J.M., WILLETT W.C., MANSON J.E., NUT CONSUMPTION AND DECREASED RISK OF SUDDEN CARDIAC DEATH IN THE PHYSICIANS' HEALTH STUDY, ARCH INTERN MED, 162, PP. 1382-1387, (2002); ELLSWORTH J.L., KUSHI L.H., FOLSOM A.R., FREQUENT NUT INTAKE AND RISK OF DEATH FROM CORONARY HEART DISEASE AND ALL CAUSES IN POSTMENOPAUSAL WOMEN: THE IOWA WOMEN'S HEALTH STUDY, NUTR METAB CARDIOVASC DIS, 11, PP. 372-377, (2001); FRASER G.E., SABATE J., BEESON W.L., STRAHAN T.M., A POSSIBLE PROTECTIVE EFFECT OF NUT CONSUMPTION ON RISK OF CORONARY HEART DISEASE. THE ADVENTIST HEALTH STUDY, ARCH INTERN MED, 152, PP. 1416-1424, (1992); HU F.B., STAMPFER M.J., MANSON J.E., ET AL., FREQUENT NUT CONSUMPTION AND RISK OF CORONARY HEART DISEASE IN WOMEN: PROSPECTIVE COHORT STUDY, BMJ, 317, PP. 1341-1345, (1998); MENSINK R.P., KATAN M.B., EFFECT OF DIETARY FATTY ACIDS ON SERUM LIPIDS AND LIPOPROTEINS. A META-ANALYSIS OF 27 TRIALS, ARTERIOSCLER THROMB, 12, PP. 911-919, (1992); LI L., TSAO R., YANG R., KRAMER J.K., HERNANDEZ M., FATTY ACID PROFILES, TOCOPHEROL CONTENTS, AND ANTIOXIDANT ACTIVITIES OF HEARTNUT (JUGLANS AILANTHIFOLIA VAR. CORDIFORMIS) AND PERSIAN WALNUT (JUGLANS REGIA L.), J AGRIC FOOD CHEM, 55, PP. 1164-1169, (2007); SABATE J., FRASER G.E., BURKE K., KNUTSEN S.F., BENNETT H., LINDSTED K.D., EFFECTS OF WALNUTS ON SERUM LIPID LEVELS AND BLOOD PRESSURE IN NORMAL MEN, N ENGL J MED, 328, PP. 603-607, (1993); SPILLER G.A., JENKINS D.A., BOSELLO O., GATES J.E., CRAGEN L.N., BRUCE B., NUTS AND PLASMA LIPIDS: AN ALMOND-BASED DIET LOWERS LDL-C WHILE PRESERVING HDL-C, J AM COLL NUTR, 17, PP. 285-290, (1998); CHISHOLM A., MANN J., SKEAFF M., ET AL., A DIET RICH IN WALNUTS FAVOURABLY INFLUENCES PLASMA FATTY ACID PROFILE IN MODERATELY HYPERLIPIDAEMIC SUBJECTS, EUR J CLIN NUTR, 52, PP. 12-16, (1998); EDWARDS K., KWAW I., MATUD J., KURTZ I., EFFECT OF PISTACHIO NUTS ON SERUM LIPID LEVELS IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, J AM COLL NUTR, 18, PP. 229-232, (1999); MORGAN W.A., CLAYSHULTE B.J., PECANS LOWER LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PEOPLE WITH NORMAL LIPID LEVELS, J AM DIET ASSOC, 100, PP. 312-318, (2000); CURB J.D., WERGOWSKE G., DOBBS J.C., ABBOTT R.D., HUANG B., SERUM LIPID EFFECTS OF A HIGH-MONOUNSATURATED FAT DIET BASED ON MACADAMIA NUTS, ARCH INTERN MED, 160, PP. 1154-1158, (2000); ZAMBON D., SABATE J., MUNOZ S., ET AL., SUBSTITUTING WALNUTS FOR MONOUNSATURATED FAT IMPROVES THE SERUM LIPID PROFILE OF HYPERCHOLESTEROLEMIC MEN AND WOMEN. A RANDOMIZED CROSSOVER TRIAL, ANN INTERN MED, 132, PP. 538-546, (2000); RAJARAM S., BURKE K., CONNELL B., MYINT T., SABATE J., AMONOUNSATURATED FATTY ACID-RICH PECAN-ENRICHED DIET FAVORABLY ALTERS THE SERUM LIPID PROFILE OF HEALTHY MEN AND WOMEN, J NUTR, 131, PP. 2275-2279, (2001); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., DOSE RESPONSE OF ALMONDS ON CORONARY HEART DISEASE RISK FACTORS: BLOOD LIPIDS, OXIDIZED LOW-DENSITY LIPOPROTEINS, LIPOPROTEIN(A), HOMOCYSTEINE, AND PULMONARY NITRIC OXIDE: A RANDOMIZED, CONTROLLED, CROSSOVER TRIAL, CIRCULATION, 106, PP. 1327-1332, (2002); ALMARIO R.U., VONGHAVARAVAT V., WONG R., KASIM-KARAKAS S.E., EFFECTS OF WALNUT CONSUMPTION ON PLASMA FATTY ACIDS AND LIPOPROTEINS IN COMBINED HYPERLIPIDEMIA, AM J CLIN NUTR, 74, PP. 72-79, (2001); KRIS-ETHERTON P.M., PEARSON T.A., WAN Y., ET AL., HIGH-MONOUNSATURATED FATTY ACID DIETS LOWER BOTH PLASMA CHOLESTEROL AND TRIACYLGLYCEROL CONCENTRATIONS, AM J CLIN NUTR, 70, PP. 1009-1015, (1999); BANEL D.K., HU F.B., EFFECTS OF WALNUT CONSUMPTION ON BLOOD LIPIDS AND OTHER CARDIOVASCULAR RISK FACTORS: A META-ANALYSIS AND SYSTEMATIC REVIEW, AM J CLIN NUTR, 90, PP. 56-63, (2009); SABATE J., CORDERO-MACINTYRE Z., SIAPCO G., TORABIAN S., HADDAD E., DOES REGULAR WALNUT CONSUMPTION LEAD TO WEIGHT GAIN?, BR J NUTR, 94, PP. 859-864, (2005); FOSTER G.D., WYATT H.R., HILL J.O., ET AL., A RANDOMIZED TRIAL OF A LOWCARBOHYDRATE DIET FOR OBESITY, N ENGL JMED, 348, 21, PP. 2082-2090, (2003); KRIS-ETHERTON P.M., ZHAO G., BINKOSKI A.E., COVAL S.M., ETHERTON T.D., THE EFFECTS OF NUTS ON CORONARY HEART DISEASE RISK, NUTR REV, 59, PP. 103-111, (2001); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); ENDO A., MONACOLIN K., A NEW HYPOCHOLESTEROLEMIC AGENT PRODUCED BY A MONASCUS SPECIES, J ANTIBIOT (TOKYO), 32, PP. 852-854, (1979); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); HUANG C.F., LI T.C., LIN C.C., LIU C.S., SHIH H.C., LAI M.M., EFFICACY OF MONASCUS PURPUREUSWENT RICE ON LOWERING LIPID RATIOS IN HYPERCHOLESTEROLEMIC PATIENTS, EUR J CARDIOVASC PREV REHABIL, 14, PP. 438-440, (2007); LIU J., ZHANG J., SHI Y., GRIMSGAARD S., ALRAEK T., FONNEBO V., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); BECKER D.J., GORDON R.Y., MORRIS P.B., ET AL., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLIN PROC, 83, PP. 758-764, (2008); THOMPSON P.D., CLARKSON P., KARAS R.H., STATIN-ASSOCIATED MYOPATHY, JAMA, 289, PP. 1681-1690, (2003); HALBERT S.C., FRENCH B., GORDON R.Y., ET AL., TOLERABILITY OF RED YEAST RICE (2,400 MG TWICE DAILY) VERSUS PRAVASTATIN (20 MG TWICE DAILY) IN PATIENTS WITH PREVIOUS STATIN INTOLERANCE, AM J CARDIOL, 105, PP. 198-204; LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); MOORE R., LETTER TO SONIA RODRIGUEZ, MASON VITAMINS, (2001); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, PP. 133-139, (2001); CARTIN-CEBA R., LU L.B., KOLPAKCHI A., A 'NATURAL' THREAT, AM J MED, 120, (2007); LAPI F., GALLO E., BERNASCONI S., ET AL., MYOPATHIES ASSOCIATED WITH RED YEAST RICE AND LIQUORICE: SPONTANEOUS REPORTS FROM THE ITALIAN SURVEILLANCE SYSTEM OF NATURAL HEALTH PRODUCTS, BR J CLIN PHARMACOL, 66, PP. 572-574, (2008); MUELLER P.S., SYMPTOMATIC MYOPATHY DUE TO RED YEAST RICE, ANN INTERN MED, 145, PP. 474-475, (2006); PRASAD G.V., WONG T., MELITON G., BHALOO S., RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, PP. 1200-1201, (2002); ROSELLE H., EKATAN A., TZENG J., SAPIENZA M., KOCHER J., SYMPTOMATIC HEPATITIS ASSOCIATED WITH THE USE OF HERBAL RED YEAST RICE, ANN INTERN MED, 149, PP. 516-517, (2008); LIN Y.L., WANG T.H., LEE M.H., SU N.W., BIOLOGICALLY ACTIVE COMPONENTS AND NUTRACEUTICALS IN THE MONASCUS-FERMENTED RICE: A REVIEW, APPL MICROBIOL BIOTECHNOL, 77, PP. 965-973, (2008); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CASTANO G., MAS FERREIRO R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14- MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); MATSUURA H., SAPONINS IN GARLIC AS MODIFIERS OF THE RISK OF CARDIOVASCULAR DISEASE, J NUTR, 131, (2001); YEH Y.Y., LIU L., CHOLESTEROL-LOWERING EFFECT OF GARLIC EXTRACTS AND ORGANOSULFUR COMPOUNDS: HUMAN AND ANIMAL STUDIES, J NUTR, 131, (2001); BOREK C., GARLIC REDUCES DEMENTIA AND HEART-DISEASE RISK, J NUTR, 136, (2006); REUTER H.D., KOCH H., LAWSON L.D., THERAPEUTIC EFFECTS AND APPLICATIONS OF GARLIC AND ITS PREPARATIONS. IN: KOCH H, LAWSON LD, EDITORS, GARLICDTHE SCIENCE AND THERAPEUTIC APPLICATION OF ALLIUM SATIVUM LAND-RELATED SPECIES, (1996); WARSHAFSKY S., KAMER R.S., SIVAK S.L., EFFECT OF GARLIC ON TOTAL SERUM CHOLESTEROL. A META-ANALYSIS, ANN INTERN MED, 119, PP. 599-605, (1993); SILAGY C., NEIL A., GARLIC AS A LIPID LOWERING AGENTDA META-ANALYSIS, J R COLL PHYSICIANS LOND, 28, PP. 39-45, (1994); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA. A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN INTERN MED, 133, PP. 420-429, (2000); GARDNER C.D., LAWSON L.D., BLOCK E., ET AL., EFFECT OF RAW GARLIC VS COMMERCIAL GARLIC SUPPLEMENTS ON PLASMA LIPID CONCENTRATIONS IN ADULTS WITH MODERATE HYPERCHOLESTEROLEMIA: A RANDOMIZED CLINICAL TRIAL, ARCH INTERN MED, 167, PP. 346-353, (2007); BERTHOLD H.K., SUDHOP T., VON BERGMANN K., EFFECT OF A GARLIC OIL PREPARATION ON SERUM LIPOPROTEINS AND CHOLESTEROL METABOLISM: A RANDOMIZED CONTROLLED TRIAL, JAMA, 279, PP. 1900-1902, (1998); GARDNER C.D., CHATTERJEE L.M., CARLSON J.J., THE EFFECT OF A GARLIC PREPARATION ON PLASMA LIPID LEVELS IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS, ATHEROSCLEROSIS, 154, PP. 213-220, (2001); ISAACSOHN J.L., MOSER M., STEIN E.A., ET AL., GARLIC POWDER AND PLASMA LIPIDS AND LIPOPROTEINS: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, ARCH INTERN MED, 158, PP. 1189-1194, (1998); SUPERKO H.R., KRAUSS R.M., GARLIC POWDER, EFFECT ON PLASMA LIPIDS, POSTPRANDIAL LIPEMIA, LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, HIGHDENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION AND LIPOPROTEIN(A), J AM COLL CARDIOL, 35, PP. 321-326, (2000); ERNST E., CARDIOVASCULAR EFFECTS OF GARLIC (ALLIUM SATIVUM): A REVIEW, PHARMATHERAPEUTICA, 5, PP. 83-89, (1987); SATYAVATI G.V., GUM GUGGUL (COMMIPHORA MUKUL)DTHE SUCCESS STORY OF AN ANCIENT INSIGHT LEADING TO A MODERN DISCOVERY, INDIAN J MED RES, 87, PP. 327-335, (1988); NITYANAND S., KAPOOR N.K., CHOLESTEROL LOWERING ACTIVITY OF THE VARIOUS FRACTIONS OF THE GUGGAL, INDIAN J EXP BIOL, 11, PP. 395-396, (1973); URIZAR N.L., LIVERMAN A.B., DODDS D.T., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, PP. 1703-1706, (2002); GOPAL K., SARAN R.K., NITYANAND S., ET AL., CLINICAL TRIAL OF ETHYL ACETATE EXTRACT OF GUM GUGULU (GUGULIPID) IN PRIMARY HYPERLIPIDEMIA, J ASSOC PHYSICIANS INDIA, 34, PP. 249-251, (1986); AGARWAL R.C., SINGH S.P., SARAN R.K., ET AL., CLINICAL TRIAL OF GUGULIPIDDA NEW HYPOLIPIDEMIC AGENT OF PLANT ORIGIN IN PRIMARY HYPERLIPIDEMIA, INDIAN J MED RES, 84, PP. 626-634, (1986); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); GARDNER C.D., COULSTON A., CHATTERJEE L., RIGBY A., SPILLER G., FARQUHAR J.W., THE EFFECT OF A PLANT-BASED DIET ON PLASMA LIPIDS IN HYPERCHOLESTEROLEMIC ADULTS: A RANDOMIZED TRIAL, ANN INTERN MED, 142, PP. 725-733, (2005); LUKACZER D., LISKA D.J., LERMAN R.H., ET AL., EFFECT OF A LOW GLYCEMIC INDEX DIET WITH SOY PROTEIN AND PHYTOSTEROLS ON CVD RISK FACTORS IN POSTMENOPAUSAL WOMEN, NUTRITION, 22, PP. 104-113, (2006); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS VS LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, JAMA, 290, PP. 502-510, (2003); JENKINS D.J., KENDALL C.W., FAULKNER D.A., ET AL., ASSESSMENT OF THE LONGER-TERM EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS IN HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 83, PP. 582-591, (2006); KESSLER R.C., DAVIS R.B., FOSTER D.F., ET AL., LONG-TERM TRENDS IN THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICAL THERAPIES IN THE UNITED STATES, ANN INTERN MED, 135, PP. 262-268, (2001)","","ELSEVIER LTD","ENGLISH","J. CLIN. LIPIDOLOGY","REVIEW","ISI","2-S2.0-79953790630","J CLIN LIPIDOLOGY",NA,"NOTREPORTED",NA,"NIJJAR PS, 2010, J CLIN LIPIDOLOGY","NIJJAR PS, 2010, J CLIN LIPIDOLOGY"
"SIRTORI C;GALLI C;ANDERSON J;SIRTORI E;ARNOLDI A","SIRTORI, CESARE R. (57203252370); GALLI, CLAUDIO (55541649200); ANDERSON, JAMES W. (57203289063); SIRTORI, ELENA (17135958500); ARNOLDI, ANNA (7004093133)","FUNCTIONAL FOODS FOR DYSLIPIDAEMIA AND CARDIOVASCULAR RISK PREVENTION",2009,"NUTRITION RESEARCH REVIEWS","22","17",64,"10.1017/S0954422409990187","DEPARTMENT OF PHARMACOLOGICAL SCIENCES, UNIVERSITY OF MILANO, ITALY;DEPARTMENT OF PHARMACOLOGICAL SCIENCES, UNIVERSITY OF MILANO, ITALY;DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES;DEPARTMENT OF ENDOCRINOLOGY, PATHOPHYSIOLOGY AND APPLIED BIOLOGY, UNIVERSITY OF MILANO, ITALY;DEPARTMENT OF ENDOCRINOLOGY, PATHOPHYSIOLOGY AND APPLIED BIOLOGY, UNIVERSITY OF MILANO, ITALY","A FOOD CAN BE REGARDED AS FUNCTIONAL IF IT CAN DEMONSTRATE A BENEFICIAL EFFICACY ON ONE OR MORE TARGET FUNCTIONS IN THE BODY IN A CONVINCING WAY. BEYOND ADEQUATE NUTRITIONAL QUALITIES, FUNCTIONAL FOODS SHOULD EITHER IMPROVE THE STATE OF HEALTH AND WELLBEING AND/OR REDUCE THE RISK OF DISEASE. FUNCTIONAL FOODS THAT ARE MARKETED WITH CLAIMS OF HEART DISEASE REDUCTION FOCUS PRIMARILY ON THE MAJOR RISK FACTORS, I.E. CHOLESTEROL, DIABETES AND HYPERTENSION. SOME OF THE MOST INNOVATIVE PRODUCTS ARE DESIGNED TO BE ENRICHED WITH PROTECTIVE INGREDIENTS, BELIEVED TO REDUCE RISK. THEY MAY CONTAIN, FOR EXAMPLE, SOLUBLE FIBRE (FROM OAT AND PSYLLIUM), USEFUL BOTH FOR LOWERING CHOLESTEROL AND BLOOD PRESSURE, OR FRUCTANS, EFFECTIVE IN DIABETES. PHYTOSTEROLS AND STANOLS LOWER LDL-CHOLESTEROL IN A DOSE-DEPENDENT MANNER. SOYA PROTEIN IS MORE HYPOCHOLESTEROLAEMIC IN SUBJECTS WITH VERY HIGH INITIAL CHOLESTEROL AND RECENT DATA INDICATE ALSO FAVOURABLE ACTIVITIES IN THE METABOLIC SYNDROME. N-3 FATTY ACIDS APPEAR TO EXERT SIGNIFICANT HYPOTRIACYLGLYCEROLAEMIC EFFECTS, POSSIBLY PARTLY RESPONSIBLE FOR THEIR PREVENTIVE ACTIVITY. DARK CHOCOLATE IS GAINING MUCH ATTENTION FOR ITS MULTIFUNCTIONAL ACTIVITIES, USEFUL BOTH FOR THE PREVENTION OF DYSLIPIDAEMIA AS WELL AS HYPERTENSION. FINALLY, CONSENSUS OPINIONS ABOUT TEA AND COFFEE HAVE NOT EMERGED YET, AND THE BENEFITS OF VITAMIN E, GARLIC, FENUGREEK AND POLICOSANOLS IN THE MANAGEMENT OF DYSLIPIDAEMIA AND PREVENTION OF ARTERIAL DISEASE ARE STILL CONTROVERSIAL. © 2009 THE AUTHORS.","CVD PREVENTION; DIABETES; DIET; FUNCTIONAL FOODS; HYPERCHOLESTEROLAEMIA; NUTRACEUTICALS","ANGIOSPERMS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; DYSLIPIDEMIAS; FATTY ACIDS; FUNCTIONAL FOOD; HUMANS; HYPERTENSION; PHYTOTHERAPY; PLANT EXTRACTS; RISK FACTORS; VITAMIN E; ALLIUM SATIVUM; TRIGONELLA FOENUM-GRAECUM; ALPHA TOCOPHEROL; BETA GLUCAN; DOCOSAHEXAENOIC ACID; FISH PROTEIN; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PRIMROSE OIL; SOYBEAN PROTEIN; STANOL ESTER; TRIACYLGLYCEROL; VEGETABLE PROTEIN; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; FATTY ACID; PLANT EXTRACT; ARTERY DISEASE; ARTICHOKE; BARLEY; CACAO; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CINNAMON; COFFEE; DIETARY FIBER; DYSLIPIDEMIA; FENUGREEK; FERMENTED PRODUCT; FOOD INTAKE; GARLIC; HIGH FIBER DIET; HUMAN; NUT; OAT; REVIEW; SEA FOOD; TEA; TRIACYLGLYCEROL BLOOD LEVEL; ANGIOSPERM; CARDIOVASCULAR DISEASE; DIET; DIET THERAPY; DYSLIPIDEMIA; FUNCTIONAL FOOD; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYTOTHERAPY; RISK FACTOR","","","DE BACKER G., AMBROSIONI E., BORCH-JOHNSEN K., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE AND PREVENTION IN CLINICAL PRACTICE, ATHEROSCLEROSIS, 171, PP. 145-155, (2003); STAMPFER M.J., HU F.B., MANSON J.E., ET AL., PRIMARY PREVENTION OF CORONARY HEART DISEASE IN WOMEN THROUGH DIET AND LIFESTYLE, N ENGL J MED, 343, PP. 16-22, (2000); KRIS-ETHERTON P.M., ETHERTON T.D., CARLSON J., ET AL., RECENT DISCOVERIES IN INCLUSIVE FOOD-BASED APPROACHES AND DIETARY PATTERNS FOR REDUCTION IN RISK FOR CARDIOVASCULAR DISEASE, CURR OPIN LIPIDOL, 13, PP. 397-407, (2002); MCCULLOUGH M., FESKANICH D., RIMM E., ET AL., ADHERENCE TO THE DIETARY GUIDELINES FOR AMERICANS AND RISK OF MAJOR CHRONIC DISEASE IN MEN, AM J CLIN NUTR, 72, PP. 1223-1231, (2000); MCCULLOUGH M., FESKANICH D., STAMPFER M., ET AL., ADHERENCE TO THE DIETARY GUIDELINES FOR AMERICANS AND RISK OF MAJOR CHRONIC DISEASE IN WOMEN, AM J CLIN NUTR, 72, PP. 1214-1222, (2000); SMITH U., CARBOHYDRATES, FAT, AND INSULIN ACTION, AM J CLIN NUTR, 59, (1994); PARK E.J., HELLERSTEIN M.K., CARBOHYDRATE-INDUCED HYPERTRIACYLGLYCEROLEMIA: HISTORICAL PERSPECTIVE AND REVIEW OF BIOLOGICAL MECHANISMS, AM J CLIN NUTR, 71, PP. 412-433, (2000); ANDERSON J.W., WARD K., HIGH-CARBOHYDRATE, HIGHFIBER DIETS FOR INSULIN-TREATED MEN WITH DIABETES MELLITUS, AM J CLIN NUTR, 32, PP. 2312-2321, (1979); ANDERSON J.W., DIETARY FIBER PREVENTS CARBOHYDRATEINDUCED HYPERTRIGLYCERIDEMIA, CURR ATHEROSCLER REP, 2, PP. 536-541, (2000); ANDERSON J.W., GARRITY T.F., WOOD C.L., ET AL., PROSPECTIVE, RANDOMIZED, CONTROLLED COMPARISON OF THE EFFECTS OF LOW-FAT AND LOW-FAT PLUS HIGH-FIBER DIETS ON SERUM LIPID CONCENTRATIONS, AM J CLIN NUTR, 56, PP. 887-894, (1992); FROST G., LEEDS A.A., DORE C.J., ET AL., GLYCAEMIC INDEX AS A DETERMINANT OF SERUM HDL-CHOLESTEROL CONCENTRATION, LANCET, 353, PP. 1045-1048, (1999); ANDERSON J.W., RANDLES K.M., KENDALL C.W., ET AL., CARBOHYDRATE AND FIBER RECOMMENDATIONS FOR INDIVIDUALS WITH DIABETES: A QUANTITATIVE ASSESSMENT AND META-ANALYSIS OF THE EVIDENCE, J AM COLL NUTR, 23, PP. 5-17, (2004); SHAI I., SCHWARZFUCHS D., HENKIN Y., ET AL., WEIGHT LOSS WITH A LOW-CARBOHYDRATE, MEDITERRANEAN, OR LOW-FAT DIET, N ENGL J MED, 359, PP. 229-241, (2008); JENKINS D., KENDALL C., MCKEOWN-EYSSEN G., ET AL., EFFECT OF A LOW-GLYCEMIC INDEX OR A HIGH-CEREAL FIBER DIET ON TYPE 2 DIABETES: A RANDOMIZED TRIAL, JAMA, 300, PP. 2742-2753, (2008); ERKKILA A., LICHTENSTEIN A., FIBER AND CARDIOVASCULAR DISEASE RISK: HOW STRONG IS THE EVIDENCE?, J CARDIOVASC NURS, 21, PP. 3-8, (2006); HALL R.S., JOHNSON S.K., BAXTER A.L., ET AL., LUPIN KERNEL FIBRE-ENRICHED FOODS BENEFICIALLY MODIFY SERUM LIPIDS IN MEN, EUR J CLIN NUTR, 59, PP. 325-333, (2005); HARA H., HAGA S., AOYAMA Y., ET AL., SHORT-CHAIN FATTY ACIDS SUPPRESS CHOLESTEROL SYNTHESIS IN RAT LIVER AND INTESTINE, J NUTR, 129, PP. 942-948, (1999); KIRBY R.W., ANDERSON J.W., SIELING B., ET AL., OAT-BRAN INTAKE SELECTIVELY LOWERS SERUM LOW-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATIONS OF HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 34, PP. 824-829, (1981); ANDERSON J.W., ZETTWOCH N., FELDMAN T., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM HYDROPHILIC MUCILLOID FOR HYPERCHOLESTEROLEMIC MEN, ARCH INTERN MED, 148, PP. 292-296, (1988); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); RIPSIN C.M., KEENAN J.M., JACOBS D.R.J., ET AL., OAT PRODUCTS AND LIPID LOWERING. A META-ANALYSIS, JAMA, 267, PP. 3317-3325, (1992); HASLER C.M., FUNCTIONAL FOODS: BENEFITS, CONCERNS AND CHALLENGES - A POSITION PAPER FROM THE AMERICAN COUNCIL ON SCIENCE AND HEALTH, J NUTR, 132, PP. 3772-3781, (2002); ANDERSON J.W., DIETARY FIBRE, COMPLEX CARBOHYDRATE AND CORONARY ARTERY DISEASE, CAN J CARDIOL, 11, SUPPL. G, (1995); ANDERSON J.W., DAVIDSON M.H., BLONDE L., ET AL., LONGTERM CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM AS AN ADJUNCT TO DIET THERAPY IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 71, PP. 1433-1438, (2000); PASSI S.J., MANCHANDA S.C., SURI S., ET AL., LIPID LOWERING EFFECT OF DIETARY FIBRE SUPPLEMENTATION THROUGH FOOD BASED APPROACH, ASIA PAC J CLIN NUTR, 28, SUPPL. 13, (2004); DAVIDSON M.H., DUGAN L.D., BURNS J.H., ET AL., THE HYPOCHOLESTEROLEMIC EFFECTS OF B-GLUCAN IN OATMEAL AND OAT BRAN. A DOSE-CONTROLLED STUDY, JAMA, 265, PP. 1833-1839, (1991); ANDERSON J.W., GILINSKY N.H., DEAKINS D.A., ET AL., LIPID RESPONSES OF HYPERCHOLESTEROLEMIC MEN TO OAT-BRAN AND WHEAT-BRAN INTAKE, AM J CLIN NUTR, 54, PP. 678-683, (1991); GERHARDT A.L., GALLO N.B., FULL-FAT RICE BRAN AND OAT BRAN SIMILARLY REDUCE HYPERCHOLESTEROLEMIA IN HUMANS, J NUTR, 128, PP. 865-869, (1998); NAUMANN E., VAN REES A.B., ONNING G., ET AL., B- GLUCAN INCORPORATED INTO A FRUIT DRINK EFFECTIVELY LOWERS SERUM LDL-CHOLESTEROL CONCENTRATIONS, AM J CLIN NUTR, 83, PP. 601-605, (2006); KEENAN J.M., GOULSON M., SHAMLIYAN T., ET AL., THE EFFECTS OF CONCENTRATED BARLEY B-GLUCAN ON BLOOD LIPIDS IN A POPULATION OF HYPERCHOLESTEROLAEMIC MEN AND WOMEN, BR J NUTR, 97, PP. 1162-1168, (2007); DAVIDSON M.H., MAKI K.C., EFFECTS OF DIETARY INULIN ON SERUM LIPIDS, J NUTR, 129, (1999); DAUBIOUL C.A., TAPER H.S., DE WISPELAERE L.D., ET AL., DIETARY OLIGOFRUCTOSE LESSENS HEPATIC STEATOSIS, BUT DOES NOT PREVENT HYPERTRIGLYCERIDEMIA IN OBESE ZUCKER RATS, J NUTR, 130, PP. 1314-1319, (2000); DELZENNE N.M., KOK N., EFFECTS OF FRUCTANS-TYPE PREBIOTICS ON LIPID METABOLISM, AM J CLIN NUTR, 73, (2001); AMORI R.E., LAU J., PITTAS A.G., EFFICACY AND SAFETY OF INCRETIN THERAPY IN TYPE 2 DIABETES: SYSTEMATIC REVIEW AND META-ANALYSIS, JAMA, 298, PP. 194-206, (2007); DAUBIOUL C.A., HORSMANS Y., LAMBERT P., ET AL., EFFECTS OF OLIGOFRUCTOSE ON GLUCOSE AND LIPID METABOLISM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: RESULTS OF A PILOT STUDY, EUR J CLIN NUTR, 59, PP. 723-726, (2005); MISIKANGAS M., PAJARI A., PAIVARINTA E., ET AL., PROMOTION OF ADENOMA GROWTH BY DIETARY INULIN IS ASSOCIATED WITH INCREASE IN CYCLIN D1 AND DECREASE IN ADHESION PROTEINS IN MIN/+ MICE MUCOSA, J NUTR BIOCHEM, 16, PP. 402-409, (2005); BJERREGAARD P., DYERBERG J., MORTALITY FROM ISCHAEMIC HEART DISEASE AND CEREBROVASCULAR DISEASE IN GREENLAND, INT J EPIDEMIOL, 17, PP. 514-519, (1988); BANG H.O., DYERBERG J., NIELSEN A.B., PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS, LANCET, 1, PP. 1143-1145, (1971); VISIOLI F., RISE P., BARASSI M.C., ET AL., DIETARY INTAKE OF FISH VS. FORMULATIONS LEADS TO HIGHER PLASMA CONCENTRATIONS OF N-3 FATTY ACIDS, LIPIDS, 38, PP. 415-418, (2003); ELVEVOLL E.O., BARSTAD H., BREIMO E.S., ET AL., ENHANCED INCORPORATION OF N-3 FATTY ACIDS FROM FISH COMPARED WITH FISH OILS, LIPIDS, 41, PP. 1109-1114, (2006); LEON H., SHIBATA M., SIVAKUMARAN S., ET AL., EFFECT OF FISH OIL ON ARRHYTHMIAS AND MORTALITY: SYSTEMATIC REVIEW, BMJ, 337, (2008); LICHTENSTEIN A.H., APPEL L.J., BRANDS M., DIET AND LIFESTYLE RECOMMENDATIONS REVISION 2006: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 114, PP. 82-96, (2006); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEINS: HUMAN STUDIES, AM J CLIN NUTR, 65, SUPPL. 5, (1997); MAKI K.C., VAN ELSWYK M.E., MCCARTHY D., ET AL., LIPID RESPONSES TO A DIETARY DOCOSAHEXAENOIC ACID SUPPLEMENT IN MEN AND WOMEN WITH BELOW AVERAGE LEVELS OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL, J AM COLL NUTR, 24, PP. 189-199, (2005); THEOBALD H.E., CHOWIENCZYK P.J., WHITTALL R., ET AL., LDL CHOLESTEROL-RAISING EFFECT OF LOW-DOSE DOCOSAHEXAENOIC ACID IN MIDDLE-AGED MEN AND WOMEN, AM J CLIN NUTR, 79, PP. 558-563, (2004); BAYS H., CLINICAL OVERVIEW OF OMACOR: A CONCENTRATED FORMULATION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, AM J CARDIOL, 98, (2006); KRIS-ETHERTON P., HILL A., N-3 FATTY ACIDS: FOOD OR SUPPLEMENTS?, J AM DIET ASSOC, 108, PP. 1125-1130, (2008); SIRTORI C.R., GALLI C., N-3 FATTY ACIDS AND DIABETES, BIOMED PHARMACOTHER, 56, PP. 397-406, (2002); SIRTORI C.R., PAOLETTI R., MANCINI M., ET AL., N-3 FATTY ACIDS DO NOT LEAD TO AN INCREASED DIABETIC RISK IN PATIENTS WITH HYPERLIPIDEMIA AND ABNORMAL GLUCOSE TOLERANCE, AM J CLIN NUTR, 65, PP. 1874-1881, (1997); SIRTORI C.R., CREPALDI G., MANZATO E., ET AL., ONE-YEAR TREATMENT WITH ETHYL ESTERS OF N-3 FATTY ACIDS IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND GLUCOSE INTOLERANCE: REDUCED TRIGLYCERIDEMIA, TOTAL CHOLESTEROL AND INCREASED HDL-C WITHOUT GLYCEMIC ALTERATIONS, ATHEROSCLEROSIS, 137, PP. 419-427, (1998); DUBEY P., CHEEMA S.K., MOLECULAR MECHANISMS INVOLVED IN THE REGULATION OF LIPID AND LIPOPROTEIN METABOLISM BY FISH OIL, FUT LIPIDOL, 1, PP. 559-568, (2006); MOORADIAN A.D., HAAS M.J., WONG N.C., THE EFFECT OF SELECT NUTRIENTS ON SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN A-I LEVELS, ENDOCR REV, 27, PP. 2-16, (2006); BORGHI C., CICERO A., RECENT EVIDENCE OF THE ROLE OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON BLOOD PRESSURE CONTROL AND HYPERTENSION-RELATED COMPLICATIONS, FUT LIPIDOL, 1, PP. 569-577, (2006); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, PP. 1090-1098, (2007); VISIOLI F., RISE P., PLASMATI E., ET AL., VERY LOW INTAKES OF N-3 FATTY ACIDS INCORPORATED INTO BOVINE MILK REDUCE PLASMA TRIACYLGLYCEROL AND INCREASE HDL-CHOLESTEROL CONCENTRATIONS IN HEALTHY SUBJECTS, PHARMACOL RES, 41, PP. 571-576, (2000); CARRERO J.J., BARO L., FONOLLA J., ET AL., CARDIOVASCULAR EFFECTS OF MILK ENRICHED WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS, OLEIC ACID, FOLIC ACID, AND VITAMINS E AND B6 IN VOLUNTEERS WITH MILD HYPERLIPIDEMIA, NUTRITION, 20, PP. 521-527, (2004); MOZAFFARIAN D., RIMM E.B., FISH INTAKE, CONTAMINANTS, AND HUMAN HEALTH: EVALUATING THE RISKS AND THE BENEFITS, JAMA, 296, PP. 1885-1899, (2006); MARANGONI F., COLOMBO C., MARTIELLO A., ET AL., LEVELS OF THE N-3 FATTY ACID EICOSAPENTAENOIC ACID IN ADDITION TO THOSE OF A LINOLENIC ACID ARE SIGNIFICANTLY RAISED IN BLOOD LIPIDS BY THE INTAKE OF FOUR WALNUTS A DAY IN HUMANS, NUTR METAB CARDIOVASC DIS, 17, PP. 457-461, (2007); BURDGE G., A-LINOLENIC ACID METABOLISM IN MEN AND WOMEN: NUTRITIONAL AND BIOLOGICAL IMPLICATIONS, CURR OPIN CLIN NUTR METAB CARE, 7, PP. 137-144, (2004); VON SCHACKY C., THE ROLE OF OMEGA-3 FATTY ACIDS IN CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 5, PP. 139-145, (2003); DJOUSSE L., ARNETT D.K., CARR J.J., ET AL., DIETARY LINOLENIC ACID IS INVERSELY ASSOCIATED WITH CALCIFIED ATHEROSCLEROTIC PLAQUE IN THE CORONARY ARTERIES: THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE FAMILY HEART STUDY, CIRCULATION, 111, PP. 2921-2926, (2005); ZHAO G., ETHERTON T.D., MARTIN K.R., ET AL., DIETARY A-LINOLENIC ACID REDUCES INFLAMMATORY AND LIPID CARDIOVASCULAR RISK FACTORS IN HYPERCHOLESTEROLEMIC MEN AND WOMEN, J NUTR, 134, PP. 2991-2997, (2004); RALLIDIS L.S., PASCHOS G., PAPAIOANNOU M.L., ET AL., THE EFFECT OF DIET ENRICHED WITH A-LINOLENIC ACID ON SOLUBLE CELLULAR ADHESION MOLECULES IN DYSLIPIDAEMIC PATIENTS, ATHEROSCLEROSIS, 174, PP. 127-132, (2004); SANDERSON P., FINNEGAN Y., WILLIAMS C., ET AL., UK FOOD STANDARDS AGENCY A-LINOLENIC ACID WORKSHOP REPORT, BR J NUTR, 88, PP. 573-579, (2002); WENDLAND E., FARMER A., GLASZIOU P., ET AL., EFFECT OF A LINOLENIC ACID ON CARDIOVASCULAR RISK MARKERS: A SYSTEMATIC REVIEW, HEART, 92, PP. 166-169, (2006); HARRIS W.S., A-LINOLENIC ACID: A GIFT FROM THE LAND?, CIRCULATION, 111, PP. 2872-2874, (2005); DAVIS H.R.J., ZHU L.J., HOOS L.M., ET AL., NIEMANN-PICK C1 LIKE 1 (NPC1L1) IS THE INTESTINAL PHYTOSTEROL AND CHOLESTEROL TRANSPORTER AND A KEY MODULATOR OF WHOLE-BODY CHOLESTEROL HOMEOSTASIS, J BIOL CHEM, 279, PP. 33586-33592, (2004); FIELD F.J., BORN E., MATHUR S.N., STANOL ESTERS DECREASE PLASMA CHOLESTEROL INDEPENDENTLY OF INTESTINAL ABC STEROL TRANSPORTERS AND NIEMANN-PICK C1-LIKE 1 PROTEIN GENE EXPRESSION, J LIPID RES, 45, PP. 2252-2259, (2004); MIETTINEN T.A., PUSKA P., GYLLING H., ET AL., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N ENGL J MED, 333, PP. 1308-1312, (1995); GYLLING H., RADHAKRISHNAN R., MIETTINEN T.A., REDUCTION OF SERUM CHOLESTEROL IN POSTMENOPAUSAL WOMEN WITH PREVIOUS MYOCARDIAL INFARCTION AND CHOLESTEROL MALABSORPTION INDUCED BY DIETARY SITOSTANOL ESTER MARGARINE: WOMEN AND DIETARY SITOSTANOL, CIRCULATION, 96, PP. 4226-4231, (1997); HALLIKAINEN M.A., UUSITUPA M.I., EFFECTS OF 2 LOW-FAT STANOL ESTER-CONTAINING MARGARINES ON SERUM CHOLESTEROL CONCENTRATIONS AS PART OF A LOW-FAT DIET IN HYPERCHOLESTEROLEMIC SUBJECTS, AM J CLIN NUTR, 69, PP. 403-410, (1999); DAVIDSON M.H., MAKI K.C., UMPOROWICZ D.M., ET AL., SAFETY AND TOLERABILITY OF ESTERIFIED PHYTOSTEROLS ADMINISTERED IN REDUCED-FAT SPREAD AND SALAD DRESSING TO HEALTHY ADULT MEN AND WOMEN, J AM COLL NUTR, 20, PP. 307-319, (2001); MAKI K.C., DAVIDSON M.H., UMPOROWICZ D.M., ET AL., LIPID RESPONSES TO PLANT-STEROL-ENRICHED REDUCED-FAT SPREADS INCORPORATED INTO A NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP I DIET, AM J CLIN NUTR, 74, PP. 33-43, (2001); NEIL H.A., MEIJER G.W., ROE L.S., RANDOMISED CONTROLLED TRIAL OF USE BY HYPERCHOLESTEROLAEMIC PATIENTS OF A VEGETABLE OIL STEROL-ENRICHED FAT SPREAD, ATHEROSCLEROSIS, 156, PP. 329-337, (2001); NTANIOS F.Y., DUCHATEAU G.S., A HEALTHY DIET RICH IN CAROTENOIDS IS EFFECTIVE IN MAINTAINING NORMAL BLOOD CAROTENOID LEVELS DURING THE DAILY USE OF PLANT STEROLENRICHED SPREADS, INT J VITAM NUTR RES, 72, PP. 32-39, (2002); MATVIENKO O.A., LEWIS D.S., SWANSON M., ET AL., A SINGLE DAILY DOSE OF SOYBEAN PHYTOSTEROLS IN GROUND BEEF DECREASES SERUM TOTAL CHOLESTEROL AND LDL CHOLESTEROL IN YOUNG, MILDLY HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 76, PP. 57-64, (2002); WINTER J., THE PHYTOSTEROL PHENOMENON, FUNCTIONAL FOODS AND NUTRACEUTICALS, PP. 24-30, (2005); CATER N.B., GARCIA-GARCIA A.B., VEGA G.L., ET AL., RESPONSIVENESS OF PLASMA LIPIDS AND LIPOPROTEINS TO PLANT STANOL ESTERS, AM J CARDIOL, 96, (2005); O'NEILL F.H., BRYNES A., MANDENO R., ET AL., COMPARISON OF THE EFFECTS OF DIETARY PLANT STEROL AND STANOL ESTERS ON LIPID METABOLISM, NUTR METAB CARDIOVASC DIS, 14, PP. 133-142, (2004); VANSTONE C.A., RAEINI-SARJAZ M., PARSONS W.E., ET AL., UNESTERIFIED PLANT STEROLS AND STANOLS LOWER LDL-CHOLESTEROL CONCENTRATIONS EQUIVALENTLY IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 76, PP. 1272-1278, (2002); RICHELLE M., ENSLEN M., HAGER C., ET AL., BOTH FREE AND ESTERIFIED PLANT STEROLS REDUCE CHOLESTEROL ABSORPTION AND THE BIOAVAILABILITY OF B-CAROTENE AND A-TOCOPHEROL IN NORMOCHOLESTEROLEMIC HUMANS, AM J CLIN NUTR, 80, PP. 171-177, (2004); SPILBURG C.A., GOLDBERG A.C., MCGILL J.B., ET AL., FATFREE FOODS SUPPLEMENTED WITH SOY STANOL-LECITHIN POWDER REDUCE CHOLESTEROL ABSORPTION AND LDL CHOLESTEROL, J AM DIET ASSOC, 103, PP. 577-581, (2003); SALO P., WESTER I., LOW-FAT FORMULATIONS OF PLANT STANOLS AND STEROLS, AM J CARDIOL, 96, (2005); CLIFTON P., PLANT STEROL AND STANOLS - COMPARISON AND CONTRASTS STEROLS VERSUS STANOLS IN CHOLESTEROL-LOWERING: IS THERE A DIFFERENCE?, ATHEROSCLER SUPPL, 3, PP. 5-9, (2002); HALLIKAINEN M.A., SARKKINEN E.S., UUSITUPA M.I., PLANT STANOL ESTERS AFFECT SERUM CHOLESTEROL CONCENTRATIONS OF HYPERCHOLESTEROLEMIC MEN AND WOMEN IN A DOSE-DEPENDENT MANNER, J NUTR, 130, PP. 767-776, (2000); CHAN Y., DEMONTY I., PELLED D., ET AL., OLIVE OIL CONTAINING OLIVE OIL FATTY ACID ESTERS OF PLANT STEROLS AND DIETARY DIACYLGLYCEROL REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND DECREASES THE TENDENCY FOR PEROXIDATION IN HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 98, PP. 563-570, (2007); DEMONTY I., RAS R., VAN DER KNAAP H., ET AL., CONTINUOUS DOSE-RESPONSE RELATIONSHIP OF THE LDL-CHOLESTEROL- LOWERING EFFECT OF PHYTOSTEROL INTAKE, J NUTR, 139, PP. 271-284, (2009); ABUMWEIS S.S., BARAKE R., JONES P., PLANT STEROLS/STANOLS AS CHOLESTEROL LOWERING AGENTS: A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, FOOD NUTR RES, (2008); DE JONGH S., VISSERS M.N., ROL P., ET AL., PLANT STEROLS LOWER LDL CHOLESTEROL WITHOUT IMPROVING ENDOTHELIAL FUNCTION IN PREPUBERTAL CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA, J INHERIT METAB DIS, 26, PP. 343-351, (2003); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); WOLFS M., DE JONG N., OCKE M.C., ET AL., EFFECTIVENESS OF CUSTOMARY USE OF PHYTOSTEROL/STANOL-ENRICHED MARGARINES ON BLOOD CHOLESTEROL LOWERING, FOOD CHEM TOXICOL, 44, PP. 1682-1688, (2006); SHRESTHA S., VOLEK J.S., UDANI J., ET AL., A COMBINATION THERAPY INCLUDING PSYLLIUM AND PLANT STEROLS LOWERS LDL CHOLESTEROL BY MODIFYING LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC INDIVIDUALS, J NUTR, 136, PP. 2492-2497, (2006); THEUWISSEN E., MENSINK R.P., SIMULTANEOUS INTAKE OF B-GLUCAN AND PLANT STANOL ESTERS AFFECTS LIPID METABOLISM IN SLIGHTLY HYPERCHOLESTEROLEMIC SUBJECTS, J NUTR, 137, PP. 583-588, (2007); DEVARAJ S., AUTRET B.C., JIALAL I., REDUCED-CALORIE ORANGE JUICE BEVERAGE WITH PLANT STEROLS LOWERS C-REACTIVE PROTEIN CONCENTRATIONS AND IMPROVES THE LIPID PROFILE IN HUMAN VOLUNTEERS, AM J CLIN NUTR, 84, PP. 756-761, (2006); MICALLEF M., GARG M., THE LIPID-LOWERING EFFECTS OF PHYTOSTEROLS AND (N-3) POLYUNSATURATED FATTY ACIDS ARE SYNERGISTIC AND COMPLEMENTARY IN HYPERLIPIDEMIC MEN AND WOMEN, J NUTR, 138, PP. 1086-1090, (2008); COATES A.M., HOWE P.R., EDIBLE NUTS AND METABOLIC HEALTH, CURR OPIN LIPIDOL, 18, PP. 25-30, (2007); KRIS-ETHERTON P.M., ZHAO G., BINKOSKI A.E., ET AL., THE EFFECTS OF NUTS ON CORONARY HEART DISEASE RISK, NUTR REV, 59, PP. 103-111, (2001); MUKUDDEM-PETERSEN J., OOSTHUIZEN W., JERLING J.C., A SYSTEMATIC REVIEW OF THE EFFECTS OF NUTS ON BLOOD LIPID PROFILES IN HUMANS, J NUTR, 135, PP. 2082-2089, (2005); ALBERT C.M., GAZIANO J.M., WILLETT W.C., ET AL., NUT CONSUMPTION AND DECREASED RISK OF SUDDEN CARDIAC DEATH IN THE PHYSICIANS' HEALTH STUDY, ARCH INTERN MED, 162, PP. 1382-1387, (2002); FELDMAN E.B., THE SCIENTIFIC EVIDENCE FOR A BENEFICIAL HEALTH RELATIONSHIP BETWEEN WALNUTS AND CORONARY HEART DISEASE, J NUTR, 132, (2002); ALASALVAR C., SHAHIDI F., CADWALLADER K.R., COMPARISON OF NATURAL AND ROASTED TURKISH TOMBUL HAZELNUT (CORYLUS AVELLANA L.) VOLATILES AND FLAVOR BY DHA/GC/MS AND DESCRIPTIVE SENSORY ANALYSIS, J AGRIC FOOD CHEM, 51, PP. 5067-5072, (2003); MERCANLIGIL S.M., ARSLAN P., ALASALVAR C., ET AL., EFFECTS OF HAZELNUT-ENRICHED DIET ON PLASMA CHOLESTEROL AND LIPOPROTEIN PROFILES IN HYPERCHOLESTEROLEMIC ADULT MEN, EUR J CLIN NUTR, 61, PP. 212-220, (2007); JOSSE A.R., KENDALL C.W., AUGUSTIN L.S., ET AL., ALMONDS AND POSTPRANDIAL GLYCEMIA - A DOSE-RESPONSE STUDY, METABOLISM, 56, PP. 400-404, (2007); GARG M.L., BLAKE R.J., WILLS R.B., MACADAMIA NUT CONSUMPTION LOWERS PLASMA TOTAL AND LDL CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC MEN, J NUTR, 133, PP. 1060-1063, (2003); QUALIFIED HEALTH CLAIMS: LETTER OF ENFORCEMENT DISCRETION - NUTS AND CORONARY HEART DISEASE, (2003); WILLETT W.C., EAT, DRINK AND BE HEALTHY. THE HARVARD MEDICAL SCHOOL GUIDE TO HEALTHY EATING, (2004); KIM D.N., LEE K.T., REINER J.M., ET AL., INCREASED STEROID EXCRETION IN SWINE FED HIGH-FAT, HIGH-CHOLESTEROL DIET WITH SOY PROTEIN, EXP MOL PATHOL, 33, PP. 25-35, (1980); TERPSTRA A.H., WOODWARD C.J., WEST C.E., ET AL., A LONGITUDINAL CROSS-OVER STUDY OF SERUM CHOLESTEROL AND LIPOPROTEINS IN RABBITS FED ON SEMI-PURIFIED DIETS CONTAINING EITHER CASEIN OR SOYA-BEAN PROTEIN, BR J NUTR, 47, PP. 213-221, (1982); SIRTORI C.R., AGRADI E., CONTI F., ET AL., SOYBEAN-PROTEIN DIET IN THE TREATMENT OF TYPE-II HYPERLIPOPROTEINAEMIA, LANCET, 1, PP. 275-277, (1977); DESCOVICH G.C., CEREDI C., GADDI A., ET AL., MULTICENTRE STUDY OF SOYBEAN PROTEIN DIET FOR OUTPATIENT HYPERCHOLESTEROLAEMIC PATIENTS, LANCET, 2, PP. 709-712, (1980); GADDI A., DESCOVICH G.C., NOSEDA G., ET AL., HYPERCHOLESTEROLAEMIA TREATED BY SOYBEAN PROTEIN DIET, ARCH DIS CHILD, 62, PP. 274-278, (1987); SIRTORI C.R., LOVATI M.R., MANZONI C., REDUCTION OF SERUM CHOLESTEROL BY SOYBEAN PROTEINS: CLINICAL EXPERIENCE AND POTENTIAL MOLECULAR MECHANISMS, NUTR METAB CARDIOVASC DIS, 8, PP. 334-340, (1998); BAKHIT R.M., KLEIN B.P., ESSEX-SORLIE D., ET AL., INTAKE OF 25 G OF SOYBEAN PROTEIN WITH OR WITHOUT SOYBEAN FIBER ALTERS PLASMA LIPIDS IN MEN WITH ELEVATED CHOLESTEROL CONCENTRATIONS, J NUTR, 124, PP. 213-222, (1994); BURSLEM J., SCHONFELD G., HOWALD M.A., ET AL., PLASMA APOPROTEIN AND LIPOPROTEIN LIPID LEVELS IN VEGETARIANS, METABOLISM, 27, PP. 711-719, (1978); ZHANG X., SHU X.O., GAO Y.T., ET AL., SOY FOOD CONSUMPTION IS ASSOCIATED WITH LOWER RISK OF CORONARY HEART DISEASE IN CHINESE WOMEN, J NUTR, 133, PP. 2874-2878, (2003); NAGATA C., TAKATSUKA N., KURISU Y., ET AL., DECREASED SERUM TOTAL CHOLESTEROL CONCENTRATION IS ASSOCIATED WITH HIGH INTAKE OF SOY PRODUCTS IN JAPANESE MEN AND WOMEN, J NUTR, 128, PP. 209-213, (1998); HALTON T.L., WILLETT W.C., LIU S., ET AL., LOWCARBOHYDRATE- DIET SCORE AND THE RISK OF CORONARY HEART DISEASE IN WOMEN, N ENGL J MED, 355, PP. 1991-2002, (2006); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); SACKS F.M., LICHTENSTEIN A., VAN HORN L., ET AL., SOY PROTEIN, ISOFLAVONES, AND CARDIOVASCULAR HEALTH: AN AMERICAN HEART ASSOCIATION SCIENCE ADVISORY FOR PROFESSIONALS FROM THE NUTRITION COMMITTEE, CIRCULATION, 113, PP. 1034-1044, (2006); SIRTORI C.R., EBERINI I., ARNOLDI A., HYPOCHOLESTEROLAEMIC EFFECTS OF SOYA PROTEINS: RESULTS OF RECENT STUDIES ARE PREDICTABLE FROM THE ANDERSON META-ANALYSIS DATA, BR J NUTR, 97, PP. 816-822, (2007); STEINBERG F.M., SOYBEANS OR SOYMILK: DOES IT MAKE A DIFFERENCE FOR CARDIOVASCULAR PROTECTION? DOES IT EVEN MATTER?, AM J CLIN NUTR, 85, PP. 927-928, (2007); HARLAND J., HAFFNER T., SYSTEMATIC REVIEW, METAANALYSIS AND REGRESSION OF RANDOMISED CONTROLLED TRIALS REPORTING AN ASSOCIATION BETWEEN AN INTAKE OF CIRCA 25 G SOYA PROTEIN PER DAY AND BLOOD CHOLESTEROL, ATHEROSCLEROSIS, 200, PP. 13-27, (2008); FOOD LABELING HEALTH CLAIMS: SOYBEAN PROTEIN AND CORONARY HEART DISEASE. FINAL RULE, FEDERAL REGISTER, 64, 206, PP. 57699-57733, (1999); SIRTORI C.R., GALLI G., LOVATI M.R., ET AL., EFFECTS OF DIETARY PROTEINS ON THE REGULATION OF LIVER LIPOPROTEIN RECEPTORS IN RATS, J NUTR, 114, PP. 1493-1500, (1984); LOVATI M.R., MANZONI C., GIANAZZA E., ET AL., SOY PROTEIN PEPTIDES REGULATE CHOLESTEROL HOMEOSTASIS IN HEP G2 CELLS, J NUTR, 130, PP. 2543-2549, (2000); LOVATI M.R., MANZONI C., CANAVESI A., ET AL., SOYBEAN PROTEIN DIET INCREASES LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY IN MONONUCLEAR CELLS FROM HYPERCHOLESTEROLEMIC PATIENTS, J CLIN INVEST, 80, PP. 1498-1502, (1987); BAUM J.A., TENG H., ERDMAN J.W.J., ET AL., LONG-TERM INTAKE OF SOY PROTEIN IMPROVES BLOOD LIPID PROFILES AND INCREASES MONONUCLEAR CELL LOW-DENSITY-LIPOPROTEIN RECEPTOR MESSENGER RNA IN HYPERCHOLESTEROLEMIC, POSTMENOPAUSAL WOMEN, AM J CLIN NUTR, 68, PP. 545-551, (1998); ANTHONY M.S., CLARKSON T.B., HUGHES JR. C.L., ET AL., SOYBEAN ISOFLAVONES IMPROVE CARDIOVASCULAR RISK FACTORS WITHOUT AFFECTING THE REPRODUCTIVE SYSTEM OF PERIPUBERTAL RHESUS MONKEYS, J NUTR, 126, PP. 43-50, (1996); GREAVES K.A., PARKS J.S., WILLIAMS J.K., ET AL., INTACT DIETARY SOY PROTEIN, BUT NOT ADDING AN ISOFLAVONE-RICH SOY EXTRACT TO CASEIN, IMPROVES PLASMA LIPIDS IN OVARIECTOMIZED CYNOMOLGUS MONKEYS, J NUTR, 129, PP. 1585-1592, (1999); SIRTORI C.R., ARNOLDI A., JOHNSON S.K., PHYTOESTROGENS: END OF A TALE?, ANN MED, 37, PP. 423-438, (2005); SIRTORI C.R., GIANAZZA E., MANZONI C., ET AL., ROLE OF ISOFLAVONES IN THE CHOLESTEROL REDUCTION BY SOY PROTEINS IN THE CLINIC, AM J CLIN NUTR, 65, PP. 166-167, (1997); GIANAZZA E., EBERINI I., ARNOLDI A., ET AL., A PROTEOMIC INVESTIGATION OF ISOLATED SOY PROTEINS WITH VARIABLE EFFECTS IN EXPERIMENTAL AND CLINICAL STUDIES, J NUTR, 133, PP. 9-14, (2003); LOVATI M.R., MANZONI C., CORSINI A., ET AL., 7S GLOBULIN FROM SOYBEAN IS METABOLIZED IN HUMAN CELL CULTURES BY A SPECIFIC UPTAKE AND DEGRADATION SYSTEM, J NUTR, 126, PP. 2831-2842, (1996); LOVATI M.R., MANZONI C., CORSINI A., ET AL., LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY IS MODULATED BY SOYBEAN GLOBULINS IN CELL CULTURE, J NUTR, 122, PP. 1971-1978, (1992); DURANTI M., LOVATI M.R., DANI V., ET AL., THE A0 SUBUNIT FROM SOYBEAN 7S GLOBULIN LOWERS PLASMA LIPIDS AND UPREGULATES LIVER B-VLDL RECEPTORS IN RATS FED A HYPERCHOLESTEROLEMIC DIET, J NUTR, 134, PP. 1334-1339, (2004); WANG M.F., YAMAMOTO S., CHUNG H.M., ET AL., ANTIHYPERCHOLESTEROLEMIC EFFECT OF UNDIGESTED FRACTION OF SOYBEAN PROTEIN IN YOUNG FEMALE VOLUNTEERS, J NUTR SCI VITAMINOL (TOKYO), 41, PP. 187-195, (1995); HORI G., WANG M.F., CHAN Y.C., ET AL., SOY PROTEIN HYDROLYZATE WITH BOUND PHOSPHOLIPIDS REDUCES SERUM CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC ADULT MALE VOLUNTEERS, BIOSCI BIOTECHNOL BIOCHEM, 65, PP. 72-78, (2001); CHO S., JUILLERAT M., LEE C., IDENTIFICATION OF LDLRECEPTOR TRANSCRIPTION STIMULATING PEPTIDES FROM SOYBEAN HYDROLYSATE IN HUMAN HEPATOCYTES, J AGRIC FOOD CHEM, 56, PP. 4372-4376, (2008); DEIBERT P., KONIG D., SCHMIDT-TRUCKSAESS A., ET AL., WEIGHT LOSS WITHOUT LOSING MUSCLE MASS IN PRE-OBESE AND OBESE SUBJECTS INDUCED BY A HIGH-SOY-PROTEIN DIET, INT J OBES RELAT METAB DISORD, 28, PP. 1349-1352, (2004); KOHNO M., HIROTSUKA M., KITO M., ET AL., DECREASES IN SERUM TRIACYLGLYCEROL AND VISCERAL FAT MEDIATED BY DIETARY SOYBEAN B-CONGLYCININ, J ATHEROSCLER THROMB, 13, PP. 247-255, (2006); AZADBAKHT L., KIMIAGAR M., MEHRABI Y., ET AL., SOY INCLUSION IN THE DIET IMPROVES FEATURES OF THE METABOLIC SYNDROME: A RANDOMIZED CROSSOVER STUDY IN POSTMENOPAUSAL WOMEN, AM J CLIN NUTR, 85, PP. 735-741, (2007); AZADBAKHT L., KIMIAGAR M., MEHRABI Y., ET AL., SOY CONSUMPTION, MARKERS OF INFLAMMATION, AND ENDOTHELIAL FUNCTION: A CROSS-OVER STUDY IN POSTMENOPAUSAL WOMEN WITH THE METABOLIC SYNDROME, DIABETES CARE, 30, PP. 967-973, (2007); MARTINS J.M., RIOTTOT M., DE ABREU M.C., ET AL., CHOLESTEROL-LOWERING EFFECTS OF DIETARY BLUE LUPIN (LUPINUS ANGUSTIFOLIUS L.) IN INTACT AND ILEORECTAL ANASTOMOSED PIGS, J LIPID RES, 46, PP. 1539-1547, (2005); SIRTORI C.R., LOVATI M.R., MANZONI C., ET AL., PROTEINS OF WHITE LUPIN SEED, A NATURALLY ISOFLAVONE-POOR LEGUME, REDUCE CHOLESTEROLEMIA IN RATS AND INCREASE LDL RECEPTOR ACTIVITY IN HEPG2 CELLS, J NUTR, 134, PP. 18-23, (2004); SPIELMANN J., SHUKLA A., BRANDSCH C., ET AL., DIETARY LUPIN PROTEIN LOWERS TRIGLYCERIDE CONCENTRATIONS IN LIVER AND PLASMA IN RATS BY REDUCING HEPATIC GENE EXPRESSION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1C, ANN NUTR METAB, 51, PP. 387-392, (2007); MARCHESI M., PAROLINI C., DIANI E., ET AL., HYPOLIPIDEMIC AND ANTI-ATHEROSCLEROTIC EFFECTS OF LUPIN PROTEINS IN A RABBIT MODEL, BR J NUTR, 100, PP. 707-710, (2008); CHIESA G., DI MARIO C., COLOMBO N., ET AL., DEVELOPMENT OF A LIPID-RICH, SOFT PLAQUE IN RABBITS, MONITORED BY HISTOLOGY AND INTRAVASCULAR ULTRASOUND, ATHEROSCLEROSIS, 156, PP. 277-287, (2001); PILVI T.K., JAUHIAINEN T., CHENG Z.J., ET AL., LUPIN PROTEIN ATTENUATES THE DEVELOPMENT OF HYPERTENSION AND NORMALISES THE VASCULAR FUNCTION OF NACL-LOADED GOTO- KAKIZAKI RATS, J PHYSIOL PHARMACOL, 57, PP. 167-176, (2006); NOWICKA G., KLOSIEWICZ-LATOSZEK L., SIRTORI C.R., ET AL., LUPIN PROTEINS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLER SUPPL, 7, (2006); LEE Y., MORI T., PUDDEY I., ET AL., EFFECTS OF LUPIN KERNEL FLOUR-ENRICHED BREAD ON BLOOD PRESSURE: A CONTROLLED INTERVENTION STUDY, AM J CLIN NUTR, 89, PP. 766-772, (2009); LASEKAN J.B., GUETH L., KHAN S., INFLUENCE OF DIETARY GOLDEN PEA PROTEIN VERSUS CASEIN ON PLASMA AND HEPATIC LIPIDS IN RATS, NUTR RES, 15, PP. 71-84, (1995); ALONSO R., GRANT G., MARZO F., THERMAL TREATMENT IMPROVES NUTRITIONAL QUALITY OF PEA SEEDS (PISUM SATIVUM L.) WITHOUT REDUCING THEIR HYPOCHOLESTEROLEMIC PROPERTIES, NUTR RES, 21, PP. 1067-1077, (2001); ZULET M.A., MACARULLA M.T., PORTILLO M.P., ET AL., LIPID AND GLUCOSE UTILIZATION IN HYPERCHOLESTEROLEMIC RATS FED A DIET CONTAINING HEATED CHICKPEA (CICER ARETINUM L.): A POTENTIAL FUNCTIONAL FOOD, INT J VITAM NUTR RES, 69, PP. 403-411, (1999); MACARULLA M.T., MEDINA C., DE DIEGO M.A., ET AL., EFFECTS OF THE WHOLE SEED AND A PROTEIN ISOLATE OF FABA BEAN (VICIA FABA) ON THE CHOLESTEROL METABOLISM OF HYPERCHOLESTEROLAEMIC RATS, BR J NUTR, 85, PP. 607-614, (2001); DABAI F.D., WALKER A.F., SAMBROOK I.E., ET AL., COMPARATIVE EFFECTS ON BLOOD LIPIDS AND FAECAL STEROIDS OF FIVE LEGUME SPECIES INCORPORATED INTO A SEMI-PURIFIED, HYPERCHOLESTEROLAEMIC RAT DIET, BR J NUTR, 75, PP. 557-571, (1996); KINGMAN S.M., WALKER A.F., LOW A.G., ET AL., COMPARATIVE EFFECTS OF FOUR LEGUME SPECIES ON PLASMA LIPIDS AND FAECAL STEROID EXCRETION IN HYPERCHOLESTEROLAEMIC PIGS, BR J NUTR, 69, PP. 409-421, (1993); MARTINS J.M., RIOTTOT M., DE ABREU M.C., ET AL., DIETARY RAW PEAS (PISUM SATIVUM L.) REDUCE PLASMA TOTAL AND LDL CHOLESTEROL AND HEPATIC ESTERIFIED CHOLESTEROL IN INTACT AND ILEORECTAL ANASTOMOSED PIGS FED CHOLESTEROL-RICH DIETS, J NUTR, 134, PP. 3305-3312, (2004); ANDERSON J.W., STORY L., SIELING B., ET AL., HYPOCHOLESTEROLEMIC EFFECTS OF OAT-BRAN OR BEAN INTAKE FOR HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 40, PP. 1146-1155, (1984); ANDERSON J.W., GUSTAFSON N.J., SPENCER D.B., ET AL., SERUM LIPID RESPONSE OF HYPERCHOLESTEROLEMIC MEN TO SINGLE AND DIVIDED DOSES OF CANNED BEANS, AM J CLIN NUTR, 51, PP. 1013-1019, (1990); COBIAC L., MCARTHUR R., NESTEL P.J., CAN EATING BAKED BEANS LOWER PLASMA CHOLESTEROL?, EUR J CLIN NUTR, 44, PP. 819-822, (1990); OOSTHUIZEN W., SCHOLTZ C.S., VORSTER H.H., ET AL., EXTRUDED DRY BEANS AND SERUM LIPOPROTEIN AND PLASMA HAEMOSTATIC FACTORS IN HYPERLIPIDAEMIC MEN, EUR J CLIN NUTR, 54, PP. 373-379, (2000); JENKINS D.J., WONG G.S., PATTEN R., ET AL., LEGUMINOUS SEEDS IN THE DIETARY MANAGEMENT OF HYPERLIPIDEMIA, AM J CLIN NUTR, 38, PP. 567-573, (1983); MACKAY S., BALL M.J., DO BEANS AND OAT BRAN ADD TO THE EFFECTIVENESS OF A LOW-FAT DIET?, EUR J CLIN NUTR, 46, PP. 641-648, (1992); FRUHBECK G., MONREAL I., SANTIDRIAN S., HORMONAL IMPLICATIONS OF THE HYPOCHOLESTEROLEMIC EFFECT OF INTAKE OF FIELD BEANS (VICIA FABA L.) BY YOUNG MEN WITH HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 66, PP. 1452-1460, (1997); WINHAM D.M., HUTCHINS A.M., AKED BEAN CONSUMPTION REDUCES SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC ADULTS, NUTR RES, 27, PP. 380-386, (2007); ZHANG X., BEYNEN A.C., INFLUENCE OF DIETARY FISH PROTEINS ON PLASMA AND LIVER CHOLESTEROL CONCENTRATIONS IN RATS, BR J NUTR, 69, PP. 767-777, (1993); SHUKLA A., BETTZIECHE A., HIRCHE F., ET AL., DIETARY FISH PROTEIN ALTERS BLOOD LIPID CONCENTRATIONS AND HEPATIC GENES INVOLVED IN CHOLESTEROL HOMEOSTASIS IN THE RAT MODEL, BR J NUTR, 96, PP. 674-682, (2006); LINDQVIST H., LANGKILDE A., UNDELAND I., ET AL., HERRING (CLUPEA HARENGUS) INTAKE INFLUENCES LIPOPROTEINS BUT NOT INFLAMMATORY AND OXIDATION MARKERS IN OVERWEIGHT MEN, BR J NUTR, 101, PP. 383-390, (2009); SIRTORI C., GALLI C., ANDERSON J., ET AL., NUTRITIONAL AND NUTRACEUTICAL APPROACHES TO DYSLIPIDEMIA AND ATHEROSCLEROSIS PREVENTION: FOCUS ON DIETARY PROTEINS, ATHEROSCLEROSIS, 203, PP. 8-17, (2009); VERCRUYSSE L., VAN CAMP J., SMAGGHE G., ACE INHIBITORY PEPTIDES DERIVED FROM ENZYMATIC HYDROLYSATES OF ANIMAL MUSCLE PROTEIN: A REVIEW, J AGRIC FOOD CHEM, 53, PP. 8106-8115, (2005); DING E.L., HUTFLESS S.M., DING X., ET AL., CHOCOLATE AND PREVENTION OF CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW, NUTR METAB (LOND), 3, (2006); KUROSAWA T., ITOH F., NOZAKI A., ET AL., SUPPRESSIVE EFFECT OF COCOA POWDER ON ATHEROSCLEROSIS IN KUROSAWA AND KUSANAGI-HYPERCHOLESTEROLEMIC RABBITS, J ATHEROSCLER THROMB, 12, PP. 20-28, (2005); GRASSI D., NECOZIONE S., LIPPI C., ET AL., COCOA REDUCES BLOOD PRESSURE AND INSULIN RESISTANCE AND IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION IN HYPERTENSIVES, HYPERTENSION, 46, PP. 398-405, (2005); SCHROETER H., HEISS C., BALZER J., ET AL., (2)-EPICATECHIN MEDIATES BENEFICIAL EFFECTS OF FLAVANOL-RICH COCOA ON VASCULAR FUNCTION IN HUMANS, PROC NATL ACAD SCI USA, 103, PP. 1024-1029, (2006); GRASSI D., LIPPI C., NECOZIONE S., ET AL., SHORT-TERM ADMINISTRATION OF DARK CHOCOLATE IS FOLLOWED BY A SIGNIFICANT INCREASE IN INSULIN SENSITIVITY AND A DECREASE IN BLOOD PRESSURE IN HEALTHY PERSONS, AM J CLIN NUTR, 81, PP. 611-614, (2005)","C. R. SIRTORI; DEPARTMENT OF PHARMACOLOGICAL SCIENCES, UNIVERSITY OF MILANO, ITALY; EMAIL: CESARE.SIRTORI@UNIMI.IT","","ENGLISH","NUT. RES. REV.","REVIEW","ISI","2-S2.0-77950363568","NUT RES REV","UNIVERSITY OF MILANO;UNIVERSITY OF MILANO;UNIVERSITY OF KENTUCKY;UNIVERSITY OF MILANO;UNIVERSITY OF MILANO","NOTREPORTED;UNIVERSITY OF MILANO;NOTREPORTED",NA,"SIRTORI CR, 2009, NUT RES REV","SIRTORI CR, 2009, NUT RES REV"
"MARINANGELI C;JONES P;KASSIS A;ESKIN M","MARINANGELI, CHRISTOPHER P.F. (12787919400); JONES, PETER J.H. (36078426500); KASSIS, AMIRA N. (12800588300); ESKIN, MICHAEL N.A. (12798272600)","POLICOSANOLS AS NUTRACEUTICALS FACT OR FICTION",2010,"CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION","50","8",73,"10.1080/10408391003626249","RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, DEPARTMENTS OF FOOD SCIENCE AND HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MANITOBA, CANADA;RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, DEPARTMENTS OF FOOD SCIENCE AND HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MANITOBA, CANADA;RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, DEPARTMENTS OF FOOD SCIENCE AND HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MANITOBA, CANADA;RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, DEPARTMENTS OF FOOD SCIENCE AND HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MANITOBA, CANADA","POLICOSANOLS (PC) ARE VERY LONG CHAIN ALIPHATIC ALCOHOLS DERIVED FROM THE WAX CONSTITUENT OF PLANTS. IN THE EARLY 1990S, RESEARCHERS AT DALMER LABORATORIES IN LA HABANA CUBA ISOLATED AND PRODUCED THE FIRST PC SUPPLEMENT FROM SUGARCANE WAX. THE ORIGINAL PC SUPPLEMENT HAS BEEN APPROVED AS A CHOLESTEROL-LOWERING DRUG IN OVER 25 COUNTRIES THROUGHOUT THE CARIBBEAN AND SOUTH AMERICA. CUBAN STUDIES CLAIM THAT 1 TO 20 MG/DAY OF THE ORIGINAL PC SUPPLEMENT ARE EFFECTIVE AT PRODUCING SIGNIFICANT REDUCTIONS IN TOTAL CHOLESTEROL (TC) AND LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C). THESE STUDIES ALSO SHOW THAT PC SUPPLEMENTS ARE POTENT ANTIOXIDANTS, PROMOTE PROPER ARTERIAL ENDOTHELIAL CELL FUNCTION, INHIBIT PLATELET AGGREGATION AND THROMBOSIS, AND SERVE AS EFFECTIVE TREATMENTS FOR INTERMITTENT CLAUDICATION. HOWEVER, FOR THE MOST PART, THOSE STUDIES REPORTING THERAPEUTIC EFFICACY OF PC WERE CARRIED OUT BY ONE RESEARCH GROUP SITUATED IN CUBA. CONVERSELY, RESEARCH GROUPS OUTSIDE OF CUBA HAVE FAILED TO VALIDATE THE CHOLESTEROL-LOWERING AND ANTIOXIDANT EFFICACY OF PC. CUBAN RESEARCHERS, HOWEVER, CONTINUE TO CLAIM THAT THE EFFICACY IS ATTRIBUTED TO THE UNIQUE PURITY AND COMPOSITION OF THE ORIGINAL PC PREPARATION, A MIXTURE NOT FOUND IN PC PRODUCTS USED BY EXTERNAL RESEARCH GROUPS. THE ABSENCE OF INDEPENDENT AND EXTERNAL STUDIES CONFIRMING THE THERAPEUTIC BENEFITS OF PC IN DISEASE PREVENTION AND TREATMENT RAISES QUESTIONS REGARDING THEIR TRUE EFFICACY. © TAYLOR AND FRANCIS GROUP, LLC.","LONG CHAIN ALCOHOLS; POLICOSANOLS; SUGAR CANE; THERAPEUTIC PROPERTIES","ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; HUMANS; HYPERCHOLESTEROLEMIA; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SACCHARUM; TREATMENT OUTCOME; TRIGLYCERIDES; SACCHARUM; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; DIET SUPPLEMENTATION; HUMAN; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; TREATMENT OUTCOME","","","ALCOCER L., FERNANDEZ L., CAMPOS E., MAS R., ACOMPARATIVESTUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, 3, PP. 85-92, (1999); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, 7, PP. 573-578, (1995); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ C., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, 3, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, 2, PP. 176-181, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, 3, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, 10, PP. 891-897, (2002); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, 3, PP. 134-137, (1996); BENITEZ M., CUAUHTEMOX R., MAS R., FERNANDEZ L., FERNANDEZ J., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, 11, PP. 859-867, (1997); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); CABRERA L., GONZALEZ V., URIBARRI E., SIERRA R., LAGUNA A., MAGRANER J., MEDEROS D., VELAZQUEZ C., STUDY OF THE STABILITY OF TABLETS CONTAINING10MGOFPOLICOSANOLASACTIVE PRINCIPLE, BOLLCHIMFARM, 141, 3, PP. 223-229, (2002); CABRERA L., RIVERO B., MAGRANER J., SIERRA R., GONZALEZ V., URIBARRI E., LAGUNA A., CORA M., TEJEDA Y., RODRIGUEZ E., VELAZQUEZ C., STABILITY STUDIES OF TABLETS CONTAINING 5 MG OF POLICOSANOL, BOLL CHIM FARM, 142, 7, PP. 277-284, (2003); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., CASTANO G., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, 4, PP. 245-254, (1995); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., DIAZ E., CASTANO G., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, 4, PP. 159-165, (1995); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, 1, PP. 61-64, (1998); CASTANO G., CANETTI M., MOREIRA M., TULA L., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., DIAZ E., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, 8, PP. 819-828, (1995); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, 2, PP. 55-66, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVESTIG, 23, 10, PP. 639-650, (2003); CASTANO G., MAS FERREIRO R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, 2, PP. 115-125, (2001); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., MOLINA V., MENENDEZ A., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, 4, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, 3, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, 3, (2001); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, 3, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, 1, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, PP. 31-44, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ J.C., ONE-YEAR OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, 3, PP. 296-303, (1995); CASTANO G., MAS R., ROCA J., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., SELMAN E., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, 2, PP. 123-130, (1999); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, 3-4, PP. 89-99, (2002); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ L.C., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 57, 9, PP. 691-698, (1996); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, 5, (2006); DAVIS P.J., POZNANSKY M.J., MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE BY CHANGES IN MICROSOMAL CHOLESTEROL CONTENT OR PHOSPHOLIPID COMPOSITION, PROC NATL ACAD SCI U S A, 84, 1, PP. 118-121, (1987); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, 6, PP. 1543-1548, (2006); ELKIND M.S., INFLAMMATION, ATHEROSCLEROSIS, AND STROKE, NEUROLOGIST, 12, 3, PP. 140-148, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGARCANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, 3, PP. 318-322, (2008); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, 5, PP. 968-975, (2006); GUYTON A.C., HALL J.E., CHAPTER36:HEMOSTASISANDBLOODCOAGULATION, TEXTBOOK OF MEDICAL PHYSIOLOGY, PP. 463-473, (1996); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED (MAYWOOD), 229, 3, PP. 215-226, (2004); JONES P.J., PENCHARZ P.B., CLANDININ M.T., ABSORPTION OF 13C- LABELED STEARIC, OLEIC, AND LINOLEIC ACIDS IN HUMANS: APPLICATION TO BREATH TESTS, J LAB CLIN MED, 105, 6, PP. 647-652, (1985); JONES P.J., PENCHARZ P.B., CLANDININ M.T., WHOLE BODY OXIDATION OF DIETARY FATTY ACIDS: IMPLICATIONS FOR ENERGY UTILIZATION, AM J CLIN NUTR, 42, 5, PP. 769-777, (1985); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, 1, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, 5, PP. 279-284, (1995); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGARCANEPOLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, 5, PP. 1003-1008, (2006); KASSIS A.N., MARINANGELI C.P., JAIN D., EBINE N., JONES P.J., LACK OF EFFECT OF SUGARCANEPOLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS, ATHEROSCLEROSIS, 194, 1, PP. 153-158, (2007); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, 10, PP. 1309-1314, (2004); MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BR J NUTR, 97, 2, PP. 381-388, (2007); MAS R., POLICOSANOL. HYPOLIPIDEMIC, ANTIOXIDANT, TREATMENT OF ATHEROSCLEROSIS, DRUGS FUTURE, 25, 6, PP. 569-586, (2000); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, 4, PP. 439-447, (1999); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, 1, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL- LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, 6, PP. 923-932, (1997); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, 3-4, PP. 199-203, (1994); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, 3, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, 4, PP. 299-304, (2001); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, 2, PP. 81-90, (1994); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., FUSTER A., LASTRETO E., YANEZ M., IRICO G., MCCOOK B., FARRE A., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POST-MENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, 1, PP. 31-41, (2001); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGARCANEAND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, 16, PP. 6289-6293, (2005); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS IN SPRAGUE-DAWLEY RATS AND IN RABBITS, J PHARM PHARMACOL, 49, 10, PP. 999-1002, (1997); OLIVIER L.M., KRISANS S.K., PEROXISOMAL PROTEIN TARGETING AND IDENTIFICATION OF PEROXISOMAL TARGETING SIGNALS IN CHOLESTEROL BIOSYNTHETIC ENZYMES, BIOCHIM BIOPHYS ACTA, 1529, 1-3, PP. 89-102, (2000); ORTENSI G., GLADSTEIN J., VALLI H., TESTONE P., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, 6, PP. 390-301, (1997); PONS P., ILLNAIT J., MAS R., RODRIGUEZ M., ALEMAN C., FERNANDEZ J.C., FERNANDEZ L., MARTIN M., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, 1, PP. 26-35, (1997); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, 4, PP. 507-513, (1992); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, 9, PP. 1084-1092, (1994); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OFPOLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, 1, PP. 27-33, (1994); REINER Z., TEDESCHI-REINER E., RICE POLICOSANOL DOES NOT HAVE ANY EFFECTS ON BLOOD COAGULATION FACTORS IN HYPERCHOLESTEROLEMIC PATIENTS, COLL ANTROPOL, 31, 4, PP. 1061-1064, (2007); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINGOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 25, 11, PP. 701-707, (2005); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, 6, PP. 565-575, (1994); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERIAND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, 1, PP. 1-7, (1998); SALLEE V.L., PERMEATION OF LONG-CHAIN FATTY ACIDS AND ALCOHOLS IN RAT INTESTINE, AM J PHYSIOL, 236, 6, (1979); SALLEE V.L., DIETSCHY J.M., DETERMINANTS OF INTESTINAL MUCOSAL UPTAKE OF SHORT- AND MEDIUM-CHAIN FATTY ACIDS AND ALCOHOLS, J LIPID RES, 14, 4, PP. 475-484, (1973); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, 3, PP. 1020-1026, (2006); STRYER L., CHAPTER 27: BIOSYNTHEIS OF MEMBRANE LIPIDS AND STEROIDS, BIOCHEMISTRY, PP. 685-712, (1995); CIRCULATION, 106, 25, PP. 3143-3421, (2002); MONOGRAPH. POLICOSANOL, ALTERN MED REV., 9, 3, PP. 312-317, (2004); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, 3, PP. 393-397, (1995); URIBARRI E., LAGUNA A., SIERRA R., RICARDO Y., PHYSICO-MECHANICAL CHARACTERIZATION OF POLICOSANOL, A NOVEL HYPOCHOLESTEROLEMIC DRUG, DRUG DEV IND PHARM, 28, 1, PP. 89-93, (2002); WANG Y., EBINE N., JIA X., JONES P.J., FAIROW C., JAEGER R., VERY LONG CHAIN FATTY ACIDS (POLICOSANOLS) AND PHYTOSTEROLS AFFECT PLASMA LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, METABOLISM, 54, 4, PP. 508-514, (2005); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, 2, PP. 165-170, (2003); WHITCOMB R.W., LINEHAN W.M., KNAZEK R.A., EFFECTS OF LONG- CHAIN, SATURATED FATTY ACIDS ON MEMBRANE MICROVISCOSITY AND ADRENOCORTICOTROPIN RESPONSIVENESS OF HUMAN ADRENOCORTICAL CELLS IN VITRO, J CLIN INVEST, 81, 1, PP. 185-188, (1988)","M. N. A. ESKIN; RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, DEPARTMENTS OF FOOD SCIENCE AND HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, HUMAN ECOLOGY BLDG, WINNIPEG, MB, R3T 2N2, CANADA; EMAIL: ESKIN@MS.UMANITOBA.CA","","ENGLISH","CRIT. REV. FOOD SCI. NUTR.","ARTICLE","ISI","2-S2.0-77949543394","CRIT REV FOOD SCI NUTR","UNIVERSITY OF MANITOBA;UNIVERSITY OF MANITOBA;UNIVERSITY OF MANITOBA;UNIVERSITY OF MANITOBA","NOTREPORTED;UNIVERSITY OF MANITOBA;NOTREPORTED",NA,"MARINANGELI CPF, 2010, CRIT REV FOOD SCI NUTR","MARINANGELI CPF, 2010, CRIT REV FOOD SCI NUTR"
"GUPTA H;PAWAR D;RIVA A;BOMBARDELLI E;MORAZZONI P","GUPTA, H. (59069449700); PAWAR, D. (57197685749); RIVA, A. (35548619200); BOMBARDELLI, E. (7005477284); MORAZZONI, P. (7003337803)","A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED TRIAL TO EVALUATE EFFICACY AND TOLERABILITY OF AN OPTIMIZED BOTANICAL COMBINATION IN THE MANAGEMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA",2012,"PHYTOTHERAPY RESEARCH","26","7",8,"10.1002/ptr.3542","DEPARTMENT OF MEDICINE, GRANT MEDICAL COLLEGE MUMBAI, MUMBAI, INDIA;DEPARTMENT OF PHARMACOLOGY, DRUG RESEARCH LABORATORY, MUMBAI, INDIA;SCIENTIFIC DEPARTMENT, 20139 MILAN, VIALE ORTLES, 12, ITALY;SCIENTIFIC DEPARTMENT, 20139 MILAN, VIALE ORTLES, 12, ITALY;SCIENTIFIC DEPARTMENT, 20139 MILAN, VIALE ORTLES, 12, ITALY","THIS STUDY COMPARED THE EFFICACY AND TOLERABILITY OF AN OPTIMIZED BOTANICAL COMBINATION CONTAINING POLICOSANOL, TOMATO EXTRACT, ORALLY BIOAVAILABLE GRAPE PROCYANIDINS AND OENOTHERA BIENNIS OIL AGAINST PLACEBO IN THE MANAGEMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA. SUCH A COMBINATION IS ENDOWED WITH BIOLOGICAL PROPERTIES TARGETED TO CHOLESTEROL CONTROL AND VASOPROTECTION. THIS RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP TRIAL CONSISTED OF A 6WEEK TREATMENT PERIOD FOLLOWING 4WEEK BASELINE PERIOD, AND A 2WEEK POST-TREATMENT FOLLOW-UP. AT BASELINE, BOTH THE GROUPS WERE COMPARABLE TO EACH OTHER. BOTH THE ACTIVE TREATMENT AND THE PLACEBO GROUP INCLUDED 30 PATIENTS (ACTIVE TREATMENT: MEAN AGE 46.80±7.43YEARS, NINE MALES; PLACEBO: MEAN AGE 45.50±6.76YEARS, EIGHT MALES). SIGNIFICANT REDUCTIONS IN THE LDL-CHOLESTEROL (LDL-C; -17.33% FROM BASELINE, P<0.001) AND TOTAL CHOLESTEROL (TC; -13.38% FROM BASELINE, P<0.0001) VALUES OVER THE TREATMENT PERIOD WERE OBSERVED WITH THE TESTED PRODUCT. THE TREATMENT ALSO RESULTED IN REDUCTIONS IN C-REACTIVE PROTEIN (CRP), MALONDIALDEHYDE (MDA) AND SUPEROXIDE DISMUTASE (SOD) VALUES, WHICH ARE INDICES OF OXIDATIVE STRESS. THIS RATIONAL COMBINATION OF DIFFERENT COMPOUNDS IS EFFECTIVE AND SAFE IN LOWERING THE ELEVATED LDL-C AND TC VALUES. IT IS ALSO EFFECTIVE IN THE MODULATION OF THE OXIDATION INDICES VALUES; HOWEVER, A FURTHER LONG TERM STUDY IN A LARGER POPULATION WOULD BE NEEDED IN ORDER TO CONFIRM THESE PRELIMINARY FINDINGS. © 2011 JOHN WILEY & SONS, LTD.","CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DIETARY SUPPLEMENT; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; POLYPHENOLS","LYCOPERSICON ESCULENTUM; OENOTHERA BIENNIS; VITACEAE; AGENTS AFFECTING LIPID METABOLISM; C REACTIVE PROTEIN; CHOLACTIV; CHOLESTEROL; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLACEBO; PLANT EXTRACT; POLICOSANOL; PRIMROSE OIL; PROCYANIDIN DERIVATIVE; SUPEROXIDE DISMUTASE; TOMATO EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; MALE; MIXED DYSLIPIDEMIA; OXIDATIVE STRESS; PARALLEL DESIGN; PRIMARY HYPERCHOLESTEROLEMIA; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE","","","ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); ARAB L., STECK S., LYCOPENE AND CARDIOVASCULAR DISEASE, AM J CLIN NUTR, 71, (2000); ARTS I.C.W., HOLLMAN P.C.H., FESKENS E.J.M., BUENO DE MESQUITA H.B., KROMHOUT D., CATECHIN INTAKE MIGHT EXPLAIN THE INVERSE RELATION BETWEEN TEA CONSUMPTION AND ISCHEMIC HEART DISEASE: THE ZUTPHEN ELDERLY STUDY, AMERICAN JOURNAL OF CLINICAL NUTRITION, 74, 2, PP. 227-232, (2001); BHATNAGAR D., SORAN N., DURRINGTON P.N., HYPERCHOLESTEROLEMIA AND ITS MANAGEMENT, BR MED J, 337, (2008); BOMBARDELLI E., MORAZZONI P., VITIS VINIFERA, FITOTERAPIA, 66, PP. 291-317, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 19, 4, PP. 117-127, (1999); DASGUPTA A., ZDUNEK T., IN VITRO LIPID PEROXIDATION OF HUMAN SERUM CATALYZED BY CUPRIC ION, LIFE SCI, 50, PP. 875-582, (1992); FAN Y.-Y., RAMOS K.S., CHAPKIN R.S., DIETARY Γ-LINOLENIC ACID ENHANCES MOUSE MACROPHAGE-DERIVED PROSTAGLANDIN E<SUB>1</SUB> WHICH INHIBITS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION, JOURNAL OF NUTRITION, 127, 9, PP. 1765-1771, (1997); FAN Y.Y., RAMOS K.S., CHAPKIN R.S., DIETARY GAMMA-LINOLENIC ACID SUPPRESSES AORTIC SMOOTH MUSCLE CELL PROLIFERATION AND MODIFIES ATHEROSCLEROTIC LESIONS IN APOLIPOPROTEIN E KNOCKOUT MICE, J NUTR, 131, (2001); FUHRMAN B., ELIS A., AVIRAM M., HYPOCHOLESTEROLEMIC EFFECT OF LYCOPENE AND Β-CAROTENE IS RELATED TO SUPPRESSION OF CHOLESTEROL SYNTHESIS AND AUGMENTATION OF LDL RECEPTOR ACTIVITY IN MACROPHAGES, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 233, 3, PP. 658-662, (1997); FUHRMAN B., PARTOUSH A., VOLKOVA N., AVIRAM M., OX-LDL INDUCES MONOCYTE-TO-MACROPHAGE DIFFERENTIATION IN VIVO: POSSIBLE ROLE FOR THE MACROPHAGE COLONY STIMULATING FACTOR-RECEPTOR (M-CSF-R), ATHEROSCLEROSIS, 196, (2008); FUKUSHIMA M., MATSUDA T., YAMAGISHI K., NAKANO M., COMPARATIVE HYPOCHOLESTEROLEMIC EFFECTS OF SIX DIETARY OILS IN CHOLESTEROL FED RATS AFTER LONG-TERM FEEDING, LIPIDS, 32, (1997); FUKUSHIMA M., SHIMADA K., OHASHI T., ET AL., INVESTIGATION OF GENE EXPRESSIONS RELATED TO CHOLESTEROL METABOLISM IN RATS FED DIETS ENRICHED IN N-6 OR IN N-3 FATTY ACID WITH A CHOLESTEROL AFTER LONG-TERM FEEDING USING QUANTITATIVE-COMPETITIVE RT-PCR ANALYSIS, J NUTR SCI VITAMINOL, 47, (2001); GLEISSNER C.A., LEITINGER N., LEY K., EFFECT OF NATIVE AND MODIFIED LOW-DENSITY LIPOPROTEINS ON MONOCYTE RECRUITMENT IN ATHEROSCLEROSIS, HYPERTENSION, 50, (2007); HADLEY C.W., CLINTON S.K., SCHWARTZ S.J., THE CONSUMPTION OF PROCESSED TOMATO PRODUCTS ENHANCES PLASMA LYCOPENE CONCENTRATIONS IN ASSOCIATION WITH A REDUCED LIPOPROTEIN SENSITIVITY TO OXIDATIVE DAMAGE, JOURNAL OF NUTRITION, 133, 3, PP. 727-732, (2003); HANSSON L.-O., LINDQUIST L., C-REACTIVE PROTEIN: ITS ROLE IN THE DIAGNOSIS AND FOLLOW-UP OF INFECTIOUS DISEASES, CURRENT OPINION IN INFECTIOUS DISEASES, 10, 3, PP. 196-201, (1997); HIROYUKI S., TAKAHIRO I., PROTECTIVE EFFECT OF DIETARY TOMATO AGAINST ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLEMIC MICE, BIOSCI BIOTECHNOL BIOCHEM, 63, PP. 78-82, (1999); HOOPER L., KROON P.A., RIMM E.B., COHN J.S., HARVEY I., LE CORNU K.A., RYDER J.J., HALL W.L., CASSIDY A., FLAVONOIDS, FLAVONOID-RICH FOODS, AND CARDIOVASCULAR RISK: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 88, 1, PP. 38-50, (2008); HORROBIN D.F., GAMMA LINOLENIC ACID: AN INTERMEDIATE IN ESSENTIAL FATTY ACID METABOLISM WITH POTENTIAL AS AN ETHICAL PHARMACEUTICAL AND AS A FOOD, REV CONTEMP PHARMACOTHER, 1, PP. 1-45, (1990); JAIN S.K., MCVIE R., DUETT J., HERBST J.J., ERYTHROCYTE MEMBRANE LIPID PEROXIDATION AND GLYCOSYLATED HEMOGLOBIN IN DIABETES, DIABETES, 38, 12, PP. 1539-1543, (1989); TOMATO NUTRIENT PREVENTS CANCER AND CARDIOVASCULAR DISEASES, ALTERN MED REV, 8, PP. 336-342, (2003); MAFFEI FACINO R., CARINI M., ALDINI G., BERTI F., ROSSONI G., BOMBARDELLI E., MORAZZONI P., DIET ENRICHED WITH PROCYANIDINS ENHANCES ANTIOXIDANT ACTIVITY AND REDUCES MYOCARDIAL POST-ISCHAEMIC DAMAGE IN RATS, LIFE SCIENCES, 64, 8, PP. 627-642, (1999); MARKLUND S., MARKLUND G., INVOLVEMENT OF THE SUPEROXIDE ANION RADICAL IN AUTOXIDATION OF PYROGALLOL AS A CONVENIENT ASSAY FOR SUPEROXIDE DISMUTASE, EUR J BIOCHEM, 47, PP. 469-474, (1974); MENENDEZ R., MAS R., AMOR A., FERNANDEZ J., GONZALEZ R., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); NUTTALL S.L., KENDALL M.J., BOMBARDELLI E., MORAZZONI P., AN EVALUATION OF THE ANTIOXIDANT ACTIVITY OF A STANDARDIZED GRAPE SEED EXTRACT, LEUCOSELECT®, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 23, 5, PP. 385-389, (1998); PAGILA D.S., VALENTINE W.N., STUDIES ON THE QUANTITATIVE AND QUALITATIVE CHARACTERIZATION OF ERYTHROCYTE GLUTATHIONE PEROXIDISE, J LAB CLIN MED, 70, PP. 158-169, (1967); SILASTE M.-L., ALFTHAN G., ARO A., KESANIEMI Y.A., HORKKO S., TOMATO JUICE DECREASES LDL CHOLESTEROL LEVELS AND INCREASES LDL RESISTANCE TO OXIDATION, BRITISH JOURNAL OF NUTRITION, 98, 6, PP. 1251-1258, (2007); URSINI F., ZAMBURLINI A., CAZZOLATO G., MAIORINO M., BITTOLO BON G., SEVANIAN A., POSTPRANDIAL PLASMA HYDROPEROXIDES: A POSSIBLE LINK BETWEEN DIET AND ATHEROSCLEROSIS, FREE RADIC BIOL MED, 25, (1998); VIELAND H., SEIDEL T., A SIMPLE SPECIFIC METHOD FOR PRECIPITATION OF LDL, J LIPID RES, 24, PP. 904-909, (1983); VIGNA G.B., COSTANTINI F., ALDINI G., CARINI M., CATAPANO A., SCHENA F., TANGERINI A., ZANCA R., BOMBARDELLI E., MORAZZONI P., MEZZETTI A., FELLIN R., FACINO R.M., EFFECT OF A STANDARDIZED GRAPE SEED EXTRACT ON LOW-DENSITY LIPOPROTEIN SUSCEPTIBILITY TO OXIDATION IN HEAVY SMOKERS, METABOLISM: CLINICAL AND EXPERIMENTAL, 52, 10, PP. 1250-1257, (2003); CARDIOVASCULAR DISEASES (CVDS). FACT SHEET NO 317, (2009); WONG N., LOPEZ V., TANG S., WILLIAMS G., PREVALENCE, TREATMENT AND CONTROL OF COMBINED HYPERTENSION AND HYPERCHOLESTEROLEMIA, AM J CARDIOL, 98, PP. 204-208, (2008)","A. RIVA; INDENA S.P.A., SCIENTIFIC DEPARTMENT, 20139 MILAN, VIALE ORTLES, 12, ITALY; EMAIL: ANTONELLA.RIVA@INDENA.COM","JOHN WILEY AND SONS LTD","ENGLISH","PHYTOTHER. RES.","ARTICLE","ISI","2-S2.0-84856297092","PHYTOTHER RES","GRANT MEDICAL COLLEGE MUMBAI;DRUG RESEARCH LABORATORY;SCIENTIFIC DEPARTMENT;SCIENTIFIC DEPARTMENT;SCIENTIFIC DEPARTMENT","NOTREPORTED;SCIENTIFIC DEPARTMENT;NOTREPORTED",NA,"GUPTA H, 2012, PHYTOTHER RES","GUPTA H, 2012, PHYTOTHER RES"
"CHERIF A;BEN M M;KAABI B;BOUKHCHINA S;PEPE C;KALLEL H","CHERIF, AICHA O. (36348325300); BEN MESSAOUDA, MHAMED (36348167800); KAABI, BELHASSEN (6505947724); BOUKHCHINA, SADOK (6507257738); PEPE, CLAUDE (7003951390); KALLEL, HABIB (22934478000)","COMPARISON OF THE CONCENTRATIONS OF LONGCHAIN ALCOHOLS POLICOSANOL IN THREE TUNISIAN PEANUT VARIETIES ARACHIS HYPOGAEA L",2010,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","58","5",21,"10.1021/jf1030345","LABORATOIRE DE BIOCHIMIE, DES LIPIDES ET DES PROTÉINES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, TUNIS, 2092 EL MANAR, TUNISIA;UNITÉ DE PHYSICO-CHIMIE MOLÉCULAIRE, IPEST, 2075 LA MARSA, B.P. 51, TUNISIA;LABORATOIRE D'EPIDÉMIOLOGIE ET D'ECOLOGIE PARASITAIRE, INSTITUT PASTEUR DE TUNIS, 1002 TUNIS, 13 PLACE PASTEUR, TUNISIA;LABORATOIRE DE BIOCHIMIE, DES LIPIDES ET DES PROTÉINES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, TUNIS, 2092 EL MANAR, TUNISIA;LABORATOIRE DE DYNAMIQUE, INTERACTIONS ET RÉACTIVITÉ, UNIVERSITÉ DE PIERRE ET MARIE CURIE, 75005 PARIS, CASE COURRIER 49, 4 PLACE JUSSIEU, FRANCE;LABORATOIRE DE BIOCHIMIE, DES LIPIDES ET DES PROTÉINES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, TUNIS, 2092 EL MANAR, TUNISIA","POLICOSANOL (PC) IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC PRIMARY ALCOHOLS. LITERATURE ABOUT THE CONTENTS AND COMPOSITIONS OF PC DERIVED FROM PEANUT VARIETIES IS SCARCE. TOTAL PC COMPOSITION AND CONTENT IN WHOLE PEANUT GRAIN SAMPLES FROM THREE VARIETIES OF PEANUT (TWO CULTIVARS, ARAC AND ARAT, AND A WILD ONE, ARAA) WERE IDENTIFIED USING A GAS CHROMATOGRAPH SYSTEM COUPLED WITH A MASS SPECTROPHOTOMETER. THE RESULTS SHOW THAT, QUALITATIVELY, 21 COMPONENTS OF PEANUT ALIPHATIC ALCOHOLS WERE IDENTIFIED (C14-C30). BESIDES (C18=), THE RESULTS EXHIBITED A PREVIOUSLY UNREPORTED MIXTURE OF PC COMPOSITIONS IN THE PEANUTS: THE UNSATURATED PC (UPC), WHICH ARE (C 20=), (C21=), (C22=), AND (C24=). THE MAIN COMPONENTS OF TOTAL PC IN TUNISIAN PEANUT KERNELS ARE DOCOSANOL (C 22), (Z)-OCTADEC-9-EN-1-OL (C18=), HEXADECANOL (C 16), AND OCTADECANOL (C18). QUANTITATIVELY, THE TOTAL PC CONTENT OF THE WHOLE PEANUT SAMPLES VARIED FROM 11.18 TO 54.19 MG/100 G OF OIL AND WAS HIGHER THAN THOSE OF BEESWAX AND WHOLE SUGAR CANE, WHICH ARE SOURCES OF DIETARY SUPPLEMENTS CONTAINING POLICOSANOL. © 2010 AMERICAN CHEMICAL SOCIETY.","DEVELOPMENT; GC-MS; PEANUTS; POLICOSANOL; WILD CULTIVARS","ARACHIS HYPOGAEA; FATTY ALCOHOLS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PLANT EXTRACTS; SEEDS; TUNISIA; ARACHIS HYPOGAEA; SACCHARUM; DIETARY SUPPLEMENTS; MIXTURES; SUGAR CANE; FATTY ALCOHOL; PLANT EXTRACT; POLICOSANOL; DEVELOPMENT; GC-MS; PEANUTS; POLICOSANOL; WILD CULTIVARS; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; MOLECULAR WEIGHT; PEANUT; PLANT SEED; TUNISIA; OILSEEDS","","","SALES J.M., RESURRECCION A.V.A., PHENOLIC PROFILE, ANTIOXIDANTS, AND SENSORY ACCEPTANCE OF BIOACTIVE-ENHANCED PEANUTS USING ULTRASOUND AND UV, FOOD CHEM., 122, 3, PP. 795-803, (2010); ARRUZAZABALA M.L., CARBAJAL D., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF TRITICUM AESTIVUM, PHYTOCHEMISTRY, 12, PP. 2217-2223, (1973); IRMAK S., RAMAKANTH S.J., FINLAY M., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, J. CEREAL SCI., 48, PP. 20-26, (2008); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS., 58, PP. 61-64, (1998); PANG W.-Y., HE F.-Y., WEI X.-M., EFFECTS OF POLICOSANOL ON SERUM CHOLESTEROL LEVELS IN HYPERLIPIDEMIA RATS, CHIN. J. PHARM. TOXICOL., 23, 6, PP. 443-449, (2009); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPL. THER. MED., 16, PP. 61-65, (2008); MARINANGELI C.P.F., JONES P.J.H., KASSIS A.N., ESKIN M.N.A., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT. REV. FOOD SCI. NUTR., 50, 3, PP. 259-267, (2010); KASSIS A.N., MARINANGELI C.P.F., JONES P.J.H., REPLY TO THE DISCUSSION BY SERGEI V. JARGIN ON EVALUATION OF CHOLESTEROL-LOWERING AND ANTIOXIDANT PROPERTIES OF SUGAR CANE POLICOSANOLS IN HAMSTERS AND HUMANS, APPL. PHYSIOL. NUTR. METAB., 34, 1, PP. 76-77, (2009); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM. J. CLIN. NUTR., 84, PP. 1543-1548, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC SUBJECTS, BR. J. NUTR., 95, PP. 968-975, (2006); OFFICIAL METHODS AND RECOMMENDED PRACTICES OF THE AMERICAN OIL CHEMIST'S SOCIETY, (1989); HERCHI W., HARRABI S., SEBEI K., ROCHUT S., BOUKHCHINA S., MAYER P., KALLEL H., PHYTOSTEROLS ACCUMULATION IN THE SEEDS OF LINUM USITATISSIMUM L, PLANT PHYSIOL. BIOCHEM., 47, PP. 880-885, (2009); LI T.S.C., BEVERIDGE T.H.J., DROVER J.C.G., PHYTOSTEROL CONTENT OF SEA BUCKTHORN SEED OIL: EXTRACTION AND IDENTIFICATION, FOOD CHEM., 101, PP. 1633-1639, (2007); BEVERIDGE T.H.J., LI T.S.C., DROVER J.C.G., PHYTOSTEROL CONTENT IN AMERICAN GINSENG SEED OIL, J. AGRIC. FOOD CHEM., 50, 4, PP. 744-750, (2002); REINA R.J., WHITE K.D., JAHNGEN E.G.E., VALIDATED METHOD FOR QUANTIFICATION AND IDENTIFICATION OF 4,4-DESMETHYLSTEROLS AND TRITERPENE DIOLS IN PLANT OILS BY THIN-LAYER CHROMATOGRAPHY-HIGH-RESOLUTION GAS CHROMATOGRAPHY-MASS SPECTROMETRY, J. AM. OIL CHEM. SOC., 80, 6, PP. 1272-1280, (1997); HARRABI S., BOUKHCHINA S., MAYER P.M., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM., 115, PP. 918-923, (2009); LOPEZ-LOPEZ A., MONTANO A., RUIZ-MENDEZ M.V., GARRIDO-FERNANDEZ A., STEROLS, FATTY ALCOHOLS, AND TRITERPENIC ALCOHOLS IN COMMERCIAL TABLE OLIVES, J. AM. OIL CHEM. SOC., 85, 3, PP. 253-262, (2008); KRAPOVICKAS A., GREGORY W.C., TAXONOMIA DEL GENERO ARACHIS (LEGUMINOSAE), BONPLONDIA, 8, PP. 1-186, (1994); GROSSO N.R., NEPOTE V., GUZMAN C.A., CHEMICAL COMPOSITION OF SOME WILD PEANUT SPECIES (ARACHIS L.) SEEDS, J. AGRIC. FOOD CHEM., 48, PP. 806-809, (2000); CHERIF O.A., TRABELSI H., BEN MESSAOUDA M., KAABI B., PELLERIN I., BOUKHCHINA S., KALLEL H., PEPE C., GAS CHROMATOGRAPHY-MASS SPECTROMETRY SCREENING FOR PHYTOCHEMICAL 4-DESMETHYLSTEROLS ACCUMULATED DURING DEVELOPMENT OF TUNISIAN PEANUT KERNELS (ARACHIS HYPOGAEA L.), J. AGRIC. FOOD CHEM., 58, 15, PP. 8709-8714, (2010); WEBER N., MANGOLD H.K., METABOLISM OF LONG-CHAIN ALCOHOLS IN CELL SUSPENSION CULTURES OF SOYA AND RAPE, PLANTA, 155, 3, PP. 225-230, (1982); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM., 53, PP. 5583-5586, (2005); WARREN P.R., BURGER R.A., SIDWELL R.W., CLARK L.L., EFFECT OF TRIACONTANOL ON NUMBERS AND FUNCTIONS OF CELLS INVOLVED IN INFLAMMATORY RESPONSES, PROC. SOC. EXP. BIOL. MED., 200, PP. 349-352, (2002); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M., A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACOLOGICAL USES, (1997); WU T.T., CHARLES A.L., HUANG T.C., DETERMINATION OF THE CONTENTS OF THE MAIN BIOCHEMICAL COMPOUNDS OF ADLAY (COXI LACHRYMAL-JOBI), FOOD CHEM., 104, PP. 1509-1515, (2007); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, NUTR. RES. (N.Y.), 27, PP. 212-217, (2007); GULZ P.G., MULLER E., PRASAD B.N., DEVELOPMENTAL AND SEASONAL VARIATIONS IN THE EPICUTICULAR WAXES OF TILIA TOMENTOSA LEAVES, PHYTOCHEMISTRY, 30, PP. 769-773, (1991); WEBER E.J., LIPIDS OF MATURING OF CORN (ZEA MAYS L.): II. CHANGES IN POLAR LIPIDS, J. AM. OIL CHEM. SOC., 46, PP. 485-488, (1970); MARCELLETTI J.F., SYNERGISTIC INHIBITION OF HERPESVIRUS REPLICATION BY DOCOSANOL AND ANTIVIRAL NUCLEOSIDE ANALOGS, ANTIVIRAL RES., 56, PP. 153-166, (2002); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH. MED. RES., 36, PP. 113-119, (2005)","A. O. CHERIF; LABORATOIRE DE BIOCHIMIE, DES LIPIDES ET DES PROTÉINES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, TUNIS, 2092 EL MANAR, TUNISIA; EMAIL: AICHA.ECHERIF@GMAIL.COM","AMERICAN CHEMICAL SOCIETY","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-78649644737","J AGRIC FOOD CHEM","FACULTÉ DES SCIENCES DE TUNIS;INSTITUT PASTEUR DE TUNIS;FACULTÉ DES SCIENCES DE TUNIS;UNIVERSITÉ DE PIERRE ET MARIE CURIE;FACULTÉ DES SCIENCES DE TUNIS","NOTREPORTED;FACULTÉ DES SCIENCES DE TUNIS;NOTREPORTED",NA,"CHERIF AO, 2010, J AGRIC FOOD CHEM","CHERIF AO, 2010, J AGRIC FOOD CHEM"
"WHAYNE T","WHAYNE, THOMAS F. (57204791430)","ATHEROSCLEROSIS CURRENT STATUS OF PREVENTION AND TREATMENT",2011,"INTERNATIONAL JOURNAL OF ANGIOLOGY","20","9",28,"10.1055/s-0031-1295520","DIVISION OF CARDIOVASCULAR MEDICINE, GILL HEART INSTITUTE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES","THE REALITY OF REGRESSION OF ATHEROSCLEROTIC PLAQUES WAS ESTABLISHED AS LONG AGO AS 1987 BY AGGRESSIVE CHOLESTEROL REDUCTION EVEN BEFORE THE ERA OF STATIN THERAPY. NEVERTHELESS, THE MOST IMPORTANT ASPECT OF PATIENT BENEFIT TO PREVENT CARDIOVASCULAR (CV) DISEASE EVENTS IS STABILIZATION OF THESE PLAQUES SO THEY WILL NOT RUPTURE. LOWERING OF LOW-DENSITY LIPOPROTEINS IS CRITICAL TO THIS GOAL AND CAN BE CONSIDERED THE GOLD STANDARD OF PREVENTIVE CV MEDICINE. THE MAJOR GOAL FOR THE HIGH-RISK PATIENT AND THE DIABETIC PATIENT IS LOWERING THESE HARMFUL LIPOPROTEINS TO LESS THAN 70 MG/DL. NO DISCUSSION OF CV DISEASE PREVENTION IS COMPLETE WITHOUT CONSIDERING TOBACCO ABUSE AND ITS ELIMINATION. EVEN SECONDHAND SMOKE HAS BEEN ESTABLISHED AS HARMFUL. CONTROL OF HYPERTENSION IS ANOTHER MAJOR ASPECT OF CV DISEASE PREVENTION, AND A BLOOD PRESSURE LESS THAN 120/80 MM HG IS IDEAL. WITH OBESITY A MAJOR PROBLEM IN THE DEVELOPED WORLD, ITS ROLE IN THE METABOLIC SYNDROME IS OF MAJOR SIGNIFICANCE AS IS THE HIGH PREVALENCE OF THIS SO-CALLED SYNDROME VERSUS COLLECTION OF SPECIFIC RISK FACTORS IN A POPULATION WITH POOR HEALTH HABITS. CONTROL OF DIABETES MELLITUS HAS ESTABLISHED BENEFIT FROM THE STANDPOINT OF CV DISEASE PREVENTION EXCEPT THAT SOME PROBLEMS HAVE BEEN REPORTED WITH EXTREMELY TIGHT BLOOD SUGAR CONTROL. EXERCISE WAS LONG CONSIDERED GOOD BUT NOW THERE ARE EVIDENCE-BASED REASONS TO RECOMMEND IT AS ESSENTIAL IN CV DISEASE PREVENTION. THERE ARE MANY UNFORESEEN FRONTIERS IN CV DISEASE PREVENTION BUT, FOR NOW, EVERYTHING POINTS TO ELEVATION OF HIGH-DENSITY LIPOPROTEINS AS THE NEXT FOCUS OF THIS PREVENTION. © 2011 BY THIEME MEDICAL PUBLISHERS, INC.","ATHEROSCLEROSIS; CHOLESTEROL; CORONARY HEART DISEASE; PERIPHERAL VASCULAR DISEASE; STATINS","ANACETRAPIB; ANTIOXIDANT; APOLIPOPROTEIN B; APOLIPOPROTEIN E; COLESTIPOL; DALCETRAPIB; EZETIMIBE; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OLIVE OIL; PITAVASTATIN; POLICOSANOL; RESVERATROL; ROSUVASTATIN; SOYBEAN PROTEIN; TORCETRAPIB; UBIDECARENONE; UNSATURATED FATTY ACID; VITAMIN D; ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TREATMENT FAILURE; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; INTENSIVE CARE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MEDITERRANEAN DIET; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RED WINE; REMISSION; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; THERAPY EFFECT; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, 3, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, 3, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, 8934, PP. 1383-1389, (1994); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); DOWNS J.R., CLEARFIELD M., WEIS S., WHITNEY E., SHAPIRO D.R., BEERE P.A., LANGENDORFER A., STEIN E.A., KRUYER W., GOTTO JR. A.M., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 279, 20, PP. 1615-1622, (1998); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., BROWN L., WARNICA J.W., ARNOLD J.M.O., WUN C.-C., DAVIS B.R., BRAUNWALD E., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, NEW ENGLAND JOURNAL OF MEDICINE, 335, 14, PP. 1001-1009, (1996); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); LIAO J.K., LAUFS U., PLEIOTROPIC EFFECTS OF STATINS, ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 45, PP. 89-118, (2005); LIBBY P., MOLECULAR BASES OF THE ACUTE CORONARY SYNDROMES, CIRCULATION, 91, 11, PP. 2844-2850, (1995); STOLL G., BENDSZUS M., INFLAMMATION AND ATHEROSCLEROSIS: NOVEL INSIGHTS INTO PLAQUE FORMATION AND DESTABILIZATION, STROKE, 37, 7, PP. 1923-1932, (2006); NISSEN S.E., NICHOLLS S.J., SIPAHI I., ET AL., EFFECT OF VERY HIGH-INTENSITY STATIN THERAPY ON REGRESSION OF CORONARY ATHEROSCLEROSIS: THE ASTEROID TRIAL, JAMA, 295, PP. 1556-1565, (2006); BLANKENHORN D.H., JOHNSON R.L., NESSIM S.A., AZEN S.P., SANMARCO M.E., SELZER R.H., THE CHOLESTEROL LOWERING ATHEROSCLEROSIS STUDY (CLAS): DESIGN, METHODS, AND BASELINE RESULTS, CONTROLLED CLINICAL TRIALS, 8, 4, PP. 356-387, (1987); BLANKENHORN D.H., NESSIM S.A., JOHNSON R.L., BENEFICIAL EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 257, 23, PP. 3233-3240, (1987); BLANKENHORN D.H., SELZER R.H., MACK W.J., ET AL., EVALUATION OF COLESTIPOL/NIACIN THERAPY WITH COMPUTER-DERIVED CORONARY END POINT MEASURES. A COMPARISON OF DIFFERENT MEASURES OF TREATMENT EFFECT, CIRCULATION, 86, 6, PP. 1701-1709, (1992); BROWN B.G., ZHAO X.-Q., CHAIT A., FISHER L.D., CHEUNG M.C., MORSE J.S., DOWDY A.A., MARINO E.K., BOLSON E.L., ALAUPOVIC P., FROHLICH J., SERAFINI L., HUSS-FRECHETTE E., WANG S., DEANGELIS D., DODEK A., ALBERS J.J., SIMVASTATIN AND NIACIN, ANTIOXIDANT VITAMINS, OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE, NEW ENGLAND JOURNAL OF MEDICINE, 345, 22, PP. 1583-1592, (2001); BROWN G., ALBERS J.J., FISHER L.D., SCHAEFER S.M., LIN J.-T., KAPLAN C., ZHAO X.-Q., BISSON B.D., FITZPATRICK V.F., DODGE H.T., REGRESSION OF CORONARY ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH LEVELS OF APOLIPOPROTEIN B, NEW ENGLAND JOURNAL OF MEDICINE, 323, 19, PP. 1289-1298, (1990); PRASAD K., LEE P., SUPPRESSION OF HYPERCHOLESTEROLEMIC ATHEROSCLEROSIS BY PENTOXIFYLLINE AND ITS MECHANISM, ATHEROSCLEROSIS, 192, 2, PP. 313-322, (2007); FALK E., SHAH P.K., FUSTER V., CORONARY PLAQUE DISRUPTION, CIRCULATION, 92, 3, PP. 657-671, (1995); SACKS F.M., SVETKEY L.P., VOLLMER W.M., APPEL L.J., BRAY G.A., HARSHA D., OBARZANEK E., CONLIN P.R., MILLER III E.R., SIMONS-MORTON D.G., KARANJA N., LIN P.-H., AICKIN M., MOST-WINDHAUSER M.M., MOORE T.J., PROSCHAN M.A., CUTLER J.A., EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION (DASH) DIET, NEW ENGLAND JOURNAL OF MEDICINE, 344, 1, PP. 3-10, (2001); KASTORINI C.M., MILIONIS H.J., ESPOSITO K., GIUGLIANO D., GOUDEVENOS J.A., PANAGIOTAKOS D.B., THE EFFECT OF MEDITERRANEAN DIET ON METABOLIC SYNDROME AND ITS COMPONENTS: A META-ANALYSIS OF 50 STUDIES AND 534,906 INDIVIDUALS, J AM COLL CARDIOL, 57, 11, PP. 1299-1313, (2011); ESTRUCH R., MARTINEZ-GONZALEZ M.A., CORELLA D., SALAS-SALVADO J., RUIZ-GUTIERREZ V., COVAS M.I., FIOL M., GOMEZ-GRACIA E., LOPEZ-SABATER M.C., VINYOLES E., AROS F., CONDE M., LAHOZ C., LAPETRA J., SAEZ G., ROS E., EFFECTS OF A MEDITERRANEAN-STYLE DIET ON CARDIOVASCULAR RISK FACTORS A RANDOMIZED TRIAL, ANNALS OF INTERNAL MEDICINE, 145, 1, PP. 1-11, (2006); FITO M., GUXENS M., CORELLA D., SAEZ G., ESTRUCH R., DE LA TORRE R., FRANCES F., CABEZAS C., LOPEZ-SABATER M.D.C., MARRUGAT J., GARCIA-ARELLANO A., AROS F., RUIZ-GUTIERREZ V., ROS E., SALAS-SALVADO J., FIOL M., SOLA R., COVAS M.-I., EFFECT OF A TRADITIONAL MEDITERRANEAN DIET ON LIPOPROTEIN OXIDATION: A RANDOMIZED CONTROLLED TRIAL, ARCHIVES OF INTERNAL MEDICINE, 167, 11, PP. 1195-1203, (2007); GRUNDY S.M., CLEEMAN J.I., BAIREY MERZ C.N., BREWER JR. H.B., CLARK L.T., HUNNINGHAKE D.B., PASTERNAK R.C., SMITH JR. S.C., STONE N.J., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, 2, PP. 227-239, (2004); WIVIOTT S.D., CANNON C.P., MORROW D.A., RAY K.K., PFEFFER M.A., BRAUNWALD E., CAN LOW-DENSITY LIPOPROTEIN BE TOO LOW? THE SAFETY AND EFFICACY OF ACHIEVING VERY LOW LOW-DENSITY LIPOPROTEIN WITH INTENSIVE STATIN THERAPY: A PROVE IT-TIMI 22 SUBSTUDY, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 46, 8, PP. 1411-1416, (2005); HSIA J., MACFADYEN J.G., MONYAK J., RIDKER P.M., CARDIOVASCULAR EVENT REDUCTION AND ADVERSE EVENTS AMONG SUBJECTS ATTAINING LOW-DENSITY LIPOPROTEIN CHOLESTEROL <50 MG/DL WITH ROSUVASTATIN. THE JUPITER TRIAL (JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION: AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN), J AM COLL CARDIOL, 57, 16, PP. 1666-1675, (2011); KASTELEIN J.J.P., AKDIM F., STROES E.S.G., ZWINDERMAN A.H., BOTS M.L., STALENHOEF A.F.H., VISSEREN F.L.J., SIJBRANDS E.J.G., TRIP M.D., STEIN E.A., GAUDET D., DUIVENVOORDEN R., VELTRI E.P., MARAIS A.D., DE GROOT E., SIMVASTATIN WITH OR WITHOUT EZETIMIBE IN FAMILIAL HYPERCHOLESTEROLEMIA, NEW ENGLAND JOURNAL OF MEDICINE, 358, 14, PP. 1431-1443, (2008); RIDKER P.M., DANIELSON E., FONSECA F.A., ET AL., ROSUVASTATIN TO PREVENT VASCULAR EVENTS IN MEN AND WOMEN WITH ELEVATED C-REACTIVE PROTEIN, N ENGL J MED, 359, PP. 2195-2207, (2008); WHAYNE JR.T.F., ZIELKE J.C., DICKSON L.G., WINTERS J.L., STATE OF THE ART TREATMENT OF THE MOST DIFFICULT LOW DENSITY LIPOPROTEIN (LDL) CHOLESTEROL PROBLEMS: LDL APHERESIS, J KY MED ASSOC, 100, 12, PP. 535-538, (2002); KAJINAMI K., TAKEKOSHI N., SAITO Y., PITAVASTATIN: EFFICACY AND SAFETY PROFILES OF A NOVEL SYNTHETIC HMG-COA REDUCTASE INHIBITOR, CARDIOVASCULAR DRUG REVIEWS, 21, 3, PP. 199-215, (2003); SMOKING AND HEALTH: REPORT OF THE ADVISORY COMMITTEE TO THE SURGEON GENERAL OF THE PUBLIC HEALTH SERVICE: SUPERINTENDENT OF DOCUMENTS, PP. 1-387, (1964); AMBROSE J.A., BARUA R.S., THE PATHOPHYSIOLOGY OF CIGARETTE SMOKING AND CARDIOVASCULAR DISEASE: AN UPDATE, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 43, 10, PP. 1731-1737, (2004); BENOWITZ N.L., CIGARETTE SMOKING AND CARDIOVASCULAR DISEASE: PATHOPHYSIOLOGY AND IMPLICATIONS FOR TREATMENT, PROGRESS IN CARDIOVASCULAR DISEASES, 46, 1, PP. 91-111, (2003); JHA P., JACOB B., GAJALAKSHMI V., GUPTA P.C., DHINGRA N., KUMAR R., SINHA D.N., DIKSHIT R.P., PARIDA D.K., KAMADOD R., BOREHAM J., PETO R., A NATIONALLY REPRESENTATIVE CASE-CONTROL STUDY OF SMOKING AND DEATH IN INDIA, NEW ENGLAND JOURNAL OF MEDICINE, 358, 11, PP. 1137-1147, (2008); MULCAHY R., HICKEY N., CIGARETTE SMOKING HABITS OF PATIENTS WITH CORONARY HEART DISEASE, BR HEART J, 28, 3, PP. 404-408, (1966); DOYLE J.T., KANNEL W.B., MCNAMARA P.M., QUICKENTON P., GORDON T., FACTORS RELATED TO SUDDENNESS OF DEATH FROM CORONARY DISEASE: COMBINED ALBANY-FRAMINGHAM STUDIES, AM J CARDIOL, 37, 7, PP. 1073-1078, (1976); SHAPER A.G., WANNAMETHEE S.G., WALKER M., PIPE AND CIGAR SMOKING AND MAJOR CARDIOVASCULAR EVENTS, CANCER INCIDENCE AND ALL-CAUSE MORTALITY IN MIDDLE-AGED BRITISH MEN, INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 32, 5, PP. 802-808, (2003); BARNOYA J., GLANTZ S.A., CARDIOVASCULAR EFFECTS OF SECONDHAND SMOKE: NEARLY AS LARGE AS SMOKING, CIRCULATION, 111, 20, PP. 2684-2698, (2005); CESARONI G., FORASTIERE F., AGABITI N., VALENTE P., ZUCCARO P., PERUCCI C.A., EFFECT OF THE ITALIAN SMOKING BAN ON POPULATION RATES OF ACUTE CORONARY EVENTS, CIRCULATION, 117, 9, PP. 1183-1188, (2008); SARGENT R.P., SHEPARD R.M., GLANTZ S.A., REDUCED INCIDENCE OF ADMISSIONS FOR MYOCARDIAL INFARCTION ASSOCIATED WITH PUBLIC SMOKING BAN: BEFORE AND AFTER STUDY, BRITISH MEDICAL JOURNAL, 328, 7446, PP. 977-980, (2004); LENG G.C., LEE A.J., FOWKES F.G.R., LOWE G.D.O., HOUSLEY E., THE RELATIONSHIP BETWEEN CIGARETTE SMOKING AND CARDIOVASCULAR RISK FACTORS IN PERIPHERAL ARTERIAL DISEASE COMPARED WITH ISCHAEMIC HEART DISEASE. THE EDINBURGH ARTERY STUDY, EUROPEAN HEART JOURNAL, 16, 11, PP. 1542-1548, (1995); CRITCHLEY J.A., CAPEWELL S., MORTALITY RISK REDUCTION ASSOCIATED WITH SMOKING CESSATION IN PATIENTS WITH CORONARY HEART DISEASE: A SYSTEMATIC REVIEW, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 290, 1, PP. 86-97, (2003); JONASON T., BERGSTROM R., CESSATION OF SMOKING IN PATIENTS WITH INTERMITTENT CLAUDICATION. EFFECTS ON THE RISK OF PERIPHERAL VASCULAR COMPLICATIONS, MYOCARDIAL INFARCTION AND MORTALITY, ACTA MEDICA SCANDINAVICA, 221, 3, PP. 253-260, (1987); MCROBBIE H., THORNLEY S., THE IMPORTANCE OF TREATING TOBACCO DEPENDENCE, REV ESP CARDIOL, 61, 6, PP. 620-628, (2008); DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PP. 1-86, (2004); WANG Y., WANG Q.J., THE PREVALENCE OF PREHYPERTENSION AND HYPERTENSION AMONG US ADULTS ACCORDING TO THE NEW JOINT NATIONAL COMMITTEE GUIDELINES: NEW CHALLENGES OF THE OLD PROBLEM, ARCHIVES OF INTERNAL MEDICINE, 164, 19, PP. 2126-2134, (2004); LEWINGTON S., CLARKE R., QIZILBASH N., PETO R., COLLINS R., AGE-SPECIFIC RELEVANCE OF USUAL BLOOD PRESSURE TO VASCULAR MORTALITY: A META-ANALYSIS OF INDIVIDUAL DATA FOR ONE MILLION ADULTS IN 61 PROSPECTIVE STUDIES, LANCET, 360, 9349, PP. 1903-1913, (2002); LEVY D., NOEL BAIREY MERZ C., CODY R.J., FOUAD-TARAZI F.M., FRANCIS C.K., PFEFFER M.A., SCOTT N.A., SWAN H.J.C., TAYLOR M.P., WEINBERGER M.H., HYPERTENSION DETECTION, TREATMENT AND CONTROL: A CALL TO ACTION FOR CARDIOVASCULAR SPECIALISTS, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 34, 4, PP. 1360-1362, (1999); DOUMAS M., PAPADEMETRIOU V., DOUMA S., ET AL., BENEFITS FROM TREATMENT AND CONTROL OF PATIENTS WITH RESISTANT HYPERTENSION, INT J HYPERTENS, 2011, PP. 318-549, (2011); PERRY JR. H.M., DAVIS B.R., PRICE T.R., APPLEGATE W.B., FIELDS W.S., GURALNIK J.M., KULLER L., PRESSEL S., STAMLER J., PROBSTFIELD J.L., EFFECT OF TREATING ISOLATED SYSTOLIC HYPERTENSION ON THE RISK OF DEVELOPING OF STROKE: THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM (SHEP), JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 284, 4, PP. 465-471, (2000); STAESSEN J.A., THIJS L., FAGARD R., CELIS H., BIRKENHAGER W.H., BULPITT C.J., DE LEEUW P.W., FLETCHER A.E., FORETTE F., LEONETTI G., MCCORMACK P., NACHEV C., O'BRIEN E., RODICIO J.L., ROSENFELD J., SARTI C., TUOMILEHTO J., WEBSTER J., YODFAT Y., ZANCHETTI A., EFFECTS OF IMMEDIATE VERSUS DELAYED ANTIHYPERTENSIVE THERAPY ON OUTCOME IN THE SYSTOLIC HYPERTENSION IN EUROPE TRIAL, JOURNAL OF HYPERTENSION, 22, 4, PP. 847-857, (2004); GRUNDY S.M., CLEEMAN J.I., DANIELS S.R., DONATO K.A., ECKEL R.H., FRANKLIN B.A., GORDON D.J., KRAUSS R.M., SAVAGE P.J., SMITH JR. S.C., SPERTUS J.A., COSTA F., DIAGNOSIS AND MANAGEMENT OF THE METABOLIC SYNDROME: AN AMERICAN HEART ASSOCIATION/NATIONAL HEART, LUNG, AND BLOOD INSTITUTE SCIENTIFIC STATEMENT, CIRCULATION, 112, 17, PP. 2735-2752, (2005); WHAYNE JR.T.F., IN DEFENSE OF THE METABOLIC SYNDROME, J CLIN LIPIDOL, 3, 4, PP. 247-249, (2009); NIH STOPS CLINICAL TRIAL ON COMBINATION CHOLESTEROL TREATMENT: LACK OF EFFICACY IN REDUCING CARDIOVASCULAR EVENTS PROMPTS DECISION, (2011); CLOFIBRATE AND NIACIN IN CORONARY HEART DISEASE, JAMA, 231, 4, PP. 360-381, (1975); PATEL A., MACMAHON S., CHALMERS J., NEAL B., BILLOT L., WOODWARD M., MARRE M., COOPER M., GLASZIOU P., GROBBEE D., HAMET P., HARRAP S., HELLER S., LIU L., MANCIA G., MOGENSEN C.E., PAN C., POULTER N., RODGERS A., WILLIAMS B., BOMPOINT S., DE GALAN B.E., JOSHI R., TRAVERT F., INTENSIVE BLOOD GLUCOSE CONTROL AND VASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NEW ENGLAND JOURNAL OF MEDICINE, 358, 24, PP. 2560-2572, (2008); FRIEDEWALD W.T., BUSE J.B., BIGGER J.T., BYINGTON R.P., CUSHMAN W.C., GERSTEIN H.C., GINSBERG H.N., GOFF JR. D.C., GRIMM JR. R.H., ISMAIL-BEIGI F., PROBSTFIELD J.L., SIMONS-MORTON D.G., EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES, NEW ENGLAND JOURNAL OF MEDICINE, 358, 24, PP. 2545-2559, (2008); THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES MELLITUS, N ENGL J MED, 329, PP. 977-986, (1993); IMPLICATIONS OF THE DIABETES CONTROL AND COMPLICATIONS TRIAL, DIABETES CARE, 26, SUPPL. 1, (2003); LEITZMANN M.F., PARK Y., BLAIR A., BALLARD-BARBASH R., MOUW T., HOLLENBECK A.R., SCHATZKIN A., PHYSICAL ACTIVITY RECOMMENDATIONS AND DECREASED RISK OF MORTALITY, ARCHIVES OF INTERNAL MEDICINE, 167, 22, PP. 2453-2460, (2007); KUJALA U.M., KAPRIO J., SARNA S., KOSKENVUO M., RELATIONSHIP OF LEISURE-TIME PHYSICAL ACTIVITY AND MORTALITY: THE FINNISH TWIN COHORT, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 279, 6, PP. 440-444, (1998); HAKIM A.A., CURB J.D., PETROVITCH H., RODRIGUEZ B.L., YANO K., ROSS G.W., WHITE L.R., ABBOTT R.D., EFFECTS OF WALKING ON CORONARY HEART DISEASE IN ELDERLY MEN: THE HONOLULU HEART PROGRAM, CIRCULATION, 100, 1, PP. 9-13, (1999); FRANCO O.H., DE LAET C., PEETERS A., JONKER J., MACKENBACH J., NUSSELDER W., EFFECTS OF PHYSICAL ACTIVITY ON LIFE EXPECTANCY WITH CARDIOVASCULAR DISEASE, ARCHIVES OF INTERNAL MEDICINE, 165, 20, PP. 2355-2360, (2005); BIJNEN F.C.H., CASPERSEN C.J., FESKENS E.J.M., SARIS W.H.M., MOSTERD W.L., KROMHOUT D., PHYSICAL ACTIVITY AND 10-YEAR MORTALITY FROM CARDIOVASCULAR DISEASES AND ALL CAUSES: THE ZUTPHEN ELDERLY STUDY, ARCHIVES OF INTERNAL MEDICINE, 158, 14, PP. 1499-1505, (1998); THOMPSON P.D., BUCHNER D., PINA I.L., BALADY G.J., WILLIAMS M.A., MARCUS B.H., BERRA K., BLAIR S.N., COSTA F., FRANKLIN B., FLETCHER G.F., GORDON N.F., PATE R.R., RODRIGUEZ B.L., YANCEY A.K., WENGER N.K., EXERCISE AND PHYSICAL ACTIVITY IN THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A STATEMENT FROM THE COUNCIL ON CLINICAL CARDIOLOGY (SUBCOMMITTEE ON EXERCISE, REHABILITATION, AND PREVENTION) AND THE COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM (SUBCOMMITTEE ON PHYSICAL ACTIVITY), CIRCULATION, 107, 24, PP. 3109-3116, (2003); LAKKA T.A., LAKKA H.-M., RANKINEN T., LEON A.S., RAO D.C., SKINNER J.S., WILMORE J.H., BOUCHARD C., EFFECT OF EXERCISE TRAINING ON PLASMA LEVELS OF C-REACTIVE PROTEIN IN HEALTHY ADULTS: THE HERITAGE FAMILY STUDY, EUROPEAN HEART JOURNAL, 26, 19, PP. 2018-2025, (2005); HOWARD A.A., ARNSTEN J.H., GOUREVITCH M.N., EFFECT OF ALCOHOL CONSUMPTION ON DIABETES MELLITUS: A SYSTEMATIC REVIEW, ANN INTERN MED, 140, 3, PP. 211-219, (2004); WALLERATH T., POLEO D., LI H., FORSTERMANN U., RED WINE INCREASES THE EXPRESSION OF HUMAN ENDOTHELIAL NITRIC OXIDE SYNTHASE: A MECHANISM THAT MAY CONTRIBUTE TO ITS BENEFICIAL CARDIOVASCULAR EFFECTS, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 41, 3, PP. 471-478, (2003); ZHANG H., ZHANG J., UNGVARI Z., ZHANG C., RESVERATROL IMPROVES ENDOTHELIAL FUNCTION: ROLE OF TNFALPHA AND VASCULAR OXIDATIVE STRESS, ARTERIOSCLER THROMB VASC BIOL, 29, 8, PP. 1164-1171, (2009); FISHER N.D.L., HUGHES M., GERHARD-HERMAN M., HOLLENBERG N.K., FLAVANOL-RICH COCOA INDUCES NITRIC-OXIDE-DEPENDENT VASODILATION IN HEALTHY HUMANS, JOURNAL OF HYPERTENSION, 21, 12, PP. 2281-2286, (2003); MARON D.J., FLAVONOIDS FOR REDUCTION OF ATHEROSCLEROTIC RISK, CURRENT ATHEROSCLEROSIS REPORTS, 6, 1, PP. 73-78, (2004); PAOLINI J.F., MITCHEL Y.B., REYES R., ET AL., EFFECTS OF LAROPIPRANT ON NICOTINIC ACID-INDUCED FLUSHING IN PATIENTS WITH DYSLIPIDEMIA, AM J CARDIOL, 101, 5, PP. 625-630, (2008); BARTER P.J., CAULFIELD M., ERIKSSON M., GRUNDY S.M., KASTELEIN J.J.P., KOMAJDA M., LOPEZ-SENDON J., MOSCA L., TARDIF J.-C., WATERS D.D., SHEAR C.L., REVKIN J.H., BUHR K.A., FISHER M.R., TALL A.R., BREWER B., EFFECTS OF TORCETRAPIB IN PATIENTS AT HIGH RISK FOR CORONARY EVENTS, NEW ENGLAND JOURNAL OF MEDICINE, 357, 21, PP. 2109-2122, (2007); YVAN-CHARVET L., KLING J., PAGLER T., ET AL., CHOLESTEROL EFFLUX POTENTIAL AND ANTIINFLAMMATORY PROPERTIES OF HIGH-DENSITY LIPOPROTEIN AFTER TREATMENT WITH NIACIN OR ANACETRAPIB, ARTERIOSCLER THROMB VASC BIOL, 30, 7, PP. 1430-1438, (2010); STEIN E.A., ROTH E.M., RHYNE J.M., BURGESS T., KALLEND D., ROBINSON J.G., SAFETY AND TOLERABILITY OF DALCETRAPIB (RO4607381/JTT-705): RESULTS FROM A 48-WEEK TRIAL, EUR HEART J, 31, 4, PP. 480-488, (2010); WHAYNE JR.T.F., WHAT SHOULD MEDICAL PRACTITIONERS KNOW ABOUT THE ROLE OF ALTERNATIVE MEDICINES IN CARDIOVASCULAR DISEASE MANAGEMENT, CARDIOVASC THER, 28, 2, PP. 106-123, (2010); WHAYNE T.F., VITAMIN D: POPULAR CARDIOVASCULAR SUPPLEMENT BUT BENEFIT MUST BE EVALUATED, INT J ANGIOL, 20, 2, PP. 63-72, (2011)","T.F. WHAYNE; WETHINGTON BUILDING, LEXINGTON, KY 40536-0200, 900 SOUTH LIMESTONE STREET, UNITED STATES; EMAIL: TWHAYN0@UKY.EDU","","ENGLISH","INT. J. ANGIOL.","REVIEW","ISI","2-S2.0-81755188469","INT J ANGIOL","UNIVERSITY OF KENTUCKY","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"WHAYNE TF, 2011, INT J ANGIOL","WHAYNE TF, 2011, INT J ANGIOL"
"LEGUIZAMÓN C;WELLER C;SCHLEGEL V;CARR T","LEGUIZAMÓN, CAROLINA (26537703900); WELLER, CURTIS L. (7102722517); SCHLEGEL, VICKI L. (7003881781); CARR, TIMOTHY P. (7103305648)","PLANT STEROL AND POLICOSANOL CHARACTERIZATION OF HEXANE EXTRACTS FROM GRAIN SORGHUM CORN AND THEIR DDGS",2009,"JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY","86","9",48,"10.1007/s11746-009-1398-z","DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, 143 FILLEY HALL, LINCOLN, NE 68583-0919, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, 143 FILLEY HALL, LINCOLN, NE 68583-0919, UNITED STATES, DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, 210 L.W. CHASE HALL, LINCOLN, NE 68583-0726, UNITED STATES;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, 143 FILLEY HALL, LINCOLN, NE 68583-0919, UNITED STATES;DEPARTMENT OF NUTRITION AND HEALTH SCIENCES, UNIVERSITY OF NEBRASKA, 110 LEVERTON HALL, LINCOLN, NE 68583-0806, UNITED STATES","PLANT STEROLS (PS) AND POLICOSANOLS (PC) HAVE BEEN ATTRIBUTED WITH PLASMA CHOLESTEROL-LOWERING PROPERTIES IN HUMANS. HEXANE EXTRACTS FROM GRAIN SORGHUM, CORN AND THEIR DISTILLERS DRIED GRAIN WITH SOLUBLES (DDGS), AN IMPORTANT CO-PRODUCT OF ETHANOL PRODUCTION, CONTAIN THESE HEALTH PROMOTING COMPOUNDS, WHICH COULD BE USED TO DEVELOP HEALTH PROMOTING DIETARY PRODUCTS. HOWEVER, LIMITED INFORMATION IS CURRENTLY AVAILABLE REGARDING OPTIMAL METHODS OF EXTRACTION AND THEIR INFLUENCE ON PLANT STEROL OR PC LEVELS AND COMPOSITIONS. THEREFORE, THE OBJECTIVE OF THIS STUDY WAS TO QUANTIFY LIPIDS, PARTICULARLY PS AND PC EXTRACTED FROM GRAIN SORGHUM AND ITS DDGS USING REFLUX AND SOXTEC METHODS. CORN AND ITS DDGS WERE ALSO EXTRACTED TO COMPARE LIPID YIELDS AND PS/PC COMPOSITIONAL PROFILES IN THESE TWO RELATED CEREALS. INTACT GRAINS WERE EXTRACTED EITHER AS WHOLE OR GROUND KERNELS. LIPID YIELDS FROM ALL THE CORN SOURCES WERE TYPICALLY GREATER THAN THOSE OBTAINED FROM GRAIN SORGHUM. LIPID YIELDS FROM DDGS WERE THE HIGHEST AMONG ALL THE FORMS OF THE GRAINS USED WHEREAS CORN/SORGHUM DDGS CONTAINED THE HIGHEST LEVELS OF PS AND PC, RESPECTIVELY. ADDITIONAL STUDY DEMONSTRATED THAT HYDROLYSIS (ACIDIC AND ALKALINE) OF GROUND SORGHUM OR SORGHUM DDGS INCREASED THE LEVELS OF TOTAL EXTRACTABLE PLANT STEROLS. OVERALL, THE SOXTEC METHOD EXTRACTED HIGHER AMOUNTS OF LIPIDS THAN THE REFLUX METHOD. © 2009 AOCS.","CORN; DDGS; GRAIN SORGHUM; LIPIDS; PLANT STEROLS; POLICOSANOLS; REFLUX; SOXTEC","SORGHUM BICOLOR BICOLOR; ZEA MAYS; ALCOHOLS; ETHANOL; HEXANE; CORN; DDGS; GRAIN SORGHUM; PLANT STEROLS; POLICOSANOLS; REFLUX; SOXTEC; LIPIDS","USDA-ARS, (58-5430-4-362); USDA-CSREES-NATIONAL, (2004-35503-14824); UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION; U.S. DEPARTMENT OF AGRICULTURE, USDA","ACKNOWLEDGMENTS THIS MANUSCRIPT IS A CONTRIBUTION OF THE UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION, SUPPORTED IN PART BY FUNDS PROVIDED THROUGH THE HATCH ACT, USDA. ADDITIONAL SUPPORT WAS PROVIDED BY THE USDA-CSREES-NATIONAL RESEARCH INITIATIVE COMPETITIVE GRANTS PROGRAM (GRANT NO. 2004-35503-14824) AND USDA-ARS SPECIFIC COOPERATIVE AGREEMENT 58-5430-4-362. MENTION OF A TRADE NAME, PROPRIETARY PRODUCTS, OR COMPANY NAME IS FOR PRESENTATION CLARITY AND DOES NOT IMPLY ENDORSEMENT BY THE AUTHORS OR THE UNIVERSITY OF NEBRASKA. THE AUTHORS THANK DR. ISMAIL M. DWEIKAT FOR PROVIDING SORGHUM SAMPLES, DR. DAVID S. JACKSON FOR PROVIDING THE CORN SAMPLES, DR LAURA NYSTRÖM FROM THE DEPARTMENT OF APPLIED CHEMISTRY AND MICROBIOLOGY AT THE UNIVERSITY OF HELSINKI FOR HER WORK ON MEASUREMENT OF STEROLS USING ACID HYDROLYSIS AND DR. DAVID B. MARX AND MAKRAM J. GEHA FROM THE DEPARTMENT OF STATISTICS AT THE UNIVERSITY OF NEBRASKA, LINCOLN FOR GUIDANCE AND ASSISTANCE WITH THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.","SIMPSON T.W., SHARPLEY A.N., HOWARTH R.W., PAERL H.W., MANKIN K.R., THE NEW GOLD RUSH: FUELING ETHANOL PRODUCTION WHILE PROTECTING WATER QUALITY, J ENVIRON QUAL, 37, PP. 318-324, (2008); TAYLOR J.R.N., SCHOBER T.J., BEAN S.R., NOVEL FOOD AND NON-FOOD USES FOR SORGHUM AND MILLETS, JOURNAL OF CEREAL SCIENCE, 44, 3, PP. 252-271, (2006); HOFFMAN L.A., BAKER A., FOREMAN L., YOUNG E., FEED GRAINS BACKGROUNDER, (2007); AWIKA J.M., ROONEY L.W., SORGHUM PHYTOCHEMICALS AND THEIR POTENTIAL IMPACT ON HUMAN HEALTH, PHYTOCHEMISTRY, 65, 9, PP. 1199-1221, (2004); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., PROPERTIES, COMPOSITION, AND ANALYSIS OF GRAIN SORGHUM WAX, JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 79, 6, PP. 521-527, (2002); OSTLUND R.E., PHYTOSTEROLS IN HUMAN NUTRITION, ANN REV NUTR, 22, PP. 533-549, (2002); LEWIS C., HEALTH CLAIM FOR FOODS THAT COULD LOWER HEART DISEASE RISK, FDA CONSUMER MAGAZINE, (2000); PLANT STEROLS AND STANOLS-PROVEN TO LOWER CHOLESTEROL, (2007); PIIRONEN V., TOIVO J., LAMPI A.-M., PLANT STEROLS IN CEREALS AND CEREAL PRODUCTS, CEREAL CHEMISTRY, 79, 1, PP. 148-154, (2002); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, 2, PP. 312-318, (2006); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CARR K., CUBAN BIOTECHNOLOGY TREADS A LONELY PATH, NATURE, 398, PP. 22-23, (1999); MARINANGELI C.P.F., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.H., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BRITISH JOURNAL OF NUTRITION, 97, 2, PP. 381-388, (2007); CARR T.P., WELLER C.L., SCHLEGEL V.L., CUPPETT S.L., GUDERIAN JR. D.M., JOHNSON K.R., GRAIN SORGHUM LIPID EXTRACT REDUCES CHOLESTEROL ABSORPTION AND PLASMA NON-HDL CHOLESTEROL CONCENTRATION IN HAMSTERS, JOURNAL OF NUTRITION, 135, 9, PP. 2236-2240, (2005); SINGH V., MOREAU R.A., HICKS K.B., YIELD AND PHYTOSTEROL COMPOSITION OF OIL EXTRACTED FROM GRAIN SORGHUM AND ITS WET-MILLED FRACTIONS, CEREAL CHEMISTRY, 80, 2, PP. 126-129, (2003); SRINIVASAN R., MOREAU R.A., RAUSCH K.D., TUMBLESON M.E., SINGH V., PHYTOSTEROL DISTRIBUTION IN FRACTIONS OBTAINED FROM PROCESSING OF DISTILLERS DRIED GRAINS WITH SOLUBLES USING SIEVING AND ELUTRIATION, CEREAL CHEM, 84, PP. 626-630, (2007); WINKLER J.K., RENNICK K.A., ELLER F.J., VAUGHN S.F., PHYTOSTEROL AND TOCOPHEROL COMPONENTS IN EXTRACTS OF CORN DISTILLER'S DRIED GRAIN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 55, 16, PP. 6482-6486, (2007); WANG L., WELLER C.L., HWANG K.T., EXTRACTION OF LIPIDS FROM GRAIN SORGHUM DDG, TRANSACTIONS OF THE AMERICAN SOCIETY OF AGRICULTURAL ENGINEERS, 48, 5, PP. 1883-1888, (2005); SOUPAS L., JUNTUNEN L., LAMPI A., PIIRONEN V., EFFECTS OF STEROLS STRUCTURE, TEMPERATURE AND LIPID MEDIUM ON PHYTOSTEROL OXIDATION, J AGRIC FOOD CHEM, 52, PP. 6485-6491, (2004); CHRISTIANSEN K., UNDERSTANDING THE PARAMETERS AFFECTING LIPID EXTRACTION FROM GRAIN SORGHUM, (2006); CHRISTIANSEN K.L., WELLER C.L., SCHLEGEL V.L., CUPPETT S.L., CARR T.P., EXTRACTION AND CHARACTERIZATION OF LIPIDS FROM THE KERNELS, LEAVES, AND STALKS OF NINE GRAIN SORGHUM PARENT LINES, CEREAL CHEMISTRY, 84, 5, PP. 463-470, (2007); HOSENEY R.C., PRINCIPLES OF CEREAL SCIENCE AND TECHNOLOGY, 2, (1994); MEMBRADO L., VELA J., FERRANDO A.C., CEBOLLA V.L., IMPROVED EXTRACTION PROCEDURES FOR COAL PRODUCTS BASED ON THE SOXTEC APPARATUS, ENERGY FUELS, 10, PP. 1005-1011, (1996); MOREAU R.A., WHITAKER B.D., HICKS K.B., PHYTOSTEROLS, PHYTOSTANOLS, AND THEIR CONJUGATES IN FOODS: STRUCTURAL DIVERSITY, QUANTITATIVE ANALYSIS, AND HEALTH-PROMOTING USES, PROGRESS IN LIPID RESEARCH, 41, 6, PP. 457-500, (2002); NYSTROM L., MOREAU A.R., LAMPI A., HICKS K.B., PIIRONEN V., ENZYMATIC HYDROLYSIS OF STERYL FERULATES AND STERYL GLYCOSIDES, EUR FOOD RES TECHNOL, 227, PP. 727-773, (2008); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEMISTRY, 81, 3, PP. 345-349, (2004)","C. L. WELLER; DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, 210 L.W. CHASE HALL, LINCOLN, NE 68583-0726, UNITED STATES; EMAIL: CWELLER1@UNL.EDU","","ENGLISH","JAOCS J AM OIL CHEM SOC","ARTICLE","ISI","2-S2.0-67649964293","JAOCS J AM OIL CHEM SOC","UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA","NOTREPORTED;UNIVERSITY OF NEBRASKA;NOTREPORTED",NA,"LEGUIZAMÓN C, 2009, JAOCS J AM OIL CHEM SOC","LEGUIZAMÓN C, 2009, JAOCS J AM OIL CHEM SOC"
"ABDUL M;JIANG X;WILLIAMS K;DAY R;ROUFOGALIS B;LIAUW W;XU H;MATTHIAS A;LEHMANN R;MCLACHLAN A","ABDUL, MOHI IQBAL MOHAMMED (37058411400); JIANG, XUEMIN (7404627579); WILLIAMS, KENNETH M. (7404142012); DAY, RICHARD O. (56962776900); ROUFOGALIS, BASIL D. (7007083904); LIAUW, WINSTON S. (6603661528); XU, HONGMEI (55493770000); MATTHIAS, ANITA (7004632195); LEHMANN, REGINALD P. (56276833500); MCLACHLAN, ANDREW J. (55316633600)","PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS OF ECHINACEA AND POLICOSANOL WITH WARFARIN IN HEALTHY SUBJECTS",2010,"BRITISH JOURNAL OF CLINICAL PHARMACOLOGY","69","7",37,"10.1111/j.1365-2125.2010.03620.x","FACULTY OF PHARMACY, PHARMACY BUILDING (A15), UNIVERSITY OF SYDNEY, SYDNEY, NSW 7826, AUSTRALIA;CLINICAL TRIALS CENTRE, ST VINCENT'S HOSPITAL, DARLINGHURST, NSW, AUSTRALIA;CLINICAL TRIALS CENTRE, ST VINCENT'S HOSPITAL, DARLINGHURST, NSW, AUSTRALIA;CLINICAL PHARMACOLOGY AND TOXICOLOGY, ST VINCENT'S HOSPITAL, DARLINGHURST, NSW, AUSTRALIA, UNIVERSITY OF NEW SOUTH WALES, KENSINGTON, NSW, AUSTRALIA;FACULTY OF PHARMACY, PHARMACY BUILDING (A15), UNIVERSITY OF SYDNEY, SYDNEY, NSW 7826, AUSTRALIA;CLINICAL TRIALS CENTRE, ST VINCENT'S HOSPITAL, DARLINGHURST, NSW, AUSTRALIA;FACULTY OF PHARMACY, PHARMACY BUILDING (A15), UNIVERSITY OF SYDNEY, SYDNEY, NSW 7826, AUSTRALIA;MEDIHERB RESEARCH LABORATORIES, EIGHT MILE PLAINS, QLD, 3/85 BRANDL STREET, AUSTRALIA;MEDIHERB RESEARCH LABORATORIES, EIGHT MILE PLAINS, QLD, 3/85 BRANDL STREET, AUSTRALIA;FACULTY OF PHARMACY, PHARMACY BUILDING (A15), UNIVERSITY OF SYDNEY, SYDNEY, NSW 7826, AUSTRALIA, CENTRE FOR EDUCATION AND RESEARCH ON AGEING, CONCORD HOSPITAL, CONCORD, NSW, AUSTRALIA","AIMS: THIS STUDY INVESTIGATED THE PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS OF ECHINACEA AND POLICOSANOL WITH WARFARIN IN HEALTHY SUBJECTS. METHODS: THIS WAS AN OPEN-LABEL, RANDOMIZED, THREE-TREATMENT, CROSS-OVER, CLINICAL TRIAL IN HEALTHY MALE SUBJECTS (N = 12) OF KNOWN CYP2C9 AND VKORC1 GENOTYPE WHO RECEIVED A SINGLE ORAL DOSE OF WARFARIN ALONE OR AFTER 2 WEEKS OF PRE-TREATMENT WITH EACH HERBAL MEDICINE AT RECOMMENDED DOSES. PHARMACODYNAMIC (INR, PLATELET ACTIVITY) AND PHARMACOKINETIC (WARFARIN ENANTIOMER CONCENTRATIONS) END POINTS WERE EVALUATED. RESULTS: THE APPARENT CLEARANCE OF (S)-WARFARIN (90% CI OF RATIO; 1.01, 1.18) WAS SIGNIFICANTLY HIGHER DURING CONCOMITANT TREATMENT WITH ECHINACEA BUT THIS DID NOT LEAD TO A CLINICALLY SIGNIFICANT CHANGE IN INR (90% CI OF AUC OF INR; 0.91, 1.31). POLICOSANOL DID NOT SIGNIFICANTLY AFFECT WARFARIN ENANTIOMER PHARMACOKINETICS OR WARFARIN RESPONSE. NEITHER ECHINACEA NOR POLICOSANOL HAD A SIGNIFICANT EFFECT ON PLATELET AGGREGATION AFTER 2 WEEKS OF PRE-TREATMENT WITH THE RESPECTIVE HERBAL MEDICINES. CONCLUSION ECHINACEA SIGNIFICANTLY REDUCED PLASMA CONCENTRATIONS OF S-WARFARIN. HOWEVER, NEITHER ECHINACEA NOR POLICOSANOL SIGNIFICANTLY AFFECTED WARFARIN PHARMACODYNAMICS, PLATELET AGGREGATION OR BASELINE CLOTTING STATUS IN HEALTHY SUBJECTS. © 2010 THE BRITISH PHARMACOLOGICAL SOCIETY.","ECHINACEA; HERB-DRUG INTERACTION; PHARMACODYNAMIC; PHARMACOKINETIC; POLICOSANOL; WARFARIN","ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ECHINACEA; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PLANT EXTRACTS; PLATELET AGGREGATION INHIBITORS; WARFARIN; YOUNG ADULT; CYTOCHROME P450 2C9; ECHINACEA EXTRACT; MEDIHERB PREMIUM ECHINACEA; POLICOSANOL; UNCLASSIFIED DRUG; WARFARIN; ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RESPONSE; ENANTIOMER; GENOTYPE; HERBAL MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STEADY STATE; THROMBOCYTE AGGREGATION; TREATMENT DURATION","","","AQUILANTE C.L., LANGAEE T.Y., LOPEZ L.M., YARANDI H.N., TROMBERG J.S., MOHUCZY D., GASTON K.L., WADDELL C.D., CHIRICO M.J., JOHNSON J.A., INFLUENCE OF COAGULATION FACTOR, VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1, AND CYTOCHROME P450 2C9 GENE POLYMORPHISMS ON WARFARIN DOSE REQUIREMENTS, CLIN PHARMACOL THER, 79, PP. 291-302, (2006); MUSZKAT M., BLOTNIK S., ELAMI A., KRASILNIKOV I., CARACO Y., WARFARIN METABOLISM AND ANTICOAGULANT EFFECT: A PROSPECTIVE, OBSERVATIONAL STUDY OF THE IMPACT OF CYP2C9 GENETIC POLYMORPHISM IN THE PRESENCE OF DRUG-DISEASE AND DRUG-DRUG INTERACTIONS, CLIN THER, 29, PP. 427-437, (2007); BARNES J., ANDERSON L.A., GIBBONS S., PHILLIPSON J.D., ECHINACEA SPECIES (ECHINACEA ANGUSTIFOLIA (DC.) HELL., ECHINACEA PALLIDA (NUTT.) NUTT., ECHINACEA PURPUREA (L.) MOENCH): A REVIEW OF THEIR CHEMISTRY, PHARMACOLOGY AND CLINICAL PROPERTIES, J PHARM PHARMACOL, 57, PP. 929-954, (2005); MATTHIAS A., ADDISON R.S., AGNEW L.L., BONE K.M., WATSON K., LEHMANN R.P., COMPARISON OF ECHINACEA ALKYLAMIDE PHARMACOKINETICS BETWEEN LIQUID AND TABLET PREPARATIONS, PHYTOMEDICINE, 14, PP. 587-590, (2007); MATTHIAS A., ADDISON R.S., PENMAN K.G., DICKINSON R.G., BONE K.M., LEHMANN R.P., ECHINACEA ALKAMIDE DISPOSITION AND PHARMACOKINETICS IN HUMANS AFTER TABLET INGESTION, LIFE SCI, 77, PP. 2018-2029, (2005); WOELKART K., KOIDL C., GRISOLD A., GANGEMI J.D., TURNER R.B., MARTH E., BAUER R., BIOAVAILABILITY AND PHARMACOKINETICS OF ALKAMIDES FROM THE ROOTS OF ECHINACEA ANGUSTIFOLIA IN HUMANS, JOURNAL OF CLINICAL PHARMACOLOGY, 45, 6, PP. 683-689, (2005); IZZO A.A., ERNST E., INTERACTIONS BETWEEN HERBAL MEDICINES AND PRESCRIBED DRUGS: A SYSTEMATIC REVIEW, DRUGS, 61, 15, PP. 2163-2175, (2001); COXETER P.D., MCLACHLAN A.J., DUKE C.C., ROUFOGALIS B.D., HERB-DRUG INTERACTIONS: AN EVIDENCE BASED APPROACH, CURR MED CHEM, 11, PP. 1513-1525, (2004); GORSKI J.C., HUANG S.M., PINTO A., HAMMAN M.A., HILLIGOSS J.K., ZAHEER N.A., DESAI M., MILLER M., HALL S.D., THE EFFECT OF ECHINACEA (ECHINACEA PURPUREA ROOT) ON CYTOCHROME P450 ACTIVITY IN VIVO, CLIN PHARMACOL THER, 75, PP. 89-100, (2004); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); SIGURET V., GOUIN I., GOLMARD J.L., GEOFFROY S., ANDREUX J.P., PAUTAS E., CYTOCHROME P450 2C9 POLYMORPHISMS (CYP2C9) AND WARFARIN MAINTENANCE DOSE IN ELDERLY PATIENTS, REV MED INTERNE, 25, PP. 271-274, (2004); WADELIUS M., CHEN L.Y., DOWNES K., GHORI J., HUNT S., ERIKSSON N., WALLERMAN O., MELHUS H., WADELIUS C., BENTLEY D., DELOUKAS P., COMMON VKORC1 AND GGCX POLYMORPHISMS ASSOCIATED WITH WARFARIN DOSE, PHARMACOGENOMICS J, 5, PP. 262-270, (2005); XU H., WILLIAMS K.M., LIAUW W.S., MURRAY M., DAY R.O., MCLACHLAN A.J., EFFECTS OF ST JOHN'S WORT AND CYP2C9 GENOTYPE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF GLICLAZIDE, BR J PHARMACOL, 153, PP. 1579-1586, (2008); LI T., LANGE L.A., LI X., SUSSWEIN L., BRYANT B., MALONE R., LANGE E.M., HUANG T.Y., STAFFORD D.W., EVANS J.P., POLYMORPHISMS IN THE VKORC1 GENE ARE STRONGLY ASSOCIATED WITH WARFARIN DOSAGE REQUIREMENTS IN PATIENTS RECEIVING ANTICOAGULATION, J MED GENET, 43, PP. 740-744, (2006); JIANG X., WILLIAMS K.M., LIAUW W.S., AMMIT A.J., ROUFOGALIS B.D., DUKE C.C., DAY R.O., MCLACHLAN A.J., EFFECT OF ST JOHN'S WORT AND GINSENG ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN IN HEALTHY SUBJECTS, BR J CLIN PHARMACOL, 57, PP. 592-599, (2004); BANFIELD C., O'REILLY R., CHAN E., ROWLAND M., PHENYLBUTAZONE-WARFARIN INTERACTION IN MAN: FURTHER STEREOCHEMICAL AND METABOLIC CONSIDERATIONS, BR J CLIN PHARMACOL, 16, PP. 669-675, (1983); WITTKOWSKY A.K., WARFARIN AND OTHER COUMARIN DERIVATIVES: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS, SEMIN VASC MED, 3, PP. 221-230, (2003); MATTHIAS A., GILLAM E.M., PENMAN K.G., MATOVIC N.J., BONE K.M., DE VOSS J.J., LEHMANN R.P., CYTOCHROME P450 ENZYME-MEDIATED DEGRADATION OF ECHINACEA ALKYLAMIDES IN HUMAN LIVER MICROSOMES, CHEM BIOL INTERACT, 155, PP. 62-70, (2005); WOELKART K., MARTH E., SUTER A., SCHOOP R., RAGGAM R.B., KOIDL C., KLEINHAPPL B., BAUER R., BIOAVAILABILITY AND PHARMACOKINETICS OF ECHINACEA PURPUREA PREPARATIONS AND THEIR INTERACTION WITH THE IMMUNE SYSTEM, INT J CLIN PHARMACOL THER, 44, PP. 401-408, (2006); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); REINER Z., TEDESCHI-REINER E., RICE POLICOSANOL DOES NOT HAVE ANY EFFECTS ON BLOOD COAGULATION FACTORS IN HYPERCHOLESTEROLEMIC PATIENTS, COLL ANTROPOL, 31, PP. 1061-1064, (2007); KUMAR V., WAHLSTROM J.L., ROCK D.A., WARREN C.J., GORMAN L.A., TRACY T.S., CYP2C9 INHIBITION: IMPACT OF PROBE SELECTION AND PHARMACOGENETICS ON IN VITRO INHIBITION PROFILES, DRUG METAB DISPOS, 34, PP. 1966-1975, (2006); HUMMEL M.A., LOCUSON C.W., GANNETT P.M., ROCK D.A., MOSHER C.M., RETTIE A.E., TRACY T.S., CYP2C9 GENOTYPE-DEPENDENT EFFECTS ON IN VITRO DRUG-DRUG INTERACTIONS: SWITCHING OF BENZBROMARONE EFFECT FROM INHIBITION TO ACTIVATION IN THE CYP2C9.3 VARIANT, MOL PHARMACOL, 68, PP. 644-651, (2005)","A. J. MCLACHLAN; FACULTY OF PHARMACY, PHARMACY BUILDING (A15), UNIVERSITY OF SYDNEY, SYDNEY, NSW 7826, AUSTRALIA; EMAIL: ANDREW.MCLACHLAN@SYDNEY.EDU.AU","","ENGLISH","BR. J. CLIN. PHARMACOL.","ARTICLE","ISI","2-S2.0-77950641040","BR J CLIN PHARMACOL","SYDNEY;CLINICAL TRIALS CENTRE;CLINICAL TRIALS CENTRE;UNIVERSITY OF NEW SOUTH WALES;SYDNEY;CLINICAL TRIALS CENTRE;SYDNEY;MEDIHERB RESEARCH LABORATORIES;MEDIHERB RESEARCH LABORATORIES;SYDNEY","NOTREPORTED;UNIVERSITY OF SYDNEY;NOTREPORTED",NA,"ABDUL MIM, 2010, BR J CLIN PHARMACOL","ABDUL MIM, 2010, BR J CLIN PHARMACOL"
"MAZZA M;MARANO G;TRAVERSI G;BRIA P;MAZZA S","MAZZA, MARIANNA (57792267300); MARANO, GIUSEPPE (57211058913); TRAVERSI, GIANANDREA (37035182000); BRIA, PIETRO (16177435500); MAZZA, SALVATORE (7005604213)","PRIMARY CEREBRAL BLOOD FLOW DEFICIENCY AND ALZHEIMERS DISEASE SHADOWS AND LIGHTS",2011,"JOURNAL OF ALZHEIMER'S DISEASE","23","14",100,"10.3233/JAD-2010-090700","DEPARTMENT OF NEUROSCIENCES, INSTITUTE OF PSYCHIATRY AND PSYCHOLOGY, CATHOLIC UNIVERSITY OF SACRED HEART OF ROME, 00136 ROME, VIA UGO DE CAROLIS, 48, ITALY;DEPARTMENT OF NEUROSCIENCES, INSTITUTE OF PSYCHIATRY AND PSYCHOLOGY, CATHOLIC UNIVERSITY OF SACRED HEART OF ROME, 00136 ROME, VIA UGO DE CAROLIS, 48, ITALY;DEPARTMENT OF NEUROSCIENCES, INSTITUTE OF PSYCHIATRY AND PSYCHOLOGY, CATHOLIC UNIVERSITY OF SACRED HEART OF ROME, 00136 ROME, VIA UGO DE CAROLIS, 48, ITALY;DEPARTMENT OF NEUROSCIENCES, INSTITUTE OF PSYCHIATRY AND PSYCHOLOGY, CATHOLIC UNIVERSITY OF SACRED HEART OF ROME, 00136 ROME, VIA UGO DE CAROLIS, 48, ITALY;DEPARTMENT OF NEUROSCIENCES, INSTITUTE OF PSYCHIATRY AND PSYCHOLOGY, CATHOLIC UNIVERSITY OF SACRED HEART OF ROME, 00136 ROME, VIA UGO DE CAROLIS, 48, ITALY","ALZHEIMER'S DISEASE (AD) IS A DEGENERATIVE DISORDER CHARACTERIZED BY A DECREASED REGIONAL CEREBRAL BLOOD FLOW (CBF). IT IS MOST LIKELY THAT A REDUCTION IN CBF COULD DISPLACE A PATHWAY LEADING TO AD GENESIS, IN SO FAR NEURON DEATH EXPLAINS A SUSTAINED REDUCTION IN THE SUPPLY OF OXYGEN, GLUCOSE, AND NUTRIENTS. NEVERTHELESS, THE CONCEPT OF SECONDARY CBF DEFICIENCY CANNOT EXPLAIN THE CRITICAL STAGES OF EARLY MEMORY LOSS WHILE, ON THE OTHER HAND, THE PICTURE OF PROGRESSIVE ISCHEMIA DUE TO PRIMARY CBF DECLINE SHEDS LIGHT ON THE COURSE OF AD IN A MOST PERSUASIVE MANNER. THE CONCEPT OF PRIMARY CBF DEFICIENCY IS EVEN MORE STRENGTHENED BY THE LACK OF CORRELATION BETWEEN DEGREE OF DEMENTIA AND AMOUNT OF CBF. VASCULAR ABNORMALITIES, FREQUENTLY OBSERVED TO CO-OCCUR WITH AD, MIGHT PLAY A CRITICAL ROLE IN THE INITIATION AND AGGRAVATION OF AD PATHOLOGY GIVEN THAT THE ELIMINATION OF AMYLOID-Β (AΒ) THROUGH A VASCULAR ROUTE IS AN IMPORTANT BRAIN AΒ CLEARANCE MECHANISM AND ITS FAILURE LEADS TO FORMATION OF VASCULAR AMYLOIDOSIS AND DENSE-CORE PLAQUES. THE GOAL OF THIS REVIEW IS TO PROVIDE SCIENTISTS COMPREHENSIVE KNOWLEDGE OF THE STATE-OF THE ART INFLUENCE VASCULAR DAMAGE AND REDUCED PERFUSION HAVE ON THE FINAL DEVELOPMENT OF AD AND TO HOPEFULLY STIMULATE MORE RESEARCH IN THIS AREA OF NEUROSCIENCE. © 2011 - IOS PRESS AND THE AUTHORS. ALL RIGHTS RESERVED.","ALZHEIMER'S DISEASE; AMYLOID-Β; BLOOD BRAIN BARRIER; CEREBRAL BLOOD FLOW; NITRIC OXIDE; REACTIVE OXYGEN SPECIES","ALPHA TOCOPHEROL; BETA CAROTENE; CHOLINESTERASE INHIBITOR; CITICOLINE; CYANOCOBALAMIN; D 003; DONEPEZIL; FISH OIL; FOLIC ACID; GALANTAMINE; GENISTEIN; GINKGO BILOBA EXTRACT; GLYCEROPHOSPHORYLCHOLINE; IDEBENONE; LEVACECARNINE; MEMANTINE; OMEGA 3 FATTY ACID; PHOSPHATIDYLSERINE; POLICOSANOL; RIVASTIGMINE; SESAMIN; TACRINE; ALZHEIMER DISEASE; ANOREXIA; BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; BRAIN PERFUSION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DIZZINESS; HEADACHE; HEMODYNAMICS; HUMAN; LIVER TOXICITY; METABOLIC PARAMETERS; MULTIINFARCT DEMENTIA; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VOMITING","","","VAN BROECK B., VAN BROECKHOVEN C., KUMAR-SINGH S., CURRENT INSIGHTS INTO MOLECULAR MECHANISMS OF ALZHEIMER DISEASE AND THEIR IMPLICATIONS FOR THERAPEUTIC APPROACHES, NEURODEGENERATIVE DISEASES, 4, 5, PP. 349-365, (2007); ZHU X., SMITH M.A., HONDA K., ALIEV G., MOREIRA P.I., NUNOMURA A., CASADESUS G., HARRIS P.L.R., SIEDLAK S.L., PERRY G., VASCULAR OXIDATIVE STRESS IN ALZHEIMER DISEASE, JOURNAL OF THE NEUROLOGICAL SCIENCES, 257, 1-2, PP. 240-246, (2007); DEDE D.S., YAVUZ B., YAVUZ B.B., CANKURTARAN M., HALIL M., ULGER Z., CANKURTARAN E.S., AYTEMIR K., KABAKCI G., ARIOGUL S., ASSESSMENT OF ENDOTHELIAL FUNCTION IN ALZHEIMER'S DISEASE: IS ALZHEIMER'S DISEASE A VASCULAR DISEASE?, JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 55, 10, PP. 1613-1617, (2007); IADECOLA C., NEUROVASCULAR REGULATION IN THE NORMAL BRAIN AND IN ALZHEIMER'S DISEASE, NATURE REVIEWS NEUROSCIENCE, 5, 5, PP. 347-360, (2004); NIEDERMEYER E., ALZHEIMER DISEASE: CAUSED BY PRIMARY DEFICIENCY OF THE CEREBRAL BLOOD FLOW, CLINICAL EEG AND NEUROSCIENCE, 37, 3, PP. 175-177, (2006); NIEDERMEYER E., CONSIDERATIONS OF THE ISCHEMIC BASIS AND THERAPY OF ALZHEIMER DISEASE, CLINICAL EEG AND NEUROSCIENCE, 38, 1, PP. 55-56, (2007); JELLINGER K.A., THE PATHOLOGY OF VASCULAR DEMENTIA: A CRITICAL UPDATE, JOURNAL OF ALZHEIMER'S DISEASE, 14, 1, PP. 107-123, (2008); DAI W., LOPEZ O.L., CARMICHAEL O.T., BECKER J.T., KULLER L.H., GACH H.M., ABNORMAL REGIONAL CEREBRAL BLOOD FLOW IN COGNITIVELY NORMAL ELDERLY SUBJECTS WITH HYPERTENSION, STROKE, 39, 2, PP. 349-354, (2008); MORETTI R., TORRE P., ANTONELLO R.M., MANGANARO D., VILOTTI C., PIZZOLATO G., RISK FACTORS FOR VASCULAR DEMENTIA: HYPOTENSION AS A KEY POINT, VASCULAR HEALTH AND RISK MANAGEMENT, 4, 2, PP. 395-402, (2008); VISWANATHAN A., ROCCA W.A., TZOURIO C., VASCULAR RISK FACTORS AND DEMENTIA: HOW TO MOVE FORWARD?, NEUROLOGY, 72, PP. 368-374, (2009); BRUN A., ENGLUND E., A WHITE MATTER DISORDER IN DEMENTIA OF THE ALZHEIMER TYPE: A PATHOANATOMICAL STUDY, ANNALS OF NEUROLOGY, 19, 3, PP. 253-262, (1986); FARKAS E., LUITEN P.G.M., CEREBRAL MICROVASCULAR PATHOLOGY IN AGING AND ALZHEIMER'S DISEASE, PROGRESS IN NEUROBIOLOGY, 64, 6, PP. 575-611, (2001); JAGUST W.J., NEUROIMAGING IN DEMENTIA, NEUROL CLIN, 18, PP. 885-902, (2000); LEE B.C.P., MINTUN M., BUCKNER R.L., MORRIS J.C., IMAGING OF ALZHEIMER'S DISEASE, JOURNAL OF NEUROIMAGING, 13, 3, PP. 199-214, (2003); RAPOPORT S.I., FUNCTIONAL BRAIN IMAGING TO IDENTIFY AFFECTED SUBJECTS GENETICALLY AT RISK FOR ALZHEIMER'S DISEASE, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97, 11, PP. 5696-5698, (2000); IADECOLA C., ATHEROSCLEROSIS AND NEURODEGENERATION: UNEXPECTED CONSPIRATORS IN ALZHEIMER'S DEMENTIA, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 23, 11, PP. 1951-1953, (2003); ROHER A.E., ESH C., KOKJOHN T.A., KALBACK W., LUEHRS D.C., SEWARD J.D., SUE L.I., BEACH T.G., CIRCLE OF WILLIS ATHEROSCLEROSIS IS A RISK FACTOR FOR SPORADIC ALZHEIMER'S DISEASE, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 23, 11, PP. 2055-2062, (2003); MATTSON M.P., CELLULAR ACTIONS OF Β-AMYLOID PRECURSOR PROTEIN AND ITS SOLUBLE AND FIBRILLOGENIC DERIVATIVES, PHYSIOLOGICAL REVIEWS, 77, 4, PP. 1081-1132, (1997); CHRISTIE R., YAMADA M., MOSKOWITZ M., HYMAN B., STRUCTURAL AND FUNCTIONAL DISRUPTION OF VASCULAR SMOOTH MUSCLE CELLS IN A TRANSGENIC MOUSE MODEL OF AMYLOID ANGIOPATHY, AMERICAN JOURNAL OF PATHOLOGY, 158, 3, PP. 1065-1071, (2001); GRETARSDOTTIR S., THORLEIFSSON G., REYNISDOTTIR S.TH., MANOLESCU A., JONSDOTTIR S., JONSDOTTIR T., GUDMUNDSDOTTIR T., BJARNADOTTIR S.M., EINARSSON O.B., GUDJONSDOTTIR H.M., HAWKINS M., GUDMUNDSSON G., GUDMUNDSDOTTIR H., ANDRASON H., GUDMUNDSDOTTIR A.S., SIGURDARDOTTIR M., CHOU T.T., NAHMIAS J., GOSS S., SVEINBJORNSDOTTIR S., VALDIMARSSON E.M., JAKOBSSON F., AGNARSSON U., GUDNASON V., THORGEIRSSON G., FINGERLE J., GURNEY M., GUDBJARTSSON D., FRIGGE M.L., KONG A., STEFANSSON K., GULCHER J.R., THE GENE ENCODING PHOSPHODIESTERASE 4D CONFERS RISK OF ISCHEMIC STROKE, NATURE GENETICS, 35, 2, PP. 131-138, (2003); LANGA K.M., FOSTER N.L., LARSON E.B., MIXED DEMENTIA: EMERGING CONCEPTS AND THERAPEUTIC IMPLICATIONS, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 292, 23, PP. 2901-2908, (2004); JELLINGER K.A., UNDERSTANDING THE PATHOLOGY OF VASCULAR COGNITIVE IMPAIRMENT, JOURNAL OF THE NEUROLOGICAL SCIENCES, 229-230, PP. 57-63, (2005); KNOPMAN D.S., DEMENTIA AND CEREBROVASCULAR DISEASE, MAYO CLINIC PROCEEDINGS, 81, 2, PP. 223-230, (2006); ZLOKOVIC B.V., NEUROVASCULAR MECHANISMS OF ALZHEIMER'S NEURODEGENERATION, TRENDS IN NEUROSCIENCES, 28, 4, PP. 202-208, (2005); BENARROCH E.E., NEUROVASCULAR UNIT DYSFUNCTION: A VASCULAR COMPONENT OF ALZHEIMER DISEASE?, NEUROLOGY, 68, PP. 1730-1732, (2007); LEE S.T., CHU K., JUNG K.H., PARK H.K., KIM D.H., BAHN J.J., KIM J.H., OH M.J., LEE S.K., KIM M., ROH J.K., REDUCED CIRCULATING ANGIOGENIC CELLS IN ALZHEIMER DISEASE, NEUROLOGY, 72, PP. 1858-1863, (2009); HRISTOV M., ERL W., WEBER P.C., ENDOTHELIAL PROGENITOR CELLS: MOBILIZATION, DIFFERENTIATION, AND HOMING, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 23, 7, PP. 1185-1189, (2003); URBICH C., DIMMELER S., ENDOTHELIAL PROGENITOR CELLS: CHARACTERIZATION AND ROLE IN VASCULAR BIOLOGY, CIRCULATION RESEARCH, 95, 4, PP. 343-353, (2004); HILL J.M., ZALOS G., HALCOX J.P.J., SCHENKE W.H., WACLAWIW M.A., QUYYUMI A.A., FINKEL T., CIRCULATING ENDOTHELIAL PROGENITOR CELLS, VASCULAR FUNCTION, AND CARDIOVASCULAR RISK, NEW ENGLAND JOURNAL OF MEDICINE, 348, 7, PP. 593-600, (2003); WERNER N., KOSIOL S., SCHIEGL T., AHLERS P., WALENTA K., LINK A., BOHM M., NICKENIG G., CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND CARDIOVASCULAR OUTCOMES, NEW ENGLAND JOURNAL OF MEDICINE, 353, 10, PP. 999-1007, (2005); KUNZ G.A., LIANG G., CUCULOSKI F., GREGG D., VATA K.C., SHAW L.K., GOLDSCHMIDT-CLERMONT P.J., DONG C., TAYLOR D.A., PETERSON E.D., CIRCULATING ENDOTHELIAL PROGENITOR CELLS PREDICT CORONARY ARTERY DISEASE SEVERITY, AMERICAN HEART JOURNAL, 152, 1, PP. 190-195, (2006); GEORGE J., SHMILOVICH H., DEUTSCH V., MILLER H., KEREN G., ROTH A., COMPARATIVE ANALYSIS OF METHODS FOR ASSESSMENT OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS, TISSUE ENG, 12, PP. 331-335, (2006); ERTEN-LYONS D., WOLTJER R.L., DODGE H., NIXON R., VOROBIK R., CALVERT J.F., LEAHY M., MONTINE T., KAYE J., FACTORS ASSOCIATED WITH RESISTANCE TO DEMENTIA DESPITE HIGH ALZHEIMER DISEASE PATHOLOGY, NEUROLOGY, 72, PP. 354-360, (2009); WELSH-BOHMER K.A., WHITE III C.L., ALZHEIMER DISEASE: WHAT CHANGES IN THE BRAIN CAUSE DEMENTIA?, NEUROLOGY, 72, (2009); BROOKMEYER R., JOHNSON E., ZIEGLER-GRAHAM K., ARRIGHI H.M., FORECASTING THE GLOBAL BURDEN OF ALZHEIMER'S DISEASE, ALZHEIMER'S AND DEMENTIA, 3, 3, PP. 186-191, (2007); NAGATA K., MARUYA H., YUYA H., TERASHI H., MITO Y., KATO H., SATO M., SATOH Y., WATAHIKI Y., HIRATA Y., YOKOYAMA E., HATAZAWA J., CAN PET DATA DIFFERENTIATE ALZHEIMER'S DISEASE FROM VASCULAR DEMENTIA?, ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 903, PP. 252-261, (2000); GRUBB JR. R.L., RAICHLE M.E., GADO M.H., CEREBRAL BLOOD FLOW, OXYGEN UTILIZATION, AND BLOOD VOLUME IN DEMENTIA, NEUROLOGY, 27, 10, PP. 905-910, (1977); MIELKE R., PIETRZYK U., JACOBS A., FINK G.R., ICHIMIYA A., KESSLER J., HERHOLZ K., HEISS W.D., HMPAO SPET AND FDG PET IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA: COMPARISON OF PERFUSION AND METABOLIC PATTERN, EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 21, 10, PP. 1052-1060, (1994); HOMMA A., NIINA R., ISHII T., HASEGAWA K., BEHAVIORAL EVALUATION OF ALZHEIMER DISEASE IN CLINICAL TRIALS: DEVELOPMENT OF THE JAPANESE VERSION OF THE GBS SCALE, ALZHEIMER DIS ASSOC DISORD, 5, PP. 40-48, (1991); FRACKOWIAK R.S.J., POZZILLI C., LEGG N.J., REGIONAL CEREBRAL OXYGEN SUPPLY AND UTILIZATION IN DEMENTIA. A CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN-15 AND POSITRON TOMOGRAPHY, BRAIN, 104, 4, PP. 753-778, (1981); TOHGI H., YONEZAWA H., TAKAHASHI S., SATO N., KATO E., KUDO M., HATANO K., SASAKI T., CEREBRAL BLOOD FLOW AND OXYGEN METABOLISM IN SENILE DEMENTIA OF ALZHEIMER'S TYPE AND VASCULAR DEMENTIA WITH DEEP WHITE MATTER CHANGES, NEURORADIOLOGY, 40, 3, PP. 131-137, (1998); BARON J.C., HUMAN HEMISPHERIC INFARCTION STUDIED WITH POSITRON EMISSION TOMOGRAPHY AND THE 150 CONTINUOUS INHALATION TECHNIQUE, COMPUTERIZED TOMOGRAPHY, PP. 231-237, (1980); TSUTSUMI K., NAGATA K., MISERY PERFUSION SYNDROME IN THE CHRONIC STAGE OF CEREBRAL INFARCTION, JPN J STROKE, 20, PP. 489-499, (1998); DE REUCK J., DECOO D., HASENBROEKX M.C., LAMONT B., SANTENS P., GOETHALS P., STRIJCKMANS K., LEMAHIEU I., ACETAZOLAMIDE VASOREACTIVITY IN VASCULAR DEMENTIA: A POSITRON EMISSION TOMOGRAPHIC STUDY, EUROPEAN NEUROLOGY, 41, 1, PP. 31-36, (1999); DE REUCK J., SANTENS P., STRIJCKMANS K., LEMAHIEU I., COBALT-55 POSITRON EMISSION TOMOGRAPHY IN VASCULAR DEMENTIA: SIGNIFICANCE OF WHITE MATTER CHANGES, JOURNAL OF THE NEUROLOGICAL SCIENCES, 193, 1, PP. 1-6, (2001); TAGLIAVINI F., GHISO J., TIMMERS W.F., GIACCONE G., BUGIANI O., FRANGIONE B., COEXISTENCE OF ALZHEIMER'S AMYLOID PRECURSOR PROTEIN AND AMYLOID PROTEIN IN CEREBRAL VESSEL WALLS, LABORATORY INVESTIGATION, 62, 6, PP. 761-767, (1990); YAMAGUCHI H., YAMAZAKI T., LEMERE C.A., FROSCH M.P., SELKOE D.J., BETA AMYLOID IS FOCALLY DEPOSITED WITHIN THE OUTER BASEMENT MEMBRANE IN THE AMYLOID ANGIOPATHY OF ALZHEIMER'S DISEASE. AN IMMUNOELECTRON MICROSCOPIC STUDY, AM J PATHOL, 141, PP. 249-259, (1992); KONDOH Y., NAGATA K., SASAKI H., HATAZAWA J., DYNAMIC FDG-PET STUDY IN PROBABLE ALZHEIMER'S DISEASE, ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 826, PP. 406-409, (1997); DE LA TORRE J.C., ALZHEIMER'S DISEASE IS A VASOCOGNOPATHY: A NEW TERM TO DESCRIBE ITS NATURE, NEUROLOGICAL RESEARCH, 26, 5, PP. 517-524, (2004); DE LA TORRE J.C., MUSSIVAND T., CAN DISTURBED BRAIN MICROCIRCULATION CAUSE ALZHEIMER'S DISEASE?, NEUROLOGICAL RESEARCH, 15, 3, PP. 146-153, (1993); CUMMINGS J.L., BENSON D.F., DEMENTIA, (1983); PLUTA R., IS THE ISCHEMIC BLOOD-BRAIN BARRIER INSUFFICIENCY RESPONSIBLE FOR FULL-BLOWN ALZHEIMER'S DISEASE?, NEUROLOGICAL RESEARCH, 28, 6, PP. 665-671, (2006); ALGOTSSON A., WINBLAD B., THE INTEGRITY OF THE BLOOD-BRAIN BARRIER IN ALZHEIMER'S DISEASE, ACTA NEUROLOGICA SCANDINAVICA, 115, 6, PP. 403-408, (2007); BOWMAN G.L., KAYE J.A., MOORE M., WAICHUNAS D., CARLSON N.E., QUINN J.F., BLOOD-BRAIN BARRIER IMPAIRMENT IN ALZHEIMER DISEASE, NEUROLOGY, 68, PP. 1809-1814, (2007); RUITENBERG A., DEN HEIJER T., BAKKER S.L.M., VAN SWIETEN J.C., KOUDSTAAL P.J., HOFMAN A., BRETELER M.M.B., CEREBRAL HYPOPERFUSION AND CLINICAL ONSET OF DEMENTIA: THE ROTTERDAM STUDY, ANNALS OF NEUROLOGY, 57, 6, PP. 789-794, (2005); QI J.P., WU H., YANG Y., WANG D.D., CHEN Y.X., GU Y.H., LIU T., CEREBRAL ISCHEMIA AND ALZHEIMER'S DISEASE: THE EXPRESSION OF AMYLIOD-BETA AND APOLIPOPROTEIN E IN HUMAN IPPOCAMPUS, J ALZHEIMERS DIS, 12, PP. 335-341, (2007); MARCO S., SKAPER S.D., AMYLOID Β-PEPTIDE<SUB>1-42</SUB> ALTERS TIGHT JUNCTION PROTEIN DISTRIBUTION AND EXPRESSION IN BRAIN MICROVESSEL ENDOTHELIAL CELLS, NEUROSCIENCE LETTERS, 401, 3, PP. 219-224, (2006); FARACI F.M., OXIDATIVE STRESS: THE CURSE THAT UNDERLIES CEREBRAL VASCULAR DYSFUNCTION?, STROKE, 36, 2, PP. 186-188, (2005); IADECOLA C., CEREBRAL CIRCULATORY DYSREGULATION IN ISCHEMIA, CEREBROVASCULAR DISEASES, PP. 319-332, (1998); DE CHAMPLAIN J., WU R., GIROUARD H., KARAS M., MIDAOUI A.E.L., LAPLANTE M.-A., WU L., OXIDATIVE STRESS IN HYPERTENSION, CLINICAL AND EXPERIMENTAL HYPERTENSION, 26, 7-8, PP. 593-601, (2004); TRAYSTMAN R.J., KIRSCH J.R., KOEHLER R.C., OXYGEN RADICAL MECHANISMS OF BRAIN INJURY FOLLOWING ISCHEMIA AND REPERFUSION, J APPL PHYSIOL, 71, PP. 1185-1195, (1991); MALINSKI T., NITRIC OXIDE AND NITROXIDATIVE STRESS IN ALZHEIMER'S DISEASE, JOURNAL OF ALZHEIMER'S DISEASE, 11, 2, PP. 207-218, (2007); MAZZA M., CAPUANO A., BRIA P., MAZZA S., GINKGO BILOBA AND DONEPEZIL: A COMPARISON IN THE TREATMENT OF ALZHEIMER'S DEMENTIA IN A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY, EUROPEAN JOURNAL OF NEUROLOGY, 13, 9, PP. 981-985, (2006); MARKESBERY W.R., CARNEY J.M., OXIDATIVE ALTERATIONS IN ALZHEIMER'S DISEASE, BRAIN PATHOLOGY, 9, 1, PP. 133-146, (1999); HOOIJMANS C.R., RUTTERS F., DEDEREN P.J., GAMBAROTA G., VELTIEN A., VAN GROEN T., BROERSEN L.M., LUTJOHANN D., HEERSCHAP A., TANILA H., KILIAAN A.J., CHANGES IN CEREBRAL BLOOD VOLUME AND AMYLOID PATHOLOGY IN AGED ALZHEIMER APP/PS1 MICE ON A DOCOSAHEXAENOIC ACID (DHA) DIET OR CHOLESTEROL ENRICHED TYPICAL WESTERN DIET (TWD), NEUROBIOLOGY OF DISEASE, 28, 1, PP. 16-29, (2007); HIRAI K., ALIEV G., NUNOMURA A., FUJIOKA H., RUSSELL R.L., ATWOOD C.S., JOHNSON A.B., KRESS Y., VINTERS H.V., TABATON M., SHIMOHAMA S., CASH A.D., SIEDLAK S.L., HARRIS P.L.R., JONES P.K., PETERSEN R.B., PERRY G., SMITH M.A., MITOCHONDRIAL ABNORMALITIES IN ALZHEIMER'S DISEASE, JOURNAL OF NEUROSCIENCE, 21, 9, PP. 3017-3023, (2001); CHANG C.Y., LIANG H.J., CHOW S.Y., CHEN S.M., LIU D.Z., HEMORHEOLOGICAL MECHANISMS IN ALZHEIMER'S DISEASE, MICROCIRCULATION, 14, PP. 627-634, (2007); SUN X., HE G., QING H., ZHOU W., DOBIE F., CAI F., STAUFENBIEL M., HUANG L.E., SONG W., HYPOXIA FACILITATES ALZHEIMER'S DISEASE PATHOGENESIS BY UP-REGULATING BACE1 GENE EXPESSION, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103, 49, PP. 18727-18732, (2006); RAINA P., SANTAGUIDA P., ISMAILA A., PATTERSON C., COWAN D., LEVINE M., BOOKER L., OREMUS M., EFFECTIVENESS OF CHOLINESTERASE INHIBITORS AND MEMANTINE FOR TREATING DEMENTIA: EVIDENCE REVIEW FOR A CLINICAL PRACTICE GUIDELINE, ANNALS OF INTERNAL MEDICINE, 148, 5, PP. 379-397, (2008); JONES R.W., HAVE CHOLINERGIC THERAPIES REACHED THEIR CLINICAL BOUNDARY IN ALZHEIMER'S DISEASE?, INT J GERIATR PSYCHIATRY, 18, PP. 7-13, (2003); RINGMAN J.M., CUMMINGS J.L., CURRENT AND EMERGING PHARMACOLOGICAL TREATMENT OPTIONS FOR DEMENTIA, BEHAVIOURAL NEUROLOGY, 17, 1, PP. 5-16, (2006); KIDD P.M., ALZHEIMER'S DISEASE, AMNESTIC MILD COGNITIVE IMPAIRMENT, AND AGE-ASSOCIATED MEMORY IMPAIRMENT: CURRENT UNDERSTANDING AND PROGRESS TOWARD INTEGRATIVE PREVENTION, ALTERNATIVE MEDICINE REVIEW, 13, 2, PP. 85-115, (2008); GUTZMANN H., KUHL K.-P., HADLER D., RAPP M.A., SAFETY AND EFFICACY OF IDEBENONE VERSUS TACRINE IN PATIENTS WITH ALZHEIMER'S DISEASE: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP MULTICENTER STUDY, PHARMACOPSYCHIATRY, 35, 1, PP. 12-18, (2002); WINBLAD B., JONES R.W., WIRTH Y., STOFFLER A., MOBIUS H.J., MEMANTINE IN MODERATE TO SEVERE ALZHEIMER'S DISEASE: A META-ANALYSIS OF RANDOMISED CLINICAL TRIALS, DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 24, 1, PP. 20-27, (2007); ALBERTS B., JOHNSON A., LEWIS J., RAFF M., ROBERTS K., WALTER P., MOLECULAR BIOLOGY OF THE CELL, 4TH EDN, (2002); BARTUS R.T., DEAN III R.L., BEER B., LIPPA A.S., THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION, SCIENCE, 217, PP. 408-414, (1982); PAULING L., ORTHOMOLECULAR PSYCHIATRY. VARYING THE CONCENTRATIONS OF SUBSTANCES NORMALLY PRESENT IN THE HUMAN BODY MAY CONTROL MENTAL DISEASE, SCIENCE, 160, PP. 265-271, (1968); AMES B.N., ELSON-SCHWAB I., SILVER E.A., HIGHDOSEVITAMIN THERAPY STIMULATES VARIANT ENZYMES WITH DECREASED COENZYME BINDING AFFINITY: RELEVANCE TO GENETIC DISEASE AND OF THE CELL, 4TH EDN, (2002); KIDD P.M., PS (PHOSPHATIDYLSERINE), NATURE'S BRAIN BOOSTER, 2ND EDN, (2007); CENACCHI T., BERTOLDIN T., FARINA C., FIORI M.G., CREPALDI G., AZZINI C.F., GIRARDELLO R., BAGOZZI B., GARUTI R., VIVALDI P., BELLONI G., BORDIN A., DURANDO M., LO STORTO M., BERTONI L., BATTISTONI A., CACACE C., ARDUINI P., BONINI A., COGNITIVE DECLINE IN THE ELDERLY: A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY ON EFFICACY OF PHOSPHATIDYLSERINE ADMINISTRATION, AGING - CLINICAL AND EXPERIMENTAL RESEARCH, 5, 2, PP. 123-133, (1993); KIDD P.M., GPC (GLYCEROPHOSPHOCHOLINE), MIND- BODY POWER FOR ACTIVE LIVING AND HEALTHY AGING, (2007); MORENO MORENO M.D.J., COGNITIVE IMPROVEMENT IN MILD TO MODERATE ALZHEIMER'S DEMENTIA AFTER TREATMENT WITH THE ACETYLCHOLINE PRECURSOR CHOLINE ALFOSCERATE: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, CLINICAL THERAPEUTICS, 25, 1, PP. 178-193, (2003); PARNETTI L., MIGNINI F., TOMASSONI D., TRAINI E., AMENTA F., CHOLINERGIC PRECURSORS IN THE TREATMENT OF COGNITIVE IMPAIRMENT OF VASCULAR ORIGIN: INEFFECTIVE APPROACHES OR NEED FOR RE-EVALUATION?, JOURNAL OF THE NEUROLOGICAL SCIENCES, 257, 1-2, PP. 264-269, (2007); CIRIACO E., BRONZETTI E., RICCI A., AMENTA F., INFLUENCE OF IPSILATERAL LESIONS OF THE NUCLEUS BASALIS MAGNOCELLULARIS AND OF CHOLINE ALPHOSCERATE TREATMENT ON HISTOCHEMICALLY REACTIVE ZINC STORES AND ON THE ULTRASTRUCTURE OF THE RAT FRONTAL CORTEX, ARCH GERONTOL GERIATR, 19, PP. 303-312, (1994); MONTGOMERY S.A., THAL L.J., AMREIN R., META-ANALYSIS OF DOUBLE BLIND RANDOMIZED CONTROLLED CLINICAL TRIALS OF ACETYL-L-CARNITINE VERSUS PLACEBO IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER'S DISEASE, INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 18, 2, PP. 61-71, (2003); ANGELUCCI L., RAMACCI M.T., TAGLIALATELA G., HULSEBOSCH C., MORGAN B., WERRBACH-PEREZ K., PEREZ-POLO R., NERVE GROWTH FACTOR BINDING IN AGED RAT CENTRAL NERVOUS SYSTEM: EFFECT OF ACETYL-L-CARNITINE, J NEUROSCI RES, 20, PP. 491-496, (1988); KALMIJN S., LAUNER L.J., OTT A., WITTEMAN J.C.M., HOFMAN A., BRETELER M.M.B., DIETARY FAT INTAKE AND THE RISK OF INCIDENT DEMENTIA IN THE ROTTERDAM STUDY, ANNALS OF NEUROLOGY, 42, 5, PP. 776-782, (1997); MORRIS M.C., EVANS D.A., BIENIAS J.L., TANGNEY C.C., BENNETT D.A., WILSON R.S., AGGARWAL N., SCHNEIDER J., CONSUMPTION OF FISH AND N-3 FATTY ACIDS AND RISK OF INCIDENT ALZHEIMER DISEASE, ARCHIVES OF NEUROLOGY, 60, 7, PP. 940-946, (2003); KYLE D.J., SCHAEFER E., PATTON G., BEISER A., LOW SERUM DOCOSAHEXAENOIC ACID IS A SIGNIFICANT RISK FACTOR FOR ALZHEIMER'S DEMENTIA, LIPIDS, 34, SUPPL., (1999); CONQUER J.A., TIERNEY M.C., ZECEVIC J., BETTGER W.J., FISHER R.H., FATTY ACID ANALYSIS OF BLOOD PLASMA OF PATIENTS WITH ALZHEIMER'S DISEASE, OTHER TYPES OF DEMENTIA, AND COGNITIVE IMPAIRMENT, LIPIDS, 35, 12, PP. 1305-1312, (2000); TULLY A.M., ROCHE H.M., DOYLE R., FALLON C., BRUCE I., LAWLOR B., COAKLEY D., GIBNEY M.J., LOW SERUM CHOLESTERYL ESTER-DOCOSAHEXAENOIC ACID LEVELS IN ALZHEIMER'S DISEASE: A CASE-CONTROL STUDY, BRITISH JOURNAL OF NUTRITION, 89, 4, PP. 483-489, (2003); FREUND-LEVI Y., ERIKSDOTTER-JONHAGEN M., CEDERHOLM T., BASUN H., FAXEN-IRVING G., GARLIND A., VEDIN I., VESSBY B., WAHLUND L.-O., PALMBLAD J., Ω-3 FATTY ACID TREATMENT IN 174 PATIENTS WITH MILD TO MODERATE ALZHEIMER DISEASE: OMEGAD STUDY - A RANDOMIZED DOUBLE-BLIND TRIAL, ARCHIVES OF NEUROLOGY, 63, 10, PP. 1402-1408, (2006); FREUND-LEVI Y., BASUN H., CEDERHOLM T., FAXEN-IRVING G., GARLIND A., GRUT M., VEDIN I., PALMBLAD J., WAHLUND L.-O., ERIKSDOTTER-JONHAGEN M., OMEGA-3 SUPPLEMENTATION IN MILD TO MODERATE ALZHEIMER'S DISEASE: EFFECTS ON NEUROPSYCHIATRIC SYMPTOMS, INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 23, 2, PP. 161-169, (2008); CORRIGAN F.M., VAN RHIJN A., HORROBIN D.F., ESSENTIAL FATTY ACIDS IN ALZHEIMER'S DISEASE, ANN N Y ACAD SCI, 640, PP. 250-252, (1991); ALVAREZ X.A., MOUZO R., PICHEL V., PEREZ P., LAREDO M., FERNANDEZ-NOVOA L., CORZO L., ZAS R., ALCARAZ M., SECADES J.J., LOZANO R., CACABELOS R., DOUBLE-BLIND PLACEBO-CONTROLLED STUDY WITH CITICOLINE IN APOE GENOTYPED ALZHEIMER'S DISEASE PATIENTS. EFFECTS ON COGNITIVE PERFORMANCE, BRAIN BIOELECTRICAL ACTIVITY AND CEREBRAL PERFUSION, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 21, 9, PP. 633-644, (1999); PARNETTI L., AMBROSOLI L., ABATE G., AZZINI C., BALESTRERI R., BARTORELLI L., BORDIN A., CREPALDI G., CRISTIANINI G., CUCINOTTA D., CUZZUPOLI M., DE CANDIA O., FABRIS F., MAGGIONI M., SCARPA R., VILLARDITA C., GIRARDELLO R., POLI A., SENIN U., POSATIRELIN FOR THE TREATMENT OF LATE-ONSET ALZHEIMER'S DISEASE: A DOUBLE-BLIND MULTICENTRE STUDY VS CITICOLINE AND ASCORBIC ACID, ACTA NEUROL SCAND, 92, PP. 135-140, (1995); FIORAVANTI M., YANAGI M., CYTIDINEDIPHOSPHOCHOLINE (CDP-CHOLINE) FOR COGNITIVE AND BEHAVIOURAL DISTURBANCES ASSOCIATED WITH CHRONIC CEREBRAL DISORDERS IN THE ELDERLY, COCHRANE DATABASE SYST REV, 18, 2, (2005); SNOWDON D., AGING WITH GRACE: WHAT THE NUN STUDY TEACHES US ABOUT LEADING LONGER, HEALTHIER, AND MORE MEANINGFUL LIVES, PP. 357-359, (2002); SUN Y., LU C.-J., CHIEN K.-L., CHEN S.-T., CHEN R.-C., EFFICACY OF MULTIVITAMIN SUPPLEMENTATION CONTAINING VITAMINS B <SUB>6</SUB> AND B<SUB>12</SUB> AND FOLIC ACID AS ADJUNCTIVE TREATMENT WITH A CHOLINESTERASE INHIBITOR IN ALZHEIMER'S DISEASE: A 26-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN TAIWANESE PATIENTS, CLINICAL THERAPEUTICS, 29, 10, PP. 2204-2214, (2007); MILLER A.L., THE METHIONINE-HOMOCYSTEINE CYCLE AND ITS EFFECTS ON COGNITIVE DISEASES, ALTERNATIVE MEDICINE REVIEW, 8, 1, PP. 7-19, (2003); SCARMEAS N., STERN Y., TANG M.-X., MAYEUX R., LUCHSINGER J.A., MEDITERRANEAN DIET AND RISK FOR ALZHEIMER'S DISEASE, ANNALS OF NEUROLOGY, 59, 6, PP. 912-921, (2006); OKEN B.S., STORZBACH D.M., KAYE J.A., THE EFFICACY OF GINKGO BILOBA ON COGNITIVE FUNCTION IN ALZHEIMER DISEASE, ARCHIVES OF NEUROLOGY, 55, 11, PP. 1409-1415, (1998); LE BARS P.L., VELASCO F.M., FERGUSON J.M., DESSAIN E.C., KIESER M., HOERR R., INFLUENCE OF THE SEVERITY OF COGNITIVE IMPAIRMENT ON THE EFFECT OF THE GINKGO BILOBA EXTRACT EGB 761® IN ALZHEIMER'S DISEASE, NEUROPSYCHOBIOLOGY, 45, 1, PP. 19-26, (2002); LE BARS P.L., RESPONSE PATTERNS OF EGB 761 IN ALZHEIMER'S DISEASE: INFLUENCE OF NEUROPSYCHOLOGICAL PROFILES, PHARMACOPSYCHIATRY, 36, PP. 50-55, (2003); NAPRYEYENKO O., BORZENKO I., GINKGO BILOBA SPECIAL EXTRACT IN DEMENTIA WITH NEUROPSYCHIATRIC FEATURES: A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL, ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 57, 1, PP. 4-11, (2007); LE BARS P.L., KATZ M.M., BERMAN N., ITIL T.M., FREEDMAN A.M., SCHATZBERG A.F., A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF AN EXTRACT OF GINKGO BILOBA FOR DEMENTIA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 278, 16, PP. 1327-1332, (1997); INDENA C., GINKGOSELECT PHYTOSOME: BIOAVAILABLE STANDARDIZED EXTRACT OF GINKGO BILOBA LEAVES, (2004); AL M., DOVER I.D., GINKGO BILOBA ALTERNATIVE MEDICINE REVIEW MONOGRAPHS, THORNE RESEARCH, PP. 168-174, (2002); WOLF H.R.D., DOES GINKGO BILOBA SPECIAL EXTRACT EGB 761® PROVIDE ADDITIONAL EFFECTS ON COAGULATION AND BLEEDING WHEN ADDED TO ACETYLSALICYLIC ACID 500MG DAILY?, DRUGS IN R AND D, 7, 3, PP. 163-172, (2006); CARLSON J.J., FARQUHAR J.W., DINUCCI E., AUSSERER L., ZEHNDER J., MILLER D., BERRA K., HAGERTY L., HASKELL W.L., SAFETY AND EFFICACY OF A GINKGO BILOBA-CONTAINING DIETARY SUPPLEMENT ON COGNITIVE FUNCTION, QUALITY OF LIFE, AND PLATELET FUNCTION IN HEALTHY, COGNITIVELY INTACT OLDER ADULTS, JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 107, 3, PP. 422-432, (2007); VELLAS B., ANDRIEU S., OUSSET P.J., OUZID M., MATHIEX-FORTUNET H., THE GUIDAGE STUDY: METHODOLOGICAL ISSUES. A 5-YEAR DOUBLEBLIND RANDOMIZED TRIAL OF THE EFFICACY OF EGB 761 FOR PREVENTION OF ALZHEIMER DISEASE IN PATIENTS OVER 70 WITH A MEMORY COMPLAINT, NEUROLOGY, 67, PP. 6-11, (2006); SHANKLE W.R., AMEN D.G., PREVENTING ALZHEIMER'S, PP. 112-116, (2004); RINKER T., THE RENEGADE PATIENT: A SMART, USER- FRIENDLY GUIDE TO EFFECTIVE HEALTHCARE, PP. 57-59, (2008); ROWE J.W., KHAN R.L., SUCCESSFUL AGING, PP. 78-88, (1999); DRACHMAN D.A., AGING OF THE BRAIN, ENTROPY, AND ALZHEIMER DISEASE, NEUROLOGY, 67, 8, PP. 1340-1352, (2006); BLACK J.E., ISAACS K.R., GREENOUGH W.T., USUAL VS. SUCCESSFUL AGING: SOME NOTES ON EXPERIENTIAL FACTORS, NEUROBIOL AGING, 12, PP. 325-328, (1991); TYAS S.L., SALAZAR J.C., SNOWDON D.A., DESROSIERS M.F., RILEY K.P., MENDIONDO M.S., KRYSCIO R.J., TRANSITIONS TO MILD COGNITIVE IMPAIRMENTS, DEMENTIA, AND DEATH: FINDINGS FROM THE NUN STUDY, AMERICAN JOURNAL OF EPIDEMIOLOGY, 165, 11, PP. 1231-1238, (2007); ALZHEIMER'S DISEASE FACTS AND FIGURE, (2008); SWAAB D.F., BRAIN AGING AND ALZHEIMER'S DISEASE, ""WEAR AND TEAR"" VERSUS ""USE IT OR LOSE IT, NEUROBIOL AGING, 12, PP. 317-324, (1991); SABBAGH M.N., THE ALZHEIMER'S ANSWER: REDUCE YOUR RISK AND KEEP YOUR BODY HEALTHY, PP. 66-67, (2008); BOWER B., GROWN-UP CONNECTIONS. MICE, MONKEYS REMAKE BRAIN LINKS AS ADULTS, SCI NEWS, 6, PP. 169-165, (2006); DOIDGE N., THE BRAIN THAT CHANGES ITSELF, PP. 161-168, (2007); GATZ M., EDUCATING THE BRAIN TO AVOID DEMENTIA: CAN MENTAL EXERCISE PREVENT ALZHEIMER DISEASE?, PLOS MED, 2, PP. 38-40, (2005); GRANT W., ACCOUNTING FOR INDIVIDUAL DIFFERENCES IN RISK OF ALZHEIMER DISEASE, PLOS MED, 2, E82, PP. 262-267, (2005); SILVERMAN J.M., CIRESI G., SMITH C.J., MARIN D.B., SCHNAIDER-BEERI M., VARIABILITY OF FAMILIAL RISK OF ALZHEIMER DISEASE ACROSS THE LATE LIFE SPAN, ARCHIVES OF GENERAL PSYCHIATRY, 62, 5, PP. 565-573, (2005); NELSON L.D., SCHEIBEL K.E., RINGMAN J.M., SAYRE J.W., AN EXPERIMENTAL APPROACH TO DETECTING DEMENTIA IN DOWN SYNDROME: A PARADIGM FOR ALZHEIMER'S DISEASE, BRAIN AND COGNITION, 64, 1, PP. 92-103, (2007); PENNINGTON B.F., MOON J., EDGIN J., STEDRON J., NADEL L., THE NEUROPSYCHOLOGY OF DOWN SYNDROME: EVIDENCE FOR HIPPOCAMPAL DYSFUNCTION, CHILD DEVELOPMENT, 74, 1, PP. 75-93, (2003); CHARTIER-HARLIN M.-C., CRAWFORD F., HOULDEN H., WARREN A., HUGHES D., FIDANI L., GOATE A., ROSSOR M., ROQUES P., HARDY J., MULLAN M., EARLY-ONSET ALZHEIMER'S DISEASE CAUSED BY MUTATIONS AT CODON 717 OF THE Β-AMYLOID PRECURSOR PROTEIN GENE, NATURE, 353, 6347, PP. 844-846, (1991); JELLINGER K.A., HEAD INJURY AND DEMENTIA, CURRENT OPINION IN NEUROLOGY, 17, 6, PP. 719-723, (2004); ANSTEY K.J., VON SANDEN C., SALIM A., O'KEARNEY R., SMOKING AS A RISK FACTOR FOR DEMENTIA AND COGNITIVE DECLINE: A META-ANALYSIS OF PROSPECTIVE STUDIES, AMERICAN JOURNAL OF EPIDEMIOLOGY, 166, 4, PP. 367-378, (2007); SABBAGH M.N., TYAS S.L., EMERY S.C., HANSEN L.A., ALFORD M.F., REID R.T., TIRABOSCHI P., THAL L.J., SMOKING AFFECTS THE PHENOTYPE OF ALZHEIMER DISEASE, NEUROLOGY, 64, PP. 1301-1303, (2005); GUSTAFSON D., ROTHENBERG E., BLENNOW K., STEEN B., SKOOG I., AN 18-YEAR FOLLOW-UP OF OVERWEIGHT AND RISK OF ALZHEIMER DISEASE, ARCHIVES OF INTERNAL MEDICINE, 163, 13, PP. 1524-1528, (2003); WHITMER R.A., GUNDERSON E.P., BARRETT-CONNOR E., QUESENBERRY JR. C.P., YAFFE K., OBESITY IN MIDDLE AGE AND FUTURE RISK OF DEMENTIA: A 27 YEAR LONGITUDINAL POPULATION BASED STUDY, BMJ, 330, PP. 1360-1365, (2005); SNOWDON D.A., GREINER L.H., MORTIMER J.A., RILEY K.P., GREINER P.A., MARKESBERY W.R., BRAIN INFARCTION AND THE CLINICAL EXPRESSION OF ALZHEIMER DISEASE: THE NUN STUDY, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 277, 10, PP. 813-817, (1997); LAUNER L.J., ROSS G.W., PETROVITCH H., MASAKI K., FOLEY D., WHITE L.R., HAVLIK R.J., MIDLIFE BLOOD PRESSURE AND DEMENTIA: THE HONOLULU-ASIA AGING STUDY, NEUROBIOLOGY OF AGING, 21, 1, PP. 49-55, (2000); PATTERSON C., FEIGHTNER J.W., GARCIA A., HSIUNG G.-Y.R., MACKNIGHT C., SADOVNICK A.D., DIAGNOSIS AND TREATMENT OF DEMENTIA: 1. RISK ASSESSMENT AND PRIMARY PREVENTION OF ALZHEIMER DISEASE, CANADIAN MEDICAL ASSOCIATION JOURNAL, 178, 5, PP. 548-556, (2008); SESHADRI S., BEISER A., SELHUB J., JACQUES P.F., ROSENBERG I.H., D'AGOSTINO R.B., WILSON P.W.F., WOLF P.A., PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR DEMENTIA AND ALZHEIMER'S DISEASE, NEW ENGLAND JOURNAL OF MEDICINE, 346, 7, PP. 476-483, (2002); ELIAS M.F., SULLIVAN L.M., D'AGOSTINO R.B., ELIAS P.K., JACQUES P.F., SELHUB J., SESHADRI S., AU R., BEISER A., WOLF P.A., HOMOCYSTEINE AND COGNITIVE PERFORMANCE IN THE FRAMINGHAM OFFSPRING STUDY: AGE IS IMPORTANT, AMERICAN JOURNAL OF EPIDEMIOLOGY, 162, 7, PP. 644-653, (2005); LUCHSINGER J.A., TANG M.-X., SHEA S., MAYEUX R., HYPERINSULINEMIA AND RISK OF ALZHEIMER DISEASE, NEUROLOGY, 63, 7, PP. 1187-1192, (2004); COLE G.M., FRAUTSCHY S.A., THE ROLE OF INSULIN AND NEUROTROPHIC FACTOR SIGNALING IN BRAIN AGING AND ALZHEIMER'S DISEASE, EXPERIMENTAL GERONTOLOGY, 42, 1-2, PP. 10-21, (2007); TAGUCHI A., VASCULAR FACTORS IN DIABETES AND ALZHEIMER'S DISEASE, J ALZHEIMERS DIS, 16, PP. 859-864, (2009); KIDD P.M., PARKINSON'S DISEASE AS MULTIFACTORIAL OXIDATIVE NEURODEGENERATION: IMPLICATIONS FOR INTEGRATIVE MANAGEMENT, ALTERNATIVE MEDICINE REVIEW, 5, 6, PP. 502-529, (2000); YOKEL R.A., BLOOD-BRAIN BARRIER FLUX OF ALUMINUM, MANGANESE, IRON AND OTHER METALS SUSPECTED TO CONTRIBUTE TO METAL-INDUCED NEURODEGENERATION, JOURNAL OF ALZHEIMER'S DISEASE, 10, 2-3, PP. 223-253, (2006); RITCHIE K.A., GILMOUR W.H., MACDONALD E.B., BURKE F.J.T., MCGOWAN D.A., DALE I.M., HAMMERSLEY R., HAMILTON R.M., BINNIE V., COLLINGTON D., HEALTH AND NEUROPSYCHOLOGICAL FUNCTIONING OF DENTISTS EXPOSED TO MERCURY, OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 59, 5, PP. 287-293, (2002); SHCHERBATYKH I., CARPENTER D.O., THE ROLE OF METALS IN THE ETIOLOGY OF ALZHEIMER'S DISEASE, JOURNAL OF ALZHEIMER'S DISEASE, 11, 2, PP. 191-205, (2007); KUO H.-K., YEN C.-J., CHANG C.-H., KUO C.-K., CHEN J.-H., SOROND F., RELATION OF C-REACTIVE PROTEIN TO STROKE, COGNITIVE DISORDERS, AND DEPRESSION IN THE GENERAL POPULATION: SYSTEMATIC REVIEW AND META-ANALYSIS, LANCET NEUROLOGY, 4, 6, PP. 371-380, (2005); SCHMIDT R., SCHMIDT H., CURB J.D., MASAKI K., WHITE L.R., LAUNER L.J., EARLY INFLAMMATION AND DEMENTIA: A 25-YEAR FOLLOW-UP OF THE HONOLULU-ASIA AGING STUDY, ANNALS OF NEUROLOGY, 52, 2, PP. 168-174, (2002); TREMBATH D., ERVIN J.F., BROOM L., SZYMANSKI M., WELSH-BOHMER K., PIEPER C., HULETTE C.M., THE DISTRIBUTION OF CEREBROVASCULAR AMYLOID IN ALZHEIMER'S DISEASE VARIES WITH APOE GENOTYPE, ACTA NEUROPATHOLOGICA, 113, 1, PP. 23-31, (2007); FARFARA D., LIFSHITZ V., FRENKEL D., NEUROPROTECTIVE AND NEUROTOXIC PROPERTIES OF GLIAL CELLS IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE: ALZHEIMER'S REVIEW SERIES, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 12, 3, PP. 762-780, (2008); BRETELER M.M., VAN DUIJN C.M., CHANDRA V., FRATIGLIONI L., GRAVES A.B., HEYMAN A., JORM A.F., KOKMEN E., KONDO K., MORTIMER J.A., ROCCA W.A., SHALAT S.L., SOININEN H., HOFMAN A., MEDICAL HISTORY AND THE RISK OF ALZHEIMER'S DISEASE: A COLLABORATIVE RE-ANALYSIS OF CASE-CONTROL STUDIES. EURODEM RISK FACTORS RESEARCH GROUP, INT J EPIDEMIOL, 20, PP. 36-42, (1991); DE JONG F.J., DEN HEIJER T., VISSER T.J., DE RIJKE Y.B., DREXHAGE H.A., HOFMAN A., BRETELER M.M.B., THYROID HORMONES, DEMENTIA, AND ATROPHY OF THE MEDIAL TEMPORAL LOBE, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 91, 7, PP. 2569-2573, (2006); LABUDOVA O., CAIRNS N., THOMAS K., KITZMUELLER E., RINK H., LUBEC G., THYROID STIMULATING HORMONE-RECEPTOR OVEREXPRESSION IN BRAIN OF PATIENTS WITH DOWN SYNDROME AND ALZHEIMER'S DISEASE, LIFE SCIENCES, 64, 12, PP. 1037-1044, (1999); DAVANIPOUR Z., TSENG C.C., LEE P.J., SOBEL E., A CASE-CONTROL STUDY OF OCCUPATIONAL MAGNETIC FIELD EXPOSURE AND ALZHEIMER'S DISEASE: RESULTS FROM THE CALIFORNIA ALZHEIMER'S DISEASE DIAGNOSIS AND TREATMENT CENTERS, BMC NEUROL, 7, PP. 13-22, (2007); MCCARTY M.F., TOWARD PREVENTION OF ALZHEIMERS DISEASE - POTENTIAL NUTRACEUTICAL STRATEGIES FOR SUPPRESSING THE PRODUCTION OF AMYLOID BETA PEPTIDES, MEDICAL HYPOTHESES, 67, 4, PP. 682-697, (2006)","M. MAZZA; DEPARTMENT OF NEUROSCIENCES, INSTITUTE OF PSYCHIATRY AND PSYCHOLOGY, CATHOLIC UNIVERSITY OF SACRED HEART OF ROME, 00136 ROME, VIA UGO DE CAROLIS, 48, ITALY; EMAIL: MARIANNAMAZZA@HOTMAIL.COM","IOS PRESS","ENGLISH","J. ALZHEIMER'S DIS.","REVIEW","ISI","2-S2.0-79951876424","J ALZHEIMER'S DIS","CATHOLIC UNIVERSITY OF SACRED HEART OF ROME;CATHOLIC UNIVERSITY OF SACRED HEART OF ROME;CATHOLIC UNIVERSITY OF SACRED HEART OF ROME;CATHOLIC UNIVERSITY OF SACRED HEART OF ROME;CATHOLIC UNIVERSITY OF SACRED HEART OF ROME","NOTREPORTED;CATHOLIC UNIVERSITY OF SACRED HEART OF ROME;NOTREPORTED",NA,"MAZZA M, 2011, J ALZHEIMER'S DIS","MAZZA M, 2011, J ALZHEIMER'S DIS"
"JUNG D;LEE M;YOON S;JUNG M","JUNG, DONG MIN (48461336000); LEE, MI JIN (55918037200); YOON, SUK HOO (57024282100); JUNG, MUN YHUNG (35336963900)","A GAS CHROMATOGRAPHYTANDEM QUADRUPOLE MASS SPECTROMETRIC ANALYSIS OF POLICOSANOLS IN COMMERCIAL VEGETABLE OILS",2011,"JOURNAL OF FOOD SCIENCE","76","8",28,"10.1111/j.1750-3841.2011.02232.x","SAMREA-UP, WANJU-KUN, JEONBUK PROVINCE 565-701, SOUTH KOREA;SAMREA-UP, WANJU-KUN, JEONBUK PROVINCE 565-701, SOUTH KOREA;BUNDANG-KU, KYONGGI-DO, SOUTH KOREA;SAMREA-UP, WANJU-KUN, JEONBUK PROVINCE 565-701, SOUTH KOREA","REPORTEDLY POLICOSANOLS (PCS) HAVE VARIOUS BENEFICIAL FUNCTIONALITIES ON HEALTH. A GAS CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (GC-MS/MS) WITH A LOW LIMIT OF DETECTION (LOD), AND HIGH SPECIFICITY, RECOVERY, AND PRECISION WAS SUCCESSFULLY ESTABLISHED FOR THE PC ANALYSIS IN VEGETABLE OILS. THE LODS FOR THE PCS WERE IN THE RANGE OF 0.002 TO 0.016 ΜG/ML. THE RELATIVE STANDARD DEVIATION (RSD) FOR THE REPEATED ANALYSIS OF PCS WAS LESS THAN 3.356%. THE MEAN RECOVERIES FOR SPIKED HEPTACOSANOL AND OCTACOSANOL IN VEGETABLE OIL WERE 102.3% AND 106.3%, RESPECTIVELY. THE TOTAL PC CONTENTS IN THE VEGETABLE OILS VARIED FROM 3.01 TO 427.83 MG/KG OIL. PERILLA SEED, GRAPE SEED, AND RICE BRAN OILS WERE FOUND TO BE HIGHLY RICH SOURCES OF PCS, CONTAINING 427.83, 245.15, AND 171.17 MG PCS/KG OIL, RESPECTIVELY. CORN, SESAME, AND SOYBEAN OILS CONTAINED ONLY A NEGLIGIBLE QUANTITY OF PCS. THE PC COMPOSITION IN VEGETABLE OILS WAS GREATLY SOURCE DEPENDENT. IN PERILLA SEED OIL, OCTACOSANOL WAS THE SINGLE MOST PREDOMINANT COMPONENT, REPRESENTING 55.93% OF THE TOTAL PC. IN GRAPE SEED OIL, HOWEVER, HEXACOSANOL IS THE MOST ABUNDANT PC, FOLLOWED BY OCTACOSANOL, TETRACOSANOL, AND TRIACONTANOL IN A DECREASING ORDER. THE MAJOR PCS IN RICE BRAN OIL WERE TRIACONTANOL, OCTACOSANOL, HEXACOSANOL, AND TETRACOSANOL, WHICH CONSTITUTED OVER 87.3% OF THE TOTAL PC. THIS REPRESENTS THE 1ST REPORT ON THE COMPOSITION AND CONTENTS OF PC IN MOST VEGETABLE OILS ANALYZED HERE. © 2011 INSTITUTE OF FOOD TECHNOLOGISTS ®.","GC-MS/MS; HEXACOSANOL; OCTACOSANOL; POLICOSANOL; VEGETABLE OIL","ALPHA-LINOLENIC ACID; ANALYTIC SAMPLE PREPARATION METHODS; CHROMATOGRAPHY, THIN LAYER; DIET; FATTY ALCOHOLS; FOOD ANALYSIS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; KOREA; LIMIT OF DETECTION; ORYZA SATIVA; PERILLA; PLANT OILS; REPRODUCIBILITY OF RESULTS; SEEDS; TANDEM MASS SPECTROMETRY; VITIS; GLYCINE MAX; PERILLA; SESAMUM INDICUM; VITACEAE; ZEA MAYS; 1 HEXACOSANOL; 1 OCTACOSANOL; 1 TRIACONTANOL; 1-HEXACOSANOL; 1-OCTACOSANOL; 1-TRIACONTANOL; FATTY ALCOHOL; LINOLENIC ACID; PERILLA SEED OIL; POLICOSANOL; RICE BRAN OIL; VEGETABLE OIL; ANALYSIS; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DIET; ETHNOLOGY; FOOD ANALYSIS; KOREA; LIMIT OF DETECTION; MASS FRAGMENTOGRAPHY; METHODOLOGY; PERILLA; PLANT SEED; REPRODUCIBILITY; RICE; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; VALIDATION STUDY; VITIS","","","ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS, J AGRIC FOOD CHEM, 54, PP. 5359-5362, (2006); ARRUZAZABALA M.L., CARNAJAL D., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MARS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 85, PP. 61-64, (1998); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN R., VARQUEZ P., PERINA J.S., TERNCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, PP. 155-162, (2009); GIACOMETTI J., DETERMINATION OF ALIPHATIC ALCOHOLS, SQUALENE, Α-TOCOPHEROL AND STEROLS IN OLIVE OILS: DIRECT METHOD INVOLVING GAS CHROMATOGRAPHY OF THE UNSAPONIFIABLE FRACTION FOLLOWING SILYLATION, ANALYST, 126, PP. 472-475, (2001); HA T., HAN S., KIM S., KIM I., LEE H., KIM H., BIOACTIVE COMPONENTS IN RICE BRAN OIL IMPROVE LIPID PROFILES IN RATS FED A HIGH-CHOLESTEROL DIET, NUTR RES, 25, PP. 597-606, (2005); HARRBI S., BOUKHCHINA S., MAYER M.P., KALLEL H., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPARATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, J SEP SCI, 25, PP. 619-623, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J AM OIL CHEM SOC, 79, PP. 529-533, (2002); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEEWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITION OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); SAKOUHI F., BOUKHCHINA S., ABSALON C., FOUQUET E., KALLEL H., POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIANOLEA EUROPAEAL. FRUITS, EUR. J LIPID SCI TECHNOL, 112, PP. 373-379, (2010); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOCASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); WANG M., LIAN H., MAO H., ZHOU J., GONG H., QIAN B., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J AGRI FOOD CHEM, 55, PP. 5552-5558, (2007)","M.Y. JUNG; COLLEGE OF FOOD SCIENCE, WOOSUK UNIV., SAMREA-UP, WANJU-KUN, JEONBUK PROVINCE 565-701, SOUTH KOREA; EMAIL: MUNJUNG@WOOSUK.AC.KR","","ENGLISH","J. FOOD. SCI.","ARTICLE","ISI","2-S2.0-79961126890","J FOOD SCI","NOTREPORTED","NOTREPORTED;WOOSUK UNIV.;NOTREPORTED",NA,"JUNG DM, 2011, J FOOD SCI","JUNG DM, 2011, J FOOD SCI"
"DE B T;VANDER S R;DE B M;DE B G;VAN B L","DE BACKER, TINE (7004152962); VANDER STICHELE, ROBERT (7004058933); DE BUYZERE, MARC (16941498400); DE BACKER, GUY (24288352300); VAN BORTEL, LUCAS (7006815657)","SILENCE OF THE LIMBS PHARMACOLOGICAL SYMPTOMATIC TREATMENT OF INTERMITTENT CLAUDICATION",2010,"CURRENT VASCULAR PHARMACOLOGY","8","4",5,"10.2174/157016110791112278","HEYMANS INSTITUTE OF CLINICAL PHARMACOLOGY, GHENT UNIVERSITY, GHENT, BELGIUM, HEART CENTRE, UNIVERSITY HOSPITAL GHENT, 9000 GHENT, DE PINTELAAN 185, BLOCK B FIRST FLOOR, BELGIUM;HEYMANS INSTITUTE OF CLINICAL PHARMACOLOGY, GHENT UNIVERSITY, GHENT, BELGIUM;HEART CENTRE, UNIVERSITY HOSPITAL GHENT, 9000 GHENT, DE PINTELAAN 185, BLOCK B FIRST FLOOR, BELGIUM;HEART CENTRE, UNIVERSITY HOSPITAL GHENT, 9000 GHENT, DE PINTELAAN 185, BLOCK B FIRST FLOOR, BELGIUM;HEYMANS INSTITUTE OF CLINICAL PHARMACOLOGY, GHENT UNIVERSITY, GHENT, BELGIUM","SEVERAL ORAL ""VASOACTIVE"" DRUGS CLAIM TO INCREASE WALKING CAPACITY IN PATIENTS WITH INTERMITTENT CLAUDICATION (IC). NAFTIDROFURYL, CILOSTAZOL, BUFLOMEDIL, AND PENTOXIFYLLINE ARE THE MOST STUDIED MOLECULES. ALTHOUGH SPANNING SEVERAL DECADES, SEVERAL STUDIES UNDERLYING THESE CLAIMS WERE NOT PROPERLY DESIGNED, UNDERPOWERED OR SHOWED CLINICALLY DOUBTFUL OUTCOMES. THE EVIDENCE FOR THESE ""VASOACTIVE"" DRUGS HAS ALWAYS BEEN RECEIVED WITH SCEPTICISM, CREATING THE NEED FOR SYSTEMATIC REVIEWS AND META-ANALYSES. THIS BRIEF REVIEW DISCUSSES THE BENEFIT-RISK ASSESSMENT OF VASOACTIVE DRUGS, BY APPLYING A SYSTEMATIC REVIEW TO EVALUATE RANDOMIZED, PLACEBO-CONTROLLED TRIALS. ORAL NAFTIDROFURYL AND CILOSTAZOL HAVE AN ACCEPTABLE SAFETY PROFILE AS WELL AS SUSTAINED EVIDENCE (DOCUMENTED BY COCHRANE ANALYSES) OF INCREASED WALKING CAPACITY. SUBSEQUENTLY, THESE DRUGS ENTERED RECOMMENDATIONS FOR PERIPHERAL ARTERIAL DISEASE (PAD). IN CONTRAST, BUFLOMEDIL AND PENTOXIFYLLINE HAVE LIMITED AND/OR DOUBTFUL EVIDENCE TO INCREASE WALKING CAPACITY. MOREOVER, THERE WERE SAFETY CONCERNS ABOUT THE NARROW THERAPEUTIC RANGE OF BUFLOMEDIL. MOST OTHER ""VASOACTIVE"" DRUGS WERE EITHER INAPPROPRIATELY OR INSUFFICIENTLY TESTED OR SHOWED NO SIGNIFICANT IF NOT NEGATIVE EFFECTS ON IC. ""VASOACTIVE"" DRUGS ARE NO SUBSTITUTES FOR LIFESTYLE OR EXERCISE THERAPY BUT ARE ADJUVANT TREATMENT TO THE WELL-APPRECIATED TRIAD OF CARDIOVASCULAR PREVENTION (ANTIPLATELET AGENTS, STATINS AND ACE-INHIBITORS), OF WHICH STATINS IN THEIR OWN RIGHT HAVE DOCUMENTED CLAIMS TO SIGNIFICANTLY INCREASE WALKING CAPACITY. ""VASOACTIVE"" DRUGS MAY HAVE A PLACE IN THE PHARMACOLOGICAL MANAGEMENT OF SYMPTOMATIC PAD IN ADDITION TO THE BASIC CARDIOVASCULAR PHARMACOTHERAPY, WHEN REVASCULARIZATION IS NOT INDICATED, WHEN EXERCISE THERAPY IS NOT FEASIBLE OR WHEN THERE IS STILL INSUFFICIENT BENEFIT. © 2010 BENTHAM SCIENCE PUBLISHERS LTD.","BUFLOMEDIL; CARDIOVASCULAR PREVENTION; CILOSTAZOL; INTERMITTENT CLAUDICATION; NAFTIDROFURYL; PENTOXIFYLLINE; RANDOMIZED CONTROLLED CLINICAL TRIAL; RISK-BENEFIT ASSESSMENT; STATINS; SYSTEMATIC REVIEW; VASOACTIVE AGENTS","ANIMALS; ANTICOAGULANTS; EXTREMITIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; NAFRONYL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ARGININE; BUFLOMEDIL; CILOSTAZOL; CLOPIDOGREL; CLORICROMEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESOGLYCAN; NAFTIDROFURYL; PENTOXIFYLLINE; PICOTAMIDE; PLACEBO; POLICOSANOL; PROSTAGLANDIN; TICLOPIDINE; VERAPAMIL; ADJUVANT THERAPY; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERANCE; ENDOVASCULAR SURGERY; EVIDENCE BASED MEDICINE; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART PROTECTION; HUMAN; INTERMITTENT CLAUDICATION; LIFESTYLE MODIFICATION; MYALGIA; NEURITIS; QUALITY OF LIFE; RENAL PROTECTION; REVASCULARIZATION; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; VASCULAR SURGERY; VASOMOTOR DISORDER; WALKING","","","DASKALOPOULOU S.S., PATHMARAJAH M., KAKKOS S.K., ET AL., ASSOCIATION BETWEEN ANKLE-BRACHIAL INDEX AND RISK FACTOR PROFILE IN PATIENTS NEWLY DIAGNOSED WITH INTERMITTENT CLAUDICATION, CIRC J, 72, PP. 441-448, (2008); WHITE C., CLINICAL PRACTICE. INTERMITTENT CLAUDICATION, N ENGL J MED, 356, PP. 1241-1250, (2007); HIRSCH A.T., HASKAL Z.J., HERTZER N.R., ET AL., J VASC INTER RADIOL, 17, PP. 1383-1397, (2006); REGENSTEINER J.G., EXERCISE REHABILITATION FOR THE PATIENT WITH INTERMITTENT CLAUDICATION: A HIGHLY EFFECTIVE YET UNDERUTILIZED TREATMENT, CURR DRUG TARGETS CARDIOVASC HAEMATOL DISORD, 4, PP. 233-239, (2004); STEWART K.J., HIATT W.R., REGENSTEINER J.G., HIRSCH A.T., EXERCISE TRAINING FOR CLAUDICATION, N ENGL J MED, 347, PP. 1941-1951, (2002); HIATT W.R., MEDICAL TREATMENT OF PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, N ENGL J MED, 344, PP. 1608-1621, (2001); JONASON T., BERGSTROM R., CESSATION OF SMOKING IN PATIENTS WITH INTERMITTENT CLAUDICATION. EFFECTS ON THE RISK OF PERIPHERAL VASCULAR COMPLICATIONS, MYOCARDIAL INFARCTION AND MORTALITY, ACTA MED SCAND, 221, PP. 253-260, (1987); BENDERMACHER B.L., WILLIGENDAEL E.M., TEIJINK J.A., PRINS M.H., SUPERVISED EXERCISE THERAPY VS NON-SUPERVISED EXERCISE THERAPY FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 2, (2006); AUNG P.P., MAXWELL H.G., JEPSON R.G., PRICE J.F., LENG G.C., LIPIDLOWERING FOR PERIPHERAL ARTERIAL DISEASE OF THE LOWER LIMB, COCHRANE DATABASE SYST REV, 4, (2007); NORGREN L., HIATT W.R., DORMANDY J.A., ET AL., INTER-SOCIETY CONSENSUS FOR THE MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (TASC II), EUR J VASC ENDOVASC SURG, 33, SUPPL. 1, (2007); MURPHY T.P., HIRSCH A.T., RICOTTA J.J., ET AL., THE CLAUDICATION: EXERCISE VS ENDOLUMINAL REVASCULARIZATION (CLEVER) STUDY: RATIONALE AND METHODS, J VASC SURG, 47, PP. 1356-1363, (2008); MOHLER III E., GIRI J., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE PATIENTS: COMPARING THE ACC/AHA AND TASC-II GUIDELINES, CURR MED RES OPIN, 24, PP. 2509-2522, (2008); HANLEY J.A., LIPPMAN-HAND A., IF NOTHING GOES WRONG, IS EVERYTHING ALL RIGHT? INTERPRETING ZERO NUMERATORS, JAMA, 249, PP. 1743-1745, (1983); DEMARIA A., META-ANALYSIS, J AM COLL CARDIOL, 52, PP. 237-238, (2008); HIGGINS J.P.T., GREEN S., COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 5.0.0: UK: COCHRANE HANDBOOK, (2008); STERNE J.A., EGGER M., FUNNEL PLOTS FOR DETECTING BIAS IN METAANALYSIS: GUIDELINES ON CHOICE OF AXIS, J CLIN EPIDEMIOL, 54, PP. 1046-1055, (2001); FLETCHER J., WHAT IS HETEROGENEITY AND IS IT IMPORTANT?, BMJ, 334, PP. 94-96, (2007); DERSIMONIAN R., LAIRD N., META-ANALYSIS IN CLINICAL TRIALS, CONTROL CLIN TRIALS, 7, PP. 177-188, (1986); BREEK J.C., DEVRIES J., VAN HECK G.L., VAN BERGE HENEGOUWEN D.P., HAMMING J.F., ASSESSMENT OF DISEASE IMPACT IN PATIENTS WITH INTERMITTENT CLAUDICATION: DISCREPANCY BETWEEN HEALTH STATUS AND QUALITY OF LIFE, J VASC SURG, 41, PP. 443-450, (2005); DE BACKER T., VANDER STICHELE R., LEHERT P., VAN BORTEL L., NAFTIDROFURYL FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 2, (2008); SPENGEL F., CLEMENT D., BOCCALON H., LIARD F., BROWN T., LEHERT P., FINDINGS OF THE NAFTIDROFURYL IN QUALITY OF LIFE (NIQOL) EUROPEAN STUDY PROGRAM, INT ANGIOL, 21, PP. 20-27, (2002); ROBLESS P., MIKHAILIDIS D.P., STANSBY G.P., CILOSTAZOL FOR PERIPHERAL ARTERIAL DISEASE, COCHRANE DATABASE SYST REV, 1, (2008); LEE S.W., PARK S.W., HONG M.K., ET AL., COMPARISON OF CILOSTAZOL AND CLOPIDOGREL AFTER SUCCESSFUL CORONARY STENTING, AM J CARDIOL, 957, PP. 859-862, (2005); BIONDI-ZOCCAI G.G., LOTRIONTE M., ANSELMINO M., ET AL., SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS APPRAISING THE IMPACT OF CILOSTAZOL AFTER PERCUTANEOUS CORONARY INTERVENTION, AM HEART J, 155, PP. 1081-1089, (2008); LEE S.W., PARK S.W., KIM Y.H., ET AL., DRUG-ELUTING STENTING FOLLOWED BY CILOSTAZOL TREATMENT REDUCES LATE RESTENOSIS IN PATIENTS WITH DIABETES MELLITUS THE DECLARE-DIABETES TRIAL (A RANDOMIZED COMPARISON OF TRIPLE ANTIPLATELET THERAPY WITH DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENT IMPLANTATION IN DIABETIC PATIENTS), J AM COLL CARDIOL, 51, PP. 1181-1187, (2008); DIAGNOSIS AND MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE. A NATIONAL CLINICAL GUIDELINE, PP. 1-34, (2006); PEDERSEN T.R., KJEKSHUS J., PYORALA K., ET AL., EFFECT OF SIMVASTATIN ON ISCHEMIC SIGNS AND SYMPTOMS IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), AM J CARDIOL, 81, PP. 333-335, (1998); MOHLER III E.R., HIATT W.R., CREAGER M.A., CHOLESTEROL REDUCTION WITH ATORVASTATIN IMPROVES WALKING DISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 108, PP. 1481-1486, (2003); ARONOW W.S., NAYAK D., WOODWORTH S., AHN C., EFFECT OF SIMVASTATIN VS PLACEBO ON TREADMILL EXERCISE TIME UNTIL THE ONSET OF INTERMITTENT CLAUDICATION IN OLDER PATIENTS WITH PERIPHERAL ARTERIAL DISEASE AT SIX MONTHS AND AT ONE YEAR AFTER TREATMENT, AM J CARDIOL, 92, PP. 711-712, (2003); MCDERMOTT M.M., GURALNIK J.M., GREENLAND P., ET AL., STATIN USE AND LEG FUNCTIONING IN PATIENTS WITH AND WITHOUT LOWER-EXTREMITY PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 107, PP. 757-761, (2003); DEY S., MUKHERJEE D., CLINICAL PERSPECTIVES ON THE ROLE OF ANTIPLATELET AND STATIN THERAPY IN PATIENTS WITH VASCULAR DISEASES, CURR VASC PHARMACOL, 1, PP. 329-333, (2003); DASKALOPOULOU S.S., ATHYROS V.G., HAMILTON G., MIKHAILIDIS D.P., LIPID-LOWERING THERAPY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, J CARDIOVASC PHARMACOL THER, 10, PP. 145-147, (2005); ALNAEB M.E., ALOBAID N., SEIFALIAN A.M., MIKHAILIDIS D.P., HAMILTON G., STATINS AND PERIPHERAL ARTERIAL DISEASE: POTENTIAL MECHANISMS AND CLINICAL BENEFITS, ANN VASC SURG, 20, PP. 696-705, (2006); PARASKEVAS K.I., HAMILTON G., MIKHAILIDIS D.P., LIAPIS C.D., OPTIMAL MEDICAL MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE, VASC ENDOVASC SURG, 41, (2007); PARASKEVAS K.I., PERREA D., MIKHAILIDIS D.P., ADDITIONAL ADVANTAGES OF PRE-OPERATIVE STATIN USE IN PATIENTS UNDERGOING NON-CARDIAC VASCULAR SURGERY, ANAESTHESIA, 63, (2008); GUYTON J.R., BENEFIT VS RISK IN STATIN TREATMENT, AM J CARDIOL, 97, (2006); DE BACKER T., BOGAERT M., VANDER STICHELE R., BUFLOMEDIL FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 1, (2008); TRUBESTEIN G., BALZER K., BISLER H., ET AL., BUFLOMEDIL IN ARTERIAL OCCLUSIVE DISEASE: RESULTS OF A CONTROLLED MULTICENTER STUDY, ANGIOLOGY, 35, PP. 500-505, (1984); DIAMANTOPOULOS E.J., GRIGORIADOU M., IFANTI G., RAPTIS S.A., CLINICAL AND HEMORHEOLOGICAL EFFECTS OF BUFLOMEDIL IN DIABETIC SUBJECTS WITH INTERMITTENT CLAUDICATION, INT ANGIOL, 20, PP. 337-344, (2001); LEVIEN, PROTOCOL NUMBER W80-BU-004LJL, (1983); RAITHEL, PROTOCOL NUMBER BU-3-P05, (1985); LUND, PROTOCOL NUMBER AB-8603, (1988); WALKER G.A., MAC HANNAFORD J.C., A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF THE EFFECT OF BUFLOMEDIL ON INTERMITTENT CLAUDICATION, FUNDAM CLIN PHARMACOL, 9, PP. 387-394, (1995); LEIZOROVICZ A., BECKER F., ORAL BUFLOMEDIL IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, 4-YEAR STUDY, CIRCULATION, 117, PP. 816-822, (2008); CONTE M.S., BUFLOMEDIL IN PERIPHERAL ARTERIAL DISEASE: TRIALS AND TRIBULATIONS, CIRCULATION, 117, PP. 717-719, (2008); JEAN M., PHARMACOVIGILANCE ET LA SÉCURITÉ D'EMPLOI DU BUFLOMÉDIL, LETTRE AUX PROFESSIONELS DE SANTÉ; DE BACKER T.L., VANDER STICHELE R.H., VAN BORTEL L.M., LETTER BY DE BACKER ET AL. REGARDING ARTICLE, ORAL BUFLOMEDIL IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, 4-YEAR STUDY, CIRCULATION, 118, (2008); HOOD S.C., MOHER D., BARBER G.G., MANAGEMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CAN MED ASSOC J, 155, PP. 1053-1059, (1996); MOHER D., PHAM B., AUSEJO M., SAENZ A., HOOD S., BARBER G.G., PHARMACOLOGICAL MANAGEMENT OF INTERMITTENT CLAUDICATION: A METAANALYSIS OF RANDOMISED TRIALS, DRUGS, 59, PP. 1057-1070, (2000); DE BACKER T.L., VANDER STICHELE R.H., WARIE H.H., BOGAERT M.G., ORAL VASOACTIVE MEDICATION IN INTERMITTENT CLAUDICATION: UTILE OR FUTILE?, EUR J CLIN PHARMACOL, 56, PP. 199-206, (2000); JACOBY D., MOHLER III. E.R., DRUG TREATMENT OF INTERMITTENT CLAUDICATION, DRUGS, 64, PP. 1657-1670, (2004); CESARONE M.R., BELCARO G., NICOLAIDES A.N., ET AL., TREATMENT OF SEVERE INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: A 40-WEEK, CONTROLLED, RANDOMIZED TRIAL, ANGIOLOGY, 53, SUPPL. 1, (2002); DE SANCTIS M.T., CESARONE M.R., BELCARO G., ET AL., TREATMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: A 12-MONTH, RANDOMIZED TRIAL--WALKING DISTANCE AND MICROCIRCULATION, ANGIOLOGY, 53, SUPPL. 1, (2002); DE SANCTIS M.T., CESARONE M.R., BELCARO G., ET AL., TREATMENT OF LONG DISTANCE INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: A 12-MONTH, RANDOMIZED TRIAL, ANGIOLOGY, 53, SUPPL. 1, (2002); BELCARO G., NICOLAIDES A.N., GRIFFIN M., ET AL., INTERMITTENT CLAUDICATION IN DIABETICS: TREATMENT WITH EXERCISE AND PENTOXIFYLLINE--A 6-MONTH, CONTROLLED, RANDOMIZED TRIAL, ANGIOLOGY, 53, SUPPL. 1, (2002); SALHIYYAH K., PALFREYMAN S., BOOTH A., MICHAELS J., PENTOXIFYLLINE FOR INTERMITTENT CLAUDICATION (PROTOCOL), COCHRANE LIBRARY, 3, PP. 1-4, (2008)","T. DE BACKER; HEYMANS INSTITUTE OF CLINICAL PHARMACOLOGY, GHENT UNIVERSITY, GHENT, BELGIUM; EMAIL: DEBACKER@UGENT.BE","","ENGLISH","CURR. VASC. PHARMACOL.","ARTICLE","ISI","2-S2.0-77952900389","CURR VASC PHARMACOL","GHENT UNIVERSITY;GHENT UNIVERSITY;UNIVERSITY HOSPITAL GHENT;UNIVERSITY HOSPITAL GHENT;GHENT UNIVERSITY","NOTREPORTED;GHENT UNIVERSITY;NOTREPORTED",NA,"DE BACKER T, 2010, CURR VASC PHARMACOL","DE BACKER T, 2010, CURR VASC PHARMACOL"
"THIPPESWAMY G;SHEELA M;SALIMATH B","THIPPESWAMY, G. (57505267400); SHEELA, M.L. (36906050200); SALIMATH, BHARATHI P. (6701866057)","OCTACOSANOL ISOLATED FROM TINOSPORA CORDIFOLIA DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NFKAPPAB AND ITS DNA BINDING ACTIVITY",2008,"EUROPEAN JOURNAL OF PHARMACOLOGY","588","9",74,"10.1016/j.ejphar.2008.04.027","DEPARTMENT OF STUDIES IN APPLIED BOTANY AND BIOTECHNOLOGY, UNIVERSITY OF MYSORE, MYSORE, 570006, MANASAGANGOTRI, INDIA;DEPARTMENT OF STUDIES IN APPLIED BOTANY AND BIOTECHNOLOGY, UNIVERSITY OF MYSORE, MYSORE, 570006, MANASAGANGOTRI, INDIA;DEPARTMENT OF STUDIES IN APPLIED BOTANY AND BIOTECHNOLOGY, UNIVERSITY OF MYSORE, MYSORE, 570006, MANASAGANGOTRI, INDIA","OCTACOSANOL IS A LONG-CHAIN ALIPHATIC ALCOHOL, WHICH IS THE MAIN COMPONENT OF POLICOSANOL USED AS A NORMOLIPIDEMIC AGENT. IT IS KNOWN THAT ANGIOGENESIS IS INVOLVED IN TUMOR GROWTH AND METASTASIS. THE PRESENT STUDY IDENTIFIED OCTACOSANOL ISOLATED FROM THE PLANT TINOSPORA CORDIFOLIA AS A NEW ANTIANGIOGENIC COMPOUND WITH INHIBITORY EFFECTS ON IN VIVO ANGIOGENESIS ASSAYS. OUR RESULTS SHOWED THAT OCTACOSANOL (I) INHIBITS PROLIFERATION OF ENDOTHELIAL CELLS AND EHRLICH ASCITES TUMOR CELLS, (II) INHIBITS NEOVASCULARIZATION INDUCED BY ANGIOGENIC FACTORS IN CHICK CHORIOALLANTOIC MEMBRANE AND RAT CORNEA IN VIVO ANGIOGENESIS ASSAYS, (III) INHIBITS SECRETION OF ASCITES FLUID IN THE GROWING TUMOR CELLS IN VIVO. CONCERNING THE MECHANISM OF ACTION, OCTACOSANOL INHIBITED SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR INTO ASCITES FLUID BY THE TUMOR CELLS. AT THE MOLECULAR LEVEL OCTACOSANOL MARKEDLY INHIBITS ACTIVITY OF MATRIX METALLOPROTEINASES (MMPS) AND TRANSLOCATION OF TRANSCRIPTION FACTOR NUCLEAR FACTOR-<KAPPA>B TO NUCLEUS. THE MECHANISM OF INHIBITION OF ANGIOGENESIS BY OCTACOSANOL REFLECTS ON ITS EFFECT ON TUMOR ANGIOGENESIS AND METASTASIS. © 2008 ELSEVIER B.V. ALL RIGHTS RESERVED.","ANGIOGENESIS; ASCITES TUMOR; NF-<KAPPA>B (NUCLEAR FACTOR-<KAPPA>B); OCTACOSANOL; VEGF (VASCULAR ENDOTHELIAL GROWTH FACTOR)","ACTIVE TRANSPORT, CELL NUCLEUS; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, EHRLICH TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CHICKENS; DNA; DOWN-REGULATION; FATTY ALCOHOLS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; NF-KAPPA B; RATS; TINOSPORA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; OCTACOSANOL; TINOSPORA CORDIFOLIA EXTRACT; VASCULOTROPIN; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; ASCITES TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA; DNA BINDING; DOWN REGULATION; DRUG ISOLATION; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SECRETION; TINOSPORA; TUMOR GROWTH; ZYMOGRAPHY","MUMBAI DEPARTMENT OF SCIENCE AND TECHNOLOGY-WOS; INDIAN COUNCIL OF MEDICAL RESEARCH, ICMR, (45/15/2002/BMS/TRM); DEPARTMENT OF ATOMIC ENERGY, GOVERNMENT OF INDIA, पऊवि","THE AUTHORS THANK INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR), NEW DELHI, INDIA FOR SENIOR RESEARCH FELLOWSHIP (T.G) (NO. 45/15/2002/BMS/TRM), DEPARTMENT OF ATOMIC ENERGY (DAE), MUMBAI DEPARTMENT OF SCIENCE AND TECHNOLOGY-WOS (MLS) FOR FINANCIAL SUPPORT AND DR. H.N. YEJURVEDI, IN CHARGE, ANIMAL FACILITY, DEPARTMENT OF ZOOLOGY, UNIVERSITY OF MYSORE, MYSORE, INDIA FOR PROVIDING ANIMALS IN TIME FOR THE EXPERIMENTS.","BATTEGAY E.J.K., ANGIOGENESIS: MECHANISTIC INSIGHTS, NEOVASCULAR DISEASES, AND THERAPEUTIC PROSPECTS, J. MOL. MED., 73, PP. 333-346, (1995); BOEHM T., FOLKMAN J., BROWDER T., O'REILLY M.S., ANTI-ANGIOGENIC THERAPY OF EXPERIMENTAL CANCER DOES NOT INDUCE ACQUIRED DRUG RESISTANCE, NATURE, 390, PP. 404-407, (1997); BORGSTROM P., HILLAN K.J., SRIRAMARAO P., FERRARA N., COMPLETE INHIBITION OF ANGIOGENESIS AND GROWTH OF MICROTUMORS BY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR NEUTRALIZING ANTIBODY, NOVEL CONCEPT OF ANGIOSTATIC THERAPY FROM INTRAVITAL VIDEOMICROSCOPY, CANCER RES., 56, PP. 4032-4039, (1996); BUSSOLINO F., MANTOVANI A., PERSICO G., MOLECULAR MECHANISMS OF BLOOD VESSEL FORMATION, TRENDS BIOCHEM.SCI., 22, PP. 251-256, (1997); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., MESA M., FERNANDEZ J., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R&D., 6, PP. 207-219, (2005); CAVALLARO U., CHRISTOFORI G., MOLECULAR MECHANISMS OF TUMOR ANGIOGENESIS AND TUMOR PROGRESSION, J. NEUROONCOL., 50, PP. 63-70, (2000); DEEPAK A.V., SALIMATH B.P., ANTIANGIOGENIC AND PROAPOPTOTIC ACTIVITY OF A NOVEL GLYCOPROTEIN FROM U. INDICA IS MEDIATED BY NF-KB AND CASPASE ACTIVATED DNASE IN ASCITES TUMOR MODEL, BIOCHIMIE, 88, PP. 297-307, (2006); DEL OLEMO E., MACHO A., ALVES M., LOPEZ J.L., EL BANOUA F., MUNOZ E., SAN FELICIANO A., LONG-CHAIN AMINOALCOHOL AND DIAMINE DERIVATIVES INDUCE APOPTOSIS THROUGH A CASPASE-3 DEPENDENT PATHWAY, BIOORG. MED. CHEM. LETT, 12, PP. 2621-2626, (2002); DIXIT S.N., KHOSA R.L., CHEMICAL INVESTIGATION OF TINOSPORA CORDIFOLIA, IND. J. APPL. CHEM., 34, PP. 46-47, (1971); ELKIN M., REICH R., NAGLER A., AINGORN E., PINES M., DE-GROOT N., HOCHBERG A., VLODAVSKY I., INHIBITION OF MATRIX METALLOPROTEINASE-2 EXPRESSION AND BLADDER CARCINOMA METASTASIS BY HOLOFUGINONE, CLIN. CANCER RES., 5, PP. 1982-1988, (1999); FASSINA G., VENE R., MORINI M., MINGHELLI S., BENELLI R., NOONAM D.M., ALBINI A., MECHANISMS OF INHIBITION OF TUMOR ANGIOGENESIS AND VASCULAR TUMOR GROWTH BY EPIGALLOCATECHIN-3-GALLATE, CLIN. CANCER RES., 10, PP. 4865-4873, (2004); FERRARA N., MOLECULAR AND BIOLOGICAL PROPERTIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR, J. MOL. MED., 77, PP. 527-543, (1999); FOLKMAN J., ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE, NAT. MED., 1, PP. 27-31, (1995); FOLKMAN J., WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT?, J.NATL. CANCER INST., 82, PP. 4-6, (1989); FOLKMAN J., TUMOR ANGIOGENESIS, CANCER MEDICINE. 5TH ED., PP. 132-152, (2000); FOLKMAN J., ANGIOGENESIS, HARRISON'S TEXTBOOK OF INTERNAL MEDICINE. 15TH ED, PP. 517-530, (2001); GURURAJ A.E., BELAKAVADI M., VENKATESH D.A., MARME D., SALIMATH B.P., MOLECULAR MECHANISMS OF ANTI-ANGIOGENIC EFFECT OF CURCUMIN, BIOCHEM. BIOPHYS. RES. COMMUN., 297, PP. 934-942, (2002); HUANG S., ROBIINSON J.B., DEGUZMAN A., BACANA C.D., FIDLER I.J., BLOCKADE OF NUCLEAR FACTOR-KAPPAB SIGNALING INHIBITS ANGIOGENESIS AND TUMORIGENICITY OF HUMAN OVARIAN CANCER CELLS BY SUPPRESSING EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND INTERLEUKIN 8, CANCER RES., 60, PP. 5334-5339, (2000); HUANG S., PETTAWAY C.A., UEHARA H., BUCANA C.D., FIDLER I.J., BLOCKADE OF NF-KB ACTIVITY IN HUMAN PROSTATE CANCER CELLS IS ASSOCIATED WITH SUPPRESSION OF ANGIOGENESIS, INVASION AND METASTASIS, ONCOGENE, 20, PP. 4188-4197, (2001); JAIN R.K., MOLECULAR REGULATION OF VESSEL MATURATION, NAT. MED., 3, PP. 685-693, (2003); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN. MED. REV., 7, PP. 203-217, (2002); JAYARAMAN T., ONDRIASOVA E., ONDRIAS K., HARNICK D.J., MARKS A.R., THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IS ESSENTIAL FOR T-CELL RECEPTOR SIGNALING. PROC, NATL. ACAD. SCI., 92, PP. 6007-6011, (1995); JOHNSON L.L., DYER R., HUPE D.J., MATRIX METALLOPROTEINASES, CURR. OPIN. CHEM. BIOL., 2, PP. 466-471, (1998); JOSKO J., MAZUREK M., TRANSCRIPTION FACTORS HAVING IMPACT ON VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENE EXPRESSION IN ANGIOGENESIS, MED. SCI. MONIT., 10, PP. 89-98, (2004); KARIN M., NUCLEAR FACTOR-KB IN CANCER DEVELOPMENT AND PROGRESSION, NATURE, 441, PP. 431-436, (2006); KARIN M., BEN-NERIAH Y., PHOSPHORYLATION MEETS UBIQUITINATION: THE CONTROL OF NF-KAPPAB ACTIVITY, ANNU. REV. IMMUNOL., 18, PP. 621-663, (2000); KHALEQUE A., MIAH M.A.W., HUQ M.S., ABDUL B.K., TINOSPORA CORDIFOLIA. III. ISOLATION OF TINOSPORIDINE, CORDIFOL, HEPTACOSANOL AND Β-SITOSTEROL, SCI. RES., 7, PP. 61-62, (1970); KIM K.J., LI B., WINER J., ARMANINI M., GILLETT N., PHILLIPS H.S., FERRARA N., INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR INDUCED ANGIOGENESIS SUPPRESSES TUMOR GROWTH IN-VIVO, NATURE, 362, PP. 841-844, (1993); KOK T.W., PATRICK Y.K., YUE N.K., MAK T.P.D., FAN L., WONG R.N.S., THE ANTI-ANGIOGENIC EFFECT OF SINOMENINE, ANGIOGENESIS, 8, PP. 3-12, (2005); LAVIE G., MANDEL M., HAZAN S., BARLIYA T., BLANK M., GRUNBAUM A., MERUELO D., SOLOMON A., ANTIANGIOGENIC ACTIVITIES OF HYPERICIN IN VIVO; POTENTIAL OPHTHALMOLOGIC APPLICATIONS, ANGIOGENESIS, 8, PP. 35-42, (2005); LEYON P.V., KUTTAN G., EFFECT OF TINOSPORA CORDIFOLIA ON THE CYTOKINE PROFILE OF ANGIOGENESIS-INDUCED ANIMALS, INT. IMMUNOPHARMACOL., 4, PP. 1569-1575, (2004); LEYON P.V., KUTTAN G., INHIBITORY EFFECT OF A POLYSACCHARIDE FROM TINOSPORA CORDIFOLIA ON EXPERIMENTAL METASTASIS, J. ETHNOPHARMACOL., 90, PP. 233-237, (2004); LUO X., BUDIHARDJO I., ZOU H., SLAUGHTER C., WANG X., BID, A BCL-2 INTERACTING PROTEIN, MEDIATES CYTOCHROME C RELEASE FROM MITOCHONDRIA IN RESPONSE TO ACTIVATION OF CELL DEATH RECEPTORS, CELL, 94, PP. 481-490, (1998); MANNA S.K., SAH N.K., NEWMAN R.A., CISNEROS A., AGGARWAL B.B., OLEANDRIN SUPPRESSES ACTIVATION OF NUCLEAR TRANSCRIPTION FACTOR-KB, ACTIVATOR PROTEIN-1 AND C-JUN NH2-TERMINAL KINASE1, CANCER RES., 60, PP. 3838-3847, (2000); MATSUBARA K., MORI M., AKAGI R., KATO N., ANTI-ANGIOGENIC EFFECT OF PYRIDOXAL 5'-PHOSPHATE, PYRIDOXAL AND PYRIDOXAMINE ON EMBRYOID BODIES DERIVED FROM MOUSE EMBRYONIC STEM CELLS, INT. J. MOL. MED., 14, PP. 819-823, (2004); MESIANO S., FERRARA N., JAFFE R.B., ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OVARIAN CANCER: INHIBITION OF ASCITES FORMATION BY IMMUNONEUTRALIZATION, AM. J. PATHOL., 153, PP. 1249-1256, (1998); MIN J.K., HAN K.Y., KIM E.C., KIM Y.M., LEE S.W., KIM O.H., KIM K.W., GHO Y.S., KWON Y.G., CAPSAICIN INHIBITS IN VITRO AND IN VIVO ANGIOGENESIS, CANCER RES., 64, PP. 644-651, (2004); MORRIS B.D., FOSTER S.P., HARRIS M.O., IDENTIFICATION OF 1-OCTACOSANAL AND 6-METHOXY-2-BENZOXAZOLINONE FROM WHEAT AS OVIPOSITIONAL STIMULANTS FOR HESSIAN FLY, MAYETIOLA DESTRUCTOR. J.CHEM, ECOL., 26, PP. 859-873, (2000); NISHI T., SHIMIZU N., HIRAMOTO M., SATO I., YAMAGUCHI Y., HASEGAWA M., AIZAWA S., TANAKA H., KATAOKA K., WATANABE H., HANDA H., SPATIAL REDOX REGULATION OF A CRITICAL CYSTEINE RESIDUE OF NF-KAPPA B IN VIVO, J. BIOL. CHEM., 277, PP. 44548-44556, (2002); QUESADA A.R., MUNOZ-CHAPULI R., MEDINA M.A., ANTI-ANGIOGENIC DRUGS: FROM BENCH TO CLINICAL TRIALS, MED. RES.REV., 26, PP. 483-530, (2006); RODRIGUEZ-NIETO S., GONZALEZ-IRIARTE M., CARMONA R., MUNOZ- CHAPULI R., MEDINA M.A., QUESADA A.R., ANTIANGIOGENIC ACTIVITY OF AEROPLYSININ-1, A BROMINATED COMPOUND ISOLATED FROM A MARINE SPONGE, FASEB J., 16, PP. 261-263, (2002); SALIMATH B.P., MARME D., FINKENZELLER G., EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR GENE IS INHIBITED BY P73, ONCOGENE, 19, PP. 3470-3476, (2000); SARAYBA M.A., LI L., TUNGSIRIPAT T., LIU N.H., SWEET P.M., PATEL A.J., OSANN K.E., CHITTIBOYINA A., BENSON S.C., PERSHADSINGH H.A., CHUCK R.S., INHIBITION OF CORNEAL NEOVASCULARIZATION BY A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-G LIGAND, EXP. EYE RES., 80, PP. 435-442, (2005); SADICK H., NAIM R., GOSSLER U., HORMANN K., RIEDEL F., ANGIOGENESIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA:VEGF165 PLASMA CONCENTRATION IN CORRELATION TO THE VEGF EXPRESSION AND MICROVESSEL DENSITY, INT. J. MOL. MED., 15, PP. 15-19, (2005); SEO U.K., LEE Y.J., KIM J.K., CHA B.Y., KIM D.W., NAM K.S., KIM C.H., LARGE-SCALE AND EFFECTIVE SCREENING OF KOREAN MEDICINAL PLANTS FOR INHIBITORY ACTIVITY ON MATRIX METALLOPROTEINASE-9, J. ETHNOPHARMACOL., 97, PP. 101-106, (2005); SHEELA M.L., RAMAKRISHNA M.K., SALIMATH B.P., ANGIOGENIC AND PROLIFERATIVE EFFECTS OF THE CYTOKINE VEGF IN EHRLICH ASCITES TUMOR CELLS IS INHIBITED BY GLYCYRRHIZA GLABRA, INT.IMMUNOPHARMACOL., 6, PP. 494-498, (2005); SHIMAMURA M., HAZATO T., ASHINO H., YAMAMOTO Y., IWASAKI E., TOBE H., YAMAMOTO K., YAMAMOTO S., INHIBITION OF ANGIOGENESIS BY HUMULONE, A BITTER ACID FROM BEER HOP, BIOCHEM. BIOPHYS. RES. COMMUN., 289, PP. 220-224, (2001); SINGH S.S., PANDEY S.C., SRIVASTAVA S., GUPTA V.S., PATRO B., GHOSH A.C., CHEMISTRY AND MEDICINAL PROPERTIES OF TINOSPORA CORDIFOLIA (GUDUCHI), IND. J. PHARMACOL., 35, PP. 83-91, (2003); TANG L.Y., REDDY M.N., RASHEVA V., LEE T.L., LIN M.J., HUNG M.S., SHEN C.K., THE EUKARYOTIC DNMT2 GENES ENCODE A NEW CLASS OF CYTOSINE-5 DNA METHYLTRANSFERASES, J. BIOL. CHEM., 278, PP. 33613-33616, (2003); THIPPESWAMY G., SALIMATH B.P., INDUCTION OF CASPASE-3 ACTIVATED DNASE MEDIATED APOPTOSIS BY HEXANE FRACTION OF TINOSPORA CORDIFOLIA IN EAT CELLS, ENV. TOXICOL AND PHARMACOL., 23, PP. 212-220, (2007); VARET J., VINCENTA L., MIRSHAHIA P., PILLEA J.V., LEGRANDA E., OPOLONC P., MISHALD Z., SORIAB J., LIA H., SORIAA C., FENOFIBRATE INHIBITS ANGIOGENESIS IN VITRO AND IN VIVO, CELL. MOL. LIFE SCI., 60, PP. 810-819, (2003); YADAV P.N., LIU Z., RAFI M.M.A., DARYLHEPTANOID FROM LESSER GALANGAL (ALPINIA OFFICINARUM) INHIBITS PROINFLAMMATORY MEDIATORS VIA INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASE, P44/42, AND TRANSCRIPTION FACTOR NUCLEAR FACTOR-KAPPA B, J. PHARMACOL. EXP. THER., 305, PP. 925-931, (2003)","B.P. SALIMATH; DEPARTMENT OF STUDIES IN APPLIED BOTANY AND BIOTECHNOLOGY, UNIVERSITY OF MYSORE, MYSORE, 570006, MANASAGANGOTRI, INDIA; EMAIL: SALIMATHUOM@REDIFFMAIL.COM","","ENGLISH","EUR. J. PHARMACOL.","ARTICLE","ISI","2-S2.0-44649153497","EUR J PHARMACOL","UNIVERSITY OF MYSORE;UNIVERSITY OF MYSORE;UNIVERSITY OF MYSORE","NOTREPORTED;UNIVERSITY OF MYSORE;NOTREPORTED",NA,"THIPPESWAMY G, 2008, EUR J PHARMACOL","THIPPESWAMY G, 2008, EUR J PHARMACOL"
"MCGOWAN M;PROULX S","MCGOWAN, MARY P. (8556405000); PROULX, SUZANNE (35620966700)","NUTRITIONAL SUPPLEMENTS AND SERUM LIPIDS DOES ANYTHING WORK",2009,"CURRENT ATHEROSCLEROSIS REPORTS","11","6",22,"10.1007/s11883-009-0070-2","CHOLESTEROL TREATMENT CENTER, CONCORD HOSPITAL, CONCORD, NH 03301, 246 PLEASANT STREET, UNITED STATES; PROULX S.","HYPERLIPIDEMIA IS A RISK FACTOR FOR THE DEVELOPMENT OF CORONARY HEART DISEASE. MANY PATIENTS DECLINE PRESCRIPTION LIPID-LOWERING AGENTS AND OPT INSTEAD FOR SUPPLEMENTS. BEFORE ANY SUPPLEMENT CAN BE ROUTINELY RECOMMENDED IT IS CRUCIAL TO EXAMINE THE TYPES OF CLINICAL TRIALS THAT HAVE BEEN PERFORMED, THE MECHANISM BY WHICH A SUPPLEMENT IS FELT TO ALTER LIPIDS, THE POPULATION STUDIED, POTENTIAL ADVERSE EFFECTS, AND THE POSSIBILITY THAT INVESTIGATORS MIGHT BE BIASED. CLINICAL TRIAL EVIDENCE STRONGLY SUPPORTS THE NOTION THAT BOTH RED YEAST RICE AND PLANT STANOLS AND STEROLS EFFECTIVELY LOWER LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL. PRELIMINARY EVIDENCE SUPPORTS THE POSSIBILITY THAT GREEN TEA CATECHINS AND BLACK TEA THEAFLAVINS MAY LOWER LDL. DATA DO NOT SUPPORT AN LDL-LOWERING CLAIM FOR GUGGULIPID, POLICOSANOL, OR CINNAMON. FINALLY, THERE IS STRONG CLINICAL TRIAL EVIDENCE SUGGESTING THAT MARINE OMEGA-3 FATTY ACIDS LOWER TRIGLYCERIDES. © 2009 CURRENT MEDICINE GROUP, LLC.","","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; PHYTOSTEROLS; RISK FACTORS; ANTILIPEMIC AGENT; BLACK TEA EXTRACT; CATECHIN; CENTRUM CARDIO MULTIVITAMIN; CHOLESTIN; CINNAMON EXTRACT; DOCOSAHEXAENOIC ACID; FISH OIL; GREEN TEA EXTRACT; GUGGULSTERONE; ICOSAPENTAENOIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURE MADE CHOLESTOFF; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; POLICOSANOL; POLYPHENOL; SIMVASTATIN; SOURCE SATURALS MEGA STRENGTH BETA SITOSTEROL; STEROL; THEAFLAVIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG; CINNAMON; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; REVIEW; RISK FACTOR; TASTE DISORDER; TEA","","","WILLIAMS A., AS ECONOMY IS DOWN, VITAMIN SALES ARE UP; HEBER D., YIP I., ASHLEY J., ET AL., CHOLESTEROL LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST RICE SUPPLEMENT, AM J CLIN NUT, 69, PP. 231-236, (1999); RIPPE J., BONOVICH K., COLFER H., ET AL., A MULTICENTER SELF-CONTROLLED STUDY OF CHOLESTIN IN SUBJECTS WITH ELEVATED CHOLESTEROL (POSTER PRESENTATION (P88)), CIRCULATION, 99, (1999); BECKER D.J., GORDON R.Y., MORRIS P.B., YORKO J., GORDON Y.J., LI M., IQBAL N., SIMVASTATIN VS THERAPEUTIC LIFESTYLE CHANGES AND SUPPLEMENTS: RANDOMIZED PRIMARY PREVENTION TRIAL, MAYO CLINIC PROCEEDINGS, 83, 7, PP. 758-764, (2008); LU Z., KOU W., DU B., ET AL., EFFECT OF XUEZHIKANG, AN EXTRACT FROM RED YEAST CHINESE RICE, ON CORONARY EVENTS IN A CHINESE POPULATION WITH PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 101, PP. 1689-1693, (2008); HEBER D., LEMBERTAS A., LU Q.Y., ET AL., ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPL MED, 7, PP. 133-139, (2001); KATAN M.B., GRUNDY S.M., JONES P., ET AL., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, PP. 965-978, (2003); FOOD LABELING: HEALTH CLAIMS: PLANT STEROL/STANOL ESTERS AND CORONARY HEART DISEASE, FED REGISTER, 65, PP. 54685-54739, (2000); MAKI K.C., DAVIDSON M.H., UMPOROWICZ D.M., ET AL., LIPID RESPONSES TO PLANT STEROL-ENRICHED REDUCED-FAT SPREADS INCORPORATED INTO A NATIONAL CHOLESTEROL EDUCATION STEP 1 DIET, AM J CLIN NUTR, 74, PP. 33-43, (2001); BLAIR S.N., CAPUZZI D.M., GOTTLIEB S.O., NGUYEN T., MORGAN J.M., CATER N.B., INCREMENTAL REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH THE ADDITION OF PLANT STANOL ESTER-CONTAINING SPREAD TO STATIN THERAPY, AMERICAN JOURNAL OF CARDIOLOGY, 86, 1, PP. 46-52, (2000); GOLDBERG A.C., OSTLUND JR. R.E., BATEMAN J.H., SCHIMMOELLER L., MCPHERSON T.B., SPILBURG C.A., EFFECT OF PLANT STANOL TABLETS ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING IN PATIENTS ON STATIN DRUGS, AMERICAN JOURNAL OF CARDIOLOGY, 97, 3, PP. 376-379, (2006); GYLLING H., RADHAKRISHNAN R., MIETTINEN T.A., REDUCTION OF SERUM CHOLESTEROL IN POSTMENOPAUSAL WOMEN WITH PREVIOUS MYOCARDIAL INFARCTION AND CHOLESTEROL MALABSORPTION INDUCED BY DIETARY SITOSTANOL ESTER MARGARINE, CIRCULATION, 96, PP. 4226-4231, (1997); DEMONTY I., RAS R.T., VAN DER KNAAP H.C., ET AL., CONTINUOUS DOSE-RESPONSE RELATIONSHIP OF THE LD-CHOLESTEROL-LOWERING EFFECT OF PHYTOSTEROL INTAKE, J. NUTR, 139, PP. 271-284, (2009); PLAT J., VAN ONSELEN E.N.M., VAN HEUGTEN M.M.A., MENSINK R.P., EFFECTS ON SERUM LIPIDS, LIPOPROTEINS AND FAT SOLUBLE ANTIOXIDANT CONCENTRATIONS OF CONSUMPTION FREQUENCY OF MARGARINES AND SHORTENINGS ENRICHED WITH PLANT STANOL ESTERS, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 54, 9, PP. 671-677, (2000); RICHELLE M., ENSLEN M., HAGER C., ET AL., BOTH FREE AND ESTERIFIED PLANT STEROLS DECREASE THE BIOAVAILABILITY OF BETACAROTENE AND ALPHA-TOCOPHEROL, IN NORMOCHOLESTEROLEMIC HUMANS, AM J CLIN NUTR, 80, PP. 171-177, (2004); NOAKES M., CLIFTON P., NTANIOS F., ET AL., AN INCREASE IN DIETARY CAROTENOIDS WHEN CONSUMING PLANT STEROLS OR STANOLS IS EFFECTIVE IN MAINTAINING PLASMA CAROTENOID CONCENTRATIONS, AM J CLIN NUTR, 75, PP. 79-86, (2002); VERMEER M.A., MULDER T.P., MOLHUIZEN H.O., THEAFLAVINS FROM BLACK TEA, ESPECIALLY THEAFLAVIN-3-GALLATE, REDUCE THE INCORPORATION OF CHOLESTEROL INTO MIXED MICELLES, J AGRIC FOOD CHEM, 56, PP. 12031-12036, (2008); BURSILL C., ROACH P.D., BOTTEMA C.D.K., PAL S., GREEN TEA UPREGULATES THE LOW-DENSITY LIPOPROTEIN RECEPTOR THROUGH THE STEROL-REGULATED ELEMENT BINDING PROTEIN IN HEPG2 LIVER CELLS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, 11, PP. 5639-5645, (2001); MARON D.J., LU G.P., CAI N.S., WU Z.G., LI Y.H., CHEN H., ZHU J.Q., JIN X.J., WOUTERS B.C., ZHAO J., CHOLESTEROL-LOWERING EFFECT OF A THEAFLAVIN-ENRICHED GREEN TEA EXTRACT: A RANDOMIZED CONTROLLED TRIAL, ARCHIVES OF INTERNAL MEDICINE, 163, 12, PP. 1448-1453, (2003); FUJITA H., YAMAGAMI T., ANTIHYPERCHOLESTEROLEMIC EFFECT OF CHINESE BLACK TEA EXTRACT IN HUMAN SUBJECTS WITH BORDERLINE HYPERCHOLESTEROLEMIA, NUTRITION RESEARCH, 28, 7, PP. 450-456, (2008); GUIDELINES FOR HYPERLIPIDEMIA JAPANESE, (2002); NITYANAND S., KAPOOR N.K., CHOLESTEROL LOWERING ACTIVITY OF THE VARIOUS FRACTIONS OF GUGGUL, INDIAN J EXP BIOL, 11, PP. 395-398, (1973); URIZAR N.L., LIVERMAN A.B., DODDS D.T., SILVA F.V., ORDENTLICH P., YAN Y., GONZALEZ F.J., HEYMAN R.A., MANGELSDORF D.J., MOORE D.D., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, 5573, PP. 1703-1706, (2002); SATYAVATI G.V., GUM GUGGAL (COMMIPHOR MUKUL)-THE SUCCESS STORY OF AN ANCIENT INSIGHT LEADING TO A MODERN DISCOVERY, INDIAN J MED RES, 87, PP. 327-329, (1988); SINGH R.B., NIAZ M.A., GHOSH S., HYPOLIPIDEMIC AND ANTIOXIDANT EFFECTS OF COMMIPHORA MUKUL AS AN ADJUNCT TO DIETARY THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CARDIOVASCULAR DRUGS AND THERAPY, 8, 4, PP. 659-664, (1994); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., CUCCHIARA A.J., DERMARDEROSIAN A.H., CIRIGLIANO M.D., RADER D.J., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 290, 6, PP. 765-772, (2003); BIANCHI A., CANTU P., FIRENZUOLI F., MAZZANTI G., MENNITI-IPPOLITO F., RASCHETTI R., RHABDOMYOLYSIS CAUSED BY COMMIPHORA MUKUL, A NATURAL LIPID-LOWERING AGENT, ANNALS OF PHARMACOTHERAPY, 38, 7-8, PP. 1222-1225, (2004); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPIDLOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, 1, PP. 8-12, (2001); DULIN M.F., HATCHER L.F., SASSER H., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, CLIN NUTR, 84, PP. 1543-1548, (2006); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AMERICAN HEART JOURNAL, 152, 5, (2006); JARVILL-TAYLOR K.J., ANDERSON R.A., GRAVES D.J., A HYDROXYCHALCONE DERIVED FROM CINNAMON FUNCTIONS AS A MIMETIC FOR INSULIN IN 3T3-L1 ADIPOCYTES, J AM COLL NUTR, 20, PP. 327-336, (2001); KHAN A., SAFDAR M., KHAN M.M.A., KHATTAK K.N., ANDERSON R.A., CINNAMON IMPROVES GLUCOSE AND LIPIDS OF PEOPLE WITH TYPE 2 DIABETES, DIABETES CARE, 26, 12, PP. 3215-3218, (2003); MANG B., WOLTERS M., SCHMITT B., ET AL., EFFECTS OF CINNAMON EXTRACT ON PLASMA GLUCOSE, HBA1C, AND SERUM LIPIDS IN DIABETES MELLITUS TYPE 2, EUR J CLIN INVEST, 36, PP. 340-344, (2006); VANSCHOONBEEK K., THOMASSEN B.J., SENDEN J.M., ET AL., CINNAMON SUPPLEMENTATION DOES NOT IMPROVE GLYCEMIC CONTROL IN POSTMENOPAUSAL TYPE 2 DIABETIC PATIENTS, J NUTR, 136, PP. 977-980, (2006); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE, CIRCULATION, 106, 21, PP. 2747-2757, (2002); OMEGA-3 POLYUNSATURATED FATTY ACIDS (OMACOR) FOR HYPERTRIGLYCERIDEMIA, MED LETT DRUGS THER, 47, (2005); DURRINGTON P.N., BHATNAGAR D., MACKNESS M.I., ET AL., AN OMEGA-3 POLYUNSATURATED FATTY ACID CONCENTRATE ADMINISTERED FOR ONE YEAR DECREASED TRIGLYCERIDES IN SIMVASTATIN TREATED PATIENTS WITH CORONARY HEART DISEASE AND PERSISTING HYPERTRIGLYCERIDEMIA, HEART, 85, PP. 544-548, (2001); HARRIS W.S., N-3 FATTY ACIDS AND LIPOPROTEINS: COMPARISON OF RESULTS FROM HUMAN AND ANIMAL STUDIES, LIPIDS, 31, 3, PP. 243-252, (1996); CHAN D.C., WATTS G.F., MORI T.A., ET AL., RANDOMIZED CONTROLLED TRIAL OF THE EFFECT OF N-3 FATTY ACID SUPPLEMENTATION ON THE METABOLISM OF APOLIPOPROTEIN B-100 AND CHYLOMICRON REMNANTS IN MEN WITH VISCERAL ADIPOSITY, AM J CLIN NUTR, 77, PP. 300-307, (2003); HARRIS W.S., LU G., RAMBJOR G.S., ET AL., INFLUENCE OF N-3 FATTY ACID SUPPLEMENTATION ON THE ENDOGENOUS ACTIVITIES OF PLASMA LIPASES, AM J CLIN NUTR, 66, PP. 254-260, (1997); PARK Y., HARRIS W.S., OMEGA-3 FATTY ACID SUPPLEMENTATION ACCELERATES CHYLOMICRON TRIGLYCERIDE CLEARANCE, J LIP RES, 44, PP. 455-463, (2002); DE CATERINA R., MADONNA R., BERTOLOTTO A., SCHMIDT E.B., N-3 FATTY ACIDS IN THE TREATMENT OF DIABETIC PATIENTS: BIOLOGICAL RATIONALE AND CLINICAL DATA, DIABETES CARE, 30, 4, PP. 1012-1026, (2007)","M. P. MCGOWAN; CHOLESTEROL TREATMENT CENTER, CONCORD HOSPITAL, CONCORD, NH 03301, 246 PLEASANT STREET, UNITED STATES; EMAIL: MMCGOWAN@CRHC.ORG","","ENGLISH","CURR. ATHEROSCLER. REP.","REVIEW","ISI","2-S2.0-70449501709","CURR ATHEROSCLER REP","CHOLESTEROL TREATMENT CENTER","NOTREPORTED;CHOLESTEROL TREATMENT CENTER;NOTREPORTED",NA,"MCGOWAN MP, 2009, CURR ATHEROSCLER REP","MCGOWAN MP, 2009, CURR ATHEROSCLER REP"
"JU N;CHANG Z;HUANG M;XIAO B;LIU H","JU, NA (36883726900); CHANG, ZHI-DONG (8650787500); HUANG, MIN-ZHANG (56301237200); XIAO, BO (55126743300); LIU, HUI-ZHOU (7409747326)","LEACHING OF POLICOSANOL FROM SUGAR REFINERY RESIDUE",2008,"GUOCHENG GONGCHENG XUEBAO/THE CHINESE JOURNAL OF PROCESS ENGINEERING","8","4",1,"","INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, KEY LABORATORY OF GREEN PROCESS AND ENGINEERING, INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, GRADUATE UNIVERSITY, CHINESE ACADEMY OF SCIENCES, BEIJING 100049, CHINA;INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, KEY LABORATORY OF GREEN PROCESS AND ENGINEERING, INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA;INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, KEY LABORATORY OF GREEN PROCESS AND ENGINEERING, INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA;INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, KEY LABORATORY OF GREEN PROCESS AND ENGINEERING, INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, GRADUATE UNIVERSITY, CHINESE ACADEMY OF SCIENCES, BEIJING 100049, CHINA;INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA, KEY LABORATORY OF GREEN PROCESS AND ENGINEERING, INSTITUTE OF PROCESSING ENGINEERING, CHINESE ACADEMY OF SCIENCES, BEIJING 100190, CHINA","LEACHING OF POLICOSANOL FROM SUGAR REFINERY RESIDUE WITH AMMONIA AS THE FIRST SOLVENT AND PETROLEUM ETHER AS THE SECOND SOLVENT WAS STUDIED. THE EFFECTS OF LEACHING TEMPERATURE, LEACHING TIME AND CONCENTRATION OF SOLVENT ON LEACHING RATE OF POLICOSANOL WERE INVESTIGATED AND OPTIMIZED. THE RESULTS SHOWED THAT THE LEACHING RATE OF POLICOSANOL APPROACHED 90% WHEN 25%-28% AMMONIA WAS USED AS THE FIRST SOLVENT TO LEACH THE ORIGINAL RESIDUE FOR 3 H UNDER 90°C, AND PETROLEUM ETHER WAS USED AS THE SECOND SOLVENT TO LEACH THE RESIDUE OF THE FIRST STEP FOR 2 H UNDER 60°C.","LEACHING; POLICOSANOL; SUGAR REFINERY RESIDUE","","","","","","","CHINESE","GUOCHENG GONGCHENG XUEBAO","ARTICLE","ISI","2-S2.0-52249089794","GUOCHENG GONGCHENG XUEBAO",NA,"NOTREPORTED",NA,"JU N, 2008, GUOCHENG GONGCHENG XUEBAO","JU N, 2008, GUOCHENG GONGCHENG XUEBAO"
"BACKES J;GIBSON C;RUISINGER J;MORIARTY P","BACKES, JAMES M. (6701399762); GIBSON, CHERYL A. (7201824292); RUISINGER, JANELLE F. (16022982400); MORIARTY, PATRICK M. (7006056255)","MODIFIEDPOLICOSANOL DOES NOT REDUCE PLASMA LIPOPROTEINS IN HYPERLIPIDEMIC PATIENTS WHEN USED ALONE OR IN COMBINATION WITH STATIN THERAPY",2011,"LIPIDS","46","6",18,"10.1007/s11745-011-3591-8","UNITED STATES;DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS, UNITED STATES;SCHOOLS OF PHARMACY AND MEDICINE, UNIVERSITY OF KANSAS MEDICAL CENTER, KS, UNITED STATES;UNITED STATES, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF CLINICAL PHARMACOLOGY, UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS, UNITED STATES","POLICOSANOL IS A POORLY ABSORBED NUTRITIONAL SUPPLEMENT USED PRIMARILY FOR CHOLESTEROL MANAGEMENT. FINDINGS FROM PREVIOUS TRIALS EVALUATING THE EFFECTS OF POLICOSANOL ARE MIXED WITH EARLY DATA REPORTING POSITIVE LIPID EFFECTS WHILE MORE RECENT STUDIES INDICATE NEGLIGIBLE EFFICACY. WE HYPOTHESIZED THAT RE-FORMULATING POLICOSANOL WOULD RESULT IN AN IMPROVEMENT IN MAJOR LIPOPROTEINS AND POSSIBLY PROVIDE SOME EXPLANATION FOR PREVIOUSLY CONFLICTING TRIAL DATA. OUR PRIMARY OBJECTIVES WERE TO ASSESS THE EFFICACY AND SAFETY OF MODIFIED-POLICOSANOL (MP) ON THE MAJOR LIPOPROTEINS AMONG HYPERLIPIDEMIC SUBJECTS RECEIVING BACKGROUND STATIN THERAPY OR AS MONOTHERAPY. THIS 8-WEEK CLINICAL TRIAL CONSISTED OF 3 ARMS. SUBJECTS RECEIVING CHRONIC STATIN THERAPY (N = 36) WERE RANDOMIZED IN A DOUBLE-BLIND DESIGN TO MP 20 MG DAILY OR PLACEBO. IN THE THIRD ARM, SUBJECTS NOT RECEIVING STATIN THERAPY (N = 18) WERE ASSIGNED OPEN-LABEL MP 20 MG DAILY. THE UTILIZATION OF MP WHEN ADDED TO BACKGROUND STATIN THERAPY OR AS MONOTHERAPY RESULTED IN NO SIGNIFICANT CHANGES IN MAJOR LIPOPROTEINS (ALL P > 0.05). THE MP THERAPY WAS WELL TOLERATED WITH NO MAJOR ADVERSE EVENTS REPORTED. CONSISTENT WITH RECENT CLINICAL TRIAL DATA, MP DEMONSTRATED AN EXCELLENT SAFETY PROFILE BUT PRODUCED NO SIGNIFICANT EFFECTS ON MAJOR LIPOPROTEINS WHEN USED AS MONOTHERAPY OR WHEN GIVEN WITH CONCOMITANT STATIN THERAPY. © 2011 AOCS.","HMG REDUCTASE; HYPERLIPIDEMIA; LOW-DENSITY LIPOPROTEIN; PLASMA LIPOPROTEINS; POLICOSANOL","ADULT; AGED; AMINO ACIDS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MIDDLE AGED; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARCOSANOL; PLACEBO; POLICOSANOL; UNCLASSIFIED DRUG; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION","MARCOR DEVELOPMENT CORPORATION; UNIVERSITY OF KANSAS, KU, (23011083)","ACKNOWLEDGMENTS THIS STUDY WAS SUPPORTED BY THE UNIVERSITY OF KANSAS GENERAL RESEARCH FUND ALLOCATION #23011083 AND BY MARCOR DEVELOPMENT CORPORATION (CARLSTADT, NJ). WE WOULD ALSO LIKE TO EXPRESS OUR SINCERE GRATITUDE TO DAVID MUELLER, R.PH., FOR HIS DILIGENCE AND EXPERTISE IN PHARMACEUTICAL COMPOUNDING AND ROGER RAJEWSKI PH.D. FOR HIS EXPERTISE AND ASSISTANCE IN PRODUCT FORMULATION.","EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT (SEE COMMENT), CIRCULATION, 106, PP. 3143-3421, (2002); GRUNDY S.M., CLEEMAN J.I., BAIREY MERZ C.N., BREWER JR. H.B., CLARK L.T., HUNNINGHAKE D.B., PASTERNAK R.C., SMITH JR. S.C., STONE N.J., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, 2, PP. 227-239, (2004); DAVIDSON M.H., COMBINATION THERAPY FOR DYSLIPIDEMIA: SAFETY AND REGULATORY CONSIDERATIONS, AM J CARDIOL, 90, (2002); KAMSTRUP P.R., TYBJAERG-HANSEN A., STEFFENSEN R., NORDESTGAARD BG: GENETICALLY ELEVATED LIPOPROTEIN (A) AND INCREASED RISK OF MYOCARDIAL INFARCTION, JAMA, 301, PP. 2331-2339, (2009); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERNATIVE MEDICINE REVIEW, 7, 3, PP. 203-217, (2002); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOLOGICAL RESEARCH, 29, 2, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES OF MEDICAL RESEARCH, 32, 1, PP. 8-12, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., GAMEZ R., MENDOZA S., MESA M., FERNANDEZ J., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS IN R AND D, 6, 4, PP. 207-219, (2005); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLINICAL DRUG INVESTIGATION, 23, 10, PP. 639-650, (2003); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL, 61, 3, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 31, SUPPL. 31, PP. 31-44, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AND AGING, 20, 2, PP. 153-163, (2003); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); FERNANDEZ J.C., MAS R., CASTANO G., MENENDEZ R., AMOR A.M., GONZALEZ R.M., ALVAREZ E., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLINICAL DRUG INVESTIGATION, 21, 2, PP. 103-113, (2001); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL, 61, 6, PP. 346-347, (2000); LCA A., MAS R., FERNANDEZ L., A COMPARATIVE STUDY OF POLICOSANOL VS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, (1997); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM: CLINICAL AND EXPERIMENTAL, 53, 10, PP. 1309-1314, (2004); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 6, PP. 1543-1548, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHERAPY RESEARCH, 22, 3, PP. 318-322, (2008); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY, COMPLEMENT THER MED, 16, PP. 61-65, (2008); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BRITISH JOURNAL OF NUTRITION, 95, 5, PP. 968-975, (2006); KASSIS A.N., JONES P.J.H., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, 5, PP. 1003-1008, (2006); KASSIS A.N., JONES P.J.H., CHANGES IN CHOLESTEROL KINETICS FOLLOWING SUGAR CANE POLICOSANOL SUPPLEMENTATION: A RANDOMIZED CONTROL TRIAL, LIPIDS IN HEALTH AND DISEASE, 7, (2008); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLINICAL DRUG INVESTIGATION, 25, 11, PP. 701-707, (2005); MARINANGELI C.P.F., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.H., COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS, BRITISH JOURNAL OF NUTRITION, 97, 2, PP. 381-388, (2007); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXPERIMENTAL BIOLOGY AND MEDICINE, 229, 3, PP. 215-226, (2004); PORTER C.J., POUTON C.W., CUINE J.F., CHARMAN W.N., ENHANCING INTESTINAL DRUG SOLUBILISATION USING LIPID-BASED DELIVERY SYSTEMS, ADV DRUG DELIV REV, 60, PP. 673-691, (2008); KULKARNI K.R., CHOLESTEROL PROFILE MEASUREMENT BY VERTICAL AUTO PROFILE METHOD, CLINICS IN LABORATORY MEDICINE, 26, 4, PP. 787-802, (2006)","J.M. BACKES; ATHEROSCLEROSIS AND LDL-APHERESIS CENTER, UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS CITY, KS 66160-7231, 3901 RAINBOW BLVD., UNITED STATES; EMAIL: JBACKES@KUMC.EDU","","ENGLISH","LIPIDS","ARTICLE","ISI","2-S2.0-80054830284","LIPIDS","UNIVERSITY OF KANSAS MEDICAL CENTER;UNIVERSITY OF KANSAS MEDICAL CENTER;UNIVERSITY OF KANSAS MEDICAL CENTER","NOTREPORTED;UNIVERSITY OF KANSAS MEDICAL CENTER;NOTREPORTED",NA,"BACKES JM, 2011, LIPIDS","BACKES JM, 2011, LIPIDS"
"BRAUN L","BRAUN, LESLEY (24068671200)","POLICOSANOL SUGARCANE WAX WANES IN TRIALS",2009,"JOURNAL OF COMPLEMENTARY MEDICINE","8","1",0,"","DEPARTMENT OF SURGERY, MONASH UNIVERSITY, ALFRED HOSPITAL, AUSTRALIA","• POLICOSANOL IS A POPULAR SUPPLEMENT USED TO REDUCE CHOLESTEROL • UP UNTIL 2006 CLINICAL TRIALS DEMONSTRATED SIGNIFICANT LIPIDLOWERING ACTIVITY • SINCE THEN, NO CLINICAL TRIALS OUTSIDE CUBA HAVE BEEN ABLE TO CONFIRM THE RESULTS • THE REASONS FOR THE DISCREPANCY ARE BEING EXPLORED.","","","","","FRANCINI-PESENTI F., ET AL., COMPLEMENT THER MED; BRAUN L., COHEN M., HERBS & NATURAL SUPPLEMENTS, (2006); BERTHOLD H.K., ET AL., JAMA, 295, 19, PP. 2262-2269, (2006); DULIN M.F., ET AL., AM J CLIN NUTR, 84, 6, PP. 1543-1548, (2006); CUBEDDU L.X., ET AL., AM HEART J, 152, 5, PP. 982-985, (2006); KASSIS A.N., JONES P.J., AM J CLIN NUTR, 84, 5, PP. 1003-1008, (2006); GREYLING A., ET AL., BR J NUTR, 95, 5, PP. 968-975, (2006); KASSIS A.N., ET AL., ATHEROSCLEROSIS, 194, 1, PP. 153-158, (2007); MARINANGELI C.P., ET AL., BR J NUTR, 97, 2, PP. 381-388, (2007); KASSIS A.N., JONES P.J., LIPIDS HEALTH DIS, 7, (2008); KASSIS A.N., ET AL., ATHEROSCLER, 194, 1, PP. 153-158, (2007)","","","ENGLISH","J. COMPLEMENTARY MED.","ARTICLE","ISI","2-S2.0-77952893980","J COMPLEMENTARY MED",NA,"NOTREPORTED",NA,"BRAUN L, 2009, J COMPLEMENTARY MED","BRAUN L, 2009, J COMPLEMENTARY MED"
"HE F;PANG W;LU J;WEI X","HE, FENG-YING (35102283700); PANG, WEI-YI (35322758000); LU, JI-PEI (7601564357); WEI, XIAO-MIN (57695804500)","EFFECT OF POLICOSANOL ON ACTIVITY OF LDLR",2009,"CHINESE PHARMACOLOGICAL BULLETIN","25","2",1,"","DEPT. OF TOXICOLOGY, SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA;DEPT. OF TOXICOLOGY, SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA;DEPT. OF TOXICOLOGY, SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA;DEPT. OF TOXICOLOGY, SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA","AIM: TO IDENTIFY THE EFFECT OF POLICOSANOL ON LDL-R ACTIVITY. METHODS: IN VITRO CELL CULTURE EXPERIMENTS CONVENTIONAL METHODS WERE USED TO OBSERVE THE DIRECT EFFECT OF POLICOSANOL ON MONONUCLEAR CELLS LDL-R. IN VIVO EXPERIMENTS SELF-CONTROL AND NEGATIVE-CONTROL GROUP DESIGN METHODS WERE USED TO OBSERVE THE EFFECT OF POLICOSANOL ON LDL-R ACTIVITY IN THE PATIENTS WITH HYPERCHOLESTEROLEMIA. LDL-R ACTIVITY WAS ANALYSED BY FLUORESCENCE FLOW CYTOMETRY AND LABELED BY THE FLUORESCENT REAGENT DII. RESULTS: POLICOSANOL 5-20 MG·L-1 OBVIOUSLY ACTIVATED THE ACTIVITY OF LDL-R IN HUMAN MONONUCLEAR CELLS, POLICOSANOL LEVELS AND THE ACTIVITY OF LDL-R IN HUMAN MONONUCLEAR CELLS SHOWED SIGNIFICANTLY DOSE-EFFECT RELATIONSHIP IN VITRO STUDY. THESE TENDENCY COULD ALSO BE SEEN IN THE PATIENTS WITH HYPERCHOLESTEROLEMIA AFTER POLICOSANOL TREATMENT FOR FOUR WEEKS IN VIVO STUDY. AS THE INCREASING OF POLICOSANOL DOSE, THE ACTIVITY OF LDL-R IN HUMAN MONONUCLEAR CELLS REMARKABLY INCREASED IN THE PATIENTS WITH HYPERCHOLESTEROLEMIA CONCLUSIONS: POLICOSANOL UP-REGULATES THE ACTIVITY OF THE LDL-R IN THE MONONUCLEAR CELLS AND REDUCE CHOLESTEROL LEVEL IN THE BODY. POLICOSANOL REDUCE LIPIDS THROUGH MULTIPLE WAYS INCLUDING LDL-R.","CLINIC TEST; FLUORESCENT LABEL; HYPERCHOLESTEROLEMIA; LOW DENSITY LIPOPROTEIN RECEPTOR; MONONUCLEAR CELLS; POLICOSANOL","CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; POLICOSANOL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; MONONUCLEAR CELL; RECEPTOR UPREGULATION; UPREGULATION","","","XU Z.C., PEI B.X., THE PROPHYLACTIC EFFECTS OF STATINS ON CARDIOVASCULAR EVENTS IN PATIENTS WITH NORMAL LEVEL OF PLASMA LIPIDS, CHIN PHAMACOL BULL, 19, 11, PP. 1209-1211, (2003); MAS R., CAS T.G., FER N.D.J., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); MIRKIN A., MAS R., MAR T.M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, 1, PP. 31-41, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PRTIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); DEV K.S., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THERAP FAST FORW, (2006); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, 3, PP. 268-279, (2002); STEPHAN Z.F., YURACHEK E.C., RAPID FLUOROMETRIC ASSAY OF LDL RECEPTOR ACTIVITY BY DIL-LABELED LDL, J LIPID RESEARCH, 34, 2, PP. 325-330, (1993); CUTHBERT J.A., RUSSELL D.W., LIPSKY P.E., REGULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR GENE EXPRESSION IN HUMAN LYMPHOCYTES, BIOL CHEM, 264, PP. 1298-1303, (1989); MENENDEZ R., FERNANDEZ S.I., DEL R.A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, 3-4, PP. 199-203, (1994); BROWN M.S., GOLDSTEIN J.L., THE SREBP PATHWAY: REGULATION OF CHOLESTEROL METABOLISM BY PROTEOLYSIS OF A MEMBRANE-BOUND TRANSCRIPTION FACTOR, CELL, 89, (1997); QIAN Y., FAN C.L., DOU X.B., ET AL., EFFECT OF CURCUMIN ON STEROL REGULATORY REPORT SYSTEM IN HEK-293, CHIN PHAMACOL BULL, 22, 7, PP. 828-830, (2006)","F.-Y. HE; DEPT. OF TOXICOLOGY, SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA; EMAIL: HEFENGYIN2006@SINA.COM.CN","PUBLICATION CENTRE OF ANHUI MEDICAL UNIVERSITY","CHINESE","CHIN. PHARMACOL. BULL.","ARTICLE","ISI","2-S2.0-70350319021","CHIN PHARMACOL BULL","GUANGXI MEDICAL UNIVERSITY;GUANGXI MEDICAL UNIVERSITY;GUANGXI MEDICAL UNIVERSITY;GUANGXI MEDICAL UNIVERSITY","NOTREPORTED;GUANGXI MEDICAL UNIVERSITY;NOTREPORTED",NA,"HE F-Y, 2009, CHIN PHARMACOL BULL","HE F-Y, 2009, CHIN PHARMACOL BULL"
"PANG W;HE F;WEI X","PANG, WEI-YI (35322758000); HE, FENG-YING (35102283700); WEI, XIAO-MIN (57695804500)","EFFECTS OF POLICOSANOL ON SERUM CHOLESTEROL LEVELS IN HYPERLIPIDEMIA RATS",2009,"CHINESE JOURNAL OF PHARMACOLOGY AND TOXICOLOGY","23","6",2,"10.3867/j.issn.1000-3002.2009.06.005","SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA;SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA;SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA","AIM: TO EXPLORE EFFECTS OF POLICOSANOL ON DEPRESSING CHOLESTEROL IN HYPERLIPIDEMIA RATS AND THE CORRELATED BIOCHEMISTRY MECHANISM. METHODS: THE RATS WERE RANDOMLY DIVIDED INTO NORMAL CONTROL, POLICOSANOL 4 MG·KG -1 PREVENTION, HYPERLIPIDEMIA MODEL, POLICOSANOL 4, 6 AND 8 MG·KG-1 AND LOVASTATIN POSITIVE CONTROL GROUPS. THE LATER 5 GROUP RATS WERE FED WITH HIGH-CHOLESTEROL DIETS FOR 4 WEEKS IN ORDER TO MAKE HYPERLIPIDEMIA MODEL AND BEGINNING FROM THE 5TH WEEK, IN ADDITION TO THE NORMAL CONTROL AND MODEL GROUPS, OTHER GROUPS WERE IG GIVEN POLICOSANOL OR LOVASTATIN ONCE A DAY FOR 6 WEEKS, RESPECTIVELY, AND POLICOSANOL PROTECTION GROUP RATS WERE IG GIVEN WITH POLICOSANOL 4 MG·KG-1 ONCE A DAY FOR 10 WEEKS, TOGETHER WITH HIGH-CHOLESTEROL DIETS EVERYDAY. TOTAL CHOLESTEROL (TC), TRIGLYCERIDES (TG), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) CONCENTRATIONS IN THE SERUM AND FECAL BILE ACID (FBA) IN THE EXREMENT WERE DETERMINED BY AUTO-BIOCHEMISTRY ANALYZER. THE ACTIVITY OF 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A (HMG-COA) REDUCTASE IN HEPATOCELLULAR MICROSOMES WAS DETECTED BY ULTRAVIOLET SPECTROPHOTOMETRIC ANALYSIS AND ACTIVITY OF LOW DENSITY LIPOPROTEIN RECEPTOR (LDL-R) IN PERIPHERAL BLOOD LYMPHOCYTE WAS DETECTED BY FLUORESCENCE LABELLED INTEGRATOR METHOD. RESULTS: COMPARED WITH HYPERLIPEMIA MODEL GROUP, THE LEVELS OF TC DECREASED (39.1% - 46.4%), LDL-C DECREASED (66.6% - 80.7%), AND FBA INCREASED (9.7% - 19.0%), THE ACTIVITY OF HMG-COA REDUCTASE DECREASED (13.8% - 23.6%), AND ACTIVITY OF LDL-R INCREASED (27.5% - 129.6%) IN POLICOSANOL PREVENTION, POLICOSANOL 4, 6 AND 8 MG·KG-1 AND LOVASTATIN GROUPS, RESPECTIVELY; HDL-C INCREASED (12.2% - 16.7%) IN POLICOSANOL PREVENTION AND POLICOSANOL 8 MG·KG-1 GROUPS; TG DECREASED IN LOVASTATIN GROUP. CONCLUSION: POLICOSANOL HAS SIGNIFICANT EFFECTS ON DECREASING CHOLESTEROL. THE DECREASING CHOLESTEROL MECHANISM SHOULD INCLUDE: CIRCLED DIGIT ONE INCREASING FBA EXCRETION; CIRCLED DIGIT TWO DECREASING THE ACTIVITY OF HMG-COA REDUCTASE; CIRCLED DIGIT THREE INCREASING ACTIVITY OF LDL-R.","CHOLESTEROL; HYPERLIPIDEMIAS; POLICOSANOL; RECEPTORS, LDL","RATTUS; BILE ACID; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; POLICOSANOL; TRIACYLGLYCEROL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; HYPERLIPIDEMIA; LIVER MICROSOME; NONHUMAN; PERIPHERAL LYMPHOCYTE; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET SPECTROPHOTOMETRY","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA J, BRAZ J MED BIOL RES, 33, 7, PP. 835-840, (2000); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATSJ, J MED FOOD, 4, 2, PP. 57-65, (2001); ZHU Y., DUO X.Y., THE DISEASE MODEL OF EXPERIMENTAL ANIMAL M TIANJIN, (1997); WILSON T.A., NICOLOSI R.J., ROGERS E.J., SACCHIERO R., GOLDBERG D.J., STUDIES OF CHOLESTEROL AND BILE ACID METABOLISM, AND EARLY ATHEROGENESIS IN HAMSTERS FED GT16-239, A NOVEL BILE ACID SEQUESTRANT (BAS) J, ATHEROSCLEROSIS, 140, 2, PP. 315-324, (1998); ZHONG C.G., HEPATOTOXICOLOGY STUDYM// WANG XR, METHODOLOGY AND TECHNOLOGY OF TOXICOLOGY EXPERIMENTS, PP. 233-234, (2007); EDWARDS P.A., LEMONGELLO D., FOGELMAN A.M., IMPROVED METHODS FOR THE SOLUBILIZATION AND ASSAY OF HEPATIC 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE J, J LIPID RES, 20, 1, PP. 40-46, (1979); MENG Z., SUN L.H., CHEN Y.Y., YE M., SU H., XING D.M., ET AL., THE EFFECT OF POMEGRANATE LEAF TANNIDE ON HYPERLIPIDEMIC MODELSJ, CHIN J EXP TRADIT MED FORM, 11, 1, PP. 22-24, (2005); DOU X.B., FAN C.L., HONG X.Q., QIAN Y., WO X.D., EFFECT OF CURCUMIN ON EXPRESSION OF LDL-R IN HUMAN LYMPHOCYTESJ, CHIN PHARM J, 40, 13, PP. 980-983, (2005); BARAK L.S., WEBB W.W., FLUORESCENT LOW DENSITY LIPOPROTEIN FOR OBSERVATION OF DYNAMICS OF INDIVIDUAL RECEPTOR COMPLEXES ON CULTURED HUMAN FIBROBLASTS J, J CELL BIOL, 90, 3, PP. 595-604, (1981); CUI Y.L., ZHAO X.L., WU F., GUO S.J., LI J.J., ZHOU H., ET AL., RELATIONSHIP BETWEEN TAQ I GENETIC POLYMORPHISM AT CHOLESTEROL ESTER TRANSFER PROTEIN LOCUS AND THE EFFICACY OF POLICOSANOL J, CHIN J NEW DRUGS, 16, 3, PP. 240-243, (2007); MCCARTY M.F., AN EZETIMIBE-POLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTSJ, MED HYPOTHESES, 64, 3, PP. 636-645, (2005); FRANCINI-PESENTI F., BROCADELLO F., BELTRAMOLLI D., NARDI M., CAREGARO L., SUGAR CANE POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN PRIMITIVE, DIET-RESISTANT HYPERCHOLESTEROLAEMIA: A DOUBLE BLIND, CONTROLLED STUDY J, COMPLEMENT THER MED, 16, 2, PP. 61-65, (2008); SCHMITZ G., BRUNING T., KOVACS E., BARLAGE S., FLUORESCENCE FLOW CYTOMETRY OF HUMAN LEUKOCYTES IN THE DETECTION OF LDL RECEPTOR DEFECTS IN THE DIFFERENTIAL DIAGNOSIS OF HYPERCHOLESTEROLEMIAJ, ARTERIOSCLER THROMB, 13, 7, PP. 1053-1065, (1993); GUIS S., BENDAHAN D., KOZAK-RIBBENS G., FIGARELLA-BRANGER D., MATTER J.P., PELLISSIER J.F., ET AL., RHABDOMYOLYSIS AND MYALGIA ASSOCIATED WITH ANTICHOLESTEROLEMIC TREATMENT AS POTENTIAL SIGNS OF MALIGNANT HYPERTHERMIA SUSCEPTIBILITY J, ARTHRITIS RHEUM, 49, 2, PP. 237-238, (2003); STEPHAN Z.F., YURACHEK E.C., RAPID FLUOROMETRIC ASSAY OF LDL RECEPTOR ACTIVITY BY DIL-LABELED LDL J, J LIPID RES, 34, 2, PP. 325-330, (1993); EBERLE D., HEGARTY B., BOSSARD P., FERRE P., FOUFELLE F., SREBP TRANSCRIPTION FACTORS: MASTER REGULATORS OF LIPID HOMEOSTASIS J, BIOCHIMIE, 86, 11, PP. 839-848, (2004)","X.-M. WEI; SCHOOL OF PUBLIC HEALTH, GUANGXI MEDICAL UNIVERSITY, NANNING 530021, CHINA; EMAIL: XIAOMINW20011@YAHOO.COM.CN","","CHINESE","CHIN. J. PHARMACOL. TOXICOL.","ARTICLE","ISI","2-S2.0-74749097419","CHIN J PHARMACOL TOXICOL","GUANGXI MEDICAL UNIVERSITY;GUANGXI MEDICAL UNIVERSITY;GUANGXI MEDICAL UNIVERSITY","NOTREPORTED;GUANGXI MEDICAL UNIVERSITY;NOTREPORTED",NA,"PANG W-Y, 2009, CHIN J PHARMACOL TOXICOL","PANG W-Y, 2009, CHIN J PHARMACOL TOXICOL"
"HARRABI S;BOUKHCHINA S;MAYER P;KALLEL H","HARRABI, SAOUSSEM (23110559100); BOUKHCHINA, SADOK (6507257738); MAYER, PAUL M. (7203028266); KALLEL, HABIB (22934478000)","POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS",2009,"FOOD CHEMISTRY","115","5",36,"10.1016/j.foodchem.2008.12.098","LABORATOIRE DE BIOCHIMIE DES LIPIDES, FACULTÉ DES SCIENCES DE TUNIS, UNIVERSITÉ TUNIS EL-MANAR, TUNIS, 2092, TUNISIA;LABORATOIRE DE BIOCHIMIE DES LIPIDES, FACULTÉ DES SCIENCES DE TUNIS, UNIVERSITÉ TUNIS EL-MANAR, TUNIS, 2092, TUNISIA;CHEMISTRY DEPARTMENT, UNIVERSITY OF OTTAWA, OTTAWA, ONT. K1N 6N5, CANADA;LABORATOIRE DE BIOCHIMIE DES LIPIDES, FACULTÉ DES SCIENCES DE TUNIS, UNIVERSITÉ TUNIS EL-MANAR, TUNIS, 2092, TUNISIA","POLICOSANOL IS A MIXTURE OF LONG-CHAIN PRIMARY ALIPHATIC ALCOHOLS. THE POLICOSANOL COMPOSITION OF WHOLE CORN KERNEL WAS DETERMINED IN THREE VARIETIES OF CORN (ASTRO, GH2547, LOCAL). THE TOTAL POLICOSANOL CONTENT OF GH2547 (20.5 MG/KG OF DRY WEIGHT) WAS HIGHER THAN THOSE OF LOCAL (16.6 MG/KG) AND ASTRO (15.2 MG/KG). THE MAJOR POLICOSANOL COMPONENTS OF WHOLE CORN KERNEL WERE DOTRIACONTANOL, TRIACONTANOL AND TETRACOSANOL. THE DISTRIBUTION OF POLICOSANOL IN THE GERM, ENDOSPERM AND PERICARP OF CORN KERNELS WAS ALSO DETERMINED. CORN PERICARP HAD HIGHER CONTENTS OF POLICOSANOLS (72.7-110.9 MG/KG) THAN THE ENDOSPERM (4.0-16.2 MG/KG) AND GERM (19.3-37.1 MG/KG) FRACTIONS. CORN PERICARP POLICOSANOL WAS MAINLY TRIACONTANOL (33.63-46.29 MG/KG), DOTRIACONTANOL (22.31-39.46 MG/KG) AND OCTACOSANOL (8.13-14.0 MG/KG). IN CONTRAST, THE CORN GERM FRACTION CONTAINED MOSTLY DOTRIACONTANOL (MORE THAN 50%) AND NO TRIACONTANOL. THE MAIN COMPONENTS OF CORN ENDOSPERM POLICOSANOL WERE TRIACONTANOL AND HEXACOSANOL. THE LEVEL OF TETRACOSANOL WAS HIGHEST IN THE GERM FRACTION AND LOWEST IN THE ENDOSPERM FRACTION. THE GREATEST CHANGE IN POLICOSANOL CONTENT (EXPRESSED AS MG/100 G OF OIL) OCCURRED DURING THE EARLY STAGES OF CORN KERNEL DEVELOPMENT. ALTHOUGH THE STRUCTURES OF THE ALCOHOL CONSTITUENTS OF POLICOSANOL ARE SIMILAR, THEIR PATTERNS OF ACCUMULATION WERE DIFFERENT. THE HIGHEST LEVELS OF OCTACOSANOL AND DOTRIACONTANOL WERE DETECTED AT 20 DAYS AFTER POLLINATION (DAP) FOLLOWED BY A RAPID DECREASE BETWEEN 20 AND 30 DAP. TRIACONTANOL LEVELS DECREASED RAPIDLY BETWEEN 10 AND 40 DAP, AND THEN REMAINED NEARLY CONSTANT. © 2009 ELSEVIER LTD. ALL RIGHTS RESERVED.","CORN KERNEL; DISTRIBUTION; ENDOSPERM; GERM; MATURATION; PERICARP; POLICOSANOL","","","","ARRUZAZABALA M.L., CARBAJAL D., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); AVATO P., BIANCHI G., MURELLI C., ALIPHATIC AND CYCLIC LIPID COMPONENTS OF SORGHUM PLANT ORGANS, PHYTOCHEMISTRY, 29, PP. 1073-1078, (1990); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); DAVIS D.L., PONELEIT C.G., STEROLS IN DEVELOPING SEED FROM LOW AND HIGH OIL ZEA MAYS STRAINS, PHYTOCHEMISTRY, 14, PP. 1201-1203, (1975); DOUCE R., IDENTIFICATION ET DOSAGE DE QUELQUES GLYCÉROPHOSPHOSPHATIDES DANS DES SOUCHES NORMALES ET TUMORALES DE SCOSONÈRES CULTIVÉS IN VITRO, CR ACAD. SCI., 259, PP. 3066-3068, (1964); FOLCH J., LEES M., SLOANE S.G.M., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDS FROM ANIMAL TISSUES, J. BIOL. CHEM., 226, PP. 497-509, (1957); GULZ P.G., MULLER E., PRASAD B.N., DEVELOPMENTAL AND SEASONAL VARIATIONS IN THE EPICUTICULAR WAXES OF TILIA TOMENTOSA LEAVES, PHYTOCHEMISTRY, 30, PP. 769-773, (1991); HARRABI S., SAKOUHI F., ST-AMAND A., BOUKHCHINA S., KALLEL H., MAYER P.M., ACCUMULATION OF PHYTOSTEROLS, TRITERPENE ALCOHOLS AND PHYTOSTANOLS IN DEVELOPING ZEA MAYS L, KERNELS. J. PLANT SCI., 2, PP. 260-272, (2007); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRICUL. FOOD CHEMISTRY, 53, PP. 5583-5586, (2005); JACKSON M.A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYZED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, J. OF SUPERCRITICAL FLUIDS, 37, PP. 173-177, (2006); LIN Y., RUDRUM M., WIELEN R.P., TRAUTWEIN E.A., MCNEIL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); MARCELLETTI J.F., SYNERGISTIC INHIBITION OF HERPESVIRUS REPLICATION BY DOCOSANOL AND ANTIVIRAL NUCLEOSIDE ANALOGS, ANTIVIRAL RESEARCH, 56, PP. 153-166, (2002); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCHIVES OF MEDICAL RESEARCH, 36, PP. 113-119, (2005); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCHIVES IN MEDICAL RESEARCH, 32, PP. 8-12, (2001); RAMANARAYAN K., BHAT A., SHRIPATHI V., SWAMY G.S., RAO K.S., TRIACONTANOL INHIBITS BOTH ENZYMATIC AND NONENZYMATIC LIPID PEROXIDATION, PHOTOCHEMISTRY, 55, PP. 59-66, (2000); RIES S.K., TRIACONTANOL AND ITS SECOND MESSENGER 9-Β-L(+)-ADENOSINE AS PLANT GROWTH SUBSTANCES, PLANT PHYSIOL., 95, PP. 986-989, (1991); SHRIPATHI V., SWAMY G.S., CHANDRASEKHAR K.S., MICROVISCOSITY OF CUCUMBER (CUCUMIS SATIVUS L.) FRUIT PROTOPLAST MEMBRANES IS ALTERED BY TRIACONTANOL AND ABSCISIC ACID, BIOCHIM. BIOPHYS. ACTA, 1229, PP. 290-295, (1997); SHRIPATHI V., SWAMY G.S., EFFECT OF TRIACONTANOL ON THE LIPID COMPOSITION OF COTTON (GOSSYPIUM HIRSUTUM L.) LEAVES AND ITS INTERACTION WITH INDOLE-3-ACETIC ACID AND BENZYL ADENINE, PLANT GROWTH REGUL., 14, PP. 45-50, (1994); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, PP. 376-383, (2003); WARREN P.R., BURGER R.A., SIDWELL R.W., CLARK L.L., EFFECT OF TRIACONTANOL ON NUMBERS AND FUNCTIONS OF CELLS INVOLVED IN INFLAMMATORY RESPONSES, PROCEEDINGS OF SOCIETY EXPERIMENTS BIOLOGY AND MEDICINE, 200, PP. 349-352, (1992); WEBER E.J., LIPIDS OF MATURING GRAIN OF CORN (ZEA MAYS L.): II. CHANGES IN POLAR LIPIDS, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 46, PP. 485-488, (1970); WEBER E.J., LIPIDS OF MATURING GRAIN OF CORN (ZEA MAYS L.): I. CHANGES IN LIPID CLASSES AND FATTY ACID COMPOSITION, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 46, PP. 485-488, (1969); WU T.-T., CHARLES A.L., HUANG T.-C., DETERMINATION OF THE CONTENTS OF THE MAIN BIOCHEMICAL COMPOUNDS OF ADLAY (COXI LACHRYMAL-JOBI), FOOD CHEMISTRY, 104, PP. 1509-1515, (2007); XU Z., FITZ E., RIEDIGER N., MOGHADASIAN M.H., DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT MICE, NUTRITION RESEARCH, 27, PP. 212-217, (2007)","S. HARRABI; LABORATOIRE DE BIOCHIMIE DES LIPIDES, FACULTÉ DES SCIENCES DE TUNIS, UNIVERSITÉ TUNIS EL-MANAR, TUNIS, 2092, TUNISIA; EMAIL: SAWSEMTAHAR@YAHOO.FR","ELSEVIER LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-62249117712","FOOD CHEM","UNIVERSITÉ TUNIS EL-MANAR;UNIVERSITÉ TUNIS EL-MANAR;UNIVERSITY OF OTTAWA;UNIVERSITÉ TUNIS EL-MANAR","NOTREPORTED;UNIVERSITÉ TUNIS EL-MANAR;NOTREPORTED",NA,"HARRABI S, 2009, FOOD CHEM","HARRABI S, 2009, FOOD CHEM"
"PRATT C","PRATT, COLEMAN (36089111900)","ALTERNATIVE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE PART 2",2010,"PRIMARY CARE - CLINICS IN OFFICE PRACTICE","37","27",8,"10.1016/j.pop.2010.02.010","DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE, TULANE UNIVERSITY HEALTH SCIENCE CENTER, SCHOOL OF MEDICINE, NEW ORLEANS, LA 70112, 1430 TULANE AVENUE TB3, UNITED STATES, DAUGHTERS OF CHARITY SERVICES NEW ORLEANS, NEW ORLEANS, LA 70119, 4164 CANAL STREET, UNITED STATES","THIS ARTICLE DISCUSSES ALTERNATIVE THERAPIES FOR SECONDARY PREVENTION AND TREATMENT OF MAJOR CARDIAC DISORDERS: CONGESTIVE HEART FAILURE, HYPERTENSION, DYSLIPIDEMIAS, AND PERIPHERAL VASCULAR DISEASE. THE ROLE OF VARIOUS THERAPIES (EG, HERBAL AND BOTANIC PREPARATIONS, SUPPLEMENTS, MIND/BODY INTERVENTIONS, OTHER ALTERNATIVE MODALITIES OF CARE) ARE ADDRESSED RELATIVE TO EACH DISEASE STATE AND WILL HOPEFULLY GIVE THE PRACTITIONER OR STUDENT A READILY ACCESSIBLE SUITE OF INTEGRATIVE THERAPIES FOR COMMON CARDIAC ILLNESSES. © 2010.","ALTERNATIVE MEDICINE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; HYPERLIPIDEMIA; HYPERTENSION; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; PERIPHERAL VASCULAR DISEASES; PHYTOTHERAPY; PLANT PREPARATIONS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; ACETYLSALICYLIC ACID; ALLYL ISOTHIOCYANATE; ALPHA TOCOPHEROL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CARNITINE; CLOPIDOGREL; CRATAEGUS EXTRACT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; FOLIC ACID; GARLIC EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; POLICOSANOL; POTASSIUM; PRAVASTATIN; PROPIONYLCARNITINE; SIMVASTATIN; UBIDECARENONE; UNINDEXED DRUG; WARFARIN; ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DIARRHEA; DIET; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG ANTAGONISM; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HERBAL MEDICINE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; LOW DRUG DOSE; MEDITATION; NAUSEA; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAXATION TRAINING; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SOCIAL ISOLATION; SPIRITUAL HEALING; YOGA","","","LLOYD-JONES D., ADAMS R., CARNETHON M., ET AL., AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE. HEART DISEASE AND STROKE STATISTICS-2009 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE, CIRCULATION, 119, 3, PP. 480-486, (2009); ORNISH D., BROWN S.E., SCHERWITZ L.W., ET AL., CAN LIFESTYLE CHANGES REVERSE CORONARY HEART DISEASE? THE LIFESTYLE HEART TRIAL, LANCET, 336, 8708, PP. 129-133, (1990); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, 23, PP. 2001-2007, (1998); KOERTGE J., WEIDNER G., ELLIOTT-ELLER M., ET AL., IMPROVEMENT IN MEDICAL RISK FACTORS AND QUALITY OF LIFE IN WOMEN AND MEN WITH CORONARY ARTERY DISEASE IN THE MULTICENTER LIFESTYLE DEMONSTRATION PROJECT, AM J CARDIOL, 91, 11, PP. 1316-1322, (2003); FRATTAROLI J., WEIDNER G., MERRITT-WORDEN T.A., ET AL., ANGINA PECTORIS AND ATHEROSCLEROTIC RISK FACTORS IN THE MULTISITE CARDIAC LIFESTYLE INTERVENTION PROGRAM, AM J CARDIOL, 101, 7, PP. 911-918, (2008); ALDANA S.G., GREENLAW R., SALBERG A., ET AL., THE EFFECTS OF AN INTENSIVE LIFESTYLE MODIFICATION PROGRAM ON CAROTID ARTERY INTIMA-MEDIA THICKNESS: A RANDOMIZED TRIAL, AM J HEALTH PROMOT, 21, 6, PP. 510-516, (2007); BUCHER H.C., HENGSTLER P., SCHINDLER C., ET AL., N-3 POLYUNSATURATED FATTY ACIDS IN CORONARY HEART DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 112, 4, PP. 298-304, (2002); BURR M.L., FEHILY A.M., GILBERT J.F., ET AL., EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART), LANCET, 2, 8666, PP. 757-761, (1989); BURR M., SECONDARY PREVENTION OF CHD IN UK MEN: THE DIET AND REINFARCTION TRIAL AND ITS SEQUEL, PROC NUTR SOC, 66, 1, PP. 9-15, (2007); BURR M.L., DUNSTAN F.D., GEORGE C.H., IS FISH OIL GOOD OR BAD FOR HEART DISEASE? TWO TRIALS WITH APPARENTLY CONFLICTING RESULTS, J MEMBR BIOL, 206, 2, PP. 155-163, (2005); YOKOYAMA M., ORIGASA H., MATSUZAKI M., ET AL., EFFECTS OF EICOSAPENTAENOIC ACID ON MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLAEMIC PATIENTS (JELIS): A RANDOMISED OPEN-LABEL, BLINDED ENDPOINT ANALYSIS, LANCET, 369, 9567, PP. 1090-1098, (2007); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO, LANCET, 354, 9177, PP. 447-455, (1999); MARCHIOLI R., SCHWEIGER C., TAVAZZI L., ET AL., EFFICACY OF N-3 POLYUNSATURATED FATTY ACIDS AFTER MYOCARDIAL INFARCTION: RESULTS OF GISSI-PREVENZIONE TRIAL. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO, LIPIDS, 36, SUPPL, (2001); SINGH R.B., NIAZ M.A., SHARMA J.P., ET AL., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF FISH OIL AND MUSTARD OIL IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL INFARCTION: THE INDIAN EXPERIMENT OF INFARCT SURVIVAL, CARDIOVASC DRUGS THER, 11, PP. 485-491, (1997); RAKEL D., INTEGRATIVE MEDICINE, (2007); ERNSTER L., DALLNER G., BIOCHEMICAL, PHYSIOLOGICAL AND MEDICAL ASPECTS OF UBIQUINONE FUNCTION, BIOCHIM BIOPHYS ACTA, 1271, PP. 195-204, (1995); SINGH R.B., WANDER G.S., RASTOGI A., ET AL., RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF COENZYME Q10 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, CARDIOVASC DRUGS THER, 12, 4, PP. 347-353, (1998); SINGH R.B., NEKI N.S., KARTIKEY K., ET AL., EFFECT OF COENZYME Q10 ON RISK OF ATHEROSCLEROSIS IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION, MOL CELL BIOCHEM, 246, 1-2, PP. 75-82, (2003); HECK A.M., DEWITT B.A., LUKES A.L., POTENTIAL INTERACTIONS BETWEEN ALTERNATIVE THERAPIES AND WARFARIN, AM J HEALTH SYST PHARM, 57, 13, PP. 1221-1227, (2000); LINDEN W., STOSSEL C., MAURICE J., PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH CORONARY ARTERY DISEASE: A META-ANALYSIS, ARCH INTERN MED, 156, 7, PP. 745-752, (1996); REES K., BENNETT P., WEST R., ET AL., PSYCHOLOGICAL INTERVENTIONS FOR CORONARY HEART DISEASE, COCHRANE DATABASE SYST REV, 2, (2004); MANCHANDA S.C., NARANG R., REDDY K.S., ET AL., RETARDATION OF CORONARY ATHEROSCLEROSIS WITH YOGA LIFESTYLE INTERVENTION, J ASSOC PHYSICIANS INDIA, 48, 7, PP. 687-694, (2000); VAN DIXHOORN J., DUIVENVOORDEN H.J., STAAL H.A., ET AL., PHYSICAL TRAINING AND RELAXATION THERAPY IN CARDIAC REHABILITATION ASSESSED THROUGH A COMPOSITE CRITERION FOR TRAINING OUTCOME, AM HEART J, 118, 3, PP. 545-552, (1989); BALLEGAARD S., BORG E., KARPATSCHOF B., ET AL., LONG-TERM EFFECTS OF INTEGRATED REHABILITATION IN PATIENTS WITH ADVANCED ANGINA PECTORIS: A NONRANDOMIZED COMPARATIVE STUDY, J ALTERN COMPLEMENT MED, 10, 5, PP. 777-783, (2004); HAMBRECHT R., WALTHER C., MOBIUS-WINKLER S., ET AL., PERCUTANEOUS CORONARY ANGIOPLASTY COMPARED WITH EXERCISE TRAINING IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: A RANDOMIZED TRIAL, CIRCULATION, 109, 11, PP. 1371-1378, (2004); CASTILLO-RICHMOND A., SCHNEIDER R.H., ALEXANDER C.N., ET AL., EFFECTS OF STRESS REDUCTION ON CAROTID ATHEROSCLEROSIS IN HYPERTENSIVE AFRICAN AMERICANS, STROKE, 31, 3, PP. 568-573, (2000); ZAMARRA J.W., SCHNEIDER R.H., BESSEGHINI I., ET AL., USEFULNESS OF THE TRANSCENDENTAL MEDITATION PROGRAM IN THE TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE, AM J CARDIOL, 77, 10, PP. 867-870, (1996); HORSTEN M., MITTLEMAN M.A., WAMALA S.P., ET AL., DEPRESSIVE SYMPTOMS AND LACK OF SOCIAL INTEGRATION IN RELATION TO PROGNOSIS OF CHD IN MIDDLE-AGED WOMEN. THE STOCKHOLM FEMALE CORONARY RISK STUDY, EUR HEART J, 21, 13, PP. 1072-1080, (2000); ZIEGELSTEIN R.C., FAUERBACH J.A., STEVENS S.S., ET AL., PATIENTS WITH DEPRESSION ARE LESS LIKELY TO FOLLOW RECOMMENDATIONS TO REDUCE CARDIAC RISK DURING RECOVERY FROM A MYOCARDIAL INFARCTION, ARCH INTERN MED, 160, PP. 1818-1823, (2000); VON RUDEN A.E., ADSON D.E., KOTLYAR M., EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON CARDIOVASCULAR MORBIDITY AND MORTALITY, J CARDIOVASC PHARMACOL THER, 13, 1, PP. 32-40, (2008); FRASURE-SMITH N., LESPERANCE F., GRAVEL G., ET AL., SOCIAL SUPPORT, DEPRESSION, AND MORTALITY DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION, CIRCULATION, 101, 16, PP. 1919-1924, (2000); PISCHKE C.R., SCHERWITZ L., WEIDNER G., ET AL., LONG-TERM EFFECTS OF LIFESTYLE CHANGES ON WELL-BEING AND CARDIAC VARIABLES AMONG CORONARY HEART DISEASE PATIENTS, HEALTH PSYCHOL, 27, 5, PP. 584-592, (2008); MORRIS E.L., THE RELATIONSHIP OF SPIRITUALITY TO CORONARY HEART DISEASE, ALTERN THER HEALTH MED, 7, 5, PP. 96-98, (2001); GORINSTEIN S., JASTRZEBSKI Z., NAMIESNIK J., ET AL., THE ATHEROSCLEROTIC HEART DISEASE AND PROTECTING PROPERTIES OF GARLIC: CONTEMPORARY DATA, MOL NUTR FOOD RES, 51, 11, PP. 1365-1381, (2007); RAHMAN K., LOWE G.M., GARLIC AND CARDIOVASCULAR DISEASE: A CRITICAL REVIEW, J NUTR, 136, 3 SUPPL, (2006); VERMA S.K., RAJEEVAN V., JAIN P., ET AL., EFFECT OF GARLIC (ALLIUM SATIVUM) OIL ON EXERCISE TOLERANCE IN PATIENTS WITH CORONARY ARTERY DISEASE, INDIAN J PHYSIOL PHARMACOL, 49, 1, PP. 115-118, (2005); KOSCIELNY J., KLUSSENDORF D., LATZA R., ET AL., THE ANTIATHEROSCLEROTIC EFFECT OF ALLIUM SATIVUM, ATHEROSCLEROSIS, 144, 1, PP. 237-249, (1999); SOBENIN I.A., PRIANISHNIKOV V.V., KUNNOVA L.M., ET AL., USE OF ALLICOR TO LOWER THE RISK OF MYOCARDIAL INFARCTION, KLIN MED (MOSK), 85, 3, PP. 25-28, (2007); WALD D.S., LAW M., MORRIS J.K., HOMOCYSTEINE AND CARDIOVASCULAR DISEASE: EVIDENCE ON CAUSALITY FROM A META-ANALYSIS, BMJ, 325, 7374, (2002); SCHNYDER G., FLAMMER Y., ROFFI M., ET AL., PLASMA HOMOCYSTEINE LEVELS AND LATE OUTCOME AFTER CORONARY ANGIOPLASTY, J AM COLL CARDIOL, 40, 10, PP. 1769-1776, (2002); SCHNYDER G., ROFFI M., FLAMMER Y., ET AL., EFFECT OF HOMOCYSTEINE-LOWERING THERAPY WITH FOLIC ACID, VITAMIN B12, AND VITAMIN B6 ON CLINICAL OUTCOME AFTER PERCUTANEOUS CORONARY INTERVENTION: THE SWISS HEART STUDY: A RANDOMIZED CONTROLLED TRIAL, JAMA, 288, 8, PP. 973-979, (2002); WALD D.S., BISHOP L., WALD N.J., ET AL., RANDOMIZED TRIAL OF FOLIC ACID SUPPLEMENTATION AND SERUM HOMOCYSTEINE LEVELS, ARCH INTERN MED, 161, 5, PP. 695-700, (2001); 2001 HEART AND STROKE STATISTICAL UPDATE, (2000); JESSUP M., BROZENA S., HEART FAILURE, N ENGL J MED, 348, PP. 2007-2018, (2003); KONSTAM M.A., PROGRESS IN HEART FAILURE MANAGEMENT? LESSONS FROM THE REAL WORLD, CIRCULATION, 102, PP. 1076-1078, (2000); HAND A., GEMMEL I., CLARK A.L., ET AL., IS THE PROGNOSIS OF HEART FAILURE IMPROVING?, J AM COLL CARDIOL, 36, PP. 2284-2286, (2000); GUO R., PITTLER M.H., ERNST E.; TAUCHERT M., PLOCH M., HUBNER W., EFFECTIVENESS OF HAWTHORN EXTRACT LI 132 COMPARED WITH ACE-I CAPTOPRIL: MULTICENTER DOUBLE-BLIND STUDY WITH 1132 NYHA STAGE II PATIENTS, MUNCH MED WOCHENSCHR, 136, SUPPL. 1, (1994); TAUCHERT M., GILDOR A., LIPINSKI J., HIGH-DOSE CRATAEGUS EXTRACT WS 1442 IN THE TREATMENT OF NYHA STAGE II HEART FAILURE, HERZ, 24, 6, PP. 465-474, (1999); TAUCHERT M., EFFICACY AND SAFETY OF CRATAEGUS EXTRACT WS 1442 IN COMPARISON WITH PLACEBO IN PATIENTS WITH CHRONIC STABLE NEW YORK HEART ASSOCIATION CLASS-III HEART FAILURE, AM HEART J, 143, 5, PP. 910-915, (2002); SCHIMIDT U., KUHN U., HUBNER W.D., EFFICACY OF THE HAWTHORN (CRATAEGUS) PREPARATION LI 132 IN 78 PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE DEFINED AS NYHA FUNCTIONAL CLASS II, PHYTOMEDICINE, 1, PP. 17-24, (1994); WEIHMAYR T., ERNST E., THERAPEUTIC EFFECTIVENESS OF CRATAEGUS, FORTSCHR MED, 114, PP. 27-29, (1996); WEIKL A., ASSMUS K.D., NEUKUM-SCHMIDT A., ET AL., CRATAEGUS SPECIAL EXTRACT WS 1442. ASSESSMENT OF OBJECTIVE EFFECTIVENESS IN PATIENTS WITH HEART FAILURE (NYHAIII), FORTSCHR MED, 114, PP. 291-296, (1996); LITTARRU G.P., HO L., FOLKERS K., DEFICIENCY OF COENZYME Q10 IN HUMAN HEART DISEASE: II, INT J VITAM NUTR RES, 42, PP. 413-434, (1972); MORISCO C., TRIMARCO B., CNDORELLI M., EFFECT OF COENZYME Q 10 THERAPY IN PATIENTS WITH CONGESTIVE HEART FAILURE: A LONG-TERM MULTICENTER RANDOMIZED STUDY, CLIN INVESTIG, 71, SUPPL. 8, (1993); LANGSJOEN P.H., LANGSJOEN A.M., OVERVIEW OF THE USE OF COQ10 IN CARDIOVASCULAR DISEASE, BIOFACTORS, 9, 2-4, PP. 273-284, (1999); SUZUKI Y., MASUMURA Y., KOBAYASHI A., ET AL., MYOCARDIAL CARNITINE DEFICIENCY IN CHRONIC HEART FAILURE, LANCET, 1, 8263, (1982); FERRARI R., MERLI E., CICCHITELLI G., ET AL., THERAPEUTIC EFFECTS OF L-CARNITINE AND PROPIONYL-L-CARNITINE ON CARDIOVASCULAR DISEASES: A REVIEW, ANN N Y ACAD SCI, 1033, PP. 79-91, (2004); GUCK T.P., ELSASSER G.N., KAVAN M.G., ET AL., DEPRESSION AND CONGESTIVE HEART FAILURE, CONGEST HEART FAIL, 9, 3, PP. 163-169, (2003); THE SEVENTH REPORT OF THE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE (JNC 7); ROUSE I.L., BEILIN L.J., MAHONEY D.P., ET AL., NUTRIENT INTAKE, BLOOD PRESSURE, SERUM AND URINARY PROSTAGLANDINS AND SERUM THROMBOANE B2 IN A CONTROLLED TRIAL WITH A LACTO-OVO-VEGETARIAN DIET, J HYPERTENS, 4, PP. 241-250, (1986); SACKS F.M., KASS E.H., LOW BLOOD PRESSURE IN VEGETARIANS: EFFECTS OF SPECIFIC FOODS AND NUTRIENTS, AM J CLIN NUTR, 48, PP. 795-800, (1988); REINHART K.M., COLEMAN C.I., TEEVAN C., ET AL., EFFECTS OF GARLIC ON BLOOD PRESSURE IN PATIENTS WITH AND WITHOUT SYSTOLIC HYPERTENSION: A META-ANALYSIS, ANN PHARMACOTHER, 42, 12, PP. 1766-1771, (2008); SILAGY C.A., NEIL H.A., A META-ANALYSIS OF THE EFFECT OF GARLIC ON BLOOD PRESSURE, J HYPERTENS, 12, 4, PP. 463-468, (1994); RIED K., FRANK O.R., STOCKS N.P., ET AL., EFFECT OF GARLIC ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS, BMC CARDIOVASC DISORD, 8, (2008); RAKEL D., INTEGRATIVE MEDICINE, (2007); APPEL L.J., MILLER E.R., SEIDLER A.J., ET AL., DOES SUPPLEMENTATION OF DIET WITH 'FISH OIL' REDUCE BLOOD PRESSURE? A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, ARCH INTERN MED, 153, 12, PP. 1429-1438, (1993); YANG H., KENNY A., THE ROLE OF FISH OIL IN HYPERTENSION, CONN MED, 71, 9, PP. 533-538, (2007); CAPPUCCIO F.P., MACGREGOR G.A., DOES POTASSIUM SUPPLEMENTATION LOWER BLOOD PRESSURE? A META-ANALYSIS OF PUBLISHED TRIALS, J HYPERTENS, 9, 5, PP. 465-473, (1991); DICKINSON H.O., NICOLSON D.J., CAMPBELL F., ET AL., (2006); WHELTON S.P., HYRE A.D., PEDERSEN B., ET AL., EFFECT OF DIETARY FIBER INTAKE ON BLOOD PRESSURE: A META-ANALYSIS OF RANDOMIZED, CONTROLLED CLINICAL TRIALS, J HYPERTENS, 23, 3, PP. 475-481, (2005); ROSENFELDT F., HILTON D., PEPE S., ET AL., SYSTEMATIC REVIEW OF EFFECT OF COENZYME Q10 IN PHYSICAL EXERCISE, HYPERTENSION AND HEART FAILURE, BIOFACTORS, 18, 1-4, PP. 91-100, (2003); TRAN M.D., HOLLY R.G., LASHBROOK J., ET AL., EFFECTS OF HATHA YOGA PRACTICE ON THE HEALTH-RELATED ASPECTS OF PHYSICAL FITNESS, PREV CARDIOL, 4, PP. 165-170, (2001); INNES K.E., BOURGUIGNON C., TAYLOR A.G., RISK INDICES ASSOCIATED WITH THE INSULIN RESISTANCE SYNDROME, CARDIOVASCULAR DISEASE, AND POSSIBLE PROTECTION WITH YOGA: A SYSTEMATIC REVIEW, J AM BOARD FAM PRACT, 18, 6, (2005); ANDERSON J.W., LIU C., KRYSCIO R.J., BLOOD PRESSURE RESPONSE TO TRANSCENDENTAL MEDITATION: A META-ANALYSIS, AM J HYPERTENS, 21, 3, PP. 310-316, (2008); SCHNEIDER R.H., STAGGERS F., ALEXANDER C.N., ET AL., A RANDOMISED CONTROLLED TRIAL OF STRESS REDUCTION FOR HYPERTENSION IN OLDER AFRICAN AMERICANS, HYPERTENSION, 26, 5, PP. 820-827, (1995); SCHNEIDER R.H., ALEXANDER C.N., STAGGERS F., ET AL., A RANDOMIZED CONTROLLED TRIAL OF STRESS REDUCTION IN AFRICAN AMERICANS TREATED FOR HYPERTENSION FOR OVER ONE YEAR, AM J HYPERTENS, 18, 1, PP. 88-98, (2005); FLAA A., EIDE I.K., KJELDSEN S.E., ET AL., SYMPATHOADRENAL STRESS REACTIVITY IS A PREDICTOR OF FUTURE BLOOD PRESSURE: AN 18-YEAR FOLLOW-UP STUDY, HYPERTENSION, 52, 2, PP. 336-341, (2008); DUCHER M., FAUVEL J.P., CERUTTI C., RISK PROFILE IN HYPERTENSION GENESIS: A FIVE-YEAR FOLLOW-UP STUDY, AM J HYPERTENS, 19, 8, PP. 775-780, (2006); RAINFORTH M.V., SCHNEIDER R.H., NIDICH S.I., ET AL., STRESS REDUCTION PROGRAMS IN PATIENTS WITH ELEVATED BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS, CURR HYPERTENS REP, 9, 6, PP. 520-528, (2007); LEE H., KIM S.Y., PARK J., ET AL., ACUPUNCTURE FOR LOWERING BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS, AM J HYPERTENS, 22, 1, PP. 122-128, (2009); WONG N.D., MING S., ZHOU H.Y., ET AL., A COMPARISON OF CHINESE TRADITIONAL AND WESTERN MEDICAL APPROACHES FOR THE TREATMENT OF MILD HYPERTENSION, YALE J BIOL MED, 64, 1, PP. 79-87, (1991); NATIONAL CHOLESTEROL EDUCATION PROGRAM. DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III); NATIONAL CHOLESTEROL EDUCATION PROGRAM. ATP III GUIDELINES AT-A-GLANCE QUICK DESK REFERENCE; GRUNDY S.M., CLEEMAN J.I., BAIREY MERZ C.N., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, PP. 227-239, (2004); FERDOWSIAN H.R., BARNARD N.D., EFFECTS OF PLANT-BASED DIETS ON PLASMA LIPIDS, AM J CARDIOL, 104, 7, PP. 947-956, (2009); KOERTGE J., WEIDNER G., ELLIOTT-ELLER M., ET AL., IMPROVEMENT IN MEDICAL RISK FACTORS AND QUALITY OF LIFE IN WOMEN AND MEN WITH CORONARY ARTERY DISEASE IN THE MULTICENTER LIFESTYLE DEMONSTRATION PROJECT, AM J CARDIOL, 91, PP. 1316-1322, (2003); BANEL D.K., HU F.B., EFFECTS OF WALNUT CONSUMPTION ON BLOOD LIPIDS AND OTHER CARDIOVASCULAR RISK FACTORS: A META-ANALYSIS AND SYSTEMATIC REVIEW, AM J CLIN NUTR, 90, 1, PP. 56-63, (2009); MUKUDDEM-PETERSEN J., OOSTHUIZEN W., JERLING J.C., A SYSTEMATIC REVIEW OF THE EFFECTS OF NUTS ON BLOOD LIPID PROFILES IN HUMANS, J NUTR, 135, 9, PP. 2082-2089, (2005); SLAVIN J.L., POSITION OF THE AMERICAN DIETETIC ASSOCIATION: HEALTH IMPLICATIONS OF DIETARY FIBER, J AM DIET ASSOC, 108, 10, PP. 1716-1731, (2008); KERCKHOFFS D.A., BROUNS F., HORNSTRA G., ET AL., EFFECTS ON THE HUMAN SERUM LIPOPROTEIN PROFILE OF BETA-GLUCAN, SOY PROTEIN AND ISOFLAVONES, PLANT STEROLS AND STANOLS, GARLIC AND TOCOTRIENOLS, J NUTR, 132, 9, PP. 2494-2505, (2002); KHOO Y.S., AZIZ Z., GARLIC SUPPLEMENTATION AND SERUM CHOLESTEROL: A META-ANALYSIS, J CLIN PHARM THER, 34, 2, PP. 133-145, (2009); ALDER R., LOOKINLAND S., BERRY J.A., ET AL., A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF GARLIC AS AN ANTI-HYPERLIPIDEMIC AGENT, J AM ACAD NURSE PRACT, 15, 3, PP. 120-129, (2003); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA. A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN INTERN MED, 133, 6, PP. 420-429, (2000); REINHART K.M., TALATI R., WHITE C.M., ET AL., THE IMPACT OF GARLIC ON LIPID PARAMETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS, NUTR RES REV, 22, 1, PP. 39-48, (2009); KOSEOGLU M., ISLETEN F., ATAY A., ET AL., EFFECTS OF ACUTE AND SUBACUTE GARLIC SUPPLEMENT ADMINISTRATION ON SERUM TOTAL ANTIOXIDANT CAPACITY AND LIPID PARAMETERS IN HEALTHY VOLUNTEERS, PHYTOTHER RES, 24, 3, PP. 374-378, (2010); LIU J., ZHANG J., SHI Y., ET AL., CHINESE RED YEAST RICE (MONASCUS PURPUREUS) FOR PRIMARY HYPERLIPIDEMIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CHIN MED, 1, (2006); BECKER D.J., GORDON R.Y., HALBERT S.C., ET AL., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, 12, PP. 830-839, (2009); BALK E.M., LICHTENSTEIN A.H., CHUNG M., ET AL., EFFECTS OF OMEGA-3 FATTY ACIDS ON SERUM MARKERS OF CARDIOVASCULAR DISEASE RISK: AN SYSTEMATIC REVIEW, ATHEROSCLEROSIS, 189, 1, PP. 19-30, (2006); ABUMWEIS S.S., BARAKE R., JONES P.J., PLANT STEROLS/STANOLS AS CHOLESTEROL LOWERING AGENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, FOOD NUTR RES, (2008); KATAN M.B., GRUNDY S.M., JONES P., ET AL., EFFECTS AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, 8, PP. 965-978, (2003); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS R D, 6, 4, PP. 207-209, (2005); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, 19, PP. 2262-2269, (2006); KASSIS A.N., JONES P.J., LACK OF CHOLESTEROL-LOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 84, 5, PP. 1003-1008, (2006); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); SONTHEIMER D.L., PERIPHERAL VASCULAR DISEASE: DIAGNOSIS AND TREATMENT, AM FAM PHYSICIAN, 73, 11, PP. 1971-1976, (2006); MURABITO J.M., D'AGOSTINO R.B., SILBERSHATZ H., ET AL., INTERMITTENT CLAUDICATION. A RISK PROFILE FROM THE FRAMINGHAM HEART STUDY, CIRCULATION, 96, PP. 44-49, (1997); GARDNER A.W., KATZEL L.I., SORKIN J.D., ET AL., EXERCISE REHABILITATION IMPROVES FUNCTIONAL OUTCOMES AND PERIPHERAL CIRCULATION IN PATIENTS WITH INTERMITTENT CLAUDICATION: A RANDOMIZED CONTROLLED TRIAL, J AM GERIATR SOC, 49, 6, PP. 755-762, (2001); GARDNER A.W., POEHLMAN E.T., EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT OF CLAUDICATION PAIN. A META-ANALYSIS, JAMA, 274, 12, PP. 975-980, (1995); HIATT W.R., CARNITINE AND PERIPHERAL ARTERIAL DISEASE, ANN N Y ACAD SCI, 1033, PP. 92-98, (2004); HORSCH S., WALTHER C., GINKGO BILOBA SPECIAL EXTRACT EGB 761 IN THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAOD): A REVIEW BASED ON RANDOMIZED, CONTROLLED STUDIES, INT J CLIN PHARMACOL THER, 42, 2, PP. 63-72, (2004); PITTLER M.H., ERNST E., GINKGO BILOBA EXTRACT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMIZED TRIALS, AM J MED, 108, 4, PP. 341-342, (2000); RATHBUN S.W., KIRKPATRICK A.C., TREATMENT OF CHRONIC VENOUS INSUFFICIENCY, CURR TREAT OPTIONS CARDIOVASC MED, 9, 2, PP. 115-126, (2007); SUTER A., BOMMER S., RECHNER J., TREATMENT OF PATIENTS WITH VENOUS INSUFFICIENCY WITH FRESH PLANT HORSE CHESTNUT SEED EXTRACT: A REVIEW OF 5 CLINICAL STUDIES, ADV THER, 23, 1, PP. 179-190, (2006); PITTLER M.H., ERNST E., HORSE-CHESTNUT SEED EXTRACT FOR CHRONIC VENOUS INSUFFICIENCY. A CRITERIA-BASED SYSTEMATIC REVIEW, ARCH DERMATOL, 134, PP. 1356-1360, (1998)","C. PRATT; DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE, TULANE UNIVERSITY HEALTH SCIENCE CENTER, SCHOOL OF MEDICINE, NEW ORLEANS, LA 70112, 1430 TULANE AVENUE TB3, UNITED STATES; EMAIL: CPRATT2@TULANE.EDU","","ENGLISH","PRIM. CARE CLIN. OFF. PRACT.","REVIEW","ISI","2-S2.0-77952921256","PRIM CARE CLIN OFF PRACT","TULANE UNIVERSITY HEALTH SCIENCE CENTER","NOTREPORTED;TULANE UNIVERSITY HEALTH SCIENCE CENTER;NOTREPORTED",NA,"PRATT C, 2010, PRIM CARE CLIN OFF PRACT","PRATT C, 2010, PRIM CARE CLIN OFF PRACT"
"DOBESH P;STACY Z;PERSSON E","DOBESH, PAUL P. (6701484199); STACY, ZACHARY A. (12773694200); PERSSON, EMILY L. (36710533600)","PHARMACOLOGIC THERAPY FOR INTERMITTENT CLAUDICATION",2009,"PHARMACOTHERAPY","29","27",14,"10.1592/phco.29.5.526","COLLEGE OF PHARMACY, UNIVERSITY OF NEBRASKA MEDICAL CENTER, OMAHA, NE, UNITED STATES, COLLEGE OF PHARMACY, UNIVERSITY OF NEBRASKA MEDICAL CENTER, 986045 NEBRASKA MEDICAL CENTER, OMAHA, NE 68198-6045, UNITED STATES;ST. LOUIS COLLEGE OF PHARMACY, ST. LOUIS, MISSOURI, UNITED STATES, DEPARTMENT OF PHARMACY, ST. LUKE'S HOSPITAL, CHESTERFIELD, MO, UNITED STATES;COLLEGE OF PHARMACY, UNIVERSITY OF NEBRASKA MEDICAL CENTER, OMAHA, NE, UNITED STATES","PERIPHERAL ARTERY DISEASE, DEFINED AS ATHEROSCLEROSIS IN THE LOWER EXTREMITIES, AFFECTS NEARLY 8.5 MILLION PEOPLE IN THE UNITED STATES. DUE TO THE FREQUENT ASYMPTOMATIC MANIFESTATION OF PERIPHERAL ARTERY DISEASE, DIAGNOSIS MAY BE DELAYED AND ITS TRUE INCIDENCE UNDERESTIMATED. HOWEVER, SOME PATIENTS MAY EXPERIENCE ACHING PAIN, NUMBNESS, WEAKNESS, OR FATIGUE, A CONDITION TERMED INTERMITTENT CLAUDICATION. PERIPHERAL ATHEROSCLEROSIS IS ASSOCIATED WITH CARDIOVASCULAR RISK AND PHYSICAL IMPAIRMENT; THEREFORE, TREATMENT GOALS ARE AIMED AT DECREASING CARDIOVASCULAR RISK, AS WELL AS IMPROVING QUALITY OF LIFE. LITTLE DEBATE EXISTS REGARDING THE MANAGEMENT OF CARDIOVASCULAR RISK REDUCTION, WHICH CONSISTS OF BOTH ANTIPLATELET THERAPY AND RISK FACTOR MODIFICATION. DESPITE RECENTLY PUBLISHED GUIDELINES, THE TREATMENT OF INTERMITTENT CLAUDICATION IS LESS WELL ESTABLISHED AND THE MANAGEMENT REMAINS CONTROVERSIAL AND UNCERTAIN. EXERCISE REMAINS THE FIRST-LINE THERAPY FOR INTERMITTENT CLAUDICATION; HOWEVER, PHARMACOLOGIC TREATMENT IS OFTEN NECESSARY. ALTHOUGH ONLY TWO PRESCRIPTION DRUGS HAVE BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF INTERMITTENT CLAUDICATION, SEVERAL SUPPLEMENTS AND INVESTIGATIONAL AGENTS HAVE BEEN EVALUATED. THERAPEUTIC OPTIMIZATION SHOULD BALANCE THE ANTICIPATED IMPROVEMENTS IN QUALITY OF LIFE WITH THE POTENTIAL SAFETY RISKS.","ANGIOGENESIS.; BUFLOMEDIL; CILOSTAZOL; INTERMITTENT CLAUDICATION; L-ARGININE; NAFTIDROFURYL; PAD; PENTOXIFYLLINE; PERIPHERAL ARTERY DISEASE; PROPIONYL-L-CARNITINE; STATINS","CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUGS, INVESTIGATIONAL; EXERCISE THERAPY; GUIDELINES AS TOPIC; HUMANS; INTERMITTENT CLAUDICATION; META-ANALYSIS AS TOPIC; NAFRONYL; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; PYRROLIDINES; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFLOMEDIL; CARNITINE; CILOSTAZOL; CLOPIDOGREL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOCOSAHEXAENOIC ACID; FIBROBLAST GROWTH FACTOR; FLUNARIZINE; FOLIC ACID; GINKGO BILOBA EXTRACT; HEARTBAR; ICOSAPENTAENOIC ACID; NAFTIDROFURYL; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIPERANOMETOZINE; PLACEBO; POLICOSANOL; PROPIONYLCARNITINE; PROSTAGLANDIN E1; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AFRICAN AMERICAN; AGE; ANGIOGENESIS; ANGIOPLASTY; ANKLE BRACHIAL INDEX; BLEEDING; BRAIN HEMORRHAGE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHELATION THERAPY; CHOLESTEROL BLOOD LEVEL; DELAYED DIAGNOSIS; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC ASPECT; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; INDIGESTION; INSOMNIA; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; LOOSE FECES; LOW DRUG DOSE; NAUSEA; NEUROTOXICITY; NONHUMAN; PAIN; PARESTHESIA; PHYSICAL DISEASE; POLYURIA; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; RACE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; TREADMILL EXERCISE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WALKING; WEAKNESS; WEIGHT REDUCTION","","","BELCH J.J.F., TOPOL E.J., AGNELLI G., ET AL., CRITICAL ISSUES IN PERIPHERAL ARTERIAL DISEASE DETECTION AND MANAGEMENT: A CALL TO ACTION, ARCH INTERN MED, 163, PP. 884-892, (2003); CRIQUI M.H., FRONEK A., BARRETT-CONNOR E., KLAUBER M.R., GABRIEL S., GOODMAN D., THE PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN A DEFINED POPULATION, CIRCULATION, 71, PP. 510-515, (1985); MEIJER W.T., HOES A.W., RUTGERS D., ET AL., PERIPHERAL ARTERIAL DISEASE IN THE ELDERLY: THE ROTTERDAM STUDY, ARTERIOSCLER THROMB VASC BIOL, 18, PP. 185-192, (1998); SELVIN E., ERLINGER T.P., PREVALENCE OF AND RISK FACTORS FOR PERIPHERAL ARTERIAL DISEASE IN THE UNITED STATES: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 1999-2000, CIRCULATION, 110, PP. 738-743, (2004); HIRSCH A.T., CRIQUI M.H., TREAT-JACOBSON D., ET AL., PERIPHERAL ARTERIAL DISEASE DETECTION, AWARENESS, AND TREATMENT IN PRIMARY CARE, JAMA, 286, PP. 1317-1324, (2001); GARCIA L.A., EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE, J ENDOVASC THER, 13, SUPPL. 2, (2006); BERNSTEIN E.F., FRONEK A., CURRENT STATUS OF NON-INVASIVE TESTS IN THE DIAGNOSIS OF PERIPHERAL ARTERIAL DISEASE, SURG CLIN NORTH AM, 62, PP. 473-487, (1982); ROSE G.A., THE DIAGNOSIS OF ISCHAEMIC HEART PAIN AND INTERMITTENT CLAUDICATION IN FIELD SURVEYS, BULL WORLD HEALTH ORGAN, 27, PP. 645-658, (1962); ROSE G., MCCARTNEY P., REID D.D., SELF-ADMINISTRATION OF A QUESTIONNAIRE ON CHEST PAIN AND INTERMITTENT CLAUDICATION, BR J PREV SOC MED, 31, PP. 42-48, (1977); LENG G.C., FOWKES F.G.R., THE EDINBURGH CLAUDICATION QUESTIONNAIRE: AN IMPROVED VERSION OF THE WHO/ROSE QUESTIONNAIRE FOR USE IN EPIDEMIOLOGICAL SURVEYS, J CLIN EPIDEMIOL, 45, PP. 1101-1109, (1992); SMITH G.D., SHIPLEY M.J., ROSE G., INTERMITTENT CLAUDICATION, HEART DISEASE RISK FACTORS, AND MORTALITY: THE WHITEHALL STUDY, CIRCULATION, 82, PP. 1925-1931, (1990); FOWKES F.G., HOUSLEY E., RIEMERSMA R.A., ET AL., SMOKING, LIPIDS, GLUCOSE INTOLERANCE, AND BLOOD PRESSURE AS RISK FACTORS FOR PERIPHERAL ATHEROSCLEROSIS COMPARED WITH ISCHEMIC HEART DISEASE IN THE EDINBURGH ARTERY STUDY, AM J EPIDEMIOL, 135, PP. 331-340, (1992); POWELL J.T., EDWARDS R.J., WORRELL P.C., ET AL., RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF PERIPHERAL ARTERIAL DISEASEIN SMOKERS: A CASE-CONTROL STUDY, ATHEROSCLEROSIS, 129, PP. 41-48, (1997); HIATT W.R., HOAG S., HAMMAN R.F., EFFECT OF DIAGNOSTIC CRITERIA ON THE PREVALENCE OF PERIPHERAL ARTERIAL DISEASE: THE SAN LUIS VALLEY DIABETES STUDY, CIRCULATION, 91, PP. 1472-1479, (1995); CRIQUI M.H., DENENBERG J.O., LANGER R.D., ET AL., THE EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE: IMPORTANCE OF IDENTIFYING THE POPULATION AT RISK, VASC MED, 2, PP. 221-226, (1997); MOST R.S., SINNOCK P., THE EPIDEMIOLOGY OF LOWER EXTREMITY AMPUTATIONS IN DIABETIC INDIVIDUALS, DIABETES CARE, 6, PP. 87-91, (1983); KATSILAMBROS N.L., TSAPOGAS P.C., ARVANITIS M.P., ET AL., RISK FACTORS FOR LOWER EXTREMITY ARTERIAL DISEASE IN NON-INSULINDEPENDENT DIABETIC PERSONS, DIABET MED, 13, PP. 243-246, (1996); INGOLFSSON I.O., SIGURDSSON G., SIGVALDASON H., ET AL., A MARKED DECLINE IN THE PREVALENCE AND INCIDENCE OF INTERMITTENT CLAUDICATION IN ICELANDIC MEN 1968-1986: A STRONG RELATIONSHIP TO SMOKING AND SERUM CHOLESTEROL THE REYKJAVIK STUDY, J CLIN EPIDEMIOL, 47, PP. 1237-1243, (1994); MURABITO J.M., D'AGOSTINO R.B., SILBERSHATZ H., ET AL., INTERMITTENT CLAUDICATION: A RISK PROFILE FROM THE FRAMINGHAM HEART STUDY, CIRCULATION, 96, PP. 44-49, (1997); KANNEL W.B., MCGEE D.L., UPDATE ON SOME EPIDEMIOLOGIC FEATURES OF INTERMITTENT CLAUDICATION: THE FRAMINGHAM STUDY, J AM GERIATR SOC, 33, PP. 13-18, (1985); ROBINSON K., ARHEART K., REFSUM H., ET AL., LOW CIRCULATING FOLATE AND VITAMIN B6 CONCENTRATIONS: RISK FACTORS FOR STROKE, PERIPHERAL VASCULAR DISEASE, AND CORONARY ARTERY DISEASE, CIRCULATION, 97, PP. 437-443, (1998); TAYLOR JR L.M., DEFRANG R.D., HARRIS JR E.J., ET AL., THE ASSOCIATION OF ELEVATED PLASMA HOMOCYST(E)INE WITH PROGRESSION OF SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 13, PP. 128-136, (1991); MOLGAARD J., MALINOW M.R., LASSVIK C., ET AL., HYPERHOMOCYST(E)INAEMIA: AN INDEPENDENT RISK FACTOR FOR INTERMITTENT CLAUDICATION, J INTERN MED, 231, PP. 273-279, (1992); HOOGEVEEN E.K., KOSTENSE P.J., BEKS P.J., ET AL., HYPERHOMOCYSTEINEMIA IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR DISEASE, ESPECIALLY IN NON-INSULIN-DEPENDENT DIABETES MELLITUS: A POPULATION-BASED STUDY, ARTERIOSCLER THROMB VASC BIOL, 18, PP. 133-138, (1998); KANNEL W.B., SKINNER J.J., SCHWARTZ M.J., SHURTLEFF D., INTERMITTENT CLAUDICATION: INCIDENCE IN THE FRAMINGHAM STUDY, CIRCULATION, 41, PP. 875-883, (1970); COLLINS T.C., PETERSON N.J., SUAREZ-ALMAZOR M., ASHTON C.M., THE PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN A RACIALLY DIVERSE POPULATION, ARCH INTERN MED, 163, PP. 1469-1474, (2003); MARGOLIS J., BARRON J.J., GROCHULSKI D., HEALTH CARE RESOURCES AND COSTS FOR TREATING PERIPHERAL ARTERY DISEASE IN A MANAGED CARE POPULATION: RESULTS FROM ANALYSIS OF ADMINISTRATIVE CLAIMS DATA, J MANAG CARE PHARM, 11, PP. 727-734, (2005); MIGLIACCIO-WALLE K., CARO J.J., ISHAK K.J., O'BRIEN J.A., COSTS AND MEDICAL CARE CONSEQUENCES ASSOCIATED WITH THE DIAGNOSIS OF PERIPHERAL ARTERIAL DISEASE, PHARMACOECONOMICS, 23, PP. 733-742, (2005); COLLABORATIVE METAANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION, AND STROKE IN HIGH RISK PATIENTS, BMJ, 324, PP. 71-86, (2002); RODERICK P.J., WILKES H.C., MEADE T.W., THE GASTROINTESTINAL TOXICITY OF ASPIRIN: AN OVERVIEW OF RANDOMISED CONTROLLED TRIALS, BR J CLIN PHARMACOL, 35, PP. 219-226, (1993); A RANDOMISED, BLINDED, TRIAL OF CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHAEMIC EVENTS (CAPRIE), LANCET, 348, PP. 1329-1339, (1996); EFFECT OF INTENSIVE DIABETES MANAGEMENT ON MACROVASCULAR EVENTS AND RISK FACTORS IN THE DIABETES CONTROL AND COMPLICATIONS TRIAL, AM J CARDIOL, 75, PP. 894-903, (1995); THE U.K. PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. INTENSIVE BLOOD-GLUCOSE CONTROL WITH SULPHONYLUREAS OR INSULIN COMPARED WITH CONVENTIONAL TREATMENT AND RISK OF COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES (UKPDS 33), LANCET, 352, PP. 837-853, (1998); YUSUF S., SLEIGHT P., POGUE J., ET AL., EFFECTS OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, RAMIPRIL, ON CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS, N ENGL J MED, 342, PP. 145-153, (2000); RADACK K., DECK C., BETA-ADRENERGIC BLOCKER THERAPY DOES NOT WORSEN INTERMITTENT CLAUDICATION IN SUBJECTS WITH PERIPHERAL ARTERIAL DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, ARCH INTERN MED, 151, PP. 1769-1776, (1991); ROSENDORFF C., BLACK H.R., CANNON C.P., ET AL., TREATMENT OF HYPERTENSION IN THE PREVENTION AND MANAGEMENT OF ISCHEMIC HEART DISEASE: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION COUNCIL FOR HIGH BLOOD PRESSURE RESEARCH AND THE COUNCILS ON CLINICAL CARDIOLOGY AND EPIDEMIOLOGY AND PREVENTION, CIRCULATION, 115, PP. 2761-2788, (2007); MRC/BNF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GARDNER A.W., SKINNER J.S., CANTWELL B.W., SMITH L.K., PROGRESSIVE VERSUS SINGLE-STAGE TREADMILL TESTS FOR THE EVALUATION OF CLAUDICATION, MED SCI SPORTS EXER, 23, PP. 402-408, (1991); CHAUDHARY H., HOLLAND A., DORMANDY J., COMPARISON OF GRADED VERSUS CONSTANT TREADMILL TEST PROTOCOLS FOR QUANTIFYING INTERMITTENT CLAUDICATION, VASC MED, 2, PP. 93-97, (1997); REICH T., GILLINGS D., EFFECTS OF PENTOXIFYLLINE ON SEVERE INTERMITTENT CLAUDICATION, ANGIOLOGY, 38, PP. 651-656, (1987); SPITZER S., BACH R., SCHIEFFER H., WALK TRAINING AND DRUG TREATMENT IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE STAGE II: A REVIEW, INT ANGIOL, 11, PP. 204-210, (1992); BARLETTA G., PERNA S., SABBA C., CATALANO A., O'BOYLE C., BREVETTI G., QUALITY OF LIFE IN PATIENTS WITH INTERMITTENT CLAUDICATION: RELATIONSHIP WITH LABORATORY EXERCISE PERFORMANCE, VASC MED, 1, PP. 3-7, (1996); BREEK J.C., HAMMING J.F., DE VRIES J., AQUARIUS A.D., VAN BERGE HENEGOUWEN D.P., QUALITY OF LIFE IN PATIENTS WITH INTERMITTENT CLAUDICATION USING THE WORLD HEALTH ORGANIZATION (WHO) QUESTIONNAIRE, EUR J VASC ENDOVASC SURG, 21, PP. 118-122, (2001); REGENSTEINER J.G., STEINER J.F., PANZER R.J., HIATT W.R., EVALUATION OF WALKING IMPAIRMENT BY QUESTIONNAIRE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, J VASC MED BIOL, 2, PP. 142-152, (1990); REGENSTEINER J.G., STEINER J.F., HIATT W.R., EXERCISE TRAINING IMPROVES FUNCTIONAL STATUS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 23, PP. 104-115, (1996); COYNE K.S., MARGOLIS M.K., GILCHRIST K.A., ET AL., EVALUATING EFFECTS OF METHODS OF ADMINISTRATION ON WALKING IMPAIRMENT QUESTIONNAIRE, J VASC SURG, 38, PP. 296-304, (2003); HIATT W.R., WOLFEL E.E., REGENSTEINER J.G., BRASS E.P., SKELETAL MUSCLE CARNITINE METABOLISM IN PATIENTS WITH UNILATERAL PERIPHERAL ARTERIAL DISEASE, J APPL PHYSIOL, 73, PP. 346-353, (1992); MCDERMOTT M.M., LIU K., GURALNIK J.M., MARTIN G.J., CRIQUI M.H., GREENLAND P., MEASUREMENT OF WALKING ENDURANCE AND WALKING VELOCITY WITH QUESTIONNAIRE: VALIDATION OF THE WALKING IMPAIRMENT QUESTIONNAIRE IN MEN AND WOMEN WITH PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 28, PP. 1072-1081, (1998); SCHIANO V., BREVETTI G., SIRICO G., SILVESTRO A., GIUGLIANO G., CHIARIELLO M., FUNCTIONAL STATUS MEASURED BY WALKING IMPAIRMENT QUESTIONNAIRE AND CARDIOVASCULAR RISK PREDICTION IN PERIPHERAL ARTERIAL DISEASE: RESULTS OF THE PERIPHERAL ARTERIOPATHY AND CARDIOVASCULAR EVENTS (PACE) STUDY, VASC MED, 11, PP. 147-154, (2006); WARE J.E., SNOW K.K., KOSINSKI M., GANDEK B., SF-36 HEALTH SURVEY: MANUAL AND INTERPRETATION GUIDE, (1993); STEWART A.L., GREENFIELD S., HAYS R.D., ET AL., FUNCTIONAL STATUS AND WELL-BEING OF PATIENTS WITH CHRONIC CONDITIONS; RESULTS FROM THE MEDICAL OUTCOMES STUDY, JAMA, 262, PP. 907-913, (1989); TARLOV A.R., WARE J.E., GREENFIELD S., NELSON E.C., PERRIN E., ZUBKOFF M., THE MEDICAL OUTCOMES STUDY: AN APPLICATION OF METHODS FOR MONITORING THE RESULTS OF MEDICAL CARE, JAMA, 262, PP. 925-930, (1989); WARE JR J.E., KOSINSKI M., BAYLISS M.S., ET AL., COMPARISON OF METHODS FOR THE SCORING AND STATISTICAL ANALYSIS OF SF-36 HEALTH PROFILE AND SUMMARY MEASURES: SUMMARY OF RESULTS FROM THE MEDICAL OUTCOMES STUDY, MED CARE, 33, (1995); IZQUIERDO-PORRERA A.M., GARDNER A.W., BRADHAM D.D., ET AL., RELATIONSHIP BETWEEN OBJECTIVE MEASURES OF PERIPHERAL ARTERIAL DISEASE SEVERITY TO SELF-REPORTED QUALITY OF LIFE IN OLDER ADULTS WITH INTERMITTENT CLAUDICATION, J VASC SURG, 41, PP. 625-630, (2005); ERNST E., PHYSICAL EXERCISE FOR PERIPHERAL VASCULAR DISEASE: A REVIEW, VASA, 16, PP. 227-231, (1982); ERNST E.W., MATRAI A., INTERMITTENT CLAUDICATION, EXERCISE AND BLOOD RHEOLOGY, CIRCULATION, 76, PP. 1110-1114, (1987); RUELL P.A., IMPERIAL E.S., BONAR F.J., THURSBY P.F., GRASS G.C., INTERMITTENT CLAUDICATION: THE EFFECT OF PHYSICAL TRAINING ON WALKING TOLERANCE AND VENOUS LACTATE CONCENTRATION, EUR J APPL PHYSIOL, 52, PP. 420-425, (1984); HIATT W.R., REGENSTEINER J.G., HARGARTEN M.E., WOLFEL E.E., BRASS E.P., BENEFIT OF EXERCISE CONDITIONING FOR PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 81, PP. 602-609, (1990); HIATT W.R., WOLFEL E.E., MEIER R.H., REGENSTEINER J.G., SUPERIORITY OF TREADMILL WALKING EXERCISE VERSUS STRENGTH TRAINING FOR PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 90, PP. 1866-1874, (1994); TISI P.V., HULSE M., CHULAKADABBA A., GOSLING P., SHEARMAN C.P., EXERCISE TRAINING FOR INTERMITTENT CLAUDICATION: DOES IT ADVERSELY AFFECT BIOCHEMICAL MARKERS OF THE EXERCISE-INDUCED INFLAMMATORY RESPONSE?, EUR J VASC ENDOVASC SURG, 14, PP. 344-350, (1997); CROWTHER R.G., SPINKS W.L., LEICHT A.S., SANGLA K., QUIGLEY F., GOLLEDGE J., EFFECTS OF A LONG-TERM EXERCISE PROGRAM ON LOWER LIMB MOBILITY, PHYSIOLOGICAL RESPONSES, WALKING PERFORMANCE, AND PHYSICAL ACTIVITY LEVELS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 47, PP. 303-309, (2008); LARSEN O.A., LASSEN N.A., EFFECT OF DAILY MUSCLE EXERCISE IN PATIENTS WITH INTERMITTENT CLAUDICATION, LANCET, 2, PP. 1093-1095, (1966); HOLM J., DAHLLOF A.G., BJORNTORP P., SCHERSTEN T., ENZYME STUDIES IN MUSCLES OF PATIENTS WITH INTERMITTENT CLAUDICATION: EFFECT OF TRAINING, SCAN J CLIN LAB INVEST, 31, SUPPL. 128, PP. 201-205, (1973); DAHLLOF A.-G., BJORNTORP P., HOLM J., SCHERSTEN T., METABOLIC ACTIVITY OF SKELETAL MUSCLE IN PATIENTS WITH PERIPHERAL ARTERIAL INSUFFICIENCY, EUR J CLIN INVEST, 4, PP. 9-15, (1974); GARDNER A.W., POEHLMAN E.T., EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT OF CLAUDICATION PAIN: A META-ANALYSIS, JAMA, 274, PP. 975-980, (1995); LENG G.C., FOWLER B., ERNST E., EXERCISE FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 2, (2000); HALPERIN J.L., FUSTER V., MEETING THE CHALLENGE OF PERIPHERAL ARTERIAL DISEASE, ARCH INTERN MED, 163, PP. 877-878, (2003); TREESAK C., KASEMSUP V., TREAT-JACOBSON D., NYMAN J.A., HIRSCH A.T., COST-EFFECTIVENESS OF EXERCISE TRAINING TO IMPROVE CLAUDICATION SYMPTOMS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, VASC MED, 9, PP. 279-285, (2004); NORGREN L., HIATT W.R., DORMANDY J.A., NEHLER M.R., HARRIS K.A., FOWKERS F.G.R., ON BEHALF OF THE TASC II WORKING GROUP. INTER-SOCIETY CONSENSUS FOR THE MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (TASC II), J VASC SURG, 45, SUPPL. S, (2007); AVIADO D.M., DETTELBACH H.R., PHARMACOLOGY OF PENTOXIFYLLINE: A HEMORHEOLOGIC AGENT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 35, PP. 407-417, (1984); BAKER D.E., CAMPBELL R.K., PENTOXIFYLLINE: A NEW AGENT FOR INTERMITTENT CLAUDICATION, DRUG INTELL CLIN PHARM, 19, PP. 345-348, (1985); SAMLASKA C.P., WINFIELD E.A., PENTOXIFYLLINE, J AM ACAD DERMATOL, 30, PP. 603-621, (1994); HIATT W.R., MEDICAL TREATMENT OF PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, N ENGL J MED, 344, PP. 1608-1621, (2001); SCHROER R., ANTITHROMBOTIC POTENTIAL OF PENTOXIFYLLINE, A HEMORHEOLOGICALLY ACTIVE DRUG, ANGIOLOGY, 36, PP. 387-398, (1985); AMBRUS J.L., AMBRUS C.M., TAHERI S.A., ET AL., RED CELL FLEXIBILITY AND PLATELET AGGREGATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE VASCULAR DISEASES AND STUDY OF THERAPEUTIC APPROACHES, ANGIOLOGY, 35, PP. 418-426, (1984); ANGELKORT B., SPURK P., HABBABA A., MAHDER M., BLOOD FLOW PROPERTIES AND WALKING PERFORMANCE IN CHRONIC ARTERIAL OCCLUSIVE DISEASE, ANGIOLOGY, 36, PP. 285-292, (1985); BOLLINGER A., FREI C., DOUBLE-BLIND STUDY OF PENTOXIFYLLINE AGAINST PLACEBO IN PATIENTS WITH INTERMITTENT CLAUDICATION, PHARMATHERAPEUTICA, 1, PP. 557-562, (1977); PORTER J.M., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE EFFICACY IN THE TREATMENT OF INTERMITTENT CLAUDICATION: MULTICENTER CONTROLLED DOUBLE-BLIND TRIAL WITH OBJECTIVE ASSESSMENT OF CHRONIC OCCLUSIVE ARTERIAL DISEASE PATIENTS, AM HEART J, 104, PP. 66-72, (1982); DI PERRI T., GUERRINI M., PLACEBO-CONTROLLED DOUBLE-BLIND STUDY WITH PENTOXIFYLLINE OF WALKING PERFORMANCE IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 34, PP. 40-45, (1983); PERHONIEMI V., SALMENKIVI K., SUNDBERG S., JOHNSON R., GORDIN H., EFFECTS OF FLUNARIZINE AND PENTOXIFYLLINE ON WALKING DISTANCE AND BLOOD RHEOLOGY IN CLAUDICATION, ANGIOLOGY, 35, PP. 366-372, (1984); DONALDSON D.R., HALL T.J., KESTER R.C., RAMSDEN C.W., WIGGINS P.A., DOES OXPENTIFYLLINE ('TRENTAL') HAVE A PLACE IN THE TREATMENT OF INTERMITTENT CLAUDICATION?, CURR MED RES OPIN, 9, PP. 35-40, (1984); STRANO A., DAVI G., AVELLONE G., NOVO S., PINTO A., DOUBLEBLIND, CROSSOVER STUDY OF THE CLINICAL EFFICACY AND THE HEMORHEOLOGICAL EFFECTS OF PENTOXIFYLLINE IN PATIENTS WITH OCCLUSIVE ARTERIAL DISEASE OF THE LOWER LIMBS, ANGIOLOGY, 35, PP. 459-466, (1984); GALLUS A.S., GLEADOW F., DUPONT P., ET AL., INTERMITTENT CLAUDICATION: A DOUBLE-BLIND CROSSOVER TRIAL OF PENTOXIFYLLINE, AUST NZ J MED, 15, PP. 402-409, (1985); LINDGARDE F., JELNES R., BJORKMAN H., ET AL., CONSERVATIVE DRUG TREATMENT IN PATIENTS WITH MODERATELY SEVERE CHRONIC OCCLUSIVE PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 80, PP. 1549-1556, (1989); DETTORI A.G., PINI M., MORATTI A., ET AL., ACENOCOUMAROL ANDPENTOXIFYLLINE IN INTERMITTENT CLAUDICATION: A CONTROLLED CLINICAL STUDY, ANGIOLOGY, 40, PP. 237-248, (1989); ERNST E., KOLLAR L., RESCH K.L., DOES PENTOXIFYLLINE PROLONG WALKING DISTANCE IN EXERCISED CLAUDICANTS? A PLACEBOCONTROLLED DOUBLE-BLIND TRIAL, ANGIOLOGY, 43, PP. 121-125, (1992); DAWSON D.L., CUTLER B.S., HIATT W.R., ET AL., A COMPARISON OF CILOSTAZOL AND PENTOXIFYLLINE FOR TREATING INTERMITTENT CLAUDICATION, AM J MED, 109, PP. 523-530, (2000); CESARONE M.R., BELCARO G., NICOLAIDES A.N., ET AL., TREATMENT OF SEVERE INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: A 40-WEEK, CONTROLLED, RANDOMIZED TRIAL, ANGIOLOGY, 53, SUPPL. 1, (2002); DE SANCTIS M.T., CESARONE M.R., BELCARO G., ET AL., TREATMENT OF LONG-DISTANCE INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: A 12-MONTH, RANDOMIZED TRIAL, ANGIOLOGY, 53, SUPPL. 1, (2002); HOOD S.C., MOHER D., BARBER G.G., MANAGEMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CAN MED ASSOC J, 155, PP. 1053-1059, (1996); GIROLAMI B., BERNARDI E., PRINS M.H., ET AL., TREATMENT OF INTERMITTENT CLAUDICATION WITH PHYSICAL TRAINING, SMOKING CESSATION, PENTOXIFYLLINE, OR NAFRONYL: A META-ANALYSIS, ARCH INTERN MED, 159, PP. 337-345, (1999); RADACK K., WYDERSKI R.J., CONSERVATIVE MANAGEMENT OF INTERMITTENT CLAUDICATION, ANN INTERN MED, 113, PP. 135-146, (1990); ERNST E., PENTOXIFYLLINE FOR INTERMITTENT CLAUDICATION: A CRITICAL REVIEW, ANGIOLOGY, 45, PP. 339-345, (1994); JACOBY D., MOHLER III E.R., DRUG TREATMENT OF INTERMITTENT CLAUDICATION, DRUGS, 64, PP. 1657-1670, (2004); DAWSON D.L., CUTLER B.S., MEISSNER M.H., STRANDNESS JR. E., CILOSTAZOL HAS BENEFICIAL EFFECTS IN TREATMENT OF INTERMITTENT CLAUDICATION: RESULTS FROM A MULTICENTER, RANDOMIZED, PROSPECTIVE, DOUBLE-BLIND TRIAL, CIRCULATION, 98, PP. 678-686, (1998); ELAM M.B., HECKMAN J.R., COURSE D.B., ET AL., EFFECTS OF THE NOVEL ANTIPLATELET AGENT CILOSTAZOL ON PLASMA LIPOPROTEINS IN PATIENTS WITH INTERMITTENT CLAUDICATION, ARTERIOSCLER THROMB VASC BIOL, 18, PP. 1942-1947, (1998); MONEY S.R., HERD J.A., ISAACSOHN J.L., ET AL., EFFECT OF CILOSTAZOL ON WALKING DISTANCE IN PATIENTS WITH INTERMITTENT CLAUDICATION, J VASC SURG, 27, PP. 267-275, (1998); BEEBE H.G., DAWSON D.L., CUTLER B.S., ET AL., A NEW PHARMACOLOGICAL TREATMENT FOR INTERMITTENT CLAUDICATION: RESULTS OF A RANDOMIZED, MULTICENTER TRIAL, ARCH INTERN MED, 159, PP. 2041-2050, (1999); STANDNESS JR D.E., DALMAN R.L., PANIAN S., ET AL., EFFECT OF CILOSTAZOL IN PATIENTS WITH INTERMITTENT CLAUDICATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, VASC ENDOVASC SURG, 36, PP. 83-91, (2002); THOMPSON P.D., ZIMET R., FORBES W.P., ZHANG P., META-ANALYSIS OF RESULTS FROM EIGHT RANDOMIZED, PLACEBO-CONTROLLED TRIALS ON THE EFFECT OF CILOSTAZOL ON PATIENTS WITH INTERMITTENT CLAUDICATION, AM J CARDIOL, 90, PP. 1314-1319, (2002); ROBLESS P., MIKHAILIDIS D.P., STANSBY G.P., CILOSTAZOL FOR PERIPHERAL ARTERIAL DISEASE, COCHRANE DATABASE SYST REV, 1, (2007); REGENSTEINER J.G., WARE JR J.E., MCCARTHY W.J., ET AL., EFFECT OF CILOSTAZOL ON TREADMILL WALKING, COMMUNITY-BASED WALKING ABILITY, AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH INTERMITTENT CLAUDICATION DUE TO PERIPHERAL ARTERIAL DISEASE: A META-ANALYSIS OF SIX RANDOMIZED CONTROLLED TRIALS, J AM GERIATR SOC, 50, PP. 1939-1946, (2002); TAMAI Y., TAKAMI H., NAKAHATA R., ONO F., MUNAKATA A., COMPARISON OF THE EFFECTS OF ACETYLSALICYLIC ACID, TICLOPIDINE AND CILOSTAZOL ON PRIMARY HEMOSTASIS USING A QUANTITATIVE BLEEDING TIME TEST APPARATUS, HAEMOSTASIS, 29, PP. 269-276, (1999); WILHITE D.B., COMEROTA A.J., SCHMIEDER F.A., ET AL., MANAGING PAD WITH MULTIPLE PLATELET INHIBITORS: THE EFFECT OF COMBINATION THERAPY ON BLEEDING TIME, J VASC SURG, 38, PP. 710-713, (2003); HIATT W.R., THE U.S. EXPERIENCE WITH CILOSTAZOL IN TREATING INTERMITTENT CLAUDICATION, ATHEROSCLER SUPPL, 6, PP. 21-31, (2006); PRATT C.M., ANALYSIS OF THE CILOSTAZOL SAFETY DATABASE, AM J CARDIOL, 87, SUPPL., (2001); ABBAS R., CHOW C.P., BROWDER N.J., ET AL., IN VITRO METABOLISM AND INTERACTION OF CILOSTAZOL WITH HUMAN HEPATIC CYTOCHROME P450 ISOFORMS, HUM EXP TOXICOL, 19, PP. 178-184, (2000); PACKER M., CARVER J.R., RODEHEFFER R.J., ET AL., EFFECT OF ORAL MILRINONE ON MORTALITY IN SEVERE CHRONIC HEART FAILURE, N ENGL J MED, 325, PP. 1468-1475, (1991); FELDMAN A.M., BRISTOW M.R., PARMLEY W.W., ET AL., EFFECTS OF VESNARINONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART FAILURE, N ENGL J MED, 329, PP. 149-155, (1993); CONE J., WANG S., TANDON N., ET AL., COMPARISON OF THE EFFECTS OF CILOSTAZOL AND MILRINONE ON INTRACELLULAR CAMP LEVELS AND CELLULAR FUNCTION IN PLATELETS AND CARDIAC CELLS, J CARDIOVASC PHARMACOL, 34, PP. 497-504, (1999); HIATT W.R., MONEY S.R., BRASS E.P., LONG-TERM SAFETY OF CILOSTAZOL IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: THE CASTLE STUDY (CILOSTAZOL: A STUDY IN LONG-TERM EFFECTS), J VASC SURG, 47, PP. 330-336, (2008); PASTORIS O., DOSSENA M., GORINI A., ET AL., ADAPTATION OF SKELETAL MUSCLE ENERGY METABOLISM TO REPEATED HYPOXIC-NORMOXIC EXPOSURES AND DRUG TREATMENT, ARCH INT PHARMACODYN THER, 274, PP. 145-158, (1985); BARRADELL L.B., BROGDEN R.N., ORAL NAFTIDROFURYL: A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN THE MANAGEMENT OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE, DRUGS AGING, 8, PP. 299-322, (1996); CLYNE C.A.C., GALLAND R.B., FOX M.J., GUSTAVE R., JANTET G.H., JAMIESON C.W., A CONTROLLED TRIAL OF NAFTIDROFURYL (PRAXILENE) IN THE TREATMENT OF INTERMITTENT CLAUDICATION, BR J SURG, 67, PP. 347-348, (1980); TRUBESTEIN G., BOHME H., HEIDRICH H., ET AL., NAFTIDROFURYL IN CHRONIC ARTERIAL DISEASE: RESULTS OF A CONTROLLED MULTICENTER STUDY, ANGIOLOGY, 35, PP. 701-708, (1984); ADHOUTE G., BACOURT F., BARRAL M., ET AL., NAFTIDROFURYL IN CHRONIC ARTERIAL DISEASE: RESULTS OF A SIX-MONTH CONTROLLED MULTICENTER STUDY USING NAFTIDROFURYL TABLETS 200 MG, ANGIOLOGY, 37, 3 PART 1, PP. 160-167, (1986); ADHOUTE G., ANDREASSIAN B., BOCCALON H., ET AL., TREATMENT OF STAGE II CHRONIC ARTERIAL DISEASE OF THE LOWER LIMBS WITH THE SEROTONERGIC ANTAGONIST NAFTIDROFURYL: RESULTS AFTER 6 MONTHS OF A CONTROLLED, MULTICENTER STUDY, J CARDIOVASC PHARMACOL, 16, SUPPL. 3, (1990); MOODY A.P., AL-KHAFFAF H.S., LEHERT P., HARRIS P.L., CHARLESWORTH D., AN EVALUATION OF PATIENTS WITH SEVERE INTERMITTENT CLAUDICATION AND THE EFFECT OF TREATMENT WITH NAFTIDROFURYL, J CARDIOVASC PHARMACOL, 23, SUPPL. 3, (1994); LEHERT P., RIPHAGEN F.E., GAMAND S., THE EFFECT OF NAFTIDROFURYL ON INTERMITTENT CLAUDICATION: A META-ANALYSIS, J CARDIOVASC PHARMACOL, 16, SUPPL. 3, (1990); TRUBESTEIN G., BALZER K., BISLER H., ET AL., BUFLOMEDIL IN ARTERIAL OCCLUSIVE DISEASE: RESULTS OF A CONTROLLED MULTICENTER STUDY, ANGIOLOGY, 35, PP. 500-505, (1984); DIAMANTOPOULOS E.J., GRIGORIADOU M., IFANTI G., RAPTIS S.A., CLINICAL AND HEMORHEOLOGICAL EFFECTS OF BUFLOMEDIL IN DIABETIC SUBJECTS WITH INTERMITTENT CLAUDICATION, INT ANGIOL, 20, PP. 337-344, (2001); DE BACKER T.L.M., BOGAERT M., VANDER STICHELE R., BUFLOMEDIL FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 2008, 1; MARIMBERT J., LETTRE AUX PROFESSIONNELS DE SANTÉ PHARMACOVIGILANCEC ET LA SÉURITÉ D'EMPLOI DU BUFLOMÉIL LETTER TO HEALTH PROFESSIONALS: PHARMACOVIGILANCE AND SAFETY OF USE OF BUFLOMEDIL, SAINT-DENIS, (2006); LEIZOROVICZ A., BECKER F., STUDY GROUP. ORAL BUFLOMEDIL IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE: A RANDOMIZED, PLACEBOCONTROLLED, 4-YEAR STUDY, CIRCULATION, 117, PP. 816-822, (2008); CITRIC ACID CYCLE, BIOCHEMISTRY, PP. 365-390, (1995); BREVETTI G., PERNA S., SABBA C., ET AL., SUPERIORITY OF LPROPIONYLCARNITINE VERSUS L-CARNITINE IN IMPROVING WALKING CAPACITY IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE: AN ACUTE, INTRAVENOUS, DOUBLE-BLIND, CROSS-OVER STUDY, EURO HEART J, 13, PP. 251-255, (1992); HIATT W.R., CARNITINE AND PERIPHERAL ARTERIAL DISEASE, ANN NY ACAD SCI, 1033, PP. 92-98, (2004); TASSANI V., CATTAPAN F., MAGNANIMI L., PESCHECHERA A., ANAPLEROTIC EFFECT OF PROPIONYL CARNITINE IN RAT HEART MITOCHONDRIA, BIOCHEM BIOPHYS RES COMMUN, 199, PP. 949-953, (1994); BREVETTI G., CHIARIELLO M., FERULANO G., ET AL., INCREASES IN WALKING DISTANCE IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE TREATED WITH L-CARNITINE: A DOUBLE-BLIND, CROSS-OVER STUDY, CIRCULATION, 77, PP. 767-773, (1988); BREVETTI G., PERNA S., SABBA C., MARTONE V.D., CONDORELLI M., PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION: DOUBLEBLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTICENTER TRIAL, J AM COLL CARDIOL, 26, PP. 1411-1416, (1995); BREVETTI G., PERNA S., SABBA C., MARTONE V.D., DI IORIO A., BARLETTA G., EFFECT OF PROPIONYL-L-CARNITINE ON QUALITY OF LIFE IN INTERMITTENT CLAUDICATION, AM J CARDIOL, 79, PP. 777-780, (1997); BREVETTI G., DIEHM C., LAMBERT D., EUROPEAN MULTICENTER STUDY ON PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION, J AM COLL CARDIOL, 34, PP. 1618-1624, (1999); HIATT W.R., REGENSTEINER J.G., CREAGER M.A., ET AL., PROPIONYL-LCARNITINE IMPROVES EXERCISE PERFORMANCE AND FUNCTIONAL STATUS IN PATIENTS WITH CLAUDICATION, AM J MED, 110, PP. 616-622, (2001); BOGER R.H., BODE-BOGER S.M., THIELE W., ET AL., RESTORING VASCULAR NITRIC OXIDE FORMATION BY L-ARGININE IMPROVES THE SYMPTOMS OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, J AM COLL CARDIOL, 32, PP. 1336-1344, (1998); MAXWELL A.J., ANDERSON B.E., COOKE J.P., NUTRITIONAL THERAPY FOR PERIPHERAL ARTERIAL DISEASE: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF HEARTBAR, VASC MED, 5, PP. 11-19, (2000); WILSON A.M., HARADA R., NAIR N., BALASUBRAMANIAN N., COOKE J.P., L-ARGININE SUPPLEMENTATION IN PERIPHERAL ARTERIAL DISEASE: NO BENEFIT AND POSSIBLE HARM, CIRCULATION, 116, PP. 188-195, (2007); BOGER R., BODE-BOGER S., THIELE W., JUNKER W., ALEXANDER K., FROLICH J., BIOCHEMICAL EVIDENCE FOR IMPAIRED NITRIC OXIDE SYNTHESIS IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, CIRCULATION, 95, PP. 2068-2074, (1997); PITTLER M.H., ERNST E., COMPLEMENTARY THERAPIES FOR PERIPHERAL ARTERIAL DISEASE: SYSTEMATIC REVIEW, ATHEROSCLEROSIS, 181, PP. 1-7, (2005); GUINOT P., CAFFREY D., LAMBE R., DARRAGH A., TANAKAN INHIBITS PLATELET-ACTIVATING-FACTOR-INDUCED PLATELET AGGREGATION IN HEALTHY MALE VOLUNTEERS, HAEMOSTASIS, 19, PP. 219-223, (1989); MAHADY G.B., GINKGO BILOBA FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE: A REVIEW OF THE LITERATURE, J CARDIOVASC NURS, 16, PP. 21-32, (2002); PITTLER M.H., ERNST E., GINKGO BILOBA EXTRACT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMIZED TRIALS, AM J MED, 108, PP. 276-281, (2000); HORSCH S., WALTHER C., GINKGO BILOBA SPECIAL EXTRACT EGB761 IN THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAOD): A REVIEW BASED ON RANDOMIZED, CONTROLLED STUDIES, INT J CLIN PHARMACOL THER, 42, PP. 63-72, (2004); ERNST E., PITTLER M.H., ALTERNATIVE THERAPY BIAS ONLINE EXCLUSIVE ARTICLE, NATURE, 385, (1997); COELHO H.F., PITTLER M.H., ERNST E., AN INVESTIGATION OF THE CONTENTS OF COMPLEMENTARY AND ALTERNATIVE MEDICINE JOURNALS, ALTERN THER HEALTH MED, 13, PP. 40-44, (2007); POLICOSANOL P.J., AM J HEALTH-SYST PHARM, 60, PP. 1112-1114, (2003); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AM J CLIN NUTR, 84, PP. 1543-1548, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ J.C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., GAMEZ R., FERNANDEZ L., ILLNAIT J., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2004); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES, 59, PP. 717-722, (1998); BOYD A.M., MARKS J., TREATMENT OF INTERMITTENT CLAUDICATION: A REAPPRAISAL OF ALPHA-TOCOPHEROL, ANGIOLOGY, 14, PP. 198-208, (1963); HAMILTON M., WILSON G.M., ARMITAGE P., BOYD J.T., THE TREATMENT OF INTERMITTENT CLAUDICATION WITH VITAMIN E, LANCET, 1, PP. 367-370, (1953); LIVINGSTONE P.D., JONES C., TREATMENT OF INTERMITTENT CLAUDICATION WITH VITAMIN E, LANCET, 2, PP. 602-604, (1958); WILLIAMS H.T.G., CLEIN L.J., MACBETH R.A., ALPHA-TOCOPHEROL IN THE TREATMENT OF INTERMITTENT CLAUDICATION: A PRELIMINARY REPORT, CAN MED ASSOC J, 87, PP. 538-541, (1962); TORNWALL M.E., VIRTAMO J., HAUKKA J.K., ET AL., THE EFFECT OF ALPHA-TOCOPHEROL AND BETA-CAROTENE SUPPLEMENTATION ON SYMPTOMS AND PROGRESSION OF INTERMITTENT CLAUDICATION IN A CONTROLLED TRIAL, ATHEROSCLEROSIS, 147, PP. 193-197, (1999); KLEIJNEN J., MACKERRAS D., VITAMIN E FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 1998, 1; KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE, CIRCULATION, 106, PP. 2747-2757, (2002); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEINS: HUMAN STUDIES, AM J CLIN NUTR, 65, 5 SUPPL., (1997); MORRIS M.C., SACKS F., ROSNER B., DOES FISH OIL LOWER BLOOD PRESSURE? A META-ANALYSIS OF CONTROLLED TRIALS, CIRCULATION, 88, PP. 523-533, (1993); APPEL L.J., MILLER E.R., SEIDLER A.J., ET AL., DOES SUPPLEMENTATION OF DIET WITH 'FISH OIL' REDUCE BLOOD PRESSURE? A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, ARCH INTERN MED, 153, PP. 1429-1438, (1993); BARCELLI U., GLAS-GREENWALT P., POLLAK V.E., ENHANCING EFFECT OF DIETARY SUPPLEMENTATION WITH OMEGA-3 FATTY ACIDS ON PLASMA FIBRINOLYSIS IN NORMAL SUBJECTS, THROMB RES, 39, PP. 307-312, (1985); AGREN J.J., VAISANEN S., HANNINEN O., ET AL., HEMOSTATIC FACTORS AND PLATELET AGGREGATION AFTER A FISH-ENRICHED DIET OR FISH OIL OR DOCOSAHEXAENOIC ACID SUPPLEMENTATION, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 57, PP. 419-421, (1997); SOMMERFIELD T., PRICE J., HIATT W.R., OMEGA-3 FATTY ACIDS FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 4, (2007); WOODCOCK B.E., SMITH E., LAMBERT W.H., ET AL., BENEFICIAL EFFECT OF FISH OIL ON BLOOD VISCOSITY IN PERIPHERAL VASCULAR DISEASE, BR MED J (CLIN RES ED), 288, PP. 592-594, (1984); GANS R.O., BILO H.J., WEERSINK E.G., ET AL., FISH OIL SUPPLEMENTATION IN PATIENTS WITH STABLE CLAUDICATION, AM J SURG, 160, PP. 490-495, (1990); PEDERSEN T.R., KJEKSHUS J., PYORALA K., ET AL., EFFECT OF SIMVASTATIN ON ISCHEMIC SIGNS AND SYMPTOMS IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), AM J CARDIOL, 81, PP. 333-335, (1998); MONDILLO S., BALLO P., BARBATI R., ET AL., EFFECTS OF SIMVASTATIN ON WALKING PERFORMANCE AND SYMPTOMS OF INTERMITTENT CLAUDICATION IN HYPERCHOLESTEROLEMIC PATIENTS WITH PERIPHERAL VASCULAR DISEASE, AM J MED, 114, PP. 359-364, (2003); ARONOW W.S., NAYAK D., WOODWORTH S., AHN C., EFFECT OF SIMVASTATIN VERSUS PLACEBO ON TREADMILL EXERCISE TIME UNTIL THE ONSET OF INTERMITTENT CLAUDICATION IN OLDER PATIENTS WITH PERIPHERAL ARTERIAL DISEASE AT SIX MONTHS AND AT ONE YEAR AFTER TREATMENT, AM J CARDIOL, 92, PP. 711-712, (2003); MOHLER III E.R., HIATT W.R., CREAGER M.A., CHOLESTEROL REDUCTION WITH ATORVASTATIN IMPROVES WALKING DISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 108, PP. 1481-1486, (2003); MCDERMOTT M.M., GURALNIK J.M., GREENLAND P., ET AL., STATIN USE AND LEG FUNCTIONING IN PATIENTS WITH AND WITHOUT LOWEREXTREMITY PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 107, PP. 757-761, (2003)","P. P. DOBESH; COLLEGE OF PHARMACY, UNIVERSITY OF NEBRASKA MEDICAL CENTER, 986045 NEBRASKA MEDICAL CENTER, OMAHA, NE 68198-6045, UNITED STATES; EMAIL: PDOBESH@UNMC.EDU","","ENGLISH","PHARMACOTHERAPY","REVIEW","ISI","2-S2.0-66249147909","PHARMACOTHERAPY","UNIVERSITY OF NEBRASKA MEDICAL CENTER;ST. LOUIS COLLEGE OF PHARMACY;UNIVERSITY OF NEBRASKA MEDICAL CENTER","NOTREPORTED;UNIVERSITY OF NEBRASKA MEDICAL CENTER;NOTREPORTED",NA,"DOBESH PP, 2009, PHARMACOTHERAPY","DOBESH PP, 2009, PHARMACOTHERAPY"
"KAEWKOOL P;KRISNANGKURA K","KAEWKOOL, PHATTARAPORN (26653550900); KRISNANGKURA, KANIT (6701651738)","TRANSESTERIFICATIONACETYLATION OF LONG CHAIN ALCOHOLS WITH ALKYL ACETATE",2010,"CHEMISTRY AND PHYSICS OF LIPIDS","163","3",6,"10.1016/j.chemphyslip.2010.06.003","DEPARTMENT OF AGRICULTURE AND ENVIRONMENT, FACULTY OF SCIENCE AND TECHNOLOGY, SURINDRA RAJAPAT UNIVERSITY, MUANG, SURIN 32000, THAILAND;THAILAND","GAS CHROMATOGRAPHIC CHARACTERIZATIONS OF FATTY ALCOHOLS ARE GENERALLY CARRIED OUT AS THE FREE ALCOHOLS, TRIMETHYL SILYL OR ACETYL DERIVATIVES. IN THIS STUDY, TRANSESTERIFICATION/ACETYLATION OF LONG CHAIN FATTY ALCOHOLS IS SIMPLY CARRIED OUT BY DISSOLVING THE ALCOHOL IN ETHYL/METHYL ACETATE AND PASSING THROUGH A MICRO-COLUMN PACKED WITH SOLID NAOH. REACTION TIMES ARE SLIGHTLY DIFFERENT FOR ALCOHOLS OF DIFFERENT CHAIN LENGTH. RICE BRAN ALCOHOLS OF 24-34 CARBON ATOM ARE SUCCESSFULLY ACETYLATED. ALSO, CASTOR OIL METHYL ESTER CAN BE INTERESTERIFIED BUT WITH LONGER REACTION TIME. © 2010 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.","CASTOR OIL; FATTY ALCOHOL; POLICOSANOL; TRANSACETYLATION; TRANSESTERIFICATION","ACETATES; ACETYLATION; CASTOR OIL; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, GEL; ESTERIFICATION; FATTY ALCOHOLS; ACETIC ACID; ACETIC ACID ETHYL ESTER; ALCOHOL DERIVATIVE; CASTOR OIL; FATTY ALCOHOL; ACETYLATION; ARTICLE; GAS CHROMATOGRAPHY; PRIORITY JOURNAL; REACTION TIME; RICE BRAN; TRANSESTERIFICATION","THAILAND RESEARCH FUND, TRF","THIS WORK WAS SUPPORTED BY THAILAND RESEARCH FUND.","BONADUCE I., COLOMBINI M.P., CHARACTERISATION OF BEESWAX IN WORKS OF ART BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY AND PYROLYSIS-GAS CHROMATOGRAPHY-MASS SPECTROMETRY PROCEDURES, J. CHROMATOGR. A, 1028, PP. 297-306, (2004); CHEN F., YAN H., CAI T.Y., QUANTITATIVE ANALYSIS OF OCTACOSANOL AND TRIACONTANOL IN EXTRACTS OF HIGHER FATTY ALCOHOLS BY GC, FOOD SCI., 24, PP. 119-121, (2003); CHEN F., WANG Z., ZHAO G., LIAO X., CAI T., GUO L., HU X., PURIFICATION PROCESS OF OCTACOSANOL EXTRACTS FROM RICE BRAN WAX BY MOLECULAR DISTILLATION, J. FOOD ENG., 79, PP. 63-68, (2007); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2006); JEYASHOKE N., KRISNANGKURA K., CHEN S.-T., MICROWAVE INDUCED RAPID TRANSMETHYLATION OF FATTY ACIDS FOR ANALYSIS OF FOOD OIL, J. CHROMATOGR. A, 818, PP. 133-137, (1998); KAEWKOOL P., KITTIRATANAPIBOON K., ARYUSUK K., KRISNANGKURA K., MICRO-REACTOR FOR TRANSESTERIFICATION OF PLANT SEED OILS, EUR. J. LIPID SCI. TECHNOL., 111, PP. 474-480, (2009); KITTIRATTANAPIBOON K., KRISNANGKURA K., SEPARATION OF ACYLGLYCEROLS, FAME AND FFA IN BIODIESEL BY SIZE EXCLUSION CHROMATOGRAPHY, EUR. J. LIPID SCI. TECHNOL., 110, PP. 422-427, (2008); KOVAL L.I., DZYUBA V.I., ILNITSKA O.L., PEKHNYO V.I., EFFICIENT TRANSESTERIFICATION OF ETHYL ACETOACETATE WITH HIGHER ALCOHOLS WITHOUT CATALYSTS, TETRAHEDRON LETT., 49, PP. 1645-1647, (2008); LERTSATHAPORNSUK V., PAIRINTRA R., ARYUSUK K., KRISNANGKURA K., MICROWAVE ASSISTED IN CONTINUOUS BIODIESEL PRODUCTION FROM WASTE FRYING PALM OIL AND ITS PERFORMANCE IN A 100 KW DIESEL GENERATOR, FUEL PROCESS. TECHNOL., 89, PP. 1330-1336, (2008); MA F., HANNA M.A., BIODIESEL PRODUCTION: A REVIEW, BIORESOUR. TECHNOL., 70, PP. 1-15, (1999); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); RIES S.K., WERT V., SWEELEY C.C., LEAVITT R.A., TRIACONTANOL: A NEW NATURALLY OCCURRING PLANT GROWTH REGULATOR, SCIENCE, 195, PP. 1339-1341, (1977); SHIRAE Y., MINO T., HASEGAWA T., SAKAMOTO M., FUJITA T., TRANSESTERIFICATION OF VARIOUS ALCOHOLS WITH VINYL ACETATE UNDER MILD CONDITIONS CATALYZED BY DIETHYLZINC USING N-SUBSTITUTED DIETHANOLAMINE AS A LIGAND, TETRAHEDRON LETT., 46, PP. 5877-5879, (2005); STAPP P.R., RABJOHN N., LITHIUM ALUMINUM ALKOXIDE CATALYZED TRANSESTERIFICATION OF PRIMARY ALCOHOLS WITH ETHYL ACETATE, J. ORG. CHEM., 24, PP. 1798-1800, (1959); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); VIOLA F., OLIARO S., BINELLO A., CRAVOTTO G., POLICOSANOL: UPDATING AND PERSPECTIVES, MEDITERR. J. NUTR. METAB., 1, PP. 77-83, (2008); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM., 55, PP. 5552-5558, (2007)","K. KRISNANGKURA; BIOCHEMICAL TECHNOLOGY DIVISION, SCHOOL OF BIORESOURCES AND TECHNOLOGY, KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI, TAKHAM, BANGKHUNTIEN, BANGKOK 10150, 49, TIENTALAY 25 RD., THAILAND; EMAIL: KANIT.KRI@KMUTT.AC.TH","","ENGLISH","CHEM. PHYS. LIPIDS","ARTICLE","ISI","2-S2.0-77956265191","CHEM PHYS LIPIDS","SURINDRA RAJAPAT UNIVERSITY","NOTREPORTED;KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI;NOTREPORTED",NA,"KAEWKOOL P, 2010, CHEM PHYS LIPIDS","KAEWKOOL P, 2010, CHEM PHYS LIPIDS"
"SHETGIRI P;DARJI K;D'MELLO P","SHETGIRI, P.P. (7801596888); DARJI, K.K. (36918188600); D'MELLO, P.M. (6507753644)","EVALUATION OF ANTIOXIDANT AND ANTIHYPERLIPIDEMIC ACTIVITY OF EXTRACTS RICH IN POLYPHENOLS",2010,"INTERNATIONAL JOURNAL OF PHYTOMEDICINE","2","9",6,"10.5138/ijpm.2010.0975.0185.02038","DEPARTMENT OF PHARMACOGNOSY AND PHYTOCHEMISTRY, PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY, RAMBHAU SALGAOKAR MARG. CUFFE PARADE, COLABA, MUMBAI-400005, INDIA;DEPARTMENT OF PHARMACOGNOSY AND PHYTOCHEMISTRY, PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY, RAMBHAU SALGAOKAR MARG. CUFFE PARADE, COLABA, MUMBAI-400005, INDIA;DEPARTMENT OF PHARMACOGNOSY AND PHYTOCHEMISTRY, PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY, RAMBHAU SALGAOKAR MARG. CUFFE PARADE, COLABA, MUMBAI-400005, INDIA","POLYPHENOLS ARE PHYTOCHEMICALS PRESENT IN PLANTS THAT CONTRIBUTE TO THEIR ANTIOXIDANT AND DIFFERENT PHARMACOLOGICAL ACTIVITIES. FLAVONOIDS COMPRISE OF ONE CLASS OF POLYPHENOLS WHICH PLAY A BENEFICIAL ROLE IN PREVENTING FREE RADICAL DAMAGE AND OWE ITS ANTIOXIDANT PROPERTY. LIPID PEROXIDATION AND LIPID-DERIVED OXIDIZED PRODUCTS HAVE BEEN IMPLICATED IN THE PATHOGENESIS OF A VARIETY OF HUMAN DISEASES. TO CLARIFY THE ROLE OF OXIDATIVE STRESS IN PREVENTION OF ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA, THE ANTIOXIDANT STATUS OF PLANT EXTRACTS OF OROXYLUM INDICUM, VITIS VINIFERA AND POLICOSANOL ISOLATED FROM, SACCHARUM OFFICINARUM WERE SELECTED FOR THE STUDY. THE EXTRACTS WERE EVALUATED BY IN VITRO METHODS BY MONITORING THE PRODUCTION OF MALONDIALDEHYDE AS THIOBARBITURIC ACID REACTING SUBSTANCES (TBARS). THE ANTIHYPPERLIPIDEMIC ACTIVITY WAS EXAMINED IN CHOLESTEROL INDUCED HYPERLIPIDEMIC MODEL USING ALBINO WISTAR RATS. THE RESULT OF THE STUDY EXHIBITED SIGNIFICANT REDUCTION IN TOTAL CHOLESTEROL, TRIGLYCERIDES, LDL-C, VLDL-C LEVELS AND REMARKABLE INCREASE IN THE LEVEL OF HDL-C WHEN COMPARED TO STANDARD LOVASTATIN DRUG. THE ARTHEROGENIC INDEX AND LDL-C: HDL-C RISK RATIO WAS ALSO REDUCED TO SIGNIFICANT EXTENT IN THE GROUP TREATED WITH EXTRACTS. THE LEVELS OF SGOT AND SGPT WERE ESTIMATED AND FOUND TO BE SIGNIFICANTLY LESS THAN THAT OF HYPERLIPIDEMIC CONTROL GROUP. THE HIGHEST ANTIHYPERLIPIDEMIC ACTIVITY WAS EXHIBITED BY TOTAL EXTRACT OF THE BARK OF OROXYLUM INDICUM FOLLOWED BY EXTRACTS OF FRUITS OF VITIS VINIFERA AND POLICOSANOL ISOLATED FROM SUGARCANE WAX. © ARJOURNALS.ORG, ALL RIGHTS RESEVED.","ANTIHYPERLIPIDEMIC; ANTIOXIDANT; OROXYLUM INDICUM; POLICOSANOL; POLYPHENOLS; VITIS VINIFERA","ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYL RADICAL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MEVINOLIN; OROXYLUM INDICUM EXTRACT; PLANT EXTRACT; POLICOSANOL; POLYPHENOL; QUERCETIN; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITIS VINIFERA EXTRACT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERLIPIDEMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; FRUIT; HYPERLIPIDEMIA; IC 50; IN VITRO STUDY; LIPID PEROXIDATION; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; OROXYLUM INDICUM; SUGARCANE; TRIACYLGLYCEROL BLOOD LEVEL","","","RAUEND S., DE LORGERIL M., LANCET, 339, PP. 1523-1526, (1993); HOFFMAN R., GAREWAL H., ARCH. INTER. MED, 155, PP. 241-246, (1995); HMAMOUCHI M., ET AL., FITOTERAPIA, 68, PP. 113-114, (1996); GU Q., LUO H., ZHENG W., LIU Z., HUANG Y., INT. J. SYST. EVOL. MICROBIOL, 56, PP. 2193-2197, (2006); MARINANGELI C.P., KASSIS A.N., JAIN D., EBINE N., CUNNANE S.C., JONES P.J.N., BR. J. NUTR, 97, PP. 381-388, (2007); GRANJA A., HERNANDEZ J., ET AL., U. S PATENT NO - 5663156 MIXTURES OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBSTENTION FROM SUGARCANE WAX AND ITS PHARMACEUTICAL USES, (1997); EDWARDS R.L., LYON T., LITWIN S.E., RABOVSKY A., SYMONS J.D., JALILI T., J. NUTR, 137, PP. 2405-2411, (2007); OHIKAWA H., OSHINI N., YAGI K., ANAL. BIO. CHEM, 95, PP. 351-358, (1979); DEVASAGAYAM T.P.A., BOLOOR K.K., RAMASARMA T., INDIAN J BIOCHEM BIOPHY, 40, PP. 300-303, (2003); LAMAISON J., PTITJEAN-FREYLET PHARM, ACTA. HELVETIA, 66, PP. 185-188, (1991); DHULEY J., NAIK S.R., RELE S., BENARJI A., PHARM. PHARMACOL. COMMUN, 5, PP. 689-670, (1999); WILIAMSON E., OKPAKO M., EVANS F.J., PHARMACOLOGICAL METHODS IN PHYTOTHERAPY RESEARCH, (1996); IACOPINI P., BALDI M., STORCHI L., SEBASTIANI CATECHIN, EPICATECHIN, QUERCETIN, RUTIN AND RESVERATROL IN RED GRAPE: CONTENT, IN VITRO ANTIOXIDANT ACTIVITY AND INTERACTIONS, JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 21, PP. 589-598, (2008); ROY M.K., NAKAHARA K., NA T.V., TRAKOONTIVAKORN G., TAKENAKA M., ISOBE S., TSUSHIDA T., BAICALEIN, A FLAVONOID EXTRACTED FROM A METHANOLIC EXTRACT OF OROXYLUM INDICUM INHIBITS PROLIFERATION OF A CANCER CELL LINE IN VITRO VIA INDUCTION OF APOPTOSIS, PHARMAZIE, 62, PP. 149-153, (2007); DAHLEN G.H., LP (A) LIPOPROTEIN IN CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, 108, PP. 111-126, (1994); EDWARDS C., BOUCHIER I., HASLETT C., CHILVERS E., ISCHAMIC (CORONARY) HEART DISEASE, DAVIDSONS PRINCIPLES AND PRACTICE OF MEDICINE, 18, PP. 245-266, (1999); FARMER I.A., GOTTO A.M., DYSLIPIDEMIA AND OTHER RISK FACTORS FOR CORONARY ARTERY DISEASE, HEART DISEASE, 5, PP. 1126-1160, (1997); GENSINI G.F., COMEGLIO M., COLELLA A., CLASSICAL RISK FACTORS AND EMERGING ELEMENTS IN THE RISK PROFILE FOR CORONARY ARTERY DISEASE, EURO. HEART J, 19, SUPP. A, (1998); OCHANI P.C.D., MELLO P., INDIAN J OF EXPERIMENTAL BIOLOGY, 47, PP. 276-282, (2009); ARDLIE N., SELLEY M., SIMONS L., ARTEROSCLEROSIS, 76, PP. 117-124, (1989); BAGCHI K., PURI S., EASTERN MEDITERRANEAN HEALTH JOURNAL, 4, PP. 350-360, (1998); AUGUSTI K.T., NARAYAN A., PILLAI L.S., INDIAN J OF EXPERIMENTAL BIOLOGY, 39, PP. 660-662, (2001); PETER P.T., THE GOOD CHOLESTEROL -HIGH-DENSITY LIPOPROTEIN, CARDIOLOGY PATIENT PAGE _RFPY1 2005","P. M. D'MELLO; DEPARTMENT OF PHARMACOGNOSY AND PHYTOCHEMISTRY, PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY, RAMBHAU SALGAOKAR MARG. CUFFE PARADE, COLABA, MUMBAI-400005, INDIA; EMAIL: DMELLOPM@REDIFFMAIL.COM","","ENGLISH","INTL. J. PHYTOMED.","ARTICLE","ISI","2-S2.0-79953324528","INTL J PHYTOMED","PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY;PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY;PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY","NOTREPORTED;PRIN. K. M. KUNDNANI COLLEGE OF PHARMACY;NOTREPORTED",NA,"SHETGIRI PP, 2010, INTL J PHYTOMED","SHETGIRI PP, 2010, INTL J PHYTOMED"
"DUNFORD N;IRMAK S;JONNALA R","DUNFORD, NURHAN TURGUT (6603296815); IRMAK, SIBEL (6603640781); JONNALA, RAMAKANTH (8355958500)","PRESSURISED SOLVENT EXTRACTION OF POLICOSANOL FROM WHEAT STRAW GERM AND BRAN",2010,"FOOD CHEMISTRY","119","3",59,"10.1016/j.foodchem.2009.07.039","DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, FAPC ROOM 103, UNITED STATES;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, FAPC ROOM 103, UNITED STATES;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, FAPC ROOM 103, UNITED STATES","POLICOSANOLS (PCS) ARE A GROUP OF LONG CHAIN ALIPHATIC ALCOHOLS THAT HAVE BEEN REPORTED TO HAVE LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL-LOWERING PROPERTIES. WHEAT IS A GOOD SOURCE OF THESE COMPOUNDS. THIS STUDY EXAMINED THE EFFECT OF SOLVENT TYPE AND TEMPERATURE ON EXTRACT YIELDS AND PC CONTENT AND COMPOSITION IN THE EXTRACTS. WHEAT GERM, STRAW AND BRAN SAMPLES WERE EXTRACTED WITH PETROLEUM ETHER, CHLOROFORM, N-HEXANE AND ETHANOL AT VARIOUS TEMPERATURES RANGING FROM 80 TO 125 °C. WHEAT GERM EXTRACT YIELDS WERE HIGHER THAN THOSE FOR STRAW AND BRAN. ETHANOL EXTRACTION RESULTED IN THE HIGHEST YIELD FROM WHEAT GERM. ETHANOL EXTRACT YIELDS FROM BOTH WHEAT GERM AND STRAW INCREASED SIGNIFICANTLY WITH INCREASING TEMPERATURE. WHEAT STRAW HAD THE HIGHEST PC CONTENT AMONG THE WHEAT FRACTIONS EXAMINED IN THE STUDY. THE PC COMPOSITION OF EXTRACTS VARIED WITH THE TYPE OF SOLVENT AND WHEAT FRACTION USED. ETHANOL AND PETROLEUM ETHER EXTRACTS OF WHEAT STRAW HAD THE HIGHEST OCTACOSANOL AND HEXACOSANOL CONTENTS, RESPECTIVELY. THIS STUDY DEMONSTRATED THAT SOLVENT TYPE AND TEMPERATURE HAVE SIGNIFICANT EFFECTS ON EXTRACT YIELDS AND PC COMPOSITION IN EXTRACTS OBTAINED FROM WHEAT FRACTIONS. © 2009 ELSEVIER LTD. ALL RIGHTS RESERVED.","BRAN; GERM; POLICOSANOL; SOLVENT EXTRACTION; STRAW; WHEAT","TRITICUM AESTIVUM; BEHENYL ALCOHOL; HEXACOSANOL; HEXANE; OCTACOSANOL; PETROLEUM; POLICOSANOL; ARTICLE; FOOD ANALYSIS; SOLVENT EXTRACTION; TEMPERATURE SENSITIVITY; WHEAT BRAN; WHEAT GERM","","","ABBOUD J.-L.M., NOTARIO R., CRITICAL COMPILATION OF SCALES OF SOLVENT PARAMETER. PART I. PURE, NON-HYDROGEN BOND DONOR SOLVENTS, PURE AND APPLIED CHEMISTRY, 71, 4, PP. 645-718, (1999); BIANCHI G., EPICUTICULAR WAX ANALYSIS IN TRITICUM AND RELATED SPECIES, GENETICS IN AGRICULTURE, 39, PP. 471-486, (1985); BIANCHI G., FIGRINI M.L., BORGHI B., CORBELLINI M., GENETIC OF WAX FORMATION IN WHEAT, GENETICS IN AGRICULTURE, 38, PP. 209-218, (1984); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, THE JOURNALS OF GERONTOLOGY: A BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 56, (2001); DUNFORD N.T., ZHANG M., PRESSURIZED SOLVENT EXTRACTION OF WHEAT GERM OIL, FOOD RESEARCH INTERNATIONAL, 36, PP. 905-909, (2003); EISENMENGER M., DUNFORD N.T., BIOACTIVE COMPONENTS OF COMMERCIAL AND SUPERCRITICAL CARBON DIOXIDE PROCESSED WHEAT GERM OIL, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 85, PP. 55-61, (2008); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, 14, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2005); JONES P.J.H., KASSIS A.N., MARINANGELI C.P.F., POLICOSANOLS LOSE THEIR LUSTRE AS CHOLESTEROL-LOWERING AGENTS, JOURNAL OF FUNCTIONAL FOODS, 1, 2, PP. 236-239, (2009); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ J., ORTA S.D., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLYCOSANOL, CURRENT THERAPEUTIC RESEARCH, 60, PP. 458-467, (1999); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOLOGY AND BEHAVIOR, 67, 1, PP. 1-7, (1999); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF DURUM WHEAT, PHYTOCHEMISTRY, 10, PP. 871-876, (1971); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF TRITICUM AESTIVUM, PHYTOCHEMISTRY, 12, PP. 2217-2223, (1973); VANDENBURG H.J., CLIFFORD A.A., BARTLE K.D., SHUANG A.Z., FACTORS AFFECTING HIGH-PRESSURE SOLVENT EXTRACTION (ACCELERATED SOLVENT EXTRACTION) OF ADDITIVES FROM POLYMERS, ANALYTICAL CHEMISTRY, 70, PP. 1943-1948, (1998); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEW, 61, 11, PP. 376-383, (2003)","N.T. DUNFORD; DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, FAPC ROOM 103, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-70449096081","FOOD CHEM","OKAHOMA STATE UNIVERSITY;OKAHOMA STATE UNIVERSITY;OKAHOMA STATE UNIVERSITY","NOTREPORTED;OKAHOMA STATE UNIVERSITY;NOTREPORTED",NA,"DUNFORD NT, 2010, FOOD CHEM","DUNFORD NT, 2010, FOOD CHEM"
"CALIGIANI A;BONZANINI F;PALLA G;CIRLINI M;BRUNI R","CALIGIANI, AUGUSTA (55904188000); BONZANINI, FRANCESCA (26633407700); PALLA, GERARDO (7005196848); CIRLINI, MARTINA (16240832900); BRUNI, RENATO (7101897768)","CHARACTERIZATION OF A POTENTIAL NUTRACEUTICAL INGREDIENT POMEGRANATE PUNICA GRANATUM L SEED OIL UNSAPONIFIABLE FRACTION",2010,"PLANT FOODS FOR HUMAN NUTRITION","65","6",98,"10.1007/s11130-010-0173-5","DIPARTIMENTO DI CHIMICA ORGANICA E INDUSTRIALE, UNIVERSITÀ DEGLI STUDI DI PARMA, 43100 PARMA, VIALE G. USBERTI 17A, ITALY;DIPARTIMENTO DI CHIMICA ORGANICA E INDUSTRIALE, UNIVERSITÀ DEGLI STUDI DI PARMA, 43100 PARMA, VIALE G. USBERTI 17A, ITALY;DIPARTIMENTO DI CHIMICA ORGANICA E INDUSTRIALE, UNIVERSITÀ DEGLI STUDI DI PARMA, 43100 PARMA, VIALE G. USBERTI 17A, ITALY;DIPARTIMENTO DI CHIMICA ORGANICA E INDUSTRIALE, UNIVERSITÀ DEGLI STUDI DI PARMA, 43100 PARMA, VIALE G. USBERTI 17A, ITALY;DIPARTIMENTO DI BIOLOGIA EVOLUTIVA E FUNZIONALE - SEZIONE DI BIOLOGIA VEGETALE, UNIVERSITÀ DEGLI STUDI DI PARMA, 43100 PARMA, VIALE G. USBERTI 11A, ITALY","THE CHEMICAL FINGERPRINTING OF THE UNSAPONIFIABLE FRACTION OF DIFFERENT PUNICA GRANATUM SEED OILS WAS PERFORMED IN ORDER TO EVALUATE THEIR POTENTIAL AS A FUNCTIONAL FOOD INGREDIENT. QUALITATIVE AND QUANTITATIVE DETERMINATIONS OF TOCOPHEROL, ALIPHATIC ALCOHOL (INCLUDING POLICOSANOL), SQUALENE, PHYTOSTEROLS AND TRITERPENE CONTENTS WERE PERFORMED BY GC-MS. A HIGH YIELD (3. 1-4. 2%) OF UNSAPONIFIABLE MATTER WAS OBTAINED AND CONSISTENT LEVELS OF SQUALENE (UP TO 800 MG/KG) AND POLICOSANOL (118-185 MG/KG) WERE NOTICED. Β-SITOSTEROL (UP TO 8069 MG/KG) AND CYCLOARTENOL (5916-7766 MG/KG) WERE PREDOMINANT IN PHYTOSTEROL AND TRITERPENE FRACTIONS, WHILE Β- AND Δ-TOCOPHEROL WERE THE MOST ABUNDANT VITAMIN E FORMS. SOME MINOR VARIATIONS WERE NOTICED BETWEEN SAMPLES. FROM THE RESULTS OBTAINED, IT CAN BE SUGGESTED THAT THE SEED OIL OF P. GRANATUM CAN BE CONSIDERED AN INTERESTING ALIMENTARY SOURCE OF SUBSTANCES OF NUTRACEUTICAL VALUE INVOLVED IN THE MODULATION OF CHOLESTEROL METABOLISM. © 2010 RSULSPRINGER SCIENCE+BUSINESS MEDIA, LLC.","FUNCTIONAL FOOD; PHYTOSTEROLS; POLICOSANOLS; PUNICA GRANATUM; SQUALENE; UNSAPONIFIABLE","BETA-TOCOPHEROL; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FUNCTIONAL FOOD; PHYTOSTEROLS; PLANT OILS; PUNICACEAE; SEEDS; SITOSTEROLS; SQUALENE; TOCOPHEROLS; TRITERPENES; LYTHRACEAE; PUNICA GRANATUM; BETA TOCOPHEROL; CYCLOARTENOL; DELTA TOCOPHEROL; DELTA-TOCOPHEROL; FATTY ALCOHOL; PHYTOSTEROL; POLICOSANOL; SITOSTEROL; SITOSTEROL DERIVATIVE; SQUALENE; TOCOPHEROL; TRITERPENE; VEGETABLE OIL; ARTICLE; CHEMISTRY; DIET SUPPLEMENTATION; FUNCTIONAL FOOD; PLANT SEED; POMEGRANATE","","","ESPIN J.C., GARCIA-CONESA M.T., TOMAS-BARBERAN F.A., NUTRACEUTICALS: FACTS AND FICTION, PHYTOCHEMISTRY, 68, PP. 2986-3008, (2007); ZEISEL S.H., REGULATION OF NUTRACEUTICALS, SCIENCE, 285, (1999); KATAN M.B., FUNCTIONAL FOODS, LANCET, 354, (1999); JONES P.J., JEW S., FUNCTIONAL FOOD DEVELOPMENT: CONCEPT TO REALITY, TRENDS FOOD SCI TECHNOL, 18, PP. 387-390, (2007); COVAS M.I., RUIZ-GUTIERREZ V., DE LA TORRE R., KAFATOS A., LAMUELA-RAVENTOS R.M., OSADA J., OWEN R.W., VISIOLI F., MINOR COMPONENTS OF OLIVE OIL: EVIDENCE TO DATE OF HEALTH BENEFITS IN HUMANS, NUTR REV, 64, PP. 20-30, (2006); DE DECKERE E.A., KORVER O., MINOR CONSTITUENTS OF RICE BRAN OIL AS FUNCTIONAL FOODS, NUTR REV, 54, PP. 120-126, (1996); NICOLOSI R.J., ROGERS E.J., AUSMAN L.M., ROGERS E.J., HEALTH BENEFITS OF UNSAPONIFIABLE CONSTITUENTS OF FATS AND OILS, TECHNOLOGIES FOR HEALTHY FOODS & NUTRACEUTICALS, (1997); RYAN E., GALVIN K., O'CONNOR T.P., MAGUIRE A.R., O'BRIEN N.M., PHYTOSTEROL, SQUALENE, TOCOPHEROL CONTENT AND FATTY ACID PROFILE OF SELECTED SEEDS, GRAINS, AND LEGUMES, PLANT FOODS HUM NUTR, 62, PP. 85-91, (2007); O'BYRNE S., GRUNDY L., PACKER S., DEVARAJ K., BALDENIUS P.P., HOPPE K., KRAEMER I., JIALAL M.G., STUDIES OF LDL OXIDATION FOLLOWING Α-, Γ-, OR Δ-TOCOTRIENYL ACETATE SUPPLEMENTATION OF HYPERCHOLESTEROLEMIC HUMANS, FREE RADIC BIOL MED, 29, PP. 834-845, (2000); LEONHARDT W., HANEFELD M., SCHAPER F., DIMINISHED SUSCEPTIBILITY TO IN VITRO OXIDATION OF LOW-DENSITY LIPOPROTEINS IN HYPERCHOLESTEROLEMIA: KEY ROLE OF ALPHA-TOCOPHEROL CONTENT, ATHEROSCLEROSIS, 144, PP. 103-107, (1999); OSTLUND R.E., RACETTE S.B., STENSON W.F., EFFECT OF TRACE COMPONENTS OF DIETARY FAT ON CHOLESTEROL METABOLISM: PHYTOSTEROLS, OXYSTEROLS AND SQUALENE, NUTR REV, 60, PP. 349-359, (2002); HE H.P., CORKE H., OIL AND SQUALENE IN AMARANTHUS GRAIN AND LEAF, J AGRIC FOOD CHEM, 51, PP. 7913-7920, (2003); CHAN P., TOMLINSON B., LEE C.B., LEE Y.S., EFFECTIVENESS AND SAFETY OF LOW-DOSE PRAVASTATIN AND SQUALENE, ALONE AND IN COMBINATION, IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, J CLIN PHARM, 36, PP. 422-427, (1996); ZHANG Z., YEUNG W.K., HUANG Y., CHEN Z.Y., EFFECT OF SQUALENE AND SHARK LIVER OIL ON SERUM CHOLESTEROL LEVEL IN HAMSTERS, INT J FOOD SCI NUTR, 53, PP. 411-418, (2002); RAO C.V., NEWMARK H.L., REDDY B.S., CHEMOPREVENTIVE EFFECT OF SQUALENE ON COLON CANCER, CARCINOGENESIS, 19, PP. 287-290, (1998); KASSIS A.N., MARINANGELI C.P.F., JONES P.J.H., REPLY TO THE DISCUSSION BY SERGEI V JARGIN ON EVALUATION OF CHOLESTEROL-LOWERING AND ANTIOXIDANT PROPERTIES OF SUGAR CANE POLICOSANOLS IN HAMSTERS AND HUMANS, APPL PHYSIOL NUTR METAB, 34, PP. 76-77, (2009); LANSKY E.P., NEWMAN R.A., PUNICA GRANATUM (POMEGRANATE) AND ITS POTENTIAL FOR PREVENTION AND TREATMENT OF INFLAMMATION AND CANCER, J ETHNOPHARMACOL, 109, PP. 177-206, (2007); YAMASAKI T., KITAGAWA N., KOYANAGI H., CHUJO H., MAEDA J., KOHNO-MURASE J., IMAMURA H., TACHIBANA K., YAMADA R., DIETARY EFFECT OF POMEGRANATE SEED OIL ON IMMUNE FUNCTION AND LIPID METABOLISM IN MICE, NUTRITION, 22, PP. 54-59, (2006); KOHNO H., SUZUKI R., YASUI Y., HOSOKAWA M., MIYASHITA K., TANAKA T., POMEGRANATE SEED OIL RICH IN CONJUGATED LINOLENIC ACID SUPPRESSES CHEMICALLY INDUCED COLON CARCINOGENESIS IN RATS, CANCER SCI, 95, PP. 481-486, (2004); KIM N.D., MEHTA R., YU W., NEEMAN I., LIVNEY T., AMICHAY A., POIRIER D., NICHOLLS P., KIRBY A., JIANG W., MANSEL R., RAMACHANDRAN C., RABI T., KAPLAN B., LANSKY E., CHEMOPREVENTIVE AND ADJUVANT THERAPEUTIC POTENTIAL OF POMEGRANATE (PUNICA GRANATUM) FOR HUMAN BREAST CANCER, BREAST CANCER RES TREAT, 71, PP. 203-217, (2002); DE NIGRIS F., BALESTRIERI M.L., WILLIAMS-IGNARRO S., D'ARMIENTO F.P., FIORITO C., IGNARRO L.J., NAPOLI C., THE INFLUENCE OF POMEGRANATE FRUIT EXTRACT IN COMPARISON TO REGULAR POMEGRANATE JUICE AND SEED OIL ON NITRIC OXIDE AND ARTERIAL FUNCTION IN OBESE ZUCKER RATS, NITRIC OXIDE, 17, PP. 50-54, (2007); LANSKY E.P., HARRISON G., FROOM P., JIANG W.G., POMEGRANATE (PUNICA GRANATUM) PURE CHEMICALS SHOW POSSIBLE SYNERGISTIC INHIBITION OF HUMAN PC-3 PROSTATE CANCER CELL INVASION ACROSS MATRIGEL<SUP>TM</SUP>, VEST NEW DRUGS, 23, PP. 121-122, (2005); MUKHERJEE C., BHATTACHARYYA D.K., DIETARY EFFECT OF PUNICIC ACID ON OXIDATIVE BEHAVIOR AND LIPID PROFILES OF BRAIN, HEART, LIVER AND KIDNEY TISSUE LIPID OF RATS, J LIPID SCI TECHNOL, 38, PP. 124-128, (2006); SAITO K., KOHNO M., YOSHIZAKI F., NIWANO Y., EXTENSIVE SCREENING FOR EDIBLE HERBAL EXTRACTS WITH POTENT SCAVENGING ACTIVITY AGAINST SUPEROXIDE ANIONS, PLANT FOODS HUM NUTR, 63, PP. 65-70, (2008); MUKHERJEE C., BHATTACHARYYA S., GHOSH S., BHATTACHARYYA D.K., DIETARY EFFECTS OF PUNICIC ACID ON THE COMPOSITION AND PEROXIDATION OF RAT PLASMA LIPID, J OLEO SCI, 51, PP. 513-522, (2002); KAUFMAN M., WIESMAN Z., POMEGRANATE OIL ANALYSIS WITH EMPHASIS ON MALDI-TOF TRIACYLGLYCEROL FINGERPRINTING, J AGRIC FOOD CHEM, 55, PP. 10405-10413, (2007); GOPALA KRISHNA A.G., PRASHANTH P.A., PRAGASAM A., RAGHAVENDRA K.V., KHATOON S., UNSAPONIFIABLE MATTER AND OXIDATIVE STABILITY OF COMMERCIAL PRODUCED INDIAN RICE BRAN OILS, J FOOD LIPIDS, 10, PP. 329-340, (2003); GUTFINGER T., LETAN A., STUDIES ON THE UNSAPONIFIABLES IN SEVERAL VEGETABLE OILS, LIPIDS, 9, PP. 658-663, (1974); BEN-ARIE R., SEGAL N., GUELFAT-REICH S., THE MATURATION AND RIPENING OF THE 'WONDERFUL' POMEGRANATE, J AM SOC HORTIC SCI, 109, PP. 898-902, (1984); MOZZON M., BOCCI F., FREGA N., A STUDY ON THE LIPIDIC FRACTION EXTRACTED FROM HIGH OLEIC SUNFLOWER SEEDS (HELIANTHUS ANNUUS L.) DURING THE RIPENING PROCESS, J AGRIC FOOD CHEM, 46, PP. 4198-4202, (1998); HUANG Z.R., LIN Y.K., FANG J.Y., BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES OF SQUALENE AND RELATED COMPOUNDS: POTENTIAL USES IN COSMETIC DERMATOLOGY, MOLECULES, 14, PP. 540-554, (2009); PADLEY F.B., GUNSTONE F.D., HARWOOD J.L., OCCURRENCE AND CHARACTERISTICS OF OILS AND FATS, THE LIPID HANDBOOK, PP. 127-130, (1994); SANCLEMENTE T., MARQUES-LOPES I., PUZO J., GARCIA-OLTIN A.L., ROLE OF NATURALLY-OCCURRING PLANT STEROLS ON INTESTINAL CHOLESTEROL ABSORPTION AND PLASMATIC LEVELS, J PHYSIOL BIOCHEM, 65, PP. 87-98, (2009); OSTLUND R.E., PHYTOSTEROLS AND CHOLESTEROL METABOLISM, CURR OPIN LIPIDOL, 15, PP. 37-41, (2004); PLANT STEROLS AND BLOOD CHOLESTEROL, EFSA J, 781, PP. 1-12, (2008); CICERO A.F.G., DE ROSA G., RICE BRAN AND ITS MAIN COMPONENTS: POTENTIAL ROLE IN THE MANAGEMENT OF CORONARY RISK FACTORS, CURR TOP NUTRACEUTICAL RES, 3, PP. 29-46, (2005); TAKEOKA G.R., DAO L.T., WONG R.Y., LUNDIN R.E., MAHONEY N.E., IDENTIFICATION OF BENZETHONIUM CHLORIDE IN COMMERCIAL GRAPEFRUIT SEED EXTRACTS, J AGRIC FOOD CHEM, 49, PP. 316-320, (2001); HARRABI S., BOUKHCHINA S., KALLEL H., MAYER P.M., POLICOSANOL DISTRIBUTION AND ACCUMULATION IN DEVELOPING CORN KERNELS, FOOD CHEM, 115, PP. 918-923, (2009); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); LOPEZ-LOPEZ A., RODRIGUEZ-GOMEZ F., RUIZ-MENDEZ M.V., CORTES-DELGADO A., GARRIDO-FERNANDEZ A., STEROLS, FATTY ALCOHOL AND TRITERPENIC ALCOHOL CHANGES DURING RIPE TABLE OLIVE PROCESSING, FOOD CHEM, 117, PP. 127-134, (2009)","R. BRUNI; DIPARTIMENTO DI BIOLOGIA EVOLUTIVA E FUNZIONALE - SEZIONE DI BIOLOGIA VEGETALE, UNIVERSITÀ DEGLI STUDI DI PARMA, 43100 PARMA, VIALE G. USBERTI 11A, ITALY; EMAIL: RENATO.BRUNI@UNIPR.IT","","ENGLISH","PLANT FOODS HUM. NUTR.","ARTICLE","ISI","2-S2.0-77957165650","PLANT FOODS HUM NUTR","UNIVERSITÀ DEGLI STUDI DI PARMA;UNIVERSITÀ DEGLI STUDI DI PARMA;UNIVERSITÀ DEGLI STUDI DI PARMA;UNIVERSITÀ DEGLI STUDI DI PARMA;UNIVERSITÀ DEGLI STUDI DI PARMA","NOTREPORTED;UNIVERSITÀ DEGLI STUDI DI PARMA;NOTREPORTED",NA,"CALIGIANI A, 2010, PLANT FOODS HUM NUTR","CALIGIANI A, 2010, PLANT FOODS HUM NUTR"
"ANASTASI U;SANTONOCETO C;GIUFFRÈ A;SORTINO O;GRESTA F;ABBATE V","ANASTASI, U. (23970161200); SANTONOCETO, C. (23971013900); GIUFFRÈ, A.M. (9279506500); SORTINO, O. (36136205300); GRESTA, F. (13410420800); ABBATE, V. (24461451400)","YIELD PERFORMANCE AND GRAIN LIPID COMPOSITION OF STANDARD AND OLEIC SUNFLOWER AS AFFECTED BY WATER SUPPLY",2010,"FIELD CROPS RESEARCH","119","8",73,"10.1016/j.fcr.2010.07.001","DIPARTIMENTO DI BIOTECNOLOGIE PER IL MONITORAGGIO AGROALIMENTARE ED AMBIENTALE, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, 89124, REGGIO CALABRIA, C.DA MELISSARI, ITALY;DIPARTIMENTO DI BIOTECNOLOGIE PER IL MONITORAGGIO AGROALIMENTARE ED AMBIENTALE, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, 89124, REGGIO CALABRIA, C.DA MELISSARI, ITALY;DIPARTIMENTO DI BIOTECNOLOGIE PER IL MONITORAGGIO AGROALIMENTARE ED AMBIENTALE, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, 89124, REGGIO CALABRIA, C.DA MELISSARI, ITALY;DIPARTIMENTO DI SCIENZE AGRONOMICHE, AGROCHIMICHE E DELLE PRODUZIONI ANIMALI, UNIVERSITÀ DEGLI STUDI DI CATANIA, 95123, CATANIA, VIA VALDISAVOIA 5, ITALY;DIPARTIMENTO DI SCIENZE AGRONOMICHE, AGROCHIMICHE E DELLE PRODUZIONI ANIMALI, UNIVERSITÀ DEGLI STUDI DI CATANIA, 95123, CATANIA, VIA VALDISAVOIA 5, ITALY;DIPARTIMENTO DI SCIENZE AGRONOMICHE, AGROCHIMICHE E DELLE PRODUZIONI ANIMALI, UNIVERSITÀ DEGLI STUDI DI CATANIA, 95123, CATANIA, VIA VALDISAVOIA 5, ITALY","SUNFLOWER HAS POTENTIAL IN MEDITERRANEAN FARMING SYSTEMS BECAUSE OF THE MODEST AUXILIARY INPUT REQUIREMENT, APPRECIABLE PRODUCTIVITY AND QUALITY OF RAW MATERIAL. THESE ASPECTS ARE AFFECTED BY THE INTERACTIONS AMONG GENETIC, ENVIRONMENTAL AND AGRONOMIC FACTORS, WHICH HAVE NOT BEEN FULLY EXPLORED. THEREFORE, THE EFFECTS OF FOUR WATER REGIMES AS PROPORTION OF CROP EVAPOTRANSPIRATION (0%, 33%, 67%, 100%) ON GRAIN YIELD AND ITS COMPONENTS, OIL YIELD AND GRAIN LIPID CONSTITUENTS, I.E. FATTY ACIDS (FAS), UNSAPONIFIABLE MATTER (UM), PHYTOSTEROL (PHY), POLICOSANOL (PC) AND TOCOPHEROL (TOC) FRACTIONS OF A STANDARD AND AN OLEIC SUNFLOWER HYBRIDS WERE ASSESSED IN A 2-YEAR FIELD EXPERIMENT. THE RELATIONSHIPS BETWEEN CROP PRODUCTIVE TRAITS AND OIL QUALITY FEATURES WERE ALSO ANALYSED.IN GENERAL, AS THE WATER SUPPLY (WS) INCREASED GRAIN YIELD AND RELATED TRAITS AS WELL AS ACHENE'S LIPID SYNTHESIS AND OIL YIELD OF EACH GENOTYPE (G) WERE POSITIVELY AFFECTED. CONVERSELY, THE SIGNIFICANT WS × G INTERACTION FOUND FOR THE GRAIN LIPID COMPOSITION INDICATED THAT THE HYBRIDS RESPONDED TO DIFFERENT WATER TREATMENTS BY MODIFYING THE PROPORTIONS OF MAJOR FAS AS WELL AS THE UM AND ITS TOTAL PHY, PC AND TOC CONCENTRATIONS, WITH NON-UNIVOCAL PERCENTAGE CHANGES OF THEIR RESPECTIVE COMPOUNDS.AN INCREASE OF THE UNSATURATION RATIO OF OIL OCCURRED WHEN WATER (RAINFALL + IRRIGATION) INPUT INCREASED, ALTHOUGH AT DIFFERENT LEVEL FOR EACH HYBRID ACCORDING TO THEIR GENETIC CONSTITUTION. BECAUSE OF THE INFLUENCE OF WARM CLIMATIC CONDITIONS, STANDARD HYBRID PROVIDED OIL WITH AN OLEIC-LINOLEIC ACID BALANCE SIMILAR TO THAT OF MID-OLEIC TYPOLOGY.WITHIN THE OIL UM, WHICH CONTAINS ALSO BIOACTIVE METABOLITES INVOLVED IN THE RESISTANCE OF THE PLANT TO VARIOUS ABIOTIC CONSTRAINS, TOTAL PHY CONCENTRATION INCREASED AND TOTAL PC CONCENTRATION DECREASED AS THE WATER (RAINFALL + IRRIGATION) INPUT WAS REDUCED, BUT TO A DIFFERENT EXTENT IN THE TWO HYBRIDS. THE MOST EFFECTIVE COMBINATIONS OF STUDIED TREATMENTS FOR TOTAL TOC CONCENTRATION WERE STANDARD HYBRID IRRIGATED AT BOTH 33% AND 67% OF ETC REPLACEMENT AND OLEIC HYBRID WITHOUT IRRIGATION.THE RESULTS SUGGEST THAT GROWING SUNFLOWER IN A WATER-LIMITED MEDITERRANEAN-TYPE ENVIRONMENT IS POSSIBLE TO PRODUCE SATISFACTORY GRAIN AND OIL YIELDS WITH AN APPROPRIATE USE OF IRRIGATION. SOME OIL QUALITY CHARACTERISTICS SUITABLE FOR DIFFERENT INDUSTRIAL USES COULD ALSO BE ACHIEVED BY A COMBINATION OF WS WITH STANDARD OR OLEIC TYPOLOGY OF SUNFLOWER HYBRIDS. © 2010 ELSEVIER B.V.","FATTY ACID; HELIANTHUS ANNUUS L.; OIL YIELD; PHYTOSTEROL; POLICOSANOL; TOCOPHEROL; WATER REGIME","HELIANTHUS; HELIANTHUS ANNUUS; AGRONOMY; DICOTYLEDON; EVAPOTRANSPIRATION; FARMING SYSTEM; FATTY ACID; GENOTYPE; HYBRID; IRRIGATION; LIPID; MEDITERRANEAN ENVIRONMENT; METABOLITE; WATER SUPPLY; YIELD RESPONSE","","","ABIDI S.L., LIST G.R., RENNIK K.A., EFFECT OF GENETIC MODIFICATION ON THE DISTRIBUTION OF MINOR CONSTITUENTS IN CANOLA OIL, J. AM. OIL CHEM. SOC., 76, PP. 463-467, (1999); ALLEN R.G., PEREIRA S., RAES M., SMITH M., (1998); ANASTASI U., CAMMARATA M., ABBATE V., YIELD POTENTIAL AND OIL QUALITY OF SUNFLOWER (OLEIC AND STANDARD) GROWN BETWEEN AUTUMN AND SUMMER, ITAL. J. AGRON., 4, 1, PP. 23-36, (2000); ANASTASI U., CAMMARATA M., SORTINO O., ABBATE V., COMPORTAMENTO AGRONOMICO E COMPOSIZIONE LIPIDICA DEGLI ACHENI DI DUE IBRIDI DI GIRASOLE (CONVENZIONALE E AD ALTO OLEICO) IN RISPOSTA AI FATTORI AMBIENTALI, RIV. AGRON., 35, PP. 76-86, (2001); BALDINI M., GIOVANARDI R., TAHMASEBI-ENFERADI S., VANNOZZI G.P., EFFECTS OF WATER REGIME ON FATTY ACID ACCUMULATION AND FINAL FATTY ACID COMPOSITION IN THE OIL OF STANDARD AND HIGH OLEIC SUNFLOWER HYBRIDS, ITAL. J. AGRON., 6, PP. 119-126, (2002); BECK J.G., MATHIEU D., LOUDET C., BUCHOUX S., DUFOURC E.J., PLANT STEROLS IN "" RAFTS"": A BETTER WAY TO REGULATE MEMBRANE THERMAL SHOCKS, FASEB J., 21, PP. 1714-1723, (2007); (1999); CONNOR D.J., JONES T.R., PALTA J.A., RESPONSE OF SUNFLOWER TO STRATEGIES OF IRRIGATION. I. GROWTH, YIELD AND THE EFFICIENCY OF WATER-USE, FIELD CROPS RES., 10, PP. 15-36, (1985); CONNOR D.J., HALL A.J., SUNFLOWER PHYSIOLOGY, SUNFLOWER TECHNOLOGY AND PRODUCTION, PP. 113-182, (1997); D'ANDRIA R., QUAGLIETTA CHIARANDA F., MAGLIULO V., MORI M., YIELD AND SOIL WATER UPTAKE OF SUNFLOWER SOWN IN SPRING AND SUMMER, AGRON. J., 87, PP. 1122-1128, (1995); DELPLANQUE B., INTÉRÊT NUTRITIONNEL DES TOURNESOLS, PROCEEDINGS OF THE 15TH INTERNATIONAL SUNFLOWER CONFERENCE, VOL. I, (2000); DOOREMBOS J., KASSAM A.H., (1979); DYER J.M., STYMNE S., GREEN A.G., CARLSSON A.S., HIGH-VALUE OILS FROM PLANTS, PLANT J., 54, PP. 640-655, (2008); (2009); FICK G.N., SUNFLOWER, OIL CROPS OF THE WORLD. THEIR BREEDING AND UTILIZATION, PP. 301-318, (1989); FLAGELLA Z., ROTUNNO T., TARANTINO E., DI CATERINA R., DE CARO A., CHANGES IN SEED AND OIL FATTY ACID COMPOSITION OF HIGH OLEIC SUNFLOWER (HELIANTHUS ANNUUS L.) HYBRIDS IN RELATION TO SOWING DATE AND THE WATER REGIME, EUR. J. AGRON., 17, PP. 221-230, (2002); FISK I.D., WHITE D.A., CARVALHO A., GRAY D.A., TOCOPHEROL - AN INTRINSIC COMPONENT OF SUNFLOWER SEED OIL BODIES, JAOCS, 83, PP. 341-344, (2006); GOKSOY A.T., DEMIR A.O., TURAN Z.M., DAGUSTU N., RESPONSES OF SUNFLOWER (HELIANTHUS ANNUUS L.) TO FULL AND LIMITED IRRIGATION AT DIFFERENT GROWTH STAGES, FIELD CROPS RES., 87, PP. 167-178, (2004); GOMEZ K.A., GOMEZ A.A., STATISTICAL PROCEDURES FOR AGRICULTURAL RESEARCH, (1984); GRASSINI P., HALL A.J., MERCAU J.L., BENCHMARKING SUNFLOWER WATER PRODUCTIVITY IN SEMIARID ENVIRONMENTS, FIELD CROPS RES., 110, PP. 251-262, (2009); GUIJUN D., XIAOLI L., ZHONGYUE C., WEIDONG P., HONGJIE L., GONGSHE L., THE DYNAMICS OF TOCOPHEROL AND THE EFFECT OF HIGH TEMPERATURE IN DEVELOPING SUNFLOWER (HELIANTHUS ANNUUS L.) EMBRYO, FOOD CHEM., 102, PP. 138-145, (2007); IZQUIERDO N.G., AGUIRREZABAL L.A.N., GENETIC VARIABILITY IN THE RESPONSE OF FATTY ACID COMPOSITION TO MINIMUM NIGHT TEMPERATURE DURING GRAIN FILLING IN SUNFLOWER, FIELD CROPS RES., 106, PP. 116-125, (2008); KAMAL-ELDIN A., ANDERSSON R., A MULTIVARIATE STUDY OF THE CORRELATION BETWEEN TOCOPHEROL CONTENT AND FATTY ACID COMPOSITION IN VEGETABLE OILS, JAOCS, 74, 4, PP. 375-380, (1997); MOZZON M., BOCCI F., FREGA N., A STUDY ON THE LIPIDIC FRACTION EXTRACTED FROM HIGH OLEIC SUNFLOWER SEEDS (HELIANTHUS ANNUUS L.) DURING THE RIPENING PROCESS, J. AGRIC. FOOD CHEM., 46, 10, PP. 4198-4202, (1998); NOLASCO S.M., AGUIRREZABAL L.A.N., CRAPISTE G.H., TOCOPHEROL OIL CONCENTRATION IN FIELD-GROWN SUNFLOWER IS ACCOUNTED FOR BY OIL WEIGHT PER SEED, J. AM. OIL CHEM. SOC., 81, PP. 1045-1051, (2004); NOLASCO S.M., AGUIRREZABAL L.A.N., LUQUEZ J., MATEO C., VARIABILITY IN OIL TOCOPHEROL CONCENTRATION AND COMPOSITION OF TRADITIONAL AND HIGH OLEIC SUNFLOWER HYBRIDS (HELIANTHUS ANNUUS L.) IN THE PAMPEAN REGION (ARGENTINA), GRASAS Y ACEITES, 57, 3, PP. 260-269, (2006); PEREIRA-IRUJO G.A., AGUIRREZABAL L.A.N., SUNFLOWER YIELD AND OIL QUALITY INTERACTIONS AND VARIABILITY: ANALYSIS THROUGH A SIMPLE SIMULATION MODEL, AGRIC. FOREST METEOROL., 143, PP. 252-265, (2007); PIIRONER V., LINDSAY D.G., MIETTINEN T.A., TOIVO J., LAMPI A.M., REVIEW. PLANT STEROLS: BIOSYNTHESIS, BIOLOGICAL FUNCTION AND THEIR IMPORTANCE TO HUMAN NUTRITION, J. SCI. FOOD. AGRIC., 80, PP. 939-966, (2000); PREVOT A., L'HUILE DE TOURNESOL AUJOURD'HUI, REV. FRANÇ. CORPS GRAS, 4, PP. 183-195, (1987); QUAGLIETTA CHIARANDA F., D'ANDRIA R., EFFECT OF DIFFERENT IRRIGATION SCHEDULING ON YIELD AND WATER UPTAKE OF A SPRING SUNFLOWER CROP (HELIANTHUS ANNUUS L.), EUR. J. AGRON., 3, 1, PP. 53-61, (1994); (2006); RINALDI M., APPLICATION OF EPIC MODEL FOR IRRIGATION SCHEDULING OF SUNFLOWER IN SOUTHERN ITALY, AGRIC. WATER MANAGE., 49, PP. 185-196, (2001); ROCHE J., BOUNIOLS A., MOULOUNGUI Z., BARRANCO T., CERNY M., MANAGEMENT OF ENVIRONMENTAL CROP CONDITIONS TO PRODUCE USEFUL SUNFLOWER OIL COMPONENTS, EUR. J. LIPID SCI. TECHNOL., 108, 4, PP. 287-297, (2006); ROCHE J., ALIGNAN M., BOUNIOLS A., CERNY M., MOULOUNGUI Z., VEAR F., MERAH O., STEROL CONTENT IN SUNFLOWER SEEDS (HELIANTHUS ANNUUS L.) AS AFFECTED BY GENOTYPES AND ENVIRONMENTAL CONDITIONS, FOOD CHEM., 121, PP. 990-995, (2010); RONDANINI D., SAVIN R., HALL A.J., DYNAMICS OF FRUIT GROWTH AND OIL QUALITY OF SUNFLOWER (HELIANTHUS ANNUUS L.) EXPOSED TO BRIEF INTERVALS OF HIGH TEMPERATURE DURING GRAIN FILLING, FIELD CROPS RES., 83, PP. 79-90, (2003); SADRAS V.O., VILLALOBOS F.J., PHYSIOLOGICAL CHARACTERISTICS RELATED TO YIELD IMPROVEMENT IN SUNFLOWER (HELIANTHUS ANNUUS L.), GENETIC IMPROVEMENT OF FIELD CROPS, PP. 287-320, (1994); SANTONOCETO C., ANASTASI U., RIGGI E., ABBATE V., ACCUMULATION DYNAMICS OF DRY MATTER, OIL AND MAJOR FATTY ACIDS IN SUNFLOWER SEEDS IN RELATION TO GENOTYPE AND WATER REGIME, ITAL. J. AGRON., 7, 1, PP. 3-14, (2003); SCHALLER H., THE ROLE OF STEROLS IN PLANT GROWTH AND DEVELOPMENT, PROG. LIPID RES., 42, PP. 163-175, (2003); SINDHU KANYA T.C., JAGANMOHAN RAO L., SHAMANTHAKA SASTRY M.C., CHARACTERIZATION OF WAX ESTERS, FREE FATTY ALCOHOLS AND FREE FATTY ACIDS OF CRUDE WAX FROM SUNFLOWER SEED OIL REFINERIES, FOOD CHEM., 101, PP. 1552-1557, (2007); SOBRINO E., TARQUIS A.M., CRUZ DIAZ M., MODELLING THE OLEIC ACID CONTENT IN SUNFLOWER OIL, AGRON. J., 95, PP. 329-334, (2003); SORIANO A.M., ORGAZ F., VILLALOBOS F.J., FERERES E., EFFICIENCY OF WATER USE OF EARLY PLANTINGS OF SUNFLOWER, EUR. J. AGRON., 21, PP. 465-476, (2004); STONE L.R., SCHLEGEL A.J., GWIN J.R., KHAN A.H., RESPONSE OF CORN, GRAIN SORGHUM, AND SUNFLOWER TO IRRIGATION IN THE HIGH PLAINS OF KANSAS, AGRIC. WATER MANAGE., 30, PP. 251-259, (1996); STUCHLIK M., ZAK S., VEGETABLE LIPIDS AS COMPONENTS OF FUNCTIONAL FOODS, BIOMED. PAP., 146, 2, PP. 3-10, (2002); TALHA M., OSMAN F., EFFECT OF SOIL WATER STRESS ON WATER ECONOMY AND OIL COMPOSITION IN SUNFLOWER (HELIANTHUS ANNUUS L.), J. AGRIC. SCI. CAMB., 84, PP. 49-56, (1975); UNGER P.W., TIME AND FREQUENCY OF IRRIGATION EFFECTS ON SUNFLOWER PRODUCTION AND WATER USE, SOIL SCI. SOC. AM. J., 46, PP. 1072-1076, (1982); UNGER P.W., IRRIGATION EFFECT ON SUNFLOWER GROWTH, DEVELOPMENT, AND WATER USE, FIELD CROPS RES., 7, PP. 181-194, (1983); VELASCO L., FERNANDEZ-MARTINEZ J.M., GARCIA-RUIZ R., DOMINGUEZ J., GENETIC AND ENVIRONMENTAL VARIATION FOR TOCOPHEROL CONTENT AND COMPOSITION SUNFLOWER COMMERCIAL HYBRIDS, J. AGRIC. SCI., 139, 4, PP. 425-429, (2002); VLAHAKIS C., HAZEBROEK J., PHYTOSTEROL ACCUMULATION IN CANOLA, SUNFLOWER AND SOYBEAN OILS: EFFECTS OF GENETICS, PLANTING LOCATION AND TEMPERATURE, J. AM. OIL CHEM. SOC., 77, PP. 49-53, (2000)","U. ANASTASI; DIPARTIMENTO DI BIOTECNOLOGIE PER IL MONITORAGGIO AGROALIMENTARE ED AMBIENTALE, UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA, 89124, REGGIO CALABRIA, C.DA MELISSARI, ITALY; EMAIL: ANASTASI@UNIRC.IT","","ENGLISH","FIELD CROPS RES.","ARTICLE","ISI","2-S2.0-77955920635","FIELD CROPS RES","UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;UNIVERSITÀ DEGLI STUDI DI CATANIA;UNIVERSITÀ DEGLI STUDI DI CATANIA;UNIVERSITÀ DEGLI STUDI DI CATANIA","NOTREPORTED;UNIVERSITÀ DEGLI STUDI MEDITERRANEA DI REGGIO CALABRIA;NOTREPORTED",NA,"ANASTASI U, 2010, FIELD CROPS RES","ANASTASI U, 2010, FIELD CROPS RES"
"SAKOUHI F;BOUKHCHINA S;ABSALON C;FOUQUET E;KALLEL H","SAKOUHI, FAOUZI (21743784700); BOUKHCHINA, SADOK (6507257738); ABSALON, CHRISTELLE (6506132616); FOUQUET, ERIC (6701413163); KALLEL, HABIB (22934478000)","POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN OLEA EUROPAEA L FRUITS",2010,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","112","6",11,"10.1002/ejlt.200900076","LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, EL MANAR, TUNISIE, TUNISIA;LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, EL MANAR, TUNISIE, TUNISIA;CENTRE D'ETUDE STRUCTURALE ET D'ANALYSE DES MOLÉCULES ORGANIQUES, INSTITUT DES SCIENCES MOLÉCULAIRES, UNIVERSITÉ DE BORDEAUX, BORDEAUX, FRANCE;CENTRE D'ETUDE STRUCTURALE ET D'ANALYSE DES MOLÉCULES ORGANIQUES, INSTITUT DES SCIENCES MOLÉCULAIRES, UNIVERSITÉ DE BORDEAUX, BORDEAUX, FRANCE;LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, EL MANAR, TUNISIE, TUNISIA","POLICOSANOL IS A MIXTURE OF BIOACTIVE MOLECULES SHOWN TO HAVE BENEFICIAL EFFECTS IN TREATING HYPERCHOLESTEROLEMIA. FOOD PRODUCTS ENRICHED IN POLICOSANOL ARE CURRENTLY AVAILABLE IN THE US MARKET. IN THE PRESENT STUDY, EIGHT POLICOSANOL COMPONENTS WERE IDENTIFIED BY GC-MS DURING THE RIPENING OF MESKI OLIVES. THE QUANTITATIVE CHARACTERIZATION OF THESE COMPOUNDS WAS PERFORMED USING GC-FID. THE RESULTS SHOWED THAT THE MAXIMUM LEVEL OF TOTAL POLICOSANOL COMPONENTS (947.20 MG/100 G OIL) WAS REACHED AT THE 26TH WEEK AFTER THE FLOWERING DATE OF MESKI OLIVES. HEXACOSANOL AND TETRACOSANOL WERE THE PREDOMINANT POLICOSANOL COMPONENTS AT MESKI OLIVEMATURITY. HOWEVER PENTACOSANOL, HEPTACOSANOL AND TRICOSANOL WERE LESS PRESENT IN THE OLIVES AND THEY ACCOUNTED FOR 14% OF THE TOTAL POLICOSANOL AT COMPLETE MATURITY OF THE FRUIT. THE TOTAL POLICOSANOL CONTENT OF MESKI OLIVES WAS HIGHER THAN THAT OF BEESWAX AND WHOLE SUGAR CANE, WHICH BELONG TO THE SOURCES OF DIETARY SUPPLEMENTS CONTAINING POLICOSANOL. THESE FINDINGS INDICATE THAT OLIVE IS A POTENTIAL SOURCE OF THESE HEALTH-ENHANCING COMPOUNDS FOR FUNCTIONAL FOODS AND NUTRACEUTICAL APPLICATIONS. © 2010 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.","ACCUMULATION; CHARACTERIZATION; OLIVE OIL; POLICOSANOL; RIPENING","OLEA EUROPAEA; OLEACEAE; SACCHARUM","","","IRMAK S., JONNALA R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, J CEREAL SCI, 48, PP. 20-26, (2008); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYM REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); KASSIS A.N., MARINANGELI C.P.F., JAIN D., EBINE N., JONES J.H., LACK OF EFFECT OF SUGAR CANE POLICOSANOL ON PLASMA CHOLESTEROL IN GOLDEN HAMSTERS, ATHEROSCLEROSIS, 194, PP. 153-158, (2007); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); CASTANO G., MAS R., FERNANDEZ L., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); LIN Y., RUDRUM M., WIELEN R.P., TRAUTWEIN E.A., MCNEIL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MIDLY ELEVATED CHOLESTEROL CONCENTRATION, METABOLISM, 53, PP. 1309-1314, (2004); WANG Y.W., JONES P.J.H., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); AWAD A.B., DOWNIE A., FINK C.S., KIM U., DIETARY PHYTOSTEROL INHIBITS THE GROWTH AND METASTASIS OF MDA-MB-231 HUMAN BREAST CANCER CELLS GROWN IN SCID MICE, ANTICANCER RES, 20, PP. 821-824, (2000); HICKS K.B., MOREAU R.A., PHYTOSTEROLS AND PHYTOSTANOLS: FUNCTIONAL FOOD CHOLESTEROL BUSTERS, FOOD TECHNOL, 12, PP. 478-480, (2001); SANTOS R., LIMAS E., SOUSA M., DA CONCEICAO CASTILHO M., RAMOS F., NORONHA DA SILVEIRA M.I., OPTIMIZATION OF ANALYTICAL PROCEDURES FOR GC-MS DETERMINATION OF PHYTOSTEROLS AND PHYTOSTANOLS IN ENRICHED MILK AND YOGHURT, FOOD CHEM, 102, PP. 113-117, (2006); CONCHILLO A., CERCACI L., ANSORENA D., RODRIGUEZ-ESTRADA M.T., LERCKER G., ASTIASANAN I., LEVELS OF PHYTOSTEROL OXIDES IN ENRICHED AND NONENRICHED SPREADS: APPLICATION OF A THIN-LAYER CHROMATOGRAPHY-GAS CHROMATOGRAPHY METHODOLOGY, J AGRIC FOOD CHEM, 53, PP. 7844-7850, (2005); SAKOUHI F., ABSALON C., HARRABI S., VITRY C., SBEI K., BOUKHCHINA S., FOUQUET E., KALLEL H., DYNAMIC ACCUMULATION OF 4-DESMETHYLSTEROLS AND PHYTOSTANOLS DURING RIPENING OF TUNISIAN MESKI OLIVES (OLEA EUROPAEA L.), FOOD CHEM, 112, PP. 897-902, (2009); GARCIA A., ALVAREZ A., CANETE R., SOVOVA R., SUPERCRITAL FLUID EXTRACTION OF SUGAR CANE CRUDE WAX, INTERNATIONAL SYMPOSIUM ON SUPERCRITICAL FLUIDS, 3, PP. 229-234, (1994); LUCAS A., GARCIA A., RINCON J., ALVAREZ A., GRACIA J., GARCIA M.A., SUPERCRITICAL CARBON DIOXIDE EXTRACTION OF FATTY AND WAXY MATERIAL FROM RICE BRAN, J AM OIL CHEM SOC, 73, PP. 1127-1131, (1997); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); ALKOWSKI C.A., DETORE G., MCNALLY R., ROOIJEN N., VOGEL S.N., REGULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE MESSENGER RNA EXPRESSION AND NITRIC OXIDE PRODUCTION BY LIPOPOLYSACCHARIDE IN VIVO: THE ROLES OF MACROPHAGES, ENDOGENOUS IFN-GAMMA, AND TNF RECEPTOR-1-MEDIATED SIGNALLING, J IMMUNOL, 158, PP. 905-912, (1997); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOASONOL IN HUMAN HEALTH, NUTRITON, 19, PP. 192-195, (2003); SHRIPATHI V., SWAMY G.S., EFFECT OF TRIACONTANOL ON THE LIPID COMPOSITION OF COTTON (GOSSYPIUM HIRSUTUM L.) LEAVES AND ITS INTERACTION WITH INDOLE-3-ACETIC AND BENZYL ASENINE, PLANT GROWTH REGUL, 14, PP. 45-50, (1994); WARREN P.R., BURGER R.A., SIDWELL R.W., CLARK L.L., EFFECT OF TRIACONTANOL ON NUMBERS AND FUNCTIONS OF CELLS INVOLVED IN INFLAMMATORY RESPONSES, PROC SOC EXP BIOL MED, 200, PP. 349-352, (2002); LUCAS A., GARCIA A., ALVAREZ A., GRACIA I., SUPERCRITICAL EXTRACTION OF LONG CHAIN N-ALCOHOLS FROM SUGAR CANE CRUDE WAX, J SUPERCRIT FLUIDS, 41, PP. 267-271, (2007); INTERNATIONAL OLIVE OIL COUNCIL, (2005); MICHAEL A., JACKSON A., ELLER F.J., ISOLATION OF LONG-CHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASE-CATALYSED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE, J SUPERCRIT FLUIDS, 37, PP. 173-177, (2006); OFFICIAL METHODS AND RECOMMENDED PRACTICES OF THE AMERICAN OIL CHEMISTS' SOCIETY, (1990); BACCOURI B., BEN TEMIME S., TAAMALLI W., DAOUD D., MSALEM M., ZARROUK M., ANALYTICAL CHARACTERISTICS OF VIRGIN OLIVE OILS FROM TWO NEW VARIETIES OBTAINED BY CONTROLLED CROSSING ON MESKI VARIETY, J FOOD LIPIDS, 14, PP. 19-34, (2007); CUNHA S.S., FERNANDES J.O., OLIVEIRA M.B.P.P., QUANTIFICATION OF FREE AND ESTERIFIED STEROLS IN PORTUGUESE OLIVE OILS BY SOLID-PHASE EXTRACTION AND GAS CHROMATOGRAPHY-MASS SPECTROMETRY, J CHROMATOGR A, 1128, PP. 220-227, (2006); FERNANDEZ-ARCHE A., MARQUEZ-MARTIN A., PUERTA VARQUEZ R., PERONA J.S., TERENCIO C., PEREZ-CAMINO C., RUIZ-GUTIERREZ V., LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS, J NUTR BIOCHEM, 20, PP. 155-162, (2009); GONZALEZ-BRAVO L., MAGRANER-HERMANDEZ J., ACOSTA-GONSALEZ P.C., PEREZ-SOUTO N., ANALYTICAL PROCEDURE FOR THE DETERMINATION OF 1-OCTACOSANOL IN PLASMA BY SOLVENT EXTRACTION AND CAPILLARY GAS CHROMATOGRAPHY, J CHROMATOGR B, 682, PP. 359-363, (1996); LAGUNA A., MAGRANCER J., CABAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M., A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACOLOGICAL USES, (1997); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); HERMENDEZ F., ILLNAIT J., MAS R., EFFECT OF POLICOSANOL ON SERUM LIPID AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 56, PP. 568-575, (1992); MENEDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ I., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOLS 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., HERNANDEZ E., FERNANDEZ J., GAMEZ R., ALVAREZ E., A RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 63, PP. 286-303, (2002); MIRKIN A., MAS R., MARTINTO M., BACCANERA R., ROBERTIS A., POUDES R., FUSTER A., LASTRETO E., YANEZ M., IRICO G., MCCOOK B., FARRE A., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001)","F. SAKOUHI; LABORATOIRE DE BIOCHIMIE DES LIPIDES, DÉPARTEMENT DE BIOLOGIE, FACULTÉ DES SCIENCES DE TUNIS, 2092 EL MANAR II, TUNISIE, TUNISIA; EMAIL: FAOUZI.SAKOUHI@FST.RNU.TN","WILEY-VCH VERLAG","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-77953589069","EUR J LIPID SCI TECHNOL","FACULTÉ DES SCIENCES DE TUNIS;FACULTÉ DES SCIENCES DE TUNIS;UNIVERSITÉ DE BORDEAUX;UNIVERSITÉ DE BORDEAUX;FACULTÉ DES SCIENCES DE TUNIS","NOTREPORTED;FACULTÉ DES SCIENCES DE TUNIS;NOTREPORTED",NA,"SAKOUHI F, 2010, EUR J LIPID SCI TECHNOL","SAKOUHI F, 2010, EUR J LIPID SCI TECHNOL"
"TRIMARCO B;BENVENUTI C;ROZZA F;CIMMINO C;GIUDICE R;CRISPO S","TRIMARCO, BRUNO (57210773404); BENVENUTI, CLAUDIO (7101839008); ROZZA, FRANCESCO (23498918300); CIMMINO, CLAUDIA SARA (36705618500); GIUDICE, RENATA (26023021700); CRISPO, SALVATORE (22940367600)","CLINICAL EVIDENCE OF EFFICACY OF RED YEAST RICE AND BERBERINE IN A LARGE CONTROLLED STUDY VERSUS DIET",2011,"MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM","4","6",50,"10.1007/s12349-010-0043-6","DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;MEDICAL DEPARTMENT, ROTTAPHARM MADAUS, MONZA, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY","EFFICACY OF A NEW PATENTED PROPRIETARY COMBINATION OF NATURAL NUTRACEUTICALS (PN) CONTAINING NATURAL HYPOLIPIDEMIC AS RED YEAST, POLICOSANOL AND BERBERINE WAS TESTED IN A LARGE STUDY ON DYSLIPIDEMIC PATIENTS IN CLINICAL PRACTICE. A PARALLEL, CONTROLLED, RANDOMIZED, MULTICENTER STUDY WAS DESIGNED. AFTER 2 WEEKS ON A STABLE DIETARY REGIMEN, THE PATIENTS WERE RANDOMIZED TO PN 1 TABLET/DAY ASSOCIATED WITH DIET (PN + D) OR DIET ALONE (D) FOR 16 WEEKS. ENTRY CRITERIA WERE: TOT-CHOL >200 MG/DL OR LDL-CHOL >150 MG/DL WITHOUT A CLEAR INDICATION FOR STATINS, OR PLASMA TRIGLYCERIDES>150 MG/DL. LIPID PATTERN AND CV PARAMETERS WERE EVALUATED AT BASELINE AND MONTHLY. 1,751 PATIENTS WERE ENROLLED IN 248 ITALIAN UNITS, 933 PATIENTS ON PN + D AND 818 ON D. THE BASELINE LIPID VALUES WERE: TOT-CHOL 255.4 VERSUS 243.1 MG/DL, LDLCHOL 170.1 VERSUS 162.2 MG/DL, HDL-CHOL 50.0 VERSUS 48.8 MG/DL, AND TG 190.5 VERSUS 184.4 MG/DL. PN CONSTANTLY AND SIGNIFICANTLY IMPROVED LIPID PARAMETERS VERSUS D GROUP: AT 16 WEEKS-19.1 VERSUS-9.4% FOR TOT-CHOL (P<0.001),-23.5 VERSUS-10.8% FOR LDLCHOL (P<0.001), +11.6 VERSUS +4.0% FOR HDL-CHOL (P<0.001),-17.9 VERSUS-11.3% FOR TG (P<0.001). IN CONCLUSIONS, PN PLUS DIET ALLOWS AN EFFECTIVE IMPROVEMENT OF BLOOD LIPIDS WITH A SIGNIFICANT REDUCTION OF GLOBAL CV RISK, SUGGESTING A ROLE FOR PN IN CHD PREVENTION. © 2011 SPRINGER-VERLAG.","BERBERINE; DYSLIPIDEMIA; METABOLIC SYNDROME; NUTRACEUTICALS; RED YEAST","ASTAXANTHIN; BERBERINE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; XUEZHIKANG; ADULT; ARTICLE; ASTHENIA; BITTER TASTE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METEORISM; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; STEATORRHEA; STOMACH PAIN; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING","","","HILL A.M., FLEMING J.A., KRIS-ETHERTON P.M., THE ROLE OF DIET AND NUTRITIONAL SUPPLEMENTS IN PREVENTING AND TREATING CARDIOVASCULAR DISEASE, CURR OPIN CARDIOL, 24, PP. 433-441, (2009); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2496, (2001); SMITH JR. S.C., ALLEN J., BLAIR S.N., BONOW R.O., BRASS L.M., FONAROW G.C., GRUNDY S.M., HIRATZKA L., JONES D., KRUMHOLZ H.M., MOSCA L., PASTERNAK R.C., PEARSON T., PFEFFER M.A., TAUBERT K.A., AHA/ACC GUIDELINES FOR SECONDARY PREVENTION FOR PATIENTS WITH CORONARY AND OTHER ATHEROSCLEROTIC VASCULAR DISEASE: 2006 UPDATE. ENDORSED BY THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 47, 10, PP. 2130-2139, (2006); CICERO A.F.G., ROVATI L.C., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS: A SINGLE-BLIND CLINICAL INVESTIGATION, ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 57, 1, PP. 26-30, (2007); RUMAWAS M.E., MEIGS J.B., DWYER J.T., MCKEOWN N.M., JACQUES P.F., MEDITERRANEAN-STYLE DIETARY PATTERN, REDUCED RISK OF METABOLIC SYNDROME TRAITS, AND INCIDENCE IN THE FRAMINGHAM OFFSPRING COHORT, AM J CLIN NUTR, 90, PP. 1608-1614, (2009); AFG C., DEROSA G., BOVE M., BORGHI C., GADDI A.V., LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME, CURR TOPICS NUTRACEUTICAL RES, 7, (2009); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT ARZNEIMITTEL-FORSCHUNG (DRUG RESEARCH), 55, PP. 312-317, (2005); DOSE-DEPENDENT EFFECTS OF FOLIC ACID ON BLOOD CONCENTRATIONS OF HOMOCYSTEINE: A META-ANALYSIS OF THE RANDOMIZED TRIALS, AM J CLIN NUTR, 82, PP. 806-812, (2005); COHEN J., A POWER PRIMER, PSYCHOL BULL, 112, 1, PP. 155-159, (1992); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L.W., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AMERICAN JOURNAL OF CLINICAL NUTRITION, 69, 2, PP. 231-236, (1999); WANG J., SU M., LU Z., ET AL., CLINICAL TRIAL OF EXTRACT OF MONASCUS PURPUREUS (RED YEAST) IN THE TREATMENT OF HYPERLIPID-EMIA, CHIN J EXP THER PREP CHIN MED, 12, PP. 1-5, (1995); BRUSQ J.-M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINI-LLAN Y., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP-KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPEMIC EFFECT OF BERBERINE, J LIPID RES FEB, 28, (2006); AFG C., ERTEK S., METABOLIC AND CARDIOVASCULAR EFFECTS OF BERBERINE: FROM PRECLINICAL EVIDENCES TO CLINICAL TRIAL RESULTS, CLIN LIPIDOL, 4, PP. 553-563, (2009); CAPUTI A.P., BENVENUTI C., ARMOWEB STUDY GROUP IMPROVING THE DIET EFFICACY IN HYPERCHOLESTEROLEMIC SUBJECTS WITH RED YEAST RICE PLUS POLICOSANOL, L'INTERNISTA/MEDICINA CLINICA.IT, 16, PP. 53-60, (2008); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., WANG Y., WANG Z., SI S., PAN H., WANG S., WU J., WANG Y., LI Z., LIU J., JIANG J.-D., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NATURE MEDICINE, 10, 12, PP. 1344-1351, (2004); AFG C., BENVENUTI C., ARMOWEB STUDY GROUP EFFICACY OF A RED YEAST RICE BASED NUTRACEUTICAL IN LARGE SUBGROUPS OF HYPERCHOLESTEROLEMIC SUBJECTS IN EVERY DAY CLINICAL PRACTICE, MEDITER J NUTR METABOL, (2010); IZZO R., DE SIMONE G., GIUDICE R., CHINALI M., TRIMARCO V., DE LUCA N., TRIMARCO B., EFFECTS OF NUTRACEUTICALS ON PREVALENCE OF METABOLIC SYNDROME AND ON CALCULATED FRAMINGHAM RISK SCORE IN SUBJECTS WITH DYSLIPIDEMIA, J HYPERTENSION, (2010)","B. TRIMARCO; DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR AND IMMUNOLOGICAL SCIENCES, FEDERICO II UNIVERSITY, BLD 2, 80131 NAPLES, VIA SERGIO PANSINI 5, ITALY; EMAIL: TRIMARCO@UNINA.IT","","ENGLISH","MEDITERR. J. NUTR. METAB.","ARTICLE","ISI","2-S2.0-80055071716","MEDITERR J NUTR METAB","FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY;FEDERICO II UNIVERSITY","NOTREPORTED;FEDERICO II UNIVERSITY;NOTREPORTED",NA,"TRIMARCO B, 2011, MEDITERR J NUTR METAB","TRIMARCO B, 2011, MEDITERR J NUTR METAB"
"CHEN Y;DUNFORD N;EDWARDS J;CARVER B;GOAD C","CHEN, YONGFEN (55046220700); DUNFORD, NURHAN T. (6603296815); EDWARDS, JEFF (26032065400); CARVER, BRETT (26643366700); GOAD, CARLA (7004431837)","POLICOSANOL CONTENT AND COMPOSITION OF WHEAT VARIETIES AS AFFECTED BY ENVIRONMENT",2009,"JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE","89","4",14,"10.1002/jsfa.3446","DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES;DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, UNITED STATES, DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES;DEPARTMENT OF PLANT AND SOIL SCIENCES, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES;DEPARTMENT OF PLANT AND SOIL SCIENCES, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES;DEPARTMENT OF STATISTICS, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK, UNITED STATES","BACKGROUND: POLICOSANOL (PC) IS A MIXTURE OF HIGH-MOLECULAR-WEIGHT ALIPHATIC PRIMARY SATURATED ALCOHOLS WHICH POSSESSES CHOLESTEROL-LOWERING PROPERTIES. LITERATURE ON PC CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES IS LIMITED. THE MAIN OBJECTIVE OF THIS STUDY WAS TO EVALUATE THE EFFECT OF GENOTYPE AND ENVIRONMENT ON PC CONTENT AND COMPOSITION IN WHEAT GRAIN. RESULTS: GRAIN SAMPLES WERE COLLECTED FROM THREE VARIETIES, JAGGER, TREGO AND INTRADA, GROWN AT THREE LOCATIONS, ALVA, BALKO AND GOODWELL, OK, IN 2005. TWO SETS OF SAMPLES WERE OBTAINED FROM GOODWELL (IRRIGATED AND DRYLAND SAMPLES). TOTAL PC CONTENT AND PC COMPOSITION IN WHOLE WHEAT GRAIN SAMPLES WERE DETERMINED USING A GAS CHROMATOGRAPHY SYSTEM. PC CONTENTS OF THE WHOLE WHEAT GRAIN SAMPLES VARIED FROM 15.9 TO 28.7MG KG-1. TRICOSANOL, TETRACOSANOL, HEXACOSANOL, OCTACOSANOL AND TRIACONTANOL WERE THEMOST ABUNDANT PC COMPONENTS. WITHIN EACH LOCATION A SIGNIFICANT VARIETY EFFECTWAS OBSERVED. THERE WAS ALSO A SIGNIFICANT LOCATION X VARIETY RANDOM EFFECT ON PC CONTENT. CONCLUSION: A FUNDAMENTAL UNDERSTANDING OF COMPOSITIONAL VARIATION IN WHEAT GRAIN REQUIRES MULTI-ENVIRONMENT TESTING OF GENOTYPES, PERHAPS OVER SEVERAL YEARS. THIS STUDY IS THE FIRST STEP TOWARDS ACHIEVING THIS GOAL BY REVEALING SIGNIFICANT GENETIC DIFFERENCES IN A LIMITED SET OF GENOTYPES. © 2008 SOCIETY OF CHEMICAL INDUSTRY.","POLICOSANOL; WHEAT; WHEAT LIPID CONTENT; WHEAT MILLING","TRITICUM AESTIVUM","","","MENENDEZ R., MAS R., AMOR A.M., FERNANDEZ J.C., GONZALEZ R.M., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ J., ORTA S.D., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLYCOSANOL, CURR THER RES, 60, PP. 458-467, (1999); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); KAHLON T.S., NUTRITIONAL IMPLICATIONS AND USES OF WHEAT AND OAT KERNEL OIL, CEREAL FOODS WORLD, 34, PP. 872-875, (1989); DUNFORD N.T., GERM OILS FROM VARIOUS SOURCES, BAILEY'S INDUSTRIAL OIL AND FAT PRODUCTS, PP. 195-231, (2005); POLLARD A., CHIBNALL A.C., PIPER S.H., CCVII. THE ISOLATION OF N-OCTACOSANOL FROM WHEAT WAX, BIOCHEM J, 27, PP. 1889-1893, (1933); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF TRITICUM AESTIVUM, PHYTOCHEMISTRY, 12, PP. 2217-2223, (1973); CURETON T.K., POHNDORF R.H., INFLUENCE OF WHEAT GERM OIL AS A DIETARY SUPPLEMENT IN A PROGRAM OF CONDITIONING EXERCISES WITH MIDDLE-AGED SUBJECTS, THE PHYSIOLOGICAL EFFECTS OF WHEAT GERM OIL ON HUMANS IN EXERCISE; FORTY-TWO PHYSICAL TRAINING PROGRAMS UTILIZING 894 HUMANS, PP. 353-373, (1972); CURETON T.K., THE PHYSIOLOGICAL EFFECTS OF WHEAT GERM OIL ON HUMANS IN EXERCISE; FORTY-TWO PHYSICAL TRAINING PROGRAMS UTILIZING 894 HUMANS, (1972); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2005); IRMAK S., JONNALA R.S., MACRITCHIE F., EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES, J CEREAL SCI, 48, PP. 20-26, (2008); OKLAHOMA MESONET; SAYASLAN A., SEIB P.A., CHUNG O.K., WET-MILLING PROPERTIES OF WAXY WHEAT FLOURS BY TWO LABORATORY METHODS, J FOOD ENG, 72, PP. 167-178, (2006); OFFICIAL METHODS OF ANALYSIS, (1995); PEYRON S., MABILLE F., DEVAUX M.F., AUTRAN J.C., INFLUENCE OF STRUCTURAL CHARACTERISTICS OF ALEURONE LAYER ON MILLING BEHAVIOR OF DURUM WHEAT (TRITICUM DURUM DESF.), CEREAL CHEM, 80, PP. 62-67, (2003); KONOPKA I., CZAPLICKI S., ROTKIEWICZ D., DIFFERENCES IN CONTENT AND COMPOSITION OF FREE LIPIDS AND CAROTENOIDS IN FLOUR OF SPRING AND WINTER WHEAT CULTIVATED IN POLAND, FOOD CHEM, 95, PP. 290-300, (2006); RUIBAL-MENDIETA N.L., DELACROIX D.L., MEURENS M., A COMPARATIVE ANALYSIS OF FREE, BOUND AND TOTAL LIPID CONTENT ON SPELT AND WINTER WHEAT WHOLEMEAL, J CEREAL SCI, 35, PP. 337-342, (2002); KONOPKA I., KOZIROK W., ROTKIEWICZ D., LIPIDS AND CAROTENOIDS OF WHEAT GRAIN AND FLOUR AND ATTEMPT OF CORRELATING THEM WITH DIGITAL IMAGE ANALYSIS OF KERNEL SURFACE AND CROSS-SECTIONS, FOOD RES INT, 37, PP. 429-438, (2004); POMERANZ Y., CHUNG O., THE LIPID COMPOSITION OF A SINGLE WHEAT KERNEL AND ITS STRUCTURAL PARTS, J CHROMATOGR A, 19, PP. 540-550, (1965); KUMAR V., RANI A., PANDEY V., SINGH A., HUSSAIN S.M., CHAUHAN G.S., EVALUATION OF EARLY MATURING SOYBEAN (GLYCINE MAX) GERMPLASM ACCESSIONS FOR FATTY ACID COMPOSITION, INDIAN J AGRIC SCI, 76, PP. 192-195, (2006)","N. T. DUNFORD; DEPARTMENT OF BIOSYSTEMS AND AGRICULTURAL ENGINEERING, ROBERT M. KERR FOOD AND AGRICULTURAL PRODUCTS CENTER, OKLAHOMA STATE UNIVERSITY, STILLWATER, OK 74078-6055, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","J. SCI. FOOD AGRIC.","ARTICLE","ISI","2-S2.0-59349108240","J SCI FOOD AGRIC","OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY","NOTREPORTED;OKLAHOMA STATE UNIVERSITY;NOTREPORTED",NA,"CHEN Y, 2009, J SCI FOOD AGRIC","CHEN Y, 2009, J SCI FOOD AGRIC"
"VAN D W A","VAN DER WESTHUIZEN, ANGELENE (36115752000)","EVIDENCEBASED PHARMACY PRACTICE EBPP DYSLIPIDAEMIA",2010,"SA PHARMACEUTICAL JOURNAL","77","9",1,"","DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF PRETORIA, SOUTH AFRICA","DYSLIPIDAEMIA IS A DISORDER OF LIPOPROTEIN METABOLISM THAT ALTERS THE CONCENTRATION OR COMPOSITION OF LIPOPROTEINS. ATHEROSCLEROSIS AND PANCREATITIS ARE THE TWO MAJOR COMPLICATIONS OF DYSLIPIDAEMIA. THE MOST COMMON DYSLIPIDAEMIA IS HYPERCHOLESTEROLAEMIA, WHICH IS ONE OF THE MAJOR RISK FACTORS FOR CORONARY HEART DISEASE (CHD) AND CEREBROVASCULAR MORBIDITY AND MORTALITY. SEVERE HYPERTRIGLYCERIDAEMIA CAN CAUSE ACUTE PANCREATITIS. INITIAL THERAPY FOR ANY LIPOPROTEIN DISORDER IS LIFESTYLE CHANGES WHICH INCLUDE SMOKING CESSATION, A DIET LOW IN SATURATED FATS, WEIGHT LOSS IF INDICATED AND REGULAR AEROBIC EXERCISE. CORRECTION OF ANY PRECIPITATING FACTORS SUCH AS UNCONTROLLED DIABETES, ALCOHOL ABUSE OR MEDICATIONS SHOULD BE UNDERTAKEN. IF LIFESTYLE CHANGES ARE NOT EFFECTIVE, THEN DRUG THERAPY SHOULD BE CONSIDERED. THE CHOICE OF DRUG THERAPY IS DEPENDENT ON THE TYPE OF LIPOPROTEIN DISORDER. THE MOST EFFECTIVE CHOLESTEROL LOWERING DRUGS ARE THE STATINS (HMG COA REDUCTASE INHIBITORS). THEY WORK BY INHIBITING THE RATE-LIMITING STEP IN CHOLESTEROL SYNTHESIS. THEY ARE THE MOST POTENT FORM OF MONOTHERAPY AS WELL AS BEING THE MOST COST EFFECTIVE. PATIENTS NOT RESPONDING TO STATIN MONOTHERAPY CAN BE TREATED WITH COMBINATION THERAPY, WHICH MAY INCLUDE BILE ACID RESINS, FIBRATES, NICOTINIC ACID OR EZETIMIBE. DIETARY SUPPLEMENTS SUCH AS PLANT STEROLS AND FISH OILS CAN ALSO ASSIST IN LOWERING CHOLESTEROL LEVELS. LIPID LOWERING IS BENEFICIAL IN PATIENTS WITH DYSLIPIDAEMIAS FOR BOTH PRIMARY AND SECONDARY PREVENTION OF CHD.","","ACETYLSALICYLIC ACID; ACIPIMOX; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID RESIN; CHOLESTEROL; COLESTYRAMINE; CYCLOSPORIN A; DIGOXIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLORA PROACTIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVACHOL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PRAVA; PRAVASTATIN; PROBUCOL; QUESTRAN LITE; ROSUVASTATIN; SIMVASTATIN; SITOSTEROL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; WARFARIN; ADD ON THERAPY; AEROBIC EXERCISE; ARTICLE; ATHEROSCLEROSIS; BLOATING; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY FIBER; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; EPIGASTRIC FULLNESS; EVIDENCE BASED PRACTICE; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MYOPATHY; NAUSEA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHARMACIST; PHARMACY; PRURITUS; RASH; SIDE EFFECT; SMOKING CESSATION; TEA; UNSPECIFIED SIDE EFFECT; WALNUT; WEIGHT REDUCTION","","","WELLS B.G., DIPIRO C.V., DIPIRO J.T., SCHWINGHAMMER T.L., PHARMACOTHERAPY HANDBOOK, (2009); LAZO J., BRUNTON L., PARKER K., GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, (2005); BLOM D.J., A CLINICAL APPROACH TO DYSLIPIDAEMIA, CME, 27, 3, PP. 108-114, (2009); BENNETT P.N., BROWN M.J., CLINICAL PHARMACOLOGY, (2009); BAYAT Z., SECONDARY DYSLIPIDAEMIA, 27, 3, PP. 115-117, (2009); LE RICHIE M. RATIONAL USE OF LIPID INVESTIGATIONS. CME, 27, 3, PP. 129-130, (2009); DE BACKER G., AMBROSIONI E., BORCH-JOHNSON K., ET AL., EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUROPEAN HEART J, 24, PP. 1601-1610, (2003); RAAL F., MARAIS A.D., SCHAMROTH C., ADOPTION OF THE EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE - GUIDE TO LIPID MANAGEMENT, SA HEART WINTER;3, PP. 1-20; EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III). THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III): FINAL REPORT, CIRCULATION, 106, PP. 3143-3221, (2002); GRUNDY S.M., CLEEMAN J.I., MERZ C.N., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, 2, PP. 227-239, (2004); LI C.L., ZHU Y., WANG Y., ET AL., MONASCUS PURPUREUS-FERMENTED RICE (RED YEAST RICE): A NATURAL FOOD PRODUCT THAT LOWERS BLOOD CHOLESTEROL IN ANIMAL MODELS OF HYPERCHOLESTEROLAEMIA, NUTR RES, 18, (1998); PATRICK L., UZICK M., CARDIOVASCULAR DISEASE: C-REACTIVE PROTEIN AND THE INFLAMMATORY DISEASE PARADIGM: HMG-COA REDUCTASE INHIBITORS, ALPHA TOCOPHEROL, RED YEAST RICE, AND OLIVE OIL POLYPHENOLS. A REVIEW OF THE LITERATURE, ALTERN MED REV, 6, (2001); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, (1999); RAJPUT M.C., LIPID-MODIFYING THERAPY, CME, 27, 3, PP. 123-126, (2009); PLAT J., MENSINK R.P., PLANT STANOL AND STEROL ESTERS IN THE CONTROL OF BLOOD CHOLESTEROL LEVELS: MECHANISM AND SAFETY ASPECTS, THE AMERICAN JOURNAL OF CARDIOLOGY, 96, 1 A, (2005); ZAMBON D., SABATE J., MUNOZ S., ET AL., SUBSTITUTING WALNUTS FOR MONOUNSATURATED FAT IMPROVES THE SERUM LIPID PROFILE OF HYPERCHOLESTEROLAEMIC MEN AND WOMEN. A RANDOMIZED CROSSOVER TRIAL, AM INTERN MED, 132, (2000); SABATE J., FRASER G.E., BURKE K., ET AL., EFFECTS OF WALNUTS ON SERUM LIPID LEVELS AND BLOOD PRESSURE IN NORMAL MEN, N ENGL J MED, 328, (1993); GEBAUER S.K., WEST S.G., KAY C.D., ET AL., EFFECTS OF PISTACHIOS ON CARDIOVASCULAR DISEASE RISK FACTORS AND POTENTIAL MECHANISMS OF ACTION: A DOSERESPONSE STUDY, AM J CLIN NUTR, 88, (2008); MARON D.J., LU G.P., CAI N.S., ET AL., CHOLESTEROL-LOWERING EFFECT OF A THEAFLAVINENRICHED GREEN TEA EXTRACT: A RANDOMIZED CONTROLLED TRIAL, ARCH INTERN MED, 163, (2003); BLOM D.J., MARAIS A.D., NEW THERAPEUTIC DEVELOPMENTS IN LIPIDOLOGY, CME, 27, 3, PP. 104-106, (2009); JONES P.H., DAVIDSON M.H., STEIN E.A., ET AL., COMPARISON OF THE EFFICACY AND SAFETY OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN ACROSS DOSES (STELLAR* TRIAL) AN, J CARDIOL, 92, (2003); KNOPP R.H., DRUG TREATMENT OF LIPID DISORDERS, N ENGL J MED, 341, PP. 498-511, (1999); EDISON R.J., MUENKE M., CENTRAL NERVOUS SYSTEM AND LIMB ANOMALIES IN CASE REPORTS OF THE FIRST-TRIMESTER STATIN EXPOSURE, N ENGL J MED, PP. 350-1579, (2004); GRUNDY S.M., MOK H.Y., ZECH L., BERMAN M., INFLUENCE OF NICOTINIC ACID ON METABOLISM OF CHOLESTEROL AND TRIGLYCERIDES IN MAN, J LIPID RES, 22, (1981); ILLINGWORTH D.R., STEIN E.A., MITCHEL Y.B., ET AL., COMPARATIVE EFFECTS OF LOVASTATIN AND NIACIN IN PRIMARY HYPERCHOLESTEROLEMIA. A PROSPECTIVE TRIAL, ARCH INTERN MED, 154, (1994); SUDHOP T., LUTJOHANN D., KODAL A., ET AL., INHIBITION OF INTESTINAL CHOLESTEROL ABSORPTION BY EZETIMIBE IN HUMANS, CIRCULATION, 106, (2002)","","","ENGLISH","SA PHARM. J.","ARTICLE","ISI","2-S2.0-77953373264","SA PHARM J",NA,"NOTREPORTED",NA,"VAN DER WESTHUIZEN A, 2010, SA PHARM J","VAN DER WESTHUIZEN A, 2010, SA PHARM J"
"BANERJEE S;GHOSHAL S;PORTER T","BANERJEE, SUBHASHIS (57358730800); GHOSHAL, SARBANI (7006765660); PORTER, TODD D. (35572403800)","ACTIVATION OF AMPKINASE BY POLICOSANOL REQUIRES PEROXISOMAL METABOLISM",2011,"LIPIDS","46","10",29,"10.1007/s11745-011-3540-6","GRADUATE CENTER FOR TOXICOLOGY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0305, UNITED STATES;DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0596, UNITED STATES;GRADUATE CENTER FOR TOXICOLOGY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0305, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0596, UNITED STATES","POLICOSANOL, A WELL-DEFINED MIXTURE OF VERY LONG CHAIN PRIMARY ALCOHOLS THAT IS AVAILABLE AS A NUTRACEUTICAL PRODUCT, HAS BEEN REPORTED TO LOWER BLOOD CHOLESTEROL LEVELS. THE PRESENT STUDIES DEMONSTRATE THAT POLICOSANOL PROMOTES THE PHOSPHORYLATION OF AMP-KINASE AND HMG-COA REDUCTASE IN HEPATOMA CELLS AND IN MOUSE LIVER AFTER INTRAGASTRIC ADMINISTRATION, PROVIDING A POSSIBLE MEANS BY WHICH POLICOSANOL MIGHT LOWER BLOOD CHOLESTEROL LEVELS. TREATMENT OF HEPATOMA CELLS WITH POLICOSANOL PRODUCED A 2.5-FOLD OR GREATER INCREASE IN THE PHOSPHORYLATION OF AMP-KINASE AND HMG-COA REDUCTASE, AND INCREASED THE PHOSPHORYLATION OF CA++/CALMODULIN-DEPENDENT KINASE KINASE (CAMKK), AN UPSTREAM AMP-KINASE KINASE. INTRAGASTRIC ADMINISTRATION OF POLICOSANOL TO MICE SIMILARLY INCREASED THE PHOSPHORYLATION OF HEPATIC HMG-COA REDUCTASE AND AMP-KINASE BY GREATER THAN 2-FOLD. SIRNA-MEDIATED SUPPRESSION OF FATTY ALDEHYDE DEHYDROGENASE, FATTY ACYL-COA SYNTHETASE 4, AND ACYL-COA ACETYLTRANSFERASE EXPRESSION IN HEPATOMA CELLS PREVENTED THE PHOSPHORYLATION OF AMP-KINASE AND HMG-COA REDUCTASE BY POLICOSANOL, INDICATING THAT METABOLISM OF THESE VERY LONG CHAIN ALCOHOLS TO ACTIVATED FATTY ACIDS IS NECESSARY FOR THE SUPPRESSION OF CHOLESTEROL SYNTHESIS, PRESUMABLY BY INCREASING CELLULAR AMP LEVELS. SUBSEQUENT PEROXISOMAL Β-OXIDATION PROBABLY AUGMENTS THIS EFFECT. © AOCS 2011.","AMP-KINASE; CA <SUP>++</SUP>/CALMODULIN-DEPENDENT KINASE KINASE; HEPATOMA CELLS; HMG-COA REDUCTASE; PEROXISOMES; POLICOSANOL","ADENYLATE KINASE; ALDEHYDE OXIDOREDUCTASES; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ANTICHOLESTEREMIC AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; ENZYME ACTIVATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPOGLYCEMIC AGENTS; LIVER; METFORMIN; MICE; MICE, INBRED C57BL; PEROXISOMES; PROTEIN-SERINE-THREONINE KINASES; RATS; RIBONUCLEOTIDES; MUS; ACETYL COENZYME A ACETYLTRANSFERASE; ADENYLATE KINASE; ALDEHYDE DEHYDROGENASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM ION; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LESSTANOL; LONG CHAIN FATTY ACID COENZYME A LIGASE; LONG CHAIN FATTY ACID COENZYME A LIGASE 4; POLICOSANOL; PROTEIN KINASE LKB1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL METABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HEPATOMA CELL; MOUSE; NONHUMAN; PEROXISOME; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE","NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE, NCCAM; NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH, NCCIH, (R21AT003488)","ACKNOWLEDGMENTS WE THANK DR. GEZA BRUCKNER FOR HELPFUL INSIGHT AND ADVICE, AND NUMEROUS ANONYMOUS REVIEWERS FOR THEIR COMMENTS AND SUGGESTIONS. THIS WORK WAS SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE [GRANT AT003488].","MARINANGELI C.P., JONES P.J., KASSIS A.N., ESKIN M.N., POLICOSANOLS AS NUTRACEUTICALS: FACT OR FICTION, CRIT REV FOOD SCI NUTR, 50, PP. 259-267, (2010); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CUBEDDU L.X., CUBEDDU R.J., HEIMOWITZ T., RESTREPO B., LAMAS G.A., WEINBERG G.B., COMPARATIVE LIPID-LOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AM HEART J, 152, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); FRANCINI-PESENTI F., BELTRAMOLLI D., DALL'ACQUA S., BROCADELLO F., EFFECT OF SUGAR CANE POLICOSANOL ON LIPID PROFILE IN PRIMARY HYPERCHOLESTEROLEMIA, PHYTOTHER RES, 22, PP. 318-322, (2008); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF MORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); WANG Y., EBINE N., JIA X., JONES P.J., FAIROW C., JAEGER R., VERY LONG CHAIN FATTY ACIDS (POLICOSANOLS) AND PHYTOSTEROLS AFFECT PLASMA LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, METABOLISM, 54, PP. 508-514, (2005); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); OLIARO-BOSSO S., CALCIO GAUDINO E., MANTEGNA S., GIRAUDO E., MEDA C., VIOLA F., CRAVOTTO G., REGULATION OF HMGCOA REDUCTASE ACTIVITY BY POLICOSANOL AND OCTACOSADIENOL, A NEW SYNTHETIC ANALOGUE OF OCTACOSANOL, LIPIDS, 44, PP. 907-916, (2009); CLARKE P.R., HARDIE D.G., REGULATION OF HMG-COA REDUCTASE: IDENTIFICATION OF THE SITE PHOSPHORYLATED BY THE AMP-ACTIVATED PROTEIN KINASE IN VITRO AND IN INTACT RAT LIVER, EMBO J, 9, PP. 2439-2446, (1990); BEG Z.H., STONIK J.A., BREWER JR. H.B., 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE: REGULATION OF ENZYMATIC ACTIVITY BY PHOSPHORYLATION AND DEPHOSPHORYLATION, PROC NATL ACAD SCI USA, 75, PP. 3678-3682, (1978); LIVAK K.J., SCHMITTGEN T.D., ANALYSIS OF RELATIVE GENE EXPRESSION DATA USING REAL-TIME QUANTITATIVE PCR AND THE 2(-DELTA DELTA C(T)) METHOD, METHODS, 25, PP. 402-408, (2001); CARLING D., SANDERS M.J., WOODS A., THE REGULATION OF AMP-ACTIVATED PROTEIN KINASE BY UPSTREAM KINASES, INT J OBES, 32, SUPPL. 4, (2008); RIZZO W.B., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); ZA'TARA G., BAR-TANA J., KALDERON B., SUTER M., MORAD E., SAMOVSKI D., NEUMANN D., HERTZ R., AMPK ACTIVATION BY LONG CHAIN FATTY ACYL ANALOGS, BIOCHEM PHARMACOL, 76, PP. 1263-1275, (2008); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); BEG Z.H., STONIK J.A., BREWER JR. H.B., MODULATION OF THE ENZYMIC ACTIVITY OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY MULTIPLE KINASE SYSTEMS INVOLVING REVERSIBLE PHOSPHORYLATION: A REVIEW, METABOLISM, 36, PP. 900-917, (1987); SHAW R.J., LAMIA K.A., VASQUEZ D., KOO S.H., BARDEESY N., DEPINHO R.A., MONTMINY M., CANTLEY L.C., THE KINASE LKB1 MEDIATES GLUCOSE HOMEOSTASIS IN LIVER AND THERAPEUTIC EFFECTS OF METFORMIN, SCIENCE, 310, PP. 1642-1646, (2005); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); HAWLEY S.A., PAN D.A., MUSTARD K.J., ROSS L., BAIN J., EDELMAN A.M., FRENGUELLI B.G., HARDIE D.G., CALMODULIN-DEPENDENT PROTEIN KINASE KINASE-BETA IS AN ALTERNATIVE UPSTREAM KINASE FOR AMP-ACTIVATED PROTEIN KINASE, CELL METAB, 2, PP. 9-19, (2005); SAKAKIBARA S., YAMAUCHI T., OSHIMA Y., TSUKAMOTO Y., KADOWAKI T., ACETIC ACID ACTIVATES HEPATIC AMPK AND REDUCES HYPERGLYCEMIA IN DIABETIC KK-A(Y) MICE, BIOCHEM BIOPHYS RES COMMUN, 344, PP. 597-604, (2006); HAIM D., BERRIOS M., VALENZUELA A., VIDELA L.A., TRACE QUANTIFICATION OF 1-OCTACOSANOL AND 1-TRIACONTANOL AND THEIR MAIN METABOLITES IN PLASMA BY LIQUID-LIQUID EXTRACTION COUPLED WITH GAS CHROMATOGRAPHY-MASS SPECTROMETRY, J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI, 877, PP. 4154-4158, (2009); KELLER S., GIMMLER F., JAHREIS G., OCTACOSANOL ADMINISTRATION TO HUMANS DECREASES NEUTRAL STEROL AND BILE ACID CONCENTRATION IN FECES, LIPIDS, 43, PP. 109-115, (2008); WONG J.M., DE SOUZA R., KENDALL C.W., EMAM A., JENKINS D.J., COLONIC HEALTH: FERMENTATION AND SHORT CHAIN FATTY ACIDS, J CLIN GASTROENTEROL, 40, PP. 235-243, (2006); KAWAGUCHI T., OSATOMI K., YAMASHITA H., KABASHIMA T., UYEDA K., MECHANISM FOR FATTY ACID ""SPARING"" EFFECT ON GLUCOSE-INDUCED TRANSCRIPTION: REGULATION OF CARBOHYDRATE-RESPONSIVE ELEMENT-BINDING PROTEIN BY AMP-ACTIVATED PROTEIN KINASE, J BIOL CHEM, 277, PP. 3829-3835, (2002); ZYDOWO M.M., SMOLENSKI R.T., SWIERCZYNSKI J., ACETATE-INDUCED CHANGES OF ADENINE NUCLEOTIDE LEVELS IN RAT LIVER, METABOLISM, 42, PP. 644-648, (1993)","T. D. PORTER; DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0596, UNITED STATES; EMAIL: TPORTER@EMAIL.UKY.EDU","","ENGLISH","LIPIDS","ARTICLE","ISI","2-S2.0-79955987899","LIPIDS","UNIVERSITY OF KENTUCKY;UNIVERSITY OF KENTUCKY;UNIVERSITY OF KENTUCKY","NOTREPORTED;UNIVERSITY OF KENTUCKY;NOTREPORTED",NA,"BANERJEE S, 2011, LIPIDS","BANERJEE S, 2011, LIPIDS"
"WANG M;LIAN H;MAO L;ZHOU J;GONG H;QIAN B;FANG Y;LI J","WANG, MEI-FEI (8575083500); LIAN, HONG-ZHEN (7005991786); MAO, LI (56732388400); ZHOU, JING-PING (16064975100); GONG, HUI-JUAN (8924957900); QIAN, BAO-YONG (37046461100); FANG, YAN (55469301300); LI, JIE (57219365884)","COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL",2007,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","55","6",33,"10.1021/jf063623q","KEY LABORATORY OF ANALYTICAL CHEMISTRY FOR LIFE SCIENCE (EDUCATION MINISTRY OF CHINA), SCHOOL OF CHEMISTRY AND CHEMICAL ENGINEERING, NANJING UNIVERSITY, NANJING, JIANGSU PROVINCE 210093, 22 HANKOU ROAD, CHINA;KEY LABORATORY OF ANALYTICAL CHEMISTRY FOR LIFE SCIENCE (EDUCATION MINISTRY OF CHINA), SCHOOL OF CHEMISTRY AND CHEMICAL ENGINEERING, NANJING UNIVERSITY, NANJING, JIANGSU PROVINCE 210093, 22 HANKOU ROAD, CHINA;SCHOOL OF PUBLIC HEALTH, NANJING MEDICAL UNIVERSITY, NANJING, JIANGSU PROVINCE 210029, 140 HANZHONG ROAD, CHINA;SCHOOL OF PUBLIC HEALTH, NANJING MEDICAL UNIVERSITY, NANJING, JIANGSU PROVINCE 210029, 140 HANZHONG ROAD, CHINA;KEY LABORATORY OF ANALYTICAL CHEMISTRY FOR LIFE SCIENCE (EDUCATION MINISTRY OF CHINA), SCHOOL OF CHEMISTRY AND CHEMICAL ENGINEERING, NANJING UNIVERSITY, NANJING, JIANGSU PROVINCE 210093, 22 HANKOU ROAD, CHINA;SCHOOL OF PUBLIC HEALTH, NANJING MEDICAL UNIVERSITY, NANJING, JIANGSU PROVINCE 210029, 140 HANZHONG ROAD, CHINA;SCHOOL OF PUBLIC HEALTH, NANJING MEDICAL UNIVERSITY, NANJING, JIANGSU PROVINCE 210029, 140 HANZHONG ROAD, CHINA;SCHOOL OF PUBLIC HEALTH, NANJING MEDICAL UNIVERSITY, NANJING, JIANGSU PROVINCE 210029, 140 HANZHONG ROAD, CHINA","A CAPILLARY GAS CHROMATOGRAPHIC (GC) METHOD HAS BEEN DEVELOPED FOR THE SEPARATION AND DETERMINATION OF POLICOSANOL COMPONENTS EXTRACTED FROM RICE BRAN WAX. A VARIAN CP-SIL 8 CB COLUMN WAS EMPLOYED, AND AN OVEN TEMPERATURE WAS PROGRAMMED. GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS) WAS USED TO IDENTIFY THE COMPOSITION OF POLICOSANOL. QUANTITATIVE ANALYSIS WAS CARRIED OUT BY MEANS OF HYDROGEN FLAME IONIZATION DETECTOR (FID) WITH DINONYL PHTHALATE (DNP) AS INTERNAL STANDARD. THE RESULTS INDICATED THAT THE EXTRACT OBTAINED BY DRY SAPONIFICATION HAS THE HIGHEST CONTENTS OF OCTACOSANOL AND TRIACONTANOL AMONG EXTRACTS BY ALL USED EXTRACTION METHODS INCLUDING DRY SAPONIFICATION, SAPONIFICATION IN ALCOHOL, SAPONIFICATION IN WATER (NEUTRALIZED AND NON-NEUTRALIZED), AND TRANSESTERIFICATION. MEANWHILE, THE GC-MS FINGERPRINT OF POLICOSANOL EXTRACTED BY DRY SAPONIFICATION HAS BEEN ESTABLISHED. EUCLIDEAN DISTANCE SIMILARITY CALCULATION SHOWED REMARKABLE CONSISTENCY OF COMPOSITIONS AND CONTENTS AMONG 12 BATCHES OF POLICOSANOL FROM A RICE BRAN WAX VARIETY. THIS PROTOCOL PROVIDED A RAPID AND FEASIBLE METHOD FOR QUALITY CONTROL OF POLICOSANOL PRODUCTS. © 2007 AMERICAN CHEMICAL SOCIETY.","EUCLIDEAN DISTANCE SIMILARITY; FINGERPRINT; GAS CHROMATOGRAPHY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; POLICOSANOL; RICE BRAN WAX","CHROMATOGRAPHY, GAS; FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; ORYZA SATIVA; SEEDS; WAXES; FATTY ALCOHOL; POLICOSANOL; WAX; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; GAS CHROMATOGRAPHY; ISOLATION AND PURIFICATION; MASS FRAGMENTOGRAPHY; METHODOLOGY; PLANT SEED; RICE","","","IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J. AGRIC. FOOD CHEM, 53, PP. 5583-5586, (2005); LEI B.F., APPLICATIONS AND PREPARATIONS OF POLICOSANOL, CHINA WESTERN CEREALS OILS TECHNOL, 3, PP. 41-44, (2003); DUAN Q.F., MA L.Y., ZHENG H., CHEN X.M., A REVIEW ON RESEARCH PROGRESS OF SOME POLICOSANOLS, J. CHEM. IND. FOR. PROD, 39, 2, PP. 42-47, (2005); LIAN H.Z., WEI Y.N., LI D.N., HPLC-UV DETECTION FOR ANALYSIS OF P-BENZOQUINONE DIOXIME AND P-NITROSOPHENOL, AND CHROMATOGRAPHIC FINGERPRINT APPLIED IN QUALITY CONTROL OF INDUSTRIAL P-BENZOQUINONE DIOXIME, J. LIQ. CHROMATOGR. RELAT. TECHNOL, 29, PP. 509-520, (2006); LIAN H.Z., WEI Y.N., CHROMATOGRAPHIC FINGERPRINTS OF INDUSTRIAL TOLUIC ACIDS ESTABLISHED FOR THEIR QUALITY CONTROL, TALANTA, 71, PP. 264-269, (2007); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); WANG Y., DIAO H.S., NI P.D., REFINING OF RICE BRAN WAX, CHINA OILS FATS, 23, 5, PP. 51-54, (1998); LIU B.M., SU X.C., CHEMICAL CONSTITUENTS ANALYSIS OF POLICOSANOL BY GC AND GC/MS, CHIN. J. CHROMATOGR, 24, 2, (2006); LIU F.J., SUN D.M., HU C.X., GAS CHROMATOGRAPHIC DETERMINATION OF TWO ALKANOLS IN THE TOTAL BEESWAX ALKANOL, SHIZHEN J. TRADIT. CHIN. MED. RES, 9, 2, PP. 128-129, (1998); LU J., ZHAO W.B., ZANG N., LI J.F., ZHANG M., WANG Y., DETERMINATION OF POLICOSANOL BY GAS CHROMATOGRAPHY, SCI. TECHNOL. FOOD IND, 25, 7, PP. 129-131, (2004); CHEN F., YAN H., CAI T.Y., QUANTITATIVE ANALYSIS OF OCTACOSANOL AND TRIACONTANOL IN EXTRACTS OF HIGHER FATTY ALCOHOLS BY GC, FOOD SCI, 24, 4, PP. 119-121, (2003); LU H.G., GAO Z.L., GUO Q.Z., QUALITATIVE AND QUANTITATIVE ANALYSIS OF N-TRIACONTANOL, CHEM. IND. TIMES, 8, PP. 29-31, (2002); JIAO C.S., WANG X.Q., ANALYSE AND EXTRACT N-OCTACOSANOL AND N-TRIACONTANOL FROM RICE BRAN WAX, CHEM. ENG, 4, PP. 14-15, (2002); LI G.H., QIAN X.M., STUDY ON THE PREPARATION AND EXTRACTION OF REFINED RICE-BRAN WAXES, J. CHIN. CEREALS OILS ASSOC, 18, 5, (2003); LIU Y.F., WANG X.G., NI B.W., LUO Y.G., STUDY ON FUNCTIONS OF AN ACTIVITY MATTER OCTACOSANOL IN RICE BRAN, CHINA OILS FATS, 26, 5, PP. 63-65, (2001); XU R.P., STUDY ON THE DEVELOPMENT OF LONG CHAIN ALIPHATIC ALCOHOLS, CEREALS OILS, 4, PP. 37-38, (2002); XU R.P., METHOD FOR PREPARING LONG CHAIN ALIPHATIC ALCOHOL FROM RICE BRAN WAX. CN; CHEN F., HUI B.D., ZHU L., CAI T.Y., SUN D.W., STUDY ON THE FACTORS RELATED TO THE TRANSESTERIFICATION REACTION EXTRACTING HIGH FATTY ALCOHOLS FROM RICE BRAN WAX, J. CHIN. CEREALS OILS ASSOC, 18, 2, PP. 75-78, (2003); ZHANG F., FU S.P., XU Q., XIAO H.B., CAI S.Q., LIANG X.M., STUDY ON GC FINGERPRINT OF THE CONSTITUENTS IN HERBA ASARI, CHINA J. CHIN. MATER. MED, 29, 5, PP. 411-413, (2004); CHEN M.J., CHENG Y.Y., LIN R.C., INVESTIGATION OF THE METHODS FOR DETERMINING THE SIMILARITY OF THE CHROMATOGRAPHIC FINGERPRINTS OF TRADITIONAL CHINESE MEDICINE, CHIN. TRADIT. PAT. MED, 24, 12, PP. 905-908, (2002)","H.-Z. LIAN; KEY LABORATORY OF ANALYTICAL CHEMISTRY FOR LIFE SCIENCE (EDUCATION MINISTRY OF CHINA), SCHOOL OF CHEMISTRY AND CHEMICAL ENGINEERING, NANJING UNIVERSITY, NANJING, JIANGSU PROVINCE 210093, 22 HANKOU ROAD, CHINA; EMAIL: HZLIAN@NJU.EDU.CN","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-34447638360","J AGRIC FOOD CHEM","NANJING UNIVERSITY;NANJING UNIVERSITY;NANJING MEDICAL UNIVERSITY;NANJING MEDICAL UNIVERSITY;NANJING UNIVERSITY;NANJING MEDICAL UNIVERSITY;NANJING MEDICAL UNIVERSITY;NANJING MEDICAL UNIVERSITY","NOTREPORTED;NANJING UNIVERSITY;NOTREPORTED",NA,"WANG M-F, 2007, J AGRIC FOOD CHEM","WANG M-F, 2007, J AGRIC FOOD CHEM"
"ASIKIN Y;CHINEN T;TAKARA K;WADA K;ASIKIN Y","ASIKIN, YONATHAN (35092077000); CHINEN, TAKESHI (57192307269); TAKARA, KENSAKU (7005621893); WADA, KOJI (7401668452); ASIKIN, YONATHAN (57343915400)","DETERMINATION OF LONGCHAIN ALCOHOL AND ALDEHYDE CONTENTS IN THE NONCENTRIFUGED CANE SUGAR KOKUTO",2008,"FOOD SCIENCE AND TECHNOLOGY RESEARCH","14","5",21,"10.3136/fstr.14.583","DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA 903-0213, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA 903-0213, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA 903-0213, JAPAN;DEPARTMENT OF BIOSCIENCE AND BIOTECHNOLOGY, FACULTY OF AGRICULTURE, UNIVERSITY OF THE RYUKYUS, SENBARU-1, NISHIHARA-CHO, OKINAWA 903-0213, JAPAN;DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY, FACULTY OF AGRICULTURAL TECHNOLOGY, BOGOR AGRICULTURAL UNIVERSITY, BOGOR 16002, KAMPUS IPB DARMAGA, INDONESIA","THE LONG-CHAIN ALCOHOL AND ALDEHYDE CONTENTS AND COMPOSITIONS WERE DETERMINED IN SEVEN TYPES OF THE NON-CENTRIFUGED CANE SUGAR KOKUTO (KOKUTO A TO G). LONG-CHAIN ALCOHOLS, KNOWN AS POLICOSANOLS, HAVE BEEN REPORTED TO HAVE BENEFICIAL EFFECTS ON HUMAN HEALTH. POLICOSANOLS WERE EXTRACTED EFFECTIVELY WITH HEXANE/METHANOL (20:1 V/V) AND LONG-CHAIN ALDEHYDES WERE EXTRACTED WITH CHLOROFORM/METHANOL (2:1 V/V). THESE COMPOUNDS WERE THEN ANALYZED BY GAS CHROMATOGRAPHY AND GAS CHROMATOGRAPHY-MASS SPECTROM-ETRY. TRIMETHYLSILYL ETHERS, THE POLICOSANOL FRAGMENTS, AND A NUMBER OF UNIQUE ALDEHYDE FRAGMENTS WERE ANALYZED TO IDENTIFY THE SOURCE COMPOUNDS. OCTACOSANOL (C28-OH) WAS CONFIRMED TO BE THE MAIN COMPONENT IN ALL KOKUTO SAMPLES. MOREOVER, THE PRODUCTION PROCESS INFLUENCED THE POLICOSANOL AND LONG-CHAIN ALDEHYDE CONTENTS IN KOKUTO. KOKUTO A, WHICH WAS PRODUCED BY AN OPEN PAN BOILING METHOD, SHOWED THE HIGHEST CONTENT OF POLICOSANOLS (86 MG/100G) AND LONG-CHAIN ALDEHYDES (9 MG/100 G). © 2008, JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY. ALL RIGHTS RESERVED.","ALDEHYDE; CANE SUGAR; KOKUTO; POLICOSANOL","CHAINS; CHROMATOGRAPHY; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; SUGAR (SUCROSE); SUGAR CANE; BENEFICIAL EFFECTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; KOKUTO; LONG CHAIN ALCOHOLS; LONG-CHAIN ALDEHYDE; POLICOSANOL; PRODUCTION PROCESS; TRIMETHYLSILYL ETHERS; ALDEHYDES","","","ADHIKARI P., HWANG K.T., PARK J.N., KIM C.K., POLI-COSANOL CONTENT AND COMPOSITION IN, J. AGRIC, 54, PP. 5359-5362, (2006); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., MESA M., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS, CURRENT THERAPEUTIC RESEARCH, 64, PP. 522-537, (2003); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS. FOOD CHEM, 95, PP. 312-318, (2006); JANSEN B., NIEROP K.G.J., HAGEMAN J.A., CLEEF A.M., VER-STRATEN J.M., THE STRAIGHT-CHAIN LIPID BIOMARKER COMPOSITION OF PLANT SPECIES RESPONSIBLE FOR THE DOMINANT BIOMASS PRODUCTION ALONG TWO ALTITUDINAL TRANSECTS IN THE ECUADORIAN ANDES, ORG. GEOCHEM, 37, PP. 1514-1536, (2006); MARRISON W.B., HOLSER R., AKIN D.E., CUTICULAR WAX FROM FLAX PROCESSING WASTE WITH HEXANE AND SUPER CRITICAL CARBON DIOXIDE EXTRACTIONS, INDUSTRIAL CROPS AND PRODUCTS, 24, PP. 119-122, (2006); NUISSIER G., BOURGEOIS P., GRIGNON-DUBOIS M., PARDON P., LESCURE M.H., COMPOSITION OF SUGARCANE WAXES IN RUM FACTORY WASTES, PHYTOCHEM, 61, PP. 721-726, (2002); PEREZ-CAMINO M.C., MOREDA W., MATEOS R., CERT A., SIMULTANEOUS DETERMINATION OF LONG-CHAIN ALIPHATIC ALDEHYDES AND WAXES IN OLIVE OILS, J. CHROMATOGR. A, 983, PP. 283-288, (2003); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J. PHAR. EXP. THER, 318, PP. 1020-1026, (2006); TAKARA K., MATSUI D., WADA K., ICHIBA T., CHINEN I., NAKASONE Y., NEW PHENOLIC COMPOUNDS FROM KOKUTO, NON-CEN-TRIFUGED CANE SUGAR. BIOSCI. BIOTECHNOL. BIOCHEM, 67, PP. 376-379, (2003); TAKARA K., MATSUI D., WADA K., ICHIBA T., NAKASONE Y., NEW ANTIOXIDATIVE PHENOLIC GLYCOSIDES ISOLATED FROM KOKUTO, NON-CENTRIFUGED CANE SUGAR. BIOSCI. BIOTECHNOL. BIOCHEM, 66, PP. 29-35, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); WANG M.F., LIAN H.Z., MAO L., ZHOU J.P., GONG H.J., QIAN B.Y., FANG Y., LI J., COMPARISON OF VARIOUS EXTRACTION METHODS FOR POLICOSANOL FROM RICE BRAN WAX AND ESTABLISHMENT OF CHROMATOGRAPHIC FINGERPRINT OF POLICOSANOL, J. AGRIC. FOOD CHEM, 55, PP. 5552-5558, (2007); WU T.T., CHARLES A.L., HUANG T.C., DETERMINATION OF THE CONTENTS OF THE MAIN BIOCHEMICAL COMPOUNDS OF ADLAY (COXILACHRYMAL-JOBI), FOOD CHEM, 104, PP. 1509-1515, (2007)","","","ENGLISH","FOOD SCI. TECHNOL. RES.","ARTICLE","ISI","2-S2.0-85004028279","FOOD SCI TECHNOL RES",NA,"NOTREPORTED",NA,"ASIKIN Y, 2008, FOOD SCI TECHNOL RES","ASIKIN Y, 2008, FOOD SCI TECHNOL RES"
"WHAYNE T","WHAYNE, THOMAS F. (57204791430)","EVALUATION AND CRITIQUE OF STATE OF THE ART DYSLIPIDEMIA MANAGEMENT IN GENERAL AND WITH A SPECIAL EMPHASIS ON THE INDIAN POPULATION",2007,"INDIAN HEART JOURNAL","59","7",9,"","GILL HEART INSTITUTE, DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0200, 900 SOUTH LIMESTONE, UNITED STATES","CLASSICALLY, THERE HAVE BEEN THREE WELL ESTABLISHED MAJOR CARDIOVASCULAR RISK FACTORS, HYPERCHOLESTEROLEMIA, HYPERTENSION AND TOBACCO ABUSE. WITH ACCUMULATING CLINICAL EVIDENCE, DIABETES CAN NOW BE ADDED AS A FOURTH MAJOR RISK FACTOR. MUCH INTEREST IN VARIOUS OTHER RISK FACTORS AND POSSIBLE CAUSATIVE FACTORS HAS BEEN GENERATED, BUT IT SHOULD BE REMEMBERED THAT OF ALL THESE, LOW DENSITY LIPOPROTEINS (LDL) REMAINS THE GOLD STANDARD FOR EVALUATING RISK. THE COMMON PERCEPTION IS THAT ONLY CAUCASIANS IN THE WESTERN WORLD HAVE SIGNIFICANT CARDIOVASCULAR (CV) RISK. HOWEVER, MUCH CLINICAL INFORMATION TO THE CONTRARY HAS ACCUMULATED AND NOW IT IS REALIZED THAT MANY OTHER ETHNIC GROUPS ALSO HAVE SIGNIFICANT CV DISEASE, SUCH AS IN INDIA, ESPECIALLY IN THE URBAN POPULATION. DYSLIPIDEMIAS OF SPECIFIC LIPOPROTEINS AND THEIR TREATMENT IS AN IMPORTANT PART OF UNDERSTANDING AND MANAGING CV DISEASE AND RISK. VARIOUS PLASMA FACTORS SUCH AS HOMOCYSTEINE AND LIPOPROTEIN (A) [LP(A)] HAVE BEEN CONSIDERED TO HAVE DEFINITE ASSOCIATIONS WITH CV DISEASE, BUT ANY TREATMENT BENEFIT REMAINS IN DOUBT. IN ADDITION, INFLAMMATORY RISK FACTORS ARE CONSIDERED TO BE OF SIGNIFICANT CLINICAL INTEREST, ESPECIALLY HIGH SENSITIVITY C-REACTIVE PROTEIN (HSCRP). WHERE DO THESE FACTORS FIT INTO ROUTINE CLINICAL PRACTICE STILL AWAITS CLARIFICATION. ONLY TWO OF THESE INFLAMMATORY RISK FACTORS CAN BE TESTED COMMERCIALLY ON A ROUTINE CLINICAL BASIS AND THESE ARE HSCRP AND LIPOPROTEIN- ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2). THEIR CLINICAL UTILLITY IS NOT ESTABLISHED AND ACCEPTANCE IS LIMITED: SOME THIRD PARTY HEALTH COVERAGE ORGANIZATIONS REFUSE TO PAY FOR SUCH ANALYSES. IN THE PAST, WOMEN HAVE BEEN LOOKED UPON AS NOT HAVING SIGNIFICANT CV DISEASE. MORE RECENTLY, EVIDENCE SUGGESTS THAT WOMEN MAY HAVE MORE CV DISEASE THAN MEN, AND THAT PHYSICIANS MAY HAVE FAILED TO REALIZE THIS AND ACT ACCORDINGLY. THE TRUE SITUATION IS THAT WOMEN HAVE LESS CV DISEASE THAN MEN PRIOR TO MENOPAUSE AND THEN THEY SLOWLY CATCH UP. HOWEVER, SOME WOMEN UNDER AGE 50 HAVE AN ESPECIALLY MALIGNANT FORM OF CV DISEASE AND IN THESE CASES, MYOCARDIAL INFARCTION MORTALITY IS TWICE THAT OF MEN. THE EXPLANATION AND MANAGEMENT IS THE SUBJECT OF MUCH CLINICAL INVESTIGATION. IN BOTH INDIA AND THE WESTERN WORLD, PERHAPS THE MOST IMPORTANT MEDICAL PROBLEM IS THE METABOLIC SYNDROME (MS) AND THIS COMBINATION OF CV RISK FACTORS MULTIPLIES THE SIGNIFICANCE OF EACH. FOR THE DIFFICULT PATIENT NOT TOLERANT OF OR SUFFICIENTLY RESPONSIVE TO CONVENTIONAL THERAPY, ALTERNATIVE DIETS AND MEDICATIONS CAN FREQUENTLY OFFER JUST ENOUGH BENEFIT IN LOWERING LDL TO ALLOW THE PATIENT TO ATTAIN THEIR TARGET LEVEL. FUTURE TREATMENTS UNDOUBTEDLY WILL INVOLVE GENETICS, BUT FOR NOW, AGGRESSIVE MEDICATION USE CAN FAVORABLY MODIFY RISK ALTHOUGH NOT ELIMINATE IT.","HIGH DENSITY LIPOPROTEINS; INFLAMMATION; LIPOPROTEINS; LOW DENSITY LIPOPROTEINS; METABOLIC SYNDROME; RISK FACTORS; VERY LOW DENSITY LIPOPROTEINS","ANTILIPEMIC AGENTS; ASIA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET; DYSLIPIDEMIAS; HOMOCYSTEINE; HUMANS; INDIA; INFLAMMATION; METABOLIC SYNDROME X; RISK FACTORS; ATORVASTATIN; C REACTIVE PROTEIN; CHYLOMICRON; CYANOCOBALAMIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; PIPEROCAINE; POLICOSANOL; PYRIDOXINE; TORCETRAPIB; VASCULAR CELL ADHESION MOLECULE 1; ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MENOPAUSE; METABOLIC SYNDROME X; REVIEW","","","SYTKOWSKI P., KANNEL W.B., D'AGOSTINO R.B., CHANGES IN RISK FACTORS AND THE DECLINE IN MORTALITY FROM CARDIOVASCULAR DISEASE. THE FRAMINGHAM HEART STUDY, N ENGL J MED, 322, PP. 1635-1641, (1990); PAIS P., FAY M.P., YUSUF S., INCREASED RISK OF ACUTE MYOCARDIAL INFARCTION ASSOCIATED WITH BEEDI AND CIGARETTE SMOKING IN INDIANS: FINAL REPORT ON TOBACCO RISKS FROM A CASE-CONTROL STUDY, INDIAN HEART J, 53, 6, PP. 731-735, (2001); NISSEN S., TUZCU E.M., SCHOENHAGEN P., ET AL., EFFECT OF INTENSIVE COMPARED WITH MODERATE LIPID-LOWERING THERAPY ON PROGRESSION OF CORONARY ATHEROSCLEROSIS: A RANDOMIZED CONTROLLED TRIAL (REVERSAL), JAMA, 291, PP. 1071-1080, (2004); CANNON C., BRAUNWALD E., MCCABE C.H., ET AL., INTENSIVE VERSUS MODERATE LIPID LOWERING WITH STATINS AFTER ACUTE CORONARY SYNDROMES (PROVE-IT), N ENGL J MED, 350, PP. 1495-1504, (2004); LAROSA J., GRUNDY S.M., WATERS D.D., ET AL., INTENSIVE LIPID LOWERING WITH ATORVASTATIN IN PATIENTS WITH STABLE CORONARY DISEASE, N ENGL J MED, 352, PP. 1425-1435, (2005); NISSEN S., NICHOLLS S.J., SIPAHI I., ET AL., EFFECT OF VERY HIGH-INTENSITY STATIN THERAPY ON REGRESSION OF CORONARY ATHEROSCLEROSIS: THE ASTEROID TRIAL, JAMA, 295, PP. 1556-1565, (2006); SNOW V., ARONSON M.D., HORNBAKE R., ET AL., LIPID CONTROL IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS: A CLINICAL PRACTICE GUIDELINE FROM THE AMERICAN COLLEGE OF PHYSICIANS, ANN INTERN MED, 140, PP. 644-649, (2004); RIDKER P., CANNON C.P., MORROW D., ET AL., C-REACTIVE PROTEIN LEVELS AND OUTCOMES AFTER STATIN THERAPY, N ENGL J MED, 352, PP. 20-28, (2005); KOENIG W., KHUSEYINOVA N., LOWEL H., ET AL., LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ADDS TO RISK PREDICTION OF INCIDENT CORONARY EVENTS BY C-REACTIVE PROTEIN IN APPARENTLY HEALTHY MIDDLE-AGED MEN FROM THE GENERAL POPULATION, CIRCULATION, 110, PP. 1903-1908, (2004); YUSUF S., HAWKEN S., OUNPUU S., ET AL., EFFECT OF POTENTIALLY MODIFIABLE RISK FACTORS ASSOCIATED WITH MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): CASE-CONTROLLED STUDY, LANCET, 364, PP. 937-952, (2004); PAIS P., POGUE J., GERSTEIN, ET AL., RISK FACTORS FOR ACUTE MYOCARDIAL INFARCTION IN INDIANS: A CASE-CONTROL STUDY, LANCET, 348, PP. 358-363, (1996); MCKEIGUE P., MILLER G.J., MARMOT M.G., CORONARY HEART DISEASE IN SOUTH ASIANS: A REVIEW, J CLIN EPIDEMIOL, 42, PP. 579-609, (1989); ENAS E., YUSUF S., MEHTA J.L., PREVALENCE OF CORONARY ARTERY DISEASE IN ASIAN INDIANS, AM J CARDIOL, 70, PP. 945-949, (1992); SARVOTHAM S., BERRY J.N., PREVALENCE OF CORONARY HEART DISEASE IN AN URBAN POPULATION IN NORTHERN INDIA, CIRCULATION, 37, PP. 939-953, (1968); CHADHA S., RADHAKRISHNAN S., RAMACHANDRAN K., ET AL., EPIDEMIOLOGICAL STUDY OF CORONARY HEART DISEASE IN URBAN POPULATION IN DELHI, INDIAN J MED RES, 92, PP. 424-430, (1990); II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); AZEN S., MACK W.J., CASHIN-HEMPHILL L., ET AL., PROGRESSION OF CORONARY ARTERY DISEASE PREDICTS CLINICAL CORONARY EVENTS. LONG-TERM FOLLOW-UP FROM THE CHOLESTEROL LOWERING ATHEROSCLEROSIS STUDY, CIRCULATION, 93, PP. 34-41, (1996); BROWN G., ALBERS J.J., FISHER L.D., ET AL., REGRESSION OF CORONARY ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH LEVELS OF APOLIPOPROTEIN B, N ENGL J MED, 323, PP. 1289-1298, (1990); CROMWELL W., OTVOS J.D., LOW-DENSITY LIPOPROTEIN PARTICLE NUMBER AND RISK FOR CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REPORTS; MACKEY R., KULLER L.H., SUTTON-TYRRELL K., ET AL., LIPOPROTEIN SUBCLASSES AND CORONARY ARTERY CALCIUM IN POSTMENOPAUSAL WOMEN FROM THE HEALTHY WOMEN STUDY, AM J CARDIOL, 90, SUPPL., (2002); KOBA S., HIRANO T., KONDO T., ET AL., SIGNIFICANCE OF SMALL DENSE LOW-DENSITY LIPOPROTEINS AND OTHER RISK FACTORS IN PATIENTS WITH VARIOUS TYPES OF CORONARY HEART DISEASE, AM HEART J, 144, PP. 1026-1035, (2002); ROBINS S., COLLINS D., WITTES J.T., ET AL., RELATION OF GEMFIBROZIL TREATMENT AND LIPID LEVELS WITH MAJOR CORONARY EVENTS, JAMA, 285, PP. 1585-1591, (2001); SACKS F., THE ROLE OF HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL IN THE PREVENTION AND TREATMENT OF CORONARY HEART DISEASE: EXPERT GROUP RECOMMENDATIONS, AM J CARDIOL, 90, PP. 139-143, (2002); MORGAN J., CAREY C., LINCOFF A., ET AL., HIGH-DENSITY LIPOPROTEIN SUBFRACTIONS AND RISK OF CORONARY ARTERY DISEASE, CURR ATHEROSCLER REPORTS; OLSSON A., XIV INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (2001); AVORN J., TORCETRAPIB AND ATORVASTATIN-SHOULD MARKETING DRIVE THE RESEARCH AGENDA?, NEW ENGL J MED, 353, PP. 2573-2576, (2005); BERENSON A., HEART PILL TO BE SOLD BY ITSELF, NEW YORK TIMES, (2006); BALLANTYNE C., ABATE N., YUAN Z., ET AL., DOSE-COMPARISON STUDY OF THE COMBINATION OF EZETIMIBE AND SIMVASTATIN (VYTORIN) VERSUS ATORVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA: THE VYTORIN VERSUS ATORVASTATIN (VYVA) STUDY, AM HEART J, 149, PP. 464-473, (2005); CHAIT A., BRUNZELL J.D., ALBERS J.J., ET AL., TYPE-III HYPERLIPOPROTEINAEMIA (REMNANT REMOVAL DISEASE): INSIGHT INTO THE PATHOGENETIC MECHANISM, LANCET, 1, PP. 1176-1178, (1977); HOKANSON J., AUSTIN M.A., PLASMA TRIGLYCERIDE LEVEL IS A RISK FACTOR FOR CARDIOVASCULAR DISEASE INDEPENDENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL: A META-ANALYSIS OF POPULATION-BASED PROSPECTIVE STUDIES, J CARDIOVASC RISK, 3, PP. 213-219, (1996); MESOTTEN D., SWINNEN J.V., VANDERHOYDONC F., ET AL., CONTRIBUTION OF CIRCULATING LIPIDS TO THE IMPROVED OUTCOME OF CRITICAL ILLNESS BY GLYCEMIC CONTROL WITH INTENSIVE INSULIN THERAPY, J CLIN ENDOCRINOL METAB, 89, PP. 219-226, (2004); DEB A., CAPLICE N.M., LIPOPROTEIN (A): NEW INSIGHTS INTO MECHANISMS OF ATHEROGENESIS, CLIN CARDIOL, 27, PP. 258-264, (2004); GOTTO A., THE NEW CHOLESTEROL EDUCATION IMPERATIVE AND SOME COMMENTS ON NIACIN, AM J CARDIOL, 81, PP. 492-494, (1998); SNEHALATHA C., RAMACHANDRAN A., SATYAVANI K., ET AL., PLASMA HOMOCYSTEINE CONCENTRATION AND CORONARY ARTERY DISEASE IN ASIAN INDIANS, J ASSOC PHYSICIANS INDIA, 50, PP. 1229-1231, (2002); DEEPA R., VELMURUGAN K., SARAVANAN G., ET AL., ABSENCE OF ASSOCIATION BETWEEN SERUM HOMOCYSTEINE LEVELS AND CORONARY ARTERY DISEASE IN SOUTH INDIAN MALES, INDIAN HEART J, 53, PP. 44-47, (2001); CHACKO K., PLASMA HOMOCYSTEINE LEVELS IN PATIENTS WITH CORONARY HEART DISEASE, INDIAN HEART J, 50, PP. 295-299, (1998); CHAMBERS J., KOONER J.S., DIABETES, IN SULIN RESISTANCE AND VASCULAR DISEASE AMONG INDIAN ASIANS AND EUROPEANS, SEMIN VASC MED, 2, PP. 199-214, (2002); DAS S., REYNOLDS T., PATNAIK A., ET AL., PLASMA HOMOCYSTEINE CONCENTRATIONS IN TYPE II DIABETIC PATIENTS IN INDIA, J DIABETES COMPLICATIONS, 13, PP. 200-203, (1999); CHAI A., ABRAMS J., HOMOCYSTEINE: A NEW CARDIAC RISK FACTOR, CLIN CARDIOL, 24, PP. 80-84, (2001); HOMOCYSTEINE LOWERING WITH FOLIC ACID AND B VITAMINS IN VASCULAR DISEASE, N ENGL J MED, 354, PP. 1567-1577, (2006); BONAA K., NJOLSTAD I., UELAND P.M., ET AL., HOMOCYSTEINE LOWERING AND CARDIOVASCULAR EVENTS AFTER ACUTE MYOCARDIAL INFARCTION, N ENGL J MED, 354, PP. 1578-1588, (2006); OLIVEIRA G., NOVEL SEROLOGIC MARKERS OF CARDIOVASCULAR RISK, CURRENT ATHEROSCLEROSIS REPORTS; EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); RIDKER P., INFLAMMATION IN ATHEROTHROMBOSIS: HOW TO USE HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) IN CLINICAL PRACTICE, AM HEART HOSP J, 2, SUPPL. 1, PP. 4-9, (2004); SHAMMAS N., DIPPEL E., INFLAMMATION AND CARDIOVASCULAR RISK: AN OVERVIEW, INTERNATIONAL J ANGIOL, 13, PP. 161-167, (2004); SAGER P., MELANI L., LIPKA L., ET AL., EFFECT OF COADMINISTRATION OF EZETIMIBE AND SIMVASTATIN ON HIGH-SENSITIVITY C-REACTIVE PROTEIN, AM J CARDIOL, 92, PP. 1414-1418, (2003); WHAYNE T., WOMEN AND CARDIOVASCULAR DISEASE-PREVENTION OF HEART DISEASE, INTERNATIONAL J ANGIOL, 14, PP. 218-214, (2006); VACCARINO V., PARSONS L., EVERY N.R., ET AL., SEX-BASED DIFFERENCES IN EARLY MORTALITY AFTER MYOCARDIAL INFARCTION, N ENGL J MED, 341, PP. 217-225, (1999); VACCARINO V., KRUMHOLZ H.M., YARZEBSKI J., ET AL., SEX DIFFERENCES IN 2-YEAR MORTALITY AFTER HOSPITAL DISCHARGE FOR MYOCARDIAL INFARCTION, ANN INTERN MED, 134, PP. 173-181, (2001); NINOMIYA J., L'ITALIEN G., CRIQUI M.H., ET AL., ASSOCIATION OF THE METABOLIC SYNDROME WITH HISTORY OF MYOCARDIAL INFARCTION AND STROKE IN THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, CIRCULATION, 109, PP. 42-46, (2004); GRUNDY S., METABOLIC SYNDROME: CONNECTING AND RECONCILING CARDIOVASCULAR AND DIABETES WORLDS, J AM COLL CARDIOL, 47, PP. 1093-1100, (2006); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); BERTHOLD H., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA, 295, PP. 2262-2269, (2006); WRIGHT C., ZIELKE J., WHAYNE T.F., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE: USE IN PATIENTS INTOLERANT OF OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INTERNAT J ANGIOL, 13, PP. 173-175, (2005); FERNANDEZ J., EFICACIA Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II, REVISTA CNIC CIENC BIOL, 30, PP. 127-132, (1999); CASTANO G., MAS R., NODARSE M., ET AL., ONE YEAR STUDY OF EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); DOWNS J., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS. AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA. WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, N ENGL J MED, 333, PP. 1301-1307, (1995); SACKS F., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N ENGL J MED, 335, PP. 1001-1009, (1996)","T.F. WHAYNE; GILL HEART INSTITUTE, DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0200, 900 SOUTH LIMESTONE, UNITED STATES; EMAIL: TWHAYN0@UKY.EDU","","ENGLISH","INDIAN HEART J.","REVIEW","ISI","2-S2.0-36349022231","INDIAN HEART J","UNIVERSITY OF KENTUCKY","NOTREPORTED;UNIVERSITY OF KENTUCKY;NOTREPORTED",NA,"WHAYNE TF, 2007, INDIAN HEART J","WHAYNE TF, 2007, INDIAN HEART J"
"IRMAK S;JONNALA R;MACRITCHIE F","IRMAK, SIBEL (6603640781); JONNALA, RAMAKANTH S. (8355958500); MACRITCHIE, FINLAY (56274970800)","EFFECT OF GENETIC VARIATION ON PHENOLIC ACID AND POLICOSANOL CONTENTS OF PEGASO WHEAT LINES",2008,"JOURNAL OF CEREAL SCIENCE","48","6",39,"10.1016/j.jcs.2007.07.007","DEPARTMENT OF GRAIN SCIENCE AND INDUSTRY, KANSAS STATE UNIVERSITY, MANHATTAN, KS 66506, UNITED STATES;DEPARTMENT OF GRAIN SCIENCE AND INDUSTRY, KANSAS STATE UNIVERSITY, MANHATTAN, KS 66506, UNITED STATES;DEPARTMENT OF GRAIN SCIENCE AND INDUSTRY, KANSAS STATE UNIVERSITY, MANHATTAN, KS 66506, UNITED STATES","TOTAL PHENOLIC ACID AND POLICOSANOL CONTENTS AND COMPOSITIONS OF BRAN FROM AN ITALIAN BREAD WHEAT VARIETY PEGASO AND ITS 11 NEAR-ISOGENIC LINES WERE MEASURED. THE NEAR-ISOGENIC WHEAT LINES DIFFERED AT ONE OR MORE LOCI CODING FOR STORAGE PROTEINS. THE GENETIC VARIATION INCLUDED DELETIONS, ADDITIONS AND/OR COMBINATIONS OF VARIATIONS. ALMOST 95% OR MORE OF PHENOLIC ACIDS WERE IN THE BOUND FORM. FERULIC ACID WAS THE PREDOMINANT BOUND PHENOLIC ACID PRESENT IN WHEAT BRAN SAMPLES. OTHER PHENOLIC ACIDS WERE P-COUMARIC, VANILLIC AND SYRINGIC ACIDS. TETRACOSANOL, DOCOSANOL, HEXACOSANOL, OCTACOSANOL, TRICOSANOL AND HENEICOSANOL WERE FOUND AS MAJOR POLICOSANOL COMPOUNDS IN THEIR DECREASING ORDER. HIGHLY SIGNIFICANT GENOTYPIC DIFFERENCES WERE OBSERVED IN TOTAL PHENOLIC ACID AND POLICOSANOL CONCENTRATIONS. NONE OF THE GENETIC LINES HAD HIGHER PHENOLIC ACID CONTENTS THAN THE PARENT LINE PEGASO, WHEREAS SOME OF THE LINES HAD MORE POLICOSANOL LEVELS. IN GENERAL, BOTH TOTAL PHENOLIC ACID COMPOSITION AND CONTENTS WERE HIGHER WITH GENETIC LINES THAT VARIED AT GLU-1 LOCI WITH 2+DY HIGH MOLECULAR WEIGHT GLUTENIN SUBUNIT (HMW-GS) (PEGASO 184), VARIATION AT GLI-D2 LOCI (PEGASO 219) AND SINGLE NULL A1 (VARIATION AT GLI-1/GLU-3 LOCI; PEGASO 30). HIGHEST TOTAL POLICOSANOL CONTENT WAS OBSERVED WITH THE DOUBLE NULL AT GLU-A1/GLU-D1 LOCI (PEGASO 236). THESE FINDINGS MAY LEAD TO NEW OPPORTUNITIES FOR WHEAT BREEDERS AND EVENTUALLY COMMERCIAL WHEAT GROWERS TO PROMOTE THE PRODUCTION OF WHEAT WITH ENHANCED LEVELS OF HEALTH BENEFICIAL COMPOUNDS. © 2007 ELSEVIER LTD. ALL RIGHTS RESERVED.","NEAR-ISOGENIC LINES; PHENOLIC ACID; POLICOSANOL; WHEAT BRAN","TRITICUM AESTIVUM","","","ADOM K.K., LIU R.H., ANTIOXIDANT ACTIVITY OF GRAINS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 50, PP. 6185-6187, (2002); ARTS I., HOLLMAN P., POLYPHENOLS AND DISEASE RISK IN EPIDEMIOLOGIC STUDIES, AMERICAN JOURNAL OF CLINICAL NUTRITION, 81, (2005); BARTOLOME B., GOMEZ-CORDOVES C., BARLEY SPENT GRAIN: RELEASE OF HYDROXYCINNAMIC ACIDS (FERULIC AND P-COUMARIC ACIDS) BY COMMERCIAL ENZYME PREPARATIONS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 79, PP. 435-439, (1999); BAUBLIS A., DECKER E.A., CLYDESDALE F.M., ANTIOXIDANT EFFECTS OF AQUEOUS EXTRACTS FROM WHEAT BASED READY-TO-EAT BREAKFAST CEREALS, FOOD CHEMISTRY, 68, PP. 1-6, (2000); BETA T., NAM S., DEXTER J.E., SAPIRSTEIN H.D., PHENOLIC CONTENT AND ANTIOXIDANT ACTIVITY OF PEARLED WHEAT AND ROLLER-MILLED FRACTIONS, CEREAL CHEMISTRY, 82, PP. 390-393, (2005); BRETT C.T., WALDRON K.W., PHYSIOLOGY AND BIOCHEMISTRY OF PLANT CELL WALLS, (1996); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTICS RESEARCH, 57, PP. 691-699, (1996); DULIN M.F., HATCHER L.F., SASSER H.C., BARRINGER T.A., POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 84, PP. 1543-1548, (2006); FOLIN O., CIOCALTEAU V., ON TYROSINE AND TRYPTOPHANE DETERMINATION IN PROTEINS, JOURNAL OF BIOLOGICAL CHEMISTRY, 73, PP. 627-650, (1927); GELINAS P., MCKINNON C.M., EFFECT OF WHEAT VARIETY, FARMING SITE, AND BREAD-BAKING ON TOTAL PHENOLICS, INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 41, PP. 329-332, (2006); GONZALEZ-BRAVO L., MAGRANER-HERNANDEZ J., ACOSTA-GONZALEZ P.C., PEREZ-SOUTO N., ANALYTICAL PROCEDURE FOR THE DETERMINATION OF 1-OCTACOSANOL IN PLASMA BY SOLVENT EXTRACTION AND CAPILLARY GAS CHROMATOGRAPHY, JOURNAL OF CHROMATOGRAPHY B, 682, PP. 359-363, (1996); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BRITISH JOURNAL OF NUTRITION, 95, PP. 968-975, (2006); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS OF WHEAT BRAN VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 53, PP. 5583-5586, (2005); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEMISTRY, 95, PP. 312-318, (2006); JACOBS D.R., MEYER K.A., KUSHI L.H., FOLSOM A.R., WHOLE GRAIN INTAKE MAY REDUCE RISK OF CORONARY HEART DISEASE DEATH IN POSTMENOPAUSAL WOMEN: THE IOWA WOMEN'S HEALTH STUDY, AMERICAN JOURNAL OF CLINICAL NUTRITION, 68, PP. 248-257, (1998); KIM K.-H., TSAO R., YANG R., CUI S.W., PHENOLIC ACID PROFILES AND ANTIOXIDANT ACTIVITIES OF WHEAT BRAN EXTRACTS AND THE EFFECT OF HYDROLYSIS CONDITIONS, FOOD CHEMISTRY, 95, PP. 466-473, (2006); KRIS-ETHERTON P.M., HECKER K.D., BONANOME A., COVAL S.M., BINKOSKI A.E., HILPERT K.F., GRIEL A.E., ETHERTON T.D., BIOACTIVE COMPOUNDS IN FOODS: THEIR ROLE IN THE PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER, AMERICAN JOURNAL OF MEDICINE, 113, (2002); LIYANA-PATHIRANA C.M., SHAHIDI F., IMPORTANCE OF INSOLUBLE-BOUND PHENOLICS TO ANTIOXIDANT PROPERTIES OF WHEAT, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 1256-1264, (2006); MACRITCHIE F., LAFIANDRA D., USE OF NEAR-ISOGENIC WHEAT LINES TO DETERMINE PROTEIN COMPOSITION-FUNCTIONALITY RELATIONSHIPS, CEREAL CHEMISTRY, 78, PP. 501-506, (2001); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ J., ORTA S.D., ILLNAIT J., RICARDO Y., PHARMACOEPIDEMIOLOGIC STUDY OF POLYCOSANOL, CURRENT THERAPEUTICS RESEARCH, 60, PP. 458-467, (1999); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOLOGICAL RESEARCH, 27, PP. 199-203, (1994); MOORE J., LIU J.-G., ZHOU K., YU L., EFFECTS OF GENOTYPE AND ENVIRONMENT ON THE ANTIOXIDANT PROPERTIES OF HARD WINTER WHEAT BRAN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 54, PP. 5313-5322, (2006); ONYENEHO S.N., HETTIARACHCHY N.S., ANTIOXIDANT ACTIVITY OF DURUM WHEAT BRAN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 45, PP. 1644-1648, (1992); ORTEGA L.L., SANCHEZ J., MAS R., FERNANDEZ L., MENDOZA S., GAMEZ R., FERNANDEZ J.C., ILLNAIT J., ALVAREZ E., EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE: A PILOT OPEN STUDY, JOURNAL OF MEDICINAL FOOD, 9, PP. 378-385, (2006); PARKER M.L., NG A., WALDRON K.W., THE PHENOLIC ACID AND POLYSACCHARIDE COMPOSITION OF CELL WALLS BRAN LAYERS OF MATURE WHEAT (TRITICUM AESTIVUM L. CV. AVALON) GRAINS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 85, PP. 2539-2547, (2005); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318, PP. 1020-1026, (2006); SINGLETON V.L., ROSSI J.A., COLORIMETRY OF TOTAL PHENOLICS WITH PHOSPHOMOLYBIC-PHOSPHOTUNGSTIC ACID REAGENTS, AMERICAN JOURNAL OF ENOLOGY AND VITICULTURE, 16, PP. 144-158, (1965); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF TRITICUM AESTIVUM, PHYTOCHEMISTRY, 12, PP. 2217-2223, (1973); WALTON T.J., WAXES, CUTIN AND SUBERIN, LIPIDS, MEMBRANES AND ASPECTS OF PHOTOBIOLOGY, PP. 105-157, (1990); YU J., VASANTHAN T., TEMELLI F., ANALYSIS OF PHENOLIC ACIDS IN BARLEY BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 4352-4360, (2001); YU L., HALEY S., PERRET J., HARRIS M., WILSON J., QIAN M., FREE RADICAL SCAVENGING PROPERTIES OF WHEAT EXTRACTS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 50, PP. 1619-1624, (2002); ZUPFER J.M., CHURCHILL K.E., RASMUSSON D.C., FULCHER R.G., VARIATION IN FERULIC ACID CONCENTRATION AMONG DIVERSE BARLEY CULTIVARS MEASURED BY HPLC AND MICROSPECTROPHOTOMETRY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 1350-1354, (1998)","S. IRMAK; DEPARTMENT OF GRAIN SCIENCE AND INDUSTRY, KANSAS STATE UNIVERSITY, MANHATTAN, KS 66506, UNITED STATES; EMAIL: SIRMAK@CU.EDU.TR","","ENGLISH","J. CEREAL SCI.","ARTICLE","ISI","2-S2.0-42949144091","J CEREAL SCI","KANSAS STATE UNIVERSITY;KANSAS STATE UNIVERSITY;KANSAS STATE UNIVERSITY","NOTREPORTED;KANSAS STATE UNIVERSITY;NOTREPORTED",NA,"IRMAK S, 2008, J CEREAL SCI","IRMAK S, 2008, J CEREAL SCI"
"MARAZZI G;CACCIOTTI L;PELLICCIA F;IAIA L;VOLTERRANI M;CAMINITI G;SPOSATO B;MASSARO R;GRIECO F;ROSANO G","MARAZZI, GIUSEPPE (6602583977); CACCIOTTI, LUCA (6506023158); PELLICCIA, FRANCESCO (7005360685); IAIA, LUIGI (57215982985); VOLTERRANI, MAURIZIO (7004062259); CAMINITI, GIUSEPPE (6603746727); SPOSATO, BARBARA (6602544961); MASSARO, ROSALBA (26649541500); GRIECO, FABRIZIA (54399955900); ROSANO, GIUSEPPE (7007131876)","LONGTERM EFFECTS OF NUTRACEUTICALS BERBERINE RED YEAST RICE POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS",2011,"ADVANCES IN THERAPY","28","8",97,"10.1007/s12325-011-0082-5","DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY;CARDIAC UNIT VANNINI HOSPITAL, ROME, ITALY;CARDIAC UNIT SAN FILIPPO NERI, ROME, ITALY;CARDIAC UNIT FATEBENEFRATELLI ISOLA TIBERINA, ROME, ITALY;DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY;DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY;DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY;DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY;DEPARTMENT OF CLINICAL MEDICINE, CARDIOVASCULAR SCIENCE, UNIVERSITY OF NAPLES FEDERICO II, ITALY;DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY","INTRODUCTION: STATINS ARE AT THE FOREFRONT OF STRATEGIES TO MANAGE DYSLIPIDEMIA, ALTHOUGH THEY ARE NOT ALWAYS WELL TOLERATED. AT 6-7 MONTHS AFTER THE DRUG WAS SUPPLIED, DISCONTINUATION RATES AVERAGED 30%. ALTERNATE AGENTS TO STATINS HAVE BEEN STUDIED. SOME NUTRACEUTICALS DEMONSTRATED AN EFFICACY IN REDUCING CHOLESTEROL CONCENTRATIONS. HOWEVER, THERE ARE NO DATA REGARDING THE USE OF NUTRACEUTICALS IN ELDERLY DYSLIPIDEMIC PATIENTS. THE PURPOSE OF THIS STUDY WAS TO EXAMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF A NUTRACEUTICAL-BASED PROTOCOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS PREVIOUSLY INTOLERANT TO STATINS. METHODS: THIS STUDY WAS PERFORMED AS A RANDOMIZED, PROSPECTIVE, PARALLEL GROUP, SINGLE-BLIND STUDY. PATIENTS WERE INCLUDED IN THE STUDY IF THEY HAD HIGH TOTAL CHOLESTEROLEMIA, HIGH LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), >75 YEARS OF AGE, STATIN-INTOLERANT, AND WERE REFUSING OTHER PHARMACEUTICAL TREATMENTS FOR HYPERCHOLESTEROLEMIA. AT THE BASELINE VISIT, ELIGIBLE PATIENTS WERE RANDOMIZED TO EITHER NUTRACEUTICAL-COMBINED PILL (CONTAINING BERBERINE 500 MG, POLICOSANOL 10 MG, RED YEAST RICE 200 MG, FOLIC ACID 0.2 MG, COENZYME Q10 2.0 MG, AND ASTAXANTHIN 0.5 MG) OR PLACEBO, AND THE FIRST DOSE WAS DISPENSED. THE EFFICACY, SAFETY, AND TOLERABILITY OF THE PROPOSED TREATMENT WERE FULLY ASSESSED AFTER 3, 6, AND 12 MONTHS OF TREATMENT. RESULTS: OUT OF 106 CONSECUTIVE PATIENTS SCREENED, 80 ELIGIBLE PATIENTS WERE RANDOMIZED TO RECEIVE EITHER NUTRACEUTICAL-COMBINED PILL (40 PATIENTS) OR PLACEBO (40 PATIENTS). NO PATIENTS WERE LOST AND NO DEATHS OCCURRED DURING THE FOLLOW-UP. THERE WAS A STATISTICALLY SIGNIFICANT REDUCTION IN TOTAL CHOLESTEROLEMIA (-20%), LDL-C (-31%), AND INSULIN RESISTANCE (-10%) WITH NUTRACEUTICAL TREATMENT. NO SIGNIFICANT CHANGES WERE DETECTED FOR PLASMA HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C). FURTHERMORE, NO STATISTICAL DIFFERENCES WERE FOUND BETWEEN BASELINE AND END-STUDY SAFETY PARAMETERS. MEDICATION COMPLIANCE AND TOLERABILITY WERE HIGH. CONCLUSION: IN THIS STUDY THE AUTHORS HAVE DEMONSTRATED THAT COMBINED NUTRACEUTICALS SIGNIFICANTLY REDUCE CHOLESTEROLEMIA AND ACHIEVED ACCEPTABLE PLASMA LDL-C LEVELS IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS WHO WERE PREVIOUSLY STATIN-INTOLERANT. COMBINED NUTRACEUTICALS IS ALSO SAFE AND WELL TOLERATED IN THESE PATIENTS. © SPRINGER HEALTHCARE 2011.","BERBERINE; ELDERLY PATIENTS; HYPERCHOLESTEROLEMIA; NUTRACEUTICALS; POLICOSANOL; RED YEAST RICE; STATIN-INTOLERANT; STATINS","AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; BERBERINE; BIOLOGICAL AGENTS; BLOOD GLUCOSE; CHOLESTEROL; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FEMALE; FOLIC ACID; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; UBIQUINONE; XANTHOPHYLLS; ASTAXANTHIN; BERBERINE; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; DRUG DERIVATIVE; FATTY ALCOHOL; FOLIC ACID; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; POLICOSANOL; UBIDECARENONE; UBIQUINONE; XANTHOPHYLL; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE","","","HEART AND STROKE STATISTICAL UPDATE; WALD N.J., LAW M.R., A STRATEGY TO REDUCE CARDIOVASCULAR DISEASE BY MORE THAN 80%, BMJ, 326, (2003); YUSUF S., HAWKEN S., OUNPUU S., ET AL., INTERHEART STUDY INVESTIGATORS, EFFECT OF POTENTIALLY MODIFIABLE RISK FACTORS ASSOCIATED WITH MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): CASECONTROL STUDY. LANCET, 364, PP. 937-952, (2004); LEWINGTON S., WHITLOCK G., CLARKE R., ET AL., BLOOD CHOLESTEROL AND VASCULAR MORTALITY BY AGE, SEX, AND BLOOD PRESSURE: A META-ANALYSIS OF INDIVIDUAL DATA FROM 61 PROSPECTIVE STUDIES WITH 55,000 VASCULAR DEATHS PROSPECTIVE STUDIES COLLABORATION, LANCET, 70, PP. 1829-1839, (2007); KRONMAL R.A., CAIN K.C., OMENN G.S., TOTAL SERUM CHOLESTEROL LEVELS AND MORTALITY RISK AS A FUNCTION OF AGE. A REPORT BASED ON THE FRAMINGHAM DATA, ARCH INTERN MED, 153, PP. 1065-1073, (1993); VAUGHAN C.J., GOTTO JR. A.M., UPDATE ON STATINS: 2003, CIRCULATION, 110, PP. 886-892, (2004); AFILALO J., DUQUE G., STEELE R., ET AL., STATINS FOR SECONDARY PREVENTION IN ELDERLY PATIENTS, J AM COLL CARDIOL, 51, PP. 37-45, (2008); THOMPSON P.D., CLARKSON P., KARAS R.H., STATIN- ASSOCIATED MYOPATHY, JAMA, 289, PP. 1682-1690, (2003); THOMPSON P.D., CLARKSON P.M., ROSENSON R.S., NATIONAL LIPID ASSOCIATION STATIN SAFETY TASK FORCE MUSCLE SAFETY EXPERT PANEL, AN ASSESSMENT OF STATIN SAFETY BY MUSCLE EXPERTS AM J CARDIOL, 97, (2006); JACKEVICIUS C.A., MAMDANI M., TU J.V., ADHERENCE WITH STATIN THERAPY IN ELDERLY PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROMES, JAMA, 288, PP. 462-467, (2002); HEESCHEN C., HAMM C.W., LAUFS U., ET AL., WITHDRAWAL OF STATINS INCREASES EVENT RATES IN PATIENTS WITH ACUTE CORONARY SYNDROMES. FOR THE PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT (PRISM) INVESTIGATORS, CIRCULATION, 105, PP. 1446-1452, (2002); THOMAS M.K., NARANG D., LAKSHMY R., ET AL., CORRELATION BETWEEN INFLAMMATION AND OXIDATIVE STRESS IN NORMOCHOLESTEROLEMIC CORONARY ARTERY DISEASE PATIENTS 'ON' AND 'OFF' ATORVASTATIN FOR SHORT TIME INTERVALS, CARDIOVASC DRUGS THER, 20, PP. 37-44, (2006); KALRA E.K., NUTRACEUTICAL - DEFINITION AND INTRODUCTION, AAPS PHARMSCI, 5, (2003); CICERO A.F.G., ROVATI L., SETNIKAR I., EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS IN HUMANS, ARZNEIMITTELFORSCHUNG, 57, PP. 26-30, (2007); KONG W., WEI J., ABIDI P., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NATURE MED, 10, PP. 1344-1351, (2004); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); BECKER D.J., GORDON R.Y., HALBERT S.C., FRENCH B., MORRIS P.B., RADER D.J., RED YEAST RICE FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS: A RANDOMIZED TRIAL, ANN INTERN MED, 150, PP. 830-839, (2009); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); GREYLING A., DE WITT C., OOSTHUIZEN W., ET AL., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); SINGH D.K., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); AFFUSO F., RUVOLO A., MICILLO F., ET AL., EFFECTS OF A NUTRACEUTICAL COMBINATION (BERBERINE, RED YEAST RICE AND POLICOSANOLS) ON LIPID LEVELS AND ENDOTHELIAL FUNCTION RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, NUTR METAB CARDIOVASC DIS, 20, PP. 656-661, (2010); NI Y.X., THERAPEUTIC EFFECT OF BERBERINE ON 60 PATIENTS WITH TYPE II DIABETES MELLITUS AND EXPERIMENTAL RESEARCH, ZHONG XI YI JIE HE ZA ZHI, 8707, PP. 711-713, (1988); BRUSQ J.M., ANCELLIN N., GRONDIN P., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMPKINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPIDEMIC EFFECTS OF BERBERINE, J LIPID RES, 47, PP. 1281-1288, (2006); ZHANG Y., LI X., ZOU D., ET AL., TREATMENT OF TYPE 2 DIABETES AND DYSLIPIDEMIA WITH THE NATURAL PLANT ALKALOID BERBERINE, J CLIN ENDOCR METAB, 93, PP. 2559-2565, (2008); PAN G.Y., HUANG Z.J., WANG G.J., THE ANTIHYPERGLYCAEMIC ACTIVITY OF BERBERINE ARISES FROM A DECREASE OF GLUCOSE ABSORPTION, PLANTA MED, 69, PP. 632-636, (2003); KONG W.J., ZHANG H., SONG D.Q., ET AL., BERBERINE REDUCES INSULIN RESISTANCE THROUGH PROTEIN KINASE C-DEPENDENT UP-REGULATION OF INSULIN RECEPTOR EXPRESSION, METABOLISM, 58, PP. 109-119, (2009)","G. MARAZZI; DEPARTMENT OF MEDICAL SCIENCES, IRCCS SAN RAFFAELE, ROME, ITALY; EMAIL: GIUSEPPE.MARAZZI@SANRAFFAELE.IT","SPRINGER HEALTHCARE","ENGLISH","ADV. THER.","ARTICLE","ISI","2-S2.0-84860585995","ADV THER","DEPARTMENT OF MEDICAL SCIENCES;CARDIAC UNIT VANNINI HOSPITAL;DEPARTMENT OF MEDICAL SCIENCES;DEPARTMENT OF MEDICAL SCIENCES;DEPARTMENT OF MEDICAL SCIENCES;DEPARTMENT OF MEDICAL SCIENCES;UNIVERSITY OF NAPLES FEDERICO II;DEPARTMENT OF MEDICAL SCIENCES","NOTREPORTED;DEPARTMENT OF MEDICAL SCIENCES;NOTREPORTED",NA,"MARAZZI G, 2011, ADV THER","MARAZZI G, 2011, ADV THER"
"GARCÍA A;GARCÍA M;RIBAS M;BROWN A","GARCÍA, ALBERTO (55711847800); GARCÍA, MIGUEL A. (57225775183); RIBAS, MAURICIO (7003643363); BROWN, ADOLFO (7408341111)","RECOVERY OF SUGAR CANE CUTICULAR WAX BY MECHANICAL SEPARATION AND SOLVENT EXTRACTION RECUPERACIÓN DE CERA DE CUTÍCULA DE CANA DE AZÚCAR MEDIANTE SEPARACIÓN MECÁNICA Y EXTRACCIÓN CON SOLVENTES",2003,"GRASAS Y ACEITES","54","5",3,"10.3989/gya.2003.v54.i2.261","LA HABANA 11 000, VIA BLANCA 804, CUBA;LA HABANA 11 000, VIA BLANCA 804, CUBA;LA HABANA 11 000, VIA BLANCA 804, CUBA;LA HABANA 11 000, VIA BLANCA 804, CUBA","THE INDUSTRIAL EXPERIENCE IN THE EXTRACTION AND REFINING OF SUGAR CANE CRUDE WAX IN CUBA FROM FILTER MUD CONFIRMS THE FEASIBILITY OF SUCH TECHNOLOGIES FOR THE PRODUCTION OF WAXES ADDRESSED TO THE PHARMACEUTICAL MARKET, TO HIGH PRICE DRUGS SUCH AS POLICOSANOL. WITH THE AIM OF DEVELOP A NEW TECHNOLOGY FOR THE RECOVERY THE NATURAL WAX THAT COVERS THE CANE STALK, THE PRESENT PAPER SHOWS A NEW ACHIEVEMENT, THE RECOVERY OF THE WAX THAT OCCURS IN THE FRACTION DERMAX, A CUTICULAR LAYER THAT REMAINS AFTER THE MECHANICAL PROCESSING OF THE SUGAR CANE IN A BLADE SEPARATOR INTERCANE®, 5 TON/H, WHICH WAS TESTED AT THE SUGAR MILL. LA REFORMA, VERACRUZ STATE IN MEXICO. TWO EXTRACTION SYSTEMS, SOXHLET AND SOXTEC WERE TESTED AND THREE DIFFERENT KIND OF ORGANIC SOLVENTS WERE EVALUATED. THE WAXY MATERIAL WAS ANALYSED BY GAS CHROMATOGRAPHY. A BRIEF DATA ABOUT THE CHEMICAL COMPOSITION OF THE NEW QUALITY OF WAX IS DISCLOSED.","CANE WAX; SUGAR CANE WAX; TILBY SEPARATOR; VEGETABLE WAX","ARUNDINARIA; SACCHARUM; SACCHARUM HYBRID CULTIVAR; GAS CHROMATOGRAPHY; ORGANIC SOLVENTS; SOLVENT EXTRACTION; SUGAR CANE; SUGAR CANE CRUDE WAXES; WAXES","","","BOURZUTSCHKY H., APPLICATION OF THE TILBY CANE SEPARATOR; GARCIA A., LASTRA J., TIO VAZQUEZ M., CERA DE CACHAZA, LA INDUSTRIA DE LOS DERIVADOS DE LA CAÑA DE AZÚCAR, (1986); GARCIA A., GARCIA M.A., SOXHTEC EXTRACTION OF CRUDE WAX FROM SUGAR CANE, THE JOURNAL OF TECATOR, 20, (1996); HONIG P., LOS LÍPIDOS DE LA CAÑA DE AZÚCAR, PRINCIPIOS DE TECNOLOGÍA AZUCARERA, (1978); ESTACIÓN PROVINCIAL DE INVESTIGACIONES DE LA CANA DE AZÚCAR, (1993); ROSS F.B., ROSS WAXES, 10TH EDITION, (1987); SPENCER M., CERA DE CAÑA DE AZÚCAR, MANUAL DE AZÚCAR DE CAÑA, (1977); TAKAMURA Y., SIGNIFICATIÓN DEL DESARROLLO DE LA CERA DE LA CANA DE AZÚCAR, II SIMPOSIO SOBRE CAÑA DE AZÚCAR, (1991)","A. GARCÍA; INST. CUBANO INVEST. DERIVADOS C.A., LA HABANA 11 000, VIA BLANCA 804, CUBA; EMAIL: ALBERTG@ICIDCA.EDU.CU","INSTITUTO DE LA GRASA","SPANISH","GRASAS ACEITES","ARTICLE","ISI","2-S2.0-0242582467","GRASAS ACEITES","NOTREPORTED","NOTREPORTED;INST. CUBANO INVEST. DERIVADOS C.A.;NOTREPORTED",NA,"GARCÍA A, 2003, GRASAS ACEITES","GARCÍA A, 2003, GRASAS ACEITES"
"","","POLICOSANOL",2004,"ALTERNATIVE MEDICINE REVIEW","9","5",10,"","","[NO ABSTRACT AVAILABLE]","","ACETYLSALICYLIC ACID; ACIPIMOX; ATORVASTATIN; MEVINOLIN; PLANT EXTRACT; POLICOSANOL; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TICLOPIDINE; BIOCHEMISTRY; BODY WEIGHT DISORDER; BULIMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG INTERACTION; DRUG MECHANISM; DRUG NUTRIENT INTERACTION; DRUG STRUCTURE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NONHUMAN; NUTRIENT; PHYTOTHERAPY; PLANT PRODUCT; POLYURIA; REVIEW; SUGARCANE; WEIGHT REDUCTION","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); MENENDEZ R., AMOR A.M., GONZALEZ R., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., FRAGA V., AMOR M.A., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR M.A., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VS. LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); CASTANO G., MAS R., ARRUZAZABALA M., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 29, PP. 105-116, (1999); VALDES S., ARRUZAZABALA M.I., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS L., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, PP. 507-513, (1992); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, PP. 1084-1092, (1994); PONS P., RODRIQUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, PP. 819-827, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 57, PP. 691-699, (1996); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL, 56 A, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 58, PP. 44-51, (1997); TORRES O., AGRAMONTE A., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 29, PP. 117-127, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); ORTENSI G., GLADSTEIN J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); ILLNAIT J., CASTANO G., MAS R., FERNANDEZ J.C., A COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND SIMVASTATIN FOR TREATING TYPE II HYPERCHOLESTEROLEMIA, CAN J CARDIOL, 13, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 859-867, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-146, (2000); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 26-35, (1997); ALCOCER L., FERNANDEZ L., COMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES CLIN EXP, 57, PP. 568-577, (1996); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., GAMEZ R., ET AL., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2004); BATISTA J., STRUSSER R., PADRON R., ET AL., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTHS OF LIPID-LOWERING THERAPY WITH POLICOSANOL, ADV THER, 13, PP. 137-148, (1996); STUSSER R., BATISTA J., PADRON R., ET AL., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, PP. 469-473, (1998); BATISTA J., STUSSER R., PENICHET M., UGUET E., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES CLIN EXP, 56, PP. 906-914, (1995); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); CELIA A.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODREGUEZ-ECHENIGUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); ALEMAN C.L., NOA M., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI-AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997)","","THORNE RESEARCH INC.","ENGLISH","ALTERN. MED. REV.","REVIEW","ISI","2-S2.0-4644227274","ALTERN MED REV",NA,"NOTREPORTED",NA,"NA, 2004, ALTERN MED REV","NA, 2004, ALTERN MED REV"
"VERDEGEM P","VERDEGEM, PETER J. E. (8666708600)","VISCOUS SOLUBLE FIBER COMBINED WITH PHYTOSTEROLS AND POLICOSANOL REDUCES LDLCHOLESTEROL AND INCREASES HDLCHOLESTEROL IN HYPERCHOLESTEROLEMIA",2007,"CURRENT TOPICS IN NUTRACEUTICAL RESEARCH","5","5",1,"","RESEARCH AND DEVELOPMENT DEPARTMENT, UNICITY INTERNATIONAL, OREM, UT 84097, 1201 NORTH 800 EAST, UNITED STATES","THIS PILOT STUDY INVESTIGATES THE EFFICACY OF A COMBINATION OF NUTRACEUTICALS IN IMPROVING LIPID LEVELS. THE TESTED PRODUCT COMBINES VISCOUS SOLUBLE FIBER WITH PHYTOSTEROLS, POLICOSANOL, AND AN EXTRACT OF CHRYSANTHEMUM MORIFOLIUM. ALL FOUR INGREDIENTS HAVE BEEN SHOWN TO HAVE CHOLESTEROL-LOWERING POTENTIAL, BUT ALL THROUGH DIFFERENT BIOLOGICAL MECHANISMS. THE TEST PRODUCT IS THE FIRST TO COMBINE THESE FOUR CHOLESTEROL-LOWERING MECHANISMS IN ONE PRODUCT. TWENTY-FIVE SUBJECTS COMPLETED AN 8-WEEK OPEN LABEL STUDY DESIGN. THE PRODUCT WAS TAKEN TWICE DAILY BEFORE THE MAIN MEALS. FASTING LIPID PANELS WERE MEASURED AT BASELINE, 4, AND 8 WEEKS. THE TOTAL CHOLESTEROL LEVELS WERE REDUCED 8.2% (P<0.05) AFTER 8 WEEKS, AND 10.7% (P<0.01) IN A SUBGROUP OF SUBJECTS WITH TOTAL CHOLESTEROL LEVELS >200 MG/DL AT BASELINE. LDL-CHOLESTEROL WAS REDUCED 4.8% (P<0.01) AND 24.5% (P<0.001), AND 30.6% (P<0.00001) IN SUBGROUPS OF SUBJECTS HAVING BASELINE LDL-CHOLESTEROL LEVELS >130 AND >160 MG/DL, RESPECTIVELY. HDL-CHOLESTEROL LEVELS WERE INCREASED 8.3% (P<0.05). THIS NUTRACEUTICAL COMBINATION THERAPY IS PROMISING AS A FIRST LINE INTERVENTION, AND MAY SERVE AS AN ADJUNCT THERAPY TO PHARMACEUTICAL LIPID LOWERING PRESCRIPTION THERAPY. COPYRIGHT © 2006 BY NEW CENTURY HEALTH PUBLISHERS, LLC.","ATHEROSCLEROSIS; CHOLESTEROL; FIBER; NUTRACEUTICALS; PHYTOSTEROLS; POLICOSANOL","","","","ANDERSON J.W., ALLGOOD L.D., TURNER J., OELTGEN P.R., DAGGY B.P., EFFECTS OF PSYLLIUM ON GLUCOSE AND SERUM LIPID RESPONSES IN MEN WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA, AMERICAN JOURNAL OF CLINICAL NUTRITION, 70, 4, PP. 466-473, (1999); ANDERSON J.W., DAVIDSON M.H., BLONDE L., BROWN W.V., HOWARD W.J., GINSBERG H., ALLGOOD L.D., WEINGAND K.W., LONG-TERM CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM AS AN ADJUNCT TO DIET THERAPY IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, AMERICAN JOURNAL OF CLINICAL NUTRITION, 71, 6, PP. 1433-1438, (2000); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 19, PP. 2262-2269, (2006); CARABIN I.G., GARY F.W., EVALUATION OF SAFETY OF INULIN AND OLIGOFRUCTOSE AS DIETARY FIBER, REGULATORY TOXICOLOGY AND PHARMACOLOGY, 30, 3, PP. 268-282, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS IN R AND D, 3, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, JOURNALS OF GERONTOLOGY - SERIES A BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 56, 3, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AND AGING, 20, 2, PP. 153-163, (2003); CASTANO G., MAS R., ROCA J., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., SELMAN E., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, 2, PP. 123-130, (1999); CHANDALIA M., BENEFICIAL EFFECTS OF HIGH DENSITY FIBER INTAKE IN PATIENTS WITH TYPE II DIABETES MELLITUS, NEW ENGLAND JOURNAL OF MEDICINE, 342, PP. 1392-1398, (2000); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); CHEN Q., DE BONT H., VAN DER ZEE L., LANSINK M., VAN NORREN K., CHOLESTEROL LOWERING SUPPLEMENT, (2000); CORVOL J.-C., BOUZAMONDO A., SIROL M., HULOT J.-S., SANCHEZ P., LECHAT P., DIFFERENTIAL EFFECTS OF LIPID-LOWERING THERAPIES ON STROKE PREVENTION A META-ANALYSIS OF RANDOMIZED TRIALS, ARCHIVES OF INTERNAL MEDICINE, 163, 6, PP. 669-676, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 19, 4, PP. 117-127, (1999); DAVIDSON M.H., EZETIMIBE: A NOVEL OPTION FOR LOWERING CHOLESTEROL, EXPERT REVIEW IN CARDIOVASCULAR THERAPY, 1, PP. 11-21, (2003); EDWARDS J.E., MOORE R.A., STATINS IN HYPERCHOLESTEROLAEMIA: A DOSE-SPECIFIC META-ANALYSIS OF LIPID CHANGES IN RANDOMISED, DOUBLE BLIND TRIALS, BMC FAMILY PRACTICE, 4, PP. 1-19, (2003); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BRITISH JOURNAL OF NUTRITION, 95, 5, PP. 968-975, (2006); HATA Y., NAKAJIMA K., LIFE-STYLE AND SERUM LIPIDS AND LIPOPROTEINS, JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 7, PP. 177-197, (2000); HUXLEY R., LEWINGTON S., CLARKE R., CHOLESTEROL, CORONARY HEART DISEASE AND STROKE: A REVIEW OF PUBLISHED EVIDENCE FROM OBSERVATIONAL STUDIES AND RANDOMIZED CONTROLLED TRIALS, SEMINARS IN VASCULAR MEDICINE, 2, PP. 315-323, (2002); IKEDA I., TANABE Y., SUGANO M., EFFECTS OF SITOSTEROL AND SITOSTANOL ON MICELLAR SOLUBILITY OF CHOLESTEROL, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 35, 4, PP. 361-369, (1989); IKEDA I., TANAKA K., SUGANO M., VAHOUNY G.V., ALLO L.L., DISCRIMINATION BETWEEN CHOLESTEROL AND SITOSTEROL FOR ABSORPTION IN RATS, JOURNAL OF LIPID RESEARCH, 29, 12, PP. 1583-1591, (1988); IKEDA I., TANAKA K., SUGANO M., VAHOUNY G.V., GALLO L.L., INHIBITION OF CHOLESTEROL ABSORPTION IN RATS BY PLANT STEROLS, JOURNAL OF LIPID RESEARCH, 29, 12, PP. 1573-1582, (1988); JENKINS D.J.A., KENDALL C.W.C., MARCHIE A., FAULKNER D.A., WONG J.M.W., DE SOUZA R., EMAM A., PARKER T.L., VIDGEN E., TRAUTWEIN E.A., LAPSLEY K.G., JOSSE R.G., LEITER L.A., SINGER W., CONNELLY P.W., DIRECT COMPARISON OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS WITH A STATIN IN HYPERCHOLESTEROLEMIC PARTICIPANTS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 81, 2, PP. 380-387, (2005); JENKINS D.J., KENDALL C.W., VUKSAN V., VIDGEN E., PARKER T., FAULKNER D., MEHLING C.C., GARSETTI M., TESTOLIN G., CUNNANE S.C., RYAN M.A., COREY P.N., SOLUBLE FIBER INTAKE AT A DOSE APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR A CLAIM OF HEALTH BENEFITS: SERUM LIPID RISK FACTORS FOR CARDIOVASCULAR DISEASE ASSESSED IN A RANDOMIZED CONTROLLED CROSSOVER TRIAL, AMERICAN JOURNAL OF CLINICAL NUTRITION, 75, PP. 834-839, (2002); KNOPP R.H., SUPERKO H.R., DAVIDSON M., INSULL W., DUJOVNE C.A., KWITEROVICH P.O., ZAVORAL J.H., GRAHAM K., O'CONNOR R.R., EDELMAN D.A., LONG-TERM BLOOD CHOLESTEROL-LOWERING EFFECTS OF A DIETARY FIBER SUPPLEMENT, AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 17, 1, PP. 18-23, (1999); KOSOGLOU T., STATKEVICH P., JOHNSON-LEVONAS A.O., PAOLINI J.F., BERGMAN A.J., ALTON K.B., EZETIMIBE: A REVIEW OF ITS METABOLISM, PHARMACOKINETICS AND DRUG INTERACTIONS, CLINICAL PHARMACOKINETICS, 44, 5, PP. 467-494, (2005); KUVIN J.T., ALSHEIKH-ALI A.A., KARAS R.H., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL-RAISING STRATEGIES, JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 47, 2, PP. 196-204, (2006); LATHE R., STEROID AND STEROL 7-HYDROXYLATION: ANCIENT PATHWAYS, STEROIDS, 67, PP. 967-977, (2002); LAW M., RUDNICKA A.R., STATIN SAFETY: A SYSTEMATIC REVIEW, AMERICAN JOURNAL OF CARDIOLOGY, 97, (2006); LIU S., BURING J.E., SESSO H.D., RIMM E.B., WILLETT W.C., MANSON J.E., A PROSPECTIVE STUDY OF DIETARY FIBER INTAKE AND RISK OF CARDIOVASCULAR DISEASE AMONG WOMEN, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 1, PP. 49-56, (2002); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MEDICAL HYPOTHESES, 59, PP. 268-279, (2002); MCPHERSON T.B., OSTLUND R.E., GOLDBERG A.C., BATEMAN J.H., SCHIMMOELLER L., SPILBURG C.A., PHYTOSTANOL TABLETS REDUCE HUMAN LDL-CHOLESTEROL, JOURNAL OF PHARMACY AND PHARMACOLOGY, 57, 7, PP. 889-896, (2005); NAM B.H., KANNEL W.B., D'AGOSTINO R.B., SEARCH FOR AN OPTIMAL ATHEROGENIC LIPID RISK PROFILE: FROM THE FRAMINGHAM STUDY, AMERICAN JOURNAL OF CARDIOLOGY, 97, PP. 372-375, (2006); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 285, PP. 2486-2497, (2001); OSTLUND JR. R.E., PHYTOSTEROLS AND CHOLESTEROL METABOLISM, CURRENT OPINIONS LIPIDOLOGY, 15, PP. 37-41, (2004); PLAT J., MENSINK R.P., PLANT STANOL AND STEROL ESTERS IN THE CONTROL OF BLOOD CHOLESTEROL LEVELS: MECHANISM AND SAFETY ASPECTS, AMERICAN JOURNAL OF CARDIOLOGY, 96, 1 SUPPL., (2005); SILVA M.A., SWANSON A.C., GANDHI P.J., TATARONIS G.R., STATIN-RELATED ADVERSE EVENTS: A META-ANALYSIS, CLINICAL THERAPEUTICS, 28, 1, PP. 26-35, (2006); SPRECHER D.L., PEARCE G.L., FIBER-MULTIVITAMIN COMBINATION THERAPY: A BENEFICIAL INFLUENCE ON LOW-DENSITY LIPOPROTEIN AND HOMOCYSTEINE, METABOLISM, 51, PP. 1166-1170, (2002); THOMPSON G.R., ADDITIVE EFFECTS OF PLANT STEROL AND STANOL ESTERS TO STATIN THERAPY, AMERICAN JOURNAL OF CARDIOLOGY, 96, (2005); THURNHOFER H., HAUSER H., UPTAKE OF CHOLESTEROL BY SMALL INTESTINAL BRUSH BORDER MEMBRANE IS PROTEIN-MEDIATED, BIOCHEMISTRY, 29, PP. 2142-2148, (1990); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTRITION REVIEWS, 61, 11, PP. 376-383, (2003); VASUDEVAN A.R., JONES P.H., EFFECTIVE USE OF COMBINATION LIPID THERAPY, CURRENT CARDIOLOGY REPORTS, 7, 6, PP. 471-479, (2005); VON BERGMANN K., SUDHOP T., LUTJOHANN D., CHOLESTEROL AND PLANT STEROL ABSORPTION: RECENT INSIGHTS, AMERICAN JOURNAL OF CARDIOLOGY, 96, 1 SUPPL., (2005); DECLARATION OF HELSINKI V: ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 284, PP. 2971-2973, (2000); YUSUF P.S., HAWKEN S., OUNPUU S., DANS T., AVEZUM A., LANAS F., MCQUEEN M., BUDAJ A., PAIS P., VARIGOS J., LISHENG L., EFFECT OF POTENTIALLY MODIFIABLE RISK FACTORS ASSOCIATED WITH MYOCARDIAL INFARCTION IN 52 COUNTRIES (THE INTERHEART STUDY): CASE-CONTROL STUDY, LANCET, 364, 9438, PP. 937-952, (2004)","P.J.E. VERDEGEM; RESEARCH AND DEVELOPMENT DEPARTMENT, UNICITY INTERNATIONAL, OREM, UT 84097, 1201 NORTH 800 EAST, UNITED STATES; EMAIL: PETER.VERDEGEM@UNICITY.NET","","ENGLISH","CURR. TOP. NUTRACEUTICAL RES.","ARTICLE","ISI","2-S2.0-84855432725","CURR TOP NUTRACEUTICAL RES","RESEARCH AND DEVELOPMENT DEPARTMENT","NOTREPORTED;RESEARCH AND DEVELOPMENT DEPARTMENT;NOTREPORTED",NA,"VERDEGEM PJE, 2007, CURR TOP NUTRACEUTICAL RES","VERDEGEM PJE, 2007, CURR TOP NUTRACEUTICAL RES"
"WANG Y;JONES P;PISCHEL I;FAIROW C","WANG, Y.W. (8397210300); JONES, P.J.H. (36078426500); PISCHEL, I. (57212705526); FAIROW, C. (6504578773)","EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS",2003,"LIPIDS","38","5",57,"10.1007/s11745-003-1047-3","CANADA;CANADA;RESEARCH AND DEVELOPMENT, DEGUSSA BIOACTIVES, CHAMPAIGN, IL, UNITED STATES;RESEARCH AND DEVELOPMENT, DEGUSSA BIOACTIVES, CHAMPAIGN, IL, UNITED STATES","THE CURRENT STUDY WAS CARRIED OUT TO EXAMINE THE EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS, ALONE AND IN COMBINATION, ON LIPID PROFILES, CHOLESTEROL BIOSYNTHESIS, AND TISSUE HISTOPATHOLOGICAL CHANGES IN HAMSTERS. FIFTY MALE GOLDEN SYRIAN HAMSTERS, WEIGHING 100 TO 120 G, WERE FED A REGULAR RODENT CHOW FOR 2 WK BEFORE BEING RANDOMLY ASSIGNED INTO 5 GROUPS OF 10 ANIMALS EACH FED SEMISYNTHETIC DIETS FOR 4 WK. GROUP 1 WAS GIVEN A CONTROL DIET THAT CONTAINED 0.25% CHOLESTEROL AND 5% FAT WITH A PUFA TO SATURATED FA RATIO OF 0.4. GROUPS 2 TO 5 WERE FED THE CONTROL DIET AND GIVEN OCTA-6 [A POLICOSANOL MIXTURE FROM SUGAR CANE WAX, 25 MG/KG BODY WEIGHT (BW)], RICEWAX (A POLICOSANOL MIXTURE FROM RICE WAX WITH 50% BEING CONVERTED TO THE CORRESPONDING ACIDS, 50 MG/KG BW), PHYTOSTEROLS (CHOLESTATINTM; 1,000 MG/KG BW), AND RICEWAX (50 MG/KG BW) PLUS PHYTOSTEROLS (1,000 MG/KG BW), RESPECTIVELY. THE RESULTS SHOWED THAT THERE WAS NO DIFFERENCE BETWEEN OCTA-6 AND RICEWAX TREATMENTS IN ANY OF THE LIPID PARAMETERS MEASURED, AND BOTH HAD SIMILAR LEVELS OF TRIGLYCERIDE (TG), TOTAL CHOLESTEROL (T-C), AND HDL CHOLESTEROL (HDL-C) AS THE CONTROL. OCTA-6 BUT NOT RICEWAX INCREASED (P= 0.03) NON-HDL-C AS COMPARED WITH THE CONTROL. PHYTOSTEROLS REDUCED T-C (P< 0.0003) AND HDL-C (P< 0.004) WITHOUT A SIGNIFICANT EFFECT ON TG AND NON-HDL-C AS COMPARED TO THE CONTROL. RICEWAX PLUS PHYTOSTEROLS HAD EFFECTS SIMILAR TO THOSE WITH PHYTOSTEROLS ALONE. FREE CHOLESTEROL SYNTHETIC RATES WERE NOT DIFFERENT AMONG THE TREATMENTS. POLICOSANOLS OR PHYTOSTEROLS DID NOT SHOW ANY TOXIC EFFECTS IN LIVER, HEART, BRAIN, OR KIDNEY. RESULTS SUGGEST THAT, ALTHOUGH PHYTOSTEROLS REDUCE T-C AND HDL-C LEVELS, POLICOSANOLS HAVE NO SIGNIFICANT FAVORABLE EFFECT IN CHANGING LIPID LEVELS IN HAMSTERS.","","ANIMALS; ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; CHOLESTEROL; CRICETINAE; DIET; DRUG SYNERGISM; FATTY ALCOHOLS; LIPIDS; LIVER; MALE; MESOCRICETUS; PHYTOSTEROLS; TRIGLYCERIDES; ANIMALIA; ARUNDINARIA; CRICETINAE; MESOCRICETUS AURATUS; RODENTIA; SACCHARUM HYBRID CULTIVAR; BIOSYNTHESIS; CHOLESTEROL; TOXICITY; CHOLESTATIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PHYTOSTEROL; POLICOSANOL; TRIACYLGLYCEROL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; HISTOPATHOLOGY; LIPID BLOOD LEVEL; MALE; NONHUMAN; RANDOMIZATION; SUGARCANE; SYRIAN HAMSTER; PHYTOSTEROLS; POLICOSANOLS; LIPIDS","TRACO LABS INC.","THIS STUDY WAS SUPPORTED BY A GRANT FROM TRACO LABS INC., CHAMPAIGN, ILLINOIS. THE AUTHORS WOULD LIKE TO THANK DR. MAHMOUD RAEINI-SARJAZ FOR ASSISTANCE OF MEASURING CHOLESTEROL BIOSYNTHESIS. THE VALUABLE TECHNICAL ADVICE OF DR. RALF JAEGER IS GRATEFULLY ACKNOWLEDGED.","MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. A BIOL. SCI. MED. SCI., 56, (2001); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 203-208, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONSALES R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); MENENDEZ R., ARUZAZABALA M.L., MAS R., DEL RIO A., GONZALEZ R., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICIENCY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARM. RES., 19, PP. 117-127, (1999); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTRATED OCTACOSANOL IN RATS, ANN. NUTR. METAB., 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-<SUP>14</SUP>C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. METAB., 39, PP. 279-284, (1995); SINGH H., POULOS A.A., A COMPARATIVE STUDY OF STEARIC ACID AND LIGNOCERIC ACID OXIDATION BY HUMAN SKIN FIBROBLASTS, ARCH. BIOCHEM. BIOPHYS., 250, PP. 171-179, (1986); SINGH H., DERWAS N., POULOS A.A., VERY LONG CHAIN FATTY ACID BETA-OXIDATION BY RAT LIVER MITOCONDRIA AND PEROXISOMES, ARCH. BIOCHEM. BIOPHYS., 259, PP. 382-390, (1987); WANDERS R.J.A., VAN ROERMUND C.W.T., VAN WIJLAND M.J.A., SCHUTGENS R.B.H., SCHAM A.W., VAN DEN BOSCH H., TAGER J.M., STUDIES OF PEROXISOMAL OXIDATION OF PALMITATE AND LIGNOCERATE IN RAT LIVER, BIOCHIM. BIOPHYS. ACTA, 919, PP. 21-25, (1987); GRANLUND L., LARSEN L.N., CHRISTIANSEN E.N., PEDERSEN J.I., ABSORPTION OF VERY-LONG-CHAIN SATURATED FATTY ACIDS IN TOTALLY HYDROGENATED FISH OIL, BR. J. NUTR., 84, PP. 681-688, (2000); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA R., MESA M., DE ARMAS M., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR. THER. RES. CLIN. EXP., 62, PP. 209-219, (2001); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL. RES., 44, PP. 299-304, (2001); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R., FRAGA V., AMOR A., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., PP. 8-12, (2001); POLLACK O.J., KRITCHEVSKY D., Β-SITOSTEROL MONOGRAPHS ON ATHEROSCLEROSIS, (1981); JONES P.J.H., MACDOUGALL D.E., NTANIOS F.Y., VANSTONE C.A., DIETARY PHYTOSTEROLS AS CHOLESTEROL-LOWERING AGENTS IN HUMANS, CAN. J. PHYSIOL. PHARMACOL., 75, PP. 217-227, (1997); JONES P.J.H., NTANIOS F.Y., RAEINI-SARJAZ M., VANSTONE C.A., CHOLESTEROL-LOWERING EFFICACY OF A SITOSTANOL-CONTAINING PHYTOSTEROL MIXTURE WITH A PRUDENT DIET IN HYPERLIPIDEMIC MEN, AM. J. CLIN. NUTR., 69, PP. 1144-1150, (1999); JONES P.J.H., RAEINI-SARJAZ M., NTANIOS F., VANSTONE A., FENG J.Y., PARSONS W.E., MODULATION OF PLASMA LIPID LEVELS AND CHOLESTEROL KINETICS BY PHYTOSTEROL VERSUS PHYTOSTANOL ESTERS, J. LIPID RES., 41, PP. 697-705, (2000); MIETTINEN T.A., VUORISTO M., NISSINEN M., JARVINEN H.J., GYLLING H., SERUM, BILIARY, AND FECAL CHOLESTEROL AND PLANT STEROLS IN CHOLECTOMIZED PATIENTS BEFORE AND DURING CONSUMPTION OF STANOL ESTER MARGARINE, AM. J. CLIN. NUTR., 71, PP. 1095-1102, (2000); OSTLUND R.E., SPILBURG C.A., STENSON W.F., SITOSTANOL ADMINISTRATION IN LECITHIN MICELLES POTENTLY REDUCES CHOLESTEROL ABSORPTION IN HUMANS, AM. J. CLIN. NUTR., 70, PP. 826-831, (1999); NTANIOS F.Y., JONES P.J., DIETARY SITOSTANOL RECIPROCALLY INFLUENCES CHOLESTEROL ABSORPTION AND BIOSYNTHESIS IN HAMSTERS AND RABBITS, ATHEROSCLEROSIS, 14, PP. 341-351, (1999); NORMEN L., DUTTA P., LIA A., ANDERSON H., SOY STEROL ESTERS AND Β-SITOSTANOL ESTER AS INHIBITORS OF CHOLESTEROL ABSORPTION IN HUMAN SMALL BOWEL, AM. J. CLIN. NUTR., 71, PP. 908-913, (2000); KRIS-ETHERTON P.M., DIETSCHY J.M., DESIGN CRITERIA FOR STUDIES EXAMINING INDIVIDUAL FATTY ACID EFFECTS ON CARDIOVASCULAR DISEASE RISK FACTORS: HUMAN AND ANIMAL STUDIES, AM. J. CLIN. NUTR., 65, (1997); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, PP. 499-502, (1972); SCHOELLER D.A., PETERSON D.W., HAYES J.M., DOUBLE-COMPARISON METHOD FOR MASS SPECTROMETRIC DETERMINATION OF HYDROGEN ISOTOPE ABUNDANCES, ANAL. CHEM., 55, PP. 827-832, (1983); SAS USER'S GUIDE: STATISTICS, VERSION 6.12, (1994); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ J., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CAN. J. PHYSIOL. PHARMACOL., 80, PP. 13-21, (2002); JONES P.J.H., AUSMAN L.M., CROLL D.H., FENG J.Y., SCHAEFER E.J., LICHTENSTEIN A.H., VALIDATION OF DEUTERIUM INCORPORATION AGAINST STEROL BALANCE FOR MEASUREMENT OF HUMAN CHOLESTEROL BIOSYNTHESIS, J. LIPID RES., 39, PP. 1111-1117, (1998); NTANIOS F.Y., JONES P.J., EFFECTS OF VARIABLE DIETARY SITOSTANOL CONCENTRATIONS ON PLASMA LIPID PROFILE AND PHYTOSTEROL METABOLISM IN HAMSTERS, BIOCHIM. BIOPHYS. ACTA, 1390, PP. 237-244, (1998); NTANIOS F.Y., MACDOUGALL D.E., JONES P.J., GENDER EFFECTS OF TALL OIL VERSUS SOYBEAN PHYTOSTEROLS AS CHOLESTEROLLOWERING AGENTS IN HAMSTERS, CAN. J. PHYSIOL. PHARMACOL., 76, PP. 780-787, (1998); NTANIOS F.Y., JONES P.J., FROHLICH J.J., DIETARY SITOSTANOL REDUCES PLAQUE FORMATION BUT NOT LECITHIN CHOLESTEROL ACYL TRANSFERASE ACTIVITY IN RABBITS, ATHEROSCLEROSIS, 138, PP. 101-110, (1998); ALEMAN C.L., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE-DAWLEY RATS: A 24 MONTH STUDY, TERATOG. CARCINOG. MUTAGEN., 14, PP. 239-249, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY, FOOD CHEM. TOXICOL., 33, PP. 573-578, (1995); ALEMAN C.L., RODEIRO I., NOA M., MENENDEZ R., GAMEZ R., HERNANDEZ C., MAS R., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J. APPL. TOXICOL., 21, PP. 179-184, (2001); RENDON A., RODRIGUEZ M.D., LOPEZ M., GARCIA H., CAJIGAS A., MAS R., FERNANDEZ I., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOL. LETT., SUPPL., (1992); WAALKENS-BERENDSEN D.H., WOLTERBEEK A.P., WIJNANDS M.V., RICHOLD M., HEPBURN P.A., SAFETY EVALUATION OF PHYTOSTEROL ESTERS. PART 3: TWO-GENERATION REPRODUCTION STUDY IN RATS WITH PHYTOSTEROL ESTERS - A NOVEL FUNCTIONAL FOOD, FOOD CHEM. TOXICOL., 37, PP. 683-696, (1999); HEPBURN P.A., HORNER S.A., SMITH M., SAFETY EVALUATION OF PHYTOSTEROL ESTERS. PART 2: SUBCHRONIC 90-DAY ORAL TOXICITY STUDY ON PHYTOSTEROL ESTERS - A NOVEL FUNCTIONAL FOOD, FOOD CHEM. TOXICOL., 37, PP. 521-532, (1999); RODEIRO I., ALEMAN C., NOA M., MENENDEZ R., MAS R., HERNANDEZ C., GARCIA M., PRE-CLINICAL ORAL TOXICITY IN RATS OF D-002, A NATURAL DRUG WITH ANTI-ULCER EFFECTS, DRUG CHEM. TOXICOL., 21, PP. 151-162, (1998); GAMEZ R., MAS R., NOA M., MENENDEZ R., ALEMAN C., ACOSTA P., GARCIA H., HERNANDEZ C., AMOR A., PEREZ J., GOICOCHEA E., ACUTE AND ORAL SUBCHRONIC TOXICITY OF D-003 IN RATS, TOXICOL. LETT., 118, PP. 31-41, (2000); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., HERNANDEZ C., MENENDEZ R., AGUILAR C., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J. MED. FOOD., 4, PP. 57-65, (2001); RODRIGUEZ M.D., GAMEZ R., RODRIGUEZ M., GARCIA H., TERATOLOGICAL EVALUATION OF D-002 IN RATS AND RABBITS, J. APPL. TOXICOL., 18, PP. 313-316, (1998); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PRE- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG. CARCINOG. MUTAGEN., 18, PP. 1-7, (1998); GAMEZ R., GONZALEZ J.E., RODEIRO I., FERNANDEZ I., ALEMAN C., RODRIGUEZ M.D., ACOSTA P.C., GARCIA H., IN VIVO GENOTOXIC EVALUATION OF D-003, A MIXTURE OF VERY LONG CHAIN ALIPHATIC ACIDS, J. MED. FOOD., 4, PP. 85-91, (2001); ALEMAN C.L., MAS R., RODEIRO I., NOA M., MENENDEZ R., GONZALEZ R.M., SOTOLONGO V., FRAGA V., CAPOTE A., JIMENEZ S., ACUTE, SUBCHRONIC, AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, TOXICOL. LETT., SUPPL., (1992)","P.J.H. JONES; SCH. OF DIETETICS/HUMAN NUTRITION, MCGILL UNIVERSITY, MACDONALD CAMPUS, STE-ANNE-DE-BELLEVUE, QUE., H9X 3V9, 21,111 LAKESHORE RD., CANADA; EMAIL: JONES@MACDONALD.MEGILL.CA","","ENGLISH","LIPIDS","ARTICLE","ISI","2-S2.0-0037316361","LIPIDS","RESEARCH AND DEVELOPMENT;RESEARCH AND DEVELOPMENT","NOTREPORTED;MCGILL UNIVERSITY;NOTREPORTED",NA,"WANG YW, 2003, LIPIDS","WANG YW, 2003, LIPIDS"
"WANG Y;EBINE N;JIA X;JONES P;FAIROW C;JAEGER R","WANG, YANWEN (8397210300); EBINE, NAOYUKI (6602098156); JIA, XIAOMING (49763376500); JONES, PETER J.H. (36078426500); FAIROW, CLINT (6504578773); JAEGER, RALF (57196533819)","VERY LONG CHAIN FATTY ACIDS POLICOSANOLS AND PHYTOSTEROLS AFFECT PLASMA LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS",2005,"METABOLISM: CLINICAL AND EXPERIMENTAL","54","6",9,"10.1016/j.metabol.2004.11.004","SCH. OF DIETETICS AND HUM. NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, CANADA, INST. FOR NUTRISCIENCES AND HEALTH, NATIONAL RESEARCH COUNCIL CANADA, CHARLOTTETOWN, PEI C1A 5T1, 93 MOUNT EDWARD ROAD, CANADA;SCH. OF DIETETICS AND HUM. NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, CANADA;SCH. OF DIETETICS AND HUM. NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, CANADA;SCH. OF DIETETICS AND HUM. NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, CANADA;RESEARCH AND DEVELOPMENT, DEGUSSA BIOACTIVES, CHAMPAIGN, IL 61822, UNITED STATES;RESEARCH AND DEVELOPMENT, DEGUSSA BIOACTIVES, CHAMPAIGN, IL 61822, UNITED STATES","THE AIM OF THE CURRENT STUDY WAS TO EXAMINE THE EFFECTS OF VERY LONG CHAIN FATTY ACIDS (VLCFA) ALONE AT 2 DIETARY LEVELS, OR IN COMBINATION OF VLCFA AT THE LOWER LEVEL WITH LECITHIN (LT) OR PHYTOSTEROLS (PS), ON LIPID PROFILES AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS. SEVENTY-FIVE MALE GOLDEN SYRIAN HAMSTERS, WEIGHING 100 TO 120 G, WERE FED A REGULAR RODENT CHOW FOR 2 WEEKS BEFORE BEING RANDOMLY ASSIGNED INTO 5 GROUPS OF 15 ANIMALS EACH FED SEMISYNTHETIC DIETS FOR 4 WEEKS. GROUP 1 WAS GIVEN A CONTROL DIET THAT CONTAINED 0.25% CHOLESTEROL AND 5% FAT WITH A POLYUNSATURATED TO SATURATED FATTY ACIDS RATIO OF 0.4. GROUPS 2 TO 5 WERE FED THE CONTROL DIET AND GIVEN 25 MG/KG BW PER DAY OF VLCFA (LICOWAX) (VLCFA25), 50 MG/KG BW PER DAY OF VLCFA (VLCFA50), 25 MG/KG BW PER DAY OF VLCFA + 1000 MG/KG BW PER DAY OF LT (VLCFA25/LT), AND 25 MG/KG BW PER DAY OF VLCFA + 1000 MG/KG BW PER DAY OF PS (CHOLESTATIN, VLCFA25/PS), RESPECTIVELY. RESULTS SHOWED THAT HDL-CHOLESTEROL (HDL-C) LEVELS WERE NOT CHANGED BY VLCFA25, ALTHOUGH INCREASED BY VLCFA50 (P <. 05) RELATIVE TO CONTROL. TOTAL CHOLESTEROL (T-C) AND NON-HDL-C LEVELS WERE NOT AFFECTED BY VLCFA25 AND VLCFA50 AS COMPARED WITH CONTROL. VLCFA25/LT HAD HIGHER (P <. 02) T-C AND HDL-C LEVELS THAN ANY OTHER TREATMENTS AND INCREASED (P <. 05) LIVER WEIGHT RELATIVE TO CONTROL. IN CONTRAST, VLCFA25/PS REDUCED T-C (P =. 0004) AND NON-HDL-C (P =. 007) WITHOUT EFFECT ON HDL-C LEVELS COMPARED WITH CONTROL. TRIGLYCERIDE LEVELS WERE NOT AFFECTED BY ANY TREATMENT. CHOLESTEROL BIOSYNTHESIS RATE WAS HIGHER (P <. 05) IN ANIMALS FED VLCFA25 AND VLCFA50 THAN THOSE FED CONTROL OR VLCFA25/LT OR VLCFA25/PS. RESULTS SUGGEST THAT PSS CAN DECREASE TOTAL AND NON-HDL-C CHOLESTEROL, WHEREAS VLCFA MAY INCREASE HDL-C IN HAMSTERS. © 2005 ELSEVIER INC. ALL RIGHTS RESERVED.","","CHOLESTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; PHYTOSTEROL; POLICOSANOL; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID; ANIMAL EXPERIMENT; ANIMAL FOOD; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; HAMSTER; LIPID BLOOD LEVEL; LIVER WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; RODENT; TRIACYLGLYCEROL BLOOD LEVEL","DEGUSSA BIOACTIVES","THIS STUDY WAS SUPPORTED BY DEGUSSA BIOACTIVES (CHAMPAIGN, ILL). APPRECIATION IS EXTENDED TO MR BINGHAM GORDON FOR TAKING CARE AND SACRIFICING ANIMALS DURING THE STUDY. THE AUTHORS WOULD LIKE TO THANK VIVIAN LAU FOR HER ASSISTANCE IN ANIMAL CARE.","MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. A BIOL. SCI. MED. SCI., 56, (2001); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 203-208, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); MENENDEZ R., ARUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICIENCY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 117-127, (1999); VARADY K.A., JONES P.J.H., WANG Y.W., POLICOSANOLS: ROLE IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR. REV., 61, PP. 376-383, (2003); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTRATED OCTACOSANOL IN RATS, ANN. NUTR. METAB., 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-<SUP>14</SUP>C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. METAB., 39, PP. 279-284, (1995); SINGH H., POULOS A.A., A COMPARATIVE STUDY OF STEARIC ACID AND LIGNOCERIC ACID OXIDATION BY HUMAN SKIN FIBROBLASTS, ARCH. BIOCHEM. BIOPHYS., 250, PP. 171-179, (1986); SINGH H., DERWAS N., POULOS A.A., VERY LONG CHAIN FATTY ACID BETA-OXIDATION BY RAT LIVER MITOCONDRIA AND PEROXISOMES, ARCH. BIOCHEM. BIOPHYS., 259, PP. 382-390, (1987); WANDERS R.J.A., VAN ROERMUND C.W.T., VAN WIJLAND M.J.A., ET AL., STUDIES OF PEROXISOMAL OXIDATION OF PALMITATE AND LIGNOCERATE IN RAT LIVER, BIOCHIM. BIOPHYS. ACTA, 919, PP. 21-25, (1987); GRANLUND L., LARSEN L.N., CHRISTIANSEN E.N., ET AL., ABSORPTION OF VERY LONG-CHAIN SATURATED FATTY ACIDS IN TOTALLY HYDROGENATED FISH OIL, BR. J. NUTR., 84, PP. 681-688, (2000); MENDOZA S., GAMEZ R., NOA M., ET AL., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR. THER. RES., 62, PP. 209-219, (2001); WANG Y.W., JONES P.J., PISCHEL I., ET AL., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); MENENDEZ R., MAS R., AMOR A.M., ET AL., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL. RES., 44, PP. 299-304, (2001); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); KRIS-ETHERTON P.M., DIETSCHY J.M., DESIGN CRITERIA FOR STUDIES EXAMINING INDIVIDUAL FATTY ACID EFFECTS ON CARDIOVASCULAR DISEASE RISK FACTORS: HUMAN AND ANIMAL STUDIES, AM. J. CLIN. NUTR., 65, (1997); JONES P.J.H., MACDOUGALL D.E., NTANIOS F.Y., ET AL., DIETARY PHYTOSTEROLS AS CHOLESTEROL-LOWERING AGENTS IN HUMANS, CAN. J. PHYSIOL. PHARMACOL., 75, PP. 217-227, (1997); JONES P.J.H., NTANIOS F.Y., RAEINI-SARJAZ M., ET AL., CHOLESTEROL-LOWERING EFFICACY OF A SITOSTANOL-CONTAINING PHYTOSTEROL MIXTURE WITH A PRUDENT DIET IN HYPERLIPIDEMIC MEN, AM. J. CLIN. NUTR., 69, PP. 1144-1150, (1999); JONES P.J., RAEINI-SARJAZ M., NTANIOS F., ET AL., MODULATION OF PLASMA LIPID LEVELS AND CHOLESTEROL KINETICS BY PHYTOSTEROL VERSUS PHYTOSTANOL ESTERS, J. LIPID RES., 41, PP. 697-705, (2000); MIETTINEN T.A., VUORISTO M., NISSINEN M., ET AL., SERUM, BILIARY, AND FECAL CHOLESTEROL AND PLANT STEROLS IN CHOLECTOMIZED PATIENTS BEFORE AND DURING CONSUMPTION OF STANOL ESTER MARGARINE, AM. J. CLIN. NUTR., 71, PP. 1095-1102, (2000); OSTLUND R.E., SPILBURG C.A., STENSON W.F., SITOSTANOL ADMINISTRATION IN LECITHIN MICELLES POTENTLY REDUCES CHOLESTEROL ABSORPTION IN HUMANS, AM. J. CLIN. NUTR., 70, PP. 826-831, (1999); NTANIOS F.Y., JONES P.J., DIETARY SITOSTANOL RECIPROCALLY INFLUENCES CHOLESTEROL ABSORPTION AND BIOSYNTHESIS IN HAMSTERS AND RABBITS, ATHEROSCLEROSIS, 14, PP. 341-351, (1999); NORMEN L., DUTTA P., LIA A., ET AL., SOY STEROL ESTERS AND BETA-SITOSTANOL ESTER AS INHIBITORS OF CHOLESTEROL ABSORPTION IN HUMAN SMALL BOWEL, AM. J. CLIN. NUTR., 71, PP. 908-913, (2000); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, PP. 499-502, (1972); NORUM K.R., BERG T., HELGERUD P., ET AL., TRANSPORT OF CHOLESTEROL, PHYSIOL. REV., 63, PP. 1343-1419, (1983); JONES P.J., SCHOELLER D.A., EVIDENCE FOR DIURNAL PERIODICITY IN HUMAN CHOLESTEROL SYNTHESIS, J. LIPID RES., 31, PP. 667-673, (1990); JONES P.J., LEITCH C.A., LI Z.C., ET AL., HUMAN CHOLESTEROL SYNTHESIS MEASUREMENT USING DEUTERATED WATER. THEORETICAL AND PROCEDURAL CONSIDERATIONS, ARTERIOSCLER. THROMB., 13, PP. 247-253, (1993); LONDON I.M., SCHWARZ H., ERYTHROCYTE METABOLISM; THE METABOLIC BEHAVIOR OF THE CHOLESTEROL OF HUMAN ERYTHROCYTES, J. CLIN. INVEST., 32, PP. 1248-1252, (1953); JONES P.J., LEITCH C.A., PEDERSON R.A., MEAL-FREQUENCY EFFECTS ON PLASMA HORMONE CONCENTRATIONS AND CHOLESTEROL SYNTHESIS IN HUMANS, AM. J. CLIN. NUTR., 57, PP. 868-874, (1993); JONES P.J.H., AUSMAN L.M., CROLL D.H., ET AL., VALIDATION OF DEUTERIUM INCORPORATION AGAINST STEROL BALANCE FOR MEASUREMENT OF HUMAN CHOLESTEROL BIOSYNTHESIS, J. LIPID RES., 39, PP. 1111-1117, (1998); DI BUONO M., JONES P.J., BEAUMIER L., ET AL., COMPARISON OF DEUTERIUM INCORPORATION AND MASS ISOTOPOMER DISTRIBUTION ANALYSIS FOR MEASUREMENT OF HUMAN CHOLESTEROL BIOSYNTHESIS, J. LIPID RES., 41, PP. 1516-1523, (2000); JONES P.J., PAPPU A.S., ILLINGWORTH D.R., ET AL., CORRESPONDENCE BETWEEN PLASMA MEVALONIC ACID LEVELS AND DEUTERIUM UPTAKE IN MEASURING HUMAN CHOLESTEROL SYNTHESIS, EUR. J. CLIN. INVEST., 22, PP. 609-613, (1992); MATTHAN N.R., RAEINI-SARJAZ M., LICHTENSTEIN A.H., ET AL., DEUTERIUM UPTAKE AND PLASMA CHOLESTEROL PRECURSOR LEVELS CORRESPOND AS METHODS FOR MEASUREMENT OF ENDOGENOUS CHOLESTEROL SYNTHESIS IN HYPERCHOLESTEROLEMIC WOMEN, LIPIDS, 35, PP. 1037-1044, (2000); NTANIOS F.Y., MACDOUGALL D.E., JONES P.J., GENDER EFFECTS OF TALL OIL VERSUS SOYBEAN PHYTOSTEROLS AS CHOLESTEROL-LOWERING AGENTS IN HAMSTERS, CAN. J. PHYSIOL. PHARMACOL., 76, PP. 780-787, (1998); LUTJOHANN D., MEESE C.O., CROASE III J.R., ET AL., EVALUATION OF DEUTERATED CHOLESTEROL AND DEUTERATED SITOSTANOL FOR MEASUREMENT OF CHOLESTEROL ABSORPTION IN HUMANS, J. LIPIDS RES., 34, PP. 1039-1046, (1993); SAS USER'S GUIDE: STATISTICS, VERSION 6.12, (1994); STEELE R.G.D., TORRIE J.H., PRINCIPLES AND PROCEDURES OF STATISTICS, (1980); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM. TOXICOL., 33, PP. 573-578, (1995); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J. MED. FOOD, 4, PP. 57-65, (2001); ALEMAN C., RODEIRO I., NOA M., ET AL., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J. APPL. TOXICOL., 21, PP. 179-184, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 269-586, (2000); NTANIOS F.Y., JONES P.J., EFFECTS OF VARIABLE DIETARY SITOSTANOL CONCENTRATIONS ON PLASMA LIPID PROFILE AND PHYTOSTEROL METABOLISM IN HAMSTERS, BIOCHIM. BIOPHYS. ACTA, 1390, PP. 237-244, (1998); BEAUMIER-GALLON G., LANFRANCHI J., VERGNES M.F., ET AL., METHOD FOR SIMULTANEOUS MEASUREMENTS OF TRACES OF HEPTADEUTERATED CHOLESTEROL AND CHOLESTEROL BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY: APPLICATION IN HUMANS, J. CHROMATOGR. B BIOMED. SCI. APPL., 718, PP. 23-32, (1998); SUMMARY OF THIRD REPORT OF NCEP EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS III, JAMA, 285, PP. 2486-2497, (2001); MENENDEZ R., MAS R., AMOR A.M., ET AL., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CAN. J. PHYSIOL. PHARMACOL., 80, PP. 13-21, (2002); NTANIOS F.Y., JONES P.J., FROHLICH J.J., DIETARY SITOSTANOL REDUCES PLAQUE FORMATION BUT NOT LECITHIN CHOLESTEROL ACYL TRANSFERASE ACTIVITY IN RABBITS, ATHEROSCLEROSIS, 138, PP. 101-110, (1998)","P.J.H. JONES; SCH. OF DIETETICS AND HUM. NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, CANADA; EMAIL: PETER.JONES@MCGILL.CA","W.B. SAUNDERS","ENGLISH","METAB. CLIN. EXP.","ARTICLE","ISI","2-S2.0-15744398986","METAB CLIN EXP","MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY;RESEARCH AND DEVELOPMENT;RESEARCH AND DEVELOPMENT","NOTREPORTED;MCGILL UNIVERSITY;NOTREPORTED",NA,"WANG Y, 2005, METAB CLIN EXP","WANG Y, 2005, METAB CLIN EXP"
"DAVIDSON M;GEOHAS C","DAVIDSON, MICHAEL H. (7401857573); GEOHAS, CHRIS T. (6507184921)","EFFICACY OF OVERTHECOUNTER NUTRITIONAL SUPPLEMENTS",2003,"CURRENT ATHEROSCLEROSIS REPORTS","5","6",9,"10.1007/s11883-003-0063-5","DEPT. OF PREVENTIVE CARDIOLOGY, RUSH-PRESBYTERIAN-ST. LUKES MED. CTR, CHICAGO, IL 60612, 1725 WEST HARRISON STREET, UNITED STATES;DEPT. OF PREVENTIVE CARDIOLOGY, RUSH-PRESBYTERIAN-ST. LUKES MED. CTR, CHICAGO, IL 60612, 1725 WEST HARRISON STREET, UNITED STATES","MORE THAN 100 MILLION PEOPLE IN THE UNITED STATES REPORT USING NUTRITIONAL SUPPLEMENTS. MOST PEOPLE ARE UNDER THE IMPRESSION THAT NUTRITIONAL SUPPLEMENTS OFFER HEALTH BENEFITS AND ARE CLOSELY REGULATED TO ENSURE SAFETY AND EFFICACY. UNFORTUNATELY, THE DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT OF 1994 ALLOWS FOR THE PROMOTION OF NUTRITIONAL SUPPLEMENTS WITHOUT REVIEW BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION; THEREFORE, IT IS IMPORTANT TO EVALUATE THE EFFICACY AND SAFETY OF THESE SUPPLEMENTS. THERE IS STRONG SCIENTIFIC EVIDENCE SUPPORTING THE USE OF PLANT STEROLS/STANOLS, OMEGA-3 FATTY ACIDS, NIACIN, FOLATE, VITAMIN B6/B12, AND TREE NUTS. THERE IS POTENTIAL EVIDENCE FOR THE HEALTH BENEFITS OF SOY PROTEIN, TEA EXTRACTS, POLICOSANOL, GUGGULIPIDS, COENZYME Q10, AND L-ARGININE. THERE HAS BEEN A LACK OF EVIDENCE FOR THE HEALTH BENEFITS OF GARLIC AND ANTIOXIDANTS. COPYRIGHT © 2003 BY CURRENT SCIENCE INC.","","CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DRUGS, NON-PRESCRIPTION; HUMANS; ACETYLSALICYLIC ACID; ALLICIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BETA CAROTENE; CAMPESTANOL; CAMPESTEROL; CATECHIN; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FLAVONOID; FOLIC ACID; GARLIC EXTRACT; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; NIASPAR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOESTROGEN; PHYTOSTEROL; POLICOSANOL; PYRIDOXINE; SITOSTANOL; SLO NIACIN; SOYBEAN PROTEIN; STANOL ESTER; UBIDECARENONE; UNINDEXED DRUG; NON PRESCRIPTION DRUG; ATHEROSCLEROSIS; CLAUDICATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE EXACERBATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; FOOD AND DRUG ADMINISTRATION; GOUT; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LAW; LIVER DYSFUNCTION; MYOPATHY; PRURITUS; REVIEW; TEA; UNITED STATES; CARDIOVASCULAR DISEASE","NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III; TEA EXTRACTS POLICOSANOL GUGGULIPID COENZYME","FUNDING TEXT 1: SUPPORTED BY NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III PLANT STEROLS/STANOLS OMEGA-3 FATTY ACIDS NIACIN FOLATE, VITAMINS B6 AND B12 TREE NUTS POTENTIAL EVIDENCE SOY PROTEIN/ISOFLAVONE TEA EXTRACTS POLICOSANOL GUGGULIPID COENZYME Q-10 L-ARGININE LACK OF EVIDENCE ANTIOXIDANTS/VITAMIN E GARLIC; FUNDING TEXT 2: NUTRITIONAL SUPPLEMENTS SUPPORTED BY THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III","NATURAL NUTRITIONAL SUPPLEMENTS HISTORICAL BACKGROUND, (2002); KLEPSER T.B., DOUCETTE W.R., HORTON M.R., ET AL., ASSESSMENT OF PATIENTS' PERCEPTIONS AND BELIEFS REGARDING HERBAL THERAPIES, PHARMACOTHERAPY, 20, PP. 83-87, (2000); THE DIETARY SUPPLEMENTS HEALTH AND EDUCATION ACT OF 1994 (DSHEA), (2002); LAW M.R., PLANT STEROL AND STANOL MARGARINES AND HEALTH, WEST J. MED., 173, PP. 43-47, (2000); DAVIDSON M., THE MOBILE LIPID CLINIC: A COMPANION HANDBOOK, (2002); HALLIKAINEN M.A., UUSITUPA M.I., EFFECTS OF 2 LOW-FAT STANOL ESTERCONTAINING MARGARINES ON SERUM CHOLESTEROL CONCENTRATIONS AS PART OF A LOW-FAT DIET IN HYPERCHOLESTEROLEMIC SUBJECTS, AM. J. CLIN. NUTR., 69, PP. 403-410, (1999); WESTSTRATE J.A., MEIJER G.W., PLANT STEROL-ENRICHED MARGARINES AND REDUCTION OF PLASMA TOTAL AND LDL-CHOLESTEROL CONCENTRATIONS IN NORMOCHOLESTEROLEMIC AND MILDLY HYPERCHOLESTEROLEMIC SUBJECTS, EUR. J. CLIN. NUTR., 52, PP. 334-343, (1998); MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N. ENGL. J. MED., 333, PP. 1308-1312, (1995); GYLLING H., RADHAKRISHNAN R., MIETTINEN T., REDUCTION OF SERUM CHOLESTEROL IN POSTMENOPAUSAL WOMEN WITH PREVIOUS MYOCARDIAL INFARCTION AND CHOLESTEROL MALABSORPTION INDUCED BY DIETARY SITOSTANOL ESTER MARGARINE: WOMEN AND DIETARY SITOSTANOL, CIRCULATION, 96, PP. 4226-4231, (1997); HARRIS W.S., CONNOR W.E., ILLINGWORTH D.R., ROTHROCK D.W., FOSTER D.M., EFFECTS OF FISH OIL ON VLDL TRIGLYCERIDE KINETICS IN HUMANS, J. LIPID RES., 31, PP. 1549-1558, (1990); MORI T.A., BURKE V., PUDDEY I.B., ET AL., PURIFIED EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS HAVE DIFFERENTIAL EFFECTS ON SERUM LIPIDS AND LIPOPROTEINS, LDL PARTICLE SIZE, GLUCOSE AND INSULIN IN MILDLY HYPERLIPIDEMIC MEN, AM. J. CLIN. NUTR., 71, PP. 1085-1094, (2000); ALBERT C.M., HENNEKENS C.H., O'DONNELL C.J., ET AL., FISH CONSUMPTION AND RISK OF SUDDEN CARDIAC DEATH, JAMA, 279, PP. 23-28, (1998); BURR M.L., FEHILY A.M., GILBERT J.F., ET AL., EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART), LANCET, 2, PP. 757-761, (1989); KRAUSS R., ECKEL R., HOWARD B., ET AL., AHA DIETARY GUIDELINES. REVISION 2000: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE NUTRITION COMMITTEE OF THE AMERICAN HEART ASSOCIATION, CIRCULATION, 102, PP. 2284-2299, (2000); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); CHESNEY C., HERD J.A., ELAM M.B., ET AL., NIACIN LOWERS FIBRINOGEN IN PATIENTS WITH PERIPHERAL ARTERY DISEASE, CIRCULATION, 94, SUPPL., (1996); WINK J., GIACOPPE G., KING J., EFFECT OF VERY LOW DOSE NIACIN ON HDL IN PATIENTS UNDERGOING LONG TERM STATIN THERAPY, AM. HEART J., 143, PP. 514-518, (2002); GUYTON J.R., GOLDBERG A.C., KREISBERG R.A., ET AL., EFFECTIVENESS OF ONCE-NIGHTLY DOSING OF EXTENDED-RELEASE NIACIN ALONE AND IN COMBINATION FOR HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 82, PP. 737-743, (1998); GARG R., MALINOW M., PETTINGER M., UPSON B., HUNNINGHAKE D., NIACIN TREATMENT INCREASES PLASMA HOMOCYSTEINE LEVELS, AM. HEART J., 138, 6 PART 1, PP. 1082-1087, (1999); EIKELBOOM J.W., LONN E., GENEST J., FLANKEY G., ET AL., HOMOCYSTEINE AND CARDIOVASCULAR DISEASE: A CRITICAL REVIEW OF THE EPIDEMIOLOGIC EVIDENCE, ANN. INTERN. MED., 131, PP. 363-375, (1999); DEBRECENI L., HOMOCYSTEINE - A RISK FACTOR FOR ATHEROSCLEROSIS, ORVOSI HETILAP, 142, PP. 1439-1444, (2001); BOUSHEY C.J., BERESFORD S.A., OMENN G.S., ET AL., A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR DISEASE: PROBABLE BENEFITS OF INCREASING FOLIC ACID INTAKES, JAMA, 274, PP. 1049-1057, (1995); FRASER G.F., SABATE J., BEESON W.L., STRAHAN T.M., A POSSIBLE PROTECTIVE EFFECT OF NUT CONSUMPTION ON RISK OF CORONARY HEART DISEASE. THE ADVENTIST HEALTH STUDY, ARCH. INTERN. MED., 152, PP. 1416-1424, (1992); ALBERT C.M., WILLETT W.C., MANSON J.E., ET AL., NUT CONSUMPTION AND THE RISK OF SUDDEN AND TOTAL CARDIAC DEATH IN THE PHYSICIANS HEALTH STUDY, CIRCULATION, 98, SUPPL. 1, PP. 1-582, (1999); SABATE J., FRASER G.E., BURKE K., ET AL., EFFECTS OF WALNUTS ON SERUM LIPID LEVELS AND BLOOD PRESSURE IN NORMAL MEN, N. ENGL. J. MED., 328, PP. 603-607, (1993); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N. ENGL. J. MED., 333, PP. 276-282, (1995); CROUSE III J.R., MORGAN T., TERRY J.G., ET AL., A RANDOMIZED TRIAL COMPARING THE EFFECT OF CASEIN WITH THAT OF SOY PROTEIN CONTAINING VARYING AMOUNTS OF ISOFLAVONES ON PLASMA CONCENTRATIONS OF LIPIDS AND LIPOPROTEINS, ARCH. INTERN. MED., 159, PP. 2070-2076, (1999); KROMHOUT D., MENOTTI A., BLOEMBERG B., ET AL., DIETARY SATURATED AND TRANS FATTY ACIDS AND CHOLESTEROL AND 25 YEAR MORTALITY FROM CORONARY HEART DISEASE: THE SEVEN COUNTRIES STUDY, PREV. MED., 24, PP. 308-315, (1995); MENENDEZ R., FRAGA V., AMER A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL. BEHAV., 67, PP. 1-7, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A SIX MONTH DOUBLE BLIND STUDY, INT. J. CLIN. PHARMACOL. RES., 21, PP. 43-57, (2001); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, PP. 31-41, (2001); NITYANAND S., KAPOOR N.K., HYPOCHOLESTEROLEMIC EFFECT OF COMMIPHORA MUKUL RESIN (GUGGAL), INDIAN J. EXP. BIOL., 9, PP. 367-377, (1971); NITYANAND S., SRIVASTAVA J.S., ASTHANA O.P., CLINICAL TRIALS WITH GUGULIPID. A NEW HYPOLIPIDAEMIC AGENT, J. ASSOC. PHYSICIANS INDIA, 37, PP. 323-328, (1989); (2002); GOUMAS G., TENTOLOURIS C., TOUSOULIS D., ET AL., THERAPEUTIC MODIFICATION OF THE L-ARGININE-ENOS PATHWAY IN CARDIOVASCULAR DISEASES, ATHEROSCLEROSIS, 154, PP. 255-267, (2001); STAMPFER M.J., HENNEKENS C.H., MANSON J.E., ET AL., VITAMIN E CONSUMPTION AND THE RISK OF CORONARY DISEASE IN WOMEN, N. ENGL. J. MED., 328, PP. 1444-1449, (1993); STEPHENS N.G., PARSONS A., SCHOFIELD P.M., ET AL., RANDOMIZED CONTROLLED TRIAL OF VITAMIN E IN PATIENTS WITH CORONARY DISEASE: CAMBRIDGE HEART ANTIOXIDANT STUDY (CHAOS), LANCET, 347, PP. 781-786, (1996); YUSUF S., DAGENAIS G., POGUE J., BOSCH J., SLEIGHT P., VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH RISK PATIENTS. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, N. ENGL. J. MED., 342, PP. 154-160, (2000); COLLINS R., ARMITAGE J., PARISH S., ET AL., MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-21, (2002); WARSHAFSKY S., KRAMER R.S., SIVAK S.L., EFFECT OF GARLIC ON TOTAL SERUM CHOLESTEROL. A META-ANALYSIS, ANN. INTERN. MED., 119, 7 PART 1, PP. 599-605, (1993); ISAACSOHN J.L., MOSER M., STEIN E.A., ET AL., GARLIC POWDER AND PLASMA LIPIDS AND LIPOPROTEINS: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, ARCH. INTERN. MED., 158, PP. 1189-1194, (1998); ADLER A.J., HOLUB B.J., EFFECT OF GARLIC AND FISH OIL SUPPLEMENTATION ON SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS IN HYPERCHOLESTEROLEMIC MEN, AM. J. CLIN. NUTR., 65, PP. 445-450, (1997)","M.H. DAVIDSON; DEPT. OF PREVENTIVE CARDIOLOGY, RUSH-PRESBYTERIAN-ST. LUKES MED. CTR, CHICAGO, IL 60612, 1725 WEST HARRISON STREET, UNITED STATES; EMAIL: MDAVIDSON@PROTOCARE.COM","CURRENT SCIENCE LTD","ENGLISH","CURR. ATHEROSCLER. REP.","REVIEW","ISI","2-S2.0-0038387257","CURR ATHEROSCLER REP","RUSH-PRESBYTERIAN-ST. LUKES MED. CTR;RUSH-PRESBYTERIAN-ST. LUKES MED. CTR","NOTREPORTED;RUSH-PRESBYTERIAN-ST. LUKES MED. CTR;NOTREPORTED",NA,"DAVIDSON MH, 2003, CURR ATHEROSCLER REP","DAVIDSON MH, 2003, CURR ATHEROSCLER REP"
"VALI S;JU Y;KAIMAL T;CHERN Y","VALI, SHAIK RAMJAN (6506199169); JU, YI-HSU (7202808830); KAIMAL, THENGUMPILLIL NARAYANA BALAGOPALA (6602617269); CHERN, YAW-TERNG (7006257878)","A PROCESS FOR THE PREPARATION OF FOODGRADE RICE BRAN WAX AND THE DETERMINATION OF ITS COMPOSITION",2005,"JAOCS, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY","82","7",92,"10.1007/s11746-005-1043-z","DEPARTMENT OF CHEMICAL ENGINEERING, NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY, TAIPEI 106-07, TAIWAN;DEPARTMENT OF CHEMICAL ENGINEERING, NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY, TAIPEI 106-07, TAIWAN, DEPARTMENT OF CHEMICAL ENGINEERING, NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY, TAIPEI 106-07, 43 SEC. 4, KEELUNG RD, TAIWAN;DEPARTMENT OF LIPID SCIENCE AND TECHNOLOGY, INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY, HYDERABAD 500 007, INDIA;DEPARTMENT OF CHEMICAL ENGINEERING, NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY, TAIPEI 106-07, TAIWAN","A TWO-STEP METHOD WAS DEVELOPED FOR THE PREPARATION OF FOOD-GRADE WAX. THE FIRST STEP INVOLVED THE SOLVENT-DEFATTING OF CRUDE WAX, WHICH GAVE A DARK BROWN, DRY, POWDERED WAX WITH A M.P. OF 75-79°C. THE MAJOR IMPURITY IN THE DEFATTED WAX WAS THE DARK BROWN RESINOUS MATTER. IN THE SECOND STEP, THE RESINOUS MATTER WAS REMOVED BY BLEACHING WITH SODIUM BOROHYDRIDE IN ISOPROPANOL. THIS STEP YIELDED A PALE YELLOW, ODORLESS WAX WITH PURITY HIGHER THAN 99% AND WITH A M.P. OF 80-83°C. THE RESINOUS MATTER WAS A MIXTURE OF ALIPHATIC ALDEHYDES, FATTY ALCOHOLS, AND FA. HIGH-TEMPERATURE GC ANALYSIS OF THE PURIFIED RICE BRAN WAX INDICATED THAT IT CONTAINED 11 MAJOR AND 9 MINOR TYPES OF SATURATED WAX ESTERS. THE MAJOR AND MINOR PEAKS CONTAINED C44-C 64 AND C45-C59 WAX ESTERS, RESPECTIVELY. RICE BRAN WAX WAS MAINLY A MIXTURE OF SATURATED ESTERS OF C22 AND C 24 FA AND C24 TO C40 ALIPHATIC ALCOHOLS, WITH C24 AND C30 BEING THE PREDOMINANT FA AND FATTY ALCOHOL, RESPECTIVELY. THE ALCOHOL PORTION OF THE WAX ESTERS ALSO CONTAINED SMALL AMOUNTS OF BRANCHED AND ODD CARBON NUMBER FATTY ALCOHOLS. COPYRIGHT © 2005 BY AOCS PRESS.","ALDEHYDE; BLEACHING; DEWAXING; FA; LIPASE-CATALYZED ESTERIFICATION; POLICOSANOL; RESINOUS MATTER; RICE BRAN WAX; SODIUM BOROHYDRIDE","GRAIN; SYNTHETIC POLYMERS; WAX; ALCOHOLS; ESTERS; RESINS; WAXES; FA; FOOD-GRADE WAX; RICE BRAN WAX; GRAIN (AGRICULTURAL PRODUCT)","NATIONAL SCIENCE COUNCIL, NSC, (NSC92-2214-E011-003)","THE FINANCIAL SUPPORT OF THE NATIONAL SCIENCE COUNCIL OF TAIWAN UNDER GRANT NSC92-2214-E011-003 IS GRATEFULLY ACKNOWLEDGED.","SAUNDERS R.M., RICE BRAN: COMPOSITION AND POTENTIAL FOOD SOURCES, FOOD REV. INT., 1, PP. 465-495, (1985); ITO M., CHARACTERIZATION OF NATURAL WAXES AND THEIR APPLICATION TO COSMETIC FOUNDATIONS, FRAGRANCE J., 31, PP. 38-46, (2003); BUFFA C.W., RICE BRAN WAX, A NEW WAX FOR COSMETICS, DRUGS, AND TOILETRIES, COSMET. TOILETRIES, 97, PP. 14-16, (1976); SCHERSL E.M., (2001); HERNANDEZ J.M., GRANJA A.L., FERREIRO R.M., VALMANA M.L.A., QUINTANA D.C., SANCHEZ V.M., GARCIA S.V., GOMEZ M.D., (2002); IWAMA F., MARUTA S., COMPOSITION OF THE HARD PORTION OF CRUDE RICE BRAN WAX, KOGYO KAGAKU ZASSHI, 72, PP. 2605-2608, (1969); YOON S.H., RHEE J.S., COMPOSITION OF WAXES FROM CRUDE RICE BRAN OIL, J. AM. OIL CHEM. SOC., 59, PP. 561-563, (1982); BELAVADI V.K., BHOWMICK D.N., AN INVESTIGATION OF RICE BRAN OIL TANK SETTLING, J. AM. OIL CHEM. SOC., 65, PP. 241-245, (1988); ITO S., SHZUKI T., FUJINO Y., WAX LIPID IN RICE BRAN, CEREAL CHEM., 60, PP. 252-253, (1983); WANG Y., DIAO H., NI P., COMPOSITION OF RICE BRAN WAX, ZHONGGUO YOUZHI, 23, PP. 39-41, (1998); YAMAGATA Y., NISHIGORI T., (1979); NAKAGAWA K., (1971); WANG Y., DIAO H., NI P., STUDY ON REFINING OF RICE BRAN WAX, ZHONGGUO YOUZHI, 23, PP. 51-54, (1998); RAO B.P., REDDY G.S.R., THIRUMALA S.D., STUDIES ON THE RICE BRAN AND RICE BRAN OIL. XIII. BLEACHING RICE BRAN WAX, J. OIL TECHNOL. ASSOC. INDIA (MUMBAI, INDIA), 2, PP. 32-33, (1970); RAO B.P., REDDI G.S., RAO S.T., (1970); OFFICIAL METHODS AND RECOMMENDED PRACTICES OF THE AOCS, 5TH EDN., (1997); SHRINER R.L., FUSON R.C., CURTIN D.Y., MORILL T.C., THE SYSTEMATIC IDENTIFICATION OF ORGANIC COMPOUNDS: A LABORATORY MANUAL, 6TH EDN., PP. 161-189, (1980); VALI S.R., SHENG H.Y., JU Y.H., AN EFFICIENT METHOD FOR THE PURIFICATION OF ARACHIDONIC ACID FROM FUNGAL SINGLE-CELL OIL (ARASCO), J. AM. OIL CHEM. SOC., 80, PP. 725-730, (2003); LU J., DREISINGER B.D., COOPER W.C., COBALT PRECIPITATION BY REDUCTION WITH BOROHYDRIDE, HYDROMETALLURGY, 45, PP. 305-322, (1997); CARTER H.A., THE CHEMISTRY OF PAPER PRESERVATION. PART 2. THE YELLOWING OF PAPER AND CONSERVATION BLEACHING, J. CHEM. EDUC., 73, PP. 1068-1073, (1996); MULTIPURPOSE ADDITIVES, U.S. FEDERAL FOOD AND DRUG ADMINISTRATION ACT, REGISTER, 3, (2004); BENNETT H., CARNAUBA WAX, INDUSTRIAL WAXES, 1, PP. 169-172, (1974); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J. AM. OIL CHEM. SOC., 79, PP. 529-533, (2002); HENON G., RECSEG K., KOVARI K., WAX ANALYSIS OF VEGETABLE OILS USING LIQUID CHROMATOGRAPHY ON A DOUBLE ADSORBENT LAYER OF SILICA GEL AND SILVER NITRATE-IMPREGNATED SILICA GEL, J. AM. OIL CHEM. SOC., 73, PP. 401-410, (2001); SACCHI R., PATUMI M., FONTANAZZA G., BARONE P., FIORDIPONTI P., MANNINA L., ROSSI E., SEGRE A.L., A HIGH-FIELD <SUP>1</SUP>H NUCLEAR MAGNETIC RESONANCE STUDY OF THE MINOR COMPONENTS IN VIRGIN OLIVE OILS, J. AM. OIL CHEM. SOC., 75, PP. 747-758, (1996)","Y.-H. JU; DEPARTMENT OF CHEMICAL ENGINEERING, NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY, TAIPEI 106-07, 43 SEC. 4, KEELUNG RD, TAIWAN; EMAIL: JU@CH.NTUST.EDU.TW","","ENGLISH","JAOCS J AM OIL CHEM SOC","ARTICLE","ISI","2-S2.0-29744446104","JAOCS J AM OIL CHEM SOC","NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY;NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY;INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY;NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY","NOTREPORTED;NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY;NOTREPORTED",NA,"VALI SR, 2005, JAOCS J AM OIL CHEM SOC","VALI SR, 2005, JAOCS J AM OIL CHEM SOC"
"GIMMLER F;SIEGERT D;KELLER S;JAHREIS G","GIMMLER, FRANZISKA (22957658400); SIEGERT, DOROTHEA (15052218900); KELLER, SYLVIA (8587403200); JAHREIS, GERHARD (7007175896)","POLICOSANOLS ARE THESE WAXY PLANT COMPONENTS CAPABLE OF LOWERING SERUMCHOLESTEROL LEVELS POLICOSANOLE PFLANZENWACHSKOMPONENTEN ALS CHOLESTEROLSENKENDES NAHRUNGSSUPPLEMENT",2006,"ERNAHRUNGS UMSCHAU","53","",0,"","INSTITUT FÜR ERNÄHRUNGSWISSENSCHAFTEN, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, JENA, GERMANY;INSTITUT FÜR ERNÄHRUNGSWISSENSCHAFTEN, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, JENA, GERMANY;INSTITUT FÜR ERNÄHRUNGSWISSENSCHAFTEN, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, JENA, GERMANY;INSTITUT FÜR ERNÄHRUNGSWISSENSCHAFTEN, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, JENA, GERMANY, INSTITUT FÜR ERNÄHRUNGSWISSENSCHAFTEN, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, 07743 JENA, DORNBURGER STR. 24, GERMANY","CARDIOVASCULAR DISEASES ARE THE MAIN CAUSE OF DEATH AND DISABILITY IN INDUSTRIALIZED COUNTRIES. DURING THE LAST FEW YEARS, POTENTIAL HEALTH PROMOTING EFFECTS OF POLICOSANOLS HAVE BEEN CONTROVERSIALLY DISCUSSED. POLICOSANOLS ARE DESCRIBED AS A MIXTURE OF NATURALLY OCCURRING LONG-CHAIN ALIPHATIC ALCOHOLS DERIVED FROM SUGAR-CANE WAX. WHEN ADMINISTERED AT 5 TO 20 MG/DAY, POLICOSANOLS ARE SAID TO LOWER SERUM CHOLESTEROL LEVELS. VARIOUS STUDIES, MOST OF THEM OF CUBAN ORIGIN, REPORT THAT POLICOSANOLS HAVE CHOLESTEROL LOWERING EFFECTS COMPARABLE TO THAT OF STATINS. BASED ON THE RESULTS OF CUBAN RESEARCH GROUPS, POLICOSANOLS ARE WORLD-WIDE DISTRIBUTED AS OTC PRODUCTS FOR WHICH SERUM CHOLESTEROL LOWERING ACTION WITHOUT SIDE-EFFECTS IS CLAIMED. HOWEVER, RECENT STUDIES OF RESEARCH GROUPS OUTSIDE OF CUBA HAVE NOT FOUND A CORRELATION BETWEEN POLICOSANOL INTERVENTION AND REDUCED SERUM CHOLESTEROL CONCENTRATIONS. IN VIEW OF THESE CONTROVERSIAL RESULTS, FURTHER RESEARCH INTO THE CHOLESTEROL LOWERING EFFECT AND ITS POTENTIAL MECHANISM OF ACTION IS RECOMMENDED. AT PRESENT, HOWEVER, THERAPEUTIC SUPPLEMENTATION OF POLICOSANOLS TO LOWER SERUM CHOLESTEROL LEVELS IS NOT ADVISABLE.","CHOLESTEROL LOWERING EFFECTS; POLICOSANOLS","SACCHARUM; ALKANOL; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLICOSANOL; ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CUBA; DRUG EFFICACY; HEALTH PROMOTION; HUMAN; REVIEW; SUGARCANE","","","BOLEGO C., BAETTA R., BELLOSTA S., CORSINI A., PAOLETTI R., SAFETY CONSIDERATIONS FOR STATINS, CURR OPIN LIPIDOL, 13, PP. 637-644, (2002); KLEID J.J., POLICOSANOL: A NEW NEUTRACEUTICAL TOOL FOR REDUCING CHOLESTEROL, JANA, 6, PP. 39-40, (2003); GOUNI-BERTHOLD I., BERTHOLD H., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CRAVOTTO G., BINELLO A., MERIZZI G., AVOGADRO M., IMPROVING SOLVENT-FREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGH-INTENSITY ULTRASOUND TREATMENT, EUR J LIPID SCI TECHNOL, 106, PP. 147-151, (2004); ARRUZAZABALA L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROGENIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); IRMAK S., DUNFORD N.T., POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES, J AGRIC FOOD CHEM, 53, PP. 5583-5586, (2005); HARGROVE J., GREENSPAN P., HARTLE K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 79, PP. 192-195, (2003); VARADY K., WANG Y., JONES P., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 62, PP. 376-383, (2003); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM, 95, PP. 312-318, (2006); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 29, PP. 105-116, (1999); FERNANDEZ J.C., MAS R., MENENDEZ R., AMOR A.M., GONZALEZ R.M., ALVAREZ E., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN DRUG INVEST, 21, PP. 103-113, (2001); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARM RES, 22, PP. 89-100, (2002); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE, ALTERN MED REV, 7, PP. 203-217, (2002); MCCARTY M.F., AN EZETIMIBE-POLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTS, MED HYPOTHESES, 64, PP. 636-645, (2005); HERNANDEZ F., ILLNAIT J., CASTANO G., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARM PHYS, 29, PP. 891-897, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHER, 25, PP. 171-183, (2005); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., FUSTER A., LASTRETO E., YANEZ IRICO G., MCCOOK B., FARRE A., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); ORTENSI G., JULIO G., HECTOR V., PEDRO A.T., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); NIKITIN IU.P., SLEPCHENKO N.Y., GRATSIANSKII N.A., NECHAEY A.S., SYRKIN A.L., POLTAVSKAIA M.G., SUMAROKOV A.V., REVOZOV A.V., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPERLIPIDEMIC DRUG POLYCOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 186-294, (1999); LIN Y., RUDRUM M., VAN DER WIELEN R., TRAUTWEIN E., MCNEILL G., SIERKSMA A., MEIJER G., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATION, METAB, 53, PP. 1309-1314, (2004); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESEROLEMIA OR COMBINED HYPERLIPIDEMIA, JAMA, 295, PP. 2262-2269, (2006); KELLER S., SIEGERT D., SCHUBERT R., JAHREIS G., UNVERÖFFENTLICHTE DATEN, (2006); GIMMLER F., UNTERSUCHUNGEN ZUM OCTACOSANOLMETABOLISMUS UND ZUM EINFLUSS EINER OCTACOSANOLGABE AUF DEN STEROLSTOFFWECHSEL JUNGER FRAUEN, DIPLOMARBEIT, (2006); TAN C.E., LOH L.M., TAI S.E., DO SINGAPORE PATIENTS REQUIRE LOWER DOSES OF STATINS? THE SGH CLINIC EXPERIENCE, SINGAPORE MED J, 44, 203, PP. 635-638; HOWARD B.V., HANNAH J.S., HEISER C.C., JABLONSKI K.A., EFFECTS OF SEX AND ETHNICITY ON RESPONSES TO A LOW-FAT DIET: A STUDY OF AFRICAN AMERICANS AND WHITES, AM J NUTR, 62, (1995); BAYS H., STEIN E.A., PHARMACOTHERAPY FOR DYSLIPIDAEMIA- CURRENT THERAPIES AND FUTURE GENTS, EXPERT OPIN PHARMACOTHER, 4, PP. 1901-1938, (2003)","G. JAHREIS; INSTITUT FÜR ERNÄHRUNGSWISSENSCHAFTEN, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, 07743 JENA, DORNBURGER STR. 24, GERMANY; EMAIL: B6JAGE@UNI-JENA.DE","","GERMAN","ERNAHR. UMSCH.","REVIEW","ISI","2-S2.0-33750579365","ERNAHR UMSCH","FRIEDRICH-SCHILLER-UNIVERSITÄT JENA;FRIEDRICH-SCHILLER-UNIVERSITÄT JENA;FRIEDRICH-SCHILLER-UNIVERSITÄT JENA;FRIEDRICH-SCHILLER-UNIVERSITÄT JENA","NOTREPORTED;FRIEDRICH-SCHILLER-UNIVERSITÄT JENA;NOTREPORTED",NA,"GIMMLER F, 2006, ERNAHR UMSCH","GIMMLER F, 2006, ERNAHR UMSCH"
"MCCARTY M","MCCARTY, M.F. (24435224500)","IATROGENIC LIPODYSTROPHY IN HIV PATIENTS THE NEED FOR VERYLOWFAT DIETS",2003,"MEDICAL HYPOTHESES","61","5",3,"10.1016/S0306-9877(03)00230-5","UNITED STATES","IN HIV PATIENTS, CHRONIC TREATMENT WITH PROTEASE INHIBITORS OFTEN PRECIPITATES A PERIPHERAL LIPODYSTROPHY ASSOCIATED WITH INSULIN RESISTANCE SYNDROME AND PREMATURE CORONARY DISEASE. IN VITRO STUDIES DEMONSTRATE THAT THESE DRUGS CAN COMPROMISE THE ABILITY OF ADIPOCYTES TO STORE TRIGLYCERIDES; IN VIVO, PERIPHERAL SUBCUTANEOUS ADIPOCYTES APPEAR TO BE MOST AFFECTED, SUCH THAT BODY FAT OFTEN REDISTRIBUTES TO VISCERAL OR TRUNCAL ADIPOSE STORES. DYSFUNCTION OF PERIPHERAL SUBCUTANEOUS ADIPOCYTES - ORDINARILY QUITE EFFICIENT FOR STORING FAT - CAN BE EXPECTED TO GIVE RISE TO AN EXCESSIVE FLUX OF FREE FATTY ACIDS (FFAS) FOLLOWING FATTY MEALS; CHRONIC OVEREXPOSURE OF TISSUES TO FFAS IS A LIKELY EXPLANATION FOR THE INSULIN RESISTANCE SYNDROME ASSOCIATED WITH LIPODYSTROPHY. THESE CONSIDERATIONS SUGGEST THAT A VERY-LOW-FAT DIET - LESS THAN 15% FAT CALORIES - MAY AMELIORATE THE CARDIOVASCULAR RISK ASSOCIATED WITH LIPODYSTROPHY; SUCH DIETS ARE KNOWN TO HAVE A FAVORABLE EFFECT ON THE INSULIN SENSITIVITY OF HEALTHY SUBJECTS. VERY-LOW-FAT WHOLE-FOOD VEGAN DIETS ARE PARTICULARLY RECOMMENDABLE IN THIS CONTEXT, AS THEY MAY HELP TO SHRINK VISCERAL FAT DEPOTS WHILE MARKEDLY REDUCING LDL CHOLESTEROL. APPROPRIATE ADJUNCTIVE MEASURES MAY INCLUDE AEROBIC EXERCISE TRAINING - BENEFICIAL BOTH FOR INSULIN SENSITIVITY AND WEIGHT CONTROL - AS WELL AS ADMINISTRATION OF STATINS OR POLICOSANOL, AND OF FIBRATES OR FISH OIL, TO DECREASE LDL AND TRIGLYCERIDES, RESPECTIVELY. DESPITE PERCEPTIONS TO THE CONTRARY, VERY-LOW-FAT DIETS CAN MEET WITH GOOD COMPLIANCE IN WELL-MOTIVATED SUBJECTS GIVEN APPROPRIATE INSTRUCTION. © 2003 ELSEVIER LTD. ALL RIGHTS RESERVED.","","FATTY ACID; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLICOSANOL; PROTEINASE INHIBITOR; STATINE; ARTICLE; BODY FAT; BODY WEIGHT; CALORIE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EXERCISE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPODYSTROPHY; LOW FAT DIET; PATHOGENESIS; PRIORITY JOURNAL; VEGETARIAN DIET","","","GRINSPOON S., INSULIN RESISTANCE IN THE HIV-LIPODYSTROPHY SYNDROME, TRENDS ENDOCRINOL METAB, 12, PP. 413-419, (2001); VAND V., BISSCHOP P.H., ROMIJN J.A., ACKERMANS M.T., LANGE J.M., ENDERT E., ET AL., LIPODYSTROPHY IN HIV-1-POSITIVE PATIENTS IS ASSOCIATED WITH INSULIN RESISTANCE IN MULTIPLE METABOLIC PATHWAYS, AIDS, 15, PP. 2093-2100, (2001); GRABER A.L., SYNDROME OF LIPODYSTROPHY, HYPERLIPIDEMIA, INSULIN RESISTANCE, AND DIABETES IN TREATED PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION, ENDOCR PRACT, 7, PP. 430-437, (2001); ESTRADA V., SERRANO-RIOS M., LARRAD M.T., VILLAR N.G., LOPEZ A.G., TELLEZ M.J., ET AL., LEPTIN AND ADIPOSE TISSUE MALDISTRIBUTION IN HIV-INFECTED MALE PATIENTS WITH PREDOMINANT FAT LOSS TREATED WITH ANTIRETROVIRAL THERAPY, J ACQUIR IMMUNE DEFIC SYNDR, 29, PP. 32-40, (2002); ZHANG B., MACNAUL K., SZALKOWSKI D., LI Z., BERGER J., MOLLER D.E., INHIBITION OF ADIPOCYTE DIFFERENTIATION BY HIV PROTEASE INHIBITORS, J CLIN ENDOCRINOL METAB, 84, PP. 4274-4277, (1999); LENHARD J.M., FURFINE E.S., JAIN R.G., ITTOOP O., ORBAND-MILLER L.A., BLANCHARD S.G., ET AL., HIV PROTEASE INHIBITORS BLOCK ADIPOGENESIS AND INCREASE LIPOLYSIS IN VITRO, ANTIVIRAL RES, 47, PP. 121-129, (2000); RANGANATHAN S., KERN P.A., THE HIV PROTEASE INHIBITOR SAQUINAVIR IMPAIRS LIPID METABOLISM AND GLUCOSE TRANSPORT IN CULTURED ADIPOCYTES, J ENDOCRINOL, 172, PP. 155-162, (2002); BODEN G., FREE FATTY ACIDS-THE LINK BETWEEN OBESITY AND INSULIN RESISTANCE, ENDOCR PRACT, 7, PP. 44-51, (2001); SANTOMAURO A.T., BODEN G., SILVA M.E., ROCHA D.M., SANTOS R.F., URSICH M.J., ET AL., OVERNIGHT LOWERING OF FREE FATTY ACIDS WITH ACIPIMOX IMPROVES INSULIN RESISTANCE AND GLUCOSE TOLERANCE IN OBESE DIABETIC AND NONDIABETIC SUBJECTS, DIABETES, 48, PP. 1836-1841, (1999); PHILLIPS D.I., CADDY S., ILIC V., FIELDING B.A., FRAYN K.N., BORTHWICK A.C., ET AL., INTRAMUSCULAR TRIGLYCERIDE AND MUSCLE INSULIN SENSITIVITY: EVIDENCE FOR A RELATIONSHIP IN NONDIABETIC SUBJECTS, METABOLISM, 45, PP. 947-950, (1996); PAN D.A., LILLIOJA S., KRIKETOS A.D., MILNER M.R., BAUR L.A., BOGARDUS C., ET AL., SKELETAL MUSCLE TRIGLYCERIDE LEVELS ARE INVERSELY RELATED TO INSULIN ACTION, DIABETES, 46, PP. 983-988, (1997); GOODPASTER B.H., THAETE F.L., SIMONEAU J.A., KELLEY D.E., SUBCUTANEOUS ABDOMINAL FAT AND THIGH MUSCLE COMPOSITION PREDICT INSULIN SENSITIVITY INDEPENDENTLY OF VISCERAL FAT, DIABETES, 46, PP. 1579-1585, (1997); JACOB S., MACHANN J., RETT K., BRECHTEL K., VOLK A., RENN W., ET AL., ASSOCIATION OF INCREASED INTRAMYOCELLULAR LIPID CONTENT WITH INSULIN RESISTANCE IN LEAN NONDIABETIC OFFSPRING OF TYPE 2 DIABETIC SUBJECTS, DIABETES, 48, PP. 1113-1119, (1999); BODEN G., LEBED B., SCHATZ M., HOMKO C., LEMIEUX S., EFFECTS OF ACUTE CHANGES OF PLASMA FREE FATTY ACIDS ON INTRAMYOCELLULAR FAT CONTENT AND INSULIN RESISTANCE IN HEALTHY SUBJECTS, DIABETES, 50, PP. 1612-1617, (2001); STEINBERG H.O., TARSHOBY M., MONESTEL R., HOOK G., CRONIN J., JOHNSON A., ET AL., ELEVATED CIRCULATING FREE FATTY ACID LEVELS IMPAIR ENDOTHELIUM-DEPENDENT VASODILATION, J CLIN INVEST, 100, PP. 1230-1239, (1997); STEINBERG H.O., PARADISI G., HOOK G., CROWDER K., CRONIN J., BARON A.D., FREE FATTY ACID ELEVATION IMPAIRS INSULIN-MEDIATED VASODILATION AND NITRIC OXIDE PRODUCTION, DIABETES, 49, PP. 1231-1238, (2000); MCCARTY M.F., DOES POSTPRANDIAL STORAGE OF TRIGLYCERIDES IN ENDOTHELIAL CELLS CONTRIBUTE TO THE ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH INSULIN RESISTANCE AND FATTY DIETS, MED HYPOTHESES, 61, PP. 167-172, (2003); SNIDERMAN A.D., CIANFLONE K., FRAYN K., THE PATHOGENETIC ROLE OF IMPAIRED FATTY ACID TRAPPING BY ADIPOCYTES IN GENERATING THE PLEIOTROPIC FEATURES OF HYPERAPOB, DIABETOLOGIA, 40, 2 SUPPL., (1997); FRAYN K.N., NON-ESTERIFIED FATTY ACID METABOLISM AND POSTPRANDIAL LIPAEMIA, ATHEROSCLEROSIS, 141, 1 SUPPL., (1998); FRAYN K.N., ADIPOSE TISSUE AND THE INSULIN RESISTANCE SYNDROME, PROC NUTR SOC, 60, PP. 375-380, (2001); MCCARTY M.F., A PARADOX RESOLVED: THE POSTPRANDIAL MODEL OF INSULIN RESISTANCE EXPLAINS WHY GYNOID ADIPOSITY APPEARS TO BE PROTECTIVE, MED HYPOTHESES, 61, PP. 173-176, (2003); OSTMAN J., ARNER P., ENGFELDT P., KAGER L., REGIONAL DIFFERENCES IN THE CONTROL OF LIPOLYSIS IN HUMAN ADIPOSE TISSUE, METABOLISM, 28, PP. 1198-1205, (1979); BOLINDER J., KAGER L., OSTMAN J., ARNER P., DIFFERENCES AT THE RECEPTOR AND POSTRECEPTOR LEVELS BETWEEN HUMAN OMENTAL AND SUBCUTANEOUS ADIPOSE TISSUE IN THE ACTION OF INSULIN ON LIPOLYSIS, DIABETES, 32, PP. 117-123, (1983); MARIN P., ANDERSSON B., OTTOSSON M., OLBE L., CHOWDHURY B., KVIST H., ET AL., THE MORPHOLOGY AND METABOLISM OF INTRAABDOMINAL ADIPOSE TISSUE IN MEN, METABOLISM, 41, PP. 1242-1248, (1992); RIMM A.A., HARTZ A.J., FISCHER M.E., A WEIGHT SHAPE INDEX FOR ASSESSING RISK OF DISEASE IN 44,820 WOMEN, J CLIN EPIDEMIOL, 41, PP. 459-465, (1988); BJORNTORP P., THE ASSOCIATIONS BETWEEN OBESITY, ADIPOSE TISSUE DISTRIBUTION AND DISEASE, ACTA MED SCAND SUPPL, 723, PP. 121-134, (1988); VAN GAAL L., VANSANT G., VAN CAMPENHOUT C., LEPOUTRE L., DE L.L., APOLIPOPROTEIN CONCENTRATIONS IN OBESE SUBJECTS WITH UPPER AND LOWER BODY FAT MASS DISTRIBUTION, INT J OBES, 13, PP. 255-263, (1989); WALTON C., LEES B., CROOK D., WORTHINGTON M., GODSLAND I.F., STEVENSON J.C., BODY FAT DISTRIBUTION, RATHER THAN OVERALL ADIPOSITY, INFLUENCES SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY MEN INDEPENDENTLY OF AGE, AM J MED, 99, PP. 459-464, (1995); CAPRIO S., HYMAN L.D., MCCARTHY S., LANGE R., BRONSON M., TAMBORLANE W.V., FAT DISTRIBUTION AND CARDIOVASCULAR RISK FACTORS IN OBESE ADOLESCENT GIRLS: IMPORTANCE OF THE INTRAABDOMINAL FAT DEPOT, AM J CLIN NUTR, 64, PP. 12-17, (1996); ARCARO G., ZAMBONI M., ROSSI L., TURCATO E., COVI G., ARMELLINI F., ET AL., BODY FAT DISTRIBUTION PREDICTS THE DEGREE OF ENDOTHELIAL DYSFUNCTION IN UNCOMPLICATED OBESITY, INT J OBES RELAT METAB DISORD, 23, PP. 936-942, (1999); CHANG C.J., WU C.H., LU F.H., WU J.S., CHIU N.T., YAO W.J., DISCRIMINATING GLUCOSE TOLERANCE STATUS BY REGIONS OF INTEREST OF DUAL-ENERGY X-RAY ABSORPTIOMETRY. CLINICAL IMPLICATIONS OF BODY FAT DISTRIBUTION, DIABETES CARE, 22, PP. 1938-1943, (1999); YAMASHITA S., NAKAMURA T., SHIMOMURA I., NISHIDA M., YOSHIDA S., KOTANI K., ET AL., INSULIN RESISTANCE AND BODY FAT DISTRIBUTION, DIABETES CARE, 19, PP. 287-291, (1996); MATSUZAWA Y., PATHOPHYSIOLOGY AND MOLECULAR MECHANISMS OF VISCERAL FAT SYNDROME: THE JAPANESE EXPERIENCE, DIABETES METAB REV, 13, PP. 3-13, (1997); BROOK R.D., BARD R.L., RUBENFIRE M., RIDKER P.M., RAJAGOPALAN S., USEFULNESS OF VISCERAL OBESITY (WAIST/HIP RATIO) IN PREDICTING VASCULAR ENDOTHELIAL FUNCTION IN HEALTHY OVERWEIGHT ADULTS, AM J CARDIOL, 88, PP. 1264-1269, (2001); ROSENTHAL M.B., BARNARD R.J., ROSE D.P., INKELES S., HALL J., PRITIKIN N., EFFECTS OF A HIGH-COMPLEX-CARBOHYDRATE, LOW-FAT, LOW-CHOLESTEROL DIET ON LEVELS OF SERUM LIPIDS AND ESTRADIOL, AM J MED, 78, PP. 23-27, (1985); BARNARD R.J., EFFECTS OF LIFE-STYLE MODIFICATION ON SERUM LIPIDS, ARCH INTERN MED, 151, PP. 1389-1394, (1991); BARNARD R.J., UGIANSKIS E.J., MARTIN D.A., INKELES S.B., ROLE OF DIET AND EXERCISE IN THE MANAGEMENT OF HYPERINSULINEMIA AND ASSOCIATED ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 69, PP. 440-444, (1992); ORNISH D., BROWN S.E., SCHERWITZ L.W., BILLINGS J.H., ARMSTRONG W.T., PORTS T.A., ET AL., CAN LIFESTYLE CHANGES REVERSE CORONARY HEART DISEASE? THE LIFESTYLE HEART TRIAL, LANCET, 336, PP. 129-133, (1990); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., BROWN S.E., GOULD K.L., MERRITT T.A., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, PP. 2001-2007, (1998); ESSELSTYN C.B., ELLIS S.G., MEDENDORP S.V., CROWE T.D., A STRATEGY TO ARREST AND REVERSE CORONARY ARTERY DISEASE: A 5-YEAR LONGITUDINAL STUDY OF A SINGLE PHYSICIAN'S PRACTICE, J FAM PRACT, 41, PP. 560-568, (1995); ESSELSTYN C.B., UPDATING A 12-YEAR EXPERIENCE WITH ARREST AND REVERSAL THERAPY FOR CORONARY HEART DISEASE (AN OVERDUE REQUIEM FOR PALLIATIVE CARDIOLOGY), AM J CARDIOL, 84, PP. 339-341, (1999); ANDERSON J.W., WARD K., HIGH-CARBOHYDRATE, HIGH-FIBER DIETS FOR INSULIN- TREATED MEN WITH DIABETES MELLITUS, AM J CLIN NUTR, 32, PP. 2312-2321, (1979); KOLTERMAN O.G., GREENFIELD M., REAVEN G.M., SAEKOW M., OLEFSKY J.M., EFFECT OF A HIGH CARBOHYDRATE DIET ON INSULIN BINDING TO ADIPOCYTES AND ON INSULIN ACTION IN VIVO IN MAN, DIABETES, 28, PP. 731-736, (1979); FUKAGAWA N.K., ANDERSON J.W., HAGEMAN G., YOUNG V.R., MINAKER K.L., HIGH-CARBOHYDRATE, HIGH-FIBER DIETS INCREASE PERIPHERAL INSULIN SENSITIVITY IN HEALTHY YOUNG AND OLD ADULTS, AM J CLIN NUTR, 52, PP. 524-528, (1990); NICHOLSON A.S., SKLAR M., BARNARD N.D., GORE S., SULLIVAN R., BROWNING S., TOWARD IMPROVED MANAGEMENT OF NIDDM: A RANDOMIZED, CONTROLLED, PILOT INTERVENTION USING A LOWFAT, VEGETARIAN DIET, PREV MED, 29, PP. 87-91, (1999); RICCARDI G., RIVELLESE A.A., DIETARY TREATMENT OF THE METABOLIC SYNDROME - THE OPTIMAL DIET, BR J NUTR, 83, 1 SUPPL., (2000); REAVEN G.M., DO HIGH CARBOHYDRATE DIETS PREVENT THE DEVELOPMENT OR ATTENUATE THE MANIFESTATIONS (OR BOTH) OF SYNDROME X? A VIEWPOINT STRONGLY AGAINST, CURR OPIN LIPIDOL, 8, PP. 23-27, (1997); ORNISH D., EAT MORE, WEIGH LESS: DR. DEAN ORNISH'S LIFE CHOICE PROGRAM FOR LOSING WEIGHT SAFELY WHILE EATING ABUNDANTLY, (1997); PRITIKIN R., THE PRITIKIN WEIGHT LOSS BREAKTHROUGH, (1999); SACKS F.M., CASTELLI W.P., DONNER A., KASS E.H., PLASMA LIPIDS AND LIPOPROTEINS IN VEGETARIANS AND CONTROLS, N ENGL J MED, 292, PP. 1148-1151, (1975); VESSBY B., UNSITUPA M., HERMANSEN K., RICCARDI G., RIVELLESE A.A., TAPSELL L.C., ET AL., SUBSTITUTING DIETARY SATURATED FOR MONOUNSATURATED FAT IMPAIRS INSULIN SENSITIVITY IN HEALTHY MEN AND WOMEN: THE KANWU STUDY, DIABETOLOGIA, 44, PP. 312-319, (2001); STORLIEN L.H., JENKINS A.B., CHISHOLM D.J., PASCOE W.S., KHOURI S., KRAEGEN E.W., INFLUENCE OF DIETARY FAT COMPOSITION ON DEVELOPMENT OF INSULIN RESISTANCE IN RATS. RELATIONSHIP TO MUSCLE TRIGLYCERIDE AND OMEGA-3 FATTY ACIDS IN MUSCLE PHOSPHOLIPID, DIABETES, 40, PP. 280-289, (1991); HARDING A.H., WILLIAMS D.E., HENNINGS S.H., MITCHELL J., WAREHAM N.J., IS THE ASSOCIATION BETWEEN DIETARY FAT INTAKE AND INSULIN RESISTANCE MODIFIED BY PHYSICAL ACTIVITY, METABOLISM, 50, PP. 1186-1192, (2001); STEFAN N., WAHL H.G., FRITSCHE A., HARING H., STUMVOLL M., EFFECT OF THE PATTERN OF ELEVATED FREE FATTY ACIDS ON INSULIN SENSITIVITY AND INSULIN SECRETION IN HEALTHY HUMANS, HORM METAB RES, 33, PP. 432-438, (2001); RESNICOW K., BARONE J., ENGLE A., MILLER S., HALEY N.J., FLEMING D., ET AL., DIET AND SERUM LIPIDS IN VEGAN VEGETARIANS: A MODEL FOR RISK REDUCTION, J AM DIET ASSOC, 91, PP. 447-453, (1991); VESSBY B., N-3 FATTY ACIDS AND BLOOD GLUCOSE CONTROL IN DIABETES MELLITUS, J INTERN MED SUPPL, 225, PP. 207-210, (1989); HOPKINS P.N., EFFECTS OF DIETARY CHOLESTEROL ON SERUM CHOLESTEROL: A META-ANALYSIS AND REVIEW, AM J CLIN NUTR, 55, PP. 1060-1070, (1992); CARROLL K.K., HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS: EFFECTS OF DIETARY PROTEIN, FED PROC, 41, PP. 2792-2796, (1982); SIRTORI C.R., LOVATI M.R., MANZONI C., MONETTI M., PAZZUCCONI F., GATTI E., SOY AND CHOLESTEROL REDUCTION: CLINICAL EXPERIENCE, J NUTR, 125, (1995); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., METAANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); JEPPESEN J., SCHAAF P., JONES C., ZHOU M.Y., CHEN Y.D., REAVEN G.M., EFFECTS OF LOW-FAT, HIGH-CARBOHYDRATE DIETS ON RISK FACTORS FOR ISCHEMIC HEART DISEASE IN POSTMENOPAUSAL WOMEN, AM J CLIN NUTR, 65, PP. 1027-1033, (1997); ABBASI F., MCLAUGHLIN T., LAMENDOLA C., KIM H.S., TANAKA A., WANG T., ET AL., HIGH CARBOHYDRATE DIETS, TRIGLYCERIDE-RICH LIPOPROTEINS, AND CORONARY HEART DISEASE RISK, AM J CARDIOL, 85, PP. 45-48, (2000); GARG A., BANTLE J.P., HENRY R.R., COULSTON A.M., GRIVER K.A., RAATZ S.K., ET AL., EFFECTS OF VARYING CARBOHYDRATE CONTENT OF DIET IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS, JAMA, 271, PP. 1421-1428, (1994); KIM H.W., CHEW B.P., WONG T.S., PARK J.S., WENG B.B., BYRNE K.M., ET AL., DIETARY LUTEIN STIMULATES IMMUNE RESPONSE IN THE CANINE, VET IMMUNOL IMMUNOPATHOL, 74, PP. 315-327, (2000); WILLETT W.C., WILL HIGH-CARBOHYDRATE/LOW-FAT DIETS REDUCE THE RISK OF CORONARY HEART DISEASE, PROC SOC EXP BIOL MED, 225, PP. 187-190, (2000); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THERAPEUTIC RES, 51, PP. 568-575, (1992); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THERAPEUTIC RES, 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2003); CONNOR W.E., DEFRANCESCO C.A., CONNOR S.L., N-3 FATTY ACIDS FROM FISH OIL. EFFECTS ON PLASMA LIPOPROTEINS AND HYPERTRIGLYCERIDEMIC PATIENTS, ANN N Y ACAD SCI, 683, PP. 16-34, (1993); MCCARTY M.F., FISH OIL MAY BE AN ANTIDOTE FOR THE CARDIOVASCULAR RISK OF SMOKING, MED HYPOTHESES, 46, PP. 337-347, (1996); MORI T.A., BEILIN L.J., LONG-CHAIN OMEGA 3 FATTY ACIDS, BLOOD LIPIDS AND CARDIOVASCULAR RISK REDUCTION, CURR OPIN LIPIDOL, 12, PP. 11-17, (2001); HARRIS W.S., ISLEY W.L., CLINICAL TRIAL EVIDENCE FOR THE CARDIOPROTECTIVE EFFECTS OF OMEGA-3 FATTY ACIDS, CURR ATHEROSCLER REP, 3, PP. 174-179, (2001); HUANG Y.J., FANG V.S., JUAN C.C., CHOU Y.C., KWOK C.F., HO L.T., AMELIORATION OF INSULIN RESISTANCE AND HYPERTENSION IN A FRUCTOSE-FED RAT MODEL WITH FISH OIL SUPPLEMENTATION, METABOLISM, 46, PP. 1252-1258, (1997); POPP-SNIJDERS C., SCHOUTEN J.A., HEINE R.J., VAN DER MEER J., VAND V., DIETARY SUPPLEMENTATION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IMPROVES INSULIN SENSITIVITY IN NON-INSULIN-DEPENDENT DIABETES, DIABETES RES, 4, PP. 141-147, (1987); RIVELLESE A.A., MAFFETTONE A., IOVINE C., DI MARINO L., ANNUZZI G., MANCINI M., ET AL., LONG-TERM EFFECTS OF FISH OIL ON INSULIN RESISTANCE AND PLASMA LIPOPROTEINS IN NIDDM PATIENTS WITH HYPERTRIGLYCERIDEMIA, DIABETES CARE, 9, PP. 1207-1213, (1996); WILLUMSEN N., SKORVE J., HEXEBERG S., RUSTAN A.C., BERGE R.K., THE HYPOTRIGLYCERIDEMIC EFFECT OF EICOSAPENTAENOIC ACID IN RATS IS REFLECTED IN INCREASED MITOCHONDRIAL FATTY ACID OXIDATION FOLLOWED BY DIMINISHED LIPOGENESIS, LIPIDS, 28, PP. 683-690, (1993); BERGE R.K., MADSEN L., VAAGENES H., TRONSTAD K.J., GOTTLICHER M., RUSTAN A.C., IN CONTRAST WITH DOCOSAHEXAENOIC ACID, EICOSAPENTAENOIC ACID AND HYPOLIPIDAEMIC DERIVATIVES DECREASE HEPATIC SYNTHESIS AND SECRETION OF TRIACYLGLYCEROL BY DECREASED DIACYLGLYCEROL ACYLTRANSFERASE ACTIVITY AND STIMULATION OF FATTY ACID OXIDATION, BIOCHEM J, 343, 1 PART, PP. 191-197, (1999); MCDOUGALL J.A., MCDOUGALL M., THE NEW MCDOUGALL COOKBOOK, (1993); BARNARD N., FOOD FOR LIFE: HOW THE NEW FOUR FOOD GROUPS CAN SAVE YOUR LIFE, (1994); BARNARD N.D., SCIALLI A.R., HURLOCK D., BERTRON P., DIET AND SEX-HORMONE BINDING GLOBULIN, DYSMENORRHEA, AND PREMENSTRUAL SYMPTOMS, OBSTET GYNECOL, 95, PP. 245-250, (2000)","M.F. MCCARTY; PANTOX LABORATORIES, SAN DIEGO, CA 92109, 4622 SANTA FE ST., UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-0242551048","MED HYPOTHESES",NA,"NOTREPORTED;PANTOX LABORATORIES;NOTREPORTED",NA,"MCCARTY MF, 2003, MED HYPOTHESES","MCCARTY MF, 2003, MED HYPOTHESES"
"GÁMEZ R;MÁS R;ARRUZAZABALA M;MENDOZA S;CASTAÑO G","GÁMEZ, R. (7003605346); MÁS, R. (7007164572); ARRUZAZABALA, M.L. (6603962476); MENDOZA, S. (7102759819); CASTAÑO, G. (56232967100)","EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS",2005,"DRUGS IN R AND D","6","8",14,"10.2165/00126839-200506010-00002","CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA","BACKGROUND: POLICOSANOL IS A MIXTURE OF HIGH-MOLECULAR-WEIGHT ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGARCANE WAX WITH CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS. OMEGA-3 FATTY ACIDS (FA) FROM FISH OIL CAN PROTECT AGAINST CORONARY DISEASE. AN ANTIARRHYTHMIC MECHANISM IS EMERGING AS THE MOST CONVINCING EXPLANATION FOR OMEGA-3 FA CARDIOVASCULAR PROTECTION, BUT TRIGLYCERIDE (TG)-LOWERING EFFECTS AND INHIBITION OF PLATELET FUNCTION COULD PLAY A ROLE. IN VIEW OF THE EFFECTS OF POLICOSANOL AND OMEGA-3 FA ON LIPID PROFILE AND PLATELET FUNCTION, POTENTIAL BENEFITS OF COMBINED THERAPY WERE EXPECTED. OBJECTIVE: TO INVESTIGATE WHETHER COMBINED THERAPY WITH POLICOSANOL AND OMEGA-3 FA WOULD OFFER SOME BENEFIT, COMPARED WITH POLICOSANOL OR OMEGA-3 FA ALONE, ON SERUM LIPID PROFILE AND PLATELET AGGREGATION IN RABBITS. METHODS: MALE RABBITS WERE RANDOMLY DISTRIBUTED IN FOUR GROUPS (N = 9 PER GROUP). A CONTROL GROUP RECEIVED VEHICLE, ONE GROUP WAS TREATED WITH POLICOSANOL 5 MG/KG AND ONE WITH OMEGA-3 FA (EICOSAPENTAENOIC ACID; EPA [47.0%], DOCOSAHEXAENOIC ACID; DHEA [41%]) 250 MG/KG, AND THE FOURTH RECEIVED POLICOSANOL 5 MG/KG + OMEGA-3 FA 250 MG/KG. TREATMENTS WERE ORALLY ADMINISTERED FOR 60 DAYS. BODYWEIGHT, FOOD CONSUMPTION AND ANIMAL BEHAVIOUR WERE RECORDED DAILY. LIPID PROFILE, PLATELET AGGREGATION AND OTHER BLOOD TESTS WERE PERFORMED AT BASELINE AND STUDY COMPLETION. RESULTS: POLICOSANOL SIGNIFICANTLY LOWERED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) [42.7%; P < 0.01] AND TOTAL CHOLESTEROL (TC) [29.4%; P < 0.05], INCREASED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) [15.4%; P < 0.05], BUT LEFT TG LEVELS UNCHANGED. OMEGA-3 FA SIGNIFICANTLY LOWERED TG (47.1%; P<0.05), BUT LEFT TC, LDL-C AND HDL-C UNCHANGED. COMBINED THERAPY DECREASED LDL-C (38.7%; P<0.05), TC (28.0%; P<0.01) AND TG (50.7%; P < 0.05), AND INCREASED HDL-C (15.4%; P < 0.05). CHANGES IN TC, LDL-C AND HDL-C OBTAINED WITH COMBINED THERAPY WERE GREATER (P < 0.05) THAN THOSE WITH OMEGA-3 FA, BUT SIMILAR TO THOSE WITH POLICOSANOL, WHEREAS THE OPPOSITE APPLIED TO TG REDUCTION. NO SIGNIFICANT CHANGES IN LIPID PROFILE WERE OBSERVED IN THE CONTROL GROUP. POLICOSANOL AND OMEGA-3 FA SIGNIFICANTLY (P < 0.05 BUT MODERATELY INHIBITED PLATELET AGGREGATION INDUCED WITH ARACHIDONIC ACID (13.3% AND 12.4%, RESPECTIVELY); COMBINED THERAPY ACHIEVED GREATER INHIBITION (23.9%; P < 0.05). ALL GROUPS SHOWED SIMILAR FOOD CONSUMPTION AND BODYWEIGHT GAIN. NO TOXIC SIGNS WERE OBSERVED IN ANY ANIMAL. CONCLUSIONS: CONCURRENT THERAPY WITH POLICOSANOL 5 M/KG AND OMEGA-3 FA 250 MG/KG LOWERED LDL-C, TC AND TG AND INCREASED HDL-C. ALL TREATMENTS INHIBITED PLATELET AGGREGATION, BUT BETTER EFFECTS WERE OBSERVED WITH POLICOSANOL + OMEGA-3 FA COMPARED WITH EITHER TREATMENT ALONE. COMBINED THERAPY WAS WELL TOLERATED. THESE RESULTS SUGGEST THAT TREATMENT WITH POLICOSANOL + OMEGA-3 FA COULD BE USEFUL FOR REGULATING LIPID PROFILE AND INHIBITING PLATELET AGGREGATION, BUT CONCLUSIVE DEMONSTRATION OF SUCH EFFECTS REQUIRES FURTHER EXPERIMENTAL AND CLINICAL STUDIES. © 2005 ADIS DATA INFORMATION BV. ALL RIGHTS RESERVED.","","ANIMALS; BODY WEIGHT; CHOLESTEROL; DRUG SYNERGISM; EATING; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; LIPIDS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; TRIGLYCERIDES; ALKANOL; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOTRIACONTANOL; HEPTACOSANOL; HEXACOSANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONACOSANOL; OCATACOSANOL; OMEGA 3 FATTY ACID; POLICOSANOL; TETRACOSANOL; TETRAICONTANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG FORMULATION; DRUG TOLERABILITY; FOOD INTAKE; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN","WEST HAVANA SCIENTIFIC POLE","THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE WEST HAVANA SCIENTIFIC POLE. THE AUTHORS HAVE NO CONFLICTS OF INTEREST DIRECTLY RELEVANT TO THE CONTENT OF THIS STUDY.","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N. ENGL. J. MED., 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, PP. 1349-1357, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMIZED CONTROLLED STUDY, LANCET, 360, PP. 1623-1630, (2002); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE: BLOOD LIPIDS AND CORONARY HEART DISEASE, (2000); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 205-208, (1994); MENDOZA S., GAMEZ R., NOA M., ET AL., THE EFFECTS OF D-003 AND POLICOSANOL ON THE LIPID PROFILE AND ENDOTHELEMIA CELLS IN NORMOCHOLESTEROLEMIC RABBITS: A HEAD TO HEAD COMPARISON, CURR. THER. RES., 62, PP. 209-220, (2001); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 13, PP. 187-195, (2000); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN. DRUG. INVEST., 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN. DRUG INVEST., 23, PP. 639-650, (2003); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR. THER. RES., 61, PP. 609-620, (2000); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG. CARCINOG. MUTAGAN, 14, PP. 107-113, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24-MONTH STUDY, TERATOG. CARCINOG. MUTAGAN, 14, PP. 239-249, (1994); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL. LETT., 90, PP. 97-106, (1997); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE DAWLEY RATS, J. MED. FOOD, 4, PP. 57-66, (2001); HARRIS W.S., PARK Y., ISLEY W.L., CARDIOVASCULAR DISEASE AND LONG CHAIN OMEGA-3 FATTY ACIDS, CURR. OPIN. LIPIDOL., 14, PP. 9-14, (2003); LEE K.W., LIP G.V., THE ROLE OF OMEGA-3 FATTY ACIDS IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, QJM, 96, PP. 465-480, (2003); RICHTNER W.O., LONG-CHAIN OMEGA-3 FATTY ACIDS FROM FISH REDUCE SUDDEN CARDIAC DEATH IN PATIENTS WITH CORONARY HEART DISEASE, EUR. J. MED. RES., 8, PP. 332-336, (2003); LEMAITRE R.N., KING I.B., MOZAFFARIAN D., ET AL., N-3 POLYUNSATURATED FATTY ACIDS, FATAL ISCHEMIC HEART DISEASE AND NON FATAL MYOCARDIAL INFARCTION IN OLDER ADULTS: THE CARDIOVASCULAR HEALTH STUDY, AM. J. CLIN. NUTR., 77, PP. 319-325, (2003); HU F.B., BRONNER L., WILLETT W.C., ET AL., FISH AND OMEGA-3 FATTY ACID INTAKE AND RISK OF CORONARY HEART DISEASE IN WOMEN, JAMA, 287, PP. 1815-1821, (2002); DE CATERINA R., MADONNA R., ZUCCHI R., ET AL., ANTIARRHYTHMIC EFFECTS OF OMEGA-3 FATTY ACIDS: FROM EPIDEMIOLOGY TO BEDSIDE, AM. HEART J., 146, PP. 420-430, (2003); MORI T.A., BEILIN L.J., LONG-CHAIN OMEGA 3 FATTY ACIDS, BLOOD LIPIDS AND CARDIOVASCULAR REDUCTION, CURR. OPIN. LIPIDOL., 12, PP. 11-17, (2001); CLUBB F.J., SCHMITZ J.M., BUTLER J.M., ET AL., EFFECT OF DIETARY OMEGA-3-FATTY ACID ON SERUM LIPIDS, PLATELET FUNCTION, AND ATHEROSCLEROSIS IN WATANABE HERITABLE HYPERLIPIDEMIC RABBITS, ARTERIOSCLEROSIS, 9, PP. 529-537, (1989); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY I.R., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, PP. 499-502, (1972); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE (L), 194, PP. 927-930, (1962); MORI T.A., BEILIN L.J., BURKE V., ET AL., INTERACTIONS BETWEEN DIETARY FAT, FISH AND FISH OILS AND THEIR EFFECTS ON PLATELET FUNCTION IN MEN AT RISK OF CARDIOVASCULAR DISEASE, ARTERIOSCLER. THROMB. VASC. BIOL., 17, (1997); KRISTENSEN S.D., IVERSEN A.M., SCHMIDT E.B., N-3 POLYUNSATURATED FATTY ACIDS AND CORONARY THROMBOSIS, LIPIDS, 36, SUPPL., (2001); DIN J.N., NEWBY D.E., FLAPAN A.D., OMEGA 3 FATTY ACIDS AND CARDIOVASCULAR DISEASE: FISHING FOR A NATURAL TREATMENT, BMJ, 32 B, PP. 30-35, (2004); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV. IBEROAM. TROMB. HEMOST., 5, PP. 17-20, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGL. LEUKOTR. ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGL. LEUKOTR. ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); SCHAFER A., ANTIPLATELET THERAPY, AM. J. MED., 101, PP. 199-209, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, PP. 293-297, (1998); NOTARBARTOLO A., DAVI G., AVERNA M., ET AL., INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA, ARTERIOSCLER. THROMB. VASC. BIOL., 15, PP. 247-251, (1995)","R. MÁS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS R D","ARTICLE","ISI","2-S2.0-13844318280","DRUGS R D","NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"GÁMEZ R, 2005, DRUGS R D","GÁMEZ R, 2005, DRUGS R D"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","ACE INHIBITION MAY DECREASE DIABETES RISK BY BOOSTING THE IMPACT OF BRADYKININ ON ADIPOCYTES",2003,"MEDICAL HYPOTHESES","60","4",18,"10.1016/S0306-9877(02)00234-7","UNITED STATES","THE FINDINGS OF THE RECENT HOPE TRIAL STRONGLY SUGGEST THAT ACE INHIBITOR THERAPY MAY REDUCE RISK FOR TYPE 2 DIABETES IN PATIENTS WHO ARE NON-DIABETIC AT BASELINE. THIS FINDING IS READILY RATIONALIZED BY PREVIOUS EVIDENCE THAT BRADYKININ, ACTING VIA B2 RECEPTORS, CAN POTENTIATE THE INSULIN RESPONSIVENESS OF BOTH ADIPOCYTES AND MUSCLE FIBERS; THIS EFFECT MAY BE MEDIATED BY A REDUCTION IN THE ACTIVITY OF A TYROSINE PHOSPHATASE THAT TARGETS THE INSULIN RECEPTOR. ACE INHIBITORS, IN TURN, INCREASE THE AVAILABILITY OF BRADYKININ BY SUPPRESSING ITS PROTEOLYTIC DEGRADATION. IN LIGHT OF THE FACT THAT THE DEVELOPMENT OF INSULIN RESISTANCE IN ADIPOCYTES IS RESPONSIBLE FOR THE EXCESSIVE FREE FATTY ACID FLUX THAT GIVES RISE TO THE DIABETIC SYNDROME, A FAVORABLE IMPACT OF ACE INHIBITION ON ADIPOCYTE INSULIN RESPONSIVENESS - COMPLEMENTED BY A POTENTIATION OF THE DIRECT ACTION OF BRADYKININ ON SKELETAL MUSCLE - OFFERS A SATISFYING EXPLANATION FOR THE PREVENTION OF DIABETES OBSERVED DURING ACE INHIBITOR THERAPY. SINCE THE POPULATION AT RISK FOR DIABETES IS HUGE AND INCREASING DRAMATICALLY, THE RECENT DEVELOPMENT OF ORALLY ABSORBABLE FOOD-DERIVED PEPTIDES WITH CLINICALLY SIGNIFICANT ACE INHIBITORY ACTIVITY - SUCH AS 'KATSUOBUSHI OLIGOPEPTIDES' DERIVED FROM BONITO - MAY MAKE IT MORE LOGISTICALLY FEASIBLE TO ACHIEVE THIS PROTECTION ON A WIDESCALE BASIS, WHILE SIMULTANEOUSLY PROMOTING BLOOD PRESSURE CONTROL AND REDUCING RISK FOR ATHEROTHROMBOTIC DISEASE. © 2003 PUBLISHED BY ELSEVIER SCIENCE LTD.","","KATSUWONUS PELAMIS; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR; CHROMIUM PICOLINATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ICATIBANT; INSULIN RECEPTOR; LOSARTAN; POLICOSANOL; PROTEIN TYROSINE PHOSPHATASE; RAMIPRIL; ADIPOCYTE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SKELETAL MUSCLE; THROMBOSIS","","","CHENG J.W., NGO M.N., CURRENT PERSPECTIVE ON THE USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN THE MANAGEMENT OF CORONARY (ATHEROSCLEROTIC) ARTERY DISEASE, ANN PHARMACOTHER, 31, PP. 1499-1506, (1997); GIBBONS G.H., VASCULOPROTECTIVE AND CARDIOPROTECTIVE MECHANISMS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITION: THE HOMEOSTATIC BALANCE BETWEEN ANGIOTENSIN II AND NITRIC OXIDE, CLIN CARDIOL, 20, PP. 11-25, (1997); MOMBOULI J.V., ACE INHIBITION, ENDOTHELIAL FUNCTION AND CORONARY ARTERY LESIONS. ROLE OF KININS AND NITRIC OXIDE, DRUGS, 54, SUPPL. 5, PP. 12-22, (1997); VANHOUTTE P.M., ENDOTHELIAL DYSFUNCTION AND INHIBITION OF CONVERTING ENZYME, EUR HEART J, 19, SUPPL. J, (1998); ENSELEIT F., HURLIMANN D., LUSCHER T.F., VASCULAR PROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND THEIR RELATION TO CLINICAL EVENTS, J CARDIOVASC PHARMACOL, 37, SUPPL. 1, (2001); KHALIL M.E., BASHER A.W., BROWN E.J.J., ALHADDAD I.A., A REMARKABLE MEDICAL STORY: BENEFITS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN CARDIAC PATIENTS, J AM COLL CARDIOL, 37, PP. 1757-1764, (2001); MANLEY H.J., ROLE OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITION IN PATIENTS WITH RENAL DISEASE, AM J HEALTH SYST PHARM, 57, SUPPL. 1, (2000); YUSUF S., GERSTEIN H., HOOGWERF B., ET AL., RAMIPRIL AND THE DEVELOPMENT OF DIABETES, JAMA, 286, PP. 1882-1885, (2001); GOLDMAN J., PFISTER D., VUKMIROVICH R., POTENTIATION OF INSULIN STIMULATION OF HEXOSE TRANSPORT BY KALLIKREIN AND BRADYKININ IN ISOLATED RAT ADIPOCYTES, MOL CELL ENDOCRINOL, 50, PP. 183-191, (1987); ISAMI S., KISHIKAWA H., ARAKI E., ET AL., BRADYKININ ENHANCES GLUT4 TRANSLOCATION THROUGH THE INCREASE OF INSULIN RECEPTOR TYROSINE KINASE IN PRIMARY ADIPOCYTES: EVIDENCE THAT BRADYKININ STIMULATES THE INSULIN SIGNALLING PATHWAY, DIABETOLOGIA, 39, PP. 412-420, (1996); CALDIZ C.I., DE CINGOLANI G.E., INSULIN RESISTANCE IN ADIPOCYTES FROM SPONTANEOUSLY HYPERTENSIVE RATS: EFFECT OF LONG-TERM TREATMENT WITH ENALAPRIL AND LOSARTAN, METABOLISM, 48, PP. 1041-1046, (1999); KISHI K., MUROMOTO N., NAKAYA Y., ET AL., BRADYKININ DIRECTLY TRIGGERS GLUT4 TRANSLOCATION VIA AN INSULIN-INDEPENDENT PATHWAY, DIABETES, 47, PP. 550-558, (1998); MOTOSHIMA H., ARAKI E., NISHIYAMA T., ET AL., BRADYKININ ENHANCES INSULIN RECEPTOR TYROSINE KINASE IN 32D CELLS RECONSTITUTED WITH BRADYKININ AND INSULIN SIGNALING PATHWAYS, DIABETES RES CLIN PRACT, 48, PP. 155-170, (2000); MIYATA T., TAGUCHI T., UEHARA M., ET AL., BRADYKININ POTENTIATES INSULIN-STIMULATED GLUCOSE UPTAKE AND ENHANCES INSULIN SIGNAL THROUGH THE BRADYKININ B2 RECEPTOR IN DOG SKELETAL MUSCLE AND RAT L6 MYOBLASTS, EUR J ENDOCRINOL, 138, PP. 344-352, (1998); HENRIKSEN E.J., JACOB S., KINNICK T.R., YOUNGBLOOD E.B., SCHMIT M.B., DIETZE G.J., ACE INHIBITION AND GLUCOSE TRANSPORT IN INSULINRESISTANT MUSCLE: ROLES OF BRADYKININ AND NITRIC OXIDE, AM J PHYSIOL, 277, (1999); TORLONE E., RAMBOTTI A.M., PERRIELLO G., ET AL., ACE-INHIBITION INCREASES HEPATIC AND EXTRAHEPATIC SENSITIVITY TO INSULIN IN PATIENTS WITH TYPE 2 (NON-INSULIN-DEPENDENT) DIABETES MELLITUS AND ARTERIAL HYPERTENSION, DIABETOLOGIA, 34, PP. 119-125, (1991); BODEN G., ROLE OF FATTY ACIDS IN THE PATHOGENESIS OF INSULIN RESISTANCE AND NIDDM PUBLISHED ERRATUM APPEARS IN DIABETES 1997;46 (3):536, DIABETES, 46, PP. 3-10, (1997); BODEN G., FREE FATTY ACIDS, INSULIN RESISTANCE, AND TYPE 2 DIABETES MELLITUS, PROC ASSOC AM PHYSICIANS, 111, PP. 241-248, (1999); BERGMAN R.N., MITTELMAN S.D., CENTRAL ROLE OF THE ADIPOCYTE IN INSULIN RESISTANCE, J BASIC CLIN PHYSIOL PHARMACOL, 9, PP. 205-221, (1998); SNIDERMAN A.D., CIANFLONE K., FRAYN K., THE PATHOGENETIC ROLE OF IMPAIRED FATTY ACID TRAPPING BY ADIPOCYTES IN GENERATING THE PLEIOTROPIC FEATURES OF HYPERAPOB, DIABETOLOGIA, 40, SUPPL. 2, (1997); HUBE F., HAUNER H., THE ROLE OF TNF-ALPHA IN HUMAN ADIPOSE TISSUE: PREVENTION OF WEIGHT GAIN AT THE EXPENSE OF INSULIN RESISTANCE?, HORM METAB RES, 31, PP. 626-631, (1999); MASON T.M., GOH T., TCHIPASHVILI V., ET AL., PROLONGED ELEVATION OF PLASMA FREE FATTY ACIDS DESENSITIZES THE INSULIN SECRETORY RESPONSE TO GLUCOSE IN VIVO IN RATS, DIABETES, 48, PP. 524-530, (1999); PURRELLO F., RABUAZZO A.M., METABOLIC FACTORS THAT AFFECT BETA-CELL FUNCTION AND SURVIVAL, DIABETES NUTR METAB, 13, PP. 84-91, (2000); KARAKI H., DOI K., SUGANO S., ET AL., ANTIHYPERTENSIVE EFFECT OF TRYPTIC HYDROLYSATE OF MILK CASEIN IN SPONTANEOUSLY HYPERTENSIVE RATS, COMP BIOCHEM PHYSIOL C, 96, PP. 367-371, (1990); YOKOYAMA K., CHIBA H., YOSHIKAWA M., PEPTIDE INHIBITORS FOR ANGIOTENSIN I-CONVERTING ENZYME FROM THERMOLYSIN DIGEST OF DRIED BONITO, BIOSCI BIOTECHNOL BIOCHEM, 56, PP. 1541-1545, (1992); MATSUFUJI H., MATSUI T., SEKI E., OSAJIMA K., NAKASHIMA M., OSAJIMA Y., ANGIOTENSIN I-CONVERTING ENZYME INHIBITORY PEPTIDES IN AN ALKALINE PROTEASE HYDROLYZATE DERIVED FROM SARDINE MUSCLE, BIOSCI BIOTECHNOL BIOCHEM, 58, PP. 2244-2245, (1994); ASTAWAN M., WAHYUNI M., YASUHARA T., YAMADA K., TADOKORO T., MAEKAWA A., EFFECTS OF ANGIOTENSIN I-CONVERTING ENZYME INHIBITORY SUBSTANCES DERIVED FROM INDONESIAN DRIED-SALTED FISH ON BLOOD PRESSURE OF RATS, BIOSCI BIOTECHNOL BIOCHEM, 59, PP. 425-429, (1995); FUJITA H., YOKOYAMA K., YASUMOTO R., YOSHIKAWA M., ANTIHYPERTENSIVE EFFECT OF THERMOLYSIN DIGEST OF DRIED BONITO IN SPONTANEOUSLY HYPERTENSIVE RAT, CLIN EXP PHARMACOL PHYSIOL SUPPL, 1, (1995); MATSUI T., LI C.H., OSAJIMA Y., PREPARATION AND CHARACTERIZATION OF NOVEL BIOACTIVE PEPTIDES RESPONSIBLE FOR ANGIOTENSIN I-CONVERTING ENZYME INHIBITION FROM WHEAT GERM, J PEPT SCI, 5, PP. 289-297, (1999); FUJITA H., YOSHIKAWA M., LKPNM: A PRODRUG-TYPE ACE-INHIBITORY PEPTIDE DERIVED FROM FISH PROTEIN, IMMUNOPHARMACOLOGY, 44, PP. 123-127, (1999); PIHLANTO-LEPPALA A., KOSKINEN P., PIILOLA K., TUPASELA T., KORHONEN H., ANGIOTENSIN I-CONVERTING ENZYME INHIBITORY PROPERTIES OF WHEY PROTEIN DIGESTS: CONCENTRATION AND CHARACTERIZATION OF ACTIVE PEPTIDES, J DAIRY RES, 67, PP. 53-64, (2000); MATSUI T., LI C.H., TANAKA T., MAKI T., OSAJIMA Y., MATSUMOTO K., DEPRESSOR EFFECT OF WHEAT GERM HYDROLYSATE AND ITS NOVEL ANGIOTENSIN I-CONVERTING ENZYME INHIBITORY PEPTIDE, ILE-VAL-TYR, AND THE METABOLISM IN RAT AND HUMAN PLASMA, BIOL PHARM BULL, 23, PP. 427-431, (2000); FUJITA H., YOKOYAMA K., YOSHIKAWA M., CLASSIFICATION AND ANTIHYPERTENSIVE ACTIVITY OF ANGIOTENSIN I-CONVERTING ENZYME INHIBITORY PEPTIDES DERIVED FROM FOOD PROTEINS, J FOOD SCIENCE, 65, PP. 564-569, (2000); GOBBETTI M., FERRANTI P., SMACCHI E., GOFFREDI F., ADDEO F., PRODUCTION OF ANGIOTENSIN-I-CONVERTING-ENZYME-INHIBITORY PEPTIDES IN FERMENTED MILKS STARTED BY LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS SS1 AND LACTOCOCCUS LACTIS SUBSP. CREMORIS FT4, APPL ENVIRON MICROBIOL, 66, PP. 3898-3904, (2000); FITZGERALD R.J., MEISEL H., MILK PROTEIN-DERIVED PEPTIDE INHIBITORS OF ANGIOTENSIN-I-CONVERTING ENZYME, BR J NUTR, 84, SUPPL. 1, (2000); WU J., DING X., HYPOTENSIVE AND PHYSIOLOGICAL EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORY PEPTIDES DERIVED FROM SOY PROTEIN ON SPONTANEOUSLY HYPERTENSIVE RATS, J AGRIC FOOD CHEM, 49, PP. 501-506, (2001); FUJITA H., YAMAGAMI T., OHSHIMA K., EFFECTS OF AN ACE-INHIBITORY AGENT, KATSUOBUSHI OLIGOPEPTIDE, IN THE SPONTANEOUSLY HYPERTENSIVE RAT AND IN BORDERLINE AND MILDLY HYPERTENSIVE SUBJECTS, NUTRITION RESEARCH, (2001); MCCARTY M.F., TOWARD PRACTICAL PREVENTION OF TYPE 2 DIABETES, MED HYPOTHESES, 54, PP. 786-793, (2000); FREEMAN D.J., NORRIE J., SATTAR N., ET AL., PRAVASTATIN AND THE DEVELOPMENT OF DIABETES MELLITUS: EVIDENCE FOR A PROTECTIVE TREATMENT EFFECT IN THE WEST OF SCOTLAND CORONARY PREVENTION STUDY, CIRCULATION, 103, PP. 357-362, (2001); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MEDICAL HYPOTHESES, (2001); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FEMANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THERAPEUTIC RES, 61, PP. 137-146, (2000); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); KOWALA M.C., VALENTINE M., RECCE R., ET AL., ENHANCED REDUCTION OF ATHEROSCLEROSIS IN HAMSTERS TREATED WITH PRAVASTATIN AND CAPTOPRIL: ACE IN ATHEROMAS PROVIDES CELLULAR TARGETS FOR CAPTOPRIL, J CARDIOVASC PHARMACOL, 32, PP. 29-38, (1998); VILLA E., RABANO A., ALBARRAN O.G., RUILOPE L.M., GARCIA-ROBLES R., EFFECTS OF CHRONIC COMBINED TREATMENT WITH CAPTOPRIL AND PRAVASTATIN ON THE PROGRESSION OF INSULIN RESISTANCE AND CARDIOVASCULAR ALTERATIONS IN AN EXPERIMENTAL MODEL OF OBESITY IN DOGS, AM J HYPERTENS, 11, PP. 844-851, (1998); NAZZARO P., MANZARI M., MERLO M., ET AL., DISTINCT AND COMBINED VASCULAR EFFECTS OF ACE BLOCKADE AND HMG-COA REDUCTASE INHIBITION IN SUBJECTS, HYPERTENSION, 33, PP. 719-725, (1999); SPOSITO A.C., MANSUR A.P., COELHO O.R., NICOLAU J.C., RAMIRES J.A., ADDITIONAL REDUCTION IN BLOOD PRESSURE AFTER CHOLESTEROL-LOWERING TREATMENT BY STATINS (LOVASTATIN OR PRAVASTATIN) IN HYPERCHOLESTEROLEMIC PATIENTS USING ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ENALAPRIL OR LISINOPRIL), AM J CARDIOL, 83, PP. 1497-1499, (1999); ESPER R.J., MACHADO R., VILARINO J., ET AL., ENDOTHELIUM-DEPENDENT RESPONSES IN PATIENTS WITH HYPERCHOLESTEROLEMIC CORONARY ARTERY DISEASE UNDER THE EFFECTS OF SIMVASTATIN AND ENALAPRIL, EITHER SEPARATELY OR COMBINED, AM HEART J, 140, PP. 684-689, (2000); LAUFS U., LA F., PLUTZKY V., LIAO J., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY HMG COA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); LAUFS U., LIAO J.K., POST-TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA STABILITY BY RHO GTPASE, J BIOL CHEM, 273, PP. 24266-24271, (1998); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS THROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER THROMB VASE BIOL, 20, PP. 61-69, (2000); HORNIG B., ARAKAWA N., DREXLER H., EFFECT OF ACE INHIBITION ON ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE, EUR HEART J, 19, SUPPL. G, (1998); PRASAD A., HUSAIN S., QUYYUMI A.A., ABNORMAL FLOW-MEDIATED EPICARDIAL VASOMOTION IN HUMAN CORONARY ARTERIES IS IMPROVED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITION: A POTENTIAL ROLE OF BRADYKININ, J AM COLL CARDIOL, 33, PP. 796-804, (1999)","","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","REVIEW","ISI","2-S2.0-0037410532","MED HYPOTHESES",NA,"NOTREPORTED",NA,"MCCARTY MF, 2003, MED HYPOTHESES","MCCARTY MF, 2003, MED HYPOTHESES-a"
"BERTHOLD H;UNVERDORBEN S;DEGENHARDT R;BULITTA M;GOUNI-BERTHOLD I","BERTHOLD, HEINER K. (9734847000); UNVERDORBEN, SUSANNE (13606183600); DEGENHARDT, RALF (6603096895); BULITTA, MICHAEL (6603165882); GOUNI-BERTHOLD, IOANNA (56216445200)","EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA A RANDOMIZED CONTROLLED TRIAL",2006,"JAMA","295","7",160,"10.1001/jama.295.19.2262","DEPARTMENT OF CLINICAL PHARMACOLOGY, INSTITUTE FOR CLINICAL RESEARCH, CENTER FOR CARDIOVASCULAR DISEASES, ROTENBURG AN DER FULDA, GERMANY, DRUG COMMISSION OF THE GERMAN MEDICAL ASSOCIATION, 10623 BERLIN, HERBERT-LEWIN-PLATZ 1, GERMANY;DEPARTMENT OF CLINICAL PHARMACOLOGY, INSTITUTE FOR CLINICAL RESEARCH, CENTER FOR CARDIOVASCULAR DISEASES, ROTENBURG AN DER FULDA, GERMANY;DEPARTMENT OF CLINICAL PHARMACOLOGY, INSTITUTE FOR CLINICAL RESEARCH, CENTER FOR CARDIOVASCULAR DISEASES, ROTENBURG AN DER FULDA, GERMANY;CLINICAL RESEARCH MANAGEMENT PHARMABERATUNG GMBH, RHEINBACH, GERMANY;DEPARTMENT OF INTERNAL MEDICINE II, UNIVERSITY OF COLOGNE, COLOGNE, GERMANY","CONTEXT: POLICOSANOL IS A NATURAL SUBSTANCE DERIVED FROM SUGAR CANE THAT IS ADVERTISED FOR ITS LIPID-LOWERING EFFECTS AS A NONPRESCRIPTION DRUG. MORE THAN 80 PLACEBO-CONTROLLED OR COMPARATIVE TRIALS, PERFORMED MOSTLY BY A SINGLE RESEARCH INSTITUTE, SUGGEST THAT POLICOSANOL AT DOSES OF 5 TO 40 MG/D HAS LIPOPROTEIN-LOWERING EFFECTS COMPARABLE WITH STATINS. OBJECTIVES: TO DETERMINE THE LIPOPROTEIN-LOWERING EFFECTS OF CUBAN SUGAR CANE-DERIVED POLICOSANOL AND TO ESTABLISH, IF EFFECTIVE, DOSE-DEPENDENCY UP TO 80 MG/D IN PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA. DESIGN, SETTING, AND PARTICIPANTS: A MULTICENTER (LIPID OUTPATIENT CLINICS AND GENERAL PRACTITIONERS IN GERMANY), RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP TRIAL CONDUCTED FROM SEPTEMBER 29, 2000, TO MAY 10, 2001, OF PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA HAVING BASELINE LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS OF AT LEAST 150 MG/DL (≥3.88 MMOL/L) AND EITHER NO OR 1 CARDIOVASCULAR RISK FACTOR OTHER THAN KNOWN CORONARY HEART DISEASE, OR BASELINE LDL-C LEVELS OF BETWEEN 150 AND 189 MG/DL (3.88-4.89 MMOL/L) AND 2 OR MORE RISK FACTORS. INTERVENTIONS: OPEN-LABEL 6-WEEK PLACEBO AND DIET RUN-IN PHASE FOLLOWED BY A DOUBLE-BLIND 12-WEEK TREATMENT PHASE AFTER RANDOMIZATION TO 5 GROUPS: 10, 20, 40, OR 80 MG/D OF POLICOSANOL OR PLACEBO. MAIN OUTCOME MEASURE: THE PERCENTAGE CHANGE OF LDL-C, WITH CHANGES IN OTHER LIPOPROTEINS AS SECONDARY OUTCOME MEASURES. RESULTS: A TOTAL OF 143 PATIENTS WERE RANDOMIZED TO 5 EQUAL GROUPS AND WERE ANALYZED ON AN INTENTION-TO-TREAT BASIS. IN NONE OF THE 5 TREATMENT GROUPS DID LDL-C LEVELS DECREASE MORE THAN 10% FROM BASELINE. NO STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN POLICOSANOL AND PLACEBO WAS OBSERVED. A NONPARAMETRIC TEST ANALYZING DOSE-DEPENDENCY YIELDED NONSIGNIFICANT RESULTS. IN NONE OF THE SECONDARY OUTCOME MEASURES, NAMELY TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), VERY LOW-DENSITY LIPOPROTEIN CHOLESTEROL, TRIGLYCERIDES, LIPOPROTEIN(A), AND RATIO OF TOTAL OR LDL-C TO HDL-C, WERE THERE ANY SIGNIFICANT EFFECTS OF POLICOSANOL. POLICOSANOL WAS TOLERATED WELL WITHOUT SERIOUS ADVERSE EVENTS. CONCLUSION: IN PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, THE SUGAR CANE-DERIVED POLICOSANOL IN USUAL AND HIGH DOSES DOES NOT DEMONSTRATE A REDUCTION IN LIPID LEVELS BEYOND PLACEBO. ©2006 AMERICAN MEDICAL ASSOCIATION. ALL RIGHTS RESERVED.","","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE","","","GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); NIKITIN IU.P., SLEPCHENKO N.V., GRATSIANSKII N.A., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC DRUG POLYCOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); SMITH JR. S.C., BLAIR S.N., BONOW R.O., ET AL., AHA/ACC SCIENTIFIC STATEMENT: AHA/ACC GUIDELINES FOR PREVENTING HEART ATTACK AND DEATH IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: 2001 UPDATE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE AMERICAN HEART ASSOCIATION AND THE AMERICAN COLLEGE OF CARDIOLOGY, CIRCULATION, 104, PP. 1577-1579, (2001); PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUR HEART J, 19, PP. 1434-1503, (1998); ASSMANN G., CULLEN P., SCHULTE H., SIMPLE SCORING SCHEME FOR CALCULATING THE RISK OF ACUTE CORONARY EVENTS BASED ON THE 10-YEAR FOLLOW-UP OF THE PROSPECTIVE CARDIOVASCULAR MUNSTER (PROCAM) STUDY, CIRCULATION, 105, PP. 310-315, (2002); AUFENANGER J., HAUX P., KATTERMANN R., IMPROVED METHOD FOR ENZYMIC DETERMINATION OF CHOLESTEROL IN LIPOPROTEINS SEPARATED BY ELECTROPHORESIS ON THIN LAYER AGAROSE GELS, J CLIN CHEM CLIN BIOCHEM, 27, PP. 807-813, (1989); TERPSTRA T.J., THE ASYMPTOTIC NORMALITY AND CONSISTENCY OF KENDALL'S TEST AGAINST TREND, WHEN TIES ARE PRESENT IN ONE RANKING, INDAGATIONES MATHEMATICAE, 14, PP. 327-333, (1952); JONCKHEERE A.R., A DISTRIBUTION-FREE K-SAMPLE TEST AGAINST ORDERED ALTERNATIVES, BIOMETRIKA, 41, PP. 133-145, (1954); HODGES J.L., LEHMANN E.L., ESTIMATES OF LOCATION BASED ON RANK TESTS, ANN MATH STATIST, 34, PP. 598-611, (1963); O'NEILL R.T., STATISTICAL ANALYSIS OF ADVERSE EVENT DATA FROM CLINICAL TRIALS, DRUG INF J, 21, PP. 9-30, (1987); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN, AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM J CARDIOL, 81, PP. 582-587, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS: A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); TAN C.E., LOH L.M., TAI E.S., DO SINGAPORE PATIENTS REQUIRE LOWER DOSES OF STATINS? THE SGH LIPID CLINIC EXPERIENCE, SINGAPORE MED J, 44, PP. 635-638, (2003); PEARSON T.A., DENKE M.A., MCBRIDE P.E., BATTISTI W.P., BRADY W.E., PALMISANO J., A COMMUNITY-BASED, RANDOMIZED TRIAL OF EZETIMIBE ADDED TO STATIN THERAPY TO ATTAIN NCEP ATP III GOALS FOR LDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC PATIENTS: THE EZETIMIBE ADD-ON TO STATIN FOR EFFECTIVENESS (EASE) TRIAL, MAYO CLIN PROC, 80, PP. 587-595, (2005); HOWARD B.V., HANNAH J.S., HEISER C.C., JABLONSKI K.A., EFFECTS OF SEX AND ETHNICITY ON RESPONSES TO A LOW-FAT DIET: A STUDY OF AFRICAN AMERICANS AND WHITES, AM J CLIN NUTR, 62, (1995); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); MCCARTY M.F., AN EZETIMIBE-POLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTS, MED HYPOTHESES, 64, PP. 636-645, (2005); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); GRUNDY S.M., CLEEMAN J.I., MERZ C.N., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, CIRCULATION, 110, PP. 227-239, (2004); ROBINSON J.G., SMITH B., MAHESHWARI N., SCHROTT H., PLEIOTROPIC EFFECTS OF STATINS: BENEFIT BEYOND CHOLESTEROL REDUCTION? A META-REGRESSION ANALYSIS, J AM COLL CARDIOL, 46, PP. 1855-1862, (2005); EISENBERG D.M., DAVIS R.B., ETTNER S.L., ET AL., TRENDS IN ALTERNATIVE MEDICINE USE IN THE UNITED STATES, 1990-1997, JAMA, 280, PP. 1569-1575, (1998)","H.K. BERTHOLD; DRUG COMMISSION OF THE GERMAN MEDICAL ASSOCIATION, 10623 BERLIN, HERBERT-LEWIN-PLATZ 1, GERMANY; EMAIL: BERTHOLD@UNI-BONN.DE","AMERICAN MEDICAL ASSOCIATION","ENGLISH","J. AM. MED. ASSOC.","ARTICLE","ISI","2-S2.0-33646675819","J AM MED ASSOC","INSTITUTE FOR CLINICAL RESEARCH;INSTITUTE FOR CLINICAL RESEARCH;INSTITUTE FOR CLINICAL RESEARCH;CLINICAL RESEARCH MANAGEMENT PHARMABERATUNG GMBH;UNIVERSITY OF COLOGNE","NOTREPORTED;DRUG COMMISSION OF THE GERMAN MEDICAL ASSOCIATION;NOTREPORTED",NA,"BERTHOLD HK, 2006, J AM MED ASSOC","BERTHOLD HK, 2006, J AM MED ASSOC"
"CASTAÑO G;MAS R;GÁMEZ R;FERNÁNDEZ J;ILLNAIT J;FERNÁNDEZ L;MENDOZA S;MESA M;GUTIÉRREZ J;LÓPEZ E","CASTAÑO, G. (7005759008); MAS, R. (7007164572); GÁMEZ, R. (7003605346); FERNÁNDEZ, J. (9432805500); ILLNAIT, J. (8631465800); FERNÁNDEZ, L. (7202848319); MENDOZA, S. (7102759819); MESA, M. (36880545700); GUTIÉRREZ, J.A. (26639209200); LÓPEZ, E. (57198355062)","CONCOMITANT USE OF POLICOSANOL AND ΒBLOCKERS IN OLDER PATIENTS",2004,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","24","12",12,"","SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA, MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, P.O. BOX 6880, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;DIAGNOSIS BRANCH, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS. IT IS SAFE AND WELL TOLERATED, EVEN IN POPULATIONS WITH HIGH CONSUMPTION OF CONCOMITANT DRUGS. THESE DATA SUGGEST THAT ADVERSE EVENTS (AE) DUE TO DRUG-TO-DRUG INTERACTIONS (DDI) WITH POLICOSANOL ARE NOT RELEVANT. EXPERIMENTAL DATA INDICATE THAT POTENTIAL DDI BETWEEN POLICOSANOL AND DRUGS METABOLIZED THROUGH THE CYTOCHROME P450 HEPATIC SYSTEM ARE NOT EXPECTED, BUT PHARMACODYNAMIC DDI CANNOT BE EXCLUDED. SEVERAL CLINICAL STUDIES HAVE SHOWN THAT POLICOSANOL DECREASED ARTERIAL PRESSURE COMPARED WITH PLACEBO, AND A PHARMACOLOGICAL INTERACTION WITH Β-BLOCKERS WAS EXPERIMENTALLY PROVEN. THEREFORE, CLINICAL DDI BETWEEN POLICOSANOL AND Β-BLOCKERS CAN BE EXPECTED. THIS STUDY INVESTIGATED WHETHER POLICOSANOL REINFORCES THE ANTIHYPERTENSIVE EFFECTS OF Β-BLOCKERS AND/OR WHETHER THIS COMBINATION IMPAIRS SOME SAFETY INDICATORS OR INDUCES SPECIFIC AE IN OLDER PATIENTS. AFTER 5 WEEKS ON A DIET-ONLY BASELINE PERIOD, 205 OLDER HYPERCHOLESTEROLEMIC PATIENTS TAKING Β-BLOCKERS WERE RANDOMIZED TO POLICOSANOL 5 MG/DAY OR PLACEBO FOR 3 YEARS. AFTER 1 YEAR ON THERAPY, POLICOSANOL SIGNIFICANTLY REDUCED (P < 0.00001 VERSUS PLACEBO) LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) (20.9%), TOTAL CHOLESTEROL (TC) (19.3%) AND TRIGLYCERIDES (TG) (25.7%), WHEREAS IT INCREASED (P < 0.01 AND P < 0.007 VERSUS PLACEBO) HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) LEVELS (4.1%). TREATMENT EFFECTS DID NOT TO WEAR OFF DURING THE 3-YEAR FOLLOW-UP. AT STUDY COMPLETION, POLICOSANOL LOWERED (P < 0.00001 VERSUS PLACEBO) LDL-C (34.3%), TC (23.2%) AND TG (21.2%) AND RAISED (P < 0.00001 VERSUS PLACEBO) HDL-C (12.3%). THIRTY-ONE PATIENTS (15.1%) DISCONTINUED THE STUDY, 22 IN THE PLACEBO GROUP (20.6%) AND NINE IN THE POLICOSANOL GROUP (9.2%). OF THESE, 20 PATIENTS (16 IN THE PLACEBO GROUP AND FOUR IN THE POLICOSANOL GROUP) WITHDREW FROM THE STUDY DUE TO AE. THE FREQUENCY OF SERIOUS ADVERSE EVENTS (SAE), MOSTLY VASCULAR, IN POLICOSANOL PATIENTS (3/98, 3.1%) WAS LOWER THAN IN THE PLACEBO GROUP (15/107, 14.0%). NO IMPAIRMENT OF SAFETY INDICATORS WAS OBSERVED. NEVERTHELESS, REDUCTIONS IN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE WERE OBSERVED IN POLICOSANOL PATIENTS COMPARED WITH THOSE IN THE PLACEBO GROUP. THE FREQUENCY OF POLICOSANOL PATIENTS REPORTING MILD OR MODERATE AE (18/98, 18.4%) WAS ALSO LOWER THAN IN THE PLACEBO GROUP (30/107, 28.0%). IN CONCLUSION, POLICOSANOL WAS WELL TOLERATED IN ELDERLY PATIENTS TAKING Β-BLOCKERS AND DID NOT INCREASE AE. ADDITIONAL REDUCTION OF BLOOD PRESSURE AND A LOWER FREQUENCY OF SAE WERE OBSERVED IN POLICOSANOL PATIENTS COMPARED WITH THOSE TAKING PLACEBO. THE CHOLESTEROL-LOWERING EFFICACY OF POLICOSANOL WAS THAT EXPECTED. THESE RESULTS PROVIDE SUPPORT THAT POLICOSANOL THERAPY ADDED TO HYPERCHOLESTEROLEMIC ELDERLY INDIVIDUALS TAKING Β-BLOCKERS COULD PROVIDE ADDITIONAL BENEFITS IN LOWERING BLOOD PRESSURE; SAE WERE NOT MORE FREQUENT IN THE POLICOSANOL GROUP THAN IN THE PLACEBO GROUP AND THERE WAS NO INCREASE IN AE.","","ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES INSIPIDUS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PROSPECTIVE STUDIES; TABLETS; TIME FACTORS; TRIGLYCERIDES; WITHHOLDING TREATMENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; VASODILATOR AGENT; VITAMIN; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE","","","MURRAY C.J.L., LOPEZ A.D., ALTERNATE PROJECTIONS OF MORTALITY AND DISABILITY BY CAUSE 1990-2020. GLOBAL BURDEN OF DISEASE STUDY, LANCET, 349, (1997); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP ON REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE. THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, (1994); SACKS P.M., PFEFFER M.A., MOYE L.A., ET AL., FOR THE CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS: THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., FOR THE WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED STUDY, LANCET, 360, (2002); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN. EPIDEMIOL., 2, (1992); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, (2001); MAS R., POLICOSANOL, ORUGS OF THE FUTURE, 25, (2000); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1999); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR. THER. RES., 56, (1995); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL., 56, (2001); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN. INVEST., 21, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN. DRUG INVEST., 21, (2001); CASTANO G., MAS R., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLEMIA, DRUGS IN R&D, 3, (2002); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, (2003); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, (1997); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 22, (2002); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, (1996); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION. A RANDOMIZED, DOUBLE-BLINDED PILOT STUDY, CURR. THER. RES., 61, (2000); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27,879 CASES, CURR. THER. RES., 59, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACO-EPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, (1999); ROLAND M., TOZER T.N., INTERACTING DRUGS, ""CLINICAL PHARMACOKINETICS."" SECOND EDITION, PP. 255-275, (1989); PEREZ-SOUTO N., ACOSTA P.C., MEDEROS C.M., ET AL., EFFECF OF ATEROMIXOL (POLICOSANOL) ON THE PHARMACOKINETICS OF ANTYPIRINE, REV. CENIC CIEN. BIOL., 22, (1991); RODEIRO I., ALEMAN C.L., MAS R., ET AL., EFFECT OF POLICOSANOL ON MICROSOMAL HEPATIC ENZYMES IN SD RATS, REV. CENIC CIEN. BIOL., 31, (2001); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS. STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOLOL, ARCH. MED. RES., 29, (1998); THE SIXTH REPORT OF THE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD PRESSURE, ARCH. INTERN. MED., 157, (1997); GUIDELINES FOR THE MANAGEMENT OF HYPERTENSION. GUIDELINES SUBCOMMITTEE, J. HYPERTENS., 17, (1999); MESSERLI F., ANTIHYPERTENSIVE THERAPY: Β-BLOCKERS AND DIURETICS-WHY DO PHYSICIANS NOT ALWAYS FOLLOW GUIDELINES?, BUMC PROCEEDINGS, 13, (2000); COMMENTARY ON ""ANTIHYPERTENSIVE THERAPY: BETA-BLOCKERS AND DIURETICS, BUMC PROCEEDINGS, 13, (2000); MAGILL M.K., GUNNING K., SAFFEL-SHRIER S., ET AL., NEW DEVELOPMENTS IN THE MANAGEMENT OF HYPERTENSION, AM. FAM. PHYSICIAN, 68, (2003); WEIR M.R., MOSER M., DIURETICS AND Β-BLOCKERS: IS THERE A RISK FOR DYSLIPIDEMIA?, AM. HEART J., 139, (2000); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); CUBAN HEALTH STATISTICAL REPORTS, (1998); GLYNN R.J., CHAE C.U., GURALNIK, TAYLOR J.O., HENNEKES C.H., PULSE PRESSURE AND MORTALITY IN OLDER PEOPLE, ARCH. INTERN. MED., 160, (2000)","G. CASTAÑO; MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, P.O. BOX 6880, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-19944428713","INT J CLIN PHARMACOL RES","SURGICAL MEDICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;SURGICAL MEDICAL RESEARCH CENTER;SURGICAL MEDICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;MEDICAL SURGICAL RESEARCH CENTER;EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2004, INT J CLIN PHARMACOL RES","CASTAÑO G, 2004, INT J CLIN PHARMACOL RES"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","COPING WITH ENDOTHELIAL SUPEROXIDE POTENTIAL COMPLEMENTARITY OF ARGININE AND HIGHDOSE FOLATE",2004,"MEDICAL HYPOTHESES","63","9",18,"10.1016/j.mehy.2002.11.006","SAN DIEGO, CA 92109, UNITED STATES, NUTRIGUARD RESEARCH, 1051 HERMES AVE, ENCINITAS CA 92024, USA, UNITED STATES","SUPEROXIDE OVERPRODUCTION IS A PROMINENT MEDIATOR OF THE ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH A RANGE OF VASCULAR DISORDERS, ACTING IN A NUMBER OF COMPLEMENTARY WAYS TO INHIBIT EFFECTIVE ENDOTHELIAL NITRIC OXIDE (NO) ACTIVITY. THE ABILITY OF SUPEROXIDE TO QUENCH NO IS WELL KNOWN, BUT OXIDANTS DERIVED FROM SUPEROXIDE ALSO APPEAR TO INHIBIT DIMETHYLARGININE DIMETHYLAMINOHYDROLASE (DDAH) AND TO OXIDIZE TETRAHYDROBIOPTERIN (THBP). THE FORMER EFFECT BOOSTS THE LEVEL OF METHYLATED ARGININES THAT ACT AS POTENT COMPETITIVE INHIBITORS OF NO SYNTHASE, WHEREAS THE LATTER EFFECT DECREASES THE ABILITY OF THIS ENZYME TO GENERATE NO, WHILE CONVERTING IT TO A FORM THAT READILY GENERATES SUPEROXIDE. THE ADVERSE IMPACT OF DDAH DEFICIENCY ON NO PRODUCTION CAN BE OFFSET WITH SUPPLEMENTAL ARGININE. ALTHOUGH SUPPLEMENTATION WITH THBP HAS THE POTENTIAL TO COMPENSATE FOR THE RAPID OXIDATIVE DESTRUCTION OF THIS COMPOUND, AND MAINTAINING OPTIMAL VITAMIN C NUTRITION MAY PROTECT OR RESTORE THE ENDOTHELIAL THBP POOL TO A LIMITED EXTENT, THE MOST PRACTICAL WAY TO OPTIMIZE NO SYNTHASE ACITIVITY IN THE CONTEXT OF THBP DEFICIT MAY BE ADMINISTRATION OF HIGH-DOSE FOLIC ACID. THE PRIMARY CIRCULATING METABOLITE OF FOLATE, 5-METHYLTETRAHYDROFOLATE (5MTHF), IS STRUCTURALLY ANALOGOUS TO THBP, AND APPEARS TO NORMALIZE THE ACTIVITY OF NO SYNTHASE IN THBP-DEPLETED ENDOTHELIAL CELLS, EITHER BECAUSE IT ""PINCH HITS"" FOR THE ABSENT THBP, OR INTERACTS ALLOSTERICALLY WITH NO SYNTHASE IN SOME OTHER WAY TO PROMOTE THE PROPER FUNCTION OF THIS ENZYME. THIS OBSERVATION MAY RATIONALIZE RECENT CLINICAL STUDIES SHOWING A FAVORABLE EFFECT OF ORAL FOLIC ACID (5-10 MG DAILY) ON DYSFUNCTIONAL ENDOTHELIUM, INDEPENDENT OF ANY CONCURRENT MODULATION OF HOMOCYSTEINE LEVELS. A RECENT STUDY REPORTS THAT, WHEREAS EITHER ARGININE OR THBP ALONE HAVE ONLY A MODEST IMPACT ON DYSFUNCTIONAL AORTIC ENDOTHELIUM DERIVED FROM HYPERCHOLESTEROLEMIC MICE, THE COMBINATION OF THE TWO PRODUCES A COMPLETE NORMALIZATION OF ENDOTHELIAL FUNCTION. IN AGGREGATE, THESE CONSIDERATIONS SUGGEST THAT JOINT ADMINISTRATION OF ARGININE AND HIGH-DOSE FOLATE MAY REPRESENT A FRUITFUL APPROACH TO PREVENTING AND TREATING VASCULAR DISORDERS - ALBEIT THE UNDERLYING OVERPRODUCTION OF SUPEROXIDE SHOULD ALSO BE ADDRESSED BY AMELIORATING RELEVANT VASCULAR RISK FACTORS. © 2004 ELSEVIER LTD. ALL RIGHTS RESERVED.","","5 METHYLTETRAHYDROFOLIC ACID; ARGININE; ASCORBIC ACID; CYANOCOBALAMIN; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZING AGENT; POLICOSANOL; RALOXIFENE; SUPEROXIDE; TETRAHYDROBIOPTERIN; AORTA; CYANOCOBALAMIN DEFICIENCY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; METABOLITE; METHYLATION; NONHUMAN; OXIDATIVE STRESS; PERNICIOUS ANEMIA; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM","","","CAI H., HARRISON D.G., ENDOTHELIAL DYSFUNCTION IN CARDIOVASCULAR DISEASES: THE ROLE OF OXIDANT STRESS, CIRC. RES., 87, PP. 840-844, (2000); WOLIN M.S., GUPTE S.A., OECKLER R.A., SUPEROXIDE IN THE VASCULAR SYSTEM, J. VASC. RES., 39, PP. 191-207, (2002); MEYER J.W., HOLLAND J.A., ZIEGLER L.M., CHANG M.M., BEEBE G., SCHMITT M.E., IDENTIFICATION OF A FUNCTIONAL LEUKOCYTE-TYPE NADPH OXIDASE IN HUMAN ENDOTHELIAL CELLS: A POTENTIAL ATHEROGENIC SOURCE OF REACTIVE OXYGEN SPECIES, ENDOTHELIUM, 7, PP. 11-22, (1999); ZHANG H., SCHMEISSER A., GARLICHS C.D., PLOTZE K., DAMME U., MUGGE A., ET AL., ANGIOTENSIN II-INDUCED SUPEROXIDE ANION GENERATION IN HUMAN VASCULAR ENDOTHELIAL CELLS: ROLE OF MEMBRANE-BOUND NADH-/NADPH-OXIDASES, CARDIOVASC. RES., 44, PP. 215-222, (1999); HARRISON D.G., ENDOTHELIAL FUNCTION AND OXIDANT STRESS, CLIN. CARDIOL., 20, (1997); HOLLAND J.A., O'DONNELL R.W., CHANG M.M., JOHNSON D.K., ZIEGLER L.M., ENDOTHELIAL CELL OXIDANT PRODUCTION: EFFECT OF NADPH OXIDASE INHIBITORS, ENDOTHELIUM, 7, PP. 109-119, (2000); COSENTINO F., LUSCHER T.F., TETRAHYDROBIOPTERIN AND ENDOTHELIAL FUNCTION, EUR. HEART. J., 19, SUPPL. G, (1998); KATUSIC Z.S., VASCULAR ENDOTHELIAL DYSFUNCTION: DOES TETRAHYDROBIOPTERIN PLAY A ROLE?, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); VASQUEZ-VIVAR J., MARTASEK P., WHITSETT J., JOSEPH J., KALYANARAMAN B., THE RATIO BETWEEN TETRAHYDROBIOPTERIN AND OXIDIZED TETRAHYDROBIOPTERIN ANALOGUES CONTROLS SUPEROXIDE RELEASE FROM ENDOTHELIAL NITRIC OXIDE SYNTHASE: AN EPR SPIN TRAPPING STUDY, BIOCHEM. J., 362, PP. 733-739, (2002); MENESHIAN A., BULKLEY G.B., THE PHYSIOLOGY OF ENDOTHELIAL XANTHINE OXIDASE: FROM URATE CATABOLISM TO REPERFUSION INJURY TO INFLAMMATORY SIGNAL TRANSDUCTION, MICROCIRCULATION, 9, PP. 161-175, (1902); RIEGER J.M., SHAH A.R., GIDDAY J.M., ISCHEMIA-REPERFUSION INJURY OF RETINAL ENDOTHELIUM BY CYCLOOXYGENASE- AND XANTHINE OXIDASE-DERIVED SUPEROXIDE, EXP. EYE RES., 74, PP. 493-501, (2002); GEWALTIG M.T., KOJDA G., VASOPROTECTION BY NITRIC OXIDE: MECHANISMS AND THERAPEUTIC POTENTIAL, CARDIOVASC. RES., 55, PP. 250-260, (2002); SHERMAN D.L., KEANEY J.F.J., BIEGELSEN E.S., DUFFY S.J., COFFRNAN J.D., VITA J.A., PHARMACOLOGICAL CONCENTRATIONS OF ASCORBIC ACID ARE REQUIRED FOR THE BENEFICIAL EFFECT ON ENDOTHELIAL VASOMOTOR FUNCTION IN HYPERTENSION, HYPERTENSION, 35, PP. 936-941, (2000); VIRDIS A., GHIADONI L., CARDINAL H., FAVILLA S., DURANTI P., BIRINDELLI R., ET AL., MECHANISMS RESPONSIBLE FOR ENDOTHELIAL DYSFUNCTION INDUCED BY FASTING HYPERHOMOCYSTINEMIA IN NORMOTENSIVE SUBJECTS AND PATIENTS WITH ESSENTIAL HYPERTENSION, J. AM. COLL. CARDIOL., 38, PP. 1106-1115, (2001); TING H.H., TIMIMI F.K., BOLES K.S., CREAGER S.J., GANZ P., CREAGER M.A., VITAMIN C IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS, J. CLIN. INVEST., 97, PP. 22-28, (1996); HEITZER T., JUST H., MUNZEL T., ANTIOXIDANT VITAMIN C IMPROVES ENDOTHELIAL DYSFUNCTION IN CHRONIC SMOKERS, CIRCULATION, 94, PP. 6-9, (1996); TING H.H., TIMIMI F.K., HALEY E.A., RODDY M.A., GANZ P., CREAGER M.A., VITAMIN C IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION IN FOREARM RESISTANCE VESSELS OF HUMANS WITH HYPERCHOLESTEROLEMIA, CIRCULATION, 95, PP. 2617-2622, (1997); SOLZBACH U., HORNIG B., JESERICH M., JUST H., VITAMIN C IMPROVES ENDOTHELIAL DYSFUNCTION OF EPICARDIAL CORONARY ARTERIES IN HYPERTENSIVE PATIENTS, CIRCULATION, 96, PP. 1513-1519, (1997); MOTOYAMA T., KAWANO H., KUGIYAMA K., HIRASHIMA O., OHGUSHI M., YOSHIMURA M., ET AL., ENDOTHELIUM-DEPENDENT VASODILATION IN THE BRACHIAL ARTERY IS IMPAIRED IN SMOKERS: EFFECT OF VITAMIN C, AM. J. PHYSIOL., 273, (1997); TIMIMI F.K., TING H.H., HALEY E.A., RODDY M.A., GANZ P., CREAGER M.A., VITAMIN C IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION IN PATIENTS WITH INSULIN-DEPENDENT DIABETES MELLITUS, J. AM. COLL. CARDIOL., 31, PP. 552-557, (1998); TADDEI S., VIRDIS A., GHIADONI L., MAGAGNA A., SALVETTI A., VITAMIN C IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION BY RESTORING NITRIC OXIDE ACTIVITY IN ESSENTIAL HYPERTENSION, CIRCULATION, 97, PP. 2222-2229, (1998); ITO K., AKITA H., KANAZAWA K., YAMADA S., TERASHIMA M., MATSUDA Y., ET AL., COMPARISON OF EFFECTS OF ASCORBIC ACID ON ENDOTHELIUM-DEPENDENT VASODILATION IN PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE SECONDARY TO IDIOPATHIC DILATED CARDIOMYOPATHY VERSUS PATIENTS WITH EFFORT ANGINA PECTORIS SECONDARY TO CORONARY ARTERY DISEASE, AM. J. CARDIOL., 82, PP. 762-767, (1998); PERTICONE F., CERAVOLO R., MAIO R., CLORO C., CANDIGLIOTA M., SCOZZAFAVA A., ET AL., EFFECTS OF ATORVASTATIN AND VITAMIN C ON ENDOTHELIAL FUNCTION OF HYPERCHOLESTEROLEMIC PATIENTS, ATHEROSCLEROSIS, 152, PP. 511-518, (2000); NATALI A., SIRONI A.M., TOSCHI E., CAMASTRA S., SANNA G., PERISSINOTTO A., ET AL., EFFECT OF VITAMIN C ON FOREARM BLOOD FLOW AND GLUCOSE METABOLISM IN ESSENTIAL HYPERTENSION, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 2401-2406, (2000); PERTICONE F., CERAVOLO R., CANDIGLIOTA M., VENTURE G., LACOPINO S., SINOPOLI F., ET AL., OBESITY AND BODY FAT DISTRIBUTION INDUCE ENDOTHELIAL DYSFUNCTION BY OXIDATIVE STRESS: PROTECTIVE EFFECT OF VITAMIN C, DIABETES, 50, PP. 159-165, (2001); BECKMAN J.A., GOLDFINE A.B., GORDON M.B., CREAGER M.A., ASCORBATE RESTORES ENDOTHELIUM-DEPENDENT VASODILATION IMPAIRED BY ACUTE HYPERGLYCEMIA IN HUMANS, CIRCULATION, 103, PP. 1618-1623, (2001); SCHINDLER T.H., MAGOSAKI N., JESERICH M., OLSCHEWSKI M., NITZSCHE E., HOLUBARSCH C., ET AL., EFFECT OF ASCORBIC ACID ON ENDOTHELIAL DYSFUNCTION OF EPICARDIAL CORONARY ARTERIES IN CHRONIC SMOKERS ASSESSED BY COLD PRESSOR TESTING, CARDIOLOGY, 94, PP. 239-246, (2000); HAMABE A., TAKASE B., UEHATA A., KURITA A., OHSUZU F., TAMAI S., IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION IN THE BRACHIAL ARTERY IN VARIANT ANGINA PECTORIS AND THE EFFECT OF INTRAVENOUS ADMINISTRATION OF VITAMIN C, AM. J. CARDIOL., 87, PP. 1154-1159, (2001); WILLIAMS M.J., SUTHERLAND W.H., MCCORMICK M.P., DE JONG S.A., MCDONALD J.R., WALKER R.J., VITAMIN C IMPROVES ENDOTHELIAL DYSFUNCTION IN RENAL ALLOGRAFT RECIPIENTS, NEPHROL. DIAL. TRANSPLANT., 16, PP. 1251-1255, (2001); TADDEI S., VIRDIS A., GHIADONI L., SALVETTI G., BERNINI G., MAGAGNA A., ET AL., AGE-RELATED REDUCTION OF NO AVAILABILITY AND OXIDATIVE STRESS IN HUMANS, HYPERTENSION, 38, PP. 274-279, (2001); PLEINER J., SCHALLER G., MITTERMAYER F., BAYERLE-EDER M., RODEN M., WOLZT M., FFA-INDUCED ENDOTHELIAL DYSFUNCTION CAN BE CORRECTED BY VITAMIN C, J. CLIN. ENDOCRINOL. METAB., 87, PP. 2913-2917, (2002); OGAWA T., KIMOTO M., SASAOKA K., PURIFICATION AND PROPERTIES OF A NEW ENZYME, NG,NG- DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, FROM RAT KIDNEY, J. BIOL. CHEM., 264, PP. 10205-10209, (1989); LEIPER J.M., SANTA M.J., CHUBB A., MACALLISTER R.J., CHARLES I.G., WHITLEY G.S., ET AL., IDENTIFICATION OF TWO HUMAN DIMETHYLARGININE DIMETHYLAMINOHYDROLASES WITH DISTINCT TISSUE DISTRIBUTIONS AND HOMOLOGY WITH MICROBIAL ARGININE DEIMINASES, BIOCHEM. J., 343, PART 1, PP. 209-214, (1999); MACALLISTER R.J., PARRY H., KIMOTO M., OGAWA T., RUSSELL R.J., HODSON H., ET AL., REGULATION OF NITRIC OXIDE SYNTHESIS BY DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, BR. J. PHARMACOL., 119, PP. 1533-1540, (1996); VALLANCE P., LEONE A., CALVER A., COLLIER J., MONCADA S., ENDOGENOUS DIMETHYLARGININE AS AN INHIBITOR OF NITRIC OXIDE SYNTHESIS, J. CARDIOVASC. PHARMACOL., 20, SUPPL. 12, (1992); LEIPER J., VALLANCE P., BIOLOGICAL SIGNIFICANCE OF ENDOGENOUS METHYLARGININES THAT INHIBIT NITRIC OXIDE SYNTHASES, CARDIOVASC. RES., 43, PP. 542-548, (1999); ITO A., TSAO P.S., ADIMOOLAM S., KIMOTO M., OGAWA T., COOKE J.P., NOVEL MECHANISM FOR ENDOTHELIAL DYSFUNCTION: DYSREGULATION OF DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, CIRCULATION, 99, PP. 3092-3095, (1999); STUHLINGER M.C., TSAO P.S., HER J.H., KIMOTO M., BALINT R.F., COOKE J.P., HOMOCYSTEINE IMPAIRS THE NITRIC OXIDE SYNTHASE PATHWAY: ROLE OF ASYMMETRIC DIMETHYLARGININE, CIRCULATION, 104, PP. 2569-2575, (2001); STUHLINGER M.C., ABBASI F., CHU J.W., LAMENDOLA C., MCLAUGHLIN T.L., COOKE J.P., ET AL., RELATIONSHIP BETWEEN INSULIN RESISTANCE AND AN ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITOR, JAMA, 287, PP. 1420-1426, (2002); MCCARTY M.F., VASCULAR ENDOTHELIUM IS THE ORGAN CHIEFLY RESPONSIBLE FOR THE CATABOLISM OF PLASMA ASYMMETRIC DIMETHYLARGININE - AN EXPLANATION FOR THE ELEVATION OF PLASMA ADMA IN DISORDERS CHARACTERIZED BY ENDOTHELIAL DYSFUNCTION, MED. HYPOTHESES, (2002); COOKE J.P., DOES ADMA CAUSE ENDOTHELIAL DYSFUNCTION?, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 2032-2037, (2000); COOKE J.P., OKA R.K., ATHEROGENESIS AND THE ARGININE HYPOTHESIS, CURR. ATHEROSCLER. REP., 3, PP. 252-259, (2001); WASCHER T.C., POSCH K., WALLNER S., HERMETTER A., KOSTNER G.M., GRAIER W.F., VASCULAR EFFECTS OF L-ARGININE: ANYTHING BEYOND A SUBSTRATE FOR THE NO-SYNTHASE?, BIOCHEM. BIOPHYS. RES. COMMUN., 234, PP. 35-38, (1997); BOGER R.H., BODE-BOGER S.M., MUGGE A., KIENKE S., BRANDES R., DWENGER A., ET AL., SUPPLEMENTATION OF HYPERCHOLESTEROLAEMIC RABBITS WITH L-ARGININE REDUCES THE VASCULAR RELEASE OF SUPEROXIDE ANIONS AND RESTORES NO PRODUCTION, ATHEROSCLEROSIS, 317, PP. 273-284, (1995); HELLER R., MUNSCHER-PAULIG F., GRABNER R., TILL U., L-ASCORBIC ACID POTENTIATES NITRIC OXIDE SYNTHESIS IN ENDOTHELIAL CELLS, J. BIOL. CHEM., 274, PP. 8254-8260, (1999); HUANG A., VITA J.A., VENEMA R.C., KEANEY J.F.J., ASCORBIC ACID ENHANCES ENDOTHELIAL NITRIC-OXIDE SYNTHASE ACTIVITY BY INCREASING INTRACELLULAR TETRAHYDROBIOPTERIN, J. BIOL. CHEM., 275, PP. 17399-17406, (2000); STROES E., KASTELEIN J., COSENTINO F., ERKELENS W., WEVER R., KOOMANS H., ET AL., TETRAHYDROBIOPTERIN RESTORES ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLEMIA, J. CLIN. INVEST., 99, PP. 41-46, (1997); MAIER W., COSENTINO F., LUTOLF R.B., FLEISCH M., SEILER C., HESS O.M., ET AL., TETRAHYDROBIOPTERIN IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE, J. CARDIOVASC. PHARMACOL., 35, PP. 173-178, (2000); HEITZER T., KROHN K., ALBERS S., MEINERTZ T., TETRAHYDROBIOPTERIN IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION BY INCREASING NITRIC OXIDE ACTIVITY IN PATIENTS WITH TYPE II DIABETES MELLITUS, DIABETOLOGIA, 43, PP. 1435-1438, (2000); SETOGUCHI S., MOHRI M., SHIMOKAWA H., TAKESHITA A., TETRAHYDROBIOPTERIN IMPROVES ENDOTHELIAL DYSFUNCTION IN CORONARY MICROCIRCULATION IN PATIENTS WITHOUT EPICARDIAL CORONARY ARTERY DISEASE, J. AM. COLL. CARDIOL., 38, PP. 493-498, (2001); FUKUDA Y., TERAGAWA H., MATSUDA K., YAMAGATA T., MATSUURA H., CHAYAMA K., TETRAHYDROBIOPTERIN RESTORES ENDOTHELIAL FUNCTION OF CORONARY ARTERIES IN PATIENTS WITH HYPERCHOLESTEROLAEMIA, HEART, 87, PP. 264-269, (2002); SETOGUCHI S., HIROOKA Y., ESHIMA K., SHIMOKAWA H., TAKESHITA A., TETRAHYDROBIOPTERIN IMPROVES IMPAIRED ENDOTHELIUM-DEPENDENT FOREARM VASODILATION IN PATIENTS WITH HEART FAILURE, J. CARDIOVASC. PHARMACOL., 39, PP. 363-368, (2002); HIGASHI Y., SASAKI S., NAKAGAWA K., FUKUDA Y., MATSUURA H., OSHIMA T., ET AL., TETRAHYDROBIOPTERIN ENHANCES FOREARM VASCULAR RESPONSE TO ACETYLCHOLINE IN BOTH NORMOTENSIVE AND HYPERTENSIVE INDIVIDUALS, AM. J. HYPERTENS., 15, PP. 326-332, (2002); FUKUDA Y., TERAGAWA H., MATSUDA K., YAMAGATA T., MATSUURA H., CHAYAMA K., TETRAHYDROBIOPTERIN IMPROVES CORONARY ENDOTHELIAL FUNCTION, BUT DOES NOT PREVENT CORONARY SPASM IN PATIENTS WITH VASOSPASTIC ANGINA, CIRC. J., 66, PP. 58-62, (2002); UEDA S., MATSUOKA H., MIYAZAKI H., USUI M., OKUDA S., IMAIZUMI T., TETRAHYDROBIOPTERIN RESTORES ENDOTHELIAL FUNCTION IN LONG-TERM SMOKERS, J. AM. COLL. CARDIOL., 35, PP. 71-75, (2000); HEITZER T., BROCKHOFF C., MAYER B., WARNHOLTZ A., MOLLNAU H., HENNE S., ET AL., TETRAHYDROBIOPTERIN IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION IN CHRONIC SMOKERS: EVIDENCE FOR A DYSFUNCTIONAL NITRIC OXIDE SYNTHASE, CIRC. RES., 86, (2000); MILSTIEN S., KATUSIC Z., OXIDATION OF TETRAHYDROBIOPTERIN BY PEROXYNITRITE: IMPLICATIONS FOR VASCULAR ENDOTHELIAL FUNCTION, BIOCHEM. BIOPHYS. RES. COMMUN., 263, PP. 681-684, (1999); KINOSHITA H., MILSTIEN S., WAMBI C., KATUSIC Z.S., INHIBITION OF TETRAHYDROBIOPTERIN BIOSYNTHESIS IMPAIRS ENDOTHELIUM-DEPENDENT RELAXATIONS IN CANINE BASILAR ARTERY, AM. J. PHYSIOL., 273, (1997); SHINOZAKI K., NISHIO Y., OKAMURA T., YOSHIDA Y., MAEGAWA H., KOJIMA H., ET AL., ORAL ADMINISTRATION OF TETRAHYDROBIOPTERIN PREVENTS ENDOTHELIAL DYSFUNCTION AND VASCULAR OXIDATIVE STRESS IN THE AORTAS OF INSULIN-RESISTANT RATS, CIRC. RES., 87, PP. 566-573, (2000); ISHII M., SHIMIZU S., NAGAI T., SHIOTA K., KIUCHI Y., YAMAMOTO T., STIMULATION OF TETRAHYDROBIOPTERIN SYNTHESIS INDUCED BY INSULIN: POSSIBLE INVOLVEMENT OF PHOSPHATIDYLINOSITOL 3-KINASE, INT. J. BIOCHEM. CELL. BIOL., 33, PP. 65-73, (2001); GORREN A.C., LIST B.M., SCHRAMMEL A., FITTERS E., HEMMENS B., WEMER E.R., ET AL., TETRAHYDROBIOPTERIN-FREE NEURONAL NITRIC OXIDE SYNTHASE: EVIDENCE FOR TWO IDENTICAL HIGHLY ANTICOOPERATIVE PTERIDINE BINDING SITES, BIOCHEMISTRY., 35, PP. 16735-16745, (1996); WEVER R.M., LUSCHER T.F., COSENTINO F., RABELINK T.J., ATHEROSCLEROSIS AND THE TWO FACES OF ENDOTHELIAL NITRIC OXIDE SYNTHASE, CIRCULATION, 97, PP. 108-112, (1998); GOKCE N., KEANEY J.F.J., FREI B., HOLBROOK M., OLESIAK M., ZACHARIAH B.J., ET AL., LONG-TERM ASCORBIC ACID ADMINISTRATION REVERSES ENDOTHELIAL VASOMOTOR DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE, CIRCULATION, 99, PP. 3234-3240, (1999); ELLIS G.R., ANDERSON R.A., LANG D., BLACKMAN D.J., MORRIS R.H., MORRIS-THURGOOD J., ET AL., NEUTROPHIL SUPEROXIDE ANION-GENERATING CAPACITY, ENDOTHELIAL FUNCTION AND OXIDATIVE STRESS IN CHRONIC HEART FAILURE: EFFECTS OF SHORT- AND LONG-TERM VITAMIN C THERAPY, J. AM. COLL. CARDIOL., 36, PP. 1474-1482, (2000); LEVINE G.N., FREI B., KOULOURIS S.N., GERHARD M.D., KEANEY J.F.J., VITA J.A., ASCORBIC ACID REVERSES ENDOTHELIAL VASOMOTOR DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE, CIRCULATION, 93, PP. 1107-1113, (1996); CHAMBERS J.C., MCGREGOR A., JEAN-MARIE J., OBEID O.A., KOONER J.S., DEMONSTRATION OF RAPID ONSET VASCULAR ENDOTHELIAL DYSFUNCTION AFTER HYPERHOMOCYSTEINEMIA: AN EFFECT REVERSIBLE WITH VITAMIN C THERAPY, CIRCULATION, 99, PP. 1156-1160, (1999); MAYS B.W., FREISCHLAG J.A., EGINTON M.T., CAMBRIA R.A., SEABROOK G.R., TOWNE J.B., ASCORBIC ACID PREVENTS CIGARETTE SMOKE INJURY TO ENDOTHELIUM-DEPENDENT ARTERIAL RELAXATION, J. SURG. RES., 84, PP. 35-39, (1999); LEKAKIS J.P., ANASTASIOU E.A., PAPAMICHAEL C.M., STAMATELOPOULOS K.S., DAGRE A.G., ALEVIZAKI M.C., ET AL., SHORT-TERM ORAL ASCORBIC ACID IMPROVES ENDOTHELIUM-DEPENDENT VASODILATATION IN WOMEN WITH A HISTORY OF GESTATIONAL DIABETES MELLITUS, DIABETES CARE, 23, PP. 1432-1434, (2000); WILLIAMS M.J., SUTHERLAND W.H., MCCORMICK M.P., DE JONG S.A., MCDONALD J.R., WALKER R.J., VITAMIN C IMPROVES ENDOTHELIAL DYSFUNCTION IN RENAL ALLOGRAFT RECIPIENTS, NEPHROL. DIAL. TRANSPLANT., 16, PP. 1251-1255, (2001); LING L., ZHAO S.P., GAO M., ZHOU Q.C., LI Y.L., XIA B., VITAMIN C PRESERVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AFTER A HIGH-FAT MEAL, CLIN. CARDIOL., 25, PP. 219-224, (2002); PULLIN C.H., BONHAM J.R., MCDOWELL I.F., LEE P.J., POWERS H.J., WILSON J.F., ET AL., VITAMIN C THERAPY AMELIORATES VASCULAR ENDOTHELIAL DYSFUNCTION IN TREATED PATIENTS WITH HOMOCYSTINURIA, J. INHERIT. METAB. DIS., 25, PP. 107-118, (2002); WILMINK H.W., STROES E.S., ERKELENS W.D., GERRITSEN W.B., WEVER R., BANGA J.D., ET AL., INFLUENCE OF FOLIC ACID ON POSTPRANDIAL ENDOTHELIAL DYSFUNCTION, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 185-188, (2000); EK A., STROM K., COTGREAVE I.A., THE UPTAKE OF ASCORBIC ACID INTO HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS AND ITS EFFECT ON OXIDANT INSULT, BIOCHEM. PHARMACOL., 50, PP. 1339-1346, (1995); VERHAAR M.C., STROES E., RABELINK T.J., FOLATES AND CARDIOVASCULAR DISEASE, ARTERIOSCLER. THROMB. VASC. BIOL., 22, PP. 6-13, (2002); STROES E.S., VAN FAASSEN E.E., YO M., MARTASEK P., BOER P., GOVERS R., ET AL., FOLIC ACID REVERTS DYSFUNCTION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE, CIRC. RES., 86, PP. 1129-1134, (2000); HYNDMAN M.E., VERMA S., ROSENFELD R.J., ANDERSON T.J., PARSONS H.G., INTERACTION OF 5-METHYLTETRAHYDROFOLATE AND TETRAHYDROBIOPTERIN ON ENDOTHELIAL FUNCTION, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 282, (2002); VERHAAR M.C., WEVER R.M., KASTELEIN J.J., VAN DAM T., KOOMANS H.A., RABELINK T.J., 5-METHYLTETRAHYDROFOLATE, THE ACTIVE FORM OF FOLIC ACID, RESTORES ENDOTHELIAL FUNCTION IN FAMILIAL HYPERCHOLESTEROLEMIA, CIRCULATION, 97, PP. 237-241, (1998); DE VRIESE A.S., VAN D.V., BLOM H.J., VANHOUTTE P.M., VERBEKE M., LAMEIRE N.H., THE IMPAIRED RENAL VASODILATOR RESPONSE ATTRIBUTED TO ENDOTHELIUM-DERIVED HYPERPOLARIZING FACTOR IN STREPTOZOTOCIN-INDUCED DIABETIC RATS IS RESTORED BY 5-METHYLTETRAHYDROFOLATE, DIABETOLOGIA, 43, PP. 1116-1125, (2000); VAN ETTEN R.W., DE KONING E.J., VERHAAR M.C., GAILLARD C.A., RABELINK T.J., IMPAIRED NO-DEPENDENT VASODILATION IN PATIENTS WITH TYPE II (NON-INSULIN-DEPENDENT) DIABETES MELLITUS IS RESTORED BY ACUTE ADMINISTRATION OF FOLATE, DIABETOLOGIA, 45, PP. 1004-1010, (2002); DOSHI S.N., MCDOWELL I.F., MOAT S.J., LANG D., NEWCOMBE R.G., KREDAN M.B., ET AL., FOLATE IMPROVES ENDOTHELIAL FUNCTION IN CORONARY ARTERY DISEASE: AN EFFECT MEDIATED BY REDUCTION OF INTRACELLULAR SUPEROXIDE?, ARTERIOSCLER. THROMB. VASC. BIOL., 21, PP. 1196-1202, (2001); KAUFMAN S., SOME METABOLIC RELATIONSHIPS BETWEEN BIOPTERIN AND FOLATE: IMPLICATIONS FOR THE ""METHYL TRAP HYPOTHESIS, NEUROCHEM. RES., 16, PP. 1031-1036, (1991); VERHAAR M.C., WEVER R.M., KASTELEIN J.J., VAN LOON D., MILSTIEN S., KOOMANS H.A., ET AL., EFFECTS OF ORAL FOLIC ACID SUPPLEMENTATION ON ENDOTHELIAL FUNCTION IN FAMILIAL HYPERCHOLESTEROLEMIA. A RANDOMIZED PLACEBO-CONTROLLED TRIAL, CIRCULATION, 100, PP. 335-338, (1999); DOSHI S.N., MCDOWELL I.F., MOAT S.J., PAYNE N., DURRANT H.J., LEWIS M.J., ET AL., FOLIC ACID IMPROVES ENDOTHELIAL FUNCTION IN CORONARY ARTERY DISEASE VIA MECHANISMS LARGELY INDEPENDENT OF HOMOCYSTEINE LOWERING, CIRCULATION, 105, PP. 22-26, (2002); GORI T., BURSTEIN J.M., AHMED S., MINER S.E., AL-HESAYEN A., KELLY S., ET AL., FOLIC ACID PREVENTS NITROGLYCERIN-INDUCED NITRIC OXIDE SYNTHASE DYSFUNCTION AND NITRATE TOLERANCE: A HUMAN IN VIVO STUDY, CIRCULATION, 104, PP. 1119-1123, (2001); UBBINK J.B., THE ROLE OF VITAMINS IN THE PATHOGENESIS AND TREATMENT OF HYPERHOMOCYST (E)INAEMIA, J. INHERIT. METAB. DIS., 20, PP. 316-325, (1997); BARCHOWSKY A., MUNRO S.R., MORANA S.J., VINCENTI M.P., TREADWELL M., OXIDANT-SENSITIVE AND PHOSPHORYLATION-DEPENDENT ACTIVATION OF NF-KAPPA B AND AP-1 IN ENDOTHELIAL CELLS, AM. J. PHYSIOL., 269, (1995); PUEYO M.E., GONZALEZ W., NICOLETTI A., SAVOIE F., ARNAL J.F., MICHEL J.B., ANGIOTENSIN II STIMULATES ENDOTHELIAL VASCULAR CELL ADHESION MOLECULE-1 VIA NUCLEAR FACTOR-KAPPAB ACTIVATION INDUCED BY INTRACELLULAR OXIDATIVE STRESS, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 645-651, (2000); OGATA N., YAMAMOTO H., KUGIYAMA K., YASUE H., MIYAMOTO E., INVOLVEMENT OF PROTEIN KINASE C IN SUPEROXIDE ANION-INDUCED ACTIVATION OF NUCLEAR FACTOR-KAPPA B IN HUMAN ENDOTHELIAL CELLS, CARDIOVASC. RES., 45, PP. 513-521, (2000); PENG H.B., LIBBY P., LIAO J.K., INDUCTION AND STABILIZATION OF I KAPPA B ALPHA BY NITRIC OXIDE MEDIATES INHIBITION OF NF-KAPPA B, J. BIOL. CHEM., 270, PP. 14214-14219, (1995); DE CATERINA R., LIBBY P., PENG H.B., THANNICKAL V.J., RAJAVASHISTH T.B., GIMBRONE M.A.J., ET AL., NITRIC OXIDE DECREASES CYTOKINE-INDUCED ENDOTHELIAL ACTIVATION. NITRIC OXIDE SELECTIVELY REDUCES ENDOTHELIAL EXPRESSION OF ADHESION MOLECULES AND PROINFLAMMATORY CYTOKINES, J. CLIN. INVEST., 96, PP. 60-68, (1995); LAROUX F.S., LEFER D.J., KAWACHI S., SCALIA R., COCKRELL A.S., GRAY L., ET AL., ROLE OF NITRIC OXIDE IN THE REGULATION OF ACUTE AND CHRONIC INFLAMMATION, ANTIOXID. REDOX SIGNAL, 2, PP. 391-396, (2000); JIANG J., VALEN G., TOKUNO S., THOREN P., PERNOW J., ENDOTHELIAL DYSFUNCTION IN ATHEROSCLEROTIC MICE: IMPROVED RELAXATION BY COMBINED SUPPLEMENTATION WITH L-ARGININE-TETRAHYDROBIOPTERIN AND ENHANCED VASOCONSTRICTION BY ENDOTHELIN, BR. J. PHARMACOL., 131, PP. 1255-1261, (2000); MEYER J.W., SCHMITT M.E., A CENTRAL ROLE FOR THE ENDOTHELIAL NADPH OXIDASE IN ATHEROSCLEROSIS, FEBS LETT., 472, PP. 1-4, (2000); HEINLOTH A., HEERMEIER K., RAFF U., WANNER C., GALLE J., STIMULATION OF NADPH OXIDASE BY OXIDIZED LOW-DENSITY LIPOPROTEIN INDUCES PROLIFERATION OF HUMAN VASCULAR ENDOTHELIAL CELLS, J. AM. SOC. NEPHROL., 11, PP. 1819-1825, (2000); INOUE N., TAKESHITA S., GAO D., ISHIDA T., KAWASHIMA S., AKITA H., ET AL., LYSOPHOSPHATIDYLCHOLINE INCREASES THE SECRETION OF MATRIX METALLOPROTEINASE 2 THROUGH THE ACTIVATION OF NADH/NADPH OXIDASE IN CULTURED AORTIC ENDOTHELIAL CELLS, ATHEROSCLEROSIS, 155, PP. 45-52, (2001); RUECKSCHLOSS U., GALLE J., HOLTZ J., ZERKOWSKI H.R., MORAWIETZ H., INDUCTION OF NAD(P)H OXIDASE BY OXIDIZED LOW-DENSITY LIPOPROTEIN IN HUMAN ENDOTHELIAL CELLS: ANTIOXIDATIVE POTENTIAL OF HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR THERAPY, CIRCULATION, 104, PP. 1767-1772, (2001); MEYER J.W., HOLLAND J.A., ZIEGLER L.M., CHANG M.M., BEEBE G., SCHMITT M.E., IDENTIFICATION OF A FUNCTIONAL LEUKOCYTE-TYPE NADPH OXIDASE IN HUMAN ENDOTHELIAL CELLS: A POTENTIAL ATHEROGENIC SOURCE OF REACTIVE OXYGEN SPECIES, ENDOTHELIUM, 7, PP. 11-22, (1999); INOGUCHI T., LI P., UMEDA F., YU H.Y., KAKIMOTO M., IMAMURA M., ET AL., HIGH GLUCOSE LEVEL AND FREE FATTY ACID STIMULATE REACTIVE OXYGEN SPECIES PRODUCTION THROUGH PROTEIN KINASE C- DEPENDENT ACTIVATION OF NAD(P)H OXIDASE IN CULTURED VASCULAR CELLS, DIABETES, 49, PP. 1939-1945, (2000); KASHIWAGI A., SHINOZAKI K., NISHIO Y., MAEGAWA H., MAENO Y., KANAZAWA A., ET AL., ENDOTHELIUM-SPECIFIC ACTIVATION OF NAD(P)H OXIDASE IN AORTAS OF EXOGENOUSLY HYPERINSULINEMIC RATS, AM. J. PHYSIOL., 277, (1999); KASHIWAGI A., SHINOZAKI K., NISHIO Y., OKAMURA T., TODA N., KIKKAWA R., FREE RADICAL PRODUCTION IN ENDOTHELIAL CELLS AS A PATHOGENETIC FACTOR FOR VASCULAR DYSFUNCTION IN THE INSULIN RESISTANCE STATE, DIABETES RES. CLIN. PRACT., 45, PP. 199-203, (1999); MCCARTY M.F., ENDOTHELIAL MEMBRANE POTENTIAL REGULATES PRODUCTION OF BOTH NITRIC OXIDE AND SUPEROXIDE-FUNDAMENTAL DETERMINANT OF VASCULAR HEALTH, MED. HYPOTHESES, 53, PP. 277-289, (1999); FEDOROVA O.V., TALAN M.I., AGALAKOVA N.I., LAKATTA E.G., BAGROV A.Y., ENDOGENOUS LIGAND OF ALPHA (L) SODIUM PUMP, MARINOBUFAGENIN, IS A NOVEL MEDIATOR OF SODIUM CHLORIDE-DEPENDENT HYPERTENSION, CIRCULATION, 105, PP. 1122-1127, (2002); LENDA D.M., SAULS B.A., BOEGEHOLD M.A., REACTIVE OXYGEN SPECIES MAY CONTRIBUTE TO REDUCED ENDOTHELIUM-DEPENDENT DILATION IN RATS FED HIGH SALT, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 279, (2000); HOWARD A.B., ALEXANDER R.W., NEREM R.M., GRIENDLING K.K., TAYLOR W.R., CYCLIC STRAIN INDUCES AN OXIDATIVE STRESS IN ENDOTHELIAL CELLS, AM. J. PHYSIOL., 272, (1997); WUNG B.S., CHENG J.J., SHYUE S.K., WANG D.L., NO MODULATES MONOCYTE CHEMOTACTIC PROTEIN-1 EXPRESSION IN ENDOTHELIAL CELLS UNDER CYCLIC STRAIN, ARTERIOSCLER. THROMB. VASC. BIOL., 21, PP. 1941-1947, (2001); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS THROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 61-69, (2000); THAKUR N.K., HAYASHI T., SUMI D., KANO H., TSUNEKAWA T., IGUCHI A., HMG-COA REDUCTASE INHIBITOR STABILIZES RABBIT ATHEROMA BY INCREASING BASAL NO AND DECREASING SUPEROXIDE, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); LAUFS U., LIAO J.K., POST-TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA STABILITY BY RHO GTPASE, J. BIOL. CHEM., 273, PP. 24266-24271, (1998); ENDRES M., LAUFS U., HUANG Z., NAKAMURA T., HUANG P., MOSKOWITZ M.A., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC. NATL. ACAD. SCI. USA, 95, PP. 8880-8885, (1998); WASSMANN S., LAUFS U., BAUMER A.T., MULLER K., AHLBORY K., LINZ W., ET AL., HMG-COA REDUCTASE INHIBITORS IMPROVE ENDOTHELIAL DYSFUNCTION IN NORMOCHOLESTEROLEMIC HYPERTENSION VIA REDUCED PRODUCTION OF REACTIVE OXYGEN SPECIES, HYPERTENSION, 37, PP. 1450-1457, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); WAGNER A.H., SCHROETER M.R., HECKER M., 17BETA-ESTRADIOL INHIBITION OF NADPH OXIDASE EXPRESSION IN HUMAN ENDOTHELIAL CELLS, FASEB J., 15, PP. 2121-2130, (2001); DANTAS A.P., TOSTES R.C., FORTES Z.B., COSTA S.G., NIGRO D., CARVALHO M.H., IN VIVO EVIDENCE FOR ANTIOXIDANT POTENTIAL OF ESTROGEN IN MICROVESSELS OF FEMALE SPONTANEOUSLY HYPERTENSIVE RATS, HYPERTENSION, 39, PP. 405-411, (2002); WASSMANN S., LAUFS U., STAMENKOVIC D., LINZ W., STASCH J.P., AHLBORY K., ET AL., RALOXIFENE IMPROVES ENDOTHELIAL DYSFUNCTION IN HYPERTENSION BY REDUCED OXIDATIVE STRESS AND ENHANCED NITRIC OXIDE PRODUCTION, CIRCULATION, 105, PP. 2083-2091, (2002); KAPPAGODA C.T., ENDOTHELIAL NITRIC OXIDE SYNTHASE AND ESTROGEN, CARDIOVASC. RES., 47, PP. 9-10, (2000); ANDERSEN M.R., STENDER S., ENDOTHELIAL NITRIC OXIDE SYNTHASE ACTIVITY IN AORTA OF NORMOCHOLESTEROLEMIC RABBITS: REGIONAL VARIATION AND THE EFFECT OF ESTROGEN, CARDIOVASC. RES., 47, PP. 192-199, (2000); MCNEILL A.M., ZHANG C., STANCZYK F.Z., DUCKLES S.P., KRAUSE D.N., ESTROGEN INCREASES ENDOTHELIAL NITRIC OXIDE SYNTHASE VIA ESTROGEN RECEPTORS IN RAT CEREBRAL BLOOD VESSELS: EFFECT PRESERVED AFTER CONCURRENT TREATMENT WITH MEDROXYPROGESTERONE ACETATE OR PROGESTERONE, STROKE, 33, PP. 1685-1691, (2002); YANG A.L., TSAI S.J., JIANG M.J., JEN C.J., CHEN H., CHRONIC EXERCISE INCREASES BOTH INDUCIBLE AND ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE EXPRESSION IN ENDOTHELIAL CELLS OF RAT AORTA, J. BIOMED. SCI., 9, PP. 149-155, (2002); NADAUD S., PHILIPPE M., ARNAL J.F., MICHEL J.B., SOUBRIER F., SUSTAINED INCREASE IN AORTIC ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION IN VIVO IN A MODEL OF CHRONIC HIGH BLOOD FLOW, CIRC. RES., 79, PP. 857-863, (1996); XIAO Z., ZHANG Z., RANJAN V., DIAMOND S.L., SHEAR STRESS INDUCTION OF THE ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE IS CALCIUM-DEPENDENT BUT NOT CALCIUM-ACTIVATED, J. CELL. PHYSIOL., 171, PP. 205-211, (1997); SILACCI P., FORMENTIN K., BOUZOURENE K., DANIEL F., BRUNNER H.R., HAYOZ D., UNIDIRECTIONAL AND OSCILLATORY SHEAR STRESS DIFFERENTIALLY MODULATE NOS III GENE EXPRESSION, NITRIC OXIDE, 4, PP. 47-56, (2000); DAVIS M.E., CAI H., DRUMMOND G.R., HARRISON D.G., SHEAR STRESS REGULATES ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION THROUGH C-SRC BY DIVERGENT SIGNALING PATHWAYS, CIRC. RES., 89, PP. 1073-1080, (2001); TESTA M., ENNEZAT P.V., VIKSTROM K.L., DEMOPOULOS L., GENTILUCCI M., LOPERFIDO F., ET AL., MODULATION OF VASCULAR ENDOTHELIAL GENE EXPRESSION BY PHYSICAL TRAINING IN PATIENTS WITH CHRONIC HEART FAILURE, ITAL. HEART J., 1, PP. 426-430, (2000); GRIFFIN K.L., WOODMAN C.R., PRICE E.M., LAUGHLIN M.H., PARKER J.L., ENDOTHELIUM-MEDIATED RELAXATION OF PORCINE COLLATERAL-DEPENDENT ARTERIOLES IS IMPROVED BY EXERCISE TRAINING, CIRCULATION, 104, PP. 1393-1398, (2001); GIELEN S., HAMBRECHT R., EFFECTS OF EXERCISE TRAINING ON VASCULAR FUNCTION AND MYOCARDIAL PERFUSION, CARDIOL. CLIN., 19, PP. 357-368, (2001); YOSHIZUMI M., PERRELLA M.A., BURNETT J.C.J., LEE M.E., TUMOR NECROSIS FACTOR DOWNREGULATES AN ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA BY SHORTENING ITS HALF-LIFE, CIRC. RES., 73, PP. 205-209, (1993); ALONSO J., DM S., MONTON M., CASADO S., LOPEZ-FARRE A., ENDOTHELIAL CYTOSOLIC PROTEINS BIND TO THE 3' UNTRANSLATED REGION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA: REGULATION BY TUMOR NECROSIS FACTOR ALPHA, MOL. CELL. BIOL., 17, PP. 5719-5726, (1997); GONZALEZ-FERNANDEZ F., JIMENEZ A., LOPEZ-BLAYA A., VELASCO S., ARRIERO M.M., CELDRAN A., ET AL., CERIVASTATIN PREVENTS TUMOR NECROSIS FACTOR-ALPHA-INDUCED DOWNREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE: ROLE OF ENDOTHELIAL CYTOSOLIC PROTEINS, ATHEROSCLEROSIS, 155, PP. 61-70, (2001); KUBOKI K., JIANG Z.Y., TAKAHARA N., HA S.W., IGARASHI M., YAMAUCHI T., ET AL., REGULATION OF ENDOTHELIAL CONSTITUTIVE NITRIC OXIDE SYNTHASE GENE EXPRESSION IN ENDOTHELIAL CELLS AND IN VIVO: A SPECIFIC VASCULAR ACTION OF INSULIN, CIRCULATION, 101, PP. 676-681, (2000); ALJADA A., DANDONA P., EFFECT OF INSULIN ON HUMAN AORTIC ENDOTHELIAL NITRIC OXIDE SYNTHASE, METABOLISM, 49, PP. 147-150, (2000); DING Y., VAZIRI N.D., COULSON R., KAMANNA V.S., ROH D.D., EFFECTS OF SIMULATED HYPERGLYCEMIA, INSULIN, AND GLUCAGON ON ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION, AM. J. PHYSIOL. ENDOCRINOL. METAB., 279, (2000); LUCKHOFF A., BUSSE R., CALCIUM INFLUX INTO ENDOTHELIAL CELLS AND FORMATION OF ENDOTHELIUM-DERIVED RELAXING FACTOR IS CONTROLLED BY THE MEMBRANE POTENTIAL, PFLUGERS ARCH., 416, PP. 305-311, (1990); MICHELL B.J., GRIFFITHS J.E., MITCHELHILL K.I., RODRIGUEZ-CRESPO I., TIGANIS T., BOZINOVSKI S., ET AL., THE AKT KINASE SIGNALS DIRECTLY TO ENDOTHELIAL NITRIC OXIDE SYNTHASE, CURR. BIOL., 9, PP. 845-848, (1999); MONTAGNANI M., CHEN H., BARR V.A., QUON M.J., INSULIN-STIMULATED ACTIVATION OF ENOS IS INDEPENDENT OF CA2+ BUT REQUIRES PHOSPHORYLATION BY AKT AT SER (1179, J. BIOL. CHEM., 276, PP. 30392-30398, (2001); LANE P., GROSS S.S., DISABLING A C-TERMINAL AUTOINHIBITORY CONTROL ELEMENT IN ENDOTHELIAL NITRIC-OXIDE SYNTHASE BY PHOSPHORYLATION PROVIDES A MOLECULAR EXPLANATION FOR ACTIVATION OF VASCULAR NO SYNTHESIS BY DIVERSE PHYSIOLOGICAL STIMULI, J. BIOL. CHEM., 277, PP. 19087-19094, (2002); BOO Y.C., SORESCU G., BOYD N., SHIOJIMA I., WALSH K., DU J., ET AL., SHEAR STRESS STIMULATES PHOSPHORYLATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE AT SER 1179 BY AKT-INDEPENDENT MECHANISMS: ROLE OF PROTEIN KINASE A, J. BIOL. CHEM., 277, PP. 3388-3396, (2002); MICHELL B.J., GRIFFITHS J.E., MITCHELHILL K.I., RODRIGUEZ-CRESPO I., TIGANIS T., BOZINOVSKI S., ET AL., THE AKT KINASE SIGNALS DIRECTLY TO ENDOTHELIAL NITRIC OXIDE SYNTHASE, CURR. BIOL., 9, PP. 845-848, (1999); BOGER R.H., SKAMIRA C., BODE-BOGER S.M., BRABANT G., VON ZUR M., FROLICH J.C., NITRIC OXIDE MAY MEDIATE THE HEMODYNAMIC EFFECTS OF RECOMBINANT GROWTH HORMONE IN PATIENTS WITH ACQUIRED GROWTH HORMONE DEFICIENCY. A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, J. CLIN. INVEST., 98, PP. 2706-2713, (1996); BOGER R.H., NITRIC OXIDE AND THE MEDIATION OF THE HEMODYNAMIC EFFECTS OF GROWTH HORMONE IN HUMANS, J. ENDOCRINOL. INVEST., 22, PP. 75-81, (1999); FLEMING I., HECKER M., BUSSE R., INTRACELLULAR ALKALINIZATION INDUCED BY BRADYKININ SUSTAINS ACTIVATION OF THE CONSTITUTIVE NITRIC OXIDE SYNTHASE IN ENDOTHELIAL CELLS, CIRC. RES., 74, PP. 1220-1226, (1994); AYAJIKI K., KINDERMANN M., HECKER M., FLEMING I., BUSSE R., INTRACELLULAR PH AND TYROSINE PHOSPHORYLATION BUT NOT CALCIUM DETERMINE SHEAR STRESS-INDUCED NITRIC OXIDE PRODUCTION IN NATIVE ENDOTHELIAL CELLS SEE COMMENTS, CIRC. RES., 78, PP. 750-758, (1996); MIZUNO S., DEMURA Y., AMESHIMA S., OKAMURA S., MIYAMORI I., ISHIZAKI T., ALKALOSIS STIMULATES ENDOTHELIAL NITRIC OXIDE SYNTHASE IN CULTURED HUMAN PULMONARY ARTERIAL ENDOTHELIAL CELLS, AM. J. PHYSIOL. LUNG CELL. MOL. PHYSIOL., 283, (2002); CELERMAJER D.S., SORENSEN K.E., SPIEGELHALTER D.J., GEORGAKOPOULOS D., ROBINSON J., DEANFIELD J.E., AGING IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION IN HEALTHY MEN YEARS BEFORE THE AGE-RELATED DECLINE IN WOMEN, J. AM. COLL. CARDIOL., 24, PP. 471-476, (1994); LYONS D., ROY S., PATEL M., BENJAMIN N., SWIFT C.G., IMPAIRED NITRIC OXIDE-MEDIATED VASODILATATION AND TOTAL BODY NITRIC OXIDE PRODUCTION IN HEALTHY OLD AGE, CLIN. SCI. (LOND.), 93, PP. 519-525, (1997); TADDEI S., GALETTA F., VIRDIS A., GHIADONI L., SALVETTI G., FRANZONI F., ET AL., PHYSICAL ACTIVITY PREVENTS AGE-RELATED IMPAIRMENT IN NITRIC OXIDE AVAILABILITY IN ELDERLY ATHLETES, CIRCULATION, 101, PP. 2896-2901, (2000); SINGH N., PRASAD S., SINGER D.R., MACALLISTER R.J., AGEING IS ASSOCIATED WITH IMPAIRMENT OF NITRIC OXIDE AND PROSTANOID DILATOR PATHWAYS IN THE HUMAN FOREARM, CLIN. SCI. (LOND.), 102, PP. 595-600, (2002); CSISZAR A., UNGVARI Z., EDWARDS J.G., KAMINSKI P., WOLIN M.S., KOLLER A., ET AL., AGING-INDUCED PHENOTYPIC CHANGES AND OXIDATIVE STRESS IMPAIR CORONARY ARTERIOLAR FUNCTION, CIRC. RES., 90, PP. 1159-1166, (2002); MATSUSHITA H., CHANG E., GLASSFORD A.J., COOKE J.P., CHIU C.P., TSAO P.S., ENOS ACTIVITY IS REDUCED IN SENESCENT HUMAN ENDOTHELIAL CELLS: PRESERVATION BY HTERT IMMORTALIZATION, CIRC. RES., 89, PP. 793-798, (2001)","M.F. MCCARTY; PANTOX LABORATORIES, 4622 SANTA FE ST., SAN DIEGO, CA 92109, UNITED STATES; EMAIL: MMCCARTY@NAI-ONLINE.COM","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-8444221172","MED HYPOTHESES","USA","NOTREPORTED;PANTOX LABORATORIES;NOTREPORTED",NA,"MCCARTY MF, 2004, MED HYPOTHESES","MCCARTY MF, 2004, MED HYPOTHESES"
"MERU A;MITTRA S;THYAGARAJAN B;CHUGH A","MERU, ASHWINKUMAR V. (14028581700); MITTRA, SHIVANI (7004619900); THYAGARAJAN, BASKARAN (15056848200); CHUGH, ANITA (9234282800)","INTERMITTENT CLAUDICATION AN OVERVIEW",2006,"ATHEROSCLEROSIS","187","16",96,"10.1016/j.atherosclerosis.2005.11.027","NEW DRUG DISCOVERY RESEARCH, DEPARTMENT OF PHARMACOLOGY, RANBAXY LABORATORIES LIMITED, GURGAON 122001, HARYANA, PLOT 20, INDIA;NEW DRUG DISCOVERY RESEARCH, DEPARTMENT OF PHARMACOLOGY, RANBAXY LABORATORIES LIMITED, GURGAON 122001, HARYANA, PLOT 20, INDIA;NEW DRUG DISCOVERY RESEARCH, DEPARTMENT OF PHARMACOLOGY, RANBAXY LABORATORIES LIMITED, GURGAON 122001, HARYANA, PLOT 20, INDIA;NEW DRUG DISCOVERY RESEARCH, DEPARTMENT OF PHARMACOLOGY, RANBAXY LABORATORIES LIMITED, GURGAON 122001, HARYANA, PLOT 20, INDIA","INTERMITTENT CLAUDICATION (IC) IS DEFINED BY LEG MUSCLE PAIN, CRAMPING AND FATIGUE BROUGHT ON BY AMBULATION/EXERCISE; RELIEVED ON REST; AND CAUSED BY INADEQUATE BLOOD SUPPLY AND IS THE PRIMARY SYMPTOM OF PERIPHERAL ARTERIAL DISEASE (PAD). PAD HAS A DETRIMENTAL EFFECT ON THE QUALITY OF LIFE. PAD IS A DEBILITATING ATHEROSCLEROTIC DISEASE OF THE LOWER LIMBS AND IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR MORBIDITY AND MORTALITY. IC IS AN EXTREMELY IMPORTANT MARKER OF ATHEROMA. UP TO 60% PATIENTS WITH IC HAVE SIGNIFICANT UNDERLYING CORONARY AND/OR CAROTID DISEASE AND 40% OF ALL PATIENTS SUFFERING FROM IC DIE OR SUFFER A STROKE WITHIN 5 YEARS OF PRESENTATION. THE THERAPEUTIC INTERVENTION OF IC ESSENTIALLY AIMS AT PROVIDING SYMPTOMATIC RELIEF AND REDUCING THE SYSTEMIC CARDIOVASCULAR COMPLICATIONS. ALTHOUGH EXERCISE THERAPY IS ONE OF THE MOST EFFICACIOUS CONSERVATIVE TREATMENTS FOR CLAUDICATION, THE PHARMACOTHERAPEUTIC GOALS CAN BE BEST ACHIEVED THROUGH AN INCREASE IN THE WALKING CAPACITY TO IMPROVE QUALITY OF LIFE AND A DECREASE IN RATES OF AMPUTATION. IN THE DEVELOPMENT OF TREATMENT FOR IC, AN AGGRESSIVE NON-PHARMACOLOGICAL INTERVENTION AND PHARMACOLOGICAL TREATMENT OF THE RISK FACTORS ASSOCIATED WITH IC ARE CONSIDERED. IN THE NEXT 2 YEARS, THE RESULTS OF MAJOR TRIALS OF DRUGS THAT STABILIZE AND REGRESS ATHEROSCLEROSIS SUCH AS STATINS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANTI-PLATELET AGENTS, RECOMBINANT GROWTH FACTORS AND IMMUNE MODULATORS WILL BE AVAILABLE FOR IC. LEVOCARNITINE (L-CARNITINE) AND A DERIVATIVE, PROPIONYL LEVOCARNITINE, ARE EMERGING AGENTS THAT INCREASE THE PAIN-FREE WALKING AND IMPROVE THE QUALITY OF LIFE IN IC PATIENTS BY WORKING AT THE METABOLISM AND EXERCISE PERFORMANCE OF ISCHEMIC MUSCLES. THIS ARTICLE PROVIDES A COMPREHENSIVE REVIEW OF THE PATHOPHYSIOLOGY INVOLVED, DIAGNOSIS OF IC AND EXISTING AND EMERGING PHARMACOTHERAPIES WITH RATIONALE FOR THEIR USE IN ITS TREATMENT. © 2005 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.","INTERMITTENT CLAUDICATION; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PHARMACOTHERAPY; RISK FACTORS","HUMANS; INTERMITTENT CLAUDICATION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RISK FACTORS; VASODILATOR AGENTS; ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; BERAPROST; BUFLOMEDIL; C REACTIVE PROTEIN; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ECRAPROST; GINKGO BILOBA EXTRACT; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIMAPROST; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; POLICOSANOL; PROSTAGLANDIN; SARPOGRELATE; SULODEXIDE; THROMBOXANE RECEPTOR BLOCKING AGENT; TICLOPIDINE; TRIACYLGLYCEROL; VASCULOTROPIN; ABDOMINAL CRAMP; ABNORMAL FECES; ANEURYSM RUPTURE; ANKLE BRACHIAL INDEX; ATHEROSCLEROTIC PLAQUE; BLOOD FLOWMETRY; BODY ODOR; BULIMIA; CEREBROVASCULAR DISEASE; COLOR ULTRASOUND FLOWMETRY; DERMATITIS; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DYSPEPSIA; ERYTHEMA; FEMORAL ARTERY; GASTROINTESTINAL SYMPTOM; HEART MUSCLE OXYGEN CONSUMPTION; HEART PALPITATION; HOMOCYSTINURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; INSULIN RESISTANCE; INTERMITTENT CLAUDICATION; LEG EDEMA; LEG ISCHEMIA; LIFE EXPECTANCY; LIFESTYLE; LOOSE FECES; NAUSEA AND VOMITING; NEUTROPENIA; NON INVASIVE MEASUREMENT; OBESITY; PATHOPHYSIOLOGY; POLYURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PULSE WAVE; QUALITY OF LIFE; RESTENOSIS; REVIEW; RISK FACTOR; SCREENING TEST; SECONDARY PREVENTION; SIDE EFFECT; SMOKING; SYMPTOM; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WEIGHT REDUCTION","","","BICK C., INTERMITTENT CLAUDICATION, NURS STAND, 17, PP. 45-52, (2003); DUPREZ D.A., DE BUYZERE M.L., HIRSCH A.T., DEVELOPING PHARMACEUTICAL TREATMENTS FOR PERIPHERAL ARTERY DISEASE, EXPERT OPIN INVESTIG DRUGS, 12, PP. 101-108, (2003); HIATT W.R., PHARMACOLOGIC THERAPY FOR PERIPHERAL ARTERIAL DISEASE AND CLAUDICATION, J VASC SURG, 36, PP. 1283-1291, (2002); LANZER P., VASCULAR MULTIMORBIDITY IN PATIENTS WITH A DOCUMENTED CORONARY ARTERY DISEASE, Z KARDIOL, 8, PP. 650-659, (2003); SCHMIEDER F.A., INTERMITTENT CLAUDICATION: MAGNITUDE OF THE PROBLEM, PATIENT EVALUATION, AND THERAPEUTIC STRATEGIES, AM J CARDIOL, 87, (2001); VASCULAR DISEASE: NURSING AND MANAGEMENT, (2001); LENG G.C., LEE A.J., FOWKES F.G., ET AL., INCIDENCE, NATURAL HISTORY AND CARDIOVASCULAR EVENTS IN SYMPTOMATIC AND ASYMPTOMATIC PERIPHERAL ARTERIAL DISEASE IN THE GENERAL POPULATION, INT J EPIDEMIOL, 25, PP. 1172-1181, (1996); MULUK S.C., MULUK V.S., KELLEY M.E., ET AL., OUTCOME EVENTS IN PATIENTS WITH CLAUDICATION: A 15-YEAR STUDY IN 2777 PATIENTS, J VASC SURG, 33, PP. 251-257, (2001); JELNES R., GAARDSTING O., HOUGAARD JENSEN K., ET AL., FATE IN INTERMITTENT CLAUDICATION: OUTCOME AND RISK FACTORS, BR MED J (CLIN RES ED), 293, PP. 1137-1140, (1986); CRIQUI M.H., LANGER R.D., FRONEK A., ET AL., MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, N ENGL J MED, 326, PP. 381-386, (1992); HOWELL M.A., COLGAN M.P., SEEGER R.W., RAMSEY D.E., SUMNER D.S., RELATIONSHIP OF SEVERITY OF LOWER LIMB PERIPHERAL VASCULAR DISEASE TO MORTALITY AND MORBIDITY: A SIX-YEAR FOLLOW-UP STUDY, J VASC SURG, 9, PP. 691-696, (1989); MCKENNA M., WOLFSON S., KULLER L., THE RATIO OF ANKLE AND ARM ARTERIAL PRESSURE AS AN INDEPENDENT PREDICTOR OF MORTALITY, ATHEROSCLEROSIS, 87, PP. 119-128, (1991); REHRING T.F., SANDHOFF B.G., STOLCPART R.S., MERENICH J.A., HOLLIS JR. H.W., ATHEROSCLEROTIC RISK FACTOR CONTROL IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 41, MAY 5, PP. 816-822, (2005); HIATT W.R., CARNITINE AND PERIPHERAL ARTERIAL DISEASE, ANN N Y ACAD SCI, 1033, PP. 92-98, (2004); JACOBY D., MOHLER III E.R., DRUG TREATMENT OF INTERMITTENT CLAUDICATION, DRUGS, 64, PP. 1657-1670, (2004); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); LEDERMAN R.J., MENDELSOHN F.O., ANDERSON R.D., ET AL., THERAPEUTIC ANGIOGENESIS WITH RECOMBINANT FIBROBLAST GROWTH FACTOR-2 FOR INTERMITTENT CLAUDICATION (THE TRAFFIC STUDY): A RANDOMIZED TRIAL, LANCET, 359, PP. 2053-2058, (2002); DE VRIES M., OUWENDIJK R., KESSELS A.G., ET AL., COMPARISON OF GENERIC AND DISEASE-SPECIFIC QUESTIONNAIRES FOR THE ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 41, FEBRUARY 2, PP. 261-268, (2005); TRANS-ATLANTIC INTER-SOCIETY CONSENSUS (TASC), MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD), EUR J VASC ENDOVASC SURG, 19, SUPPL. A, (2000); LABS K.H., DORMANDY J.A., JAEGER K.A., STUERZEBECHER C.S., HIATT W.R., TRANSATLANTIC CONFERENCE ON CLINICAL TRIAL GUIDELINES IN PERIPHERAL ARTERIAL DISEASE: CLINICAL TRIAL METHODOLOGY. BASEL PAD CLINICAL TRIAL METHODOLOGY GROUP, CIRCULATION, 100, OCTOBER 17, (1999); DORMANDY J.A., RUTHERFORD R.B., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD). TASC WORKING GROUP. TRANSATLANTIC INTER-SOCIETY CONSENSUS (TASC), J VASC SURG, 31, (2003); WEITZ J.I., BYRNE J., CLAGETT G.P., ET AL., DIAGNOSIS AND TREATMENT OF CHRONIC ARTERIAL INSUFFICIENCY OF THE LOWER EXTREMITIES: A CRITICAL REVIEW, CIRCULATION, 94, PP. 3026-3049, (1996); DIEHM C., EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE, VASA, 33, PP. 183-189, (2004); OURIEL K., COMPARISON OF SURGICAL AND THROMBOLYTIC TREATMENT OF PERIPHERAL ARTERIAL DISEASE, REV CARDIOVASC MED, 3, SUPPL. 2, (2002); OURIEL K., ZARINS C.K., DOPPLER ANKLE PRESSURE: AN EVALUATION OF THREE METHODS OF EXPRESSION, ARCH SURG, 117, PP. 1297-1300, (1982); ROSE S.C., NONINVASIVE VASCULAR LABORATORY FOR EVALUATION OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE: PART II-CLINICAL APPLICATIONS: CHRONIC, USUALLY ATHEROSCLEROTIC, LOWER EXTREMITY ISCHEMIA, J VASC INTERV RADIOL, 11, PP. 1257-1275, (2000); HAYOZ D., BOUNAMEAUX H., CANOVA C.R., SWISS ATHEROTHROMBOSIS SURVEY: A FIELD REPORT ON THE OCCURRENCE OF SYMPTOMATIC AND ASYMPTOMATIC PERIPHERAL ARTERIAL DISEASE, J INTERN MED, 258, SEPTEMBER 3, PP. 238-243, (2005); KANNEL W.B., MCGEE D.L., UPDATE ON SOME EPIDEMIOLOGIC FEATURES OF INTERMITTENT CLAUDICATION: THE FRAMINGHAM STUDY, J AM GERIATR SOC, 33, PP. 8-13, (1985); INGOLFSSON I.O., SIGURDSSON G., SIGVALDSON H., THORGEIRSSON G., SIGFUSSON N., A MARKED DECLINE IN THE PREVALENCE AND INCIDENCE OF INTERMITTENT CLAUDICATION IN ICELANDIC MEN 1968-1986: A STRONG RELATIONSHIP TO SMOKING AND SERUM CHOLESTEROL-THE REYKJAVIK STUDY, J CLIN EPIDEMIOL, 47, PP. 1237-1243, (1994); BOWLIN S.J., MEDALIE J.H., FLOCKE S.A., ZYZANSKI S.J., GOLDBOURT U., EPIDEMIOLOGY OF INTERMITTENT CLAUDICATION IN MIDDLE-AGED MEN, AM J EPIDEMIOL, 140, PP. 418-430, (1994); CRIQUI M.H., FRONEK A., BARRETT-CONNOR E., ET AL., THE PREVALENCE OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN A DEFINED POPULATION, CIRCULATION, 71, PP. 510-515, (1985); KANNEL W.B., MCGEE D.L., UPDATE ON SOME EPIDEMIOLOGIC FEATURES OF INTERMITTENT CLAUDICATION: THE FRAMINGHAM STUDY, J AM GERIATR SOC, 33, PP. 13-18, (1985); BAINTON D., SWEETNAM P., BAKER I., ELWOOD P., PERIPHERAL VASCULAR DISEASE: CONSEQUENCE FOR SURVIVAL AND ASSOCIATION WITH RISK FACTORS IN THE SPEEDWELL PROSPECTIVE HEART DISEASE STUDY, BR HEART J, 72, PP. 128-132, (1994); DAGENAIS G.R., MAURICE S., ROBITAILLE N.-M., GINGRAS S., LUPIEN P.J., INTERMITTENT CLAUDICATION IN QUEBEC MEN FROM 1974-1986: THE QUEBEC CARDIOVASCULAR STUDY, CLIN INVEST MED, 14, PP. 93-100, (1991); BARON A.D., VASCULAR REACTIVITY, AM J CARDIOL, 84, (1999); BLAKE G.J., RIDKER P.M., INFLAMMATORY BIOMARKERS AND CARDIOVASCULAR RISK PREDICTION, J INTERN MED, 252, PP. 283-294, (2002); URSELLA S., MAZZONE M., PORTALE G., ET AL., HOW TO USE THE C-REACTIVE PROTEIN IN CARDIAC DISEASES, MINERVA CARDIOANGIOL, 53, PP. 59-68, (2005); RIBA R., NICOLAOU A., TROXLER M., ET AL., ALTERED PLATELET REACTIVITY IN PERIPHERAL VASCULAR DISEASE COMPLICATED WITH ELEVATED PLASMA HOMOCYSTEINE LEVELS, ATHEROSCLEROSIS, 175, PP. 69-75, (2004); MUELLER T., DIEPLINGER B., GEGENHUBER A., ET AL., SERUM TOTAL 8-ISO-PROSTAGLANDIN F<SUB>2Α</SUB>: A NEW AND INDEPENDENT PREDICTOR OF PERIPHERAL ARTERIAL DISEASE, J VASC SURG, 40, PP. 768-773, (2004); MORROW J.D., THE ISOPROSTANES: THEIR QUANTIFICATION AS AN INDEX OF OXIDANT STRESS STATUS IN VIVO, DRUG METAB REV, 32, AUGUST-NOVEMBER 3-4, PP. 377-385, (2000); ROBERT L.J., MORROW J.D., MEASUREMENT OF F(2)-ISOPROTANES AS AN INDEX OF OXIDATIVE STRESS IN VIVO, FREE RADIC BIOL MED, 28, PP. 505-513, (2000); BLANN A.D., LIP G.Y., VIRCHOW'S TRIAD REVISITED: THE IMPORTANCE OF SOLUBLE COAGULATION FACTORS, THE ENDOTHELIUM, AND PLATELETS, THROMB RES, 101, FEBRUARY 4, PP. 321-327, (2001); BEHRENDT D., GANZ P., ENDOTHELIAL FUNCTION FROM VASCULAR BIOLOGY TO CLINICAL APPLICATIONS, AM J CARDIOL, 90, (2002); ROSS R., ATHEROSCLEROSIS-AN INFLAMMATORY DISEASE, N ENGL J MED, 340, PP. 115-126, (1999); MAKIN A., SILVERMAN S.H., LIP G.Y.H., PERIPHERAL VASCULAR DISEASE AND VIRCHOW'S TRIAD FOR THROMBOGENESIS, QJM, 95, PP. 199-210, (2002); BONEU B., ABBAL M., PLANTE J., BIERME R., FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE, LANCET, I, (1975); MUTIN M., CANAVY I., BLANN A., ET AL., DIRECT EVIDENCE OF ENDOTHELIAL INJURY IN ACUTE MYOCARDIAL INFARCTION AND UNSTABLE ANGINA BY DEMONSTRATION OF CIRCULATING ENDOTHELIAL CELLS, BLOOD, 93, PP. 2951-2958, (1999); BLANN A.D., SEIGNEUR M., STEINER M., BOISSEAU M.R., MCCOLLUM C.N., CIRCULATING ENDOTHELIAL CELL MARKERS IN PERIPHERAL VASCULAR DISEASE: RELATIONSHIP TO THE LOCATION AND EXTENT OF ATHEROSCLEROTIC DISEASE, EUR J CLIN INVEST, 27, PP. 916-921, (1997); TISI P., SHEARMAN C., THE EVIDENCE FOR EXERCISE-INDUCED INFLAMMATION IN INTERMITTENT CLAUDICATION: SHOULD WE ENCOURAGE PATIENTS TO STOP WALKING?, EUR J VASC ENDOVASC SURG, 15, PP. 7-17, (1998); EDWARDS A.T., BLANN A.D., SUAREZ-MENDEZ V.J., LARDI A.M., MCCOLLUM C.N., SYSTEMIC RESPONSE IN PATIENTS WITH INTERMITTENT CLAUDICATION AFTER TREADMILL EXERCISE, BR J SURG, 81, PP. 1738-1741, (1994); VILES-GONZALEZ J.F., FUSTER V., BADIMON J.J., ATHEROSCLEROSIS: A WIDESPREAD DISEASE WITH UNPREDICTABLE AND LIFE THREATENING CONSEQUENCES, EUR HEART J, 25, PP. 1197-1207, (2004); BLANN A.D., MCCOLLUM C.N., CIRCULATING ENDOTHELIAL CELL/LEUKOCYTE ADHESION MOLECULES IN ATHEROSCLEROSIS, THROMB HAEMOST, 72, PP. 151-154, (1994); CASSAR K., BACHOO P., BRITTENDEN J., THE ROLE OF PLATELETS IN PERIPHERAL VASCULAR DISEASE, EUR J VASC ENDOVASC SURG, 25, PP. 6-15, (2003); OURIEL K., PERIPHERAL ARTERIAL DISEASE, LANCET, 358, PP. 1257-1264, (2001); SCHOOP W., LENY H., PREVENTION OF PERIPHERAL ARTEROAL OCCLUSIVE DISEASE WITH ANTIAGGREGANTS, THROMB HAEMOST, PP. 50-137, (1983); HARKER L.A., ROLE OF PLATELETS AND THROMBOSIS IN MECHANISMS OF ACUTE OCCLUSION AND RESTENOSIS AFTER ANGIOPLASTY, AM J CARDIOL, 60, PP. 20-28, (1987); BRADBURY A.W., THE ROLE OF CILOSTAZOL (PLETAL) IN THE MANAGEMENT OF INTERMITTENT CLAUDICATION, INT J CLIN PRACT, 57, PP. 405-409, (2003); HIATT W.R., HOAG S., HAMMEN R.F., EFFECT OF DIAGNOSTIC CRITERIA ON THE PREVALENCE OF PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 92, PP. 1472-1479, (1995); REUNANEN A., TAKKUNEN H., AROMAA A., PREVALENCE OF INTERMITTENT CLAUDICATION AND ITS EFFECT ON MORTALITY, ACTA MED SCAN, 211, PP. 249-256, (1982); MURABITO J.M., TEMPORAL TRENDS IN THE INCIDENCE OF INTERMITTENT CLAUDICATION FROM 1950 TO 1999, AM J EPIDEMIOL, 162, SEPTEMBER 5, PP. 430-437, (2005); HOBBS J., VARICOSE VEINS, ABC OF VASCULAR DISEASES, PP. 51-54, (1995); CRIQUI M.H., SYSTEMIC ATHEROSCLEROSIS RISK AND THE MANDATE FOR INTERVENTION IN ATHEROSCLEROTIC PERIPHERAL ARTERIAL DISEASE, AM J CARDIOL, 88, (2001); SMITH JR. S.C., BLAIR S.N., BONOW R.O., ET AL., AHA/ACC SCIENTIFIC STATEMENT: AHA/ACC GUIDELINES FOR PREVENTING HEART ATTACK AND DEATH IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: 2001 UPDATE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE AMERICAN HEART ASSOCIATION AND THE AMERICAN COLLEGE OF CARDIOLOGY, CIRCULATION, 104, SEPTEMBER 13, PP. 1577-1579, (2001); DORMANDY J.A., RUTHERFORD R.B., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD). TASC WORKING GROUP. TRANSATLANTIC INTER-SOCIETY CONSENSUS (TASC), J VASC SURG, 31, (2003); CHAUDHARY H., HOLLAND A., DORMANDY J., COMPARISON OF GRADED VERSUS CONSTANT TREADMILL TEST PROTOCOLS FOR QUANTIFYING INTERMITTENT CLAUDICATION, VASC MED, 2, PP. 93-97, (1997); SCHAINFELD R.M., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE AND INTERMITTENT CLAUDICATION, J AM BOARD FAM PRACT, 14, PP. 443-450, (2001); HASHIGUCHI M., OHNO K., SAITO R., STUDIES ON THE EFFECTIVENESS AND SAFETY OF CILOSTAZOL, BERAPROST SODIUM, PROSTAGLANDIN E<SUB>1</SUB> FOR THE TREATMENT OF INTERMITTENT CLAUDICATION, YAKUGAKU ZASSHI, 124, 6, PP. 321-332, (2004); COLLABORATIVE OVERVIEW OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY-I: PREVENTION OF DEATH, MYOCARDIAL INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BMJ, 308, PP. 81-106, (1994); COLLABORATIVE METAANALYSIS OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION, AND STROKE IN HIGH RISK PATIENTS, BMJ, 324, PP. 71-86, (2002); KRUPSKI W.C., WEISS D.G., RAPP J.H., CORSON J.D., HOBSON II R.W., ADVERSE EFFECTS OF ASPIRIN IN THE TREATMENT OF ASYMPTOMATIC CAROTID ARTERY STENOSIS. THE VA COOPERATIVE ASYMPTOMATIC CAROTID ARTERY STENOSIS STUDY GROUP, J VASC SURG, 16, PP. 588-597, (1992); HESS H., MIETASCHK A., DEICHSEL G., DRUG INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE. A PROSPECTIVE DOUBLE BLIND ARTERIOGRAPHICALLY CONTROLLED TRIAL, LANCET, 1, PP. 415-419, (1985); DORFFLER-MELLY J., KOOPMAN M.M., PRINS M.H., BULLER H.R., ANTIPLATELET AND ANTICOAGULANT DRUGS FOR PREVENTION OF RESTENOSIS/REOCCLUSION FOLLOWING PERIPHERAL ENDOVASCULAR TREATMENT, COCHRANE DATABASE SYST REV, JANUARY 1, (2005); GIROLAMI B., BERNARDI E., PRINS M.H., ET AL., ANTIPLATELET THERAPY AND OTHER INTERVENTIONS AFTER REVASCULARISATION PROCEDURES IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: A META-ANALYSIS, EUR J VASC ENDOVASC SURG, 19, PP. 370-380, (2000); A RANDOMISED, BLINDED, TRIAL OF CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHAEMIC EVENTS (CAPRIE), LANCET, 348, PP. 1329-1339, (1996); SCHLEINITZ M.D., WEISS J.P., OWENS D.K., CLOPIDOGREL VERSUS ASPIRIN FOR SECONDARY PROPHYLAXIS OF VASCULAR EVENTS: A COST-EFFECTIVENESS ANALYSIS, AM J MED, 116, PP. 797-806, (2004); BHATT D.L., TOPOL E.J., CLOPIDOGREL ADDED TO ASPIRIN VERSUS ASPIRIN ALONE IN SECONDARY PREVENTION AND HIGH-RISK PRIMARY PREVENTION: RATIONALE AND DESIGN OF THE CLOPIDOGREL FOR HIGH ATHEROTHROMBOTIC RISK AND ISCHEMIC STABILIZATION, MANAGEMENT, AND AVOIDANCE (CHARISMA) TRIAL, AM HEART J, 148, PP. 263-268, (2004); HACKAM D.G., GOODMAN S.G., ANAND S.S., MANAGEMENT OF RISK IN PERIPHERAL ARTERY DISEASE: RECENT THERAPEUTIC ADVANCES, AM HEART J, 150, PP. 35-40, (2005); HANKEY G.J., SUDLOW C.L., DUNBABIN D.W., THIENOPYRIDINE DERIVATIVES (TICLOPIDINE, CLOPIDOGREL) VERSUS ASPIRIN FOR PREVENTING STROKE AND OTHER SERIOUS VASCULAR EVENTS IN HIGH VASCULAR RISK PATIENTS, COCHRANE DATABASE SYST REV, 2, (2000); STEINHUBL S.R., TAN W.A., FOODY J.M., TOPOL E.J., INCIDENCE AND CLINICAL COURSE OF THROMBOTIC THROMBOCYTOPENIC PURPURA DUE TO TICLOPIDINE FOLLOWING CORONARY STENTING. EPISTENT INVESTIGATORS. EVALUATION OF PLATELET IIB/IIIA INHIBITOR FOR STENTING, JAMA, 281, PP. 806-810, (1999); MAJHAIL N.S., LICHTIN A.E., CLOPIDOGREL AND THROMBOTIC THROMBOCYTOPENIC PURPURA: NO CLEAR CASE FOR CASUALTY, CLEVE CLIN J MED, 70, PP. 466-470, (2003); MANGIAFICO R.A., FIORE C.E., PHARMACOTHERAPY FOR INTERMITTENT CLAUDICATION: FROM CONSENSUS-BASED TO EVIDENCE-BASED TREATMENT, VASC DIS PREV, 1, PP. 1-15, (2004); PORTER J.M., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE EFFICACY IN THE TREATMENT OF INTERMITTENT CLAUDICATION: MULTICENTER CONTROLLED DOUBLE-BLIND TRIAL WITH OBJECTIVE ASSESSMENT IN CHRONIC OCCLUSIVE ARTERIAL DISEASE PATIENTS, AM HEART J, 104, PP. 66-72, (1982); WARD A., CLISSOLD S.P., PENTOXIFYLLINE: A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND ITS THERAPEUTIC EFFICACY, DRUGS, 34, PP. 50-97, (1987); LINDGARDE F., JELNES R., BJORKMAN H., ET AL., CONSERVATIVE DRUG TREATMENT IN PATIENTS WITH MODERATELY SEVERE CHRONIC OCCLUSIVE PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 80, PP. 1549-1556, (1989); BACHER A., EGGENSPERGER E., KOPPENSTEINER R., ET AL., PENTOXIFYLLINE ATTENUATES THE INCREASE IN WHOLE BLOOD VISCOSITY AFTER TRANSFUSION, ACTA ANAESTHESIOL SCAND, 49, JANUARY 1, PP. 41-46, (2005); BAKER D.E., CAMPBELL R.K., PENTOXIFYLLINE: A NEW AGENT FOR INTERMITTENT CLAUDICATION, DRUG INTELL CLIN PHARM, 19, PP. 345-348, (1985); CHEN Y.M., CHIANG W.C., LIN S.L., ET AL., DUAL REGULATION OF TUMOR NECROSIS FACTOR-ALPHA-INDUCED CCL2/MONOCYTE CHEMOATTRACTANT PROTEIN-1 EXPRESSION IN VASCULAR SMOOTH MUSCLE CELLS BY NUCLEAR FACTOR-KAPPAB AND ACTIVATOR PROTEIN-1: MODULATION BY TYPE III PHOSPHODIESTERASE INHIBITION, J PHARMACOL EXP THER, 309, PP. 978-986, (2004); CHEN Y.M., TU C.J., HUNG K.Y., ET AL., INHIBITION BY PENTOXIFYLLINE OF TNF-ALPHA-STIMULATED FRACTALKINE PRODUCTION IN VASCULAR SMOOTH MUSCLE CELLS: EVIDENCE FOR MEDIATION BY NF-KAPPA B DOWN-REGULATION, BR J PHARMACOL, 138, PP. 950-958, (2003); XUEREB J.M., SIE P., BONEU B., ET AL., UP-REGULATION OF TISSUE FACTOR EXPRESSION BY PLATELET-DERIVED GROWTH FACTOR IN HUMAN VASCULAR SMOOTH MUSCLE CELLS IN CULTURE-ROLE OF MITOGEN-ACTIVATED PROTEIN KINASE AND EFFECTS OF INTRACELLULAR CYCLIC AMP, THROMB HAEMOST, 78, PP. 1520-1526, (1997); RADACK K., WYDERSKI R.J., CONSERVATIVE MANAGEMENT OF INTERMITTENT CLAUDICATION, ANN INTERN MED, 113, PP. 135-146, (1990); HOOD S.C., MOHER D., BARBER G.G., MANAGEMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CMAJ, 155, PP. 1053-1059, (1996); ERNST E., PENTOXYFILLINE FOR INTERMITTENT CLAUDICATION: A CRITICAL REVIEW, ANGIOLOGY, 45, PP. 339-345, (1994); WAYBILL P.N., A PRACTICAL APPROACH TO HYPERTENSION IN THE 21ST CENTURY, VASC INTERV RADIOL, 14, AUGUST 8, PP. 961-975, (2003); KAMBAYASHI J., LIU Y., SUN B., ET AL., CILOSTAZOL AS A UNIQUE ANTITHROMBOTIC AGENT, CURR PHARM DES, 9, PP. 2289-2302, (2003); LIU Y., SHAKUR Y., YOSHITAKE M., ET AL., CILOSTAZOL (PLETAL): A DUAL INHIBITOR OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE TYPE 3 AND ADENOSINE UPTAKE, CARDIOVASC DRUG REV, 19, PP. 369-386, (2001); WANG T., ELAMB M.B., FORBES W.P., ET AL., REDUCTION OF REMNANT LIPOPROTEIN CHOLESTEROL CONCENTRATIONS BY CILOSTAZOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ATHEROSCLEROSIS, 171, PP. 337-342, (2003); PRATT C.M., ANALYSIS OF THE CILOSTAZOL SAFETY DATABASE, AM J CARDIOL, 87, (2001); BEEBE H.G., DAWSON D.L., CUTLER B.S., ET AL., A NEW PHARMACOLOGICAL TREATMENT FOR INTERMITTENT CLAUDICATION: RESULTS OF A RANDOMIZED, MULTICENTER TRIAL, ARCH INTERN MED, 159, PP. 2041-2050, (1999); CONNERS M.S., MONEY S.R., CAN CLAUDICATION BE IMPROVED WITH MEDICATION?, SEMIN VASC SURG, 15, PP. 237-244, (2002); CHALOTHORN D., ZHANG H., CLAYTON J.A., ET AL., CATECHOLAMINES AUGMENT COLLATERAL VESSEL GROWTH AND ANGIOGENESIS IN HIND LIMB ISCHEMIA, AM J PHYSIOL HEART CIRC PHYSIOL, 289, (2005); DUBOURG A., SCAMUFFA R.F., AN EXPERIMENTAL OVERVIEW OF A NEW VASOACTIVE DRUG: BUFLOMEDIL HCL, ANGIOLOGY, 32, PP. 663-675, (1981); PASINI F.L., CAPECCHI P.L., ACCIAVATTI A., ET AL., PHARMACOLOGICAL PRECONDITIONING OF ISCHEMIA, CLIN HEMORHEOL MICROCIRC, 17, PP. 73-84, (1997); PASINI F.L., CAPECCHI P.L., PERRI T.D., ADENOSINE AND CHRONIC ISCHEMIA OF THE LOWER LIMBS, VASC MED, 5, PP. 243-250, (2000); LEHERT P., RIPHAGEN F.E., GAMAND S., THE EFFECT OF NAFTIDROFURYL ON INTERMITTENT CLAUDICATION: A META-ANALYSIS, J CARDIOVASC PHARMACOL, 16, (1990); MARCONI A., DARQUENNE S., BOULMERKA A., ET AL., NAFTIDROFURYL-DRIVEN REGULATION OF ENDOTHELIAL ICAM-1 INVOLVES NITRIC OXIDE, FREE RADIC BIOL MED, 34, PP. 616-625, (2003); BARRADELL L.B., BROGDEN R.N., ORAL NAFTIDROFURYL. A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN THE MANAGEMENT OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE, DRUGS AGING, 8, PP. 299-322, (1996); ZANDER J.F., AERHUS L.L., KATUSIC Z.S., ET AL., EFFECTS OF NAFTIDROFURYL ON ADRENERGIC NERVES, ENDOTHELIUM AND SMOOTH MUSCLE IN ISOLATED CANINE BLOOD VESSELS, J PHARMACOL EXP THER, 239, PP. 760-767, (1986); KIEFFER E., BAHNINI A., MOUREN X., ET AL., A NEW STUDY DEMONSTRATES THE EFFICACY OF NAFTIDROFURYL IN THE TREATMENT OF INTERMITTENT CLAUDICATION: FINDINGS OF THE NAFTIDROFURYL CLINICAL ISCHEMIA STUDY (NCIS), INT ANGIOL, 20, PP. 58-65, (2001); D'HOOGE D., LEHERT P., CLEMENT D.L., NAFTIDROFURYL IN QUALITY OF LIFE (NIQOL): A BELGIAN STUDY, INT ANGIOL, 20, PP. 288-294, (2001); HAYASHI T., SUMI D., MATSUI-HIRAI H., ET AL., SARPOGRELATE HCL, A SELECTIVE 5-HT2A ANTAGONIST, RETARDS THE PROGRESSION OF ATHEROSCLEROSIS THROUGH A NOVEL MECHANISM, ATHEROSCLEROSIS, 168, PP. 23-31, (2003); KANAYAMA M., HASHIMOTO T., SHIGENOBU K., ET AL., NEW TREATMENT OF LUMBAR DISC HERNIATION INVOLVING 5-HT<SUB>2A</SUB> RECEPTOR INHIBITOR: A RANDOMIZED CONTROLLED TRIAL, J NEUROSURG: SPINE, 2, PP. 441-446, (2005); RASHID M., MANIVETB P., NISHIOD H., ET AL., IDENTIFICATION OF THE BINDING SITES AND SELECTIVITY OF SARPOGRELATE, A NOVEL 5-HT2 ANTAGONIST, TO HUMAN 5-HT2A, 5-HT2B AND 5-HT2C RECEPTOR SUBTYPES BY MOLECULAR MODELLING, LIFE SCI, 73, PP. 193-207, (2003); MARTINDALE: THE COMPLETE DRUG REFERENCE-MICROMEDEX HEALTHCARE SERIES, 117, (2003); HIATT W.R., TREATMENT OF DISABILITY IN PERIPHERAL ARTERIAL DISEASE: NEW DRUGS, CURR DRUG TARGETS CARDIOVASC HAEMATOL DISORD, 4, SEPTEMBER 3, PP. 227-231, (2004); MOHER D., PHAM B., AUSEJO M., ET AL., PHARMACOLOGICAL MANAGEMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMISED TRIALS, DRUGS, 59, PP. 1057-1070, (2000); JOSEPH P., ALTERNATIVE THERAPIES-POLICOSANOL, AM J HEALTH SYST PHARM, 60, PP. 1112-1115, (2003); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); APPLETON J., ARGININE: CLINICAL POTENTIAL OF A SEMI-ESSENTIAL AMINO, ALTERN MED REV, 7, PP. 512-522, (2002); BOGER R.H., BODE-BOGER S.M., THIELE W., ET AL., RESTORING VASCULAR NITRIC OXIDE FORMATION BY L-ARGININE IMPROVES THE SYMPTOMS OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, J AM COLL CARDIOL, 32, PP. 1336-1344, (1998); COCCHERI S., SCONDOTTO G., AGNELLI G., ET AL., ARTERIAL ARM OF THE SUAVIS (SULODEXIDE ARTERIAL VENOUS ITALIAN STUDY) GROUP. SULODEXIDE IN THE TREATMENT OF INTERMITTENT CLAUDICATION. RESULTS OF A RANDOMIZED, DOUBLE BLIND, MULTICENTRE, PLACEBO-CONTROLLED STUDY, EUR HEART J, 23, PP. 1057-1065, (2002); PITTLER M.H., ERNST E., GINKGO BILOBA EXTRACT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMIZED TRIALS, AM J MED, 108, PP. 276-281, (2000); COOPER L.T., BERAPROST FOR THE TREATMENT OF INTERMITTENT CLAUDICATION, J AM COLL CARDIOL, 41, PP. 1687-1689, (2003); DEY S., MUKHERJEE D., CLINICAL PERSPECTIVES ON THE ROLE OF ANTI-PLATELET AND STATIN THERAPY IN PATIENTS WITH VASCULAR DISEASES, CURR VASC PHARMACOL, 1, PP. 329-333, (2003); ARONOW W.S., NAYAK D., WOODWORTH S., ET AL., EFFECT OF SIMVASTATIN VERSUS PLACEBO ON TREADMILL EXERCISE TIME UNTIL THE ONSET OF INTERMITTENT CLAUDICATION IN OLDER PATIENTS WITH PERIPHERAL ARTERIAL DISEASE AT SIX MONTHS AND AT ONE YEAR AFTER TREATMENT, AM J CARDIOL, 92, PP. 711-712, (2003); DASKALOPOULOU S.S., DASKALOPOULOS M.E., LIAPIS C.D., ET AL., PERIPHERAL ARTERIAL DISEASE: A MISSED OPPORTUNITY TO ADMINISTER STATINS SO AS TO REDUCE CARDIAC MORBIDITY AND MORTALITY, CURR MED CHEM, 12, PP. 443-452, (2005); ROSENSON R.S., STATINS IN ATHEROSCLEROSIS LIPID-LOWERING AGENTS WITH ANTIOXIDANT CAPABILITIES, ATHEROSCLEROSIS, 173, PP. 1-12, (2004); DAVIGNON J., JACOB R.F., MASON R.P., THE ANTIOXIDANT EFFECTS OF STATINS, CORON ARTERY DIS, 15, PP. 251-258, (2004); KANG S., WU Y., LI X., EFFECTS OF STATIN THERAPY ON THE PROGRESSION OF CAROTID ATHEROSCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS, ATHEROSCLEROSIS, 177, PP. 433-442, (2004); GROBBEE D.E., BOTS M.L., ATHEROSCLEROTIC DISEASE REGRESSION WITH STATINS: STUDIES USING VASCULAR MARKERS, INT J CARDIOL, 96, PP. 447-459, (2004); ARTENIE A., ARTENIE R., UNGUREANU D., ET AL., HDL-CHOLESTEROL-ACTIVE OR PASSIVE PARTICIPANT IN ATHEROSCLEROSIS PATHOGENESIS?, REV MED CHIR SOC MED NAT IASI, 108, PP. 503-508, (2004); MACRURY S.M., MUIR M., HUME R., SEASONAL AND CLIMATIC VARIATION IN CHOLESTEROL AND VITAMIN C: EFFECT OF VITAMIN C SUPPLEMENTATION, SCOTT MED J, 37, PP. 49-52, (1992); LENG G.C., HORROBIN D.F., FOWKES F.G., ET AL., PLASMA ESSENTIAL FATTY ACIDS, CIGARETTE SMOKING, AND DIETARY ANTIOXIDANTS IN PERIPHERAL ARTERIAL DISEASE. A POPULATION-BASED CASE-CONTROL STUDY, ARTERIOSCLER THROMB, 14, PP. 471-478, (1994); LONN E., YUSUF S., DZAVIK V., ET AL., EFFECTS OF RAMIPRIL AND VITAMIN E ON ARTERIOSCLEROSIS: THE STUDY TO EVALUATE CAROTID ULTRASOUND CHANGES IN PATIENTS TREATED WITH RAMIPRIL AND VITAMIN E (SECURE), CIRCULATION, 103, PP. 919-925, (2001); YUSUF S., SLEIGHT P., POGUE J., ET AL., THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS. EFFECTS OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, RAMIPRIL, ON CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS, N ENGL J MED, 342, PP. 145-153, (2000); HOBBS S.D., THOMAS M.E., BRADBURY A.W., MANIPULATION OF THE RENNIN ANGIOTENSIN SYSTEM IN PERIPHERAL ARTERIAL DISEASE, EUR J ENDOVASC SURG, 28, PP. 573-582, (2004); MUZAFFAR S., SHUKLA N., LOBO C., ET AL., ILOPROST INHIBITS NADPH OXIDASE EXPRESSION AND SUPEROXIDE RELEASE IN PORCINE PULMONARY ARTERIES AND CELLS STIMULATED WITH THROMBOXANE A2, ISOPROSTANE F2Α AND CYTOKINES, BR J PHARMACOL, 141, PP. 488-496, (2004); VAN BEEK T.A., BOMBARDELLI E., MORAZZONI P., PETERLONGO F., GINKGO BILOBA L, FITOTERAPIA, 69, PP. 195-244, (1998); KLEIJNEN J., KNIPSCHILD P., TER RIET G., VITAMIN E AND CARDIOVASCULAR DISEASE, EUR J CLIN PHARMACOL, 37, PP. 541-544, (1989); KLEIJNEN J., KNIPSCHILD P., GINKGO BILOBA, LANCET, 340, PP. 1136-1139, (1992); MACRURY S.M., MUIR M., HUME R., SEASONAL AND CLIMATIC VARIATION IN CHOLESTEROL AND VITAMIN C: EFFECT OF VITAMIN C SUPPLEMENTATION, SCOTT MED J, 37, PP. 49-52, (1992); LENG G.C., HORROBIN D.F., FOWKES F.G., ET AL., PLASMA ESSENTIAL FATTY ACIDS, CIGARETTE SMOKING, AND DIETARY ANTIOXIDANTS IN PERIPHERAL ARTERIAL DISEASE. A POPULATION-BASED CASE-CONTROL STUDY, ARTERIOSCLER THROMB, 14, PP. 471-478, (1994); TORNWALL M.E., VIRTAMO J., HAUKKA J.K., ET AL., PROSPECTIVE STUDY OF DIET, LIFESTYLE, AND INTERMITTENT CLAUDICATION IN MALE SMOKERS, AM J EPIDEMIOL, 151, PP. 892-901, (2000); SILVESTRO A., SCOPACASA F., OLIVA G., ET AL., VITAMIN C PREVENTS ENDOTHELIAL DYSFUNCTION INDUCED BY ACUTE EXERCISE IN PATIENTS WITH INTERMITTENT CLAUDICATION, ATHEROSCLEROSIS, 165, PP. 277-283, (2002); KLEIJNEN J., MACKERRAS D., VITAMIN E FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST REV, 2, (2000); KLEIJNEN J., KNIPSCHILD P., TER RIET G., VITAMIN E AND CARDIOVASCULAR DISEASE, EUR J CLIN PHARMACOL, 37, PP. 541-544, (1989); BARANDON L., LEROUX L., DUFOURCQ P., ET AL., GENE THERAPY FOR CHRONIC PERIPHERAL ARTERIAL DISEASE: WHAT ROLE FOR THE VASCULAR SURGEON?, ANN VASC SURG, 18, PP. 758-765, (2004); BLANN A.D., BELGORE F.M., MCCOLLUM C.N., ET AL., VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTOR, FLT-1, IN THE PLASMA OF PATIENTS WITH CORONARY OR PERIPHERAL ATHEROSCLEROSIS, OR TYPE II DIABETES, CLIN SCI (LOND), 102, FEBRUARY 2, PP. 187-194, (2002); DONNELLY R., YEUNG J.M.C., THERAPEUTIC ANGIOGENESIS: A STEP FORWARD IN INTERMITTENT CLAUDICATION, LANCET, 359, PP. 2048-2050, (2002); RAJAGOPALAN S., MOHLER E.R., LEDERMAN R.J., ET AL., REGIONAL ANGIOGENESIS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR IN PERIPHERAL ARTERIAL DISEASE: A PHASE II RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ADENOVIRAL DELIVERY OF VASCULAR ENDOTHELIAL GROWTH FACTOR 121 IN PATIENTS WITH DISABLING INTERMITTENT CLAUDICATION, CIRCULATION, 108, PP. 1933-1938, (2003); RAJAGOPALAN S., OLIN J.W., YOUNG S., ET AL., DESIGN OF THE DEL-1 FOR THERAPEUTIC ANGIOGENESIS TRIAL (DELTA-1), A PHASE II MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VLTS-589 IN SUBJECTS WITH INTERMITTENT CLAUDICATION SECONDARY TO PERIPHERAL ARTERIAL DISEASE, HUM GENE THER, 15, PP. 619-624, (2004); HEISTAD D.D., ARMSTRONG M.L., LOPEZ J.A., WHAT CAUSES SPASM OF ATHEROSCLEROTIC ARTERIES? IS REGRESSION OF PLAQUES BENEFICIAL?, TRANS AM CLIN CLIMATOL ASSOC, 101, PP. 103-110, (1989); HEGLE R.A., IS REGRESSION OF CORONARY ATHEROSCLEROSIS POSSIBLE BY INFUSION RECOMBINANT APOLIPOPROTEIN A-I?, JAMC, 170, (2004); TAYLOR A., SHAW L.J., FAYAD Z., ET AL., TRACKING ATHEROSCLEROSIS REGRESSION: A CLINICAL TOOL IN PREVENTIVE CARDIOLOGY, ATHEROSCLEROSIS, 180, PP. 1-10, (2005); DE BACKER T.L., VANDER STICHELE R.H., WARIE H.H., ET AL., ORAL VASOACTIVE MEDICATION IN INTERMITTENT CLAUDICATION: UTILE OR FUTILE, EUR J CLIN PHARMACOL, 56, PP. 199-206, (2000); DIEHM C., KAREEM S., LAWALL H., EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE, VASA, 33, PP. 183-189, (2004); CHAN A.W., EXPANDING ROLES OF THE CARDIOVASCULAR SPECIALISTS IN PANVASCULAR DISEASE PREVENTION AND TREATMENT, CAN J CARDIOL, 20, PP. 535-544, (2004)","A.V. MERU; NEW DRUG DISCOVERY RESEARCH, DEPARTMENT OF PHARMACOLOGY, RANBAXY LABORATORIES LIMITED, GURGAON 122001, HARYANA, PLOT 20, INDIA; EMAIL: ASHWINKUMAR.MERU@RANBAXY.COM","","ENGLISH","ATHEROSCLEROSIS","REVIEW","ISI","2-S2.0-33745602004","ATHEROSCLEROSIS","RANBAXY LABORATORIES LIMITED;RANBAXY LABORATORIES LIMITED;RANBAXY LABORATORIES LIMITED;RANBAXY LABORATORIES LIMITED","NOTREPORTED;RANBAXY LABORATORIES LIMITED;NOTREPORTED",NA,"MERU AV, 2006, ATHEROSCLEROSIS","MERU AV, 2006, ATHEROSCLEROSIS"
"CAMPAGNOLI C;ABBÀ C;AMBROGGIO S;PERIS C;PERONA M;SANSEVERINO P","CAMPAGNOLI, CARLO (57219248857); ABBÀ, CHIARA (6505958867); AMBROGGIO, SIMONA (6505818887); PERIS, CLEMENTINA (7003783485); PERONA, MARCO (7003407946); SANSEVERINO, PATRIZIA (57722523500)","POLYUNSATURATED FATTY ACIDS PUFAS MIGHT REDUCE HOT FLUSHES AN INDICATION FROM TWO CONTROLLED TRIALS ON SOY ISOFLAVONES ALONE AND WITH A PUFA SUPPLEMENT",2005,"MATURITAS","51","7",47,"10.1016/j.maturitas.2004.11.002","UNIT OF ENDOCRINOLOGICAL GYNECOLOGY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY;UNIT OF ENDOCRINOLOGICAL GYNECOLOGY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY;UNIT OF ENDOCRINOLOGICAL GYNECOLOGY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY;UNIT OF ENDOCRINOLOGICAL GYNECOLOGY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY;UNIT OF CLINICAL CHEMISTRY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY;UNIT OF ENDOCRINOLOGICAL GYNECOLOGY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY","OBJECTIVES: TO INVESTIGATE THE EFFECT ON HOT FLUSHES OF A SOY ISOFLAVONE EXTRACT ALONE (STUDY A) AND WITH THE ADDITION OF A SUPPLEMENT OF POLYUNSATURATED FATTY ACIDS, PUFAS (STUDY B). METHODS: SUBJECTS WERE POSTMENOPAUSAL WOMEN (29 IN STUDY A, 28 IN STUDY B) WITH MORE THAN FIVE TROUBLESOME HOT FLUSHES PER DAY. BOTH STUDIES WERE DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIALS WITH CROSS-OVER DESIGN, OF 24-WEEK DURATION. AFTER A 2-WEEK OBSERVATION PERIOD, THEY WERE RANDOMIZED TO RECEIVE TWO CAPSULES PER DAY PROVIDING 60 MG OF ISOFLAVONES OR PLACEBO FOR 12 WEEKS; THEREAFTER, WOMEN WHO HAD TAKEN ISOFLAVONES WERE GIVEN PLACEBO FOR A SECOND 12-WEEK PERIOD, AND VICE-VERSA. WOMEN IN THE STUDY B WERE GIVEN ALSO TWO CAPSULES PER DAY CONTAINING A PUFA SUPPLEMENT FOR THE ENTIRE 24-WEEK TEST PERIOD. RESULTS: BOTH STUDIES SHOWED THE ISOFLAVONE EXTRACT TO HAVE NO GREATER EFFICACY ON HOT FLUSHES THAN THE PLACEBO. DURING THE 24 WEEKS OF THE STUDY B THERE WAS A PROGRESSIVE AND HIGHLY SIGNIFICANT REDUCTION IN THE NUMBER OF HOT FLUSHES, INDEPENDENT OF WHETHER THE WOMEN HAD BEGUN WITH ISOFLAVONES OR WITH PLACEBO. CONCLUSION: IN THESE TWO TRIALS THE ISOFLAVONE EXTRACT DID NOT SHOW GREATER EFFICACY ON THE HOT FLUSHES THAN THE PLACEBO. THE REDUCTION OF HOT FLUSHES OBSERVED IN THE STUDY B MIGHT BE DUE TO THE PUFA SUPPLEMENT. PUFAS, PARTICULARLY OMEGA (Ω) 3-FATTY ACIDS, COULD REDUCE HOT FLUSHES THROUGH THEIR INFLUENCE ON NEURONAL MEMBRANES AND/OR THE MODULATION OF THE NEUROTRANSMITTER FUNCTION AND THE SEROTONINERGIC SYSTEM. STUDIES SPECIFICALLY DESIGNED TO DOCUMENT THE ACTION OF PUFAS ON HOT FLUSHES WOULD BE WELCOME. © 2004 PUBLISHED BY ELSEVIER IRELAND LTD.","HOT FLUSHES; MENOPAUSE; POLYUNSATURATED FATTY ACIDS (PUFAS); SOY ISOFLAVONES","BODY MASS INDEX; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, UNSATURATED; FEMALE; HOT FLASHES; HUMANS; ISOFLAVONES; MIDDLE AGED; PLANT EXTRACTS; POSTMENOPAUSE; SOYBEANS; TREATMENT OUTCOME; ALPHA TOCOPHEROL; DAIDZEIN; DOCOSAHEXAENOIC ACID; FISH OIL; GAMMA LINOLENIC ACID; GENISTEIN; GLYCOSIDE; ICOSAPENTAENOIC ACID; ISOFLAVONE; PHOSPHATIDYLCHOLINE; PLACEBO; POLICOSANOL; POLYUNSATURATED FATTY ACID; RECAPTA; SAPONIN; SOYSELECT; THIOCTIC ACID; ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; ERYTHEMA; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOYBEAN; WEIGHT GAIN","MEDESTEA INTERNATIONAL","THIS STUDY WAS FUNDED BY MEDESTEA INTERNATIONAL, TURIN, ITALY. THE AUTHORS ARE INDEBTED TO DR. ANTONIO SOLETI FOR HIS ASSISTANCE IN THE PREPARATION OF THE MANUSCRIPT. THE AUTHORS ARE ALSO INDEBTED TO THE COLLEAGUES OF THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY OF THE UNIVERSITY OF TURIN (DIR. PROF. M. MASSOBRIO) FOR THE SUPPORT IN THE RECRUITMENT OF THE PATIENTS.","MURKIES A.L., LOMBARD C., STRAUSS B.J., WILCOX G., BURGER H.G., MORTON M.S., DIETARY FLOUR SUPPLEMENTATION DECREASES POST-MENOPAUSAL HOT FLUSHES: EFFECT OF SOY AND WHEAT, MATURITAS, 21, PP. 189-195, (1995); ALBERTAZZI P., PANSINI F., BONACCORSI G., ZANOTTI L., FORINI E., DE ALOYSIO D., THE EFFECT OF DIETARY SOY SUPPLEMENTATION ON HOT FLUSHES, OBSTET GYNECOL, 91, PP. 6-11, (1998); WASHBURN S., BURKE G.L., MORGAN T., ANTHONY N., EFFECT OF SOY PROTEIN SUPPLEMENTATION ON SERUM LIPOPROTEINS, BLOOD PRESSURE AND MENOPAUSAL SYMPTOMS IN PERIMENOPAUSAL WOMEN, MENOPAUSE, 6, PP. 7-13, (1999); BABER R.J., TEMPLEMAN C., MORTON T., KELLY G.E., WEST L., RANDOMISED PLACEBO-CONTROLLED TRIAL OF ISOFLAVONE SUPPLEMENT AND MENOPAUSAL SYMPTOMS IN WOMEN, CLIMACTERIC, 2, PP. 85-92, (1999); QUELLA S.K., LOPRINZI C.L., BARTON D.L., ET AL., EVALUATION OF SOY PHYTOESTROGENS FOR THE TREATMENT OF HOT FLASHES IN BREAST CANCER SURVIVORS: A NORTH CENTRAL CANCER TREATMENT GROUP TRIAL, J CLIN ONCOL, 18, PP. 1068-1074, (2000); KOTSOPOULOS D., DALAIS F.S., LIANG Y.L., MCGRANTH B.P., TEEDE H.J., THE EFFECTS OF SOY PROTEIN CONTAINING PHYTOESTROGENS ON MENOPAUSAL SYMPTOMS IN POSTMENOPAUSAL WOMEN, CLIMACTERIC, 3, PP. 161-167, (2000); YEHUDA S., CARASSO R.L., MODULATION OF LEARNING, PAIN THRESHOLDS AND THERMOREGULATION IN THE RAT BY PREPARATIONS OF FREE PURIFIED LINOLENIC AND LINOLEIC ACIDS: DETERMINATION OF THE OPTIMAL Ω3 TO Ω6 RATIO, PROC NATL ACAD SCI U S A, 90, PP. 10345-10349, (1993); YEHUDA S., RABINOVITZ S., CARASSO R., MOSTOFSKY D., THE ROLE OF POLYUNSATURATED FATTY ACIDS IN RESTORING THE AGING NEURONAL MEMBRANE, NEUROBIOL AGING, 23, PP. 843-853, (2002); BROCCALI G., BERTI M., PISTPLESI E., CESTARO B., A CHOLESTEROL AND SUCROSE RICH DIET PROMOTES LIPOPROTEIN PEROXIDATION AND IMPAIRS INSULIN SENSITIVITY IN RATS, FOOD BIOCHEM, 27, PP. 19-33, (2003); SCAMBIA G., MANGO D., SIGNORILE P.G., ET AL., CLINICAL EFFECTS OF A STANDARDISED SOY EXTRACT IN POSTMENOPAUSAL WOMEN: A PILOT STUDY, MENOPAUSE, 7, PP. 105-111, (2000); UPMALIS D.H., LOBO R., BRADLEY L., WARREN M., CONE F.L., LAMIA C.A., VASOMOTOR SYMPTOM RELIEF BY SOY ISOFLAVONE EXTRACT TABLETS IN POSTMENOPAUSAL WOMEN: A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY, MENOPAUSE, 7, PP. 236-242, (2000); VAN DE WEIJER P.H.M., BARENTSEN R., ISOFLAVONES FROM RED CLOVER (PROMENSIL) SIGNIFICANTLY REDUCE MENOPAUSAL HOT FLUSH SYMPTOMS COMPARED WITH PLACEBO, MATURITAS, 42, PP. 187-193, (2002); GERMAIN A.S., PETERSON C.T., ROBINSON J.G., ALEKEL D.L., ISOFLAVONE-RICH OR ISOFLAVONE-POOR SOY PROTEIN DOES NOT REDUCE MENOPAUSAL SYMPTOMS DURING 24 WEEKS OF TREATMENT, MENOPAUSE, 8, PP. 17-26, (2001); PENOTTI M., FABIO E., MODENA A.B., RINALDI M., OMODEI U., VIGANO P., EFFECT OF SOY-DERIVED ISOFLAVONES ON HOT FLUSHES, ENDOMETRIAL THICKNESS AND PULSATILITY INDEX OF THE UTERINE AND CEREBRAL ARTERIES, FERTIL STERIL, 79, PP. 1112-1117, (2003); TICE J., ETTINGER B., ENSRUD K., WALLACE R., BLACKWELL T., CUMMINGS S., PHYTOESTROGEN SUPPLEMENTS FOR THE TREATMENT OF HOT FLASHES: THE ISOFLAVONE CLOVER EXTRACT (ICE) STUDY, JAMA, 290, PP. 207-214, (2003); ALBERTAZZI P., PURDIE D., THE NATURE AND UTILITY OF THE PHYTOESTROGENS: A REVIEW OF THE EVIDENCE, MATURITAS, 42, PP. 173-185, (2002); YEHUDA S., OMEGA-6/OMEGA-3 RATIO AND BRAIN-RELATED FUNCTIONS, WORLD REV NUTR DIET, 92, PP. 37-56, (2003); CHALON S., VANCASSEL S., ZIMMER L., GUILLOTEAU D., DURAND G., POLYUNSATURATED FATTY ACIDS AND CEREBRAL FUNCTION: FOCUS ON MONOAMINERGIC NEUROTRANSMISSION, LIPIDS, 36, PP. 937-944, (2001); BERENDSEN H., THE ROLE OF SEROTONIN IN HOT FLUSHES, MATURITAS, 36, PP. 155-164, (2000); SLOPIEN R., MECZEKALSKI B., WARENIK-SZYMANKIEWICCCZ A., RELATIONSHIP BETWEEN CLIMACTERIC SYMPTOMS AND SERUM SEROTONIN LEVELS IN POSTMENOPAUSAL WOMEN, CLIMACTERIC, 6, PP. 53-57, (2003); LONGAN A.C., NEUROBEHAVIOR ASPECTS OF OMEGA-3 FATTY ACIDS: POSSIBLE MECHANISMS AND THERAPEUTIC VALUE IN MAJOR DEPRESSION, ALTER MED REV, 8, PP. 410-425, (2003); VAN WEST D., MAES M., POLYUNSATURATED FATTY ACIDS IN DEPRESSION, ACTA NEUROPSYCHIATR, 15, PP. 15-21, (2003); LEE K.W., LIP G.H., THE ROLE OF OMEGA-3 FATTY ACIDS IN THE SECONDARY PREVENTION OF CARDIOVASCOLAR DISEASE, Q J MED, 96, PP. 465-480, (2003); ALBERTAZZI P., COUPLAND K., POLYUNSATURATED FATTY ACIDS. IS THERE A ROLE IN POSTMENOPAUSAL OSTEOPOROSIS PREVENTION?, MATURITAS, 42, PP. 13-22, (2002)","C. CAMPAGNOLI; UNIT OF ENDOCRINOLOGICAL GYNECOLOGY, OSPEDALE GINECOLOGICO SANT'ANNA, AZIENDA OSPEDALIERA OIRM-S.ANNA, 10126 TORINO, CORSO SPEZIA 60, ITALY; EMAIL: GINENDOCRINOL@OIRMSANTANNA.PIEMONTE.IT","","ENGLISH","MATURITAS","ARTICLE","ISI","2-S2.0-19444373600","MATURITAS","UNIT OF CLINICAL CHEMISTRY","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"CAMPAGNOLI C, 2005, MATURITAS","CAMPAGNOLI C, 2005, MATURITAS"
"","","POLICOSANOL A SWEET NOTHING FOR HIGH CHOLESTEROL",2006,"HARVARD HEART LETTER : FROM HARVARD MEDICAL SCHOOL","17","",0,"","","[NO ABSTRACT AVAILABLE]","","ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; HUMANS; HYPERCHOLESTEROLEMIA; TREATMENT FAILURE; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ARTICLE; HUMAN; HYPERCHOLESTEROLEMIA; TREATMENT FAILURE","","","","","","ENGLISH","HARV HEART LETT","ARTICLE","ISI","2-S2.0-39049188153","HARV HEART LETT",NA,"NOTREPORTED",NA,"NA, 2006, HARV HEART LETT","NA, 2006, HARV HEART LETT"
"WRIGHT C;ZIELKE J;WHAYNE J T","WRIGHT, CHRISTOPHER M. (56264133700); ZIELKE, JUDY C. (36748268300); WHAYNE JR., THOMAS F. (57204791430)","POLICOSANOL AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE USE IN PATIENTS INTOLERANT OF OR INADEQUATELY RESPONSIVE TO STATIN THERAPY",2004,"INTERNATIONAL JOURNAL OF ANGIOLOGY","13","2",11,"10.1007/s00547-005-2002-5","GILL HEART INSTITUTE, DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES;GILL HEART INSTITUTE, DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES;UNITED STATES","POLICOSANOL IS A COMPOUND DERIVED FROM SUGARCANE WAX WITH LOW-DENSITY-LIPOPROTEIN (LDL) CHOLESTEROL-LOWERING PROPERTIES. THE AIM OF THIS STUDY IS TO EVALUATE THE EFFECT OF POLICOSANOL ON LDL CHOLESTEROL REDUCTION IN PATIENTS INTOLERANT OF STATIN THERAPY OR ON CONCOMITANT STATIN THERAPY BUT NOT AT TARGET LDL CHOLESTEROL LEVELS. TWENTY-ONE PATIENTS TREATED WITH POLICOSANOL 10 MG TWICE A DAY FOR 156 ± 63 DAYS WERE ANALYZED RETROSPECTIVELY. PRE- AND POSTTREATMENT FASTING LIPID PROFILES WERE COLLECTED AND STATISTICAL ANALYSIS WAS PERFORMED AS PAIRED T-TESTS. DATA WERE FURTHER ANALYZED INTO SUBGROUPS BASED ON THE PRESENCE OR ABSENCE OF STATIN THERAPY. IN THE 21 PATIENTS, LDL CHOLESTEROL DECREASED BY 17% (P < 0.001) AND TOTAL CHOLESTEROL DECREASED BY 9.4% (P < 0.001). NO SIGNIFICANT CHANGES WERE SEEN IN HIGH-DENSITY- LIPOPROTEIN (HDL) CHOLESTEROL OR TRIGLYCERIDE LEVELS. IN THE 6 PATIENTS TREATED WITH A STATIN AND POLICOSANOL, THERE WAS ALSO A 17% LDL CHOLESTEROL REDUCTION (P = 0.005). IN THE 15 PATIENTS TREATED ONLY WITH POLICOSANOL, LDL CHOLESTEROL WAS ALSO DECREASED BY 17% (P = 0.003). POLICOSANOL USE WAS OBSERVED TO BE ASSOCIATED WITH A MILD-TO-MODERATE (17%) DECREASE IN LDL CHOLESTEROL. THIS ASSOCIATION WAS OBSERVED IN PATIENTS INTOLERANT OF STATIN THERAPY AND IN THOSE RECEIVING ADJUNCTIVE POLICOSANOL WITH STATIN THERAPY.","","ALCOHOL DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIET RESTRICTION; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS","","","GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); JAMAL S.M., EISENBERG M.J., CHRISTOPOULOS S., RHABDOMYOLYSIS ASSOCIATED WITH HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS, AM HEART J, 147, PP. 956-965, (2004); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); ALLEVA R., TOMASETTI M., BATTINO M., ET AL., THE ROLES OF COENZYME Q10 AND VITAMIN E ON THE PEROXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN SUBTRACTIONS, PROC NATL ACAD SCI USA, 92, PP. 9388-9391, (1995); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS IN NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCELEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., DE LA ROSA M.C., MAS R., ET AL., EFFECT OF POLICOSANOL ON FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); FRAGA V., MENEDEZ R., AMOR A.M., ET AL., EFFECT OF POLICOSANOL ON IN VIVO AND IN VITRO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., MAS R., ET AL., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997)","T.F. WHAYNE JR.; DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF KENTUCKY, 326 WETHINGTON BUILDING, LEXINGTON, KY 40536-0200, 900 SOUTH LIMESTONE AVE., UNITED STATES; EMAIL: TWHAYN0@UKY.EDU","","ENGLISH","INT. J. ANGIOL.","ARTICLE","ISI","2-S2.0-24644517051","INT J ANGIOL","UNIVERSITY OF KENTUCKY;UNIVERSITY OF KENTUCKY","NOTREPORTED;UNIVERSITY OF KENTUCKY;NOTREPORTED",NA,"WRIGHT CM, 2004, INT J ANGIOL","WRIGHT CM, 2004, INT J ANGIOL"
"KNOX J;GASTER B","KNOX, JEFFREY (16022302800); GASTER, BARAK (6602518165)","DIETARY SUPPLEMENTS FOR THE PREVENTION AND TREATMENT OF CORONARY ARTERY DISEASE",2007,"JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE","13","12",17,"10.1089/acm.2006.6206","DEPARTMENT OF MEDICINE, UNIVERSITY OF WASHINGTON, SEATTLE, WA, UNITED STATES;DEPARTMENT OF MEDICINE, UNIVERSITY OF WASHINGTON, SEATTLE, WA, UNITED STATES, CAMPUS MAIL 354760, SEATTLE, WA 98105, 4245 ROOSEVELT WAY NE, UNITED STATES","PURPOSE: WITH THE RECENT GROWTH IN THE USE OF DIETARY SUPPLEMENTS, IT IS INCREASINGLY IMPORTANT FOR CLINICIANS TO BE FAMILIAR WITH THE EVIDENCE FOR AND AGAINST THEIR EFFICACY. WE SET OUT TO SYSTEMATICALLY REVIEW THE DIETARY SUPPLEMENTS AVAILABLE FOR THE PREVENTION AND TREATMENT OF CORONARY ARTERY DISEASE. METHODS: BETWEEN MAY 2004 AND MAY 2006, WE SEARCHED MEDLINE,® THE COCHRANE LIBRARY, AND PRO-QUEST USING THE MESH TERMS HYPERTENSION, HYPERCHOLESTEROLEMIA, MYOCARDIAL INFARCTION, DIETARY SUPPLEMENTS, AND HERB-DRUG INTERACTIONS. THE MESH TERMS OF INDIVIDUAL SUPPLEMENTS IDENTIFIED WERE THEN ADDED TO THE SEARCH. REFERENCE LISTS OF PERTINENT PAPERS WERE ALSO SEARCHED TO FIND APPROPRIATE PAPERS FOR INCLUSION. WE INCLUDED RANDOMIZED CONTROLLED TRIALS PUBLISHED IN ENGLISH OF AT LEAST 1 WEEK'S DURATION THAT STUDIED THE EFFICACY OF SUPPLEMENTS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, OR HYPERTENSION, OR IN THE PREVENTION OF CARDIAC EVENTS. QUALIFYING PAPERS WERE IDENTIFIED AND ASSIGNED A JADAD QUALITY SCORE. IN AREAS OF UNCERTAINTY, A SECOND INVESTIGATOR INDEPENDENTLY SCORED THE TRIAL. RESULTS: FIFTEEN (15) SUPPLEMENTS WERE IDENTIFIED. OF THESE, MOST HAD LITTLE DATA AVAILABLE AND MOST OF THE DATA WERE OF POOR QUALITY. THE SUPPLEMENTS WITH THE MOST SUPPORTING DATA WERE POLICOSANOL AND GARLIC, BOTH FOR HYPERLIPIDEMIA. CONCLUSIONS: A GROWING BODY OF LITERATURE EXISTS FOR NUMEROUS SUPPLEMENTS IN THE PREVENTION OF CORONARY ARTERY DISEASE, BUT MUCH OF THESE DATA ARE INCONCLUSIVE. CLINICIANS SHOULD BECOME FAMILIAR WITH THE EXTENT AND LIMITATIONS OF THIS LITERATURE SO THAT THEY MAY COUNSEL THEIR PATIENTS BETTER. © MARY ANN LIEBERT, INC.","","CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DIETARY SUPPLEMENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERCHOLESTEROLEMIA; MEDICINE, HERBAL; MYOCARDIAL INFARCTION; PHYTOTHERAPY; PLANT EXTRACTS; RESEARCH DESIGN; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BLACK CURRANT EXTRACT; CALCIUM; CHROMIUM; COMMIPHORA MUKUL EXTRACT; CRATAEGUS EXTRACT; CYNARA SCOLYMUS EXTRACT; GARLIC EXTRACT; GUGUL; MAGNESIUM; POLICOSANOL; RED CLOVER EXTRACT; UBIDECARENONE; UNCLASSIFIED DRUG; ANAPHYLAXIS; ASTHMA; BLEEDING; BULIMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; DATA BASE; DIET SUPPLEMENTATION; DRUG EFFICACY; FATIGUE; FLATULENCE; FOUL BODY ODOR; FUNCTIONAL DISEASE; GARLIC; GASTROINTESTINAL SYMPTOM; HALITOSIS; HEADACHE; HEART INFARCTION; HERB; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; INTESTINE OBSTRUCTION; MEDICAL LITERATURE; MEDLINE; NAUSEA; NEPHROLITHIASIS; POLYURIA; PRIORITY JOURNAL; RASH; REVIEW; SCORING SYSTEM; SWEAT GLAND DISEASE; TREATMENT DURATION","","","SATIA-ABOUTA J.K.A., PATTERSON R.E., LITTMAN A.J., ET AL., DIETARY SUPPLEMENT USE AND MEDICAL CONDITIONS: THE VITAL STUDY, AM J PREV MED, 24, 1, PP. 43-51, (2003); JADAD A.R.M.R., CARROLL D., JENKINSON C., ET AL., ASSESSING THE QUALITY OF REPORTS OF RANDOMIZED CLINICAL TRIALS: IS BLINDING NECESSARY?, CONTROL CLIN TRIALS, 17, PP. 1-12, (1996); VIRTAMO J., RAPOLA J.M., RIPATTI S., ET AL., EFFECT OF VITAMIN E AND BETA CAROTENE ON THE INCIDENCE OF PRIMARY NONFATAL MYOCARDIAL INFARCTION AND FATAL CORONARY HEART DISEASE, ARCH INTERN MED, 158, PP. 668-675, (1998); TORNWALL M.E., VIRTAMO J., KORHONEN P.A., ET AL., EFFECT OF ALPHA-TOCOPHEROL AND BETA-CAROTENE SUPPLEMENTATION ON CORONARY HEART DISEASE DURING THE 6-YEAR POST-TRIAL FOLLOW-UP IN THE ATBC STUDY, EUR HEART J, 25, PP. 1171-1178, (2004); LEE I.M.C.N., MANSON J.E., BURING J.E., HENNEKENS C.H., BETA-CAROTENE SUPPLEMENTATION AND INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE: THE WOMEN'S HEALTH STUDY, J NATL CANCER INST, 91, PP. 2102-2106, (1999); HENNEKENS C.H., BURING J.E., MANSON J.E., ET AL., LACK OF EFFECT OF LONG-TERM SUPPLEMENTATION WITH BETA CAROTENE ON THE INCIDENCE OF MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE, N ENGL J MED, 334, PP. 1145-1149, (1996); VIVEKANANTHAN D.P., PENN M.S., SAPP S.K., ET AL., USE OF ANTIOXIDANT VITAMINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE: META-ANALYSIS OF RANDOMISED TRIALS, LANCET, 361, PP. 2017-2023, (2003); DIPLOCK A.T., SAFETY OF ANTIOXIDANT VITAMINS AND BETA-CAROTENE, AM J CLIN NUTR, 62, 6 SUPPL., (1995); OLSON J., CAROTENOIDS, MODERN NUTRITION IN HEALTH AND DISEASE, PP. 525-542, (1999); SINGH R.B., WANDER G.S., RASTOGI A., ET AL., RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF COENZYME Q10 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, CARDIOVASC DRUGS THER, 12, PP. 347-353, (1998); SINGH R.B., NEKI N.S., KARTIKEY K., ET AL., EFFECT OF COENZYME Q10 ON RISK OF ATHEROSCLEROSIS IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION, MOL CELL BIOCHEM, 246, PP. 75-82, (2003); TRAN M.T., MITCHELL T.M., KENNEDY D.T., GILES J.T., ROLE OF COENZYME Q10 IN CHRONIC HEART FAILURE, ANGINA, AND HYPERTENSION, PHARMACOTHERAPY, 21, PP. 797-806, (2001); STEPHENS N.G., PARSONS A., SCHOFIELD P.M., ET AL., RANDOMISED CONTROLLED TRIAL OF VITAMIN E IN PATIENTS WITH CORONARY DISEASE: CAMBRIDGE HEART ANTIOXIDANT STUDY (CHAOS), LANCET, 347, PP. 781-786, (1996); YUSUF S., DAGENAIS G., POGUE J., ET AL., VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, NEJM, 342, PP. 154-160, (2000); LONN E., BOSCH J., YUSUF S., ET AL., EFFECTS OF LONG-TERM VITAMIN E SUPPLEMENTATION ON CARDIOVASCULAR EVENTS AND CANCER: A RANDOMIZED CONTROLLED TRIAL, JAMA, 293, PP. 1338-1347, (2005); BOOTH S.L., GOLLY I., SACHECK J.M., ET AL., EFFECT OF VITAMIN E SUPPLEMENTATION ON VITAMIN K STATUS IN ADULTS WITH NORMAL COAGULATION STATUS, AM J CLIN NUTR, 80, PP. 143-148, (2004); DEFERNE J.L., LEEDS A.R., RESTING BLOOD PRESSURE AND CARDIOVASCULAR REACTIVITY TO MENTAL ARITHMETIC IN MILD HYPERTENSIVE MALES SUPPLEMENTED WITH BLACKCURRANT SEED OIL, J HUM HYPERTENS, 10, PP. 531-537, (1996); LASARIDIS A.N., KAISIS C.N., ZANANIRI K.I., ET AL., INCREASED NATRIURETIC ABILITY AND HYPOTENSIVE EFFECT DURING SHORT-TERM HIGH CALCIUM INTAKE IN ESSENTIAL HYPERTENSION, NEPHRON, 51, PP. 517-523, (1989); CAPPUCCIO F.P., MARKANDU N.D., SINGER D.R., ET AL., DOES ORAL CALCIUM SUPPLEMENTATION LOWER HIGH BLOOD PRESSURE? A DOUBLE BLIND STUDY, J HYPERTENS, 5, PP. 67-71, (1987); GALLOE A.M., GRAUDAL N., MOLLER J., BRO H., ET AL., EFFECT OF ORAL CALCIUM SUPPLEMENTATION ON BLOOD PRESSURE IN PATIENTS WITH PREVIOUSLY UNTREATED HYPERTENSION: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY, J HUM HYPERTENS, 7, PP. 43-45, (1993); GROBBEE D.E., HOFMAN A., EFFECT OF CALCIUM SUPPLEMENTATION ON DIASTOLIC BLOOD PRESSURE IN YOUNG PEOPLE WITH MILD HYPERTENSION, LANCET, 2, PP. 703-707, (1986); MCCARRON D.A., MORRIS C.D., BLOOD PRESSURE RESPONSE TO ORAL CALCIUM IN PERSONS WITH MILD TO MODERATE HYPERTENSION. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL, ANN INTERN MED, 103, 6, (1985); MEESE R.B., GONZALES D.G., CASPARIAN J.M., ET AL., THE INCONSISTENT EFFECTS OF CALCIUM SUPPLEMENTS UPON BLOOD PRESSURE IN PRIMARY HYPERTENSION, AM J MED SCI, 294, PP. 219-224, (1987); NOWSON C., MORGAN T., EFFECT OF CALCIUM CARBONATE ON BLOOD PRESSURE IN NORMOTENSIVE AND HYPERTENSIVE PEOPLE, HYPERTENSION, 13, 6 PART 1, PP. 630-639, (1989); PETERSEN L.J., RUDNICKI M., HOJSTED J., LONG-TERM ORAL CALCIUM SUPPLEMENTATION REDUCES DIASTOLIC BLOOD PRESSURE IN END STAGE RENAL DISEASE. A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY, INT J ARTIF ORGANS, 17, PP. 37-40, (1994); SIANI A.S.P., GUGLIELMI S., MANCINI M., CLINICAL STUDIES OF THE EFFECTS OF DIFFERENT ORAL CALCIUM INTAKES IN ESSENTIAL HYPERTENSION, J HYPERTENS, 5, SUPPL. 5, (1987); STRAZZULLO P., SIANI A., GUGLIEMI S., ET AL., CONTROLLED TRIAL OF LONG-TERM ORAL CALCIUM SUPPLEMENTATION IN ESSENTIAL HYPERTENSION, HYPERTENSION, 8, PP. 1084-1088, (1986); TANJI J.L., LEW E.Y., WONG G.Y., ET AL., DIETARY CALCIUM SUPPLEMENTATION AS A TREATMENT FOR MILD HYPERTENSION, J AM BOARD FAM PRACT, 4, PP. 145-150, (1991); ZHOU C., FAN S., ZHOU L., ET AL., CLINICAL OBSERVATION OF TREATMENT OF HYPERTENSION WITH CALCIUM, AM J HYPERTENS, 7, 4 PART 1, PP. 363-367, (1994); ZOCCALI C., MALLAMACI F., DELFINO D., ET AL., DOUBLE-BLIND RANDOMIZED, CROSSOVER TRIAL OF CALCIUM SUPPLEMENTATION IN ESSENTIAL HYPERTENSION, J HYPERTENS, 6, PP. 451-455, (1988); GRIFFITH L.E., GUYATT G.H., COOK R.J., ET AL., THE INFLUENCE OF DIETARY AND NONDIETARY CALCIUM SUPPLEMENTATION ON BLOOD PRESSURE: AN UPDATED METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J HYPERTENS, 12, 1 PART 1, PP. 84-92, (1999); CURHAN G.C., WILLETT W.C., SPEIZER F.E., ET AL., COMPARISON OF DIETARY CALCIUM WITH SUPPLEMENTAL CALCIUM AND OTHER NUTRIENTS AS FACTORS AFFECTING THE RISK FOR KIDNEY STONES IN WOMEN, ANN INTERN MED, 126, PP. 497-504, (1997); SINGH R.B., NIAZ M.A., RASTOGI S.S., ET AL., EFFECT OF HYDROSOLUBLE COENZYME Q10 ON BLOOD PRESSURES AND INSULIN RESISTANCE IN HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE, J HUM HYPERTENS, 13, PP. 203-208, (1999); BURKE B.E., NEUENSCHWANDER R., OLSON R.D., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF COENZYME Q10 IN ISOLATED SYSTOLIC HYPERTENSION, SOUTH MED J, 94, PP. 1112-1117, (2001); MARTIN N., BARDISA L., PANTOJA C., ET AL., EXPERIMENTAL CARDIOVASCULAR DEPRESSANT EFFECTS OF GARLIC (ALLIUM SATIVUM) DIALYSATE, J ETHNOPHARMACOL, 37, PP. 145-149, (1992); PANTOJA C.V., CHIANG L.C., NORRIS B.C., CONCHA J.B., DIURETIC, NATRIURETIC AND HYPOTENSIVE EFFECTS PRODUCED BY ALLIUM SATIVUM (GARLIC) IN ANAESTHETIZED DOGS, J ETHNOPHARMACOL, 31, PP. 325-331, (1991); SHARIFI A.M., DARABI R., AKBARLOO N., INVESTIGATION OF ANTIHYPERTENSIVE MECHANISM OF GARLIC IN 2K1C HYPERTENSIVE RAT, J ETHNOPHARMACOL, 86, PP. 219-224, (2003); AUER W.E.A., HERTKORN E., HOEHFELD E., ET AL., HYPERTENSION AND HYPERLIPIDAEMIA: GARLIC HELPS IN MILD CASES, BR J CLIN PRACT SUPPL, 69, PP. 3-6, (1990); HOLZGARTNER H.S.U., KUHN U., COMPARISON OF THE EFFICACY AND TOLERANCE OF A GARLIC PREPARATION VS. BEZAFIBRATE, ARZNEIMITTELFORSCHUNG, 42, PP. 1473-1477, (1992); TURNER B., MOLGAARD C., MARCKMANN P., EFFECT OF GARLIC (ALLIUM SATIVUM) POWDER TABLETS ON SERUM LIPIDS, BLOOD PRESSURE AND ARTERIAL STIFFNESS IN NORMO-LIPIDAEMIC VOLUNTEERS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, BR J NUTR, 92, PP. 701-706, (2004); ACKERMANN R.T.M.C., RAMIREZ G., GARDNER C.D., ET AL., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCH INTERN MED, 161, PP. 813-824, (2001); PEREZ-PIMIENTO A.J., MONEO I., SANTAOLALLA M., ET AL., ANAPHYLACTIC REACTION TO YOUNG GARLIC, ALLERGY, 54, PP. 626-629, (1999); BRAZIER N.L., DRUG-HERB INTERACTION AMONG COMMONLY USED CONVENTIONAL MEDICINES: A COMPENDIUM FOR HEALTH CARE PROFESSIONALS, AM J THER, 10, PP. 163-169, (2003); BURNHAM B., GARLIC AS A POSSIBLE RISK FOR POSTOPERATIVE BLEEDING, PLAST RECONSTR SURG, 95, PP. 213-219, (1995); FOSTER B.C., FOSTER M.S., VANDENHOEK S., ET AL., AN IN VITRO EVALUATION OF HUMAN CYTOCHROME P450 3A4 AND P-GLYCOPROTEIN INHIBITION BY GARLIC, J PHARM PHARM SCI, 4, PP. 176-184, (2001); MILLER A.L., BOTANICAL INFLUENCES ON CARDIOVASCULAR DISEASE, ALTERN MED REV, 3, PP. 422-431, (1998); WALKER A.F., MARAKIS G., MORRIS A.P., ROBINSON P.A., PROMISING HYPOTENSIVE EFFECT OF HAWTHORN EXTRACT: A RANDOMIZED DOUBLE-BLIND PILOT STUDY OF MILD, ESSENTIAL HYPERTENSION, PHYTOTHER RES, 16, PP. 48-54, (2002); BARNES J.A.L., PHILLIPSON J.D., HERBAL MEDICINES: A GUIDE FOR HEALTHCARE PROFESSIONALS, (2001); MOTOYAMA T., SANO H., FUKUZAKI H., ORAL MAGNESIUM SUPPLEMENTATION IN PATIENTS WITH ESSENTIAL HYPERTENSION, HYPERTENSION, 13, PP. 227-232, (1989); PLUM-WIRELL M., STEGMAYR B.G., WESTER P.O., NUTRITIONAL MAGNESIUM SUPPLEMENTATION DOES NOT CHANGE BLOOD PRESSURE NOR SERUM OR MUSCLE POTASSIUM AND MAGNESIUM IN UNTREATED HYPERTENSION. A DOUBLE-BLIND CROSSOVER STUDY, MAGNES RES, 7, PP. 277-283, (1994); CAPPUCCIO F.P., MARKANDU N.D., BEYNON G.W., ET AL., LACK OF EFFECT OF ORAL MAGNESIUM ON HIGH BLOOD PRESSURE: A DOUBLE BLIND STUDY, BR MED J (CLIN RES ED), 291, PP. 235-238, (1985); FERRARA L.A., IANNUZZI R., CASTALDO A., ET AL., LONG-TERM MAGNESIUM SUPPLEMENTATION IN ESSENTIAL HYPERTENSION, CARDIOLOGY, 81, PP. 25-33, (1992); HENDERSON D.G., SCHIERUP J., SCHODT T., EFFECT OF MAGNESIUM SUPPLEMENTATION ON BLOOD PRESSURE AND ELECTROLYTE CONCENTRATIONS IN HYPERTENSIVE PATIENTS RECEIVING LONG TERM DIURETIC TREATMENT, BR MED J (CLIN RES ED), 293, PP. 664-665, (1986); SANJULIANI A.F., DE ABREU FAGUNDES V.G., FRANCISCHETTI E.A., EFFECTS OF MAGNESIUM ON BLOOD PRESSURE AND INTRACELLULAR ION LEVELS OF BRAZILIAN HYPERTENSIVE PATIENTS, INT J CARDIOL, 56, PP. 177-183, (1996); WIDMAN L., WESTER P.O., STEGMAYR B.K., WIRELL M., THE DOSE-DEPENDENT REDUCTION IN BLOOD PRESSURE THROUGH ADMINISTRATION OF MAGNESIUM: A DOUBLE BLIND PLACEBO CONTROLLED CROSSOVER STUDY, AM J HYPERTENS, 6, PP. 41-45, (1993); WIRELL M.P., WESTER P.O., STEGMAYR B.G., NUTRITIONAL DOSE OF MAGNESIUM IN HYPERTENSIVE PATIENTS ON BETA BLOCKERS LOWERS SYSTOLIC BLOOD PRESSURE: A DOUBLE-BLIND, CROSS-OVER STUDY, J INTERN MED, 236, PP. 189-195, (1994); ZEMEL P.C., ZEMEL M.B., URBERG M., ET AL., METABOLIC AND HEMODYNAMIC EFFECTS OF MAGNESIUM SUPPLEMENTATION IN PATIENTS WITH ESSENTIAL HYPERTENSION, AM J CLIN NUTR, 51, PP. 665-669, (1990); WITTEMAN J.C., GROBBEE D.E., DERKX F.H., ET AL., REDUCTION OF BLOOD PRESSURE WITH ORAL MAGNESIUM SUPPLEMENTATION IN WOMEN WITH MILD TO MODERATE HYPERTENSION, AM J CLIN NUTR, 60, PP. 129-135, (1994); REYES A., LEARY W.P., ACOSTA-BARRIOS T.N., DAVIS W.H., MAGNESIUM SUPPLEMENTATION IN HYPERTENSION TREATED WITH HYDROCHLOROTHIAZIDE, CURR THER RES, 36, PP. 332-340, (1984); JEE S.H., MILLER 3RD E.R., GUALLAR E., ET AL., THE EFFECT OF MAGNESIUM SUPPLEMENTATION ON BLOOD PRESSURE: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, AM J HYPERTENS, 15, 6, PP. 91-696, (2002); DUFFY S.J., GOKCE N., HOLBROOK M., ET AL., TREATMENT OF HYPERTENSION WITH ASCORBIC ACID, LANCET, 354, PP. 2048-2049, (1999); GHOSH S.K., EKPO E.B., SHAH I.U., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL TRIAL OF VITAMIN C TREATMENT IN ELDERLY PATIENTS WITH HYPERTENSION, GERONTOLOGY, 40, PP. 268-272, (1994); LOVAT L.B., LU Y., PALMER A.J., ET AL., DOUBLE-BLIND TRIAL OF VITAMIN C IN ELDERLY HYPERTENSIVES, J HUM HYPERTENS, 7, PP. 403-405, (1993); BENDICH A., LANGSETH L., THE HEALTH EFFECTS OF VITAMIN C SUPPLEMENTATION: A REVIEW, J AM COLL NUTR, 14, PP. 124-136, (1995); TRAXER O., HUET B., POINDEXTER J., ET AL., EFFECT OF ASCORBIC ACID CONSUMPTION ON URINARY STONE RISK FACTORS, J UROL, 170, 2 PART 1, PP. 397-401, (2003); GOGEL H.K., TANDBERG D., STRICKLAND R.G., SUBSTANCES THAT INTERFERE WITH GUAIAC CARD TESTS: IMPLICATIONS FOR GASTRIC ASPIRATE TESTING, AM J EMERG MED, 7, PP. 474-480, (1989); JAFFE R.M., KASTEN B., YOUNG D.S., MACLOWRY J.D., FALSE-NEGATIVE STOOL OCCULT BLOOD TESTS CAUSED BY INGESTION OF ASCORBIC ACID (VITAMIN C), ANN INTERN MED, 83, PP. 824-826, (1975); BOSHTAM M., RAFIEI M., SADEGHI K., SARRAF-ZADEGAN N., VITAMIN E CAN REDUCE BLOOD PRESSURE IN MILD HYPERTENSIVES, INT J VITAM NUTR RES, 72, PP. 309-314, (2002); ENGLISCH W., BECKERS C., UNKAUF M., ET AL., EFFICACY OF ARTICHOKE DRY EXTRACT IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ARZNEIMITTELFORSCHUNG, 50, PP. 260-265, (2000); SCHROEDER H.A., NASON A.P., TIPTON I.H., CHROMIUM DEFICIENCY AS A FACTOR IN ATHEROSCLEROSIS, J CHRONIC DIS, 23, PP. 123-142, (1970); SIMONOFF M.L., HAMON C., PEERS M., SIMONOFF G.N., LOW PLASMA CHROMIUM IN PATIENTS WITH CORONARY ARTERY AND HEART DISEASES, BIOL TRACE ELEM RES, 6, PP. 431-439, (1984); PRESS R.I., GELLER J., EVANS G.W., THE EFFECT OF CHROMIUM PICOLINATE ON SERUM CHOLESTEROL AND APOLIPOPROTEIN FRACTIONS IN HUMAN SUBJECTS, WEST J MED, 152, PP. 41-45, (1990); ROEBACK JR J.R., HLA K.M., CHAMBLESS L.E., FLETCHER R.H., EFFECTS OF CHROMIUM SUPPLEMENTATION ON SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN MEN TAKING BETA-BLOCKERS. A RANDOMIZED, CONTROLLED TRIAL, ANN INTERN MED, 115, PP. 917-924, (1991); GUPTA N.P., GARLIC AND GARLIC-DERIVED COMPOUNDS INHIBIT HUMAN SQUALENE MONOOXYGENASE, J NUTR, 131, (2001); YEH Y.Y., YEH S.M., GARLIC REDUCES PLASMA LIPIDS BY INHIBITING HEPATIC CHOLESTEROL AND TRIACYLGLYCEROL SYNTHESIS, LIPIDS, 29, PP. 189-193, (1994); BERTHOLD H.S.T., VON BERGMANN K., EFFECT OF A GARLIC OIL PREPARATION ON SERUM LIPOPROTEINS AND CHOLESTEROL METABOLISM: A RANDOMIZED CONTROLLED TRIAL, JAMA, 279, PP. 1900-1902, (1998); ADLER A.H., EFFECT OF GARLIC AND FISH-OIL SUPPLEMENTATION ON SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS IN HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 65, PP. 445-450, (1997); JAIN A.K.V.R., GOTZKOWSKY S., MCMAHON F.G., CAN GARLIC REDUCE LEVELS OF SERUM LIPIDS? A CONTROLLED CLINICAL STUDY, AM J MED, 94, 6, PP. 632-635, (1993); KANNAR D.W.N., SAVIGE G.S., WAHLQVIST M.L., HYPOCHOLESTEROLEMIC EFFECT OF AN ENTERIC-COATED GARLIC SUPPLEMENT, J AM COLL NUTR, 20, PP. 225-231, (2001); LULEY C.L.-L.W., MOLLER B., MARTIN T., SCHWARTZKOPFF W., LACK OF EFFICACY OF DRIED GARLIC IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ARZNEIMITTELFORSCHUNG, 36, PP. 766-768, (1986); MADER F.H., TREATMENT OF HYPERLIPIDAEMIA WITH GARLIC-POWDER TABLETS: EVIDENCE FROM THE GERMAN ASSOCIATION OF GENERAL PRACTITIONERS' MULTICENTRIC PLACEBO-CONTROLLED DOUBLE-BLIND STUDY, ARZNEIMITTELFORSCHUNG, 40, 10, PP. 1111-1116, (1990); MCCRINDLE B.W., HELDEN E., CONNER W.T., GARLIC EXTRACT THERAPY IN CHILDREN WITH HYPERCHOLESTEROLEMIA, ARCH PEDIATR ADOLESC MED, 152, PP. 1089-1094, (1998); NEIL H.A., SILAGY C.A., LANCASTER T., ET AL., GARLIC POWDER IN THE TREATMENT OF MODERATE HYPERLIPIDAEMIA: A CONTROLLED TRIAL AND META-ANALYSIS, J R COLL PHYSICIANS LOND, 30, PP. 329-334, (1996); PELEG A., HERSHCOVICI T., LIPA R., ET AL., EFFECT OF GARLIC ON LIPID PROFILE AND PSYCHOPATHOLOGIC PARAMETERS IN PEOPLE WITH MILD TO MODERATE HYPERCHOLESTEROLEMIA, ISR MED ASSOC J, 5, PP. 637-640, (2003); PLENGVIDHYA C., SITPRIJA S., CHINAYON S., ET AL., EFFECTS OF SPRAY DRIED GARLIC PREPARATION ON PRIMARY HYPERLIPOPROTEINEMIA, J MED ASSOC THAI, 71, PP. 248-252, (1988); SATITVIPAWEE P., RAWDAREE P., INDRABHAKTI S., ET AL., NO EFFECT OF GARLIC EXTRACT SUPPLEMENT ON SERUM LIPID LEVELS IN HYPERCHOLESTEROLEMIC SUBJECTS, J MED ASSOC THAI, 86, PP. 750-757, (2003); SIMONS L.A., BALASUBRAMANIAM S., VON KONIGSMARK M., ET AL., ON THE EFFECT OF GARLIC ON PLASMA LIPIDS AND LIPOPROTEINS IN MILD HYPERCHOLESTEROLAEMIA, ATHEROSCLEROSIS, 113, PP. 219-225, (1995); STEINER M.K.A., HOLBERT D., LIN R.I., A DOUBLE-BLIND CROSSOVER STUDY IN MODERATELY HYPERCHOLESTEROLEMIC MEN THAT COMPARED THE EFFECT OF AGED GARLIC EXTRACT AND PLACEBO ADMINISTRATION ON BLOOD LIPIDS, AM J CLIN NUTR, 64, PP. 866-870, (1996); SUPERKO H.R., KRAUSS R.M., GARLIC POWDER, EFFECT ON PLASMA LIPIDS, POSTPRANDIAL LIPEMIA, LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, HIGH-DENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION AND LIPOPROTEIN(A), J AM COLL CARDIOL, 35, PP. 321-326, (2000); TANAMAI J., VEERAMANOMAI S., INDRAKOSAS N., THE EFFICACY OF CHOLESTEROL-LOWERING ACTION AND SIDE EFFECTS OF GARLIC ENTERIC COATED TABLETS IN MAN, J MED ASSOC THAI, 87, PP. 1156-1161, (2004); VORBERG G., SCHNEIDER B., THERAPY WITH GARLIC: RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY, BR J CLIN PRACT SUPPL, 69, PP. 7-11, (1990); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA. A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, ANN INTERN MED, 133, PP. 420-429, (2000); SINGH V., KAUL S., CHANDER R., KAPOOR N.K., STIMULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY IN LIVER MEMBRANE OF GUGGULSTERONE TREATED RATS, PHARMACOL RES, 22, PP. 37-44, (1990); URIZAR N.L., LIVERMAN A.B., DODDS D.T., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, PP. 1703-1706, (2002); SINGH R.B., NIAZ M.A., GHOSH S., HYPOLIPIDEMIC AND ANTIOXIDANT EFFECTS OF COMMIPHORA MUKUL AS AN ADJUNCT TO DIETARY THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CARDIOVASC DRUGS THER, 8, PP. 659-664, (1994); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); BIANCHI A., CANTU P., FIRENZUOLI F., ET AL., RHABDOMYOLYSIS CAUSED BY COMMIPHORA MUKUL, A NATURAL LIPID-LOWERING AGENT, ANN PHARMACOTHER, 38, PP. 1222-1225, (2004); SAPER R.B., KALES S.N., PAQUIN J., ET AL., HEAVY METAL CONTENT OF AYURVEDIC HERBAL MEDICINE PRODUCTS, JAMA, 292, PP. 2868-2873, (2004); BROBST D.E., DING X., CREECH K.L., ET AL., GUGGULSTERONE ACTIVATES MULTIPLE NUCLEAR RECEPTORS AND INDUCES CYP3A GENE EXPRESSION THROUGH THE PREGNANE X RECEPTOR, J PHARMACOL EXP THER, 310, PP. 528-535, (2004); DALVI S.S., NAYAK V.K., POHUJANI S.M., ET AL., EFFECT OF GUGULIPID ON BIOAVAILABILITY OF DILTIAZEM AND PROPRANOLOL, J ASSOC PHYSICIANS INDIA, 42, PP. 454-455, (1994); KIRSTEN R., HEINTZ B., NELSON K., ET AL., MAGNESIUM PYRIDOXAL 5-PHOSPHATE GLUTAMATE REDUCES HYPERLIPIDAEMIA IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY, EUR J CLIN PHARMACOL, 34, PP. 133-137, (1988); KNIPSCHEER H.C., KINDT I., VAN DEN ENDE A., ET AL., MAGNESIUM PYRIDOXAL-5′-PHOSPHATE GLUTAMATE, ""A VITAMIN B6 DERIVATIVE,"" DOES NOT AFFECT LIPOPROTEIN LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA, EUR J CLIN PHARMACOL, 51, PP. 499-503, (1997); SCHUITEMAKER G.E., VAN DER POL G.A., ARETZ C.P., DINANT G.J., A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMISED TRIAL OF MAGNESIUM-PYRIDOXAL- 5′-PHOSPHATE-GLUTAMATE FOR HYPERCHOLESTEROLAEMIA AND OTHER CLINICAL-CHEMICAL RISK FACTORS OF CARDIOVASCULAR DISEASE IN A PRIMARY CARE SETTING, EUR J CLIN PHARMACOL, 56, PP. 857-863, (2001); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); ANEIROS E.M., CALDERON B., ILLNAIT J., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 176-182, (1995); ANEIROS E.C.B., MAS R., ILLNAIT J., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, PP. 304-312, (1993); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CANETTI M.M.M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); CASTANO G.C.M., MOREIRA M., TULA L., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, PP. 819-828, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G.T.L., CANETTI M., MORERA M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 57, PP. 691-699, (1996); CASTANO G.M.R., FERNANDEZ J.C., FERNANDEZ L., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-146, (2000); MARCELLO S.G.J., TESONE P., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 61, PP. 346-357, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P.M., ILLNAIT J., FERNANDEZ L., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, PP. 507-513, (1992); PONS P.R., MAS R., ILLNAIT J., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, PP. 1084-1092, (1994); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ZARDOYA R.T.L., CASTANO G., MAS R., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES CLIN EXP, 57, PP. 568-577, (1996); NESTEL P.J., POMEROY S., KAY S., ET AL., ISOFLAVONES FROM RED CLOVER IMPROVE SYSTEMIC ARTERIAL COMPLIANCE BUT NOT PLASMA LIPIDS IN MENOPAUSAL WOMEN, J CLIN ENDOCRINOL METAB, 84, PP. 895-898, (1999); HOWES J.B., SULLIVAN D., LAI N., ET AL., THE EFFECTS OF DIETARY SUPPLEMENTATION WITH ISOFLAVONES FROM RED CLOVER ON THE LIPOPROTEIN PROFILES OF POST MENOPAUSAL WOMEN WITH MILD TO MODERATE HYPERCHOLESTEROLAEMIA, ATHEROSCLEROSIS, 152, PP. 143-147, (2000); CLOAREC M.J., PERDRISET G.M., LAMBERDIERE F.A., ET AL., ALPHA-TOCOPHEROL: EFFECT ON PLASMA LIPOPROTEINS IN HYPERCHOLESTEROLEMIC PATIENTS, ISR J MED SCI, 23, PP. 869-872, (1987); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., ET AL., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLES-TEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 17, 295, PP. 2262-2269, (2006); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); ALCOCER L., FERNANDEZ L., CAMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); BENITEZ M.R.C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 859-867, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G.M.R., NODARSE M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); ORTENSI G.G.J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); FERNANDEZ L.M.R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ZAVA D.T., DOLLBAUM C.M., BLEN M., ESTROGEN AND PROGESTIN BIOACTIVITY OF FOODS, HERBS, AND SPICES, PROC SOC EXP BIOL MED, 217, PP. 369-378, (1998)","B. GASTER; CAMPUS MAIL 354760, SEATTLE, WA 98105, 4245 ROOSEVELT WAY NE, UNITED STATES; EMAIL: BARAKG@U.WASHINGTON.EDU","","ENGLISH","J. ALTERN. COMPLEMENT. MED.","REVIEW","ISI","2-S2.0-33847245319","J ALTERN COMPLEMENT MED","UNIVERSITY OF WASHINGTON;UNIVERSITY OF WASHINGTON","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"KNOX J, 2007, J ALTERN COMPLEMENT MED","KNOX J, 2007, J ALTERN COMPLEMENT MED"
"MEYER F","MEYER, F.P. (58458235900)","ENJOY A CAREFREE FUTURE WITH POLICOSANOL MIT POLICOSANOL UNBESCHWERT DIE ZUKUNFT GENIEßEN",2005,"TAGLICHE PRAXIS","46","3",0,"","39167 GROß RODENSLEBEN, MAGDEBURGER STRAßE 29, GERMANY","SHORT-TIME CLINICAL TRIALS WERE CONDUCTED TO TEST POLICOSANOL (10 MG/D) - AN ORGANIC SUBSTANCE MADE OF RICE BRAN - AGAINST LOVASTATIN (20 MG/D), ATORVASTATIN (10 MG/D), AND PRAVASTATIN (10 MG/D) ON A FEW PATIENTS WITH DIABETES MELLITUS, INTERMITTENT CLAUDICATION AND/OR HYPERCHOLESTEROLEMIA. THE ONLY CONSISTENT EFFECT WAS AN INCREASE OF HDL-CHOLESTEROL (BY 5 TO 18%). LDL-CHOLESTEROL WAS STRONGER DECREASED BY ACCURATE DOSED ATORVASTATIN COMPARED TO POLICOSANOL (30% AND 23% RESPECTIVELY). THE EFFECT OF POLICOSANOL WAS SLIGHTLY MORE EFFICIENT COMPARED TO THE OTHER, HOWEVER, UNDERDOSED STATINS. IN CASE OF INTERMITTENT CLAUDICATION (STAGE II) POLICOSANOL WAS SLIGHTLY MORE EFFICIENT COMPARED TO LOVASTATIN WHICH WAS FULLY UNSUITABLE. CONTROLLED CLINICAL ENDPOINT STUDIES TO ALLOW STATEMENTS ON REDUCTION OF LARGE CARDIOVASCULAR EVENTS ARE STILL MISSING.","ATORVASTATIN; DIABETES MELLITUS; HYPERCHOLESTEROLEMIA; INTERMITTENT CLAUDICATION; LOVASTATIN; POLICOSANOL; PRAVASTATIN","ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLICOSANOL; PRAVASTATIN; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INTERMITTENT CLAUDICATION; REVIEW","","","CRESPO N., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); POLICOSANOL VERSUS ATORVASTATIN EFFECTIVE IN CHOLESTEROL LOWERING AND INCREASED HDL-C LEVELS, CARDIOVASC J S AFR, 15, (2004); CASTANO G., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003)","","MEDIENGRUPPE OBERFRANKEN - FACHVERLAGE GMBH & CO. KG","GERMAN","TAGL. PRAX.","REVIEW","ISI","2-S2.0-24944434299","TAGL PRAX",NA,"NOTREPORTED",NA,"MEYER FP, 2005, TAGL PRAX","MEYER FP, 2005, TAGL PRAX"
"WEEKS B;PEREZ P","WEEKS, BENJAMIN S. (35510006900); PEREZ, PEDRO P. (7201902636)","POLICOSANOLPLUS AND NEUROPREVIN AMELIORATE PESTICIDEMEDIATED INHIBITION OF NEURITE OUTGROWTH AND NEURITE DEGENERATION",2006,"MEDICAL SCIENCE MONITOR","12","5",4,"","DEPARTMENT OF BIOLOGY, ENVIRONMENTAL SCIENCES PROGRAM, ADELPHI UNIVERSITY, GARDEN CITY, NY, UNITED STATES;MOUNT SINAI, NY, UNITED STATES, MOUNT SINAI, NY 11766, 9 SEAN LANE, UNITED STATES","BACKGROUND: PESTICIDE EXPOSURE IS A RECOGNIZED RISK FACTOR FOR NEURODEGENERATIVE DISEASES. RECENTLY, BIFENTHRIN, A PYRETHROID PESTICIDE, WAS SHOWN TO INHIBIT THE FORMATION OF NEURITES AND CAUSE NEURITE RETRACTION, RAISING CONCERN THAT THESE NEWER AND LESS TOXIC PESTICIDES MAY ALSO CONTRIBUTE TO NEURODEGENERATIVE DISEASES. POLICOSANOLPLUS® AND NEUROPREVIN™ ARE NUTRACEUTICAL SUPPLEMENTS WHICH PROMOTE THE SURVIVAL OF NEURITES IN NEURONAL CELL CULTURES. HERE WE DETERMINE IF POLICOSANOLPLUS® AND NEUROPREVIN™ CAN AMELIORATE THE NEURODEGENERATIVE EFFECTS OF BIFENTHRIN. MATERIAL/METHODS: PC12 CELLS WERE TREATED WITH NGF, BIFENTHRIN, POLICOSANOLPLUS® AND NEUROPREVIN™ IN VARIOUS COMBINATIONS AND THE FORMATION OF NEURITES WAS ASSESSED MICROSCOPICALLY AT TIMES RANGING FROM 12 TO 72 HOURS POST TREATMENT. BIFENTHRIN WAS ALSO WITHHELD AT THE TIME OF NGF, POLICOSANOLPLUS® AND NEUROPREVIN™ TREATMENT AND ADDED AFTER NEURITE FORMED TO ASSESS NEURITE RETRACTION. RESULTS: BIFENTHRIN (1X10-6 M) INHIBITS NEURITE OUTGROWTH, IN THE ABSENCE OF CELL DEATH, BY MORE THAN 50% AT 12 HOURS AND BY MORE THAN 80% AT 72 HOURS. WITH ADDITION OF POLICOSANOLPLUS® AND/OR NEUROPREVIN™ AT THE TIME OF CELL SEEDING, BIFENTHRIN DOES NOT INHIBIT NEURITE OUTGROWTH. ADDITION OF BIFENTHRIN TO DIFFERENTIATED CELLS RESULTS IN A RETRACTION OF 90% OF NEURITES, WHILE THOSE WITH POLICOSANOLPLUS® AND NEUROPREVIN™ SHOW NO SIGNIFICANT RETRACTION OF NEURITES. CONCLUSIONS: THE PESTICIDE, BIFENTHRIN, INHIBITS NEURITE FORMATION AND CAUSES NEURITE RETRACTION. POLICOSANOLPLUS® AND NEUROPREVIN™ ARE NUTRACEUTICAL SUPPLEMENTS WHICH AMELIORATE THE EFFECTS OF BIFENTHRIN ON NEURITE OUTGROWTH AND RETRACTION. DIETARY SUPPLEMENTATION WITH POLICOSANOLPLUS® AND NEUROPREVIN™ MAY PROTECT AGAINST DEVELOPMENTAL AND LONG-TERM NEURODEGENERATIVE EVENTS THAT RESULT FROM EXPOSURE TO PESTICIDES. © MED SCI MONIT, 2006.","BIFENTHRIN; NEURITE OUTGROWTH; NEURITE RETRACTION; NEURODEGENERATION; NUTRACEUTICALS","ANIMALS; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; HUMANS; LINDANE; NERVE DEGENERATION; NERVE GROWTH FACTOR; NEURITES; NEUROPROTECTIVE AGENTS; PC12 CELLS; PESTICIDES; PYRETHRINS; RATS; BIFENTHRIN; LINDANE; NERVE GROWTH FACTOR; NEUROPREVIN; NUTRACEUTICAL; PESTICIDE; POLICOSANOLPLUS; PYRETHROID; FATTY ALCOHOL; LINDANE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; PESTICIDE; POLICOSANOL; PYRETHROID; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; NERVE CELL CULTURE; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER GROWTH; NEUROTOXICITY; NONHUMAN; RAT; ANIMAL; CELL STRAIN; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; NERVE DEGENERATION; NEURITE; PATHOLOGY","","","AZZOUZ M., KENEL P.F., WARTER J.-M., ET AL., ENHANCEMENT OF MOUSE SCIATIC NERVE REGENERATION BY THE LONG CHAIN FATTY ALCOHOL, N-HEXACOSANOL, EXP NEUROL, 138, 2, PP. 189-197, (1996); BORG J., KESSLAK P.J., COTMAN C.W., PERIPHERAL ADMINISTRATION OF A LONG-CHAIN FATTY ALCOHOL PROMOTES SEPTAL CHOLINERGIC NEURONS SURVIVAL AFTER FIMBRIA-FORNIX TRANSECTION, BRAIN RES, 518, 1-2, PP. 295-298, (1990); BORG J., TOAZARA J., HIETTER H., ET AL., NEUROTROPHIC EFFECT OF NATURALLY OCCURRING LONG-CHAIN FATTY ALCOHOLS ON CULTURED CNS NEURONS, FEBS LETT, 213, 2, PP. 406-410, (1987); MCCARTY M.F., DOWN-REGULATION OF MICROGLIAL ACTIVATION MAY REPRESENT A PRACTICAL STRATEGY FOR COMBATING NEURODEGENERATIVE DISORDERS, MED HYPOTHESES, 67, 2, PP. 251-269, (2006); WEEKS B., PEREZ P., POLICOSANOLPLUS® AND NEUROPREVIN™ ENHANCE NEURITE REGENERATION AND PREVENT NEURITE DEGENERATION: DIETARY SUPPLEMENTS FOR NERVE REPAIR AND PREVENTION, AND REDUCTION OF NEURODEGENERATIVE DISORDERS, JANA, 9, 2, PP. 24-29, (2006); LASKOWSKI D.A., PHYSICAL AND CHEMICAL PROPERTIES OF PYRETHROIDS, REV ENVIRON CONTAM TOXICOL, 174, PP. 49-170, (2002); SHAFER T.J., MEYER D.A., CROFTON K.M., DEVELOPMENTAL NEUROTOXICITY OF PYRETHROID INSECTICIDES: CRITICAL REVIEW AND FUTURE RESEARCH NEEDS, ENVIRON HEALTH PERSPECT, 13, PP. 23-36, (2005); CASIDA J.E., PYRETHRUM FLOWERS AND PYRETHROID INSECTICIDES, ENVIRON HEALTH PERSPECT, 34, PP. 189-202, (1980); DESI I., DOBRONYI I., VARGA L., IMMUNO-, NEURO-, AND GENERAL TOXICOLOGIC ANIMAL STUDIES ON A SYNTHETIC PYRETHROID: CYPERMETHRIN, ECOTOXICOL ENVIRO SAFETY, 12, PP. 220-232, (1986); SODERLUND D.M., BLOOMQUIST J.R., NEUROTOXIC ACTIONS OF PYRETHROID INSECTICIDES, ANNU REV ENTOMOL, 34, PP. 77-96, (1989); WARMKE J.W., REENAN R.A., WANG P., ET AL., FUNCTIONAL EXPRESSION OF DROSOPHILA PARA SODIUM CHANNELS. MODULATION BY THE MEMBRANE PROTEIN TIPE AND TOXIN PHARMACOLOGY, J GEN PHYSIOL, 110, PP. 119-133, (1997); SHAFER T.J., MEYER D.A., EFFECTS OF PYRETHROIDS ON VOLTAGE-SENSITIVE CALCIUM CHANNELS: A CRITICAL EVALUATION OF STRENGTHS, WEAKNESSES, DATA NEEDS, AND RELATIONSHIP TO ASSESSMENT OF CUMULATIVE NEUROTOXICITY, TOXICOL APPL PHARMACOL, 196, PP. 303-318, (2004); SODERLUND D.M., CLARK J.M., SHEETS L.P., ET AL., MECHANISMS OF PYRETHROID NEUROTOXICITY: IMPLICATIONS FOR CUMULATIVE RISK ASSESSMENT, TOXICOLOGY, 171, PP. 3-59, (2002); TABAREAN I.V., NARAHASHI T., KINETICS OF MODULATION OF TETRODOTOXIN-SENSITIVE AND TETRODOTOXIN- RESISTANT SODIUM CHANNELS BY TETRAMETHRIN AND DELTAMETHRIN, J PHARMACOL EXP THER, 299, PP. 988-997, (2001); NARAHASHI T., NEURORECEPTORS AND ION CHANNELS AS THE BASIS FOR DRUG ACTION: PAST, PRESENT, AND FUTURE, J PHARMACOL EXP THER, 294, PP. 1-26, (2000); VAIS H., WILLIAMSON M.S., DEVONSHIRE A.L., USHERWOOD P.N., THE MOLECULAR INTERACTIONS OF PYRETHROID INSECTICIDES WITH INSECT AND MAMMALIAN SODIUM CHANNELS, PEST MANAG SCI, 57, PP. 877-888, (2001); TRAINER V.L., MOREAU E., GUEDIN D., ET AL., NEUROTOXIN BINDING AND ALLOSTERIC MODULATION AT RECEPTOR SITES 2 AND 5 ON PURIFIED AND RECONSTITUTED RAT BRAIN SODIUM CHANNELS, J BIOL CHEM, 268, PP. 17114-17119, (1993); KAREN D.J., LI W., HARP P.R., ET AL., STRIATAL DOPAMINERGIC PATHWAYS AS A TARGET FOR THE INSECTICIDES PERMETHRIN AND CHLORPYRIFOS, NEUROTOXICOLOGY, 22, 6, PP. 811-817, (2001); WU A., LIU Y., PROLONGED EXPRESSION OF C-FOS AND C-JUN IN THE CEREBRAL CORTEX OF RATS AFTER DELTAMETHRIN TREATMENT, BRAIN RES MOL BRAIN RES, 110, 1, PP. 147-151, (2003); ABDEL-RAHMAN A., SHETTY A.K., ABOU-DONIA M.B., SUBCHRONIC DERMAL APPLICATION OF N,N-DIETHYL M-TOLUAMIDE (DEET) AND PERMETHRIN TO ADULT RATS, ALONE OR IN COMBINATION, CAUSES DIFFUSE NEURONAL CELL DEATH AND CYTOSKELETAL ABNORMALITIES IN THE CEREBRAL CORTEX AND THE HIPPOCAMPUS, AND PURKINJE NEURON LOSS IN THE CEREBELLUM, EXP NEUROL, 172, PP. 153-171, (2001); HOUGARD J.M., ZAIM S.D., GUILLET P., BIFENTHRIN: A USEFUL PYRETHROID INSECTICIDE FOR TREATMENT OF MOSQUITO NETS, J MED ENTOMOL, 39, PP. 526-533, (2002); TRAN V., HOFFMAN N., MOFUNANAYA A., ET AL., BIFENTHRIN INHIBITS NEURITE OUTGROWTH IN DIFFERENTIATING PC12 CELLS, MED SCI MONIT, 12, 2, (2006); HOFFMAN N., TRAN V., DANIYAN A., ET AL., BIFENTHRIN ACTIVATES HOMOTYPIC AGGREGATION IN HUMAN T-CELL LINES, MED SCI MONIT, 12, 3, (2006); WU A., LI L., LIU Y., DELTAMETHRIN INDUCES APOPTOTIC CELL DEATH IN CULTURED CEREBRAL CORTICAL NEURONS, TOXICOL APPL PHARMACOL, 187, PP. 50-57, (2003); GROSSE G., THIELE T., HEUCKENDORF E., ET AL., DELTAMETHRIN DIFFERENTIALLY AFFECTS NEURONAL SUBTYPES IN HIPPOCAMPAL PRIMARY CULTURE, NEUROSCIENCE, 112, PP. 233-241, (2002); IMAMURA L., HASEGAWA H., KURASHINA K., ET AL., REPRESSION OF ACTIVITY-DEPENDENT C-FOS AND BRAIN-DERIVED NEUROTROPHIC FACTOR MRNA EXPRESSION BY PYRETHROID INSECTICIDES ACCOMPANYING A DECREASE IN CA(2+) INFLUX INTO NEURONS, J PHARMACOL EXP THER, 295, 3, PP. 1175-1182, (2000); NANDI A., CHANDI D., LECHESA R., ET AL., BIFENTHRIN CAUSES NEURITE RETRACTION IN THE ABSENCE OF CELL DEATH: A MODEL FOR PESTICIDE NEURODEGENERATION, MED SCI MONIT, 12, 5, (2006); BROWN T., RUMSBY P.C., CAPLETON A.C., ET AL., PESTICIDES AND PARKINSON'S DISEASE - IS THERE A LINK?, ENVIRON HEALTH PERSPECT, 114, 2, PP. 156-164, (2006); HITMI A., COUDRET A., BARTHOMEUF C., THE PRODUCTION OF PYRETHRINS BY PLANT CELL AND TISSUE CULTURES OF CHRYSANTHEMUM CINERARIAEFOLIUM AND TAGETES SPECIES, CRIT REV BIOCHEM MOL BIOL, 35, 5, PP. 317-337, (2000); NANDI A., CHANDI D., THURBER C., ET AL., THE BIOLOGICAL EFFECTS OF BIFENTHRIN ON T-CELLS AND NEURONS: A COMPARISON OF ACTIVITY, CATRINA, 1, 1, PP. 9-14, (2006); MATTSON M.P., DUAN W., WAN R., GUO Z., PROPHYLACTIC ACTIVATION OF NEUROPROTECTIVE STRESS RESPONSE PATHWAYS BY DIETARY AND BEHAVIORAL MANIPULATIONS, NEURORX, 1, 1, PP. 111-116, (2004); DRISKO J.A., THE USE OF ANTIOXIDANTS IN TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES: A CASE REPORT, J AM COLL NUTR, 21, 1, PP. 22-25, (2002)","P.P. PEREZ; MOUNT SINAI, NY 11766, 9 SEAN LANE, UNITED STATES; EMAIL: INNTEAM@AOL.COM","","ENGLISH","MED. SCI. MONIT.","ARTICLE","ISI","2-S2.0-33845500753","MED SCI MONIT","ADELPHI UNIVERSITY","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"WEEKS BS, 2006, MED SCI MONIT","WEEKS BS, 2006, MED SCI MONIT"
"MÁS R","MÁS, R. (7007164572)","D003 ANTIPLATELET THERAPY TREATMENT OF LIPOPROTEIN DISORDERS",2004,"DRUGS OF THE FUTURE","29","13",34,"10.1358/dof.2004.029.08.828449","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA","D-003 IS A MIXTURE OF VERY-HIGH-MOLECULAR-WEIGHT ALIPHATIC ACIDS PURIFIED FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) WAX WITH CHOLESTEROL-LOWERING AND PLEIOTROPIC EFFECTS POTENTIALLY BENEFICIAL FOR PREVENTING ATHEROSCLEROSIS AND ITS COMPLICATIONS. D-003 INHIBITS CHOLESTEROL BIOSYNTHESIS THROUGH THE REGULATION OF HMG-COA REDUCTASE ACTIVITY. FOLLOWING ORAL ADMINISTRATION TO RABBITS AND DOGS, IT DOSE-DEPENDENTLY REDUCED SERUM LEVELS OF TOTAL (TC) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), WHEREAS IT INCREASED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND HAD NO EFFECT ON TRIGLYCERIDES (TG); THESE EFFECTS PERSISTED AFTER LONG-TERM TREATMENT. FURTHER EXPERIMENTS IN HYPERCHOLESTEROLEMIC RABBITS SHOWED THAT D-003 PREVENTED THE INCREASE IN SERUM LDL AND INHIBITED DE NOVO SYNTHESIS OF CHOLESTEROL, INCREASING THE BINDING OF LDL TO LIVER HOMOGENATES AND THE REMOVAL OF SERUM LDL. D-003 ALSO HAS ANTIOXIDANT AND ANTIPLATELET EFFECTS. D-003 CONSISTENTLY PREVENTED EXPERIMENTAL ARTERIAL THROMBOSIS AND ISCHEMIA, AND INHIBITED THE DEVELOPMENT OF FOAM CELLS AND CUFF-INDUCED CAROTID NEOINTIMAL PROLIFERATION IN RABBITS. ORALLY ADMINISTERED D-003 ALSO EXERTED EXTRAVASCULAR EFFECTS, THE MOST RELEVANT BEING PREVENTION OF BONE LOSS INDUCED BY OVARIECTOMY IN RATS. RESULTS FROM EXPERIMENTAL TOXICOLOGY STUDIES HAVE NOT SHOWN ANY D-003-RELATED TOXICITY. IN HEALTHY SUBJECTS, D-003 (5-50 MG/DAY) OVER THE SHORT TERM LOWERED SERUM LDL-C AND TC, INCREASED HDL-C AND HAD NO EFFECT ON TG. BLEEDING TIME WAS INCREASED ON THE HIGHEST DOSE, BUT INDIVIDUAL VALUES WERE NORMAL. D-003 (10 AND 20 MG/DAY) FOR 10-14 DAYS SIGNIFICANTLY INHIBITED PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID AND COLLAGEN, BUT NOT ADP, HAD NO EFFECT ON COAGULATION TIME, LOWERED SERUM TXB2 AND INCREASED PGI2 LEVELS. D-003 (5 AND 10 MG/DAY) PREVENTED LDL FROM UNDERGOING LIPID PEROXIDATION. IN A PLACEBO-CONTROLLED DOSE-EFFECT STUDY IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, D-003 (5-40 MG/DAY FOR 8 WEEKS) SIGNIFICANTLY AND DOSE-DEPENDENTIY LOWERED SERUM LDL-C AND TC, AND INCREASED HDL-C. ANOTHER STUDY IN OLDER HYPERCHOLESTEROLEMIC PATIENTS SHOWED THAT D-003 (5 AND 10 MG/DAY) REDUCED LDL-C AND TC, RAISED HDL-C, AND AT THE HIGHER DOSE MODERATELY REDUCED TG. ANTIOXIDANT EFFECTS WERE ALSO OBSERVED AND THE TREATMENT WAS WELL TOLERATED.","","1 DOTRIACONTANOIC ACID; 1 HENTRIACONTANOIC ACID; 1 HEPTACOSANOIC ACID; 1 HEXACOSANOIC ACID; 1 HEXATRIACONTANOIC ACID; 1 NONACOSANOIC ACID; 1 OCTACOSANOIC ACID; 1 TETRATRIACONTANOIC ACID; 1 TRIACONTANOIC ACID; 1 TRITRIACONTANOIC ACID; ACETYLSALICYLIC ACID; ALIPHATIC CARBOXYLIC ACID; CARBON TETRACHLORIDE; CHOLESTEROL; D 003; DICOUMAROL; DRUG METABOLIZING ENZYME; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENALINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PARACETAMOL; PLANT EXTRACT; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; ATHEROSCLEROSIS; BLEEDING TIME; BLOOD CLOTTING TIME; BULIMIA; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG MEGADOSE; FOAM CELL; GASTRITIS; GINGIVA BLEEDING; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; INFLUENZA; INSOMNIA; LIPID PEROXIDATION; LIPOPROTEIN DEFICIENCY; LIVER HOMOGENATE; LONG TERM EXPOSURE; MOLECULAR WEIGHT; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PLEIOTROPY; POLYURIA; RABBIT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STOMACH PH; SUGARCANE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION","","","MURRAY C.J.L., LOPEZ A.D., ALTERNATE PROJECTIONS OF MORTALITY AND DISABILITY BY CAUSE 1990-2020. GLOBAL BURDEN DISEASE STUDY, LANCET, 349, PP. 1498-1504, (1997); WORLD HEALTH REPORT 1998: LIFE IN THE 21ST CENTURY - A VISION OF ALL GENEVA, (1998); SANS S., KESTELOOT H., KROMHOUT D., THE BURDEN OF THE EUROPEAN SOCIETY OF CARDIOVASCULAR MORTALITY AND MORBIDITY IN EUROPE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOVASCULAR MORTALITY AND MORBIDITY STATISTICS IN EUROPE, EUR HEART J, 18, PP. 1231-1248, (1997); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA - J AM MED ASSOC, 285, PP. 2486-2497, (2001); GOTTO A.M., ASSMAN G., CARMENA R., DAVIGNON J., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE. SECOND EDITION, (2000); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR HEART J, 19, SUPPL. A, (1998); FALK E., FERNANDEZ-ORTIZ A., ROLE OF THROMBOSIS IN ATHEROSCLEROSIS AND ITS COMPLICATIONS, AM J CARDIOL, 75, (1995); HALLER H., ENDOTHELIAL FUNCTION: GENERAL CONSIDERATIONS, DRUGS, 53, SUPPL. 1, PP. 1-10, (1997); LUSCHER T.F., BARTON M., BIOLOGY OF THE ENDOTHELIUM, CLIN CARDIOL, 20, 11 SUPPL. 2, (1997); SHAH P.K., PLAQUE DISRUPTION AND CORONARY THROMBOSIS: NEW INSIGHTS INTO PATHOGENESIS AND PREVENTION, CLIN CARDIOL, 20, 11 SUPPL. 2, (1997); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA - J AM MED ASSOC, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA - J AM MED ASSOC, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, NEW ENGL J MED, 317, PP. 1237-1245, (1987); ANDERSON K.M., WILSON P.W.F., ODELL P.M., ET AL., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS P.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, NEW ENGL J MED, 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, NEW ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ISLES G.G., LORIMER A.R., MACFARLANE P.W., MCKILLOP J.H., PACKARD C.J., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, NEW ENGL J MED, 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA - J AM MED ASSOC, 279, PP. 1615-1622, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMIZED CONTROLLED STUDY, LANCET, 360, PP. 1623-1630, (2002); PEARSON T.A., MARX H.J., THE RAPID REDUCTION IN CARDIAC EVENTS WITH LIPID-LOWERING THERAPY: MECHANISMS AND IMPLICATIONS, AM J CARDIOL, 72, PP. 1072-1073, (1993); CORSINI A., BERNINI F., QUARATO P., ET AL., NON-LIPID-RELATED EFFECTS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, CARDIOLOGY, 87, PP. 458-468, (1996); GRAW A., CAN THE CLINICAL EFFICACY OF THE HMG COA REDUCTASE INHIBITORS BE EXPLAINED SOLELY BY THEIR EFFECTS ON LDL-CHOLESTEROL?, ATHEROSCLEROSIS, 125, PP. 267-269, (1996); DELANTY N., VAUGHAN C.J., VASCULAR EFFECTS OF STATINS IN STROKE, STROKE, 28, PP. 2315-2320, (1997); BELLOSTA S., FERRI N., ARNABOLDI L., ET AL., PLEIOTROPIC EFFECTS OF STATINS IN ATHEROSCLEROSIS AND DIABETES, DIABETES CARE, 23, SUPPL. 2, (2000); CORSINI A., PAZZUCCONI F., ARNABOLDI L., ET AL., DIRECT EFFECTS OF STATINS ON THE VASCULAR WALL, J CARDIOVASC PHARMACOL, 31, PP. 773-778, (1998); DAVIGNON J., THE PLEIOTROPIC EFFECT OF DRUGS AFFECTING LIPID METABOLISM, ATHEROSCLEROSIS XI, 1998. PROCEEDINGS OF THE XITH INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS (OCT 5-8, PARIS), PP. 63-77, (1997); SHEPHERD J., FIBRATES AND STATINS IN THE TREATMENT OF HYPERLIPIDAEMIA: AN APPRAISAL OF THEIR EFFICACY AND SAFETY, EUR HEART J, 16, PP. 5-13, (1995); FARNIER J.A., GOTTO A.M., CHOOSING THE RIGHT LIPID-REGULATING AGENT, DRUGS, 52, PP. 649-661, (1996); BAKER S.K., TARNOPOLSKY M.A., STATIN MYOPATHIES: PATHOPHYSIOLOGIC AND CLINICAL PERSPECTIVES, CLIN INVEST MED, 24, PP. 258-272, (2001); GAIST D., GARCIA A., HUERTA C., ET AL., LIPID-LOWERING DRUGS AND RISK OF MYOPATHY: A POPULATION BASED FOLLOW-UP STUDY, EPIDEMIOL, 12, PP. 565-569, (2001); PASTERNAK R.C., SMITH JR. S., BAIREY-MERZ C.N., ET AL., ACC/AHA/NHLBI CLINICAL ADVISORY ON THE USE AND SAFETY OF STATINS, J AM COLL CARDIOL, 40, PP. 567-572, (2002); COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY-I: PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BMJ - BR MED J, 308, PP. 81-106, (1994); CAIRNS J.A., LEWIS JR. H.D., MEADE T.W., SUTTON G.C., THEROUX P., ANTITHROMBOTIC AGENTS IN CORONARY ARTERY DISEASE, CHEST, 108, 4 SUPPL., (1995); SHERMAN D.G., DYKEN JR. M.L., GENT M., HARRISON M.J.G., HART R.G., MOHR J.P., ANTITHROMBOTIC THERAPY FOR CEREBROVASCULAR DISORDERS. AN UPDATE, CHEST, 108, 4 SUPPL., (1995); SCHAFER A., ANTIPLATELET THERAPY, AM J MED, 101, PP. 199-209, (1996); PATRONO C., COLLER B., DALEN J.E., FITZGERALD G.A., FUSTER V., GENT M., HIRSCH J., ROTH G., PLATELET-ACTIVE DRUGS: THE RELATIONSHIPS AMONG DOSE, EFFECTIVENESS, AND SIDE EFFECTS, CHEST, 119, 1 SUPPL., (2001); AWTRY E.H., LOSCALZO J., ASPIRIN, CIRCULATION, 101, PP. 1206-1208, (2000); HASSAN M., AMONKAR M., ASPIRIN FOR PRIMARY AND SECONDARY PROPHYLAXIS OF CARDIOVASCULAR DISEASE, CURR THER RES, 62, PP. 676-690, (2001); MCTAVISH D., FAULDS D., GOA K.L., TICLOPIDINE. AN UPDATED REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN PLATELET-DEPENDENT DISORDERS, DRUGS, 40, PP. 238-259, (1990); COUKELL A.J., MARKHAM A., CLOPIDOGREL, DRUGS, 54, PP. 745-750, (1997); A RANDOMIZED, BLINDED, TRIAL OF CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT HIGH RISK OF ISCHEMIC EVENTS (CAPRIE), LANCET, 348, PP. 1329-1339, (1996); TANEMOTO K., KANAOKA Y., KUINOSE M., ASSESSMENT OF ANTITHROMBOTIC AGENTS USING THE PLATELET AGGREGATION TEST, CURR THER RES, 61, PP. 798-806, (2000); GONZALES BRAVO L., MARRERO DELANGE D., LAGUNA GRANJA A., MAS FERREIRO R.M., DE LOURDES ARRUZAZABALA VALMANA M., CARBAJAL QUINTANA D., CORA MEDINA M., MENENDEZ SOTO DEL VALLE R.; MENDEZ ANTOLIN E., MARRERO DELANGE D., GONZALEZ CANAVACIOLO V., LAGUNA GRANJA A., CG DETERMINATION OF LONG CHAIN FATTY ACIDS THAT COMPOSE D003 IN 5-MG FILM-COATED TABLETS, J PHARM BIOMED ANAL, 31, PP. 613-620, (2003); MENDEZ ANTOLIN E., MARRERO DELANGE D., GONZALEZ CANAVACIOLO V., TEJEDA DIAZ Y., SIERRA PEREZ R., CORA MEDINA M., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ACIDS THAT COMPOSE D003 IN 10 MG FILM-COATED TABLETS, FARMACO, 59, PP. 543-547, (2004); GAMEZ R., MENDOZA S., MAS R., MESA R., CASTANO G., RODRIGUEZ B., MARRERO D., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES, 61, PP. 460-468, (2000); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA R., MESA M., DE ARMAS M., THE EFFECTS OF D-003 AND POLICOSANOL ON THE LIPID PROFILE AND ENDOTHELEMIA CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES, 62, PP. 209-220, (2001); MAS R., POLICOSANOL, DRUGS FUT, 25, PP. 569-586, (2000); GAMEZ R., MENDOZA S., MAS R., NOA M., ARRUZAZABALA L., CARBAJAL D., CASTANO G., GOICOCHEA E., MESA M., MENDOZA N., COMPARISON OF THE CHOLESTEROL-LOWERING EFFECTS AND TOXICITY OF D-003 AND LOVASTATIN ON NORMOCHOLESTEROLEMIC RABBITS, DRUGS R&D, 4, PP. 219-229, (2003); MENDOZA S., GAMEZ R., MAS R., GOICOCHEA E., EFFECTS OF D-003, A MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ACIDS, FLUVASTATIN AND THE COMBINED THERAPY D-003 PLUS FLUVASTATIN ON THE LIPID PROFILE OF NORMOCHOLESTEROLEMIC RABBITS, INT J TISSUE REACT, 25, PP. 81-89, (2003); GAMEZ R., MAS R., NOA M., MENENDEZ R., GARCIA H., GONZALEZ J., FEREZ Y., GOICOCHEA E., EFFECTS OF CHRONIC ADMINISTRATION OF D-003, A MIXTURE OF SUGAR CANE WAX HIGH MOLECULAR WEIGHT ACIDS, IN BEAGLE DOGS, DRUGS EXP CLIN RES, 30, PP. 75-88, (2004); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); KROON P.A., HAND K.M., HUFF J.W., ALBERTS A.W., THE EFFECTS OF MEVINOLIN ON SERUM CHOLESTEROL LEVELS OF RABBITS WITH HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 44, PP. 41-48, (1982); CHAO Y.S., KROON P.A., YAMIN T.T., ET AL., REGULATION OF HEPATIC RECEPTOR-DEPENDENT DEGRADATION OF LDL BY MEVINOLIN IN RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BIOCHIM BIOPHYS ACTA, 754, PP. 134-141, (1983); MENENDEZ R., MAS R., PEREZ J., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CAN J PHYSIOL PHARMACOL, 82, PP. 22-29, (2004); AVIRAM M., MACROPHAGES, LDL OXIDATION AND ATHEROSCLEROSIS, ATHEROSCLEROSIS XI, 1998. PROCEEDINGS OF THE XITH INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, PP. 483-492, (1997); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ J., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, CAN J PHYSIOL PHARMACOL, 80, PP. 13-21, (2002); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., VALDES S., ANTIPLATELET AND ANTITHROMBOTIC EFFECT OF D003, PHARMACOL RES, 42, PP. 137-143, (2000); GAMEZ R., MAS R., NOA M., MENENDEZ R., GARCIA H., GONZALEZ J., PEREZ Y., GOICOCHEA E., SIX-MONTH TOXICITY STUDY OF ORAL ADMINISTRATION OF D-003 IN SPRAGUE DAWLEY RATS, DRUGS R&D, 2, PP. 375-386, (2002); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., MAS R., D-003 AND WARFARIN ON THE BLEEDING TIME AND VENOUS THROMBOSIS EXPERIMENTALLY INDUCED IN RATS, J MED FOOD, 7, PP. 260-263, (2004); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., D-003, A NEW COMPOUND WITH EFFECTS ON ARACHIDONIC ACID METABOLITES, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 67, PP. 19-24, (2002); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., SYNERGISTIC EFFECT OF D-003 AND ASPIRIN ON EXPERIMENTAL THROMBOSIS MODEL, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 68, PP. 305-310, (2003); NOA M., MAS R., MENDOZA N., ET AL., EFFECTS OF D-003 ON FOAM CELLS INDUCED WITH CARRAGEENAN IN EXPERIMENTAL MODELS, REV CNIC CIEN BIOL, 36, (2004); NOA M., MAS R., MENDOZA N., ET AL., EFFECTS OF D-003 ON SMOOTH MUSCLE CELL PROLIFERATION IN CUFFED RABBITS; CARBAJAL D., NOA M., MOLINA V., ARRUZAZABALA M.L., MAS R., MENDOZA S., GONZALEZ J., EFFECT OF D-003 ON ISOPROTERENOL-INDUCED MYOCARDIAL NECROSIS IN RATS, J MED FOOD, 6, PP. 13-18, (2003); CARBAJAL D., ARRUZAZABLA M.L., NOA M., ET AL., PROTECTIVE EFFECT OF D-003 ON EXPERIMENTAL SPINAL CORD ISCHEMIA IN RABBITS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 70, PP. 1-6, (2004); NOA M., MENDOZA S., MAS R., MENDOZA N., EFFECT OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT PRIMARY ACIDS FROM SUGAR CANE WAX, ON CI<SUB>4</SUB>C-INDUCED LIVER ACUTE INJURY IN RATS, DRUGS EXP CLIN RES, 28, PP. 177-183, (2003); MENDOZA S., NOA M., MAS R., MENDOZA N., EFFECT OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT PRIMARY ACIDS FROM SUGAR CANE WAX, ON PARACETAMOL-INDUCED LIVER DAMAGE IN RATS, INT J TISSUE REACT, 25, PP. 91-98, (2003); RUSSELL R.G., ROGERS M.J., FRITH J.C., LUCKMAN S.P., COXON F.P., BENFORD H.L., CROUCHER P.I., SHIPMAN C., FLEISCH H.A., THE PHARMACOLOGY OF BIPHOSPHONATES AND NEW INSIGHTS INTO THEIR MECHANISM OF ACTION, J BONE MINER RES, 14, SUPPL. 2, PP. 53-65, (1999); FISHER J.E., ROGERS M.J., HALASY J.M., LUCKMAN S.P., HUGUES D.E., MASARACHIA P.J., WESOLOWSKI G., RUSSELL R.G.G., RODAN G.A., RESZKA A.A., ALENDRONATE MECHANISM OF ACTION: GERANYLGERANIOL, AN INTERMEDIATE OF THE MEVALONATE PATHWAY, PREVENTS INHIBITION OF OSTEOCLASTS FORMATION, BONE RESORPTION AND KINASE ACTIVATION IN VITRO, PROC NATL ACAD SCI USA, 96, PP. 133-138, (1999); NOA M., MAS R., MENDOZA S., GAMEZ R., MENDOZA N., EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ACIDS FROM SUGARCANE WAX, ON BONES OF OVARIECTOMIZED RATS, DRUGS EXP CLIN RES, 30, PP. 35-41, (2004); GAMEZ R., RODEIRO I., GONZALEZ J., ET AL., EFFECTS OF D-003 ON HEPATIC MICROSOMAL METABOLIZYING ENZYMES, J MED FOOD, (2004); MENENDEZ R., MARRERO D., MENDEZ E., ET AL., PLASMA LEVELS OF OCTACOSANOIC ACID AFTER ENDOGENOUS DOSING WITH D-003 TO RABBITS, REV CNIC CIEN BIOL, 36, (2004); MENENDEZ R., MAS R., PEREZ Y., ET AL., PHARMACOKINETIC STUDY OF 3H-OCTACOSANOIC ACID IN MALE RATS, REV CNIC CIEN BIOL, 36, (2004); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); GAMEZ R., MAS R., NOA M., ET AL., ACUTE AND SUBCHRONIC ORAL TOXICITY OF D-003 IN RATS, TOXICOL LETT, 118, PP. 31-41, (2000); GAMEZ R., MAS R., NOA M., ET AL., ACUTE TOXICOLOGY OF D-003 IN RABBITS, REV CNIC CIEN BIOL, 36, (2004); GAMEZ R., RODEIRO I., FERNANDEZ I., ACOSTA P., PRELIMINARY EVALUATION OF THE CYTOTOXIC AND GENOTOXIC POTENTIAL OF D-003: MIXTURE OF VERY LONG CHAIN ALIPHATIC ACIDS, TERATOG CARCINOG MUTAG, 22, PP. 175-181, (2002); GAMEZ R., GONZALEZ J.E., RODEIRO I., FERNANDEZ I., ALEMAN C., RODRIGUEZ M.D., ACOSTA P.C., GARCIA H., IN VIVO GENOTOXIC EVALUATION OF D-003, A MIXTURE OF VERY LONG CHAIN ALIPHATIC ACIDS, J MED FOOD, 4, PP. 85-91, (2001); GONZALEZ J.E., GAMEZ R., RODEIRO I., ET AL., STUDY ON THE GENOTOXIC EFFECT OF D-003 IN SD RATS USING ALKALINE ELECTROPHORESIS OF INDIVIDUAL CELLS IN GEL (PILOT STUDY), REV CNIC CIEN BIOL, 35, PP. 125-127, (2004); RODRIGUEZ M.D., GAMEZ R., GONZALEZ J.E., GARCIA H., ACOSTA C.P., GOICOCHEA E., LACK OF DEVELOPMENTAL TOXICITY OF D-003: A MIXTURE OF LONG-CHAIN FATTY ACIDS IN RATS, FOOD CHEM TOXICOL, 41, PP. 89-93, (2003); RODRIGUEZ M.D., GONZALEZ J.E., GARCIA H., ET AL., TERATOGENESIS STUDY OF D-003 IN THE RABBIT; GAMEZ R., MAS R., NOA M., ET AL., CARCINOGENESIS STUDY OF D-003 IN SPRAGUE DAWLEY RATS: PARTIAL REPORT OF A 1-YEAR STUDY, REV CNIC CIEN BIOL, 36, (2004); SCHLEDE E., MISCHKE U., DIENER W., KAYSER D., THE INTERNATIONAL VALIDATION STUDY OF THE ACUTE TOXIC CLASS METHOD (ORAL), ARCH TOXICOL, 69, PP. 659-670, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., ASSESSMENT OF THE EFFECTS OF D-003, A NEW ANTIPLATELET AND HYPOCHOLESTEROLEMIC COMPOUND ON HEALTHY VOLUNTEERS: A PHASE I CLINICAL STUDY, DRUGS R&D, 3, PP. 337-348, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., CASTANO G., GAMEZ R., EFFECTS OF D-003, A NEW COMPOUND PURIFIED FROM SUGAR CANE WAX, ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS: A RANDOMIZED, DOUBLE-BLINDED CLINICAL STUDY, CLIN DRUG INVEST, 23, PP. 107-118, (2003); CASTANO G., MENENDEZ R., MAS R., LEDON N., FERNANDEZ J., PEREZ J., GONZALEZ R.M., LEZCAY M., EFFECTS OF D-003 ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY VOLUNTEERS, CLIN DRUG INVEST, 23, PP. 193-203, (2003); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFFECTS OF ONE MONTH TREATMENT WITH D-003, A MIXTURE OF VERY LONG CHAIN FATTY ACIDS PURIFIED FROM SUGAR CANE WAX, ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL, REV CNIC CIEN BIOL, 36, (2004); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., A RANDOMISED, DOUBLE-BLINDED CLINICAL STUDY OF THE EFFECTS OF POLICOSANOIC (D-003), A NEW SUBSTANCE PURIFIED FROM SUGAR CANE WAX, ON PLATELET AGGREGATION AND PLASMA LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, INT J PHARMACOL CLIN RES, (2004); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF D-003 (5-40 MG/DAY) ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A PHASE II CLINICAL STUDY, CLIN DRUG INVEST, 23, PP. 789-802, (2003); MENENDEZ R., MAS R., PEREZ Y., ET AL., EFFECT OF D-003, A MIXTURE OF VERY HIGH MOLECULAR WEIGHT ALIPHATIC ACIDS PURIFIED FROM SUGARCANE WAX, ON SERUM LIPID PEROXIDATION (LPO) MARKERS IN ELDERLY","R. MÁS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS FUTURE","ARTICLE","ISI","2-S2.0-6344291874","DRUGS FUTURE","NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"MÁS R, 2004, DRUGS FUTURE","MÁS R, 2004, DRUGS FUTURE"
"NOA M;MENDOZA S;MÁS R;MENDOZA N","NOA, MIRIAM (7003318964); MENDOZA, SARAHÍ (7102759819); MÁS, ROSA (7007164572); MENDOZA, NILDA (7006243358)","EFFECT OF POLICOSANOL ON CARBON TETRACHLORIDEINDUCED ACUTE LIVER DAMAGE IN SPRAGUEDAWLEY RATS",2003,"DRUGS IN R AND D","4","6",11,"10.2165/00126839-200304010-00003","HAVANA CITY, AVENUE 25, 158 STREET, CUBA;HAVANA CITY, AVENUE 25, 158 STREET, CUBA;HAVANA CITY, AVENUE 25, 158 STREET, CUBA;HAVANA CITY, AVENUE 25, 158 STREET, CUBA","BACKGROUND: POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGARCANE (SACCHARUM OFFICINARUM, L.) WAX. BENEFICIAL PLEIOTROPIC EFFECTS OF POLICOSANOL, SUCH AS INHIBITION OF THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN TO LIPID PEROXIDATION, HAVE BEEN SHOWN. POLICOSANOL HAS A GOOD SAFETY PROFILE AND WELL TOLERATED AND, TO DATE, NO DRUG-RELATED ADVERSE EFFECTS HAVE BEEN DEMONSTRATED. SPECIFICALLY, POLICOSANOL HAS NOT BEEN SHOWN TO AFFECT LIVER FUNCTION OR TO INCREASE LIVER ENZYME LEVELS IN EXPERIMENTAL OR CLINICAL STUDIES. AIM: THIS STUDY WAS CONDUCTED TO DETERMINE WHETHER POLICOSANOL PREVENTS LIVER DAMAGE INDUCED BY CARBON TETRACHLORIDE (CCL4) IN RATS, SINCE THIS MODEL HAS BEEN ASSOCIATED WITH AN INCREASED RATE OF LIPID PEROXIDATION. METHODS:. MALE SPRAGUE-DAWLEY RATS WERE RANDOMISED TO FOUR EXPERIMENTAL GROUPS: NEGATIVE CONTROLS (NO CCL4 OR POLICOSANOL, GROUP 1); POSITIVE CONTROLS (CCL4 BUT NO POLICOSANOL, GROUP 2); POLICOSANOL 25 MG/KG (GROUP 3) AND POLICOSANOL 100 MG/KG (GROUP 4). ACUTE LIVER INJURY WAS INDUCED IN GROUPS 2, 3 AND 4 BY CCL4 SUSPENDED IN OLIVE OIL AND ADMINISTERED AT A DOSE OF 1590 MG/KG VIA INTRAPERITONEAL INJECTION. EIGHTEEN HOURS AFTER CCL4 DOSING, THE RATS WERE ANAESTHETISED AND THEIR LIVERS REMOVED FOR HISTOPATHOLOGICAL STUDIES. RESULTS: POLICOSANOL 25 AND 100 MG/KG DOSE DEPENDENTLY AND SIGNIFICANTLY (P < 0.01) DECREASED THE PERCENTAGE OF BALLOONED CELLS AND HEPATOCYTES WITH LIPID INCLUSIONS AND INCREASED THE PERCENTAGE OF NORMAL HEPATOCYTES COMPARED WITH POSITIVE CONTROLS. THE PERCENTAGE INHIBITION OF THE OCCURRENCE OF BALLOONED CELLS AND HEPATOCYTES WITH LIPIDS WAS MARKED, REACHING 71 AND 49%, RESPECTIVELY, WITH THE HIGHER DOSE (100 MG/KG). THE PERCENTAGE OF SWOLLEN HEPATOCYTES WAS UNCHANGED BY POLICOSANOL COMPARED WITH POSITIVE CONTROLS. NO HISTOLOGICAL ALTERATIONS IN LIVER SECTIONS WERE FOUND IN THE NEGATIVE CONTROL GROUP. NECROTIC AREAS AND INFLAMMATORY INFILTRATES WERE OBSERVED IN THE LIVER OF SEVEN OF EIGHT (87.5%) ANIMALS IN THE POSITIVE CONTROL GROUP. HOWEVER, ONLY ONE OF EIGHT (12.5%) ANIMALS TREATED WITH POLICOSANOL 25 MG/KG AND NONE (0%) TREATED WITH THE HIGHER DOSE (100 MG/KG) SHOWED SUCH A PATTERN. CONCLUSIONS: POLICOSANOL PROTECTED AGAINST THE HISTOLOGICAL CHANGES CHARACTERISTIC OF CCL4-INDUCED HEPATIC INJURY IN RATS, A MODEL OF HEPATOTOXICITY IN WHICH THE PROCESS OF LIPID PEROXIDATION PLAYS A ROLE. FURTHER STUDIES AIMED AT DEMONSTRATING THE CONNECTION BETWEEN SUCH HEPATOPROTECTIVE AND ANTIOXIDANT EFFECTS OF POLICOSANOL MUST BE INITIATED.","","ANIMALS; CARBON TETRACHLORIDE; FATTY ALCOHOLS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; ANTIOXIDANT; CARBON TETRACHLORIDE; HYPOCHOLESTEROLEMIC AGENT; LIVER ENZYME; LIVER PROTECTIVE AGENT; LOW DENSITY LIPOPROTEIN; OLIVE OIL; PLANT EXTRACT; POLICOSANOL; SUGARCANE EXTRACT; UNCLASSIFIED DRUG; CARBON TETRACHLORIDE; FATTY ALCOHOL; POLICOSANOL; ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL COUNT; CELL INCLUSION; CELL SWELLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG PURIFICATION; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; LIVER CELL; LIVER FUNCTION; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZATION; RAT; STATISTICAL ANALYSIS; SUGARCANE; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; LIVER; PATHOLOGY; SPRAGUE DAWLEY RAT","HAVANA CITY WEST SCIENTIFIC ORGANIZATION","THIS STUDY WAS SPONSORED THROUGH A RESEARCH GRANT APPROVED BY THE SCIENTIFIC TECHNICAL COUNCIL OF THE HAVANA CITY WEST SCIENTIFIC ORGANIZATION.","PLAA G.L., HEWITT W.R., DETECTION AND EVALUATION OF CHEMICALLY INDUCED LIVER INJURY, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 599-628, (1989); RECKNAGEL R.O., GLENDE E.A., WALLER R.L., LOWRY K., LIPID PEROXIDATION: BIOCHEMISTRY, MEASUREMENT, AND SIGNIFICANCE IN LIVER CELL INJURY, TOXICOLOGY OF THE LIVER, PP. 213-241, (1982); WENDEL A., MEASUREMENT OF IN VIVO LIPID PEROXIDATION AND TOXICOLOGICAL SIGNIFICANCE, FREE RADIC. BIOL. MED., 3, PP. 355-358, (1987); MENENDEZ R., FRAGA V., SOTOLONGO V., ET AL., EFECTO DE LA ADMINISTRACIÓN ORAL DEL POLICOSANOL SOBRE EL METABOLISMO LIPÍDICO DE RATAS NORMOCOLESTEROLÉMICAS, REV. MEX. CIEN. FARM, 24, PP. 16-18, (1993); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTHS STUDY, CURR. THER. RES., 56, PP. 819-828, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, PP. 245-254, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 390-401, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3 YEAR OPEN FOLLOW-UP, CURR. THER. RES., 58, PP. 868-875, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, PP. 379-391, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. A. BIOL. SCI. MED. SCI., 56, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); MAS R., POLICOSANOL, DRUGS FUT., 25, PP. 569-586, (2000); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL. BEHAV., 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, PP. 225-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR. THER. RES., 61, PP. 609-620, (2000); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, TOXICOL. LETT., 2, (1992); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1994); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J. MED. FOOD, 4, PP. 57-66, (2001); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG. CARCINOG. MUTAG., 14, PP. 239-249, (1994); ALEMAN C., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM. TOXICOL., 33, PP. 573-578, (1995); CORO R.M., BORRAJERO I., DIGIPAT. UN SISTEMA CUBANO PARA MORFOMETRÍA DE IMÁGENES, REV. LATINOAM. PATOL., 39, PP. 9-10, (1996); CHARBONNEAU M., IIJIMA M., COTE M.G., ET AL., TEMPORAL ANALYSIS OF RAT LIVER INJURY FOLLOWING POTENTIATION OF CARBON TETRACHLORIDE HEPATOTOXICITY WITH KETONIC OR KETOGENIC COMPOUNDS, TOXICOLOGY, 32, PP. 95-112, (1985); MARTINEZ-CALVA A., CAMPOS-APAEZ E., ROSALES-VEGA E., ET AL., VITAMIN E IMPROVES MEMBRANE LIPID ALTERATIONS INDUCED BY CCL<SUB>4</SUB> INTOXICATION, J. APPL. TOXICOL., 4, PP. 270-272, (1984); MURIEL P., MOURELLE M., PREVENTION BY SILYMARIN OF MEMBRANE ALTERATIONS IN ACUTE CCL4 LIVER DAMAGE, J. APPL. TOXICOL., 10, PP. 275-279, (1990); RODEIRO I., ALEMAN C.L., MAS R., ET AL., EFECTOS DEL POLICOSANOL SOBRE LAS ENZIMAS MICROSOMALES HEPÁTICAS EN RATAS S.D, REVISTA CENIC CIEN. BIOL., 31, PP. 113-116, (2000); PEREZ-SOUTO N., ACOSTA P.C., MEDEROS C.M., ET AL., EFECTO DEL POLICOSANOL SOBRE LA FAMACOCINÉTICA DE LA ANTIPIRINA, REV. CENIC CIEN. BIOL., 22, PP. 77-78, (1991); NAGAI H., AOKI M., SHIMAZAWA T., ET AL., EFFECT OF OKY-046 AND ONO-3708 ON LIVER INJURY IN MICE, JPN. J. PHARMACOL., 51, PP. 191-197, (1989)","M. NOA; CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RES., HAVANA CITY, AVENUE 25, 158 STREET, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS R D","ARTICLE","ISI","2-S2.0-0041355283","DRUGS R D","NOTREPORTED","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RES.;EMAIL: CLINICA@ENET.CU",NA,"NOA M, 2003, DRUGS R D","NOA M, 2003, DRUGS R D"
"NOA M;MÁS R;MENDOZA S;GÁMEZ R;MENDOZA N;GONZÁLEZ J","NOA, M. (7003318964); MÁS, R. (7007164572); MENDOZA, S. (7102759819); GÁMEZ, R. (7003605346); MENDOZA, N. (7006243358); GONZÁLEZ, J. (35607356200)","POLICOSANOL PREVENTS BONE LOSS IN OVARIECTOMIZED RATS",2004,"DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH","30","6",6,"","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA","OSTEOPOROSIS IS CHARACTERIZED BY REDUCED BONE MASS, ABNORMAL BONE ARCHITECTURE AND INCREASED FRACTURE RISK. OVARIECTOMY IMPAIRS BONE MASS AND METABOLISM IN RATS AND OVARIECTOMIZED RATS ARE CONSIDERED AS A SUITABLE MODEL OF POSTMENOPAUSAL OSTEOPOROSIS. MEVALONATE IS REQUIRED FOR PRODUCING LIPOIDS THAT ARE IMPORTANT IN OSTEOCLAST ACTIVITY AND THUS DRUGS AFFECTING MEVALONATE PRODUCTION CAN PREVENT BONE LOSS IN RODENTS. POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG ISOLATED FROM SUGAR CANE WAX THAT INHIBITS CHOLESTEROL BIOSYNTHESIS THROUGH AN INDIRECT REGULATION OF HYDROXYMETHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE ACTIVITY. THE PURPOSE OF THIS STUDY WAS TO DETERMINE WHETHER POLICOSANOL COULD PREVENT BONE LOSS IN THE BONES OF OVARIECTOMIZED RATS BY COMPARING ITS EFFECTS WITH THOSE INDUCED BY ESTRADIOL. SPRAGUE DAWLEY FEMALE RATS WERE RANDOMLY DISTRIBUTED IN FOUR GROUPS: A SHAM-OPERATED GROUP TREATED WITH TWEEN/H2O VEHICLE AND THREE GROUPS OF OVARIECTOMIZED RATS TREATED WITH 17 ΒΒ-ESTRADIOL (30 ΜG/KG/DAY) OR POLICOSANOL (50 AND 200 MG/KG/DAY), RESPECTIVELY, FOR 3 MONTHS. AT TREATMENT COMPLETION THE RATS WERE SACRIFICED, THEIR BONES REMOVED AND VARIABLES OF BONE RESORPTION AND FORMATION WERE INVESTIGATED BY HISTOMORPHOMETRY. OVARIECTOMY INCREASED TRABECULAR SEPARATION BUT DIMINISHED THE NUMBER AND THICKNESS OF TRABECULES. ESTRADIOL AND POLICOSANOL PREVENTED THESE EFFECTS COMPARED WITH OVARIECTOMIZED CONTROLS. BOTH TREATMENTS ALSO PREVENTED AN INCREASE IN THE NUMBER OF OSTEOCLASTS AND THEIR SURFACE AREA INDUCED BY OVARIECTOMY. ESTRADIOL, BUT NOT POLICOSANOL, SIGNIFICANTLY PREVENTED AN INCREASE OF OSTEOBLAST SURFACE AREA COMPARED WITH OVARIECTOMIZED CONTROLS. IN CONCLUSION, POLICOSANOL PREVENTED BONE LOSS AND DECREASED BONE RESORPTION IN OVARIECTOMIZED RATS, SUGGESTING THAT IT SHOULD BE POTENTIALLY USEFUL IN PREVENTING BONE LOSS IN POSTMENOPAUSAL WOMEN.","","ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; FATTY ALCOHOLS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTUBATION, GASTROINTESTINAL; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; ESTRADIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RAT; SUGARCANE; TRABECULAR BONE","","","WATTS N.B., OSTEOPOROSIS: PREVENTION, DETECTION AND TREATMENT, J. MED. ASSOC. GA., 86, 3, (1997); LOOKER A.C., JOHNSTON C.C., WAHNER H.W., ET AL., PREVALENCE OF LOW FEMORAL BONE DENSITY IN OLDER US WOMEN FROM NHANES III, J. BONE MINER. RES., 10, (1995); KALU D.N., THE OVARIECTOMIZED RAT MODEL OF POSTMENOPAUSAL BONE LOSS, BONE MINER., 15, (1991); AERSSENS J., VAN AUDEKERCKE R., GEUSENS P., ET AL., MECHANICAL PROPERTIES, BONE MINERAL CONTENT, AND BONE COMPOSITION (COLLAGEN, OSTEOCALCIN, IGF-1) OF THE RAT FEMUR. INFLUENCE OF OVARIECTOMY AND NANDROLONE DECANOATE (ANABOLIC STEROID) TREATMENT, CALCIF. TISSUE INT., 53, (1993); BAGI C., AMMANN P., RIZZOLI R., MILLER S., EFFECT OF ESTROGEN DEFICIENCY ON CANCELLOUS AND CORTICAL BONE STRUCTURE AND STRENGTH OF THE FEMORAL NECK IN RATS, CALCIF. TISSUE INT., 61, (1997); THOMPSON D.D., SIMMONS H.A., PIRIE C.M., KE H.Z., FDA GUIDELINES AND ANIMAL MODELS FOR OSTEOPOROSIS, BONE, 17, SUPPL. 4, (1995); JOSSE R.G., EFFECTS OF OVARIAN HORMONE THERAPY ON SKELETAL AND EXTRASKELETAL TISSUES IN WOMEN, J. CAN. MED. ASSOC., 155, (1996); RUSSELL R.G., ROGERS M.J., FRITH J.C., ET AL., THE PHARMACOLOGY OF BIPHOSPHONATES AND NEW INSIGHTS INTO THEIR MECHANISM OF ACTION, J. BONE MIN. RES., 14, SUPPL. 2, (1999); FISHER J.E., ROGERS M.J., HALASY J.M., ET AL., ALENDRONATE MECHANISM OF ACTION: GERANYLGERANIOL, AN INTERMEDIATE OF THE MEVALONATE PATHWAY, PREVENTS INHIBITION OF OSTEOCLASTS FORMATION, BONE RESORPTION AND KINASE ACTIVATION IN VITRO, PROC. NATL. ACAD. SCI. USA, 96, (1999); MUNDY G., GARRET R., HARRIS S., ET AL., STIMULATION OF BONE FORMATION IN VITRO AND IN RODENTS BY STATINS, J. SCIENCE, 286, (1999); MEIER C., SCHLIENGER R., KRAENZLIN M., HMG-COA REDUCTASE INHIBITORS AND THE RISK OF FRACTURES, JAMA, 283, (2000); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, (2000); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 13, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. A, 56, (2001); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN. DRUG INVEST., 21, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, (1999); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL. RES., 29, (1996); MENENDEZ R., ARRUZAZABALA M.L., AMOR A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, (1997); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, (2001); NOA M., MAS R., MENDOZA S., ET AL., EFFECTS OF D-003, A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ACIDS FROM SUGAR CANE WAX, ON BONES OF OVARIECTOMIZED RATS, DRUG EXP. CLIN. RES., 30, 1, (2004); MOSEKILDE L., DANIELSEN C., KNUDSEN B., THE EFFECT OF AGING AND OVARIECTOMY ON THE VERTEBRAL BONE MASS AND BIOCHEMICAL PROPERTIES OF MATURE RATS, BONE, 14, (1993); PARFITT A., DREZNER M., GLORIEUX F., ET AL., BONE HISTOMORPHOMETRY: STANDARDIZATION OF NOMENCLATURE, SYMBOLS, AND UNITS, J. BONE MIN. RES., 2, (1987); CORO R.M., BORRAJERO I., DIGIPAT. UN SISTEMA CUBANO PARA MORFOMETRIA DE IMÁGENES, REV. LATINOAM PATOL., 39, (1996); PARHAMI F., MORROW A., BALUCAN J., TINTUT Y., LIPID OXIDATION PRODUCTS HAVE OPPOSITE EFFECTS ON CALCIFYING VASCULAR CELL AND BONE CELL DIFFERENTIATION. A POSSIBLE EXPLANATION FOR THE PARADOX OF ARTERIAL CALCIFICATION IN OSTEOPOROTIC PATIENTS, ARTERIOSCLER. THROMB. VASC. BIOL., 17, (1997); XU H., WATKINS B., SEIFERT M., VITAMIN E STIMULATES TRABECULAR BONE FORMATION AND ALTERS EPIPHYSEAL CARTILAGE MORPHOMETRY, CALCIF. TISSUE INT., 57, (1995); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT. J. CLIN. PHARMACOL., 50, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION. A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR. THER. RES., 61, (2000); JENSEN J.E., KOLLERUP G., SORENSEN H.A., SORENSON O.H., INTRAINDIVIDUAL VARIABILITY ON BONE MARKERS IN THE URINE, SCAND. J. CLIN. LAB. INVEST., 57, (1997)","M. NOA; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY 6990, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS EXP. CLIN. RES.","ARTICLE","ISI","2-S2.0-4043162668","DRUGS EXP CLIN RES","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"NOA M, 2004, DRUGS EXP CLIN RES","NOA M, 2004, DRUGS EXP CLIN RES"
"CHI H;KA Y;HUANG Y;ZHEN Y","CHI, HO NG (37045252600); KA, YIU LEUNG (37045523400); HUANG, YU (57020209200); ZHEN, YU CHEN (7101794144)","POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOWDENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS",2005,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","53","4",38,"10.1021/jf051269a","FOOD AND NUTRITIONAL SCIENCES PROGRAM, DEPARTMENT OF BIOCHEMISTRY, CHINESE UNIVERSITY OF HONG KONG, SHATIN, NT, HONG KONG;FOOD AND NUTRITIONAL SCIENCES PROGRAM, DEPARTMENT OF BIOCHEMISTRY, CHINESE UNIVERSITY OF HONG KONG, SHATIN, NT, HONG KONG;DEPARTMENT OF PHYSIOLOGY, CHINESE UNIVERSITY OF HONG KONG, SHATIN, NT, HONG KONG;FOOD AND NUTRITIONAL SCIENCES PROGRAM, DEPARTMENT OF BIOCHEMISTRY, CHINESE UNIVERSITY OF HONG KONG, SHATIN, NT, HONG KONG","POLICOSANOL IS A GROUP OF LONG CHAIN PRIMARY ALCOHOLS AND HAS BEEN SHOWN TO REDUCE BLOOD CHOLESTEROL LEVELS AND TO INHIBIT THE OXIDATION OF LOW-DENSITY LIPOPROTEIN (LDL). THE PRESENT STUDY EXAMINED (I) THE EFFECT OF POLICOSANOL SUPPLEMENTATION IN THE DIET ON THE FECAL EXCRETION OF NEUTRAL AND ACIDIC STEROLS IN HAMSTERS AND (II) THE ANTIOXIDANT ACTIVITY OF POLICOSANOL IN HUMAN LDL. GOLDEN SYRIAN HAMSTERS WERE DIVIDED INTO FOUR GROUPS (N = 12/EACH) FED ONE OF THE FOUR DIETS CONTAINING 0 (CONTROL), 0.38, 0.75, AND 1.50 G KG-1 POLICOSANOL FOR 6 WEEKS. IT WAS FOUND THAT HAMSTERS GIVEN 0.38-1.5 G KG -1 DIETS HAD A SERUM TOTAL CHOLESTEROL LEVEL LOWERED BY 15-25% AND HAD A HIGH-DENSITY LIPOPROTEIN CHOLESTEROL ELEVATED BY 7-16.8%. IT WAS FOUND THAT POLICOSANOL INCREASED THE EXCRETION OF ACIDIC STEROLS BY 25-73%. CONTRARY TO THAT IN PREVIOUS REPORTS, POLICOSANOL HAD NO APPARENT ANTI-LDL OXIDATION ACTIVITY WHEN 1-TETRACOSANOL, 1-HEXACOSANOL, AND 1-OCTACOSANOL WERE INCUBATED IN HUMAN LDL. POLICOSANOL ALSO POSSESSED NO SCAVENGING ACTIVITY ON THE FREE RADICAL2,2-DIPHENYL-1-PICRYLHYDRAZYL. THESE DATA PROVIDE EVIDENCE THAT IN ADDITION TO THE EFFECT OF HMG-COA REDUCTASE, THE CHOLESTEROL-LOWERING ACTIVITY OF POLICOSANOL IS PARTIALLY MEDIATED BY ITS INHIBITION ON THE ABSORPTION OF BILE ACIDS, BUT THESE DATA DISPROVE THE CLAIM THAT POLICOSANOL IS AN ANTIOXIDANT. © 2005 AMERICAN CHEMICAL SOCIETY.","CHOLESTEROL; HDL; LDL; OCTACOSANOL; POLICOSANOL; PRIMARY ALCOHOL; TRIACONTANOL; TRIGLYCERIDE","ANIMALS; ANTIOXIDANTS; BILE ACIDS AND SALTS; CHOLESTEROL; CRICETINAE; DIET; FATTY ALCOHOLS; FECES; HUMANS; LIPID PEROXIDATION; LIPIDS; LIPOPROTEINS, LDL; MALE; MESOCRICETUS; CRICETINAE; MESOCRICETUS AURATUS; ANTIOXIDANT; BILE ACID; CHOLESTEROL; FATTY ALCOHOL; LIPID; LOW DENSITY LIPOPROTEIN; POLICOSANOL; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DIET; DRUG EFFECT; FECES; HAMSTER; HUMAN; LIPID PEROXIDATION; MALE; METABOLISM; SYRIAN HAMSTER","","","CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONSALEZ R., LEZCAY M., ALVAREZ E., EFFECTS OF POLICAOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT. J. CLIN. PHASMACOL. RES., 22, PP. 89-99, (2002); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECTS OF POLICOSANOL ON POST-MENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 14, PP. 187-195, (2000); PONS P., MAS R., ILLNAIT J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA, CURR. THER. RES., 52, PP. 507-513, (1992); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD. CHEM. TOXICOL., 32, PP. 565-575, (1994); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); NOA M., MAS R., DE LA ROSA M.C., GRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J. PHARM. PHARMACOL., 47, PP. 289-291, (1995); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATION, METABOLISM, 53, PP. 1309-1314, (2004); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); MCCARTY M.F., POLICOSANOL SAFELY DOW-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW-DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV., 67, PP. 1-7, (1999); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); ZHANG Z., YEUNG W.K., HUANG Y., CHEN Z.Y., HYPERLIPIDEMIC ACTIVITY OF DIETARY SQUALENE AND SHARK LIVER OIL IN HAMSTERS, INT. J. FOOD SCI. NUTR., 53, PP. 411-418, (2002); CHAN P.T., FONG W.P., CHEUNG Y.L., HUANG Y., HO W.K.K., CHEN Z.Y., JASMINE GREEN EPICATECHINS ARE HYPOLIPIDEMIC IN HAMSTERS FED A HIGH FAT DIET, J. NUTR., 129, PP. 1094-1101, (1999); ZHANG A., CHAN P.T., LUK Y.S., HO W.K.K., CHEN Z.Y., INHIBITORY EFFECT OF JASMINE GREEN TEA EPICATECHIN ISOMERS ON LDL-OXIDATION, J. NUTR. BIOCHEM., 8, PP. 334-340, (1997); LOWRY O.H., ROSEBROUGH N.J., FARR A.L., RANDALL R., PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT, J. BIOL. CHEM., 193, PP. 265-275, (1951); BLOIS M.S., ANTIOXIDANT DETERMINATION BY THE USE OF STABLE FREE RADICAL, NATURE, 181, PP. 1199-1200, (1958); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DUSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. PHYSIOL., 29, PP. 891-897, (2002); MENENDEZ R., MAS R., AMOR A.M.A., GONZALEZ R.M.A., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, PP. 255-262, (2000); MAS R., CASTANO G., FERNANDEZ J., GAMEZ R., ILLNAIT J., FERNANDEZ L., LOPEZ E., MESA M., ALVAREZ E., MENDOZA S., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA. PAC. J. CLIN. NUTR., 13, (2004)","Y.C. ZHEN; FOOD AND NUTRITIONAL SCIENCES PROGRAM, DEPARTMENT OF BIOCHEMISTRY, CHINESE UNIVERSITY OF HONG KONG, SHATIN, NT, HONG KONG; EMAIL: ZHENYUCHEN@CUHK.EDU.HK","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-23844479225","J AGRIC FOOD CHEM","CHINESE UNIVERSITY OF HONG KONG;CHINESE UNIVERSITY OF HONG KONG;CHINESE UNIVERSITY OF HONG KONG;CHINESE UNIVERSITY OF HONG KONG","NOTREPORTED;CHINESE UNIVERSITY OF HONG KONG;NOTREPORTED",NA,"CHI HN, 2005, J AGRIC FOOD CHEM","CHI HN, 2005, J AGRIC FOOD CHEM"
"AUNG P;MAXWELL H;JEPSON R;PRICE J;LENG G","AUNG, PHYU PHYU (6508368050); MAXWELL, H.G. (25958757300); JEPSON, R.G. (7003267314); PRICE, J.F. (57189291344); LENG, G.C. (21334820200)","LIPIDLOWERING FOR PERIPHERAL ARTERIAL DISEASE OF THE LOWER LIMB",2007,"COCHRANE DATABASE OF SYSTEMATIC REVIEWS","","",182,"10.1002/14651858.CD000123.pub2","PUBLIC HEALTH SCIENCES, UNIVERSITY OF EDINBURGH, EDINBURGH EH8 9AG, TEVIOT PLACE, UNITED KINGDOM; MAXWELL H.G.; JEPSON R.G.; PRICE J.F.; LENG G.C.","BACKGROUND: LIPID-LOWERING THERAPY IS RECOMMENDED FOR SECONDARY PREVENTION IN PEOPLE WITH CORONARY ARTERY DISEASE. IT MAY ALSO REDUCE CARDIOVASCULAR EVENTS AND/OR LOCAL DISEASE PROGRESSION IN PEOPLE WITH LOWER LIMB PERIPHERAL ARTERIAL DISEASE (PAD). OBJECTIVES: TO ASSESS THE EFFECTS OF LIPID-LOWERING THERAPY ON ALL-CAUSE MORTALITY, CARDIOVASCULAR EVENTS AND LOCAL DISEASE PROGRESSION IN PATIENTS WITH PAD OF THE LOWER LIMB. SEARCH STRATEGY: THE AUTHORS SEARCHED THE COCHRANE PERIPHERAL VASCULAR DISEASES GROUP'S SPECIALISED REGISTER (LAST SEARCHED FEBRUARY 2007) AND THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL) (LAST SEARCHED ISSUE 2, 2007) FOR PUBLICATIONS DESCRIBING RANDOMISED CONTROLLED TRIALS OF LIPID-LOWERING THERAPY IN PERIPHERAL ARTERIAL DISEASE OF THE LOWER LIMB. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS OF LIPID-LOWERING THERAPY IN PATIENTS WITH PAD OF THE LOWER LIMB. DATA COLLECTION AND ANALYSIS: THREE AUTHORS INDEPENDENTLY ASSESSED TRIAL QUALITY AND EXTRACTED DATA. MAIN RESULTS: EIGHTEEN TRIALS WERE INCLUDED, INVOLVING A TOTAL OF 10,049 PARTICIPANTS. TRIALS DIFFERED CONSIDERABLY IN THEIR INCLUSION CRITERIA, OUTCOMES MEASURED, AND TYPE OF LIPID-LOWERING THERAPY USED. ONLY ONE TRIAL (PQRST) REPORTED A DETRIMENTAL EFFECT OF ACTIVE TREATMENT ON BLOOD LIPID/LIPOPROTEIN LEVELS. THE POOLED RESULTS FROM ALL ELIGIBLE TRIALS INDICATED THAT LIPID-LOWERING THERAPY HAD NO STATISTICALLY SIGNIFICANT EFFECT ON OVERALL MORTALITY (ODDS RATIO (OR) 0.86; 95% CONFIDENCE INTERVAL (CI) 0.49 TO 1.50) OR ON TOTAL CARDIOVASCULAR EVENTS (OR 0.8; 95% CI 0.59 TO 1.09). HOWEVER, SUBGROUP ANALYSIS WHICH EXCLUDED PQRST SHOWED THAT LIPID-LOWERING THERAPY SIGNIFICANTLY REDUCED THE RISK OF TOTAL CARDIOVASCULAR EVENTS (OR 0.74; CI 0.55 TO 0.98). THIS WAS PRIMARILY DUE TO A POSITIVE EFFECT ON TOTAL CORONARY EVENTS (OR 0.76; 95% CI 0.67 TO 0.87). GREATEST EVIDENCE OF EFFECTIVENESS CAME FROM THE USE OF SIMVASTATIN IN PEOPLE WITH A BLOOD CHOLESTEROL ≥ 3.5 MMOL/LITRE (HPS). POOLING OF THE RESULTS FROM SEVERAL SMALL TRIALS ON A RANGE OF DIFFERENT LIPID-LOWERING AGENTS INDICATED AN IMPROVEMENT IN TOTAL WALKING DISTANCE (WEIGHTED MEAN DIFFERENCE (WMD) 152 M; 95% CI 32.11 TO 271.88) AND PAIN-FREE WALKING DISTANCE (WMD 89.76 M; 95% CI 30.05 TO 149.47) BUT NO SIGNIFICANT IMPACT ON ANKLE BRACHIAL INDEX (WMD 0.04; 95% CI -0.01 TO 0.09). AUTHORS' CONCLUSIONS: LIPID-LOWERING THERAPY IS EFFECTIVE IN REDUCING CARDIOVASCULAR MORTALITY AND MORBIDITY IN PEOPLE WITH PAD. IT MAY ALSO IMPROVE LOCAL SYMPTOMS. UNTIL FURTHER EVIDENCE ON THE RELATIVE EFFECTIVENESS OF DIFFERENT LIPID-LOWERING AGENTS IS AVAILABLE, USE OF A STATIN IN PEOPLE WITH PAD AND A BLOOD CHOLESTEROL LEVEL ≥3.5 MMOL/LITRE IS MOST INDICATED. COPYRIGHT © 2008 THE COCHRANE COLLABORATION. PUBLISHED BY JOHN WILEY & SONS, LTD.","ANTILIPEMIC AGENTS [*THERAPEUTIC USE]; ARTERIOSCLEROSIS [*DRUG THERAPY]; FEMALE; HUMANS; LEG [*BLOOD SUPPLY]; MALE; PERIPHERAL VASCULAR DISEASES [*DRUG THERAPY]; RANDOMIZED CONTROLLED TRIALS AS TOPIC","ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; ATORVASTATIN; BETAPYRIDYL CARBINOL; BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; POLICOSANOL; PROBUCOL; SIMVASTATIN; SULODEXIDE; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ASTHENIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFECT; DRUG WITHDRAWAL; EPIGASTRIC FULLNESS; GAIT; GASTROINTESTINAL SYMPTOM; GRANULOMA; HEARTBURN; HUMAN; INJECTION SITE PAIN; LEG ARTERY; LEG DISEASE; LIPID BLOOD LEVEL; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MUSCLE CRAMP; MYALGIA; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT","","","COLLINS R., ARMITAGE J., PARISH S., SLEIGH P., PETO R., HEART PROTECTION STUDY COLLABORATIVE GROUP. MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL-LOWERING WITH SIMVASTATIN IN 5963 PEOPLE WITH DIABETES: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 361, 9374, PP. 2005-2016, (2003); COLLINS R., ARMITAGE J., PARISH S., SLEIGHT P., PETO R., HEART PROTECTION STUDY COLLABORATIVE GROUP. EFFECTS OF CHOLESTEROL-LOWERING WITH SIMVASTATIN ON STROKE AND OTHER MAJOR VASCULAR EVENTS IN 20536 PEOPLE WITH CEREBROVASCULAR DISEASE OR OTHER HIGH-RISK CONDITIONS, LANCET, 363, 9411, PP. 757-767, (2004); COLLINS R., PETO R., ARMITAGE J., THE MRC/BHF HEART PROTECTION STUDY: PRELIMINARY RESULTS, INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 56, 1, PP. 53-56, (2002); MRC/BHF HEART PROTECTION STUDY OF ANTIOXIDANT VITAMIN SUPPLEMENTATION IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL. SEE COMMENTS., LANCET, 360, 9326, PP. 23-33, (2002); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20, 536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL. SEE COMMENTS., LANCET, 360, 9326, PP. 7-22, (2002); RANDOMIZED TRIAL OF THE EFFECTS OF CHOLESTEROL-LOWERING WITH SIMVASTATIN ON PERIPHERAL VASCULAR AND OTHER MAJOR VASCULAR OUTCOMES IN 20,536 PEOPLE WITH PERIPHERAL ARTERIAL DISEASE AND OTHER HIGH-RISK CONDITIONS, JOURNAL OF VASCULAR SURGERY, 45, 4, PP. 645-654, (2007); THE EFFECTS OF CHOLESTEROL LOWERING WITH SIMVASTATIN ON CAUSE-SPECIFIC MORTALITY AND ON CANCER INCIDENCE IN 20,536 HIGH-RISK PEOPLE: A RANDOMISED PLACEBO-CONTROLLED TRIAL, BMC MEDICINE, 3, (2005); MIHAYLOVA B., BRIGGS A., ARMITAGE J., PARISH S., GRAY A., COLLINS R., HEART PROTECTION COLLABORATIVE GROUP. COST-EFFECTIVENESS OF SIMVASTATIN IN PEOPLE AT DIFFERENT LEVELS OF VASCULAR DISEASE RISK: ECONOMIC ANALYSIS OF A RANDOMISED TRIAL IN 20,536 INDIVIDUALS.SEE COMMENT, LANCET, 365, 9473, PP. 1779-1785, (2005); JAMSHIDI Y., FLAVELL D.M., HAWE E., MACCALLUM P.K., MEADE T.W., HUMPHRIES S.E., GENETIC DETERMINANTS OF THE RESPONSE TO BEZAFIBRATE TREATMENT IN THE LOWER EXTREMITY ARTERIAL DISEASE EVENT REDUCTION (LEADER) TRIAL, ATHEROSCLEROSIS, 163, 1, PP. 183-192, (2002); *MEADE T., ZUHRIE R., COOK C., COOPER J., BEZAFIBRATE IN MEN WITH LOWER EXTREMITY ARTERIAL DISEASE: RANDOMISED CONTROLLED TRIAL, BMJ, 325, 7373, PP. 1139-1141, (2002); MEADE T.W., DESIGN AND INTERMEDIATE RESULTS OF THE LOWER EXTREMITY ARTERIAL DISEASE EVENT REDUCTION (LEADER) TRIAL OF BEZAFIBRATE IN MEN WITH LOWER EXTREMITY ARTERIAL DISEASE, CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2, 4, PP. 195-204, (2001); HOLME I., MALMAEUS I., OLSSON A.G., NILSSON S., WALLDIUS G., REPEATED MEASUREMENTS OVER TIME: STATISTICAL ANALYSIS OF THE ANGIOGRAPHIC OUTCOMES IN THE PROBUCOL QUANTITATIVE REGRESSION SWEDISH TRIAL (PQRST), CLINICAL TRIALS & META-ANALYSIS, 28, 2, PP. 95-108, (1993); JOHANSSON J., OLSSON A.G., BERGSTRAND L., ELINDER L.S., NILSSON S., ERIKSON U., ET AL., LOWERING OF HDL2B BY PROBUCOL PARTLY EXPLAINS THE FAILURE OF THE DRUG TO AFFECT FEMORAL ATHEROSCLEROSIS IN SUBJECTS WITH HYPERCHOLESTEROLEMIA. A PROBUCOL QUANTITATIVE REGRESSION SWEDISH TRIAL (PQRST) REPORT, ARTERIOSCLEROSIS, THROMBOSIS & VASCULAR BIOLOGY, 15, 8, PP. 1049-1056, (1995); REGNSTROM J., WALLDIUS G., NILSSON S., ELINDER L.S., JOHANSSON J., MOLGAARD J., ET AL., THE EFFECT OF PROBUCOL ON LOW DENSITY LIPOPROTEIN OXIDATION AND FEMORAL ATHEROSCLEROSIS, ATHEROSCLEROSIS, 125, 2, PP. 217-229, (1996); WALLDIUS G., CARLSON L.A., ERIKSON U., OLSSON A.G., JOHANSSON J., MOLGAARD J., ET AL., DEVELOPMENT OF FEMORAL ATHEROSCLEROSIS IN HYPERCHOLESTEROLEMIC PATIENTS DURING TREATMENT WITH CHOLESTYRAMINE AND PROBUCOL/PLACEBO: PROBUCOL QUANTITATIVE REGESSION TRIAL (PQRST): A STATUS REPORT, AMERICAN JOURNAL OF CARDIOLOGY, 62, 3, (1988); *WALLDIUS G., ERIKSON U., OLSSON A.G., BERGSTRAND L., HADELL K., JOHANSSON J., ET AL., THE EFFECT OF PROBUCOL ON FEMORAL ATHEROSCLEROSIS: THE PROBUCOL QUANTITATIVE REGRESSION SWEDISH TRIAL (PQRST), AMERICAN JOURNAL OF CARDIOLOGY, 74, 9, PP. 875-883, (1994); WALLDIUS G., REGNSTROM J., NILSSON J., JOHANSSON J., SCHAFER-ELINDER L., MOELGAARD J., ET AL., THE ROLE OF LIPIDS AND ANTIOXIDATIVE FACTORS FOR THE DEVELOPEMENT OF ATHEROSCLEROSIS. THE PROBUCOL QUANTITATIVE REGRESSION SWEDISH TRIAL (PQRST), AMERICAN JOURNAL OF CARDIOLOGY, 71, 6, (1993); DUFFIELD R.G., MILLER N.E., JAMIESON C.W., LEWIS B., A CONTROLLED TRIAL OF PLASMA LIPID REDUCTION IN PERIPHERAL ATHEROSCLEROSIS - AN INTERIM REPORT, BRITISH JOURNAL OF SURGERY, 69, SUPPL., (1982); LEWIS B., RANDOMISED CONTROLLED TRIAL OF THE TREATMENT OF HYPERLIPIDAEMIA ON PROGRESSION OF ATHEROSCLEROSIS, ACTA MEDICA SCANDINAVICA SUPPLEMENTUM, 701, PP. 53-57, (1985); *EGAN D.A., GARG R., WILT T.J., PETTINGER M.B., DAVIS K.B., CROUSE J., ET AL., RATIONALE AND DESIGN OF THE ARTERIAL DISEASE MULTIPLE INTERVENTION TRIAL (ADMIT) PILOT STUDY, AMERICAN JOURNAL OF CARDIOLOGY, 83, 4, PP. 569-575, (1999); ELAM M.B., HUNNINGHAKE D.B., DAVIS K.B., GARG R., JOHNSON C., EGAN D., ET AL., EFFECT OF NIACIN ON LIPID AND LIPOPROTEIN LEVELS AND GLYCEMIC CONTROL IN PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: THE ADMIT STUDY: A RANDOMIZED TRIAL. ARTERIAL DISEASE MULTIPLE INTERVENTION TRIAL, JAMA, 284, 10, PP. 1263-1270, (2000); GARG R., ELAM M.B., CROUSE 3RD J.R., DAVIS K.B., KENNEDY J.W., EGAN D., ET AL., EFFECTIVE AND SAFE MODIFICATION OF MULTIPLE ATHEROSCLEROTIC RISK FACTORS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, AMERICAN HEART JOURNAL, 140, 5, PP. 792-803, (2000); GARG R., MALINOW M., PETTINGER M., UPSON B., HUNNINGHAKE D., NIACIN TREATMENT INCREASES PLASMA HOMOCYST(E)INE LEVELS, AMERICAN HEART JOURNAL, 138, 6 PART 1, PP. 1082-1087, (1999); PETTINGER M.B., WACLAWIW M.A., DAVIS K.B., THOMASON T., GARG R., GRIFFIN B., ET AL., COMPLIANCE TO MULTIPLE INTERVENTIONS IN A HIGH RISK POPULATION, ANNALS OF EPIDEMIOLOGY, 9, 7, PP. 408-418, (1999); PHILIPP C.S., CISAR L.A., SAIDI P., KOSTIS J.B., EFFECT OF NIACIN SUPPLEMENTATION ON FIBRINOGEN LEVELS IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE, AMERICAN JOURNAL OF CARDIOLOGY, 82, 5, PP. 697-699, (1998); BLANKENHORN D.H., BROOKS S.H., ANGIOGRAPHIC TRIALS OF LIPID-LOWERING THERAPY, ARTERIOSCLEROSIS, 1, 4, PP. 242-249, (1981); *BLANKENHORN D.H., JOHNSON R.L., NESSIM S.A., AZEN S.P., SANMARCO M.E., SELZER R.H., THE CHOLESTEROL LOWERING ATHEROSCLEROSIS STUDY (CLAS): DESIGN, METHODS AND BASELINE RESULTS, CONTROLLED CLINICAL TRIALS, 8, 4, PP. 356-387, (1987); BLANKENHORN D.H., NESSIM S.A., JOHNSON R.L., SANMARCO M.E., AZEN S.P., CASHIN-HEMPHILL L., BENEFICIAL EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS, JAMA, 257, 23, PP. 3233-3240, (1987); MACK W.J., SELZER R.H., POGODA J.M., LEE P.L., SHIRCORE A.M., AZEN S.P., ET AL., COMPARISON OF COMPUTER- AND HUMAN-DERIVED CORONARY ANGIOGRAPHIC END-POINT MEASURES FOR CONTROLLED THERAPY TRIALS, ARTERIOSCLEROSIS & THROMBOSIS, 12, 3, PP. 348-356, (1992); *O'HARA J., JOLLY P.N., NICOL C.G., THE THERAPEUTIC EFFICACY OF INOSITOL NICOTINATE (HEXOPAL) IN INTERMITTENT CLAUDICATION: A CONTROLLED TRIAL, BRITISH JOURNAL OF CLINICAL PRACTICE, 42, 9, PP. 377-383, (1988); *MITROPOULOS K.A., ARMITAGE J.M., COLLINS R., MEADE T.W., REEVES B.E., WALLENDSZUS K.R., ET AL., RANDOMIZED PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF SIMVASTATIN ON HAEMOSTATIC VARIABLES, LIPOPROTEINS AND FREE FATTY ACIDS. THE OXFORD CHOLESTEROL STUDY GROUP, EUROPEAN HEART JOURNAL, 18, 2, PP. 235-241, (1997); HEALD, HEALD CL, FOWKES FGR, MURRAY G, PRICE JF ON BEHALF OF THE INTERNATIONAL ABI COLLABORATION. RISK OF MORTALITY AND CARDIOVASCULAR DISEASE ASSOCIATED WITH THE ANKLE-BRACHIAL INDEX: SYSTEMATIC REVIEW, ATHEROSCLEROSIS, 189, 1, PP. 61-69, (2006); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS. THE LONG TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP, NEW ENGLAND JOURNAL OF MEDICINE, 339, 19, PP. 1349-1357, (1998); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994)","P. P. AUNG; PUBLIC HEALTH SCIENCES, UNIVERSITY OF EDINBURGH, EDINBURGH EH8 9AG, TEVIOT PLACE, UNITED KINGDOM; EMAIL: PHYUPHYU.AUNG@ED.AC.UK","JOHN WILEY AND SONS LTD","ENGLISH","COCHRANE DATABASE SYST. REV.","REVIEW","ISI","2-S2.0-44949206501","COCHRANE DATABASE SYST REV","UNIVERSITY OF EDINBURGH","NOTREPORTED;UNIVERSITY OF EDINBURGH;NOTREPORTED",NA,"AUNG PP, 2007, COCHRANE DATABASE SYST REV","AUNG PP, 2007, COCHRANE DATABASE SYST REV"
"KASSIS A;JONES P","KASSIS, AMIRA N. (12800588300); JONES, PETER J.H. (36078426500)","LACK OF CHOLESTEROLLOWERING EFFICACY OF CUBAN SUGAR CANE POLICOSANOLS IN HYPERCHOLESTEROLEMIC PERSONS",2006,"AMERICAN JOURNAL OF CLINICAL NUTRITION","84","5",37,"10.1093/ajcn/84.5.1003","CANADA;CANADA, SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, 21111 LAKESHORE ROAD, CANADA","BACKGROUND: MORE THAN 50 STUDIES HAVE REPORTED SUBSTANTIAL REDUCTIONS IN PLASMA LIPID CONCENTRATIONS IN RESPONSE TO 2-40 MG CUBAN SUGAR CANE POLICOSANOL (SCP) MIXTURES/D. HOWEVER, SEVERAL ANIMAL AND HUMAN TRIALS CONDUCTED OUTSIDE OF CUBA THAT USED NON-CUBAN MIXTURES HAVE FAILED TO REPRODUCE THE EFFICACY OF POLICOSANOLS OBSERVED IN EARLIER STUDIES. OBJECTIVE: THE OBJECTIVE WAS TO EVALUATE LIPID-MODULATING ACTIONS OF THE AUTHENTIC CUBAN SCPS ON PLASMA LIPIDS IN HEALTHY HYPERCHOLESTEROLEMIC VOLUNTEERS. DESIGN: TWENTY-ONE VOLUNTEERS CONSUMED, UNDER SUPERVISION, 10 MG SCPS/D OR A PLACEBO INCORPORATED IN MARGARINE AS AN AFTERNOON SNACK, FOR A PERIOD OF 28 D WITH THE USE OF A RANDOMIZED, DOUBLE-BLIND CROSSOVER STUDY DESIGN. SUBJECTS MAINTAINED THEIR HABITUAL DIET AND PHYSICAL ACTIVITY AND WERE WEIGHED DAILY THROUGHOUT THE STUDY PERIOD. BLOOD WAS COLLECTED AT DAYS 1, 2, 28, AND 29 OF THE FEEDING TRIAL, AND LIPID CONCENTRATIONS WERE MEASURED. RESULTS: BODY WEIGHTS DID NOT VARY SIGNIFICANTLY THROUGHOUT THE TRIAL AND DID NOT AFFECT PLASMA LIPID VALUES. NO SIGNIFICANT DIFFERENCE WAS OBSERVED BETWEEN TREATMENT AND CONTROL GROUPS IN PLASMA TOTAL, LDL-, HDL-CHOLESTEROL, AND TRIACYLGLYCEROL CONCENTRATIONS. CONCLUSION: PRESENT RESULTS SHOW NO BENEFICIAL EFFECTS OF CUBAN SCPS ON LIPID INDICATORS IN HYPERCHOLESTEROLEMIC PERSONS AND QUESTION THE CLINICAL USEFULNESS OF POLICOSANOL MIXTURES AS CHOLESTEROL-LOWERING NEUTRACEUTICAL AGENTS. © 2006 AMERICAN SOCIETY FOR NUTRITION.","CHOLESTEROL-LOWERING EFFECT; DOUBLE-BLIND CROSSOVER STUDY DESIGN; HYPERCHOLESTEROLEMIC PERSONS; LDL CHOLESTEROL; SUGAR CANE POLICOSANOLS","ANIMALIA; SACCHARUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CUBA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EATING HABIT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SUGARCANE","","","ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES EXP, 56, PP. 176-182, (1995); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES CLIN EXP, 58, PP. 868-875, (1997); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, PP. 819-828, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ J.C., ONE-YEAR OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-303, (1995); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); CASTANO G., MAS FERREIRO R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CASTANO G., MAS R., GAMEZ R., ET AL., CONCOMITANT USE OF POLICOSANOL AND BETA-BLOCKERS IN OLDER PATIENTS, INT J CLIN PHARMACOL RES, 24, PP. 65-77, (2004); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); FERNANDEZ J., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN DRUG INVEST, 21, PP. 103-113, (2001); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., CLINICAL USE: EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-499, (2001); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); ORTENSI G., GLADSTEIN J., VALLI H., TESTONE P., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, PP. 507-513, (1992); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, PP. 1084-1092, (1994); PONS P., RODRIGUEZ M., ROBAINA C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 5, PP. 701-707, (2005); TEDESCHI-REINER E., REINER Z., ROMIC Z., IVANKOVIC D., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTILIPEMIC EFFICACY AND TOLERABILITY OF FOOD SUPPLEMENT POLICOSANOL IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, LIJEC VJESN, 127, PP. 273-279, (2005); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); FRIEDEWALD W.T., LEVY R.I., FRIEDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., CASTANO G., GAMEZ R., EFFECTS OF D-003, A NEW COMPOUND PURIFIED FROM SUGARCANE WAX, ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, CLIN DRUG INVEST, 23, PP. 107-118, (2003); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2263-2269, (2006); JONES P.J., NTANIOS F.Y., RAEINI-SARJAZ M., VANSTONE C.A., CHOLESTEROL-LOWERING EFFICACY OF A SITOSTANOL-CONTAINING PHYTOSTEROL MIXTURE WITH A PRUDENT DIET IN HYPERLIPIDEMIC MEN, AM J CLIN NUTR, 69, PP. 403-410, (1999); VANSTONE C.A., RAEINI-SARJAZ M., PARSONS W.E., JONES P.J., UNESTERIFIED PLANT STEROLS AND STANOLS LOWER LDL-CHOLESTEROL CONCENTRATIONS EQUIVALENTLY IN HYPERCHOLESTEROLEMIC PERSONS, AM J CLIN NUTR, 76, PP. 1272-1278, (2002); DENKE M.A., LACK OF EFFICACY OF LOW-DOSE SITOSTANOL THERAPY AS AN ADJUNCT TO A CHOLESTEROL-LOWERING DIET IN MEN WITH MODERATE HYPERCHOLESTEROLEMIA, AM J CLIN NUTR, 61, PP. 392-396, (1995); JONES P.J., VANSTONE C.A., RAEINI-SARJAZ M., ST-ONGE M.P., PHYTOSTEROLS IN LOW- AND NONFAT BEVERAGES AS PART OF A CONTROLLED DIET FAIL TO LOWER PLASMA LIPID LEVELS, AM J CLIN NUTR, 69, PP. 1144-1150, (2003); URIBARRI E., LAGUNA A., SIERRA R., RICARDO Y., PHYSICO-MECHANICAL CHARACTERIZATION OF POLICOSANOL, A NOVEL HYPOCHOLESTEROLEMIC DRUG, DRUG DEV IND PHARM, 28, PP. 89-93, (2002); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MANNAERTS G.P., VAN VELDHOVEN P.P., CASTEELS M., PEROXISOMAL LIPID DEGRADATION VIA BETA- AND ALPHA-OXIDATION IN MAMMALS, CELL BIOCHEM BIOPHYS, 32, PP. 73-87, (2000); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005)","P.J.H. JONES; SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE-ANNE-DE-BELLEVUE, QUE. H9X 3V9, 21111 LAKESHORE ROAD, CANADA; EMAIL: PETER.JONES@MCGILL.CA","AMERICAN SOCIETY FOR NUTRITION","ENGLISH","AM. J. CLIN. NUTR.","ARTICLE","ISI","2-S2.0-33750908247","AM J CLIN NUTR","MCGILL UNIVERSITY","NOTREPORTED;MCGILL UNIVERSITY;NOTREPORTED",NA,"KASSIS AN, 2006, AM J CLIN NUTR","KASSIS AN, 2006, AM J CLIN NUTR"
"TEDESCHI-REINER E;REINER Ž;ROMIĆ Ž;IVANKOVIĆ D","TEDESCHI-REINER, EUGENIA (6603094621); REINER, ŽELJKO (55411641000); ROMIĆ, ŽELJKO (35578715100); IVANKOVIĆ, DAVOR (7005845009)","A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF THE ANTILIPEMIC EFFICACY AND TOLERABILITY OF FOOD SUPPLEMENT POLICOSANOL IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA RANDOMIZIRANO DVOSTRUKO SLIJEPO PLACEBOM KONTROLIRANO ISPITIVANJE ANTILIPEMIČKE UČINKOVITOSTI I NEŠKODLJIVOSTI DIJETETSKE NAMIRNICE POLIKOZANOLA U BOLESNIKA S UMJERENOM HIPERLIPIDEMIJOM",2005,"LIJECNICKI VJESNIK","127","6",6,"","KLINIKA ZA OČNE BOLESTI, KLINIČKE BOLNICE SESTRE MILOSRDNICE, ZAGREB, CROATIA;KLINIKA ZA UNUTRAŠNJE BOLESTI, KLINIČKOGA BOLNIČKOG CENTRA ZAGREB, MEDICINSKOG FAKULTETA SVEUČILIŠTA, ZAGREB, CROATIA, KLINIKA ZA UNUTRAŠNJE BOLESTI, KBC ZAGREB, 10 000 ZAGREB, KIŠPATIĆEVA 12, CROATIA;ZAVOD ZA LABORATORIJSKU DIJAGNOSTIKU, KLINIČKE BOLNICE DUBRAVA, ZAGREB, CROATIA;ŠKOLA NARODNOG ZDRAVLJA ANDRIJA ŠTAMPAR, MEDICINSKOG FAKULTETA SVEUČILIŠTA, ZAGREB, CROATIA","THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY WAS PERFORMED IN 67 PATIENTS OF BOTH SEXES AGED 20 TO 78 YEARS WITH MODERATE HYPERCHOLESTEROLEMIA TO INVESTIGATE THE ANTILIPEMIC EFFICACY AND TOLERABILITY OF FOOD SUPPLEMENT POLICOSANOL - A MIXTURE OF ALIPHATIC PRIMARY ALCOHOLS FROM RICE (ORYZA SP.). AFTER A 8-WEEK RUN-IN PERIOD IN WHICH PATIENTS WERE PLACED ON THERAPEUTIC LIFESTYLE CHANGES, IN PARTICULAR CHOLESTEROL-LOWERING DIET, THEY WERE RANDOMLY ASSIGNED TO RECEIVE POLICOSANOL 10 MG CAPSULES OR PLACEBO CAPSULES ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. DURING NEXT 8 WEEKS THOSE RECEIVING POLICOSANOL DURING THE FIRST 8 WEEKS, RECEIVED PLACEBO AND THOSE TAKING PLACEBO DURING THE FIRST 8 WEEKS, RECEIVED POLICOSANOL. TOTAL CHOLESTEROL (C), LDL-C, HDL-C, HDL2-C, HDL3-C, TRIGLYCERIDES, OXIDIZED LDL, APOPROTEINS A I AND B AND LIPOPROTEIN (A) AS WELL AS AST, ALT, GGT, CK, BLOOD GLUCOSE AND BILIRUBIN WERE DETERMINED BEFORE THE TREATMENT, AFTER THE FIRST PART OF THE STUDY I.E. AFTER THE FIRST 8 WEEKS AND AT THE END OF THE STUDY, I.E AFTER THE SECOND 8 WEEKS. POLICOSANOL SIGNIFICANTLY REDUCED PLASMA TOTAL CHOLESTEROL AND INCREASED APOPROTEIN A I BUT DID NOT CHANGE PLASMA TRIGLYCERIDES, HDL-C, HDL2-C, HDL3-C, LDL-C, OXIDIZED LDL, LP (A) AND APOPROTEIN B. IT WAS WELL TOLERATED, WITH NO DRUG-RELATED EFFECTS ON SAFETY PARAMETERS SUCH AS SERUM AMINOTRANSFERASES, BLOOD GLUCOSE, BILIRUBIN, AND CK, NEITHER DID IT CAUSE ANY CLINICAL ADVERSE REACTIONS.","ANTICHOLESTEREMIC AGENTS - THERAPEUTIC USE, PHARMACOLOGY; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS - THERAPEUTIC USE, PHARMACOLOGY; HYPERCHOLESTEROLEMIA - DRUG THERAPY","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; ALKANOL; AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BILIRUBIN; CREATINE KINASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RICE","","","HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO, PP. 1-67, (2004); REINER Z., TEDESCHI-REINER E., NOVIJE SPOZNAJE O PATOFIZIOLOGIJI ATEROSKLEROZE, LIJEČ VJESN, 123, PP. 26-31, (2001); REINER Z., STATINI U PRIMARNOJ I SEKUNDARNOJ PREVENCIJI KORONARNE BOLESTI, MEDICUS, 12, PP. 85-90, (2003); REINER Z., ULOGA I MJESTO HIPOLIPEMIKA DANAS, MEDICUS, 11, PP. 37-47, (2002); PONS P., MAS R., ILLNAIT J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 51, PP. 568-575, (1992); ANEIROS E., MAS R., CALDERON, EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MOREIRO, ILLNAIT J., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRO M., MAS R., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); MENENDEZ R., FERNANDEZ I., DEL RIO A., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALES R.M., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA M.L., MAS R., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., RODEIRO, POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); CASTANO G., MAS FERREIRO R., FERNANDEZ J., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); BURSTEIN M., SCHOLNICK H.R., MORFIN R., RAPID METHOD FOR THE ISOLATION OF LIPOPROTEINS FROM HUMAN SERUM BY PRECIPITATION WITH POLYANIONS, J LIPID RES, 11, PP. 583-595, (1970); WIELAND H., SEIDEL D., A SIMPLE SPECIFIC METHOD FOR PRECIPITATION OF LOW DENSITY LIPOPROTEINS, J LIPID RES, 24, PP. 904-909, (1983); GIDEZ L.I., MILLER G.J., BURSTEIN M., SLAGLE S., EDER H.A., SEPARATION AND QUANTITATION OF SUBCLASES OF HUMAN PLASMA HIGH DENSITY LIPOPROTEINS BY A SIMPLE PRECIPITATION PROCEDURE, J LIPID RES, 23, PP. 1206-1223, (1982); THOMAS L., CLINICAL LABORATORY DIAGNOSTICS, (1998); ITABE H., YAMAMOTO H., IMANAKA T., SENSITIVE DETECTION OF OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEIN USING A MONOCLONAL ANTIBODY, J LIPID RES, 37, PP. 45-53, (1996); HERNANDEZ F., ILLNAIT J., MAS R., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G., MAS R., FERNANDEZ J., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, 8, PP. 522-537, (2003); MAS R., CASTANO G., ILLNAIT J., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ L., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY, CURR THER RES, 62, PP. 194-208, (2001); CASTANO G., MAS R., FERNANDEZ L., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., HERNANDEZ E., FERNANDEZ J.C., GAMEZ R., GUTIERREZ C., ALVAREZ E., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 63, 4, PP. 286-303, (2002); CRESPO N., ALVAREZ R., MAS R., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 4-51, (1997); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 154-162, (1997); CASTANO G., MAS R., FERNANDEZ L., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); ORTENSI G., GLADSTEIN J., VAILI H., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., WHEAT GERM POLICOSANOL DOES NOT LOWER BLOOD CHOLESTEROL CONCENTRATIONS IN HEALTHY ADULTS, ATHEROSCLEROSIS, 4, 2, (2003)","","","CROATIAN","LIJEC. VJESN.","ARTICLE","ISI","2-S2.0-32144448331","LIJEC VJESN",NA,"NOTREPORTED",NA,"TEDESCHI-REINER E, 2005, LIJEC VJESN","TEDESCHI-REINER E, 2005, LIJEC VJESN"
"BAYS H;STEIN E","BAYS, HAROLD (7003857915); STEIN, EVAN A. (7202194876)","PHARMACOTHERAPY FOR DYSLIPIDAEMIA CURRENT THERAPIES AND FUTURE AGENTS",2003,"EXPERT OPINION ON PHARMACOTHERAPY","4","37",168,"10.1517/14656566.4.11.1901","L-MARC RESEARCH CENTER, LOUISVILLE, KY 40213, 3288 ILLINOIS AVENUE, UNITED STATES;CINCINNATI, OH 45229, UNITED STATES","CURRENT LIPID-ALTERING AGENTS THAT LOWER LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) PRIMARILY THROUGH INCREASED HEPATIC LDL RECEPTOR ACTIVITY INCLUDE STATINS, BILE ACID SEQUESTRANTS/RESINS AND CHOLESTEROL ABSORPTION INHIBITORS SUCH AS EZETIMIBE, PLANT STANOLS/STEROLS, POLYPHENOLS, AS WELL AS NUTRACEUTICALS SUCH AS OAT BRAN, PSYLLIUM AND SOY PROTEINS; THOSE CURRENTLY IN DEVELOPMENT INCLUDE NEWER STATINS, PHYTOSTANOL ANALOGUES, SQUALENE SYNTHASE INHIBITORS, BILE ACID TRANSPORT INHIBITORS AND SREBP CLEAVAGE-ACTIVATING PROTEIN (SCAP) ACTIVATING LIGANDS. OTHER CURRENT AGENTS THAT AFFECT LIPID METABOLISM INCLUDE NICOTINIC ACID (NIACIN), ACIPIMOX, HIGH-DOSE FISH OILS, ANTIOXIDANTS AND POLICOSANOL, WHILST THOSE IN DEVELOPMENT INCLUDE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS, ACYLCOENZYME A: CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS, GEMCABENE, LIFIBROL, PANTOTHENIC ACID ANALOGUES, NICOTINIC ACID-RECEPTOR AGONISTS, ANTI-INFLAMMATORY AGENTS (SUCH AS LP-PLA2 ANTAGONISTS AND AGI-1067) AND FUNCTIONAL OILS. CURRENT AGENTS THAT AFFECT NUCLEAR RECEPTORS INCLUDE PPAR-Α AND -Γ AGONISTS, WHILE IN DEVELOPMENT ARE NEWER PPAR-Α, -Γ AND -Δ AGONISTS, AS WELL AS DUAL PPAR-Α/Γ AND 'PAN' PPAR-Α/Γ/Δ AGONISTS. LIVER X RECEPTOR (LXR), FARNESOID X RECEPTOR (FXR) AND STEROL-REGULATORY ELEMENT BINDING PROTEIN (SREBP) ARE ALSO NUCLEAR RECEPTOR TARGETS OF INVESTIGATIONAL AGENTS. AGENTS IN DEVELOPMENT ALSO MAY AFFECT HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) BLOOD LEVELS OR FLUX AND INCLUDE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITORS (SUCH AS TORCETRAPIB), CETP VACCINES, VARIOUS HDL 'THERAPIES' AND UPREGULATORS OF ATP-BINDING CASSETTE TRANSPORTER (ABC) A1, LECITHIN CHOLESTEROL ACYLTRANSFERASE (LCAT) AND SCAVENGER RECEPTOR CLASS B TYPE 1 (SRB1), AS WELL AS SYNTHETIC APOLIPOPROTEIN (APO)E-RELATED PEPTIDES. FIXED-DOSE COMBINATION LIPID-ALTERING DRUGS ARE CURRENTLY AVAILABLE SUCH AS EXTENDED-RELEASE NIACIN/LOVASTATIN, WHILST ATORVASTATIN/AMLODIPINE, EZETIMIBE/SIMVASTATIN, ATORVASTATIN/CETP INHIBITOR, STATIN/PPAR AGONIST EXTENDED-RELEASE NIACIN/SIMVASTATIN AND PRAVASTATIN/ASPIRIN ARE UNDER DEVELOPMENT. FINALLY, CURRENT AND FUTURE LIPID-ALTERING DRUGS MAY INCLUDE ANTI-OBESITY AGENTS WHICH COULD FAVOURABLY AFFECT LIPID LEVELS.","ABC A1; ACAT; ACIPIMOX; ADIPOSOPATHY; AGI-1067; CETP; CHOLESTEROL; CRP; EZETIMIBE; FM-VP4; FXR; GEMCABENE; HDL-C; IMPLITAPIDE; JUPITER; LARGE UNILAMELLAR VESIDES; LCAT; LDL-C; LIFIBROL; LIPID; LP-PLA<SUB>2</SUB>; LXR; MTP; NIACIN; PAF-AH; PANTETHINE; PANTOTHENIC ACID; PHYTOSTANOL; PPAR; RXR; SQUALENE SYNTHASE; SRBI; SREBP; STANOL; STEROL; TORCETRAPIB; TRIGLYCERIDE","ACIPIMOX; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; EZETIMIBE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIFIBROL; LIGAND; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROLIDE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NICOTINIC ACID; NICOTINIC AGENT; PANTOTHENIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; POLICOSANOL; POLYPHENOL DERIVATIVE; PRAVASTATIN; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; SIMVASTATIN; SITOSTANOL; SOYBEAN PROTEIN; SQUALENE SYNTHASE INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNINDEXED DRUG; ABDOMINAL PAIN; ANEMIA; BLEEDING TENDENCY; BRAN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; DYSPEPSIA; GALLSTONE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEPATITIS; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; LIVER FAILURE; MYALGIA; MYOPATHY; NAUSEA; OAT; PRURITUS; REVIEW; RHABDOMYOLYSIS; SYNCOPE; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; VERTIGO","","","CANTOS J.G., ISKANDRIAN A.E., MAJOR RISK FACTORS FOR CARDIOVASCULAR DISEASE-DEBUNKING THE 'ONLY 50% MYTH, JAMA, 290, 7, PP. 947-949, (2003); BAYS H.E., EXISTING AND INVESTIGATIONAL COMBINATION DRUG THERAPY FOR HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, AM. J. CARDIOL., 90, SUPPL., (2002); EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, 19, PP. 2486-2497, (2001); SACKS F.M., THE ROLE OF HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL IN THE PREVENTION AND TREATMENT OF CORONARY HEART DISEASE: EXPERT GROUP RECOMMENDATIONS, AM. J. CARDIOL., 90, PP. 139-143, (2002); BAYS H.E., EZETIMIBE, EXPERT OPIN. INVESTIG. DRUGS, 11, 11, PP. 1587-1604, (2002); LAROSA J.C., PLEIOTROPIC EFFECTS OF STATINS AND THEIR CLINICAL SIGNIFICANCE, AM. J. CARDIOL., 88, 3, PP. 291-293, (2001); JONES P.H., DAVIDSON M.H., STEIN E.A., BAYS H.E., ET AL., COMPARISON OF EFFICACY AND SAFETY OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN ACROSS DOSES (STELLAR TRIAL), AM. J. CARDIOL., 92, PP. 152-160, (2003); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS. THE AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); SEVER P.S., DAHLOF B., POULTER N.R., ET AL., PREVENTION OF CORONARY AND STROKE EVENTS WITH ATORVASTATIN IN HYPERTENSIVE PATIENTS WHO HAVE AVERAGE OR LOWER THAN AVERAGE CHOLESTEROL CONCENTRATIONS, IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL - LIPID LOWERING ARM (ASCOT-LLA): A MULTICENTRE RANDOMISED CONTROLLED TRIAL, LANCET, 361, PP. 1149-1158, (2003); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 19, PP. 1349-1357, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); STEIN E.A., STRUTT K., SOUTHWORTH H., ET AL., COMPARISON OF ROSUVASTATIN VERSUS ATORVASTATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYERCHOLESTEROLEMIA, AM. J. CARDIOL.; NEZASA K., TADAO A., KIMURA K., TAKAICHI M., INAZAWA K., KOIKE M., PHARMACOKINETICS AND DISPOSITION OF ROSUVASTATIN, A NEW 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR IN RAT, XENOBIOTICA, 32, 8, PP. 715-727, (2002); (2003); (2003); DAVIDSON M.H., COMBINATION THERAPY FOR DYSLIPIDEMIA: SAFETY AND REGULATORY CONSIDERATIONS, AM. J. CARDIOL., 90, SUPPL., (2002); BREWER H.B., BENEFIT-RISK ASSESSMENT OF ROSUVASTATIN 10 TO 40 MILLIGRAMS, AM. J. CARDIOL., 92, SUPPL., (2003); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 351-364, (1984); BAYS H.E., DUJOVNE C.A., COLESEVELAM -A NON-SYSTEMIC LIPID-ALTERING DRUG, EXPERT OPIN. PHARMACOTHER., 4, 5, PP. 779-790, (2003); BAYS H.E., MOORE P.B., DREHOBL M.A., ET AL., EZETIMIBE STUDY GROUP EFFECTIVENESS AND TOLERABILITY OF EZETIMIBE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: POOLED ANALYSIS OF TWO PHASE II STUDIES, CLIN. THER., 23, 8, PP. 1209-1230, (2001); BAYS H.E., WEISS S., GAGNE C., ET AL., EZETIMIBE ADDED TO ONGOING STATIN THERAPY FOR TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, ORAL CONTRIBUTIONS AMER. COLL. CARDIOL., 39, 5 SUPPL. A, PP. 833-834, (2002); GAGNE C., BAYS H.E., WEISS S.R., ET AL., EFFICACY AND SAFETY OF EZETIMIBE ADDED TO ONGOING STATIN THERAPY FOR TREATMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 90, PP. 1084-1091, (2002); ZHU Y., STATKEVICH P., KOSOGLOU T., ET AL., EFFECT OF EZETIMIBE (SCH 58235) ON THE ACTIVITY OF DRUG METABOLIZING ENZYMES IN VIVO, CLIN. PHARMACOL. THER., 67, (2000); CATAPANO A.L., EZETIMIBE: A SELECTIVE INHIBITOR OF CHOLESTEROL ABSORPTION, EUR. HEART J., 3, SUPPL. E, (2001); VON BERGMANN K., SALEN G., LUTJOHANN D., MUSLINER T., MUSSER B., EZETIMIBE EFFECTIVELY REDUCES SERUM PLANT STEROLS IN PATIENTS WITH SITOSTEROLEMIA, ATHEROSCLEROSIS SUPPL., 3, 2, (2002); PLAT J., MENSINK R.P., EFFECT OF PLANT STANOL ESTERS ON LDL RECEPTOR PROTEIN EXPRESSION AND ON LDL RECEPTOR AND HMG-COA REDUCTASE MRNA EXPRESSION IN MONONUCLEAR BLOOD CELLS OF HEALTHY MEN AND WOMEN, FED. AM. SOC. EXP. BIOL. J., 16, 2, PP. 258-260, (2002); MIETTINEN T.A., GYLLING H., REGULATION OF CHOLESTEROL METABOLISM BY DIETARY PLANT STEROLS, CURR. OPIN. LIPIDOL, 10, PP. 9-14, (1999); MIETTINEN T.A., CHOLESTEROL ABSORPTION INHIBITION: A STRATEGY FOR CHOLESTEROL LOWERING THERAPY, INT. J. CLIN. PRACT., 55, 10, PP. 710-716, (2001); RAEINI-SARJAZ M., NTANIOS F.Y., VANSTONE C.A., JONES P.J., NO CHANGES IN SERUM FAT-SOLUBLE VITAMIN AND CAROTENOID CONCENTRATIONS WITH THE INTAKE OF PLANT STEROL/STANOL ESTERS IN THE CONTEXT OF A CONTROLLED DIET, METABOLISM, 51, 5, PP. 652-656, (2002); TAMMI A., RONNEMAA T., GYLLING H., ET AL., PLANT STANOL ESTER MARGARINE LOWERS SERUM TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION OF HEALTHY CHILDREN: THE STRIP PROJECT, J. PEDIATR., 136, 4, PP. 503-510, (2000); ANDERSON R.A., A HOLISTIC APPROACH TO PREVENTION AND HEALTH PROMOTION: INFLUENCES OF PHYSICAL ACTIVITY, FOOD SUPPLEMENTS, AND MIND-BODY INTERACTIONS ON LONGEVITY AND CARDIAC DISEASE, CLIN. FAM. PRACT., 4, 4, (2002); ANDERSSON M., ELLEGARD I., ANDERSSON H., OAT BRAN STIMULATES BILE ACID SYNTHESIS WITHIN 8 HOURS AS MEASURED BY 7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE, AM. J. CLIN. NUTR., 76, 5, PP. 1111-1116, (2002); YU J.N.J., CUNNINGHAM J.A., THOUIN S.R., ET AL., HYPERLIPIDEMIA, PRIM. CARE, 27, 3, PP. 541-587, (2000); OLSON B.H., ANDERSON S.M., BECKER M.P., ET AL., PSYLLIUM-ENRICHED CEREALS LOWER BLOOD TOTAL CHOLESTEROL AND LDL CHOLESTEROL, BUT NOT HDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC ADULTS: RESULTS OF A META-ANALYSIS, J. NUTR., 127, 10, PP. 1973-1980, (1997); SPRECHER D.L., HARRIS B.V., GOLDBERG A.C., ET AL., EFFICACY OF PSYLLIUM IN REDUCING SERUM CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS ON HIGH OR LOW FAT DIETS, ANN. INTERN. MED., 119, 7 PART 1, PP. 627-628, (1993); CLARKSON T., ANTHONY M., MORGAN T.M., INHIBITION OF POSTMENOPAUSAL ATHEROSCLEROSIS PROGRESSION: A COMPARISON OF THE EFFECTS OF CONJUGATED EQUINE ESTROGENS AND SOY PHYTOESTROGENS, J. CLIN. ENDOCRINOL. METAB., 86, PP. 41-47, (2001); ANDERSON J.J.B., GARNER S.C., EDITORIAL: SOY PHYTOESTROGENS, LIPID REDUCTIONS, AND ATHEROSCLEROSIS DELAY IN OVARIECTOMIZED PRIMATES, J. CLIN. ENDOCRINOL. METAB., 86, 1, PP. 39-41, (2001); SIRTORI S.R., RISKS AND BENEFITS OF SOY PHYTOESTROGENS IN CARDIOVASCULAR DISEASES, CANCER, CLIMACTERIC SYMPTOMS AND OSTEOPOROSIS, DRUG SAF., 24, 9, PP. 665-682, (2001); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., ET AL., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N. ENGL. J. MED., 333, PP. 276-282, (1995); BAUM J.A., TENG H., ERDMAN J.W., ET AL., LONG-TERM INTAKE OF SOY PROTEIN IMPROVES BLOOD LIPID PROFILES AND INCREASES MONONUCLEAR CELL LOW-DENSITY-LIPOPROTEIN RECEPTOR MESSENGER RNA IN HYPERCHOLESTEROLEMIC, POSTMENOPAUSAL WOMEN, AM. J. CLIN. NUTR., 68, 3, PP. 545-551, (1998); ADAMS M.R., GOLDEN D.L., ANTHONY M.S., ET AL., THE INHIBITORY EFFECT OF SOY PROTEIN ISOLATE ON ATHEROSCLEROSIS IN MICE DOES NOT REQUIRE THE PRESENCE OF LDL RECEPTORS OR ALTERATIONS OF PLASMA LIPOPROTEINS, J. NUTR., 132, PP. 43-49, (2002); CHORAZY P.A., HIMELHOCH S., HOPWOOD N.J., ET AL., PERSISTENT HYPOTHYROIDISM IN AN INFANT RECEIVING A SOY FORMULA: CASE REPORT AND REVIEW OF THE LITERATURE, PEDIATRICS, 96, 1 PART 1, PP. 148-150, (1995); WILSON G.R., THYROID DISORDERS, CLIN. FAM. PRACT., 4, 3, (2002); MARON D.J., LU G.P., CAI N.S., ET AL., CHOLESTEROL-LOWERING EFFECT OF A THEAFLAVIN-ENRICHED GREEN TEA EXTRACT, ARCH. INTERN. MED., 163, 12, PP. 1448-1453, (2003); TAVINTHARAN S., KASHYAP M.L., THE BENEFITS OF NIACIN IN ATHEROSCLEROSIS, CURR. ATHEROSCLER., 3, PP. 74-82, (2001); KNOPP R.H., GINSBERG J., ALBERS J.J., ET AL., CONTRASTING EFFECTS OF UNMODIFIED AND TIME RELEASE FORMS OF NIACIN ON LIPOPROTEINS IN HYPERLIPIDAEMIC SUBJECTS. CLUES TO MECHANISM OF ACTION OF NIACIN, METABOLISM, 34, PP. 642-650, (1985); MCKENNEY J.M., PROCTOR J.D., HARRIS S., CHINCHILI V.M., A COMPARISON OF THE EFFICACY AND TOXIC EFFECTS OF SUSTAINED RELEASE VERSUS IMMEDIATE RELEASE NIACIN IN HYPERCHOLESTEROLEMIC PATIENTS, JAMA, 271, 9, PP. 672-677, (1994); MULLIN G.E., GREENSON J.K., MITCHELL M.C., FULMINANT HEPATIC FAILURE AFTER INGESTION OF SUSTAINED-RELEASE NICOTINIC ACID, ANN. INTERN. MED., 111, 3, PP. 253-255, (1989); ETCHASON J.A., MILLAR T.D., SQUIRES R.W., ET AL., NIACIN-INDUCED HEPATITIS: A POTENTIAL SIDE EFFECT WITH LOW-DOSE TIME-RELEASE NIACIN, MAYO CLIN. PROC., 66, PP. 23-28, (1991); KNOPP R.H., ALAGONA P., DAVIDSON M., ET AL., EQUIVALENT EFFICACY OF A TIME-RELEASE FORM OF NIACIN (NIASPAN) GIVEN ONCE-A-NIGHT VERSUS PLAIN NIACIN IN THE MANAGEMENT OF HYPERLIPIDEMIA, METABOLISM, 47, 9, PP. 1097-1104, (1998); GOLDBERG A., ALAGONA P., CAPUZZI D.M., ET AL., MULTIPLE DOSE EFFICACY AND SAFETY OF AN EXTENDED RELEASE FORM OF NIACIN IN THE MANAGEMENT OF HYPERLIPIDEMIA, AM. J. CARDIOL., 85, 9, PP. 1100-1105, (2000); MORGAN J.M., CAPUZZI D.M., GUYTON J.R., A NEW EXTENDED-RELEASE NIACIN (NIASPAN): EFFICACY, TOLERABILITY, AND SAFETY IN HYPERCHOLESTEROLEMIC PATIENTS, AM. J. CARDIOL., 82, 12 A, (1998); SOGA T., KAMOHARA M., TAKASAKI J., ET AL., MOLECULAR IDENTIFICATION OF NICOTINIC ACID RECEPTOR, BIOCHEM. BIOPHYS. RES. COMMUN., 303, 1, PP. 364-369, (2003); YESHURUN D., HAMOOD H., NASCHITZ J., ACIPIMOX (OLBETAM) AS A SECONDARY HYPOLIDEMIC AGENT IN COMBINED HYPERTRIGLYCERIDEMIA AND HYPERLIPIDEMIA, HAREFUAH, 138, 8, PP. 650-653, (2000); BODEN G., PATHOGENESIS OF TYPE 2 DIABETES, ENDOCRINOL. METAB. CLINICS, PP. 801-815, (2001); CIAMPELLI M., MUZJ G., LEONI F., ET AL., METABOLIC AND ENDOCRINE CONSEQUENCES OF ACUTE SUPPRESSION OF FFA'S BY ACIPIMOX IN POLYCYSTIC OVARY SYNDROME, J. CLIN. ENDOCRINOL. METAB., 86, 11, PP. 5324-5329, (2001); HOLUB B.J., CLINICAL NUTRITION: 4. OMEGA-3-FATTY ACIDS IN CARDIOVASCULAR CARE, CAN. MED. ASSOC. J., 166, 5, PP. 608-615, (2002); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE, CIRCULATION, 21, PP. 2747-2757, (2002); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEINS: HUMAN STUDIES, AM. J. CLIN. NUTR., 65, 5 SUPPL., (1997); GLAUBER H., WALLACE P., GRIVER K., BRECHTEL G., ADVERSE METABOLIC EFFECT OF OMEGA-3 FATTY ACIDS IN NON-INSULIN DIABETES MELLITUS, ANN. INTERN. MED., 108, PP. 663-668, (1988); BAYS H.E., DUJOVNE C.A., DRUGS FOR TREATMENT OF PATIENTS WITH HIGH CHOLESTEROL BLOOD LEVELS AND OTHER DYSLIPIDEMIAS, PROG. DRUG RES., 43, PP. 9-41, (1994); VONTORI V.M., FARMER A., WOLLAN P.C., DINNEEN S.F., FISH OIL SUPPLEMENTATION IN TYPE 2 DIABETES: A QUANTITATIVE SYSTEMATIC REVIEW, DIABETES CARE, 23, 9, PP. 1217-1218, (2000); FRIEDBERG C.E., JANSSEN M.J., HEINE R.J., GROBBEE D.E., FISH OIL AND GLYCEMIC CONTROL IN DIABETES. A META-ANALYSIS, DIABETES CARE, 21, 4, PP. 494-500, (1998); LEAF A., JORGENSEN M.B., JACOBS A.K., ET AL., DO FISH OILS PREVENT RESTENOSIS AFTER CORONARY ANGIOPLASTY?, CIRCULATION, 90, PP. 2248-2257, (1994); ERITSLAND J., ARNESEN H., GRONSETH K., ET AL., EFFECT OF DIETARY SUPPLEMENTATION WITH N-3 FATTY ACIDS ON CORONARY ARTERY BYPASS GRAFT PATENCY, AM. J. CARDIOL., 77, PP. 31-36, (1996); BAYS H.E., DUJOVNE C.A., ANTIOXIDANTS IN THE TREATMENT OF ATHEROSCLEROTIC DISEASE, J. CLIN. INVEST. ARTERIOSCLEROSIS, 5, PP. 30-39, (1993); BAYS H.E., DUJOVNE C.A., THE USE OF ANTIOXIDANTS IN CLINICAL PRACTICE: PAST, PRESENT AND FUTURE, CHOICES IN CARDIOL., 8, PP. 6-8, (1994); BURING J.E., VITAMIN E HAD NO EFFECT ON THE RISK OF CARDIOVASCULAR DEATH, MI, AND STROKE IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS BUT WITHOUT LV DYSFUNCTION OR HF. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, EVIDENCE-BASED CARDIOVASC. MED., 4, 4, (2000); MRC/BHF HEART PROTECTION STUDY OF ANTIOXIDANT VITAMIN SUPPLEMENTATION IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 23-33, (2002); BROWN B.G., ZHAO X.Q., CHAIT A., ET AL., SIMVASTATIN AND NIACIN, ANTIOXIDANT VITAMINS, OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE, N. ENGL. J. MED., 345, PP. 1583-1592, (2001); WASSERMAN M.A., SUNDELL C.L., KUNSCH C., ET AL., CHEMISTRY AND PHARMACOLOGY OF VASCULAR PROTECTANTS: A NOVEL APPROACH TO THE TREATMENT OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE, AM. J. CARDIOL., 91, 3 A, (2003); WALLDIUS G., ERIKSON U., OLSSON A.G., ET AL., THE EFFECT OF PROBUCOL ON FEMORAL ATHEROSCLEROSIS: THE PROBUCOL QUANTITATIVE REGRESSION SWEDISH TRIAL (PQRST), AM. J. CARDIOL., 74, PP. 875-883, (1994); JOHANSSON J., OLSSON A.G., BERGSTRAND L., ET AL., LOWERING OF HDL2B BY PROBUCOL PARTLY EXPLAINS THE FAILURE OF THE DRUG TO AFFECT FEMORAL ATHEROSCLEROSIS IN SUBJECTS WITH HYPERCHOLESTEROLEMIA. A PROBUCOL QUANTITATIVE REGRESSION SWEDISH TRIAL (PQRST) REPORT, ARTERIOSCLER. THROMB. VASC. BIOL., 15, PP. 1049-1056, (1995); GOUNI-BERHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING DRUG, AM. HEART J., 143, 2, PP. 356-365, (2002); ZIOUZENKOVA O., PERREY S., MARX N., ET AL., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS, CURR. ATHEROSCLER. REP., 4, 1, PP. 59-64, (2002); FRUCHART J.C., DURIEZ P., STAELS B., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA ACTIVATORS REGULATE GENES GOVERNING LIPOPROTEIN METABOLISM, VASCULAR INFLAMMATION AND ATHEROSCLEROSIS, CURR. OPIN. LIPIDOL., 10, 3, PP. 245-257, (1999); MANNINEN V., KOSKINEN P., MANTTARI M., HUTTUNEN J., CANTER D., FRICK H., PREDICTIVE VALUE FOR CORONARY HEART DISEASE OF BASELINE HIGH-DENSITY AND LOW DENSITY LIPOPROTEIN CHOLESTEROL AMONG FREDERICKSON TYPE IIA SUBJECTS IN THE HELSINKI HEART STUDY, AM. J. CARDIOL., 66, (1990); RUBINS H.B., ROBINS S.J., COLLINS D., ET AL., GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL, N. ENGL. J. MED., 341, PP. 410-418, (1999); BALLANTYNE C.M., CORSINI A., DAVIDSON M.H., ET AL., RISK FOR MYOPATHY WITH STATIN THERAPY IN HIGH-RISK PATIENTS, ARCH. INTERN. MED., 163, PP. 553-564, (2003); PRUEKSARITANONT T., ZHAO J., MA B., ET AL., MECHANISTIC STUDIES ON METABOLIC INTERACTIONS BETWEEN GEMFIBROZIL AND STATINS. DEPARTMENT OF DRUG METABOLISM. MERCK RESEARCH LABORATORIES: WEST POINT, PENNSYLVANIA, J. PHARMACOL. EXP. THER., 301, PP. 1042-1051, (2002); PRUEKSARITANONT T., SUBRAMANIAN R., FANG X., ET AL., GLUCURONIDATION OF STATINS IN ANIMALS AND HUMANS: A NOVEL MECHANISM OF STATIN LACTONIZATION. DEPARTMENT OF DRUG METABOLISM, MERCK RESEARCH LABORATORIES, WEST POINT, PENNSYLVANIA, DRUG METAB. DISPOS., 30, PP. 505-512, (2002); ELLEN R.L.B., MCPHERSON A., LONG TERM EFFICACY AND SAFETY OF FENOFIBRATE AND A STATIN IN THE TREATMENT OF COMBINED HYPERLIPIDEMIA, AM. J. CARDIOL., 81, (1998); MCKENNEY J.M., NEW CHOLESTEROL GUIDELINES, NEW TREATMENT CHALLENGES, PHARMACOTHERAPY, 22, 7, PP. 853-863, (2002); BAYS H.E., DUJOVNE C.A., DRUG INTERACTIONS OF LIPID-ALTERING DRUGS, DRUG SAF., 19, 5, PP. 355-371, (1998); BAYS H.E., DUJOVNE C.A., MCGOVERN M.E., ET AL., COMPARISON OF ONCE-DAILY, NIACIN EXTENDED-RELEASE/LOVASTATIN WITH STANDARD DOSES OF ATORVASTATIN AND SINIVASTATIN (THE ADVICOR VERSUS OTHER CHOLESTEROL-MODULATING AGENTS TRIAL EVALUATION), AM. J. CARDIOL., 91, PP. 667-672, (2003); HEILBRONN L.K., NOAKES M., CLIFTON P.M., ENERGY RESTRICTION AND WEIGHT LOSS ON VERY-LOW-FAT DIETS REDUCE C-REACTIVE PROTEIN CONCENTRATIONS IN OBESE, HEALTHY WOMEN, ARTERIOSCLER. THROMB. VASC. BIOL., 21, PP. 968-970, (2001); BAYS H.E., MCGOVERN M.E., SIMMONS P.D., KOHLER R.M., SUPERKO R.H., NIACIN EXTENDED-RELEASE/LOVASTATIN ONCE-DAILY COMBINATION IMPROVES LOW-DENSITY AND HIGH-DENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION COMPARED TO STARTING DOSES OF ATORVASTATIN AND SIMVASTATIN, (2003); BAYS H.E., MCGOVERN M.E., ONCE-DAILY NIACIN EXTENDED-RELEASE/LOVASTATIN COMBINATION TABLET HAS MORE FAVORABLE EFFECTS ON LIPOPROTEIN PARTICLE SIZE AND SUBCLASS DISTRIBUTION COMPARED TO ATORVASTATIN AND SIMVASTATIN, PREV. CARDIOL., (2003); STEIN E.A., MANAGEMENT OF DYSLIPIDEMIA IN THE HIGH-RISK PATIENT, AM. HEART J., 144, 6 SUPPL., (2002); BAYS H.E., ATHEROGENIC DYSLIPIDAEMIA IN TYPE 2 DIABETES AND METABOLIC SYNDROME, BR. J. DIABETES VASC. DIS., 3, 5, (2003); LUKIC T., PRITCHARD H., WASAN K.M., DISODIUM ASCORBYL PHYTOSTANYL PHOSPHATES, FM-VP4, DECREASES BLOOD LIPIDS AND BODY WEIGHT WITHOUT OBSERVED TOXICITY, (2003); HIYOSHI H., YANAGIMACHI M., ITO M., ET AL., EFFECT OF ER-27856, A NOVEL SQUALENE SYNTHASE INHIBITOR ON PLASMA CHOLESTEROL IN RHESUS MONKEYS: COMPARISON WITH 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS, J. LIPID RES., 41, PP. 1136-1144, (2000); ROSENBERG S.H., SQUALENE SYNTHASE INHIBITORS, EXP. OPIN. THER. PATENTS, 8, 5, PP. 521-530, (1998); ROOT C., SMITH C.D., SUNDSETH S.S., ET AL., ILEAL BILE ACID TRANSPORTER INHIBITION, CYP7A1 INDUCTION, AND ANTILIPEMIC ACION OF 264W94, J. LIPID RES., 43, PP. 1320-1330, (2002); STEIN E.A., RHYNE J.M., MCKENNEY J., ET AL., INTESTINAL BILE ACID TRANSPORT (IBAT) INHIBITION: RESULTS OF A 4 WEEK PILOT STUDY OF 264W94, A NOVEL IBAT INHIBITOR IN HYPERCHOLESTEROLEMIA, (2001); SHAH P.K., EMERGING NON-STATIN LDL-LOWERING THERAPIES FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS, REV. CARDIOVAS. MED., 4, 3, PP. 136-141, (2003); GRAND-PERRET T., BOUILLOT A., PERROT A., ET AL., SCAP LIGANDS ARE POTENT LIPID-LOWERING DRUGS, NAT. MED., 7, 12, PP. 1332-1338, (2001); WETTERAU J.R., GREGG R.E., HARRITY T.W., ET AL., AN MTP INHIBITOR THAT NORMALIZES ATHEROGENIC LIPOPROTEIN LEVELS IN WHHL RABBITS, SCIENCE, 282, PP. 751-754, (1998); OHASHI K., MTP INHIBITORS AND ACAT INHIBITORS. AN UPDATE, NIPPON RINSHO. JAP. J. CLIN. MED., 60, 5, PP. 975-983, (2002); SHIOMI M., ITO T., MTP INHIBITOR DECREASES PLASMA CHOLESTEROL LEVELS IN LDL RECEPTOR DEFICIENT WHHL RABBITS BY LOWERING THE VLDL SECRETION, EUR. J. PHARMACOL., 431, 1, PP. 127-131, (2001); MATSUDA K., ACAT INHIBITORS AS ANTIATHEROSCLEROTIC AGENTS: COMPOUNDS AND MECHANISMS, MED. RES. REV., 14, PP. 271-305, (1994); LI L., POWNALL H.J., EFFECTS OF HIGH-DENSITY LIPOPROTEIN (2) ON CHOLESTEROL TRANSPORT AND ACYL-COENZYME A: CHOLESTEROL ACYLTRANSFERASE ACTIVITY IN P388D1 MACROPHAGES, BIOCHIM. BIOPHYS. ACTA, PP. 111-122, (2001); BOCAN T.M., KRAUSE B.R., ROSEBURY W.S., ET AL., THE ACAT INHIBITOR AVASIMIBE REDUCES MACROPHAGES AND MATRIX METALLOPROTEINASE EXPRESSION IN ATHEROSCLEROTIC LESIONS OF HYPERCHOLESTEROLEMIC RABBITS, ARTERIOSCLER. THROMB. VASC. BIOL., 20, 1, PP. 70-79, (2000); HIRAKAWA Y., SHIMOKAWA H., LIPID-LOWERING DRUGS, NIPPON YAKURIGAKU ZASSHI, 118, PP. 389-395, (2001); INSULL W., KOREN M., DAVIGNON J., ET AL., EFFICACY AND SHORT-TERM SAFETY OF A NEW ACAT INHIBITOR, AVASIMIBE, ON LIPIDS, LIPOPROTEINS, AND APOLIPOPROTEINS IN PATIENTS WITH COMBINED HYPERLIPIDEMIA, ATHEROSCLEROSIS, 157, PP. 137-144, (2001); TARDIF J.C., LESPERANCE G.J., LAMBERT J., ET AL., DESIGN FEATURES OF THE AVASIMIBE AND PROGRESSION OF CORONARY LESIONS ASSESSED BY INTRAVASCULAR ULTRASOUND (A-PLUS) CLINICAL TRIAL, AM. HEART J., 144, 4, PP. 589-596, (2002); BISGAIER C.L., ESSENBURG A.D., BARBETT B.C., ET AL., A NOVEL COMPOUND THAT ELEVATES HIGH DENSITY LIPOPROTEIN AND ACTIVATES THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR, J. LIPID RES., 39, PP. 17-30, (1998); BAYS H.E., MCKENNEY J.M., DUJOVNE C.A., ET AL., EFFECTIVENESS AND TOLERABILITY OF A NEW LIPID-ALTERING AGENT, GEMCABENE, IN PATIENTS WITH LOW LEVELS OF HIGH DENSITY LIPOPROTEIN-CHOLESTEROL, AM. J. CARDIOL., 92, PP. 538-543, (2003); LOCKER P.K., JUNGBLUTH G.L., FRANCOM S.F., HUGHES G.S., LIFIBROL: A NOVEL LIPID-LOWERING DRUG FOR THE THERAPY OF HYPERCHOLESTEROLEMIA, CLIN. PHARMACOL. THER., 57, 1, PP. 73-88, (1995); VEGA G.L., VON BERGMANN K., GRUNDY S.M., ET AL., EFFECT OF LIFIBROL ON THE METABOLISM OF LOW DENSITY LIPOPROTEINS AND CHOLESTEROL, J. INTERN. MED., 246, 1, PP. 1-9, (1999); WINKLER K., SCHAEFER J.R., KLIMA B., ET AL., HDL STEADY STATE LEVELS ARE NOT AFFECTED, BUT HDL APO A-1 TURNOVER IS ENHANCED BY LIFIBROL IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA, ATHEROSCLEROSIS, 150, 1, PP. 113-120, (2000); PAPE M.E., CRAMER C.T., HOPSON K.L., ET AL., NOVEL PANTOTHENIC ACID ANALOGUES THAT REGULATE LIPID METABOLISM THROUGH A MECHANISM INVOLVING ACTIVATION OF AMP -ACTIVATED PROTEIN KINASE, (2002); WINDER W.W., HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE, A METABOLIC MASTER SWITCH: POSSIBLE ROLES IN TYPE 2 DIABETES MELLITUS, AM. J. PHYSIOL., 277, 1 PART 1, (1999); GADDI A., DESCOVICH G.C., NOSEDA G., ET AL., CONTROLLED EVALUATION OF PANTETHINE, A NATURAL HYPOLIPIDEMIC COMPOUND, IN PATIENTS WITH DIFFERENT FORMS OF HYPERLIPOPROTEINEMIA, ATHEROSCLEROSIS, 50, 1, PP. 73-83, (1984); CORONEL F., TORNERO F., TORRENTE J., ET AL., TREATMENT OF HYPERLIPEMIA IN DIABETIC PATIENTS ON DIALYSIS WITH A PHYSIOLOGICAL SUBSTANCE, AM. J. NEPHROL., 11, 1, PP. 32-36, (1991); OSONO Y., HIROSE N., NAKAJIMA K., HATA Y., THE EFFECTS OF PANTETHINE ON FATTY LIVER AND FAT DISTRIBUTION, J. ATHEROSCLER. THROMB., 7, 1, PP. 55-58, (2000); KAMOHARA S.T., MATSUMOTO T.J., SAITO T., ET AL., MOLECULAR IDENTIFICATION OF NICOTINIC ACID RECEPTOR, BIOCHEM. BIOPHYS. RES. COMMUN., 303, 1, PP. 364-369, (2003); WISE A., FOORD W.A., FRASER N.J., ET AL., MOLECULAR IDENTIFICATION OF HIGH AND LOW AFFINITY RECEPTORS FOR NICOTINIC ACID, BIOL. CHEM., 278, 11, PP. 9869-9874, (2003); TUNARU S., KERO J., SCHAUB A., ET AL., PUMA-G AND HM74 ARE RECEPTORS FOR NICOTINIC ACID AND MEDIATE ITS ANTI-LIPOLYTIC EFFECT, NAT. MED., 9, 3, PP. 352-355, (2003); KUDO M.M., PHOSPHOLIPASE A2, J. BIOCHEM. (TOKYO), 131, 3, PP. 285-292, (2002); DADA N., KIM N.W., WOLFERT R.L., LP-PLA2: AN EMERGING BIOMARKER OF CORONARY HEART DISEASE, EXP. REV. MOL. DIAGN., 2, 1, PP. 17-22, (2002); CASLAKE M.J., PACKARD C.J., LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE) AND CARDIOVASCULAR DISEASE, CURR. OPIN. LIPIDOL, 14, 4, PP. 347-352, (2003); GOTTO A.M., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDES AS THERAPEUTIC TARGETS FOR PREVENTING AND TREATING CORONARY HEART DISEASE, AM. HEART J., 144, 6, (2002); MACPHEE C.H., SUCKLING K.E., LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2): A TARGET DIRECTED AT THE ATHEROSCERLOTIC PLAQUE, EXPERT OPIN. THER. TARGETS, 6, 3, PP. 309-314, (2002); TSIMIHODIMOS V., KARABINA S.A., TAMBAKI A.P., ET AL., ATORVASTATIN PREFERENTIALLY REDUCES LDL-ASSOCIATED PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE IN DYSLIPIDEMIAS OF TYPE IIA AND TYPE IIB, ATERIOSCLER. THROM. VASC. BIOL., 22, 2, PP. 306-311, (2002); TARDIF J.C., CLINICAL RESULTS WITH AGI-1067: A NOVEL ANTIOXIDANT VASCULAR PROTECTANT, AM. J. CARDIOLOGY, 91, 3 A, (2003); SASAHARA M., RAINES E.W., CHAIT A., ET AL., INHIBITION OF HYPERCHOLESTEROLEMIA-INDUCED ATHEROSCLEROSIS IN THE NON-HUMAN PRIMATE BY PROBUCOL. IS THE EXTENT OF ATHEROSCLEROSIS RELATED TO RESISTANCE OF LDL TO OXIDATION?, J. CLIN. INVEST., 94, PP. 155-164, (1994); SAWAYAMA Y., SHINIZU C., MAEDA N., ET AL., EFFECTS OF PROBUCOL AND PRAVASTATIN ON COMMON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH ASYMPTOMATIC HYPERCHOLESTEROLEMIA, J. AM. COLL. CARDIOL., 39, PP. 610-616, (2002); YOU ARE WHAT YOU EAT, LANCET ONCOL., 3, 9, (2002); ST-ONGE M.P., LAMARCHE B., MAUGER J.F., JONES P.J., CONSUMPTION OF FUNCTIONAL OIL RICH IN PHYTOSTEROLS AND MEDIUM CHAIN TRIGLYCERIDE OIL IMPROVES PLASMA LIPID PROFILES, J. NUTR., 133, 6, PP. 1815-1820, (2003); BOURQUE C., ST-ONGE M.P., PAPAMANDJARIS A.A., ET AL., CONSUMPTION OF AN OIL COMPOSED OF MEDIUM CHAIN TRIACYGLYCEROLS, PHYTOSTEROLS, AND N-3 FATTY ACIDS IMPROVES CARDIOVASCULAR RISK PROFILE IN OVERWEIGHT WOMEN, METABOLISM, 52, 6, PP. 771-777, (2003); ZUCKERMAN S.H., KAUFFMAN R.F., EVANS G.F., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA, GAMMA COAGONIST LY465608 INHIBITS MACROPHAGE ACTIVATION AND ATHEROSCLEROSIS IN APOLIPOPROTEIN E KNOCKOUT MICE, LIPIDS, 37, 5, PP. 487-494, (2002); LJUNG B., BAMBBERG K., DAHLLOF B., ET AL., AZ 242, A NOVEL PPAR ALPHA/GAMMA AGONIST WITH BENEFICIAL EFFECTS ON INSULIN RESISTANCE AND CARBOHYDRATE AND LIPID METABOLISM IN OB/OB MICE AND OBESE ZUCHER RATS, J. LIPID RES., 43, PP. 1855-1863, (2002); RUBIN K., ANDERSON T.B., MASIMIREMBWA C.M., TESAGLITAZAR (GALIDA™) DOES NOT INHIBIT THE MAJOR DRUG-METABOLIZING CYTOCHROME P450 ENZYMES, (2003); ERICSSON H., BERGSTRAND S., FRYKLUND L., ET AL., PHARMACOKINETICS OF TESAGLITAZAR (GALIDA®) IN HEALTHY MALE SUBJECTS, DIABETES, 52, SUPPL. 1, (2003); SAMUELSSON S., BERGH S., OHMAN P.K., ERICSSON H., FOOD DOES NOT AFFECT THE PHARMACOKINETICS OF TESAGLITAZAR (GALIDA®), DIABETES, 52, SUPPL. 1, (2003); DAVIS T., TESAGLITAZAR (ASTRAZENECA), IDRUGS, 5, 9, PP. 924-926, (2002); CHEN Y.E., FU M., ZHANG J., ET AL., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS AND THE CARDIOVASCULAR SYSTEM, VIT. HORM., 66, PP. 157-188, (2003); OLIVER W.R., SHENK J.L., SNAITH M.R., ET AL., A SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST PROMOTES REVERSE CHOLESTEROL TRANSPORT, PROC. NATL. ACAD. SCI. USA, 98, 9, PP. 5306-5311, (2001); BALASUBRAMANYAM A., NOVEL RECEPTORS AND THEIR FUNCTIONS DEFINE PATHWAYS OF LIPID METABOLISM AND MECHANISMS OF ATHEROSCLEROSIS, (2003); OSBORNE T.F., STEROL REGULATORY ELEMENT BINDING PROTEINS (SREBP): KEY REGULATORS OF NUTRITIONAL HOMEOSTASIS AND INSULIN ACTION, J. BIOL. CHEM., 275, 42, PP. 32379-32382, (2000); LUND E.G., MENKE J.G., SPARROW C.P., LIVER X RECEPTOR AGONISTS AS POTENTIAL THERAPEUTIC AGENTS FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS, ARTERIOSCLER. THROM. VASC. BIOL., 23, PP. 1169-1177, (2003); SCHULTZ J.R., TU H., LUK A., ET AL., ROLE OF LXRS IN CONTROL OF LIPOGENESIS, GENES DEV., 14, 22, PP. 2831-2838, (2000); EDWARDS P.A., KAST H.R., ANISFELD A.M., BAREING IT ALL: THE ADOPTION OF LXR AND FXR AND THEIR ROLES IN LIPID HOMEOSTASIS, J. LIPID RES., 43, 1, PP. 2-12, (2002); REPA J.J., BERGE K.E., POMAJZL C., RICHARDSON J.A., HOBBS H., MANGELSDORF D.J., REGULATION OF ATP BINDING CASSETTE STEROL TRANSPORTERS ABCG5 AND ABCG8 BY THE LIVER X RECEPTORS ALPHA AND BETA, J. BIOL. CHEM., 277, 21, PP. 18793-18800, (2002); OSTLUND R.E., CHOLESTEROL ABSORPTION, CURR. OPIN. GASTROENTEROL., 18, PP. 254-258, (2002); REPA J.J., TURLEY S.D., LOBACCORO J.A., ET AL., REGULATION OF ABSORPTION AND ABC1-MEDIATED EFFLUX OF CHOLESTEROL BY RXR HETERODIMERS, SCIENCE, 289, (2000); CHAWLA A., REPA J.J., EVANS R.M., MANGELSDORF D.J., NUCLEAR RECEPTORS AND LIPID PHYSIOLOGY: OPENING THE X-FILES, SCIENCE, 294, PP. 1866-1870, (2001); NIESOR E.J., FLACH J., LOPES-ANTONI A., PEREZ A., BENTZEN C.L., THE NUCLEAR RECEPTORS FXR AND LXR ALPHA: POTENTIAL TARGETS FOR THE DEVELOPMENT OF DRUGS AFFECTING LIPID METABOLISM AND NEOPLASTIC DISEASES, CURR. PHARMA. DES., 7, 4, PP. 231-259, (2001); SPARROW C.P., BAFFIC J., LAM M.H., ET AL., A POTENT SYNTHETIC LXR AGONIST IS MORE EFFECTIVE THAN CHOLESTEROL LOADING AT INDUCING ABCA1 MRNA AND STIMULATING CHOLESTEROL EFFLUX, J. BIOL. CHEM., 277, 12, PP. 10021-10027, (2002); URIZAR N.L., LIVERMAN A.B., DODDS D.T., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, PP. 1703-1706, (2002); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA. A RANDOMIZED, CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); DAVIES P.J., BERRY S.A., SHIPLEY G.L., ET AL., METABOLIC EFFECTS OF REXINOIDS; TISSUE SPECIFIC REGULATION OF LIPOPROTEIN LIPASE ACTIVITY, MOLEC. PHARMACOL., 59, 2, PP. 170-176, (2001); SPADY D.K., DIETSCHY J.M., STEROL SYNTHESIS IN VIVO IN 18 TISSUES OF THE SQUIRREL MONKEY, GUINEA PIG, RABBIT, HAMSTER, AND RAT, J. LIPID RES., 24, PP. 303-315, (1983); DIETSCHY J.M., TURLEY S.D., SPADY D.K., ROLE OF LIVER IN THE MAINTENANCE OF CHOLESTEROL AND LOW DENSITY LIPOPROTEIN HOMEOSTASIS IN DIFFERENT ANIMAL SPECIES, INCLUDING HUMANS, J. LIPID RES., 34, 10, PP. 1637-1659, (1993); RADER D.J., HIGH-DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS, AM. J. CARDIOL., 90, SUPPL. 8, (2002); JOLLEY C.D., WOOLLETT L.A., TURLEY S.D., DIETSCHY J.M., CENTRIPETAL CHOLESTEROL FLUX TO THE LIVER IS DICTATED BY EVENTS IN THE PERIPHERAL ORGANS AND NOT BY THE PLASMA HIGH DENSITY LIPOPROTEIN OR APOLIPOPROTEIN A-1 CONCENTRATION, J. LIPID RES., 39, PP. 2143-2149, (1998); PRICE M.J., SHAH P.K., NEW STRATEGIES IN MANAGING AND PREVENTING ATHEROSCLEROSIS: FOCUS ON HDL, REV. CARDIOVASC. MEDICINE, 3, 3, PP. 129-136, (2002); WATTS G.F., THE YIN AND YANG OF CHOLESTERYL ESTER TRANSFER PROTEIN AND ATHEROSCLEROSIS, CLIN. SCI., 103, PP. 595-597, (2002); ZHONG S., SHARP D.S., GROVE J.S., ET AL., INCREASED CORONARY ARTERY DISEASE IN JAPANESE-AMERICAN MEN WITH MUTATION IN THE CHOLESTERYL ESTER TRANSFER PROTEIN GENE DESPITE INCREASED HDL LEVELS, J. CLIN. INVEST., 97, PP. 2917-2923, (1996); BARTER P., CETP AND ATHEROSCLEROSIS, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 2029-2031, (2000); BARTER P.J., BREWER B., CHAPMAN M.J., ET AL., CHOLESTERYL ESTER TRANSFER PROTEIN: A NOVEL TARGET FOR RAISING HDL AND INHIBITING ATHEROSCLEROSIS, ARTERIOSCLER. THROMB. VASC. BIOL., 23, (2003); KOTHARI H.V., POIRIER K.J., LEE W.H., SATOH Y., INHIBITION OF CHOLESTEROL ESTER TRANSFER PROTEIN CGS 25159 AND CHANGES IN LIPOPROTEINS IN HAMPSTERS, ATHEROSCLEROSIS, 128, 1, PP. 59-66, (1997); WANG J., QIANG H., ZHANG C.D., ZHUANG Y., CETP GENE MUTATION (D442G) INCREASES LOW-DENSITY LIPOPROTEIN PARTICLE SIZE IN PATIENTS WITH CORONARY HEART DISEASE, CLIN. CHIM. ACTA, 322, 1-2, PP. 85-90, (2002); DE GROOTH G.J., KUIVENHOVEN J.A., STALENHOEF A.F., ET AL., EFFICACY AND SAFETY OF A NOVEL CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR JTT-705, IN HUMANS: A RANDOMIZED PHASE II DOSE-RESPONSE STUDY, CIRCULATION, 105, 18, PP. 2159-2165, (2002); RITTERSHAUS C.W., MILLER D.P., THOMAS L.J., ET AL., VACCINE-INDUCED ANTIBODIES INHIBIT CETP ACTIVITY IN VIVO AND REDUCE AORTIC LESIONS IN RABBIT MODEL OF ATHEROSCLEROSIS, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 2106-2112, (2000); NEWTON R.S., KRAUSE B.R., HDL THERAPY FOR THE ACUTE TREATMENT OF ATHEROSCLEROSIS, ATHEROSCLEROSIS SUPPL., 3, 4, PP. 31-38, (2002); KRAUSE B.R., AUERBACH B.J., REVERSE CHOLESTEROL TRANSPORT AND FUTURE PHARMACOLOGICAL APPROACHES TO THE TREATMENT OF ATHEROSCLEROSIS, CURR. OPIN. INVESTIG. DRUGS, 2, 3, PP. 375-381, (2001); ALAM K., MEIDELL R.S., SPADY D.K., EFFECT OF UP-REGULATING INDIVIDUAL STEPS IN THE REVERSE CHOLESTEROL TRANSPORT PATHWAY ON REVERSE CHOLESTEROL TRANSPORT IN NORMOLIPIDEMIC MICE, J. BIOL. CHEM., 276, 19, PP. 15641-15649, (2001); ANANTHARAMAIAH G.M., DATTA G., GARBER D.W., TOWARD THE DESIGN OF PEPTIDE MIMICS OF ANTIATHEROGENIC APOLIPOPROTEINS A-1 AND E, CURR. SCIENCE, 81, 1, PP. 53-65, (2001); DATTA G., GARBER D.W., CHUNG B.H., ET AL., CATIONIC DOMAIN 141-150 OF APOE COVALENTLY LINKED TO A CLASS A AMPHIPATHIC HELIX ENHANCES ATHEROGENIC LIPOPROTEIN METABOLISM IN VITRO AND IN VIVO, J. LIPID RES., 42, 6, PP. 959-966, (2001); MARCHIOLI R., PRAVASTATIN REDUCES MORTALITY IN PEOPLE WITH AND WITHOUT HISTORY OF CORONARY HEART DISEASE, EVIDENCE BASED CARDIOVASC. MEDICINE, 6, 3, PP. 101-102, (2002); VERHEUGT F.W.A., GERSH B.J., ASPIRIN BEYOND PLATELET INHIBITION, AM. J. CARDIOL., 90, 1, PP. 39-41, (2002); FORD E.S., GILES W.H., DIETZ W.H., PREVALENCE OF THE METABOLIC SYNDROME AMONG US ADULTS, JAMA, 287, PP. 356-359, (2002); BAYS H.E., DUJOVNE C.A., ANTI-OBESITY DRUG DEVELOPMENT, EXP. OPIN. INVESTIG. DRUGS, 11, 9, PP. 1189-1204, (2002); DAVIDSON M., HAUPTMAN J., DIGIROLOAMO M., ET AL., WEIGHT CONTROL AND RISK FACTOR REDUCTION IN OBESE SUBJECTS TREATED FOR 2 YEARS WITH ORLISTAT, JAMA, 281, PP. 235-242, (1999); SJOSTROM L., RISSANEN A., ANDERSEN T., ET AL., RANDOMIZED PLACEBO CONTROLLED TRIAL OF ORLISTAT FOR WEIGHT LOSS AND PREVENTION OF WEIGHT REGAIN IN OBESE PATIENTS, LANCET, 352, PP. 167-172, (1998); MITTENDORFER B., OSTLUND R., PATTERSON B.W., ET AL., ORLISTAT INHIBITS DAILY CHOLESTEROL ABSORPTION, OBES. RES., 9, 10, PP. 599-604, (2001)","H. BAYS; L-MARC RESEARCH CENTER, LOUISVILLE, KY 40213, 3288 ILLINOIS AVENUE, UNITED STATES; EMAIL: HBAYSMD@AOL.COM","ASHLEY PUBLICATIONS LTD","ENGLISH","EXPERT OPIN. PHARMACOTHER.","REVIEW","ISI","2-S2.0-0242490816","EXPERT OPIN PHARMACOTHER","L-MARC RESEARCH CENTER","NOTREPORTED;L-MARC RESEARCH CENTER;NOTREPORTED",NA,"BAYS H, 2003, EXPERT OPIN PHARMACOTHER","BAYS H, 2003, EXPERT OPIN PHARMACOTHER"
"PÉREZ L;LEYVA I;FERRER B;SUÁREZ V;PADRÓN Y;ABRAHAM C;ORTIZ A","PÉREZ, LÁZARO O. DEL VALLE (35584715500); LEYVA, ISABEL TORRES (23467458400); FERRER, BERTHA BEATRIZ SOCARRÁS (35580156900); SUÁREZ, VIANED MARSÁN (15048671600); PADRÓN, YANELKYS COS (15048622100); ABRAHAM, CONSUELO MACÍAS (15047572500); ORTIZ, ANISSA GRAMATGES (23467487700)","EFFECT IN VITRO OF ATEROMIXOL ON THE HUMAN LYMPHOCYTES AND NEUTROPHILES EFECTO IN VITRO DEL ATEROMIXOL SOBRE LOS LINFOCITOS Y NEUTRÓFILOS HUMANOS",2007,"REVISTA CUBANA DE HEMATOLOGIA, INMUNOLOGIA Y HEMOTERAPIA","23","",0,"","INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA, INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA, CIUDAD DE LA HABANA, APARTADO POSTAL 8070, CP 10800, CUBA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA","ATEROMIXOL IS A PRODUCT DEVELOPED BY THE NATIONAL CENTER OF SCIENTIFIC RESEARCH AND COMMERCIALIZED BY DELMER LABORATORIES OF HAVANA CITY . ITS ACTIVE PRINCIPLE IS POLYCOSANOL, WHICH IS COMPOSED OF A MIXTURE OF PRIMARY ALIPHATIC HIGHER ALCOHOLS OBTAINED FROM THE WAX OF SACCHARUM OFFICINARUM L. THE EFFECT IN VITRO OF ATEROMIXOL, KNOWN AS PPG, ON THE LYMPHOCYTES AND NEUTROPHILES OF 15 VOLUNTARY BLOOD DONORS WITH DIAGNOSIS OF CELLULAR IMMUNODEFICIENCY WAS STUDIED BY THE LYMPHOBLASTIC TRANSFORMATION TEST, WITH THE USE OF TRITIATED TIMIDINE, THE ACTIVE ROSETTE TECHNIQUE AND THE PHAGOCYTIC FUNCTION TEST. NO SIGNIFICANT DIFFERENCES WERE OBSERVED IN THE STATISTICAL ANALYSIS OF THE EXPERIMENTAL CONDITIONS WITHOUT ATEROMIXOL AND WITH DILUTIONS FROM 500 M G/ML TO 3.90 M G/ML. © 2008 2000, EDITORIAL CIENCIAS MÉDICAS.","ACTIVE ROSETTE; BLASTIC TRANSFORMATION; LYMPHOCYTES; PHAGOCYTIC FUNCTION","","","","MUANZA D.N., EULER K.L., WILLIAMS L., SCREENING AND ANTITUMOUR AND ANTI-VIH ACTIVITIES OF NINE MEDICINAL PLANTS FROM ZAIRE, INT J PHARMACOGN, 33, PP. 98-106, (1995); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ J., GONZALEZ R.M., ET AL., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURED FATTY ACIDS, CAN J PHYSIOL PHARMACOL, 80, PP. 13-21, (2002); GARCIA L., GARCIA V., ROJO D.M., SANCHEZ E., PLANTAS CON PROPIEDADES ANTIOXIDANTES, REV CUBANA INVEST BIOMED, 20, PP. 231-235, (2001); HERNANDEZ M., PRIETO E., PLANTAS QUE CONTIENEN POLIFENOLES. ANTIOXIDANTES DENTRO DEL ESTILO DE VIDA, REV CUBANA INVEST BIOMED, 18, PP. 12-14, (1999); MINSAP, PLANTAS MEDICINALES, FITOMED III, PP. 16-17, (1994); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., ET AL., EFFECTS OF POLICOSANOL AND IOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DISLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., EFFECTS OF POLICOSANOL AND IOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CABRERA L., URIBARI E., LAGUNA A., SIERRA R., MEDEROS D., GONZALEZ M., ET AL., STUDY OF THE INTERACTION BETWEEN POLICOSANOL AND EXCIPIENTS, BOLL CHIM FARM, 141, PP. 138-142, (2002); BOYUM A., ISOLATION OF MONONUCLEAR CELLS AND GRANULOCYTES FROM HUMAN BLOOD, SCAND J CLIN LAB INVEST, 10, PP. 1041-1049, (1968); DEL VALLE L.O., MACIAS C., TORRES I., SOCARRAS B.B., MARSAN V., SANCHEZ M., EFECTO IN VITRO DE LA ESPIRULINA SOBRE LOS LINFOCITOS HUMANOS, REV CUBANA HEMATOL INMUNOL HEMOTER, 18, 2, (2002); TORRES I., DEL VALLE L., MARSAN V., SOCARRAS B., MACIAS C., EVALUACIÓN EVOLUTIVA DE LA FUNCIÓN FAGOCÍTICA DE LOS POLIMORFONUCLEARES, REV CUBANA HEMATOL INMUNOL HEMOTER, 20, 2, (2004); DEL VALLE L., MACIAS C., ESQUIVEL I., RODRIGUEZ J., ALPIZAR Y., EL ATEROMIXOL Y LA TRANSFORMACIÓN BLÁSTICA, REV CUBANA HEMATOL INMUNOL HEMOTER, 15, 2, PP. 146-147, (1999)","L.O.D.V. PÉREZ; INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA, CIUDAD DE LA HABANA, APARTADO POSTAL 8070, CP 10800, CUBA; EMAIL: IHIDIR@HEMATO.SLD.CU","","SPANISH","REV. CUBA. HEMATOL. IMUNOL. HEMOTERAPIA","ARTICLE","ISI","2-S2.0-38349076670","REV CUBA HEMATOL IMUNOL HEMOTERAPIA","INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA","NOTREPORTED;INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA;NOTREPORTED",NA,"PÉREZ LODV, 2007, REV CUBA HEMATOL IMUNOL HEMOTERAPIA","PÉREZ LODV, 2007, REV CUBA HEMATOL IMUNOL HEMOTERAPIA"
"CASTAÑO G;MAS R;FERNÁNDEZ L;ILLNAIT J;MESA M;ALVAREZ E;LEZCAY M","CASTAÑO, GLADYS (56232967100); MAS, ROSA (7007164572); FERNÁNDEZ, LILIA (7202848319); ILLNAIT, JOSÉ (8631465800); MESA, MEYLIN (36880545700); ALVAREZ, ESTRELLA (15053135600); LEZCAY, MAGNOLIA (6508023242)","COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA",2003,"DRUGS AND AGING","20","10",76,"10.2165/00002512-200320020-00006","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA","BACKGROUND: HYPERCHOLESTEROLAEMIA IS A RISK FACTOR FOR CORONARY HEART DISEASE (CHD), CLINICAL STUDIES HAVE SHOWN THAT LOWERING ELEVATED SERUM TOTAL CHOLESTEROL (TC) LEVELS, AND PARTICULARLY LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) LEVELS, REDUCES THE FREQUENCY OF CORONARY MORBIDITY AND DEATHS, WHEREAS HIGH SERUM LEVELS OF HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) PROTECT AGAINST CHD. POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGAR CANE WAX WITH A THERAPEUTIC DOSAGE RANGE FROM 5-20 MG/DAY. ATORVASTATIN IS AN HMG-COA REDUCTASE INHIBITOR WHICH ACROSS ITS DOSAGE RANGE (10-80 MG/DAY) HAS SHOWN SIGNIFICANTLY GREATER LIPID-LOWERING EFFECTS THAN ALL PREVIOUSLY MARKETED STATINS. OBJECTIVE: THIS STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA. PATIENTS AND METHODS: THIS RANDOMISED, SINGLE-BLIND, PARALLEL-GROUP STUDY WAS CONDUCTED IN OLDER PATIENTS (60-80 YEARS) WITH TYPE II HYPERCHOLESTEROLAEMIA. AFTER 4 WEEKS ON A CHOLESTEROL-LOWERING DIET, 75 PATIENTS WERE RANDOMISED TO POLICOSANOL OR ATORVASTATIN 10MG TABLETS TAKEN ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. AN INTERIM AND FINAL CHECK-UP WERE PERFORMED AT 4 AND 8 WEEKS, RESPECTIVELY, AFTER TREATMENT WAS INITIATED. RESULTS: AT 4 (P < 0.0001) AND 8 (P < 0.00001) WEEKS, POLICOSANOL 10 MG/DAY SIGNIFICANTLY LOWERED SERUM LDL-C LEVELS BY 17.5 AND 23.1%, RESPECTIVELY COMPARED WITH BASELINE; CORRESPONDING VALUES FOR ATORVASTATIN WERE 28.4 AND 29.8%. AT STUDY COMPLETION, POLICOSANOL SIGNIFICANTLY (P < 0.0001) REDUCED SERUM TC (16.4%), LDL-C/HDL-C RATIO (25.5%) AND TC/HDL-C RATIO (19.3%), AS WELL AS (P < 0.001) TRIGLYCERIDE LEVELS (15.4%). ATORVASTATIN SIGNIFICANTLY (P < 0.0001) DECREASED SERUM TC (22.6%), LDL-C/HDL-C (26.2%) AND TC/HDL-C (19.8%) RATIOS, AS WELL AS (P < 0.001) TRIGLYCERIDE LEVELS (15.5%). ATORVASTATIN WAS SIGNIFICANTLY MORE EFFECTIVE THAN POLICOSANOL IN REDUCING LDL-C AND TC, BUT SIMILAR IN REDUCING BOTH ATHEROGENIC RATIOS AND TRIGLYCERIDE LEVELS. POLICOSANOL, BUT NOT ATORVASTATIN, SIGNIFICANTLY (P < 0.05) INCREASED SERUM HDL-C LEVELS BY 5.3%. BOTH TREATMENTS WERE WELL TOLERATED. AT STUDY COMPLETION, ATORVASTATIN MILDLY, BUT SIGNIFICANTLY (P < 0.05) INCREASED CREATINE PHOSPHOKINASE (CPK) AND CREATININE, WHEREAS POLICOSANOL SIGNIFICANTLY REDUCED AST AND GLUCOSE (P < 0.01) AND CPK (P < 0.05) LEVELS. ALL INDIVIDUAL VALUES, HOWEVER, REMAINED WITHIN NORMAL LIMITS. THREE ATORVASTATIN BUT NO POLICOSANOL PATIENTS WITHDREW FROM THE STUDY BECAUSE OF ADVERSE EVENTS: MUSCLE CRAMPS (1 PATIENT), GASTRITIS (1 PATIENT) AND UNCONTROLLED HYPERTENSION, ABDOMINAL PAIN AND MYALGIA (1 PATIENT). OVERALL, NO POLICOSANOL AND SEVEN ATORVASTATIN PATIENTS (18.9%) REPORTED A TOTAL OF NINE MILD OR MODERATE ADVERSE EVENTS DURING THE STUDY (P < 0.01). CONCLUSIONS: THIS STUDY SHOWS THAT POLICOSANOL (10 MG/DAY) ADMINISTERED FOR 8 WEEKS WAS LESS EFFECTIVE THAN ATORVASTATIN (10 MG/DAY) IN REDUCING SERUM LDL-C AND TC LEVELS IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA. POLICOSANOL, BUT NOT ATORVASTATIN, HOWEVER, SIGNIFICANTLY INCREASED SERUM HDL-C LEVELS, WHEREAS BOTH DRUGS SIMILARLY REDUCED ATHEROGENIC RATIOS AND SERUM TRIGLYCERIDES. POLICOSANOL WAS BETTER TOLERATED THAN ATORVASTATIN AS REVEALED BY PATIENT WITHDRAWAL ANALYSIS AND OVERALL FREQUENCY OF ADVERSE EVENTS. NEVERTHELESS, FURTHER STUDIES MUST BE CONDUCTED IN LARGER SAMPLE SIZES AND USING DOSE-TITRATION METHODS TO ACHIEVE TARGET LIPID LEVELS IN ORDER TO REACH WIDER CONCLUSIONS.","","AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FATTY ALCOHOLS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PYRROLES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDYL; CREATINE KINASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE RELAXANT AGENT; POLICOSANOL; STATINE DERIVATIVE; TRIACYLGLYCEROL; VITAMIN; ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; AGING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MORBIDITY; MORTALITY; MUSCLE CRAMP; MUSCLE DISEASE; MYALGIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; SUGARCANE; TRIACYLGLYCEROL BLOOD LEVEL","WEST HAVANA SCIENTIFIC POLE","THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE WEST HAVANA SCIENTIFIC POLE. MOST OF THE AUTHORS HAVE BEEN INVOLVED IN THE DEVELOPMENT OF THE POLICOSANOL SCIENTIFIC PROJECT. NO ADDITIONAL PAYMENT OR REWARD HAS BEEN RECEIVED FOR CONDUCTING THIS STUDY.","ANDERSON K.M., WILSON P.W.F., ODELL P.M., ET AL., AN UPDATED CORONARY RISK PROFILE: A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOY L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE, BLOOD LIPIDS AND CORONARY HEART DISEASE. 2ND ED., (2000); KRUMHOLZ H.M., SEEMAN T.E., MERRILL S.S., ET AL., LACK OF ASSOSCIATION BETWEEN CHOLESTEROL AND CORONARY HEART DISEASE MORTALITY AND MORBIDITY AND ALL-CAUSE MORTALITY IN PERSONS OLDER THAN 70 YEARS, JAMA, 272, PP. 1335-1340, (1994); BILHEIMER D.W., CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN ELDERLY, ATHEROSCLEROSIS, 91, (1991); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN EPIDEMIOL, 2, PP. 161-176, (1992); LEA A.P., MCTAVISH D., ATORVASTATIN: A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN HYPERLIPIDAEMIA CONTROL, DRUGS, 53, PP. 828-847, (1997); JONES P., KAFANEK S., LAURORA I., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM J CARDIOL, 81, PP. 582-587, (1998); BLACK D.M., BAKKER-ARKEMA R., NAWROCKI J.W., AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN (LIPITOR), A NEW HMGCOA REDUCTASE INHIBITOR, ARCH INTERN MED, 158, PP. 577-584, (1998); SCHUSTER H., BERGER J., LUFT F., RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP TRIAL OF ATORVASTATIN AND FLUVASTATIN ON PLASMA LIPID LEVELS IN PATIENTS WITH UNTREATED HYPERLIPIDAEMIA, BR J CARDIOL, 5, PP. 597-602, (1998); DART A., JERUMS G., NICHOLSON G., ET AL., A MULTICENTER, DOUBLE-BLIND, ONE-YEAR STUDY COMPARING SAFETY AND EFFICACY OF ATORVASTATIN VERSUS SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA, AM J CARDIOL, 80, PP. 39-44, (1997); DAVIDSON M., MCKENNEY J., STEIN E., ET AL., COMPARISON OF ONE YEAR EFFICACY AND SAFETY OF ATORVASTATIN VERSUS LOVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 79, PP. 1475-1481, (1997); LAGUNA A., MAGRANER J., ARRUZAZABALA M.L., ET AL.; MAS R., POLICOSANOL, EN DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEARS STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOI VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 6-14, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL MED SCI, 56, (2001); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN INVEST, 21, PP. 103-113, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); NAWROCKI J.W., WEISS S.R., DAVIDSON M.H., ET AL., REDUCTION OF LDL CHOLESTEROL BY 25% TO 60% IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA BY ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR, ARTERIOSCLER THROMB VASC BIOL, 15, PP. 678-682, (1995); DEMIR M., ACARTURK E., SASMAZ I., ET AL., EFFECTS OF ATORVASTATIN ON LIPID PROFILE AND COAGULATION PARAMETERS, CURR THER RES, 62, PP. 691-698, (2001); CASTANO G., NODARSE M., MAS R., ET AL., ESTUDIO COMPARATIVO DE LA EFICACIA Y TOLERABILIDAD DEL POLICOSANOL, LA SIMVASTATINA Y SU TERAPIA COMBINADA EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA TIPO II, REV CENIC CIEN BIOL, 29, PP. 9-15, (1998); ZARDOVA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996)","R. MAS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS AGING","ARTICLE","ISI","2-S2.0-0345505338","DRUGS AGING","MEDICAL SURGICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTER","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2003, DRUGS AGING","CASTAÑO G, 2003, DRUGS AGING"
"","","CHOLESTEROLLOWERING ACTION OF POLICOSANOL COMPARES WELL TO THAT OF PRAVASTATIN AND LOVASTATIN",2003,"CARDIOVASCULAR JOURNAL OF SOUTH AFRICA : OFFICIAL JOURNAL FOR SOUTHERN AFRICA CARDIAC SOCIETY [AND] SOUTH AFRICAN SOCIETY OF CARDIAC PRACTITIONERS","14","",0,"","","[NO ABSTRACT AVAILABLE]","","ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; PRAVASTATIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; POLICOSANOL; PRAVASTATIN; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME","","","","","","ENGLISH","CARDIOVASC J S AFR","ARTICLE","ISI","2-S2.0-85009052170","CARDIOVASC J S AFR",NA,"NOTREPORTED",NA,"NA, 2003, CARDIOVASC J S AFR","NA, 2003, CARDIOVASC J S AFR"
"WHAYNE J T","WHAYNE JR., THOMAS F. (57204791430)","WOMEN AND CARDIOVASCULAR DISEASE PREVENTION OF HEART DISEASE",2006,"INTERNATIONAL JOURNAL OF ANGIOLOGY","14","6",6,"10.1007/s00547-005-2031-0","LEXINGTON, KY 40536-0200, 900 S. LIMESTONE STREET, UNITED STATES","THE SPECIFIC CHARACTERISTICS OF CARDIOVASCULAR (CV) DISEASE IN WOMEN ARE DISCUSSED, EMPHASIZING THAT CORONARY HEART DISEASE (CHD) IS THE MAJOR HEALTH PROBLEM IN WOMEN BUT, OVERALL, WOMEN ARE STILL LESS LIKELY TO DIE OF CHD THAN MEN. THIS IS CLARIFIED BY THE FACT THAT WOMEN UNDER AGE 75 ARE MORE LIKELY TO DIE FROM A MYOCARDIAL INFARCTION WHEN ONE OCCURS AND THAT CHD, WHEN IT IS PRESENT, IS ESPECIALLY MALIGNANT IN WOMEN UNDER THE AGE OF 50. SEPARATE FROM RISK ARE THE ISSUES OF PREVENTION AND TREATMENT. THE LATEST IN PREVENTION WITH AGGRESSIVE TREATMENT OF CHOLESTEROL ESPECIALLY IS EMPHASIZED AND DISCUSSED. REGARDLESS OF GENDER, THE GUIDELINES FOR LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL LOWERING HAVE BECOME MORE AND MORE INTENSIVE WITH BENEFIT ACCRUING TO THE PATIENT WITH HIGH CV RISK OF EITHER SEX AT LEVELS OF LDL CHOLESTEROL BELOW 70 MG/DL. INFLAMMATORY RISK FACTORS AS WELL AS HOMOCYSTEINE AND LIPOPROTEIN (A) HAVE BEEN SHOWN TO MAKE A DIFFERENCE AND THEIR CONTROL HAS ASSUMED INCREASED IMPORTANCE. THERE ARE NOW MULTIPLE THERAPEUTIC OPTIONS FOR ATTAINING BLOOD LIPID GOALS AND THE MAJOR THERAPEUTIC OPTIONS ARE DISCUSSED. STATINS ARE STILL PRIMARY IN CONTROLLING LDL CHOLESTEROL BUT NUMEROUS OTHER MEDICATIONS CONTRIBUTE SECONDARY ADDITIONAL BENEFITS OR ARE PRIMARY BECAUSE OF SPECIFIC METABOLIC PROBLEMS SUCH AS THE METABOLIC SYNDROME AND HYPERTRIGLYCERIDEMIA. WHEN CHD IS ESTABLISHED OR THE RISK FOR CHD IS HIGH, IT IS ESSENTIAL TO TREAT AGGRESSIVELY ALL MAJOR RISK FACTORS: HYPERCHOLESTEROLEMIA, HYPERTENSION, CIGARETTE SMOKING, DIABETES MELLITUS, AND METABOLIC SYNDROME. SUCH MANAGEMENT DELAYS DEVELOPMENT OF CLINICAL CHD AND SAVES LIVES.","","CERIVASTATIN; CHOLESTEROL; EZETIMIBE; GEMFIBROZIL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; POLICOSANOL; ARTICLE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; GENDER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS","","","ARBUSTINI E., DELBELLO B., MORBINI P., PLAQUE EROSION IS A MAJOR SUBSTRATE FOR CORONARY THROMBOSIS IN ACUTE MYOCARDIAL INFARCTION, HEART, 82, PP. 269-272, (1999); BACKMAN J., KYRKLUND C., NEUVONEN M., NEUVONEN P.J., GEMFIBROZIL GREATLY INCREASES PLASMA CONCENTRATIONS OF CERIVASTATIN, CLIN PHARMACOL THER, 72, PP. 685-691, (2002); BAYS H., MOORE P.B., DREHOBL M.A., ET AL., EFFECTIVENESS AND TOLERABILITY OF EZETIMIBE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: POOLED ANALYSIS OF TWO PHASE II STUDIES, CLIN THER, 23, PP. 1209-1230, (2001); BERGLUND L., RAMAKRISHNAN R., LIPOPROTEIN(A): AN ELUSIVE CARDIOVASCULAR RISK FACTOR, ARTERIOSCLER THROMB VASE BIOL, 24, PP. 2219-2226, (2004); BERTHOLD H., PARHOFER K.G., RITTER M.M., ADDO M., WASMUTH J.C., SCHLIEFER K., SPENGLER U., ROCKSTROH J.K., INFLUENCE OF PROTEASE INHIBITOR THERAPY ON LIPOPROTEIN METABOLISM, J INTERN MED, 246, PP. 567-575, (1999); CANNON C., BRAUNWALD E., MCCABE C.H., RADER D.J., ROULEAU J.L., BELDER R., JOYAL S.V., INTENSIVE VERSUS MODERATE LIPID LOWERING WITH STATINS AFTER ACUTE CORONARY SYNDROMES (PROVE-IT), N ENGL J MED, 350, PP. 1495-1504, (2004); CANTO J., SHLIPAK M.G., ROGERS W.J., MALMGREN J.A., FREDERICK P.D., LAMBREW C.T., ORNATO J.P., BARRON H.V., KIEFE C.I., PREVALENCE, CLINICAL CHARACTERISTICS AND MORTALITY AMONG PATIENTS WITH MYOCARDIAL INFARCTION PRESENTING WITHOUT CHEST PAIN, JAMA, 283, PP. 3223-3229, (2000); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CHAI A., ABRAMS J., HOMOCYSTEINE: A NEW CARDIAC RISK FACTOR, CLIIN CARDIOL, 24, PP. 80-84, (2001); CHIQUETTE E., RAMIREZ G., DEFRONZO R., A META-ANALYSIS COMPARING THE EFFECT OF THIAZOLIDINEDIONES ON CARDIOVASCULAR RISK FACTORS, ARCH INTERN MED, 164, PP. 2097-2104, (2004); CLEARFIELD M., CORONARY HEART DISEASE RISK REDUCTION IN POSTMENOPAUSAL WOMEN: THE ROLE OF STATIN THERAPY AND HORMONE REPLACEMENT THERAPY, PREV CARDIOL, 7, PP. 131-136, (2004); CRANE F., BIOCHEMICAL FUNCTIONS OF COENZYME Q10, J AM COLL NUTRI, 20, PP. 591-598, (2001); DAVIDSON M., OSE L., FROHLICH J., SCOTT R.S., DUJOVNE C.A., ESCOBAR I.D., BERTOLANII M.C., CIHON F., MACCUBBIN D.L., MERCURI M., DIFFERENTIAL EFFECTS OF SIMVASTATIN AND ATORVASTATIN ON HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN A-L ARE CONSISTENT ACROSS HYPERCHOLESTEROLEMIC PATIENT SUBGROUPS, CLIN CARDIOL, 26, PP. 509-514, (2003); DAVIGNON J., THE CARDIOPROTECTIVE EFFECTS OF STATINS, CURR ATHEROSCLER REP, 6, PP. 27-35, (2004); DOWNS J., CLEARFIELD M., WEIS S., WHITNEY E., SHAPIRO D.R., BEERE P.A., LANGENDORFER A., STEIN E.A., KRUYER W., GOTTO A.M., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS. AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); GLASER R., HERRMAN H.C., MURPHY S.A., DEMOPOULOS L.A., DIBATTISTE P.M., CANNON C.P., BRAUNWALD E., BENEFIT OF AN EARLY INVASIVE MANAGEMENT STRATEGY IN WOMEN WITH ACUTE CORONARY SYNDROMES, JAMA, 288, PP. 3124-3129, (2002); GORDON T., CASTELLI W.P., HJORTLAND M.C., KANNEL W.B., DAWBER T.R., HIGH DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART DISEASE. THE FRAMINGHAM STUDY, AM J MED, 62, PP. 707-714, (1977); GOTTO A., THE NEW CHOLESTEROL EDUCATION IMPERATIVE AND SOME COMMENTS ON NIACIN, AM J CARDIOL, 81, PP. 492-494, (1998); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HERZ M., JOHNS D., REVIRIEGO J., GROSSMAN L.D., GODIN C., DURAN S., HAWKINS F., LOCHNAN H., ESCOBAR-JIMENEZ F., HARDIN P.A., KONDOY C.S., TAN M.H., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF THE EFFECTS OF PIOGLITAZONE ON GLYCEMIC CONTROL AND DYSLIPIDEMIA ORAL ANTIHYPERGLYCEMIC MEDICATION-NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS, CLIN THER, 25, PP. 1074-1095, (2003); HOCHMAN J., TAMIS J.E., THOMPSON T.D., WEAVER W.D., WHITE H.D., VAN DE WERF F., AYLWARD P., TOPOL E.J., CALIFF R.M., SEX, CLINICAL PRESENTATION, AND OUTCOME IN PATIENTS WITH ACUTE CORONARY SYNDROMES, N ENGL J MED, 341, PP. 226-232, (1999); HULLEY S., GRADY D., BUSH T., FURBERG C., HERRINGTON D., RIGGS B., VITTINGHOFF E., RANDOMIZED TRIAL OF ESTROGEN PLUS PROGESTIN FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN, JAMA, 280, PP. 605-613, (1998); ISTVAN E.S., DEISENHOFER J., STRUCTURAL MECHANISM FOR STATIN INHIBITION OF HMG-COA REDUCTASE, SCIENCE, 292, PP. 1160-1164, (2001); JHA A., VAROSY P.D., KANAYA A.M., HUNNINGHAKE D.B., HLATKY M.A., WATERS D.D., FURBERG C.D., SHLIPAK M.G., DIFFERENCES IN MEDICAL CARE AND DISEASE OUTCOMES AMONG BLACK AND WHITE WOMEN WITH HEART DISEASE, CIRCULATION, 108, PP. 1089-1094, (2003); JONES P., DAVIDSON M.H., STEIN E.A., BAYS H.E., MCKENNEY J.M., MILLER E., CAIN V.A., BLASETTO J.W., COMPARISON OF THE EFFICACY AND SAFETY OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN ACROSS DOSES (STELLAR TRIAL), AM J CARDIOL, 92, PP. 152-160, (2003); KALIN M., ZUMOFF B., SEX HORMONES AND CORONARY DISEASE: A REVIEW OF THE CLINICAL STUDIES, STEROIDS, 55, PP. 330-352, (1990); KENT S., FLAHERTY P.J., COYLE L.C., MARKWOOD T.T., TAYLOR A.J., EFFECT OF ATORVASTATIN AND PRAVASTATIN ON SERUM C-REACTIVE PROTEIN, AM HEART J, 145, (2003); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); LOWE D., RUMLEY A., MCMAHON A.D., FORD I., O'REILLY D.S.J., PACKARD C.J., INTERLEUKIN-6, FIBRIN D-DIMER, AND COAGULATION FACTORS VII AND XIIA IN PREDICTION OF CORONARY HEART DISEASE, ARTERIOSCLER THROMB VASC BIOL, 24, PP. 1529-1534, (2004); MANNINEN V., ELO M.O., FRICK M.H., HAAPA K., HEINONEN O.P., HEINSALMI P., HELO P., HUTTUNEN J.K., KAITANIEMI P., KOSKINEN P., ET AL., LIPID ALTERATIONS AND DECLINE IN THE INCIDENCE OF CORONARY HEART DISEASE IN THE HELSINKI HEART STUDY, JAMA, 260, PP. 641-651, (1988); MARON D., FLAVONOIDS FOR REDUCTION OF ATHEROSCLEROTIC RISK, CURR ATHEROSCLER REP, 6, PP. 73-78, (2004); MARRUGAT J., SALA J., MASIA R., PAVESI M., SANZ G., VALLE V., MOLINA L., SERES L., ELOSUA R., MORTALITY DIFFERENCES BETWEEN MEN AND WOMEN FOLLOWING FIRST MYOCARDIAL INFARCTION, JAMA, 280, PP. 1405-1409, (1998); MESOTTEN D., SWINNEN J.V., VANDERHOYDONC F., WOUTERS P.J., VAN DEN BERGHE G., CONTRIBUTION OF CIRCULATING LIPIDS TO THE IMPROVED OUTCOME OF CRITICAL ILLNESS BY GLYCEMIC CONTROL WITH INTENSIVE INSULIN THERAPY, J CLIN ENDOCRINOL METAB, 89, PP. 219-226, (2004); NINOMIYA J., LITALIEN G., CRIQUI M.H., WHYTE J.L., GAMST A., CHEN R.S., ASSOCIATION OF THE METABOLIC SYNDROME WITH HISTORY OF MYOCARDIAL INFARCTION AND STROKE IN THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, CIRCULATION, 109, PP. 42-46, (2004); NISSEN S., TUZCU E.M., SCHOENHAGEN P., BROWN B.G., GANZ P., VOGEL R.A., CROWE T., EFFECT OF INTENSIVE COMPARED WITH MODERATE LIPID-LOWERING THERAPY ON PROGRESSION OF CORONARY ATHEROSCLEROSIS: A RANDOMIZED CONTROLLED TRIAL (REVERSAL), JAMA, 291, PP. 1071-1080, (2004); ORNISH D., SCHERWITZ L.M., BILLINGS J.H., BROWN S.E., GOULD K.L., MERRITT T.A., SPARLER S., ARMSTRONG W.T., PORTS T.A., KIRKEEIDE R., HOGEBOOM C., BRAND R.J., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 281, PP. 2001-2007, (1999); PEARSON T., LAURORA I., CHU H., KAFONEK S., THE LIPID TREATMENT ASSESSMENT PROJECT (L-TAP): A MULTICENTER SURVEY TO EVALUATE THE PERCENTAGES OF DYSLIPIDEMIC PATIENTS RECEIVING LIPID-LOWERING THERAPY AND ACHIEVING LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS, ARCH INTERN MED, 160, PP. 459-467, (2000); THE EFFECT OF AGGRESSIVE LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND LOW-DOSE ANTICOAGULATION ON OBSTRUCTIVE CHANGES IN SAPHENOUS-VEIN CORONARY-ARTERY BYPASS GRAFTS, N ENGL J MED, 337, PP. 153-162, (1997); RIDKER P., INFLAMMATION IN ATHEROTHROMBOSIS: HOW TO USE HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) IN CLINICAL PRACTICE, AM HEART HOSP J, 2, 1 SUPPL., PP. 4-9, (2004); SACKS F., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., BROWN L., WARNICA J.W., ARNOLD J.M., WUN C.C., DAVIS B.R., BRAUNWALD E., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); SAGER P., MELANI L., LIPKA L., STRONY J., YANG B., SURESH R., VELTRI E., EFFECT OF COADMINISTRATION OF EZETIMIBE AND SIMVASTATIN ON HIGH-SENSITIVITY C-REACTIVE PROTEIN, AM J CARDIOL, 92, PP. 1414-1418, (2003); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SHEPHERD J., COBBE S.M., FORD I., ISLES C.G., LORIMER A.R., MACFARLANE P.W., MCKILLOP J.G., PACKARD C.J., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA. WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, N ENGL J MED, 333, PP. 1301-1307, (1995); STAMLER J., WENTWORTH D., NEATON J.D., IS RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND RISK OF PREMATURE DEATH FROM CORONARY HEART DISEASE CONTINUOUS AND GRADED? FINDINGS IN 356,222 PRIMARY SCREENEES OF THE MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT), JAMA, 256, PP. 2823-2828, (1986); STUDER M., BRIEL M., LEIMENSTOLL B., GLASS T.R., BUCHER H.C., EFFECT OF DIFFERENT ANTILIPIDEMIC AGENTS AND DIETS ON MORTALITY, ARCH INTERN MED, 165, PP. 725-730, (2005); SZMITKO P., VERMA S., ANTIATHEROGENIC POTENTIAL OF RED WINE: CLINICIAN UPDATE, AM J PHYSIOL HEART CIRC PHYSIOL, 288, (2005); TARDIF J., ANTIOXIDANTS AND ATHEROSCLEROSIS: EMERGING DRUG THERAPIES, CURR ATHEROSCLER REP, 7, PP. 71-77, (2005); VACCARINO V., PARSONS L., EVERY N.R., BARREN H.V., KRUMHOLZ H.M., SEX-BASED DIFFERENCES IN EARLY MORTALITY AFTER MYOCARDIAL INFARCTION, N ENGL J MED, 341, PP. 217-225, (1999); VACCARINO V., KRUMHOLZ H.M., YARZEBSKI J., GORE J.M., GOLDBERG R.J., SEX DIFFERENCES IN 2-YEAR MORTALITY AFTER HOSPITAL DISCHARGE FOR MYOCARDIAL INFARCTION, ANN INTERN MED, 134, PP. 173-181, (2001); WALLERATH T., POLEO D., LI H., FORSTERMANN U., RED WINE INCREASES THE EXPRESSION OF HUMAN ENDOTHELIAL NITRIC OXIDE SYNTHASE: A MECHANISM THAT MAY CONTRIBUTE TO ITS BENEFICIAL CARDIOVASCULAR EFFECTS, J AM COLL CARDIOL, 41, PP. 471-478, (2003); WHAYNE T., ZIELKE J.C., DICKSON L.G., WINTERS J.L., STATE OF THE ART TREATMENT OF THE MOST DIFFICULT LOW DENSITY LIPOPROTEIN (LDL) CHOLESTEROL PROBLEMS:LDLAPHERESIS, J KY MED ASSOC, 100, PP. 535-538, (2002); WRIGHT C., ZIELKE J., WHAYNE T.F., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE: USE IN PATIENTS INTOLERANT OF OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INT J ANGIOL, 13, PP. 173-175, (2005); ZEFF R., KONGTAHWORN C., IANNONE L.A., GORDON D.F., BROWN T.M., PHILLIPS S.J., SKINNER J.R., SPECTOR M., INTERNAL MAMMARY ARTERY VERSUS SAPHENOUS VEIN GRAFT TO THE LEFT ANTERIOR DESCENDING CORONARY ARTERY: PROSPECTIVE RANDOMIZED STUDY WITH 10-YEAR FOLLOW-UP, ANN THORC SURG, 45, PP. 533-536, (1988)","","","ENGLISH","INT. J. ANGIOL.","ARTICLE","ISI","2-S2.0-33747410920","INT J ANGIOL",NA,"NOTREPORTED",NA,"WHAYNE JR TF, 2006, INT J ANGIOL","WHAYNE JR TF, 2006, INT J ANGIOL"
"IRMAK S;DUNFORD N","IRMAK, SIBEL (6603640781); DUNFORD, NURHAN TURGUT (6603296815)","POLICOSANOL CONTENTS AND COMPOSITIONS OF WHEAT VARIETIES",2005,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","53","3",75,"10.1021/jf050508r","OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES;OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES","POLICOSANOL (PC) IS THE COMMON NAME FOR A MIXTURE OF HIGH MOLECULAR WEIGHT (20-36 CARBON) ALIPHATIC PRIMARY ALCOHOLS, WHICH ARE CONSTITUENTS OF PLANT EPICUTICULAR WAXES. WHEAT GERM OIL HAS BEEN REPORTED TO IMPROVE HUMAN PHYSICAL FITNESS, AND THIS EFFECT IS ATTRIBUTED TO ITS HIGH PC, SPECIFICALLY ITS HIGH OCTACOSANOL (OC) CONTENT. ALTHOUGH THE PC COMPOSITION OF WHEAT LEAVES HAS BEEN STUDIED EXTENSIVELY, INFORMATION ON PC CONTENT AND COMPOSITION OF WHEAT GRAIN FRACTIONS IS SCARCE. THE OBJECTIVE OF THIS STUDY WAS TO EXAMINE THE PC CONTENTS AND COMPOSITIONS OF WHEAT GRAIN FRACTIONS OF 31 VARIETIES GROWN IN OKLAHOMA. PC COMPOSITIONS OF THE SAMPLES WERE IDENTIFIED USING A GAS CHROMATOGRAPH COUPLED WITH A MASS SPECTROMETER. THE PC CONTENT OF WHEAT BRAN WAS HIGHER THAN THAT OF THE GERM, SHORTS, AND FLOUR. THE TREGO AND INTRADA VARIETIES HAD THE HIGHEST PC CONTENT AMONG THE 31 WHEAT VARIETIES STUDIED. TETRACOSANOL (C24), HEXACOSANOL (C26), AND OC (C28) WERE THE MAJOR PC COMPONENTS IN ALL VARIETIES. THIS STUDY SHOWED THAT WHEAT VARIETIES GROWN UNDER IDENTICAL GROWING CONDITIONS AND MANAGEMENT DIFFER SIGNIFICANTLY IN PC CONTENT AND COMPOSITION. © 2005 AMERICAN CHEMICAL SOCIETY.","OCTACOSANOL; PLANT WAX; POLICOSANOL; WHEAT","FATTY ALCOHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; SEEDS; SPECIES SPECIFICITY; TRITICUM; TRITICUM AESTIVUM; FATTY ALCOHOL; POLICOSANOL; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; MASS FRAGMENTOGRAPHY; PLANT SEED; SPECIES DIFFERENCE; WHEAT","","","ATWELL W.A., AN OVERVIEW OF WHEAT DEVELOPMENT, CULTIVATION, AND PRODUCTION, CEREAL FOODS WORLD, 46, PP. 59-62, (2001); THE WHEAT IMPROVEMENT PROGRAM, (2004); POLLARD A., CHIBNALL A.C., PIPER S.H., CCVII. THE ISOLATION OF N-OCTACOSANOL FROM WHEAT WAX, BIOCHEM. J., 27, (1933); BIANCHI G., EPICUTICULAR WAX ANALYSIS IN TRITICUM AND RELATED SPECIES, GENET. AGR., 39, PP. 471-486, (1985); BIANCHI G., FIGINI M.L., BORGHI B., CORBELLINI M., CHEMICAL GENETICS OF WAX FORMATION IN WHEAT, GEN. AGRIC., 38, PP. 209-218, (1984); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF TRITICUM AESTIVUM, PHYTOCHEMISTRY, 12, PP. 2217-2223, (1973); TULLOCH A.P., WEENINK R.O., COMPOSITION OF THE LEAF WAX OF LITTLE CLUB WHEAT, CAN. J. CHEM., 47, PP. 3119-3126, (1969); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF DURUM WHEAT, PHYTOCHEMISTRY, 10, PP. 871-876, (1971); BIANCHI G., FIGINI M.L., EPICUTICULAR WAXES OF GLAUCOUS AND NONGLAUCOUS DURUM WHEAT LINES, J. AGRIC. FOOD CHEM., 34, PP. 429-433, (1986); BIANCHI G., SCOLE F., BORGHI B., CORBELLINI M., EPICUTICULAR WAXES OF HEXAPLOID AND OCTAPLOID TRITICALES, PHYTOCHEMISTRY, 21, PP. 639-642, (1982); CONSOLAZIO C.F., MATOUS L.O., NELSON R.A., ISAAC G.J., HURSH L.M., EFFECT OF OCTACOSANOL, WHEAT GERM OIL, AND VITAMIN E ON PERFORMANCE OF SWIMMING RATS, J. APPL. PHYSIOL., 19, PP. 265-267, (1964); CURETON T.K., IMPROVEMENTS IN PHYSICAL FITNESS ASSOCIATED WITH A COURSE OF U.S. NAVY UNDERWATER TRAINEES, WITH AND WITHOUT DIETARY SUPPLEMENTS, RES. Q., 34, PP. 440-453, (1963); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERREIRO R.M., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ARRUZAZABALA M.L., CARBAJAL D., R M., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, PP. 691-699, (1996); VALDES S., ARRUZAZABALA M.L., FERNANDEZ E., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARM. RES., 16, PP. 67-72, (1996); KATO S., KARINO K.-I., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR. J. NUTR., 73, PP. 433-441, (1995); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH. MED. RES., 28, PP. 355-360, (1997); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); BAI S., XIE L., LIU C., ZHENG Q., CHEN J., EFFECTS OF OCTACOSANOL IN FOOD PHYSIOOGICAL PARAMETERS IN TAIL-SUSPENDED RATS, SPACE MED. MED. ENG., 10, PP. 450-452, (1997); IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE, AND WHEAT EXTRACTS, FOOD CHEM., (2005); CURETON T.K., EFFECTS OF WHEAT GERM OIL AND VITAMIN E ON NORMAL HUMAN SUBJECTS IN PHYSICAL TRAINING PROGRAMS, AM. J. PHYSIOL., 179, PP. 628-634, (1954); SAINT-JOHN M., MCNAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME, AND CHEST AND GRIP STRENGTH, INT. CLIN. NUTR. REV., 6, PP. 81-87, (1986); TODD A.R., BERGEL F., WALDMANN H., WORK T.S., CCLXXVI. STUDIES ON VITAMIN E. I. THE ISOLATION OF SOME CRYSTALLINE ALCOHOLS FROM THE UNSAPONIFIABLE MATTER OF RICE AND WHEAT GERM OILS, BIOCHEM. J., 31, PP. 2247-2256, (1937); YU L., HALEY S., PERRET J., HARRIS M., ANTIOXIDANT PROPERTIES OF HARD WINTER WHEAT EXTRACTS, FOOD CHEM., 78, PP. 457-461, (2002); WETTSTEIN-KNOWLES P.V., GENETICS AND BIOSYNTHESIS OF PLANT EPICUTICULAR WAXES, ADVANCES IN THE BIOCHEMISTRY AND PHYSIOLOGY OF PLANT LIPIDS, PP. 1-26, (1979)","N.T. DUNFORD; OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-22644436719","J AGRIC FOOD CHEM","OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY","NOTREPORTED;OKLAHOMA STATE UNIVERSITY;NOTREPORTED",NA,"IRMAK S, 2005, J AGRIC FOOD CHEM","IRMAK S, 2005, J AGRIC FOOD CHEM"
"","","COMPLEMENTARY CARE HOW STATIN ALTERNATIVES STACK UP SOME HELP CONTROL CHOLESTEROL OTHERS ARE POTENTIALLY HARMFUL",2005,"HEART ADVISOR / THE CLEVELAND CLINIC","8","1",0,"","","[NO ABSTRACT AVAILABLE]","","ANTICHOLESTEREMIC AGENTS; CHOLESTYRAMINE; COLESTIPOL; FATTY ALCOHOLS; HUMANS; NIACIN; PHYTOTHERAPY; PSYLLIUM; COLESTIPOL; COLESTYRAMINE; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; ISPAGULA; NICOTINIC ACID; POLICOSANOL; ARTICLE; HUMAN; METHODOLOGY; PHYTOTHERAPY","","","","","","ENGLISH","HEART ADVIS","ARTICLE","ISI","2-S2.0-15244361814","HEART ADVIS",NA,"NOTREPORTED",NA,"NA, 2005, HEART ADVIS","NA, 2005, HEART ADVIS"
"SETNIKAR I;SENIN P;ROVATI L","SETNIKAR, IVO (7006351979); SENIN, PAOLO (6508101258); ROVATI, LUCIO C. (35429590100)","ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT",2005,"ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH","55","5",23,"10.1055/s-0031-1296865","ROTTA RESEARCH LABORATORIUM, DIVISION OF ROTTAPHARM SPA, MONZA, ITALY, ROTTAPHARM SPA, 20052 MONZA, VIA VALOSA DI SOPRA, 9, ITALY;ROTTA RESEARCH LABORATORIUM, DIVISION OF ROTTAPHARM SPA, MONZA, ITALY;ROTTA RESEARCH LABORATORIUM, DIVISION OF ROTTAPHARM SPA, MONZA, ITALY","THE EFFECTS OF POLICOSANOL (P), OF EXTRACT OF RED YEAST RICE (RICE FERMENTED WITH MONASCUS PURPUREUS) (RYE) AND OF ASTAXANTHIN (A) (CONSTITUENTS OF ARMOLIPID®) WERE INVESTIGATED IN A MODEL OF EXPERIMENTAL ATHEROSCLEROSIS PROVOKED IN THE RABBIT BY ATHEROGENIC CHOLESTEROL-ENRICHED FEED (ACEF). P AND RYE AND THEIR COMBINATION WERE ABLE TO LOWER THE INCREASE OF SERUM TOTAL CHOLESTEROL AND OF LDL CHOLESTEROL ELICITED BY 3-MONTH FEEDING WITH ACEF. THEY ALSO WERE ABLE TO REDUCE THE INCREASE OF BLOOD MALONDIALDEHYDE (MDA), A TRACER OF LIPID PEROXIDATION BY THE FREE RADICALS RELEASED BY ACEF. WHEN COMBINED, THE SUBSTANCES DEVELOPED EITHER ADDITIVE OR POTENTIATED EF-FECTS, SUPPORTING THE RATIONALE OF THEIR COMBINATION. REMARKABLE WAS THE PROTECTIVE EFFECT ON LIPID INFILTRATION IN THE AORTIC WALL PROVOKED BY ACEF, WHICH WAS REDUCED BY P AND BY RYE AND ALMOST COMPLETELY PREVENTED BY THE ADDITION OF A TO THE P-RYE COMBINATION. THE RESULTS SUPPORT THE RATIONALE OF A COMBINATION OF P, RYE AND A AS A USEFUL FOOD SUPPLEMENT IN HYPERLIPEMIC PATIENTS. © ECV · EDITIO CANTOR VERLAG.","ARMOLIPID®; ASTAXANTHIN; ATHEROSCLEROSIS, EXPERIMENTAL; POLICOSANOL; RED YEAST RICE EXTRACT","ASTAXANTHIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLANT EXTRACT; POLICOSANOL; RED YEAST RICE EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; FAT INTAKE; FEMALE; HYPERLIPIDEMIA; LIPID PEROXIDATION; MONASCUS; NONHUMAN; PHYTOTHERAPY; RABBIT; TREATMENT OUTCOME","","","CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STENOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, (2005); GRIGORE L., REDAELLI L., MAGGI F.M., ET AL., ARMOLIPID, A NUTRITIONAL SUPPLEMENT, EFFECTIVELY REDUCES PLASMA TOTAL AND LDL CHOLESTEROL IN MODERATE HYPERCHOLESTEROLEMIA, DRUGS AFFECTING LIPID METABOLISM, (2004); HEBER D., LEMBERTAS A., LU Q.Y., ET AL., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J. ALTERN. COMPLEMENT MED., 7, (2001); HEBER D., YIP I., ASHELY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM. J. CLIN. NUTR., 69, (1999); HOLMAN R.S., MCGILL JR. H.C., STRONG J.P., ET AL., TECHNICS FOR STUDYING ATHEROSCLEROTIC LESIONS, LAB. INVEST., 7, (1958); IWAMOTO T., HOSODA K., HIRANO R., ET AL., INHIBITION OF LOW-DENSITY LIPOPROTEIN OXIDATION BY ASTAXANTHIN, J. ATHEROSCLER. THROMB., 7, (2000); MENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, (1997); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, (2001); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, (2000); POLICOSANOL, PP. 367-372, (2001); RED YEAST RICE, PP. 393-397, (2001); POLI A., ASTAXANTINA NATURALE, INTEGR. NUTR., 6, (2003); POLICOSANOL MONOGRAPH, ALTERNATIVE MED. REV., 9, (2004); PRASAD K., KALRA J., CHAUDHARY A.K., ET AL., EFFECT OF POLYMORPHONUCLEAR LEUKOCYTE DERIVED OXYGEN FREE RADICALS AND HYPOCHLOROUS ACID ON CARDIAC FUNCTION AND SOME BIOCHEMICAL PARAMETERS, AM. HEART J., 119, (1990); PRASAD K., KALRA J., EXPERIMENTAL ATHEROSCLEROSIS AND OXYGEN FREE RADICALS, ANGIOLOGY, 40, (1989); PRASAD K., KALRA J., OXYGEN FREE RADICALS AND HYPERCHOLESTEROLEMIC ATHEROSCLEROSIS: EFFECT OF VITAMIN E, AM. HEART J., 125, (1993); SANS S., KESTELOOD H., KROMHOUT D., THE BURDEN OF CARDIOVASCULAR DISEASES MORTALITY IN EUROPE, EUR. HEART J., 18, (1997); STEINBERG D., LOW DENSITY LIPOPROTEIN OXIDATION AND ITS PATHOBIOLOGICAL SIGNIFICANCE, J. BIOL. CHEM., 272, (1997); EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUR. HEART J., 24, (2003); WANG J., LU Z., CHI J., ET AL., MULTICENTER CLINICAL TRIAL OF THE SERUM LIPID-LOWERING EFFECTS OF A MONASCUS PURPUREUS (RED YEAST) RICE PREPARATION FROM TRADITIONAL CHINESE MEDICINE, CURR. THER. RES., 58, (1997)","I. SETNIKAR; ROTTAPHARM SPA, 20052 MONZA, VIA VALOSA DI SOPRA, 9, ITALY; EMAIL: IVO.SETNIKAR@ROTTA.COM","EDITIO CANTOR VERLAG GMBH","ENGLISH","ARZNEIM.-FORSCH. DRUG RES.","ARTICLE","ISI","2-S2.0-21244477529","ARZNEIM-FORSCH DRUG RES","ROTTA RESEARCH LABORATORIUM;ROTTA RESEARCH LABORATORIUM;ROTTA RESEARCH LABORATORIUM","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"SETNIKAR I, 2005, ARZNEIM-FORSCH DRUG RES","SETNIKAR I, 2005, ARZNEIM-FORSCH DRUG RES"
"FERNÁNDEZ S;MÁS R;GAMEZ R;DIAZ A;FERNÁNDEZ J;ORTA S;ILLNAIT J;CASTAÑO G;MENDOZA S;VALDÉS F;ALVAREZ E","FERNÁNDEZ, SALOME (7202872681); MÁS, ROSA (7007164572); GAMEZ, RAFAEL (7003605346); DIAZ, ARQUÍMEDES (57214115282); FERNÁNDEZ, JULIO (9432805500); ORTA, SANTA DEIBIS (8621035100); ILLNAIT, JOSÉ (8631465800); CASTAÑO, GLADYS (56232967100); MENDOZA, SARAHI (7102759819); VALDÉS, FRANCISCO (7005154956); ALVAREZ, ESTRELLA (15053135600)","A PHARMACOLOGICAL SURVEILLANCE STUDY OF THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION",2004,"AMERICAN JOURNAL GERIATRIC PHARMACOTHERAPY","2","10",15,"10.1016/j.amjopharm.2004.12.004","PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;HAVANA, CUBA;PLAYA, HAVANA, CUBA;HAVANA, CUBA;PLAYA, HAVANA, CUBA;HAVANA, CUBA;PLAYA, HAVANA, CUBA;HAVANA, CUBA;HAVANA, CUBA","BACKGROUND: POLICOSANOL IS A DRUG DERIVED FROM SUGAR CANE WAX THAT HAS CHOLESTEROL-LOWERING AND ANTIPLATELET PROPERTIES. RANDOMIZED, CONTROLLED STUDIES ARE THE GOLD STANDARD FOR DEMONSTRATING DRUG EFFICACY, SAFETY, AND TOLERABILITY, BUT POSTMARKETING SURVEILLANCE STUDIES ARE ENCOURAGED FOR CORROBORATING DRUG EFFECTS. A VALID PROOF OF THE SAFETY OF A DRUG IS A WELL-DOCUMENTED, GOOD TOLERABILITY PROFILE IN OLDER INDIVIDUALS, SINCE THIS POPULATION IS MORE PRONE TO DRUG-RELATED ADVERSE EVENTS (AES). OBJECTIVE: THIS STUDY INVESTIGATED THE TOLERABILITY OF POLICOSANOL IN THE ELDERLY POPULATION BY MONITORING THE INCIDENCE AND NATURE OF AES OCCURING IN OLDER CUBAN PATIENTS TREATED WITH POLICOSANOL IN ROUTINE CLINICAL PRACTICE. METHODS: ALL PATIENTS AGED ≥60 YEARS TREATED WITH POLICOSANOL AT 7 MAJOR MEDICAL CENTERS FROM JANUARY 2000 TO MAY 2003 WERE INCLUDED. POLICOSANOL (5, 10, OR 20 MG/D) WAS PRESCRIBED TO PATIENTS ELIGIBLE TO RECEIVE CHOLESTEROL-LOWERING AND/OR ANTIPLATELET DRUGS, WITH THE DOSAGE RECOMMENDED ACCORDING TO THEIR INDIVIDUAL ATHEROSCLEROTIC RISK. PATIENTS HAD FOLLOW-UP VISITS APPROXIMATELY EVERY 6 MONTHS. DATA ON AES AND OTHER RELEVANT INFORMATION, INCLUDING CHANGES IN POLICOSANOL TREATMENT, CONCOMITANT MEDICATIONS, AND DISCONTINUATIONS, WERE RECORDED ON INDIVIDUAL CASE-REPORT FORMS. RESULTS: THIS STUDY INCLUDED 2252 PATIENTS (1306 WOMEN, 946 MEN): 647 (28.7%), 244 (10.8%), AND 173 (7.7%) PATIENTS HAD CORONARY, CEREBROVASCULAR, AND PERIPHERAL ARTERY DISEASE, RESPECTIVELY. A TOTAL OF 1485 PATIENTS HAD HYPERCHOLESTEROLEMIA (65.9%), 1322 (58.7%) HAD HYPERTENSION, AND 323 (14.3%) HAD DIABETES MELLITUS. OF THE ENROLLED PATIENTS, 1123 (49.9%), 644 (28.6%), AND 485 (21.5%) RECEIVED POLICOSANOL 5, 10, AND 20 MG/D, RESPECTIVELY. TREATMENT DURATION VARIED: 2169 (96.3%), 1861 (82.6%), 1116 (49.6%), AND 412 (18.3%) PATIENTS WERE TREATED FOR 6, 12, 24, AND 36 MONTHS, RESPECTIVELY. THIRTY-ONE PATIENTS (1.4%) EXPERIENCED SERIOUS AES, 18 OF THEM FATAL. DEATH WAS MOST OFTEN DUE TO VASCULAR EVENTS: MYOCARDIAL INFARCTION (4 PATIENTS), SUDDEN CARDIAC ARREST (1), VENTRICULAR ARRHYTHMIA (2), ISCHEMIC STROKE (1), LUNG THROMBOEMBOLISM (1), CANCER (5), PENUMONIA (1), PERITONITIS (1), LUNG EDEMA (1), AND DEHYDRATION (1). ANOTHER 13 PATIENTS (0.6%) WERE HOSPITALIZED, AND 61 (2.7%) REPORTED MODERATE OR MILD AES. OVERALL, 21 PATIENTS (0.9%) DISCONTINUED PREMATURELY FROM THE STUDY, 18 OF THEM DUE TO A FATAL SERIOUS AE. CONCLUSIONS: LONG-TERM TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS AT HIGH VASCULAR RISK WAS VERY GOOD, AS ASSESSED UNDER CONDITIONS OF ROUTINE CLINICAL PRACTICE. THESE RESULTS ARE CONSISTENT WITH THOSE OBTAINED IN RANDOMIZED, DOUBLE-BLIND CLINICAL STUDIES OF OLDER PATIENTS TREATED WITH POLICOSANOL. COPYRIGHT © 2004 EXCERPTA MEDICA, INC.","ADVERSE EVENTS; CHOLESTEROL; ELDERLY; POLICOSANOL; POSTMARKETING SURVEILLANCE","AGED; ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; POLICOSANOL; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; ATHEROSCLEROSIS; BRADYCARDIA; BRONCHITIS; CATARACT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL PRACTICE; COLON CANCER; CONTRACTURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CUBA; CYSTITIS; DEHYDRATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; GASTRODUODENAL ULCER; GLAUCOMA; HEALTH CARE FACILITY; HEARING IMPAIRMENT; HEART ARREST; HEART INFARCTION; HEART MURMUR; HEART VENTRICLE ARRHYTHMIA; HEARTBURN; HEMORRHOID; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INFLUENZA; KIDNEY CYST; LUNG CANCER; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MUSCLE CRAMP; PATIENT INFORMATION; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PERITONITIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM DISEASE; RISK ASSESSMENT; STOMACH CANCER; TESTIS DISEASE; THORAX PAIN; VISUAL IMPAIRMENT","WREST HAVANA SCIENTIFIC POLE","THIS STUDY WAS SUPPORTED BY A RESEATCH PROJECT FROM THE WREST HAVANA SCIENTIFIC POLE, NO PAYMENT WAS RECDVED FROM ANY AUTHOR FOR CONDUCTING THE STUDY. SIX OF FILE AUTHORS, HOWEVER, HAVE BEEN ASSOCIATED WITH THE SCIENTIFIC DES""ELOPMENT OFPOLICOSANOL.","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP ON REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY, LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMIZED CONTROLLED STUDY, LANCET, 360, PP. 1623-1630, (2002); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN. EPIDEMIOL., 2, PP. 161-176, (1992); BILHEIMER D.W., CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN THE ELDERLY, ATHEROSCLEROSIS, 91, SUPPL., (1991); MAS R, POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT J NUTR., 77, PP. 923-932, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES. CLIN. EXP., 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 13, PP. 1-9, (2000); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATION ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. CLIN. PHARM. RES., 19, PP. 105-116, (1999); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN. INVEST., 21, PP. 103-113, (2001); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. A., 56, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN. DRUG INVEST., 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, PP. 153-163, (2002); MAS R., CASTANO G., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL ON MORBIDITY AND MORTALITY IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, J. AM. COLL. CARDIOL., 39, SUPPL. B, (2002); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 117-127, (1999); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN. DRUG INVEST., 23, PP. 639-650, (2003); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 10, PP. 119-124, (1998); ALEMAN C., MAS R., RODEIRO I., ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, TOXICOL. LETT., SUPPL., (1992); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLEDOGS: ONE YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG. CARCINOG. MUTAGEN., 14, PP. 239-249, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG. CARCINOG. MUTAGEN., 14, PP. 107-113, (1994); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR. THER. RES. CLIN. EXP., 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES. CLIN. EXP., 60, PP. 458-467, (1999); NARANJO C.A., BUSTO U., SELLERS E.M., ET AL., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN. PHARMACOL. THER., 30, PP. 239-245, (1981); BAKER S.K., TARNOPOLSKY M.A., STATIN MYOPATHIES: PATHOPHYSIOLOGIC AND CLINICAL PERSPECTIVES, CLIN. INVEST. MED., 24, PP. 258-272, (2001); GAIST D., GARCIA A., HUERTA C., ET AL., LIPID-LOWERING DRUGS AND RISK OF MYOPATHY: A POPULATION-BASED FOLLOWUP STUDY, EPIDEMIOLOGY, 12, PP. 565-569, (2001); PASTERNAK R.C., SMITH JR. S.C., BAIREY MERZ C.N., ET AL., ACC/AHA/NHLBI CLINICAL ADVISORY ON THE USE AND SAFETY OF STATINS, J. AM. COLL. CARDIOL., 40, PP. 567-572, (2002); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES. CLIN. EXP., 57, PP. 568-577, (1996); SNIDER S.R., OCTACOSANOL IN PARKINSONISM, ANN. NEUROL., 16, (1984)","R. MÁS; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RES., PLAYA, HAVANA, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","AM. J. GERIATR. PHARMACOTHER.","ARTICLE","ISI","2-S2.0-20144374934","AM J GERIATR PHARMACOTHER","NOTREPORTED","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RES.;EMAIL: CLINICA@ENET.CU",NA,"FERNÁNDEZ S, 2004, AM J GERIATR PHARMACOTHER","FERNÁNDEZ S, 2004, AM J GERIATR PHARMACOTHER"
"ROZNER S;GARTI N","ROZNER, SHOSHANA (13806036500); GARTI, NISSIM (7005289095)","THE ACTIVITY AND ABSORPTION RELATIONSHIP OF CHOLESTEROL AND PHYTOSTEROLS",2006,"COLLOIDS AND SURFACES A: PHYSICOCHEMICAL AND ENGINEERING ASPECTS","282-283","21",118,"10.1016/j.colsurfa.2005.12.032","CASALI INSTITUTE OF APPLIED CHEMISTRY, THE CHEMISTRY INSTITUTE, THE HEBREW UNIVERSITY OF JERUSALEM, JERUSALEM, 91904, ISRAEL;CASALI INSTITUTE OF APPLIED CHEMISTRY, THE CHEMISTRY INSTITUTE, THE HEBREW UNIVERSITY OF JERUSALEM, JERUSALEM, 91904, ISRAEL","CHOLESTEROL IS AN ESSENTIAL LIPID FOR MAMMALIAN LIFE, BUT A HIGH CHOLESTEROL LEVEL CAN ALMOST GUARANTEE THE EVENTUAL ONSET OF VASCULAR DISEASES AND, IN SOME CASES, CAN LEAD TO DEATH. IT HAS BEEN SHOWN THAT THERE IS A DIRECT CONNECTION BETWEEN HIGH CHOLESTEROL LEVELS AND VASCULAR DISEASES. SOME METHODS FOR LOWERING THE SERUM CHOLESTEROL LEVEL, THEREBY PREVENTING THE DEVELOPMENT OF THESE DISEASES, HAVE BEEN DEVELOPED AND THOSE INCLUDE DRUGS AND FOOD ADDITIVES. SINCE BOTH DRUGS AND FOOD ADDITIVES ACT TO INHIBIT THE UPTAKE OF CHOLESTEROL, UNDERSTANDING THE STEROL ABSORPTION PROCESS IS THE KEY TO UNDERSTANDING EXACTLY HOW DRUGS AND FOOD ADDITIVES REDUCE SERUM CHOLESTEROL LEVELS. THE MAJOR DRAWBACK OF USING ANTI-CHOLESTEROL DRUGS IS RELATED TO THEIR SIDE EFFECTS, AND THEREFORE, NATURAL FOOD ADDITIVES CALLED PLANT STEROLS (PHYTOSTEROLS) HAVE BEEN DEVELOPED AS AN ATTRACTIVE ALTERNATIVE. PHYTOSTEROLS ARE STEROLS THAT ARE SYNTHESIZED ONLY IN PLANTS AND THAT ARE STRUCTURALLY SIMILAR TO CHOLESTEROL BUT WITH THE INCLUSION OF AN EXTRA HYDROPHOBIC CARBON CHAIN AT THE C-24 POSITION. PHYTOSTEROLS AND THEIR ESTERS REDUCE CHOLESTEROL LEVEL IN THE BLOOD IN SPITE OF THE FACT THAT THEY ARE POORLY ABSORBED INTO THE BLOOD STREAM. THE MECHANISM BY WHICH PHYTOSTEROLS/PHYTOSTEROL ESTERS INTERFERE WITH CHOLESTEROL ABSORPTION IS NOT COMPLETELY CLEAR, BUT BASED ON THE PRESENT UNDERSTANDING, THREE DISTINCT FEATURES HAVE BEEN RECOGNIZED: (1) PHYSICO-CHEMICAL EFFECTS (E.G. COMPETITIVE SOLUBILIZATION AND CO-CRYSTALLIZATION); (2) EFFECTS AT THE ABSORPTION SITE (E.G. HYDROLYSIS BY LIPASES AND ESTERASES); (3) EFFECTS ON INTRA-CELLULAR TRAFFICKING OF STEROLS. DUE TO PHYTOSTEROLS' POOR SOLUBILIZATION IN OIL AND WATER, THEY MUST BE TAKEN IN HIGH DOSES TO ACHIEVE A REDUCTION IN CHOLESTEROL LEVEL. ONE OF THE GOALS OF THE FOOD AND PHARMACEUTICAL INDUSTRIES, THEREFORE, IS TO DEVELOP PRODUCTS THAT EFFECTUATE THE SAME DECREASE IN CHOLESTEROL LEVEL BUT IN SMALLER STEROL DOSES ACHIEVED BY INCREASING STEROL BIOAVAILABILITY. THE FIRST LINE OF PRODUCTS TO MEET THE INCREASED BIOAVAILABILITY CRITERION WAS THE OIL-SOLUBLE ESTERIFIED PHYTOSTEROLS COMBINED WITH FATTY ACIDS, WHICH EXHIBIT SOLUBILITY IN OIL 10 TIMES HIGHER THAN THAT OF PURE PHYTOSTEROLS. THE THREE PRIMARY METHODS OF PHYTOSTEROL INCLUSION IN FOOD ARE SUSPENSION, PRECIPITATION AND MICROEMULSION. © 2005 ELSEVIER B.V. ALL RIGHTS RESERVED.","CHD; CHOLESTEROL; COMPETITIVE ABSORPTION; MECHANISM; MICRO CRYSTALS; MICROEMULSION; OXYSTEROLS; PHYTOSTEROLS; STATINS; SUSPENSION","CARDIOVASCULAR SYSTEM; CRYSTALS; DISEASES; DRUG PRODUCTS; LIPIDS; MICROEMULSIONS; SUSPENSIONS (FLUIDS); 24 METHYLCHOLESTEROL; BECEL PRO ACTIVE; BENOCOL; CAMPESTANOL; CAMPOSTEROL; CARDIO AID L; CARDIO AID P; CERIVASTATIN; CHOLESSTOLIFE; CHOLESTATIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL SUCCESS; CHYLOMICRON; COMPACTIN; CYCLOARTENOL; DIMINICOL; EZETIMIBE; FATTY ACID ESTER; FLORA PRO ACTIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOGICOL; MEVINOLIN; OXYSTEROL; PHYTOSTANYL ESTER DERIVATIVE; PHYTOSTEROL; PHYTOTOSTERYL ESTER DERIVATIVE; PHYTROL; POLICOSANOL; PROSTEROL; REDUCOL; SIMVASTATIN; SITOSTANOL; SITOSTEROL; SITOSTEROL DERIVATIVE; STANOL ESTER; STEROL DERIVATIVE; STIGMASTEROL; TAKE CONTROL; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CHD; COMPETITIVE ABSORPTION; MICRO CRYSTALS; OXYSTEROLS; PHYTOSTEROLS; ARTICLE; ATHEROGENESIS; CARCINOGENESIS; CARDIOVASCULAR RISK; CELL TRANSPORT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL INTAKE; CHOLESTEROL SYNTHESIS; CRYSTALLIZATION; CYTOTOXICITY; DIET THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG ISOLATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; EMULSION; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC DISORDER; GENOTOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID ABSORPTION; LIPID METABOLISM; MICROEMULSION; MUSCLE WEAKNESS; NONHUMAN; PHYSICAL CHEMISTRY; PHYTOCHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SITOSTEROLEMIA; SOLUBILIZATION; STEROL ANALYSIS; SUSPENSION; CHOLESTEROL","","","BLOCH K., BIOCHEMISTRY OF LIPIDS, LIPOPROTEINS AND MEMBRANES, SERIES NEW COMPREHENSIVE BIOCHEMISTRY, (1991); LARS BASTIAANSE E.M., HOLD K.M., DER LAARSE A.V., CARDIOVASCULAR RES., 33, (1997); OHVO-REKILA H., RAMSTEDT B., LEPPIMAKI P., SLOTTE J.P., PROGRESS LIPID RES., 41, (2002); OSTLUND JR. R.E., ANNU. REV. NUTRITION, 22, (2002); KIRKWOOD A., PRITCHARD J.R., SCHWARZ S.M., MEDOW M.S., STEMERMAN M.B., AM. J. PHYSIOL., 260, (1991); YEAGLE P.L., BIOCHIMICA ET BIOPHYSICA ACTA, 822, (1985); PRIOR I.A., HANCOCK J.F., J. CELL SCI., 114, (2001); SIMONS M., KELLER P., DICHGANS J., SCHULZ J.B., NEUROLOGY, 57, (2001); TRAVIS A.J., KOPF G.S., J. CLIN. INVEST., 110, (2002); LIPID BIOCHEMISTRY, (1991); PHYSIOLOGY OF MEMBRANE FLUIDITY, 1, (1984); MEMBRANE FLUIDITY IN BIOLOGY, 4, (1985); BURGER K., GIMPL G., FAHRENHOLZ F., CELL. MOL. LIFE SCI., 57, (2000); STEINBERG D., J. LIPID RES., 46, (2005); STEHBENS W.E., EXP. MOL. PATHOL., 70, (2001); FUENTES R.M., NOTKOLA I.L., SHEMEIKKA S., TUOMILEHTO J., NISSINEN A., PREV. MED., 31, (2000); LIND S., RYSTEDT E., ERIKSSON M., WIKLUND O., ANGELIN B., EGGERTSEN G., ATHEROSCLEROSIS, 163, (2002); HELLSTROM H.R., MED. HYPOTHESES, 57, (2001); WALD N.J., LAW M.R., ATHEROSCLEROSIS, 118, (1995); LAW M.R., WALD N.J., THOMPSON S.G., BR. MED. J., 308, (1994); NAGADOME S., OKAZAKI Y., LEE S., SASAKI Y., SUGIHARA G., LANGMUIR, 17, (2001); IN TEXTBOOK OF ENDOCRINOLOGY, (1985); IN TEXTBOOK OF ENDOCRINOLOGY, (1985); TABAS I., J. CLIN. INVEST., 110, (2002); ALBERT A.D., BOESZE-BATTAGLIA K., PROGRESS LIPID RES., 44, (2005); CATTOPADHYAY A., JAFURULLA M., KALIPATNAPU S., PUCADYIL T.J., HARIKUMAR K.G., BIOCHEM. BIOPHYS. RES. COMMUN., 327, (2005); PFRIEGER F.W., BIOCHIMICA ET BIOPHSICA ACTA, 1610, (2003); KOUDINOV A.R., KOUDINOVA N.V., FASEB J. EXPRESS, 15, (2001); BOSINGER S.L.W., BRANDL E., INT. DAIRY J., 3, (1993); BROWN A.J., JESSUP W., ATHEROSCLEROSIS, 142, (1999); PIE J.E., SPAHIS K., SEILLAN C., J. AGRIC. FOOD CHEM., 38, (1990); JOHNSON K.A., MORROW C.J., KNIGHT G.D., SCALLEN T.J., J. LIPID RES., 35, (1994); HARIK-KHAN R., HOLMES R.P., J. STEROID BIOCHEM., 36, (1990); BISWAS S., MACDOUGALL J.D.B., COOK R.P., BR. J. EXP. PATHOL., 45, (1964); MACDOUGALL J.D.B., BISWAS S., COOK R.P., BR. J. EXP. PATHOL., 46, (1965); IMAI H., WERTHESSEN N.T., TAYLOR C.B., LEE K.T., ARCH. PATHOL. LAB. MED., 100, (1976); STEINBERG D., PARTHASARATHY S., CAREW T.E., KHOO J.C., WITZTUM J.L., N. ENGL. J. MED., 320, (1989); KRUT L.H., ATHEROSCLEROSIS, 43, (1982); KRUT L.H., ATHEROSCLEROSIS, 43, PP. 105-118, (1982); KANDUTSCH A.A., CHEN H.W., LIPIDS, 13, (1978); KANDUTSCH A.A., CHEN H.W., HEINIGER H.J., SCIENCE, 201, (1978); KANDUTSCH A.A., CHEN H.W., J. BIOL. CHEM., 252, (1977); BLACK H.S., LO W.B., NATURE (LONDON), 234, (1971); BLACK H.S., CHAN J.T., ONCOLOGY, 33, (1976); BLACK H.S., DOUGLAS D.R., CANCER RES., 32, (1972); WILSON M.D., RUDEL L.L., J. LIPID RES., 35, (1994); WESTSTRATE J.A., MEIJER G.W., BIOCHIMICA ET BIOPHYSICA ACTA, 1508, (2000); HENDRIKS H.F.J., WESTSTRATE J.A., VAN VLIET T., MEIJER G.W., EUR. J. NUTRITION, 53, (1999); AMUNDSEN A.L., OSE L., NENSETER M.S., NTANIOS F.Y., AM. J. CLIN. NUTRITION, 76, (2002); CHONG P.H., SEEGER J.D., FRANKLIN C., AM. J. MED., 111, (2001); ENDO A., INT. CONGRESS SERIES, 1262, (2004); MAGGINI M., RASCHETTI R., TRAVERSA G., BIANCHI C., CAFFARI B., DA CAS R., PANEI P., HEALTH POLICY, 69, (2004); HARRY R.D., INT. CONGRESS SERIES, 1262, (2004); YETLEY E.A., PARK Y.K., DIET AND HEART DISEASE-HEALTH CLAIMS, J. NUTRITION, 125, (1995); VANHANEN H.T., KAJANDER J., LEHTOVIRTA H., MIETTINEN T.A., CLIN. SCI., 87, (1994); MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., N. ENGL. J. MED., 333, (1995); METHODS IN PLANT BIOCHEMISTRY, 7, (1991); METHODS IN PLANT BIOCHEMISTRY, 7, (1991); MOREAU R.A., WHITAKER B.D., HICKS K.B., PROGRESS LIPID RES., 41, (2002); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., MAYO CLIN. PROC., 78, PP. 965-978, (2003); BAYS H.E., MOORE P.B., DREHOBL M.A., ROSENBLATT S., TOTH P.D., CLIN. THER., 23, (2001); KIM S.K., RHEE J.S., STEROLS FROM SOY OIL DEODORIZATION, KOREAN J. FOOD SCI. TECHNOL., 14, (1982); DAGUET D., COIC J.P., OLÉAQINEUX, CORP GRAS, LIPIDES, 6, (1999); POULOS A., GREINER J.W., FEVIG G.A., IND. ENG. CHEM., 53, (1961); XU W.L., HANG Y.B., QIAN J.H., SHA O., WANG Y.Q., SEPARATION PURIF. TECHNOL., 41, (2005); TRAUTWEIN E.A., DUCHATEAU G.S.M.J.E., LIN Y., MEL'NIKOV S.M., MOLHUIZEN H.O.F., NTANIOS F.Y., EUR. J. LIPID SCI. TECHNOL., 105, (2003); HUI D.Y., HOWLES P.N., SEMIN. DEV. BIOL., 16, (2005); HERNELL O., STAGGERS J.E., CAREY M.C., BIOCHEMISTRY, 29, (1990); YAO L., HEUBI J.E., BUCKLEY D.D., FIERRA H., SETCHELL K.D.R., GRANHOLM N.A., J. LIPID RES., 43, (2002); YOUNG S.C., HUI D.Y., BIOCHEM. J., 339, (1999); SURPURIYA V., HIGUCHI W.I., BIOCHIMICA ET BIOPHYSICA ACTA, 290, (1972); EMBLETON J.K., POUTON C.W., ADVANCED DRUG DELIVERY REV., 25, (1997); HUMBERSTONE A.J., CHARMAN W.N., ADVANCED DRUG DELIVERY REV., 25, (1997); ROS E., ATHEROSCLEROSIS, 151, (2000); ALBRECHT C., ELLIOTT J.I., SARDINI A., LITMAN T., STIEGER B., MEIER P.L., HIGGINS C.F., BIOCHIMICA ET BIOPHYSICA ACTA, 1567, (2002); SATO Y., NISIKAWA K., AIKAWA K., MIMURA K., MURAKAMI-MUROFUSHI K., ARAI H., INOUE K., BIOCHIMICA ET BIOPHYSICA ACTA, 1257, (1995); FIELD F.J., MATHUR S.N., J. LIPID RES., 24, (1983); MEL'NIKOV S.M., SEIJEN TEN HOORN J.W.M., EIJKELENBOOM A.P.A.M., CHEM. PHYS. LIPIDS, 127, (2004); IKEDA I., TANAKA K., SUGANO M., BIOCHIMICA ET BIOPHYSICA ACTA, 732, (1983); IKEDA I., TANAKA K., SUGANO M., VAHOUNY G.V., GALLO L.L., J. LIPID RES., 29, (1988); IKEDA I., TANAKA K., SUGANO M., VAHOUNY G.V., GALLO L.L., J. LIPID RES., 29, (1988); IKEDA I., TANABE Y., SUGANO M., J. NUTRITION SCI. VITAMINOL., 35, (1989); CHRISTIANSEN L., KARJALAINEN M., SEPPANEN-LAAKSO T., HILTUNEN R., YLIRUUSI J., INT. J. PHARMACEUTICS, 254, PP. 155-166, (2003); MEL'NIKOV S.M., SEIJEN TEN HOORN J.W.M., BERTRAND B., CHEM. PHYS. LIPIDS, 127, PP. 15-33, (2003); MEL'NIKOV S.M., SEIJEN TEN HOORN J.W.M., EIJKELENBOOM A.P.A.M., CHEM. PHYS. LIPIDS, 127, PP. 121-141, (2004); BOSNER M.S., WOLFF A.A., OSTLUND R.E., CARDIOVASCULAR DRUGS THER., 3, (1999); WENG W., LI L., VAN BENNEKUM A.M., POTTER S.H., HARRISON E.H., BLANER W.S., BRESLOW J.L., FISHER E.A., BIOCHEMISTRY, 38, (1999); IKEDA I., MATSUOKA R., HAMADA T., MISTUI K., IMABAYASHI S., UCHINO A., SATO M., KUWANO E., ITAMURA T., YAMADA K., TANAKA K., IMAIZUMI K., BIOCHIMICA ET BIOPHYSICA ACTA, 1571, (2002); NISSINEN M., GLLING H., VUORISTO M., MIETTINEN T.A., AM. J. PHYSIOL., 202, (2002); KRAMER W., GLOMBIK H., PETRY S., HEUER H., SCHAFER H., WENDLER W., CORSIERO D., GIRBIG F., WEYLAND C., FEBS LETT., 487, (2000); OSTLUND JR. R.E., CURR. OPIN. LIPIDOL., 15, (2004); FIELD F.J., BORN E., MATHUR S.T., J. LIPID RES., 45, (2004); PLAT J., MENSINK P., FASEB J., 16, (2002); PLAT J., MENSINK P., AM. J. CARDIOL., 96, (2005); KRAUSE B.R., ANDERSON M., BISGAIER C.L., BOCAN T., BOUSLEY R., DEHART P., ESSENBURG A., HAMELEHLE K., HOMAN R., KIEFT K., J. LIPID RES., 34, (1993); NTANIOS F.Y., JONES P.J., FROHLICH J.J., METABOLISM, 48, (1999); KALOGERIS T.J., STORY J.A., J. NUTRITION, 122, (1992); PETERSON D.W., PROC. SOC. EXP. BIOL. MED., 78, (1951); GYLLING H., SIIMES M.A., MIETTINEN T.A., J. LIPID RES., 36, (1995); JONES P.J.H., NTANIOS F.Y., RAEINI-SARJAZ M., VANSTONE C.A., AM. J. CLIN. NUTRITION, 69, (1999); MOGHADASAIN M.H., GODIN D.V., MCMANUS B.M., FROHLICH J.J., LIFE SCI., 64, (1999); PRITCHARD P.H., LI M., ZAMFIR C., LUKIC T., NOVAK E., MOGHADASIAM M.H., CARDIOVASCULAR DRUGS THER., 17, (2003); QUILEZ J., GARCIA-LORDA P., SALSAS-SALVADO J., CLIN. NUTRITION, 22, (2003); LEA L.J., HEPBURN P.A., WOLFREYS A.M., BALDRICK P., FOOD CHEM. TOXICOL., 42, (2004); DUTTA P.C., J. AM. OIL CHEMISTS SOC., 74, (1997); MOGHADASIAN M.H., LIFE SCI., 67, (2000); HEINEMANN T., KULLAK-UBLICK G.A., PIETRUCK B., VON BERGMANN K., EUR. J. CLIN. PHARMACOL., 40, (1991); LAW M., BR. MED. J., 320, (2000); PLAT J., VAN ONSELEN E.M.M., VAN HEUGTEN M.M.A., MENSINK R.P., EUR. J. CLIN. NUTRITION, 54, (2000); ENGEL R., SCHUBERT H., INNOVATIVE FOOD SCI. EMERG. TECHNOL., 6, (2005); MATTSON F.H., VOLPENHEIN R.A., ERICKSON B.A., J. NUTRITION, 35, (1977); DELANEY B., STEVENS L.A., SCHMELZER W., HAWORTH J., MCCURRY S., HILFINGER J.M., KIM J.S., TSUME Y., AMIDON G.L., KRITCHEVSKY D., J. NUTRITIONAL BIOCHEM., 15, (2004); BONSDORFF- NIKANDER A., KARJALAINEN M., RANTANEN J., CHRISTIANSEN L., YLIRUUSI J., EUR. J. PHARMACEUTICAL SCI., 19, (2003); CHRISTIANSEN L.I., LAHTEENMAKI P.L.A., MNNELIN M.R., SEPPANEN-LAAKSO T.E., HILTUNEN R.V.K., YLIRUUSI J.K., EUR. J. NUTRITION, 40, (2001); SPERNATH A., YAGHMUR A., ASERIN A., HOFFMAN R., GARTI N., J. AGRIC. FOOD CHEM., 51, (2003); GARTI N., AMAR-YULI I., SPERNATH A., HOFFMAN R., PHYS. CHEM. CHEM. PHYS., 6, (2004)","N. GARTI; CASALI INSTITUTE OF APPLIED CHEMISTRY, THE CHEMISTRY INSTITUTE, THE HEBREW UNIVERSITY OF JERUSALEM, JERUSALEM, 91904, ISRAEL; EMAIL: GARTI@HUJI.AC.IL","ELSEVIER","ENGLISH","COLLOIDS SURF. A PHYSICOCHEM. ENG. ASP.","ARTICLE","ISI","2-S2.0-33744540664","COLLOIDS SURF A PHYSICOCHEM ENG ASP","THE HEBREW UNIVERSITY OF JERUSALEM;THE HEBREW UNIVERSITY OF JERUSALEM","NOTREPORTED;THE HEBREW UNIVERSITY OF JERUSALEM;NOTREPORTED",NA,"ROZNER S, 2006, COLLOIDS SURF A PHYSICOCHEM ENG ASP","ROZNER S, 2006, COLLOIDS SURF A PHYSICOCHEM ENG ASP"
"CRAVOTTO G;BINELLO A;MERIZZI G;AVOGADRO M","CRAVOTTO, GIANCARLO (7003394420); BINELLO, ARIANNA (6603442129); MERIZZI, GIANFRANCO (6505601363); AVOGADRO, MILVIO (23048781900)","IMPROVING SOLVENTFREE EXTRACTION OF POLICOSANOL FROM RICE BRAN BY HIGHINTENSITY ULTRASOUND TREATMENT",2004,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","106","4",61,"10.1002/ejlt.200300914","DIPTO. DI SCI. E TECN. DEL FARMACO, UNIVERSITÀ DI TORINO, TORINO, ITALY, DIPTO. DI SCI. E TECN. DEL FARMACO, UNIVERSITÈ DI TORINO, 10125 TORINO, VIA P. GIURIA 9, ITALY;DIPTO. DI SCI. E TECN. DEL FARMACO, UNIVERSITÀ DI TORINO, TORINO, ITALY;MEDESTEA RESEARCH AND PRODUCTION SRI, COLLERETTO GIACOSA (TO), ITALY;RICERCA E SVILUPPO RISO SCOTTI SPA, PAVIA, ITALY","RICE BRAN, A RICH SOURCE OF NUTRIENTS AND PHARMACOLOGICALLY ACTIVE COMPOUNDS, IS CURRENTLY DISCARDED OR USED AS LIVESTOCK FEED, ONLY SMALL AMOUNTS BEING EARMARKED FOR OIL PRODUCTION. OIL EXTRACTION CAN BE EFFICIENTLY PERFORMED IN 30 MIN UNDER HIGH-INTENSITY ULTRASOUND EITHER WITH HEXANE OR WITHOUT ANY ORGANIC SOLVENT, USING A BASIC AQUEOUS SOLUTION INSTEAD. UNDER SONOCHEMICAL CONDITIONS BRAN WAX CAN ALSO BE HYDROLYZED YIELDING POLICOSANOL (COMMON NAME FOR A MIXTURE OF C24-C34 LINEAR SATURATED FATTY ALCOHOLS). WE SUGGEST THAT WAX, A WASTE OF RICE OIL MANUFACTURE, SHOULD BE EXPLOITED TO RECOVER ITS ALCOHOLIC MOIETY THAT IS VERY RICH IN POLICOSANOL. QUANTITATIVE DATA ON EXTRACTION AND PURIFICATION OF POLICOSANOL ARE PRESENTED. BOTH THE FIRST BRAN FRACTION FROM RICE POLISHING AND THE DISCARDED WAX FROM THE MANUFACTURE OF RICE OIL ARE CONVENIENT AND PROFITABLE STARTING MATERIALS FOR THE PRODUCTION OF POLICOSANOL.","EXTRACTION UNDER HIGH-INTENSITY ULTRASOUND; POLICOSANOL; RICE OIL; RICE WAX; SONOCHEMICAL HYDROLYSIS","HEXANE; ORGANIC SOLVENT; POLICOSANOL; AQUEOUS SOLUTION; ARTICLE; CHEMICAL ANALYSIS; EXTRACTION; HYDROLYSIS; QUANTITATIVE ANALYSIS; RICE BRAN; ULTRASOUND","","","SAUNDERS R.M., RICE BRAN: COMPOSITION AND POTENTIAL FOOD USES, FOOD. REV. INT., 1, PP. 465-495, (1985); RUKMINI C., RAGHURAM T.C., NUTRITIONAL AND BIOCHEMICAL ASPECTS OF THE HYPOLIPIDEMIC ACTION OF RICE BRAN OIL - A REVIEW, J. AM. COLL. NUTR., 10, PP. 593-601, (1991); RAGHURAM T.C., BRAJMAJI R.U., RUKMINI C., STUDIES ON HYPOLIPIDEMIC EFFECTS OF DIETARY RICE BRAN OIL IN HUMAN SUBJECTS, NUTR. REP. INT., 39, PP. 889-895, (1989); ORTHOEFER F.T., RICE BRAN OIL: HEALTHY LIPID SOURCE, FOOD TECHNOL., 50, PP. 62-64, (1996); JULIANO B.O., COMPARATIVE NUTRITIVE VALUE OF VARIOUS STAPLE FOODS, FOOD REV. INT., 15, PP. 399-434, (1999); JARIWALLA R.J., RICE-BRAN PRODUCTS: PHYTONUTRIENTS WITH POTENTIAL APPLICATIONS IN PREVENTIVE AND CLINICAL MEDICINE, DRUGS EXP. CLIN. RES., 27, PP. 17-26, (2001); SUGANO M., TSUJI E., RICE BRAN OIL AND CHOLESTEROL METABOLISM, J. NUTR., 127, PP. 521-524, (1997); QURESHI A.A., SALSER W.A., PARMAR R., EMESON E.E., NOVEL TOCOTRIENOLS OF RICE BRAN INHIBIT ATHEROSCLEROTIC LESIONS IN C57BL/6 APOE-DEFICIENT MICE, J. NUTR., 131, PP. 2606-2618, (2001); TINARELLI A., LA QUALITÀ NEL RISO, II RISO NELLE SUE CARATTERISTICHE E QUALITÀ, (1997); NARAYANA T., KAIMAL B., VALI S.R., SURYA B.V., RAO K., CHAKRABARTI P.P., VIJAYALAKSHMI P., KALE V., NARAYANA K., RANI P., RAJAMMA O., BHASKAR P.S., RAO T.C., ORIGIN OF PROBLEMS ENCOUNTERED IN RICE BRAN OIL PROCESSING, EUR. J. LIPID SCI. TECHNOL., 104, PP. 203-211, (2002); DE B.K., DAS R., DUTTA B.K., BHATTACHARYYA D.K., MEMBRANE DEGUMMING AND DEWAXING OF RICE BRAN OIL AND ITS REFINING, FETT/LIPID, 100, PP. 416-421, (1998); PRABHU A.V., TAMBE S.P., GANDHI N.N., SAWANT S.B., JOSHI J.B., RICE BRAN LIPASE: EXTRACTION, ACTIVITY, AND STABILITY, BIOTECHNOL. PROGR., 15, PP. 1083-1089, (1999); HUI Y.H., EDN., (1996); NAKAMURA H., EFFECT OF Γ-ORYZANOL ON HEPATIC CHOLESTEROL BIOSYNTHESIS AND FAECAL EXCRETION OF CHOLESTEROL METABOLITES, RADIOISOTOPES, 15, PP. 371-374, (1966); KAHLON T.S., CHOW F.I., SAYRE R.N., CHOLESTEROL-LOWERING PROPERTIES OF RICE BRAN, CEREAL FOOD WORLD, 39, PP. 99-103, (1994); XU Z., HUA N., GODBER J.S., ANTIOXIDANT ACTIVITY OF TOCOPHEROLS, TOCOTRIENOLS, AND Γ-ORYZANOL COMPONENTS FROM RICE BRAN AGAINST CHOLESTEROL OXIDATION ACCELERATED BY 2,2′-AZOBIS(2-METHYLPROPIONAMIDINE) DIHYDROCHLORIDE, J. AGRIC. FOOD CHEM., 49, PP. 2077-2081, (2001); WILSON T.A., IDREIS H.M., TAYLOR C.M., NICOLOSI R.J., WHOLE FAT RICE BRAN REDUCES THE DEVELOPMENT OF EARLY AORTIC ATHEROSCLEROSIS IN HYPERCHOLESTEROLEMIC HAMSTERS COMPARED WITH WHEAT BRAN, J. NUTR. RES., 22, PP. 1319-1332, (2002); DUNFORD N.T., HEALTH BENEFITS AND PROCESSING OF LIPID BASED NUTRITIONALS, FOOD TECHNOL., 55, PP. 38-44, (2001); QURESHI A.A., MO H.B., PACKER L., PETERSON D.M., ISOLATION AND IDENTIFICATION OF NOVEL TOCOTRIENOLS FROM RICE BRAN WITH HYPOCHOLESTEROLEMIC, ANTIOXIDANT, AND ANTITUMOR PROPERTIES, J. AGRIC. FOOD CHEM., 48, PP. 3130-3134, (2000); CICERO A.F.G., GADDI A., RICE BRAN OIL AND GAMMA-ORYZANOL IN THE TREATMENT OF HYPERLIPOPROTEINAEMIA AND OTHER CONDITIONS, PHYTOTHER. RES., 15, PP. 277-289, (2001); ABDUL-HAMID A., LUAN Y.S., FUNCTIONAL PROPERTIES OF DIETARY FIBER PREPARED FROM DEFATTED BRAN, FOOD CHEM., 68, PP. 15-19, (2000); MAS R., POLICOSANOL-HYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSIS, DRUG OF THE FUTURE, 25, PP. 569-586, (2000); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., FUSTER A., LASTRETO E., YANEZ M., IRICO G., MCCOOK B., FARRE A., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, PP. 31-41, (2001); CARR K., CUBAN BIOTECHNOLOGY TREADS A LONELY PATH, NATURE, 398, PP. 22-23, (1999); MAS F.R., CARBAJAL Q.D., GONZALES B.L., LAGUNA G.A., MARRERO D.D.; EBRINGEROVA A., HROMADKOVA Z., EFFECT OF ULTRASOUND ON THE EXTRACTABILITY OF CORN BRAN HEMICELLULOSES, ULTRASON. SONOCHEM., 9, PP. 225-229, (2002); TOMA M., VINATORU M., PANIWNYK L., MASON T.J., INVESTIGATION OF THE EFFECTS OF ULTRASOUND ON VEGETAL TISSUES DURING SOLVENT EXTRACTION, ULTRASON. SONOCHEM., 8, PP. 137-142, (2001); CRAVOTTO G.; CRAVOTTO G., OMICCIOLI G., STEVANATO L., AN IMPROVED SONOCHEMICAL REACTOR, ULTRASON. SONOCHEM.; AOAC: AOAC OFFICIAL METHODS OF ANALYSIS, 16TH EDN., (1995); EDN., (1986); CRAVOTTO G., OMICCIOLI G., VAZZOLER E.; HANMOUNGJAI P., PYLE L., NIRANJAN K., EXTRACTION OF RICE BRAN OIL USING AQUEOUS MEDIA, J. CHEM. TECHNOL. BIOTECHNOL., 75, PP. 348-352, (2000); MASON T.J., EDN., (2002); KEIL F.J., SWAMY K.M., REACTORS FOR SONOCHEMICAL ENGINEERING - PRESENT STATUS, REV. CHEM. ENG., 15, PP. 85-155, (1999); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED. HYPOTHESES, 59, PP. 268-279, (2002); WANG Y.W., JONES P.J.H., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003)","G. CRAVOTTO; DIPTO. DI SCI. E TECN. DEL FARMACO, UNIVERSITÈ DI TORINO, 10125 TORINO, VIA P. GIURIA 9, ITALY; EMAIL: GIANCARLO.CRAVOTTO@UNITO.IT","","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","2-S2.0-1842863618","EUR J LIPID SCI TECHNOL","UNIVERSITÀ DI TORINO;UNIVERSITÀ DI TORINO;COLLERETTO GIACOSA (TO)","NOTREPORTED;UNIVERSITÈ DI TORINO;NOTREPORTED",NA,"CRAVOTTO G, 2004, EUR J LIPID SCI TECHNOL","CRAVOTTO G, 2004, EUR J LIPID SCI TECHNOL"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","IGFI ACTIVITY MAY BE A KEY DETERMINANT OF STROKE RISK A CAUTIONARY LESSON FOR VEGANS",2003,"MEDICAL HYPOTHESES","61","11",12,"10.1016/S0306-9877(02)00241-4","UNITED STATES","IGF-I ACTS ON VASCULAR ENDOTHELIUM TO ACTIVATE NITRIC OXIDE SYNTHASE, THEREBY PROMOTING VASCULAR HEALTH; THERE IS REASON TO BELIEVE THAT THIS PROTECTION IS ESPECIALLY CRUCIAL TO THE CEREBRAL VASCULATURE, HELPING TO WARD OFF THROMBOTIC STROKES. IGF-I MAY ALSO PROMOTE THE STRUCTURAL INTEGRITY OF CEREBRAL ARTERIES, THEREBY OFFERING PROTECTION FROM HEMORRHAGIC STROKE. THESE CONSIDERATIONS MAY HELP TO EXPLAIN WHY TALLNESS IS ASSOCIATED WITH LOW STROKE RISK, WHEREAS GROWTH HORMONE DEFICIENCY INCREASES STROKE RISK - AND WHY AGE-ADJUSTED STROKE MORTALITY HAS BEEN EXCEPTIONALLY HIGH IN RURAL ASIANS EATING QUASI-VEGAN DIETS, BUT HAS BEEN DECLINING STEADILY IN ASIA AS DIETS HAVE BECOME PROGRESSIVELY HIGHER IN ANIMAL PRODUCTS. THERE IS GOOD REASON TO SUSPECT THAT LOW-FAT VEGAN DIETS TEND TO DOWN-REGULATE SYSTEMIC IGF-I ACTIVITY; THIS EFFECT WOULD BE EXPECTED TO INCREASE STROKE RISK IN VEGANS. FURTHERMORE, EPIDEMIOLOGY SUGGESTS THAT LOW SERUM CHOLESTEROL, AND POSSIBLY ALSO A LOW DIETARY INTAKE OF SATURATED FAT - BOTH CHARACTERISTIC OF THOSE ADOPTING LOW-FAT VEGAN DIETS - MAY ALSO INCREASE STROKE RISK. VEGANS ARE THUS WELL ADVISED TO ADOPT PRACTICAL COUNTERMEASURES TO MINIMIZE STROKE RISK - THE MOST DEFINITIVE OF WHICH MAY BE SALT RESTRICTION. A HIGH POTASSIUM INTAKE, AEROBIC EXERCISE TRAINING, WHOLE GRAINS, MODERATE ALCOHOL CONSUMPTION, LOW-DOSE ASPIRIN, STATIN OR POLICOSANOL THERAPY, GREEN TEA, AND SUPPLEMENTATION WITH FISH OIL, TAURINE, ARGININE, AND B VITAMINS - AS WELL AS PHARMACOTHERAPY OF HYPERTENSION IF WARRANTED - ARE OTHER PRACTICAL MEASURES FOR LOWERING STROKE RISK. ALTHOUGH LOW-FAT VEGAN DIETS MAY MARKEDLY REDUCE RISK FOR CORONARY DISEASE, DIABETES, AND MANY COMMON TYPES OF CANCER, AN INCREASED RISK FOR STROKE MAY REPRESENT AN 'ACHILLES HEEL'. NONETHELESS, VEGANS HAVE THE POTENTIAL TO ACHIEVE A TRULY EXCEPTIONAL 'HEALTHSPAN' IF THEY FACE THIS PROBLEM FORTHRIGHTLY BY RESTRICTING SALT INTAKE AND TAKING OTHER PRACTICAL MEASURES THAT PROMOTE CEREBROVASCULAR HEALTH. © 2003 PUBLISHED BY ELSEVIER SCIENCE LTD.","","ANIMALIA; ACETYLSALICYLIC ACID; ARGININE; CHOLESTEROL; COUMARIN ANTICOAGULANT; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLICOSANOL; SOMATOMEDIN C; TAURINE; VITAMIN B GROUP; ALCOHOL CONSUMPTION; ASIA; BLOOD PRESSURE REGULATION; BRAIN BLOOD VESSEL; CANCER; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; EXERCISE; GROWTH HORMONE DEFICIENCY; HEALTH PROMOTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION PREVENTION; HIGH POTASSIUM INTAKE; HUMAN; MORTALITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RURAL AREA; SODIUM RESTRICTION; STROKE; TEA","","","TSUKAHARA H., GORDIENKO D.V., TONSHOFF B., GELATO M.C., GOLIGORSKY M.S., DIRECT DEMONSTRATION OF INSULIN-LIKE GROWTH FACTOR-I-INDUCED NITRIC OXIDE PRODUCTION BY ENDOTHELIAL CELLS, KIDNEY INT, 45, PP. 598-604, (1994); MOTANI A., FORSTER L., TULL S., ANGGARD E.E., FERNS G.A., INSULIN-LIKE GROWTH FACTOR-I MODULATES MONOCYTE ADHESION TO EAHY 926 ENDOTHELIAL CELLS, INT J EXP PATHOL, 77, PP. 31-35, (1996); MICHELL B.J., GRIFFITHS J.E., MITCHELHILL K.I., ET AL., THE AKT KINASE SIGNALS DIRECTLY TO ENDOTHELIAL NITRIC OXIDE SYNTHASE, CURR BIOL, 9, PP. 845-848, (1999); SCHINI-KERTH V.B., DUAL EFFECTS OF INSULIN-LIKE GROWTH FACTOR-I ON THE CONSTITUTIVE AND INDUCIBLE NITRIC OXIDE (NO) SYNTHASE-DEPENDENT FORMATION OF NO IN VASCULAR CELLS, J ENDOCRINOL INVEST, 22, PP. 447-453, (1999); OSTERZIEL K.J., BODE-BOGER S.M., STROHM O., ET AL., ROLE OF NITRIC OXIDE IN THE VASODILATOR EFFECT OF RECOMBINANT HUMAN GROWTH HORMONE IN PATIENTS WITH DILATED CARDIOMYOPATHY, CARDIOVASC RES, 45, PP. 447-453, (2000); ISENOVIC E., MUNIYAPPA R., MILIVOJEVIC N., RAO Y., SOWERS J.R., ROLE OF PI3-KINASE IN ISOPROTERENOL AND IGF-1 INDUCED ECNOS ACTIVITY, BIOCHEM BIOPHYS RES COMMUN, 285, PP. 954-958, (2001); BOGER R.H., SKAMIRA C., BODE-BOGER S.M., BRABANT G., VON ZUR M., FROLICH J.C., NITRIC OXIDE MAY MEDIATE THE HEMODYNAMIC EFFECTS OF RECOMBINANT GROWTH HORMONE IN PATIENTS WITH ACQUIRED GROWTH HORMONE DEFICIENCY. A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, J CLIN INVEST, 98, PP. 2706-2713, (1996); BOGER R.H., NITRIC OXIDE AND THE MEDIATION OF THE HEMODYNAMIC EFFECTS OF GROWTH HORMONE IN HUMANS, J ENDOCRINOL INVEST, 22, PP. 75-81, (1999); MCCARTY M.F., UP-REGULATION OF ENDOTHELIAL NITRIC OXIDE ACTIVITY AS A CENTRAL STRATEGY FOR PREVENTION OF ISCHEMIC STROKE - JUST SAY NO TO STROKE!, MED HYPOTHESES, 55, PP. 386-403, (2000); ENDRES M., LAUFS U., HUANG Z., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC NATL ACAD SCI USA, 95, PP. 8880-8885, (1998); LAUFS U., LIAO J.K., DIRECT VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS, TRENDS CARDIOVASC MED, 10, PP. 143-148, (2000); HUANG Z., HUANG P.L., MA J., ET AL., ENLARGED INFARCTS IN ENDOTHELIAL NITRIC OXIDE SYNTHASE KNOCKOUT MICE ARE ATTENUATED BY NITRO-L-ARGININE, J CEREB BLOOD FLOW METAB, 16, PP. 981-987, (1996); STAGLIANO N.E., DIETRICH W.D., PRADO R., GREEN E.J., BUSTO R., THE ROLE OF NITRIC OXIDE IN THE PATHOPHYSIOLOGY OF THROMBOEMBOLIC STROKE IN THE RAT, BRAIN RES, 759, PP. 32-40, (1997); HUANG P.L., LESSONS LEARNED FROM NITRIC OXIDE SYNTHASE KNOCKOUT ANIMALS, SEMIN PERINATOL, 24, PP. 87-90, (2000); KIMOTO-KINOSHITA S., NISHIDA S., TOMURA T.T., DECREASE OF ENDOTHELIAL NITRIC OXIDE SYNTHASE IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RAT CEREBRAL CORTEX, NEUROSCI LETT, 288, PP. 103-106, (2000); FOSTER J., RICH C.B., FLORINI J.R., INSULIN-LIKE GROWTH FACTOR I, SOMATOMEDIN C, INDUCES THE SYNTHESIS OF TROPOELASTIN IN AORTIC TISSUE, COLL RELAT RES, 7, PP. 161-169, (1987); BADESCH D.B., LEE P.D., PARKS W.C., STENMARK K.R., INSULIN-LIKE GROWTH FACTOR I STIMULATES ELASTIN SYNTHESIS BY BOVINE PULMONARY ARTERIAL SMOOTH MUSCLE CELLS, BIOCHEM BIOPHYS RES COMMUN, 160, PP. 382-387, (1989); WOLFE B.L., RICH C.B., GOUD H.D., ET AL., INSULIN-LIKE GROWTH FACTOR-I REGULATES TRANSCRIPTION OF THE ELASTIN GENE, J BIOL CHEM, 268, PP. 12418-12426, (1993); CONN K.J., RICH C.B., JENSEN D.E., ET AL., INSULIN-LIKE GROWTH FACTOR-I REGULATES TRANSCRIPTION OF THE ELASTIN GENE THROUGH A PUTATIVE RETINOBLASTOMA CONTROL ELEMENT. A ROLE FOR SP3 ACTING AS A REPRESSOR OF ELASTIN GENE TRANSCRIPTION, J BIOL CHEM, 271, PP. 28853-28860, (1996); BAI H., POLLMAN M.J., INISHI Y., GIBBONS G.H., REGULATION OF VASCULAR SMOOTH MUSCLE CELL APOPTOSIS. MODULATION OF BAD BY A PHOSPHATIDYLINOSITOL 3-KINASE-DEPENDENT PATHWAY, CIRC RES, 85, PP. 229-237, (1999); SCHEIDEGGER K.J., JAMES R.W., DELAFONTAINE P., DIFFERENTIAL EFFECTS OF LOW DENSITY LIPOPROTEINS ON INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) AND IGF-1 RECEPTOR EXPRESSION IN VASCULAR SMOOTH MUSCLE CELLS, J BIOL CHEM, 275, PP. 26864-26869, (2000); PATEL V.A., ZHANG Q.J., SIDDLE K., ET AL., DEFECT IN INSULIN-LIKE GROWTH FACTOR-1 SURVIVAL MECHANISM IN ATHEROSCLEROTIC PLAQUE-DERIVED VASCULAR SMOOTH MUSCLE CELLS IS MEDIATED BY REDUCED SURFACE BINDING AND SIGNALING, CIRC RES, 88, PP. 895-902, (2001); BARKER D.J., OSMOND C., GOLDING J., HEIGHT AND MORTALITY IN THE COUNTIES OF ENGLAND AND WALES, ANN HUM BIOL, 17, PP. 1-6, (1990); NJOLSTAD I., ARNESEN E., LUND-LARSEN P.G., BODY HEIGHT, CARDIOVASCULAR RISK FACTORS, AND RISK OF STROKE IN MIDDLE-AGED MEN AND WOMEN. A 14-YEAR FOLLOW-UP OF THE FINNMARK STUDY, CIRCULATION, 94, PP. 2877-2882, (1996); WANNAMETHEE S.G., SHAPER A.G., WHINCUP P.H., WALKER M., ADULT HEIGHT, STROKE, AND CORONARY HEART DISEASE, AM J EPIDEMIOL, 148, PP. 1069-1076, (1998); PARKER D.R., LAPANE K.L., LASATER T.M., CARLETON R.A., SHORT STATURE AND CARDIOVASCULAR DISEASE AMONG MEN AND WOMEN FROM TWO SOUTHEASTERN NEW ENGLAND COMMUNITIES, INT J EPIDEMIOL, 27, PP. 970-975, (1998); HART C.L., HOLE D.J., SMITH G.D., RISK FACTORS AND 20-YEAR STROKE MORTALITY IN MEN AND WOMEN IN THE RENFREW/PAISLEY STUDY IN SCOTLAND, STROKE, 30, PP. 1999-2007, (1999); DAVEY S.G., HART C., UPTON M., ET AL., HEIGHT AND RISK OF DEATH AMONG MEN AND WOMEN: AETIOLOGICAL IMPLICATIONS OF ASSOCIATIONS WITH CARDIORESPIRATORY DISEASE AND CANCER MORTALITY, J EPIDEMIOL COMMUNITY HEALTH, 54, PP. 97-103, (2000); MCCARRON P., GREENWOOD R., EBRAHIM S., ELWOOD P., SMITH G.D., ADULT HEIGHT IS INVERSELY ASSOCIATED WITH ISCHAEMIC STROKE. THE CAERPHILLY AND SPEEDWELL COLLABORATIVE STUDIES, J EPIDEMIOL COMMUNITY HEALTH, 54, PP. 239-240, (2000); HART C.L., HOLE D.J., SMITH G.D., COMPARISON OF RISK FACTORS FOR STROKE INCIDENCE AND STROKE MORTALITY IN 20 YEARS OF FOLLOW-UP IN MEN AND WOMEN IN THE RENFREW/PAISLEY STUDY IN SCOTLAND, STROKE, 31, PP. 1893-1896, (2000); MCCARRON P., HART C.L., HOLE D., SMITH G.D., THE RELATION BETWEEN ADULT HEIGHT AND HAEMORRHAGIC AND ISCHAEMIC STROKE IN THE RENFREW/PAISLEY STUDY, J EPIDEMIOL COMMUNITY HEALTH, 55, PP. 404-405, (2001); REED D.M., RESCH J.A., HAYASHI T., MACLEAN C., YANO K., A PROSPECTIVE STUDY OF CEREBRAL ARTERY ATHEROSCLEROSIS, STROKE, 19, PP. 820-825, (1988); ALBANES D., JONES D.Y., SCHATZKIN A., MICOZZI M.S., TAYLOR P.R., ADULT STATURE AND RISK OF CANCER, CANCER RES, 48, PP. 1658-1662, (1988); ALBANES D., HEIGHT, EARLY ENERGY INTAKE, AND CANCER. EVIDENCE MOUNTS FOR THE RELATION OF ENERGY INTAKE TO ADULT MALIGNANCIES, BMJ, 317, PP. 1331-1332, (1998); ZIEGLER R.G., ANTHROPOMETRY AND BREAST CANCER, J NUTR, 127, (1997); SAMARAS T.T., ELRICK H., HEIGHT, BODY SIZE AND LONGEVITY, ACTA MED OKAYAMA, 53, PP. 149-169, (1999); GUNNELL D., HEIGHT, INSULIN-LIKE GROWTH FACTORS AND CANCER RISK, GROWTH HORM IGF RES, 10, SUPPL. A, (2000); FRIEDENREICH C.M., REVIEW OF ANTHROPOMETRIC FACTORS AND BREAST CANCER RISK, EUR J CANCER PREV, 10, PP. 15-32, (2001); ROSEN T., BENGTSSON B.A., PREMATURE MORTALITY DUE TO CARDIOVASCULAR DISEASE IN HYPOPITUITARISM, LANCET, 336, PP. 285-288, (1990); BULOW B., HAGMAR L., MIKOCZY Z., NORDSTROM C.H., ERFURTH E.M., INCREASED CEREBROVASCULAR MORTALITY IN PATIENTS WITH HYPOPITUITARISM, CLIN ENDOCRINOL (OXF), 46, PP. 75-81, (1997); ROSEN T., WILHELMSEN L., BENGTSSON B.A., ALTERED LIPID PATTERN EXPLAINS INCREASED CARDIOVASCULAR MORTALITY IN HYPOPITUITARY PATIENTS WITH GROWTH HORMONE DEFICIENCY, CLIN ENDOCRINOL (OXF), 48, PP. 525-526, (1998); KULLER L., REISLER D.M., AN EXPLANATION FOR VARIATIONS IN DISTRIBUTION OF STROKE AND ARTERIOSCLEROTIC HEART DISEASE AMONG POPULATIONS AND RACIAL GROUPS, AM J EPIDEMIOL, 93, PP. 1-9, (1971); REED D.M., THE PARADOX OF HIGH RISK OF STROKE IN POPULATIONS WITH LOW RISK OF CORONARY HEART DISEASE, AM J EPIDEMIOL, 131, PP. 579-588, (1990); VARTIAINEN E., DU D.J., MARKS J.S., ET AL., MORTALITY, CARDIOVASCULAR RISK FACTORS, AND DIET IN CHINA, FINLAND, AND THE UNITED STATES, PUBLIC HEALTH REP, 106, PP. 41-46, (1991); REED D., JACOBS D.R.J., HAYASHI T., ET AL., A COMPARISON OF LESIONS IN SMALL INTRACEREBRAL ARTERIES AMONG JAPANESE MEN IN HAWAII AND JAPAN, STROKE, 25, PP. 60-65, (1994); HE J., KLAG M.J., WU Z., WHELTON P.K., STROKE IN THE PEOPLE'S REPUBLIC OF CHINA. II. META-ANALYSIS OF HYPERTENSION AND RISK OF STROKE, STROKE, 26, PP. 2228-2232, (1995); STOLL B.A., WESTERN DIET, EARLY PUBERTY, AND BREAST CANCER RISK, BREAST CANCER RES TREAT, 49, PP. 187-193, (1998); MCCARTY M.F., VEGAN PROTEINS MAY REDUCE RISK OF CANCER, OBESITY, AND CARDIOVASCULAR DISEASE BY PROMOTING INCREASED GLUCAGON ACTIVITY, MED HYPOTHESES, 53, PP. 459-485, (1999); KAGAN A., POPPER J.S., RHOADS G.G., YANO K., DIETARY AND OTHER RISK FACTORS FOR STROKE IN HAWAIIAN JAPANESE MEN, STROKE, 16, PP. 390-396, (1985); OMURA T., HISAMATSU S., TAKIZAWA Y., MINOWA M., YANAGAWA H., SHIGEMATSU I., GEOGRAPHICAL DISTRIBUTION OF CEREBROVASCULAR DISEASE MORTALITY AND FOOD INTAKES IN JAPAN, SOC SCI MED, 24, PP. 401-407, (1987); REED D.M., RESCH J.A., HAYASHI T., MACLEAN C., YANO K., A PROSPECTIVE STUDY OF CEREBRAL ARTERY ATHEROSCLEROSIS, STROKE, 19, PP. 820-825, (1988); SHIMAMOTO T., KOMACHI Y., INADA H., ET AL., TRENDS FOR CORONARY HEART DISEASE AND STROKE AND THEIR RISK FACTORS IN JAPAN, CIRCULATION, 79, PP. 503-515, (1989); KLAG M.J., WHELTON P.K., THE DECLINE IN STROKE MORTALITY. AN EPIDEMIOLOGIC PERSPECTIVE, ANN EPIDEMIOL, 3, PP. 571-575, (1993); SEINO F., DATE C., NAKAYAMA T., ET AL., DIETARY LIPIDS AND INCIDENCE OF CEREBRAL INFARCTION IN A JAPANESE RURAL COMMUNITY, J NUTR SCI VITAMINOL (TOKYO), 43, PP. 83-99, (1997); SCHWAB S., SPRANGER M., KREMPIEN S., HACKE W., BETTENDORF M., PLASMA INSULIN-LIKE GROWTH FACTOR I AND IGF BINDING PROTEIN 3 LEVELS IN PATIENTS WITH ACUTE CEREBRAL ISCHEMIC INJURY, STROKE, 28, PP. 1744-1748, (1997); BARNARD R.J., EFFECTS OF LIFE-STYLE MODIFICATION ON SERUM LIPIDS, ARCH INTERN MED, 151, PP. 1389-1394, (1991); BARNARD R.J., JUNG T., INKELES S.B., DIET AND EXERCISE IN THE TREATMENT OF N1DDM. THE NEED FOR EARLY EMPHASIS, DIABETES CARE, 17, PP. 1469-1472, (1994); BARNARD R.J., UGIANSKIS E.J., MARTIN D.A., INKELES S.B., ROLE OF DIET AND EXERCISE IN THE MANAGEMENT OF HYPERINSULINEMIA AND ASSOCIATED ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 69, PP. 440-444, (1992); ORNISH D., BROWN S.E., SCHERWITZ L.W., ET AL., CAN LIFESTYLE CHANGES REVERSE CORONARY HEART DISEASE? THE LIFESTYLE HEART TRIAL, LANCET, 336, PP. 129-133, (1990); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, PP. 2001-2007, (1998); ORNISH D., EAT MORE, WEIGH LESS: DR. DEAN ORNISH'S LIFE CHOICE PROGRAM FOR LOSING WEIGHT SAFELY WHILE EATING ABUNDANTLY, (1997); NICHOLSON A.S., SKLAR M., BARNARD N.D., GORE S., SULLIVAN R., BROWNING S., TOWARD IMPROVED MANAGEMENT OF N1DDM: A RANDOMIZED, CONTROLLED, PILOT INTERVENTION USING A LOWFAT, VEGETARIAN DIET, PREV MED, 29, PP. 87-91, (1999); BARNARD N., FOOD FOR LIFE - HOW THE NEW FOUR FOOD GROUPS CAN SAVE YOUR LIFE?, (1993); MCDOUGALL J., LITZAU K., HAVER E., SAUNDERS V., SPILLER G.A., RAPID REDUCTION OF SERUM CHOLESTEROL AND BLOOD PRESSURE BY A TWELVE-DAY, VERY LOW FAT, STRICTLY VEGETARIAN DIET, J AM COLL NUTR, 14, PP. 491-496, (1995); MCCARTY M.F., THE ORIGINS OF WESTERN OBESITY: A ROLE FOR ANIMAL PROTEIN?, MED HYPOTHESES, 54, PP. 488-494, (2000); TROWELL H.C., NON-INFECTIOUS DISEASE IN AFRICA, (1960); BURKITT D.P., TROWELL H.C., REFINED CARBOHYDRATE FOODS AND DISEASE, (1975); TROWELL H.C., BURKITT D.P., WESTERN DISEASES: THEIR EMERGENCE AND PREVENTION, (1981); CAMPBELL T.C., JUNSHI C., DIET AND CHRONIC DEGENERATIVE DISEASES: PERSPECTIVES FROM CHINA, AM J CLIN NUTR, 59, (1994); CAMPBELL T.C., PARPIA B., CHEN J., DIET, LIFESTYLE, AND THE ETIOLOGY OF CORONARY ARTERY DISEASE: THE CORNELL CHINA STUDY, AM J CARDIOL, 82, (1998); CAMPBELL T.C., CHEN J., ENERGY BALANCE: INTERPRETATION OF DATA FROM RURAL CHINA, TOXICOL SCI, 52, PP. 87-94, (1999); ARMSTRONG B., DOLL R., ENVIRONMENTAL FACTORS AND CANCER INCIDENCE AND MORTALITY IN DIFFERENT COUNTRIES, WITH SPECIAL REFERENCE TO DIETARY PRACTICES, INT J CANCER, 15, PP. 617-631, (1975); GRAY G.E., PIKE M.C., HENDERSON B.E., BREAST-CANCER INCIDENCE AND MORTALITY RATES IN DIFFERENT COUNTRIES IN RELATION TO KNOWN RISK FACTORS AND DIETARY PRACTICES, BR J CANCER, 39, PP. 1-7, (1979); ROSE D.P., BOYAR A.P., WYNDER E.L., INTERNATIONAL COMPARISONS OF MORTALITY RATES FOR CANCER OF THE BREAST, OVARY, PROSTATE, AND COLON, AND PER CAPITA FOOD CONSUMPTION, CANCER, 58, PP. 2363-2371, (1986); KESTELOOT H., LESAFFRE E., JOOSSENS J.V., DAIRY FAT, SATURATED ANIMAL FAT, AND CANCER RISK, PREV MED, 20, PP. 226-236, (1991); GUO W.D., CHOW W.H., ZHENG W., LI J.Y., BLOT W.J., DIET, SERUM MARKERS AND BREAST CANCER MORTALITY IN CHINA, JPN J CANCER RES, 85, PP. 572-577, (1994); HEBERT J.R., ROSEN A., NUTRITIONAL, SOCIOECONOMIC, AND REPRODUCTIVE FACTORS IN RELATION TO FEMALE BREAST CANCER MORTALITY: FINDINGS FROM A CROSS-NATIONAL STUDY, CANCER DETECT PREV, 20, PP. 234-244, (1996); KOO L.C., MANG O.W., HO J.H., AN ECOLOGICAL STUDY OF TRENDS IN CANCER INCIDENCE AND DIETARY CHANGES IN HONG KONG, NUTR CANCER, 28, PP. 289-301, (1997); TROWELL H.C., BURKITT D.P., TREATMENT AND PREVENTION: A NOTE ON AUTOIMMUNE DISEASE IN SUB-SAHARAL AFRICANS, WESTERN DISEASES: THEIR EMERGENCE AND PREVENTION, PP. 436-443, (1981); MCCARTY M.F., UP-REGULATION OF LYMPHOCYTE APOPTOSIS AS A STRATEGY FOR PREVENTING AND TREATING AUTOIMMUNE DISORDERS: A ROLE FOR WHOLE-FOOD VEGAN DIETS, FISH OIL, AND DOPAMINE AGONISTS, MED HYPOTHESES, 57, PP. 258-275, (2001); KJELDSEN-KRAGH J., HAUGEN M., BORCHGREVINK C.F., ET AL., CONTROLLED TRIAL OF FASTING AND ONE-YEAR VEGETARIAN DIET IN RHEUMATOID ARTHRITIS, LANCET, 338, PP. 899-902, (1991); KJELDSEN-KRAGH J., RHEUMATOID ARTHRITIS TREATED WITH VEGETARIAN DIETS, AM J CLIN NUTR, 70, (1999); MCCARTY M.F., MORTALITY FROM WESTERN CANCERS ROSE DRAMATICALLY AMONG AFRICAN-AMERICANS DURING THE 20TH CENTURY: ARE DIETARY ANIMAL PRODUCTS TO BLAME?, MED HYPOTHESES, 57, PP. 169-174, (2001); SACKS F.M., ROSNER B., KASS E.H., BLOOD PRESSURE IN VEGETARIANS, AM J EPIDEMIOL, 100, PP. 390-398, (1974); BEILIN L.J., ROUSE I.L., ARMSTRONG B.K., MARGETTS B.M., VANDONGEN R., VEGETARIAN DIET AND BLOOD PRESSURE LEVELS: INCIDENTAL OR CAUSAL ASSOCIATION?, AM J CLIN NUTR, 48, PP. 806-810, (1988); ISO H., JACOBS D.R.J., WENTWORTH D., NEATON J.D., COHEN J.D., SERUM CHOLESTEROL LEVELS AND SIX-YEAR MORTALITY FROM STROKE IN 350,977 MEN SCREENED FOR THE MULTIPLE RISK FACTOR INTERVENTION TRIAL, N ENGL J MED, 320, PP. 904-910, (1989); YANO K., REED D.M., MACLEAN C.J., SERUM CHOLESTEROL AND HEMORRHAGIC STROKE IN THE HONOLULU HEART PROGRAM, STROKE, 20, PP. 1460-1465, (1989); JACOBS D.R., THE RELATIONSHIP BETWEEN CHOLESTEROL AND STROKE, HEALTH REP, 6, PP. 87-93, (1994); IRIBARREN C., JACOBS D.R., SADLER M., CLAXTON A.J., SIDNEY S., LOW TOTAL SERUM CHOLESTEROL AND INTRACEREBRAL HEMORRHAGIC STROKE: IS THE ASSOCIATION CONFINED TO ELDERLY MEN?, STROKE, 27, PP. 1993-1998, (1996); OKUMURA K., ISEKI K., WAKUGAMI K., ET AL., LOW SERUM CHOLESTEROL AS A RISK FACTOR FOR HEMORRHAGIC STROKE IN MEN: A COMMUNITY-BASED MASS SCREENING IN OKINAWA, JAPAN, JPN CIRC J, 63, PP. 53-58, (1999); MCGEE D., REED D., STEMMERMAN G., RHOADS G., YANO K., FEINLEIB M., THE RELATIONSHIP OF DIETARY FAT AND CHOLESTEROL TO MORTALITY IN 10 YEARS: THE HONOLULU HEART PROGRAM, INT J EPIDEMIOL, 14, PP. 97-105, (1985); GILLMAN M.W., CUPPLES L.A., MILLEN B.E., ELLISON R.C., WOLF P.A., INVERSE ASSOCIATION OF DIETARY FAT WITH DEVELOPMENT OF ISCHEMIC STROKE IN MEN, JAMA, 278, PP. 2145-2150, (1997); ISO H., STAMPFER M.J., MANSON J.E., ET AL., PROSPECTIVE STUDY OF FAT AND PROTEIN INTAKE AND RISK OF INTRAPARENCHYMAL HEMORRHAGE IN WOMEN, CIRCULATION, 103, PP. 856-863, (2001); MENEELY G.R., BATTARBEE H.D., HIGH SODIUM-LOW POTASSIUM ENVIRONMENT AND HYPERTENSION, AM J CARDIOL, 38, PP. 768-785, (1976); TROWELL H.C., HYPERTENSION, OBESITY, DIABETES MELLITUS AND CORONARY HEART DISEASE, WESTERN DISEASES: THEIR EMERGENCE AND PREVENTION, PP. 3-32, (1981); MACGREGOR G.A., DE WARDENER H.E., SALT, DIET AND HEALTH: NEPTUNE'S POISONED CHALICE: THE ORIGINS OF HIGH BLOOD PRESSURE, (1998); LINDEBERG S., APPARENT ABSENCE OF CEREBROVASCULAR DISEASE IN MELANESIANS, (1994); MOORE R.D., THE HIGH BLOOD PRESSURE SOLUTION, (2001); DENTON D., WEISINGER R., MUNDY N.I., ET AL., THE EFFECT OF INCREASED SALT INTAKE ON BLOOD PRESSURE OF CHIMPANZEES, NAT MED, 1, PP. 1009-1016, (1995); PERRY I.J., BEEVERS D.G., SALT INTAKE AND STROKE: A POSSIBLE DIRECT EFFECT, J HUM HYPERTENS, 6, PP. 23-25, (1992); YUAN C., MANUNTA P., CHEN S., HAMLYN J.M., HADDY F.J., PAMNANI M.B., ROLE OF OUABAIN-LIKE FACTORS IN HYPERTENSION: EFFECTS OF OUABAIN AND CERTAIN ENDOGENOUS OUABAIN-LIKE FACTORS IN HYPERTENSION, J CARDIOVASC PHARMACOL, 22, 2 SUPPL., (1993); MCCARTY M.F., ENDOTHELIAL MEMBRANE POTENTIAL REGULATES PRODUCTION OF BOTH NITRIC OXIDE AND SUPEROXIDE - A FUNDAMENTAL DETERMINANT OF VASCULAR HEALTH, MED HYPOTHESES, 53, PP. 277-289, (1999); LINDEBERG S., LUNDH B., APPARENT ABSENCE OF STROKE AND ISCHAEMIC HEART DISEASE IN A TRADITIONAL MELANESIAN ISLAND: A CLINICAL STUDY IN KITAVA, J INTERN MED, 233, PP. 269-275, (1993); CAPPUCCIO F.P., MACGREGOR G.A., DOES POTASSIUM SUPPLEMENTATION LOWER BLOOD PRESSURE? A META-ANALYSIS OF PUBLISHED TRIALS, J HYPERTENS, 9, PP. 465-473, (1991); WHELTON P.K., HE J., CUTLER J.A., ET AL., EFFECTS OF ORAL POTASSIUM ON BLOOD PRESSURE. META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS, JAMA, 277, PP. 1624-1632, (1997); KHAW K.T., BARRETT-CONNOR E., DIETARY POTASSIUM AND STROKE-ASSOCIATED MORTALITY. A 12-YEAR PROSPECTIVE POPULATION STUDY, N ENGL J MED, 316, PP. 235-240, (1987); ASCHERIO A., RIMM E.B., HERNAN M.A., ET AL., INTAKE OF POTASSIUM, MAGNESIUM, CALCIUM, AND FIBER AND RISK OF STROKE AMONG US MEN, CIRCULATION, 98, PP. 1198-1204, (1998); ISO H., STAMPFER M.J., MANSON J.E., ET AL., PROSPECTIVE STUDY OF CALCIUM, POTASSIUM, AND MAGNESIUM INTAKE AND RISK OF STROKE IN WOMEN, STROKE, 30, PP. 1772-1779, (1999); BAZZANO L.A., HE J., OGDEN L.G., ET AL., DIETARY POTASSIUM RETAKE AND RISK OF STROKE IN US MEN AND WOMEN: NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY I EPIDEMIOLOGIC FOLLOW-UP STUDY, STROKE, 32, PP. 1473-1480, (2001); MCCABE R.D., BAKARICH M.A., SRIVASTAVA K., YOUNG D.B., POTASSIUM INHIBITS FREE RADICAL FORMATION, HYPERTENSION, 24, PP. 77-82, (1994); YOUNG D.B., LIN H., MCCABE R.D., POTASSIUM'S CARDIOVASCULAR PROTECTIVE MECHANISMS, AM J PHYSIOL, 268, (1995); YANG B.C., LI D.Y., WENG Y.F., LYNCH J., WINGO C.S., MEHTA J.L., INCREASED SUPEROXIDE ANION GENERATION AND ALTERED VASOREACTIVITY IN RABBITS ON LOW-POTASSIUM DIET, AM J PHYSIOL, 274, (1998); CHEN J., GAO J., THE CHINESE TOTAL DIET STUDY IN 1990. PART II. NUTRIENTS, J AOAC INT, 76, PP. 1206-1213, (1993); GU D., HE J., WU X., DUAN X., WHELTON P.K., EFFECT OF POTASSIUM SUPPLEMENTATION ON BLOOD PRESSURE IN CHINESE: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL, J HYPERTENS, 19, PP. 1325-1331, (2001); HU G., TIAN H., A COMPARISON OF DIETARY AND NON-DIETARY FACTORS OF HYPERTENSION AND NORMAL BLOOD PRESSURE IN A CHINESE POPULATION, J HUM HYPERTENS, 15, PP. 487-493, (2001); TUCKER K.L., HANNAN M.T., CHEN H., CUPPLES L.A., WILSON P.W., KIEL D.P., POTASSIUM, MAGNESIUM, AND FRUIT AND VEGETABLE INTAKES ARE ASSOCIATED WITH GREATER BONE MINERAL DENSITY IN ELDERLY MEN AND WOMEN, AM J CLIN NUTR, 69, PP. 727-736, (1999); WACHMAN A., BERNSTEIN D.S., DIET AND OSTEOPOROSIS, LANCET, 1, PP. 958-959, (1968); LIU S., MANSON J.E., STAMPFER M.J., ET AL., WHOLE GRAIN CONSUMPTION AND RISK OF ISCHEMIC STROKE IN WOMEN: A PROSPECTIVE STUDY, JAMA, 284, PP. 1534-1540, (2000); HERMAN B., LEYTEN A.C., VAN LUIJK J.H., FRENKEN C.W., OP D.C.A., SCHULTE B.P., AN EVALUATION OF RISK FACTORS FOR STROKE IN A DUTCH COMMUNITY, STROKE, 13, PP. 334-339, (1982); SACCO R.L., GAN R., BODEN-ALBALA B., ET AL., LEISURE-TIME PHYSICAL ACTIVITY AND ISCHEMIC STROKE RISK: THE NORTHERN MANHATTAN STROKE STUDY, STROKE, 29, PP. 380-387, (1998); LEE I.M., HENNEKENS C.H., BERGER K., BURING J.E., MANSON J.E., EXERCISE AND RISK OF STROKE IN MALE PHYSICIANS, STROKE, 30, PP. 1-6, (1999); AGNARSSON U., THORGEIRSSON G., SIGVALDASON H., SIGFUSSON N., EFFECTS OF LEISURE-TIME PHYSICAL ACTIVITY AND VENTILATORY FUNCTION ON RISK FOR STROKE IN MEN: THE REYKJAVIK STUDY, ANN INTERN MED, 130, PP. 987-990, (1999); SESSA W.C., PRITCHARD K., SEYEDI N., WANG J., HINTZE T.H., CHRONIC EXERCISE IN DOGS INCREASES CORONARY VASCULAR NITRIC OXIDE PRODUCTION AND ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE GENE EXPRESSION, CIRC RES, 74, PP. 349-353, (1994); BOWLES D.K., WOODMAN C.R., LAUGHLIN M.H., CORONARY SMOOTH MUSCLE AND ENDOTHELIAL ADAPTATIONS TO EXERCISE TRAINING, EXERC SPORT SCI REV, 28, PP. 57-62, (2000); LAUGHLIN M.H., POLLOCK J.S., AMANN J.F., HOLLIS M.L., WOODMAN C.R., PRICE E.M., TRAINING INDUCES NONUNIFORM INCREASES IN ENOS CONTENT ALONG THE CORONARY ARTERIAL TREE, J APPL PHYSIOL, 90, PP. 501-510, (2001); JENSEN-URSTAD K., BOUVIER F., JENSEN-URSTAD M., PRESERVED VASCULAR REACTIVITY IN ELDERLY MALE ATHLETES, SCAND J MED SCI SPORTS, 9, PP. 88-91, (1999); CLARKSON P., MONTGOMERY H.E., MULLEN M.J., ET AL., EXERCISE TRAINING ENHANCES ENDOTHELIAL FUNCTION IN YOUNG MEN, J AM COLL CARDIOL, 33, PP. 1379-1385, (1999); HAMBRECHT R., FIEHN E., WEIGL C., ET AL., REGULAR PHYSICAL EXERCISE CORRECTS ENDOTHELIAL DYSFUNCTION AND IMPROVES EXERCISE CAPACITY IN PATIENTS WITH CHRONIC HEART FAILURE, CIRCULATION, 98, PP. 2709-2715, (1998); KATZ S.D., YUEN J., BIJOU R., LEJEMTEL T.H., TRAINING IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION IN RESISTANCE VESSELS OF PATIENTS WITH HEART FAILURE, J APPL PHYSIOL, 82, PP. 1488-1492, (1997); HIGASHI Y., SASAKI S., SASAKI N., ET AL., DAILY AEROBIC EXERCISE IMPROVES REACTIVE HYPEREMIA IN PATIENTS WITH ESSENTIAL HYPERTENSION, HYPERTENSION, 33, PP. 591-597, (1999); LEWIS T.V., DART A.M., CHIN-DUSTING J.P., KINGWELL B.A., EXERCISE TRAINING INCREASES BASAL NITRIC OXIDE PRODUCTION FROM THE FOREARM IN HYPERCHOLESTEROLEMIC PATIENTS, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 2782-2787, (1999); SACCO R.L., ELKIND M., BODEN-ALBALA B., ET AL., THE PROTECTIVE EFFECT OF MODERATE ALCOHOL CONSUMPTION ON ISCHEMIC STROKE, JAMA, 281, PP. 53-60, (1999); YAMORI Y., HORIE R., TANASE H., FUJIWARA K., NARA Y., LOVENBERG W., POSSIBLE ROLE OF NUTRITIONAL FACTORS IN THE INCIDENCE OF CEREBRAL LESIONS IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS, HYPERTENSION, 6, PP. 49-53, (1984); BERGER K., AJANI U.A., KASE C.S., ET AL., LIGHT-TO-MODERATE ALCOHOL CONSUMPTION AND RISK OF STROKE AMONG US MALE PHYSICIANS, N ENGL J MED, 341, PP. 1557-1564, (1999); SUTER P.M., VETTER W., ALCOHOL AND ISCHEMIC STROKE, NUTR REV, 57, PP. 310-314, (1999); MALARCHER A.M., GILES W.H., CROFT J.B., ET AL., ALCOHOL INTAKE, TYPE OF BEVERAGE, AND THE RISK OF CEREBRAL INFARCTION IN YOUNG WOMEN, STROKE, 32, PP. 77-83, (2001); AIKENS M.L., BENZA R.L., GRENETT H.E., ET AL., ETHANOL INCREASES SURFACE-LOCALIZED FIBRINOLYTIC ACTIVITY IN CULTURED ENDOTHELIAL CELLS, ALCOHOL CLIN EXP RES, 21, PP. 1471-1478, (1997); AIKENS M.L., GRENETT H.E., BENZA R.L., TABENGWA E.M., DAVIS G.C., BOOYSE F.M., ALCOHOL-INDUCED UPREGULATION OF PLASMINOGEN ACTIVATORS AND FIBRINOLYTIC ACTIVITY IN CULTURED HUMAN ENDOTHELIAL CELLS, ALCOHOL CLIN EXP RES, 22, PP. 375-381, (1998); GRENETT H.E., AIKENS M.L., TORRES J.A., ET AL., ETHANOL TRANSCRIPTIONALLY UPREGULATES T-PA AND U-PA GENE EXPRESSION IN CULTURED HUMAN ENDOTHELIAL CELLS, ALCOHOL CLIN EXP RES, 22, PP. 849-853, (1998); GRENETT H.E., AIKENS M.L., TABENGWA E.M., DAVIS G.C., BOOYSE F.M., ETHANOL DOWNREGULATES TRANSCRIPTION OF THE PAI-1 GENE IN CULTURED HUMAN ENDOTHELIAL CELLS, THROMB RES, 97, PP. 247-255, (2000); HILLBOM M., JUVELA S., KARTTUNEN V., MECHANISMS OF ALCOHOL-RELATED STROKES, NOVARTIS FOUND SYMP, 216, PP. 193-204, (1998); KELI S.O., FESKENS E.J., KROMHOUT D., FISH CONSUMPTION AND RISK OF STROKE. THE ZUTPHEN STUDY, STROKE, 25, PP. 328-332, (1994); GILLUM R.F., MUSSOLINO M.E., MADANS J.H., THE RELATIONSHIP BETWEEN FISH CONSUMPTION AND STROKE INCIDENCE. THE NHANES I EPIDEMIOLOGIC FOLLOW-UP STUDY (NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY), ARCH INTERN MED, 156, PP. 537-542, (1996); ISO H., REXRODE K.M., STAMPFER M.J., ET AL., INTAKE OF FISH AND OMEGA-3 FATTY ACIDS AND RISK OF STROKE IN WOMEN, JAMA, 285, PP. 304-312, (2001); ZHANG J., SASAKI S., AMANO K., KESTELOOT H., FISH CONSUMPTION AND MORTALITY FROM ALL CAUSES, ISCHEMIC HEART DISEASE, AND STROKE: AN ECOLOGICAL STUDY, PREV MED, 28, PP. 520-529, (1999); LAWSON D.L., MEHTA J.L., SALDEEN K., MEHTA P., SALDEEN T.G., OMEGA-3 POLYUNSATURATED FATTY ACIDS AUGMENT ENDOTHELIUM-DEPENDENT VASORELAXATION BY ENHANCED RELEASE OF EDRF AND VASODILATOR PROSTAGLANDINS, EICOSANOIDS, 4, PP. 217-223, (1991); MCVEIGH G.E., BRENNAN G.M., JOHNSTON G.D., ET AL., DIETARY FISH OIL AUGMENTS NITRIC OXIDE PRODUCTION OR RELEASE IN PATIENTS WITH TYPE 2 (NON-INSULIN-DEPENDENT) DIABETES MELLITUS, DIABETOLOGIA, 36, PP. 33-38, (1993); FRANCONI F., BENNARDINI F., MATTANA A., ET AL., PLASMA AND PLATELET TAURINE ARE REDUCED IN SUBJECTS WITH INSULIN-DEPENDENT DIABETES MELLITUS: EFFECTS OF TAURINE SUPPLEMENTATION, AM J CLIN NUTR, 61, PP. 1115-1119, (1995); HAYES K.C., PRONCZUK A., ADDESA A.E., STEPHAN Z.F., TAURINE MODULATES PLATELET AGGREGATION IN CATS AND HUMANS, AM J CLIN NUTR, 49, PP. 1211-1216, (1989); APPEL L.J., MILLER E.R., SEIDLER A.J., WHELTON P.K., DOES SUPPLEMENTATION OF DIET WITH 'FISH OIL' REDUCE BLOOD PRESSURE? A META-ANALYSIS OF CONTROLLED CLINICAL TRIALS, ARCH INTERN MED, 153, PP. 1429-1438, (1993); KOHASHI N., OKABAYASHI T., HAMA J., KATORI R., DECREASED URINARY TAURINE IN ESSENTIAL HYPERTENSION, PROG CLIN BIOL RES, 125, PP. 73-87, (1983); FUJITA T., ANDO K., NODA H., ITO Y., SATO Y., EFFECTS OF INCREASED ADRENOMEDULLARY ACTIVITY AND TAURINE IN YOUNG PATIENTS WITH BORDERLINE HYPERTENSION, CIRCULATION, 75, PP. 525-532, (1987); YAMORI Y., NARA Y., IKEDA K., MIZUSHIMA S., IS TAURINE A PREVENTIVE NUTRITIONAL FACTOR OF CARDIOVASCULAR DISEASES OR JUST A BIOLOGICAL MARKER OF NUTRITION?, ADV EXP MED BIOL, 403, PP. 623-629, (1996); RANA S.K., SANDERS T.A., TAURINE CONCENTRATIONS IN THE DIET, PLASMA, URINE AND BREAST MILK OF VEGANS COMPARED WITH OMNIVORES, BR J NUTR, 56, PP. 17-27, (1986); TIJSSEN J.G., LOW-DOSE AND HIGH-DOSE ACETYLSALICYLIC ACID, WITH AND WITHOUT DIPYRIDAMOLE: A REVIEW OF CLINICAL TRIAL RESULTS, NEUROLOGY, 51, (1998); FORBES C.D., SECONDARY STROKE PREVENTION WITH LOW-DOSE ASPIRIN, SUSTAINED RELEASE DIPYRIDAMOLE ALONE AND IN COMBINATION, THROMB RES, 92, (1998); DIENER H.C., RINGLEB P., ANTITHROMBOTIC SECONDARY PREVENTION AFTER STROKE, CURR TREAT OPTIONS CARDIOVASC MED, 4, PP. 429-440, (2002); PLEHN J.F., DAVIS B.R., SACKS F.M., ET AL., REDUCTION OF STROKE INCIDENCE AFTER MYOCARDIAL INFARCTION WITH PRAVASTATIN: THE CHOLESTEROL AND RECURRENT EVENTS (CARE) STUDY, CIRCULATION, 99, PP. 216-223, (1999); DI MASCIO R., MARCHIOLI R., TOGNONI G., CHOLESTEROL REDUCTION AND STROKE OCCURRENCE: AN OVERVIEW OF RANDOMIZED CLINICAL TRIALS, CEREBROVASC DIS, 10, PP. 85-92, (2000); ANSELL B.J., CHOLESTEROL, STROKE RISK, AND STROKE PREVENTION, CURR ATHEROSCLER REP, 2, PP. 92-96, (2000); VAUGHAN C.J., DELANTY N., BASSON C.T., STATIN THERAPY AND STROKE PREVENTION, CURR OPIN CARDIOL, 16, PP. 219-224, (2001); LAUFS U., LIAO J.K., POST-TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA STABILITY BY RHO GTPASE, J BIOL CHEM, 273, PP. 24266-24271, (1998); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS THROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 61-69, (2000); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS F.R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); COOKE J.P., OKA R.K., ATHEROGENESIS AND THE ARGININE HYPOTHESIS, CURR ATHEROSCLER REP, 3, PP. 252-259, (2001); WASCHER T.C., POSCH K., WALLNER S., HERMETTER A., KOSTNER G.M., GRAIER W.F., VASCULAR EFFECTS OF L-ARGININE: ANYTHING BEYOND A SUBSTRATE FOR THE NO-SYNTHASE?, BIOCHEM BIOPHYS RES COMMUN, 234, PP. 35-38, (1997); BOGER R.H., BODE-BOGER S.M., BRANDES R.P., ET AL., DIETARY L-ARGININE REDUCES THE PROGRESSION OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS: COMPARISON WITH LOVASTATIN, CIRCULATION, 96, PP. 1282-1290, (1997); BOGER R.H., BODE-BOGER S.M., THIELE W., CREUTZIG A., ALEXANDER K., FROLICH J.C., RESTORING VASCULAR NITRIC OXIDE FORMATION BY L-ARGININE IMPROVES THE SYMPTOMS OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, J AM COLL CARDIOL, 32, PP. 1336-1344, (1998); MAXWELL A.J., ANDERSON B., ZAPIEN M.P., COOKE J.P., ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLEMIA IS REVERSED BY A NUTRITIONAL PRODUCT DESIGNED TO ENHANCE NITRIC OXIDE ACTIVITY, CARDIOVASC DRUGS THER, 14, PP. 309-316, (2000); MAXWELL A.J., ANDERSON B.E., COOKE J.P., NUTRITIONAL THERAPY FOR PERIPHERAL ARTERIAL DISEASE: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF HEARTBAR, VASC MED, 5, PP. 11-19, (2000); YAMADA M., HUANG Z., DALKARA T., ET AL., ENDOTHELIAL NITRIC OXIDE SYNTHASE-DEPENDENT CEREBRAL BLOOD FLOW AUGMENTATION BY L-ARGININE AFTER CHRONIC STATIN TREATMENT, J CEREB BLOOD FLOW METAB, 20, PP. 709-717, (2000); STIER C.T.J., SIM G.J., LEVINE S., DIETARY ARGININE FAILS TO PROTECT AGAINST CEREBROVASCULAR DAMAGE IN STROKE-PRONE HYPERTENSIVE RATS, BRAIN RES, 549, PP. 354-356, (1991); SATO Y., NAKATSUKA H., WATANABE T., ET AL., POSSIBLE CONTRIBUTION OF GREEN TEA DRINKING HABITS TO THE PREVENTION OF STROKE, TOHOKU J EXP MED, 157, PP. 337-343, (1989); SADAKATA S., FUKAO A., HISAMICHI S., MORTALITY AMONG FEMALE PRACTITIONERS OF CHANOYU (JAPANESE 'TEA-CEREMONY'), TOHOKU J EXP MED, 166, PP. 475-477, (1992); UCHIDA S., OZAKI M., AKASHI T., YAMASHITA K., NIWA M., TANIYAMA K., EFFECTS OF (-)-EPIGALLOCATECHIN-3-O-GALLATE (GREEN TEA TANNIN) ON THE LIFE SPAN OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS, CLIN EXP PHARMACOL PHYSIOL, 22, 1 SUPPL., (1995); RAMASAMY S., DRUMMOND G.R., AHN J., ET AL., MODULATION OF EXPRESSION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY NORDIHYDROGUAIARETIC ACID, A PHENOLIC ANTIOXIDANT IN CULTURED ENDOTHELIAL CELLS, MOL PHARMACOL, 56, PP. 116-123, (1999); PRESTERA T., TALALAY P., ELECTROPHILE AND ANTIOXIDANT REGULATION OF ENZYMES THAT DETOXIFY CARCINOGENS, PROC NATL ACAD SCI USA, 92, PP. 8965-8969, (1995); JOSHIPURA K.J., ASCHERIO A., MANSON J.E., ET AL., FRUIT AND VEGETABLE INTAKE IN RELATION TO RISK OF ISCHEMIC STROKE, JAMA, 282, PP. 1233-1239, (1999); KELI S.O., HERTOG M.G., FESKENS E.J., KROMHOUT D., DIETARY FLAVONOIDS, ANTIOXIDANT VITAMINS, AND INCIDENCE OF STROKE: THE ZUTPHEN STUDY, ARCH INTERN MED, 156, PP. 637-642, (1996); HERTOG M.G., SWEETNAM P.M., FEHILY A.M., ELWOOD P.C., KROMHOUT D., ANTIOXIDANT FLAVONOLS AND ISCHEMIC HEART DISEASE IN A WELSH POPULATION OF MEN: THE CAERPHILLY STUDY, AM J CLIN NUTR, 65, PP. 1489-1494, (1997); YOCHUM L., KUSHI L.H., MEYER K., FOLSOM A.R., DIETARY FLAVONOID INTAKE AND RISK OF CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN, AM J EPIDEMIOL, 149, PP. 943-949, (1999); KNEKT P., ISOTUPA S., RISSANEN H., ET AL., QUERCETIN INTAKE AND THE INCIDENCE OF CEREBROVASCULAR DISEASE, EUR J CLIN NUTR, 54, PP. 415-417, (2000); FOLSOM A.R., RASMUSSEN M.L., CHAMBLESS L.E., ET AL., PROSPECTIVE ASSOCIATIONS OF FASTING INSULIN, BODY FAT DISTRIBUTION, AND DIABETES WITH RISK OF ISCHEMIC STROKE, DIABETES CARE, 22, PP. 1077-1083, (1999); WANNAMETHEE S.G., PERRY I.J., SHAPER A.G., NONFASTING SERUM GLUCOSE AND INSULIN CONCENTRATIONS AND THE RISK OF STROKE, STROKE, 30, PP. 1780-1786, (1999)","","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-0041409578","MED HYPOTHESES",NA,"NOTREPORTED",NA,"MCCARTY MF, 2003, MED HYPOTHESES","MCCARTY MF, 2003, MED HYPOTHESES-a-b"
"STUDER M;BRIEL M;LEIMENSTOLL B;GLASS T;BUCHER H","STUDER, MARCO (7005938662); BRIEL, MATTHIAS (6602288897); LEIMENSTOLL, BERND (11241778000); GLASS, TRACY R. (56982603100); BUCHER, HEINER C. (35309243900)","EFFECT OF DIFFERENT ANTILIPIDEMIC AGENTS AND DIETS ON MORTALITY A SYSTEMATIC REVIEW",2005,"ARCHIVES OF INTERNAL MEDICINE","165","5",312,"10.1001/archinte.165.7.725","BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, BASEL, SWITZERLAND, DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY HOSPITAL BASEL, BASEL, SWITZERLAND;BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, BASEL, SWITZERLAND;DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY HOSPITAL BASEL, BASEL, SWITZERLAND;BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, BASEL, SWITZERLAND;BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, BASEL, SWITZERLAND, BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, KANTONSSPITAL BASEL, CH-4031 BASEL, HEBELSTRASSE 10, SWITZERLAND","BACKGROUND: GUIDELINES FOR THE PREVENTION AND TREATMENT OF HYPERLIPIDEMIA ARE OFTEN BASED ON TRIALS USING COMBINED CLINICAL END POINTS. MORTALITY DATA ARE THE MOST RELIABLE DATA TO ASSESS EFFICACY OF INTERVENTIONS. WE AIMED TO ASSESS EFFICACY AND SAFETY OF DIFFERENT LIPID-LOWERING INTERVENTIONS BASED ON MORTALITY DATA. METHODS: WE CONDUCTED A SYSTEMATIC SEARCH OF RANDOMIZED CONTROLLED TRIALS PUBLISHED UP TO JUNE 2003, COMPARING ANY LIPID-LOWERING INTERVENTION WITH PLACEBO OR USUAL DIET WITH RESPECT TO MORTALITY. OUTCOME MEASURES WERE MORTALITY FROM ALL, CARDIAC, AND NONCARDIOVASCULAR CAUSES. RESULTS: A TOTAL OF 97 STUDIES MET ELIGIBILITY CRITERIA, WITH 137140 INDIVIDUALS IN INTERVENTION AND 138976 INDIVIDUALS IN CONTROL GROUPS. COMPARED WITH CONTROL GROUPS, RISK RATIOS FOR OVERALL MORTALITY WERE 0.87 FOR STATINS (95% CONFIDENCE INTERVAL [CI], 0.81-0.94), 1.00 FOR FIBRATES (95% CI, 0.91-1.11), 0.84 FOR RESINS (95% CI, 0.66-1.08), 0.96 FOR NIACIN (95% CI, 0.86-1.08), 0.77 FOR N-3 FATTY ACIDS (95% CI, 0.63-0.94), AND 0.97 FOR DIET (95% CI, 0.91-1.04). COMPARED WITH CONTROL GROUPS, RISK RATIOS FOR CARDIAC MORTALITY INDICATED BENEFIT FROM STATINS (0.78; 95% CI, 0.72-0.84), RESINS (0.70; 95% CI, 0.50-0.99) AND N-3 FATTY ACIDS (0.68; 95% CI, 0.52-0.90). RISK RATIOS FOR NON-CARDIOVASCULAR MORTALITY OF ANY INTERVENTION INDICATED NO ASSOCIATION WHEN COMPARED WITH CONTROL GROUPS, WITH THE EXCEPTION OF FIBRATES (RISK RATIO, 1.13; 95% CI, 1.01-1.27). CONCLUSIONS: STATINS AND N-3 FATTY ACIDS ARE THE MOST FAVORABLE LIPID-LOWERING INTERVENTIONS WITH REDUCED RISKS OF OVERALL AND CARDIAC MORTALITY. ANY POTENTIAL REDUCTION IN CARDIAC MORTALITY FROM FIBRATES IS OFFSET BY AN INCREASED RISK OF DEATH FROM NONCARDIOVASCULAR CAUSES.","","ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DIET, FAT-RESTRICTED; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; GARLIC EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; POLICOSANOL; PROBUCOL; RESIN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART DEATH; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW","","","RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); BUCHER H.C., GRIFFITH L.E., GUYATT G.H., SYSTEMATIC REVIEW ON THE RISK AND BENEFIT OF DIFFERENT CHOLESTEROL-LOWERING INTERVENTIONS, ARTERIOSCLERTHROMB VASC BIOL, 19, PP. 187-195, (1999); ROSS S.D., ALLEN I.E., CONNELLY J.E., ET AL., CLINICAL OUTCOMES IN STATIN TREATMENT TRIALS: A META-ANALYSIS, ARCH INTERN MED, 159, PP. 1793-1802, (1999); ROSENSON R.S., TANGNEY C.C., ANTIATHEROTHROMBOTIC PROPERTIES OF STATINS: IMPLICATIONS FOR CARDIOVASCULAR EVENT REDUCTION, JAMA, 279, PP. 1643-1650, (1998); POGUE J., YUSUF S., OVERCOMING THE LIMITATIONS OF CURRENT META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, LANCET, 351, PP. 47-52, (1998); SMITH G.D., SONG F., SHELDON T.A., CHOLESTEROL LOWERING AND MORTALITY: THE IMPORTANCE OF CONSIDERING INITIAL LEVEL OF RISK, BMJ, 306, PP. 1367-1373, (1993); ROSSOUW J.E., ANDERSON G.L., PRENTICE R.L., ET AL., RISKS AND BENEFITS OF ESTROGEN PLUS PROGESTIN IN HEALTHY POSTMENOPAUSAL WOMEN: PRINCIPAL RESULTS FROM THE WOMEN'S HEALTH INITIATIVE RANDOMIZED CONTROLLED TRIAL, JAMA, 288, PP. 321-333, (2002); JUNI P., WITSCHI A., BLOCH R., EGGER M., THE HAZARDS OF SCORING THE QUALITY OF CLINICAL TRIALS FOR META-ANALYSIS, JAMA, 282, PP. 1054-1060, (1999); MCALISTER F.A., LAUPACIS A., WELLS G.A., SACKETT D.L., USERS' GUIDES TO THE MEDICAL LITERATURE, XIX: APPLYING CLINICAL TRIAL RESULTS B: GUIDELINES FOR DETERMINING WHETHER A DRUG IS EXERTING (MORE THAN) A CLASS EFFECT, JAMA, 282, PP. 1371-1377, (1999); EGGER M., DAVEY S.G., SCHNEIDER M., MINDER C., BIAS IN META-ANALYSIS DETECTED BY A SIMPLE, GRAPHICAL TEST, BMJ, 315, PP. 629-634, (1997); HIGGINS J.P., THOMPSON S.G., DEEKS J.J., ALTMAN D.G., MEASURING INCONSISTENCY IN META-ANALYSES, BMJ, 327, PP. 557-560, (2003); HIGGINS J.P., THOMPSON S.G., QUANTIFYING HETEROGENEITY IN A META-ANALYSIS, STAT MED, 21, PP. 1539-1558, (2002); FLEISS J.L., THE STATISTICAL BASIS OF META-ANALYSIS, STAT METHODS MED RES, 2, PP. 121-145, (1993); THOMPSON S.G., SHARP S.J., EXPLAINING HETEROGENEITY IN META-ANALYSIS: A COMPARISON OF METHODS, STAT MED, 18, PP. 2693-2708, (1999); MARX A., BUCHER H.C., NUMBERS NEEDED TO TREAT DERIVED FROM META-ANALYSIS: A WORD OF CAUTION, ACP J CLUB, 138, (2003); DIN J.N., NEWBY D.E., FLAPAN A.D., OMEGA 3 FATTY ACIDS AND CARDIOVASCULAR DISEASE - FISHING FORA NATURAL TREATMENT, BMJ, 328, PP. 30-35, (2004); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GRUNDY S.M., CLEEMAN J.I., MERZ C.N., ET AL., IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES, ARTERIOSCLER THROMB VASC BIOL, 24, (2004); BUCHER H.C., HENGSTLER P., SCHINDLER C., MEIER G., N-3 POLYUNSATURATED FATTY ACIDS IN CORONARY HEART DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 112, PP. 298-304, (2002); OXMAN A.D., GUYATT G.H., A CONSUMER'S GUIDE TO SUBGROUP ANALYSES, ANN INTERN MED, 116, PP. 78-84, (1992)","H.C. BUCHER; BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, KANTONSSPITAL BASEL, CH-4031 BASEL, HEBELSTRASSE 10, SWITZERLAND; EMAIL: HBUCHER@UHBS.CH","","ENGLISH","ARCH. INTERN. MED.","REVIEW","ISI","2-S2.0-17644421390","ARCH INTERN MED","UNIVERSITY HOSPITAL BASEL;UNIVERSITY HOSPITAL BASEL;UNIVERSITY HOSPITAL BASEL;UNIVERSITY HOSPITAL BASEL;UNIVERSITY HOSPITAL BASEL","NOTREPORTED;UNIVERSITY HOSPITAL BASEL;NOTREPORTED",NA,"STUDER M, 2005, ARCH INTERN MED","STUDER M, 2005, ARCH INTERN MED"
"TAYLOR J;RAPPORT L;LOCKWOOD G","TAYLOR, JOHANNA C. (8986193100); RAPPORT, LISA (36897838000); LOCKWOOD, G. BRIAN (7102722685)","OCTACOSANOL IN HUMAN HEALTH",2003,"NUTRITION","19","3",129,"10.1016/S0899-9007(02)00869-9","UNIVERSITY OF MANCHESTER, MANCHESTER, UNITED KINGDOM;UNIVERSITY OF MANCHESTER, MANCHESTER, UNITED KINGDOM;UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PL, UNITED KINGDOM","IN SUMMARY, OCTACOSANOL HAS MANY USES FOR TREATING VARIOUS CONDITIONS. THE MOST WIDELY STUDIED OF THESE ARE ITS CHOLESTEROL-LOWERING PROPERTIES, AND MANY STUDIES HAVE SHOWN THAT OCTACOSANOL IS VERY EFFECTIVE IN LOWERING LDL AND INCREASING HDL. IN ADDITION, IT HAS BEEN SHOWN THAT POLICOSANOL IS AS EFFECTIVE AS ASPIRIN IN TERMS OF ITS ANTIAGGREGATORY EFFECTS. PERHAPS OCTACOSANOL COULD BE GIVEN AS A SINGLE SUPPLEMENT TO PATIENTS WITH HIGH LDL CHOLESTEROL AND PERHAPS HYPERTENSION OR HIGH RISK OF CLOT FORMATION. OCTACOSANOL (POLICOSANOL) ALSO OFFERS CYTOPROTECTIVE EFFECTS. THIS AFFORDS AN OPPORTUNITY FOR OCTACOSANOL TO BE TAKEN AS AN ALTERNATIVE TO ASPIRIN IN PATIENTS WHO HAVE A HISTORY OF OR SUFFER FROM GASTRIC IRRITATION. THUS, OCTACOSANOL COULD BE AN IDEAL ALTERNATIVE IN THREE TYPES OF CONDITIONS, WHICH COMMONLY OCCUR SIMULTANEOUSLY. HIGH LDL CHOLSTEROL IN RELATION TO HYPERTENSION, WHERE AN ANTIAGGREGATORY AGENT IS REQUIRED BUT THE PATIENT SUFFERS GASTRIC IRRITATION. BECAUSE ONLY ONE TYPE OF MEDICATION IS NEEDED, PATIENTS WOULD HAVE A HIGH DEGREE OF COMPLIANCE. MORE STUDIES SHOULD INVESTIGATED WHETHER THERE ARE ANY LONG-TERM PROBLEMS WITH OCTACOSANOL. WITH REGARD TO THE USE OF OCTACOSANOL AS A NUTRITIONAL SUPPLEMENT BY ATHLETES, THIS COULD BE ADVANTAGEOUS BECAUSE SOME STUDIES HAVE SUGGESTED THAT OCTACOSANOL CAN IMPROVE STAMINA AND EXERCISE CAPABILITY. HOWEVER, MANY CLAIMS FOR IMPROVING ATHLETIC PERFORMANCE HAVE YET TO BE PROVEN. FEW STUDIES HAVE INVESTIGATED COMBINATIONS OF OCTACOSANOL WITH OTHER TREATMENTS. THERE MAY BE PROBLEMS OR BENEFITS IN TAKING MEDICATION THAT HAS THE SAME INDICATION. IF, FOR EXAMPLE, A STATIN WERE TAKEN WITH OCTACOSANOL, THE COMBINED EFFECTS MIGHT BE EXTREMELY BENEFICIAL BECAUSE LDL CHOLESTEROL LEVELS ALMOST DEFINITELY WOULD BE LOWERED. HOWEVER, PROBLEMS WOULD ARISE IF OCTACOSANOL WERE TO BE TAKEN WITH ANTICOAGULATION THERAPY, SUCH AS WARFARIN OR ASPIRIN, BECAUSE OCTACOSANOL MAY ACT SYNERGISTICALLY AND AN OVERDOSE COULD HAVE DRASTIC CONSEQUENCES. BECAUSE THERE ARE NO DEFINED LIMITS OF OCTACOSANOL DOSING, PATIENTS MAY BE INCLINED TO TAKE MORE TABLETS AND THIS COULD RESULT IN A RISK OF HEMORRHAGE. THERE ALSO MAY BE CONTRAINDICATIONS WITH OTHER THERAPY, SO PATIENTS ON MULTIPLE THERAPY SHOULD TAKE OCTACOSANOL WITH CAUTION. OCTACOSANOL HAS THE POTENTIAL TO TREAT NUMEROUS CONDITIONS WITHOUT MAJOR SIDE EFFECTS AND THUS WOULD BE BENEFICIAL TO MANY PATIENTS. ALSO, THERE ARE OPPORTUNITIES FOR OCTACOSANOL TO BE TAKEN AS A DUAL-ACTION TREATMENT FOR HYPERTENSION AND HIGH CHOLESTEROL, WITH NO GASTRIC IRRITATION OR MUSCLE PROBLEMS. THIS COULD BE AN IMPORTANT DRUG FOR THE FUTURE, WITH THE EVER-INCREASING PROBLEM OF OBESITY AND INCREASED RISK OF ATHEROSCLEROSIS AND CHD THROUGHOUT THE WORLD.","","ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALCOHOL; CARNITINE; CHOLESTEROL; CIMETIDINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; INDOMETACIN; LOW DENSITY LIPOPROTEIN; OCTACOSANOL; POLICOSANOL; PRAVASTATIN; THROMBOXANE A2; ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BLOOD FLOW; BRAIN ISCHEMIA; CELL MEMBRANE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; EXERCISE; FAMILY HISTORY; HEALTH; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER; LIVER CELL; LIVER FUNCTION; NAUSEA; NONHUMAN; NUTRITION; OBESITY; PLASMA; PRIORITY JOURNAL; RASH; RISK FACTOR; SHORT SURVEY; SMOKING; STOMACH PAIN; STRENGTH; THROMBOCYTE AGGREGATION; TRAINING; VISUAL IMPAIRMENT","","","KATO S., KARINO K., HASEGAWA J., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH FAT DIET, BR J NUTR, 73, (1995); SAINT-JOHN M., MCNAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME AND CHEST AND GRIP STRENGTH, INT CLIN NUTR REV, 6, (1986); RANG H.P., DALE M.M., RITTER J.M., PHARMACOLOGY, 4TH ED., (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, (2000); CRAIG C.R., STITZEL R.E., MODERN PHARMACOLOGY, 907, (1994); WALKER R., HYPERLIPIDAEMIA, CLINICAL PHARMACY AND THERAPEUTICS 2ND ED, (1999); SHIMURA S., HASEGAWA T., TAKANO S., ET AL., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTR REP INT, 36, (1987); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, (1994); HERNANDEZ F., ILLAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, (1992); BRITISH NATIONAL FORMULARY, 124, (2001); BELLINGHAM C., CERIVASTATIN WITHDRAWAL: THE IMPACTS, PHARM J, 267, (2001); CASTANO G., MAS R., ARRUZAZABALA M.DE L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 4, (1999); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVEST, 21, (2001); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARM RES, 19, (1999); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, CURR THER RES, 55, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, CURR THER RES, 56, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLAEMIA, CURR THER RES, 56, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA: A 12-MONTH STUDY, CURR THER RES, 56, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, CURR THER RES, 57, (1996); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, (1999); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, (1997); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EF-FECT OF POLICOSANOL ON CEREBRAL ISCHAEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A <SUB>2</SUB> , PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, (1993); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, (1999); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREAGATION IN TYPE II HYPERCHOLESTEROLAEMIC PATIENTS, TISSUE REACT, 20, (1998); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, (1993); DURDEN BELTZ S., DOERING P.L., EFFICACY OF NUTRITIONAL SUPPLEMENTS USED BY ATHLETES, CLIN PHARM, 12, (1993); COCKERILL D.L., BUCCI L.R., INCREASES IN MUSCLE GIRTH AND DECREASES IN BODY FAT ASSOCIATED WITH A NUTRITIONAL SUPPLEMENT PROGRAM, CHIROPRACT SPORTS MED, 1, (1987); CARBAJAL D., MOLINA V., VALDES S., ET AL., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J PHARM PHARMACOL, 47, (1995); CARBAJAL D., MOLINA V., VALDES S., ET AL., POSSIBLE CYTOPROTECTIVE MECHANISM IN RATS OF D-002, AN ANTI-ULCEROGENIC PRODUCT ISOLATED FROM BEESWAX, J PHARM PHARMACOL, 48, (1996)","G.B. LOCKWOOD; SCH. OF PHARM./PHARMACEUTICAL SCI., UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PL, UNITED KINGDOM; EMAIL: BRIAN.LOCKWOOD@MAN.AC.UK","ELSEVIER INC.","ENGLISH","NUTRITION","ARTICLE","ISI","2-S2.0-0037319261","NUTRITION","UNIVERSITY OF MANCHESTER;UNIVERSITY OF MANCHESTER;UNIVERSITY OF MANCHESTER","NOTREPORTED;UNIVERSITY OF MANCHESTER;NOTREPORTED",NA,"TAYLOR JC, 2003, NUTRITION","TAYLOR JC, 2003, NUTRITION"
"","","NEW POLICOSANOL PRODUCT COMBINES NATURAL CHOLESTEROL LOWERING WITH OMEGA3 FATTY ACIDS TO LOWER CV RISK",2006,"CARDIOVASCULAR JOURNAL OF SOUTH AFRICA : OFFICIAL JOURNAL FOR SOUTHERN AFRICA CARDIAC SOCIETY [AND] SOUTH AFRICAN SOCIETY OF CARDIAC PRACTITIONERS","17","",1,"","","[NO ABSTRACT AVAILABLE]","","ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; FATTY ACIDS, OMEGA-3; HUMANS; HYPERCHOLESTEROLEMIA; PHYTOTHERAPY; HYPOCHOLESTEROLEMIC AGENT; OMEGA 3 FATTY ACID; ARTICLE; CEREBROVASCULAR ACCIDENT; HUMAN; HYPERCHOLESTEROLEMIA; PHYTOTHERAPY","","","","","","ENGLISH","CARDIOVASC J S AFR","ARTICLE","ISI","2-S2.0-33750934369","CARDIOVASC J S AFR",NA,"NOTREPORTED",NA,"NA, 2006, CARDIOVASC J S AFR","NA, 2006, CARDIOVASC J S AFR"
"BRIEL M;STUDER M;GLASS T;BUCHER H","BRIEL, MATTHIAS (6602288897); STUDER, MARCO (7005938662); GLASS, TRACY R. (56982603100); BUCHER, HEINER C. (35309243900)","EFFECTS OF STATINS ON STROKE PREVENTION IN PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS",2004,"AMERICAN JOURNAL OF MEDICINE","117","10",124,"10.1016/j.amjmed.2004.04.022","SWITZERLAND;SWITZERLAND;SWITZERLAND;SWITZERLAND, BASEL INST. FOR CLIN. EPIDEMIOLOGY, UNIVERSITY HOSPITAL BASEL, CH - 4031 BASEL, SWITZERLAND, SWITZERLAND","TO ASSESS IF LIPID-LOWERING INTERVENTIONS (STATINS, FIBRATES, RESINS, N-3 FATTY ACIDS, DIET) PREVENT NONFATAL AND FATAL STROKES IN PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE. WE SYSTEMATICALLY SEARCHED THE LITERATURE UP TO AUGUST 2002 TO RETRIEVE ALL RANDOMIZED CONTROLLED TRIALS OF LIPID-LOWERING INTERVENTIONS THAT REPORTED NONFATAL AND FATAL STROKE AND MORTALITY DATA. THE SEARCH YIELDED 65 TRIALS WITH 200,607 PATIENTS FOR A META-ANALYSIS TO DETERMINE WHETHER TREATMENT EFFECTS DIFFERED BETWEEN TYPES OF LIPID-LOWERING INTERVENTIONS AND BETWEEN PATIENT SAMPLES WITH AND WITHOUT CORONARY HEART DISEASE. THE RISK RATIO FOR NONFATAL AND FATAL STROKE FOR STATINS AS COMPARED WITH CONTROL INTERVENTIONS WAS 0.82 (95% CONFIDENCE INTERVAL [CI]: 0.76 TO 0.90). THE CORRESPONDING RISK RATIOS FOR STATINS AS COMPARED WITH CONTROL WERE 0.75 (95% CI: 0.65 TO 0.87) FOR PATIENTS WITH CORONARY HEART DISEASE AND 0.77 (95% CI: 0.62 TO 0.95) FOR THOSE WITHOUT CORONARY HEART DISEASE. THE CONFIDENCE INTERVALS OF RISK RATIOS FOR NONFATAL AND FATAL STROKE ASSOCIATED WITH FIBRATES, RESINS, N-3 FATTY ACIDS, AND DIET ALL INCLUDED 1, AS DID THE CONFIDENCE INTERVALS FOR THESE INTERVENTIONS IN PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE. WEIGHTED META-REGRESSION ANALYSIS SUGGESTED A STRONGER ASSOCIATION OF STROKE REDUCTION WITH STATIN TREATMENT THAN WITH THE EXTENT OF CHOLESTEROL REDUCTION. THIS META-ANALYSIS SUGGESTS THAT STATINS REDUCE THE INCIDENCE OF STROKE IN PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE. © 2004 BY ELSEVIER INC.","","AGED; ANTILIPEMIC AGENTS; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVALS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINOLEIC ACID; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; POLICOSANOL; PRAVASTATIN; PROBUCOL; RESIN; SIMVASTATIN; SOYBEAN OIL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DIETARY INTAKE; DRUG EFFECT; GARLIC; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK; STROKE","","","MURRAY C.J., LOPEZ A.D., MORTALITY BY CAUSE FOR EIGHT REGIONS OF THE WORLD: GLOBAL BURDEN OF DISEASE STUDY, LANCET, 349, PP. 1269-1276, (1997); HELGASON C.M., WOLF P.A., AMERICAN HEART ASSOCIATION PREVENTION CONFERENCE IV: PREVENTION AND REHABILITATION OF STROKE: EXECUTIVE SUMMARY, CIRCULATION, 96, PP. 701-707, (1997); SACCO R.L., BENJAMIN E.J., BRODERICK J.P., ET AL., AMERICAN HEART ASSOCIATION PREVENTION CONFERENCE: IV. PREVENTION AND REHABILITATION OF STROKE. RISK FACTORS, STROKE, 28, PP. 1507-1517, (1997); HACHINSKI V., GRAFFAGNINO C., BEAUDRY M., ET AL., LIPIDS AND STROKE: A PARADOX RESOLVED, ARCH NEUROL, 53, PP. 303-308, (1996); CHOLESTEROL, DIASTOLIC BLOOD PRESSURE, AND STROKE: 13,000 STROKES IN 450,000 PEOPLE IN 45 PROSPECTIVE COHORTS, LANCET, 346, PP. 1647-1653, (1995); BUCHER H.C., GRIFFITH L.E., GUYATT G.H., EFFECT OF HMGCOA REDUCTASE INHIBITORS ON STROKE: A META-ANALYSIS OF RANDOMIZED, CONTROLLED TRIALS, ANN INTERN MED, 128, PP. 89-95, (1998); CORVOL J.C., BOUZAMONDO A., SIROL M., ET AL., DIFFERENTIAL EFFECTS OF LIPID-LOWERING THERAPIES ON STROKE PREVENTION: A META-ANALYSIS OF RANDOMIZED TRIALS, ARCH INTERN MED, 163, PP. 669-676, (2003); BELLOSTA S., FERRI N., BERNINI F., ET AL., NON-LIPID-RELATED EFFECTS OF STATINS, ANN MED, 32, PP. 164-176, (2000); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISED CONTROLLED TRIAL, LANCET, 360, PP. 1623-1630, (2002); MAJOR OUTCOMES IN MODERATELY HYPERCHOLESTEROLEMIC, HYPERTENSIVE PATIENTS RANDOMIZED TO PRAVASTATIN VS USUAL CARE: THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT-LLT), JAMA, 288, PP. 2998-3007, (2002); SEVER P.S., DAHLOF B., POULTER N.R., ET AL., PREVENTION OF CORONARY AND STROKE EVENTS WITH ATORVASTATIN IN HYPERTENSIVE PATIENTS WHO HAVE AVERAGE OR LOWER-THAN-AVERAGE CHOLESTEROL CONCENTRATIONS, IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL-LIPID LOWERING ARM (ASCOT-LLA): A MULTICENTRE RANDOMISED CONTROLLED TRIAL, LANCET, 361, PP. 1149-1158, (2003); ACHESON J., HUTCHINSON E.C., CONTROLLED TRIAL OF CLOFIBRATE IN CEREBRAL VASCULAR DISEASE, ATHEROSCLEROSIS, 15, PP. 177-183, (1972); THE TREATMENT OF CEREBROVASCULAR DISEASE WITH CLOFIBRATE: FINAL REPORT OF THE VETERANS ADMINISTRATION COOPERATIVE STUDY OF ATHEROSCLEROSIS, NEUROLOGY SECTION, STROKE, 4, PP. 684-693, (1973); THE CORONARY DRUG PROJECT: FINDINGS LEADING TO DISCONTINUATION OF THE 2.5-MG DAY ESTROGEN GROUP, JAMA, 226, PP. 652-657, (1973); BUCHWALD H., VARCO R.L., MATTS J.P., ET AL., EFFECT OF PARTIAL ILEAL BYPASS SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA: REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH), N ENGL J MED, 323, PP. 946-955, (1990); THOMPSON S.G., SHARP S.J., EXPLAINING HETEROGENEITY IN META-ANALYSIS: A COMPARISON OF METHODS, STAT MED, 18, PP. 2693-2708, (1999); DERSIMONIAN R., LAIRD N., META-ANALYSIS IN CLINICAL TRIALS, CONTROL CLIN TRIALS, 7, PP. 177-188, (1986); EGGER M., DAVEY S.G., SCHNEIDER M., MINDER C., BIAS IN META-ANALYSIS DETECTED BY A SIMPLE, GRAPHICAL TEST, BMJ, 315, PP. 629-634, (1997); FLEISS J.L., THE STATISTICAL BASIS OF META-ANALYSIS, STAT METHODS MED RES, 2, PP. 121-145, (1993); HIGGINS J.P., THOMPSON S.G., DEEKS J.J., ALTMAN D.G., MEASURING INCONSISTENCY IN META-ANALYSES, BMJ, 327, PP. 557-560, (2003); MCALISTER F.A., LAUPACIS A., WELLS G.A., SACKETT D.L., USERS' GUIDES TO THE MEDICAL LITERATURE: XIX. APPLYING CLINICAL TRIAL RESULTS. B. GUIDELINES FOR DETERMINING WHETHER A DRUG IS EXERTING (MORE THAN) A CLASS EFFECT, JAMA, 282, PP. 1371-1377, (1999); BRADFORD R.H., SHEAR C.L., CHREMOS A.N., ET AL., EXPANDED CLINICAL EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS: I. EFFICACY IN MODIFYING PLASMA LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, ARCH INTERN MED, 151, PP. 43-49, (1991); BLANKENHORN D.H., AZEN S.P., KRAMSCH D.M., ET AL., CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY: THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS). THE MARS RESEARCH GROUP, ANN INTERN MED, 119, PP. 969-976, (1993); WEINTRAUB W.S., BOCCUZZI S.J., KLEIN J.L., ET AL., LACK OF EFFECT OF LOVASTATIN ON RESTENOSIS AFTER CORONARY ANGIOPLASTY: LOVASTATIN RESTENOSIS TRIAL STUDY GROUP, N ENGL J MED, 331, PP. 1331-1337, (1994); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); EFFECT OF SIMVASTATIN ON CORONARY ATHEROMA: THE MULTICENTRE ANTI-ATHEROMA STUDY (MAAS), LANCET, 344, PP. 633-638, (1994); WATERS D., HIGGINSON L., GLADSTONE P., ET AL., EFFECTS OF MONOTHERAPY WITH AN HMG-COA REDUCTASE INHIBITOR ON THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AS ASSESSED BY SERIAL QUANTITATIVE ARTERIOGRAPHY: THE CANADIAN CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL, CIRCULATION, 89, PP. 959-968, (1994); EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL/LITER (200 TO 300 MG/DL) PLUS TWO ADDITIONAL ATHEROSCLEROTIC RISK FACTORS: THE PRAVASTATIN MULTINATIONAL STUDY GROUP FOR CARDIAC RISK PATIENTS, AM J CARDIOL, 72, PP. 1031-1037, (1993); FURBERG C.D., PITT B., BYINGTON R.P., ET AL., REDUCTION IN CORONARY EVENTS DURING TREATMENT WITH PRAVASTATIN: PLAC I AND PLAC II INVESTIGATORS. PRAVASTATIN LIMITATION OF ATHEROSCLEROSIS IN THE CORONARY ARTERIES, AM J CARDIOL, 76, (1995); JUKEMA J.W., BRUSCHKE A.V., VAN BOVEN A.J., ET AL., EFFECTS OF LIPID LOWERING BY PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ARTERY DISEASE IN SYMPTOMATIC MEN WITH NORMAL TO MODERATELY ELEVATED SERUM CHOLESTEROL LEVELS: THE REGRESSION GROWTH EVALUATION STATIN STUDY (REGRESS), CIRCULATION, 91, PP. 2528-2540, (1995); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA: WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, N ENGL J MED, 333, PP. 1301-1307, (1995); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS: CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N ENGL J MED, 335, PP. 1001-1009, (1996); SALONEN R., NYYSSONEN K., PORKKALA E., ET AL., KUOPIO ATHEROSCLEROSIS PREVENTION STUDY (KAPS): A POPULATION-BASED PRIMARY PREVENTIVE TRIAL OF THE EFFECT OF LDL LOWERING ON ATHEROSCLEROTIC PROGRESSION IN CAROTID AND FEMORAL ARTERIES, CIRCULATION, 92, PP. 1758-1764, (1995); ATHYROS V.G., PAPAGEORGIOU A.A., MERCOURIS B.R., ET AL., TREATMENT WITH ATORVASTATIN TO THE NATIONAL CHOLESTEROL EDUCATIONAL PROGRAM GOAL VERSUS 'USUAL' CARE IN SECONDARY CORONARY HEART DISEASE PREVENTION: THE GREEK ATORVASTATIN AND CORONARY-HEART-DISEASE EVALUATION (GREACE) STUDY, CURR MED RES OPIN, 18, PP. 220-228, (2002); SATO S., KOBAYASHI T., AWATA N., ET AL., RANDOMIZED, CONTROLLED TRIAL OF SECONDARY PREVENTION OF CORONARY SCLEROSIS IN NORMOCHOLESTEROLEMIC PATIENTS USING PRAVASTATIN: TWO-YEAR FOLLOW-UP OF THE PREVENTION OF CORONARY SCLEROSIS STUDY, CURR THER RES, 62, PP. 473-485, (2001); BERTRAND M.E., MCFADDEN E.P., FRUCHART J.C., ET AL., PREDICT. EFFECT OF PRAVASTATIN ON ANGIOGRAPHIC RESTENOSIS AFTER CORONARY BALLOON ANGIOPLASTY, J AM COLL CARDIOL, 30, PP. 863-869, (1997); HOLDAAS H., FELLSTROM B., JARDINE A.G., ET AL., ALERT: EFFECT OF FLUVASTATIN ON CARDIAC OUTCOMES IN RENAL TRANSPLANT RECIPIENTS: A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED TRIAL, LANCET, 361, PP. 2024-2031, (2003); SERRUYS P.W., DE FEYTER P., MACAYA C., ET AL., FLUVASTATIN FOR PREVENTION OF CARDIAC EVENTS FOLLOWING SUCCESSFUL FIRST PERCUTANEOUS CORONARY INTERVENTION: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, PP. 3215-3222, (2002); WHITE H.D., SIMES R.J., ANDERSON N.E., ET AL., PRAVASTATIN THERAPY AND THE RISK OF STROKE, N ENGL J MED, 343, PP. 317-326, (2000); TEO K.K., BURTON J.R., BULLER C.E., ET AL., LONG-TERM EFFECTS OF CHOLESTEROL LOWERING AND ANGIOTENSIN-CONVERTING ENZYME INHIBITION ON CORONARY ATHEROSCLEROSIS: THE SIMVASTATIN/ENALAPRIL CORONARY ATHEROSCLEROSIS TRIAL (SCAT), CIRCULATION, 102, PP. 1748-1754, (2000); ZANCHETTI A., CREPALDI G., BOND M.G., ET AL., EFFECTS OF FOSINOPRIL AND PRAVASTATIN ON PROGRESSION OF ASYMPTOMATIC CAROTID ATHEROSCLEROSIS IN HYPERTENSION: RESULTS OF THE PLAQUE HYPERTENSION LIPID LOWERING ITALIAN STUDY (PHYLLIS), J HYPERTENS, 21, (2003); HEDBLAD B., WIKSTRAND J., JANZON L., ET AL., LOW-DOSE METOPROLOL CR/XL AND FLUVASTATIN SLOW PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS: MAIN RESULTS FROM THE BETA-BLOCKER CHOLESTEROL-LOWERING ASYMPTOMATIC PLAQUE STUDY (BCAPS), CIRCULATION, 103, PP. 1721-1726, (2001); ADAMS JR. H.P., BYINGTON R.P., HOEN H., ET AL., EFFECT OF CHOLESTEROL-LOWERING MEDICATIONS ON PROGRESSION OF MILD ATHEROSCLEROTIC LESIONS OF THE CAROTID ARTERIES AND ON THE RISK OF STROKE, CEREBROVASC DIS, 5, PP. 171-177, (1995); LIEM A.H., VAN BOVEN A.J., VEEGER N.J., ET AL., EFFECT OF FLUVASTATIN ON ISCHAEMIA FOLLOWING ACUTE MYOCARDIAL INFARCTION: A RANDOMIZED TRIAL, EUR HEART J, 23, PP. 1931-1937, (2002); ARNTZ H.R., AGRAWAL R., WUNDERLICH W., ET AL., BENEFICIAL EFFECTS OF PRAVASTATIN (+/- CHOLESTYRAMINE/NIACIN) INITIATED IMMEDIATELY AFTER A CORONARY EVENT (THE RANDOMIZED LIPID-CORONARY ARTERY DISEASE L-CAD STUDY), AM J CARDIOL, 86, PP. 1293-1298, (2000); KAYIKCIOGLU M., CAN L., KULTURSAY H., ET AL., EARLY USE OF PRAVASTATIN IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING CORONARY ANGIOPLASTY, ACTA CARDIOL, 57, PP. 295-302, (2002); TRIAL OF CLOFIBRATE IN THE TREATMENT OF ISCHAEMIC HEART DISEASE: FIVE-YEAR STUDY BY A GROUP OF PHYSICIANS OF THE NEWCASTLE UPON TYNE REGION, BMJ, 4, PP. 767-775, (1971); CLOFIBRATE AND NIACIN IN CORONARY HEART DISEASE, JAMA, 231, PP. 360-381, (1975); ISCHAEMIC HEART DISEASE: A SECONDARY PREVENTION TRIAL USING CLOFIBRATE. REPORT BY A RESEARCH COMMITTEE OF THE SCOTTISH SOCIETY OF PHYSICIANS, BMJ, 4, PP. 775-784, (1971); FRICK M.H., ELO O., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); A CO-OPERATIVE TRIAL IN THE PRIMARY PREVENTION OF ISCHAEMIC HEART DISEASE USING CLOFIBRATE: REPORT FROM THE COMMITTEE OF PRINCIPAL INVESTIGATORS, BR HEART J, 40, PP. 1069-1118, (1978); BEGG T.B., RIFKIND B.M., EVALUATION OF CLOFIBRATE THERAPY IN PERIPHERAL ARTERIOPATHY, MINERVA MED, 62, PP. 3469-3475, (1971); SECONDARY PREVENTION BY RAISING HDL CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CORONARY ARTERY DISEASE: THE BEZAFIBRATE INFARCTION PREVENTION (BIP) STUDY, CIRCULATION, 102, PP. 21-27, (2000); BLOOMFIELD R.H., DAVENPORT J., BABIKIAN V., ET AL., REDUCTION IN STROKE WITH GEMFIBROZIL IN MEN WITH CORONARY HEART DISEASE AND LOW HDL CHOLESTEROL: THE VETERANS AFFAIRS HDL INTERVENTION TRIAL (VA-HIT), CIRCULATION, 103, PP. 2828-2833, (2001); MEADE T., ZUHRIE R., COOK C., COOPER J., BEZAFIBRATE IN MEN WITH LOWER EXTREMITY ARTERIAL DISEASE: RANDOMISED CONTROLLED TRIAL, BMJ, 325, (2002); EFFECT OF FENOFIBRATE ON PROGRESSION OF CORONARY-ARTERY DISEASE IN TYPE 2 DIABETES: THE DIABETES ATHEROSCLEROSIS INTERVENTION STUDY, A RANDOMISED STUDY, LANCET, 357, PP. 905-910, (2001); FRICK M.H., HEINONEN O.P., HUTTUNEN J.K., ET AL., EFFICACY OF GEMFIBROZIL IN DYSLIPIDAEMIC SUBJECTS WITH SUSPECTED HEART DISEASE: AN ANCILLARY STUDY IN THE HELSINKI HEART STUDY FRAME POPULATION, ANN MED, 25, PP. 41-45, (1993); WATTS G.F., LEWIS B., BRUNT J.N., ET AL., EFFECTS ON CORONARY ARTERY DISEASE OF LIPID-LOWERING DIET, OR DIET PLUS CHOLESTYRAMINE, IN THE ST THOMAS' ATHEROSCLEROSIS REGRESSION STUDY (STARS), LANCET, 339, PP. 563-569, (1992); DORR A.E., GUNDERSEN K., SCHNEIDER J.C., ET AL., COLESTIPOL HYDROCHLORIDE IN HYPERCHOLESTEROLEMIC PATIENTS - EFFECT ON SERUM CHOLESTEROL AND MORTALITY, J CHRONIC DIS, 31, PP. 5-14, (1978); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); GROSS L., FIGUEREDO R., LONG-TERM CHOLESTEROL-LOWERING EFFECT OF COLESTIPOL RESIN IN HUMANS, J AM GERIATR SOC, 21, PP. 552-556, (1973); DE LORGERIL M., RENAUD S., MAMELLE N., ET AL., MEDITERRANEAN ALPHA-LINOLENIC ACID-RICH DIET IN SECONDARY PREVENTION OF CORONARY HEART DISEASE, LANCET, 343, PP. 1454-1459, (1994); SACKS F.M., STONE P.H., GIBSON C.M., ET AL., CONTROLLED TRIAL OF FISH OIL FOR REGRESSION OF HUMAN CORONARY ATHEROSCLEROSIS: HARP RESEARCH GROUP, J AM COLL CARDIOL, 25, PP. 1492-1498, (1995); SINGH R.B., DUBNOV G., NIAZ M.A., ET AL., EFFECT OF AN INDO-MEDITERRANEAN DIET ON PROGRESSION OF CORONARY ARTERY DISEASE IN HIGH RISK PATIENTS (INDO-MEDITERRANEAN DIET HEART STUDY): A RANDOMISED SINGLE-BLIND TRIAL, LANCET, 360, PP. 1455-1461, (2002); LENG G.C., LEE A.J., FOWKES F.G., ET AL., RANDOMIZED CONTROLLED TRIAL OF GAMMA-LINOLENIC ACID AND EICOSAPENTAENOIC ACID IN PERIPHERAL ARTERIAL DISEASE, CLIN NUTR, 17, PP. 265-271, (1998); JOHANSEN O., BREKKE M., SELJEFLOT I., ET AL., N-3 FATTY ACIDS DO NOT PREVENT RESTENOSIS AFTER CORONARY ANGIOPLASTY: RESULTS FROM THE CART STUDY. CORONARY ANGIOPLASTY RESTENOSIS TRIAL, J AM COLL CARDIOL, 33, PP. 1619-1626, (1999); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO, LANCET, 354, PP. 447-455, (1999); VON SCHACKY C., ANGERER P., KOTHNY W., ET AL., THE EFFECT OF DIETARY OMEGA-3 FATTY ACIDS ON CORONARY ATHEROSCLEROSIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, ANN INTERN MED, 130, PP. 554-562, (1999); BEMELMANS W.J., BROER J., FESKENS E.J., ET AL., EFFECT OF AN INCREASED INTAKE OF ALPHA-LINOLENIC ACID AND GROUP NUTRITIONAL EDUCATION ON CARDIOVASCULAR RISK FACTORS: THE MEDITERRANEAN ALPHA-LINOLENIC ENRICHED GRONINGEN DIETARY INTERVENTION (MARGARIN) STUDY, AM J CLIN NUTR, 75, PP. 221-227, (2002); SINGH R.B., RASTOGI S.S., VERMA R., ET AL., RANDOMISED CONTROLLED TRIAL OF CARDIOPROTECTIVE DIET IN PATIENTS WITH RECENT ACUTE MYOCARDIAL INFARCTION: RESULTS OF ONE YEAR FOLLOW UP, BMJ, 304, PP. 1015-1019, (1992); LEREN P., THE EFFECT OF PLASMA CHOLESTEROL LOWERING DIET IN MALE SURVIVORS OF MYOCARDIAL INFARCTION, ACTA MED SCAND, 466, PP. 1-92, (1966); DAYTON S., PEARCE M.L., HASHIMOTO S., ET AL., A CONTROLLED CLINICAL TRIAL OF A DIET HIGH IN UNSATURATED FAT IN PREVENTING COMPLICATIONS OF ATHEROSCLEROSIS, CIRCULATION, 40, (1969); CONTROLLED TRIAL OF SOYA-BEAN OIL IN MYOCARDIAL INFARCTION, LANCET, 2, PP. 693-699, (1968); FRANTZ I.D., DAWSON E.A., ASHMAN P.L., ET AL., TEST OF EFFECT OF LIPID LOWERING BY DIET IN CARDIOVASCULAR RISK: THE MINNESOTA CORONARY SURVEY, ATHEROSCLEROSIS, 9, PP. 129-135, (1989); MULTIPLE RISK FACTOR INTERVENTION TRIAL: RISK FACTOR CHANGES AND MORTALITY RESULTS, JAMA, 248, PP. 1465-1477, (1982); HJERMANN I., VELVE B.K., HOLME I., LEREN P., EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE: REPORT FROM THE OSLO STUDY GROUP OF A RANDOMISED TRIAL IN HEALTHY MEN, LANCET, 2, PP. 1303-1310, (1981); MIETTINEN T.A., HUTTUNEN J.K., NAUKKARINEN V., ET AL., MULTIFACTORIAL PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES IN MIDDLE- AGED MEN: RISK FACTOR CHANGES, INCIDENCE, AND MORTALITY, JAMA, 254, PP. 2097-2102, (1985); WILHELMSEN L., BERGLUND G., ELMFELDT D., ET AL., THE MULTIFACTOR PRIMARY PREVENTION TRIAL IN GOTEBORG, SWEDEN, EUR HEART J, 7, PP. 279-288, (1986); CARLSON L.A., ROSENHAMER G., REDUCTION OF MORTALITY IN THE STOCKHOLM ISCHAEMIC HEART DISEASE SECONDARY PREVENTION STUDY BY COMBINED TREATMENT WITH CLOFIBRATE AND NICOTINIC ACID, ACTA MED SCAND, 223, PP. 405-418, (1988); CASTANO G., MAS F.R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); KOSCIELNY J., KLUSSENDORF D., LATZA R., ET AL., THE ANTIATHEROSCLEROTIC EFFECT OF ALLIUM SATIVUM, ATHEROSCLEROSIS, 144, PP. 237-249, (1999); MARX A., BUCHER H.C., NUMBERS NEEDED TO TREAT DERIVED FROM META-ANALYSIS: A WORD OF CAUTION, ACP J CLUB, 138, PP. 11-12, (2003); THOMPSON S.G., HIGGINS J.P., HOW SHOULD META-REGRESSION ANALYSES BE UNDERTAKEN AND INTERPRETED?, STAT MED, 21, PP. 1559-1573, (2002); ARAD Y., NEWSTEIN D., ROTH M., GUERCI A.D., RATIONALE AND DESIGN OF THE ST. FRANCIS HEART STUDY: A RANDOMIZED CLINICAL TRIAL OF ATORVASTATIN PLUS ANTIOXIDANTS IN ASYMPTOMATIC PERSONS WITH ELEVATED CORONARY CALCIFICATION, CONTROL CLIN TRIALS, 22, PP. 553-572, (2001); KAWAGUCHI A., MITSUDO K., NOBUYOSHI M., ET AL., ANGIOGRAPHIC INTERVENTION TRIAL USING HMG COA REDUCTASE INHIBITOR TO EVALUATE RETARDATION OF OBSTRUCTIVE MULTIPLE ATHEROMA IN WEST JAPAN (ATHEROMA STUDY): RATIONALE, DESIGN AND BASELINE, J CARDIOVASC RISK, 9, PP. 7-16, (2002); DIERCKS G.F., JANSSEN W.M., VAN BOVEN A.J., ET AL., RATIONALE, DESIGN, AND BASELINE CHARACTERISTICS OF A TRIAL OF PREVENTION OF CARDIOVASCULAR AND RENAL DISEASE WITH FOSINOPRIL AND PRAVASTATIN IN NONHYPERTENSIVE, NONHYPERCHOLESTEROLEMIC SUBJECTS WITH MICROALBUMINURIA (THE PREVENTION OF RENAL AND VASCULAR ENDSTAGE DISEASE INTERVENTION TRIAL PREVEND IT), AM J CARDIOL, 86, PP. 635-638, (2000); ISAACSOHN J.L., DAVIDSON M.H., HUNNINGHAKE D., ET AL., AGGRESSIVE LIPID-LOWERING INITIATION ABATES NEW CARDIAC EVENTS (ALLIANCE) - RATIONALE AND DESIGN OF ATORVASTATIN VERSUS USUAL CARE IN HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY ARTERY DISEASE, AM J CARDIOL, 86, PP. 250-252, (2000); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS. AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); GREENLAND S., QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE, EPIDEMIOL REV, 9, PP. 1-30, (1987); OXMAN A.D., GUYATT G.H., A CONSUMER'S GUIDE TO SUBGROUP ANALYSES, ANN INTERN MED, 116, PP. 78-84, (1992); YANO K., REED D.M., MACLEAN C.J., SERUM CHOLESTEROL AND HEMORRHAGIC STROKE IN THE HONOLULU HEART PROGRAM, STROKE, 20, PP. 1460-1465, (1989); PUDDEY I.B., LOW SERUM CHOLESTEROL AND THE RISK OF CEREBRAL HAEMORRHAGE, ATHEROSCLEROSIS, 119, PP. 1-6, (1996); SIMOONS M.L., MAGGIONI A.P., KNATTERUD G., ET AL., INDIVIDUAL RISK ASSESSMENT FOR INTRACRANIAL HAEMORRHAGE DURING THROMBOLYTIC THERAPY, LANCET, 342, PP. 1523-1528, (1993); BUCHER H.C., GRIFFITH L.E., GUYATT G.H., SYSTEMATIC REVIEW ON THE RISK AND BENEFIT OF DIFFERENT CHOLESTEROL-LOWERING INTERVENTIONS, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 187-195, (1999); DEANFIELD J.E., CLINICAL TRIALS: EVIDENCE AND UNANSWERED QUESTIONS - HYPERLIPIDAEMIA, CEREBROVASC DIS, 16, PP. 25-32, (2003)","BASEL INST. FOR CLIN. EPIDEMIOLOGY, MEDICAL OUTPATIENT CLINICS, DEPT. INT. MED. , UNIV. HOSP. B., SWITZERLAND; EMAIL: BRIELM@UHBS.CH","","ENGLISH","AM. J. MED.","REVIEW","ISI","2-S2.0-4644300229","AM J MED","UNIVERSITY HOSPITAL BASEL","UNIV. HOSP. B.;NOTREPORTED",NA,"BRIEL M, 2004, AM J MED","BRIEL M, 2004, AM J MED"
"HWANG K;WELLER C;CUPPETT S;HANNA M","HWANG, KEUM T. (7402426615); WELLER, CURTIS L. (7102722517); CUPPETT, SUSAN L. (7003349552); HANNA, MILFORD A. (55707974900)","POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS",2004,"CEREAL CHEMISTRY","81","4",45,"10.1094/CCHEM.2004.81.3.345","INST. FOR MOLEC. BIOL. AND GENETICS, CHONBUK NATIONAL UNIVERSITY, JEONJU, JEONBUK, 561-756, SOUTH KOREA;DEPT. OF BIOL. SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0726, UNITED STATES;DEPT. OF FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0919, UNITED STATES;INDUST. AGRICULTURAL PRODUCTS CENTER, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0730, UNITED STATES","GRAIN SORGHUM CAN BE A MAJOR SOURCE OF POLICOSANOLS, LONG-CHAINED ALCOHOLS, THAT HAVE BENEFICIAL PHYSIOLOGICAL ACTIVITIES. SORGHUM DRIED DISTILLERS GRAINS (DDG), A BY-PRODUCT OF ETHANOL PRODUCTION FROM GRAIN SORGHUM, CONTAIN A LARGE AMOUNT OF POLICOSANOLS. CONTENT AND COMPOSITION OF POLICOSANOLS IN LONG-CHAINED LIPIDS EXTRACTED FROM GRAIN SORGHUM KERNELS AND DDG WERE DETERMINED. LONG-CHAINED LIPIDS WERE EXTRACTED USING HOT HEXANE OR HOT ETHANOL. THE MAJOR COMPONENTS OF THE LONG-CHAINED LIPIDS EXTRACTED FROM GRAIN SORGHUM KERNELS, AS DETERMINED USING HPLC, WERE POLICOSANOLS (37-44%), ALDEHYDES (44-55%), AND ACIDS (4-5%). LONG-CHAINED LIPIDS FROM DDG CONTAINED 52% POLICOSANOLS. 23% ALDEHYDES, 6.4% ACIDS, AND 17% WAX ESTERS/STERYL ESTERS. COMPOSITION OF POLICOSANOLS IN DDG MATCHED THE COMPOSITION IN GRAIN SORGHUM KERNELS, AS DETERMINED BY GAS CHROMATOGRAPHY, EVEN THOUGH THE CONTENT OF POLICOSANOLS IN DDG WAS GREATER THAN THE CONTENT IN GRAIN SORGHUM KERNELS. POLICOSONAL COMPOSITION RANGES WERE 0-1% C22:0, 0-3% C24:0, 6-8% C26:0, 1% C27:0, 43-47% C28:0, 1-2% C29:0, 40-43% C30:0, AND 1-4% C32:0.","","SORGHUM BICOLOR BICOLOR; ALDEHYDES; ESTERS; ETHANOL; GAS CHROMATOGRAPHY; ALCOHOL; ALDEHYDE; ESTER; HEXANE; LIPID; LONG CHAIN FATTY ACID; POLICOSANOL; STEROL ESTER; UNCLASSIFIED DRUG; COMPOSITION RANGES; DRIED DISTILLERS GRAINS; ETHANOL PRODUCTION; GRAIN SORGHUM; LARGE AMOUNTS; PHYSIOLOGICAL ACTIVITY; POLICOSANOLS; STERYL ESTERS; WAX ESTERS; ALCOHOL PRODUCTION; ARTICLE; FOOD COMPOSITION; GAS CHROMATOGRAPHY; GRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEED KERNEL; SORGHUM; LIPIDS","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 205-208, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); AVATO P., BIANCHI G., MURELLI C., ALIPHATIC AND CYCLIC LIPID COMPONENTS OF SORGHUM PLANT ORGANS, PHYTOCHEMISTRY, 29, PP. 1073-1078, (1990); BIANCHI G., AVATO P., MARIANI G., COMPOSITION OF SURFACE WAX FROM SORGHUM GRAIN, CEREAL CHEM., 56, PP. 491-492, (1979); BITMAN J., WOOD D.L., AN IMPROVED COPPER REAGENT FOR QUANTITATIVE DENSITOMETRIC THIN-LAYER CHROMATOGRAPHY OF LIPIDS, J. LIQ. CHROMATOGR., 5, PP. 1155-1162, (1982); BUNGER W.B., KUMMEROW F.A., A COMPARISON OF SEVERAL METHODS FOR THE SEPARATION OF UNSAPONIFIABLE MATERIAL FROM CARNAUBA AND GRAIN SORGHUM WAXES, J. AOCS, 28, PP. 121-123, (1951); CANNON C., KUMMEROW F.A., A COMPARISON OF PLANT AND GRAIN WAX FROM TWO VARIETIES OF SORGHUM, J. AOCS, 34, PP. 519-520, (1957); DALTON J.L., MITCHELL H.L., FRACTIONATION OF GRAIN SORGHUM WAX, AGRIC. FOOD CHEM., 7, PP. 570-573, (1959); GONZALEZ-CANAVACIOLO V.L., MAGRANER-HERNANDEZ J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN FIVE-MILLIGRAM FILM-COATED TABLETS, J. AOAC INT., 82, PP. 834-839, (1999); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J. AOCS, 79, PP. 529-533, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPARATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, J. SEPARATION SCI., 25, PP. 619-623, (2002); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. METAB., 39, PP. 279-284, (1995); KATO S., KARINO K.-I., HASEGAWA S., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., HAMATANI K., TAKAHASHI M., OGASAWARA J., MASUSHIGE S., HASEGAWA T., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DICT, BRIT. J. NUTR., 73, PP. 433-441, (1995); KAWANISHI K., AOKI K., HASHIMOTO Y., MATSUNOBU A., FREE PRIMARY ALCOHOLS IN OILS AND WAXES FROM GERMS, KERNELS AND OTHER COMPONENTS OF NUTS, SEEDS, FRUITS AND CEREALS, J. AOCS, 68, PP. 869-872, (1991); NORDBACK J., LUNDBERG E., HIGH RESOLUTION SEPARATION OF NON-POLAR LIPID CLASSES BY HPLC-ELSD USING ALUMINA AS STATIONARY PHASE, J. HIGH RES. CHROMATOGR., 22, PP. 483-486, (1999); SEITZ L.M., COMPOSITION OF SORGHUM GRAIN WAX, CEREAL FOODS WORLD, 22, (1977); STEWART M.E., DOWNING D.T., SEPARATION OF WAX ESTERS FROM STERYL ESTERS BY CHROMATOGRAPHY ON MAGNESIUM HYDROXIDE, LIPIDS, 16, PP. 355-359, (1981); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH OCTACOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT. J. CLIN. PHARM. THERAPY, 36, PP. 469-473, (1998); WELLER C.L., CUPPETT S.L., HUA L.C., LOCHTE-WATSON K.R., GAUDOIN C., ARRAULT J., HUBBARD C., MUA J.P., SOLVENT INFLUENCE ON YIELD AND FRACTIONS OF GRAIN SORGHUM WAX, (2000)","C.L. WELLER; DEPT. OF BIOL. SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583-0726, UNITED STATES; EMAIL: CWELLER1@UNL.EDU","AMERICAN ASSOCIATION OF CEREAL CHEMISTS","ENGLISH","CEREAL CHEM.","ARTICLE","ISI","2-S2.0-2342550094","CEREAL CHEM","CHONBUK NATIONAL UNIVERSITY;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA","NOTREPORTED;UNIVERSITY OF NEBRASKA;NOTREPORTED",NA,"HWANG KT, 2004, CEREAL CHEM","HWANG KT, 2004, CEREAL CHEM"
"CASTAÑO G;FERNÁNDEZ L;MAS R;ILLNAIT J;MESA M;FERNÁNDEZ J","CASTAÑO, GLADYS (56232967100); FERNÁNDEZ, LILIA (7202848319); MAS, ROSA (7007164572); ILLNAIT, JOSÉ (8631465800); MESA, MEYLIN (36880545700); FERNÁNDEZ, J.C. (9432805500)","COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS",2003,"CLINICAL DRUG INVESTIGATION","23","11",31,"10.2165/00044011-200323100-00003","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, PO BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: DIABETES MELLITUS AND HYPERCHOLESTEROLAEMIA INCREASE THE RISK FOR CORONARY HEART DISEASE, WITH TYPE 2 DIABETES MELLITUS BEING THE MOST PREVALENT FORM OF DIABETES, FREQUENTLY ACCOMPANIED BY DYSLIPIDAEMIA. THE MAIN GOAL OF DYSLIPIDAEMIA CONTROL IN NONDIABETIC AND DIABETIC PATIENTS IS TO LOWER ELEVATED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) LEVELS. POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG, PURIFIED FROM SUGARCANE WAX, WITH A THERAPEUTIC RANGE OF 5-20 MG/ DAY, WHICH SIGNIFICANTLY REDUCES LDL-C LEVELS. ATORVASTATIN IS AN HMG-COA REDUCTASE INHIBITOR THAT, ACROSS ITS DOSE RANGE (10-80 MG/DAY), HAS SHOWN SIGNIFICANTLY GREATER LIPID-LOWERING EFFECTS THAN ALL PREVIOUSLY MARKETED STATINS. OBJECTIVE: TO COMPARE THE EFFECTS ON LIPID PROFILE AND PLATELET AGGREGATION OF POLICOSANOL AND ATORVASTATIN IN PATIENTS WITH DYSLIPIDAEMIA DUE TO TYPE 2 DIABETES. PATIENTS AND METHODS: THIS RANDOMISED, SINGLE-BLIND, PARALLEL-GROUP STUDY WAS CONDUCTED IN PATIENTS WITH TYPE 2 DIABETES (FASTING GLUCOSE <7 MMOL/L AND GLYCOSYLATED HAEMOGLOBIN [HBA 1C] <8.5%) AND HIGH LDL-C LEVELS (>3.0 MMOL/ L). AFTER 6 WEEKS ON A CHOLESTEROL-LOWERING DIET, 40 PATIENTS WERE RANDOMISED TO POLICOSANOL OR ATORVASTATIN 10MG TABLETS TAKEN ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. ASSESSMENTS OF LIPID PROFILE, PLATELET AGGREGATION TESTS, SAFETY INDICATORS AND ADVERSE EVENTS WERE PERFORMED. RESULTS: AFTER 8 WEEKS OF THERAPY, POLICOSANOL SIGNIFICANTLY LOWERED LDL-C BY 25.7% (P < 0.0001 VERSUS BASELINE) AND TOTAL CHOLESTEROL (TC) BY 18.2% (P < 0.001 VERSUS BASELINE). IN TURN, ATORVASTATIN 10 MG/DAY DECREASED LDL-C BY 41.9% AND TC BY 31.5% (P < 0.0001 VERSUS BASELINE). ATORVASTATIN WAS MORE EFFECTIVE THAN POLICOSANOL IN REDUCING LDL-C AND TC (P < 0.001). POLICOSANOL ALSO SIGNIFICANTLY REDUCED THE TC/HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) RATIO (25.2%; P < 0.0001) AND TRIGLYCERIDES (15.6%; P < 0.001), WHILE ATORVASTATIN LOWERED TC/HDL-C BY 30.5% (P < 0.0001) AND TRIGLYCERIDES BY 13.9% (P < 0.001); THE REDUCTIONS ON THESE VARIABLES WERE SIMILAR IN THE TWO GROUPS. POLICOSANOL, BUT NOT ATORVASTATIN, SIGNIFICANTLY INCREASED HDL-C (11.1%; P < 0.01), THE EFFECT BEING SIGNIFICANTLY DIFFERENT FROM THAT OF ATORVASTATIN (P < 0.0001). ALSO, POLICOSANOL, BUT NOT ATORVASTATIN, SIGNIFICANTLY INHIBITED PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID 0.75 AND 1.5 MMOL/L (39.0% AND 33.3%, RESPECTIVELY) AND BY COLLAGEN 0.25 AND 0.5 ΜG/ML (15.7% AND 28.5%, RESPECTIVELY) [P < 0.001]; THESE INHIBITIONS WERE SIGNIFICANTLY DIFFERENT (P < 0.05) FROM THE CHANGES THAT OCCURRED WITH ATORVASTATIN. NEITHER DRUG SIGNIFICANTLY CHANGED PLATELET AGGREGATION ELICITED BY ADENOSINE DIPHOSPHATE (ADP). BOTH TREATMENTS WERE WELL TOLERATED, WITH GLYCAEMIC CONTROL BEING UNAFFECTED. NEITHER DRUG IMPAIRED PHYSICAL SAFETY INDICATORS OR GLUCOSE CONTROL INDICATORS (FASTING GLUCOSE AND HBA1C. ATORVASTATIN SIGNIFICANTLY INCREASED LEVELS OF ALANINE AMINO-TRANSFERASE (ALT) [P < 0.05] AND CREATINE PHOSPHOKINASE (CPK) [P < 0.01], WHILE POLICOSANOL DID NOT SIGNIFICANTLY CHANGE ANY SAFETY INDICATOR. ONLY THREE ATORVASTATIN RECIPIENTS SHOWED INDIVIDUAL VALUES OF ALT AND CPK THAT WERE MODERATELY ENHANCED (<3 TIMES ABOVE THE NORMAL UPPER LIMIT). NO PATIENTS WITHDREW FROM THE STUDY. FOUR PATIENTS REPORTED ADVERSE EVENTS: TWO POLICOSANOL (INSOMNIA AND PRURITUS) AND TWO ATORVASTATIN (MYALGIA AND RAISED ARTERIAL BLOOD PRESSURE) RECIPIENTS. CONCLUSION: POLICOSANOL (10 MG/DAY) FOR 8 WEEKS WAS LESS EFFECTIVE THAN SIMILAR DOSES OF ATORVASTATIN IN REDUCING LDL-C AND TC IN PATIENTS WITH DYSLIPIDAEMIA DUE TO TYPE 2 DIABETES, BUT MORE EFFECTIVE IN INCREASING HDL-C. BOTH DRUGS SIMILARLY REDUCED THE TC/HDL-C RATIO AND TRIGLYCERIDES. POLICOSANOL SHOWED ADDITIONAL ADVANTAGES REGARDING INHIBITION OF PLATELET AGGREGATION. NEVERTHELESS, FURTHER STUDIES OF LONGER DURATION AND USING DOSE-TITRATION SCHEMES TO ACHIEVE LDL-C GOALS ARE NEEDED FOR WIDER CONCLUSIONS ABOUT THE RESPECTIVE EFFECTS OF THESE TWO DRUGS IN SUCH A POPULATION SUBSET.","","ADENOSINE DIPHOSPHATE; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; CREATINE KINASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INSOMNIA; LIPID COMPOSITION; MALE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION","WEST HAVANA SCIENTIFIC POLE","THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE WEST HAVANA SCIENTIFIC POLE, CUBA. THE AUTHORS HAVE NO CONFLICTS OF INTEREST DIRECTLY RELEVANT TO THE CONTENT OF THIS STUDY.","WORLD HEALTH REPORT 1998: LIFE IN THE 21ST CENTURY: A VISION OF ALL, (1998); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE: BLOOD LIPIDS AND CORONARY HEART DISEASE. 2ND ED., (2000); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOY L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); MRC/BFH HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); LAAKSO M., EPIDEMIOLOGY OF DIABETIC DYSLIPIDEMIA, DIABETES REV, 3, PP. 408-422, (1995); SASAKI A., UEHARA M., HORIUCHI N., ET AL., A 15 YEAR OLD FOLLOW-UP STUDY OF PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) IN OSAKA, JAPAN: LONG-TERM PROGNOSIS AND CAUSES OF DEATH, DIABETES RES CLIN PRACT, 34, PP. 47-55, (1996); LEE W.L., CHEUNG A.M., CAPE D., ET AL., IMPACT OF DIABETES ON CORONARY ARTERY DISEASE IN WOMEN AND MEN: A META ANALYSIS OF PROSPECTIVE STUDIES, DIABETES CARE, 23, PP. 962-968, (2000); HALLER H., ENDOTHELIAL FUNCTION: GENERAL CONSIDERATIONS, DRUGS, 53, 1 SUPPL., PP. 1-10, (1997); LUSCHER T.F., BARTON M., BIOLOGY OF THE ENDOTHELIUM, CLIN CARDIOL, 20, 2 SUPPL., (1997); ASPIRIN IN DIABETES, DIABETES CARE, 25, 1 SUPPL., (2002); REPORTS OF THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS, DIABETES CARE, 25, 1 SUPPL., (2002); BETHERIDGE J., DIABETIC DYSLIPIDEMIA, AM J MED, 96, 6, (1994); HAFFNER S.M., MANAGEMENT OF DYSLIPIDEMIA IN ADULTS WITH DIABETES, DIABETES CARE, 21, PP. 160-178, (1998); MANAGEMENT OF DYSLIPIDEMIA IN ADULTS WITH DIABETES, DIABETES CARE, 25, 1 SUPPL., (2002); PACKARD C., CASLAKE M., SHEPEHERD J., THE ROLE OF SMALL, DENSE LOW DENSITY LIPOPROTEIN (LDL): A NEW LOOK, INT J CARDIOL, 74, 1 SUPPL., (2000); HUNT J.V., DEAN R.T., WOLFF S.P., OXIDATIVE GLYCATION AND FREE RADICAL PRODUCTION: A CAUSAL MECHANISM OF DIABETIC COMPLICATION, FREE RADIC RES COMMUN, 12-13, PP. 115-123, (1991); LEA A.P., MCTAVISH D., ATORVASTATIN: A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL ON HYPERLIPIDAEMIA CONTROL, DRUGS, 53, PP. 828-847, (1997); NAWROCKI J.W., WEISS S.R., DAVIDSON M.H., ET AL., REDUCTION OF LDL CHOLESTEROL BY 25% TO 60% IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA BY ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR, ARTERIOSCLER THROMBOSIS VASC BIOL, 15, PP. 678-682, (1995); DEMIR M., ACARTURK E., SASMAZ I., ET AL., EFFECTS OF ATORVASTATIN ON LIPID PROFILE AND COAGULATION PARAMETERS, CURR THER RES, 62, PP. 691-698, (2001); JONES P., KAFANEK S., LAURORA I., ET AL., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM J CARDIOL, 81, PP. 582-587, (1998); SCHUSTER H., BERGER J., LUFT F., RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP TRIAL OF ATORVASTATIN AND FLUVASTATIN ON PLASMA LIPID LEVELS IN PATIENTS WITH UNTREATED HYPERLIPIDAEMIA, BR J CARDIOL, 5, PP. 597-602, (1998); DART A., JERUMS G., NICHOLSON G., ET AL., A MULTICENTER, DOUBLE-BLIND, ONE-YEAR STUDY COMPARING SAFETY AND EFFICACY OF ATORVASTATIN VERSUS SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA, AM J CARDIOL, 80, PP. 39-44, (1997); DAVIDSON M., MCKENNEY J., STEIN E., ET AL., COMPARISON OF ONE-YEAR EFFICACY AND SAFETY OF ATORVASTATIN VERSUS LOVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 79, PP. 1475-1481, (1997); ATHYROS V.G., PAPAGEORGIOUS A.A., ATHYROU V., ET AL., ATORVASTATIN AND MICRONIZED FENOFIBRATE ALONE AND IN COMBINATION IN TYPE 2 DIABETES WITH COMBINED DYSLIPIDEMIA, DIABETES CARE, 25, PP. 1198-1202, (2002); BLACK D.M., BAKKER-ARKEMA R., NAWROCKI J.W., AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN (LIPITOR), A NEW HMGCOA REDUCTASE INHIBITOR, ARCH INTERN MED, 158, PP. 577-584, (1998); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEARS STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II, INT J CLIN PHARMACOL RES, PP. 159-165, (1995); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 6-14, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN INVEST, 21, PP. 103-113, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, PP. 153-163, (2003); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, IM J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); CORSINI A., PAZZUCCONI F., ARNABOLDI L., ET AL., DIRECT EFFECTS OF STATINS ON THE VASCULAR WALL, J CARDIOVASC PHARMACOL, 31, PP. 773-778, (1998); BELLOSTA S., FERRI N., ARNABOLDI L., ET AL., PLEIOTROPIC EFFECTS OF STATINS IN ATHEROSCLEROSIS AND DIABETES, DIABETES CARE, 23, 2 SUPPL., (2000); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE, 194, PP. 927-930, (1962); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); DAVI G., CATALANO I., AVERNA M., ET AL., THROMBOXANE SYNTHESIS AND PLATELET FUNCTION IN DIABETES MELLITUS, N ENGL J MED, 322, PP. 1769-1774, (1990); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003)","","","ENGLISH","CLIN. DRUG INVEST.","ARTICLE","ISI","2-S2.0-0142074299","CLIN DRUG INVEST",NA,"NOTREPORTED",NA,"CASTAÑO G, 2003, CLIN DRUG INVEST","CASTAÑO G, 2003, CLIN DRUG INVEST"
"DULIN M;HATCHER L;SASSER H;BARRINGER T","DULIN, MICHAEL F. (6602707145); HATCHER, LAUREN F. (6701340788); SASSER, HOWELL C. (6602157376); BARRINGER, THOMAS A. (6603697078)","POLICOSANOL IS INEFFECTIVE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA A RANDOMIZED CONTROLLED TRIAL",2006,"AMERICAN JOURNAL OF CLINICAL NUTRITION","84","5",84,"10.1093/ajcn/84.6.1543","CAROLINAS MEDICAL CENTER DEPARTMENT OF FAMILY MEDICINE, CHARLOTTE, NC, UNITED STATES, CHARLOTTE, NC 28232-2861, PO BOX 32861, UNITED STATES;CENTER FOR CARDIOVASCULAR HEALTH, CHARLOTTE, NC, UNITED STATES;R STUART DICKSON INSTITUTE FOR HEALTH STUDIES, CHARLOTTE, NC, UNITED STATES;CENTER FOR CARDIOVASCULAR HEALTH, CHARLOTTE, NC, UNITED STATES","BACKGROUND: POLICOSANOL IS ONE OF THE FASTEST GROWING OVER-THE-COUNTER SUPPLEMENTS SOLD IN THE UNITED STATES. THE USE OF POLICOSANOL TO TREAT ELEVATED CHOLESTEROL IS BASED ON CLINICAL TRIALS CONDUCTED IN CUBA, WHICH SHOWED SUGAR CANE-DERIVED POLICOSANOL TO BE SIMILAR IN EFFICACY TO STATINS. RECENT STUDIES HAVE CHALLENGED THESE FINDINGS, BUT THERE HAVE BEEN NO TRIALS CONDUCTED IN NORTH AMERICA THAT HAVE EXAMINED THE ABILITY OF SUGAR CANE-DERIVED POLICOSANOL TO LOWER CHOLESTEROL. OBJECTIVES: THIS STUDY INVESTIGATED THE EFFICACY OF SUGAR CANE-DERIVED POLICOSANOL IN HEALTHY ADULTS WITH MILD HYPERCHOLESTEROLEMIA. THE PRIMARY OUTCOME WAS THE PERCENTAGE CHANGE IN LDL CHOLESTEROL AFTER 8 WK OF THERAPY. SECONDARY OUTCOME MEASURES INCLUDED CHANGES IN TOTAL CHOLESTEROL, HDL CHOLESTEROL, TRIACYLGLYCEROLS, C-REACTIVE PROTEIN, AND NUCLEAR MAGNETIC RESONANCE-DETERMINED LIPOPROTEIN PROFILE. DIETARY HABITS, WEIGHT, AND BLOOD PRESSURE WERE ALSO MONITORED. DESIGN: AMBULATORY, COMMUNITY-DWELLING HEALTHY ADULTS WITH MILD HYPERCHOLESTEROLEMIA (N = 40) WERE ASSIGNED TO RECEIVE ORAL POLICOSANOL (20 MG) OR PLACEBO ONCE DAILY FOR 8 WK. THIS WAS A DOUBLEBLIND, RANDOMIZED CONTROLLED TRIAL CONDUCTED FROM JANUARY THROUGH AUGUST 2005. RESULTS: NO SIGNIFICANT DIFFERENCES IN THE CHANGE IN LDL CHOLESTEROL WERE OBSERVED BETWEEN THE PLACEBO (N = 20) AND POLICOSANOL (N = 20) GROUPS. ALSO, NO SIGNIFICANT CHANGES IN SECONDARY OUTCOME MEASURES, INCLUDING TOTAL CHOLESTEROL, HDL CHOLESTEROL, TRIACYLGLYCEROL, C-REACTIVE PROTEIN, AND NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY-DETERMINED PROFILES WERE OBSERVED. POLICOSANOL WAS WELL TOLERATED, AND NO SIGNIFICANT ADVERSE EVENTS WERE NOTED. CONCLUSION: POLICOSANOL DOES NOT ALTER THE SERUM LIPID PROFILE OVER AN 8-WK PERIOD IN ADULTS WITH MILD HYPERCHOLESTEROLEMIA. © 2006 AMERICAN SOCIETY FOR NUTRITION.","ALIPHATIC ALCOHOLS; CHOLESTEROL; HDL; LDL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLICOSANOL","SACCHARUM; ANTIALLERGIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALTODEXTRIN; MULTIVITAMIN; OCTA 60; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; UNSPECIFIED SIDE EFFECT","","","GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); KAHN T., OVER THE COUNTER SUPPLEMENTS FOR CHOLESTEROL LOWERING, PHARMACIST'S/PRESCRIBER'S LETTER, 22, (2006); BAYER ONE-A-DAY CHOLESTEROL PLUS; NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); MAS R., CASTANO G., FERNANDEZ J., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH TYPE 2 DIABETES, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); POLICOSANOL MONOGRAPH, 9, PP. 312-317, (2004); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, PP. 207-219, (2005); MAS R., CASTANO G., FERNANDEZ J., ET AL., LONG-TERM EFFECTS OF POLICOSANOL ON OBESE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON-INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); LIN Y., RUDRUM M., VAN DER WIELEN R.P., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, SUPPL., (2004); CONNOR S.L., GUSTAFSON J.R., SEXTON G., BECKER N., ARTAUD-WILD S., CONNOR W.E., THE DIET HABIT SURVEY: A NEW METHOD OF DIETARY ASSESSMENT THAT RELATES TO PLASMA CHOLESTEROL CHANGES, J AM DIET ASSOC, 92, PP. 41-47, (1992); OTVOS J.D., MEASUREMENT OF LIPOPROTEIN SUBCLASS PROFILES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, CLIN LAB, 48, PP. 171-180, (2002); OTVOS J.D., JEYARAJAH E.J., BENNETT D.W., KRAUSS R.M., DEVELOPMENT OF A PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPIC METHOD FOR DETERMINING PLASMA LIPOPROTEIN CONCENTRATIONS AND SUBSPECIES DISTRIBUTIONS FROM A SINGLE, RAPID MEASUREMENT, CLIN CHEM, 38, PP. 1632-1638, (1992); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); NIKITIN IU.P., SLEPCHENKO N.V., GRATSIANSKII N.A., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC DRUG POLYCOSANOL IN RUSSIA, TER ARKH, 72, PP. 7-10, (2000); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLEMIC PATIENTS, CLIN DRUG INVEST, 25, PP. 701-707, (2005); TEDESCHI-REINER E., REINER Z., ROMIC Z., IVANKOVIC D., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTILIPEMIC EFFICACY AND TOLERABILITY OF FOOD SUPPLEMENT POLICOSANOL IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, LIJEC VJESN, 127, PP. 273-279, (2005); FONG R.L., WARD H.J., THE EFFICACY OF LOVASTATIN IN LOWERING CHOLESTEROL IN AFRICAN AMERICANS WITH PRIMARY HYPERCHOLESTEROLEMIA, AM J MED, 102, PP. 387-391, (1997)","M.F. DULIN; CHARLOTTE, NC 28232-2861, PO BOX 32861, UNITED STATES; EMAIL: MICHAEL.DULIN@CAROLINASHEALTHCARE.ORG","AMERICAN SOCIETY FOR NUTRITION","ENGLISH","AM. J. CLIN. NUTR.","ARTICLE","ISI","2-S2.0-33845496494","AM J CLIN NUTR","CAROLINAS MEDICAL CENTER DEPARTMENT OF FAMILY MEDICINE;CENTER FOR CARDIOVASCULAR HEALTH;R STUART DICKSON INSTITUTE FOR HEALTH STUDIES;CENTER FOR CARDIOVASCULAR HEALTH","NOTREPORTED;NOTREPORTED;EMAIL: MICHAEL.DULIN@CAROLINASHEALTHCARE.ORG",NA,"DULIN MF, 2006, AM J CLIN NUTR","DULIN MF, 2006, AM J CLIN NUTR"
"CASTAÑO G;MENÉNDEZ R;MÁS R;AMOR A;FERNÁNDEZ J;GONZÁLEZ R;LEZCAY M;ALVAREZ E","CASTAÑO, G. (7005759008); MENÉNDEZ, R. (7102205059); MÁS, ROSA (7007164572); AMOR, A. (35569426800); FERNÁNDEZ, J.L. (59115166400); GONZÁLEZ, R.L. (57213211304); LEZCAY, M. (6508023242); ALVAREZ, E. (15053135600)","EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS",2002,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","22","10",45,"","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","IN THIS PILOT, RANDOMIZED, DOUBLE-BLIND STUDY, WE COMPARED THE EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS. AFTER 4 WEEKS ON A CHOLESTEROL-LOWERING DIET, 36 PATIENTS WERE RANDOMIZED TO POLICOSANOL (10 MG/DAY) OR LOVASTATIN (20 MG/DAY) TABLETS O.I.D. FOR 8 WEEKS. POLICOSANOL SIGNIFICANTLY (P < 0.001) LOWERED SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) (29.9%), TOTAL CHOLESTEROL (21.1%), TRIGLYCERIDES (13.6%) AND THE LDL-C/HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) (36.7%) AND TOTAL CHOLESTEROL/HDL-C (28.9%) RATIOS AND SIGNIFICANTLY (P < 0.01) INCREASED HDL-C (12.5%). LOVASTATIN SIGNIFICANTLY (P < 0.001) LOWERED LDL-C (25%), TOTAL CHOLESTEROL (18%), TRIGLYCERIDES (10.9%) AND THE LDL-C/HDL-C (30.4%) AND TOTAL CHOLESTEROL/HDL-C RATIOS (23.9%) AND SIGNIFICANTLY (P < 0.01) RAISED HDL-C (8.3%). POLICOSANOL WAS MORE EFFECTIVE (P < 0.05) THAN LOVASTATIN IN REDUCING BOTH RATIOS AND IN INCREASING (P < 0.05) HDL-C. POLICOSANOL, BUT NOT LOVASTATIN, SIGNIFICANTLY RAISED THE LAG TIME (20.9%) OF CU+2-INDUCED LDL PEROXIDATION AND TOTAL PLASMA ANTIOXIDANT ACTIVITY (24.2%) (P < 0.05). BOTH POLICOSANOL AND LOVASTATIN SIGNIFICANTLY DECREASED THE PROPAGATION RATE (41.9% AND 41.6% RESPECTIVELY, P < 0.001), MAXIMAL DIENE PRODUCTION (8.3% AND 5.7%) AND PLASMA LEVELS OF THIOBARBITURIC ACID REACTIVE SUBSTANCES (9.7% AND 11.5%, P < 0.001). BOTH TREATMENTS WERE WELL TOLERATED. ONLY ONE PATIENT IN THE LOVASTATIN GROUP WITHDREW FROM THE TRIAL DUE TO ADVERSE EVENTS. IN CONCLUSION, POLICOSANOL AND LOVASTATIN ADMINISTERED SHORT TERM TO PATIENTS WITH DYSLIPIDEMIA SECONDARY TO TYPE 2 DIABETES WERE EFFECTIVE IN LOWERING CHOLESTEROL AND IN INHIBITING THE EXTENT OF LIPID PEROXIDATION. POLICOSANOL (10 MG/DAY) WAS SLIGHTLY MORE EFFECTIVE THAN LOVASTATIN (20 MG/DAY) IN REDUCING THE LDL-C/ HDL-C AND TOTAL CHOLESTEROL/HDL-C RATIOS, IN INCREASING HDL-C LEVELS AND IN PREVENTING LDL OXIDATION. NEVERTHELESS, SINCE THIS WAS A PILOT STUDY, FURTHER CLINICAL STUDIES PERFORMED IN LARGER SAMPLE SIZES OF DIABETIC PATIENTS ARE NEEDED FOR DEFINITIVE CONCLUSIONS.","","AGED; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPID PEROXIDATION; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKADIENE; ANTIDIABETIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; COPPER ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MUSCLE RELAXANT AGENT; POLICOSANOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; ABDOMINAL DISCOMFORT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PARALLEL DESIGN; PATIENT SELECTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO","","","FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N. ENG. J. MED., 317, (1987); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENG. J. MED., 339, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, (2001); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, (1994); ATHEROSCLEROSIS, 110, (1994); WETTERHALL S.F., OLSON D.R., DESTEFANO F., ET AL., TRENDS IN DIABETES AND DIABETIC COMPLICATIONS, DIABETES CARE, 15, (1992); SASAKI A., UEHARA M., HORIUCHI N., ET AL., A 15 YEAR FOLLOW-UP STUDY OF PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) IN OSAKA, JAPAN. LONG-TERM PROGNOSIS AND CAUSES OF DEATH, DIABETES RES. CLIN. PRACT., 34, (1996); ROSENGREN A., WELIN L., TSIPOGIANNI L., ET AL., IMPACT OF CARDIOVASCULAR RISK FACTORS ON CORONARY HEART DISEASE AND MORTALITY AMONG MIDDLE AGED DIABETIC MEN: A GENERAL POPULATION STUDY, BR. MED. J., 299, (1989); LAAKSO M., RONNEMAA T., LEHTO S., ET AL., DOES NIDDM INCREASE THE RISK FOR CORONARY HEART DISEASE SIMILARLY ON BOTH LOW- AND HIGH-RISK POPULATIONS?, DIABETOLOGIA, 38, (1995); LAAKSO M., EPIDEMIOLOGY OF DIABETIC DYSLIPIDEMIA, DIABETES REV., 3, (1995); BUCCALA R., MAKITA Z., VEGA G., GRUNDY S.M., ET AL., MODIFICATION OF LOW DENSITY LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL INSUFFICIENCY, PROC. NATL. ACAD. SCI. USA, 91, (1994); HUNT J.V., DEAN R.T., WOLFF S.P., OXIDATIVE GLYCATION AND FREE RADICAL PRODUCTION: A CAUSAL MECHANISM OF DIABETIC COMPLICATION, FREE RAD. RES. COMMUN., 12-13, (1991); JENNINGS P.E., JONES A.F., FLORKOUSKI C.M., ET AL., INCREASED DIENE CONJUGATES IN DIABETIC SUBJECTS WITH MICROANGIOPATHY, DIABETIC MED., 4, (1987); ABBOT C.A., MACKNESS M.I., KUMAR S., ET AL., SERUM PARAOXONASE ACTIVITY, CONCENTRATION AND PHENOTYPE DISTRIBUTION IN DIABETES MELLITUS AND ITS RELATIONSHIP TO SERUM LIPIDS AND LIPOPROTEIN, ARTERIOSCLER. THROMB. VASC. BIOL., 15, (1995); IKEDA Y., SUCHIRO T., INOUE M., SERUM PARAOXONASE ACTIVITY AND ITS RELATION TO DIABETIC COMPLICATIONS IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS, METAB. CLIN. EXP., 47, (1998); MACKNESS B., DURRINGTON P.N., ABUASHIA B., ET AL., LOW PARAOXONASE ACTIVITY IN TYPE II DIABETES MELLITUS COMPLICATED BY RETINOPATHY, CLIN. SCI., 98, (2000); HENWOOD J.M., HEEL R.C., LOVASTATIN: A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC PROPERTIES AND THERAPEUTIC USE IN HYPERLIPIDEMIA, DRUGS, 36, (1988); MITCHEL Y.B., THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, (1992); WALKER J.F., WORLDWIDE EXPERIENCES WITH SIMVASATIN/LOVASTATIN, EUR. HEART. J., 13, SUPPL. B, (1992); AVIRAM M., DANKNER G., COGAN U., ET AL., LOVASTATIN INHIBITS LOW-DENSITY LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES: IN VITRO AND IN VIVO STUDIES, METABOLISM, 41, (1992); CHEN L., HAUGHT W.H., YANG B., ET AL., PRESERVATION OF ENDOGENOUS ANTIOXIDANT ACTIVITY AND INHIBITION OF LIPID PEROXIDATION AS A COMMON MECHANISM OF ANTIATHEROGENIC EFFECTS OF VITAMIN E, LOVASTATIN AND AMLOPIDINE, J. AM. COLL. CARDIOL., 30, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, (1994); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HIPERLIPOPROTEINEMIA: A 12-MONTH STUDY, CURR. THER. RES., 56, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, (1996); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 14, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECT OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, (1999); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN. INVEST., 21, (2001); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN. DRUG INVEST., 21, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARM. RES., 19, 4, (1999); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR. THER. RES., 59, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT. J. CLIN. PHARMACOL., 50, (2000); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RAMDOMIZED DOUBLE-BIND PILOT STUDY, CURR. THER. RES., 61, (2000); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); KLEINVELD H.A., HARK-LEMMERS H.L.M., STALENHOEF A.F.H., ET AL., IMPROVED MEASUREMENTS OF LOW-DENSITY LIPOPROTEIN SUSCEPTIBILITY TO COPPER-INDUCED OXIDATION: APPLICATION OF A SHORT PROCEDURE FOR ISOLATING LOW-DENSITY LIPOPROTEIN, CLIN. CHEM., 38, (1992); ESTERBAUER H., STRIEGL H., PUHL H., ET AL., CONTINUOS MONITORING OF IN VITRO OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN, FREE RAD. RES. COMMUN., 6, (1989); MARKWELL M.A., HASS S.M., BIEBER L.L., ET AL., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM., 87, (1987); OKAHUA H., OHISHIWNAD K., YAGI K., ASSAY OF LIPID PEROXIDES IN ANIMAL TISSUE BY TBA, ANAL. BIOCHEM., 95, (1979); GARG A., GRUNDY S.M., LOVASTATIN FOR LOWERING CHOLESTEROL LEVELS IN NON-INSULIN DEPENDENT DIABETES MELLITUS, N. ENGL. J. MED., 318, (1988); GOLBERG R., LA BELLE P., ZUOKIS R., RONCA P., COMPARISON OF THE EFFECTS OF LOVASTATIN AND GEMFIBROZIL ON LIPIDS AND GLUCOSE CONTROL IN NON-INSULIN-DEPENDENT-DIABETES MELLITUS, AM. J. CARDIOL., 66, (1990); BRADFORD R.H., SHEAR C.S., CHREMOS A.N., EXPANDED CLINICAL EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS. I. EFFICACY IN MODIFYING PLASMA LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8,245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, ARCH. INTERN. MED., 151, (1991); PALOMAKI A., MALMINIEMI K., MALMINIEMI O., ET AL., EFFECTS OF LOVASTATIN THERAPY ON SUSCEPTIBILITY OF LDL TO OXIDATION DURING ALPHA-TOCOPHEROL SUPPLEMENTATION, ARTERIOSCLER. THROMB. VASC. BIOL., 19, (1999); PALOMAKI A., MALMINIEMI K., METSA-KELETA T., ENHANCED OXIDIZABILITY OF UBOQUINOL AND ALPHA-TOCOPHEROL DURING LOVASTATIN TREATMENT, FEBS LETT., 410, (1997); MAXWELL S.R.J., THOMASON H., SANDLER D., ET AL., ANTIOXIDANT STATUS IN PATIENTS WITH UNCOMPLICATED INSULIN-DEPENDENT AND NON-INSULIN-DEPENDENT DIABETES MELLITUS, EUR. J. CLIN. INVEST., 27, (1997); JANERO D.R., MALONDIALDEHYDE AND THIOBARBITURIC ACID-REACTIVITY AS DIAGNOSTIC INDICES OF LIPID PEROXIDATION AND PEROXIDATIVE TISSUE INJURY, FREE RAD. BIOL. MED., 9, (1990)","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0038715438","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"CASTAÑO G, 2002, INT J CLIN PHARMACOL RES","CASTAÑO G, 2002, INT J CLIN PHARMACOL RES"
"BROWN D","BROWN, DONALD (57213913818)","POLICOSANOL INEFFECTIVE FOR TREATING HYPERLIPIDEMIA",2006,"ALTERNATIVE THERAPIES IN WOMENS HEALTH","8","1",0,"","AMERICAN BOTANICAL COUNCIL, UNITED STATES, BASTYR UNIVERSITY, SEATTLE, UNITED STATES, OFFICE OF DIETARY SUPPLEMENTS, NATIONAL INSTITUTES OF HEALTH, UNITED STATES, NATURE'S WAY, INC.","IN A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL, THE EFFICACY OF POLICOSANOL WAS STUDIED IN ADULTS WITH HYPERLIPIDEMIA. THE TRIAL INCLUDED 143 SUBJECTS (AGED 18-80 YEARS) WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA. INCLUSION CRITERIA INCLUDED AN LDL-C LEVEL OF AT LEAST 150 MG/DL (≥ 3.88 MMOL/L) AND EITHER NO OR ONE CARDIOVASCULAR RISK FACTOR OTHER THAN KNOWN CORONARY HEART DISEASE, OR BASELINE LDL-C LEVELS OF BETWEEN 150-189 MG/DL (3.88-4.89 MMOL/L) AND TWO OR MORE RISK FACTORS. FOLLOWING AN OPEN-LABEL, SIX-WEEK PLACEBO AND DIET RUN-IN PHASE, SUBJECTS WERE RANDOMIZED TO ONE OF FIVE GROUPS: 10, 20, 40, OR 80 MG/D OF POLICOSANOL OR PLACEBO. THE POLICOSANOL IN THE STUDY WAS DERIVED FROM SUGAR CANE AND WAS PROVIDED BY DALMER LABORATORIES (LA HABANA, CUBA). THE TABLETS WERE MANUFACTURED BY MADAUS AG (COLOGNE, GERMANY). THE TREATMENT PERIOD WAS 12 WEEKS. THE MAIN PRIMARY OUTCOME MEASURE WAS THE PERCENTAGE CHANGE OF LDL-C, WITH CHANGES IN OTHER LIPOPROTEINS (TC, VLDL-C, HDL-C, LIPOPROTEIN[A] AND TRIGLYCERIDES) AS SECONDARY OUTCOME MEASURES. IN ADDITION TO SCREENING AND BASELINE BLOOD DRAWS, PATIENTS WERE SEEN FOR BLOOD DRAWS AT WEEKS 6 AND 12. THE PER-PROTOCOL ANALYSIS WAS COMPLETED ON 129 PATIENTS (PLACEBO, N = 25; 10 MG POLICOSANOL, N = 26; 20 MG, N = 25; 40 MG, N = 24; 80 MG, N = 29). LDL-C LEVELS DID NOT DECREASE BY MORE THAN 103% OF BASELINE IN ANY OF THE FIVE TREATMENT GROUPS. NO STATISTICALLY SIGNIFICANT DIFFERENCE WAS FOUND BETWEEN PLACEBO AND ANY OF THE FOUR POLICOSANOL GROUPS. A NONPARAMETRIC TEST ANALYZING DOSE-DEPENDENCY YIELDED NONSIGNIFICANT RESULTS. THERE WERE NO SIGNIFICANT EFFECTS FOR POLICOSANOL ON ANY OF THE SECONDARY MEASURES INCLUDING RATIO OF TC OR LDL-C TO HDL-C. POLICOSANOL WAS WELL TOLERATED WITHOUT ANY SERIOUS ADVERSE EVENTS.","","","","","GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GREYLING A., ET AL., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006)","","","ENGLISH","ALTERN. THER. WOMENS HEALTH","REVIEW","ISI","2-S2.0-33845995470","ALTERN THER WOMENS HEALTH",NA,"NOTREPORTED",NA,"BROWN D, 2006, ALTERN THER WOMENS HEALTH","BROWN D, 2006, ALTERN THER WOMENS HEALTH"
"LIN Y;RUDRUM M;VAN D W R;TRAUTWEIN E;MCNEILL G;SIERKSMA A;MEIJER G","LIN, YUGUANG (56169671000); RUDRUM, MIKE (8152691400); VAN DER WIELEN, REGGY P.J. (6602749651); TRAUTWEIN, ELKE A. (7004887034); MCNEILL, GERALD (7005688294); SIERKSMA, AAFJE (6603477144); MEIJER, GERT W. (7201531104)","WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS",2004,"METABOLISM: CLINICAL AND EXPERIMENTAL","53","5",67,"10.1016/j.metabol.2004.05.006","UNILEVER HEALTH INSTITUTE, UNILEVER RANDD, VLAARDINGEN, NETHERLANDS, UNILEVER HEALTH INSTITUTE, UNILEVER RANDD, PO BOX 114, 3130 THE, AC VLAARDINGEN, NETHERLANDS;UNILEVER HEALTH INSTITUTE, UNILEVER RANDD, VLAARDINGEN, NETHERLANDS;UNILEVER HEALTH INSTITUTE, UNILEVER RANDD, VLAARDINGEN, NETHERLANDS;UNILEVER HEALTH INSTITUTE, UNILEVER RANDD, VLAARDINGEN, NETHERLANDS;LODERS CROKLAAN, GLEN ELLYN, IL, UNITED STATES;UNILEVER HEALTH INSTITUTE, UNILEVER RANDD, VLAARDINGEN, NETHERLANDS;LODERS CROKLAAN, GLEN ELLYN, IL, UNITED STATES","SUGAR CANE POLICOSANOL, A MIXTURE OF LONG-CHAIN PRIMARY ALCOHOLS (∼67% AS OCTACOSANOL), HAS BEEN REPORTED TO LOWER PLASMA LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL. WE INVESTIGATED THE EFFECT OF WHEAT GERM POLICOSANOL (WGP) ON PLASMA LIPID PROFILES IN 58 ADULTS (30 MEN AND 28 WOMEN, AGED 49 ± 11 YEARS) WITH NORMAL TO MILDLY ELEVATED PLASMA CHOLESTEROL CONCENTRATIONS IN A DOUBLE-BLIND, RANDOMIZED, PARALLEL PLACEBO-CONTROLLED STUDY. SUBJECTS CONSUMED CHOCOLATE PELLETS WITH OR WITHOUT 20 MG/D WGP FOR 4 WEEKS. PLASMA LIPID CONCENTRATIONS, ROUTINE BLOOD CHEMISTRY AND HEMATOLOGY WERE DETERMINED AT THE START AND THE END OF THE STUDY. THE INITIAL PLASMA TOTAL, LDL-CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL, AND TRIACYLGLYCEROL CONCENTRATIONS IN THE WGP AND THE CONTROL GROUPS WERE IDENTICAL. OVER THE 4 WEEKS, NEITHER THE WGP NOR THE CONTROL TREATMENT SIGNIFICANTLY CHANGED PLASMA TOTAL CHOLESTEROL, LDL- AND HDL-CHOLESTEROL, OR TRIACYLGLYCEROL CONCENTRATIONS WHEN COMPARED TO BASELINE VALUES. IN ADDITION, THERE WAS NO SIGNIFICANT DIFFERENCE IN PLASMA LIPID PROFILES BETWEEN THE WGP AND THE CONTROL GROUPS AT THE END OF THE STUDY. WGP DID NOT RESULT IN ANY ADVERSE EFFECTS AS INDICATED BY PLASMA ACTIVITIES OF L-Γ-GLUTAMYLTRANSFERASE (Γ-GT), ALT, AST, BILIRUBIN CONCENTRATIONS, AND BLOOD CELL PROFILES. CHEMICAL ANALYSIS SHOWED THAT WGP CONSISTS OF 8% HEXACOSANOL, 67% OCTACOSANOL, 12% TRIACOSANOL, AND 13% OTHER LONG-CHAIN ALCOHOLS, WHICH IS SIMILAR TO THE COMPOSITION OF SUGAR CANE POLICOSANOL. IN CONCLUSION, WGP AT 20 MG/D HAD NO BENEFICIAL EFFECTS ON BLOOD LIPID PROFILES. IT THEREFORE SEEMS UNLIKELY THAT THE LONG CHAIN (C24-34) ALCOHOLS HAVE ANY CHOLESTEROL-LOWERING ACTIVITY. © 2004 ELSEVIER INC. ALL RIGHTS RESERVED.","","ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BILIRUBIN; CHOLESTEROL; DIET; DIETARY FATS; DOUBLE-BLIND METHOD; ENERGY METABOLISM; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; TRITICUM; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEXACOSANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTACOSANOL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ANALYTIC METHOD; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD EXAMINATION; CACAO; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; WHEAT GERM","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); ALEMAN C., RODEIRO I., NOA M., ET AL., ONE-YEAR DOG TOXICITY STUDY OF D-002, A MIXTURE OF ALIPHATIC ALCOHOLS, J APPL TOXICOL, 21, PP. 179-184, (2001); RODRIGUEZ M.D., GAMEZ R., SANCHEZ M., ET AL., DEVELOPMENTAL TOXICITY OF D-002 (A MIXTURE OF ALIPHATIC PRIMARY ALCOHOLS) IN RATS AND RABBITS, J APPL TOXICOL, 18, PP. 313-316, (1998); WANG Y.W., JONES P.J., PISCHEL I., ET AL., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ORTENSI G., GLADSTEIN J., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THERAPEUT RES, 58, PP. 390-401, (1997); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTH, 59, PP. 268-279, (2002); YATCILLA M., POLICOSANOLS, CHOLESTEROL SOLUTION OR CONTROVERSIAL PROBLEM?, NUTRACEUTICALS WORLD APRIL, PP. 28-34, (2002); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); FEUNEKES G.I., VAN STAVEREN W.A., DE VRIES J.H., ET AL., RELATIVE AND BIOMARKER-BASED VALIDITY OF A FOOD-FREQUENCY QUESTIONNAIRE ESTIMATING INTAKE OF FATS AND CHOLESTEROL, AM J CLIN NUTR, 58, PP. 489-496, (1993); WESTSTRATE J.A., MEIJER G.W., PLANT STEROL-ENRICHED MARGARINES AND REDUCTION OF PLASMA TOTAL- AND LDL-CHOLESTEROL CONCENTRATIONS IN NORMOCHOLESTEROLAEMIC AND MILDLY HYPERCHOLESTEROLAEMIC SUBJECTS, EUR J CLIN NUTR, 52, PP. 334-343, (1998); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); RODEIRO I., ALEMAN C., NOA M., ET AL., PRECLINICAL ORAL TOXICOLOGY IN RATS OF D-002, A NATURAL DRUG WITH ANTIULCER EFFECTS, DRUG CHEM TOXICOL, 21, PP. 151-162, (1998); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); ALCOCER L., FERNANDEZ L., CAMPOS E., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); BATISTA J., STUSSER R., SAEZ F., ET AL., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); ARRUZAZABALA M.D., CARBAJAL D., MAS R., ET AL., EFFECTS OF D-003, A NEW COMPOUND PURIFIED FROM SUGARCANE WAX, ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS - A RANDOMISED, DOUBLE-BLIND CLINICAL STUDY, CLIN DRUG INVEST, 23, PP. 107-118, (2003); CABRERA L., RIVERO B., MAGRANER J., ET AL., STABILITY STUDIES OF TABLETS CONTAINING 5 MG OF POLICOSANOL, BOLL CHIM FARM, 142, PP. 277-284, (2003); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001)","","","ENGLISH","METAB. CLIN. EXP.","ARTICLE","ISI","2-S2.0-4544224336","METAB CLIN EXP",NA,"NOTREPORTED",NA,"LIN Y, 2004, METAB CLIN EXP","LIN Y, 2004, METAB CLIN EXP"
"COLUSSI G;CATENA C;BAROSELLI S;NADALINI E;LAPENNA R;CHIUCH A;SECHI L","COLUSSI, GIAN LUCA (8723796700); CATENA, CRISTIANA (7003677862); BAROSELLI, SARA (8723796600); NADALINI, ELISA (8723796800); LAPENNA, ROBERTA (8723796500); CHIUCH, ALESSANDRA (16318341600); SECHI, LEONARDO A. (35482238800)","OMEGA3 FATTY ACIDS FROM BIOCHEMISTRY TO THEIR CLINICAL USE IN THE PREVENTION OF CARDIOVASCULAR DISEASE",2007,"RECENT PATENTS ON CARDIOVASCULAR DRUG DISCOVERY","2","8",41,"10.2174/157489007779606158","DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY;DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY;DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY;DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY;DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY;DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY;DIVISION OF INTERNAL MEDICINE, DEPARTMENT OF EXPERIMENTAL AND CLINICAL PATHOLOGY AND MEDICINE, UNIVERSITY OF UDINE, UDINE, ITALY, HYPERTENSION UNIT, CLINICA MEDICA, UNIVERSITÀ DI UDINE, 33100 UDINE, PIAZALLE S. M. DELLA MISERICORDIA, 1, ITALY","Ω-3 AND Ω-6 POLYUNSATURATED FATTY ACIDS (PUFA) ARE THE MAJOR FAMILIES OF PUFA THAT CAN BE FOUND AS COMPONENTS OF THE HUMAN DIET. AFTER INGESTION, BOTH Ω-3 AND Ω-6 PUFA ARE DISTRIBUTED TO EVERY CELL IN THE BODY WHERE THEY ARE INVOLVED IN A MYRIAD OF PHYSIOLOGICAL PROCESSES, INCLUDING REGULATION OF CARDIOVASCULAR, IMMUNE, HORMONAL, METABOLIC, NEURONAL, AND VISUAL FUNCTIONS. AT THE CELL LEVEL, THESE EFFECTS ARE MEDIATED BY CHANGES IN MEMBRANE PHOSPHOLIPIDS STRUCTURE, INTERFERENCE WITH EICOSANOID INTRACELLULAR SIGNALING, AND REGULATION OF GENE EXPRESSION. TWO LONG-CHAIN Ω-3 PUFAS, THE DOCOSAHEXAENOIC (DRA) AND EICOSAPENTAENOIC (EPA) ACID, ARE FOUND IN FATTY FISH AND OTHER MARINE SOURCES AND MIGHT BE THE PUTATIVE DIETARY COMPONENTS THOUGHT TO MODIFY THE CARDIOVASCULAR RISK IN SUBJECTS CONSUMING HIGH AMOUNTS OF SUCH FOOD. EVIDENCE OF AN INVERSE RELATIONSHIP BETWEEN FATTY FISH INTAKE AND CARDIOVASCULAR RISK HAS, IN FACT, EMERGED IN STUDIES PERFORMED MORE THAN TWENTY YEARS AGO IN ESKIMOS AND HAS BEEN SUBSEQUENTLY CONFIRMED IN OTHER ETHNIC GROUPS. THE BENEFITS OF Ω-3 PUFA MIGHT RELATE PRINCIPALLY TO PREVENTION OF CORONARY HEART DISEASE, CORONARY ARTERY RESTENOSIS AFTER ANGIOPLASTY, AND SUDDEN ARRHYTHMIC DEATH. IN THIS BRIEF REVIEW, WE WILL COVER THE GENERAL BIOCHEMICAL ASPECTS OF Ω-3 PUFA, SUMMARIZE THE EVIDENCE RELATING THESE FATTY ACIDS WITH CONTROL OF CARDIOVASCULAR RISK FACTORS AND PREVENTION OF CARDIOVASCULAR EVENTS, AND OVERVIEW THE MOST RECENT AND RELEVANT PATENTS THAT ARE RELATED TO THESE ISSUES. MORE SPECIFICALLY, WE WILL DEAL WITH THE POSSIBILITY TO USE PUFA IN ASSOCIATION WITH OTHER MOLECULES THAT CAN POTENTIATE THEIR ANTIINFLAMMATORY AND ANTIATHEROGENIC EFFECTS. © 2007 BENTHAM SCIENCE PUBLISHERS LTD.","Ω-3 POLYUNSATURATED FATTY ACID; Ω-6 POLYUNSATURATED FATTY ACIDS; ARRHYTHMIA; ASPIRIN; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY HEART DISEASE; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; INFLAMMATION; POLICOSANOL; STATINS","ANIMALS; ARRHYTHMIAS, CARDIAC; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIET; FATTY ACIDS, OMEGA-3; HUMANS; HYPERTENSION; ALPHA TOCOPHEROL; ATORVASTATIN; DOCOSAHEXAENOIC ACID; ESAPENT; ESKIM; ICOSANOID; ICOSAPENTAENOIC ACID; MEMBRANE PHOSPHOLIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; SIMVASTATIN; UNCLASSIFIED DRUG; ADD ON THERAPY; ANGIOPLASTY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET; ENDOCRINE FUNCTION; ESKIMO; ETHNIC GROUP; FATTY ACID TRANSPORT; FISH; FOOD INTAKE; GENE EXPRESSION REGULATION; HEART ARRHYTHMIA; HUMAN; IMMUNE SYSTEM; INGESTION; ISCHEMIC HEART DISEASE; MONOTHERAPY; NERVOUS SYSTEM; PRIORITY JOURNAL; REGULATORY MECHANISM; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SUDDEN DEATH; VISION","","","KRIS-ETHERTON P.M., TAYLOR D.S., YU-POTH S., ET AL., POLYUNSATURATED FATTY ACIDS IN THE FOOD CHAIN IN THE UNITED STATES, AM J CLIN NUTR, 71, (2000); BANG H.O., DYERBERG J., HJOORNE T., THE COMPOSITION OF FOOD CONSUMED BY GREENLAND ESKIMOS, ACTA MED SCAND, 200, PP. 69-73, (1976); BANG H.O., DYERBERG J., SINCLAIR H.M., THE COMPOSITION OF THE ESKIMO FOOD IN NORTH WESTERN GREENLAND, AM J CLIN NUTR, 33, PP. 2657-2661, (1980); MIDDAUGH J.P., CARDIOVASCULAR DEATHS AMONG ALASKAN NATIVES, 1980-86, AM J PUBLIC HEALTH, 80, PP. 282-285, (1990); NEWMAN W.P., MIDDAUGH J.P., PROPST M.T., ROGER D.R., ATHEROSCLEROSIS IN ALASKA NATIVES AND NON-NATIVES, LANCET, 341, PP. 1056-1057, (1993); JUMP D.B., THE BIOCHEMISTRY OF N-3 POLYUNSATURATED FATTY ACIDS, J BIOL CHEM, 277, PP. 8755-8758, (2002); IKONEN E., ROLES OF LIPID RAFTS IN MEMBRANE TRANSPORT, CURR OPIN CELL BIOL, 13, PP. 470-477, (2001); HWANG D., FATTY ACIDS AND IMMUNE RESPONSES-A NEW PERSPECTIVE IN SEARCHING FOR CLUES TO MECHANISMS, ANNU REV NUTR, 20, PP. 431-456, (2000); SELLMAYER A., HRBOTICKY N., WEBER P.C., LIPIDS IN VASCULAR FUNCTION, LIPIDS, 34, (1999); SERHAN C.N., CLISH C.B., (2006); LINDEBERG S., LUNDH B., APPARENT ABSENCE OF STROKE AND ISCHAEMIC HEART DISEASE IN A TRADITIONAL MELANESIAN ISLAND: A CLINICAL STUDY IN KITAVA, J INTERN MED, 233, PP. 269-275, (1993); HIRAI A., TERANO T., TAMURA Y., YOSHIDA S., EICOSAPENTAENOIC ACID AND ADULT DISEASES IN JAPAN: EPIDEMIOLOGICAL AND CLINICAL ASPECTS, J INTERN MED, 225, PP. 69-75, (1989); KROMHOUT D., BOSSCHIETER E.B., DE LEZENNE COULANDER C., THE INVERSE RELATION BETWEEN FISH CONSUMPTION AND 20-YEAR MORTALITY FROM CORONARY HEART DISEASE, N ENGL J MED, 312, PP. 1205-1209, (1985); SHEKELLE R.B., MISSEL L.V., PAUL O., ET AL., FISH CONSUMPTION AND MORTALITY FROM CORONARY HEART DISEASE, N ENGL J MED, 313, (1985); DAVIGLUS M.L., STAMLER J., ORENCIA A.J., ET AL., FISH CONSUMPTION AND THE 30-YEAR RISK OF FATAL MYOCARDIAL INFARCTION, N ENGL J MED, 336, PP. 1046-1053, (1997); OOMEN C.M., FESKENS E.J., RASANEN L., ET AL., FISH CONSUMPTION AND CORONARY HEART DISEASE MORTALITY IN FINLAND, ITALY, AND THE NETHERLANDS, AM J EPIDEMIOL, 151, PP. 999-1006, (2000); HU F.B., BRONNER L., WILLET W.C., ET AL., FISH AND OMEGA-3 FATTY ACID INTAKE AND RISK OF CORONARY HEART DISEASE IN WOMEN, JAMA, 287, PP. 1815-1821, (2002); MOZAFFARIAN D., LEMAITRE R.N., KULLER L.H., ET AL., CARDIAC BENEFITS OF FISH CONSUMPTION MAY DEPEND ON THE TYPE OF FISH MEAL CONSUMED: THE CARDIOVASCULAR HEALTH STUDY, CIRCULATION, 107, PP. 1372-1377, (2003); CURB J.D., REED D.M., FISH CONSUMPTION AND MORTALITY FROM CORONARY HEART DISEASE, N ENGL J MED, 313, (1985); VOLLET S., HEUCH I., BJELKE E., FISH CONSUMPTION AND MORTALITY FROM CORONARY HEART DISEASE, N ENGL J MED, 313, PP. 820-821, (1985); ASCHERIO A., RIMM E.B., STAMPFER M.J., ET AL., DIETARY INTAKE OF MARINE N-3 FATTY ACIDS, FISH INTAKE, AND THE RISK OF CORONARY DISEASE AMONG MEN, N ENGL J MED, 332, PP. 977-982, (1995); SALONEN J.T., NYYSSONEN K., SALONEN R., FISH INTAKE AND THE RISK OF CORONARY DISEASE, N ENGL J MED, 333, (1995); RODRIGUEZ B.L., SHARP D.S., ABBOT R.D., ET AL., FISH INTAKE MAY LIMIT THE INCREASE IN CORONARY HEART DISEASE MORBIDITY AND MORTALITY AMONG HEAVY SMOKERS: THE HONOLULU HEART PROGRAM, CIRCULATION, 94, PP. 952-956, (1996); ALBERT C.M., HENNEKENS C.H., O'DONNELL C.J., ET AL., FISH CONSUMPTION AND RISK OF SUDDEN CARDIAC DEATH, JAMA, 279, PP. 23-28, (1998); OSLER M., ANDREASEN A.H., HOIDRUP S., NO INVERSE ASSOCIATION BETWEEN FISH CONSUMPTION AND RISK OF DEATH FROM ALL-CAUSES, AND INCIDENCE OF CORONARY HEART DISEASE IN MIDDLE-AGED, DANISH ADULTS, J CLIN EPIDEMIOL, 56, PP. 274-279, (2003); GUALLAR E., HENNEKENS C.H., SACKS F.M., ET AL., A PROSPECTIVE STUDY OF PLASMA FISH OIL LEVELS, AND INCIDENCE OF MYOCARDIAL INFARCTION IN US MALE PHYSICIANS, J AM COLL CARDIOL, 25, PP. 387-394, (1995); SISCOVICK D.S., RAGHUNATHAN T.E., KING I., ET AL., DIETARY INTAKE AND CELL MEMBRANE LEVELS OF LONG-CHAIN N-3 POLYUNSATURATED FATTY ACIDS AND THE RISK OF PRIMARY CARDIAC ARREST, JAMA, 274, PP. 1363-1367, (1995); BURR M.L., FEHILY A.M., GILBERT J.F., ET AL., EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART), LANCET, 2, PP. 757-761, (1989); DE LORGERIL M., RENAUD S., MAMELLE N., ET AL., MEDITERRANEAN ALPHA-LINOLENIC ACID-RICH DIET IN SECONDARY PREVENTION OF CORONARY HEART DISEASE, LANCET, 343, PP. 1454-1459, (1994); DE LORGERIL M., SALEN P., MARTIN J.L., MONJAUD I., DELAYE J., MAMELLE N., MEDITERRANEAN DIET, TRADITIONAL RISK FACTORS, AND THE RATE OF CARDIOVASCULAR COMPLICATIONS AFTER MYOCARDIAL INFARCTION: FINAL REPORT OF THE LYON DIET HEART STUDY, CIRCULATION, 99, PP. 779-785, (1999); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO, LANCET, 3554, PP. 447-455, (1999); ALBERT C.M., CAMPOS H., STAMPFER M.J., ET AL., BLOOD LEVELS OF LONG-CHAIN N-3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH, N ENGL J MED, 346, PP. 1113-1118, (2002); GUALLAR A., ARO A., JIMENEZ F.J., MARTIN-MORENO J.M., ET AL., OMEGA-3 FATTY ACIDS IN ADIPOSE TISSUE AND RISK OF MYOCARDIAL INFARCTION: THE EURAMIC STUDY, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 1111-1118, (1999); HE K., SONG Y., DAVIGLUS M.L., ET AL., ACCUMULATED EVIDENCE OF FISH OIL CONSUMPTION AND CORONARY HEART DISEASE MORTALITY: A META-ANALYSIS OF COHORT STUDIES, CIRCULATION, 109, PP. 2705-2711, (2004); KONIG A., BOUZAN C., COHEN J.T., ET AL., A QUANTITATIVE ANALYSIS OF FISH CONSUMPTION AND CORONARY HEART DISEASE MORTALITY, AM J PREV MED, 29, PP. 335-346, (2005); HARPER C.R., JACOBSON T.A., USEFULNESS OF OMEGA-3 FATTY ACIDS AND THE PREVENTION OF CORONARY HEART DISEASE, AM J CARDIOL, 96, PP. 1521-1529, (2005); BUCHER H.C., HENGSTLER P., SCHINDLER C., ET AL., N-3 POLYUNSTAURATED FATTY ACIDS IN CORONARY HEART DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 112, PP. 298-304, (2002); WHELTON S.P., HE J., WHELTON P.K., ET AL., META-ANALYSIS OF OBSERVATIONAL STUDIES ON FISH INTAKE AND CORONARY HEART DISEASE, AM J CARDIOL, 93, PP. 1119-1123, (2004); YZEBE D., LIEVRE M., FISH OILS IN THE CARE OF CORONARY HEART DISEASE PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, FUNDAM CLIN PHARMACOL, 18, PP. 581-592, (2004); HOOPER L., THOMPSON R.L., HARRISON R.A., ET AL., OMEGA 3 FATTY ACIDS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, COCHRANE DATABASE SYST REV, (2004); COVINGTON M.B., OMEGA-3 FATTY ACIDS, AM FAM PHYSICIAN, 70, PP. 133-140, (2004); HOWE P.R., DIETARY FATS AND HYPERTENSION. FOCUS ON FISH OIL, ANN N Y ACAD SCI, 827, PP. 339-352, (1997); BONAA K.H., BJERVE K.S., STRAUME B., ET AL., EFFECT OF EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS ON BLOOD PRESSURE IN HYPERTENSION. A POPULATION-BASED INTERVENTION TRIAL FROM THE TROMSO STUDY, N ENGL J MED, 322, PP. 795-801, (1990); PRISCO D., PANICCIA R., BANDINELLI B., ET AL., EFFECT OF MEDIUM-TERM SUPPLEMENTATION WITH A MODERATE DOSE OF N-3 POLYUNSATURATED FATTY ACIDS ON BLOOD PRESSURE IN MILD HYPERTENSIVE PATIENTS, THROMB RES, 91, PP. 105-112, (1998); KNAPP H.R., FITZGERALD G.A., THE ANTIHYPERTENSIVE EFFECTS OF FISH OIL. A CONTROLLED STUDY OF POLYUNSATURATED FATTY ACID SUPPLEMENTS IN ESSENTIAL HYPERTENSION, N ENGL J MED, 320, PP. 1037-1043, (1989); MORRIS M.C., SACKS F., ROSNER B., DOES FISH OIL LOWER BLOOD PRESSURE? A META-ANALYSIS OF CONTROLLED TRIALS, CIRCULATION, 88, PP. 523-533, (1993); HARRIS W.S., GINSBERG H.N., ARUNAKUL N., ET AL., SAFETY AND EFFICACY OF OMACOR IN SEVERE HYPERTRIGLYCERIDEMIA, J CARDIOVASC RISK, 4, PP. 385-391, (1997); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEINS: HUMAN STUDIES, AM J CLIN NUTR, 65, PP. 1645-1654, (1997); HONG H., XU Z.M., PANG B.S., ET AL., EFFECTS OF SIMVASTAIN COMBINED WITH OMEGA-3 FATTY ACIDS ON HIGH SENSITIVE C-REACTIVE PROTEIN, LIPIDEMIA, AND FIBRINOLYSIS IN PATIENTS WITH MIXED DYSLIPIDEMIA, CHIN MED SCI J, 19, PP. 145-149, (2004); NORDOY A., HANSEN J.B., BROX J., ET AL., EFFECTS OF ATORVASTATIN AND OMEGA-3 FATTY ACIDS ON LDL SUBFRACTIONS AND POSTPRANDIAL HYPERLIPEMIA IN PATIENTS WITH COMBINED HYPERLIPEMIA, NUTR METAB CARDIOVASC DIS, 11, PP. 7-16, (2001); NORDOY A., BONAA K.H., SANDSET P.M., ET AL., EFFECT OF OMEGA-3 FATTY ACIDS AND SIMVASTATIN ON HEMOSTATIC RISK FACTORS AND POSTPRANDIAL HYPERLIPEMIA IN PATIENTS WITH COMBINED HYPERLIPEMIA, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 259-265, (2000); CATENA C., NOVELLO M., LAPENNA R., ET AL., NEW RISK FACTORS FOR ATHEROSCLEROSIS IN HYPERTENSION: FOCUS ON THE PROTHROMBOTIC STATE AND LIPOPROTEIN(A), J HYPERTENS, 23, PP. 1617-1631, (2005); COLUSSI G.L., BAROSELLI S., SECHI L.A., Ω-3 POLYUNSATURATED FATTY ACIDS DECREASE PLASMA LIPOPROTEIN(A) LEVELS IN HYPERTENSIVE SUBJECTS, CLIN NUTR, 23, PP. 1246-1247, (2004); O'LEARY D.H., POLAK J.F., KRONMAL R.A., ET AL., CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS. CARDIOVASCULAR HEALTH STUDY COLLABORATIVE RESEARCH GROUP, N ENGL J MED, 340, PP. 14-22, (1999); YAMADA T., MALCOM G.T., STRONG J.P., ET AL., DIFFERENCE IN ATHEROSCLEROSIS BETWEEN THE POPULATIONS OF A FISHING AND A FARMING VILLAGE IN JAPAN, ANN NY ACAD SCI, 811, PP. 412-419, (1997); DJOUSSE L., FOLSOM A.R., PROVINCE M.A., HUNT S.C., ELLISON R.C., DIETARY LINOLENIC ACID AND CAROTID ATHEROSCLEROSIS : THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE FAMILY HEART STUDY, AM J CLIN NUTR, 77, PP. 819-825, (2003); ANGERER P., KOTHNY W., STORK S., VON SCHACKY C., EFFECT OF DIETARY SUPPLEMENTATION WITH OMEGA-3 FATTY ACIDS ON PROGRESSION OF ATHEROSCLEROSIS IN CAROTID ARTERIES, CARDIOVASC RES, 54, PP. 183-190, (2002); DE CATERINA R., MADONNA R., MASSARO M., EFFECTS OF OMEGA-3 FATTY ACIDS ON CYTOKINES AND ADHESION MOLECULES, CURR ATHEROSCLER REP, 6, PP. 485-491, (2004); MILES E.A., THIES F., WALLACE F.A., ET AL., INFLUENCE OF AGE AND DIETARY FISH OIL ON PLASMAS SOLUBLE ADHESION MOLECULE CONCENTRATIONS, CLIN SCI, 100, PP. 91-100, (2001); BAUMANN K.H., HESSEL F., LARASS I., ET AL., DIETARY Ω-3, Ω-6, AND Ω-9 UNSATURATED FATTY ACIDS AND GROWTH FACTOR AND CYTOKINE GENE EXPRESSION IN UNSTIMULATED AND STIMULATED MONOCYTES, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 59-66, (1999); SPERLING R.I., BENINCASO A.I., KNOELL C.T., LARKIN J.K., AUSTEN K.F., ROBINSON D.R., DIETARY Ω-3 POLYUNSATURATED FATTY ACIDS INHIBIT PHOSPHOINOSITIDE FORMATION AND CHEMOTAXIS IN NEUTROPHILS, J CLIN INVEST, 91, PP. 651-660, (1993); LIBBY P., INFLAMMATION IN ATHEROSCLEROSIS, NATURE, 420, PP. 868-874, (2002); MASSARO M., BASTA G., LAZZERINI G., ET AL., QUENCHING OF INTRACELLULAR ROS GENERATION AS A MECHANISM FOR OLEATE-INDUCED REDUCTION OF ENDOTHELIAL ACTIVATION AND EARLY ATHEROGENESIS, THROMB HAEMOST, 88, PP. 335-344, (2002); DE CATERINA R., CYBULSKY M.I., CLINTON S.K., GIMBRONE JR M.A., LIBBY P., THE OMEGA-3 FATTY ACID DOCOSAHEXAENOATE REDUCES CYTOKINE-INDUCED EXPRESSION OF PROATHEROGENIC AND PROINFLAMMATORY PROTEINS IN HUMAN ENDOTHELIAL CELLS, ARTERIOSCLER THROMB, 14, PP. 1829-1836, (1994); DE CATERINA R., BERNINI W., CARLUCCIO M.A., LIAO J.K., LIBBY P., STRUCTURAL REQUIREMENTS FOR INHIBITION OF CYTOKINE-INDUCED ENDOTHELIAL ACTIVATION BY UNSATURATED FATTY ACIDS, J LIPID RES, 39, PP. 1062-1070, (1998); MARCHIOLI R., SCHWEIGER C., TAVAZZI L., VALAGUSSA F., EFFECT OF Ω-3 POLYUNSATURATED FATTY ACIDS AFTER MYOCARDIAL INFARCTION: RESULTS OF GISSI-PREVENZIONE TRIAL. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO DEL MIOCARDIO, LIPIDS, 36, (2001); SINGH R.B., NIAZ M.A., SHARMA J.P., KUMAR R., RASTOGI V., MOSHIRI M., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF FISH OIL AND MUSTARD OIL IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL INFARCTION: THE INDIAN EXPERIMENT OF INFARCT SURVIVAL-4, CARDIOVASC; DRUGS THER, 11, PP. 485-491, (1997); SINGH R.B., DUBNOV G., NIAZ M.A., ET AL., EFFECT OF INDO-MEDITERRANEAN DIET ON PROGRESSION OF CORONARY ARTERY DISEASE IN HIGH-RISK PATIENTS (INDO-MEDITERRANEAN DIET HEART STUDY): A RANDOMIZED SINGLE-BLIND TRIAL, LANCET, 360, PP. 1455-1461, (2002); MARCHIOLI R., BARZI F., BOMBA E., ET AL., EARLY PROTECTION AGAINST SUDDEN CARDIAC DEATH BY N-3 POLYUNSATURATED FATTY ACIDS AFTER MYOCARDIAL INFARCTION, CIRCULATION, 105, PP. 1897-1903, (2002); MATTHAN N.R., JORDAN H., CHUNG M., LICHTENSTEIN A.H., LATHROP D.A., LAU J., A SYSTEMATIC REVIEW META-ANALYSIS OF THE IMPACT OF Ω-3 FATTY ACIDS ON SELECTED ARRHYTHMIA OUTCOMES IN ANIMAL MODELS, METABOLISM, 54, PP. 1557-1565, (2005); RAITT M., CONNER W., MORRIS C., ET AL., ANTIARRHYTHMIC EFFECTS OF N-3 POLYUNSATURATED FATTY ACIDS IN SURVIVORS OF VENTRICULAR TACHYARRHYTHMIAS, CIRCULATION, 108, (2003); MAGGIONI A.P., TAVAZZI L., MARCHIOLI R., TOGNONI G., AVANZINI F., RONCAGLIONI M.G., PERSPECTIVES ON N-3 PUFAS: PRIMARY PREVENTION, ANTIARRHYTHMIC EFFECTS, CONGESTIVE HEAT FAILURE, EUR HEART J, 3, (2002); BROWER I.A., ZOCK P.L., WEVER E.F.D., ET AL., RATIONALE AND DESIGN OF RANDOMIZED CONTROLLED CLINICAL TRIAL ON SUPPLEMENTAL INTAKE OF N-3 FATTY ACIDS AND INCIDENCE OF CARDIAC ARRHYTHMIA: SOFA, EUR J CLIN NUTR, 57, PP. 1323-1330, (2003); SCHREPF R., LIMMERT T., WEBER P.C., THEISEN K., SELLMAYER A., IMMEDIATE EFFECTS OF N-3 FATTY ACID INFUSION ON THE INDUCTION OF SUSTAINED VENTRICULAR TACHYCARDIA, LANCET, 363, PP. 1441-1442, (2004); CALO L., BIANCONI L., COLIVICCHI F., ET AL., N-3 FATTY ACIDS FOR THE PREVENTION OF ATRIAL FIBRILLATION AFTER CORONARY ARTERY BYPASS SURGERY: A RANDOMIZED, CONTROLLED TRIAL, J AM COLL CARDIOL, 45, PP. 1723-1728, (2005); MCLENNAN P.L., ABEYWARDENA M.Y., CHARNOCK J.S., DIETARY FISH OIL PREVENTS VENTRICULAR FIBRILLATION FOLLOWING CORONARY ARTERY OCCLUSION AND REPERFUSION, AM HEART J, 116, PP. 709-717, (1988); LEAF A., JORGENSEN M.B., JACOBS A.K., ET AL., DO FISH OIL PREVENT RESTENOSIS AFTER CORONARY ANGIOPLASTY?, CIRCULATION, 90, PP. 2248-2257, (1994); GRIMMINGER F., GRIMM H., FUHRER D., ET AL., OMEGA-3 LIPID INFUSION IN A HEART ALLOTRANSPLANT MODEL: SHIFT IN FATTY ACID AND LIPID MEDIATOR PROFILES AND PROLONGATION OF TRANSPLANT SURVIVAL, CIRCULATION, 93, PP. 365-371, (1996); KANG J.X., LEAF A., EFFECTS OF LONG-CHAIN POYUNSATURATED FATTY ACIDS ON THE CONTRACTION OF NEONATAL RAT CARDIAC MYOCYTES, PROC NATL ACAD SCI USA, 91, PP. 9886-9890, (1994); MCLENNAN P.L., MYOCARDIAL MEMBRANE FATTY ACIDS AND THE ANTIARRHYTHMIC ACTIONS OF DIETARY FISH OIL IN ANIMAL MODELS, LIPIDS, 36, (2001); LEIFERT W.R., JAHANGIRI A., MCMURCHIE E.J., MEMBRANE FLUIDITY CHANGES ARE ASSOCIATED WITH ANTIARRHYTHMIC EFFECTS OF DOCOSA-HEXAENOIC ACID IN ADULT RAT CARDIOMYOCYTES, J NUTR BIOCHEM, 11, PP. 38-44, (2000); GRYNBERG A., FOURNIER A., SERGIEL J.P., ATHIAS P., MEMBRANE DOCOSAHEXAENOIC ACID VS. EICOSAPENTAENOIC ACID AND THE BEATING FUNCTION OF THE CARDIOMYOCYTE AND ITS REGULATION THROUGH THE ADRENERGIC RECEPTORS, LIPIDS, 31, PP. 205-210, (1996); DAI J., WILLIAMS S.A., ZEIGHELHOFFER A., STRUCTURE-ACTIVITY RELATIONSHIP OF THE EFFECT OF DIETARY SUPPLEMENTATION OF FISH OIL ON EXPERIMENTAL MYOCARDIAL INFARCTION, CIRC RES, 52, PP. 167-171, (1995); CHARNOCK J.S., OMEGA-3 POLYUNSATURATED FATTY ACIDS AND VENTRICULAR FIBRILLATION: THE POSSIBLE INVOLVEMENT OF EICOSANOIDS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 61, PP. 243-247, (1999); XIAO Y.F., KANG J.X., MORGAN J.P., LEAF A., BLOCKING AFFECTS OF POLYUNSATURATED FATTY ACIDS ON NA<SUP>+</SUP> CHANNELS OF NEONATAL RAT VENTRICULAR MYOCYTES, PROC NATL ACAD SCI USA, 92, PP. 11000-11004, (1995); XIAO Y.F., GOMEZ A.M., MORGAN J.P., LEDERER W.J., LEAF A., SUPPRESSION OF VOLTAGE-GATED L-TYPE CA<SUP>2+</SUP> CURRENTS BY POLYUNSATURATED FATTY ACIDS IN ADULT AND NEONATAL RAT VENTRICULAR MYOCYTES, PROC NATL ACAD SCI USA, 94, PP. 4182-4187, (1997); BERLIN R.; KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE. AMERICAN HEART ASSOCIATION NUTRITION COMMITTEE, CIRCULATION, 106, PP. 2747-2757, (2002); VAN DE WERF F., ARDISSINO D., BETRIU A., ET AL., MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH ST-SEGMENT ELEVATION, EUR HEART J, 24, PP. 26-66, (2003)","L.A. SECHI; HYPERTENSION UNIT, CLINICA MEDICA, UNIVERSITÀ DI UDINE, 33100 UDINE, PIAZZALE S. M. DELLA MISERICORDIA, 1, ITALY; EMAIL: SECHI@UNIUD.IT","","ENGLISH","RECENT PAT. CARDIOVASC. DRUG DISCOV.","REVIEW","ISI","2-S2.0-34249301400","RECENT PAT CARDIOVASC DRUG DISCOV","UNIVERSITY OF UDINE;UNIVERSITY OF UDINE;UNIVERSITY OF UDINE;UNIVERSITY OF UDINE;UNIVERSITY OF UDINE;UNIVERSITY OF UDINE;UNIVERSITY OF UDINE","NOTREPORTED;UNIVERSITÀ DI UDINE;NOTREPORTED",NA,"COLUSSI GL, 2007, RECENT PAT CARDIOVASC DRUG DISCOV","COLUSSI GL, 2007, RECENT PAT CARDIOVASC DRUG DISCOV"
"CALVO R J;LIMA R E","CALVO ROMERO, J.M. (7006201358); LIMA RODRÍGUEZ, E.M. (6506214878)","NATURAL TREATMENTS OF HYPERCHOLESTEROLEMIA TRATAMIENTOS NATURALES DE LA HIPERCOLESTEROLEMIA",2006,"REVISTA CLINICA ESPANOLA","206","2",0,"10.1157/13094900","SERVICIO DE MEDICINA INTERNA, HOSPITAL CIUDAD DE CORIA, CORIA, CÁCERES, SPAIN, 06010 BADAJOZ, C./ SERGIO LUNA 15, SPAIN;MEDICINA FAMILIAR Y COMUNITARIA, ÁREA DE SALUD DE CORIA, CÁCERES, SPAIN","IN THIS ARTICLE WE BRIEFLY REVIEW THE EVIDENCE ON THE EFFECT OF DIFFERENT «NATURAL» PRODUCTS ON CHOLESTEROLEMIA. PLANT STANOLS AND STEROLS REDUCE CHOLESTEROL INTESTINAL ABSORPTION AND DECREASE TOTAL AND LDL CHOLESTEROL BY APPROXIMATELY 10%. POLYCOSANOL IS A MIXTURE OF SATURATED ALCOHOLS THAT SEEM TO INHIBIT CHOLESTEROL HEPATIC SYNTHESIS AND DECREASE TOTAL AND LDL CHOLESTEROL BY UP TO 25%. THE EFFECTS ON THE CHOLESTOROLEMIA OF SOY AND SOLUBLE FIBER ARE MODEST.","HYPERCHOLESTEROLEMIA; POLYCOSANOL; TREATMENT","DIETARY FIBER; FATTY ALCOHOLS; HUMANS; HYPERCHOLESTEROLEMIA; PHYTOSTEROLS; PLANT PREPARATIONS; SITOSTEROLS; SOYBEANS; ALCOHOL; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; PHYTOSTEROL; STANOL ESTER; 1 OCTACOSANOL; 1-OCTACOSANOL; FATTY ALCOHOL; PHYTOSTEROL; PLANT MEDICINAL PRODUCT; SITOSTEROL DERIVATIVE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DIETARY FIBER; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LIVER; REVIEW; SOYBEAN; DIETARY FIBER","INSTITUTE OF INFECTION AND IMMUNITY","EN LOS ÚLTIMOS AÑOS SE HAN PUBLICITADO AMPLIAMENTE LOS EFECTOS BENEFICIOSOS SOBRE LA COLESTEROLEMIA DE DI-FERENTES PRODUCTOS «NATURALES». LAS RECOMENDACIONES DEL ATP III INCLUYEN EL CONSUMO DE ESTANOLES O ESTE-ROLES VEGETALES, SOJA Y FIBRA SOLUBLE COMO OPCIONES PARA CONSEGUIR UNA MAYOR REDUCCIÓN DEL COLESTEROL LDL1.EN ESTE ARTÍCULO REALIZAMOS UNA BREVE REVISIÓN DE LA EVI-DENCIA DISPONIBLE SOBRE EL EFECTO EN LA COLESTEROLEMIA DE VARIOS PRODUCTOS «NATURALES».","THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, PP. 3143-3421, (2002); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, PP. 965-978, (2003); MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N ENGL J MED, 333, PP. 1308-1312, (1995); NGUYEN T.T., DALE L.C., VON BERGMANN K., CROGHAN I.T., CHOLESTEROL-LOWERING EFFECT OF STANOL ESTER IN A US POPULATION OF MILDLY HYPERCHOLESTEROLEMIC MEN AND WOMEN: A RANDOMIZED CONTROLLED TRIAL, MAYO CLIN PROC, 74, PP. 1198-1206, (1999); ALGORTA PINEDA J., CHINCHETRU RANEDO M.J., AGUIRRE ANDA J., FRANCISCO TERREROS S., EFICACIA HIPOCOLESTEROLEMIANTE DE UN YOGUR QUE CONTIENE ÉSTERES DE ESTANOL VEGETAL, REV CLIN ESP, 205, PP. 63-66, (2005); O'NEILL F.H., SANDERS T.A., THOMPSON G.R., COMPARISON OF EFFICACY OF PLANT STANOL ESTER AND STEROL ESTER: SHORT-TERM AND LONGER-TERM STUDIES, AM J CARDIOL, 96, 1 A, (2005); THOMPSON G.R., ADDITIVE EFFECTS OF PLANT STEROL AND STANOL ESTERS TO STATIN THERAPY, AM J CARDIOL, 96, 1 A, (2005); BLAIR S.N., CAPUZZI D.M., GOTTLIEB S.O., NGUYEN T., MORGAN J.M., CATER N.B., INCREMENTAL REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH THE ADDITION OF PLANT STANOL ESTER-CONTAINING SPREAD TO STATIN THERAPY, AM J CARDIOL, 86, PP. 46-52, (2000); HOMMA Y., IKEDA I., ISHIKAWA T., TATENO M., SUGANO M., NAKAMURA H., DECREASE IN PLASMA LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, CHOLESTERYL ESTER TRANSFER PROTEIN, AND OXIDIZED LOW-DENSITY LIPOPROTEIN BY PLANT STANOL ESTER-CONTAINING SPREAD: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL, NUTRITION, 19, PP. 369-374, (2003); PLAT J., VAN ONSELEN E.N., VAN HEUGTEN M.M., MENSINK R.P., EFFECTS ON SERUM LIPIDS, LIPOPROTEINS AND FAT SOLUBLE ANTIOXIDANT CONCENTRATIONS OF CONSUMPTION FREQUENCY OF MARGARINES AND SHORTENINGS ENRICHED WITH PLANT STANOL ESTERS, EUR J CLIN NUTR, 54, PP. 671-677, (2000); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); PUSKA P., KORPELAINEN V., HOIE L.H., SKOVLUND E., LAHTI T., SMERUD K.T., SOY IN HYPERCHOLESTEROLAEMIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EUR J CLIN NUTR, 56, PP. 352-357, (2002); ZHAN S., HO S.C., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN CONTAINING ISOFLAVONES ON THE LIPID PROFILE, AM J CLIN NUTR, 81, PP. 397-408, (2005); HOIE L.H., MORGENSTERN E.C., GRUENWALD J., GRAUBAUM H.J., BUSCH R., LUDER W., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL COMPARES THE CHOLESTEROL-LOWERING EFFECTS OF TWO DIFFERENT SOY PROTEIN PREPARATIONS IN HYPERCHOLESTEROLEMIC SUBJECTS, EUR J NUTR, 44, PP. 65-71, (2005); SIRTORI C.R., LOVATI M.R., SOY PROTEINS AND CARDIOVASCULAR DISEASE, CURR ATHEROSCLER REP, 3, PP. 47-53, (2001); DESROCHES S., MAUGER J.F., AUSMAN L.M., LICHTENSTEIN A.H., LAMARCHE B., SOY PROTEIN FAVORABLY AFFECTS LDL SIZE INDEPENDENTLY OF ISOFLAVONES IN HYPERCHOTESTEROLEMIC MEN AND WOMEN, J NUTR, 134, PP. 574-579, (2004); BRICARELLO L.P., KASINSKI N., BERTOLAMI M.C., FALUDI A., PINTO L.A., RELVAS W.G., ET AL., COMPARISON BETWEEN THE EFFECTS OF SOY MILK AND NON-FAT COW MILK ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, NUTRITION, 20, PP. 200-204, (2004); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., ELASHOFF R.M., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); THOMPSON COON J.S., ERNST E., HERBS FOR SERUM CHOLESTEROL REDUCTION: A SYSTEMATIC VIEW, J FAM PRACT, 52, PP. 468-478, (2003); ULBRICHT C., BASCH E., SZAPARY P., HARNMERNESS P., AXENTSEV S., BOON H., ET AL., GUGGUL FOR HYPERLIPIDEMIA: A REVIEW BY THE NATURAL STANDARD RESEARCH COLLABORATION, COMPLEMENT THER MED, 13, PP. 279-290, (2005); JENKINS D.J., KENDALL C.W., FAULKNER D., VIDGEN E., TRAUTWEIN E.A., PARKER T.L., ET AL., A DIETARY PORTFOLIO APPROACH TO CHOLESTEROL REDUCTION: COMBINED EFFECTS OF PLANT STEROLS, VEGETABLE PROTEINS, AND VISCOUS FIBERS IN HYPERCHOLESTEROLEMIA, METABOLISM, 51, PP. 1596-1604, (2002)","J.M. CALVO ROMERO; 06010 BADAJOZ, C./ SERGIO LUNA 15, SPAIN; EMAIL: JMCROMERO@ERESMAS.COM","EDICIONES DOYMA, S.L.","SPANISH","REV. CLIN. ESP.","ARTICLE","ISI","2-S2.0-33845288334","REV CLIN ESP","HOSPITAL CIUDAD DE CORIA;CÁCERES","NOTREPORTED;NOTREPORTED;EMAIL: JMCROMERO@ERESMAS.COM",NA,"CALVO ROMERO JM, 2006, REV CLIN ESP","CALVO ROMERO JM, 2006, REV CLIN ESP"
"CASTAÑO G;FERŃANDEZ L;MAS R;ILLNAIT J;GÁMEZ R;MENDOZA S;MESA M;FERNÁNDEZ J","CASTAÑO, G. (56232967100); FERŃANDEZ, L. (7202848319); MAS, R. (7007164572); ILLNAIT, J. (8631465800); GÁMEZ, R. (7003605346); MENDOZA, S. (7102759819); MESA, M. (36880545700); FERNÁNDEZ, J. (9432805500)","EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA",2005,"DRUGS IN R AND D","6","12",29,"10.2165/00126839-200506040-00003","SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), HAVANA CITY, 6990 OR 6880, PLAYA, PO BOX, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS PURIFIED FROM SUGARCANE WAX. THE MIXTURE HAS CHOLESTEROL-LOWERING EFFICACY, ITS SPECIFIC EFFECTS BEING TO REDUCE SERUM TOTAL (TC) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), AND TO INCREASE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C). THE EFFECTS OF POLICOSANOL ON TRIGLYCERIDES (TG) ARE MODEST AND INCONSISTENT. OMEGA-3 FATTY ACIDS (FA) FROM FISH OIL PROTECT AGAINST CORONARY DISEASE, MAINLY THROUGH ANTIARRHYTHMIC AND ANTIPLATELET EFFECTS. OMEGA-3 FA ALSO HAVE LIPID-MODIFYING EFFECTS, MOSTLY RELATING TO TG REDUCTION. THUS, POTENTIAL BENEFITS COULD BE EXPECTED FROM COMBINED THERAPY WITH OMEGA-3 FA AND POLICOSANOL. OBJECTIVE: TO INVESTIGATE WHETHER COMBINED THERAPY WITH OMEGA-3 FA + POLICOSANOL OFFERS BENEFITS COMPARED WITH OMEGA-3 FA + PLACEBO WITH RESPECT TO THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA. METHODS: THIS RANDOMISED, DOUBLE-BLIND STUDY WAS CONDUCTED IN 90 PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA. AFTER 5 WEEKS ON A CHOLESTEROL-LOWERING DIET, PATIENTS WERE RANDOMISED TO OMEGA-3 FA + PLACEBO, OMEGA-3 FA + POLICOSANOL 5 MG/DAY OR OMEGA-3 FA + POLICOSANOL 10 MG/DAY FOR 8 WEEKS. OMEGA-3 FA WAS SUPPLIED AS 1G CAPSULES (TWO PER DAY); PLACEBO AND POLICOSANOL WERE PROVIDED IN TABLET FORM. PHYSICAL SIGNS AND LABORATORY MARKERS WERE ASSESSED AT BASELINE AND AFTER 4 AND 8 WEEKS ON THERAPY. DRUG COMPLIANCE AND ADVERSE EXPERIENCES (AES) WERE ASSESSED AT WEEKS 4 AND 8. THE PRIMARY EFFICACY VARIABLE WAS LDL-C REDUCTION; OTHER LIPID PROFILE MARKERS WERE SECONDARY VARIABLES. RESULTS: AFTER 8 WEEKS, OMEGA-3 FA + POLICOSANOL 5 AND 10 MG/DAY, BUT NOT OMEGA-3 FA + PLACEBO, SIGNIFICANTLY REDUCED LDL-C BY 21.1% AND 24.4%, RESPECTIVELY (BOTH P < 0.0001). OMEGA-3 FA + POLICOSANOL 5 MG/DAY ALSO SIGNIFICANTLY LOWERED TC (12.7%; P < 0.01) AND TG (13.6%; P < 0.05), AND SIGNIFICANTLY INCREASED HDL-C (+14.4%; P < 0.001). OMEGA-3 FA + POLICOSANOL 10 MG/DAY SIGNIFICANTLY DECREASED TC (15.3%; P < 0.001) AND TG (14.7%; P < 0.01), AND SIGNIFICANTLY INCREASED HDL-C (+15.5%; P < 0.0001). OMEGA-3 FA + PLACEBO SIGNIFICANTLY REDUCED TG (14.2%; P < 0.05) BUT HAD NO SIGNIFICANT EFFECT ON OTHER LIPID PROFILE VARIABLES. THE PROPORTION OF RANDOMISED PATIENTS IN THE OMEGA-3 FA + POLICOSANOL 5 OR 10 MG/DAY GROUPS THAT ACHIEVED LDL-C TARGETS OR REDUCTIONS =15% WAS SIGNIFICANTLY GREATER THAN IN THE OMEGA-3 FA + PLACEBO GROUP (P < 0.001). COMBINED THERAPY WITH OMEGA-3 FA + POLICOSANOL 5 OR 10 MG/ DAY RESULTED IN SIGNIFICANTLY GREATER CHANGES IN LDL-C, TC AND HDL-C THAN TREATMENT WITH OMEGA-3 FA + PLACEBO, BUT DID NOT MODIFY THE TG RESPONSE COMPARED WITH THE OMEGA-3 FA + PLACEBO GROUP. FOUR PATIENTS (TWO IN THE OMEGA-3 FA + PLACEBO GROUP AND TWO IN THE OMEGA-3 FA + POLICOSANOL 10 MG/DAY GROUP) WITHDREW FROM THE STUDY; NONE OF THESE WITHDRAWALS WAS DUE TO AES. TWO PATIENTS REPORTED MILD AES, NAMELY NAUSEA/ HEADACHE (ONE IN THE OMEGA-3 FA + PLACEBO GROUP) AND HEARTBURN (ONE IN THE OMEGA-3 FA + POLICOSANOL 5 MG/DAY GROUP). CONCLUSIONS: POLICOSANOL 5 OR 10 MG/DAY ADMINISTERED CONCOMITANTLY WITH OMEGA-3 FA 1 G/DAY IMPROVED LDL-C, TC AND HDL-C, MAINTAINED THE REDUCTION IN TG ATTRIBUTABLE TO OMEGA-3 FA MONOTHERAPY, AND WAS WELL TOLERATED. TREATMENT WITH OMEGA-3 FA + POLICOSANOL COULD BE USEFUL FOR REGULATING LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, BUT FURTHER STUDIES INVOLVING LARGER SAMPLE SIZES ARE NEEDED BEFORE DEFINITIVE CONCLUSIONS CAN BE DRAWN. © 2005 ADIS DATA INFORMATION BV. ALL RIGHTS RESERVED.","","AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; TRIGLYCERIDES; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL","WEST HAVANA SCIENTIFIC POLE","THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE WEST HAVANA SCIENTIFIC POLE. THE PEOPLE INVOLVED IN THIS STUDY DID NOT RECEIVE ANY FINANCIAL OR OTHER COMPENSATION FOR THEIR PARTICIPATION IN THE STUDY.","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMIZED CONTROLLED STUDY, LANCET, 360, PP. 1623-1630, (2002); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., THE ILIB LIPID HAND-BOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE. 2ND ED., (2000); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 187-195, (2000); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, PP. 153-163, (2003); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCHCASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE DAWLEY RATS, J MED FOOD, 4, PP. 57-66, (2001); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); HARRIS W.S., PARK Y., ISLEY W.L., CARDIOVASCULAR DISEASE AND LONG CHAIN OMEGA-3 FATTY ACIDS, CURR OPIN LIPIDOL, 14, PP. 9-14, (2003); LEE K.W., LIP G.V., THE ROLE OF OMEGA-3 FATTY ACIDS IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, QJM, 96, PP. 465-480, (2003); RICHTNER W.O., LONG-CHAIN OMEGA-3 FATTY ACIDS FROM FISH REDUCE SUDDEN CARDIAC DEATH IN PATIENTS WITH CORONARY HEART DISEASE, EUR J MED RES, 8, PP. 332-336, (2003); LEMAITRE R.N., KING I.B., MOZAFFARIAN D., ET AL., N-3 POLYUNSATURATED FATTY ACIDS, FATAL ISCHEMIC HEART DISEASE AND NON FATAL MYOCARDIAL INFARCTION IN OLDER ADULTS: THE CARDIOVASCULAR HEALTH STUDY, AM J CLIN NUTR, 77, PP. 319-325, (2003); HU F.B., BRONNER L., WILLETT W.C., ET AL., FISH AND OMEGA-3 FATTY ACID INTAKE AND RISK OF CORONARY HEART DISEASE IN WOMEN, JAMA, 287, PP. 1815-1821, (2002); DE CATERINA R., MADONNA R., ZUCCHI R., ET AL., ANTIARRHYTHMIC EFFECTS OF OMEGA-3 FATTY ACIDS: FROM EPIDEMIOLOGY TO BEDSIDE, AM HEART J, 146, PP. 420-430, (2003); MORI T.A., BEILIN L.J., LONG-CHAIN OMEGA 3 FATTY ACIDS, BLOOD LIPIDS AND CARDIOVASCULAR REDUCTION, CURR OPIN LIPIDOL, 12, PP. 11-17, (2001); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); NARANJO C.A., BUSTO U., SELLERS E.M., ET AL., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN PHARMACOL THER, 30, PP. 239-245, (1981); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY I.R., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SUZUKAWA M., ABBEY M., HOWE P.R.C., ET AL., EFFECTS OF FISH OIL FATTY ACIDS ON LOW-DENSITY LIPOPROTEIN SIZE, OXIDIZABILITY, AND UPTAKE BY MACROPHAGES, J LIPID RES, 36, PP. 473-484, (1995); HARRIS W., FISH OIL AND PLASMA LIPID AND LIPOPROTEIN METABOLISM IN HUMANS: A CRITICAL REVIEW, J LIPID RES, 30, PP. 785-807, (1989); NESTEL P.J., EFFECTS OF N-3 FATTY ACIDS ON LIPID METABOLISM, ANNU REV NUTR, 10, PP. 149-167, (1990); SANDSET P.M., LUND H., NORSETH J., ET AL., TREATMENT WITH HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS IN HYPERCHOLESTEROLEMIA INDUCES CHANGES IN COMPONENTS OF THE EXTRINSIC COAGULATION SYSTEM, ARTERIOSCLER THROMB VASC BIOL, 11, PP. 138-145, (1991); CONTACOS C., BARTER P.J., SULLIVAN D.R., EFFECT OF PRAVASTATIN AND OMEGA 3 FATTY ACIDS ON PLASMA LIPIDS AND LIPOPROTEINS PATIENTS WITH COMBINED HYPERLIPIDAEMIA, ARTERIOSCLER THROMB, 13, PP. 1755-1762, (1993); NORDOY A., BONAA K.H., NILSEN H., ET AL., EFFECTS OF SIMVASTATIN AND OMEGA 3 FATTY ACIDS ON PLASMA LIPOPROTEIN AND LIPID PEROXIDATION IN PATIENTS WITH COMBINED HYPERLIPIDAEMIA, J INTERN MED, 243, PP. 163-170, (1998); DURRINGTON P.N., BHATNAGAR D., MACKNESS M.I., ET AL., THE EFFECTS OF AN OMEGA-3 FATTY POLYUNSATURATED ACID CONCENTRATE ADMINISTERED FOR ONE YEAR TO SIMVASTATIN TREATED PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE AND PERSISTING HYPERTRIGLYCERIDEMIA, HEART, 85, PP. 544-548, (2001); CHAN D.C., WATTS G.F., BARRETT H.R., ET AL., EFFECT OF ATORVASTATIN AND FISH OIL ON PLASMA HIGH-SENSITIVITY CREACTIVE PROTEIN CONCENTRATIONS IN INDIVIDUALS WITH VISCERAL OBESITY, CLIN CHEM, 48, PP. 877-883, (2002); BHATNAGAR D., MACKNESS M.I., DURRINGTON P.N., TREATMENT OF MIXED HYPERLIPIDAEMIA USING A COMBINATION OF OMEGA-3 FATTY ACIDS AND HMGCOA REDUCTASE INHIBITORS, EUR HEART J SUPPL, SUPPL. D, (2001)","R. MAS; CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), HAVANA CITY, 6990 OR 6880, PLAYA, PO BOX, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS R D","ARTICLE","ISI","2-S2.0-22244482805","DRUGS R D","NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC);EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2005, DRUGS R D","CASTAÑO G, 2005, DRUGS R D"
"CHAN D;WATTS G","CHAN, DICK C. (7402216503); WATTS, GERALD F. (7202153447)","DYSLIPIDEMIA IN THE METABOLIC SYNDROME",2004,"JOURNAL OF DRUG EVALUATION","2","31",4,"10.1080/14791130410001728524","LIPOPROTEIN RESEARCH UNIT, SCHOOL OF MEDICINE AND PHARMACOLOGY, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA;LIPOPROTEIN RESEARCH UNIT, SCHOOL OF MEDICINE AND PHARMACOLOGY, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA","[NO ABSTRACT AVAILABLE]","","ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; COLESTYRAMINE; CYCLOSPORIN; DEXFENFLURAMINE; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INSULIN; ISPAGULA; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID DERIVATIVE; PHYTOSTEROL; PLACEBO; POLICOSANOL; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL; UNINDEXED DRUG; ALCOHOL CONSUMPTION; ARTHRALGIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY ATHEROSCLEROSIS; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DYSLIPIDEMIA; DYSPEPSIA; ERECTILE DYSFUNCTION; FATTY ACID METABOLISM; FLATULENCE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIVER DYSFUNCTION; LOW CALORY DIET; LOW FAT DIET; METABOLIC SYNDROME X; MORTALITY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRURITUS; REVIEW; SIDE EFFECT; SMOKING CESSATION; THROMBOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION","NATIONAL HEART FOUNDATION; ROYAL PERTH HOSPITAL MEDICAL RESEARCH FOUNDATION, RPH-MRF; NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL, NHMRC; RAINE MEDICAL RESEARCH FOUNDATION","THIS WORK WAS SUPPORTED BY GRANTS FROM THE NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL AND THE NATIONAL HEART FOUNDATION. SUPPORT WAS ALSO PROVIDED BY THE RAINE MEDICAL RESEARCH FOUNDATION AND THE ROYAL PERTH HOSPITAL MEDICAL RESEARCH FOUNDATION. DCC IS A POSTDOCTORAL RESEARCH FELLOW OF RAINE/NATIONAL HEART FOUNDATION.","HODGE A.M., ZIMMETT P.Z., THE EPIDEMIOLOGY OF OBESITY, BAILLIERES CLIN. ENDOCRINOL. METAB., 8, PP. 577-599, (1994); BJORNTORP P., OBESITY, LANCET, 350, PP. 423-426, (1997); DESPRES J.-P., MOORJANI S., LUPIEN P.J., ET AL., REGIONAL DISTRIBUTION OF BODY FAT, PLASMA LIPOPROTEINS AND CARDIOVASCULAR DISEASE, ARTERIOSCLER. THROMB. VASC. BIOL., 10, PP. 497-511, (1990); EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, JAMA, 285, PP. 2486-2497, (2001); DEFINITION, DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS AND ITS COMPLICATION: REPORT OF A WHO CONSULATION, (1999); REAVEN G.M., THE INSULIN RESISTANCE SYNDROME, CURR. ATHEROSCLER. REP., 5, PP. 364-371, (2003); ISOMAA B., ALMGREN P., TUOMI T., ET AL., CARDIOVASCULAR MORBIDITY AND MORTALITY ASSOCIATED WITH THE METABOLIC SYNDROME, DIABETES CARE, 24, PP. 683-689, (2001); LAKKA H.M., LAAKSONEN D.E., LAKKA T.A., ET AL., THE METABOLIC SYNDROME AND TOTAL AND CARDIOVASCULAR DISEASE MORTALITY IN MIDDLE-AGED MEN, JAMA, 288, PP. 2709-2716, (2002); TURNER R.C., MILLNS H., NEIL H.A.W., ET AL., RISK FACTORS FOR CORONARY ARTERY DISEASE IN NON-INSULIN DEPENDENT DIABETES MELLITUS: UNITED KINGDOM PROSPECTIVE DIABETES STUDY, BMJ, 316, PP. 823-828, (1998); FORD E.S., GILES W.H., DIETZ W.H., PREVALENCE OF THE METABOLIC SYNDROME AMONG US ADULTS: FINDINGS FROM THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, JAMA, 287, PP. 356-359, (2002); PARK Y.W., ZHU S., PALANIAPPAN L., ET AL., THE METABOLIC SYNDROME: PREVALENCE AND ASSOCIATED RISK FACTOR FINDINGS IN THE US POPULATION FROM THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1994, ARCH. INTERN. MED., 163, PP. 427-436, (2003); LAMARCHE B., ABDOMINAL OBESITY AND ITS METABOLIC COMPLICATIONS: IMPLICATIONS FOR THE RISK OF ISCHAEMIC HEART DISEASE, CORON ARTERY DIS., 9, PP. 473-481, (1998); VISSCHER T., SEIDELL J.C., THE PUBLIC HEALTH IMPACT OF OBESITY, ANNU. REC. PUBLIC HEALTH, 22, PP. 355-375, (2001); BORKAN G.A., GERZOF S.G., ROBBINS A.H., ET AL., ASSESSMENT OF ABDOMINAL FAT CONTENT BY COMPUTED TOMOGRAPHY, AM. J. CLIN. NUTR., 36, PP. 172-177, (1982); DESPRES J.-P., PRUD'HOMME D., POULIOT M.C., ET AL., ESTIMATION OF DEEP ABDOMINAL ADIPOSE TISSUE ACCUMULATION FROM SIMPLE ANTHROPOMETRIC MEASUREMENTS IN MEN, AM. J. CLIN. NUTR., 54, PP. 471-477, (1991); KAHN B.B., FLIER J.S., OBESITY AND INSULIN RESISTANCE, J. CLIN. INVEST., 106, PP. 473-481, (2000); GINSBERG H.N., INSULIN RESISTANCE AND CARDIOVASCULAR DISEASE, J. CLIN. INVEST., 106, PP. 453-458, (2000); CHAN D.C., WATTS G.F., BARRETT P.H.R., ET AL., WAIST CIRCUMFERENCE, WAIST-TO-HIP RATIO AND BODY MASS INDEX AS PREDICTORS OF ADIPOSE TISSUE COMPARTMENTS IN MEN, QJM, 96, PP. 441-447, (2003); WAJCHENBERG B.L., SUBCUTANEOUS AND VISCERAL ADIPOSE TISSUE: THEIR RELATION TO THE METABOLIC SYNDROME, ENDOCR. REV., 21, PP. 697-738, (2000); BJORNTORP P., ABDOMINAL OBESITY AND THE METABOLIC SYNDROME, ANN. MED., 24, PP. 465-468, (1992); KAPLAN N.M., THE DEADLY QUARTET: UPPER BODY OBESITY, GLUCOSE INTOLERANCE, HYPERTRIGLYCERIDEMIA, AND HYPERTENSION, ARCH. INTERN. MED., 158, PP. 1514-1520, (1989); BALKAU B., CHARLES M.A., DRIVSHOLM T., ET AL., FREQUENCY OF THE WHO METABOLIC SYNDROME IN EUROPEAN COHORTS, AND AN ALTERNATIVE DEFINITION OF AN INSULIN RESISTANCE SYNDROME, DIABETES METAB., 28, PP. 364-376, (2002); ALEXANDER C.M., LANDSMAN P.B., TEUTSCH S.M., ET AL., NCEP-DEFINED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGED 50 YEARS AND OLDER, DIABETES, 52, PP. 1210-1214, (2003); HANSON R.L., IMPERATORE G., BENNETT P.H., ET AL., COMPONENTS OF THE METABOLIC SYNDROME AND INCIDENCE OF TYPE 2 DIABETES, DIABETES, 51, PP. 3120-3127, (2002); MEIGS J.B., D'AGOSTINO R.B., WILSON P.W., ET AL., RISK VARIABLE CLUSTERING IN THE INSULIN RESISTANCE SYNDROME. THE FRAMINGHAM OFFSPRING STUDY, DIABETES, 46, PP. 1594-1600, (1997); DEFRONZO R.A., FERRANNINI E., KOIVISTO V., NEW CONCEPTS IN THE PATHOGENESIS AND TREATMENT OF NONINSULIN-DEPENDENT DIABETES MELLITUS, AM. J. MED., 74, PP. 52-81, (1983); BODEN G., ROLE OF FATTY ACIDS IN THE PATHOGENESIS OF INSULIN RESISTANCE AND NIDDM, DIABETES, 46, PP. 3-10, (1997); ROITH D., ZICK Y., RECENT ADVANCES IN OUR UNDERSTANDING OF INSULIN ACTION AND INSULIN RESISTANCE, DIABETES CARE, 24, PP. 588-597, (2001); LEWIS G.F., CARPENTIER A., ADELI K., ET AL., DISORDERED FAT STORAGE AND MOBILIZATION IN THE PATHOGENESIS OF INSULIN RESISTANCE AND TYPE 2 DIABETES, ENDOCR. REV., 23, PP. 201-229, (2002); MCGARRY J.D., DYSREGULATION OF FATTY ACID METABOLISM IN THE ETIOLOGY OF TYPE 2 DIABETES, DIABETES, 51, PP. 7-18, (2002); LEWIS G.F., FATTY ACID REGULATION OF VERY LOW DENSITY LIPOPROTEIN PRODUCTION, CURR. OPIN. LIPIDOL., 8, PP. 146-153, (1997); UKKOLA O., SANTANIEMI M., ADIPONECTIN: A LINK BETWEEN EXCESS ADIPOSITY AND ASSOCIATED COMORBIDITIES?, J. MOL. MED., 80, PP. 696-702, (2002); COOPER A.D., HEPATIC UPTAKE OF CHYLOMICRON REMNANTS, J. LIPID RES., 38, PP. 2173-2192, (1997); KARPE F., POSTPRANDIAL LIPOPROTEIN METABOLISM AND ATHEROSCLEROSIS, J. INTERN. MED., 246, PP. 341-355, (1999); BAYNES C., HENDERSON A.D., ANYAOKU V., ET AL., THE ROLE OF INSULIN INSENSITIVITY AND HEPATIC LIPASE IN THE DYSLIPIDAEMIA OF TYPE 2 DIABETES, DIABETIC MEDICINE, 8, PP. 560-566, (1991); TALMUD P.J., GENETIC DETERMINANTS OF PLASMA TRIGLYCERIDES: IMPACT OF RARE AND COMMON MUTATIONS, CURR. ATHEROSCLER. REP., 3, PP. 191-199, (2001); MAHLEY R.W., INNERARITY T.L., RALL JR. S.C., ET AL., PLASMA LIPOPROTEINS: APOLIPOPROTEIN STRUCTURE AND FUNCTION, J. LIPID RES., 25, PP. 1277-1294, (1984); SHACHTER N.S., APOLIPOPROTEINS C-I AND C-III AS IMPORTANT MODULATORS OF LIPOPROTEIN METABOLISM, CURR. OPIN. LIPIDOL., 12, PP. 297-304, (2001); TWISK J., GILLIAN-DANIEL D.L., TEBON A., ET AL., THE ROLE OF THE LDL RECEPTOR IN APOLIPOPROTEIN B SECRETION, J. CLIN. INVEST., 105, PP. 521-532, (2000); BROWN M.S., GOLDSTEIN J.L., A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS, SCIENCE, 232, PP. 34-47, (1986); VON ECKARDSTEIN A., NOFER J.R., ASSMANN G., HIGH DENSITY LIPOPROTEINS AND ARTERIOSCLEROSIS. ROLE OF CHOLESTEROL EFFLUX AND REVERSE CHOLESTEROL TRANSPORT, ARTERIOSCLER. THROMB. VASC. BIOL., 21, PP. 13-27, (2001); RADER D.J., REGULATION OF REVERSE CHOLESTEROL TRANSPORT AND CLINICAL IMPLICATIONS, AM. J. CARDIOL., 92, (2003); BROUSSEAU M.E., ATP-BINDING CASSETTE TRANSPORT A1, FATTY ACIDS, AND CHOLESTEROL ABSORPTION, CURR. OPIN. LIPIDOL., 14, PP. 35-40, (2003); FIELDING C., FIELDING P.E., MOLECULAR PHYSIOLOGY OF REVERSE CHOLESTEROL TRANSPORT, J. LIPID RES., 36, PP. 211-218, (1995); HUUSKONEN J., OLKKONEN V.M., JAUHIAINEN M., ET AL., THE IMPACT OF PHOSPHOLIPID TRANSFER PROTEIN (PLTP) ON HDL METABOLISM, ATHEROSCLEROSIS, 155, PP. 269-281, (2001); RIGOTTI A., MIETTINEN H.E., KRIEGER M., THE ROLE OF THE HIGH-DENSITY LIPOPROTEIN RECEPTOR SR-BI IN THE LIPID METABOLISM OF ENDOCRINE AND OTHER TISSUES, ENDOCR. REV., 24, PP. 357-387, (2003); BRUCE C., CHOUINARD R.A., TALL A.R., PLASMA LIPID TRANSFER PROTEINS, HIGH-DENSITY LIPOPROTEINS, AND REVERSE CHOLESTEROL TRANSPORT, ANN. REV. NUTR., 18, PP. 297-330, (1998); GINSBERG H.N., HUANG L.S., THE INSULIN RESISTANCE SYNDROME: IMPACT ON LIPOPROTEIN METABOLISM AND ATHEROTHROMBOSIS, J. CARDIOVASC. RISK, 7, PP. 325-331, (2000); TASKINEN M.R., DIABETIC DYSLIPIDAEMIA: FROM BASIC RESEARCH TO CLINICAL PRACTICE, DIABETOLOGIA, 46, PP. 733-749, (2003); MAZZONE T., FOSTER D., CHAIT A., IN VIVO STIMULATION OF LOW-DENSITY LIPOPROTEIN DEGRATION BY INSULIN, DIABETES, 33, PP. 333-338, (1984); HORTON J.D., GOLDSTEIN J.L., BROWN M.S., SREBPS: ACTIVATORS OF THE COMPLETE PROGRAM OF CHOLESTEROL AND FATTY ACID SYNTHESIS IN THE LIVER, J. CLIN. INVEST., 109, PP. 1125-1131, (2002); RICHES F.M., WATTS G.F., NAOUMOVA R.P., ET AL., HEPATIC SECRETION OF VERY-LOW-DENSITY LIPOPROTEIN APOLIPOPROTEIN B-100 STUDIED WITH A STABLE ISOTOPE TECHNIQUE IN MEN WITH VISCERAL OBESITY, INT. J. OBES. RELAT. METAB. DISORD., 22, PP. 414-423, (1998); WATTS G.F., CHAN D.C., BARRETT P.H.R., ADIPOSE TISSUE COMPARTMENTS AND THE KINETICS OF VERY-LOW-DENSITY-LIPOPROTEIN B-100 IN NON-OBESE MEN, METABOLISM, 51, PP. 1206-1210, (2002); WATTS G.F., CHAN D.C., BARRETT P.H.R., ET AL., ADIPOSE TISSUE COMPARTMENTS AND THE KINETICS OF VERY-LOW-DENSITY-LIPOPROTEIN B100 IN OVERWEIGHT-OBESE MEN, OBESITY RES., 11, PP. 152-159, (2003); LEMIEUX I., PASCOT A., COUILLARD C., ET AL., HYPERTRIGLYCERIDEMIC WAIST: A MARKER OF THE ATHEROGENIC METABOLIC TRIAD (HYPERINSULINEMIA; HYPERAPOLIPOPROTEIN B; SMALL, DENSE LDL) IN MEN?, CIRCULATION, 102, PP. 179-184, (2000); MEKKI N., CHRISTOFILIS M.A., CHARBONNIER M., ET AL., INFLUENCE OF OBESITY AND BODY FAT DISTRIBUTION ON POSTPRANDIAL LIPEMIA AND TRIGLYCERIDE-RICH LIPOPROTEINS IN ADULT WOMEN, J. CLIN. ENDOCRINOL. METAB., 84, PP. 184-191, (1999); LEWIS G.F., O'MEARA N.M., SOLTYS P.A., ET AL., FASTING HYPERTRIGLYCERIDEMIA IN NONINSULIN-DEPENDENT DIABETES MELLITUS IS AN IMPORTANT PREDICTOR OF POSTPRANDIAL LIPID AND LIPOPROTEIN ABNORMALITIES, J. CLIN. ENDOCRINOL. METAB., 72, PP. 934-944, (1991); MAMO J.C., WATTS G.F., BARRETT P.H., ET AL., POSTPRANDIAL DYSLIPIDEMIA IN MEN WITH VISCERAL OBESITY: AN EFFECT OF REDUCED LDL RECEPTOR EXPRESSION?, AM. J. PHYSIOL., 81, (2001); GINSBERG H.N., ILLINGWORTH D.R., POSTPRANDIAL DYSLIPIEMIA: AN ATHEROGENIC DISORDER COMMON IN PATIENTS WITH DIABETES MELLITTIS, AM. J. CARDIOL., 88, SUPPL., (2001); KARPE F., POSTPRANDIAL LIPOPROTEIN METABOLISM AND ATHEROSCLEROSIS, J. INTERN. MED., 246, PP. 341-355, (1999); TASKINEN M.R., LIPOPROTEIN LIPASE IN DIABETES, DIAB. METAB. REV., 3, PP. 551-570, (1987); PANAROTTO D., REMILLARD P., BOUFFARD L., ET AL., INSULIN RESISTANCE AFFECTS THE REGULATION OF LIPOPROTEIN LIPASE IN THE POSTPRANDIAL PERIOD AND IN AN ADIPOSE TISSUE-SPECIFIC MANNER, EUR. J. CLIN. INVEST., 32, PP. 84-92, (2003); KOBAYASHI J., TASHIRO J., MURANO S., ET AL., LIPOPROTEIN LIPASE MASS AND ACTIVITY IN POST-HEPARIN PLASMA FROM SUBJECTS WITH INTRA-ABDOMINAL VISCERAL FAT ACCUMULATION, CLIN. ENDOCRINOL., 48, PP. 515-520, (1998); CHAN D.C., WATTS G.F., BARRETT P.H., ET AL., MARKERS OF TRIGLYCERIDE-RICH LIPOPROTEIN REMNANT METABOLISM IN VISCERAL OBESITY, CLIN. CHEM., 48, PP. 278-283, (2002); REDGRAVE T.G., WATTS G.F., MARTINS I.J., ET AL., CHYLOMICRON REMNANT METABOLISM IN FAMILIAL DYSLIPIDEMIAS STUDIED WITH A REMNANT-LIKE EMULSION BREATH TEST, J. LIPID RES., 42, PP. 710-715, (2001); HAIDARI M., LEUNG N., MAHBUB F., ET AL., FASTING AND POSTPRANDIAL OVERPRODUCTION OF INTESTINALLY DERIVED LIPOPROTEINS IN AN ANIMAL MODEL OF INSULIN RESISTANCE. EVIDENCE THAT CHRONIC FRUCTOSE FEEDING IN THE HAMSTER IS ACCOMPANIED BY ENHANCED INTESTINAL DE NOVO LIPOGENESIS AND APOB48-CONTAINING LIPOPROTEIN OVERPRODUCTION, J. BIOL. CHEM., 277, PP. 31646-31655, (2002); MILLER M., THE EPIDEMIOLOGY OF TRIGLYCERIDE AS A CORONARY ARTERY DISEASE RISK FACTOR, CLIN. CARDIOL., 22, (1999); HOKANSON J.E., AUSTIN M.A., PLASMA TRIGLYCERIDE LEVEL IS A RISK FACTOR FOR CARDIOVASCULAR DISEASE INDEPENDENT OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL: A META-ANALYSIS OF POPULATION-BASED PROSPECTIVE STUDIES, J. CARDIOVASC. RISK, 3, PP. 213-219, (1996); JEPPESEN J., HEIN H.O., SUADICANI P., ET AL., TRIGLYCERIDE CONCENTRATION AND ISCHEMIC HEART DISEASE: AN EIGHT-YEAR FOLLOW-UP IN THE COPENHAGEN MALE STUDY, CIRCULATION, 97, PP. 1029-1036, (1998); TASKINEN M.R., IS LIVER THE CULPRIT OF DIABETIC DYSLIPIDEMIA?, ATHEROSCLEROSIS, 4, (2003); SNIDERMAN A.D., CIANFLONE K., SUBSTRATE DELIVERY AS A DETERMINANT OF HEPATIC APOB SECRETION, ARTERIOSCLER. THROMB. VASC. BIOL., 13, PP. 629-636, (1993); THOMPSON G.R., NAOUMOVA R., WATTS G.F., ROLE OF CHOLESTEROL IN REGULATING APOLIPOPROTEIN B SECRETION BY THE LIVER, J. LIPID RES., 37, PP. 439-447, (1996); ADELI K., TAGHIBIGLOU C., VAN IDERSTINE S.C., ET AL., MECHANISMS OF HEPATIC VERY LOW-DENSITY LIPOPROTEIN OVERPRODUCTION IN INSULIN RESISTANCE, TRENDS CARDIOVASC. MED., 11, PP. 170-176, (2001); LEWIS G.F., STEINER G., ACUTE EFFECTS OF INSULIN IN THE CONTROL OF VLDL PRODUCTION IN HUMANS. IMPLICATIONS FOR THE INSULIN-RESISTANT STATE, DIABETES CARE, 19, PP. 390-393, (1996); MALMSTROM R., PACKARD C.J., CASLAKE M., ET AL., EFFECTS OF INSULIN AND ACIPIMOX ON VLDL1 AND VLDL2 APOLIPOPROTEIN B PRODUCTION IN NORMAL SUBJECTS, DIABETES, 47, PP. 779-787, (1998); TASKINEN M.R., PACKARD C.J., SHEPHERD J., EFFECT OF INSULIN THERAPY ON METABOLIC FATE OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS IN NIDDM, DIABETES, 39, PP. 1017-1027, (1990); CHAN D.C., WATTS G.F., REDGRAVE T.G., ET AL., APOLIPOPROTEIN B-100 KINETICS IN VISCERAL OBESITY: ASSOCIATIONS WITH PLASMA APOLIPOPROTEIN C-III CONCENTRATION, METABOLISM, 29, PP. 1041-1046, (2002); RICHES F.M., WATTS G.F., VAN BOCKXMEER F.M., ET AL., APOLIPOPROTEIN B SIGNAL PEPTIDE AND APOLIPOPROTEIN E GENOTYPES AS DETERMINANTS OF THE HEPATIC SECRETION OF VLDL APOB IN OBESE MEN, J. LIPID RES., 39, PP. 1752-1758, (1998); WATTS G.F., RICHES F.M., HUMPHRIES S.E., ET AL., GENOTYPIC ASSOCIATIONS OF THE HEPATIC SECRETION OF VLDL APOLIPOPROTEIN B-100 IN OBESITY, J. LIPID RES., 41, PP. 481-488, (2000); HODIS H.N., MACK W.J., TRIGLYCERIDE-RICH LIPOPROTEINS AND PROGRESSION OF ATHEROSCLEROSIS, EUR. HEART J., 19, (1998); AUSTIN M.A., TRIGLYCERIDE, SMALL, DENSE LOW-DENSITY LIPOPROTEIN, AND THE ATHEROGENIC LIPOPROTEIN PHENOTYPE, CURR. ATHEROSCLER. REP., 2, PP. 200-207, (2000); STEINBERG D., PARTHASARATHY S., CAREW T.E., ET AL., BEYOND CHOLESTEROL. MODIFICATIONS OF LOW-DENSITY LIPOPROTEIN THAT INCREASE ITS ATHEROGENICITY, N. ENGL. J. MED., 320, PP. 915-924, (1989); VAKKILAINEN J., STEINER G., ANSQUER J.C., ET AL., RELATIONSHIPS BETWEEN LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, PLASMA LIPOPROTEINS, AND PROGRESSION OF CORONARY ARTERY DISEASE: THE DIABETES ATHEROSCLEROSIS INTERVENTION STUDY (DAIS), CIRCULATION, 107, PP. 1733-1737, (2003); STEINBRECHER U.P., WITZTUM J.L., GLUCOSYLATION OF LOW-DENSITY LIPOPROTEINS TO AN EXTENT COMPARABLE TO THAT SEEN IN DIABETES SLOWS THEIR CATABOLISM, DIABETES, 33, PP. 130-134, (1984); CUMMINGS M.H., WATTS G.F., PAL C., ET AL., INCREASED HEPATIC SECRETION OF VERY-LOW-DENSITY LIPOPROTEIN APOLIPOPROTEIN B-100 IN OBESITY: A STABLE ISOTOPE STUDY, CLIN. SCI., 88, PP. 225-233, (1995); WATTS G.F., BARRETT P.H.R., JI J., ET AL., DIFFERENTIAL REGULATION OF LIPOPROTEIN KINETICS BY ATORVASTATIN AND FENOFIBRATE IN SUBJECTS WITH THE METABOLIC SYNDROME, DIABETES, 52, PP. 803-811, (2003); PONT F., DUVILLARD L., FLORENTIN E., ET AL., EARLY KINETIC ABNORMALITIES OF APOB-CONTAINING LIPOPROTEINS IN INSULIN-RESISTANT WOMEN WITH ABDOMINAL OBESITY, ARTERIOSCLER. THROMB. VASC. BIOL., 22, PP. 1726-1733, (2002); DUVILLARD L., PONT F., FLORENTIN E., ET AL., METABOLIC ABNORMALITIES OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS IN NON-INSULIN-DEPENDENT DIABETES: A STABLE ISOTOPE KINETIC STUDY, EUR. J. CLIN. INVEST., 30, PP. 685-694, (2000); MARSH J.B., WELTY F.K., LICHTENSTEIN A.H., ET AL., APOLIPOPROTEIN B METABOLISM IN HUMANS: STUDIES WITH STABLE ISOTOPE-LABELED AMINO ACID PRECURSORS, ATHEROSCLEROSIS, 162, PP. 227-244, (2002); BARRETT P.H., WATTS G.F., KINETIC STUDIES OF LIPOPROTEIN METABOLISM IN THE METABOLIC SYNDROME INCLUDING EFFECTS OF NUTRITIONAL INTERVENTIONS, CURR. OPIN. LIPIDOL., 14, PP. 61-68, (2003); DESPRES J.P., LEMIEUX I., DAGENAIS G.R., ET AL., HDL-CHOLESTEROL AS A MARKER OF CORONARY HEART DISEASE RISK: THE QUEBEC CARDIOVASCULAR STUDY, ATHEROSCLEROSIS, 153, PP. 263-272, (2000); GORDON D.J., PROSTFIELD J.L., GARRISON R.J., ET AL., HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR DISEASE: FOUR PROSPECTIVE AMERICAN STUDIES, CIRCULATION, 79, PP. 8-15, (1989); ASSMANN G., SCHULTE H., VON ECKARDSTEIN A., ET AL., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AS A PREDICTOR OF CORONARY HEART DISEASE RISK. THE PROCAM EXPERIENCE AND PATHOPHYSIOLOGICAL IMPLICATIONS FOR REVERSE CHOLESTEROL TRANSPORT, ATHEROSCLEROSIS, 124, (1996); LAMARCHE B., RASHID S., LEWIS G.F., HDL METABOLISM IN HYPERTRIGLYCERIDEMIC STATES: AN OVERVIEW, CLINICA CHIMICA ACTA, 286, PP. 145-161, (1999); MURAKAMI T., MICHELAGNOLI S., LONGHI R., ET AL., TRIGLYCERIDES ARE MAJOR DETERMINANTS OF CHOLESTEROL ESTERIFICATION/TRANSFER AND HDL REMODELING IN HUMAN PLASMA, ARTERIOSCLER. THROMB. VASC. BIOL., 15, PP. 1819-1828, (1995); LAMARCHE B., UFFELMAN K.D., CARPENTIER A., ET AL., TRIGLYCERIDE ENRICHMENT OF HDL ENHANCES IN VIVO METABOLIC CLEARANCE OF HDL APO A-I IN HEALTHY MEN, J. CLIN. INVEST., 103, PP. 1191-1199, (1999); PIETZSCH J., JULIUS U., NITZSCHE S., ET AL., IN VIVO EVIDENCE FOR INCREASED APOLIPOPROTEIN A-I CATABOLISM IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE, DIABETES, 47, PP. 1928-1934, (1998); FRENAIS R., OUGUERRAM K., MAUGEAIS C., ET AL., HIGH DENSITY LIPOPROTEIN APOLIPOPROTEIN AI KINETICS IN NIDDM: A STABLE ISOTOPE STUDY, DIABETOLOGIA, 40, PP. 578-583, (1997); DUVILLARD L., PONT F., FLORENTIN E., ET AL., INEFFICIENCY OF INSULIN THERAPY TO CORRECT APOLIPOPROTEIN A-I METABOLIC ABNORMALITIES IN NON-INSULIN-DEPENDENT DIABETES MELLITUS, ATHEROSCLEROSIS, 152, PP. 229-237, (2000); PONT F., DUVILLARD L., FLORENTIN E., ET AL., HIGH-DENSITY LIPOPROTEIN APOLIPOPROTEIN A-1 KINETICS IN OBESE INSULIN RESISTANT PATIENTS. AN IN VIVO STABLE ISOTOPE STUDY, INT. J. OBES., 26, PP. 1151-1158, (2002); DESPRES J.P., FERLAND M., MOORJANI S., ET AL., ROLE OF HEPATIC-TRIGLYCERIDE LIPASE ACTIVITY IN THE ASSOCIATION BETWEEN INTRA-ABDOMINAL FAT AND PLASMA HDL CHOLESTEROL IN OBESE WOMEN, ARTERIOSCLER. THROMB. VASC. BIOL., 9, PP. 485-492, (1989); BARTER P.J., RYE K.A., CHOLESTERYL ESTER TRANSFER PROTEIN, HIGH DENSITY LIPOPROTEIN AND ARTERIAL DISEASE, CURR. OPIN. LIPIDOL., 12, PP. 377-382, (2001); WITZTUM J.L., FISHER M., PIETRO T., ET AL., NONENZYMATIC GLUCOSYLATION OF HIGH-DENSITY LIPOPROTEIN ACCELERATES ITS CATABOLISM IN GUINEA PIGS, DIABETES, 31, PP. 1029-1032, (1982); GINSBERG H.N., STALENHOEF A.F., THE METABOLIC SYNDROME: TARGETING DYSLIPIDAEMIA TO REDUCE CORONARY RISK, J. CARDIOVASC. RISK, 10, PP. 121-128, (2003); DYSLIPIDAEMIA MANAGEMENT IN ADULTS WITH DIABETES, DIABETES CARE, 27, SUPPL. 1, (2004); MOOSER V., CARR A., ANTIRETROVIRAL THERAPY-ASSOCIATED HYPERLIPIDAEMIA IN HIV DISEASE, CURR. OPIN. LIPIDOL., 12, PP. 313-319, (2001); SZNAJDERMAN M., HYPERTENSION AND LIPIDS, BLOOD PRESSURE, S1, PP. 14-17, (1996); SRINIVASAN S.R., BERENSON G.S., APOLIPOPROTEINS B AND A-I AS PREDICTORS OF RISK OF CORONARY ARTERY DISEASE, LANCET, 358, PP. 2012-2013, (2001); WALLDIUS G., JUNGNER I., HOLME I., ET AL., HIGH APOLIPOPROTEIN B, LOW APOLIPOPROTEIN A-I, AND IMPROVEMENT IN THE PREDICTION OF FATAL MYOCARDIAL INFARCTION (AMORIS STUDY): A PROSPECTIVE STUDY, LANCET, 358, PP. 2026-2033, (2001); GAEDE P., VEDEL P., LARSEN N., ET AL., MULTIFACTORIAL INTERVENTION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETES, NEW ENGL. J. MED., 348, PP. 383-393, (2003); STAMPFER M.J., HU F.B., MANSON J.E., ET AL., PRIMARY PREVENTION OF CORONARY HEART DISEASE IN WOMEN THROUGH DIET AND LIFESTYLE, NEW ENGL. J. MED., 343, PP. 16-22, (2000); KNOWLER W.C., BARRETT-CONNOR E., FOWLER S.E., ET AL., REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR METFORMIN, N. ENGL. J. MED., 346, PP. 393-403, (2002); TUOMILEHTO J., LINDSTROM J., ERIKSSON J.G., ET AL., PREVENTION OF TYPE 2 DIABETES MELLITUS BY CHANGES IN LIFESTYLE AMONG SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE, NEW ENGL. J. MED., 344, PP. 1343-1350, (2001); VAN GAAL L.F., WAUTERS M.A., DE LEEUW I.H., THE BENEFICIAL EFFECTS OF MODEST WEIGHT LOSS ON CARDIOVASCULAR RISK FACTORS, INT. J. OBES. RELAT. METAB. DISORD., 21, (1997); DATTILO A.M., KRIS-ETHERTON P.M., EFFECTS OF WEIGHT REDUCTION ON BLOOD LIPIDS AND LIPOPROTEINS: A META-ANALYSIS, AM. J. CLIN. NUTR., 56, PP. 320-328, (1992); FLYNN M.M., ZMUDA J.M., MILOSAVLJEVIC D., ET AL., LIPOPROTEIN RESPONSE TO A NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP II DIET WITH AND WITHOUT ENERGY RESTRICTION, METABOLISM, 48, PP. 822-826, (1999); RICHES F.M., WATTS G.F., HUA J., ET AL., REDUCTION IN VISCERAL ADIPOSE TISSUE IS ASSOCIATED WITH IMPROVEMENT IN APOLIPOPROTEIN B-100 METABOLISM IN OBESE MEN, J. CLIN. ENDOCRINOL. METAB., 84, PP. 2854-2861, (1999); ATKINS R.C., DR ATKINS' NEW DIET REVOLUTION, (1998); FOSTER G.D., WYATT H.R., HILL J.O., ET AL., A RANDOMIZED TRIAL OF A LOW-CARBOHYDRATE DIET FOR OBESITY, NEW ENGL. J. MED., 348, PP. 2082-2090, (2003); SAMAHA F.F., IQBAL N., SESHADRI P., ET AL., A LOW-CARBOHYDRATE AS COMPARED WITH A LOW-FAT DIET IN SEVERE OBESITY, NEW ENGL. J. MED., 348, PP. 2074-2081, (2003); SISCOVICK D.S., EKELUND L.G., HYDE J.S., ET AL., PHYSICAL ACTIVITY AND CORONARY HEART DISEASE AMONG ASYMPTOMATIC HYPERCHOLESTEROLEMIC MEN, AM. J. PUBLIC HEALTH, 78, PP. 1428-1431, (1988); WESTHEIM A., OS I., PHYSICAL ACTIVITY AND THE METABOLIC CARDIOVASCULAR SYNDROME, J. CARDIOVASC. PHARMACOL., 20, (1992); MANSON J.E., GREENLAND P., LACROIX A.Z., ET AL., WALKING COMPARED WITH VIGOROUS EXERCISE FOR THE PREVENTION OF CARDIOVASCULAR EVENTS IN WOMEN, NEW ENGL. J. MED., 347, PP. 716-725, (2002); KRAUS W.E., HOUMARD J.A., DUSCHA B.D., ET AL., EFFECTS OF THE AMOUNT AND INTENSITY OF EXERCISE ON PLASMA LIPOPROTEINS, NEW ENGL. J. MED., 347, PP. 1483-1492, (2002); COUILLARD C., DESPRES J.P., LAMARCHE B., ET AL., EFFECTS OF ENDURANCE EXERCISE TRAINING ON PLASMA HDL CHOLESTEROL LEVELS DEPEND ON LEVELS OF TRIGLYCERIDES: EVIDENCE FROM MEN OF THE HEALTH, RISK FACTORS, EXERCISE TRAINING AND GENETICS (HERITAGE) FAMILY STUDY, ARTERIOSCLER. THROMB. VAS. BIOL., 21, PP. 1226-1232, (2001); ALAM S., STOLINSKI M., PENTECOST C., ET AL., THE EFFECT OF A 6-MONTH EXERCISE PROGRAMME ON VLDL APOLIPOPROTEIN B SECRETION IN TYPE 2 DIABETES, J. CLIN. ENDOCRINOL. METAB., 89, PP. 688-694, (2004); SVIRIDOV D., KINGWELL B., HOANG A., ET AL., SINGLE SESSION EXERCISE STIMULATES FORMATION OF PRE BETA 1-HDL IN LEG MUSCLE, J. LIPID RES., 44, PP. 522-526, (2003); ZMUDA J.M., YURGALEVITCH S.M., FLYNN M.M., ET AL., EXERCISE TRAINING HAS LITTLE EFFECT ON HDL LEVELS AND METABOLISM IN MEN WITH INITIALLY LOW HDL CHOLESTEROL, ATHEROSCLEROSIS, 137, PP. 215-221, (1998); PEARSON T.A., ALCOHOL AND HEART DISEASE, CIRCULATION, 94, PP. 3023-3025, (1996); BERGER K., AJANI U.A., KASE C.S., ET AL., LIGHT-TO-MODERATE ALCOHOL CONSUMPTION AND RISK OF STROKE AMONG U.S. MALE PHYSICIANS, NEW ENGL. J. MED., 34, PP. 1557-1564, (1999); DE OLIVEIRA E., SILVA E.R., FOSTER D., MCGEE HARPER M., ET AL., ALCOHOL CONSUMPTION RAISES HDL CHOLESTEROL LEVELS BY INCREASING THE TRANSPORT RATE OF APOLIPOPROTEINS A-I AND A-II, CIRCULATION, 102, PP. 2347-2352, (2000); MALMENDIER C.L., DELCROIX C., EFFECT OF ALCOHOL INTAKE ON HIGH AND LOW DENSITY LIPOPROTEIN METABOLISM IN HEALTHY VOLUNTEERS, CLINICA CHIMICA ACTA, 152, PP. 281-288, (1985); MORI T.A., BEILIN L.J., LONG-CHAIN OMEGA 3 FATTY ACIDS, BLOOD LIPIDS AND CARDIOVASCULAR RISK REDUCTION, CURR. OPIN. LIPIDOL., 12, PP. 11-17, (2001); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS, AND CARDIOVASCULAR DISEASE, CIRCULATION, 106, PP. 2747-2757, (2002); MORI T.A., BURKE V., PUDDEY I.B., ET AL., PURIFIED EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS HAVE DIFFERENTIAL EFFECTS ON SERUM LIPIDS AND LIPOPROTEINS, LDL PARTICLE SIZE, GLUCOSE, AND INSULIN IN MILDLY HYPERLIPIDEMIC MEN, AM. J. CLIN. NUTR., 71, PP. 1085-1094, (2000); DUNSTAN D.W., MORI T.A., PUDDEY I.B., ET AL., THE INDEPENDENT AND COMBINED EFFECTS OF AEROBIC EXERCISE AND DIETARY FISH INTAKE OR SERUM LIPIDS AND GLYCEMIC CONTROL IN NIDDM. A RANDOMIZED CONTROLLED STUDY, DIABETES CARE, 20, PP. 913-921, (1997); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MAKI K.C., DAVIDSON M.H., UMPOROWICZ D.M., ET AL., LIPID RESPONSES TO PLANT-STEROL-ENRICHED REDUCED-FAT SPREADS INCORPORATED INTO A NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP I DIET, AM. J. CLIN. NUTR., 74, PP. 33-43, (2001); CLIFTON P., PLANT STEROL AND STANOLS-COMPARISON AND CONTRASTS. STEROL VERSE STANOLS IN CHOLESTEROL-LOWERING: IS THERE A DIFFERENCE, ATHEROSCLEROSIS, 3, (2002); GYLLING H., MIETTINEN T.A., EFFECTS OF INHIBITING CHOLESTEROL ABSORPTION AND SYNTHESIS ON CHOLESTEROL AND LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC NON-INSULIN-DEPENDENT DIABETIC MEN, J. LIPID RES., 37, PP. 1776-1785, (1996); GYLLING H., MIETTINEN T.A., SERUM CHOLESTEROL AND CHOLESTEROL AND LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLAEMIC NIDDM PATIENTS BEFORE AND DURING SITOSTANOL ESTER-MARGARINE TREATMENT, DIABETOLOGIA, 37, PP. 773-780, (1994); LIFESTYLE AND RISK FACTOR MANAGEMENT AND USE OF DRUG THERAPIES IN CORONARY PATIENTS FROM 15 COUNTRIES: PRINCIPLE RESULTS FROM EUROASPIRE II EURO HEART SURVEY, EUR. HEART J., 22, PP. 554-572, (2001); PEARSON T.A., MCBRIDE P.E., MILLER N.H., ET AL., TWENTY-SEVENTH BETHESDA CONFERENCE: MATCHING THE INTENSITY OF RISK FACTOR MANAGEMENT WITH THE HAZARD FOR CORONARY DISEASE EVENTS. TASK FORCE 8. ORGANIZATION OF PREVENTIVE CARDIOLOGY SERVICE, J. AM. COLL. CARDIOL., 27, PP. 1039-1047, (1996); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); RUBINS H.B., ROBINS S.J., COLLINS D., ET AL., GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, N. ENGL. J. MED., 341, PP. 410-418, (1999); BROWN A.S., BAKKER-ARKEMA R.G., YELLEN L., ET AL., TREATING PATIENTS WITH DOCUMENTED ATHEROSCLEROSIS TO NATIONAL CHOLESTEROL EDUCATION PROGRAM-RECOMMENDED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL GOALS WITH ATORVASTATIN, FLUVASTATIN, LOVASTATIN AND SIMVASTATIN, J. AM. COLL. CARDIOL., 32, PP. 665-672, (1998); STEIN E.A., LANE M., LASKARZEWSKI P., COMPARISON OF STATINS IN HYPERTRIGLYCERIDEMIA, AM. J. CARDIOL., 81, (1998); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); GOLDBERG R.B., MELLIES M.J., SACKS F.M., ET AL., CARDIOVASCULAR EVENTS AND THEIR REDUCTION WITH PRAVASTATIN IN DIABETIC AND GLUCOSE-INTOLERANT MYOCARDIAL INFARCTION SURVIVORS WITH AVERAGE CHOLESTEROL LEVELS: SUBGROUP ANALYSES IN THE CHOLESTEROL AND RECURRENT EVENTS (CARE) TRIAL, CIRCULATION, 98, PP. 2513-2519, (1998); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, PP. 1349-1357, (1998); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, PP. 1349-1357, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); HAFFNER S.M., ALEXANDER C.M., COOK T.J., ET AL., REDUCED CORONARY EVENTS IN SIMVASTATIN-TREATED PATIENTS WITH CORONARY HEART DISEASE AND DIABETES OR IMPAIRED FASTING GLUCOSE LEVELS: SUBGROUP ANALYSES IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY, ARCH. INTERN. MED., 159, PP. 2661-2667, (1999); KEECH A., COLQUHOUN D., BEST J., ET AL., SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS WITH LONG-TERM PRAVASTATIN IN PATIENTS WITH DIABETES OR IMPAIRED FASTING GLUCOSE: RESULTS FROM THE LIPID TRIAL, DIABETES CARE, 26, PP. 2713-2721, (2003); SEVER P.S., DAHLOF B., POULTER N.R., ET AL., PREVENTION OF CORONARY AND STROKE EVENTS WITH ATORVASTATIN IN HYPERTENSIVE PATIENTS WHO HAVE AVERAGE OR LOWER-THAN-AVERAGE CHOLESTEROL CONCENTRATIONS, IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL-LIPID LOWERING ARM (ASCOT-LLA): A MULTICENTRE RANDOMISED CONTROLLED TRIAL, LANCET, 361, PP. 1149-1158, (2003); AGUILAR-SALINAS C.A., BARRETT H., SCHONFELD G., METABOLIC MODES OF ACTION OF THE STATINS IN THE HYPERLIPOPROTEINEMIAS, ATHEROSCLEROSIS, 141, PP. 203-207, (1998); CHAN D.C., WATTS G.F., BARRETT P.H.R., ET AL., MECHANISM OF ACTION OF AN HMGCOA REDUCTASE INHIBITOR ON APOLIPOPROTEIN B-100 KINETICS IN VISCERAL OBESITY, J. CLIN. ENDO. METAB., 87, PP. 2283-2289, (2002); WATTS G.F., CHAN D.C., BARRETT P.H., ET AL., EFFECT OF A STATIN ON HEPATIC APOLIPOPROTEIN B-100 SECRETION AND PLASMA CAMPESTEROL LEVELS IN THE METABOLIC SYNDROME, INT. J. OBES., 27, PP. 862-865, (2003); ASZTALOS B.F., HORVATH K.V., MCNAMARA J.R., ET AL., COMPARING THE EFFECTS OF FIVE DIFFERENT STATINS ON THE HDL SUBPOPULATION PROFILES OF CORONARY HEART DISEASE PATIENTS, ATHEROSCLEROSIS, 164, PP. 361-369, (2002); MARTIN G., DUEZ H., BLANQUART C., ET AL., STATIN-INDUCED INHIBITION OF THE RHO-SIGNALING PATHWAY ACTIVATES PPARΑ AND INDUCES HDL APOA-I, J. CLIN. INVEST., 107, PP. 1423-1432, (2001); JONES P., KAFONEK S., LAURORA I., ET AL., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN, AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 81, PP. 582-587, (1998); WIERZBICKI A.S., MIKHAILIDIS D.P., DOSE-RESPONSE EFFECTS OF ATORVASTATIN AND SIMVASTATIN ON HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLAEMIC PATIENTS: A REVIEW OF FIVE COMPARATIVE STUDIES, INT. J. CARDIOL., 84, PP. 53-57, (2002); RASHID S., UFFELMAN K.D., BARRETT P.H.R., ET AL., EFFECT OF ATORVASTATIN ON HIGH-DENSITY LIPOPROTEIN APOLIPOPROTEIN A-I PRODUCTION AND CLEARANCE IN THE NEW ZEALAND WHITE RABBIT, CIRCULATION, 106, PP. 2955-2960, (2002); SACKS F.M., THE RELATIVE ROLE OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN CORONARY ARTERY DISEASE: EVIDENCE FROM LARGE-SCALE STATIN AND FIBRATE TRIALS, AM. J. CARDIOL., 88, (2000); SACKS F.M., TONKIN A.M., CRAVEN T., ET AL., CORONARY HEART DISEASE IN PATIENTS WITH LOW LDL-CHOLESTEROL: BENEFIT OF PRAVASTATIN IN DIABETICS AND ENHANCED ROLE FOR HDL-CHOLESTEROL AND TRIGLYCERIDES AS RISK FACTORS, CIRCULATION, 105, PP. 1424-1428, (2002); WATTS G.F., DIMMITT S.B., FIBRATES, DYSLIPOPROTEINAEMIA AND CARDIOVASCULAR DISEASE, CURR. OPIN. LIPIDOL., 10, PP. 561-574, (1999); STAELS B., DALLONGEVILLE J., AUWERX J., ET AL., MECHANISM OF ACTION OF FIBRATES ON LIPID AND LIPOPROTEIN METABOLISM, CIRCULATION, 98, PP. 2088-2093, (1998); ROBINS S.J., RUBINS H.B., FAAS F.H., ET AL., INSULIN RESISTANCE AND CARDIOVASCULAR EVENTS WITH LOW HDL CHOLESTEROL: THE VETERANS AFFAIRS HDL INTERVENTION TRIAL (VA-HIT), DIABETES CARE, 26, PP. 1513-1517, (2003); ROBINS S.J., COLLINS D., WITTES J.T., ET AL., RELATION OF GEMFIBROZIL TREATMENT AND LIPID LEVELS WITH MAJOR CORONARY EVENTS: VA-HIT: A RANDOMIZED CONTROLLED TRIAL, JAMA, 285, PP. 1585-1591, (2001); SECONDARY PREVENTION BY RAISING HDL CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CORONARY ARTERY DISEASE: THE BEZAFIBRATE INFARCTION PREVENTION (BIP) STUDY, CIRCULATION, 102, PP. 21-27, (2000); FRICK M.H., ELO O., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N. ENGL. J. MED., 317, PP. 1237-1245, (1987); TENKANEN L., MANTTARI M., MANNINEN V., SOME CORONARY RISK FACTORS RELATED TO THE INSULIN RESISTANCE SYNDROME AND TREATMENT WITH GEMFIBROZIL: EXPERIENCE FROM THE HELSINKI HEART STUDY, CIRCULATION, 92, PP. 1779-1785, (1995); EFFECT OF FENOFIBRATE ON PROGRESSION OF CORONARY-ARTERY DISEASE IN TYPE 2 DIABETES: A RANDOMISED STUDY, LANCET, 357, PP. 905-910, (2001); VAKKILAINEN J., STEINER G., ANSQUER J.C., ET AL., RELATIONSHIPS BETWEEN LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, PLASMA LIPOPROTEINS, AND PROGRESSION OF CORONARY ARTERY DISEASE: THE DIABETES ATHEROSCLEROSIS INTERVENTION STUDY (DAIS), CIRCULATION, 107, PP. 1733-1737, (2003); BERGE J., MOLLER D.E., THE MECHANISMS OF ACTION OF PPARS, ANN. REV. MED., 53, PP. 409-435, (2002); KELLER H., DREYER C., MEDIN J., ET AL., FATTY ACIDS AND RETINOIDS CONTROL LIPID METABOLISM THROUGH ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-RETINOID X RECEPTOR HETERODIMERS, PROC. NATL. ACAD. SCI. USA, 90, PP. 2160-2164, (1993); SCHOONJANS K., PEINADO-ONSURBE J., LEFEBVRE A.M., ET AL., PPARALPHA AND PPARGAMMA ACTIVATORS DIRECT A DISTINCT TISSUE-SPECIFIC TRANSCRIPTIONAL RESPONSE VIA A PPRE IN THE LIPOPROTEIN LIPASE GENE, EMBO J., 15, PP. 5336-5348, (1996); CASLAKE M.J., PACKARD C.J., GAW A., ET AL., FENOFIBRATE AND LDL METABOLIC HETEROGENEITY IN HYPERCHOLESTEROLEMIA, ARTERIOSCLE. THROMB., 13, PP. 702-711, (1993)","","","ENGLISH","J. DRUG EVAL.","REVIEW","ISI","2-S2.0-3442878984","J DRUG EVAL",NA,"NOTREPORTED",NA,"CHAN DC, 2004, J DRUG EVAL","CHAN DC, 2004, J DRUG EVAL"
"PARRA J;REDDY K","PARRA, JAVIER L. (8401137100); REDDY, K. RAJENDER (55760553200)","HEPATOTOXICITY OF HYPOLIPIDEMIC DRUGS",2003,"CLINICS IN LIVER DISEASE","7","18",88,"10.1016/S1089-3261(03)00024-2","ALBERT EINSTEIN MEDICAL CENTER, PHILADELPHIA, PA, UNITED STATES;UNIVERSITY OF PENNSYLVANIA, 3 RAVDIN, PHILADELPHIA, PA 19104, 3400 STREET, UNITED STATES","DYSLIPIDEMIC CONDITIONS AND THEIR CARDIOVASCULAR RELATED COMPLICATIONS ARE COMMON. EFFECTIVE PRIMARY AND SECONDARY PREVENTION STRATEGIES INCLUDE THERAPIES TO LOWER LDL AND TOTAL CHOLESTEROL AND TO INCREASE HDL. FURTHER, IT SEEMS THAT THERE IS A NEED FOR THERAPEUTIC REDUCTION IN TRIGLYCERIDES AS IT EMERGES AS AN INDEPENDENT RISK FACTOR FOR CVD. MANY CLINICAL TRIALS HAVE BEEN DESIGNED TO EVALUATE PHARMACOLOGIC COMPOUNDS IN THE TREATMENT OF THE DYSLIPIDEMIAS AND THEY SEEM TO HAVE SHOWN A SAFE PROFILE, BOTH IN THE EXPERIMENT PHASES AND IN POST-MARKETING OBSERVATION STUDIES. NEVERTHELESS, SPORADIC REPORTS OF HEPATOTOXICITY WITH STATINS AND NIACIN STILL ARISE (TABLE 2). ALTHOUGH ROUTINE HEPATIC BIOCHEMICAL TEST MONITORING IS RECOMMENDED, THE COST-EFFECTIVENESS IS QUESTIONABLE BECAUSE OFTEN THESE REACTIONS ARE IDIOSYNCRATIC AND MAY NOT BE IDENTIFIED BY THIS ROUTINE SCREENING. THE RISK/BENEFIT RATIO IS IN FAVOR OF USING THESE MEDICATIONS IN INDIVIDUALS AT RISK. THERE IS NO EVIDENCE TO SUGGEST INTRINSIC HEPATOTOXIC ACTIVITY AS SUCH. DRUGS THAT LOWER TRIGLYCERIDES SUCH AS FIBRATES, HAVE BEEN OBSERVED TO IMPROVE HEPATIC BIOCHEMICAL TESTS, ALTHOUGH IN SMALL SERIES. THIS LEADS TO SPECULATION WHETHER TREATMENT WITH FIBRATES WOULD BE BENEFICIAL FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), A CONDITION THAT IS EMERGING AS ONE OF ENORMOUS MAGNITUDE.","","AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHLOROQUINE; CHLORZOXAZONE; COLESEVELAM; COLESTIPOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; METFORMIN; MEVINOLIN; NICOTINIC ACID; POLICOSANOL; PRAVASTATIN; SIMVASTATIN; TROGLITAZONE; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG ALCOHOL INTERACTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EOSINOPHILIA; FATIGUE; FATTY LIVER; FEVER; FLATULENCE; FLUSHING; HEADACHE; HUMAN; IMPOTENCE; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; METABOLIC ACIDOSIS; MYALGIA; MYOPATHY; NAUSEA; PAIN; PATHOGENESIS; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; REVIEW; RHABDOMYOLYSIS; TOXIC HEPATITIS","","","CARDIOVASCULAR DISEASES PREVENTION AND CONTROL, WORLD HEALTH REPORT, (2002); PLAN AND OPERATION OF THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-94, VITAL HEALTH STATISTICS 1, 32, PP. 20-22, (1994); RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE, LANCET, 344, PP. 1383-1389, (1994); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION INCIDENCE OF CORONARY HEART DISEASE. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 351-364, (1984); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1998); WILSON P.W.F., ESTABLISHED RISK FACTORS AND CORONARY ARTERY DISEASE: THE FRAMINGHAM STUDY, AM J HYPERTENS, 7, (1994); GRIMM R.H. JR., THE MULTIPLE RISK FACTOR INTERVENTION TRIAL IN THE US. A SUMMARY OF RESULTS AT FOUR YEARS IN SPECIAL INTERVENTION AND USUAL CARE MEN, PREV MED, 12, PP. 185-190, (1983); SHEPHERD J., THE WEST OF SCOTLAND CORONARY PREVENTION STUDY: A TRIAL OF CHOLESTEROL REDUCTION IN SCOTTISH MEN, AM J CARDIOL, 76, (1995); LENNEMAS H., PHARMAKODYNAMICS AND PHARMAKOKINETICS OF THE HMG COA REDUCTASE INHIBITORS: SIMILARITIES AND DIFFERENCES, CLIN PHARMACOKINET, 32, PP. 403-425, (1997); WHITE C.M., A REVIEW OF HMG COA REDUCTASE INHIBITORS, US PHARMACIST, 23, (1998); GERSON R.J., MACDONALD J.S., ANIMAL SAFETY AND TOXICOLOGY OF SIMVASTATIN AND RELATED HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS, AM J MED, 87, (1989); SLATER E.E., MACDONALD J.S., MECHANISM OF ACTION AND BIOLOGICAL PROFILE OF HMG COA REDUCTASE INHIBITORS. A NEW THERAPEUTIC ALTERNATIVE, DRUGS, 36, SUPPL. 3, PP. 72-82, (1988); MULDOON M.F., MANUCK S.M., MATTHEWS K.M., LOWERING CHOLESTEROL CONCENTRATIONS AND MORTALITY: A QUANTITATIVE REVIEW OF PRIMARY PREVENTION TRIALS, BMJ, 301, PP. 309-314, (1990); DAVEY SMITH G., PEKKANEN J., SHOULD THERE BE A MORATORIUM ON THE USE OF CHOLESTEROL LOWERING DRUGS?, BMJ, 304, PP. 431-434, (1992); KRITCHEVSKY S.B., KRITCHEVSKY D., SERUM CHOLESTEROL AND CANCER RISK: AN EPIDEMIOLOGIC PERSPECTIVE, ANNU REV NUTR, 12, PP. 391-416, (1992); MULDOON M.F., MANUCK S.B., MENDELSOHN A.B., ET AL., CHOLESTEROL REDUCTION AND NON-ILLNESS MORTALITY: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, BMJ, 322, 7277, PP. 11-15, (2001); WHITE C.M., ET AL., A REVIEW OF HMG-COA REDUCTASE INHIBITORS, US PHARMACIST, 23, (1998); HAMELIN B., ET AL., HYDROPHILICITY/LYPOPHILICITY: RELEVANCE OF THE PHARMACOLOGY AND CLINICAL EFFECTS OF HMG COA REDUCTASE INHIBITORS, TRENDS PHARMACOL SCI, 19, PP. 26-37, (1998); BOTTORF M., HANSTEN P., LONG TERM SAFETY OF HEPATIC HYDROXYMETHYL GLUTARYL COENZYME A REDUCTASE INHIBITORS, ARCH INTERN MED, 160, PP. 2273-2280, (2000); AZIE N.E., BRATER D.C., ET AL., INTERACTION OF DILTIAZEM WITH LOVASTATIN AND PRAVASTATIN, CLIN PHARMACOL THER, 64, PP. 369-377, (1998); KANTOLA T., KIVIST K.T., ET AL., EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF ATORVASTATIN, CLIN PHARMACOL THER, 64, PP. 58-65, (1998); NEUVONEN P.J., JALAVA K.M., ET AL., ITRACOONAZOLE DRASTICALLY INCREASES THE CONCENTRATIONS OF LOVASTATIN AND LOVASTATIN ACID, CLIN PHARMACOL THER, 60, PP. 54-61, (1996); NEUVONEN P.J., KANTOLA T., ET AL., SIMVASTATIN BUT NOT PRAVASTATIN IS VERY SUSCEPTIBLE TO INTERACTION WITH THE CYP3A4 INHIBITOR ITRACONAZOLE, CLIN PHARMACOL THER, 63, PP. 332-341, (1998); PHYSICIAN'S DESK REFERENCE. 53RD EDITION, (1999); TOLMAN K.G., DEFINING PATIENT RISKS FROM EXPANDED PREVENTIVE THERAPIES, AM J CARDIOL, 85, (2000); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, SUPPL. 3, PP. 63-71, (1988); SHEK A., ET AL., STATIN-FIBRATE COMBINATION THERAPY, ANN PHARMACOTHER, 35, PP. 908-917, (2001); WALKER J.F., HMG-COA REDUCTASE INHIBITORS: CURRENT CLINICAL EXPERIENCE, DRUGS, 36, SUPPL. 3, PP. 83-86, (1988); BOCCUZI S.J., BOCANEGRA T.S., WALKER J.F., ET AL., LONG-TERM SAFETY AND EFFICACY PROFILE OF SIMVASTATIN, AM JOUR CARDIOL, 68, PP. 1127-1131, (1991); PEDERSEN T.R., BERG K., COOK T.J., ET AL., SAFETY AND TOLERABILITY OF CHOLESTEROL LOWERING WITH SIMVASTATIN DURING 5 YEARS IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY, ARCH INT MED, 156, PP. 2085-2092, (1996); BALLARE M., CAMPANINI M., AIROLDI G., ET AL., HEPATOTOXICITY OF HYDROXY-METHYL-GLUTARYL-COENZYME A REDUCTASE INHIBITORS, MINERVA GASTROENTEROL DIETOL, 38, PP. 41-44, (1992); DAVIGNON J., MONTIGNY M., DUFOUR R., HMG-COA REDUCTASE INHIBITORS: A LOOK BACK AND A LOOK AHEAD, CAN J CARDIOL, 8, PP. 843-864, (1992); CALDWELL S.H., HESPENHEIDE E.E., VON BORSTEL R.W., MYOSITIS, MICROVESICULAR HEPATITIS, AND PROGRESSION TO CIRRHOSIS FROM TROGLITAZONE ADDED TO SIMVASTATIN, DIG DIS SCI, 46, PP. 376-378, (2001); HEUER T., GERADS H., PAUW M., GABBERT H.E., REIS H.E., TOXIC LIVER DAMAGE CAUSED BY HMG-COA REDUCTASE INHIBITOR, MED KLIN, 95, PP. 642-644, (2000); BIELECKI J.W., SCHRANER C., BRINER V., KUHN M., RHABDOMYOLYSIS AND CHOLESTATIC HEPATITIS UNDER TREATMENT WITH SIMVASTATIN AND CHLORZOXAZONE CYP2E1 SUBSTRATE, SCHWEIZ MED WOCHENSCHR, 129, PP. 514-518, (1999); KOOMSTRA J.J., OTTERVANGER J.P., FEHMERS M.C., STRICKER B.H., CLINICALLY MANIFEST LIVER LESIONS DURING USE OF SIMVASTATIN, NED TIJDSCHR GENEESKD, 140, PP. 846-848, (1996); MANTELL G., BURKE M.T., STAQQERS J., EXTENDED CLINICAL SAFETY PROFILE OF LOVASTATIN, AM J CARDIOL, 66, (1990); TOBERT J.A., SHEAR C.L., CHREMOS A.N., MANTELL G.E., CLINICAL EXPERIENCE WITH LOVASTATIN, AM J CARDIOL, 65, (1990); TOLMAN K., THE LIVER AND LOVASTATIN, AM J CARDIOL, 89, PP. 1374-1380, (2002); BRUGUERA M., JOVA P., RODES J., HEPATITIS ASSOCIATED WITH TREATMENT WITH LOVASTATIN. PRESENTATION OF 2 CASES, GASTROENTEROL HEPATOL, 21, PP. 127-128, (1998); HUCHZERMEYER H., MUNZENMAIER R., LOVASTATIN-INDUCED ACUTE CHOLESTATIC HEPATITIS, DTSCH MED WOCHENSCHR, 120, PP. 252-256, (1995); GRIMBERT S., PESSAYRE D., DEGOTT C., BENHAMOU J.P., ACUTE HEPATITIS INDUCED BY HMG-COA REDUCTASE INHIBITOR, LOVASTATIN, DIG DIS SCI, 39, PP. 2032-2033, (1994); BLACK D.M., BAKKER-ARKEMA R.G., NAWROCKI J.W., AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN (LIPITOR), A NEW HMG-COA REDUCTASE INHIBITOR, ARCH INTERN MED, 158, PP. 577-584, (1998); JIMENEZ-ALONSO J., OSORIO J.M., GUTIERREZ-CABELLO F., ET AL., ATORVASTATIN-INDUCED CHOLESTATIC HEPATITIS IN A YOUNG WOMAN WITH SYSTEMIC LUPUS ERYTHEMATOSUS, ARCH INTERN MED, 159, PP. 1811-1812, (1999); PFEFFER M., KEECH A., SACKS F., COBBE S., SAFETY AND TOLERABILITY OF PRAVASTATIN IN LONG-TERM CLINICAL TRIALS, PROSPECTIVE PRAVASTATIN POOLING PROJECT CIRCULATION, 105, PP. 2341-2346, (2002); HARTLEB M., RYMARCZYK G., JANUSZEWSKI K., ACUTE CHOLESTATIC HEPATITIS ASSOCIATED WITH PRAVASTATIN, AM J GASTROENTEROL, 94, PP. 1388-1390, (1999); DESLYPERE J.P., CLINICAL IMPLICATIONS OF THE BIOPHARMACEUTICAL PROPERTIES OF FLUVASTATIN, AM J CARDIOL, 73, (1994); TALK PAPER AUGUST FDA; INTERNATIONAL TASK FORCE FOR PREVENTION OF CORONARY HEART DISEASE. SCIENTIFIC BACKGROUND AND NEW CLINICAL GUIDELINES: RECOMMENDATIONS OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY, NUTR METAB CARDIOVASC DIS, 2, PP. 113-156, (1992); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM(NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, JAMA, 269, PP. 3015-3023, (1993); FRICK M.H., ELO O., ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA: SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); HUTTUNEN J., MANNINEN V., ET AL., THE HELSINKI HEART STUDY: CENTRAL FINDINGS AND CLINICAL IMPLICATIONS, ANN MED, 23, PP. 155-159, (1991); HUTTUNEN J., HEINONEN O., ET AL., THE HELSINKI HEART STUDY: AN 8.5-YEAR SAFETY AND MORTALITY FOLLOW-UP, J INTERN MED, 235, PP. 31-39, (1994); ERICSSON C.-G., HAMSTEN A., ET AL., ANGIOGRAPHIC ASSESSMENT OF EFFECTS OF BEZAFIBRATE ON PROGRESSION OF CORONARY ARTERY DISEASE IN YOUNG MALE POSTINFARCTION PATIENTS, LANCET, 347, PP. 849-853, (1996); FRICK M.H., SYVANNE M., ET AL., PREVENTION OF THE ANGIOGRAPHIC PROGRESSION OF CORONARY AND VEINGRAFT ATHEROSCLEROSIS BY GEMFIBROZIL AFTER CORONARY BYPASS SURGERY IN MEN WITH LOW LEVELS OF HDL CHOLESTEROL, CIRCULATION, 96, PP. 2137-2143, (1997); BLANE G.F., COMPARATIVE TOXICITY AND SAFETY PROFILE OF FENOFIBRATE AND OTHER FIBRIC ACID DERIVATIVES, AM J MED, 83, PP. 26-36, (1987); BLANE G.F., REVIEW OF EUROPEAN CLINICAL EXPERIENCE WITH FENOFIBRATE, CARDIOLOGY, 76, SUPPL. 1, PP. 1-13, (1989); STAELS B., DALLONGEVILLE J., ET AL., MECHANISM OF ACTION OF FIBRATES ON LIPID AND LIPOPROTEIN METABOLISM, CIRCULATION, 98, PP. 2088-2093, (1998); GUAY D.R., MICRONIZED FENOFIBRATE: A NEW FIBRIC ACID HYPOLIPIDEMIC AGENT, ANN PHARMACOTHER, 33, PP. 1083-1103, (1999); GANNE-CARRIE N., DE LEUSSE A., GUETTIER C., ET AL., AUTOIMMUNE HEPATITIS INDUCED BY FIBRATES, GASTROENTEROL CLIN BIOL, 22, PP. 525-529, (1998); LELOUCH S., PELLETIER G., SINICO M., FENOFIBRATE-INDUCED ACUTE HEPATITIS WITH PSEUDO-CHOLANGITIS, GASTROENTEROL CLIN BIOL, 16, PP. 597-599, (1992); RADER J.I., CALVERT R.J., HATHCOCK J.N., HEPATIC TOXICITY OF UNMODIFIED AND TIME-RELEASE PREPARATIONS OF NIACIN, AM J MED, 92, PP. 77-81, (1992); HENKIN Y., OBERMAN A., HURST D.C., SEGREST J.P., NIACIN REVISITED: CLINICAL OBSERVATIONS ON AN IMPORTANT BUT UNDERUTILIZED DRUG, AM J MED, 91, PP. 239-246, (1991); KRISTENSEN T., OLCOTT E.W., EFFECTS OF NIACIN THERAPY THAT SIMULATE NEOPLASIA: HEPATIC STEATOSIS WITH CONCURRENT HEPATIC DYSFUNCTION, J COMPUT ASSIST TOMOGR, 23, PP. 314-317, (1999); LAWRENCE S.P., TRANSIENT FOCAL HEPATIC DEFECTS RELATED TO SUSTAINED-RELEASE NIACIN, J CLIN GASTROENTEROL, 16, PP. 234-236, (1993); DALTON T.A., BERRY R.S., HEPATOTOXICITY ASSOCIATED WITH SUSTAINED-RELEASE NIACIN, AM J MED, 93, PP. 102-104, (1992); FERENCHICK G., ROVNER D., HEPATITIS AND HEMATEMESIS COMPLICATING NICOTINIC ACID USE, AM J MED SCI, 298, PP. 191-193, (1989); PATTERSON D.J., DEW E.W., GVORKEY F., GRAHAM D.Y., NIACIN HEPATITIS, SOUTH MED J, 76, PP. 239-241, (1983); ETCHASON J.A., MILLER T.D., SQUIRES R.W., ET AL., NIACIN-INDUCED HEPATITIS: A POTENTIAL SIDE EFFECT WITH LOW-DOSE TIME-RELEASE NIACIN, MAYO CLIN PROC, 66, PP. 23-28, (1991); HENKON Y., JOHNSON K.C., SEGREST J.P., RECHALLENGE WITH CRYSTALLINE NIACIN AFTER DRUG-INDUCED HEPATITIS FROM SUSTAINED-RELEASE NIACIN, JAMA, 264, PP. 241-243, (1990); BROWN W.V., NIACIN FOR LIPID DISORDERS. INDICATIONS, EFFECTIVENESS, AND SAFETY, POSTGRAD MED, 98, PP. 185-193, (1995); JACOBSON T.A., AMOROSA L.F., COMBINATION THERAPY WITH FLUVASTATIN AND NIACIN IN HYPERCHOLESTEROLEMIA: A PRELIMINARY REPORT ON SAFETY, AM J CARDIOL, 73, (1994); PATEL S.D., TAYLOR H.C., INTRAHEPATIC CHOLESTASIS DURING NICOTINIC ACID THERAPY, CLEVE CLIN J MED, 61, PP. 70-82, (1994); SCHWAB R.A., BACHHUBER B.H., DELIRIUM AND LACTIC ACIDOSIS CAUSED BY ETHANOL AND NIACIN COINGESTION, AM J EMERG MED, 9, PP. 363-365, (1991); CLEMENTZ G.L., HOLMES A.W., NICOTINIC ACID-INDUCED FULMINANT HEPATIC FAILURE, J CLIN GASTROENTEROL, 9, PP. 582-584, (1987); DAVIDSON M.H., DILLON M.A., GORDON B., ET AL., COLESEVELAM HYDROCHLORIDE (CHOLESTAGEL): A NEW, POTENT BILE ACID SEQUESTRANT ASSOCIATED WITH A LOW INCIDENCE OF GASTROINTESTINAL SIDE EFFECTS, ARCH INTERN MED, 159, PP. 1893-1900, (1999); SHEPHERD J., PACKARD C.J., MORGAN H.G., THIRD J.L., STEWART J.M., LAWRIE T.D., THE EFFECTS OF CHOLESTYRAMINE ON HIGH-DENSITY LIPOPROTEIN METABOLISM, ATHEROSCLEROSIS, 33, PP. 433-444, (1979); SIRMANS S.M., BECK J.K., BAHN H.L., FREEMAN D.A., COLESTIPOL-INDUCED HEPATOTOXICITY, ANN PHARMACOTHER, 21, PP. 513-516, (2001); DAVIDSON M.H., DICKLIN M.R., MAKI K.C., KLEINPELL R.M., COLESEVELAM HYDROCHLORIDE: A NON-ABSORBED, POLYMERIC CHOLESTEROL-LOWERING AGENT, EXPERT OPIN INVESTIG DRUGS, 9, PP. 2663-2671, (2000); DUNSTAN D.W., MORI T.A., PUDDEY I.B., ET AL., THE INDEPENDENT AND COMBINED EFFECTS OF AEROBIC EXERCISE AND DIETARY FISH INTAKE ON SERUM LIPIDS AND GLYCEMIC CONTROL IN NIDDM: A RANDOMIZED CONTROLLED STUDY, DIABETES CARE, 20, PP. 913-921, (1997); MORI T.A., WATTS G.F., BURKE V., ET AL., DIFFERENTIAL EFFECTS OF EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID ON VASCULAR REACTIVITY OF THE FOREARM MICROCIRCULATION IN HYPERLIPIDEMIC, OVERWEIGHT MEN, CIRCULATION, 102, PP. 1264-1269, (2000); MINIHANE A.M., KHAN S., LEIGH-FIRBANK E.C., ET AL., APOE POLYMORPHISM AND FISH OIL SUPPLEMENTATION IN SUBJECTS WITH AN ATHEROGENIC LIPOPROTEIN PHENOTYPE, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 1990-1997, (2000); DUNSTAN D.W., MORI T.A., PUDDEY I.B., ET AL., THE INDEPENDENT AND COMBINED EFFECTS OF AEROBIC EXERCISE AND DIETARY FISH INTAKE ON SERUM LIPIDS AND GLYCEMIC CONTROL IN NIDDM: A RANDOMIZED CONTROLLED STUDY, DIABETES CARE, 20, PP. 913-921, (1997); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); ISAACSOHN J.L., GARLIC POWDER AND PLASMA LIPIDS AND LIPOPROTEINS: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, ARCH INTERN MED, 158, PP. 1189-1194, (1998); MCQUEEN M.J., CHOLESTATIC JAUNDICE ASSOCIATED WITH LOVASTATIN (MEVACOR) THERAPY, CAN MED ASSOC J, 142, PP. 841-842, (1990); LOVASTATIN AND CHOLESTASIS, CANADIAN MEDICAL ASSOCIATION JOURNAL, 148, 3, (1993)","K.R. REDDY; UNIVERSITY OF PENNSYLVANIA, 3 RAVDIN, PHILADELPHIA, PA 19104, 3400 STREET, UNITED STATES; EMAIL: RAJENDER.REDDY@UPHS.UPENN.EDU","W.B. SAUNDERS","ENGLISH","CLIN. LIVER DIS.","REVIEW","ISI","2-S2.0-0037709132","CLIN LIVER DIS","ALBERT EINSTEIN MEDICAL CENTER;UNIVERSITY OF PENNSYLVANIA","NOTREPORTED;UNIVERSITY OF PENNSYLVANIA;NOTREPORTED",NA,"PARRA JL, 2003, CLIN LIVER DIS","PARRA JL, 2003, CLIN LIVER DIS"
"SINGH D;LI L;PORTER T","SINGH, DEV K. (7403594038); LI, LI (57196177941); PORTER, TODD D. (35572403800)","POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMPKINASE",2006,"JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS","318","6",136,"10.1124/jpet.106.107144","PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES;PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES;PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY, UNITED STATES, COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0082, UNITED STATES","POLICOSANOL IS A MIXTURE OF LONG-CHAIN PRIMARY ALCOHOLS THAT HAS BEEN SHOWN TO DECREASE SERUM CHOLESTEROL IN ANIMALS AND IN HUMANS. THE HYPOCHOLESTEROLEMIC EFFECT RESULTS FROM A DECREASE IN CHOLESTEROL SYNTHESIS BY SUPPRESSION OF HMG-COA REDUCTASE ACTIVITY, BUT THE MECHANISM OF THIS SUPPRESSION AND THE ACTIVE COMPONENTS OF POLICOSANOL HAVE NOT BEEN ESTABLISHED. IN THE PRESENT STUDY, WE INVESTIGATED THE ABILITY OF POLICOSANOL AND ITS PRINCIPAL COMPONENTS TO INHIBIT CHOLESTEROL SYNTHESIS IN CULTURED RAT HEPATOMA CELLS. MAXIMAL INHIBITION BY POLICOSANOL YIELDED A 30% DECREASE IN [14C]ACETATE INCORPORATION WITHOUT EVIDENCE OF CELLULAR TOXICITY. OCTACOSANOL (C28, THE MAJOR CONSTITUENT OF POLICOSANOL), HEPTACOSANOL (C27), AND HEXACOSANOL (C26) YIELDED SMALLER AND STATISTICALLY INSIGNIFICANT DECREASES IN CHOLESTEROL SYNTHESIS, WHEREAS TRIACONTANOL (1-HYDROXYTRIACONTANE; C30) REPLICATED THE INHIBITION OBTAINED WITH POLICOSANOL. AT PHARMACOLOGICAL CONCENTRATIONS (<5 ΜG/ML), POLICOSANOL AND TRIACONTANOL DECREASED [14C]ACETATE INCORPORATION INTO CHOLESTEROL WITHOUT AFFECTING THE INCORPORATION OF [14C]MEVALONATE, INDICATING THAT THESE COMPOUNDS ACT AT OR ABOVE HMG-COA REDUCTASE. POLICOSANOL AND TRIACONTANOL DID NOT DIRECTLY INHIBIT HMG-COA REDUCTASE, AND INCUBATION OF THESE COMPOUNDS WITH HEPATOMA CELLS DID NOT AFFECT REDUCTASE ENZYME LEVELS. HOWEVER, REDUCTASE ACTIVITY WAS DECREASED BY UP TO 55% IN LYSATES PREPARED FROM THESE CELLS, SUGGESTING THAT HMG-COA REDUCTASE ACTIVITY WAS DOWN-REGULATED BY POLICOSANOL TREATMENT. CONSISTENT WITH THIS HYPOTHESIS, A 3-FOLD INCREASE IN AMP-KINASE PHOSPHORYLATION WAS NOTED IN POLICOSANOLTREATED CELLS. BECAUSE AMP-KINASE IS ACTIVATED BY PHOSPHORYLATION AND IS WELL ESTABLISHED TO SUPPRESS HMG-COA REDUCTASE ACTIVITY, THESE RESULTS SUGGEST THAT POLICOSANOL OR A METABOLITE DECREASES HMG-COA REDUCTASE ACTIVITY BY ACTIVATING AMP-KINASE. COPYRIGHT © 2006 BY THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS.","","ADENYLATE KINASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHOLESTEROL; ENZYME ACTIVATION; FATTY ALCOHOLS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ADENYLATE KINASE; CHOLESTEROL; HEXACOSANOL; MEVALONIC ACID; OCTACOSANOL; POLICOSANOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL LYSATE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEPATOMA CELL; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; RAT","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON NORMOCHOLESTEROLEMIC RABBITS, BIOL RES, 27, PP. 205-210, (1994); BEG Z.H., STONIK J.A., BREWER JR. H.B., PHOSPHORYLATION OF HEPATIC 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE AND MODULATION OF ITS ENZYMIC ACTIVITY BY CALCIUM-ACTIVATED AND PHOSPHOLIPID-DEPENDENT PROTEIN KINASE, J BIOL CHEM, 260, PP. 1682-1687, (1985); BEG Z.H., STONIK J.A., BREWER JR. H.B., MODULATION OF THE ENZYMIC ACTIVITY OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY MULTIPLE KINASE SYSTEMS INVOLVING REVERSIBLE PHOSPHORYLATION: A REVIEW, METABOLISM, 36, PP. 900-917, (1987); BEG Z.H., STONIK J.A., BREWER JR. H.B., PHOSPHORYLATION AND MODULATION OF THE ENZYMIC ACTIVITY OF NATIVE AND PROTEASE-CLEAVED PURIFIED HEPATIC 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE BY A CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE, J BIOL CHEM, 262, PP. 13228-13240, (1987); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA, J AM MED ASSOC, 295, PP. 2262-2269, (2006); BROWN M.S., GOLDSTEIN J.L., SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY AND INHIBITION OF GROWTH OF HUMAN FIBROBLASTS BY 7-KETOCHOLESTEROL, J BIOL CHEM, 249, PP. 7306-7314, (1974); CARLING D., ZAMMIT V.A., HARDIE D.G., A COMMON BICYCLIC PROTEIN KINASE CASCADE INACTIVATES THE REGULATORY ENZYMES OF FATTY ACID AND CHOLESTEROL BIOSYNTHESIS, FEBS LETT, 223, PP. 217-222, (1987); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., FERNANDEZ J., MESA M., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, SUPPL., PP. 31-44, (2005); CASTANO G., MAS R., FERNANDEZ L., LOPEZ E., GUTIERREZ J.A., ILLNAIT J., FERNANDEZ J.C., GAMEZ R., ALVAREZ E., ASSESSMENT OF THE EFFECTS OF D-003, A NEW ANTIPLATELET AND LIPID-LOWERING COMPOUND, IN HEALTHY VOLUNTEERS. A PHASE I CLINICAL STUDY, DRUGS R.D., 3, PP. 337-348, (2002); CLARK H., CARLING D., SAGGERSON D., COVALENT ACTIVATION OF HEART AMP-ACTIVATED PROTEIN KINASE IN RESPONSE TO PHYSIOLOGICAL CONCENTRATIONS OF LONG-CHAIN FATTY ACIDS, EUR J BIOCHEM, 271, PP. 2215-2224, (2004); FERRER A., CAELLES C., MASSOT N., HEGARDT F.G., ACTIVATION OF RAT LIVER CYTOSOLIC 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE KINASE BY ADENOSINE 5′-MONOPHOSPHATE, BIOCHEM BIOPHYS RES COMMUN, 132, PP. 497-504, (1985); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HARDIE D.G., MINIREVIEW: THE AMP-ACTIVATED PROTEIN KINASE CASCADE: THE KEY SENSOR OF CELLULAR ENERGY STATUS, ENDOCRINOLOGY, 144, PP. 5179-5183, (2003); HARDIE D.G., PAN D.A., REGULATION OF FATTY ACID SYNTHESIS AND OXIDATION BY THE AMP-ACTIVATED PROTEIN KINASE, BIOCHEM SOC TRANS, 30, PP. 1064-1070, (2002); HAWLEY S.A., BOUDEAU J., REID J.L., MUSTARD K.J., UDD L., MAKELA T.P., ALESSI D.R., HARDIE D.G., COMPLEXES BETWEEN THE LKB1 TUMOR SUPPRESSOR, STRAD ALPHA/BETA AND MO25 ALPHA/BETA ARE UPSTREAM KINASES IN THE AMP-ACTIVATED PROTEIN KINASE CASCADE, J BIOL, 2, (2003); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); KAHN B.B., ALQUIER T., CARLING D., HARDIE D.G., AMP-ACTIVATED PROTEIN KINASE: ANCIENT ENERGY GAUGE PROVIDES CLUES TO MODERN UNDERSTANDING OF METABOLISM, CELL METAB, 1, PP. 15-25, (2005); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); MENENDEZ R., MAS R., PEREZ J., GONZALEZ R.M., JIMENEZ S., ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN FATTY ACIDS PREVENTS CASEIN-INDUCED ENDOGENOUS HYPERCHOLESTEROLEMIA IN RABBITS, CAN J PHYSIOL PHARMACOL, 82, PP. 22-29, (2004); RIZZO W.B., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); SHAW R.J., KOSMATKA M., BARDEESY N., HURLEY R.L., WITTERS L.A., DEPINHO R.A., CANTLEY L.C., THE TUMOR SUPPRESSOR LKB1 KINASE DIRECTLY ACTIVATES AMP-ACTIVATED KINASE AND REGULATES APOPTOSIS IN RESPONSE TO ENERGY STRESS, PROC NATL ACAD SCI USA, 101, PP. 3329-3335, (2004); SHAW R.J., LAMIA K.A., VASQUEZ D., KOO S.H., BARDEESY N., DEPINHO R.A., MONTMINY M., CANTLEY L.C., THE KINASE LKB1 MEDIATES GLUCOSE HOMEOSTASIS IN LIVER AND THERAPEUTIC EFFECTS OF METFORMIN, SCIENCE (WASH DC), 310, PP. 1642-1646, (2005); SINGH H., DERWAS N., POULOS A., VERY LONG CHAIN FATTY ACID BETA-OXIDATION BY RAT LIVER MITOCHONDRIA AND PEROXISOMES, ARCH BIOCHEM BIOPHYS, 259, PP. 382-390, (1987); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); WRIGHT C.M., ZIELKE J.C., WHAYNE T.F., POLICOSANOL, AN ALIPHATIC ALCOHOL SUGARCANE DERIVATIVE: USE IN PATIENTS INTOLERANT OF OR INADEQUATELY RESPONSIVE TO STATIN THERAPY, INT J ANGIOL, 13, PP. 173-175, (2005); ZANG M., ZUCCOLLO A., HOU X., NAGATA D., WALSH K., HERSCOVITZ H., BRECHER P., RUDERMAN N.B., COHEN R.A., AMP-ACTIVATED PROTEIN KINASE IS REQUIRED FOR THE LIPID-LOWERING EFFECT OF METFORMIN IN INSULIN-RESISTANT HUMAN HEPG2 CELLS, J BIOL CHEM, 279, PP. 47898-47905, (2004); ZHOU G., MYERS R., LI Y., CHEN Y., SHEN X., FENYK-MELODY J., WU M., VENTRE J., DOEBBER T., FUJII N., ET AL., ROLE OF AMP-ACTIVATED PROTEIN KINASE IN MECHANISM OF METFORMIN ACTION, J CLIN INVESTIG, 108, PP. 1167-1174, (2001)","T.D. PORTER; COLLEGE OF PHARMACY, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40536-0082, UNITED STATES; EMAIL: TPORTER@EMAIL.UKY.EDU","","ENGLISH","J. PHARMACOL. EXP. THER.","ARTICLE","ISI","2-S2.0-33747597580","J PHARMACOL EXP THER","UNIVERSITY OF KENTUCKY;UNIVERSITY OF KENTUCKY;UNIVERSITY OF KENTUCKY","NOTREPORTED;UNIVERSITY OF KENTUCKY;NOTREPORTED",NA,"SINGH DK, 2006, J PHARMACOL EXP THER","SINGH DK, 2006, J PHARMACOL EXP THER"
"MORRISON I W;HOLSER R;AKIN D","MORRISON III, W. HERBERT (7202130759); HOLSER, RONALD (6603876005); AKIN, DANNY E. (7006727733)","CUTICULAR WAX FROM FLAX PROCESSING WASTE WITH HEXANE AND SUPER CRITICAL CARBON DIOXIDE EXTRACTIONS",2006,"INDUSTRIAL CROPS AND PRODUCTS","24","3",25,"10.1016/j.indcrop.2005.11.001","AGRICULTURAL RESEARCH SERVICE, U.S. DEPARTMENT OF AGRICULTURE, R.B. RUSSELL AGRICULTURAL RESEARCH CENTER, ATHENS, GA 30604, P.O. BOX 5677, UNITED STATES;AGRICULTURAL RESEARCH SERVICE, U.S. DEPARTMENT OF AGRICULTURE, NATIONAL CENTER FOR AGRICULTURAL UTILIZATION RESEARCH, PEORIA, IL 61604, 1815 N UNIVERSITY STREET, UNITED STATES;AGRICULTURAL RESEARCH SERVICE, U.S. DEPARTMENT OF AGRICULTURE, R.B. RUSSELL AGRICULTURAL RESEARCH CENTER, ATHENS, GA 30604, P.O. BOX 5677, UNITED STATES","THE WASTE MATERIAL PRODUCED WHEN FLAX FIBER IS PROCESSED HAS POTENTIALLY VALUABLE CO-PRODUCTS. THE DUST WAS EXTRACTED WITH CO2 UNDER SUPER CRITICAL FLUID EXTRACTION (SCFE) CONDITIONS OR HEXANE TO ISOLATE THE CUTICULAR WAXES THAT CONTAIN POLICOSANOLS. POLICOSANOL IS A GENERAL TERM FOR LONG CHAIN ALCOHOLS AND HAVE BEEN SHOWN TO IMPROVE BLOOD CHEMISTRY. SCFE YIELDED 7.4% WAX COMPARED WITH 4.0% WITH HEXANE. THERE WERE SLIGHT BUT STATISTICAL DIFFERENCES IN EXTRACT COMPOSITIONS FOR C-20, C-22, AND C-26 ALCOHOLS AND LARGER SIGNIFICANT DIFFERENCES FOR C-16, C-18, AND C-20 FATTY ACIDS DEPENDING UPON THE EXTRACTION METHODS USED. RECOVERY OF WAX FROM THE WASTE PRODUCED FROM FLAX PROCESSING CAN PROVIDE AN ATTRACTIVE VALUE ADDED PRODUCT WITH POSITIVE HEALTH BENEFITS. © 2005 ELSEVIER B.V. ALL RIGHTS RESERVED.","FLAX; HEXANE EXTRACTION; POLICOSANOLS; SUPER CRITICAL FLUID EXTRACTION","ALKANES; FATTY ACIDS; FLAX; WAX; LINUM USITATISSIMUM; CARBON DIOXIDE; FATTY ACIDS; PARAFFINS; SUPERCRITICAL FLUID EXTRACTION; WAXES; ALCOHOL; CARBON DIOXIDE; EXTRACTION METHOD; FLAX FIBER; FLUID; WASTE DISPOSAL; WAX; CARBON DIOXIDE; EXTRACTION METHOD; WAX; HEXANE EXTRACTION; POLICOSANOLS; SUPER CRITICAL FLUID EXTRACTION; FLAX","","","AWIKA J.M., ROONEY L.W., SORGHUM PHYTOCHEMICALS AND THEIR POTENTIAL IMPACT ON HUMAN HEALTH, PHYTOCHEMISTRY, 65, PP. 1199-1221, (2004); BULLY N.R., FATTORI M., MEISEN A., SUPERCRITICAL FLUID EXTRACTION OF VEGETABLE OIL SEEDS CANOLA, VARIETY CANDLE, J. AM. OIL CHEM. SOC., 67, PP. 1362-1365, (1984); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); GUTIERREZ A., DEL RIO J.C., LIPIDS FROM FLAX FIBER AND THEIR FATE IN ALKALINE PULPING, J. AGRIC. FOOD CHEM., 51, PP. 4965-4971, (2003); HOLSER R.A., BOST G., VAN BOVEN M., PHYTOSTEROLS COMPOSITION OF HYBRID HIBISCUS SEED OIL, J. AGRIC. FOOD CHEM., 52, PP. 2546-2548, (2004); MORRISON III W.H., AKIN D.E., CHEMICAL COMPOSITION OF COMPONENTS COMPRISING BAST TISSUE IN FLAX, J. AGRIC. FOOD CHEM., 49, PP. 2333-2338, (2001); TAYLOR J.C.M., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRACEUTICALS, 19, PP. 192-195, (2003); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR. REV., 61, PP. 376-383, (2003)","W.H. MORRISON III; AGRICULTURAL RESEARCH SERVICE, U.S. DEPARTMENT OF AGRICULTURE, R.B. RUSSELL AGRICULTURAL RESEARCH CENTER, ATHENS, GA 30604, P.O. BOX 5677, UNITED STATES; EMAIL: WHMORRISON@QARU.ARS.USDA.GOV","","ENGLISH","IND. CROPS PROD.","ARTICLE","ISI","2-S2.0-33747353078","IND CROPS PROD","R.B. RUSSELL AGRICULTURAL RESEARCH CENTER;NATIONAL CENTER FOR AGRICULTURAL UTILIZATION RESEARCH;R.B. RUSSELL AGRICULTURAL RESEARCH CENTER","NOTREPORTED;R.B. RUSSELL AGRICULTURAL RESEARCH CENTER;NOTREPORTED",NA,"MORRISON III WH, 2006, IND CROPS PROD","MORRISON III WH, 2006, IND CROPS PROD"
"GISBERTZ S;HISSINK R;DEVRIES J;MOLL F","GISBERTZ, S.S. (9247751500); HISSINK, R.J. (9247751600); DEVRIES, J.-P.P.M. (9247751700); MOLL, F.L. (7103009095)","FUTURE PERSPECTIVES IN THE TREATMENT OF FEMOROPOPLITEAL ARTERIAL OCCLUSIONS",2005,"JOURNAL OF CARDIOVASCULAR SURGERY","46","13",4,"","DEPARTMENT OF VASCULAR SURGERY, ST. ANTONIUS HOSPITAL, NIEUWEGEIN, NETHERLANDS;DEPARTMENT OF VASCULAR SURGERY, UNIVERSITY MEDICAL CENTER, 3508 GA UTRECHT, P.O. BOX 85500, NETHERLANDS;DEPARTMENT OF VASCULAR SURGERY, ST. ANTONIUS HOSPITAL, NIEUWEGEIN, NETHERLANDS;DEPARTMENT OF VASCULAR SURGERY, UNIVERSITY MEDICAL CENTER, 3508 GA UTRECHT, P.O. BOX 85500, NETHERLANDS","FEMORO-POPLITEAL OCCLUSIVE DISEASE REPRESENTS THE MOST FREQUENT LOCALIZATION OF ATHEROSCLEROSIS IN THE LOWER EXTREMITIES. TREATMENT OF THIS DISEASE HAS CHANGED REMARKABLY IN THE LAST DECADE. A DEFINITE TREATMENT STRATEGY HAS STILL TO BE ESTABLISHED. THE PATHOPHYSIOLOGY IS DESCRIBED. A GENERAL OVERVIEW OF THE STATE-OF-THE ART TREATMENT MODALITIES AND THE MOST RECENT DEVELOPMENTS IS GIVEN. THIS IS DIVIDED INTO NON-INTERVENTIONAL PREVENTIVE AND SUPPORTIVE THERAPY, ENDOVASCULAR INTERVENTIONAL THERAPY, AND SURGICAL INTERVENTIONAL THERAPY. THE DEVELOPMENT OF MEDICAL THERAPY HAS EXPANDED ENORMOUSLY AND IS PROGRESSING STILL. IN THE WIDE RANGE OF INTERVENTIONAL TREATMENT MODALITIES, THERE HAS BEEN A CHANGE FROM INVASIVE BYPASS SURGERY TO MORE REFINED TECHNIQUES LIKE ENDARTERECTOMY AND PERCUTANEOUS ENDOVASCULAR THERAPY. THIS TREND TOWARDS RESTORING THE PATENCY OF THE ARTERY USING THE VESSEL WALL ITSELF AS A CONDUIT, LEADS TO A TERM ENCOMPASSING ALL THESE TREATMENT MODALITIES, KNOWN AS RESTORATIVE INTERVENTION. PERI-PROCEDURAL RISKS OF RESTORATIVE INTERVENTIONS ARE OF A MUCH LESSER DEGREE COMPARED TO BYPASS SURGERY. REPORTS OF PATENCY RATES SHOW A STEADY INCREASE. IT IS EXPECTED THAT PATENCY RATES WILL EVENTUALLY EQUAL OR EVEN SURPASS THOSE OF BYPASS SURGERY. IN CONCLUSION, A TREATMENT STRATEGY FOR FEMORO-POPLITEAL OCCLUSIONS IN THE FUTURE IS PROPOSED AS FOLLOWS: THE FIRST LINE OF INTERVENTIONAL THERAPY IN FEMORO-POPLITEAL OCCLUSIONS SHOULD BE A RESTORATIVE INTERVENTION. WITH ADEQUATE ADJUVANT MEDICAL THERAPY AND SUFFICIENT MONITORING, THIS WILL BE THE DEFINITE TREATMENT FOR THE MAJORITY OF PATIENTS. BYPASS SURGERY SHOULD BE REGARDED AS THE SECOND LINE OF INTERVENTIONAL THERAPY AND SHOULD BE RESERVED FOR THOSE PATIENTS IN WHOM RESTORATIVE INTERVENTIONS FAIL.","ARTERIAL OCCLUSIVE DISEASE; ATHEROSCLEROSIS; ENDOVASCULAR SURGICAL PROCEDURES; POPLITEAL ARTERY; SUPERFICIAL FEMORAL ARTERY","ANGIOSCOPY; ARTERIAL OCCLUSIVE DISEASES; BLOOD VESSEL PROSTHESIS IMPLANTATION; FEMORAL ARTERY; HUMANS; POPLITEAL ARTERY; ACETYLSALICYLIC ACID; ANGIOGENIC FACTOR; ANTITHROMBOCYTIC AGENT; ARGININE; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; GINKGO BILOBA EXTRACT; GLYCERYL TRINITRATE; HOMOCYSTEINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NAFTIDROFURYL; OXIDIZED LOW DENSITY LIPOPROTEIN; PENTOXIFYLLINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; POLICOSANOL; PROPIONYLCARNITINE; PROSTAGLANDIN E1; TICLOPIDINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL; WARFARIN; ADJUVANT THERAPY; ANTICOAGULATION; ATHEROGENESIS; BLEEDING; BRACHYTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; ENDARTERECTOMY; ENDOVASCULAR SURGERY; EXCIMER LASER; FEMORAL ARTERY; FEMOROPOPLITEAL BYPASS; GRAFT FAILURE; GRAFT PATENCY; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; KINESIOTHERAPY; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; RECANALIZATION; REVIEW; RISK FACTOR; SAFETY; SMOKING CESSATION; SURGICAL RISK; SYSTEMATIC REVIEW; VEIN GRAFT","","","BERGAMINI T.M., TOWNE J.B., BANDYK D.F., SEABROOK G.R., SCHMITT D.D., EXPERIENCE WITH IN SITU SAPHENOUS VEIN BYPASSES DURING 1981 TO 1989: DETERMINANT FACTORS OF LONG-TERM PATENCY, J. VASC. SURG., 13, PP. 137-147, (1991); BERGAN J.J., VEITH F.J., BERNHARD V.M., YAO J.S., FLINN W.R., GUPTA S.K., ET AL., RANDOMIZATION OF AUTOGENOUS VEIN AND POLYTETRAFLUORETHYLENE GRAFTS IN FEMORAL-DISTAL RECONSTRUCTION, SURGERY, 92, PP. 921-930, (1982); KLINKERT P., SCHEPERS A., BURGER D.H., VAN BOCKEL J.H., BRESLAU P.J., VEIN VERSUS POLYTETRAFLUOROETHYLENE IN ABOVE-KNEE FEMOROPOPLITEAL BYPASS GRAFTING: FIVE-YEAR RESULTS OF A RANDOMIZED CONTROLLED TRIAL, J. VASC. SURG., 37, PP. 149-155, (2003); SALA F., HASSEN-KHODJA R., LECIS A., BOUILLANNE P.J., DECLEMY S., BATT M., LONG-TERM OUTCOME OF FEMORAL ABOVE-KNEE POPLITEAL ARTERY BYPASS USING AUTOLOGOUS SAPHENOUS VEIN VERSUS EXPANDED POLYTETRAFLUOROETHYLENE GRAFTS, ANN. VASC. SURG., 17, PP. 401-407, (2003); TAYLOR JR. L.M., EDWARDS J.M., PORTER J.M., PRESENT STATUS OF REVERSED VEIN BYPASS GRAFTING: FIVE-YEAR RESULTS OF A MODERN SERIES, J. VASC. SURG., 11, PP. 193-205, (1990); DOTTER C.T., JUDKINS M.P., TRANSLUMINAL TREATMENT OF ARTERIOSCLEROTIC OBSTRUCTION. DESCRIPTION OF A NEW TECHNIC AND A PRELIMINARY REPORT OF ITS APPLICATION, CIRCULATION, 30, PP. 654-670, (1964); KHER N., MARSH J.D., PATHOBIOLOGY OF ATHEROSCLEROSIS - A BRIEF REVIEW, SEMIN. THROMB. HEMOST., 30, PP. 665-672, (2004); LINDBOM A., ARTERIOSCLEROSIS AND ARTERIAL THROMBOSIS IN THE LOWER LIMB; A ROENTGENOLOGICAL STUDY, ACTA RADIOL. SUPPL., 80, PP. 1-80, (1950); SCHOLTEN F.G., WENSING P.J., ATHEROGENESIS IN THE DISTAL PART OF THE FEMORAL ARTERY: A FUNCTIONAL ANATOMICAL STUDY OF LOCAL FACTORS, (1995); CARO C.G., FITZ-GERALD J.M., SCHROTER R.C., ARTERIAL WALL SHEAR AND DISTRIBUTION OF EARLY ATHEROMA IN MAN, NATURE, 223, PP. 1159-1160, (1969); LENG G.C., FOWLER B., ERNST E., EXERCISE FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST. REV., 2, (2000); ERNST E., FIALKA V., A REVIEW OF THE CLINICAL EFFECTIVENESS OF EXERCISE THERAPY FOR INTERMITTENT CLAUDICATION, ARCH. INTERN. MED., 153, PP. 2357-2360, (1993); WILLIAMS L.R., EKERS M.A., COLLINS P.S., LEE J.F., VASCULAR REHABILITATION: BENEFITS OF A STRUCTURED EXERCISE/RISK MODIFICATION PROGRAM, J. VASC. SURG., 14, PP. 320-326, (1991); PATTERSON R.B., PINTO B., MARCUS B., COLUCCI A., BRAUN T., ROBERTS M., VALUE OF A SUPERVISED EXERCISE PROGRAM FOR THE THERAPY OF ARTERIAL CLAUDICATION, J. VASC. SURG., 25, PP. 312-318, (1997); GARDNER A.W., POEHLMAN E.T., EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT OF CLAUDICATION PAIN. A META-ANALYSIS, JAMA, 274, PP. 975-980, (1995); COLLABORATIVE META-ANALYSIS OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY FOR PREVENTION OF DEATH, MYOCARDIAL INFARCTION, AND STROKE IN HIGH RISK PATIENTS, BMJ, 324, PP. 71-86, (2002); A RANDOMISED, BLINDED, TRIAL OF CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHAEMIC EVENTS (CAPRIE), LANCET, 348, PP. 1329-1339, (1996); DIENER H.C., BOGOUSSLAVSKY J., BRASS L.M., CIMMINIELLO C., CSIBA L., KASTE M., ET AL., ASPIRIN AND CLOPIDOGREL COMPARED WITH CLOPIDOGREL ALONE AFTER RECENT ISCHAEMIC STROKE OR TRANSIENT ISCHAEMIC ATTACK IN HIGH-RISK PATIENTS (MATCH): RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, LANCET, 364, PP. 331-337, (2004); BALSANO F., COCCHERI S., LIBRETTI A., NENCI G.G., CATALANO M., FORTUNATO G., ET AL., TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION: A 21-MONTH DOUBLE-BLIND TRIAL, J. LAB. CLIN. MED., 114, PP. 84-91, (1989); JOHNSON W.C., WILLIFORD W.O., BENEFITS, MORBIDITY, AND MORTALITY ASSOCIATED WITH LONG-TERM ADMINISTRATION OF ORAL ANTICOAGULANT THERAPY TO PATIENTS WITH PERIPHERAL ARTERIAL BYPASS PROCEDURES: A PROSPECTIVE RANDOMIZED STUDY, J. VASC. SURG., 35, PP. 413-421, (2002); EFFICACY OF ORAL ANTICOAGULANTS COMPARED WITH ASPIRIN AFTER INFRAINGUINAL BYPASS SURGERY (THE DUTCH BYPASS ORAL ANTICOAGULANTS OR ASPIRIN STUDY): A RANDOMISED TRIAL, LANCET, 355, PP. 346-351, (2000); DORFFLER-MELLY J., KOOPMAN M.M., PRINS M.H., BULLER H.R., ANTIPLATELET AND ANTICOAGULANT DRUGS FOR PREVENTION OF RESTENOSIS/REOCCLUSION FOLLOWING PERIPHERAL ENDOVASCULAR TREATMENT, COCHRANE DATABASE SYST. REV., 1, (2005); PORTER J.M., CUTLER B.S., LEE B.Y., REICH T., REICHLE F.A., SCOGIN J.T., ET AL., PENTOXIFYLLINE EFFICACY IN THE TREATMENT OF INTERMITTENT CLAUDICATION: MULTICENTER CONTROLLED DOUBLE-BLIND TRIAL WITH OBJECTIVE ASSESSMENT OF CHRONIC OCCLUSIVE ARTERIAL DISEASE PATIENTS, AM. HEART J., 104, PP. 66-72, (1982); HOOD S.C., MOHER D., BARBER G.G., MANAGEMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CMAJ, 155, PP. 1053-1059, (1996); DAWSON D.L., CUTLER B.S., MEISSNER M.H., STRANDNESS JR. D.E., CILOSTAZOL HAS BENEFICIAL EFFECTS IN TREATMENT OF INTERMITTENT CLAUDICATION: RESULTS FROM A MULTICENTER, RANDOMIZED, PROSPECTIVE, DOUBLE-BLIND TRIAL, CIRCULATION, 98, PP. 678-686, (1998); DAWSON D.L., CUTLER B.S., HIATT W.R., HOBSON R.W., MARTIN J.D., BORTEY E.B., ET AL., A COMPARISON OF CILOSTAZOL AND PENTOXIFYLLINE FOR TREATING INTERMITTENT CLAUDICATION, AM. J. MED., 109, PP. 523-530, (2000); STRANDNESS JR. D.E., DALMAN R.L., PANIAN S., RENDELL M.S., COMP P.C., ZHANG P., ET AL., EFFECT OF CILOSTAZOL IN PATIENTS WITH INTERMITTENT CLAUDICATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, VASC. ENDOVASCULAR SURG., 36, PP. 83-91, (2002); MONEY S.R., HERD J.A., ISAACSOHN J.L., DAVIDSON M., CUTLER B., HECKMAN J., ET AL., EFFECT OF CILOSTAZOL ON WALKING DISTANCES IN PATIENTS WITH INTERMITTENT CLAUDICATION CAUSED BY PERIPHERAL VASCULAR DISEASE, J. VASC. SURG., 27, PP. 267-274, (1998); ISHIZAKA N., TAGUCHI J., KIMURA Y., IKARI Y., AIZAWA T., TOGO M., ET AL., EFFECTS OF A SINGLE LOCAL ADMINISTRATION OF CILOSTAZOL ON NEOINTIMAL FORMATION IN BALLOON-INJURED RAT CAROTID ARTERY, ATHEROSCLEROSIS, 142, PP. 41-46, (1999); TAKE S., MATSUTANI M., UEDA H., HAMAGUCHI H., KONISHI H., BABA Y., ET AL., EFFECT OF CILOSTAZOL IN PREVENTING RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, AM. J. CARDIOL., 79, PP. 1097-1099, (1997); TSUCHIKANE E., FUKUHARA A., KOBAYASHI T., KIRINO M., YAMASAKI K., KOBAYASHI T., ET AL., IMPACT OF CILOSTAZOL ON RESTENOSIS AFTER PERCUTANEOUS CORONARY BALLOON ANGIOPLASTY, CIRCULATION, 100, PP. 21-26, (1999); PITTLER M.H., ERNST E., GINKGO BILOBA EXTRACT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMIZED TRIALS, AM. J. MED., 108, PP. 276-281, (2000); CASTANO G., MAS F.R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); JACOBY D., MOHLER III E.R., DRUG TREATMENT OF INTERMITTENT CLAUDICATION, DRUGS, 64, PP. 1657-1670, (2004); BREVETTI G., PERNA S., SABBA C., MARTONE V.D., CONDORELLI M., PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION: DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTICENTER STUDY, J. AM. COLL. CARDIOL., 26, PP. 1411-1416, (1995); BREVETTI G., PERNA S., SABBA C., MARTONE V.D., DI IORIO A., BARLETTA G., EFFECT OF PROPIONYL-L-CARNITINE ON QUALITY OF LIFE IN INTERMITTENT CLAUDICATION, AM. J. CARDIOL., 79, PP. 777-780, (1997); BREVETTI G., DIEHM C., LAMBERT D., EUROPEAN MULTICENTER STUDY ON PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION, J. AM. COLL. CARDIOL., 34, PP. 1618-1624, (1999); BREVETTI G., CHIARIELLO M., FERULANO G., POLICICCHIO A., NEVOLA E., ROSSINI A., ET AL., INCREASES IN WALKING DISTANCE IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE TREATED WITH L-CARNITINE: A DOUBLE-BLIND, CROSS-OVER STUDY, CIRCULATION, 77, PP. 767-773, (1988); BREVETTI G., DI LISA F., PERNA S., MENABO R., BARBATO R., MARTONE V.D., ET AL., CARNITINE-RELATED ALTERATIONS IN PATIENTS WITH INTERMITTENT CLAUDICATION: INDICATION FOR A FOCUSED CARNITINE THERAPY, CIRCULATION, 93, PP. 1685-1689, (1996); BOGER R.H., BODE-BOGER S.M., THIELE W., CREUTZIG A., ALEXANDER K., FROLICH J.C., RESTORING VASCULAR NITRIC OXIDE FORMATION BY L-ARGININE IMPROVES THE SYMPTOMS OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, J. AM. COLL. CARDIOL., 32, PP. 1336-1344, (1998); DIEHM C., BALZER K., BISLER H., BULLING B., CAMCI M., CREUTZIG A., ET AL., EFFICACY OF A NEW PROSTAGLANDIN E1 REGIMEN IN OUTPATIENTS WITH SEVERE INTERMITTENT CLAUDICATION: RESULTS OF A MULTICENTER PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL, J. VASC. SURG., 25, PP. 537-544, (1997); REITER M., BUCEK R.A., STUMPFLEN A., MINAR E., PROSTANOIDS FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST. REV., 1, (2004); WALKER S.R., TENNANT S., MACSWEENEY S.T., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO ASSESS THE IMMEDIATE EFFECT OF SUBLINGUAL GLYCERYL TRINITRATE ON THE ANKLE BRACHIAL PRESSURE INDEX, CLAUDICATION, AND MAXIMUM WALKING DISTANCE OF PATIENTS WITH INTERMITTENT CLAUDICATION, J. VASC. SURG., 28, PP. 895-900, (1998); BAGGER J.P., HELLIGSOE P., RANDSBAEK F., KIMOSE H.H., JENSEN B.S., EFFECT OF VERAPAMIL IN INTERMITTENT CLAUDICATION A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY AFTER INDIVIDUAL DOSE-RESPONSE ASSESSMENT, CIRCULATION, 95, PP. 411-414, (1997); BAFFOUR R., BERMAN J., GARB J.L., RHEE S.W., KAUFMAN J., FRIEDMANN P., ENHANCED ANGIOGENESIS AND GROWTH OF COLLATERALS BY IN VIVO ADMINISTRATION OF RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR IN A RABBIT MODEL OF ACUTE LOWER LIMB ISCHEMIA: DOSE-RESPONSE EFFECT OF BASIC FIBROBLAST GROWTH FACTOR, J. VASC. SURG., 16, PP. 181-191, (1992); ISNER J.M., WALSH K., SYMES J., PIECZEK A., TAKESHITA S., LOWRY J., ET AL., ARTERIAL GENE THERAPY FOR THERAPEUTIC ANGIOGENESIS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE, CIRCULATION, 91, PP. 2687-2692, (1995); TSURUMI Y., TAKESHITA S., CHEN D., KEARNEY M., ROSSOW S.T., PASSERI J., ET AL., DIRECT INTRAMUSCULAR GENE TRANSFER OF NAKED DNA ENCODING VASCULAR ENDOTHELIAL GROWTH FACTOR AUGMENTS COLLATERAL DEVELOPMENT AND TISSUE PERFUSION, CIRCULATION, 94, PP. 3281-3290, (1996); BAUMGARTNER I., PIECZEK A., MANOR O., BLAIR R., KEARNEY M., WALSH K., ET AL., CONSTITUTIVE EXPRESSION OF PHVEGF165 AFTER INTRAMUSCULAR GENE TRANSFER PROMOTES COLLATERAL VESSEL DEVELOPMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA, CIRCULATION, 97, PP. 1114-1123, (1998); ISNER J.M., BAUMGARTNER I., RAUH G., SCHAINFELD R., BLAIR R., MANOR O., ET AL., TREATMENT OF THROMBOANGIITIS OBLITERANS (BUERGER'S DISEASE) BY INTRAMUSCULAR GENE TRANSFER OF VASCULAR ENDOTHELIAL GROWTH FACTOR: PRELIMINARY CLINICAL RESULTS, J. VASC. SURG., 28, PP. 964-973, (1998); COMEROTA A.J., THROM R.C., MILLER K.A., HENRY T., CHRONOS N., LAIRD J., ET AL., NAKED PLASMID DNA ENCODING FIBROBLAST GROWTH FACTOR TYPE 1 FOR THE TREATMENT OF END-STAGE UNRECONSTRUCTIBLE LOWER EXTREMITY ISCHEMIA: PRELIMINARY RESULTS OF A PHASE I TRIAL, J. VASC. SURG., 35, PP. 930-936, (2002); LEDERMAN R.J., MENDELSOHN F.O., ANDERSON R.D., SAUCEDO J.F., TENAGLIA A.N., HERMILLER J.B., ET AL., THERAPEUTIC ANGIOGENESIS WITH RECOMBINANT FIBROBLAST GROWTH FACTOR-2 FOR INTERMITTENT CLAUDICATION (THE TRAFFIC STUDY): A RANDOMISED TRIAL, LANCET, 359, PP. 2053-2058, (2002); HUGHSON W.G., MANN J.I., TIBBS D.J., WOODS H.F., WALTON I., INTERMITTENT CLAUDICATION: FACTORS DETERMINING OUTCOME, BR. MED. J., 1, PP. 1377-1379, (1978); JUERGENS J.L., BARKER N.W., HINES JR. E.A., ARTERIOSCLEROSIS OBLITERANS: REVIEW OF 520 CASES WITH SPECIAL REFERENCE TO PATHOGENIC AND PROGNOSTIC FACTORS, CIRCULATION, 21, PP. 188-195, (1960); JONASON T., RINGQVIST I., FACTORS OF PROGNOSTIC IMPORTANCE FOR SUBSEQUENT REST PAIN IN PATIENTS WITH INTERMITTENT CLAUDICATION, ACTA MED. SCAND., 218, PP. 27-33, (1985); WILLIGENDAEL E.M., TEIJINK J.A., BARTELINK M.L., KUIKEN B.W., BOITEN J., MOLL F.L., ET AL., INFLUENCE OF SMOKING ON INCIDENCE AND PREVALENCE OF PERIPHERAL ARTERIAL DISEASE, J. VASC. SURG., 40, PP. 1158-1165, (2004); MYERS K.A., KING R.B., SCOTT D.F., JOHNSON N., MORRIS P.J., THE EFFECT OF SMOKING ON THE LATE PATENCY OF ARTERIAL RECONSTRUCTIONS IN THE LEGS, BR. J. SURG., 65, PP. 267-271, (1978); AMELI F.M., STEIN M., PROVAN J.L., PROSSER R., THE EFFECT OF POSTOPERATIVE SMOKING ON FEMOROPOPLITEAL BYPASS GRAFTS, ANN. VASC. SURG., 3, PP. 20-25, (1989); GREENHALGH R.M., LAING S.P., COLE P.V., TAYLOR G.W., SMOKING AND ARTERIAL RECONSTRUCTION, BR. J. SURG., 68, PP. 605-607, (1981); QUICK C.R., COTTON L.T., THE MEASURED EFFECT OF STOPPING SMOKING ON INTERMITTENT CLAUDICATION, BR. J. SURG., 69, SUPPL., (1982); MURABITO J.M., D'AGOSTINO R.B., SILBERSHATZ H., WILSON W.F., INTERMITTENT CLAUDICATION. A RISK PROFILE FROM THE FRAMINGHAM HEART STUDY, CIRCULATION, 96, PP. 44-49, (1997); GORDON T., KANNEL W.B., PREDISPOSITION TO ATHEROSCLEROSIS IN THE HEAD, HEART, AND LEGS. THE FRAMINGHAM STUDY, JAMA, 221, PP. 661-666, (1972); WEITZ J.I., BYRNE J., CLAGETT G.P., FARKOUH M.E., PORTER J.M., SACKETT D.L., ET AL., DIAGNOSIS AND TREATMENT OF CHRONIC ARTERIAL INSUFFICIENCY OF THE LOWER EXTREMITIES: A CRITICAL REVIEW, CIRCULATION, 94, PP. 3026-3049, (1996); KANNEL W.B., CASTELLI W.P., GORDON T., CHOLESTEROL IN THE PREDICTION OF ATHEROSCLEROTIC DISEASE. NEW PERSPECTIVES BASED ON THE FRAMINGHAM STUDY, ANN. INTERN. MED., 90, PP. 85-91, (1979); KASTELEIN J.J., THE FUTURE OF BEST PRACTICE, ATHEROSCLEROSIS, 143, SUPPL. 1, (1999); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); THE EFFECTS OF CHOLESTEROL LOWERING WITH SIMVASTATIN ON CAUSE-SPECIFIC MORTALITY AND ON CANCER INCIDENCE IN 20,536 HIGH-RISK PEOPLE: A RANDOMISED PLACEBO-CONTROLLED TRIAL ISRCTN48489393, BMC MED., 3, (2005); MOHLER III E.R., HIATT W.R., CREAGER M.A., CHOLESTEROL REDUCTION WITH ATORVASTATIN IMPROVES WALKING DISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 108, PP. 1481-1486, (2003); MCDERMOTT M.M., GURALNIK J.M., GREENLAND P., PEARCE W.H., CRIQUI M.H., LIU K., ET AL., STATIN USE AND LEG FUNCTIONING IN PATIENTS WITH AND WITHOUT LOWER-EXTREMITY PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 107, PP. 757-761, (2003); HYNES N., AKHTAR Y., MANNING B., AREMU M., OIAKHINAN K., COURTNEY D., ET AL., SUBINTIMAL ANGIOPLASTY AS A PRIMARY MODALITY IN THE MANAGEMENT OF CRITICAL LIMB ISCHEMIA: COMPARISON TO BYPASS GRAFTING FOR AORTOILIAC AND FEMOROPOPLITEAL OCCLUSIVE DISEASE, J. ENDOVASC. THER., 11, PP. 460-471, (2004); LOFBERG A.M., KARACAGIL S., LJUNGMAN C., WESTMAN B., BOSTROM A., HELLBERG A., ET AL., PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY OF THE FEMOROPOPLITEAL ARTERIES IN LIMBS WITH CHRONIC CRITICAL LOWER LIMB ISCHEMIA, J. VASC. SURG., 34, PP. 114-121, (2001); DORMANDY J.A., RUTHERFORD R.B., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD), J. VASC. SURG., 31, 1 PART 2, (2000); CHENG S.W., TING A.C., HO P., ANGIOPLASTY AND PRIMARY STENTING OF HIGH-GRADE, LONG-SEGMENT SUPERFICIAL FEMORAL ARTERY DISEASE: IS IT WORTHWHILE?, ANN. VASC. SURG., 17, PP. 430-437, (2003); CONROY R.M., GORDON I.L., TOBIS J.M., HIRO T., KASAOKA S., STEMMER E.A., ET AL., ANGIOPLASTY AND STENT PLACEMENT IN CHRONIC OCCLUSION OF THE SUPERFICIAL FEMORAL ARTERY: TECHNIQUE AND RESULTS, J. VASC. INTERV. RADIOL., 11, PP. 1009-1020, (2000); FOWKES F.G., GILLESPIE I.N., ANGIOPLASTY (VERSUS NON SURGICAL MANAGEMENT) FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE SYST. REV., 2, (2000); SAPOVAL M.R., LONG A.L., RAYNAUD A.C., BEYSSEN B.M., FIESSINGER J.N., GAUX J.C., FEMOROPOPLITEAL STENT PLACEMENT: LONG-TERM RESULTS, RADIOLOGY, 184, PP. 833-839, (1992); DO-DAI-DO TRILLER J., WALPOTH B.H., STIRNEMANN P., MAHLER F., A COMPARISON STUDY OF SELF-EXPANDABLE STENTS VS BALLOON ANGIOPLASTY ALONE IN FEMOROPOPLITEAL ARTERY OCCLUSIONS, CARDIOVASC. INTERVENT. RADIOL., 15, PP. 306-312, (1992); VROEGINDEWEIJ D., VOS L.D., TIELBEEK A.V., BUTH J., VD BOSCH H.C., BALLOON ANGIOPLASTY COMBINED WITH PRIMARY STENTING VERSUS BALLOON ANGIOPLASTY ALONE IN FEMOROPOPLITEAL OBSTRUCTIONS: A COMPARATIVE RANDOMIZED STUDY, CARDIOVASC. INTERVENT. RADIOL., 20, PP. 420-425, (1997); CEJNA M., THURNHER S., ILLIASCH H., HORVATH W., WALDENBERGER P., HORNIK K., ET AL., PTA VERSUS PALMAZ STENT PLACEMENT IN FEMOROPOPLITEAL ARTERY OBSTRUCTIONS: A MULTICENTER PROSPECTIVE RANDOMIZED STUDY, J. VASC. INTERV. RADIOL., 12, PP. 23-31, (2001); CEJNA M., SCHODER M., LAMMER J., PTA VS STENT IN FEMORO-POPLITEAL OBSTRUCTION, RADIOLOGE, 39, PP. 144-150, (1999); GRENACHER L., SAAM T., GEIER A., MULLER-HULSBECK S., CEJNA M., KAUFFMANN G.W., ET AL., PTA VERSUS PALMAZ STENT PLACEMENT IN FEMOROPOPLITEAL ARTERY STENOSES: RESULTS OF A MULTICENTER PROSPECTIVE RANDOMIZED STUDY (REFSA), ROFO, 176, PP. 1302-1310, (2004); GRIMM J., MULLER-HULSBECK S., JAHNKE T., HILBERT C., BROSSMANN J., HELLER M., RANDOMIZED STUDY TO COMPARE PTA ALONE VERSUS PTA WITH PALMAZ STENT PLACEMENT FOR FEMOROPOPLITEAL LESIONS, J. VASC. INTERV. RADIOL., 12, PP. 935-942, (2001); GRAY B.H., OLIN J.W., LIMITATIONS OF PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY WITH STENTING FOR FEMOROPOPLITEAL ARTERIAL OCCLUSIVE DISEASE, SEMIN. VASC. SURG., 10, PP. 8-16, (1997); GRAY B.H., SULLIVAN T.M., CHILDS M.B., YOUNG J.R., OLIN J.W., HIGH INCIDENCE OF RESTENOSIS/REOCCLUSION OF STENTS IN THE PERCUTANEOUS TREATMENT OF LONG-SEGMENT SUPERFICIAL FEMORAL ARTERY DISEASE AFTER SUBOPTIMAL ANGIOPLASTY, J. VASC. SURG., 25, PP. 74-83, (1997); ANSEL G.M., ENDOVASCULAR TREATMENT OF SUPERFICIAL FEMORAL AND POPLITEAL ARTERIAL OCCLUSIVE DISEASE, J. INVASIVE CARDIOL., 12, PP. 382-388, (2000); LAMMER J., DAKE M.D., BLEYN J., KATZEN B.T., CEJNA M., PIQUET P., ET AL., PERIPHERAL ARTERIAL OBSTRUCTION: PROSPECTIVE STUDY OF TREATMENT WITH A TRANSLUMINALLY PLACED SELF-EXPANDING STENT-GRAFT, RADIOLOGY, 217, PP. 95-104, (2000); DORRUCCI V., TREATMENT OF SUPERFICIAL FEMORAL ARTERY OCCLUSIVE DISEASE, J. CARDIOVASC. SURG. (TORINO), 45, PP. 193-201, (2004); BERGERON P., PINOT J.J., POYEN V., BENICHOU H., KHANOYAN P., RUDONDY P., ET AL., LONG-TERM RESULTS WITH THE PALMAZ STENT IN THE SUPERFICIAL FEMORAL ARTERY, J. ENDOVASC. SURG., 2, PP. 161-167, (1995); CHATELARD P., GUIBOURT C., LONG-TERM RESULTS WITH A PALMAZ STENT IN THE FEMOROPOPLITEAL ARTERIES, J. CARDIOVASC. SURG. (TORINO), 37, 3 SUPPL. 1, PP. 67-72, (1996); GORDON I.L., CONROY R.M., AREFI M., TOBIS J.M., STEMMER E.A., WILSON S.E., THREE-YEAR OUTCOME OF ENDOVASCULAR TREATMENT OF SUPERFICIAL FEMORAL ARTERY OCCLUSION, ARCH. SURG., 136, PP. 221-228, (2001); STRECKER E.P., BOOS I.B., GOTTMANN D., FEMOROPOPLITEAL ARTERY STENT PLACEMENT: EVALUATION OF LONG-TERM SUCCESS, RADIOLOGY, 205, PP. 375-383, (1997); MEWISSEN M.W., SELF-EXPANDING NITINOL STENTS IN THE FEMOROPOPLITEAL SEGMENT: TECHNIQUE AND MID-TERM RESULTS, TECH. VASC. INTERV. RADIOL., 7, PP. 2-5, (2004); CHO L., ROFFI M., MUKHERJEE D., BHATT D.L., BAJZER C., YADAV J.S., SUPERFICIAL FEMORAL ARTERY OCCLUSION: NITINOL STENTS ACHIEVE BETTER FLOW AND REDUCE THE NEED FOR MEDICATIONS THAN BALLOON ANGIOPLASTY ALONE, J. INVASIVE CARDIOL., 15, PP. 198-200, (2003); VOGEL T.R., SHINDELMAN L.E., NACKMAN G.B., GRAHAM A.M., EFFICACIOUS USE OF NITINOL STENTS IN THE FEMORAL AND POPLITEAL ARTERIES, J. VASC. SURG., 38, PP. 1178-1184, (2003); HENRY M., AMOR M., BEYAR R., HENRY I., PORTE J.M., MENTRE B., ET AL., CLINICAL EXPERIENCE WITH A NEW NITINOL SELF-EXPANDING STENT IN PERIPHERAL ARTERIES, J. ENDOVASC. SURG., 3, PP. 369-379, (1996); JAHNKE T., VOSHAGE G., MULLER-HULSBECK S., GRIMM J., HELLER M., BROSSMANN J., ENDOVASCULAR PLACEMENT OF SELF-EXPANDING NITINOL COIL STENTS FOR THE TREATMENT OF FEMOROPOPLITEAL OBSTRUCTIVE DISEASE, J. VASC. INTERV. RADIOL., 13, PP. 257-266, (2002); DUDA S.H., PUSICH B., RICHTER G., LANDWEHR P., OLIVA V.L., TIELBEEK A., ET AL., SIROLIMUS-ELUTING STENTS FOR THE TREATMENT OF OBSTRUCTIVE SUPERFICIAL FEMORAL ARTERY DISEASE: SIX-MONTH RESULTS, CIRCULATION, 106, PP. 1505-1509, (2002); LUGMAYR H.F., HOLZER H., KASTNER M., RIEDELSBERGER H., AUTERITH A., TREATMENT OF COMPLEX ARTERIOSCLEROTIC LESIONS WITH NITINOL STENTS IN THE SUPERFICIAL FEMORAL AND POPLITEAL ARTERIES: A MIDTERM FOLLOW-UP, RADIOLOGY, 222, PP. 37-43, (2002); SCHEINERT D., SCHEINERT S., SAX J., PIORKOWSKI C., BRAUNLICH S., ULRICH M., ET AL., PREVALENCE AND CLINICAL IMPACT OF STENT FRACTURES AFTER FEMOROPOPLITEAL STENTING, J. AM. COLL. CARDIOL., 45, PP. 312-315, (2005); CRAGG A.H., DAKE M.D., TREATMENT OF PERIPHERAL VASCULAR DISEASE WITH STENT-GRAFTS, RADIOLOGY, 205, PP. 307-314, (1997); HENRY M., AMOR M., CRAGG A., PORTE J.M., HENRY I., AMICABILE C., ET AL., OCCLUSIVE AND ANEURYSMAL PERIPHERAL ARTERIAL DISEASE: ASSESSMENT OF A STENT-GRAFT SYSTEM, RADIOLOGY, 201, PP. 717-724, (1996); KESSEL D.O., WIJESINGHE L.D., ROBERTSON I., SCOTT D.J., RAAT H., STOCKX L., ET AL., ENDOVASCULAR STENT-GRAFTS FOR SUPERFICIAL FEMORAL ARTERY DISEASE: RESULTS OF 1-YEAR FOLLOW-UP, J. VASC. INTERV. RADIOL., 10, PP. 289-296, (1999); AHMADI R., SCHILLINGER M., MACA T., MINAR E., FEMOROPOPLITEAL ARTERIES: IMMEDIATE AND LONG-TERM RESULTS WITH A DACRON-COVERED STENT-GRAFT, RADIOLOGY, 223, PP. 345-350, (2002); JAHNKE T., ANDRESEN R., MULLER-HULSBECK S., SCHAFER F.K., VOSHAGE G., HELLER M., ET AL., HEMOBAHN STENT-GRAFTS FOR TREATMENT OF FEMOROPOPLITEAL ARTERIAL OBSTRUCTIONS: MIDTERM RESULTS OF A PROSPECTIVE TRIAL, J. VASC. INTERV. RADIOL., 14, PP. 41-51, (2003); FISHER M., LANGHOFF R., SCHULTE K.L., HEMOBAHN-ENDOPROSTHESIS: LONG-TERM EXPERIENCE (< OR = 4 YEARS FOLLOW-UP) WITH PERCUTANEOUS APPLICATION IN STENOSIS AND OCCLUSIONS OF THE SUPERFICIAL FEMORAL ARTERY, ZENTRALBL CHIR., 128, PP. 740-745, (2003); BRAY P.J., ROBSON W.J., BRAY A.E., PERCUTANEOUS TREATMENT OF LONG SUPERFICIAL FEMORAL ARTERY OCCLUSIVE DISEASE: EFFICACY OF THE HEMOBAHN STENT-GRAFT, J. ENDOVASC. THER., 10, PP. 619-628, (2003); SAXON R.R., COFFMAN J.M., GOODING J.M., PONEC D.J., ENDOGRAFT USE IN THE FEMORAL AND POPLITEAL ARTERIES, TECH. VASC. INTERV. RADIOL., 7, PP. 6-15, (2004); DUDA S.H., BOSIERS M., LAMMER J., SCHEINERT D., ZELLER T., TIELBEEK A., ET AL., SIROLIMUS-ELUTING VERSUS BARE NITINOL STENT FOR OBSTRUCTIVE SUPERFICIAL FEMORAL ARTERY DISEASE: THE SIROCCO II TRIAL, J. VASC. INTERV. RADIOL., 16, PP. 331-338, (2005); BOLIA A., MILES K.A., BRENNAN J., BELL P.R., PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY OF OCCLUSIONS OF THE FEMORAL AND POPLITEAL ARTERIES BY SUBINTIMAL DISSECTION, CARDIOVASC. INTERVENT. RADIOL., 13, PP. 357-363, (1990); REEKERS J.A., KROMHOUT J.G., JACOBS M.J., PERCUTANEOUS INTENTIONAL EXTRALUMINAL RECANALISATION OF THE FEMOROPOPLITEAL ARTERY, EUR. J. VASC. SURG., 8, PP. 723-728, (1994); YILMAZ S., SINDEL T., YEGIN A., LULECI E., SUBINTIMAL ANGIOPLASTY OF LONG SUPERFICIAL FEMORAL ARTERY OCCLUSIONS, J. VASC. INTERV. RADIOL., 14, PP. 997-1010, (2003); MCCARTHY R.J., NEARY W., ROOBOTTOM C., TOTTLE A., ASHLEY S., SHORT-TERM RESULTS OF FEMOROPOPLITEAL SUBINTIMAL ANGIOPLASTY, BR. J. SURG., 87, PP. 1361-1365, (2000); SHAW M.B., DENUNZIO M., HINWOOD D., NASH R., CALLUM K.G., BRAITHWAITE B.D., THE RESULTS OF SUBINTIMAL ANGIOPLASTY IN A DISTRICT GENERAL HOSPITAL, EUR. J. VASC. ENDOVASC. SURG., 24, PP. 524-527, (2002); LONDON N.J., SRINIVASAN R., NAYLOR A.R., HARTSHORNE T., RATLIFF D.A., BELL P.R., ET AL., SUBINTIMAL ANGIOPLASTY OF FEMOROPOPLITEAL ARTERY OCCLUSIONS: THE LONG-TERM RESULTS, EUR. J. VASC. SURG., 8, PP. 148-155, (1994); LIPSITZ E.C., OHKI T., VEITH F.J., SUGGS W.D., WAIN R.A., CYNAMON J., ET AL., DOES SUBINTIMAL ANGIOPLASTY HAVE A ROLE IN THE TREATMENT OF SEVERE LOWER EXTREMITY ISCHEMIA?, J. VASC. SURG., 37, PP. 386-391, (2003); LIPSITZ E.C., VEITH F.J., OHKI T., THE VALUE OF SUBINTIMAL ANGIOPLASTY IN THE MANAGEMENT OF CRITICAL LOWER EXTREMITY ISCHEMIA: FAILURE IS NOT ALWAYS ASSOCIATED WITH A RETHREATENED LIMB, J. CARDIOVASC. SURG. (TORINO), 45, PP. 231-237, (2004); REEKERS J.A., PERCUTANEOUS INTENTIONAL EXTRALUMINAL (SUBINTIMAL) REVASCULARIZATION (PIER) FOR CRITICAL LOWER LIMB ISCHEMIA: TOO GOOD TO BE TRUE?, J. ENDOVASC. THER., 9, PP. 419-421, (2002); WAKSMAN R., ENDOVASCULAR BRACHYTHERAPY: OVERCOMING ""PRACTICAL"" OBSTACLES, AM. J. CARDIOL., 81, 7 A, (1998); SCHILLINGER M., MINAR E., ADVANCES IN VASCULAR BRACHYTHERAPY OVER THE LAST 10 YEARS: FOCUS ON FEMOROPOPLITEAL APPLICATIONS, J. ENDOVASC. THER., 11, SUPPL. 2, (2004); WYTTENBACH R., GALLINO A., ALERCI M., MAHLER F., COZZI L., DI VALENTINO M., ET AL., EFFECTS OF PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY AND ENDOVASCULAR BRACHYTHERAPY ON VASCULAR REMODELING OF HUMAN FEMOROPOPLITEAL ARTERY BY NONINVASIVE MAGNETIC RESONANCE IMAGING, CIRCULATION, 110, PP. 1156-1161, (2004); HAGENAARS T., A PO I.F., VAN SAMBEEK M.R., COEN V.L., VAN TONGEREN R.B., GESCHER F.M., ET AL., GAMMA RADIATION INDUCES POSITIVE VASCULAR REMODELING AFTER BALLOON ANGIOPLASTY: A PROSPECTIVE, RANDOMIZED INTRAVASCULAR ULTRASOUND SCAN STUDY, J. VASC. SURG., 36, PP. 318-324, (2002); SCHEINERT D., LAIRD JR. J.R., SCHRODER M., STEINKAMP H., BALZER J.O., BIAMINO G., EXCIMER LASER-ASSISTED RECANALIZATION OF LONG, CHRONIC SUPERFICIAL FEMORAL ARTERY OCCLUSIONS, J. ENDOVASC. THER., 8, PP. 156-166, (2001); WISSGOTT C., SCHEINERT D., RADEMAKER J., WERK M., SCHEDEL H., STEINKAMP H.J., TREATMENT OF LONG SUPERFICIAL FEMORAL ARTERY OCCLUSIONS WITH EXCIMER LASER ANGIOPLASTY: LONG-TERM RESULTS AFTER 48 MONTHS, ACTA RADIOL., 45, PP. 23-29, (2004); STEINKAMP H.J., RADEMAKER J., WISSGOTT C., SCHEINERT D., WERK M., SETTMACHER U., ET AL., PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY VERSUS BALLOON DILATION FOR TREATMENT OF POPLITEAL ARTERY OCCLUSIONS, J. ENDOVASC. THER., 9, PP. 882-888, (2002); KLINKERT P., POST P.N., BRESLAU P.J., VAN BOCKEL J.H., SAPHENOUS VEIN VERSUS PTFE FOR ABOVE-KNEE FEMOROPOPLITEAL BYPASS. A REVIEW OF THE LITERATURE, EUR. J. VASC. ENDOVASC. SURG., 27, PP. 357-362, (2004); BERGLUND J., BJORCK M., ELFSTROM J., LONG-TERM RESULTS OF ABOVE KNEE FEMORO-POPLITEAL BYPASS DEPEND ON INDICATION FOR SURGERY AND GRAFT-MATERIAL, EUR. J. VASC. ENDOVASC. SURG., 29, PP. 412-418, (2005); CONNOLLY J.E., IN SITU SAPHENOUS VEIN BYPASS-FORTY YEARS LATER, WORLD J. SURG., 29, SUPPL. 1, (2005); SAYERS R.D., WATT P.A., BELL P.R., THURSTON H., ENDOTHELIUM-DERIVED RELAXING FACTOR IS ABSENT IN EXPERIMENTAL IN SITU VEIN GRAFTS, EUR. J. VASC. SURG., 8, (1994); ROSENTHAL D., ANGIOSCOPY IN VASCULAR SURGERY, CARDIOVASC. SURG., 5, PP. 245-255, (1997); HARRIS P.L., VEITH F.J., SHANIK G.D., NOTT D., WENGERTER K.R., MOORE D.J., PROSPECTIVE RANDOMIZED COMPARISON OF IN SITU AND REVERSED INFRAPOPLITEAL VEIN GRAFTS, BR. J. SURG., 80, PP. 173-176, (1993); WATELET J., SOURY P., MENARD J.F., PLISSONNIER D., PELLLON C., LESTRAT J.P., ET AL., FEMOROPOPLITEAL BYPASS: IN SITU OR REVERSED VEIN GRAFTS? TEN-YEAR RESULTS OF A RANDOMIZED PROSPECTIVE STUDY, ANN. VASC. SURG., 11, PP. 510-519, (1997); MOODY A.P., EDWARDS P.R., HARRIS P.L., IN SITU VERSUS REVERSED FEMOROPOPLITEAL VEIN GRAFTS: LONG-TERM FOLLOW-UP OF A PROSPECTIVE, RANDOMIZED TRIAL, BR. J. SURG., 79, PP. 750-752, (1992); DAVIDOVIC L.B., MARKOVIC D.M., VOJNOVIC B.R., LOTINA S.T., KOSTIC D.M., CINARA I.S., ET AL., FEMORO-POPLITEAL RECONSTRUCTIONS: ""IN SITU"" VERSUS ""REVERSED"" TECHNIQUE, CARDIOVASC. SURG., 9, PP. 356-361, (2001); DAVIES A.H., MAGEE T.R., BAIRD R.N., SHEFFIELD E., HORROCKS M., VEIN COMPLIANCE: A PREOPERATIVE INDICATOR OF VEIN MORPHOLOGY AND OF VEINS AT RISK OF VASCULAR GRAFT STENOSIS, BR. J. SURG., 79, PP. 1019-1021, (1992); LEATHER R.P., SHAH D.M., CHANG B.B., KAUFMAN J.L., RESURRECTION OF THE IN SITU SAPHENOUS VEIN BYPASS. 1000 CASES LATER, ANN. SURG., 208, PP. 435-442, (1988); TOWNE J.B., SCHMITT D.D., SEABROOK G.R., BANDYK D.F., THE EFFECT OF VEIN DIAMETER ON PATENCY OF IN SITU GRAFTS, J. CARDIOVASC. SURG. (TORINO), 32, PP. 192-196, (1991); MAMODE N., SCOTT R.N., GRAFT TYPE FOR FEMORO-POPLITEAL BYPASS SURGERY, COCHRANE DATABASE SYST. REV., 2, (2000); VAN DER HEIJDEN F.H., EIKELBOOM B.C., REEDT DORTLAND R.W., VAN DER G.Y., STEIJLING J.J., LEGEMATE D.A., ET AL., LONG-TERM RESULTS OF SEMICLOSED ENDARTERECTOMY OF THE SUPERFICIAL FEMORAL ARTERY AND THE OUTCOME OF FAILED RECONSTRUCTIONS, J. VASC. SURG., 18, PP. 271-279, (1993); MOLL F.L., HO G.H., CLOSED SUPERFICIAL FEMORAL ARTERY ENDARTERECTOMY: A 2-YEAR FOLLOW-UP, CARDIOVASC. SURG., 5, PP. 398-400, (1997); HO G.H., MOLL F.L., REMOTE ENDARTERECTOMY IN SFA OCCLUSIVE DISEASE, EUR. J. RADIOL., 28, PP. 205-210, (1998); SMEETS L., HO G.H., HAGENAARS T., VAN DEN BERG J.C., TEIJINK J.A., MOLL F.L., REMOTE ENDARTERECTOMY: FIRST CHOICE IN SURGICAL TREATMENT OF LONG SEGMENTAL SFA OCCLUSIVE DISEASE?, EUR. J. VASC. ENDOVASC. SURG., 25, PP. 583-589, (2003); NELSON P.R., POWELL R.J., PROIA R.R., SCHERMERHORN M.L., FILLINGER M.F., ZWOLAK R.M., ET AL., RESULTS OF ENDOVASCULAR SUPERFICIAL FEMORAL ENDARTERECTOMY, J. VASC. SURG., 34, PP. 526-531, (2001); GALLAND R.B., WHITELEY M.S., GIBSON M., SIMMONS M.J., TORRIE E.P., MAGEE T.R., MAINTENANCE OF PATENCY FOLLOWING REMOTE SUPERFICIAL FEMORAL ARTERY ENDARTERECTOMY, CARDIOVASC. SURG., 8, PP. 533-537, (2000); HO G.H., VAN BUREN P.A., MOLL F.L., VAN DER BOM J.G., EIKELBOOM B.C., THE IMPORTANCE OF REVISION OF EARLY RESTENOSIS AFTER ENDOVASCULAR REMOTE ENDARTERECTOMY IN SFA OCCLUSIVE DISEASE, EUR. J. VASC. ENDOVASC. SURG., 19, PP. 35-42, (2000); HEIJMEN R.H., TEIJINK J.A., VAN DEN BERG J.C., OVERTOOM T.T., PASTERKAMP G., MOLL F.L., USE OF A BALLOON-EXPANDABLE, RADIALLY REINFORCED EPTFE ENDOGRAFT AFTER REMOTE SFA ENDARTERECTOMY: A SINGLE-CENTER EXPERIENCE, J. ENDOVASC. THER., 8, PP. 408-416, (2001); TEIJINK J.A., VAN DEN BERG J.C., MOLL F.L., A MINIMALLY INVASIVE TECHNIQUE IN OCCLUSIVE DISEASE OF THE SUPERFICIAL FEMORAL ARTERY: REMOTE ENDARTERECTOMY USING THE MOLLRING CUTTER, ANN. VASC. SURG., 15, PP. 594-598, (2001); MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE PAD), EUR. J. VASC. ENDOVASC. SURG., 19, SUPPL. A, (2000)","F.L. MOLL; DEPARTMENT OF VASCULAR SURGERY, UNIVERSITY MEDICAL CENTER UTRECHT, 3508 GA UTRECHT, P.O. BOX 85500, NETHERLANDS; EMAIL: F.L.MOLL@UMCUTRECHT.NL","","ENGLISH","J. CARDIOVASC. SURG.","REVIEW","ISI","2-S2.0-27744495927","J CARDIOVASC SURG","ST. ANTONIUS HOSPITAL;UNIVERSITY MEDICAL CENTER;ST. ANTONIUS HOSPITAL;UNIVERSITY MEDICAL CENTER","NOTREPORTED;UNIVERSITY MEDICAL CENTER UTRECHT;NOTREPORTED",NA,"GISBERTZ SS, 2005, J CARDIOVASC SURG","GISBERTZ SS, 2005, J CARDIOVASC SURG"
"JACOBY D;MOHLER I E","JACOBY, DOUGLAS (7005087541); MOHLER III, EMILE R. (35370495800)","DRUG TREATMENT OF INTERMITTENT CLAUDICATION",2004,"DRUGS","64","13",63,"10.2165/00003495-200464150-00004","DEPARTMENT OF MEDICINE, CARDIOVASCULAR DIVISION, UNIV. OF PA SCHOOL OF MEDICINE, PHILADELPHIA, PA, UNITED STATES;DEPARTMENT OF MEDICINE, CARDIOVASCULAR DIVISION, UNIV. OF PA SCHOOL OF MEDICINE, PHILADELPHIA, PA, UNITED STATES, UNIV. OF PA SCHOOL OF MEDICINE, PHI BUILDING, PHILADELPHIA, PA 19104, 51 N. 39TH STREET, UNITED STATES","THE US FDA HAS APPROVED TWO DRUGS FOR THE MANAGEMENT OF INTERMITTENT CLAUDICATION: PENTOXIFYLLINE AND CILOSTAZOL. THE MECHANISM OF ACTION THAT PROVIDES SYMPTOM RELIEF WITH PENTOXIFYLLINE IS POORLY UNDERSTOOD BUT IS THOUGHT TO INVOLVE RED BLOOD CELL DEFORMABILITY AS WELL AS A REDUCTION IN FIBRINOGEN CONCENTRATION, PLATELET ADHESIVENESS AND WHOLE BLOOD VISCOSITY. THE RECOMMENDED DOSE OF PENTOXIFYLLINE IS 400MG THREE TIMES DAILY WITH MEALS. CILOSTAZOL IS A POTENT, REVERSIBLE, PHOSPHODIESTERASE III INHIBITOR. THE INHIBITION OF PHOSPHODIESTERASE ALLOWS FOR THE INCREASED AVAILABILITY OF CYCLIC ADENOSINE MONOPHOSPHATE (CAMP). CAMP MEDIATES MANY AGONIST-INDUCED PLATELET INHIBITORY, VASODILATORY AND VASCULAR ANTIPROLIFERATIVE RESPONSES. CILOSTAZOL, AT A DOSE OF 100MG TWICE DAILY, IS RECOMMENDED TO BE TAKEN 30 MINUTES BEFORE OR 2 HOURS AFTER BREAKFAST AND DINNER. IN ADDITION TO PENTOXIFYLLINE AND CILOSTAZOL, CLINICAL TRIALS INDICATE MANY OTHER DRUGS MAY RELIEVE THE SYMPTOMS OF INTERMITTENT CLAUDICATION. GINKGO BILOBA, AVAILABLE AS AN OVER-THE-COUNTER EXTRACT, PROVIDES SYMPTOM RELIEF COMPARABLE TO PENTOXIFYLLINE. TWO EUROPEAN AGENTS, NAFTIDROFURYL AND BUFLOMEDIL, ALSO HAVE EFFICACY THAT IS REPORTED TO BE SIMILAR TO PENTOXIFYLLINE. POLICOSANOL IS A MIXTURE OF FATTY ALCOHOLS DERIVED FROM HONEYBEE WAX WHICH, ACCORDING TO VERY LIMITED DATA, REDUCES SYMPTOMS OF CLAUDICATION. AMINO ACIDS, CERTAIN PEPTIDES AND PROSTAGLANDINS MAY HAVE A THERAPEUTIC ROLE. FINALLY, NOVEL APPROACHES INCLUDING ANGIOGENESIS MEDIATED BY GROWTH FACTORS, ARE CURRENTLY UNDER INVESTIGATION.","","ANIMALS; CLINICAL TRIALS; HUMANS; INTERMITTENT CLAUDICATION; PENTOXIFYLLINE; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS; APIS MELLIFERA; GINKGO BILOBA; ACETYLSALICYLIC ACID; AMINO ACID DERIVATIVE; ARGININE; BUFLOMEDIL; CARNITINE; CILOSTAZOL; CIMETIDINE; GINKGO BILOBA EXTRACT; GLUTATHIONE; HISTAMINE H2 RECEPTOR ANTAGONIST; NAFTIDROFURYL; OMEPRAZOLE; PENTOXIFYLLINE; PEPTIDE DERIVATIVE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; POLICOSANOL; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; SOMATOMEDIN C; SULODEXIDE; TICLOPIDINE; UNINDEXED DRUG; WARFARIN; XANTHINE; ANGINA PECTORIS; ANGIOGENESIS; BLEEDING; BLOOD VISCOSITY; BRADYCARDIA; CARDIOTOXICITY; CLINICAL TRIAL; CRYSTALLIZATION; DEATH; DERMATITIS; DISEASE EXACERBATION; DIZZINESS; DRUG HYPERSENSITIVITY; DYSPEPSIA; ERYTHEMA; ERYTHROCYTE DEFORMABILITY; FIBRINOGEN BLOOD LEVEL; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART PALPITATION; HEPATITIS; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOTENSION; INSOMNIA; INTERMITTENT CLAUDICATION; IRRITABILITY; KIDNEY FAILURE; NAUSEA; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PHARYNGITIS; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; STROKE; SYNCOPE; TACHYCARDIA; THROMBOCYTE ADHESIVENESS; TRANSIENT ISCHEMIC ATTACK; UREA NITROGEN BLOOD LEVEL; URTICARIA; VOMITING","","","HIRSCH A.T., CRIQUI M.H., TREAT-JACOBSON D., ET AL., PERIPHERAL ARTERIAL DISEASE DETECTION, AWARENESS, AND TREATMENT IN PRIMARY CARE, JAMA, 286, 11, PP. 1317-1324, (2001); CRIQUI M.H., FRONEK A., BARRETT-CONNOR E., ET AL., THE PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN A DEFINED POPULATION, CIRCULATION, 71, PP. 510-515, (1985); WEITZ J.I., BYRNE J., CLAGETT G.P., ET AL., DIAGNOSIS AND TREATMENT OF CHRONIC ARTERIAL INSUFFICIENCY OF THE LOWER EXTREMITIES: A CRITICAL REVIEW, CIRCULATION, 94, PP. 3026-3049, (1996); DORMANDY J.A., RUTHERFORD R.B., MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD): TASC WORKING GROUP. TRANSATLANTIC INTER-SOCIETY CONCENSUS (TASC), J VASC SURG, 31, 1 PART 2, (2000); SCHAINFELD R.M., POTENTIAL EMERGING THERAPEUTIC STRATEGIES TO PREVENT RESTENOSIS IN THE PERIPHERAL VASCULATURE, CATHETER CARDIOVASC INTERV, 56, 3, PP. 421-431, (2002); MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD). TRANSATLANTIC INTER-SOCIETY CONSENSUS (TASC), EUR J VASC ENDOVASC SURG, 19, SUPPL. A, (2000); ISNER J.M., ROSENFIELD K., REDEFINING THE TREATMENT OF PERIPHERAL ARTERY DISEASE: ROLE OF PERCUTANEOUS REVASCULARIZATION, CIRCULATION, 88, 4 PART 1, PP. 1534-1557, (1993); WARD A., CLISSOLD S.P., PENTOXIFYLLINE: A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND ITS THERAPEUTIC EFFICACY, DRUGS, 34, 1, PP. 50-97, (1987); PORTER J.M., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE EFFICACY IN THE TREATMENT OF INTERMITTENT CLAUDICATION: MULTICENTER CONTROLLED DOUBLE-BLIND TRIAL WITH OBJECTIVE ASSESSMENT OF CHRONIC OCCLUSIVE ARTERIAL DISEASE PATIENTS, AM HEART J, 104, PP. 66-72, (1982); REICH T., CUTLER B.C., LEE B.Y., ET AL., PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION OF THE LOWER LIMBS, ANGIOLOGY, 35, PP. 389-395, (1984); ROEKAERTS F., DELEERS L., TRENTAL 400 IN THE TREATMENT OF INTERMITTENT CLAUDICATION: RESULTS OF LONG-TERM, PLACEBO-CONTROLLED ADMINISTRATION, ANGIOLOGY, 35, PP. 396-406, (1984); ROSSNER M., MULLER R., ON THE ASSESSMENT OF THE EFFICACY OF PENTOXIFYLLINE (TRENTAL), J MED, 18, PP. 1-15, (1987); HOOD S.C., MOHER D., BARBER G.G., MANAGEMENT OF INTERMITTENT CLAUDICATION WITH PENTOXIFYLLINE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, CMAJ, 155, 8, PP. 1053-1059, (1996); LACY C., DRUG INFORMATION HANDBOOK, (1978); REILLY M.P., MOHLER III E.R., CILOSTAZOL: TREATMENT OF INTERMITTENT CLAUDICATION, ANN PHARMACOTHER, 35, 1, PP. 48-56, (2001); HASLAM R.J., DICKINSON N.T., JANG E.K., CYCLIC NUCLEOTIDES AND PHOSPHODIESTERASES IN PLATELETS, THROMB HAEMOST, 82, 2, PP. 412-423, (1999); KONSTANTOPOULOS K., GROTTA J.C., SILLS C., ET AL., SHEAR-INDUCED PLATELET AGGREGATION IN NORMAL SUBJECTS AND STROKE PATIENTS, THROMB HAEMOST, 74, 5, PP. 1329-1334, (1995); MATSUMOTO Y., MARUKAWA K., OKUMURA H., ET AL., COMPARATIVE STUDY OF ANTIPLATELET DRUGS IN VITRO: DISTINCT EFFECTS OF CAMP-ELEVATING DRUGS AND GPIIB/IIIA ANTAGONISTS ON THROMBIN-INDUCED PLATELET RESPONSES, THROMB RES, 95, 1, PP. 19-29, (1999); MINAMI N., SUZUKI Y., YAMAMOTO M., ET AL., INHIBITION OF SHEAR STRESS-INDUCED PLATELET AGGREGATION BY CILOSTAZOL, A SPECIFIC INHIBITOR OF CGMP-INHIBITED PHOSPHODIESTERASE, IN VITRO AND EX VIVO, LIFE SCI, 61, 25, PP. 383-389, (1997); TANAKA T., ISHIKAWA T., HAGIWARA M., ET AL., EFFECTS OF CILOSTAZOL, A SELECTIVE CAMP PHOSPHODIESTERASE INHIBITOR ON THE CONTRACTION OF VASCULAR SMOOTH MUSCLE, PHARMACOLOGY, 36, 5, PP. 313-320, (1988); SAITOH S., SAITO T., OTAKE A., ET AL., CILOSTAZOL, A NOVEL CYCLIC AMP PHOSPHODIESTERASE INHIBITOR, PREVENTS REOCCLUSION AFTER CORONARY ARTERIAL THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR, ARTERIOSCLER THROMB, 13, 4, PP. 563-570, (1993); MOHLER III E.R., BEEBE H.G., SALLES-CUHNA S., ET AL., EFFECTS OF CILOSTAZOL ON RESTING ANKLE PRESSURES AND EXERCISE-INDUCED ISCHEMIA IN PATIENTS WITH INTERMITTENT CLAUDICATION, VASC MED, 6, 3, PP. 151-156, (2001); TAKAHASHI S., OIDA K., FUJIWARA R., ET AL., EFFECT OF CILOSTAZOL, A CYCLIC AMP PHOSPHODIESTERASE INHIBITOR, ON THE PROLIFERATION OF RAT AORTIC SMOOTH MUSCLE CELLS IN CULTURE, J CARDIOVASC PHARMACOL, 20, 6, PP. 900-906, (1992); MATOUSOVIC K., GRANDE J.P., CHINI C.C., ET AL., INHIBITORS OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES TYPE-III AND TYPE-IV SUPPRESS MITOGENESIS OF RAT MESANGIAL CELLS, J CLIN INVEST, 96, 1, PP. 401-410, (1995); IKEDA U., IKEDA M., KANO S., ET AL., EFFECT OF CILOSTAZOL, A CAMP PHOSPHODIESTERASE INHIBITOR, ON NITRIC OXIDE PRODUCTION BY VASCULAR SMOOTH MUSCLE CELLS, EUR J PHARMACOL, 314, 1-2, PP. 197-202, (1996); ISHIZAKA N., TAGUCHI J., KIMURA Y., ET AL., EFFECTS OF A SINGLE LOCAL ADMINISTRATION OF CILOSTAZOL ON NEOINTIMAL FORMATION IN BALLOON-INJURED RAT CAROTID ARTERY, ATHEROSCLEROSIS, 142, 1, PP. 41-46, (1999); TAKE S., MATSUTANI M., UEDA H., ET AL., EFFECT OF CILOSTAZOL IN PREVENTING RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, AM J CARDIOL, 79, 8, PP. 1097-1099, (1997); TSUCHIKANE E., FUKUHARA A., KOBAYASHI T., ET AL., IMPACT OF CILOSTAZOL ON RESTENOSIS AFTER PERCUTANEOUS CORONARY BALLOON ANGIOPLASTY, CIRCULATION, 100, PP. 21-26, (1999); ELAM M.B., HECKMAN J., CROUSE J.R., ET AL., EFFECT OF THE NOVEL ANTIPLATELET AGENT CILOSTAZOL ON PLASMA LIPOPROTEINS IN PATIENTS WITH INTERMITTENT CLAUDICATION, ARTERIOSCLER THROMB VASC BIOL, 18, 12, PP. 1942-1947, (1998); OKUDA Y., KIMURA Y., YAMASHITA K., CILOSTAZOL, CARDIOVASC DRUG REV, 11, PP. 452-465, (1993); BEEBE H.G., DAWSON D.L., CUTLER B.S., ET AL., A NEW PHARMACOLOGICAL TREATMENT FOR INTERMITTENT CLAUDICATION: RESULTS OF A RANDOMIZED, MULTICENTER TRIAL, ARCH INTERN MED, 159, 17, PP. 2041-2050, (1999); DAWSON D.L., CUTLER B.S., HIATT W.R., ET AL., A COMPARISON OF CILOSTAZOL AND PENTOXIFYLLINE FOR TREATING INTERMITTENT CLAUDICATION, AM J MED, 109, 7, PP. 523-530, (2000); DAWSON D.L., CUTLER B.S., MEISSNER M.H., ET AL., CILOSTAZOL HAS BENEFICIAL EFFECTS IN TREATMENT OF INTERMITTENT CLAUDICATION: RESULTS FROM A MULTICENTER, RANDOMIZED, PROSPECTIVE, DOUBLE-BLIND TRIAL, CIRCULATION, 98, 7, PP. 678-686, (1998); MONEY S.R., HERD J.A., ISAACSOHN J.L., ET AL., EFFECT OF CILOSTAZOL ON WALKING DISTANCES IN PATIENTS WITH INTERMITTENT CLAUDICATION CAUSED BY PERIPHERAL VASCULAR DISEASE, J VASC SURG, 27, PP. 267-274, (1998); DONNELLY R., EVIDENCE-BASED SYMPTOM RELIEF OF INTERMITTENT CLAUDICATION: EFFICACY AND SAFETY OF CILOSTAZOL, DIABETES OBES METAB, 4, 2 SUPPL., (2002); CARISKI A.T., CILOSTAZOL: A NOVEL TREATMENT OPTION FOR INTERMITTENT CLAUDICATION, INT J CLIN PRACT, 119, SUPPL., PP. 11-18, (2001); PRATT C.M., ANALYSIS OF THE CILOSTAZOL SAFETY DATABASE, AM J CARDIOL, 87, 12 A, (2001); AMERICAN HOSPITAL FORMULARY SERVICE DRUG INFORMATION ONLINE UPDATES ONLINE; SWEETMAN S.C., MARTINDALE: THE COMPLETE DRUG REFERENCE - MICROMEDEX HEALTHCARE SERIES ELECTRONIC VERSION, 117, (2003); MOHER D., PHAM B., AUSEJO M., ET AL., PHARMACOLOGICAL MANAGEMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMISED TRIALS, DRUGS, 59, 5, PP. 1057-1070, (2000); PITTLER M.H., ERNST E., GINKGO BILOBA EXTRACT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS OF RANDOMIZED TRIALS, AM J MED, 108, 4, PP. 276-281, (2000); CONNERS M.S., MONEY S.R., CAN CLAUDICATION BE IMPROVED WITH MEDICATION?, SEMIN VASC SURG, 15, 4, PP. 237-244, (2002); ERNST E., THE RISK-BENEFIT PROFILE OF COMMONLY USED HERBAL THERAPIES: GINKGO, ST JOHN'S WORT, GINSENG, ECHINACEA, SAW PALMETTO, AND KAVA, ANN INTERN MED, 136, 1, PP. 42-53, (2002); LETZEL H., SCHOOP W., GINKGO BILOBA EXTRACT EGB 761 AND PENTOXIFYLLINE IN INTERMITTENT CLAUDICATION: SECONDARY ANALYSIS OF THE CLINICAL EFFECTIVENESS, VASA, 21, 4, PP. 403-410, (1992); CASTANO G., MAS F.R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, 2, PP. 115-125, (2001); FERNANDEZ J.C., MAS R., CASTANO G., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVEST, 21, 2, PP. 103-113, (2001); LEHERT P., RIPHAGEN F.E., GAMAND S., THE EFFECT OF NAFTIDROFURYL ON INTERMITTENT CLAUDICATION: A META-ANALYSIS, J CARDIOVASC PHARMACOL, 16, 3 SUPPL., (1990); MAASS U., AMBERGER H.G., BOHME H., ET AL., NAFTIDROFURYL IN ARTERIAL OCCLUSIVE DISEASE: CONTROLLED MULTICENTER DOUBLE-BLIND STUDY WITH ORAL ADMINISTRATION, DTSCH MED WOCHENSCHR, 109, 19, PP. 745-750, (1984); KIEFFER E., BAHNINI A., MOUREN X., ET AL., A NEW STUDY DEMONSTRATES THE EFFICACY OF NAFTIDROFURYL IN THE TREATMENT OF INTERMITTENT CLAUDICATION: FINDINGS OF THE NAFTIDROFURYL CLINICAL ISCHEMIA STUDY (NCIS), INT ANGIOL, 20, 1, PP. 58-65, (2001); ADHOUTE G., BACOURT F., BARRAL M., ET AL., NAFTIDROFURYL IN CHRONIC ARTERIAL DISEASE: RESULTS OF A SIX MONTH CONTROLLED MULTICENTER STUDY USING NAFTIDROFURYL TABLETS 200 MG, ANGIOLOGY, 37, 3 PART 1, PP. 160-167, (1986); D'HOOGE D., LEHERT P., CLEMENT D.L., NAFTIDROFURYL IN QUALITY OF LIFE (NIQOL): A BELGIAN STUDY, INT ANGIOL, 20, 4, PP. 288-294, (2001); DE BACKER T.L., VANDER STICHELE R.H., BOGAERT M.G., BUFLOMEDIL FOR INTERMITTENT CLAUDICATION, COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 1, (2001); WALKER G.A., MAC HANNAFORD J.C., A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF THE EFFECT OF BUFLOMEDIL ON INTERMITTENT CLAUDICATION, FUNDAM CLIN PHARMACOL, 9, 4, PP. 387-394, (1995); ROSAS G., CERDEYRA C., LUCAS M.A., ET AL., COMPARISON OF SAFETY AND EFFICACY OF BUFLOMEDIL AND NAFTIDROFURYL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 32, 5, PP. 291-297, (1981); CHACON-QUEVEDO A., EGUARAS M.G., CALLEJA F., ET AL., COMPARATIVE EVALUATION OF PENTOXIFYLLINE, BUFLOMEDIL, AND NIFEDIPINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION OF THE LOWER LIMBS, ANGIOLOGY, 45, 7, PP. 647-653, (1994); TRUEBESTEIN G., TRUEBESTEIN R., DONG Q.D., COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF BUFLOMEDIL AND PENTOXIFYLLINE IN PATIENTS WITH ARTERIAL OCCLUSIVE DISEASE, ANGIOLOGY, 32, PP. 705-710, (1981); FAGHER B., PERSSON S., PERSSON G., ET AL., BLOOD VISCOSITY DURING LONG-TERM TREATMENT WITH TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND STUDY, ANGIOLOGY, 44, 4, PP. 300-306, (1993); ARCAN J.C., BLANCHARD J., BOISSEL J.P., ET AL., MULTICENTER DOUBLE-BLIND STUDY OF TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND THE PREVENTION OF ITS COMPLICATIONS, ANGIOLOGY, 39, 9, PP. 802-811, (1988); BALSANO F., COCCHERI S., LIBRETTI A., ET AL., TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION: A 21-MONTH DOUBLE-BLIND TRIAL, J LAB CLIN MED, 114, PP. 84-91, (1989); FAGHER B., LONG-TERM EFFECTS OF TICLOPIDINE ON LOWER LIMB BLOOD FLOW, ANKLE/BRACHIAL INDEX AND SYMPTOMS IN PERIPHERAL ARTERIOSCLEROSIS: A DOUBLE-BLIND STUDY: THE STIMS GROUP IN LUND. SWEDISH TICLOPIDINE MULTICENTER STUDY, ANGIOLOGY, 45, PP. 777-788, (1994); HAYNES R., SANDLER R., LARSON E.B., A CRITICAL APPRAISAL OF TICLOPIDINE, A NEW ANTIPLATELET AGENT, ARCH INTERN MED, 152, PP. 1376-1380, (1992); BREVETTI G., PERNA S., SABBA C., ET AL., PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION: DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTICENTER STUDY, J AM COLL CARDIOL, 26, PP. 1411-1416, (1995); BREVETTI G., PERNA S., SABBA C., ET AL., EFFECT OF PROPIONYL-L-CARNITINE ON QUALITY OF LIFE IN INTERMITTENT CLAUDICATION, AM J CARDIOL, 79, PP. 777-780, (1997); BREVETTI G., DIEHM C., LAMBERT D., EUROPEAN MULTICENTER STUDY ON PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION, J AM COLL CARDIOL, 34, 5, PP. 1618-1624, (1999); HIATT W.R., REGENSTEINER J.G., CREAGER M.A., ET AL., PROPIONYL-L-CARNITINE IMPROVES EXERCISE PERFORMANCE AND FUNCTIONAL STATUS IN PATIENTS WITH CLAUDICATION, AM J MED, 110, 8, PP. 616-622, (2001); BREVETTI G., PERNA S., SABBA C., ET AL., SUPERIORITY OF L-PROPIONYL-CARNITINE VS L-CARNITINE IN IMPROVING WALKING CAPACITY IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE: AN ACUTE, INTRAVENOUS, DOUBLE-BLIND, CROSS-OVER STUDY, EUR HEART J, 13, 2, PP. 251-255, (1992); JAFF M.R., PHARMACOTHERAPY FOR PERIPHERAL ARTERIAL DISEASE: EMERGING THERAPEUTIC OPTIONS, ANGIOLOGY, 53, 6, PP. 627-633, (2002); BOGER R.H., BODE-BOGER S.M., THIELE W., ET AL., RESTORING VASCULAR NITRIC OXIDE FORMATION BY L-ARGININE IMPROVES THE SYMPTOMS OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE, J AM COLL CARDIOL, 32, 5, PP. 1336-1344, (1998); AROSIO E., DE MARCHI S., ZANNONI M., ET AL., EFFECT OF GLUTATHIONE INFUSION ON LEG ARTERIAL CIRCULATION, CUTANEOUS MICROCIRCULATION, AND PAIN-FREE WALKING DISTANCE IN PATIENTS WITH PERIPHERAL OBSTRUCTIVE ARTERIAL DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, MAYO CLIN PROC, 77, 8, PP. 754-759, (2002); COOPER L.T., BERAPROST FOR THE TREATMENT OF INTERMITTENT CLAUDICATION, J AM COLL CARDIOL, 41, 10, PP. 1687-1689, (2003); REITER M., BUCEK R.A., STUMPFLEN A., ET AL., PROSTANOIDS IN THE TREATMENT OF INTERMITTENT CLAUDICATION: A META-ANALYSIS, VASA, 31, 4, PP. 219-224, (2002); COCCHERI S., SCONDOTTO G., AGNELLI G., ET AL., SULODEXIDE IN THE TREATMENT OF INTERMITTENT CLAUDICATION: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, MULTICENTRE, PLACEBO-CONTROLLED STUDY, EUR HEART J, 23, 13, PP. 1057-1065, (2002); GADDI A., GALETTI C., ILLUMINATI B., ET AL., META-ANALYSIS OF SOME RESULTS OF CLINICAL TRIALS ON SULODEXIDE THERAPY IN PERIPHERAL OCCLUSIVE ARTERIAL DISEASE, J INT MED RES, 24, 5, PP. 389-406, (1996); COMEROTA A.J., THROM R.C., MILLER K.A., ET AL., NAKED PLASMID DNA ENCODING FIBROBLAST GROWTH FACTOR TYPE 1 FOR THE TREATMENT OF END-STAGE UNRECONSTRUCTABLE LOWER EXTREMITY ISCHEMIA: PRELIMINARY RESULTS OF A PHASE I TRIAL, J VASC SURG, 35, 5, PP. 930-936, (2002); LEDERMAN R.J., MENDELSOHN F.O., ANDERSON R.D., ET AL., THERAPEUTIC ANGIOGENESIS WITH RECOMBINANT FIBROBLAST GROWTH FACTOR-2 FOR INTERMITTENT CLAUDICATION (THE TRAFFIC STUDY): A RANDOMISED TRIAL, LANCET, 359, 9323, PP. 2053-2058, (2002); BAUMGARTNER I., PIECZEK A., MANOR O., ET AL., CONSTITUTIVE EXPRESSION OF PHVEGF165 AFTER INTRAMUSCULAR GENE TRANSFER PROMOTES COLLATERAL VESSEL DEVELOPMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA, CIRCULATION, 97, PP. 1114-1123, (1998); MOHLER III E.R., RAJAGOPALAN S., OLIN J.W., ET AL., ADENOVIRAL-MEDIATED GENE TRANSFER OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN CRITICAL LIMB ISCHEMIA: SAFETY RESULTS FROM A PHASE I TRIAL, VASC MED, 8, 1, PP. 9-13, (2003); MANNINEN H.I., MAKINEN K., GENE THERAPY TECHNIQUES FOR PERIPHERAL ARTERIAL DISEASE, CARDIOVASC INT RADIOL, 25, 2, PP. 98-108, (2002); KHAN T.A., SELLKE F.W., LAHAM R.J., GENE THERAPY PROGRESS AND PROSPECTS: THERAPEUTIC ANGIOGENESIS FOR LIMB AND MYOCARDIAL ISCHEMIA, GENE THER, 10, 4, PP. 285-291, (2003)","E.R. MOHLER III; UNIV. OF PA SCHOOL OF MEDICINE, PHI BUILDING, PHILADELPHIA, PA 19104, 51 N. 39TH STREET, UNITED STATES; EMAIL: MOHLERE@UPHS.UPENN.EDU","","ENGLISH","DRUGS","REVIEW","ISI","2-S2.0-4344685960","DRUGS","UNIV. OF PA SCHOOL OF MEDICINE;UNIV. OF PA SCHOOL OF MEDICINE","NOTREPORTED;UNIV. OF PA SCHOOL OF MEDICINE;NOTREPORTED",NA,"JACOBY D, 2004, DRUGS","JACOBY D, 2004, DRUGS"
"DOG T;RILEY D","DOG, TIERAONA LOW (6603331026); RILEY, DAVID (7402919742)","MANAGEMENT OF HYPERLIPIDEMIA",2003,"ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE","9","12",12,"","","[NO ABSTRACT AVAILABLE]","","ACETYLSALICYLIC ACID; ALLICIN; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHOLESTIN; CITRININ; CYNARA SCOLYMUS EXTRACT; DILTIAZEM; FIBRIC ACID DERIVATIVE; GUGGULSTERONE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PRAVASTATIN; PROPRANOLOL; RESIN; SELENIUM; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; WARFARIN; ABDOMINAL PAIN; AMMI VISNAGA; ARTICHOKE; BLEEDING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMIPHORA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRATAEGUS; DIARRHEA; DIET; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MECHANISM; EPIDURAL HEMATOMA; FLUSHING; FOOD DRUG INTERACTION; GARLIC; GINGER; GOUT; HEADACHE; HERBAL MEDICINE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER TOXICITY; MONASCUS PURPUREUS; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; REVIEW; RICE; RISK FACTOR; SIDE EFFECT; TEA","","","EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 285, MAY 16, (2001); AUSTIN M.A., HOKANSON J.E., EDWARDS K.L., HYPERTRIGLYCERIDEMIA AS A CARDIOVASCULAR RISK FACTOR, AM J CARDIOL, 81, (1998); ASSMANN G., SCHULTE H., FUNKE H., VON ECKARDSTEIN A., THE EMERGENCE OF TRIGLYCERIDES AS A SIGNIFICANT INDEPENDENT RISK FACTOR IN CORONARY ARTERY DISEASE, EUR HEART J, 19, SUPPL. M, (1998); KRAUSS R.M., ATHEROGENICITY OF TRIGLYCERIDE-RICH LIPOPROTEINS, AM J CARDIOL, 81, (1998); RASHID S., UFFELMAN K.D., LEWIS G.F., THE MECHANISM OF HDL LOWERING IN HYPERTRIGLYCERIDEMIC, INSULIN-RESISTANT STATES, J DIABETES COMPLICATIONS, 16, 1, PP. 24-28, (2002); GILL J.M., HERD S.L., TSETSONIS N.V., HARDMAN A.E., ARE THE REDUCTIONS IN TRIACYLGLYCEROL AND INSULIN LEVELS AFTER EXERCISE RELATED?, CLIN SCI, 102, 2, PP. 223-231, (2002); GORDON D.J., PROBSTFIELD J.L., GARRISON R.J., NEATON J.D., CASTELLI W.P., KNOKE J.D., JACOBS D.R. JR., BANGDIWALA S., TYROLER H.A., HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR DISEASE: FOUR PROSPECTIVE AMERICAN STUDIES, CIRCULATION, 79, PP. 8-15, (1989); KNOPP R.H., ESTROGEN REPLACEMENT THERAPY FOR REDUCTION OF CARDIOVASCULAR RISK IN WOMEN, CURR OPINION LIPIDOLOGY, 2, PP. 240-247, (1991); GREENDALE G.A., REBOUSSIN B.A., HOGAN P., ET AL., SYMPTOM RELIEF AND SIDE EFFECTS OF POSTMENOPAUSAL HORMONES/PROGESTIN INTERVENTIONS TRIAL, OBSTET GYNECOL, 92, PP. 982-988, (1998); OTTOSON U.B., JOHANSSON B.G., VON SCHOULTZ B., SUBTRACTIONS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL DURING ESTROGEN REPLACEMENT THERAPY: A COMPARISON BETWEEN PROGESTOGENS AND NATURAL PROGESTERONE, AM J OBSTET GYNECOL, 151, PP. 746-750, (1985); HARGROVE J.T., MAXSON W.S., WENTZ A.C., BURNETT L.S., MENOPAUSAL HORMONE REPLACEMENT THERAPY WITH CONTINUOUS DAILY ORAL MICRONIZED ESTRADIOL AND PROGESTERONE, OBSTET GYNECOL, 73, PP. 606-612, (1989); JENSEN J., RIIS B.J., STROM V., ET AL., LONG-TERM EFFECTS OF PERCUTANEOUS ESTROGENS AND ORAL PROGESTERONE ON SERUM LIPOPROTEINS ON SERUM LIPOPROTEINS IN POSTMENOPAUSAL WOMEN, AM J OBSTET GYNECOL, 156, PP. 6-71, (1987); GRAHAM I.M., DALY L.E., REFSUM H.M., ET AL., PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR DISEASE: THE EUROPEAN CONCERTED ACTION PROJECT, JAMA, 277, 22, PP. 1775-1781, (1997); ALI A., MEHRA M.R., MODULATORY IMPACT OF CARDIAC REHABILITATION ON HYPERHOMOCYSTEINEMIA IN PATIENTS WITH CORONARY ARTERY DISEASE AND ""NORMAL"" LIPID LEVELS, AM J CARDIOL, 82, PP. 1543-1545, (1998); YEROMENKO Y., LAVIE L., HOMOCYSTEINE AND CARDIOVASCULAR RISK IN PATIENTS WITH DIABETES MELLITUS, NUTR METAB CARDIOVASC DIS, 11, PP. 108-116, (2001); ALEXANDER J.K., OBESITY AND CORONARY HEART DISEASE, AM J MED SCI, 321, PP. 215-224, (2001); FALLEST-STROBL P.C., KOCH D.D., STEIN J.H., ET AL., HOMOCYSTEINE: A NEW RISK FACTOR FOR ATHEROSCLEROSIS, AM FAM PHYS, 56, 6, PP. 1607-1612, (1997); WANG T.J., STAFFORD R.S., AUSIELLO J.C., CHAISSON C.E., RANDOMIZED CLINICAL TRIALS AND RECENT PATTERNS IN THE USE OFSTATINS, AM HEART J, 141, 6, PP. 957-963, (2001); KEY T.J.A., THOROGOOD M., APPLEBY P.N., ET AL., DIETARY HABITS AND MORTALITY IN 11,000 VEGETARIANS AND HEALTH CONSCIOUS PEOPLE: RESULTS OF A 17 YEAR FOLLOW UP, BMJ, 313, PP. 775-779, (1996); NESS A.R., POWLES J.W., FRUIT AND VEGETABLES AND CARDIOVASCULAR DISEASE: A REVIEW, INT J EPIDEMIOL, 26, PP. 1-13, (1997); DE OLIVEIRA E SILVA E.R., SEIDMAN C.E., TIAN J.J., ET AL., EFFECTS OF SHRIMP CONSUMPTION ON PLASMA LIPOPROTEINS, AM J CLIN NUTR, 64, PP. 712-717, (1996); VORSTER H.H., BENADE A.J., BARNARD H.C., ET AL., EGG INTAKE DOES NOT CHANGE PLASMA LIPOPROTEIN AND COAGULATION PROFILES, AM J CLIN NUTR, 55, PP. 400-410, (1992); LICHTENSTEIN A.H., AUSMAN L.M., JALBERT S.M., ET AL., EFFECTS OF DIFFERENT FORMS OF DIETARY HYDROGENATED FATS ON SERUM LIPOPROTEIN CHOLESTEROL LEVELS, N ENGL J MED, 340, PP. 1933-1940, (1999); GRUNDY S.M., DENKE M.A., DIETARY INFLUENCES ON SERUM LIPIDS AND LIPOPROTEINS, J LIPID RES, 31, 7, PP. 1149-1172, (1990); GINSBERG H.N., BARR S.L., GILBERT A., ET AL., REDUCTION OF PLASMA CHOLESTEROL LEVELS IN NORMAL MEN ON AN AMERICAN HEART ASSOCIATION STEP 1 DIET WITH ADDED MONOUNSATURATED FAT, N ENGL J MED, 322, 9, PP. 574-579, (1990); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); TEIXEIRA S.R., POTTER S.M., WEIGEL R., ET AL., EFFECTS OF FEEDING 4 LEVELS OF SOY PROTEIN FOR 3 AND 6 WEEKS ON BLOOD LIPIDS AND APOLIPOPROTEINS IN MODERATELY HYPERCHOLES-TEROLEMIC MEN, AM J CLIN NUTR, 71, PP. 1077-1084, (2000); CROUSE J.R. III, MORGAN T., TERRY J.G., ET AL., A RANDOMIZED TRIAL COMPARING THE EFFECT OF CASEIN WITH THAT OF SOY PROTEIN CONTAINING VARYING AMOUNTS OF ISOFLAVONES ON PLASMA CONCENTRATIONS OF LIPIDS AND LIPOPROTEINS, ARCH INTERN MED, 159, PP. 2070-2076, (1999); NESTEL P., ISOFLAVONES: THEIR EFFECTS ON CARDIOVASCULAR RISK AND FUNCTIONS, CURR OPIN LIPIDOL, 14, 1, PP. 3-8, (2003); HARRIS W.S., NONPHARMACOLOGIC TREATMENT OF HYPERTRIGLYCERIDEMIA: FOCUS ON FISH OILS, CLIN CARDIOL, 22, 6 SUPPL., PP. 1140-1143, (1999); BUCHER H.C., HENGSTLER P., SCHINDLER C., MEIER G., N-3 POLYUNSATURATED FATTYACIDS IN CORONARY HEART DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, AM J MED, 112, 4, PP. 298-304, (2002); ABEYWARDENA M.Y., HEAD R.J., LONGCHAIN N-3 POLYUNSATURATED FATTY ACIDS AND BLOOD VESSEL FUNCTION, CARDIOVASC RES, 52, 3, PP. 361-371, (2001); PANAYIOTOU A., SAMARTZIS D., NOMIKOS T., ET AL., LIPID FRACTIONS WITH AGGREGATORY AND ANTIAGGREGATARY ACTIVITY TOWARD PLATELETS IN FRESH AND FRIED COD (GADUS MORHUA): CORRELATION WITH PLATELET-ACTIVATING FACTOR AND ATHEROGENESIS, J AGRIC FOOD CHEM, 48, 12, PP. 6372-6379, (2000); NIEUWENHUYS C.M., FEIJGE M.A., OFFERMANS R.F., KESTER A.D., HORNSTRA G., HEEMSKERK J.W., MODULATION OF RAT PLATELET ACTIVATION BY VESSEL WALL-DERIVED PROSTAGLANDIN AND PLATELET-DERIVED THROMBOXANE: EFFECTS OF DIETARY, FISH OIL ON THROMBOXANE-PROSTAGLANDIN BALANCE, ATHEROSCLEROSIS, 154, 2, PP. 355-366, (2001); PAKALA R., PAKALA R., BENEDICT C.R., THROMBOXANE A2 FAILS TO INDUCE PROLIFERATION OF SMOOTH MUSCLE CELLS ENRICHED WITH EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 60, 4, PP. 275-281, (1999); WEBER P., RAEDERSTORFF D., TRIGLYCERIDE-LOWERING EFFECT OF OMEGA-3 LC-POLYUNSATURATED FATTY ACIDS - A REVIEW, NUTR METAB CARDIOVASC DIS, 10, 1, PP. 28-37, (2000); FARMER A., MONTORI V., DINNEEN S., CLAR C., FISH OIL IN PEOPLE WITH TYPE 2 DIABETES MELLITUS, COCHRANE DATABASE SYST REV, 3, (2001); JULA A., MARNLEMI J., HUUPPONEN R., VIRTANEN A., RASTAS M., RONNEMAA T., EFFECTS OF DIET AND SIMVASTATIN ON SERUM LIPIDS, INSULIN, AND ANTIOXIDANTS IN HYPERCHOLESTEROLEMIC MEN: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, 5, PP. 598-605, (2002); GREKAS D., KASSIMATIS E., MAKEDOU A., BACHARAKI D., BAMICHAS G., TOURKANTONIS A., COMBINED TREATMENT WITH LOW-DOSE PRAVASTATIN AND FISH OIL IN POST-RENAL TRANSPLANTATION DISLIPIDEMIA, NEPHRON, 88, 4, PP. 329-333, (2001); PLAT J., MENSINK R.P., EFFECTS OF PLANT STEROLS AND STANOLS ON LIPID METABOLISM AND CARDIOVASCULAR RISK, NUTR METAB CARDIOVASC DIS, 11, 1, PP. 31-40, (2001); WONG N.C., THE BENEFICIAL EFFECTS OF PLANT STEROLS ON SERUM CHOLESTEROL, CAN J CARDIOL, 17, 6, PP. 715-821, (2001); VANHANEN H.T., BLOMQVIST S., EHNHOLM C., ET AL., SERUM CHOLESTEROL, CHOLESTEROL, PRECURSORS, AND PLANT STEROLS IN HYPERCHOLESTEROLEMIC SUBJECTS WITH DIFFERENT APO E PHENOTYPES DURING DIETARY SITOSTANOL ESTER TREATMENT, J LIPID RES, 34, PP. 1535-1544, (1993); LAW M., PLANT STEROL AND STANOL MARGARINES AND HEALTH, BR MED J, 320, PP. 861-864, (2000); BLAIR S.N., CAPUZZI D.M., GOTTLIEB S.O., NGUYEN T., MORGAN J.M., CATER N.B., INCREMENTAL REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH THE ADDITION OF PLANT STANOL ESTER-CONTAINING SPREAD TO STATIN THERAPY, AM J CARDIOL, 86, 1, PP. 46-52, (2000); EAGLES C.J., MARTIN U., NON-PHARMACOLOGICAL MODIFICATION OF CARDIAC RISK FACTORS: PART 3. SMOKING CESSATION AND ALCOHOL CONSUMPTION, J CLIN PHARM THER, 23, PP. 1-9, (1998); RIMM E.B., WILLIAMS P., FOSHER K., CRIQUI M., STAMPFER M.J., MODERATE ALCOHOL INTAKE AND LOWER RISK OF CORONARY HEART DISEASE: META-ANALYSIS OF EFFECTS ON LIPIDS AND HAEMOSTATIC FACTORS, BMJ, 319, 7224, PP. 1523-1528, (1999); GAZIANO J.M., HENNEKENS C.H., GODFRIED S.L., ET AL., TYPE OF ALCOHOLIC BEVERAGE AND RISK OF MYOCARDIAL INFARCTION, AM J CARDIOL, 83, PP. 52-57, (1999); RIFICI V.A., STEPHAN E.M., SCHNEIDER S.H., KHACHADURIAN A.K., RED WINE INHIBITS THE CELL-MEDIATED OXIDATION OF LDL AND HDL, J AM COLL NUTR, 18, PP. 137-143, (1999); BURNS J., CROZIER A., LEAN M.E., ALCOHOL CONSUMPTION AND MORTALITY: IS WINE DIFFERENT FROM OTHER ALCOHOLIC BEVERAGES?, NUTR METAB CARDIOVASC DIS, 11, 4, PP. 249-258, (2001); ROTONDO S., DI CASTELNUOVO A., DE GAETANO G., THE RELATIONSHIP BETWEEN WINE CONSUMPTION AND CARDIOVASCULAR RISK: FROM EPIDEMIOLOGICAL EVIDENCE TO BIOLOGICAL PLAUSIBILITY, ITAL HEART J, 2, 1, PP. 1-8, (2001); WONG N.C., THE BENEFICIAL EFFECTS OF PLANT STEROLS ON SERUM CHOLESTEROL, CAN J CARDIOL, 17, 6, PP. 715-215, (2001); CRIQUI M.H., DO KNOWN CARDIOVASCULAR RISK FACTORS MEDIATE THE EFFECT OF ALCOHOL ON CARDIOVASCULAR DISEASE?, NOVARTIS FOUND SYMP, 216, PP. 159-167, (1998); MOSCA L., GRUNDY S.M., JUDELSON D., ET AL., GUIDE TO PREVENTIVE CARDIOLOGY FOR WOMEN: AHA/ACC SCIENTIFIC STATEMENT: CONSENSUS PANEL STATEMENT, CIRCULATION, 99, PP. 2480-2484, (1999); STEIN J.H., KEEVIL J.G., WIEBE D.A., ET AL., PURPLE GRAPE JUICE IMPROVES ENDOTHELIAL FUNCTION AND REDUCES THE SUSCEPTIBILITY OF LDL CHOLESTEROL TO OXIDATION IN PATIENTS WITH CORONARY ARTERY DISEASE, CIRCULATION, 100, PP. 1050-1055, (1999); CARMENA R., ASCASO J.F., REAL J.T., IMPACT OF OBESITY IN PRIMARY HYPERLIPIDEMIAS, NUTR METAB CARDIOVASC DIS, 11, 5, PP. 354-359, (2001); GORDON D.J., FACTORS AFFECTING HIGH DENSITY LIPOPROTEINS, ENDOCRINOL METAB CLIN NORTH AM, 27, PP. 699-709, (1998); WILLETT W., HENNEKENS C.H., CASTELLI W., ET AL., EFFECTS OF CIGARETTE SMOKING ON FASTING TRIGLYCERIDE, TOTAL CHOLESTEROL, AND HDL-CHOLESTEROL IN WOMEN, AM HEART J, 105, 3, PP. 417-421, (1983); GIDDING S.S., ACTIVE AND PASSIVE TOBACCO EXPOSURE, PROG PEDIATR CARDIOL, 12, 2, PP. 195-198, (2001); PIEPHO R.W., THE PHARMACOKINETICS AND PHARMACODYNAMICS OF AGENTS PROVEN TO RAISE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, AM J CARDIOL, 86, 12 A, (2000); WILLETT W., HENNEKENS C.H., CASTELLI W., ET AL., EFFECTS OF CIGARETTE SMOKING ON FASTING TRIGLYCERIDE, TOTAL CHOLESTEROL, AND HDL-CHOLESTEROL IN WOMEN, AM HEART J, 105, 3, PP. 417-421, (1983); BROWN B.G., ZHAO X.Q., CHAIT A., ET AL., SIMVASTATIN AND NIACIN, ANTIOXIDANT VITAMINS OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE, N ENGL J MED, 29, 22, PP. 1583-1592, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); CARMENA R., ASCASO J.F., REAL J.T., IMPACT OF OBESITY IN PRIMARY HYPERLIPIDEMIAS, NUTR METAB CARDIOVASC DIS, 11, 5, PP. 354-359, (2001); HEBER D., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); STUART M.D., CHINESE MATERIA MEDICA - VEGETABLE KINGDOM, (1979); MCCARTHY M., FDA BANS RED YEAST RICE PRODUCT, LANCET, 351, (1998); KEITHLEY J.K., SWANSON B., SHA B.E., ZELLER J.M., KESSLER H.A., SMITH K.Y., A PILOT STUDY OF THE SAFETY AND EFFICACY OF CHOLESTIN IN TREATING HIV-RELATED DYSLIPIDEMIA, NUTRITION, 18, 2, PP. 201-204, (2002); HEBER D., ET AL., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 7, 2, PP. 133-139, (2001); PERREAULT S., HAMILTON V.H., LAVOIE F., GROVER S., TREATING HYPERLIPIDEMIA H FOR THE PRIMARY PREVENTION OF CORONARY DISEASE: ARE HIGHER DOSES OFLOVOSTATIN COST-EFFECTIVE?, ARCH INTERN MED, 158, PP. 375-381, (1998); SILAGY C.A., NEIL H.A., A META-ANALYSIS OF THE EFFECT OF GARLIC ON BLOOD PRESSURE, J HYPERTEN, 12, PP. 463-468, (1994); WARSHAFSKY S., KAMER R.S., SIVAK S.L., EFFECT OF GARLIC ON TOTAL SERUM CHOLESTEROL. A META-ANALYSIS, ANN INTERN MED, 119, PP. 599-605, (1993); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPEREHOLESTEROLEMIA, ANN INTERN MED, 133, PP. 420-429, (2000); GORDON D.J., FACTORS AFFECTING HIGH DENSITY LIPOPROTEINS, ENDOCRINOL METAB CLIN NORTH AM, 27, PP. 699-709, (1998); GARLIC: EFFECTS ON CARDIOVASCULAR RISKS AND DISEASE, PROTECTIVE EFFECTS AGAINST CANCER, AND CLINICAL ADVERSE EFFECTS, SUMMARY, EVIDENCE REPORT/TECHNOLOGY ASSESSMENT: NUMBER 20, (2000); LAWSON L.D., WANG Z.J., PAPADIMITRIOU D., ALLICIN RELEASE UNDER SIMULATED GASTROINTESTINAL CONDITIONS FROM GARLIC POWDER TABLETS EMPLOYED IN CLINICAL TRIALS ON SERUM CHOLESTEROL, PLANTA MED, 67, 1, PP. 13-18, (2001); LAWSON L.D., WANG Z.J., LOW ALLICIN RELEASE FROM GARLIC SUPPLEMENTS: A MAJOR PROBLEM DUE TO THE SENSITIVITIES OF ALLIINASE ACTIVITY, J AGRIC FOOD CHEM, 49, 5, PP. 2592-2599, (2001); SILAGY C.A., NEIL H.A., GARLIC AS A LIPID LOWERING AGENT - A META-ANALYSIS, J R COLL PHYSICIANS LOUD, 28, 1, PP. 39-45, (1994); SIEGEL G., WALTER A., SCHNALKE F., ET AL., POTASSIUM CHANNEL ACTIVATION, HYPERPOLARIZATION, AND VASCULAR RELAXATION, Z KARDIOL, 80, SUPPL. 7, PP. 9-24, (1991); SIEGEL G., EMDEN J., WENZEL K., MIRONNEAU J., STOCK G., POTASSIUM CHANNEL ACTIVATION IN VASCULAR SMOOTH MUSCLE, ADV EXP MED BIOL, 311, PP. 53-72, (1992); LEGNANI C., FRASCARO M., GUAZZALOCA G., ET AL., EFFECTS OF A DRIED GARLIC PREPARATION ON FIBRINOLYSIS AND PLATELET AGGREGATION IN HEALTHY SUBJECTS, ARZNEIMITTELFORSCHUNG, 43, PP. 119-122, (1993); GADKARI J.V., JOSH V.D.J., EFFECT OF INGESTION OF RAW GARLIC ON SERUM CHOLESTEROL LEVEL, CLOTTING TIME AND FIBRIPOLYTIC ACTIVITY IN NORMAL SUBJECTS, J POSTGRAD MED, 37, PP. 128-131, (1991); GEBHARDT R., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN PRIMARY CULTURED RAT HEPATOCYTES BY ARTICHOKE (CYNARA SCOLYMUS L.) EXTRACTS, J PHARMACOL EXP THER, 286, 3, PP. 1122-1128, (1998); LAWSON L.D., GARLIC: A REVIEW OF ITS MEDICINAL EFFECTS AND INDICATED ACTIVE COMPOUNDS, PHYTOMEDICINES OF EUROPE: CHEMISTRY AND BIOLOGICAL ACTIVITY, PP. 176-209, (1998); LAWSON L.D., RANSOM D.K., HUGHES B.G., INHIBITION OF WHOLE BLOOD PLATELET-AGGREGATION BY COMPOUNDS IN GARLIC CLOVE EXTRACTS AND COMMERCIAL GARLIC PRODUCTS, THROMB RES, 65, PP. 141-156, (1992); ALI M., THOMSON M., CONSUMPTION OF A GARLIC CLOVE A DAY COULD BE BENEFICIAL IN PREVENTING THROMBOSIS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 53, 3, PP. 211-212, (1995); ALI M., BORDIA T., MUSTAFA T., EFFECT OF RAW VERSUS BOILED AQUEOUS EXTRACT OF GARLIC AND ONION ON PLATELET AGGREGATION, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 60, 1, PP. 43-47, (1999); KOSCIELNY J., SCHMITT R., RADTKE H., LATZA R., KIESEWETTER H., GARLIC STUDY VINDICATED BY OFFICIAL INVESTIGATION, NATURE, 404, 6778, (2000); BURNHAM B.E., GARLIC AS A POSSIBLE RISK FOR POSTOPERATIVE BLEEDING, PLAST RECONSTRUC SURG, 95, (1995); ROSE K.D., CROISSANT P.D., PARLIAMENT C.F., LEVIN M.B., SPONTANEOUS SPINAL EPIDURAL HEMATOMA WITH ASSOCIATED PLATELET DYSFUNCTION FROM EXCESSIVE GARLIC CONSUMPTION: A CASE REPORT, NEUROSURGERY, 26, PP. 880-882, (1990); VAES L.P., CHYKA P.A., INTERACTIONS OF WARFARIN WITH GARLIC, GINGER, GINKGO, OR GINSENG: NATURE OF THE EVIDENCE, ANN PHARMACOTHER, 34, 12, PP. 1478-1482, (2000); SINGH K., CHANDLER R., KAPOOR N.K., GUGGULSTERONE, A POTENT HYPOLIPIDAEMIC, PREVENTS OXIDATION OF LOW DENSITY LIPOPROTEIN, PHYTOTHER RES, 11, PP. 291-294, (1997); URIZAR N.L., LIVERMAN A.B., DODDS D.T., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR THE FXR, SCIENCE, (2002); NITYANAND S., KAPOOR N.K., HYPOEHOLESTEROLEMIC EFFECT OF COMMIPHORA MUKUL RESIN (GUGGAL), INDIAN J EXP BIOL, 9, PP. 367-377, (1971); NITYANAND S., SRIVASTAVA J.S., ASTHANA O.P., CLINICAL TRIALS WITH GUGULIPID - A NEW HYPOLIPIDEMIC AGENT, J ASSOC PHYS INDIA, 37, PP. 323-338, (1989); BURNHAM B.E., GARLIC AS A POSSIBLE RISK FOR POSTOPERATIVE BLEEDING, PLAST RECONSTRUC SURG, 95, (1995); SINGH R.B., NIAZ M.A., GHOSH S., HYPOLIPIDEMIE AND ANTIOXIDANT EFFECTS OF COMMIPHORA MUKUL AS AN ADJUNCT TO DIETARY THERAPY IN PATIENTS WITH HYPERCHOES HYPERCHOLESTEROLEMIA, CARDIOVASC DRUGS THER, 8, 4, PP. 659-664, (1994); MCGUFFIN M., HOBBS C., UPTON R., GOLDBERG A., AMERICAN HERBAL PRODUCTS ASSOCIATION'S BOTANICAL SAFETY HANDBOOK, (1997); DALVI S.S., NAYAK V.K., POHUJANI S.M., DESAI N.K., KSHIRSAGAR N.A., GUPTA K.C., EFFECT OF GUGULIPID ON BIOAVAILABILITY OF DILTIAZEM AND PROPANOLOL, J ASSOC PHYS IND, 42, PP. 454-455, (1994); KIRCHHOFF R., BECKERS C.H., KIRCHHOFF G.M., TRINCZEK-GARTNER H., PETROWITZ O., REIMANN H.-J., INCREASE IN CHOLERESIS BY MEANS OF ARTICHOKE EXTRACT. RESULTS OF A RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY, PHYTOMEDICINE, 1, PP. 107-115, (1994); HECKERS H., DITTMAR K., SCHMAHL F.W., HUTH K., INEFFICIENCY OF CYNARIN AS THERAPEUTIC REGIMEN IN FAMILIAL TYPE 11 HYPERLIPOPROTEINAEMIA, ATHEROSCLEROSIS, 26, 2, PP. 249-253, (1977); ENGLISCH W., BECKERS C., UNKAUF M., RUEPP M., ZINSERLING V., EFFICACY OF ARTICHOKE DRY EXTRACT IN PATIENTS WITH HYPERLIPOPROTEINEMIA, ARZNEIMITTELFORSCHUNG, 50, 3, PP. 260-265, (2000); COOK N.C., SAMMAN S., FLAVONOIDS - CHEMISTRY, METABOLISM, CARDIOPROTECTIVE EFFECTS, AND DIETARY SOURCES, J NUTR BIOCHEM, 7, PP. 66-76, (1996); MANACH C., REGERAT F., TEXIER O., ET AL., BIOAVAILABILITY, METABOLISM AND PHYSIOLOGICAL IMPACT OF4-OXO-FLAVONOIDS, NUTR RES, 16, PP. 517-544, (1996); AVIRAM M., FUHRMAN B., POLYPHENOLIC FLAVONOIDS INHIBIT MACROPHAGE-MEDIATED OXIDATION OF LDL AND ATTENUATE ATHEROGENESIS, ATHEROSCLEROSIS, 137, (1998); XIA J., ALLENBRAND B., SUN G.Y., DIETARY SUPPLEMENTATION OF GRAPE POLYPHENOLS AND CHRONIC ETHANOL ADMINISTRATION ON LDL OXIDATION AND PLATELET FUNCTION IN RATS, LIFE SCI, 63, PP. 383-390, (1998); FUHRMAN B., BUCH S., VAYA J., ET AL., LICORICE EXTRACT AND ITS MAJOR POLYPHENOL GLABRIDIN PROTECT LOW-DENSITY LIPOPROTEIN AGAINST LIPID PEROXIDATION: IN VITRO AND EX VIVO STUDIES IN HUMANS AND IN ATHEROSCLEROTIC APOLIPOPROTEIN E-DEFICIENT MICE, AM J CLIN NUTR, 66, PP. 267-275, (1997); YANG M., WANG C., CHEN H., GREEN, OOLONG AND BLACK TEA EXTRACTS MODULATE LIPID METABOLISM IN HYPERLIPIDEMIA RATS FED HIGH-SUCROSE DIET, J NUTR BIOCHEM, 12, 1, PP. 14-20, (2001); SILAGY C.A., NEFF H.A., GARLIC AS A LIPID LOWERING AGENT - A META-ANALYSIS, J R COLL PHYSICIANS LOND, 28, 1, PP. 39-45, (1994); BURSILL C., ROACH P.D., BOTTEMA C.D., PAL S., GREEN TEA UPREGULATES THE LOW-DENSITY LIPOPROTEM RECEPTOR THROUGH THE STEROL-REGULATED ELEMENT BINDING PROTEIN IN HEPG2 LIVER CELLS, J AGRIC FOOD CHEM, 49, 11, PP. 5639-5645, (2001); YANG T.T., KOO M.W., CHINESE GREEN TEA LOWERS CHOLESTEROL LEVEL THROUGH AN INCREASE IN FECAL LIPID EXCRETION, LIFE SCI, 66, 5, PP. 411-423, (2000); BROWN B.G., ZHAO X.Q., CHAIT A., ET AL., SIMVASTATIN AND NIACIN, ANTIOXIDANT VITAMINS, OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE, N ENGL J MED, 29, 22, PP. 1583-1592, (2001); PETERS U., POOLE C., ARAB L., DOES TEA AFFECT CARDIOVASCULAR DISEASE?, A META-ANALYSIS AMERICAN JOURNAL OF EPIDEMIOLOGY, 154, 6, PP. 495-503, (2001); ASAI A., MIYAZAWA T., DIETARY CURCUMINOIDS PREVENT HIGH-FAT DIET-INDUCED LIPID ACCUMULATION IN RAT LIVER AND EPIDIDYMAL ADIPOSE TISSUE, J NUTR, 131, 11, PP. 2932-2935, (2001); KAMAL-ELDIN A., FRANK J., RAZDAN A., TENGBLAD S., BASU S., VESSBY B., EFFECTS OF DIETARY PHENOLIC COMPOUNDS ON TOCOPHEROL, CHOLESTEROL, AND FATTY ACIDS IN RATS, LIPIDS, 35, 4, PP. 427-435, (2000); RAMIREZ-TORTOSA M.C., MESA M.D., AGUILERA M.C., ET AL., ORAL ADMINISTRATION OF A TURMERIC EXTRACT INHIBITS LDL OXIDATION AND HAS HYPOCHOLESTEROLEMIC EFFECTS IN RABBITS WITH EXPERIMENTAL ATHEROSCLEROSIS, ATHEROSCLEROSIS, 147, 2, PP. 371-378, (1999); SHAH B.H., NAWAZ Z., PERTANI S.A., ET AL., INHIBITORY EFFECT OF CURCUMIN, A FOOD SPICE FROM TURMERIC, ON PLATELET-ACTIVATING FACTOR- AND ARACHIDONIC ACID-MEDIATED PLATELET AGGREGATION THROUGH INHIBITION OF THROMBOXANE FORMATION AND CA2+ SIGNALING, BIOEHEM PHARMACOL, 58, 7, PP. 1167-1172, (1999); RASYID A., LELO A., THE EFFECT OF CURCUMIN AND PLACEBO ON HUMAN GALL-BLADDER FUNCTION: AN ULTRASOUND STUDY, ALIMENT PHARMACOL THER, 13, 2, PP. 245-249, (1999); TANABE M., CHEN Y.D., SAITO K., KANO Y., CHOLESTEROL BIOSYNTHESIS INHIBITORY COMPONENT FROM ZINGIBER OFFICINALE ROSCOE, CHEM PHARM BULL, 41, 4, PP. 710-713, (1993); SRINIVASAN K., SAMBAIAH K., THE EFFECT OF SPICES ON CHOLESTEROL 7 ALPHA-HYDROXYLASE ACTIVITY AND ON SERUM AND HEPATIC CHOLESTEROL LEVELS IN THE RAT, INT J VITAM NUTR RES, 61, 4, PP. 364-369, (1991); BHANDARI U., SHARMA J.N., ZAFAR R., THE PROTECTIVE ACTION OF ETHANOLIC GINGER (ZINGIBER OFFICINALE) EXTRACT IN CHOLESTEROL FED RABBITS, J ETHNOPHARMACOL, 61, 2, PP. 167-171, (1998); BORDIA A., VERMA S.K., SRIVASTAVA K.C., EFFECT OF GINGER (ZINGIBER OFFICINALE ROSC,) AND FENUGREEK (TRIGONELA FOENUM GRAECUM L.) ON BLOOD LIPIDS, BLOOD SUGAR AND PLATELET AGGREGATION IN PATIENTS WITH CORONARY ARTERY DISEASE, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 56, 5, PP. 379-384, (1997); WEIDNER M.S., SIGWART K., THE SAFETY OF GINGER EXTRACT IN THE RAT, J ETHNOPHARMACOL, 73, 3, PP. 513-520, (2000); ZHANG Z., HO W.K., HUANG Y., JAMES A.E., LAM L.W., CHEN Z.Y., HAWTHORN FRUIT IS HYPOLIPIDEMIC IN RABBITS FED A HIGH CHOLESTEROL DIET, J NUTR, 132, 1, PP. 5-10, (2002); RAJENDRAN S., DEEPALAKSHMI P.D., PARASAKTHY K., DEVARAJ H., DEVARAJ S.N., EFFECT OF TINCTURE OF CRATAEGUS ON THE LDL-RECEPTOR ACTIVITY OF HEPATIC PLASMA MEMBRANE OF RATS FED AN ATHEROGENIC DIET, ATHEROSCLEROSIS, 123, 1-2, PP. 235-241, (1996); MULLER A., LINKE W., KLAUS W., CRATAEGUS EXTRACT BLOCKS POTASSIUM CURRENTS IN GUINEA PIG VENTRICULAR CARDIAC MYOCYTES, PLANTA MED, 65, 4, PP. 335-339, (1999); SCHWINGER R.H., PIETSCH M., FRANK K., ET AL., CRATAEGUS SPECIAL EXTRACT WS 1442 INCREASES FORCE OF CONTRACTION IN HUMAN MYOCARDIUM CAMP-INDEPENDENTLY, J CARDIOVASC PHARMACOL, 35, 5, PP. 700-707, (2000)","","INNOVISION COMMUNICATIONS","ENGLISH","ALTERN. THER. HEALTH MED.","REVIEW","ISI","2-S2.0-0038293050","ALTERN THER HEALTH MED",NA,"NOTREPORTED",NA,"DOG TL, 2003, ALTERN THER HEALTH MED","DOG TL, 2003, ALTERN THER HEALTH MED"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","DOWNREGULATION OF MICROGLIAL ACTIVATION MAY REPRESENT A PRACTICAL STRATEGY FOR COMBATING NEURODEGENERATIVE DISORDERS",2006,"MEDICAL HYPOTHESES","67","18",74,"10.1016/j.mehy.2006.01.013","NATURAL ALTERNATIVES INTERNATIONAL, SAN MARCOS, CA 92078, 1185 LINDA VISTA DR, UNITED STATES","CHRONIC NEURODEGENERATIVE DISORDERS ARE CHARACTERIZED BY ACTIVATION OF MICROGLIA IN THE AFFECTED NEURAL PATHWAYS. PEROXYNITRITE, PROSTANOIDS, AND CYTOKINES GENERATED BY THESE MICROGLIA CAN POTENTIATE THE EXCITOTOXICITY THAT CONTRIBUTES TO NEURONAL DEATH AND DYSFUNCTION IN THESE DISORDERS - BOTH BY DIRECT EFFECTS ON NEURONS, AND BY IMPAIRING THE CAPACITY OF ASTROCYTES TO SEQUESTER AND METABOLIZE GLUTAMATE. THIS SUGGESTS A VICIOUS CYCLE IN WHICH THE DEATH OF NEURONS LEADS TO MICROGLIAL ACTIVATION, WHICH IN TURN POTENTIATES NEURONAL DAMAGE. IF THIS MODEL IS CORRECT, MEASURES WHICH DOWN-REGULATE MICROGLIAL ACTIVATION MAY HAVE A FAVORABLE EFFECT ON THE INDUCTION AND PROGRESSION OF NEURODEGENERATIVE DISEASE, INDEPENDENT OF THE PARTICULAR TRIGGER OR TARGET INVOLVED IN A GIVEN DISORDER. CONSISTENT WITH THIS POSSIBILITY, THE ANTIBIOTIC MINOCYCLINE, WHICH INHIBITS MICROGLIAL ACTIVATION, SHOWS BROAD UTILITY IN RODENT MODELS OF NEURODEGENERATION. OTHER AGENTS WHICH MAY HAVE POTENTIAL IN THIS REGARD INCLUDE PPARΓ AGONISTS, GENISTEIN, VITAMIN D, COX-2 INHIBITORS, STATINS (AND POSSIBLY POLICOSANOL), CAFFEINE, CANNABINOIDS, AND SESAMIN; SOME OF THESE AGENTS COULD ALSO BE EXPECTED TO BE DIRECTLY PROTECTIVE TO NEURONS THREATENED WITH EXCITOTOXICITY. TO ACHIEVE OPTIMAL CLINICAL OUTCOMES, REGIMENS WHICH DOWN-REGULATE MICROGLIAL ACTIVATION COULD BE USED IN CONJUNCTION WITH COMPLEMENTARY MEASURES WHICH ADDRESS OTHER ASPECTS OF EXCITOTOXICITY. © 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ANIMALS; DOWN-REGULATION; HUMANS; MICROGLIA; MINOCYCLINE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RODENTIA; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; BENZODIAZEPINE; CAFFEINE; CALCITRIOL; CANNABINOID; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; EPIGALLOCATECHIN GALLATE; FOLIC ACID; GENISTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; KAVA EXTRACT; MEMANTINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; POLICOSANOL; RESVERATROL; SESAMIN; SILYMARIN; TAURINE; TAURINE DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG; VITAMIN D; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN PERFUSION; CANNABIS ADDICTION; CELL ACTIVATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EXCITOTOXICITY; EXERCISE; GENETIC RISK; HUMAN; HUNTINGTON CHOREA; MICROGLIA; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA","","","LIU B., HONG J.S., ROLE OF MICROGLIA IN INFLAMMATION-MEDIATED NEURODEGENERATIVE DISEASES: MECHANISMS AND STRATEGIES FOR THERAPEUTIC INTERVENTION, J PHARMACOL EXP THER, 304, PP. 1-7, (2003); MRAK R.E., GRIFFIN W.S., GLIA AND THEIR CYTOKINES IN PROGRESSION OF NEURODEGENERATION, NEUROBIOL AGING, 26, PP. 349-354, (2005); BLASKO I., STAMPFER-KOUNTCHEV M., ROBATSCHER P., VEERHUIS R., EIKELENBOOM P., GRUBECK-LOEBENSTEIN B., HOW CHRONIC INFLAMMATION CAN AFFECT THE BRAIN AND SUPPORT THE DEVELOPMENT OF ALZHEIMER'S DISEASE IN OLD AGE: THE ROLE OF MICROGLIA AND ASTROCYTES, AGING CELL, 3, PP. 169-176, (2004); VILA M., JACKSON-LEWIS V., GUEGAN C., WU D.C., TEISMANN P., CHOI D.K., ET AL., THE ROLE OF GLIAL CELLS IN PARKINSON'S DISEASE, CURR OPIN NEUROL, 14, PP. 483-489, (2001); TEISMANN P., TIEU K., COHEN O., CHOI D.K., WU D.C., MARKS D., ET AL., PATHOGENIC ROLE OF GLIAL CELLS IN PARKINSON'S DISEASE, MOV DISORD, 18, PP. 121-129, (2003); SARGSYAN S.A., MONK P.N., SHAW P.J., MICROGLIA AS POTENTIAL CONTRIBUTORS TO MOTOR NEURON INJURY IN AMYOTROPHIC LATERAL SCLEROSIS, GLIA, (2005); SAPP E., KEGEL K.B., ARONIN N., HASHIKAWA T., UCHIYAMA Y., TOHYAMA K., ET AL., EARLY AND PROGRESSIVE ACCUMULATION OF REACTIVE MICROGLIA IN THE HUNTINGTON DISEASE BRAIN, J NEUROPATHOL EXP NEUROL, 60, PP. 161-172, (2001); ALDSKOGIUS H., REGULATION OF MICROGLIA - POTENTIAL NEW DRUG TARGETS IN THE CNS, EXPERT OPIN THER TARGETS, 5, PP. 655-668, (2001); TORREILLES F., SALMAN-TABCHEH S., GUERIN M., TORREILLES J., NEURODEGENERATIVE DISORDERS: THE ROLE OF PEROXYNITRITE, BRAIN RES BRAIN RES REV, 30, PP. 153-163, (1999); KIM W.K., KO K.H., POTENTIATION OF N-METHYL-D-ASPARTATE-MEDIATED NEUROTOXICITY BY IMMUNOSTIMULATED MURINE MICROGLIA, J NEUROSCI RES, 54, PP. 17-26, (1998); LIBERATORE G.T., JACKSON-LEWIS V., VUKOSAVIC S., MANDIR A.S., VILA M., MCAULIFFE W.G., ET AL., INDUCIBLE NITRIC OXIDE SYNTHASE STIMULATES DOPAMINERGIC NEURODEGENERATION IN THE MPTP MODEL OF PARKINSON DISEASE, NAT MED, 5, PP. 1403-1409, (1999); LIU B., GAO H.M., WANG J.Y., JEOHN G.H., COOPER C.L., HONG J.S., ROLE OF NITRIC OXIDE IN INFLAMMATION-MEDIATED NEURODEGENERATION, ANN NY ACAD SCI, 962, PP. 318-331, (2002); QIN L., LIU Y., COOPER C., LIU B., WILSON B., HONG J.S., MICROGLIA ENHANCE Β-AMYLOID PEPTIDE-INDUCED TOXICITY IN CORTICAL AND MESENCEPHALIC NEURONS BY PRODUCING REACTIVE OXYGEN SPECIES, J NEUROCHEM, 83, PP. 973-983, (2002); WU D.C., TEISMANN P., TIEU K., VILA M., JACKSON-LEWIS V., ISCHIROPOULOS H., ET AL., NADPH OXIDASE MEDIATES OXIDATIVE STRESS IN THE 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MODEL OF PARKINSON'S DISEASE, PROC NATL ACAD SCI USA, 100, PP. 6145-6150, (2003); GAO H.M., LIU B., HONG J.S., CRITICAL ROLE FOR MICROGLIAL NADPH OXIDASE IN ROTENONE-INDUCED DEGENERATION OF DOPAMINERGIC NEURONS, J NEUROSCI, 23, PP. 6181-6187, (2003); ZEKRY D., EPPERSON T.K., KRAUSE K.H., A ROLE FOR NOX NADPH OXIDASES IN ALZHEIMER'S DISEASE AND OTHER TYPES OF DEMENTIA?, IUBMB LIFE, 55, PP. 307-313, (2003); GAO H.M., LIU B., ZHANG W., HONG J.S., CRITICAL ROLE OF MICROGLIAL NADPH OXIDASE-DERIVED FREE RADICALS IN THE IN VITRO MPTP MODEL OF PARKINSON'S DISEASE, FASEB J, 17, PP. 1954-1956, (2003); QIN L., LIU Y., WANG T., WEI S.J., BLOCK M.L., WILSON B., ET AL., NADPH OXIDASE MEDIATES LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY AND PROINFLAMMATORY GENE EXPRESSION IN ACTIVATED MICROGLIA, J BIOL CHEM, 279, PP. 1415-1421, (2004); ZHANG W., WANG T., QIN L., GAO H.M., WILSON B., ALI S.F., ET AL., NEUROPROTECTIVE EFFECT OF DEXTROMETHORPHAN IN THE MPTP PARKINSON'S DISEASE MODEL: ROLE OF NADPH OXIDASE, FASEB J, 18, PP. 589-591, (2004); ZHAO W., XIE W., LE W., BEERS D.R., HE Y., HENKEL J.S., ET AL., ACTIVATED MICROGLIA INITIATE MOTOR NEURON INJURY BY A NITRIC OXIDE AND GLUTAMATE-MEDIATED MECHANISM, J NEUROPATHOL EXP NEUROL, 63, PP. 964-977, (2004); BEAL M.F., EXCITOTOXICITY AND NITRIC OXIDE IN PARKINSON'S DISEASE PATHOGENESIS, ANN NEUROL, 44, (1998); DOBLE A., THE ROLE OF EXCITOTOXICITY IN NEURODEGENERATIVE DISEASE: IMPLICATIONS FOR THERAPY, PHARMACOL THER, 81, PP. 163-221, (1999); MATTSON M.P., EXCITOTOXIC AND EXCITOPROTECTIVE MECHANISMS: ABUNDANT TARGETS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS, NEUROMOLECULAR MED, 3, PP. 65-94, (2003); ARUNDINE M., TYMIANSKI M., MOLECULAR MECHANISMS OF CALCIUM-DEPENDENT NEURODEGENERATION IN EXCITOTOXICITY, CELL CALCIUM, 34, PP. 325-337, (2003); MATTSON M.P., CHAN S.L., NEURONAL AND GLIAL CALCIUM SIGNALING IN ALZHEIMER'S DISEASE, CELL CALCIUM, 34, PP. 385-397, (2003); NOVELLI A., REILLY J.A., LYSKO P.G., HENNEBERRY R.C., GLUTAMATE BECOMES NEUROTOXIC VIA THE N-METHYL-D-ASPARTATE RECEPTOR WHEN INTRACELLULAR ENERGY LEVELS ARE REDUCED, BRAIN RES, 451, PP. 205-212, (1988); RIOBO N.A., CLEMENTI E., MELANI M., BOVERIS A., CADENAS E., MONCADA S., ET AL., NITRIC OXIDE INHIBITS MITOCHONDRIAL NADH: UBIQUINONE REDUCTASE ACTIVITY THROUGH PEROXYNITRITE FORMATION, BIOCHEM J, 359, PP. 139-145, (2001); RADI R., CASSINA A., HODARA R., QUIJANO C., CASTRO L., PEROXYNITRITE REACTIONS AND FORMATION IN MITOCHONDRIA, FREE RADIC BIOL MED, 33, PP. 1451-1464, (2002); STEWART V.C., HEALES S.J., NITRIC OXIDE-INDUCED MITOCHONDRIAL DYSFUNCTION: IMPLICATIONS FOR NEURODEGENERATION, FREE RADIC BIOL MED, 34, PP. 287-303, (2003); MURRAY J., TAYLOR S.W., ZHANG B., GHOSH S.S., CAPALDI R.A., OXIDATIVE DAMAGE TO MITOCHONDRIAL COMPLEX I DUE TO PEROXYNITRITE: IDENTIFICATION OF REACTIVE TYROSINES BY MASS SPECTROMETRY, J BIOL CHEM, 278, PP. 37223-37230, (2003); MARK R.J., HENSLEY K., BUTTERFIELD D.A., MATTSON M.P., AMYLOID Β-PEPTIDE IMPAIRS ION-MOTIVE ATPASE ACTIVITIES: EVIDENCE FOR A ROLE IN LOSS OF NEURONAL CA2<SUP>+</SUP> HOMEOSTASIS AND CELL DEATH, J NEUROSCI, 15, PP. 6239-6249, (1995); MARK R.J., LOVELL M.A., MARKESBERY W.R., UCHIDA K., MATTSON M.P., A ROLE FOR 4-HYDROXYNONENAL, AN ALDEHYDIC PRODUCT OF LIPID PEROXIDATION, IN DISRUPTION OF ION HOMEOSTASIS AND NEURONAL DEATH INDUCED BY AMYLOID Β-PEPTIDE, J NEUROCHEM, 68, PP. 255-264, (1997); TROTTI D., ROSSI D., GJESDAL O., LEVY L.M., RACAGNI G., DANBOLT N.C., ET AL., PEROXYNITRITE INHIBITS GLUTAMATE TRANSPORTER SUBTYPES, J BIOL CHEM, 271, PP. 5976-5979, (1996); SORG O., HORN T.F., YU N., GRUOL D.L., BLOOM F.E., INHIBITION OF ASTROCYTE GLUTAMATE UPTAKE BY REACTIVE OXYGEN SPECIES: ROLE OF ANTIOXIDANT ENZYMES, MOL MED, 3, PP. 431-440, (1997); AYATA C., AYATA G., HARA H., MATTHEWS R.T., BEAL M.F., FERRANTE R.J., ET AL., MECHANISMS OF REDUCED STRIATAL NMDA EXCITOTOXICITY IN TYPE I NITRIC OXIDE SYNTHASE KNOCK-OUT MICE, J NEUROSCI, 17, PP. 6908-6917, (1997); XIA Y., DAWSON V.L., DAWSON T.M., SNYDER S.H., ZWEIER J.L., NITRIC OXIDE SYNTHASE GENERATES SUPEROXIDE AND NITRIC OXIDE IN ARGININE-DEPLETED CELLS LEADING TO PEROXYNITRITE-MEDIATED CELLULAR INJURY, PROC NATL ACAD SCI USA, 93, PP. 6770-6774, (1996); VASQUEZ-VIVAR J., HOGG N., MARTASEK P., KAROUI H., PRITCHARD JR. K.A., KALYANARAMAN B., TETRAHYDROBIOPTERIN-DEPENDENT INHIBITION OF SUPEROXIDE GENERATION FROM NEURONAL NITRIC OXIDE SYNTHASE, J BIOL CHEM, 274, PP. 26736-26742, (1999); GRIMA G., BENZ B., DO K.Q., GLIAL-DERIVED ARGININE, THE NITRIC OXIDE PRECURSOR, PROTECTS NEURONS FROM NMDA-INDUCED EXCITOTOXICITY, EUR J NEUROSCI, 14, PP. 1762-1770, (2001); HUANG Z., HUANG P.L., PANAHIAN N., DALKARA T., FISHMAN M.C., MOSKOWITZ M.A., EFFECTS OF CEREBRAL ISCHEMIA IN MICE DEFICIENT IN NEURONAL NITRIC OXIDE SYNTHASE, SCIENCE, 265, PP. 1883-1885, (1994); DAWSON V.L., KIZUSHI V.M., HUANG P.L., SNYDER S.H., DAWSON T.M., RESISTANCE TO NEUROTOXICITY IN CORTICAL CULTURES FROM NEURONAL NITRIC OXIDE SYNTHASE-DEFICIENT MICE, J NEUROSCI, 16, PP. 2479-2487, (1996); BAUER M.K., LIEB K., SCHULZE-OSTHOFF K., BERGER M., GEBICKE-HAERTER P.J., BAUER J., ET AL., EXPRESSION AND REGULATION OF CYCLOOXYGENASE-2 IN RAT MICROGLIA, EUR J BIOCHEM, 243, PP. 726-731, (1997); AKUNDI R.S., CANDELARIO-JALIL E., HESS S., HULL M., LIEB K., GEBICKE-HAERTER P.J., ET AL., SIGNAL TRANSDUCTION PATHWAYS REGULATING CYCLOOXYGENASE-2 IN LIPOPOLYSACCHARIDE-ACTIVATED PRIMARY RAT MICROGLIA, GLIA, (2005); BEZZI P., CARMIGNOTO G., PASTI L., VESCE S., ROSSI D., RIZZINI B.L., ET AL., PROSTAGLANDINS STIMULATE CALCIUM-DEPENDENT GLUTAMATE RELEASE IN ASTROCYTES, NATURE, 391, PP. 281-285, (1998); CASPER D., YAPARPALVI U., REMPEL N., WERNER P., IBUPROFEN PROTECTS DOPAMINERGIC NEURONS AGAINST GLUTAMATE TOXICITY IN VITRO, NEUROSCI LETT, 289, PP. 201-204, (2000); HEWETT S.J., ULIASZ T.F., VIDWANS A.S., HEWETT J.A., CYCLOOXYGENASE-2 CONTRIBUTES TO N-METHYL-D-ASPARTATE-MEDIATED NEURONAL CELL DEATH IN PRIMARY CORTICAL CELL CULTURE, J PHARMACOL EXP THER, 293, PP. 417-425, (2000); SALZBERG-BRENHOUSE H.C., CHEN E.Y., EMERICH D.F., BALDWIN S., HOGELAND K., RANELLI S., ET AL., INHIBITORS OF CYCLOOXYGENASE-2, BUT NOT CYCLOOXYGENASE-1 PROVIDE STRUCTURAL AND FUNCTIONAL PROTECTION AGAINST QUINOLINIC ACID-INDUCED NEURODEGENERATION, J PHARMACOL EXP THER, 306, PP. 218-228, (2003); MIRJANY M., HO L., PASINETTI G.M., ROLE OF CYCLOOXYGENASE-2 IN NEURONAL CELL CYCLE ACTIVITY AND GLUTAMATE-MEDIATED EXCITOTOXICITY, J PHARMACOL EXP THER, 301, PP. 494-500, (2002); FLODEN A.M., LI S., COMBS C.K., Β-AMYLOID-STIMULATED MICROGLIA INDUCE NEURON DEATH VIA SYNERGISTIC STIMULATION OF TUMOR NECROSIS FACTOR Α AND NMDA RECEPTORS, J NEUROSCI, 25, PP. 2566-2575, (2005); GLAZNER G.W., MATTSON M.P., DIFFERENTIAL EFFECTS OF BDNF, ADNF9, AND TNFΑ ON LEVELS OF NMDA RECEPTOR SUBUNITS, CALCIUM HOMEOSTASIS, AND NEURONAL VULNERABILITY TO EXCITOTOXICITY, EXP NEUROL, 161, PP. 442-452, (2000); HUANG T.L., O'BANION M.K., INTERLEUKIN-1Β AND TUMOR NECROSIS FACTOR-Α SUPPRESS DEXAMETHASONE INDUCTION OF GLUTAMINE SYNTHETASE IN PRIMARY MOUSE ASTROCYTES, J NEUROCHEM, 71, PP. 1436-1442, (1998); HU S., SHENG W.S., EHRLICH L.C., PETERSON P.K., CHAO C.C., CYTOKINE EFFECTS ON GLUTAMATE UPTAKE BY HUMAN ASTROCYTES, NEUROIMMUNOMODULATION, 7, PP. 153-159, (2000); LIAO S.L., CHEN C.J., DIFFERENTIAL EFFECTS OF CYTOKINES AND REDOX POTENTIAL ON GLUTAMATE UPTAKE IN RAT CORTICAL GLIAL CULTURES, NEUROSCI LETT, 299, PP. 113-116, (2001); WANG Z., PEKARSKAYA O., BENCHEIKH M., CHAO W., GELBARD H.A., GHORPADE A., ET AL., REDUCED EXPRESSION OF GLUTAMATE TRANSPORTER EAAT2 AND IMPAIRED GLUTAMATE TRANSPORT IN HUMAN PRIMARY ASTROCYTES EXPOSED TO HIV-1 OR GP120, VIROLOGY, 312, PP. 60-73, (2003); ROZOVSKY I., FINCH C.E., MORGAN T.E., AGE-RELATED ACTIVATION OF MICROGLIA AND ASTROCYTES: IN VITRO STUDIES SHOW PERSISTENT PHENOTYPES OF AGING, INCREASED PROLIFERATION, AND RESISTANCE TO DOWN-REGULATION, NEUROBIOL AGING, 19, PP. 97-103, (1998); MACKENZIE I.R., MUNOZ D.G., NON-STEROIDAL ANTI-INFLAMMATORY DRUG USE AND ALZHEIMER-TYPE PATHOLOGY IN AGING, NEUROLOGY, 50, PP. 986-990, (1998); SHENG J.G., MRAK R.E., GRIFFIN W.S., ENLARGED AND PHAGOCYTIC, BUT NOT PRIMED, INTERLEUKIN-1 Α-IMMUNOREACTIVE MICROGLIA INCREASE WITH AGE IN NORMAL HUMAN BRAIN, ACTA NEUROPATHOL (BERL), 95, PP. 229-234, (1998); BARCIA C., SANCHEZ B.A., FERNANDEZ-VILLALBA E., BAUTISTA V., POZA Y.P., FERNANDEZ-BARREIRO A., ET AL., EVIDENCE OF ACTIVE MICROGLIA IN SUBSTANTIA NIGRA PARS COMPACTA OF PARKINSONIAN MONKEYS 1 YEAR AFTER MPTP EXPOSURE, GLIA, 46, PP. 402-409, (2004); LANGSTON J.W., FORNO L.S., TETRUD J., REEVES A.G., KAPLAN J.A., KARLUK D., EVIDENCE OF ACTIVE NERVE CELL DEGENERATION IN THE SUBSTANTIA NIGRA OF HUMANS YEARS AFTER 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE EXPOSURE, ANN NEUROL, 46, PP. 598-605, (1999); HIRSCH E.C., BREIDERT T., ROUSSELET E., HUNOT S., HARTMANN A., MICHEL P.P., THE ROLE OF GLIAL REACTION AND INFLAMMATION IN PARKINSON'S DISEASE, ANN NY ACAD SCI, 991, PP. 214-228, (2003); JENNER P., OXIDATIVE MECHANISMS IN NIGRAL CELL DEATH IN PARKINSON'S DISEASE, MOV DISORD, 13, SUPPL. 1, PP. 24-34, (1998); GAO H.M., JIANG J., WILSON B., ZHANG W., HONG J.S., LIU B., MICROGLIAL ACTIVATION-MEDIATED DELAYED AND PROGRESSIVE DEGENERATION OF RAT NIGRAL DOPAMINERGIC NEURONS: RELEVANCE TO PARKINSON'S DISEASE, J NEUROCHEM, 81, PP. 1285-1297, (2002); ARIMOTO T., BING G., UP-REGULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN THE SUBSTANTIA NIGRA BY LIPOPOLYSACCHARIDE CAUSES MICROGLIAL ACTIVATION AND NEURODEGENERATION, NEUROBIOL DIS, 12, PP. 35-45, (2003); CHOI S.H., JOE E.H., KIM S.U., JIN B.K., THROMBIN-INDUCED MICROGLIAL ACTIVATION PRODUCES DEGENERATION OF NIGRAL DOPAMINERGIC NEURONS IN VIVO, J NEUROSCI, 23, PP. 5877-5886, (2003); IRAVANI M.M., KASHEFI K., MANDER P., ROSE S., JENNER P., INVOLVEMENT OF INDUCIBLE NITRIC OXIDE SYNTHASE IN INFLAMMATION-INDUCED DOPAMINERGIC NEURODEGENERATION, NEUROSCIENCE, 110, PP. 49-58, (2002); VERSIJPT J.J., DUMONT F., VAN LAERE K.J., DECOO D., SANTENS P., AUDENAERT K., ET AL., ASSESSMENT OF NEUROINFLAMMATION AND MICROGLIAL ACTIVATION IN ALZHEIMER'S DISEASE WITH RADIOLABELLED PK11195 AND SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY. A PILOT STUDY, EUR NEUROL, 50, PP. 39-47, (2003); BIANCA V.D., DUSI S., BIANCHINI E., DAL P.I., ROSSI F., Β-AMYLOID ACTIVATES THE O-2 FORMING NADPH OXIDASE IN MICROGLIA, MONOCYTES, AND NEUTROPHILS. A POSSIBLE INFLAMMATORY MECHANISM OF NEURONAL DAMAGE IN ALZHEIMER'S DISEASE, J BIOL CHEM, 274, PP. 15493-15499, (1999); GE Y.W., LAHIRI D.K., REGULATION OF PROMOTER ACTIVITY OF THE APP GENE BY CYTOKINES AND GROWTH FACTORS: IMPLICATIONS IN ALZHEIMER'S DISEASE, ANN NY ACAD SCI, 973, PP. 463-467, (2002); BLASKO I., MARX F., STEINER E., HARTMANN T., GRUBECK-LOEBENSTEIN B., TNFΑ PLUS IFNΓ INDUCE THE PRODUCTION OF ALZHEIMER Β-AMYLOID PEPTIDES AND DECREASE THE SECRETION OF APPS, FASEB J, 13, PP. 63-68, (1999); SASTRE M., DEWACHTER I., LANDRETH G.E., WILLSON T.M., KLOCKGETHER T., VAN LEUVEN F., ET AL., NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ AGONISTS MODULATE IMMUNOSTIMULATED PROCESSING OF AMYLOID PRECURSOR PROTEIN THROUGH REGULATION OF Β-SECRETASE, J NEUROSCI, 23, PP. 9796-9804, (2003); QIN W., HO L., POMPL P.N., PENG Y., ZHAO Z., XIANG Z., ET AL., CYCLOOXYGENASE (COX)-2 AND COX-1 POTENTIATE Β-AMYLOID PEPTIDE GENERATION THROUGH MECHANISMS THAT INVOLVE Γ-SECRETASE ACTIVITY, J BIOL CHEM, 278, PP. 50970-50977, (2003); TIKKA T., FIEBICH B.L., GOLDSTEINS G., KEINANEN R., KOISTINAHO J., MINOCYCLINE, A TETRACYCLINE DERIVATIVE, IS NEUROPROTECTIVE AGAINST EXCITOTOXICITY BY INHIBITING ACTIVATION AND PROLIFERATION OF MICROGLIA, J NEUROSCI, 21, PP. 2580-2588, (2001); HE Y., APPEL S., LE W., MINOCYCLINE INHIBITS MICROGLIAL ACTIVATION AND PROTECTS NIGRAL CELLS AFTER 6-HYDROXYDOPAMINE INJECTION INTO MOUSE STRIATUM, BRAIN RES, 909, PP. 187-193, (2001); KIM S.S., KONG P.J., KIM B.S., SHEEN D.H., NAM S.Y., CHUN W., INHIBITORY ACTION OF MINOCYCLINE ON LIPOPOLYSACCHARIDE-INDUCED RELEASE OF NITRIC OXIDE AND PROSTAGLANDIN E2 IN BV2 MICROGLIAL CELLS, ARCH PHARM RES, 27, PP. 314-318, (2004); SUK K., MINOCYCLINE SUPPRESSES HYPOXIC ACTIVATION OF RODENT MICROGLIA IN CULTURE, NEUROSCI LETT, 366, PP. 167-171, (2004); BLUM D., CHTARTO A., TENENBAUM L., BROTCHI J., LEVIVIER M., CLINICAL POTENTIAL OF MINOCYCLINE FOR NEURODEGENERATIVE DISORDERS, NEUROBIOL DIS, 17, PP. 359-366, (2004); ZEMKE D., MAJID A., THE POTENTIAL OF MINOCYCLINE FOR NEUROPROTECTION IN HUMAN NEUROLOGIC DISEASE, CLIN NEUROPHARMACOL, 27, PP. 293-298, (2004); POCOCK J.M., LIDDLE A.C., MICROGLIAL SIGNALLING CASCADES IN NEURODEGENERATIVE DISEASE, PROG BRAIN RES, 132, PP. 555-565, (2001); BERNARDO A., LEVI G., MINGHETTI L., ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ (PPAR-Γ) AND ITS NATURAL LIGAND 15-DEOXY-Δ12,14-PROSTAGLANDIN J2 IN THE REGULATION OF MICROGLIAL FUNCTIONS, EUR J NEUROSCI, 12, PP. 2215-2223, (2000); KIM E.J., KWON K.J., PARK J.Y., LEE S.H., MOON C.H., BAIK E.J., EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS ON LPS-INDUCED NEURONAL DEATH IN MIXED CORTICAL NEURONS: ASSOCIATED WITH INOS AND COX-2, BRAIN RES, 941, PP. 1-10, (2002); STORER P.D., XU J., CHAVIS J.A., DREW P.D., CYCLOPENTENONE PROSTAGLANDINS PGA(2) AND 15-DEOXY-Δ(12,14) PGJ(2) SUPPRESS ACTIVATION OF MURINE MICROGLIA AND ASTROCYTES: IMPLICATIONS FOR MULTIPLE SCLEROSIS, J NEUROSCI RES, 80, PP. 66-74, (2005); DEHMER T., HENEKA M.T., SASTRE M., DICHGANS J., SCHULZ J.B., PROTECTION BY PIOGLITAZONE IN THE MPTP MODEL OF PARKINSON'S DISEASE CORRELATES WITH I Κ B Α INDUCTION AND BLOCK OF NF Κ B AND INOS ACTIVATION, J NEUROCHEM, 88, PP. 494-501, (2004); BREIDERT T., CALLEBERT J., HENEKA M.T., LANDRETH G., LAUNAY J.M., HIRSCH E.C., PROTECTIVE ACTION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ AGONIST PIOGLITAZONE IN A MOUSE MODEL OF PARKINSON'S DISEASE, J NEUROCHEM, 82, PP. 615-624, (2002); CAMACHO I.E., SERNEELS L., SPITTAELS K., MERCHIERS P., DOMINGUEZ D., DE STROOPER B., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Γ INDUCES A CLEARANCE MECHANISM FOR THE AMYLOID-Β PEPTIDE, J NEUROSCI, 24, PP. 10908-10917, (2004); INESTROSA N.C., GODOY J.A., QUINTANILLA R.A., KOENIG C.S., BRONFMAN M., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Γ IS EXPRESSED IN HIPPOCAMPAL NEURONS AND ITS ACTIVATION PREVENTS Β-AMYLOID NEURODEGENERATION: ROLE OF WNT SIGNALING, EXP CELL RES, 304, PP. 91-104, (2005); FEINSTEIN D.L., GALEA E., GAVRILYUK V., BROSNAN C.F., WHITACRE C.C., DUMITRESCU-OZIMEK L., ET AL., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ AGONISTS PREVENT EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, ANN NEUROL, 51, PP. 694-702, (2002); PERSHADSINGH H.A., HENEKA M.T., SAINI R., AMIN N.M., BROESKE D.J., FEINSTEIN D.L., EFFECT OF PIOGLITAZONE TREATMENT IN A PATIENT WITH SECONDARY MULTIPLE SCLEROSIS, J NEUROINFLAMMATION, 1, (2004); URYU S., HARADA J., HISAMOTO M., ODA T., TROGLITAZONE INHIBITS BOTH POST-GLUTAMATE NEUROTOXICITY AND LOW-POTASSIUM-INDUCED APOPTOSIS IN CEREBELLAR GRANULE NEURONS, BRAIN RES, 924, PP. 229-236, (2002); BENEDETTI M.D., MARAGANORE D.M., BOWER J.H., MCDONNELL S.K., PETERSON B.J., AHLSKOG J.E., ET AL., HYSTERECTOMY, MENOPAUSE, AND ESTROGEN USE PRECEDING PARKINSON'S DISEASE: AN EXPLORATORY CASE-CONTROL STUDY, MOV DISORD, 16, PP. 830-837, (2001); SAWADA H., SHIMOHAMA S., ESTROGENS AND PARKINSON DISEASE: NOVEL APPROACH FOR NEUROPROTECTION, ENDOCRINE, 21, PP. 77-79, (2003); WOOTEN G.F., CURRIE L.J., BOVBJERG V.E., LEE J.K., PATRIE J., ARE MEN AT GREATER RISK FOR PARKINSON'S DISEASE THAN WOMEN?, J NEUROL NEUROSURG PSYCHIATRY, 75, PP. 637-639, (2004); CURRIE L.J., HARRISON M.B., TRUGMAN J.M., BENNETT J.P., WOOTEN G.F., POSTMENOPAUSAL ESTROGEN USE AFFECTS RISK FOR PARKINSON DISEASE, ARCH NEUROL, 61, PP. 886-888, (2004); VEGETO E., BONINCONTRO C., POLLIO G., SALA A., VIAPPIANI S., NARDI F., ET AL., ESTROGEN PREVENTS THE LIPOPOLYSACCHARIDE-INDUCED INFLAMMATORY RESPONSE IN MICROGLIA, J NEUROSCI, 21, PP. 1809-1818, (2001); BAKER A.E., BRAUTIGAM V.M., WATTERS J.J., ESTROGEN MODULATES MICROGLIAL INFLAMMATORY MEDIATOR PRODUCTION VIA INTERACTIONS WITH ESTROGEN RECEPTOR Β, ENDOCRINOLOGY, 145, PP. 5021-5032, (2004); DLUZEN D.E., MCDERMOTT J.L., LIU B., ESTROGEN ALTERS MPTP-INDUCED NEUROTOXICITY IN FEMALE MICE: EFFECTS ON STRIATAL DOPAMINE CONCENTRATIONS AND RELEASE, J NEUROCHEM, 66, PP. 658-666, (1996); GRANDBOIS M., MORISSETTE M., CALLIER S., DI PAOLO T., OVARIAN STEROIDS AND RALOXIFENE PREVENT MPTP-INDUCED DOPAMINE DEPLETION IN MICE, NEUROREPORT, 11, PP. 343-346, (2000); RAMIREZ A.D., LIU X., MENNITI F.S., REPEATED ESTRADIOL TREATMENT PREVENTS MPTP-INDUCED DOPAMINE DEPLETION IN MALE MICE, NEUROENDOCRINOLOGY, 77, PP. 223-231, (2003); D'ASTOUS M., MORISSETTE M., DI PAOLO T., EFFECT OF ESTROGEN RECEPTOR AGONISTS TREATMENT IN MPTP MICE: EVIDENCE OF NEUROPROTECTION BY AN ER Α AGONIST, NEUROPHARMACOLOGY, 47, PP. 1180-1188, (2004); HENDERSON V.W., HORMONE THERAPY AND ALZHEIMER'S DISEASE: BENEFIT OR HARM?, EXPERT OPIN PHARMACOTHER, 5, PP. 389-406, (2004); BRINTON R.D., IMPACT OF ESTROGEN THERAPY ON ALZHEIMER'S DISEASE: A FORK IN THE ROAD?, CNS DRUGS, 18, PP. 405-422, (2004); WANG L., ANDERSSON S., WARNER M., GUSTAFSSON J.A., MORPHOLOGICAL ABNORMALITIES IN THE BRAINS OF ESTROGEN RECEPTOR Β KNOCKOUT MICE, PROC NATL ACAD SCI USA, 98, PP. 2792-2796, (2001); TAKAHASHI N., TONCHEV A.B., KOIKE K., MURAKAMI K., YAMADA K., YAMASHIMA T., ET AL., EXPRESSION OF ESTROGEN RECEPTOR-Β IN THE POSTISCHEMIC MONKEY HIPPOCAMPUS, NEUROSCI LETT, 369, PP. 9-13, (2004); SAVASKAN E., OLIVIERI G., MEIER F., RAVID R., MULLER-SPAHN F., HIPPOCAMPAL ESTROGEN Β-RECEPTOR IMMUNOREACTIVITY IS INCREASED IN ALZHEIMER'S DISEASE, BRAIN RES, 908, PP. 113-119, (2001); TRIEU V.N., UCKUN F.M., GENISTEIN IS NEUROPROTECTIVE IN MURINE MODELS OF FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS AND STROKE, BIOCHEM BIOPHYS RES COMMUN, 258, PP. 685-688, (1999); BANG O.Y., HONG H.S., KIM D.H., KIM H., BOO J.H., HUH K., ET AL., NEUROPROTECTIVE EFFECT OF GENISTEIN AGAINST Β-AMYLOID-INDUCED NEUROTOXICITY, NEUROBIOL DIS, 16, PP. 21-28, (2004); ZENG H., CHEN Q., ZHAO B., GENISTEIN AMELIORATES Β-AMYLOID PEPTIDE (25-35)-INDUCED HIPPOCAMPAL NEURONAL APOPTOSIS, FREE RADIC BIOL MED, 36, PP. 180-188, (2004); WANG X., CHEN S., MA G., YE M., LU G., GENISTEIN PROTECTS DOPAMINERGIC NEURONS BY INHIBITING MICROGLIAL ACTIVATION, NEUROREPORT, 16, PP. 267-270, (2005); MCCARTY M.F., ISOFLAVONES MADE SIMPLE - GENISTEIN'S AGONIST ACTIVITY FOR THE Β-TYPE ESTROGEN RECEPTOR MEDIATES THEIR HEALTH BENEFITS, MED HYPOTHESES, 66, PP. 1093-1114, (2006); SQUADRITO F., ALTAVILLA D., MORABITO N., CRISAFULLI A., D'ANNA R., CORRADO F., ET AL., THE EFFECT OF THE PHYTOESTROGEN GENISTEIN ON PLASMA NITRIC OXIDE CONCENTRATIONS, ENDOTHELIN-1 LEVELS AND ENDOTHELIUM DEPENDENT VASODILATION IN POSTMENOPAUSAL WOMEN, ATHEROSCLEROSIS, 163, PP. 339-347, (2002); MORABITO N., CRISAFULLI A., VERGARA C., GAUDIO A., LASCO A., FRISINA N., ET AL., EFFECTS OF GENISTEIN AND HORMONE-REPLACEMENT THERAPY ON BONE LOSS IN EARLY POSTMENOPAUSAL WOMEN: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY, J BONE MINER RES, 17, PP. 1904-1912, (2002); DUBAL D.B., SHUGHRUE P.J., WILSON M.E., MERCHENTHALER I., WISE P.M., ESTRADIOL MODULATES BCL-2 IN CEREBRAL ISCHEMIA: A POTENTIAL ROLE FOR ESTROGEN RECEPTORS, J NEUROSCI, 19, PP. 6385-6393, (1999); ZHAO L., WU T.W., BRINTON R.D., ESTROGEN RECEPTOR SUBTYPES Α AND Β CONTRIBUTE TO NEUROPROTECTION AND INCREASED BCL-2 EXPRESSION IN PRIMARY HIPPOCAMPAL NEURONS, BRAIN RES, 1010, PP. 22-34, (2004); CARSWELL H.V., MACRAE I.M., GALLAGHER L., HARROP E., HORSBURGH K.J., NEUROPROTECTION BY A SELECTIVE ESTROGEN RECEPTOR Β AGONIST IN A MOUSE MODEL OF GLOBAL ISCHEMIA, AM J PHYSIOL HEART CIRC PHYSIOL, 287, (2004); MILLER N.R., JOVER T., COHEN H.W., ZUKIN R.S., ETGEN A.M., ESTROGEN CAN ACT VIA ESTROGEN RECEPTOR Α AND Β TO PROTECT HIPPOCAMPAL NEURONS AGAINST GLOBAL ISCHEMIA-INDUCED CELL DEATH, ENDOCRINOLOGY, (2005); SAWADA H., IBI M., KIHARA T., HONDA K., NAKAMIZO T., KANKI R., ET AL., ESTRADIOL PROTECTS DOPAMINERGIC NEURONS IN A MPP+PARKINSON'S DISEASE MODEL, NEUROPHARMACOLOGY, 42, PP. 1056-1064, (2002); GARCION E., SINDJI L., MONTERO-MENEI C., ANDRE C., BRACHET P., DARCY F., EXPRESSION OF INDUCIBLE NITRIC OXIDE SYNTHASE DURING RAT BRAIN INFLAMMATION: REGULATION BY 1,25-DIHYDROXYVITAMIN D3, GLIA, 22, PP. 282-294, (1998); GARCION E., WION-BARBOT N., MONTERO-MENEI C.N., BERGER F., WION D., NEW CLUES ABOUT VITAMIN D FUNCTIONS IN THE NERVOUS SYSTEM, TRENDS ENDOCRINOL METAB, 13, PP. 100-105, (2002); LEFEBVRE D.C., MONTERO-MENEI C.N., BERNARD R., COUEZ D., VITAMIN D3 INHIBITS PROINFLAMMATORY CYTOKINES AND NITRIC OXIDE PRODUCTION BY THE EOC13 MICROGLIAL CELL LINE, J NEUROSCI RES, 71, PP. 575-582, (2003); NAVEILHAN P., NEVEU I., WION D., BRACHET P., 1,25-DIHYDROXYVITAMIN D3, AN INDUCER OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR, NEUROREPORT, 7, PP. 2171-2175, (1996); SANCHEZ B., LOPEZ-MARTIN E., SEGURA C., LABANDEIRA-GARCIA J.L., PEREZ-FERNANDEZ R., 1,25-DIHYDROXYVITAMIN D(3) INCREASES STRIATAL GDNF MRNA AND PROTEIN EXPRESSION IN ADULT RATS, BRAIN RES MOL BRAIN RES, 108, PP. 143-146, (2002); WANG J.Y., WU J.N., CHERNG T.L., HOFFER B.J., CHEN H.H., BORLONGAN C.V., ET AL., VITAMIN D(3) ATTENUATES 6-HYDROXYDOPAMINE-INDUCED NEUROTOXICITY IN RATS, BRAIN RES, 904, PP. 67-75, (2001); GARCION E., NATAF S., BEROD A., DARCY F., BRACHET P., 1,25-DIHYDROXYVITAMIN D3 INHIBITS THE EXPRESSION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN RAT CENTRAL NERVOUS SYSTEM DURING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS, BRAIN RES MOL BRAIN RES, 45, PP. 255-267, (1997); NEVEU I., NAVEILHAN P., MENAA C., WION D., BRACHET P., GARABEDIAN M., SYNTHESIS OF 1,25-DIHYDROXYVITAMIN D3 BY RAT BRAIN MACROPHAGES IN VITRO, J NEUROSCI RES, 38, PP. 214-220, (1994); TREVES T.A., PEDRO-CUESTA J., PARKINSONISM MORTALITY IN THE US. 1. TIME AND SPACE DISTRIBUTION, ACTA NEUROL SCAND, 84, PP. 389-397, (1991); EISEN A., CALNE D., AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON'S DISEASE AND ALZHEIMER'S DISEASE: PHYLOGENETIC DISORDERS OF THE HUMAN NEOCORTEX SHARING MANY CHARACTERISTICS, CAN J NEUROL SCI, 19, PP. 117-123, (1992); BETEMPS E.J., BUNCHER C.R., BIRTHPLACE AS A RISK FACTOR IN MOTOR NEURONE DISEASE AND PARKINSON'S DISEASE, INT J EPIDEMIOL, 22, PP. 898-904, (1993); VIETH R., VITAMIN D SUPPLEMENTATION, 25-HYDROXYVITAMIN D CONCENTRATIONS, AND SAFETY, AM J CLIN NUTR, 69, PP. 842-856, (1999); CHEN H., ZHANG S.M., HERNAN M.A., SCHWARZSCHILD M.A., WILLETT W.C., COLDITZ G.A., ET AL., NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND THE RISK OF PARKINSON DISEASE, ARCH NEUROL, 60, PP. 1059-1064, (2003); MCGEER P.L., SCHULZER M., MCGEER E.G., ARTHRITIS AND ANTI-INFLAMMATORY AGENTS AS POSSIBLE PROTECTIVE FACTORS FOR ALZHEIMER'S DISEASE: A REVIEW OF 17 EPIDEMIOLOGIC STUDIES, NEUROLOGY, 47, PP. 425-432, (1996); MINGHETTI L., NICOLINI A., POLAZZI E., CREMINON C., MACLOUF J., LEVI G., INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION IN ACTIVATED RAT MICROGLIAL CULTURES IS DOWNREGULATED BY EXOGENOUS PROSTAGLANDIN E2 AND BY CYCLOOXYGENASE INHIBITORS, GLIA, 19, PP. 152-160, (1997); KLEGERIS A., MCGEER P.L., CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITORS PROTECT AGAINST MONONUCLEAR PHAGOCYTE NEUROTOXICITY, NEUROBIOL AGING, 23, PP. 787-794, (2002); TEISMANN P., FERGER B., INHIBITION OF THE CYCLOOXYGENASE ISOENZYMES COX-1 AND COX-2 PROVIDE NEUROPROTECTION IN THE MPTP-MOUSE MODEL OF PARKINSON'S DISEASE, SYNAPSE, 39, PP. 167-174, (2001); YAN Q., ZHANG J., LIU H., BABU-KHAN S., VASSAR R., BIERE A.L., ET AL., ANTI-INFLAMMATORY DRUG THERAPY ALTERS Β-AMYLOID PROCESSING AND DEPOSITION IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE, J NEUROSCI, 23, PP. 7504-7509, (2003); DRACHMAN D.B., ROTHSTEIN J.D., INHIBITION OF CYCLOOXYGENASE-2 PROTECTS MOTOR NEURONS IN AN ORGANOTYPIC MODEL OF AMYOTROPHIC LATERAL SCLEROSIS, ANN NEUROL, 48, PP. 792-795, (2000); LEVESQUE L.E., BROPHY J.M., ZHANG B., THE RISK FOR MYOCARDIAL INFARCTION WITH CYCLOOXYGENASE-2 INHIBITORS: A POPULATION STUDY OF ELDERLY ADULTS, ANN INTERN MED, (2005); KALMIJN S., LAUNER L.J., OTT A., WITTEMAN J.C., HOFMAN A., BRETELER M.M., DIETARY FAT INTAKE AND THE RISK OF INCIDENT DEMENTIA IN THE ROTTERDAM STUDY, ANN NEUROL, 42, PP. 776-782, (1997); GRANT W.B., CAMPBELL A., ITZHAKI R.F., SAVORY J., THE SIGNIFICANCE OF ENVIRONMENTAL FACTORS IN THE ETIOLOGY OF ALZHEIMER'S DISEASE, J ALZHEIMERS DIS, 4, PP. 179-189, (2002); MORRIS M.C., EVANS D.A., BIENIAS J.L., TANGNEY C.C., BENNETT D.A., WILSON R.S., ET AL., CONSUMPTION OF FISH AND N-3 FATTY ACIDS AND RISK OF INCIDENT ALZHEIMER DISEASE, ARCH NEUROL, 60, PP. 940-946, (2003); LI G., HIGDON R., KUKULL W.A., PESKIND E., VAN VALEN M.K., TSUANG D., ET AL., STATIN THERAPY AND RISK OF DEMENTIA IN THE ELDERLY: A COMMUNITY-BASED PROSPECTIVE COHORT STUDY, NEUROLOGY, 63, PP. 1624-1628, (2004); ZANDI P.P., SPARKS D.L., KHACHATURIAN A.S., TSCHANZ J., NORTON M., STEINBERG M., ET AL., DO STATINS REDUCE RISK OF INCIDENT DEMENTIA AND ALZHEIMER DISEASE? THE CACHE COUNTY STUDY, ARCH GEN PSYCHIATRY, 62, PP. 217-224, (2005); WOLOZIN B., KELLMAN W., RUOSSEAU P., CELESIA G.G., SIEGEL G., DECREASED PREVALENCE OF ALZHEIMER DISEASE ASSOCIATED WITH 3-HYDROXY-3-METHYGLUTARYL COENZYME A REDUCTASE INHIBITORS, ARCH NEUROL, 57, PP. 1439-1443, (2000); JICK H., ZORNBERG G.L., JICK S.S., SESHADRI S., DRACHMAN D.A., STATINS AND THE RISK OF DEMENTIA, LANCET, 356, PP. 1627-1631, (2000); ROCKWOOD K., KIRKLAND S., HOGAN D.B., MACKNIGHT C., MERRY H., VERREAULT R., ET AL., USE OF LIPID-LOWERING AGENTS, INDICATION BIAS, AND THE RISK OF DEMENTIA IN COMMUNITY-DWELLING ELDERLY PEOPLE, ARCH NEUROL, 59, PP. 223-227, (2002); ZAMRINI E., MCGWIN G., ROSEMAN J.M., ASSOCIATION BETWEEN STATIN USE AND ALZHEIMER'S DISEASE, NEUROEPIDEMIOLOGY, 23, PP. 94-98, (2004); KUO Y.M., EMMERLING M.R., BISGAIER C.L., ESSENBURG A.D., LAMPERT H.C., DRUMM D., ET AL., ELEVATED LOW-DENSITY LIPOPROTEIN IN ALZHEIMER'S DISEASE CORRELATES WITH BRAIN ABETA 1-42 LEVELS, BIOCHEM BIOPHYS RES COMMUN, 252, PP. 711-715, (1998); LESSER G., KANDIAH K., LIBOW L.S., LIKOUREZOS A., BREUER B., MARIN D., ET AL., ELEVATED SERUM TOTAL AND LDL CHOLESTEROL IN VERY OLD PATIENTS WITH ALZHEIMER'S DISEASE, DEMENT GERIATR COGN DISORD, 12, PP. 138-145, (2001); SURYADEVARA V., STOREY S.G., ARONOW W.S., AHN C., ASSOCIATION OF ABNORMAL SERUM LIPIDS IN ELDERLY PERSONS WITH ATHEROSCLEROTIC VASCULAR DISEASE AND DEMENTIA, ATHEROSCLEROTIC VASCULAR DISEASE WITHOUT DEMENTIA, DEMENTIA WITHOUT ATHEROSCLEROTIC VASCULAR DISEASE, AND NO DEMENTIA OR ATHEROSCLEROTIC VASCULAR DISEASE, J GERONTOL A BIOL SCI MED SCI, 58, (2003); SABBAGH M., ZAHIRI H.R., CEIMO J., COOPER K., GAUL W., CONNOR D., ET AL., IS THERE A CHARACTERISTIC LIPID PROFILE IN ALZHEIMER'S DISEASE?, J ALZHEIMERS DIS, 6, PP. 585-589, (2004); LIEBERMAN A., LYONS K., LEVINE J., MYERBURG R., STATINS, CHOLESTEROL, CO-ENZYME Q10, AND PARKINSON'S DISEASE, PARKINSONISM RELAT DISORD, 11, PP. 81-84, (2005); CORDLE A., LANDRETH G., 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS ATTENUATE Β-AMYLOID-INDUCED MICROGLIAL INFLAMMATORY RESPONSES, J NEUROSCI, 25, PP. 299-307, (2005); PAHAN K., SHEIKH F.G., NAMBOODIRI A.M., SINGH I., LOVASTATIN AND PHENYLACETATE INHIBIT THE INDUCTION OF NITRIC OXIDE SYNTHASE AND CYTOKINES IN RAT PRIMARY ASTROCYTES, MICROGLIA, AND MACROPHAGES, J CLIN INVEST, 100, PP. 2671-2679, (1997); NAIDU A., XU Q., CATALANO R., CORDELL B., SECRETION OF APOLIPOPROTEIN E BY BRAIN GLIA REQUIRES PROTEIN PRENYLATION AND IS SUPPRESSED BY STATINS, BRAIN RES, 958, PP. 100-111, (2002); BI X., BAUDRY M., LIU J., YAO Y., FU L., BRUCHER F., ET AL., INHIBITION OF GERANYLGERANYLATION MEDIATES THE EFFECTS OF 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS ON MICROGLIA, J BIOL CHEM, 279, PP. 48238-48245, (2004); FASSBENDER K., SIMONS M., BERGMANN C., STROICK M., LUTJOHANN D., KELLER P., ET AL., SIMVASTATIN STRONGLY REDUCES LEVELS OF ALZHEIMER'S DISEASE Β-AMYLOID PEPTIDES ABETA 42 AND ABETA 40 IN VITRO AND IN VIVO, PROC NATL ACAD SCI USA, 98, PP. 5856-5861, (2001); PARVATHY S., EHRLICH M., PEDRINI S., DIAZ N., REFOLO L., BUXBAUM J.D., ET AL., ATORVASTATIN-INDUCED ACTIVATION OF ALZHEIMER'S Α SECRETASE IS RESISTANT TO STANDARD INHIBITORS OF PROTEIN PHOSPHORYLATION-REGULATED ECTODOMAIN SHEDDING, J NEUROCHEM, 90, PP. 1005-1010, (2004); COLE S.L., GRUDZIEN A., MANHART I.O., KELLY B.L., OAKLEY H., VASSAR R., STATINS CAUSE INTRACELLULAR ACCUMULATION OF AMYLOID PRECURSOR PROTEIN, Β-SECRETASE-CLEAVED FRAGMENTS, AND AMYLOID Β-PEPTIDE VIA AN ISOPRENOID-DEPENDENT MECHANISM, J BIOL CHEM, 280, PP. 18755-18770, (2005); ZACCO A., TOGO J., SPENCE K., ELLIS A., LLOYD D., FURLONG S., ET AL., 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS PROTECT CORTICAL NEURONS FROM EXCITOTOXICITY, J NEUROSCI, 23, PP. 11104-11111, (2003); BOSEL J., GANDOR F., HARMS C., SYNOWITZ M., HARMS U., DJOUFACK P.C., ET AL., NEUROPROTECTIVE EFFECTS OF ATORVASTATIN AGAINST GLUTAMATE-INDUCED EXCITOTOXICITY IN PRIMARY CORTICAL NEURONES, J NEUROCHEM, 92, PP. 1386-1398, (2005); SPARKS D.L., CONNOR D.J., BROWNE P.J., LOPEZ J.E., SABBAGH M.N., HMG-COA REDUCTASE INHIBITORS (STATINS) IN THE TREATMENT OF ALZHEIMER'S DISEASE AND WHY IT WOULD BE ILL-ADVISE TO USE ONE THAT CROSSES THE BLOOD-BRAIN BARRIER, J NUTR HEALTH AGING, 6, PP. 324-331, (2002); LAUFS U., LA F.V., PLUTZKY J., LIAO J.K., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY HMG COA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); ENDRES M., LAUFS U., HUANG Z., NAKAMURA T., HUANG P., MOSKOWITZ M.A., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC NATL ACAD SCI USA, 95, PP. 8880-8885, (1998); JUNG K.H., CHU K., JEONG S.W., HAN S.Y., LEE S.T., KIM J.Y., ET AL., HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, PROMOTES SENSORIMOTOR RECOVERY, SUPPRESSING ACUTE INFLAMMATORY REACTION AFTER EXPERIMENTAL INTRACEREBRAL HEMORRHAGE, STROKE, 35, PP. 1744-1749, (2004); SIRONI L., CIMINO M., GUERRINI U., CALVIO A.M., LODETTI B., ASDENTE M., ET AL., TREATMENT WITH STATINS AFTER INDUCTION OF FOCAL ISCHEMIA IN RATS REDUCES THE EXTENT OF BRAIN DAMAGE, ARTERIOSCLER THROMB VASC BIOL, 23, PP. 322-327, (2003)","M.F. MCCARTY; NATURAL ALTERNATIVES INTERNATIONAL, SAN MARCOS, CA 92078, 1185 LINDA VISTA DR, UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-33744735681","MED HYPOTHESES",NA,"NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"MCCARTY MF, 2006, MED HYPOTHESES","MCCARTY MF, 2006, MED HYPOTHESES"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","MARINOBUFAGENIN MAY MEDIATE THE IMPACT OF SALTY DIETS ON LEFT VENTRICULAR HYPERTROPHY BY DISRUPTING THE PROTECTIVE FUNCTION OF CORONARY MICROVASCULAR ENDOTHELIUM",2005,"MEDICAL HYPOTHESES","64","9",4,"10.1016/j.mehy.2003.11.043","PANTOX LABORATORIES, SAN DIEGO, CA 92109, 4622 SANTA FE STREET, UNITED STATES","INDIVIDUALS WHO EAT SALTY DIETS AND WHO ARE ""SALT-SENSITIVE"" TEND TO HAVE INCREASED LEFT VENTRICULAR MASS, INDEPENDENT OF BLOOD PRESSURE; THIS PHENOMENON AWAITS AN EXPLANATION. IT IS CLEAR THAT LOCAL UP-REGULATION OF ANGIOTENSIN II (ANGII) PRODUCTION AND ACTIVITY PLAY A KEY ROLE IN THE INDUCTION OF LEFT VENTRICULAR HYPERTROPHY (LVH). RECENT EVIDENCE SUGGESTS THAT A HEALTHY CORONARY MICROVASCULAR ENDOTHELIUM OPPOSES THIS EFFECT BY SERVING AS A PARACRINE SOURCE OF NITRIC OXIDE (NO), A NATURAL ANTAGONIST OF ANGII ACTIVITY, AND THAT UP-REGULATION OF THIS MECHANISM CAN ACCOUNT FOR THE PROTECTIVE ROLE OF BRADYKININ WITH RESPECT TO LVH. THE CORONARY MICROVASCULATURE ALSO POSSESSES NAD(P)H OXIDASE ACTIVITY THAT CAN GENERATE SUPEROXIDE, INIMICAL TO THE BIOACTIVITY OF ENDOTHELIAL NO. THERE IS NOW GOOD REASON TO BELIEVE THAT THE TRITERPENOID MARINOBUFAGENIN (MBG), A SELECTIVE INHIBITOR OF THE Α-1 ISOFORM OF THE SODIUM PUMP, MEDIATES THE IMPACT OF SALTY DIETS ON BLOOD PRESSURE; PRODUCTION OF MBG BY THE ADRENAL CORTEX IS BOOSTED WHEN SALT-SENSITIVE ANIMALS ARE FED SALTY DIETS. IT IS HYPOTHESIZED THAT CORONARY MICROVASCULAR ENDOTHELIUM EXPRESSES THE Α-1 ISOFORM OF THE SODIUM PUMP, AND THAT MBG THUS CAN TARGET THIS ENDOTHELIUM. IF THAT IS THE CASE, MBG WOULD BE EXPECTED TO DECREASE MEMBRANE POTENTIAL IN THESE CELLS; AS A CONSEQUENCE, SUPEROXIDE PRODUCTION WOULD BE UP-REGULATED, NO SYNTHASE ACTIVITY WOULD BE DOWN-REGULATED, AND MYOCARDIAL NO BIOACTIVITY WOULD THUS BE SUPPRESSED. THIS WOULD OFFER A SATISFYING EXPLANATION FOR THE IMPACT OF SALT AND SALT-SENSITIVITY ON RISK FOR LVH. IF EXPRESSION OF THE Α-1 ISOFORM OF THE SODIUM PUMP IS A MORE GENERAL PROPERTY OF VASCULAR ENDOTHELIUM, MBG MAY SUPPRESS NO BIOACTIVITY IN OTHER REGIONS OF THE VASCULAR TREE, THEREBY CONTRIBUTING TO OTHER ADVERSE EFFECTS ELICITED BY SALTY DIETS: REDUCED ARTERIAL COMPLIANCE, MEDIAL HYPERTROPHY, IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION, HYPERTENSIVE/DIABETIC GLOMERULOPATHY, INCREASED RISK FOR STROKE, AND HYPERTENSION. © 2004 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MARINOBUFAGENIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLICOSANOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TRITERPENOID; UNCLASSIFIED DRUG; ADRENAL CORTEX; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; CELL MEMBRANE POTENTIAL; CORONARY BLOOD VESSEL; CORONARY MICROVASCULAR ENDOTHELIUM; DIABETIC NEPHROPATHY; DIET; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION","","","MARCUS M.L., KOYANAGI S., HARRISON D.G., DOTY D.B., HIRATZKA L.F., EASTHAM C.L., ABNORMALITIES IN THE CORONARY CIRCULATION THAT OCCUR AS A CONSEQUENCE OF CARDIAC HYPERTROPHY, AM. J. MED., 75, PP. 62-66, (1983); RAKUSAN K., FLANAGAN M.F., GEVA T., SOUTHERN J., VAN PRAAGH R., MORPHOMETRY OF HUMAN CORONARY CAPILLARIES DURING NORMAL GROWTH AND THE EFFECT OF AGE IN LEFT VENTRICULAR PRESSURE-OVERLOAD HYPERTROPHY, CIRCULATION, 86, PP. 38-46, (1992); AMANN K., BUZELLO M., SIMONAVICIENE A., MILTENBERGER-MILTENYI G., KOCH A., NABOKOV A., ET AL., CAPILLARY/MYOCYTE MISMATCH IN THE HEART IN RENAL FAILURE-A ROLE FOR ERYTHROPOIETIN?, NEPHROL. DIAL. TRANSPLANT., 15, PP. 964-969, (2000); LI X., LI R., YU W., SHI H., WEI L., CHARACTERISTICS OF CORONARY MICROVASCULAR LESIONS IN AUTOPSIED ELDERLY WITH HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY, CHIN. MED. J. (ENGL.), 115, PP. 658-663, (2002); KAHAN T., THE IMPORTANCE OF LEFT VENTRICULAR HYPERTROPHY IN HUMAN HYPERTENSION, J. HYPERTENS. SUPPL., 16, (1998); AGABITI-ROSEI E., MUIESAN M.L., PROGNOSTIC SIGNIFICANCE OF LEFT VENTRICULAR HYPERTROPHY REGRESSION, ADV. EXP. MED. BIOL., 432, PP. 199-205, (1997); BENJAMIN E.J., LEVY D., WHY IS LEFT VENTRICULAR HYPERTROPHY SO PREDICTIVE OF MORBIDITY AND MORTALITY?, AM. J. MED. SCI., 317, PP. 168-175, (1999); DEVEREUX R.B., ROMAN M.J., LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSION: STIMULI, PATTERNS, AND CONSEQUENCES, HYPERTENS. RES., 22, PP. 1-9, (1999); HANRATTY C., MCAULEY D., SILKE B., EPIDEMIOLOGY AND TREATMENT OF LEFT VENTRICULAR HYPERTROPHY IN THE ELDERLY, CORON. ARTERY DIS., 10, PP. 633-640, (1999); ARMARIO P., DEL REY R.H., SANCHEZ P., MARTIN-BARANERA M., TORRES G., JULIA J., ET AL., DETERMINANTS OF LEFT VENTRICULAR MASS IN UNTREATED MILDLY HYPERTENSIVE SUBJECTS: HOSPITALET STUDY IN MILD HYPERTENSION, AM. J. HYPERTENS., 12, PP. 1084-1090, (1999); BEIL A.H., SCHMIEDER R.E., MESSERLI F.H., SALT INTAKE, BLOOD PRESSURE, AND CARDIOVASCULAR STRUCTURE, CARDIOVASC. DRUGS THER., 8, PP. 425-432, (1994); DU C.G., PELLERIN F., WOJEWODSKA H., RIBSTEIN J., GROLLEAU R., MIMRAN A., DETERMINANTS OF LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE SUBJECTS THAT HAVE NEVER BEEN TREATED: ROLE OF THE SODIUM INTAKE, ARCH. MAL. COEUR. VAISS., 82, PP. 1105-1108, (1989); LANGENFELD M.R., SCHMIEDER R.E., SALT AND LEFT VENTRICULAR HYPERTROPHY: WHAT ARE THE LINKS?, J. HUM. HYPERTENS., 9, PP. 909-916, (1995); SCHMIEDER R.E., LANGENFELD M.R., FRIEDRICH A., SCHOBEL H.P., GATZKA C.D., WEIHPRECHT H., ANGIOTENSIN II RELATED TO SODIUM EXCRETION MODULATES LEFT VENTRICULAR STRUCTURE IN HUMAN ESSENTIAL HYPERTENSION, CIRCULATION, 94, PP. 1304-1309, (1996); MESSERLI F.H., SCHMIEDER R.E., WEIR M.R., SALT. A PERPETRATOR OF HYPERTENSIVE TARGET ORGAN DISEASE?, ARCH. INTERN. MED., 157, PP. 2449-2452, (1997); CAMPESE V.M., SALT SENSITIVITY IN HYPERTENSION. RENAL AND CARDIOVASCULAR IMPLICATIONS, HYPERTENSION, 23, PP. 531-550, (1994); HEIMANN J.C., DRUMOND S., ALVES A.T., BARBATO A.J., DICHTCHEKENIAN V., MARCONDES M., LEFT VENTRICULAR HYPERTROPHY IS MORE MARKED IN SALT-SENSITIVE THAN IN SALT-RESISTANT HYPERTENSIVE PATIENTS, J. CARDIOVASC. PHARMACOL., 17, SUPPL. 2, (1991); MUSIARI L., CERIATI R., TALIANI U., MONTESI M., NOVARINI A., EARLY ABNORMALITIES IN LEFT VENTRICULAR DIASTOLIC FUNCTION OF SODIUM-SENSITIVE HYPERTENSIVE PATIENTS, J. HUM. HYPERTENS., 13, PP. 711-716, (1999); FERRARA L.A., DE SIMONE G., PASANISI F., MANCINI M., LEFT VENTRICULAR MASS REDUCTION DURING SALT DEPLETION IN ARTERIAL HYPERTENSION, HYPERTENSION, 6, PP. 755-759, (1984); JULA A.M., KARANKO H.M., EFFECTS ON LEFT VENTRICULAR HYPERTROPHY OF LONG-TERM NON-PHARMACOLOGICAL TREATMENT WITH SODIUM RESTRICTION IN MILD-TO-MODERATE ESSENTIAL HYPERTENSION, CIRCULATION, 89, PP. 1023-1031, (1994); OZKAHYA M., OK E., CIRIT M., AYDIN S., AKCICEK F., BASCI A., ET AL., REGRESSION OF LEFT VENTRICULAR HYPERTROPHY IN HAEMODIALYSIS PATIENTS BY ULTRAFILTRATION AND REDUCED SALT INTAKE WITHOUT ANTIHYPERTENSIVE DRUGS, NEPHROL. DIAL. TRANSPLANT., 13, PP. 1489-1493, (1998); DE SIMONE G., DEVEREUX R.B., CAMARGO M.J., WALLERSON D.C., SEALEY J.E., LARAGH J.H., REDUCTION OF DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN SALT-LOADED DAHL SALT-SENSITIVE RATS BY ANGIOTENSIN II RECEPTOR INHIBITION, AM. J. HYPERTENS., 9, PP. 216-222, (1996); ENNEZAT P.V., HOUEL R., HELOIRE F., TOLLE V., SU J.B., COHEN A., ET AL., EFFECTS OF HIGH SODIUM INTAKE ON VENTRICULAR REMODELING IN MICE, ARCH. MAL. COEUR VAISS, 91, PP. 935-939, (1998); MORGAN T.O., AUBERT J.F., WANG Q., SODIUM, ANGIOTENSIN II, BLOOD PRESSURE, AND CARDIAC HYPERTROPHY, KIDNEY INT. SUPPL., 67, (1998); SUGIMOTO K., FUJIMURA A., TAKASAKI I., TOKITA Y., IWAMOTO T., TAKIZAWA T., ET AL., EFFECTS OF RENIN- ANGIOTENSIN SYSTEM BLOCKADE AND DIETARY SALT INTAKE ON LEFT VENTRICULAR HYPERTROPHY IN DAHL SALT-SENSITIVE RATS, HYPERTENS. RES., 21, PP. 163-168, (1998); HIRSCH A.T., PINTO Y.M., SCHUNKERT H., DZAU V.J., POTENTIAL ROLE OF THE TISSUE RENIN-ANGIOTENSIN SYSTEM IN THE PATHOPHYSIOLOGY OF CONGESTIVE HEART FAILURE, AM. J. CARDIOL., 66, (1990); SCHUNKERT H., DZAU V.J., TANG S.S., HIRSCH A.T., APSTEIN C.S., LORELL B.H., INCREASED RAT CARDIAC ANGIOTENSIN CONVERTING ENZYME ACTIVITY AND MRNA EXPRESSION IN PRESSURE OVERLOAD LEFT VENTRICULAR HYPERTROPHY. EFFECTS ON CORONARY RESISTANCE, CONTRACTILITY, AND RELAXATION, J. CLIN. INVEST., 86, PP. 1913-1920, (1990); MEGGS L.G., COUPET J., HUANG H., CHENG W., LI P., CAPASSO J.M., ET AL., REGULATION OF ANGIOTENSIN II RECEPTORS ON VENTRICULAR MYOCYTES AFTER MYOCARDIAL INFARCTION IN RATS, CIRC. RES., 72, PP. 1149-1162, (1993); SUZUKI J., MATSUBARA H., URAKAMI M., INADA M., RAT ANGIOTENSIN II (TYPE 1 A) RECEPTOR MRNA REGULATION AND SUBTYPE EXPRESSION IN MYOCARDIAL GROWTH AND HYPERTROPHY, CIRC. RES., 73, PP. 439-447, (1993); LYER S.N., RAIZADA M.K., KATOVICH M.J., ATI RECEPTOR DENSITY CHANGES DURING DEVELOPMENT OF HYPERTENSION IN HYPERINSULINEMIC RATS, CLIN. EXP. HYPERTENS., 18, PP. 793-810, (1996); FAREH J., TOUYZ R.M., SCHIFFRIN E.L., THIBAULT G., CARDIAC TYPE-1 ANGIOTENSIN II RECEPTOR STATUS IN DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSION IN RATS, HYPERTENSION, 30, PP. 1253-1259, (1997); RITCHIE R.H., MARSB J.D., LANCASTER W.D., DIGLIO C.A., SCHIEBINGER R.J., BRADYKININ BLOCKS ANGIOTENSIN II-INDUCED HYPERTROPHY IN THE PRESENCE OF ENDOTHELIAL CELLS, HYPERTENSION, 31, PP. 39-44, (1998); LIJNEN P., PETROV V., ANTAGONISM OF THE RENIN-ANGIOTENSIN SYSTEM, HYPERTROPHY AND GENE EXPRESSION IN CARDIAC MYOCYTES, METH. FIND EXP. CLIN. PHARMACOL., 21, PP. 363-374, (1999); BRILLA C.G., SCHEER C., RUPP H., RENIN-RANGIOTENSIN SYSTEM AND MYOCARDIAL COLLAGEN MATRIX: MODULATION OF CARDIAC FIBROBLAST FUNCTION BY ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONISM, J. HYPERTENS. SUPPL., 15, (1997); DAHLOF B., PENNERT K., HANSSON L., REVERSAL OF LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS. A METAANALYSIS OF 109 TREATMENT STUDIES, AM. J. HYPERTENS., 5, PP. 95-110, (1992); DAHLOF B., ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND EFFECTS ON LEFT VENTRICULAR HYPERTROPHY, BLOOD PRESS. SUPPL., 2, PP. 35-40, (1994); SCHMIEDER R.E., MARTUS P., KLINGBEIL A., REVERSAL OF LEFT VENTRICULAR HYPERTROPHY IN ESSENTIAL HYPERTENSION. A META-ANALYSIS OF RANDOMIZED DOUBLE-BLIND STUDIES, JAMA, 275, PP. 1507-1513, (1996); CARSON P., GILES T., HIGGINBOTHAM M., HOLLENBERG N., KANNEL W., SIRAGY H.M., ANGIOTENSIN RECEPTOR BLOCKERS: EVIDENCE FOR PRESERVING TARGET ORGANS, CLIN. CARDIOL., 24, PP. 183-190, (2001); WHITE M., CARDIOPROTECTIVE EFFECT OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, CAN. J. CARDIOL., 15, SUPPL. F, (1999); DIAMOND J.A., GHARAVI A., ROYCHOUDHURY D., MACHAC J., HENZLOVA M.J., TRAVIS A., ET AL., EFFECT OF LONG-TERM EPROSARTAN VERSUS ENALAPRIL ANTIHYPERTENSIVE THERAPY ON LEFT VENTRICULAR MASS AND CORONARY FLOW RESERVE IN STAGE I-II HYPERTENSION. EPROSARTAN STUDY GROUP, CURR. MED. RES. OPIN., 15, PP. 1-8, (1999); HARTMAN J.C., THE ROLE OF BRADYKININ AND NITRIC OXIDE IN THE CARDIOPROTECTIVE ACTION OF ACE INHIBITORS, ANN. THORAC. SURG., 60, PP. 789-792, (1995); GOHLKE P., LINZ W., SCHOLKENS B.A., KUWER I., BARTENBACH S., SCHNELL A., ET AL., ANGIOTENSIN-CONVERTING ENZYME INHIBITION IMPROVES CARDIAC FUNCTION. ROLE OF BRADYKININ, HYPERTENSION, 23, PP. 411-418, (1994); LINZ W., WIEMER G., SCHOLKENS B.A., ACE-INHIBITION INDUCES NO-FORMATION IN CULTURED BOVINE ENDOTHELIAL CELLS AND PROTECTS ISOLATED ISCHEMIC RAT HEARTS, J. MOL. CELL CARDIOL., 24, PP. 909-919, (1992); RITCHIE R.H., SCHIEBINGER R.J., LAPOINTE M.C., MARSH J.D., ANGIOTENSIN II-INDUCED HYPERTROPHY OF ADULT RAT CARDIOMYOCYTES IS BLOCKED BY NITRIC OXIDE, AM. J. PHYSIOL., 275, (1998); SHAH A.M., MACCARTHY P.A., PARACRINE AND AUTOCRINE EFFECTS OF NITRIC OXIDE ON MYOCARDIAL FUNCTION, PHARMACOL. THER., 86, PP. 49-86, (2000); MACCARTHY P.A., GRIEVE D.J., LI J.M., DUNSTER C., KELLY F.J., SHAH A.M., IMPAIRED ENDOTHELIAL REGULATION OF VENTRICULAR RELAXATION IN CARDIAC HYPERTROPHY: ROLE OF REACTIVE OXYGEN SPECIES AND NADPH OXIDASE, CIRCULATION, 104, PP. 2967-2974, (2001); ACKERMANN A., FERNANDEZ-ALFONSO M.S., SANCHEZ D.R., ORTEGA T., PAUL M., GONZALEZ C., MODULATION OF ANGIOTENSIN-CONVERTING ENZYME BY NITRIC OXIDE, BR. J. PHARMACOL., 124, PP. 291-298, (1998); USUI M., EGASHIRA K., KITAMOTO S., KOYANAGI M., KATOH M., KATAOKA C., ET AL., PATHOGENIC ROLE OF OXIDATIVE STRESS IN VASCULAR ANGIOTENSIN-CONVERTING ENZYME ACTIVATION IN LONG-TERM BLOCKADE OF NITRIC OXIDE SYNTHESIS IN RATS, HYPERTENSION, 34, PP. 546-551, (1999); CAHILL P.A., REDMOND E.M., FOSTER C., SITZMANN J.V., NITRIC OXIDE REGULATES ANGIOTENSIN II RECEPTORS IN VASCULAR SMOOTH MUSCLE CELLS, EUR. J. PHARMACOL., 288, PP. 219-229, (1995); ICHIKI T., USUI M., KATO M., FUNAKOSHI Y., ITO K., EGASHIRA K., ET AL., DOWNREGULATION OF ANGIOTENSIN II TYPE 1 RECEPTOR GENE TRANSCRIPTION BY NITRIC OXIDE, HYPERTENSION, 31, PP. 342-348, (1998); KATOH M., EGASHIRA K., USUI M., ICHIKI T., TOMITA H., SHIMOKAWA H., ET AL., CARDIAC ANGIOTENSIN II RECEPTORS ARE UPREGULATED BY LONG-TERM INHIBITION OF NITRIC OXIDE SYNTHESIS IN RATS, CIRC. RES., 83, PP. 743-751, (1998); MILLATT L.J., ABDEL-RAHMAN E.M., SIRAGY H.M., ANGIOTENSIN II AND NITRIC OXIDE: A QUESTION OF BALANCE, REGUL. PEPT., 81, PP. 1-10, (1999); LINZ W., WIEMER G., SCHAPER J., ZIMMERMANN R., NAGASAWA K., GOHLKE P., ET AL., ANGIOTENSIN CONVERTING ENZYME INHIBITORS, LEFT VENTRICULAR HYPERTROPHY AND FIBROSIS, MOL. CELL BIOCHEM., 147, PP. 89-97, (1995); GEROVA M., HARTMANNOVA B., DOLEZEL S., JEZEK L., LONG-TERM INHIBITION OF NO SYNTHASE INDUCES CARDIAC HYPERTROPHY WITH A DECREASE IN ADRENERGIC INNERVATION, PHYSIOL. RES., 45, PP. 339-344, (1996); BERNATOVA I., PECHANOVA O., PELOUCH V., SIMKO F., REGRESSION OF CHRONIC L -NAME-TREATMENT- INDUCED LEFT VENTRICULAR HYPERTROPHY: EFFECT OF CAPTOPRIL, J. MOL. CELL CARDIOL., 32, PP. 177-185, (2000); SIMKO F., SIMKO J., THE POTENTIAL ROLE OF NITRIC OXIDE IN THE HYPERTROPHIC GROWTH OF THE LEFT VENTRICLE, PHYSIOL. RES., 49, PP. 37-46, (2000); PACCA S.R., DE AZEVEDO A.P., DE OLIVEIRA C.F., DE L. I., DE NUCCI G., ANTUNES E., ATTENUATION OF HYPERTENSION, CARDIOMYOCYTE HYPERTROPHY, AND MYOCARDIAL FIBROSIS BY BETA-ADRENOCEPTOR BLOCKERS IN RATS UNDER LONG-TERM BLOCKADE OF NITRIC OXIDE SYNTHESIS, J. CARDIOVASC. PHARMACOL., 39, PP. 201-207, (2002); HADDY F.J., OVERBECK H.W., THE ROLE OF HUMORAL AGENTS IN VOLUME EXPANDED HYPERTENSION, LIFE SCI., 19, PP. 935-947, (1976); MACGREGOR G.A., DE WARDENER H.E., IS A CIRCULATING SODIUM TRANSPORT INHIBITOR INVOLVED IN THE PATHOGENESIS OF ESSENTIAL HYPERTENSION?, CLIN. EXP. HYPERTENS., 3, PP. 815-830, (1981); HADDY F.J., NATRIURETIC HORMONE-THE MISSING LINK IN LOW RENIN HYPERTENSION?, BIOCHEM. PHARMACOL., 31, PP. 3159-3161, (1982); BLAUSTEIN M.P., HAMLYN J.M., SODIUM TRANSPORT INHIBITION, CELL CALCIUM, AND HYPERTENSION. THE NATRIURETIC HORMONE/NA+-CA2+ EXCHANGE/HYPERTENSION HYPOTHESIS, AM. J. MED., 77, PP. 45-59, (1984); HADDY F.J., PAMNANI M.B., ROLE OF OUABAIN-LIKE FACTORS AND NA-K-ATPASE INHIBITORS IN HYPERTENSION-SOME OLD AND RECENT FINDINGS, CLIN. EXP. HYPERTENS., 20, PP. 499-508, (1998); FEDOROVA O.V., DORIS P.A., BAGROV A.Y., ENDOGENOUS MARINOBUFAGENIN-LIKE FACTOR IN ACUTE PLASMA VOLUME EXPANSION, CLIN. EXP. HYPERTENS., 20, PP. 581-591, (1998); FEDOROVA O.V., KOLODKIN N.I., AGALAKOVA N.I., LAKATTA E.G., BAGROV A.Y., MARINOBUFAGENIN, AN ENDOGENOUS Α-1 SODIUM PUMP LIGAND, IN HYPERTENSIVE DAHL SALT-SENSITIVE RATS, HYPERTENSION, 37, PP. 462-466, (2001); FEDOROVA O.V., TALAN M.I., AGALAKOVA N.I., LAKATTA E.G., BAGROV A.Y., ENDOGENOUS LIGAND OF Α (L) SODIUM PUMP, MARINOBUFAGENIN, IS A NOVEL MEDIATOR OF SODIUM CHLORIDE-DEPENDENT HYPERTENSION, CIRCULATION, 105, PP. 1122-1127, (2002); FEDOROVA O.V., BAGROV A.Y., INHIBITION OF NA/K ATPASE FROM RAT AORTA BY TWO NA/K PUMP INHIBITORS, OUABAIN AND MARINOBUFAGENIN: EVIDENCE OF INTERACTION WITH DIFFERENT Α-SUBUNIT ISOFORMS, AM. J. HYPERTENS., 10, PP. 929-935, (1997); CAPPUCCIO F.P., MARKANDU N.D., SAGNELLA G.A., MACGREGOR G.A., THE EFFECT OF ORAL DIGOXIN ON SODIUM EXCRETION, RENIN-ANGIOTENSIN- ALDOSTERONE SYSTEM AND BLOOD PRESSURE IN NORMOTENSIVE SUBJECTS, POSTGRAD. MED. J., 62, PP. 265-268, (1986); DMITRIEVA R.I., BAGROV A.Y., LALLI E., SASSONE-CORSI P., STOCCO D.M., DORIS P.A., MAMMALIAN BUFADIENOLIDE IS SYNTHESIZED FROM CHOLESTEROL IN THE ADRENAL CORTEX BY A PATHWAY THAT IS INDEPENDENT OF CHOLESTEROL SIDE-CHAIN CLEAVAGE, HYPERTENSION, 36, PP. 442-448, (2000); FEDOROVA O.V., LAKATTA E.G., BAGROV A.Y., ENDOGENOUS NA, K PUMP LIGANDS ARE DIFFERENTIALLY REGULATED DURING ACUTE NACL LOADING OF DAHL RATS, CIRCULATION, 102, PP. 3009-3014, (2000); FRIDMAN A.I., MATVEEV S.A., AGALAKOVA N.I., FEDOROVA O.V., LAKATTA E.G., BAGROV A.Y., MARINOBUFAGENIN, AN ENDOGENOUS LIGAND OF ALPHA-1 SODIUM PUMP, IS A MARKER OF CONGESTIVE HEART FAILURE SEVERITY, J. HYPERTENS., 20, PP. 1189-1194, (2002); GONICK H.C., DING Y., VAZIRI N.D., BAGROV A.Y., FEDOROVA O.V., SIMULTANEOUS MEASUREMENT OF MARINOBUFAGENIN, OUABAIN, AND HYPERTENSION-ASSOCIATED PROTEIN IN VARIOUS DISEASE STATES, CLIN. EXP. HYPERTENS., 20, PP. 617-627, (1998); LOPATIN D.A., AILAMAZIAN E.K., DMITRIEVA R.I., SHPEN V.M., FEDOROVA O.V., DORIS P.A., ET AL., CIRCULATING BUFODIENOLIDE AND CARDENOLIDE SODIUM PUMP INHIBITORS IN PREECLAMPSIA, J. HYPERTENS., 17, PP. 1179-1187, (1999); BLAUSTEIN M.P., SODIUM IONS, CALCIUM IONS, BLOOD PRESSURE REGULATION, AND HYPERTENSION: A REASSESSMENT AND A HYPOTHESIS, AM. J. PHYSIOL., 232, (1977); PERRY I.J., BEEVERS D.G., SALT INTAKE AND STROKE: A POSSIBLE DIRECT EFFECT, J. HUM. HYPERTENS., 6, PP. 23-25, (1992); XIE J.X., SASAKI S., JOOSSENS J.V., KESTELOOT H., THE RELATIONSHIP BETWEEN URINARY CATIONS OBTAINED FROM THE INTERSALT STUDY AND CEREBROVASCULAR MORTALITY, J. HUM. HYPERTENS., 6, PP. 17-21, (1992); FRANSEN P., HENDRICKX J., BRUTSAERT D.L., SYS S.U., DISTRIBUTION AND ROLE OF NA (+)/K (+) ATPASE IN ENDOCARDIAL ENDOTHELIUM, CARDIOVASC. RES., 52, PP. 487-499, (2001); HADDY F.J., POTASSIUM, NA+-K+ PUMP INHIBITOR AND LOW-RENIN HYPERTENSION, CLIN. INVEST. MED., 10, PP. 547-554, (1987); GLITSCH H.G., ELECTROPHYSIOLOGY OF THE SODIUM-POTASSIUM-ATPASE IN CARDIAC CELLS, PHYSIOL. REV., 81, PP. 1791-1826, (2001); BUSSE R., LUCKHOFF A., MULSCH A., CELLULAR MECHANISMS CONTROLLING EDRF/NO FORMATION IN ENDOTHELIAL CELLS, BASIC RES. CARDIOL., 86, SUPPL. 2, PP. 7-16, (1991); HE P., CURRY F.E., ENDOTHELIAL CELL HYPERPOLARIZATION INCREASES CA2+I AND VENULAR MICROVESSEL PERMEABILITY, J. APPL. PHYSIOL., 76, PP. 2288-2297, (1994); MCCABE R.D., BAKARICH M.A., SRIVASTAVA K., YOUNG D.B., POTASSIUM INHIBITS FREE RADICAL FORMATION, HYPERTENSION, 24, PP. 77-82, (1994); AL-MEHDI A.B., ISCHIROPOULOS H., FISHER A.B., ENDOTHELIAL CELL OXIDANT GENERATION DURING K (+)-INDUCED MEMBRANE DEPOLARIZATION, J. CELL PHYSIOL., 166, PP. 274-280, (1996); MCCARTY M.F., ENDOTHELIAL MEMBRANE POTENTIAL REGULATES PRODUCTION OF BOTH NITRIC OXIDE AND SUPEROXIDE - A FUNDAMENTAL DETERMINANT OF VASCULAR HEALTH, MED. HYPOTHESES, 53, PP. 277-289, (1999); SOHN H.Y., KELLER M., GLOE T., MORAWIETZ H., RUECKSCHLOSS U., POHL U., THE SMALL G-PROTEIN RAC MEDIATES DEPOLARIZATION-INDUCED SUPEROXIDE FORMATION IN HUMAN ENDOTHELIAL CELLS, J. BIOL. CHEM., 275, PP. 18745-18750, (2000); MEYER J.W., HOLLAND J.A., ZIEGLER L.M., CHANG M.M., BEEBE G., SCHMITT M.E., IDENTIFICATION OF A FUNCTIONAL LEUKOCYTE-TYPE NADPH OXIDASE IN HUMAN ENDOTHELIAL CELLS:A POTENTIAL ATHEROGENIC SOURCE OF REACTIVE OXYGEN SPECIES, ENDOTHELIUM, 7, PP. 11-22, (1999); ZHANG H., SCHMEISSER A., GARLICHS C.D., PLOTZE K., DAMME U., MUGGE A., ET AL., ANGIOTENSIN II-INDUCED SUPEROXIDE ANION GENERATION IN HUMAN VASCULAR ENDOTHELIAL CELLS: ROLE OF MEMBRANE-BOUND NADH-/NADPH-OXIDASES, CARDIOVASC. RES., 44, PP. 215-222, (1999); HOLLAND J.A., O'DONNELL R.W., CHANG M.M., JOHNSON D.K., ZIEGLER L.M., ENDOTHELIAL CELL OXIDANT PRODUCTION: EFFECT OF NADPH OXIDASE INHIBITORS, ENDOTHELIUM, 7, PP. 109-119, (2000); MEYER J.W., SCHMITT M.E., A CENTRAL ROLE FOR THE ENDOTHELIAL NADPH OXIDASE IN ATHEROSCLEROSIS, FEBS LETT., 472, PP. 1-4, (2000); KATUSIC Z.S., VASCULAR ENDOTHELIAL DYSFUNCTION: DOES TETRAHYDROBIOPTERIN PLAY A ROLE?, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); BOEGEHOLD M.A., FLOW-DEPENDENT ARTERIOLAR DILATION IN NORMOTENSIVE RATS FED LOW- OR HIGH-SALT DIETS, AM. J. PHYSIOL., 269, (1995); LENDA D.M., SAULS B.A., BOEGEHOLD M.A., REACTIVE OXYGEN SPECIES MAY CONTRIBUTE TO REDUCED ENDOTHELIUM-DEPENDENT DILATION IN RATS FED HIGH SALT, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 279, (2000); LI J.M., MULLEN A.M., SHAH A.M., PHENOTYPIC PROPERTIES AND CHARACTERISTICS OF SUPEROXIDE PRODUCTION BY MOUSE CORONARY MICROVASCULAR ENDOTHELIAL CELLS, J. MOL. CELL CARDIOL., 33, PP. 1119-1131, (2001); LI J.M., MULLEN A.M., YUN S., WIENTJES F., BROUNS G.Y., THRASHER A.J., ET AL., ESSENTIAL ROLE OF THE NADPH OXIDASE SUBUNIT P47 (PHOX) IN ENDOTHELIAL CELL SUPEROXIDE PRODUCTION IN RESPONSE TO PHORBOL ESTER AND TUMOR NECROSIS FACTOR-ALPHA, CIRC. RES., 90, PP. 143-150, (2002); LANG D., MOSFER S.I., SHAKESBY A., DONALDSON F., LEWIS M.J., CORONARY MICROVASCULAR ENDOTHELIAL CELL REDOX STATE IN LEFT VENTRICULAR HYPERTROPHY: THE ROLE OF ANGIOTENSIN II, CIRC. RES., 86, PP. 463-469, (2000); MILSTIEN S., KATUSIC Z., OXIDATION OF TETRAHYDROBIOPTERIN BY PEROXYNITRITE: IMPLICATIONS FOR VASCULAR ENDOTHELIAL FUNCTION, BIOCHEM. BIOPHYS. RES. COMMUN., 263, PP. 681-684, (1999); STUHLINGER M.C., ABBASI F., CHU J.W., LAMENDOLA C., MCLAUGHLIN T.L., COOKE J.P., ET AL., RELATIONSHIP BETWEEN INSULIN RESISTANCE AND AN ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITOR, JAMA, 287, PP. 1420-1426, (2002); MCCARTY M.F., COPING WITH ENDOTHELIAL SUPEROXIDE: POTENTIAL COMPLEMENTARITY OF ARGININE AND HIGH-DOSE FOLATE, MED HYPOTHESES, (2004); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS TAROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER THROMB. VASE. BIOL., 20, PP. 61-69, (2000); THAKUR N.K., HAYASHI T., SUMI D., KANO H., TSUNEKAWA T., IGUCHI A., HMG-COA REDUCTASE INHIBITOR STABILIZES RABBIT ATHEROMA BY INCREASING BASAL NO AND DECREASING SUPEROXIDE, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); WASSMANN S., LAUFS U., BAUMER A.T., MULLER K., AHLBORY K., LINZ W., ET AL., HMG-COA REDUCTASE INHIBITORS IMPROVE ENDOTHELIAL DYSFUNCTION IN NORMOCHOLESTEROLEMIC HYPERTENSION VIA REDUCED PRODUCTION OF REACTIVE OXYGEN SPECIES, HYPERTENSION, 37, PP. 1450-1457, (2001); LAUFS U., LA F., PLUTZKY V., LIAO J., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY HMG COA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); LAUFS U., LIAO J.K., POST-TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA STABILITY BY RHO GTPASE, J. BIOL. CHEM., 273, PP. 24266-24271, (1998); LAUFS U., GERTZ K., DIRNAGL U., BOHM M., NICKENIG G., ENDRES M., ROSUVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR, UPREGULATES ENDOTHELIAL NITRIC OXIDE SYNTHASE AND PROTECTS FROM ISCHEMIC STROKE IN MICE, BRAIN RES., 942, PP. 23-30, (2002); LUO J.D., ZHANG W.W., ZHANG G.P., GUAN J.X., CHEN X., SIMVASTATIN INHIBITS CARDIAC HYPERTROPHY AND ANGIOTENSIN-CONVERTING ENZYME ACTIVITY IN RATS WITH AORTIC STENOSIS, CLIN. EXP. PHARMACOL. PHYSIOL., 26, PP. 903-908, (1999); HAYASHIDANI S., TSUTSUI H., SHIOMI T., SUEMATSU N., KINUGAWA S., IDE T., ET AL., FLUVASTATIN, A 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR, ATTENUATES LEFT VENTRICULAR REMODELING AND FAILURE AFTER EXPERIMENTAL MYOCARDIAL INFARCTION, CIRCULATION, 105, PP. 868-873, (2002); OI S., HANEDA T., OSAKI J., KASHIWAGI Y., NAKAMURA Y., KAWABE J., ET AL., LOVASTATIN PREVENTS ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY IN CULTURED NEONATAL RAT HEART CELLS, EUR. J. PHARMACOL., 376, PP. 139-148, (1999); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); COOKE J.P., OKA R.K., ATHEROGENESIS AND THE ARGININE HYPOTHESIS, CURR. ATHEROSCLER. REP., 3, PP. 252-259, (2001); VERHAAR M.C., STROES E., RABELINK T.J., FOLATES AND CARDIOVASCULAR DISEASE, ARTERIOSCLER. THROMB. VASC. BIOL., 22, PP. 6-13, (2002); ZOCCALI C., MALLAMACI F., MAAS R., BENEDETTO F.A., TRIPEPI G., MALATINO L.S., ET AL., LEFT VENTRICULAR HYPERTROPHY, CARDIAC REMODELING AND ASYMMETRIC DIMETHYLARGININE (ADMA) IN HEMODIALYSIS PATIENTS, KIDNEY INT., 62, PP. 339-345, (2002); AVOLIO A.P., CLYDE K.M., BEARD T.C., COOKE H.M., HO K.K., O'ROURKE M.F., IMPROVED ARTERIAL DISTENSIBILITY IN NORMOTENSIVE SUBJECTS ON A LOW SALT DIET, ARTERIOSCLEROSIS, 6, PP. 166-169, (1986); MCCARTY M.F., MONOSELENOLIPOIC ACID MAY BE AN OUTSTANDING PHARMACEUTICAL ANTIOXIDANT WITH DIRECT THIOREDOXIN-LIKE ACTIVITY, MED. HYPOTHESES, 55, PP. 185-186, (2000); SAFAR M.E., THUILLIEZ C., RICHARD V., BENETOS A., PRESSURE-INDEPENDENT CONTRIBUTION OF SODIUM TO LARGE ARTERY STRUCTURE AND FUNCTION IN HYPERTENSION, CARDIOVASC. RES., 46, PP. 269-276, (2000); SEALS D.R., TANAKA H., CLEVENGER C.M., MONAHAN K.D., REILING M.J., HIATT W.R., ET AL., BLOOD PRESSURE REDUCTIONS WITH EXERCISE AND SODIUM RESTRICTION IN POSTMENOPAUSAL WOMEN WITH ELEVATED SYSTOLIC PRESSURE: ROLE OF ARTERIAL STIFFNESS, J. AM. COLL. CARDIOL., 38, PP. 506-513, (2001); KINLAY S., CREAGER M.A., FUKUMOTO M., HIKITA H., FANG J.C., SELWYN A.P., ET AL., ENDOTHELIUM-DERIVED NITRIC OXIDE REGULATES ARTERIAL ELASTICITY IN HUMAN ARTERIES IN VIVO, HYPERTENSION, 38, PP. 1049-1053, (2001); FITCH R.M., VERGONA R., SULLIVAN M.E., WANG Y.X., NITRIC OXIDE SYNTHASE INHIBITION INCREASES AORTIC STIFFNESS MEASURED BY PULSE WAVE VELOCITY IN RATS, CARDIOVASC. RES., 51, PP. 351-358, (2001); WILKINSON I.B., MACCALLUM H., COCKCROFT J.R., WEBB D.J., INHIBITION OF BASAL NITRIC OXIDE SYNTHESIS INCREASES AORTIC AUGMENTATION INDEX AND PULSE WAVE VELOCITY IN VIVO, BR. J. CLIN. PHARMACOL., 53, PP. 189-192, (2002); TOBIAN L., SALT AND HYPERTENSION. LESSONS FROM ANIMAL MODELS THAT RELATE TO HUMAN HYPERTENSION, HYPERTENSION, 17, PP. 152-158, (1991); LEE R.M., TRIGGLE C.R., MORPHOMETRIC STUDY OF MESENTERIC ARTERIES FROM GENETICALLY HYPERTENSIVE DAHL STRAIN RATS, BLOOD VESSELS, 23, PP. 199-224, (1986); HAMPTON J.A., BERNARDO D.A., KHAN N.A., LACHER D.A., RAPP J.P., GOHARA A.F., ET AL., MORPHOMETRIC EVALUATION OF THE RENAL ARTERIAL SYSTEM OF DAHL SALT-SENSITIVE AND SALT-RESISTANT RATS ON A HIGH SALT DIET. JI. INTERLOBULAR ARTERIES AND INTRALOBULAR ARTERIOLES, LAB. INVEST., 60, PP. 839-846, (1989); LABAT C., LACOLLEY P., LAJEMI M., DE GASPARO M., SAFAR M.E., BENETOS A., EFFECTS OF VALSARTAN ON MECHANICAL PROPERTIES OF THE CAROTID ARTERY IN SPONTANEOUSLY HYPERTENSIVE RATS UNDER HIGH-SALT DIET, HYPERTENSION, 38, PP. 439-443, (2001); HAYAKAWA H., RAIJ L., THE LINK AMONG NITRIC OXIDE SYNTHASE ACTIVITY, ENDOTHELIAL FUNCTION, AND AORTIC AND VENTRICULAR HYPERTROPHY IN HYPERTENSION, HYPERTENSION, 29, PP. 235-241, (1997); MATHEW R., FAN N.Y., YUAN N., CHANDER P.N., GEWITZ M.H., STIER C.T.J., INHIBITION OF NOS ENHANCES PULMONARY VASCULAR CHANGES IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS, AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., 278, (2000); LUSCHER T.F., RAIJ L., VANHOUTTE P.M., ENDOTHELIUM-DEPENDENT VASCULAR RESPONSES IN NORMOTENSIVE AND HYPERTENSIVE DAHL RATS, HYPERTENSION, 9, PP. 157-163, (1987); MIYOSHI A., SUZUKI H., FUJIWARA M., MASAI M., IWASAKI T., IMPAIRMENT OF ENDOTHELIAL FUNCTION IN SALT-SENSITIVE HYPERTENSION IN HUMANS, AM. J. HYPERTENS., 10, PP. 1083-1090, (1997); LIU Y., RUSCH N.J., LOMBARD J.H., LOSS OF ENDOTHELIUM AND RECEPTOR-MEDIATED DILATION IN PIAL ARTERIOLES OF RATS FED A SHORT-TERM HIGH SALT DIET, HYPERTENSION, 33, PP. 686-688, (1999); LENDA D.M., SAULS B.A., BOEGEHOLD M.A., REACTIVE OXYGEN SPECIES MAY CONTRIBUTE TO REDUCED ENDOTHELIUM-DEPENDENT DILATION IN RATS FED HIGH SALT, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 279, (2000); SOMERS M.J., MAVROMATIS K., GALIS Z.S., HARRISON D.G., VASCULAR SUPEROXIDE PRODUCTION AND VASOMOTOR FUNCTION IN HYPERTENSION INDUCED BY DEOXYCORTICOSTERONE ACETATE-SALT, CIRCULATION, 101, PP. 1722-1728, (2000); BRAGULAT E., DE LA SIERRA A., ANTONIO M.T., COCA A., ENDOTHELIAL DYSFUNCTION IN SALT-SENSITIVE ESSENTIAL HYPERTENSION, HYPERTENSION, 37, PP. 444-448, (2001); KAGOTA S., TAMASHIRO A., YAMAGUCHI Y., NAKAMURA K., KUNITOMO M., HIGH SALT INTAKE IMPAIRS VASCULAR NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE SYSTEM IN SPONTANEOUSLY HYPERTENSIVE RATS, J. PHARMACOL. EXP. THER., 302, PP. 344-351, (2002); ALIEN T.J., WALDRON M.J., CASLEY D., JERUMS G., COOPER M.E., SALT RESTRICTION REDUCES HYPERFILTRATION, RENAL ENLARGEMENT, AND ALBUMINURIA IN EXPERIMENTAL DIABETES, DIABETES, 46, PP. 19-24, (1997); DWORKIN L.D., BENSTEIN J.A., TOLBERT E., FEINER H.D., SALT RESTRICTION INHIBITS RENAL GROWTH AND STABILIZES INJURY IN RATS WITH ESTABLISHED RENAL DISEASE, J. AM. SOC. NEPHROL., 7, PP. 437-442, (1996); ALIEN T.J., WALDRON M.J., CASLEY D., JERUMS G., COOPER M.E., SALT RESTRICTION REDUCES HYPERFILTRATION, RENAL ENLARGEMENT, AND ALBUMINURIA IN EXPERIMENTAL DIABETES, DIABETES, 46, PP. 19-24, (1997); CIANCIARUSO B., BELLIZZI V., MINUTOLO R., TAVERA A., CAPUANO A., CONTE G., ET AL., SALT INTAKE AND RENAL OUTCOME IN PATIENTS WITH PROGRESSIVE RENAL DISEASE, MINER. ELECTROLYTE METAB., 24, PP. 296-301, (1998); CAMPESE V.M., PARISE M., KARUBIAN F., BIGAZZI R., ABNORMAL RENAL HEMODYNAMICS IN BLACK SALT-SENSITIVE PATIENTS WITH HYPERTENSION, HYPERTENSION, 18, PP. 805-812, (1991); HAYAKAWA H., RAIJ L., NITRIC OXIDE SYNTHASE ACTIVITY AND RENAL INJURY IN GENETIC HYPERTENSION, HYPERTENSION, 31, PP. 266-270, (1998); ZHOU X.J., VAZIRI N.D., ZHANG J., WANG H.W., WANG X.Q., ASSOCIATION OF RENAL INJURY WITH NITRIC OXIDE DEFICIENCY IN AGED SHR: PREVENTION BY HYPERTENSION CONTROL WITH ATI BLOCKADE, KIDNEY INT., 62, PP. 914-921, (2002); KLAHR S., THE ROLE OF NITRIC OXIDE IN HYPERTENSION AND RENAL DISEASE PROGRESSION, NEPHROL. DIAL. TRANSPLANT., 16, SUPPL. 1, PP. 60-62, (1902); FUJIWARA N., OSANAI T., KAMADA T., KATOH T., TAKAHASHI K., OKUMURA K., STUDY ON THE RELATIONSHIP BETWEEN PLASMA NITRITE AND NITRATE LEVEL AND SALT SENSITIVITY IN HUMAN HYPERTENSION:MODULATION OF NITRIC OXIDE SYNTHESIS BY SALT INTAKE, CIRCULATION, 101, PP. 856-861, (2000); FACCHINI F.S., DONASCIMENTO C., REAVEN G.M., YIP J.W., NI X.P., HUMPHREYS M.H., BLOOD PRESSURE, SODIUM INTAKE, INSULIN RESISTANCE, AND URINARY NITRATE EXCRETION, HYPERTENSION, 33, PP. 1008-1012, (1999); ENDRES M., LAUFS U., HUANG Z., NAKAMURA T., HUANG P., MOSKOWITZ M.A., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC. NATL. ACAD. SCI. USA, 95, PP. 8880-8885, (1998); MCCARTY M.F., UP-REGULATION OF ENDOTHELIAL NITRIC OXIDE ACTIVITY AS A CENTRAL STRATEGY FOR PREVENTION OF ISCHEMIC STROKE -JUST SAY NO TO STROKE!, MED. HYPOTHESES, 55, PP. 386-403, (2000); REHMAN A., RAHMAN A.R., RASOOL A.H., EFFECT OF ANGIOTENSIN II ON PULSE WAVE VELOCITY IN HUMANS IS MEDIATED THROUGH ANGIOTENSIN II TYPE 1 (AT(1)) RECEPTORS, J. HUM. HYPERTENS., 16, PP. 261-266, (2002); MAHMUD A., FEELY J., REDUCTION IN ARTERIAL STIFFNESS WITH ANGIOTENSIN II ANTAGONIST IS COMPARABLE WITH AND ADDITIVE TO ACE INHIBITION, AM. J. HYPERTENS., 15, PP. 321-325, (2002); BATAINEH A., RAIJ L., ANGIOTENSIN II, NITRIC OXIDE, AND END-ORGAN DAMAGE IN HYPERTENSION, KIDNEY INT. SUPPL., 68, (1998); MCCARTY M.F., VASCULAR ENDOTHELIUM IS THE ORGAN CHIEFLY RESPONSIBLE FOR THE CATABOLISM OF PLASMA ASYMMETRIC DIMETHYLARGININE - AN EXPLANATION FOR THE ELEVATION OF PLASMA ADMA IN DISORDERS CHARACTERIZED BY ENDOTHELIAL DYSFUNCTION, MED HYPOTHESES, (2004); MATSUOKA H., ITOH S., KIMOTO M., KOHNO K., TAMAI O., WADA Y., ET AL., ASYMMETRICAL DIMETHYLARGININE, AN ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITOR, IN EXPERIMENTAL HYPERTENSION, HYPERTENSION, 29, PP. 242-247, (1997); BAGROV A.Y., ROUKOYATKINA N.I., PINAEV A.G., DMITRIEVA R.I., FEDOROVA O.V., EFFECTS OF TWO ENDOGENOUS NA+,K (+)-ATPASE INHIBITORS, MARINOBUFAGENIN AND OUABAIN, ON ISOLATED RAT AORTA, EUR. J. PHARMACOL., 274, PP. 151-158, (1995); BAGROV A.Y., FEDOROVA O.V., EFFECTS OF TWO PUTATIVE ENDOGENOUS DIGITALIS-LIKE FACTORS, MARINOBUFAGENIN AND OUABAIN, ON THE NA+, K+-PUMP IN HUMAN MESENTERIC ARTERIES, J. HYPERTENS., 16, PP. 1953-1958, (1998); DE WARDENER H.E., MACGREGOR G.A., HARMFUL EFFECTS OF DIETARY SALT IN ADDITION TO HYPERTENSION, J. HUM. HYPERTENS., 16, PP. 213-223, (2002); DAHL L.K., SALT AND HYPERTENSION, AM. J. CLIN. NUTR., 25, PP. 231-244, (1972); PAGE L.B., DAMON A., MOELLERING R.C.J., ANTECEDENTS OF CARDIOVASCULAR DISEASE IN SIX SOLOMON ISLANDS SOCIETIES, CIRCULATION, 49, PP. 1132-1146, (1974); MENEELY G.R., BATTARBEE H.D., HIGH SODIUM-LOW POTASSIUM ENVIRONMENT AND HYPERTENSION, AM. J. CARDIOL., 38, PP. 768-785, (1976); TROWELL H.C., HYPERTENSION, OBESITY, DIABETES MELLITUS AND CORONARY HEART DISEASE, WESTERN DISEASES: THEIR EMERGENCE AND PREVENTION, PP. 3-32, (1981); CARVALHO J.J., BARUZZI R.G., HOWARD P.F., POULTER N., ALPERS M.P., FRANCO L.J., ET AL., BLOOD PRESSURE IN FOUR REMOTE POPULATIONS IN THE INTERSALT STUDY, HYPERTENSION, 14, PP. 238-246, (1989); LINDEBERG S., LUNDH B., APPARENT ABSENCE OF STROKE AND ISCHAEMIC HEART DISEASE IN A TRADITIONAL MELANESIAN ISLAND: A CLINICAL STUDY IN KITAVA, J. INTERN. MED., 233, PP. 269-275, (1993); GELEIJNSE J.M., HOFMAN A., WITTEMAN J.C., HAZEBROEK A.A., VALKENBURG H.A., GROBBEE D.E., LONG-TERM EFFECTS OF NEONATAL SODIUM RESTRICTION ON BLOOD PRESSURE, HYPERTENSION, 29, PP. 913-917, (1997); WEINBERGER M.H., SALT SENSITIVITY IS ASSOCIATED WITH AN INCREASED MORTALITY IN BOTH NORMAL AND HYPERTENSIVE HUMANS, J. CLIN. HYPERTENS. (GREENWICH), 4, PP. 274-276, (2002); HE F.J., MARKANDU N.D., SAGNELLA G.A., MACGREGOR G.A., IMPORTANCE OF THE RENIN SYSTEM IN DETERMINING BLOOD PRESSURE FALL WITH SALT RESTRICTION IN BLACK AND WHITE HYPERTENSIVES, HYPERTENSION, 32, PP. 820-824, (1998); ALDERMAN M.H., SALT, BLOOD PRESSURE, AND HUMAN HEALTH, HYPERTENSION, 36, PP. 890-893, (2000); ALDERMAN M.H., OOI W.L., COHEN H., MADHAVAN S., SEALEY J.E., LARAGH J.H., PLASMA RENIN ACTIVITY: A RISK FACTOR FOR MYOCARDIAL INFARCTION IN HYPERTENSIVE PATIENTS, AM. J. HYPERTENS., 10, PP. 1-8, (1997); ALDERMAN M.H., MADHAVAN S., COHEN H., SEALEY J.E., LARAGH J.H., LOW URINARY SODIUM IS ASSOCIATED WITH GREATER RISK OF MYOCARDIAL INFARCTION AMONG TREATED HYPERTENSIVE MEN, HYPERTENSION, 25, PP. 1144-1152, (1995); ALDERMAN M.H., COHEN H., MADHAVAN S., DIETARY SODIUM INTAKE AND MORTALITY: THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES I), LANCET, 351, PP. 781-785, (1998); DE WARDENER H., MACGREGOR G.A., SODIUM INTAKE AND MORTALITY, LANCET, 351, PP. 1508-1510, (1998); DE WARDENER H.E., SALT REDUCTION AND CARDIOVASCULAR RISK: THE ANATOMY OF A MYTH, J. HUM. HYPERTENS., 13, PP. 1-4, (1999); VAN BUREN M., RABELINK A.J., BIJLSMA J.A., KOOMANS H.A., NATRIURETIC AND KALIURETIC RESPONSE TO POTASSIUM LOAD: MODULATION BY SODIUM INTAKE, NEPHROL. DIAL. TRANSPLANT., 8, PP. 495-500, (1993); KRISHNA G.G., KAPOOR S.C., POTASSIUM SUPPLEMENTATION AMELIORATES MINERALOCORTICOID-INDUCED SODIUM RETENTION, KIDNEY INT., 43, PP. 1097-1103, (1993); CORUZZI P., BRAMBILLA L., BRAMBILLA V., GUALERZI M., ROSSI M., PARATI G., ET AL., POTASSIUM DEPLETION AND SALT SENSITIVITY IN ESSENTIAL HYPERTENSION, J. CLIN. ENDOCRINOL. METAB., 86, PP. 2857-2862, (2001); CORTI R., BURNETT J.C.J., ROULEAU J.L., RUSCHITZKA F., LUSCHER T.F., VASOPEPTIDASE INHIBITORS: A NEW THERAPEUTIC CONCEPT IN CARDIOVASCULAR DISEASE?, CIRCULATION, 104, PP. 1856-1862, (2001)","M.F. MCCARTY; PANTOX LABORATORIES, SAN DIEGO, CA 92109, 4622 SANTA FE STREET, UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-13444256342","MED HYPOTHESES","PANTOX LABORATORIES","NOTREPORTED;PANTOX LABORATORIES;NOTREPORTED",NA,"MCCARTY MF, 2005, MED HYPOTHESES","MCCARTY MF, 2005, MED HYPOTHESES"
"PÉREZ R;CANAVACIOLO V;DÍAZ Y;CASTELLANOS H;HERNÁNDEZ V","PÉREZ, ROXANA SIERRA (55439804300); CANAVACIOLO, VICTOR L. GONZÁLEZ (18433666300); DÍAZ, YANET TEJEDA (55396370000); CASTELLANOS, HERIBERTO CAMPAÑÁ (8227471500); HERNÁNDEZ, VIRGEN MILIÁN (57196894474)","DETERMINATION BY GAS CHROMATOGRAPHY OF THE THERMAL DEGRADATION PRODUCTS OF THE 10 MG POLICOSANOL TABLETS DETERMINACIÓN POR CROMATOGRAFÍA GASEOSA DE LOS PRODUCTOS DE DEGRADACIÓN TÉRMICA DE LAS TABLETAS CON 10 MG DE POLICOSANOL",2005,"ACTA FARMACEUTICA BONAERENSE","24","4",0,"","CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, ATABEY, PLAYA, CIUDAD HABANA, CALLE 198 S.N. E/ 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, ATABEY, PLAYA, CIUDAD HABANA, CALLE 198 S.N. E/ 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, ATABEY, PLAYA, CIUDAD HABANA, CALLE 198 S.N. E/ 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, ATABEY, PLAYA, CIUDAD HABANA, CALLE 198 S.N. E/ 19 Y 21, CUBA;CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, ATABEY, PLAYA, CIUDAD HABANA, CALLE 198 S.N. E/ 19 Y 21, CUBA","AN ANALYTICAL METHOD FOR DETERMINING HEXACOSANYL, OCTACOSANYL AND TRIACONTANYL PALMITATES AND STEARATES, ALL THERMAL DEGRADATION PRODUCTS OF 10 MG-POLICOSANOL TABLETS, WAS DEVELOPED AND VALIDATED. THE METHOD IS BASED ON THE EXTRACTION OF THESE PRODUCTS WITH N-HEXANE AND THEIR FURTHER GAS CHROMATOGRAPHY (GC) ANALYSIS USING A PACKED COLUMN AND DOCOSANYL STEARATE AS INTERNAL STANDARD, PREVIOUS CALCULATION OF THE MASS CORRECTION FACTORS WITH STANDARDS SYNTHESIZED FOR SUCH AIM. THE ASSESSMENT OF METHOD DEMONSTRATED THAT IT WAS LINEAR IN A CONCENTRATION RANGE FROM 2.5 TO 30% OF DEGRADATION, WITH RECOVERIES (99.77 - 100.90%) NOT SIGNIFICANTLY DIFFERENT FROM 100% FOR P = 0.05, ACCORDING TO THE STUDENT T TEST. ALSO, THE METHOD HAS A GOOD PRECISION IN REPEATABILITY AND INTERMEDIATE PRECISION CONDITIONS, ACCORDING TO THE COEFFICIENT OF VARIATION (CV < 4%). THE LIMITS OF DETECTION AND QUANTIFICATION: 0.003 AND 0.011 MG, RESPECTIVELY, DEMONSTRATE THAT THE METHOD CAN BE USED EVEN FOR TABLETS WITH LESS THAN A 2% OF DEGRADATION EXTENT.","DEGRADATION PRODUCTS; POLICOSANOL; TABLETS; VALIDATION","HEXACOSANOL; HEXANE; OCTACOSANOL; PALMITIC ACID; POLICOSANOL; STEARIC ACID; ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG DEGRADATION; GAS CHROMATOGRAPHY; REPRODUCIBILITY; STATISTICAL ANALYSIS; TABLET; THERMOSTABILITY","","","ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., CURR. THER. RES., 56, PP. 176-179, (1995); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., INT. J. CLIN. PHARMACOL. RES., 19, PP. 117-127, (1999); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., ALVAREZ E., CLIN. DRUG INVEST., 21, PP. 485-497, (2001); LAGUNA A., MAGRANER J., CARVAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; CABRERA L., SIERRA R., GONZALEZ V., URIBARRI E., LAGUNA A., MAGRANER J., RICARDO Y., VELASQUEZ C., BOLL. CHIM. FARMAC., (2004); GONZALEZ V., MAGRANER J., CABRERA L., RIVERO B., REV. CENIC CIENC. QUÍM., 29, PP. 27-30, (1998); KATTNER G., GRAEVE M., ERNST W., J. CHROMATOGR., 513, PP. 327-332, (1990); TAVA A., CUNICO C., CREMONA R., PICCININI E., J. HIGH RES. CHROMATOGR., 19, PP. 43-48, (1996); 3AQ12A: IMPURITIES IN NEW MEDICINAL PRODUCTS, (1996); CABRERA L., GONZALEZ V., URIBARRI E., SIERRA R., MAGRANER J., MEDEROS D., VELAZQUEZ C., BOLL. CHIM. FARMAC., 141, PP. 223-229, (2002); LEILANI A., CHAMPANA H., MILIAN V., LOUPY A., PETIT A.; HORWITZ W., J. AM. OFFIC. ANAL. CHEM., 65, PP. 525-530, (1982); SIERRA R., GONZALEZ V.L., MAGRANER J., J. AM. OFFIC. ANAL. CHEM., 85, PP. 563-566, (2002); 3AQ14A: VALIDATION OF ANALYTICAL PROCEDURES, (1994)","","","SPANISH","ACTA FARM. BONAER.","ARTICLE","ISI","2-S2.0-18844393115","ACTA FARM BONAER",NA,"NOTREPORTED",NA,"PÉREZ RS, 2005, ACTA FARM BONAER","PÉREZ RS, 2005, ACTA FARM BONAER"
"CASTAÑO G;MÁS R;FERNÁNDEZ L;GÁMEZ R;ILLNAIT J","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, LILIA (7202848319); GÁMEZ, RAFAEL (7003605346); ILLNAIT, JOSÉ (8631465800)","EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION A DOUBLEBLIND COMPARATIVE PILOT STUDY",2003,"ANGIOLOGY","54","13",26,"10.1177/000331970305400104","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, P.O. BOX 6880, CUBA;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA; GÁMEZ R.;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS. THE PRESENT STUDY WAS UNDERTAKEN TO COMPARE THE EFFECTS OF POLICOSANOL AND LOVASTATIN ON PATIENTS WITH MODERATELY SEVERE INTERMITTENT CLAUDICATION. THE STUDY HAD A 4-WEEK BASELINE STEP, FOLLOWED BY A 20-WEEK DOUBLE BLINDED, RANDOMIZED TREATMENT PERIOD. TWENTY-EIGHT PATIENTS WHO MET STUDY ENTRY CRITERIA WERE RANDOMIZED TO POLICOSANOL 10 MG OR LOVASTATIN 20 MG TABLETS ONCE DAILY. WALKING DISTANCES IN A TREADMILL (CONSTANT SPEED 3.2 KM/HR, SLOPE 10°, TEMPERATURE 25°C) WERE ASSESSED BEFORE AND AFTER 20 WEEKS OF TREATMENT. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. COMPARED WITH BASELINE, POLICOSANOL INCREASED SIGNIFICANTLY (P < 0.01) THE INITIAL CLAUDICATION DISTANCE (ICD) FROM 160.39 ± 15.82 M TO 211.31 ± 21.48 M (+33.7%) AND THE ABSOLUTE CLAUDICATION DISTANCE (ACD) (P < 0.001) FROM 236.39 ± 25.44 M TO 288.09 ± 28.47 M (+24.3%); MEANWHILE BOTH VARIABLES REMAINED UNCHANGED AFTER LOVASTATIN THERAPY. CHANGES IN ICD AND ACD WERE SIGNIFICANTLY LARGER IN THE POLICOSANOL THAN IN THE LOVASTATIN GROUP (P < 0.01). POLICOSANOL, BUT NOT LOVASTATIN, SIGNIFICANTLY INCREASED (P < 0.05) THE ANKLE/ARM INDEX, ALTHOUGH BETWEEN-GROUP DIFFERENCES WERE NOT SIGNIFICANT. THE FREQUENCY OF PATIENTS REPORTING IMPROVEMENT ON QUALITY OF LIFE DOMAINS WAS GREATER IN THE POLICOSANOL THAN IN THE LOVASTATIN GROUP. POLICOSANOL SIGNIFICANTLY (P < 0.001) LOWERED TOTAL CHOLESTEROL (TC) AND LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) BY 17.5% AND 31.0%, RESPECTIVELY, AND MEANWHILE INCREASED (P < 0.01) HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) LEVELS BY 31.5%. LOVASTATIN REDUCED (P < 0.01) TC (18.0%), LDL-C (22.6%), AND (P < 0.05) TRIGLYCERIDES (9.8%). IN ADDITION, POLICOSANOL, BUT NOT LOVASTATIN, MODERATELY, BUT SIGNIFICANTLY, REDUCED (P < 0.05) FIBRINOGEN LEVELS, SO THAT FINAL VALUES AND PERCENT CHANGES IN BOTH GROUPS WERE DIFFERENT (P < 0.01). TREATMENTS WERE WELL TOLERATED. ONLY 1 LOVASTATIN PATIENT WITHDREW FROM THE STUDY BECAUSE OF A NONFATAL MYOCARDIAL INFARCTION. FIVE LOVASTATIN PATIENTS, BUT NONE FROM THE POLICOSANOL GROUP, EXPERIENCED 6 ADVERSE EVENTS (AE) (P < 0.01). THE PRESENT RESULTS INDICATE THAT POLICOSANOL, BUT NOT LOVASTATIN, IS A SUITABLE ALTERNATIVE TO MANAGE PATIENTS WITH INTERMITTENT CLAUDICATION BECAUSE OF PLEIOTROPIC PROPERTIES BEYOND ITS CHOLESTEROL-LOWERING EFFECTS.","","HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLICOSANOL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREADMILL","","","VERHAEGHE R., EPIDÉMIOLOGIE ET PRONOSTIC DE L'ARTÉRIOPATHIE OBLITÉRANTE DES MEMBRES INFÉRIEURS, DRUGS, 56, SUPPL. 3, PP. 1-10, (1998); BALKAN B., VRAY M., ESCHWEGP E., EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE, J CARDIOVASC PHARMACOL, 23, SUPPL. 3, PP. 8-16, (1994); MARQUIS P., EVALUATION DE L'IMPACT DE L'ARTÉRIOPATHIC OBLITÉRANTE DES MEMBRES INFERIEURS SUR LA QUALITÉ DE VIE, DRUGS, 56, SUPPL. 3, PP. 25-35, (1998); CRIQUI M., LANGER R.D., FRONEK A., MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, N ENGL J MED, 326, PP. 381-386, (1992); DORMANDY J.A., MURRAY G.D., THE FATE OF THE CLAUDICANT: A PROSPECTIVE STUDY OF 1969 CLAUDICANTS, EUR VASC SURG, 5, PP. 131-133, (1991); SECOND EUROPEAN CONSENSUS DOCUMENT ON CHRONIC CRITICAL LEG ISCHEMIA, CIRCULATION, 84, SUPPL. IV, PP. 1-26, (1991); FOWKES F.G.R., HOUSLEY E., RIEMERSMA R.A., ET AL., SMOKING, LIPIDS, GLUCOSE INTOLERANCE AND BLOOD PRESSURE AS RISK FACTORS FOR PERIPHERAL ATHEROSCLEROSIS COMPARED WITH ISCHEMIC HEART DISEASE IN THE EDINBURGH ARTERY STUDY, AM J EPIDEMIOL, 135, PP. 331-340, (1992); LOWE G.D.O., FOWKES F.G.R., DAWES J., ET AL., BLOOD VISCOSITY, FIBRINOGEN AND ACTIVATION OF COAGULATION AND LEUCOCYTES IN PERIPHERAL ARTERIAL DISEASE AND THE NORMAL POPULATION IN THE EDINBURGH ARTERY STUDY, CIRCULATION, 87, PP. 1915-1920, (1993); BOWLIN S.J., MEDALIE J.H., FLOCKE S.A., ET AL., EPIDEMIOLOGY OF INTERMITTENT CLAUDICATION IN MIDDLE-AGED MEN, AM J EPIDEMIOL, 140, PP. 418-430, (1994); RIDKER P.M., STAMPFER M.J., RIFAI N., NOVEL RISK FACTORS FOR SYSTEMIC ATHEROSCLEROSIS: A COMPARISON OF C-REACTIVE PROTEIN, FIBRINOGEN, HOMOCYSTEINE, LIPOPROTEIN (A) AND STANDARD CHOLESTEROL SCREENING AS PREDICTORS OF PERIPHERAL ARTERIAL DISEASE, JAMA, 285, PP. 2481-2485, (2001); QUICK C.R.G., COTTON L.T., THE MEASURED EFFECT OF STOPPING SMOKING ON INTERMITTENT CLAUDICATION, BR J SURG, 69, (1982); GARDNER A.W., POEHLMAN E.T., EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT CLAUDICATION PAIN. A META-ANALYSIS, JAMA, 274, PP. 975-980, (1995); REICH T., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION OF THE LOWER LIMB, ANGIOLOGY, 35, PP. 389-393, (1984); TONNESEN K.H., ALBUQUERQUE P., BAITSCH G., ET AL., DOUBLE-BLIND, CONTROLLED MULTICENTER STUDY OF INDUBOFEN VERSUS PLACEBO IN PATIENTS WITH INTERMITTENT CLAUDICATION, INT ANGIOL, 12, PP. 371-377, (1993); LINDAGARDE F., BJORKMAN H., ADIELSSON G., ET AL., CONSERVATIVE DRUG TREATMENT IN PATIENTS WITH MODERATELY SEVERE CHRONIC OCCLUSIVE PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 80, PP. 1549-1556, (1989); VERHAEGHE R., PLATELETS IN PERIPHERAL ARTERIAL DISEASE, CRIT ISCHAEMIA, 4, PP. 21-25, (1994); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL (MED SCI), (2000); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN INVEST, 21, PP. 103-113, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY, TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON-INSULIN-DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAM TROMB HEMOST, 5, PP. 17-20, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMB HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAG LEUK ESS FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED DOUBLE-BIND PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INTERN J CARDIOL, 67, PP. 125-132, (1999); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, J PHARMACOL RES, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); WEIS S., CLEARFIELD M., DOWNS J.R., ET AL., THE AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY (AFCAPS/TEXCAPS). PRIMARY PREVENTION OF ACUTE MAJOR CORONARY EVENTS IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL, CHOLESTEROL-LOWERING THERAPY: EVALUATION OF CLINICAL EVIDENCE, PP. 151-172, (2000); FARNIER M., DAVIGNON J., CURRENT AND FUTURE TREATMENT OF HYPERLIPIDEMIA; THE ROLE OF STATINS, AM J CARDIOL, 82, (1998); FARNIER J.A., GOTTO A.M., CHOOSING THE RIGHT LIPID-REGULATING AGENT: A GUIDE TO SELECTION, DRUGS, 52, PP. 649-661, (1996); WHEELER D.C., ARE THERE POTENTIAL NON-LIPID LOWERING USES OF STATINS?, DRUGS, 56, PP. 517-522, (1998); CORSINI A., PAZZUCCONI F., ARNABOLDI L., ET AL., DIRECT EFFECTS OF STATINS ON THE VASCULAR WALL, J CARDIOVASC PHARMACOL, 31, PP. 773-777, (1998); HENWOOD J.M., HEEL R.C., LOVASTATIN: A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC PROPERTIES AND THERAPEUTIC USE IN HYPERLIPIDAEMIA, DRUGS, 36, PP. 429-454, (1988); ILLINGWORTH R., USE OF LOVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, CLIN THER, 16, PP. 2-26, (1994); IATT W.R., NAWAZ D., REGENSTERNER J.G., ET AL., THE EVALUATION OF EXERCISE PERFORMANCE IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE, J CARDIOPULMONARY REHABIL, 12, PP. 525-532, (1998); HEIDRICH H., ALLENBERG J., CACHOVAN M., ET AL., GUIDELINES FOR THERAPEUTIC STUDIES ON PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN FONTAINE STAGES II-IV, VASA, 21, PP. 339-343, (1992); SECOND REPORT OF THE EXPERT PANEL ON DETECTION. EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II). III DRUG TREATMENT, CIRCULATION, 89, PP. 1405-1419, (1994); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331; GOTTO A., ASSMANN G., CARMENA R., ET AL., THE INTERNATIONAL LIPID INFORMATION BUREAU (ILIB): LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE, ED. 2, (2000); TOFLER G.H., ET AL., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH, N ENGL J MED, 316, PP. 1514-1518, (1987); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-205, (1996); SEIGLER L., WU T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); FOWKES F.G.R., LENG G.C., LEE A.J., ET AL., THE ANKLE ARM INDEX AS A PREDICTOR OF CARDIOVASCULAR EVENTS AND DEATH IN THE GENERAL POPULATION, CAN J CARDIOL, 13, SUPPL. 13, (1997)","R. MÁS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, P.O. BOX 6880, CUBA; EMAIL: CLINICA@IP.ETECSA.CU","WESTMINSTER PUBLICATIONS INC.","ENGLISH","ANGIOLOGY","ARTICLE","ISI","2-S2.0-0037274601","ANGIOLOGY","MEDICAL SURGICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@IP.ETECSA.CU",NA,"CASTAÑO G, 2003, ANGIOLOGY","CASTAÑO G, 2003, ANGIOLOGY"
"GREYLING A;DE W C;OOSTHUIZEN W;JERLING J","GREYLING, A. (58367813800); DE WITT, C. (36338935100); OOSTHUIZEN, W. (26324137000); JERLING, J.C. (6603600042)","EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS",2006,"BRITISH JOURNAL OF NUTRITION","95","7",71,"10.1079/BJN20061715","SCHOOL OF PHYSIOLOGY, NUTRITION AND CONSUMER SCIENCES, NORTH-WEST UNIVERSITY, POTCHESFSTROOM CAMPUS, SOUTH AFRICA;SCHOOL OF PHYSIOLOGY, NUTRITION AND CONSUMER SCIENCES, NORTH-WEST UNIVERSITY, POTCHESFSTROOM CAMPUS, SOUTH AFRICA;SCHOOL OF PHYSIOLOGY, NUTRITION AND CONSUMER SCIENCES, NORTH-WEST UNIVERSITY, POTCHESFSTROOM CAMPUS, SOUTH AFRICA;SCHOOL OF PHYSIOLOGY, NUTRITION AND CONSUMER SCIENCES, NORTH-WEST UNIVERSITY, POTCHESFSTROOM CAMPUS, SOUTH AFRICA","POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS THAT IS EXTRACTED FROM PURIFIED SUGAR CANE WAX OR A VARIETY OF OTHER PLANT SOURCES, AND HAS BEEN SHOWN TO HAVE BENEFICIAL EFFECTS ON SERUM LIPID CONCENTRATIONS. THE OBJECTIVE OF THIS STUDY WAS TO INVESTIGATE THE EFFECTS OF A POLICOSANOL SUPPLEMENT (OCTA-60) ON LIPID PROFILES OF HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS. NINETEEN HYPERCHOLESTEROLAEMIC AND FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS COMPLETED THIS RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY. THE SUBJECTS RECEIVED EITHER A DAILY DOSE OF 20 MG POLICOSANOL OR PLACEBO FOR 12 WEEKS. AFTER A WASH-OUT PERIOD OF 4 WEEKS, THE INTERVENTIONS WERE CROSSED OVER. LIPID LEVELS WERE MEASURED AT BASELINE AND AT THE END OF EACH INTERVENTION PERIOD. NO SIGNIFICANT DIFFERENCES IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL FROM BASELINE TO END OR BETWEEN POLICOSANOL AND PLACEBO WERE SEEN IN THE HYPERCHOLESTEROLAEMIC OR FAMILIAL HYPERCHOLESTEROLAEMIC GROUPS. THERE WERE SMALL REDUCTIONS IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL FROM BASELINE TO END IN THE HYPERCHOLESTEROLAEMIC GROUP, BUT THESE CHANGES DID NOT DIFFER SIGNIFICANTLY FROM THE CHANGES WITH THE PLACEBO, INDICATING THAT THE OBSERVED DECREASE IN CHOLESTEROL IN THE POLICOSANOL GROUP WAS NOT DUE TO THE SPECIFIC EFFECT OF POLICOSANOL TREATMENT. THE DIFFERENCES IN RESPONSE MAY BE ASCRIBED TO THE DIFFERENCES IN COMPOSITION OF THE HIGHER ALIPHATIC PRIMARY ALCOHOLS IN THE PREVIOUSLY USED PRODUCTS, COMPARED WITH THE LOCAL POLICOSANOL SUPPLEMENT. AN INTAKE OF 20 MG/D POLICOSANOL FOR 12 WEEKS HAD NO SIGNIFICANT EFFECT ON SERUM LIPID LEVELS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC PATIENTS WHEN COMPARED WITH PLACEBO INTAKE. © THE AUTHORS 2006.","CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLAEMIA; LIPIDS; POLICOSANOL","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME; SACCHARUM; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTA 60; PLACEBO; POLICOSANOL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EDEMA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEADACHE; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO","","","ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., CAPOTE A., MENENDEZ R., AMOR A., FRAGA V., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANETTI M.M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., DIAZ E., CASTANO G., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., TULA L., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., DIAZ E., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., MESA M., FERNANDEZ J.C., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., MOLINA V., MENENDEZ A., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., CESAR FERNANDEZ J., PONTIGAS V., SUAZO M., FERNANDEZ L., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 59, PP. 737-745, (1998); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS RD, 3, PP. 159-172, (2002); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 154-162, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., FERNANDEZ J.C., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES, 62, PP. 194-208, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., HERNANDEZ E., FERNANDEZ J.C., GAMEZ R., GUTIERREZ C., ALVAREZ E., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 63, PP. 286-303, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ J., LOPEZ E., ILLNAIT J., FERNANDEZ L., MESA M., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, PP. 522-537, (2003); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LESCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, PP. 89-99, (2002); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C, EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); CIVEIRA F., GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 173, PP. 55-68, (2004); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON-INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); FERNANDEZ J.C., MAS R., CASTANO G., MENENDEZ R., AMOR A.M., GONZALEZ R.M., ALVAREZ E., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVESTIG, 21, PP. 103-113, (2001); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES, 59, PP. 717-722, (1998); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GAMEZ R., ALEMAN C.L., MAS R., NOA M., RODEIRO I., GARCIA H., HERNANDEZ C., MENENDEZ R., AGUILAR C., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-65, (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED (MAYWOOD), 229, PP. 215-226, (2004); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); MCNAMARA D.J., CARDIOVASCULAR DISEASE, MODERN NUTRITION IN HEALTH AND DISEASE, PP. 1533-1544, (1994); MARCELLO S., GLADSTEIN J., TESONE P., MAS R., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, 61, PP. 346-357, (2000); MARGETTS B., NELSON M., DESIGN CONCEPTS IN NUTRITIONAL EPIDEMIOLOGY, (1997); MAS R., POLICOSANOL. HYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSIS, DRUGS FUTURE, 25, PP. 569-586, (2000); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ L., FERNANDEZ J., ORTA S.D., ILLNAIT J., RICARDO Y., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES., 21, PP. 31-41, (2001); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, (2004); ORTENSI G., JULIO G., HECTOR V., PEDRO A.T., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); PAPPU A.S., ILLINGWORTH D.R., THE EFFECTS OF LOVASTATIN AND SIMVASTATIN ON THE DIURNAL PERIODICITY OF PLASMA MEVALONATE CONCENTRATIONS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 165, PP. 137-144, (2002); PONS P., ILLNAIT J., MAS R., RODRIGUEZ M., ALEMAN C., CESAR FERNANDEZ J., FERNANDEZ L., MARTIN M., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 26-35, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); SAUVAGE NOLTING P.R., DEFESCHE J.C., BUIRMA R.J., HUTTEN B.A., LANSBERG P.J., KASTELEIN J.J., PREVALENCE AND SIGNIFICANCE OF CARDIOVASCULAR RISK FACTORS IN A LARGE COHORT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA, J INTERN MED, 253, PP. 161-168, (2003); SIAVOSHIAN S., SIMONEAU C., MAUGEAIS P., MARKS L., RODARY L., GARDETTE J., KREMPF M., MEASUREMENT OF MEVALONIC ACID IN HUMAN URINE BY BENCH TOP GAS CHROMATOGRAPHY-MASS SPECTROMETRY, CLIN CHIM ACTA, 243, PP. 129-136, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV., 61, PP. 376-383, (2003); WANG Y.W., JONES P.J.H., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003)","J.C. JERLING; SCHOOL OF PHYSIOLOGY, NUTRITION AND CONSUMER SCIENCES, NORTH-WEST UNIVERSITY, POTCHEFSTROOM CAMPUS, SOUTH AFRICA; EMAIL: VGEJCJ@PUK.AC.ZA","","ENGLISH","BR. J. NUTR.","ARTICLE","ISI","2-S2.0-33744458949","BR J NUTR","NORTH-WEST UNIVERSITY;NORTH-WEST UNIVERSITY;NORTH-WEST UNIVERSITY;NORTH-WEST UNIVERSITY","NOTREPORTED;NORTH-WEST UNIVERSITY;NOTREPORTED",NA,"GREYLING A, 2006, BR J NUTR","GREYLING A, 2006, BR J NUTR"
"CHEN J;WESLEY R;SHAMBUREK R;PUCINO F;CSAKO G","CHEN, JUDY T. (9740467200); WESLEY, ROBERT (55384357900); SHAMBUREK, ROBERT D. (6701748801); PUCINO, FRANK (6701705695); CSAKO, GYORGY (57204299898)","METAANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA PLANT STEROLS AND STANOLS VERSUS POLICOSANOL",2005,"PHARMACOTHERAPY","25","12",113,"10.1592/phco.25.2.171.56942","PURDUE UNIVERSITY, WEST LAFAYETTE, IN, UNITED STATES, DEPARTMENT OF PHARMACY PRACTICE, PURDUE UNIVERSITY, R. HEINE PHARMACY BUILDING, WEST LAFAYETTE, IN 47907-2091, 575 STADIUM MALL DRIVE, UNITED STATES;NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD, UNITED STATES;NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD, UNITED STATES;DEPARTMENT OF PHARMACY, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD, UNITED STATES;DEPARTMENT OF LABORATORY MEDICINE, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD, UNITED STATES","STUDY OBJECTIVE. TO COMPARE THE EFFICACY AND SAFETY OF PLANT STEROLS AND STANOLS AS WELL AS POLICOSANOL IN THE TREATMENT OF CORONARY HEART DISEASE, AS MEASURED BY A REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL) LEVELS. DESIGN. SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PATIENTS. A TOTAL OF 4596 PATIENTS FROM 52 ELIGIBLE STUDIES. MEASUREMENTS AND MAIN RESULTS. WE SEARCHED MEDLINE, EMBASE, THE WEB OF SCIENCE, AND THE COCHRANE LIBRARY FROM JANUARY 1967-JUNE 2003 TO IDENTIFY PERTINENT STUDIES. REDUCTION OF LDL LEVELS WAS THE PRIMARY END POINT; EFFECTS ON OTHER LIPID PARAMETERS AND WITHDRAWAL OF STUDY PATIENTS DUE TO ADVERSE EFFECTS WERE THE SECONDARY END POINTS. WEIGHTED ESTIMATES OF PERCENT CHANGE IN LDL WERE -11.0% FOR PLANT STEROL AND STANOL ESTERS 3.4 G/DAY (RANGE 2-9 G/DAY [893 PATIENTS]) VERSUS -2.3% FOR PLACEBO (769 PATIENTS) IN 23 ELIGIBLE STUDIES, COMPARED WITH -23.7% FOR POLICOSANOL 12 MG/DAY (RANGE 5-40 MG/DAY [1528 PATIENTS]) VERSUS -0.11% FOR PLACEBO (1406 PATIENTS) IN 29 ELIGIBLE STUDIES. CUMULATIVE P VALUES WERE SIGNIFICANTLY DIFFERENT FROM PLACEBO FOR BOTH (P<0.0001). THE NET LDL REDUCTION IN THE TREATMENT GROUPS MINUS THAT IN THE PLACEBO GROUPS WAS GREATER WITH POLICOSANOL THAN PLANT STEROLS AND STANOLS (-24% VERSUS -10%, P<0.0001). POLICOSANOL ALSO AFFECTED TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL), AND TRIGLYCERIDE LEVELS MORE FAVORABLY THAN PLANT STEROLS AND STANOLS. POLICOSANOL CAUSED A CLINICALLY SIGNIFICANT DECREASE IN THE LDL:HDL RATIO. POOLED WITHDRAWAL RATE DUE TO ADVERSE EFFECTS AND COMBINED RELATIVE RISK FOR PATIENTS WHO WITHDREW WERE 0% AND 0.84, RESPECTIVELY (95% CONFIDENCE INTERVAL [CI] 0.36-1.95, P=0.69), FOR PLANT STEROLS AND STANOLS ACROSS 20 STUDIES VERSUS 0.86% AND 0.31, RESPECTIVELY (95% CI 0.20-0.48, P<0.0001), FOR POLICOSANOL ACROSS 28 STUDIES. CONCLUSION. PLANT STEROLS AND STANOLS AND POLICOSANOL ARE WELL TOLERATED AND SAFE; HOWEVER, POLICOSANOL IS MORE EFFECTIVE THAN PLANT STEROLS AND STANOLS FOR LDL LEVEL REDUCTION AND MORE FAVORABLY ALTERS THE LIPID PROFILE, APPROACHING ANTILIPEMIC DRUG EFFICACY.","CHOLESTEROL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LDL; NATURAL THERAPY; PLANT STANOLS; PLANT STEROLS; POLICOSANOL","ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FATTY ALCOHOLS; HUMANS; HYPERLIPIDEMIAS; PHYTOSTEROLS; RANDOMIZED CONTROLLED TRIALS; SITOSTEROLS; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; POLICOSANOL; STANOL ESTER; TRIACYLGLYCEROL; APPETITE DISORDER; ARTHRALGIA; ASTHENIA; BULIMIA; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EMBASE; EPIGASTRIC PAIN; FECES COLOR; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; LEG CRAMP; LEUKOPENIA; MEDLINE; META ANALYSIS; MUSCLE CRAMP; NAUSEA; NERVOUSNESS; POLYDIPSIA; PRURITUS; REVIEW; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SYSTEMATIC REVIEW; TIME SERIES ANALYSIS","NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NHLBI, (Z01HL002064); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NHLBI","","THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) FINAL REPORT, CIRCULATION, 106, 25, PP. 3143-3421, (2002); EISENBERG D.M., DAVIS R.B., ETTNER S.L., ET AL., TRENDS IN ALTERNATIVE MEDICINE USE IN THE UNITED STATES, 1990-1997: RESULTS OF A FOLLOW-UP NATIONAL SURVEY, JAMA, 280, 18, PP. 1569-1575, (1998); MACLENNAN A.H., WILSON D.H., TAYLOR A.W., THE ESCALATING COST AND PREVALENCE OF ALTERNATIVE MEDICINE, PREV MED, 35, 2, PP. 166-173, (2002); GYLLING H., MIETTINEN T.A., CHOLESTEROL REDUCTION BY DIFFERENT PLANT STANOL MIXTURES AND WITH VARIABLE FAT INTAKE, METABOLISM, 48, 5, PP. 575-580, (1999); PLAT J., MENSINK R.P., VEGETABLE OIL-BASED VERSUS WOOD-BASED STANOL ESTER MIXTURES: EFFECTS ON SERUM LIPIDS AND HEMOSTATIC FACTORS IN NON-HYPERCHOLESTEROLEMIC SUBJECTS, ATHEROSCLEROSIS, 148, 1, PP. 101-112, (2000); HALLIKAINEN M.A., UUSITUPA M.I., EFFECTS OF 2 LOW-FAT STANOL ESTERCONTAINING MARGARINES ON SERUM CHOLESTEROL CONCENTRATIONS AS PART OF A LOW-FAT DIET IN HYPERCHOLESTEROLEMIC SUBJECTS, EUR J CLIN NUTR, 69, 3, PP. 403-410, (1999); HALLIKAINEN M.A., SARKKINEN E.S., GYLLING H., ERKKILA A.T., UUSITUPA M.I., COMPARISON OF THE EFFECTS OF PLANT STEROL ESTER AND PLANT STANOL ESTER-ENRICHED MARGARINES IN LOWERING SERUM CHOLESTEROL CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC SUBJECTS ON A LOW-FAT DIET, EUR J CLIN NUTR, 54, 9, PP. 715-725, (2000); LAW M., PLANT STEROL AND STANOL MARGARINES AND HEALTH, BMJ, 320, 7238, PP. 861-864, (2000); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, 2, PP. 356-365, (2002); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, 3, PP. 203-217, (2002); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 58, 1, PP. 44-51, (1997); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., FERNANDEZ J.C., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR THER RES CLIN EXP, 62, 3, PP. 194-208, (2001); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, 1, PP. 27-33, (1994); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, 3, PP. 304-312, (1993); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, 1, PP. 43-57, (2001); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, 4, PP. 245-254, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, 3, PP. 296-304, (1995); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, 1, PP. 31-41, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, 3, PP. 187-195, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, 4, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, 3, (2001); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF D-003, A NEW HYPOCHOLESTEROLAEMIC AND ANTIPLATELET COMPOUND, ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY VOLUNTEERS, CLIN DRUG INVEST, 23, 3, PP. 193-203, (2003); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, 4, PP. 159-165, (1995); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, 9, PP. 1084-1092, (1994); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, 8, PP. 819-828, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, 3, PP. 154-162, (1997); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS F.R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, 3, PP. 393-397, (1995); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, 7, PP. 485-497, (2001); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, 2, PP. 176-182, (1995); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 3, 3, PP. 159-172, (2002); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES CLIN EXP, 57, 7, PP. 568-577, (1996); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 57, 9, PP. 691-699, (1996); MENENDEZ R., MAS R., AMOR A.M., FERNANDEZ J.C., GONZALEZ R.M., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR THER RES CLIN EXP, 61, 9, PP. 609-620, (2000); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, 3, PP. 255-262, (2000); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, 4, PP. 507-513, (1992); ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, 10, PP. 891-897, (2002); BATISTA J., STUSSER R., PENICHET M., UGUET E., DOPPLER-ULTRASOUND PILOT-STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES CLIN EXP, 56, 9, PP. 906-914, (1995); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES CLIN EXP, 51, 4, PP. 568-575, (1992); BATISTA J.F., STUSSER R.J., PADRON R., SOSA F., PEREZTOL O., PEREZ B., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTHS OF LIPID-LOWERING THERAPY WITH POLICOSANOL, ADV THER, 13, 3, PP. 137-148, (1996); DAVIDSON M.H., MAKI K.C., UMPOROWICZ D.M., ET AL., SAFETY AND TOLERABILITY OF ESTERIFIED PHYTOSTEROLS ADMINISTERED IN REDUCED-FAT SPREAD AND SALAD DRESSING TO HEALTHY ADULT MEN AND WOMEN, J AM COLL NUTR, 20, 4, PP. 307-319, (2001); MIETTINEN T.A., PUSKA P., GYLLING H., VANHANEN H., VARTIAINEN E., REDUCTION OF SERUM CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION, N ENGL J MED, 333, 20, PP. 1308-1312, (1995); HOMMA Y., IKEDA I., ISHIKAWA T., TATENO M., SUGANO M., NAKAMURA H., DECREASE IN PLASMA LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, CHOLESTERYL ESTER TRANSFER PROTEIN, AND OXIDIZED LOW-DENSITY LIPOPROTEIN BY PLANT STANOL ESTER-CONTAINING SPREAD: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL, NUTRITION, 19, 4, PP. 369-374, (2003); TIKKANEN M.J., HOGSTROM P., TUOMILEHTO J., KEINANEN-KIUKAANNIEMI S., SUNDVALL J., KARPPANEN H., EFFECT OF A DIET BASED ON LOW-FAT FOODS ENRICHED WITH NONESTERIFIED PLANT STEROLS AND MINERAL NUTRIENTS ON SERUM CHOLESTEROL, AM J CARDIOL, 88, 10, PP. 1157-1162, (2001); VANHANEN H.T., KAJANDER J., LEHTOVIRTA H., MIETTINEN T.A., SERUM LEVELS, ABSORPTION EFFICIENCY, FAECAL ELIMINATION AND SYNTHESIS OF CHOLESTEROL DURING INCREASING DOSES OF DIETARY SITOSTANOL ESTERS IN HYPERCHOLESTEROLAEMIC SUBJECTS, CLIN SCI, 87, 1, PP. 61-67, (1994); TEMME E.H., VAN HOYDONCK P.G., SCHEUTEN E.G., KESTELOOT H., EFFECTS OF A PLANT STEROL-ENRICHED SPREAD ON SERUM LIPIDS AND LIPOPROTEINS IN MILDLY HYPERCHOLESTEROLAEMIC SUBJECTS, ACTA CARDIOL, 57, 2, PP. 111-115, (2002); GYLLING H., RADHAKRISHNAN R., MIETTINEN T.A., REDUCTION OF SERUM CHOLESTEROL IN POSTMENOPAUSAL WOMEN WITH PREVIOUS MYOCARDIAL INFARCTION AND CHOLESTEROL MALABSORPTION INDUCED BY DIETARY SITOSTANOL ESTER MARGARINE: WOMEN AND DIETARY SITOSTANOL, CIRCULATION, 96, 12, PP. 4226-4231, (1997); CLEGHORN C.L., SKEAFF C.M., MANN J., CHISHOLM A., PLANT STEROLENRICHED SPREAD ENHANCES THE CHOLESTEROL-LOWERING POTENTIAL OF A FAT-REDUCED DIET, EUR J CLIN NUTR, 57, 1, PP. 170-176, (2003); LOTTENBERG A.M., NUNES V.S., NAKANDAKARE E.R., ET AL., THE HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN I405V POLYMORPHISM IS ASSOCIATED WITH PLASMA CHOLESTEROL CONCENTRATION AND ITS REDUCTION BY DIETARY PHYTOSTEROL ESTERS, J NUTR, 133, 6, PP. 1800-1805, (2003); MENSINK R.P., EBBING S., LINDHOUT M., PLAT J., VAN HEUGTEN M.M., EFFECTS OF PLANT STANOL ESTERS SUPPLIED IN LOW-FAT YOGHURT ON SERUM LIPIDS AND LIPOPROTEINS, NON-CHOLESTEROL STEROLS AND FAT SOLUBLE ANTIOXIDANT CONCENTRATIONS, ATHEROSCLEROSIS, 160, 1, PP. 205-213, (2002); SPILBURG C.A., GOLDBERG A.C., MCGILL J.B., ET AL., FAT-FREE FOODS SUPPLEMENTED WITH SOY STANOL-LECITHIN POWDER REDUCE CHOLESTEROL ABSORPTION AND LDL CHOLESTEROL, J AM DIET ASSOC, 103, 5, PP. 577-581, (2003); BLOMQVIST S.M., JAUHIAINEN M., VANTOL A., ET AL., EFFECT OF SITOSTANOL ESTER ON COMPOSITION AND SIZE DISTRIBUTION OF LOW-DENSITY AND HIGH-DENSITY-LIPOPROTEIN, NUTR METAB CARDIOVASC DIS, 3, 4, PP. 158-164, (1993); VANHANEN H.T., BLOMQVIST S., EHNHOLM C., ET AL., SERUM CHOLESTEROL, CHOLESTEROL PRECURSORS, AND PLANT STEROLS IN HYPERCHOLESTEROLEMIC SUBJECTS WITH DIFFERENT APOE PHENOTYPES DURING DIETARY SITOSTANOL ESTER TREATMENT, J LIPID RES, 34, 9, PP. 1535-1544, (1993); MAKI K.C., DAVIDSON M.H., UMPOROWICZ D.M., ET AL., LIPID RESPONSES TO PLANT-STEROL-ENRICHED REDUCED-FAT SPREADS INCORPORATED INTO A NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP 1 DIET, AM J CLIN NUTR, 74, 1, PP. 33-43, (2001); SIMONS L.A., ADDITIVE EFFECT OF PLANT STEROL-ESTER MARGARINE AND CERIVASTATIN IN LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 90, 7, PP. 737-740, (2002); DE GRAAF J., SAUVAGE NOLTING P.R., VAN DAM M., ET AL., CONSUMPTION OF TALL OIL-DERIVED PHYTOSTEROLS IN A CHOCOLATE MATRIX SIGNIFICANTLY DECREASES PLASMA TOTAL AND LOW-DENSITY LIPOPROTEIN-CHOLESTEROL LEVELS, BR J NUTR, 88, 5, PP. 479-488, (2002); MATVIENKO O.A., LEWIS D.S., SWANSON M., ET AL., A SINGLE DAILY DOSE OF SOYBEAN PHYTOSTEROLS IN GROUND BEEF DECREASES SERUM TOTAL CHOLESTEROL AND LDL CHOLESTEROL IN YOUNG, MILDLY HYPERCHOLESTEROLEMIC MEN, AM J CLIN NUTR, 76, 1, PP. 57-64, (2002); ANDERSSON A., KARLSTROM B., MOHSEN R., VESSBY B., CHOLESTEROL-LOWERING EFFECTS OF A STANOL ESTER-CONTAINING LOW-FAT MARGARINE USED IN CONJUNCTION WITH A STRICT LIPID-LOWERING DIET, EUR HEART J, 1, SUPPL. S, (1999); JONES P.J., NTANIOS F.Y., RAEINI-SARJAZ M., VANSTONE C.A., CHOLESTEROL-LOWERING EFFICACY OF A SITOSTANOL-CONTAINING PHYTOSTEROL MIXTURE WITH A PRUDENT DIET IN HYPERLIPIDEMIC MEN, AM J CLIN NUTR, 69, 6, PP. 1144-1150, (1999); LEE Y.M., HAASTERT B., SCHERBAUM W., HAUNER H., A PHYTOSTEROL-ENRICHED SPREAD IMPROVES THE LIPID PROFILE OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS: A RANDOMIZED CONTROLLED TRIAL UNDER FREE-LIVING CONDITIONS, EUR J NUTR, 42, 2, PP. 111-117, (2003); WILLIAMS C.L., BOLLELLA M., STROBINO B.A., BOCCIA L., CAMPANARO L., LIPID-LOWERING EFFECTS OF A PLANT STANOL ESTER SPREAD IN YOUNG CHILDREN, EUR HEART J, 1, SUPPL., (1999); PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUR HEART J, 19, 10, PP. 1434-1503, (1998); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANDS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO CLIN PROC, 78, 8, PP. 965-978, (2003); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, 3 SUPPL., PP. 63-71, (1988); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, 2, PP. 197-204, (1996); RADER D.J., THERAPY TO REDUCE RISK OF CORONARY HEART DISEASE, CLIN CARDIOL, 26, 1, PP. 2-8, (2003); ZEMA M.J., GEMFIBROZIL, NICOTINIC ACID AND COMBINATION THERAPY IN PATIENTS WITH ISOLATED HYPOALPHALIPOPROTEINEMIA: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY, J AM COLL CARDIOL, 35, 3, PP. 640-646, (2000); HELLER F.R., DESAGER J.P., HARVENGT C., PLASMA LIPID CONCENTRATIONS AND LECITHIN:CHOLESTEROL ACYLTRANSFERASE ACTIVITY IN NORMOLIPIDEMIC SUBJECTS GIVEN FENOFIBRATE AND COLESTIPOL, METABOLISM, 30, 1, PP. 67-71, (1981); PHYSICIANS' DESK REFERENCE, 57TH ED., (2003); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); LAW M.R., WALD N.J., THOMPSON S.G., BY HOW MUCH AND HOW QUICKLY DOES REDUCTION IN SERUM CHOLESTEROL CONCENTRATION LOWER RISK OF ISCHAEMIC HEART DISEASE?, BMJ, 308, 6925, PP. 367-372, (1994); GOULD A.L., ROSSOUW J.E., SANTANELLO N.C., HEYSE J.F., FURBERG C.D., CHOLESTEROL REDUCTION YIELDS CLINICAL BENEFIT: IMPACT OF STATIN TRIALS, CIRCULATION, 97, 10, PP. 946-952, (1998); OSE L., LUURILA O., ERIKSSON J., OLSSON A., LITHELL H., WIDGREN B., CERIVASTATIN GENDER EFFECT: SUB-ANALYSES OF RESULTS FROM A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND STUDY: CERIVASTATIN STUDY GROUP, CURR MED RES OPIN, 16, 2, PP. 80-87, (2000); DAWSON P.A., RUDEL L.L., INTESTINAL CHOLESTEROL ABSORPTION, CURR OPIN LIPIDOL, 10, 4, PP. 315-320, (1999); HEINEMANN T., AXTMANN G., VON BERGMANN K., COMPARISON OF INTESTINAL ABSORPTION OF CHOLESTEROL WITH DIFFERENT PLANT STEROLS IN MAN, EUR J CLIN INVEST, 23, 12, PP. 827-831, (1993); LICHTENSTEIN A.H., DECKELBAUM R.J., AMERICAN HEART ASSOCIATION SCIENCE ADVISORY: STANOL/STEROL ESTER-CONTAINING FOODS AND BLOOD CHOLESTEROL LEVELS: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE NUTRITION COMMITTEE OF THE COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM OF THE AMERICAN HEART ASSOCIATION, CIRCULATION, 103, 8, PP. 1177-1179, (2001); BLAIR S.N., CAPUZZI D.M., GOTTLIEB S.O., NGUYEN T., MORGAN J.M., CATER N.B., INCREMENTAL REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH THE ADDITION OF PLANT STANOL ESTER-CONTAINING SPREAD TO STATIN THERAPY, AM J CARDIOL, 86, 1, PP. 46-52, (2000); WILT T.J., MACDONALD R., ISHANI A., Β-SITOSTEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW, BJU INT, 83, 9, PP. 976-983, (1999); LING W.H., JONES P.J., DIETARY PHYTOSTEROLS: A REVIEW OF METABOLISM, BENEFITS AND SIDE EFFECTS, LIFE SCI, 57, 3, PP. 195-206, (1995); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, 2, PP. 192-195, (2003); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES CLIN EXP, 60, 8, PP. 458-467, (1999); ORTENSI G., GLADSTEIN J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, 6, PP. 390-401, (1997); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, 3, PP. 286-294, (1999); NIKITIN I., SLEPCHENKO N.V., GRATSIANSKII N.A., ET AL., RESULTS OF THE MULTICENTER CONTROLLED STUDY OF THE HYPOLIPIDEMIC DRUG POLYCOSANOL IN RUSSIA, TER ARKH, 72, 12, PP. 7-10, (2000); DENKE M.A., LACK OF EFFICACY OF LOW-DOSE SITOSTANOL THERAPY AS AN ADJUNCT TO A CHOLESTEROL-LOWERING DIET IN MEN WITH MODERATE HYPERCHOLESTEROLEMIA, J LIPID RES, 61, 2, PP. 392-396, (1995); JENKINS D.J., KENDALL C.W., MARCHIE A., ET AL., EFFECTS OF A DIETARY PORTFOLIO OF CHOLESTEROL-LOWERING FOODS VS LOVASTATIN ON SERUM LIPIDS AND C-REACTIVE PROTEIN, JAMA, 290, 4, PP. 502-510, (2003); ABRAMOWICZ M., THREE NEW DRUGS FOR HYPERLIPIDEMIA, MED LETT DRUGS THER, 45, 1151, PP. 17-19, (2003)","J.T. CHEN; DEPARTMENT OF PHARMACY PRACTICE, PURDUE UNIVERSITY, R. HEINE PHARMACY BUILDING, WEST LAFAYETTE, IN 47907-2091, 575 STADIUM MALL DRIVE, UNITED STATES; EMAIL: JTCHEN@PHARMACY.PURDUE.EDU","","ENGLISH","PHARMACOTHERAPY","REVIEW","ISI","2-S2.0-13544277440","PHARMACOTHERAPY","PURDUE UNIVERSITY;NATIONAL INSTITUTES OF HEALTH;NATIONAL INSTITUTES OF HEALTH;NATIONAL INSTITUTES OF HEALTH;NATIONAL INSTITUTES OF HEALTH","NOTREPORTED;PURDUE UNIVERSITY;NOTREPORTED",NA,"CHEN JT, 2005, PHARMACOTHERAPY","CHEN JT, 2005, PHARMACOTHERAPY"
"URIBARRI E;LAGUNA A;GONZÁLEZ M","URIBARRI, E. (6505806794); LAGUNA, A. (7006455910); GONZÁLEZ, M. (57214372109)","STUDIES OF WET GRANULATION IN SMALL SCALE HIGH SHEAR MIXER OF 20 MG TABLETS OF POLICOSANOL",2003,"BOLLETTINO CHIMICO FARMACEUTICO","142","3",5,"","LABORATORIES MEDSOL, HAVANA, CUBA;LABORATORIES MEDSOL, HAVANA, CUBA;LABORATORIES MEDSOL, HAVANA, CUBA","IT WAS STUDIED THE INFLUENCE OF THREE FACTORS IN THE MANUFACTURING PROCESS OF TABLETS CONTAINING 20 MG OF POLICOSANOL IN A SMALL SCALE WHEN WAS USED A HIGH SHEAR MIXER. A FACTORIAL DESIGN WITHOUT REPETITIONS WAS USED, CONSIDERING AS INDEPENDENT VARIABLES: VOLUME OF BINDER SOLUTION, KNEADING TIME AND THE USE OR NOT OF CHOPPER. DATA ANALYSIS WAS CARRIED OUT USING THE YATES ALGORITHM, CONSIDERING THE EFFECT OF THESE THREE FACTORS OVER THE DIAMETER OF THE GRANULES, THE PERCENT OF FINE POWDERS IN GRANULATE AND THE COMPRESSION FORCES. THE DIAMETER OF THE GRANULES WAS INCREASED WITH AN INCREASE IN THE VOLUME OF THE BINDER SOLUTION ADDED AND WITH AN INCREASE IN THE KNEADING TIME AND WAS DECREASED WHEN THE CHOPPER WAS USED. THE PERCENT OF FINE POWDERS, PRESENT IN GRANULATE, WAS SIGNIFICANTLY DIMINISHED WITH AN INCREASE OF THE VOLUME OF BINDER SOLUTION AND DIMINISHED WITH AN INCREASE IN THE KNEADING TIME, THE INFLUENCE OF THE USE OF CHOPPER WAS INSIGNIFICANT. THE COMPRESSION FORCES DIMINISHED WITH THE USE OF CHOPPER, WITH THE INCREASE OF THE VOLUME OF BINDER SOLUTION USED AND ARE NOT AFFECTED WITH THE CHANGES IN THE KNEADING TIME.","","ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; POWDERS; TABLETS; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ARTICLE; CHEMISTRY; POWDER; TABLET","","","","","","ENGLISH","BOLL CHIM FARM","ARTICLE","ISI","2-S2.0-1842834053","BOLL CHIM FARM",NA,"NOTREPORTED",NA,"URIBARRI E, 2003, BOLL CHIM FARM","URIBARRI E, 2003, BOLL CHIM FARM"
"ORTEGA L;SÁNCHEZ J;MÁS R;FERNÁNDEZ L;MENDOZA S;GÁMEZ R;FERNÁNDEZ J;ILLNAIT J;ALVAREZ E","ORTEGA, L.L. (54888379200); SÁNCHEZ, J. (55452596800); MÁS, R. (7007164572); FERNÁNDEZ, L. (7202848319); MENDOZA, S. (7102759819); GÁMEZ, R. (7003605346); FERNÁNDEZ, J.C. (9432805500); ILLNAIT, J. (8631465800); ALVAREZ, E. (15053135600)","EFFECTS OF POLICOSANOL ON PATIENTS WITH ISCHEMIC STROKE A PILOT OPEN STUDY",2006,"JOURNAL OF MEDICINAL FOOD","9","7",10,"10.1089/jmf.2006.9.378","NATIONAL INSTITUTE OF NEUROLOGY, HAVANA CITY, CUBA;NATIONAL INSTITUTE OF NEUROLOGY, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA","STROKE IS A MAJOR HEALTH PROBLEM WORLDWIDE. ITS PHARMACOLOGICAL MANAGEMENT INCLUDES THROMBOLYTIC THERAPY FOR THE ACUTE PHASE AND ANTIPLATELET DRUGS FOR STROKE RECOVERY AND PREVENTION. STATINS CAN HELP IN THE ACUTE PHASE AND IN PREVENTING STROKE IN SECONDARY PREVENTION PATIENTS. POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS, WITH PROTECTIVE EFFECTS IN STROKE MODELS. THIS OBSERVATIONAL STUDY INVESTIGATED THE EFFECTS OF POLICOSANOL (20 MG/DAY) ADMINISTERED DURING THE ACUTE PHASE AND FOR 5 YEARS LATER ON THE NEUROLOGICAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE TREATED WITH ANTIPLATELETS AND VITAMINS. AFTER HOSPITAL DISCHARGE, PATIENTS WERE FOLLOWED UP EVERY 3 (FIRST YEAR) AND 6 (THEREAFTER) MONTHS. NEUROLOGICAL IMPROVEMENT WAS ASSESSED WITH THE MODIFIED CANADIAN NEUROLOGICAL SCALE. ADVERSE EVENTS WERE RECORDED. FIFTY PATIENTS WERE INCLUDED; ALL COMPLETED THE STUDY. NEUROLOGICAL SCORE IMPROVED THROUGHOUT THE STUDY. NO PATIENT DIED, AND MOST [40 (80.0%)] DID NOT EXPERIENCE NEW VASCULAR EVENTS; ONLY ONE (2.0%) SUFFERED A NEW STROKE, AND TWO (4.0%) SUFFERED MORE THAN ONE TRANSIENT ISCHEMIC ATTACK. THE TIME TO THE FIRST RECURRENT EVENT WAS 46.2 MONTHS. POLICOSANOL PERSISTENTLY LOWERED SERUM TOTAL CHOLESTEROL, WITH SUCH REDUCTION CORRELATING WITH THE NEUROLOGICAL IMPROVEMENT (R = 0.995253301). TRIGLYCERIDES WERE UNCHANGED. TREATMENT WAS WELL TOLERATED. POLICOSANOL ADMINISTERED TO PATIENTS SUFFERING ISCHEMIC STROKE TREATED WITH ASPIRIN AND VITAMINS SHOWED GOOD RESULTS ON NEUROLOGICAL OUTCOMES AND RECURRENT EVENTS. THIS STUDY, HOWEVER, HAS LIMITATIONS, SINCE IT WAS OPEN AND UNCONTROLLED, AND PATIENTS ALSO CONSUMED ASPIRIN AND VITAMINS. NEW RANDOMIZED, CONTROLLED STUDIES ARE NEEDED TO ASSESS THE USEFULNESS OF POLICOSANOL IN STROKE MANAGEMENT. © MARY ANN LIEBERT, INC. AND KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION.","ANTIPLATELET DRUGS; CHOLESTEROL-LOWERING DRUGS; POLICOSANOL; STROKE","AGED; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; FATTY ALCOHOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; VITAMINS; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLICOSANOL; TRIACYLGLYCEROL; VASODILATOR AGENT; VITAMIN; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LIPID; POLICOSANOL; VITAMIN; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INSOMNIA; IRRITABILITY; MALE; NEUROPROTECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SECONDARY PREVENTION; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; FOLLOW UP; MIDDLE AGED; PILOT STUDY; RECURRENT DISEASE","","","DIRNAGL U., COSTANTINO I., MOSKOWITZ M.A., PATHOBIOLOGY OF ISCHEMIC STROKE: AN INTEGRATED VIEW, TRENDS NEUROSCI, 22, PP. 391-397, (1999); BRONNER L.L., KUNTER D.S., MANSOM J.E., PRIMARY PREVENTION OF STROKE, N ENGL J MED, 333, PP. 1392-1400, (1995); DE FREITAS G.R., BOGOUSSLAVSKY J., PRIMARY STROKE PREVENTION, EUR J NEUROL, 8, PP. 1-15, (2001); ENFERMEDAD CEREBROVASCULAR (ECB) ACTUALIZACION, (2003); BAMFORD J., CLINICAL EXAMINATION IN DIAGNOSIS AND SUBCLASSIFICATION OF STROKE, LANCET, 339, PP. 400-402, (1992); TRAN H., ANAND S., ORAL ANTIPLATELEL THERAPY IN CEREBROVASCULAR DISEASE, CORONARY ARTERIAL DISEASES AND PERIPHERAL ARTERIAL DISEASE, JAMA, 292, PP. 1867-1874, (2004); LAW M.R., WALD N.J., RUDNICKA A.R., QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS, BMJ, 326, PP. 1423-1428, (2003); ROSENSON R.S., TANGNEY C.C., ANTIATHEROTHROMBOTIC PROPERTIES OF STATINS: IMPLICATIONS FOR CARDIOVASCULAR EVENT REDUCTION, JAMA, 279, PP. 1643-1650, (1998); LAUFS U., LIAO J.K., DIRECT VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS, TRENDS CARDIOVASC MED, 10, PP. 143-148, (2000); LAUFS U., LA FATA V., PLUTZKY J., LIAO J.K., UP-REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY HMG COA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); HENRY R.Y., KENDALL M.J., DOES CHOLESTEROL LOWERING PREVENT STROKE?, J CLIN PHARMACOL THER, 23, PP. 337-344, (1998); PEARSON T.A., PRIMARY AND SECONDARY PREVENTION OF CORONARY ARTERY DISEASE: TRIALS OF LIPID LOWERING WITH STATINS, AM J CARDIOL, 82, SUPPL., (1998); HANKEY G.J., WARLOW C.P., TREATMENT AND SECONDARY PREVENTION OF STROKE: EVIDENCE, COSTS, AND EFFECTS ON INDIVIDUALS AND POPULATIONS, LANCET, 354, PP. 1457-1463, (1999); DI MASCIO R., MARCHIOLI R., TOGNONI G., CHOLESTEROL REDUCTION AND STROKE OCCURRENCE: AN OVERVIEW OF RANDOMIZED CONTROLLED TRIALS, CEREBROVASC DIS, 10, PP. 85-92, (2000); CHOLESTEROL, DIASTOLIC BLOOD PRESSURE, AND STROKE: 13,000 STROKES IN 450,000 PEOPLE IN 45 PROSPECTIVE COHORTS, LANCET, 346, PP. 1647-1653, (1995); VAUTHEY C., DE FREITAS G.R., VAN MELLE G., ET AL., BETTER OUTCOME AFTER STROKE WITH HIGHER SERUM CHOLESTEROL LEVELS, NEUROLOGY, 54, PP. 1944-1948, (2000); BUCHWALD H., CAMPOS C.T., BOEN J.R., ET AL., DISEASE-FREE INTERVAL AFTER PARTIAL ILEAL BYPASS IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: REPORT FROM THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH), J AM COLL CARDIOL, 26, PP. 351-357, (1995); ENDRES M., LAUFS U., HUANG Z., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC NATL ACAD SCI USA, 95, PP. 8880-8885, (1998); CHEN J., ZHANG Z.G., LI Y., ET AL., STATINS INDUCE ANGIOGENESIS, NEUROGENESIS, AND SYNAPTOGENESIS AFTER STROKE, ANN NEUROL, 53, PP. 743-751, (2003); VAUGHAN C.J., DELANTY N., NEUROPROTECTIVE PROPERTIES OF STATINS IN CEREBRAL ISCHEMIA AND STROKE, STROKE, 30, PP. 1969-1973, (1999); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 187-195, (2000); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, PP. 153-163, (2003); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A, 56, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLEMIA, DRUGS R&D, 3, PP. 159-172, (2002); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-128, (1999); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION. A RANDOMISED, DOUBLE-BLINDED PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND PILOT COMPARATIVE STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CASTANO G., MAS R., GAMEZ R., ET AL., EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLINDED PILOT COMPARATIVE STUDY, ANGIOLOGY, 55, PP. 361-371, (2004); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); MAS R., CASTANO G., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL (5-10 MG/DAY) ON MORBIDITY AND MORTALITY IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, J AM COLL CARDIOL, 39, SUPPL. B, (2002); COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY - I: PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BMJ, 308, PP. 81-106, (1994); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); FERNANDEZ S., MAS R., GAMEZ R., ET AL., A PHARMACOLOGICAL SURVEILLANCE OF POLICOSANOL TOLERABILITY IN THE ELDERLY, AM J GERIATR PHARMACOTHER, 2, PP. 219-229, (2004); COTE R., BATTISTA R.N., WOLFSON C., BOUCHER J., ADAM J., HACHINSKI V.C.C., THE CANADIAN NEUROLOGICAL SCALE. VALIDATION AND RELIABILITY ASSESSMENT, NEUROLOGY, 39, PP. 638-643, (1989); NARANJO C.A., BUSTO U., SELLERS E.M., ET AL., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN PHARMACOL THER, 30, PP. 239-245, (1981); O'BRIEN P.C., SHAMPO M.A., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); YOON S.S., DAMBROSIA J., CHALELA J., RISING STATIN USE AND EFFECT ON ISCHEMIC STROKE OUTCOME, BMC MED, 2, PP. 1741-1747, (2004); COTE R., HACHINSKI V.C., SHURVELL B.L., NORRIS J.W., WOLFSON C., THE CANADIAN NEUROLOGICAL SCALE. A PRELIMINARY STUDY IN ACUTE STROKE, STROKE, 17, PP. 731-737, (1986); BUSHNELL C.D., JOHNSTON D.C., GOLDSTEIN L.B., RETROSPECTIVE ASSESSMENT OF INITIAL STROKE SEVERITY: COMPARISON OF THE NIH STROKE SCALE AND THE CANADIAN NEUROLOGICAL SCALE, STROKE, 32, PP. 656-660, (2001); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); LOVE S., OXIDATIVE STRESS IN BRAIN ISCHEMIA, BRAIN PATHOL, 9, PP. 119-131, (1999); GILGUN-SHERKI Y., ROSENBAUM Z., MELAMED E., OFFEN D., ANTIOXIDANT THERAPY IN ACUTE CENTRAL NERVOUS SYSTEM INJURY: CURRENT STATE, PHARMACOL REV, 54, PP. 271-284, (2002); MARTINEZ-VILA E., IRIMIA P., FACTORES DE RIESGO DEL ICTUS, ANAL SISTEMA SANITARIO NAVARRA, 23, SUPPL. 3, PP. 25-31, (2000)","R. MÁS; CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","J. MED. FOOD","ARTICLE","ISI","2-S2.0-33750617773","J MED FOOD","NATIONAL INSTITUTE OF NEUROLOGY;NATIONAL INSTITUTE OF NEUROLOGY;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"ORTEGA LL, 2006, J MED FOOD","ORTEGA LL, 2006, J MED FOOD"
"CASTAÑO G;ARRUZAZABALA M;FERNÁNDEZ L;MAS R;CARBAJAL D;MOLINA V;ILLNAIT J;MENDOZA S;GÁMEZ R;MESA M;FERNÁNDEZ J","CASTAÑO, GLADYS (56232967100); ARRUZAZABALA, MARIA L. (6603962476); FERNÁNDEZ, LILIA (7202848319); MAS, ROSA (7007164572); CARBAJAL, DAISY (8777025000); MOLINA, VIVIAN (7006062814); ILLNAIT, JOSÉ (8631465800); MENDOZA, SARAHÍ (7102759819); GÁMEZ, RAFAEL (7003605346); MESA, MELBIS (36880545700); FERNÁNDEZ, JULIO (9432805500)","EFFECTS OF COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA3 FATTY ACIDS ON PLATELET AGGREGATION A RANDOMIZED DOUBLEBLIND CLINICAL STUDY",2006,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","67","18",19,"10.1016/j.curtheres.2006.06.004","SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: POLICOSANOL IS A MIXTURE OF LONG-CHAIN PRIMARY ALIPHATIC ALCOHOLSPURIFIED FROM SUGAR CANE WAX THAT HAS CHOLESTEROL LOWERING AND ANTIPLATELET EFFECTS. OMEGA-3 FATTY ACIDS (FA) HAVE TRIGLYCERIDE LOWERING AND ANTIPLATELET EFFECTS. COMBINATION TREATMENT WITH POLICOSANOL AND OMEGA-3 FA (Ω23FA) HAS BEEN ASSOCIATED WITH SIGNIFICANT INHIBITION OF PLATELET AGGREGATION IN RABBITS COMPARED WITH EITHER DRUG ALONE. OBJECTIVE: THE AIM OF THIS STUDY WAS TO INVESTIGATE THE EFFECTS OF COMBINATION TREATMENT WITH Ω3FA (1 G/D) AND POLICOSANOL (Ω3FA+POLI) COMPARED WITH Ω3FA (1 G/D) PLUS PLACEBO (Ω3FA+PLA) ON PLATELET AGGREGATION IN HUMAN PATIENTS WITH HYPERCHOLESTEROLEMIA. METHODS: THIS RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY AT THE SURGICAL MEDICAL RESEARCH CENTER (HAVANA CITY, CUBA) RECRUITED OUTPATIENTS FROM LIPID CLINICS, WITH SOME ATHEROSCLEROTIC RISK FACTORS. OUTPATIENTS OF BOTH SEXES AGED 20 TO 75 YEARS WITH SERUM TOTAL CHOLESTEROL (TC) LEVELS ≥5 AND <6 MMOL/L WERE ELIGIBLE TO ENROLL. THEY WERE INCLUDED IN THE STUDY AT THE END OF A 4-WEEK DIET STABILIZATION PERIOD IF THEIR PLATELET AGGREGATION TO ARACHIDONIC ACID (AA) WAS ≥50% AND SERUM TC LEVEL REMAINED ≥5 MMOL/L. PATIENTS WERE THEN EVENLY RANDOMIZED TO RECEIVE Ω3FA (1 G/D) + PLACEBO OR Ω3FA (1 G/D) + POLICOSANOL (10 MG/D) TO BE TAKEN PO WITH THE EVENING MEAL FOR 21 DAYS. TREATMENT WAS ASSIGNED ACCORDING TO A RANDOMIZATION CODE USING BALANCED BLOCKS AND A 1:1 ALLOCATION RATIO. INHIBITION OF PLATELET AGGREGATION TO AA WAS THE PRIMARY EFFICACY VARIABLE, WHILE EFFECTS ON PLATELET AGGREGATION TO COLLAGEN AND EPINEPHRINE AND ON LIPID PROFILE WERE SECONDARY VARIABLES. DRUG COMPLIANCE AND ADVERSE EVENTS (AES) WERE MONITORED. TOLERABILITY WAS ASSESSED USING PHYSICAL EXAMINATIONS AND LABORATORY TEST RESULTS. RESULTS: SIXTY-FOUR SUBJECTS WERE INITIALLY ENROLLED. FIFTY-FOUR PATIENTS (30 WOMEN, 24 MEN; MEAN [SD] AGE, 58.4 [12] YEARS, [RANGE, 40-70 YEARS]) MET THE INCLUSION CRITERIA AND WERE RANDOMIZED TO TREATMENT; 2 GROUPS OF 27. AFTER 21 DAYS, PLATELET AGGREGATION TO AA WAS SIGNIFICANTLY INHIBITED IN THE 2 GROUPS. Ω3FA+POLI INHIBITED PLATELET AGGREGATION TO ALL AGONISTS BY ≥20%. PLATELET AGGREGATION TO AA 1.0 AND 1.5 MM WAS INHIBITED WITH COMBINATION TREATMENT (39.6% AND 33.9%, RESPECTIVELY; BOTH P < 0.001 VS BASELINE; P < 0.001 AND P < 0.01, RESPECTIVELY, VS Ω3FA+PLA) AND WITH Ω3FA+PLA (11.0% AND 13.3%; BOTH, P < 0.001). COMBINATION TREATMENT WAS MORE EFFECTIVE IN INHIBITING PLATELET AGGREGATION TO AA 1.0 AND 1.5 MM IN 28.6% (P < 0.001) AND 20.6% (P < 0.01), RESPECTIVELY. PLATELET AGGREGATION TO COLLAGEN 1 ΜG/ML WAS SIGNIFICANTLY INHIBITED WITH COMBINATION TREATMENT AND WITH Ω3FA+PLA COMPARED WITH BASELINE (43.2% AND 15.1%, RESPECTIVELY; BOTH, P < 0.001), BUT THE EFFECTS OF COMBINATION TREATMENT WERE SIGNIFICANTLY GREATER (P < 0.01). PLATELET AGGREGATION TO EPINEPHRINE 0.1 MM WAS INHIBITED WITH Ω3FA+POLI AND Ω3FA+PLA (34.8% AND 20.1%; BOTH, P < 0.001), WITH SIMILAR RESULTS FOR BOTH GROUPS. BLEEDING TIME DID NOT CHANGE SIGNIFICANTLY FOR EITHER GROUP AND Ω3FA+PLA DID NOT SIGNIFICANTLY CHANGE THE LIPID PROFILE. COMBINATION TREATMENT DID SIGNIFICANTLY REDUCE LEVELS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (17.4%; P < 0.001 VS BASELINE, P < 0.05 VS Ω3FA+PLA) AND TC (10.1%; P < 0.001 VS BASELINE, P < 0.05 VS Ω3FA+PLA), INCREASE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS (18.0%; P < 0.001 VS BASELINE), BUT DID NOT SIGNIFICANTLY CHANGE TRIGLYCERIDE LEVELS. THREE PATIENTS (2 FROM THE Ω3FA+POLI GROUP AND 1 FROM THE Ω3FA+PLA GROUP) WITHDREW FROM THE TRIAL, THOUGH NONE WERE DUE TO AES. TWO PATIENTS RECEIVING COMBINATION TREATMENT REPORTED MILD AES (HEADACHE). ALL TREATMENTS WERE WELL TOLERATED. CONCLUSIONS: IN THESE PATIENTS, POLICOSANOL (10 MG/D) ADMINISTERED CONCOMITANTLY WITH Ω3FA (1 G/D) ENHANCED THE INHIBITION OF PLATELET AGGREGATION TO AA AND COLLAGEN, BUT NOT TO EPINEPHRINE, COMPARED WITH Ω3FA+PLA, WITHOUT SIGNIFICANTLY AFFECTING BLEEDING TIME. CONCOMITANT TREATMENT WAS ALSO ASSOCIATED WITH REDUCED LEVELS OF LDL-C AND TC AND RAISED HDL-C LEVELS. ALL TREATMENTS WERE WELL TOLERATED. © 2006 EXCERPTA MEDICA, INC.","ANTIPLATELET DRUGS; CHOLESTEROL-LOWERING DRUGS; OMEGA-3 FATTY ACIDS; PLATELET AGGREGATION; POLICOSANOL","ADRENALIN; ARACHIDONIC ACID; COLLAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CITY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUBA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEAL; MEDICAL RESEARCH; OUTPATIENT; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX; THROMBOCYTE AGGREGATION INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL","WEST HAVANA SCIENTIFIC POLE","THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE WEST HAVANA SCIENTIFIC POLE (HAVANA, CUBA).","WU K.K., RECENT ADVANCES IN HEMOSTATIC RISK FACTORS AND CARDIOVASCULAR DISEASES, FIBRINOLYSIS & PROTEOLYSIS, 11, SUPPL. 1, PP. 31-34, (1997); MURRAY C.J., LOPEZ A.D., ALTERNATIVE PROJECTIONS OF MORTALITY AND DISABILITY BY CAUSE 1990-2020. GLOBAL BURDEN OF DISEASE STUDY, LANCET, 349, PP. 1498-1504, (1997); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION, TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION, TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROLLEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED., 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., (PROSPECTIVE STUDY OF PRAVASTATIN IN THE ELDERLY AT RISK). PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMISEDCONTROLLED TRIAL, LANCET, 360, PP. 1623-1630, (2002); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); GOTTO JR. A.M., ASSMANN G., CARMENA R., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE: BLOOD LIPIDS AND CORONARY HEART DISEASE. 2ND ED, (2000); FALK E., FERNANDEZ-ORTIZ A., ROLE OF THROMBOSIS IN ATHEROSCLEROSIS AND ITS COMPLICATIONS, AM J CARDIOL, 75, (1995); SCHAFER A.I., ANTIPLATELET THERAPY, AM J MED, 101, PP. 199-209, (1996); HALLER H., ENDOTHELIAL FUNCTION. GENERAL CONSIDERATIONS, DRUGS, 53, SUPPL. 1, PP. 1-10, (1997); LUSCHER T.F., BARTON M., BIOLOGY OF THE ENDOTHELIUM, CLIN CARDIOL, 20, SUPPL. 2, PP. 113-1110, (1997); SHAH P.K., PLAQUE DISRUPTION AND CORONARY THROMBOSIS: NEW INSIGHT INTO PATHOGENESIS AND PREVENTION, CLIN CARDIOL., 20, SUPPL. 12, PP. 1138-1144, (1997); COLLABORATIVE OVERVIEW OF RANDOMISED TRIALS OF ANTIPLATELET THERAPY-I: PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE BY PROLONGEDANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BMJ, 308, PP. 81-106, (1994); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR HEART J, 19, SUPPL. A, (1998); HASSAN M., AMONKAR M., ASPIRIN USE FOR PRIMARY AND SECONDARY PROPHYLAXIS OF CARDIOVASCULAR DISEASE, CURR THER RES CLIN EXP, 62, PP. 676-690, (2001); PATRONO C., COLLER B., DALEN J.E., ET AL., PLATELET-ACTIVE DRUGS: THE RELATIONSHIPS AMONG DOSE, EFFECTIVENESS, AND SIDE EFFECTS, CHEST, 119, SUPPL. 1, (2001); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); ORTENSI G., GLADSTEIN J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CL IN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENTDIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION IN PATIENTS WITH DYSLIPIDAEMIA AND TYPE 2DIABETES MELLITUS, CLIN DRUG INVEST, 23, PP. 639-650, (2003); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO INVITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR THER RES CLIN EXP, 61, PP. 609-620, (2000); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-65, (2001); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); ALEMAN C.L., MAS FERREIRO R., NOA PUIG M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES CLIN EXP, 60, PP. 458-467, (1999); HARRIS W.S., PARK Y., ISLEY W.L., CARDIOVASCULAR DISEASE AND LONG-CHAIN OMEGA-3 FATTY ACIDS, CURR OPIN LIPIDOL, 14, PP. 9-14, (2003); LEE K.W., LIP G.Y., THE ROLE OF OMEGA-3 FATTY ACIDS IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, QJM, 96, PP. 465-480, (2003); RICHTER W.O., LONG-CHAIN OMEGA-3 FATTY ACIDS FROM FISH REDUCE SUDDEN CARDIAC DEATH IN PATIENTS WITH CORONARY HEART DISEASE, EUR J MED RES, 8, PP. 332-336, (2003); LEMAITRE R.N., KING I.B., MOZAFFARIAN D., ET AL., N-3 POLYUNSATURATED FATTY ACIDS, FATAL ISCHEMIC HEART DISEASE, AND NONFATAL MYOCARDIAL INFARCTION IN OLDER ADULTS: THE CARDIOVASCULAR HEALTH STUDY, AM J CLIN NUTR, 77, PP. 319-325, (2003); OH R., PRACTICAL APPLICATIONS OF FISH OIL (OMEGA-3 FATTY ACIDS) IN PRIMARY CARE, J AM BOARD FAM PRACT, 18, PP. 28-36, (2005); DE CATERINA R., MADONNA R., ZUCCHI R., LA ROVERE M.T., ANTIARRHYTHMIC EFFECTS OF OMEGA-3 FATTY ACIDS: FROM EPIDEMIOLOGY TO BEDSIDE, AM HEART J, 146, PP. 420-430, (2003); MORI T.A., BEILIN L.J., LONG-CHAIN OMEGA 3 FATTY ACIDS, BLOOD LIPIDS AND CARDIOVASCULAR RISK REDUCTION, CURR OPIN LIPIDOL, 12, PP. 11-17, (2001); GAMEZ R., MAZ R., ARRUZAZABALA M.L., ET AL., EFFECTS OF CONCURRENT THERAPY WITH POLICOSANOL AND OMEGA-3 FATTY ACIDS ON LIPID PROFILE AND PLATELET AGGREGATION OF RABBITS, DRUGS R D, 6, PP. 11-19, (2005); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, PP. 207-219, (2005); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); NARANJO C.A., BUSTO U., SELLERS E.M., ET AL., A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG REACTIONS, CLIN PHARMACOL THER, 30, PP. 239-245, (1981); BORN G.V., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE, 194, PP. 927-929, (1962); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE ANDMAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRA-CENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); DIN J.N., NEWBY D.E., FLAPAN A.D., OMEGA 3 FATTY ACIDS AND CARDIOVASCULAR DISEASE-FISHING FOR A NATURAL TREATMENT, BMJ, 328, PP. 30-35, (2004); MASLEY S.C., DIETARY THERAPY FOR PREVENTING AND TREATING CORONARY ARTERY DISEASE, AM FAM PHYSICIAN, 57, PP. 1299-1306, (1998); MORI T.A., BEILIN L.J., BURKE V., ET AL., INTERACTIONS BETWEEN DIETARY FAT, FISH, AND FISH OILS AND THEIR EFFECTS ON PLATELET FUNCTION IN MEN AT RISK OF CARDIOVASCULAR DISEASE, ARTERIOSCLER THROMB VASC BIOL, 17, PP. 279-286, (1997); AGREN J.J., VAISANEN S., HANNINEN O., ET AL., HEMOSTATIC FACTORS AND PLATELET AGGREGATION AFTER A FISH-ENRICHED DIET OR FISH OIL OR DOCOSAHEXAENOIC ACID SUPPLEMENTATION, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 57, PP. 419-421, (1997); WINTHER K., MYRUP B., HOLMER G., ET AL., DECREASED PLATELET ACTIVITY WITHOUT CHANGE IN FIBRINOLYTIC ACTIVITY AFTER LOW DOSAGES OF FISH OIL, ANGIOLOGY, 44, PP. 39-44, (1993); VON SCHACKY C., FISCHER S., WEBER P.C., LONG-TERM EFFECTS OF DIETARY MARINE OMEGA-3 FATTY ACIDS UPON PLASMA AND CELLULAR LIPIDS, PLATELET FUNCTION, AND EICOSANOID FORMATION IN HUMANS, J CLIN INVEST, 76, PP. 1626-1631, (1985); VON SCHACKY C., WEBER P.C., METABOLISM AND EFFECTS ON PLATELET FUNCTION OF THE PURIFIED EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS IN HUMANS, J CLIN INVEST, 76, PP. 2446-2450, (1985); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., PHARMACOLOGICAL STUDY OF THE INTERACTION BETWEEN POLICOSANOL AND ASPIRIN IN EXPERIMENTATION ANIMALS, REV IBEROAM TROMB HEMOST, 5, PP. 17-20, (1992); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998)","R. MAS; CENTER OF NATURALPRODUCTS, NATIONAL CENTER OF SCIENTIFIC RESEARCH, HAVANA CITY, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-33746021653","CURR THER RES CLIN EXP","SURGICAL MEDICAL RESEARCH CENTER;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;NATIONAL CENTER OF SCIENTIFIC RESEARCH;SURGICAL MEDICAL RESEARCH CENTER;SURGICAL MEDICAL RESEARCH CENTER;SURGICAL MEDICAL RESEARCH CENTER;SURGICAL MEDICAL RESEARCH CENTER;NATIONAL CENTER OF SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER OF SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2006, CURR THER RES CLIN EXP","CASTAÑO G, 2006, CURR THER RES CLIN EXP"
"CICERO A;ROVATI L;SETNIKAR I","CICERO, ARRIGO F. G. (7003403707); ROVATI, LUCIO C. (35429590100); SETNIKAR, IVO (7006351979)","EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROLLOWERING AGENTS A SINGLEBLIND CLINICAL INVESTIGATION",2007,"ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH","57","4",118,"10.1055/s-0031-1296582","G. DESCOVICH ATHEROSCLEROSIS AND DYSMETABOLIC DISEASE RESEARCH CENTER, D. CAMPANACCI CLINICAL MEDICINE AND APPLIED BIOTECHNOLOGY DEPARTMENT, UNIVERSITY OF BOLOGNA, BOLOGNA, ITALY;MONZA, ITALY;20052 MONZA, VIA VALOSA DI SOPRA, 9, ITALY","BERBERINE (BERB) AND A COMBINATION (COMB) OF BERBERINE (CAS 2086-83-1) WITH POLICOSANOL (CAS 557-61-9), RED YEAST EXTRACT (CONTAINING MONACOLIN, CAS 557-61-9), FOLIC ACID AND ASTAXANTHIN WERE ORALLY ADMINISTERED DAILY FOR 4 WEEKS TO 40 SUBJECTS WITH MODERATE DYSLIPIDEMIAS DIVIDED IN TWO PARALLEL GROUPS EACH OF 20 SUBJECTS. TOTAL CHOLESTEROL (TC), LDL, HDL, NON HDL, APOB, APOA, LP(A) AND TRIGLYCERIDES (TG) WERE MEASURED BEFORE AND AT THE END OF TREATMENTS. BERB AND COMB SIGNIFICANTLY REDUCED TC (RESPECTIVELY BY 16 % AND 20 %), LDL (BY 20 % AND 25 %), APOB (BY 15 % AND 29 %) AND TG (BY 22 % AND 26 %), AND INCREASED HDL (BY 6.6 % AND 5.1 %). ADVERSE EVENTS OR IMPAIRMENTS OF LIVER TRANSAMINASES OR OF CPK WERE NOT OBSERVED. IN CONCLUSION, FOOD SUPPLEMENTS CONTAINING NATURAL PRODUCTS SUCH AS BERBERINE, POLICOSANOL, RED YEAST EXTRACTS, FOLIC ACID AND ASTAXANTHIN COULD BE A USEFUL SUPPORT TO DIET AND LIFE STYLE CHANGES TO CORRECT DYSLIPIDEMIAS AND TO REDUCE CARDIOVASCULAR RISK IN SUBJECTS WITH MODERATE MIXED DYSLIPIDEMIAS. © ECV EDITIO CANTOR VERLAG.","BERBERINE; CAS 2086-83-1; CAS 557-61-9; FOOD SUPPLEMENTS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MONACOLIN; POLICOSANOL","APOLIPOPROTEIN A; APOLIPOPROTEIN B; ASTAXANTHIN; BERBERINE; FOLIC ACID; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; POLICOSANOL; RED YEAST EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ABSENCE OF SIDE EFFECTS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; DYSLIPIDEMIA; HERBAL MEDICINE; HUMAN; LIFESTYLE MODIFICATION; MEDICINAL PLANT; MONOTHERAPY; RED YEAST; TREATMENT OUTCOME; YEAST","","","III A., EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2496, (2001); SMITH JR S.C., ALLEN J., BLAIR S.N., BONOW R.O., BRASS L.M., FONAROW G.C., ET AL., AHA/ACC GUIDELINES FOR SECONDARY PREVENTION FOR PATIENTS WITH CORONARY AND OTHER ATHEROSCLEROTIC VASCULAR DISEASE: 2006 UPDATE ENDORSED BY THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, J AM COLL CARDIOL, 47, PP. 2130-2139, (2006); CHOLESTEROL TREATMENT TRIALISTS' COLLABORATORS. EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS, LANCET, 366, PP. 1267-1278, (2005); BULLER N., GILLEN D., CASCIANO R., DOYLE J., WILSON K., A PHARMACOECONOMIC EVALUATION OF THE MYOCARDIAL ISCHAEMIA REDUCTION WITH AGGRESSIVE CHOLESTEROL LOWERING (MIRACL) STUDY IN THE UNITED KINGDOM, PHARMACOECONOMICS, 21, SUPPL. 1, PP. 25-31, (2003); PROSSER L.A., STINNETT A.A., GOLDMAN P.A., WILLIAMS L.W., HUNINK M.G., GOLDMAN L., ET AL., COST-EFFECTIVENESS OF CHOLESTEROL LOWERING THERAPIES ACCORDING TO PATIENT CHARACTERISTICS, ANN INTERN MED, 132, PP. 769-774, (2000); DE BACKER G., AMBROSIONI E., BORCH-JOHNSEN K., BROTONS C., CIFKOVA R., DALLONGEVILLE J., ET AL., THIRD JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE. EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE. THIRD JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE, EUR HEART J, 24, PP. 1601-1610, (2003); PEARSON T.A., BAZZARRE T.L., DANIELS S.R., FAIR J.M., FORTMANN S.P., FRANKLIN B.A., ET AL., AMERICAN HEART ASSOCIATION GUIDE FOR IMPROVING CARDIOVASCULAR HEALTH AT THE COMMUNITY LEVEL. A STATEMENT FOR PUBLIC HEALTH PRACTITIONERS, HEALTHCARE PROVIDERS, AND HEALTH POLICY MAKERS FROM THE AMERICAN HEART ASSOCIATION EXPERT PANEL ON POPULATION AND PREVENTION SCIENCE, CIRCULATION, 107, PP. 645-651, (2003); PLATT R., CURRENT CONCEPTS IN OPTIMUM NUTRITION FOR CARDIOVASCULAR DISEASE, PREV CARDIOL, 3, PP. 83-87, (2000); SETNIKAR I., SENIN P., ROVATI L.C., ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT AND ASTAXANTHIN IN THE RABBIT, ARZNEIMITTEL-FORSCHUNG (DRUG RESEARCH), 55, PP. 312-317, (2005); GRIGORE L., REDAELLI L., MAGGI F.M., ROVATI L., CATAPANO A.L., ARMOLIPID, A NUTRITIONAL SUPPLEMENT, EFFECTIVELY REDUCES PLASMA TOTAL AND LDL CHOLESTEROL IN MODERATE HYPERCHOLESTEROLEMIA ABSTRACT, DRUGS AFFECTING LIPID METABOLISM, (2004); LANZONI G., BENVENUTI C., TORTORA L., CONTROLLED CLINICAL STUDY ON RED YEAST AND POLICOSANOLS ADDED TO DIET IN CONTROLLING CHOLESTEROLEMIA IN HYPERCHOLESTEROLEMIC SUBJECTS IN THE DAILY CLINICAL PRACTICE, ITAL HEART J, 6, SUPPL. 8, (2005); BENVENUTI C., CAPUTI A.P., CLINICAL EFFICACY AND THERAPEUTIC SAFETY OF RED YEAST AND POLICOSANOL COMBINED WITH DIET IN A CONTROLLED STUDY VERSUS DIET ONLY IN 1902 CASES OF HYPERCHOLESTEROLEMIA ABSTRACT, NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF CARDIOLOGY, (2006); CICERO A.F.G., LAGHI L., SETNIKAR I., A HELP TO DIET FROM ACTIVE NATURAL PRODUCTS: A PILOT STUDY ON LIPID PROFILE, BR J SPORTS MED, 40, (2006); BARTUS M., LOMNICKA M., LORKOWSKA B., FRANCZYK M., KOSTOGRYS R.B., PISULEWSKI P.M., ET AL., HYPERTRIGLYCERIDEMIA BUT NOT HYPERCHOLESTEROLEMIA INDUCES ENDOTHELIAL DYSFUNCTION IN THE RAT, PHARMACOL REP, 57, PP. 127-137, (2005); CARON M.F., WHITE C.M., EVALUATION OF THE ANTIHYPERLIPIDEMIC PROPERTIES OF DIETARY SUPPLEMENTS, PHARMACOTHERAPY, 21, PP. 481-487, (2001); KONG W., WEI J., ABIDI P., LIN M., INABA S., LI C., ET AL., BERBERINE IS A NOVEL CHOLESTEROL-LOWERING DRUG WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS, NAT MED, 10, PP. 1344-1351, (2004); BRUSQ J.-M., ANCELLIN N., GRONDIN P., GUILLARD R., MARTIN S., SAINILLAN Y., ET AL., INHIBITION OF LIPID SYNTHESIS THROUGH ACTIVATION OF AMP-KINASE: AN ADDITIONAL MECHANISM FOR THE HYPOLIPEMIC EFFECT OF BERBERINE, J LIPID RES, (2006); LEE Y.S., KIM W.S., KIM K.H., YOON M.J., CHO H.J., SHEN Y., ET AL., BERBERINE, A NATURAL PLANT PRODUCT, ACTIVATES AMP-ACTIVATED PROTEIN KINASE WITH BENEFICIAL METABOLIC EFFECTS IN DIABETIC AND INSULIN-RESISTANT STATES, DIABETES, 55, PP. 2256-2264, (2006); NORMAN G.R., STREINER D.L., BIOSTATISTICS. THE BARE ESSENTIAL, PP. 139-144, (2000); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHEMPY, 25, PP. 171-183, (2005); CICERO A.F., BRANCALEONI M., LAGHI L., DONATI F., MINO M., ANTIHYPERLIPIDAEMIC EFFECT OF A MONASCUS PURPUREUS BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE: A PILOT STUDY, COMPLEMENT THER MED, 13, PP. 273-278, (2005); LIN C.C., LI T.C., LAI M.M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 153, PP. 679-686, (2005); BARNES J., ANDERSEN L.A., PHILIPSON J.D., HERBAL MEDICINE, PP. 277-288, (2002); ABIDI P., ZHOU Y., JIANG J.D., LIU J., EXTRACELLULAR SIGNAL-REGULATED KINASE-DEPENDENT STABILIZATION OF HEPATIC LOW-DENSITY LIPOPROTEIN RECEPTOR MRNA BY HERBAL MEDICINE BERBERINE, ARTERIOSCLER THROMB VASC BIOL, 25, PP. 2170-2176, (2005); SHAH B.H., NAWAZ Z., SAEED S.A., GILANI A.H., AGONIST-DEPENDENT DIFFERENTIAL EFFECTS OF BERBERINE IN HUMAN PLATELET AGGREGATION, PHYTOTHER RES, 12, PP. 60-62, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); CHO B.J., IM E.K., KWON J.H., LEE K.H., SHIN H.J., OH J., ET AL., BERBERINE INHIBITS THE PRODUCTION OF LYSOPHOSPHATIDYLCHOLINE-INDUCED REACTIVE OXYGEN SPECIES AND THE ERK1/2 PATHWAY IN VASCULAR SMOOTH MUSCLE CELLS, MOL CELLS, 20, PP. 429-434, (2005); ZENG X.-H., ZENG X.-J., LI Y.-Y., EFFICACY AND SAFETY OF BERBERINE FOR CONGESTIVE HEART FAILURE SECONDARY TO ISCHEMIC OR IDIOPATHIC DILATED CARDIOMYOPATHY, AM J CARDIOL, 92, PP. 173-176, (2003)","I. SETNIKAR; ROTTAPHARM S.P.A., 20052 MONZA, VIA VALOSA DI SOPRA, 9, ITALY; EMAIL: IVO.SETNIKAR@ROTTAPHARM.COM","EDITIO CANTOR VERLAG GMBH","ENGLISH","ARZNEIM.-FORSCH. DRUG RES.","ARTICLE","ISI","2-S2.0-33846799217","ARZNEIM-FORSCH DRUG RES","UNIVERSITY OF BOLOGNA","NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"CICERO AFG, 2007, ARZNEIM-FORSCH DRUG RES","CICERO AFG, 2007, ARZNEIM-FORSCH DRUG RES"
"AWIKA J;ROONEY L","AWIKA, JOSEPH M. (6508387803); ROONEY, LLOYD W. (7004536380)","SORGHUM PHYTOCHEMICALS AND THEIR POTENTIAL IMPACT ON HUMAN HEALTH",2004,"PHYTOCHEMISTRY","65","22",678,"10.1016/j.phytochem.2004.04.001","CEREAL QUALITY LABORATORY, SOIL AND CROP SCIENCES DEPARTMENT, TEXAS AANDM UNIVERSITY, COLLEGE STATION, TX 77843-2474, UNITED STATES;CEREAL QUALITY LABORATORY, SOIL AND CROP SCIENCES DEPARTMENT, TEXAS AANDM UNIVERSITY, COLLEGE STATION, TX 77843-2474, UNITED STATES","SORGHUM IS A RICH SOURCE OF VARIOUS PHYTOCHEMICALS INCLUDING TANNINS, PHENOLIC ACIDS, ANTHOCYANINS, PHYTOSTEROLS AND POLICOSANOLS. THESE PHYTOCHEMICALS HAVE POTENTIAL TO SIGNIFICANTLY IMPACT HUMAN HEALTH. SORGHUM FRACTIONS POSSESS HIGH ANTIOXIDANT ACTIVITY IN VITRO RELATIVE TO OTHER CEREALS OR FRUITS. THESE FRACTIONS MAY OFFER SIMILAR HEALTH BENEFITS COMMONLY ASSOCIATED WITH FRUITS. AVAILABLE EPIDEMIOLOGICAL EVIDENCE SUGGESTS THAT SORGHUM CONSUMPTION REDUCES THE RISK OF CERTAIN TYPES OF CANCER IN HUMANS COMPARED TO OTHER CEREALS. THE HIGH CONCENTRATION OF PHYTOCHEMICALS IN SORGHUM MAY BE PARTLY RESPONSIBLE. SORGHUMS CONTAINING TANNINS ARE WIDELY REPORTED TO REDUCE CALORIC AVAILABILITY AND HENCE WEIGHT GAIN IN ANIMALS. THIS PROPERTY IS POTENTIALLY USEFUL IN HELPING REDUCE OBESITY IN HUMANS. SORGHUM PHYTOCHEMICALS ALSO PROMOTE CARDIOVASCULAR HEALTH IN ANIMALS. SUCH PROPERTIES HAVE NOT BEEN REPORTED IN HUMANS AND REQUIRE INVESTIGATION, SINCE CARDIOVASCULAR DISEASE IS CURRENTLY THE LEADING KILLER IN THE DEVELOPED WORLD. THIS PAPER REVIEWS AVAILABLE INFORMATION ON SORGHUM PHYTOCHEMICALS, HOW THE INFORMATION RELATES TO CURRENT PHYTONUTRIENT RESEARCH AND HOW IT HAS POTENTIAL TO COMBAT COMMON NUTRITION-RELATED DISEASES INCLUDING CANCER, CARDIOVASCULAR DISEASE AND OBESITY. © 2004 ELSEVIER LTD. ALL RIGHTS RESERVED.","ANTHOCYANINS; CANCER; CARDIOVASCULAR DISEASE; GRAMINEAE; HUMAN HEALTH; OBESITY; PHENOLIC ACIDS; PHYTOCHEMICALS; PHYTOSTEROLS; POLICOSANOLS; SORGHUM BICOLOR; TANNINS","ANIMALS; ANTHOCYANINS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CEREALS; FATTY ALCOHOLS; FLAVONOIDS; FRUIT; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; OBESITY; PHENOLS; PHYTOSTEROLS; PROANTHOCYANIDINS; SORGHUM; TANNINS; ANIMALIA; POACEAE; SORGHUM BICOLOR; 7 O METHYLAPIGENINIDIN; ANTHOCYANIN; APIGENINIDIN; APIGENINIDIN 5 GLUCOSIDE; CAFFEIC ACID; CATECHIN; CINNAMIC ACID; COUMARIC ACID; EPICATECHIN GALLATE; ERIODICTOYL; ERIODICTOYL 5 O BETA GLUCOSIDE; FERULIC ACID; FLAVAN DERIVATIVE; GALLIC ACID; GENTISIC ACID; LUTEOLINIDIN; LUTEOLINIDIN 5 GLUCOSIDE; NARINGENIN; PHENOL DERIVATIVE; PHYTOSTEROL; POLICOSANOL; PROCYANIDIN DERIVATIVE; PROTOCATECHUIC ACID; SALICYLIC ACID; SINAPIC ACID; SYRINGIC ACID; TANNIN DERIVATIVE; TAXIFOLIN; TAXIFOLIN 7 O BETA GLUCOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CEREAL; DISEASE CONTROL; DRUG ACTIVITY; DRUG POTENCY; FOOD INTAKE; FRUIT; HUMAN; NONHUMAN; NUTRITIONAL VALUE; OBESITY; PHYTOCHEMISTRY; REVIEW; SORGHUM","UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT, USAID","WE THANK XIANLI WU AND RON PRIOR OF ARKANSAS CHILDREN'S NUTRITION CENTER, LITTLE ROCK, AR, FOR PROVIDING ORAC DATA ON FRUITS; CHERYL EARP OF RICETECH, BEAMOUNT, TX, FOR THE SORGHUM BRAN PHOTOMICROGRAPH; CASSANDRA MCDONOUGH AND RALPH WANISKA OF CEREAL QUALITY LAB, TEXAS A&M FOR VALUABLE ADVICE. THE REVIEW IS PARTLY BASED ON RESEARCH SUPPORTED BY TEXAS ADVANCED TECHNOLOGY PROGRAM AND USAID TITLE XII COLLABORATIVE RESEARCH SUPPORT PROGRAM. ","ABDEL-AAL E.M., HUCL P., COMPOSITION AND STABILITY OF ANTHOCYANINS IN BLUE-GRAINED WHEAT, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 2174-2180, (2003); ADAMSON G.E., LAZARUS S.A., MITCHELL A.E., PRIOR R.L., CAO G., JACOBS P.H., KREMERS B.G., HAMMERSTONE J.F., RUCHER R.B., RITTER K.A., SCHMIDTZ H.H., HPLC METHOD FOR THE QUANTIFICATION OF PROCYANIDINS IN COCOA AND CHOCOLATE SAMPLES AND CORRELATION TO TOTAL ANTIOXIDANT CAPACITY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 47, PP. 4184-4188, (1999); ADOM K.K., LIU R.H., ANTIOXIDANT ACTIVITY OF GRAINS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 50, PP. 6182-6187, (2002); AGULLO E., RODRIGUEZ M.S., EVALUATION OF 3 RAPID METHODS TO DETERMINE TANNINS IN SORGHUM GRAINS, ANALES DE LA ASOCIACIÓN QUÍMICA ARGENTINA, 83, PP. 83-87, (1995); AL-MAMARY M., AL-HABORI M., AL-AGHBARI A., AL-OBEIDI A., IN VIVO EFFECTS OF DIETARY SORGHUM TANNINS ON RABBIT DIGESTIVE ENZYMES AND MINERAL ABSORPTION, NUTRITION RESEARCH, 21, PP. 1393-1401, (2001); AMBULA M.K., OGUHO G.W., TUITOEK J.K., EFFECTS OF SORGHUM TANNINS, A TANNIN BINDER (POLYVINYLPYRROLIDONE) AND SORGHUM INCLUSION LEVEL ON THE PERFORMANCE OF BROILER CHICKS, ASIAN-AUSTRALIAN JOURNAL OF ANIMAL SCIENCE, 14, PP. 1276-1281, (2001); ANDERSON J.W., WHOLE GRAIN PROTECTS AGAINST ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, PROCEEDINGS OF THE NUTRITION SOCIETY, 62, PP. 135-142, (2003); ANDREASEN M.F., CHRISTENSEN L.P., MEYER A.S., HANSEN A.S., CONTENTS OF PHENOLIC ACIDS AND FERULIC ACID DEHYDRODIMERS IN 17 RYE (SECALE CEREALE L.) VARIETIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 48, PP. 2837-2842, (2000); ANDREASEN M.F., KROON P.A., WILLIAMSON G., GARCIA-CONESA M., ESTERASE ACTIVITY ABLE TO HYDROLYZE DIETARY ANTIOXIDANT HYDROXYCINNAMATES IS DISTRIBUTED ALONG THE INTESTINE OF MAMMALS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 5679-5684, (2001); ANDREASEN M.F., KROON P.A., WILLIAMSON G., GARCIA-CONESA M., INTESTINAL RELEASE AND UPTAKE OF PHENOLIC ANTIOXIDANT DIFERULIC ACID, FREE RADICAL BIOLOGY AND MEDICINE, 31, PP. 304-314, (2001); ASTLEY S.B., DIETARY ANTIOXIDANTS - PAST, PRESENT AND FUTURE?, TRENDS IN FOOD SCIENCE AND TECHNOLOGY, 14, PP. 63-98, (2003); AVATO P., BIANCHI G., MURELLI C., ALIPHATIC AND CYCLIC LIPID COMPONENTS OF SORGHUM PLANT ORGANS, PHYTOCHEMISTRY, 29, PP. 1073-1078, (1990); AWIKA J.M., ANTIOXIDANT PROPERTIES OF SORGHUM, (2003); AWIKA J.M., (2000); AWIKA J.M., DYKES L., GU L., ROONEY L.W., PRIOR R.L., PROCESSING OF SORGHUM (SORGHUM BICOLOR) AND SORGHUM PRODUCTS ALTERS PROCYANIDIN OLIGOMER AND POLYMER DISTRIBUTION AND CONTENT, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 5516-5521, (2003); AWIKA J.M., ROONEY L.W., WU X., PRIOR R.L., CISNEROS-ZEVALLOS L., SCREENING METHODS TO MEASURE ANTIOXIDANT ACTIVITY OF SORGHUM (SORGHUM BICOLOR) AND SORGHUM PRODUCTS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 6657-6662, (2003); BACON J.R., RHODES M.J.C., DEVELOPMENT OF A COMPETITIVE ASSAY FOR THE EVALUATION OF OF THE BINDING OF HUMAN PAROTID SALIVARY PROTEINS TO DIETARY COMPLEX PHENOLS AND TANNINS USING A PEROXIDASE-LABELLED TANNIN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 5083-5088, (1998); BATE-SMITH E.C., LUTEOFOROL (3<SUP>′</SUP>,4,4<SUP>′</SUP>,5,7- PENTAHYDROXYFLAVAN) IN SORGHUM VULGARE L, PHYTOCHEMISTRY, 8, PP. 1803-1810, (1969); BLESSIN C.W., VANETTEN C.H., DIMLER R.J., AN EXAMINATION OF ANTHOCYANOGENS IN GRAIN SORGHUMS, CEREAL CHEMISTRY, 40, PP. 241-250, (1963); BORS W., MICHEL C., STETTMAIER K., ELECTRON PARAMAGNETIC RESONANCE STUDIES OF RADICAL SPECIES OF PROANTHOCYANIDINS AND GALLATE ESTERS, ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 374, PP. 347-355, (2000); BOVERIS A.D., GALATRO A., SAMBROTTA L., RICCO R., GURNI A.A., PUNTARULO S., ANTIOXIDANT CAPACITY OF 3-DEOXYANTHOCYANIDIN FROM SOYBEAN, PHYTOCHEMISTRY, 58, PP. 1097-1105, (2001); BRANDON M.J., FOO L.Y., PORTER L.J., MEREDITH P., PROANTHOCYANIDINS OF BARLEY AND SORGHUM COMPOSITION AS A FUNCTION OF MATURITY OF BARLEY EARS, PHYTOCHEMISTRY, 21, PP. 2953-2957, (1982); BRIDLE P., TIMBERLAKE C.F., ANTHOCYANINS AS NATURAL FOOD COLORS-SELECTED ASPECTS, FOOD CHEMISTRY, 58, PP. 103-109, (1997); BRONNUN-HANSEN K., JACOBSEN F., FLINK J.M., ANTHOCYANIN COLORANTS FROM ELDERBERRY (SAMBUCUS NIGRA L.). 1. PROCESS CONSIDERATION OF PRODUCTION OF LIQUID EXTRACT, JOURNAL OF FOOD TECHNOLOGY, 20, PP. 703-711, (1985); BUNGER W.B., KUMMEROW F.A., A COMPARISON OF SEVERAL METHODS FOR THE SEPARATION OF UNSAPONIFIABLE MATERIAL FROM CARNAUBA AND GRAIN SORGHUM WAXES, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 28, PP. 121-123, (1951); BURNS R.E., METHODS FOR ESTIMATION OF TANNIN IN GRAIN SORGHUM, AGRONOMY JOURNAL, 63, (1971); CARMONA A., BORGUDD L., BORGES G., LEVY-BENSHIMOL A., EFFECTS OF BLACK BEAN TANNINS ON IN VITRO CARBOHYDRATE DIGESTION AND ABSORPTION, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 7, PP. 445-450, (1996); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., ALVAREZ E., EFFECTS OF LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOLOGY RESEARCH, 22, 34, PP. 89-99, (2002); CEVALLOS-CASALS B.A., CISNEROS-ZEVALLOS L., STOICHIOMETRIC AND KINETIC STUDIES OF PHENOLIC ANTIOXIDANTS FROM ANDEAN PURPLE CORN AND RED-FLESHED SWEET POTATO, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 3313-3319, (2003); CHEN F., COLE P., MI Z.B., XING L.Y., CORN AND WHEAT-FLOUR CONSUMPTION AND MORTALITY FROM ESOPHAGEAL CANCER IN SHANXI, CHINA, INTERNATIONAL JOURNAL OF CANCER, 53, PP. 902-906, (1993); CHO S.-H., CHOI Y., HA T.-Y., IN VITRO AND IN VIVO EFFECTS OF PROSOMILLET, BUCKWHEAT AND SORGHUM ON CHOLESTEROL METABOLISM, FASEB JOURNAL, 14, 4, (2000); CHUNG K.-T., TIT Y.W., CHENG I.W., YAO-WEN H., YUAN L., TANNINS AND HUMAN HEALTH: A REVIEW, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 38, 6, PP. 421-464, (1998); CLIFFORD M.N., ANTHOCYANINS - NATURE, OCCURRENCE AND DIETARY BURDEN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 80, PP. 1063-1072, (2000); COUSINS B.W., TANKSLEY T.D., KNABE D.A., ZEBROWSKA T., NUTRIENT DIGESTIBILITY AND PERFORMANCE OF PIGS FED SORGHUMS VARYING IN TANNIN CONCENTRATION, JOURNAL OF ANIMAL SCIENCE, 53, PP. 1524-1529, (1981); CUMMINGS D.P., AXTEL J.D., RELATIONSHIPS OF PIGMENTED TESTA TO NUTRITIONAL QUALITY OF SORGHUM GRAIN IN INHERITANCE AND IMPROVEMENT OF PROTEIN QUALITY IN SORGHUM, (1973); DALTON J.L., MITCHELL H.L., FRACTIONATION OF GRAIN SORGHUM WAX, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 7, PP. 570-573, (1959); DEPREZ S., BREZILLON C., RABOT S., PHILIPPE C., MILA I., LAPIERRE C., SCALBERT A., POLYMERIC PROANTHOCYANIDINS ARE CATABOLIZED BY HUMAN COLONIC MICROFLORA INTO LOW-MOLECULAR WEIGHT PHENOLIC ACIDS, JOURNAL OF NUTRITION, 130, PP. 2733-2738, (2000); DEPREZ S., MILA I., HUNEAU J.F., TOME D., SCALBERT A., TRANSPORT OF PROANTHOCYANIDIN DIMER, TRIMER, AND POLYMER ACROSS MONOLAYERS OF HUMAN INTESTINAL EPITHELIAL CACO-2 CELLS, ANTIOXIDANTS AND REDOX SIGNALING, 3, PP. 957-967, (2001); DESHPANDE S.S., CHERYAN M., TANNIN ANALYSIS OF FOOD PRODUCTS, CRC CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 24, PP. 401-449, (1986); DESHPANDE S.S., CHERYAN M., SALUNKHE D.K., EVALUATION OF VANILLIN ASSAY FOR TANNIN ANALYSIS OF DRY BEANS, JOURNAL OF FOOD SCIENCE, 50, PP. 905-910, (1985); DUNFORD N.T., KING J.W., PHYTOSTEROL ENRICHMENT OF RICE BRAN BY A SUPERCRITICAL CARBON DIOXIDE FRACTION TECHNIQUE, JOURNAL OF FOOD SCIENCE, 65, PP. 1395-1399, (2000); EARP C.F., DOHERTY C.A., ROONEY L.W., FLUORESCENCE MICROSCOPY OF THE PERICARP, ALEURONE LAYER AND ENDOSPERM CELL WALLS OF THREE SORGHUM CULTIVARS, CEREAL CHEMISTRY, 60, PP. 408-410, (1983); ELLER M.S., OSTROM K., GILCHREST B.A., DNA DAMAGE ENHANCES MELANOGENESIS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 93, PP. 1087-1092, (1996); ELLIS E.B., MORPHOLOGICAL CHARACTERISTICS IN RELATION TO SEED DETERIORATION IN SORGHUM, (1972); FANG N., YU S., BADGER T., CHARACTERIZATION OF TRITERPENE ALCOHOL AND STEROL FERULATES IN RICE BRAN USING LC-MS/MS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 3260-3267, (2003); FEATHERSON W.R., ROGLER J.C., INFLUENCE OF TANNIN ON THE UTILIZATION OF SORGHUM GRAIN BY RATS AND CHICKENS, NUTRITION REPORTS INTERNATIONAL, 11, PP. 491-497, (1975); FENSTER C., WHITE FOOD SORGHUM IN THE AMERICAN DIET, US GRAINS COUNCIL 43RD BOARD OF DELEGATES' MEETING, (2003); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECTS OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCHIVES OF MEDICAL RESEARCH, 28, PP. 355-360, (1997); FRANCIS F.J., FOOD COLORANTS: ANTHOCYANINS, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 28, PP. 273-314, (1989); FULEKI T., FRANCIS F.J., QUANTITATIVE METHODS FOR ANTHOCYANINS. 1. EXTRACTION AND DETERMINATION OF TOTAL ANTHOCYANIN IN CRANBERRIES, JOURNAL OF FOOD SCIENCE, 33, PP. 72-77, (1968); GARCIA-VIGUERA C., ZAFRILLA P., TOMAS-BARBERAN F.A., THE USE OF ACETONE AS AN EXTRACTION SOLVENT FOR ANTHOCYANINS FROM STRAWBERRY FRUIT, PHYTOCHEMICAL ANALYSIS, 9, PP. 247-277, (1998); GOMEZ-CORDOVEZ, BARTOLOMEZ B., VIEIRA W., VIRADIR V.M., EFFECTS OF WINE PHENOLICS AND SORGHUM TANNINS ON TYROSINASE ACTIVITY AND GROWTH OF MELANOMA CELLS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 1620-1624, (2001); GORDON L.A., (2001); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); GOUS F., TANNINS AND PHENOLS IN BLACK SORGHUM, (1989); GRIMMER H.R., PARBHOO V., MCGARTH R.M., ANTIMUTAGENICITY OF POLYPHENOL-RICH FRACTIONS FROM SORGHUM BICOLOR GRAIN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 59, PP. 251-256, (1992); GRINBERG L.N., NEWMARK H., KITROSSKY N., RAHAMIN E., CHEVION M., RACHMILEWITZ E.A., PROTECTIVE EFFECT OF TEA POLYPHENOLS AGAINST OXIDATIVE DAMAGE TO RED BLOOD CELL, BIOCHIMICA ET BIOPHYSICA ACTA, 1201, PP. 284-288, (1997); GU L., KELM M., HAMMERSTONE J.F., BEECHER G., CUNNIGHAM D., VANNOZZI S., PRIOR L., FRACTIONATION OF POLYMERIC PROCYANIDINS FROM LOWBUSH BLUEBERRY AND QUANTIFICATION OF PROCYANIDINS IN SELECTED FOODS WITH AN OPTIMIZED NORMAL-PHASE HPLC-MS FLUORESCENT DETECTION METHOD, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 50, PP. 4852-4860, (2002); GUJER R., MAGNOLATO D., SELF R., GLUCOSYLATED FLAVONOIDS AND OTHER PHENOLIC COMPOUNDS FROM SORGHUM, PHYTOCHEMISTRY, 25, PP. 1431-1436, (1986); GUPTA R.K., HASLAM E., PLANT PROANTHOCYANIDINS. 5. SORGHUM POLYPHENOLS, JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, 4, 8, PP. 892-896, (1978); HAGERMAN A.E., BUTLER L.G., PROTEIN PRECIPITATION METHOD FOR THE QUANTITATIVE DETERMINATION OF TANNINS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 26, PP. 809-812, (1978); HAGERMAN A.E., BUTLER L.G., CONDENSED TANNIN PURIFICATION AND CHARACTERIZATION OF TANNIN-ASSOCIATED PROTEINS, JOURNAL OF AGRICULTRUAL AND FOOD CHEMISTRY, 28, PP. 947-952, (1980); HAGERMAN A.E., BUTLER L.G., THE SPECIFICITY OF PROANTHOCYANIDIN-PROTEIN INTERACTIONS, JOURNAL OF BIOLOGICAL CHEMISTRY, 256, PP. 4494-4497, (1981); HAGERMAN A.E., RIEDL K.M., JONES G.A., SOVIK K.N., RITCHARD N.T., HARTZFELD P.W., RIECHEL T.K., HIGH MOLECULAR WEIGHT PLANT POLYPHENOLICS (TANNINS) AS BIOLOGICAL ANTIOXIDANTS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 1887-1892, (1998); HAHN D.H., PHENOLS OF SORGHUM AND MAIZE: THE EFFECT OF GENOTYPE AND ALKALI PROCESSING, (1984); HAHN D.H., ROONEY L.W., FAUBION J.M., SORGHUM PHENOLIC ACIDS, THEIR HPLC SEPARATION AND THEIR RELATION TO FUNGAL RESISTANCE, CEREAL CHEMISTRY, 60, PP. 255-259, (1983); HAHN D.H., ROONEY L.W., EFFECTS OF GENOTYPE ON TANNINS AND PHENOLS OF SORGHUM, CEREAL CHEMISTRY, 63, PP. 4-8, (1986); HAMMERSTONE J.F., LAZARUS S.A., MITCHEL A.E., RUCKER R., SCHMITZ H.H., IDENTIFICATION OF PROCYANIDINS IN COCOA (THEOBROMA COCOA) AND CHOCOLATE USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY/MASS SPECTROPHOTOMETRY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 47, PP. 490-496, (1999); HAMMERSTONE J.F., LAZARUS S.A., SCHMITZ H.H., PROCYANIDIN CONTENT AND VARIATION IN SOME COMMONLY CONSUMED FOODS, JOURNAL OF NUTRITION, 130, (2000); HASLAM E., POLYPHENOL-PROTEIN INTERACTIONS, BIOCHEMICAL JOURNAL, 139, PP. 285-288, (1974); HEINONEN I.M., MEYER A.S., FRANKEL E.N., ANTIOXIDANT ACTIVITY OF BERRY PHENOLICS ON HUMAN LOW-DENSITY LIPOPROTEIN AND LIPOSOME OXIDATION, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 4107-4112, (1998); HELSPER J.P.F.G., KOLODZIEJ H., HOOGENDIJK J.M., VAN NOREL A., CHARACTERIZATION AND TRYPSIN INHIBITOR ACTIVITY OF PROANTHOCYANIDINS FROM VICIA FABA, PHYTOCHEMISTRY, 34, PP. 1255-1260, (1993); HIGDON J.V., FREI B., TEA CATECHINS AND POLYPHENOLS: HEALTH EFFECTS, METABOLISM, AND ANTIOXIDANT FUNCTIONS, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 43, PP. 89-143, (2003); HILL J.O., WYATT H.R., REED G.W., PETERS J.C., OBESITY AND THE ENVIRONMENT: WHERE DO WE GO FROM HERE?, SCIENCE, 299, PP. 853-855, (2003); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., PROPERTIES, COMPOSITION, AND ANALYSIS OF GRAIN SORGHUM WAX, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 79, PP. 521-526, (2002); JAMBUBATHAN R., MERTZ E.T., RELATIONSHIP BETWEEN TANNIN LEVELS, RAT GROWTH, AND DISTRIBUTION OF PROTEINS IN SORGHUM, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 21, PP. 692-696, (1973); JONKER D., VAN DER HOEK G.D., GLATZ C.H., HOMAN C., POSTHUMUS M.A., KATAN M.B., COMBINED DETERMINATION OF FREE, ESTERIFIED AND GLYCOSYLATED PLANT STEROLS IN FOODS, NUTRITION REPORTS INTERNATIONAL, 32, PP. 943-951, (1985); KALLITHRAKA S., GARCIA-VIGUERA C., BRIDLE P., BAKKER J., SURVEY OF SOLVENTS FOR THE EXTRACTION OF GRAPE SEED PHENOLICS, PHYTOCHEMICAL ANALYSIS, 6, PP. 265-267, (1995); KAMBAL A.E., BATE-SMITH E.C., A GENETIC AND BIOCHEMICAL STUDY ON PERICARP PIGMENTS IN A CROSS BETWEEN TWO CULTIVARS OF GRAIN SORGHUM, SORGHUM BICOLOR, HEREDITY, 37, PP. 413-416, (1976); KAMEI H., KOJIMA T., HASEGAWA M., KOIDE T., UMEDA T., YUKAWA T., TERABE K., SUPPRESSION OF TUMOR CELL GROWTH BY ANTHOCYANINS IN-VITRO, CANCER INVESTIGATION, 13, PP. 590-594, (1995); KARAIVANOVA M., DRENSKA D., OVCHAROV R., A MODIFICATION OF THE TOXIC EFFECTS OF PLATINUM COMPLEXES WITH ANTHOCYANINS, EKSPERIMETNALNA MEDITSNA I MORFOLOGIIA, 29, 2, PP. 19-24, (1990); KELI S.O., HERTOG M.G., FESKEN E.J., KROMHOUT D., DIETARY FLAVONOIDS, ANTIOXIDANT VITAMINS, AND INCIDENCES OF STROKE: THE ZUTPHEN STUDY, ARCHIVES OF INTERNAL MEDICINE, 156, PP. 637-642, (1996); KENNEDY J.A., HAYASAKA Y., VIDAL S., WATERS E.J., JONES G.P., COMPOSITION OF GRAPE SKIN PROANTHOCYANIDINS AT DIFFERENT STAGES OF BERRY DEVELOPMENT, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 5348-5355, (2001); KING D., FAN M.Z., EJETA G., ASEM E.K., ADEOLA O., THE EFFECTS OF TANNINS ON NUTRIENT UTILIZATION IN THE WHITE PEKIN DUCK, BRITISH POULTRY SCIENCE, 41, PP. 629-630, (2000); KLOPFENSTEIN C.F., VARRIANO-MARSTON E., HOSENEY R.C., CHOLESTEROL-LOWERING EFFECT OF SORGHUM DIET IN GUINEA PIGS, NUTRITION REPORTS INTERNATIONAL, 24, PP. 621-626, (1981); KROON P.A., FAULDS C.B., RYDEN P., ROBERTSON J.A., WILLIAMSON G., RELEASE OF COVALENTLY BOUND FERULIC ACID FROM FIBER IN HUMAN COLON, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 45, PP. 661-667, (1997); KRUEGER C.G., VESTLING M.A., REED J.D., MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY OF HETEROPOLYFLAVAN-3-OLS AND GLUCOSYLATED HETEROPOLYFLAVANS IN SORGHUM (SORGHUM BICOLOR (L.) MOENCH), JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 51, PP. 538-543, (2003); KUSHI L.H., MEYER K.A., JACOBS D.R., CEREALS, LEGUMES, AND CHRONIC DISEASE RISK REDUCTION: EVIDENCE FROM EPIDEMIOLOGIC STUDIES, AMERICAN JOURNAL OF CLINICAL NUTRITION, 70, SUPPL., (1999); LAPIDOT T., HAREL S., AKIRI B., GRANIT R., KANNER J., PH-DEPENDENT FORMS OF RED WINE ANTHOCYANINS AS ANTIOXIDANTS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 47, PP. 67-70, (1999); LEA A.G.H., BRIDLE P., TIMBERLAKE C.F., SINGLETON V.L., THE PROCYANIDINS OF WHITE GRAPES AND WINES, AMERICAN JOURNAL OF ENOLOGY AND VITICULTURE, (1979); LEE S.M., PAN B.S., EFFECTS OF DIETARY SORGHUM DISTILLERY RESIDUE ON HEMATOLOGICAL CHARACTERISTICS OF CULTURED GREY MULLET (MUGIL CEPHALUS) - AN ANIMAL MODEL FOR PRESCREENING ANTIOXIDANT AND BLOOD THINNING ACTIVITIES, JOURNAL OF FOOD BIOCHEMISTRY, 27, PP. 1-18, (2003); LIETTI A., CRISTONI A., PICCI M., STUDIES OF VACCINIUM MYRTILLUS ANTHOCYANOSIDES. I. VASOPROTECTIVE AND ANTI-INFLAMMATORY ACTIVITY, ARZNEIM-FORSCH., 26, PP. 829-832, (1976); LIN B.B., CHEN H.L., HUANG P.C., EFFECTS OF INSTANT PAUCHONG TEA, CATECHIN, AND CAFFEINE ON SERUM-CHOLESTEROL AND SERUM LOW-DENSITY-LIPOPROTEIN IN MICE, NUTRITION REPORTS INTERNATIONAL, 34, PP. 821-829, (1986); LIZARDO R., PEINIAU J., AUMAITRE A., EFFECT OF SORGHUM ON PERFORMANCE, DIGESTIBILITY OF DIETARY-COMPONENTS AND ACTIVITIES OF PANCREATIC AND INTESTINAL ENZYMES IN THE WEANED PIGLET, ANIMAL FEED SCIENCE AND TECHNOLOGY, 56, PP. 67-82, (1995); LOTITO S.B., ACTIS-GORETTA L., RENART M.L., CALIGIURI M., REIN D., SCHMITZ H.H., STEINBERG F.M., KEEN C.L., FRAGA C.G., INFLUENCE OF OLIGOMER CHAIN LENGTH ON ANTIOXIDANT ACTIVITY OF PROCYANIDINS, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 276, PP. 945-951, (2000); LU Y., FOO L.Y., UNUSUAL ANTHOCYANIN REACTIONS WITH ACETONE LEADING TO PROANTHOCYANIN FORMATION, TETRAHEDRON LETTERS, 42, PP. 1371-1373, (2001); MAILLARD M.N., BERSET C., EVOLUTION OF ANTIOXIDANT ACTIVITY DURING KILNING - ROLE OF INSOLUBLE BOUND PHENOLIC-ACIDS OF BARLEY AND MALT, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 43, PP. 1789-1793, (1995); MAKKAR H.P.S., PROTEIN PRECIPITATION METHODS FOR QUANTITATION OF TANNINS: A REVIEW, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 37, PP. 1197-1202, (1989); MATSUMOTO H., INABA H., KISHI M., TOMINAGA S., HIRAYAMA M., TSUDA T., ORALLY ADMINISTERED DELPHINIDIN-3-RUTINOSIDE AND CYANIDIN-3-RUTINOSIDE ARE DIRECTLY ABSORBED IN RATS AND HUMANS AND APPEAR IN BLOOD AS THE INTACT FORMS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 1546-1551, (2001); MAXSON E.D., ROONEY L.W., EVALUATION OF METHODS FOR TANNIN ANALYSIS IN SORGHUM GRAIN, CEREAL CHEMISTRY, 49, PP. 719-729, (1972); MCCARTHY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MEDICAL HYPOTHESES, 59, PP. 268-279, (2002); MILBURY P.E., CAO G., PRIOR R.L., BLUMBERG J., BIOAVAILABILITY OF ELDERBERRY ANTHOCYANINS, MECHANISMS OF AGING AND DEVELOPMENT, 123, PP. 997-1006, (2002); MISRA K., SESHADRI T.R., CHEMICAL COMPONENTS OF SORGHUM DURRA GLUMES, INDIAN JOURNAL OF CHEMISTRY, 5, (1967); MITRE-DIESTE C.M., GORDON L.A., AWIKA J., SUHENDRO E.L., ROONEY L.W., COOKIES MADE WITH SORGHUM BRANS HIGH IN PHENOLS AND CATECHINS, (2000); MOREAU R.A., POWELL M.J., HICKS K.B., EXTRACTION AND QUANTITATIVE ANALYSIS OF OIL FROM COMMERCIAL CORN, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 44, PP. 2149-2154, (1996); MORTON J.F., TENTATIVE CORRELATIONS OF PLANT USAGE AND ESOPHAGEAL CANCER ZONES, ECONOMIC BOTANY, 24, PP. 217-226, (1970); MORTON J.F., FURTHER ASSOCIATION OF PLANT TANNINS AND HUMAN CANCER, QUARTERLY JOURNAL OF CRUDE DRUG RESEARCH, 12, PP. 1829-1841, (1972); MOYER A.R., HUMER K.E., FINN C.E., FREI B., WROLSTAD R.E., ANTHOCYANINS, PHENOLICS, AND ANTIOXIDANT CAPACITY IN DIVERSE SMALL FRUITS: VACCINIUM, RUBUS, AND RIBERS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 50, PP. 519-525, (2002); MURIU J.I., NJOKA-NJIRU E.N., TUITOEK J.K., NANUA J.N., EVALUATION OF SORGHUM (SORGHUM BICOLOR) AS REPLACEMENT FOR MAIZE IN THE DIET OF GROWING RABBITS (ORYCTOLAGUS CUNICULUS), ASIAN-AUSTRALIAN JOURNAL OF ANIMAL SCIENCE, 15, PP. 565-569, (2002); NACZK M., SHAHIDI F., NUTRITIONAL IMPLICATIONS OF CANOLA CONDENSED TANNINS, ANTINUTRIENTS AND CHEMICALS IN FOOD: ACS SYMPOSIUM SERIES, 662, PP. 186-208, (1997); NGUZ K., VAN GAVER D., HUYGHEBAERT A., IN NITRO INHIBITION OF DIGESTIVE ENZYMES BY SORGHUM CONDENSED TANNINS (SORGHUM BICOLOR L. (MOENCH)), SCIENCES DES ALIMENTS, 18, PP. 507-514, (1998); NIP W.K., BURNS E.E., PIGMENT CHARACTERIZATION IN GRAIN SORGHUM. I. RED VARIETIES, CEREAL CHEMISTRY, 46, PP. 490-495, (1969); NIP W.K., BURNS E.E., PIGMENT CHARACTERIZATION IN GRAIN SORGHUM. II. WHITE VARIETIES, CEREAL CHEMISTRY, 48, PP. 74-80, (1971); NORDKVIST E., SALOMONSSON A.-C., AMAN P., DISTRIBUTION OF INSOLUBLE BOUND PHENOLIC ACIDS IN BARLEY GRAIN, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 35, PP. 657-661, (1984); OSTLUND R.E., PHYTOSTEROLS IN HUMAN NUTRITION, ANNUAL REVIEWS OF NUTRITION, 22, PP. 533-549, (2002); OTERDOOM H.J., TANNIN, SORGHUM, AND OESOPHAGEAL CANCER, LANCET, 2, 8450, (1985); PACE-ASCIAK C.R., ROUNOVA O., HAHN S.E., DIAMANDIS E.P., GOLDBERG D.M., WINE AND GRAPE JUICE AS MODULATORS OF PLATELET AGGREGATION IN HEALTHY HUMAN SUBJECTS, CLINICA CHIMICA ACTA, 246, PP. 163-182, (1996); PALE E., KOUDABONAFOS M., NACRO M., VANHAELEN M., VANHAELENFASTRE R., OTTINGER R., 7-O-METHYLAPIGENINIDIN, AN ANTHOCYANIDIN FROM SORGHUM CAUDATUM, PHYTOCHEMISTRY, 45, PP. 1091-1092, (1997); PARBHOO V., GRIMMER H.R., CAMERON-CLARKE A., MCGARTH R.M., INDUCTION OF CYTOCHROME P-450 IN RAT LIVER BY A POLYPHENOL-RICH EXTRACT FROM A BIRD-RESISTANT SORGHUM GRAIN, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 69, PP. 247-252, (1995); PEPPING J., POLICOSANOL, AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 60, PP. 1112-1114, (2003); PIETTA P.G., GARDANA C., MAURI P.L., IDENTIFICATION OF GINKGO BILOBA FLAVONOL METABOLITES AFTER ORAL ADMINISTRATION TO HUMANS, JOURNAL OF CHROMATOGRAPHY, 693, PP. 249-255, (1997); PIIRONEN V., TOIVO J., LAMPI A.M., PLANT STEROLS IN CEREALS AND CEREAL PRODUCTS, CEREAL CHEMISTRY, 79, PP. 148-154, (2002); PRICE M.L., VAN SCOYOC S., BUTLER L.G., A CRITICAL EVALUATION OF VANILLIN REACTION AS AN ASSAY FOR TANNIN IN SORGHUM, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 26, PP. 1214-1218, (1978); PRIOR R.L., CAO G., MARTIN A., SOFIC E., MCEWENS J., O'BRIEN C., LISCHNER N., EHLENFELDT M., KALT W., KREWER G., MAINLAND C.M., ANTIOXIDANT CAPACITY AS INFLUENCED BY TOTAL PHENOLIC AND ANTHOCYANIN CONTENT, MATURITY, AND VARIETY OF VACCINIUM SPECIES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 46, PP. 2686-2693, (1998); PUTMAN L.J., BUTLER L.G., SEPARATION OF HIGH MOLECULAR WEIGHT SORGHUM PROCYANIDINS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 37, PP. 943-946, (1989); RIEDL K.M., HAGERMAN A.E., TANNIN-PROTEIN COMPLEXES AS RADICAL SCAVENGERS AND RADICAL SINKS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 49, PP. 4917-4923, (2001); REMY S., FULCRAND H., LABARBE B., CHEYNIER V., MOUTONET M., FIRST CONFIRMATION IN RED WINE OF PRODUCTS RESULTING FROM DIRECT ANTHOCYANIN-TANNIN REACTIONS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 80, PP. 745-751, (2000); RENAUD S., DE LORGERIL M., WINE, ALCOHOL, PLATELETS, AND THE FRENCH PARADOX FOR CORONARY HEART DISEASE, LANCET, 339, PP. 1523-1526, (1992); RIGAUD J., ESCRIBANO-BAILON M.T., PRIEUR C., SOUQUET J.M., CHEYNIER V., NORMAL-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC SEPARATION OF PROCYANIDINS FROM CACAO BEANS AND GRAPE SEEDS, JOURNAL OF CHROMATOGRAPHY A, 654, PP. 255-260, (1993); RIOS L.Y., BENNETT R.N., LAZARUS S.A., REMESY C., SCALBERT A., WILLIAMSON G., COCOA PROCYANIDINS ARE STABLE DURING GASTRIC TRANSIT IN HUMANS, AMERICAN JOURNAL OF CLINICAL NUTRITION, 76, PP. 1106-1110, (2002); ROGERS E.J., RICE S.M., NICOLOSI R.J., CARPENTER D.R., MCCLELLAND C.A., ROMANCZYK L.J., IDENTIFICATION AND QUANTIFICATION OF Y-ORYZANOL COMPONENTS AND SIMULTANEOUS ASSESSMENT OF TOCOLS IN RICE BRAN OIL, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 70, PP. 301-307, (1993); ROONEY L.W., FOOD AND NUTRITIONAL QUALITY OF SORGHUM AND MILLET, INTSORMIL 2001 ANNUAL REPORT, PP. 105-114, (2001); ROONEY L.W., SULLINS R.D., THE STRUCTURE OF SORGHUM AND ITS RELATION TO PROCESSING AND NUTRITIONAL VALUE, PROCEEDINGS OF A SYMPOSIUM ON SORGHUMS AND MILLETS FOR HUMAN FOOD, PP. 91-109, (1977); ROONEY T.K., ROONEY L.W., LUPTON J.R., PHYSIOLOGICAL CHARACTERISTICS OF SORGHUM AND MILLET BRANS IN THE RAT MODEL, CEREAL FOODS WORLD, 37, PP. 782-786, (1992); ROSS J.A., KASUM C.M., DIETARY FLAVONOIDS: BIOAVAILABILITY, METABOLIC EFFECTS, AND SAFETY, ANNUAL REVIEWS OF NUTRITION, 22, PP. 19-22, (2002); RYU S.N., PARK S.Z., HO C.T., HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF ANTHOCYANIN PIGMENTS IN SOME VARIETIES OF BLACK RICE, JOURNAL OF FOOD AND DRUG ANALYSIS, 6, PP. 729-736, (1998); SANTOS-BUELGA C., SCALBERT A., PROANTHOCYANIDINS AND TANNIN-LIKE COMPOUNDS - NATURE, OCCURRENCE, DIETARY INTAKE AND EFFECTS ON NUTRITION AND HEALTH, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 80, PP. 1097-1117, (2000); SARNI-MANCHADO P., CHEYNIER V., MOUTOUNET M., INTERACTIONS OF GRAPE SEED TANNINS WITH SALIVARY PROTEINS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 47, PP. 42-47, (1999); SATO Y., NAKATSUKA H., WATANABE T., HISAMICHI S., SHIMIZU H., FUJISAKU S., ICHINOWATARI Y., IDA Y., SUDA S., KATO K., IKEDA M., POSSIBLE CONTRIBUTION OF GREEN TEA DRINKING HABITS TO THE PREVENTION OF STROKE, TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 157, PP. 337-343, (1989); SEITZ L.M., COMPOSITION OF SORGHUM GRAIN WAX, CEREAL FOODS WORLD, 22, (1977); SCALBERT A., MORAND C., MANACH C., REMESY C., ABSORPTION AND METABOLISM OF POLYPHENOLS IN THE GUT AND IMPACT ON HEALTH, BIOMEDICINE AND PHARMACOTHERAPY, 56, PP. 276-282, (2002); SINGH V., MOREAU R.A., HICKS K.B., YIELD AND PHYTOSTEROL COMPOSITION OF OIL EXTRACTED FROM GRAIN SORGHUM AND ITS WET-MILLED FRACTIONS, CEREAL CHEMISTRY, 80, 2, PP. 126-129, (2003); SISTINO J.J., EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN THE LAST DECADE: TREATMENT OPTIONS AND IMPLICATIONS FOR PERFUSION IN THE 21ST CENTURY, PERFUSION, 18, PP. 73-77, (2003); SLAVIN J.L., JACOBS D., MARQUART L., GRAIN PROCESSING AND NUTRITION, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 40, PP. 309-326, (2000); SPENCER J., CHAUDRY F., PANNALA A., SRAI S., DEBNAM E., RICE-EVANS C., DECOMPOSITION OF COCOA PROCYANIDINS IN THE GASTRIC MILIEU, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 272, PP. 236-241, (2000); STAFFORD H.A., FLAVONOIDS AND RELATED PHENOLIC COMPOUNDS PRODUCED IN THE FIRST INTERNODE OF SORGHUM VULGARE PRESERVED IN DARKNESS AND IN LIGHT, PLANT PHYSIOLOGY, 40, PP. 130-139, (1965); STEADMAN K.J., BURGOON M.S., LEWIS B.A., EDWARDSON E., OBENDORF R.L., MINERALS, PHYTIC ACID, TANNIN AND RUTIN IN BUCKWHEAT SEED MILLING FRACTIONS, JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 81, PP. 1094-1100, (2001); STLEGER A.S., COCHRANE A.L., MOORE F., FACTORS ASSOCIATED WITH CARDIAC MORTALITY IN DEVELOPED COUNTRIES WITH PARTICULAR REFERENCE TO CONSUMPTION OF WINE, LANCET, 1, 8124, PP. 1017-1020, (1979); SWEENY J.G., IACOBUCCI G.A., SYNTHESIS OF ANTHOCYANIDINS - III: TOTAL SYNTHESIS OF APIGENINIDIN AND LUTEOLINIDIN CHLORIDES, TETRAHEDRON, 37, PP. 1481-1483, (1981); TAPIERO H., TEW K.D., NGUYEN B.G., MATHE G., POLYPHENOLS: DO THEY PLAY A ROLE IN THE PREVENTION OF HUMAN PATHOLOGIES?, BIOMEDICINE AND PHARMACOTHERAPY, 56, PP. 200-207, (2002); TEBIB K., ROUANET J.M., BESANCON P., ANTIOXIDANT EFFECTS OF DIETARY POLYMERIC GRAPE SEED TANNINS IN TISSUE OF RATS FED A HIGH CHOLESTEROL-VITAMIN E-DEFICIENT DIET, FOOD CHEMISTRY, 59, PP. 135-141, (1997); TEDESCO I., RUSSO M., RUSSO P., IACOMINO G., RUSSO G.L., CARRATURO F., FARUOLO C., MOIO L., ANTIOXIDANT EFFECT OF RED WINE POLYPHENOLS ON RED BLOOD CELLS, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 11, PP. 114-119, (2000); TIMBERLAKE C.F., BRIDLE P., ANTHOCYANINS, DEVELOPMENTS IN FOOD COLOR - 1, PP. 115-149, (1980); TIPTON K.W., FLOYD E.H., MARSHALL J.G., MCDEVITT J.B., RESISTANCE OF CERTAIN GRAIN SORGHUM HYBRIDS TO BIRD DAMAGE IN LOUISIANA, AGRONOMY JOURNAL, 62, PP. 211-213, (1970); TORRE L.C., BARRIT B.H., QUANTITATIVE EVALUATION OF RUBUS FRUIT ANTHOCYANIN PIGMENTS, JOURNAL OF FOOD SCIENCE, 42, PP. 488-490, (1997); TREUTTER D., CHEMICAL REACTION DETECTION OF CATECHINS AND PROANTHOCYANIDINS WITH 4-DIMETHYLAMINOCINNAMALDEHYDE, JOURNAL OF CHROMATOGRAPHY, 467, PP. 185-193, (1989); UMMADI P., CHENOWETH W.L., UEBERSAX M.A., THE INFLUENCE OF EXTRUSION PROCESSING ON IRON DIALYZABILITY, PHYTATES, AND TANNINS IN LEGUMES, JOURNAL OF FOOD PROCESSING AND PRESERVATION, 19, PP. 119-131, (1995); DATA, (2003); SORGHUM PRODUCTION AND USAGE DATA, (2001); VAN RENSBURG S.J., EPIDEMIOLOGICAL AND DIETARY EVIDENCE FOR A SPECIFIC NUTRITIONAL PREDISPOSITION TO ESOPHAGEAL CANCER, JOURNAL OF THE NATIONAL CANCER INSTITUTE, 67, PP. 243-251, (1981); VIDAL-VALVERDE C., FRIAS J., ESTRELLA M.I., GOROSPE M.J., RUIZ R., BACON J., EFFECTS OF PROCESSING ON SOME ANTINUTRITIONAL FACTORS OF LENTILS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 42, PP. 2291-2295, (1994); WANG H., CAO G., PRIOR R.L., OXYGEN RADICAL ABSORBING CAPACITY OF ANTHOCYANINS, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 45, PP. 304-309, (1997); WANISKA R.D., POE J.H., BANDYOPADHYAY R., EFFECTS OF GROWTH CONDITIONS ON GRAIN MOLDING AND PHENOLS IN SORGHUM CARYOPSIS, JOURNAL OF CEREAL SCIENCE, 10, PP. 217-225, (1989); WATTERSON J.J., BUTLER L., OCCURRENCE OF AN UNUSUAL LEUCOANTHOCYANIDIN AND ABSENCE OF PROANTHOCYANIDIN IN SORGHUM LEAVES, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 31, PP. 41-45, (1983); WEIHRAUCH J.L., GARDNER J.M., STEROL CONTENT OF FOODS OF PLANT ORIGIN, JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 73, PP. 39-46, (1978); WELLER C.L., HWANG K.T., RECOVERABLE LIPIDS FROM GRAIN SORGHUM DRY DISTILLER'S GRAIN, PROCEEDINGS OF THE 23RD BIENNIAL SORGHUM INDUSTRY CONFERENCE, (2003); WU X., CAO G., PRIOR R.L., ABSORPTION AND METABOLISM OF ANTHOCYANINS IN ELDERLY WOMEN AFTER CONSUMPTION OF ELDERBERRY OR BLUEBERRY, JOURNAL OF NUTRITION, 132, PP. 1865-1871, (2002); WYATT H.R., THE PREVALENCE OF OBESITY, PRIMARY CARE, 30, (2003); XU Z.M., GODGERS J.S., COMPARISON OF SUPERCRITICAL FLUID AND SOLVENT EXTRACTION METHODS IN EXTRACTING GAMMA-ORYZANOL FROM RICE BRAN, JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 77, PP. 547-551, (2000); YANG C.S., LANDAU J.M., HUANG M.-T., NEWMARK H.L., INHIBITION OF CARCINOGENESIS BY DIETARY POLYPHENOLIC COMPOUNDS, ANNUAL REVIEW OF NUTRITION, 21, PP. 381-406, (2001); YANG T.T.C., KOO M.W.L., INHIBITORY EFFECTS OF CHINESE GREEN TEA ON ENDOTHELIAL CELL-INDUCED LDL OXIDATION, ATHEROSCLEROSIS, 148, PP. 67-73, (2000); YANG Y., CHIEN M., CHARACTERIZATION OF GRAPE PROCYANIDINS USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY AND MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 48, PP. 3990-3996, (2000); YASUMATSU K., NAKAYAMA T.O.M., CHICHESTER C.O., FLAVONOIDS OF SORGHUM, JOURNAL OF FOOD SCIENCE, 30, PP. 663-667, (1965); YU C.-L., SWAMINATHAN B., MUTAGENICITY OF PROANTHOCYANIDINS, FOOD AND CHEMICAL TOXICOLOGY, 25, 2, PP. 135-139, (1987)","J.M. AWIKA; CEREAL QUALITY LABORATORY, SOIL AND CROP SCIENCES DEPARTMENT, TEXAS AANDM UNIVERSITY, COLLEGE STATION, TX 77843-2474, UNITED STATES; EMAIL: JAWIKA@TAMU.EDU","","ENGLISH","PHYTOCHEMISTRY","REVIEW","ISI","2-S2.0-2942525374","PHYTOCHEMISTRY","TEXAS AANDM UNIVERSITY;TEXAS AANDM UNIVERSITY","NOTREPORTED;TEXAS AANDM UNIVERSITY;NOTREPORTED",NA,"AWIKA JM, 2004, PHYTOCHEMISTRY","AWIKA JM, 2004, PHYTOCHEMISTRY"
"NOA M;MAS R","NOA, MIRIAM (7003318964); MAS, ROSA (7007164572)","PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC PLAQUE ON AORTAS IN MONKEYS",2005,"ARCHIVES OF MEDICAL RESEARCH","36","6",22,"10.1016/j.arcmed.2005.03.039","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, POST BOX 6960, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND. POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG ISOLATED FROM SUGAR CANE WAX WITH CONCOMITANT ANTIPLATELET EFFECTS. PREVIOUS STUDIES HAVE SHOWN THAT POLICOSANOL PREVENTS LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RABBITS AND RATS, INCLUDING FOAM CELL FORMATION, AS WELL AS THE DEVELOPMENT OF FOAM CELLS IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS. POLICOSANOL ALSO INHIBITS SMOOTH MUSCLE CELLS PROLIFERATION INDUCED ON RABBIT CUFFED ARTERY AND ON FORCEPS-INDUCED ARTERIAL WALL DAMAGE. FURTHERMORE, POLICOSANOL ADMINISTERED LONG TERM LOWERED SERUM CHOLESTEROL AND PREVENTED THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS IN MACACA ARCTOIDES MONKEYS. THE PRESENT STUDY WAS UNDERTAKEN TO DETERMINE WHETHER POLICOSANOL COULD CHANGE SOME CHARACTERISTIC FEATURES OF ATHEROSCLEROTIC LESIONS, SUCH AS MACROPHAGE NUMBER AND IMMUNOHISTOCHEMICAL LOCALIZATION OF APOA-1 AND APOB IN AORTAS OF M. ARCTOIDES MONKEYS. METHODS. FOURTEEN ADULT MALE MONKEYS WEIGHING 6-10 KG AND RECEIVING A LOW FAT, PROTEIN-RICH DIET WERE RANDOMLY DISTRIBUTED IN THREE GROUPS: CONTROL GROUP (SIX MONKEYS) AND TWO OTHER GROUPS (FOUR MONKEYS/GROUP) TREATED WITH POLICOSANOL (2.5 AND 25 MG/KG) FOR 54 WEEKS. SAMPLES OF ARTERIES WERE EXAMINED BY LIGHT MICROSCOPY. MONOCLONAL ANTIBODIES WERE USED TO EVALUATE THE PRESENCE OF MACROPHAGE, APOA-1 AND APOB. RESULTS. POLICOSANOL REDUCED THE PRESENCE OF MACROPHAGES AND THE OCCURRENCE OF APOB, WHEREAS INCREASED APOA-1 LOCALIZATION IN AORTIC ATHEROSCLEROTIC LESIONS COMPARED WITH CONTROL MONKEYS. CONCLUSIONS. THESE RESULTS SUGGEST THE POLICOSANOL POTENTIAL BENEFIT ON PLAQUE COMPOSITION AND STABILITY AND COULD EXPLAIN THE PROTECTIVE EFFECTS OF POLICOSANOL ON ATHEROSCLEROSIS DEVELOPMENT. © 2005 IMSS. PUBLISHED BY ELSEVIER INC.","MACACA ARCTOIDES MONKEYS; PLAQUE COMPOSITION; POLICOSANOL","ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; DIET; FATTY ALCOHOLS; HUMANS; MACACA; MACROPHAGES; MALE; PLATELET AGGREGATION INHIBITORS; PROTECTIVE AGENTS; RANDOM ALLOCATION; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; MONOCLONAL ANTIBODY; POLICOSANOL; ANIMAL MODEL; AORTA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MICROSCOPY; MONKEY; NONHUMAN; PROTEIN LOCALIZATION; REDUCTION","","","FALK E., SHAH P., FUSTER V., CORONARY PLAQUE DISRUPTION, CIRCULATION, 92, PP. 657-671, (1995); VINK A., SCHONEVELD A., RICHARD W., FALK E., PASTERKAMP G., PLAQUE BURDEN, ARTERIAL REMODELING AND PLAQUE VULNERABILITY: DETERMINED BY SYSTEMIC FACTORS?, J AM COLL CARDIOL, 38, PP. 718-723, (2001); ZAMAN A., HELFT G., WORTHLEY S., BADIMON J., THE ROLE OF PLAQUE RUPTURE AND THROMBOSIS IN CORONARY ARTERY DISEASE, ATHEROSCLEROSIS, 149, PP. 251-266, (2000); FALK E., PLAQUE RUPTURE WITH SEVERE PRE-EXISTING STENOSIS PRECIPITATING CORONARY ATHEROSCLEROTIC PLAQUES UNDERLYING FATAL OCCLUSIVE THROMBI, BR HEART J, 50, PP. 127-134, (1983); VAN DER WAL A., BECKER A., VAN DER LOOS C., DAS P., SITE OF INTIMAL RUPTURE OR EROSION OF THROMBOSED CORONARY ATHEROSCLEROTIC PLAQUES IS CHARACTERIZED BY AN INFLAMMATORY PROCESS IRRESPECTIVE OF THE DOMINANT PLAQUE MORPHOLOGY, CIRCULATION, 89, PP. 36-44, (1994); MORENO P., FALK E., PALACIOS I., NEWEL J., FUSTER V., FALLON J., MACROPHAGE INFILTRATION IN ACUTE CORONARY SYNDROMES: IMPLICATIONS FOR PLAQUE RUPTURE, CIRCULATION, 90, PP. 775-778, (1994); IP J., FUSTER V., BADIMON L., BADIMON J., TAUBMAN M., CHESEBRO J., SYNDROME OF ACCELERATED ATHEROSCLEROSIS: ROLE OF VASCULAR INJURY AND SMOOTH MUSCLE CELL PROLIFERATION, J AM COLL CARDIOL, 15, PP. 1667-1687, (1990); COOPER M., REISON D., ROSE E., ACCELERATED ATHEROSCLEROSIS, ISCHEMIC HEART DIS, 6, PP. 581-589, (1991); LA ROSA J.C., HUNNINGHAKE D., BUSH D., THE CHOLESTEROL FACTS. A SUMMARY OF THE EVIDENCE RELATING DIETARY FATS, SERUM CHOLESTEROL AND CORONARY HEART DISEASE, CIRCULATION, 81, PP. 1721-1733, (1990); ANDERSON K.M., ODELL P.W., KANNEL W.B., AN UPDATE CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); FUSTER V., BADIMON L., BADIMON J.J., CHESEBRO J.H., THE PATHOGENESIS OF CORONARY ARTERY DISEASE AND THE ACUTE CORONARY SYNDROMES (1), N ENGL J MED, 326, PP. 242-250, (1992); FUSTER V., BADIMON L., BADIMON J.J., CHESEBRO J.H., THE PATHOGENESIS OF CORONARY ARTERY DISEASE AND THE ACUTE CORONARY SYNDROMES (2), N ENGL J MED, 326, PP. 310-318, (1992); TALL A., BRUCE C., SHARP D., JI Y., SUN Y., WANG N., GENETIC DETERMINANTS OF HDL AND THEIR RELATIONSHIPS TO ATHEROSCLEROSIS, ATHEROSCLEROSIS XI, (1998); GORDON D., RIFKIND B.M., HIGH DENSITY LIPOPROTEIN: THE CLINICAL IMPLICATIONS OF RECENT STUDIES, N ENGL J MED, 351, PP. 1311-1316, (1989); BRUNZELL J.D., SNIDERMAN A.D., ALBERS J.J., KWITEROVICH P.O., APOLIPOPROTEINS B AND A-1 AND CORONARY ARTERY DISEASE IN HUMANS, ARTERIOSCLEROSIS, 4, PP. 79-83, (1984); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LEZCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A, 56, (2001); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.L., GONZALEZ R.L., LEZCAY M., ALVAREZ E., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED TO TYPE 2 DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 22, 3-4, PP. 89-99, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, PP. 155-163, (2003); MENENDEZ R., AMOR A., RODEIRO I., GONZALEZ R.M., ACOSTA P., ALFONSO J., MAS R., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); NOA M., MAGRANER J., MAS R., EFECTO DEL ATEROMIXOL EN LAS LESIONES AORTICAS INDUCIDAS POR LIPOFUNDIN EN CONEJOS, PROG CIENCIAS MEDICAS (VENEZUELA), 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., MAS R., DE LA ROSA M.C., EFFECT OF POLICOSANOL ON FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); NOA M., MAS R., AGUILAR C., RAMOS M.E., MESA A.R., LARIOT C.A., EFFECT OF POLICOSANOL ON DAMAGED ARTERIAL WALL INDUCED BY FORCEPS IN RABBITS, J ELECTRON MICROSC, 4, PP. 629-630, (1998); RODRIGUEZ C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXIC, 32, PP. 565-575, (1994); CORO R.M., BORRAJERO I., DIGIPAT. UN SISTEMA CUBANO PARA MORFOMETRÍA DE IMÁGENES, REV LATINOAM PATOL, 34, PP. 9-10, (1996); NOA M., MENDOZA S., MAS R., MENDOZA N., EFFECT OF POLICOSANOL ON CARBON TETRACHLORIDE-INDUCED ACUTE LIVER DAMAGE IN SPRAGUE-DAWLEY RATS, DRUGS RES DEV, 4, PP. 29-35, (2003); SHIOMI M., ITO T., TSUKADA T., YATA T., UEDA M., CELL COMPOSITION OF CORONARY AND AORTIC ATHEROSCLEROTIC LESIONS IN WHHL RABBITS DIFFERS: AN IMMUNOHISTOCHEMICAL STUDY, ARTERIOSCL THROMB, 14, PP. 931-937, (1994); VESSELINOVITCH D., ANIMAL MODELS OF ATHEROSCLEROSIS: THEIR CONTRIBUTIONS AND PITFALLS, ARTERY, 5, PP. 193-206, (1979); OREKHOV A., ANDREEVA E., MIKHAILKOVA I., GORDON D., CELL PROLIFERATION IN NORMAL AND ATHEROSCLEROTIC HUMAN AORTA: PROLIFERATIVE SPLASH IN LIPID-RICH LESIONS, ATHEROSCLEROSIS, 139, PP. 41-48, (1998); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., MOLINA V., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARM, 50, PP. 255-262, (2000); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGL LEUKOTR ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGL LEUKOTR ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); MATRISIAN L.M., THE MATRIX DEGRADING METALLOPROTEINASES, BIOESSAYS, 14, PP. 455-463, (1992); SKRINSKA V., KONIECZKOWSKI M., GERRITY R., GALANG C., REBEC M., SUPRESSION OF FOAM CELL LESIONS IN HYPERCHOLESTEROLEMIC RABBITS BY INHIBITION OF THROMBOXANE A2 SYNTHESIS, ARTERIOSCLEROSIS, 8, PP. 220-225, (1988); SSSS G., RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); BUSTOS C., HERNANDEZ-PRESA M., ORTEGO M., TUNON J., ORTEGA L., PEREZ F., DIAZ C., HERNANDEZ G., EGIDO G., HMG-COA REDUCTASE INHIBITION BY ATORVASTATIN REDUCES NEOINTIMAL INFLAMMATION IN A RABBIT MODEL OF ATHEROSCLEROSIS, J AM COLL CARDIOL, 32, PP. 2057-2064, (1998); AIKAWA M., RABKIN E., SUGIYAMA S., VOGLIC S.J., FUKUMOTO Y., FURUKAWA Y., SHIOMI M., SCHOEN F.J., LIBBY P., AN HMG-COA REDUCTASE INHIBITOR, CERIVASTATIN, SUPPRESSES GROWTH OF MACROPHAGES EXPRESSING MATRIX METALLOPROTEINASES AND TISSUE FACTOR IN VIVO AND IN VITRO, CIRCULATION, 103, PP. 276-283, (2001); LIBBY P., CURRENT CONCEPTS OF THE PATHOGENESIS OF THE ACUTE CORONARY SYNDROMES, CIRCULATION, 104, PP. 365-378, (2001); AIKAWA M., RABKIN E., OKADA Y., LIPID LOWERING BY DIET REDUCES MATRIX METALLOPROTEINASE ACTIVITY AND INCREASES COLLAGEN CONTENT OF RABITT ATHEROMA: A POTENTIAL MECHANISM OF LESION STABILIZATION, CIRCULATION, 97, PP. 2433-2444, (1998); MALLAT Z., TEDGUI A., CURRENT PERSPECTIVE ON THE ROLE OF APOPTOSIS IN ATHEROTHROMBOTIC DISEASE, CIRC RES, 88, PP. 998-1003, (2001); TEDGUI A., MALLAT Z., APOPTOSIS AS A DETERMINANT OF ATHEROTHROMBOSIS, THROMB HAEMOST, 86, PP. 420-426, (2001); BEST P., HASDAI D., SANGIORGI G., SCHWARTZ R., HOLMES D., SIMARI R., LERMAN A., APOPTOSIS. BASIC CONCEPTS AND IMPLICATIONS IN CORONARY ARTERY DISEASE, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 14-22, (1999); HOFF H.F., LIE J., TITUS J., JACKSON R., DEBAKEY M., BAYARDO R., GOTTO A.M., LIPOPROTEINS IN ATHEROSCLEROTIC LESIONS. LOCALIZATION BY IMMUNOFLUORESCENCE OF APO LOW-DENSITY LIPOPROTEINS IN HUMAN ATHEROSCLEROTIC ARTERIES FROM NORMAL AND HYPERLIPOPROTEINEMICS, ARCH PATHOL, 99, PP. 253-258, (1975); HOFF H.F., HEIDEMAN C.L., NOON J.P., MEYER J.S., LOCALIZATION OF APOLIPOPROTEINS IN HUMAN CAROTID ARTERY PLAQUES, STROKE, 6, PP. 531-534, (1975); YOMANTAS S., EELNER V., SCHAFFNER T., WISSLER R., IMMUNOHISTOCHEMICAL LOCALIZATION OF APOLIPOPROTEIN B IN HUMAN ATHEROSCLEROTIC LESIONS, ARCH PATHOL LAB MED, 108, PP. 374-378, (1984); NOA M., SORELL L., HERRERA M., ILLNAIT J., IMMUNOHISTOCHEMICAL LOCALIZATION OF APOLIPOPROTEIN B IN ATHEROSCLEROTIC LESIONS. ADVANCES IN LIPOPROTEIN AND ATHEROSCLEROSIS RESEARCH, DIAGNOSTIC AND TREATMENT, PROC OF THE 6TH INT DRESDEN LIPID SYMPOSIUM, PP. 760-763, (1988); BOCAN T., BROWN S., GUYTON J., HUMAN AORTIC FIBROLIPID LESIONS. IMMUNOHISTOCHEMICAL LOCALIZATION OF APOLIPOPROTEIN B AND APOLIPOPROTEIN A, ARTERIOSCLEROSIS, 8, PP. 499-508, (1988); MACKNESS M.I., ARROL S., ABBOTT C.A., DURRINGTON P.N., PROTECTION OF LOW-DENSITY LIPOPROTEIN AGAINST OXIDATIVE BY HIGH-DENSITY LIPOPROTEIN ASSOCIATED PARAOXONASE, ATHEROSCLEROSIS, 104, PP. 129-135, (1993); BARTER P., RYE K.A., CLAY M., ASHBY D., BAKER P., XIA P., ANTIATHEROGENIC EFFECTS OF HIGH DENSITY LIPOPROTEINS: MECHANISMS, ATHEROSCLEROSIS XI, (1998); SPECTOR W.S., NUTRITION, DIGESTION AND METABOLISM, HANDBOOK OF BIOLOGICAL DATA, PP. 187-196, (1956)","M. NOA; CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, POST BOX 6960, CUBA; EMAIL: CLINICA@ENET.CUT","","ENGLISH","ARCH. MED. RES.","ARTICLE","ISI","2-S2.0-23744511721","ARCH MED RES","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CUT",NA,"NOA M, 2005, ARCH MED RES","NOA M, 2005, ARCH MED RES"
"MCCARTY M;BLOCK K","MCCARTY, MARK F. (24435224500); BLOCK, KEITH I. (35501295200)","TOWARD A CORE NUTRACEUTICAL PROGRAM FOR CANCER MANAGEMENT",2006,"INTEGRATIVE CANCER THERAPIES","5","21",19,"10.1177/1534735406288443","BLOCK CENTER FOR INTEGRATIVE CANCER CARE, EVANSTON, IL, UNITED STATES, BLOCK CENTER FOR INTEGRATIVE CANCER CARE, EVANSTON, IL 60201, 1800 SHERMAN AVENUE, UNITED STATES;BLOCK CENTER FOR INTEGRATIVE CANCER CARE, EVANSTON, IL, UNITED STATES","AS PREVIOUSLY SUGGESTED, IT MAY BE FEASIBLE TO IMPEDE TUMOR-EVOKED ANGIOGENESIS WITH A NUTRACEUTICAL PROGRAM COMPOSED OF GLYCINE, FISH OIL, EPIGALLOCATECHIN-3-GALLATE, SELENIUM, AND SILYMARIN, COMPLEMENTED BY A LOW-FAT VEGAN DIET, EXERCISE TRAINING, AND, IF FEASIBLE, A SALICYLATE AND THE DRUG TETRATHIOMOLYBDATE. IT IS NOW PROPOSED THAT THE SCOPE OF THIS PROGRAM BE EXPANDED TO ADDRESS ADDITIONAL COMMON NEEDS OF CANCER PATIENTS: BLOCKING THE PROCESS OF METASTASIS; BOOSTING THE CYTOTOXIC CAPACITY OF INNATE IMMUNE DEFENSES (NATURAL KILLER [NK] CELLS); PREVENTING CACHEXIA, THROMBOEMBOLISM, AND TUMOR-INDUCED OSTEOLYSIS; AND MAINTAINING OPTIMAL MICRONUTRIENT STATUS. MODIFIED CITRUS PECTIN, A GALECTIN-3 ANTAGONIST, HAS IMPRESSIVE ANTIMETASTATIC POTENTIAL. MUSHROOM Β-GLUCANS AND PROBIOTIC LACTOBACILLI CAN AMPLIFY NK ACTIVITY VIA STIMULATORY EFFECTS ON MACROPHAGES. SELENIUM, Β-CAROTENE, AND GLUTAMINE CAN ALSO INCREASE THE NUMBER AND/OR CYTOTOXIC ACTIVITY OF NK CELLS. CACHECTIC LOSS OF MUSCLE MASS CAN BE OPPOSED BY FISH OIL, GLUTAMINE, AND Β-HYDROXY-Β-METHYLBUTYRATE. FISH OIL, POLICOSANOL, AND VITAMIN D MAY HAVE POTENTIAL FOR CONTROL OF OSTEOLYSIS. HIGH-DOSE ASPIRIN OR SALICYLATES, BY PREVENTING NF-ΚB ACTIVATION, CAN BE EXPECTED TO AID PREVENTION OF METASTASIS AND CACHEXIA WHILE DOWN-REGULATING OSTEOLYSIS, BUT THEIR IMPACTS ON INNATE IMMUNE DEFENSES WILL NOT BE ENTIRELY FAVORABLE. A NUTRITIONAL INSURANCE FORMULA CRAFTED FOR THE SPECIAL NEEDS OF CANCER PATIENTS CAN BE INCLUDED IN THIS REGIMEN. TO MINIMIZE PATIENT INCONVENIENCE, THIS COMPLEX CORE NUTRACEUTICAL PROGRAM COULD BE CONFIGURED AS AN OIL PRODUCT, A POWDER, AND A CAPSULE PRODUCT, WITH THE NUTRITIONAL INSURANCE FORMULA PROVIDED IN TABLETS. IT WOULD BE OF INTEREST TO TEST THIS PROGRAM IN NUDE MOUSE XENOGRAFT MODELS.","Β-GLUCAN; FISH OIL; HYDROXYMETHYLBUTYRATE; MODIFIED CITRUS PECTIN; SALICYLATE","ANIMALS; CACHEXIA; CHEMISTRY, PHARMACEUTICAL; HEALTH SERVICES NEEDS AND DEMAND; HEALTH STATUS; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; MICRONUTRIENTS; NEOPLASM METASTASIS; NEOPLASMS; NUTRITION PHYSIOLOGY; OSTEOLYSIS, ESSENTIAL; PATIENT SATISFACTION; THROMBOEMBOLISM; 3 HYDROXYBUTYRIC ACID; BETA CAROTENE; BETA GLUCAN; CHROMIUM; COLECALCIFEROL DERIVATIVE; COPPER; EPIGALLOCATECHIN GALLATE; FISH OIL; GALECTIN 3; GALECTIN 3 ANTAGONIST; GLUTAMINE; GLYCINE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYCOPENE; MAGNESIUM; MODIFIED CITRUS PECTIN; NATTOKINASE; NUTRACEUTICAL; PECTIN; POLICOSANOL; PROBIOTIC AGENT; SALICYLIC ACID DERIVATIVE; SELENIUM; SILYMARIN; TAURINE; TETRATHIOMOLYBDIC ACID; TRACE ELEMENT; UNCLASSIFIED DRUG; VITAMIN D; ANTINEOPLASTIC ACTIVITY; CACHEXIA; CANCER; DRUG CAPSULE; DRUG FORMULATION; DRUG MEGADOSE; EXERCISE; HEALTH PROGRAM; HUMAN; IMMUNITY; LACTOBACILLUS; LOW FAT DIET; MACROPHAGE; METASTASIS; METASTASIS INHIBITION; MUSCLE ATROPHY; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; NUTRACEUTICAL PROGRAM; NUTRITIONAL INSURANCE FORMULA; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OSTEOLYSIS; OSTEOPENIA; POWDER; PRIORITY JOURNAL; REVIEW; TABLET; THROMBOEMBOLISM; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VEGETARIAN DIET","","","MCCARTY M.F., A WHOLLY NUTRITIONAL ""MULTIFOCAL ANGIOSTATIC THERAPY"" FOR CONTROL OF DISSEMINATED CANCER, MED HYPOTHESES, 61, PP. 1-15, (2003); MCCARTY M.F., BLOCK K.I., MULTIFOCAL ANGIOSTATIC THERAPY - AN UPDATE, INTEGR CANCER THER, 4, PP. 301-314, (2005); GLINSKII O.V., HUXLEY V.H., GLINSKY G.V., PIENTA K.J., RAZ A., GLINSKY V.V., MECHANICAL ENTRAPMENT IS INSUFFICIENT AND INTERCELLULAR ADHESION IS ESSENTIAL FOR METASTATIC CELL ARREST IN DISTANT ORGANS, NEOPLASIA, 7, PP. 522-527, (2005); TAKENAKA Y., FUKUMORI T., RAZ A., GALECTIN-3 AND METASTASIS, GLYCOCONJ J, 19, PP. 543-549, (2004); MEROMSKY L., LOTAN R., RAZ A., IMPLICATIONS OF ENDOGENOUS TUMOR CELL SURFACE LECTINS AS MEDIATORS OF CELLULAR INTERACTIONS AND LUNG COLONIZATION, CANCER RES, 46, PP. 5270-5275, (1986); BEUTH J., KO H.L., SCHIRRMACHER V., UHLENBRUCK G., PULVERER G., INHIBITION OF LIVER TUMOR CELL COLONIZATION IN TWO ANIMAL TUMOR MODELS BY LECTIN BLOCKING WITH D-GALACTOSE OR ARABINOGALACTAN, CLIN EXP METASTASIS, 6, PP. 115-120, (1988); GLINSKY G.V., PRICE J.E., GLINSKY V.V., MOSSINE V.V., KIRIAKOVA G., METCALF J.B., INHIBITION OF HUMAN BREAST CANCER METASTASIS IN NUDE MICE BY SYNTHETIC GLYCOAMINES, CANCER RES, 56, PP. 5319-5324, (1996); INUFUSA H., NAKAMURA M., ADACHI T., ET AL., ROLE OF GALECTIN-3 IN ADENOCARCINOMA LIVER METASTASIS, JNT J ONCOL, 19, PP. 913-919, (2001); RAZ A., MEROMSKY L., LOTAN R., DIFFERENTIAL EXPRESSION OF ENDOGENOUS LECTINS ON THE SURFACE OF NONTUMORIGENIC, TUMORIGENIC, AND METASTATIC CELLS, CANCER RES, 46, PP. 3667-3672, (1986); IRIMURA T., MATSUSHITA Y., SUTTON R.C., ET AL., INCREASED CONTENT OF AN ENDOGENOUS LACTOSE-BINDING LECTIN IN HUMAN COLORECTAL CARCINOMA PROGRESSED TO METASTATIC STAGES, CANCER RES, 51, PP. 387-393, (1991); NANGIA-MAKKER P., HONJO Y., SARVIS R., ET AL., GALECTIN-3 INDUCES ENDOTHELIAL CELL MORPHOGENESIS AND ANGIOGENESIS, AM J PATHOL, 156, PP. 899-909, (2000); NANGIA-MAKKER P., HOGAN V., HONJO Y., ET AL., INHIBITION OF HUMAN CANCER CELL GROWTH AND METASTASIS IN NUDE MICE BY ORAL INTAKE OF MODIFIED CITRUS PECTIN, J NATL CANCER INST, 94, PP. 1854-1862, (2002); NAKAHARA S., OKA N., RAZ A., ON THE ROLE OF GALECTIN-3 IN CANCER APOPTOSIS, APAPTOSIS, 10, PP. 267-275, (2005); KIM H.R., LIN H.M., BILIRAN H., RAZ A., CELL CYCLE ARREST AND INHIBITION OF ANOIKIS BY GALECTIN-3 IN HUMAN BREAST EPITHELIAL CELLS, CANCER RES, 59, PP. 4148-4154, (1999); PIENTA K.J., NAIK H., AKHTAR A., ET AL., INHIBITION OF SPONTANEOUS METASTASIS IN A RAT PROSTATE CANCER MODEL BY ORAL ADMINISTRATION OF MODIFIED CITRUS PECTIN, J NATL CANCER INST, 87, PP. 348-353, (1995); HAYASHI A., GILLEN A.C., LOTT J.R., EFFECTS OF DAILY ORAL ADMINISTRATION OF QUERCETIN CHALCONE AND MODIFIED CITRUS PECTIN ON IMPLANTED COLON-25 TUMOR GROWTH IN BALB-C MICE, ALTERN MED REV, 5, PP. 546-552, (2000); GUESS B.W., SCHOLZ M.C., STRUM S.B., LAM R.Y., JOHNSON H.J., JENNRICH R.I., MODIFIED CITRUS PECTIN (MCP) INCREASES THE PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN MEN WITH PROSTATE CANCER: A PHASE II PILOT STUDY, PROSTATE CANCER PROSTATIC DIS, 6, PP. 301-304, (2003); SCHMID H.P., MCNEAL J.E., STAMEY T.A., OBSERVATIONS ON THE DOUBLING TIME OF PROSTATE CANCER: THE USE OF SERIAL PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH UNTREATED DISEASE AS A MEASURE OF INCREASING CANCER VOLUME, CANCER, 71, PP. 2031-2040, (1993); AGGARWAL B.B., NUCLEAR FACTOR-KAPPAB: THE ENEMY WITHIN, CANCER CELL, 6, PP. 203-208, (2004); DUMIC J., LAUC G., FLOGEL M., EXPRESSION OF GALECTIN-3 IN CELLS EXPOSED TO STRESS-ROLES OF JUN AND NF-KAPPAB, CELL PHYSIOL BIOCHEM, 10, PP. 149-158, (2000); LIU L., SAKAI T., SANO N., FUKUI K., NUCLING MEDIATES APOPTOSIS BY INHIBITING EXPRESSION OF GALECTIN-3 THROUGH INTERFERENCE WITH NUCLEAR FACTOR KAPPAB SIGNALLING, BIOCHEM J, 380, PP. 31-41, (2004); TOZAWA K., SAKURADA S., KOHRI K., OKAMOTO T., EFFECTS OF ANTI-NUCLEAR FACTOR KAPPA B REAGENTS IN BLOCKING ADHESION OF HUMAN CANCER CELLS TO VASCULAR ENDOTHELIAL CELLS, CANCER RES, 55, PP. 4162-4167, (1995); DHAWAN S., SINGH S., AGGARWAL B.B., INDUCTION OF ENDOTHELIAL CELL SURFACE ADHESION MOLECULES BY TUMOR NECROSIS FACTOR IS BLOCKED BY PROTEIN TYROSINE PHOSPHATASE INHIBITORS: ROLE OF THE NUCLEAR TRANSCRIPTION FACTOR NF-KAPPA B, EUR J IMMUNOL, 27, PP. 2172-2179, (1997); ANDREWS E.J., WANG J.H., WINTER D.C., LAUG W.E., REDMOND H.P., TUMOR CELL ADHESION TO ENDOTHELIAL CELLS IS INCREASED BY ENDOTOXIN VIA AN UPREGULATION OF BETA-1 INTEGRIN EXPRESSION, J SURG RES, 97, PP. 14-19, (2001); TOZAWA K., KAWAI N., HAYASHI Y., SASAKI S., KOHRI K., OKAMOTO T., GOLD COMPOUNDS INHIBIT ADHESION OF HUMAN CANCER CELLS TO VASCULAR ENDOTHELIAL CELLS, CANCER LETT, 196, PP. 93-100, (2003); LLOYD JR. F.P., SLIVOVA V., VALACHOVICOVA T., SLIVA D., ASPIRIN INHIBITS HIGHLY INVASIVE PROSTATE CANCER CELLS, INT J ONCOL, 23, PP. 1277-1283, (2003); ANDELA V.B., GORDON A.H., ZOTALIS G., ET AL., NFKAPPAB: A PIVOTAL TRANSCRIPTION FACTOR IN PROSTATE CANCER METASTASIS TO BONE, CLIN ORTHOP RELAT RES, (2003); SLIVA D., SIGNALING PATHWAYS RESPONSIBLE FOR CANCER CELL INVASION AS TARGETS FOR CANCER THERAPY, CURR CANCER DRUG TARGETS, 4, PP. 327-336, (2004); KOPP E., GHOSH S., INHIBITION OF NF-KAPPA B BY SODIUM SALICYLATE AND ASPIRIN, SCIENCE, 265, PP. 956-959, (1994); YIN M.J., YAMAMOTO Y., GAYNOR R.B., THE ANTI-INFLAMMATORY AGENTS ASPIRIN AND SALICYLATE INHIBIT THE ACTIVITY OF I (KAPPA) B KINASE-BETA, NATURE, 396, PP. 77-80, (1998); FUTAKUCHI M., OGAWA K., SANO M., TAMANO S., TAKESHITA F., SHIRAI T., SUPPRESSION OF LUNG METASTASIS BY ASPIRIN BUT NOT INDOMETHACIN IN AN IN VIVO MODEL OF CHEMICALLY INDUCED HEPATOCELLULAR CARCINOMA, JPN J CANCER RES, 93, PP. 1175-1181, (2002); FUTAKUCHI M., OGAWA K., TAMANO S., TAKAHASHI S., SHIRAI T., SUPPRESSION OF METASTASIS BY NUCLEAR FACTOR KAPPAB INHIBITORS IN AN IN VIVO LUNG METASTASIS MODEL OF CHEMICALLY INDUCED HEPATOCELLULAR CARCINOMA, CANCER SCI, 95, PP. 18-24, (2004); MURONO S., YOSHIZAKI T., SATO H., TAKESHITA H., FURUKAWA M., PAGANO J.S., ASPIRIN INHIBITS TUMOR CELL INVASIVENESS INDUCED BY EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1 THROUGH SUPPRESSION OF MATRIX METALLOPROTEINASE-9 EXPRESSION, CANCER RES, 60, PP. 2555-2561, (2000); JIANG M.C., LIAO C.F., LEE P.H., ASPIRIN INHIBITS MATRIX METALLOPROTEINASE-2 ACTIVITY, INCREASES E-CADHERIN PRODUCTION, AND INHIBITS IN VITRO INVASION OF TUMOR CELLS, BIOCHEM BIOPHYS RES COMMUN, 282, PP. 671-677, (2001); ABIRU S., NAKAO K., ICHIKAWA T., ET AL., ASPIRIN AND NS-398 INHIBIT HEPATOCYTE GROWTH FACTOR-INDUCED INVASIVENESS OF HUMAN HEPATOMA CELLS, HEPATOLOGY, 35, PP. 1117-1124, (2002); GAO X.Q., HAN J.X., HUANG H.Y., YAN S., SONG C.Z., HUANG H.N., EFFECTS OF ASPIRIN ON METASTASIS-ASSOCIATED GENE EXPRESSION DETECTED BY CDNA MICROARRAY, ACTA PHARMACOL SIN, 25, PP. 1327-1333, (2004); PAN Q., KLEER C.G., VAN GOLEN K.L., ET AL., COPPER DEFICIENCY INDUCED BY TETRATHIOMOLYBDATE SUPPRESSES TUMOR GROWTH AND ANGIOGENESIS, CANCER RES, 62, PP. 4854-4859, (2002); PAN Q., BAO L.W., MERAJVER S.D., TETRATHIOMOLYBDATE INHIBITS ANGIOGENESIS AND METASTASIS THROUGH SUPPRESSION OF THE NFKAPPAB SIGNALING CASCADE, MOL CANCER RES, 1, PP. 701-706, (2003); DHANALAKSHMI S., SINGH R.P., AGARWAL C., AGARWAL R., SILIBININ INHIBITS CONSTITUTIVE AND TNFALPHA-INDUCED ACTIVATION OF NF-KAPPAB AND SENSITIZES HUMAN PROSTATE CARCINOMA DU145 CELLS TO TNFALPHA-INDUCED APOPTOSIS, ONCOGENE, 21, PP. 1759-1767, (2002); SINGLETON JR. P.T., SALSALATE: ITS ROLE IN THE MANAGEMENT OF RHEUMATIC DISEASE, CLIN THER, 3, PP. 80-102, (1980); LAMY S., GINGRAS D., BELIVEAU R., GREEN TEA CATECHINS INHIBIT VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PHOSPHORYLATION, CANCER RES, 62, PP. 381-385, (2002); DEMEULE M., BROSSARD M., PAGE M., GINGRAS D., BELIVEAU R., MATRIX METALLOPROTEINASE INHIBITION BY GREEN TEA CATECHINS, BIOCHEM BIOPHYS ACTA, 1478, PP. 51-60, (2000); GARBISA S., SARTOR L., BIGGIN S., SALVATO B., BENELLI R., ALBINI A., TUMOR GELATINASES AND INVASION INHIBITED BY THE GREEN TEA FLAVANOL EPIGALLOCATECHIN-3-GALLATE, CANCER, 91, PP. 822-832, (2001); SAZUKA M., MURAKAMI S., ISEMURA M., SATOH K., NUKIWA T., INHIBITORY EFFECTS OF GREEN TEA INFUSION ON IN VITRO INVASION AND IN VIVO METASTASIS OF MOUSE LUNG CARCINOMA CELLS, CANCER LETT, 98, PP. 27-31, (1995); BALIGA M.S., MELETH S., KATIYAR S.K., GROWTH INHIBITORY AND ANTIMETASTATIC EFFECT OF GREEN TEA POLYPHENOLS ON METASTASIS-SPECIFIC MOUSE MAMMARY CARCINOMA 4T1 CELLS IN VITRO AND IN VIVO SYSTEMS, CLIN CANCER RES, 11, PP. 1918-1927, (2005); ROITT I.M., DELVES P.J., ROITT'S ESSENTIAL IMMUNOLOGY. 10TH ED., (2001); WU J., LANIER L.L., NATURAL KILLER CELLS AND CANCER, ADV CANCER RES, 90, PP. 127-156, (2003); HALLETT W.H., MURPHY W.J., NATURAL KILLER CELLS: BIOLOGY AND CLINICAL USE IN CANCER THERAPY, CELL MOL IMMUNOL, 1, PP. 12-21, (2004); GARRIDO F., CABRERA T., CONCHA A., GLEW S., RUIZ-CABELLO F., STERN P.L., NATURAL HISTORY OF HLA EXPRESSION DURING TUMOUR DEVELOPMENT, IMMUNOL TODAY, 14, PP. 491-499, (1993); BUBENIK J., TUMOUR MHC CLASS I DOWNREGULATION AND IMMUNOTHERAPY, ONCOL REP, 10, PP. 2005-2008, (2003); KIREMIDJIAN-SCHUMACHER L., ROY M., WISHE H.I., COHEN M.W., STOTZKY G., SUPPLEMENTATION WITH SELENIUM AUGMENTS THE FUNCTIONS OF NATURAL KILLER AND LYMPHOKINE-ACTIVATED KILLER CELLS, BIOL TRACE ELEM RES, 52, PP. 227-239, (1996); KIREMIDJIAN-SCHUMACHER L., ROY M., SELENIUM AND IMMUNE FUNCTION, Z ERNAHRUNGSWISS, 37, 1 SUPPL., PP. 50-56, (1998); KIREMIDJIAN-SCHUMACHER L., ROY M., WISHE H.I., COHEN M.W., STOTZKY G., SUPPLEMENTATION WITH SELENIUM AND HUMAN IMMUNE CELL FUNCTIONS. II. EFFECT ON CYTOTOXIC LYMPHOCYTES AND NATURAL KILLER CELLS, BIOL TRACE ELEM RES, 41, PP. 115-127, (1994); WOOD S.M., BECKHAM C., YOSIOKA A., DARBAN H., WATSON R.R., BETA-CAROTENE AND SELENIUM SUPPLEMENTATION ENHANCES IMMUNE RESPONSE IN AGED HUMANS, INTEGR MED, 2, PP. 85-92, (2000); PETRIE H.T., KLASSEN L.W., KLASSEN P.S., O'DELL J.R., KAY H.D., SELENIUM AND THE IMMUNE RESPONSE: 2. ENHANCEMENT OF MURINE CYTOTOXIC T-LYMPHOCYTE AND NATURAL KILLER CELL CYTOTOXICITY IN VIVO, J LEUKOC BIOL, 45, PP. 215-220, (1989); NESARETNAM K., RADHAKRISHNAN A., SELVADURAY K.R., ET AL., EFFECT OF PALM OIL CAROTENE ON BREAST CANCER TUMORIGENICITY IN NUDE MICE, LIPIDS, 37, PP. 557-560, (2002); CARLOS T.F., RIONDEL J., MATHIEU J., GUIRAUD P., MESTRIES J.C., FAVIER A., BETA-CAROTENE ENHANCES NATURAL KILLER CELL ACTIVITY IN ATHYMIC MICE, IN VIVO, 11, PP. 87-91, (1997); SANTOS M.S., MEYDANI S.N., LEKA L., ET AL., NATURAL KILLER CELL ACTIVITY IN ELDERLY MEN IS ENHANCED BY BETA-CAROTENE SUPPLEMENTATION, AM J CLIN NUTR, 64, PP. 772-777, (1996); SANTOS M.S., GAZIANO J.M., LEKA L.S., BEHARKA A.A., HENNEKENS C.H., MEYDANI S.N., BETA-CAROTENE-INDUCED ENHANCEMENT OF NATURAL KILLER CELL ACTIVITY IN ELDERLY MEN: AN INVESTIGATION OF THE ROLE OF CYTOKINES, AM J CLIN NUTR, 68, PP. 164-170, (1998); TAPAZOGLOU E., PRASAD A.S., HILL G., BREWER G.J., KAPLAN J., DECREASED NATURAL KILLER CELL ACTIVITY IN PATIENTS WITH ZINC DEFICIENCY WITH SICKLE CELL DISEASE, J LAB CLIN MED, 105, PP. 19-22, (1985); OZTURK G., ERBAS D., IMIR T., BOR N.M., DECREASED NATURAL KILLER (NK) CELL ACTHITY IN ZINC-DEFICIENT RATS, GEN PHARMACOL, 25, PP. 1499-1503, (1994); PRASAD A.S., ZINC AND IMMUNITY, MOL CELL BIOCHEM, 188, PP. 63-69, (1998); BOGDEN J.D., OLESKE J.M., LAVENHAR M.A., ET AL., EFFECTS OF ONE YEAR OF SUPPLEMENTATION WITH ZINC AND OTHER MICRONUTRIENTS ON CELLULAR IMMUNITY IN THE ELDERLY, J AM COLL NUTR, 9, PP. 214-225, (1990); STEPHENSON R.A., LUFT B.J., PEDROTTI P.W., REMINGTON J.S., INHIBITION OF MOUSE NATURAL KILLER CELL ACTIVITY BY ZINC, J NATL CANCER INST, 74, PP. 1067-1070, (1985); IBS K.H., RINK L., ZINC-ALTERED IMMUNE FUNCTION, J NUTR, 133, (2003); OSHIMAN K., FUJIMIYA Y., EBINA T., SUZUKI I., NOJI M., ORALLY ADMINISTERED BETA-1,6-D-POLYGLUCOSE EXTRACTED FROM AGARICUS BLAZEI RESULTS IN TUMOR REGRESSION IN TUMOR-BEARING MICE, PLANTA MED, 68, PP. 610-614, (2002); SEE D., MASON S., ROSHAN R., INCREASED TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) AND NATURAL KILLER CELL (NK) FUNCTION USING AN INTEGRATIVE APPROACH IN LATE STAGE CANCERS, IMMUNOL INVEST, 31, PP. 137-153, (2002); LEE Y.L., KIM H.J., LEE M.S., ET AL., ORAL ADMINISTRATION OF AGARICUS BLAZEI (H1 STRAIN) INHIBITED TUMOR GROWTH IN A SARCOMA 180 INOCULATION MODEL, EXP ANIM, 52, PP. 371-375, (2003); TAKIMOTO H., WAKITA D., KAWAGUCHI K., KUMAZAWA Y., POTENTIATION OF CYTOTOXIC ACTIVITY IN NAIVE AND TUMOR-BEARING MICE BY ORAL ADMINISTRATION OF HOT-WATER EXTRACTS FROM AGARICUS BRAZEI FRUITING BODIES, BIOL PHARM BULL, 27, PP. 404-406, (2004); AHN W.S., KIM D.J., CHAE G.T., ET AL., NATURAL KILLER CELL ACTIVITY AND QUALITY OF LIFE WERE IMPROVED BY CONSUMPTION OF A MUSHROOM EXTRACT, AGARICUS BLAZEI MURILL KYOWA, IN GYNECOLOGICAL CANCER PATIENTS UNDERGOING CHEMOTHERAPY, INT J GYNECOL CANCER, 14, PP. 589-594, (2004); KASAI H., HE L.M., KAWAMURA M., ET AL., IL-12 PRODUCTION INDUCED BY AGARICUS BLAZEI RACTION H (ABH) INVOLVES TOLL-LIKE RECEPTOR (TLR), EVID BASED COMPLEMENT ALTERNAT MED, 1, PP. 259-267, (2004); KOBAYASHI H., YOSHIDA R., KANADA Y., ET AL., SUPPRESSING EFFECTS OF DAILY ORAL SUPPLEMENTATION OF BETA-GLUCAN EXTRACTED FROM AGARICUS BLAZEI MURILL ON SPONTANEOUS AND PERITONEAL DISSEMINATED METASTASIS IN MOUSE MODEL, J CANCER RES CLIN ONCOL, 131, PP. 527-538, (2005); GAO Y., ZHOU S., JIANG W., HUANG M., DAI X., EFFECTS OF GANOPOLY (A GANODERMA LUCIDUM POLYSACCHARIDE EXTRACT) ON THE IMMUNE FUNCTIONS IN ADVANCED-STAGE CANCER PATIENTS, IMMUNOL INVEST, 32, PP. 201-215, (2003); KOHGUCHI M., KUNIKATA T., WATANABE H., ET AL., IMMUNO-POTENTIATING EFFECTS OF THE ANTLER-SHAPED FRUITING BODY OF GANODERMA LUCIDUM (ROKKAKU-REISHI), BIOSCI BIOTECHNOL BIOCHEM, 68, PP. 881-887, (2004); GAO Y., GAO H., CHAN E., ET AL., ANTITUMOR ACTIVITY AND UNDERLYING MECHANISMS OF GANOPOLY, THE REFINED POLYSACCHARIDES EXTRACTED FROM GANODERMA LUCIDUM, IN MICE, IMMUNOL INVEST, 34, PP. 171-198, (2005); MORINAGA H., TAZAWA K., TAGOH H., MURAGUCHI A., FUJIMAKI M., AN IN VIVO STUDY OF HEPATIC AND SPLENIC INTERLEUKIN-1 BETA MRNA EXPRESSION FOLLOWING ORAL PSK OR LEM ADMINISTRATION, JPN J CANCER RES, 85, PP. 1298-1303, (1994); KURASHIGE S., AKUZAWA Y., ENDO F., EFFECTS OF LENTINUS EDODES, GRIFOLA FRONDOSA AND PLEUROTUS OSTREATUS ADMINISTRATION ON CANCER OUTBREAK, AND ACTIVITIES OF MACROPHAGES AND LYMPHOCYTES IN MICE TREATED WITH A CARCINOGEN, N-BUTYL-N-BUTANOLNITROSOAMINE, IMMUNOPHARMACOL IMMUNOTOXICOL, 19, PP. 175-183, (1997); NG M.L., YAP A.T., INHIBITION OF HUMAN COLON CARCINOMA DEVELOPMENT BY LENTINAN FROM SHIITAKE MUSHROOMS (LENTINUS EDODES), J ALTERN COMPLEMENT MED, 8, PP. 581-589, (2002); KASAI H., HE L.M., KAWAMURA M., ET AL., IL-12 PRODUCTION INDUCED BY AGARICUS BLAZEI FRACTION H (ABH) INVOLVES TOLL-LIKE RECEPTOR (TLR), EVID BASED COMPLEMENT ALTERNAT MED, 1, PP. 259-267, (2004); SHAO B.M., DAI H., XU W., LIN Z.B., GAO X.M., IMMUNE RECEPTORS FOR POLYSACCHARIDES FROM GANODERMA LUCIDUM, BIOCHEM BIOPHYS RES COMMUN, 323, PP. 133-141, (2004); HSU H.Y., HUA K.F., LIN C.C., LIN C.H., HSU J., WONG C.H., EXTRACT OF REISHI POLYSACCHARIDES INDUCES CYTOKINE EXPRESSION VIA TLR4-MODULATED PROTEIN KINASE SIGNALING PATHWAYS, J IMMUNOL, 173, PP. 5989-5999, (2004); GAO Y., TANG W., DAI X., ET AL., EFFECTS OF WATER-SOLUBLE GANODERMA LUCIDUM POLYSACCHARIDES ON THE IMMUNE FUNCTIONS OF PATIENTS WITH ADVANCED LUNG CANCER, J MED FOOD, 8, PP. 159-168, (2005); DEVERE WHITE R.W., HACKMAN R.M., SOARES S.E., BECKETT L.A., SUN B., EFFECTS OF A MUSHROOM MYCELIUM EXTRACT ON THE TREATMENT OF PROSTATE CANCER, UROLOGY, 60, PP. 640-644, (2002); MATSUZAKI T., CHIN J., MODULATING IMMUNE RESPONSES WITH PROBIOTIC BACTERIA, IMMUNOL CELL BIOL, 78, PP. 67-73, (2000); NAGAO F., NAKAYAMA M., MUTO T., OKUMURA K., EFFECTS OF A FERMENTED MILK DRINK CONTAINING LACTOBACILLUS CASEI STRAIN SHIROTA ON THE IMMUNE SYSTEM IN HEALTHY HUMAN SUBJECTS, BIOSCI BIOTECHNOL BIOCHEM, 64, PP. 2706-2708, (2000); TAKAGI A., MATSUZAKI T., SATO M., NOMOTO K., MOROTOMI M., YOKOKURA T., ENHANCEMENT OF NATURAL KILLER CYTOTOXICITY DELAYED MURINE CARCINOGENESIS BY A PROBIOTIC MICROORGANISM, CARCINOGENESIS, 22, PP. 599-605, (2001); SHEIH Y.H., CHIANG B.L., WANG L.H., LIAO C.K., GILL H.S., SYSTEMIC IMMUNITY-ENHANCING EFFECTS IN HEALTHY SUBJECTS FOLLOWING DIETARY CONSUMPTION OF THE LACTIC ACID BACTERIUM LACTOBACILLUS RHAMNOSUS HN001, J AM COLL NUTR, 20, PP. 149-156, (2001); GILL H.S., RUTHERFURD K.J., CROSS M.L., DIETARY PROBIOTIC SUPPLEMENTATION ENHANCES NATURAL KILLER CELL ACTIVITY IN THE ELDERLY: AN INVESTIGATION OF AGE-RELATED IMMUNOLOGICAL CHANGES, J CLIN IMMUNOL, 21, PP. 264-271, (2001); LIM B.K., MAHENDRAN R., LEE Y.K., BAY B.H., CHEMOPREVENTIVE EFFECT OF LACTOBACILLUS RHAMNOSUS ON GROWTH OF A SUBCUTANEOUSLY IMPLANTED BLADDER CANCER CELL LINE IN THE MOUSE, JPN J CANCER RES, 93, PP. 36-41, (2002); HORI T., KIYOSHIMA J., YASUI H., EFFECT OF AN ORAL ADMINISTRATION OF LACTOBACILLUS CASEI STRAIN SHIROTA ON THE NATURAL KILLER ACTIVITY OF BLOOD MONONUCLEAR CELLS IN AGED MICE, BIOSCI BIOTECHNOL BIOCHEM, 67, PP. 420-422, (2003); PARRA M.D., MARTINEZ DE MORENTIN B.E., COBO J.M., MATEOS A., MARTINEZ J.A., DAILY INGESTION OF FERMENTED MILK CONTAINING LACTOBACILLUS CASEI DN114001 IMPROVES INNATE-DEFENSE CAPACITY IN HEALTHY MIDDLE-AGED PEOPLE, J PHYSIOL BIOCHEM, 60, PP. 85-91, (2004); MATSUZAKI T., TAKAGI A., IKEMURA H., MATSUGUCHI T., YOKOKURA T., ANTITUMOR ACTIVITY AND ACTION MECHANISMS OF LACTOBACILLUS CASEI THROUGH THE REGULATION OF IMMUNE RESPONSES, BIOFACTORS, 22, PP. 63-66, (2004); MORIMOTO K., TAKESHITA T., NANNO M., TOKUDOME S., NAKAYAMA K., MODULATION OF NATURAL KILLER CELL ACTIVITY BY SUPPLEMENTATION OF FERMENTED MILK CONTAINING LACTOBACILLUS CASEI IN HABITUAL SMOKERS, PREV MED, 40, PP. 589-594, (2005); FAHR M.J., KORNBLUTH J., BLOSSOM S., SCHAEFFER R., KLIMBERG V.S., HARRY M. VARS RESEARCH AWARD. GLUTAMINE ENHANCES IMMUNOREGULATION OF TUMOR GROWTH, JPEN J PARENTER ENTERAL NUTR, 18, PP. 471-476, (1994); KLIMBERG V.S., KORNBLUTH J., CAO Y., DANG A., BLOSSOM S., SCHAEFFER R.F., GLUTAMINE SUPPRESSES PGE2 SYNTHESIS AND BREAST CANCER GROWTH, J SURG RES, 63, PP. 293-297, (1996); SHEWCHUK L.D., BARACOS V.E., FIELD C.J., DIETARY L-GLUTAMINE SUPPLEMENTATION REDUCES THE GROWTH OF THE MORRIS HEPATOMA 7777 IN EXERCISE-TRAINED AND SEDENTARY RATS, J NUTR, 127, PP. 158-166, (1997); KAUFMANN Y., KORNBLUTH J., FENG Z., FAHR M., SCHAEFER R.F., KLIMBERG V.S., EFFECT OF GLUTAMINE ON THE INITIATION AND PROMOTION PHASES OF DMBA-INDUCED MAMMARY TUMOR DEVELOPMENT, JPEN J PARENTER ENTERAL NUTR, 27, PP. 411-418, (2003); YAKAR I., MELAMED R., SHAKHAR G., ET AL., PROSTAGLANDIN E(2) SUPPRESSES NK ACTIVITY IN VIVO AND PROMOTES POSTOPERATIVE TUMOR METASTASIS IN RATS, ANN SURG ONCOL, 10, PP. 469-479, (2003); KUNDU N., WALSER T.C., MA X., FULTON A.M., CYCLOOXYGENASE INHIBITORS MODULATE NK ACTIVITIES THAT CONTROL METASTATIC DISEASE, CANCER IMMUNOL IMMUNOTHER, 54, PP. 981-987, (2005); PORZSOLT F., WOLF W., MODULATION OF NATURAL KILLER ACTIVITY BY ASPIRIN: I. IN VITRO EFFECT OF ASPIRIN, J INTERFERON RES, 3, PP. 11-17, (1983); UHLENBRUCK G., LOTZERICH H., BERNHARDT J., ROGALLA K., ACETYLSALICYLIC ACID HAS NO EFFECTS ON VARIOUS ISOLATED IMMUNE CELLS IN VITRO, EUR J APPL PHYSIOL OCCUP PHYSIOL, 66, PP. 473-476, (1993); KANG B.Y., CHUNG S.W., KIM S.H., CHO D., KIM T.S., INVOLVEMENT OF NUCLEAR FACTOR-KAPPAB IN THE INHIBITION OF INTERLEUKIN-12 PRODUCTION FROM MOUSE MACROPHAGES BY BAICALEIN, A FLAVONOID IN SCUTELLARIA BAICALENSIS, PLANTA MED, 69, PP. 687-691, (2003); KANG B.Y., KIM S.H., CHO D., KIM T.S., INHIBITION OF INTERLEUKIN-12 PRODUCTION IN MOUSE MACROPHAGES VIA DECREASED NUCLEAR FACTOR-KAPPAB DNA BINDING ACTIVITY BY MYRICETIN, A NATURALLY OCCURRING FLAVONOID, ARCH PHARM RES, 28, PP. 274-279, (2005); WASHIZU J., NISHIMURA H., NAKAMURA N., NIMURA Y., YOSHIKAI Y., THE NF-KAPPAB BINDING SITE IS ESSENTIAL FOR TRANSCRIPTIONAL ACTIVATION OF THE IL-15 GENE, IMMUNOGENETICS, 48, PP. 1-7, (1998); HACKSTEIN H., MORELLI A.E., LARREGINA A.T., ET AL., ASPIRIN INHIBITS IN VITRO MATURATION AND IN VIVO IMMUNOSTIMULATORY FUNCTION OF MURINE MYELOID DENDRITIC CELLS, J IMMUNOL, 166, PP. 7053-7062, (2001); HILLEN H.F., THROMBOSIS IN CANCER PATIENTS, ANN ONCOL, 11, 3 SUPPL., PP. 273-276, (2000); FERNANDEZ P.M., PATIERNO S.R., RICKLES F.R., TISSUE FACTOR AND FIBRIN IN TUMOR ANGIOGENESIS, SEMIN THROMB HEMOST, 30, PP. 31-44, (2004); OETH P., PARRY G.C., MACKMAN N., REGULATION OF THE TISSUE FACTOR GENE IN HUMAN MONOCYTIC CELLS. ROLE OF AP-1, NF-KAPPA B/REL, AND SP1 PROTEINS IN UNINDUCED AND LIPOPOLYSACCHARIDE- INDUCED EXPRESSION, ARTERIOSCLER THROMB VASC BIOL, 17, PP. 365-374, (1997); MUSHIAKE H., TSUNODA T., NUKATSUKA M., SHIMAO K., FUKUSHIMA M., TAHARA H., DENDRITIC CELLS MIGHT BE ONE OF KEY FACTORS FOR ELICITING ANTITUMOR EFFECT BY CHEMOIMMUNOTHERAPY IN VIVO, CANCER IMMUNOL IMMUNOTHER, 54, PP. 120-128, (2005); PETRIE H.T., KLASSEN L.W., KLASSEN P.S., O'DELL J.R., KAY H.D., SELENIUM AND THE IMMUNE RESPONSE: 2. ENHANCEMENT OF MURINE CYTOTOXIC T-LYMPHOCYTE AND NATURAL KILLER CELL CYTOTOXICITYIN VIVO, J LEUKOC BIOL, 45, PP. 215-220, (1989); ROY M., KIREMIDJIAN-SCHUMACHER L., WISHE H.I., COHEN M.W., STOTZKY G., SELENIUM AND IMMUNE CELL FUNCTIONS. II. EFFECT ON LYMPHOCYTE-MEDIATED CYTOTOXICITY, PROC SOC EXP BIOL MED, 193, PP. 143-148, (1990); ROY M., KIREMIDJIAN-SCHUMACHER L., WISHE H.I., COHEN M.W., STOTZKY G., SUPPLEMENTATION WITH SELENIUM RESTORES AGE-RELATED DECLINE IN IMMUNE CELL FUNCTION, PROC SOC EXP BIOL MED, 209, PP. 369-375, (1995); MIZUNO M., MORIMOTO M., MINATO K., TSUCHIDA H., POLYSACCHARIDES FROM AGARICUS BLAZEI STIMULATE LYMPHOCYTE T-CELL SUBSETS IN MICE, BIOSCI BIOTECHNOL BIOCHEM, 62, PP. 434-437, (1998); CAO L.Z., LIN Z.B., REGULATORY EFFECT OF GANODERMA LUCIDUM POLYSACCHARIDES ON CYTOTOXIC T-LYMPHOCYTES INDUCED BY DENDRITIC CELLS IN VITRO, ACTA PHARMACOL SIN, 24, PP. 321-326, (2003); MATSUZAKI T., HASHIMOTO S., YOKOKURA T., EFFECTS ON ANTITUMOR ACTIVITY AND CYTOKINE PRODUCTION IN THE THORACIC CAVITY BY INTRAPLEURAL ADMINISTRATION OF LACTOBACILLUS CASEI IN TUMOR-BEARING MICE, MED MICROBIOL IMMUNOL (BERL), 185, PP. 157-161, (1996); BRUERA E., ABC OF PALLIATIVE CARE. ANOREXIA, CACHEXIA, AND NUTRITION, BMJ, 315, PP. 1219-1222, (1997); TISDALE M.J., CANCER CACHEXIA, LANGENBECKS ARCH SURG, 389, PP. 299-305, (2004); WHITEHOUSE A.S., TISDALE M.J., INCREASED EXPRESSION OF THE UBIQUITIN-PROTEASOME PATHWAY IN MURINE MYOTUBES BY PROTEOLYSIS-INDUCING FACTOR (PIF) IS ASSOCIATED WITH ACTIVATION OF THE TRANSCRIPTION FACTOR NF-KAPPAB, BR J CANCER, 89, PP. 1116-1122, (2003); WYKE S.M., RUSSELL S.T., TISDALE M.J., INDUCTION OF PROTEASOME EXPRESSION IN SKELETAL MUSCLE IS ATTENUATED BY INHIBITORS OF NF-KAPPAB ACTIVATION, BR J CANCER, 91, PP. 1742-1750, (2004); WYKE S.M., TISDALE M.J., NF-KAPPAB MEDIATES PROTEOLYSIS-INDUCING FACTOR INDUCED PROTEIN DEGRADATION AND EXPRESSION OF THE UBIQUITIN-PROTEASOME SYSTEM IN SKELETAL MUSCLE, BR J CANCER, 92, PP. 711-721, (2005); CAI D., FRANTZ J.D., TAWA JR. N.E., ET AL., IKKBETA/NF-KAPPAB ACTIVATION CAUSES SEVERE MUSCLE WASTING IN MICE, CELL, 119, PP. 285-298, (2004); LORITE M.J., CARIUK P., TISDALE M.J., INDUCTION OF MUSCLE PROTEIN DEGRADATION BY A TUMOUR FACTOR, BR J CANCER, 76, PP. 1035-1040, (1997); CABAL-MANZANO R., BHARGAVA P., TORRES-DUARTE A., MARSHALL J., BHARGAVA P., WAINER I.W., PROTEOLYSIS-INDUCING FACTOR IS EXPRESSED IN TUMOURS OF PATIENTS WITH GASTROINTESTINAL CANCERS AND CORRELATES WITH WEIGHT LOSS, BR J CANCER, 84, PP. 1599-1601, (2001); GOMES-MARCONDES M.C., SMITH H.J., COOPER J.C., TISDALE M.J., DEVELOPMENT OF AN IN-VITRO MODEL SYSTEM TO INVESTIGATE THE MECHANISM OF MUSCLE PROTEIN CATABOLISM INDUCED BY PROTEOLYSIS-INDUCING FACTOR, BR J CANCER, 86, PP. 1628-1633, (2002); TISDALE M.J., TUMOR-HOST INTERACTIONS, J CELL BIOCHEM, 93, PP. 871-877, (2004); WILLIAMS M.L., TORRES-DUARTE A., BRANT L.J., BHARGAVA P., MARSHALL J., WAINER I.W., THE RELATIONSHIP BETWEEN A URINARY CACHECTIC FACTOR AND WEIGHT LOSS IN ADVANCED CANCER PATIENTS, CANCER INVEST, 22, PP. 866-870, (2004); WHITEHOUSE A.S., KHAL J., TISDALE M.J., INDUCTION OF PROTEIN CATABOLISM IN MYOTUBES BY 15(S)- HYDROXYEICOSATETRAENOIC ACID THROUGH INCREASED EXPRESSION OF THE UBIQUITIN-PROTEASOME PATHWAY, BR J CANCER, 89, PP. 737-745, (2003); WYKE S.M., KHAL J., TISDALE M.J., SIGNALLING PATHWAYS IN THE INDUCTION OF PROTEASOME EXPRESSION BY PROTEOLYSIS-INDUCING FACTOR IN MURINE MYOTUBES, CELL SIGNAL, 17, PP. 67-75, (2005); SMITH H.J., WYKE S.M., TISDALE M.J., ROLE OF PROTEIN KINASE C AND NF-KAPPAB IN PROTEOLYSIS-INDUCING FACTOR-INDUCED PROTEASOME EXPRESSION IN C(2) C(12) MYOTUBES, BR J CANCER, 90, PP. 1850-1857, (2004); SMITH H.J., WYKE S.M., TISDALE M.J., MECHANISM OF THE ATTENUATION OF PROTEOLYSIS-INDUCING FACTOR STIMULATED PROTEIN DEGRADATION IN MUSCLE BY BETA-HYDROXY-BETA-METHYLBUTYRATE, CANCER RES, 64, PP. 8731-8735, (2004); PANTON L.B., RATHMACHER J.A., BAIER S., NISSEN S., NUTRITIONAL SUPPLEMENTATION OF THE LEUCINE METABOLITE BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) DURING RESISTANCE TRAINING, NUTRITION, 16, PP. 734-739, (2000); VUKOVICH M.D., STUBBS N.B., BOHLKEN R.M., BODY COMPOSITION IN 70-YEAR-OLD ADULTS RESPONDS TO DIETARY BETA-HYDROXY-BETA-METHYLBUTYRATE SIMILARLY TO THAT OF YOUNG ADULTS, J NUTR, 131, PP. 2049-2052, (2001); ALON T., BAGCHI D., PREUSS H.G., SUPPLEMENTING WITH BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) TO BUILD AND MAINTAIN MUSCLE MASS: A REVIEW, RES COMMUN MOL PATHOL PHARMACOL, 111, PP. 139-151, (2002); SMITH H.J., MUKERJI P., TISDALE M.J., ATTENUATION OF PROTEASOME-INDUCED PROTEOLYSIS IN SKELETAL MUSCLE BY Β-HYDROXY-Β-METHYLBUTYRATE IN CANCER-INDUCED MUSCLE LOSS, CANCER RES, 65, PP. 277-283, (2005); TISDALE M.J., BECK S.A., INHIBITION OF TUMOUR-INDUCED LIPOLYSIS IN VITRO AND CACHEXIA AND TUMOUR GROWTH IN VIVO BY EICOSAPENTAENOIC ACID, BIOCHEM PHARMACOL, 41, PP. 103-107, (1991); WHITEHOUSE A.S., SMITH H.J., DRAKE J.L., TISDALE M.J., MECHANISM OF ATTENUATION OF SKELETAL MUSCLE PROTEIN CATABOLISM IN CANCER CACHEXIA BY EICOSAPENTAENOIC ACID, CANCER RES, 61, PP. 3604-3609, (2001); JHO D.H., BABCOCK T.A., TEVAR R., HELTON W.S., ESPAT N.J., EICOSAPENTAENOIC ACID SUPPLEMENTATION REDUCES TUMOR VOLUME AND ATTENUATES CACHEXIA IN A RAT MODEL OF PROGRESSIVE NON-METASTASIZING MALIGNANCY, JPEN J PARENTER ENTERAL NUTR, 26, PP. 291-297, (2002); WIGMORE S.J., ROSS J.A., FALCONER J.S., ET AL., THE EFFECT OF POLYUNSATURATED FATTY ACIDS ON THE PROGRESS OF CACHEXIA IN PATIENTS WITH PANCREATIC CANCER, NUTRITION, 12, (1996); BARBER M.D., ROSS J.A., VOSS A.C., TISDALE M.J., FEARON K.C., THE EFFECT OF AN ORAL NUTRITIONAL SUPPLEMENT ENRICHED WITH FISH OIL ON WEIGHT-LOSS IN PATIENTS WITH PANCREATIC CANCER, BR J CANCER, 81, PP. 80-86, (1999); WIGMORE S.J., BARBER M.D., ROSS J.A., TISDALE M.J., FEARON K.C., EFFECT OF ORAL EICOSAPENTAENOIC ACID ON WEIGHT LOSS IN PATIENTS WITH PANCREATIC CANCER, NUTR CANCER, 36, PP. 177-184, (2000); FEARON K.C., VON MEYENFELDT M.F., MOSES A.G., ET AL., EFFECT OF A PROTEIN AND ENERGY DENSE N-3 FATTY ACID ENRICHED ORAL SUPPLEMENT ON LOSS OF WEIGHT AND LEAN TISSUE IN CANCER CACHEXIA: A RANDOMISED DOUBLE BLIND TRIAL, GUT, 52, PP. 1479-1486, (2003); JATOI A., ROWLAND K., LOPRINZI C.L., ET AL., AN EICOSAPENTAENOIC ACID SUPPLEMENT VERSUS MEGESTROL ACETATE VERSUS BOTH FOR PATIENTS WITH CANCER-ASSOCIATED WASTING: A NORTH CENTRAL CANCER TREATMENT GROUP AND NATIONAL CANCER INSTITUTE OF CANADA COLLABORATIVE EFFORT, J CLIN ONCOL, 22, PP. 2469-2476, (2004); TESSITORE L., COSTELLI P., BACCINO F.M., PHARMACOLOGICAL INTERFERENCE WITH TISSUE HYPERCATABOLISM IN TUMOUR-BEARING RATS, BIOCHEM J, 299, PP. 71-78, (1994); MCCARTY M., PRE-ADMINISTRATION OF HIGH-DOSE ASPIRIN OR SALICYLATE, SUPPRESSORS OF NF-KAPPAB ACTIVATION, MAY INCREASE THE CHEMOSENSITIVITY OF MANY CANCERS - AN EXAMPLE OF PRO-APOPTOTIC SIGNAL MODULATION THERAPY, MED HYPOTHESES; SADIK C.D., SIES H., SCHEWE T., INHIBITION OF 15-LIPOXYGENASES BY FLAVONOIDS: STRUCTURE-ACTIVITY RELATIONS AND MODE OF ACTION, BIOCHEM PHARMACOL, 65, PP. 773-781, (2003); SHIMOI K., OKADA H., FURUGORI M., ET AL., INTESTINAL ABSORPTION OF LUTEOLIN AND LUTEOLIN 7-O-BETA-GLUCOSIDE IN RATS AND HUMANS, FEBS LETT, 438, PP. 220-224, (1998); KAWAII S., TOMONO Y., KATASE E., OGAWA K., YANO M., ANTIPROLIFERATIVE ACTIVITY OF FLAVONOIDS ON SEVERAL CANCER CELL LINES, BIOSCI BIOTECHNOL BIOCHEM, 63, PP. 896-899, (1999); BAGLI E., STEFANIOTOU M., MORBIDELLI L., ET AL., LUTEOLIN INHIBITS VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS; INHIBITION OF ENDOTHELIAL CELL SURVIVAL AND PROLIFERATION BY TARGETING PHOSPHATIDYLINOSITOL 3′-KINASE ACTIVITY, CANCER RES, 64, PP. 7936-7946, (2004); KIMBALL S.R., JEFFERSON L.S., CONTROL OF PROTEIN SYNTHESIS BY AMINO ACID AVAILABILITY, CURR OPIN CLIN NUTR METAB CARE, 5, PP. 63-67, (2002); HAMMARQVIST F., SANDGREN A., ANDERSSON K., ET AL., GROWTH HORMONE TOGETHER WITH GLUTAMINE-CONTAINING TOTAL PARENTERAL NUTRITION MAINTAINS MUSCLE GLUTAMINE LEVELS AND RESULTS IN A LESS NEGATIVE NITROGEN BALANCE AFTER SURGICAL TRAUMA, SURGERY, 129, PP. 576-586, (2001); BOZA J.J., TURINI M., MOENNOZ D., ET AL., EFFECT OF GLUTAMINE SUPPLEMENTATION OF THE DIET ON TISSUE PROTEIN SYNTHESIS RATE OF GLUCOCORTICOID-TREATED RATS, NUTRITION, 17, PP. 35-40, (2001); YOSHIDA S., KAIBARA A., ISHIBASHI N., SHIROUZU K., GLUTAMINE SUPPLEMENTATION IN CANCER PATIENTS, NUTRITION, 17, PP. 766-768, (2001); CLARK R.H., FELEKE G., DIN M., ET AL., NUTRITIONAL TREATMENT FOR ACQUIRED IMMUNODEFICIENCY VIRUS-ASSOCIATED WASTING USING BETA-HYDROXY BETA-METHYLBUTYRATE, GLUTAMINE, AND ARGININE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, JPEN J PARENTER ENTERAL NUTR, 24, PP. 133-139, (2000); MAY P.E., BARBER A., D'OLIMPIO J.T., HOURIHANE A., ABUMRAD N.N., REVERSAL OF CANCER-RELATED WASTING USING ORAL SUPPLEMENTATION WITH A COMBINATION OF BETA-HYDROXY-BETA-METHYLBUTYRATE, ARGININE, AND GLUTAMINE, AM J SURG, 183, PP. 471-479, (2002); MARCORA S., LEMMEY A., MADDISON P., DIETARY TREATMENT OF RHEUMATOID CACHEXIA WITH BETA-HYDROXY-BETA- METHYLBUTYRATE, GLUTAMINE AND ARGININE: A RANDOMISED CONTROLLED TRIAL, CLIN NUTR, 24, PP. 442-454, (2005); LANG C.H., FROST R.A., ROLE OF GROWTH HORMONE, INSULIN-LIKE GROWTH FACTOR-I, AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS IN THE CATABOLIC RESPONSE TO INJURY AND INFECTION, CURR OPIN CLIN NUTR METAB CARE, 5, PP. 271-279, (2002); SINGLETON J.R., FELDMAN E.L., INSULIN-LIKE GROWTH FACTOR-I IN MUSCLE METABOLISM AND MYOTHERAPIES, NEUROBIOL DIS, 8, PP. 541-554, (2001); FRANCH H.A., PRICE S.R., MOLECULAR SIGNALING PATHWAYS REGULATING MUSCLE PROTEOLYSIS DURING ATROPHY, CURR OPIN CLIN NUTR METAB CARE, 8, PP. 271-275, (2005); LEROITH D., ROBERTS JR. C.T., THE INSULIN-LIKE GROWTH FACTOR SYSTEM AND CANCER, CANCER LETT, 195, PP. 127-137, (2003); JENKINS P.J., BUSTIN S.A., EVIDENCE FOR A LINK BETWEEN IGF-I AND CANCER, EUR J ENDOCRINOL, 51, 1 SUPPL., (2004); FRASCA F., PANDINI G., VIGNERI R., GOLDFINE I.D., INSULIN AND HYBRID INSULIN/IGF RECEPTORS ARE MAJOR REGULATORS OF BREAST CANCER CELLS, BREAST DIS, 17, PP. 73-89, (2003); BASERGA R., THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR AS A TARGET FOR CANCER THERAPY, EXPERT OPIN THER TARGETS, 9, PP. 753-768, (2005); OH J.S., KUCAB J.E., BUSHEL P.R., ET AL., INSULIN-LIKE GROWTH FACTOR-1 INSCRIBES A GENE EXPRESSION PROFILE FOR ANGIOGENIC FACTORS AND CANCER PROGRESSION IN BREAST EPITHELIAL CELLS, NEOPLASIA, 4, PP. 204-217, (2002); SHIGEMATSU S., YAMAUCHI K., NAKAJIMA K., IIJIMA S., AIZAWA T., HASHIZUME K., IGF-1 REGULATES MIGRATION AND ANGIOGENESIS OF HUMAN ENDOTHELIAL CELLS, ENDOCR J, 46, SUPPL., (1999); REINMUTH N., FAN F., LIU W., ET AL., IMPACT OF INSULIN-LIKE GROWTH FACTOR RECEPTOR-I FUNCTION ON ANGIOGENESIS, GROWTH, AND METASTASIS OF COLON CANCER, LAB INVEST, 82, PP. 1377-1389, (2002); STOELTZING O., LIU W., REINMUTH N., ET AL., REGULATION OF HYPOXIA-INDUCIBLE FACTOR-LALPHA, VASCULAR ENDOTHELIAL GROWTH FACTOR, AND ANGIOGENESIS BY AN INSULIN-LIKE GROWTH FACTOR-I RECEPTOR AUTOCRINE LOOP IN HUMAN PANCREATIC CANCER, AM J PATHOL, 163, PP. 1001-1011, (2003); BOYD D.B., INSULIN AND CANCER, INTEGR CANCER THER, 2, PP. 315-329, (2003); BARNARD R.J., NGO T.H., LEUNG P.S., ARONSON W.J., GOLDING L.A., A LOW-FAT DIET AND/OR STRENUOUS EXERCISE ALTERS THE IGF AXIS IN VIVO AND REDUCES PROSTATE TUMOR CELL GROWTH IN VITRO, PROSTATE, 56, PP. 201-206, (2003); BARNARD R.J., PREVENTION OF CANCER THROUGH LIFESTYLE CHANGES, EVID BASED COMPLEMENT ALTERNAT MED, 1, PP. 233-239, (2004); ALLEN N.E., APPLEBY P.N., DAVEY G.K., KEY T.J., HORMONES AND DIET: LOW INSULIN-LIKE GROWTH FACTOR-I BUT NORMAL BIOAVAILABLE ANDROGENS IN VEGAN MEN, BR J CANCER, 83, PP. 95-97, (2000)","M.F. MCCARTY; BLOCK CENTER FOR INTEGRATIVE CANCER CARE, EVANSTON, IL 60201, 1800 SHERMAN AVENUE, UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","","ENGLISH","INTEGR. CANCER THER.","REVIEW","ISI","2-S2.0-33646581315","INTEGR CANCER THER","BLOCK CENTER FOR INTEGRATIVE CANCER CARE;BLOCK CENTER FOR INTEGRATIVE CANCER CARE","NOTREPORTED;BLOCK CENTER FOR INTEGRATIVE CANCER CARE;NOTREPORTED",NA,"MCCARTY MF, 2006, INTEGR CANCER THER","MCCARTY MF, 2006, INTEGR CANCER THER"
"VARADY K;WANG Y;JONES P","VARADY, KRISTA A. (8048074800); WANG, YANWEN (8397210300); JONES, PETER J.H. (36078426500)","ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE",2003,"NUTRITION REVIEWS","61","7",96,"10.1301/nr.2003.nov.376-383","CANADA;CANADA;CANADA","POLICOSANOLS ARE A MIXTURE OF ALIPHATIC ALCOHOLS DERIVED FROM PURIFIED SUGAR CANE. WHEN ADMINISTERED AT 5 TO 20 MG/DAY, POLICOSANOLS HAVE BEEN SHOWN TO DECREASE THE RISK OF ATHEROMA FORMATION BY REDUCING PLATELET AGGREGATION, ENDOTHELIAL DAMAGE, AND FOAM CELL FORMATION IN ANIMALS. ADDITIONALLY, POLICOSANOLS HAVE BEEN SHOWN TO LOWER TOTAL AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL LEVELS BY 13 TO 23% AND 19 TO 31%, RESPECTIVELY, WHILE INCREASING HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL FROM 8 TO 29%. POLICOSANOLS ARE THOUGHT TO IMPROVE LIPID PROFILES BY REDUCING HEPATIC CHOLESTEROL BIOSYNTHESIS WHILE ENHANCING LDL CLEARANCE. WHEN COMPARED WITH STATINS, POLICOSANOIS EXHIBIT COMPARABLE CHOLESTEROL-LOWERING EFFECTS AT MUCH SMALLER DOSES. THE MIXTURE IS WELL TOLERATED WHEN ADMINISTERED TO ANIMALS; HOWEVER, A MORE PRECISE SAFETY PROFILE IS NEEDED FOR HUMANS. IN SUMMARY, POLICOSANOLS ARE A PROMISING RESOURCE IN THE PREVENTION AND THERAPY OF CARDIOVASCULAR DISEASE (CVD), BUT THESE RESULTS NEED TO BE CONFIRMED IN INDEPENDENT LABORATORIES.","CARDIOVASCULAR DISEASE; CHOLESTEROL; POLICOSANOLS","ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FATTY ALCOHOLS; HUMANS; LIVER; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; ANIMALIA; ARUNDINARIA; SACCHARUM; ACIPIMOX; ANTICOAGULANT AGENT; MEVINOLIN; POLICOSANOL; PRAVASTATIN; ATHEROMA; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL LIVER LEVEL; CLINICAL TRIAL; DRUG TOLERABILITY; ENDOTHELIUM LESION; HEADACHE; HUMAN; NONHUMAN; POLYURIA; REVIEW; SAFETY; SIDE EFFECT; THROMBOCYTE AGGREGATION; WEIGHT REDUCTION","","","SINGH B.K., MEHTA J.L., MANAGEMENT OF DYSLIPIDEMIA IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE, CURR OPIN CARDIOL, 17, PP. 503-511, (2002); STRAUS S.E., MAJUMDAR S.R., MCALISTER F.A., NEW EVIDENCE FOR STROKE PREVENTION: SCIENTIFIC REVIEW, JAMA, 288, PP. 1388-1395, (2002); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); URIBARRI E., LAGUNA A., SIERRA R., RICARDO Y., PHYSICO-MECHANICAL CHARACTERIZATION OF POLICOSANOL, A NOVEL HYPOCHOLESTEROLEMIC DRUG, DRUG DEV IND PHARM, 28, PP. 89-93, (2002); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); SHAH A.B., BEAMER N., COULL B.M., ENHANCED IN VIVO PLATELET ACTIVATION IN SUBTYPES OF ISCHEMIC STROKE, STROKE, 16, PP. 643-647, (1985); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); MONCADA S., VANE J.P., PHARMACOLOGY AND ENDOGENOUS ROLE OF PROSTAGLANDIN THROMBOXANE A2 AND PROSTACYCLIN, PHARMACOL REV, 30, PP. 293-331, (1979); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); HLADOVEC J., KORNALIK F., ANTITHROMBOTIC ACTIVITY OF AN UNSATURATED FATTY ACID PREPARATION, THROMB RES, 58, PP. 505-510, (1990); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS IN SPRAGUE-DAWLEY RATS AND IN RABBITS, J PHARM PHARMACOL, 49, PP. 999-1002, (1997); MUNRO J.M., COTRAN R.S., THE PATHOGENESIS OF ATHEROSCLEROSIS: ATHEROGENESIS AND INFLAMMATION, LAB INVEST, 58, PP. 249-261, (1988); NOA M., DE LA ROSA M.C., MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, (1996); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); KAWAMURA N., MOSER H.W., KISHIMOTO Y., VERY LONG CHAIN FATTY ACID OXIDATION IN RAT LIVER, BIOCHEM BIOPHYS RES COMMUN, 99, PP. 1216-1225, (1981); WANG Y.W., JONES P.J., PISHEL K., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); PONS P., MAS R., ILLNAIT J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA, CURR THER RES, 52, PP. 507-513, (1992); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERREIRO R.M., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS RES DEVEL, 3, PP. 159-172, (2002); BHATNAGAR D., LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDAEMIA, PHARMACOL THER, 79, PP. 205-230, (1998); YALE B.M., THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, PP. 33-36, (1992); BOLEGO C., BAETTA R., BELLOSTA S., CORSINI A., PAOLETTI R., SAFETY CONSIDERATIONS FOR STATINS, CURR OPIN LIPIDOL, 13, PP. 637-644, (2002); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); ALCOCER L., FERNANDEZ L., CAMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); STEINBERG D., PARTHASARATHY S., CAREW T.E., KHOO J.C., WITZTUM J.L., BEYOND CHOLESTEROL. MODIFICATIONS OF LOW-DENSITY LIPOPROTEIN THAT INCREASE ITS ATHEROGENICITY, N ENGL J MED, 320, PP. 915-924, (1989); AVIRAM M., MODIFIED FORMS OF LOW DENSITY LIPOPROTEIN AND ATHEROSCLEROSIS, ATHEROSCLEROSIS, 98, PP. 1-9, (1993); BROWN M.S., GOLDSTEIN J.L., LIPOPROTEIN METABOLISM IN THE MACROPHAGE: IMPLICATIONS FOR CHOLESTEROL DEPOSITION IN ATHEROSCLEROSIS, ANNU REV BIOCHEM, 52, PP. 223-261, (1983); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., ILLNAIT J., ET AL., EFFECTS OF D-002 ON LIPID PEROXIDATION IN OLDER SUBJECTS, J MED FOOD, 4, PP. 71-77, (2001); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); RENDON A., RODRIGUEZ M.D., LOPEZ M., ET AL., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOL LETT, 63, (1992); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); PONS P., RODRIGUEZ, ROBAINA C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARM RES, 14, PP. 27-33, (1994); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ILLNAIT J., LOPEZ E., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA, DRUGS RES DEVEL, 3, PP. 159-172, (2002); MAS R., RIVAS P., IZQUIERDO J.E., PHARMOCOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999)","","INTERNATIONAL LIFE SCIENCES INSTITUTE","ENGLISH","NUTR. REV.","REVIEW","ISI","2-S2.0-0345687218","NUTR REV",NA,"NOTREPORTED",NA,"VARADY KA, 2003, NUTR REV","VARADY KA, 2003, NUTR REV"
"ADHIKARI P;KEUM T;JAE N;CHOONG K","ADHIKARI, PRAKASH (57196770202); KEUM, TAEK HWANG (8220995600); JAE, NAM PARK (37046185300); CHOONG, KI KIM (37045955200)","POLICOSANOL CONTENT AND COMPOSITION IN PERILLA SEEDS",2006,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","54","3",52,"10.1021/jf060688k","DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU 561-756, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU 561-756, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU 561-756, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU 561-756, SOUTH KOREA","POLICOSANOLS, LONG-CHAIN ALCOHOLS, HAVE MANY BENEFICIAL PHYSIOLOGICAL ACTIVITIES. CONTENTS AND COMPOSITIONS IN PERILLA SEEDS (PERILLA FRUTESCENS) PRODUCED IN KOREA AND CHINA WERE DETERMINED. WAXY MATERIALS WERE EXTRACTED FROM PERILLA SEEDS USING HOT HEXANE. YIELD OF THE WAXY MATERIALS FROM PERILLA SEEDS WAS 72.1 MG/100 G OF DRY WEIGHT. CONTENTS AND COMPOSITIONS OF THE WAXY MATERIALS AND POLICOSANOLS WERE IDENTIFIED AND QUANTIFIED BY TLC, HPLC, AND GC. MAJOR COMPONENTS OF THE WAXY MATERIALS FROM KOREAN AND CHINESE PERILLA SEEDS WERE POLICOSANOLS (25.5 AND 34.8%, RESPECTIVELY), HYDROCARBONS (18.8 AND 10.5%), WAX ESTERS, STERYL ESTERS AND ALDEHYDES (53.0 AND 49.8%), ACIDS (1.7 AND 2.1%), AND TRIACYLGLYCEROLS (1.0 AND 2.9%), DETERMINED BY HPLC. FOR COMPARISON, WAXY MATERIALS OF SESAME SEEDS WERE ALSO ANALYZED. YIELD OF THE WAXY MATERIALS FROM SESAME SEEDS WERE 8.6 MG/100 G. LESS THAN 5% POLICOSANOLS WERE DETECTED IN THE WAXY MATERIALS EXTRACTED FROM SESAME SEEDS PRODUCED IN KOREA AND CHINA. WAX ESTERS OR STERYL ESTERS ACCOUNTED FOR 93-95% OF THE SESAME WAXY MATERIALS. POLICOSANOLS IN THE PERILLA SEEDS WERE COMPOSED OF 67-68% OCTACOSANOL, 16-17% HEXACOSANOL, 6-9% TRIACONTANOL, AND OTHERS. © 2006 AMERICAN CHEMICAL SOCIETY.","OCTACOSANOL; PERILLA SEEDS; POLICOSANOLS; SESAME SEEDS; WAX","ALDEHYDE-LYASES; ESTERS; FATTY ALCOHOLS; HYDROCARBONS; PERILLA; SEEDS; WAXES; PERILLA; PERILLA FRUTESCENS; SESAMUM INDICUM; ALDEHYDE DECARBONYLASE; ESTER; FATTY ALCOHOL; HYDROCARBON; LYASE; POLICOSANOL; WAX; ARTICLE; CHEMISTRY; PERILLA; PLANT SEED","","","IRMAK S., DUNFORD N.T., MILLIGAN J., POLICOSANOL CONTENTS OF BEESWAX, SUGAR CANE AND WHEAT EXTRACTS, FOOD CHEM., 95, PP. 312-318, (2005); HWANG K.T., KIM J.E., WELLER C.L., POLICOSANOL CONTENTS AND COMPOSITIONS IN WAX-LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN, CEREAL CHEM., 82, PP. 242-245, (2005); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOTRIENES ESS. FATTY ACIDS, 58, PP. 61-64, (1998); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. METAB., 39, PP. 279-284, (1995); STUSSER R., BATISTA J., PARDON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH OCTACOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT. J. CLIN. PHARMACOL. THER., 36, PP. 469-473, (1998); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN. EXP. PHARMACOL. PHYSIOL., 29, PP. 891-897, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METAB.-CLIN. EXP., 53, PP. 1309-1314, (2004); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITION OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEM., 81, PP. 345-349, (2004); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J. AM. OIL CHEM. SOC., 79, PP. 529-533, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPARATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, J. SEP. SCI., 25, PP. 619-623, (2002); SHIN H.S., KIM S.W., LIPID COMPOSITION OF PERILLA SEED, J. AM. OIL CHEM. SOC., 71, PP. 619-622, (1994); LONGVAH T., DEOSTHALE Y.G., CHEMICAL AND NUTRITIONAL STUDIES ON HANSHI (PERILLA FRUTESCENS), A TRADITIONAL OILSEED FROM NORTHEAST INDIA, J. AM. OIL CHEM. SOC., 68, PP. 781-784, (1991)","T.H. KEUM; DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU 561-756, SOUTH KOREA; EMAIL: KEUM@CHONBUK.AC.KR","","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","2-S2.0-33746930165","J AGRIC FOOD CHEM","CHONBUK NATIONAL UNIVERSITY;CHONBUK NATIONAL UNIVERSITY;CHONBUK NATIONAL UNIVERSITY;CHONBUK NATIONAL UNIVERSITY","NOTREPORTED;CHONBUK NATIONAL UNIVERSITY;NOTREPORTED",NA,"ADHIKARI P, 2006, J AGRIC FOOD CHEM","ADHIKARI P, 2006, J AGRIC FOOD CHEM"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","TOWARD PREVENTION OF ALZHEIMERS DISEASE POTENTIAL NUTRACEUTICAL STRATEGIES FOR SUPPRESSING THE PRODUCTION OF AMYLOID BETA PEPTIDES",2006,"MEDICAL HYPOTHESES","67","15",33,"10.1016/j.mehy.2006.04.067","NATURAL ALTERNATIVES INTERNATIONAL, SAN MARCOS, CA 92078, 1185 LINDA VISTA DR, UNITED STATES","ALZHEIMERS DISEASE (AD) CAN BE VIEWED AS A VICIOUS CYCLE IN WHICH EXCESS PRODUCTION AND DEPOSITION OF AMYLOID BETA (AΒ) PEPTIDES PROMOTE MICROGLIAL ACTIVATION, AND THE RESULTANT PRODUCTION OF INFLAMMATORY MEDIATORS FURTHER BOOSTS AΒ PRODUCTION WHILE INDUCING DEATH AND DYSFUNCTION OF NEURONS. AΒ PRODUCTION IS MEDIATED BY BETA- AND GAMMA-SECRETASE ACTIVITIES; IT IS PREVENTED BY ALPHA-SECRETASE ACTIVITY, AND INSULIN-DEGRADING ENZYME (IDE) CATABOLIZES AΒ. HIGH CELLULAR CHOLESTEROL CONTENT INCREASES AΒ SYNTHESIS BY BOOSTING BETA-SECRETASE ACTIVITY; INHIBITION OF CHOLESTEROL SYNTHESES AND/OR STIMULATION OF CHOLESTEROL EXPORT THUS DIMINISHES AΒ PRODUCTION. PPARΓ ACTIVITY DECREASES AΒ PRODUCTION BY PROMOTING HARMLESS CATABOLISM OF AMYLOID PRECURSOR PROTEIN WHILE BLOCKING THE UP-REGULATORY IMPACT OF CYTOKINES ON BETA-SECRETASE EXPRESSION. NITRIC OXIDE PRODUCED BY THE HEALTHY CEREBRAL MICROVASCULATURE CAN SUPPRESS AΒ PRODUCTION BY BOOSTING EXPRESSION OF ALPHA-SECRETASE WHILE SUPPRESSING THAT OF BETA-SECRETASE; CONVERSELY, CEREBRAL ISCHEMIA PROVOKES INCREASED APP EXPRESSION. GOOD INSULIN SENSITIVITY AND EFFICIENT BRAIN INSULIN FUNCTION PROTECT BY INHIBITING GAMMA-SECRETASE ACTIVITY AND INCREASING EXPRESSION OF IDE. THE DHA PROVIDED BY FISH OIL DIMINISHES CEREBRAL AΒ DEPOSITION IN RODENT AD MODELS, FOR UNCLEAR REASONS. VARIOUS MEASURES WHICH OPPOSE MICROGLIAL ACTIVATION CAN INHIBIT UP-REGULATION OF BETA-SECRETASE AND GAMMA-SECRETASE BY OXIDANTS AND CYTOKINES, RESPECTIVELY. THESE CONSIDERATIONS SUGGEST THAT A NUMBER OF NUTRACEUTICAL OR LIFESTYLE MEASURES MAY HAVE POTENTIAL FOR PREVENTING OR SLOWING AD: POLICOSANOL; 9-CIS-BETA-CAROTENE; ISOMERIZED HOPS EXTRACT; DHA; MEASURES WHICH PROMOTE EFFICIENT ENDOTHELIAL NO GENERATION, SUCH AS LOW-SALT/POTASSIUM-RICH DIETS, EXERCISE TRAINING, HIGH-DOSE FOLATE, AND FLAVANOL-RICH COCOA; CHROMIUM PICOLINATE AND CINNAMON EXTRACT AS AIDS FOR INSULIN SENSITIVITY; AND VARIOUS AGENTS WHICH CAN OPPOSE MICROGLIAL ACTIVATION, INCLUDING VITAMIN D, GENISTEIN, AND SESAMIN. THE IMPACT OF THESE MEASURES ON AΒ PRODUCTION IN RODENT MODELS OF AD SHOULD BE EVALUATED, WITH THE INTENT OF DEFINING PRACTICAL STRATEGIES FOR AD PREVENTION. © 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN ISCHEMIA; CHOLESTEROL; ENDOPEPTIDASES; INSULYSIN; MODELS, BIOLOGICAL; NITRIC OXIDE; NUTRITION PHYSIOLOGY; PEPTIDE FRAGMENTS; PHYSICAL CONDITIONING, ANIMAL; PPAR GAMMA; CINNAMOMUM VERUM; HUMULUS LUPULUS; RODENTIA; THEOBROMA CACAO; AMYLOID BETA PROTEIN; BETA SECRETASE; CHOLESTEROL; CYCLOOXYGENASE 2; FISH OIL; GAMMA SECRETASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NUTRACEUTICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLICOSANOL; PROSTAGLANDIN E2; AEROBIC EXERCISE; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DIET SUPPLEMENTATION; DOWN REGULATION; ENZYME ACTIVITY; HEALTH PROMOTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID RAFT; MICROGLIA; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; NUTRITIONAL HEALTH; PRIORITY JOURNAL; REPERFUSION INJURY; RISK FACTOR; SPA TREATMENT; TRANSGENIC MOUSE; UBIQUITINATION; UPREGULATION","","","HARDY J., SELKOE D.J., THE AMYLOID HYPOTHESIS OF ALZHEIMER'S DISEASE: PROGRESS AND PROBLEMS ON THE ROAD TO THERAPEUTICS, SCIENCE, 297, PP. 353-356, (2002); BLASKO I., STAMPFER-KOUNTCHEV M., ROBATSCHER P., VEERHUIS R., EIKELENBOOM P., GRUBECK-LOEBENSTEIN B., HOW CHRONIC INFLAMMATION CAN AFFECT THE BRAIN AND SUPPORT THE DEVELOPMENT OF ALZHEIMER'S DISEASE IN OLD AGE: THE ROLE OF MICROGLIA AND ASTROCYTES, AGING CELL, 3, PP. 169-176, (2004); MCCARTY M.F., DOWN-REGULATION OF MICROGLIAL ACTIVATION MAY REPRESENT A PRACTICAL STRATEGY FOR COMBATING NEURODEGENERATIVE DISORDERS, MED HYPOTHESES, 67, PP. 251-269, (2006); SIMONS M., KELLER P., DE STROOPER B., BEYREUTHER K., DOTTI C.G., SIMONS K., CHOLESTEROL DEPLETION INHIBITS THE GENERATION OF BETA-AMYLOID IN HIPPOCAMPAL NEURONS, PROC NATL ACAD SCI USA, 95, PP. 6460-6464, (1998); FASSBENDER K., SIMONS M., BERGMANN C., STROICK M., LUTJOHANN D., KELLER P., ET AL., SIMVASTATIN STRONGLY REDUCES LEVELS OF ALZHEIMER'S DISEASE BETA-AMYLOID PEPTIDES ABETA 42 AND ABETA 40 IN VITRO AND IN VIVO, PROC NATL ACAD SCI USA, 98, PP. 5856-5861, (2001); RIDDELL D.R., CHRISTIE G., HUSSAIN I., DINGWALL C., COMPARTMENTALIZATION OF BETA-SECRETASE (ASP2) INTO LOW-BUOYANT DENSITY, NONCAVEOLAR LIPID RAFTS, CURR BIOL, 11, PP. 1288-1293, (2001); EHEHALT R., KELLER P., HAASS C., THIELE C., SIMONS K., AMYLOIDOGENIC PROCESSING OF THE ALZHEIMER BETA-AMYLOID PRECURSOR PROTEIN DEPENDS ON LIPID RAFTS, J CELL BIOL, 160, PP. 113-123, (2003); URANO Y., HAYASHI I., ISOO N., REID P.C., SHIBASAKI Y., NOGUCHI N., ET AL., ASSOCIATION OF ACTIVE GAMMA-SECRETASE COMPLEX WITH LIPID RAFTS, J LIPID RES, 46, PP. 904-912, (2005); CHAUHAN N.B., SIEGEL G.J., FEINSTEIN D.L., EFFECTS OF LOVASTATIN AND PRAVASTATIN ON AMYLOID PROCESSING AND INFLAMMATORY RESPONSE IN TGCRND8 BRAIN, NEUROCHEM RES, 29, PP. 1897-1911, (2004); PETANCESKA S.S., DEROSA S., OLM V., DIAZ N., SHARMA A., THOMAS-BRYANT T., ET AL., STATIN THERAPY FOR ALZHEIMER'S DISEASE: WILL IT WORK?, J MOL NEUROSCI, 19, PP. 155-161, (2002); ZAMRINI E., MCGWIN G., ROSEMAN J.M., ASSOCIATION BETWEEN STATIN USE AND ALZHEIMER'S DISEASE, NEUROEPIDEMIOLOGY, 23, PP. 94-98, (2004); JICK H., ZORNBERG G.L., JICK S.S., SESHADRI S., DRACHMAN D.A., STATINS AND THE RISK OF DEMENTIA, LANCET, 356, PP. 1627-1631, (2000); WOLOZIN B., KELLMAN W., RUOSSEAU P., CELESIA G.G., SIEGEL G., DECREASED PREVALENCE OF ALZHEIMER DISEASE ASSOCIATED WITH 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, ARCH NEUROL, 57, PP. 1439-1443, (2000); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); FLINT O.P., MASTERS B.A., GREGG R.E., DURHAM S.K., HMG COA REDUCTASE INHIBITOR-INDUCED MYOTOXICITY: PRAVASTATIN AND LOVASTATIN INHIBIT THE GERANYLGERANYLATION OF LOW-MOLECULAR-WEIGHT PROTEINS IN NEONATAL RAT MUSCLE CELL CULTURE, TOXICOL APPL PHARMACOL, 145, PP. 99-110, (1997); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); CASTANO G., MAS R., FERNANDEZ L., LOPEZ E., GUTIERREZ J.A., ILLNAIT J., ET AL., ASSESSMENT OF THE EFFECTS OF D-003, A NEW ANTIPLATELET AND LIPID-LOWERING COMPOUND, IN HEALTHY VOLUNTEERS. A PHASE I CLINICAL STUDY, DRUGS RD, 3, PP. 337-348, (2002); GAMEZ R., MENDOZA S., MAS R., NOA M., ARRUZAZABALA L., CARBAJAL D., ET AL., COMPARISON OF THE CHOLESTEROL-LOWERING EFFECTS AND TOXICITY OF D-003 AND LOVASTATIN IN NORMOCHOLESTEROLAEMIC RABBITS, DRUGS RD, 4, PP. 219-229, (2003); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MENDOZA S., GAMEZ R., ET AL., A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLINDED STUDY, DRUGS EXP CLIN RES, 31, SUPPL, PP. 31-44, (2005); ORAM J.F., HEINECKE J.W., ATP-BINDING CASSETTE TRANSPORTER A1: A CELL CHOLESTEROL EXPORTER THAT PROTECTS AGAINST CARDIOVASCULAR DISEASE, PHYSIOL REV, 85, PP. 1343-1372, (2005); MURTHY S., BORN E., MATHUR S.N., FIELD F.J., LXR/RXR ACTIVATION ENHANCES BASOLATERAL EFFLUX OF CHOLESTEROL IN CACO-2 CELLS, J LIPID RES, 43, PP. 1054-1064, (2002); ZHANG Y., BEYER T.P., BRAMLETT K.S., YAO S., BURRIS T.P., SCHMIDT R.J., ET AL., LIVER X RECEPTOR AND RETINOIC X RECEPTOR MEDIATED ABCA1 REGULATION AND CHOLESTEROL EFFLUX IN MACROPHAGE CELLS-MESSENGER RNA MEASURED BY BRANCHED DNA TECHNOLOGY, MOL GENET METAB, 77, PP. 150-158, (2002); WANG N., TALL A.R., REGULATION AND MECHANISMS OF ATP-BINDING CASSETTE TRANSPORTER A1-MEDIATED CELLULAR CHOLESTEROL EFFLUX, ARTERIOSCLER THROMB VASC BIOL, 23, PP. 1178-1184, (2003); KOLDAMOVA R.P., LEFTEROV I.M., IKONOMOVIC M.D., SKOKO J., LEFTEROV P.I., ISANSKI B.A., ET AL., 22R-HYDROXYCHOLESTEROL AND 9-CIS-RETINOIC ACID INDUCE ATP-BINDING CASSETTE TRANSPORTER A1 EXPRESSION AND CHOLESTEROL EFFLUX IN BRAIN CELLS AND DECREASE AMYLOID BETA SECRETION, J BIOL CHEM, 278, PP. 13244-13256, (2003); BROWN III J., THEISLER C., SILBERMAN S., MAGNUSON D., GOTTARDI-LITTELL N., LEE J.M., ET AL., DIFFERENTIAL EXPRESSION OF CHOLESTEROL HYDROXYLASES IN ALZHEIMER'S DISEASE, J BIOL CHEM, 279, PP. 34674-34681, (2004); SUN Y., YAO J., KIM T.W., TALL A.R., EXPRESSION OF LIVER X RECEPTOR TARGET GENES DECREASES CELLULAR AMYLOID BETA PEPTIDE SECRETION, J BIOL CHEM, 278, PP. 27688-27694, (2003); KOLDAMOVA R.P., LEFTEROV I.M., STAUFENBIEL M., WOLFE D., HUANG S., GLORIOSO J.C., ET AL., THE LIVER X RECEPTOR LIGAND T0901317 DECREASES AMYLOID BETA PRODUCTION IN VITRO AND IN A MOUSE MODEL OF ALZHEIMER'S DISEASE, J BIOL CHEM, 280, PP. 4079-4088, (2005); COSTET P., LUO Y., WANG N., TALL A.R., STEROL-DEPENDENT TRANSACTIVATION OF THE ABC1 PROMOTER BY THE LIVER X RECEPTOR/RETINOID X RECEPTOR, J BIOL CHEM, 275, PP. 28240-28245, (2000); SCHWARTZ K., LAWN R.M., WADE D.P., ABC1 GENE EXPRESSION AND APOA-I-MEDIATED CHOLESTEROL EFFLUX ARE REGULATED BY LXR, BIOCHEM BIOPHYS RES COMMUN, 274, PP. 794-802, (2000); YOSHIKAWA T., SHIMANO H., AMEMIYA-KUDO M., YAHAGI N., HASTY A.H., MATSUZAKA T., ET AL., IDENTIFICATION OF LIVER X RECEPTOR-RETINOID X RECEPTOR AS AN ACTIVATOR OF THE STEROL REGULATORY ELEMENT-BINDING PROTEIN 1C GENE PROMOTER, MOL CELL BIOL, 21, PP. 2991-3000, (2001); WILLY P.J., UMESONO K., ONG E.S., EVANS R.M., HEYMAN R.A., MANGELSDORF D.J., LXR, A NUCLEAR RECEPTOR THAT DEFINES A DISTINCT RETINOID RESPONSE PATHWAY, GENES DEV, 9, PP. 1033-1045, (1995); BEN AMOTZ A., MOKADY S., AVRON M., THE BETA-CAROTENE-RICH ALGA DUNALIELLA BARDAWIL AS A SOURCE OF RETINOL IN A RAT DIET, BR J NUTR, 59, PP. 443-449, (1988); WANG X.D., KRINSKY N.I., BENOTTI P.N., RUSSELL R.M., BIOSYNTHESIS OF 9-CIS-RETINOIC ACID FROM 9-CIS-BETA-CAROTENE IN HUMAN INTESTINAL MUCOSA IN VITRO, ARCH BIOCHEM BIOPHYS, 313, PP. 150-155, (1994); HEBUTERNE X., WANG X.D., JOHNSON E.J., KRINSKY N.I., RUSSELL R.M., INTESTINAL ABSORPTION AND METABOLISM OF 9-CIS-BETA-CAROTENE IN VIVO: BIOSYNTHESIS OF 9-CIS-RETINOIC ACID, J LIPID RES, 36, PP. 1264-1273, (1995); URBACH J., RANDO R.R., ISOMERIZATION OF ALL-TRANS-RETINOIC ACID TO 9-CIS-RETINOIC ACID, BIOCHEM J, 299, PP. 459-465, (1994); KOJIMA R., FUJIMORI T., KIYOTA N., TORIYA Y., FUKUDA T., OHASHI T., ET AL., IN VIVO ISOMERIZATION OF RETINOIC ACIDS. RAPID ISOMER EXCHANGE AND GENE EXPRESSION, J BIOL CHEM, 269, PP. 32700-32707, (1994); LANSINK M., VAN BENNEKUM A.M., BLANER W.S., KOOISTRA T., DIFFERENCES IN METABOLISM AND ISOMERIZATION OF ALL-TRANS-RETINOIC ACID AND 9-CIS-RETINOIC ACID BETWEEN HUMAN ENDOTHELIAL CELLS AND HEPATOCYTES, EUR J BIOCHEM, 247, PP. 596-604, (1997); BACHMANN H., DESBARATS A., PATTISON P., SEDGEWICK M., RISS G., WYSS A., ET AL., FEEDBACK REGULATION OF BETA,BETA-CAROTENE 15,15′-MONOOXYGENASE BY RETINOIC ACID IN RATS AND CHICKENS, J NUTR, 132, PP. 3616-3622, (2002); KURIE J.M., LEE J.S., GRIFFIN T., LIPPMAN S.M., DRUM P., THOMAS M.P., ET AL., PHASE I TRIAL OF 9-CIS RETINOIC ACID IN ADULTS WITH SOLID TUMORS, CLIN CANCER RES, 2, PP. 287-293, (1996); SHAISH A., HARARI A., HANANSHVILI L., COHEN H., BITZUR R., LUVISH T., ET AL., 9-CIS BETA-CAROTENE-RICH POWDER OF THE ALGA DUNALIELLA BARDAWIL INCREASES PLASMA HDL-CHOLESTEROL IN FIBRATE-TREATED PATIENTS, ATHEROSCLEROSIS, (2006); REFOLO L.M., MALESTER B., LAFRANCOIS J., BRYANT-THOMAS T., WANG R., TINT G.S., ET AL., HYPERCHOLESTEROLEMIA ACCELERATES THE ALZHEIMER'S AMYLOID PATHOLOGY IN A TRANSGENIC MOUSE MODEL, NEUROBIOL DIS, 7, PP. 321-331, (2000); SHIE F.S., JIN L.W., COOK D.G., LEVERENZ J.B., LEBOEUF R.C., DIET-INDUCED HYPERCHOLESTEROLEMIA ENHANCES BRAIN A BETA ACCUMULATION IN TRANSGENIC MICE, NEUROREPORT, 13, PP. 455-459, (2002); KIVIPELTO M., HELKALA E.L., LAAKSO M.P., HANNINEN T., HALLIKAINEN M., ALHAINEN K., ET AL., APOLIPOPROTEIN E EPSILON4 ALLELE, ELEVATED MIDLIFE TOTAL CHOLESTEROL LEVEL, AND HIGH MIDLIFE SYSTOLIC BLOOD PRESSURE ARE INDEPENDENT RISK FACTORS FOR LATE-LIFE ALZHEIMER DISEASE, ANN INTERN MED, 137, PP. 149-155, (2002); KUO Y.M., EMMERLING M.R., BISGAIER C.L., ESSENBURG A.D., LAMPERT H.C., DRUMM D., ET AL., ELEVATED LOW-DENSITY LIPOPROTEIN IN ALZHEIMER'S DISEASE CORRELATES WITH BRAIN ABETA 1-42 LEVELS, BIOCHEM BIOPHYS RES COMMUN, 252, PP. 711-715, (1998); LESSER G., KANDIAH K., LIBOW L.S., LIKOUREZOS A., BREUER B., MARIN D., ET AL., ELEVATED SERUM TOTAL AND LDL CHOLESTEROL IN VERY OLD PATIENTS WITH ALZHEIMER'S DISEASE, DEMENT GERIATR COGN DISORD, 12, PP. 138-145, (2001); SABBAGH M., ZAHIRI H.R., CEIMO J., COOPER K., GAUL W., CONNOR D., ET AL., IS THERE A CHARACTERISTIC LIPID PROFILE IN ALZHEIMER'S DISEASE?, J ALZHEIMERS DIS, 6, PP. 585-589, (2004); TAN Z.S., SESHADRI S., BEISER A., WILSON P.W., KIEL D.P., TOCCO M., ET AL., PLASMA TOTAL CHOLESTEROL LEVEL AS A RISK FACTOR FOR ALZHEIMER DISEASE: THE FRAMINGHAM STUDY, ARCH INTERN MED, 163, PP. 1053-1057, (2003); MIELKE M.M., ZANDI P.P., SJOGREN M., GUSTAFSON D., OSTLING S., STEEN B., ET AL., HIGH TOTAL CHOLESTEROL LEVELS IN LATE LIFE ASSOCIATED WITH A REDUCED RISK OF DEMENTIA, NEUROLOGY, 64, PP. 1689-1695, (2005); WOOD W.G., IGBAVBOA U., ECKERT G.P., JOHNSON-ANUNA L.N., MULLER W.E., IS HYPERCHOLESTEROLEMIA A RISK FACTOR FOR ALZHEIMER'S DISEASE?, MOL NEUROBIOL, 31, PP. 185-192, (2005); ARVILL A., BODIN L., EFFECT OF SHORT-TERM INGESTION OF KONJAC GLUCOMANNAN ON SERUM CHOLESTEROL IN HEALTHY MEN, AM J CLIN NUTR, 61, PP. 585-589, (1995); CHEN H.L., SHEU W.H., TAI T.S., LIAW Y.P., CHEN Y.C., KONJAC SUPPLEMENT ALLEVIATED HYPERCHOLESTEROLEMIA AND HYPERGLYCEMIA IN TYPE 2 DIABETIC SUBJECTS - A RANDOMIZED DOUBLE-BLIND TRIAL, J AM COLL NUTR, 22, PP. 36-42, (2003); MARTINO F., MARTINO E., MORRONE F., CARNEVALI E., FORCONE R., NIGLIO T., EFFECT OF DIETARY SUPPLEMENTATION WITH GLUCOMANNAN ON PLASMA TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL IN HYPERCHOLESTEROLEMIC CHILDREN, NUTR METAB CARDIOVASC DIS, 15, PP. 174-180, (2005); MORUISI K.G., OOSTHUIZEN W., OPPERMAN A.M., PHYTOSTEROLS/STANOLS LOWER CHOLESTEROL CONCENTRATIONS IN FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS: A SYSTEMATIC REVIEW WITH META-ANALYSIS, J AM COLL NUTR, 25, PP. 41-48, (2006); MCPHERSON T.B., OSTLUND R.E., GOLDBERG A.C., BATEMAN J.H., SCHIMMOELLER L., SPILBURG C.A., PHYTOSTANOL TABLETS REDUCE HUMAN LDL-CHOLESTEROL, J PHARM PHARMACOL, 57, PP. 889-896, (2005); KUROWSKA E.M., MANTHEY J.A., HYPOLIPIDEMIC EFFECTS AND ABSORPTION OF CITRUS POLYMETHOXYLATED FLAVONES IN HAMSTERS WITH DIET-INDUCED HYPERCHOLESTEROLEMIA, J AGRIC FOOD CHEM, 52, PP. 2879-2886, (2004); LI R.W., THERIAULT A.G., AU K., DOUGLAS T.D., CASASCHI A., KUROWSKA E.M., ET AL., CITRUS POLYMETHOXYLATED FLAVONES IMPROVE LIPID AND GLUCOSE HOMEOSTASIS AND MODULATE ADIPOCYTOKINES IN FRUCTOSE-INDUCED INSULIN RESISTANT HAMSTERS, LIFE SCI, (2006); QURESHI A.A., QURESHI N., WRIGHT J.J., SHEN Z., KRAMER G., GAPOR A., ET AL., LOWERING OF SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC HUMANS BY TOCOTRIENOLS (PALMVITEE), AM J CLIN NUTR, 53, (1991); PARKER R.A., PEARCE B.C., CLARK R.W., GORDON D.A., WRIGHT J.J., TOCOTRIENOLS REGULATE CHOLESTEROL PRODUCTION IN MAMMALIAN CELLS BY POST-TRANSCRIPTIONAL SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, J BIOL CHEM, 268, PP. 11230-11238, (1993); QURESHI A.A., BRADLOW B.A., BRACE L., MANGANELLO J., PETERSON D.M., PEARCE B.C., ET AL., RESPONSE OF HYPERCHOLESTEROLEMIC SUBJECTS TO ADMINISTRATION OF TOCOTRIENOLS, LIPIDS, 30, PP. 1171-1177, (1995); BERTOLINI S., DONATI C., ELICIO N., DAGA A., CUZZOLARO S., MARCENARO A., ET AL., LIPOPROTEIN CHANGES INDUCED BY PANTETHINE IN HYPERLIPOPROTEINEMIC PATIENTS: ADULTS AND CHILDREN, INT J CLIN PHARMACOL THER TOXICOL, 24, PP. 630-637, (1986); ETO M., WATANABE K., CHONAN N., ISHII K., LOWERING EFFECT OF PANTETHINE ON PLASMA BETA-THROMBOGLOBULIN AND LIPIDS IN DIABETES MELLITUS, ARTERY, 15, PP. 1-12, (1987); CORONEL F., TORNERO F., TORRENTE J., NARANJO P., DE OLEO P., MACIA M., ET AL., TREATMENT OF HYPERLIPEMIA IN DIABETIC PATIENTS ON DIALYSIS WITH A PHYSIOLOGICAL SUBSTANCE, AM J NEPHROL, 11, PP. 32-36, (1991); SACKS F.M., CASTELLI W.P., DONNER A., KASS E.H., PLASMA LIPIDS AND LIPOPROTEINS IN VEGETARIANS AND CONTROLS, N ENGL J MED, 292, PP. 1148-1151, (1975); RESNICOW K., BARONE J., ENGLE A., MILLER S., HALEY N.J., FLEMING D., ET AL., DIET AND SERUM LIPIDS IN VEGAN VEGETARIANS: A MODEL FOR RISK REDUCTION, J AM DIET ASSOC, 91, PP. 447-453, (1991); BARNARD N.D., SCIALLI A.R., BERTRON P., HURLOCK D., EDMONDS K., TALEV L., EFFECTIVENESS OF A LOW-FAT VEGETARIAN DIET IN ALTERING SERUM LIPIDS IN HEALTHY PREMENOPAUSAL WOMEN, AM J CARDIOL, 85, PP. 969-972, (2000); SASTRE M., DEWACHTER I., LANDRETH G.E., WILLSON T.M., KLOCKGETHER T., VAN LEUVEN F., ET AL., NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS MODULATE IMMUNOSTIMULATED PROCESSING OF AMYLOID PRECURSOR PROTEIN THROUGH REGULATION OF BETA-SECRETASE, J NEUROSCI, 23, PP. 9796-9804, (2003); D'ABRAMO C., MASSONE S., ZINGG J.M., PIZZUTI A., MARAMBAUD P., DALLA P.B., ET AL., ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN AMYLOID PRECURSOR PROTEIN PROCESSING AND AMYLOID BETA-MEDIATED CELL DEATH, BIOCHEM J, 391, PP. 693-698, (2005); SASTRE M., DEWACHTER I., ROSSNER S., BOGDANOVIC N., ROSEN E., BORGHGRAEF P., ET AL., NONSTEROIDAL ANTI-INFLAMMATORY DRUGS REPRESS BETA-SECRETASE GENE PROMOTER ACTIVITY BY THE ACTIVATION OF PPARGAMMA, PROC NATL ACAD SCI USA, 103, PP. 443-448, (2006); CAMACHO I.E., SERNEELS L., SPITTAELS K., MERCHIERS P., DOMINGUEZ D., DE STROOPER B., PEROXISOME-PROLIFERATOR-ACTIVATED RECEPTOR GAMMA INDUCES A CLEARANCE MECHANISM FOR THE AMYLOID-BETA PEPTIDE, J NEUROSCI, 24, PP. 10908-10917, (2004); HENEKA M.T., SASTRE M., DUMITRESCU-OZIMEK L., HANKE A., DEWACHTER I., KUIPERI C., ET AL., ACUTE TREATMENT WITH THE PPARGAMMA AGONIST PIOGLITAZONE AND IBUPROFEN REDUCES GLIAL INFLAMMATION AND ABETA1-42 LEVELS IN APPV717I TRANSGENIC MICE, BRAIN, 128, PP. 1442-1453, (2005); BERNARDO A., LEVI G., MINGHETTI L., ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA (PPAR-GAMMA) AND ITS NATURAL LIGAND 15-DEOXY-DELTA12, 14-PROSTAGLANDIN J2 IN THE REGULATION OF MICROGLIAL FUNCTIONS, EUR J NEUROSCI, 12, PP. 2215-2223, (2000); KIM E.J., KWON K.J., PARK J.Y., LEE S.H., MOON C.H., BAIK E.J., EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS ON LPS-INDUCED NEURONAL DEATH IN MIXED CORTICAL NEURONS: ASSOCIATED WITH INOS AND COX-2, BRAIN RES, 941, PP. 1-10, (2002); STORER P.D., XU J., CHAVIS J.A., DREW P.D., CYCLOPENTENONE PROSTAGLANDINS PGA(2) AND 15-DEOXY-DELTA(12,14) PGJ(2) SUPPRESS ACTIVATION OF MURINE MICROGLIA AND ASTROCYTES: IMPLICATIONS FOR MULTIPLE SCLEROSIS, J NEUROSCI RES, 80, PP. 66-74, (2005); STORER P.D., XU J., CHAVIS J., DREW P.D., PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS INHIBIT THE ACTIVATION OF MICROGLIA AND ASTROCYTES: IMPLICATIONS FOR MULTIPLE SCLEROSIS, J NEUROIMMUNOL, 161, PP. 113-122, (2005); YAJIMA H., IKESHIMA E., SHIRAKI M., KANAYA T., FUJIWARA D., ODAI H., ET AL., ISOHUMULONES, BITTER ACIDS DERIVED FROM HOPS, ACTIVATE BOTH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND GAMMA AND REDUCE INSULIN RESISTANCE, J BIOL CHEM, 279, PP. 33456-33462, (2004); YAJIMA H., NOGUCHI T., IKESHIMA E., SHIRAKI M., KANAYA T., TSUBOYAMA-KASAOKA N., ET AL., PREVENTION OF DIET-INDUCED OBESITY BY DIETARY ISOMERIZED HOP EXTRACT CONTAINING ISOHUMULONES, IN RODENTS, INT J OBES (LOND), 29, PP. 991-997, (2005); MIURA Y., HOSONO M., OYAMADA C., ODAI H., OIKAWA S., KONDO K., DIETARY ISOHUMULONES, THE BITTER COMPONENTS OF BEER, RAISE PLASMA HDL-CHOLESTEROL LEVELS AND REDUCE LIVER CHOLESTEROL AND TRIACYLGLYCEROL CONTENTS SIMILAR TO PPARALPHA ACTIVATIONS IN C57BL/6 MICE, BR J NUTR, 93, PP. 559-567, (2005); SHIMURA M., HASUMI A., MINATO T., HOSONO M., MIURA Y., MIZUTANI S., ET AL., ISOHUMULONES MODULATE BLOOD LIPID STATUS THROUGH THE ACTIVATION OF PPAR ALPHA, BIOCHIM BIOPHYS ACTA, 1736, PP. 51-60, (2005); XU J., STORER P.D., CHAVIS J.A., RACKE M.K., DREW P.D., AGONISTS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AND THE RETINOID X RECEPTOR INHIBIT INFLAMMATORY RESPONSES OF MICROGLIA, J NEUROSCI RES, 81, PP. 403-411, (2005); KLIEWER S.A., UMESONO K., NOONAN D.J., HEYMAN R.A., EVANS R.M., CONVERGENCE OF 9-CIS RETINOIC ACID AND PEROXISOME PROLIFERATOR SIGNALLING PATHWAYS THROUGH HETERODIMER FORMATION OF THEIR RECEPTORS, NATURE, 358, PP. 771-774, (1992); MUKHERJEE R., DAVIES P.J., CROMBIE D.L., BISCHOFF E.D., CESARIO R.M., JOW L., ET AL., SENSITIZATION OF DIABETIC AND OBESE MICE TO INSULIN BY RETINOID X RECEPTOR AGONISTS, NATURE, 386, PP. 407-410, (1997); DE LA TORRE J.C., ALZHEIMER DISEASE AS A VASCULAR DISORDER: NOSOLOGICAL EVIDENCE, STROKE, 33, PP. 1152-1162, (2002); DE LA TORRE J.C., IS ALZHEIMER'S DISEASE A NEURODEGENERATIVE OR A VASCULAR DISORDER? DATA, DOGMA, AND DIALECTICS, LANCET NEUROL, 3, PP. 184-190, (2004); ROHER A.E., ESH C., RAHMAN A., KOKJOHN T.A., BEACH T.G., ATHEROSCLEROSIS OF CEREBRAL ARTERIES IN ALZHEIMER DISEASE, STROKE, 35, PP. 2623-2627, (2004); ROHER A.E., KOKJOHN T.A., BEACH T.G., AN ASSOCIATION WITH GREAT IMPLICATIONS: VASCULAR PATHOLOGY AND ALZHEIMER DISEASE, ALZHEIMER DIS ASSOC DISORD, 20, PP. 73-75, (2006); LUCHSINGER J.A., REITZ C., HONIG L.S., TANG M.X., SHEA S., MAYEUX R., AGGREGATION OF VASCULAR RISK FACTORS AND RISK OF INCIDENT ALZHEIMER DISEASE, NEUROLOGY, 65, PP. 545-551, (2005); LINDEBERG S., LUNDH B., APPARENT ABSENCE OF STROKE AND ISCHAEMIC HEART DISEASE IN A TRADITIONAL MELANESIAN ISLAND: A CLINICAL STUDY IN KITAVA, J INTERN MED, 233, PP. 269-275, (1993); LINDEBERG S., NILSSON-EHLE P., VESSBY B., LIPOPROTEIN COMPOSITION AND SERUM CHOLESTEROL ESTER FATTY ACIDS IN NONWESTERNIZED MELANESIANS, LIPIDS, 31, PP. 153-158, (1996); LINDEBERG S., ELIASSON M., LINDAHL B., AHREN B., LOW SERUM INSULIN IN TRADITIONAL PACIFIC ISLANDERS - THE KITAVA STUDY, METABOLISM, 48, PP. 1216-1219, (1999); MCCARTY M.F., UP-REGULATION OF ENDOTHELIAL NITRIC OXIDE ACTIVITY AS A CENTRAL STRATEGY FOR PREVENTION OF ISCHEMIC STROKE - JUST SAY NO TO STROKE!, MED HYPOTHESES, 55, PP. 386-403, (2000); TROWELL H.C., BURKITT D.P., TREATMENT AND PREVENTION: A NOTE ON AUTOIMMUNE DISEASE IN SUB-SAHARAL AFRICANS, WESTERN DISEASES: THEIR EMERGENCE AND PREVENTION, PP. 436-443, (1981); DE LA TORRE J.C., IMPAIRED CEREBROMICROVASCULAR PERFUSION. SUMMARY OF EVIDENCE IN SUPPORT OF ITS CAUSALITY IN ALZHEIMER'S DISEASE, ANN NY ACAD SCI, 924, PP. 136-152, (2000); PLUTA R., FROM BRAIN ISCHEMIA-REPERFUSION INJURY TO POSSIBLE SPORADIC ALZHEIMER'S DISEASE, CURR NEUROVASC RES, 1, PP. 441-453, (2004); DE LA TORRE J.C., PAPPAS B.A., PREVOT V., EMMERLING M.R., MANTIONE K., FORTIN T., ET AL., HIPPOCAMPAL NITRIC OXIDE UPREGULATION PRECEDES MEMORY LOSS AND A BETA 1-40 ACCUMULATION AFTER CHRONIC BRAIN HYPOPERFUSION IN RATS, NEUROL RES, 25, PP. 635-641, (2003); ALIEV G., SMITH M.A., OBRENOVICH M.E., DE LA TORRE J.C., PERRY G., ROLE OF VASCULAR HYPOPERFUSION-INDUCED OXIDATIVE STRESS AND MITOCHONDRIA FAILURE IN THE PATHOGENESIS OF ALZHEIMER DISEASE, NEUROTOX RES, 5, PP. 491-504, (2003); KALARIA R.N., BHATTI S.U., PALATINSKY E.A., PENNINGTON D.H., SHELTON E.R., CHAN H.W., ET AL., ACCUMULATION OF THE BETA AMYLOID PRECURSOR PROTEIN AT SITES OF ISCHEMIC INJURY IN RAT BRAIN, NEUROREPORT, 4, PP. 211-214, (1993); BAIDEN-AMISSAH K., JOASHI U., BLUMBERG R., MEHMET H., EDWARDS A.D., COX P.M., EXPRESSION OF AMYLOID PRECURSOR PROTEIN (BETA-APP) IN THE NEONATAL BRAIN FOLLOWING HYPOXIC ISCHAEMIC INJURY, NEUROPATHOL APPL NEUROBIOL, 24, PP. 346-352, (1998); SHI J., YANG S.H., STUBLEY L., DAY A.L., SIMPKINS J.W., HYPOPERFUSION INDUCES OVEREXPRESSION OF BETA-AMYLOID PRECURSOR PROTEIN MRNA IN A FOCAL ISCHEMIC RODENT MODEL, BRAIN RES, 853, PP. 1-4, (2000); WEBSTER N.J., GREEN K.N., PEERS C., VAUGHAN P.F., ALTERED PROCESSING OF AMYLOID PRECURSOR PROTEIN IN THE HUMAN NEUROBLASTOMA SH-SY5Y BY CHRONIC HYPOXIA, J NEUROCHEM, 83, PP. 1262-1271, (2002); WEN Y., ONYEWUCHI O., YANG S., LIU R., SIMPKINS J.W., INCREASED BETA-SECRETASE ACTIVITY AND EXPRESSION IN RATS FOLLOWING TRANSIENT CEREBRAL ISCHEMIA, BRAIN RES, 1009, PP. 1-8, (2004); STAMLER J.S., ALZHEIMER'S DISEASE. A RADICAL VASCULAR CONNECTION, NATURE, 380, PP. 108-111, (1996); MCCARTY M.F., VASCULAR NITRIC OXIDE MAY LESSEN ALZHEIMER'S RISK, MED HYPOTHESES, 51, PP. 465-476, (1998); PAK T., CADET P., MANTIONE K.J., STEFANO G.B., MORPHINE VIA NITRIC OXIDE MODULATES BETA-AMYLOID METABOLISM: A NOVEL PROTECTIVE MECHANISM FOR ALZHEIMER'S DISEASE, MED SCI MONIT, 11, (2005); GREEN D.J., MAIORANA A., O'DRISCOLL G., TAYLOR R., EFFECT OF EXERCISE TRAINING ON ENDOTHELIUM-DERIVED NITRIC OXIDE FUNCTION IN HUMANS, J PHYSIOL, 561, PP. 1-25, (2004); IKEDA Y., BIRO S., KAMOGAWA Y., YOSHIFUKU S., ETO H., ORIHARA K., ET AL., REPEATED THERMAL THERAPY UPREGULATES ARTERIAL ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION IN SYRIAN GOLDEN HAMSTERS, JPN CIRC J, 65, PP. 434-438, (2001); IKEDA Y., BIRO S., KAMOGAWA Y., YOSHIFUKU S., ETO H., ORIHARA K., ET AL., REPEATED SAUNA THERAPY INCREASES ARTERIAL ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION AND NITRIC OXIDE PRODUCTION IN CARDIOMYOPATHIC HAMSTERS, CIRC J, 69, PP. 722-729, (2005); LOPEZ D., ORTA X., CASOS K., SAIZ M.P., PUIG-PARELLADA P., FARRIOL M., ET AL., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE IN RAT AORTA AFTER INGESTION OF FISH OIL-RICH DIET, AM J PHYSIOL HEART CIRC PHYSIOL, 287, (2004); STROES E.S., VAN FAASSEN E.E., YO M., MARTASEK P., BOER P., GOVERS R., ET AL., FOLIC ACID REVERTS DYSFUNCTION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE, CIRC RES, 86, PP. 1129-11234, (2000); DAS U.N., FOLIC ACID SAYS NO TO VASCULAR DISEASES, NUTRITION, 19, PP. 686-692, (2003); MOAT S.J., CLARKE Z.L., MADHAVAN A.K., LEWIS M.J., LANG D., FOLIC ACID REVERSES ENDOTHELIAL DYSFUNCTION INDUCED BY INHIBITION OF TETRAHYDROBIOPTERIN BIOSYNTHESIS, EUR J PHARMACOL, 530, PP. 250-258, (2006); CERSOSIMO E., DEFRONZO R.A., INSULIN RESISTANCE AND ENDOTHELIAL DYSFUNCTION: THE ROAD MAP TO CARDIOVASCULAR DISEASES, DIABETES METAB RES REV, (2006); LAUFS U., LA F.V., PLUTZKY J., LIAO J.K., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY HMG COA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); ENDRES M., LAUFS U., HUANG Z., NAKAMURA T., HUANG P., MOSKOWITZ M.A., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC NATL ACAD SCI USA, 95, PP. 8880-8885, (1998); FISHER N.D., HUGHES M., GERHARD-HERMAN M., HOLLENBERG N.K., FLAVANOL-RICH COCOA INDUCES NITRIC-OXIDE-DEPENDENT VASODILATION IN HEALTHY HUMANS, J HYPERTENS, 21, PP. 2281-2286, (2003); SCHROETER H., HEISS C., BALZER J., KLEINBONGARD P., KEEN C.L., HOLLENBERG N.K., ET AL., (-)-EPICATECHIN MEDIATES BENEFICIAL EFFECTS OF FLAVANOL-RICH COCOA ON VASCULAR FUNCTION IN HUMANS, PROC NATL ACAD SCI USA, 103, PP. 1024-1029, (2006); WASSMANN S., LAUFS U., BAUMER A.T., MULLER K., AHLBORY K., LINZ W., ET AL., HMG-COA REDUCTASE INHIBITORS IMPROVE ENDOTHELIAL DYSFUNCTION IN NORMOCHOLESTEROLEMIC HYPERTENSION VIA REDUCED PRODUCTION OF REACTIVE OXYGEN SPECIES, HYPERTENSION JID - 7906255, 37, PP. 1450-1457, (2001); HOLLENBERG N.K., MARTINEZ G., MCCULLOUGH M., MEINKING T., PASSAN D., PRESTON M., ET AL., AGING, ACCULTURATION, SALT INTAKE, AND HYPERTENSION IN THE KUNA OF PANAMA, HYPERTENSION, 29, PP. 171-176, (1997); SOMERS M.J., MAVROMATIS K., GALIS Z.S., HARRISON D.G., VASCULAR SUPEROXIDE PRODUCTION AND VASOMOTOR FUNCTION IN HYPERTENSION INDUCED BY DEOXYCORTICOSTERONE ACETATE-SALT, CIRCULATION, 101, PP. 1722-1728, (2000); BAYORH M.A., GANAFA A.A., SOCCI R.R., SILVESTROV N., ABUKHALAF I.K., THE ROLE OF OXIDATIVE STRESS IN SALT-INDUCED HYPERTENSION, AM J HYPERTENS, 17, PP. 31-36, (2004); KETONEN J., MERASTO S., PAAKKARI I., MERVAALA E.M., HIGH SODIUM INTAKE INCREASES VASCULAR SUPEROXIDE FORMATION AND PROMOTES ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE, BLOOD PRESS, 14, PP. 373-382, (2005); MCCABE R.D., BAKARICH M.A., SRIVASTAVA K., YOUNG D.B., POTASSIUM INHIBITS FREE RADICAL FORMATION, HYPERTENSION, 24, PP. 77-82, (1994); YOUNG D.B., LIN H., MCCABE R.D., POTASSIUM'S CARDIOVASCULAR PROTECTIVE MECHANISMS, AM J PHYSIOL, 268, (1995); MCCARTY M.F., ENDOTHELIAL MEMBRANE POTENTIAL REGULATES PRODUCTION OF BOTH NITRIC OXIDE AND SUPEROXIDE-A FUNDAMENTAL DETERMINANT OF VASCULAR HEALTH, MED HYPOTHESES, 53, PP. 277-289, (1999); WANG Q., ROWAN M.J., ANWYL R., BETA-AMYLOID-MEDIATED INHIBITION OF NMDA RECEPTOR-DEPENDENT LONG-TERM POTENTIATION INDUCTION INVOLVES ACTIVATION OF MICROGLIA AND STIMULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE AND SUPEROXIDE, J NEUROSCI, 24, PP. 6049-6056, (2004); NATHAN C., CALINGASAN N., NEZEZON J., DING A., LUCIA M.S., LA PERLE K., ET AL., PROTECTION FROM ALZHEIMER'S-LIKE DISEASE IN THE MOUSE BY GENETIC ABLATION OF INDUCIBLE NITRIC OXIDE SYNTHASE, J EXP MED, 202, PP. 1163-1169, (2005); EL GAYAR S., THURING-NAHLER H., PFEILSCHIFTER J., ROLLINGHOFF M., BOGDAN C., TRANSLATIONAL CONTROL OF INDUCIBLE NITRIC OXIDE SYNTHASE BY IL-13 AND ARGININE AVAILABILITY IN INFLAMMATORY MACROPHAGES, J IMMUNOL, 171, PP. 4561-4568, (2003); SCHULMAN S.P., BECKER L.C., KASS D.A., CHAMPION H.C., TERRIN M.L., FORMAN S., ET AL., L-ARGININE THERAPY IN ACUTE MYOCARDIAL INFARCTION: THE VASCULAR INTERACTION WITH AGE IN MYOCARDIAL INFARCTION (VINTAGE MI) RANDOMIZED CLINICAL TRIAL, JAMA, 295, PP. 58-64, (2006); SUO Z., FANG C., CRAWFORD F., MULLAN M., SUPEROXIDE FREE RADICAL AND INTRACELLULAR CALCIUM MEDIATE A BETA(1-42) INDUCED ENDOTHELIAL TOXICITY, BRAIN RES, 762, PP. 144-152, (1997); PRICE J.M., SUTTON E.T., HELLERMANN A., THOMAS T., BETA-AMYLOID INDUCES CEREBROVASCULAR ENDOTHELIAL DYSFUNCTION IN THE RAT BRAIN, NEUROL RES, 19, PP. 534-538, (1997); KHALIL Z., POLIVIOU H., MAYNARD C.J., BEYREUTHER K., MASTERS C.L., LI Q.X., MECHANISMS OF PERIPHERAL MICROVASCULAR DYSFUNCTION IN TRANSGENIC MICE OVEREXPRESSING THE ALZHEIMER'S DISEASE AMYLOID ABETA PROTEIN, J ALZHEIMERS DIS, 4, PP. 467-478, (2002); KUUSISTO J., KOIVISTO K., MYKKANEN L., HELKALA E.L., VANHANEN M., HANNINEN T., ET AL., ASSOCIATION BETWEEN FEATURES OF THE INSULIN RESISTANCE SYNDROME AND ALZHEIMER'S DISEASE INDEPENDENTLY OF APOLIPOPROTEIN E4 PHENOTYPE: CROSS SECTIONAL POPULATION BASED STUDY, BMJ, 315, PP. 1045-1049, (1997); CRAFT S., ASTHANA S., SCHELLENBERG G., CHERRIER M., BAKER L.D., NEWCOMER J., ET AL., INSULIN METABOLISM IN ALZHEIMER'S DISEASE DIFFERS ACCORDING TO APOLIPOPROTEIN E GENOTYPE AND GENDER, NEUROENDOCRINOLOGY, 70, PP. 146-152, (1999); RAZAY G., WILCOCK G.K., HYPERINSULINAEMIA AND ALZHEIMER'S DISEASE, AGE AGEING, 23, PP. 396-399, (1994); LIOLITSA D., POWELL J., LOVESTONE S., GENETIC VARIABILITY IN THE INSULIN SIGNALLING PATHWAY MAY CONTRIBUTE TO THE RISK OF LATE ONSET ALZHEIMER'S DISEASE, J NEUROL NEUROSURG PSYCHIATRY, 73, PP. 261-266, (2002); WATSON G.S., CRAFT S., THE ROLE OF INSULIN RESISTANCE IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE: IMPLICATIONS FOR TREATMENT, CNS DRUGS, 17, PP. 27-45, (2003); KERNAN W.N., INZUCCHI S.E., VISCOLI C.M., BRASS L.M., BRAVATA D.M., HORWITZ R.I., INSULIN RESISTANCE AND RISK FOR STROKE, NEUROLOGY, 59, PP. 809-815, (2002); BROWN W.V., METABOLIC SYNDROME AND RISK OF STROKE, CLIN CORNERSTONE, 6, SUPPL. 3, (2004); PLUM L., SCHUBERT M., BRUNING J.C., THE ROLE OF INSULIN RECEPTOR SIGNALING IN THE BRAIN, TRENDS ENDOCRINOL METAB, 16, PP. 59-65, (2005); ZHAO L., TETER B., MORIHARA T., LIM G.P., AMBEGAOKAR S.S., UBEDA O.J., ET AL., INSULIN-DEGRADING ENZYME AS A DOWNSTREAM TARGET OF INSULIN RECEPTOR SIGNALING CASCADE: IMPLICATIONS FOR ALZHEIMER'S DISEASE INTERVENTION, J NEUROSCI, 24, PP. 11120-11126, (2004); QIU W.Q., FOLSTEIN M.F., INSULIN, INSULIN-DEGRADING ENZYME AND AMYLOID-BETA PEPTIDE IN ALZHEIMER'S DISEASE: REVIEW AND HYPOTHESIS, NEUROBIOL AGING, 27, PP. 190-198, (2006); QIU W.Q., WALSH D.M., YE Z., VEKRELLIS K., ZHANG J., PODLISNY M.B., ET AL., INSULIN-DEGRADING ENZYME REGULATES EXTRACELLULAR LEVELS OF AMYLOID BETA-PROTEIN BY DEGRADATION, J BIOL CHEM, 273, PP. 32730-32738, (1998); FARRIS W., MANSOURIAN S., CHANG Y., LINDSLEY L., ECKMAN E.A., FROSCH M.P., ET AL., INSULIN-DEGRADING ENZYME REGULATES THE LEVELS OF INSULIN, AMYLOID BETA-PROTEIN, AND THE BETA-AMYLOID PRECURSOR PROTEIN INTRACELLULAR DOMAIN IN VIVO, PROC NATL ACAD SCI USA, 100, PP. 4162-4167, (2003); PHIEL C.J., WILSON C.A., LEE V.M., KLEIN P.S., GSK-3ALPHA REGULATES PRODUCTION OF ALZHEIMER'S DISEASE AMYLOID-BETA PEPTIDES, NATURE, 423, PP. 435-439, (2003); FISHEL M.A., WATSON G.S., MONTINE T.J., WANG Q., GREEN P.S., KULSTAD J.J., ET AL., HYPERINSULINEMIA PROVOKES SYNCHRONOUS INCREASES IN CENTRAL INFLAMMATION AND {BETA}-AMYLOID IN NORMAL ADULTS, ARCH NEUROL, (2005); OTT A., STOLK R.P., VAN HARSKAMP F., POLS H.A., HOFMAN A., BRETELER M.M., DIABETES MELLITUS AND THE RISK OF DEMENTIA: THE ROTTERDAM STUDY, NEUROLOGY, 53, PP. 1937-1942, (1999); LUCHSINGER J.A., TANG M.X., STERN Y., SHEA S., MAYEUX R., DIABETES MELLITUS AND RISK OF ALZHEIMER'S DISEASE AND DEMENTIA WITH STROKE IN A MULTIETHNIC COHORT, AM J EPIDEMIOL, 154, PP. 635-641, (2001); KAIYALA K.J., PRIGEON R.L., KAHN S.E., WOODS S.C., SCHWARTZ M.W., OBESITY INDUCED BY A HIGH-FAT DIET IS ASSOCIATED WITH REDUCED BRAIN INSULIN TRANSPORT IN DOGS, DIABETES, 49, PP. 1525-1533, (2000); BANKS W.A., THE SOURCE OF CEREBRAL INSULIN, EUR J PHARMACOL, 490, PP. 5-12, (2004); HO L., QIN W., POMPL P.N., XIANG Z., WANG J., ZHAO Z., ET AL., DIET-INDUCED INSULIN RESISTANCE PROMOTES AMYLOIDOSIS IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE, FASEB J, 18, PP. 902-904, (2004); ANDERSON R.A., CHENG N., BRYDEN N.A., POLANSKY M.M., CHENG N., CHI J., ET AL., ELEVATED INTAKES OF SUPPLEMENTAL CHROMIUM IMPROVE GLUCOSE AND INSULIN VARIABLES IN INDIVIDUALS WITH TYPE 2 DIABETES, DIABETES, 46, PP. 1786-1791, (1997); GHOSH D., BHATTACHARYA B., MUKHERJEE B., MANNA B., SINHA M., CHOWDHURY J., ET AL., ROLE OF CHROMIUM SUPPLEMENTATION IN INDIANS WITH TYPE 2 DIABETES MELLITUS, J NUTR BIOCHEM, 13, PP. 690-697, (2002); KIM D.S., KIM T.W., KANG J.S., CHROMIUM PICOLINATE SUPPLEMENTATION IMPROVES INSULIN SENSITIVITY IN GOTO-KAKIZAKI DIABETIC RATS, J TRACE ELEM MED BIOL, 17, PP. 243-247, (2004); RABINOVITZ H., FRIEDENSOHN A., LEIBOVITZ A., GABAY G., ROCAS C., HABOT B., EFFECT OF CHROMIUM SUPPLEMENTATION ON BLOOD GLUCOSE AND LIPID LEVELS IN TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS, INT J VITAM NUTR RES, 74, PP. 178-182, (2004); WANG Z.Q., ZHANG X.H., RUSSELL J.C., HULVER M., CEFALU W.T., CHROMIUM PICOLINATE ENHANCES SKELETAL MUSCLE CELLULAR INSULIN SIGNALING IN VIVO IN OBESE, INSULIN-RESISTANT JCR:LA-CP RATS, J NUTR, 136, PP. 415-420, (2006); KHAN A., SAFDAR M., ALI KHAN M.M., KHATTAK K.N., ANDERSON R.A., CINNAMON IMPROVES GLUCOSE AND LIPIDS OF PEOPLE WITH TYPE 2 DIABETES, DIABETES CARE, 26, PP. 3215-3218, (2003); QIN B., NAGASAKI M., REN M., BAJOTTO G., OSHIDA Y., SATO Y., CINNAMON EXTRACT (TRADITIONAL HERB) POTENTIATES IN VIVO INSULIN-REGULATED GLUCOSE UTILIZATION VIA ENHANCING INSULIN SIGNALING IN RATS, DIABETES RES CLIN PRACT, 62, PP. 139-148, (2003); QIN B., NAGASAKI M., REN M., BAJOTTO G., OSHIDA Y., SATO Y., CINNAMON EXTRACT PREVENTS THE INSULIN RESISTANCE INDUCED BY A HIGH-FRUCTOSE DIET, HORM METAB RES, 36, PP. 119-125, (2004)","M.F. MCCARTY; NATURAL ALTERNATIVES INTERNATIONAL, SAN MARCOS, CA 92078, 1185 LINDA VISTA DR, UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-33745941367","MED HYPOTHESES",NA,"NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"MCCARTY MF, 2006, MED HYPOTHESES","MCCARTY MF, 2006, MED HYPOTHESES-a"
"REINER Ž;TEDESCHI-REINER E;ROMIĆ Ž","REINER, ŽELJKO (55411641000); TEDESCHI-REINER, EUGENIA (6603094621); ROMIĆ, ŽELJKO (35578715100)","EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS HOMOCYSTEINE FIBRINOGEN AND CREACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS",2005,"CLINICAL DRUG INVESTIGATION","25","6",49,"10.2165/00044011-200525110-00003","DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY HOSPITAL CENTRE ZAGREB, ZAGREB, CROATIA, UNIVERSITY HOSPITAL CENTRE ZAGREB, REBRO, ZAGREB, 10000, KIŠPATIĆEVA 12, CROATIA;DEPARTMENT OF OPHTHALMOLOGY, SESTRE MILOSRDNICE UNIVERSITY HOSPITAL, ZAGREB, CROATIA;DEPARTMENT OF LABORATORY DIAGNOSTICS, DUBRAVA UNIVERSITY HOSPITAL, ZAGREB, CROATIA","BACKGROUND: POLICOSANOL IS AN AGENT THAT INCLUDES MIXTURES OF ALIPHATIC PRIMARY ALCOHOLS EXTRACTED PRIMARILY FROM SUGAR-CANE WAX. THIS MIXTURE HAS BEEN SHOWN TO LOWER TOTAL AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL IN ANIMAL MODELS, HEALTHY VOLUNTEERS AND HYPERCHOLESTEROLAEMIC PATIENTS. PATIENTS AND METHODS: THIS STUDY INVESTIGATED THE EFFICACY AND TOLERABILITY OF RICE POLICOSANOL (ORYZA SP.) 10 MG/DAY IN 70 HYPERCHOLESTEROLAEMIC PATIENTS OF BOTH SEXES AGED 20-78 YEARS IN A RANDOMISED, DOUBLE-BLIND, CROSSOVER, PLACEBO-CONTROLLED, SINGLE-CENTRE TRIAL. AFTER AN 8-WEEK RUN-IN PERIOD DURING WHICH PATIENTS WERE PLACED ON THERAPEUTIC LIFESTYLE CHANGES, IN PARTICULAR A CHOLESTEROL-LOWERING DIET, THEY WERE RANDOMLY ASSIGNED TO RECEIVE RICE POLICOSANOL 10MG TABLETS OR PLACEBO TABLETS ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. DURING THE NEXT 8 WEEKS THOSE PATIENTS WHO RECEIVED POLICOSANOL DURING THE FIRST 8 WEEKS RECEIVED PLACEBO, AND THOSE WHO RECEIVED PLACEBO DURING THE FIRST 8 WEEKS, RECEIVED POLICOSANOL. TOTAL, LDL, HIGH-DENSITY LIPOPROTEIN (HDL), HDL2 AND HDL3 CHOLESTEROL, TRIGLYCERIDES, OXIDISED LDL (OX-LDL), APOPROTEINS (APOS) AI AND B, LIPOPROTEIN (A) [LP(A)], FIBRINOGEN, HOMOCYSTEINE AND C-REACTIVE PROTEIN (CRP) LEVELS WERE MEASURED. RESULTS: RICE POLICOSANOL SIGNIFICANTLY REDUCED PLASMA TOTAL CHOLESTEROL FROM 7.37 ± 1.42 MMOL/L TO 6.99 ± 1.33 MMOL/L (P = 0.007) AND INCREASED APO AI FROM 1.49 ± 0.39 MMOL/L TO 1.58 ± 0.38 MMOL/L (P = 0.037) BUT DID NOT CHANGE PLASMA TRIGLYCERIDES, HDL, HDL2, HDL3 AND LDL CHOLESTEROL, OX-LDL, LP(A), APO B, FIBRINOGEN, HOMOCYSTEINE OR CRP LEVELS. CONCLUSION: RICE POLICOSANOL 10 MG/DAY MODERATELY DECREASED PLASMA TOTAL CHOLESTEROL AND INCREASED APO AI. RICE POLICOSANOL WAS ALSO WELL TOLERATED, WITH NO DRUG-RELATED EFFECTS ON SAFETY PARAMETERS SUCH AS SERUM AMINOTRANSFERASES AND CREATINE PHOSPHOKINASE DETECTED OR FOUND ON PHYSICAL EXAMINATION. © 2005 ADIS DATA INFORMATION BV. ALL RIGHTS RESERVED.","","AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CREATINE KINASE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2 CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 3 CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAL; OXIDATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RICE; TABLET; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL","MILSING LTD","TO DATE, THE CONTENT OF THIS MANUSCRIPT HAS NOT BEEN PRESENTED AT ANY MEETING. THE STUDY WAS SUPPORTED BY AN UNRESTRICTED SCIENTIFIC GRANT FROM MILSING LTD, ZAGREB, CROATIA. THE AUTHORS HAVE NO CONFLICTS OF INTEREST DIRECTLY RELEVANT TO THE CONTENT OF THIS STUDY.","REINER Z., STATINS IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE, MEDICUS, 12, PP. 85-90, (2003); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G., MAS R., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY, CURR THER RES, 64, 8, PP. 522-537, (2003); MAS R., CASTANO G., ILLINAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY, CURR THER RES, 62, PP. 194-208, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUGS AGING, 20, 2, PP. 153-163, (2003); CASTANO G., MAS R., FERNANDEZ L., ET AL., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 63, 4, PP. 286-303, (2002); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 4-51, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); ORTENSI G., GLADSTEIN J., VAILI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CASTANO G., MAS FERREIRO R., FERNANDEZ J., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); CASTANO G., MAS R., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), CIRCULATION, 89, PP. 1329-1445, (1993); BURSTEIN M., SCHOLNICK H.R., MORFIN R., RAPID METHOD FOR THE ISOLATION OF LIPOPROTEINS FROM HUMAN SERUM BY PRECIPITATION WITH POLYANIONS, J LIPID RES, 11, PP. 583-595, (1970); WIELAND H., SEIDEL D., A SIMPLE SPECIFIC METHOD FOR PRECIPITATION OF LOW DENSITY LIPOPROTEINS, J LIPID RES, 24, PP. 904-909, (1983); GIDEZ L.I., MILLER G.J., BURSTEIN M., ET AL., SEPARATION AND QUANTITATION OF SUBCLASSES OF HUMAN PLASMA HIGH DENSITY LIPOPROTEINS BY A SIMPLE PRECIPITATION PROCEDURE, J LIPID RES, 23, PP. 1206-1223, (1982); THOMAS L., CLINICAL LABORATORY DIAGNOSTICS, (1998); ITABE H., YAMAMOTO H., IMANAKA T., ET AL., SENSITIVE DETECTION OF OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEIN USING A MONOCLONAL ANTIBODY, J LIPID RES, 37, PP. 45-53, (1996); CLAUSS A., RAPID PHYSIOLOGICAL COAGULATION METHOD IN DETERMINATION OF FIBRINOGEN, ACTA HAEMATOL, 17, PP. 237-246, (1957); STABLER S.P., MARCELL P.D., PODELL E.R., ET AL., QUANTITATION OF TOTAL HOMOCYSTEINE, TOTAL CYSTEINE AND METHIONINE IN NORMAL SERUM AND URINE USING CAPILLARY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, ANAL BIOCHEM, 162, PP. 185-196, (1987); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICA-TION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, 2, PP. 171-183, (2005); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED DOUBLE-BLIND PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., ET AL., WHEAT GERM POLICOSANOL DOES NOT LOWER BLOOD CHOLESTEROL CONCENTRATIONS IN HEALTHY ADULTS, ATHEROSCLEROSIS, 4, 2, (2003)","Ž. REINER; UNIVERSITY HOSPITAL CENTRE ZAGREB, REBRO, ZAGREB, 10000, KIŠPATIĆEVA 12, CROATIA; EMAIL: ZREINER@KBC-ZAGREB.HR","","ENGLISH","CLIN. DRUG INVEST.","ARTICLE","ISI","2-S2.0-27644565636","CLIN DRUG INVEST","UNIVERSITY HOSPITAL CENTRE ZAGREB;SESTRE MILOSRDNICE UNIVERSITY HOSPITAL;DUBRAVA UNIVERSITY HOSPITAL","NOTREPORTED;UNIVERSITY HOSPITAL CENTRE ZAGREB;NOTREPORTED",NA,"REINER Ž, 2005, CLIN DRUG INVEST","REINER Ž, 2005, CLIN DRUG INVEST"
"MUSA R;YUNOKI K;KINOSHITA M;ODA Y;OHNISHI M","MUSA, RENAGULI (6701465328); YUNOKI, KEITA (8429098100); KINOSHITA, MIKIO (7401852262); ODA, YUJI (7402101404); OHNISHI, MASAO (7202428522)","INCREASED LEVELS OF POLICOSANOL AND VERY LONGCHAIN FATTY ACIDS IN POTATO PULP FERMENTED WITH RHIZOPUS ORYZAE",2004,"BIOSCIENCE, BIOTECHNOLOGY AND BIOCHEMISTRY","68","3",7,"10.1271/bbb.68.2401","OBIHIRO, HOKKAIDO 080-8555, JAPAN, U. GRAD. SCH. OF AGRIC. SCIENCE, IWATE UNIVERSITY, MORIOKA, IWATE 020-8550, JAPAN;OBIHIRO, HOKKAIDO 080-8555, JAPAN, U. GRAD. SCH. OF AGRIC. SCIENCE, IWATE UNIVERSITY, MORIOKA, IWATE 020-8550, JAPAN;OBIHIRO, HOKKAIDO 080-8555, JAPAN;MEMURO, KASAI, HOKKAIDO 082-0071, JAPAN;OBIHIRO, HOKKAIDO 080-8555, JAPAN, U. GRAD. SCH. OF AGRIC. SCIENCE, IWATE UNIVERSITY, MORIOKA, IWATE 020-8550, JAPAN","SIGNIFICANT AMOUNTS OF POLICOSANOL AND VERY LONG-CHAIN FATTY ACIDS (VLFAS) RANGING IN CARBON LENGTH FROM 22 TO 30 WERE FOUND IN THE LIPOPHILIC FRACTION OBTAINED FROM POTATO PULP FERMENTED WITH RHIZOPUS ORYZAE. IT IS BELIEVED THAT THESE COMPOUNDS WOULD HAVE ORIGINALLY BEEN PRESENT AS SUBERIN-RELATED COMPOUNDS, BUT NOT AS WAX, IN THE PERIDERM OF POTATO TUBERS AND CONCENTRATED INTO POTATO PULP DURING THE PROCESS OF STARCH PRODUCTION. MOREOVER, THE POLICOSANOL AND VLFAS EXTRACTED FROM POTATO PULP WITH ORGANIC SOLVENTS WERE FOUND TO HAVE INCREASED AFTER FERMENTATION.","FUNCTIONAL LIPIDS; OCTACOSANOL; POTATO PULP; RHIZOPUS ORYZAE; VERY LONG-CHAIN FATTY ACIDS","ALCOHOLS; CARBON; FATTY ACIDS; FERMENTATION; PLANTS; POTATO STARCH; PULPS; CHROMATOGRAPHY, THIN LAYER; FATTY ACIDS; FATTY ALCOHOLS; FERMENTATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LACTIC ACID; RHIZOPUS; SOLANUM TUBEROSUM; RHIZOPUS; RHIZOPUS ORYZAE; SOLANUM TUBEROSUM; ALCOHOLS; CARBON; FERMENTATION; PULP; VEGETATION; FATTY ACID; FATTY ALCOHOL; LACTIC ACID; POLICOSANOL; ARTICLE; CHEMISTRY; FERMENTATION; MASS FRAGMENTOGRAPHY; METABOLISM; POTATO; RHIZOPUS; THIN LAYER CHROMATOGRAPHY; LIPOPHILIC FRACTION; POLICOSANOLS; POTATO PULP; VERY LONG-CHAIN FATTY ACIDS (VLFA); FATTY ACIDS","SPECIAL COORDINATION FUNDS FOR PROMOTING SCIENCE AND TECHNOLOGY; MINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, MEXT","THIS WORK WAS SUPPORTED IN PART BY SPECIAL COORDINATION FUNDS FOR PROMOTING SCIENCE AND TECHNOLOGY (LEADING RESEARCH UTILIZING POTENTIAL OF REGIONAL SCIENCE AND TECHNOLOGY) FROM THE JAPANESE MINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY.","ODA Y., SAITO K., YAMAUCHI H., MORI M., LACTIC ACID FERMENTATION OF POTATO PULP BY THE FUNGUS RHIZOPUS ORYZAE, CURR. MICROBIOL., 45, PP. 1-4, (2002); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ J., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003, A MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, CAN. J. PHYSIOL. PHARMACOL., 80, PP. 13-21, (2002); SAITO K., KAWAMURA Y., ODA Y., ROLE OF THE PECTINOLYTIC ENZYME IN THE LACTIC ACID FERMENTATION OF POTATO PULP BY RHIZOPUS ORYZAE, J. IND. MICROBIOL. BIOTECHNOL., 30, PP. 440-444, (2003); FUJINO Y., OHNISHI M., CONSTITUENTS OF CERAMIDE AND CERAMIDE MONOHEXOSIDE IN RICE BRAN, CHEM. PHYS. LIPIDS, 17, PP. 275-289, (1976); ODA Y., YAJIMA Y., KINOSHITA M., OHNISHI M., DIFFERENCES OF RHIZOPUS ORYZAE STRAINS IN ORGANIC ACID SYNTHESIS AND FATTY ACID COMPOSITION, FOOD MICROBIOL., 20, PP. 371-375, (2003); OHNISHI M., OBATA S., FUJINO Y., COMPOSITION AND MOLECULAR SPECIES OF WAXY LIPIDS IN WHEAT GRAIN, CEREAL CHEM., 63, PP. 193-196, (1886); FAUCONNIER M.L., WELTI R., BLEE E., MARLIER M., LIPID AND OXYLIPIN PROFILES DURING AGING AND SPROUT DEVELOPMENT IN POTATO TUBERS (SOLANUM TUBEROSUM L.), BIOCHIM. BIOPHY. ACTA, 1633, PP. 118-126, (2003); GRACA J., PEREIRA H., SUBERIN STRUCTURE IN POTATO PERIDERM: GLYCEROL, LONG-CHAIN MONOMERS, AND GLYCERYL AND FERULOYL DIMERS, J. AGRIC. FOOD CHEM., 48, PP. 5476-5483, (2000); BERNARDS M., LEWIS N.G., ALKYL FERULATES IN WOUND HEALING POTATO TUBERS, PHYTOCHEMISTRY, 31, PP. 3409-3412, (1992)","M. OHNISHI; DEPARTMENT OF BIORESOURCE SCIENCE, OBIHIRO UNIV. AGRIC. AND VET. MED., OBIHIRO, HOKKAIDO 080-8555, JAPAN; EMAIL: MOHNISHI@OBIHIRO.AC.JP","","ENGLISH","BIOSCI. BIOTECHNOL. BIOCHEM.","ARTICLE","ISI","2-S2.0-11144283640","BIOSCI BIOTECHNOL BIOCHEM","MORIOKA;MORIOKA;MORIOKA","NOTREPORTED;OBIHIRO UNIV. AGRIC. AND VET. MED.;NOTREPORTED",NA,"MUSA R, 2004, BIOSCI BIOTECHNOL BIOCHEM","MUSA R, 2004, BIOSCI BIOTECHNOL BIOCHEM"
"MCCARTY M","MCCARTY, M.F. (24435224500)","A SHIFT IN MYOCARDIAL SUBSTRATE IMPROVED ENDOTHELIAL FUNCTION AND DIMINISHED SYMPATHETIC ACTIVITY MAY CONTRIBUTE TO THE ANTIANGINAL IMPACT OF VERYLOWFAT DIETS",2004,"MEDICAL HYPOTHESES","62","9",8,"10.1016/S0306-9877(03)00232-9","UNITED STATES","A NEW CATEGORY OF ANTI-ANGINAL DRUG - EXEMPLIFIED BY RANOLAZINE - IS BELIEVED TO WORK BY PARTIALLY INHIBITING CARDIAC OXIDATION OF FATTY ACIDS; OXIDATION OF GLUCOSE REQUIRES LESS OXYGEN PER MOL OF ATP GENERATED, AND THUS IS PREFERABLE TO FAT OXIDATION WHEN OXYGEN AVAILABILITY IS LIMITING IN UNDERPERFUSED CARDIAC TISSUE. UNFORTUNATELY, THERE IS NO REASON TO BELIEVE THAT THESE DRUGS INHIBIT FAT OXIDATION SELECTIVELY IN THE HEART; THUS, CHRONIC USE OF THESE DRUGS CAN BE EXPECTED TO INCREASE BODY FAT STORES UNTIL THE ORIGINAL RATE OF FAT OXIDATION IS RESTORED BY MASS ACTION - PRESUMABLY NEGATING THE THERAPEUTIC BENEFIT IN ANGINA, WHILE EXACERBATING THE MANIFOLD ADVERSE EFFECTS OF INSULIN RESISTANCE SYNDROME. THE RATIONAL WAY TO DECREASE CARDIAC METABOLIC RELIANCE ON FATTY ACIDS IS TO CONSUME A VERY-LOW-FAT QUASI-VEGAN DIET (I.E., 10% FAT CALORIES). INDEED, SUCH DIETS ARE KNOWN TO HAVE A RAPID AND SUBSTANTIAL THERAPEUTIC IMPACT ON ANGINAL SYMPTOMS, WHILE CONCURRENTLY BENEFITING INSULIN SENSITIVITY, MARKEDLY IMPROVING SERUM LIPID PROFILE, PROMOTING LEANNESS, AND LESSENING CORONARY RISK. A REDUCTION IN DIURNAL INSULIN SECRETION MIGHT ALSO BE ACHIEVED, WHICH WOULD BE EXPECTED TO DECREASE SYMPATHETIC ACTIVITY. WHILE REDUCED MYOCARDIAL DEMAND FOR OXYGEN DOUBTLESS CONTRIBUTES TO THE BENEFICIAL IMPACT OF SUCH DIETS ON ANGINA, IT IS LIKELY THAT IMPROVED CARDIAC PERFUSION CONSEQUENT TO IMPROVED ENDOTHELIUM-DEPENDENT VASODILATION ALSO PLAYS A ROLE IN THIS REGARD. SUPPLEMENTAL CARNITINE, ALSO BENEFICIAL IN ANGINA, APPEARS TO IMPROVE UTILIZATION OF GLUCOSE IN THE ISCHEMIC MYOCARDIUM BY LOWERING ELEVATED ACETYL-COA LEVELS AND THEREBY DISINHIBITING PYRUVATE DEHYDROGENASE. CERTAIN OTHER NUTRACEUTICALS MAY AID CONTROL OF ANGINA BY IMPROVING ENDOTHELIAL FUNCTION. IN THE LONGER TERM, THESE MEASURES HAVE THE POTENTIAL TO SLOW OR REVERSE THE PROGRESSION OF STENOTIC LESIONS THAT UNDERLIE MOST CASES OF ANGINA. THESE SAFE AND RELATIVELY INEXPENSIVE NUTRITIONAL STRATEGIES FOR COPING WITH ANGINA DESERVE FAR MORE ATTENTION THAN ORTHODOX MEDICAL PRACTICE HAS THUS FAR ACCORDED THEM. © 2003 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ANGINA; ACETYL COENZYME A; ACETYLCARNITINE; ADENOSINE TRIPHOSPHATE; ANTIANGINA PECTORIS AGENT; ARGININE; CARNITINE; DIPYRIDAMOLE; FATTY ACID; FISH OIL; GLUCOSE; HEPARIN; INSULIN; ISOPRENALINE; LACTIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; OLEIC ACID; OXYGEN; PLACEBO; POLICOSANOL; PYRUVATE DEHYDROGENASE; RANOLAZINE; STATIN; TAURINE; TRIACYLGLYCEROL; TRIMETAZIDINE; UBIDECARENONE; ANGINA PECTORIS; BODY FAT; CALORIE; CARDIOVASCULAR RISK; CELL FUNCTION; CORONARY RISK; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG USE; ENDOTHELIUM CELL; EXERCISE; FATTY ACID OXIDATION; GENERAL CONDITION IMPROVEMENT; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART PERFUSION; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; LIPOLYSIS; LONG TERM CARE; LOW FAT DIET; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SAFETY; STENOSIS; SUPPLEMENTATION; SYMPATHETIC TONE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASODILATATION; VEGETARIAN DIET","","","MCCORMACK J.G., BARR R.L., WOLFF A.A., LOPASCHUK G.D., RANOLAZINE STIMULATES GLUCOSE OXIDATION IN NORMOXIC, ISCHEMIC, AND REPERFUSED ISCHEMIC RAT HEARTS, CIRCULATION, 93, PP. 135-142, (1996); CLARKE B., WYATT K.M., MCCORMACK J.G., RANOLAZINE INCREASES ACTIVE PYRUVATE DEHYDROGENASE IN PERFUSED NORMOXIC RAT HEARTS: EVIDENCE FOR AN INDIRECT MECHANISM, J MOL CELL CARDIOL, 28, PP. 341-350, (1996); MCCORMACK J.G., BARACOS V.E., BARR R., LOPASCHUK G.D., EFFECTS OF RANOLAZINE ON OXIDATIVE SUBSTRATE PREFERENCE IN EPITROCHLEARIS MUSCLE, J APPL PHYSIOL, 81, PP. 905-910, (1996); MCCORMACK J.G., STANLEY W.C., WOLFF A.A., RANOLAZINE: A NOVEL METABOLIC MODULATOR FOR THE TREATMENT OF ANGINA, GEN PHARMACOL, 30, PP. 639-645, (1998); ZACHAROWSKI K., BLACKBURN B., THIEMERMANN C., RANOLAZINE, A PARTIAL FATTY ACID OXIDATION INHIBITOR, REDUCES MYOCARDIAL INFARCT SIZE AND CARDIAC TROPONIN T RELEASE IN THE RAT, EUR J PHARMACOL, 418, PP. 105-110, (2001); DEMAISON L., FANTINI E., SENTEX E., GRYNBERG A., ATHIAS P., TRIMETAZIDINE: IN VITRO INFLUENCE ON HEART MITOCHONDRIAL FUNCTION, AM J CARDIOL, 76, (1995); LOPASCHUK G.D., TREATING ISCHEMIC HEART DISEASE BY PHARMACOLOGICALLY IMPROVING CARDIAC ENERGY METABOLISM, AM J CARDIOL, 82, (1998); MODY F.V., SINGH B.N., MOHIUDDIN I.H., COYLE K.B., BUXTON D.B., HANSEN H.W., ET AL., TRIMETAZIDINE-INDUCED ENHANCEMENT OF MYOCARDIAL GLUCOSE UTILIZATION IN NORMAL AND ISCHEMIC MYOCARDIAL TISSUE: AN EVALUATION BY POSITRON EMISSION TOMOGRAPHY, AM J CARDIOL, 82, (1998); KANTOR P.F., LUCIEN A., KOZAK R., LOPASCHUK G.D., THE ANTIANGINAL DRUG TRIMETAZIDINE SHIFTS CARDIAC ENERGY METABOLISM FROM FATTY ACID OXIDATION TO GLUCOSE OXIDATION BY INHIBITING MITOCHONDRIAL LONG-CHAIN 3-KETOACYL COENZYME A THIOLASE, CIRC RES, 86, PP. 580-588, (2000); BODEN G., ROLE OF FATTY ACIDS IN THE PATHOGENESIS OF INSULIN RESISTANCE AND NIDDM, DIABETES, 46, PP. 3-10, (1997); SANTOMAURO A.T., BODEN G., SILVA M.E., ROCHA D.M., SANTOS R.F., URSICH M.J., ET AL., OVERNIGHT LOWERING OF FREE FATTY ACIDS WITH ACIPIMOX IMPROVES INSULIN RESISTANCE AND GLUCOSE TOLERANCE IN OBESE DIABETIC AND NONDIABETIC SUBJECTS, DIABETES, 48, PP. 1836-1841, (1999); BODEN G., PATHOGENESIS OF TYPE 2 DIABETES. INSULIN RESISTANCE, ENDOCRINOL METAB CLIN NORTH AM, 30, PP. 801-815, (2001); EGAN B.M., LU G., GREENE E.L., VASCULAR EFFECTS OF NON-ESTERIFIED FATTY ACIDS: IMPLICATIONS FOR THE CARDIOVASCULAR RISK FACTOR CLUSTER, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 60, PP. 411-420, (1999); UNGER R.H., LOPOTOXICITY IN THE PATHOGENESIS OF OBESITY-DEPENDENT NIDDM. GENETIC AND CLINICAL IMPLICATIONS, DIABETES, 44, PP. 863-870, (1995); MASON T.M., GOH T., TCHIPASHVILI V., SANDHU H., GUPTA N., LEWIS G.F., ET AL., PROLONGED ELEVATION OF PLASMA FREE FATTY ACIDS DESENSITIZES THE INSULIN SECRETORY RESPONSE TO GLUCOSE IN VIVO IN RATS, DIABETES, 48, PP. 524-530, (1999); PAOLISSO G., TAGLIAMONTE M.R., RIZZO M.R., GUALDIERO P., SACCOMANNO F., GAMBARDELLA A., ET AL., LOWERING FATTY ACIDS POTENTIATES ACUTE INSULIN RESPONSE IN FIRST DEGREE RELATIVES OF PEOPLE WITH TYPE II DIABETES, DIABETOLOGIA, 41, PP. 1127-1132, (1998); STEINBERG H.O., PARADISI G., HOOK G., CROWDER K., CRONIN J., BARON A.D., FREE FATTY ACID ELEVATION IMPAIRS INSULIN-MEDIATED VASODILATION AND NITRIC OXIDE PRODUCTION, DIABETES, 49, PP. 1231-1238, (2000); SNIDERMAN A.D., CIANFLONE K., METABOLIC DISRUPTIONS IN THE ADIPOCYTE-HEPATOCYTE FATTY ACID AXIS AS CAUSES OF HYPERAPOB, INT J OBES RELAT METAB DISORD, 19, 1 SUPPL., (1995); SNIDERMAN A.D., CIANFLONE K., FRAYN K., THE PATHOGENETIC ROLE OF IMPAIRED FATTY ACID TRAPPING BY ADIPOCYTES IN GENERATING THE PLEIOTROPIC FEATURES OF HYPERAPOB, DIABETOLOGIA, 40, 2 SUPPL., (1997); SCHRAUWEN P., VAN MARKEN L., SARIS W.H., WESTERTERP K.R., CHANGES IN FAT OXIDATION IN RESPONSE TO A HIGH-FAT DIET, AM J CLIN NUTR, 66, PP. 276-282, (1997); SCHRAUWEN P., WAGENMAKERS A.J., VAN MARKEN L., SARIS W.H., WESTERTERP K.R., INCREASE IN FAT OXIDATION ON A HIGH-FAT DIET IS ACCOMPANIED BY AN INCREASE IN TRIGLYCERIDE-DERIVED FATTY ACID OXIDATION, DIABETES, 49, PP. 640-646, (2000); WILLETT W.C., DIETARY FAT AND OBESITY: AN UNCONVINCING RELATION, AM J CLIN NUTR, 68, PP. 1149-1150, (1998); LASSERS B.W., KAIJSER L., WAHLQVIST M.L., CARLSON L.A., RELATIONSHIP IN MAN BETWEEN PLASMA FREE FATTY ACIDS AND MYOCARDIAL METABOLISM OF CARBOHYDRATE SUBSTRATES, LANCET, 2, PP. 448-450, (1971); PRITIKIN N., OPTIMAL DIETARY RECOMMENDATIONS: A PUBLIC HEALTH RESPONSIBILITY, PREV MED, 11, PP. 733-739, (1982); ORNISH D., SCHERWITZ L.W., DOODY R.S., KESTEN D., MCLANAHAN S.M., BROWN S.E., ET AL., EFFECTS OF STRESS MANAGEMENT TRAINING AND DIETARY CHANGES IN TREATING ISCHEMIC HEART DISEASE, JAMA, 249, PP. 54-59, (1983); ORNISH D., BROWN S.E., SCHERWITZ L.W., BILLINGS J.H., ARMSTRONG W.T., PORTS T.A., ET AL., CAN LIFESTYLE CHANGES REVERSE CORONARY HEART DISEASE? THE LIFESTYLE HEART TRIAL, LANCET, 336, PP. 129-133, (1990); ORNISH D., AVOIDING REVASCULARIZATION WITH LIFESTYLE CHANGES: THE MULTICENTER LIFESTYLE DEMONSTRATION PROJECT, AM J CARDIOL, 82, (1998); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., BROWN S.E., GOULD K.L., MERRITT T.A., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, PP. 2001-2007, (1998); ESSELSTYN C.B., ELLIS S.G., MEDENDORP S.V., CROWE T.D., A STRATEGY TO ARREST AND REVERSE CORONARY ARTERY DISEASE: A 5-YEAR LONGITUDINAL STUDY OF A SINGLE PHYSICIAN'S PRACTICE, J FAM PRACT, 41, PP. 560-568, (1995); ESSELSTYN C.B., UPDATING A 12-YEAR EXPERIENCE WITH ARREST AND REVERSAL THERAPY FOR CORONARY HEART DISEASE (AN OVERDUE REQUIEM FOR PALLIATIVE CARDIOLOGY), AM J CARDIOL, 84, PP. 339-341, (1999); GOULD K.L., MARTUCCI J.P., GOLDBERG D.I., HESS M.J., EDENS R.P., LATIFI R., ET AL., SHORT-TERM CHOLESTEROL LOWERING DECREASES SIZE AND SEVERITY OF PERFUSION ABNORMALITIES BY POSITRON EMISSION TOMOGRAPHY AFTER DIPYRIDAMOLE IN PATIENTS WITH CORONARY ARTERY DISEASE. A POTENTIAL NONINVASIVE MARKER OF HEALING CORONARY ENDOTHELIUM, CIRCULATION, 89, PP. 1530-1538, (1994); THUESEN L., NIELSEN T.T., THOMASSEN A., BAGGER J.P., HENNINGSEN P., BENEFICIAL EFFECT OF A LOW-FAT LOW-CALORIE DIET ON MYOCARDIAL ENERGY METABOLISM IN PATIENTS WITH ANGINA PECTORIS, LANCET, 2, PP. 59-62, (1984); GOULD K.L., ORNISH D., KIRKEEIDE R., BROWN S., STUART Y., BUCHI M., ET AL., IMPROVED STENOSIS GEOMETRY BY QUANTITATIVE CORONARY ARTERIOGRAPHY AFTER VIGOROUS RISK FACTOR MODIFICATION, AM J CARDIOL, 69, PP. 845-853, (1992); SIMONSEN S., KJEKSHUS J.K., THE EFFECT OF FREE FATTY ACIDS ON MYOCARDIAL OXYGEN CONSUMPTION DURING ATRIAL PACING AND CATECHOLAMINE INFUSION IN MAN, CIRCULATION, 58, PP. 484-491, (1978); WOJTCZAK L., SCHONFELD P., EFFECT OF FATTY ACIDS ON ENERGY COUPLING PROCESSES IN MITOCHONDRIA, BIOCHIM BIOPHYS ACTA, 1183, PP. 41-57, (1993); ROWE M.J., NEILSON J.M., OLIVER M.F., CONTROL OF VENTRICULAR ARRHYTHMIAS DURING MYOCARDIAL INFARCTION BY ANTILIPOLYTIC TREATMENT USING A NICOTINIC-ACID ANALOGUE, LANCET, 1, PP. 295-300, (1975); OLIVER M.F., OPIE L.H., EFFECTS OF GLUCOSE AND FATTY ACIDS ON MYOCARDIAL ISCHAEMIA AND ARRHYTHMIAS, LANCET, 343, PP. 155-158, (1994); FAZEKAS T., SZEKERES L., EFFECTS OF THE LIPOLYSIS INHIBITING AGENT BETA-PYRIDYLCARBINOL (RONICOL) IN ACUTE MYOCARDIAL ISCHAEMIA, ACTA PHYSIOL HUNG, 74, PP. 169-174, (1989); LAZAR H.L., ENHANCED PRESERVATION OF ACUTELY ISCHEMIC MYOCARDIUM AND IMPROVED CLINICAL OUTCOMES USING GLUCOSE-INSULIN-POTASSIUM (GIK) SOLUTIONS, AM J CARDIOL, 80, (1997); FATH-ORDOUBADI F., BEATT K.J., GLUCOSE-INSULIN-POTASSIUM THERAPY FOR TREATMENT OF ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF RANDOMIZED PLACEBO-CONTROLLED TRIALS, CIRCULATION, 96, PP. 1152-1156, (1997); STEINBERG H.O., TARSHOBY M., MONESTEL R., HOOK G., CRONIN J., JOHNSON A., ET AL., ELEVATED CIRCULATING FREE FATTY ACID LEVELS IMPAIR ENDOTHELIUM-DEPENDENT VASODILATION, J CLIN INVEST, 100, PP. 1230-1239, (1997); PLOTNICK G.D., CORRETTI M.C., VOGEL R.A., EFFECT OF ANTIOXIDANT VITAMINS ON THE TRANSIENT IMPAIRMENT OF ENDOTHELIUM-DEPENDENT BRACHIAL ARTERY VASOACTIVITY FOLLOWING A SINGLE HIGH-FAT MEAL, JAMA, 278, PP. 1682-1686, (1997); ONG P.J., DEAN T.S., HAYWARD C.S., DELLA M.P., SANDERS T.A., COLLINS P., EFFECT OF FAT AND CARBOHYDRATE CONSUMPTION ON ENDOTHELIAL FUNCTION, LANCET, 354, (1999); NG C.K., CHAN A.P., CHENG A., IMPAIRMENT OF ENDOTHELIAL FUNCTION - A POSSIBLE MECHANISM FOR ATHEROSCLEROSIS OF A HIGH-FAT MEAL INTAKE, ANN ACAD MED SINGAPORE, 30, PP. 499-502, (2001); ZHAO S.P., LIU L., GAO M., ZHOU Q.C., LI Y.L., XIA B., IMPAIRMENT OF ENDOTHELIAL FUNCTION AFTER A HIGH-FAT MEAL IN PATIENTS WITH CORONARY ARTERY DISEASE, CORON ARTERY DIS, 12, PP. 561-565, (2001); DAVDA R.K., STEPNIAKOWSKI K.T., LU G., ULLIAN M.E., GOODFRIEND T.L., EGAN B.M., OLEIC ACID INHIBITS ENDOTHELIAL NITRIC OXIDE SYNTHASE BY A PROTEIN KINASE C-INDEPENDENT MECHANISM, HYPERTENSION, 26, PP. 764-770, (1995); INOGUCHI T., LI P., UMEDA F., YU H.Y., KAKIMOTO M., IMAMURA M., ET AL., HIGH GLUCOSE LEVEL AND FREE FATTY ACID STIMULATE REACTIVE OXYGEN SPECIES PRODUCTION THROUGH PROTEIN KINASE C-DEPENDENT ACTIVATION OF NAD (P)H OXIDASE IN CULTURED VASCULAR CELLS, DIABETES, 49, PP. 1939-1945, (2000); STEPNIAKOWSKI K.T., GOODFRIEND T.L., EGAN B.M., FATTY ACIDS ENHANCE VASCULAR ALPHA-ADRENERGIC SENSITIVITY, HYPERTENSION, 25, PP. 774-778, (1995); HAASTRUP A.T., STEPNIAKOWSKI K.T., GOODFRIEND T.L., EGAN B.M., INTRALIPID ENHANCES ALPHA 1-ADRENERGIC RECEPTOR MEDIATED PRESSOR SENSITIVITY, HYPERTENSION, 32, PP. 693-698, (1998); TOMITA T., EZAKI M., MIWA M., NAKAMURA K., INOUE Y., RAPID AND REVERSIBLE INHIBITION BY LOW DENSITY LIPOPROTEIN OF THE ENDOTHELIUM-DEPENDENT RELAXATION TO HEMOSTATIC SUBSTANCES IN PORCINE CORONARY ARTERIES. HEAT AND ACID LABILE FACTORS IN LOW DENSITY LIPOPROTEIN MEDIATE THE INHIBITION, CIRC RES, 66, PP. 18-27, (1990); HEIN T.W., KUO L., LDLS IMPAIR VASOMOTOR FUNCTION OF THE CORONARY MICROCIRCULATION: ROLE OF SUPEROXIDE ANIONS, CIRC RES, 83, PP. 404-414, (1998); FUKAGAWA N.K., ANDERSON J.W., HAGEMAN G., YOUNG V.R., MINAKER K.L., HIGH-CARBOHYDRATE, HIGH-FIBER DIETS INCREASE PERIPHERAL INSULIN SENSITIVITY IN HEALTHY YOUNG AND OLD ADULTS, AM J CLIN NUTR, 52, PP. 524-528, (1990); BARNARD R.J., UGIANSKIS E.J., MARTIN D.A., INKELES S.B., ROLE OF DIET AND EXERCISE IN THE MANAGEMENT OF HYPERINSULINEMIA AND ASSOCIATED ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 69, PP. 440-444, (1992); BARNARD R.J., EFFECTS OF LIFE-STYLE MODIFICATION ON SERUM LIPIDS, ARCH INTERN MED, 151, PP. 1389-1394, (1991); BOTKER H.E., MOLLER N., OVESEN P., MENGEL A., SCHMITZ O., ORSKOV H., ET AL., INSULIN RESISTANCE IN MICROVASCULAR ANGINA (SYNDROME X), LANCET, 342, PP. 136-140, (1993); FUH M.M., JENG C.Y., YOUNG M.M., SHEU W.H., CHEN Y.D., REAVEN G.M., INSULIN RESISTANCE, GLUCOSE INTOLERANCE, AND HYPERINSULINEMIA IN PATIENTS WITH MICROVASCULAR ANGINA, METABOLISM, 42, PP. 1090-1092, (1993); SWAN J.W., WALTON C., GODSLAND I.F., CROOK D., OLIVER M.F., STEVENSON J.C., INSULIN RESISTANCE SYNDROME AS A FEATURE OF CARDIOLOGICAL SYNDROME X IN NON-OBESE MEN, BR HEART J, 71, PP. 41-44, (1994); LANGES K., VOLK C., SCHNEIDER M.A., KOSCHYK D.H., RINNINGER F., NIENABER C.A., THE SIGNIFICANCE OF INSULIN RESISTANCE AND HYPERLIPIDEMIA IN MICROVASCULAR ANGINA (SYNDROME X), Z KARDIOL, 84, PP. 180-189, (1995); VESTERGAARD H., SKOTT P., STEFFENSEN R., WROBLEWSKI H., PEDERSEN O., KASTRUP J., INSULIN-RESISTANT GLUCOSE METABOLISM IN PATIENTS WITH MICROVASCULAR ANGINA-SYNDROME X, METABOLISM, 44, PP. 876-882, (1995); GODSLAND I.F., CROOK D., STEVENSON J.C., COLLINS P., ROSANO G.M., LEES B., ET AL., INSULIN RESISTANCE SYNDROME IN POSTMENOPAUSAL WOMEN WITH CARDIOLOGICAL SYNDROME X, BR HEART J, 74, PP. 47-52, (1995); GOODFELLOW J., OWENS D., HENDERSON A., CARDIOVASCULAR SYNDROMES X, ENDOTHELIAL DYSFUNCTION AND INSULIN RESISTANCE, DIABETES RES CLIN PRACT, 31, SUPPL., (1996); MCDOUGALL J., LITZAU K., HAVER E., SAUNDERS V., SPILLER G.A., RAPID REDUCTION OF SERUM CHOLESTEROL AND BLOOD PRESSURE BY A TWELVE-DAY, VERY LOW FAT, STRICTLY VEGETARIAN DIET, J AM COLL NUTR, 14, PP. 491-496, (1995); RAMSAY L.E., YEO W.W., JACKSON P.R., DIETARY REDUCTION OF SERUM CHOLESTEROL CONCENTRATION: TIME TO THINK AGAIN, BMJ, 303, PP. 953-957, (1991); YU-POTH S., ZHAO G., ETHERTON T., NAGLAK M., JONNALAGADDA S., KRIS-ETHERTON P.M., EFFECTS OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM'S STEP I AND STEP II DIETARY INTERVENTION PROGRAMS ON CARDIOVASCULAR DISEASE RISK FACTORS: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 632-646, (1999); HU F.B., STAMPFER M.J., MANSON J.E., RIMM E., COLDITZ G.A., ROSNER B.A., ET AL., DIETARY FAT INTAKE AND THE RISK OF CORONARY HEART DISEASE IN WOMEN, N ENGL J MED, 337, PP. 1491-1499, (1997); WILLETT W.C., WILL HIGH-CARBOHYDRATE/LOW-FAT DIETS REDUCE THE RISK OF CORONARY HEART DISEASE?, PROC SOC EXP BIOL MED, 225, PP. 187-190, (2000); ANDERSON J.W., WARD K., LONG-TERM EFFECTS OF HIGH-CARBOHYDRATE, HIGH-FIBER DIETS ON GLUCOSE AND LIPID METABOLISM: A PRELIMINARY REPORT ON PATIENTS WITH DIABETES, DIABETES CARE, 1, PP. 77-82, (1978); KOLTERMAN O.G., GREENFIELD M., REAVEN G.M., SAEKOW M., OLEFSKY J.M., EFFECT OF A HIGH CARBOHYDRATE DIET ON INSULIN BINDING TO ADIPOCYTES AND ON INSULIN ACTION IN VIVO IN MAN, DIABETES, 28, PP. 731-736, (1979); ASTRUP A., THE ROLE OF DIETARY FAT IN THE PREVENTION AND TREATMENT OF OBESITY. EFFICACY AND SAFETY OF LOW-FAT DIETS, INT J OBES RELAT METAB DISORD, 25, 1 SUPPL., (2001); KRIEGER D.R., LANDSBERG L., MECHANISMS IN OBESITY-RELATED HYPERTENSION: ROLE OF INSULIN AND CATECHOLAMINES, AM J HYPERTENS, 1, PP. 84-90, (1988); FACCHINI F.S., STOOHS R.A., REAVEN G.M., ENHANCED SYMPATHETIC NERVOUS SYSTEM ACTIVITY. THE LINCHPIN BETWEEN INSULIN RESISTANCE, HYPERINSULINEMIA, AND HEART RATE, AM J HYPERTENS, 9, PP. 1013-1017, (1996); SCHERRER U., SARTORI C., INSULIN AS A VASCULAR AND SYMPATHOEXCITATORY HORMONE: IMPLICATIONS FOR BLOOD PRESSURE REGULATION, INSULIN SENSITIVITY, AND CARDIOVASCULAR MORBIDITY, CIRCULATION, 96, PP. 4104-4113, (1997); ELLIS F.R., SANDERS T., LETTER: ANGINA AND VEGETARIAN DIET, LANCET, 1, (1976); ELLIS F.R., SANDERS T.A., ANGINA AND VEGAN DIET, AM HEART J, 93, PP. 803-805, (1977); SACKS F.M., CASTELLI W.P., DONNER A., KASS E.H., PLASMA LIPIDS AND LIPOPROTEINS IN VEGETARIANS AND CONTROLS, N ENGL J MED, 292, PP. 1148-1151, (1975); RESNICOW K., BARONE J., ENGLE A., MILLER S., HALEY N.J., FLEMING D., ET AL., DIET AND SERUM LIPIDS IN VEGAN VEGETARIANS: A MODEL FOR RISK REDUCTION, J AM DIET ASSOC, 91, PP. 447-453, (1991); ERNST E., PIETSCH L., MATRAI A., EISENBERG J., BLOOD RHEOLOGY IN VEGETARIANS, BR J NUTR, 56, PP. 555-560, (1986); HOSTMARK A.T., LYSTAD E., VELLAR O.D., HOVI K., BERG J.E., REDUCED PLASMA FIBRINOGEN, SERUM PEROXIDES, LIPIDS, AND APOLIPOPROTEINS AFTER A 3-WEEK VEGETARIAN DIET, PLANT FOODS HUM NUTR, 43, PP. 55-61, (1993); FAMODU A.A., OSILESI O., MAKINDE Y.O., OSONUGA O.A., FAKOYA T.A., OGUNYEMI E.O., ET AL., THE INFLUENCE OF A VEGETARIAN DIET ON HAEMOSTATIC RISK FACTORS FOR CARDIOVASCULAR DISEASE IN AFRICANS, THROMB RES, 95, PP. 31-36, (1999); HADDAD E.H., BERK L.S., KETTERING J.D., HUBBARD R.W., PETERS W.R., DIETARY INTAKE AND BIOCHEMICAL, HEMATOLOGIC, AND IMMUNE STATUS OF VEGANS COMPARED WITH NONVEGETARIANS, AM J CLIN NUTR, 70, (1999); DINTENFASS L., EFFECT OF LOW-FAT, LOW-PROTEIN DIET ON BLOOD VISCOSITY FACTORS, MED J AUST, 1, (1982); CRANE M.G., SAMPLE C., REGRESSION OF DIEBETIC NEUROPATHY WITH TOTAL VEGETARIAN (VEGAN) DIET, J NUTR MED, 4, PP. 431-439, (1994); MCCARTY M.F., FAVORABLE IMPACT OF A VEGAN DIET WITH EXERCISE ON HEMORHEOLOGY - IMPLICATIONS FOR CONTROL OF DIABETIC NEUROPATHY, MED HYPOTHESES, (2001); REMER T., PIETRZIK K., MANZ F., A MODERATE INCREASE IN DAILY PROTEIN INTAKE CAUSING AN ENHANCED ENDOGENOUS INSULIN SECRETION DOES NOT ALTER CIRCULATING LEVELS OR URINARY EXCRETION OF DEHYDROEPIANDROSTERONE SULFATE, METABOLISM, 45, PP. 1483-1486, (1996); BEILIN L.J., ROUSE I.L., ARMSTRONG B.K., MARGETTS B.M., VANDONGEN R., VEGETARIAN DIET AND BLOOD PRESSURE LEVELS: INCIDENTAL OR CAUSAL ASSOCIATION?, AM J CLIN NUTR, 48, PP. 806-810, (1988); SCIARRONE S.E., STRAHAN M.T., BEILIN L.J., BURKE V., ROGERS P., ROUSE I.L., BIOCHEMICAL AND NEUROHORMONAL RESPONSES TO THE INTRODUCTION OF A LACTO-OVOVEGETARIAN DIET, J HYPERTENS, 11, PP. 849-860, (1993); IYER R.N., KHAN A.A., GUPTA A., VAJIFDAR B.U., LOKHANDWALA Y.Y., L-CARNITINE MODERATELY IMPROVES THE EXERCISE TOLERANCE IN CHRONIC STABLE ANGINA, J ASSOC PHYSICIANS INDIA, 48, PP. 1050-1052, (2000); FERNANDEZ C., PROTO C., L-CARNITINE IN THE TREATMENT OF CHRONIC MYOCARDIAL ISCHEMIA. AN ANALYSIS OF 3 MULTICENTER STUDIES AND A BIBLIOGRAPHIC REVIEW, CLIN TER, 140, PP. 353-377, (1992); CACCIATORE L., CERIO R., CIARIMBOLI M., COCOZZA M., COTO V., D'ALESSANDRO A., ET AL., THE THERAPEUTIC EFFECT OF L-CARNITINE IN PATIENTS WITH EXERCISE-INDUCED STABLE ANGINA: A CONTROLLED STUDY, DRUGS EXP CLIN RES, 17, PP. 225-235, (1991); CHERCHI A., LAI C., ANGELINO F., TRUCCO G., CAPONNETTO S., MERETO P.E., ET AL., EFFECTS OF L-CARNITINE ON EXERCISE TOLERANCE IN CHRONIC STABLE ANGINA: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED CROSSOVER STUDY, INT J CLIN PHARMACOL THER TOXICOL, 23, PP. 569-572, (1985); KAMIKAWA T., SUZUKI Y., KOBAYASHI A., HAYASHI H., MASUMURA Y., NISHIHARA K., ET AL., EFFECTS OF L-CARNITINE ON EXERCISE TOLERANCE IN PATIENTS WITH STABLE ANGINA PECTORIS, JPN HEART J, 25, PP. 587-597, (1984); NEGRAO C.E., JI L.L., SCHAUER J.E., NAGLE F.J., LARDY H.A., CARNITINE SUPPLEMENTATION AND DEPLETION: TISSUE CARNITINES AND ENZYMES IN FATTY ACID OXIDATION, J APPL PHYSIOL, 63, PP. 315-321, (1987); BRODERICK T.L., QUINNEY H.A., LOPASCHUK G.D., CARNITINE STIMULATION OF GLUCOSE OXIDATION IN THE FATTY ACID PERFUSED ISOLATED WORKING RAT HEART, J BIOL CHEM, 267, PP. 3758-3763, (1992); BRODERICK T.L., PANAGAKIS G., DIDOMENICO D., GAMBLE J., LOPASCHUK G.D., SHUG A.L., ET AL., L-CARNITINE IMPROVEMENT OF CARDIAC FUNCTION IS ASSOCIATED WITH A STIMULATION IN GLUCOSE BUT NOT FATTY ACID METABOLISM IN CARNITINE-DEFICIENT HEARTS, CARDIOVASC RES, 30, PP. 815-820, (1995); CALVANI M., REDA E., ARRIGONI-MARTELLI E., REGULATION BY CARNITINE OF MYOCARDIAL FATTY ACID AND CARBOHYDRATE METABOLISM UNDER NORMAL AND PATHOLOGICAL CONDITIONS, BASIC RES CARDIOL, 95, PP. 75-83, (2000); STANLEY W.C., LOPASCHUK G.D., HALL J.L., MCCORMACK J.G., REGULATION OF MYOCARDIAL CARBOHYDRATE METABOLISM UNDER NORMAL AND ISCHAEMIC CONDITIONS. POTENTIAL FOR PHARMACOLOGICAL INTERVENTIONS, CARDIOVASC RES, 33, PP. 243-257, (1997); LAUFS U., LIAO J.K., POST-TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA STABILITY BY RHO GTPASE, J BIOL CHEM, 273, PP. 24266-24271, (1998); ENDRES M., LAUFS U., HUANG Z., NAKAMURA T., HUANG P., MOSKOWITZ M.A., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC NATL ACAD SCI USA, 95, PP. 8880-8885, (1998); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS THROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 61-69, (2000); LAUFS U., LIAO J.K., TARGETING RHO IN CARDIOVASCULAR DISEASE, CIRC RES, 87, PP. 526-528, (2000); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THERAPEUTIC RES, 51, PP. 568-575, (1992); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A: BIOL SCI MED SCI, 56, (2001); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THERAPEUTIC RES, 60, PP. 379-391, (1999); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE - POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, (2001); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, PP. 469-473, (1998); MCCARTY M.F., COENZYME Q VERSUS HYPERTENSION: DOES COQ. DECREASE ENDOTHELIAL SUPEROXIDE GENERATION?, MED HYPOTHESES, 53, PP. 300-304, (1999); LAWSON D.L., MEHTA J.L., SALDEEN K., MEHTA P., SALDEEN T.G., OMEGA-3 POLYUNSATURATED FATTY ACIDS AUGMENT ENDOTHELIUM-DEPENDENT VASORELAXATION BY ENHANCED RELEASE OF EDRF AND VASODILATOR PROSTAGLANDINS, EICOSANOIDS, 4, PP. 217-223, (1991); KIM P., SHIMOKAWA H., VANHOUTTE P.M., DIETARY OMEGA-3 FATTY ACIDS AND ENDOTHELIUM-DEPENDENT RESPONSES IN PORCINE CEREBRAL ARTERIES, STROKE, 23, PP. 407-413, (1992); DE CATERINA R., CYBULSKY M.A., CLINTON S.K., GIMBRONE M.A.J., LIBBY P., OMEGA-3 FATTY ACIDS AND ENDOTHELIAL LEUKOCYTE ADHESION MOLECULES, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 52, PP. 191-195, (1995); GOODFELLOW J., BELLAMY M.F., RAMSEY M.W., JONES C.J., LEWIS M.J., DIETARY SUPPLEMENTATION WITH MARINE OMEGA-3 FATTY ACIDS IMPROVE SYSTEMIC LARGE ARTERY ENDOTHELIAL FUNCTION IN SUBJECTS WITH HYPERCHOLESTEROLEMIA, J AM COLL CARDIOL, 35, PP. 265-270, (2000); COOKE J.P., OKA R.K., ATHEROGENESIS AND THE ARGININE HYPOTHESIS, CURR ATHEROSCLER REP, 3, PP. 252-259, (2001); MAXWELL A.J., ANDERSON B., ZAPIEN M.P., COOKE J.P., ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLEMIA IS REVERSED BY A NUTRITIONAL PRODUCT DESIGNED TO ENHANCE NITRIC OXIDE ACTIVITY, CARDIOVASC DRUGS THER, 14, PP. 309-316, (2000); HAMBRECHT R., HILBRICH L., ERBS S., GIELEN S., FIEHN E., SCHOENE N., ET AL., CORRECTION OF ENDOTHELIAL DYSFUNCTION IN CHRONIC HEART FAILURE: ADDITIONAL EFFECTS OF EXERCISE TRAINING AND ORAL L-ARGININE SUPPLEMENTATION, J AM COLL CARDIOL, 35, PP. 706-713, (2000); KAMIKAWA T., KOBAYASHI A., YAMASHITA T., HAYASHI H., YAMAZAKI N., EFFECTS OF COENZYME Q10 ON EXERCISE TOLERANCE IN CHRONIC STABLE ANGINA PECTORIS, AM J CARDIOL, 56, PP. 247-251, (1985); SINGH R.B., WANDER G.S., RASTOGI A., SHUKLA P.K., MITTAL A., SHARMA J.P., ET AL., RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF COENZYME Q10 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, CARDIOVASC DRUGS THER, 12, PP. 347-353, (1998); SAYNOR R., GILLOTT T., CHANGES IN BLOOD LIPIDS AND FIBRINOGEN WITH A NOTE ON SAFETY IN A LONG TERM STUDY ON THE EFFECTS OF N-3 FATTY ACIDS IN SUBJECTS RECEIVING FISH OIL SUPPLEMENTS AND FOLLOWED FOR SEVEN YEARS, LIPIDS, 27, PP. 533-538, (1992); WALKER H.A., MCGING E., FISHER I., BOGER R.H., BODE-BOGER S.M., JACKSON G., ET AL., ENDOTHELIUM-DEPENDENT VASODILATION IS INDEPENDENT OF THE PLASMA L-ARGININE/ADMA RATIO IN MEN WITH STABLE ANGINA: LACK OF EFFECT OF ORAL L-ARGININE ON ENDOTHELIAL FUNCTION, OXIDATIVE STRESS AND EXERCISE PERFORMANCE, J AM COLL CARDIOL, 38, PP. 499-505, (2001); BEDNARZ B., WOLK R., CHAMIEC T., HERBACZYNSKA-CEDRO K., WINEK D., CEREMUZYNSKI L., EFFECTS OF ORAL L-ARGININE SUPPLEMENTATION ON EXERCISE-INDUCED QT DISPERSION AND EXERCISE TOLERANCE IN STABLE ANGINA PECTORIS, INT J CARDIOL, 75, PP. 205-210, (2000); FUJITA H., YAMABE H., YOKOYAMA M., EFFECT OF L-ARGININE ADMINISTRATION ON MYOCARDIAL THALLIUM-201 PERFUSION DURING EXERCISE IN PATIENTS WITH ANGINA PECTORIS AND NORMAL CORONARY ANGIOGRAMS, J NUCL CARDIOL, 7, PP. 97-102, (2000); KOBAYASHI N., NAKAMURA M., HIRAMORI K., EFFECTS OF INFUSION OF L-ARGININE ON EXERCISE-INDUCED MYOCARDIAL ISCHEMIC ST-SEGMENT CHANGES AND CAPACITY TO EXERCISE OF PATIENTS WITH STABLE ANGINA PECTORIS, CORON ARTERY DIS, 10, PP. 321-326, (1999); BLUM A., PORAT R., ROSENSCHEIN U., KEREN G., ROTH A., LANIADO S., ET AL., CLINICAL AND INFLAMMATORY EFFECTS OF DIETARY L-ARGININE IN PATIENTS WITH INTRACTABLE ANGINA PECTORIS, AM J CARDIOL, 83, PP. 1488-1490, (1999); SICUTERI F., FRANCHI G., FANCIULLACCI M., GIOTTI A., GUIDOTTI A., ANTI-ANGINOUS EFFECT OF A NON-CORONARO-DILATOR SULFURATED AMINO ACID, CLIN TER, 49, PP. 205-219, (1969); MCCARTY M.F., THE REPORTED CLINICAL UTILITY OF TAURINE IN ISCHEMIC DISORDERS MAY REFLECT A DOWN-REGULATION OF NEUTROPHIL ACTIVATION AND ADHESION, MED HYPOTHESES, 53, PP. 290-299, (1999); ZHANG R., BRENNAN M.L., FU X., AVILES R.J., PEARCE G.L., PENN M.S., ET AL., ASSOCIATION BETWEEN MYELOPEROXIDASE LEVELS AND RISK OF CORONARY ARTERY DISEASE, JAMA, 286, PP. 2136-2142, (2001); WRIGHT C.E., LIN T.T., LIN Y.Y., STURMAN J.A., GAULL G.E., TAURINE SCAVENGES OXIDIZED CHLORINE IN BIOLOGICAL SYSTEMS, PROG CLIN BIOL RES, 179, PP. 137-147, (1985); KOYAMA I., NAKAMORI K., NAGAHAMA T., OGASAWARA M., NEMOTO M., THE REACTIVITY OF TAURINE WITH HYPOCHLOROUS ACID AND ITS APPLICATION FOR EYE DROPS, ADV EXP MED BIOL, 403, PP. 9-18, (1996); RASCHKE P., MASSOUDY P., BECKER B.F., TAURINE PROTECTS THE HEART FIROM NEUTROPHIL-INDUCED REPERFUSION INJURY, FREE RADIC BIOL MED, 19, PP. 461-471, (1995)","M.F. MCCARTY; PANTOX LABORATORIES, SAN DIEGO, CA 92109, 4622 SANTA FE ST., UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-1042288659","MED HYPOTHESES",NA,"NOTREPORTED;PANTOX LABORATORIES;NOTREPORTED",NA,"MCCARTY MF, 2004, MED HYPOTHESES","MCCARTY MF, 2004, MED HYPOTHESES-a"
"CUBEDDU L;CUBEDDU R;HEIMOWITZ T;RESTREPO B;LAMAS G;WEINBERG G","CUBEDDU, LUIGI X. (7005746668); CUBEDDU, ROBERTO J. (57196542794); HEIMOWITZ, TODD (36339712000); RESTREPO, BEATRIZ (57225426405); LAMAS, GERVASIO A. (7006432469); WEINBERG, GLORIA B. (35872340800)","COMPARATIVE LIPIDLOWERING EFFECTS OF POLICOSANOL AND ATORVASTATIN A RANDOMIZED PARALLEL DOUBLEBLIND PLACEBOCONTROLLED TRIAL",2006,"AMERICAN HEART JOURNAL","152","",53,"10.1016/j.ahj.2006.08.009","DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL AND ADMINISTRATIVE SCIENCES, NOVA SOUTHEASTERN UNIVERSITY, FORT LAUDERDALE, FL, UNITED STATES;DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL AND ADMINISTRATIVE SCIENCES, NOVA SOUTHEASTERN UNIVERSITY, FORT LAUDERDALE, FL, UNITED STATES;DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL AND ADMINISTRATIVE SCIENCES, NOVA SOUTHEASTERN UNIVERSITY, FORT LAUDERDALE, FL, UNITED STATES;DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL AND ADMINISTRATIVE SCIENCES, NOVA SOUTHEASTERN UNIVERSITY, FORT LAUDERDALE, FL, UNITED STATES;DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL AND ADMINISTRATIVE SCIENCES, NOVA SOUTHEASTERN UNIVERSITY, FORT LAUDERDALE, FL, UNITED STATES;DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES, DEPARTMENT OF PHARMACEUTICAL AND ADMINISTRATIVE SCIENCES, NOVA SOUTHEASTERN UNIVERSITY, FORT LAUDERDALE, FL, UNITED STATES","BACKGROUND: POLICOSANOL, COMMONLY DERIVED FROM PURIFIED SUGAR CANE WAX, HAS BEEN REPORTED TO EXERT LIPID-LOWERING EFFECTS. POLICOSANOL IS AVAILABLE IN THE UNITED STATES AS A NUTRITIONAL SUPPLEMENT DESPITE NO US RESEARCH CLINICAL EXPERIENCE. THIS TRIAL WAS DESIGNED TO RIGOROUSLY ESTABLISH THE LIPID-LOWERING EFFICACY OF POLICOSANOL AS MONOTHERAPY AND ITS POTENTIAL ADDITIVE AND POSSIBLY SYNERGISTIC EFFECTS WHEN ADDED TO STATIN THERAPY. METHODS: A RANDOMIZED, PARALLEL, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED DESIGN WAS USED. PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS FROM 140 TO 189 MG/DL WERE ASSIGNED INTO 1 OF 4 GROUPS TO RECEIVE POLICOSANOL 20 MG, ATORVASTATIN 10 MG, COMBINATION THERAPY, OR PLACEBO FOR 12 WEEKS. RESULTS: A TOTAL OF 99 PATIENTS WERE EXAMINED. BASELINE CHARACTERISTICS WERE SIMILAR AMONG ALL TREATMENT GROUPS. POLICOSANOL (20 MG/D FOR 12 WEEKS) DID NOT SIGNIFICANTLY CHANGE PLASMA TOTAL CHOLESTEROL, LDL-C, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, OR TRIGLYCERIDE LEVELS WHEN COMPARED WITH BASELINE VALUES OR WITH VALUES OF PLACEBO-TREATED PATIENTS. ATORVASTATIN (10 MG/D FOR 12 WEEKS) REDUCED TOTAL CHOLESTEROL BY 27% AND LDL-C BY 35%. ADDITION OF POLICOSANOL TO ATORVASTATIN FAILED TO PRODUCE ANY FURTHER REDUCTION IN LIPID LEVELS ABOVE THAT OF ATORVASTATIN ALONE. POLICOSANOL WAS SAFE AND DID NOT AFFECT LIVER ENZYME OR CREATININE PHOSPHOKINASE LEVELS. CONCLUSIONS: POLICOSANOL DID NOT REDUCE LDL-C OR TOTAL CHOLESTEROL LEVELS EITHER ALONE OR IN COMBINATION WITH ATORVASTATIN. THIS OBSERVATION SUPPORTS THE NEED FOR SYSTEMATIC EVALUATION OF AVAILABLE PRODUCTS CONTAINING POLICOSANOL TO DETERMINE THEIR CLINICAL LIPID-LOWERING EFFICACY UNDER RIGOROUS EXPERIMENTAL CONDITIONS. WE PROPOSE THAT POLICOSANOL SHOULD BE ADDED TO THE LIST OF NUTRITIONAL SUPPLEMENTS LACKING SCIENTIFIC VALIDITY TO SUPPORT THEIR USE. © 2006 MOSBY, INC. ALL RIGHTS RESERVED.","","ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESSTOR; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIPID LOWERING ACTIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION","PHARMED GROUP IN MIAMI","THIS STUDY WAS SUPPORTED BY A GRANT FROM PHARMED GROUP IN MIAMI, FL, THE PHARMACEUTICAL SUPPLIER OF CHOLESSTOR TO THE MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL. ","EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL, EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); CONTI C.R., EVOLUTION OF NCEP GUIDELINES: ATP1-ATPIII RISK ESTIMATION FOR CORONARY HEART DISEASE IN 2002. NATIONAL CHOLESTEROL EDUCATION PROGRAM, CLIN CARDIOL, 25, PP. 89-90, (2002); S INVESTIGATORS, RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF CAPS/TEXCAPS: AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); LIPID INVESTIGATORS, PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS: THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP, N ENGL J MED, 339, PP. 1349-1357, (1998); JANIKULA M., POLICOSANOL: A NEW TREATMENT FOR CARDIOVASCULAR DISEASE?, ALTERN MED REV, 7, PP. 203-217, (2002); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOL IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-364, (2002); CHEN J.T., WESLEY R., SHAMBUREK R.D., ET AL., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ARRUZAZABALA M.L., MOLINA V., MAS R., ET AL., ANTIPLATELET EFFECTS OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); CASTANO G., MAS R., NORDASE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5M TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CRESPO N., ALVAREZ, MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 58, PP. 44-51, (1997); TORRES O., AGRAMONTE A., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 24, PP. 27-33, (1994); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); PONS S., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); ORTENSI G., GLADSTEIN J., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); ILLNAIT J., CASTANO G., MAS R., ET AL., A COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND SIMVASTATIN FOR TREATING TYPE II HYPERCHOLESTEROLEMIA, CAN J CARDIOL, 13, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 859-867, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-146, (2000); CASTANO G., MAS R., ARRUZAZABALA M., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 29, PP. 105-116, (1999); LIN Y., RUDRUM M., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, SUPPL, (2004); WANG Y.W., JONES P.J., PISCHEL I., ET AL., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003)","G.B. WEINBERG; DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MOUNT SINAI MEDICAL CENTER, MIAMI BEACH, FL, UNITED STATES; EMAIL: G-WEINBERG@MSMC.COM","MOSBY INC.","ENGLISH","AM. HEART J.","ARTICLE","ISI","2-S2.0-33750407566","AM HEART J","NOVA SOUTHEASTERN UNIVERSITY;NOVA SOUTHEASTERN UNIVERSITY;NOVA SOUTHEASTERN UNIVERSITY;NOVA SOUTHEASTERN UNIVERSITY;NOVA SOUTHEASTERN UNIVERSITY;NOVA SOUTHEASTERN UNIVERSITY","NOTREPORTED;MOUNT SINAI MEDICAL CENTER;NOTREPORTED",NA,"CUBEDDU LX, 2006, AM HEART J","CUBEDDU LX, 2006, AM HEART J"
"SCHARNAGL H;MÄRZ W","SCHARNAGL, HUBERT (7004216113); MÄRZ, WINFRIED (57220877383)","NEW LIPIDLOWERING AGENTS ACTING ON LDL RECEPTORS",2005,"CURRENT TOPICS IN MEDICINAL CHEMISTRY","5","9",37,"10.2174/1568026053544524","CLINICAL INSTITUTE OF MEDICAL AND CLINICAL LABORATORY DIAGNOSTICS, MEDICAL UNIVERSITY, A-8036 GRAZ, AUENBRUGGERPLATZ 15, AUSTRIA;CLINICAL INSTITUTE OF MEDICAL AND CLINICAL LABORATORY DIAGNOSTICS, MEDICAL UNIVERSITY, A-8036 GRAZ, AUENBRUGGERPLATZ 15, AUSTRIA","THE TREATMENT OF DYSLIPOPROTEINEMIA HAS PROVEN A SUCCESSFUL STRATEGY IN THE PREVENTION OF CARDIOVASCULAR DISEASES. THE MAJOR TARGET OF HYPOLIPIDEMIC DRUGS IS THE REDUCTION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C). HMG-COA REDUCTASE INHIBITORS (HMGRI) EFFECTIVELY LOWER LDL-C BY INHIBITING THE MEVALONATE PATHWAY AND ENHANCING THE ACTIVITY OF THE LDL RECEPTOR (LDL-R). NUMEROUS CLINICAL STUDIES DEMONSTRATED CONVINCINGLY, THAT THE REDUCTION OF LDL-C LOWERS THE INCIDENCE OF CARDIOVASCULAR EVENTS IN PRIMARY AND SECONDARY PREVENTION. TWO NEW HMGRI, ROSUVASTATIN AND PITAVASTATIN, HAVE BEEN EVALUATED IN CLINICAL TRIALS. BOTH DRUGS DEMONSTRATED EFFICACY IN LOWERING ATHEROGENIC LIPOPROTEINS. IN ADDITION TO THE REDUCTION OF LDL-C, THEY MAY HAVE A HIGHER POTENCY TO TOWER TRIACYLGLYCERIDES (TG) AND TO INCREASE HDL CHOLESTEROL (HDL-C) COMPARED TO CURRENTLY AVAILABLE HMGRI. OTHER THERAPEUTIC STRATEGIES EXAMINED IN EXPERIMENTAL ANIMALS ARE THE INHIBITION OF SQUALENE SYNTHASE, THE FIRST ENZYME OF THE MEVALONATE PATHWAY, WHICH IS SPECIFICALLY COMMITTED TO CHOLESTEROL BIOSYNTHESIS, AND THE DIRECT UP-REGULATION OF LDL RECEPTOR ACTIVITY. THE LATTER COMPOUNDS, THE SCAP LIGANDS, ARE THE FIRST MEMBERS OF A NEW CLASS OF HYPOLIPIDEMIC AGENTS AFFECTING THE TRANSCRIPTIONAL REGULATION OF GENES INVOLVED IN LIPID METABOLISM. RECENT TREATMENT GUIDELINES EMPHASISE THE IMPORTANCE OF MODIFYING LIPID METABOLISM BEYOND LOWERING LDL-C, MAINLY BY LOWERING TG AND RAISING HDL-C. ALTHOUGH THESE ACTIONS ARE NOT PRIMARY TARGETS OF THE COMPOUNDS DISCUSSED HERE, IT IS INTERESTING THAT DRUGS INDUCING THE LDL-R USUALLY ALSO LOWER TG AND, IN THE CASE OF HMGRI, INCREASE HDL-C. © 2005 BENTHAM SCIENCE PUBLISHERS LTD.","CORONARY ARTERY DISEASE; HMG-COA REDUCTASE INHIBITORS; LDL CHOLESTEROL; LDL RECEPTOR; SCAP LIGANDS; SQUALENE SYNTHASE INHIBITORS","ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPIDS; MEVALONIC ACID; RECEPTORS, LDL; TRANSCRIPTION, GENETIC; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; ER 27856; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GW 300; GW 532; GW 575; GW 707; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIFIBROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; MEVINOLIN; NEW DRUG; PITAVASTATIN; POLICOSANOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; TAK 475; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YM 53601; ABDOMINAL PAIN; ASTHENIA; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DYSLIPOPROTEINEMIA; ENZYME INHIBITION; HUMAN; LIPID METABOLISM; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; RECEPTOR UPREGULATION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL","","","DOWNS J.R., CLEARFIELD M., WEIS S., WHITNEY E., SHAPIRO D.R., BEERE P.A., LANGENDORFER A., STEIN E.A., KRUYER W., GOTTO JR. A.M., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., BROWN L., WARNICA J.W., ARNOLD J.M., WUN C.C., DAVIS B.R., BRAUNWALD E., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, PP. 1001-1009, (1996); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SHEPHERD J., COBBE S.M., FORD I., ISLES C.G., LORIMER A.R., MACFARLANE P.W., MCKILLOP J.H., PACKARD C.J., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENGL. J. MED., 339, PP. 1349-1357, (1998); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); BROWN M.S., GOLDSTEIN J.L., A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS, SCIENCE, 232, PP. 34-47, (1986); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, PP. 425-430, (1990); ENDO A., THE DISCOVERY AND DEVELOPMENT OF HMG-COA REDUCTASE INHIBITORS, J. LIPID RES., 33, PP. 1569-1582, (1992); BROWN M.S., GOLDSTEIN J.L., THE SREBP PATHWAY: REGULATION OF CHOLESTEROL METABOLISM BY PROTEOLYSIS OF A MEMBRANE-BOUND TRANSCRIPTION FACTOR, CELL, 89, PP. 331-340, (1997); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN, AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM. J. CARDIOL., 81, PP. 582-587, (1998); BALLANTYNE C.M., MCKENNEY J., TRIPPE B.S., EFFICACY AND SAFETY OF AN EXTENDED-RELEASE FORMULATION OF FLUVASTATIN FOR ONCE-DAILY TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 86, PP. 759-763, (2000); BUCKETT L., BALLARD P., DAVIDSON R., DUNKLEY C., MARTIN L., STAFFORD J., MCTAGGART F., SELECTIVITY OF ZD4522 FOR INHIBITION OF CHOLESTEROL SYNTHESIS IN HEPATIC VERSUS NON-HEPATIC CELLS, ATHEROSCLEROSIS, 151, (2000); MCTAGGART F., BUCKETT L., DAVIDSON R., HOLDGATE G., MCCORMICK A., SCHNECK D., SMITH G., WARWICK M., PRECLINICAL AND CLINICAL PHARMACOLOGY OF ROSUVASTATIN, A NEW 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR, AM. J. CARDIOL., 87, (2001); SMITH G., DAVIDSON R., BLOOR S., BURNS K., CALNAN C., MCAULAY P., TORR N., WARD W., MCTAGGART F., PHARMACOLOGICAL PROPERTIES OF ZD4522 - A NEW HMG-COA REDUCTASE INHIBITOR, ATHEROSCLEROSIS, 151, (2000); NEZASA K., HIGAKI K., MATSUMURA T., INAZAWA K., HASEGAWA H., NAKANO M., KOIKE M., LIVER-SPECIFIC DISTRIBUTION OF ROSUVASTATIN IN RATS: COMPARISON WITH PRAVASTATIN AND SIMVASTATIN, DRUG METAB. DISP., 30, PP. 1158-1163, (2002); WINDASS A., BLEASBY K., LAUFFART B., BROWN C.D., THE HMG-COA0 REDUCTASE INHIBITOR ROSUVASTATIN IS A HIGH-AFFFINITY SUBSTRATE OF THE HEPATIC ORGANIC ANION TRANSPORTER OATP-C, ATHEROSCLEROSIS, 2, (2001); WARWICK M.J., DANE A.L., SCHNECK D.W., RAZA A., SINGLE- AND MULTIPLE-DOSE PHARMACOKINETICS AND SAFETY OF THE NEW HMG-COA REDUCTASE INHIBITOR ZD4522, ATHEROSCLEROSIS, 151, (2000); HOLDGATE G., WARD W.H.J., DAVIDSON R.G., MCTAGGART F., ROSUVASTATIN: KINETICS OF INHIBITION OF HMG-COA REDUCTASE, XIV INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (2001); MCCORMICK A.D., MCKILLOP D.C.J.B., MILES G.S., BAB T., TOUCHI A., YAMAGUCHI Y., ZD4522 - AN HMG-COA REDUCTASE INHIBITOR FREE METABILICALLY MEDIATED DRUG INTERACTIONS: METABOLIS STUDIES IN HUMAN IN VITRO SYSTEMS, J. CLIN. PHARMACOL., 40, (2000); COOPER K.J., MARTIN P.D., DANE A.L., WARWICK M.J., SCHNECK D.W., NWOSE O.M., ERYTHROMYCIN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OF ROSUVASTATIN, EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, (2001); OLSSON A.G., PEARS J., MCKELLAR J., MIZAN J., RAZA A., EFFECT OF ROSUVASTATIN ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 88, PP. 504-508, (2001); BROWN W.V., BAYS H.E., HASSMAN D.R., MCKENNEY J., CHITRA R., HUTCHINSON H., MILLER E., EFFICACY AND SAFETY OF ROSUVASTATIN COMPARED WITH PRAVASTATIN AND SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, 52-WEEK TRIAL, AM. HEART J., 144, PP. 1036-1043, (2002); DAVIDSON M., MA P., STEIN E.A., GOTTO JR. A.M., RAZA A., CHITRA R., HUTCHINSON H., COMPARISON OF EFFECTS ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH ROSUVASTATIN VERSUS ATORVASTATIN IN PATIENTS WITH TYPE IIA OR IIB HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 89, PP. 268-275, (2002); JONES P.H., DAVIDSON M.H., STEIN E.A., BAYS H.E., MCKENNEY J.M., MILLER E., CAIN V.A., BLASETTO J.W., COMPARISON OF THE EFFICACY AND SAFETY OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN ACROSS DOSES (STELLAR* TRIAL), AM. J. CARDIOL., 92, PP. 152-160, (2003); OLSSON A.G., ISTAD H., LUURILA O., OSE L., STENDER S., TUOMILEHTO J., WIKLUND O., SOUTHWORTH H., PEARS J., WILPSHAAR J.W., EFFECTS OF ROSUVASTATIN AND ATORVASTATIN COMPARED OVER 52 WEEKS OF TREATMENT IN PATIENTS WITH HYPERCHOLESTEROLEMIA, AM. HEART J., 144, PP. 1044-1051, (2002); PAOLETTI R., FAHMY M., MAHLA G., MIZAN J., SOUTHWORTH H., ROSUVASTATIN DEMONSTRATES GREATER REDUCTION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL COMPARED WITH PRAVASTATIN AND SIMVASTATIN IN HYPERCHOLESTEROLAEMIC PATIENTS: A RANDOMIZED, DOUBLE-BLIND STUDY, J. CARDIOVASC. RISK, 8, PP. 383-390, (2001); SCHUSTER H., BARTER P.J., STENDER S., CHEUNG R.C., BONNET J., MORRELL J.M., WATKINS C., KALLEND D., RAZA A., EFFECTS OF SWITCHING STATINS ON ACHIEVEMENT OF LIPID GOALS: MEASURING EFFECTIVE REDUCTIONS IN CHOLESTEROL USING ROSUVASTATIN THERAPY (MERCURY I) STUDY, AM. HEART J., 147, (2004); SCHNECK D.W., KNOPP R.H., BALLANTYNE C.M., MCPHERSON R., CHITRA R.R., SIMONSON S.G., COMPARATIVE EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ACROSS THEIR DOSE RANGES IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND WITHOUT ACTIVE ARTERIAL DISEASE, AM. J. CARDIOL., 91, PP. 33-41, (2003); MCKENNEY J.M., JONES P.H., ADAMCZYK M.A., CAIN V.A., BRYZINSKI B.S., BLASETTO J.W., COMPARISON OF THE EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN IN ACHIEVING LIPID GOALS: RESULTS FROM THE STELLAR TRIAL, CURR. MED. RES. OPIN., 19, PP. 689-698, (2003); STEIN E.A., STRUTT K., SOUTHWORTH H., DIGGLE P.J., MILLER E., COMPARISON OF ROSUVASTATIN VERSUS ATORVASTATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 92, PP. 1287-1293, (2003); HUNNINGHAKE D.B., STEIN E.A., BAYS H.E., RADER D.J., CHITRA R.R., SIMONSON S.G., SCHNECK D.W., ROSUVASTATIN IMPROVES THE ATHEROGENIC AND ATHEROPROTECTIVE LIPID PROFILES IN PATIENTS WITH HYPERTRIGLYCERIDEMIA, CORON. ARTERY DIS., 15, PP. 115-123, (2004); STEIN E.A., LANE M., LASKARZEWSKI P., COMPARISON OF STATINS IN HYPERTRIGLYCERIDEMIA, AM. J. CARDIOL., 81, 4 A, (1998); CASLAKE M.J., STEWART G., DAY S.P., DALY E., MCTAGGART F., CHAPMAN M.J., DURRINGTON P., LAGGNER P., MACKNESS M., PEARS J., PACKARD C.J., PHENOTYPE-DEPENDENT AND -INDEPENDENT ACTIONS OF ROSUVASTATIN ON ATHEROGENIC LIPOPROTEIN SUBFRACTIONS IN HYPERLIPIDAEMIA, ATHEROSCLEROSIS, 171, PP. 245-253, (2003); DURRINGTON P., TUOMILEHTO J., HAMANN A., KALLEND D., SMITH K., ROSUVASTATIN AND FENOFIBRATE ALONE AND IN COMBINATION IN TYPE 2 DIABETES PATIENTS WITH COMBINED HYPERLIPIDAEMIA, DIABETOLOGIA RES. CLIN. PRACT., 64, PP. 137-151, (2004); CAPUZZI D.M., MORGAN J.M., WEISS R.J., CHITRA R.R., HUTCHINSON H.G., CRESSMAN M.D., BENEFICIAL EFFECTS OF ROSUVASTATIN ALONE AND IN COMBINATION WITH EXTENDED-RELEASE NIACIN IN PATIENTS WITH A COMBINED HYPERLIPIDEMIA AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, AM. J. CARDIOL., 91, PP. 1304-1310, (2003); BALLANTYNE C., MILLER E., CHITRA R., ROSUVASTATIN ALONE PRODUCES SIMILAR LIPID BENEFITS COMPARED WITH ROSUVASTATIN PLUS CHOLESTYRAMINE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (2001); BREWER JR. H.B., BENEFIT-RISK ASSESSMENT OF ROSUVASTATIN 10 TO 40 MILLIGRAMS, AM. J. CARDIOL., 92, (2003); AOKI T., NISHIMURA H., NAKAGAWA S., KOJIMA J., SUZUKI H., TAMAKI T., WADA Y., YOKOO N., SATO F., KIMATA H., KITAHARA M., TOYODA K., SAKASHITA M., SAITO Y., PHARMACOLOGICAL PROFILE OF A NOVEL SYNTHETIC INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, ARZNEIMITTELFORSCHUNG, 47, PP. 904-909, (1997); FUJINO H., YAMADA I., KOJIMA J., HIRANO M., MATSUMOTO H., YONEDA M., STUDIES ON THE METABOLIC FATE OF NK-104, A NEW INHIBITOR OF HMG-COA REDUCTASE (5): IN VITRO METABOLISM AND PLASMA PROTEIN BINDING IN ANIMALS AND HUMAN, XENO METAB. DISP., 14, PP. 415-424, (1999); FUJINO H., KOJIMA J., YAMADA I., KANDA H., KIMATA H., STUDIES ON THE METABOLIC FATE OF NK-104, A NEW INHIBITOR OF HMG-COA REDUCTASE (4): INTERSPECIES VARIATION IN LABORATORY ANIMALS AND HUMANS, XENO METAB. DISP., 14, PP. 79-91, (1999); FUJINO H., YAMADA I., SHIMADA S., NAGAO T., YONEDA M., METABOLIC FATE OF PITAVASTATIN (NK-104), A NEW INHIBITOR OF 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A REDUCTASE. EFFECTS ON DRUG-METABOLIZING SYSTEMS IN RATS AND HUMANS, ARZNEIMITTELFORSCHUNG, 52, PP. 745-753, (2002); FUJINO H., SAITO T., TSUNENARI Y., KOJIMA J., INTERACTION BETWEEN SEVERAL MEDICINES AND STATINS, ARZNEIMITTELFORSCHUNG, 53, PP. 145-153, (2003); SUZUKI H., AOKI T., TAMAKI T., SATO F., KITAHARA M., SAITO Y., HYPOLIPIDEMIC EFFECT OF NK-104, A POTENT HMG-COA REDUCTASE INHIBITOR, IN GUINEA PIGS, ATHEROSCLEROSIS, 146, PP. 259-270, (1999); SUZUKI H., YAMAZAKI H., AOKI T., TAMAKI T., SATO F., KITAHARA M., SAITO Y., HYPOLIPIDEMIC EFFECT OF NK-104 AND OTHER 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS IN GUINEA PIGS, ARZNEIMITTELFORSCHUNG, 51, PP. 38-45, (2001); AOKI T., YAMAZAKI H., SUZUKI H., TAMAKI T., SATO F., KITAHARA M., SAITO Y., CHOLESTEROL-LOWERING EFFECT OF NK-104, A 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITOR, IN GUINEA PIG MODEL OF HYPERLIPIDEMIA, ARZNEIMITTELFORSCHUNG, 51, PP. 197-203, (2001); SUZUKI H., YAMAZAKI H., AOKI T., KOJIMA J., TAMAKI T., SATO F., KITAHARA M., SAITO Y., LIPID-LOWERING AND ANTIATHEROSCLEROTIC EFFECT OF NK-104, A POTENT 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR, IN WATANABE HERITABLE HYPERLIPIDEMIC RABBITS, ARZNEIMITTELFORSCHUNG, 50, PP. 995-1003, (2000); AOKI T., YAMAZAKI H., TAMAKI T., SATO F., KITAHARA M., SAITO Y., TRIGLYCERIDE-LOWERING EFFECT OF PITAVASTATIN IN A GUINEA PIG MODEL OF POSTPRANDIAL LIPEMIA, ARZNEIMITTELFORSCHUNG, 53, PP. 154-158, (2003); SAITO Y., YAMADA N., TERAMOTO T., ITAKURA H., HATA Y., NAKAYA N., MABUCHI H., TUSHIMA M., SASAKI J., GOTO Y., OGAWA N., CLINICAL EFFICACY OF PITAVASTATIN, A NEW 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR, IN PATIENTS WITH HYPERLIPIDEMIA. DOSE-FINDING STUDY USING THE DOUBLE-BLIND, THREE-GROUP PARALLEL COMPARISON, ARZNEIMITTELFORSCHUNG, 52, PP. 251-255, (2002); SAZAKI J., IKEDA Y., YAMAMOTO K., AGETA M., ARAKAWA K., EFFICACY AND SAFETY OF A NEW HMG-COA REDUCTASE INHIBITOR, NK-104, IN PATIENTS WITH HYPERTRIGLYCERIDEMIA; RANDOMIZED DOUBLE-BLIND, CROSS-OVER PLACEBO-CONTROLLED STUDY, ATHEROSCLEROSIS, 151, (2000); TERMAMOTO T., SAITO Y., NAKAYA N., GROUP T.J.I.S., CLINICAL EVALUATION OF NK-104 (ITAVASTATIN) IN LONG-TERM TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA, ATHEROSCLEROSIS, 151, (2000); KAJINAMI K., MABUCHI H., SAITO Y., NK-104: A NOVEL SYNTHETIC HMG-COA REDUCTASE INHIBITOR, EXPERT OPIN. INVESTIG. DRUGS, 9, PP. 2653-2661, (2000); SAITO Y., YAMADA N., TERAMOTO T., ITAKURA H., HATA Y., NAKAYA N., MABUCHI H., TUSHIMA M., SASAKI J., OGAWA N., GOTO Y., A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING THE EFFICACY AND SAFETY OF PITAVASTATIN VERSUS PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 162, PP. 373-379, (2002); KAJINAMI K., KOIZUMI J., UEDA K., MIYAMOTO S., TAKEGOSHI T., MABUCHI H., EFFECTS OF NK-104, A NEW HYDROXYMETHYLGLUTARYL-COENZYME REDUCTASE INHIBITOR, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 85, PP. 178-183, (2000); NOJI Y., HIGASHIKATA T., INAZU A., NOHARA A., UEDA K., MIYAMOTO S., KAJINAMI K., TAKEGOSHI T., KOIZUMI J., MABUCHI H., LONG-TERM TREATMENT WITH PITAVASTATIN (NK-104), A NEW HMG-COA REDUCTASE INHIBITOR, OF PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 163, PP. 157-164, (2002); SONE H., TAKAHASHI A., SHIMANO H., ISHIBASHI S., YOSHINO G., MORISAKI N., SAITO Y., KAWAZU S., TERAMOTO T., FUJITA T., SHIBA T., IWAMOTO Y., KUZUYA N., AKANUMA Y., YAMADA N., HMG-COA REDUCTASE INHIBITOR DECREASES SMALL DENSE LOW-DENSITY LIPOPROTEIN AND REMNANT-LIKE PARTICLE CHOLESTEROL IN PATIENTS WITH TYPE-2 DIABETES, LIFE SCI., 71, PP. 2403-2412, (2002); TANSEY T.R., SHECHTER I., STRUCTURE AND REGULATION OF MAMMALIAN SQUALENE SYNTHASE, BIOCHIM. BIOPHYS. ACTA, 1529, PP. 49-62, (2000); MCTAGGART F., BROWN G.R., DAVIDSON R.G., FREEMAN S., HOLDGATE G.A., MALLION K.B., MIRRLEES D.J., SMITH G.J., WARD W.H., INHIBITION OF SQUALENE SYNTHASE OF RAT LIVER BY NOVEL 3′ SUBSTITUTED QUINUCLIDINES, BIOCHEM. PHARMACOL., 51, PP. 1477-1487, (1996); CIOSEK JR. C.P., MAGNIN D.R., HARRITY T.W., LOGAN J.V., DICKSON JR. J.K., GORDON E.M., HAMILTON K.A., JOLIBOIS K.G., KUNSELMAN L.K., LAWRENCE R.M., LIPOPHILIC 1,1-BISPHOSPHONATES ARE POTENT SQUALENE SYNTHASE INHIBITORS AND ORALLY ACTIVE CHOLESTEROL LOWERING AGENTS IN VIVO, J. BIOL. CHEM., 268, PP. 24832-24837, (1993); BILLER S.A., FORSTER C., GORDON E.M., HARRITY T., RICH L.C., MARRETTA J., CIOSEK JR. C.P., ISOPRENYL PHOSPHINYLFORMATES: NEW INHIBITORS OF SQUALENE SYNTHETASE, J. MED. CHEM., 34, PP. 1912-1914, (1991); AMIN D., RUTLEDGE R.Z., NEEDLE S.N., GALCZENSKI H.F., NEUENSCHWANDER K., SCOTESE A.C., MAGUIRE M.P., BUSH R.C., HELE D.J., BILDER G.E., PERRONE M.H., RPR 107393, A POTENT SQUALENE SYNTHASE INHIBITOR AND ORALLY EFFECTIVE CHOLESTEROL-LOWERING AGENT: COMPARISON WITH INHIBITORS OF HMG-COA REDUCTASE, J. PHARMACOL. EXP. THER., 281, PP. 746-752, (1997); BERGSTROM J.D., KURTZ M.M., REW D.J., AMEND A.M., KARKAS J.D., BOSTEDOR R.G., BANSAL V.S., DUFRESNE C., VAN MIDDLESWORTH F.L., HENSENS O.D., ZARAGOZIC ACIDS: A FAMILY OF FUNGAL METABOLITES THAT ARE PICOMOLAR COMPETITIVE INHIBITORS OF SQUALENE SYNTHASE, PROC. NATL. ACAD. SCI. USA, 90, PP. 80-84, (1993); CHAN C., ANDREOTTI D., COX B., DYMOCK B.W., HUTSON J.L., KEELING S.E., MCCARTHY A.D., PROCOPIOU P.A., ROSS B.C., SAREEN M., SCICINSKI J.J., SHARRATT P.J., SNOWDEN M.A., WATSON N.S., THE SQUALESTATINS: DECARBOXY AND 4-DEOXY ANALOGUES AS POTENT SQUALENE SYNTHASE INHIBITORS, J. MED. CHEM., 39, PP. 207-216, (1996); UGAWA T., KAKUTA H., MORITANI H., MATSUDA K., ISHIHARA T., YAMAGUCHI M., NAGANUMA S., LIZUMI Y., SHIKAMA H., YM-53601, A NOVEL SQUALENE SYNTHASE INHIBITOR, REDUCES PLASMA CHOLESTEROL AND TRIGLYCERIDE LEVELS IN SEVERAL ANIMAL SPECIES, BR. J. PHARMACOL., 131, PP. 63-70, (2000); UGAWA T., KAKUTA H., MORITANI H., SHIKAMA H., EXPERIMENTAL MODEL OF ESCAPE PHENOMENON IN HAMSTERS AND THE EFFECTIVENESS OF YM-53601 IN THE MODEL, BR. J. PHARMACOL., 135, PP. 1572-1578, (2002); HIYOSHI H., YANAGIMACHI M., ITO M., OHTSUKA I., YOSHIDA I., SAEKI T., TANAKA H., EFFECT OF ER-27856, A NOVEL SQUALENE SYNTHASE INHIBITOR, ON PLASMA CHOLESTEROL IN RHESUS MONKEYS: COMPARISON WITH 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS, J. LIPID RES., 41, PP. 1136-1144, (2000); NISHIMOTO T., AMANO Y., TOZAWA R., ISHIKAWA E., IMURA Y., YUKIMASA H., SUGIYAMA Y., LIPID-LOWERING PROPERTIES OF TAK-475, A SQUALENE SYNTHASE INHIBITOR, IN VIVO AND IN VITRO, BR. J. PHARMACOL., 139, PP. 911-918, (2003); UGAWA T., KAKUTA H., MORITANI H., INAGAKI O., EFFECT OF YM-53601, A NOVEL SQUALENE SYNTHASE INHIBITOR, ON THE CLEARANCE RATE OF PLASMA LDL AND VLDL IN HAMSTERS, BR. J. PHARMACOL., 137, PP. 561-569, (2002); HIYOSHI H., YANAGIMACHI M., ITO M., SAEKI T., YOSHIDA I., OKADA T., IKUTA H., SHINMYO D., TANAKA K., KURUSU N., TANAKA H., SQUALENE SYNTHASE INHIBITORS REDUCE PLASMA TRIGLYCERIDE THROUGH A LOW-DENSITY LIPOPROTEIN RECEPTOR-INDEPENDENT MECHANISM, EUR. J. PHARMACOL., 431, PP. 345-352, (2001); AMANO Y., NISHIMOTO T., TOZAWA R., ISHIKAWA E., IMURA Y., SUGIYAMA Y., LIPID-LOWERING EFFECTS OF TAK-475, A SQUALENE SYNTHASE INHIBITOR, IN ANIMAL MODELS OF FAMILIAL HYPERCHOLESTEROLEMIA, EUR. J. PHARMACOL., 466, PP. 155-161, (2003); EDWARDS P.A., TABOR D., KAST H.R., VENKATESWARAN A., REGULATION OF GENE EXPRESSION BY SREBP AND SCAP, BIOCHIM. BIOPHYS. ACTA, 1529, PP. 103-113, (2000); HORTON J.D., GOLDSTEIN J.L., BROWN M.S., SREBPS: ACTIVATORS OF THE COMPLETE PROGRAM OF CHOLESTEROL AND FATTY ACID SYNTHESIS IN THE LIVER, J. CLIN. INVEST., 109, PP. 1125-1131, (2002); GRAND-PERRET T., BOUILLOT A., PERROT A., COMMANS S., WALKER M., ISSANDOU M., SCAP LIGANDS ARE POTENT NEW LIPID-LOWERING DRUGS, NAT. MED., 7, PP. 1332-1338, (2001); SCHARNAGL H., MARZ W., WIELAND H., LIFIBROL: FIRST MEMBER OF A NEW CLASS OF LIPID-LOWERING DRUGS?, EXP. OPIN. INVEST. DRUGS, 6, PP. 583-591, (1997); SCHARNAGL H., SCHLIACK M., LOSER R., NAUCK M., GIERENS H., JECK N., WIELAND H., GROSS W., MARZ W., THE EFFECTS OF LIFIBROL (K12.148) ON THE CHOLESTEROL METABOLISM OF CULTURED CELLS: EVIDENCE FOR STEROL INDEPENDENT STIMULATION OF THE LDL RECEPTOR PATHWAY, ATHEROSCLEROSIS, 153, PP. 69-80, (2000); WINKLER K., SCHAFER J.R., KLIMA B., NUBER C., SATTLER A., FRIEDRICH I., KOSTER W., STEINMETZ A., WIELAND H., MARZ W., LIFIBROL ENHANCES THE LOW DENSITY LIPOPROTEIN APOLIPOPROTEIN B-100 TURNOVER IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA, ATHEROSCLEROSIS, 144, PP. 167-175, (1999); WINKLER K., SCHAEFER J.R., KLIMA B., NUBER C., FRIEDRICH I., KOSTER W., GIERENS H., SCHARNAGL H., SOUFI M., WIELAND H., MARZ W., HDL STEADY STATE LEVELS ARE NOT AFFECTED, BUT HDL APOA-I TURNOVER IS ENHANCED BY LIFIBROL IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA, ATHEROSCLEROSIS, 150, PP. 113-120, (2000); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); PEDERSEN T.R., OLSSON A.G., FAERGEMAN O., KJEKSHUS J., WEDEL H., BERG K., WILHELMSEN L., HAGHFELT T., THORGEIRSSON G., PYORALA K., MIETTINEN T., CHRISTOPHERSEN B., TOBERT J.A., MUSLINER T.A., COOK T.J., LIPOPROTEIN CHANGES AND REDUCTION IN THE INCIDENCE OF MAJOR CORONARY HEART DISEASE EVENTS IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), CIRCULATION, 97, PP. 1453-1460, (1998); SACKS F.M., MOYE L.A., DAVIS B.R., COLE T.G., ROULEAU J.L., NASH D.T., PFEFFER M.A., BRAUNWALD E., RELATIONSHIP BETWEEN PLASMA LDL CONCENTRATIONS DURING TREATMENT WITH PRAVASTATIN AND RECURRENT CORONARY EVENTS IN THE CHOLESTEROL AND RECURRENT EVENTS TRIAL, CIRCULATION, 97, PP. 1446-1452, (1998)","H. SCHARNAGL; CLINICAL INSTITUTE OF MEDICAL AND CLINICAL LABORATORY DIAGNOSTICS, MEDICAL UNIVERSITY, A-8036 GRAZ, AUENBRUGGERPLATZ 15, AUSTRIA; EMAIL: HUBERT.SCHARNAGL@KLINIKUM-GRAZ.AT","","ENGLISH","CURR. TOP. MED. CHEM.","REVIEW","ISI","2-S2.0-18044405167","CURR TOP MED CHEM","MEDICAL UNIVERSITY;MEDICAL UNIVERSITY","H. SCHARNAGL;MEDICAL UNIVERSITY;EMAIL: HUBERT.SCHARNAGL@KLINIKUM-GRAZ.AT",NA,"SCHARNAGL H, 2005, CURR TOP MED CHEM","SCHARNAGL H, 2005, CURR TOP MED CHEM"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","VASCULAR ENDOTHELIUM IS THE ORGAN CHIEFLY RESPONSIBLE FOR THE CATABOLISM OF PLASMA ASYMMETRIC DIMETHYLARGININE AN EXPLANATION FOR THE ELEVATION OF PLASMA ADMA IN DISORDERS CHARACTERIZED BY ENDOTHELIAL DYSFUNCTION",2004,"MEDICAL HYPOTHESES","63","9",22,"10.1016/j.mehy.2002.11.008","PANTOX LABORATORIES, 4622 SANTA FE STREET, SAN DIEGO, CA, UNITED STATES, NUTRIGUARD RESEARCH, 1051 HERMES AVENUE, ENCINITAS, CA 92024, USA, UNITED STATES","PLASMA LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA), AN ENDOGENOUSLY PRODUCED COMPETITIVE INHIBITOR OF NITRIC OXIDE SYNTHASE (NOS), HAVE BEEN FOUND TO BE ELEVATED IN A LARGE NUMBER OF DISORDERS CHARACTERIZED BY ENDOTHELIAL DYSFUNCTION; THIS REMARKABLE PHENOMENON HAS YET TO RECEIVE A PLAUSIBLE EXPLANATION. ADMA ARISES BY PROTEOLYSIS OF METHYLATED PROTEINS THROUGHOUT THE BODY; THE MAJORITY OF THIS ADMA IS CATABOLIZED BY THE ENZYME DIMETHYLARGININE DIMETHYLAMINOHYDROLASE (DDAH), FOUND IN MANY TISSUES, INCLUDING THOSE THAT EXPRESS NOS. SINCE THE PRODUCTION OF ADMA CAN BE CONSIDERED CONSTITUTIVE, AND LITTLE INTACT ADMA EMERGES IN THE URINE, IMPAIRED CATABOLISM IS MOST LIKELY RESPONSIBLE FOR ELEVATIONS OF PLASMA ADMA. THE ASSOCIATION OF ELEVATED ADMA WITH ENDOTHELIOPATHY IS READILY EXPLAINED IF WE ASSUME THAT VASCULAR ENDOTHELIUM IS THE ORGAN CHIEFLY RESPONSIBLE FOR THE CATABOLISM OF PLASMA ADMA - A VIEW THAT IS CREDIBLE OWING TO THE PRIVILEGED ACCESS OF ENDOTHELIUM TO PLASMA, THE CAPACITY OF ENDOTHELIUM FOR ACTIVE TRANSPORT OF ARGININE (AND METHYLATED ARGININES), AND THE AMPLE DDAH ACTIVITY OF HEALTHY ENDOTHELIAL CELLS - AND FURTHER ASSUME THAT ENDOTHELIAL DYSFUNCTION IS OFTEN ATTENDED BY A LOSS OF DDAH ACTIVITY AND/OR AN IMPAIRMENT OF ARGININE TRANSPORT, REDUCING THE EFFICIENCY OF ADMA CATABOLISM. INDEED, THERE IS RECENT EVIDENCE THAT DDAH IS INHIBITED BY ENDOTHELIAL OXIDATIVE STRESS, A TYPICAL FEATURE OF ENDOTHELIOPATHY; THERE IS ALSO SOME REASON TO SUSPECT THAT ARGININE TRANSPORT MAY BE LESS EFFICIENT IN DYSFUNCTIONAL ENDOTHELIUM. FROM THIS PERSPECTIVE, INCREASED PLASMA ADMA IS NOT THE PRIMARY CAUSE OF THE ENDOTHELIAL DYSFUNCTION IN VARIOUS DISORDERS, BUT RATHER ITS EFFECT - THOUGH THE RISE IN ADMA CAN THEN EXACERBATE THIS DYSFUNCTION BY INHIBITING ENDOTHELIAL NOS. SUPPLEMENTAL ARGININE SHOULD BE OF SOME CLINICAL BENEFIT IN DISORDERS CHARACTERIZED BY ELEVATED ADMA, SINCE IT CAN OFFSET THAT ADVERSE IMPACT OF ADMA ON NOS ACTIVITY, AND POSSIBLY EXERT OTHER BENEFICIAL EFFECTS ON ENDOTHELIUM - BUT IT CANNOT BE EXPECTED TO REVERSE THE PRIMARY CAUSE OF THE ENDOTHELIAL DYSFUNCTION. WHETHER OR NOT ADMA PLAYS AN IMPORTANT PATHOGENIC ROLE, IT SEEMS LIKELY TO EMERGE AS A POTENT RISK FACTOR FOR ADVERSE VASCULAR EVENTS, SINCE IT MAY BE VIEWED AS A BAROMETER OF ENDOTHELIAL HEALTH. © 2004 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ARGININE; BIOLOGICAL MARKER; DIMETHYLARGININASE; DITHIOTHREITOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; POLICOSANOL; AGING; ATHEROSCLEROSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ENDOTHELIUM LESION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE; LIPID DIET; NONHUMAN; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RENAL OSTEODYSTROPHY; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; URINE; VASCULAR ENDOTHELIUM","","","LEIPER J., VALLANCE P., BIOLOGICAL SIGNIFICANCE OF ENDOGENOUS METHYLARGININES THAT INHIBIT NITRIC OXIDE SYNTHASES, CARDIOVASC. RES., 43, PP. 542-548, (1999); LISCHWE M.A., ROBERTS K.D., YEOMAN L.C., BUSCH H., NUCLEOLAR SPECIFIC ACIDIC PHOSPHOPROTEIN C23 IS HIGHLY METHYLATED, J. BIOL. CHEM., 257, PP. 14600-14602, (1982); VALLANCE P., LEONE A., CALVER A., COLLIER J., MONCADA S., ENDOGENOUS DIMETHYLARGININE AS AN INHIBITOR OF NITRIC OXIDE SYNTHESIS, J. CARDIOVASC. PHARMACOL., 20, SUPPL. 12, (1992); PALMER R.M., REES D.D., ASHTON D.S., MONCADA S., SC L-ARGININE IS THE PHYSIOLOGICAL PRECURSOR FOR THE FORMATION OF NITRIC OXIDE IN ENDOTHELIUM-DEPENDENT RELAXATION, BIOCHEM. BIOPHYS. RES. COMMUN., 153, PP. 1251-1256, (1988); OGAWA T., KIMOTO M., SASAOKA K., PURIFICATION AND PROPERTIES OF A NEW ENZYME, NG,NG-DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, FROM RAT KIDNEY, J. BIOL. CHEM., 264, PP. 10205-10209, (1989); LEIPER J.M., SANTA M.J., CHUBB A., MACALLISTER R.J., CHARLES I.G., WHITLEY G.S., ET AL., IDENTIFICATION OF TWO HUMAN DIMETHYLARGININE DIMETHYLAMINOHYDROLASES WITH DISTINCT TISSUE DISTRIBUTIONS AND HOMOLOGY WITH MICROBIAL ARGININE DEIMINASES, BIOCHEM. J., 343, PART 1, PP. 209-214, (1999); MACALLISTER R.J., PARRY H., KIMOTO M., OGAWA T., RUSSELL R.J., HODSON H., ET AL., REGULATION OF NITRIC OXIDE SYNTHESIS BY DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, BR. J. PHARMACOL., 119, PP. 1533-1540, (1996); BOGER R.H., SYDOW K., BORLAK J., THUM T., LENZEN H., SCHUBERT B., ET AL., LDL CHOLESTEROL UPREGULATES SYNTHESIS OF ASYMMETRICAL DIMETHYLARGININE IN HUMAN ENDOTHELIAL CELLS: INVOLVEMENT OF S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES, CIRC. RES., 87, PP. 99-105, (2000); OGAWA T., KIMOTO M., WATANABE H., SASAOKA K., METABOLISM OF NG,NG-AND NG,N<SUP>′</SUP>G- DIMETHYLARGININE IN RATS, ARCH. BIOCHEM. BIOPHYS., 252, PP. 526-537, (1987); MCDERMOTT J.R., STUDIES ON THE CATABOLISM OF NG-METHYLARGININE, NG, NG-DIMETHYLARGININE AND NG, NG-DIMETHYLARGININE IN THE RABBIT, BIOCHEM. J., 154, PP. 179-184, (1976); NAKAJIMA T., MATSUOKA Y., KAKIMOTO Y., ISOLATION AND IDENTIFICATION OF N-G-MONOMETHYL, N-G, N-G-DIMETHYL- AND N-G,N<SUP>′</SUP>G-DIMETHYLARGININE FROM THE HYDROLYSATE OF PROTEINS OF BOVINE BRAIN, BIOCHIM. BIOPHYS. ACTA, 230, PP. 212-222, (1971); VALLANCE P., LEONE A., CALVER A., COLLIER J., MONCADA S., ACCUMULATION OF AN ENDOGENOUS INHIBITOR OF NITRIC OXIDE SYNTHESIS IN CHRONIC RENAL FAILURE, LANCET, 339, PP. 572-575, (1992); WAHBI N., DALTON R.N., TURNER C., DENTON M., ABBS I., SWAMINATHAN R., DIMETHYLARGININES IN CHRONIC RENAL FAILURE, J. CLIN. PATHOL., 54, PP. 470-473, (2001); KIELSTEIN J.T., BOGER R.H., BODE-BOGER S.M., FROLICH J.C., HALLER H., RITZ E., ET AL., MARKED INCREASE OF ASYMMETRIC DIMETHYLARGININE IN PATIENTS WITH INCIPIENT PRIMARY CHRONIC RENAL DISEASE, J. AM. SOC. NEPHROL., 13, PP. 170-176, (2002); ZOCCALI C., BENEDETTO F.A., MAAS R., MALLAMACI F., TRIPEPI G., MALATINO L.S., ET AL., ASYMMETRIC DIMETHYLARGININE, C-REACTIVE PROTEIN, AND CAROTID INTIMA-MEDIA THICKNESS IN END-STAGE RENAL DISEASE, J. AM. SOC. NEPHROL., 13, PP. 490-496, (2002); XIAO S., WAGNER L., SCHMIDT R.J., BAYLIS C., CIRCULATING ENDOTHELIAL NITRIC OXIDE SYNTHASE INHIBITORY FACTOR IN SOME PATIENTS WITH CHRONIC RENAL DISEASE, KIDNEY INT., 59, PP. 1466-1472, (2001); KIELSTEIN J.T., BOGER R.H., BODE-BOGER S.M., FROLICH J.C., HALLER H., RITZ E., ET AL., MARKED INCREASE OF ASYMMETRIC DIMETHYLARGININE IN PATIENTS WITH INCIPIENT PRIMARY CHRONIC RENAL DISEASE, J. AM. SOC. NEPHROL., 13, PP. 170-176, (2002); ROSTAND S.G., DRUEKE T.B., PARATHYROID HORMONE, VITAMIN D, AND CARDIOVASCULAR DISEASE IN CHRONIC RENAL FAILURE, KIDNEY INT., 56, PP. 383-392, (1999); COEN G., CALABRIA S., BELLINGHIERI G., PECCHINI F., CONTE F., CHIAPPINI M.G., ET AL., PARATHYROIDECTOMY IN CHRONIC RENAL FAILURE: SHORT- AND LONG-TERM RESULTS ON PARATHYROID FUNCTION, BLOOD PRESSURE AND ANEMIA, NEPHRON, 88, PP. 149-155, (2001); KAUTZKY-WILIER A., PACINI G., BARNAS U., LUDVIK B., STRELI C., GRAF H., ET AL., INTRAVENOUS CALCITRIOL NORMALIZES INSULIN SENSITIVITY IN UREMIC PATIENTS, KIDNEY INT., 47, PP. 200-206, (1995); FLISER D., FRANEK E., FODE P., STEFANSKI A., SCHMITT C.P., LYONS M., ET AL., SUBACUTE INFUSION OF PHYSIOLOGICAL DOSES OF PARATHYROID HORMONE RAISES BLOOD PRESSURE IN HUMANS, NEPHROL. DIAL TRANSPLANT., 12, PP. 933-938, (1997); GUNAL A.I., CELIKER H., CELEBI H., USTUNDAG B., GUNAL S.Y., INTRAVENOUS ALFACALCIDOL IMPROVES INSULIN RESISTANCE IN HEMODIALYSIS PATIENTS, CLIN. NEPHROL., 48, PP. 109-113, (1997); CROSS J.M., DONALD A.E., KHARBANDA R., DEANFIELD J.E., WOOLFSON R.G., MACALLISTER R.J., ACUTE ADMINISTRATION OF L-ARGININE DOES NOT IMPROVE ARTERIAL ENDOTHELIAL FUNCTION IN CHRONIC RENAL FAILURE, KIDNEY INT., 60, PP. 2318-2323, (2001); BODE-BOGER S.M., BOGER R.H., KIENKE S., JUNKER W., FROLICH J.C., ELEVATED L-ARGININE/DIMETHYLARGININE RATIO CONTRIBUTES TO ENHANCED SYSTEMIC NO PRODUCTION BY DIETARY L-ARGININE IN HYPERCHOLESTEROLEMIC RABBITS, BIOCHEM. BIOPHYS. RES. COMMUN., 219, PP. 598-603, (1996); BOGER R.H., BODE-BOGER S.M., SZUBA A., TSAO P.S., CHAN J.R., TANGPHAO O., ET AL., ASYMMETRIC DIMETHYLARGININE (ADMA): A NOVEL RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION: ITS ROLE IN HYPERCHOLESTEROLEMIA, CIRCULATION, 98, PP. 1842-1847, (1998); CHAN J.R., BOGER R.H., BODE-BOGER S.M., TANGPHAO O., TSAO P.S., BLASCHKE T.F., ET AL., ASYMMETRIC DIMETHYLARGININE INCREASES MONONUCLEAR CELL ADHESIVENESS IN HYPERCHOLESTEROLEMIC HUMANS, ARTERIOSCLER. THROMB. VASE. BIOL., 20, PP. 1040-1046, (2000); GOONASEKERA C.D., REES D.D., WOOLARD P., FREND A., SHAH V., DILLON M.J., NITRIC OXIDE SYNTHASE INHIBITORS AND HYPERTENSION IN CHILDREN AND ADOLESCENTS, J. HYPERTENS., 15, PP. 901-909, (1997); SURDACKI A., NOWICKI M., SANDMANN J., TSIKAS D., BOEGER R.H., BODE-BOEGER S.M., ET AL., REDUCED URINARY EXCRETION OF NITRIC OXIDE METABOLITES AND INCREASED PLASMA LEVELS OF ASYMMETRIC DIMETHYLARGININE IN MEN WITH ESSENTIAL HYPERTENSION, J. CARDIOVASC. PHARMACOL., 33, PP. 652-658, (1999); ITO A., EGASHIRA K., NARISHIGE T., MURAMATSU K., TAKESHITA A., RENIN-ANGIOTENSIN SYSTEM IS INVOLVED IN THE MECHANISM OF INCREASED SERUM ASYMMETRIC DIMETHYLARGININE IN ESSENTIAL HYPERTENSION, JPN. CIRC. J., 65, PP. 775-778, (2001); DELLES C., SCHNEIDER M.P., JOHN S., GEKLE M., SCHMIEDER R.E., ANGIOTENSIN CONVERTING ENZYME INHIBITION AND ANGIOTENSIN II ATI-RECEPTOR BLOCKADE REDUCE THE LEVELS OF ASYMMETRICAL N (G), N (G)-DIMETHYLARGININE IN HUMAN ESSENTIAL HYPERTENSION, AM. J. HYPERTENS., 15, PP. 590-593, (2002); BOGER R.H., BODE-BOGER S.M., SYDOW K., HEISTAD D.D., LENTZ S.R., PLASMA CONCENTRATION OF ASYMMETRIC DIMETHYLARGININE, AN ENDOGENOUS INHIBITOR OF NITRIC OXIDE SYNTHASE, IS ELEVATED IN MONKEYS WITH HYPERHOMOCYST (E)INEMIA OR HYPERCHOLESTEROLEMIA, ARTERIOSCLER. THROMB. VASE. BIOL., 20, PP. 1557-1564, (2000); BOGER R.H., LENTZ S.R., BODE-BOGER S.M., KNAPP H.R., HAYNES W.G., ELEVATION OF ASYMMETRICAL DIMETHYLARGININE MAY MEDIATE ENDOTHELIAL DYSFUNCTION DURING EXPERIMENTAL HYPERHOMOCYST (E)INAEMIA IN HUMANS, CLIN. SCI. (LOND), 100, PP. 161-167, (2001); MIYAZAKI H., MATSUOKA H., COOKE J.P., USUI M., UEDA S., OKUDA S., ET AL., ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITOR: A NOVEL MARKER OF ATHEROSCLEROSIS, CIRCULATION, 99, PP. 1141-1146, (1999); ASAGAMI T., ABBASI F., STUELINGER M., LAMENDOLA C., MCLAUGHLIN T., COOKE J.P., ET AL., METFORMIN TREATMENT LOWERS ASYMMETRIC DIMETHYLARGININE CONCENTRATIONS IN PATIENTS WITH TYPE 2 DIABETES, METABOLISM, 51, PP. 843-846, (2002); STUHLINGER M.C., ABBASI F., CHU J.W., LAMENDOLA C., MCLAUGHLIN T.L., COOKE J.P., ET AL., RELATIONSHIP BETWEEN INSULIN RESISTANCE AND AN ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITOR, JAMA, 287, PP. 1420-1426, (2002); LUNDMAN P., ERIKSSON M.J., STUHLINGER M., COOKE J.P., HAMSTEN A., TORNVALL P., MILD-TO-MODERATE HYPERTRIGLYCERIDEMIA IN YOUNG MEN IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION AND INCREASED PLASMA CONCENTRATIONS OF ASYMMETRIC DIMETHYLARGININE, J. AM. COLL. CARDIOL., 38, PP. 111-116, (2001); USUI M., MATSUOKA H., MIYAZAKI H., UEDA S., OKUDA S., IMAIZUMI T., INCREASED ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITOR IN PATIENTS WITH CONGESTIVE HEART FAILURE, LIFE SCI., 62, PP. 2425-2430, (1998); FENG Q., LU X., FORTIN A.J., PETTERSSON A., HEDNER T., KLINE R.L., ET AL., ELEVATION OF AN ENDOGENOUS INHIBITOR OF NITRIC OXIDE SYNTHESIS IN EXPERIMENTAL CONGESTIVE HEART FAILURE, CARDIOVASC. RES., 37, PP. 667-675, (1998); ZOCCALI C., MALLAMACI F., MAAS R., BENEDETTO F.A., TRIPEPI G., MALATINO L.S., ET AL., LEFT VENTRICULAR HYPERTROPHY, CARDIAC REMODELING AND ASYMMETRIC DIMETHYLARGININE (ADMA) IN HEMODIALYSIS PATIENTS, KIDNEY INT., 62, PP. 339-345, (2002); PETTERSSON A., HEDNER T., MILSOM I., INCREASED CIRCULATING CONCENTRATIONS OF ASYMMETRIC DIMETHYL ARGININE (ADMA), AN ENDOGENOUS INHIBITOR OF NITRIC OXIDE SYNTHESIS, IN PREECLAMPSIA, ACTA OBSTET. GYNECOL. SCAND., 77, PP. 808-813, (1998); XIONG Y., YUAN L.W., DENG H.W., LI Y.J., CHEN B.M., ELEVATED SERUM ENDOGENOUS INHIBITOR OF NITRIC OXIDE SYNTHASE AND ENDOTHELIAL DYSFUNCTION IN AGED RATS, CLIN. EXP. PHARMACOL. PHYSIOL., 28, PP. 842-847, (2001); LU R., HU C.P., WU X.P., LIAO E.Y., LI Y.J., EFFECT OF AGE ON BONE MINERAL DENSITY AND THE SERUM CONCENTRATION OF ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITORS IN RATS, COMP. MED., 52, PP. 224-228, (2002); PLOTNICK G.D., CORRETTI M.C., VOGEL R.A., EFFECT OF ANTIOXIDANT VITAMINS ON THE TRANSIENT IMPAIRMENT OF ENDOTHELIUM-DEPENDENT BRACHIAL ARTERY VASOACTIVITY FOLLOWING A SINGLE HIGH-FAT MEAL, JAMA, 278, PP. 1682-1686, (1997); LING L., ZHAO S.P., GAO M., ZHOU Q.C., LI Y.L., XIA B., VITAMIN C PRESERVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AFTER A HIGH-FAT MEAL, CLIN. CARDIOL., 25, PP. 219-224, (2002); STEINBERG H.O., TARSHOBY M., MONESTEL R., HOOK G., CRONIN J., JOHNSON A., ET AL., ELEVATED CIRCULATING FREE FATTY ACID LEVELS IMPAIR ENDOTHELIUM- DEPENDENT VASODILATION, J. CLIN. INVEST., 100, PP. 1230-1239, (1997); STEINBERG H.O., PARADISI G., HOOK G., CROWDER K., CRONIN J., BARON A.D., FREE FATTY ACID ELEVATION IMPAIRS INSULIN-MEDIATED VASODILATION AND NITRIC OXIDE PRODUCTION, DIABETES, 49, PP. 1231-1238, (2000); FRAYN K.N., NON-ESTERIFIED FATTY ACID METABOLISM AND POSTPRANDIAL LIPAEMIA, ATHEROSCLEROSIS, 141, SUPPL. 1, (1998); FARD A., TUCK C.H., DONIS J.A., SCIACCA R., DI TULLIO M.R., WU H.D., ET AL., ACUTE ELEVATIONS OF PLASMA ASYMMETRIC DIMETHYLARGININE AND IMPAIRED ENDOTHELIAL FUNCTION IN RESPONSE TO A HIGH-FAT MEAL IN PATIENTS WITH TYPE 2 DIABETES, ARTERIOSCLER. THROMB. VASE. BIOL., 20, PP. 2039-2044, (2000); BOGER R.H., BODE-BOGER S.M., ASYMMETRIC DIMETHYLARGININE, DERANGEMENTS OF THE ENDOTHELIAL NITRIC OXIDE SYNTHASE PATHWAY, AND CARDIOVASCULAR DISEASES, SEMIN. THROMB. HEMOST., 26, PP. 539-545, (2000); COOKE J.P., OKA R.K., ATHEROGENESIS AND THE ARGININE HYPOTHESIS, CURR. ATHEROSCLER. REP., 3, PP. 252-259, (2001); TSIKAS D., BOGER R.H., SANDMANN J., BODE-BOGER S.M., FROLICH J.C., ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITORS ARE RESPONSIBLE FOR THE L-ARGININE PARADOX, FEBS LETT., 478, PP. 1-3, (2000); ARNAL J.F., DINH-XUAN A.T., PUEYO M., DARBLADE B., RAMI J., ENDOTHELIUM-DERIVED NITRIC OXIDE AND VASCULAR PHYSIOLOGY AND PATHOLOGY, CELL. MOL. LIFE SCI., 55, PP. 1078-1087, (1999); COLLINS T., ENDOTHELIAL NUCLEAR FACTOR-KAPPA B AND THE INITIATION OF THE ATHEROSCLEROTIC LESION, LAB. INVEST., 68, PP. 499-508, (1993); ITO A., TSAO P.S., ADIMOOLAM S., KIMOTO M., OGAWA T., COOKE J.P., NOVEL MECHANISM FOR ENDOTHELIAL DYSFUNCTION: DYSREGULATION OF DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, CIRCULATION, 99, PP. 3092-3095, (1999); LEIPER J.M., SANTA M.J., CHUBB A., MACALLISTER R.J., CHARLES I.G., WHITLEY G.S., ET AL., IDENTIFICATION OF TWO HUMAN DIMETHYLARGININE DIMETHYLAMINOHYDROLASES WITH DISTINCT TISSUE DISTRIBUTIONS AND HOMOLOGY WITH MICROBIAL ARGININE DEIMINASES, BIOCHEM. J., 343, PART 1, PP. 209-214, (1999); WASCHER T.C., POSCH K., WALLNER S., HERMETTER A., KOSTNER G.M., GRAIER W.F., VASCULAR EFFECTS OF L-ARGININE: ANYTHING BEYOND A SUBSTRATE FOR THE NO- SYNTHASE?, BIOCHEM. BIOPHYS. RES. COMMUN., 234, PP. 35-38, (1997); STUHLINGER M.C., TSAO P.S., HER J.H., KIMOTO M., BALINT R.F., COOKE J.P., HOMOCYSTEINE IMPAIRS THE NITRIC OXIDE SYNTHASE PATHWAY: ROLE OF ASYMMETRIC DIMETHYLARGININE, CIRCULATION, 104, PP. 2569-2575, (2001); MEYER J.W., HOLLAND J.A., ZIEGLER L.M., CHANG M.M., BEEBE G., SCHMITT M.E., IDENTIFICATION OF A FUNCTIONAL LEUKOCYTE-TYPE NADPH OXIDASE IN HUMAN ENDOTHELIAL CELLS :A POTENTIAL ATHEROGENIC SOURCE OF REACTIVE OXYGEN SPECIES, ENDOTHELIUM, 7, PP. 11-22, (1999); ZHANG H., SCHMEISSER A., GARLICHS C.D., PLOTZE K., DAMME U., MUGGE A., ET AL., ANGIOTENSIN II-INDUCED SUPEROXIDE ANION GENERATION IN HUMAN VASCULAR ENDOTHELIAL CELLS: ROLE OF MEMBRANE-BOUND NADH-/NADPH-OXIDASES, CARDIOVASC. RES., 44, PP. 215-222, (1999); HARRISON D.G., ENDOTHELIAL FUNCTION AND OXIDANT STRESS, CLIN. CARDIOL., 20, SUPPL. 2, PP. 11-17, (1997); HOLLAND J.A., O'DONNELL R.W., CHANG M.M., JOHNSON D.K., ZIEGLER L.M., ENDOTHELIAL CELL OXIDANT PRODUCTION: EFFECT OF NADPH OXIDASE INHIBITORS, ENDOTHELIUM, 7, PP. 109-119, (2000); KATUSIC Z.S., VASCULAR ENDOTHELIAL DYSFUNCTION: DOES TETRAHYDROBIOPTERIN PLAY A ROLE, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); CAI H., HARRISON D.G., ENDOTHELIAL DYSFUNCTION IN CARDIOVASCULAR DISEASES: THE ROLE OF OXIDANT STRESS, CIRC. RES., 87, PP. 840-844, (2000); WOLIN M.S., GUPTE S.A., OECKLER R.A., SUPEROXIDE IN THE VASCULAR SYSTEM, J. VASCUL. RES., 39, PP. 191-207, (2002); RIEGER J.M., SHAH A.R., GIDDAY J.M., ISCHEMIA-REPERFUSION INJURY OF RETINAL ENDOTHELIUM BY CYCLOOXYGENASE- AND XANTHINE OXIDASE-DERIVED SUPEROXIDE, EXP. EYE. RES., 74, PP. 493-501, (2002); MENESHIAN A., BULKLEY G.B., THE PHYSIOLOGY OF ENDOTHELIAL XANTHINE OXIDASE: FROM URATE CATABOLISM TO REPERFUSION INJURY TO INFLAMMATORY SIGNAL TRANSDUCTION, MICROCIRCULATION, 9, PP. 161-175, (1902); JOHN S., SCHMIEDER R.E., IMPAIRED ENDOTHELIAL FUNCTION IN ARTERIAL HYPERTENSION AND HYPERCHOLESTEROLEMIA: POTENTIAL MECHANISMS AND DIFFERENCES, J. HYPERTENS., 18, PP. 363-374, (2000); ZALBA G., BEAUMONT J., SAN JOSE G., FORTUNO A., FORTUNO M.A., DIEZ J., VASCULAR OXIDANT STRESS: MOLECULAR MECHANISMS AND PATHOPHYSIOLOGICAL IMPLICATIONS, J. PHYSIOL. BIOCHEM., 56, PP. 57-64, (2000); PERTICONE F., CERAVOLO R., MAIO R., CLORO C., CANDIGLIOTA M., SCOZZAFAVA A., ET AL., EFFECTS OF ATORVASTATIN AND VITAMIN C ON ENDOTHELIAL FUNCTION OF HYPERCHOLESTEROLEMIC PATIENTS, ATHEROSCLEROSIS, 152, PP. 511-518, (2000); LANG D., KREDAN M.B., MOAT S.J., HUSSAIN S.A., POWELL C.A., BELLAMY M.F., ET AL., HOMOCYSTEINE-INDUCED INHIBITION OF ENDOTHELIUM-DEPENDENT RELAXATION IN RABBIT AORTA: ROLE FOR SUPEROXIDE ANIONS, ARTERIOSCLER THROMB. VASE. BIOL., 20, PP. 422-427, (2000); MCDOWELL I.F., LANG D., HOMOCYSTEINE AND ENDOTHELIAL DYSFUNCTION: A LINK WITH CARDIOVASCULAR DISEASE, J. NUTR., 130, (2000); EBERHARDT R.T., FORGIONE M.A., CAP A., LEOPOLD J.A., RUDD M.A., TROLLIET M., ET AL., ENDOTHELIAL DYSFUNCTION IN A MURINE MODEL OF MILD HYPERHOMOCYST (E)INEMIA, J. CLIN. INVEST., 106, PP. 483-491, (2000); MEYER J.W., SCHMITT M.E., A CENTRAL ROLE FOR THE ENDOTHELIAL NADPH OXIDASE IN ATHEROSCLEROSIS, FEBS LETT., 472, PP. 1-4, (2000); RUECKSCHLOSS U., GALLE J., HOLTZ J., ZERKOWSKI H.R., MORAWIETZ H., INDUCTION OF NAD (P)H OXIDASE BY OXIDIZED LOW-DENSITY LIPOPROTEIN IN HUMAN ENDOTHELIAL CELLS: ANTIOXIDATIVE POTENTIAL OF HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR THERAPY, CIRCULATION, 104, PP. 1767-1772, (2001); HATHAWAY C.A., HEISTAD D.D., PIEGORS D.J., MILLER F.J.J., REGRESSION OF ATHEROSCLEROSIS IN MONKEYS REDUCES VASCULAR SUPEROXIDE LEVELS, CIRC. RES., 90, PP. 277-283, (2002); INOGUCHI T., LI P., UMEDA F., YU H.Y., KAKIMOTO M., IMAMURA M., ET AL., HIGH GLUCOSE LEVEL AND FREE FATTY ACID STIMULATE REACTIVE OXYGEN SPECIES PRODUCTION THROUGH PROTEIN KINASE C-DEPENDENT ACTIVATION OF NAD (P)H OXIDASE IN CULTURED VASCULAR CELLS, DIABETES, 49, PP. 1939-1945, (2000); HINK U., LI H., MOLLNAU H., OELZE M., MATHEIS E., HARTMANN M., ET AL., MECHANISMS UNDERLYING ENDOTHELIAL DYSFUNCTION IN DIABETES MELLITUS, CIRC. RES., 88, (2001); WAUTIER M.P., CHAPPEY O., CORDA S., STERN D.M., SCHMIDT A.M., WAUTIER J.L., ACTIVATION OF NADPH OXIDASE BY AGE LINKS OXIDANT STRESS TO ALTERED GENE EXPRESSION VIA RAGE, AM. J. PHYSIOL. ENDOCRINOL. METAB., 280, (2001); PERTICONE F., CERAVOLO R., CANDIGLIOTA M., VENTURA G., LACOPINO S., SINOPOLI F., ET AL., OBESITY AND BODY FAT DISTRIBUTION INDUCE ENDOTHELIAL DYSFUNCTION BY OXIDATIVE STRESS: PROTECTIVE EFFECT OF VITAMIN C, DIABETES, 50, PP. 159-165, (2001); SHINOZAKI K., HIRAYAMA A., NISHIO Y., YOSHIDA Y., OHTANI T., OKAMURA T., ET AL., CORONARY ENDOTHELIAL DYSFUNCTION IN THE INSULIN-RESISTANT STATE IS LINKED TO ABNORMAL PTERIDINE METABOLISM AND VASCULAR OXIDATIVE STRESS, J. AM. COLL. CARDIOL., 38, PP. 1821-1828, (2001); PLEINER J., SCHALLER G., MITTERMAYER F., BAYERLE-EDER M., RODEN M., WOLZT M., FFA-INDUCED ENDOTHELIAL DYSFUNCTION CAN BE CORRECTED BY VITAMIN C, J. CLIN. ENDOCRINOL. METAB., 87, PP. 2913-2917, (2002); INDIK J.H., GOLDMAN S., GABALLA M.A., OXIDATIVE STRESS CONTRIBUTES TO VASCULAR ENDOTHELIAL DYSFUNCTION IN HEART FAILURE, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); RICHARTZ B.M., WERNER G.S., FERRARI M., FIGULLA H.R., REVERSIBILITY OF CORONARY ENDOTHELIAL VASOMOTOR DYSFUNCTION IN IDIOPATHIC DILATED CARDIOMYOPATHY: ACUTE EFFECTS OF VITAMIN C, AM. J. CARDIOL., 88, PP. 1001-1005, (2001); SHARMA R., DAVIDOFF M.N., OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN HEART FAILURE, CONGEST. HEART FAIL., 8, PP. 165-172, (2002); MOTOYAMA T., KAWANO H., HIRAI N., TSUNODA R., MORIYAMA Y., MIYAO Y., ET AL., THE RELATIONSHIP OF LEFT VENTRICULAR MASS TO ENDOTHELIUM-DEPENDENT VASODILATION OF THE BRACHIAL ARTERY IN PATIENTS WITH HYPERTENSION, CARDIOLOGY, 96, PP. 7-15, (1902); DAVIDGE S.T., OXIDATIVE STRESS AND ALTERED ENDOTHELIAL CELL FUNCTION IN PREECLAMPSIA, SEMIN. REPROD. ENDOCRINOL., 16, PP. 65-73, (1998); ROGGENSACK A.M., ZHANG Y., DAVIDGE S.T., EVIDENCE FOR PEROXYNITRITE FORMATION IN THE VASCULATURE OF WOMEN WITH PREECLAMPSIA, HYPERTENSION, 33, PP. 83-89, (1999); HUBEL C.A., OXIDATIVE STRESS IN THE PATHOGENESIS OF PREECLAMPSIA, PROC. SOC. EXP. BIOL. MED., 222, PP. 222-235, (1999); CHAMBERS J.C., FUSI L., MALIK I.S., HASKARD D.O., DE SWIET M., KOONER J.S., ASSOCIATION OF MATERNAL ENDOTHELIAL DYSFUNCTION WITH PREECLAMPSIA, JAMA, 285, PP. 1607-1612, (2001); VAN DER LOO B., LABUGGER R., SKEPPER J.N., BACHSCHMID M., KILO J., POWELL J.M., ET AL., ENHANCED PEROXYNITRITE FORMATION IS ASSOCIATED WITH VASCULAR AGING, J. EXP. MED., 192, PP. 1731-1744, (2000); CSISZAR A., UNGVARI Z., EDWARDS J.G., KAMINSKI P., WOLIN M.S., KOLLER A., ET AL., AGING-INDUCED PHENOTYPIC CHANGES AND OXIDATIVE STRESS IMPAIR CORONARY ARTERIOLAR FUNCTION, CIRC. RES., 90, PP. 1159-1166, (2002); BAE J.H., BASSENGE E., KIM K.B., KIM Y.N., KIM K.S., LEE H.J., ET AL., POSTPRANDIAL HYPERTRIGLYCERIDEMIA IMPAIRS ENDOTHELIAL FUNCTION BY ENHANCED OXIDANT STRESS, ATHEROSCLEROSIS, 155, PP. 517-523, (2001); HOLMGREN A., THIOREDOXIN STRUCTURE AND MECHANISM: CONFORMATIONAL CHANGES ON OXIDATION OF THE ACTIVE-SITE SULFHYDRYLS TO A DISULFIDE, STRUCTURE, 3, PP. 239-243, (1995); MCCARTY M.F., OXIDANTS DOWNSTREAM FROM SUPEROXIDE INHIBIT NITRIC OXIDE PRODUCTION BY VASCULAR ENDOTHELIUM - A KEY ROLE FOR SELENIUM-DEPENDENT ENZYMES IN VASCULAR HEALTH, MED. HYPOTH., 53, PP. 315-325, (1999); HOLBEN D.H., SMITH A.M., THE DIVERSE ROLE OF SELENIUM WITHIN SELENOPROTEINS: A REVIEW, J. AM. DIET ASSOC., 99, PP. 836-843, (1999); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS THROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER. THROMB. VASE. BIOL., 20, PP. 61-69, (2000); THAKUR N.K., HAYASHI T., SUMI D., KANO H., TSUNEKAWA T., IGUCHI A., HMG-COA REDUCTASE INHIBITOR STABILIZES RABBIT ATHEROMA BY INCREASING BASAL NO AND DECREASING SUPEROXIDE, AM. J. PHYSIOL. HEART CIRC. PHYSIOL., 281, (2001); LAUFS U., LIAO J.K., DIRECT VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS, TRENDS CARDIOVASC. MED., 10, PP. 143-148, (2000); ENDRES M., LAUFS U., HMG-COA REDUCTASE INHIBITOR AND RISK OF STROKE, NERVENARZT, 69, PP. 717-721, (1998); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES, 32, PP. 8-12, (2001); BOGER R.H., BODE-BOGER S.M., MUGGE A., KIENKE S., BRANDES R., DWENGER A., ET AL., SUPPLEMENTATION OF HYPERCHOLESTEROLAEMIC RABBITS WITH L-ARGININE REDUCES THE VASCULAR RELEASE OF SUPEROXIDE ANIONS AND RESTORES NO PRODUCTION, ATHEROSCLEROSIS, 117, PP. 273-284, (1995); MCDONALD K.K., ZHARIKOV S., BLOCK E.R., KILBERG M.S., A CAVEOLAR COMPLEX BETWEEN THE CATIONIC AMINO ACID TRANSPORTER 1 AND ENDOTHELIAL NITRIC-OXIDE SYNTHASE MAY EXPLAIN THE ""ARGININE PARADOX, J. BIOL. CHEM., 272, PP. 31213-31216, (1997); HARDY T.A., MAY J.M., COORDINATE REGULATION OF L-ARGININE UPTAKE AND NITRIC OXIDE SYNTHASE ACTIVITY IN CULTURED ENDOTHELIAL CELLS, FREE RADIC. BIOL. MED., 32, PP. 122-131, (2002); HELLER R., MUNSCHER-PAULIG F., GRABNER R., TILL U., L-ASCORBIC ACID POTENTIATES NITRIC OXIDE SYNTHESIS IN ENDOTHELIAL CELLS, J. BIOL. CHEM., 274, PP. 8254-8260, (1999); MILSTIEN S., KATUSIC Z., OXIDATION OF TETRAHYDROBIOPTERIN BY PEROXYNITRITE: IMPLICATIONS FOR VASCULAR ENDOTHELIAL FUNCTION, BIOCHEM. BIOPHYS. RES. COMMUN., 263, PP. 681-684, (1999); HUANG A., VITA J.A., VENEMA R.C., KEANEY J.F.J., ASCORBIC ACID ENHANCES ENDOTHELIAL NITRIC-OXIDE SYNTHASE ACTIVITY BY INCREASING INTRACELLULAR TETRAHYDROBIOPTERIN, J. BIOL. CHEM., 275, PP. 17399-17406, (2000); COSENTINO F., LUSCHER T.F., TETRAHYDROBIOPTERIN AND ENDOTHELIAL FUNCTION, EUR. HEART. J., 19, SUPPL. G, (1998); VASQUEZ-VIVAR J., MARTASEK P., WHITSETT J., JOSEPH J., KALYANARAMAN B., THE RATIO BETWEEN TETRAHYDROBIOPTERIN AND OXIDIZED TETRAHYDROBIOPTERIN ANALOGUES CONTROLS SUPEROXIDE RELEASE FROM ENDOTHELIAL NITRIC OXIDE SYNTHASE: AN EPR SPIN TRAPPING STUDY, BIOCHEM. J., 362, PP. 733-739, (2002); HEITZER T., KROHN K., ALBERS S., MEINERTZ T., TETRAHYDROBIOPTERIN IMPROVES ENDOTHELIUM-DEPENDENT VASODILATION BY INCREASING NITRIC OXIDE ACTIVITY IN PATIENTS WITH TYPE II DIABETES MELLITUS, DIABETOLOGIA, 43, PP. 1435-1438, (2000); SETOGUCHI S., MOHRI M., SHIMOKAWA H., TAKESHITA A., TETRAHYDROBIOPTERIN IMPROVES ENDOTHELIAL DYSFUNCTION IN CORONARY MICROCIRCULATION IN PATIENTS WITHOUT EPICARDIAL CORONARY ARTERY DISEASE, J. AM. COLL. CARDIOL., 38, PP. 493-498, (2001); FUKUDA Y., TERAGAWA H., MATSUDA K., YAMAGATA T., MATSUURA H., CHAYAMA K., TETRAHYDROBIOPTERIN RESTORES ENDOTHELIAL FUNCTION OF CORONARY ARTERIES IN PATIENTS WITH HYPERCHOLESTEROLAEMIA, HEART, 87, PP. 264-269, (2002); SETOGUCHI S., HIROOKA Y., ESHIMA K., SHIMOKAWA H., TAKESHITA A., TETRAHYDROBIOPTERIN IMPROVES IMPAIRED ENDOTHELIUM-DEPENDENT FOREARM VASODILATION IN PATIENTS WITH HEART FAILURE, J. CARDIOVASC. PHARMACOL., 39, PP. 363-368, (2002); HIGASHI Y., SASAKI S., NAKAGAWA K., FUKUDA Y., MATSUURA H., OSHIMA T., ET AL., TETRAHYDROBIOPTERIN ENHANCES FOREARM VASCULAR RESPONSE TO ACETYLCHOLINE IN BOTH NORMOTENSIVE AND HYPERTENSIVE INDIVIDUALS, AM. J. HYPERTENS., 15, PP. 326-332, (2002); FUKUDA Y., TERAGAWA H., MATSUDA K., YAMAGATA T., MATSUURA H., CHAYAMA K., TETRAHYDROBIOPTERIN IMPROVES CORONARY ENDOTHELIAL FUNCTION, BUT DOES NOT PREVENT CORONARY SPASM IN PATIENTS WITH VASOSPASTIC ANGINA, CIRC. J., 66, PP. 58-62, (2002); BARCHOWSKY A., MUNRO S.R., MORANA S.J., VINCENTI M.P., TREADWELL M., OXIDANT-SENSITIVE AND PHOSPHORYLATION-DEPENDENT ACTIVATION OF NF-KAPPA B AND AP-1 IN ENDOTHELIAL CELLS, AM. J. PHYSIOL., 269, (1995); PUEYO M.E., GONZALEZ W., NICOLETTI A., SAVOIE F., ARNAL J.F., MICHEL J.B., ANGIOTENSIN II STIMULATES ENDOTHELIAL VASCULAR CELL ADHESION MOLECULE-1 VIA NUCLEAR FACTOR-KAPPAB ACTIVATION INDUCED BY INTRACELLULAR OXIDATIVE STRESS, ARTERIOSCLER. THROMB. VASE. BIOL., 20, PP. 645-651, (2000); OGATA N., YAMAMOTO H., KUGIYAMA K., YASUE H., MIYAMOTO E., INVOLVEMENT OF PROTEIN KINASE C IN SUPEROXIDE ANION-INDUCED ACTIVATION OF NUCLEAR FACTOR-KAPPA B IN HUMAN ENDOTHELIAL CELLS, CARDIOVASC. RES., 45, PP. 513-521, (2000); PENG H.B., LIBBY P., LIAO J.K., INDUCTION AND STABILIZATION OF I KAPPA B ALPHA BY NITRIC OXIDE MEDIATES INHIBITION OF NF-KAPPA B, J. BIOL. CHEM., 270, PP. 14214-14219, (1995); DE CATERINA R., LIBBY P., PENG H.B., THANNICKAL V.J., RAJAVASHISTH T.B., GIMBRONE M.A.J., ET AL., NITRIC OXIDE DECREASES CYTOKINE-INDUCED ENDOTHELIAL ACTIVATION. NITRIC OXIDE SELECTIVELY REDUCES ENDOTHELIAL EXPRESSION OF ADHESION MOLECULES AND PROINFLAMMATORY CYTOKINES, J. CLIN. INVEST., 96, PP. 60-68, (1995); LAROUX F.S., LEFER D.J., KAWACHI S., SCALIA R., COCKRELL A.S., GRAY L., ET AL., ROLE OF NITRIC OXIDE IN THE REGULATION OF ACUTE AND CHRONIC INFLAMMATION, ANTIOXID. REDOX. SIGNAL., 2, PP. 391-396, (2000); SPIECKER M., DARIUS H., KABOTH K., HUBNER F., LIAO J.K., DIFFERENTIAL REGULATION OF ENDOTHELIAL CELL ADHESION MOLECULE EXPRESSION BY NITRIC OXIDE DONORS AND ANTIOXIDANTS, J. LEUKOC. BIOL., 63, PP. 732-739, (1998); ACHAN V., IRAN C.T., ARRIGONI F., WHITLEY G.S., LEIPER J.M., VALLANCE P., ALL-TRANS-RETINOIC ACID INCREASES NITRIC OXIDE SYNTHESIS BY ENDOTHELIAL CELLS: A ROLE FOR THE INDUCTION OF DIMETHYLARGININE DIMETHYLAMINOHYDROLASE, CIRC. RES., 90, PP. 764-769, (2002); BOGLE R.G., CCADE S.B., MONCADA S., PEARSON J.D., MANN G.E., BRADYKININ AND ATP STIMULATE L-ARGININE UPTAKE AND NITRIC OXIDE RELEASE IN VASCULAR ENDOTHELIAL CELLS, BIOCHEM. BIOPHYS. RES. COMMUN., 180, PP. 926-932, (1991); BOGLE R.G., BAYDOUN A.R., PEARSON J.D., MANN G.E., REGULATION OF SC L-ARGININE TRANSPORT AND NITRIC OXIDE RELEASE IN SUPERFUSED PORCINE AORTIC ENDOTHELIAL CELLS, J. PHYSIOL., 490, PART 1, PP. 229-241, (1996); SOBREVIA L., YUDILEVICH D.L., MANN G.E., ACTIVATION OF A2-PURINOCEPTORS BY ADENOSINE STIMULATES L-ARGININE TRANSPORT (SYSTEM Y+) AND NITRIC OXIDE SYNTHESIS IN HUMAN FETAL ENDOTHELIAL CELLS, J. PHYSIOL., 499, PART 1, PP. 135-140, (1997); POSCH K., SCHMIDT K., GRAIER W.F., SELECTIVE STIMULATION OF L-ARGININE UPTAKE CONTRIBUTES TO SHEAR STRESS-INDUCED FORMATION OF NITRIC OXIDE, LIFE. SCI., 64, PP. 663-670, (1999); ZHARIKOV S.I., HERRERA H., BLOCK E.R., ROLE OF MEMBRANE POTENTIAL IN HYPOXIC INHIBITION OF L-ARGININE UPTAKE BY LUNG ENDOTHELIAL CELLS, AM. J. PHYSIOL., 272, (1997); ZHARIKOV S.I., BLOCK E.R., CHARACTERIZATION OF L-ARGININE UPTAKE BY PLASMA MEMBRANE VESICLES ISOLATED FROM CULTURED PULMONARY ARTERY ENDOTHELIAL CELLS, BIOCHIM. BIOPHYS. ACTA, 1369, PP. 173-183, (1998); MCCABE R.D., BAKARICH M.A., SRIVASTAVA K., YOUNG D.B., POTASSIUM INHIBITS FREE RADICAL FORMATION, HYPERTENSION, 24, PP. 77-82, (1994); MCCARTY M.F., ENDOTHELIAL MEMBRANE POTENTIAL REGULATES PRODUCTION OF BOTH NITRIC OXIDE AND SUPEROXIDE - FUNDAMENTAL DETERMINANT OF VASCULAR HEALTH, MED. HYPOTH., 53, PP. 277-289, (1999); SOHN H.Y., KELLER M., GLOE T., MORAWIETZ H., RUECKSCHLOSS U., POHL U., THE SMALL G-PROTEIN RAC MEDIATES DEPOLARIZATION-INDUCED SUPEROXIDE FORMATION IN HUMAN ENDOTHELIAL CELLS, J. BIOL. CHEM., 275, PP. 18745-18750, (2000); YOKOYAMA M., HIRATA K., MIYAKE R., AKITA H., ISHIKAWA Y., FUKUZAKI H., LYSOPHOSPHATIDYLCHOLINE: ESSENTIAL ROLE IN THE INHIBITION OF ENDOTHELIUM-DEPENDENT VASORELAXATION BY OXIDIZED LOW DENSITY LIPOPROTEIN, BIOCHEM. BIOPHYS. RES. COMMUN., 168, PP. 301-308, (1990); MUROHARA T., KUGIYAMA K., OHGUSHI M., SUGIYAMA S., OHTA Y., YASUE H., LPC IN OXIDIZED LDL ELICITS VASOCONTRACTION AND INHIBITS ENDOTHELIUM- DEPENDENT RELAXATION, AM. J. PHYSIOL., 267, (1994); HEINLOTH A., HEERMEIER K., RAFF U., WANNER C., GALLE J., STIMULATION OF NADPH OXIDASE BY OXIDIZED LOW-DENSITY LIPOPROTEIN INDUCES PROLIFERATION OF HUMAN VASCULAR ENDOTHELIAL CELLS, J. AM. SOC. NEPHROL., 11, PP. 1819-1825, (2000); KIKUTA K., SAWAMURA T., MIWA S., HASHIMOTO N., MASAKI T., HIGH-AFFINITY ARGININE TRANSPORT OF BOVINE AORTIC ENDOTHELIAL CELLS IS IMPAIRED BY LYSOPHOSPHATIDYLCHOLINE, CIRC. RES., 83, PP. 1088-1096, (1998); JIN L., ABOU-MOHAMED G., CALDWELL R.B., CALDWELL R.W., ENDOTHELIAL CELL DYSFUNCTION IN A MODEL OF OXIDATIVE STRESS, MED. SCI. MONIT., 7, PP. 585-591, (2001); XIAO S., WAGNER L., MAHANEY J., BAYLIS C., UREMIC LEVELS OF UREA INHIBIT L-ARGININE TRANSPORT IN CULTURED ENDOTHELIAL CELLS, AM. J. PHYSIOL. RENAL PHYSIOL., 280, (2001); XIAO S., ERDELY A., WAGNER L., BAYLIS C., UREMIC LEVELS OF BUN DO NOT CAUSE NITRIC OXIDE DEFICIENCY IN RATS WITH NORMAL RENAL FUNCTION, AM. J. PHYSIOL. RENAL PHYSIOL., 280, (2001); KAYE D.M., AHLERS B.A., AUTELITANO D.J., CHIN-DUSTING J.P., IN VIVO AND IN VITRO EVIDENCE FOR IMPAIRED ARGININE TRANSPORT IN HUMAN HEART FAILURE, CIRCULATION, 102, PP. 2707-2712, (2000); AZUMA H., SATO J., HAMASAKI H., SUGIMOTO A., ISOTANI E., OBAYASHI S., ACCUMULATION OF ENDOGENOUS INHIBITORS FOR NITRIC OXIDE SYNTHESIS AND DECREASED CONTENT OF L-ARGININE IN REGENERATED ENDOTHELIAL CELLS, BR. J. PHARMACOL., 115, PP. 1001-1004, (1995); VALKONEN V.P., PAIVA H., SALONEN J.T., LAKKA T.A., LEHTIMAKI T., LAAKSO J., ET AL., RISK OF ACUTE CORONARY EVENTS AND SERUM CONCENTRATION OF ASYMMETRICAL DIMETHYLARGININE, LANCET, 358, PP. 2127-2128, (2001); ZOCCALI C., BODE-BOGER S., MALLAMACI F., BENEDETTO F., TRIPEPI G., MALATINO L., ET AL., PLASMA CONCENTRATION OF ASYMMETRICAL DIMETHYLARGININE AND MORTALITY IN PATIENTS WITH END-STAGE RENAL DISEASE: A PROSPECTIVE STUDY, LANCET, 358, PP. 2113-2117, (2001); YOO J.H., LEE S.C., ELEVATED LEVELS OF PLASMA HOMOCYST (E)INE AND ASYMMETRIC DIMETHYLARGININE IN ELDERLY PATIENTS WITH STROKE, ATHEROSCLEROSIS, 158, PP. 425-430, (2001)","M.F. MCCARTY; PANTOX LABORATORIES, 4622 SANTA FE STREET, SAN DIEGO, CA, UNITED STATES; EMAIL: MMCCARTY@NAI-ONLINE.COM","CHURCHILL LIVINGSTONE","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-8444238877","MED HYPOTHESES","PANTOX LABORATORIES","NOTREPORTED;PANTOX LABORATORIES;NOTREPORTED",NA,"MCCARTY MF, 2004, MED HYPOTHESES","MCCARTY MF, 2004, MED HYPOTHESES-a-b"
"CASTAÑO G;FERNÁNDEZ L;MAS R;ILLNAIT J;FERNÁNDEZ J;MESA M;ALVAREZ E;LEZCAY M","CASTAÑO, G. (7005759008); FERNÁNDEZ, L. (7202848319); MAS, R. (7007164572); ILLNAIT, J. (8631465800); FERNÁNDEZ, J. (9432805500); MESA, M. (36880545700); ALVAREZ, E. (15053135600); LEZCAY, M. (6508023242)","COMPARISON OF THE EFFICACY SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",2002,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","22","11",21,"","MEDICAL AND SURGICAL RESEARCH CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;MEDICAL AND SURGICAL RESEARCH CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;MEDICAL AND SURGICAL RESEARCH CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND OCTA-60 IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. AFTER 4 WEEKS ON A DIET, 110 PATIENTS WERE RANDOMIZED TO POLICOSANOL OR OCTA-60 5 MG TABLETS ONCE A DAY FOR 5 WEEKS. THE DOSE WAS THEN DOUBLED TO 10 MG/DAY FOR THE NEXT 5 WEEKS. POLICOSANOL 5 AND 10 MG/DAY SIGNIFICANTLY LOWERED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) (P<0.0001 AND P<0.00001), THE MAIN EFFICACY VARIABLE, BY 18.6% AND 30.2%, WHILE OCTA-60 SIGNIFICANTLY REDUCED (P<0.05) LDL-C BY 10.0% AT STUDY COMPLETION ONLY. THE FREQUENCY OF POLICOSANOL PATIENTS REACHING REDUCTIONS OF LDL-C ≥15% AFTER 5 MG/DAY (37/55; 67.3%) AND 10 MG/DAY (47/55; 88.7%) WAS GREATER (P<0.01 AND P<0.01) THAN IN THE OCTA-60 GROUP, WHICH WAS 5/55 (9.1%) AND 20/55 (36.4%). LIKEWISE, THE FREQUENCY OF PATIENTS REACHING LDL-C VALUES OF <3.4 MMOL/L AT STUDY COMPLETION WAS GREATER (P<0.001) IN THE POLICOSANOL GROUP (39/55, 70.9%) THAN IN THE OCTA-60 GROUP (6/55, 10.9%). POLICOSANOL 5 AND 10 MG/DAY SIGNIFICANTLY LOWERED (P<0.00001) TOTAL CHOLESTEROL (TC) (13.4% AND 20.4%), LDL-C/HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) (22.1% AND 37.0%) AND TC/HDL-C (17.2% AND 28.2%). OCTA-60 AT 10 MG/DAY LOWERED (P<0.05) TC (8.7%), LDL-C/HDL-C (12.6%) AND TC/HDL-C (9.4%). HDL-C WAS INCREASED (P<0.001 AND 0.0001) BY POLICOSANOL 5 AND 10 MG/DAY (5.6% AND 12.5%) BUT WAS UNCHANGED BY OCTA-60. IN BOTH GROUPS, TRIGLYCERIDES REMAINED UNCHANGED. BOTH TREATMENTS WERE SAFE AND WELL TOLERATED. OCTA-60, BUT NOT POLICOSANOL, SIGNIFICANTLY INCREASED GLUCOSE AND ALANINE AMINOTRANSFERASE, BUT INDIVIDUAL VALUES WERE WITHIN THE NORMAL RANGE. FOUR PATIENTS (TWO FROM EACH GROUP) DISCONTINUED THE TRIAL, BUT ONLY ONE (IN THE OCTA-60 GROUP) DID SO BECAUSE OF AN ADVERSE EVENT (AE) (SKIN RASH). OVERALL, THREE PATIENTS (ALL FROM THE OCTA-60 GROUP) REPORTED AES. IN CONCLUSION, ORIGINAL POLICOSANOL AT 5 AND 10 MG/DAY, BUT NOT OCTA 60, WAS EFFECTIVE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. THUS, POLICOSANOL REACHED THE EFFICACY CRITERION FOR LDL-C REDUCTION IN BOTH STEPS, WHILE OCTA-60 FAILED TO REACH THIS GOAL. IN ADDITION, POLICOSANOL WAS BETTER TOLERATED THAN OCTA-60.","","ADULT; AGED; ALCOHOLS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; ALANINE AMINOTRANSFERASE; ALCOHOL DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LESSTANOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTA 60; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ALCOHOL DERIVATIVE; FATTY ALCOHOL; POLICOSANOL; ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; BLOOD; CHEMISTRY; COMPARATIVE STUDY; MIDDLE AGED; NONPARAMETRIC TEST","","","ANDERSON K.M., WILSON P.W.F., ODELL P.M., ET AL., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, (1991); LIPID RESEARCH CLINICS PROGRAM. THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, (1984); SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, 1, (1994); SACKS F.M., PFEFFER M.A., MOY L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N. ENG. J. MED., 339, (1998); DOWNS J.R., CLEARFIELD M., WEISS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, (2001); CORONARY HEART DISEASE. REDUCING THE RISK. THE SCIENTIFIC BACKGROUND FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE. A WORLDWIDE VIEW, NUTR. METAB. CARDIOVASC. DIS., 9, (1999); LAGUNA A., MAGRANER J., ARRUZAZABALA M.L., MAS R., ET AL.; MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, (2000); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANAL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., FRAGA V., SOTOLONGO V., ET AL., EFECTO DE LA ADMINISTRACIÓN ORAL DEL POLICOSANOL SOBRE EL METABOLISMO LIPÍDICO DE RATAS NORMOCOLESTEROLÉMICAS, REV. MEX. CIEN. FARM., 24, (1993); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANAL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, (2001); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, (1994); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, (1996); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 14, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. MED. SCI., 56, (2001); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN. INVEST., 21, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLEBLIND STUDY, INT. J. CLIN. PHARMACOL. RES., 21, (2001); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, (2001); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN. DRUG INVEST., 21, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AN NON INSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, (2000); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27879 CASES, CURR. THER. RES., 59, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, (1999); MAS R., CASTANO C., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL (5-10 MG/D) ON MORBIDITY AND MORTALITY OF OLDER HYPERCHOLESTEROLEMIC PATIENTS, AM. COLL. CARDIOL., 39, SUPPL.; CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., SELMAN E., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, (1998); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ J., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, (2001); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, (1996); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISS. REACT., 20, (1998); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGL. LEUKOTR. ESSENT. FATTY ACIDS, 58, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT. J. CLIN. PHARMACOL., 50, (2000); MENENDEZ R., MAS R., AMOR A., FERNANDEZ J.C., GONZALEZ R., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLEBLIND PILOT STUDY, CURR. THER. RES., 61, (2000); MAS R., D-002: A PRODUCT OBTAINED FROM BEESWAX, DRUGS OF THE FUTURE, 26, (2001); CARBAJAL D., ARRUZAZABALA M.L., MAS R., ET AL., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J. PHARM. PHAMACOL., 47, (1995); CARBAJAL D., MOLINA V., VALDES S., ET AL., POSSIBLE CYTOPROTECTIVE MECHANISM IN RATS OF D-002 AN ANTI-ULCEROGENIC PRODUCT ISOLATED FROM BEESWAX, J. PHARM. PHARMACOL., 48, (1996); CARBAJAL D., MOLINA V., VALDES S., ET AL., ANTI-INFLAMMATORY ACTIVITY OF D-002: AN ACTIVE PRODUCT ISOLATED FROM BEESWAX, PROSTAGL. LEUKOTR. ESSENT. FATTY ACIDS, 59, (1998); HANO O., ILLNAIT J., MAS R., FERNANDEZ L., PINOL F., FERNANDEZ J., EFFECTS OF D-002, A PRODUCT ISOLATED FROM BEESWAX, ON DUODENAL ULCER: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, CURR. THER. RES., 62, (2001); MENENDEZ R., MAS R., ILLNAIT J., ET AL., EFFECTS OF D-002 ON LIPID PEROXIDATION IN OLDER SUBJECTS, J. MED. FOOD, 4, (2001); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF D-002 TREATMENT ON THE IN VITRO SUSCEPTIBILITY OF WHOLE PLASMA IN HEALTHY VOLUNTEERS, ARCH. MED. RES., 32, (2001); MOLINA V., VALDES S., CARBAJAL D., ET AL., ANTIOXIDANT EFFECTS OF D-002 ON GASTRIC MUCOSA OF RATS WITH INJURY INDUCED EXPERIMENTALLY, J. MED. FOOD, 4, (2001); PRODUCT LESSTANOL BRAND. NATURAL OCTACOSANOL (POLICOSANOL) 60%, PRODUCT CODE OCTA- 60, PP. 1-2, (2000); URRIBARRI E., LAGUNA A., SIERRA R., RICARDO Y., PHYSICOMECHANICAL CHARACTERIZATION OF POLICOSANOL, A NOVEL HYPOCHOLESTEROLEMIC DRUG, DRUG DEVELOP. PHARM. IND., (2001); GONZALEZ V.L., MAGRANER J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF THE FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN 5 MG FILM-COATED TABLETS, J. AOAC INT., 82, (1999); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, (1996); DE SMET P.A.G.M., THE ROLE OF PLANT-DERIVED DRUGS AND HERBAL MEDICINES IN HEALTHCARE, DRUG, 54, (1997); ADVERSE EFFECTS TO HERBAL MEDICINES. AN INCREASING PROBLEM?, DRUGS THER. PERSPECT., 11, (1998)","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0036457642","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"CASTAÑO G, 2002, INT J CLIN PHARMACOL RES","CASTAÑO G, 2002, INT J CLIN PHARMACOL RES-a"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","AN EZETIMIBEPOLICOSANOL COMBINATION HAS THE POTENTIAL TO BE AN OTC AGENT THAT COULD DRAMATICALLY LOWER LDL CHOLESTEROL WITHOUT SIDE EFFECTS",2005,"MEDICAL HYPOTHESES","64","9",7,"10.1016/j.mehy.2003.12.051","NUTRIGUARD RESEARCH, 1051 HERMES AVENUE, ENCINITAS, CA, UNITED STATES","ALTHOUGH MANY RISK FACTORS INFLUENCE ATHEROGENESIS, LDL APPEARS TO PLAY A PRIMARY ROLE IN THIS PROCESS. IN PROSPECTIVE EPIDEMIOLOGY, CORONARY RISK INCREASES AS LDL CHOLESTEROL INCREASES, THROUGHOUT THE ENTIRE RANGE OF CONCENTRATIONS ENCOUNTERED IN HEALTHY HUMANS. CORONARY RISK IS MINIMAL IN INDIVIDUALS AND POPULATIONS WHOSE SERUM CHOLESTEROL REMAINS QUITE LOW THROUGHOUT LIFE. THUS, PRACTICAL STRATEGIES FOR ACHIEVING LARGE REDUCTIONS OF LDL CHOLESTEROL IN THE GENERAL POPULATION COULD HAVE A DRAMATIC IMPACT ON CORONARY MORTALITY RATES. DIETARY MEASURES HAVE LIMITED POTENTIAL IN THIS REGARD; MODEST RESTRICTION OF SATURATED FAT HAS A RATHER TRIVIAL EFFECT ON LDL CHOLESTEROL, AND THE VERY-LOW-FAT QUASI-VEGAN DIETS THAT DO HAVE A NOTABLE EFFECT IN THIS REGARD CURRENTLY HAVE LITTLE APPEAL TO THE MAJORITY OF THE POPULATION. WITH RESPECT TO PHARMACOTHERAPY, MOST AVAILABLE HYPOLIPIDEMIC AGENTS WITH REASONABLY POTENT ACTIVITY ENTAIL SIDE EFFECTS OR COMPLIANCE DIFFICULTIES THAT WOULD RENDER THEIR USE TOO EXPENSIVE OR IMPRACTICAL FOR POPULATION-WIDE APPLICATION. HOWEVER, TWO AGENTS MAY HAVE GREAT POTENTIAL IN THIS REGARD: POLICOSANOL AND EZETIMIBE. THE FORMER, A MIXTURE OF LONG-CHAIN ALCOHOLS DERIVED FROM SUGAR CANE WAX, HAS EFFECTS ON SERUM LIPIDS COMPARABLE TO THOSE OF STATINS, AND MAY WORK BY DOWN-REGULATING EXPRESSION OF HMG-COA REDUCTASE. HOWEVER, UNLIKE STATINS, POLICOSANOL APPEARS TO BE DEVOID OF SIDE EFFECTS OR RISKS. EZETIMIBE IS A NEWLY APPROVED DRUG THAT IS A POTENT AND HIGHLY SPECIFIC INHIBITOR OF AN INTESTINAL STEROL PERMEASE; IN DAILY DOSES AS LOW AS 10 MG, IT SUPPRESSES INTESTINAL ABSORPTION OF CHOLESTEROL AND DECREASES SERUM LDL CHOLESTEROL BY APPROXIMATELY 18%. NO SIDE EFFECTS HAVE BEEN SEEN IN CLINICAL DOSES, AND THE FACT THAT ITS HYPOLIPIDEMIC ACTIVITY IS ADDITIVE TO THAT OF STATINS HAS GENERATED CONSIDERABLE INTEREST. BOTH POLICOSANOL AND EZETIMIBE CAN BE ADMINISTERED ONCE DAILY. FUTURE STUDIES SHOULD DETERMINE WHETHER POLICOSANOL, LIKE STATINS, INTERACTS ADDITIVELY WITH EZETIMIBE. IF SO, IT MAY BE FEASIBLE SOMEDAY TO PRODUCE A TABLET COMBINING POLICOSANOL AND EZETIMIBE THAT COULD REDUCE LDL CHOLESTEROL BY ABOUT 40%, WITHOUT SIDE EFFECTS, AND THAT COULD BE RECOMMENDED TO VIRTUALLY ANYONE WHOSE LDL CHOLESTEROL LEVELS WERE NOT ALREADY IDEAL. © 2004 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; DRUGS, NON-PRESCRIPTION; FATTY ALCOHOLS; HUMANS; LIPOPROTEINS, LDL; ARUNDINARIA; SACCHARUM; ACETYLSALICYLIC ACID; ALCOHOL; ANTILIPEMIC AGENT; COLESTYRAMINE; DRUG ADDITIVE; EZETIMIBE; FIBRIC ACID DERIVATIVE; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; NICOTINIC ACID; OXYTETRACYCLINE; PANTETHINE; PERMEASE; PHYTOSTEROL; POLICOSANOL; SATURATED FATTY ACID; SIMVASTATIN; STEROL; WAX; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; CORONARY RISK; DIET RESTRICTION; DOWN REGULATION; DRUG POTENCY; DRUG TOLERANCE; FLUSHING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; INTESTINE ABSORPTION; LIFE; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LOW FAT DIET; MORTALITY; MUSCLE INJURY; NONHUMAN; PATIENT COMPLIANCE; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUGARCANE; TABLET","","","ROBERTS W.C., ATHEROSCLEROTIC RISK FACTORS - ARE THERE TEN OR IS THERE ONLY ONE?, AM. J. CARDIOL., 64, PP. 552-554, (1989); EVANS M., ROBERTS A., REES A., THE FUTURE DIRECTION OF CHOLESTEROL-LOWERING THERAPY, CURR. OPIN. LIPIDOL., 13, PP. 663-669, (2002); SZATROWSKI T.P., PETERSON JR. A.V., SHIMIZU Y., PRENTICE R.L., MASON M.W., FUKUNAGA Y., ET AL., SERUM CHOLESTEROL, OTHER RISK FACTORS, AND CARDIOVASCULAR DISEASE IN A JAPANESE COHORT, J. CHRONIC DIS., 37, PP. 569-584, (1984); CHEN Z., PETO R., COLLINS R., MACMAHON S., LU J., LI W., SERUM CHOLESTEROL CONCENTRATION AND CORONARY HEART DISEASE IN POPULATION WITH LOW CHOLESTEROL CONCENTRATIONS, BMJ, 303, PP. 276-282, (1991); VERSCHUREN W.M., JACOBS D.R., BLOEMBERG B.P., KROMHOUT D., MENOTTI A., ARAVANIS C., ET AL., SERUM TOTAL CHOLESTEROL AND LONG-TERM CORONARY HEART DISEASE MORTALITY IN DIFFERENT CULTURES. TWENTY-FIVE-YEAR FOLLOW-UP OF THE SEVEN COUNTRIES STUDY, JAMA, 274, PP. 131-136, (1995); HOWARD B.V., ROBBINS D.C., SIEVERS M.L., LEE E.T., RHOADES D., DEVEREUX R.B., ET AL., LDL CHOLESTEROL AS A STRONG PREDICTOR OF CORONARY HEART DISEASE IN DIABETIC INDIVIDUALS WITH INSULIN RESISTANCE AND LOW LDL: THE STRONG HEART STUDY, ARTERIOSCLER. THROMB. VASC. BIOL., 20, PP. 830-835, (2000); MEDIENE-BENCHEKOR S., BROUSSEAU T., RICHARD F., BENHAMAMOUCH S., AMOUYEL P., BLOOD LIPID CONCENTRATIONS AND RISK OF MYOCARDIAL INFARCTION, LANCET, 358, PP. 1064-1065, (2001); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMISED PLACEBO-CONTROLLED TRIAL, LANCET, 360, PP. 7-22, (2002); BRAUN L.T., DAVIDSON M.H., CHOLESTEROL-LOWERING DRUGS BRING BENEFITS TO HIGH-RISK POPULATIONS EVEN WHEN LDL IS NORMAL, J. CARDIOVASC. NURS., 18, PP. 44-49, (2003); TAUBES G., NUTRITION. THE SOFT SCIENCE OF DIETARY FAT, SCIENCE, 291, PP. 2536-2545, (2001); JACOBS D., BLACKBURN H., HIGGINS M., REED D., ISO H., MCMILLAN G., ET AL., REPORT OF THE CONFERENCE ON LOW BLOOD CHOLESTEROL: MORTALITY ASSOCIATIONS, CIRCULATION, 86, PP. 1046-1060, (1992); LAW M.R., THOMPSON S.G., WALD N.J., ASSESSING POSSIBLE HAZARDS OF REDUCING SERUM CHOLESTEROL, BMJ, 308, PP. 373-379, (1994); IRIBARREN C., REED D.M., CHEN R., YANO K., DWYER J.H., LOW SERUM CHOLESTEROL AND MORTALITY. WHICH IS THE CAUSE AND WHICH IS THE EFFECT?, CIRCULATION, 92, PP. 2396-2403, (1995); HEBERT P.R., GAZIANO J.M., CHAN K.S., HENNEKENS C.H., CHOLESTEROL LOWERING WITH STATIN DRUGS, RISK OF STROKE, AND TOTAL MORTALITY. AN OVERVIEW OF RANDOMIZED TRIALS, JAMA, 278, PP. 313-321, (1997); PETO R., BOREHAM J., CHEN J., LI J., CAMPBELL T.C., BRUN T., PLASMA CHOLESTEROL, CORONARY HEART DISEASE, AND CANCER, BMJ, 298, (1989); CAMPBELL T.C., JUNSHI C., DIET AND CHRONIC DEGENERATIVE DISEASES: PERSPECTIVES FROM CHINA, AM. J. CLIN. NUTR., 59, (1994); TANG J.L., ARMITAGE J.M., LANCASTER T., SILAGY C.A., FOWLER G.H., NEIL H.A., SYSTEMATIC REVIEW OF DIETARY INTERVENTION TRIALS TO LOWER BLOOD TOTAL CHOLESTEROL IN FREE-LIVING SUBJECTS, BMJ, 316, PP. 1213-1220, (1998); BARNARD R.J., EFFECTS OF LIFE-STYLE MODIFICATION ON SERUM LIPIDS, ARCH. INTERN. MED., 151, PP. 1389-1394, (1991); ORNISH D., SERUM LIPIDS AFTER A LOW-FAT DIET, JAMA, 279, PP. 1345-1346, (1998); SACKS F.M., CASTELLI W.P., DONNER A., KASS E.H., PLASMA LIPIDS AND LIPOPROTEINS IN VEGETARIANS AND CONTROLS, NEW ENGL. J. MED., 292, PP. 1148-1151, (1975); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., BROWN S.E., GOULD K.L., MERRITT T.A., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, PP. 2001-2007, (1998); ESSELSTYN C.B., ELLIS S.G., MEDENDORP S.V., CROWE T.D., A STRATEGY TO ARREST AND REVERSE CORONARY ARTERY DISEASE: A 5-YEAR LONGITUDINAL STUDY OF A SINGLE PHYSICIAN'S PRACTICE, J. FAM. PRACT., 41, PP. 560-568, (1995); ESSELSTYN C.B., UPDATING A 12-YEAR EXPERIENCE WITH ARREST AND REVERSAL THERAPY FOR CORONARY HEART DISEASE (AN OVERDUE REQUIEM FOR PALLIATIVE CARDIOLOGY), AM. J. CARDIOL., 84, PP. 339-341, (1999); ROBBINS J., DIET FOR A NEW AMERICA, (1998); BARNARD N., FOOD FOR LIFE: HOW THE NEW FOUR FOOD GROUPS CAN SAVE YOUR LIFE, (1994); MCCARTY M.F., EATING TO LIVE - HOW A LOW-FAT, LOW-SALT, WHOLE-FOOD VEGAN DIET CAN HELP YOU STAY LEAN AND HEALTHY INTO RIPE OLD AGE, (2002); HAMILTON-CRAIG I., THE HEART PROTECTION STUDY: IMPLICATIONS FOR CLINICAL PRACTICE. THE BENEFITS OF STATIN THERAPY DO NOT COME WITHOUT FINANCIAL COST, MED. J. AUST., 177, PP. 407-408, (2002); SIMONS L.A., SIMONS J., MCMANUS P., DUDLEY J., DISCONTINUATION RATES FOR USE OF STATINS ARE HIGH, BMJ, 321, (2000); JACKEVICIUS C.A., MAMDANI M., TU J.V., ADHERENCE WITH STATIN THERAPY IN ELDERLY PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROMES, JAMA, 288, PP. 462-467, (2002); GARG R., MALINOW M., PETTINGER M., UPSON B., HUNNINGHAKE D., NIACIN TREATMENT INCREASES PLASMA HOMOCYST(E)INE LEVELS, AM. HEART J., 138, PP. 1082-1087, (1999); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM. J. CLIN. NUTR., 69, PP. 30-42, (1999); VUKSAN V., JENKINS D.J., SPADAFORA P., SIEVENPIPER J.L., OWEN R., VIDGEN E., ET AL., KONJAC-MANNAN (GLUCOMANNAN) IMPROVES GLYCEMIA AND OTHER ASSOCIATED RISK FACTORS FOR CORONARY HEART DISEASE IN TYPE 2 DIABETES. A RANDOMIZED CONTROLLED METABOLIC TRIAL, DIABETES CARE, 22, PP. 913-919, (1999); VUKSAN V., SIEVENPIPER J.L., OWEN R., SWILLEY J.A., SPADAFORA P., JENKINS D.J., ET AL., BENEFICIAL EFFECTS OF VISCOUS DIETARY FIBER FROM KONJAC-MANNAN IN SUBJECTS WITH THE INSULIN RESISTANCE SYNDROME: RESULTS OF A CONTROLLED METABOLIC TRIAL, DIABETES CARE, 23, PP. 9-14, (2000); KATAN M.B., GRUNDY S.M., JONES P., LAW M., MIETTINEN T., PAOLETTI R., EFFICACY AND SAFETY OF PLANT STANOLS AND STEROLS IN THE MANAGEMENT OF BLOOD CHOLESTEROL LEVELS, MAYO. CLIN. PROC., 78, PP. 965-978, (2003); JUDD J.T., BAER D.J., CHEN S.C., CLEVIDENCE B.A., MUESING R.A., KRAMER M., ET AL., PLANT STEROL ESTERS LOWER PLASMA LIPIDS AND MOST CAROTENOIDS IN MILDLY HYPERCHOLESTEROLEMIC ADULTS, LIPIDS, 37, PP. 33-42, (2002); JONES P.J., VANSTONE C.A., RAIENI-SARJAZ M., ST ONGE M.P., PHYTOSTEROLS IN LOW-AND NON-FAT BEVERAGES AS PART OF A CONTROLLED DIET FAIL TO LOWER PLASMA LIPID LEVELS, J. LIPID RES., 44, PP. 1713-1719, (2003); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., CUCCHIARA A.J., DERMARDEROSIAN A.H., CIRIGLIANO M.D., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 290, PP. 765-772, (2003); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER., 53, PP. 265-269, (1993); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF POLICOSANOL, CURR. THER. RES., 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT. J. CLIN. PHARMACOL. RES., 15, PP. 159-165, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS F.R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT. J. CLIN. PHARMACOL. THER., 34, PP. 134-137, (1996); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, PP. 691-699, (1996); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. A: BIOL. SCI. MED. SCI., 56, (2001); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT. J. CLIN. PHARMACOL. THER., 36, PP. 469-473, (1998); CASTANO G., MAS R., ROCA J., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO G., MAS F.R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., ALEMAN C., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES., 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, PP. 293-297, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAG. LEUKOTR. ESS. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 20, PP. 119-124, (1998); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV. MED. CHIL., 127, PP. 286-294, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., NOA M., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 117-127, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR. THER. RES., 61, PP. 137-146, (2000); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); ALEMAN C.L., MAS F.R., NOA P.M., RODEIRO G.I., HERNANDEZ O.C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG. CARCINOG. MUTAGEN., 14, PP. 239-249, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG. CARCINOG. MUTAGEN., 14, PP. 107-113, (1994); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM. TOXICOL., 33, PP. 573-578, (1995); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT., 90, PP. 97-106, (1997); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG. CARCINOG. MUTAGEN., 18, PP. 1-7, (1998); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, PP. 923-932, (1997); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL. RES., 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, PP. 8-12, (2001); MIRKIN A., MAS R., MARTINTO M., BOCCANERA R., ROBERTIS A., POUDES R., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT. J. CLIN. PHARMACOL. RES., 21, PP. 31-41, (2001); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT. J. CLIN. PHARMACOL. RES, 22, PP. 55-66, (2002); ROSENBLUM S.B., HUYNH T., AFONSO A., DAVIS JR. H.R., YUMIBE N., CLADER J.W., ET AL., DISCOVERY OF 1-(4-FLUOROPHENYL)-(3R)-3-(4-FLUOROPHENYL)-(3S)- HYDROXYPROPYL-(4S)-(4 -HYDROXYPHENYL)-2-AZETIDINONE (SCH 58235): A DESIGNED, POTENT, ORALLY ACTIVE INHIBITOR OF CHOLESTEROL ABSORPTION, J. MED. CHEM., 41, PP. 973-980, (1998); SUDHOP T., LUTJOHANN D., KODAL A., IGEL M., TRIBBLE D.L., SHAH S., ET AL., INHIBITION OF INTESTINAL CHOLESTEROL ABSORPTION BY EZETIMIBE IN HUMANS, CIRCULATION, 106, PP. 1943-1948, (2002); REPA J.J., DIETSCHY J.M., TURLEY S.D., INHIBITION OF CHOLESTEROL ABSORPTION BY SCH 58053 IN THE MOUSE IS NOT MEDIATED VIA CHANGES IN THE EXPRESSION OF MRNA FOR ABCA1, ABCG5, OR ABCG8 IN THE ENTEROCYTE, J. LIPID RES., 43, PP. 1864-1874, (2002); VAN HEEK M., FARLEY C., COMPTON D.S., HOOS L.M., SMITH-TORHAN A., DAVIS H.R., EZETIMIBE POTENTLY INHIBITS CHOLESTEROL ABSORPTION BUT DOES NOT AFFECT ACUTE HEPATIC OR INTESTINAL CHOLESTEROL SYNTHESIS IN RATS, BRIT. J. PHARMACOL., 138, PP. 1459-1464, (2003); BROWN W.V., CHOLESTEROL ABSORPTION INHIBITORS: DEFINING NEW OPTIONS IN LIPID MANAGEMENT, CLIN. CARDIOL., 26, PP. 259-264, (2003); TURLEY S.D., DIETSCHY J.M., STEROL ABSORPTION BY THE SMALL INTESTINE, CURR. OPIN. LIPIDOL., 14, PP. 233-240, (2003); KNOPP R.H., DUJOVNE C.A., LE BEAUT A., LIPKA L.J., SURESH R., VELTRI E.P., EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF EZETIMIBE IN PRIMARY HYPERCHOLESTEROLAEMIA: A POOLED ANALYSIS FROM TWO CONTROLLED PHASE III CLINICAL STUDIES, INT. J. CLIN. PRACT., 57, PP. 363-368, (2003); DAVIS JR. H.R., PULA K.K., ALTON K.B., BURRIER R.E., WATKINS R.W., THE SYNERGISTIC HYPOCHOLESTEROLEMIC ACTIVITY OF THE POTENT CHOLESTEROL ABSORPTION INHIBITOR, EZETIMIBE, IN COMBINATION WITH 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS IN DOGS, METABOLISM, 50, PP. 1234-1241, (2001); KOSOGLOU T., MEYER I., VELTRI E.P., STATKEVICH P., YANG B., ZHU Y., ET AL., PHARMACODYNAMIC INTERACTION BETWEEN THE NEW SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR EZETIMIBE AND SIMVASTATIN, BRIT. J. CLIN. PHARMACOL., 54, PP. 309-319, (2002); GAGNE C., BAYS H.E., WEISS S.R., MATA P., QUINTO K., MELINO M., ET AL., EFFICACY AND SAFETY OF EZETIMIBE ADDED TO ONGOING STATIN THERAPY FOR TREATMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 90, PP. 1084-1091, (2002); DAVIDSON M.H., MCGARRY T., BETTIS R., MELANI L., LIPKA L.J., LEBEAUT A.P., ET AL., EZETIMIBE COADMINISTERED WITH SIMVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, J. AM. COLL. CARDIOL., 40, PP. 2125-2134, (2002); KERZNER B., CORBELLI J., SHARP S., LIPKA L.J., MELANI L., LEBEAUT A., ET AL., EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH LOVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 91, PP. 418-424, (2003); MELANI L., MILLS R., HASSMAN D., LIPETZ R., LIPKA L., LEBEAUT A., ET AL., EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL, EUR. HEART J., 24, PP. 717-728, (2003); AIDE M., EZETIMIBE (ZETIA): A NOVEL LIPID-LOWERING AGENT, PHARMA. NOTE, 18, PP. 1-4, (2003); ZHU Y., STATKEVICH P., KOSOGLOU T., ZAMBAS D., PATRICK J., CAYEN M.N., ET AL., EFFECT OF EZETIMIBE (SCH 58235) ON THE ACTIVITY OF METABOLIZING ENZYMES IN VIVO (ABSTR), CLIN. PHARMACOL. THER., 67, (2000); HARRIS M., DAVIS W., BROWN W.V., EZETIMIBE, DRUGS TODAY (BARC.), 39, PP. 229-247, (2003); ARSENIO L., CARONNA S., LATEANA M., MAGNATI G., STRATA A., ZAMMARCHI G., HYPERLIPIDEMIA, DIABETES AND ATHEROSCLEROSIS: EFFICACY OF TREATMENT WITH PANTETHINE, ACTA. BIOMED. ATENEO. PARMENSE., 55, PP. 25-42, (1984); GADDI A., DESCOVICH G.C., NOSEDA G., FRAGIACOMO C., COLOMBO L., CRAVERI A., ET AL., CONTROLLED EVALUATION OF PANTETHINE, A NATURAL HYPOLIPIDEMIC COMPOUND, IN PATIENTS WITH DIFFERENT FORMS OF HYPERLIPOPROTEINEMIA, ATHEROSCLEROSIS, 50, PP. 73-83, (1984); MURAI A., MIYAHARA T., TANAKA T., SAKO Y., NISHIMURA N., KAMEYAMA M., THE EFFECTS OF PANTETHINE ON LIPID AND LIPOPROTEIN ABNORMALITIES IN SURVIVORS OF CEREBRAL INFARCTION, ARTERY, 12, PP. 234-243, (1985); ARSENIO L., BODRIA P., MAGNATI G., STRATA A., TROVATO R., EFFECTIVENESS OF LONG-TERM TREATMENT WITH PANTETHINE IN PATIENTS WITH DYSLIPIDEMIA, CLIN. THER., 8, PP. 537-545, (1986); DONATI C., BARBI G., CAIRO G., PRATI G.F., DEGLI E.E., PANTETHINE IMPROVES THE LIPID ABNORMALITIES OF CHRONIC HEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTER CLINICAL TRIAL, CLIN. NEPHROL., 25, PP. 70-74, (1986); BERTOLINI S., DONATI C., ELICIO N., DAGA A., CUZZOLARO S., MARCENARO A., ET AL., LIPOPROTEIN CHANGES INDUCED BY PANTETHINE IN HYPERLIPOPROTEINEMIC PATIENTS: ADULTS AND CHILDREN, INT. J. CLIN. PHARMACOL. THER. TOXICOL., 24, PP. 630-637, (1986); ETO M., WATANABE K., CHONAN N., ISHII K., LOWERING EFFECT OF PANTETHINE ON PLASMA Β-THROMBOGLOBULIN AND LIPIDS IN DIABETES MELLITUS, ARTERY, 15, PP. 1-12, (1987); CORONEL F., TORNERO F., TORRENTE J., NARANJO P., DE OLEO P., MACIA M., ET AL., TREATMENT OF HYPERLIPEMIA IN DIABETIC PATIENTS ON DIALYSIS WITH A PHYSIOLOGICAL SUBSTANCE, AM. J. NEPHROL., 11, PP. 32-36, (1991); RANGANATHAN S., JACKSON R.L., HARMONY J.A., EFFECT OF PANTETHINE ON THE BIOSYNTHESIS OF CHOLESTEROL IN HUMAN SKIN FIBROBLASTS, ATHEROSCLEROSIS, 44, PP. 261-273, (1982); CIGHETTI G., DEL PUPPO M., PARONI R., GALLI K.M., MODULATION OF HMG-COA REDUCTASE ACTIVITY BY PANTETHEINE/PANTETHINE, BIOCHIM. BIOPHYS. ACTA, 963, PP. 389-393, (1988); CIGHETTI G., DEL PUPPO M., PARONI R., GALLI G., KIENLE M.G., EFFECTS OF PANTETHINE ON CHOLESTEROL SYNTHESIS FROM MEVALONATE IN ISOLATED RAT HEPATOCYTES, ATHEROSCLEROSIS, 60, PP. 67-77, (1986); CIGHETTI G., DEL PUPPO M., PARONI R., FIORICA E., GALLI K.M., PANTETHINE INHIBITS CHOLESTEROL AND FATTY ACID SYNTHESES AND STIMULATES CARBON DIOXIDE FORMATION IN ISOLATED RAT HEPATOCYTES, J. LIPID RES., 28, PP. 152-161, (1987); MCCARTY M.F., INHIBITION OF ACETYL-COA CARBOXYLASE BY CYSTAMINE MAY MEDIATE THE HYPOTRIGLYCERIDEMIC ACTIVITY OF PANTETHINE, MED. HYPOTHESES, 56, PP. 314-317, (2001); WITTWER C.T., GRAVES C.P., PETERSON M.A., JORGENSEN E., WILSON D.E., THOENE J.G., ET AL., PANTETHINE LIPOMODULATION: EVIDENCE FOR CYSTEAMINE MEDIATION IN VITRO AND IN VIVO, ATHEROSCLEROSIS, 68, PP. 41-49, (1987); VUKSAN V., JENKINS D.J., SPADAFORA P., SIEVENPIPER J.L., OWEN R., VIDGEN E., ET AL., KONJAC-MANNAN (GLUCOMANNAN) IMPROVES GLYCEMIA AND OTHER ASSOCIATED RISK FACTORS FOR CORONARY HEART DISEASE IN TYPE 2 DIABETES. A RANDOMIZED CONTROLLED METABOLIC TRIAL, DIABETES CARE, 22, PP. 913-919, (1999)","M.F. MCCARTY; NUTRIGUARD RESEARCH, 1051 HERMES AVENUE, ENCINITAS, CA, UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-11144314202","MED HYPOTHESES","NUTRIGUARD RESEARCH","NOTREPORTED;NUTRIGUARD RESEARCH;NOTREPORTED",NA,"MCCARTY MF, 2005, MED HYPOTHESES","MCCARTY MF, 2005, MED HYPOTHESES-a"
"MILLER K;LIEBOWITZ R;NEWBY L","MILLER, KELLY L. (55455954400); LIEBOWITZ, RICHARD S. (6603656320); NEWBY, L.KRISTIN (7005939882)","COMPLEMENTARY AND ALTERNATIVE MEDICINE IN CARDIOVASCULAR DISEASE A REVIEW OF BIOLOGICALLY BASED APPROACHES",2004,"AMERICAN HEART JOURNAL","147","10",93,"10.1016/j.ahj.2003.10.021","DIV. OF GENERAL INTERNAL MEDICINE, DEPARTMENT OF MEDICINE, DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NC, UNITED STATES;DIV. OF GENERAL INTERNAL MEDICINE, DEPARTMENT OF MEDICINE, DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NC, UNITED STATES;DIVISION OF CARDIOLOGY, DEPARTMENT OF MEDICINE, DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NC, UNITED STATES, DUKE CLINICAL RESEARCH INSTITUTE, DURHAM, NC 27715-7969, PO BOX 17969, UNITED STATES","BACKGROUND THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICAL (CAM) PRACTICES IN THE UNITED STATES IS GROWING RAPIDLY. IN THIS MANUSCRIPT, WE REVIEW SOME OF THE MOST COMMONLY USED BIOLOGICALLY BASED APPROACHES, INCLUDING HERBS, SUPPLEMENTS, AND OTHER PHARMACOLOGICAL THERAPIES, THAT ARE ENCOUNTERED IN CARING FOR PATIENTS WITH CARDIOVASCULAR DISEASE, FOCUSING ON POTENTIAL EFFECTS, ADVERSE EFFECTS, AND TREATMENT INTERACTIONS. METHODS BETWEEN NOVEMBER 2002 AND APRIL 2003, WE SEARCHED MEDLINE AND THE NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE (NCCAM) WEB SITE AND ITS VARIOUS REFERENCES AND SEVERAL COMPLEMENTARY MEDICINE TEXT BOOKS. THE KEY WORDS USED WERE: ""CARDIOVASCULAR DISEASES,"" ""CORONARY DISEASE,"" ""HEART FAILURE, CONGESTIVE,"" ""COMPLEMENTARY AND ALTERNATIVE MEDICINE,"" ""COMPLEMENTARY THERAPIES,"" ""DRUG INTERACTIONS,"" AND ""PLANTS, MEDICINAL."" A KEYWORD SEARCH OF EACH INDIVIDUAL SUPPLEMENT IDENTIFIED WAS ALSO PERFORMED. ADDITIONALLY, WE RELIED ON EXPERT OPINION IN THE FIELD. RESULTS POTENTIALLY SERIOUS ADVERSE EFFECTS AND INTERACTIONS WITH CONVENTIONAL CARDIOVASCULAR THERAPIES EXIST FOR MANY HERBS AND SUPPLEMENTS. THERE ARE CURRENTLY SCARCE MECHANISTIC DATA AND VERY LIMITED DATA ON THE EFFECT OF CAM THERAPIES ON CLINICAL OUTCOMES. CONCLUSIONS RANDOMIZED CLINICAL TRIALS WITH ADEQUATE POWER TO DETECT EFFECTS OF CAM THERAPIES ON CLINICAL OUTCOMES AND SAFETY ARE NEEDED. UNTIL THESE DATA ARE AVAILABLE, CLINICIANS MUST BE AWARE OF THE INCREASING USE OF CAM APPROACHES BY THEIR PATIENTS AND THE POTENTIAL FOR INTERACTIONS WITH CONVENTIONAL THERAPIES AND SHOULD FOCUS ON TREATMENT WITH PROVEN, EVIDENCE-BASED STRATEGIES.","","CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT PREPARATIONS; ALPHA TOCOPHEROL; AMIODARONE; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CARNITINE; CRATAEGUS EXTRACT; CYCLOSPORIN; DIGOXIN; DILTIAZEM; GARLIC EXTRACT; GINGER EXTRACT; GINSENG EXTRACT; GUGGULSTERONE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAVA EXTRACT; KETOCONAZOLE; MACROLIDE; POLICOSANOL; PROPRANOLOL DERIVATIVE; PROTEINASE INHIBITOR; SPASMOLYTIC AGENT; TANACETUM PARTHENIUM EXTRACT; UBIDECARENONE; UNINDEXED DRUG; VASOACTIVE AGENT; VERAPAMIL; WARFARIN; CARDIOVASCULAR AGENT; PLANT MEDICINAL PRODUCT; ACUPUNCTURE; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ANGINA PECTORIS; ANXIETY DISORDER; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DEPRESSION; DIET SUPPLEMENTATION; EXERCISE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPERTENSION; HYPOCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOCYTOSIS; LIVER DISEASE; LIVER TOXICITY; LUNG FIBROSIS; MEDICINAL PLANT; MYOPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THYROID DISEASE; VITAMIN SUPPLEMENTATION; ALTERNATIVE MEDICINE; CARDIOVASCULAR DISEASE; DRUG INTERACTION; PHYTOTHERAPY","","","EISENBERG D.M., KESSLER R.C., FOSTER C., UNCONVENTIONAL MEDICINE IN THE UNITED STATES, N ENGL J MED, 328, PP. 246-252, (1993); EISENBERG D.M., DAVIS R.B., ETTNER S.L., ET AL., TRENDS IN ALTERNATIVE MEDICINE USE IN THE UNITED STATES, 1990-1997: RESULTS OF A FOLLOW-UP NATIONAL SURVEY, JAMA, 280, PP. 1569-1575, (1998); ASTIN J.A., WHY PATIENTS USE ALTERNATIVE MEDICINE: RESULTS OF A NATIONAL STUDY, JAMA, 279, PP. 1548-1553, (1998); PRIORITIES FOR RESEARCH; HEPTINSTALL S., GROENEWEGEN W.A., SPANGENBERG P., ET AL., EXTRACTS OF FEVERFEW MAY INHIBIT PLATELET BEHAVIOR VIA NEUTRALIZATION OF SULPHYDRYL GROUPS, J PHARM PHARMACOL, 39, PP. 459-465, (1987); MAKHEJA A.N., BAILEY J., THE ACTIVE PRINCIPLE IN FEVERFEW, LANCET, 2, (1981); HEPTINSTALL S., WHITE A., WILLIAMSON L., ET AL., EXTRACTS OF FEVERFEW INHIBIT GRANULE SECRETIONS IN BLOOD PLATELETS AND POLYMORPHONUCLEAR LEUCOCYTES, LANCET, 1, PP. 1071-1074, (1985); BORDIA A., EFFECT OF GARLIC ON HUMAN PLATELET AGGREGATION IN VITRO, ATHEROSCLEROSIS, 30, PP. 355-360, (1978); BORDIA A., VERMA S.K., SRIVASTAVA K.C., EFFECT OF GARLIC ON PLATELET AGGREGATION IN HUMANS: A STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH CORONARY ARTERY DISEASE, PROSTAGLANDINS LEUKOTRIENES ESSENTIAL FATTY ACIDS, 55, PP. 201-205, (1996); BACKON J., GINGER: INHIBITION OF THROMBOXANE SYNTHETASE AND STIMULATION OF PROSTACYCLIN: RELEVANCE FOR MEDICINE AND PSYCHIATRY, MED HYPOTHESES, 20, PP. 271-278, (1986); LEBARS P.L., KATZ M.M., BERMAN N., A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF AN EXTRACT OF GINKGO BILOBA FOR DEMENTIA, JAMA, 278, PP. 1327-1332, (1997); CHUNG K.F., MCCUSKER M., PAGE C.P., ET AL., EFFECT OF GINKGOLIDE MIXTURE IN ANTAGONIZING SKIN AND PLATELET RESPONSES TO PLATELET ACTIVATING FACTOR IN MAN, LANCET, 1, PP. 248-251, (1987); ROWIN J., LEWIS S.L., SPONTANEOUS BILATERAL SUBDURAL HEMATOMAS ASSOCIATED WITH CHRONIC GINKGO BILOBA INGESTION, NEUROLOGY, 46, PP. 1775-1776, (1996); GILBERT G.J., GINKGO BILOBA, NEUROLOGY, 48, (1997); MATTHEWS JR. M.K., ASSOCIATION OF GINKGO BILOBA WITH INTRACEREBRAL HEMORRHAGE, NEUROLOGY, 50, PP. 1933-1934, (1998); VALE S., SUBARACHNOID HAEMORRHAGE ASSOCIATED WITH GINKGO BILOBA, LANCET, 352, (1998); CHAN T.Y.K., DRUG INTERACTIONS AS A CAUSE OF OVERANTICOAGULATION AND BLEEDINGS IN CHINESE PATIENTS RECEIVING WARFARIN, INT J CLIN PHARMACOL THER, 36, PP. 403-405, (1998); IZZAT M.B., YIM A.P.C., EL-ZUFARI M.H., A TASTE OF CHINESE MEDICINE!, ANN THORAC SURG, 66, PP. 941-942, (1998); YU C.M., CHAN J.C.N., SANDERSON J.E., CHINESE HERBS AND WARFARIN POTENTIATION BY 'DANSHEN, J INTERN MED, 241, PP. 337-339, (1997); TAM L.S., CHAN T.Y.K., LEUNG W.K., ET AL., WARFARIN INTERACTIONS WITH CHINESE TRADITIONAL MEDICINES: DANSHEN AND METHYL SALICYLATE MEDICATED OIL, AUST N Z J MED, 25, (1995); JANETZKY K., MORREALE A.P., PROBABLE INTERACTIONS BETWEEN WARFARIN AND GINSENG, AM J HEALTH SYST PHARM, 54, PP. 692-693, (1997); HENDERSON L., YUE Q.Y., BERGQUIST C., ET AL., ST JOHN'S WORT (HYPERICUM PERFORATUM) DRUG INTERACTIONS AND CLINICAL OUTCOMES, BR J CLIN PHARM, 54, PP. 349-356, (2002); MILLER L.G., HERBAL MEDICINALS: SELECTED CLINICAL CONSIDERATIONS FOCUSING ON KNOWN OR POTENTIAL DRUG-HERB INTERACTIONS, ARCH INT MED, 158, PP. 2200-2211, (1998); HEPATIC TOXICITY POSSIBLY ASSOCIATED WITH KAVA-CONTAINING PRODUCTS - UNITED STATES, GERMANY AND SWITZERLAND, 1999-2002, JAMA, 289, PP. 36-37, (2003); SEARCH OF INDIVIDUAL HERBS AND SUPPLEMENTS; FUSHIMI R., TACHI J., AMINO N., ET AL., CHINESE MEDICINE INTERFERING WITH DIGOXIN IMMUNOASSAYS, LANCET, 1, (1989); SUGA T., CHEMISTRY AND PHARMACOLOGY OF CHAN-SU, TAISHA, CHIN MED J (ENGL), 10, SUPPL., PP. 762-773, (1973); MCRAE S., ELEVATED SERUM DIGOXIN LEVELS IN A PATIENT TAKING DIGOXIN AND SIBERIAN GINSENG, CMAJ, 155, PP. 293-295, (1996); AWANG D.V., SIBERIAN GINSENG TOXICITY MAY BE A CASE OF MISTAKEN IDENTITY, CMAJ, 155, (1996); JOHNE A., BROCKMOLLER J., BAUER S., ET AL., PHARMACOKINETIC INTERACTION OF DIGOXIN WITH AN HERBAL EXTRACT FROM ST. JOHN'S WORT (HYPERICUM PERFORATUM), CLIN PHARMACOL THER, 66, PP. 338-345, (1999); SCHLICHE H., PHYTOTHERAPY IN PAEDIATRICS: HANDBOOK FOR PHYSICIANS AND PHARMACISTS, (1997); FDA WARNS CONSUMERS AGAINST DIETARY SUPPLEMENT PRODUCTS THAT MAY CONTAIN DIGITALIS MISLABELED AS PLANTAIN, (1997); SLIFMAN N.R., OBERMEYER W.R., ALOI B.K., ET AL., CONTAMINATION OF BOTANICAL DIETARY SUPPLEMENTS BY DIGITALIS LANATA, N ENGL J MED, 339, PP. 806-811, (1998); EFFECT OF HYPERICUM PERFORATUM (ST JOHN'S WORT) IN MAJOR DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, PP. 1807-1814, (2002); RUSCHITZKA F., MEIER P.J., TURINA M., ET AL., ACUTE HEART TRANSPLANT REJECTION DUE TO SAINT JOHN'S WORT, LANCET, 355, PP. 548-549, (2000); PEPPING J., COENZYME Q10, AM J HEALTH SYST PHARM, 56, PP. 519-520, (1999); JELLIN J.M., GREGORY P.J., BATZ F., ET AL., PHARMACIST'S LETTER/PRESCIBER'S LETTER NATURAL MEDICINE COMPREHENSIVE DATABASE, PP. 379-382, (2003); LANGSJOEN P., LANGSJOEN P., WILLIS R., ET AL., TREATMENT OF ESSENTIAL HYPERTENSION WITH COENZYME Q10, MOL ASPECTS MED, 15, SUPPL., PP. 265-272, (1994); COMBS A.B., PORTER T.H., FOLKERS K., ANTICOAGULANT ACTIVITY OF NAPHTHOQUINONE ANALOG OF VITAMIN K AND AN INHIBITOR OF COENZYME Q10-ENZYME SYSTEMS, RES COMMUN CHEM PATHOL PHARMACOL, 13, PP. 109-114, (1976); LANDBO C., ALMDAL T.P., INTERACTION BETWEEN WARFARIN AND COENZYME Q10, UGESKR LAEGER, 160, PP. 3226-3227, (1998); SPIGSET O., REDUCED EFFECT OF WARFARIN CAUSED BY UBIDECARENONE, LANCET, 344, PP. 1372-1373, (1994); FOLKERS K., VADHANAVIKIT S., MORTENSEN S.A., BIOCHEMICAL RATIONALE AND MYOCARDIAL TISSUE DATA ON THE EFFECTIVE THERAPY OF CARDIOMYOPATHY WITH COENZYME Q10, PROC NATL ACAD SCI U S A, 82, PP. 901-904, (1985); MORTENSEN S.A., PERSPECTIVES ON THERAPY OF CARDIOVASCULAR DISEASE WITH COENZYME Q10 (UBIQUINONE), CLIN INVESTIGATOR, 71, SUPPL., PP. 116-123, (1993); LANGSJOEN P.H., LANGSJOEN P.H., FOLKERS K., LONG-TERM EFFICACY AND SAFETY OF COENZYME Q10 THERAPY FOR IDIOPATHIC DILATED CARDIOMYOPATHY, AM J CARDIOL, 65, PP. 521-523, (1990); MORISCO C., TRIMARCO B., CONDORELLI M., EFFECT OF COENZYME Q10 THERAPY IN PATIENTS WITH CONGESTIVE CARDIAC FAILURE: A LONG TERM MULTICENTER RANDOMIZED STUDY, CLIN INVESTIGATOR, 71, SUPPL., PP. 134-136, (1993); SOJA A.M., MORTENSEN S.A., TREATMENT OF CHF WITH COQ10 ILLUMINATED BY META-ANALYSES OF CLINICAL TRIALS, MOL ASPECTS MED, 18, SUPPL., PP. 159-168, (1997); BAGGIO E., GANDINI R., PLANCHER A.C., ET AL., ITALIAN MULTICENTER STUDY ON THE SAFETY AND EFFICACY OF COENZYME Q10 AS ADJUNCTIVE THERAPY IN HEART FAILURE, MOL ASPECTS MED, 15, SUPPL., PP. 287-294, (1994); HOFMAN-BANG C., REHNQVIST N., SWEDBERG K., ET AL., COENZYME Q10 AS AN ADJUNCTIVE IN THE TREATMENT OF CHRONIC CONGESTIVE HEART FAILURE, J CARD FAIL, 1, PP. 101-107, (1995); WATSON P.S., SCALIA G.M., GALBRAITH A., ET AL., LACK OF EFFECT OF COENZYME Q ON LEFT VENTRICULAR FUNCTION IN PATIENTS WITH CONGESTIVE HEART FAILURE, J AM COLL CARDIOL, 33, PP. 1549-1552, (1999); KHATTA M., ALEXANDER B.S., KRICHTEN C.M., ET AL., THE EFFECT OF COENZYME Q10 IN PATIENTS WITH CONGESTIVE HEART FAILURE, ANN INT MED, 132, PP. 636-640, (2000); LAAKSONEN R., OJALA J.P., TIKKANEN M.J., ET AL., SERUM UBIQUINONE CONCENTRATIONS AFTER SHORT-AND LONG-TERM TREATMENT WITH HMG-COA REDUCTASE INHIBITORS, EUR J CLIN PHARMACOL, 46, PP. 313-317, (1994); WATTS G.F., CASTELLUCCIO C., RICE-EVANS C., ET AL., PLASMA COENZYME Q (UBIQUINONE) CONCENTRATIONS IN PATIENTS TREATED WITH SIMVASTATIN, J CLIN PATHOL, 46, PP. 1055-1057, (1993); KAMIKAWA T., KOBAYASHI A., YAMASHITA T., ET AL., EFFECTS OF COENZYME Q10 ON EXERCISE TOLERANCE IN CHRONIC STABLE ANGINA PECTORIS, AM J CARDIOL, 56, PP. 247-251, (1985); BURKE B.E., NEUENSCHWANDER R., OLSON R.D., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF COENZYME Q10 IN ISOLATED SYSTOLIC HYPERTENSION, SOUTH MED J, 94, PP. 1112-1117, (2001); DIGIESI V., CANTINI F., ORADEI A., ET AL., COENZYME Q10 IN ESSENTIAL HYPERTENSION, MOL ASPECTS MED, 15, SUPPL., PP. 257-263, (1994); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); ORTENSI G., GLADSTEIN J., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARM RES, 19, PP. 117-127, (1999); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB> , PROSTAGLANDINS LEUKOTRIENES ESSENTIAL FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., MAS R., ET AL., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOTRIENES ESSENTIAL FATTY ACIDS, 50, PP. 249-251, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARM RES, 16, PP. 67-72, (1996); HEBER D., YIP I., ASHLEY J.M., ET AL., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); URIZAR N.L., LIVERMAN A.B., DODDS D.T., ET AL., A NATURAL PRODUCT THAT LOWERS CHOLESTEROL AS AN ANTAGONIST LIGAND FOR FXR, SCIENCE, 296, PP. 1703-1706, (2002); SINGH R.B., NIAZ M.A., GHOSH S., HYPOLIPIDEMIC AND ANTIOXIDANT EFFECTS OF COMMIPHORA MUKUL AS AN ADJUNCT TO DIETARY THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CARDIOVASC DRUGS THER, 8, PP. 659-664, (1994); DALVI S.S., NAYAK V.K., POHUJANI S.M., ET AL., EFFECT OF GUGULIPID ON BIOAVAILABILITY OF DILTIAZEM AND PROPRANOLOL, J ASSOC PHYSICIANS INDIA, 42, PP. 454-455, (1994); OPIE L.H., ROLE OF CARNITINE IN FATTY ACID METABOLISM OF NORMAL AND ISCHEMIC MYOCARDIUM, AM HEART J, 97, PP. 375-388, (1979); SHUG A.L., THOMSEN J.H., FOLTS J.D., ET AL., CHANGES IN TISSUE LEVELS OF CARNITINE AND OTHER METABOLITES DURING ISCHAEMIA AND ANOXIA, ARCH BIOCHEM BIOPHYS, 187, PP. 25-33, (1978); COLONNA P., ILICETO S., MYOCARDIAL INFARCTION AND LEFT VENTRICULAR REMODELING: RESULTS OF THE CEDIM TRIAL: CARNITINE ECOCARDIOGRAFIA DIGITALIZZATA INFARTO MIOCARDICO, AM HEART J, 139, SUPPL., PP. 124-130, (2000); LIEDTKE A.J., DEMAISON L., NELLIS S.H., EFFECTS OF L-PROPIONYLCARNITINE ON MECHANICAL RECOVERY DURING REFLOW IN INTACT HEARTS, AM J PHYSIOL, 255, PP. 169-176, (1988); WHITE H.D., NORRIS R.M., BROWN M.A., ET AL., LEFT VENTRICULAR END-SYSTOLIC VOLUME AS THE MAJOR DETERMINANT OF SURVIVAL AFTER RECOVERY FROM MYOCARDIAL INFARCTION, CIRCULATION, 76, PP. 44-51, (1987); ST JOHN SUTTON M., PFEFFER M.A., PLAPPERT T., ET AL., QUANTITATIVE TWO-DIMENSIONAL ECHOCARDIOGRAPHIC MEASUREMENTS ARE MAJOR PREDICTORS OF ADVERSE CARDIOVASCULAR EVENTS AFTER ACUTE MYOCARDIAL INFARCTION: THE PROTECTIVE EFFECTS OF CAPTOPRIL, CIRCULATION, 89, PP. 68-75, (1994); ILICETO S., SCRUTINIO D., BRUZZI P., ET AL., EFFECTS OF L-CARNITINE ADMINISTRATION ON LEFT VENTRICULAR REMODELING AFTER ACUTE ANTERIOR MYOCARDIAL INFARCTION: THE L-CARNITINE ECOCARDIOGRAFIA DIGITALIZZATA INFARTO MIOCARDICO (CEDIM) TRIAL, J AM COLL CARDIOL, 26, PP. 380-387, (1995); PFEFFER M.A., BRAUNWALD E., MOYE L.A., ET AL., EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION: RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL, N ENGL J MED, 327, PP. 669-677, (1992); FELDMAN A., THE ROLE OF ENERGY METABOLISM DEFECTS IN CARDIOMYOPATHY: FROM INBORN ERRORS TO ISCHEMIA: INTRODUCTION, AM HEART J, 139, SUPPL., PP. 61-62, (2000); WINTER S.C., BUIST N.R., CARDIOMYOPATHY IN CHILDHOOD, MITOCHONDRIAL DYSFUNCTION, AND THE ROLE OF L-CARNITINE, AM HEART J, 139, SUPPL., PP. 63-69, (2000); RIZOS I., THREE-YEAR SURVIVAL OF PATIENTS WITH HEART FAILURE CAUSED BY DILATED CARDIOMYOPATHY AND L-CARNITINE ADMINISTRATION, AM HEART J, 139, PP. 130-133, (2000); JEEJEEBHOY F., KEITH M., FREEMAN M., ET AL., NUTRITIONAL SUPPLEMENTATION WITH MYO VIVE REPLETES ESSENTIAL CARDIAC MYOCYTE NUTRIENTS AND REDUCES LEFT VENTRICULAR SIZE IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION, AM HEART J, 143, PP. 1092-1100, (2002); POPPING S., FISCHER Y., KAMMERMEIER H., CRATAEGUS-WIRKUNG AUF KONTRAKTION UND O<SUB>2</SUB>-VERBRAUCH ISOLIERTER HERZZELLEN, MÜNCH MED WSCHR, 136, SUPPL., PP. 39-46, (1994); KRZEMINSKI T., CHATTERJEE S.S., ISCHEMIA AND EARLY REPERFUSION INDUCED ARRHYTHMIAS: BENEFICIAL EFFECTS OF AN EXTRACT OF CRATAEGUS OXYACANTHA, PHARM PHARMACOL LETT, 3, PP. 45-48, (1993); BRIXIUS K., FRANK K., MUNCH G., ET AL., WS 1442 (CRATAEGUS-SPEZIAL-EXTRAKT) WIRKT AM INSUFFIZIENTEN MENSCHLICHEN MYOKARD KONTRAKTIONSKRAFT-STEIGERND, HERZ-KREISLAUF, 30, PP. 28-33, (1998); MUNCH G., BRIXIUS K., FRANK K., ET AL., WS 1442 (EXTRACT OF CRATAEGUS SPECIES) INCREASES FORCE OF CONTRACTION IN HUMAN FAILING MYOCARDIUM BY INHIBITION OF THE NA<SUP>+</SUP>/K <SUP>+</SUP>-ATPASE, CIRCULATION, 96, SUPPL., (1997); HOLUBARSCH C.J., COLUCCI W.S., MEINERTZ T., ET AL., SURVIVAL AND PROGNOSIS: INVESTIGATION OF CRATAEGUS EXTRACT WS 1442 IN CONGESTIVE HEART FAILURE (SPICE) RATIONALE, STUDY DESIGN AND STUDY PROTOCOL, EUR J HEART FAIL, 2, PP. 431-437, (2000); WIEHMAYR T., ERNST E., DIE THERAPEUTISCHE WIRKSAMKEIT VON CRATAEGUS, FORTSCHR MED, 1-2, PP. 27-29, (1996); VILLARRUZ M.V., DANS A., TAN F., CHELATION THERAPY FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: COCHRANE PERIPHERAL VASCULAR DISEASES GROUP COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 4, (2002); KNUDTSON M.L., WYSE D.G., GALBRAITH P.D., ET AL., CHELATION THERAPY FOR ISCHEMIC HEART DISEASE: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, PP. 481-486, (2002); CLINICAL TRIALS: TRIAL TO ASSESS CHELATION THERAPY (TACT); BROWN B.G., ZHAO X.Q., CHAIT A., ET AL., SIMVASTATIN AND NIACIN, ANTIOXIDANT VITAMINS OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE, N ENGL J MED, 345, PP. 1583-1592, (2001)","L.K. NEWBY; DUKE CLINICAL RESEARCH INSTITUTE, DURHAM, NC 27715-7969, PO BOX 17969, UNITED STATES; EMAIL: NEWBY001@MC.DUKE.EDU","MOSBY INC.","ENGLISH","AM. HEART J.","ARTICLE","ISI","2-S2.0-2342432385","AM HEART J","DUKE UNIVERSITY MEDICAL CENTER;DUKE UNIVERSITY MEDICAL CENTER;DUKE UNIVERSITY MEDICAL CENTER","NOTREPORTED;DUKE CLINICAL RESEARCH INSTITUTE;NOTREPORTED",NA,"MILLER KL, 2004, AM HEART J","MILLER KL, 2004, AM HEART J"
"IRMAK S;DUNFORD N;MILLIGAN J","IRMAK, SIBEL (6603640781); DUNFORD, NURHAN TURGUT (6603296815); MILLIGAN, JEFF (8849248000)","POLICOSANOL CONTENTS OF BEESWAX SUGAR CANE AND WHEAT EXTRACTS",2006,"FOOD CHEMISTRY","95","6",122,"10.1016/j.foodchem.2005.01.009","OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES;OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES;OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES","POLICOSANOL (PC) IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC PRIMARY ALCOHOLS. CURRENTLY, A NUMBER OF DIETARY SUPPLEMENTS CONTAINING PC ARE COMMERCIALLY AVAILABLE IN THE US MARKET. THE MAJORITY OF THESE PRODUCTS ARE PREPARED FROM BEESWAX OR SUGAR CANE EXTRACTS. THE MAIN OBJECTIVE OF THIS STUDY WAS TO COMPARE THE PC CONTENTS AND COMPOSITIONS OF BEESWAX, SUGAR CANE AND WHEAT AS PC SOURCES. THE PC CONTENTS AND COMPOSITIONS OF SEVERAL COMMERCIAL DIETARY SUPPLEMENTS WERE ALSO ANALYZED. THE PRECIPITATE FORMED DURING THE COLD STORAGE OF COMMERCIALLY HEXANE-EXTRACTED WHEAT GERM OIL (WGO) CONTAINED THE HIGHEST TOTAL PC (628 MG/KG) AMONG THE WHEAT EXTRACTS AND MILLING PRODUCTS EXAMINED IN THIS STUDY. THE TOTAL PC CONTENTS OF WHEAT STRAW (164 MG/KG) AND SUGAR CANE PEEL (270 MG/KG) WERE OF THE SAME ORDER OF MAGNITUDE. THE TOTAL PC CONTENTS OF BROWN BEESWAX WERE ABOUT 20 AND 45 TIMES HIGHER THAN THOSE OF THE WGO-SOLIDS AND SUGAR CANE PEEL, RESPECTIVELY. COMMERCIAL DIETARY SUPPLEMENTS CONTAINED LESS TOTAL PC THAN WERE CLAIMED ON THE PRODUCT LABELS. THE PC COMPOSITIONS OF THE SAMPLES ANALYZED IN THIS STUDY VARIED SIGNIFICANTLY WITH THE SOURCE. WHEAT CAN BE A VIABLE PC SOURCE FOR FURTHER PRODUCT DEVELOPMENT OR HEALTH BENEFITS. © 2005 ELSEVIER LTD. ALL RIGHTS RESERVED.","BEESWAX; DIETARY SUPPLEMENT; POLICOSANOL; SUGAR CANE; WHEAT","SACCHARUM; TRITICUM AESTIVUM; OIL; POLICOSANOL; PROPOLIS; ARTICLE; CHEMICAL COMPOSITION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; NONHUMAN; PRECIPITATION; SOLID; STATISTICAL SIGNIFICANCE; SUGARCANE; WHEAT","OKLAHOMA WHEAT RESEARCH FOUNDATION","THIS RESEARCH PROJECT WAS FUNDED BY THE OKLAHOMA WHEAT RESEARCH FOUNDATION. THE MANUSCRIPT IS PUBLISHED WITH APPROVAL OF THE DIRECTOR, OKLAHOMA AGRICULTURAL EXPERIMENT STATION. THE AUTHORS THANK ADM MILLING, (ENID, OK) AND VITAMINS, INC., (CHICAGO, IL) FOR PROVIDING WHEAT MILLING PRODUCTS AND GERM OIL, RESPECTIVELY.","ALEMAN C.L., MAS R., HERNANDEZ C., RODIERO I., CEREJIDO E., NOA M., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAUGE DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); ARRUZAZABALA M.L., CARBAJAL D., GARCIA M.R.M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 56, (2001); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTICS RESEARCH, 57, PP. 691-699, (1996); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AMERICAN HEART JOURNAL, 143, PP. 356-365, (2002); JIMENEZ J.J., BERNAL J.L., AUMENTE S., TORIBIO L., BERNAL J.J., QUALITY ASSURANCE OF COMMERCIAL BEESWAX: II. GAS CHROMATOGRAPHY-ELECTRON IMPACT IONIZATION MASS SPECTROMETRY OF ALCOHOLS AND ACIDS, JOURNAL OF CHROMATOGRAPHY A, 1007, PP. 101-116, (2003); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ J., ORTA S.D., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLYCOSANOL, CURRENT THERAPEUTICS RESEARCH, 60, PP. 458-467, (1999); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOLOGICAL RESEARCH, 27, PP. 199-203, (1994); MENENDEZ R., FRAGA V., AMOR A.M., GONZALES R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOLOGY AND BEHAVIOUR, 67, PP. 1-7, (1999); PONS P., RODRIGUEZ R.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 14, PP. 27-33, (1994); RENDON A., RODRIGUEZ M.D., LOPEZ M., GARCIA H., DE LA CAJIGAS A., MAS R., ET AL., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS. ABSTRACTS OF THE 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY, ROME, TOXICOLOGY LETTERS, 63, (1992); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); TULLOCH A.P., HOFFMAN L.L., LEAF WAX OF TRITICUM AESTIVUM, PHYTOCHEMISTRY, 12, PP. 2217-2223, (1973); VARADY K.A., WANG Y., JONES P.J.H., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDOVASCULAR DISEASE, NUTRITON REVIEWS, 61, PP. 376-383, (2003); WALTON T.J., WAXES, CUTIN AND SUBERIN, LIPIDS, MEMBRANES AND ASPECTS OF PHOTOBIOLOGY, 4, PP. 105-157, (1990)","N.T. DUNFORD; OKLAHOMA STATE UNIVERSITY, DEPARTMENT OF PLANT AND SOIL SCIENCES, FOOD AND AGRICULTURAL PRODUCTS RESEARCH AND TECHNOLOGY CENTER, STILLWATER, OK 74078, UNITED STATES; EMAIL: NURHAN.DUNFORD@OKSTATE.EDU","","ENGLISH","FOOD CHEM.","ARTICLE","ISI","2-S2.0-25144451186","FOOD CHEM","OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY;OKLAHOMA STATE UNIVERSITY","NOTREPORTED;OKLAHOMA STATE UNIVERSITY;NOTREPORTED",NA,"IRMAK S, 2006, FOOD CHEM","IRMAK S, 2006, FOOD CHEM"
"DUMOFF A","DUMOFF, ALAN (6701790824)","WHERE THE DANGER LIES MISPLACED CONCERNS MISDRAWN STANDARDS OF INFORMED CONSENT",2003,"ALTERNATIVE AND COMPLEMENTARY THERAPIES","9","5",4,"10.1089/107628003322490724","","[NO ABSTRACT AVAILABLE]","","ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRATE; PLACEBO; POLICOSANOL; ALTERNATIVE MEDICINE; ANGINA PECTORIS; CHELATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; HUMAN; HYPERLIPIDEMIA; INFORMED CONSENT; MANIPULATIVE MEDICINE; MEDICAL PRACTICE; MYOPATHY; NEUROPATHY; PHYSICIAN; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURGEON; TREATMENT OUTCOME","","","ALTERNATIVE MEDICINE, (2002); KNUDTSON M.L., ET AL., CHELATION THERAPY FOR ISCHEMIC HEART DISEASE: A RANDOMIZED CONTROLLED TRIAL, JAMA, 287, PP. 481-486, (2002); TO ERR IS HUMAN: BUILDING A SAFER HEALTH SYSTEM, (2000); MANAGING THE RISKS FROM MEDICAL PRODUCT USE: CREATING A RISK MANAGEMENT FRAMEWORK. REPORT TO THE FDA COMMISSIONER FROM THE TASK FORCE ON RISK MANAGEMENT, (1999); LAZAROU J., POMERANZ B., INCIDENCE OF ADVERSE DRUG REACTIONS IN HOSPITALIZED PATIENTS: A META-ANALYSIS OF PROSPECTIVE STUDIES, JAMA, 279, PP. 1200-1205, (1998); FOURTH DECENNIAL INTERNATIONAL CONFERENCE ON NOSOCOMAL AND HEALTHCARE-ASSOCIATED INFECTIONS, MMWR, 49, (2000); (2003); BOODMAN S., NO END TO ERRORS: THREE YEARS AFTER A LANDMARK REPORT FOUND PERVASIVE MEDICAL MISTAKES IN AMERICAN HOSPITALS, LITTLE HAS BEEN DONE TO REDUCE DEATH AND INJURY, WASHINGTON POST, (2002); LAURETTI W.J., THE COMPARATIVE SAFETY OF CHIROPRACTIC, CURRENT CONTROVERSIES IN CHIROPRACTIC, PP. 229-244, (1997); GOLDSTEIN A., PRACTICE V. PRIVACY ON PELVIC EXAMS: MED STUDENT'S TRAINING INTRUSIVE AND NEEDS PATIENT CONSENT, ACTIVISTS SAY, WASHINGTON POST, (2003); DAVIDSON M.H., GEOHAS C.T., EFFICACY OF OVER-THE-COUNTER NUTRITIONAL SUPPLEMENTS, CURR ATHEROSCLER REP, 5, PP. 15-21, (2003); CASTANO G., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999)","","MARY ANN LIEBERT INC.","ENGLISH","ALTERN. COMPLEMENT. THER.","REVIEW","ISI","2-S2.0-0142182125","ALTERN COMPLEMENT THER",NA,"NOTREPORTED",NA,"DUMOFF A, 2003, ALTERN COMPLEMENT THER","DUMOFF A, 2003, ALTERN COMPLEMENT THER"
"CASTAÑO G;MÁS R;GÁMEZ R;FERNÁNDEZ L;ILLNAIT J","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); GÁMEZ, RAFAEL (7003605346); FERNÁNDEZ, LILIA (7202848319); ILLNAIT, JOSÉ (8631465800)","EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH INTERMITTENT CLAUDICATION A DOUBLEBLINDED PILOT COMPARATIVE STUDY",2004,"ANGIOLOGY","55","10",17,"10.1177/000331970405500403","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY DEPARTMENT, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY DEPARTMENT, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY DEPARTMENT, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY DEPARTMENT, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS. THE PRESENT STUDY WAS UNDERTAKEN TO COMPARE THE EFFECTS OF POLICOSANOL AND TICLOPIDINE IN PATIENTS WITH MODERATELY SEVERE INTERMITTENT CLAUDICATION (IC). THE STUDY HAD A 4-WEEK BASELINE STEP, FOLLOWED BY A 20-WEEK DOUBLE-BLINDED, RANDOMIZED TREATMENT PERIOD. TWENTY-EIGHT ELIGIBLE PATIENTS WERE RANDOMIZED TO POLICOSANOL 10 MG OR TICLOPIDINE 250 MG TABLETS TWICE DAILY (BID). WALKING DISTANCES IN A TREADMILL (CONSTANT SPEED 3.2 KM/HR, SLOPE 10°, TEMPERATURE 25°C) WERE ASSESSED BEFORE AND AFTER 20 WEEKS OF TREATMENT. BOTH GROUPS WERE SIMILAR AT BASELINE. COMPARED WITH BASELINE, POLICOSANOL SIGNIFICANTLY INCREASED (P < 0.01) MEAN VALUES OF INITIAL (ICD) AND ABSOLUTE (ACD) CLAUDICATION DISTANCES FROM 162.1 TO 273.2 M AND FROM 255.8 TO 401.0 M, RESPECTIVELY. TICLOPIDINE ALSO RAISED SIGNIFICANTLY (P < 0.01) ICD (166.2 TO 266.3 M) AND ACD (252.9 TO 386.4 M). COMPARISONS BETWEEN GROUPS DID NOT SHOW SIGNIFICANT DIFFERENCES. POLICOSANOL, BUT NOT TICLOPIDINE, SIGNIFICANTLY (P < 0.05), BUT MODESTLY, INCREASED THE ANKLE/ARM PRESSURE RATIO. AFTER 10 WEEKS, POLICOSANOL SIGNIFICANTLY (P < 0.001) LOWERED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C), TOTAL CHOLESTEROL (TC) (P < 0.01), AND TC/HDL-C AND RAISED (P < 0.05) HIGH-DENSITY LIPOPROTEIN- CHOLESTEROL (HDL-C). AT STUDY COMPLETION, POLICOSANOL LOWERED (P < 0.001) LDL-C (30.2%), TC (16.9%), AND TC/HDL-C (33.9%), INCREASED (P < 0.01) HDL-C (+31.7%), AND LEFT TRIGLYCERIDES UNCHANGED. TICLOPIDINE DID NOT AFFECT THE LIPID PROFILE VARIABLE. POLICOSANOL INDUCED MODEST, BUT SIGNIFICANT, REDUCTIONS (P < 0.01) OF FIBRINOGEN LEVELS COMPARED WITH BASELINE AND TICLOPIDINE. TREATMENTS WERE WELL TOLERATED AND DID NOT IMPAIR SAFETY INDICATORS. THREE TICLOPIDINE PATIENTS (21.4%) WITHDREW FROM THE TRIAL, ONLY 1 OWING TO A SERIOUS ADVERSE EXPERIENCE (AE) (UNSTABLE ANGINA). THREE OTHER TICLOPIDINE PATIENTS EXPERIENCED MILD AE (HEADACHE, DIARRHEA, AND ACIDITY). IT IS CONCLUDED THAT POLICOSANOL (10 MG BID) CAN BE AS EFFECTIVE AS TICLOPIDINE (250 MG BID) FOR IMPROVING WALKING DISTANCES OF CLAUDICANT PATIENTS, AND IT COULD BE ADVANTAGEOUS FOR THE GLOBAL RISK OF THESE INDIVIDUALS OWING TO ITS CHOLESTEROL-LOWERING EFFECTS. THIS STUDY IS, HOWEVER, JUST A PILOT COMPARISON, SO THAT FURTHER STUDIES IN LARGER SAMPLE SIZES ARE NEEDED FOR DEFINITIVE CONCLUSIONS OF THE COMPARATIVE EFFECTS OF BOTH DRUGS ON PATIENTS WITH IC.","","ADULT; AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FATTY ALCOHOLS; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME FACTORS; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; ORAL ANTIDIABETIC AGENT; POLICOSANOL; TICLOPIDINE; TRIACYLGLYCEROL; ADULT; AGED; ANKLE ARM PRESSURE RATIO; ANKLE PRESSURE; ARM; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEADACHE; HUMAN; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH HYPERACIDITY; STOMACH PH; TREADMILL; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; WALKING; WALKING DISTANCE","","","VERHAEGHE R., EPIDÉMIOLOGIE ET PRONOSTIC DE L'ARTÉRIOPATHIE OBLITÉRANTE DES MEMBRES INFÉRIEURS, DRUGS, 56, SUPPL. 3, PP. 1-10, (1998); BALKAN B., VRAY M., ESCHWEGP E., EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE, J CARDIOVASC PHARMACOL, 23, SUPPL. 3, PP. 8-16, (1994); MURRAY C.J.L., LOPEZ A.D., ALTERNATE PROJECTIONS OF MORTALITY AND DISABILITY BY CAUSE 1990-2020. GLOBAL BURDEN DISEASE STUDY, LANCET, 349, PP. 1498-1504, (1997); MARQUIS P., EVALUATION DE L'IMPACT DE L'ARTÉRIOPATHIC OBLITÉRANTE DES MEMBRES INFERIEURS SUR LA QUALITÉ DE VIE, DRUGS, 56, SUPPL. 3, PP. 25-35, (1998); FOWKES F.G.R., LENG G.C., LEE A.J., ET AL., THE ANKLE ARM INDEX AS A PREDICTOR OF CARDIOVASCULAR EVENTS AND DEATH IN THE GENERAL POPULATION, CAN J CARDIOL, 13, SUPPL. B, (1997); CRIQUI M., LANGER R.D., FRONEK A., MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, N ENGL J MED, 326, PP. 381-386, (1992); DORMANDY J.A., MURRAY G.D., THE FATE OF THE CLAUDICANT: A PROSPECTIVE STUDY OF 1969 CLAUDICANTS, EUR VASC SURG, 5, PP. 131-133, (1991); FOWKES F.G.R., HOUSLEY E., RIEMERSMA R.A., ET AL., SMOKING, LIPIDS, GLUCOSE INTOLERANCE AND BLOOD PRESSURE AS RISK FACTORS FOR PERIPHERAL ATHEROSCLEROSIS COMPARED WITH ISCHEMIC HEART DISEASE IN THE EDINBURGH ARTERY STUDY, AM J EPIDEMIOL, 135, PP. 331-340, (1992); LOWE G.D.O., FOWKES F.G.R., DAWES J., ET AL., BLOOD VISCOSITY, FIBRINOGEN AND ACTIVATION OF COAGULATION AND LEUCOCYTES IN PERIPHERAL ARTERIAL DISEASE AND THE NORMAL POPULATION IN THE EDINBURGH ARTERY STUDY, CIRCULATION, 87, PP. 1915-1920, (1993); BOWLIN S.J., MEDALIE J.H., FLOCKE S.A., ET AL., EPIDEMIOLOGY OF INTERMITTENT CLAUDICATION IN MIDDLE-AGED MEN, AM J EPIDEMIOL, 140, PP. 418-430, (1994); RIDKER P.M., STAMPFER M.J., RIFAI N., NOVEL RISK FACTORS FOR SYSTEMIC ATHEROSCLEROSIS: A COMPARISON OF C-REACTIVE PROTEIN, FIBRINOGEN, HOMOCYSTEINE, LIPOPROTEIN (A) AND STANDARD CHOLESTEROL SCREENING AS PREDICTORS OF PERIPHERAL ARTERIAL DISEASE, JAMA, 285, PP. 2481-2485, (2001); QUICK C.R.G., COTTON L.T., THE MEASURED EFFECT OF STOPPING SMOKING ON INTERMITTENT CLAUDICATION, BR J SURG, 69, (1982); REICH T., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION OF THE LOWER LIMB, ANGIOLOGY, 35, PP. 389-393, (1984); TONNESEN K.H., ALBUQUERQUE P., BAITSCH G., ET AL., DOUBLE-BLIND, CONTROLLED MULTICENTER STUDY OF INDUBOFEN VERSUS PLACEBO IN PATIENTS WITH INTERMITTENT CLAUDICATION, INT ANGIOL, 12, PP. 371-377, (1993); CLAGETT G.P., KRUPSKI W.C., ANTITHROMBOTIC THERAPY IN PERIPHERAL OCCLUSIVE DISEASE, CHEST, 108, SUPPL. 4, (1995); VERHAEGHE R., PLATELETS IN PERIPHERAL ARTERIAL DISEASE, CRIT ISCHAEMIA, 4, PP. 21-25, (1994); SALTIEL E., WARD A., TICLOPIDINE. A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN PLATELET-DEPENDENT DISEASE STATES, DRUGS, 34, PP. 222-226, (1987); SCHAFER A.I., ANTIPLATELET THERAPY, AM J MED, 101, PP. 199-209, (1996); HAINES S.T., BUSSEY H.I., THROMBOSIS AND THE PHARMACOLOGY OF ANTITHROMBOTIC AGENTS, ANN PHAMACOTHER, 29, PP. 892-905, (1995); ARCAN J.C., BLANCHARD J., BOISSEL J.P., ET AL., MULTICENTER DOUBLE-BLIND STUDY OF TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND THE PREVENTION OF ITS COMPLICATIONS, ANGIOLOGY, 39, PP. 802-809, (1988); CLOAREC M., ARCAN J.C., CAILLARD P.H., ET AL., DOUBLE-BLIND CLINICAL TRIAL OF TICLOPIDINE VERSUS PLACEBO IN PERIPHERAL ATHEROSCLEROTIC DISEASE OF THE LEGS, ANGIOLOGIE, 77, SUPPL., PP. 14-18, (1988); BALSANO F., COCHERI S., LIBRETTI A., ET AL., TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION: A 21-MONTH DOUBLE-BLIND TRIAL, J LAB CLIN MED, 114, PP. 84-88, (1989); BOISSEL T.P., PEYRIEUX J.C., DESTORS J.M., IS IT POSSIBLE TO REDUCE THE RISK OF CARDIOVASCULAR EVENTS IN SUBJECTS SUFFERING FROM INTERMITTENT CLAUDICATION OF THE LOWER LIMBS?, THROMB HAEMOST, 62, PP. 681-684, (1989); JANZON L., BERGQVIST D., BOBERG J., ET AL., PREVENTION OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH INTERMITTENT CLAUDICATION: EFFECTS OF TICLOPIDINE. RESULTS FROM STIMS, THE SWEDISH TICLOPIDINE MULTICENTER STUDY, SCAND J MED, 227, PP. 301-310, (1990); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-58, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); CASTANO G., MAS R., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLEMIA, DRUGS R&D, 3, PP. 159-172, (2002); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY, TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAM TROMB HEMOST, 5, PP. 17-20, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMB HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); MENENDEZ R., SOTOLONGO V., FRAGA V., ET AL., NIVELES PLASMÁTICOS Y EXCRECIÓN DE LA RADIACTIVIDAD TOTAL EN VOLUNTARIOS SANOS TRAS LA ADMINISTRACIÓN ORAL DE OCTACOSANOL-3H, REV CENIC CIEN BIOL, 27, PP. 32-35, (1996); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE-BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 54, PP. 25-38, (2003); CASTANO G., MAS R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); LATT W.R., NAWAZ D., REGENSTERNER J.G., ET AL., THE EVALUATION OF EXERCISE PERFORMANCE IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE, J CARDIOPULM REHABIL, 12, PP. 525-532, (1998); HEIDRICH H., ALLENBERG J., CACHOVAN M., ET AL., GUIDELINES FOR THERAPEUTIC STUDIES ON PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN FONTAINE STAGES II-IV, VASA, 21, PP. 339-343, (1992); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP): SECOND REPORT OF THE EXPERT PANEL ON DETECTION. EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II). III DRUG TREATMENT, CIRCULATION, 89, PP. 1405-1419, (1994); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF HE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, ATHEROSCLEROSIS, 110, PP. 116-121, (1994); EUR HEART J, 15, PP. 1300-1331, (1994); GOTTO A., ASSMANN G., CARMENA R., ET AL., THE INTERNATIONAL LIPID INFORMATION BUREAU (ILIB): LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE, ED. 2, (2000); TOFLER G.H., BREZINSKI D., SCHAFER A., ET AL., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH, N ENGL J MED, 316, PP. 1514-1518, (1987); PARKER T.S., MCNAMARA D.J., BROWN C., MEVALONIC ACID IN HUMAN PLASMA: RELATIONSHIP OF CONCENTRATION AND CIRCADIAN RHYTHM TO CHOLESTEROL SYNTHESIS RATES IN MAN, PROC NATL ACAD SCI USA, 79, PP. 3037-3041, (1982); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-205, (1996); SEIGLER L., WU T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT THE PREPARATIVE ULTRACENTRIFUGUE, CLIN CHEM, 18, PP. 499-502, (1972)","R. MÁS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","ANGIOLOGY","ARTICLE","ISI","2-S2.0-3142760853","ANGIOLOGY","MEDICAL SURGICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2004, ANGIOLOGY","CASTAÑO G, 2004, ANGIOLOGY"
"MARINANGELI C;KASSIS A;JAIN D;EBINE N;CUNNANE S;JONES P","MARINANGELI, CHRISTOPHER P.F. (12787919400); KASSIS, AMIRA N. (12800588300); JAIN, DEEPAK (56206778500); EBINE, NAOYUKI (6602098156); CUNNANE, STEPHEN C. (7102460295); JONES, PETER J.H. (36078426500)","COMPARISON OF COMPOSITION AND ABSORPTION OF SUGARCANE POLICOSANOLS",2007,"BRITISH JOURNAL OF NUTRITION","97","7",26,"10.1017/S0007114507336763","SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE. ANNE DE BELLEVUE, QC H9X 3V9, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE. ANNE DE BELLEVUE, QC H9X 3V9, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE. ANNE DE BELLEVUE, QC H9X 3V9, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE. ANNE DE BELLEVUE, QC H9X 3V9, CANADA;RESEARCH CENTRE ON AGING, UNIVERSITÉ DE SHERBROOKE, SHERBROOKE, QC J1H 4C4, CANADA;SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE. ANNE DE BELLEVUE, QC H9X 3V9, CANADA, RICHARDSON CENTRE FOR FUNCTIONAL FOODS AND NUTRACEUTICALS, UNIVERSITY OF MANITOBA, WINNIPEG, MB R3T 6C5, 196 INNOVATION DRIVE, CANADA","POLICOSANOLS (PC) EXIST AS VERY-LONG-CHAIN ALCOHOLS DERIVED FROM SUGARCANE CURRENTLY USED IN MANY COUNTRIES AS A CHOLESTEROL-LOWERING THERAPY. PC PURITY AND RELATIVE PERCENTAGE COMPOSITION HAVE BEEN SUGGESTED AS PRIMARY REASONS WHY THE ORIGINAL CUBAN PC (OPC) SUPPLEMENTS POSSESS LIPIDLOWERING EFFICACY. THE PURPOSE OF THE PRESENT STUDY WAS, FIRST, TO COMPARE THE RELATIVE PERCENTAGE PURITY AND PC COMPOSITION OF BOTH OPC AND ALTERNATIVE SOURCES OF PC (APC). A SECOND OBJECTIVE WAS TO FEED SYRIAN HAMSTERS A DIET CONTAINING 0·275 MG PC/G OF EITHER THE OPC OR AN APC PRODUCT (APC1) AND COMPARE SUBSEQUENT TISSUE, PLASMA AND FAECAL PC LEVELS. FIVE ANIMALS FROM THE APC1 DIETARY GROUP RECEIVED A DIET CONTAINING TEN TIMES THE ORIGINAL AMOUNT OF PC. RESULTS INDICATE THAT THE APC FORMULATIONS HAVE A COMPOSITION THAT IS HIGHLY CONSISTENT WITH THE OPC SUPPLEMENT, WITH OCTACOSANOL BEING PRESENT WITHIN THE CITED 60-70% RANGE. PC WERE UNDETECTABLE IN THE SMALL INTESTINE, LIVER, ADIPOSE OR PLASMA IN ANIMALS FED EITHER SOURCE. HAMSTERS FED OPC EXCRETED OCTACOSANOL (C28) MORE RAPIDLY (P<0·05) THAN HAMSTERS RECEIVING APC1. IF THE CHOLESTEROL-LOWERING EFFICACY OF PC MIXTURES IS DEPENDENT ON THEIR PURITY AND COMPOSITION, THEN SUGARCANE-DERIVED APC PRODUCTS SHOULD POSSESS SIMILAR THERAPEUTIC PROPERTIES AS THE OPC SUPPLEMENT. © THE AUTHORS 2007.","ABSORPTION; CHOLESTEROL; COMPOSITION; POLICOSANOLS; SUGARCANE","ABSORPTION; ANIMALS; ANTICHOLESTEREMIC AGENTS; CRICETINAE; CUBA; DIETARY SUPPLEMENTS; FATTY ALCOHOLS; FECES; MESOCRICETUS; SACCHARUM; TISSUE DISTRIBUTION; ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS; LESSTANOL; OCTACOSANOL; POLICOSANOL; UNCLASSIFIED DRUG; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG FORMULATION; DRUG PURITY; DRUG TISSUE LEVEL; FECES ANALYSIS; NONHUMAN; SUGARCANE; SYRIAN HAMSTER","","","ALCOCER L., FERNANDEZ L., CAMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 176-181, (1995); MONOGRAPH. POLICOSANOL, ALTERN MED REV, 9, PP. 312-317, (2004); ARRUZAZABALA M.L., CARBEJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); BERNARD A., CARLIER H., ABSORPTION AND INTESTINAL CATABOLISM OF FATTY ACIDS IN THE RAT: EFFECT OF CHAIN LENGTH AND UNSATURATION, EXP PHYSIOL, 76, PP. 445-455, (1991); BERTHOLD H.K., UNVERDORBEN S., DEGENHARDT R., BULITTA M., GOUNI-BERTHOLD I., EFFECT OF POLICOSANOL ON LIPID LEVELS AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL, JAMA, 295, PP. 2262-2269, (2006); CASTANO G., FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL VERSUS OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 22, PP. 55-66, (2002); CASTANO G., MAS R., FERNANDEZ J., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL. 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LEZCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS AGING, 20, PP. 153-163, (2003); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON-INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); DAVIS P.J., POZNANSKY M.J., MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE BY CHANGES IN MICROSOMAL CHOLESTEROL CONTENT OR PHOSPHOLIPID COMPOSITION, PROC NATL ACAD SCI USA, 84, PP. 118-121, (1987); FOLCH J., LEES M., SLOANE STANLEY G.H., A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES, J BIOL CHEM, 226, PP. 497-509, (1957); GAMEZ R., MENDOZA S., MAS R., NOA M., ARRUZAZABALA L., CARBAJAL D., CASTANO G., GOICOCHEA E., MESA M., MENDOZA N., COMPARISON OF THE CHOLESTEROL-LOWERING EFFECTS AND TOXICITY OF D-003 AND LOVASTATIN IN NORMOCHOLESTEROLAEMIC RABBITS, DRUGS R D, 4, PP. 219-229, (2003); GARCIA-PELAYO M.C., GARCIA-PEREGRIN E., MARTINEZ-CAYUELA M., MODIFICATION OF PHOSPHOLIPIDS FATTY ACID COMPOSITION IN REUBER H35 HEPATOMA CELLS: EFFECT ON HMG-COA REDUCTASE ACTIVITY, J CELL BIOCHEM, 90, PP. 586-591, (2003); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); GREYLING A., DE WITT C., OOSTHUIZEN W., JERLING J.C., EFFECTS OF A POLICOSANOL SUPPLEMENT ON SERUM LIPID CONCENTRATIONS IN HYPERCHOLESTEROLAEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIC SUBJECTS, BR J NUTR, 95, PP. 968-975, (2006); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED (MAYWOOD), 229, PP. 215-226, (2004); HODGE V.J., GOULD S.J., SUBRAMANI S., MOSER H.W., KRISANS S.K., NORMAL CHOLESTEROL SYNTHESIS IN HUMAN CELLS REQUIRES FUNCTIONAL PEROXISOMES, BIOCHEM BIOPHYS RES COMMUN, 181, PP. 537-541, (1991); JAKOBS B.S., WANDERS R.J., CONCLUSIVE EVIDENCE THAT VERY-LONG-CHAIN FATTY ACIDS ARE OXIDIZED EXCLUSIVELY IN PEROXISOMES IN HUMAN SKIN FIBROBLASTS, BIOCHEM BIOPHYS RES COMMUN, 178, PP. 842-847, (1991); JIMENEZ J.J., BERNAL J.L., AUMENTE S., TORIBIO L., BERNAL JR J., QUALITY ASSURANCE OF COMMERCIAL BEESWAX II. GAS CHROMATOGRAPHY-ELECTRON IMPACT IONIZATION MASS SPECTROMETRY OF ALCOHOLS AND ACIDS, J CHROMATOGR A, 1007, PP. 101-116, (2003); JONES P.J., PENCHARZ P.B., CLANDININ M.T., ABSORPTION OF <SUP>13</SUP>C-LABELED STEARIC, OLEIC, AND LINOLEIC ACIDS IN HUMANS: APPLICATION TO BREATH TESTS, J LAB CLIN MED, 105, PP. 647-652, (1985); JONES P.J., PENCHARZ P.B., CLANDININ M.T., WHOLE BODY OXIDATION OF DIETARY FATTY ACIDS: IMPLICATIONS FOR ENERGY UTILIZATION, AM J CLIN NUTR, 42, PP. 769-777, (1985); JONKERS I.J., LEDEBOER M., STEENS J., SMELT A.H., MASCLEE A.A., EFFECTS OF VERY LONG CHAIN VERSUS LONG CHAIN TRIGLYCERIDES ON GASTROINTESTINAL MOTILITY AND HORMONE RELEASE IN HUMANS, DIG DIS SCI, 45, PP. 1719-1726, (2000); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); KRIS-ETHERTON P.M., DIETSCHY J., DESIGN CRITERIA FOR STUDIES EXAMINING INDIVIDUAL FATTY ACID EFFECTS ON CARDIOVASCULAR DISEASE RISK FACTORS: HUMAN AND ANIMAL STUDIES, AM J CLIN NUTR, 65, (1997); LEE T., CHARACTERIZATION OF FATTY ALCOHOL: NAD<SUP>+</SUP> OXIDOREDUCTASE FROM RAT LIVER, J BIOL CHEM, 254, PP. 2892-2896, (1979); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., MEIJER G.W., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); MCLAUGHLIN J., GRAZIA LUCA M., JONES M.N., D'AMATO M., DOCKRAY G.J., THOMPSON D.G., FATTY ACID CHAIN LENGTH DETERMINES CHOLECYSTOKININ SECRETION AND EFFECT ON HUMAN GASTRIC MOTILITY, GASTROENTEROLOGY, 116, PP. 46-53, (1999); MANDEL H., GETSIS M., ROSENBLAT M., BERANT M., AVIRAM M., REDUCED CELLULAR CHOLESTEROL CONTENT IN PEROXISOME-DEFICIENT FIBROBLASTS IS ASSOCIATED WITH IMPAIRED UPTAKE OF THE PATIENT'S LOW DENSITY LIPOPROTEIN AND WITH REDUCED CHOLESTEROL SYNTHESIS, J LIPID RES, 36, PP. 1385-1391, (1995); MANNAERTS G.P., VAN VELDHOVEN P.P., CASTEELS M., PEROXISOMAL LIPID DEGRADATION VIA Β- AND Α-OXIDATION IN MAMMALS, CELL BIOCHEM BIOPHYS, 32, PP. 73-87, (2000); MAS R., POLICOSANOL. HYPOLIPIDEMIC, ANTIOXIDANT, TREATMENT OF ATHEROSCLEROSIS, DRUGS FUTURE, 25, PP. 569-586, (2000); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA A.P., MESA M., DE ARMAS M., COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES CLIN EXP, 62, PP. 209-220, (2001); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., GONZALEZ R.M., GONZALEZ P.C., ALFONSO J.L., MAS R., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., MARRERO D., MAS R., FERNANDEZ I., GONZALEZ L., GONZALEZ R.M., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH MED RES, 36, PP. 113-119, (2005); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); MURPHY K.J., SAINT D.A., HOWE P.R., LACK OF EFFECT OF SUGAR CANE AND SUNFLOWER SEED POLICOSANOLS ON PLASMA CHOLESTEROL IN RABBITS, ASIA PAC J CLIN NUTR, 13, (2004); CH N., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005); OLIVIER L.M., KRISANS S.K., PEROXISOMAL PROTEIN TARGETING AND IDENTIFICATION OF PEROXISOMAL TARGETING SIGNALS IN CHOLESTEROL BIOSYNTHETIC ENZYMES, BIOCHIM BIOPHYS ACTA, 1529, PP. 89-102, (2000); ORTENSI G., GLADSTEIN J., VALLI H., TESTONE P., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-301, (1997); PONS P., ILLNAIT J., MAS R., RODRIGUEZ M., ALEMAN C., FERNANDEZ J.C., FERNANDEZ L., MARTIN M., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 26-35, (1997); REINER Z., TEDESCHI-REINER E., ROMIC Z., EFFECTS OF RICE POLICOSANOL ON SERUM LIPOPROTEINS, HOMOCYSTEINE, FIBRINGOGEN AND C-REACTIVE PROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS, CLIN DRUG INVEST, 25, PP. 701-707, (2005); RIZZO W.B., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); SALLEE V.L., PERMEATION OF LONG-CHAIN FATTY ACIDS AND ALCOHOLS IN RAT INTESTINE, AM J PHYSIOL, 236, (1979); SALLEE V.L., DIETSCHY J.M., DETERMINANTS OF INTESTINAL MUCOSAL UPTAKE OF SHORT- AND MEDIUM-CHAIN FATTY ACIDS AND ALCOHOLS, J LIPID RES, 14, PP. 475-484, (1973); SCOTT R.P.W., PERRY J.A., INTRODUCTION TO ANALYTICAL GAS CHROMATOGRAPHY, (1998); SINGH D., LI L., PORTER T.D., POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY ACTIVATION OF AMP-KINASE, J PHARMACOL EXP THER, 318, PP. 1020-1026, (2006); WANDERS R.J., VAN GRUNSVEN E.G., JANSEN G.A., LIPID METABOLISM IN PEROXISOMES: ENZYMOLOGY, FUNCTIONS AND DYSFUNCTIONS OF THE FATTY ACID Α- AND Β-OXIDATION SYSTEMS IN HUMANS, BIOCHEM SOC TRANS, 28, PP. 141-149, (2000); WANDERS R.J., VREKEN P., FERDINANDUSSE S., JANSEN G.A., WATERHAM H.R., VAN ROERMUND C.W., VAN GRUNSVEN E.G., PEROXISOMAL FATTY ACID Α- AND Β-OXIDATION IN HUMANS: ENZYMOLOGY, PEROXISOMAL METABOLITE TRANSPORTERS AND PEROXISOMAL DISEASES, BIOCHEM SOC TRANS, 29, PP. 250-267, (2001); WANG Y., EBINE N., JIA X., JONES P.J., FAIROW C., JAEGER R., VERY LONG CHAIN FATTY ACIDS (POLICOSANOLS) AND PHYTOSTEROLS AFFECT PLASMA LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, METABOLISM, 54, PP. 508-514, (2005); WANG Y.W., JONES P.J., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003); WHITCOMB R.W., LINEHAN W.M., KNAZEK R.A., EFFECTS OF LONG-CHAIN, SATURATED FATTY ACIDS ON MEMBRANE MICROVISCOSITY AND ADRENOCORTICOTROPIN RESPONSIVENESS OF HUMAN ADRENOCORTICAL CELLS IN VITRO, J CLIN INVEST, 81, PP. 185-188, (1988); WHITNEY E.N., ROLFES S.R., UNDERSTANDING NUTRITION, PP. 64-91, (2002)","P.J.H. JONES; SCHOOL OF DIETETICS AND HUMAN NUTRITION, MCGILL UNIVERSITY, STE. ANNE DE BELLEVUE, QC H9X 3V9, CANADA; EMAIL: PETER_JONES@UMANITOBA.CA","","ENGLISH","BR. J. NUTR.","ARTICLE","ISI","2-S2.0-34247646976","BR J NUTR","MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY;MCGILL UNIVERSITY;UNIVERSITÉ DE SHERBROOKE;MCGILL UNIVERSITY","NOTREPORTED;MCGILL UNIVERSITY;NOTREPORTED",NA,"MARINANGELI CPF, 2007, BR J NUTR","MARINANGELI CPF, 2007, BR J NUTR"
"POTERA C","POTERA, CAROL (7006785474)","CUBAN BIOTECH ADVANCES IN A RANGE OF DIVERSE AREAS",2004,"GENETIC ENGINEERING NEWS","24","",1,"","","CUBA SEEKS TO CHANGE ITS REPUTATION FROM A HAVEN FOR CIGAR AND SUGAR CANE PRODUCTION TO HIGH-TECHNOLOGY BIORESEARCH.","","ARUNDINARIA; HELICOBACTER; HELICOBACTER PYLORI; HUMAN IMMUNODEFICIENCY VIRUS; PSEUDOMONAS; SACCHARUM; SACCHARUM HYBRID CULTIVAR; ANTILIPEMIC AGENT; CANCER VACCINE; CHOLERA VACCINE; DENGUE VACCINE; EPIDERMAL GROWTH FACTOR; HEBERBIOVAC HB; HELICOBACTER PYLORI VACCINE; HEPATITIS A VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; INDUSTRIAL ENZYME; MENINGITIS VACCINE; MONOCLONAL ANTIBODY; PERTUSSIS VACCINE; POLICOSANOL; PSEUDOMONAS VACCINE; RECOMBINANT ENZYME; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT INTERFERON; RECOMBINANT PROTEIN; SALMONELLOSIS VACCINE; STREPTOKINASE; TETANUS TOXOID; TYPHOID VACCINE; VAX SPIRAL; VAX TET; VAX TIVY; ARTICLE; BIOTECHNOLOGY; CUBA; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; SUGARCANE; VACCINE PRODUCTION","","","","","","ENGLISH","GENET. ENG. NEWS","ARTICLE","ISI","2-S2.0-3042835546","GENET ENG NEWS",NA,"NOTREPORTED",NA,"POTERA C, 2004, GENET ENG NEWS","POTERA C, 2004, GENET ENG NEWS"
"NIES L;CYMBALA A;KASTEN S;LAMPRECHT D;OLSON K","NIES, LESLIE K. (15063106100); CYMBALA, ALICIA A. (15062554700); KASTEN, SHEILA L. (22935009600); LAMPRECHT, DONALD G. (15063106000); OLSON, KARI L. (56421421800)","COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR THE MANAGEMENT OF DYSLIPIDEMIA",2006,"ANNALS OF PHARMACOTHERAPY","40","8",24,"10.1345/aph.1H040","DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO, UNITED STATES, SCHOOL OF PHARMACY, UNIVERSITY OF COLORADO, DENVER AND HEALTH SCIENCES CENTER, UNITED STATES;DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO, UNITED STATES;DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO, UNITED STATES, SCHOOL OF PHARMACY, UNIVERSITY OF COLORADO, DENVER AND HEALTH SCIENCES CENTER, UNITED STATES;DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO, UNITED STATES, SCHOOL OF PHARMACY, UNIVERSITY OF COLORADO, DENVER AND HEALTH SCIENCES CENTER, UNITED STATES;DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO, UNITED STATES, SCHOOL OF PHARMACY, UNIVERSITY OF COLORADO, DENVER AND HEALTH SCIENCES CENTER, UNITED STATES, DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO 80011-9045, 16601 E. CENTRETECH PARKWAY, UNITED STATES","OBJECTIVE: TO REVIEW THE LITERATURE ON SELECT ALTERNATIVE THERAPIES FOR THE MANAGEMENT OF DYSLIPIDEMIA. DATA SOURCES: SEARCHES OF MEDLINE AND PUBMED (1965-MARCH 2006) WERE CONDUCTED USING THE KEY TERMS OMEGA-3-FATTY ACIDS, POLICOSANOL, PLANT STANOLS AND STEROLS, FLAXSEED, RED YEAST RICE, GUGGULIPID, GARLIC, FIBER, ALMONDS, AND CHOLESTEROL AND/OR LIPIDS. STUDY SELECTION AND DATA EXTRACTION: META-ANALYSES, PUBLISHED IN ENGLISH AND INVOLVING ADULTS, THAT INCORPORATED RANDOMIZED, CONTROLLED TRIALS ON ALTERNATIVE THERAPIES FOR DYSLIPIDEMIA WERE REVIEWED. ADDITIONALLY, TRIALS PUBLISHED SUBSEQUENT TO THE META-ANALYSES WERE REVIEWED. ARTICLES DEEMED RELEVANT WERE INCLUDED IN THIS REVIEW. DATA SYNTHESIS: OF THE AFOREMENTIONED ALTERNATIVE THERAPIES, RANDOMIZED CONTROLLED TRIALS WERE FOUND FOR OMEGA-3-FATTY ACIDS, POLICOSANOL, PLANT STANOLS AND STEROLS, FLAXSEED, RED YEAST RICE, GUGGULIPID, GARLIC, FIBER, ALMONDS, AND SOY. STUDIES FOR EACH OF THESE AGENTS REPORT VARYING DEGREES OF LIPID REDUCTION. BASED ON PUBLISHED DATA, EFFECTIVE THERAPEUTIC OPTIONS FOR LIPID-LOWERING INCLUDE INTAKE OF FIBER, INTAKE OF PLANT STANOLS/STEROLS, REPLACEMENT OF ANIMAL PROTEIN WITH SOY PROTEIN, AND SUBSTITUTION OF FOODS HIGH IN SATURATED FAT WITH THOSE WITH MONOUNSATURATED FATTY ACIDS (EG, DRY ROASTED ALMONDS). ADDING OMEGA-3-FATTY ACIDS IS EFFECTIVE FOR REDUCING TRIGLYCERIDES IN PATIENTS WITH HYPERTRIGLYCERIDEMIA. WELL-DESIGNED STUDIES WITH LONG-TERM OUTCOME DATA ARE NECESSARY TO FURTHER DEFINE THE ROLE FOR GUGGUL, RED YEAST RICE, POLICOSANOL, GARLIC, AND FLAXSEED IN THE MANAGEMENT OF DYSLIPIDEMIA. CONCLUSIONS: ALTERNATIVE THERAPEUTIC APPROACHES WITH COMPLEMENTARY THERAPIES ARE BECOMING INCREASINGLY POPULAR AMONG PATIENTS. IT IS IMPORTANT FOR HEALTHCARE PROVIDERS TO BE FAMILIAR WITH THE SAFETY AND EFFICACY OF THESE AGENTS TO FACILITATE OPTIMAL OUTCOMES FOR PATIENTS WITH DYSLIPIDEMIA.","ALTERNATIVE THERAPY; DYSLIPIDEMIA; NATURAL MEDICINE","COMPLEMENTARY THERAPIES; DYSLIPIDEMIAS; HUMANS; META-ANALYSIS; PHYTOSTEROLS; PHYTOTHERAPY; ALPHA CAROTENE; BETA CAROTENE; EZETIMIBE; GARLIC EXTRACT; GUGGULSTERONE; ISPAGULA; MONACOLIN J; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; POLICOSANOL; SIMVASTATIN; SOYBEAN PROTEIN; STANOL ESTER; STEROL DERIVATIVE; TRIACYLGLYCEROL; ABDOMINAL PAIN; ALMOND; ALTERNATIVE MEDICINE; BLOATING; BULIMIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSLIPIDEMIA; DYSPEPSIA; FLATULENCE; GARLIC; GASTROINTESTINAL SYMPTOM; HALITOSIS; HEARTBURN; HUMAN; HYPERTRIGLYCERIDEMIA; INSOMNIA; LINSEED; MEDLINE; META ANALYSIS; NAUSEA; ODOR; PLANT FIBER; POLYURIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RICE; SIDE EFFECT; SOYBEAN; SYSTEMATIC REVIEW; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION","","","EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); BRUNO J.J., ELLIS J.J., HERBAL USE AMONG US ELDERLY: 2002 NATIONAL HEALTH INTERVIEW SURVEY, ANN PHARMACOTHER, 39, PP. 643-648, (2005); KELLY J.P., KAUFMAN D.W., KELLEY K., ROSENBERG L., ANDERSON T.E., MITCHELL A.A., RECENT TRENDS IN USE OF HERBAL AND OTHER NATURAL TRENDS, ARCH INTERN MED, 165, PP. 281-286, (2005); PARK Y., HARRIS W.S., OMEGA-3 FATTY ACID SUPPLEMENTATION ACCELERATES CHYLOMICRON TRIGLYCERIDE CLEARANCE, J LIPID RES, 44, PP. 455-463, (2003); WEBER P., RAEDERSTORFF D., TRIGLYCERIDE-LOWERING EFFECT OF OMEGA-3 LC-POLYUNSATURATED FATTY ACIDS - A REVIEW, NUTR METAB CARDIOVASC DIS, 10, PP. 28-37, (2000); HARRIS W.S., GINSBERG H.N., ARUNAKUL N., ET AL., SAFETY AND EFFICACY OF OMACORIN SEVERE HYPERTRIGLYCERIDEMIA, J CARDIOVASC RISK, 4, PP. 385-391, (1997); HARRIS W.S., N-3 FATTY ACIDS AND SERUM LIPOPROTEIN: HUMAN STUDIES, AM J CLIN NUTR, 65, SUPPL., (1997); KRIS-ETHERTON P.M., HARRIS W.S., APPEL L.J., FISH CONSUMPTION, FISH OIL, OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE, CIRCULATION, 106, PP. 2747-2757, (2002); CONTACOS C., BARTER P.J., SULLIVAN D.R., EFFECT OF PRAVASTATIN AND OMEGA-3 FATTY ACIDS ON PLASMA LIPIDS AND LIPOPROTEINS IN PATIENTS WITH COMBINED HYPERLIPIDEMIA, ARTERIOSCLER THROMB, 13, PP. 1755-1762, (1993); DURRINGTON P.N., BHATNAGAR D., MACKNESS M.I., ET AL., AN OMEGA-3 POLYUN-SATURATED FATTY ACID CONCENTRATE ADMINISTERED FOR ONE YEAR DECREASED TRIGLYCERIDES IN SIMVASTATIN TREATED PATIENTS WITH CORONARY HEART DISEASE AND PERSISTING HYPERTRIGLYCERIDAEMIA, HEART, 85, PP. 544-548, (2001); NORDOY A., BONAA K.H., NILSEN H., BERGE R.K., HANSEN J.B., INGEBRETSEN O.C., EFFECTS OF SIMVASTATIN AND OMEGA-3 FATTY ACIDS ON PLASMA LIPOPROTEINS AND LIPID PEROXIDATION IN PATIENTS WITH COMBINED HYPERLIPIDAEMIA, J INTERN MED, 243, PP. 163-170, (1998); DAVIDSON M.H., MAKI K.C., KALKOWSKI J., SCHAEFER E.J., TORRI S.A., DRENNAN K.M., EFFECTS OF DOCOSAHEXAENOIC ACID ON SERUM LIPOPROTEINS IN PATIENTS WITH COMBINED HYPERLIPIDEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, J AM COLL NUTR, 16, PP. 236-243, (1997); CONNOR W.E., PRINCE M.J., ULLMANN D., ET AL., THE HYPOTRIGLYCERIDEMIC EFFECT OFFISH OIL IN ADULT-ONSET DIABETES WITHOUT ADVERSE GLUCOSE CONTROL, ANN N Y ACAD SCI, 683, PP. 337-340, (1993); FRIEDBERG C.E., JANSSEN M.J., HEINE R.J., GROBBEE D.E., FISH OIL AND GLYCEMIC CONTROL IN DIABETES: A META-ANALYSIS, DIABETES CARE, 21, PP. 494-500, (1998); ERITSLAND J., SAFETY CONSIDERATIONS OF POLYUNSATURATED FATTY ACIDS, AM J CLIN NUTR, 71, SUPPL., (2000); LAW M., PLANT STEROL AND STANOL MARGARINES AND HEALTH, BMJ, 320, PP. 861-864, (2000); CHEN J.T., WESLEY R., SHAMBUREK R.D., PUCINO F., CSAKO G., META-ANALYSIS OF NATURAL THERAPIES FOR HYPERLIPIDEMIA: PLANT STEROLS AND STANOLS VERSUS POLICOSANOL, PHARMACOTHERAPY, 25, PP. 171-183, (2005); DEVARAJ S., JIALAL I., VEGA-LOPEZ S., PLANT STEROL-FORTIFIED ORANGE JUICE EFFECTIVELY LOWERS CHOLESTEROL LEVELS IN MILDLY HYPERCHOLESTEROLEMIC HEALTHY INDIVIDUALS, ARTERIOSCLER THROMB VASC BIOL, 24, (2004); LAU V.W., JOURNOUD M., JONES P.J., PLANT STEROLS ARE EFFICACIOUS IN LOWERING PLASMA LDL AND NON-HDL CHOLESTEROL IN HYPERCHOLESTEROLEMIC TYPE 2 DIABETIC AND NONDIABETIC PERSONS, AM J CLIN NUTR, 81, PP. 1351-1358, (2005); BLAIR S.N., CAPUZZI D.M., GOTTLIEB S.O., NGUYEN T., MORGAN J.M., CATER N.B., INCREMENTAL REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH THE ADDITION OF PLANT STANOL ESTER-CONTAINING SPREAD TO STATIN THERAPY, AM J CARDIOL, 86, PP. 46-52, (2000); HALLIKAINEN M.A., SARKKINEN E.S., UUSITUPA M.I., PLANT STANOL ESTERS AFFECT SERUM CHOLESTEROL CONCENTRATIONS OF HYPERCHOLESTEROLEMIC MEN AND WOMEN IN A DOSE-DEPENDENT MANNER, J NUTR, 130, PP. 767-776, (2000); PLAT J., VAN ONSELEN E.N., VAN HEUGTEN M.M., MENSINK R.P., EFFECTS ON SERUM LIPIDS, LIPOPROTEINS AND FAT SOLUBLE ANTIOXIDANT CONCENTRATIONS OF CONSUMPTION FREQUENCY OF MARGARINES AND SHORTENINGS ENRICHED WITH PLANT STANOL ESTERS, EUR J CLIN NUTR, 54, PP. 671-677, (2000); SUDHOP T., LUTJOHANN D., KODAL A., ET AL., INHIBITION OF INTESTINAL CHOLESTEROL ABSORPTION BY EZETIMIBE IN HUMANS, CIRCULATION, 106, PP. 1943-1948, (2002); JAKULJ L., TRIP M.D., SUDHOP T., VON BERGMANN K., KASTELEIN J.J., VISSERS M.N., INHIBITION OF CHOLESTEROL ABSORPTION BY THE COMBINATION OF DIETARY PLANT STEROLS AND EZETIMIBE: EFFECTS ON PLASMA LIPID LEVELS, J LIPID RES, 46, PP. 2696-2698, (2005); FERNANDEZ M.L., SOLUBLE FIBER AND NONDIGESTIBLE CARBOHYDRATE EFFECTS ON PLASMA LIPIDS AND CARDIOVASCULAR RISK, CURR OPIN LIPIDOL, 12, PP. 35-40, (2001); BROWN L., ROSNER B., WILLETT W.W., SACKS F.M., CHOLESTEROL-LOWERING EFFECTS OF DIETARY FIBER: A META-ANALYSIS, AM J CLIN NUTR, 69, PP. 30-42, (1999); ROMERO A.L., ROMERO J.E., GALAVIZ S., FERNANDEZ M.L., COOKIES ENRICHED WITH PSYLLIUM OR OAT BRAN LOWER PLASMA LDL CHOLESTEROL IN NORMAL AND HYPERCHOLESTEROLEMIC MEN FROM NORTHERN MEXICO, J AM COLL NUTR, 17, PP. 601-608, (1998); BEHALL K.M., SCHOLFIELD D.J., HALLFRISCH J., LIPIDS SIGNIFICANTLY REDUCED BY DIETS CONTAINING BARLEY IN MODERATELY HYPERCHOLESTEROLEMIC MEN, J AM COLL NUTR, 23, PP. 55-62, (2004); ANDERSON J.W., ALLGOOD L.D., LAWRENCE A., ET AL., CHOLESTEROL-LOWERING EFFECTS OF PSYLLIUM INTAKE ADJUNCTIVE TO DIET THERAPY IN MEN AND WOMEN WITH HYPERCHOLESTEROLEMIA: META-ANALYSIS OF 8 CONTROLLED TRIALS, AM J CLIN NUTR, 71, PP. 472-479, (2000); MOREYRA A.E., WILSON A.C., KORAYM A., EFFECT OF COMBINING PSYLLIUM FIBER WITH SIMVASTATIN IN LOWERING CHOLESTEROL, ARCH INTERN MED, 165, PP. 1161-1166, (2005); ERDMAN J.W., SOY PROTEIN AND CARDIOVASCULAR DISEASE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE NUTRITION COMMITTEE OF THE AHA, CIRCULATION, 102, PP. 2555-2559, (2000); ANDERSON J.W., JOHNSTONE B.M., COOK-NEWELL M.E., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN INTAKE ON SERUM LIPIDS, N ENGL J MED, 333, PP. 276-282, (1995); ZHAN S., HO S.C., META-ANALYSIS OF THE EFFECTS OF SOY PROTEIN CONTAINING ISOFLAVONES ON THE LIPID PROFILE, AM J CLIN NUTR, 81, PP. 397-408, (2005); ZHUO X., MELBY M.K., WATANABE S., SOY ISOFLAVONE INTAKE LOWERS SERUM LDL CHOLESTEROL: A META-ANALYSIS OF 8 RANDOMIZED CONTROLLED TRIALS IN HUMANS, J NUTR, 134, PP. 2395-2400, (2004); WEGGEMANS R.M., TRAUTWEIN E.A., RELATION BETWEEN SOY-ASSOCIATED ISOFLAVONES AND LDL AND HDL CHOLESTEROL CONCENTRATIONS IN HUMANS: A META-ANALYSIS, EUR J CLIN NUTR, 57, PP. 940-946, (2003); HOIE L., GRAUBAUM H., HARDE A., GRUENWALD J., WERNECKE K., LIPID-LOWERING EFFECT OF 2 DOSAGES OF A SOY PROTEIN SUPPLEMENT IN HYPERCHOLESTEROLEMIA, ADV THER, 22, PP. 175-186, (2005); WEST G.S., HILPERT K.F., JUTURU V., ET AL., EFFECTS OF INCLUDING SOY PROTEIN IN A BLOOD CHOLESTEROL-LOWERING DIET ON MARKERS OF CARDIAC RISK IN MEN AND IN POSTMENOPAUSAL WOMEN WITH AND WITHOUT HORMONE REPLACEMENT, J WOMENS HEALTH, 14, PP. 253-262, (2005); WANG Y., JONES P.J.H., AUSMAN L.M., LICHTENSTEIN A.H., SOY PROTEIN REDUCES TRIGLYCERIDE LEVELS AND TRIGLYCERIDE FATTY ACID FRACTIONAL SYNTHESIS RATE IN HYPERCHOLESTEROLEMIC SUBJECTS, ATHEROSCLEROSIS, 173, PP. 269-275, (2004); HERMANSEN K., HANSEN B., JACOBSEN R., ET AL., EFFECTS OF SOY SUPPLEMENTATION ON BLOOD LIPIDS AND ARTERIAL FUNCTION IN HYPERCHOLESTEROLEMIC SUBJECTS, EUR J CLIN NUTR, 59, PP. 843-850, (2005); BLUM A., LANG N., VIGDER F., ET AL., EFFECTS OF SOY PROTEIN ON ENDOTHELIUM-DEPENDENT VASODILATATION AND LIPID PROFILE IN POSTMENOPAUSAL WOMEN WITH MILD HYPERCHOLESTEROLEMIA, CLIN INVEST MED, 26, PP. 20-26, (2003); YUNSHENG M., CHIRIBOGA D., OLENDZKI B.C., NICOLOSI R., MERRIAM P.A., OCKENE I.S., EFFECT OF SOY PROTEIN CONTAINING ISOFLAVONES ON BLOOD LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS: A RANDOMIZED CONTROLLED TRIAL, J AM COLL NUTR, 24, PP. 275-285, (2005); TEEDE J.H., DALAIS F.S., KOTSOPOULOS D., LIANG Y.L., DAVIS S., MCGRATH B.P., DIETARY SOY HAS BOTH BENEFICIAL AND POTENTIALLY ADVERSE CARDIOVASCULAR EFFECTS: A PLACEBO-CONTROLLED STUDY IN MEN AND POSTMENOPAUSAL WOMEN, J CLIN ENDOCRINOL METAB, 86, PP. 3053-3060, (2001); KREIJKAMP-KASPERS S., KOK L., GROBBEE D.E., ET AL., EFFECT OF SOY PROTEIN CONTAINING ISOFLAVONES ON COGNITIVE FUNCTION, BONE MINERAL DENSITY, AND PLASMA LIPIDS IN POSTMENOPAUSAL WOMEN, JAMA, 292, PP. 65-73, (2004); JELLIN J.M., GREGORY B.J., BATZ F., ET AL., PHARMACIST'S LETTER/PRESCRIBER'S LETTER. NATURAL MEDICINE'S COMPREHENSIVE DATABASE; FDA APPROVES NEW HEALTH CLAIM FOR SOY PROTEIN AND CORONARY HEART DISEASE, (1999); YEH Y.Y., LIU L., CHOLESTEROL-LOWERING EFFECT OF GARLIC EXTRACTS AND ORGANOSULFUR COMPOUNDS: HUMAN AND ANIMAL STUDIES, J NUTR, 3, (2001); STEVINSON C., PITTLER M.H., ERNST E., GARLIC FOR TREATING HYPERCHOLESTEROLEMIA, ANN INTERN MED, 133, PP. 420-429, (2000); ACKERMANN R., MULROW C.D., RAMIREZ G., GARDNER C.D., MARBIDONI L., LAWRENCE V.A., GARLIC SHOWS PROMISE FOR IMPROVING SOME CARDIOVASCULAR RISK FACTORS, ARCH INTERN MED, 161, PP. 813-824, (2001); PELEG A., HERSHCOVICI T., LIPA R., ANBAR R., REDLER M., BEIGEL Y., EFFECT OF GARLIC ON LIPID PROFILE AND PSYCHOPATHOLOGIC PARAMETERS IN PEOPLE WITH MILD TO MODERATE HYPERCHOLESTEROLEMIA, ISR MED ASSOC J, 9, PP. 637-640, (2003); SATITVIPAWEE P., RAWDAREE P., INDRABHAKTI S., RATANASUWAN T., GETN-GERN P., VIWATWONGKASEM C., NO EFFECT OF GARLIC EXTRACT SUPPLEMENT ON SERUM LIPID LEVELS IN HYPERCHOLESTEROLEMIC SUBJECTS, J MED ASSOC THAI, 86, PP. 750-757, (2003); KANNAR D., WATTANAPENPAIBOON N., SAVIGE G.S., WAHLQVIST M.L., HYPOCHOLESTEROLEMIC EFFECT OF AN ENTERIC-COATED GARLIC SUPPLEMENT, J AM COLL NUTR, 20, PP. 225-231, (2001); GARDNER C.D., CHATTERJEE L.M., CARLSON J.J., THE EFFECT OF A GARLIC PREPARATION ON PLASMA LIPID LEVELS IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS, ATHEROSCLEROSIS, 154, PP. 213-220, (2001); VAES L.P., CHYKA P.A., INTERACTIONS OF WARFARIN WITH GARLIC, GINGER, GINKGO, OR GINSENG: NATURE OF THE EVIDENCE, ANN PHARMACOTHER, 34, PP. 1478-1482, (2000); DELGODA R., WESTLAKE A.C., HERBAL INTERACTIONS INVOLVING CYTOCHROME P450 ENZYMES: A MINI REVIEW, TOXICOL REV, 23, PP. 239-249, (2004); SZAPARY P.O., WOLFE M.L., BLOEDON L.T., ET AL., GUGGULIPID FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, JAMA, 290, PP. 765-772, (2003); SINGH R.B., NIAZ M.A., GHOSH S., HYPOLIPIDEMIC AND ANTIOXIDANT EFFECTS OF COMMIPHORA MUKUL AS AN ADJUNCT TO DIETARY THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CARDIOVASC DRUGS THER, 8, PP. 659-664, (1994); NITYANAND S., SRIVASTAVA J.S., ASTHANA O.P., CLINICAL TRIALS WITH GUGGULIPID. A NEW HYPOLIPIDAEMIC AGENT, J ASSOC PHYSICIANS INDIA, 37, PP. 323-328, (1989); BLANCHI A., CANTU P., FIRENZUOLI F., MAZZANTI G., MENNITI-IPPOLITO F., RASCHETTI R., RHABDOMYOLYSIS CAUSED BY COMMIPHORA MUKUL, A NATURAL LIPID-LOWERING AGENT, ANN PHARMACOTHER, 38, PP. 1222-1225, (2004); BROBST D.E., DING X., CREECH K.L., GOODWIN B., KELLEY B., STAUDINGER J.L., GUGGULSTERONE ACTIVATES MULTIPLE NUCLEAR RECEPTORS AND INDUCES CYP3A GENE EXPRESSION THROUGH THE PREGNANE X RECEPTOR, J PHARMACOL EXP THER, 310, PP. 528-535, (2004); DALVI S.S., NAYAK V.K., POHUJANI S.M., DESAI N.K., KSHIRSAGAR N.A., GUPTA K.C., EFFECT OF GUGGULIPID ON BIOAVAILABILITY OF DILTIAZEM AND PROPRANOLOL, J ASSOC PHYSICIANS INDIA, 42, PP. 454-455, (1994); HEBER D., LEMBERTAS A., LU Q.Y., BOWERMAN S., GO V.L., AN ANALYSIS OF NINE PROPRIETARY CHINESE RED YEAST RICE DIETARY SUPPLEMENTS: IMPLICATIONS OF VARIABILITY IN CHEMICAL PROFILE AND CONTENTS, J ALTERN COMPLEMENT MED, 2, PP. 133-139, (2001); HEBER D., YIP I., ASHLEY J.M., ELASHOFF D.A., GO V.L., CHOLESTEROL-LOWERING EFFECTS OF A PROPRIETARY CHINESE RED-YEAST-RICE DIETARY SUPPLEMENT, AM J CLIN NUTR, 69, PP. 231-236, (1999); LIN C., LII T., LAI M., EFFICACY AND SAFETY OF MONASCUS PURPUREUS WENT RICE IN SUBJECTS WITH HYPERLIPIDEMIA, EUR J ENDOCRINOL, 152, PP. 679-686, (2005); PRASAD G.V., WONG T., MELITON G., BHALOO S., RHABDOMYOLYSIS DUE TO RED YEAST RICE (MONASCUS PURPUREUS) IN A RENAL TRANSPLANT RECIPIENT, TRANSPLANTATION, 74, PP. 1200-1201, (2002); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALES R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ORTENSI G., GLADSTEIN J., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CRESPO N., ILLNAIT J., MAS R., FERAANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPEREHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVEST, 21, PP. 103-113, (2001); CASTANO G., MAS R., GAMEZ R., ET AL., CONCOMITANT USE OF POLICOSANOL AND Β-BLOCKERS IN OLDER PATIENTS, INT J CLIN PHARM RES, 24, PP. 65-77, (2004); CASTANO G., FERNANDEZ L., MAS R., ET AL., EFFECTS OF ADDITION OF POLICOSANOL TO OMEGA-3 FATTY ACID THERAPY ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, DRUGS R D, 6, PP. 207-219, (2005); LIN Y., RUDRUM M., VAN DER WIELEN R.P.J., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., GAMEZ R., ALVAREZ E., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPEREHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM HEART J, 143, PP. 356-365, (2002); NASH S.D., WESTPFAL M., CARDIOVASCULAR BENEFITS OF NUTS, AM J CARDIOL, 95, PP. 963-965, (2005); SABATE J., HADDAD E., TANZMAN J.S., JAMBAZIAN P., RAJARAM S., SERUM LIPID RESPONSE TO THE GRADUATED ENRICHMENT OF A STEP I DIET WITH ALMONDS: A RANDOMIZED FEEDING TRIAL, AM J CLIN NUTR, 77, PP. 1379-1384, (2003); JENKINS D.A., KENDALL C.C., MARCHIE A., ET AL., DOSE RESPONSE OF ALMONDS ON CORONARY HEART DISEASE RISK FACTORS: BLOOD LIPIDS, OXIDIZED LOW-DENSITY LIPOPROTEINS, LIPOPROTEIN(A), HOMOCYSTEINE, AND PULMONARY NITRIC OXIDE - A RANDOMIZED CONTROLLED, CROSSOVER TRIAL, CIRCULATION, 106, PP. 1327-1332, (2002); ZAMBON D., SABATE J., MUNOZ S., ET AL., SUBSTITUTING WALNUTS FOR MONOUN-SATURATED FAT IMPROVES SERUM LIPID PROFILE OF HYPERCHOLESTEROLEMIC MEN AND WOMEN: A RANDOMIZED CROSSOVER TRIAL, ANN INTERN MED, 132, PP. 538-546, (2000); KRAUSS R., ECKEL R., HOWARD B., ET AL., AHA DIETARY GUIDELINES, CIRCULATION, 102, PP. 2296-2311, (2000); CUNNANE S.C., HAMADEH M.J., LIEDE A.C., THOMPSON L.U., WOLEVER T.M., JENKINS D.J., NUTRITIONAL ATTRIBUTES OF TRADITIONAL FLAXSEED IN HEALTHY YOUNG ADULTS, AM J CLIN NUTR, 61, PP. 62-68, (1995); JENKINS D.J., KENDALL C.W., GARSETTI M., ET AL., HEALTH ASPECTS OF PARTIALLY DEFATTED FLAXSEED, INCLUDING EFFECTS ON SERUM LIPIDS, OXIDATIVE MEASURES, AND EX VIVO ANDROGEN AND PROGESTIN ACTIVITY: A CONTROLLED CROSSOVER TRIAL, AM J CLIN NUTR, 69, PP. 395-402, (1999); LEMAY A., DODIN S., KADRI N., JACQUES H., FOREST J.C., FLAXSEED DIETARY SUPPLEMENT VERSUS HORMONE REPLACEMENT THERAPY IN HYPERCHOLESTEROLEMIC MENOPAUSAL WOMEN, OBSTET GYNECOL, 100, PP. 495-504, (2002); LUCAS E.A., WILD R.D., HAMMOND L.J., ET AL., FLAXSEED IMPROVES LIPID PROFILE WITHOUT ALTERING BIOMARKERS OF BONE METABOLISM IN POSTMENOPAUSAL WOMEN, J CLIN ENDOCRINOL METAB, 87, PP. 1527-1532, (2002); DODIN S., LEMAY A., JACQUES H., LEGARE F., FOREST J.C., MASSE B., THE EFFECTS OF FLAXSEED DIETARY SUPPLEMENT ON LIPID PROFILE, BONE MINERAL DENSITY, AND SYMPTOMS IN MENOPAUSAL WOMEN: A RANDOMIZED, DOUBLE-BLIND, WHEAT GERM PLACEBO-CONTROLLED CLINICAL TRIAL, J CLIN ENDOCRINOL METAB, 90, PP. 1390-1397, (2005); MICROMEDEX HEALTHCARE SERIES (ELECTRONIC VERSION)","K.L. OLSON; DEPARTMENT OF PHARMACY, KAISER PERMANENTE OF COLORADO, AURORA, CO 80011-9045, 16601 E. CENTRETECH PARKWAY, UNITED STATES; EMAIL: KARI.OLSON@KP.ORG","","ENGLISH","ANN. PHARMACOTHER.","REVIEW","ISI","2-S2.0-33751010229","ANN PHARMACOTHER","UNIVERSITY OF COLORADO;UNIVERSITY OF COLORADO;UNIVERSITY OF COLORADO;UNIVERSITY OF COLORADO","NOTREPORTED;NOTDECLARED;NOTREPORTED",NA,"NIES LK, 2006, ANN PHARMACOTHER","NIES LK, 2006, ANN PHARMACOTHER"
"MCCARTY M","MCCARTY, MARK F. (24435224500)","ADJUVANT STRATEGIES FOR PREVENTION OF GLOMERULOSCLEROSIS",2006,"MEDICAL HYPOTHESES","67","19",22,"10.1016/j.mehy.2004.11.048","NUTRIGUARD RESEARCH, ENCINITAS, CA 92024, 1051 HERMES AVE, UNITED STATES","THE GLOMERULOSCLEROSIS WHICH FREQUENTLY COMPLICATES DIABETES AND SEVERE HYPERTENSION IS MEDIATED PRIMARILY BY INCREASED MESANGIAL PRODUCTION AND ACTIVATION OF TRANSFORMING GROWTH FACTOR-BETA (TGF-Β), WHICH ACTS ON MESANGIAL CELLS TO BOOST THEIR PRODUCTION OF MATRIX PROTEINS WHILE SUPPRESSING EXTRACELLULAR PROTEOLYTIC ACTIVITY. HYPERGLYCEMIA AND GLOMERULAR HYPERTENSION WORK IN VARIOUS COMPLEMENTARY WAYS TO STIMULATE SUPEROXIDE PRODUCTION VIA NADPH OXIDASE IN MESANGIAL CELLS; THE RESULTING OXIDANT STRESS RESULTS IN THE INDUCTION AND ACTIVATION OF TFG-Β. NITRIC OXIDE, GENERATED BY GLOMERULAR CAPILLARIES AND BY MESANGIAL CELLS THEMSELVES, FUNCTIONS PHYSIOLOGICALLY TO OPPOSE MESANGIAL TGF-Β OVERPRODUCTION; HOWEVER, NO BIOACTIVITY IS COMPROMISED BY OXIDANT STRESS. IN ADDITION TO LOW-PROTEIN DIETS AND DRUGS THAT SUPPRESS ANGIOTENSIN II ACTIVITY, A VARIETY OF OTHER AGENTS AND MEASURES MAY HAVE POTENTIAL FOR IMPEDING THE PROCESS OF GLOMERULOSCLEROSIS. THESE INCLUDE VITAMIN E, WHICH BLUNTS THE RISE IN MESANGIAL DIACYLGLYCEROL LEVELS INDUCED BY HYPERGLYCEMIA; STATINS AND (POSSIBLY) POLICOSANOL, WHICH DOWN-REGULATE NADPH OXIDASE ACTIVITY BY DIMINISHING ISOPRENYLATION OF RAC1; LIPOIC ACID, WHOSE POTENT ANTIOXIDANT ACTIVITY ANTAGONIZES THE IMPACT OF OXIDANT STRESS ON TGF-Β EXPRESSION; PYRIDOXAMINE, WHICH INHIBITS PRODUCTION OF ADVANCED GLYCATION ENDPRODUCTS; ARGININE, HIGH-DOSE FOLATE, VITAMIN C, AND SALT RESTRICTION, WHICH MAY SUPPORT GLOMERULAR PRODUCTION OF NITRIC OXIDE; AND ESTROGEN AND SOY ISOFLAVONES, WHICH MAY INDUCE NITRIC OXIDE SYNTHASE IN GLOMERULAR CAPILLARIES WHILE ALSO INTERFERING WITH TGF-Β SIGNALING. FURTHER RESEARCH ALONG THESE LINES MAY ENABLE THE DEVELOPMENT OF COMPLEX NUTRACEUTICALS WHICH HAVE IMPORTANT CLINICAL UTILITY FOR CONTROLLING AND PREVENTING GLOMERULOSCLEROSIS AND RENAL FAILURE. MOST OF THESE MEASURES MAY LIKEWISE REDUCE RISK FOR LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVES, INASMUCH AS THE SIGNALING MECHANISMS WHICH MEDIATE THIS DISORDER APPEAR SIMILAR TO THOSE INVOLVED IN GLOMERULOSCLEROSIS. © 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.","","ADJUVANTS, IMMUNOLOGIC; ANIMALS; GLOMERULAR MESANGIUM; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MODELS, BIOLOGICAL; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; TRANSFORMING GROWTH FACTOR BETA; ADENOSINE TRIPHOSPHATASE INHIBITOR; ALPHA TOCOPHEROL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; APOPTOSIS SIGNAL REGULATING KINASE 1; ARGININE; ASCORBIC ACID; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FOLIC ACID; GENISTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE; LOSARTAN; MARINOBUFAGENIN; MEVINOLIN; NITRIC OXIDE; NUTRACEUTICAL; POLICOSANOL; PYRIDOXAMINE; RAC1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; TAURINE; TETRAHYDROBIOPTERIN; THIOCTIC ACID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ARTICLE; CLINICAL TRIAL; DIABETIC PATIENT; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; GLYCATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISOPRENYLATION; KIDNEY FAILURE; MEDICAL RESEARCH; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN RESTRICTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SODIUM RESTRICTION","","","FOGO A.B., MESANGIAL MATRIX MODULATION AND GLOMERULOSCLEROSIS, EXP NEPHROL, 7, PP. 147-159, (1999); CHEN S., JIM B., ZIYADEH F.N., DIABETIC NEPHROPATHY AND TRANSFORMING GROWTH FACTOR-BETA: TRANSFORMING OUR VIEW OF GLOMERULOSCLEROSIS AND FIBROSIS BUILD-UP, SEMIN NEPHROL, 23, PP. 532-543, (2003); SCHNAPER H.W., HAYASHIDA T., HUBCHAK S.C., PONCELET A.C., TGF-BETA SIGNAL TRANSDUCTION AND MESANGIAL CELL FIBROGENESIS, AM J PHYSIOL RENAL PHYSIOL, 284, (2003); ZIYADEH F.N., MEDIATORS OF DIABETIC RENAL DISEASE: THE CASE FOR TGF-BETA AS THE MAJOR MEDIATOR, J AM SOC NEPHROL, 15, SUPPL. 1, (2004); SHARMA K., JIN Y., GUO J., ZIYADEH F.N., NEUTRALIZATION OF TGF-BETA BY ANTI-TGF-BETA ANTIBODY ATTENUATES KIDNEY HYPERTROPHY AND THE ENHANCED EXTRACELLULAR MATRIX GENE EXPRESSION IN STZ-INDUCED DIABETIC MICE, DIABETES, 45, PP. 522-530, (1996); ZIYADEH F.N., HOFFMAN B.B., HAN D.C., IGLESIAS-DE LA CRUZ M.C., HONG S.W., ISONO M., ET AL., LONG-TERM PREVENTION OF RENAL INSUFFICIENCY, EXCESS MATRIX GENE EXPRESSION, AND GLOMERULAR MESANGIAL MATRIX EXPANSION BY TREATMENT WITH MONOCLONAL ANTITRANSFORMING GROWTH FACTOR-BETA ANTIBODY IN DB/DB DIABETIC MICE, PROC NATL ACAD SCI USA, 97, PP. 8015-8020, (2000); CHEN S., IGLESIAS-DE LA CRUZ M.C., JIM B., HONG S.W., ISONO M., ZIYADEH F.N., REVERSIBILITY OF ESTABLISHED DIABETIC GLOMERULOPATHY BY ANTI-TGF-BETA ANTIBODIES IN DB/DB MICE, BIOCHEM BIOPHYS RES COMMUN, 300, PP. 16-22, (2003); BENIGNI A., ZOJA C., CORNA D., ZATELLI C., CONTI S., CAMPANA M., ET AL., ADD-ON ANTI-TGF-BETA ANTIBODY TO ACE INHIBITOR ARRESTS PROGRESSIVE DIABETIC NEPHROPATHY IN THE RAT, J AM SOC NEPHROL, 14, PP. 1816-1824, (2003); KOPP J.B., FACTOR V.M., MOZES M., NAGY P., SANDERSON N., BOTTINGER E.P., ET AL., TRANSGENIC MICE WITH INCREASED PLASMA LEVELS OF TGF-BETA 1 DEVELOP PROGRESSIVE RENAL DISEASE, LAB INVEST, 74, PP. 991-1003, (1996); MOZES M.M., BOTTINGER E.P., JACOT T.A., KOPP J.B., RENAL EXPRESSION OF FIBROTIC MATRIX PROTEINS AND OF TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA) ISOFORMS IN TGF-BETA TRANSGENIC MICE, J AM SOC NEPHROL, 10, PP. 271-280, (1999); SUZUKI S., EBIHARA I., TOMINO Y., KOIDE H., TRANSCRIPTIONAL ACTIVATION OF MATRIX GENES BY TRANSFORMING GROWTH FACTOR-BETA 1 IN MESANGIAL CELLS, EXP NEPHROL, 1, PP. 229-237, (1993); WILSON H.M., REID F.J., BROWN P.A., POWER D.A., HAITES N.E., BOOTH N.A., EFFECT OF TRANSFORMING GROWTH FACTOR-BETA 1 ON PLASMINOGEN ACTIVATORS AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN RENAL GLOMERULAR CELLS, EXP NEPHROL, 1, PP. 343-350, (1993); HANSCH G.M., WAGNER C., BURGER A., DONG W., STAEHLER G., STOECK M., MATRIX PROTEIN SYNTHESIS BY GLOMERULAR MESANGIAL CELLS IN CULTURE: EFFECTS OF TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) AND PLATELET-DERIVED GROWTH FACTOR (PDGF) ON FIBRONECTIN AND COLLAGEN TYPE IV MRNA, J CELL PHYSIOL, 163, PP. 451-457, (1995); PONCELET A.C., SCHNAPER H.W., REGULATION OF HUMAN MESANGIAL CELL COLLAGEN EXPRESSION BY TRANSFORMING GROWTH FACTOR-BETA 1, AM J PHYSIOL, 275, (1998); TADA H., ISOGAI S., THE FIBRONECTIN PRODUCTION IS INCREASED BY THROMBOSPONDIN VIA ACTIVATION OF TGF-BETA IN CULTURED HUMAN MESANGIAL CELLS, NEPHRON, 79, PP. 38-43, (1998); WEISS R.H., RAMIREZ A., TGF-BETA- AND ANGIOTENSIN-II-INDUCED MESANGIAL MATRIX PROTEIN SECRETION IS MEDIATED BY PROTEIN KINASE C, NEPHROL DIAL TRANSPLANT, 13, PP. 2804-2813, (1998); KAIZUKA M., YAMABE H., OSAWA H., OKUMURA K., FUJIMOTO N., THROMBIN STIMULATES SYNTHESIS OF TYPE IV COLLAGEN AND TISSUE INHIBITOR OF METALLOPROTEINASES-1 BY CULTURED HUMAN MESANGIAL CELLS, J AM SOC NEPHROL, 10, PP. 1516-1523, (1999); BARICOS W.H., CORTEZ S.L., DEBOISBLANC M., XIN S., TRANSFORMING GROWTH FACTOR-BETA IS A POTENT INHIBITOR OF EXTRACELLULAR MATRIX DEGRADATION BY CULTURED HUMAN MESANGIAL CELLS, J AM SOC NEPHROL, 10, PP. 790-795, (1999); CHIN B.Y., MOHSENIN A., LI S.X., CHOI A.M., CHOI M.E., STIMULATION OF PRO-ALPHA(1)(I) COLLAGEN BY TGF-BETA(1) IN MESANGIAL CELLS: ROLE OF THE P38 MAPK PATHWAY, AM J PHYSIOL RENAL PHYSIOL, 280, (2001); ZDUNEK M., SILBIGER S., LEI J., NEUGARTEN J., PROTEIN KINASE CK2 MEDIATES TGF-BETA1-STIMULATED TYPE IV COLLAGEN GENE TRANSCRIPTION AND ITS REVERSAL BY ESTRADIOL, KIDNEY INT, 60, PP. 2097-2108, (2001); SINGH R., SONG R.H., ALAVI N., PEGORARO A.A., SINGH A.K., LEEHEY D.J., HIGH GLUCOSE DECREASES MATRIX METALLOPROTEINASE-2 ACTIVITY IN RAT MESANGIAL CELLS VIA TRANSFORMING GROWTH FACTOR-BETA1, EXP NEPHROL, 9, PP. 249-257, (2001); RUNYAN C.E., SCHNAPER H.W., PONCELET A.C., SMAD3 AND PKCDELTA MEDIATE TGF-BETA1-INDUCED COLLAGEN I EXPRESSION IN HUMAN MESANGIAL CELLS, AM J PHYSIOL RENAL PHYSIOL, 285, (2003); HUANG Y., HARAGUCHI M., LAWRENCE D.A., BORDER W.A., YU L., NOBLE N.A., A MUTANT, NONINHIBITORY PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 DECREASES MATRIX ACCUMULATION IN EXPERIMENTAL GLOMERULONEPHRITIS, J CLIN INVEST, 112, PP. 379-388, (2003); SINGH L.P., GREEN K., ALEXANDER M., BASSLY S., CROOK E.D., HEXOSAMINES AND TGF-BETA1 USE SIMILAR SIGNALING PATHWAYS TO MEDIATE MATRIX PROTEIN SYNTHESIS IN MESANGIAL CELLS, AM J PHYSIOL RENAL PHYSIOL, 286, (2004); MCLENNAN S.V., WANG X.Y., MORENO V., YUE D.K., TWIGG S.M., CONNECTIVE TISSUE GROWTH FACTOR MEDIATES HIGH GLUCOSE EFFECTS ON MATRIX DEGRADATION THROUGH TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE TYPE 1: IMPLICATIONS FOR DIABETIC NEPHROPATHY, ENDOCRINOLOGY, (2004); HA H., LEE S.H., KIM K.H., EFFECTS OF REBAMIPIDE IN A MODEL OF EXPERIMENTAL DIABETES AND ON THE SYNTHESIS OF TRANSFORMING GROWTH FACTOR-BETA AND FIBRONECTIN, AND LIPID PEROXIDATION INDUCED BY HIGH GLUCOSE IN CULTURED MESANGIAL CELLS, J PHARMACOL EXP THER, 281, PP. 1457-1462, (1997); HA H., KIM K.H., PATHOGENESIS OF DIABETIC NEPHROPATHY: THE ROLE OF OXIDATIVE STRESS AND PROTEIN KINASE C, DIABETES RES CLIN PRACT, 45, PP. 147-151, (1999); LEHMANN R., SCHLEICHER E.D., MOLECULAR MECHANISM OF DIABETIC NEPHROPATHY, CLIN CHIM ACTA, 297, PP. 135-144, (2000); LAL M.A., BRISMAR H., EKLOF A.C., APERIA A., ROLE OF OXIDATIVE STRESS IN ADVANCED GLYCATION END PRODUCT-INDUCED MESANGIAL CELL ACTIVATION, KIDNEY INT, 61, PP. 2006-2014, (2002); HA H., LEE H.B., REACTIVE OXYGEN SPECIES AS GLUCOSE SIGNALING MOLECULES IN MESANGIAL CELLS CULTURED UNDER HIGH GLUCOSE, KIDNEY INT SUPPL, 77, (2000); IGLESIAS-DE LA CRUZ M.C., RUIZ-TORRES P., ALCAMI J., DIEZ-MARQUES L., ORTEGA-VELAZQUEZ R., CHEN S., ET AL., HYDROGEN PEROXIDE INCREASES EXTRACELLULAR MATRIX MRNA THROUGH TGF-BETA IN HUMAN MESANGIAL CELLS, KIDNEY INT, 59, PP. 87-95, (2001); LEE H.B., YU M.R., YANG Y., JIANG Z., HA H., REACTIVE OXYGEN SPECIES-REGULATED SIGNALING PATHWAYS IN DIABETIC NEPHROPATHY, J AM SOC NEPHROL, 14, (2003); RADEKE H.H., CROSS A.R., HANCOCK J.T., JONES O.T., NAKAMURA M., KAEVER V., ET AL., FUNCTIONAL EXPRESSION OF NADPH OXIDASE COMPONENTS (ALPHA- AND BETA-SUBUNITS OF CYTOCHROME B558 AND 45-KDA FLAVOPROTEIN) BY INTRINSIC HUMAN GLOMERULAR MESANGIAL CELLS, J BIOL CHEM, 266, PP. 21025-21029, (1991); JONES S.A., HANCOCK J.T., JONES O.T., NEUBAUER A., TOPLEY N., THE EXPRESSION OF NADPH OXIDASE COMPONENTS IN HUMAN GLOMERULAR MESANGIAL CELLS: DETECTION OF PROTEIN AND MRNA FOR P47PHOX, P67PHOX, AND P22PHOX, J AM SOC NEPHROL, 5, PP. 1483-1491, (1995); LI J.M., SHAH A.M., ROS GENERATION BY NONPHAGOCYTIC NADPH OXIDASE: POTENTIAL RELEVANCE IN DIABETIC NEPHROPATHY, J AM SOC NEPHROL, 14, (2003); KITADA M., KOYA D., SUGIMOTO T., ISONO M., ARAKI S., KASHIWAGI A., ET AL., TRANSLOCATION OF GLOMERULAR P47PHOX AND P67PHOX BY PROTEIN KINASE C-BETA ACTIVATION IS REQUIRED FOR OXIDATIVE STRESS IN DIABETIC NEPHROPATHY, DIABETES, 52, PP. 2603-2614, (2003); CRAVEN P.A., PHILLIPS S.L., MELHEM M.F., LIACHENKO J., DERUBERTIS F.R., OVEREXPRESSION OF MANGANESE SUPEROXIDE DISMUTASE SUPPRESSES INCREASES IN COLLAGEN ACCUMULATION INDUCED BY CULTURE OF MESANGIAL CELLS IN HIGH-MEDIA GLUCOSE, METABOLISM, 50, PP. 1043-1048, (2001); KIRITOSHI S., NISHIKAWA T., SONODA K., KUKIDOME D., SENOKUCHI T., MATSUO T., ET AL., REACTIVE OXYGEN SPECIES FROM MITOCHONDRIA INDUCE CYCLOOXYGENASE-2 GENE EXPRESSION IN HUMAN MESANGIAL CELLS: POTENTIAL ROLE IN DIABETIC NEPHROPATHY, DIABETES, 52, PP. 2570-2577, (2003); WILMER W.A., DIXON C.L., HEBERT C., LU L., ROVIN B.H., PPAR-ALPHA LIGANDS INHIBIT H2O2-MEDIATED ACTIVATION OF TRANSFORMING GROWTH FACTOR-BETA1 IN HUMAN MESANGIAL CELLS, ANTIOXID REDOX SIGNAL, 4, PP. 877-884, (2002); CRAVEN P.A., MELHEM M.F., PHILLIPS S.L., DERUBERTIS F.R., OVEREXPRESSION OF CU<SUP>2+</SUP>/ZN<SUP>2+</SUP> SUPEROXIDE DISMUTASE PROTECTS AGAINST EARLY DIABETIC GLOMERULAR INJURY IN TRANSGENIC MICE, DIABETES, 50, PP. 2114-2125, (2001); DERUBERTIS F.R., CRAVEN P.A., MELHEM M.F., SALAH E.M., ATTENUATION OF RENAL INJURY IN DB/DB MICE OVEREXPRESSING SUPEROXIDE DISMUTASE: EVIDENCE FOR REDUCED SUPEROXIDE-NITRIC OXIDE INTERACTION, DIABETES, 53, PP. 762-768, (2004); KOYA D., LEE I.K., ISHII H., KANOH H., KING G.L., PREVENTION OF GLOMERULAR DYSFUNCTION IN DIABETIC RATS BY TREATMENT WITH D-ALPHA-TOCOPHEROL, J AM SOC NEPHROL, 8, PP. 426-435, (1997); AMIRI F., GARCIA R., REGULATION OF ANGIOTENSIN II RECEPTORS AND PKC ISOFORMS BY GLUCOSE IN RAT MESANGIAL CELLS, AM J PHYSIOL, 276, (1999); KOYA D., HANEDA M., NAKAGAWA H., ISSHIKI K., SATO H., MAEDA S., ET AL., AMELIORATION OF ACCELERATED DIABETIC MESANGIAL EXPANSION BY TREATMENT WITH A PKC BETA INHIBITOR IN DIABETIC DB/DB MICE, A RODENT MODEL FOR TYPE 2 DIABETES, FASEB J, 14, PP. 439-447, (2000); WHITESIDE C.I., DLUGOSZ J.A., MESANGIAL CELL PROTEIN KINASE C ISOZYME ACTIVATION IN THE DIABETIC MILIEU, AM J PHYSIOL RENAL PHYSIOL, 282, (2002); TUTTLE K.R., ANDERSON P.W., A NOVEL POTENTIAL THERAPY FOR DIABETIC NEPHROPATHY AND VASCULAR COMPLICATIONS: PROTEIN KINASE C BETA INHIBITION, AM J KIDNEY DIS, 42, PP. 456-465, (2003); HANEDA M., ARAKI S., TOGAWA M., SUGIMOTO T., ISONO M., KIKKAWA R., MITOGEN-ACTIVATED PROTEIN KINASE CASCADE IS ACTIVATED IN GLOMERULI OF DIABETIC RATS AND GLOMERULAR MESANGIAL CELLS CULTURED UNDER HIGH GLUCOSE CONDITIONS, DIABETES, 46, PP. 847-853, (1997); HAN W.K., SAPIRSTEIN A., HUNG C.C., ALESSANDRINI A., BONVENTRE J.V., CROSS-TALK BETWEEN CYTOSOLIC PHOSPHOLIPASE A2 ALPHA (CPLA2 ALPHA) AND SECRETORY PHOSPHOLIPASE A2 (SPLA2) IN HYDROGEN PEROXIDE-INDUCED ARACHIDONIC ACID RELEASE IN MURINE MESANGIAL CELLS: SPLA2 REGULATES CPLA2 ALPHA ACTIVITY THAT IS RESPONSIBLE FOR ARACHIDONIC ACID RELEASE, J BIOL CHEM, 278, PP. 24153-24163, (2003); GORIN Y., RICONO J.M., KIM N.H., BHANDARI B., CHOUDHURY G.G., ABBOUD H.E., NOX4 MEDIATES ANGIOTENSIN II-INDUCED ACTIVATION OF AKT/PROTEIN KINASE B IN MESANGIAL CELLS, AM J PHYSIOL RENAL PHYSIOL, 285, (2003); HENDERSON L.M., BANTING G., CHAPPELL J.B., THE ARACHIDONATE-ACTIVABLE, NADPH OXIDASE-ASSOCIATED H+ CHANNEL. EVIDENCE THAT GP91-PHOX FUNCTIONS AS AN ESSENTIAL PART OF THE CHANNEL, J BIOL CHEM, 270, PP. 5909-5916, (1995); LAI K.N., LEUNG J.C., LAI K.B., TO W.Y., YEUNG V.T., LAI F.M., GENE EXPRESSION OF THE RENIN-ANGIOTENSIN SYSTEM IN HUMAN KIDNEY, J HYPERTENS, 16, PP. 91-102, (1998); SINGH R., SINGH A.K., ALAVI N., LEEHEY D.J., MECHANISM OF INCREASED ANGIOTENSIN II LEVELS IN GLOMERULAR MESANGIAL CELLS CULTURED IN HIGH GLUCOSE, J AM SOC NEPHROL, 14, PP. 873-880, (2003); VIDOTTI D.B., CASARINI D.E., CRISTOVAM P.C., LEITE C.A., SCHOR N., BOIM M.A., HIGH GLUCOSE CONCENTRATION STIMULATES INTRACELLULAR RENIN ACTIVITY AND ANGIOTENSIN II GENERATION IN RAT MESANGIAL CELLS, AM J PHYSIOL RENAL PHYSIOL, 286, (2004); JAIMES E.A., GALCERAN J.M., RAIJ L., ANGIOTENSIN II INDUCES SUPEROXIDE ANION PRODUCTION BY MESANGIAL CELLS, KIDNEY INT, 54, PP. 775-784, (1998); PARK S.Y., SONG C.Y., KIM B.C., HONG H.K., LEE H.S., ANGIOTENSIN II MEDIATES LDL-INDUCED SUPEROXIDE GENERATION IN MESANGIAL CELLS, AM J PHYSIOL RENAL PHYSIOL, 285, (2003); SESHIAH P.N., WEBER D.S., ROCIC P., VALPPU L., TANIYAMA Y., GRIENDLING K.K., ANGIOTENSIN II STIMULATION OF NAD(P)H OXIDASE ACTIVITY: UPSTREAM MEDIATORS, CIRC RES, 91, PP. 406-413, (2002); KSHIRSAGAR A.V., JOY M.S., HOGAN S.L., FALK R.J., COLINDRES R.E., EFFECT OF ACE INHIBITORS IN DIABETIC AND NONDIABETIC CHRONIC RENAL DISEASE: A SYSTEMATIC OVERVIEW OF RANDOMIZED PLACEBO-CONTROLLED TRIALS, AM J KIDNEY DIS, 35, PP. 695-707, (2000); HAMILTON R.A., KANE M.P., DEMERS J., ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND TYPE 2 DIABETIC NEPHROPATHY: A META-ANALYSIS, PHARMACOTHERAPY, 23, PP. 909-915, (2003); PARVING H.H., LEHNERT H., BROCHNER-MORTENSEN J., GOMIS R., ANDERSEN S., ARNER P., THE EFFECT OF IRBESARTAN ON THE DEVELOPMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES, N ENGL J MED, 345, PP. 870-878, (2001); BRENNER B.M., COOPER M.E., DE ZEEUW D., KEANE W.F., MITCH W.E., PARVING H.H., ET AL., EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY, N ENGL J MED, 345, PP. 861-869, (2001); RUILOPE L.M., SEGURA J., LOSARTAN AND OTHER ANGIOTENSIN II ANTAGONISTS FOR NEPHROPATHY IN TYPE 2 DIABETES MELLITUS: A REVIEW OF THE CLINICAL TRIAL EVIDENCE, CLIN THER, 25, PP. 3044-3064, (2003); TSUJI H., IEHARA N., MASEGI T., IMURA M., OHKAWA J., ARAI H., ET AL., RIBOZYME TARGETING OF RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN MOUSE MESANGIAL CELLS, BIOCHEM BIOPHYS RES COMMUN, 245, PP. 583-588, (1998); YAMAMOTO Y., YAMAGISHI S., YONEKURA H., DOI T., TSUJI H., KATO I., ET AL., ROLES OF THE AGE-RAGE SYSTEM IN VASCULAR INJURY IN DIABETES, ANN NY ACAD SCI, 902, PP. 163-170, (2000); LU C., HE J.C., CAI W., LIU H., ZHU L., VLASSARA H., ADVANCED GLYCATION ENDPRODUCT (AGE) RECEPTOR 1 IS A NEGATIVE REGULATOR OF THE INFLAMMATORY RESPONSE TO AGE IN MESANGIAL CELLS, PROC NATL ACAD SCI USA, 101, PP. 11767-11772, (2004); WAUTIER M.P., CHAPPEY O., CORDA S., STERN D.M., SCHMIDT A.M., WAUTIER J.L., ACTIVATION OF NADPH OXIDASE BY AGE LINKS OXIDANT STRESS TO ALTERED GENE EXPRESSION VIA RAGE, AM J PHYSIOL ENDOCRINOL METAB, 280, (2001); ARIMA S., ITO S., THE MECHANISMS UNDERLYING ALTERED VASCULAR RESISTANCE OF GLOMERULAR AFFERENT AND EFFERENT ARTERIOLES IN DIABETIC NEPHROPATHY, NEPHROL DIAL TRANSPLANT, 18, PP. 1966-1969, (2003); RISER B.L., CORTES P., YEE J., SHARBA A.K., ASANO K., RODRIGUEZ-BARBERO A., ET AL., MECHANICAL STRAIN- AND HIGH GLUCOSE-INDUCED ALTERATIONS IN MESANGIAL CELL COLLAGEN METABOLISM: ROLE OF TGF-BETA, J AM SOC NEPHROL, 9, PP. 827-836, (1998); HORI Y., KATOH T., HIRAKATA M., JOKI N., KANAME S., FUKAGAWA M., ET AL., ANTI-LATENT TGF-BETA BINDING PROTEIN-1 ANTIBODY OR SYNTHETIC OLIGOPEPTIDES INHIBIT EXTRACELLULAR MATRIX EXPRESSION INDUCED BY STRETCH IN CULTURED RAT MESANGIAL CELLS, KIDNEY INT, 53, PP. 1616-1625, (1998); INGRAM A.J., LY H., THAI K., KANG M., SCHOLEY J.W., ACTIVATION OF MESANGIAL CELL SIGNALING CASCADES IN RESPONSE TO MECHANICAL STRAIN, KIDNEY INT, 55, PP. 476-485, (1999); CORTES P., RISER B.L., YEE J., NARINS R.G., MECHANICAL STRAIN OF GLOMERULAR MESANGIAL CELLS IN THE PATHOGENESIS OF GLOMERULOSCLEROSIS: CLINICAL IMPLICATIONS, NEPHROL DIAL TRANSPLANT, 14, PP. 1351-1354, (1999); INGRAM A.J., JAMES L., LY H., THAI K., SCHOLEY J.W., STRETCH ACTIVATION OF JUN N-TERMINAL KINASE/STRESS-ACTIVATED PROTEIN KINASE IN MESANGIAL CELLS, KIDNEY INT, 58, PP. 1431-1439, (2000); WUNG B.S., CHENG J.J., SHYUE S.K., WANG D.L., NO MODULATES MONOCYTE CHEMOTACTIC PROTEIN-1 EXPRESSION IN ENDOTHELIAL CELLS UNDER CYCLIC STRAIN, ARTERIOSCLER THROMB VASC BIOL, 21, PP. 1941-1947, (2001); CHEN Q., LI W., QUAN Z., SUMPIO B.E., MODULATION OF VASCULAR SMOOTH MUSCLE CELL ALIGNMENT BY CYCLIC STRAIN IS DEPENDENT ON REACTIVE OXYGEN SPECIES AND P38 MITOGEN-ACTIVATED PROTEIN KINASE, J VASC SURG, 37, PP. 660-668, (2003); HAYASHI K., EPSTEIN M., LOUTZENHISER R., FORSTER H., IMPAIRED MYOGENIC RESPONSIVENESS OF THE AFFERENT ARTERIOLE IN STREPTOZOTOCIN-INDUCED DIABETIC RATS: ROLE OF EICOSANOID DERANGEMENTS, J AM SOC NEPHROL, 2, PP. 1578-1586, (1992); SINGH N.K., NEPHROPROTECTION IN DIABETES MELLITUS, CLIN EXP HYPERTENS, 21, PP. 85-94, (1999); MARTINS D., NORRIS K., COMBATING DIABETIC NEPHROPATHY WITH DRUG THERAPY, CURR DIAB REP, 1, PP. 148-156, (2001); MCCALL A.L., HYPERTENSION MANAGEMENT IN PATIENTS WITH DIABETIC NEPHROPATHY, CURR HYPERTENS REP, 6, PP. 272-279, (2004); ANDERSON S., RENNKE H.G., BRENNER B.M., NIFEDIPINE VERSUS FOSINOPRIL IN UNINEPHRECTOMIZED DIABETIC RATS, KIDNEY INT, 41, PP. 891-897, (1992); GRUDEN G., ZONCA S., HAYWARD A., THOMAS S., MAESTRINI S., GNUDI L., ET AL., MECHANICAL STRETCH-INDUCED FIBRONECTIN AND TRANSFORMING GROWTH FACTOR-BETA1 PRODUCTION IN HUMAN MESANGIAL CELLS IS P38 MITOGEN-ACTIVATED PROTEIN KINASE-DEPENDENT, DIABETES, 49, PP. 655-661, (2000); WEIGERT C., SAUER U., BRODBECK K., PFEIFFER A., HARING H.U., SCHLEICHER E.D., AP-1 PROTEINS MEDIATE HYPERGLYCEMIA-INDUCED ACTIVATION OF THE HUMAN TGF-BETA1 PROMOTER IN MESANGIAL CELLS, J AM SOC NEPHROL, 11, PP. 2007-2016, (2000); WEIGERT C., BRODBECK K., KLOPFER K., HARING H.U., SCHLEICHER E.D., ANGIOTENSIN II INDUCES HUMAN TGF-BETA 1 PROMOTER ACTIVATION: SIMILARITY TO HYPERGLYCAEMIA, DIABETOLOGIA, 45, PP. 890-898, (2002); BURT D.J., GRUDEN G., THOMAS S.M., TUTT P., DELL'ANNA C., VIBERTI G.C., ET AL., P38 MITOGEN-ACTIVATED PROTEIN KINASE MEDIATES HEXOSAMINE-INDUCED TGFBETA1 MRNA EXPRESSION IN HUMAN MESANGIAL CELLS, DIABETOLOGIA, 46, PP. 531-537, (2003); NAITO T., MASAKI T., NIKOLIC-PATERSON D.J., TANJI C., YORIOKA N., KOHNO N., ANGIOTENSIN II INDUCES THROMBOSPONDIN-1 PRODUCTION IN HUMAN MESANGIAL CELLS VIA P38 MAPK AND JNK: A MECHANISM FOR ACTIVATION OF LATENT TGF-BETA1, AM J PHYSIOL RENAL PHYSIOL, 286, (2004); WANG S., SKORCZEWSKI J., FENG X., MEI L., MURPHY-ULLRICH J.E., GLUCOSE UP-REGULATES THROMBOSPONDIN 1 GENE TRANSCRIPTION AND TRANSFORMING GROWTH FACTOR-BETA ACTIVITY THROUGH ANTAGONISM OF CGMP-DEPENDENT PROTEIN KINASE REPRESSION VIA UPSTREAM STIMULATORY FACTOR 2, J BIOL CHEM, 279, PP. 34311-34322, (2004); POCZATEK M.H., HUGO C., DARLEY-USMAR V., MURPHY-ULLRICH J.E., GLUCOSE STIMULATION OF TRANSFORMING GROWTH FACTOR-BETA BIOACTIVITY IN MESANGIAL CELLS IS MEDIATED BY THROMBOSPONDIN-1, AM J PATHOL, 157, PP. 1353-1363, (2000); YEVDOKIMOVA N., WAHAB N.A., MASON R.M., THROMBOSPONDIN-1 IS THE KEY ACTIVATOR OF TGF-BETA1 IN HUMAN MESANGIAL CELLS EXPOSED TO HIGH GLUCOSE, J AM SOC NEPHROL, 12, PP. 703-712, (2001); DANIEL C., TAKABATAKE Y., MIZUI M., ISAKA Y., KAWASHI H., RUPPRECHT H., ET AL., ANTISENSE OLIGONUCLEOTIDES AGAINST THROMBOSPONDIN-1 INHIBIT ACTIVATION OF TGF-BETA IN FIBROTIC RENAL DISEASE IN THE RAT IN VIVO, AM J PATHOL, 163, PP. 1185-1192, (2003); DANIEL C., WIEDE J., KRUTZSCH H.C., RIBEIRO S.M., ROBERTS D.D., MURPHY-ULLRICH J.E., ET AL., THROMBOSPONDIN-1 IS A MAJOR ACTIVATOR OF TGF-BETA IN FIBROTIC RENAL DISEASE IN THE RAT IN VIVO, KIDNEY INT, 65, PP. 459-468, (2004); WILMER W.A., DIXON C.L., HEBERT C., CHRONIC EXPOSURE OF HUMAN MESANGIAL CELLS TO HIGH GLUCOSE ENVIRONMENTS ACTIVATES THE P38 MAPK PATHWAY, KIDNEY INT, 60, PP. 858-871, (2001); SAITOH M., NISHITOH H., FUJII M., TAKEDA K., TOBIUME K., SAWADA Y., ET AL., MAMMALIAN THIOREDOXIN IS A DIRECT INHIBITOR OF APOPTOSIS SIGNAL-REGULATING KINASE (ASK) 1, EMBO J, 17, PP. 2596-2606, (1998); TOBIUME K., MATSUZAWA A., TAKAHASHI T., NISHITOH H., MORITA K., TAKEDA K., ET AL., ASK1 IS REQUIRED FOR SUSTAINED ACTIVATIONS OF JNK/P38 MAP KINASES AND APOPTOSIS, EMBO REP, 2, PP. 222-228, (2001); LIU H., NISHITOH H., ICHIJO H., KYRIAKIS J.M., ACTIVATION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) BY TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR 2 REQUIRES PRIOR DISSOCIATION OF THE ASK1 INHIBITOR THIOREDOXIN, MOL CELL BIOL, 20, PP. 2198-2208, (2000); LIU Y., MIN W., THIOREDOXIN PROMOTES ASK1 UBIQUITINATION AND DEGRADATION TO INHIBIT ASK1-MEDIATED APOPTOSIS IN A REDOX ACTIVITY-INDEPENDENT MANNER, CIRC RES, 90, PP. 1259-1266, (2002); SONG J.J., RHEE J.G., SUNTHARALINGAM M., WALSH S.A., SPITZ D.R., LEE Y.J., ROLE OF GLUTAREDOXIN IN METABOLIC OXIDATIVE STRESS. GLUTAREDOXIN AS A SENSOR OF OXIDATIVE STRESS MEDIATED BY H<SUB>2</SUB>O<SUB>2</SUB>, J BIOL CHEM, 277, PP. 46566-46575, (2002); SONG J.J., LEE Y.J., DIFFERENTIAL ROLE OF GLUTAREDOXIN AND THIOREDOXIN IN METABOLIC OXIDATIVE STRESS-INDUCED ACTIVATION OF APOPTOSIS SIGNAL-REGULATING KINASE 1, BIOCHEM J, 373, PP. 845-853, (2003); CHO S.G., LEE Y.H., PARK H.S., RYOO K., KANG K.W., PARK J., ET AL., GLUTATHIONE S-TRANSFERASE MU MODULATES THE STRESS-ACTIVATED SIGNALS BY SUPPRESSING APOPTOSIS SIGNAL-REGULATING KINASE 1, J BIOL CHEM, 276, PP. 12749-12755, (2001); DORION S., LAMBERT H., LANDRY J., ACTIVATION OF THE P38 SIGNALING PATHWAY BY HEAT SHOCK INVOLVES THE DISSOCIATION OF GLUTATHIONE S-TRANSFERASE MU FROM ASK1, J BIOL CHEM, 277, PP. 30792-30797, (2002); IZUMI Y., KIM S., YOSHIYAMA M., IZUMIYA Y., YOSHIDA K., MATSUZAWA A., ET AL., ACTIVATION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 IN INJURED ARTERY AND ITS CRITICAL ROLE IN NEOINTIMAL HYPERPLASIA, CIRCULATION, 108, PP. 2812-2818, (2003); HIROTANI S., OTSU K., NISHIDA K., HIGUCHI Y., MORITA T., NAKAYAMA H., ET AL., INVOLVEMENT OF NUCLEAR FACTOR-ΚB AND APOPTOSIS SIGNAL-REGULATING KINASE 1 IN G-PROTEIN-COUPLED RECEPTOR AGONIST-INDUCED CARDIOMYOCYTE HYPERTROPHY, CIRCULATION, 105, PP. 509-515, (2002); IZUMIYA Y., KIM S., IZUMI Y., YOSHIDA K., YOSHIYAMA M., MATSUZAWA A., ET AL., APOPTOSIS SIGNAL-REGULATING KINASE 1 PLAYS A PIVOTAL ROLE IN ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY AND REMODELING, CIRC RES, 93, PP. 874-883, (2003); KLAHR S., THE ROLE OF NITRIC OXIDE IN HYPERTENSION AND RENAL DISEASE PROGRESSION, NEPHROL DIAL TRANSPLANT, 16, SUPPL. 1, PP. 60-62, (1902); TRACHTMAN H., FUTTERWEIT S., PINE E., MANN J., VALDERRAMA E., CHRONIC DIABETIC NEPHROPATHY: ROLE OF INDUCIBLE NITRIC OXIDE SYNTHASE, PEDIATR NEPHROL, 17, PP. 20-29, (2002); FUJIHARA C.K., DE NUCCI G., ZATZ R., CHRONIC NITRIC OXIDE SYNTHASE INHIBITION AGGRAVATES GLOMERULAR INJURY IN RATS WITH SUBTOTAL NEPHRECTOMY, J AM SOC NEPHROL, 5, PP. 1498-1507, (1995); KANG D.H., NAKAGAWA T., FENG L., JOHNSON R.J., NITRIC OXIDE MODULATES VASCULAR DISEASE IN THE REMNANT KIDNEY MODEL, AM J PATHOL, 161, PP. 239-248, (2002); CRAVEN P.A., STUDER R.K., FELDER J., PHILLIPS S., DERUBERTIS F.R., NITRIC OXIDE INHIBITION OF TRANSFORMING GROWTH FACTOR-BETA AND COLLAGEN SYNTHESIS IN MESANGIAL CELLS, DIABETES, 46, PP. 671-681, (1997); WANG S., SHIVA S., POCZATEK M.H., DARLEY-USMAR V., MURPHY-ULLRICH J.E., NITRIC OXIDE AND CGMP-DEPENDENT PROTEIN KINASE REGULATION OF GLUCOSE-MEDIATED THROMBOSPONDIN 1-DEPENDENT TRANSFORMING GROWTH FACTOR-BETA ACTIVATION IN MESANGIAL CELLS, J BIOL CHEM, 277, PP. 9880-9888, (2002); NOIRI E., SATOH H., TAGUCHI J., BRODSKY S.V., NAKAO A., OGAWA Y., ET AL., ASSOCIATION OF ENOS GLU298ASP POLYMORPHISM WITH END-STAGE RENAL DISEASE, HYPERTENSION, 40, PP. 535-540, (2002); NAGASE S., SUZUKI H., WANG Y., KIKUCHI S., HIRAYAMA A., UEDA A., ET AL., ASSOCIATION OF ECNOS GENE POLYMORPHISMS WITH END STAGE RENAL DISEASES, MOL CELL BIOCHEM, 244, PP. 113-118, (2003); SHIN S.Y., BAEK S.H., CHANG K.Y., PARK C.W., YANG C.W., JIN D.C., ET AL., RELATIONS BETWEEN ENOS GLU298ASP POLYMORPHISM AND PROGRESSION OF DIABETIC NEPHROPATHY, DIABETES RES CLIN PRACT, 65, PP. 257-265, (2004); PARK H.S., YU J.W., CHO J.H., KIM M.S., HUH S.H., RYOO K., ET AL., INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 BY NITRIC OXIDE THROUGH A THIOL REDOX MECHANISM, J BIOL CHEM, 279, PP. 7584-7590, (2004); WANG S., WU X., LINCOLN T.M., MURPHY-ULLRICH J.E., EXPRESSION OF CONSTITUTIVELY ACTIVE CGMP-DEPENDENT PROTEIN KINASE PREVENTS GLUCOSE STIMULATION OF THROMBOSPONDIN 1 EXPRESSION AND TGF-BETA ACTIVITY, DIABETES, 52, PP. 2144-2150, (2003); FRIPPIAT C., DEWELLE J., REMACLE J., TOUSSAINT O., SIGNAL TRANSDUCTION IN H2O2-INDUCED SENESCENCE-LIKE PHENOTYPE IN HUMAN DIPLOID FIBROBLASTS, FREE RADIC BIOL MED, 33, PP. 1334-1346, (2002); YAMAGUCHI K., SHIRAKABE K., SHIBUYA H., IRIE K., OISHI I., UENO N., ET AL., IDENTIFICATION OF A MEMBER OF THE MAPKKK FAMILY AS A POTENTIAL MEDIATOR OF TGF-BETA SIGNAL TRANSDUCTION, SCIENCE, 270, PP. 2008-2011, (1995); SHIBUYA H., YAMAGUCHI K., SHIRAKABE K., TONEGAWA A., GOTOH Y., UENO N., ET AL., TAB1: AN ACTIVATOR OF THE TAK1 MAPKKK IN TGF-BETA SIGNAL TRANSDUCTION, SCIENCE, 272, PP. 1179-1182, (1996); HANAFUSA H., NINOMIYA-TSUJI J., MASUYAMA N., NISHITA M., FUJISAWA J., SHIBUYA H., ET AL., INVOLVEMENT OF THE P38 MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY IN TRANSFORMING GROWTH FACTOR-BETA-INDUCED GENE EXPRESSION, J BIOL CHEM, 274, PP. 27161-27167, (1999); ONO K., OHTOMO T., NINOMIYA-TSUJI J., TSUCHIYA M., A DOMINANT NEGATIVE TAK1 INHIBITS CELLULAR FIBROTIC RESPONSES INDUCED BY TGF-BETA, BIOCHEM BIOPHYS RES COMMUN, 307, PP. 332-337, (2003); DEFERRARI G., RAVERA M., BERRUTI V., TREATMENT OF DIABETIC NEPHROPATHY IN ITS EARLY STAGES, DIABETES METAB RES REV, 19, PP. 101-114, (2003); WANG P.H., LAU J., CHALMERS T.C., METAANALYSIS OF THE EFFECTS OF INTENSIVE GLYCEMIC CONTROL ON LATE COMPLICATIONS OF TYPE I DIABETES MELLITUS, ONLINE J CURR CLIN TRIAL, DOC NO 60, (1993); BRETZEL R.G., PREVENTION AND SLOWING DOWN THE PROGRESSION OF THE DIABETIC NEPHROPATHY THROUGH ANTIHYPERTENSIVE THERAPY, J DIABETES COMPLICAT, 11, PP. 112-122, (1997); BRENNER B.M., MEYER T.W., HOSTETTER T.H., DIETARY PROTEIN INTAKE AND THE PROGRESSIVE NATURE OF KIDNEY DISEASE: THE ROLE OF HEMODYNAMICALLY MEDIATED GLOMERULAR INJURY IN THE PATHOGENESIS OF PROGRESSIVE GLOMERULAR SCLEROSIS IN AGING, RENAL ABLATION, AND INTRINSIC RENAL DISEASE, N ENGL J MED, 307, PP. 652-659, (1982); KLAHR S., BUERKERT J., PURKERSON M.L., ROLE OF DIETARY FACTORS IN THE PROGRESSION OF CHRONIC RENAL DISEASE, KIDNEY INT, 24, PP. 579-587, (1983); FOUQUE D., LAVILLE M., BOISSEL J.P., CHIFFLET R., LABEEUW M., ZECH P.Y., CONTROLLED LOW PROTEIN DIETS IN CHRONIC RENAL INSUFFICIENCY: META-ANALYSIS, BMJ, 304, PP. 216-220, (1992); PEDRINI M.T., LEVEY A.S., LAU J., CHALMERS T.C., WANG P.H., THE EFFECT OF DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF DIABETIC AND NONDIABETIC RENAL DISEASES: A META-ANALYSIS, ANN INTERN MED, 124, PP. 627-632, (1996); NAKAMURA H., TAKASAWA M., KASHARA S., TSUDA A., MOMOTSU T., ITO S., ET AL., EFFECTS OF ACUTE PROTEIN LOADS OF DIFFERENT SOURCES ON RENAL FUNCTION OF PATIENTS WITH DIABETIC NEPHROPATHY, TOHOKU J EXP MED, 159, PP. 153-162, (1989); KONTESSIS P., JONES S., DODDS R., TREVISAN R., NOSADINI R., FIORETTO P., ET AL., RENAL, METABOLIC AND HORMONAL RESPONSES TO INGESTION OF ANIMAL AND VEGETABLE PROTEINS, KIDNEY INT, 38, PP. 136-144, (1990); JIBANI M.M., BLOODWORTH L.L., FODEN E., GRIFFITHS K.D., GALPIN O.P., PREDOMINANTLY VEGETARIAN DIET IN PATIENTS WITH INCIPIENT AND EARLY CLINICAL DIABETIC NEPHROPATHY: EFFECTS ON ALBUMIN EXCRETION RATE AND NUTRITIONAL STATUS, DIABET MED, 8, PP. 949-953, (1991); BARSOTTI G., MORELLI E., CUPISTI A., MEOLA M., DANI L., GIOVANNETTI S., A LOW-NITROGEN LOW-PHOSPHORUS VEGAN DIET FOR PATIENTS WITH CHRONIC RENAL FAILURE, NEPHRON, 74, PP. 390-394, (1996); SOROKA N., SILVERBERG D.S., GREEMLAND M., BIRK Y., BLUM M., PEER G., ET AL., COMPARISON OF A VEGETABLE-BASED (SOYA) AND AN ANIMAL-BASED LOW-PROTEIN DIET IN PREDIALYSIS CHRONIC RENAL FAILURE PATIENTS, NEPHRON, 79, PP. 173-180, (1998); MELHEM M.F., CRAVEN P.A., LIACHENKO J., DERUBERTIS F.R., ALPHA-LIPOIC ACID ATTENUATES HYPERGLYCEMIA AND PREVENTS GLOMERULAR MESANGIAL MATRIX EXPANSION IN DIABETES, J AM SOC NEPHROL, 13, PP. 108-116, (2002); CRAVEN P.A., DERUBERTIS F.R., KAGAN V.E., MELHEM M., STUDER R.K., EFFECTS OF SUPPLEMENTATION WITH VITAMIN C OR E ON ALBUMINURIA, GLOMERULAR TGF-BETA, AND GLOMERULAR SIZE IN DIABETES, J AM SOC NEPHROL, 8, PP. 1405-1414, (1997); KOYA D., HANEDA M., KIKKAWA R., KING G.L., D-ALPHA-TOCOPHEROL TREATMENT PREVENTS GLOMERULAR DYSFUNCTIONS IN DIABETIC RATS THROUGH INHIBITION OF PROTEIN KINASE C-DIACYLGLYCEROL PATHWAY, BIOFACTORS, 7, PP. 69-76, (1998); BURSELL S.E., KING G.L., CAN PROTEIN KINASE C INHIBITION AND VITAMIN E PREVENT THE DEVELOPMENT OF DIABETIC VASCULAR COMPLICATIONS?, DIABETES RES CLIN PRACT, 45, PP. 169-182, (1999); KEDZIORA-KORNATOWSKA K., SZRAM S., KORNATOWSKI T., SZADUJKIS-SZADURSKI L., KEDZIORA J., BARTOSZ G., EFFECT OF VITAMIN E AND VITAMIN C SUPPLEMENTATION ON ANTIOXIDATIVE STATE AND RENAL GLOMERULAR BASEMENT MEMBRANE THICKNESS IN DIABETIC KIDNEY, NEPHRON EXP NEPHROL, 95, (2003); ALDERSON N.L., CHACHICH M.E., FRIZZELL N., CANNING P., METZ T.O., JANUSZEWSKI A.S., ET AL., EFFECT OF ANTIOXIDANTS AND ACE INHIBITION ON CHEMICAL MODIFICATION OF PROTEINS AND PROGRESSION OF NEPHROPATHY IN THE STREPTOZOTOCIN DIABETIC RAT, DIABETOLOGIA, 47, PP. 1385-1395, (2004); TADA H., ISHII H., ISOGAI S., PROTECTIVE EFFECT OF D-ALPHA-TOCOPHEROL ON THE FUNCTION OF HUMAN MESANGIAL CELLS EXPOSED TO HIGH GLUCOSE CONCENTRATIONS, METABOLISM, 46, PP. 779-784, (1997); LEE I.K., KOYA D., ISHI H., KANOH H., KING G.L., D-ALPHA-TOCOPHEROL PREVENTS THE HYPERGLYCEMIA INDUCED ACTIVATION OF DIACYLGLYCEROL (DAG)-PROTEIN KINASE C (PKC) PATHWAY IN VASCULAR SMOOTH MUSCLE CELL BY AN INCREASE OF DAG KINASE ACTIVITY, DIABETES RES CLIN PRACT, 45, PP. 183-190, (1999); STUDER R.K., CRAVEN P.A., DERUBERTIS F.R., ANTIOXIDANT INHIBITION OF PROTEIN KINASE C-SIGNALED INCREASES IN TRANSFORMING GROWTH FACTOR-BETA IN MESANGIAL CELLS, METABOLISM, 46, PP. 918-925, (1997); GAEDE P., POULSEN H.E., PARVING H.H., PEDERSEN O., DOUBLE-BLIND, RANDOMISED STUDY OF THE EFFECT OF COMBINED TREATMENT WITH VITAMIN C AND E ON ALBUMINURIA IN TYPE 2 DIABETIC PATIENTS, DIABET MED, 18, PP. 756-760, (2001); HIRNEROVA E., KRAHULEC B., STRBOVA L., STECOVA A., DEKRET J., HAJOVSKA A., EFFECT OF VITAMIN E THERAPY ON PROGRESSION OF DIABETIC NEPHROPATHY, VNITR LEK, 49, PP. 529-534, (2003); BURSELL S.E., CLERMONT A.C., AIELLO L.P., AIELLO L.M., SCHLOSSMAN D.K., FEENER E.P., ET AL., HIGH-DOSE VITAMIN E SUPPLEMENTATION NORMALIZES RETINAL BLOOD FLOW AND CREATININE CLEARANCE IN PATIENTS WITH TYPE 1 DIABETES, DIABETES CARE, 22, PP. 1245-1251, (1999); LONN E., YUSUF S., HOOGWERF B., POGUE J., YI Q., ZINMAN B., ET AL., EFFECTS OF VITAMIN E ON CARDIOVASCULAR AND MICROVASCULAR OUTCOMES IN HIGH-RISK PATIENTS WITH DIABETES: RESULTS OF THE HOPE STUDY AND MICRO-HOPE SUBSTUDY, DIABETES CARE, 25, PP. 1919-1927, (2002); KOYA D., JIROUSEK M.R., LIN Y.W., ISHII H., KUBOKI K., KING G.L., CHARACTERIZATION OF PROTEIN KINASE C BETA ISOFORM ACTIVATION ON THE GENE EXPRESSION OF TRANSFORMING GROWTH FACTOR-BETA, EXTRACELLULAR MATRIX COMPONENTS, AND PROSTANOIDS IN THE GLOMERULI OF DIABETIC RATS, J CLIN INVEST, 100, PP. 115-126, (1997); KOYA D., KING G.L., PROTEIN KINASE C ACTIVATION AND THE DEVELOPMENT OF DIABETIC COMPLICATIONS, DIABETES, 47, PP. 859-866, (1998); KELLY D.J., ZHANG Y., HEPPER C., GOW R.M., JAWORSKI K., KEMP B.E., ET AL., PROTEIN KINASE C BETA INHIBITION ATTENUATES THE PROGRESSION OF EXPERIMENTAL DIABETIC NEPHROPATHY IN THE PRESENCE OF CONTINUED HYPERTENSION, DIABETES, 52, PP. 512-518, (2003); WHEELER G.D., RUBOXISTAURIN (ELI LILLY), IDRUGS, 6, PP. 159-163, (2003); BAYES M., RABASSEDA X., PROUS J.R., GATEWAYS TO CLINICAL TRIALS, METHOD FIND EXP CLIN PHARMACOL, 25, PP. 653-682, (2003); WASSMANN S., LAUFS U., BAUMER A.T., MULLER K., KONKOL C., SAUER H., ET AL., INHIBITION OF GERANYLGERANYLATION REDUCES ANGIOTENSIN II-MEDIATED FREE RADICAL PRODUCTION IN VASCULAR SMOOTH MUSCLE CELLS: INVOLVEMENT OF ANGIOTENSIN AT1 RECEPTOR EXPRESSION AND RAC1 GTPASE, MOL PHARMACOL, 59, PP. 646-654, (2001); WASSMANN S., LAUFS U., MULLER K., KONKOL C., AHLBORY K., BAUMER A.T., ET AL., CELLULAR ANTIOXIDANT EFFECTS OF ATORVASTATIN IN VITRO AND IN VIVO, ARTERIOSCLER THROMB VASC BIOL, 22, PP. 300-305, (2002); MAACK C., KARTES T., KILTER H., SCHAFERS H.J., NICKENIG G., BOHM M., ET AL., OXYGEN FREE RADICAL RELEASE IN HUMAN FAILING MYOCARDIUM IS ASSOCIATED WITH INCREASED ACTIVITY OF RAC1-GTPASE AND REPRESENTS A TARGET FOR STATIN TREATMENT, CIRCULATION, 108, PP. 1567-1574, (2003); SASAKI T., KURATA H., NOMURA K., UTSUNOMIYA K., IKEDA Y., AMELIORATION OF PROTEINURIA WITH PRAVASTATIN IN HYPERCHOLESTEROLEMIC PATIENTS WITH DIABETES MELLITUS, JPN J MED, 29, PP. 156-163, (1990); LAM K.S., CHENG I.K., JANUS E.D., PANG R.W., CHOLESTEROL-LOWERING THERAPY MAY RETARD THE PROGRESSION OF DIABETIC NEPHROPATHY, DIABETOLOGIA, 38, PP. 604-609, (1995); TONOLO G., CICCARESE M., BRIZZI P., PUDDU L., SECCHI G., CALVIA P., ET AL., REDUCTION OF ALBUMIN EXCRETION RATE IN NORMOTENSIVE MICROALBUMINURIC TYPE 2 DIABETIC PATIENTS DURING LONG-TERM SIMVASTATIN TREATMENT, DIABETES CARE, 20, PP. 1891-1895, (1997); FRIED L.F., FORREST K.Y., ELLIS D., CHANG Y., SILVERS N., ORCHARD T.J., LIPID MODULATION IN INSULIN-DEPENDENT DIABETES MELLITUS: EFFECT ON MICROVASCULAR OUTCOMES, J DIABETES COMPLICATIONS, 15, PP. 113-119, (2001); ELISAF M., MIKHAILIDIS D.P., STATINS AND RENAL FUNCTION, ANGIOLOGY, 53, PP. 493-502, (2002); ATHYROS V.G., PAPAGEORGIOU A.A., ELISAF M., MIKHAILIDIS D.P., STATINS AND RENAL FUNCTION IN PATIENTS WITH DIABETES MELLITUS, CURR MED RES OPIN, 19, PP. 615-617, (2003)","M.F. MCCARTY; NUTRIGUARD RESEARCH, ENCINITAS, CA 92024, 1051 HERMES AVE, UNITED STATES; EMAIL: MCCARTY@PANTOX.COM","","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-33645215219","MED HYPOTHESES","NUTRIGUARD RESEARCH","NOTREPORTED;NUTRIGUARD RESEARCH;NOTREPORTED",NA,"MCCARTY MF, 2006, MED HYPOTHESES","MCCARTY MF, 2006, MED HYPOTHESES-a-b"
"KEUM T;JI E;WELLER C","KEUM, TAEK HWANG (8220995600); JI, EUN KIM (36885849700); WELLER, CURTIS L. (7102722517)","POLICOSANOL CONTENTS AND COMPOSITIONS IN WAXLIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN",2005,"CEREAL CHEMISTRY","82","3",24,"10.1094/CC-82-0242","DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU, JEONBUK, 561-756, SOUTH KOREA;DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU, JEONBUK, 561-756, SOUTH KOREA;DEPARTMENT OF BIOLOGICAL SYSTEMS ENGINEERING, UNIVERSITY OF NEBRASKA, LINCOLN, NE 68583, UNITED STATES","POLICOSANOLS, LONG-CHAINED ALCOHOLS, HAVE BEEN REPORTED TO HAVE BENEFICIAL PHYSIOLOGICAL ACTIVITIES. CONTENT AND COMPOSITION OF POLICOSANOLS IN WAX-LIKE MATERIALS EXTRACTED FROM SELECTED CEREALS OF KOREAN ORIGIN WERE DETERMINED. WAX-LIKE MATERIALS WERE EXTRACTED USING HOT HEXANE. YIELDS OF WAX-LIKE MATERIALS FROM UNPOLISHED GRAIN SORGHUM, POLISHED GRAIN SORGHUM, BROWN RICE, PURPLE RICE, WHEAT, AND MAIZE WERE 223, 37, 33, 61, 10, AND 10 MG/100 G OF DRY KERNELS, RESPECTIVELY. POLICOSANOL CONTENTS, AS DETERMINED USING HPLC, IN THE WAX-LIKE MATERIALS FROM THE CEREALS WERE 33, 29, 6, 0, AND 2% (W/W, DB), RESPECTIVELY. MAJOR ALCOHOLS IN THE POLICOSANOLS FROM GRAIN SORGHUM WERE OCTACOSANOL AND TRIACONTANOL. DOCOSANOL WAS THE MAJOR ALCOHOL IN THE POLICOSANOLS FROM BROWN RICE, PURPLE RICE, WHEAT, AND MAIZE. © 2005 AACC INTERNATIONAL, INC.","","SORGHUM BICOLOR BICOLOR; TRITICUM AESTIVUM; ZEA MAYS; EXTRACTION; 'DRY' [; BROWN RICE; GRAIN SORGHUM; OCTACOSANOL; PHYSIOLOGICAL ACTIVITY; POLICOSANOLS; PURPLE RICE; GRAIN (AGRICULTURAL PRODUCT)","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 205-208, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); AVATO P., BIANCHI G., MURELLI C., ALIPHATIC AND CYCLIC LIPID COMPONENTS OF SORGHUM PLANT ORGANS, PHYTOCHEMISTRY, 29, PP. 1073-1078, (1990); BIANCHI G., AVATO P., MARIANI G., COMPOSITION OF SURFACE WAX FROM SORGHUM GRAIN, CEREAL CHEM., 56, PP. 491-492, (1979); BIANCHI G., AVATO P., SALAMINI F., SURFACE WAXES FROM GRAIN, LEAVES, AND HUSKS OF MAIZE (ZEA MAYS L.), CEREAL CHEM., 61, PP. 45-46, (1984); GOUNI-BERTHOLD I., BERTHOLD H.K., POLICOSANOL: CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPID-LOWERING AGENT, AM. HEART J., 143, PP. 356-365, (2002); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP. BIOL. MED., 229, PP. 215-226, (2004); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., SHOEMAKER R.K., ALDEHYDES IN GRAIN SORGHUM WAX, J. AM. OIL CHEM. SOC., 79, PP. 529-533, (2002); HWANG K.T., CUPPETT S.L., WELLER C.L., HANNA M.A., HPLC OF GRAIN SORGHUM WAX CLASSES HIGHLIGHTING SEPARATION OF ALDEHYDES FROM WAX ESTERS AND STERYL ESTERS, J. SEPARATION SCI., 25, PP. 619-623, (2002); HWANG K.T., WELLER C.L., CUPPETT S.L., HANNA M.A., POLICOSANOL CONTENTS AND COMPOSITIONS OF GRAIN SORGHUM KERNELS AND DRIED DISTILLERS GRAINS, CEREAL CHEM., 81, PP. 345-349, (2004); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. METAB., 39, PP. 279-284, (1995); KATO S., KARINO K.-I., HASEGAWA S., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., HAMATANI K., TAKAHASHI M., OGASAWARA J., MASUSHIGE S., HASEGAWA T., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR. J. NUTR., 73, PP. 433-441, (1995); KAWANISHI K., AOKI K., HASHIMOTO Y., MATSUNOBU A., FREE PRIMARY ALCOHOLS IN OILS AND WAXES FROM GERMS, KERNELS AND OTHER COMPONENTS OF NUTS, SEEDS, FRUITS AND CEREALS, J. AM. OIL CHEM. SOC., 68, PP. 869-872, (1991); PLACE A.R., COMPARATIVE ASPECTS OF LIPID DIGESTION AND ABSORPTION: PHYSIOLOGICAL CORRELATES OF WAX ESTER DIGESTION, AM. J. PHYSIOL., 263, (1992); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH OCTACOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT. J. CLIN. PHARMACOL. THER., 36, PP. 469-473, (1998); WANG Y.W., JONES P.J.H., PISCHEL I., FAIROW C., EFFECTS OF POLICOSANOLS AND PHYTOSTEROLS ON LIPID LEVELS AND CHOLESTEROL BIOSYNTHESIS IN HAMSTERS, LIPIDS, 38, PP. 165-170, (2003)","T.H. KEUM; DEPARTMENT OF FOOD SCIENCE AND HUMAN NUTRITION, CENTER FOR HEALTHCARE TECHNOLOGY DEVELOPMENT, CHONBUK NATIONAL UNIVERSITY, JEONJU, JEONBUK, 561-756, SOUTH KOREA; EMAIL: KEUM@CHONBUK.AC.KR","AMERICAN ASSOCIATION OF CEREAL CHEMISTS","ENGLISH","CEREAL CHEM.","ARTICLE","ISI","2-S2.0-19044396141","CEREAL CHEM","CHONBUK NATIONAL UNIVERSITY;CHONBUK NATIONAL UNIVERSITY;UNIVERSITY OF NEBRASKA","NOTREPORTED;CHONBUK NATIONAL UNIVERSITY;NOTREPORTED",NA,"KEUM TH, 2005, CEREAL CHEM","KEUM TH, 2005, CEREAL CHEM"
"XU Z;FITZ E;RIEDIGER N;MOGHADASIAN M","XU, ZUYUAN (57216277871); FITZ, EVELYN (24166246200); RIEDIGER, NATALIE (15924105700); MOGHADASIAN, MOHAMMED H. (7003746142)","DIETARY OCTACOSANOL REDUCES PLASMA TRIACYLGLYCEROL LEVELS BUT NOT ATHEROGENESIS IN APOLIPOPROTEIN EKNOCKOUT MICE",2007,"NUTRITION RESEARCH","27","5",20,"10.1016/j.nutres.2007.01.015","DEPARTMENT OF HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MAN. R2H 2A6, CANADA, CANADIAN CENTRE FOR AGRI-FOOD RESEARCH IN HEALTH AND MEDICINE, ST. BONIFACE GENERAL HOSPITAL RESEARCH CENTRE, WINNIPEG, MAN. R2H 2A6, CANADA;DEPARTMENT OF HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MAN. R2H 2A6, CANADA, CANADIAN CENTRE FOR AGRI-FOOD RESEARCH IN HEALTH AND MEDICINE, ST. BONIFACE GENERAL HOSPITAL RESEARCH CENTRE, WINNIPEG, MAN. R2H 2A6, CANADA;DEPARTMENT OF HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MAN. R2H 2A6, CANADA, CANADIAN CENTRE FOR AGRI-FOOD RESEARCH IN HEALTH AND MEDICINE, ST. BONIFACE GENERAL HOSPITAL RESEARCH CENTRE, WINNIPEG, MAN. R2H 2A6, CANADA;DEPARTMENT OF HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MAN. R2H 2A6, CANADA, CANADIAN CENTRE FOR AGRI-FOOD RESEARCH IN HEALTH AND MEDICINE, ST. BONIFACE GENERAL HOSPITAL RESEARCH CENTRE, WINNIPEG, MAN. R2H 2A6, CANADA","EPIDEMIOLOGICAL AND CLINICAL STUDIES HAVE SHOWN A SIGNIFICANT POSITIVE CORRELATION BETWEEN ELEVATED PLASMA LEVELS OF CHOLESTEROL AND TRIACYLGLYCEROL (TG) AND THE INCIDENCE OF CORONARY ARTERY DISEASE. SEVERAL DIETARY AND PHARMACOLOGIC AGENTS HAVE BEEN USED TO IMPROVE PLASMA LIPOPROTEIN PROFILE AND REDUCE THE RISK FOR CARDIOVASCULAR DISEASES. SOME CLINICAL TRIALS HAVE SHOWN BENEFICIAL EFFECTS OF DIETARY POLICOSANOL ON PLASMA LIPIDS; HOWEVER, LONG-TERM EFFECTS HAVE NOT BEEN DOCUMENTED. OCTACOSANOL IS ONE OF THE MAJOR COMPONENTS OF POLICOSANOL MIXTURES. THIS STUDY INVESTIGATED THE LONG-TERM EFFECTS OF DIETARY OCTACOSANOL ON PLASMA LIPIDS AND ATHEROGENESIS IN APOLIPOPROTEIN E-KNOCKOUT (APO E-KO) MICE, A MODEL OF SPONTANEOUS ATHEROSCLEROSIS. APO E-KO MICE WERE FED A 0.2% (WT/WT) CHOLESTEROL-SUPPLEMENTED DIET IN THE PRESENCE (TREATED GROUP, N = 5) OR ABSENCE (CONTROL GROUP, N = 5) OF 1% (WT/WT) DIETARY OCTACOSANOL FOR 12 WEEKS. DIETARY OCTACOSANOL SIGNIFICANTLY REDUCED THE LEVELS OF PLASMA TG BY APPROXIMATELY 70% BY WEEK 5 OF THE STUDY, AS COMPARED WITH THE CONTROL GROUP. HOWEVER, PLASMA TOTAL CHOLESTEROL LEVELS WERE SLIGHTLY INCREASED IN THE TREATED GROUP COMPARED WITH THE CONTROL GROUP. A DECREASE IN THE RATIO OF HDL TO TOTAL CHOLESTEROL WAS OBSERVED IN THE OCTACOSANOL-TREATED GROUP COMPARED WITH CONTROLS (0.06 VS 0.08). DESPITE THESE CHANGES IN PLASMA LIPID PROFILE, DIETARY OCTACOSANOL HAD NO SIGNIFICANT EFFECTS ON THE EXTENT AND SEVERITY OF AORTIC ATHEROSCLEROSIS IN THIS MODEL. IN CONCLUSION, OUR DATA INDICATE THAT DIETARY OCTACOSANOL REDUCES PLASMA TG LEVELS IN APO E-KO MICE FED A ""WESTERN-TYPE"" DIET. THE POTENTIAL LIPID-LOWERING AND ANTIATHEROGENIC EFFECTS OF DIETARY OCTACOSANOL MERIT FURTHER INVESTIGATION. © 2007 ELSEVIER INC. ALL RIGHTS RESERVED.","APO E-KO MICE; ATHEROSCLEROSIS; LIPOPROTEINS; OCTACOSANOL; POLICOSANOL","MUS; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OCTACOSANOL; TRIACYLGLYCEROL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFECT; FEEDING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL","","","SINGH B.K., MEHTA J.L., MANAGEMENT OF DYSLIPIDEMIA IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE, CURR OPIN CARDIOL, 17, PP. 503-511, (2002); TAYLOR J.C., RAPPORT L., LOCKWOOD G.B., OCTACOSANOL IN HUMAN HEALTH, NUTRITION, 19, PP. 192-195, (2003); HARGROVE J.L., GREENSPAN P., HARTLE D.K., NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES, EXP BIOL MED, 229, PP. 215-226, (2004); VARADY K.A., WANG Y., JONES P.J., ROLE OF POLICOSANOLS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE, NUTR REV, 61, PP. 376-383, (2003); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); MCCARTY M.F., POLICOSANOL SAFELY DOWN-REGULATES HMG-COA REDUCTASE-POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN, MED HYPOTHESES, 59, PP. 268-279, (2002); MENENDEZ R., MAS R., AMOR A.M., RODEIROS I., GONZALEZ R.M., ALFONSO J.L., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, PHARMACOL RES, 44, PP. 299-304, (2001); SHIMURA S., HASEGAWA T., TAKANO S., SUZUKI T., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTR REP INT, 36, PP. 1029-1038, (1987); MOGHADASIAN M.H., FROHLICH J.J., MCMANUS B.M., ADVANCES IN EXPERIMENTAL DYSLIPIDEMIA AND ATHEROSCLEROSIS, LAB INVEST, 81, PP. 1173-1183, (2001); NASHED B., YEGANEH B., HAYGLASS K.T., MOGHADASIAN M.H., ANTIATHEROGENIC EFFECTS OF DIETARY PLANT STEROLS ARE ASSOCIATED WITH INHIBITION OF PROINFLAMMATORY CYTOKINE PRODUCTION IN APO E-KO MICE, J NUTR, 135, PP. 2438-2444, (2005); YEGANEH B., MOSHTAGHI-KASHANIAN G.R., DECLERCQ V., MOGHADASIAN M.H., COMBINATION OF DIETARY PHYTOSTEROLS PLUS NIACIN OR FENOFIBRATE: EFFECTS ON LIPID PROFILE AND ATHEROSCLEROSIS IN APO E-KO MICE, J NUTR BIOCHEM, 16, PP. 222-228, (2005); MOGHADASIAN M.H., MCMANUS B.M., PRITCHARD P.H., FROHLICH J.J., TALL OIL""-DERIVED PHYTOSTEROLS REDUCE ATHEROSCLEROSIS IN APO E-DEFICIENT MICE, ARTERIOSCLER THROMB VASC BIOL, 17, PP. 119-126, (1997); MOGHADASIAN M.H., MCMANUS B.M., GODIN D.V., RODRIGUES B., FROHLICH J.J., PROATHEROGENIC AND ANTIATHEROGENIC EFFECTS OF PROBUCOL AND PHYTOSTEROLS IN APOLIPOPROTEIN E-DEFICIENT MICE: POSSIBLE MECHANISMS OF ACTION, CIRCULATION, 99, PP. 1733-1739, (1999); MOGHADASIAN M.H., NGUYEN L.B., SHEFER S., MCMANUS B.M., FROHLICH J.J., HISTOLOGIC, HEMATOLOGIC, AND BIOCHEMICAL CHARACTERISTICS OF APO E-DEFICIENT MICE: EFFECTS OF DIETARY CHOLESTEROL AND PHYTOSTEROLS, LAB INVEST, 79, PP. 355-364, (1999); KATO S., KARINO K., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BR J NUTR, 73, PP. 433-441, (1995); KIM H., PARK S., HAN D.S., PARK T., OCTACOSANOL SUPPLEMENTATION INCREASES RUNNING ENDURANCE TIME AND IMPROVES BIOCHEMICAL PARAMETERS AFTER EXHAUSTION IN TRAINED RATS, J MED FOOD, 6, PP. 345-351, (2003); PRITCHARD P.H., LI M., ZAMFIR C., LUKIC T., NOVAK E., MOGHADASIAN M.H., COMPARISON OF CHOLESTEROL-LOWERING EFFICACY AND ANTI-ATHEROGENIC PROPERTIES OF HYDROGENATED VERSUS NON-HYDROGENATED (PHYTROL) TALL OIL-DERIVED PHYTOSTEROLS IN APO E-DEFICIENT MICE, CARDIOVASC DRUGS THER, 17, PP. 443-449, (2003); LUKIC T., WASAN K.M., ZAMFIR D., MOGHADASIAN M.H., PRITCHARD P.H., DISODIUM ASCORBYL PHYTOSTANYL PHOSPHATE REDUCES PLASMA CHOLESTEROL CONCENTRATIONS AND ATHEROSCLEROTIC LESION FORMATION IN APOLIPOPROTEIN E-DEFICIENT MICE, METABOLISM, 52, PP. 425-431, (2003); ELAM M.B., HUNNINGHAKE D.B., DAVIS K.B., GARG R., JOHNSON C., EGAN D., ET AL., EFFECT OF NIACIN ON LIPID AND LIPOPROTEIN LEVELS AND GLYCEMIC CONTROL IN PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: THE ADMIT STUDY: A RANDOMIZED TRIAL. ARTERIAL DISEASE MULTIPLE INTERVENTION TRIAL, JAMA, 284, PP. 1263-1270, (2000); KUWABARA K., MURAKAMI K., TODO M., AOKI T., ASAKI T., MURAI M., ET AL., A NOVEL SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONIST, 2-METHYL-C-5-4-5-METHYL-2-(4-METHYLPHENYL)-4-OXAZOLYLBUTYL-1,3-DIOXANE-R-2-CARBOXYLIC ACID (NS-220), POTENTLY DECREASES PLASMA TRIGLYCERIDE AND GLUCOSE LEVELS AND MODIFIES LIPOPROTEIN PROFILES IN KK-AY MICE, J PHARMACOL EXP THER, 309, PP. 970-977, (2004); MOGHADASIAN M.H., MCMANUS B.M., NGUYEN L.B., SHEFER S., NADJI M., GODIN D.V., ET AL., PATHOPHYSIOLOGY OF APOLIPOPROTEIN E DEFICIENCY IN MICE: RELEVANCE TO APO E-RELATED DISORDERS IN HUMANS, FASEB J, 15, PP. 2623-2630, (2001); MOGHADASIAN M.H., DIETARY PHYTOSTEROLS REDUCE PROBUCOL-INDUCED ATHEROGENESIS IN APO E-KO MICE, ATHEROSCLEROSIS, 188, PP. 28-34, (2006); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); ARRUZAZABALA M.L., NOA M., MENENDEZ R., MAS R., CARBAJAL D., VALDES S., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); LIN Y., RUDRUM M., VAN DER WIELEN R.P., TRAUTWEIN E.A., MCNEILL G., SIERKSMA A., ET AL., WHEAT GERM POLICOSANOL FAILED TO LOWER PLASMA CHOLESTEROL IN SUBJECTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL CONCENTRATIONS, METABOLISM, 53, PP. 1309-1314, (2004); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NG C.H., LEUNG K.Y., HUANG Y., CHEN Z.Y., POLICOSANOL HAS NO ANTIOXIDANT ACTIVITY IN HUMAN LOW-DENSITY LIPOPROTEIN BUT INCREASES EXCRETION OF BILE ACIDS IN HAMSTERS, J AGRIC FOOD CHEM, 53, PP. 6289-6293, (2005)","M.H. MOGHADASIAN; DEPARTMENT OF HUMAN NUTRITIONAL SCIENCES, UNIVERSITY OF MANITOBA, WINNIPEG, MAN. R2H 2A6, CANADA; EMAIL: MMOGHADASIAN@SBRC.CA","","ENGLISH","NUTR. RES.","ARTICLE","ISI","2-S2.0-34047252206","NUTR RES","UNIVERSITY OF MANITOBA;UNIVERSITY OF MANITOBA;UNIVERSITY OF MANITOBA;UNIVERSITY OF MANITOBA","NOTREPORTED;UNIVERSITY OF MANITOBA;NOTREPORTED",NA,"XU Z, 2007, NUTR RES","XU Z, 2007, NUTR RES"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;LÓPEZ E;ILLNAIT J;FERNÁNDEZ L;MESA M","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, JULIO (9432805500); LÓPEZ, ERNESTO (57198355062); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILIA (7202848319); MESA, MEYLIN (36880545700)","EFFECTS OF POLICOSANOL ON BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL LEVELS A PROSPECTIVE DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP COMPARATIVE STUDY",2003,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","64","15",15,"10.1016/j.curtheres.2003.09.002","MEDICAL SURGICAL RESEARCH CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, 6990 CUBANACÁN, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL SURGICAL RESEARCH CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL SURGICAL RESEARCH CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","BACKGROUND: HYPERCHOLESTEROLEMIA IS A MAJOR RISK FACTOR FOR CORONARY HEART DISEASE. CLINICAL STUDIES HAVE SHOWN THAT LOWERING ELEVATED SERUM CHOLESTEROL LEVELS, PARTICULARLY LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), IS BENEFICIAL FOR PATIENTS WITH BORDERLINE TO MILDLY ELEVATED SERUM TOTAL CHOLESTEROL (TC) LEVELS (5.0-6.0 MMOL/L). POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG MADE FROM PURIFIED SUGAR CANE WAX. THE THERAPEUTIC RANGE OF POLICOSANOL IS 5 TO 20 MG/D. OBJECTIVE: THIS STUDY INVESTIGATED THE EFFICACY AND TOLERABILITY OF POLICOSANOL 5 MG/D IN PATIENTS WITH BORDERLINE TO MILDLY ELEVATED SERUM TC LEVELS. METHODS: THIS 14-WEEK, SINGLE-CENTER, PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, COMPARATIVE STUDY WAS CONDUCTED IN MEN AND WOMEN AGED 25 TO 75 YEARS WITH A SERUM TC LEVEL ≥4.8 TO <6.0 MMOL/L. AFTER A 6-WEEK RUN-IN PERIOD IN WHICH PATIENTS WERE PLACED ON THERAPEUTIC LIFESTYLE CHANGES, IN PARTICULAR A CHOLESTEROL-LOWERING DIET, PATIENTS WERE RANDOMLY ASSIGNED TO RECEIVE POLICOSANOL 5-MG TABLETS OR PLACEBO TABLETS ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS, AND THE DIET WAS CONTINUED THROUGHOUT THE STUDY. LIPID PROFILE VARIABLES, SAFETY INDICATORS, ADVERSE EVENTS (AES), AND COMPLIANCE WITH STUDY MEDICATIONS WERE ASSESSED. RESULTS: ONE HUNDRED PATIENTS (71 WOMEN, 29 MEN; MEAN [SD] AGE, 52 [10] YEARS) ENTERED THE STUDY AFTER THE DIETARY RUN-IN PERIOD. AFTER 8 WEEKS OF TREATMENT, THE MEAN (SD) SERUM LDL-C LEVEL DECREASED SIGNIFICANTLY IN THE POLICOSANOL GROUP (P < 0.001 VS BASELINE AND PLACEBO) FROM 3.57 (0.30) MMOL/L TO 2.86 (0.41) MMOL/L (CHANGE, -19.9%). SIGNIFICANTLY MORE PATIENTS IN THE POLICOSANOL GROUP (42 PATIENTS [84%]) ACHIEVED A ≥15% DECREASE IN SERUM LDL-C THAN IN THE PLACEBO GROUP (2 PATIENTS [4%]) (P < 0.001). ALSO IN THE POLICOSANOL GROUP, THE MEAN (SD) SERUM TC LEVEL DECREASED SIGNIFICANTLY, FROM 5.20 (0.22) MMOL/L TO 4.56 (0.44) MMOL/L (P < 0.001 VS BASELINE AND PLACEBO) (CHANGE, -12.3%); THE MEAN (SD) TRIGLYCERIDE (TG) LEVEL DECREASED SIGNIFICANTLY, FROM 1.59 (0.57) MMOL/L TO 1.48 (0.57) MMOL/L (P < 0.01 VS BASELINE; P < 0.05 VS PLACEBO) (CHANGE, -6.9%); AND THE MEAN (SD) HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVEL INCREASED SIGNIFICANTLY FROM 1.05 (0.18) MMOL/L TO 1.16 (0.21) MMOL/L (P < 0.001 VS BASELINE AND PLACEBO) (CHANGE, +10.5%). THE PERCENTAGE CHANGES WERE SIGNIFICANTLY DIFFERENT BETWEEN THE POLICOSANOL AND PLACEBO GROUPS FOR SERUM LDL-C, TC, AND HDL-C LEVELS (P < 0.001, P < 0.001, AND P < 0.05, RESPECTIVELY), BUT NOT FOR TG. IN THE PLACEBO GROUP, CHANGES IN LIPID PROFILE VARIABLES FROM BASELINE WERE NOT SIGNIFICANT. POLICOSANOL DID NOT SIGNIFICANTLY IMPAIR ANY SAFETY INDICATOR AND WAS WELL TOLERATED. THREE PATIENTS (3%) (1 PATIENT [2%] IN THE POLICOSANOL GROUP; 2 PATIENTS [4%] IN THE PLACEBO GROUP) WITHDREW FROM THE TRIAL, NONE BECAUSE OF AES. TWO PATIENTS (1 PATIENT [2%] EACH IN THE POLICOSANOL AND PLACEBO GROUPS) WITHDREW FROM THE STUDY BECAUSE OF AN UNWILLINGNESS TO RETURN FOR FOLLOW-UP; 1 PATIENT (2%) IN THE PLACEBO GROUP HAD A CHANGE OF ADDRESS AND COULD NOT BE FOLLOWED UP. OVERALL, 4 PATIENTS (4%) (1 PATIENT [2%] IN THE POLICOSANOL GROUP; 3 [6%], PLACEBO) REPORTED AES; ALL WERE MILD. OF THE PATIENTS WHO RECEIVED PLACEBO AND REPORTED AES, ALL 3 (6%) EXPERIENCED HEARTBURN, AND 1 (2%) ALSO EXPERIENCED DRY SKIN, WHILE THE POLICOSANOL-TREATED PATIENT (2%) WHO REPORTED AN AE EXPERIENCED HEADACHE. CONCLUSIONS: IN THIS STUDY OF PATIENTS WITH BORDERLINE TO MILDLY ELEVATED SERUM TC LEVELS, BASED ON THE CRITERION THAT ≥70% OF POLICOSANOL-TREATED PATIENTS REACHED THE LDL-C GOAL OF A DECREASE ≥15% FROM BASELINE WHENEVER THIS PROPORTION WAS DIFFERENT WITH RESPECT TO PLACEBO, 8 WEEKS OF TREATMENT WITH POLICOSANOL 5 MG/D WAS EFFECTIVE. THE DECREASED LDL-C, TC, AND TG LEVELS, INCREASED HDL-C LEVEL, AND GOOD TOLERABILITY FOUND WITH THIS TREATMENT SUPPORT ITS USE IN SUCH PATIENTS. COPYRIGHT © 2003 EXCERPTA MEDICA, INC.","BORDERLINE DYSLIPIDEMIA; CHOLESTEROL-LOWERING DRUGS; HYPERCHOLESTEROLEMIA; POLICOSANOL","HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HEADACHE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUGARCANE; TREATMENT OUTCOME","","","ANDERSON K.M., WILSON P.W., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. 1. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS: RESULTS OF AFCAPS/TEXCAPS. AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY, JAMA, 279, PP. 1615-1622, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); EXPERT PANEL OF DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR HEART J, 19, SUPPL. A, (1998); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE. 2D ED., (2000); ILLINGWORTH D.R., TOBERT J.A., A REVIEW OF CLINICAL TRIALS COMPARING HMG-COA REDUCTASE INHIBITORS, CLIN THER, 16, PP. 366-385, (1994); GRUNDY S.M., STATIN TRIALS AND GOALS OF CHOLESTEROL-LOWERING THERAPY, CIRCULATION, 97, PP. 1436-1439, (1998); HSU I., SPINLER S.A., JOHNSON N.E., COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF HMG-COA REDUCTASE INHIBITOR MONOTHERAPY IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, ANN PHARMACOTHER, 29, PP. 743-759, (1995); BAKER S.K., TARNOPOLSKY M.A., STATIN MYOPATHIES: PATHOPHYSIOLOGIC AND CLINICAL PERSPECTIVES, CLIN INVEST MED, 24, PP. 258-272, (2001); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 859-867, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN DRUG INVEST, 21, PP. 103-113, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES CLIN EXP, 60, PP. 458-467, (1999); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SMITH D.G., LESLIE S.J., SZUCS T.D., ET AL., COST OF TREATING TO A MODIFIED EUROPEAN ATHEROESCLEROSIS SOCIETY LDL-C TARGET. COMPARISON OF ATORVASTATIN WITH FLUVASTATIN, PRAVASTATIN AND SIMVASTATIN, CLIN DRUG INVEST, 17, PP. 185-193, (1999); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., INTERACTION POLICOSANOL-WARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS, PHARMACOL RES, 38, PP. 89-91, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE 11 HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN DRUG INVEST, (2003); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR THER RES CLIN EXP, 61, PP. 609-620, (2000); MAS R., CASTANO G., FERNANDEZ J., ET AL., EFFECTS OF POLICOSANOL (5-10 MG/DAY) IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, J AM COLL CARDIOL, 39, SUPPL. B, (2002); MOLINA CUEVAS V., ARRUZAZABALA M.L., CARBAJAL QUINTANA D., ET AL., EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS. STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOLOL, ARCH MED RES, 29, PP. 21-24, (1998)","R. MÁS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA, 6990 CUBANACÁN, CUBA; EMAIL: CLINICA@ENET.CU","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0344945606","CURR THER RES CLIN EXP","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2003, CURR THER RES CLIN EXP","CASTAÑO G, 2003, CURR THER RES CLIN EXP"
"CASTAÑO G;MÁS R;FERNÁNDEZ L;ILLNAIT J;MENDOZA S;GÁMEZ R;FERNÁNDEZ J;MESA M","CASTAÑO, G. (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, L. (7202848319); ILLNAIT, J. (8631465800); MENDOZA, S. (7102759819); GÁMEZ, R. (7003605346); FERNÁNDEZ, J. (9432805500); MESA, M. (36880545700)","A COMPARISON OF THE EFFECTS OF D003 AND POLICOSANOL 5 AND 10 MGDAY IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA A RANDOMIZED DOUBLEBLINDED STUDY",2005,"DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH","31","13",23,"","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, AVENUE 25 AND 158 STREET, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA","THE MAIN GOAL OF HYPERCHOLESTEROLEMIA MANAGEMENT FOR CORONARY PREVENTION IS TO REDUCE SERUM LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS. D-003 IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ACIDS PURIFIED FROM SUGARCANE WAX, WHILE POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG PURIFIED FROM THE SAME SOURCE, CONSISTING IN A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS. NO PREVIOUS COMPARATIVE STUDY OF BOTH DRUGS IN HUMANS HAS BEEN REPORTED. THIS RANDOMIZED, DOUBLE-BLIND STUDY COMPARES THE EFFICACY AND TOLERABILITY OF D-003 AND POLICOSANOL (5 AND 10 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. AFTER A BASELINE PERIOD, 100 PATIENTS WERE RANDOMIZED TO D-003 OR POLICOSANOL BOTH AT 5 MG/DAY AND 10 MG/DAY, FOR 8 WEEKS. D-003 AND POLICOSANOL 5 MG/DAY REDUCED (P < 0.0001) LDL-C BY 26.9% AND 20.9%, RESPECTIVELY. THESE REDUCTIONS INCREASED WITH 10 MG/DAY (35.1% FOR D-003, 25.1% FOR POLICOSANOL. THE REDUCTIONS OF LDL-C ACHIEVED WITH D-003 5 MG/DAY AND 10 MG/DAY WERE GREATER (P < 0.05 AND P < 0.007, RESPECTIVELY) THAN WITH POLICOSANOL. THE FREQUENCY OF PATIENTS TREATED WITH D-003 (5 MG/DAY) REACHING LDL-C REDUCTIONS ≥ 15% (22/25, 88%) WAS GREATER (P < 0.01) THAN WITH POLICOSANOL (5 MG/DAY) (19/25, 76%), AND THE SAME WAS TRUE FOR D-003 10 MG/DAY (25/25, 100%) AND POLICOSANOL (22/25, 88%; P < 0.01). D-003 AND POLICOSANOL (5 MG/DAY) ALSO LOWERED (P < 0.001) TOTAL CHOLESTEROL (TC) (16.2% AND 13.5%, RESPECTIVELY), AND INCREASED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) BY 15.3% (D-003) AND 6.7% (POLICOSANOL). AT 10 MG/DAY, D-003 AND POLICOSANOL REDUCED (P < 0.001) TC (21.3% AND 16.0%, RESPECTIVELY), WHILE HDL-C WAS INCREASED BY 17.3% AND 9.8%, RESPECTIVELY, D-003 BEING MORE EFFECTIVE THAN POLICOSANOL. TREATMENTS DID NOT AFFECT TRIGLYCERIDES. BOTH DRUGS WERE WELL TOLERATED, WITH D-003 TOLERATED AS WELL AS POLICOSANOL. THREE PATIENTS DISCONTINUED THE STUDY, NONE DUE TO ADVERSE EVENTS (AES). SEVEN PATIENTS (THREE FROM THE D-003 GROUP AND FOUR FROM THE POLICOSANOL GROUP) EXPERIENCED MILD AES. IN CONCLUSION, D-003 (5 AND 10 MG/DAY) ADMINISTERED TO PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WAS MORE EFFECTIVE THAN POLICOSANOL IN LOWERING LDL-C AND TC, AND IN INCREASING HDL-C. D-003 COULD BE USEFUL FOR TREATING TYPE II HYPERCHOLESTEROLEMIA, BUT THIS SUBJECT DESERVES FURTHER CLINICAL RESEARCH. © 2005 BIOSCIENCE EDIPRINT INC.","","AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; D 003; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE RELAXANT AGENT; NITRATE; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLEEDING TIME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SUGARCANE","","","MURRAY C.J.L., LOPEZ A.D., ALTERNATE PROJECTIONS OF MORTALITY AND DISABILITY BY CAUSE 1990-2020. GLOBAL BURDEN DISEASE STUDY, LANCET, 349, (1997); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N. ENGL. J. MED., 317, (1987); RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, (1996); MRC/BHF HEART PROTECTION STUDY OF CHOLESTEROL LOWERING WITH SIMVASTATIN IN 20,536 HIGH-RISK INDIVIDUALS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL, LANCET, 360, (2002); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); SHEPHERD J., BLAUW G.J., MURPHY M.B., ET AL., PRAVASTATIN IN ELDERLY INDIVIDUALS AT RISK OF VASCULAR DISEASE (PROSPER): A RANDOMIZED CONTROLLED STUDY, LANCET, 360, (2002); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, (2001); PYORALA K., DE BACKER G., GRAHAM I., RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, (1994); SMITH D.G., LESLIE S.J., SZUCS T.D., MCBRIDE S., ET AL., COST OF TREATING TO A MODIFIED EUROPEAN ATHEROESCLEROSIS SOCIETY LDL-C TARGET. COMPARISON OF ATORVASTATIN WITH FLUVASTATIN, PRAVASTATIN AND SIMVASTATIN, CLIN. DRUG INVEST., 17, (1999); MULS E., DE BACKER G., DE BACQUER D., ET AL., LIPI-WATCH, A BELGIAN/LUXEMBOURG SURVEY ON ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY LIPID GOALS, PHARMACOEPIDEMIOL., 19, (2000); LEA A.P., MCTAVISH D., ATORVASTATIN: A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN THE MANAGEMENT OF HYPERLIPIDEMIA, DRUGS, 53, (1997); DAVIDSON M.H., ROSUVASTATIN: A HIGHLY EFFICACIOUS STATIN FOR THE TREATMENT OF DYSLIPIDEMIA, EXPERT OPIN. INVEST. DRUGS, 11, (2002); OSE L., KASTELEIN J.J.P., SCOTT R., ET AL., EFFICACY AND SIX-MONTH SAFETY OF SIMVASTATIN 80 MG/D: RESULTS FROM THE WORLDWIDE SIMVASTATIN EXPANDED DOSE PROGRAM (WSEDP), NUTR. METAB. CARDIOV. DIS., 8, (1998); BAKER S.K., TARNOPOLSKY M.A., STATIN MYOPATHIES: PATOPHYSIOLOGIC AND CLINICAL PERSPECTIVES, CLIN. INVEST. MED., 24, (2001); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, (2000); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1998); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CASTANO G., MENENDEZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED TO TYPE 2 DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 22, (2002); CASTANO G., FERNANDEZ L., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND ATORVASTATIN ON LIPID PROFILE AND PLATELET AGGREGATION ON PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS, CLIN. DRUG INVEST., 23, (2003); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, (1996); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., 32, (2001); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 20, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT. J. CLIN. PHARMACOL., 50, (2000); MAS R., D-003: A NEW SUBSTANCE WITH PROMISING LIPID MODIFYING AND PLEIOTROPIC EFFECTS FOR ATHEROSCLEROSIS MANAGEMENT, DRUGS OF THE FUTURE, 29, (2004); MENENDEZ R., MARRERO D., MAS R., ET AL., IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM, ARCH. MED. RES., 36, (2005); GAMEZ R., MENDOZA S., MAS R., ET AL., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR. THER. RES., 61, (2000)","R. MÁS; CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, AVENUE 25 AND 158 STREET, CUBA; EMAIL: CLINICA@ENET.CU","","ENGLISH","DRUGS EXP. CLIN. RES.","ARTICLE","ISI","2-S2.0-31344440243","DRUGS EXP CLIN RES","MEDICAL SURGICAL RESEARCH CENTER;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTER","NOTREPORTED;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@ENET.CU",NA,"CASTAÑO G, 2005, DRUGS EXP CLIN RES","CASTAÑO G, 2005, DRUGS EXP CLIN RES"
"MOLINA V;ARRUZAZABALA M;CARBAJAL D;MÁS R","MOLINA, V. (7006062814); ARRUZAZABALA, M.L. (6603962476); CARBAJAL, D. (8777025000); MÁS, R. (7007164572)","SYNERGISTIC EFFECT OF D003 AND ASPIRIN ON EXPERIMENTAL THROMBOSIS MODELS",2003,"PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS","68","5",13,"10.1016/S0952-3278(03)00020-6","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA 6880, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA 6880, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA 6880, AVE 25 AND 158, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA 6880, AVE 25 AND 158, CUBA","D-003 IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC SATURATED ACIDS PURIFIED FROM SUGARCANE WAX, WITH ANTIPLATELET AND ANTITHROMBOTIC EFFECTS EXPERIMENTALLY DEMONSTRATED. OCTACOSANOIC ACID IS THE MAIN COMPONENT OF D-003, FOLLOWED BY TRIACONTANOIC, DOTRIACONTANOIC, AND TETRACONTANOIC ACIDS, WHILE OTHER ACIDS ARE MINOR COMPONENTS. THIS WORK INVESTIGATES THE EFFECTS OF COMBINATION THERAPY D-003 + ASPIRIN (ASA) ON ARACHIDONIC ACID (AA)-INDUCED SUDDEN DEATH IN MICE AND BLEEDING TIME IN RATS. IN ADDITION, THE EFFECTS OF D-003 ON SERUM LEVELS OF TWO METABOLITES OF AA: THROMBOXANE A2 AND PROSTACYCLIN, ASSESSED THROUGH THE MEASUREMENT OF THEIR STABLE METABOLITES: THROMBOXANE B2 (TXB2) AND 6 KETO PGF1Α BY RADIOIMMUNOASSAY KITS, WERE ALSO INVESTIGATED. COMBINATION THERAPY OF D-003 (50MG/KG) AND ASA (3MG/KG) SIGNIFICANTLY INCREASED BLEEDING TIME IN RATS IN A SYNERGISTIC MANNER COMPARED WITH D-003 OR ASA ALONE. MOREOVER, THE COMBINED TREATMENT OF D-003 (200 MG/KG) AND ASA (5 MG/KG) IN MICE PROTECTED AGAINST AA-INDUCED SUDDEN DEATH (83% SURVIVORS) IN A SYNERGISTIC MANNER WHICH WAS COMPARED WITH EACH TREATMENT ALONE (33% SURVIVORS). THESE RESULTS INDICATE THAT ANTIPLATELET EFFECTS OF D-003 ARE NOT MEDIATED BY A CYCLOOXYGENASE INHIBITION. D-003 AND ASA MONOTHERAPIES REDUCED SERUM TXB2 LEVELS, WHEREAS D-003, BUT NOT ASA, SIGNIFICANTLY INCREASED 6 KETO PGF1Α LEVELS. © 2003 ELSEVIER SCIENCE LTD. ALL RIGHTS RESERVED.","","SACCHARUM HYBRID CULTIVAR; 6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; D 003; NATURAL PRODUCT; POLICOSANOL; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; LIPID COMPOSITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SINGLE DRUG DOSE; SUDDEN DEATH; SUGARCANE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS","","","WILSON J.M., FERGUSON J.J., PLATELET-ENDOTHELIAL INTERACTIONS IN ATHEROTHROMBOTIC DISEASE: THERAPEUTIC IMPLICATIONS, CLIN. CARDIOL., 22, 11, PP. 687-698, (1999); CATTANEO M., SECONDARY PREVENTION OF VASCULAR EVENTS BY PROLONGED ANTIPLATELET THERAPY, BR. MED. J., 296, PP. 320-331, (1988); BASISTA M., DOBRANOWSKI J., GRYGLEWSKI R.J., PROSTACYCLIN AND THROMBOXANE GENERATING SYSTEMS IN RABBITS PRETREATED WITH ASPIRIN, PHARMACOL. RES. COMMUN., 10, PP. 759-763, (1978); VARGAFTIG B.B., THE INHIBITION OF CYCLOOXYGENASE OF RABBIT PLATELETS BY ASPIRIN IS PREVENTED BY SALICYLIC ACID AND BY PHENANTHROLINES, EUR. J. PHARMACOL., 50, PP. 231-241, (1978); MERINO J., LIVIO M., RAJTAR G., DE CAETANO G., SALICYLATE REVERSES IN VITRO ASPIRIN INHIBITION OF RAT PLATELET AND VASCULAR PROSTAGLANDIN GENERATION, BIOCHEM. PHARMACOL., 29, PP. 293-297, (1980); GONZALEZ L., MARRERO D., LAGUNA A., MAS R., ARRUZAZABALA M.L., CARBAJAL D., CORA M., MENENDEZ R., (1998); GAMEZ R., MENDOZA S., MAS R., MESA R., CASTANO G., MARRERO D., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR. THER. RES., 61, PP. 8-16, (2000); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., VALDES S., ANTIPLATELET AND ANTITHROMBOTIC EFFECTS OF D-003, PHARMACOL. RES., 42, 2, PP. 137-143, (2000); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLOGICO DE LA INTERACCIN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACION, REV. IBEROAMER. TROMB. HEMOST., 5, PP. 17-20, (1992); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 50, (1994); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES., 16, 2-3, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, 4, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J. TISSUE REACTIONS, 20, 4, PP. 57-62, (1998); RIZZO E., CRAFT D., DAMMANN A., PHILLIP M., FATTY ALCOHOL METABOLISM IN CULTURED FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J. CLIN. CHEM., 262, PP. 17412-17419, (1990); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB., 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. METAB., 39, PP. 279-284, (1995); KABIR Y., KIMURA S., METABOLISM OF OCTACOSANOL IN LIVER AND MUSCLE OF RAT, ACTA ALIMENT, 24, 1, PP. 39-46, (1995); DEL PRINCIPE D., MENICHELLI A., DE MATTEIS M., DI CORPO M.L., DI GIULIO S., FINAZZI-AGRO A.F., HYDROGEN PEROXIDE HAS A ROLE IN THE AGGREGATION OF HUMAN PLATELETS, FEBS LETT., 1, (1985); IULIANO L., COLAVITA A.R., LEO R., PRATICO D., VIOLI F., OXYGEN FREE RADICALS AND PLATELET ACTIVATION, FREE RADICAL BIOL. MED., 22, (1997); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH. MED. RES., 28, PP. 355-360, (1997); MENENDEZ R., MAS R., AMOR A.M., LEDON N., PEREZ Y., GONZALEZ R.M., RODEIRO I., ZAYAS M., JIMENEZ S., INHIBITION OF RATS LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, CAN. J. PHYSIOL. PHARMACOL., 12, PP. 1-8, (2001); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); PHILP R.B., PAUL M.L., KILLACKEY J.J., KILLACKEY B.A., THE INFLUENCE OF DOSE, TIME OF ADMINISTRATION, BODY TEMPERATURE AND SALICYLATE KITETICS ON THE ANTITHROMBOTIC ACTION OF ACETYLSALICYLIC ACID IN MALE RATS, HAEMOSTASIS, 13, (1983); DAVISON C., SALICYLATE METABOLISM IN MAN, ANN. NY ACAD. SCI., 179, PP. 249-268, (1971); MAJERUS P.W., ARACHIDONATE METABOLISM IN VASCULAR DISORDERS, J. CLIN. INVEST., 72, PP. 1521-1525, (1983); DEJANA E., VILLA S., GAETANO G., BLEEDING TIME IN RATS: A COMPARISON OF DIFFERENT EXPERIMENTAL CONDITIONS, THROMB. HAEMOST., 48, (1982); KOHLER C., WOODING W., ELLENBOGEN L., INTRAVENOUS ARACHIDONATE IN THE MOUSE: A MODEL FOR THE EVALUATION OF ANTI-THROMBOTIC DRUGS, THROMB. RES., 9, PP. 67-80, (1976); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., D-003, A POTENTIAL ANTITHROMBOTIC COMPOUND ISOLATED FROM SUGAR CANE WAX WITH EFFECTS ON ARACHIDONIC ACID METABOLITES, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 67, PP. 19-24, (2002); DARIUS H., LEFER A., BLOCKADE OF THROMBOXANE AND THE PREVENTION OF EICOSANOID-INDUCED SUDDEN DEATH IN MICE, PROC. SOC. EXP. BIOL. MED., 180, PP. 364-368, (1985); BASSENGE E., ENDOTHELIAL FUNCTION IN DIFFERENT ORGANS, PROGR. CARDIOVASC. DIS., 39, PP. 209-228, (1996); MONCADA S., GRYGLEWSKI R.J., BUNTING S., VANE J.R., AN ENZYME ISOLATED FROM ARTERIES TRANSFORMS PROSTAGLANDIN ENDOPEROXIDES TO AN UNSTABLE SUBSTANCE THAT INHIBITS PLATELET AGGREGATION, NATURE, 263, PP. 663-665, (1976); HAMPTON K.K., CERLETTI C., LOIZOU L.A., BUCCHI F., DONATI M.B., DAVIES J.A., DE GAETANO G., PRENTICE C.R., COAGULATION, FIBRINOLYTIC AND PLATELET FUNCTION IN PATIENTS ON LONG TERM THERAPY WITH ASPIRIN 300 MG OR 1,2 MG DAILY COMPARED WITH PLACEBO, THROMB. HAEMOST., 64, 1, PP. 17-20, (1990); FITZGERALD G.A., OATES J.A., HAWIGER J., MAAS R.L., ROBERTS L.J., LAWSON J.A., BRASH A.R., ENDOGENOUS BIOSYNTHESIS OF PROSTACYCLIN AND THROMBOXANE AND PLATELET FUNCTION DURING CHRONIC ADMINISTRATION OF ASPIRIN IN MAN, J. CLIN. INVEST., 71, PP. 676-688, (1988); RAO G.H.R., WHITE J.G., INFLUENCE OF VARIOUS DOSES OF ASPIRIN (IN VIVO) ON PLATELET ARACHIDONIC ACID METABOLISM (EX VIVO) AND FUNCTION, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 51, PP. 63-67, (1994); JANES M., WALSH J., EFFECT OF ASPIRIN AND ALCOHOL ON PLATELET AND VASCULAR PROSTACYCLIN SYNTHESIS, THROMB. RES., 39, PP. 587-593, (1985); SILVER M.J., HOCH W., KOCSIS J.J., INGERMAN C.M., SMITH J.B., ARACHIDONIC ACID CAUSES SUDDEN DEATH IN RABBITS, SCIENCE (WASHINGTON, DC), 183, PP. 1085-1087, (1974); SMITH J.B., THE PROSTANOIDS IN HEMOSTASIS AND THROMBOSIS, AM. J. PATHOL., 99, PP. 743-804, (1980); LEFER A.M., BURKE S.E., SMITH J.B., ROLE OF THROMBOXANES AND PROSTAGLANDIN ENDOPEROXIDES IN THE PATHOGENESIS OF EICOSANOID INDUCED SUDDEN DEATH, THROMB. RES., 32, PP. 311-320, (1983); MYERS A., PENHOS J., RAMEY E., RAMWELL P., THROMBOXANE AGONISM AND ANTAGONISM IN A MOUSE SUDDEN DEATH MODEL, J. PHARMACOL. EXP. THER., 224, PP. 369-372, (1983); DI PASQUALE G., MELLACE D., INHIBITION OF ARACHIDONIC ACID INDUCED MORTALITY IN RABBITS WITH SEVERAL NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, AGENTS ACTIONS, 7, PP. 481-485, (1977); KUSTER L.J., FROLICH J.C., PLATELET AGGREGATION AND THROMBOXANE RELEASE INDUCED BY ARACHIDONIC ACID, COLLAGEN, ADP AND PLATELET ACTIVATING FACTOR FOLLOWING LOW DOSE ACETYLSALICYLIC ACID IN MAN, PROSTAGLANDINS, 32, PP. 415-423, (1986); EDMONDS L.C., LEFER A.M., PROTECTIVE ACTIONS OF A NEW THROMBOXANE SYNTHETASE INHIBITOR IN ARACHIDONATE INDUCED SUDDEN DEATH, LIFE SCI, 35, PP. 1763-1768, (1984); MAKKAR R.R., EIGLER N.L., KAUL S., FRIMERMAN A., NAKAMURA M., SHAH P.K., FORRESTER J.S., HERBERT J.M., LITVACK F., EFFECTS OF CLOPIDOGREL, ASPIRIN AND COMBINED THERAPY IN A PORCINE EX VIVO MODEL OF HIGH-SHEAR INDUCED STENT THROMBOSIS, EUR. HEART J., 19, 10, PP. 1538-1546, (1998); HERBERT J.M., DOL F., BERNAT A., FALOTICO R., LALE A., SAVI P., THE ANTIAGGREGATING AND ANTITHROMBOTIC ACTIVITY OF CLOPIDOGREL IS POTENTIATED BY ASPIRIN IN SEVERAL EXPERIMENTAL MODELS IN THE RABBIT, THROMB. HAEMOST., 80, 3, PP. 512-518, (1998); NEGRESCU E.V., GRUNBERG B., KRATZER M.A., LORENZ R., SIESS W., INTERACTION OF ANTIPLATELET DRUGS IN VITRO: ASPIRIN, ILOPROST, AND THE NITRIC OXIDE DONORS SIN-1 AND SODIUM NITROPRUSSIDE, CARDIOVASC. DRUGS THER., 9, 4, PP. 619-629, (1995)","V. MOLINA; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA 6880, AVE 25 AND 158, CUBA; EMAIL: CLINICA@IP.ETECSA.CU","CHURCHILL LIVINGSTONE","ENGLISH","PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS","ARTICLE","ISI","2-S2.0-0037733976","PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@IP.ETECSA.CU",NA,"MOLINA V, 2003, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS","MOLINA V, 2003, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS"
"MENÉNDEZ R;MARRERO D;MÁS R;FERNÁNDEZ I;GONZÁLEZ L;GONZÁLEZ R","MENÉNDEZ, ROBERTO (7102205059); MARRERO, DAVID (36485087800); MÁS, ROSA (7007164572); FERNÁNDEZ, IVON (57197123091); GONZÁLEZ, LUIS (57214377527); GONZÁLEZ, ROSA MARIA (57191737509)","IN VITRO AND IN VIVO STUDY OF OCTACOSANOL METABOLISM",2005,"ARCHIVES OF MEDICAL RESEARCH","36","6",48,"10.1016/j.arcmed.2004.12.006","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, P.O. BOX 6412, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND. POLICOSANOL IS A MIXTURE OF VERY-LONG-CHAIN ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING EFFECTS, WHOSE MAIN COMPONENT IS OCTACOSANOL. SCARCE DATA ABOUT THE METABOLISM OF OCTACOSANOL AND THE OTHER FATTY ALCOHOLS COMPOSING POLICOSANOL HAVE BEEN PUBLISHED. METHODS. HUMAN FIBROBLASTS WERE CULTURED IN PRESENCE OF 3H-OCTACOSANOL DURING 0.5, 2 AND 4 H. LIPID EXTRACTS WERE ANALYZED BY THIN LAYER CHROMATOGRAPHY, AND THE SPOTS CORRESPONDING TO OCTACOSANOL AND OCTACOSANOIC ACID WERE IDENTIFIED COMPARING WITH AUTHENTIC STANDARDS. SPOTS WERE SCRAPED, TRANSFERRED TO VIALS AND RADIOACTIVITY WAS MEASURED. FOR CORROBORATING THE PRESENCE OF OCTACOSANOL AND OCTACOSANOIC ACID, SAMPLES WERE ANALYZED BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS). THE IN VIVO STUDY OF OCTACOSANOL METABOLISM WAS CONDUCTED IN RATS AND MACACA ARCTOIDES MONKEYS. RATS WERE ORALLY ADMINISTERED WITH POLICOSANOL (60 MG/KG) AND FREE OCTACOSANOL AND OCTACOSANOIC ACID WERE IDENTIFIED IN LIVER AND PLASMA BY GC-MS AT VARIOUS TIME INTERVALS. MONKEYS WERE ORALLY AND ENDOVENOUSLY TREATED WITH POLICOSANOL (10 MG/KG) AND THE PRESENCE OF FREE OCTACOSANOL, OCTACOSANOIC ACID AND SOME CHAIN-SHORTENED FA WAS INVESTIGATED. RESULTS. WHEN FIBROBLASTS WERE CULTURED IN PRESENCE OF 3H-OCTACOSANOL, THREE SPOTS WERE FOUND: A FIRST ONE CORRESPONDED TO OCTACOSANOIC ACID, A SECOND TO OCTACOSANOL AND A THIRD ONE REMAINED UNIDENTIFIED. THE RADIOACTIVITY ON THE SPOT OF OCTACOSANOIC ACID SLIGHTLY DECREASED THROUGHOUT THE INCUBATION BUT INCREASED IN THE THIRD SPOT. OCTACOSANOL AND FREE OCTACOSANOIC ACIDS WERE ALSO IDENTIFIED IN PLASMA OF MONKEYS ORALLY ADMINISTERED WITH POLICOSANOL. IN ADDITION, PLASMA SAMPLES SHOWED FREE SATURATED ACIDS, PALMITIC ACID BEING THE MOST ABUNDANT, FOLLOWED BY OLEIC AND MYSTIRIC ACIDS. UNSATURATED ACIDS (OLEIC AND PALMITOLEIC) WERE ALSO OBSERVED. CONCLUSIONS. THE PRESENT STUDY DEMONSTRATES THAT OCTACOSANOIC ACID IS FORMED AFTER INCUBATION OF FIBROBLAST CULTURES WITH 3H-OCTACOSANOL AND AFTER ORAL DOSING WITH POLICOSANOL TO RATS. IN ADDITION, WE DEMONSTRATED THAT SHORTENED SATURATED (MYRISTIC, PALMITIC AND STEARIC) AND UNSATURATED (OLEIC, PALMITOLEIC) FA ARE ALSO FORMED AFTER ORAL DOSING WITH POLICOSANOL TO MONKEYS. THE PRESENT RESULTS ARE CONSISTENT WITH THE FACT THAT OCTACOSANOL METABOLISM IS LINKED TO FA METABOLISM VIA Β-OXIDATION, BUT FURTHER STUDIES NEED TO EXPLORE THE OCCURRENCE OF MORE METABOLITES PROVING SUCH HYPOTHESIS. © 2005 IMSS. PUBLISHED BY ELSEVIER INC.","CHAIN-SHORTENED FATTY ACIDS; OCTACOSANOIC ACID; OCTACOSANOL METABOLISM; POLICOSANOL","LIPID; OCTACOSANOL; POLICOSANOL; SATURATED FATTY ACID; SHORT CHAIN FATTY ACID; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FIBROBLAST CULTURE; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MACACA; MALE; MASS SPECTROMETRY; NONHUMAN; RADIATION DETECTION; RAT; THIN LAYER CHROMATOGRAPHY","","","LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO V., MESA R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL SÉRICOS EN PERROS BEAGLE, REV CNIC CIEN BIOL, 22, PP. 60-63, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); MENENDEZ R., ARRUZAZABALA M.L., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); HERNANDEZ J., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ J.C., GONZALEZ M., CORDOVI N., FERNANDEZ L., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., EFFECTS OF POLICOSANOL IN LOWERING CHOLESTEROL LEVEL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-181, (1995); CANETTI M., MORERA M.S., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-251, (1995); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HIPERCOLESTEROLEMIA AND NON INSULIN-DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., LOPEZ L.E., ALVAREZ E., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ALVAREZ E., LESCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); MAS R., CASTANO G., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); CASTANO G., MAS, FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERENTOL MED SCI, 56, (2001); CASTANO G., MAS R., FERNANDEZ L., GAMEZ R., ILLNAIT J., EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DOUBLE BLIND COMPARATIVE PILOT STUDY, ANGIOLOGY, 53, PP. 231-239, (2002); CASTANO G., MAS R., FERNANDEZ L., ILLNAIT J., MESA M., ALVAREZ E., LESCAY M., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND ATORVASTATIN IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, DRUG AGING, 20, PP. 153-163, (2003); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARIA M., FRAGA V., EFFECTS OF POLICOSANOL IN PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES IN PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-195, (1996); ARRUZAZABALA M.L., MOLINA V., MAS R., FERNANDEZ L., CARBAJAL D., VALDES S., CASTANO G., ANTIPLATELET EFFECT OF POLICOSANOL (20 AND 40 MG/DAY) IN HEALTHY VOLUNTEERS AND DYSLIPIDEMIC PATIENTS, CLIN EXP PHARMACOL PHYSIOL, 29, PP. 891-897, (2002); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECTS OF POLICOSANOL ON IN VITRO AND IN VIVO RAT MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER-INDUCED RAT LIPOPROTEIN LIPID PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1997); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 20, PP. 255-262, (2000); PEREZ-SOUTO N., GONZALEZ L., MAGRANER J., GONZALEZ L., MEDEROS C.M., REYES J.L., TORRES O., ADMINISTRACIÓN INTRAVENOSA DE ATEROMIXOL (PPG) EN PERROS BEAGLE, CERDOS Y RATAS. DETERMINACIÓN DE NIVELES PLASMÁTICOS DE 1-OCTACOSANOL, REV CENIC CIEN BIOL, 22, PP. 15-18, (1991); MAS R., POLICOSANOL. DRUGS OF THE FUTURE, 25, PP. 569-586, (2000); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL TO RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-<SUP>14</SUP>C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); KABIR Y., KIMURA S., DISTRIBUTION OF RADIOACTIVE OCTACOSANOL IN RESPONSE TO EXERCISE IN RATS, DIE NAHRUNG, 4, PP. 373-377, (1994); WANDERS R.J.A., VREKEN P., FERDINANDUSSE S., JANSEN G.A., WATERHAM H.R., VAN ROERMUND C.W.T., VAN GRUNSVEN G.E., PEROXISOMAL FATTY ACID Α- AND Β-OXIDATION IN HUMANS: ENZYMOLOGY, PEROXISOMAL METABOLITE TRANSPORTERS AND PEROXISOMAL DISEASES, BIOCHEM SOC TRANS, 29, PP. 250-267, (2001); LAZAROW P.B., THE ROLE OF PEROXISOMES IN MAMMALIAN CELLULAR METABOLISM, J INHERIT METAB, 10, PP. 11-22, (1987); OSMUNDEN H., BREMER J., PERDERSEN J.I., METABOLIC ASPECTS OF PEROXISOMAL Β-OXIDATION, BIOCHEM BIOPHYS ACTA, 1085, PP. 141-158, (1991); VEGA L., DUCAT L., GARCIA L., MARCAJE DEL 1-OCTACOSANOL CON TRITIO, NUCLEUS, 13, PP. 12-16, (1993); EVANS E., TRITIUM AND ITS COMPOUNDS, (1974); MILLS G.L., LANE P.A., WEECH P.K., A GUIDEBOOK TO LIPOPROTEIN TECHNIQUE, LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, PP. 20-89, (1984); MARRERO D., GONZALEZ L., TRACE DETERMINATION OF OCTACOSANOL IN RAT PLASMA BY SOLID-PHASE EXTRACTION WITH TENAX GC AND CAPILLARY GAS CHROMATOGRAPHY, J CHROMATOGR B, 762, PP. 43-49, (2002); TOCHER D.R., LEAVER M.J., HODGSON P.A., RECENT ADVANCES IN THE BIOCHEMISTRY AND MOLECULAR BIOLOGY OF FATTY ACYL DESATURASES, PROG LIPID RES, 37, PP. 73-117, (1998)","R. MENÉNDEZ; LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, P.O. BOX 6412, CUBA; EMAIL: CPN.BIOQUIMICA@CNIC.EDU.CU","ELSEVIER INC.","ENGLISH","ARCH. MED. RES.","ARTICLE","ISI","2-S2.0-17444397048","ARCH MED RES","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"MENÉNDEZ R, 2005, ARCH MED RES","MENÉNDEZ R, 2005, ARCH MED RES"
"ALCOCER L;FERNÁNDEZ L;CAMPOS E;MAS R","ALCOCER, L. (59157703200); FERNÁNDEZ, L. (7202848319); CAMPOS, E. (57190684719); MAS, ROSA (7007164572)","A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1999,"INTERNATIONAL JOURNAL OF TISSUE REACTIONS","21","7",16,"","DEPARTMENT OF CARDIOLOGY, MEXICO GENERAL HOSPITAL, MEXICO CITY, MEXICO;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF CARDIOLOGY, MEXICO GENERAL HOSPITAL, MEXICO CITY, MEXICO;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990-6880, CUBA","AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND ACIPIMOX WAS CONDUCTED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. PRIOR TO ENTRY INTO ACTIVE TREATMENT, ALL PATIENTS FOLLOWED A STANDARD CHOLESTEROL-LOWERING DIET FOR 12 WEEKS. SIXTY-THREE PATIENTS WERE RANDOMIZED TO RECEIVE EITHER POLICOSANOL (10 MG/DAY) OR ACIPIMOX (750 MG/DAY) TABLETS FOR 8 WEEKS UNDER DOUBLE-BLIND CONDITIONS. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (P <0.0001) (15.8%), LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL (21%) AND THE RATIOS OF LDL-CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN (HDL)- CHOLESTEROL (15.8%) AND CHOLESTEROL TO HDL-CHOLESTEROL (11.5%). ACIPIMOX SIGNIFICANTLY LOWERED BOTH CHOLESTEROL AND LDL CHOLESTEROL BY 7.5%. THE PERCENT CHANGES OF TOTAL CHOLESTEROL, LDL-CHOLESTEROL AND BOTH RATIOS WERE LARGER IN THE POLICOSANOL GROUP THAN IN THE ACIPIMOX GROUP. BOTH DRUGS WERE WELL TOLERATED. ACIPIMOX SIGNIFICANTLY INCREASED (P >0.001) ASPARTATE AMINO TRANSFERASE LEVELS BUT ONLY FOUR PATIENTS SHOWED INCREASES ABOVE THE NORMAL LIMIT. POLICOSANOL SIGNIFICANTLY REDUCED CREATININE VALUES (P >0.05) BUT NO PATIENTS HAD VALUES OUT OF THE NORMAL RANGE. FOUR PATIENTS WITHDREW FROM THE STUDY (TWO FROM EACH GROUP) BUT NONE WITHDREW BECAUSE OF ADVERSE EFFECTS. NO ADVERSE EFFECTS WERE REPORTED IN THE POLICOSANOL GROUP, WHILE FIVE PATIENTS ON ACIPIMOX REPORTED ADVERSE EFFECTS (HOT FLUSHES, NAUSEA, VOMITING, HEADACHE, HYPOCHONDRIAL PAIN AND LEG EDEMA). THESE RESULTS INDICATE THAT POLICOSANOL (10 MG/DAY) WAS MORE EFFECTIVE AND WELL TOLERATED THAN WAS ACIPIMOX (750 MG/DAY) IN THIS STUDY POPULATION.","","AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; ACIPIMOX; AMINOTRANSFERASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL","","","GOTTO A.M. JR., LA ROSA J.C., HUNNINGHAKE D., ET AL., THE CHOLESTEROL FACTS. A SUMMARY OF THE EVIDENCE RELATING DIETARY FATS, SERUM CHOLESTEROL, AND CORONARY HEART DISEASE, CIRCULATION, 81, (1990); MARGOLIS S., CLINICAL REVIEW: DIAGNOSIS AND MANAGEMENT OF ABNORMAL PLASMA LIPIDS, J. CLIN. ENDOCRIN. METAB., 70, (1990); FRICK M.H., ELO D., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DISLIPIDEMIA, N. ENGL. J. MED., 317, (1987); LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: LA. REDUCTIONS IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, (1984); SHEPERD J., COBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); TIKKANEN M.J., NIKKILA E.A., CURRENT PHARMACOLOGIC TREATMENT OF ELEVATED SERUM CHOLESTEROL, CIRCULATION, 76, (1987); BAHATNAGAR D., LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDEMIA, PHARMACOL. THER., 79, (1998); WIERZBICKI A.S., DIAGNOSIS AND MANAGEMENT OF HYPERLIPIDAEMIA, INT. J. CLIN. PRACT., 51, (1997); FARNIER M., DAVIGNON J., CURRENT AND FUTURE TREATMENT OF HYPERLIPIDEMIA: THE ROLE OF STATINS, AM. J. CARDIOL., 82, (1998); YALE B.M., THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, SUPPL., (1992); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.D.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, (1997); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 4, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, (1994); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE 11 HYPERCHOLESTEROLEMIA, ADV. THER., 12, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR. THER. RES., 56, (1995); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, LA PRENSA MÉDICA ARGENTINA, 83, (1996); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER, 65, (1998); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); FERNANDEZ L., MAS R., ILLNAIT J., FERNARDEZ J.C., POLICOSANOL: RESULTS OF POSTMARKETING SURVEILLANCE CONTROL EN 27 879 CASES, CURR. THER. RES., 59, (1998); BUCKLEY B.M., LONG-TERM SAFETY PROFILE OF ACIPMOX. PHARMACOLOGICAL BASIS AND CLINICAL EVIDENCE, ATHEROSCLEROSIS REV., 22, (1991); FRANCESCHINI G., BERNINI F., MICHELAGNOI S., ET AL., LIPOPROTEIN CHANGES AND INCREASED AFFINITY OF LDL FOR THEIR RECEPTORS AFTER ACIPIMOX TREATMENT IN HYPERTRIGLYCERIDEMIA, ATHEROSCLEROSIS, 81, (1990); TOMVALL P., WALLDIUS G., A COMPARISON BETWEEN NICOTINIC ACID AND ACIPIMOX IN HYPERTRIGLYCERIDEMIA - EFFECTS ON SERUM LIPIDS, LIPOPROTEINS, GLUCOSE TOLERANCE AND TOLERABILITY, J. INT. MED., 230, (1991); DAVIDOFF P., RUIZ F., VARAS M.A., ET AL., ACIPIMOX IN PRIMARY HYPERLIPIDEMIA: SAFETY AND EFFICACY EVALUATED IN SIX MONTHS, REV. MED. CHIL., 119, (1991); LAVEZZARI M., MILANESI G., OGGIONI E., PAMPARANA F., RESULTS OF A PHASE IV STUDY CARRIED OUT WITH ACIPIMOX IN TYPE II DIABETIC PATIENTS WITH CONCOMITANT HYPERLIPOPROTEINEMIA, J. INT. MED. RES., 17, (1989); PARAGH G., BALOGH Z., BODA J., MOHACSI A., JUHASZ A., LEOVEY A., EFFECT OF ACIPIMOX ON DIABETES MELLITUS-ASSOCIATED HYPERLIPOPROTEINEMIA, ORV. HETIL., 134, (1993); FULCHER G.R., CATALANO C., WALKER M., ET AL., A DOUBLE BLIND STUDY OF THE EFFECT OF ACIPIMOX ON SERUM LIPIDS, BLOOD GLUCOSE CONTROL AND INSULIN ACTION IN NON-OBESE PATIENTS WITH TYPE II DIABETES MELLITUS, DIABET. MED., 9, (1992); DEAN J.D., MCCARTHY S., BETTERIDGE D.J., WHATELY SMITH C., POWELL J., OWENS D.R., THE EFFECT OF ACIPIMOX IN PATIENTS WITH TYPE II DIABETES AND PERSISTENT HYPERLIPIDAEMIA, DIABET. MED., 9, (1992); PONTIROLI A.E., FATTOR B., POZZA G., PIANEZZOLA E., STROLIN-BENEDETTI M.L., ACIPIMOX-INDUCED FACIAL SKIN FLUSH: FREQUENCY, THERMOGRAPHIC EVALUATION AND RELATIONSHIP TO PLASMA ACIPIMOX LEVEL, EUR. J. CLIN. PHARMACOL., 43, (1992); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTOR LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, (1996); WRIGHT E.C., NON-COMPLIANCE OR HOW MANY AUNTS HAS MATILDA?, THE LANCET, 342, (1993)","","","ENGLISH","INT. J. TISSUE REACT.","ARTICLE","ISI","2-S2.0-17544397761","INT J TISSUE REACT",NA,"NOTREPORTED",NA,"ALCOCER L, 1999, INT J TISSUE REACT","ALCOCER L, 1999, INT J TISSUE REACT"
"MÁS R;RIVAS P;IZQUIERDO J;HERNÁNDEZ R;FERNÁNDEZ L;FERNÁNDEZ J;ORTA S;ILLNAIT J;RICARDO Y","MÁS, ROSA (7007164572); RIVAS, PEDRO (57213201933); IZQUIERDO, JOSÉ E. (7102685496); HERNÁNDEZ, REYNALDO (57200891789); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO (9432805500); ORTA, SANTA D. (8621035100); ILLNAIT, JOSE (8631465800); RICARDO, YAMILET (19036229900)","PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL",1999,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","60","9",37,"10.1016/S0011-393X(99)80024-1","NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;HAVANA, CUBA;HAVANA, CUBA;HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CUBAN STATE CENTER FOR DRUG CONTROL, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG THAT IS PURIFIED FROM SUGARCANE WAX AND HAS CONCOMITANT ANTIPLATELET EFFECTS. THIS PHARMACOEPIDEMIOLOGIC, OPEN-LABEL, COHORT STUDY INCLUDED 6611 PATIENTS (3602 POLICOSANOL-TREATED PATIENTS, 3009 CONTROLS) OF BOTH SEXES (74.0% MEN, 26.0% WOMEN; MEAN AGE, 51 ± 6 YEARS) MANAGED IN A ROUTINE CLINICAL PRACTICE FROM AUGUST 1991 TO DECEMBER 1996. BOTH GROUPS SHOWED SIMILAR CHARACTERISTICS AT BASELINE, EXCEPT FOR HYPERTENSION, ISCHEMIC CARDIOVASCULAR DISEASE, AND VASCULAR EVENTS, WHICH WERE MORE FREQUENT IN THE POLICOSANOL GROUP THAN IN THE CONTROL GROUP. CONCOMITANT MEDICATIONS WERE SIMILAR IN BOTH GROUPS. DURING THE FOLLOW-UP PERIOD, HOSPITALIZATIONS FOR ANY REASON WERE REPORTED MORE FREQUENTLY IN THE CONTROL GROUP THAN IN THE POLICOSANOL GROUP (310 [10.3%] VS 271 [7.5%]; P < 0.0001), AS WERE HOSPITALIZATIONS REQUIRING SPECIAL CARE (48 [1.6%] IN THE CONTROL GROUP VS 35 [0.97%] IN THE POLICOSANOL GROUP; P < 0.05). FIVE PATIENTS (0.08%) DIED DURING THE STUDY: 3 MEN IN THE CONTROL GROUP DIED OF MYOCARDIAL INFARCTION (1) OR STROKE (2); IN THE POLICOSANOL GROUP, 1 WOMAN DIED OF INTOXICATION AND 1 MAN DIED OF RESPIRATORY ARREST. THE PREVIOUS HISTORY OF SERIOUS VASCULAR ADVERSE EVENTS (AES) WAS MORE FREQUENT IN THE POLICOSANOL GROUP (34 EVENTS, 0.94%) THAN IN THE CONTROL GROUP (14 EVENTS, 0.47%) (P < 0.05). HOWEVER, DURING THE PRESENT FOLLOWUP A LOWER RATE OF SUCH EVENTS OCCURRED IN POLICOSANOL-TREATED PATIENTS (23 EVENTS, 0.64%) THAN IN THE CONTROL GROUP (34 EVENTS, 1.13%) (P < 0.05). TWENTY-SIX PATIENTS (0.72%) DISCONTINUED POLICOSANOL THERAPY BECAUSE OF AES. THE MOST FREQUENTLY REPORTED AES (>0.3% OF THE STUDY POPULATION) THAT DID NOT RESULT IN DISCONTINUATION OF THERAPY WERE WEIGHT LOSS (1.75%), POLYURIA (0.68%), HEADACHE (0.61%), DIZZINESS (0.44%), AND POLYPHAGIA (0.36%), WITH NO SIGNIFICANT BETWEEN-GROUP DIFFERENCES IN FREQUENCY. RESULTS OF THE PRESENT STUDY CORROBORATE THE GOOD TOLERABILITY OF POLICOSANOL IN ROUTINE CLINICAL USE AND SUPPORT ITS RISK-TO-BENEFIT RATIO IN THE STUDY POPULATION.","COHORT STUDY; PHARMACOEPIDEMIOLOGY; PHARMACOLOGIC SURVEILLANCE; POLICOSANOL","ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ADULT; ARTICLE; BULIMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PHASE 4 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; STROKE; VASCULAR DISEASE; VERTIGO; WASTING SYNDROME; WEIGHT REDUCTION","","","FERNER R.B., NEWLY LICENSED DRUGS, BR MED J, 313, PP. 1157-1158, (1996); EDWARDS R., COMPETING IN DRUG SAFETY, LANCET, 342, PP. 631-632, (1992); PORTA M.S., HARTZEMA A.G., THE CONTRIBUTION OF EPIDEMIOLOGY TO THE STUDY OF DRUGS, DRUG INTELL CLIN PHARM, 21, PP. 741-747, (1987); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4 S), LANCET, 344, PP. 1383-1389, (1994); SHEPERD J., COBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ORTENSI G., GTADSTEIN J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CANETTI M.M., MOREIRA M., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CASTANO G., MAS R., FERNANDEX J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 59, PP. 737-745, (1998); MAS R., CASTANO G., FERNANDEZ J.C., ET AL., EFFECT OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA PLUS TWO OR MORO ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCTIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAMER TROMB HEMOS, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); RODRIGUEZ M.D., GARCIN H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAG, 14, PP. 107-113, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG, 14, PP. 239-249, (1994); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY ON 27,879 PATIENTS, CURR THER RES, 59, PP. 717-722, (1998)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0032788819","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"MÁS R, 1999, CURR THER RES CLIN EXP","MÁS R, 1999, CURR THER RES CLIN EXP"
"CASTAÑO G;MÁS R;FERNÁNDEZ L;ILLNAIT J;GÁMEZ R;FERNÁNDEZ J","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, LILIA (7202848319); ILLNAIT, JOSÉ (8631465800); GÁMEZ, RAFAEL (7003605346); FERNÁNDEZ, JULIO C. (9432805500)","COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MGD IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY",2001,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","62","14",11,"10.1016/S0011-393X(01)80031-X","CENTER FOR MEDICAL SURGICAL RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA HAVANA CITY, P.O. BOX 6880 OR 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: POLICOSANOL IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX THAT HAS DEMONSTRATED DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA ASSOCIATED WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS. THE 20 MG/D DOSAGE IS PARTICULARLY USEFUL FOR PATIENTS AT HIGH CORONARY RISK AND TO DATE THIS DOSAGE HAS BEEN ADMINISTERED AS TWO 10-MG TABLETS ONCE DAILY. OBJECTIVE: THIS 8-WEEK STUDY WAS UNDERTAKEN TO COMPARE THE CHOLESTEROL-LOWERING EFFECTS AND TOLERABILITY OF 2 DOSING REGIMENS OF POLICOSANOL 20 MG/D: TWO 10-MG TABLETS VERSUS ONE 20-MG TABLET TAKEN ONCE DAILY WITH THE EVENING MEAL. METHODS: IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, AFTER 4 WEEKS OF DIETARY STABILIZATION, 62 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WERE RANDOMLY ASSIGNED IN A 1:1:1 RATIO TO RECEIVE 2 PLACEBO TABLETS, 2 POLICOSANOL 10-MG TABLETS, OR 1 POLICOSANOL 20-MG TABLET PLUS 1 MATCHED PLACEBO TABLET. PHYSICAL EXAMINATIONS WERE PERFORMED AND LIPID PROFILES AND BLOOD SAMPLES WERE OBTAINED AT BASELINE AND AFTER 4 AND 8 WEEKS OF THERAPY. THE INCIDENCE OF ADVERSE EVENTS (AES) AND COMPLIANCE WITH STUDY MEDICATIONS WERE ALSO EVALUATED AT WEEK 4 AND WEEK 8 OF TREATMENT. RESULTS: THE 2 POLICOSANOL 20 MG/D REGIMENS WERE SIMILARLY EFFECTIVE. POLICOSANOL ADMINISTERED AS TWO 10-MG TABLETS SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (TC) (16.0%, P < 0.001 VS BASELINE), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (35.9%, P < 0.001), AS WELL AS THE TC:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) RATIO (37.3%, P < 0.001) AND LDL-C:HDL-C RATIO (52.4%, P < 0.001). THE REGIMEN SIGNIFICANTLY INCREASED HDL-C LEVELS (38.0%, P < 0.001 VS BASELINE). THE 20-RAG POLICOSANOL TABLET ALSO SIGNIFICANTLY DECREASED TC (20.0%), LDL-C (37.8%), TC:HDL-C RATIO (39.9%), AND LDL-C:HDL-C RATIO (52.4%) (ALL P < 0.001), WHEREAS IT SIGNIFICANTLY RAISED HDL-C LEVELS (39.4%, P < 0.001). TRIGLYCERIDE LEVELS DID NOT CHANGE SIGNIFICANTLY IN EITHER GROUP. THE DIFFERENCES BETWEEN TREATMENT GROUPS WERE NOT SIGNIFICANT. NO SIGNIFICANT CHANGES IN LIPID PROFILE VARIABLES WERE OBSERVED IN THE PLACEBO GROUP. BOTH POLICOSANOL 20 MG/D REGIMENS WERE WELL TOLERATED. NO DRUG-RELATED CLINICAL OR BLOOD BIOCHEMISTRY ABNORMALITIES WERE OBSERVED AFTER 8 WEEKS OF TREATMENT. FIVE PATIENTS (8.1%) WITHDREW FROM THE STUDY, 2 FROM THE PLACEBO GROUP, 2 FROM THE 10-MG TABLET GROUP, AND 1 FROM THE 20-MG TABLET GROUP. ONE OF THESE PATIENTS (IN THE PLACEBO GROUP) WITHDREW FROM THE STUDY BECAUSE OF AN AE (DUODENAL ULCER). THE OTHER AES REPORTED DURING THE STUDY WERE MILD, AND THE FREQUENCY OF AE REPORTS WAS SIMILAR IN ALL THE GROUPS. CONCLUSIONS: THESE RESULTS DEMONSTRATE THAT POLICOSANOL 20 MG/D IS AN EFFECTIVE AND WELL-TOLERATED CHOLESTEROL-LOWERING REGIMEN WHETHER ADMINISTERED AS A 20-MG TABLET ONCE DAILY OR TWO 10-MG TABLETS ONCE DAILY WITH THE EVENING MEAL.","CHOLESTEROL-LOWERING DRUGS; HIGHER ALIPHATIC PRIMARY ALCOHOLS; HYPERCHOLESTEROLEMIA; LIPID-LOWERING THERAPY; POLICOSANOL","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME","","","EPSTEIN F.H., CARDIOVASCULAR DISEASE EPIDEMIOLOGY. A JOURNEY FROM THE PAST INTO THE FUTURE, CIRCULATION, 93, PP. 1755-1764, (1996); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, JAMA, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); ATHEROSCLEROSIS, 110, PP. 121-161, (1994); PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUR HEART J, 19, PP. 1434-1503, (1998); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR HEART J, 19, SUPPL. A, (1998); ANDERSON K.M., WILSON P.W., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A.M., HUNT D., LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY. CLINICAL IMPLICATIONS FOR CARDIOVASCULAR PRACTICE, CHOLESTEROL-LOWERING THERAPY: EVALUATION OF CLINICAL TRIAL EVIDENCE, PP. 173-190, (2000); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS. RESULTS OF AFCAPS/TEXCAPS, JAMA, 279, PP. 1615-1622, (1998); GOTTO A., ASSMANN G., CARMENA R., ET AL., LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE. 2ND ED., PP. 106-156, (2000); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, PP. 507-513, (1992); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, PP. 819-828, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES CLIN EXP, 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 859-867, (1997); CANETTI M., MOREIRA M., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES CLIN EXP, 58, PP. 868-875, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES CLIN EXP, 59, PP. 737-745, (1998); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES CLIN EXP, 60, PP. 379-391, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-147, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECT OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL; TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON-INSULIN-DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES CLIN EXP, 60, PP. 458-467, (1999); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW-DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOWDENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DE-TERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); O'BRIEN P.C., SHAMPO M.A., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); PARKER T.S., MC NAMARA D.J., BROWN C., MEVALONIC ACID IN HUMAN PLASMA: RELATIONSHIP OF CONCENTRATION AND CIRCADIAN RHYTHM TO CHOLESTEROL SYNTHESIS IN MAN, PROC NATL ACAD SCI USA, 79, PP. 3037-3041, (1982); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA, AM J CARDIOL, 81, PP. 582-587, (1998); SMITH D.G., LESLIE S.J., SZUCS T.D., ET AL., COST OF TREATING TO A MODIFIED EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET. COMPARISON OF ATORVASTATIN WITH FLUVASTATIN, PRAVASTATIN AND SIMVASTATIN, CLIN DRUG INVEST, 17, PP. 185-193, (1999); MULS E., DE BACKER G., DE BACQUER D., ET AL., LIPI-WATCH, A BELGIAN/LUXEMBOURG SURVEY ON ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY LIPID GOALS, PHARMACOEPIDEMIOLOGY, 19, PP. 219-229, (2000)","R. MÁS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, P.O. BOX 6880, CUBA; EMAIL: DALMER@IP.ETECSA.CU","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0035060556","CURR THER RES CLIN EXP","CENTER FOR MEDICAL SURGICAL RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"CASTAÑO G, 2001, CURR THER RES CLIN EXP","CASTAÑO G, 2001, CURR THER RES CLIN EXP"
"CATALÁ I M;LAHUERTA Z L;MARTÍNEZ C J","CATALÁ ICARDO, M. (6601978280); LAHUERTA ZAMORA, L. (6603396811); MARTÍNEZ CALATAYUD, J. (7005853454)","SOLIDPHASE REACTORS AS HIGH STABILITY REAGENT SOURCES IN FLOW ANALYSIS SELECTIVE FLOW INJECTION SPECTROPHOTOMETRIC DETERMINATION OF CYSTEINE IN PHARMACEUTICAL FORMULATIONS",1998,"ANALYST","123","4",19,"10.1039/a801787e","DEPARTAMENTO DE QUÍMICA, COLEGIO UNIVERSITARIO DE FARMACIA, C.E.U. SAN PABLO, 46113 MONCADA, VALENCIA, SPAIN;DEPARTAMENTO DE QUÍMICA, COLEGIO UNIVERSITARIO DE FARMACIA, C.E.U. SAN PABLO, 46113 MONCADA, VALENCIA, SPAIN;DEPARTAMENTO DE QUIMICA ANALITICA, UNIVERSITAT DE VALÈNCIA, 46100 BURJASSOT, VALENCIA, DOCTOR MOLINER, 50, SPAIN","THE FLOW INJECTION SPECTROPHOTOMETRIC DETERMINATION OF CYSTEINE WAS CARRIED OUT BY REACTION WITH COBALT(II) IONS ENTRAPPED IN A POLYMERIC MATERIAL AND FILLING A PACKED-BED REACTOR; THE RELEASED COBALT(II) COMPLEXED WITH THE AMINO ACID WAS MONITORED AT 360 NM. THE METHOD WORKED WITH A HIGH REPEATABILITY, EVEN WITH INDEPENDENT REACTORS, DAYS AND SOLUTIONS. SELECTIVITY OF THE PROCEDURE WAS TESTED WITH TWENTY DIFFERENT FOREIGN COMPOUNDS FOUND IN PHARMACEUTICAL FORMULATIONS CONTAINING CYSTEINE, PARENT AMINO ACIDS INCLUDED; NO SERIOUS INTERFERENCES WERE OBSERVED. THE CALIBRATION GRAPH FOR CYSTEINE WAS LINEAR OVER THE RANGE 1-90 ΜG ML-1 WITH A RELATIVE STANDARD DEVIATION OF 0.8% AT 60 ΜG ML-1 (N = 158). THE CALCULATED SAMPLE THROUGHPUT WAS 90 H-1. THE METHOD WAS APPLIED TO DETERMINE THE CONTENT OF CYSTEINE IN PHARMACEUTICAL FORMULATIONS.","CYSTEINE; FLOW INJECTION; PHARMACEUTICALS; SIMPLEX OPTIMISATION; SOLID-PHASE REACTORS; SPECTROPHOTOMETRY","COBALT; CYSTEINE; PIL FOOD; POLICOSANOL; UNCLASSIFIED DRUG; ANALYTIC METHOD; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG FORMULATION; FLOW INJECTION ANALYSIS; REPRODUCIBILITY; SOLID PHASE REACTOR; SPECTROPHOTOMETRY","","","PICKERING W.F., CHEM. ANAL., 53, (1964); GARCIA MATEO J.V., MARTINEZ CALATAYUD J., CHEM. ANAL. (WARSAW), 38, (1993); MARTINEZ CALATAYUD J., FLOW INJECTION ANALYSIS OF PHARMACEUTICALS. AUTOMATION IN THE LABORATORY, (1996); GARCIA MATEO J.V., MARTINEZ CALATAYUD J., PHARM. TECHNOL. INT., 4, (1992); GARCIA MATEO J.V., MARTINEZ CALATAYUD J., PHARM. TECHNOL. INT., 4, (1992); GARCIA MATEO J.V., MARTINEZ CALATAYUD J., ANAL. CHIM. ACTA, 274, (1993); LAHUERTA ZAMORA L., GARCIA MATEO J.V., MARTINEZ CALATAYUD J., ANAL. CHIM. ACTA, 265, (1992); LAHUERTA ZAMORA L., MARTINEZ CALATAYUD J., TALANTA, 40, (1993); LAHUERTA ZAMORA L., MARTINEZ CALATAYUD J., ANAL. CHIM. ACTA, 280, (1994); LOPEZ PAZ J.L., MARTINEZ CALATAYUD J., J. PHARM. BIOMED. ANAL., 11, (1993); CATALA ICARDO M., LAHUERTA ZAMORA L., MARTINEZ CALATAYUD J., LRA, 10, (1998); LOPEZ GOMEZ A.V., GARCIA MATEO J.V., MARTINEZ CALATAYUD J., ANALYST; ALWARTHAN A.A., AL-LOHEDAN H.A., TALANTA, 41, (1994); AMER M.M., EL-TARRAS M.F., FATTAH S.A., METWALLY F.M., EGYPT J. PHARM. SCI., 30, (1989); SEN A.K., DAS T.K., INDIAN DRUGS, 27, (1989); KUMAR Y., RATHORE Y.K.S., MATHUR S.C., MURUGESAN N., SETHI P.D., INDIAN DRUGS, 29, (1992); HERNANDEZ-MARTINEZ J., MARTINEZ P.J., GUTIERREZ P., MARTINEZ M.I., TALANTA, 39, (1992); BESADA A., ANAL. LETT., 21, (1988); CHATTERJEE P.K., JAIN C.L., SETHI P.D., INDIAN J. PHARM. SCI., 49, (1987); JIE N.Q., YANG J.H., ZHAN Z.G., ANAL. LETT., 26, (1993); KHODARI M., ALI A.M., EL-MAALI N.A., ANAL. LETT., 26, (1993); MACDONALD A., NIEMAN T.A., ANAL. CHEM., 57, (1985); ALWARTHAN A.A., AL-TAMRAH S.A., AKEL A.A., ANAL. CHIM. ACTA, 292, (1994); FEIGL F., ANÁLISIS CUALITATIVO MEDIANTE REACCIONES A LA GOTO. APLICACIONES INORGÁNICAS Y ORGÁNICAS, (1949); WILLARD H., KAUFMANN S., ANAL. CHEM., 19, (1947); SHIPMAN W.H., LAI J.R., ANAL. CHEM., 28, (1956); MORGAN S.L., DEMING S.N., ANAL. CHEM., 46, (1974); NELDER J.A., MEAD R., COMPUT. J., (1965); MARTINEZ CALATAYUD J., GARCIA MATEO J.V., RECENT RESEARCH DEVELOPMENTS IN PURE AND APPLIED ANALYTICAL CHEMISTRY; BJERRUM J., SCHWARZENBACH G., SILLEN L.G., STABILITY CONSTANTS OF METAL-ION COMPLEXES, (1964); MARTELL A.E., CALVIN M., CHEMISTRY OF THE CHELATE COMPOUNDS, (1956); BRITISH PHARMACOPOEIA, (1993); MARTINDALE, THE EXTRA PHARMACOPOEIA, (1993)","","ROYAL SOCIETY OF CHEMISTRY","ENGLISH","ANALYST","ARTICLE","ISI","2-S2.0-0031683025","ANALYST",NA,"NOTREPORTED",NA,"CATALÁ ICARDO M, 1998, ANALYST","CATALÁ ICARDO M, 1998, ANALYST"
"RE L;BAROCCI S;CAPITANI C;VIVANI C;RICCI M;RINALDI L;PAOLUCCI G;SCARPANTONIO A;LEÓN-FERNÁNDEZ O;MORALES M","RE, L. (7003874125); BAROCCI, S. (7003911727); CAPITANI, C. (57151054300); VIVANI, C. (8044625300); RICCI, M. (58354861700); RINALDI, L. (57197316842); PAOLUCCI, G. (8044625400); SCARPANTONIO, A. (8044625500); LEÓN-FERNÁNDEZ, O.S. (7004479917); MORALES, M.A. (57193551559)","EFFECTS OF SOME NATURAL EXTRACTS ON THE ACETYLCHOLINE RELEASE AT THE MOUSE NEUROMUSCULAR JUNCTION",1999,"PHARMACOLOGICAL RESEARCH","39","6",33,"10.1006/phrs.1998.0433","SCHOOL OF BIOLOGICAL SCIENCES, UNIVERSITY OF ACONA, 60131 ANCONA, VIA RANIERI, 2, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;INST. OF EXP. AND CLINICAL MEDICINE, LABORATORY OF PHARMACOLOGY, UNIVERSITY OF ANCONA, 60131 ANCONA, ITALY;CUBA;DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF CHILE, SANTIAGO 7, CASILLA 70.000, CHILE","NATURAL EXTRACTS HAVE BEEN PROVED TO BE USEFUL IN DIFFERENT HUMAN PATHOLOGICAL CONDITIONS. THE SCIENTIFIC CONSIDERATION OF THE THERAPEUTIC POTENTIAL OF PLANT EXTRACTS IS STILL INAPPROPRIATE DUE TO THE LACK OF BOTH PHARMACOLOGICAL AND EPIDEMIOLOGICAL BASIC STUDIES. HERE, WE STARTED FROM AN ELECTROPHYSIOLOGICAL POINT OF VIEW, A STUDY ON THE EFFECTS OF TWO EXTRACTS ON THE ACETYLCHOLINE (ACH) RELEASE AT THE NEUROMUSCULAR JUNCTION. THE EXTRACTS PURIFIED FROM SUGAR CANE (POLICOSANOL) AND PSIDIUM GUAJAVA (QUERCETIN) HAVE BEEN SUBMITTED TO THIS STUDY. THE WIDE EPIDEMIOLOGY OF THESE AGENTS SUGGESTS THERAPEUTIC POTENTIALS NOT YET WELL OUTLINED AT THE BASIC LEVEL. OUR DATA DEMONSTRATE SOME INTERACTIONS IN THE MODULATION OF THE ACH RELEASE AT THE MOUSE NEURO-MUSCULAR JUNCTION, WHICH ARE WELL CORRELATED WITH THE SUGGESTED MOLECULAR MECHANISMS. POLICOSANOL ENHANCES TO A SMALL EXTENT EITHER THE SPONTANEOUS OR THE EVOKED ACH RELEASE. FURTHERMORE, AN INCREASE OF THE RATE OF THE CONFORMATIONAL CHANGE INDUCED AT THE NICOTINIC RECEPTOR-CHANNEL COMPLEX BY ACH IS ALSO OBSERVED. QUERCETIN INDUCED A REDUCTION OF THE ACH EVOKED RELEASE. THE POSSIBILITY THAT THIS EFFECT COULD BE ASCRIBED TO SOME INTERACTION WITH PRESYNAPTIC CALCIUM CHANNEL IS NOTEWORTHY. THE RESULTS ARE DISCUSSED IN TERMS OF A POSSIBLE INTERFERENCE WITH ACETYLCHOLINESTERASE BY POLICOSANOL AND OF A PRESYNAPTIC MOLECULAR ACTION OF QUERCETIN MODULATING THE CYTOSOLIC CALCIUM CONCENTRATION.","CALCIUM; LOOSE PATCH CLAMP; NATURAL EXTRACTS; NEUROMUSCULAR JUNCTION","ACETYLCHOLINE; CALCIUM CHANNEL; NICOTINIC RECEPTOR; POLICOSANOL; QUERCETIN; ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ELECTROPHYSIOLOGY; MOUSE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL","MURST; CONSIGLIO NAZIONALE DELLE RICERCHE, CNR","THE PRESENT SCIENTI®C WORK WAS SUPPORTED BY CNR AND MURST FUNDS GIVEN TO L. RE.","COX P.A., BALICK M.J., THE ETHNOBOTANICAL APPROACH TO DRUG DISCOVERY, SCI AM, 270, 6, (1994); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, 3-4, (1994); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, 3-4, (1994); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 50, 5, (1994); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, 3, (1993); LUTTERODT G.D., INHIBITION OF GASTROINTESTINAL RELEASE OF ACETYLCHOLINE BY QUERCETIN AS A POSSIBLE MODE OF ACTION OF PSIDIUM GUAJAVA LEAF EXTRACTS IN THE TREATMENT OF ACUTE DIARRHOEAL DISEASE, J ETHNOPHARMACOL, 25, 3, (1989); LOZOYA X., BECERRIL G., MARTINEZ M., MODEL OF INTRALUMINAL PERFUSION OF THE GUINEA PIG ILEUM IN VITRO IN THE STUDY OF THE ANTIDIARRHEAL PROPERTIES OF THE GUAVA PSIDIUM GUAJAVA, ARCH INVEST MED MEX, 21, 2, (1990); MORALES M.A., TORTORIELLO J., MECKES M., PAZ D., LOZOYA X., CALCIUM-ANTAGONIST EFFECT OF QUERCETIN AND ITS RELATION WITH THE SPASMOLYTIC PROPERTIES OF PSIDIUM GUAJAVA L, ARCH MED RES, 25, 1, (1994); STUHMER W., ROBERTS W.M., ALMERS W., THE LOOSE PATCH CLAMP, SINGLE CHANNEL RECORDING, (1983); RE L., COLA V., FULGENZI G., MARINELLI F., CONCETTONI C., ROSSINI L., POSTSYNAPTIC EFFECTS OF METHOCTRAMINE AT THE MOUSE NEUROMUSCULAR JUNCTION, NEUROSCIENCE, 57, (1993); RE L., COLA V., FULGENZI G., MARINELLI F., CONCETTONI C., ROSSINI L., MUSCARINIC RECEPTORS IN MOUSE NEUROMUSCULAR JUNCTION: ON THE EFFECTS OF SOME AGONISTS AND ANTAGONISTS, GEN PHARMACOL, 24, (1993); RE L., MORETTI V., ROSSINI L., GIUSTI P., SODIUM-ACTIVATED POTASSIUM CURRENT IN MOUSE DIAPHRAGM, FEBS, 270, (1990); RE L., GIUSTI P., CONCETTONI C., DI SARRA B., COMPUTERISED ESTIMATION OF SPONTANEOUS AND EVOKED ACETYLCHOLINE RELEASE AT THE NEUROMUSCULAR JUNCTION, J PHARMACOL METH, 22, (1989); KATZ B., MILEDI R., THE BINDING OF ACETYLCHOLINE TO RECEPTORS AND ITS REMOVAL FROM THE SYNAPTIC CLEFT, J PHYSIOL, 231, (1973); KORDAS M., ON THE ROLE OF JUNCTIONAL CHOLINESTERASE IN DETERMINING THE TIME COURSE OF THE END-PLATE CURRENT, J PHYSIOL, 270, (1977); FATT P., KATZ B., SPONTANEOUS SUBTHRESHOLD ACTIVITY AT MOTOR NERVE ENDINGS, J PHYSIOL, 117, (1952); MAGLEBY K.L., STEVENS C.F., A QUANTITATIVE DESCRIPTION OF END-PLATE CURRENTS, J PHYSIOL, 223, (1972)","","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0033106170","PHARMACOL RES",NA,"NOTREPORTED",NA,"RE L, 1999, PHARMACOL RES","RE L, 1999, PHARMACOL RES"
"CASTAÑO G;MÁS R;FERNÁNDEZ L;FERNÁNDEZ J;ILLNAIT J;LÓPEZ L;ALVAREZ E","CASTAÑO, G. (56232967100); MÁS, R. (7007164572); FERNÁNDEZ, L. (7202848319); FERNÁNDEZ, J.C. (9432805500); ILLNAIT, J. (8631465800); LÓPEZ, L.E. (57924898800); ALVAREZ, E. (15053135600)","EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA",2000,"GYNECOLOGICAL ENDOCRINOLOGY","14","8",62,"10.3109/09513590009167681","CASTAÑO G.;NATL. CENTER FOR SCIENTIFIC RESEARCH, CNIC, CUBANACÁN, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6990, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, CNIC, CUBANACÁN, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, CNIC, CUBANACÁN, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, CNIC, CUBANACÁN, HAVANA CITY, CUBA; LÓPEZ L.E.;NATL. CENTER FOR SCIENTIFIC RESEARCH, CNIC, CUBANACÁN, HAVANA CITY, CUBA","THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL, A CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGAR-CANE WAX, IN POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA. A TOTAL OF 244 WOMEN WHO HAD EXPERIENCED THE MENOPAUSE AND SHOWED ELEVATED SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS DESPITE 6 WEEKS ON A STANDARD LIPID-LOWERING DIET WERE RANDOMIZED TO RECEIVE PLACEBO OR POLICOSANOL 5 MG/DAY FOR 12 WEEKS, AFTER WHICH THE DOSE WAS DOUBLED TO 10 MG/DAY FOR THE NEXT 12 WEEKS. POLICOSANOL (5 AND 10 MG/DAY) SIGNIFICANTLY LOWERED LDL-C LEVELS (17.7% AND 25.2%, RESPECTIVELY) AND TOTAL CHOLESTEROL (12.6% AND 16.7%, RESPECTIVELY), AS WELL AS THE RATIOS OF LDL-C TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) (17.0% AND 29.3%, RESPECTIVELY) AND TOTAL CHOLESTEROL TO HDL-C (16.7% AND 27.2%, RESPECTIVELY), COMPARED TO THE BASELINE AND PLACEBO; AT THE SAME TIME, POLICOSANOL SIGNIFICANTLY RAISED HDL-C LEVELS BY 16.5% AND 29.3%, RESPECTIVELY. THE DRUG WAS SAFE AND WELL TOLERATED. NO DRUG-RELATED ADVERSE EVENTS WERE OBSERVED, AND EVEN THE EXTENT OF ADVERSE EVENTS WAS LESS IN THE POLICOSANOL GROUP THAN IN THE PLACEBO GROUP. FOUR SERIOUS ADVERSE EVENTS OCCURRED IN THE PLACEBO GROUP (ONE MYOCARDIAL INFARCTION, TWO CASES OF HYPERTENSIVE STATUS AND ONE SURGICAL INTERVENTION) COMPARED TO NONE IN THE POLICOSANOL GROUP. IN CONCLUSION, POLICOSANOL IS EFFECTIVE, SAFE AND WELL TOLERATED IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN.","CHOLESTEROL-LOWERING DRUGS; DYSLIPIDEMIA; POLICOSANOL; POSTMENOPAUSE; TYPE II HYPERCHOLESTEROLEMIA","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW FAT DIET; MAJOR CLINICAL STUDY; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","BUSH T.L., THE EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN, ANN NY ACAD SCI, 592, PP. 263-271, (1990); KNAPP R.G., SUTHERLAND S.E., KEIL J.E., ET AL., A COMPARISON OF THE EFFECTS OF CHOLESTEROL ON CHD MORTALITY IN BLACK AND WHITE WOMEN: TWENTY-EIGHT YEARS OF FOLLOW-UP IN THE CHARLESTON HEART STUDY, J CLIN EPIDEMIOL, 45, PP. 1119-1129, (1992); NABULSI A.A., FOLSOM A.R., WHITE A., ET AL., ASSOCIATION OF HORMONE REPLACEMENT THERAPY WITH VARIOUS CARDIOVASCULAR RISK FACTORS IN POSTMENOPAUSAL WOMEN, N ENGL J MED, 328, PP. 1069-1075, (1993); SEMPOS C.T., CLEEMAN J.I., CARROLL M.D., ET AL., PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG US ADULTS: AN UPDATE BASED ON GUIDELINES FROM THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL, J AM MED ASSOC, 269, PP. 3009-3014, (1993); LAROSA J.C., MANAGEMENT OF POSTMENOPAUSAL WOMEN WHO HAVE HYPERLIPIDEMIA, AM J MED, 96, SUPPL. 6A, (1994); ARCA M., LERNA G., GRUNDY S., HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN: METABOLIC DEFECTS AND RESPONSE TO LOW DOSE LOVASTATIN, J AM MED ASSOC, 271, PP. 453-459, (1994); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN EPIDEMIOL, 2, PP. 161-176, (1992); EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN WOMEN. SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), J AM MED ASSOC, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., ON BEHALF OF THE TASK FORCE. PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); ATHEROSCLEROSIS, 110, PP. 121-161, (1994); HONG M.K., ROMM P.A., REAGAN K., ET AL., EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON SERUM LIPID VALUES AND ANGIOGRAPHICALLY DEFINED CORONARY ARTERY DISEASE IN POSTMENOPAUSAL WOMEN, AM J CARDIOL, 69, PP. 176-178, (1992); TIKKANEN M.J., NIKKILA E.A., MENOPAUSE ESTROGEN AND RISK FOR CORONARY HEART DISEASE, ACTA OBSTET GYNECOL SCAND, 40, PP. 39-43, (1987); GAMBRELL D.R. JR., TERAN A.Z., CHANGES IN LIPIDS AND LIPOPROTEINS WITH LONG-TERM ESTROGEN DEFICIENCY AND HORMONE REPLACEMENT THERAPY, AM J OBSTET GYNECOL, 165, PP. 307-317, (1991); WALSH B.W., SCHIFF I., ROSNER B., ET AL., EFFECTS OF POSTMENOPAUSAL ESTROGEN REPLACEMENT ON THE CONCENTRATIONS AND METABOLISM OF PLASMA LIPOPROTEINS, N ENGL J MED, 325, PP. 1196-1204, (1991); FLETCHER C.D., FARISH E., HART D.M., ET AL., EFFECT OF LIPOPROTEINS OF TRISEQUENS, A COMBINED HORMONE PREPARATION, MATURITAS, 6, PP. 279-283, (1984); PLUNKETT E.R., WOLFE B.M., PROLONGED EFFECTS OF A NOVEL, LOW-DOSAGE CONTINUOUS PROGESTIN/CYCLIC ESTROGEN REPLACEMENT PROGRAM IN POSTMENOPAUSAL WOMEN, AM J OBSTET GYNECOL, 166, PP. 117-121, (1992); EFFECTS OF ESTROGEN OR ESTROGEN/PROGESTIN REGIMENS ON HEART DISEASE RISK FACTORS IN POSTMENOPAUSAL WOMEN. THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL, J AM MED ASSOC, 273, PP. 199-208, (1995); VILLECCO A.S., DE ALOYSIO D., FODERARO S., ET AL., COMPARISON OF THE EFFECTS OF SIMVASTATIN VERSUS HORMONE REPLACEMENT THERAPY IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 515-529, (1995); DAVIDSON M.H., TESTOLIN L.M., MAKI K.C., ET AL., A COMPARISON OF ESTROGEN REPLACEMENT, PRAVASTATIN, AND COMBINED TREATMENT FOR THE MANAGEMENT OF HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN, ARCH INTERN MED, 157, PP. 1186-1192, (1997); DARLING G.M., JOHNS J.A., MCCLOUD P.I., ET AL., ESTROGEN AND PROGESTIN COMPARED WITH SIMVASTATIN FOR HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN, N ENGL J MED, 337, PP. 595-601, (1997); FARNIER M., DAVIGNON J., CURRENT AND FUTURE TREATMENT OF HYPERLIPIDEMIA: THE ROLE OF STATINS, AM J CARDIOL, 82, (1998); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR THER RES, 56, PP. 819-828, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATM IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ARRUZAZABALA M.DE.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.DE.L., MAS R., ET AL., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGL LEUK ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGL LEUK ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 10, PP. 119-124, (1998); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, (2000); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); NOA M., MAS R., DE LA ROSA M.C., ET AL., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); SIEGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); CONNOR W.E., CONNOR S.L., THE DIETARY TREATMENT OF HYPERLIPIDEMIA: RATIONALE, TECHNIQUE AND EFFICACY, MED CLIN NORTH AM, 66, PP. 485-518, (1982); BARRETT-CONNOR E., ESTROGEN REPLACEMENT THERAPY AND ATHEROSCLEROSIS. ATHEROSCLEROSIS XI, PROCEEDINGS OF THE XITH INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, PP. 811-816, (1998); NASR A., BRECKWOLDT M., ESTROGEN REPLACEMENT THERAPY AND CARDIOVASCULAR PROTECTION: LIPID MECHANISMS ARE THE TIP OF AN ICEBERG, GYNECOL ENDOCRINOL, 12, PP. 43-59, (1998)","","PARTHENON PUBLISHING GROUP LTD","ENGLISH","GYNECOL. ENDOCRINOL.","ARTICLE","ISI","2-S2.0-0033936923","GYNECOL ENDOCRINOL",NA,"NOTREPORTED",NA,"CASTAÑO G, 2000, GYNECOL ENDOCRINOL","CASTAÑO G, 2000, GYNECOL ENDOCRINOL"
"NOA M;MÁS R;MESA R","NOA, MIRIAM (7003318964); MÁS, ROSA (7007164572); MESA, ROSARIO (7003836140)","EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY",1998,"INTERNATIONAL JOURNAL OF CARDIOLOGY","67","7",18,"10.1016/S0167-5273(98)00305-2","CUBA;CUBA;CUBA","WE STUDIED THE EFFECT OF POLICOSANOL ON SMOOTH MUSCLE CELL PROLIFERATION IN THE CUFFED CAROTID ARTERY OF THE RABBIT. POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE WAX, WITH CHOLESTEROL LOWERING EFFECTS PROVED IN EXPERIMENTAL MODELS AND PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. IT ACTS BY INHIBITING CHOLESTEROL BIOSYNTHESIS. THE POSITIONING OF A NONOCCLUSIVE SILICONE COLLAR AROUND THE RABBIT CAROTID ARTERY RESULTS IN THE FORMATION OF A NEOINTIMA. WE WISHED TO DETERMINE WHETHER POLICOSANOL ORALLY ADMINISTERED PREVENTED INTIMAL THICKENING. COLLARS WERE PLACED AROUND THE LEFT CAROTID FOR 15 DAYS. THE CONTRALATERAL ARTERY WAS SHAM OPERATED. WE INCLUDED THREE EXPERIMENTAL GROUPS: A CONTROL RECEIVED VEHICLE AND TWO OTHERS POLICOSANOL AT 5 AND 25 MG KG UNTIL SACRIFICED. SAMPLES OF ARTERIES WERE EXAMINED BY LIGHT AND ELECTRON MICROSCOPY: TO EVALUATE INTIMAL THICKENING THE CROSS-SECTIONAL AREA OF INTIMA AND MEDIA WERE MEASURED. NEOINTIMA WAS SIGNIFICANTLY REDUCED IN POLICOSANOL-TREATED ANIMALS COMPARED WITH CONTROLS. THE SMOOTH MUSCLE CELL PROLIFERATION WAS STUDIED BY THE IMMUNOHISTOCHEMICAL DETECTION OF PROLIFERATING CELL NUCLEAR ANTIGEN AND A SIGNIFICANT REDUCTION WAS OBSERVED IN POLICOSANOL TREATED RABBITS. IT IS CONCLUDED THAT POLICOSANOL HAS A PROTECTIVE EFFECT ON THE NEOINTIMA FORMATION IN THIS EXPERIMENTAL MODEL.","POLICOSANOL; SMOOTH MUSCLE CELL PROLIFERATION","ANIMALS; ANTICHOLESTEREMIC AGENTS; CAROTID ARTERIES; CELL NUCLEUS; ENDOTHELIUM, VASCULAR; FATTY ALCOHOLS; MALE; MICROSCOPY, ELECTRON; MUSCLE, SMOOTH, VASCULAR; PROLIFERATING CELL NUCLEAR ANTIGEN; RABBITS; TUNICA INTIMA; TUNICA MEDIA; ALCOHOL; CYCLINE; POLICOSANOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE","","","RAINES B., ROSS R., SMOOTH MUSCLE CELL AND THE PATHOGENESIS OF THE LESIONS OF ATHEROSCLEROSIS, BR HEART J, 69, PP. 30-37, (1993); IP J., FUSTER V., BADIMON L., BADIMON J., TAUBMAN M., CHESEBRO J., SYNDROME OF ACCELERATED ATHEROSCLEROSIS: ROLE OF VASCULAR INJURY AND SMOOTH MUSCLE CELL PROLIFERATION, J AM COLL CARDIOL, 15, PP. 1667-1687, (1990); COOPER M., REISON D., ROSE B., ACCELERATED ATHEROSCLEROSIS, ISCHEMIC HEART DIS, 6, PP. 581-589, (1991); ROSS R., GLOMNET J., KARIYA B., HARKER L., A PLATELET-DEPENDENT SERUM FACTOR THAT STIMULATES THE PROLIFERATION OF ARTERIAL SMOOTH MUSCLE CELLS IN VITRO, PROC NAIL ACAD SCI, 71, PP. 1207-1210, (1974); SOMA M., CORSINI A., PAOLETTI R., CHOLESTEROL AND MEVALONIC ACID MODULATION IN CELL METABOLISM AND MULTIPLICATION, TOXICOL LETT, 64-65, PP. 1-15, (1992); RODRIGUEZ C., MESA R., MAS R., AMOR A.M., CASTANO G., ESTUDIO DEL EFECTO SOBRE LIPIDOS Y LIPOPROTEINAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARETOIDES), ARCH VENEZOLANOS DE FARMACOL Y TERAP, 11, PP. 74-79, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MEDICAS (VENEZUELA), 5, PP. 21-28, (1991); PENS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEFMIA, CURR THER RES, 52, 3, PP. 507-512, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 127-133, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLENNA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THERAP RES, 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ET AL., POLICOSANOL FOR CHOLESTEROL-LOWERING LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLERMIA, CURR THERAP RES, 56, PP. 176-182, (1995); SOLTERO I., FUENMAYOR I., COLMENARES J., ARIAS F., ENSAYO DOBLE CIEGO PARA LA EVALUACION DEL POLICOSANOL EN EL TRATAMIENTO DE LA HIPERLIPOPROTEINEMIA TIPO II, ARCH VENEZOLANOS DE FARMACOL Y TERAP, 12, PP. 65-70, (1993); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO PACIENTES CON HIPERHIPIDEMIAS TIPO II, ARCH VENEZOLANOS DE FARMACOL Y TERAP, 2, PP. 71-76, (1993); TORRES O., AGRAMONTE A.T., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLAST, BIOL RES, 27, PP. 199-203, (1994); ARRUZAZABALA M.L., CARBUJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS; ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 49, PP. 695-697, (1993); NOA M., MAGRANER J., MAS K., EFECTO DEL ATEROMIXOL EN LAS LESIONES AORTICAS INDUCIDAS POR LIPOFUNDIN EN CONEJOS, PROGRESOS EN CIENCIAS MÉDICAS (VENEZUELA), 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., MAS K., DE IN ROSA M.C., EFFECT OF POLICOSANOL ON FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FD CHEM TOXIC, 32, PP. 565-575, (1994); GUIDE TO THE CARE AND USE OF EXPERIMENTAL ANIMALS, 1-2, (1980); KOCKX M., DEMEYER G., JACOB W., BULT H., HERMAN A., TRIPHASIC SEQUENCE OF NEOINTIMAL FORMATION IN THE CUFFED ARTERY OF THE RABBIT, ARTERIOSCL THROMB, 12, PP. 1447-1457, (1992); KISANUKI A., ASADA Y., HATAKEYAMA K., HAYASBI T., SUMIYOSHI A., CONTRIBUTION OF THE ENDOTHELIUM TO INTIMAL THICKENING IN NORMOCHOLESTEROLEMIC AND HYPEREHOLESTEROLEMIC RABBITS, ARTERIOSCLER THROMB, 12, PP. 1198-1205, (1992); BOOTH R., MARTINN J., HONEY A., HASSALL D., BEESLEY J., MONCADA S., RAPID DEVELOPMENT OF ATHEROSCLEROTIC LESIONS IN THE RABBIT CAROTID ARTERY INDUCED BY PERIVASCULAR MANIPULATION, ATHEROSCLEROSIS, 76, PP. 257-268, (1989); DE MEYER G., BULT H., MARTIN J., VAN HOYDONCK A., HERMAN A., THE EFFECT OF A DEVELOPING NEOINTIMA ON SEROTONERGIC AND ADRENERGIC CONTRACTIONS, EUR J PHARMACOL, 187, PP. 519-524, (1990); DE MEYER G., BULT H., VAN HOYDONCK A., JORDAENS F., BUYSSERRS N., HERMAN A., A NEOINTIMA FORMATION IMPAIRS ENDOTHELIAL MUSCARINIC RECEPTORS WHILE ENHANCING PROSTACYCLIN-MEDIATED IN THE RABBIT CAROTID ARTERY, CIRC RES, 68, PP. 1669-1680, (1991); DE MEYER G., BULT H., KOCKX M., HERMAN A., EFFECT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITION ON INTIMAL THICKENING IN RABBIT COLLARED CAROTID ARTERY, J CARDIOVASC PHARMACOL, 26, 4, PP. 614-620, (1995); KOCKX M., DE MEYER G., ANDRIES L., BULT H., JACOB W., HERMAN A., THE ENDOTHELIUM DURING CUFF-INDUCED NEOINTIMA FORMATION IN THE RABBIT CAROTID ARTERY, ARTERIOSCLER THROMB, 13, PP. 1874-1884, (1993); BRAVO K., FRANK K., BLUNDELL P.A., MACDONALD-BRAVO H., CYCLIN/PCNA IS THE AUXILIARY PROTEIN OF DNA POLYMERASE Δ, NATURE, 326, PP. 515-517, (1987); GALAND P., DEGRAEF C., CYCLIN/PCNA IMMUNOSTAINING AS AN ALTERNATIVE TO TRITIATED THYMIDINE PULSE LABELLING FOR MARKING S PHASE CELLS IN PARAFFIN SECTIONS FROM ANIMAL AND HUMAN TISSUES, CELL TISSUE KINETIC, 22, PP. 383-392, (1989); VAN DIERENDONCK J.H., WIJSMANN KEIJZER R., VAN DE VELDE C.J.H., CORNELISSE C.J., CELL-CYCLE RELATED STAINING PATTERNS OF ANTIPROLIFERATING CELL NUCLEAR ANTIGEN MONOCLONAL ANTIBODIES: COMPARISON WITH BRDURD LABELLING AND KI-67 STAINING, AM J PATHOL, 138, PP. 1165-1172, (1991); DIETRICH D., TOXICOLOGICAL AND PATHOLOGICAL APPLICATIONS OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA), A NOVEL MARKER FOR CELL PROLIFERATION, CRIT REV TOXICOL, 23, 1, PP. 77-109, (1993); BENNETT M., EVAN G., SCHWARTZ S., APOPTOSIS OF HUMAN VASCULAR SMOOTH MUSCLE CELLS DERIVED FROM NORMAL VESSELS AND CORONARY ATHEROSCLEROTIC PLAQUES, J CLIN INVEST, 95, PP. 2266-2274, (1995); ANGELINI A., VISONA A., PETTENAZZO E., CALABRESE F., YACOUB A., PROLIFERATION AND CELLULAR DEATH (APOPTOSIS) IN AN ANIMAL MODEL OF ACCELERATED ATHEROSCLEROSIS, ATHEROSCLEROSIS, 134; BAR P.R., APOPTOSIS - THE CELL'S SILENT EXIT, LIFE SCI, 59, PP. 369-378, (1996); OBERHAMMER F., ROBERTS R., APOPTOSIS: A WIDESPREAD PROCESS INVOLVED IN LIVER ADAPTATION AND CARCINOGENESIS, THE LIVER: BIOLOGY AND PATHOBIOLOGY. 3RD ED., (1994); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, PP. 425-430, (1990); RUSSELL D., CHOLESTEROL BIOSYNTHESIS AND METABOLISM, CARDIOVASC DRUGS THER, 6, PP. 103-110, (1992); SOMA M., BAETTA R., DORMETTI E., PSOLETTI R., FUMAGALLI R., MODULATION OF THE MEVALONATE PATHWAY IN ATHEROSCLEROSIS AND TUMORS, ABSTRACTS XII INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (1995); POMERANTZ K.B., HAJIAR D.P., EICOSANOIDS IN REGULATION OF ARTERIAL SMOOTH MUSCLE CELL PHENOTYPE, PROLIFERATIVE, CAPACITY AND CHOLESTEROL METABOLISM, ARTERIOSCLEROSIS, 9, PP. 413-429, (1989)","","","ENGLISH","INT. J. CARDIOL.","ARTICLE","ISI","2-S2.0-0032442354","INT J CARDIOL",NA,"NOTREPORTED",NA,"NOA M, 1998, INT J CARDIOL","NOA M, 1998, INT J CARDIOL"
"MENÉNDEZ R;ARRUZAZABALA L;MÁS R;DEL R A;AMOR A;GONZÁLEZ R;CARBAJAL D;FRAGA V;MOLINA V;ILLNAIT J","MENÉNDEZ, ROBERTO (7102205059); ARRUZAZABALA, LOURDES (6602817815); MÁS, ROSA (7007164572); DEL RÍO, ARMANDO (57189524365); AMOR, ANA M. (35569426800); GONZÁLEZ, ROSA M. (57191737509); CARBAJAL, DAISY (8777025000); FRAGA, VIVIAN (6602491407); MOLINA, VIVIAN (7006062814); ILLNAIT, JOSÉ (8631465800)","CHOLESTEROLLOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCHCASEIN DIET",1997,"BRITISH JOURNAL OF NUTRITION","77","9",121,"10.1079/BJN19970090","DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA","THE EFFECT OF POLICOSANOL, A MIXTURE OF HIGH-MOLECULAR-WEIGHT ALIPHATIC ALCOHOLS ISOLATED FROM SUGAR-CANE WAX, ON CASEIN-INDUCED HYPERCHOLESTEROLAEMIA IN RABBITS WAS STUDIED. WHEN POLICOSANOL WAS ADMINISTERED BY THE ORAL ROUTE ONCE DAILY FOR 30 D (50 MG/KG) THE INCREASES IN PLASMA TOTAL CHOLESTEROL AND LDL-CHOLESTEROL (LDC-C) WERE SIGNIFICANTLY REDUCED WHEN COMPARED WITH THE CONTROL GROUP. THE INCORPORATION OF 3H2O INTO STEROLS IN THE LIVER WAS SIGNIFICANTLY DEPRESSED, SUGGESTING INHIBITION OF HEPATIC CHOLESTEROL BIOSYNTHESIS. THE ORAL ADMINISTRATION OF POLICOSANOL RAISED THE RATE OF REMOVAL OF 125I-LABELLED LDL FROM SERUM. KINETIC PARAMETERS CALCULATED FOLLOWING INJECTION OF [125I]LDL SHOWED THAN IN CASEIN-FED RABBITS, THE TERMINAL HALF-LIFE (T( 1/4 )) WAS SIGNIFICANTLY DECREASED AFTER POLICOSANOL TREATMENT. THE HEPATIC LDL-BINDING ACTIVITY WAS INCREASED AFTER POLICOSANOL ADMINISTRATION WHICH SUGGESTED THAT THE ENHANCED CLEARANCE WAS DUE, AT LEAST IN PART, TO INCREASED RECEPTOR-MEDIATED UPTAKE OF LDL BY THE LIVER. CONSIDERED TOGETHER, THESE RESULTS SUGGEST THAT POLICOSANOL CAN SIGNIFICANTLY REDUCE THE INCREASE OF PLASMA LDL-C IN RABBITS FED ON A WHEAT STARCH-CASEIN DIET BY REDUCING CHOLESTEROL BIOSYNTHESIS IN THE LIVER. SUCH AN EFFECT COULD ACCOUNT FOR THE ENHANCEMENT OF LDL CATABOLISM THROUGH THE RECEPTOR-MEDIATED PATHWAY.","CHOLESTEROL BIOSYNTHESIS; HYPERCHOLESTEROLAEMIA; LDL; POLICOSANOL","ANIMALS; ANTICHOLESTEREMIC AGENTS; CASEINS; CHOLESTEROL; CHOLESTEROL, LDL; FATTY ALCOHOLS; HYPERCHOLESTEROLEMIA; IODINE RADIOISOTOPES; LIVER; MALE; PROTEIN BINDING; RABBITS; RECEPTORS, LDL; TRITICUM; ANIMALIA; ARUNDINARIA; ORYCTOLAGUS CUNICULUS; SACCHARUM; TRITICUM AESTIVUM; CASEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; STARCH; STEROL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET; HALF LIFE TIME; HYPERCHOLESTEROLEMIA; KINETICS; MALE; NONHUMAN; RABBIT; RECEPTOR BINDING; WHEAT","","","ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURRENT THERAPEUTIC RESEARCH, 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 176-182, (1995); ARRUZAZABALA L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON NORMOCHOLESTEROLEMIC RABBITS, BIOLOGICAL RESEARCH, 27, PP. 205-208, (1994); BEYNEN A.C., VAN DER MEER R., WEST C.E., MECHANISM OF CASEIN-INDUCED HYPERCHOLESTEROLEMIA: PRIMARY AND SECONDARY FEATURES, ATHEROSCLEROSIS, 60, PP. 291-293, (1986); BROWN M., GOLDSTEIN J., A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS, SCIENCE, 232, PP. 34-47, (1986); GUIDE TO THE CARE AND USE OF EXPERIMENTAL ANIMALS, (1980); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ONE-YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADVANCES IN THERAPY, 12, PP. 245-254, (1995); CARROLL K.K., PLASMA CHOLESTEROL AND LIVER CHOLESTEROL BIOSYNTHESIS IN RABBITS FED COMMERCIAL OR SEMISYNTHETIC DIET WITH AND WITHOUT ADDED FATS OR OILS, ATHEROSCLEROSIS, 13, PP. 67-76, (1971); CASTANO G., CANETTI M., MOREIRA M., TULA L., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A ONE-YEAR STUDY, CURRENT THERAPEUTIC RESEARCH, 56, PP. 819-828, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE-A-DAY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 296-304, (1995); CHAO Y., KROON P.A., YAMIN T.T., THOMPSON G.M., ALBERTS A.W., REGULATION OF HEPATIC RECEPTOR-DEPENDENT DEGRADATION OF LDL BY MEVINOLIN IN RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BIOCHIMICA ET BIOPHYSICA ACTA, 754, PP. 134-141, (1983); CRUZ-BUSTILLO D., MEDEROS D., MAS R., ARRUZAZABALA L., LAGUNA A., BARRETO D., MARTINEZ O., EFECTO HIPOCOLESTEROLEMICO DEL ATEROMIXOL (PPG) SOBRE EL CERDO EN CEBA, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 62-63, (1991); DECKERE E.A.M., KLOOTS W.J., VAN AMELSVOORT J.M.M., RESISTANT STARCH DECREASES SERUM TOTAL CHOLESTEROL AND TRIACYLGLYCEROL CONCENTRATIONS IN RATS, JOURNAL OF NUTRITION, 123, PP. 2142-2151, (1993); HAVEL R.J., ELDER H.A., BRAGDON J.A., THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM, JOURNAL OF CLINICAL INVESTIGATION, 34, PP. 345-348, (1955); HERNANDEZ G., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 568-575, (1993); JESKE D.J., DIETSCHY J.M., REGULATION OF RATES OF CHOLESTEROL SYNTHESIS IN VIVO IN THE LIVER AND CARCASS OF THE RAT MEASURED USING <SUP>3</SUP>H-WATER, JOURNAL OF LIPID RESEARCH, 21, PP. 364-376, (1980); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANNALS OF NUTRITION AND METABOLISM, 37, PP. 33-38, (1993); KATO S., KARINO K., HASEGAWA S., NAGASAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., TAGO K., OKUMORI H., HAMATANI K., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH-FAT DIET, BRITISH JOURNAL OF NUTRITION, 73, PP. 433-441, (1995); KAWAMURA N., MOSER H.W., KISHIMOTO Y., VERY LONG CHAIN FATTY OXIDATION IN RAT LIVER, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 99, PP. 1216-1225, (1981); KHOSLA P., SAMMAN S., CARROLL K.K., DECREASED RECEPTOR-MEDIATED LDL CATABOLISM IN CASEIN-FED RABBITS PRECEDES THE INCREASE IN PLASMA CHOLESTEROL LEVELS, JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2, PP. 203-209, (1991); KHOSLA P., SAMMAN S., CARROLL K.K., HUFF M.W., TURNOVER OF <SUP>125</SUP>I-VLDL AND <SUP>131</SUP>I-LDL APOLIPOPROTEIN B IN RABBITS FED DIETS CONTAINING CASEIN OR SOY PROTEIN, BIOCHIMICA ET BIOPHYSICA ACTA, 1002, PP. 157-163, (1989); KOSUKE J., KUSUNOSE E., NODA Y., KUSUNOSE M., SOME PROPERTIES OF THE FATTY ALCOHOL SYSTEM AND RECONSTITUTION OF MICROSOMAL OXIDATION ACTIVITY IN INTESTINAL MUCOSA, BIOCHIMICA ET BIOPHYSICA ACTA, 878, PP. 412-418, (1986); KROON P.A., HAND K.M., HUFF J.W., ALBERTS A.W., THE EFFECTS OF MEVINOLIN ON SERUM CHOLESTEROL LEVELS OF RABBITS WITH ENDOGENOUS HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 44, PP. 41-49, (1982); LOWRY O.H., ROSEBROUGH N.J., FARR A.L., RANDALL R.J., PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT, JOURNAL OF BIOLOGICAL CHEMISTRY, 193, PP. 265-275, (1951); MCCARTHY P.A., NEW APPROACHES TO ATHEROSCLEROSIS: AN OVERVIEW, MEDICINAL RESEARCH REVIEWS, 2, PP. 139-159, (1993); MCFARLANE A.S., EFFICIENT TRACER LABELLING WITH IODINE, NATURE, 182, PP. 53-57, (1958); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R., FRAGA V., AMOR A., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOLOGICAL RESEARCH, 27, PP. 199-203, (1994); MENENDEZ R., FRAGA V., SOTOLONGO V., AMOR A., DEL RIO A., GONZALEZ R., JIMENEZ S., MAS R., EFECTO DEL POLICOSANOL SOBRE EL METABOLISMO LIPIDICO EN RATAS NORMOCOLESTEROLEMICAS, REVISTA MEXICANA DE CIENCIAS FARMACÉUTICAS, 24, PP. 16-18, (1993); NIELSEN L.B., STENDER S., KJELDSEN K., EFFECT OF LOVASTATIN ON CHOLESTEROL ABSORPTION IN CHOLESTEROL-FED RABBITS, PHARMACOLOGY AND TOXICOLOGY, 72, PP. 148-151, (1993); NOA M., ARRUZAZABALA L., CARBAJAL D., MAS R., ILLNAIT J., EFECTOS DEL POLICOSANOL SOBRE LA HIPERCOLESTEROMIA EXÓGENA EN CONEJOS, REVISTA CNIC CIENCIAS BIOLÓGICAS, (1997); NOTARI R., PHARMACOKINETIC PARAMETERS, BIOPHARMACEUTICALS AND CLINICAL PHARMACOKINETICS: AN INTRODUCTION, 3RD ED., (1980); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 507-513, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASE OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, JOURNAL OF CLINICAL PHARMACOLOGICAL RESEARCH, 14, PP. 27-33, (1994); RIZZO E., CRAFT D., DAMMANN A., PHILLIPS M., FATTY ALCOHOL METABOLISM IN CULTURED FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, JOURNAL OF BIOLOGICAL CHEMISTRY, 262, PP. 17412-17419, (1990); RIZZO W., DAMMANN A., CRAFT D., SJÖGRE-LARSSON SYNDROME. IMPAIRED FATTY ALCOHOL OXIDATION IN CULTURED FIBROBLASTS DUE TO A DEFICIENT FATTY ALCOHOL:NICOTINAMIDE ADENINE NUCLEOTIDE OXIDOREDUCTASE ACTIVITY, JOURNAL OF CLINICAL INVESTIGATION, 81, PP. 738-744, (1988); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACCACA ARCTOIDES), FOOD AND CHEMICAL TOXICOLOGY, 32, PP. 565-575, (1994); RUDLING M.J., PETERSON C.O., A SIMPLE BINDING ASSAY FOR DETERMINATION OF LOW-DENSITY LIPOPROTEIN RECEPTORS IN CELL HOMOGENATES, BIOCHIMICA ET BIOPHYSICA ACTA, 833, PP. 359-365, (1985); RUDLING M.J., PETERSON C.O., LDL RECEPTORS IN BOVINE TISSUES ASSAYED AS THE HEPARIN-SENSITIVE BINDING OF <SUP>125</SUP>I-LABELLED LDL IN HOMOGENATES: RELATION BETWEEN LIVER LDL RECEPTORS AND SERUM CHOLESTEROL IN FETUS AND POST TERM, BIOCHIMICA ET BIOPHYSICA ACTA, 836, PP. 96-104, (1985); SAMMAN S., KHOSLA P., CARROLL K.K., EFFECTS OF CASEIN AND SOY PROTEIN ON METABOLISM OF RADIOLABELLED LOW DENSITY APOLIPOPROTEIN B IN RABBITS, LIPIDS, 24, PP. 169-171, (1989); SCHOLZ K.E., BEYNEN A.C., WEST C.E., COMPARISON BETWEEN THE HYPERCHOLESTEROLEMIA IN RABBITS INDUCED BY SEMIPURIFIED DIETS CONTAINING EITHER CHOLESTEROL OR CASEIN, ATHEROSCLEROSIS, 44, PP. 85-97, (1982); SINGH H., DERWAS N., POULOS A.A., VERY LONG CHAIN FATTY ACID Β-OXIDATION BY RAT LIVER MITOCHONDRIA AND PEROXISOMES, ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 359, PP. 382-390, (1987); SINGH H., POULOS A.A., A COMPARATIVE STUDY OF STEARIC ACID AND LIGNOCERIC ACID OXIDATION BY HUMAN SKIN FIBROBLASTS, ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 250, PP. 171-179, (1986); SOLTERO I., FUENTEMAYOR I., COLMERARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCHIVOS VENEZOLANOS DE FARMACOLGIA Y TERAPÉUTICA, 12, PP. 65-70, (1993); SPADY D.K., DIETSCHY J.M., STEROL SYNTHESIS IN VIVO IN 18 TISSUES OF THE SQUIRREL MONKEY, GUINEA PIG, RABBIT, HAMSTER AND RAT, JOURNAL OF LIPID RESEARCH, 24, PP. 303-315, (1983); TERPSTRA A.H.M., WOODWARD C.J.H., SANCHEZ-MUNIZ F.J., IMPROVED TECHNIQUES FOR THE SEPARATION OF SERUM LIPOPROTEINS BY DENSITY GRADIENT ULTRACENTRIFUGATION: VISUALIZATION BY PRESTAINING AND RAPID SEPARATION OF SERUM LIPOPROTEINS FROM SMALL VOLUMES OF SERUM, ANALYTICAL BIOCHEMISTRY, 111, PP. 157-159, (1981); TOPPING D.L., SOLUBLE-FIBER POLYSACCHARIDES-EFFECTS ON PLASMA CHOLESTEROL AND COLONIE FERMENTATION, NUTRITION REVIEWS, 49, PP. 195-203, (1991); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); WANDERS R.J.A., VAN ROERMUND C.W.T., VAN WIJLAND M.J.A., SCHUTGENS R.B.H., SCHAM A.W., VAN DEN BOSCH H., TAGER J.M., STUDIES ON THE PEROXISOMAL OXIDATION OF PALMITATE AND LIGNOCERATE IN RAT LIVER, BIOCHIMICA ET BIOPHYSICA ACTA, 919, PP. 21-25, (1987)","","","ENGLISH","BR. J. NUTR.","ARTICLE","ISI","2-S2.0-0343052967","BR J NUTR",NA,"NOTREPORTED",NA,"MENÉNDEZ R, 1997, BR J NUTR","MENÉNDEZ R, 1997, BR J NUTR"
"GÁMEZ R;ALEMÁN C;MÁS R;NOA M;RODEIRO I;GARCÍA H;HERNÁNDEZ C;MENENDEZ R;AGUILAR C","GÁMEZ, RAFAEL (7003605346); ALEMÁN, CELIA L. (7102849611); MÁS, ROSA (7007164570); NOA, MIRIAM (7003318964); RODEIRO, IDANIA (6602314378); GARCÍA, HAYDEE (7202282339); HERNÁNDEZ, CARIDAD (15720846000); MENENDEZ, ROBERTO (7102205059); AGUILAR, CARIDAD (7102461194)","A 6MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUEDAWLEY RATS",2001,"JOURNAL OF MEDICINAL FOOD","4","8",20,"10.1089/109662001300341707","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGAR CANE. PREVIOUS TOXICOLOGICAL STUDIES HAVE NOT DEMONSTRATED ANY POLICOSANOL-RELATED TOXICITY, EVEN WITH LONG-TERM ORAL ADMINISTRATION AT 500 MG/KG, A DOSE 1, 724 TIMES LARGER THAN THE MAXIMAL THERAPEUTIC DOSE (20 MG/DAY) RECOMMENDED TO DATE. THE PRESENT STUDY WAS UNDERTAKEN TO INVESTIGATE THE ORAL TOXICITY OF POLICOSANOL ADMINISTERED FOR 6 MONTHS IN DOSES UP TO 5, 000 MG/KG TO SPRAGUE-DAWLEY RATS. ANIMALS WERE RANDOMLY DISTRIBUTED IN FIVE GROUPS (15 ANIMALS PER DOSE PER SEX): A CONTROL AND FOUR GROUPS GIVEN ORAL POLICOSANOL (50, 500, 2, 500, OR 5, 000 MG/KG). EIGHT TREATED RATS (6 MALES, 2 FEMALES) DIED DURING THE STUDY, FIVE OF THEM (4 MALES, 1 FEMALE) FROM AMONG THOSE RECEIVING THE HIGHEST DOSE (5, 000 MG/KG). ACCORDING TO NECROPSY, ALL DEATHS WERE RELATED TO GAVAGE MANIPULATION OF HIGHER DOSES. ALTHOUGH THE DIFFERENCES WERE NOT SIGNIFICANT, BODY WEIGHT GAIN AND FOOD CONSUMPTION IN THE GROUPS RECEIVING 2, 500 OR 5, 000 MG/KG TENDED TO BE LOWER THAN IN THE CONTROL GROUP. NEVERTHELESS, NO DRUG-RELATED TOXICITY SYMPTOMS WERE DETECTED. ANALYSIS OF BLOOD BIOCHEMISTRY, HEMATOLOGY, ORGAN WEIGHT RATIOS, AND HISTOPATHOLOGICAL FINDINGS DID NOT SHOW SIGNIFICANT DIFFERENCES COMPARED WITH CONTROLS, NOR ANY TENDENCY WITH THE DOSE. THEREFORE, THE PRESENT STUDY DID NOT SHOW ANY NEW EVIDENCE OF ORAL TOXICITY OF POLICOSANOL, AND THE FINDINGS OBSERVED WERE A CONSEQUENCE OF LONG-TERM ADMINISTRATION BY GASTRIC GAVAGE OF THE HIGHLY CONCENTRATED SUSPENSIONS NEEDED TO REACH THE HIGHER DOSES. IT IS CONCLUDED THAT POLICOSANOL CHRONICALLY ADMINISTERED BY THE ORAL ROUTE IS SAFE AND THAT NO DRUG-RELATED TOXICITY WAS DEMONSTRATED.","","ANIMALIA; ARUNDINARIA; SACCHARUM; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CHEMISTRY; DRUG EFFECT; DRUG SCREENING; FEMALE; FOOD INTAKE; HEMATOLOGY; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TOXICITY TESTING; WEIGHT GAIN","","","LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA L., MAS R., GARCIA M.; MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., FRAGA V., AMOR A., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ARRUZAZABALA L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUANA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON NORMOCHOLESTEROLAEMIC RABBITS, BIOL RES, 27, PP. 205-208, (1994); ROGRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACCACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ G.M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPID LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); BATISTA J., STRUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERCHOLESTEROLEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); CASTANO G., TULA L., CANETTI M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., DIAZ E., FERNANDEZ L., EFFECT OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-575, (1996); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3 YEAR OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); CASTANO G., MAS R., FERNANDEZ J.C., PONTIGAS V., SUAZO M., FERNANDEZ L., OPEN STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 59, PP. 737-745, (1998); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27, 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 44-51, (1997); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); ORTENSI G., GLADSTEIN H., VALLI H., TEASONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 360-401, (1997); PONS P., ILLNAIT J., MAS R., RODRIGUEZ M., ALEMAN C., FERNANDEZ J.C., FERNANDEZ L., MARTIN M., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 26-35, (1997); ALEMAN C.L., MAS R., RODEIRO I., NOA M., HERNANDEZ C., CAPOTE A., MENENDEZ R., GONZALEZ R.M., AMOR A., JIMENEZ S., TOXICOLOGÍA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REVISTA CNIC CIENCIAS BIOLOGÌCAS, 22, PP. 102-105, (1991); FERNANDEZ I., RENDON A., DE LAS CAJIGAS A., LOPEZ M., ESTUDIO GENOTOXICO DEL ATEROMIXOL (PPG) UN NUEVO MEDICAMENTO HIPOLIPEMIANTE, REVISTA CNIC CIENCIS BIOLOGÍCAS, 22, PP. 98-101, (1991); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A., SOTOLONGO V., FRAGA V., CAPOTE A., JIMENEZ S., ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, TOXICOL LETT, (1992); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., MENENDEZ R., AMOR A., SOTOLONGO V., FRAGA V., CAPOTE A., JIMENEZ S., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); MESA R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RATS AND RABBITS, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); CHHABRA R.S., HUFF J.E., SCHWETZ B.S., SELKIRK J., AN OVERVIEW OF PRECHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY EXPERIMENTAL STUDY DESIGNS AND CRITERIA USED BY THE NATIONAL TOXICOLOGY PROGRAM, ENVIRON HEALTH PERSPECT, 86, PP. 313-321, (1990); STEVENS K.R., MYLECRAINE L., ISSUES IN CHRONIC TOXICOLOGY, PRINCIPLES AND METHODS IN TOXICOLOGY, PP. 663-694; GAD S.C., WEIL C.S., STATISTICS FOR TOXICOLOGIST, PRINCIPLES AND METHODS IN TOXICOLOGY, PP. 273-320; MACDONALD J., GERSON R., KORNSBRUST J., KLOSS M., PRAHALADA S., BERRY P., ALBERTS W., BOKELMAN D., PRECLINICAL SAFETY EVALUATION OF LOVASTATIN, AM J CARDIOL, 62, PP. 16J-27J, (1988); GERSON R.J., MACDONALD J.S., ALBERTS A.W., KORNBRUST D.J., MAJKA J.A., STUBBS R.J., BOKELMAN D.L., ANIMAL SAFETY AND TOXICOLOGY OF SIMVASTATIN AND RELATED HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, AM J MED, 87, PP. 28S-38S, (1989); VON KEUTZ E., SCHLUTER G., PRECLINICAL SAFETY EVALUATION OF CERIVASTATIN, A NOVEL HMG-COA REDUCTASE INHIBITOR, AM J CARDIOL, 82, PP. 11J-17J, (1998); WALKER J.F., SIMVASTATIN: THE CLINICAL PROFILE, AM J MED, 87, PP. 4A44S-4A46S, (1989); RODEIRO I., ALEMAN C., MAS R., ACOSTA P., RODRIGUEZ M., GAMEZ R., RODRIGUEZ M., GARCIA H., EFECTOS DEL POLICOSANOL SOBRE LAS ENZIMAS MICROSOMALES HEPÁTICAS EN RATAS SPRAGUE DAWLEY, REVISTA CNIC CIENCIAS BIOLÓGICAS, 31, PP. 113-116; ASHBY J., BRADY A., ELCOMBE C., ELLIOTT B., ISHMAEL J., ODUM J., TUGWOOD J., KETTLE S., PURCHASE I., MECHANISTICALLY-BASED HUMAN HAZARD ASSESSMENT OF PEROXISOME PROLIFERATOR-INDUCED HEPATOCARCINOGENESIS, HUM EXP TOXICOL, 13, PP. S1-S117, (1994); CASEY H.W., AYERS K.M., ROBINSON F.R., THE URINARY SYSTEM, PATHOLOGY OF LABORATORY ANIMALS, PP. 115-173, (1978); CLAPP M.J., THE EFFECT OF DIET ON SOME PARAMETERS MEASURED IN TOXICOLOGICAL STUDIES IN THE RAT, LAB ANIM, 14, PP. 253-261, (1980); DAGLE G.E., ZWICKER G.M., RENNE R.A., MORPHOLOGY OF SPONTANEOUS BRAIN TUMORS IN THE RAT, VET PATHOL, 16, PP. 318-324, (1979)","","","ENGLISH","J. MED. FOOD","ARTICLE","ISI","2-S2.0-0034906478","J MED FOOD",NA,"NOTREPORTED",NA,"GÁMEZ R, 2001, J MED FOOD","GÁMEZ R, 2001, J MED FOOD"
"RODRÍGUEZ M;SÁNCHEZ M;GARCÍA H","RODRÍGUEZ, MARÍA D. (57220829332); SÁNCHEZ, MARIBEL (57220881836); GARCÍA, HAYDEÉ (7202282339)","MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS",1997,"TOXICOLOGY LETTERS","90","9",20,"10.1016/S0378-4274(96)03844-1","DEPARTMENT OF TOXICOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;DEPARTMENT OF TOXICOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;DEPARTMENT OF TOXICOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA","THE HYPOCHOLESTEROLAEMIC DRUG POLICOSANOL WAS ADMINISTERED TO SPRAGUE-DAWLEY RATS OF BOTH SEXES THROUGHOUT THREE SUCCESSIVE GENERATIONS AT CONCENTRATIONS OF 0, 5, 50 AND 500 MG/KG BW/DAY BY GAVAGE. FOR EACH GENERATION TWO LITTERS WERE REARED UNTIL THEY WERE AT LEAST 3 WEEKS OLD. NO CLINICAL SIGNS WHICH COULD BE RELATED TO THE ADMINISTRATION OF THE TEST SUBSTANCE WERE OBSERVED IN THE F0, F(1B), AND F(2B) PARENTS. THERE WERE NO DIFFERENCES AMONG GROUPS IN THE NUMBER OF ANIMALS THAT CONCEIVED, THE NUMBER OF PUPS BORN LIVE OR DEAD, THE RATE OF MALE TO FEMALE PUPS, THE NUMBER OF PUPS THAT SURVIVED UNTIL WEANING AND THE PUPS' BODY WEIGHTS THROUGH THE LACTANCY. THE FOLLOWING TEST SHOWED NO TREATMENT-RELATED EFFECTS ON F3B OFFSPRING: RIGHTING ON A SURFACE, AIR RIGHTING, CORNEAL, PIRMAL AND PAIN REFLEXES, AUDITORY STARTLE AND VISUAL PLACING. THE RESULTS OF THE PRESENT STUDY DID NOT DEMONSTRATE ANY DELETERIOUS EFFECTS ON THE FERTILITY,, REPRODUCTIVE PERFORMANCE OR DEVELOPMENT OF RATS ADMINISTERED POLICOSANOL AT LEVELS OF UP TO 500 MG/KG BW/DAY OVER THREE SUCCESSIVE GENERATIONS.","DEVELOPMENT; HYPOCHOLESTEROLAEMIC; REPRODUCTIVE PERFORMANCE","ANIMALS; ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; FEMALE; FERTILITY; GROWTH; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCTION; ANIMALIA; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; DRUG SAFETY; FEMALE; FERTILITY; LACTATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGENY; RAT; REPRODUCTION","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCHIVES VENEZOLANES DE FARMACOLOGIA Y TERAPEÚTICA, 11, PP. 80-86, (1992); RODRIGUEZ C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACO ARCTOIDES), FOOD CHEM. TOXICOL., 32, PP. 565-575, (1994); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLAST, BIOL. RES., 27, PP. 199-203, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ R., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MÉDICAS (VENEZUELA), 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER. RES., 53, PP. 265-269, (1993); ANEIROS E., CALDERON B., MAS R., ILNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR. THER. RES., 53, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); CANETTI M., MORERA M., ILLNAIT J., MAS R., FERANDEZ L., CASTANO G., FERNANDEZ J.C., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, PP. 245-254, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 205-208, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., (1994); ALEMAN C., MAS R., RODEIRO I., NOA M., MENENDEZ R., GONZALEZ R.M., FRAGA V., CAPOTE A., JIMENEZ S., ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, TOXICOL. LETT., SUPPL., (1992); ALEMAN C., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., CAPOTE A., MENENDEZ R., AMOR A., FRAGA V., SOTOLONGO V., JIMENEZ S., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1992); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GARNEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); RENDON A., RODRIGUEZ M.D., LOPEZ M., GARCIA H., DE LAS CAJIGAS A., MAS R., FERNANDEZ I., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOL. LETT., SUPPL., (1992); ALEMAN C., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE-DAWLEY RATS: A 24 MONTH STUDY, TERATOGEN. CARCINOGEN. MUTAGEN., 14, PP. 239-249, (1994); ALEMAN C., NOA M., CEREJIDO E., HERNANDEZ C., RODEIRO I., MAS R., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM. TOXICOL., 33, PP. 573-578, (1995); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOGEN. CARCINOGEN. MUTAGEN., 14, PP. 107-113, (1994)","","","ENGLISH","TOXICOL. LETT.","ARTICLE","ISI","2-S2.0-0031557124","TOXICOL LETT",NA,"NOTREPORTED",NA,"RODRÍGUEZ MD, 1997, TOXICOL LETT","RODRÍGUEZ MD, 1997, TOXICOL LETT"
"PRAT M H;ROMÁN A O;PINO O E","PRAT M, HERNÁN (6508363554); ROMÁN A, OSCAR (6602611272); PINO O, EUGENIA (6504476174)","COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMGCOA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA EFECTO COMPARATIVO DE POLICOSANOL CON DOS INHIBIDORES DE LA HMGCOA REDUCTASA EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA TIPO II",1999,"REVISTA MEDICA DE CHILE","127","8",21,"","PRAT M H.; ROMÁN A O.;QUÍMICO-FARMACÉUTICO","BACKGROUND: POLICOSANOL IS A NEW CHOLESTEROL LOWERING AGENT DERIVED FROM SUGAR CANE. AIM: TO COMPARE THE CHOLESTEROL LOWERING EFFICACY OF POLICOSANOL WITH HMG COA INHIBITORS. PATIENTS AND METHODS: PATIENTS WITH A LDL CHOLESTEROL OVER 160 MG/DL WERE STUDIED. IF, AFTER 6 WEEKS OF DIET, CHOLESTEROL PERSISTED ELEVATED, THEY WERE DOUBLY BLIND RANDOMIZED TO RECEIVE POLICOSANOL 10 MG/DAY (55 PATIENTS), LOVASTATIN 20 MG/DAY (26 PATIENTS) OR SIMVASTATIN 10 MG/DAY (25 PATIENTS). SERUM CHOLESTEROL WAS MEASURED AGAIN AFTER 8 WEEKS OF THERAPY. RESULTS: INITIAL DEMOGRAPHIC AND LABORATORY DATA WERE SIMILAR AMONG TREATMENT GROUPS. A 24% LDL CHOLESTEROL REDUCTION WAS OBTAINED WITH POLICOSANOL, COMPARED WITH A 22% REDUCTION WITH LOVASTATIN AND A 15% REDUCTION WITH SIMVASTATIN. HDL CHOLESTEROL SIGNIFICANTLY INCREASED IN PATIENTS ON POLICOSANOL AND DID NOT CHANGE IN THE OTHER TREATMENT GROUPS. ADVERSE EFFECTS OF POLICOSANOL WERE MILD AND UNSPECIFIC. NO CHANGES IN HEPATIC ENZYMES WERE OBSERVED. CONCLUSIONS: POLICOSANOL IS A SAFE AND EFFECTIVE CHOLESTEROL REDUCING AGENT.","ANTICHOLESTEREMIC AGENTS; HYPERCHOLESTEROLEMIA; LOVASTATIN; POLICOSANOL; SIMVASTATIN","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MALE; MIDDLE AGED; SIMVASTATIN; FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL","","","STAMLER J., WENTWORTH D., NEATON J.D., IS THE RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND RISK OF PREMATURE DEATH FROM CORONARY HEART DISEASE CONTINUOUS AND GRADED? FINDINGS IN 356222 PRIMARY SCREENINGS OF THE MULTIPLE RISK FACTORS INTERVENTION TRIAL, JAMA, 256, PP. 2-823, (1986); CASTELLI W.P., GARRISON R.J., WILSON P.W.F., ABBOT R.D., KALOUSDIAN W.B., INCIDENCE OF CORONARY HEART DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS: THE FRAMINGHAM STUDY, JAMA, 256, PP. 2835-2838, (1986); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); MANNINEN V., ELO M.O., FRICK M.H., HAAPA K., HEINONEN O.P., HEINSALMI P., ET AL., LIPID ALTERATIONS AND DECLINE IN THE INCIDENCE OF CORONARY HEART DISEASE IN THE HEKSINKI HEART STUDY, JAMA, 260, PP. 641-651, (1988); BROWN G., ALDERS J.J., FISHER L.D., SHAEFER S.M., LIN J.T., KAPLAN C., ET AL., REGRESSION OF CORONARY ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH LEVELS OF APOLIPOPROTEIN B, N ENGL J MED, 323, PP. 1289-1298, (1990); RANDOMISED TRIAL OF CHOLESTEROL-LOWERING IN 4.444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1394, (1994); SHEPERD J., COBBE S.M., CHRISTOPHER G., LORMER A.R., MCFARLANE P.W., MCKILLON J.H., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, NEW ENGL J MED, 333, PP. 1301-1351, (1995); HJERMANN I., VELVE BYRE K., HOLME L., LEREN P., EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE, LANCET, 2, PP. 1303-1310, (1981); REPORT OF THE EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, JAMA, 269, PP. 3015-3023, (1993); MABUCHI H., HABA T., TATAMI R., MIYAMOTO S., SAKAI Y., WAKASUGI T., ET AL., EFFECTS OF AN INHIBITOR OF HMG COA REDUCTASA ON SERUM LIPOPROTEINS AND UBIQUIONE 10 LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA, N ENGL J MED, 305, PP. 478-482, (1981); SHEPERD J., PHARMACOLOGIC MODULATION OF PLASMA CHOLESTEROL LEVELS, PP. 127-131, (1987); THERAPEUTIC RESPONSE TO LOVASTATIN (MEVINOLIN) IN NON FAMILIAL HYPERCHOLESTEROLEMIA, JAMA, 256, PP. 829-834, (1986); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); TIKKANEN M., HELVE E., KAARSALA E., LEHTONEN A., MALBERG W., OKSA H., ET AL., COMPARISON BETWEEN LOVASTATIN AND GEMFIBROZIL IN THE TREATMENT OF PRIMARY LIYPERCHOLESTEROLEMIA. THE FINNISH MULTICENTER STUDY, AM J CARDIOL, 62, (1988); TOBERT J.A., SHEAR C.L., CHREMS A., MANTELL G., CLINICAL EXPERIENCE WITH LOVASTATIN, AM J CARDIOL, 65, (1990); TODD P.A., GOA K.L., SIMVASTATIN: A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTICAL POTENTIAL IN HYPERCHOLESTEROLEMIA, DRUGS, 40, PP. 583-607, (1990); MITCHEL Y.B., THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, (1992); COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN FOR HYPERCHOLESTEROLEMIA, AM J CARDIOL, 71, PP. 1408-1414, (1993); MCTAVISH D., SORKIN E.M., PRAVASTATIN. A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLAEMIA, DRUGS, 42, PP. 65-89, (1991); JACOB B., BENGHOZI R., PFISTER P., HOLMES D., COMPARISON OF FLUVASTATIN VERSUS PRAVASTATIN TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 76, (1995); DAVIDSON M., MCFINNEY J., STEIN E., SCHROTT H., BAKKER-ARKEMA R., FAYYAD R., ET AL., COMPARISON OF THE ONE YEAR EFFICACY AND SAFETY OF ATORVASTATIN VERSUS LOVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 79, PP. 1475-1479, (1997); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM J CARDIOL, 81, PP. 582-587, (1998); GOLDSTEIN J.L., BROWN M.S., PROGRESS IN UNDERSTANDING THE LDL RECEPTOR AND HNG-COA REDUCTASE, TWO MEMBRANE PROTEINS THAT REGULATE THE PLASMA CHOLESTEROL, J LIPID RES, 25, PP. 1450-1454, (1984); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); HERNANDEZ R., FRAGA V., SOTOLONGO V., AMOR A.M., DEL RIO A., GONZALEZ R.M., ET AL., EFECTO DE LA ADMINISTRUCIÓN ORAL DE POLICOSANOL SOBRE EL METABOLISMO LIPÍDICO DE RATAS NORMOCOLESTEROLÉMICAS, REV MEX CIENCIAS FARMACÉUTICAS, 24, PP. 16-18, (1993); HERNANDEZ F., ILLINAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 1-8, (1992); ANEIROS E., CALDERON B., MAS R., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); CASTANO G., TULA L., CANETTI M., MAS R., ILLINAIT J., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLINAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., CAPOTE A., ET AL., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM, (1993); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGUE, CLIN CHEM, 18, PP. 499-502, (1972); ROMAN O., PINO M.E., VALENZUELA M.A., EFFECTS OF PINDOLOL AND CLOPAMIDE ON BLOOD LIPIDS IN ARTERIAL HYPERTENSIVE PATIENTS, CARDIOLOGY, 74, PP. 219-225, (1987); WEINERGER M.H., ANTIHYPERTENSIVE THERAPY AND LIPIDS: PARADOXICAL INFLUENCES ON CARDIOVASCULAR DISEASE RISK, AM J MED, 80, SUPPL. 2A, PP. 64-70, (1986); ALLAIN C.H.L., POON L.S., ENZYMATIC DETERMINATION OF TOTAL SERUM CHOLESTEROL AND HYPERTENSIVE DRUGS, CLIN CHEM, 20, PP. 470-475, (1974); TIFFANY T.O., MORTON J.M., HALL E.M., GARRETT A.S., CLINICAL EVALUATION OF KINETIC ENZYMATIC FIXED TIME AND INTEGRAL ANALYSIS OF SERUM TRIGLYCERIDES, CLIN CHEM, 20, PP. 477-480, (1974); LOPEZ M.F., STONE P., ELLIS S., COLWELL J.A., CHOLESTEROL DETERMINATION IN HIGH DENSITY LIPOPROTEINS SEPARATED BY THREE DIFFERENT METHODS, CLIN CHEM, 23, PP. 882-884, (1977); WAUGH A.E., ELEMENTS OF STATISTICAL METHODS, (1952); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF SUCCESIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); WALKER J.F., SIMVASTATIN: THE CLINICAL PROFILE, AM J MED, 87, (1989); BOCUZZI S.J., KEEGAN M.E., HIRSH L.J., SHAPIRO D.R., PLITKIN D.J., MITCHEL Y.B., LONG-TERM EXPERIENCE WITH SIMVASTATIN, DRUG INVEST, 5, PP. 135-140, (1993); STALENHOFF A.R.H., MARC J.T.M., STUITT P.M.J., EFFICACY AND TOLERABILITY OF SIMVASTATIN, AM J MED, 87, SUPPL. 4A, (1989); MOLGAARD J., LUNDH B.J., VON SCHENCK H., LONG-TERM EFFICACY AND SAFETY OF SIMVASTATIN ALONE AND IN COMBINATION THERAPY IN TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 91, (1991)","QUÍMICO-FARMACÉUTICO; EMAIL: OROMAN@MACHI.MED.UCHILE.CL","","SPANISH","REV. MED. CHILE","ARTICLE","ISI","2-S2.0-0033091942","REV MED CHILE","NOTREPORTED","NOTREPORTED;NOTREPORTED",NA,"PRAT M H, 1999, REV MED CHILE","PRAT M H, 1999, REV MED CHILE"
"PONS P;ILLNAIT J;MÁS R;RODRÍGUEZ M;ALEMÁN C;FERNÁNDEZ J;FERNÁNDEZ L;MARTIN M","PONS, PEDRO (18635378600); ILLNAIT, JOSÉ (8631465800); MÁS, ROSA (7007164572); RODRÍGUEZ, MIRTA (57213557891); ALEMÁN, CELIA (7102849611); FERNÁNDEZ, JULIO CÉSAR (9432805500); FERNÁNDEZ, LILIA (7202848319); MARTIN, MIRTA (57214667920)","A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA",1997,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","58","9",22,"10.1016/S0011-393X(97)80074-4","PLAZA POLICLINICAL CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;PLAZA POLICLINICAL CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;PLAZA POLICLINICAL CENTER, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CALIXTO GARCIA HOSPITAL, HAVANA, CUBA","THIRTY PATIENTS WITH TYPE II PRIMARY HYPERCHOLESTEROLEMIA WERE ENROLLED IN A RANDOMIZED, DOUBLE-MASKED, PARALLEL, COMPARATIVE STUDY OF POLICOSANOL - A NEWER CHOLESTEROL-LOWERING AGENT OBTAINED FROM SUGAR CANE WAX - AND PROBUCOL. PRIOR TO RANDOMIZATION, ALL PATIENTS STARTED OR CONTINUED ON A STANDARD, FIRST-STEP CHOLESTEROL-LOWERING DIET FOR 6 WEEKS. PATIENTS WERE RANDOMIZED TO RECEIVE EITHER POLICOSANOL (5 MG TWICE DAILY) OR PROBUCOL (500 MG TWICE DAILY) FOR 8 WEEKS. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. WITH POLICOSANOL, TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), AND TRIGLYCERIDES DECREASED SIGNIFICANTLY BY 18.0%, 22.7%, AND 16.2%, RESPECTIVELY. IN ADDITION, POLICOSANOL SIGNIFICANTLY LOWERED THE RATIOS OF TOTAL CHOLESTEROL:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND LDL-C:HDL-C, BY 20.8% AND 25.5%, RESPECTIVELY. PROBUCOL SIGNIFICANTLY LOWERED TOTAL CHOLESTEROL (7.8%) AND LDL-C (11.8%), AS WELL AS THE RATIOS OF LDL-C:HDL-C (15.0%) AND TOTAL CHOLESTEROL:HDL-C (11.4%). NEITHER POLICOSANOL NOR PROBUCOL TREATMENT SIGNIFICANTLY CHANGED HDL-C LEVELS. BOTH DRUGS WERE WELL TOLERATED; NO PATIENT WITHDREW FROM THE TRIAL. ADVERSE EXPERIENCES REPORTED WERE MILD AND DID NOT DIFFER SIGNIFICANTLY BETWEEN GROUPS. IT IS CONCLUDED THAT BOTH DRUGS ARE ADEQUATE ALTERNATIVES FOR TREATING PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, WITH POLICOSANOL BEING MORE EFFECTIVE THAN PROBUCOL IN THIS SHORT-TERM STUDY.","HYPERCHOLESTEROLEMIA; POLICOSANOL; PROBUCOL","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; PROBUCOL; TRIACYLGLYCEROL; ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; INSOMNIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOMITING","","","STAMLER J., WENTWORTH D., NEATON J.D., IS THE RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND RISK OF PREMATURE DEATH FROM CORONARY HEART DISEASE CONTINUOUS AND GRADED? FINDINGS IN 356 222 PRIMARY SCREENINGS OF THE MULTIPLE RISK FACTOR INTERVENTION TRIAL, JAMA, 256, (1986); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO D., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DISLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); O'CONNOR P., FEELY J., SHEPHERD J., LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); TIKKANEN M.J., NIKKILA E.A., CURRENT PHARMACOLOGIC TREATMENT OF ELEVATED SERUM CHOLESTEROL, CIRCULATION, 76, PP. 529-533, (1987); OELBAUM R.S., GALTON D.J., MANAGEMENT OF HYPERCHOLESTEROLAEMIA, CURR OPINION CARDIOL., 3, PP. 255-263, (1988); TOBERT J.A., NEW DEVELOPMENTS IN LIPID-LOWERING THERAPY: THE ROLE OF INHIBITORS OF HYDROXYMETHYL-GLUTARYL-COENZYME A REDUCTASE, CIRCULATION, 76, PP. 534-538, (1987); SIRTORI C.R., MANZONI C., LOVATI M.R., MECHANISMS OF LIPID-LOWERING AGENTS, CARDIOLOGY, 78, PP. 226-235, (1991); BOCCUZZI S.J., KEEGAN M.E., HIRSCH L.J., ET AL., LONG TERM EXPERIENCE WITH SIMVASTATIN, DRUG INVEST., 5, PP. 135-140, (1993); STEINER A., WEISSER B., VETTER W., A COMPARATIVE STUDY OF THE ADVERSE EFFECTS OF TREATMENTS FOR HYPERLIPIDAEMIA, DRUG SAFETY, 6, PP. 118-130, (1991); O'CONNOR O., FEELY J., SHEPHERD J., LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES., 27, PP. 205-208, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZ FARMACOL TER., 11, PP. 74-79, (1992); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES., 51, PP. 1-8, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZ FARMACOL TER., 12, PP. 71-76, (1993); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES., 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, AD THER.; CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES.; PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES., 53, PP. 265-269, (1993); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A 12-MONTH STUDY, CURR THER RES., 56, PP. 819-828, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES., 27, PP. 199-203, (1994); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE, SUBCHRONICAL AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT., 70, PP. 77-87, (1994); MESA A.D.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL., 32, PP. 565-575, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG., 14, PP. 239-249, (1994); BUCKLEY M.M., KAREN L., GOA A., PRICE A.H., BRODGEN R.N., PROBUCOL: A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN HYPERCHOLESTEROLEMIA, DRUGS, 37, PP. 761-800, (1989); DUJOVNE C.A., KREHBIEL P., CHERNOFF S.B., CONTROLLED STUDIES OF THE EFFICACY AND SAFETY OF COMBINED PROBUCOL-COLESTIPOL THERAPY, AM J CARDIOL., 57, (1986); DURRINGTON P.N., MILLER J.P., DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF PROBUCOL IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA, ATHEROSCLEROSIS, 55, PP. 187-194, (1985); ENJALBERT M., LUSSIER-CACAN S., DUBREUIL-QUIDOZ S., ET AL., USEFULNESS OF PROBUCOL IN TREATING PRIMARY HYPERCHOLESTEROLEMIA, CAN MED ASSOC J., 123, PP. 754-757, (1980); FELLIN R., GASPAROTTO A., VALERIO G., ET AL., EFFECT OF PROBUCOL TREATMENT ON LIPOPROTEIN CHOLESTEROL AND DRUG LEVELS IN BLOOD AND LIPOPROTEINS IN FAMILIAL HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 59, PP. 47-56, (1986); ROUFFY J., BAKIR R., CHANU B., ET AL., PROBUCOL: AN EVALUATION OF EFFECTS ON PLASMA LIPIDS AND LIPOPROTEINS IN 34 CASES OF PRIMARY TYPES IIA AND IIB HYPERLIPOPROTEINEMIA, DIET AND DRUGS IN ATHEROSCLEROSIS. NEW YORK: RAVEN PRESS, PP. 237-244, (1980); BEAUMONT V., BUXTORF J.C., JACOTOT B., BEAUMONT J.L., SHORT- AND LONG-TERM TRIALS OF PROBUCOL IN TYPE II HYPERLIPOPROTEINEMIA, DIET AND DRUGS IN ATHEROSCLEROSIS, PP. 209-214, (1980); BOYDEN T.W., TOTMAN L., SYNERGISTIC EFFECTS OF PROBUCOL AND CHOLESTYRAMINE TO LOWER SERUM CHOLESTEROL, J CLIN PHARMACOL., 21, PP. 48-51, (1981); A MULTICENTER COMPARISON OF LOVASTATIN AND PROBUCOL FOR TREATMENT OF SEVERE PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL., 66, (1990); DAVIGNON J., XHIGNESSE M., MAILOUX H., ET AL., COMPARATIVE STUDY OF LOVASTATIN VERSUS PROBUCOL IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS REVIEWS, 18, PP. 139-151, (1988); IKEDA T., OCHI H., OHTANI I., ET AL., COMPARISON OF THE EFFECTS OF SMALL DOSES OF PROBUCOL AND PRAVASTATIN ON SERUM LIPIDS AND APOLIPOPROTEINS IN NONOBESE, NON-INSULIN-DEPENDENT DIABETES MELLITUS PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 51, PP. 593-599, (1992); CRISTOL L.S., JIALAL I., GRUNDY S.M., EFFECT OF LOW-DOSE THERAPY ON LDL OXIDATION AND THE PLASMA LIPOPROTEIN PROFILE IN MALE VOLUNTEERS, ATHEROSCLEROSIS, 97, PP. 11-20, (1992); PATERSON J.R., RUMLEY A.G., OLDROYD K.G., ET AL., PROBUCOL REDUCES PLASMA LIPID PEROXIDES IN MAN, ATHEROSCLEROSIS, 97, PP. 63-66, (1992); REGNSTROM J., WALLDIUS G., CARLSON L.A., NILSSON J., EFFECT OF PROBUCOL TREATMNT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS TO BECOME OXIDATIVELY MODIFIED IN VITRO, ATHEROSCLEROSIS, 82, PP. 43-51, (1990); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM., 18, PP. 499-502, (1972); ILLINGWORTH D.R., AN OVERVIEW OF LIPID LOWERING DRUGS, DRUGS, 36, 3 SUPPL., PP. 63-71, (1988)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0031019054","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"PONS P, 1997, CURR THER RES CLIN EXP","PONS P, 1997, CURR THER RES CLIN EXP"
"MCCARTY M","MCCARTY, M.F (24435224500)","POLICOSANOL SAFELY DOWNREGULATES HMGCOA REDUCTASE POTENTIAL AS A COMPONENT OF THE ESSELSTYN REGIMEN",2002,"MEDICAL HYPOTHESES","59","11",40,"10.1016/S0306-9877(02)00226-8","MCCARTY M.F, PANTOX LABORATORIES, SAN DIEGO, UNITED STATES","MANY OF THE WIDE-RANGING HEALTH BENEFITS CONFERRED BY STATIN THERAPY ARE MEDIATED, NOT BY REDUCTIONS IN LDL CHOLESTEROL, BUT RATHER BY INHIBITION OF ISOPRENYLATION REACTIONS ESSENTIAL TO THE ACTIVATION OF RHO FAMILY GTPASES; THIS MAY BE THE MECHANISM PRIMARILY RESPONSIBLE FOR THE FAVORABLE IMPACT OF STATINS ON RISK FOR ISCHEMIC STROKE, SENILE DEMENTIA, AND FRACTURES, AS WELL AS THE ANTI-HYPERTENSIVE AND PLATELET-STABILIZING ACTIONS OF THESE DRUGS. INDEED, THE EXTENT OF THESE BENEFITS IS SUCH AS TO SUGGEST THAT MOST ADULTS WOULD BE WISE TO TAKE STATINS; HOWEVER, OWING TO THE SIGNIFICANT EXPENSE OF STATIN THERAPY, AS WELL AS TO THE POTENTIAL FOR DANGEROUS SIDE EFFECTS THAT MANDATES REGULAR PHYSICIAN FOLLOW-UP, THIS STRATEGY APPEARS IMPRACTICAL. HOWEVER, POLICOSANOL, A MIXTURE OF LONG-CHAIN ALIPHATIC ALCOHOLS EXTRACTABLE FROM SUGAR CANE WAX, HAS SHOWN CHOLESTEROL-LOWERING POTENCY COMPARABLE TO THAT OF STATINS, AND YET APPEARS TO BE DEVOID OF TOXIC RISK. RECENT EVIDENCE INDICATES THAT POLICOSANOL DOWN-REGULATES CELLULAR EXPRESSION OF HMG-COA REDUCTASE, AND THUS HAS THE POTENTIAL TO SUPPRESS ISOPRENYLATION REACTIONS MUCH LIKE STATINS DO. CONSISTENT WITH THIS POSSIBILITY, THE RESULTS OF CERTAIN CLINICAL AND ANIMAL STUDIES DEMONSTRATE THAT POLICOSANOL HAS MANY EFFECTS ANALOGOUS TO THOSE OF STATINS THAT ARE NOT LIKELY EXPLAINED BY REDUCTIONS OF LDL CHOLESTEROL. HOWEVER, UNLIKE STATINS, POLICOSANOL DOES NOT DIRECTLY INHIBIT HMG-COA REDUCTASE, AND EVEN IN HIGH CONCENTRATIONS IT FAILS TO DOWN-REGULATE THIS ENZYME BY MORE THAN 50% - THUS LIKELY ACCOUNTING FOR THE SAFETY OF THIS NUTRACEUTICAL. IN LIGHT OF THE FACT THAT POLICOSANOL IS QUITE INEXPENSIVE AND IS BECOMING AVAILABLE AS A NON-PRESCRIPTION DIETARY SUPPLEMENT, IT MAY REPRESENT A PRACTICAL RESOURCE THAT COULD ENABLE THE GENERAL PUBLIC TO ENJOY HEALTH BENEFITS COMPARABLE TO THOSE CONFERRED BY STATINS. IN A LONG-TERM CLINICAL STUDY ENROLLING PATIENTS WITH SIGNIFICANT SYMPTOMATIC CORONARY DISEASE, ESSELSTYN HAS DEMONSTRATED THAT A LOW-FAT, WHOLE-FOOD VEGAN DIET, COUPLED WITH SUFFICIENT STATIN THERAPY TO MAINTAIN SERUM CHOLESTEROL BELOW 150 MG/DL, CAN STOP THE PROGRESSION OF CORONARY DISEASE AND VIRTUALLY ELIMINATE FURTHER RISK FOR HEART ATTACK. A COMPARABLE REGIMEN, IN WHICH POLICOSANOL IS USED IN PLACE OF STATINS, MAY REPRESENT A PRACTICAL STRATEGY WHEREBY NEARLY EVERYONE WILLING TO COMMIT TO HEALTH-PROTECTIVE EATING CAN EITHER PREVENT CORONARY DISEASE, OR PREVENT PRE-EXISTING CORONARY DISEASE FROM PROGRESSING TO A LIFE-THREATENING EVENT. © 2002 PUBLISHED BY ELSEVIER SCIENCE LTD.","","ANIMALIA; ARUNDINARIA; SACCHARUM; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; STATIN; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; DOWN REGULATION; DRUG COST; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FOLLOW UP; FRACTURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISOPRENYLATION; LONG TERM CARE; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SENILE DEMENTIA; SIDE EFFECT; THROMBOCYTE","","","RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); SACKS F.M., PFEIFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); GAW A., CAN THE CLINICAL EFFICACY OF THE HMG COA REDUCTASE INHIBIT EFFECTS ON LDL-CHOLESTEROL?, ATHEROSCLEROSIS, 125, PP. 267-269, (1996); VAUGHAN C.J., MURPHY M.B., BUCKLEY B.M., STATINS DO MORE THAN JUST LOWER CHOLESTEROL, LANCET, 348, PP. 1079-1082, (1996); BELLOSTA S., BERNINI F., FERRI N., ET AL., DIRECT VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS, ATHEROSCLEROSIS, 137, SUPPL., (1998); ENDRES M., LAUFS U., HMG-COA REDUCTASE INHIBITOR AND RISK OF STROKE, NERVENARZT, 69, PP. 717-721, (1998); JARVISALO M.J., TOIKKA J.O., VASANKARI T., ET AL., HMG COA REDUCTASE INHIBITORS ARE RELATED TO IMPROVED SYSTEMIC ENDOTHELIAL FUNCTION IN CORONARY ARTERY DISEASE, ATHEROSCLEROSIS, 147, PP. 237-242, (1999); SOTIRIOU C.G., CHENG J.W., BENEFICIAL EFFECTS OF STATINS IN CORONARY ARTERY DISEASE - BEYOND LOWERING CHOLESTEROL, ANN PHARMACOTHER, 34, PP. 1432-1439, (2000); LAUFS U., LIAO J.K., DIRECT VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS, TRENDS CARDIOVASC MED, 10, PP. 143-148, (2000); VAN AELST L., D'SOUZA-SCHOREY C., RHO GTPASES AND SIGNALING NETWORKS, GENES DEV, 11, PP. 2295-2322, (1997); LAUFS U., LIAO J.K., TARGETING RHO IN CARDIOVASCULAR DISEASE, CIRC RES, 87, PP. 526-528, (2000); LAUFS U., LA F.V., PLUTZKY J., LIAO J.K., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE BY HMG COA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); ENDRES M., LAUFS U., HUANG Z., ET AL., STROKE PROTECTION BY 3-HYDROXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE INHIBITORS MEDIATED BY ENDOTHELIAL NITRIC OXIDE SYNTHASE, PROC NATL ACAD SCI USA, 95, PP. 8880-8885, (1998); LAUFS U., LIAO J.K., POST-TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE MRNA STABILITY BY RHO GTPASE, J BIOL CHEM, 273, PP. 24266-24271, (1998); LAUFS U., GERTZ K., HUANG P., ET AL., ATORVASTATIN UPREGULATES TYPE III NITRIC OXIDE SYNTHASE IN THROMBOCYTES, DECREASES PLATELET ACTIVATION, AND PROTECTS FROM CEREBRAL ISCHEMIA IN NORMOCHOLESTEROLEMIC MICE, STROKE, 31, PP. 2442-2449, (2000); WAGNER A.H., KOHLER T., RUCKSCHLOSS U., JUST I., HECKER M., IMPROVEMENT OF NITRIC OXIDE-DEPENDENT VASODILATATION BY HMG-COA REDUCTASE INHIBITORS THROUGH ATTENUATION OF ENDOTHELIAL SUPEROXIDE ANION FORMATION, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 61-69, (2000); WASSMANN S., LAUFS U., BAUMER A.T., ET AL., INHIBITION OF GERANYLGERANYLATION REDUCES ANGIOTENSIN II-MEDIATED FREE RADICAL PRODUCTION IN VASCULAR SMOOTH MUSCLE CELLS: INVOLVEMENT OF ANGIOTENSIN AT1 RECEPTOR EXPRESSION AND RAC1 GTPASE, MOL PHARMACOL, 59, PP. 646-654, (2001); SOMA M.R., PAROLINI C., DONETTI E., FUMAGALLI R., PAOLETTI R., INHIBITION OF ISOPRENOID BIOSYNTHESIS AND ARTERIAL SMOOTHMUSCLE CELL PROLIFERATION, J CARDIOVASC PHARMACOL, 25, SUPPL. 4, (1995); LAUFS U., MARRA D., NODE K., LIAO J.K., 3-HYDROXY-3- METHYLGLUTARYL-COA REDUCTASE INHIBITORS ATTENUATE VASCULAR SMOOTH MUSCLE PROLIFERATION BY PREVENTING RHO GTPASE-INDUCED DOWN-REGULATION OF P27(KIP1), J BIOL CHEM, 274, PP. 21926-21931, (1999); HERNANDEZ-PERERA O., PEREZ-SALA D., SORIA E., LAMAS S., INVOLVEMENT OF RHO GTPASES IN THE TRANSCRIPTIONAL INHIBITION OF PREPROENDOTHELIN-1 GENE EXPRESSION BY SIMVASTATIN IN VASCULAR ENDOTHELIAL CELLS, CIRC RES, 87, PP. 616-622, (2000); PRUEFER D., SCALIA R., LEFER A.M., SIMVASTATIN INHIBITS LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS AND PROTECTS AGAINST INFLAMMATORY PROCESSES IN NORMOCHOLESTEROLEMIC RATS, ARTERIOSCLER THROMB VASC BIOL, 19, PP. 2894-2900, (1999); FERRO D., BASILI S., ALESSANDRI C., MANTOVANI B., CORDOVA C., VIOLI F., SIMVASTATIN REDUCES MONOCYTE-TISSUE-FACTOR EXPRESSION TYPE IIA HYPERCHOLESTEROLAEMIA, LANCET, 350, (1997); BERNINI F., DIDONI G., BONFADINI G., BELLOSTA S., FUMAGALLI R., REQUIREMENT FOR MEVALONATE IN ACETYLATED LDL INDUCTION OF CHOLESTEROL ESTERIFICATION IN MACROPHAGES, ATHEROSCLEROSIS, 104, PP. 19-26, (1993); UMETANI N., KANAYAMA Y., OKAMURA M., NEGORO N., TAKEDA T., LOVASTATIN INHIBITS GENE EXPRESSION OF TYPE-I SCAVENGER RECEPTOR IN THP-1 HUMAN MACROPHAGES, BIOCHIM BIOPHYS ACTA, 1303, PP. 199-206, (1996); ESSIG M., NGUYEN G., PRIE D., ESCOUBET B., SRAER J.D., FRIEDLANDER G., 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS INCREASE FIBRINOLYTIC ACTIVITY IN RAT AORTIC ENDOTHELIAL CELLS. ROLE OF GERANYLGERANYLATION AND RHO PROTEINS, CIRC RES, 83, PP. 683-690, (1998); BOURCIER T., LIBBY P., HMG COA REDUCTASE INHIBITORS REDUCE PLASMINOGEN ACTIVATOR INHIBITOR-1 EXPRESSION BY HUMAN VASCULAR SMOOTH MUSCLE AND ENDOTHELIAL CELLS, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 556-562, (2000); BRAND K., PAGE S., WALLI A.K., NEUMEIER D., BAEUERLE P.A., ROLE OF NUCLEAR FACTOR-KAPPA B IN ATHEROGENESIS, EXP PHYSIOL, 82, PP. 297-304, (1997); THURBERG B.L., COLLINS T., THE NUCLEAR FACTOR-KAPPA B/ INHIBITOR OF KAPPA B AUTOREGULATORY SYSTEM AND ATHEROSCLEROSIS, CURR OPIN LIPIDOL, 9, PP. 387-396, (1998); WEBER C., ERL W., MODULATION OF VASCULAR CELL ACTIVATION, FUNCTION, AND APOPTOSIS: ROLE OF ANTIOXIDANTS AND NUCLEAR FACTOR-KAPPA B, CURR TOP CELL REGUL, 36, PP. 217-235, (2000); BLAUW G.J., LAGAAY A.M., SMELT A.H., WESTENDORP R.G., STROKE, STATINS, AND CHOLESTEROL A META-ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIALS WITH HMG-COA REDUCTASE INHIBITORS, STROKE, 28, PP. 946-950, (1997); WARSHAFSKY S., PACKARD D., MARKS S.J., ET AL., EFFICACY OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS FOR PREVENTION OF STROKE, J GEN INT MED, 14, PP. 763-774, (1999); TONOLO G., MELIS M.G., FORMATO M., ET AL., ADDITIVE EFFECTS OF SIMVASTATIN BEYOND ITS EFFECTS ON LDL CHOLESTEROL IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS, EUR J CLIN INVEST, 30, PP. 980-987, (2000); WOLOZIN B., KELLMAN W., RUOSSEAU P., CELESIA G.G., SIEGEL G., DECREASED PREVALENCE OF ALZHEIMER DISEASE ASSOCIATED WITH 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, ARCH NEUROL, 57, PP. 1439-1443, (2000); JICK H., ZOMBERG G.L., JICK S.S., SESHADRI S., DRACHMAN D.A., STATINS AND THE RISK OF DEMENTIA, LANCET, 356, PP. 1627-1631, (2000); STAMLER J.S., ALZHEIMER'S DISEASE A RADICAL VASCULAR CONNECTION, NATURE, 380, PP. 108-111, (1996); MCCARTY M.F., VASCULAR NITRIC OXIDE MAY LESSEN ALZHEIMER'S RISK, MED HYPOTHESES, 51, PP. 465-476, (1998); MCCARTY M.F., VASCULAR NITRIC OXIDE, SEX HORMONE REPLACEMENT, AND FISH OIL MAY HELP TO PREVENT ALZHEIMER'S DISEASE BY SUPPRESSING SYNTHESIS OF ACUTE-PHASE CYTOKINES, MED HYPOTHESES, 53, PP. 369-374, (1999); FASSBENDER K., SIMONS M., BERGMANN C., ET AL., SIMVASTATIN STRONGLY REDUCES LEVELS OF ALZHEIMER'S DISEASE BETA-AMYLOID PEPTIDES ABETA 42 AND ABETA 40 IN VITRO AND IN VIVO, PROC NATL ACAD SCI USA, 98, PP. 5856-5861, (2001); BORGHI C., PRANDIN M.G., COSTA F.V., BACCHELLI S., DEGLI E.D., AMBROSIONI E., USE OF STATINS AND BLOOD PRESSURE CONTROL IN TREATED HYPERTENSIVE PATIENTS WITH HYPERCHOLESTEROLEMIA, J CARDIOVASC PHARMACOL, 35, PP. 549-555, (2000); SPOSITO A.C., MANSUR A.P., COELHO O.R., NICOLAU J.C., RAMIRES J.A., ADDITIONAL REDUCTION IN BLOOD PRESSURE AFTER CHOLESTEROL-LOWERING TREATMENT BY STATINS (LOVASTATIN OR PRAVASTATIN) IN HYPERCHOLESTEROLEMIC PATIENTS USING ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ENALAPRIL OR LISINOPRIL), AM J CARDIOL, 83, PP. 1497-1499, (1999); GLORIOSO N., TROFFA C., FILIGHEDDU F., ET AL., EFFECT OF THE HMG-COA REDUCTASE INHIBITORS ON BLOOD PRESSURE IN PATIENTS WITH ESSENTIAL HYPERTENSION AND PRIMARY HYPERCHOLESTEROLEMIA, HYPERTENSION, 34, PP. 1281-1286, (1999); WANG P.S., SOLOMON D.H., MOGUN H., AVORN J., HMG-COA REDUCTASE INHIBITORS AND THE RISK OF HIP FRACTURES IN ELDERLY PATIENTS, JAMA, 283, PP. 3211-3216, (2000); CHAN K.A., ANDRADE S.E., BOLES M., ET AL., INHIBITORS OF HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE AND RISK OF FRACTURE AMONG OLDER WOMEN, LANCET, 355, PP. 2185-2188, (2000); EDWARDS C.J., HART D.J., SPECTOR T.D., ORAL STATINS AND INCREASED BONE-MINERAL DENSITY IN POSTMENOPAUSAL WOMEN, LANCET, 355, PP. 2218-2219, (2000); MUNDY G., GARRETT R., HARRIS S., ET AL., STIMULATION OF BONE FORMATION IN VITRO AND IN RODENTS BY STATINS, SCIENCE, 286, PP. 1946-1949, (1999); GOALSTONE M.L., WALL K., LEITNER J.W., ET AL., INCREASED AMOUNTS OF FARNESYLATED P21RAS IN TISSUES OF HYPERINSULINAEMIC ANIMALS, DIABETOLOGIA, 42, PP. 310-316, (1999); GOALSTONE M.L., LEITNER J.W., WALL K., ET AL., EFFECT OF INSULIN ON FARNESYLTFRANSFERASE. SPECIFICITY OF INSULIN ACTION AND POTENTIATION OF NUCLEAR EFFECTS OF INSULIN-LIKE GROWTH FACTOR-1, EPIDERMAL GROWTH FACTOR, AND PLATELET-DERIVED GROWTH FACTOR, J BIOL CHEM, 273, PP. 23892-23896, (1998); GOALSTONE M., CAREL K., LEITNER J.W., DRAZNIN B., INSULIN STIMULATES THE PHOSPHORYLATION AND ACTIVITY OF FARNESYLTRANSFERASE VIA THE RAS-MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY, ENDOCRINOLOGY, 138, PP. 5119-5124, (1997); LEITNER J.W., KLINE T., CAREL K., GOALSTONE M., DRAZNIN B., HYPERINSULINEMIA POTENTIATES ACTIVATION OF P21 RAS BY GROWTH FACTORS, ENDOCRINOLOGY, 138, PP. 2211-2214, (1997); GOALSTONE M.L., LEITNER J.W., GOLOVCHENKO I., ET AL., INSULIN PROMOTES PHOSPHORYLATION AND ACTIVATION OF GERANYLGERANYLTRANSFERASE II. STUDIES WITH GERANYLGERANYLATION OF RAB-3 AND RAB-4, J BIOL CHEM, 274, PP. 2880-2884, (1999); DRAZNIN B., MILES P., KRUSZYNSKA Y., ET AL., EFFECTS OF INSULIN ON PRENYLATION AS A MECHANISM OF POTENTIALLY DETRIMENTAL INFLUENCE OF HYPERINSULINEMIA, ENDOCRINOLOGY, 141, PP. 1310-1316, (2000); CUSI K., MAEZONO K., OSMAN A., ET AL., INSULIN RESISTANCE DIFFERENTIALLY AFFECTS THE PI 3-KINASE- AND MAP KINASE-MEDIATED SIGNALING IN HUMAN MUSCLE, J CLIN INVEST, 105, PP. 311-320, (2000); MICHELL B.J., GRIFFITHS J.E., MITCHELHILL K.I., ET AL., THE AKT KINASE SIGNALS DIRECTLY TO ENDOTHELIAL NITRIC OXIDE SYNTHASE, CURR BIOL, 9, PP. 845-848, (1999); MONTAGNANI M., CHEN H., BARR V.A., QUON M.J., INSULIN-STIMULATED ACTIVATION OF ENOS IS INDEPENDENT OF CA++ BUT REQUIRES PHOSPHORYLATION BY AKT AT SER1 179, J BIOL CHEM, (2001); KASHIWAGI A., SHINOZAKI K., NISHIO Y., OKAMURA T., TODA N., KIKKAWA R., FREE RADICAL PRODUCTION IN ENDOTHELIAL CELLS AS A PATHOGENETIC FACTOR FOR VASCULAR DYSFUNCTION IN THE INSULIN RESISTANCE STATE, DIABETES RES CLIN PRACT, 45, PP. 199-203, (1999); KASHIWAGI A., SHINOZAKI K., NISHIO Y., ET AL., ENDOTHELIUM-SPECIFIC ACTIVATION OF NAD(P)H OXIDASE IN AORTAS OF EXOGENOUSLY HYPERINSULINEMIC RATS, AM J PHYSIOL, 277, (1999); MCCARTY M.F., INSULIN'S STIMULATION OF ENDOTHELIAL SUPEROXIDE GENERATION MAY REFLECT UP-REGULATION OF ISOPRENYL TRANSFERASE ACTIVITY THAT PROMOTES RAC TRANSLOCATION, MED HYPOTHESES, 58, PP. 472-475, (2002); BORNBRUST D.J., MACDONALD J.S., PETER C.P., ET AL., TOXICITY OF THE HMG-COENZYME A REDUCTASE INHIBITOR, LOVASTATIN, TO RABBITS, J PHARMACOL EXP THER, 248, PP. 498-505, (1989); MASTERS B.A., PALMOSKI M.J., FLINT O.P., GREGG R.E., WANG-IVERSON D., DURHAM S.K., IN VITRO MYOTOXICITY OF THE 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, PRAVASTATIN, LOVASTATIN, AND SIMVASTATIN, USING NEONATAL RAT SKELETAL MYOCYTES, TOXICOL APPL PHARMACOL, 131, PP. 163-174, (1995); FLINT O.P., MASTERS B.A., GREGG R.E., DURHAM S.K., INHIBITION OF CHOLESTEROL SYNTHESIS BY SQUALENE SYNTHASE INHIBITORS DOES NOT INDUCE MYOTOXICITY IN VITRO, TOXICOL APPL PHARMACOL, 145, PP. 91-98, (1997); FLINT O.P., MASTERS B.A., GREGG R.E., DURHAM S.K., HMG COA REDUCTASE INHIBITOR-INDUCED MYOTOXICITY: PRAVASTATIN AND LOVASTATIN INHIBIT THE GERANYLGERANYLATION OF LOW-MOLECULAR-WEIGHT PROTEINS IN NEONATAL RAT MUSCLE CELL CULTURE, TOXICOL APPL PHARMACOL, 145, PP. 99-110, (1997); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ALEMAN C.L., MAS F.R., NOA P.M., RODEIRO G.I., HERNANDEZ O.C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POSTNATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER, 53, PP. 265-269, (1993); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF POLICOSANOL, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS F.R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., FERNANDEZ L., ALVAREZ E., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A: BIOL SCI MED SCI, 56, (2001); PRAT H., ROMAN O., PINO E., COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMG-COA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA, REV MED CHIL, 127, PP. 286-294, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CRESPO N., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., CASTANO G., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ALVAREZ E., LEZCAY M., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); PARKER R.A., PEARCE B.C., CLARK R.W., GORDON D.A., WRIGHT J.J., TOCOTRIENOLS REGULATE CHOLESTEROL PRODUCTION IN MAMMALIAN CELLS BY POST-TRANSCRIPTIONAL SUPPRESSION OF 3HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, J BIOL CHEM, 268, PP. 11230-11238, (1993); ELSON C.E., PEFFLEY D.M., HENTOSH P., MO H., ISOPRENOID-MEDIATED INHIBITION OF MEVALONATE SYNTHESIS: POTENTIAL APPLICATION TO CANCER, PROC SOC EXP BIOL MED, 221, PP. 294-311, (1999); ARNADOTTIR M., ERIKSSON L.O., THYSELL H., KARKAS J.D., PLASMA CONCENTRATION PROFILES OF SIMVASTATIN 3-HYDROXY-3-METHYL-GLUTARYL-COENZYME A REDUCTASE INHIBITORY ACTIVITY IN KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT CICLOSPORIN, NEPHRON, 65, PP. 410-413, (1993); PENTIKAINEN P.J., SARAHEIMO M., SCHWARTZ J.I., ET AL., COMPARATIVE PHARMACOKINETICS OF LOVASTATIN, SIMVASTATIN AND PRAVASTATIN IN HUMANS, J CLIN PHARMACOL, 32, PP. 136-140, (1992); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO G., MAS F.R., FERNANDEZ L., GAMEZ R., ILLNAIT J., FERNANDEZ C., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); STUSSER R., BATISTA J., PADRON R., SOSA F., PEREZTOL O., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, PP. 469-473, (1998); KLEINVELD H.A., DEMACKER P.N., DE HAAN A.F., STALENHOEF A.F., DECREASED IN VITRO OXIDIZABILITY OF LOW-DENSITY LIPOPROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS TREATED WITH 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS, EUR J CLIN INVEST, 23, PP. 289-295, (1993); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); KOCKX M.M., DE MEYER G.R., JACOB W.A., BULT H., HERMAN A.G., TRIPHASIC SEQUENCE OF NEOINTIMAL FORMATION IN THE CUFFED CAROTID ARTERY OF THE RABBIT, ARTERIOSCLER THROMB, 12, PP. 1447-1457, (1992); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); QURESHI A.A., QURESHI N., WRIGHT J.J., ET AL., LOWERING OF SERUM CHOLESTEROL IN HYPERCHOLESTEROLEMIC HUMANS BY TOCOTRIENOLS (PALMVITEE), AM J CLIN NUTR, 53, (1991); QURESHI A.A., BRADLOW B.A., BRACE L., ET AL., RESPONSE OF HYPERCHOLESTEROLEMIC SUBJECTS TO ADMINISTRATION OF TOCOTRIENOLS, LIPIDS, 30, PP. 1171-1177, (1995); TOMEO A.C., GELLER M., WATKINS T.R., GAPOR A., BIERENBAUM M.L., ANTIOXIDANT EFFECTS OF TOCOTRIENOLS IN PATIENTS WITH HYPERLIPIDEMIA AND CAROTID STENOSIS, LIPIDS, 30, PP. 1179-1183, (1995); BLACK T.M., WANG P., MAEDA N., COLEMAN R.A., PALM TOCOTRIENOLS PROTECT APO E +/- MICE FROM DIET-INDUCED ATHEROMA FORMATION, J NUTR, 130, PP. 2420-2426, (2000); ROSENTHAL M.B., BARNARD R.J., ROSE D.P., INKELES S., HALL J., PRITIKIN N., EFFECTS OF A HIGH-COMPLEX-CARBOHYDRATE, LOW-FAT, LOW-CHOLESTEROL DIET ON LEVELS OF SERUM LIPIDS AND ESTRADIOL, AM J MED, 78, PP. 23-27, (1985); BARNARD R.J., EFFECTS OF LIFE-STYLE MODIFICATION ON SERUM LIPIDS, ARCH INT MED, 151, PP. 1389-1394, (1991); TANG J.L., ARMITAGE J.M., LANCASTER T., SILAGY C.A., FOWLER G.H., NEIL H.A., SYSTEMATIC REVIEW OF DIETARY INTERVENTION TRIALS TO LOWER BLOOD TOTAL CHOLESTEROL IN FREE-LIVING SUBJECTS, BMJ, 316, PP. 1213-1220, (1998); HOPKINS P.N., EFFECTS OF DIETARY CHOLESTEROL ON SERUM CHOLESTEROL: A META-ANALYSIS AND REVIEW, AM J CLIN NUTR, 55, PP. 1060-1070, (1992); CARROLL K.K., HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS: EFFECTS OF DIETARY PROTEIN, FED PROC, 41, PP. 2792-2796, (1982); KRITCHEVSKY D., PROTEIN AND ATHEROSCLEROSIS, J NUTR SCI VITAMINOL (TOKYO), 36, SUPPL. 2, (1990); JENKINS D.J., WOLEVER T.M., COLLIER G.R., ET AL., METABOLIC EFFECTS OF A LOW-GLYCEMIC-INDEX DIET, AM J CLIN NUTR, 46, PP. 968-975, (1987); ESSELSTYN C.B., ELLIS S.G., MEDENDORP S.V., CROWE T.D., A STRATEGY TO ARREST AND REVERSE CORONARY ARTERY DISEASE: A 5-YEAR LONGITUDINAL STUDY OF A SINGLE PHYSICIAN'S PRACTICE, J FAM PRACT, 41, PP. 560-568, (1995); ESSELSTYN C.B., UPDATING A 12-YEAR EXPERIENCE WITH ARREST AND REVERSAL THERAPY FOR CORONARY HEART (DISEASE AN OVERDUE REQUIEM FOR PALLIATIVE CARDIOLOGY), AM J CARDIOL, 84, PP. 339-341, (1999); ORNISH D., SCHERWITZ L.W., BILLINGS J.H., ET AL., INTENSIVE LIFESTYLE CHANGES FOR REVERSAL OF CORONARY HEART DISEASE, JAMA, 280, PP. 2001-2007, (1998); BARNARD R.J., UGIANSKIS E.J., MARTIN D.A., INKELES S.B., ROLE OF DIET AND EXERCISE IN THE MANAGEMENT OF HYPERINSULINEMIA AND ASSOCIATED ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 69, PP. 440-444, (1992); FUKAGAWA N.K., ANDERSON J.W., HAGEMAN G., YOUNG V.R., MINAKER K.L., HIGH-CARBOHYDRATE, HIGH-FIBER DIETS INCREASE PERIPHERAL INSULIN SENSITIVITY IN HEALTHY YOUNG AND OLD ADULTS, AM J CLIN NUTR, 52, PP. 524-528, (1990); NICHOLSON A.S., SKLAR M., BARNARD N.D., GORE S., SULLIVAN R., BROWNING S., TOWARD IMPROVED MANAGEMENT OF NIDDM: A RANDOMIZED, CONTROLLED, PILOT INTERVENTION USING A LOWFAT, VEGETARIAN DIET, PREV MED, 29, PP. 87-91, (1999); ERNST E., PIETSCH L., MATRAI A., EISENBERG J., BLOOD RHEOLOGY IN VEGETARIANS, BR J NUTR, 56, PP. 555-560, (1986); MCCARTY M.F., FAVORABLE IMPACT OF A VEGAN DIET WITH EXERCISE ON HEMORHEOLOGY - IMPLICATIONS FOR CONTROL OF DIABETIC NEUROPATHY, MED HYPOTHESES, 58, PP. 476-486, (2002); REED M.J., CHRISTODOULIDES A., KOISTINEN R., SEPPALA M., TEALE J.D., GHILCHIK M.W., THE EFFECT OF ENDOCRINE THERAPY WITH MEDROXYPROGESTERONE ACETATE, 4-HYDROXYANDROSTENEDIONE OR TAMOXIFEN ON PLASMA CONCENTRATIONS OF INSULIN-LIKE GROWTH FACTOR (IGF)-I, IGF-II AND IGFBP-1 IN WOMEN WITH ADVANCED BREAST CANCER, INT J CANCER, 52, PP. 208-212, (1992); HOWARD B.V., ROBBINS D.C., SIEVERS M.L., ET AL., LDL CHOLESTEROL AS A STRONG PREDICTOR OF CORONARY HEART DISEASE IN DIABETIC INDIVIDUALS WITH INSULIN RESISTANCE AND LOW LDL: THE STRONG HEART STUDY, ARTERIOSCLER THROMB VASC BIOL, 20, PP. 830-835, (2000); ZANCHETTI A., HANSSON L., DAHLOF B., ET AL., EFFECTS OF INDIVIDUAL RISK FACTORS ON THE INCIDENCE OF CARDIOVASCULAR EVENTS IN THE TREATED HYPERTENSIVE PATIENTS OF THE HYPERTENSION OPTIMAL TREATMENT STUDY, J HYPERTENS, 19, PP. 1149-1159, (2001); HEYDEN S., SCHNEIDER K.A., FODOR G.J., FAILURE TO REDUCE CHOLESTEROL AS EXPLANATION FOR THE LIMITED EFFICACY OF ANTIHYPERTENSIVE TREATMENT IN THE REDUCTION OF CHD. EXAMINATION OF THE EVIDENCE FROM SIX HYPERTENSION INTERVENTION TRIALS, KLIN WOCHENSCHR, 65, PP. 828-832, (1987); BARNARD R.J., JUNG T., INKELES S.B., DIET AND EXERCISE IN THE TREATMENT OF NIDDM. THE NEED FOR EARLY EMPHASIS, DIABETES CARE, 17, PP. 1469-1472, (1994); GREENAMYRE J.T., GARCIA-OSUNA M., GREENE J.G., THE ENDOGENOUS COFACTORS, THIOCTIC ACID AND DIHYDROLIPOIC ACID, ARE NEUROPROTECTIVE AGAINST NMDA AND MALONIC ACID LESIONS OF STRIATUM, NEUROSCI LETT, 171, PP. 17-20, (1994); SACKS F.M., ROSNER B., KASS E.H., BLOOD PRESSURE IN VEGETARIANS, AM J EPIDEMIOL, 100, PP. 390-398, (1974); BEILIN L.J., ROUSE I.L., ARMSTRONG B.K., MARGETTS B.M., VANDONGEN R., VEGETARIAN DIET AND BLOOD PRESSURE LEVELS: INCIDENTAL OR CAUSAL ASSOCIATION?, AM J CLIN NUTR, 48, PP. 806-810, (1988); ESSELSTYN C.B., IN CHOLESTEROL LOWERING, MODERATION KILLS, CLEVE CLIN J MED, 67, PP. 560-564, (2000); COOKE J.P., IS ATHEROSCLEROSIS AN ARGININE DEFICIENCY DISEASE?, J INVESTIG MED, 46, PP. 377-380, (1998); MAXWELL A.J., ANDERSON B., ZAPIEN M.P., COOKE J.P., ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLEMIA IS REVERSED BY A NUTRITIONAL PRODUCT DESIGNED TO ENHANCE NITRIC OXIDE ACTIVITY, CARDIOVASC DRUGS THER, 14, PP. 309-316, (2000); MAXWELL A.J., ANDERSON B.E., COOKE J.P., NUTRITIONAL THERAPY FOR PERIPHERAL ARTERIAL DISEASE: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF HEARTBAR, VASC MED, 5, PP. 11-19, (2000); WOLF A., ZALPOUR C., THEILMEIER G., ET AL., DIETARY L-ARGININE SUPPLEMENTATION NORMALIZES PLATELET AGGREGATION IN HYPERCHOLESTEROLEMIC HUMANS, J AM COLL CARDIOL, 29, PP. 479-485, (1997); SIMOPOULOS A.P., OMEGA-3 FATTY ACIDS IN THE PREVENTION-MANAGEMENT OF CARDIOVASCULAR DISEASE, CAN J PHYSIOL PHARMACOL, 75, PP. 234-239, (1997); DIETARY SUPPLEMENTATION WITH N-3 POLYUNSATURATED FATTY ACIDS AND VITAMIN E AFTER MYOCARDIAL INFARCTION: RESULTS OF THE GISSI-PREVENZIONE TRIAL, LANCET, 354, PP. 447-455, (1999); SINGH R.B., NIAZ M.A., RASTOGI S.S., SHUKLA P.K., THAKUR A.S., EFFECT OF HYDROSOLUBLE COENZYME Q10 ON BLOOD PRESSURES AND INSULIN RESISTANCE IN HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE, J HUM HYPERTENS, 13, PP. 203-208, (1999); SINGH R.B., WANDER G.S., RASTOGI A., ET AL., RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF COENZYME Q10 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, CARDIOVASC DRUGS THER, 12, PP. 347-353, (1998); BAGGIO E., GANDINI R., PLANCHER A.C., PASSRI M., CARMOSINO G., ITALIAN MULTICENTER STUDY ON THE SAFETY AND EFFICACY OF COENZYME Q10 AS ADJUNCTIVE THERAPY IN HEART FAILURE, MOL ASPECTS MED, 15, SUPPL., (1994); AZUMA J., LONG-TERM EFFECT OF TAURINE IN CONGESTIVE HEART FAILURE: PRELIMINARY REPORT, ADV EXP MED BIOL, 359, PP. 425-433, (1994); FUJITA T., ANDO K., NODA H., ITO Y., SATO Y., EFFECTS OF INCREASED ADRENOMEDULLARY ACTIVITY AND TAURINE IN YOUNG PATIENTS WITH BORDERLINE HYPERTENSION, CIRCULATION, 75, PP. 525-532, (1987); HAYES K.C., PRONCZUK A., ADDESA A.E., STEPHAN Z.F., TAURINE MODULATES PLATELET AGGREGATION IN CATS AND HUMANS, AM J CLIN NUTR, 49, PP. 1211-1216, (1989); SIANI A., PAGANO E., IACONE R., IACOVIELLO L., SCOPACASA F., STRAZZULLO P., BLOOD PRESSURE AND METABOLIC CHANGES DURING DIETARY L-ARGININE SUPPLEMENTATION IN HUMANS, AM J HYPERTENS, 13, PP. 547-551, (2000); HOWE P.R., CAN WE RECOMMEND FISH OIL FOR HYPERTENSION?, CLIN EXP PHARMACOL PHYSIOL, 22, PP. 199-203, (1995); DIGIESI V., CANTINI F., ORADEI A., ET AL., COENZYME Q10 IN ESSENTIAL HYPERTENSION, MOL ASPECTS MED, 15, SUPPL., (1994); FRASER G.E., SABATE J., BEESON W.L., STRAHAN T.M., A POSSIBLE PROTECTIVE EFFECT OF NUT CONSUMPTION ON RISK OF CORONARY HEART DISEASE. THE ADVENTIST HEALTH STUDY, ARCH INT MED, 152, PP. 1416-1424, (1992); CAPPUCCIO F.P., MACGREGOR G.A., DOES POTASSIUM SUPPLEMENTATION LOWER BLOOD PRESSURE? A META-ANALYSIS OF PUBLISHED TRIALS, J HYPERTENS, 9, PP. 465-473, (1991); WASCHER T.C., POSCH K., WALLNER S., HERMETTER A., KOSTNER G.M., GRAIER W.F., VASCULAR EFFECTS OF L-ARGININE: ANYTHING BEYOND A SUBSTRATE FOR THE NO- SYNTHASE?, BIOCHEM BIOPHYS RES COMMUN, 234, PP. 35-38, (1997); COOKE J.P., OKA R.K., ATHEROGENESIS AND THE ARGININE HYPOTHESIS, CURR ATHEROSCLER REP, 3, PP. 252-259, (2001); YAMADA M., HUANG Z., DALKARA T., ET AL., ENDOTHELIAL NITRIC OXIDE SYNTHASE-DEPENDENT CEREBRAL BLOOD FLOW AUGMENTATION BY L-ARGININE AFTER CHRONIC STATIN TREATMENT, J CEREB BLOOD FLOW METAB, 20, PP. 709-717, (2000); CONNOR W.E., DEFRANCESCO C.A., CONNOR S.L., N-3 FATTY ACIDS FROM FISH OIL. EFFECTS ON PLASMA LIPOPROTEINS AND HYPERTRIGLYCERIDEMIC PATIENTS, ANN NY ACAD SCI, 683, PP. 16-34, (1993); KOBAYASHI A., MASUMURA Y., YAMAZAKI N., L-CARNITINE TREATMENT FOR CONGESTIVE HEART FAILURE - EXPERIMENTAL AND CLINICAL STUDY, JPN CIRC J, 56, PP. 86-94, (1992); BREVETTI G., CHIARIELLO M., FERULANO G., ET AL., INCREASES IN WALKING DISTANCE IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE TREATED WITH L-CARNITINE: A DOUBLE-BLIND, CROSS-OVER STUDY, CIRCULATION, 77, PP. 767-773, (1988); CHERCHI A., LAI C., ANGELINO F., ET AL., EFFECTS OF L-CARNITINE ON EXERCISE TOLERANCE IN CHRONIC STABLE ANGINA: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED CROSSOVER STUDY, INT J CLIN PHARMACOL THER TOXICOL, 23, PP. 569-572, (1985); SINGH R.B., NIAZ M.A., AGARWAL P., BEEGUM R., RASTOGI S.S., SACHAN D.S., A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF L-CARNITINE IN SUSPECTED ACUTE MYOCARDIAL INFARCTION, POSTGRAD MED J, 72, PP. 45-50, (1996); UBBINK J.B., THE ROLE OF VITAMINS IN THE PATHOGENESIS AND TREATMENT OF HYPERHOMOCYST(E)INAEMIA, J INHERIT METAB DIS, 20, PP. 316-325, (1997); STEINBERG D., IS THERE A POTENTIAL THERAPEUTIC ROLE FOR VITAMIN E OR OTHER ANTIOXIDANTS IN ATHEROSCLEROSIS?, CURR OPIN LIPIDOL, 11, PP. 603-607, (2000); MCCARTY M.F., OXIDANTS DOWNSTREAM FROM SUPEROXIDE INHIBIT NITRIC OXIDE PRODUCTION BY VASCULAR ENDOTHELIUM - A KEY ROLE FOR SELENIUM-DEPENDENT ENZYMES IN VASCULAR HEALTH, MED HYPOTHESES, 53, PP. 315-325, (1999); ANDERSON R.A., CHENG N., BRYDEN N.A., POLANSKY M.M., CHI J., FENG J., ELEVATED INTAKES OF SUPPLEMENTAL CHROMIUM IMPROVE GLUCOSE AND INSULIN VARIABLES IN INDIVIDUALS WITH TYPE 2 DIABETES, DIABETES, 46, PP. 1786-1791, (1997); CEFALU W.T., BELL-FARROW A.D., WANG Z.Q., ET AL., THE EFFECT OF CHROMIUM SUPPLEMENTATION ON CARBOHYDRATE METABOLISM AND BODY COMPOSITION, DIABETES, 46, SUPPL. 1, (1997); MCCARTY M.F., UP-REGULATION OF ENDOTHELIAL NITRIC OXIDE ACTIVITY AS A CENTRAL STRATEGY FOR PREVENTION OF ISCHEMIC STROKE - JUST SAY NO TO STROKE!, MED HYPOTHESES, 55, PP. 386-403, (2000)","","ELSEVIER","ENGLISH","MED. HYPOTHESES","ARTICLE","ISI","2-S2.0-0036734326","MED HYPOTHESES",NA,"NOTREPORTED",NA,"MCCARTY MF, 2002, MED HYPOTHESES","MCCARTY MF, 2002, MED HYPOTHESES"
"NOA M;MÁS R;MESA R","NOA, MIRIAM (7003318964); MÁS, ROSA (7007164572); MESA, ROSARIO (7003836140)","A COMPARATIVE STUDY OF POLICOSANOL VS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY",2001,"PHARMACOLOGICAL RESEARCH","43","6",18,"10.1006/phrs.2000.0736","DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG ISOLATED FROM SUGAR CANE WAX, WHICH ACTS BY INHIBITING CHOLESTEROL BIOSYNTHESIS. PREVIOUS STUDIES HAVE DEMONSTRATED THAT POLICOSANOL INHIBITED SMOOTH MUSCLE CELL (SMC) PROLIFERATION IN THE CUFFED CAROTID ARTERY OF THE RABBIT AND IN ARTERIAL WALL DAMAGE INDUCED BY FORCEPS IN THE CENTRAL ARTERY OF THE EAR OF RABBITS. THE PRESENT STUDY WAS UNDERTAKEN TO COMPARE THE EFFECTS OF POLICOSANOL AND LOVASTATIN ON SMC PROLIFERATION IN THE CUFFED CAROTID ARTERY OF RABBITS. COLLARS WERE PLACED AROUND THE LEFT CAROTID FOR 7 AND 15 DAYS. THE CONTRALATERAL ARTERY WAS SHAM OPERATED. WE STUDIED EIGHT EXPERIMENTAL GROUPS: TWO CONTROLS GROUPS RECEIVING VEHICLE FOR 7 AND 15 DAYS, RESPECTIVELY, A SATELLITE SHAM OPERATED CONTROL GROUP, FOUR GROUPS TREATED WITH POLICOSANOL AT 5 AND 25 MG KG-1 FOR 7 AND 15 DAYS AND A REFERENCE GROUP RECEIVING LOVASTATIN AT 20 MG KG-1 FOR 15 DAYS. SAMPLES OF ARTERIES WERE EXAMINED BY LIGHT AND ELECTRON MICROSCOPY. TO EVALUATE INTIMAL THICKENING THE CROSS-SECTIONAL AREAS OF INTIMA AND MEDIA WERE MEASURED. NEOINTIMA WAS SIGNIFICANTLY REDUCED IN TREATED ANIMALS COMPARED WITH CONTROLS, BUT THE REDUCTION IN LOVASTATIN ANIMALS WAS SIGNIFICANTLY LOWER THAN IN POLICOSANOL-TREATED GROUPS. THE SMC PROLIFERATION WAS STUDIED BY THE IMMUNOHISTOCHEMICAL DETECTION OF PROLIFERATING CELL NUCLEAR ANTIGEN AND THE REDUCTION OBSERVED IN POLICOSANOL-TREATED RABBITS WAS SIGNIFICANTLY LARGER THAN IN LOVASTATIN-TREATED ANIMALS. IT IS CONCLUDED THAT THE PROTECTIVE EFFECT OF POLICOSANOL AGAINST NEOINTIMA FORMATION IN THIS EXPERIMENTAL MODEL WAS SLIGHTLY BETTER THAN THAT OF LOVASTATIN. © 2001 ACADEMIC PRESS.","LOVASTATIN; POLICOSANOL; SMOOTH MUSCLE CELL PROLIFERATION","CELL NUCLEUS ANTIGEN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; POLICOSANOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME","","","RAINES E., ROSS R., SMOOTH MUSCLE CELL AND THE PATHOGENESIS OF THE LESIONS OF ATHEROSCLEROSIS, BR HEART J, 69, PP. 30-37, (1993); IP J., FUSTER V., BADIMON L., BADIMON J., TAUBMAN M., CHESEBRO J., SYNDROME OF ACCELERATED ATHEROSCLEROSIS: ROLE OF VASCULAR INJURY AND SMOOTH MUSCLE CELL PROLIFERATION, J AM COLL CARDIOL, 15, PP. 1667-1687, (1990); COOPER M., REISON D., ROSE E., ACCELERATED ATHEROSCLEROSIS, ISCHEMIC HEART DIS, 6, PP. 581-589, (1991); SOMA M., CORSINI A., PAOLETTI R., CHOLESTEROL AND MEVALONIC ACID MODULATION IN CELL METABOLISM AND MULTIPLICATION, TOXICOL LETT, 64-65, PP. 1-15, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL SUCCESIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, 1, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., POLICOSANOL FOR CHOLESTEROL-LOWERING LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); MENENDEZ R., AMOR A.M., GONZALEZ R., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., MAS R., DE LA ROSA M.C., EFFECT OF POLICOSANOL ON FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); RODRIGUEZ C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FUNDAM CHEM TOXICOL, 32, PP. 565-575, (1994); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON SMOOTH MUSCLE CELL PROLIFERATION IN THE CUFFED CAROTID ARTERY OF THE RABBIT, INT J CARDIOL, 67, PP. 125-132, (1998); NOA M., MAS R., AGUILAR C., RAMOS M.E., LARIOT C., EFFECT OF POLICOSANOL ON DAMAGED ARTERIAL WALL INDUCED BY FORCEPS IN RABBITS, ELECTRON MICROSCOPY, 4, (1998); KOCKX M., DEMEYER G., JACOB W., BULT H., HERMAN A., TRIPHASIC SEQUENCE OF NEOINTIMAL FORMATION IN THE CUFFED ARTERY OF THE RABBIT, ARTERIOSCLER THROMB, 12, PP. 1447-1457, (1992); KISUNUKI A., ASADA Y., HATAKEYAMA K., HAYASHI T., SUMIYOSHI A., CONTRIBUTION OF THE ENDOTHELIUM TO INTIMAL THICKENING IN NORMOCHOLESTEROLEMIC AND HYPERCHOLESTEROLEMIC RABBITS, ARTERIOSCLER THROMB, 12, PP. 1198-1205, (1992); DE MEYER G., BULT H., KOCKX M., HERMAN A., EFFECT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITION ON INTIMAL THICKENING IN RABBIT COLLARED CAROTID ARTERY, J CARDIOVASC PHARMACOL, 26, PP. 614-620, (1995); ZHU B.Q., SIEVERS R.E., SUN Y.P., ISENBERG W.M., PARMLEY W.W., EFFECT OF LOVASTATIN ON SUPPRESSION AND REGRESSION OF ATHEROSCLEROSIS IN LIPID-FED RABBITS, J CARDIOVASC PHARMACOL, 19, PP. 246-255, (1992); DIETRICH D., TOXICOLOGICAL AND PATHOLOGICAL APPLICATIONS OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA), A NOVEL ENDOGENOUS MARKER FOR CELL PROLIFERATION, CRIT REV TOXICOL, 23, PP. 77-109, (1993); RUSSELL D., CHOLETEROL BIOSYNTHESIS AND METABOLISM, CARDIOVASC DRUGS THER, 6, PP. 103-110, (1992); SOMA M.R., PAROLINI C., DONNETTI E., FUMAGALLI R., PAOLETTI R., INHIBITION OF ISOPRENOID BIOSYNTHESIS AND ARTERIAL SMOOTH MUSCLE CELL PROLIFERATION, J CARDIOVASC PHARMACOL, 25, (1995); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2.</SUB>, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); POMERANTZ K.B., HAJJAR D.P., EICOSANOIDS IN REGULATION OF ARTERIAL SMOOTH MUSCLE CELL PHENOTYPE, PROLIFERATIVE, CAPACITY AND CHOLESTEROL METABOLISM, ARTERIOSCLEROSIS, 9, PP. 413-429, (1989); WEISSBERG P.L., CLESHAM G.J., BENNET M.R., IS VASCULAR SMOOTH MUSCLE CELL BENEFICIAL?, LANCET, 347, PP. 305-307, (1996); DAVIES M.J., ACUTE CORONARY THROMBOSIS, THE ROLE OF PLAQUE DISRUPTION AND ITS INHIBITION AND PREVENTION, EUR HEART J, 16, PP. 3-7, (1995); SCHACHTER M., CALCIUM ANTAGONISTS AND ATHEROSCLEROSIS, INT J CARDIOL, 62, (1997); BELLOSTA S., BERNINI F., FERRI N., QUARATO P., CANAVESI M., ARNABOLDI L., FUMAGALLI R., PAOLETTI R., CORSINI A., DIRECT VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS, ATHEROSCLEROSIS, 137, (1998); SHIOMI M., ITO T., EFFECT OF CERIVASTATIN SODIUM, A NEW INHIBITOR OF HMG-COA REDUCTASE, ON PLASMA LIPID LEVELS, PROGRESSION OF ATHEROSCLEROSIS, AND THE LESIONAL COMPOSITION IN THE PLAQUES OF WHHL RABBITS, BR J PHARMACOL, 126, PP. 961-968, (1999); DAVIGNON J., THE PLEIOTROPIC EFFECTS OF DRUGS AFFECTING LIPID METABOLISM, ATHEROSCLEROSIS XI, PP. 63-77, (1998); SHAH P.K., FALK E., BADIMON J.J., FERNANDEZ-ORTIZ A., MAILHAC A., LEVY G., FALLON J.T., REGNSTROM J., FUSTER V., HUMAN MONOCYTE DERIVED MACROPHAGES INDUCE COLLAGEN BREAKDOWN IN FIBROUS CAP OR ATHEROSCLEROTIC PLAQUES: POTENTIAL ROLE OF MATRIX DEGRADING METALLOPROTEINASES AND IMPLICATIONS FOR PLAQUE RUPTURE, CIRCULATION, 92, PP. 1565-1569, (1995); BENNETT M., EVAN G., SCHWARTZ S., APOPTOSIS OF HUMAN VASCULAR SMOOTH MUSCLE CELLS DERIVED FROM NORMAL VESSELS AND CORONARY ATHEROSCLEROTIC PLAQUES, J CLIN INVEST, 95, PP. 2266-2274, (1995); BR P.R., APOPTOSIS - THE CELL'S SILENT EXIT, LIFE SCI, 59, PP. 369-378, (1996); HARDWICK S.J., HEGYI L., CLARE K., APOPTOSIS IN HUMAN MONOCYTEMACROPHAGES EXPOSED TO OXIDIZED LOW DENSITY LIPOPROTEIN, J PATHOL, 179, PP. 294-302, (1996); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); REEDQUIST K.A., POPE T.K., ROESS D.A., LOVASTATIN INHIBITS PROLIFERATION AND DIFFERENTIATION AND CAUSES APOPTOSIS IN LIPOPOLYSACCHARIDE-STIMULATED MURINE B CELLS, BIOCHEM BIOPHYS RES COMMUN, 211, PP. 665-670, (1995); OBERHAMMER F., ROBERTS R., APOPTOSIS: A WIDESPREAD PROCESS INVOLVED IN LIVER ADAPTATION AND CARCINOGENESIS, THE LIVER: BIOLOGY AND PATHOBIOLOGY, (1994); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 39-47, (1999)","M. NOA; DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA; EMAIL: DALMER@IP.ETECSA.CU","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0034968683","PHARMACOL RES","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"NOA M, 2001, PHARMACOL RES","NOA M, 2001, PHARMACOL RES"
"ARRUZAZABALA M;CARBAJAL D;MÁS R;VALDÉS S;MOLINA V","ARRUZAZABALA, M.L. (6603962476); CARBAJAL, D. (8777025000); MÁS, R. (7007164572); VALDÉS, S. (8777025100); MOLINA, V. (7006062814)","PHARMACOLOGICAL INTERACTION BETWEEN POLICOSANOL AND NITROPRUSSIDE IN RATS",2001,"JOURNAL OF MEDICINAL FOOD","4","3",1,"10.1089/109662001300341716","CENTER OF NATIONAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA LA HABANA, 25 AVE, CUBA;CENTER OF NATIONAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA LA HABANA, 25 AVE, CUBA;CENTER OF NATIONAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA LA HABANA, 25 AVE, CUBA;CENTER OF NATIONAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA LA HABANA, 25 AVE, CUBA;CENTER OF NATIONAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA LA HABANA, 25 AVE, CUBA","POLICOSANOL IS A NATURAL MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE WAX (SACCHARUM OFFICINARUM L.). IT HAS CHOLESTEROL-LOWERING EFFECTS DEMONSTRATED IN EXPERIMENTAL MODELS AND IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, WITH POSITIVE PLEIOTROPIC PROPERTIES SUCH AS INHIBITION OF PLATELET AGGREGATION AND LIPID PEROXIDATION. POLICOSANOL REDUCED THROMBOXANE A2 AND MALONDIALDEHYDE (MDA) SERUM LEVELS IN ANIMALS AND HUMAN BEINGS. BECAUSE NITRIC OXIDE (NO) CAN BE DESTROYED BY OXYGEN-DERIVED RADICALS AND POLICOSANOL POSSESSES AN ANTIOXIDANT EFFECT, THE PURPOSE OF THIS STUDY WAS TO DETERMINE THE PUTATIVE INTERACTION BETWEEN POLICOSANOL AND NITROPRUSSIDE (AN NO-CONTAINING SUBSTANCE) ON PLATELET AGGREGATION AND ARTERIAL BLOOD PRESSURE IN RATS. THE PERCENTAGE OF INHIBITION OF ADENOSINE DIPHOSPHATE-INDUCED AGGREGATION (PREINCUBATION WITH NITROPRUSSIDE) WAS HIGHER IN PLATELET-RICH PLASMA OF POLICOSANOL-TREATED ANIMALS THAN IN CONTROL ANIMALS. PRETREATMENT WITH SINGLE DOSES OF POLICOSANOL SIGNIFICANTLY INCREASED THE NITROPRUSSIDE-INDUCED HYPOTENSIVE EFFECT.","","ANIMALIA; ARUNDINARIA; SACCHARUM OFFICINARUM; ADENOSINE DIPHOSPHATE; ALCOHOL DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MALONALDEHYDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; POLICOSANOL; THROMBOXANE A2; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID PEROXIDATION; MALE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION INHIBITION","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 203-208, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., AMOR A., CASTANO G., ESTUDIO DEL EFECTO SOBRE LIPIDOS Y LIPOPROTEINS SERICAS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPÉUTICA, 11, PP. 74-79, (1992); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., EFFECTS OF HYPERCHOLESTEROLEMIA IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J., EFFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MEDICAS, 5, PP. 21-28, (1991); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKO ESSEN FATTY ACIDS, 49, PP. 695-697, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACION, REVISTA IBEROAMERICANA DE TROMBOSIS Y HEMOSTASIS, 5, PP. 17-20, (1992); CARBAJAL D., ARRUZAZABALA M.L., MOLINA V., MAS R., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKO ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); FRAGA V., MENENDEZ R., AMOR A., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); BOHME E., GRAF H., SCHULTZ G., EFFECTS OF SODIUM NITROPRUSSIDE AND OTHER SMOOTH MUSCLE RELAXANTS ON CYCLIC GMP FORMATION IN SMOOTH MUSCLE AND PLATELETS, ADV CYCLIC NUCLEOTIDE RES, 9, PP. 131-143, (1978); SCHAFER A.I., ALEXANDER R.W., HANDIN R.I., INHIBITION OF PLATELET FUNCTION BY ORGANIC NITRATE VASODILATORS, BLOOD, 55, PP. 649-654, (1980); MEHTA J., MEHTA P., COMPARATIVE EFFECTS OF NITROPRUSSIDE AND NITROGLYCERIN ON PLATELET AGGREGATION IN PATIENTS WITH HEART FAILURE, J CARDIOVASC PHARMACOL, 2, PP. 25-33, (1980); GERZER R., KARRENBROCK B., SIESS W., HEIM J.M., DIRECT COMPARISON OF THE EFFECTS OF NITROPRUSSIDE, SIN 1, AND VARIOUS NITRATES ON PLATELET AGGREGATION AND SOLUBLE GUANYLATE CYCLASE ACTIVITY, THROMB RES, 52, PP. 11-21, (1988); GRYGLEWSKI R.J., PALMER R.M.J., MONCADA S., SUPEROXIDE ANION IS INVOLVED IN THE BREAKDOWN OF ENDOTHELIUM-DERIVED VASCULAR RELAXING FACTOR, NATURE, 320, PP. 454-456, (1986); RADOMSKI M.W., PALMER R.M.J., MONCADA S., THE ANTIAGGREGATING PROPERTIES OF VASCULAR ENDOTHELIUM: INTERACTIONS BETWEEN PROSTACYCLIN AND NITRIC OXIDE, BR J PHARMACOL, 92, PP. 639-646, (1987); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE, 194, PP. 927-929, (1962); MARTIN W., FURCHGOTT R.F., VILLANI G.M., JOTH-IANANDAN D., PHOSPHODIESTERASE INHIBITORS INDUCE ENDOTHELIUM-DEPENDENT RELAXATION OF RAT AND RABBIT AORTA BY POTENTIATING THE EFFECTS OF SPONTANEOUSLY RELEASED ENDOTHELIUM-DERIVED RELAXING FACTOR, J PHARMACOL EXP THER, 237, PP. 539-547, (1986); RADOMSKI M.W., PALMER R.M.J., MONCADA S., COMPARATIVE PHARMACOLOGY OF ENDOTHELIUM-DERIVED RELAXING FACTOR, NITRIC OXIDE AND PROSTACYCLIN IN PLATELETS, BR J PHARMACOL, 92, PP. 181-187, (1987); MARCUS A.J., SILK S.T., SAFIER L.B., ULLMAN H.L., SUPEROXIDE PRODUCTION AND REDUCING ACTIVITY IN HUMAN PLATELETS, J CLIN INVEST, 59, PP. 149-158, (1977)","M.L. ARRUZAZABALA; CENTER OF NATIONAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, PLAYA LA HABANA, 25 AVE, CUBA; EMAIL: DALMER@IP.ETECSA.CU","MARY ANN LIEBERT INC.","ENGLISH","J. MED. FOOD","ARTICLE","ISI","2-S2.0-0034906631","J MED FOOD","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"ARRUZAZABALA ML, 2001, J MED FOOD","ARRUZAZABALA ML, 2001, J MED FOOD"
"CABRERA L;URIBARRI E;LAGUNA A;SIERRA R;MEDEROS D;GONZÁLEZ M;GONZÁLEZ V","CABRERA, L. (57212875001); URIBARRI, E. (6505806794); LAGUNA, A. (7006455910); SIERRA, R. (7006854525); MEDEROS, D. (7801384134); GONZÁLEZ, M. (57214372109); GONZÁLEZ, V. (7102097566)","STUDY OF THE INTERACTION BETWEEN POLICOSANOL AND EXCIPIENTS",2002,"BOLLETTINO CHIMICO FARMACEUTICO","141","4",2,"","PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA","POLICOSANOL IS AN ACTIVE PRINCIPLE, COMPOSED BY 8 FATTY ALCOHOLS: 1-TETRACOSANOL, 1-HEXACOSANOL, 1-HEPTACOSANOL, 1-OCTACOSANOL, 1-NONA-COSANOL, 1-TRIACONTANOL, 1-DOTRIACONTANOL AND 1-TETRATRIACONTANOL THAT SHOWS A VERY STABLE, WELL DEFINED AND REPRODUCIBLE COMPOSITION FROM BATCH TO BATCH THAT IS ANALYSED USING GAS CHROMATOGRAPHY. CONTINUING THE STUDIES OF THE COMPATIBILITY AMONG POLICOSANOL AND DIFFERENT TABLET EXCIPIENTS, IT WAS STUDIED IF THE MIXTURES OF THOSE EXCIPIENTS WITH POLICOSANOL PRODUCE CHEMICAL INTERACTIONS BETWEEN THEM, THE SAMPLES WERE ANALYSED USING GAS CHROMATOGRAPHY AND WAS DETERMINED IF IT WAS AFFECTED THE CONTENT OF POLICOSANOL IN THEM. WHEN ALL THE SAMPLES WERE ANALYSED, NO CHANGES IN THE POLICOSANOL CONTENT OF THE SAMPLES WERE OBSERVED, AND IT WAS CONSIDERED THAT NO INTERACTIONS ARE PRODUCED IN ANY OF THE MIXTURES POLICOSANOL/EXCIPIENTS UNDER STUDY.","CHEMICAL INTERACTIONS; PHARMACEUTICAL EXCIPIENTS; POLICOSANOL","ANTICHOLESTEREMIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GAS; DRUG COMPOUNDING; EXCIPIENTS; FATTY ALCOHOLS; INDICATORS AND REAGENTS; TABLETS; 1 DOTRIACONTANOL; 1 HEPTACOSANOL; 1 HEXACOSANOL; 1 NONACOSANOL; 1 OCTACOSANOL; 1 TETRACOSANOL; 1 TETRATRIACONTANOL; 1 TRIACONTANOL; CARBOXYMETHYLSTARCH SODIUM; CROSCARMELLOSE SODIUM; DOCUSATE SODIUM; DODECYL SULFATE SODIUM; EXCIPIENT; FATTY ALCOHOL; GELATIN; LACTOSE; MAGNESIUM STEARATE; METHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; POLICOSANOL; POLYSORBATE 80; POVIDONE; STARCH; SUCROSE; TALC; UNCLASSIFIED DRUG; ARTICLE; CHEMICAL INTERACTION; GAS CHROMATOGRAPHY; REPRODUCIBILITY; TABLET","","","MARTINEZ L., URIBARRI E., LAGUNA A., ARCH. PHARM., 332, (1999); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; LAGUNA A., MAGRANER J., RAMOS R., URIBARRI E., PERDOMO U.G., CARBAJAL D., ARRUZAZABALA M.L., MARTINEZ J., LORENZO M., MONTEJO L., MAS R.; URIBARRI E., LAGUNA A., SIERRA R., RICARDO Y., DRUG DEV. PHARM. IND., 28, 1, PP. 89-93, (2002); PECK G.E., BALEY G.J., MC CURDY V.E., BANKER G.S., TABLET FORMULATION AND DESIGN OF PHARMACEUTICAL DOSAGE FORMS: TABLETS, 1, (1989); GONZALEZ V.L., MAGRANER J., LAGUNA A., VELAZQUEZ C., LORENZO M., REV. C.N.I.C. CIENCIAS QUÍMICAS, 29, PP. 123-126, (1998); MOLLER H., STABILITY TESTING IN RELATION TO GUIDELINES IN THE EC, JAPAN AND USA. A RECOMMENDATION IN STABILITY STUDIES, (1993); GREENSPAN L., J. RES. NATL. BUREAU OF STANDARDS A. PHYSICS AND CHEMISTRY, 81, PP. 89-96, (1977); MAGRANER J., GONZALEZ V.L., JOURNAL OF AOAC INTERNATIONAL, 82, 4, PP. 834-839, (1999)","","","ENGLISH","BOLL. CHIM. FARM.","ARTICLE","ISI","2-S2.0-0036301457","BOLL CHIM FARM",NA,"NOTREPORTED",NA,"CABRERA L, 2002, BOLL CHIM FARM","CABRERA L, 2002, BOLL CHIM FARM"
"RAPPORT L;LOCKWOOD B","RAPPORT, LISA (36897838000); LOCKWOOD, BRIAN (7102722685)","3 OCTACOSANOL",2000,"PHARMACEUTICAL JOURNAL","265","1",10,"","UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PL, OXFORD ROAD, UNITED KINGDOM;UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PL, OXFORD ROAD, UNITED KINGDOM","AN INCREASINGLY POPULAR SUPPLEMENT, OCTACOSANOL IS OFTEN USED BY ATHLETES. ALTHOUGH RESEARCH IS STILL IN ITS INFANCY, OCTACONASOL MAY ALSO HAVE A GASTROPROTECTIVE AND LIPID LOWERING ROLE. THIS ARTICLE REVIEWS THE EVIDENCE.","","ALCOHOL DERIVATIVE; AMPHETAMINE DERIVATIVE; ANABOLIC AGENT; OCTACOSANOL; POLICOSANOL; PROSTAGLANDIN; THROMBOXANE; ATHLETE; DIET SUPPLEMENTATION; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MOTOR NEURON DISEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; SHORT SURVEY; STOMACH PROTECTION; STOMACH ULCER","","","KATO S., KARINO K., HASEGAWA J., NAGASAKI A., EGUCHI M., ICHINOSE T., ET AL., OCTACOSANOL AFFECTS LIPID METABOLISM IN RATS FED ON A HIGH FAT DIET, BR J NUT, 73, PP. 433-442, (1995); BELTZ S.D., DOERING P.L., EFFICACY OF NUTRITIONAL SUPPLEMENTS USED BY ATHLETES, CLIN PHARM, 12, PP. 900-908, (1993); COCKERILL D.L., BUCCI L.R., INCREASES IN MUSCLE GIRTH AND DECREASES IN BODY FAT ASSOCIATED WITH A NUTRITIONAL SUPPLEMENT PROGRAM, CHIRO SPORTS MED, 1, PP. 73-76, (1987); SAINT-JOHN M., MCNAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY, REACTION TIME AND CHEST AND GRIP STRENGTH, INT CLIN NUTR REV, 6, PP. 81-87, (1986); SHIMURA S., HASEGAWA T., TAKANO S., SUZUKI T., STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTR REP INT, 36, PP. 1029-1038, (1987); SNIDER S.R., OCTACOSANOL IN PARKINSONISM, ANN NEUROL, 16, (1984); ANDREOLI T.E., BENNETT J.C., CARPENTER C.C.J., PLUM F., CECIL ESSENTIALS OF MEDICINE (4TH ED), (1997); TANDAN R., BRADLEY W.G., AMYOTROPHIC LATERAL SCLEROSIS, PART 1, ANN NEUROL, 18, PP. 271-280, (1985); NORRIS F.H., DENYS E.H., FALLAT R.J., TRIAL OF OCTACOSANOL ON AMYOTROPHIC LATERAL, SCLEROSIS, NEUROL, 36, PP. 1263-1264, (1986); NORRIS F.H., DENYS E.H., NUTRITIONAL SUPPLEMENTS IN AMYOTROPHIC LATERAL SCLEROSIS, ADV EXP MED BIOL, 209, PP. 183-189, (1987); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CUR THER RES, 51, PP. 568-575, (1992); PONS P., JIMENEZ A., RODRIGUES M., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANTO G., FERNANDEZ L., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); TORRES O., AGRAMONTE A.J., ILLNAIT J., FERREIRO R.M., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); NOA M., HERRERA M., MAGRANER J., MAS R., EFFECT OF POLICOSANOL ON ISOPRENALINE-INDUCED MYOCARDIAL NECROSIS IN RATS, J PHARM PHARMACOL, 46, PP. 282-285, (1994); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J PHARM PHARMACOL, 47, PP. 731-733, (1995); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., RODEIRO I., MAS R., ET AL., POSSIBLE CYTOPROTECTIVE MECHANISM IN RATS OF D-002, AN ANTI-ULCEROGENIC PRODUCT ISOLATED FROM BEESWAX, J PHARM PHARMACOL, 48, PP. 858-860, (1996); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROM RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHAEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993)","B. LOCKWOOD; SCH. PHARM. AND PHARMACEUTICAL SCI., UNIVERSITY OF MANCHESTER, MANCHESTER M13 9PL, OXFORD ROAD, UNITED KINGDOM; EMAIL: LOCKWOOD@FS1.PA.MAN.AC.UK","PHARMACEUTICAL PRESS","ENGLISH","PHARM. J.","ARTICLE","ISI","2-S2.0-0034729901","PHARM J","UNIVERSITY OF MANCHESTER;UNIVERSITY OF MANCHESTER","NOTREPORTED;UNIVERSITY OF MANCHESTER;NOTREPORTED",NA,"RAPPORT L, 2000, PHARM J","RAPPORT L, 2000, PHARM J"
"NIKITIN Y;SLEPCHENKO N;GRATSIANSKY N;NECHAEV A;SYRKIN A;POLTAVSKAYA M;SUMAROKOV A;REVAZOV A","NIKITIN, YU.P. (7102172021); SLEPCHENKO, N.V. (6506128998); GRATSIANSKY, N.A. (7004708293); NECHAEV, A.S. (7004823952); SYRKIN, A.L. (7103104759); POLTAVSKAYA, M.G. (57219951375); SUMAROKOV, A.V. (57196700703); REVAZOV, A.V. (57191396559)","RESULTS OF A MULTICENTER CONTROLLED STUDY OF A HYPOLIPIDEMIC DRUG POLYCOSANOL IN RUSSIA",2000,"TERAPEVTICHESKII ARKHIV","72","2",14,"","","AIM. TO COMPARE EFFICACY AND TOLERANCE OF POLYCOSANOL VS BESAFIBRATE IN PATIENTS WITH HYPERCHOLESTEROLEMIA (HCE). MATERIAL AND METHODS. A MULTICENTER CONTROLLED DOUBLE BLIND RANDOMISED TRIAL ENTERED 113 PATIENTS WITH HCE. AFTER 5 WEEKS OF DIET THE PATIENTS WERE RANDOMISED INTO TWO GROUPS. 59 PATIENTS OF GROUP 1 RECEIVED POLYCOSANOL (10 MG/DAY), 54 PATIENTS OF GROUP 2 WERE GIVEN BESAFIBRATE (400 MG/DAY)FOR 8 WEEKS. RESULTS. THE 8-WEEK COURSE OF TREATMENT WAS COMPLETED BY 103 PATIENTS (91%): 57(97%) PATIENTS OF GROUP 1 AND 46(85%) PATIENTS OF GROUP 2. IN GROUP 1 TOTAL CHOLESTEROL DIMINISHED BY AN AVERAGE OF 15%, LDLP CHOLESTEROL FELL BY 18%, TRIGLYCERIDES BY 15%, WHILE IN GROUP 2 A RESPECTIVE DECREASE WAS 8, 11 AND 6%. SIDE EFFECTS IN GROUP 1 WERE MILD. CONCLUSION. A HYPOLIPIDEMIC EFFECT OF POLYCOSANOL IN A DAILY DOSE 10 MG IS SUPERIOR TO THAT OF BESAFIBRATE IN A DAILY DOSE 400 MG.","BESAFIBRATE; HYPERCHOLESTEROLEMIA; POLYCOSANOL; TREATMENT","ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; RUSSIA; 1 OCTACOSANOL; 1-OCTACOSANOL; ANTILIPEMIC AGENT; FATTY ALCOHOL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION","","","PYORALA K., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, PP. 1300-1331, (1994); SHEPHERD J., COBBE S., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); RANDOMIZED TRAIL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); JUCEMA J.W., BRUSCHKE A.V.G., VAN BOVEN A.J., ET AL., EFFECTS OF LIPID-LOWERING BY PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ARTERY DISEASE IN SYMPTOMATIC MEN WITH NORMAL TO MODERATELY ELEVATED SERUM CHOLESTEROL LEVELS: THE REGRESSION GROWTH EVALUATION STATIN STUDY (REGRESS), CIRCULATION, 91, PP. 2528-2540, (1995); SALONEN R., NYYSSONEN K., PARKKALA-SARATAHO E., SALONEN J.T., THE KUOPIO ATHEROSCLEROSIS PREVENTION STUDY (KAPS): EFFECT OF PRAVASTATIN TREATMENT ON LIPIDS, OXIDATION RESISTANCE OF LIPOPROTEINS, AND ATHEROSCLEROTIC PROGRESSION, AM. J. CARDIOL., 76, PP. 34-39, (1995); RUBINS H., ROBINS S., ET AL., DISTRIBUTION OF LIPIDS IN 8500 MEN WITH CORONARY ARTERY DISEASE, AM. J. CARDIOL., 75, PP. 1196-1201; MENENDEZ R., FERNANDAZ I., DEL RIO A., ET AL., POLYCOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURES HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); HERNANDEZ E., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLYCOSANOL IN SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLYCOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR. THER. RES., 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLYCOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY ON THE EFFECT OF POLYCOSANOL (5MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILILY OF POLYCOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, J. CLIN. PHARMACOL. RES., 15, PP. 159-165, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY ON THE EFFICACY AND SAFETY OF POLYCOSANOL (5 MG TWICE DAY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 296-304, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLYCOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A ONE-YEAR STUDY, CURR. THER. RES., PP. 819-828; PONS P., RODRIGUEZ M., ROBANA C., ET AL., EFFECTS OF POLYCOSANOL SUCCESSIVE DOSE INCREASES IN LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLYCOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH. VENEZOL. FARMACOL. TER., 12, PP. 71-76, (1993); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, PP. 449-451, (1974); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); ARNTZ H.-R., KLEMENS U.H., LANG P.D., VOLLMAR J., VERGLEICH VON BEZAFIBRAT UND CLOFIBRAT BEI HYPERLIPOPROTEINENIE TYP IIA UND LIB, MED. KLIN., 73, (1978)","","","RUSSIAN","TER. ARKH.","ARTICLE","ISI","2-S2.0-24044444613","TER ARKH",NA,"NOTREPORTED",NA,"NIKITIN YUP, 2000, TER ARKH","NIKITIN YUP, 2000, TER ARKH"
"CASTAÑO G;MÁS R;ROCA J;FERNÁNDEZ L;ILLNAIT J;FERNÁNDEZ J;SELMAN E","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); ROCA, JUAN (8132453500); FERNÁNDEZ, LILIA (7202848319); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, JULIO CÉSAR (9432805500); SELMAN, EUGENIO (57188975924)","A DOUBLEBLIND PLACEBOCONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION",1999,"ANGIOLOGY","50","7",43,"10.1177/000331979905000205","MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, PO BOX 6880 OR 6990, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CLINICAL PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA; SELMAN E.","THIS STUDY WAS UNDERTAKEN TO EVALUATE THE EFFICACY AND TOLERABILITY OF POLICOSANOL, A NEW CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS, IN PATIENTS WITH INTERMITTENT CLAUDICATION. AFTER A BASELINE PERIOD OF 6 WEEKS, 62 PATIENTS WERE RANDOMIZED TO RECEIVE, UNDER DOUBLE-BLIND CONDITIONS, EITHER PLACEBO (31 PATIENTS) OR POLICOSANOL (31), 10 MG TWICE DAILY. WALKING DISTANCES IN A TREADMILL (CONSTANT SPEED 3.2 KM/HR, SLOPE 10°) WERE ASSESSED BEFORE AND AFTER 6 MONTHS OF TREATMENT. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. POLICOSANOL INCREASED SIGNIFICANTLY (P<0.01) THE INITIAL CLAUDICATION DISTANCE FROM 132.5 ± 13.5 M (BASELINE) TO 205.7 ± 36.3 M (AFTER THERAPY) AND THE ABSOLUTE CLAUDICATION DISTANCE (P<0.0001) FROM 229.5 ± 22.0 M TO 365.4 ± 46.9 M; MEANWHILE BOTH VARIABLES REMAINED UNCHANGED IN THE PLACEBO GROUP (P<0.05). THE REDUCTION OF LOWER LIMB SYMPTOMS SHOWED A GREATER BENEFIT IN THE POLICOSANOL GROUP. THERE WAS NO SIGNIFICANT CHANGE IN EITHER GROUP IN THE ANKLE/ARM PRESSURE RATIO. THE TREATMENT WAS WELL TOLERATED. THERE WERE 10 DISCONTINUATIONS (SEVEN PLACEBO, THREE POLICOSANOL) FROM THE STUDY. SIX WITHDRAWALS OCCURRED BECAUSE OF ADVERSE EVENTS (AE); ALL WERE IN PLACEBO PATIENTS. THERE WERE FIVE SERIOUS VASCULAR AES IN THE PLACEBO GROUP BUT NONE IN THE POLICOSANOL GROUP (P<0.05). OVERALL, 12/31 (38.7%) PLACEBO PATIENTS AND 3/31 (9.7%) POLICOSANOL PATIENTS EXPERIENCED AES AFTER RANDOMIZATION, WHICH SHOWED A LESSER INCIDENCE OF AES IN THE POLICOSANOL GROUP (P<0.01). THE PRESENT STUDY DEMONSTRATES A BENEFICIAL EFFECT OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION.","","PLACEBO; POLICOSANOL; ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; WEIGHT REDUCTION","","","ROSS R., GLOMSET J.A., THE PATHOGENESIS OF ATHEROSCLEROSIS, N ENGL J MED, 295, PP. 369-377, (1976); HESS H., MIETASHK A., DEICHSEL G., DRUG-INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE. A PROSPECTIVE DOUBLE-BLIND ARTERIOGRAPHICALLY CONTROLLED TRIAL, LANCET, 1, PP. 415-419, (1985); ARCAN J.C., BLANCHARD J., BOISSEL J.P., ET AL., MULTICENTER DOUBLE-BLIND STUDY OF TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND THE PREVENTION OF ITS COMPLICATIONS, ANGIOLOGY, 39, PP. 802-809, (1988); SIGNORINI G.P., SALMISTRARO G., MARAGLINO G., EFFICACY OF INDOBUFEN IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 39, PP. 742-745, (1988); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTENIS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESS IN MEDICAL SCIENCES, 5, PP. 21-28, (1991); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL FARMACOL TERAP, 12, PP. 71-76, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, PRENSA MÉDICA ARGENTINA, 83, PP. 665-672, (1996); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 44-51, (1997); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 26-35, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 154-162, (1997); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV LBEROAMER TROMB HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAG LEUK ESS FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.D.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, (1997); PORTER J.M., CUTLER B.C., LEE B.Y., ET AL., PENTOXIFYLLINE EFFICACY IN THE TREATMENT OF INTERMITTENT CLAUDICATION: MULTICENTER CONTROLLED DOUBLE-BLIND TRIAL WITH OBJECTIVE ASSESSMENT OF CHRONIC OCCLUSIVE ARTERIAL DISEASE PATIENTS, AM HEART J, 104, PP. 66-72, (1982); REICH T., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION OF THE LOWER LIMB, ANGIOLOGY, 35, PP. 389-393, (1984); VERSTRAETE M., RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF KATANSERIN IN CLAUDICANTS. CHANGES IN CLAUDICATION DISTANCE AND ANKLE SYSTOLIC PRESSURE, CIRCULATION, 80, (1989)","","WESTMINSTER PUBLICATIONS INC.","ENGLISH","ANGIOLOGY","ARTICLE","ISI","2-S2.0-17444436621","ANGIOLOGY",NA,"NOTREPORTED",NA,"CASTAÑO G, 1999, ANGIOLOGY","CASTAÑO G, 1999, ANGIOLOGY"
"TORRES O;AGRAMONTE A;ILLNAIT J;FERREIRO R;FERNÁNDEZ L;FERNÁNDEZ J","TORRES, OMAYDA (7006437235); AGRAMONTE, A.J. (36739720800); ILLNAIT, JOSE (8631465800); FERREIRO, ROSA MÁS (6602148780); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO C. (9432805500)","TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH PELICOSANOL",1995,"DIABETES CARE","18","4",119,"","JULIO TRIGO HOSPITAL, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;JULIO TRIGO HOSPITAL, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA; ILLNAIT J.;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA; FERNÁNDEZ L.; FERNÁNDEZ J.C.","OBJECTIVE - TO DETERMINE WHETHER ELEVATED LEVELS OF CHOLESTEROL AND LOWDENSITY LIPOPROTEIN (LDL) CHOLESTEROL IN NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) PATIENTS COULD BE DECREASED BY POLICOSANOL, A NEW CHOLESTEROL-LOWERING DRUG. NIDDM PREDISPOSES PATIENTS TO CORONARY ARTERY DISEASE (CAD) THROUGH THE DIRECT ACTION OF HYPERGLYCEMIA ON THE ARTERIES AS WELL AS THE DYSLIPIDEMIA INDUCED BY NIDDM. RESEARCH DESIGN AND METHODS - THIS DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL WAS PERFORMED IN 29 PATIENTS WITH NIDDM AND HYPERCHOLESTEROLEMIA. AFTER STABLE GLYCEMIC CONTROL WAS ACHIEVED BY DIET AND/OR ORAL HYPOGLYCEMIC DRUGS, PATIENTS WERE INSTRUCTED TO FOLLOW A CHOLESTEROL-LOWERING DIET FOR 6 WEEKS. PATIENTS WHO MET ENTRY CRITERIA RECEIVED, UNDER DOUBLE-BLIND CONDITIONS, POLICOSANOL (5 MG) OR PLACEBO TABLETS TWICE A DAY FOR 12 WEEKS. RESULTS - POLICOSANOL (10 MG/DAY) SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL BY 17.5% AND LDL CHOLESTEROL BY 21.8% COMPARED WITH BASELINE AND PLACEBO. FURTHER-MORE, HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL WAS RAISED BY 11.3% (NOT SIGNIFICANT), AND TRIGLYCERIDES SHOWED A STATISTICALLY NONSIGNIFICANT DECREASE OF 6.6%. THESE CHANGES IN LIPID PROFILE WERE SIMILAR TO THOSE INDUCED BY POLICOSANOL IN NONDIABETIC PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA. CONCLUSIONS - GLYCEMIC CONTROL WAS UNAFFECTED BY TREATMENT. NO CLINICALLY OR BIOCHEMICALLY ADVERSE EFFECTS ATTRIBUTABLE TO TREATMENT WERE OBSERVED. ONLY ONE PATIENT (PLACEBO) WITHDREW FROM THE TRIAL BECAUSE OF AN ADVERSE EXPERIENCE (ERYTHEMA). WE CONCLUDED THAT POLICOSANOL IS EFFECTIVE AND SAFE IN PATIENTS WITH NIDDM AND HYPERCHOLESTEROLEMIA.","","ALANINE AMINOTRANSFERASE; ALCOHOL DERIVATIVE; ANTILIPEMIC AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; CHOLESTEROL; CREATININE; GLIBENCLAMIDE; GLUCOSE; HEXACOSANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTACOSANOL; ORAL ANTIDIABETIC AGENT; POLICOSANOL; PRAVASTATIN; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL","","","RUDERMAN N.B., HAUDENSCHILD C., DIABETES AS AN ATHEROGENIC FACTOR, PROG CARDIOVASC DIS, 26, PP. 373-412, (1984); WEST K.M., AHUJA M.M.S., BENNETT P.H., CZYZYK A., DE ACOSTA O.M., FULLER J.H., THE ROLE OF CIRCULATING GLUCOSE AND TRIGLYCERIDE CONCENTRATIONS AND THEIR INTERACTIONS WITH OTHER ""RISK FACTORS"" AS DETERMINANT OF ARTERIAL DISEASE IN NINE DIABETIC POPULATION SAMPLES FROM THE WHO MULTINATIONAL STUDY, DIABETES CARE, 6, PP. 361-369, (1983); LAAKSO M., VOUTILAINEN E., SARLUND H., ARO A., PYORALA K., PENTILA I., SERUM LIPIDS AND LIPOPROTEINS IN MIDDLE-AGED NON-INSULIN-DEPENDENT DIABETES, ATHEROSCLEROSIS, 56, PP. 271-281, (1985); HIRAMATZU K., BIERMAN E.L., CHAIT A., METABOLISM OF LDL FROM PATIENTS WITH DIABETIC HYPERTRIGLYCERIDEMIA BY CULTURED HUMAN SKIN FIBROBLASTS, DIABETES, 34, PP. 8-14, (1985); LOPES-VIRELLA M.F., KLEIN R.L., LYONS T.J., STEVENSON H.C., WITZTUM J.L., GLYCOSYLATION OF LOW-DENSITY LIPOPROTEINS ENHANCES CHOLESTERYL ESTER SYNTHESIS IN HUMAN MONOCYTE-DERIVED MACROPHAGES, DIABETES, 37, PP. 550-557, (1988); INGELFINGER J.A., BENNETT P.H., LIEBOW I.M., MILLER M., CORONARY HEART DISEASE IN THE PIMA INDIANS: ELECTROCARDIOGRAPHIC FINDING AND POSTMORTEM EVIDENCE OF MYOCARDIAL INFARCTION IN A POPULATION WITH HIGH PREVALENCE OF DIABETES MELLITUS, DIABETES, 25, PP. 561-565, (1976); MENENDEZ R., FERNANDEZ I., SOTOLONGO V., AMOR A.M., FRAGA V., DEL RIO A., ALFONSO J.L., GONZALEZ R., MAS R., POLICOSANOL: UN ESTUDIO DE SUS EFECTOS SOBRE LA BIOSÍNTESIS DEL COLESTEROL, REV FARMACOL CLIN EXP, I CONGRESO IBEROAMERICANO DE FARMACOLOGIA, (1992); MENENDEZ R., FERNANDEZ I., ARRUZAZABALA M.D.L., ILLNAIT J., DEL RIO A., GONZALEZ R., CARBAJAL D., SOTOLONGO V., FRAGA V., AMOR A.M., MOLINA V., EFFECTS OF POLICOSANOL ON CHOLESTEROL BIOSYNTHESIS AND LDL PROCESSING, 62ND EUROPEAN ATHEROSCLEROSIS SOCIETY, JERUSALEM, (1993); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CENIC CIENC BIOL, 22, PP. 60-61, (1991); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., EFECTO DEL ATEROMIXOL (PPG) SOBRE EL PREFIL LIPÍDICO EN CONEJOS NORMOLCOLESTEROLÉMICOS, ARCH VENEZ FARMACOL TERAPÉUTICA, 11, PP. 80-86, (1991); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF ATEROMIXOL ON SERUM AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ILLNAIT J., CASTANO G., NODARSE M., PONTIGAS V., HERNANDEZ L., MAS R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA TIPO II, REV CENIC CIENC BIOL, 22, PP. 74-76, (1991); CASTANO G., ZARDOYA R., ILLNAIT J., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J.C., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGR CIENC MÉD, 5, PP. 21-30, (1991); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF ATEROMIXOL (POLICOSANOL) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., EFFECTS OF ATEROMIXOL (POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF LOW PLASMA LOW-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); ILLIINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, 3 SUPPL., PP. 63-71, (1988); YOSHINO G., KASUMI T., IWAI M., MATSUSHITO M., MATSUBA K., VENOYAM R., IWATANI I., BABA S., LONG-TERM TREATMENT OF HYPERCHOLESTEROLEMIA NON-INSULIN-DEPENDENT DIABETES (NIDDM) WITH PRAVASTATIN (CS-514), ATHEROSCLEROSIS, 75, PP. 67-72, (1989); GARG A., SCATT M., GRUNDY M.D., TREATMENT OF DYSLIPIDEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH LOVASTATIN, AM J CARDIOL, 62, (1988); GOLBERG R., LA BELLE P., ZUPKIS R., RONCA P., COMPARISON OF THE EFFECTS OF LOVASTATIN AND GEMFIBROZIL ON LIPIDS AND GLUCOSE CONTROL IN NON-INSULIN-DEPENDENT DIABETES MELLITUS, AM J CARDIOL, 66, (1990)","","AMERICAN DIABETES ASSOCIATION INC.","ENGLISH","DIABETES CARE","ARTICLE","ISI","2-S2.0-0028897637","DIABETES CARE",NA,"NOTREPORTED",NA,"TORRES O, 1995, DIABETES CARE","TORRES O, 1995, DIABETES CARE"
"FONTANI G;MAFFEI D;LODI L","FONTANI, GIULIANO (7003337518); MAFFEI, DOMENICO (21035162000); LODI, LEDA (7004903156)","POLICOSANOL REACTION TIME AND EVENTRELATED POTENTIALS",2000,"NEUROPSYCHOBIOLOGY","41","7",6,"10.1159/000026649","ISTITUTO DI FISIOLOGIA UMANA, UNIVERSITÀ DI SIENA, 1-53100 SIENA, VIA A. MORO, ITALY; MAFFEI D.; LODI L.","THE AIM OF THE PRESENT STUDY WAS TO COMPARE THE RESULTS OF A 1-WEEK, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL INVESTIGATING THE EFFECTS OF ISOPOLICOSANOL AND OCTACOSANOL ON REACTIVITY AND RELATED BRAIN ACTIVITY. IN PARTICULAR, REACTION TIME IRT) AND EVENT-RELATED POTENTIALS SUCH AS CONTINGENT NEGATIVE VARIATIONS (CNV) AND P300 (P3) HAVE BEEN STUDIED. THIRTY SEDENTARY HEALTHY STUDENTS WERE TESTED BEFORE AND AFTER TREATMENT (3.6 MG/DIE FOR 7 DAYS) WITH ORALLY ADMINISTERED TABLETS OF PLACEBO (GROUP A), ISOPOLICOSANOL (B) AND OCTACOSANOL (C). RT WERE STUDIED ACCORDING TO THREE PROCEDURES: SIMPLE RT (SRT), GO/NO-GO RT (GRT) AND CHOICE RI (CRT). RESULTS SHOW THAT BEFORE TREATMENT, THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN GROUPS A, B AND C. AFTER TREATMENT, THE RT OF GROUP A WAS UNCHANGED, WHILE THE RT OF GROUPS B AND C WERE REDUCED. IN GROUP B, IN THE SRT TEST, THE REDUCTION OF RT WAS ACCOMPANIED BY ELECTRICAL DATA EXHIBITING INCREASED AMPLITUDES OF CNV AND SHORTER LATENCIES OF P3. THESE RESULTS SHOW THAT THE MAIN EFFECT ON REACTIVITY AND EVENT-RELATED POTENTIALS CAN BE ASCRIBED TO POLICOSANOL AND IS MAINLY EVIDENT IN THE SRT TEST. COPYRIGHT (C) 2000 S. KARGER AG, BASEL.","CONTINGENT NEGATIVE VARIATIONS; EVENT-RELATED POTENTIALS; P300; POLICOSANOL; REACTION TIME","OCTACOSANOL; PLACEBO; POLICOSANOL; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REACTION TIME","","","BIRBAUMER N., ELBERT T., CANAVAN A.G.M., ROCKSTROH B., SLOW POTENTIALS OF THE CEREBRAL CORTEX AND BEHAVIOR, PHYSIOL REV, 70, PP. 1-41, (1990); PICTON T.W., HILLYARD S.A., ENDOGENOUS EVENTRELATED POTENTIALS, HUMAN EVENT-RELATED POTENTIALS, PP. 361-426, (1988); TEECE J.J., CONTINGENT NEGATIVE VARIATION (CNV) AND PSYCHOLOGICAL PROCESSES IN MAN, PSYCHOL BULL, 77, PP. 73-108, (1972); WALTER W.G., BRAIN MECHANISM AND PERCEPTION, BR J PHYSIOL OPT, 22, PP. 1-9, (1965); LOW M.D., COATS A.C., RETTIG G.M., KELLAWAY P., CONTINGENT NEGATIVE VARIATION IN RHESUS MONKEY: AN EEG SIGN OF A SPECIFIC MENTAL PROCESS, PERCEPT MOTOR SKILLS, 22, PP. 443-446, (1966); HULL C.L., ESSENTIALS OF BEHAVIOR, (1951); CREMONA-METEYARD S.L., CLARK C.R., WRIGHT M.J., GEFFEN G.M., COVERT ORIENTATION OF VISUAL ATTENTION AFTER CLOSED HEAD INJURY, NEUROPSYCHOLOGIA, 30, PP. 123-132, (1992); NAATANEN R., SELECTIVE ATTENTION AND EVOKED POTENTIALS IN HUMANS - A CRITICAL REVIEW, BEHAV BIOL, 2, PP. 237-307, (1975); NOUGIER V., RIPOLL H., STEIN J.F., PROCESSUS ATTENTIONNELS ET PRATIQUE SPORTIVE DE HAUT NIVEAU, RECHERCHES EN APS, 2, PP. 209-221, (1987); RUGG M.D., COWAN C.P., NAGY M.E., MILNER A.D., JACOBSON L., BROOKS D.N., CNV ABNORMALITIES FOLLOWING CLOSED HEAD INJURY, BRAIN, 112, PP. 489-505, (1989); SEGALOWITZ S.J., DYWAN J., UNSAL A., ATTENTIONAL FACTORS IN RESPONSE TIME VARIABILITY AFTER TRAUMATIC BRAIN INJURY: AN ERP STUDY, J INT NEUROPSYCHOL SOC, 3, PP. 95-107, (1997); TEECE J.J., ATTENTION AND EVOKED POTENTIALS IN MAN, ATTENTION: CONTEMPORARY THEORY AND ANALYSIS, (1970); TEECE J.J., SCHEFF N.M., ATTENTION REDUCTION AND SUPPRESSED DIRECT-CURRENT POTENTIALS IN THE HUMAN BRAIN, SCIENCE, 164, PP. 331-333, (1969); COLES M.G.H., MODEM MIND-BRAIN READING: PSYCHOPHYSIOLOGY. PHYSIOLOGY, AND COGNITION, PSYCHOPHYSIOLOGY, 26, PP. 251-269, (1989); HORST R.L., JOHNSON R., DONCHIN E., EVENT RELATED BRAIN POTENTIALS AND SUBJECTIVE PROBABILITY IN A LEARNING TASK, MEM COGNIL, 8, PP. 476-488, (1980); SQUIRES K.C., WICKENS C., SQUIRES N.K., DONCHIN E., THE EFFECT OF STIMULUS SEQUENCE ON THE WAVEFORM OF THE CORTICAL EVENT RELATED POTENTIAL, SCIENCE, 193, PP. 1142-1146, (1976); KUTAS M., MCCARTHY G., DONCHIN E., AUGMENTING MENTAL CHRONOMETRY: THE P300 AS A MEASURE OF STIMULUS EVALUATION TIME, SCIENCE, 197, PP. 792-795, (1977); DONCHIN E., COLES M.G.H., IS THE P300 COMPONENT A MANIFESTATION OF CONTEXT UPDATING?, BEHAV BRAIN SCI, 11, PP. 357-374, (1988); POLICH J., KOK A., COGNITIVE AND BIOLOGICAL DETERMINANTS OFP300: AN INTEGRATIVE REVIEW, BIOL PSYCHOL, 41, PP. 103-146, (1995); NEHLIG A., DAVAL J.L., DEBRY G., CAFFEINE AND THE CENTRAL NERVOUS SYSTEM: MECHANISMS OF ACTION, BIOCHEMICAL, METABOLIC AND PSYCHOSTIMULANT EFFECTS, BRAIN RES REV, 17, PP. 139-170, (1992); MENENDEZ R., ARRUZZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARHAJAL D., ERAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLACMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); KAHIR J., KIMURA S., DISTRIBUTION OF RADIOACTIVE OCTACOSANOL IN RESPONSE TO EXERCISE IN RATS, NAHRUNG, 38, PP. 373-377, (1994); CURETON T.K., THE PHYSIOLOGICAL EFFECTS OF WHEAT GERM OIL ON HUMANS IN EXERCISE, (1972); FONTANI G., MAFFEI D., CAMELI S., POLIDORI F., REACTIVITY AND EVENT-RELATED POTENTIALS DURING ADDITIONAL TESTS IN ATHLETES, EUR J APPL PHYSIOL; KOLEV V., DEMIRAL T., YORDANOVA Y., ADEMOGLU A., ISOGLU-ALKAC U., TIME-FREQUENCY ANALYSIS REVEALS MULTIPLE FUNCTIONAL COMPONENTS DURING ODDBALL P300, NEUROREPORT, 8, PP. 2061-2065, (1497); SAMAR V.J., SWARTZ KP., RAGHUVEER M.R., MULTIRESOLUTION ANALYSIS OF EVENT-RELATED POTENTIALS BY WAVELET DECOMPOSITION, BRAIN COGN, 27, PP. 398-438, (1995); TEECE J.J., CATTANACH L., CONTINGENT NEGATIVE VARIATION, ELECTROENCEPHALOGRAPHY: BASIC PRINCIPLES, CLINICAL APPLICATIONS AND RELATED FIELDS, PP. 543-561, (1982); WEI J., DING H., ELIMINATION OF CONDITIONING MOVEMENT COMPONENT IN WAVE EML AND DIFFERENCE BETWEEN WAVES V AND C, CHINESE SCI BULL, 35, PP. 227-231, (1990); TAGHAVY A., KUGLER F.A., THE PATTERN FLASH ELICITED P300-COMPLEX (PF-P300): A NEW METHOD FOR STUDYING COGNITIVE PROCESSES OF THE BRAIN, INT J NEUROSCI, 38, PP. 179-188, (1988); ABT K., PLANNING CONTROLLED CLINICAL TRIALS ON THE BASIS OF DESCRIPTIVE DATA ANALYSIS, STAT MED, 10, PP. 777-795, (1941); KING D.J., HENRY G., THE EFFECT OF NEUROLEPTICS ON COGNITIVE AND PSYCHOMOTOR FUNCTION. A PRELIMINARY STUDY IN HEALTHY VOLUNTEERS, BR J PSYCHIATRY, 160, PP. 647-653, (1992); LORIST M.M., SNEL J., KOK A., INFLUENCE OF CAFFEINE ON INFORMATION PROCESSING STAGES IN WELL RESTED AND FATIGUED SUBJECTS, PSYCHOPHARMACOLOGY, 113, PP. 411-421, (1994); RIEDEL W., HOGERVOST E., LEBOUX R., VERHEY F., VAN PRAAG H., JOLLES J., CAFFEINE ATTENUATED SEOPOLAMINE-INDUCED MEMORY IMPAIRMENTS IN HUMANS, PSYCHOPHARMACOLOGY, 122, PP. 158-168, (1995); KABIR J., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993)","","S. KARGER AG","ENGLISH","NEUROPSYCHOBIOLOGY","ARTICLE","ISI","2-S2.0-0034060971","NEUROPSYCHOBIOLOGY",NA,"NOTREPORTED",NA,"FONTANI G, 2000, NEUROPSYCHOBIOLOGY","FONTANI G, 2000, NEUROPSYCHOBIOLOGY"
"CASTAO G;MÁS R;FERNÁNDEZ L;ILLNAIT J;HERNÁNDEZ E;FERNÁNDEZ J;GÁMEZ R;GUTIÉRREZ C;ALVAREZ E","CASTAO, GLADYS (15826287100); MÁS, ROSA (7007164572); FERNÁNDEZ, LILIA (7202848319); ILLNAIT, JOSÉ (8631465800); HERNÁNDEZ, ERIC (7402296774); FERNÁNDEZ, JULIO C. (9432805500); GÁMEZ, RAFAEL (7003605346); GUTIÉRREZ, CARLOS (16222746900); ALVAREZ, ESTRELLA (15053135600)","A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA",2002,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","63","17",14,"10.1016/S0011-393X(02)80033-9","MEDICAL SURGICAL RESEARCH CENTER HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: ATHEROSCLEROSIS BEGINS IN CHILDHOOD AND IS INFLUENCED BY RISK FACTORS FOR CORONARY HEART DISEASE (CHD), OF WHICH HYPERCHOLESTEROLEMIA IS CRUCIAL. THE RATIONALE FOR TREATING HYPERCHOLESTEROLEMIA IN CHILDHOOD IS TO LIMIT ATHEROSCLEROSIS DEVELOPMENT, FOR WHICH ADHERENCE TO A CHOLESTEROL-LOWERING DIET IS THE FIRST-CHOICE THERAPY. NEVERTHELESS, PHARMACOLOGICAL INTERVENTION WITH BILE ACID-BINDING RESINS MAY BE PRESCRIBED FOR PATIENTS OLDER THAN 10 YEARS, MAINLY THOSE WITH FAMILY HISTORY OF CHD, MULTIPLE RISK FACTORS, AND/OR SEVERE HYPERCHOLESTEROLEMIA. RESINS ARE EFFECTIVE AND TOLERABLE IN THIS POPULATION, BUT THEIR CLINICAL USE HAS BEEN LIMITED BECAUSE OF POOR COMPLIANCE DUE TO UNPALATABILITY; OTHER EFFECTIVE CHOLESTEROL-LOWERING DRUGS HAVE NOT BEEN RECOMMENDED IN THIS POPULATION BECAUSE OF THE POTENTIAL IMPACT OF DRUG-RELATED ADVERSE EFFECTS SUCH AS INCREASES IN TRANSAMINASES, MYOPATHIES, AND GASTROINTESTINAL DISTURBANCES. THUS, THE NEED FOR SAFER, EASY-TO-TAKE, AND EFFECTIVE CHOLESTEROL-LOWERING AGENTS FOR THIS POPULATION CONTINUES. POLICOSANOL IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING EFFECTS PROVEN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA DUE TO TYPE 2 DIABETES MELLITUS. POLICOSANOL SHOWS GOOD SAFETY AND TOLERABILITY PROFILES, WITH NO EVIDENCE OF DRUG-RELATED ADVERSE EVENTS (AES) TO DATE. THIS BACKGROUND SUPPORTS THE IDEA THAT POLICOSANOL COULD BE A GOOD CANDIDATE FOR TREATING HYPERCHOLESTEROLEMIA IN CHILDREN AND ADOLESCENTS, BUT IT REQUIRES CLINICAL DEMONSTRATION. OBJECTIVE: THIS 12-WEEK STUDY WAS UNDERTAKEN TO INVESTIGATE THE CHOLESTEROL-LOWERING EFFECTS AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC PATIENTS AGED 11 TO 19 YEARS. METHODS: IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, AFTER 4 WEEKS OF DIETARY STABILIZATION, ADOLESCENTS WITH TYPE II HYPERCHOLESTEROLEMIA WERE RANDOMLY ASSIGNED (1:1 RATIO) TO RECEIVE PLACEBO OR POLICOSANOL 5-MG TABLETS ONCE DAILY FOR 12 WEEKS. PHYSICAL EXAMINATIONS WERE PERFORMED, AND LIPID PROFILES AND BLOOD SAMPLES WERE OBTAINED AT BASELINE AND AFTER 6 AND 12 WEEKS OF THERAPY. THE TREATMENT WAS CONSIDERED EFFECTIVE IF MEAN REDUCTIONS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) WERE >15%. IN ADDITION, THE PERCENTAGES OF PATIENTS REACHING FINAL VALUES OF LDL-C <3.4 MMOL/L AND OPTIMAL VALUES OF <2.8 MMOL/L WERE ALSO EVALUATED. THE DOSES WERE DOUBLED IF LDL-C VALUES WERE ≥3.4 MMOL/L AFTER 6 WEEKS OF THERAPY. THE INCIDENCE OF AES AND COMPLIANCE WITH STUDY MEDICATIONS WERE ALSO EVALUATED AFTER 6 AND 12 WEEKS OF TREATMENT. RESULTS: FIFTY-FIVE PATIENTS WERE ENROLLED IN THE STUDY (28 POLICOSANOL, 27 PLACEBO). TWENTY-THREE PATIENTS (17 PLACEBO, 6 POLICOSANOL) REQUIRED DOSE TITRATION AT 6 WEEKS. AFTER 12 WEEKS OF THERAPY, POLICOSANOL SIGNIFICANTLY DECREASED LDL-C WITH RESPECT TO BASELINE AND PLACEBO (BOTH P < 0.001), SHOWING A MEAN REDUCTION OF 32.6%. TOTAL CHOLESTEROL (TC) AND TC/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND LDL-C/HDL-C RATIOS WERE REDUCED BY 21.9%, 27.8%, AND 37.2%, RESPECTIVELY, IN THE POLICOSANOL GROUP (P < 0.001, COMPARED WITH BASELINE AND PLACEBO). HDL-C ROSE 10.1% (P < 0.001), COMPARED WITH BASELINE AND PLACEBO. TRIGLYCERIDES WERE UNAFFECTED BY POLICOSANOL. LDL-C, TC, AND BOTH ATHEROGENIC RATIOS WERE REDUCED SIGNIFICANTLY IN THE POLICOSANOL GROUP (P < 0.001), AND SIGNIFICANT INCREASES IN HDL-C VALUES WERE OBSERVED AT THE 6-WEEK INTERIM CHECKUP (P < 0.001 VS BASELINE, P < 0.01 VS PLACEBO). TWENTY-FIVE (89.3%) OF 28 PATIENTS IN THE POLICOSANOL GROUP SHOWED LDL-C REDUCTIONS >15% COMPARED WITH 2 (7.4%) OF 27 PATIENTS IN THE PLACEBO GROUP (P < 0.001). IN ADDITION, 26 (92.8%) OF 28 POLICOSANOL PATIENTS REACHED LDL-C VALUES <3.4 MMOL/L COMPARED WITH 4 (14.8%) OF 27 PATIENTS IN THE PLACEBO GROUP (P < 0.001). LIKEWISE, THE RESPONSE RATE FOR ACHIEVEMENT OF OPTIMAL VALUES (LDL-C <2.8 MMOL/L) WAS ALSO LARGER IN THE POLICOSANOL GROUP (20/28; 71.4%) THAN IN THE PLACEBO GROUP (0/27; 0.0%) (P < 0.001). POLICOSANOL WAS WELL TOLERATED, WITH NO DRUG-RELATED EFFECTS FOUND ON PHYSICAL EXAMINATION. BLOOD BIOCHEMISTRY DETERMINATIONS REVEALED SIGNIFICANTLY LOWER ALANINE AMINOTRANSFERASE LEVELS IN THE POLICOSANOL GROUP AFTER 6 WEEKS OF THERAPY COMPARED WITH PLACEBO (P < 0.05), AS WELL AS SIGNIFICANT REDUCTIONS IN ASPARTATE AMINOTRANSFERASE LEVELS AT 6 WEEKS (P < 0.01) AND 12 WEEKS (P < 0.05) COMPARED WITH BASELINE. NO PATIENTS WITHDREW FROM THE STUDY, AND ONLY 3 PATIENTS (2 PLACEBO, 1 POLICOSANOL) EXPERIENCED MILD AES DURING THE STUDY; THE PLACEBO PATIENTS REPORTED ABDOMINAL PAIN AND CONSTIPATION (1 EACH), AND THE POLICOSANOL PATIENT REPORTED POLYPHAGIA. CONCLUSIONS: POLICOSANOL 5 MG/D APPEARS TO BE WELL TOLERATED AND EFFECTIVE AS SHORT-TERM TREATMENT OF HYPERCHOLESTEROLEMIA IN ADOLESCENTS.","ADOLESCENTS; CHOLESTEROL-LOWERING DRUGS; HYPERCHOLESTEROLEMIA; LIPID-LOWERING THERAPY; POLICOSANOL","ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TABLET; TREATMENT OUTCOME","MEDICAL SURGICAL RESEARCH CENTER; STATE CENTER FOR QUALITY DRUG CONTROL; CITY, UNIVERSITY OF LONDON, CITY","THIS STUDY WAS CONDUCTED AT THE MEDICAL SURGICAL RESEARCH CENTER (HAVANA CITY, CUBA), AND THE PROTOCOL WAS APPROVED BY THE ETHICS COMMITTEE OF THIS INSTITUTION AND BY THE STATE CENTER FOR QUALITY DRUG CONTROL.","EPSTEIN F.H., CARDIOVASCULAR DISEASE EPIDEMIOLOGY. A JOURNEY FROM THE PAST INTO THE FUTURE, CIRCULATION, 93, PP. 1755-1764, (1996); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUR HEART J, 19, PP. 1434-1503, (1998); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR HEART J, 19, SUPPL. A, (1998); GOTTO A., ASSMANN G., CARMENA R., ET AL., LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE. 2ND ED., PP. 106-156, (2000); ANDERSON K.M., WILSON P.W., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE: A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); PREVENTION OF CARDIOVASCULAR EVENTS AND DEATH WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); WEIS S., CLEARFIELD M., DOWNS J.R., GOTTO A., THE AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY (AFCAPS/TEXCAPS): PRIMARY PREVENTION OF ACUTE MAJOR CORONARY EVENTS IN WOMEN AND MEN WITH AVERAGE CHOLESTEROL, CHOLESTEROL-LOWERING THERAPY: EVALUATION OF CLINICAL TRIAL EVIDENCE, PP. 151-172, (2000); RELATIONSHIP OF ATHEROSCLEROSIS IN YOUNG MEN TO SERUM LIPOPROTEIN CHOLESTEROL CONCENTRATIONS AND SMOKING: A PRELIMINARY REPORT FROM THE PATHOBIOLOGICAL DETERMINANTS OF ATHEROSCLEROSIS IN YOUTH (PDAY) RESEARCH GROUP, JAMA, 264, PP. 3018-3024, (1990); LEE J., LAUER R.M., CLARKE W.R., LIPOPROTEINS IN THE PROGENY OF YOUNG MEN WITH CORONARY ARTERY DISEASE: CHILDREN WITH INCREASED RISK, PEDIATRICS, 78, PP. 330-337, (1986); LAUER R.M., LEE J., CLARKE W.R., FACTORS AFFECTING THE RELATIONSHIP BETWEEN CHILDHOOD AND ADULT CHOLESTEROL LEVELS: THE MUSCATINE STUDY, PEDIATRICS, 82, PP. 309-318, (1988); DENNISON B.A., KIKUCHI D.A., SRINIVASAN S.R., ET AL., PARENTAL HISTORY OF CARDIOVASCULAR DISEASE AS AN INDICATION FOR SCREENING FOR LIPOPROTEIN ABNORMALITIES IN CHILDREN, J PEDIATR, 115, PP. 186-194, (1989); NATIONAL CHOLESTEROL EDUCATION PROGRAM: REPORT OF THE EXPERT PANEL ON BLOOD CHOLESTEROL LEVELS IN CHILDREN AND ADOLESCENTS, PEDIATRICS, 89, PP. 525-584, (1992); KLEINMAN R.N., FINBERG L.F., KLISH W.J., LAUER R.M., DIETARY GUIDELINES FOR CHILDREN: U.S. RECOMMENDATIONS, J NUTR, 126, 4 SUPPL., (1996); EFFICACY AND SAFETY OF LOWERING DIETARY INTAKE OF FAT AND CHOLESTEROL IN CHILDREN WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL: THE DIETARY INTERVENTION STUDY IN CHILDREN (DISC), JAMA, 273, PP. 1429-1435, (1995); LAPINLEIMU H., VIIKARI J., JOKINEN E., ET AL., PROSPECTIVE RANDOMISED TRIAL IN 1062 INFANTS OF DIET LOW IN SATURATED FAT AND CHOLESTEROL, LANCET, 345, PP. 471-476, (1995); THOMPSON G.R., LIPID LOWERING IN THE YOUNG, HEART, 76, PP. 1-2, (1996); FISHER E.A., VAN HORN L., MCGILL H.C. JR., NUTRITION AND CHILDREN: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE NUTRITION COMMITTEE, AMERICAN HEART ASSOCIATION, CIRCULATION, 95, PP. 2332-2333, (1997); TONSTAD S., A RATIONAL APPROACH TO TREATING HYPERCHOLESTEROLAEMIA IN CHILDREN: WEIGHING THE RISKS AND BENEFITS, DRUG SAF, 16, PP. 330-341, (1997); LIACOURAS C.A., COATES P.M., GALLAGHER P.R., CORTNER J.A., USE OF CHOLESTYRAMINE IN THE TREATMENT OF CHILDREN WITH FAMILIAL COMBINED HYPERLIPIDEMIA, J PEDIATR, 122, PP. 477-482, (1993); FARMER J.A., GOTTO A.M., CHOOSING THE RIGHT LIPID-REGULATING AGENT: A GUIDE TO SELECTION, DRUGS, 52, PP. 649-661, (1996); BOTTORFF M., FIRE AND FORGET?"" PHARMACOLOGICAL CONSIDERATIONS IN CORONARY CARE, ATHEROSCLEROSIS, 147, SUPPL. 1, (1999); FARMER J.A., TORRE-AMIONE G., COMPARATIVE TOLERABILITY OF THE HMG-COA REDUCTASE INHIBITORS, DRUG SAF, 23, PP. 197-213, (2000); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CANETTI M.M., MOREIRA M., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES CLIN EXP, 58, PP. 868-875, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES CLIN EXP, 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-147, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES CLIN EXP, 57, PP. 568-577, (1996); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, PP. 819-828, (1995); ORTENSI G., GLADSTEIN J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECT OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. 819-828, (2001); FERNANDEZ J.C., MAS R., CASTANO G., ET AL., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, CLIN DRUG INVEST, 21, PP. 103-113, (2001); MAS R., CASTANO G., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY DISEASE, CLIN DRUG INVEST, 21, PP. 485-497, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, PP. 117-127, (1999); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY, LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAG, 14, PP. 107-113, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24-MONTH STUDY, TERATOG CARCINOG MUTAG, 14, PP. 239-249, (1994); ALEMAN C., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997); GAMEZ R., ALEMAN C.L., MAS R., ET AL., A 6-MONTH STUDY ON THE TOXICITY OF HIGH DOSES OF POLICOSANOL ORALLY ADMINISTERED TO SPRAGUE-DAWLEY RATS, J MED FOOD, 4, PP. 57-66, (2001); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES CLIN EXP, 60, PP. 458-467, (1999); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); O'BRIEN P.C., SHAMPO M.A., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); PARKER T.S., MCNAMARA D.J., BROWN C., ET AL., MEVALONIC ACID IN HUMAN PLASMA: RELATIONSHIP OF CONCENTRATION AND CIRCADIAN RHYTHM TO CHOLESTEROL SYNTHESIS RATES IN MAN, PROC NATL ACAD SCI U S A, 79, PP. 3037-3041, (1982); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN, AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM J CARDIOL, 81, PP. 582-587, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR THER RES CLIN EXP, 61, PP. 609-620, (2000); KELISHADI R., ASGARY S., NADERI G., ET AL., EVALUATION OF LDL OXIDE METABOLITES IN CHILDREN OF HIGH RISK FAMILIES, JPN J CARDIOVASC DIS PREV, 36, SUPPL., (2001)","R. MÁS; CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA; EMAIL: CLINICA@IP.ETECSA.CU","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0036260528","CURR THER RES CLIN EXP","MEDICAL SURGICAL RESEARCH CENTER HAVANA CITY;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTER HAVANA CITY;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;EMAIL: CLINICA@IP.ETECSA.CU",NA,"CASTAO G, 2002, CURR THER RES CLIN EXP","CASTAO G, 2002, CURR THER RES CLIN EXP"
"MARRERO D D;GONZÁLEZ B L","MARRERO DELANGE, DAVID (6508318323); GONZÁLEZ BRAVO, LUIS (57220758268)","TRACE DETERMINATION OF 1OCTACOSANOL IN RAT PLASMA BY SOLIDPHASE EXTRACTION WITH TENAX GC AND CAPILLARY GAS CHROMATOGRAPHY",2001,"JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES AND APPLICATIONS","762","6",6,"10.1016/S0378-4347(01)00331-0","CENTER OF NATURAL PRODUCTS, CNIC, HAVANA, AVE. 25 AND 158, PLAYA, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, HAVANA, AVE. 25 AND 158, PLAYA, CUBA","1-OCTACOSANOL IS THE MAJOR COMPONENT OF POLICOSANOL, A NEW NATURAL LOWERING-CHOLESTEROL AGENT. A SENSITIVE SOLID-PHASE EXTRACTION WITH A TENAX GC CAPILLARY GAS CHROMATOGRAPHY METHOD FOR DETERMINING THE PROPORTION OF THIS FATTY ALCOHOL IN PLASMA AFTER ITS DENATURATION WITH TRICHLOROACETIC ACID WAS DEVELOPED. THE TRIMETHYLSILYL ETHER DERIVATIVE OF THE TARGET ANALYTE OBTAINED FROM THE ORGANIC EXTRACT SHOWED EXCELLENT CHROMATOGRAPHIC PROPERTIES AND WAS DETECTABLE IN THE LOW NANOGRAM RANGE (1 NG/ML). ADEQUATE SEPARATION FROM PLASMA'S EXTRACT WAS ACHIEVED WITH A FUSED-SILICA CAPILLARY COLUMN (30 M×0.25 MM I.D.) WITH SPB-5 (0.5 ΜM FILM THICKNESS) AND OPERATED WITH TEMPERATURE PROGRAMMING FROM 100 TO 200°C AT 40°C/MIN AND FROM 200°C INCREASED AT 10°C/MIN TO 320°C, THEN HELD FOR 30 MIN, THE CARRIER GAS FLOW-RATE (ARGON) WAS 1 ML/MIN. QUANTIFICATION WAS PERFORMED BY THE INTERNAL STANDARD METHOD USING 1-HEXACOSANOL. THE RELIABLE RELATIVE RETENTION PARAMETERS AND THE MASS RESPONSE FACTORS VALUES, AND THEIR CONFIDENCE LEVELS, ENSURE A PROPER GC SENSITIVITY, NECESSARY FOR THE DETERMINATION OF THE ALCOHOL BEING ANALYZED. THE METHOD WAS EVALUATED TO A CONCENTRATION RANGE FROM 6 TO 47.6 NG/ML OF PLASMA OBTAINING RECOVERIES FROM 95 TO 98%. THE CORRELATION BETWEEN THE THEORETICAL CONCENTRATION VALUES AND THE CORRESPONDING EXPERIMENTAL VALUES WAS APPROPRIATE (Y=0.9718X-0.0915; R2=0.9998). THE METHOD SHOWED A GOOD WITHIN-DAY (RSD=4.3%) AND BETWEEN-DAY (RSD=6.0%) PRECISION ACCORDING TO THE ACCEPTANCE CRITERIA (<10%). THIS PROCEDURE WAS SUCCESSFULLY APPLIED TO THE STUDY OF 1-OCTACOSANOL IN RAT PLASMA SAMPLES AFTER A SINGLE ORAL ADMINISTRATION (40 MG/KG) OF POLICOSANOL. © 2001 PUBLISHED BY ELSEVIER SCIENCE B.V.","1-OCTACOSANOL","ANIMALS; CHROMATOGRAPHY, GAS; FATTY ALCOHOLS; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; ALCOHOLS; CHOLESTEROL; EXTRACTION; PLASMAS; SILICA; 1 OCTACOSANOL; ARGON; ETHER DERIVATIVE; FATTY ALCOHOL; HEXACOSANOL; HYPOCHOLESTEROLEMIC AGENT; OCTACOSANOL; POLICOSANOL; POLY 2,6 DIPHENYL 4 PHENYLENE OXIDE; SILICON DIOXIDE; TRICHLOROACETIC ACID; TRIMETHYLSILYL DERIVATIVE; UNCLASSIFIED DRUG; ACCURACY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CONTROLLED STUDY; CORRELATION FUNCTION; DENATURATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAT; SOLID PHASE EXTRACTION; STANDARD; TRACE DETERMINATION; GAS CHROMATOGRAPHY","","","LAGUNA A., MAGRANER J., CARVAJAL D., ARRUZAZABALA M.L., MAS M., GARCIA M.; LAGUNA A., MAGRANER J., CARVAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; GONZALEZ V.L., MAGRANER J., J. AOAC INT., 82, (1999); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R., J. BIOL. RES., 27, (1994); RODRIGUEZ C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., FRAGA V., AMOR A.M., SOTOLONGO V., LAGUNA A., FOOD CHEM. TOXICOL., 32, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ R., CORDOVI N., FERNANDEZ J.C., CURR. THER. RES., 51, (1992); CANETTI M., MORERA M., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ADV. THER., 12, (1995); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., CLIN. PHARMACOL. RES., 14, (1994); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 58, (1998); CASTANO G., CANETTI M., MORERA M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., CURR. THER. RES., 56, (1995); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., CURR. THER. RES., 60, (1999); GONZALEZ L., MAGRANER J., ACOSTA P.C., PEREZ N., J. CHROMATOGR. B, 682, (1996); MAJORS R., LC·GC, 9, (1991); FURTON K.G., REIN J., ANAL. CHIM. ACTA, 236, (1990); PELLIZZARI E.D., BUNCH J.E., BERKELEY R.E., MCRAE J., ANALYT. LETT., 9, (1976); PANKOW J.F., ISABELLE L.M., KRISTENSEN T.J., J. CHROMATOGR., 245, (1982); ZLATKIS A., LICHTENSTEIN H.A., TISHBEE A., CHROMATOGRAPHIA, 6, (1973); ZLATKIS A., BERTSCH W., LICHTENSTEIN H.A., TISHBEE A., SHUNBO F., LIEBICH H.M., ANAL. CHEM., 45, (1973); VAN WIJK R., J. CHROMATOGR. SCI., 8, (1970); SAKODYNSKY K., PANINA L., KLINSKAYA N., CHROMATOGRAPHIA, 7, (1974); VREULS J.J., DE JONG G.J., GHIJSEN R.T., BRINKMAN U.A.TH., J. MICROCOL. SEP., 5, (1993); HARVEY D.J., J. CHROMATOGR., 494, (1989); SINGH E.J., GERSHBEIN L.L., J. CHROMATOGR., 29, (1967); PACHLA L.A., WRIGHT D.S., REYNOLDS D.L., J. CLIN. PHARMACOL., 26, (1986); KARNES H.T., MARCH C., PHARM. RES., 10, (1993)","D. MARRERO DELANGE; CENTER OF NATURAL PRODUCTS, CNIC, HAVANA, AVE. 25 AND 158, PLAYA, CUBA; EMAIL: DAVID_DELANGE@YAHOO.COM","","ENGLISH","J. CHROMATOGR. B BIOMED. SCI. APPL.","ARTICLE","ISI","2-S2.0-0035812952","J CHROMATOGR B BIOMED SCI APPL","CENTER OF NATURAL PRODUCTS;CENTER OF NATURAL PRODUCTS","NOTREPORTED;CENTER OF NATURAL PRODUCTS;NOTREPORTED",NA,"MARRERO DELANGE D, 2001, J CHROMATOGR B BIOMED SCI APPL","MARRERO DELANGE D, 2001, J CHROMATOGR B BIOMED SCI APPL"
"CRESPO N;ALVAREZ R;MÁS R;ILLNAIT J;FERNÁNDEZ L;FERNÁNDEZ J","CRESPO, NELSON (6603919799); ALVAREZ, RAFAEL (57198274359); MÁS, ROSA (7007164572); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO CÉSAR (9432805500)","EFFECTS OF POLICOSANOL ON PATIENTS WITH NONINSULINDEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA A PILOT STUDY",1997,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","58","7",56,"10.1016/S0011-393X(97)80077-X","ENRIQUE CABRERA NATIONAL HOSPITAL, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;ENRIQUE CABRERA NATIONAL HOSPITAL, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","A RANDOMIZED, DOUBLE-MASKED, 12-WEEK, PLACEBO-CONTROLLED PILOT STUDY WAS CONDUCTED TO DETERMINE THE EFFICACY AND TOLERABILITY OF POLICOSANOL 5 MG TWICE DAILY, A NEW CHOLESTEROL-LOWERING DRUG, IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA. AFTER GLYCEMIC CONTROL WAS ACHIEVED THROUGH TREATMENT WITH DIET AND ORAL HYPOGLYCEMIC DRUGS, PATIENTS WERE INSTRUCTED TO FOLLOW A LIPID-LOWERING DIET AND TO DISCONTINUE ALL LIPID-LOWERING DRUGS FOR 6 WEEKS. SUBSEQUENTLY, PATIENTS WHO MET THE ENTRY CRITERIA RECEIVED POLICOSANOL OR PLACEBO TABLETS TO BE TAKEN TWICE DAILY TOR 12 WEEKS. WHEN COMPARED WITH BASELINE, POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL BY 28.9%, LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) BY 44.4%, AND TOTAL CHOLESTEROL:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) RATIO BY 38.3% AND LDL-C:HDL-C RATIO BY 51.6%. SIGNIFICANT BETWEEN-GROUP DIFFERENCES WERE ALSO SEEN: POLICOSANOL TREATMENT RAISED HDL-C LEVELS BY 23.5% COMPARED WITH PLACEBO. LEVELS OF TRIGLYCERIDE, GLUCOSE, AND GLYCATED HEMOGLOBIN WERE NOT SIGNIFICANTLY CHANGED AFTER THERAPY. NO PATIENT WITHDREW FROM THE TRIAL BECAUSE OF ADVERSE EXPERIENCES. ONLY TWO PATIENTS, BOTH FROM THE PLACEBO GROUP, REPORTED MILD ADVERSE EXPERIENCES (NERVOUSNESS). IT IS CONCLUDED THAT POLICOSANOL IS EFFECTIVE AND WELL TOLERATED IN THE TREATMENT OF PATIENTS WITH NIDDM AND HYPERCHOLESTEROLEMIA.","HYPERCHOLESTEROLEMIA; NON-INSULIN-DEPENDENT DIABETES MELLITUS; POLICOSANOL","CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","STEINER G., DIABETES AND ATHEROSCLEROSIS. AN OVERVIEW, DIABETES, 30, PP. 1-7, (1981); RUDERMAN N.B., HAUDENSCHILD C., DIABETES AS AN ATHEROGENIC FACTOR, PROG CARDIOVASC DIS., 26, PP. 373-412, (1984); CASTELLI W.P., EPIDEMIOLOGY OF CORONARY HEART DISEASE: THE FRAMINGHAM STUDY, AM J MED., 76, PP. 3-12, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS, JAMA, 251, PP. 351-373, (1984); BARRET-CONNOR E., GRUNDY S.M., HOLDBROOCK M.J., PLASMA LIPIDS AND DIABETES MELLITUS IN AN ADULT COMMUNITY, AM J EPIDEMIOL., 115, PP. 657-663, (1982); LAAKSO M., VOUTILAINEN E., SARLUND H., ET AL., SERUM LIPIDS AND LIPOPROTEINS IN MIDDLE-AGED NON-INSULIN-DEPENDENT DIABETES, ATHEROSCLEROSIS, 56, PP. 271-281, (1985); BRIONES E.R., MAO S.J.T., PALUMBO P.J., ET AL., ANALYSIS OF PLASMA LIPIDS AND APOLIPOPROTEINS IN INSULIN-DEPENDENT AND NON-INSULIN-DEPENDENT DIABETICS, METABOLISM, 33, PP. 42-49, (1984); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., POPULATION SUBSETS: MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS, THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE, PP. 1-195, (1995); WITZTUM J.L., MAHONEY L.M., RANKS M.J., ET AL., NON-ENZYMATIC GLYCOSYLATION OF LDL ALTERS ITS BIOLOGIC ACTIVITY, DIABETES, 31, PP. 283-291, (1982); LOPES-VIRELLA M.F., KLEIN R.L., LYONS T.J., ET AL., GLYCOSYLATION OF LOW DENSITY LIPOPROTEINS ENHANCES CHOLESTERYL ESTER SYNTHESIS IN HUMAN MONOCYTE-DERIVED MACROPHAGES, DIABETES, 37, PP. 550-557, (1988); PREVALENCE OF SMALL VESSEL AND LARGE VESSEL DISEASE IN DIABETIC PATIENTS FROM 14 CENTRES: THE WORLD HEALTH ORGANIZATION MULTINATIONAL STUDY OF VASCULAR DISEASE IN DIABETICS, DIABETOLOGIA, 28, SUPPL., PP. 615-640, (1985); ABBATE S.L., BRUNZELL D., PATHOPHYSIOLOGY OF HYPERLIPIDEMIA IN DIABETES MELLITUS, J CARDIOVASC PHARMACOL., 16, (1990); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-30, (1991); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES., 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES., 53, PP. 265-269, (1993); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE AND TOLERABILITY TO TREATMENT, CURR THER RES., 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 296-304, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER., 12, PP. 245-254, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES., 15, PP. 159-165, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 57, PP. 691-699, (1996); MENENDEZ R., FRAGA V., SOTOLONGO V., ET AL., EFECTO DE LA ADMINISTRACIÓN ORAL DEL POLICOSANOL SOBRE EL METABOLISMO LIPÍDICO DE RATAS NORMOCOLESTEROLÉMICAS, REV MEX CIEN FARMAC., 24, PP. 16-18, (1993); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES., 27, PP. 199-203, (1994); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE SUBCHRONIC AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT., 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); ALEMAN C.L., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY, FOOD CHEM TOXICOL., 33, PP. 573-578, (1995); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT., 73, PP. 81-90, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS. (MACACA ARCTOIDES), FOOD CHEM TOXICOL., 32, PP. 565-575, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); TORRES O., ILLNAIT J., MAS R., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1993); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM., 27, PP. 838-841, (1981); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); YOSHINO G., KASUMI T., IWAI M., ET AL., TRATAMIENTO A LARGO PLAZO DE LA HIPERCOLESTEROLEMIA EN DIABÉTICOS NO INSULINO DEPENDIENTES CON PRAVASTATINA, ATHEROSCLEROSIS, 75, PP. 67-72, (1989); GARG A., SCATT M., GRUNDY M.D., TREATMENT OF DYSLIPIDEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH LOVASTATIN, AM J CARDIOL., 62, (1988); GOLBERG R., LA BELLE P., ZUPKIS R., RONCA P., COMPARISON OF THE EFFECTS OF LOVASTATIN AND GEMFIBROZIL ON LIPIDS AND GLUCOSE CONTROL IN NON-INSULIN-DEPENDENT DIABETES MELLITUS, AM J CARDIOL., 66, (1990)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0031018756","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CRESPO N, 1997, CURR THER RES CLIN EXP","CRESPO N, 1997, CURR THER RES CLIN EXP"
"CANETTI M;MOREIRA M;ILLNAIT J;MAS R;FERNANDEZ L;FERNANDEZ J;CASTANO G","CANETTI, M. (7004415986); MOREIRA, M. (9433321400); ILLNAIT, J. (8631465800); MAS, R. (7007164572); FERNANDEZ, L. (7202848319); FERNANDEZ, J.C. (9432805500); CASTANO, G. (7005759008)","ONEYEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1995,"ADVANCES IN THERAPY","12","9",50,"","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA","A 1-YEAR, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL 5 MG TWICE A DAY WAS CONDUCTED IN 97 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WHOSE TOTAL AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL WAS INADEQUATELY CONTROLLED BY DIET. AFTER 2 MONTHS OF POLICOSANOL THERAPY, SIGNIFICANT REDUCTIONS IN TOTAL AND LDL CHOLESTEROL WERE NOTED THAT PERSISTED DURING THE 1-YEAR FOLLOW-UP. TWELVE MONTHS AFTER THERAPY, LDL-C AND TOTAL CHOLESTEROL DECREASED BY 27.5% AND 16.3%, RESPECTIVELY. RATIOS OF LDL TO HIGH-DENSITY LIPOPROTEIN (HDL) AND TOTAL CHOLESTEROL TO HDL WERE ALSO SIGNIFICANTLY DECREASED AFTER 2 MONTHS; REDUCTIONS OF 37.1% AND 28%, RESPECTIVELY, WERE APPARENT 1 YEAR AFTER TREATMENT. HDL INCREASED DURING THE STUDY, BUT THE INCREASE (25.9%) REACHED STATISTICAL SIGNIFICANCE ONLY AFTER 12 MONTHS OF THERAPY. TRIGLYCERIDES CHANGED NONSIGNIFICANTLY COMPARED WITH BASELINE AND PLACEBO. SIX PATIENTS (4 FROM THE PLACEBO GROUP AND 2 FROM THE POLICOSANOL GROUP) WITHDREW FROM THE TRIAL; NO PATIENT WITHDREW BECAUSE OF ADVERSE EXPERIENCES. NO DRUG-RELATED CLINICAL OR BIOCHEMICAL DISTURBANCES WERE OBSERVED. ADVERSE EXPERIENCES REPORTED WERE MILD AND TRANSIENT AND DID NOT DIFFER SIGNIFICANTLY FROM THOSE SEEN WITH PLACEBO. POLICOSANOL (10 MG/D) ADMINISTERED FOR 1 YEAR SHOWED SUSTAINED EFFICACY, AS WELL AS VERY GOOD SAFETY AND TOLERABILITY.","HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; POLICOSANOL","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; RANDOMIZED CONTROLLED TRIAL","","","","","","ENGLISH","ADV. THER.","ARTICLE","ISI","2-S2.0-0029083862","ADV THER",NA,"NOTREPORTED",NA,"CANETTI M, 1995, ADV THER","CANETTI M, 1995, ADV THER"
"CARBAJAL D;ARRUZAZABALA M;VALDÉS S;MÁS R","CARBAJAL, D. (8777025000); ARRUZAZABALA, M.L. (6603962476); VALDÉS, S. (8777025100); MÁS, R. (7007164572)","INTERACTION POLICOSANOLWARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS",1998,"PHARMACOLOGICAL RESEARCH","38","2",10,"10.1006/phrs.1998.0324","CENTER OF NATURAL PRODUCTS, CNIC, PLAYA, HAVANA, 25 AVE AND 158, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, PLAYA, HAVANA, 25 AVE AND 158, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, PLAYA, HAVANA, 25 AVE AND 158, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, PLAYA, HAVANA, 25 AVE AND 158, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH HYPOCHOLESTEROLEMIC EFFECTS DEMONSTRATED IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS AND TYPE II HYPERCHOLESTEROLEMIC PATIENTS. IN ADDITION, ANTIPLATELET EFFECTS OF POLICOSANOL HAVE BEEN SHOWN IN EXPERIMENTAL MODELS AND HEALTHY VOLUNTEERS. THIS STUDY INVESTIGATED THE EFFECTS OF THE CONCOMITANT ADMINISTRATION OF POLICOSANOL AND WARFARIN ON BLEEDING TIME AND EXPERIMENTALLY-INDUCED VENOUS THROMBOSIS IN RATS. POLICOSANOL DID NOT CHANGE THE BLEEDING TIME, MEANWHILE WARFARIN ALONE AND THE COMBINATION POLICOSANOL + WARFARIN INDUCED A MODERATE, BUT SIGNIFICANT PROLONGATION OF THE BLEEDING TIME. THE ADDITION OF POLICOSANOL TO WARFARIN THERAPY DID NOT ENHANCE THE PROLONGATION OF THE BLEEDING TIME INDUCED BY WARFARIN ALONE. A SIGNIFICANT REDUCTION OF THROMBUS WEIGHT WAS OBSERVED AFTER POLICOSANOL OR WARFARIN MONOTHERAPIES. WHEN THE COMBINATION WAS USED INSTEAD OF EITHER DRUG ALONE, NO SIGNIFICANT BENEFITS WERE OBSERVED ON THE REDUCTION OF THROMBUS WEIGHT.","BLEEDING TIME; POLICOSANOL; THROMBOSIS; WARFARIN","ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; WARFARIN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; VEIN THROMBOSIS","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., AMOR A., CASTANO G., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEINAS SÉRICAS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCH VENEZ FARMACOL TERAP, 11, (1992); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL SUCCESIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES XIV, 27, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., EFFECTS OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, (1995); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, (1991); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOTRIENES ESSENTIAL FATTY ACIDS, 49, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., ESTUDIO FARMACOLOGICO DE LA INTERACCION ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAMER TROMB HEMOST, 5, (1992); CARBAJAL D., ARRUZAZABALA M.L., MOLINA V., MAS R., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOTRIENES ESSENTIAL FATTY ACIDS, 50, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 33, (1996); O'REILLY R.A., ANTICOAGULANT, ANTITHROMBOTIC AND THROMBOLYTIC-DRUGS, THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7TH ED., (1990); DEJANA E., VILLA S., GAETANO G., BLEEDING TIME IN RATS: A COMPARISON OF DIFFERENT EXPERIMENTAL CONDITIONS, THROMB HAEMOST, 48, (1982); REYERS I., MYSLIEWIEC M., MUSSONI L., DONATI M.B., STASIS-INDUCED VENOUS THROMBOSIS, STANDARDIZATION OF ANIMAL MODELS OF THROMBOSIS, (1983)","","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0032145343","PHARMACOL RES",NA,"NOTREPORTED",NA,"CARBAJAL D, 1998, PHARMACOL RES","CARBAJAL D, 1998, PHARMACOL RES"
"MENÉNDEZ R;MÁS R;AMOR A;LEDÓN N;PÉREZ J;GONZÁLEZ R;RODEIRO I;ZAYAS M;JIMÉNEZ S","MENÉNDEZ, R. (7102205059); MÁS, R. (7007164572); AMOR, A.M. (35569426800); LEDÓN, N. (6602262840); PÉREZ, J. (7403417470); GONZÁLEZ, R.M. (57191737509); RODEIRO, I. (6602314378); ZAYAS, M. (24323402600); JIMÉNEZ, S. (19735040200)","INHIBITION OF RAT LIPOPROTEIN LIPID PEROXIDATION BY THE ORAL ADMINISTRATION OF D003 A MIXTURE OF VERY LONGCHAIN SATURATED FATTY ACIDS",2002,"CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY","80","8",60,"10.1139/y01-088","LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA;LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA","PREVIOUS RESULTS HAVE DEMONSTRATED THAT POLICOSANOL, A MIXTURE OF ALIPHATIC PRIMARY ALCOHOLS ISOLATED AND PURIFIED FROM SUGAR CANE WAX, WHOSE MAIN COMPONENT IS OCTACOSANOL, INHIBITED LIPID PEROXIDATION IN EXPERIMENTAL MODELS AND HUMAN BEINGS. D003 IS A DEFINED MIXTURE OF VERY LONG-CHAIN SATURATED FATTY ACIDS, ALSO ISOLATED AND PURIFIED FROM SUGAR CANE WAX, WHOSE MAIN COMPONENT IS OCTACOSANOIC ACID FOLLOWED BY TRAICONTANOIC, DOTRIACONTANOIC, AND TETRACONTANOIC ACIDS. SINCE VERY LONG-CHAIN FATTY ACIDS ARE STRUCTURALLY RELATED TO THEIR CORRESPONDING ALCOHOLS, WE INVESTIGATED THE EFFECT OF ORAL TREATMENT WITH D003 (0.5, 5, 50, AND 100 MG/KG) OVER 4 WEEKS IN REDUCING THE SUSCEPTIBILITY OF RAT LIPOPROTEIN TO OXIDATIVE MODIFICATION. THE COMBINED RAT LIPOPROTEIN FRACTION VLDL + LDL WAS SUBJECTED TO SEVERAL OXIDATION SYSTEMS, INCLUDING THOSE CONTAINING METAL IONS (CUSO4), THOSE HAVING THE CAPACITY TO GENERATE FREE RADICALS 2,2-AZOBIS-2-AMIDINOPROPANE HYDROCHLORIDE (AAPH), AND A MORE PHYSIOLOGICAL SYSTEM (RESIDENT MACROPHAGES). D003 (5, 50, AND 100 MG/KG) SIGNIFICANTLY INHIBITED COPPER-MEDIATED CONJUGATED-DIENE GENERATION IN A CONCENTRATION-DEPENDENT MANNER. D003 INCREASED LAG PHASE BY 53.1, 115.3, AND 119.3%, RESPECTIVELY, AND DECREASED THE RATE OF CONJUGATE-DIENE GENERATION BY 16.6, 21.5, AND 19.6%, RESPECTIVELY. D003 ALSO INHIBITED AZO-COMPOUND INITIATED AND MACROPHAGE-MEDIATED LIPID PEROXIDATION AS JUDGED BY THE SIGNIFICANT DECREASE IN THIOBARBITURIC ACID REACTIVE SUBSTANCE (TBARS) GENERATION. IN ALL THE SYSTEMS THE MAXIMUM EFFECT WAS ATTAINED AT 50 MG/KG. THERE WAS ALSO A PARALLEL ATTENUATION IN THE REDUCTION OF LYSINE AMINO GROUPS AND A SIGNIFICANT REDUCTION OF CARBONYL CONTENT AFTER OXIDATION OF LIPO-PROTEIN SAMPLES. TAKEN TOGETHER, THE PRESENT RESULTS INDICATE THAT ORAL ADMINISTRATION OF D003 PROTECTS LIPOPROTEIN FRACTIONS AGAINST LIPID PEROXIDATION IN THE LIPID AS WELL IN THE PROTEIN MOIETY.","D003; LIPOPROTEIN LIPID PEROXIDATION; VERY LONG-CHAIN SATURATED FATTY ACIDS","ANIMALS; AZO COMPOUNDS; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; LIPID PEROXIDATION; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MACROPHAGES; MALE; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES; ALKADIENE; AZO COMPOUND; D 003; FREE RADICAL; LOW DENSITY LIPOPROTEIN; POLICOSANOL; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID; VERY LOW DENSITY LIPOPROTEIN; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG ISOLATION; DRUG PURIFICATION; LIPID PEROXIDATION; MACROPHAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; RAT","","","ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNNDEZ L., EFFECTS OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-181, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL LOWERING EFFECT OF POLICOSANOL ON NORMOCHOLESTEROLEMIC RABBITS, BIOL. RES., 27, PP. 205-210, (1994); AVIRAM M., MODIFIED FORMS OF LOW-DENSITY LIPOPROTEIN AND ATHEROSCLEROSIS, ATHEROSCLEROSIS, 98, PP. 1-9, (1993); BROWN M.S., GOLDSTEIN J.L., LIPOPROTEIN METABOLISM IN THE MACROPHAGE: IMPLICATIONS FOR CHOLESTEROL DEPOSITION IN ATHEROSCLEROSIS, ANNU. REV. BIOCHEM., 52, PP. 223-261, (1983); CAMPILONGO R., SARDINI P., FIELDMAN R., EFFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTSE ARGENTINOS CON HIPERCOLSTEROLEMIA TIPO II. ESTUDIO ABIERTO, LA PRENSA MÉDICA ARGENTINA, 83, PP. 665-672, (1997); CANETTI M., MORERA M.S., ILLNAIT J., MAS R., FERNANDEZ J., CASTANO G., FERNANDEZ J.C., ONE-YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THERAPY, 12, PP. 245-251, (1995); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., SELLMAN E., A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF THE EFFECT OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY J. VASC. DIS., 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLANIT J., LOPEZ L.E., ALVAREZ E., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 13, PP. 1-9, (2000); CHAPMAN M.J., ANIMAL LIPOPROTEIN: CHEMISTRY, STRUCTURE AND COMPARATIVE ASPECTS, J. LIPID RES., 21, PP. 789-853, (1980); COWAN C.L., STEFFEN R.P., LYSOPHOSPHATIDYLCHOLINE INHIBITS RELAXATION OF RABBIT ABDOMINAL AORTA MEDIATED BY ENDOTHELIUM-DERIVED NITRIC OXIDE AND ENDOTHELIUM-DERIVED HYPERPOLARIZING FACTOR INDEPENDENT OF PROTEIN KINASE C ACTIVATION, ARTERIORCLER. THROMB. VASC. BIOL., 15, PP. 2290-2297, (1995); DE WHALLEY C.V., RAMKIN S.M., HOULT J.R., JESSUP W., LEAKER D.S., FLAVONOIDS INHIBIT THE OXIDATIVE MODIFICATION OF LOW-DENSITY LIPOPROTEIN BY MACROPHAGES, BIOCHEM. PHARMACOL., 39, PP. 1743-1750, (1987); DIEBER-ROTHENEDER M., OUHL H., WAEG G., STRIEGL G., ESTERBAUER H., EFFECT OF ORAL SUPPLMENTATION WITH D-ALPHA-TOCOPHEROL ON THE VITAMIN CONTENT OF HUMAN LOW DENSITY LIPOPROTEIN AND ITS OXIDATION RESISTANCE, J. LIPID. RES., 32, PP. 1325-1332, (1991); FERNANDEZ J.C., MAS R., CASTANO G., MENENDEZ R., AMOR A.M., GONZALEZ R.M., ALVAREZ E., COMPARISON OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL VS FLUVASTATINE IN ELDERLY HYPERCHOLESTEROLEMIC WOMEN, CLIN. INVEST., 21, PP. 103-113, (2001); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH. MED. RES., 28, PP. 355-360, (1997); FREI B., GAZIANO J.M., CONTENT OF ANTIOXIDANT, PRE-FORMED LIPID HYDROPEROXIDES AND CHOLESTEROL AS PREDICTORS OF SUSCEPTIBILITY OF HUMAN LDL TO METAL ION-DEPENDENT AND INDEPENDENT OXIDATION, J. LIPID RES., 34, PP. 2135-2145, (1993); FREI B., STOCKER R., AMES B.N., ANTIOXIDANT DEFENSES AND LIPID PEROXIDATION IN HUMAN BLOOD PLASMA, PROC. NATL. ACAD. SCI. U.S.A., 85, PP. 9748-9752, (1988); FRICK M.E., ELO O., HAAPA K., HELSINKI HEART STUDY: PRIMARY INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE AGE MEN WITH DISLYPIDEMIA, N. ENGL. J. MED., 317, PP. 1237-1245, (1987); GEISEG S.P., ESTERBAUER H., LOW-DENSITY LIPOPROTEIN IS SATURABLE BY PRO-OXIDANT COPPER, FEBS LETT., 343, PP. 188-194, (1994); GONZALEZ L., MARRERO D., LAGUNA A., MAS R., ARRUZAZABALA M.L., CARBAJAL D., CORA M., MENENDEZ R., A MIXTURE OF PRIMARY FATTY ACIDS OBTAINED FROM SUGAR CANE WAX, (1998); HABERLAND M.E., FONG D., CHENG L., MALONDIALDEHYDE-ALTERED PROTEIN OCCURS IN THE ATHEROMA OF WATANABE HERITABLE HYPERLIPIDEMIC RABBITS, SCIENCE, 241, PP. 215-218, (1988); HARATS D., BEN-NAIM, DABACH Y., HOLLAANDER G., HAVIVI E., STEN O., STEN Y., Β-CAROTENE INHIBITS THE OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN, BIOCHEM. BIOPHYS. ACTA, 1086, PP. 134-138, (1991); HAZELL L.J., VAN DEN BERG J.J.M., STOCKER R., OXIDATION OF LOW-DENSITY LIPOPROTEIN BY HYPOCHLORITE CAUSES AGGREGATION THAT IS MEDIATED BY MODIFICATION OF LYSINE RESIDUES RATHER THAT LIPID OXIDATION, BIOCHEM. J., 302, PP. 297-304, (1994); HERNANDEZ F., INNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOV N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); HOFF H.F., GAUBATZ J.W., ISOLATION, PURIFICATION AND CHARACTERIZATION OF A LIPOPROTEIN CONTAINING APO B FROM HUMAN AORTA, ATHEROSCLEROSIS, 42, PP. 273-297, (1982); JAILAL I., NORKUS E.P., CRISTOL L., GRUNDY S.M., Β-CAROTENE INHIBITS THE OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN, BIOCHIM. BIOPHYS. ACTA, 1086, PP. 134-138, (1991); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN. NUTR. METAB., 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-<SUP>14</SUP>C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN. NUTR. MET., 39, PP. 279-284, (1995); KABIR Y., KIMURA S., METABOLISM OF OCTACOSANOL IN LIVER AND MUSCLE OF RATS, ACTA ALIMENTARIA, 24, PP. 39-46, (1995); KRIEGER M., THEN OTHER SIDE OF SCAVENGER RECEPTOR: PATTERN RECOGNITION FOR HOST DEFENSE, CURR. OPIN. LIPIDOL., 8, PP. 275-280, (1997); LASSER N.L., ROHEIN P.S., EDELSEIN D., EDER H.A., SERUM LIPOPROTEIN OF NORMAL AND CHOLESTEROL-FED RATS, J. LIPID RES., 14, PP. 1-8, (1973); LEAKE D.S., RANKIN S., THE MODIFICATION OF LDL BY MACROPHAGES, BIOCHEM. J., 270, PP. 741-744, (1990); THE LIPID RESEARCH CLINICS PRIMARY PREVENTION TRIAL RESULT. II THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); MARKWELL M.A., HASS S.M., BIEBER L.L., TOLBERT N.R., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM., 87, PP. 206-210, (1987); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, 6, PP. 569-586, (2000); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1998); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., FERNANDEZ L., FERENANDEZ J.C., ORTA S.D., ILLANIT J., RICARDO Y., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, PP. 458-467, (1999); MENDOZA S., GAMEZ R., NOA M., MAS R., CASTANO G., MESA R., MESA M., DE ARMAS M., THE EFFECTS OF D003 AND POLICOSANOL ON THE LIPID PROFILE AND ENDOTHELEMIA IN NORMOCHOLESTEROLEMIC RABBITS: A HEAD TO HEAD COMPARISON, CURR. THER. RES., 62, PP. 209-220, (2001); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROEMIA INDUCED BY WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL. & BEHAV., 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., FERNANDEZ J.C., GONZALEZ R.M., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED ;LIPID PEROXIDATION. A RANDOMIZED, DOUBLE-BLIND PILOT STUDY, CURR. THER. RES., 61, PP. 609-620, (2000); MENENDEZ R., MAS R., AMOR A.M., GONZALEZ R.M., FERNANDEZ J.C., RODEIRO I., ZAYAS M., JIMENEZ S., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW-DENSITY LIPO-PROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, PP. 255-262, (2000); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., MAS R., VALDES S., ANTIPLATELET AND ANTITHROMBOTIC EFFECT OF D003, PHARMACOL. RES., 42, PP. 137-143, (2001); OHKAWA H., OHISHI N., YAGI K., ASSAY FOR LIPID PEROXIDES IN ANIMAL TISSUE BY TBA, ANAL. BIOCHEM., 95, PP. 351-358, (1978); PARTHASARATHY S., KHOO J.C., ELIZANBETH M., BARNETT J., WITZTUM J.L., STEINBERG D., LOW-DENSITY LIPOPROTEIN RICH IN OLEIC ACID IS PROTECTED AGAINST OXIDATIVE MODIFICATION: IMPLICATION FOR DIETARY PREVENTION OF ATHEROSCLEROSIS, PROC. NATL. ACAD. SCI. U.S.A., 87, PP. 3894-3898, (1990); PRINCEN H.M., VAM POPPEL G., VOGELEZANG C., BUYTENHEK R., KOK F.J., SUPPLEMENTATION WITH VITAMIN E BUT NOT BETA-CAROTENE IN VIVO PROTECTS LOW-DENSITY LIPOPROTEIN FROM LIPID PEROXIDATION IN VITRO. EFFECT OF CIGARETTE SMOKING, ARTERIOSC. THROMB., 12, PP. 554-562, (1992); PUHL H., WAEG G., ESTERBAUER H., METHODS TO DETERMINE OXIDATION OF LOW-DENSITY LIPOPROTEIN, METHODS OF ENZYMOLOGY,, 233, PP. 425-441, (1994); REZNICK A.Z., PACKER L., OXIDATIVE DAMAGE TO PROTEINS. SPECTROPHOTOMETRIC METHOD FOR CARBONYL ASSAY, METHODS IN ENZYMOLOGY, 233, PP. 357-363, (1994); RIZZO E., DAMMANN A., CRAFT D., SJÖGRE-LAARSSON SYNDROME. IMPAIRED FATTY ALCOHOL OXIDATION IN CULTURED FIBROBLASTS DUE TO DEFICIENT FATTY ALCOHOL:NICOTINAMIDE ADENINE NUCLEOSIDE OXIDOREDUCTASE ACTIVITY, J. CLIN. INVST., 81, PP. 738-744, (1988); RIZZO E., CRAFT D., DAMMANN A., PHILIP M., FATTY ALCOHOL METABOLISM IN CULTURED FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J. CLIN. CHEM., 262, PP. 17412-17419, (1990); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS, FOOD. CHEM. TOXICOL., 11, PP. 74-83, (1994); ROSENFELD M.E., PALINSKI W., YLA-HERTTUALA S., BUTLER S., WITZTUM J.L., DISTRIBUTION OF OXIDATION SPECIFIC LIPID-PROTEIN ADDUCTS AND APOLIPOPROTEIN B IN ATHEROSCLEROTIC LESIONS OF VARYING SEVERITY FROM WHHL RABBITS, ATHEROSCLEROSIS, 10, PP. 336-349, (1990); SCACCINI C., NARDINI M., D'AQUINO M., GENTILI V., DI FELICE M., TOMASSI G., EFFECT OF DIETARY OILS ON LIPID PEROXIDATION AND ANTIOXIDANT PARAMETERS OF RAT PLASMA AND LIPOPROTEIN FRACTIONS, J. LIPID RES., 33, PP. 627-633, (1992); RANDOMIZED TRIAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE. THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SINGH H., POULOS A.A., A COMPARATIVE STUDY OF STEARIC ACID AND LIGNOCERIC ACID OXIDATION BY HUMAN SKIN FIBROBLASTS, ARCH. BIOCHEM. BIOPHYS., 250, PP. 171-179, (1986); SINGH H., DERWAS N., POULOS A.A., VERY LONG CHAIN ACID Β-OXIDATION BY THE RAT LIVER MITOCHONDRIA AND PEROXISOMES, ARCH. BIOCHEM. BIOPHYS., 359, PP. 382-3909, (1987); STEINBERG D., PARTHASARANTHY S., CAREW T.E., KHOO J.C., WITZTUM J.L., BEYOND CHOLESTEROL. MODIFICATION OF LOW-DENSITY LIPOPROTEIN THAT INCREASES ITS ATHEROGENICITY, N. ENGL. J. MED., 320, PP. 915-924, (1989); STEINBRECHER U.P., OXIDATION OF HUMAN LOW-DENSITY LIPOPROTEIN RESULTS IN DERIVATIZATION OF LYSINE RESIDUES OF APOLIPOPROTEIN B BY LIPID PEROXIDES, J. BIOL. CHEM., 262, PP. 3603-3608, (1987); TANNER F.C., NOLL G., BOULANGER C.M., LUSCHER T.F., OXIDIZED LOW-DENSITY LIPOPROTEIN INHIBITS RELAXATION OF PORCINE CORONARY ARTERIES. ROLE OF SCAVENGER RECEPTOR AND ENDOTHELIUM-DERIVED NITRIC OXIDE, CIRCULATION, 83, PP. 2012-2020, (1991); THOMAS M.J., CHEN Q., FRANKLIN C., RUDEL L., A COMPARISON OF THE KINETICS OF LOW-DENSITY LIPOPROTEIN OXIDATION INITIATED BY COPPER OR BY AZOBIS (2 AMIDINOPROPANE), FREE RAD. BIOL. MED., 23, PP. 927-935, (1997); WANDERS R.J.A., VAN ROERMUND C.W.T., VAN WIJLAND M.J.A., SCHUTGENS R.B.H., SCHAM A.W., VAN DEN BOSCH H., TAGER J.M., STUDIES OF PEROXISOMAL OXIDATION OF PALMITATE AND LIGNOCERATE IN RAT LIVER, BIOCHIM. ET BIOPHYS. ACTA, 919, PP. 21-25, (1987)","R. MENÉNDEZ; LABORATORY OF BIOCHEMISTRY, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6412, CUBA; EMAIL: DALMER@IP.ETECSA.CU","","ENGLISH","CAN. J. PHYSIOL. PHARMACOL.","ARTICLE","ISI","2-S2.0-0036188392","CAN J PHYSIOL PHARMACOL","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"MENÉNDEZ R, 2002, CAN J PHYSIOL PHARMACOL","MENÉNDEZ R, 2002, CAN J PHYSIOL PHARMACOL"
"ORTENSI G;GLADSTEIN J;VALLI H;TESONE P","ORTENSI, GRACIELA (57199548030); GLADSTEIN, JULIO (6701715271); VALLI, HECTOR (55945613000); TESONE, PEDRO A. (6603284821)","A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA",1997,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","58","11",67,"10.1016/S0011-393X(97)80099-9","HOSPITAL J. M. RAMOS MEJÍA, BUENOS AIRES, ARGENTINA;HOSPITAL J. M. RAMOS MEJÍA, BUENOS AIRES, ARGENTINA;HOSPITAL J. M. RAMOS MEJÍA, BUENOS AIRES, ARGENTINA;HOSPITAL J. M. RAMOS MEJÍA, BUENOS AIRES, ARGENTINA, 1425 BUENOS AIRES, BILLINGHURST 1650-4B, ARGENTINA","FIFTY-THREE ELDERLY PATIENTS (60 TO 77 YEARS OF AGE) WITH PRIMARY HYPERCHOLESTEROLEMIA (TOTAL SERUM CHOLESTEROL ≤240 MG/DL) WERE ENROLLED IN A RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP, COMPARATIVE STUDY OF POLICOSANOL- A NEW CHOLESTEROL-LOWERING AGENT OBTAINED FROM SUGARCANE WAX-AND SIMVASTATIN. BEFORE RANDOMIZATION, ALL PATIENTS WERE ADVISED TO FOLLOW A STANDARD CHOLESTEROL-LOWERING DIET FOR 6 WEEKS. PATIENTS WERE RANDOMIZED TO RECEIVE EITHER POLICOSANOL OR SIMVASTATIN, BOTH AT DOSES OF 10 MG/D FOR 8 WEEKS. WITH POLICOSANOL, TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), AND TRIGLYCERIDES WERE SIGNIFICANTLY REDUCED 14.7%, 17.9%, AND 13.8%, RESPECTIVELY. SIMVASTATIN SIGNIFICANTLY LOWERED TOTAL CHOLESTEROL 15.2%, LDL- C 19.8%, AND TRIGLYCERIDES 8.7%. NEITHER POLICOSANOL NOR SIMVASTATIN SIGNIFICANTLY CHANGED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS. TOTAL CHOLESTEROL:HDL-C AND LDL-C:HDL-C RATIOS WERE SIGNIFICANTLY LOWERED BY BOTH THERAPIES. THE EFFECTS OF BOTH DRUGS ON LIPID PROFILE VARIABLES WERE STATISTICALLY SIMILAR. BOTH DRUGS WERE WELL TOLERATED. NO PATIENTS WERE WITHDRAWN FROM THE TRIAL BECAUSE OF ADVERSE EXPERIENCES AND ONLY TWO, ONE IN EACH GROUP, REPORTED AN ADVERSE EFFECT (HEADACHE). IT IS CONCLUDED THAT BOTH DRUGS ARE ADEQUATE ALTERNATIVES FOR TREATING HYPEREHOLESTEROLEMIA IN ELDERLY PATIENTS.","ELDERLY; HYPERCHOLESTEROLEMIA; POLICOSANOL; SIMVASTATIN","ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; POLICOSANOL; SIMVASTATIN; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME","ELEA LABORATORIES; SINTYAL LABORATORIES; UNIVERSIDAD DE BUENOS AIRES, UBA","THIS STUDY WAS SUPPORTED BY GRANTS FROM ELEA LABORATORIES, AND SINTYAL LABORATORIES, BUENOS AIRES, ARGENTINA.","STAMLER J., WENTWORTH D., NEATON J.D., IS THE RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND RISK OF PREMATURE DEATH FROM CORONARY HEART DISEASE CONTINUOUS AND GRADED? FINDINGS IN 356 222 PRIMARY SCREENINGS OF THE MULTIPLE RISK FACTOR INTERVENTION TRIAL, JAMA, 256, PP. 2823-2827, (1986); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO D., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DISLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); TESONE P.A., ASCIUTTO A., ORTENSI G., GLADSTEIN J., LIPID PROFILE ASSESSMENT IN THE ELDERLY, REV SOC ARGENT NUTRITION, 3, PP. 37-40, (1992); KARVONEN M.J., PREVENTION OF CARDIOVASCULAR DISEASE AMONG ELDERLY, BULL WHO, 66, PP. 7-14, (1988); BENFANTE R., REED D., IS ELEVATED SERUM CHOLESTEROL LEVEL A RISK FACTOR FOR CORONARY HEART DISEASE IN THE ELDERLY?, JAMA, 263, PP. 393-396, (1990); BILHEIMER D.W., CLINICAL CONSIDERATION REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN THE ELDERLY, ATHEROSCLEROSIS, 91, SUPPL., (1991); DENKE M.A., GRUNDY S.M., HYPERCHOLESTEROLEMIA IN ELDERLY PERSONS: RESOLVING THE TREATMENT DILEMMA, ANN INTERN MED, 112, PP. 780-792, (1990); DAWLING S., CROME P., CLINICAL PHARMACOKINETIC CONSIDERATIONS IN THE ELDERLY. AN UPDATE, CLIN PHARMACOKINET, 17, PP. 236-241, (1989); GOLDBERG P.B., ROBERTS J., PHARMACOLOGICAL BASIS FOR DEVELOPING RATIONAL DRUG REGIMENS FOR ELDERLY PATIENTS, MED CLIN NORTH AM, 67, PP. 315-331, (1983); GURWITZ J.H., AVORN J., THE AMBIGUOUS RELATION BETWEEN AGING AND ADVERSE DRUG REACTIONS, ANN INTERN MED, 114, PP. 956-958, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VEN FARMACOL TER, 11, PP. 80-86, (1992); RODRIGUEZ C., MESA R., MAS R., ET AL., ESTUDIO DEL EFECTO SOBRE LIPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VEN FARMACOL TER, 11, PP. 74-79, (1992); MENENDEZ R., FRAGA V., SOTOLONGO V., ET AL., EFECTO DE LA ADMINISTRACIÓN ORAL DEL POLICOSANOL SOBRE EL METABOLISMO LIPÍDICO DE RATAS NORMOCOLESTEROLÉMICAS, REV MEX CIEN FARM, 24, PP. 16-18, (1993); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 1-8, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROG CIEN MÉD, 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VEN FARMACOL TER, 12, PP. 71-76, (1993); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1997); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE, SUBCHRONICAL AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); FERNA;NDEZ S.I., RENDON A., DE LAS CAJIGAS A., ET AL., ESTUDIO GENOTOXICO DEL ATEROMIXOL (PPG), UN NUEVO MEDICAMENTO HIPOLIPEMIANTE, REV CIENC BIOL, 22, PP. 98-101, (1991); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAG, 14, PP. 107-113, (1994); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUES C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG, 14, PP. 239-249, (1994); ALEMAN C., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); ALBERTS A.W., CHEN J., KURON G., ET AL., MEVINOLIN, A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYL GLUTARYL-COENZYME A REDUCTASE AND A CHOLESTEROL LOWERING AGENT, PROC NATL ACAD SCI USA, 77, PP. 3957-3961, (1980); ILLINGWORTH D.R., THERAPEUTIC USE OF LOVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, CLIN THER, 16, PP. 2-26, (1994); MATTI J., TIKKANEN M.D., ESKI A., ET AL., CURRENT PHARMACOLOGIC TREATMENT OF ELEVATED SERUM CHOLESTEROL, CIRCULATION, 76, PP. 529-533, (1987); MITCHEL Y.B., THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, SUPPL., (1992); WALKER J.F., SIMVASTATIN: THE CLINICAL PROFILE, AM J MED, 87, SUPPL. 4A, (1989); FARNIER M., COMPARISON OF SIMVASTATIN AND CIPROFIBRATE IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA - A FRENCH MULTICENTRE STUDY, ATHEROSCLEROSIS, 97, SUPPL., (1992); PIETRO D.A., ALEXANDER S., MANTELL G., ET AL., EFFECTS OF SIMVASTATIN AND PROBUCOL IN HYPERCHOLESTEROLEMIA, AM J CARDIOL, 63, PP. 682-686, (1989); TIKKANEN M.J., BOCANEGRA T.S., WALKER J.F., ET AL., COMPARISON OF LOW DOSES OF SIMVASTATIN AND GEMFIBROZIL IN THE TREATMENT OF ELEVATED PLASMA CHOLESTEROL: A MULTICENTER STUDY, AM J MED, 87, SUPPL. 4A, (1989); SCHULZACK P., BOJANOVSKI M., JOCHIM A., ET AL., COMPARISON BETWEEN SIMVASTATIN AND BEZAFIBRATE IN EFFECT ON PLASMA LIPOPROTEINS AND APOLIPOPROTEINS IN PRIMARY HYPERCHOLESTEROLEMIA, LANCET, 1, PP. 611-613, (1988); FARNIER M., COMPARISON OF SIMVASTATIN AND CIPROFIBRATE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 97, PP. 59-66, (1992); ZIEGLER O., DROUIN P., SAFETY, TOLERABILITY AND EFFICACY OF SIMVASTATIN AND FENOFIBRATE - A MULTICENTER STUDY, CARDIOLOGY, 77, PP. 50-57, (1990); FARNIER M., BONNEFOUS F., DEBBAS N., ET AL., COMPARATIVE EFFICACY AND SAFETY OF MICRONIZED FENOFIBRATE AND SIMVASTATIN IN PATIENTS WITH PRIMARY TYPE IIA OR IIB HYPERLIPIDEMIA, ARCH INTERN MED, 154, PP. 441-449, (1994); KUHN P., DARIOLI R., BOVET P., ET AL., DOSE-DEPENDENT LIPID-LOWERING EFFECTS OF SIMVASTATIN (MK-733) IN THE ELDERLY, CURR THER RES, 46, PP. 381-389, (1989); BOCCUZZI S.J., KEEGAN M.E., HIRSCH L.J., ET AL., LONG TERM EXPERIENCE WITH SIMVASTATIN, DRUG INVEST, 5, PP. 135-140, (1993); MALINI P.L., DE DIVITIIS O., DI SOMMA S., ET AL., A COMPARATIVE STUDY OF SIMVASTATIN VERSUS PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 97, SUPPL., (1992); MOLGAARD J., LUNDH B.J., VON SCHENCK H., ET AL., LONG-TERM EFFICACY AND SAFETY OF SIMVASTATIN ALONE AND IN COMBINATION THERAPY IN TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 91, SUPPL., (1991); EFFICACY AND SAFETY OF SIMVASTATIN AND PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (A COMPARATIVE STUDY IN DIFFERENT COUNTRIES), AM J CARDIOL, 70, PP. 1-7, (1992); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT PREPARATIVE ULTRACENTRIFUGUE, CLIN CHEM, 18, PP. 499-502, (1972); ILLINGWORTH D.R., AN OVERVIEW OF LIPID LOWERING DRUGS, DRUGS, 36, 3 SUPPL., PP. 63-71, (1988); STALENHOFF A.R.H., MARC J.T.M., STUYT P.M.J., EFFICACY AND TOLERABILITY OF SIMVASTATIN (MK-733), AM J MED, 87, SUPPL. 4A, (1989); VOLPE R., GINNETTI M.G., URBINATI G.C., ET AL., EFFICACY AND SAFETY OF PRAVASTATIN AND SIMVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA COMPARED IN A CROSS-OVER STUDY, 3RD INTERNATIONAL SYMPOSIUM ON TREATMENT OF SEVERE DYLIPOPROTEINEMIA IN THE PREVENTION OF CORONARY HEART DISEASE, PP. 271-279, (1990); VOLPE R., AREA M., GINNETTI M.G., ET AL., THE EFFICACY AND SAFETY OF PRAVASTATIN AND SIMVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 51, PP. 422-430, (1992); VOLPE R., AREA M., GINNETTI M.G., ET AL., EFFICACY AND SAFETY OF SIMVASTATIN IN LONG-TERM TREATMENT OF SEVERE PRIMARY HYPERCHOLESTEROLEMIA, MOLECULAR BIOLOGY OF ATHEROSCLEROSIS, PP. 619-621, (1992); NAKANDAKARE E., GARCIA R.C., ROCHA J.C., ET AL., EFFECTS OF SIMVASTATIN, BEZAFIBRATE AND GEMFIBROZIL ON THE QUANTITY AND COMPOSITION OF PLASMA LIPOPROTEINS, ATHEROSCLEROSIS, 85, PP. 211-217, (1990)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0030857721","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"ORTENSI G, 1997, CURR THER RES CLIN EXP","ORTENSI G, 1997, CURR THER RES CLIN EXP"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;PONTIGAS V;SUAZO M;FERNÁNDEZ L","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, JULIO CÉSAR (9432805500); PONTIGAS, VIRGINIA (7801672672); SUAZO, MAGNOLIA (6603540652); FERNÁNDEZ, LILIA (7202848319)","OPENLABEL STUDY OF THE EFFICACY SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK",1998,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","59","8",12,"10.1016/S0011-393X(98)85033-9","CENTER FOR MEDICAL SURGICAL RESEARCH, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, P.O. BOX 6990, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR MEDICAL SURGICAL RESEARCH, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR MEDICAL SURGICAL RESEARCH, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR MEDICAL SURGICAL RESEARCH, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","IN THE PRESENT OPEN-LABEL, SHORT-TERM STUDY THE EFFECTS OF POLICOSANOL IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH GLOBAL CORONARY RISK WERE INVESTIGATED. AFTER DIETARY STABILIZATION DURING A 5-WEEK BASELINE PERIOD, 54 PATIENTS WERE INSTRUCTED TO TAKE POLICOSANOL 20 MG ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. ALL OF THE PATIENTS HAD A FAMILY HISTORY OF DEATH CAUSED BY CORONARY ARTERY DISEASE AND ONE OR MORE PERSONAL CORONARY RISK FACTORS OTHER THAN HYPERCHOLESTEROLEMIA (EG, HYPERTENSION [64.8%], PREVIOUS CORONARY EVENTS [40.7%], SMOKING [31.5%], AND OBESITY [18.5%]). FIFTY PERCENT OF THE PATIENTS WERE POSTMENOPAUSAL WOMEN AND 24.1% WERE MEN AGED >45 YEARS. IN ADDITION, 25 PATIENTS (46.3%) SHOWED SEVERE HYPERCHOLESTEROLEMIA (TOTAL CHOLESTEROL >7.8 MMOL/L). AT 8 WEEKS, POLICOSANOL SIGNIFICANTLY REDUCED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (22.6%) AND TOTAL CHOLESTEROL (16.9%) AND SIGNIFICANTLY INCREASED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) (20.0%). CONSEQUENTLY, THE RATIOS OF TOTAL CHOLESTEROL:HDL-C AND LDL-C:HDL-C DECREASED SIGNIFICANTLY (25.5% AND 29.9%, RESPECTIVELY). TRIGLYCERIDES DID NOT CHANGE SIGNIFICANTLY AFTER TREATMENT WITH POLICOSANOL. FORTY PATIENTS (80%) OF THE 50 PATIENTS WHO COMPLETED THE STUDY HAD >15% REDUCTIONS IN LDL-C LEVELS AFTER 8 WEEKS OF THERAPY. THE TREATMENT WAS WELL TOLERATED. NO DRUG-RELATED CLINICAL OR BLOOD BIOCHEMICAL ADVERSE EFFECTS WERE DETECTED. FOUR PATIENTS REPORTED MILD ADVERSE EFFECTS, BUT NONE OF THE PATIENTS WITHDREW FROM THE STUDY BECAUSE OF SUCH EFFECTS. THE PRESENT STUDY SUGGESTS THAT POLICOSANOL 20 MG ONCE DAILY IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH GLOBAL CORONARY RISK WAS SAFE, WELL TOLERATED, AND EFFECTIVE IN LOWERING CHOLESTEROL. THIS HIGHEST RECOMMENDED DOSAGE NEEDS TO BE STUDIED FURTHER AMONG A LARGER POPULATION FOR A LONGER DURATION TO MAKE RECOMMENDATIONS FOR LOWERING CHOLESTEROL AND TO JUDGE THE EFFECTS OF POLICOSANOL ON THE OUTCOMES OF PATIENTS WITH GLOBAL CORONARY RISK.","CHOLESTEROLLOWERING DRUGS; DYSLIPIDEMIA; POLICOSANOL; TYPE II HYPERCHOLESTEROLEMIA","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIAPHORESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO D., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DISLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4 S), LANCET, 344, PP. 1383-1389, (1994); SHEPERD J., COBBE S.M., CHRISTOPHER G., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, NEJM, 333, PP. 1301-1307, (1995); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); O'CONNOR P., FEELY J., SHEPERD J., LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); STEINER A., WEISSER B., VETTER W., A COMPARATIVE STUDY OF THE ADVERSE EFFECTS OF TREATMENT FOR HYPERLIPIDEMIA, DRUG SAFETY, 6, PP. 118-130, (1991); DESLYPERE J.P., THE ROLE OF HMG-COA REDUCTASE INHIBITORS IN THE TREATMENT OF HYPERLIPIDEMIA: A REVIEW OF FLUVASTATIN, CURR THER RES., 56, PP. 111-128, (1995); PLOSKER G.L., MCTAVISH D., SIMVASTATIN: A REAPPRAISAL OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN HYPERCHOLESTEROLEMIA, DRUGS, 50, PP. 334-363, (1995); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES., 54, PP. 304-315, (1993); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL FARMACOL TERAP., 12, PP. 71-76, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES., 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A 12-MONTH STUDY, CURR THER RES., 56, PP. 819-828, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES., 57, PP. 568-577, (1996); CASTANO G., ILLNAIT J., FERNANDEZ L., ET AL., ESTUDIO DOSIS-EFECTO DE LA ACCIÓN HIPOCOLESTEROLÉMICA DEL POLICOSANOL EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, REV CENIC CIEN BIOL., 27, PP. 38-40, (1996); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 57, PP. 691-699, (1996); CASTANO G., NODARSE M., MAS R., ET AL., COMPARACIÓN DE LOS EFECTOS DEL POLICOSANOL Y LA LOVASTATINA EN PACIENTES CON HIPERCOLESTEROLEMIA PRIMARIA TIPO II, REV CENIC CIEN BIOL., 27, PP. 57-63, (1996); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 154-162, (1997); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, PRENSA MÉD ARGENT, 83, PP. 665-672, (1996); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 26-35, (1997); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 44-51, (1997); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 390-401, (1997); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, 248, (1992); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT., 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG., 14, PP. 239-249, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT., 73, PP. 81-90, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL., 32, PP. 565-575, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAG., 14, PP. 107-113, (1994); ALEMAN C., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY, FOOD CHEM TOXICOL., 33, PP. 573-578, (1995); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTOR LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED., 100, PP. 197-204, (1996); ASSMANN G., SCHULTE H., DIABETES MELLITUS AND HYPERTENSION IN THE ELDERLY: CONCOMITANT HYPERLIPIDEMIA AND CORONARY HEART DISEASE RISK, AM J CARDIOL., 63, SUPPL. H, PP. 33-37, (1989); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT THE USE OF PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM., 18, PP. 499-502, (1972); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING, DRUGS, 86, 3 SUPPL., PP. 63-71, (1988)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0031787854","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 1998, CURR THER RES CLIN EXP","CASTAÑO G, 1998, CURR THER RES CLIN EXP"
"MÁS R","MÁS, ROSA (7007164572)","POLICOSANOL HYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSIS",2000,"DRUGS OF THE FUTURE","25","17",70,"10.1358/dof.2000.025.06.574693","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HABANA CITY, P.O. BOX 6880 OR 6990, PLAYA, CUBA","NATURAL MIXTURE OF HIGH-MOLECULAR-WEIGHT ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) WAX WHOSE MAIN COMPONENT IS OCTACOSANOL, FOLLOWED BY TRIACONTANOL AND HEXACOSANOL, WHEREAS TETRACOSANOL, HEPTACOSANOL, NONACOSANOL, DOTRIACONTANOL AND TETRATIACONTANOL ARE MINOR COMPONENTS.","","ACETYLSALICYLIC ACID; ALCOHOL DERIVATIVE; ANTILIPEMIC AGENT; ANTIOXIDANT; OCTACOSANOL; POLICOSANOL; ATHEROSCLEROSIS; CHEMICAL COMPOSITION; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFECT; DRUG METABOLISM; HUMAN; LIPID BLOOD LEVEL; MOLECULAR WEIGHT; NONHUMAN; REVIEW","","","WORLD HEALTH REPORT. LIFE IN THE 21ST CENTURY. A VISION FOR ALL, (1998); SANS S., KESTELOOT H., KROMHOUT D., THE BURDEN OF CARDIOVASCULAR DISEASES MORTALITY IN EUROPE. TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY ON CARDIOVASCULAR MORTALITY AND MORBIDITY STATISTICS IN EUROPE, EUR HEART J, 18, PP. 1231-1248, (1997); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, JAMA - J AM MED ASSOC, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., POOLE-WILSON P., WOOD D., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR HEART J, 19, SUPPL. A, (1998); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA - J AM MED ASSOC, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA - J AM MED ASSOC, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, NEW ENGL J MED, 317, PP. 1237-1245, (1987); LAROSA J.C., HUNNINGHAKE D., BUSH D., THE CHOLESTEROL FACTS. A SUMMARY OF THE EVIDENCE RELATING DIETARY FATS, SERUM CHOLESTEROL, AND CORONARY HEART DISEASE, CIRCULATION, 81, PP. 1721-1733, (1990); ANDERSON K.M., WILSON P.W., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, NEW ENGL J MED, 335, PP. 1001-1009, (1996); SIMES R.J., BAKER J., MACMAHON S., HAGUE W., COLQUHOUN D., WEST M., ARULCHELVAM M., SHAW J., TONKIN A., PRAVASTATIN REDUCES TOTAL MORTALITY IN PATIENTS WITH CORONARY HEART DISEASE AND AVERAGE CHOLESTEROL LEVELS: RELATIONSHIP OF BASELINE CHOLESTEROL AND TREATMENT EFFECTS IN THE LIPID TRIAL, J AM COLL CARDIOL, 31, 2 SUPPL. A, PP. 1116-1124, (1998); SHEPHERD J., COBBE S.M., FORD I., ISLES C.G., LORIMER A.R., MACFARLANE P.W., MCKILLOP J.H., PACKARD C.J., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA. WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, NEW ENGL J MED, 333, PP. 1301-1307, (1995); PEARSON T.A., MARX H.J., THE RAPID REDUCTION IN CARDIAC EVENTS WITH LIPID-LOWERING THERAPY: MECHANISMS AND IMPLICATIONS, AM J CARDIOL, 72, PP. 1072-1073, (1993); BYINGTON R.P., JUKEMA J.W., SALONEN J.T., PITT B., BRUSCHKE A.V., HOEN H., FURBERG C.D., MANCINI G.B., REDUCTION IN CARDIOVASCULAR EVENTS DURING PRAVASTATIN THERAPY. POOLED ANALYSIS OF CLINICAL EVENTS OF THE PRAVASTATIN ATHEROSCLEROSIS INTERVENTION PROGRAM, CIRCULATION, 92, PP. 2419-2425, (1995); CORSINI A., BERNINI F., QUARATO P., DONETTI E., BELLOSTA S., FUMAGALLI R., PAOLETTI R., SOMA V.M., NON-LIPID-RELATED EFFECTS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, CARDIOLOGY, 87, PP. 458-468, (1996); GAW A., CAN THE CLINICAL EFFICACY OF THE HMG-COA REDUCTASE INHIBITORS BE EXPLAINED SOLELY BY THEIR EFFECTS ON LDL-CHOLESTEROL?, ATHEROSCLEROSIS, 125, PP. 267-269, (1996); FARNIER M., DAVIGNON J., CURRENT AND FUTURE TREATMENT OF HYPERLIPIDEMIA: THE ROLE OF STATINS, AM J CARDIOL, 82, (1998); DAVIGNON J., THE PLEIOTROPIC EFFECT OF DRUGS AFFECTING LIPID METABOLISM, ATHEROSCLEROSIS, 134, PP. 63-77, (1997); DENKE M.A., GRUNDY S.M., HYPERCHOLESTEROLEMIA IN ELDERLY PERSONS: RESOLVING THE TREATMENT DILEMMA, ANN INTERN MED, 112, PP. 780-792, (1990); CAPURSO A., LIPID METABOLISM AND CARDIOVASCULAR RISK: SHOULD HYPERCHOLESTEROLEMIA BE TREATED IN THE ELDERLY?, J HYPERTENS, 10, 2 SUPPL., (1992); BILHEIMER D.W., CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN THE ELDERLY, ATHEROSCLEROSIS, 91, SUPPL., (1991); STEINER A., WEISSER B., VETTER W., A COMPARATIVE REVIEW OF THE ADVERSE EFFECTS OF TREATMENTS FOR HYPERLIPIDAEMIA, DRUG SAF, 6, PP. 118-130, (1991); WALKER J.F., WORLDWIDE EXPERIENCE WITH SIMVASTATIN/LOVASTATIN, EUR HEART J, 13, SUPPL. B, PP. 21-22, (1992); FARNIER J.A., GOTTO A.M., CHOOSING THE RIGHT LIPID-REGULATING AGENT, DRUGS, 52, PP. 649-661, (1996); BHATNAGAR D., LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDAEMIA, PHARMACOL THER, 79, PP. 205-230, (1998); LAGUNA GRANJA A., MAGRANER HERNANDEZ J., RAMOS LEZCANO R.P., URRIBARI HERNANDEZ E., PERDOMO NARANJO U.G., CARBAJAL FERNANDEZ D., ARRUZAZABALA M.L., MARTINEZ ROJAS J.M., LORENZO OTERO M.J., MONTEJO LORET DE MOLA L., MAS FERREIRO R., PHARMACEUTICAL FORMULATIONS CONTAINING A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS IN TREATMENT OF HYPERCHOLESTEROLAEMIA AND HYPERLIPOPROTEINAEMIA TYPE II AND STIMULATION OF SEXUAL BEHAVIOR IN ANIMALS AND HUMANS; LAGUNA GRANJA A., MAGRANER HERNANDEZ J., CARBAJAL QUINTANA D., ARRUZAZABALA VALMANA M.L., MAS FERREIRO R., GARCIA MESA M., A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ITS OBTENTION FROM SUGAR CANE WAX AND ITS PHARMACEUTICAL USES; GONZALEZ CANAVACIOLO V.L., MAGRANER HERNANDEZ J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN FIVE-MILLIGRAM FILM-COATED TABLETS, J AOAC INT, 82, PP. 834-839, (1999); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); KROON P.A., HAND K.M., HUFF J.W., ALBERTS A.W., THE EFFECTS OF MEVINOLIN ON SERUM CHOLESTEROL LEVELS OF RABBITS WITH ENDOGENOUS HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 44, PP. 41-48, (1982); CHAO Y.S., KROON P.A., YAMIN T.T., THOMPSON G.M., ALBERTS A.W., REGULATION OF HEPATIC RECEPTOR-DEPENDENT DEGRADATION OF LDL BY MEVINOLIN IN RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BIOCHIM BIOPHYS ACTA, 754, PP. 134-141, (1983); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ARRUZAZABALA M.L., NOA M., MENENDEZ R., ET AL., EFFECTS OF POLICOSANOL ON ATHEROSCLEROSIS LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZIL J MED BIOL RES, (1999); ARRUZAZABALA M.L., CARVAJAL D., MAS R., ET AL., EFFECT OF ATEROMIXOL (PPG) ON CHOLESTEROL LEVELS IN BEAGLE DOGS, REV CENIC CIEN BIOL, 22, PP. 60-61, (1991); CRUZ-BUSTILLO D., MEDEROS C.M., MAS R., ET AL., HYPOCHOLESTEROLEMIC EFFECT OF ATEROMIXOL (PPG) IN FATTENING SWINE, REV CENIC CIEN BIOL, 22, PP. 62-63, (1991); RODRIGUEZ C., MESA R., MAS R., ET AL., STUDY OF THE EFFECT ON SERUM LIPIDS AND LIPOPROTEINS AND TOLERANCE TO ORAL TREATMENT WITH INCREASING DOSES OF POLICOSANOL IN MONKEYS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP, 11, PP. 74-79, (1992); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); ALBERTS A.W., CHEN J., KURON G., ET AL., MEVINOLIN: A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT, PROC NATL ACAD SCI USA, 77, PP. 3957-3961, (1980); PARKER R.A., CLARK R.W., SIT S.Y., LANIER T.L., GROSSO R.A., WRIGHT J.J., SELECTIVE INHIBITION OF CHOLESTEROL SYNTHESIS IN LIVER VERSUS EXTRAHEPATIC TISSUES BY HMC-COA REDUCTASE INHIBITORS, J LIPID RES, 31, PP. 1271-1282, (1990); SHAW M.K., NEWTON R.S., SLISKOVIC D.R., ROTH B.D., FERGUSON E., KRAUSE B.R., HEP-G2 CELLS AND PRIMARY RAT HEPATOCYTES DIFFER IN THEIR RESPONSE TO INHIBITORS OF HMG-COA REDUCTASE, BIOCHEM BIOPHYS RES COMMUN, 170, PP. 726-734, (1990); ALBERTS A.W., HMG-COA REDUCTASE INHIBITORS - THE DEVELOPMENT, ATHEROSCLER REV, 11, PP. 123-131, (1998); MENENDEZ R., FRAGA V., SOTOLOGO V., ET AL., EFFECT OF ORAL ADMINISTRATION OF POLICOSANOL ON LIPID METABOLISM OF NORMOCHOLESTEROLEMIC RATS, REV MEX CIEN FARM, 24, PP. 16-18, (1993); AVIRAM M., MACROPHAGES, LDL OXIDATION AND ATHEROSCLEROSIS, ATHEROSCLEROSIS, 134, PP. 483-492, (1997); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); HALLER H., ENDOTHELIAL FUNCTION. GENERAL CONSIDERATIONS, DRUGS, 53, SUPPL. 1, PP. 1-10, (1997); AVIRAM M., PLATELETS AND THE VESSEL WALL LESION, CURR OPIN LIPIDOL, 3, PP. 344-348, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., INTERACTION POLICOSANOL-WARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS, PHARMACOL RES, 38, PP. 89-91, (1998); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., PHARMACOLOGICAL STUDY OF THE INTERACTION BETWEEN POLICOSANOL AND ASPIRIN IN EXPERIMENTAL ANIMALS, REV IBEROAM TROMB HEMOST, 5, PP. 17-20, (1992); CORSINI A., RAITERI M., SOMA M.R., GABBIANI G., PAOLETTI R., SIMVASTATIN BUT NOT PRAVASTATIN HAS A DIRECT INHIBITORY EFFECT ON RAT AND HUMAN MYOCYTE PROLIFERATION, CLIN BIOCHEM, 25, PP. 399-400, (1992); WEISSBERG P.L., CLESHAM G.J., BENNETT M.R., IS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION BENEFICIAL?, LANCET, 347, PP. 305-307, (1996); NOA M., MAS R., AGUILAR C., ET AL., EFFECT OF POLICOSANOL ON DAMAGED ARTERIAL WALL INDUCED BY FORCEPS IN RABBITS, J ELECTRON MICROSC, 4, PP. 629-630, (1998); NEGRE-AMINOU P., VAN ERCK M., COHEN L.H., ANTIPROLIFERATIVE POTENCIES OF 6 VASTATINS IN CULTURED HUMAN CELLS: INVOLVEMENT OF THE RAS-MEDIATED SIGNALLING PATHWAY, 66TH CONG EUR ATHEROSCLER SOC, (1996); NOA M., MAS R., DE LA ROSA M.C., J. EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., DE LA ROSA M.C., MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); NOA M., HERRERA M., MAGRANER J., MAS R., EFFECT OF POLICOSANOL ON ISOPRENALINE-INDUCED MYOCARDIAL NECROSIS IN RATS, J PHARM PHARMACOL, 46, PP. 282-285, (1994); CARBAJAL D., ARRUZAZABALA M.L., MOLINA V., ET AL., EFFECT OF POLICOSANOL AND ITS INTERACTION WITH ASPIRIN IN MODELS OF CEREBRAL ISCHEMIA, ARCH VENEZOL FARMACOL TERAP, 12, PP. 42-44, (1993); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., VALDES S., NOA M., MAS R., FRAGA V., MENENDEZ R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS IN SPRAGUE-DAWLEY RATS AND IN RABBITS, J PHARM PHARMACOL, 49, PP. 999-1002, (1997); MOLINA CUEVAS V., ARRUZAZABALA M.L., CARBAJAL QUINTANA D., MAS FERREIRO R., VALDES GARCIA S., EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS. STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOLOL, ARCH MED RES, 29, PP. 21-24, (1998); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, (1999); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., MAS R., CARBAJAL D., ALEMAN C., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS P., ALTMAN R., EFFECT OF POLICOSANOL ON PLATELET FUNCTION IN HEALTHY VOLUNTEERS, REV IBEROAM TROMB HEMOST, 9, PP. 58-62, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., CARBAJAL D., FERNANDEZ L., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., CARBAJAL D., MENDOZA S., FERNANDEZ L., VALDES S., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); GARCIA M., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II DIABETES MELLITUS; PEREZ SOUTO N., MAGRANER J., GONZALEZ L., ET AL., INTRAVENOUS ADMINISTRATION OF ATEROMIXOL (PPG) IN BEAGLE DOGS, PIGS AND RATS, REV CENIC CIEN BIOL, 22, PP. 15-19, (1991); H-OCTACOSANOL; MENENDEZ R., SOTOLONGO V., FRAGA V., ET AL., PLASMA LEVELS AND EXCRETION OF TOTAL RADIOACTIVITY IN HEALTHY VOLUNTEERS AFTER ORAL ADMINISTRATION OF <SUP>3</SUP>H-OCTACOSANOL, REV CENIC CIEN BIOL, 27, PP. 32-35, (1996); RIZZO W.B., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATLY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); PEREZ SOUTO N., ACOSTA P.C., MEDEROS C.M., ET AL., EFFECT OF ATEROMIXOL (PPG) ON THE PHARMACOKINETICS OF ANTIPYRINE, REV CENIC CIEN BIOL, 22, PP. 77-78, (1991); ALEMAN C.L., MAS R., RODEIRO I., ET AL., ACUTE TOXICOLOGY OF ATEROMIXOL (PPG) IN RODENTS, REV CENIC CIEN BIOL, 22, PP. 102-105, (1991); ALEMAN C.L., MAS R., RODEIRO I., ET AL., ACUTE. SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, TOXICOL LETT, 64-65, SPEC. ISSUE, (1992); GAMEZ R., ALEMAN C.L., NOA M., ET AL., SUBCHRONIC TOXICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS WITH THE MAXIMUM TOLERATED DOSES; ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATE, TOXICOL LETT, 70, PP. 77-87, (1994); FERNANDEZ S.I., RENDON A., DE LAS CAJIGAS A., ET AL., GENOTOXICITY OF POLICOSANOL; RENDON A., RODRIGUEZ M.D., LOPEZ M., ET AL., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOL LETT, 64-65, SPEC. ISSUE, (1992); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI-AND POSTNATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997); ALEMAN C.L., MAS FERREIRO R., NOA PUIG M., RODEIRO GUERRA I., HERNANDEZ ORTEGA C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ORTEGA C.H., GUERRA I.R., FERREIRO R.M., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); FRIEDERICKSON D.S., LEVY R.I., FAMILIAL HYPERLIPOPROTEINEMIAS, THE METABOLIC BASIS OF INHERITED DISEASE, PP. 545-614, (1972); PREVALENCE OF SMALL VESSEL AND LARGE VESSEL DISEASE IN DIABETIC PATIENTS FROM 14 CENTRES: THE WORLD HEALTH ORGANIZATION MULTINATIONAL STUDY OF VASCULAR DISEASE IN DIABETICS, DIABETOLOGIA, 28, SUPPL., PP. 615-640, (1985); CASTANO G., ILLNAIT J., FERNANDEZ L., ET AL., DOSE-EFFECT STUDY OF THE HYPOCHOLESTEROLEMIC ACTION OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, REV CENIC CIEN BIOL, 27, PP. 38-40, (1993); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 59, PP. 737-745, (1998); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CASTANO G., MAS R., ROCA J., FERNANDEZ L., ILLNAIT J., FERNANDEZ J.C., SELMAN E., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO M.R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, (1999); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFFECTS OF TREATMENT WITH ATEROMIXOL (PPG) (5 MG) IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, PCM, 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); OROZCO J., GALLARDO R., ILLNAIT J., ET AL., STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL (5 MG/DAY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 27, PP. 41-45, (1993); SOLTERO I., FUENMAYOR I., COLMENARES J., ET AL., DOUBLE-BLIND STUDY FOR THE EVALUATION OF POLICOSANOL IN THE TREATMENT OF TYPE II HYPERLIPOPROTEINEMIA, ARCH VENEZOL FARMACOL TERAP, 12, PP. 65-70, (1993); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 154-162, (1997); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY OF THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., DIAZ E., CASTANO G., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, (1999); MARTINTO M., MIRKIN M., BOCANERA R., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN; TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS FERREIRO R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J., ALEMAN C., PONTIGAS V., LESCAY M., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); CASTANO G., CANETTI M., MOREIRA M., TULA L., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., DIAZ E., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL, (1999); ZARDOYA R., TULA L., CASTANO G., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); DAVALOS J.M., MEDEROS H., RODRIGUEZ J., ET AL., EFFECT OF POLICOSANOL IN HYPERCHOLESTEROLEMIA DUE TO NEPHROTIC SYNDROME, X LATINOAM CONGR NEPHROL HYPERTENS, (1996); LAURENZI M., MANCINI M., MENOTTI A., STAMLER J., STAMLER R., TREVISAN M., ZANCHETTI A., MULTIPLE RISK FACTORS IN HYPERTENSION: RESULTS FROM THE GUBBIO STUDY, J HYPERTENS, 8, SUPPL., (1990); GOLDMAN L., HASHIMOTO B., COOK E.F., LOSCALZO A., COMPARATIVE REPRODUCIBILITY AND VALIDITY OF SYSTEMS FOR ASSESSING CARDIOVASCULAR FUNCTIONAL CLASS: ADVANTAGES OF A NEW SPECIFIC ACTIVITY SCALE, CIRCULATION, 64, PP. 1227-1234, (1981); GUTIERREZ C., FERNANDEZ L., FERNANDEZ J.C., ET AL., STUDY OF THE EFFICACY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: OPEN STUDY, REV CENIC CIEN BIOL, 27, PP. 36-37, (1993); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN ARGENTINIAN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: OPEN STUDY, LA PRENSA MÉDICA ARGENTINA, 83, PP. 665-672, (1996); NIGRO N.B., NIGRO B., NIGRO J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 30, PP. 127-132, (1999); CANETTI M., MORERA M., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); CASTANO G., NODARSE M., MAS R., ET AL., COMPARISON OF THE EFFECTS OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH PRIMARY TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 27, PP. 57-63, (1996); ROMAN O., COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HYPERTENSION; CASTANO G., MAS R., FERNANDEZ J.C., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL VS LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, CURR THER RES, (2000); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, CURR THER RES, (1999); ORTENSI G., GLADSTEIN J., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CASTANO G., NODARSE M., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL, SIMVASTATIN AND THEIR COMBINATION THERAPY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 29, PP. 9-15, (1998); PRATS H., POLICOSANOL VS SIMVASTATIN: A COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA; BURLANDO G., GARCIA A., MOLLERACH J., ET AL., A COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND SIMVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS (NIDDM); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CASTA-O G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL, (1999); SOLTERO I., FUENMAYOR I., COLMENARES J., COMPARATIVE DOUBLE-BLIND STUDY OF THE EFFICACY AND TOLERANCE OF POLICOSANOL VS. BEZAFIBRATE IN PATIENTS WITH TYPE II HYPERLIPIDEMIAS, ARCH VENEZOL FARMACOL TERAP, 12, PP. 71-76, (1993); PONS P., FERNANDEZ L., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFECTS OF POLICOSANOL AND BEZAFIBRATE IN PATIENTS WITH PRIMARY TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 27, PP. 71-77, (1996); SUMAROKOV D., SIRKIN V., GRASIANSKI D., ET AL., BEZAFIBRATE VS. POLICOSANOL: COMPARATIVE STUDY OF THEIR EFFICACY, SAFETY AND TOLERABILITY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA IN RUSSIAN PATIENTS, REV CENIC CIEN BIOL, 30, PP. 133-139, (1999); CANETTI M., MORERA M.S., ILLNAIT J., ET AL., COMPARATIVE STUDY OF THE EFFECTS OF POLICOSANOL AND GEMFIBROZIL IN PATIENTS WITH PRIMARY TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 27, PP. 64-70, (1996); CASTANO G., MAS R., TABARES I., ET AL., COMPARATIVE STUDY OF POLICOSANOL, GEMFIBROZIL AND POLICOSANOL-GEMFIBROZIL COMBINATION THERAPY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, REV CENIC CIEN BIOL, 29, PP. 17-23, (1998); ALCOCER L., FERNANDEZ L., CAMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 26-35, (1997); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); MARCELLO S., GLADSTEIN J., TESONE P., ET AL., EFFECTS OF COMBINATION BEZAFIBRATE + POLICOSANOL VERSUS BEZAFIBRATE + PLACEBO THERAPY IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, (2000); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27,879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999)","","PROUS SCIENCE","ENGLISH","DRUGS FUTURE","REVIEW","ISI","2-S2.0-0343081551","DRUGS FUTURE",NA,"NOTREPORTED",NA,"MÁS R, 2000, DRUGS FUTURE","MÁS R, 2000, DRUGS FUTURE"
"ALEMÁN C;PUIG M;ELIAS E;ORTEGA C;GUERRA I;FERREIRO R;BRIÑIS F","ALEMÁN, C.L. (7102849611); PUIG, M.N. (7101853051); ELIAS, E.C. (16165481900); ORTEGA, C.H. (7005784679); GUERRA, I.R. (25122327400); FERREIRO, R.M. (6602148780); BRIÑIS, F. (6504396479)","CARCINOGENICITY OF POLICOSANOL IN MICE AN 18MONTH STUDY",1995,"FOOD AND CHEMICAL TOXICOLOGY","33","5",45,"10.1016/0278-6915(95)00026-X","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL (TRADE NAME ATEROMIXOL) IS A NEW CHOLESTEROL-LOWERING DRUG THAT HAS BEEN ISOLATED AND PURIFIED FROM SUGAR CANE WAX. THE EFFECTS OF POLICOSANOL (50-500 MG/KG) ADMINISTERED ORALLY FOR 18 MONTHS TO MALE AND FEMALE SWISS MICE WERE INVESTIGATED. NO DIFFERENCES IN DAILY CLINICAL OBSERVATIONS, WEIGHT GAIN, FOOD CONSUMPTION AND MORTALITY (SURVIVAL ANALYSIS) BETWEEN GROUPS WERE FOUND. HISTOPATHOLOGICAL STUDY SHOWED THAT THE FREQUENCY OF NEOPLASTIC (BENIGN AND MALIGNANT) LESIONS WAS SIMILAR IN THE CONTROL AND POLICOSANOL-TREATED GROUPS. THE LESIONS OBSERVED WERE SIMILAR TO THE SPONTANEOUS LESIONS IN SWISS MICE REPORTED IN PREVIOUS STUDIES. AS NO DRUG-RELATED INCREASE IN THE OCCURRENCE OF MALIGNANT OR BENIGN NEOPLASM WAS FOUND, NOT ACCELERATION IN TUMOUR GROWTH IN ANY SPECIFIC GROUP OBSERVED, THIS STUDY SHOWS NO EVIDENCE OF POLICOSANOL-INDUCED CARCINOGENICITY IN SWISS MICE. © 1995.","","ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMAL; ANTICHOLESTEREMIC AGENTS; COMPARATIVE STUDY; EATING; FATTY ALCOHOLS; FEMALE; HEART; KIDNEY; LIVER; LONGITUDINAL STUDIES; LUNG; MALE; MICE; MYOCARDIUM; NEOPLASMS, EXPERIMENTAL; ORGAN WEIGHT; SPLEEN; SURVIVAL ANALYSIS; THYMUS GLAND; WEIGHT GAIN; ANIMALIA; ARUNDINARIA; SACCHARUM; ALKANOL; ANTILIPEMIC AGENT; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION","","","ALEMAN, MAS, HERNANDEZ, RODEIRO, CEREJIDO, NOA, CAPOTE, MENENDEZ, AMOR, GONZALEZ, SOTOLONGO JIMENEZ, A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1992); ALEMAN, MAS, NOA, RODEIRO, HERNANDEZ, CAPOTE, CARCINOGENICITY OF POLICOSANOL IN SPRAGUE-DAWLEY RATS: A 24 MONTH STUDY, TERATOGENESIS, CARCINOGENESIS AND MUTAGENESIS., (1994); ALEMAN, MAS, RODEIRO, NOA, MENENDEZ, GONZALEZ, SOTOLONGO, FRAGA, CAPOTE, JIMENEZ, ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, TOXICOLOGY LETTERS, (1992); ANEIROS, CALDERON, MAS, ILLNAIT, CASTANO, FERNANDEZ, FERNANDEZ, EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURRENT THERAPEUTIC RESEARCH, 53, PP. 304-312, (1993); ARRUZAZABALA, CARBAJAL, MAS, GARCIA, FRAGA, EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1992); ARRUZAZABALA, CARBAJAL, MAS, ILLNAIL, LAGUNA, CASTANO, EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPIDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPÉUTICA, 11, PP. 80-86, (1992); ARRUZAZABALA, CARBAJAL, MAS, MOLINA, VALDEOS, MAS, EFFECTS OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTA-CYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 49, PP. 695-697, (1993); CARR, KOLBYE, A CRITIQUE OF THE USE OF THE MAXIMUM TOLERATED DOSE IN BIOASSAYS TO ASSESS CANCER RISKS FROM CHEMICALS, REGULATORY TOXICOLOGY AND PHARMACOLOGY, 14, PP. 78-87, (1991); CHHABRA, HUFF, SCHWETZ, SELKIR, AN OVERVIEW OF PRECHRONIC AND CHRONIC TOXICITY/ CARCINOGENICITY EXPERIMENTAL STUDY DESIGNS CRITERIA USED BY THE NATIONAL TOXICOLOGY PROGRAM, ENVIRONMENTAL HEALTH PERSPECTIVES, 86, PP. 313-321, (1990); CLAYSON, NUTRITION AND EXPERIMENTAL CARCINO-GENESIS: A REVIEW, CANCER RESEARCH, 35, PP. 3292-3300, (1975); FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, PERGAMON INFOLINE, (1985); GAD, WEIL, STATISTICS FOR TOXICOLOGISTS, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 435-481, (1989); GOODMAN, WILSON, PREDICTING THE CARCINO-GENICITY OF CHEMICALS IN HUMANS FROM RODENT BIOASSAY DATA, ENVIRONMENTAL HEALTH PERSPECTIVES, 94, PP. 195-218, (1991); GORROD, TESTING FOR TOXICITY, (1981); HERNANDEZ, ILLNAIT, MAS, CASTANO, FERNANDEZ, GONZALEZ, CORDOVI, FERNANDEZ, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THRAPEUTICS RESEARCH, 51, PP. 1-8, (1991); IARC, LONG-TERM AND SHORT-TERM SCREENING ASSAYS FROM CARCINOGENS: A CRITICAL APPRAISAL, PP. 21-83, (1980); ILLNAIT, CASTANO, NODARSE, PONTIGAS, HERNANDEZ, MAS, EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERPROTEINEMIA DEL TIPO 11, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 74-76, (1991); JONES, MOHR, HUNT, RESPIRATORY SYSTEM, (1985); MENENDEZ, FRAGA, SOTOLONGO, AMOR, DEL RIO, GONZALEZ, JIMENEZ, MAS, EFECTO DE LA ADMINISTRACIÓN ORAL DEL POLICOSANOL SOBRE EL METABOLISMO LIPIDICO DE RATAS NORMOCOLESTEROLÉMICAS, REVISTA MEXICANA DE CIENCIAS FARMACEÚTICAS, 24, PP. 16-18, (1993); NATIONAL RESEARCH COUNCIL (US), LONG-TERM HOLDING OF LABORATORY RODENTS, ILAR NEWS, 19, PP. LI-L15, (1976); PATTENGALE, FRITH, CONTRIBUTIONS OF RECENT RESEARCH TO THE CLASSIFICATION OF SPONTANEOUS LYMPHOID CELL NEOPLASM IN MICE, CRC CRITICAL REVIEWS IN TOXICOLOGY, 16, PP. 185-212, (1986); PONS, ILLNAIT, RODRIGUEZ, MAS, FERNANDEZ, ROBAINA, FERNANDEZ, EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPER-CHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 1-7, (1992); PONS, JIMENEZ, RODRIGUEZ, ILLNAIT, MAS, FERNANDEZ, FERNANDEZ, EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURRENT THERAPEUTICS RESEARCH, 53, PP. 265-269, (1993); PONS, RODRIGUEZ, ROBAINA, ILLNAIT, MAS, FERNANDEZ, FERNANDEZ, EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, CLINICAL PHARMACOLOGICAL RESEARCH, 14, PP. 27-33, (1994); RAO, PIEGORSCH, HASEMAN, INFLUENCE OF BODY WEIGHT ON THE INCIDENCE OF SPONTANEOUS TUMORS IN RATS AND MICE OF LONG-TERM STUDIES, AMERICAN JOURNAL OF CLINICAL NUTRITION, 45, PP. 252-260, (1987); RENDON, RODRIGUEZ, LOPEZ, GARCIA, CAJIGAS, MAS, FERNANDEZ, POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOLOGY LETTERS, (1992); ROBENS, PIERGORSCH, SHUELER, METHODS IN TESTING FOR CARCINOGENICITY, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 251-273, (1989); ROSS, BRAS, FOOD PREFERENCE AND LENGTH OF LIFE, SCIENCE, 190, PP. 165-167, (1976); SHIMKIM, STONER, LUNG TUMOURS IN MICE: APPLICATION TO CARCINOGENESIS BIOASSAY, ADVANCES IN CANCER RESEARCH, PP. 1-58, (1975); STEVENS, GALLO, PRACTICAL CONSIDERATIONS IN THE CONDUCT OF CHRONIC TOXICITY STUDIES, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 237-250, (1989); TAMANO, HAGIWARA, SHIBATA, KURATA, ITO, SPONTANEOUS TUMOURS IN AGING (C57BL6N X C3H/HEN)F(B6C3F1) MICE, TOXICOLOGIC PATHOLOGY, 16, PP. 321-326, (1988); TOHT, DELLA PORTA, SHUBIK, THE OCCURRENCE OF MALIGNANT LYMPHOMAS IN URETHAN-TREATED SWISS MICE, BRITISH JOURNAL OF CANCER, 15, PP. 322-326, (1961); TUCKER, THE EFFECT OF LONG TERM FOOD RESTRICTION ON TUMOURS IN RODENTS, INTERNATIONAL JOURNAL OF CANCER, 23, PP. 803-807, (1979)","","","ENGLISH","FOOD CHEM. TOXICOL.","ARTICLE","ISI","2-S2.0-0029164702","FOOD CHEM TOXICOL",NA,"NOTREPORTED",NA,"ALEMÁN CL, 1995, FOOD CHEM TOXICOL","ALEMÁN CL, 1995, FOOD CHEM TOXICOL"
"CARBAJAL D;ARRUZAZABALA M;VALDÉS S;MÁS R","CARBAJAL, D. (8777025000); ARRUZAZABALA, M.L. (6603962476); VALDÉS, S. (8777025100); MÁS, R. (7007164572)","EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS",1998,"PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS","58","3",71,"10.1016/S0952-3278(98)90130-2","CENTER OF NATURAL PRODUCTS, CNIC, CUBANACÁN HABANA, 25, AVE P O 6880, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, CUBANACÁN HABANA, 25, AVE P O 6880, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, CUBANACÁN HABANA, 25, AVE P O 6880, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, CUBANACÁN HABANA, 25, AVE P O 6880, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH HYPOCHOLESTEROLEMIC EFFECTS DEMONSTRATED IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS AND PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. IN ADDITION, ANTIPLATELET EFFECTS OF POLICOSANOL HAVE BEEN SHOWN IN EXPERIMENTAL MODELS AND HEALTHY VOLUNTEERS. THIS STUDY REPORTS THE RESULTS OF A 2-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL INVESTIGATING THE EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION AND THROMBOXANE B2 AND PROSTACYCLIN (6 KETO PGF(1Α)) PRODUCTION AFTER STIMULATION WITH COLLAGEN IN HEALTHY VOLUNTEERS. THE VOLUNTEERS WERE ON A PLACEBO-BASELINE PERIOD FOR 7 DAYS AND THEREAFTER THEY RECEIVED RANDOMLY, UNDER DOUBLE-BLIND CONDITIONS, PLACEBO OR POLICOSANOL (10 MG/DAY) FOR 15 DAYS. PLATELET AGGREGATION WAS DETERMINED AT BASELINE AND AFTER 15 DAYS OF TREATMENT. SIGNIFICANT REDUCTIONS OF ARACHIDONIC ACID AND COLLAGEN-INDUCED PLATELET AGGREGATION WERE OBSERVED. THROMBOXANE, BUT NOT PROSTACYCLIN, GENERATION INDUCED BY COLLAGEN WAS ALSO INHIBITED BY POLICOSANOL.","","6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID DERIVATIVE; COLLAGEN; POLICOSANOL; PROSTACYCLIN; THROMBOXANE B2; ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, PP. 203-208, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., AMOR A.Y., CASTANO G., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEINAS SÉRICAS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPÉUTICA, 11, PP. 74-79, (1991); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURRENT THERAPEUTIC RESEARCH, 53, PP. 265-269, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., EFFECTS OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 176-182, (1995); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESO EN CIENCIAS MÉDICAS, 5, PP. 21-28, (1991); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADVANCE THERAPEUTIC, 12, PP. 245-254, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARIA M., ESTUDIO FARMACOLOGICO DE LA INTERACCION ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTATIÓN REVISTA, IBEROAMERICANA DE TROMBOSISY HEMOSTASIA, 5, PP. 17-20, (1992); CARBAJAL D., ARRUZAZABALA M.L., MOLINA V., MAS R., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOLOGICAL RESEARCH, 33, PP. 131-135, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, XII INTERNATIONAL SYMPOSIUM OF DRUG AFFECTING LIPID METABOLISM, (1995); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN PLAQUETARIA EN VOLUNTARIOS SANOS, REVISTA IBEROAMERICANA DE TROMBOSISY HEMOSTASIA, 9, PP. 58-62, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFFECT OF POLICOSANOL ON PLATELET FUNCTION IN HEALTHY VOLUNTEERS, 14TH INTERNATIONAL CONGRESS ON THROMBOSIS, (1996); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE (LOND), 194, PP. 927-929, (1962); HAMBERG M., SVENSSON J., WAKABAYASHI T., SAMUELSSON B., ISOLATION AND STRUCTURE OF TWO PROSTAGLANDIN ENDOPEROXIDES THAT CAUSE PLATELET AGGREGATION, PROC NATL ACAD SCI USA, 71, PP. 345-349, (1974); BAUMGARTNER H.R., PLATELET INTERACTION WITH COLLAGEN FIBRILS IN FLOWING BLOOD. I REACTION OF HUMAN PLATELETS WITH CHYMOTRYPSIN-DIGESTED SUBENDOTHELIUM, THROMB HAEMOST, 37, PP. 1-16, (1977); BLACKWELL G.J., DUNCOMBE W.G., FLOWER R.J., PARSONS M.F., VANE J.R., THE DISTRIBUTION AND METABOLISM OF ARACHIDONIC ACID IN RABBIT PLATELETS DURING AGGREGATION AND ITS MODIFICATION BY DRUGS, BR J PHANNACOL, 59, PP. 353-366, (1977); KENNEDY I., COLEMAN R.A., HUMPHREY P.P.A., LEVY G.P., LUMPLEY P., STUDIES ON THE CHARACTERISATION OF PROSTANOID RECEPTORS: A PROPOSED CLASSIFICATION, PROSTAGLANDINS, 24, PP. 667-689, (1982); GREEN K., VESTERQVIST O., IN VIVO SYNTHESIS OF THROMBOXANE AND PROSTACYCLIN IN MAN IN HEALTH AND DISEASE. DATA FROM GC-MS MEASUREMENTS OF MAJOR URINARY METABOLITES, ADV PROSTAGLANDIN THROMBOXANE LEUKOT RES, 16, PP. 309-324, (1986); FITZGERALD G.A., HEALY C., DAUGHERTY J., THROMBOXANE A<SUB>2</SUB> BIOSYNTHESIS IN HUMAN DISEASE, FED PROC, 46, PP. 154-158, (1987); CATELLA F., LAWSON J.A., FITZGERALD D.J., FITZGERALD G.A., ANALYSIS OF MULTIPLE THROMBOXANE METABOLITES IN PLASMA AND URINE, ADV PROSTAGLANDIN THROMBOXANE LEUKOT RES, 17 B, PP. 611-614, (1987); ROTH G.J., STANFORD N.S., MAJERUS P.W., ACETYLATION OF PROSTAGLANDIN SYNTHETASE BY ASPIRIN, PROC NATL ACAD SCI USA, 72, PP. 3073-3076, (1975)","","CHURCHILL LIVINGSTONE","ENGLISH","PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS","ARTICLE","ISI","2-S2.0-0031962129","PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS",NA,"NOTREPORTED",NA,"CARBAJAL D, 1998, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS","CARBAJAL D, 1998, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS"
"","","A CLOSE LOOK AT COENZYME Q10 AND POLICOSANOL DO THESE SUPPLEMENTS LIVE UP TO THEIR CLAIMS FOR IMPROVING HEART HEALTH",2002,"HARVARD HEART LETTER : FROM HARVARD MEDICAL SCHOOL","13","",1,"","","[NO ABSTRACT AVAILABLE]","","ANTICHOLESTEREMIC AGENTS; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; FATTY ALCOHOLS; HEALTH PROMOTION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; SELF MEDICATION; UBIQUINONE; UNITED STATES; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; UBIDECARENONE; UBIQUINONE; ARTICLE; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASE; HEALTH PROMOTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; METHODOLOGY; QUALITY OF LIFE; SELF MEDICATION; UNITED STATES","","","","","","ENGLISH","HARV HEART LETT","ARTICLE","ISI","2-S2.0-84921537652","HARV HEART LETT",NA,"NOTREPORTED",NA,"NA, 2002, HARV HEART LETT","NA, 2002, HARV HEART LETT"
"BATISTA J;STUSSER R;SAÉZ F;PÉREZ B","BATISTA, J. (7005814235); STUSSER, R. (6602973165); SAÉZ, F. (57198082935); PÉREZ, B. (57213758299)","EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLEAGED PATIENTS A 14MONTH PILOT STUDY",1996,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","34","3",27,"","CARDIOVASCULAR LABORATORY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA, CTRO. DE INVESTIGACTONES CLINICAS, KOHLY, PLAYA, HAVANA-13, 34 ST. # 4501E/47Y 45, CUBA;EPIDEMIOLOGY AND BIOSTATISTICS, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CLINICAL BIOCHEMISTRY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;STATISTICAL COMPUTATION, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA","TO FIND OUT THE LONG-TERM LIPID-LOWERING EFFICACY OF POLICOSANOL IN LOW DOSE AND ITS INFLUENCE IN THE EVOLUTION OF CORONARY HEART DISEASE (CHD), A PILOT CLINICAL RANDOMIZED SINGLE-BLIND, PLACEBO-CONTROLLED TRIAL WAS CONDUCTED ON 23 MIDDLE-AGED OUTPATIENTS, WITH WELL DOCUMENTED DIAGNOSIS OF CHRONIC CHD AND PRIMARY OR MARGINAL HYPERLIPIDEMIA. TWELVE PATIENTS RECEIVED POLICOSANOL TABLETS OF 1 MG TWICE DAILY, AND 11 PATIENTS PLACEBO IN THE SAME FASHION, FOLLOWED WITH REST AND STRESS ELECTROCARDIOGRAM (ECG), AND SERUM LIPID BLOOD SAMPLES BY 14 MONTHS. THE TREATED GROUP SHOWED SIGNIFICANT REDUCTION OF TOTAL CHOLESTEROL IN 14.8% (P≤0.001) AND OF LOW DENSITY LIPOPROTEIN (LDL) IN 15.6% (P≤0.05), AGAINST NON SIGNIFICANT INCREASE OF 3% AND 5.5%, RESPECTIVELY, IN THE PLACEBO GROUP. NO PATIENT HAD NEW CORONARY EVENTS IN BOTH GROUPS, BUT 5 OF 12 TREATED PATIENTS EXHIBITED A CLINICAL TENDENCY TO IMPROVE THEIR CHD, IN COMPARISON WITH NO ONE IN THE PLACEBO GROUP (P≤0.05). THESE FINDINGS SHOW THE EFFECTIVENESS OF LOW DOSE OF POLICOSANOL LOWERING TOTAL CHOLESTEROL AND LDL LEVELS AND SUGGEST A CHD IMPROVEMENT IN MIDDLE-AGED PATIENTS WITH PRIMARY OR MARGINAL HYPERLIPIDEMIA.","CORONARY HEART DISEASE; LIPID-LOWERING-DRUG; POLICOSANOL; PRIMARY HYPERLIPIDEMIA","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PILOT PROJECTS; ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STRESS; TRIACYLGLYCEROL BLOOD LEVEL","","","ASSMANN G., LIPIDSTOFFWECHSEL UND ATHEROSKLEROSE, (1982); BENZULY K.H., PADGETT R.C., SANJAY K., ET AL., FUNCTIONAL IMPROVEMENT PRECEDES STRUCTURAL REGRESSION OF ATHEROSCLEROSIS, CIRCULATION, 89, PP. 1810-1818, (1994); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-303, (1995); EICHSTADT H.W., ESKOTTER H., HOFFMANN I., AMTHAUER H.W., WEIDINGER G., IMPROVEMENT OF MYOCARDIAL PERFUSION BY SHORT-TERM FLUVASTATIN THERAPY IN CORONARY ARTERY DISEASE, AM J CARDIOL, 76, (1995); GOULD K.L., REVERSAL OF CORONARY ATHEROSCLEROSIS CLINICAL PROMISE AS THE BASIS FOR NONINVASIVE MANAGEMENT OF CORONARY ARTERY DISEASE, CIRCULATION, 90, PP. 1558-1571, (1994); GOULD A.L., ROSSOUW J.E., SANTANELLO N.C., HEYSE J.F., FURBERG C.D., CHOLESTEROL REDUCTION YIELDS CLINICAL BENEFIT. A NEW LOOK AT OLD DATA, CIRCULATION, 91, PP. 2274-2282, (1995); GRUNDY S.M., NATIONAL CHOLESTEROL EDUCATION PROGRAM: SECOND REPORT OF THE EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, CIRCULATION, 89, PP. 1329-1445, (1994); HASKELL W.L., ALDERMAN E.L., FAIR J.M., ET AL., EFFECTS OF INTENSIVE MULTIPLE RISK FACTOR REDUCTION ON CORONARY ATHEROSCLEROSIS AND CLINICAL CARDIAC EVENTS IN MEN AND WOMEN WITH CORONARY ARTERY DISEASE, CIRCULATION, 89, PP. 975-990, (1994); HAVEL R.J., RAPAPORT E., DRUG THERAPY: MANAGEMENT OF PRIMARY HYPERLIPIDEMIA, N ENGL J MED, 332, PP. 1491-1498, (1995); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); JUKEMA J., BRUSCHKE A., VAN BOVEN A., ET AL., EFFECTS OF LIPID LOWERING BY PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ARTERY DISEASE IN SYMPTOMATIC MEN WITH NORMAL TO MODERATELY ELEVATED SERUM CHOLESTEROL LEVELS. THE REGRESSION GROWTH EVALUATION STATIN STUDY (REGRESS), CIRCULATION, 91, PP. 2528-2540, (1995); KANNEL W.B., CASTELLI W.P., GORDON T., MCNAMARA P.M., SERUM CHOLESTEROL, LIPOPROTEINS, AND THE RISK OF CORONARY HEART DISEASE, ANN INTERN MED, 74, PP. 1-12, (1971); LEVINE G.N., KEANEY J.F., VITA J.A., MEDICAL PROGRESS. CHOLESTEROL REDUCTION IN CARDIOVASCULAR DISEASE, N ENGL J MED, 332, PP. 512-521, (1995); MARCHIOLI R., PRIETO J., TOGNONI G., SURROGATE ENDPOINTS: THE CASE OF TRIALS ON CORONARY ATHEROSCLEROTIC PLAQUE REGRESSION, CLIN TRIALS META ANAL, 29, PP. 139-176, (1994); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, (1995); MULLER C., XANTHOMATA, HYPERCHOLESTEROLEMIA, ANGINA PECTORIS, ACTA MED SCAND, 89, SUPPL., PP. 75-84, (1938); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., RODRGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP (4S), LANCET, 344, PP. 1383-1389, (1994); SCHMIEDER R.E., SCHOBEL H.P., IS ENDOTHELIAL DYSFUNCTION REVERSIBLE?, AM J CARDIOL, 76, SUPPL., (1995); SCHULER G., HAMBRECHT R., SCHLIERF G., ET AL., MYOCARDIAL PERFUSION AND REGRESSION OF CORONARY ARTERY DISEASE IN PATIENTS ON A REGIMEN OF INTENSIVE PHYSICAL EXERCISE AND LOW FAT DIET, J AM COLL CARDIOL, 19, PP. 34-42, (1992); SUPERKO H.R., KRAUSE R.M., CORONARY ARTERY DISEASE REGRESSION. CONVINCING EVIDENCE FOR THE BENEFIT OF AGGRESSIVE LIPOPROTEIN MANAGEMENT, CIRCULATION, 90, PP. 1056-1069, (1994); WALTHER A., WEIDMAN P., RIESEN W., MORDASIM R., ZUM EINFLUß VON DIURETIKA UND BETAREZEPTORENBLOCKERN AUF DIE PLASMALIPOPROTEINE IN HYPERLIPOPROTEINÄMIE, PP. 95-101, (1984); WATERS D., HIGGINSON L., GLADSTONE P., ET AL., EFFECTS OF MONOTHERAPY WITH A HMG-COA REDUCTASE INHIBITOR ON THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AS ASSESSED BY SERIAL QUANTITATIVE ARTERIOGRAPHY. THE CANADIAN CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL, CIRCULATION, 89, PP. 959-968, (1994)","","","ENGLISH","INT. J. CLIN. PHARMACOL. THER.","ARTICLE","ISI","2-S2.0-0030000776","INT J CLIN PHARMACOL THER",NA,"NOTREPORTED",NA,"BATISTA J, 1996, INT J CLIN PHARMACOL THER","BATISTA J, 1996, INT J CLIN PHARMACOL THER"
"CRESPO N;ILLNAIT J;MÁS R;FERNÁNDEZ L;FERNÁNDEZ J;CASTAÑO G","CRESPO, N. (6603919799); ILLNAIT, J. (8631465800); MÁS, ROSA (7007164572); FERNÁNDEZ, L. (7202848319); FERNÁNDEZ, J. (9432805500); CASTAÑO, G. (7005759008)","COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS",1999,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","19","10",79,"","ENRIQUE CABRERA HOSPITAL, HAVANA, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HABANA, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HABANA, CUBA, CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HABANA, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HABANA, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA, CUBA","THIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) AND LOVASTATIN (20 MG/DAY) IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS. AFTER 6 WEEKS ON A LIPID LOWERING DIET, 53 PATIENTS WERE RANDOMIZED TO RECEIVE EITHER POLICOSANOL OR LOVASTATIN TABLETS THAT WERE TAKEN O.I.D. FOR 12 WEEKS UNDER DOUBLE-BLIND CONDITIONS. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. POLICOSANOL SIGNIFICANTLY (P < 0.001) LOWERED LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL (20.4%), TOTAL CHOLESTEROL (14.2%) AND THE RATIO OF LDL-CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL (23.7%). LOVASTATIN SIGNIFICANTLY (P < 0.01) LOWERED LDL-CHOLESTEROL (16.8%), TOTAL CHOLESTEROL (14.0%) AND THE RATIO (P < 0.05) OF LDL-CHOLESTEROL TO HDL-CHOLESTEROL (14.9%). TRIGLYCERIDE LEVELS DID NOT SIGNIFICANTLY CHANGE AFTER THERAPY. POLICOSANOL, BUT NOT LOVASTATIN, SIGNIFICANTLY INCREASED (P < 0.01) LEVELS OF HDL-CHOLESTEROL (7.5%). COMPARISON BETWEEN GROUPS SHOWED THAT CHANGES IN HDL-CHOLESTEROL INDUCED BY POLICOSANOL WERE SIGNIFICANTLY GREATER (P < 0.01) THAN THOSE INDUCED BY LOVASTATIN. BOTH TREATMENTS WERE SAFE AND WELL TOLERATED. LOVASTATIN MODERATELY BUT SIGNIFICANTLY (P < 0.05) INCREASED LEVELS OF ASPARTATE AMINOTRANSFERASE, CREATINE PHOSPHOKINASE AND ALKALINE PHOSPHATASE. ADVERSE REACTIONS WERE MORE FREQUENT IN THE LOVASTATIN GROUP (P < 0.01) THAN IN THE POLICOSANOL GROUP. IN CONCLUSION, POLICOSANOL ADMINISTERED AT 10 MG/DAY PRODUCES MORE ADVANTAGEOUS CHANGES IN HDL-CHOLESTEROL AND HAS A BETTER SAFETY AND TOLERABILITY PROFILE THAN LOVASTATIN 20 MG/DAY.","","ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HEADACHE; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLICOSANOL; TRIACYLGLYCEROL; ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; VERTIGO","","","WETTERHALI S.F., OLSON D.R., DESTEFANO F., ET AL., TRENDS IN DIABETES AND DIABETIC COMPLICATIONS, DIABETES CARE, 15, (1992); SASAKI A., UEHARA M., HORIUCHI N., ET AL., A 15-YEAR FOLLOW-UP STUDY OF PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) IN OSAKA, JAPAN LONG-TERM PROGNOSIS AND CAUSES OF DEATH, DIABETES RES. CLIN. PRACT., 34, (1996); ROSENGREN A., WELIN L., TSIPOGIANNI A., ET AL., IMPACT OF CARDIOVASCULAR RISK FACTORS ON CORONARY HEART DISEASE AND MORTALITY AMONG MIDDLE AGED DIABETIC MEN: A GENERAL POPULATION STUDY, BR MED. J., 299, (1989); LAAKSO M., RONNEMAA T., LEHTO S., ET AL., DOES NIDDM INCREASE THE RISK FOR CORONARY HEART DISEASE SIMILARLY IN BOTH LOW- AND HIGH-RISK POPULATIONS?, DIABETOLOGIA, 38, (1995); ABBOT R.D., DONAHUE P.P., KANNELV W.B., ET AL., THE IMPACT OF DIABETES ON SURVIVAL FOLLOWING MYOCARDIAL INFACRTION IN MEN VS WOMEN: THE FRAMINGHAM STUDY, JAMA, 260, (1988); MALMBERG K., RYDEN L., MYOCARDIAL INFARCTION IN PATIENTS WITH DIABETES, EUR. HEART J., 9, (1988); PYORALA K., LAAKSO M., UUSITUPA M., DIABETES AND ATHEROSCLEROSIS. AN EPIDEMIOLOGICAL VIEW, DIABETES METAB. REV., 3, (1987); LAAKSO M., EPIDEMIOLOGY OF DIABETIC DYSLIPIDEMIA, DIABETES REV., 3, (1995); SCHEEN A.J., LEFEBVRE P.J., PATHOPHYSIOLOGY OF TYPE 2 DIABETES, HANDBOOK OF EXPERIMENTAL PHARMACOLOGY: ORAL ANTIDIABETICS, PP. 7-42, (1995); BETTERIDGE D.J., DIABETIC DYSLIPIDEMIA, AM. J. MED., 96, (1994); SIEGEL R.D., CUPPLESS A., SCHAEFER E.J., ET AL., LIPOPROTEINS APOLIPOPROTEINS, AND LOW-DENSITY LIPOPROTEIN SIZE AMONG DIABETES IN THE FRAMINGHAM OFFSPRING, METABOL., 45, (1996); CHISOLM G.M., IRWIN K.C., PENN M.S., LIPOPRCTEIN OXIDATION AND LIPOPROTEIN-INDUCED CELL INJURY IN DIABETES, DIABETES, 41, (1992); BUCALA R., MAKITA A., VEGA G., ET AL., MODIFICATION OF LOW-DENSITY LIPOPROTEIN BY ADVANCED GLYCATION END PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL INSUFFICIENCY, PROC. NATL. ACAD. SCI., 91, (1994); LOPES-VIRELLA M.F., KLEIN R.L., LYONS T.J., STEVENSON H.C., WITZTUM J.L., GLYCOSYLATION OF LOW DENSITY LIPOPROTEINS ENHACES CHOLESTERYL ESTER SYNTHESIS IN HUMAN MONOCYTE-DERIVED MACROPHAGES, DIABETES, 37, (1998); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, (1984); FRICK M.E., ELO O., HAAPA K., HELSINKI HEART STUDY: PRIMARY INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE AGED MEN WITH DISLYPIDEMIA, N. ENGL. J. MED., 317, (1987); KOSKINEN P., MANTTARI M., MANNINEN V., ET AL., CORONARY HEART DISEASE INCIDENCE IN NIDDM PATIENTS IN THE HELSINKI HEART STUDY, DIABETES CARE, 15, (1992); PYORALA K., PEDERSEN T.R., KJEKSHUS J., ET AL., CHOLESTEROL LOWERING WITH SIMVASTATIN IMPROVES PROGNOSIS OF DIABETIC PATIENTS WITH CORONARY HEART DISEASE, DIABETES CARE, 20, (1997); SAVAGE P.J., CARDIOVASCULAR COMPLICATIONS OF DIABETES MELLIOTUS: WHAT WE KNOW AND WHAT WE NEED TO KNOW ABOUT THEIR PREVENTION, ANN. INTERN. MED., 124, (1996); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, (1993); SOCIETY STRATEGIES FOR THE PREVENTION OF CORONARY HEART DISEASE: A POLICY STATEMENT OT THE EUROPEAN ATHEROSCLEROSIS SOCIETY, EUR. HEART. J., 8, (1987); HENWOOD J.M., HEEL R.C., LOVASTATIN: A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC PROPERTIES AND THERAPEUTIC USE IN HYPERLIPIDAEMIA, DRUGS, 36, (1988); MITCHEL Y.B., THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, (1992); WALKER J.F., WORLWIDE EXPERIENCES WITH SIMVASATIN/LOVASTATIN, EUR. HEART. J., 13, SUPPL. B, (1992); GARG A., GRUNDY M.D., MANAGEMENT OF DYSLIPIDEMIA IN NIDDM, DIABETES CARE, 13, (1990); GOLBERG R., LA BELLE P., ZUPKIS R., RONCA P., COMPARISON OF THE EFFECTS OF LOVASTATIN AND GENFIBROZIL ON LIPIDS AND GLUCOSE CONTROL IN NON-INSULIN-DEPENDENT DIABETES MELLITUS, AM. J. CARDIOL., 66, (1990); YOSHINO G., KASUMI T., IWAI M., ET AL., TRATAMIENTO A LARGO PLAZO DE LA HIPERCOLESTEROLEMIA EN DIABETICOS NO INSULINO DEPENDIENTES CON PRAVASTATINA, ATHEROSCLEROSIS, 75, (1989); CASSADER M., RUIU G., AMBINO R., ALEMANNO N., VEGLIA F., PAGANO G., HYPERCHOLESTEROLEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS: DIFFERENT EFFECT OF SIMVASTATIN ON VLDL AND LDL CHOLESTEROL LEVELS, ATHEROSCLEROSIS, 99, (1993); SUGIMOTO T., PRAVASTATIN VERSUS SIMVASTATIN IN HYPERLIPIDEMIC PATIENTS WITH TYPE 2 DIABETES MELLITUS, CURR. THER. RES., 60, (1999); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMANFIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPEROHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J. CLIN. PHARMACOL RES., 14, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL ON LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERRIBILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HIPERLIPOPROTEINEMIA: A 12-MONTH STUDY, CURR. THER. RES., 56, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES OF SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, (1996); CAMPILONGO R., SANDINI R., FELDMAN R., ET AL., ETICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, LA PRENSA MEDICA ARGENTINA, 83, (1996); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEN L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR. THER. RES., 59, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECT OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROIEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY J. VASC. DIS., 50, (1996); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPORCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AMER. J. MED., 100, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); NESTE R.W., NEW INSIGHTS IN DIABETES AND CORONARY ARTERY DISEASE, PROC. XITH INT. SYMP. ATHEROSCLEROSIS, (1997); ATHEROSCLEROSIS, 11, (1998); RANDOMIZED TIRAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORTONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PAITENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENG. J. MED., 35, (1996); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, (1984); SHEPERD J., COBBE S.M., CHRISTOPHER G., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENG. J. MED., 333, (1995); CASTANO G., ILLNAIT J., FERNANDEZ L., ET AL., ESTUDIO DOSISEFECFO DE LA ACCION HIPOCOLESTEROLIMICA DEL POLICOSANOL EN PACIENTES CON HIPERIRPOPROTEINEMIA TIPO II, REV. CENIC CIEN. BIOL., 27, (1996); CASTANO G., NODARSE M., MAS R., ET AL., COMPARACIONES DE LOS EFECTOS DEL POLICOSANOL Y LA LOVASTATINA EN PACIENTES CON HIPERCOLESTEROLEMIA PRIMARIA TIPO II, REV. CENIC CIEN. BIOL., 27, (1996); BRADFORD R.H., SHEAR C.S., CHREMOS A.N., EXPANDED CLINICAL EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS. I. EFFICACY IN MODIFYING PLASMA LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8 245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA, ARCH. INTERN. MED., 151, (1991); DAVIDSON M., MCKENNEY J., STEIN E., ET AL., COMPARISON OF ONE-YEAR EFFICACY AND SAFETY OF ATORVASTATIN VERSUS LOVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 79, (1997); D'AGOSTINC R.B., KANNEL W.B., STEPANIANS M.N., ET AL., EFFICACY AND TOLERABILITY OF LOVASTATIN IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CLIN THER., 14, (1992); SYVANNE M., KAHN J., VITRANEN K.S., ET AL., HDLS CONTAINING APOLIPOPROTEINS A-I AND A-II (LPA-I, A-II) AS MARKERS OF CORONARY ARTERY DISEASE IN MEN WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS, CIRCULATION, 92, (1995)","R. MAS; CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER SCIENTIFIC RESEARCH, HAVANA, PO BOX 6990, CUBA; EMAIL: DALMER@IP.ETECSA.CU","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0033358535","INT J CLIN PHARMACOL RES","ENRIQUE CABRERA HOSPITAL;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;SURGICAL MEDICAL RESEARCH CENTER","NOTREPORTED;NATIONAL CENTER SCIENTIFIC RESEARCH;NOTREPORTED",NA,"CRESPO N, 1999, INT J CLIN PHARMACOL RES","CRESPO N, 1999, INT J CLIN PHARMACOL RES"
"TANCER R","TANCER, ROBERT S. (6507820911)","THE PHARMACEUTICAL INDUSTRY IN CUBA",1995,"CLINICAL THERAPEUTICS","17","7",12,"10.1016/0149-2918(95)80056-5","THE AMERICAN GRADUATE SCHOOL OF INTERNATIONAL MANAGEMENT, GLENDALE, UNIVERSITY OF ARIZONA MEDICAL SCHOOL, TUCSON, AZ, UNITED STATES","CUBA HAS DEVELOPED A RELATIVELY SOPHISTICATED PHARMACEUTICAL SECTOR, ORIGINALLY TO PROVIDE MEDICINAL PRODUCTS FOR HER OWN POPULATION AND, MORE RECENTLY, TO EARN HARD CURRENCY THROUGH EXPORTS. CUBA HAS ACHIEVED BOTH OF THESE GOALS DESPITE THE US TRADE EMBARGO, WHICH ISOLATES CUBA FROM COMMERCIAL RELATIONS WITH US FIRMS. CUBA IS OPENING ITS ECONOMY TO FIRMS FROM OTHER COUNTRIES THROUGH THE USE OF JOINT VENTURES AND OTHER FORMS OF COOPERATION. US FIRMS ARE UNABLE TO AVAIL THEMSELVES OF THESE OPPORTUNITIES, AND THE OPPORTUNITIES ARE THUS BEING LOST. IN THE CASE OF PHARMACEUTICALS, THE CUBANS RECOGNIZE THAT THEY NEED ASSISTANCE, PARTICULARLY IN THE AREAS OF MARKETING AND PACKAGING. ALLOWING THE PARTICIPATION OF US FIRMS IN THE CUBAN PHARMACEUTICAL INDUSTRY COULD ENHANCE THE POSSIBILITY OF IMPROVING WORLDWIDE HEALTH CARE. © 1995.","","BIOTECHNOLOGY; CUBA; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; HUMANS; HEPATITIS B VACCINE; HYPOCHOLESTEROLEMIC AGENT; MENINGOCOCCUS VACCINE; POLICOSANOL; PPG 5; UNCLASSIFIED DRUG; ARTICLE; BIOTECHNOLOGY; CUBA; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMIC ASPECT; HEALTH CARE; MARKETING; UNITED STATES","","","GREENHOUSE, ALLIES OF US SEEK TO BLOCK BILL TIGHTENING CUBAN CURBS, THE NEW YORK TIMES; CUBA'S FAMILY DOCTOR PROGRAMME, (1992); CUBA'S FAMILY DOCTOR PROGRAMME, (1992); CUBA'S FAMILY DOCTOR PROGRAMME, (1992); CUBA'S FAMILY DOCTOR PROGRAMME, (1992); CUBA'S FAMILY DOCTOR PROGRAMME, (1992); BUTLER, CUBA'S REVOLUTIONARY MEDICINE, CUBA'S REVOLUTIONARY MEDICINE, 1; HEMMES, HOSP HEALTH NET, (1994); CHARACTERIZATION OF BIOTECHNOLOGY AND THE MEDICAL-PHARMACEUTICAL INDUSTRY IN CUBA, (1994); BLANCO, LA INDUSTRIA BIOFARMACÉUTICA EN CUBA: POSIBILIDADES Y DESAFIOS/THE CUBAN BIOPHARMACEUTICAL INDUSTRY OPPORTUNITIES AND CHALLENGES, CUBA FOREIGN TRADE, PP. 48-49, (1994); BEHIND CUBAN SMILES, FINANCIAL TIMES; CUBAN DRUG INDUSTRY A RISING STAR, PHARM MANUFACTURING REV, (1994); FEINSILVER, CAN BIOTECHNOLOGY SAVE THE REVOLUTION?, NACLA REPORT ON THE AMERICAS, 26, 5, (1993); DECRETO LEY 50 SOBRE ASOCIACION ECONOMICA ENTRE ENTIDADES CUBANS Y EXTRANJERAS, INTRODUCTION TO COPY OF LAW DISTRIBUTED BY CUBAN CHAMBER OF COMMERCE AND OBTAINED BY AUTHOR IN HAVANA, (1994); CUBA: HANDBOOK OF TRADE STATISTICS, (1993)","","","ENGLISH","CLIN. THER.","ARTICLE","ISI","2-S2.0-0029155909","CLIN THER",NA,"NOTREPORTED",NA,"TANCER RS, 1995, CLIN THER","TANCER RS, 1995, CLIN THER"
"RODRÍGUEZ M;GÁMEZ R;SÁNCHEZ M;GARCÍA H","RODRÍGUEZ, MARÍA D. (57220829332); GÁMEZ, RAFAEL (7003605346); SÁNCHEZ, MARIBEL (57220881836); GARCÍA, HAYDEE (7202282339)","DEVELOPMENTAL TOXICITY OF D002 A MIXTURE OF ALIPHATIC PRIMARY ALCOHOLS IN RATS AND RABBITS",1998,"JOURNAL OF APPLIED TOXICOLOGY","18","3",13,"10.1002/(SICI)1099-1263(1998090)18:5<313::AID-JAT513>3.0.CO;2-8","DEPARTMENT OF TOXICOLOGY, NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF TOXICOLOGY, NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF TOXICOLOGY, NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;DEPARTMENT OF TOXICOLOGY, NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA","D-002 IS A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS, PRIMARILY ISOLATED AND PURIFIED FROM BEESWAX, THAT HAS MODERATE ANTI-INFLAMMATORY AND EFFECTIVE ANTI-ULCER ACTIVITY. IN THE PRESENT STUDY THE DEVELOPMENTAL TOXICITY IN SPRAGUE-DAWLEY RATS AND NEW ZEALAND WHITE RABBITS WAS EVALUATED. DOSES OF 100, 320 AND 1000 MG KG-1 WERE ADMINISTERED ONCE DAILY BY GAVAGE TO PREGNANT FEMALES ON GESTATION DAYS 6-15 (RATS) OR 6-18 (RABBITS). REPRODUCTIVE INDICES WERE DETERMINED AND FOETUSES WERE EXAMINED FOR EXTERNAL, VISCERAL AND SKELETAL MALFORMATIONS. THERE WAS NO INDICATION OF EMBRYOTOXICITY, FETOTOXICITY OR TERATOGENICITY IN ANY OF THE TREATED GROUPS. IT IS CONCLUDED THAT D-002 IS DEVOID OF TERATOGENIC OR EMBRYOTOXIC EFFECTS IN THESE STRAINS.","DEVELOPMENTAL TOXICITY; POLICOSANOL; RABBIT; RAT","ANIMALS; FATTY ALCOHOLS; FEMALE; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS; ALCOHOL DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTIULCER AGENT; D 002; PROPOLIS; UNCLASSIFIED DRUG; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG SAFETY; EMBRYOTOXICITY; FEMALE; FETOTOXICITY; FETUS; FETUS DEATH; FETUS MALFORMATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; SKELETON MALFORMATION; TERATOGENICITY","","","CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., ANTI-ULCER ACTIVITY OF HIGHER PRIMARY ALCOHOLS OF BEESWAX, J. PHARM. PHARMACOL., 47, PP. 731-733, (1995); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., POSSIBLE MECHANISM CYTOPROTECTIVE OF D-002, J. PHARM. PHARMACOL., 48, PP. 858-860, (1996); CARBAJAL D., MOLINA V., VALDES S., ARRUZAZABALA L., MAS R., MAGRANER J., ANTI-INFLAMMATORY ACTIVITY OF D-002: AN ACTIVE PRODUCT ISOLATED FROM BEESWAX, PROSTAGLAND. LEUKOTRIENE. ESSENT. FATTY ACIDS; RODEIRO I., ALEMAN C., MAS R., NOA M., BRINIS F., HERNANDEZ C., TOXICOLOGÍA AGUDA ORAL DEL D-002 EN RATAS SPRAGUE-DAWLEY, REV. CENIC CIENC. BIOL, 26, PP. 34-36, (1995); RODEIRO I., (1996); RODEIRO I., ALEMAN C., NOA M., MENENDEZ R., MAS R., HERNANDEZ C., GARCIA M., PRECLINICAL ORAL TOXICOLOGY IN RATS OF D-002, A NATURAL DRUG WITH ANTIULCER EFFECTS, DRUG CHEM. TOXICOL., 21, PP. 151-162, (1998); KOPF R., LORENZ D., SALEWSKI E., PROCEDURE FOR STAINING IMPLANTATION SITES OF FRESH RAT UTERI, NAUNYN-SCHMIEDEBERG'S ARCH. EXP. PATHOL. PHARMACOL., 247, PP. 121-135, (1964); STUCKHART J.L., POPPE S.M., FRESH VISCERAL EXAMINATION OF RAT AND RABBIT FOETUSES USED IN TERATOGENICITY TESTING, TERATOGEN. CARCINOGEN. MUTAGEN., 4, PP. 181-188, (1984); DAWSON A.B., A NOTE ON THE STAINING OF THE SKELETON OF CLEARED SPECIMENS WITH ALIZARIN RED S, STAIN. TECHNOL., 1, PP. 123-124, (1926); PALMER A.K., SPONTANEOUS MALFORMATIONS OF THE NEW ZEALAND WHITE RABBIT: THE BACKGROUND TO SAFETY EVALUATION TEST, LAB. ANIM., 2, PP. 195-206, (1968); KHERA K.S., COMMON FOETAL ABERRATIONS AND THEIR TERATOLOGIC SIGNIFICANCE: A REVIEW, FUNDAM. APPL. TOXICOL., 1, PP. 13-18, (1981); MANSON J., KANG T., TEST METHODS FOR ASSESSING FEMALE REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 311-359, (1989)","","","ENGLISH","J. APPL. TOXICOL.","ARTICLE","ISI","2-S2.0-0031684255","J APPL TOXICOL",NA,"NOTREPORTED",NA,"RODRÍGUEZ MD, 1998, J APPL TOXICOL","RODRÍGUEZ MD, 1998, J APPL TOXICOL"
"URIBARRI E;LAGUNA A;SIERRA R;RICARDO Y","URIBARRI, E. (6505806794); LAGUNA, A. (7006455910); SIERRA, R. (7006854525); RICARDO, Y. (19036229900)","PHYSICOMECHANICAL CHARACTERIZATION OF POLICOSANOL A NOVEL HYPOCHOLESTEROLEMIC DRUG",2002,"DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY","28","4",9,"10.1081/DDC-120001489","LABORATORIOS MEDSOL, LISA, HAVANA, AVE. 23 AND 266, CUBA;PLAYA, HAVANA, P.O. BOX 6990, CUBA;PLAYA, HAVANA, P.O. BOX 6990, CUBA;PLAYA, HAVANA, P.O. BOX 6990, CUBA","AS PART OF THE FORMULATION STUDIES OF POLICOSANOL, A NEW HYPOCHOLESTEROLEMIC DRUG, A PHYSICO-MECHANICAL CHARACTERIZATION WAS DEVELOPED. THERMAL ANALYSIS, USING DIFFERENTIAL SCANNING CALORIMETRY WAS USED TO EVALUATE THE PURITY OF POLICOSANOL FROM BATCH TO BATCH AND, ALSO, THE PARTICLE SIZE DISTRIBUTION. THE DEGREE OF WETTABILITY OF POLICOSANOL WAS STUDIED BY MEASURING THE CONTACT ANGLE AND SOLUBILITY IN DIFFERENT SOLVENTS. THE COMPRESSIBILITY AND COHESION OF PARTICLES WERE EVALUATED USING A PROFILE OF COMPRESSION FORCES, RANGING BETWEEN 6.5 KN AND 39.0 KN. ALSO, OTHER PROPERTIES SUCH AS FLOW PROPERTIES, TRUE DENSITY, AND TAPPED AND BULK DENSITY WERE MEASURED. THE INDUSTRIAL BATCHES OF POLICOSANOL THAT WERE STUDIED SHOW AN ADEQUATE PURITY AND A UNIFORM DISTRIBUTION OF THE PARTICLE SIZES. POLICOSANOL SHOWS GOOD FLOW PROPERTIES, COMPRESSIBILITY, AND COHESION AS WELL AS A LOW SOLUBILITY IN THE MAJORITY OF THE SOLVENTS USED IN THE PHARMACEUTICAL INDUSTRY, AND ITS SOLUBILITY IN WATER OR IN AQUEOUS SOLUTIONS WAS, MAINLY, NULL. THE WETTABILITY OF POLICOSANOL IN THE DIFFERENT SOLVENTS SHOWS THE FOLLOWING ORDER: METHYLENE CHLORIDE > ETHANOL > ACETONE ≫ WATER.","","ANTICHOLESTEREMIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; FATTY ALCOHOLS; PARTICLE SIZE; SOLUBILITY; SOLVENTS; ACETONE; ALCOHOL; DICHLOROMETHANE; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; SOLVENT; WATER; ARTICLE; DENSITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG INDUSTRY; DRUG PURITY; DRUG SOLUBILITY; PARTICLE SIZE; TABLET COMPRESSION; TABLET FORMULATION; TABLET PROPERTY; THERMAL ANALYSIS; WETTABILITY","","","WELLS J.I., PHARMACEUTICAL FORMLATION: THE PHYSICOCHEMICAL PROPERTIES OF DRUG SUBSTANCES, 13, (1988); ARRUZAZAZBALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., BIOL. RES., 27, PP. 205-208, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., BR. J. NUTR., 77, PP. 923-932, (1997); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., CURR. THER. RES. CLIN., 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., MAS R., ET AL., CURR. THER. RES. CLIN., 55, PP. 1084-1092, (1994); CASTANO G., TULA L., CANETTI M., ET AL., CURR. THER. RES. CLIN., 57, PP. 691-699, (1995); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; LIEBERMAN H., LACHMAN L., SCHWARTZ J., PHARMACEUTICAL DOSAGE FORM: TABLETS, VOL. 1, 2ND EDN., 1, (1986); REMINGTON R., THE SCIENCE AND PRACTICE OF PHARMACY, 18TH EDN., (1990); JONES T.M., PILPEL N., J. PHARM. PHARMACOL., 18, SUPPL., (1966)","A. LAGUNA; CENTER OF NATURAL PRODUCTS, C.N.I.C., PLAYA, HAVANA, P.O. BOX 6990, CUBA; EMAIL: DALMER@IP.ETECSA.CU","","ENGLISH","DRUG DEV. IND. PHARM.","ARTICLE","ISI","2-S2.0-0036214585","DRUG DEV IND PHARM","LABORATORIOS MEDSOL","NOTREPORTED;CENTER OF NATURAL PRODUCTS;NOTREPORTED",NA,"URIBARRI E, 2002, DRUG DEV IND PHARM","URIBARRI E, 2002, DRUG DEV IND PHARM"
"MARTÍNEZ L;URIBARRI E;LAGUNA A","MARTÍNEZ, LUIS (57197030971); URIBARRI, EVANGELINA (6505806794); LAGUNA, ABILIO (7006455910)","CHARACTERIZATION AND COMPATIBILITY STUDIES BETWEEN POLICOSANOL A NEW HYPOCHOLESTEROLEMIC DRUG AND TABLET EXCIPIENTS USING DIFFERENTIAL SCANNING CALORIMETRY DSC",1999,"ARCHIV DER PHARMAZIE","332","2",9,"10.1002/(SICI)1521-4184(199912)332:12<439::AID-ARDP439>3.0.CO;2-5","ANALYTICAL DEPARTMENT, CIDEM, CERRO, HAVANA, AVE 26 AND PUENTES GRANDES, CUBA;LABORATORIOS MEDSOL, LISA, HAVANA, AVE 23 AND 266, CUBA;PLAYA, HAVANA, P. BOX 6880, CUBA","CHARACTERISATION OF POLICOSANOL, A NEW ACTIVE PRINCIPLE COMPOSED OF 8 HIGH MOLECULAR WEIGHT FATTY ALCOHOLS, VIZ. 1-TETRACOSANOL, 1-HEXACOSANOL, 1- HEPTACOSANOL, 1-OCTACOSANOL, 1-NONACOSANOL, 1-TRIACONTANOL, 1-DOTRIACONTANOL, AND 1-TETRATRIACONTANOL, SHOWS IT HAVE A VERY STABLE, WELL DEFINED COMPOSITION WHICH IS REPRODUCIBLE FROM BATCH TO BATCH. COMPATIBILITY STUDIES BY DIFFERENTIAL SCANNING CALORIMETRY (DSC) AND THERMOGRAVIMETRY (TG) GAVE VERY USEFUL PHYSICOCHEMICAL INFORMATION AND REVEAL THE CHARACTERISTIC TRANSITIONS, AS WELL AS THE THERMAL STABILITY OF THIS DRUG. DSC FACILITATED COMPATIBILITY STUDIES BETWEEN POLICOSANOL AND SEVERAL TABLET EXCIPIENTS GENERALLY USED FOR THE MANUFACTURE OF THIS PHARMACEUTICAL DOSAGE FORM. IT IS SEEN THAT THE COMBINATION OF POLICOSANOL WITH EACH EXCIPIENT IN EVERY ONE OF THE RATIOS USED DID NOT PRODUCE ANY CHANGES IN THE MELTING POINT OF POLICOSANOL OR THOSE OF THE EXCIPIENTS MIXED WITH IT. ALSO, NO NEW PEAKS WERE OBSERVED IN THE POLICOSANOL/EXCIPIENT MIXTURES. IT CAN BE CONCLUDED FROM THESE RESULTS THAT NO DISSOLUTION OF POLICOSANOL IN THE EXCIPIENTS OCCURS, AND ALSO THAT NO PHYSICOCHEMICAL INTERACTIONS TAKE PLACE BETWEEN THEM.","DSC; EXCIPIENTS; INTERACTIONS; POLICOSANOL; THERMOGRAVIMETRY","HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ANALYSIS; DRUG DOSAGE FORM; DRUG STABILITY; MELTING POINT; PRIORITY JOURNAL; REPRODUCIBILITY; TABLET FORMULATION; THERMOGRAVIMETRY","","","LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; LAGUNA A., MAGRANER J., RAMOS R., URIBARRI E., PERDOMO U.G., CARBAJAL D., ARRUZAZABALA M.L., MARTINEZ J., LORENZO M., MONTEJO L., MAS R.; URIBARRI E., LAGUNA A., RICARDO Y., DRUG DEVELOP. IND. PHARMACY, (1999); PECK G.E., BALEY G.J., MCCURDY V.E., BANKER G.S., TABLET FORMULATION AND DESIGN OF PHARMACEUTICAL DOSAGE FORMS: TABLETS, 1, (1989); WELLS J.I., PHARMACEUTICAL FORMULATION, THE PHYSICOCHEMICAL PROPERTIES OF DRUG SUBSTANCES, (1988); MULLER B.W., ACTA PHARM. TECHNOL., 23, (1977); BOTHA B.W., LOTTER A.P., DRUG DEVELOP. IND. PHARMACY, 16, PP. 673-683, (1990); BOTHA S.A., LOTTER A.P., DRUG DEVELOP. IND. PHARMACY, 15, PP. 415-426, (1990); BOTHA S.A., LOTTER A.P., DRUG DEVELOP. IND. PHARMACY, 16, PP. 1945-1954, (1990); CIRANNI E., ET AL., DRUG DEVELOP. IND. PHARMACY, 12, PP. 603-620, (1986)","","","ENGLISH","ARCH. PHARM.","ARTICLE","ISI","2-S2.0-0343049107","ARCH PHARM",NA,"NOTREPORTED",NA,"MARTÍNEZ L, 1999, ARCH PHARM","MARTÍNEZ L, 1999, ARCH PHARM"
"CASTAÑO G;FERREIRO R;FERNÁNDEZ L;GÁMEZ R;ILLNAIT J;FERNÁNDEZ J","CASTAÑO, GLADYS (56232967100); FERREIRO, ROSA MÁS (6602148780); FERNÁNDEZ, LILIA (7202848319); GÁMEZ, RAFAEL (7003605346); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, JULIO CÉSAR (9432805500)","A LONGTERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION",2001,"ANGIOLOGY","52","10",37,"10.1177/000331970105200205","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS. THIS STUDY WAS UNDERTAKEN TO INVESTIGATE THE LONG-TERM EFFECTS OF POLICOSANOL ADMINISTERED TO PATIENTS WITH MODERATELY SEVERE INTERMITTENT CLAUDICATION. THE STUDY CONSISTED OF A 6-WEEK SINGLE-BLIND, PLACEBO-CONTROLLED RUN IN PHASE, FOLLOWED BY A 2-YEAR DOUBLE-BLIND, RANDOMIZED TREATMENT STEP. FIFTY-SIX PATIENTS WHO MET STUDY ENTRY CRITERIA WERE RANDOMIZED TO RECEIVE PLACEBO OR POLICOSANOL 10 MG TWICE DAILY. WALKING DISTANCES ON A TREADMILL (CONSTANT SPEED 3.2 KM/H, SLOPE 10°, TEMPERATURE 25°C) WERE ASSESSED BEFORE AND AFTER 6, 12, 18, AND 24 MONTHS OF TREATMENT. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. AFTER 6 MONTHS OF THERAPY, POLICOSANOL SIGNIFICANTLY INCREASED (P < 0.01) THE INITIAL CLAUDICATION DISTANCE FROM 125.9 ±8.7 M TO 201.1 ±24.8 M AND THE ABSOLUTE CLAUDICATION DISTANCE FROM 219.5 ± 14.1 M TO 380.7 ±50.2 M. BOTH VARIABLES REMAINED UNCHANGED IN THE PLACEBO GROUP (P<0.01). THESE EFFECTS DID NOT WEAR OFF BUT IMPROVED AFTER LONG-TERM THERAPY, SO THAT FINAL VALUES WERE 333.5 ±28.6 M (INITIAL CLAUDICATION DISTANCE) AND 648.9 ±54.1 M (ABSOLUTE CLAUDICATION DISTANCE); BOTH SIGNIFICANTLY GREATER (P<0.0001) THAN THOSE OBTAINED IN THE PLACEBO GROUP, WHICH SHOWED VALUES OF 137.9 ±21.8 M (INITIAL CLAUDICATION DISTANCE) AND 237.7 ±28.1 M (ABSOLUTE CLAUDICATION DISTANCE), RESPECTIVELY. AT STUDY COMPLETION, 21 POLICOSANOL AND 5 PLACEBO PATIENTS ATTAINED INCREASES IN CLAUDICATION DISTANCE VALUES > 50% (P < 0.001). POLICOSANOL, BUT NOT PLACEBO, SIGNIFICANTLY INCREASED THE ANKLE/ARM PRESSURE INDEX. IN ADDITION, FROM MONTH 6 UP TO STUDY COMPLETION, THE FREQUENCY OF PATIENTS REPORTING IMPROVEMENT OF LOWER LIMB SYMPTOMS WAS GREATER IN THE POLICOSANOL GROUP THAN IN THE PLACEBO GROUP. THE TREATMENT WAS TOLERATED WELL. THERE WERE 16 WITHDRAWALS (12 PLACEBO, 4 POLICOSANOL) FROM THE STUDY. EIGHT PATIENTS IN THE PLACEBO GROUP EXPERIENCED A TOTAL OF 10 SERIOUS ADVERSE EVENTS, 8 OF WHICH WERE VASCULAR EVENTS, COMPARED WITH NONE IN THE POLICOSANOL GROUP (P<0.01). IN ADDITION, 3 PATIENTS IN THE POLICOSANOL GROUP AND 3 PATIENTS IN THE PLACEBO GROUP REPORTED MILD ADVERSE EVENTS DURING THE STUDY. THE PRESENT RESULTS DEMONSTRATE THE LONG-TERM USEFULNESS OF POLICOSANOL THERAPY TO TREAT PATIENTS WITH INTERMITTENT CLAUDICATION.© 2001 SAGE PUBLICATIONS.","","ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL; DOUBLE-BLIND METHOD; EXERCISE TEST; FATTY ALCOHOLS; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; TIME FACTORS; TRIGLYCERIDES; WALKING; PLACEBO; POLICOSANOL; ADULT; AGED; AMNESIA; ANKLE PRESSURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INSOMNIA; INTERMITTENT CLAUDICATION; LEG; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREADMILL EXERCISE; UNSTABLE ANGINA PECTORIS; VERTIGO; WALKING","","","VERHAEGHE R., EPIDEMIOLOGIC ET PRONOSTIC DE L'ARTERIOPATHIC OBLITERANTE DES MEMBRES INFERIEURS, DRUG, 56, PP. 1-10, (1998); MARQUIS P., EVALUATION DE L'IMPACT DE L'ARTERIOPATHIC OBLITERANTE DES MEMBRES INFERIEUOS SUR LA QUARTE DE VIE, DRUGS, 56, PP. 25-35, (1998); CRIQUI M., LANGER R.D., FRONEK A., A MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE, N ENGL J MED, 326, PP. 381-386, (1992); BOWLIN S.J., MEDALIE J.H., FLOCKE S.A., ET AL., EPIDEMIOLOGY OF INTERMITTENT CLAUDICATION IN MIDDLE-AGED MEN, AM J EPIDEMIOL, 140, PP. 418-430, (1994); FOWKES F.G.R., HOUSLEY E., RIEMERSMA R.A., ET AL., SMOKING, LIPIDS, GLUCOSE INTOLERANCE AND BLOOD PRESSURE AS RISK FACTORS FOR PERIPHERAL ATHEROSCLEROSIS COMPARED WITH ISCHEMIC HEART DISEASE IN THE EDINBURGH ARTERY STUDY, AM J EPIDEMIOL, 135, PP. 331-340, (1992); LOWE G.D.O., FOWKES F.G.R., DAWES J., ET AL., BLOOD VISCOSITY, FIBRINOGEN AND ACTIVATION OF COAGULATION AND LEUCOCYTES IN PERIPHERAL ARTERIAL DISEASE AND THE NORMAL POPULATION IN THE EDINBURGH ARTERY STUDY, CIRCULATION, 87, PP. 1915-1920, (1993); SECOND EUROPEAN CONSENSUS DOCUMENT ON CHRONIC CRITICAL LEG ISCHEMIA, CIRCULATION, 84, PP. 1-26, (1991); GARDNER A.W., POEHLMAN E.T., EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT OF CLAUDICATION PAIN. A META-ANALYSIS, JAMA, 274, PP. 975-980, (1995); LINDAGARDE F., BJORKMAN H., ADIELSSON G., ET AL., CONSERVATIVE DRUG TREATMENT IN PATIENTS WITH MODERATELY SEVERE CHRONIC OCCLUSIVE PERIPHERAL ARTERIAL DISEASE, CIRCULATION, 80, PP. 1549-1556, (1989); REICH T., CUTLER B.S., LEE B.Y., ET AL., PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION OF THE LOWER LIMB, ANGIOLOGY, 35, PP. 389-393, (1984); TONNESEN K.H., ALBUERQUE P., BAITSCH G., ET AL., DOUBLE-BLIND, CONTROLLED MULTICENTER STUDY OF INDUBOFEN VERSUS PLACEBO IN PATIENTS WITH INTERMITTENT CLAUDICATION, INTERN ANGIOL, 12, PP. 371-377, (1993); VERHAEGHE R., PLATELETS IN PERIPHERAL ARTERIAL DISEASE, CRIT ISCHAEMIA, 4, PP. 21-25, (1994); GRESELE P., CATALANO M., GIAMMARESI C., ET AL., PLATELET ACTIVATION MARKERS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE. A PROSPECTIVE COMPARISON OF DIFFERENT PLATELET FUNCTION TESTS, THROMB HAEMOST, 78, PP. 1434-1437, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTHS STUDY, CURR THER RES, 56, PP. 819-828, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A 2-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THERA, 65, PP. 439-447, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 44-51, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAMER TROMB HEMOST, 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOCYTES ESSENTIAL FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.D.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); IATT W.R., NAWAZ D., REGENSTERNER J.G., ET AL., THE EVALUATION OF EXERCISE PERFORMANCE IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE, J CARDIOPULM REHABIL, 12, PP. 525-532, (1998); HEIDRICH H., ALLENBERG J., CACHOVAN M., ET AL., GUIDELINES FOR THERAPEUTIC STUDIES ON PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN FONTAINE STAGES II-IV, VASA, 21, PP. 339-343, (1992); EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). SECOND REPORT OF THE EXPERT PANEL ON DETECTION. EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II). III DRUG TREATMENT, CIRCULATION, 89, PP. 1405-1419, (1994); SEIGLER L., WU T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRA-CENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TEST IN AS SINGLE-EXPERIMENT 5. COMPARING 2 THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); FOWKES F.G.R., LENG G.C., LEE A.J., ET AL., THE ANKLE ARM INDEX AS A PREDICTORS OF CARDIOVASCULAR EVENTS AND DEATH IN THE GENERAL POPULATIONS. ABSTRACTS FROM THE 4TH INTERNATIONAL CONFERENCE IN PREVENTIVE CARDIOLOGY 267B, CAN J CARDIOL, 13, (1997); CASTANO G., FERNANDEZ J.C., MAS R., ET AL., A LONG-TERM OPEN STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1998)","","","ENGLISH","ANGIOLOGY","ARTICLE","ISI","2-S2.0-0035115699","ANGIOLOGY",NA,"NOTREPORTED",NA,"CASTAÑO G, 2001, ANGIOLOGY","CASTAÑO G, 2001, ANGIOLOGY"
"BATISTA J;STÜSSER R;PENICHET M;UGUET E","BATISTA, JUAN (7005814235); STÜSSER, RODOLFO (6602973165); PENICHET, MANUEL (36858021400); UGUET, ENRIQUE (18736551200)","DOPPLERULTRASOUND PILOT STUDY OF THE EFFECTS OF LONGTERM POLICOSANOL THERAPY ON CAROTIDVERTEBRAL ATHEROSCLEROSIS",1995,"CURRENT THERAPEUTIC RESEARCH","56","8",12,"10.1016/0011-393X(95)85094-5","CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;ENRIQUE CABRERA NATIONAL HOSPITAL, HAVANA UNIVERSITY, HAVANA, CUBA","THIS PILOT STUDY WAS CONDUCTED TO DOCUMENT THE BENEFICIAL LIPID-LOWERING EFFECT OF POLICOSANOL ON HEMODYNAMIC CAROTID-VERTEBRAL ATHEROSCLEROSIS (CVA) ABNORMALITIES. TWENTY-TWO PATIENTS WITH MILD CVA, INCLUDING 12 PATIENTS WITH TYPE II HYPERLIPIDEMIA, WERE ENROLLED IN THIS RANDOMIZED, DOUBLE-BLIND, PHASE II, PLACEBO-CONTROLLED TRIAL. ELEVEN PATIENTS RECEIVED 5 MG OF ORAL POLICOSANOL TWICE DAILY, AND 11 PATIENTS RECEIVED PLACEBO TWICE DAILY; ALL PATIENTS WERE TREATED FOR 1 YEAR. FIVE FUNCTIONAL DOPPLER-ULTRASOUND FLOW PARAMETERS WERE MEASURED ON SIX ARTERIES PER PATIENT AND CLASSIFIED BY USING AN OBJECTIVE RESPONSE SYSTEM. IN THE POLICOSANOL GROUP, PROGRESSION AND STABILIZATION OF DISEASE WERE ABSENT, MIXED RESPONSE WAS LOWER, AND REGRESSION WAS SIX TIMES MORE FREQUENT (6 OF 11 PATIENTS); THESE FINDINGS WERE NOT STATISTICALLY SIGNIFICANT COMPARED WITH THE PLACEBO GROUP (P = 0.06). THE PROGRESSION/REGRESSION (P:R) RATIO IN THE POLICOSANOL GROUP HAD A MEAN (0.5) TWO TIMES LOWER THAN THAT IN THE CONTROL GROUP (1.2) (P = 0.03). THE DECREASE IN THE P:R RATIO WAS ASSOCIATED INDEPENDENTLY WITH A MODERATE PERCENT REDUCTION OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO. ALTHOUGH THE SAMPLE SIZE AND 1-YEAR FOLLOW-UP DO NOT ALLOW CONCLUSIONS TO BE DRAWN, THESE RESULTS SUGGEST THAT POLICOSANOL, IN COMBINATION WITH A LOW-FAT DIET, IMPROVES HEMODYNAMIC ABNORMALITIES IN PATIENTS WITH MILD CVA AND NORMAL LIPID LEVELS OR TYPE II HYPERLIPIDEMIA. © 1995.","","ALKANOL; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HEMODYNAMICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRAL ARTERY","","","BLANKENHORN, REGRESSION OF ATHEROSCLEROSIS WHAT DOES IT MEAN?, THE AMERICAN JOURNAL OF MEDICINE, 90, PP. 42S-47S, (1991); CASHIN-HEMPHILL, FEMORAL AND CORONARY ANGIOGRAPHIC TRIALS, THE AMERICAN JOURNAL OF CARDIOLOGY, 71, PP. 20B-25B, (1993); SUPERKO, KRAUSS, CORONARY ARTERY DISEASE REGRESSION CONVINCING EVIDENCE FOR THE BENEFIT OF AGGRESSIVE LIPOPROTEIN MANAGEMENT, CIRCULATION, 90, PP. 1056-1069, (1994); LEVINE, KEANEY, VITA, CHOLESTEROL REDUCTION IN CARDIOVASCULAR DISEASE. CLINICAL BENEFITS AND POSSIBLE MECHANISMS, NEJM, 332, PP. 512-520, (1995); HENNERICI, KLEOPHAS, GRIESW, REGRESSION OF CAROTID PLAQUES DURING LOW DENSITY LIPOPROTEIN CHOLESTEROL ELIMINATION, STROKE, 22, PP. 989-992, (1991); BLANKENHORN, SELZER, CRAWFORD, ET AL., BENEFICIAL EFFECTS OF COLESTIPOL-NIACIN THERAPY ON THE COMMON CAROTID ARTERY, CIRCULATION, 88, PP. 20-28, (1993); FURBERG, ADAMS, APPLEGATE, ET AL., EFFECT OF LOVASTATIN ON EARLY CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS, CIRCULATION, 90, PP. 1679-1687, (1994); RODRIGUEZ-ECHENIQUE, MESA, MAS, EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD AND CHEMICAL TOXICOLOGY, 32, PP. 565-575, (1994); HERNANDEZ, ILLNAIT, MAS, EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS, MAS, ILNAIT, EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); NOA, ILERRERA, MAS, EFFECT OF ATEROMIXOL (POLICOSANOL) ON ENDOTHELIAL INJURY IN RATS, REV CENIC CIENC BIOL, 22, PP. 79-80, (1991); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); SPENCER, REID, QUANTITATION OF CAROTID STENOSIS WITH CONTINUOUS WAVE (CW) DOPPLER ULTRASOUND, STROKE, 10, PP. 326-330, (1979); GOHLKE, EFFECT OF THE LDL/HDL-CHOLESTEROL QUOTIENT ON PROGRESSION AND REGRESSION OF ARTERIOSCLEROTIC LESIONS. AN ANALYSIS OF CONTROLLED ANGIOGRAPHIC INTERVENTION STUDIES, WIEN KLIN WOCHENSCHR, 104, PP. 309-313, (1992); PRATI, VANUZZO, CASAROLI, ET AL., PREVALENCE AND DETERMINANTS OF CAROTID ATHEROSCLEROSIS IN A GENERAL POPULATION, STROKE, 23, PP. 1705-1711, (1992); HOMER, INGALL, BAKER, ET AL., SERUM LIPIDS AND LIPOPROTEINS ARE LESS POWERFUL PREDICTORS OF EXTRACRANIAL CAROTID ARTERY ATHEROSCLEROSIS THAN ARE CIGARETTE SMOKING AND HYPERTENSION, MAYO CLIN PROC, 66, PP. 259-267, (1991); BENZULY, PADGETT, SANJAY, ET AL., FUNCTIONAL IMPROVEMENT PRECEDES STRUCTURAL REGRESSION OF ATHEROSCLEROSIS, CIRCULATION, 89, PP. 1810-1818, (1994); SACKS, PASTERNAK, GIBSON, ET AL., THE EFFECT ON CORONARY ARTERY STENOSIS OF INTENSIVE PHARMACOLOGIC STEP THERAPY TO IMPROVE LDL AND HDL IN PATIENTS WITH NORMAL LIPID LEVELS, CIRCULATION, 86, PP. I-743, (1992); BARTH, ARNTZENIUS, PROGRESSION AND REGRESSION OF ATHEROSCLEROSIS, WHAT ROLES FOR LDL-CHOLESTEROL AND HDL-CHOLESTEROL: A PERSPECTIVE, EUR HEART J, 12, PP. 952-957, (1991)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0029028857","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"BATISTA J, 1995, CURR THER RES CLIN EXP","BATISTA J, 1995, CURR THER RES CLIN EXP"
"NOA M;MÁS R;DE L R M;MAGRANER J","NOA, M. (7003318964); MÁS, R. (7007164570); DE LA ROSA, M.C. (7101829119); MAGRANER, J. (6603353869)","EFFECT OF POLICOSANOL ON LIPOFUNDININDUCED ATHEROSCLEROTIC LESIONS IN RATS",1995,"JOURNAL OF PHARMACY AND PHARMACOLOGY","47","2",29,"10.1111/j.2042-7158.1995.tb05797.x","NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS ISOLATED FROM SUGAR CANE WAX, SHOWING CHOLESTEROL‐LOWERING EFFECTS AND PREVENTING THE DEVELOPMENT OF LIPOFUNDIN‐INDUCED LESIONS IN NEW ZEALAND RABBITS. THIS STUDY WAS CONDUCTED TO DETERMINE WHETHER POLICOSANOL ORALLY ADMINISTERED TO RATS ALSO PROTECTS AGAINST THE DEVELOPMENT OF LIPOFUNDIN‐INDUCED ATHEROSCLEROTIC LESIONS. FIFTY FOUR MALE WISTAR RATS WERE RANDOMLY DISTRIBUTED AMONGST A NEGATIVE CONTROL GROUP, A POSITIVE CONTROL GROUP INTRAVENOUSLY INJECTED WITH LIPOFUNDIN FOR EIGHT DAYS, AND FOUR EXPERIMENTAL GROUPS ALSO INJECTED WITH LIPOFUNDIN, BUT ORALLY RECEIVING POLICOSANOL AT 0·5, 2·5, 5 AND 25 MG KG−1, RESPECTIVELY. POLICOSANOL TREATMENT WAS ORALLY ADMINISTERED ONCE‐A‐DAY FOR EIGHT DAYS, WHILE CONTROL GROUPS SIMILARLY RECEIVED EQUIVALENT AMOUNTS OF VEHICLE. A SIGNIFICANT REDUCTION OF THE ATHEROSCLEROTIC LESIONS IN THE TREATED ANIMALS WAS OBSERVED. IT IS CONCLUDED THAT POLICOSANOL HAS A PROTECTIVE EFFECT ON LIPOFUNDIN‐INDUCED AORTIC LESIONS IN WISTAR RATS. 1995 ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN","","ANIMAL; ANTICHOLESTEREMIC AGENTS; AORTA; ARTERIOSCLEROSIS; DRUG COMBINATIONS; FATTY ALCOHOLS; MALE; PHOSPHOLIPIDS; RATS; RATS, WISTAR; SORBITOL; HYPOCHOLESTEROLEMIC AGENT; LIPOFUNDIN; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT","","","ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR. THER. RES., 54, PP. 304-312, (1993); ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 50-51, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA AGREGACIÓN PLAQUETARIA, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 52-53, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., MOLINA V., VALDES S., ESTUDIO EXPERIMENTAL DE LOS EFECTOS DEL POLICOSANOL SOBRE LA AGREGACIÓN PLAQUETARIA, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS HIPERCOLESTERIOLÉMICOS, ARCHIVOS VENEZOLANOS DE FARMACOLOGÍA Y TERAPÉUTICA, 11, PP. 80-86, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., FRAGA V., EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J.C., EFECTORS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEIMAI TIPO II., PROGRESOS EN CIENCIAS MÉDICAS (VENEZUELA), 5, (1991); CRUZ-BUSTILLO D., MEDEROS C.M., MAS R., ARRUZAZABALA M.L., BARRETO B., MARTINEZ O., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 54-55, (1991); HAUST M.D., ATHEROSCLEROSIS IN CHILDHOOD, PERSPECTIVES IN PEDIATRIC PATHOLOGY, 4, (1978); HAUST M.D., LIGHT AND ELECTRON MICROSCOPY OF HUMAN ATHEROSCLEROTIC LESIONS, THE THROMBOTIC PROCESS IN ATHEROGENESIS. EURENIUS, (1978); HAUST M.D., DERIVATION AND PROGRESSION OF ATHEROSCLEROTIC PLAQUES, PROCEEDINGS OF THE 6TH INTERNATIONAL SYMPOSIUM OF ATHEROSCLEROSIS, (1983); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 1-8, (1992); ILLNAIT J., CASTANO G., NODARSE M., PONTIGAS V., HERNANDEZ L., MAS R., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPO‐PROTEINEMIA DEL TIPO II, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 80-83, (1991); JELLINEK H., HARSING J., FUZCESI, A NEW MODEL FOR ARTERIOSCLEROSIS. AN ELECTRON MICROSCOPY STUDY OF THE LESIONS INDUCED BY I.V. ADMINISTERED FAT, ATHEROSCLEROSIS, 43, PP. 7-18, (1982); JORIS I., ZAND T., MAJNO G., STUDIES ON THE PATHOGENESIS OF ATHEROSCLEROSIS, AM. J. PATHOL., 113, PP. 341-358, (1983); KANNEL W.B., CATELLI W.P., GORDON T., MCNAMARA P.M., SERUM CHOLESTEROL, LIPOPROTEINS AND RISK OF CORONARY HEART DISEASE, ANN. INTERN. MED., 74, PP. 1-12, (1971); KEYS A., CORONARY HEART DISEASE IN SEVEN COUNTRIES., CIRCULATION, 41, (1970); KRITCHEVSKY D., DAVIDSON L.M., KRIEK N.P., DU PLESSIS J.P., INFLUENCE OF NATIVE AND RANDOMIZED PEANUT OIL ON LIPID METABOLISM AND AORTIC SUDANOPHILIA IN THE VERVET MONKEY, ATHEROSCLEROSIS, 4, PP. 53-58, (1982); NOA M., ILLNAIT J., INDUCTION OF AORTIC PLAQUES IN GUINEA PIGS BY EXPOSURE OF KEROSENE, ARCH. ENVIRON. HEALTH, 42, PP. 320-324, (1987); NOA M., MAS R., EFFECT OF ATEROMIXOL ON LIPOFUNDIN‐INDUCED ATHEROSCLEROTIC LESION IN RABBITS, PROGRESOS EN CIENCIAS MÉDICAS (VENEZUELA), 6, PP. 14-19, (1992); OSBORNE J., LEFER A., CARDIOPROTECTIVE ACTIONS OF THROMBOXANE RECEPTOR ANTAGONISM IN ISCHEMIC ATHEROSCLEROTIC RABBITS., AM J PHYSIOL, 255, (1988); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, PP. 507-512, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER. RES., 53, PP. 265-269, (1993); RODRIGUEZ ECHENIQUE C., MESA R., MAS R., AMOR A.M., CASTANO G., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTÉINAS SÉRICOS Y LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCH. VENEZOLANOS FARMACOL. TERAPÉUTICA, 11, PP. 74-79, (1992); SKRINSKA V., KONIECZKOWSKI M., GERRITY R., GALANG C., REVEC M., SUPPRESSION OF FOAM CELL LESIONS IN HYPERCHOLESTEROLEMIC RABBITS BY INHIBITION OF THROMBOXANE A<SUB>2</SUB> SYNTHESIS, ARTERIOSCLEROSIS, 8, PP. 220-225, (1988); VESSELINOVITCH D., WISSLER R.W., REVERSAL OF ATHEROSCLEROSIS. COMPARISON OF NON HUMAN PRIMATE MODELS, ATHEROSCLEROSIS, (1980)","","","ENGLISH","J. PHARM. PHARMACOL.","ARTICLE","ISI","2-S2.0-0028924304","J PHARM PHARMACOL",NA,"NOTREPORTED",NA,"NOA M, 1995, J PHARM PHARMACOL","NOA M, 1995, J PHARM PHARMACOL"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;ILLNAIT J","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, JULIO CÉSAR (9432805500); ILLNAIT, JOSÉ (8631465800)","COMPARATIVE EFFECTS OF TWO ONCEDAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1997,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","58","8",12,"10.1016/S0011-393X(97)80010-0","CENTER FOR MEDICAL SURGICAL RESEARCH, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR MEDICAL SURGICAL RESEARCH, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;CENTER FOR MEDICAL SURGICAL RESEARCH, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER FOR MEDICAL SURGICAL RESEARCH, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THIS RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY COMPARES THE EFFECTS OF TWO DIFFERENT DOSAGE SCHEDULES OF POLICOSANOL ADMINISTERED AT 10 MG/D - TWO 5-MG TABLETS VERSUS ONE 10-MG TABLET TAKEN ONCE A DAY WITH THE EVENING MEAL FOR 10 WEEKS. AFTER 4 WEEKS ON A STEP ONE CHOLESTEROL-LOWERING DIET, 60 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WERE RANDOMLY ASSIGNED TO RECEIVE EITHER TWO POLICOSANOL 5-MG TABLETS, ONE POLICOSANOL 10-MG TABLET AND ONE MATCHED PLACEBO TABLET, OR TWO PLACEBO TABLETS. BOTH REGIMENS WERE SIMILARLY EFFECTIVE. TWO 5-MG TABLETS OF POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (14.1%), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (21.1%), AND THE RATIOS OF TOTAL CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) (22.8%) AND LDL-C TO HDL-C (27.9%). ONE 10-MG TABLET OF POLICOSANOL ALSO SIGNIFICANTLY DECREASED TOTAL CHOLESTEROL (14.6%), LDL-C (23.2%), AND THE RATIOS OF TOTAL CHOLESTEROL TO HDL-C (29.5%) AND LDL-C TO HDL-C (35.8%). HDL-C LEVELS WERE SIGNIFICANTLY RAISED IN BOTH TREATED GROUPS (17.9% AND 28.9%, RESPECTIVELY). TRIGLYCERIDES DID NOT SIGNIFICANTLY CHANGE IN ANY GROUP. DIFFERENCES BETWEEN TREATED GROUPS WERE NOT SIGNIFICANT. THE PLACEBO GROUP DID NOT SHOW SIGNIFICANT CHANGES ON LIPID PROFILE VARIABLES. BOTH POLICOSANOL SCHEDULES WERE WELL TOLERATED. NO DRUG-RELATED CLINICAL OR BLOOD BIOCHEMISTRY DISTURBANCES WERE PRODUCED. TWO PATIENTS WITHDREW FROM THE STUDY - ONE TAKING PLACEBO AND THE OTHER RECEIVING TWO 5-MG TABLETS OF POLICOSANOL. THE PATIENT ON PLACEBO WITHDREW BECAUSE OF AN ADVERSE EXPERIENCE (PRURITUS); NO OTHER ADVERSE EXPERIENCES WERE REPORTED DURING THE STUDY. THESE RESULTS DEMONSTRATE THAT POLICOSANOL ADMINISTERED ONCE DAILY WITH THE EVENING MEAL AS A 10-MG TABLET IS EQUIVALENT TO TAKING TWO 5-MG TABLETS AT THE SAME TIME.","CHOLESTEROL-LOWERING DRUG; DYSLIPIDEMIA; LIPID-LOWERING DRUG; POLICOSANOL; TYPE II HYPERCHOLESTEROLEMIA","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; MAJOR CLINICAL STUDY; MALE; MEAL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TABLET","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I: REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II: THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4 S), LANCET, 344, PP. 1383-1389, (1994); SHEPERD J., COBBE S.M., CHRISTOPHER G., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, NEJM, 333, PP. 1301-1307, (1995); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J., 15, PP. 1300-1331, (1994); ATHEROSCLEROSIS, 110, PP. 121-161, (1994); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP, 11, PP. 74-79, (1992); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL FARMACOL TERAP, 12, PP. 71-76, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., TULA L., CANETTI MORERA M., ET AL., EFFECT OF POLICOSANOL (10 MG/DAY) IN HYPERTENSIVE PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN IN DIET, BR J NUTR; ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG, 14, PP. 239-249, (1994); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE SUBCHRONICAL AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1994); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); PARKER T.S., MCNAMARA D.J., BROWN C., MEVALONIC ACID IN HUMAN PLASMA: RELATIONSHIP OF CONCENTRATION AND CIRCADIAN RHYTHM TO CHOLESTEROL SYNTHESIS RATES IN MAN, PROC NATL ACAD SCI USA, 79, PP. 3037-3041, (1982)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0030889985","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 1997, CURR THER RES CLIN EXP","CASTAÑO G, 1997, CURR THER RES CLIN EXP"
"NOA M;HERRERA M;MAGRANER J;MÁS R","NOA, MIRIAM (7003318964); HERRERA, M. (13905446800); MAGRANER, J. (6603353869); MÁS, ROSA (7007164570)","EFFECT OF POLICOSANOL ON ISOPRENALINEINDUCED MYOCARDIAL NECROSIS IN RATS",1994,"JOURNAL OF PHARMACY AND PHARMACOLOGY","46","3",14,"10.1111/j.2042-7158.1994.tb03794.x","NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","ABSTRACT— POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) AND OCTACOSANOL REPRESENTS ITS MAIN COMPONENT. THIS STUDY WAS CONDUCTED TO EXAMINE THE EFFECTS OF POLICOSANOL ON MYOCARDIAL NECROSIS INDUCED BY SUBCUTANEOUS INJECTION OF ISOPRENALINE IN RATS. A SIGNIFICANT REDUCTION (P < 0·01) OF INFARCT SIZE, POLYMORPHONUCLEAR CELLS AND MAST CELLS WAS OBSERVED IN ANIMALS TREATED WITH POLICOSANOL AT 5 OR 25 MG KG−1, WHILE ANIMALS RECEIVING ONLY ACETYSALICYLIC ACID PRETREATMENT SHOWED A SIGNIFICANT DECREASE IN THE INFARCT AREA (P < 0·05). NO SIGNIFICANT DIFFERENCES IN POLYMORPHONUCLEAR AND MAST CELLS WERE OBTAINED WHEN COMPARED WITH POSITIVE CONTROL DATA. IT IS CONCLUDED THAT POLICOSANOL DELAYS THE EVOLUTION OF INFARCTION, SHOWING A PROTECTIVE EFFECT ON THE MYOCARDIAL NECROSIS INDUCED BY ISOPRENALINE IN THIS EXPERIMENTAL MODEL. 1994 ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN","","ADMINISTRATION, ORAL; ANIMAL; ASPIRIN; FATTY ALCOHOLS; GLYCOSAMINOGLYCANS; HEART; ISOPROTERENOL; MALE; MAST CELLS; MYOCARDIUM; NECROSIS; NEUTROPHILS; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; ACETYLSALICYLIC ACID; ALKANOL; ISOPRENALINE; OCTACOSANOL; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART MUSCLE NECROSIS; MALE; MAST CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; POLYMORPHONUCLEAR CELL; RAT","","","ARRUZAZABALA M.L., CARBAJAL D., GARCIA M., MAS R., EFECTOS DEL ATEROMIXOL SOBRE LA AGREGACIÓN PLAQUETARIA, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 60-61, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., MOLINA V., VALDES S., (1992); BREZINSKI M., YANAGISAWA A., DARIUS H., LEFER A., ANTIISCHEMIC ACTIONS OF A NEW THROMBOXANE RECEPTOR ANTAGONIST DURING ACUTE MYOCARDIAL ISCHEMIA IN CATS, AM. HEART J., 110, PP. 1161-1165, (1985); BREZINSKI M., YANAGISAWA A., LEFER A., CARDIOPROTECTIVE ACTIONS OF A SPECIFIC THROMBOXANE RECEPTOR ANTAGONIST IN ACUTE MYOCARDIAL ISCHEMIA, J. CARDIOVASC. PHARMACOL., 9, PP. 65-73, (1987); CARBAJAL D., ARRUZAZABALA M.L., MAS R., EFECTO DEL POLICOSANOL EN MODELOS DE ISQUEMIA CEREBRAL, ARCHIVO VENEZOLANO DE FARMACOLOGIA Y TERAPÉUTICA, 12, PP. 42-44, (1993); ELLIS E., OELZ O., ROBERTS L., PAYNE M., SWEETMAN B., CORONARY ARTERIAL SMOOTH MUSCLE CONTRACTION BY A SUBSTANCE RELEASED FROM PLATELETS: EVIDENCE THAT IT IS THROMBOXANE A<SUB>2</SUB>, SCIENCE, 193, PP. 1135-1140, (1976); ENGLER R.L., CONSEQUENCES OF ACTIVATION AND ADENOSINEMEDIATED INHIBITION OF GRANULOCYTES DURING MYOCARDIAL ISCHEMIA, FED. PROC., 46, PP. 2407-2410, (1987); FANTONE J.C., WARD P.A., ROLE OF OXYGEN‐DERIVED FREE RADICALS AND METABOLITES IN LEUKOCYTE‐DEPENDENT INFLAMMATORY REACTIONS, AM. J. PATHOL., 107, PP. 397-404, (1982); GOODMAN D., THE ROLE OF ARACHIDONIC METABOLITES IN CARDIOVASCULAR HOMEOSTASIS. BIOCHEMICAL, HISTOLOGICAL AND CLINICAL CARDIOVASCULAR EFFECTS OF NON‐STEROIDAL ANTI‐INFLAMMATORY DRUGS AND THEIR INTERACTIONS WITH CARDIOVASCULAR DRUGS, DRUGS, 33, PP. 47-55, (1987); HOCK C., BREZINSKI M., LEFER A., ANTI‐ISCHEMIC ACTIONS OF A NEW THROMBOXANE RECEPTOR ANTAGONIST, SQ‐29,548, IN ACUTE MYOCARDIAL ISCHEMIA, EUR. J. PHARMACOL., 122, PP. 213-217, (1986); KORMOCZY P.S., VERTESI C., MIKUS E., TARDOS L., KOVACS G., CARDIOPROTECTIVE EFFECT OF PROSTACYCLIN AND 7‐OXO‐PGI<SUB>2</SUB> IN RATS AGAINST CHRONIC ISOPROTERENOL DAMAGE, PROSTAGLANDINS, 33, PP. 4-12, (1987); MULLANE K., READ S., SALMON J., MONCADA S., ROLE OF LEUKOCYTES IN ACUTE MYOCARDIAL INFARCTION IN ANESTHETIZED DOGS, J. PHARMACOL. EXP. THER., 228, PP. 510-519, (1984); MURATA K., YOKOYAMA Y., ACIDIC GLYCOSAMINOGLYCANS IN HUMAN ATHEROSCLEROTIC CEREBRAL ARTERIAL TISSUES, ATHEROSCLEROSIS, 78, PP. 69-79, (1989); NOA M., AGUILAR C., CAPOTE A., DE LA ROSA M.C., TINCIÓN DE AZUL DE STEVENEL PARA CORTES DE TEJIDOS INCLUIDOS EN PARAFINA Y COMO COLARACIÓN ESPECIAL PARA MUCOPOLISACÁRIDOS ÁCIDOS, PATOLOGÍA (MÉXICO), 23, PP. 21-27, (1985); PEREZ-CAO A., GIL LOYZAGA P., MERCHAN PEREZ A., TAMARGO J.A., A MORPHOMETRICAL METHOD TO ESTIMATE ISOPROTERENOL‐INDUCED INFARCT SIZE IN THE RAT, METHODS FIND EXP CLIN PHARMACOL, 11, PP. 309-314, (1989); ROMSON J.L., BUSH L.R., JOLLY S.R., CARDIOPROTECTIVE EFFECTS OF IBUPROFEN IN EXPERIMENTAL REGIONAL AND GLOBAL MYOCARDIAL ISCHEMIA, J. CARDIOVASC. PHARMACOL., 4, PP. 187-195, (1982); ROMSON J.L., HOOK B., KUNKEL S., ABRAMS G., SCHORK M., LUCHESI B., REDUCTION OF THE EXTENT OF ISCHEMIC MYOCARDIAL INJURY BY NEUTROPHIL DEPLETION IN THE DOG, CIRCULATION, 67, PP. 1016-1021, (1983); SEIBOLD J., GIORNO R., CLAMAN H., DERMAL MAST CELL DE‐GRANULATION IN SYSTEMIC SCLEROSIS, ARTHRITIS RHEUM., 33, PP. 1702-1709, (1990); VESTERQVIST O., EDHAG O., GREEN K., HENRIKSSON P., IN VIVO PRODUCTION OF THROMBOXANE IN ACUTE HUMAN MYOCARDIAL INFARCTION: A PRELIMINARY STUDY, THROMB. RES., 37, PP. 459-467, (1985); WALINSKY P., SMITH J., LEFER A., LEBENTHAL M., URBAN P., GREENSPAN A., THROMBOXANE A<SUB>2</SUB> IN ACUTE MYOCARDIAL INFARCTION, AM. HEART J., 108, PP. 868-873, (1984); WARGOVICH T., MEHTA J., NICHOLS W., REDUCTION IN MYOCARDIAL NEUTROPHIL ACCUMULATION AND INFARCT SIZE FOLLOWING ADMINISTRATION OF THROMBOXANE INHIBITOR U‐63, 557A, AM. HEART J., 114, PP. 1078-1085, (1987); WEISSMAN G., SMOLEN J., KORCHAK H., RELEASE OF INFLAMMATORY MEDIATORS FROM STIMULATED NEUTROPHILS, N. ENGL. J. MED., 303, PP. 27-35, (1980); WEXLER B., KITTINGER G., MYOCARDIAL NECROSIS IN RATS: SERUM ENZYMES, ADRENAL STEROID AND HISTOPATHOLOGICAL ALTERATIONS, CIRCULATION RESEARCH, 13, PP. 159-171, (1963); WHITE F., WHITE S., ISOPROTERENOL INDUCED MYOCARDIAL NECROSIS ASSOCIATED WITH STRESS PROTEIN SYNTHESIS IN RAT HEART AND THORACIC AORTA, CARDIOVASC. RES., 20, PP. 512-515, (1986)","","","ENGLISH","J. PHARM. PHARMACOL.","ARTICLE","ISI","2-S2.0-0028265006","J PHARM PHARMACOL",NA,"NOTREPORTED",NA,"NOA M, 1994, J PHARM PHARMACOL","NOA M, 1994, J PHARM PHARMACOL"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;FERNÁNDEZ L;ALVAREZ E;LEZCAY M","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, JULIO CÉSAR (9432805500); FERNÁNDEZ, LILIA (7202848319); ALVAREZ, ERNESTO (57197027849); LEZCAY, MAGNOLIA (6508023242)","EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS",2000,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","61","9",30,"10.1016/S0011-393X(00)80011-9","MEDICAL SURGICAL RESEARCH CENTER, HAVANA, CUBA;NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA, CUBA","OBJECTIVE: THIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL 10 MG/D AND LOVASTATIN 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WHO WERE AT HIGH RISK FOR CORONARY EVENTS. METHODS: AFTER 4 WEEKS ON A LIPID-LOWERING DIET, 59 PATIENTS WHO MET STUDY CONDUCT CRITERIA WERE ASSIGNED RANDOMLY TO RECEIVE, IN A DOUBLE-BLIND TRIAL, POLICOSANOL OR LOVASTATIN TABLETS QD FOR 12 WEEKS. RESULTS: POLICOSANOL SIGNIFICANTLY (P < 0.00001) REDUCED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (32.4%), TOTAL CHOLESTEROL (TC) (22.4%), AND THE RATIOS OF LDL-C/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) (39.3%) AND TC/HDL-C (32.0%). LOVASTATIN SIGNIFICANTLY (P < 0.0001) REDUCED LDL-C (27.6%), TC (19.8%), AND THE RATIOS (P < 0.001) OF LDL-C/HDL-C (32.8%) AND TC/HDL-C (25.2%). POLICOSANOL SIGNIFICANTLY (P < 0.05) INCREASED LEVELS OF HDL-C (14.3%); LOVASTATIN TREATMENT DID NOT SIGNIFICANTLY AFFECT HDL-C LEVELS. BETWEEN-GROUP COMPARISONS THUS SHOWED THAT POLICOSANOL WAS MORE EFFECTIVE (P < 0.05) THAN LOVASTATIN IN REDUCING THE LDL-C/HDL-C RATIO AND INCREASING HDL-C LEVELS. BOTH TREATMENTS WERE WELL TOLERATED. LOVASTATIN SIGNIFICANTLY (P < 0.05) INCREASED CREATINE KINASE LEVELS; INDIVIDUAL VALUES IN BOTH GROUPS, HOWEVER, REMAINED WITHIN NORMAL LIMITS. TWO PATIENTS RECEIVING LOVASTATIN DISCONTINUED THE STUDY BECAUSE OF MODERATE ADVERSE EXPERIENCES (RASH AND GASTROINTESTINAL DISTURBANCES). NO PATIENT IN THE POLICOSANOL GROUP WITHDREW FROM THE STUDY. CONCLUSIONS: WE CONCLUDED THAT POLICOSANOL 10 MG/D AND LOVASTATIN 20 MG/D WERE SIMILARLY EFFECTIVE AND WELL TOLERATED IN TREATING PATIENTS WITH TYPE II HYPERCHOLESTEROLEMLA AND CONCOMITANT MULTIPLE CORONARY RISK FACTORS. MODEST ADVANTAGES WERE SHOWN WITH REGARD TO THE CHANGES IN HDL-C LEVELS AND THE LDL-C/HDL-C RATIO.","CHOLESTEROL-LOWERING DRUGS; HYPERCHOLESTEROLEMIA; LOVASTATIN; POLICOSANOL","ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLICOSANOL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FAMILY HISTORY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NERVOUSNESS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SMOKING","","","ANDERSON K.M., WILSON P.W., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS. THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED., 335, PP. 1001-1009, (1996); SIMES R.J., BAKER J., MACMAHON S., ET AL., PRAVASTATIN REDUCES TOTAL MORTALITY IN PATIENTS WITH CORONARY HEART DISEASE AND AVERAGE CHOLESTEROL LEVELS: RELATIONSHIP OF BASELINE CHOLESTEROL AND TREATMENT EFFECTS IN THE LIPID TRIAL, ABSTRACT OF THE 47TH ANNUAL SCIENTIFIC SESSION OF THE ACC, (1998); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA. WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP, N ENGL J MED., 333, PP. 1301-1307, (1995); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J., 15, PP. 1300-1331, (1994); BERGSTROM J.D., WONG G.A., EDWARDS P.A., EDMOND J., THE REGULATION OF ACETOACETYL-COA SYNTHETASE ACTIVITY BY MODULATORS OF CHOLESTEROL SYNTHESIS IN VIVO AND THE UTILIZATION OF ACETOACETATE FOR CHOLESTEROGENESIS, J BIOL CHEM., 259, PP. 14548-14553, (1984); ILLINGWORTH D.R., TOBERT J.A., A REVIEW OF CLINICAL TRIALS COMPARING HMG-COA REDUCTASE INHIBITORS, CLIN THER., 16, PP. 366-385, (1994); BILHEIMER D.W., GRUNDY S.M., BROWN M.S., GOLDSTEIN J.L., MEVINOLIN AND COLESTIPOL STIMULATE RECEPTOR-MEDIATED CLEARANCE OF LOW DENSITY LIPOPROTEIN FROM PLASMA IN FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES, PROC NAT ACAD SCI USA., 80, PP. 4124-4128, (1983); CHAO Y.S., KROON P.A., YAMIN T.T., ET AL., REGULATION OF HEPATIC RECEPTOR-DEPENDENT DEGRADATION OF LDL BY MEVINOLIN IN RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BIOCHIM BIOPHYS ACTA., 754, PP. 134-141, (1983); ILLINGWORTH D.R., THERAPEUTIC USE OF LOVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, CLIN THER., 16, PP. 2-26, (1994); WALKER J.F., WORLDWIDE EXPERIENCE WITH SIMVASTATIN/LOVASTATIN, EUR HEART J., 13, SUPPL. B, PP. 21-22, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 176-182, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER., 12, PP. 245-254, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR THER RES., 56, PP. 819-828, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES IN SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES., 57, PP. 568-577, (1996); CANETTI M.M., MOREIRA M., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN-EXTENSION FOLLOW-UP, CURR THER RES., 58, PP. 868-875, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 859-867, (1997); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 390-401, (1997); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE., 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES., 58, PP. 44-51, (1997); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR., 77, PP. 923-932, (1996); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER., 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES., 59, PP. 737-745, (1998); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED., 100, PP. 197-204, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM., 18, PP. 499-502, (1972)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0034119313","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 2000, CURR THER RES CLIN EXP","CASTAÑO G, 2000, CURR THER RES CLIN EXP"
"ARRUZAZABALA M;MÁS R;MOLINA V;CARBAJAL D;MENDOZA S;FERNÁNDEZ L;VALDÉS S","ARRUZAZABALA, M.L. (6603962476); MÁS, R. (7007164572); MOLINA, V. (7006062814); CARBAJAL, D. (8777025000); MENDOZA, S. (7102759819); FERNÁNDEZ, L. (7202848319); VALDÉS, S. (8777025100)","EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS",1998,"INTERNATIONAL JOURNAL OF TISSUE REACTIONS","20","5",37,"","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, AVE 25 P.O 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH CONCOMITANT ANTIPLATELET EFFECTS PROVED IN EXPERIMENTAL MODELS AND HEALTHY VOLUNTEERS. THIS STUDY REPORTS THE RESULTS OF A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL INVESTIGATING THE EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS. PATIENTS STARTED OR CONTINUED ON A STEP-ONE CHOLESTEROL-LOWERING THERAPY FOR 4 WEEKS AND THOSE WITH TOTAL CHOLESTEROL >5.2 MMOL/L DESPITE DIETARY CONDITIONS WERE RANDOMIZED TO RECEIVE UNDER DOUBLE-BLIND CONDITIONS PLACEBO OR POLICOSANOL (10 MG/DAY) FOR 30 DAYS. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID (3.2 MM), COLLAGEN (0.5-1 ΜG/ML) AND ADP (0.5-1 UM) WERE DETERMINED AT BASELINE AND AFTER 30 DAYS OF TREATMENT. POLICOSANOL SIGNIFICANTLY REDUCED PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID AND COLLAGEN, MEANWHILE IT ONLY INHIBITED SIGNIFICANTLY THE PLATELET AGGREGATION INDUCED BY THE LOWEST DOSES OF ADP (0.5 UM). NO ADVERSE EVENTS OCCURRED DURING THE TRIAL. ONLY ONE PATIENT (PLACEBO) DISCONTINUED FROM THE STUDY BECAUSE OF ARTHRALGIA.","","ADENOSINE DIPHOSPHATE; ANTICHOLESTEREMIC AGENTS; ARACHIDONIC ACID; COLLAGEN; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; ARACHIDONIC ACID; COLLAGEN; PLACEBO; POLICOSANOL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION","","","ANDERSEN K.M., WILSON P.W.F., ODEL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, J.A.M.A., 251, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, J.A.M.A., 251, (1984); BROWN G., ALBERS J.J., FISHER I.D., ET AL., REGRESSION OF CORONARY ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH LEVELS OF APOLIPOPROTEIN B, N. ENGL. J. MED., 323, (1990); BLANKENHORN D.H., AZEN S.P., KRAMSH D.M., ET AL., CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY: THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS), ANN. INTERN. MED., 119, (1993); JUKEMA J.W., BRUSCHKE A.V.G., BOWEN A.J., ET AL., ON BEHALF OF THE REGRESS STUDY GROUP. EFFECTS OF LIPID LOWERING BY PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ARTERY DISEASE IN SYMPTOMATIC MEN WITH NORMAL TO MODERATELY ELEVATED SERUM CHOLESTEROL LEVELS: THE REGGRESSION GROWTH EVALUATION STATIN STUDY (REGRESS), CIRCULATION, 91, (1995); PACKMAN M.A., MUSTARD J.F., THE ROLE OF PLATELETS IN THE DEVELOPMENT AND COMPLICATIONS OF ATHEROSCLEROSIS, SEM. HAEMATOL., 23, (1981); COLLABORATIVE OVERVIEW OF RANDOMISED TRIALS ANTIPLATELET THERAPY I: PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STOKE BY PROLONGUED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BRIT. MED. J., 308, (1994); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, (1992); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER. RES., 53, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF POLICOSANOL SUCCESIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J. CLIN. PHARMACOL., 14, (1994); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., EFFECTS OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, (1996)","","","ENGLISH","INT. J. TISSUE REACT.","ARTICLE","ISI","2-S2.0-0032467742","INT J TISSUE REACT",NA,"NOTREPORTED",NA,"ARRUZAZABALA ML, 1998, INT J TISSUE REACT","ARRUZAZABALA ML, 1998, INT J TISSUE REACT"
"ARRUZAZABALA M;VALDÉS S;MÁS R;CARBAJAL D;FERNÁNDEZ L","ARRUZAZABALA, M.L. (6603962476); VALDÉS, S. (8777025100); MÁS, R. (7007164572); CARBAJAL, D. (8777025000); FERNÁNDEZ, L. (7202848319)","COMPARATIVE STUDY OF POLICOSANOL ASPIRIN AND THE COMBINATION THERAPY POLICOSANOLASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS",1997,"PHARMACOLOGICAL RESEARCH","36","4",51,"10.1006/phrs.1997.0201","DEPARTMENT OF PHARMACOLOGY, CENTRE OF NATURAL PRODUCTS, CNIC, PLAYA, HABANA, AVENUE 25 AND 158 APDO 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTRE OF NATURAL PRODUCTS, CNIC, PLAYA, HABANA, AVENUE 25 AND 158 APDO 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTRE OF NATURAL PRODUCTS, CNIC, PLAYA, HABANA, AVENUE 25 AND 158 APDO 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTRE OF NATURAL PRODUCTS, CNIC, PLAYA, HABANA, AVENUE 25 AND 158 APDO 6880, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTRE OF NATURAL PRODUCTS, CNIC, PLAYA, HABANA, AVENUE 25 AND 158 APDO 6880, CUBA","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED IN 43 HEALTHY VOLUNTEERS TO COMPARE THE EFFECTS OF POLICOSANOL (20 MG DAY-1), ASPIRIN (ASA) (100 MG DAY-1) AND COMBINATION THERAPY (POLICOSANOL 20 MG DAY-1 PLUS ASA 100 MG DAY-1) ON PLATELET AGGREGATION. THE HEALTHY VOLUNTEERS WERE RANDOMLY TREATED FOR 7 DAYS. BOTH, PLATELET AGGREGATION AND COAGULATION TIME WERE MEASURED AT BASELINE AND AFTER THERAPY. WHEN POLICOSANOL WAS ADMINISTERED PLATELET AGGREGATION INDUCED BY ADP (37.3%), EPINEPHRINE (32.6%) AND COLLAGEN (40.5%) WERE SIGNIFICANTLY REDUCED. MEANWHILE, ASPIRIN SIGNIFICANTLY REDUCED PLATELET AGGREGATION INDUCED BY COLLAGEN (61.4%) AND EPINEPHRINE (21.9%) BUT NOT ADP-INDUCED AGGREGATION. COMBINED THERAPY SIGNIFICANTLY INHIBITED AGGREGATION INDUCED BY ALL THE AGONISTS REACHING THE HIGHEST REDUCTIONS OF PLATELET AGGREGATION INDUCED BY COLLAGEN (71.3%) AND EPINEPHRINE (57.5%). COAGULATION TIME DID NOT CHANGE SIGNIFICANTLY IN ANY GROUP. NO SUBJECT WITHDREW FROM THE TRIAL. FOUR VOLUNTEERS REPORTED MILD ADVERSE EXPERIENCES DURING THE STUDY: THREE ASA-TREATED CASES REFERRED HEADACHE, EPIGASTRALGIA AND NOSE BLEEDING, MEANWHILE ONE PATIENT RECEIVING COMBINATION THERAPY REPORTED GUM BLEEDING. THE PRESENT RESULTS DEMONSTRATE THAT POLICOSANOL (20 MG DAY-1) IS AS EFFECTIVE AS ASA (100 MG DAY-1). MOREOVER, COMBINATION THERAPY SHOWS SOME ADVANTAGES COMPARED WITH THE RESPECTIVE MONOTHERAPIES.","ASPIRIN; CLINICAL TRIAL; HEALTHY VOLUNTEERS; PLATELET AGGREGATION; POLICOSANOL","ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; COLLAGEN; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIGASTRIC PAIN; EPISTAXIS; FEMALE; GINGIVA BLEEDING; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION","","","DE ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 203-208, (1994); RODRIGUEZ C., MESA R., MAS R., AMOR A.M., CASTANO G., ESTUDIO DEL EFECTO SOBRE LIPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DEL POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCH VENEZOLANOS DE FARMACOLOGÍA Y TERAPÉUTICA, 11, PP. 74-79, (1992); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 52, PP. 265-269, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILNAITT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., EFFECTS OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., ZARDOYA R., ILNAITT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J.C., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM., 5, PP. 21-28, (1991); CANETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE A DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); DE ARRUZAZABALA M.L., CARBAJAL D., MAS R., GRACIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); DE ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUK. ESSENTIAL FATTY ACIDS, 49, PP. 695-697, (1993); DE ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GRACIA M., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV. IBEROAMER. TROMB HEMOSTASIA, 5, PP. 17-20, (1992); CARBAJAL D., DE ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL OF EXPERIMENTAL THROMBOSIS MODEL, PROSTAGLANDINS, LEUK. ESSENTIAL FATTY ACIDS, 50, PP. 249-251, (1994); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE (LOND), 194, PP. 927-929, (1962); MAFFRAND J.P., BERNAT A., DELABASSEE D., DEFREYN G., CAZENAVE J.P., GORDON J.L., ADP PLAYS A KEY ROLE IN THROMBOGENESIS IN RATS, THROMB HAEMOST, 59, PP. 225-230, (1988); UNITED KINGDOM TRANSIENT ISCHAEMIC ATTACK (UK-TIA) ASPIRIN TRIAL: INTERIM RESULTS, BR MED J, 296, PP. 316-320, (1988); HENRIKSSON P., WENNMALON A., EDLHAG O., VESTERQVIST O., GREEN K., IN VIVO PRODUCTION OF PROSTAGLANDIN AND THROMBOXANE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, BRIT HEART J, 55, PP. 543-548, (1986); DE CATERINA R., GIANNESSI D., BOEM A., BERNINI W., BATTAGLIA D., MICHELLASSI C., DELL'AMICO F., L'ABBATE A., PATRIGNANI P., PATRONO C., EQUAL ANTI-PLATELET EFFECTS OF ASPIRIN 50 MG OR 324 MG/DAY IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION, THROMBOSIS HAEMOSTASIS, 54, PP. 528-532, (1985); BEAUFILS M., DONSIMONI R., UZAN S., COLAN J.C., PREVENTION OF PRE-ECLAMPSIA BY EARLY ANTI-PLATELET THERAPY, LANCET, 1, PP. 840-842, (1985); WALLENBURG H.C.S., ROTMANS N., PREVENTION OF RECURRENT IDIOPATHIC FETAL GROWTH RETARDATION BY LOW-DOSE ASPIRIN AND DYPYRIDAMOLE, AM J OBSTET GYNECOL, 157, PP. 1230-1235, (1987); RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH OR NEITHER AMONG 17,187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION ISIS-2, LANCET, 2, PP. 349-360, (1988); SULLIVAN M.H.F., ZOSMER A., GLEESON R.P., ELDER M.G., EQUIVALENT INHIBITION OF IN VIVO PLATELET FUNCTION BY LOW DOSE AND HIGH DOSE ASPIRIN TREATMENT, PROSTAGLANDINS LEUK ESSENTIAL FATTY ACIDS, 39, PP. 319-321, (1990); PATRONO C., ASPIRIN AS AN ANTIPLATELET DRUG, NEW ENGL J MED, 330, PP. 1287-1293, (1994); TOFLER G.H., BREZINSKI D., SCHAFER A., CZEISLER C., RUTHERFORD J., WILLICH S., GLEASON R., WILLIAMS G., MULLER J., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH, NEW ENGL J MED, 316, PP. 1514-1518, (1987); MULLER J.E., STONE P.H., TURI Z.G., ORCADIAN VARIATION IN THE FREQUENCY OF ONSET OF ACUTE MYOCARDIAL INFARCTION, NEW ENGL J MED, 313, PP. 1315-1322, (1985); MULLER J.E., LUDMER P.L., WILLICH S.N., CIRCADIAN VARIATION IN THE FREQUENCY OF SUDDEN CARDIAC DEATH, CIRCULATION, 75, PP. 131-138, (1987)","","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0031257654","PHARMACOL RES",NA,"NOTREPORTED",NA,"ARRUZAZABALA ML, 1997, PHARMACOL RES","ARRUZAZABALA ML, 1997, PHARMACOL RES"
"MENDOZA S;GÁMEZ R;NOA M;MÁS R;CASTAÑO G;MESA R;MESA M;DE A M","MENDOZA, SARAHÍ (7102759819); GÁMEZ, RAFAEL (7003605346); NOA, MIRIAM (7003318964); MÁS, ROSA (7007164572); CASTAÑO, GLADYS (56232967100); MESA, ROSARIO (7003836140); MESA, MEILIS (36880545700); DE ARMAS, MICHEL (15767210000)","COMPARISON OF THE EFFECTS OF D003 AND POLICOSANOL ON LIPID PROFILE AND ENDOTHELIAL CELLS IN NORMOCHOLESTEROLEMIC RABBITS",2001,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","62","11",34,"10.1016/S0011-393X(01)80032-1","CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBANACÁN HAVANA CITY, AVE 25 AND 158, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","BACKGROUND: POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGAR CANE WAX THAT CONSISTS OF A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS. D-003 IS A MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ACIDS ISOLATED FROM THE SAME SOURCE WITH EXPERIMENTALLY PROVEN CHOLESTEROL-LOWERING EFFECTS. OBJECTIVE: THE PRESENT STUDY WAS UNDERTAKEN TO COMPARE THE CHOLESTEROL-LOWERING EFFECTS OF D-003 AND POLICOSANOL IN NORMOCHOLESTEROLEMIC NEW ZEALAND RABBITS. IN ADDITION, THE EFFECTS OF THE 2 DRUGS ON LEVELS OF PLASMA CIRCULATING ENDOTHELIAL CELLS (PCEC) BEFORE AND AFTER CITRATE-INDUCED ENDOTHELIAL DAMAGE WERE COMPARED. METHODS: ANIMALS WERE RANDOMLY DISTRIBUTED TO 3 EXPERIMENTAL GROUPS: 1 CONTROL AND 2 TREATMENT GROUPS. RABBITS IN THE TREATMENT GROUPS RECEIVED ORALLY ADMINISTERED POLICOSANOL OR D-003 DAILY AT 5 MG/KG, THE LOWEST EFFECTIVE DOSE OF POLICOSANOL IN THIS MODEL, FOR 30 DAYS. RESULTS: AFTER 15 DAYS OF TREATMENT, BOTH D-003 AND POLICOSANOL SIGNIFICANTLY (P < 0.05) LOWERED SERUM LEVELS OF TOTAL CHOLESTEROL (TC) COMPARED WITH BASELINE, BUT ONLY D-003 SIGNIFICANTLY REDUCED (P < 0.05) LEVELS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C). AT 15 DAYS, THE ABSOLUTE VALUES OF TC AND LDL-C WERE SIGNIFICANTLY LOWER (P < 0.05) ONLY IN THE D-003 GROUP COMPARED WITH THE CONTROL GROUP, AND LDL-C REDUCTIONS WERE SIGNIFICANTLY GREATER (P < 0.05) IN THE D-003 GROUP (45.3%) THAN IN THE POLICOSANOL GROUP (38.1%). NO OTHER SIGNIFICANT CHANGES IN LIPID PROFILE WERE OBSERVED AT THIS INTERIM ASSESSMENT. AFTER 30 DAYS, THE REDUCTIONS IN LDL-C AND TC WERE ENHANCED IN BOTH GROUPS, WITH THE PERCENTAGE REDUCTIONS IN LDL-C SIGNIFICANTLY GREATER (P < 0.05) IN THE D-003 GROUP (81.6%) THAN IN THE POLICOSANOL GROUP (68.7%). PERCENT CHANGES IN TC WERE SIMILAR IN BOTH TREATMENT GROUPS - D-003 (42.4%) AND POLICOSANOL (41.2%), ALTHOUGH FINAL VALUES OF TC IN THE D-003 GROUP WERE SIGNIFICANTLY LOWER (P < 0.05) THAN IN THE POLICOSANOL GROUP. BOTH DRUGS SIGNIFICANTLY RAISED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS VERSUS BASELINE (P < 0.05), BUT THE PERCENT INCREASES IN THE D-003 GROUP (78.8%) WERE LARGER THAN IN THE POLICOSANOL GROUP (47.1%). SERUM TRIGLYCERIDE LEVELS DID NOT CHANGE SIGNIFICANTLY IN EITHER TREATMENT GROUP. NO SIGNIFICANT CHANGES IN LIPID PROFILE WERE OBSERVED IN THE CONTROL GROUP. THE PCEC COUNT AT STUDY COMPLETION BEFORE AND AFTER CITRATE-INDUCED ENDOTHELIAL DAMAGE WAS SIGNIFICANTLY LOWER (P < 0.001) IN THE TREATMENT GROUPS THAN IN THE CONTROL GROUP, BUT WAS STATISTICALLY SIMILAR BETWEEN TREATMENT GROUPS. HOWEVER, THE INCREASES IN PCEC COUNT AFTER CITRATE-INDUCED DAMAGE IN THE D-003 GROUP WAS SIGNIFICANTLY (P < 0.05) LOWER THAN IN THE OTHER GROUPS. CONCLUSIONS: D-003 ADMINISTERED ORALLY AT 5 MG/KG FOR 30 DAYS TO NORMOCHOLESTEROLEMIC RABBITS INDUCED MORE BENEFICIAL CHANGES IN SERUM LDL-C LEVELS THAN POLICOSANOL AT THE SAME DOSE. IN ADDITION, A SLIGHTLY GREATER BENEFICIAL EFFECT ON HDL-C LEVELS AND PCEC COUNT WAS NOTED WITH D-003 VERSUS POLICOSANOL. ALTHOUGH D-003 WAS MORE EFFECTIVE THAN POLICOSANOL IN THESE EXPERIMENTAL CONDITIONS, ADDITIONAL COMPARATIVE STUDIES THAT INCLUDE A WIDE DOSE RANGE OF BOTH DRUGS MUST BE CONDUCTED BEFORE DEFINITIVE CONCLUSIONS CAN BE MADE ABOUT THE COMPARATIVE CHOLESTEROL-LOWERING EFFECTS OF D-003.","CHOLESTEROL-LOWERING DRUGS; D-003; ENDOTHELIAL CELLS; POLICOSANOL","CHOLESTEROL; CITRIC ACID; D 003; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; UNCLASSIFIED DRUG; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 35, PP. 1001-1009, (1996); TONKIN A.M., HUNT D., LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY, CHOLESTEROL LOWERING-THERAPY, PP. 173-190, (2000); SHEPHERD J., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); LAGUNA A., MAGRANER J., MAS R., ET AL.; ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THEN RES CLIN EXP, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPO PROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES IN SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THEN RES CLIN EXP, 57, PP. 568-577, (1996); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1997); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 44-51, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECTS OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 253-262, (2000); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS IN SPRAGUE-DAWLEY RATS AND RABBITS, J PHARM PHARMACOL, 49, PP. 999-1002, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 19, PP. 105-116, (1999); GONZALEZ L., MARRERO D., LAGUNA A., ET AL.; GAMEZ R., MENDOZA S., MAS R., ET AL., DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS OF D-003 ON NORMOCHOLESTEROLEMIC RABBITS, CURR THER RES CLIN EXP, 61, PP. 8-16, (2000); MENENDEZ R., MAS R., MARRERO D., ET AL., INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D-003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS, ATHEROSCLEROSIS, 151, (2000); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., ANTITHROMBOTIC EFFECTS OF D003, PHARMACOL RES, 42, PP. 137-143, (2000); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., INTERACTION OF POLICOSANOL-WARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS, PHARMACOL RES, 38, PP. 89-91, (1998); HLADOVEC J., PREROVSKY I., STANEK V., FABIAN J., CIRCULATING ENDOTHELIAL CELLS IN ACUTE MYOCARDIAL INFARCTION AND ANGINA PECTORIS, KLIN WOCHENSCHR, 56, PP. 1033-1036, (1978); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); HLADOVEC J., ROSSMAN P., CIRCULATING ENDOTHELIAL CELLS ISOLATED TOGETHER WITH PLATELETS AND THE EXPERIMENTAL MODIFICATION OF THEIR COUNTS IN RATS, THROMB RES, 3, PP. 665-674, (1973); O'BRIEN P.C., SHAMPO M.A., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); KABIR Y., KIMURA S., METABOLISM OF OCTACOSANOL IN LIVER AND MUSCLE OF RAT, ACTA ALIMENTARIA, 24, PP. 39-46, (1995); MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); RIZZO E., CRAFT D.A., DAMMANN A.L., PHILLIPS M.W., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); HALLER H., ENDOTHELIAL FUNCTION. GENERAL CONSIDERATIONS, DRUGS, 53, SUPPL. 1, PP. 1-10, (1997); LUSCHER T.F., BARTON M., BIOLOGY OF THE ENDOTHELIUM, CLIN CARDIOL, 20, SUPPL. 2, PP. 3-10, (1997); DAVIS J., LEWIS H.D., FRANCIS-OLIVER A., PREVENTION OF EXERCISE-INDUCED ENDOTHELEMIA BY ISRADIPINE IN MEN WITH ANGINA PECTORIS, CARDIOLOGY, 84, PP. 375-379, (1994); CASACO A., CARBAJAL D., FRIMAN M., NOA M., INTERFERENCE OF LEVAMISOLE WITH FORSSMAN SHOCK, THROMB RES, 59, PP. 629-637, (1990); FRIMAN M., NOA M., PAUSTE H., ET AL., EFFECT OF CNIC-4 (LOBENZARIT) ON CIRCULATING ENDOTHELIAL CELLS OF RATS. ADVANCES IN LIPOPROTEIN AND ATHEROSCLEROSIS RESEARCH, DIAGNOSTICS AND TREATMENT, PROCEEDINGS OF THE 6TH INTERNATIONAL DRESDEN LIPID SYMPOSIUM, PP. 749-752, (1988)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0035057937","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"MENDOZA S, 2001, CURR THER RES CLIN EXP","MENDOZA S, 2001, CURR THER RES CLIN EXP"
"MOLINA V;ARRUZAZABALA M;CARBAJAL D;VALDÉS S;NOA M;MÁS R;FRAGA V;MENÉNDEZ R","MOLINA, V. (7006062814); ARRUZAZABALA, M.L. (6603962476); CARBAJAL, D. (8777025000); VALDÉS, S. (8777025100); NOA, M. (7003318964); MÁS, R. (7007164572); FRAGA, V. (6602491407); MENÉNDEZ, R. (7102205059)","EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS",1999,"BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH","32","7",19,"10.1590/S0100-879X1999001000014","DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, CNIC, CUBANACAN, PLAYA, HAVANA, AVE 25 AND 158, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE WAX, WHOSE MAIN COMPONENT IS OCTACOSANOL. AN INHIBITORY EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND CEREBRAL ISCHEMIA IN ANIMAL MODELS HAS BEEN REPORTED. THUS, THE OBJECTIVE OF THE PRESENT STUDY WAS TO EVALUATE THE EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA INDUCED BY UNILATERAL CAROTID LIGATION AND BILATERAL CLAMPING AND RECIRCULATION IN MONGOLIAN GERBILS. POLICOSANOL (200 MG/KG) ADMINISTERED IMMEDIATELY AFTER UNILATERAL CAROTID LIGATION AND AT 12- OR 24-H INTERVALS FOR 48 H SIGNIFICANTLY INHIBITED MORTALITY AND CLINICAL SYMPTOMS WHEN COMPARED WITH CONTROLS, WHEREAS LOWER DOSES (100 MG/KG) WERE NOT EFFECTIVE. CONTROL ANIMALS SHOWED SWELLING (TISSUE VACUOLIZATION) AND NECROSIS OF NEURONS IN ALL AREAS OF THE BRAIN STUDIED (FRONTAL CORTEX, HIPPOCAMPUS, STRIATUM AND OLFACTORY TUBERCLE), SHOWING A SIMILAR INJURY PROFILE. IN THE GROUP TREATED WITH 200 MG/KG POLICOSANOL SWELLING AND NECROSIS WERE SIGNIFICANTLY REDUCED WHEN COMPARED WITH THE CONTROL GROUP. IN ANOTHER EXPERIMENTAL MODEL, COMPARISON BETWEEN GROUPS SHOWED THAT THE BRAIN WATER CONTENT OF CONTROLS GERBILS (N = 15) WAS SIGNIFICANTLY HIGHER AFTER 15 MIN OF CLAMPING AND 4 H OF RECIRCULATION THAN IN SHAM-OPERATED ANIMALS (N = 130, WHEREAS POLICOSANOL (200 MG/KG) (N = 19) SIGNIFICANTLY REDUCED THE EDEMA COMPARED WITH THE COMPARED GROUP, WITH A CEREBRAL WATER CONTENT IDENTICAL TO THAT OF THE SHAM-OPERATED ANIMALS. CAMP LEVELS IN THE BRAIN OF CONTROL-LIGATED MONGOLIAN GERBILS (N = 8) WERE SIGNIFICANTLY LOWER THAN THOSE OF SHAM-OPERATED ANIMALS (N = 10). THE POLICOSANOL-TREATED GROUP (N = 10) SHOWED SIGNIFICANTLY HIGHER CAMP LEVELS (2.68 PMOL/G OF TISSUE) THAN THE POSITIVE CONTROL (1.91 PMOL/G OF TISSUE) AND SIMILAR TO THOSE OF NON-LIGATED GERBILS (2.97 PMOL/G OF TISSUE). IN CONCLUSION, OUR RESULTS SHOW AN ANTI-ISCHEMIC EFFECT OF POLICOSANOL ADMINISTERED AFTER INDUCTION OF CEREBRAL ISCHEMIA, IN TWO DIFFERENT EXPERIMENTAL MODELS IN MONGOLIAN GERBILS, SUGGESTING A POSSIBLE THERAPEUTIC EFFECT IN CEREBRAL VASCULAR DISORDERS.","CEREBRAL ISCHEMIA; GERBILS; POLICOSANOL; REPERFUSION BRAIN EDEMA","POLICOSANOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; GERBIL; HISTOPATHOLOGY; INTRAGASTRIC DRUG ADMINISTRATION; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, PP. 205-208, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOLOGICAL RESEARCH, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRITISH JOURNAL OF NUTRITION, 77, PP. 923-932, (1997); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 1-8, (1992); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 296-304, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 296-304, (1995); CANETTI M., MORERA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADVANCES IN THERAPY, 12, PP. 245-254, (1995); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 58, PP. 859-867, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., GARCIA M., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN DEL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REVISTA IBEROAMÉRICANA DE TROMBOSIS Y HEMOSTASIS, 5, PP. 17-20, (1992); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., MAS R., FERNANDEZ L., MOLINA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOLOGICAL RESEARCH, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 58, PP. 61-64, (1998); LEVINE S., PAYAN H., EFFECTS OF ISCHEMIA AND OTHER PROCEDURES ON THE BRAIN AND RETINA OF THE GERBIL (MERIONES UNGUICULATUS), EXPERIMENTAL NEUROLOGY, 16, PP. 255-262, (1966); BERRY K., WISNIEWSKI H.M., SVARZBEIN L., BAEZ S., ON THE RELATIONSHIP OF BRAIN VASCULATURE TO PRODUCTION OF NEUROLOGICAL DEFICIT AND MORPHOLOGICAL CHANGES FOLLOWING ACUTE UNILATERAL COMMON CAROTID ARTERY LIGATION IN GERBILS, JOURNAL OF NEUROLOGICAL SCIENCES, 25, PP. 75-92, (1975); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 49, PP. 695-697, (1993); TAYLOR M.D., PALMER G.C., CALLAHAN A.S., PROTECTIVE ACTION BY METHYLPREDNISOLONE, ALLOPURINOL AND INDOMETHACIN AGAINST STROKE-INDUCED DAMAGE TO ADENYLATE CYCLASE IN GERBIL CEREBRAL CORTEX, STROKE, 15, PP. 329-335, (1984); PLUM F., POSNER J., ALOND E., EDEMA AND NECROSIS IN EXPERIMENTAL CEREBRAL INFARCTION, ARCHIVES OF NEUROLOGY, 9, PP. 563-570, (1963); PAYAN H.M., CONARD J.R., CAROTID LIGATION IN GERBIL, STROKE, 8, PP. 194-196, (1977); HARRISON M.J.G., BROWNHILL D., LEWIS P.D., RUSSELL R.W.R., CEREBRAL EDEMA FOLLOWING CAROTID ARTERY LIGATION IN THE GERBIL, ARCHIVES OF NEUROLOGY, 28, PP. 389-391, (1973); SCHMIDT-KASTNER R., FREUD T., SELECTIVE VULNERABILITY OF THE HIPPOCAMPUS IN BRAIN ISCHEMIA, NEUROSCIENCE, 40, PP. 599-636, (1991); SIMS N.R., ZAIDAN E., BIOCHEMICAL CHANGES ASSOCIATED WITH SELECTIVE NEURONAL DEATH FOLLOWING SHORT-TERM CEREBRAL ISCHEMIA, INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELLULAR BIOLOGY, 27, PP. 531-550, (1995); CHRISTIE-POPE B.C., PALMER G., CHRONISTER R.B., CALLAHAN A., ADENYLATE CYCLASE AND HISTOPATHOLOGICAL CHANGES IN THE GERBIL BRAIN FOLLOWING PROLONGED UNILATERAL ISCHEMIA AND RECIRCULATION, STROKE, 16, PP. 710-717, (1985); SHAH A.B., BEAMER N., COULL B., ENHANCED IN VIVO PLATELET ACTIVATION IN SUBTYPES OF ISCHEMIC STROKE, STROKE, 16, (1985); MONCADA S., VANE J.P., PHARMACOLOGY AND ENDOGENOUS ROLE OF PROSTAGLANDIN, THROMBOXANE A<SUB>2</SUB> AND PROSTACYCLIN, PHARMACOLOGICAL REVIEWS, 30, PP. 293-331, (1979); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 50, PP. 249-251, (1994); SIESJO B.K., CELL DAMAGE IN THE BRAIN: A SPECULATIVE SYNTHESIS, JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 12, PP. 155-185, (1981); TAMURA A., YAMAMOTO M., SHIMIZU M., KIRINO T., SANO K., BEHAVIORAL CHANGE AFTER LOCAL CEREBRAL ISCHEMIA IN THE RAT, JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 5, 1 SUPPL., (1985); CONGER J.D., WEIL J.V., ABNORMAL VASCULAR FUNCTION FOLLOWING ISCHEMIA-REPERFUSION INJURY, JOURNAL OF INVESTIGATIONS IN MEDICINE, 43, PP. 431-442, (1995); SCHWARTZ J.P., MRSULJA B.J., PASSONEAU J.V., KLATZO L., ALTERATIONS OF CYCLIC NUCLEOTIDE-RELATED ENZYMES AND ATPASE DURING UNILATERAL ISCHEMIA AND RECIRCULATION IN GERBIL CEREBRAL CORTEX, JOURNAL OF NEUROCHEMISTRY, 27, PP. 101-107, (1984); RAICHLE M.E., THE PATHOPHYSIOLOGY OF BRAIN ISCHEMIA, ANNALS OF NEUROLOGY, 13, PP. 2-10, (1983); PICKARD J.D., ROLE OF PROSTAGLANDINS AND ARACHIDONIC ACID DERIVATIVES IN THE COUPLING OF CEREBRAL BLOOD FLOW TO CEREBRAL METABOLISM, JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1, PP. 361-384, (1981); OLIVER C.N., STARKE-REED P.E., STADTMAN E.R., LIU G.J., CARNEY J.M., FLOYD R.A., OXIDATIVE DAMAGE TO BRAIN PROTEINS, LOSS OF GLUTAMINE SYNTHETASE ACTIVITY, AND PRODUCTION OF FREE RADICALS DURING ISCHEMIA REPERFUSION-INDUCED INJURY TO GERBIL BRAIN, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, 87, PP. 5144-5147, (1990); YOSHIDA S., INOH S., ASANO T., SANO K., KUBOTA M., SHIMAZAKI H., UETA N., EFFECT OF TRANSIENT ISCHEMIA ON FREE FATTY ACIDS AND PHOSPHOLIPIDS IN THE GERBIL BRAIN. LIPID PEROXIDATION AS A POSSIBLE CAUSE OF POSTISCHEMIC INJURY, JOURNAL OF NEUROSURGERY, 53, PP. 323-331, (1980); PHILLIS J.W., PERKINS L.M., SMITH-BARBOUR M., O'REAGAN M.H., OXYPURINOL-ENHANCED POSTISCHEMIC RECOVERY OF THE RAT BRAIN INVOLVES PRESERVATION OF ADENINE NUCLEOTIDES, JOURNAL OF NEUROCHEMISTRY, 64, PP. 2177-2184, (1995); HIMORI N., SUZUKI T., UENO K.I., ANIRACETAM, A PYRROLIDONE-TYPE COGNITION ENHANCER, ATTENUATES THE HYDROXYL FREE RADICAL FORMATION IN THE BRAIN OF MICE WITH BRAIN ISCHEMIA, JOURNAL OF PHARMACY AND PHARMACOLOGY, 47, PP. 253-258, (1995); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCHIVES OF MEDICAL RESEARCH, 28, PP. 355-360, (1997)","M.L. ARRUZAZABALA; CENTER FOR NATURAL PRODUCTS, CNIC, PLAYA, HAVANNA, AVE 25 AND 158, CUBA; EMAIL: DALMER@IP.ETECSA.CU","ASSOCIACAO BRASILEIRA DE DIVULGACAO CIENTIFICA","ENGLISH","BRAZ. J. MED. BIOL. RES.","ARTICLE","ISI","2-S2.0-0032701309","BRAZ J MED BIOL RES","NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH;NATL. CENTER OF SCIENTIFIC RESEARCH","NOTREPORTED;CENTER FOR NATURAL PRODUCTS;NOTREPORTED",NA,"MOLINA V, 1999, BRAZ J MED BIOL RES","MOLINA V, 1999, BRAZ J MED BIOL RES"
"MENÉNDEZ R;MÁS R;AMOR A;FERNÁNDEZ J;GONZÁLEZ R","MENÉNDEZ, ROBERTO (7102205059); MÁS, ROSA (7007164572); AMOR, ANA MARÍA (35569426800); FERNÁNDEZ, JULIO CESAR (9432805500); GONZÁLEZ, ROSA MARÍA (57191737509)","EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOWDENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPERMEDIATED LIPID PEROXIDATION A RANDOMIZED DOUBLEBLIND PILOT STUDY",2000,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","61","11",32,"10.1016/S0011-393X(00)88013-3","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","OBJECTIVE: THE AIM OF THE STUDY WAS TO INVESTIGATE THE EFFECTS OF POLLCOSANOL ADMINISTERED AT ITS STARTING DOSAGE (5 MG/D) ON LOW-DENSITY LIPOPROTEIN (LDL) PEROXIDATION IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK. BACKGROUND: OXIDATION OF LDL HAS BEEN SUGGESTED AS A STEP IN THE DEVELOPMENT OF ATHEROSCLEROSIS. POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG THAT INHIBITS LIPID PEROXIDATION IN EXPERIMENTAL ROODELS AND HEALTHY VOLUNTEERS. METHODS: IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, AFTER 6 WEEKS OF DIETARY STABILIZATION, 20 PATIENTS WERE RANDOMLY ASSIGNED TO RECEIVE PLACEBO OR POLICOSANOL 5-MG TABLETS ONCE DAILY FOR 12 WEEKS. LDL ISOLATED AT BASELINE AND AFTER 12 WEEKS OF THERAPY WAS SUBMITTED TO IN VITRO COPPER-CATALYZED TIME-COURSE EXPERIMENTS. RESULTS: THE 2 GROUPS WERE STATISTICALLY SIMILAR AT RANDOMIZATION. WHEN COMPARED WITH BASELINE, POLICOSANOL SIGNIFICANTLY DECREASED (P < 0.05) TOTAL CHOLESTEROL (TC) BY 15.7%, LDL-CHOLESTEROL (LDL-C) BY 19.6%, THE RATIO OF TC TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) BY 18.1%, AND THE RATIO OF LDL-C TO HDL-C BY 23.2%, WHEREAS IT SIGNIFICANTLY INCREASED (P < 0.05) HDL-C BY 5.4%; THE CHANGE IN TRIGLYCERIDES DID NOT REACH STATISTICAL SIGNIFICANCE. WHEN COMPARED WITH PLACEBO, POLICOSANOL SIGNIFICANTLY DECREASED TC, THE RATIO OF TC TO HDL-C, AND THE RATIO OF LDL-C TO HDL-C (P < 0.05), AS WELL AS LDL-C (P < 0.01), WHEREAS IT SIGNIFICANTLY INCREASED HDL-C (P < 0.05). THE PERCENTAGE OF CHANGE VERSUS PLACEBO WAS SIGNIFICANT FOR TC (P < 0.001), LDL-C (P < 0.01), HDL-C (P < 0.05), AND THE RATIOS OF TC TO HDL-C AND LDL-C TO HDL-C (P < 0.05). TREATMENT WAS SAFE AND WELL TOLERATED. NO DRUG-RELATED DISTURBANCES IN SAFETY INDICATORS WERE FOUND. THREE PATIENTS WITHDREW FROM THE STUDY; HOWEVER, NONE WITHDREW BECAUSE OF ADVERSE EXPERIENCES. LAG PHASE WAS SIGNIFICANTLY PROLONGED BY 30.9% IN THE POLICOSANOL-TREATED GROUP COMPARED WITH BASELINE VALUES (59.87 ± 19.12 VS 51.68 ± 18.33 MIN, RESPECTIVELY; P < 0.05). IN CONTRAST, NO SIGNIFICANT CHANGES WERE FOUND IN THE LIPID PROFILE OR THE INDICATORS OF LIPID PEROXIDATION IN THE PLACEBO GROUP FROM BASELINE TO THE END OF THE STUDY. THE FREQUENCY OF PATIENTS SHOWING INCREASES IN LAG TIME WAS GREATER IN THE POLICOSANOL GROUP THAN IN THE PLACEBO GROUP. POLICOSANOL TENDED TO DECREASE DIENE PROPAGATION RATE, BUT THE MEAN REDUCTION (11.3%) DID NOT REACH STATISTICAL SIGNIFICANCE WHEN COMPARED WITH PLACEBO. CONCLUSIONS: THE PRESENT STUDY DEMONSTRATED THAT POLICOSANOL 5 MG/D NOT ONLY LOWERED TC, LDL-C, AND ATHEROGENIC INDICES, AND INCREASED HDL-C, BUT ALSO SIGNIFICANTLY DECREASED THE SUSCEPTIBILITY OF LDL TO COPPER ION-INDUCED LIPID PEROXIDATION IN VITRO IN HYPER-CHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK.","COPPER-MEDIATED OXIDATION; HYPERCHOLESTEROLEMIC PATIENTS; LOW-DENSITY LIPOPROTEIN PEROXIDATION; POLICOSANOL","COPPER ION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","STEINBERG D., PARTHASARATHY S., CAREW T.E., ET AL., BEYOND CHOLESTEROL. MODIFICATIONS OF LOW-DENSITY LIPOPROTEIN THAT INCREASE ITS ATHEROGENICITY, N ENGL J MED, 320, PP. 915-924, (1989); AVIRAM M., MODIFIED FORMS OF LOW DENSITY LIPOPROTEIN AND ATHEROSCLEROSIS, ATHEROSCLEROSIS, 98, PP. 1-9, (1993); ESTERBAUER H., WAG G., PUHL H., LIPID PEROXIDATION AND ITS ROLE IN ATHEROSCLEROSIS, BR MED BULL, 49, PP. 566-576, (1993); HEINECKE J.W., FREE RADICAL MODIFICATION OF LOW-DENSITY LIPOPROTEIN: MECHANISM AND BIOLOGICAL CONSEQUENCES, FREE RAD BIOL MED, 3, PP. 65-73, (1987); STEINBRECHER U.P., ZHANG H., LOUGHEED M., ROLE OF OXIDATIVELY MODIFIED LDL IN ATHEROSCLEROSIS, FREE RAD BIOL MED, 9, PP. 155-168, (1990); FAGGIOTTO A., ROSS R., STUDIES ON HYPERCHOLESTEROLEMIA IN NONHUMAN PRIMATES. II. FATTY STREAK CONVERSION TO FIBROUS PLAQUE, ARTERIOSCLEROSIS, 4, PP. 341-356, (1984); YLA-HERTTUALA S., PALINSKI W., ROSENFELD M.E., ET AL., EVIDENCE FOR THE PRESENCE OF OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEIN IN ATHEROSCLEROTIC LESIONS OF RABBITS AND MAN, J CLIN INVEST, 84, PP. 1086-1095, (1989); PALINSKI W., ROSENFELD M.E., YLA-HERTTUALA S., ET AL., LOW DENSITY LIPOPROTEIN UNDERGOES OXIDATIVE MODIFICATION IN VIVO, PROC NATL ACAD SCI USA, 86, PP. 1372-1376, (1989); QUINN M.T., PARTHASARATHY S., FONG L.G., STEINBERG D., OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEINS: A POTENTIAL ROLE IN RECRUITMENT AND RETENTION OF MONOCYTE/MACROPHAGES DURING ATHEROSCLEROSIS, PROC NATL ACAD SCI USA, 84, PP. 2995-2998, (1987); FROSTEGARD J., NILSSON J., HAEGERSTRAND A., ET AL., OXIDIZED LOW DENSITY LIPOPROTEIN INDUCES DIFFERENTIATION AND ADHESION OF HUMAN MONOCYTES AND THE MONOCYTE CELL LINE U937, PROC NATL ACAD SCI USA, 87, PP. 904-908, (1990); LEHR H.A., SEEMULLER J., HUBNER C., ET AL., OXIDIZED LDL-INDUCED LEUKOCYTE/ENDOTHELIUM INTERACTION IN VIVO INVOLVES THE RECEPTOR FOR PLATELET-ACTIVATING FACTOR, ATHEROSCLER THROMB, 13, PP. 1013-1018, (1993); AVIRAM M., MALONDIALDEHYDE AFFECTS THE PHYSICO-CHEMICAL AND BIOLOGICAL CHARACTERISTIC OF OXIDIZED LOW DENSITY LIPOPROTEIN, ATHEROSCLEROSIS, 84, PP. 141-143, (1990); AVIRAM M., MODIFIED FORMS OF LOW DENSITY LIPOPROTEIN AFFECT PLATELET AGGREGATION IN VITRO, THROMB RES, 53, PP. 561-567, (1989); SCHUFF-WERNER P., CLAUS G., ARMSTRONG V.W., ET AL., ENHANCED PROCOAGULATORY ACTIVITY (PCA) OF HUMAN MONOCYTES/MACROPHAGES AFTER IN VITRO STIMULATION WITH CHEMICALLY MODIFIED LDL, ATHEROSCLEROSIS, 78, PP. 109-112, (1989); AVIRAM M., PRESSER D., PLATELET SECRETORY SUBSTANCES ENHANCE IN VITRO PLASMA COAGULATION, ISR J MED SCI, 26, PP. 585-587, (1990); LAVY A., BROOK G.J., DANKNER G., ET AL., ENHANCED IN VITRO OXIDATION OF PLASMA LIPOPROTEINS DERIVED FROM HYPERCHOLESTEROLEMIC PATIENTS, METABOLISM, 40, PP. 794-799, (1991); LIU K.Z., CUDDY T.E., PIERCE G.N., OXIDATIVE STATUS OF LIPOPROTEINS IN CORONARY DISEASE PATIENTS, AM HEART J, 123, PP. 285-290, (1992); REGNSTROM J.N., NILSSON J., TORNVALL P., ET AL., SUSCEPTIBILITY TO LOW-DENSITY LIPOPROTEIN OXIDATION AND CORONARY ATHEROSCLEROSIS IN MAN, LANCET, 339, PP. 1183-1186, (1992); COMINACINI L., GARBIN U., PASTORINO A.M., ET AL., PREDISPOSITION TO LDL OXIDATION IN PATIENTS WITH AND WITHOUT ANGIOGRAPHICALLY ESTABLISHED CORONARY ARTERY DISEASE, ATHEROSCLEROSIS, 99, PP. 63-70, (1993); KEIDAR S., KAPLAN M., SHAPIRA C., ET AL., LOW DENSITY LIPOPROTEIN ISOLATED FROM PATIENTS WITH ESSENTIAL HYPERTENSION EXHIBITS INCREASED PROPENSITY FOR OXIDATION AND ENHANCED UPTAKE BY MACROPHAGES A POSSIBLE ROLE FOR ANGIOTENSIN II, ATHEROSCLEROSIS, 107, PP. 71-84, (1994); NISHIGAKI I., HAGIHARA M., TSUNEKAWA H., ET AL., LIPID PEROXIDE LEVELS OF SERUM LIPOPROTEIN FRACTIONS OF DIABETIC PATIENTS, BIOCHEM MED, 25, PP. 373-378, (1981); AVIRAM M., DANKNER G., COGAN U., ET AL., LOVASTATIN INHIBITS LOW-DENSITY LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES: IN VITRO AND IN VIVO STUDIES, METABOLISM, 41, PP. 229-235, (1992); KLEINVELD H.A., DEMACKER P.N., DE HAAN A., STALENHOEF A.F., DECREASED IN VITRO OXIDIZABILITY OF LOW-DENSITY LIPOPROTEIN IN HYPERCHOLESTEROLAEMIC PATIENTS TREATED WITH 3-HYDROXY-3-METHYLGLUTARYL COA REDUCTASE, EUR J CLIN INVEST, 23, PP. 289-295, (1993); HUSSEIN O., SCHLEZINGER S., ROSENBLAT M., ET AL., REDUCED SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) TO LIPID PEROXIDATION AFTER FLUVASTATIN THERAPY IS ASSOCIATED WITH THE HYPOCHOLESTEROLEMIC EFFECT OF THE DRUG AND ITS BINDING TO THE LDL, ATHEROSCLEROSIS, 128, PP. 11-18, (1997); REGNSTROM J.N., WALLDIUS G., CARLSON A., NILSSON J., EFFECT OF PROBUCOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS TO BECOME OXIDATIVELY MODIFIED IN VITRO, ATHEROSCLEROSIS, 82, PP. 43-51, (1990); REAVEN P., PARTHASARATHY S., BELTZ W., WITZTUM J.L., EFFECT OF PROBUCOL DOSAGE ON PLASMA LIPID AND LIPOPROTEIN LEVELS AND ON PROTECTION OF LOW DENSITY LIPOPROTEIN AGAINST IN VITRO OXIDATION IN HUMANS, ATHEROSCLEROSIS, 12, PP. 318-324, (1992); CRISTOL L.S., JIALAL I., GRUNDY S.M., EFFECT OF LOW-DOSE PROBUCOL ON LDL OXIDATION AND THE PLASMA LIPOPROTEIN PROFILE IN MALE VOLUNTEERS, ATHEROSCLEROSIS, 97, PP. 11-20, (1992); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEIN IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON D., ET AL., EFFECTS OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE-A-DAY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); ZARDOYA R., TULA I., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES IN SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); ORTENSI G., GLADSTEIN H., VALL H., TESONE P., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CASTANO G., MAS R., ILLNAIT J., ET AL., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPER-CHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVARES R., MAS R., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 44-51, (1997); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); FRAGA V., MENENDEZ R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, (1999); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN IN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); KLEINVELD H.A., HAK-LEMMERS H.L., STALENHOEF A.F., DEMACKER P.N., IMPROVED MEASUREMENTS OF LOW-DENSITY LIPOPROTEIN SUSCEPTIBILITY TO COPPER-INDUCED OXIDATION: APPLICATION OF A SHORT PROCEDURE FOR ISOLATING LOW-DENSITY LIPOPROTEIN, CLIN CHEM, 38, PP. 2066-2072, (1992); ESTERBAUER H., STRIEGL H., PUHL H., ROTHENEDER M., CONTINUOUS MONITORING OF IN VITRO OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN, FREE RAD RES COMMUN, 6, PP. 67-75, (1989); MARKWELL M.A., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-210, (1978); SECOND REPORT OF THE EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), CIRCULATION, 89, PP. 1333-1445, (1994)","R. MAS; CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA; EMAIL: DALMER@IP.ETECSA.CU","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0033823403","CURR THER RES CLIN EXP","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"MENÉNDEZ R, 2000, CURR THER RES CLIN EXP","MENÉNDEZ R, 2000, CURR THER RES CLIN EXP"
"RODRÍGUEZ M;GARCÍA H","RODRÍGUEZ, MARÍA D. (57220829332); GARCÍA, HAYDEE (7202282339)","TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT",1994,"TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS","14","6",45,"10.1002/tcm.1770140302","DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THE PRESENT STUDIES EVALUATED THE TERATOGENIC POTENTIAL AND REPRODUCTIVE TOXICITY OF POLICOSANOL, A NEW HYPOCHOLESTEROLEMIC DRUG. POLICOSANOL WAS ADMINISTERED BY ORAL GAVAGE TO SPRAGUE‐DAWLEY RATS AND NEW ZEALAND WHITE RABBITS DURING THE PERIOD OF ORGANOGENESIS AT DOSAGES UP TO 500 AND 1,000 MG/KG/DAY, RESPECTIVELY. THERE WAS NO EVIDENCE OF TERATOGENICITY OR ANY OTHER EMBRYONAL TOXICITY. IN A FERTILITY AND REPRODUCTIVE STUDY FEMALE RATS WERE TREATED WITH POLICOSANOL BY ORAL GAVAGE AT DOSAGES UP TO 500 MG/KG/DAY, 2 WEEKS PRIOR TO MATING AND THROUGHOUT MATING AND PREGNANCY TO DAY 21 OF LACTATION. MALES WERE GIVEN TREATMENT 60 DAYS BEFORE AND DURING MATING. REPRODUCTIVE PARAMETERS OF MOTHERS WERE NORMAL. THERE WAS NO EVIDENCE THAT TREATMENT AFFECTED THE SURVIVAL, POSTNATAL GROWTH, OR BEHAVIOR OF THE OFFSPRING. NO MATERNAL TREATMENT‐RELATED ADVERSE SIDE EFFECTS OCCURRED IN THESE STUDIES. IT IS CONCLUDED THAT POLICOSANOL WAS NOT TERATOGENIC IN EITHER RATS OR RABBITS, NOR DID IT INDUCE REPRODUCTIVE TOXICITY IN RATS. © 1994 WILEY‐LISS, INC. COPYRIGHT © 1994 WILEY‐LISS, INC., A WILEY COMPANY","FERTILITY; FETUS; HYPOCHOLESTEROLEMIC DRUG; OFFSPRING; REPRODUCTIVE TOXICITY","ABNORMALITIES, DRUG-INDUCED; ANIMAL; ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; FEMALE; FERTILITY; FETUS; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCTION; ANIMALIA; ORYCTOLAGUS CUNICULUS; ANTILIPEMIC AGENT; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; BIRTH DEFECT; CONTROLLED STUDY; EMBRYOTOXICITY; FEMALE; FERTILITY; FETUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; REPRODUCTION; TERATOGENICITY","","","CASTANO G, ZARDOYA R, ILLNAIT J, MAS R, FERNANDEZ L, SURRIBAS E, NODARSE M, FERNANDEZ J, EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROG CIENC MÉD (VENEZ), 5, PP. 21-28, (1991); HERNANDEZ F, ILLNAIT J, MAS R, CASTANO G, FERNANDEZ L, GONZALEZ M, CORDOVI N, FERNANDEZ J, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 1-8, (1992); PONS P, ILLNAIT J, RODRIGUEZ M, MAS R, FERNANDEZ L, ROBAINA C, FERNANDEZ J, EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 1-7, (1992); ARRUZAZABALA ML, CARBAJAL D, MAS R, CASTANO G, SOTOLONGO R, MESA R, EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CENIC CIENC BIOL, 22, PP. 60-61, (1991); ARRUZAZABALA ML, CARBAJAL D, MAS R, ILLNAIT J, LAGUNA A, CASTANO G, EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZ FARMACOL TER, 11, PP. 2-4, (1992); CRUZ-BUSTILLO D, MEDEROS CM, MAS R, ARRUZAZABALA ML, BARRETO B, MARTINEZ O, EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CENIC CIENC BIOL, 22, PP. 62-64, (1991); ALEMAN C, MAS R, RODEIRO I, NOA M, HERNANDEZ C, CAPOTE A, MENENDEZ R, GONZALEZ RM, AMOR AM, JIMENEZ S, TOXICOLOGÍA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REV CENIC CIENC BIOL, 22, PP. 102-105, (1991); ALEMAN C, MAS R, HERNANDEZ C, RODEIRO I, CEREJIDO E, NOA M, CAPOTE A, MENENDEZ R, AMOR A, FRAGA V, SOTOLONGO V, JIMENEZ S; RODRIGUEZ-ECHENIQUE C, MESA R, MAS R, MENENDEZ M, NOA M, GONZALEZ R, AMOR A, FRAGA V, LAGUNA A, (1992); RENDON A, RODRIGUEZ MD, LOPEZ M, GARCIA H, DE LAS CAJIGAS A, MAS R, FERNANDEZ I, (1992); WILSON JG, EMBRYOLOGICAL CONSIDERATIONS IN TERATOLOGY, TERATOLOGY, PRINCIPLES AND TECHNIQUES, PP. 262-277, (1965); DAWSON AB, A NOTE ON THE STAINING OF THE SKELETON OF CLEARED SPECIMENS WITH ALIZARIN RED S, STAIN TECHNOL, 1, PP. 123-124, (1926); STUCKHARDT JL, POPPE SM, FRESH VISCERAL EXAMINATION OF RAT AND RABBIT FETUSES USED IN TERATOGENICITY TESTING, TERATOGEN CARCINOGEN MUTAGEN, 4, PP. 181-188, (1984); MANSON JM, KANG YJ, TEST METHODS FOR ASSESSING FEMALE REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 311-359, (1989)","","","ENGLISH","TERATOG. CARCINOG. MUTAG.","ARTICLE","ISI","2-S2.0-0028174497","TERATOG CARCINOG MUTAG",NA,"NOTREPORTED",NA,"RODRÍGUEZ MD, 1994, TERATOG CARCINOG MUTAG","RODRÍGUEZ MD, 1994, TERATOG CARCINOG MUTAG"
"FERRER J","FERRER, JOSÉ ILLNAIT (58413016500)","FARMACOTERAPIA DE LA DISLIPIDEMIA EN EL ANCIANO",1999,"REVISTA CUBANA DE MEDICINA GENERAL INTEGRAL","15","7",4,"","CIENCIAS, LABORATORIO CLÍNICO, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, CUBA, CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS, CUBANACÁN, PLAYA, CIUDAD DE LA HABANA, AVE. 25 Y 158, CUBA","THE AGED PATIENT HAS PECULIAR CHARACTERISTICS WHICH DETERMINE THAT DRUGS HAVE A DYNAMICS DIFFERENT FROM THAT OF THE YOUNGER PATIENTS. THIS IS ALSO VALID FOR ANTILIPEMIC DRUGS. THE CONVINIENCE OF INDICATING ANTILIPEMIC TREATMENT IN THE ELDERLY HAS BROUGHT ABOUT INTERESTING CONTROVERSIES; HOWEVER, THERE SEEMS TO BE CONSENSUS IN THE SENSE THAT DISLIPIDEMIA MUST BE TREATED IN THOSE OLD PATIENTS WITH GOOD LIFE EXPECTANCY. DRUGS MUST BE SELECTED ACCORDING TO THE INDIVIDUAL CHARACTERISTICS OF THE AGED PATIENT. POLICOSANOL IS ONE OF THE DRUGS THAT DUE TO ITS EFFICACY AND TOLERABILITY IS BETTER FOR THE CONDITIONS OF THE DISLIPIDEMIC ELDERLY.","AGING HEALTH; ANTICHOLESTEREMIC AGENTS/THERAPEUTIC USE; HYPERLIPIDEMIA/DRUG THERAPY; LIFE EXPECTANCY","","","","BILHEIMER D.W., CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN ELDERLY, ATHEROSCLEROSIS, (1991); GOTTO A.M., ASSMANN N.G., CARMENA R., DAVIGNON J., FERNANDEZ-CRUZ A., PAOLETTI R., THE ILIB SPECTIAL CONSIDERATION IN THE ELDERLY, HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE, (1995); DENKE M.A., GRUNDY S.M., HYPERCHOLESTEROLEMIA IN THE ELDERLY PERSONS. RESOLVING THE TREATMENT DILEMA, ANN INTERN MED, 122, 5, PP. 780-792, (1990); KIRBY B., LIPOPROTEIN IN THE ELDERLY, INT MED RES, 19, 2, PP. 164-180, (1991); RAMDOMISED TRIAL FOR CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE (4S), LANCET, 344, 2, PP. 383-389, (1994); LA ROSA J.C., DISLIPIDEMIA IN WOMEN AND ELDERLY, MED CLIN NORTH AM, 78, 1, PP. 164-180, (1994); CROOKS J., O'MALEY K., STEVENSON I.H., PHARMACOKINETICS IN THE ELDERLY, CLIN PHARMACOKINET, 1, 1, PP. 280-296, (1976); VESTAL R.E., A REVIEW OF PHARMACOLOGY AND AGING, DRUGS, 16, 3, PP. 352-358, (1994); ROSSMANN I., BODILY CHANGES WITH AGING, HANDBOOK OF GERIATRIC PSYCHIATRY, (1980); DRUGS AND AGING. NEW YORK MC, (1980); COUNTERMAN J., SMIT J.W.A., BAR P.R., ERKELENS D.W., A COMPARISON OF THE EFFECTS OF SIMVASTATIN AND PRAVASTATIN MONOTHERAPY ON MUSCLE HISTOLOGY AND PERMEABILITY IN HYPERCHOLESTEROLEMIC PATIENTS, BR J PHARMACOL, 39, 1, PP. 135-141, (1995); MC CULLEY K.K., POSTNER J.D., THE APPLICATION OF BLOOD FLOW MEASUREMENT TO THE STUDY OF AGING MUSCLE, J GERONTOL, 50, SPEC., PP. 130-136, (1995); MC DONALD J.S., KORNBURST D.J., KLOSS M.W., PRAHALADA S., BERRY P.H., ET AL., PRECLINICAL EVALUATION OF LOVASTATIN, AMER J CARDIOL, 62, 11, (1988); HEDELBRAND R.D., HEPPERLEN T.W., LOVASTATIN AND HYPOSPERMIA, ANN INTERN MED, 112, 7, PP. 194-201, (1990); KLIMOV A.N., IMMUNOREACTIVITY AND ATHEROSCLEROSIS, SOC MED REV CARDIOL, 4, 1, PP. 337-345, (1985); BANNWAARTH E., MIREMONT G., PAPAPIETRO P.M., LUPUS LIKE SINDROME ASSOCIATED WITH SIMVASTATIN, ARCH INTERN MED, 152, 5, (1992); LATIES A.M., KEATES E.U., TAYLOR H.R., CHREMOS A.N., SHERM C.L., LIPPS E.A., ET AL., THE HUMAN LENS AFTER 48 WEEKS OF TREATMENT WITH SIMVASTATIN, NEW RNG J MED, 323, 10, PP. 683-684, (1990); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBIT CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESING IN HUMAN CULTURED, BIOL RES, 27, 2, PP. 199-201, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS ON NORMOCHOLESTEROLEMIA RATS, BIOL RES, 1, 29, PP. 253-257, (1996); BROWN M.S., GOLDSTEIN J.L., A GENERAL SCHEME OF REGULATION OF CHOLESTEROL METABOLISM IN MAMMALIANCELLS, DISTURBANCES IN LIPIDS AND LIPOPROTEINS METABOLISM, PP. 1-173, (1978); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5MG) EN PACIENTES CON HIPERCOLESTEROLEMIA TIPO II, PROGRESOS EN CIENCIAS MÉDICAS, 5, 6, PP. 21-28, (1991); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ I., GONZALEZ M., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, 4, PP. 568-575, (1992); CAMPILONGO R., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES CON HIPERCHOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, PRENSA MED ARGENT, 83, 1, PP. 665-672, (1996); CRUZ-BUSTILLO D., MEDEROS C.M., MAS R., ARRUZAZABALA M.L., BARRETO B., MARTINEZ O., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO DE CEBA, REV CENIC CIENCIAS BIOL, 22, 1-2, PP. 62-63, (1991); NOA M., MAS R., EFFECT OF POLICOSANOL ON FOAM CELLS FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARMACOL, 56, 7, PP. 62-63, (1996); NOA M., MAS R., BRINIS F., MESA R., EFFECT OF POLICOSANOL IN CIRCULATING ENDOTELIAL CELLS IN EXPERIMENTAL MODEL, J PHARM PHARMACOL, (1996); RODRIGUEZ-ECHENIQUE C., MESA R., NOA M., MENENDEZ R., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL IN CRONICELY ADMINISTERED MALE MONKEYS (MACACA ARCTOIDES), FD CHEM TOXIC, 32, 6, (1994); BATISTA J., STUSSER R., PENICHET M., UGUET E., DOPLER ULTRASOUD PILOT STUDY OF THE EFFECTS OF LONG TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES, 13, 3, PP. 137-148, (1995); BATISTA J., STUSSER R., PADRON R., SOSA F., PERZTOL O., PEREZ B., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 21 MONTH OF LIPID LOWERING THERAPY WITH POLICOSANOL, 13, 3, PP. 137-148, (1996); BATISTA J., STUSSER R., SAES F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE AGED PATIENTS. A 14-MONTH PILOT STUDY, INT CLIN PHARMACOL THER, 13, 2, PP. 137-148, (1996); ARRUZAZABALA M.L., CARVAJAL D., MAS R., GARCIA M., FRAGA V., EFFECT OF POLICOSANOLON PLATELET AGGREGATION IN RATS, THROMB RES, 3, PP. 321-327, (1993); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARVAJAL D., EFFECT OF POLICOSANOL SUCCESIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 33, 1, PP. 1-5, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN PLAQUETARIA EN VOLUNTARIOS SANOS, REV IBEROAM TROM HEMOSTAS, 42, 9, PP. 58-62, (1996); CUTTER R.G., ANTIOXIDANT, AGEING AND LONGEVITY, FREE RADICALS IN BIOLOGY, PP. 371-380, (1984); SNODDERLY M.D., EVIDENCE FOR PROTECTION AGAINST AGED-RELATED MUSCULAR DEGENERATION BY CAROTENOIDS AND ANTIOXIDANT VITAMINS, AM J CLIN NUTR, 62, SUPPL., (1995); ALEMAN C., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN RATS AND RABBITS, TOXICOL LETT, 70, 1, PP. 77-87, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN RATS AND RABBITS. TERATOGENESIS, CARCINOG MUTAGEN, 14, 2, PP. 107-113, (1994); ALEMAN C., NOA M., CEREJIDO E., MAS R., RODEIRO I., HERNANDEZ C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: A 18 MONTH STUDY, FOOD CHEM TOXICOL, 33, 6, PP. 575-578, (1995); ARRUZAZABALA M.L., CARVAJAL D., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO EN CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZ FARMACOL TERAP, 11, 2, PP. 80-86, (1992); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., CASTANO G., ET AL., ONE YEAR STUDY ON THE EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, 9, PP. 665-672, (1994); CANETTI M., MORERA M., ILLNAIT J., MAS R., FERNANDEZ L., ROBAINA C., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 57, 7, PP. 568-577, (1996); CASTANO G., NODARSE M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., COMPARACIÓN DE LOS EFECTOS DEL POLICOSANOL Y LA LOVASTATINA EN PACIENTES CON HIPERCOLESTEROLEMIA PRIMARIA TIPO II, REV CENIC CIENC BIOL, 27, 1-3, PP. 57-63, (1996); CANETTI M., MORALES M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO J., ESTUDIO COMPARATIVE DE LOS EFECTOS DEL POLICOSANOL Y EL GEMFIBROZIL EN PACIENTES CON HIPERCOLESTEROLEMIA TIPO II, REV CENIC CIENC BIOL, 57, 1-3, PP. 64-70, (1996); PONS P., FERNANDEZ L., MAS R., ILLNAIT J., ROBAINA C., RODRIGUEZ M., ESTUDIO COMPARATIVO DEL POLICOSANOL Y EL BEZAFIBRATO EN PACIENTES CON HIPERCOLESTEROLEMIA PRIMARIA TIPO II, REV CENIC CIENC BIOL, 27, 1-3, PP. 71-77, (1996); PONS P., ILLNAIT J., MAS R., RODRIGUEZ M., ALEMAN C., FERNANDEZ J.C., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RESS, 58, 1, PP. 26-35, (1997); TORRES O., AGRAMONTE A.L., ILLNAIT J., MAS R., FERNANDEZ R., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NDDM WITH POLICOSANOL IN HYPERTENSIVE PATIENTS WITH POLICOSANOL, DIABETIC CARE, 18, 4, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., MAS R., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULINE-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, 1, PP. 44-51, (1997); ZARDOYA R., TULA L., CASTANO G., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIA PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, 7, PP. 819-828, (1995); CASTANO G., CANETTI M., MORERA M., TULA L., MAS R., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. A 12 MONTH STUDY, CURR THER RES, 56, 8, PP. 691-728, (1995)","","","SPANISH","REV. CUBA. MED. GEN. INTEGR.","ARTICLE","ISI","2-S2.0-52549095535","REV CUBA MED GEN INTEGR",NA,"NOTREPORTED",NA,"FERRER JI, 1999, REV CUBA MED GEN INTEGR","FERRER JI, 1999, REV CUBA MED GEN INTEGR"
"CASTAÑO G;TULA L;CANETTI M;MORERA M;MÁS R;ILLNAIT J;FERNÁNDEZ L;FERNÁNDEZ J","CASTAÑO, GLADYS (56232967100); TULA, LEONE (9434741100); CANETTI, MIGUEL (7004415986); MORERA, MARTA (57050941200); MÁS, ROSA (7007164570); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO CÉSAR (9432805500)","EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1996,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","57","8",46,"10.1016/S0011-393X(96)80074-9","MEDICAL-SURGICAL RESEARCH CENTER, HAVANA, CUBA;LUIS DÍAZ SOTO HOSPITAL, HAVANA, CUBA;SALVADOR ALLENDE HOSPITAL, HAVANA, CUBA;SALVADOR ALLENDE HOSPITAL, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THE RESULTS OF A 1-YEAR, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL ADMINISTERED AT 10 MG DAILY IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HYPERTENSION TREATED WITH BETA-BLOCKERS, DIURETICS, OR CALCIUM ANTAGONISTS ARE REPORTED. THE TRIAL INCLUDED 58 PATIENTS WITH TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LCL-C) LEVELS NOT CONTROLLED SUFFICIENTLY DURING A 12-WEEK DIET-ONLY PERIOD. TWO MONTHS AFTER INITIATING THERAPY, TREATMENT WITH POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL, LDL-C, AND RATIOS OF LDL-C:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND TOTAL CHOLESTEROL:HDL-C. THE TREATMENT EFFECT ON THESE EFFICACY VARIABLES WAS MAINTAINED DURING THE 1-YEAR FOLLOW-UP. THUS 12 MONTHS AFTER THERAPY REDUCTIONS OF 19.1% IN LDL-C, 13.0% IN TOTAL CHOLESTEROL, 20.0% IN TOTAL CHOLESTEROL: HDL-C, AND 24.2% IN LDL-C:HDL-C HAD BEEN OBTAINED. NO CHANGES IN ANY LIPID PROFILE VARIABLES WERE SEEN IN THE PLACEBO GROUP THROUGHOUT THE STUDY. AT THE END OF THE THERAPY, POLICOSANOL HAD INCREASED HDL-C SIGNIFICANTLY (17.1%), WHILE TRIGLYCERIDES DID NOT CHANGE SIGNIFICANTLY. NO PATIENT WITHDREW FROM THE STUDY AND NO DRUG-RELATED CLINICAL OR BIOCHEMICAL SIDE EFFECTS WERE OBSERVED. ONLY TWO PATIENTS (ONE IN EACH GROUP) REPORTED MILD ADVERSE EVENTS. © 1996, ALL RIGHTS RESERVED.","","BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","ANDERSON KM, WILSON PWF, ODELL PM, KANNEL WB, AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); STAMLER J, WENTWORTH D, NEATON JD, PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF HYPERCHOLESTEROLEMIA IN MEN WITH HYPERTENSION, JAMA, 80, PP. 33-36, (1986); LAURENZI M, MANCINI M, MENOTTI A, ET AL., MULTIPLE RISK FACTORS IN HYPERTENSION: RESULTS FROM THE GUBBIO STUDY, JOURNAL OF HYPERTENSION, 8, (1990); O'CONNOR P, FEELY J, SHEPERD J, LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); BROWN WV, HOWARD WJ, FIELD L, NICOTINIC ACID AND ITS DERIVATIVES, DRUG TREATMENT OF HYPERLIPIDEMIA, PP. 189-213, (1991); BUCKLEY MMT, GOA KL, PRICE AH, BROGDEN RN, PROBUCOL: A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN HYPERCHOLESTEROLAEMIA, DRUGS, 37, PP. 761-800, (1989); WALKER JF, WORLDWIDE EXPERIENCE WITH SIMVASTATIN/LOVASTATIN, EUR HEART J, 13, PP. 21-22, (1992); DESLYPERE JP, THE ROLE OF HMG-COA REDUCTASE INHIBITORS IN THE TREATMENT OF HYPERLIPIDEMIA: A REVIEW OF FLUVASTATIN, CURR THER RES, 56, PP. 111-128, (1995); BULPITT CJ, DOLLERY CT, SIDE EFFECTS OF HYPOTENSIVE AGENTS EVALUATED BY A SELF-ADMINISTERED QUESTIONNAIRE, BMJ, 3, PP. 485-488, (1973); FRIMODT-MOELLER J, LOLDRUP POULSEN D, KORNERUP HJ, BECH P, QUALITY OF LIFE, SIDE EFFECTS AND EFFICACY OF LISINOPRIL COMPARED WITH METOPROLOL IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION, J HUM HYPERTENS, 5, PP. 215-221, (1991); DURRINGTON PN, DIABETES, HYPERTENSION AND HYPERLIPIDAEMIA, POSTGRAD MED J, 69, (1993); ARRUZAZABALA ML, CARBAJAL D, MAS R, ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); RODRIGUEZ C, MESA R, MAS R, ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VEN DE FARMACOL Y TER, 11, PP. 74-79, (1992); HERNANDEZ F, ILLNAIT J, MAS R, ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 4, PP. 568-575, (1992); CASTANO G, ZARDOYA R, ILLNAIT J, ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-27, (1991); PONS P, MAS R, ILLNAIT J, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P, JIMENEZ A, RODRIGUEZ M, ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); PONS P, RODRIGUEZ M, ROBAINA C, ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASE OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P, RODRIGUEZ M, MAS R, ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, PP. 1084-1092, (1994); ANEIROS E, MAS R, CALDERON B, ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G, MAS R, NODARSE M, ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 296-304, (1995); CANETTI M, MOREIRA M, ILLNAIT J, ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M, MOREIRA M, ILLNAIT J, ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, (1995); TORRES O, AGRAMONTE AJ, ILLNAIT J, TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); FRIEDEWALD WT, LEVY RI, FRIEDERICKSON SD, ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGUE, CLIN CHEM., 18, PP. 499-502, (1972); SEIGLER L, WU WT, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); ILLINGWORTH DR, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); O'BRIEN PC, SHAMPO MC, STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0029829726","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 1996, CURR THER RES CLIN EXP","CASTAÑO G, 1996, CURR THER RES CLIN EXP"
"FERNÁNDEZ J;MÁS R;CASTAÑO G;MENÉNDEZ R;AMOR A;GONZÁLEZ R;ALVAREZ E","FERNÁNDEZ, J.C. (9432805500); MÁS, R. (7007164570); CASTAÑO, G. (56232967100); MENÉNDEZ, R. (7102205059); AMOR, A.M. (35569426800); GONZÁLEZ, R.M. (57191737509); ALVAREZ, E. (15053135600)","COMPARISON OF THE EFFICACY SAFETY AND TOLERABILITY OF POLICOSANOL VERSUS FLUVASTATIN IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN",2001,"CLINICAL DRUG INVESTIGATION","21","10",31,"10.2165/00044011-200121020-00003","NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","OBJECTIVE: TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL WITH THAT OF FLUVASTATIN IN OLDER HYPERCHOLESTEROLAEMIC WOMEN. DESIGN AND SETTING: RANDOMISED, SINGLE-BLIND, PARALLEL-GROUP STUDY PERFORMED AT A SINGLE CENTRE IN CUBA. PATIENTS AND PARTICIPANTS: 70 WOMEN AGED 60 TO 80 YEARS WITH TYPE II HYPERCHOLESTEROLAEMIA. METHODS: PATIENTS WERE RANDOMISED AFTER 4 WEEKS' DIETARY STABILISATION ON A STEP-ONE CHOLESTEROL-LOWERING DIET TO TREATMENT WITH POLICOSANOL (10MG) OR FLUVASTATIN (20MG) TABLETS ONCE DAILY FOR 8 WEEKS. RESULTS: POLICOSANOL SIGNIFICANTLY LOWERED LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) [29,2%, P < 0.001], TOTAL CHOLESTEROL (TC) [19.3%, P <0.001], TRIGLYCERIDES (7%, P < 0,05) AND THE RATIOS OF LDL-C (39.8%, P < 0.001) AND TC (31.6%, P < 0.001) TO HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND SIGNIFICANTLY INCREASED HDL-C (19.8%, P < 0.001). FLUVASTATIN SIGNIFICANTLY LOWERED LDL-C (22.9%, P < 0.001). TC (16,7%, P < 0.001), TRIGLYCERIDES (8.2%, P < 0.05). LDL-C/HDL-C (28.4%, P < 0.001) AND TC/HDL-C (22.8%, P < 0.001), AND SIGNIFICANTLY INCREASED HDL-C (9.2%, P < 0.001). POLICOSANOL WAS MORE EFFECTIVE THAN FLUVASTATIN IN REDUCING LDL-C (P < 0.01), TC/HDL-C (P < 0.01) AND LDL-C/HDL-C (P < 0.001) AS WELL AS IN INCREASING HDL-C (P < 0.01). POLICOSANOL, BUT NOT FLUVASTATIN, SIGNIFICANTLY INCREASED LAG TIME FOR LDL LIPID PEROXIDATION (36.5%. P < 0.001) AND SIGNIFICANTLY DECREASED THE DIENE PEROXIDATION RATE (15.5%, P < 0.05). BOTH TREATMENTS WERE WELL TOLERATED, FIVE FLUVASTATIN, BUT NO POLICOSANOL RECIPIENTS DISCONTINUED THE STUDY, THREE BECAUSE OF ADVERSE EVENTS (CHEST PAIN AND GASTRIC DISCOMFORT, SKIN RASH, AND DIZZINESS). OVERALL, THREE POLICOSANOL AND FIVE FLUVASTATIN RECIPIENTS REPORTED ADVERSE EVENTS DURING THE STUDY. CONCLUSIONS: THE CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL 10 MG/DAY ADMINISTERED FOR 8 WEEKS TO OLDER WOMEN WITH TYPE II HYPERCHOLESTEROLAEMIA WERE SLIGHTLY BETTER THAN THOSE OF FLUVASTATIN 20 MG/DAY WITH RESPECT TO THE EXTENT OF THE CHANGES IN LDL-C, ATHEROGENIC INDICES AND HDL-C LEVELS. IN ADDITION, POLICOSANOL, BUT NOT FLUVASTATIN, SIGNIFICANTLY INHIBITED THE SUSCEPTIBILITY OF LDL TO UNDERGO LIPID PEROXIDATION IN THIS PARTICULAR STUDY POPULATION. NEVERTHELESS, FURTHER STUDIES IN LARGER POPULATIONS AND WITH HIGHER DOSAGES MUST BE CONDUCTED TO CORROBORATE THE PRESENT RESULTS.","","ANTILIPEMIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUBA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; STOMACH DISEASE; THORAX PAIN; VERTIGO","","","ANDERSON K.M., WILSON P.W.F., ODELL P.M., ET AL., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOY L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A.M., HUNT D., LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY. CLINICAL IMPLICATIONS FOR CARDIOVASCULAR PRACTICE, CHOLESTEROLLOWERING THERAPY: EVALUATION OF CLINICAL TRIAL EVIDENCE, PP. 173-190, (2000); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, 1, PP. 300-331, (1994); BLUM C.B., COMPARISON OF PROPERTIES OF FOUR INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, AM J CARDIOL, 73, PP. 3D-11D, (1994); GARNETT W.R., THE PHARMACOLOGY OF FLUVASTATIN, A NEW HMG-COA REDUCTASE INHIBITORS, CLIN CARDIOL, 17, PP. 3-19, (1994); PARKER R.A., CLARK R.W., SIT S.Y., ET AL., SELECTIVE INHIBITION OF CHOLESTEROL SYNTHESIS IN LIVER VERSUS EXTRAHEPATIC TISSUES BY HMG-COA REDUCTASE INHIBITORS, J LIPID RES, 31, PP. 1271-1282, (1990); PATERNITTI J., NEW DRUGS FOR INHIBITING CHOLESTEROL SYNTHESIS EXPERIMENTAL STUDIES WITH FLUVASTATIN, CAN J CARDIOL, 8, PP. 21A-22A, (1992); TROENDLE A., CLINICAL REVIEW OF FLUVASTATIN SHORT-TERM: LONG-TERM DATA CLIN CARDIOL, 17, 4, PP. 11-15, (1994); DAVIDSON M.H., FLUVASTATIN LONG TERM EXTENSION TRIAL (FLUENT): SUMMARY OF EFFICACY AND SAFETY, AM J MED, 96, PP. 41S-44S, (1994); PLOSKER G.L., WAGSTAFF A.J., FLUVASTATIN: A REVIEW OF ITS PHARMACOLOGY AND USE IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA, DRUGS, 51, 3, PP. 433-459, (1996); BAGGIO G., DE CANDIA O., FORTE P.L., ET AL., EFFICACY AND SAFETY OF FLUVASTATIN, A NEW HMG COA REDUCTASE INHIBITOR, IN ELDERLY HYPERCHOLESTEROLAEMIC WOMEN, DRUGS, 47, PP. 59-63, (1994); LAGUNA A., MAGRANER J., ARRUZAZABALA M.L., ET AL.; MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPEREHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURT THER RES, 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 6-14, (1999); CASTANO G., MAS R., FERNANDEZ J.C., FERNANDEZ L., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WHIR TYPE 11 HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AN NON INSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 19, 4, PP. 105-116, (2000); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT J NUTR, 77, PP. 923-932, (1996); CASTANO G., MAS R., FENANDEZ L., ET AL., EFFECT OF POLICOSANOL, ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); CASTANO G., MAS R., FENANDEZ J.C., ET AL., EFFECT OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL, (2000); INSULL J.W., BLACH D., DUYOUNE C., ET AL., EFFICACY AND SAFETY OF ONCE DAILY AS TWICE-DAILY DOSING WITH FLUVASTATIN, A SYNTHETIC REDUCTASE INHIBITOR, IN PRIMARY HYPERCHOLESTEROLEMIA, ARCH INTERN MED, 154, PP. 2449-2455, (1994); JACOTOT B., BANGA J.D., PFISTER P., ET AL., EFFICACY OF A LOW DOSERANGE OF FLUVASTATIN (XU62-320) IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA. A DOSE-RESPONSE STUDY IN 431 PATIENTS, BR J CLIN PHARMACOL, 38, PP. 257-263, (1994); BETTERIDGE D.J., DURRINGTON P.N., FAIRHUST G.J., ET AL., COMPARISON OF LIPID-LOWERING EFFECTS OF LOW- DOSE FLUVASTATIN AND CONVENTIONAL-DOSE GEMFIBROZIL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, AM J MED, 96, PP. 45S-54S, (1994); ILLINGWORTH D.R., TOBERT J.A., A REVIEW OF CLINICAL TRIALS COMPARING HMG-COA REDUCTASE INHIBITORS, CLIN THER, 16, 3, PP. 366-385, (1994); ILLINGWORTH D.R., STEIN E.A., KNOPP R.H., ET AL., A RANDOMIZED MULTICENTER TRIAL, COMPARING THE EFFICACY OF SIMVASTATIN AND FLUVASTATIN, J CARDIOVASC PHARMACOL THER, 1, 1, PP. 23-30, (1996); OSE L., SCOTT R., DOUBLEBLIND COMPARISON OF THE EFFICACY AND TOLERABILITY OF SIM4 VASTATIN AND FLUVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CLIN DRUG INVEST, 10, 3, PP. 127-138, (1995); BUZZI A.P., PASTORE M.A., ARGENTINE MULTICENTER EVALUATION OF FLUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, 12, PP. 1013-1028, (1997); JACOTOT B., BENGHOZI R., PFISTER P., ET AL., COMPARISON OF FLUVASTATIN VERSUS PRAVASTATIN TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, AM J CARDIOL, 76, 2, PP. 54A-56A, (1995); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR THER RES, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); DAVIGNON J., THE PLEIOTROPIC EFFECTS OF DRUGS AFFECTING LIPID METABOLISM, PROCEEDINGS OF THE XITH INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, PP. 63-77; MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION: A RANDOMIZED, DOUBLEBLIND PILOT STUDY, CURR THER RES, 61, PP. 609-620, (2000); HUSSEIN O., SCHLEZINGER S., ROSENBEST M., ET AL., REDUCED SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) TO LIPID PEROXIDATION AFTER FLUVASTATIN THERAPY NO ASSOCIATED WITH THE HYPOCHOLESTEROLEMIC EFFECT OF THE DRUG AND ITS BINDING TO THE LDL, ATHEROSCLEROSIS, 128, PP. 11-18, (1997); LEONHARDT W., KURKTSCHEN T., MEISSNER D., ET AL., EFFECTS OF PRAVASTATIN THERAPY ON LIPIDS, ANTIOXIDANTS, OXIDATIONS OF LOW DENSITY LIPOPROTEINS AND TRACE METALS, EUR J CLIN PHARMACOL, 53, PP. 65-69, (1992); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROREIN FOR CHOLESTEROL, DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); KLEINVELD H.A., HARK-LEMMERS H.L.M., STALENHOEF A.F.H., ET AL., IMPROVED MEASUREMENTS OF LOW-DENSITY LIPOPROTEIN SUSCEPTIBILITY TO COPPER-INDUCED OXIDATION: APPLICATION OF A SHORT PROCEDURE FOR ISOLATING LOW-DENSITY LIPOPROTEIN, CLIN CHEM, 38, PP. 2066-2072, (1992); ESTERBAUER H., STRIEGL H., PUHL H., ET AL., CONTINUOUS MONITORING OF IN VITRO OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN, FREE RADIC RES COMMUN, 6, PP. 67-75, (1989); MARKWELL M.A., HASS S.M., BIEBER L.L., ET AL., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-210, (1987); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); LUSCHER T.F., BARTON M., BIOLOGY OF ENDOTHELIUM, CLIN CARDIOL, 20, PP. II3-II10, (1997); NASR A., BRECKWOLDT M., ESTROGEN REPLACEMENT THERAPY AND CARDIOVASCULAR PROTECTION: LIPID MECHANISM ARE THE TIP OF AN INBERZ, GYNECOL ENDOCRINOL, 12, PP. 43-59, (1998); MIJATOVIC V., VAN DER MOOREN M.J., STEHOUWER C.D.A., ET AL., POSTMENOPAUSAL HORMONE REPLACEMENT, RISK ESTIMATORS FOR CORONARY ARTERY DISEASE AND CARDIOVASCULAR PROTECTION, GYNECOL ENDOCRINOL, 13, PP. 130-144, (1999)","","","ENGLISH","CLIN. DRUG INVEST.","ARTICLE","ISI","2-S2.0-0035092189","CLIN DRUG INVEST",NA,"NOTREPORTED",NA,"FERNÁNDEZ JC, 2001, CLIN DRUG INVEST","FERNÁNDEZ JC, 2001, CLIN DRUG INVEST"
"CAMPILONGO R;SANDIN D;FELDMAN R;BARRIOS O;ABBONIZIO A;MASNU R;VENTURINI A;ESTEGUY A;HERRERA M;CIABURRI L;ROSENTHAL P;VALSMARIS M;MARTINO O;ANTONIOLI A;LAGO P;WINGIEL M;VAZZANO A;LAURO R C;MELE O;LOZANO D;MONTERO N;PELLEGRINI H;MOTTO M;BLUNTRITT M;PICCO S;CERRUTI J;ARENA A;SOSA A;HERNANDORENA T;NAVEIRA A;LATI A","CAMPILONGO, R. (6503911642); SANDIN, D. (6701735744); FELDMAN, R. (55708136400); BARRIOS, O. (6506950437); ABBONIZIO, A. (6504612636); MASNU, R. (6504463153); VENTURINI, A. (7007147720); ESTEGUY, A. (6504452040); HERRERA, M. (7202049954); CIABURRI, L. (6504288690); ROSENTHAL, P. (7102734577); VALSMARIS, M. (6505674728); MARTINO, O. (6603906870); ANTONIOLI, A. (6602679574); LAGO, P. (7006164080); WINGIEL, M. (6504134955); VAZZANO, A. (6506579683); LAURO RODRIGUEZ, C. (6505719818); MELE, O. (6504587095); LOZANO, D. (6603933156); MONTERO, N. (6603213403); PELLEGRINI, H. (6603063427); MOTTO, M. (7004198416); BLUNTRITT, M. (6504056463); PICCO, S. (6701412005); CERRUTI, J. (6506218534); ARENA, A. (7005542425); SOSA, A. (7006027099); HERNANDORENA, T. (6504284168); NAVEIRA, A. (57859954000); LATI, A. (6503969303)","EFICACIA SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES CON HIPERCOLESTEROLEMIA TIPO II ESTUDIO ABIERTO",1996,"PRENSA MEDICA ARGENTINA","83","7",15,"","","THIS STUDY INVESTIGATES THE EFFICACY AND TOLERABILITY OF POLICOSANOL (5 OR 10 MG/D) IN 159 PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA INCLUDED IN THE TRIAL AFTER A 4 WEEK DIE-ONLY PERIOD. PATIENTS WERE TREATED WITH ONE 5 MG TABLET TAKEN AT THE DINNER TIME (5 MG/D) OR TWO DAILY TABLETS TAKEN AT LUNCH AND DINNER TIME (10 MG/D) FOR 12 WEEKS ACCORDING TO PHYSICIANS PRESCRIPTION'S: 101 PATIENTS RECEIVED 5 MG/D AND 58 CASES WERE TREATED WITH 10 MG/D. TOTAL CHOLESTEROL, LDL-C AND TRIGLYCERIDE VALUES WERE SIGNIFICANTLY LARGER IN THE 10 MG GROUP THAN IN 5 MG GROUP, WHICH INDICATES A PREVALENCE OF SEVERE HUYPERCHOLESTEROLAEMIA IN THE 10 MG GROUP. POLICOSANOL ADMINISTERED AT 5 MG/D SIGNIFICANTLY REDUCED (P<0,001) CHOLESTEROL (18,0%) LDL-C (24.3%) AND THE RATIOS OF LDL-C TO HDL-C (25.4%) AND CHOLESTEROL TO HDL-C (19.8%). ADMINISTRATION OF POLICOSANOL AT 10 MG/D SIGNIFICANTLY LOWERED (P<0,001) CHOLETEROL (22.4%), LDL-C (29.2%) AND THE RATIOS OF LDL-C TO HDL-C (29.9%) AND CHOLESTEROL TO HDL-C (26.0%). LEVELS OF HDL-C SIGNIFICANTLY RAISED (P<0,05) BY 7.7% (5 MG/D) AND 12.8% (10 MG/D), MEANWHILE TTRIGLYCERIDES LOWERED (P<0,01) BY 8,2 AND (P<0.05) 7,3%, RESPECTIVELY. BOTH DOSES WERE SAFE AND WELL TOLERATED. NO DRUG-RELATED CLINICAL OR BLOOD BIOCHEMISTRY DISTURBANCES WERE PRODUCED. BLOOD DIASTOLIC AND SYSTOLIC PRESSURE SIGNIFICANTLY AND MILDLY REDUCED AFTER THERAPY IN BOTH GROUPS. THREE PATIENS REPORTED SOME ADVERSE EXPERIENCE DURING THE STUDY: TWO WERE 5 MG TREATED PATIENTS (DIZZINESS AND GASTRITIS) AND OTHER FROM THE 10 MG GROUP REPORTED NAUSEAS AND EPIGASTRALGIA. THESE RESULTS CORROBORATE PREVIOUS DATA OBTAINED IN RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDIES AND SHOWS THAT POLICOSANOL IS EFFECTIVE AND WELL TOLERATED FOR TREATING TYPE II HYPERCHOLAESTEROLEMIA. A MODERATE INCREASE OF EFFICACY WAS OBSERVED WITH POLICOSANOL AT 10 MG/D, MEANWHILE THE EXCELLENT SAFETY AND TOLERABILY OF THE TREATMENT REMAINED UNCHANGED AT THIS DOSAGE.","","","","","ALEMAN C.L., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., CAPOTE A., MENENDEZ R., AMOR A.M., GONZALEZ R.M., SOTOLONGO V., JIMENEZ S., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL. LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEYRATS: A 24 MONTHS STUDY, TERATOGENESIS, CARCINOGENESIS AND MUTAGENESIS, 14, PP. 239-249, (1994); ALEMAN C.L., NOA M., CEREJIDO E., MAS R., RODEIRO I., HERNANDEZ C., BRINIS F., CARCINOGENICITY OF POLICOSANOL IN MICE: A 18 MONTHS STUDY, FOOD AND CHEM. TOXICOL., 33, PP. 573-578, (1995); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMY, CURR. THER. RES., 56, PP. 176-182, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 205-208, (1994); BOCCUZZI S.J., KEEGAN M.E., HIRSCH L.J., SHAPIRO D.R., PLITKIN D.J., MITCHEL Y.B., LONG TERM EXPERIENCE WITH SIMVASTATIN, DRUG INVEST., 5, PP. 135-140, (1993); CANNETTI M., MOREIRA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ONE YEAR STUDY ON THE EFFECT OF POLISOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, AD. THER., 12, PP. 245-254; CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J.C., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TRATMENT OF TYPE II HUYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 296-304, (1995); CASTANO G., TULA L., CANETTI M., MORERA M., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL (10 MG/DAY) IN HYUPERTENSIVE PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., (1996); FRICK M.H., ELO D., HAAPA D., ET AL., HELSINKI HEART STUDY; PRIMARY-INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DISLIPIDEMIA, N. ENGL. J. MED., 317, PP. 1237-1245, (1987); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION ON THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGUE, CLIN. CHEM., 18, PP. 499-502, (1972); HEEL R.C., ET AL., COLESTIPOL. A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN PATIENTS WITH HYPERCHOLESTEROLAEMIA, DRUGS, 19, PP. 161-180, (1980); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., JIMENEZ S., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); MONK J.P., TODD P.A., BEZAFIBRATE: A REVIEW OF TIS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN HYPERLIPIDAEMIA, DRUGS, 33, PP. 539-576, (1987); NEATON J.D., WENTWORTH D., SERUM CHOLESTEROL, BLOOD PRESSURE, CIGARETTE SMOKIN AND DEATH FROM CORONARY HEAR DISEASE. OVERALL FINDINGS AND DIFFERENCES BY AGE FOR 316, 099 WHITE MEN, ARCH INTERN. MED., 64, PP. 152-156, (1992); O'CONNOR O., FEELY J., SHEPHERD J., LIPID LOWERING DRUGS, BR. MED. J., 300, PP. 667-672, (1990); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTROLEMIA AND TOLERABILITY TO TREATMENT, J. CLIN. PHARMACOL. RES., 14, 1, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 55, PP. 1084-1092, (1994); RODRIGUEZ C., MESA R., MAS R., AMOR A.M., CASTANO G., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH. VENEZOL. FARMACOL. TERAP., 11, PP. 74-79, (1992); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMBASTATIN SURVIVAL STUDY (4S), THE LANCET, 344, PP. 1383-1389, (1994); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH. VENEZOL. FARMACOL. TERAP., 12, PP. 71-76, (1993); STEINER A., WEISSER B., VETTER W., A COMPARATIVE STUDY OF THE ADVERSE EFFECTS OF TREATMENTS FOR HUYPERLIPIDAEMIA, DRUG SAFETY, 6, PP. 118-130, (1991); STRATEGIES FOR THE PREVENTION OF CORONARY HEART DISEASE: A POLICY STATEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY, EUR. HEART. J., 8, PP. 77-88, (1987); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL/LITER (200 TO 300 MG/DL) PLUS TWO ADDITIONAL ATHEROSCLEROTIC RISK FACTORS, AM. J. CARDIOL, 72, PP. 1031-1033, (1993); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995)","","","SPANISH","PRENSA MED. ARGENT.","ARTICLE","ISI","2-S2.0-0001452846","PRENSA MED ARGENT",NA,"NOTREPORTED",NA,"CAMPILONGO R, 1996, PRENSA MED ARGENT","CAMPILONGO R, 1996, PRENSA MED ARGENT"
"ARRUZAZABALA M;NOA M;MENÉNDEZ R;MÁS R;CARBAJAL D;VALDÉS S;MOLINA V","ARRUZAZABALA, M.L. (6603962476); NOA, M. (7003318964); MENÉNDEZ, R. (7102205059); MÁS, R. (7007164572); CARBAJAL, D. (8777025000); VALDÉS, S. (8777025100); MOLINA, V. (7006062814)","PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA",2000,"BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH","33","5",41,"10.1590/S0100-879X2000000700015","DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA, LABORATORY OF HISTOLOGY, DEPARTMENT OF PHARMACOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, 25 AVE AND 158 ST. P. O. BOX 6990, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF PHARMACOLOGY, CENTER OF NATURAL PRODUCTS, NATL. CENTER OF SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A MIXTURE OF HIGHER ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX, WITH CHOLESTEROL-LOWERING EFFECTS DEMONSTRABLE IN EXPERIMENTAL MODELS AND IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. THE PROTECTIVE EFFECTS OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS EXPERIMENTALLY INDUCED BY LIPOFUNDIN IN RABBITS AND RATS AND SPONTANEOUSLY DEVELOPED IN STUMPTAIL MONKEYS HAVE BEEN DESCRIBED. THE PRESENT STUDY WAS CONDUCTED TO DETERMINE WHETHER POLICOSANOL ADMINISTERED ORALLY TO RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA ALSO PROTECTS AGAINST THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS. MALE NEW ZEALAND RABBITS WEIGHING 1.5 TO 2 KG WERE RANDOMLY DIVIDED INTO THREE EXPERIMENTAL GROUPS WHICH RECEIVED 25 OR 200 MG/KG POLICOSANOL (N = 7) ORALLY FOR 60 DAYS WITH ACACIA GUM AS VEHICLE OR ACACIA GUM ALONE (CONTROL GROUP. N = 9). ALL ANIMALS RECEIVED A CHOLESTEROL-RICH DIET (0.5%) DURING THE ENTIRE PERIOD. CONTROL ANIMALS DEVELOPED MARKED HYPERCHOLESTEROLEMIA, MACROSCOPIC LESIONS AND ARTERIAL INTIMAL THICKENING. INTIMA THICKNESS WAS SIGNIFICANTLY LESS (32.5 ± 7 AND 25.4 ± 4 ΜM) IN HYPERCHOLESTEROLEMIC RABBITS TREATED WITH POLICOSANOL THAN IN CONTROLS (57.6 ± 9 ΜM). IN MOST POLICOSANOL-TREATED ANIMALS, ATHEROSCLEROTIC LESIONS WERE NOT PRESENT, AND IN OTHERS, THICKNESS OF FATTY STREAKS HAD LESS FOAM CELL LAYERS THAN IN CONTROLS. WE CONCLUDE THAT POLICOSANOL HAS A PROTECTIVE EFFECT ON THE ATHEROSCLEROTIC LESIONS OCCURRING IN THIS EXPERIMENTAL MODEL.","ATHEROSCLEROTIC LESIONS; EXOGENOUS HYPERCHOLESTEROLEMIA; POLICOSANOL; RABBITS","ACACIA; ANIMALIA; ARUNDINARIA; ORYCTOLAGUS CUNICULUS; SACCHARUM; CHOLESTEROL; LIPOFUNDIN; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DOSE RESPONSE; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; RABBIT","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REVISTA DEL CENTRO NACIONAL DE INVESTIGACIONES CIENTÍFICAS DE CIENCIAS BIOLÓGICAS, 22, PP. 60-61, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGICAL RESEARCH, 27, PP. 205-208, (1994); RODRIGUEZ C., MESA R., MAS R., AMOR A.M., CASTANO G., ESTUDIO DEL EFECTO SOBRE LOS LIPIDOS Y LIPOPROTEINAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS DRECIENTES DE ATEROMIXOL (PPG) EN MONOS MACACA ARCTOIDES. ARCHIVOS VENEZOLANOS DE FARMACOLOGÍA Y TERAPEÚTICA, 11, PP. 74-79, (1992); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J.C., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MÉDICAS, 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURRENT THERAPEUTIC RESEARCH, 53, PP. 265-269, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, JOURNAL OF CLINICAL PHARMACOLOGICAL RESEARCH, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, PP. 1084-1092, (1994); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURRENT THERAPEUTIC RESEARCH, 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., POLICOSANOL FOR CHOLESTEROL-LOWERING LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 176-182, (1995); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCHIVES VENEZOLANOS DE FARMACOLOGÍA Y TERAPEÚTICA, 12, PP. 71-76, (1993); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., DIAZ E., FERNANDEZ L., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURRENT THERAPEUTIC RESEARCH, 57, PP. 568-577, (1996); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., JIMENEZ S., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOLOGICAL RESEARCH, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRITISH JOURNAL OF NUTRITION, 77, PP. 923-932, (1997); MENENDEZ R., FRAGA V., SOTOLONGO V., AMOR A.M., DEL RIO A., GONZALEZ R.M., JIMENEZ S., MAS R., EFECTO DE LA ADMINISTRACIÓN ORAL DEL POLICOSANOL SOBRE EL METABOLISMO LIPIDICO DE RATAS NORMOCOLESTEROLÉMICAS, REVISTA MEXICANA DE CIENCIAS FARMACEÚTICAS, 24, PP. 16-18, (1993); KROON P.A., HAND K.M., HUFF J.W., ALBERTS A.W., THE EFFECTS OF MEVINOLIN ON SERUM CHOLESTEROL LEVELS OF RABBITS WITH ENDOGENOUS HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 44, PP. 41-48, (1982); CHAO Y.S., KROON P.A., YAMIN T.T., THOMSON G.M., ALBERTS A.W., REGULATION OF HEPATIC RECEPTOR-DEPENDENT DEGRADATION OF LDL BY MEVINOLIN IN RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BIOCHIMICA ET BIOPHYSICS ACTA, 754, PP. 134-141, (1983); RODRIGUEZ C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FOOD AND CHEMICAL TOXICOLOGY, 32, PP. 565-575, (1994); NOA M., MAS R., ATEROMIXOL Y LESIÓN ATEROSCLERÓTICA EN CONEJOS INDUCIDA POR LIPOFUNDIN, PROGRESOS EN CIENCIAS MÉDICAS, 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, JOURNAL OF PHARMACY AND PHARMACOLOGY, 47, PP. 289-291, (1995); NOA M., MAS R., DE LA ROSA M.C., EFFECT OF POLICOSANOL ON FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, JOURNAL OF PHARMACY AND PHARMACOLOGY, 48, PP. 306-309, (1996); BROWN M.S., GOLDSTEIN J.L., RECEPTOR MEDIATED CONTROL OF CHOLESTEROL METABOLISM, SCIENCE, 191, PP. 150-152, (1976); ANDERSEN J.M., TURKEY S.D., DIETCHY J.M., RELATIVE RATES OF STEROL SYNTHESIS IN THE LIVER AND VARIOUS EXTRAHEPATIC TISSUES OF NORMAL AND CHOLESTEROL-FED RABBITS. RELATIONSHIP TO PLASMA LIPOPROTEIN AND TISSUE CHOLESTEROL LEVELS, BIOCHIMICA ET BIOPHYSICA ACTA, 711, PP. 421-430, (1982); ATKINSON D., HOOVER R., BERRY K., SWILT L., CHOLESTEROL-FED HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDEMIC RABBITS: A NEW MODEL FOR ATHEROSCLEROSIS, ATHEROSCLEROSIS, 79, PP. 123-136, (1989); KRITCHEVSKY D., TEPPER A., KLURFELD D., INFLUENCE OF MEVILONIN ON EXPERIMENTAL ATHEROSCLEROSIS IN RABBITS, PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 13, PP. 921-926, (1981); KOBAYASHI M., ISHIDA F., TAKAHASHI T., TAGUCHI K., PREVENTIVE EFFECT OF MK-733 (SIMVASTATIN), AN INHIBITOR OF HMG-COA REDUCTASE, ON HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS INDUCED BY CHOLESTEROL FEEDING IN RABBITS, JAPANESE JOURNAL OF PHARMACOLOGY, 49, PP. 125-133, (1989); NIELSEN L.B., STENDER S., KJELDSEN K., EFFECT OF LOVASTATIN ON CHOLESTEROL ABSORPTION IN CHOLESTEROL-FED RABBITS, PHARMACOLOGY AND TOXICOLOGY, 72, PP. 148-151, (1993); ISHIDA F., SAKO A., IIZUKA Y., SAWASAKI Y., AIZASWA A., KAMEI T., EFFECTS OF MK-733, AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, ON ABSORPTION AND EXCRETION OF (H)CHOLESTEROL IN RABBITS, BIOCHIMICA ET BIOPHYSICA ACTA, 963, PP. 35-41, (1988); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); SKRINSKA V., KONIECZKOWSKI M., GERRITY R., GALANG C., REBEC M., SUPPRESSION OF FOAM CELL LESIONS IN HYPERCHOLESTEROLEMIC RABBITS BY INHIBITION OF THROMBOXANE A SYNTHESIS, ATHEROSCLEROSIS, 8, PP. 359-367, (1988); OSBORNE J., LEFFER A., CARDIOPROTECTIVE ACTIONS OF THROMBOXANE RECEPTOR ANTAGONISM IN ISCHEMIC ATHEROSCLEROTIC RABBITS, AMERICAN JOURNAL OF PHYSIOLOGY, 255, (1988); HAJJAR D.P., POMERANTZ K.B., EICOSANOIDS AND THEIR ROLE IN ATHEROSCLEROSIS, ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 82, PP. 21-23, (1989); WILLIS A.L., SMITH D.L., THERAPEUTIC IMPACT OF EICOSANOIDS IN ATHEROSCLEROTIC DISEASE, EICOSANOIDS, 2, PP. 69-71, (1989); FREDRICH M., MULLER B., PROSTACYCLIN AND ATHEROSCLEROSIS, PROSTACYCLIN: NEW PERSPECTIVES FOR BASIC RESEARCH AND NOVEL THERAPEUTIC INDICATIONS, (1992); JELLINEK H., STOCK G., TAKACSM E., LIPOFUNDIN ARTERIOSCLEROSIS AND ILOPROST TREATMENT, PROSTACYCLIN AND ITS STABLE ANALOGUE ILOPROST, (1987); BRAUN M., HOHLFELD TH., KIENBAUM P., WEBER A., SARBIA M., SCHROR K., ANTIATHEROSCLEROTIC EFFECTS OF ORAL CICAPROST IN EXPERIMENTAL HYPERCHOLESTEROLEMIA IN RABBITS, ATHEROSCLEROSIS, 103, PP. 93-105, (1994); BOCAN TH., MAZUR M., MUELLER S., BROWN E., ANTIATHEROSCLEROTIC ACTIVITY OF INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE IN CHOLESTEROL-FED RABBITS: A BIOCHEMICAL AND MORPHOLOGICAL EVALUATION, ATHEROSCLEROSIS, 111, PP. 127-142, (1994); ALEMAN C., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., MENENDEZ R., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); ALEMAN C., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS. A 24 MONTHS STUDY, TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS, 14, PP. 239-249, (1994)","","ASSOCIACAO BRASILEIRA DE DIVULGACAO CIENTIFICA","ENGLISH","BRAZ. J. MED. BIOL. RES.","ARTICLE","ISI","2-S2.0-0033866211","BRAZ J MED BIOL RES",NA,"NOTREPORTED",NA,"ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES","ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES"
"MENENDEZ R;FERNANDEZ S;DEL R A;GONZALEZ R;FRAGA V;AMOR A;MAS R","MENENDEZ, R. (7102205059); FERNANDEZ, S.I. (7202872681); DEL RIO, A. (57189524365); GONZALEZ, R.M. (57191737509); FRAGA, V. (6602491407); AMOR, A.M. (35569426800); MAS, R.M. (7007164572)","POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS",1994,"BIOLOGICAL RESEARCH","27","4",126,"","CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA;CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA;CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA;CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA;CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA;CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA;CTR NAC INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, LABORATORIO DE BIOQUIMICA, LA HABANA, APARTADO POSTAL 6880, CUBA","POLICOSANOL IS A MIXTURE OF ALIPHATIC PRIMARY ALCOHOLS ISOLATED AND PURIFIED FROM SUGAR CANE WAX, THAT INDUCES CHOLESTEROL-LOWERING EFFECTS IN EXPERIMENTAL MODELS AND HUMAN BEINGS. WHEN HUMAN LUNG FIBROBLASTS WERE INCUBATED WITH POLICOSANOL FOR 48 HOURS PRIOR TO THE EXPERIMENT, A DOSE DEPENDENT INHIBITION OF 14C-ACETATE INCORPORATION INTO TOTAL CHOLESTEROL WAS OBSERVED, WHEREAS LABELED MEVALONATE INCORPORATION WAS NOT INHIBITED. EVEN WHEN CHOLESTEROL SYNTHESIS WAS NOT STRONGLY INHIBITED, LOW DENSITY LIPOPROTEIN (LDL) PROCESSING WAS MARKEDLY ENHANCED. THUS, LDL BINDING, INTERNALIZATION AND DEGRADATION WERE SIGNIFICANTLY INCREASED AFTER POLICOSANOL TREATMENT. IN ADDITION, DESPITE THE FACT THAT CHOLESTEROL GENERATION WAS NOT INHIBITED AT THE LOWEST DOSE OF POLICOSANOL ASSAYED, LDL PROCESSING WAS SIGNIFICANTLY INCREASED. THE CURRENT DATA INDICATE THAT POLICOSANOL INHIBITS CHOLESTEROL SYNTHESIS AT THE EARLIEST STEPS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY. ON THE OTHER HAND, THIS STUDY SUGGESTS THAT THE INCREASE IN LDL PROCESSING MAY BE PARTIALLY EXPLAINED BY THE INHIBITION OF CHOLESTEROL BIOSYNTHESIS, EVEN THOUGH AN STEROL-INDEPENDENT MECHANISM MIGHT BE RESPONSIBLE FOR THE ENHANCEMENT OF LDL-RECEPTOR ACTIVITY.","CHOLESTEROL BIOSYNTHESIS; CULTURED FIBROBLASTS; LOW DENSITY LIPOPROTEIN PROCESSING; POLICOSANOL","ANTICHOLESTEREMIC AGENTS; CELLS, CULTURED; CHOLESTEROL; FATTY ALCOHOLS; FIBROBLASTS; HUMAN; LIPOPROTEINS, LDL; ALCOHOL DERIVATIVE; CARBON 14; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; POLICOSANOL; SUGAR; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DEGRADATION; DOSE RESPONSE; FETUS; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; INTERNALIZATION; LIPOPROTEIN METABOLISM; LUNG FIBROBLAST","","","","","","ENGLISH","BIOL. RES.","ARTICLE","ISI","2-S2.0-0028568193","BIOL RES",NA,"NOTREPORTED",NA,"MENENDEZ R, 1994, BIOL RES","MENENDEZ R, 1994, BIOL RES"
"CASTAÑO G;CANETTI M;MOREIRA M;TULA L;MÁS R;ILLNAIT J;FERNÁNDEZ L;FERNÁNDEZ J;DÍAZ E","CASTAÑO, GLADYS (56232967100); CANETTI, MIGUEL (7004415986); MOREIRA, MARTA (9433321400); TULA, LEONEL (9434741100); MÁS, ROSA (7007164572); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILLA (7202848319); FERNÁNDEZ, JULIO C. (9432805500); DÍAZ, EDUARDO (16738702300)","EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA A 12MONTH STUDY",1995,"CURRENT THERAPEUTIC RESEARCH","56","9",52,"10.1016/0011-393X(95)85065-1","CENTER FOR MEDICAL-SURGICAL RESEARCH, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;SALVADOR ALLENDE HOSPITAL, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;SALVADOR ALLENDE HOSPITAL, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;LUIS DÍAZ SOTO HOSPITAL, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THIS STUDY REPORTS THE RESULTS OF A 12-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL AT DAILY DOSES OF 10 MG IN THE TREATMENT OF ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. THE STUDY INCLUDED 62 ELDERLY PATIENTS OF BOTH SEXES WITH TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) NOT CONTROLLED SUFFICIENTLY DURING A DIET-ONLY PERIOD. TWO MONTHS AFTER THERAPY, POLICOSANOL SIGNIFICANTLY (P < 0.001) REDUCED TOTAL CHOLESTEROL AND LDL-C. THE TREATMENT EFFECT ON CHOLESTEROL, AND RATIOS OF LDL-C:HDL-C AND TOTAL CHOLESTEROL: HDL-C WAS SHOWN NOT TO WEAR OFF DURING THE 12-MONTH FOLLOW-UP. PERCENT REDUCTIONS WERE MAINTAINED, OR EVEN INCREASED, 12 MONTHS AFTER THERAPY BY 23.1% (LDL-C), 15.6% (TOTAL CHOLESTEROL), 25.2% (LDL-C:HDL-C), AND 19% (TOTAL CHOLESTEROL:HDL-C) (P < 0.00001). ALL LIPID PROFILE VARIABLES REMAINED UNCHANGED IN THE PLACEBO GROUP THROUGHOUT THE ENTIRE STUDY. AT THE END OF THE TREATMENT PERIOD, HDL-C WAS INCREASED BY 8%. TRIGLYCERIDES WERE NOT SIGNIFICANTLY CHANGED. ONLY TWO PATIENTS, BOTH IN THE PLACEBO GROUP, WITHDREW FROM THE STUDY, BUT NEITHER DID SO BECAUSE OF ADVERSE EFFECTS. NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE EFFECTS WERE OBSERVED. ADVERSE EFFECTS REPORTED WERE MILD AND TRANSIENT, AND NO SIGNIFICANT DIFFERENCES WERE SEEN WHEN COMPARED WITH THOSE REPORTED BY THE PLACEBO GROUP. OUR RESULTS INDICATE THAT POLICOSANOL ADMINISTERED AT 10 MG/D FOR 12 MONTHS SHOWS A MAINTAINED EFFICACY, AND VERY GOOD SAFETY AND TOLERABILITY IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA. © 1995.","","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS REDUCTION OF INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); FRICK, ELO, HAAPA, ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); KARVONEN, PREVENTION OF CARDIOVASCULAR DISEASE AMONG THE ELDERLY, BULL WHO, 66, PP. 7-14, (1988); BENFANTE, REED, IS ELEVATED SERUM CHOLESTEROL LEVEL A RISK FACTOR FOR CORONARY HEART DISEASE IN THE ELDERLY?, JAMA, 263, PP. 393-396, (1990); BILHEIMER, CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN THE ELDERLY, ATHEROSCLEROSIS, 91, PP. S35-S57, (1991); DENKE, GRUNDY, HYPERCHOLESTEROLEMIA IN ELDERLY PERSONS: RESOLVING THE TREATMENT DILEMMA, ANN INTERN MED, 112, PP. 780-792, (1990); AGNER, HANSEN, FASTING SERUM CHOLESTEROL AND TRIGLYCERIDES IN A TEN-YEAR PROSPECTIVE STUDY IN OLD AGE, ACTA MED SCAND, 214, PP. 33-41, (1983); CIRCULATING CHOLESTEROL LEVEL AND RISK OF DEATH FROM CANCER IN MEN AGED 40 TO 69 YEARS EXPERIENCE OF AN INTERNATIONAL COLLABORATIVE GROUP, JAMA, 248, PP. 2853-2868, (1982); GOLDBERG, ROBERTS, PHARMACOLOGICAL BASIS FOR DEVELOPING RATIONAL DRUG REGIMENS FOR ELDERLY PATIENTS, MED CLIN NORTH AM, 67, PP. 315-331, (1983); GURWITZ, AVORN, THE AMBIGUOUS RELATION BETWEEN AGING AND ADVERSE DRUG REACTIONS, ANN INTERN MED, 114, (1991); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZOL FARMACOL TERAP, 11, PP. 80-86, (1992); ARRUZAZABALA, CARBAJAL, MAS, ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); RODRIGUEZ, MESA, MAS, ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP, 11, PP. 74-79, (1992); RODRIGUEZ, MESA, MAS, ET AL., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FOOD AND CHEMICAL TOXICOLOGY, 32, PP. 565-567, (1994); HERNANDEZ, ILLNAIT, MAS, ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROG CIEN MED, 5, PP. 21-28, (1991); PONS, MAS, ILLNAIT, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); ANEIROS, CALDERON, MAS, ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); ANEIROS, MAS, CALDERON, ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); TORRES, AGRAMONTE, ILLNAIT, ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); PONS, RODRIGUEZ, ROBAINA, ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILES OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 1, PP. 27-33, (1994); PONS, RODRIGUEZ, MAS, ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL (5 MG/D) IN TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, PP. 1084-1093, (1994); CASTANO, MAS, NODARSE, ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 296-304, (1995); PONS, JIMENEZ, RODRIGUEZ, ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); FRIEDEWALD, LEVY, FRIEDERICKSON, ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHO-TUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); ILLINGWORTH, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); O'BRIEN, SHAMPO, STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0029155739","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 1995, CURR THER RES CLIN EXP","CASTAÑO G, 1995, CURR THER RES CLIN EXP"
"MESA A;MÁS R;NOA M;HERNÁNDEZ C;RODEIRO I;GÁMEZ R;GARCÍA M;CAPOTE A;ALEMÁN C","MESA, A.R. (57197360815); MÁS, R. (7007164572); NOA, M. (7003318964); HERNÁNDEZ, C. (15720846000); RODEIRO, I. (6602314378); GÁMEZ, R. (7003605346); GARCÍA, M. (7404278799); CAPOTE, A. (16155693300); ALEMÁN, C.L. (7102849611)","TOXICITY OF POLICOSANOL IN BEAGLE DOGS ONEYEAR STUDY",1994,"TOXICOLOGY LETTERS","73","9",58,"10.1016/0378-4274(94)90098-1","CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA;CUBANACAN, PLAYA, CUBA","POLICOSANOL IS A NEW CHEMICAL ENTITY COMPOSED OF 8 HIGHER ALIPHATIC ALCOHOLS OBTAINED FROM SUGAR CANE (SACCHARUM OFFICINARUM) L. WAX, WHOSE CHOLESTEROL-LOWERING EFFECTS HAVE BEEN DEMONSTRATED IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS AND PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. THIS STUDY INVESTIGATED THE ORAL TOXICITY OF POLICOSANOL ADMINISTERED FOR 52 WEEKS TO BEAGLE DOGS. TWENTY-FOUR BEAGLE DOGS (12 MALES AND 12 FEMALES) WERE DISTRIBUTED RANDOMLY IN 3 EXPERIMENTAL GROUPS (4 ANIMALS/GROUP): A CONTROL AND 2 TREATED GROUPS RECEIVING POLICOSANOL AT 30 AND 180 MG/KG DAILY (7 DAYS/WEEK) BY GAVAGE. NO MORTALITY WAS OBSERVED IN ANY GROUP. OVERALL, POLICOSANOL WAS WELL TOLERATED THROUGHOUT THE STUDY AND NO TOXIC SYMPTOMS WERE OBSERVED. ALL GROUPS SHOWED SIMILAR WEIGHT GAIN AND FOOD CONSUMPTION. LIPID PROFILE DETERMINATIONS SHOWED THAT POLICOSANOL DECREASED TOTAL CHOLESTEROL BY 20% APPROXIMATELY FROM 8 TO 52 WEEKS. CHOLESTEROL-LOWERING EFFECTS DID NOT WEAR OFF DURING THE STUDY, THUS DEMONSTRATING THE PERSISTENCE OF THE EFFECTIVENESS. TRIGLYCERIDES AND HIGH DENSITY LIPOPROTEINCHOLESTEROL (HDL-C) WERE NOT CHANGED SIGNIFICANTLY. NO BLOOD BIOCHEMISTRY OR HISTOPATHOLOGICAL DISTURBANCES ATTRIBUTABLE TO TREATMENT WERE OBSERVED. THIS STUDY HAS SHOWN THAT NO DRUG-RELATED TOXICITY WAS INDUCED BY POLICOSANOL ADMINISTERED UP TO 180 MG/KG/DAY FOR 52 WEEKS TO BEAGLE DOGS. SINCE THIS DOSE IS APPROXIMATELY 620 TIMES HIGHER THAN THE MAXIMAL RECOMMENDED THERAPEUTIC DOSE (20 MG/DAY) IT INDICATES A GOOD SAFETY MARGIN OF THIS PRODUCT. © 1994.","ALIPHATIC PRIMARY ALCOHOLS; BEAGLE DOGS; CHOLESTEROL-LOWERING DRUG; CHRONIC TOXICITY; POLICOSANOL","ADMINISTRATION, ORAL; ANIMAL; ANTICHOLESTEREMIC AGENTS; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; DOGS; FATTY ALCOHOLS; FEMALE; LIPIDS; MALE; ORGAN WEIGHT; RANDOM ALLOCATION; TIME FACTORS; ANIMALIA; ARUNDINARIA; CANIS FAMILIARIS; SACCHARUM OFFICINARUM; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALKANOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; PENTOBARBITAL; POLICOSANOL; TRIACYLGLYCEROL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOD INTAKE; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; WEIGHT GAIN","","","LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS: IB, THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, 251, PP. 365-374, (1984); CATAPANO, LEONETTI, POLI, IPERCOLESTEROLEMIA ED IPERTENSIONE ARTERIOSA: PRIMARI FATTORI DDI RISCHIO NELLA GENESI DELL'ATEROSCLEROSI, (1992); OESBAUM, GALTON, MANAGEMENT OF HYPERCHOLESTEROLAEMIA, CURRENT OPINION IN CARDIOLOGY, 3, PP. 255-263, (1988); MARTINDALE, THE EXTRA PHARMACOPEIA, PP. 1201-1202, (1989); ARRUZAZABALA, CARBAJAL, MAS, ILLNAIT, LAGUNA, CASTANO, EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPIDICO DE CONEJOS COLESTEROLÉMICOS, ARCHIVOS VENEZOLANOS DE FARMACOLOGÍA Y TERAPÉUTICA, 11, 2, PP. 80-86, (1992); CRUZ-BUSTILLO, MEDEROS, MAS, ARRUZAZABALA, BARRETO, MARTINEZ, EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 62-63, (1991); RODRIGUEZ-ECHENIQUE, MESA, MAS, MENENDEZ, NOA, GONZALEZ, AMOR, FRAGA, LAGUNA, VARIACIONES DEL PERFIL LIPIDICO EN MONOS (MACACA ARCTOIDES) TRATADOS CON POLICOSANOL, NÚMERO ESPECIAL LER CONGRESO IBEROAMERICANO DE FANNACOLOGÍA, BENALMÁDENA, (1992); ARRUZAZABALA, CARBAJAL, MAS, GARCIA, EFECTOS DEL ATEROMIXOL SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REVISTA CNIC CIENCIAS BIOLÓGICAS, 22, (1991); HERNANDEZ, ILLNAIT, MAS, CASTANO, FERNANDEZ, GONZALEZ, CORDOVI, FEMANDEZ, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 1-7, (1992); ANEIROS, CALDERON, MAS, ILLNAIT, CASTANO, FEMANDEZ, FERNANDEZ, EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE AND TOLERABILITY TO TREATMENT, CURR. THER. RES., (1993); CASTANO, ZARDOYA, ILLNAIT, MAS, FERNANDEZ, FERNANDEZ, EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PP. 5-21, (1991); PONS, MAS, ILLNAIT, FERNANDEZ, FERNANDEZ, EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 1-7, (1992); PONS, JIMENEZ, RODRIGUEZ, ILLNAIT, MAS, FERNANDEZ, FERNANDEZ, EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURRENT THERAPEUTIC RESEARCH, 53, 1, (1993); MENENDEZ, FERNANDEZ, SOTOLONGO, AMOR, FRAGA, DEL RIO, ALFONSO, GONZALEZ, MAS, POLICOSANOL: UN ESTUDIO DE SUS EFECTOS SOBRE LA BIOSINTESIS DEL COLESTEROL, NÚMERO ESPECIAL LER CONGRESO IBEROAMERICANO DE FARMACOLOGÍA, (1992); ALEMAN, MAS, RODEIRO, NOA, HERNANDEZ, CAPOTE, MENENDEZ, GONZALEZ, AMOR, JIMENEZ, TOXICOLOGIA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REVISTA CNIC, CIENCIAS BIOLÓGICAS, 22, 1-2, PP. 102-105, (1991); CHAN, O'HARA, HAYES, PRINCIPLES AND METHODS FOR ACUTE AND SUBCHRONIC TOXICITY, PRINCIPLES AND METHODS OF TOXICOLOY, PP. 1-51, (1982); ALEMAN, MAS, HERNANDEZ, RODEIRO, MENENDEZ, GONZALEZ, SOTOLONGO, AMOR, NOA, CAPOTE, JIMENEZ, ATEROMIXOL: TOXICOLOGÍA SUBCRÓNICA EN RATAS, ARCHIVOS VENEZOLANOS DE FARMACOLOGÍA Y TERAPEÚTICA, (1992); ALEMAN, MAS, HERNANDEZ, RODEIRO, NOA, MENENDEZ, GONZALEZ, AMOR, SOTOLONGO, FRAGA, CAPOTE, JIMENEZ, ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); RODRIGUEZ-ECHENIQUE, MESA, MAS, MENENDEZ, NOA, GONZALEZ, AMOR, FRAGA, LAGUNA, TOXICOLOGICAL STUDY OF POLICOSANOL LONG-TERM ADMINISTRATION ON MACACA ARCTOIDES MONKEYS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ALBERST, CHEN, KURON, HUNT, HUFF, HOFFMAN, ROTHROCK, LOPEZ, JOSUA, HARRIS, STAPLEY, ALBERTS-SCHONBERG, HENSON, MEVINOLIN: A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 77, (1980); GERSON, MACDONALD, ALBERTS, DOUGLAS, KORNSBRUST, MAJKA, STUBBS, BOKELMAN, ANIMAL SAFETY AND TOXICOLOGY OF SIMVASTATIN AND RELATED HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS, AM. J. MED., 87, PP. 28-38, (1989); STEVENS, GALLO, PRACTICAL CONSIDERATIONS IN THE CONDUCT OF CHRONIC TOXICITY STUDIES, PRINCIPLES AND METHODS OF TOXICOLOGY, PP. 53-77, (1986); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, PP. 838-841, (1981); CHHABRA, HUFF, SCHWETZ, SELKIRK, AN OVERVIEW OF PRECHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY EXPERIMENTAL STUDY-SIGNS AND CRITERIA USED BY THE NATIONAL TOXICOLOGY PROGRAM, ENV. HEALTH PERSPECT., 86, PP. 313-321, (1990); O'BRIEN, SHAMPO, STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TEST IN A SINGLE EXPERIMENT 5. COMPARING TWO THERAPIES WITH RESPECT SEVERAL ENDPRINTS, MAYO CLIN. PROC., 63, PP. 1140-1143, (1988); WOFFORD, SCHROER, GOHS, GALLO, BRODECK, FALK, RUHREN, REFERENCE RANGE DATA BASE FOR SERUM CHEMISTRY AND HEMATOLOGY VALUES IN LABORATORY ANIMALS, J. TOXICOL. ENVIRON. HEALTH, 18, PP. 161-188, (1986); GERSON, MACDONALD, ALBERTS, CHEN, YUDKOVITZ, GREENSPAN, RUBIN, BOKELMAN, ON THE ETIOLOGY OF SUBCAPSULAR LENTICULAR OPACITIES PRODUCED IN DOGS RECEIVING HMG-COA REDUCTASE INHIBITORS, (1990); MACDONALD, GERSON, KORNBRUST, KLOSS, PRAHALADA, BERRY, ALBERTS, BOKELMAN, PRECLINICAL EVALUATION OF LOVASTATIN, AM. J. CARDIOL., 62, PP. 16-27, (1988)","","","ENGLISH","TOXICOL. LETT.","ARTICLE","ISI","2-S2.0-0028144949","TOXICOL LETT",NA,"NOTREPORTED",NA,"MESA AR, 1994, TOXICOL LETT","MESA AR, 1994, TOXICOL LETT"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;FERNÁNDEZ L;ILLNAIT J;LÓPEZ E","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, JULIO C. (9432805500); FERNÁNDEZ, LILIA (7202848319); ILLNAIT, JOSÉ (8631465800); LÓPEZ, ERNESTO (57198355062)","EFFECTS OF POLICOSANOL ON OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA",2002,"DRUGS IN R AND D","3","13",33,"10.2165/00126839-200203030-00004","SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA","OBJECTIVE: THIS STUDY WAS CONDUCTED TO INVESTIGATE THE EFFECTS OF POLICOSANOL ADMINISTERED FOR 12 MONTHS ON THE LIPID PROFILE OF OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA AND NO HISTORY OF CORONARY HEART DISEASE (CHD) OR CEREBROVASCULAR DISEASE. PATIENTS AND PARTICIPANTS: 589 OLDER MALE AND FEMALE PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA AND NO HISTORY OF CHD OR CEREBROVASCULAR DISEASE WERE INCLUDED. METHODS: THIS WAS A PROSPECTIVE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PARALLEL GROUPS TREATED WITH POLICOSANOL (5 TO 10 MG/DAY) FOR 1 YEAR. AFTER 6 WEEKS ON A STANDARD STEP I CHOLESTEROL-LOWERING DIET, 589 PATIENTS WERE RANDOMISED TO POLICOSANOL (5MG) OR PLACEBO TABLETS, TO BE TAKEN ONCE DAILY FOR 12 MONTHS. THE DOSAGE WAS DOUBLED TO 10 MG/DAY IF TOTAL CHOLESTEROL VALUES WERE >6.1 MMO1/L AFTER 6 MONTHS OF THERAPY. RESULTS: POLICOSANOL SIGNIFICANTLY (P < 0.00001) LOWERED SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) [20.5%], TOTAL CHOLESTEROL (TC) [15.4%], TRIGLYCERIDES (11.9%), LDL-C/HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) RATIO [22.2%] AND TC/HDL-C RATIO (20.1%), AND INCREASED (P < 0.0001) HDL-C (12.7%). THE FREQUENCY OF VASCULAR AND ALL-CAUSE SERIOUS ADVERSE EVENTS (SAES) WAS LOWER (P < 0.05) IN THE POLICOSANOL RECIPIENTS (TWO VASCULAR SAES, 0.7%; FIVE ALL-CAUSE SAES, 1.7%) THAN IN THE PLACEBO RECIPIENTS (SIX VASCULAR SAES, 2.0%; 12 ALL-CAUSE SAES, 4.1 %). SIMILARLY, TOTAL ADVERSE EVENTS (AES) WERE LESS FREQUENT IN THE POLICOSANOL-TREATED GROUP (29; 9.8%) COMPARED WITH THE PLACEBO GROUP (52; 17.7%) [P < 0.01]. THREE PLACEBO RECIPIENTS AND NO POLICOSANOL RECIPIENTS DIED DURING THE STUDY AS A RESULT OF MYOCARDIAL INFARCTION (TWO PATIENTS) AND SUDDEN CARDIAC ARREST (ONE). POLICOSANOL WAS WELL TOLERATED, AND NO DRUG-RELATED DISTURBANCES IN SAFETY INDICATORS WERE FOUND. POLICOSANOL SIGNIFICANTLY DECREASED SYSTOLIC BLOOD PRESSURE (BP) COMPARED WITH BASELINE AND PLACEBO, WHICH COULD BE AN ADDITIONAL ADVANTAGE IN THIS POPULATION AT HIGH CORONARY RISK. CONCLUSIONS: POLICOSANOL ADMINISTERED LONG TERM IS EFFECTIVE IN LOWERING LDL-C AND TC AS WELL AS INCREASING HDL-C LEVELS IN OLDER PATIENTS WITH HYPERTENSION AND TYPE II HYPERCHOLESTEROLAEMIA WITHOUT A HISTORY OF CHD OR CEREBROVASCULAR DISEASE. IN ADDITION, POLICOSANOL TREATMENT ALSO SHOWS BENEFITS IN THE OCCURRENCE OF SAES OF VASCULAR AETIOLOGY, ON THE GENERAL AE PROFILE AND THE REDUCTION OF BP IN TREATED PATIENTS COMPARED WITH BASELINE.","","AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NITRATE; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; FATTY ALCOHOL; LIPID; POLICOSANOL; ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HEADACHE; HEART ARREST; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL ANALYSIS; STOMACH PH; THORAX PAIN; ULCER; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VERTIGO; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTENSION; MIDDLE AGED","NATIONAL CENTER FOR SCIENTIFIC RESEARCH; TECHNICAL PROJECT COUNCIL","THIS TRIAL WAS SUPPORTED BY A RESEARCH PROJECT GRANT FROM THE TECHNICAL PROJECT COUNCIL TO THE CENTER OF NATURAL PRODUCTS FROM THE NATIONAL CENTER FOR SCIENTIFIC RESEARCH, IN WHICH OTHER INSTITUTIONS BELONGING TO THE CUBAN HEALTH SYSTEM ALSO PARTICIPATED, ALL OF THEM WITHOUT SPECIFIC ADDITIONAL PAYMENT. POLICOSANOL WAS SUPPLIED BY LABORATORIOS DALMER (HAVANA CITY, CUBA). THIS WORK WAS APPROVED BY THE POLICOSANOL IN HYPERCHOLESTEROLEMIA ASSOCIATED WITH HYPERTENSION IN THE ELDERLY (PHHE) GROUP.","WORLD HEALTH REPORT 1998: LIFE IN THE 21ST CENTURY - A VISION OF ALL GENEVA, (1998); ANDERSON K.M., WILSON P.W.F., ODELL P.M., ET AL., AN UPDATED RISK PROFILE: A STATEMENT OF HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); ZANCHETTI A., HYPERLIPIDEMIA IN THE HYPERTENSIVE PATIENT, AM. J. MED., 96, SUPPL. A, (1994); STAMLER J., WENTWORTH D., NEATON J.D., PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF HYPERCHOLESTEROLEMIA IN MEN WITH HYPERTENSION, JAMA, 80, SUPPL. 2A, PP. 33-36, (1986); LAURENZI M., MANCINI M., MENOTTI A., ET AL., MULTIPLE RISK FACTORS IN HYPERTENSION: RESULTS FROM THE GUBBIO STUDY, J. HYPERTENS., 8, SUPPL. 201, (1990); 1993 GUIDELINES FOR THE MANAGEMENT OF MILD HYPERTENSION: MEMORANDUM FOR A WORLD HEALTH ORGANIZATION/INTERNATIONAL SOCIETY OF HYPERTENSION MEETING, J. HYPERTENS., 11, PP. 905-918, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE: RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, PP. 1300-1331, (1994); EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4 444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, PP. 1001-1009, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, NEW ENGL. J. MED., 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, PP. 1301-1307, (1995); WEIS S., CLEARFIELD M., DOWNS J.R., GOTTO A., PRIMARY PREVENTION OF ACUTE MAJOR CORONARY EVENTS IN WOMEN AND MEN WITH AVERAGE CHOLESTEROL IN CHOLESTEROL-LOWERING THERAPY, EVALUATION OF CLINICAL TRIAL EVIDENCE, PP. 151-172, (2000); BURT V.L., WHELTON P., ROCCELLA E.J., ET AL., PREVALENCE OF HYPERTENSION IN THE US ADULT POPULATION: RESULTS FROM THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 1988-1991, HYPERTENSION, 25, PP. 305-313, (1995); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN. EPIDEMIOL., 2, PP. 161-176, (1992); CAPURSO A., LIPID METABOLISM AND CARDIOVASCULAR RISK: SHOULD HYPERCHOLESTEROLEMIA BE TREATED IN THE ELDERLY, J. HYPERTENS., 10, PP. 565-568, (1992); GOTTO A.M., ASSMAN G., CARMENA R., ET AL., THE ILIB LIPID HANDBOOK FOR CLINICAL PRACTICE: BLOOD LIPIDS AND CORONARY HEART DISEASE, (2000); THE SIXTH REPORT OF THE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD PRESSURE, ARCH. INTERN. MED., 157, PP. 2413-2446, (1997); WHELTON P.K., EPIDEMIOLOGY OF HYPERTENSION, LANCET, 344, PP. 101-106, (1994); MACMAHON S., PETO R., CUTLER J., ET AL., BLOOD PRESSURE, STROKE AND CORONARY HEART DISEASE I: PROLONGED DIFFERENCES IN BLOOD PRESSURE: PROSPECTIVE OBSERVATIONAL STUDIES CORRECTED FOR THE REGRESSION DILUTION BIAS, LANCET, 335, PP. 765-774, (1990); KANNEL W.B., ELEVATED SYSTOLIC BLOOD PRESSURE AS A CARDIOVASCULAR RISK FACTOR, AM. J. CARDIOL., 85, PP. 251-255, (2000); BLACK H.R., THE PARADIGM HAS SHIFTED TO SYSTOLIC BLOOD PRESSURE, HYPERTENSION, 34, PP. 386-387, (1999); PSATY B.M., FURBERG C.D., KULLER L.H., ET AL., THE ASSOCIATION BETWEEN BLOOD PRESSURE LEVEL AND THE RISK OF MYOCARDIAL INFARCTION, STROKE AND TOTAL MORTALITY. THE CARDIOVASCULAR HEALTH STUDY, ARCH. INTERN. MED., 161, PP. 1183-1192, (2001); KAPLAN N.M., WHAT IS THE GOAL BLOOD PRESSURE FOR THE TREATMENT OF HYPERTENSION, ARCH. INTERN. MED., 161, PP. 1480-1482, (2001); MOSER M., IS IT TIME FOR A NEW APPROACH TO THE INITIAL TREATMENT OF HYPERTENSION, ARCH. INTERN. MED., 161, PP. 1140-1144, (2001); LAWRENCE J., APPEL M.P.H., ESPELAND M.A., ET AL., EFFECTS OF REDUCED SODIUM INTAKE ON HYPERTENSION CONTROL IN OLDER INDIVIDUALS: RESULTS FROM THE TRIAL OF NONPHARMACOLOGIC INTERVENTION IN THE ELDERLY (TONE), ARCH. INTERN. MED., 161, PP. 685-693, (2001); DRUG TREATMENT OF HYPERTENSION IN THE ELDERLY, DRUGS: THER. AND PERSPECT., 1, PP. 7-12, (1993); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER. RES., 53, PP. 265-269, (1993); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTHS STUDY, CURR. THER. RES., 56, PP. 819-828, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, PP. 245-254, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 390-401, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3 YEARS OPEN FOLLOW-UP, CURR. THER. RES., 58, PP. 868-875, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1998); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, PP. 379-391, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL, PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERONTOL. MED. SCI., 56, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1996); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL. LETT., 70, PP. 77-87, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL. LETT., 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG. CARCINOG. MUTAGEN., 14, PP. 107-113, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTHS STUDY, TERATOG. CARCINOG. MUTAGEN., 14, PP. 239-249, (1994); ALEMAN C., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: A 18 MONTHS STUDY, FD. CHEM. TOXICOL., 33, PP. 573-578, (1995); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL. LETT., 90, PP. 97-106, (1997); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG. CARCINOG. MUTAGEN., 18, PP. 1-7, (1998); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, PP. 458-467, (1999); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, PP. 499-502, (1972); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, PP. 197-204, (1996); LESLIE S.J., SMITH D.G., CAMPBELL L.M., ET AL., TREATING TO LDL-C TARGET: RESOURCE UTILIZATION WITH ATORVASTATIN COMPARED WITH FLUVASTATIN, PRAVASTATIN AND SIMVASTATIN IN PATIENTS WITH CHD, 13TH INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (1998); WOOD D., DE BACKER G., FAERGERMAN O., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE, EUR. HEART J., 19, PP. 1434-1503, (1998); MULS E., DE BACKER G., DE BACQUER D., ET AL., LIPI-WATCH, A BELGIAN/LUXEMBOURG SURVEY ON ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY LIPID GOALS, CLIN. DRUG INVEST., 19, PP. 219-229, (2000); WOOD D., DE BACKER G., FAERGEMAN O., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE, EUR. HEART J., 19, PP. 1434-1503, (1998); SANTANELLO N.C., BARBER B.L., APPLEGATE W.B., ET AL., EFFECT OF PHARMACOLOGIC LIPID LOWERING ON HEALTH-RELATED QUALITY OF LIFE IN OLDER PERSONS: RESULTS FROM THE CHOLESTEROL REDUCTION IN SENIORS PROGRAM (CRISP) PILOT STUDY, J. AM. GERIATR. SOC., 4 S, PP. 8-14, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV. IBEROAM. TROMB. HEMOST., 5, PP. 17-20, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 20, PP. 119-124, (1998); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL. BEHAV., 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, PP. 225-262, (2000); MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION, CURR. THER. RES., 61, PP. 609-620, (2000); SPOSITO A.C., MANSUR A.P., COELHO O.R., ET AL., ADDITIONAL REDUCTION IN BLOOD PRESSURE AFTER CHOLESTEROL-LOWERING TREATMENT WITH STATINS (LOVASTATIN OR PRAVASTATIN) IN HYPERCHOLESTEROLEMIC PATIENTS USING ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ENALAPRIL OR LISINOPRIL), AM. J. CARDIOL., 83, PP. 1497-1499, (1999); LAUFS U., LA FATA V., PLUTZKY J., ET AL., UPREGULATION OF ENDOTHELIAL NITRIC OXIDE BY HMGCOA REDUCTASE INHIBITORS, CIRCULATION, 97, PP. 1129-1135, (1998); MOLINA V., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS: STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOLOL, ARCH. MED. RES., 29, PP. 21-24, (1998)","R. MÁS; NATIONAL CENTER SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN HAVANA CITY, P.O. BOX 6880, CUBA; EMAIL: CLINICA@IP.ETECSA.CU","","ENGLISH","DRUGS R D","ARTICLE","ISI","2-S2.0-0036043705","DRUGS R D","SURGICAL MEDICAL RESEARCH CENTER;CENTER OF NATURAL PRODUCTS;CENTER OF NATURAL PRODUCTS;CENTER OF NATURAL PRODUCTS;SURGICAL MEDICAL RESEARCH CENTER;SURGICAL MEDICAL RESEARCH CENTER","NOTREPORTED;NATIONAL CENTER SCIENTIFIC RESEARCH;EMAIL: CLINICA@IP.ETECSA.CU",NA,"CASTAÑO G, 2002, DRUGS R D","CASTAÑO G, 2002, DRUGS R D"
"RODNÍGUEZ M;GARCIA H","RODNÍGUEZ, MARIA D. (6504734917); GARCIA, HAYDEE (7202282339)","EVALUATION OF PERI AND POSTNATAL TOXICITY OF POLICOSANOL IN RATS",1998,"TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS","18","6",24,"10.1002/(SICI)1520-6866(1998)18:1<1::AID-TCM1>3.0.CO;2-K","DEPARTMENT OF TOXICOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;DEPARTMENT OF TOXICOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THE EFFECTS OF POLICOSANOL, A NEWLY DEVELOPMENTED HYPOCHOLESTEROLEMIC DRUG ADMINISTERED DURING THE PERINATAL AND POSTNATAL PERIODS, WERE STUDIED IN SPRAGUE-DAWLEY RATS. THIS COMPOUND WAS ADMINISTERED ORALLY TO FEMALE RATS AT DOSE LEVELS OF 0 (CONTROL), 5, 50, AND 500 MG/KG/DAY, FROM CLAY 15 OF PREGNANCY TO DAY 21 AFTER PARTURITION. THE ANIMALS WERE ALLOWED TO DELIVER AND THEIR OFFSPRING WERE EXAMINED FOR POSTNATAL GROWTH AND DEVELOPMENT. NO SIGNS OF TOXIC EFFECTS RELATED TO THE TEST MATERIAL WERE OBSERVED IN THE DAMS F0 DURING PREGNANCY AND LACTATION. NO ADVERSE EFFECTS WERE OBSERVED ON THE POSTNATAL GROWTH, BEHAVIOURS, OR REPRODUCTIVE ABILITY OF PUPS F1. THE PHYSICAL AND SENSORIAL DEVELOPMENT OF PUPS F2 WAS ALSO NORMAL. THESE RESULTS CONFIRM THAT POLICOSANOL DOES NOT AFFECT THE REPRODUCTIVE PERFORMANCE OR FETAL/NEONATAL DEVELOPMENT.","FERTILITY; FETUS; HYPOCHOLESTEROLEMIC DRUG; OFFSPRING; POLICOSANOL","ANIMALS; ANIMALS, NEWBORN; ANTICHOLESTEREMIC AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; FATTY ALCOHOLS; FEMALE; LACTATION; MALE; PREGNANCY; PREGNANCY, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; SEX RATIO; SURVIVAL RATE; ANIMALIA; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FERTILITY; FETOTOXICITY; FETUS DEVELOPMENT; GROWTH RETARDATION; INTRAGASTRIC DRUG ADMINISTRATION; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REVISTA CENIC CIENCIAS BIOL, 22, PP. 60-61, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZOLANOS FARMACOL Y TERAPEÚTICA, 11, PP. 2-4, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS CIENCIAS MED, 5, PP. 21-28, (1991); CRUZ-BUSTILLO D., MEDERO C.M., MAS R., ARRUZAZABALA M.L., BARRETO B., MARTINEZ O., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REVISTA CENIC CIENCIAS BIOL, 22, PP. 62-64, (1991); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ R., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THER RES, 51, PP. 568-575, (1992); PONS P., ILLNAIT J., RODRIGUEZ M., MAS R., FERNANDEZ L., ROBAINA C., FERNANDEZ J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THER RES, 52, PP. 507-513, (1992); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOGENESIS CARCINOGENESIS MUTAGENESIS, 14, PP. 107-113, (1994); CHRISTIAN M.S., HOBERMAN A.M., CURRENT IN VIVO REPRODUCTIVE TOXICITY AND DEVELOPMENT TOXICITY (TERATOLOGY) TEST METHODS: A GUIDE TO GENERAL TOXICOLOGY, KARGER CONTINUING EDUCATION SERIES, VOL. 5, 2ND REVISED EDITION, 5, PP. 91-99, (1989); ALEMAN C., MAS R., RODEIRO I., NOA M., HERNANDEZ C., CAPOTE A., MENENDEZ R., GONZALEZ R.M., AMO A.M., JIRNENEZ S., TOXICOLOGÍA AGUDA DEL ATEROMIXOL (PPG) ON ROEDORES, REVISTA CENIC CIENCIAS BIOL, 22, PP. 102-105, (1991); ALEMAN C., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., CAPOTE A., MENENDEZ R., AMOR A., FRAGA V., SOTOLONGO V., JIMENEZ S., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1992); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., GARCIA M., CAPOTE A., ALEMAN C.L., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALEZ R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FD CHEM TOXICOL, 32, PP. 565-575, (1992); RENDON A., RODRIGUEZ M.D., LOPEZ M., GARCIA H., DE LAS CAJIGAS A., MAS R., FERNANDEZ I., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOLOGY LETTERS SUPPLEMENT, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); BROWN M.S., GOLDSTEIN J.L., MULTIVALENT FEEDBACK REGULATION OF HMG-COA REDUCTASE, A CONTROL MECHANISM COORDINATING ISOPRENOID SYNTHESIS AND CELL GROWTH, J LIPID RES, 21, PP. 505-517, (1980); KORNBRUST D.J., MACDONALD J.S., PETER C.P., DUCHAI D.M., STUBSS R.J., GERMERSHAUSEN J.I., ALBERTS A.W., TOXICITY OF THE HMG-COENZYME A REDUCTASE INHIBITOR, LOVASTATIN, TO RABBITS, J PHARMACOL EXP THERAPEUTICS, 248, PP. 498-505, (1989); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., MAS R.M., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLAST, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R.M., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., ARRUZAZABALA L., MAS R.M., DEL RIO A., AMOR A.M., GONZALEZ R.M., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTRITION, 77, PP. 1-10, (1997)","","","ENGLISH","TERATOG. CARCINOG. MUTAG.","ARTICLE","ISI","2-S2.0-0031864685","TERATOG CARCINOG MUTAG",NA,"NOTREPORTED",NA,"RODNÍGUEZ MD, 1998, TERATOG CARCINOG MUTAG","RODNÍGUEZ MD, 1998, TERATOG CARCINOG MUTAG"
"CANETTI M;MOREIRA M;MÁS R;ILLNAIT J;FERNÁNDEZ L;FERNÁNDEZ J","CANETTI, M. MIGUEL (7004415986); MOREIRA, MARTA (9433321400); MÁS, ROSA (7007164572); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO C. (9432805500)","EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA A 3YEAR OPENEXTENSION FOLLOWUP",1997,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","58","7",29,"10.1016/S0011-393X(97)80053-7","SALVADOR ALLENDE HOSPITAL, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL IS A NEW CHOLESTEROL-LOWERING DRUG THAT IS PURIFIED FROM SUGARCANE WAX. THE PRESENT STUDY INVESTIGATED THE LONG-TERM EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. EIGHTY-FIVE PATIENTS WHO PARTICIPATED IN A PREVIOUS DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY WERE GIVEN POLICOSANOL (10 MG/D) IN A 3-YEAR OPEN-EXTENSION PERIOD. THE DURATION OF THE POLICOSANOL TREATMENT WAS 5 YEARS FOR THOSE PATIENTS WHO HAD PREVIOUSLY RECEIVED POLICOSANOL (N = 42) AND 3 YEARS FOR THOSE PREVIOUSLY TREATED WITH PLACEBO (N = 43). EFFICACY WAS MAINTAINED DURING THE ENTIRE TREATMENT PERIOD. POLICOSANOL SIGNIFICANTLY LOWERED CHOLESTEROL LEVELS IN BOTH GROUPS, COMPARED WITH PRETREATMENT, BASELINE VALUES, BY 20% IN THE GROUP RECEIVING POLICOSANOL FOR THE ENTIRE 5 YEARS, AND BY 17% IN THOSE RECEIVING POLICOSANOL FOR 3 YEARS (PREVIOUSLY RECEIVING PLACEBO). FIVE PATIENTS WITHDREW FROM THE STUDY, NONE BECAUSE OF ADVERSE EVENTS. NO DRUG-RELATED DISTURBANCES WERE OBSERVED IN THE SAFETY INDICATORS. THIS LONG-TERM STUDY SHOWS THAT POLICOSANOL IS BOTH EFFECTIVE AND WELL TOLERATED, WHICH IS IN AGREEMENT WITH RESULTS OF PREVIOUS SHORT- AND LONG-TERM TRIALS.","CHOLESTEROL-LOWERING DRUGS; HYPERCHOLESTEROLEMIA; LONG-TERM FOLLOW-UP; POLICOSANOL","CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL","","","EDLAVITCH S.A., POSTMARKETING SURVEILLANCE METHODOLOGIES, PHARMACOEPIDEMIOLOGY, 22, PP. 68-78, (1988); ARRUZAZABALA M.D.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP, 11, PP. 74-79, (1992); ALEMAN C.L., MAS R., NOA C., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG., 14, PP. 239-249, (1994); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); RENDON A., RODRIGUEZ M.D., LOPEZ M., ET AL., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, TOXICOL LETT, SUPPL., (1992); RODRIGUEZ C., MESA R., MAS R., ET AL., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1993); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAG., 14, PP. 107-113, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 4, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF ATEROMIXOL (POLICOSANOL) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL DE FARMACOL Y TERAP, 12, PP. 71-76, (1993); PONS P., MAS R., ILLNAIT J., ET AL., EFFECTS OF ATEROMIXOL (POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAM DE TROMBOSIS Y HEMOSTASIA, 5, PP. 17-20, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFECTO DEL POLICOSANOL SOBRE LA AGREGACIÓN PLAQUETARIA EN VOLUNTARIOS SANOS, SYMPOSIUM ON DRUG AFFECTING LIPID METABOLISM, (1995); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 33, PP. 1-5, (1996); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M., DE LA ROSA M.C., MAS R., EFFECT OF POLICOSANOL ON FOAM CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); BACISTA J., STUSSER R., PENICHET M., UGUET E., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES, 56, PP. 906-914, (1995); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988); BOCCUZZI S.J., KEEGAN M.E., HIRSCH L.J., ET AL., LONG-TERM EXPERIENCE WITH SIMVASTATIN, DRUG INVEST, 5, PP. 135-140, (1993)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0031406655","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CANETTI MM, 1997, CURR THER RES CLIN EXP","CANETTI MM, 1997, CURR THER RES CLIN EXP"
"BATISTA J;STÜSSER R;PADRÓN R;SOSA F;PEREZTOL O;PÉREZ B","BATISTA, JUAN F. (7005814235); STÜSSER, RODOLFO J. (6602973165); PADRÓN, RENÉ (18735349800); SOSA, FELIX (8928992600); PEREZTOL, OSVALDO (8928993000); PÉREZ, BEATRIZ (57213758299)","FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTHS OF LIPIDLOWERING THERAPY WITH POLICOSANOL",1996,"ADVANCES IN THERAPY","13","11",7,"","DEPARTMENT OF CLINICAL EPIDEMIOLOGY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA, CTRO. DE INVEST. CLÍNICAS, KOHLY, PLAYA HAVANA 13, CALLE 34 #4501 ENTRE 47 Y 45, CUBA;DEPARTMENT OF CLINICAL EPIDEMIOLOGY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CARDIOVASCULAR LABORATORY, HAVANA UNIVERSITY, CALIXTO GARCÍA HOSPITAL, HAVANA, CUBA;CARDIOVASCULAR LABORATORY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;DEPARTMENT OF CARDIOLOGY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;DEPARTMENT OF CLINICAL EPIDEMIOLOGY, CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA","TO EXAMINE THE EFFECTS OF LONG-TERM LIPID-LOWERING THERAPY WITH POLICOSANOL ON CORONARY ARTERY DISEASE (CAD), A 20-MONTH EXPLORATORY PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL WAS CONDUCTED IN 45 PATIENTS WITH ISCHEMIA, AS DOCUMENTED BY TOMOGRAPHIC 201THALLIUM-LABELED MYOCARDIAL PERFUSION SCINTIGRAPHY (201TL MPS). FIFTEEN PATIENTS RECEIVED POLICOSANOL 5 MG TWICE DAILY, 15 PATIENTS RECEIVED POLICOSANOL 5 MG TWICE DAILY PLUS ASPIRIN 125 MG, AND 15 PATIENTS RECEIVED PLACEBO PLUS ASPIRIN, ISCHEMIC SEGMENTS (IS) WERE ASSESSED SERIALLY BY MPS IN REGIONS NOT RELATED TO INFARCTED AREAS. EXERCISE ELECTROCARDIOGRAPHY, BIDIMENSIONAL ECHOCARDIOGRAPHIC EXAMINATION, AND SERUM LIPID TESTS WERE ALSO PERFORMED. FORTY-ONE PATIENTS COMPLETED THE FOLLOW-UP STUDY, 38 WITH PRIMARY HYPERLIPIDEMIA, 37 WITH A PRIOR MYOCARDIAL INFARCTION. PROPORTIONS OF FUNCTIONAL NONPROGRESSION OF IS IN THE GROUPS TAKING POLICOSANOL ALONE (.75) AND POLICOSANOL PLUS ASPIRIN (.73) WERE DOUBLE THOSE OF THE GROUP RECEIVING PLACEBO PLUS ASPIRIN (.36) (P = .04, Χ2(1DF) = 4.01; P = .04, Χ2(1DF) = 4.14). SETS OF MEAN CHANGES AFTER TREATMENT OF IS, MAXIMUM OXYGEN UPTAKE, AND LEFT VENTRICULAR EJECTION FRACTION IMPROVED SIMULTANEOUSLY WITH POLICOSANOL THERAPY (P = .066, F(3.22DF) = 2.76; P = .006, F(3.25DF) = 5.19) BUT REMAINED IMPAIRED WITHOUT IT. LIPID PARAMETERS WERE ALSO EVALUATED. RESULTS SUGGEST THAT LONG-TERM LIPID-LOWERING THERAPY WITH POLICOSANOL IMPROVES MYOCARDIAL ISCHEMIA, EXERCISE CAPACITY, AND LEFT VENTRICULAR FUNCTION IN CAD PATIENTS. THIS RESPONSE WAS ENHANCED WHEN POLICOSANOL WAS GIVEN WITH ASPIRIN.","<SUP>201</SUP>THALLIUM-LABELLED MYOCARDIAL PERFUSION SCINTIGRAPHY; CORONARY ARTERY DISEASE; EJECTION FRACTION; LIPID-LOWERING DRUG; MAXIMUM OXYGEN UPTAKE; POLICOSANOL","ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; PLACEBO; POLICOSANOL; THALLIUM; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY","","","ORNISH D., BROWN S., SCHERWITZ L., ET AL., CAN LIFESTYLE CHANGES REVERSE CORONARY HEART DISEASE?, LANCET, 336, PP. 129-133, (1990); SCHULER G., HAMBRECHT R., SCHIERF G., ET AL., REGULAR EXERCISE AND LOW-FAT DIET. EFFECTS ON PROGRESSION OF CORONARY ARTERY DISEASE, CIRCULATION, 86, PP. 1-11, (1992); GOULD K., REVERSAL OF CORONARY ATHEROSCLEROSIS. CLINICAL PROMISE AS THE BASIS FOR NONINVASIVE MANAGEMENT OF CORONARY ARTERY DISEASE, CIRCULATION, 90, PP. 1558-1571, (1994); GOULD K., ORNISH D., SCHERWITZ L., ET AL., CHANGES IN MYOCARDIAL PERFUSION ABNORMALITIES BY POSITRON EMISSION TOMOGRAPHY AFTER LONG-TERM, INTENSE RISK FACTOR MODIFICATION, JAMA, 274, PP. 894-901, (1995); LEVINE G., KEANEY J., VITA J., MEDICAL PROGRESS. CHOLESTEROL REDUCTION IN CARDIOVASCULAR DISEASE. CLINICAL BENEFITS AND POSSIBLE MECHANISMS, N ENGL J MED., 332, PP. 512-521, (1995); BATISTA J., STUSSER R., REGRESIÓN DE LA ATEROSCLEROSIS HUMANA. RESULTADOS DE ENSAYOS CLÍNICOS CON EL USO PROLONGADO DE HIPOLIPEMIANTES, REV CUB MED; GOULD K., MARTUCCI J., GOLDBERG D., ET AL., SHORT-TERM CHOLESTEROL LOWERING DECREASES SIZE AND SEVERITY OF PERFUSION ABNORMALITIES BY POSITRON EMISSION TOMOGRAPHY AFTER DIPYRIDAMOLE IN PATIENTS WITH CORONARY ARTERY DISEASE. A POTENTIAL NONINVASIVE MARKER OF HEALING CORONARY ENDOTHELIUM, CIRCULATION, 89, PP. 1530-1538, (1994); EICHSTADT H., ESKOTTER H., HOFFMANN I., AMTHAUR H., WEIDINGER G., IMPROVEMENT OF MYOCARDIAL PERFUSION BY SHORT-TERM FLUVASTATIN THERAPY IN CORONARY ARTERY DISEASE, AM J CARDIOL., 76, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE-DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 296-303, (1995); ARRUZAZABALA M., VALDES S., MAS R., FERNANDEZ I., CARBAJAL D., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, REV CENIC CIENC BIOL., 26, (1995); NOA M., HERRERA M., MAS R., EFFECT OF ATEROMIXOL (POLICOSANOL) ON ENDOTHELIAL INJURY IN RATS, REV CENIC CIENC BIOL., 22, PP. 79-80, (1991); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL., 32, PP. 565-575, (1994); BATISTA J., STUSSER R., PENICHET M., UGUET E., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES., 56, PP. 906-914, (1995); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J PHARMACOL THER., 34, PP. 134-137, (1996); GRUNDY S., NATIONAL CHOLESTEROL EDUCATION PROGRAM: SECOND REPORT OF THE EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, CIRCULATION, 89, PP. 1329-1446, (1994); BRUCE R., EXERCISE TESTING OF PATIENTS WITH CORONARY ARTERY DISEASE: PRINCIPLES AND NORMAL STANDARDS FOR EVALUATION, ANN CLIN RES., 3, PP. 323-332, (1971); RISK STRATIFICATION AND SURVIVAL AFTER MYOCARDIAL INFARCTION, N ENGL J MED., 309, PP. 331-336, (1983); BROWN B., STEWART B., ZHAO X., ET AL., WHAT BENEFIT CAN BE DERIVED FROM TREATING NORMOCHOLESTEROLEMIC PATIENTS WITH CORONARY ARTERY DISEASE?, AM J CARDIOL., 76, SUPPL., (1995); JUKEMA J., BRUSCHKE A., VAN BOVEN A., ET AL., EFFECTS OF LIPID LOWERING BY PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ARTERY DISEASE IN SYMPTOMATIC MEN WITH NORMAL TO MODERATELY ELEVATED SERUM CHOLESTEROL LEVELS. THE REGRESSION GROWTH EVALUATION STATIN STUDY (REGRESS), CIRCULATION, 91, PP. 2528-2540, (1995); BENZULY K., PADGETT R., SANJAY K., ET AL., FUNCTIONAL IMPROVEMENT PRECEDES STRUCTURAL REGRESSION OF ATHEROSCLEROSIS, CIRCULATION, 89, PP. 1810-1818, (1994); SCHMIEDER R., SCHOBEL H., IS ENDOTHELIAL DYSFUNCTION REVERSIBLE?, AM J CARDIOL., 76, SUPPL., (1995); WHITE H., FRENCH J., HAMER A., ET AL., FREQUENT REOCCLUSION OF PATIENT INFARCT-RELATED ARTERIES BETWEEN 4 WEEKS AND 1 YEAR: EFFECTS OF ANTIPLATELET THERAPY, J AM COLL CARDIOL., 25, PP. 218-223, (1995)","","","ENGLISH","ADV. THER.","ARTICLE","ISI","2-S2.0-0030002177","ADV THER",NA,"NOTREPORTED",NA,"BATISTA JF, 1996, ADV THER","BATISTA JF, 1996, ADV THER"
"MÁS R;CASTAÑO G;ILLNAIT J;FERNÁNDEZ L;FERNÁNDEZ J;ALEMÁN C;PONTIGAS V;LESCAY M","MÁS, ROSA (7007164572); CASTAÑO, GLADYS (56232967100); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO (9432805500); ALEMÁN, CELIA (7102849611); PONTIGAS, VIRGINIA (7801672672); LESCAY, MAGNOLIA (6505513899)","EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS",1999,"CLINICAL PHARMACOLOGY AND THERAPEUTICS","65","8",126,"10.1016/S0009-9236(99)70139-6","CENTER OF NATURAL PRODUCTS, NATL. CTR. FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA CITY, PO BOX 6990, CUBA; CASTAÑO G.; ILLNAIT J.; FERNÁNDEZ L.; FERNÁNDEZ J.; ALEMÁN C.; PONTIGAS V.; LESCAY M.","INTRODUCTION: THIS STUDY WAS UNDERTAKEN TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL, A NEW CHOLESTEROL-LOWERING DRUG, IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS. PATIENTS AND METHODS: AFTER 5 WEEKS OF A STANDARD STEP-1 LIPID- LOWERING DIET, 437 PATIENTS WERE RANDOMIZED TO RECEIVE, UNDER DOUBLE-BLIND CONDITIONS, 5 MG POLICOSANOL OR PLACEBO ONCE A DAY WITH THE EVENING MEAL FOR 12 WEEKS AND 10 MG POLICOSANOL OR PLACEBO FOR THE NEXT 12 WEEKS. RESULTS: BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. POLICOSANOL (5 AND 10 MG/DAY) SIGNIFICANTLY REDUCED (P < .001) SERUM LOW-DENSITY LIPOPROTEIN CHOLESTEROL (18.2% AND 25.6%, RESPECTIVELY) AND CHOLESTEROL (13.0% AND 17.4%), AND IT SIGNIFICANTLY RAISED (P < .01) HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (15.5% AND 28.4%). TRIGLYCERIDES REMAINED UNCHANGED AFTER THE FIRST 12 WEEKS AND LOWERED SIGNIFICANTLY (5.2%; P < .01) AT STUDY COMPLETION. POLICOSANOL WAS SAFE AND WELL TOLERATED, AND NO DRUG-RELATED DISTURBANCES WERE OBSERVED. TWO MALE PATIENTS WHO RECEIVED PLACEBO DIED DURING THE STUDY - ONE BECAUSE OF A MYOCARDIAL INFARCTION AND THE OTHER BECAUSE OF A CARDIAC ARREST THAT OCCURRED DURING A SURGICAL INTERVENTION. THERE WERE 11 SERIOUS ADVERSE EVENTS (5.1%) IN 10 PATIENTS WHO RECEIVED PLACEBO (4.6%), 7 OF WHICH WERE VASCULAR, COMPARED WITH NO SERIOUS ADVERSE EVENTS REPORTED IN PATIENTS RECEIVING POLICOSANOL (P < .01). CONCLUSIONS: SUBJECTS IN THE GROUP TREATED WITH POLICOSANOL DID NOT HAVE SERIOUS ADVERSE EVENTS DURING THE 24-WEEK STUDY. THIS STUDY SHOWS THAT POLICOSANOL IS EFFECTIVE, SAFE, AND WELL TOLERATED IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS.","","CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL","","","I: REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); CORONARY PRIMARY PREVENTION TRIAL RESULTS; II: THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., HEINONEN O.P., HEINSALMI P., HELO P., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA: SAFETY OF TREATMENT, CHANGES IN RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, N ENGL J MED, 317, PP. 1237-1245, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SHEPHERD S., COBBE S.M., FORD I., IGLES C.G., LORMER A.R., MACFARLANE P.W., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); SACKS F.M., PFEFFER M.A., MOYE L.A., ROULEAU J.L., RUTHERFORD J.D., COLE T.G., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS. CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS, N ENGL J MED, 335, PP. 1001-1009, (1996); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); ASSMANN G., SCHULTE H., DIABETES MELLITUS AND HYPERTENSION IN THE ELDERLY: CONCOMITANT HYPERLIPIDEMIA AND CORONARY HEART DISEASE RISK, AM J CARDIOL, 63, SUPPL. H, PP. 33-37, (1989); O'CONNOR P., FEELY J., SHEPERD J., LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); STEINER A., WEISSER B., VETTER W., A COMPARATIVE STUDY OF THE ADVERSE EFFECTS OF TREATMENT FOR HYPERLIPIDEMIA, DRUG SAF, 6, PP. 118-130, (1991); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R.M., FRAGA V., AMOR A.M., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., DEL RIO A., AMOR A.M., GONZALEZ R.M., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); MENENDEZ R., AMOR A.M., GONZALEZ R.M., FRAGA V., MAS R., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., ET AL., ONE YEAR EFFICACY AND SAFELY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CANETTI M., MORERA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., TULA L., ILLNAIT J., FERNANDEZ L., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR THER RES, 56, PP. 819-828, (1995); CASTANO G., TULA L., CANETTI M., MAS R., ILLNAIT J., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., MAS R., ILLNAIT J., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II, ESTUDIO ABIERTO. LA PRENSA MÉDICA ARGENTINA, 83, PP. 665-672, (1996); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 154-162, (1997); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANETTI M., MORERA M.S., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3 YEAR OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); ALEMAN C.L., RODEIRO I., NOA M., HERNANDEZ C., MAS R., GONZALEZ R.M., ET AL., ACUTE SUBCHRONICAL AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ALEMAN C., MAS R., HERNANDEZ C., RODEIRO I., CEREJIDO E., NOA M., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); MESA A.R., MAS R., NOA M., HERNANDEZ C., RODEIRO I., GAMEZ R., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); ALEMAN C., NOA M., CEREJIDO E., MAS R., RODEIRO I., HERNANDEZ C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, SUPPL. 3, PP. 63-71, (1988); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL/L (200 TO 300 MG/DL) PLUS TWO ADDITIONAL ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 72, PP. 1031-1037, (1993); PLOSKER G.L., MCTAVISH D., SIMVASTATIN: A REAPPRAISAL OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN HYPERCHOLESTEROLAEMIA, DRUGS, 50, PP. 334-363, (1995); ILLINGWORTH R., THERAPEUTIC USE OF LOVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, CLIN THER, 16, PP. 2-26, (1994); BLANKENHORN D.H., NESSIM S.A., JOHNSON R.L., SANMARCO M.E., AZEN S.P., CASHIN-HEMPHILL L., BENEFICIAL EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS, JAMA, 247, PP. 3233-3240, (1987); BROWN G., ALBERS J.J., FISHER L.D., SCHAEFER B.A., LIN J.T., KAPLAN C., ET AL., REGRESSION OF CORONARY ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH LEVELS OF APOLIPOPROTEIN B, N ENGL J MED, 323, PP. 12879-12898, (1990); BUCHWALD H., VARCO R.L., MATTS J.P., LONG J.M., FITCH L.L., CAMPBELL G.S., ET AL., EFFECT OF PARTIAL ILEAL BYPASS SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA: REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH), N ENGL J MED, 323, PP. 946-955, (1990); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS P., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAMER TROMB HEMOST, 9, PP. 58-62, (1996); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., MAS R., FERNANDEZ L., MOLINA V., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOK ESSENT FATTY ACIDS, 58, PP. 61-64, (1998)","","MOSBY INC.","ENGLISH","CLIN. PHARMACOL. THER.","ARTICLE","ISI","2-S2.0-0032970949","CLIN PHARMACOL THER",NA,"NOTREPORTED",NA,"MÁS R, 1999, CLIN PHARMACOL THER","MÁS R, 1999, CLIN PHARMACOL THER"
"CANETTI M;MOREIRA M;MAS R;ILLNAIT J;FERNANDEZ L;FERNANDEZ J;DIAZ E;CASTANO G","CANETTI, M. (7004415986); MOREIRA, M. (9433321400); MAS, R. (7007164572); ILLNAIT, J. (8631465800); FERNANDEZ, L. (7202848319); FERNANDEZ, J. (9432805500); DIAZ, E. (16738702300); CASTANO, G. (56232967100)","A TWOYEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA",1995,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","15","6",80,"","CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA;CENTRE OF NATURAL PRODUCTS, NATIONAL CENTRE SCIENTIFIC RESEARCH, HAVANA CITY, AVE. 25 AND 158, CUBA","THIS IS A REPORT OF THE RESULTS OF A TWO YEARS' RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL ADMINISTERED AT 5 MG TWICE-A-DAY IN THE TREATMENT OF TYPE II HYPERLIPOPROTEINAEMIA. THE STUDY INCLUDED 69 PATIENTS FROM BOTH SEXES, IN WHOM TOTAL CHOLESTEROL AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL (LDL-C) WERE NOT CONTROLLED SUFFICIENTLY BY DIET. THE TREATMENT EFFECT ON TOTAL CHOLESTEROL AND LDL-C WAS MAINTAINED DURING THE 2-YEAR FOLLOW UP. THUS, PERCENT REDUCTIONS 24 MONTHS AFTER THERAPY WERE 25% (LDL-C) AND 18% (CHOLESTEROL). ALL COMPARISONS WITH PLACEBO WERE SIGNIFICANT. SIMILARLY, RATIOS OF LDL-C TO HDL-C AND CHOLESTEROL TO HDL-C WERE SIGNIFICANTLY REDUCED AND SUCH DECREASES WERE MAINTAINED DURING THE STUDY. POLICOSANOL RAISED SIGNIFICANTLY THE VALUES OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) DURING THE STUDY AND MAXIMAL INCREASES WERE REACHED 12 MONTHS AFTER THERAPY (+21%). FROM THIS TIME THE INCREASES MILDLY DECLINED TO +14% AND +11.2% RESPECTIVELY AT 18 AND 24 MONTHS AFTER THERAPY. NO SIGNIFICANT CHANGES IN TRIGLYCERIDES WERE OBSERVED AS COMPARED WITH BASELINE OR PLACEBO. NO PATIENT WITHDREW FROM THE STUDY BECAUSE OF ADVERSE EFFECTS. NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE SIDE-EFFECTS WERE OBSERVED. ANY ADVERSE EXPERIENCES REPORTED WERE MILD AND TRANSIENT; MOREOVER, NO SIGNIFICANT DIFFERENCES WERE OBTAINED WHEN COMPARED WITH THOSE REPORTED BY THE PLACEBO GROUP. THE RESULTS INDICATE THAT POLICOSANOL ADMINISTERED FOR TWO YEARS TO PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA SHOWS A MAINTAINED EFFICACY AS WELL AS VERY GOOD SAFETY AND TOLERABILITY.","","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPOPROTEINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL","","","","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0029589212","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"CANETTI M, 1995, INT J CLIN PHARMACOL RES","CANETTI M, 1995, INT J CLIN PHARMACOL RES"
"CUEVAS V;ARRUZAZABALA M;QUINTANA D;FERREIRO R;GARCIA S","CUEVAS, V.M. (7006062814); ARRUZAZABALA, M.L. (6603962476); QUINTANA, D.C. (8777025000); FERREIRO, R.M. (6602148780); GARCIA, S.V. (57199484510)","EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOLOL",1998,"ARCHIVES OF MEDICAL RESEARCH","29","3",10,"","CENTRO DE PRODUCTOS NATURALES, CNIC, PLAYA, HAVANA, AVE. 25 Y 158 CUBANACAN, CUBA;CENTRO DE PRODUCTOS NATURALES, CNIC, PLAYA, HAVANA, AVE. 25 Y 158 CUBANACAN, CUBA;CENTRO DE PRODUCTOS NATURALES, CNIC, PLAYA, HAVANA, AVE. 25 Y 158 CUBANACAN, CUBA;CENTRO DE PRODUCTOS NATURALES, CNIC, PLAYA, HAVANA, AVE. 25 Y 158 CUBANACAN, CUBA;CENTRO DE PRODUCTOS NATURALES, CNIC, PLAYA, HAVANA, AVE. 25 Y 158 CUBANACAN, CUBA","BACKGROUND: POLICOSANOL IS A NATURAL MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE WAX (SACCHARUM OFFICINARUM, L) WITH CHOLESTEROL-LOWERING EFFECTS DEMONSTRATED IN EXPERIMENTAL MODELS AND IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA. THE PURPOSE OF THIS STUDY IS TO DETERMINE THE EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE AND ITS INTERACTION WITH PROPRANOLOL AND NIFEDIPINE. METHODS: SINGLE DOSES OF POLICOSANOL (25, 50 AND 200 MG/KG) ORALLY ADMINISTERED TO SPONTANEOUSLY HYPERTENSIVE RATS (SHR) DID NOT SIGNIFICANTLY CHANGE ARTERIAL PRESSURE. RESULTS: THE STUDY ON PHARMACOLOGICAL INTERACTIONS BETWEEN POLICOSANOL (200 MG/KG) AND BOTH ANTIHYPERTENSIVE AGENTS REVEALED THAT PRETREATMENT WITH HIGH DOSES OF POLICOSANOL SIGNIFICANTLY INCREASED PROPRANOLOL-INDUCED HYPOTENSIVE EFFECTS, WHILE THE EFFECTS OF NIFEDIPINE REMAINED UNCHANGED. CONCLUSIONS: OUR RESULTS SHOW THAT POLICOSANOL DOES NOT ANTAGONIZE THE HYPOTENSIVE EFFECT OF Β-BLOCKERS BUT IT CAN INCREASE THE HYPOTENSIVE EFFECT OF Β-BLOCKERS WITHOUT MODIFYING CARDIAC FREQUENCY.","ARTERIAL PRESSURE; NIFEDIPINE; POLICOSANOL; PROPRANOLOL","ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG INTERACTIONS; FATTY ALCOHOLS; MALE; NIFEDIPINE; PROPRANOLOL; RATS; RATS, INBRED SHR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; POLICOSANOL; PROPRANOLOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HEART RATE; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE","","","","","","ENGLISH","ARCH. MED. RES.","ARTICLE","ISI","2-S2.0-0031923069","ARCH MED RES",NA,"NOTREPORTED",NA,"CUEVAS VM, 1998, ARCH MED RES","CUEVAS VM, 1998, ARCH MED RES"
"MÁS R;CASTAÑO G;FERNÁNDEZ L;ILLNAIT J;FERNÁNDEZ J;ALVAREZ E","MÁS, R. (7007164572); CASTAÑO, G. (7005759008); FERNÁNDEZ, L. (7202848319); ILLNAIT, J. (8631465800); FERNÁNDEZ, J. (9432805500); ALVAREZ, E. (15053135600)","EFFECTS OF POLICOSANOL ON LIPID PROFILE AND CARDIAC EVENTS IN OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY DISEASE",2001,"CLINICAL DRUG INVESTIGATION","21","12",32,"10.2165/00044011-200121070-00004","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","OBJECTIVE: THIS STUDY WAS UNDERTAKEN TO INVESTIGATE THE EFFECTS OF POLICOSANOL ADMINISTERED FOR 1 YEAR ON THE LIPID PROFILE AND CARDIAC EVENTS OF OLDER HYPERCHOLESTEROLAEMIC PATIENTS WITH CORONARY HEART DISEASE (CHD). PATIENTS: 280 OLDER PATIENTS OF BOTH SEXES WITH TYPE II HYPERCHOLESTEROLAEMIA AND CHD WERE INCLUDED. METHODS: PATIENTS WERE RANDOMISED AFTER 6 WEEKS OF A STANDARD STEP I CHOLESTEROL-LOWERING DIET TO TREATMENT WITH POLICOSANOL (5MG) OR PLACEBO TABLETS ONCE DAILY FOR 1 YEAR. THE STARTING DOSE WAS 5 MG/DAY, WHICH WAS DOUBLED TO 10 MG/DAY IF PREDEFINED GOALS WERE NOT REACHED AFTER 6 MONTHS ON THERAPY. CARDIAC EVENTS WERE DEFINED AS DEATH FROM CARDIOVASCULAR CAUSES [FATAL MYOCARDIAL INFARCTION (MI), SUDDEN CARDIAC DEATH] AND NONFATAL MI, UNSTABLE ANGINA PECTORIS OR CORONARY SURGERY. RESULTS: POLICOSANOL SIGNIFICANTLY (P < 0.00001) LOWERED SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) [21.3%], TOTAL CHOLESTEROL (TC) [15.9%], TC TO HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) RATIO [22.7%] AND LDL-C/HDL-C RATIO (26.1%), AS WELL AS TRIGLYCERIDES (7.8%, P < 0.001). HDL-C WAS SIGNIFICANTLY INCREASED (18.2%, P < 0.001). THE FREQUENCY OF CARDIAC EVENTS WAS LOWER (P < 0.001) IN POLICOSANOL (1 EVENT, 0.7%) THAN IN PLACEBO (11 EVENTS, 7.9%) RECIPIENTS. LIKEWISE, THE FREQUENCY OF ALL VASCULAR SERIOUS ADVERSE EVENTS (FOUR EVENTS, 2.9%) AND ALL-CAUSE HOSPITALISATIONS IN THE POLICOSANOL GROUP (FIVE EVENTS, 3.6%) WAS LOWER (P < 0.001) THAN IN THE PLACEBO GROUP (15 AND 20 EVENTS, 10.7 AND 14.3%, RESPECTIVELY). NO PATIENT DIED DURING THE STUDY. POLICOSANOL WAS WELL TOLERATED. CONCLUSIONS: LONG-TERM POLICOSANOL IS EFFECTIVE IN LOWERING LDL-C AND TC AND IN INCREASING HDL-C LEVELS IN OLDER PATIENTS WITH CHD, AND ALSO SHOWED BENEFITS IN THE OCCURRENCE OF CARDIAC EVENTS AND OVERALL FREQUENCY OF SERIOUS ADVERSE EVENTS OF VASCULAR AETIOLOGY.","","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS","NATIONAL CENTER FOR SCIENTIFIC RESEARCH; TECHNICAL PROJECT COUNCIL FOR THE CENTER OF NATURAL PRODUCTS","THIS TRIAL WAS SUPPORTED BY A RESEARCH PROJECT GRANT FROM THE TECHNICAL PROJECT COUNCIL FOR THE CENTER OF NATURAL PRODUCTS FROM THE NATIONAL CENTER FOR SCIENTIFIC RESEARCH; OTHER INSTITUTIONS BELONGING TO THE CUBAN HEALTH SYSTEM ALSO PARTICIPATED IN THIS WORK FREE OF CHARGE. POLICOSANOL WAS SUPPLIED BY LABORATORIOS DALMER (HAVANA CITY, CUBA).","1998: LIFE IN THE 21ST CENTURY - A VISION OF ALL, (1998); BROWN M.S., GOLDSTEIN J.L., HEART ATTACKS: GONE WITH THE CENTURY?, SCIENCE, 272, (1996); LIPID RESEARCH CLINICS PROGRAM THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); LIPID RESEARCH CLINICS PROGRAM THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II THE RELATIONSHIP ON REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS. THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); TONKIN A., AYLWARD P., COLQHOUN D., ET AL., PREVENTION OF CARDIOVASCULAR EVENTS AND DEATHS WITH PRAVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND A BROAD RANGE OF INITIAL CHOLESTEROL LEVELS, N ENGL J MED, 339, PP. 1349-1357, (1998); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); DENKE M.A., GRUNDY S.M., HYPERCHOLESTEROLEMIA IN ELDERLY PERSONS: RESOLVING THE TREATMENT DILEMMA, ANN INT MED, 112, PP. 780-792, (1990); BILHEIMER D.W., CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN THE ELDERLY, ATHEROSCLEROSIS, 91, (1991); CAPURSO A., LIPID METABOLISM AND CARDIOVASCULAR RISK: SHOULD HYPERCHOLESTEROLEMIA BE TREATED IN THE ELDERLY?, J HYPERTENSION, 10, PP. 565-568, (1992); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN EPIDEMIOL, 2, PP. 161-176, (1992); MASAKI K.H., PETROVITCH H., RODRIGUEZ B.L., ET AL., THE VALUE OF RISK FACTOR MODIFICATION IN OLD AGE, CARDIOLOGY ELDERLY, 1, PP. 391-397, (1993); SEMPOS C.T., CLEEMAN J.I., CARROL M.D., ET AL., PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG US ADULTS: AN UPDATE BASED ON GUIDELINES FROM THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL, JAMA, 269, PP. 3009-3014, (1993); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLAEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3 YEARS OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1998); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPER-CHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); ALEMAN C., MAS R., RODEIRO I., ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS. ABSTRACT OF THE 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY, ROME, 28 JUNE-3 JULY 1992, TOXICOL LETT, SUPPL., (1992); RENDON A., RODRIGUEZ M.D., LOPEZ M., ET AL., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS. ABSTRACT OF THE 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY, ROME, 28 JUNE-3 JULY 1992, TOXICOL LETT, SUPPL., (1992); MESA ADEL R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTHS STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); ALEMAN C., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTHS' STUDY, FED CHEM TOXICOL, 33, PP. 573-578, (1995); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLAEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTHS' STUDY, CURR THER RES, 56, PP. 819-828, (1993); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); MAS R., RIVAS P., IZQUIERDO J.E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); LESLIE S.J., SMITH D.G., CAMPBELL L.M., ET AL., TREATING TO LDL-C TARGET: RESOURCE UTILIZATION WITH ATORVASTATIN COMPARED WITH FLUVASTATIN, PRAVASTATIN AND SIMVASTATIN IN PATIENTS WITH CHD, PROCEEDINGS OF THE 13TH INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, (1998); WOOD D., DE BACKER G., FAERGERMAN O., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE, EUR HEART J, 19, PP. 1434-1503, (1998); MULS E., DE BACKER G., DE BACQUER D., ET AL., LIPI-WATCH, A BELGIAN/LUXEMBOURG SURVEY ON ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY LIPID GOALS, CLIN DRUG INVEST, 19, PP. 219-229, (2000); PEDERSEN T.R., THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S)- CHAPTER 2 IN CHOLESTEROL-LOWERING THERAPY, EVALUATION OF CLINICAL TRIAL EVIDENCE, 54, (2000); RIEGGER G., ABLETSHAUSER C., LUDWIG M., ET AL., THE EFFECT OF FLUVASTATIN ON CARDIAC EVENTS IN PATIENTS WITH SYMPTOMATIC CORONARY ARTERY DISEASE DURING ONE YEAR TREATMENT, ATHEROSCLEROSIS, 144, PP. 263-270, (1999); SANTANELLO N.C., BARBER B.L., APPLEGATE W.B., ET AL., EFFECT OF PHARMACOLOGIC LIPID LOWERING ON HEALTH-RELATED QUALITY OF LIFE IN OLDER PERSONS: RESULTS FROM THE CHOLESTEROL REDUCTION IN SENIORS PROGRAM (CRISP) PILOT STUDY, AM J GERIATR SOC, 4 S, PP. 8-14, (1997); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAM TROMBO HEMOST, 9, PP. 58-62, (1996); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISS REACT, 20, PP. 119-124, (1998); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL; MENENDEZ R., MAS R., AMOR A., ET AL., EFFECTS OF POLICOSANOL ON THE LOW DENSITY LIPOPROTEIN (LDL) ISOLATED ON HYPERCHOLESTEROLEMIC PATIENTS AT HIGH CORONARY RISK TO IN VITRO COPPER-MEDIATED LIPID PEROXIDATION, CURR THER RES, 61, PP. 609-620, (2000); ARRUZAZABALA M.D., NOA M., MENENDEZ R., ET AL., EFFECTS OF POLICOSANOL ON ATHEROSCLEROSIS LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); GLYNN R.J., CHAE C.U., GURALNIK TAYLOR J.O., ET AL., PULSE PRESSURE AND MORTALITY IN OLDER PEOPLE, ARCH INTERN MED, 160, PP. 2765-2772, (2000)","R. MÁS; CENTER OF NATURAL PRODUCTS, NATIONAL CTR. FOR SCIENTIFIC RES., CUBANACÁN HAVANA CITY, PO BOX 6880 OR 6990, CUBA; EMAIL: DALMER@ETECSA@IP.COM.CU","ADIS INTERNATIONAL LTD","ENGLISH","CLIN. DRUG INVEST.","ARTICLE","ISI","2-S2.0-0034913131","CLIN DRUG INVEST","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;MEDICAL SURGICAL RESEARCH CENTER;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CTR. FOR SCIENTIFIC RES.;NOTREPORTED",NA,"MÁS R, 2001, CLIN DRUG INVEST","MÁS R, 2001, CLIN DRUG INVEST"
"CASTAÑO G;MÁS R;NODARSE M;ILLNAIT J;FERNÁNDEZ L;FERNÁNDEZ J","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); NODARSE, MANUEL (18735541400); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILLA (7202848319); FERNÁNDEZ, JULIO CÉSAR (9432805500)","ONEYEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL 5 MG TWICE DAILY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA",1995,"CURRENT THERAPEUTIC RESEARCH","56","8",57,"10.1016/0011-393X(95)85034-1","MEDICAL-SURGICAL RESEARCH CENTER, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL-SURGICAL RESEARCH CENTER, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THIS STUDY REPORTS THE RESULTS OF A 12-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL (5 MG TWICE DAILY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. AFTER A LOW-FAT, LOW-CHOLESTEROL DIET FOR AT LEAST 12 WEEKS, 74 PATIENTS WERE RANDOMIZED TO RECEIVE PLACEBO OR POLICOSANOL (5 MG) TABLETS FOR 12 MONTHS. TABLETS WERE TAKEN TWICE DAILY BEFORE THE MORNING AND EVENING MEALS. LIPID PROFILE AND SAFETY INDICATORS WERE CONTROLLED REGULARLY THROUGHOUT THE STUDY. SIGNIFICANT REDUCTIONS OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) WERE ACHIEVED AFTER 2 MONTHS OF THERAPY. THE TREATMENT EFFECT CONTINUED DURING THE 12-MONTH FOLLOW-UP. AFTER 12 MONTHS, TOTAL CHOLESTEROL HAD DECREASED BY 17.2% AND LDL-C BY 26.4%. SIMILARLY, RATIOS OF LDL-C TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND TOTAL CHOLESTEROL TO HDL-C WERE ALSO SIGNIFICANTLY REDUCED IN THE POLICOSANOL GROUP, DECREASING BY 33.3% (LDL-C:HDL-C) AND 25.3% (CHOLESTEROL:HDL-C) AFTER 12 MONTHS. IN ADDITION, A SIGNIFICANT, SUSTAINED INCREASE IN HDL-C OF 13% TO 15% OCCURRED IN THE POLICOSANOL-TREATED GROUP. NO SIGNIFICANT CHANGES IN TRIGLYCERIDES WERE OBSERVED COMPARED WITH BASELINE OR PLACEBO. NINE PATIENTS DISCONTINUED THE TRIAL (FIVE FROM THE PLACEBO GROUP AND FOUR FROM THE POLICOSANOL GROUP), NONE OF THEM BECAUSE OF ADVERSE EFFECTS. THE ADVERSE EXPERIENCES REPORTED WERE MILD AND TRANSIENT. NO SIGNIFICANT DIFFERENCES WERE OBTAINED COMPARED WITH THOSE REPORTED BY THE PLACEBO GROUP. NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE EFFECTS WERE DETECTED. IT IS CONCLUDED THAT POLICOSANOL ADMINISTERED AT 5 MG TWICE DAILY FOR 12 MONTHS SHOWS A PERSISTENT EFFICACY AND IS SAFE AND WELL TOLERATED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. © 1995.","","ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; RANDOMIZED CONTROLLED TRIAL; RASH; TABLET; VERTIGO","","","LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS IA REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 251, PP. 251-364, (1984); LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS IB THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK, ELO, HAAPA, HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEM- FIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANGE OF RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, NEJM, 317, PP. 1237-1245, (1987); TOBERT, EFFICACY AND LONG-TERM ADVERSE EFFECT PATTERN OF LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 62, PP. 28J-33J, (1988); BLUM, LEVY, CURRENT THERAPY FOR HYPERCHOLESTEROLEMIA, JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 261, PP. 3582-3587, (1988); FINDLAY, SIMVASTATIN: THE CLINICAL PROFILE, AM J MED, 87, PP. 44-45, (1989); KANNEL, D'AGGOSTINO, STEPANIANS, D'AGOSTINO, EFFICACY AND TOLERABILITY OF LOVASTATIN IN A SIX-MONTH STUDY ANALYSIS BY GENDER AGE AND HYPERTENSIVE STATUS, THE AMERICAN JOURNAL OF CARDIOLOGY, 66, PP. 1B-10B, (1990); O'CONNOR, FEELY, SHEPHERD, LIPID-LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); MANTELL, BURKE, STAGGERS, EXTENDED CLINICAL SAFETY PROFILE OF LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 66, PP. 11B-15B, (1990); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CENIC CIEN BIOL, 22, PP. 60-61, (1991); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VEN FARMACOL TER, 11, PP. 80-86, (1992); CRUZ-BUSTILLO, MEDEROS, MAS, ET AL., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CENIC CIEN BIOL, 22, PP. 62-63, (1991); RODRIGUEZ, MESA, MAS, ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VEN FARMACOL TER, 11, PP. 74-79, (1992); HERNANDEZ, ILLNAIT, R, ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ILLNAIT, CASTANO, NODARSE, ET AL., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II, REV CENIC CIEN BIOL, 22, PP. 74-76, (1991); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); PONS, MAS, ILLNAIT, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS, JIMENEZ, RODRIGUEZ, ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); SOLTERO, FUENMAYOR, COLMENARES, ARIAS, ENSAYO DOBLE CIEGO PARA LA EVALUACIÓN DEL POLICOSANOL EN EL TRATAMIENTO DE LA HIPERLIPOPROTEINEMIA TIPO II, ARCH VEN FARMACOL TER, 12, PP. 65-70, (1993); SOLTERO, FUENMAYOR, COLMENARES, ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VEN FARMACOL TER, 12, PP. 71-76, (1993); ANEIROS, CALDERON, MAS, ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS, RODRIGUEZ, ROBAINA, ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); ALEMAN, MAS, RODEIRO, ET AL., TOXICOLOGÍA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REV CENIC CIEN BIOL, 22, PP. 102-105, (1991); ALEMAN, MAS, HERNANDEZ, ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); FERNANDEZ, RENDON, DE LAS CAJIGAS, LOPEZ, ESTUDIO GENOTÓXICO DEL ATEROMIXOL (PPG), UN NUEVO MEDICAMENTO HIPOLIPEMIANTE, REV CENIC CIEN BIOL, 22, PP. 98-101, (1991); MESA, MAS, NOA, ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ, GARCIA, TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS, 14, PP. 107-113, (1994); PONS, RODRIGUEZ, MAS, ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, PP. 1084-1092, (1994); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHO-TUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD, LEVY, FREDERICKSON, ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 449-451, (1974); ILLINGWORTH, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); O'BRIEN, SHAMPO, STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL END POINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0028931289","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 1995, CURR THER RES CLIN EXP","CASTAÑO G, 1995, CURR THER RES CLIN EXP-a"
"NOA M;DE L R M;MAS R","NOA, M. (7003318964); DE LA ROSA, M.C. (7101829119); MAS, R. (7007164572)","EFFECT OF POLICOSANOL ON FOAMCELL FORMATION IN CARRAGEENANINDUCED GRANULOMAS IN RATS",1996,"JOURNAL OF PHARMACY AND PHARMACOLOGY","48","3",21,"10.1111/j.2042-7158.1996.tb05922.x","LABORATORY OF HISTOLOGY, NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, LA HABANA, POST BOX 6990, CUBA, LABORATORY OF HISTOLOGY, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, POST BOX 6990, CUBA;LABORATORY OF HISTOLOGY, NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, LA HABANA, POST BOX 6990, CUBA;LABORATORY OF HISTOLOGY, NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, LA HABANA, POST BOX 6990, CUBA","POLICOSANOL IS A NEW CHOLESTEROL-LOWERING DRUG ISOLATED AND PURIFIED FROM SUGAR-CANE WAX, WHICH PREVENTS THE DEVELOPMENT OF LIPOFUNDIN-INDUCED LESIONS AND FOAM-CELL FORMATION IN NEW ZEALAND RABBITS AND WISTAR RATS. THIS STUDY WAS CONDUCTED TO EXAMINE THE EFFECTS OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS. EIGHTEEN WISTAR RATS WERE RANDOMLY DISTRIBUTED IN THREE EXPERIMENTAL GROUPS WHICH RECEIVED ORALLY FOR 20 DAYS TWEEN 20 H2O AS VEHICLE (CONTROL GROUP) OR POLICOSANOL AT 2.5 OR 25 MG KG-1. AT THE 11TH DAY, LIPOFUNDIN WAS INJECTED INTRAPERITONEALLY FOR 8 DAYS TO INDUCE FORMATION OF FOAM CELLS IN THE GRANULOMA. AT DAY 13, CARRAGEENAN WAS INJECTED SUBCUTANEOUSLY FOR GRANULOMA INDUCTION AND SEVEN DAYS LATER ANIMALS WERE KILLED. A SIGNIFICANT REDUCTION OF THE FOAM-CELL FORMATION IN GRANULOMAS OF POLICOSANOL-TREATED RATS WAS OBSERVED. IT IS CONCLUDED THAT POLICOSANOL PREVENTS THE DEVELOPMENT OF FOAM CELLS IN CARRAGEENAN-INDUCED GRANULOMAS (EXTRAVASCULAR MEDIUM) IN RATS.","","CARRAGEENAN; HYPOCHOLESTEROLEMIC AGENT; LIPOFUNDIN; POLICOSANOL; POLYSORBATE 20; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FOAM CELL; GRANULOMA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., LONGO R.Y., MESA R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV. CENIC CIENCIAS BIOLÓGICAS, 22, PP. 60-61, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA AGREGACIÓN PLAQUETARIA, REV. CENIC CIENCIAS BIOLÓGICAS, 22, PP. 72-73, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ILLNAIT J., LAGUNA A.Y., CASTANO G., EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCHIVES VENEZOLANOS DE FARMACOLOGÍA Y TERAPÉUUCA, 11, PP. 82-86, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THOMB. RES., 69, PP. 321-327, (1993); HAUST M.D., DERIVATION AND PROGRESSION OF ATHEROSCLEROTIC PLAQUES, PROCEEDINGS OF THE 6TH INTERNATIONAL SYMPOSIUM OF ATHEROSCLEROSIS, (1983); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); ILLNAIT J., CASTANO G., NODARSE M., PONTIGAS V., HERNANDEZ L., MAS R., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPO-PROTEINEMIA DEL TIPO II, REV. CENIC CIENCIAS BIOLÓGICAS, 22, PP. 80-83, (1991); JELLINEK H., HARSING J., FUZCESI S., A NEW MODEL FOR ARTERIOSCLEROSIS. AN ELECTRON MICROSCOPY STUDY OF THE LESIONS INDUCED BY I.V. ADMINISTERED FAT, ATHEROSCLEROSIS, 43, PP. 7-18, (1982); KELLEY J., SUENRAM A., VALENTE A., SPRAGUE E., ROZEK M., SCHWARTZ C., EVOLUTION OF FOAM CELLS IN SUBCUTANEOUS RABBIT CARRAGEENAN GRANULOMAS. II. TISSUE AND MACROPHAGE LIPID COMPOSITION, AM. J. PATHOL., 120, PP. 391-401, (1985); MARTINEZ R., HISTOQUÍMICA, (1979); MUNRO M., COTRAN R., THE PATHOGENESIS OF ATHEROSCLEROSIS: ATHEROGENESIS AND INFLAMMATION, LAB. INVEST, 58, PP. 249-261, (1988); NOA M., MAGRANER J.Y., MAS R., EFECTO DEL ATEROMIXOL EN LAS LESIONES AÓRTICAS INDUCIDAS POR LIPOFUNDIN EN CONEJOS, PROG. CIENCIAS MÉDICAS, 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED LESIONS IN RATS, J. PHARM. PHARMACOL., 47, PP. 289-291, (1995); SCHWARTZ C., GHIDONI J., KELLEY J., SPRAGUE E., VALENTE A., SUENRAM C., EVOLUTION OF FOAM CELLS IN SUBCUTANEOUS RABBIT CARRAGEENAN GRANULOMAS: I. LIGHT MICROSCOPY AND ULTRASTRUCTURE, AM. J. PATHOL., 118, PP. 134-150, (1985); SKRINSKA V., KONIECZKOWSKI M., GERRITY R., GALANG C., REBEC M., SUPPRESSION OF FOAM CELL LESIONS IN HYPERCHOLESTEROLEMIC RABBITS BY INHIBITION OF THROMBOXANE A<SUB>2</SUB> SYNTHESIS, ARTERIOSCLEROSIS, 8, PP. 220-225, (1988); YAMAMOTO A., TAKAICHI SH., HARA H., NISHIKAWA O., YOKOYAMA SH., YAMAMURA T., YAMAGUCHI T., PROBUCOL PREVENTS LIPID STORAGE IN MACROPHAGES, ATHEROSCLEROSIS, 62, PP. 209-217, (1986)","","BLACKWELL PUBLISHING LTD","ENGLISH","J. PHARM. PHARMACOL.","ARTICLE","ISI","2-S2.0-0029904158","J PHARM PHARMACOL",NA,"NOTREPORTED",NA,"NOA M, 1996, J PHARM PHARMACOL","NOA M, 1996, J PHARM PHARMACOL"
"NOA M;MÁS R;MESA R","NOA, MIRIAM (7003318964); MÁS, ROSA (7007164572); MESA, ROSARIO (7003836140)","EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS IN SPRAGUEDAWLEY RATS AND IN RABBITS",1997,"JOURNAL OF PHARMACY AND PHARMACOLOGY","49","3",10,"10.1111/j.2042-7158.1997.tb06031.x","NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, LABORATORY OF HISTOLOGY, CENTRE OF NATURAL PRODUCTS, NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, 25 AVE AND 158 ST, CUBA;NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTRE FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THE EFFECT OF POLICOSANOL ON CIRCULATING ENDOTHELIAL CELLS HAS BEEN STUDIED IN DIFFERENT EXPERIMENTAL MODELS WITH ENDOTHELIUM DAMAGE. ORAL ADMINISTRATION OF 25 MG KG-1 POLICOSANOL TO SPRAGUE-DAWLEY RATS RESULTED IN SIGNIFICANT PROTECTION OF THE ENDOTHELIAL LINING AGAINST THE DESQUAMATING EFFECT OF CITRATE. ORAL ADMINISTRATION OF 5 MG KG-1 POLICOSANOL TO SPONTANEOUSLY HYPERTENSIVE RATS (SHR) RESULTED IN A SIGNIFICANT REDUCTION OF CIRCULATING ENDOTHELIAL CELLS COMPARED WITH CONTROLS. MOREOVER, COMPARISON BETWEEN GROUPS REVEALED A LOWER FREQUENCY OF AORTIC LESIONS IN POLICOSANOL-TREATED ANIMALS THAN IN CONTROLS. ON THE OTHER HAND, ADMINISTRATION OF 5 MG KG-1 POLICOSANOL TO RABBITS WITH INTIMAL HYPERPLASIA INDUCED BY CUFF PLACEMENT IN THE CAROTID ARTERY RESULTED IN LEVELS OF CIRCULATING ENDOTHELIAL CELLS SIGNIFICANTLY LOWER THAN IN CONTROLS. THESE RESULTS DEMONSTRATE THE PROTECTIVE EFFECT OF POLICOSANOL IN DIFFERENT EXPERIMENTAL MODELS AND SUGGEST ITS POTENTIAL FOR ENDOTHELIAL PROTECTION.","","CITRIC ACID; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CIRCULATION; CONTROLLED STUDY; DESQUAMATION; ENDOTHELIUM CELL; ENDOTHELIUM LESION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; RAT; VASCULAR ENDOTHELIUM","","","ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR. THER. RES., 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., POLICOSANOL FOR CHOLESTEROL-LOWERING LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-182, (1995); ARRUZAZABALA M.L., CARBAJAL D., GARCIA M., LEVAMISOL: UN INHIBIDOR DE LA ENZIMA TROMBOXANO SINTETASA, REV. LATINOAMERICANA DE TROMBOSIS Y HEMOSTASIS, 3, PP. 19-21, (1990); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF ATEROMIXOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 49, PP. 695-699, (1993); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL. RES., 27, PP. 205-208, (1994); BOOTH R., MARTINN J., HONEY A., HASSALL D., BEESLEY J., MONCADA S., RAPID DEVELOPMENT OF ATHEROSCLEROTIC LESIONS IN THE RABBIT CAROTID ARTERY INDUCED BY PERIVASCULAR MANIPULATION, ATHEROSCLEROSIS, 76, PP. 257-268, (1989); CADROY Y., HARKER L., PLATELETS, THROMBOSIS AND ANTITHROMBOTIC THERAPIES, CARDIOVASCULAR PHARMACOLOGY. 3RD EDN, (1990); CARBAJAL D., GONZALEZ R., EFECTO DEL CNIC-4 (LOBENZARIT) COMO ANTAGONIST DEL TXA<SUB>2</SUB>, REVISTA CENIC CIENCIAS BIOLÓGICAS., 21, PP. 2-3, (1990); CASACO A., CARBAJAL D., FRIMAN M., NOA M., INTERFERENCE OF LEVAMISOLE WITH FORSSMAN SHOCK, THROMB. RES., 59, PP. 629-638, (1990); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J.C., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MÉDICAS, 5, PP. 21-28, (1991); DAVIS J.W., SHELTON L., EIGENBERG D.A., HIGNITE C.E., WATANABE I.S., EFFECTS OF TOBACCO AND NON-TOBACCO CIGARETTE SMOKING ON ENDOTHELIUM AND PLATELETS, CLIN. PHARMACOL. THER., 37, PP. 529-533, (1985); DAVIS J.W., SHELTON L., EIGENBERG D.A., HIGNITE C.E., LACK OF EFFECT OF ASPIRIN ON CIGARETTE SMOKE-INDUCED INCREASE IN CIRCULATING ENDOTHELIAL CELLS, HAEMOSTASIS, 17, PP. 66-69, (1987); DAVIS J.W., SHELTON L., WATANABE I.S., ARNOLD J., PASSIVE SMOKING AFFECTS ENDOTHELIUM AND PLATELETS, ARCH. INTERN. MED., 149, PP. 386-389, (1987); DAVIS J., LEWIS H.D., FRANCIS-OLIVER A., PREVENTION OF EXERCISE-INDUCED ENDOTHELEMIA BY ISRADIPINE IN MEN WITH ANGINA PECTORIS, CARDIOLOGY, 84, PP. 375-379, (1994); DE CLERCK F., EFFECTS OF PHARMACOLOGICAL AGENTS ON ERYTHROCYTE DEFORMABILITY AND ENDOTHELIAL CELL INJURY, J. CEREB. BLOOD FLOW METAB., 2, 1 SUPPL., (1982); DE CLERCK F., LOOTS W., SOMERS Y., VAN GORP L., VERHEYEN A., WOUTERS L., THROMBOXANE A<SUB>2</SUB>-INDUCED VASCULAR ENDOTHELIAL CELL DAMAGE AND RESPIRATORY SMOOTH MUSCLE CELL CONTRACTION: INHIBITION BY FLUNARIZINE, A CA-OVERLOAD BLOCKER, ARCH. INT. PHARMACODYN. THER., 274, PP. 4-23, (1985); FRIMAN M., NOA M., PAUSTE H., QUINTELA A., ILLNAIT J., EFFECT OF CNIC-4 (LOBENZARIT) ON CIRCULATING ENDOTHELIAL CELLS OF RATS, PROC. 6TH INT. DRESDEN LIPID SYMP., ADV. LIPOPROTEIN AND ATHEROSCLEROSIS RES. DIAGN. TREAT., (1988); HADJIISKY P., MORPHOGENESE DE L'ARTHERIOPATHIE CENTRALE PERIPHERIQUE DU RAT SPONTANEMENT HYPERTENDU. 1. CHARACTERISTIQUES HISTOLOGIQUES, PAROI ARTERIELLE, 6, PP. 169-182, (1980); HADJIISKY P., METABOLIC AND STRUCTURAL BEHAVIOUR OF HYPERTENSIVE ARTERIES: POSSIBLE RELATIONSHIPS WITH ATHEROGENESIS AND TENSIOGENESIS, ANGIOLOGY, (1984); HAUST M.D., DERIVATION AND PROGRESSION OF ATHEROSCLEROTIC PLAQUE, PROC. 6TH INT. SYMP. ATHEROSCLEROSIS, (1983); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); HLADOVEC J., ENDOTHELIAL INJURY BY NICOTINE AND ITS PREVENTION, EXPERIENTIA, 34, PP. 1585-1586, (1978); HLADOVEC J., ANTITHROMBOTIC DRUGS IN THROMBOSIS MODELS, (1989); HLADOVEC J., DE CLERCK F., PROTECTION BY FLUNARIZINE AGAINST ENDOTHELIAL CELL INJURY IN VIVO, ANGIOLOGY, 32, PP. 448-462, (1981); HLADOVEC J., KORNALIK F., ANTITHROMBOTIC ACTIVITY OF AN UNSATURATED FATTY ACID PREPARATION, THROMB RES., 58, PP. 505-510, (1990); HLADOVEC J., ROSSMAN P., CIRCULATING ENDOTHELIAL CELLS ISOLATED TOGETHER WITH PLATELETS AND THE EXPERIMENTAL MODIFICATION OF THEIR COUNTS IN RATS, THROMB. RES., 3, PP. 665-674, (1973); HLADOVEC J., PREROVSKY I., STANEK V., FABIAN J., CIRCULATING ENDOTHELIAL CELLS IN ACUTE MYOCARDIAL INFARCTION AND ANGINA PECTORIS, KLIN. WOCHENSCHR., 56, PP. 1033-1036, (1978); KOCKX M., DE MEYER G., JACOB W., BULT H., HERMAN A., TRIPHASIC SEQUENCE OF NEOINTIMAL FORMATION IN THE CUFFED ARTERY OF THE RABBIT, ARTERIOSCLEROSIS THROMB., 12, PP. 1447-1457, (1992); KOCKX M., DE MEYER G., ANDRIES L., BULT H., JACOB W., HERMAN A., THE ENDOTHELIUM DURING CUFF-INDUCED NEOINTIMA FORMATION IN THE RABBIT CAROTIDA ARTERY, ARTERIOSCLEROSIS THROMB., 13, PP. 1874-1884, (1993); MRHOVA O., ALBRETCH I., URBANOVA D., VESSEL WALL METABOLISM IN SHR RATS IN RELATION TO ATHEROSCLEROSIS, ANN. NEW YORK ACAD. SCI., 275, PP. 302-310, (1976); NOA M., MAS R., ATEROMIXOL Y LESION ATEROSCLERÓTICA EN CONEJOS INDUCIDA POR LIPOFUNDIN, PROGRESOS EN CIENCIAS MÉDICAS, 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA M.C., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J. PHARM. PHARMACOL., 47, PP. 289-291, (1995); NOA M., MAS R., DE LA ROSA M.C., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J. PHARM. PHARMACOL, 48, PP. 306-309, (1996); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA, CURR. THER. RES., 52, PP. 507-512, (1992); PONS O., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE JJ HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA, CURR. THER. RES., 55, PP. 1084-1092, (1994); RODRIGUEZ C., MESA R., MAS R., ILLNAIT J., LAGUNA A., CASTANO G., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEINAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTE DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH. VENEZOL. FARMACOL. TERAP., 11, PP. 74-79, (1992); SHIMAMOTO T., HIDAKA H., MORIYA K., KOBAYASHI M., TAKAHASHI T., NUMAN F., HYPERREACTIVE ARTERIAL ENDOTHELIAL CELLS: A CLUE FOR TREATMENT OF ATHEROSCLEROSIS, ANN. NEW YORK ACAD. SCI., 275, PP. 266-285, (1976); SOLTERO I., FUENMAYOR I., COLMENARES J., ARIAS F., ENSAYO DOBLE CIEGO PARA LA EVALUACIÓN DEL POLICOSANOL EN EL TRATAMIENTO DE LA HIPERLIPOPROTEINEMIA TIPO II, ARCH. VENEZOL. FARMACOL. TERAP., 12, PP. 65-70, (1993); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH. VENEZOL. FARMACOL. TERAP., 12, PP. 71-76, (1993); STIER CH., ITSKOVITZ H., THROMBOXANE A<SUB>2</SUB> AND THE DEVELOPMENT OF HYPERTENSION IN SPONTANEOUSLY HYPERTENSIVE RATS, EUR. J. PHARMACOL., 146, PP. 129-135, (1988); TORRES O., AGRAMONTE S.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLAEMIA IN NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995)","","BLACKWELL PUBLISHING LTD","ENGLISH","J. PHARM. PHARMACOL.","ARTICLE","ISI","2-S2.0-0030669221","J PHARM PHARMACOL",NA,"NOTREPORTED",NA,"NOA M, 1997, J PHARM PHARMACOL","NOA M, 1997, J PHARM PHARMACOL"
"STÜSSER R;BATISTA J;PADRÓN R;SOSA F;PEREZTOL O","STÜSSER, R. (6602973165); BATISTA, J. (7005814235); PADRÓN, R. (18735349800); SOSA, F. (8928992600); PEREZTOL, O. (8928993000)","LONGTERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISEECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS",1998,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","36","4",27,"","CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA, CTRO. DE INVEST. CLÍNICAS, KOHLY, PLAYA, CP 11300 HAVANA 13, CALLE 34#4501/45-47, CUBA;CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA;CLINICAL RESEARCH CENTER, HAVANA UNIVERSITY, HAVANA, CUBA","THIS STUDY EXAMINED THE EFFECTS OF LONG-TERM LIPID-LOWERING THERAPY WITH POLICOSANOL ON THE CLINICAL EVOLUTION, AND EXERCISE-ECG TESTING RESPONSES OF 45 CORONARY HEART DISEASE (CHD) PATIENTS WITH MYOCARDIAL ISCHEMIA, DOCUMENTED BY EXERCISE 201T1-MYOCARDIAL PERFUSION SCINTIGRAPHY, IN AN OVERALL RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, MADE FOR DIFFERENT TEST ENDPOINTS. FIFTEEN PATIENTS WERE TREATED WITH 5 MG OF POLICOSANOL TWICE DAILY; ANOTHER 15 PATIENTS WERE ADMINISTERED THE SAME DRUG DOSE PLUS 125 MG ASPIRIN; AND THE OTHER 15 PATIENTS RECEIVED PLACEBO PLUS EQUAL ASPIRIN DOSE. THEY WERE FOLLOWED FOR 20 MONTHS, PREVIOUS BASELINE OBSERVATIONS, WITH TREADMILL EXERCISE-ECG, BESIDES SERUM LIPID TEST. BENEFICIAL CHANGES ON PROPORTIONS AMONG THE 2 POLICOSANOL GROUPS AND THE PLACEBO GROUP, SHOWED AN INCREMENT ON FUNCTIONAL CAPACITY CLASS, A DECREMENT ON REST AND EXERCISE ANGINA, AND A SIGNIFICANT DECREASE IN CARDIAC EVENTS, AND IN ISCHEMIC ST SEGMENT RESPONSE, ESPECIALLY IN THE POLICOSANOL PLUS ASPIRIN GROUP (P = 0.05, X2(2DF) = 5.8; P = 0.04, P = 0.02; FISHER). AFTER TREATMENT, SETS OF MEAN CHANGES REVEALED AN INCREASE ON MAXIMUM OXYGEN UPTAKE, AND A DECLINE ON DOUBLE PRODUCT SIMULTANEOUSLY IN BOTH POLICOSANOL GROUPS (P ≤ 0.02, P ≤ 0.002; PILLAIS, HOTELLINGS' T2), WHILE THE PLACEBO GROUP WAS IMPAIRED. AEROBIC FUNCTIONAL CAPACITY PERCENT SHOWED AN INCREMENT IN POLICOSANOL GROUPS (P ≤ 0.05, PAIRED T). LIPID LEVELS IMPROVED AS OTHER ENDPOINTS ALREADY REPORTED. A SUPPOSED ERGOGENIC EFFECT OF OCTACOSANOL, POLICOSANOL'S MAIN ACTIVE COMPOUND, WAS NOT DETECTED WITH THIS DESIGN. THESE RESULTS SHOW THAT POLICOSANOL-TREATED CHD PATIENTS IMPROVED CLINICAL EVOLUTION, AND EXERCISE-ECG RESPONSES, OWING TO THE AMELIORATION OF MYOCARDIAL ISCHEMIA, EVEN MORE WHEN ADMINISTERED WITH ASPIRIN.","CORONARY HEART DISEASE; ERGOGENIC EFFECT; EXERCISE-ECG TESTING; LIPID-LOWERING EFFECT; OCTACOSANOL; PLATELET ANTIAGGREGANT EFFECT; POLICOSANOL","ANTICHOLESTEREMIC AGENTS; ASPIRIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE TEST; FATTY ALCOHOLS; HUMANS; PLATELET AGGREGATION INHIBITORS; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; POLICOSANOL; THALLIUM 201; ADULT; AEROBIC METABOLISM; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; ST SEGMENT; TREADMILL EXERCISE","","","AHA MEDICAL SCIENTIFIC STATEMENT. 1994 REVISIONS TO CLASSIFICATION OF FUNCTIONAL CAPACITY AND OBJECTIVE ASSESSMENT OF PATIENTS WITH DISEASES OF THE HEART, CIRCULATION, 90, PP. 644-645, (1994); ARRUZAZABALA M., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, REV CENIC CIENC BIOL, 26, (1995); BATISTA J., STUSSER R., PENICHET M., ET AL., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES, 56, PP. 906-914, (1995); BATISTA J., STUSSER K., SAEZ F., ET AL., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); BATISTA J., STUSSER R., PADRON R., ET AL., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTHS OF LIPID-LOWERING THERAPY WITH POLICOSANOL, ADV THER, 13, PP. 137-148, (1996); BELTZ S., DOERING P., EFFICACY OF NUTRITIONAL SUPPLEMENTS USED IN ATHLETES, CLIN PHARM, 12, PP. 900-908, (1993); BLANKENHORN D., NESSIM S., JOHNSON R., ET AL., BENEFICIAL EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY BYPASS GRAFTS, JAMA, 57, PP. 3233-3240, (1987); BLANKENHORN D.H., SELZER R.H., CRAWFORD D.W., ET AL., BENEFICIAL EFFECTS OF COLESTIPOL-NIACIN THERAPY ON THE COMMON CAROTID ARTERY, CIRCULATION, 88, PP. 20-28, (1993); BOGATY P., GUIMOND J., ROBITAILLE N.M., ET AL., A REAPPRAISAL OF EXERCISE ELECTROCARDIOGRAPHIC INDEXES OF THE SEVERITY OF ISCHEMIC HEART DISEASE: ANGIOGRAPHIC AND SCINTIGRAPHIC CORRELATES, JACC, 29, PP. 1497-1504, (1997); BRUCE R., EXERCISE TESTING OF PATIENTS WITH CORONARY ARTERY DISEASE: PRINCIPLES AND NORMAL STANDARDS FOR EVALUATION, ANN CLIN RES, 3, PP. 323-332, (1971); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE-DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-303, (1995); FLETCHER G.F., BALADY G., FROELICHER V.F., ET AL., AHA MEDICAL SCIENTIFIC STATEMENT. EXERCISE STANDARDS. A STATEMENT FOR HEALTH CARE PROFESSIONALS FROM THE AMERICAN HEART ASSOCIATION, CIRCULATION, 91, PP. 580-615, (1995); GRUNDY S., NATIONAL CHOLESTEROL EDUCATION PROGRAM: SECOND REPORT OF THE EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, CIRCULATION, 89, PP. 1329-1446, (1994); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); KABIR Y., KIMURA S., TISSUE DISTRIBUTION OF (8-14C)-OCTACOSANOL IN LIVER AND MUSCLE OF RATS AFTER SERIAL ADMINISTRATION, ANN NUTR METAB, 39, PP. 279-284, (1995); NOHARA R., HOSOKAWA L., LINXUE L., ET AL., LONG-TERM CHOLESTEROL-LOWERING TREATMENT AND MYOCARDIAL PERFUSION, J NUCL CARD, 4, (1997); NORRIS F., DENYS E., NUTRITIONAL SUPPLEMENTS IN AMYOTROPHIC LATERAL SCLEROSIS, ADV EXP MED BIOL, 209, PP. 183-189, (1987); SAINT-JOHN M., MC NAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY REACTION TIME AND CHEST AND GRIP STRENGTH, INT CLIN NUTR REV, 6, PP. 81-87, (1986); SCHELL W.D., MYERS J.N., REGRESSION OF ATHEROSCLEROSIS: A REVIEW, PROGR CARDIOVASC DIS, 39, PP. 483-496, (1997); SCHULER G., SCHLIERF G., WIRTH A., ET AL., LOW-FAT DIET AND REGULAR, SUPERVISED PHYSICAL EXERCISE IN PATIENTS WITH SYMPTOMATIC CORONARY ARTERY DISEASE: REDUCTION OF STRESS-INDUCED MYOCARDIAL ISCHEMIA, CIRCULATION, 77, PP. 172-181, (1988); SCHULER G., HAMBRECHT R., SCHIERF G., ET AL., REGULAR EXERCISE AND LOW-FAT DIET. EFFECTS ON PROGRESSION OF CORONARY ARTERY DISEASE, CIRCULATION, 86, PP. 1-11, (1992); THEIN L.A., THEIN J.M., LANDRY G.L., ERGOGENIC AIDS, PHYS THER, 75, PP. 426-439, (1995); VICKERS A., CASSILETH B., ERNST F., ET AL., HOW SHOULD WE RESEARCH UNCONVENTIONAL THERAPIES? A PANEL REPORT FROM THE CONFERENCE ON COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH METHODOLOGY, NATIONAL INSTITUTES OF HEALTH, INT J TECHNO ASSESS HEALTH CARE, 13, PP. 11-121, (1997); WHITE H., FRENCH J., HAMER A., ET AL., FREQUENT REOCCLUSSION OF PATIENT INFARCT-RELATED ARTERIES BETWEEN 4 WEEKS AND 1 YEAR: EFFECTS OF ANTIPLATELET THERAPY, J AM COLL CARDIOL, 25, PP. 218-223, (1995)","","","ENGLISH","INT. J. CLIN. PHARMACOL. THER.","ARTICLE","ISI","2-S2.0-0031679774","INT J CLIN PHARMACOL THER",NA,"NOTREPORTED",NA,"STÜSSER R, 1998, INT J CLIN PHARMACOL THER","STÜSSER R, 1998, INT J CLIN PHARMACOL THER"
"MENÉNDEZ R;FRAGA V;AMOR A;GONZÁLEZ R;MÁS R","MENÉNDEZ, ROBERTO (7102205059); FRAGA, VIVIAN (6602491407); AMOR, ANA MA. (35569426800); GONZÁLEZ, ROSA MA. (57191737509); MÁS, ROSA (7007164572)","ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER IONINDUCED RAT LIPOPROTEIN PEROXIDATION",1999,"PHYSIOLOGY AND BEHAVIOR","67","6",49,"10.1016/S0031-9384(99)00004-9","HAVANA, CUBA;HAVANA, CUBA;HAVANA, CUBA;HAVANA, CUBA;HAVANA, CUBA","POLICOSANOL, A NEW CHOLESTEROL-LOWERING AGENT, IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) WAX, WHICH PREVENTS THE ONSET OF ESPONTANEOUSLY AND EXPERIMENTALLY INDUCED ATHEROSCLEROTIC LESIONS IN EXPERIMENTAL MODELS. BECAUSE THE OXIDATION OF LOW-DENSITY LIPOPROTEIN (LDL) MAY PLAY A ROLE IN THE PATHOGENESIS OF ATHEROSCLEROSIS, WE INVESTIGATE THE EFFECT OF POLICOSANOL ON COPPER OXIDATIVE SUSCEPTIBILITY OF RAT LIPOPROTEIN FRACTIONS (VLDL + LDL). RATS FED NORMAL DIET WERE TREATED WITH POLICOSANOL (250-500 MG/KG/DAY) FOR UP TO 4 WEEKS. EDTA-FREE LIPOPROTEIN PARTICLES WERE OXIDIZED IN A CELL-FREE SYSTEM BY THE ADDITION OF COPPER IONS, AND CONJUGATED DIENES GENERATION WAS MONITORED BY CHANGES OF OPTICAL DENSITY AT 234 NM. THIOBARBITURIC ACID-REACTIVE SUBSTANCES (TBARS) CONTENT AND LYSINE-AMINO GROUP REACTIVITY WERE INVESTIGATED. AFTER ADMINISTRATION, THERE WAS NO CHANGE IN CHOLESTEROL, TRIGLYCERIDES, AND PHOSPHOLIPID CONTENT OF LIPOPROTEIN FRACTIONS; HOWEVER, POLICOSANOL SIGNIFICANTLY PROLONGS THE LAG TIME AND REDUCES THE PROPAGATION RATE OF DIENE GENERATION. ALSO, POLICOSANOL REDUCES TBARS CONTENT AND INCREASES LYSINE REACTIVITY IN LIPOPROTEIN FRACTIONS TREATED WITH CU2+. IN CONCLUSION, POLICOSANOL, IN ADDITION TO ITS CHOLESTEROL-LOWERING EFFECT, HAS OTHER PROPERTIES THAT ENABLES IT TO REDUCE THE POTENTIAL OF LIPOPROTEIN TO UNDERGO LIPID PEROXIDATION. SUCH EFFECT CAN BE CONSIDERED OF PROMISSORY VALUE IN THE MANAGEMENT OF ATHEROSCLEROSIS. COPYRIGHT (C) 1999 ELSEVIER SCIENCE INC.","CONJUGATED DIENE; LIPID PEROXIDATION; LIPOPROTEIN FRACTIONS; LYSINE-AMINO GROUP REACTIVITY; POLICOSANOL; THIOBARBITURIC ACID REACTIVE SUBSTANCES","COPPER ION; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OCTACOSANOL; POLICOSANOL; THIOBARBITURIC ACID; VERY LOW DENSITY LIPOPROTEIN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; LIPID COMPOSITION; LIPID PEROXIDATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT","","","ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASE OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY TO TREATMENT, CURR. THER. RES., 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-182, (1995); ARRUZAZABALA L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON NORMOCHOLESTEROLEMIC RABBITS, BIOL. RES., 27, PP. 205-208, (1994); AVIRAM M., MALONDIALDEHYDE AFFECTS THE PHYSICO-CHEMICAL AND BIOLOGICAL CHARACTERISTICS OF OXIDIZED LOW DENSITY LIPOPROTEIN, ATHEROSCLEROSIS, 84, PP. 141-143, (1990); AVIRAM M., MODIFIED FORMS OF LOW DENSITY LIPOPROTEIN AND ATHEROSCLEROSIS, ATHEROSCLEROSIS, 98, PP. 1-9, (1993); AVIRAM M., DANKNER G., COGAN U., HOCHGRAF E., BROOK J.G., LOVASTATIN INHIBITS LOW-DENSITY LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES: IN VITRO AND IN VIVO STUDIES, METABOLISM, 41, PP. 229-235, (1992); BONNE C., MULLER A., LATOUR E., TISSIE G., EMERIT I., MODAT G., DORNAND J., ROCH M., GIROUD J.P., GRISWOLD D.E., MARSHALL P.J., COQUELET C., 2-(2-HYDROXY-4-METHYLPHENYL)AMINOTHIAZOLE HYDROCHLORIDE AS A DUAL INHIBITOR OF CYCLOXYGENASE/LIP-OXYGENASE AND A FREE RADICAL SCAVENGER, DRUG RES., 39, PP. 1242-1245, (1989); CANETTI M., MORERA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, PP. 245-254, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG-TWICE-A-DAY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 296-304, (1995); CHAPMAN M.J., ANIMAL LIPOPROTEIN: CHEMISTRY, STRUCTURE AND COMPARATIVE ASPECTS, J. LIPID RES., 21, PP. 789-853, (1980); CRUZ-BUSTILLO D., MEDEROS D., MAS R., ARRUZAZABALA M., LAGUNA A., BARRETO D., MARTINEZ O., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) SOBRE EL CERDO EN CEBA, REV. CNIC CIEN. BIOL., 22, PP. 62-63, (1991); DIEBER-ROTHENEDER M., PUHL H., WAEG G., STRIEGL G., ESTERBAUER H., EFFECT OF ORAL SUPPLEMENTATION WITH D-ALPHA-TOCOPHEROL ON THE VITAMIN E CONTENT OF HUMAN LOW DENSITY LIPOPROTEIN AND ITS OXIDATION RESISTANCE, J. LIPID RES., 32, PP. 1325-1332, (1991); ENDO A., TSUJITA Y., KURODA M., TANSAWA K., EFFECTS OF ML-236B ON CHOLESTEROL METABOLISM IN MICE AND RATS: LACK OF HYPOCHOLESTEROLEMIC ACTVITY IN NORMAL ANIMALS, BIOCHEM. BIOPHYS. ACTA, 575, PP. 266-276, (1979); ESTERBAUER H., WAG G., PUHL H., LIPID PEROXIDATION AND ITS ROLE IN ATHEROSCLEROSIS, BR. MED. BULL., 49, PP. 566-576, (1993); FEARS R., RICHARDS D.H., FERRES H., THE EFFECT OF COMPACTIN, A POTENT INHIBITOR OF 3-HYDROXY-METHYL-GLUTARYL COENZYME-A REDUCTASE ACTIVITY, ON CHOLESTEROGENESIS AND SERUM CHOLESTEROL LEVELS IN RATS AND CHICKS, ATHEROSCLEROSIS, 35, PP. 439-449, (1978); FREI B., GAZIANO J.M., CONTENT OF ANTIOXIDANT, PREFORMED LIPID HYDROPEROXIDES AND CHOLESTEROL AS PREDICTORS OF SUSCEPTIBILITY OF HUMAN LDL TO METAL ION-DEPENDENT AND -INDEPENDENT OXIDATION, J. LIPID RES., 34, PP. 2135-2145, (1993); HABERLAND M.E., FONG D., CHENG L., MALONDIALDEHYDE-ALTERED PROTEIN OCCURS IN ATHEROMA OF WATANABE HERITABLE HYPERLIPIDEMIC RABBITS, SCIENCE, 241, PP. 215-218, (1988); HARATS D., BEN-NAIM M., DABACH Y., HOLLANDER G., HAVIVI E., STEN O., STEN Y., EFFECT OF VITAMIN C AND E SUPPLEMENTATION ON SUSCEPTIBILITY OF PLASMA LIPOPROTEIN TO PEROXIDATION INDUCED BY ACUTE SMOKING, ATHEROSCLERSIS, 85, PP. 47-54, (1990); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1993); JAILAL I., NORKUS E.P., CRISTOL L., GRUNDY S.M., Β-CAROTENE INHIBITS THE OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN, BIOCHIM. BIOPHYS. ACTA, 1086, PP. 134-138, (1991); KABIR Y., KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL TO RATS, ANN. NUTR. METAB., 37, PP. 33-38, (1993); KOSUKE J., KUSUNOSE E., NODA Y., KUSUNOSE M., SOME PROPERTIES OF THE FATTY ALCOHOL SYSTEM AND RECONSTITUTION OF MICROSOME OXIDATION ACTIVITY IN INTESTINAL MUCOSA, BIOCHEM. BIOPHYS. ACTA, 878, PP. 412-418, (1986); LASSER N.L., ROHEIN P.S., EDELSTEIN D., EDER H.A., SERUM LIPOPROTEIN OF NORMAL AND CHOLESTEROL-FED RATS, J. LIPID RES., 14, PP. 1-8, (1973); LIU K., CUDDY E., PIERCE G.N., OXIDATIVE STATUS OF LIPOPROTEIN IN CORONARY DISEASE PATIENTS, AM. HEART. J., 123, PP. 285-290, (1992); MARKWELL M.A., HAAS S.M., BIEBER L.L., TOLBERT N.E., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLIFY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL. BIOCHEM., 87, PP. 206-210, (1987); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A., GONZALEZ R., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R., FRAGA V., AMOR A., JIMENEZ S., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED FIBROBLASTS, BIOL. RES., 27, PP. 31-33, (1994); MENENDEZ R., SOTOLONGO V., FRAGA V., AMOR A.M., GONZALEZ R.M., DEL RIO A., JIMENEZ S., PEREZ-SOUTO N., MAS R., NIVELES PLASMÁTICOS Y EXCRECIÓN DE LA RADIACTIVIDAD TOTAL EN VOLUNTARIOS SANOS TRAS LA ADMINISTRACIÓN ORAL DE OCTACOSANOL-<SUP>3</SUP>H, REVISTA CNIC CIEN. BIOL., 27, PP. 32-35, (1996); NENSETER M.S., HALVORSEN B., ROSVOLD O., RUSTAN A.C., DREVON C.A., PARACETAMOL INHIBITS COPPER ION-INDUCED, AZO COMPOUND-INITIATED AND MONONUCLEAR CELL-MEDIATED OXIDATIVE MODIFICATION OF LDL, ARTERIOSCLER. THROMB., 15, PP. 1338-1344, (1995); NOA M., MAS R., ATEROMIXOL Y LA LESIÓN ATEROSCLERÓTICA EN CONEJOS INDUCIDA POR LIPOFUNDÍN, PCM, 6, PP. 14-19, (1992); NOA M., MAS R., DE LA ROSA R., MAGRANER J., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESION IN RATS, J. PHARM. PHARMACOL., 47, PP. 289-290, (1994); PARTHASARATHY S., KHOO J.C., ELIZANBETH M., BARNETT J., WITZTUM J.L., STEINBERG D., LOW DENSITY LIPOPROTEIN RICH IN OLEIC ACID IS PROTECTED AGAINST OXIDATIVE MODIFICATION: IMPLICATION FOR DIETARY PREVENTION OF ATHEROSCLEROSIS, PROC. NATL. ACAD. SCI. USA, 87, PP. 3894-3898, (1990); PARTHASARATHY S., QUINN M.T., SCHWENKE D.C., CAREW T.E., STEINBERG D., OXIDATIVE MODIFICATION OF VERY LOW DENSITY LIPOPROTEIN: POTENTIAL ROLE IN MONOCYTE RECRUITMENT AND FOAM CELL FORMATION, ARTERIOSCLEROSIS, 9, PP. 398-404, (1989); PARTHASARATHY S., YOUNG S.G., WITZTUM J.L., PITTMAN R.C., STEINBERG D., PROBUCOL INHIBITS OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN, J. CLIN. INVST., 77, PP. 641-644, (1986); PEARCE B.C., PARKER R.A., DEASON M.E., DISHINO D.D., GILLESPIE E., QURESHI A.A., VOLK K., WRIGHT J.J.K., INHIBITORS OF CHOLESTEROL BIOSYNTHESIS. 2. HYPOCHOLESTEROLEMIC AND ANTIOXIDANT ACTIVITIES OF BEZOPYRAM AND TETRAHYDRONAPTHALENE ANALOGUES OF THE TOCOTRIENOLS, J. MED. CHEM., 37, PP. 526-541, (1992); PENTIKAINEN M.O., LINDSTEDT K.A., KOVANEN P.T., INHIBITION OF THE OXIDATIVE MODIFICATION OF LDL BY NITECAPONE, ARTERIOSCLER. THROMB., 15, PP. 740-747, (1995); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, PP. 507-513, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASE OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); PRINCEN H.M.G., VAN POPPEL G., VOGELEZANG C., BUYTENHEK R., KOK F.J., SUPPLEMENTATION WITH VITAMIN E BUT NOT BETA-CAROTENE IN VIVO PROTECTS LOW-DENSITY LIPOPROTEIN FROM LIPID PEROXIDATION IN VITRO: EFFECT OF CIGARETTE SMOKING, ARTERIOSCLER. THROMB., 12, PP. 554-562, (1992); PUHL H., WAEG G., ESTERBAUER H., METHODS TO DETERMINE OXIDATION OF LOW-DENSITY LIPOPROTEINS, METHODS IN ENZYMOLOGY, VOL. 233, PP. 425-441, (1994); RIJKE Y.B., HESSEL E.M.A.J., BERKEL T.J.C., RECOGNITION SITES ON RAT LIVER CELLS FOR OXIDATIVELY MODIFIED VERY LOW DENSITY LIPOPROTEIN, ARTERIOSCLER. THROMB., 12, PP. 41-49, (1992); RIZZO W., CRAFT D., DAMMANN A., PHILLIPS M., FATTY ALCOHOL METABOLISM IN CULTURED FIBROBLASTS. EVIDENCE FOR A FATTY ALCOHOL CYCLE, J. BIOL. CHEM., 262, PP. 17412-17419, (1990); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., MENENDEZ R., GONZALEZ R.M., AMOR A.M., SOTOLONGO V., LAGUNA A., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 11, PP. 74-79, (1994); RUIZ-LARREA M.B., LEAL A.M., LIZA M., LACORT M., DE GROOT H., ANTIOXIDANT EFFECTS OF ESTRADIOL AND 2-HYDROXYESTRADIOL ON IRON-INDUCED LIPID PEROXIDATION OF RAT LIVER MICROSOMES, STEROIDS, 59, PP. 383-388, (1994); SCACCINI C., NARDINI M., D'AQUINO M., GENTILI V., DI FELICE M., TOMASSI G., EFFECT OF DIETARY OILS ON LIPID PEROXIDATION AND ON ANTIOXIDANT PARAMETERS OF RAT PLASMA AND LIPOPROTEIN FRACTIONS, J. LIPID RES., 33, PP. 627-633, (1992); SINGH H., DERWAS N., POULOS A.A., VERY LONG CHAIN FATTY ACID Β-OXIDATION BY RAT LIVER MITOCONDRIA AND PEROXISOMES, ARCH. BIOCHEM. BIOPHYS., 359, PP. 382-390, (1987); SOLTERO I., FUENTEMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH. VEN. FARMACOL. TER., 12, PP. 71-76, (1993); STEINBERG D., PARTHASARANTHY S., CAREW T.E., KHOO J.C., WITZTUM J.L., BEYOND CHOLESTEROL. MODIFICATION OF LOW-DENSITY LIPOPROTEIN THAT INCREASES ITS ATHEROGENICITY, N. ENGL. J. MED., 320, PP. 915-924, (1989); STEINBRECHER U.P., OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN RESULTS IN DERIVATIZATION OF LYSINE RESIDUES OF APOLIPOPROTEIN B BY LIPID PEROXIDE DECOMPOSITION PRODUCTS, J. BIOL. CHEM., 262, PP. 3603-3608, (1987); STEINBRECHER U.P., WITZTUM J.L., PARTHASARATHY S., STEINBERG D., DECREASE IN REACTIVE AMINO GROUPS DURING OXIDATION OR ENDOTHELIAL CELL MODIFICATION OF LDL, ARTERIOSCLEROSIS, 7, PP. 135-143, (1987); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); WANDERS R.J.A., VAN ROERMUND C.W.T., VAN WIJLAND M.J.A., SCHUTGENS R.B.H., SCHAM A.W., VAN DEN BOSCH H., TAGER J.M., STUDIES ON THE PEROXISOMAL OXIDATION OF PALMITATE AND LIGNOCERATE IN RAT LIVER, BIOCHEM. BIOPHYS. ACTA, 919, PP. 21-25, (1987); WEGLICKI W.B., MAK I.T., ANTIOXIDANT DRUG MECHANISM: TRANSITION METAL-BINDING AND VASODILATATION, MOL. CELL BIOCHEM., 118, PP. 105-111, (1992); WITZTUM J.L., STEINBERG D., ROLE OF OXIDIZED LOW DENSITY LIPOPROTEIN IN ATHEROSCLEROSIS, J. CLIN. INVEST., 88, PP. 1785-1789, (1991); YLA-HERTTUALA S., PALINSKI W., ROSENFELD M.E., PARTHASARATHY S., CAREW T.E., BUTLER S., WITZTUM J.L., STEINBERG D., EVIDENCE OF THE PRESENCE OF OXIDATIVELY MODIFIED LDL IN ATHEROSCLEROTIC LESIONS IN RABBITS AND MAN, J. CLIN. INVEST., 84, PP. 1086-1095, (1989)","","ELSEVIER INC.","ENGLISH","PHYSIOL. BEHAV.","ARTICLE","ISI","2-S2.0-0344848563","PHYSIOL BEHAV",NA,"NOTREPORTED",NA,"MENÉNDEZ R, 1999, PHYSIOL BEHAV","MENÉNDEZ R, 1999, PHYSIOL BEHAV"
"CABRERA L;GONZÁLEZ V;URIBARRI E;SIERRA R;LAGUNA A;MAGRANER J;MEDEROS D;VELÁZQUEZ C","CABRERA, L. (57212875001); GONZÁLEZ, V. (7102097566); URIBARRI, E. (6505806794); SIERRA, R. (7006854525); LAGUNA, A. (7006455910); MAGRANER, J. (6603353869); MEDEROS, D. (7801384134); VELÁZQUEZ, C. (7004670124)","STUDY OF THE STABILITY OF TABLETS CONTAINING 10 MG OF POLICOSANOL AS ACTIVE PRINCIPLE",2002,"BOLLETTINO CHIMICO FARMACEUTICO","141","6",3,"","PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA;PLAYA, HAVANA, CUBA","THE STABILITY STUDIES OF TABLETS CONTAINING 10 MG OF POLICOSANOL, A NEW CHOLESTEROL LOWERING DRUG, WERE CONDUCTED TO PREDICT AN EXPIRATION DATE AND TO SEARCH THE APPEARANCE OF PUTATIVE DEGRADATION PRODUCTS. ALL QUALITY SPECIFICATION PARAMETERS SUCH AS COLOUR, MOISTURE CONTENT, HARDNESS, DISINTEGRATION, POLICOSANOL CONTENT AND MICROBIOLOGICAL LIMITS OF THE TABLETS WERE DONE. THE EFFECT OF DRASTIC TREATMENTS SUCH AS ACID AND BASIC HYDROLYSIS, OXIDATIVE AND PHOTOLYTIC DEGRADATION AS WELL AS THERMOLYSIS ON SUCH PARAMETERS WAS STUDIED. IN ADDITION; STUDIES UNDER DRASTIC CONDITIONS OF STORAGE (40°C AND 75% R.H.) AND UNDER AMBIENT CONDITIONS OF STORAGE FOR CLIMATIC ZONES II AND IV WERE PERFORMED. THESE STUDIES DEMONSTRATE THAT THESE TABLETS ARE A STABLE PHARMACEUTICAL FORMULATION, WITHOUT SIGNIFICANT CHANGES ON THEIR QUALITY CRITERIA AT THE STRESSED CONDITIONS STUDIED. THE CHROMATOGRAPHIC PROFILE OF THE SAMPLES AFTER 9 MONTHS OF THERMAL DEGRADATION SHOWS CHROMATOGRAPHIC PEAKS THAT CORRESPONDS TO THE OCTACOSANOYL, TRIACONTANOYL AND HEXACOSANOYL ESTERS OF PALMITATE AND STEARATE, BEING THE ONLY DEGRADATION PRODUCTS OBSERVED ON THESE STUDIES.","DEGRADATION; POLICOSANOL; PRODUCTS; STABILITY; TABLETS","DRUG STABILITY; EXCIPIENTS; FATTY ALCOHOLS; HARDNESS; HEAT; HYDROLYSIS; MASS SPECTROMETRY; OXIDATION-REDUCTION; PHOTOLYSIS; PLATELET AGGREGATION INHIBITORS; TABLETS; DRUG METABOLITE; HEXACOSANOL; OCTACOSANOL; PALMITATE HEXACOSANOYL ESTER; PALMITATE OCTACOSANOYL ESTER; PALMITATE TRIACONTANOYL ESTER; PALMITIC ACID; POLICOSANOL; STEARATE HEXACOSANOYL ESTER; STEARATE OCTACOSANOYL ESTER; STEARATE TRIACONTANOYL ESTER; STEARIC ACID; UNCLASSIFIED DRUG; ARTICLE; CHROMATOGRAPHY; COLOR; DRUG DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG QUALITY; DRUG STABILITY; DRUG STORAGE; EXPIRATION DATE; HEATING; HYDROLYSIS; HYPERCHOLESTEROLEMIA; MOISTURE; OXIDATIVE STRESS; PHOTODEGRADATION; PHOTOLYSIS; PREDICTION; TABLET DISINTEGRATION; TABLET HARDNESS; TABLET PROPERTY","","","GRIMM W., KRUMMEN K., STABILITY TESTING, (1993); STABILITY TESTS ON ACTIVE INGREDIENTS AND FINISHED PRODUCTS, 3, PP. 21-30; GUIDELINE FOR SUBMITTING DOCUMENTATION FOR THE STABILITY OF HUMAN DRUGS AND BIOLOGIC, (1987); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; LARMOND E., METHODS FOR SENSORY EVALUATION OF FOOD, (1976); SIERRA R., MAGRANER J., ABSTRACT ON THE XIII SCIENTIFIC SEMINAR CNIC, (2000); MAGRANER J., GONZALEZ V., JOURNAL OF AOAC INTERNATIONAL, 82, 4, PP. 834-839, (1999); GREENSPAN L., J. RES. NAT. BUREAU OF STANDARD, 81A: NO. 1.87- STANDARD PROCEDURES: PROTOCOL FOR THE VALIDATION OF ANALYTICAL METHODS, (1977)","","","ENGLISH","BOLL. CHIM. FARM.","ARTICLE","ISI","2-S2.0-0036331856","BOLL CHIM FARM",NA,"NOTREPORTED",NA,"CABRERA L, 2002, BOLL CHIM FARM","CABRERA L, 2002, BOLL CHIM FARM-a"
"FRAGA V;MENENDEZ R;AMOR A;GONZALEZ R;JIMENEZ S;MAS R","FRAGA, V. (6602491407); MENENDEZ, R. (23987873400); AMOR, A.M. (35569426800); GONZALEZ, R.M. (57191737509); JIMENEZ, S. (19735040200); MAS, R. (7007164572)","EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION",1997,"ARCHIVES OF MEDICAL RESEARCH","28","5",38,"","CTR NACL INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, CUBANACAN, PLAYA, LA HABANA, AVE. 25 Y 158, CUBA;CTR NACL INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, CUBANACAN, PLAYA, LA HABANA, AVE. 25 Y 158, CUBA;CTR NACL INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, CUBANACAN, PLAYA, LA HABANA, AVE. 25 Y 158, CUBA;CTR NACL INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, CUBANACAN, PLAYA, LA HABANA, AVE. 25 Y 158, CUBA;CTR NACL INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, CUBANACAN, PLAYA, LA HABANA, AVE. 25 Y 158, CUBA;CTR NACL INVESTIGACIONES CIENTIFICAS, CENTRO DE PRODUCTOS NATURALES, CUBANACAN, PLAYA, LA HABANA, AVE. 25 Y 158, CUBA","POLICOSANOL, A DEFINED MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC ALCOHOL ISOLATED AND PURIFIED FROM SUGAR CANE (SACCHARUM OFFICINARUM, L) WAX IS A NEW CHOLESTEROL-LOWERING AGENT EFFECTIVE IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS, AND PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. ALSO, POLICOSANOL PREVENTS THE ONSET OF SPONTANEOUSLY- AND EXPERIMENTALLY-INDUCED ATHEROSCLEROTIC LESIONS AND CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS. FREE RADICALS ARE LINKED TO MANY DISEASES INCLUDING ATHEROSCLEROSIS AND ISCHEMIA/REOXIDATION CELLULAR INJURY. THEREFORE, IN THIS STUDY THE AUTHORS EVALUATE THE ANTIOXIDANT ACTIVITY OF POLICOSANOL ON RAT LIVER MICROSOMES. THE EXTENT OF LIPID PEROXIDATION WAS MEASURED BY THIOBARBITURIC ACID REACTIVE SUBSTANCES (TBARS). WHEN POLICOSANOL WAS ADMINISTERED ORALLY (100 AND 250 MG/KG) FOR UP TO 4 WEEKS, A PARTIAL PREVENTION OF RAT IN VITRO MICROSOMAL LIPID PEROXIDATION WAS NOTED. THE FORMATION OF TBARS IN MICROSOMES ISOLATED FROM TREATED RATS WAS SIGNIFICANTLY DECREASED BY ABOUT 50%, WHEN PEROXIDATION WAS INITIATED BY FE3+/ADP/ NADPH, FE2+/ASCORBATE AND CCL4/NADPH-GENERATING SYSTEM. ALSO, ORAL ADMINISTRATION OF POLICOSANOL IN RATS PROVIDES A PARTIAL INHIBITION OF LIPID PEROXIDATION, BUT THE MECHANISM SUPPORTING SUCH EFFECT REMAINS TO BE ELUCIDATED. THIS BENEFICIAL EFFECT OF POLICOSANOL ON MEMBRANE LIPID PEROXIDATION MAY BE USEFUL IN PROTECTING TO SOME EXTENT AGAINST FREE RADICAL-ASSOCIATED DISEASES.","MICROSOMAL LIPID PEROXIDATION; POLICOSANOL; THIOBARBITURATE ACID REACTIVE SUBSTANCES","ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; FATTY ALCOHOLS; LIPID PEROXIDATION; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES; ADENOSINE DIPHOSPHATE; ALKANOL; CARBON TETRACHLORIDE; FERRIC ION; FERROUS ASCORBATE; FREE RADICAL; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE LIPID; POLICOSANOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUGAR; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; GERBIL; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIVER MICROSOME; MALE; MOLECULAR WEIGHT; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT","","","","","","ENGLISH","ARCH. MED. RES.","ARTICLE","ISI","2-S2.0-0030866544","ARCH MED RES",NA,"NOTREPORTED",NA,"FRAGA V, 1997, ARCH MED RES","FRAGA V, 1997, ARCH MED RES"
"VALDES S;ARRUZAZABALA M;FERNANDEZ L;MAS R;CARBAJAL D;ALEMAN C;MOLINA V","VALDES, S. (8777025100); ARRUZAZABALA, M.L. (6603962476); FERNANDEZ, L. (7202848319); MAS, R. (7007164572); CARBAJAL, D. (8777025000); ALEMAN, C. (7102849611); MOLINA, V. (7006062814)","EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS",1996,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","16","5",37,"","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, CNIC, CUBANACAN, HABANA, 25 AVE P.O. 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACAN, HAVANA, CUBA","POLICOSANOL IS A NEW DRUG WHOSE CHOLESTEROL-LOWERING EFFECTS HAVE BEEN DEMONSTRATED IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS, AND PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA. THE EFFECT OF POLICOSANOL ON PLATELET AGGREGATION WAS INVESTIGATED IN A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY CONDUCTED ON HEALTHY VOLUNTEERS. THIS INCLUDED A TRIAL OF THE EFFECTS OF SINGLE DOSES (5 TO 50 MG) AND A STUDY OF THE EFFECTS OF REPEATED DOSES ADMINISTERED FOR 7 DAYS. IN THE SINGLE-DOSE STUDY, THE PERCENTAGE OF PLATELET AGGREGATION IN RESPONSE TO THE THRESHOLD CONCENTRATION OF ADP AND EPINEPHRINE MEASURED FROM 8:00 TO 10:00 INCREASED SIGNIFICANTLY IN THE PLACEBO GROUP, WHILE POLICOSANOL (5, 10, 25 AND 50 MG), ADMINISTERED ORALLY, INHIBITED THE INCREASE OF PLATELET AGGREGATION INDUCED BY ADP AND EPINEPHRINE DETERMINED AT THE SAME TIME. POLICOSANOL ADMINISTERED AT 20 MG/DAY FOR 7 DAYS SIGNIFICANTLY INHIBITED PLATELET AGGREGATION INDUCED BY ADP AND EPINEPHRINE, ALTHOUGH THE INHIBITION REACHED BY THE 10 MG/DAY DOSE TENDED TO BE LESS SIGNIFICANT (P = 0.06). A MODEST EFFECT (P = 0.068) ON COLLAGEN-INDUCED PLATELET AGGREGATION WAS ONLY OBSERVED AT THE HIGHEST DOSE (50 MG/DAY). THE LOW DOSE (5 MG/DAY) WAS INEFFECTIVE. POLICOSANOL DID NOT AFFECT THE COAGULATION TIME WHEN ADMINISTERED AT SINGLE OR REPEATED DOSES. NO SIDE-EFFECTS WERE REPORTED IN TREATED OR PLACEBO GROUPS.","","ADULT; BLOOD COAGULATION TESTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; POLICOSANOL; ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION","","","ARRUZAZABALA M.L., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOLOGY RES., 27, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., AMOR A., CASTANO G., ESTUDIO DEL EFECTO SOBRE LIPIDOS Y LIPOPROTEINES SÉRICAS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCH. VENEZOLANOS DE FAMNACOLOGIA Y TERAPEÚTICA, 11, PP. 74-79, (1992); HERNANDEZ F., ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); PONS P., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR, THER, RES., 52, PP. 507-513, (1992); PONS P., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER. RES., 53, PP. 265-269, (1993); ILLNAIT J., ET AL., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II, REV. CENIC CIENCI AS BIOLÓGICAS, 22, PP. 74-76, (1991); CASTANO G., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); SOLTEROL, FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, ARCH. VENEZOLANES FARMAC. Y TERAP., 12, PP. 71-76, (1993); PONS P., ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); BRADLOW B.A., CHETTY N., BIRNBAUM M., BAKER S.G., SETTEL H.C., PATELET FUNCTION IN FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTH AFRICA AND THE EFFECT OF PROBUCOL, THROMB. RES., 26, PP. 91-99, (1982); CARVALHO A.C.A., COLMAN R.W., LEES R.S., PLATELET FUNCTION IN HYPERLIPOPROTEINEMIA, N. ENGL. J. MED., 290, PP. 434-438, (1974); COLMAN R.W., PLATELET FUNCTION IN HYPERBETALIPOPROTEINEMIA, THROMB HAEMOST., 39, PP. 284-293, (1978); TREMOLI, ET AL., INCREASED PLATELET SENSITIVITY AND THROMBOXANE B<SUB>2</SUB> FORMATION IN TYPE IIA HYPERLIPOPROTEINAEMIC PATIENTS, EUR. J. CLIN. INVEST., 14, PP. 329-333, (1984); VIENER A., AVIRAM M., BROOK J.G., ABNORMAL PLASMA LIPO-PROTEIN COMPOSITION IN HYPERCHOLESTEROLEMIC PATIENTS INDUCES PLATELET ACTIVATION, EUR. J. CLIN. INVEST., 14, PP. 207-213, (1984); KRAMER R.M., JAKUBOWSKI J.A., VAILLANCOURT R., DEYKIN D., EFFECT OF MEMBRANE CHOLESTEROL ON PHOSPHOLIPID METABOLISM IN THROMBIN-STIMULATED PLATELETS, J. BIOL. CHEM., 257, PP. 6844-6849, (1982); BIZOS R., WONG L.K., VAILLANCOURT R., LEES R.S., CARVALHO A.C., PLATELET PROSTAGLANDIN ENDOPEROXIDE FORMATION IN HYPERLIPIDEMIA, THROMB. HAEMOST., 38, (1977); PRISCO D., ET AL., ALTERED LIPID COMPOSITION AND THROMBOXANE A<SUB>2</SUB> FORMATION IN PLATELETS FROM PATIENTS AFFECTED BY HYPERLIPO-PROTEINEMIA, THROMB RES., 50, PP. 593-604, (1988); TREMOLI E., MADERNA P., SIRTORI M., SIRTORI C.R., PLATELET AGGREGATION AND MALONDIALDEHYDE FORMATION IN TYPE IIA HYPERCHOLESTEROLEMIC PATIENTS, HAEMOSTASIS, 8, PP. 47-53, (1979); TREMOLI E., FOLCO G., AGRADI E., GALLI C., PLATELET THROMBOXANE AND SERUM CHOLESTEROL, LANCET, 1, PP. 106-107, (1979); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROM-BOSIS RES., 69, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUK. ESSEN. FATTY ACIDS, 49, (1993); MENENDEZ R., ET AL., NIVELES PLASMÁTICOS Y EXCRETIÓN DE LA RADIACTIVIDAD EN VOLUNTARIES SANOS TRAS LA ADMINISTRACIÓN ORAL DE OCTACOSANOL 3H, REV. CENIC CIENC. BIOL., 23, PP. 1-2, (1992); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE (LOND.), 194, (1962); TOFLER G.H., ET AL., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH, N. ENGL. J. MED., 316, PP. 1514-1518, (1987); GOTTO A.M., AHA CONFERENCE REPORT ON CHOLESTEROL, CIRCULATION, 80, PP. 717-748, (1989); BRIONES E.R., STEIGER D., PALUMBO P.J., KOTTKE B.A., PRIMARY HYPERCHOLESTEROLEMIA: EFFECT OF TREATMENT ON SERUM LIPIDS, LIPO-PROTEIN FRACTIONS, CHOLESTEROL ABSORPTION, STEROL BALANCE AND PLATELET AGGREGATION, MAYO CLIN. PROC., 59, PP. 251-257, (1984); ZUCKER M.L., ET AL., PLATELET FUNCTION IN HYPERCHOLESTEROLAEMICS BEFORE AND AFTER HYPOLIPIDEMIC DRUG THERAPY, HAEMOSTASIS, 16, PP. 57-64, (1986); SIRTORI M., ET AL., CLOFIBRATE AND TIADENOL TREATMENT IN HYPERLIPOPROTEINEMIAS: A COMPARATIVE TRIAL OF DRUGS AFFECTING LIPOPROTEIN CATABOLISM AND BIOSYNTHESIS, ATHEROSCLEROSIS, 49, PP. 149-161, (1983); SCHROR K., LOBEL P., STEINHAGEN-THIESSEN E., SIMVASTATIN REDUCES PLATELET THROMBOXANE FORMATION AND RESTORES NORMAL PLATELET SENSITIVITY AGAINST PROSTACYCLIN IN TYPE IIA HYPERCHOLESTEROLEMIA, EICOSANOIDS, 2, PP. 67-73, (1990); DIMINNO G., ET AL., INCREASED FIBRINOGEN BINDING TO PLATELETS FROM PATIENTS WITH FAMILIAR HYPERCHOLESTEROLEMIA, ATEROSCLEROSIS, 6, PP. 203-211, (1986); BANGA J.D., SIXMA J.J., DIABETES MELLITUS, VASCULAR DISEASE AND THROMBOSIS, CLIN. HAEMATOL., 15, PP. 465-492, (1986)","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0030512730","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"VALDES S, 1996, INT J CLIN PHARMACOL RES","VALDES S, 1996, INT J CLIN PHARMACOL RES"
"FERNÁNDEZ L;MÁS R;ILLNAIT J;FERNÁNDEZ J","FERNÁNDEZ, LILIA (7202848319); MÁS, ROSA (7007164572); ILLNAIT, JOSE (8631465800); FERNÁNDEZ, JULIO CÉSAR (9432805500)","POLICOSANOL RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27879 PATIENTS",1998,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","59","5",49,"10.1016/S0011-393X(98)85030-3","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","IN THIS POSTMARKETING SURVEILLANCE STUDY, THE TOLERABILITY OF POLICOSANOL, A NEW CHOLESTEROL-LOWERING DRUG, WAS ASSESSED. THE STUDY POPULATION CONSISTED OF 27,879 PATIENTS FROM SIX MAJOR CUBAN MEDICAL CENTERS: 17,225 PATIENTS (61.8%) WERE FOLLOWED UP FOR 2 YEARS AND 10,654 (38.2%) FOR 4 YEARS. MOST PATIENTS (95.2%) RECEIVED POLICOSANOL 5 MG/D ORALLY, AND THE REMAINDER (4.8%) RECEIVED 10 TO 15 MG/D ORALLY. ALL OF THE PATIENTS WERE TREATED FOR AT LEAST 1 MONTH. DURING THE STUDY, 86 PATIENTS (0.31%) REPORTED ADVERSE EFFECTS (AES), THE MOST FREQUENT OF WHICH WAS WEIGHT LOSS (0.08%). TWENTY-TWO PATIENTS (0.08%) DISCONTINUED TREATMENT BECAUSE OF AES. THE INCIDENCE OF AES DID NOT SHOW ANY APPARENT RELATIONSHIP TO DRUG DOSAGE. IN TERMS OF THE TYPE AND PROFILE OF AES, THE RESULTS OF THE PRESENT STUDY WERE SIMILAR TO THOSE REPORTED IN OTHER RANDOMIZED, DOUBLE-MASKED CLINICAL STUDIES. THE PREDICTIVE VALUE OF PREMARKETING STUDIES WAS CONFIRMED AS WELL AS THE TOLERABILITY OF LONG-TERM POLICOSANOL THERAPY, BUT ONLY IF THE INSTRUCTIONS IN THE PACKAGE BROCHURE WERE FOLLOWED.","CHOLESTEROL-LOWERING DRUGS; POLICOSANOL; POSTMARKETING SURVEILLANCE","POLICOSANOL; ADULT; ARTICLE; BULIMIA; CUBA; DOSE RESPONSE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; POLYURIA; PRESCRIPTION; PRIORITY JOURNAL; WEIGHT REDUCTION","","","FERNER R.B., NEWLY LICENSED DRUGS, BMJ, 313, PP. 1157-1158, (1996); GUIDELINES ON POSTMARKETING SURVEILLANCE, BMJ, 296, PP. 399-400, (1988); VENULET J., POTENTIAL ROLE OF POSTMARKETING RESEARCH, DRUGS EXP CLIN RES., 13, PP. 673-683, (1987); RAWLINS M.D., POSTMARKETING SURVEILLANCE OF ADVERSE REACTIONS TO DRUGS, BMJ, 288, PP. 879-880, (1984); MENENDEZ R., AMOR M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES., 29, PP. 253-257, (1996); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR., 77, PP. 923-932, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES., 27, PP. 205-208, (1994); RODRIGUEZ C., MESA R., MAS R., ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCH VENEZOL FARMACOL TERAP., 11, PP. 74-79, (1992); RODRIGUEZ C., MESA R., MAS R., ET AL., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL., 32, PP. 565-575, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT., 73, PP. 81-90, (1994); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES., 52, PP. 507-513, (1992); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL FARMACOL TERAP., 12, PP. 71-76, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 296-304, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTH STUDY, CURR THER RES., 56, PP. 819-828, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER., 12, PP. 245-254, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J CLIN PHARMACOL RES., 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES., 57, PP. 568-577, (1996); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 57, PP. 691-699, (1996); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, PRENSA MED ARGENT., 83, PP. 665-672, (1996); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 26-35, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 154-162, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR THER RES., 58, PP. 868-875, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 859-867, (1997); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 390-401, (1997); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 44-51, (1997); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., EFFECTOS DEL ATEROMIXOL (PPG) SOBRE LA AGREGACIÓN PLAQUETARIA, REV CIENC BIOL., 22, PP. 72-73, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES., 69, PP. 321-327, (1992); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES., 14, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES., 34, PP. 181-185, (1996); SCAZZIOTA A., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV IBEROAMER TROMBOSIS HEMOSTASIA, 9, PP. 58-62, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES.; MOLGAARD J., LUNDH B.J., VON SCHENCK H., ET AL., LONG-TERM EFFICACY AND SAFETY OF SIMVASTATIN ALONE AND IN COMBINATION THERAPY IN TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 91, SUPPL., (1991)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0031729810","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"FERNÁNDEZ L, 1998, CURR THER RES CLIN EXP","FERNÁNDEZ L, 1998, CURR THER RES CLIN EXP"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;ILLNAIT J;FERNÁNDEZ L;ALVAREZ E","CASTAÑO, G. (56232967100); MÁS, R. (7007164570); FERNÁNDEZ, J.C. (9432805500); ILLNAIT, J. (8631465800); FERNÁNDEZ, L. (7202848319); ALVAREZ, E. (15053135600)","EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK",2001,"JOURNALS OF GERONTOLOGY - SERIES A BIOLOGICAL SCIENCES AND MEDICAL SCIENCES","56","6",64,"10.1093/gerona/56.3.m186","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, HAVANA CITY, P.O. BOX 6880, CUBA","BACKGROUND. THE PRESENT STUDY WAS UNDERTAKEN TO INVESTIGATE THE EFFECTS OF POLICOSANOL IN OLDER PATIENT, WITH TYPE II HYPERCHOLESTEROLEMIA AND MORE THAN ONE CONCOMITANT ATHEROSCLEROTIC RISK FACTOR. METHODS. AFTER 6 WEEKS ON A LIPID-LOWERING DIET, 179 PATIENT RANDOMLY RECEIVED A PLACEBO OR POLICOSANOL AT DOSES OF 5 FOLLOWED BY 10 MG PER DAY FOR SUCCESSIVE 12-WEEK PERIODS OF EACH DOSE. POLICOSANOL (5 AND 10 MG/D) SIGNIFICANTLY (P < .001) REDUCED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C: 16.9% AND 24.4%. RESPECTIVELY) AND TOTAL CHOLESTEROL (TC: 12.8% AND 16.2%. RESPECTIVELY), WHILE SIGNIFICANTLY (P < .01) INCREASING (P < .001) HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) BY 14.6% AND 29.1%. RESPECTIVELY. RESULTS. POLICOSANOL SIGNIFICANTLY DECREASED (P < .01) THE RATIOS OF LDL-C TO H DL-C (29.1%) AND TC TO HDL-C (28%) AT STUDY COMPLETION, ALTHOUGH TRIGLYCERIDES REMAINED UNCHANGED. POLICOSANOL, BUT NOT THE PLACEBO, SIGNIFICANTLY IMPROVED (P .01) CARDIOVASCULAR CAPACITY, WHICH WAS ASSESSED USING THE SPECIFIC ACTIVITY SCALE. NO SERIOUS ADVERSE EXPERIENCES OCCURRED IN POLICOSANOL PATIENTS (P < .01), COMPARED WITH SEVEN ADVERSE EXPERIENCES 17.9%) REPORTED BY PLACEBO PATIENTS. CONCLUSIONS. THIS STUDY SHOWS THAT POLICOSANOL IS EFFECTIVE, SAFE, AND WELL TOLERATED IN OLDER HYPERCHOLESTEROLEMIC PATIENTS.","","AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR SYSTEM; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RISK FACTORS; SAFETY; TREATMENT OUTCOME; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); BENFANTI R., REED D., IS ELEVATED SERUM CHOLESTEROL LEVEL A RISK FACTOR FOR CORONARY HEART DISEASE IN THE ELDERLY?, JAMA, 263, PP. 393-396, (1990); MANOLIO T.A., PEARSON T.A., WENGER N.K., BARRET-CONNOR E., PAVME G.H., HARLAN W.R., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN. REVIEW OF AN NHLBI WORKSHOP, ANN EPIDEMIOL, 2, PP. 161-176, (1992); MASAKI K.H., PETROVITCH H., RODRIGUEZ B.L., CURB J.D., THE VALUE OF RISK FACTOR MODIFICATION IN OLD AGE, CARDIOL ELDERLY, 1, PP. 391-397, (1993); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVATATIN IN MEN WITH HYPERCHOLETEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED, 335, PP. 1001-1009, (1996); DENKE M.A., GRUNDY S.M., HYPERCHOLESTEROLEMIA IN ELDERLY PERSONS: RESOLVING THE TREATMENT DILEMMA, ANN INT MED, 112, PP. 780-792, (1990); SEMPOS C.T., CLEEMAN J.I., CARROL M.D., ET AL., PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG US ADULTS: AN UPDATE BASED ON GUIDELINES FROM THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL, JAMA, 269, PP. 3009-3014, (1993); BILHEIMER D.W., CLINICAL CONSIDERATIONS REGARDING TREATMENT OF HYPERCHOLESTEROLEMIA IN ELDERLY, ATHEROSCLEROSIS, 91, PP. S35-S57, (1991); COHEN D.L., SERUM CHOLESTEROL AND OLDER PEOPLE, BR J HOSP MED, 46, PP. 323-325, (1991); CAPURSO A., LIPID METABOLISM AND CARDIOVASCULAR RISK: SHOULD HYPERCHOLESTEROLEMIA BE TREATED IN THE ELDERLY?, J HYPERTENS, 10, PP. 565-568, (1992); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY. EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, ATHEROSCLEROSIS, 110, PP. 121-161, (1994); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1996); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTH VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESLEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEORLEMIA TIPO II. ESTUDIO ABIERTO, LA PRENSA MÉDICA ARGENTINA, 83, PP. 665-672, (1996); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANETTI M., MOREIRA M.S., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLENTIA: A 3-YEAR OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 6-14, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); CASTANO G., CANETTI M., MORERA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR THER RES, 56, PP. 819-828, (1995); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., RODEIRO I., HERNANDEZ C., CAPOTE A., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24-MONTH STUDY, TERATOGONESIS, CARCINOG MUTAGEN, 14, PP. 239-249, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: A ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOGENESIS, CARCINOG MUTAGEN, 14, PP. 107-113, (1994); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); GOLDMAN L., HASHIMOTO B., COOK F., LOSELZO A., COMPARATIVE REPRODUCIBILITY AND VALIDITY OF SYSTEMS FOR ASSESSING CARDIOVASCULAR FUNCTIONAL CLASS: ADVANTAGES OF A NEW SPECIFIC ACTIVITY SCALE, CIRCULATION, 64, PP. 1227-1234, (1981); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); RUBIN S.M., SIDNEY S., BLACK D.M., BROWNER W.S., HULLEY S.B., CUMMINGS S.R., HIGH BLOOD CHOLESTEROL IN ELDERLY MEN AND THE EXCESS RISK FOR CORONARY HEART DISEASE, ANN INT MED, 113, PP. 916-920, (1990); DAVIGNON J., METHODS AND ENDPOINT ISSUES IN CLINICAL DEVELOPMENT OF LIPID-ACTING AGENTS WITH PLEIOTROPIC EFFECTS, AM J CARDIOL, 81, 8A, PP. 17F-24F, (1998); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASE ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., INTERACTION OF POLICOSANOL-WARFARIN ON BLEEDING TIME AND THROMBOSIS IN RATS, PHARMACOL RES, 38, 2, PP. 89-91, (1998); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLAN PHARMACOL; BHATNAGAR D., LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDAEMIA, PHARMACOL THER, 79, PP. 205-230, (1998); MOLINA CUEVAS V., ARRUZAZABALA M.L., CARBAJAL QUINTANA D., MAS FERREIRO R., VALDES GARCIA S., EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS. STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOLOL, ARCH MED RES, 29, PP. 21-24, (1998); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., SELMAN E., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1998); EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FRONT 5.2 TO 7.8 MMOL/L T200 TO 300 MG/DL) PLUS TWO ADDITIONAL ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 72, PP. 1031-1037, (1993)","","","ENGLISH","J. GERONTOL. SER. A BIOL. SCI. MED. SCI.","ARTICLE","ISI","2-S2.0-0035116259","J GERONTOL SER A BIOL SCI MED SCI",NA,"NOTREPORTED",NA,"CASTAÑO G, 2001, J GERONTOL SER A BIOL SCI MED SCI","CASTAÑO G, 2001, J GERONTOL SER A BIOL SCI MED SCI"
"ARRUZAZABALA M;MOLINA V;MAS R;FERNÁNDEZ L;CARBAJAL D;VALDÉS S;CASTAÑO G","ARRUZAZABALA, MARÍA LOURDES (6603962476); MOLINA, VIVIAN (7006062814); MAS, ROSA (7007164572); FERNÁNDEZ, LILIA (7202848319); CARBAJAL, DAISY (8777025000); VALDÉS, SURIA (8777025100); CASTAÑO, GLADYS (56232967100)","ANTIPLATELET EFFECTS OF POLICOSANOL 20 AND 40 MGDAY IN HEALTHY VOLUNTEERS AND DYSLIPIDAEMIC PATIENTS",2002,"CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY","29","6",63,"10.1046/j.1440-1681.2002.03746.x","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBANACÁN, CUBA;SURGICAL MEDICAL RESEARCH CENTER, HAVANA CITY, CUBA","1. THE PRESENT STUDY WAS UNDERTAKEN TO COMPARE THE EFFECTS OF A HIGHER DOSE OF POLICOSANOL, A CHOLESTEROL-LOWERING DRUG, (40 MG/DAY) WITH THE EFFECTS OF 20 MG/DAY POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS AND TYPE II HYPERCHOLESTEROLAEMIC PATIENTS. 2. STUDY SUBJECTS WERE RANDOMIZED TO RECEIVE, UNDER DOUBLE-BLIND CONDITIONS, PLACEBO OR POLICOSANOL (20 OR 40 MG/DAY) FOR 30 DAYS ONCE A DAY. BLOOD SAMPLING WAS PERFORMED AT BASELINE AND AFTER 30 DAYS ON THERAPY. 3. PLATELET AGGREGATION WAS INDUCED WITH THREE AGGREGATING AGENTS: ARACHIDONIC ACID (AA), COLLAGEN AND LOW DOSES OF ADP. 4. POLICOSANOL (20 AND 40 MG/DAY) MODERATELY YET SIGNIFICANTLY REDUCED PLATELET AGGREGATION, BUT NO DIFFERENCES WERE OBSERVED IN THE EFFECTS PRODUCED BY EITHER DOSE OF POLICOSANOL. IN HEALTHY VOLUNTEERS, POLICOSANOL AT 20 AND 40 MG/DAY INHIBITED AGGREGATION INDUCED BY 2 MMOL/L AA (28.2 AND 24.9%, RESPECTIVELY), 1 ΜG/ML COLLAGEN (21.1 AND 20.2%) AND 1 ΜMOL/L ADP (30.9 AND 29.1%). CHANGES THAT OCCURRED FOLLOWING THE ADMINSTRATION OF PLACEBO WERE NOT SIGNIFICANT, ALTHOUGH AN UPWARD TREND FOR COLLAGEN- AND ADP-INDUCED AGGREGATION OCCURRED IN NORMAL AND HYPERCHOLESTEROLAEMIC SUBJECTS, RESPECTIVELY, THUS PARTIALLY MASKING THE EFFECTS OF POLICOSANOL ON THESE RESPONSES. 5. THE ANTIPLATELET EFFECTS OF POLICOSANOL AT 20 AND 40 MG/DAY IN HYPERCHOLESTEROLAEMIC PATIENTS WERE ALSO SIMILAR, SO THAT BOTH DOSES INHIBITED AGGREGATION INDUCED BY 1.5 MMOL/L AA (20.1 AND 33.0%, RESPECTIVELY), 0.5 ΜG/ML COLLAGEN (22.7 AND 21.1%) AND 1 ΜMOL/L ADP (40.5 AND 34.7%). 6. IN ADDITION, AFTER 30 DAYS OF THERAPY, 20 AND 40 MG/DAY POLICOSANOL SIGNIFICANTLY (P < 0.01) REDUCED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (15.9 AND 17.0%, RESPECTIVELY) AND TOTAL CHOLESTEROL (12.4 AND 12.3%, RESPECTIVELY; P < 0.05), YET INCREASED HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL VALUES BY 5% IN BOTH GROUPS (P < 0.05). 7. TRIGLYCERIDES WERE DECREASED COMPARED WITH BASELINE, BUT NOT WITH RESPECT TO THE PLACEBO. 8. WE CONCLUDE THAT THE ANTIPLATELET EFFECTS INDUCED BY 40 MG/DAY POLICOSANOL ADMINISTERED FOR 30 DAYS TO HEALTHY VOLUNTEERS AND TO HYPERCHOLESTEROLAEMIC PATIENTS WERE SIMILAR TO THE EFFECTS INDUCED BY 20 MG/DAY POLICOSANOL. THUS, NO ENHANCEMENT OF THE RESPONSE WAS ACHIEVED WITH THE USE OF A HIGHER DOSE OF POLICOSANOL IN STUDY PATIENTS.","ANTIPLATELET DRUGS; HEALTHY VOLUNTEERS; HYPERCHOLESTEROLAEMIA; PLATELET AGGREGATION; POLICOSANOL","ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STATISTICS, NONPARAMETRIC; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; REDUCTION; TASK PERFORMANCE; THROMBOCYTE AGGREGATION","","","WILSON J.M., FERGUSON J.J., PLATELET-ENDOTHELIAL INTERACTIONS IN ATHEROTHROMBOTIC DISEASE: THERAPEUTIC IMPLICATIONS, CLIN. CARDIOL., 23, PP. 687-698, (1999); COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS ANTIPLATELET THERAPY I. PREVENTION OF DEATH, MYOCARDIAL INFARCTION AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BMJ, 308, PP. 81-106, (1994); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR. HEART J., 19, SUPPL. A, (1998); LAGUNA A., MAGRANER J., CARBAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M.; MAS R., POLICOSANOL, DRUGS FUTURE, 25, PP. 569-586, (2000); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THER. RES., 51, PP. 568-575, (1992); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR. J. CLIN. PHARMACOL., 50, PP. 255-262, (2000); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, PP. 27-33, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, PP. 176-182, (1995); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 55, PP. 1084-1092, (1994); BENITEZ M., ROMERO C., MAS R., FERNANDEZ L., FERNANDEZ J.C., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 859-867, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, PP. 439-447, (1999); ALCOCER A., FERNANDEZ L., CAMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT. J. TISSUE REACT., 21, PP. 57-64, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 13, PP. 1-9, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR. THER. RES., 61, PP. 137-146, (2000); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION, ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, PP. 245-254, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEARS STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT. J. CLIN. PHARMACOL. RES., 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTHS STUDY, CURR. THER. RES., 56, PP. 819-828, (1995); CANETTI M., MORERA M., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR. THER. RES., 58, PP. 868-875, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 59, PP. 737-745, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., COMPARISON OF TWO REGIMENS OF POLICOSANOL ADMINISTERED AT 20 MG/D IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY, CURR. THER. RES., 62, PP. 194-208, (2001); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, PP. 379-391, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6 MONTHS DOUBLE-BLIND STUDY, INT. J. CLIN. PHARMACOL. RES., 21, PP. 43-57, (2001); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, PP. 44-51, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NON INSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL. RES., 19, PP. 105-116, (1999); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR. J. NUTR., 77, PP. 923-932, (1997); MENENDEZ R., AMOR A., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH. MED. RES., (2002); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV. IBEROAM TROMB. HEMOST., 5, PP. 17-20, (1992); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, PP. 321-327, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A <SUB>2</SUB> , PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D., ARRUZAZABALA M.L., MAS R., MOLINA V., VALDES S., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 50, PP. 249-251, (1994); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES., 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., FERNANDEZ L., CARBAJAL D., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, PP. 181-185, (1996); SCAZZIOTA A., PONS S., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV. IBEROAM TROMB. HEMOST., 9, PP. 58-62, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 58, PP. 61-64, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISSUE REACT., 20, PP. 119-124, (1998); SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III), JAMA, 285, PP. 2486-2497, (2001); TOFLER G.H., BREZINSKI D., SCHAFER A., ET AL., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH, N. ENGL. J. MED., 316, PP. 1514-1518, (1987); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE, 194, PP. 927-932, (1962); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, PP. 499-502, (1972); SCHETMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, PP. 197-204, (1996); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN. PROC., 63, PP. 1140-1143, (1988); SCHAFER A.I., ANTIPLATELET THERAPY, AM. J. MED., 101, PP. 199-209, (1996); SCHROR K., PLATELET REACTIVITY AND ARACHIDONIC ACID METABOLISM IN TYPE II HYPERLIPOPROTEINAEMIA AND ITS MODIFICATION BY CHOLESTEROL-LOWERING AGENTS, EICOSANOIDS, 2, PP. 39-46, (1989); NOTARBARTOLO A., DAVI G., AVERNA M., ET AL., INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA, ARTERIOSCLER. THROMB. VASC. BIOL., 15, PP. 247-251, (1995); CASTANO G., NODARSE M., MAS R., ET AL., ESTUDIO COMPARATIVO DE LA EFICACIA Y TOLERABILIDAD DEL POLICOSANOL, LA SIMVASTATINA Y DE SU TERAPIA COMBINADA EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA TIPO II, REV. CENIC CIEN BIOL., 29, PP. 9-15, (1998); ARRUZAZABALA M.L., VALDAS S., MAS R., FERNANDEZ L., CARVAJAL D., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, PP. 293-297, (1998); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL. RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27 879 CASES, CURR. THER. RES., 59, PP. 717-722, (1998)","R. MAS; CENTER OF NATURAL PRODUCTS, NATL. CTR. OF SCIENTIFIC RES. (CNIC), CUBANACÁN, HAVANA, AVE 25 PO 6880, CUBA; EMAIL: CLINICA@IP.ETECSA.CU","","ENGLISH","CLIN. EXP. PHARMACOL. PHYSIOL.","ARTICLE","ISI","2-S2.0-0036049409","CLIN EXP PHARMACOL PHYSIOL","NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;NATIONAL CENTER FOR SCIENTIFIC RESEARCH;SURGICAL MEDICAL RESEARCH CENTER","NOTREPORTED;NATL. CTR. OF SCIENTIFIC RES. (CNIC);EMAIL: CLINICA@IP.ETECSA.CU",NA,"ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL PHYSIOL","ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL PHYSIOL"
"MENÉNDEZ R;AMOR A;RODEIRO I;GONZÁLEZ R;GONZÁLEZ P;ALFONSO J;MÁS R","MENÉNDEZ, ROBERTO (7102205059); AMOR, ANA MA (35569426800); RODEIRO, IDANIA (6602314378); GONZÁLEZ, ROSA MA (57191737509); GONZÁLEZ, PILAR C. (18835136000); ALFONSO, JOSÉ L. (7006132135); MÁS, ROSA (7007164570)","POLICOSANOL MODULATES HMGCOA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS",2001,"ARCHIVES OF MEDICAL RESEARCH","32","4",130,"10.1016/S0188-4409(00)00265-4","LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA;LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA;LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA;LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA;LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA;LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA;LABORATORIO DE BIOQUI�?MICA, CENTRO DE PRODUCTOS NATURALES, CENTRO NACIONAL DE INVESTIGACIÓN CIENTI�?FICA, HAVANA, CUBA","BACKGROUND. CHOLESTEROL BIOSYNTHESIS IS STRICTLY CONTROLLED BY 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE. METHODS. TRANSFER OF CULTURED FIBROBLASTS TO A LIPID-DEPLETED MEDIUM (LDM) UP-REGULATES THE ENZYME LEVELS. THIS, IN TURN, IS FOLLOWED BY AN ACCELERATED BIOSYNTHESIS OF CHOLESTEROL. RESULTS. EXPOSURE OF VERO FIBROBLASTS TO LDM AND POLICOSANOL (0.5-50 ΜG/ML), A NEW CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGARCANE (SACCHARUM OFFICINARUM L.) WAX, DECREASED IN A DOSE-DEPENDENT MANNER CHOLESTEROL BIOSYNTHESIS FROM [14C]-ACETATE AND 3H-WATER, BUT NOT FROM [14C]-MEVALONATE. CONCLUSIONS. THIS SUGGESTS AN EFFECT ON HMG-COA REDUCTASE, THE RATE-CONTROLLING ENZYME IN CHOLESTEROL BIOSYNTHESIS. WHEN ENZYME ACTIVITY WAS MEASURED IN THE PRESENCE OF VARIOUS CONCENTRATIONS OF POLICOSANOL (0.5-50 ΜG/ML), REDUCTASE WAS NOT SUPPRESSED. THEREFORE, THERE WAS NO EVIDENCE FOR A COMPETITIVE OR NONCOMPETITIVE INHIBITION OF ENZYME ACTIVITY. HOWEVER, AFTER TREATMENT OF INTACT CELLS WITH POLICOSANOL (50 ΜG/ML) IN THE PRESENCE OF LDM, A SUPPRESSIVE EFFECT ON ENZYME ACTIVITY WAS OBSERVED, SUGGESTING A MODULATORY EFFECT OF POLICOSANOL ON REDUCTASE ACTIVITY. THE PREVIOUS INHIBITION OF ENZYME UP-REGULATION BY POLICOSANOL SUGGESTS TO DATE A DEPRESSION OF DE NOVO SYNTHESIS OF HMG-COA REDUCTASE AND/OR STIMULATION OF ITS DEGRADATION. HOWEVER, THE EXACT MECHANISM BY WHICH POLICOSANOL INHIBITS THE ACTIVITY OF HMG-COA REDUCTASE STILL REMAINS UNCLEAR. FURTHER STUDIES ARE NEEDED TO CLARIFY THE PRECISE MECHANISM OF ITS INHIBITORY ACTION ON CHOLESTEROL BIOSYNTHESIS. © 2001 IMSS.","CHOLESTEROL BIOSYNTHESIS; HMG-COA REDUCTASE; POLICOSANOL","ANIMALS; ANTICHOLESTEREMIC AGENTS; CERCOPITHECUS AETHIOPS; CHOLESTEROL; FATTY ALCOHOLS; FIBROBLASTS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; VERO CELLS; ACETIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; POLICOSANOL; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL","","","RODWELL V.W., MCNAMARA D.J., SHAPIRO D.J.K., REGULATION OF HEPATIC HMG-COA REDUCTASE, ADV ENZYMOL, 38, (1973); BROWN M.S., GOLDSTEIN J.L., MULTIVALENT FEED-BACK REGULATION OF HMG-COA REDUCTASE, A CONTROL MECHANISM COORDINATING ISOPRENOID SYNTHESIS AND CELL GROWTH, J LIPID RES, 2, (1980); GRUNDY S.M., HMG-COA REDUCTASE INHIBITORS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, N ENGL J MED, 319, (1988); ARIENS A.J., A GENERAL INTRODUCTION TO THE FIELD OF DRUG DOSING, (1963); RODWELL V.W., NORDSTROM J.L., MITSCHELEN J.J., REGULATION OF HMG-COA REDUCTASE, ADV LIPID RES, 14, (1976); ENDO A., THE DISCOVERY AND DEVELOPMENT OF HMG-COA REDUCTASE INHIBITORS, J LIPID RES, 33, (1992); ARRUZAZABALA L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON NORMOCHOLESTEROLEMIC RABBITS, BIOL RES, 27, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., DEL RIO A., AMOR A., GONZALEZ R., CARBAJAL D., FRAGA V., MOLINA V., ILLNAIT J., CHOLESTEROL LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, (1997); CRUZ-BUSTILLO D., MEDEROS C.M., MAS R., ARRUZAZABALA L., BARRETO B., MARTINEZ O., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CENIC CIEN BIOL, 22, (1991); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., NOA M., MENENDEZ R., GONZALES R.M., AMOR A.M., FRAGA V., SOTOLONGO V., LAGUNA A., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 11, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, (1993); ANEIROS E., CALDERON B., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASE OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, (1995); CAMPILONGO R., SANDINI P., FIELDMAN R., EFICACIA SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II, ESTUDIO ABIERTO. LA PRENSA MED ARGENTINA, 83, (1997); CANETTI M., MORERA M., ILLNAIT J., MAS R., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, (1995); CANETTI M., MORERA M.S., MAS R., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA; A ONE-YEAR OPEN FOLLOW-UP, CURR THER RES, 58, (1997); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., SELLMAN E., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECT OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOL J VASC DIS, 50, (1998); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, (1999); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE STUDY OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, (1997); MAS R., CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ALEMAN C., PONTIGAS V., LESCAY M., EFFECT OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, (1998); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ILLANIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., EFFECT OF SUCCESSIVE DOSE INCREASE OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, XIV, (1994); SOLTERO I., FUENTEMAYOR I., COLMENARES J., ESTUDIOS COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL FARMACOL TERAPIA, 12, (1993); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); MENENDEZ R., AMOR A., GONZALEZ R., FRAGA V., MAS R., EFFECTS OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, (1996); MENENDEZ R., FRAGA V., SOTOLONGO V., AMOR A., DEL RIO A., GONZALEZ R., JIMENEZ S., MAS R., EFECTO DE LA ADMINISTRACIÓN ORAL DE POLICOSANOL SOBRE EL METABOLISMO LIPÍDICO DE RATAS NORMOCOLESTEROLÉMICAS, REV MEX CIENCIAS FARMACEUTICAS, 24, (1993); MENENDEZ R., FERNANDEZ I., DEL RIO A., GONZALEZ R., FRAGA V., AMOR A., JIMENEZ S., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED FIBROBLASTS, BIOL RES, 27, (1994); COHEN L.H., VAN VLIET A., ROODENBURG L., JANSEN M.C., GRIFFIOEN M., PRAVASTATIN INHIBITED THE CHOLESTEROL SYNTHESIS IN HUMAN HEPATOMA CELL LINE HEPG2 LESS THAN SIMVASTATIN AND LOVASTATIN, WHICH REFLECTED IN THE UP-REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE AND SQUALENE SYNTHASE, BIOCHEM PHARMACOL, 45, (1993); LOWRY O.H., ROSEBROUGH N.J., FARR A.L., RANDALL R.J., PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT, J BIOL CHEM, 193, (1951); BERKHOUT T.A., HAVEKES L.M., PEARCE N.J., GROOT P.H.E., THE EFFECT OF (-)-HYDROXYCITRATE ON THE ACTIVITY OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR AND 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE LEVELS IN THE HUMAN HEPATOMA CELL LINE HEPG2, BIOCHEM J, 272, (1990); BROWN M.S., GOLDSTEIN J.L., SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ACTIVITY AND INHIBITION OF GROWTH OF HUMAN FIBROBLASTS BY 7-KETOCHOLESTEROL, J BIOL CHEM, 249, (1974); BROWN M.S., DANA S.E., GOLDSTEIN J.L., REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A IN CULTURED FIBROBLASTS, J BIOL CHEM, 249, (1974); GOLDSTEIN J.L., BROWN M.S., REGULATION OF THE MEVALONATE PATHWAY, NATURE, 343, (1990); LAKSHMANAN M.R., VEECH R.L., MEASUREMENT OF RATE OF RAT LIVER STEROL SYNTHESIS IN VIVO USING TRITIATED WATER, J BIOL CHEM, 262, (1977); FIELD F.J., SHREVES T., FUJIWARA D., MURTHY S., ALBRIGHT E., MATHUR S.N., REGULATION OF GENE EXPRESSION AND SYNTHESIS AND DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY MICELLAR CHOLESTEROL IN CACO-2 CELLS, J LIPID RES, 32, (1991); FAUST J.R., LUSKEY K.L., CHIN D.J., GOLDSTEIN J.L., BROWN M.S., REGULATION OF SYNTHESIS AND DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY LOW DENSITY LIPOPROTEIN AND 25-HYDROXYCHOLESTEROL IN UT-1 CELLS, PROC NATL ACAD SCI USA, 79, (1982); EDWARDS P.A., LAN S.F., FOGEIMAN A.M., HIGH DENSITY LIPOPROTEIN AND LECITHIN DISPERSIONS INCREASE THE ACTIVITY OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY INCREASING THE RATE OF SYNTHESIS AND DECREASING THE RATE OF DEGRADATION OF ENZYME, J BIOL CHEM, 259, (1984)","","","ENGLISH","ARCH. MED. RES.","ARTICLE","ISI","2-S2.0-0035098624","ARCH MED RES",NA,"NOTREPORTED",NA,"MENÉNDEZ R, 2001, ARCH MED RES","MENÉNDEZ R, 2001, ARCH MED RES"
"RODRÍGUEZ-ECHENIQUE C;MESA R;MÁS R;NOA M;MENÉNDEZ R;GONZÁLEZ R;AMOR A;FRAGA V;SOTOLONGO V;LAGUNA A","RODRÍGUEZ-ECHENIQUE, C. (6504286626); MESA, R. (7003836140); MÁS, R. (7007164572); NOA, M. (7003318964); MENÉNDEZ, R. (7102205059); GONZÁLEZ, R.M. (57191737509); AMOR, A.M. (35569426800); FRAGA, V. (6602491407); SOTOLONGO, V. (6506317930); LAGUNA, A. (7006455910)","EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS MACACA ARCTOIDES",1994,"FOOD AND CHEMICAL TOXICOLOGY","32","10",60,"10.1016/0278-6915(94)90115-5","DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","POLICOSANOL, ADMINISTERED ORALLY, HAS SHOWN A CHOLESTEROL-LOWERING EFFECT IN DIFFERENT EXPERIMENTAL MODELS. BECAUSE LIPID-LOWERING THERAPY IS ADMINISTERED CHRONICALLY, IT IS NECESSARY TO KNOW THE EFFECTS OF THESE DRUGS AFTER LONG-TERM ADMINISTRATION. 18 ADULT MALE MACACA ARCTOIDES MONKEYS WERE USED TO STUDY THE CHOLESTEROL-LOWERING EFFECTS AND POSSIBLE TOXICITY PRODUCED BY ORAL ADMINISTRATION OF POLICOSANOL (0.25, 2.5 AND 25 MG/KG) FOR 54 WK. AFTER 8 WK, A SIGNIFICANT REDUCTION OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL WAS OBSERVED IN POLICOSANOL-TREATED ANIMALS WHEN COMPARED WITH THE CONTROLS; THIS EFFECT PERSISTED THROUGHOUT THE STUDY. THE ANIMALS' BEHAVIOURAL REPERTOIRE, PHYSICAL CONDITION, HAEMATOLOGY AND BLOOD BIOCHEMISTRY, AS WELL AS SPERMIOGRAM ANALYSIS AND ELECTROCARDIOGRAPHY, WERE MONITORED DURING THE STUDY; OPHTHALMOLOGICAL AND PATHOLOGICAL ANATOMY EXAMINATIONS WERE PERFORMED AT THE END OF THE ADMINISTRATION PERIOD. NO DRUG-RELATED TOXICITY WAS DETECTED BY ANY EXAMINATION. THE RESULTS GAVE FURTHER EVIDENCE OF THE MARKED AND PERSISTENT CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL THAT HAD BEEN OBSERVED IN DIFFERENT EXPERIMENTAL MODELS. THERE WAS A SIGNIFICANT REDUCTION OF SPONTANEOUS AORTIC ATHEROSCLEROTIC LESIONS IN TREATED ANIMALS COMPARED WITH CONTROLS. POLICOSANOL (0.25-25 MG/KG) ADMINISTERED ORALLY FOR 54 WK BROUGHT ABOUT A PERSISTENT REDUCTION IN BLOOD CHOLESTEROL LEVELS AND WAS VERY SAFE AND WELL TOLERATED DURING LONG-TERM ADMINISTRATION. © 1994.","","ADMINISTRATION, ORAL; ANIMAL; AORTA; ARTERIOSCLEROSIS; BEHAVIOR, ANIMAL; CHOLESTEROL; COMPARATIVE STUDY; ELECTROCARDIOGRAPHY; EYE; FATTY ALCOHOLS; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MACACA; MALE; SPERMATOGENESIS; ANIMALIA; MACACA ARCTOIDES; ANTILIPEMIC AGENT; POLICOSANOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CORONARY ARTERY; CORONARY RISK; ELECTROCARDIOGRAPHY; HYPERCHOLESTEROLEMIA; MALE; MONKEY; NONHUMAN; RAT; SPERMIOGRAM","","","AHFS, AMERICAN HOSPITAL FORMULARY SERVICE '89: ANTILIPEMIC AGENTS. SECTION 24:06, (1989); ALEMAN, MAS, RODEIRO, NOA, HERNANDEZ, CAPOTE, MENENDEZ, GONZALEZ, AMOR, JIMENEZ, TOXICOLOGIA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 102-105, (1991); ALEMAN, MAS, HERNANDEZ, RODEIRO, NOA, MENENDEZ, GONZALEZ, AMOR, SOTOLONGO, FRAGA, CAPOTE, JIMENEZ, ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, ABSTRACTS OF THE 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ARRUZAZABALA, CARBAJAL, MAS, CASTANO, SOTOLONGO, EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL SÉRICO EN PERROS BEAGLE, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 60-61, (1991); ARRUZAZABALA, CARBAJAL, MAS, GARCIA, EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA AGREGACIÓN PLAQUETARIA, REVISTA CENIC, CIENCIAS BIOLÓGICAS, 22, PP. 72-73, (1991); ARRUZAZABALA, CARBAJAL, MAS, GARCIA, FRAGA, EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1993); ARRUZAZABALA, CARBAJAL, MAS, ILLNAIT, LAGUNA, CASTANO, EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPIDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEÚTICA, 11, PP. 80-86, (1992); ATKINSON, HOOVER, BERRY, SWIFT, CHOLESTEROL-FED HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDEMIC RABBITS: A NEW MODEL FOR ATHEROSCLEROSIS, ATHEROSCLEROSIS, 79, PP. 123-136, (1989); BELLINGER, GREENE, CORBETT, ELECTROCARDIOGRAPHIC STUDIES IN AFRICAN GREEN MONKEYS, LABORATORY ANIMAL SCIENCE, 30, PP. 854-859, (1980); BERTRAND, THE BEHAVIORAL REPERTOIRE OF THE STUMPTAIL MACAQUE, BIBLIOTHECA PRIMATOLOGICA, (1969); CANADIAN COUNCIL ON ANIMAL CARE, GUIDE TO THE CARE AND USE OF EXPERIMENTAL ANIMALS, (1984); CASTANO, ZARDOYA, ILLNAIT, MAS, FERNANDEZ, SURRIBAS, NODARSE, FERNANDEZ, EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MÉDICAS, 5, PP. 21-28, (1991); CHEITLIN, VIRMANI, MYOCARDIAL INFARCTION IN THE ABSENCE OF CORONARY ATHEROSCLEROTIC DISEASE, NON-ATHEROSCLEROTIC ISCHEMIC HEART DISEASE, PP. 1-30, (1989); CONTI, LARGE VESSEL CORONARY VASOSPASM: DIAGNOSIS, NATURAL HISTORY AND TREATMENT, AMERICAN JOURNAL OF CARDIOLOGY, 55, PP. 41B-49B, (1985); CRUZ-BUSTILLO, MEDEROS, MAS, ARRUZAZABALA, BARRETO, MARTINEZ, EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, 1-2, PP. 62-64, (1991); ELLIS, OELZ, ROBERTS, CORONARY ARTERIAL SMOOTH MUSCLE CONTRACTION BY A SUBSTANCE RELEASED FROM PLATELETS, EVIDENCE THAT IT IS A THROMBOXANE A2, 193, PP. 1135-1137, (1976); GLUECK, RELATIONSHIP OF LIPID DISORDERS TO CORONARY HEART DISEASE, AMERICAN JOURNAL OF MEDICINE, 74, (1983); GUZMAN-FLORES, GARCIA-CASTELLS, ERVIN, EL MONO COMO INVESTIGADOR DEL MONO, XVI CONGRESO NACIONAL DE CIENCÍAS FISIOLÓGICAS, ZACATECAS. ESTRACTO DE LAS COMMUNICACIONES, (1973); HAINLINE, STANDARD METHODS OF CLINICAL CHEMISTRY, QUÍMICA CLINICA, PRINCIPIOS Y TÉCNICAS, 2, PP. 891-971, (1958); HAUST, LIGHT AND ELECTRON MICROSCOPY OF HUMAN ATHEROSCLEROTIC LESIONS, THE THROMBOTIC PROCESS IN ATHEROGENESIS, PP. 33-59, (1980); HAUST, DERIVATION AND PROGRESSION OF ATHEROSCLEROTIC PLAQUES, PROCEEDINGS OF THE 6TH INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, PP. 350-360, (1983); HERNANDEZ, ILLNAIT, MAS, CASTANO, FERNANDEZ, GONZALEZ, CORDOVI, FERNANDEZ, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 2-8, (1992); HLADOVEC, PREROVSKY, STANEK, FABIAN, CIRCULATING ENDOTHELIAL CELLS IN ACUTE MYOCARDIAL INFARCTION AND ANGINA PECTORIS, KLINISCHE WOCHENSCHRIFT, 56, PP. 1033-1036, (1978); HOWARD, THE BABOON IN ATHEROSCLEROSIS RESEARCH: COMPARISON WITH OTHER SPECIES AND USE IN TESTING DRUGS AFFECTING LIPID METABOLISM, ATHEROSCLEROSIS DRUGS DISCOVERY, (1976); ILLNAIT, CASTANO, NODARSE, PONTIGAS, FERNANDEZ, MAS, EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II. REPORTE PRELIMINAR, REVISTA CENIC. CIENCIAS BIOLÓGICAS, 22, PP. 74-76, (1991); JACOBSEN, PROSTAGLANDINS AND CARDIOVASCULAR DISEASE, SURGERY, 93, PP. 564-573, (1983); KRAMSCH, HALLANDER, RENAUD, INDUCTION OF FIBROUS PLAQUES VS FOAM CELL LESIONS IN M. FASCICULARIS BY VARYING THE COMPOSITION OF DIETARY FATS, CIRCULATION, 48, (1973); KRITCHEVSKY, EXPERIMENTAL ATHEROSCLEROSIS IN RABBITS FED CHOLESTEROL-FREE DIETS. COMPARISON OF PEANUT, CORN, BUTTER AND COCONUT OILS, EXPERIMENTAL AND MOLECULAR PATHOLOGY, 24, (1972); KUMAR, BERENSON, RUIZ, ACID MUCOPOLYSACCHARIDES OF HUMAN AORTA, PART 2. VARIATIONS WITH ATHEROSCLEROTIC INVOLVEMENT, 7, PP. 583-590, (1967); LEVY, CHOLESTEROL, LIPOPROTEINS, APOPROTEINS AND HEART DISEASE: PRESENT STATUS AND FUTURE PROSPECTS, CLINICAL CHEMISTRY, 27, (1981); LEVY, CHOLESTEROL AND DISEASE: WHAT ARE THE FACTS?, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 284, (1982); LEVY, CURRENT STATUS OF CHOLESTEROL CONTROVERSY, AMERICAN JOURNAL OF MEDICINE, 74, PP. 1-4, (1983); MCGREGOR, MORAZAIN, RENAUD, COMPARISON OF THE EFFECTS OF DIETARY SHORT AND LONG CHAIN SATURATED FATTY ACIDS ON PLATELET FUNCTIONS, PLATELET PHOSPHOLIPIDS, AND BLOOD COAGULATION IN RATS, LABORATORY INVESTIGATION, 43, (1980); MALINOW, AN ELECTROCARDIOGRAPHIC STUDY OF MACACA MULATTA, FOLIA PRIMATOLOGICA, 4, PP. 51-65, (1966); MALINOW, BLATON, REGRESSION OF ATHEROSCLEROTIC LESIONS, ARTERIOSCLEROSIS, 4, PP. 292-295, (1984); MALINOW, MARUFFO, PERLEY, EXPERIMENTAL ATHEROSCLEROSIS IN SQUIRREL MONKEYS (SAIMIRI SCIURUS), JOURNAL OF PATHOLOGY AND BACTERIOLOGY, 92, PP. 491-510, (1966); MASTROIANNI, MANSON, COLLECTION OF MONKEY SEMEN BY ELECTROEJACULATION, PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 112, PP. 1025-1027, (1963); MIDDLETON, CLARKSON, LOFLAND, PRICHARD, DIET AND ATHEROSCLEROSIS OF SQUIRREL MONKEYS, ARCHIVES OF PATHOLOGY, 83, (1967); NOA, AGUILAR, CAPOTE, DE LA ROSA, TINCIÓN DE AZUL DE STEVENEL PARA CORTEX DE TEJIDOS INCLUIDOS EN PARAFINA Y COMO COLORACIÓN ESPECIAL PARA MUCOPOLISACARIDOS ÁCIDOS, PATOLOGIA (MEJICANA), 23, PP. 21-25, (1985); NOA, HERRERA, MAS, EFECTO DEL ATEROMIXOL (PPG) SOBRE EL DAÑO ENDOTELIAL EN RATAS, REVISTA CENIC, CIENCIAS BIOLÓGICAS, 22, PP. 79-80, (1991); NOA, ILLNAIT, INDUCTION OF AORTIC PLAQUES IN GUINEA PIGS BY EXPOSURE TO KEROSENE, ARCHIVES OF ENVIRONMENTAL HEALTH, 42, PP. 31-36, (1987); O'CONNOR, FEELY, SHEPHERD, LIPID LOWERING DRUGS, BRITISH MEDICAL JOURNAL, 300, (1990); PICK, JOHNSON, GLICK, DELETERIOUS EFFECTS OF HYPERTENSION ON THE DEVELOPMENT OF AORTIC AND CORONARY ATHEROSCLEROSIS IN STUMPTAIL MACAQUES (MACACA SPECIOSA) ON AN ATHEROGENIC DIET, CIRCULATION RESEARCH, 35, PP. 472-482, (1974); RENAUD, KINLOUGH, MUSTARD, RELATIONSHIP BETWEEN PLATELET AGGREGATION AND THE THROMBOTIC TENDENCY IN RATS FED HYPERLIPIDEMIC DIETS, LABORATORY INVESTIGATION, 22, (1970); RODRIGUEZ-ECHENIQUE, MESA, MAS, AMOR, CASTANO, ESTUDIO DEL EFECTO SOBRE LOS LIPIDOS Y LIPOPROTEINAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE ATEROMIXOL (PPG) EN MONOS MACACA ARCTOIDES, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEÚTICA, 11, PP. 74-79, (1992); RODRIGUEZ-ECHENIQUE, MESA, MAS, MENENDEZ, CASTANO, GONZALEZ, AMOR, ILLNAIT, VARIACIONES DEL PERFIL LIPIDICO EN MONOS MACACA ARCTOIDES TRATADOS CON POLICOSANOL, REVISTA DE FARMACOLOGIA CLINICA Y EXPERIMENTAL, NȦUMERO ESPECIAL 1992, (1992); RODRIGUEZ-ECHENIQUE, MESA, MAS, MENENDEZ, NOA, GONZALEZ, AMOR, FRAGA, LAGUNA, TOXICOLOGICAL STUDY OF POLICOSANOL LONG-TERM ADMINISTRATION ON MACACA ARCTOIDES MONKEYS, ABSTRACTS OF THE 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ROUSSEL, AUSTIN, IMPROVED ELECTROEJACULATION OF PRIMATES, JOURNAL OF THE INSTITUTE OF ANIMAL TECHNICIANS, 19, PP. 22-32, (1968); SACKETT, INSOLATION REARING IN MONKEYS: DIFFUSE AND SPECIFIC EFFECTS ON LATER BEHAVIOR, ETHOLOGY AND HUMAN BEHAVIOR, PP. 61-110, (1972); SCHETTLER, HABENITCH, ATHEROSCLEROSIS AND CORONARY HEART DISEASE, ARZNEIMITTEL-FORSCHUNG, 39, PP. 948-950, (1989); SEIGLER, WU, SEPARATION OF SERUM HIGH DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLINICAL CHEMISTRY, 27, (1981); SMITH, BYRD, STUDYING THE BEHAVIORAL EFFECTS OF DRUGS IN GROUP-LIVING NONHUMAN PRIMATES, ETHOPHARMACOLOGY: PRIMATE MODELS OF NEUROPSYCHIATRIC DISORDERS, PP. 1-32, (1983); SOLIS, DIFERENCIAS INDIVIDUALES EN LA CONDUCTA SOCIAL DEL MONO VERDE (CORCOPITHECUS AETHIOPS). MSC DISSERTATION IN PSYCHOLOGY, (1985); SPECTOR, NUTRITION, DIGESTION AND METABOLISM, HANDBOOK OF BIOLOGICAL DATA, (1956); SPECTOR, HANDBOOK OF BIOLOGICAL DATA, (1956); VALERIO, LEVERAGE, MUNSTER, SEMEN EVALUATION IN MACAQUES, LABORATORY ANIMAL CARE, 20, PP. 734-740, (1970); VESSELINOVITCH, ANIMAL MODELS AND THE STUDY OF ATHEROSCLEROSIS, ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, 112, PP. 1011-1017, (1988); VESSELINOVITCH, WISSLER, SCHAFFNET, BORENSZTAJN, THE EFFECT OF VARIOUS DIETS ON ATHEROGENESIS IN RHESUS MONKEYS, ATHEROSCLEROSIS, 35, PP. 189-207, (1980); VOSS, SACHSSE, RED CELL AND PLASMA CHOLINESTERASE ACTIVITIES IN MICROSAMPLES OF HUMAN AND ANIMAL BLOOD DETERMINED SIMULTANEOUSLY BY A MODIFIED ACETYLTHIOCHOLINE/DTNB PROCEDURE, TOXICOLOGIC PHARMACOLOGY, 16, PP. 764-772, (1970); WAGNER, SALISBURY, AORTIC TOTAL GLYCOSAMINOGLYCANS AND DERMATAN SULFATE CHANGES IN ATHEROSCLEROTIC RHESUS MONKEYS, LABORATORY INVESTIGATION, 39, PP. 322-328, (1978); WANLESS, THE EFFECT OF DIETARY CHOLESTEROL ON PLATELET SURVIVAL IN THE RABBIT: A STUDY USING C-SEROTONIN AND CHROMIUM DOUBLE-LABELED PLATELETS, THROMBOSIS AND HAEMOSTASIS, 52, (1984)","","","ENGLISH","FOOD CHEM. TOXICOL.","ARTICLE","ISI","2-S2.0-0028122593","FOOD CHEM TOXICOL",NA,"NOTREPORTED",NA,"RODRÍGUEZ-ECHENIQUE C, 1994, FOOD CHEM TOXICOL","RODRÍGUEZ-ECHENIQUE C, 1994, FOOD CHEM TOXICOL"
"DE L A M;CARBAJAL D;MAS R;MOLINA V;VALDES S;LAGUNA A","DE LOURDES ARRUZAZABALA, M. (6603962476); CARBAJAL, D. (8777025000); MAS, R. (7007164572); MOLINA, V. (7006062814); VALDES, S. (8777025100); LAGUNA, A. (7006455910)","CHOLESTEROLLOWERING EFFECTS OF POLICOSANOL IN RABBITS",1994,"BIOLOGICAL RESEARCH","27","3",112,"","DEPARTAMENTO DE FARMACOLOGIA, DIRECCION DE PRODUCTOS NATURALES, CNIC, LA HABANA, AVE. 25 Y 158 CUBANACAN, CUBA;DEPARTAMENTO DE FARMACOLOGIA, DIRECCION DE PRODUCTOS NATURALES, CNIC, LA HABANA, AVE. 25 Y 158 CUBANACAN, CUBA;DEPARTAMENTO DE FARMACOLOGIA, DIRECCION DE PRODUCTOS NATURALES, CNIC, LA HABANA, AVE. 25 Y 158 CUBANACAN, CUBA;DEPARTAMENTO DE FARMACOLOGIA, DIRECCION DE PRODUCTOS NATURALES, CNIC, LA HABANA, AVE. 25 Y 158 CUBANACAN, CUBA;DEPARTAMENTO DE FARMACOLOGIA, DIRECCION DE PRODUCTOS NATURALES, CNIC, LA HABANA, AVE. 25 Y 158 CUBANACAN, CUBA;DEPARTAMENTO DE FARMACOLOGIA, DIRECCION DE PRODUCTOS NATURALES, CNIC, LA HABANA, AVE. 25 Y 158 CUBANACAN, CUBA","POLICOSANOL IS A NATURAL MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS ISOLATED AND PURIFIED FRONT SUGAR CANE (SACCHARUM OFFICINARUM, L.) WAX, WHOSE MAIN COMPONENT IS OCTACOSANOL. POLICOSANOL (5-200 MG/KG) ORALLY ADMINISTERED FOR 4 WEEKS TO NORMOCHOLESTEROLEMIC NEW ZEALAND RABBITS SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) SERUM LEVELS IN A DOSE DEPENDENT MANNER. SERUM TRIGLYCERIDE LEVELS OF TREATED AND CONTROL ANIMALS WERE SIGNIFICANTLY DIFFERENT, BUT THE REDUCTION OBSERVED WAS NOT DOSE-DEPENDENT. HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS REMAINED UNCHANGED. RESULTS INDICATE THAT THE REDUCTION IN TOTAL CHOLESTEROL VALUES INDUCED BY POLICOSANOL IS MAINLY MEDIATED THROUGH A DECREASE IN LDL-C LEVELS.","CHOLESTEROL-LOWERING EFFECTS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; SERUM TRIGLYCERIDE LEVELS","ANIMAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; RABBITS; TRIGLYCERIDES; ALCOHOL DERIVATIVE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTACOSANOL; POLICOSANOL; SUGAR; TRIACYLGLYCEROL; WAX; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL","","","","","","ENGLISH","BIOL. RES.","ARTICLE","ISI","2-S2.0-0028577437","BIOL RES",NA,"NOTREPORTED",NA,"DE LOURDES ARRUZAZABALA M, 1994, BIOL RES","DE LOURDES ARRUZAZABALA M, 1994, BIOL RES"
"CASTAÑO G;MÁS R;ARRUZAZABALA M;NOA M;ILLNAIT J;FERNÁNDEZ J;MOLINA V;MENÉNDEZ A","CASTAÑO, G. (7005759008); MÁS, ROSA (7007164572); ARRUZAZABALA, M.D.L. (6603962476); NOA, M. (7003318964); ILLNAIT, J. (8631465800); FERNÁNDEZ, J.C. (9432805500); MOLINA, V. (7006062814); MENÉNDEZ, A. (57526322000)","EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS",1999,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","19","11",85,"","MEDICAL SURGICAL RESEARCH CENTER, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;PLAZA VETERANS HOUSE, HAVANA, CUBA","THIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFECTS OF POLICOSANOL AND PRAVASTATIN ADMINISTERED AT 10 MG/DAY ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK. AFTER 6 WEEKS ON A LIPID-LOWERING DIET, PATIENTS WITH LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL LEVELS > 3.4 MMOL/L WERE RANDOMIZED TO RECEIVE, UNDER DOUBLE-BLIND CONDITIONS, POLICOSANOL OR PRAVASTATIN 10 MG TABLETS THAT WERE TAKEN WITH THE EVENING MEAL FOR 8 WEEKS. POLICOSANOL SIGNIFICANTLY (P < 0.00001) LOWERED LDL-CHOLESTEROL (19.3%, TOTAL CHOLESTEROL (73.9%) AND THE RATIOS OF LDL-CHOLESTEROL/HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL (28.3%) AND TOTAL CHOLESTEROL/HDL-CHOLESTEROL (24.4%). PRAVASTATIN SIGNIFICANTLY (P < 0.00001) LOWERED LDL-CHOLESTEROL (15.6%), TOTAL CHOLESTEROL (11.8%) AND THE RATIOS (P < 0.0001) OF LDL-CHOLESTEROL/HDL-CHOLESTEROL (18.9%) AND TOTAL CHOLESTEROL/HDL-CHOLESTEROL (15.7%). POLICOSANOL, BUT NOT PRAVASTATIN, SIGNIFICANTLY INCREASED (P < 0.001) LEVELS OF HDL-CHOLESTEROL (18.4%)) AND REDUCED (P < 0.01) TRIGLYCERIDES (14.1%). POLICOSANOL WAS MORE EFFECTIVE (P < 0.05) THAN PRAVASTATIN IN INHIBITING PLATELET AGGREGATION INDUCED BY ALL AGONISTS AND IT SIGNIFICANTLY REDUCED (P < 0.0001) PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID AT 1.5 AND 3 MMOL/L BY 42.2% AND 69.5%, RESPECTIVELY, PLATELET AGGREGATION INDUCED BY COLLAGEN 0.5 ΜG/ML (P < 0.05) (16.6%) AND THAT INDUCED BY ADENOSINE DIPHOSPHATE 1 ΜMOL/L (P < 0.01) (20.3%). PRAVASTATIN SIGNIFICANTLY REDUCED (P < 0.001) (27%) ONLY PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID 3 MMOL/L. BOTH DRUGS SIGNIFICANTLY DECREASED (P < 0.00001) ENDOTHELEMIA LEVELS BUT FINAL VALUES WERE SIGNIFICANTLY LOWER (P < 0.001) IN THE POLICOSANOL THAN IN THE PRAVASTATIN GROUP. BOTH TREATMENTS WERE SAFE AND WELL TOLERATED. PRAVASTATIN SIGNIFICANTLY (P < 0.01) INCREASED SERUM LEVELS OF ALANINE AMINE TRANSFERASE BUT INDIVIDUAL VALUES REMAINED WITHIN NORMAL. TWO PATIENTS ON PRAVASTATIN DISCONTINUED THE STUDY BECAUSE OF ADVERSE EXPERIENCES (MYOCARDIAL INFARCTION AND JAUNDICE, RESPECTIVELY). IN CONCLUSION, THE EFFECTS OF POLICOSANOL (10 MG/DAY) ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK ARE MORE FAVORABLE THAN THOSE INDUCED BY THE SAME DOSES OF PRAVASTATIN.","","AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; MIDDLE AGED; PLATELET AGGREGATION; PRAVASTATIN; TREATMENT OUTCOME; ADENOSINE DIPHOSPHATE; ALANINE AMINOTRANSFERASE; ARACHIDONIC ACID; COLLAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; PRAVASTATIN; TRIACYLGLYCEROL; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BULIMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG TOLERABILITY; ENDOTHELIUM LESION; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; TABLET; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL","","","RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE. THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, (1994); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, (1996); SIMES R.J., BAKER J., MACMAHON S., ET AL., PRAVASTATIN REDUCES TOTAL MORTALITY IN PATIENTS WITH CORONARY HEART DISEASE AND AVERAGE CHOLESTEROL LEVELS: RELATIONSHIP OF BASELINE CHOLESTEROL AND TREATMENT EFFECTS IN THE LIPID TRIAL, PROC. 47TH ANNUAL SCIENTIFIC SESSION OF THE ACC, (1998); PEARSON T.A., MARX H.J., THE RAPID REDUCTION IN CARDIAC EVENTS WITH LIPID-LOWERING THERAPY: MECHANISMS AND IMPLICATIONS, AM. J. CARDIOL., 72, (1993); EFFECT OF SIMVASTATIN ON CORONARY ATHEROMA: THE MULTICENTRE ANTI-ATHEROMA STUDY (MAAS), LANCET, 344, (1994); DAVIGNON J., THE PLEIOTROPIC EFFECTS OF DRUGS AFFECTING LIPID METABOLISM. ATHEROSCLEROSIS XI, PROC. XITH INT. SYMP. ATHEROSCLEROSIS, PP. 63-77, (1997); EGASHIRA K., HIROOKA Y., KAI H., ET AL., REDUCTION IN SERUM CHOLESTEROL WITH PRAVASTATIN IMPROVES ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CIRCULATION, 89, (1994); ANDREW P.L., MCTAVISH D., ATORVASTATIN: A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN THE MANAGEMENT OF HYPERLIPIDAEMIAS, DRUGS, 53, (1997); VAN BOVEN A.J., JUKEMA J.W., ZWINDERMAN A.H., ET AL., REDUCTION OF TRANSIENT MYOCARDIAL ISCHEMIA WITH PRAVASTATIN IN ADDITION TO CONVENTIONAL TREATMENT IN PATIENTS WITH ANGINA PECTORIS, CIRCULATION, 94, (1996); DE DIVITIIS M., RUBBA P., SOMMA S., ET AL., EFFECTS OF SHORT-TERM REDUCTION IN SERUM CHOLESTEROL WITH SIMVASTATIN IN PATIENTS WITH STABLE ANGINA PECTORIS AND MILD TO MODERATE HYPERCHOLESTEROLEMIA, AM. J. CARDIOL., 77, (1996); LUSCHER T.F., BARTON M., BIOLOGY OF THE ENDOTHELIUM, CLIN. CARDIOL., 20, (1997); HOLLER H., ENDOTHELIAL FUNCTION: GENERAL CONSIDERATIONS, DRUGS, 53, SUPPL., (1997); AMES B.N., SHIGENAGA M.K., OXIDANTS ARE A MAJOR CONTRIBUTOR TO AGING, ANN. N.Y. ACAD. SCI., 663, (1992); NASR A., BRECKWOLDT M., REVIEW: ESTROGEN REPLACEMENT THERAPY AND CARDIOVASCULAR PROTECTION, LIPID MECHANISMS ARE THE TIP OF AN ICEBERG, GYNECOL. ENDOCRINOL., 12, (1998); DAVIS J.W., LEWIS D., FRANCIS-OLIVER A., PREVENTION OF EXERCISE-INDUCED ENDOTHELIOMA BY ISRADIPINE IN MEN WITH ANGINA PECTORIS, CARDIOLOGY, 84, (1994); STAMLER J.S., VAUGHAN D.E., COSCALZO J., SYNERGISTIC DESEGREGATION ON PLATELETS BY TISSUE-TYPE PLASMINOGEN ACTIVATOR, PROSTAGLANDIN E AND NITROGLYCERIN, CIRC. RES., 65, (1989); DAVI G., AVERNA M., CATALANO I., ET AL., INCREASED THROMBOXANE BIOSYNTHESIS IN TYPE IIA HYPERCHOLESTEROLEMIA, CIRCULATION, 85, (1992); FITZGERALD D.J., ROY L., CATELLA F., ET AL., PLATELET ACTIVATION IN UNSTABLE CORONARY DISEASE, N. ENGL. J. MED., 315, (1986); LACOSTE L., LAM J.Y.T., COMPARATIVE EFFECT OF PRAVASTATIN AND SIMVASTATIN ON PLATELET-THROMBUS FORMATION IN HYPERCHOLESTERLEMIC CORONARY PATIENTS, J. AM. COLL. CARDIOL., 27, (1996); LACOSTE L., LAM J.Y.T., HUNG J., ET AL., HYPERLIPIDEMIA AND CORONARY DISEASE CORRECTION OF THE INCREASED THROMBOGENIC POTENTIAL WITH CHOLESTEROL REDUCTION, CIRCULATION, 92, (1995); NOTARBARTOLO A., DAVI G., AVERNA M., ET AL., INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA, ARTERIOESCLER. THROMB. VASC. BIOL., 15, (1995); MCTAVISH D., SORKIN E.M., PRAVASTATIN. A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLAEMIA, DRUGS, 42, (1991); HARIA M., MCTAVISH D., PRAVASTATIN: A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFECTIVENESS IN THE MANAGEMENT OF CORONARY HEART DISEASE, DRUGS, 53, (1997); MELLIES M.J., DE VAULT A.R., KASSLER-TAUB K., ET AL., PRAVASTATIN EXPERIENCE IN ELDERLY AND NON-ELDERLY PATIENTS, ATHEROESCLEROSIS, 101, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV. THER., 12, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES IN SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, (1996); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR. THER RES., 58, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 59, (1998); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); PONS P., JIMENEZ A., RODRIGUEZ M., ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR. THER. RES., 53, (1993); CASTANO G., CANETTI M., MORERA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR. THER. RES., 56, (1995); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPER-CHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, (1996); ARRUZAZABALA M.D.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESIVE DOSE INCREASE ON PLATELET AGGREGATION HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, (1996); SCAZZIOTA A., PONS P., ALTMAN R., EFECTO DEL POLICOSANOL SOBRE LA FUNCIÓN DE LAS PLAQUETAS EN VOLUNTARIOS SANOS, REV. IBEROAMER. TROMB. HEMOST., 9, (1996); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 58, (1998); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT. J. TISS. REACT., 20, (1998); ARRUZAZABALA M.D.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, (1997); FRAGA V., MENENDEZ R., AMOR A.M., ET AL., EFFECT OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH. MED. RES., 28, (1997); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT. J. CARDIO., 67, (1998); RODRIGUEZ C., MESA R., MAS R., ET AL., EFFECT OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM. TOXICOL., 32, (1994); NOA M., MAS R., DE LA ROSA M.C., ET AL., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RATS, J. PHARM. PHARMACOL., 47, (1995); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, (1998); MAS R., RIVAS P., IZQUIERDO E., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, (1999); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE, 194, (1962); HLADOVEC J., ROSSMANN P., CIRCULATING ENDOTHELIAL CELLS ISOLATED TOGETHER WITH PLATELETS AND THE EXPERIMENTAL MODIFICATION OF THEIR COUNTS IN RATS, THROMB. RES., 3, (1973); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN. REVIEW OF AN NHLBI WORKSHOP, ANN. EPIDEMIOL., 2, (1992); MASAKI K.M., PETROVITCH H., RODRIGUEZ B.L., ET AL., THE VALUE OF RISK FACTOR MODIFICATION IN OLD AGE, CARDIOL ELDERLY, 1, (1993); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, (1993); PYRALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, (1994); ATHEROSCLEROSIS, 110, (1994); DOUGHERTY J.H. JR., LEVY D.E., WESKLEER B.B., PLATELET ACTIVATION ON ACUTE CEREBRAL ISCHEMIC SERIAL MEASUREMENTS OF PLATELET FUNCTION IN CEREBROVASCULAR DISEASE, LANCET, 309, (1997); KOUDSTAAD P.J., CEABATTIONI G., VAN GIJN J., ET AL., INCREASED THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CEREBRAL ISCHEMIA, STROKE, 24, (1993); ARRJZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV. IBEROAMER. TROMB. HEMOST., 5, (1992); ARRUZAZABALA M.L., CARBAJAL D., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB>, PROSTAGLANDINS LEUKOT. ESSENT. FATTY ACIDS, 49, (1993); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL IN CIRCULATING ENDOTHELIAL CELLS IN EXPERIMENTAL MODELS IN SPRAGUE DAWLEY RATS AND IN RABBITS, J. PHARM. PHARMACOL., 49, (1997)","R. MAS; CENTER FOR NATURAL PRODUCTS, NATIONAL CENTER SCIENTIFIC RESEARCH, HAVANA, PO BOX 6990, CUBA; EMAIL: DALMER@IP.ETECSA.CU","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0343526455","INT J CLIN PHARMACOL RES","MEDICAL SURGICAL RESEARCH CENTER;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATIONAL CENTER SCIENTIFIC RESEARCH;NOTREPORTED",NA,"CASTAÑO G, 1999, INT J CLIN PHARMACOL RES","CASTAÑO G, 1999, INT J CLIN PHARMACOL RES"
"MENENDEZ R;AMOR A;GONZALEZ R;FRAGA V;MAS R","MENENDEZ, ROBERTO (7102205059); AMOR, ANA M. (35569426800); GONZALEZ, ROSA M. (57191737509); FRAGA, VIVIAN (6602491407); MAS, ROSA (7007164572)","EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS",1996,"BIOLOGICAL RESEARCH","29","4",61,"","CUBANACÁN, PLAYA, LA HABANA, AVENIDA 25 Y 158, CUBA;LA HABANA, CUBA;LA HABANA, CUBA;LA HABANA, CUBA;LA HABANA, CUBA","WE HAVE SUGGESTED PREVIOUSLY, MEASURING 14C-ACETATE INCORPORATION INTO FREE CHOLESTEROL, THAT ORAL ADMINISTRATION OF POLICOSANOL INHIBITS HEPATIC CHOLESTEROL BIOSYNTHESIS IN RATS. NEVERTHELESS, SINCE ACETATE HAS LIMITATIONS TO STUDY CHOLESTEROL SYNTHESIS IN VIVO, WE NOW INVESTIGATE RATES OF INCORPORATION OF LABELED WATER INTO HEPATIC STEROL AFTER POLICOSANOL TREATMENT. ABSOLUTE RATES OF INCORPORATION OF 3H-WATER IN STEROLS WERE DEPRESSED BY POLICOSANOL BY ABOUT 20%, GIVING A MORE ACCURATE DEGREE OF CHOLESTEROL BIOSYNTHESIS INHIBITION IN THIS SPECIES. SINCE POLICOSANOL DID NOT INHIBIT LABELED MEVALONATE INCORPORATION INTO CHOLESTEROL IN RAT LIVER, WE ALSO STUDIED THE EFFECT OF POLICOSANOL ON HYDROXY-METHLGLUTARYL-COENZYME A (HMG-COA) REDUCTASE. REDUCTASE ACTIVITY ASSAYED IN MICROSOMES TREATED WITH POLICOSANOL REMAINED UNCHANGED, SUGGESTING THAT CHOLESTEROL SYNTHESIS IS NOT INHIBITED BY A DIRECT ACTION OF POLICOSANOL ON THIS ENZYME.","CHOLESTEROL BIOSYNTHESIS; HEPATIC STEROL; POLICOSANOL; RAT LIVER","ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; FATTY ALCOHOLS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIVER; MALE; MICROSOMES; RATS; RATS, WISTAR; ACETIC ACID; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; POLICOSANOL; STEROL; WATER; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT","","","ANDERSEN J.M., DIETSCHY J., ABSOLUTE RALES OF CHOLESTEROL SYNTHESIS IN EXTRAHEPATIC TISSUES MEASURED WITH <SUP>3</SUP>H-LABELED WATER AND <SUP>14</SUP>C-LABELED SUBSTRATES, J LIPID RES, 20, PP. 740-752, (1979); ANEIROS E., CALDERON E., MAS R., ILLNAIT J., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-412, (1993); ANEIROS E., MAS R., CALDERON E., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CENTRO NACIONAL INVEST CIENTÍF, 22, PP. 60-61, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALUES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-207, (1994); BROWN M.S., GOLDSTEIN M.S., DIETSCHY J.M., ACTIVE AND INACTIVE FORMS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE IN THE LIVER OF THE RAT: COMPARISON WITH THE RATE OF CHOLESTEROL SYNTHESIS IN DIFFERENT PHYSIOLOGICAL STATES, J BIOL CHEM, 254, PP. 5144-5149, (1979); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE A DAY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CRUZ-BUSTILLO D., MEDEROS R., MAS R., ARRUZAZABALA M.L., LAGUNA A., BARRETO B., MARTINEZ O., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) SOBRE EL CERDO EN CEBA, REV CENTRO NACIONAL INVEST CIENTÍF, 22, PP. 62-63, (1991); DIETSCHY J.M., MCGARRY J.D., LIMITATIONS OF ACETATE AS A SUBSTRATE FOR MEASURING CHOLESTEROL SYNTHESIS IN LIVER, J BIOL CHEM, 10, PP. 52-58, (1974); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); JESKE D.J., DIETSCHY J.M., REGULATION OF RATES OF CHOLESTEROL SYNTHESIS IN VIVO IN THE LIVER AND CARCASS OF THE RAT MEASURED USING <SUP>3</SUP>H-WATER, J LIPID RES, 21, PP. 364-375, (1980); LOWRY O.H., ROSEBROUGH N.J., FARR A.L., RANDALL R.J., PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT, J BIOL CHEM, 193, PP. 265-275, (1951); MENENDEZ R., FERNANDEZ S., DEL RIO A., GONZALEZ R., FRAGA V., AMOR A., MAS R., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCED LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 103-107, (1994); MENENDEZ R., SOTOLONGO V., GONZALEZ R., AMOR A., FRAGA V., EFECTO DEL POLICOSANOL SOBRE EL METABOLISME LIPÍDICO EN RATAS NORMOCOLESTEROLÉMICAS, REV MEX FARM, 24, PP. 16-18, (1993); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1993); PONS P., RODRIGUEZ M., MAS R., ILLNAIT J., FERNANDEZ L., ROBAINA C., FERNANDEZ J.C., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., AMOR A., CASTANO G., ESTUDIO DEL EFECTO SOBRE LOS LIPIDOS Y LIPOPROTEÍNAS SÉRICOS Y LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DEL ATEROMIXOL EN MONOS MACACA ARCTOIDES, ARCH VEN FARMACOL TERAP, 11, PP. 74-79, (1991); SOLTERO I., FUENTEMAYOR I., COLMENARES J., ESTUDIO A DOBLE CIEGO PARA LA EVALUACIÓN DEL POLICOSANOL EN EL TRATAMIENTO DE LA HIPERLIPOPROTEINEMIA TIPO II, ARCH VEN FARMACOL TERAP, 12, PP. 65-70, (1993); SPADY D., DIETSCHY J., STEROL SYNTHESIS IN VIVO IN 18 TISSUES OF THE SQUIRREL MONKEY, GUINEA PIG, RABBIT, HAMSTER AND RAT, J LIPID RES, 24, PP. 303-315, (1983); TURLEY S.P., ANDERSEN J.M., DIETSCHY J.M., RATES OF STEROL SYNTHESIS AND UPTAKE IN THE MAJOR ORGANS OF THE RAT IN VIVO, J LIPID RES, 22, PP. 551-567, (1981)","","","ENGLISH","BIOL. RES.","ARTICLE","ISI","2-S2.0-0029973317","BIOL RES",NA,"NOTREPORTED",NA,"MENENDEZ R, 1996, BIOL RES","MENENDEZ R, 1996, BIOL RES"
"ZARDOYA R;TULA L;CASTAÑO G;MÁS R;ILLNAIT J;FERNÁNDEZ J;DÍAZ E;FERNÁNDEZ L","ZARDOYA, RAMIRO (18736684200); TULA, LEONEL (9434741100); CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164570); ILLNAIT, JOSE (8631465800); FERNÁNDEZ, JULIO C. (9432805500); DÍAZ, EDUARDO (16738702300); FERNÁNDEZ, LILIA (7202848319)","EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION",1996,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","57","9",56,"10.1016/S0011-393X(96)80068-3","CARLOS J. FINLAY HOSPITAL, HAVANA CITY, CUBA;LUIS DÍAZ SOTO HOSPITAL, HAVANA CITY, CUBA;CENTER FOR MEDICAL-SURGICAL RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","FORTY-SIX PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION WERE INCLUDED IN A 12-WEEK, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL 5 OR 10 MG/D. PATIENTS FOLLOWED A STANDARD CHOLESTEROL-LOWERING DIET FOR AT LEAST 6 WEEKS AND WERE THEN RANDOMIZED TO RECEIVE POLICOSANOL OR PLACEBO TABLETS. ALL GROUPS WERE STATISTICALLY SIMILAR AT RANDOMIZATION. THE STUDY OF THE 5-MG DOSE COMPRISED 24 PATIENTS. IN THIS STUDY, POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (13.6%), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (19.1%), AND THE RATIOS OF CHOLESTEROL:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) (21.1%) AND LDL-C:HDL-C (25.5%). HDL-C INCREASED SIGNIFICANTLY BY 11.5%, WHILE TRIGLYCERIDES DID NOT CHANGE SIGNIFICANTLY. THE STUDY OF THE 10-MG DOSE COMPRISED 22 PATIENTS. POLICOSANOL SIGNIFICANTLY LOWERED TOTAL CHOLESTEROL (15.4%), LDL-C (22.3%), AND THE CHOLESTEROL:HDL-C (26.1%) AND LDL-C:HDL-C (32.2%) RATIOS. THE INCREASE IN HDL-C LEVELS (17.9%) TENDED TOWARD SIGNIFICANCE, WHILE THE CHANGES IN TRIGLYCERIDE LEVELS WERE NOT SIGNIFICANT. THE LIPID PROFILE OF THE PLACEBO GROUP WAS NOT CHANGED SIGNIFICANTLY; NO CLINICAL, BIOCHEMICAL, OR HEMATOLOGIC ADVERSE EFFECTS WERE OBSERVED; AND THE LIVER FUNCTION INDICATORS THAT WERE ABNORMAL AT BASELINE HAD NOT DETERIORATED FURTHER. NO PATIENT WITHDREW FROM THE STUDY BECAUSE OF ADVERSE EVENTS. SEVEN PATIENTS (FOUR FROM THE PLACEBO GROUP AND THREE FROM THE POLICOSANOL GROUP) REPORTED AT LEAST ONE ADVERSE EXPERIENCE, ALL OF WHICH WERE MILD AND TRANSIENT. THE COMPARISONS BETWEEN GROUPS DID NOT SHOW ANY SIGNIFICANT DIFFERENCES. THE RESULTS DEMONSTRATE THAT POLICOSANOL IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION. © 1996, ALL RIGHTS RESERVED.","","ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; BIOCHEMICAL MARKER; CHOLESTEROL; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; URIC ACID; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DYSFUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO","","","LIPID RESEARCH CLINICS PROGRAM. LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); LIPID RESEARCH CLINICS PROGRAM. LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); TIKKANEN MJ, NIKKILA EA, CURRENT PHARMACOLOGIC TREATMENT OF ELEVATED SERUM CHOLESTEROL, CIRCULATION, 76, PP. 529-533, (1987); O'CONNOR P, FEELY J, SHEPHERD J, LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); OELBAUM RS, GALTON DJ, MANAGEMENT OF HYPERCHOLESTEROLAEMIA, CURRENT OPINION IN CARDIOLOGY, 3, PP. 255-263, (1988); TOBERT JA, NEW DEVELOPMENTS IN LIPID-LOWERING THERAPY: THE ROLE OF INHIBITORS OF HYDROXYMETHYL-GLUTARYL-COENZYME A REDUCTASE, CIRCULATION, 76, PP. 534-538, (1987); TOBERT JA, EFFICACY AND LONG-TERM ADVERSE EFFECT PATTERN OF LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 62, PP. 28J-34J, (1988); TOBERT JA, SHEAR CL, CHREMOS AN, ET AL., CLINICAL EXPERIENCE WITH LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 65, PP. 23F-26F, (1990); MANTELL G, BURKE T, STAGGERS J, EXTENDED CLINICAL SAFETY PROFILE OF LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 66, PP. 11B-15B, (1990); MCTAVISH D, SORKIN EM, PRAVASTATIN. A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLAEMIA, DRUGS, 42, PP. 65-89, (1991); SIRTORI CR, MANZONI C, LOVATI MR, MECHANISMS OF LIPID-LOWERING AGENTS, CARDIOLOGY, 78, PP. 226-235, (1991); WALKER JF, SIMVASTATIN: THE CLINICAL PROFILE, AM J MED, 87, PP. 445-465, (1989); YALE BM, THE LONG-TERM TOLERABILITY PROFILE OF LOVASTATIN AND SIMVASTATIN, ATHEROSCLEROSIS, 97, (1992); ARRUZAZABALA DE IM, CARBAJAL D, MAS R, ET AL., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTE-ROLÉMICOS, ARCH VENEZOL FARMACOL TERAP, 11, PP. 80-86, (1992); ARRUZAZABALA DE IM, CARBAJAL D, MAS R, ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL IN RABBITS, BIOL RES, 27, PP. 205-208, (1994); CRUZ-BUSTILLO D, MEDEROS CM, MAS R, ET AL., EFECTO HIPOCOLESTEROLÉMICO DEL POLICOSANOL EN EL CERDO EN CEBA, REV CENIC CIEN BIOL, 22, PP. 62-63, (1991); RODRIGUEZ C, MESA R, MAS R, ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP, 11, PP. 74-79, (1992); HERNANDEZ F, ILLNAIT J, MAS R, ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G, ZARDOYA R, ILLNAIT J, ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROG CIEN MED, 5, PP. 21-28, (1991); CASTANO G, MAS R, NODARSE M, ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 56, PP. 296-304, (1995); ANEIROS E, CALDERON B, MAS R, ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY, CURR THER RES, 54, PP. 304-312, (1993); ANEIROS E, MAS R, CALDERON B, ET AL., POLICOSANOL FOR CHOLESTEROL-LOWERING LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 166-182, (1995); PONS P, ILLNAIT J, RODRIGUEZ M, ET AL., EFFICACY AND SAFETY OF ATEROMIXOL (POLICOSANOL) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P, RODRIGUEZ M, ROBAINA C, ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P, ILLNAIT J, RODRIGUEZ M, ET AL., EFFECTS OF ATEROMIXOL (POLICOSANOL) IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); PONS P, RODRIGUEZ M, MAS R, ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, PP. 1084-1092, (1994); TORRES O, AGRAMONTE AJ, ILLNAIT J, ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); FERNANDEZ SI, RENDON A, DE LAS CAJIGAS A, ET AL., ESTUDIO GENOTÓXICO DEL ATEROMIXOL (PPG), UN NUEVO MEDICAMENTO HIPOLIPEMIANTE, REV CENIC CIEN BIOL, 22, PP. 98-101, (1991); ALEMAN CL, MAS R, NOA M, ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24-MONTH STUDY, TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS, 14, PP. 239-249, (1994); ALEMAN CL, NOA M, CEREJODI E, ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD AND CHEMICAL TOXICOLOGY, 33, PP. 573-578, (1995); ALEMAN CL, MAS R, HERNANDEZ C, ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); RODRIGUEZ C, MESA R, MAS R, ET AL., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); MESA AR, MAS R, NOA M, ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT., 73, PP. 81-90, (1994); SEIGLER L, WU WT, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD WT, LEVY RI, FREDERICKSON SD, ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); ILLINGWORTH DR, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0029945522","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"ZARDOYA R, 1996, CURR THER RES CLIN EXP","ZARDOYA R, 1996, CURR THER RES CLIN EXP"
"MARCELLO S;GLADSTEIN J;TESONE P;MÁS R","MARCELLO, SUSANA (57212968291); GLADSTEIN, JULIO (6701715271); TESONE, PEDRO (6603284821); MÁS, ROSA (7007164572)","EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA A PILOT STUDY",2000,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","61","11",11,"10.1016/S0011-393X(00)80004-1","BUENOS AIRES, ARGENTINA;BUENOS AIRES, ARGENTINA;BUENOS AIRES, ARGENTINA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA","OBJECTIVE: THE GOAL OF THIS RANDOMIZED, DOUBLE-BLIND, CLINICAL PILOT STUDY WAS TO COMPARE THE EFFICACY AND TOLERABILITY OF THE COMBINATION THERAPY BEZAFIBRATE PLUS POLICOSANOL VERSUS BEZAFIBRATE PLUS PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA. METHODS: AFTER 6 WEEKS OF A STANDARD LIPID-LOWERING DIET, 29 PATIENTS WERE ASSIGNED RANDOMLY TO RECEIVE, UNDER DOUBLE-BLIND CONDITIONS, BEZAFIBRATE 400 MG/D PLUS POLICOSANOL 10 MG/D OR BEZAFIBRATE 400 MG/D PLUS PLACEBO. TREATMENTS WERE TAKEN ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. RESULTS: BEZAFIBRATE PLUS POLICOSANOL SIGNIFICANTLY REDUCED LEVELS OF TOTAL CHOLESTEROL (TC) (20.8%; P < 0.001), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (27.7%; P < 0.001), TRIGLYCERIDES (30.2%; P < 0.001), AND THE ATHEROGENIC RATIOS OF LDL-C TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL- C) (36.8%) AND TC TO HDL-C (29.8%). BEZAFIBRATE PLUS PLACEBO SIGNIFICANTLY LOWERED LEVELS OF TC (9.2%; P < 0.05), LDL-C (10.7%; P < 0.05), TRIGLYCERIDES (29.2%; P < 0.001), AND BOTH ATHEROGENIC RATIOS (LDL-C TO HDL-C [13.3%] AND TC TO HDL-C [13.8%][P < 0.05]). LEVELS OF HDL-C INCREASED SIGNIFICANTLY IN BOTH GROUPS (BY 14.5% [P < 0.01] AFTER BEZAFIBRATE PLUS POLICOSANOL THERAPY AND BY 8.0% [P < 0.05] AFTER BEZAFIBRATE PLUS PLACEBO THERAPY). BETWEEN-GROUP COMPARISONS SHOWED THAT PERCENTAGE REDUCTIONS OF TC, LDL-C, HDL-C, AND ATHEROGENIC INDICES WERE SIGNIFICANTLY LARGER IN THE BEZAFIBRATE PLUS POLICOSANOL GROUP THAN IN THE BEZAFIBRATE PLUS PLACEBO GROUP. NONE OF THE OTHER BETWEEN-GROUP DIFFERENCES WERE SIGNIFICANT. THERE WERE NO DRUG-RELATED EFFECTS ON SAFETY INDICATORS. THE COMBINATION OF BEZAFIBRATE AND POLICOSANOL WAS VERY WELL TOLERATED. NO PATIENT DISCONTINUED THE STUDY BECAUSE OF ADVERSE EFFECTS AND ONLY 1 PATIENT WHO WAS RECEIVING BEZAFIBRATE PLUS PLACEBO REPORTED A MILD ADVERSE EFFECT (SKIN DRYNESS) DURING THE STUDY. CONCLUSIONS: WE CONCLUDED THAT THE COADMINISTRATION OF POLICOSANOL AND BEZAFIBRATE COMBINED THE BENEFITS OF BOTH DRUGS ON PATIENTS' LIPID PROFILES AND THAT THE SAFETY AND TOLERABILITY OF THIS COMBINATION WAS VERY GOOD. FURTHER CLINICAL STUDIES USING LARGER SAMPLE SIZES MUST BE CONDUCTED TO CORROBORATE THESE RESULTS.","BEZAFIBRATE; COMBINATION THERAPY; DYSLIPIDEMIA; POLICOSANOL","BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; HUMAN; LIPID ANALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N ENGL J MED., 317, PP. 1237-1245, (1987); ANDERSON K.M., WILSON P.W.F., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N ENGL J MED., 335, PP. 1001-1009, (1996); TONKIN A., A LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID), VORTRAG AUF DER 70 JAHRSTAGUNG DER AMERICAN HEART ASSOCIATION (AHA), 12, (1997); SHEPHERD S., COBBE S.M., CHRISTOPHER G., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED., 333, PP. 1301-1307, (1995); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); LIPID HANDBOOK FOR CLINICAL PRACTICE, BLOOD LIPIDS AND CORONARY HEART DISEASE, (1995); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR HEART J., 15, PP. 1300-1331, (1994); CRIQUI M.H., HEISS G., COHN K., ET AL., PLASMA TRIGLYCERIDE LEVEL AND MORTALITY FROM CORONARY HEART DISEASE, N ENGL J MED., 328, PP. 1220-1225, (1993); FREEDMAN D.S., GRUCHOW H.W., ANDERSON A.J., ET AL., RELATION OF TRIGLYCERIDE LEVELS TO CORONARY ARTERY DISEASE: THE MILWAUKEE CARDIOVASCULAR DATA REGISTRY, AM J EPIDEMIOL., 127, PP. 1118-1130, (1988); DURRINGTON P.N., CAN WE AFFORD TO TREAT HYPERLIPIDAEMIA AS WE SHOULD? STRATEGIES FOR RATIONAL TREATMENT, ATHEROSCLEROSIS, 139, SUPPL. 1, (1998); BHATNAGAR D., LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDAEMIA, PHARMACOL THER., 79, PP. 205-230, (1998); FARMER J.A., GOTTO A.M., CHOOSING THE RIGHT LIPID-REGULATING AGENT. A GUIDE TO SELECTION, DRUGS, 52, PP. 649-661, (1996); GAW A., PACKARD C.J., SHEPHERD J., FIBRATES, PRINCIPLES AND TREATMENT OF LIPOPROTEIN DISORDERS. HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, PP. 325-348, (1994); KUMAR S., DURRINGTON P.N., BHATNAGAR D., LAING I., SUPPRESSION OF NONESTERIFIED FATTY ACIDS TO TREAT TYPE A INSULIN RESISTANCE SYNDROME, LANCET, 343, PP. 1073-1074, (1994); SHEPHERD J., THE FIBRATES IN CLINICAL PRACTICE: FOCUS ON MICRONISED FENOFIBRATE, ATHEROSCLEROSIS, 110, SUPPL. 1, (1994); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED., 100, PP. 197-204, (1996); TOBERT J.A., EFFICACY AND LONG-TERM ADVERSE EFFECT PATTERN OF LOVASTATIN, AM J CARDIOL., 62, (1988); MARAIS G.E., LARSON K.K., RHABDOMYOLYSIS AND ACUTE RENAL FAILURE INDUCED BY COMBINATION LOVASTATIN AND GEMFIBROZIL THERAPY, ANN INTERN MED., 112, PP. 228-230, (1990); PIERCE L.R., WYSOWSKI D.K., GROSS T.P., MYOPATHY AND RHABDOMYOLYSIS ASSOCIATED WITH LOVASTATIN-GEMFIBROZIL COMBINATION THERAPY, JAMA, 264, PP. 71-75, (1990); LEITERSDORF E., MURATTI E.N., ELIAV O., ET AL., EFFICACY AND SAFETY OF A COMBINATION FLUVASTATIN-BEZAFIBRATE TREATMENT FOR FAMILIAL HYPERCHOLESTEROLEMIA: COMPARATIVE ANALYSIS WITH A FLUVASTATIN-CHOLESTYRAMINE COMBINATION, AM J MED., 96, PP. 401-407, (1994); MONK J.P., TODD P.A., BEZAFIBRATE. A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN HYPERLIPIDAEMIA, DRUGS, 33, PP. 539-576, (1987); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLAESTEROLAEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES., 15, PP. 159-165, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES IN SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES., 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES., 58, PP. 859-867, (1997); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER., 65, PP. 6-14, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES., 58, PP. 44-51, (1997); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES., 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR., 77, PP. 923-932, (1997); CASTANO G., MAS R., TABARES I., ET AL., ESTUDIO COMPARATIVO DEL POLICOSANOL, GEMFIBROZIL Y LA TERAPIA COMBINADA POLICOSANOL-GEMFIBROZIL EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA TIPO II. REV, CENIC CIEN BIOL., 29, PP. 17-23, (1998); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN CHEM., 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FREDRICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA, WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM., 18, PP. 499-502, (1972); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV., 67, PP. 1-7, (1999); MENENDEZ R., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL.; BARTER P.J., RYE K.A., CLAY M.A., ET AL., ANTIATHEROGENIC EFFECTS OF HIGH-DENSITY LIPOPROTEINS: MECHANISM. ATHEROSCLEROSIS XI, PROCEEDINGS OF THE XITH INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, PP. 811-816, (1997)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0033921769","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"MARCELLO S, 2000, CURR THER RES CLIN EXP","MARCELLO S, 2000, CURR THER RES CLIN EXP"
"MENÉNDEZ R;MÁS R;AMOR A;GONZÁLEZ R;FERNÁNDEZ J;RODEIRO I;ZAYAS M;JIMÉNEZ S","MENÉNDEZ, ROBERTO (7102205059); MÁS, ROSA (7007164572); AMOR, ANA MA. (35569426800); GONZÁLEZ, ROSA MA. (57191737509); FERNÁNDEZ, JULIO C. (9432805500); RODEIRO, IDANIA (6602314378); ZAYAS, MIRTA (24323402600); JIMÉNEZ, SONIA (19735040200)","EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN LDL ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO",2000,"BRITISH JOURNAL OF CLINICAL PHARMACOLOGY","50","7",91,"10.1046/j.1365-2125.2000.00250.x","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA, SOTO DEL VALLE, CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, PO BOX 6880, CUBA","AIMS: THE AIM OF THIS STUDY WAS TO INVESTIGATE THE EFFECT OF POLICOSANOL ON THE SUSCEPTIBILITY OF LDL-C TO IN VITRO LIPID PEROXIDATION IN HUMAN HEALTHY VOLUNTEERS. METHODS: THE EFFECT OF POLICOSANOL (5 AND 10 MG DAY-1) ON LDL-C OXIDATION WAS STUDIED IN A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL CONDUCTED IN 69 SUBJECTS. LDL-C SAMPLES ISOLATED AT BASELINE AND AFTER 8 WEEKS WERE SUBJECTED TO IN VITRO TESTS OF LDL-C OXIDATION. WE TESTED THE SUSCEPTIBILITY OF LDL-C TO LIPID PEROXIDATION IN A CELL-FREE SYSTEM BY THE ADDITION OF COPPER IONS AS WELL AS IN A MORE PHYSIOLOGICAL SYSTEM, MACROPHAGE-MEDIATED OXIDATION. RESULTS: AT BASELINE ALL GROUPS WERE WELL MATCHED REGARDING ALL VARIABLES. AFTER 8 WEEKS OF THERAPY POLICOSANOL ADMINISTERED AT 5 AND 10 MG, SIGNIFICANTLY AND IN A DOSE-DEPENDENT MANNER INCREASED THE LAG PHASE OF CONJUGATED DIENE GENERATION (MEAN ± S.D.) FROM 83.79 ± 29.16 MIN TO 94.90 ± 25.50 MIN (5 MG DAY-1) AND FROM 82.74 ± 17.16 MIN TO 129.89 ± 35.71 MIN (10 MG DAY-1), WHILE IN THE PLACEBO GROUP LDL-C OXIDATION DID NOT CHANGE SIGNIFICANTLY. POLICOSANOL (10 MG DAY-1), BUT NOT PLACEBO, SIGNIFICANTLY DECREASED THE RATE OF CONJUGATED DIENE GENERATION. COMPARISON WITH PLACEBO AFTER THERAPY ALSO SHOWED SIGNIFICANT DIFFERENCES. MACROPHAGE MEDIATED-OXIDATION WAS ALSO INHIBITED BY POLICOSANOL AS EVIDENT BY MEASURING THIOBARBITURIC ACID REACTIVE SUBSTANCES (TBARS). POLICOSANOL (10 MG DAY-1) SIGNIFICANTLY LOWERED MALONDIALDEHYDE (MDA) GENERATION FROM 8.50 ± 0.91 TO 5.76 ± 1.01 NMOL MG PROTEIN. COMPARISON WITH PLACEBO AFTER 5 AND 10 MG DAY-1 SHOWED SIGNIFICANT DIFFERENCES. POLICOSANOL SIGNIFICANTLY LOWERED TOTAL CHOLESTEROL BY 10.5% (5 MG DAY-1) AND 12.4% (10 MG DAY-1) AND LDL-C BY 16.7% AND 20.2%, RESPECTIVELY. ALSO, POLICOSANOL (10 MG DAY-1) INCREASED HDL-C BY 15.2%. FIVE SUBJECTS WITHDREW FROM THE STUDY, NONE BECAUSE OF ADVERSE EXPERIENCES. NO CLINICAL OR BLOOD BIOCHEMICAL DRUG-RELATED DISTURBANCES WERE FOUND. CONCLUSIONS: THE PRESENT STUDY DEMONSTRATED THAT POLICOSANOL ADMINISTERED WITHIN ITS THERAPEUTIC DOSAGE FOR LOWERING CHOLESTEROL (5 AND 10 MG DAY-1), DECREASED THE SUSCEPTIBILITY OF LDL-C TO LIPID PEROXIDATION IN VITRO.","COPPER-MEDIATED OXIDATION; HEALTHY VOLUNTEERS; LDL LIPID PEROXIDATION; MACROPHAGE-MEDIATED OXIDATION; POLICOSANOL","ADULT; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COPPER; FATTY ALCOHOLS; FEMALE; HUMANS; KINETICS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; OXIDATION-REDUCTION; ALKADIENE; COPPER ION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLACEBO; POLICOSANOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; ADULT; ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","FRICK M.E., ELO O., HAAPA K., HELSINKI HEART STUDY: PRIMARY INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE AGED MEN WITH DISLYPIDEMIA, N ENGL J MED, 317, PP. 1237-1245, (1987); THE LIPID RESEARCH CLINICS PRIMARY PREVENTION TRIAL RESULT. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULT. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, JAMA, 251, PP. 365-374, (1984); RANDOMIZED TRIAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE. THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); ESTERBAUER H., GEBICKI J., PUHL H., LIPID PEROXIDATION AND ITS ROLE IN ATHEROSCLEROSIS, BR MED BULL, 49, PP. 566-576, (1993); WITZTUM J.L., STEINBERG D., ROLE OF OXIDIZED LOW DENSITY LIPOPROTEIN IN ATHEROGENESIS, J CLIN INVEST, 88, PP. 1785-1792, (1991); STEINBRECHER U.P., OXIDATION OF HUMAN LOW DENSITY LIPOPROTEIN RESULTS IN DERIVATIZATION OF LYSINE RESIDUES OF APOLIPOPROTEIN B BY LIPID PEROXIDE DECOMPOSITION PRODUCTS, J BIOL CHEM, 262, PP. 3603-3608, (1987); BROWN M.S., GOLDSTEIN J.L., LIPOPROTEIN METABOLISM IN THE MACROPHAGE: IMPLICATION FOR CHOLESTEROL DEPOSITION IN ATHEROSCLEROSIS, ANN REV BIOCHEM, 52, PP. 223-261, (1993); LEAKE D.S., EFFECTS OF MILDLY OXIDIZED LOW DENSITY LIPOPROTEIN ON ENDOTHELIAL CELL FUNCTION, CURR OPIN LIPIDOL, 2, PP. 301-305, (1991); CHILSOM G.M., CYTOTOXICITY OF OXIDIZED LIPOPROTEINS, CURR OPIN LIPIDOL, 2, PP. 311-316, (1991); SCHMIDT K., GRAIER W.F., KOSTNER G.M., MAYER B., KUKOVETZ W.R., ACTIVATION OF SOLUBLE GUANYLATE CYCLASE BY NITROVASODILATORS IS INHIBITED BY OXIDIZED LOW-DENSITY LIPOPROTEIN, BIOCHEM BIOPHYS RES COMMUN, 172, PP. 614-619, (1990); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON NORMOCHOLESTEROLEMIC RABBITS, BIOL RES, 27, PP. 205-208, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEIN IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1993); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., EFFECTS OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CAMPILONGO R., SARDINI P., FELDMAN R., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINOS CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, LA PRENSA MEDICA ARGENTINA, 83, PP. 665-672, (1996); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEARS STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., MAS R., FERNANDEZ L., FERNANDEZ J.C., ILLNAIT J., SELLMAN E., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECT OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY J VASC DIS, 50, (1998); CASTANO G., MAS R., NODARSE M., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., ONE-YEAR-STUDY ON THE EFFICACY AND SAFETY OF POLICOSANOL (5MG-TWICE-A-DAY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., MAS R., FERNANDEZ J.C., LOPEZ L.E., FERNANDEZ L., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, (1999); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ERDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12 MONTHS STUDY, CURR THER RES, 56, PP. 819-828, (1995); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL ATEROMIXOL (PPG 5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECT OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, (1998); ORTENSI G., GLADSTEIN H., VALL H., TESONE P., A COMPARATIVE STUDY OF POLICOSANOL VS SIMVASTATIN IN ERDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECT OF SUCCESSIVE DOSE OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); SOLTERO I., FUENTEMAYOR I., COLMENARES J., ARIAS F., ENSAYO A DOBLE CIEGO PARA LA EVALUACION DEL POLICOSANOL EN EL TRATAMIENTO DE LA HIPERLIPOPROTEINEMIA TIPO II, ARCH VENEZOL DE FARMACOL Y TERAP, 12, PP. 65-70, (1993); TORRES O., AGRAMONTE A.J., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J.C., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ZARDOYA R., TULA I., CASTANO G., MAS R., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); FRAGA V., MENENDEZ R., AMOR A.M., GONZALEZ R.M., JIMENEZ S., MAS R., EFFECTS OF POLICOSANOL ON IN VITRO AND IN VIVO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R., FRAGA V., AMOR A.M., GONZALEZ R.M., MAS R., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN IN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); KLEINVELD H.A., HAK-LEMMERS H.L.M., STALENHOEF A.F.H., DEMACKER P.N.M., IMPROVED MEASUREMENTS OF LOW-DENSITY-LIPOPROTEIN SUSCEPTIBILITY TO COPPER-INDUCED OXIDATION: APPLICATION OF A SHORT PROCEDURE FOR ISOLATING LOW-DENSITY-LIPOPROTEIN, CLIN CHEM, 38, PP. 2066-2072, (1992); TERSPTRA A.H.M., WOODYARD C.J.H., SANCHEZ-MUNIZ F.J., IMPROVED TECHNIQUE FOR SEPARATION OF SERUM LIPOPROTEIN BY DENSITY GRADIENT CENTRIFUGATION: VISUALIZATION BY PRESTAINING AND RAPID SEPARATION OF SERUM LIPOPROTEIN FROM SMALL VOLUMES OF SERUM, ANAL BIOCHEM, 111, PP. 149-151, (1981); MARKWELL M.A., HASS S.M., BIEBER L.L., TOLBERT N.R., A MODIFICATION OF THE LOWRY PROCEDURE TO SIMPLY PROTEIN DETERMINATION IN MEMBRANE AND LIPOPROTEIN SAMPLES, ANAL BIOCHEM, 87, PP. 206-210, (1987); DE WHALLEY C.V., RAMKIN S.M., HOULT J.R., JESSUP W., LEAKER D.S., FLAVONOIDS INHIBITS THE OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN BY MACROPHAGES, BIOCHEM PHARMACOL, 39, PP. 1743-1750, (1990); OHKAWA H., OHISHI N., YAGI K., ASSAY FOR LIPID PEROXIDES IN ANIMAL TISSUES BY THIOBARBITURIC ACID REACTION, ANAL BIOCHEM, 95, PP. 351-358, (1978); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATION FOR PERFORMING MULTIPLE TEST IN A SINGLE-EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENPOINTS, MAYO CLIN-PROC, 63, PP. 1140-1143, (1988); CRISTOL L.S., JIALAL I., GRUNDY S.M., EFFECT OF LOW DOSE OF PROBUCOL THERAPY ON THE LDL-C OXIDATION AND THE PLASMA PROFILE IN MALE VOLUNTEERS, ATHEROSCLEROSIS, 97, PP. 11-20, (1992); LEAKE D.S., RANKIN S., THE MODIFICATION OF LDL-C BY MACROPHAGES, BIOCHEM J, 270, (1990); REAVEN P., PARTHASARATHY S., BELTZ W., WITZTUM J., EFFECTS OF PROBUCOL DOSAGE ON PLASMA LIPOPROTEIN LEVELS AND ON PROTECTION OF LOW-DENSITY LIPOPROTEIN AGAINST IN VITRO OXIDATION IN HUMANS, ATHEROSCLEROSIS, 12, PP. 318-322, (1992); REGNSTROM J., WALLDIUS G., CARLSON A., NILSSON J., EFFECTS OF PROBUCOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS TO BECOME OXIDATIVELY MODIFIED, ATHEROSCLEROSIS, 82, PP. 43-46, (1990); DAUGHERTY A., ZWEFEL B.S., SCHONFELD G., THE EFFECTS OF PROBUCOL ON THE PROGRESSION AF ATHEROSCLEROSIS IN MATURE WATANABE HERITABLE HYPERLIPIDEMIC RABBITS, BR J PHARMACOL, 103, PP. 1013-1018, (1991); SASAHARA M., RAINES E.W., CHAIT A., ET AL., INHIBITION OF HYPERCHOLESTEROLEMIA-INDUCED ATHEROSCLEROSIS IN THE NONHUMAN PRIMATE BY PROBUCOL, J CLIN INVEST, 94, PP. 155-164, (1994); KLUNVELD H.A., DEMACKER P.N., DE NOON A., STALINHOLF A.F., DECREASED IN VITRO OXIDABILITY OF LOW DENSITY LIPOPROTEIN IN HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH 3 HYDROXY-3-METHYLGLUTARYL COA REDUCTASE INHIBITORS, EUR J CLIN INVEST, 23, PP. 289-295, (1993); HUSSEIN O., SCHLEZINGER S., ROSENBEST M., KUDAL S., AVIRAM M., REDUCED SUSCEPTIBILITY, OF LOW-DENSITY LIPOPROTEIN (LDL) TO LIPID PEROXIDATION AFTER FLUVASTATIN THERAPY NO ASSOCIATED WITH THE HYPOCHOLESTEROLEMIC EFFECT OF THE DRUG AND ITS BINDING TO THE LDL, ATHEROSCLEROSIS, 128, PP. 11-18, (1997); KAWAMURA M., HASE K., MIYAZAKI S., IN VITRO INHITION OF LOW-DENSITY LIPOPROTEIN OXIDATION BY GEMFIBROZIL METABOLITE, CLIN CHEM, 42, PP. 644-645, (1996); BREDIE J.H., DE BRUIN T.W.A., DEMACKER P.N.M., KASTELEIN J.J.P., STALENHOEF A.F.H., COMPARISON OF GEMBROZIL VS SIMVASTATIN IN FAMILIAL COMBINED HYPERLIPIDEMIA AND EFFECTS ON APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS, LOW-DENSITY LIPOPROTEIN SUBFRACTION PROFILE, AND LOW DENSITY-LIPOPROTEIN OXIDIZABILITY, AM J CARDIOL, 75, PP. 348-353, (1995); COMINACI L., GARBIN U., PASTORINO A.M., ET AL., PREDISPOSITION TO LDL-C OXIDATION IN PATIENTS WITH AND WITHOUT ANGIOGRAPHICALLY ESTABLISHED CORONARY ARTERY DISEASE, ATHEROSCLEROSIS, 99, PP. 63-70, (1993); LAVY A., BROOK G.J., DANKNER G., AMOTZ A.M., AVIRAM M., ENHANCED IN VITRO OXIDATION OF PLASMA LIPOPROTEIN DERIVED FROM HYPERCHOLESTEROLEMIC PATIENTS, METABOLISM, 40, PP. 794-799, (1991); LIU K., CUDDY E., PIERCE N., OXIDATIVE STATUS OF LIPOPROTEINS IN CORONARY DISEASE PATIENTS, AM HEART J, 123, PP. 285-290, (1992); REGNSTROM J.N., NILSSON J., TORNAVALL P., LANDOU C., HAMSTEN S., SUSCEPTIBILITY TO LOW-DENSITY LIPOPROTEIN OXIDATION AND CORONARY ATHEROSCLEROSIS IN MAN, LANCET, 339, PP. 1183-1185, (1992)","","","ENGLISH","BR. J. CLIN. PHARMACOL.","ARTICLE","ISI","2-S2.0-0033813254","BR J CLIN PHARMACOL",NA,"NOTREPORTED",NA,"MENÉNDEZ R, 2000, BR J CLIN PHARMACOL","MENÉNDEZ R, 2000, BR J CLIN PHARMACOL"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;LÓPEZ L;FERNÁNDEZ L","CASTAÑO, GLADYS (56232967100); MÁS, ROSA (7007164572); FERNÁNDEZ, JULIO CÉSAR (9432805500); LÓPEZ, LUIS ERNESTO (57924898800); FERNÁNDEZ, LILIA (7202848319)","A LONGTERM OPENLABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK",1999,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","60","12",35,"10.1016/S0011-393X(99)80016-2","MEDICAL SURGICAL RESEARCH CENTER, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;MEDICAL SURGICAL RESEARCH CENTER, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA","IN THE PRESENT LONG-TERM, OPEN-LABEL STUDY, THE EFFECTS OF POLICOSANOL (20 MG/D) WERE INVESTIGATED IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA IN PATIENTS WITH HIGH GLOBAL CORONARY RISK. AFTER DIETARY STABILIZATION DURING A 5-WEEK BASELINE PERIOD, 68 PATIENTS TOOK POLICOSANOL 20 MG ONCE DAILY WITH THE EVENING MEAL FOR 12 MONTHS. ALL OF THE PATIENTS HAD NONLIPID CORONARY RISK FACTORS, SUCH AS A FAMILY HISTORY OF CORONARY DISEASE (88.2%), HYPERTENSION (70.6%), PREVIOUS CORONARY EVENTS (60.3%), AND SEVERE HYPERCHOLESTEROLEMIA (TOTAL CHOLESTEROL >7.8 MMOL/L) (60.3%). AFTER 2 MONTHS OF TREATMENT WITH POLICOSANOL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND TOTAL CHOLESTEROL DECREASED SIGNIFICANTLY (P < 0.00001) BY 24.7% AND 15.9%, RESPECTIVELY, AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) INCREASED SIGNIFICANTLY (P < 0.0001) BY 31.1%. THE RATIOS OF TOTAL CHOLESTEROL TO HDL-C AND LDL-C TO HDL-C DECREASED SIGNIFICANTLY (P < 0.00001) BY 29.3% AND 37.8%, RESPECTIVELY. THESE EFFECTS CONTINUED TO INCREASE, ALTHOUGH MODERATELY, DURING THE 12-MONTH FOLLOW-UP. AT THE END OF THE STUDY, REDUCTIONS WERE NOTED IN TOTAL CHOLESTEROL (30.0%), LDL-C (44.8%), TOTAL CHOLESTEROL TO HDL-C RATIO (54.1%), AND LDL-C TO HDL-C RATIO (62.7%), WHEREAS HDL-C INCREASED BY 68.5%. TRIGLYCERIDES, WHICH DECREASED SIGNIFICANTLY FROM 4 UNTIL 12 MONTHS, WERE 21.2% LOWER AT 12 MONTHS THAN AT BASELINE. OF 59 PATIENTS WHO COMPLETED THE STUDY, 56 (94.9%) HAD REDUCTIONS IN LDL-C ≥15% AT STUDY COMPLETION. THE TREATMENT WAS WELL TOLERATED; NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE EFFECTS (AES) WERE DETECTED. NONE OF THE PATIENTS WITHDREW FROM THE STUDY BECAUSE OF AES, AND ONLY 4 PATIENTS REPORTED MILD AES DURING THE STUDY. RESULTS OF THE PRESENT STUDY SHOW THAT POLICOSANOL 20 MG ONCE DAILY FOR 1 YEAR WAS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH GLOBAL CORONARY RISK.","CHOLESTEROL-LOWERING DRUG; HIGH CORONARY RISK; LONG-TERM STUDY; POLICOSANOL","HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIAPHORESIS; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; PRIORITY JOURNAL; RISK FACTOR; VERTIGO","","","ANDERSON K.M., WILSON P.W.F., ODELL P.M., KANNEL W.B., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, PP. 356-362, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO D., HAAPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-INTERVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DISLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); RANDOMIZED TRIAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4 S), LANCET, 344, PP. 1383-1389, (1994); SHEPERD J., COBBE S.M., CHRISTOPHER G., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, NEJM, 333, PP. 1301-1307, (1995); SACKS F.M., PFEFFER M.A., MOYE L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, NEJM, 35, PP. 1001-1009, (1996); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); PREVENTION OF CORONARY HEART DISEASE. SCIENTIFIC BACKGROUND AND NEW CLINICAL GUIDELINES. RECOMMENDATIONS OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY PREPARED BY THE INTERNATIONAL TASK FORCE FOR PREVENTION OF CORONARY HEART DISEASE, NUTR METAB CARDIOVASC DIS, 2, PP. 113-156, (1992); BAHATNAGAR D., LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDAEMIA, PHARMACOL THER, 79, PP. 205-230, (1998); ILLINGWORTH D.R., TOBERT J.A., A REVIEW OF THE CLINICAL STUDIES COMPARING HMGCOA REDUCTASE INHIBITORS, CLIN THER, 16, PP. 1-20, (1994); DESLYPERE J.P., THE ROLE OF HMG-COA REDUCTASE INHIBITORS IN THE TREATMENT OF HYPERLIPIDEMIA: A REVIEW OF FLUVASTATIN, CURR THER RES, 56, PP. 111-128, (1995); GAW A., SHEPERD J., FIBRIC ACID DERIVATIVES, CURR OP LIPIDS, 2, PP. 39-46, (1991); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A STARCH-CASEIN DIET, BRIT J NUTR, 77, PP. 923-932, (1997); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES OF SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., COMPARATIVE EFFECTS OF TWO ONCE-DAILY REGIMENS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 154-162, (1997); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 26-35, (1998); CAMPILONGO R., SANDINI P., FELDMAN R., ET AL., EFICACIA, SEGURIDAD Y TOLERABILIDAD DEL POLICOSANOL EN PACIENTES ARGENTINES CON HIPERCOLESTEROLEMIA TIPO II. ESTUDIO ABIERTO, PRENSA MÉD ARGENT, 83, PP. 665-672, (1996); ORTENSI G., GLADSTEIN H., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CANNETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPEN FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); MAS R., CASTANO G., FERNANDEZ J.C., ET AL., EFFECT OF PELICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA PLUS TWO OR MORE ADDITIONAL CORONARY RISK FACTORS, ABSTRACT EVENTO CLIN PHARMACOL THER, 65, PP. 6-14, (1999); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) AND HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 44-51, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY ON THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 59, PP. 737-745, (1998); ALEMAN C.L., RODEIRO I., NOA M., ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF POLICOSANOL IN RATS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAG, 14, PP. 239-249, (1994); ALEMAN C., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAG, 14, PP. 107-113, (1994); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT THE USE OF PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); GOLDMAN L., HASHIMOTO B., COOK F., LOSCLZO A., COMPARATIVE REPRODUCIBILITY AND VALIDITY OF SYSTEMS FOR ASSESSING CARDIOVASCULAR FUNCTIONAL CLASS: ADVANTAGES OF A NEW SPECIFIC ACTIVITY SCALE, CIRCULATION, 64, PP. 1227-1234, (1981); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTOR LIMITING ACHIEVEMENT OF LIPID GOALS, AM J MED, 100, PP. 197-204, (1996); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1998); ARRUZAZABALA M.D.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); CARBAJAL D., ARRUZAZABALA M.D.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV; NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0032777501","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"CASTAÑO G, 1999, CURR THER RES CLIN EXP","CASTAÑO G, 1999, CURR THER RES CLIN EXP"
"BENÍTEZ M;ROMERO C;MÁS R;FERNÁNDEZ L;FERNÁNDEZ J","BENÍTEZ, MIGUEL (57198217772); ROMERO, CUAUHTÉMOC (7202170060); MÁS, ROSA (7007164572); FERNÁNDEZ, LILIA (7202848319); FERNÁNDEZ, JULIO C. (9432805500)","A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1997,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","58","8",46,"10.1016/S0011-393X(97)80052-5","PUEBLA UNIVERSITY HOSPITAL, PUEBLA, MEXICO;PUEBLA UNIVERSITY HOSPITAL, PUEBLA, MEXICO;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA, CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THIS RANDOMIZED, DOUBLE-MASKED STUDY COMPARED THE SHORT-TERM EFFICACY AND TOLERABILITY OF POLICOSANOL AND PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. AFTER FOLLOWING A STEP I CHOLESTEROL-LOWERING DIET FOR 6 WEEKS, 24 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WERE RANDOMLY ASSIGNED TO RECEIVE POLICOSANOL OR PRAVASTATIN ADMINISTERED AT THE SAME DOSE (10 MG/D) FOR 6 WEEKS. BOTH GROUPS WERE STATISTICALLY SIMILAR AT RANDOMIZATION. POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (15.7%), LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL (24.2%), AND TRIGLYCERIDES (8.7%), AS WELL AS THE ATHEROGENIC RATIOS OF TOTAL CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL (25.7%), AND LDL CHOLESTEROL TO HDL CHOLESTEROL (33.0%). PRAVASTATIN SIGNIFICANTLY LOWERED TOTAL CHOLESTEROL BY 15.3%, LDL CHOLESTEROL BY 19.6%, TRIGLYCERIDES BY 13.9%, AND THE ATHEROGENIC RATIOS OF TOTAL CHOLESTEROL TO HDL CHOLESTEROL (18.7%) AND LDL CHOLESTEROL TO HDL CHOLESTEROL (22.8%). MEAN VALUES OF HDL CHOLESTEROL WERE SIGNIFICANTLY INCREASED BY 13.6% AFTER TREATMENT WITH POLICOSANOL, AND WERE INCREASED BY 4.7% AFTER TREATMENT WITH PRAVASTATIN. COMPARISONS BETWEEN GROUPS SHOWED THAT THE PERCENTAGE CHANGE IN LDL AND HDL CHOLESTEROL LEVELS, AND IN ATHEROGENIC RATIOS WERE SIGNIFICANTLY HIGHER IN THE POLICOSANOL GROUP THAN IN THE PRAVASTATIN GROUP. BOTH DRUGS WERE WELL TOLERATED. A SIGNIFICANT INCREASE IN MEAN ASPARTATE AMINOTRANSFERASE LEVEL WAS OBSERVED IN THE PRAVASTATIN GROUP, BUT INDIVIDUAL VALUES REMAINED WITHIN THE NORMAL RANGE. NO PATIENT WITHDREW FROM THE STUDY BECAUSE OF ADVERSE EVENTS. FOUR MODERATE ADVERSE EVENTS (NAUSEA, DIZZINESS, ABDOMINAL PAIN, AND PRURITUS) MERE REPORTED BY PRAVASTATIN-TREATED PATIENTS. THE OTHER ADVERSE EVENTS REPORTED (FIVE IN EACH GROUP) WERE CLASSIFIED AS MILD. THESE RESULTS SUGGEST THAT BOTH POLICOSANOL AND PRAVASTATIN ARE SUITABLE ALTERNATIVES FOR TREATING TYPE II HYPERCHOLESTEROLEMIA, BUT THAT POLICOSANOL ADMINISTERED AT 10 MG/D SHOWS MODEST ADVANTAGES COMPARED WITH PRAVASTATIN ADMINISTERED AT THE SAME DOSE.","CHOLESTEROL-LOWERING DRUGS; POLICOSANOL; PRAVASTATIN; TYPE II HYPERCHOLESTEROLEMIA","ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; PRAVASTATIN; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL","","","THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. II. THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGE MEN WITH DYSLIPIDEMIA, NEJM, 317, PP. 1237-1245, (1987); DESIGN AND BASELINE RESULTS OF THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY OF PATIENTS WITH STABLE ANGINA AND/OR PREVIOUS MYOCARDIAL INFARCTION, AM J CARDIOL, 71, PP. 393-400, (1993); SHEPHERD J., COBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, NEJM, 333, PP. 1301-1307, (1995); O'CONNOR P., FEELY J., SHEPHERD J., LIPID LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); KATHAWALA F.G., HMGCOA-REDUCTASE INHIBITORS: AN EXCITING DEVELOPMENT IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, MED RES REV, 11, PP. 121-146, (1991); BLUM C.B., COMPARISON OF PROPERTIES OF FOUR INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, AM J CARDIOL, 73, (1994); ILLINGWORTH D.R., ERKELENS D.W., KELLER U., ET AL., DEFINED DAILY DOSES IN RELATION TO HYPOLIPIDAEMIC EFFICACY OF LOVASTATIN, PRAVASTATIN AND SIMVASTATIN, LANCET, 343, PP. 1554-1555, (1994); DESLYPERE J.P., THE ROLE OF HMGCOA REDUCTASE INHIBITORS IN THE TREATMENT OF HYPERLIPIDEMIA: A REVIEW OF FLUVASTATIN, CURR THER RES, 56, PP. 111-128, (1995); MCTAVISH D., SORKIN E.M., PRAVASTATIN: A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLEMIA, DRUGS, 42, PP. 65-89, (1991); EPIDEMIOLOGY OF HYPERLIPIDEMIA AND THE EFFICACY OF PRAVASTATIN THERAPY, CURR THER RES, 54, PP. 290-299, (1993); LA ROSA J.C., PRAVASTATIN: A NEW HYDROPHILIC HMGCOA REDUCTASE INHIBITOR, INTERNATIONAL CONGRESS SYMPOSIUM SERIES, PP. 39-43, (1989); EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL/L (200 TO 300 MG/DL) PLUS TWO ADDITIONAL ATHEROSCLEROTIC RISK FACTORS, AM J CARDIOL, 72, PP. 1031-1037, (1993); NEWMAN T.J., KASSLER-TRAUB K.B., GELARDEN R.T., ET AL., SAFETY OF PRAVASTATIN IN LONG-TERM CLINICAL TRIAL CONDUCTED IN THE UNITED STATES, J DRUG DEV, 3, PP. 275-281, (1990); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., DE ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH CASSEIN DIET, BR J NUTR, (1996); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO G., ZARDOYA R., ILLNAIT J., ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); ALEMAN C., MAS R., HERNANDEZ C., ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); ALEMAN C.L., MAS R., NOA M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24-MONTH STUDY, TERATOG CARCINOG MUTAG., 14, PP. 239-249, (1994); ALEMAN C., NOA M., CEREJIDO E., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); FRIEDEWALD W.T., LEVY R.I., FREDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN IN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); SEIGLER W., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, 3 SUPPL., PP. 63-71, (1988); HUNNINGHEKE D.B., KNOPP R.H., SCHONFELD G., ET AL., EFFICACY AND SAFETY OF PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. I. A DOSE-RESPONSE STUDY, ATHEROSCLEROSIS, 85, PP. 81-89, (1990); GUILLEN M.A., KORNHAUSER C., SAMANIEGO V., ET AL., ONCE-DAILY PRAVASTATIN COMPARED WITH DIETARY ADVICE IN PATIENTS WITH BORDERLINE AND MODERATE PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 303-316, (1995)","","EXCERPTA MEDICA INC.","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0031406593","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"BENÍTEZ M, 1997, CURR THER RES CLIN EXP","BENÍTEZ M, 1997, CURR THER RES CLIN EXP"
"SLEPCHENKO N;NECHAEV A;BLIZNEVSKAYA E;KARASEV A;IVANOVA M;GRATSIANSKY N;NIKITIN Y","SLEPCHENKO, N.V. (6506128998); NECHAEV, A.S. (7004823952); BLIZNEVSKAYA, E.V. (36836470300); KARASEV, A.V. (18340379100); IVANOVA, M.V. (13406041800); GRATSIANSKY, N.A. (7004708293); NIKITIN, YU.P. (7102172021)","COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF POLICOSANOL AND BESAFIBRATE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1997,"KARDIOLOGIYA","37","4",0,"","","POLICOSANOL IS A NOVEL HYPOLIPIDEMIC DRUG CONTAINING HIGH ALIPHATIC ALCOHOL OBTAINED FROM SUGAR-CANE. MAIN COMPONENT OF THE DRUG IS OCTOSANOL. DOUBLE BLIND RANDOMIZED COMPARATIVE STUDY OF POLICOSANOL (2 MG B.I.D.) AND BESAFIBRATE (200 MG B.I.D.) WAS CONDUCTED IN 56 PATIENTS WITH HYPERCHOLESTEROLEMIA (TOTAL CHOLESTEROL OVER 240 MG/DL). POLICOSANOL WAS GIVEN TO 30 AND BESAFIBRATE - TO 26 PATIENTS. DURATION OF THE STUDY WAS 13 WEEKS (5 WEEKS ""DIET"" AND 8 WEEKS TREATMENT). TOTAL CHOLESTEROL DECREASED BY 11 AND 4%, LOW DENSITY LIPOPROTEIN CHOLESTEROL - BY 14 AND 7% TRIGLYCERIDES - BY 15,5 AND 4,3% IN POLICOSANOL AND BESAFIBRATE TREATED PATIENTS, RESPECTIVELY (P<0,05). LEVEL OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL REMAINED UNCHANGED IN BOTH GROUPS. SIDE EFFECTS OF POLICOSANOL WERE TRANSITORY BUT CAUSED DISCONTINUATION OF TREATMENT IN 2/30 PATIENTS (COMPARED TO 4/26 PATIENTS IN BESAFIBRATE GROUP). IN THIS SHORT TERM STUDY POLICOSANOL DEMONSTRATED MODERATE HYPOCHOLESTEROLEMIC ACTIVITY AND ACCEPTABLE TOLERABILITY WHILE BESAFIBRATE WAS UNEXPECTEDLY INEFFECTIVE POSSIBLY DUE TO LOW DOSE.","BESAFIBRATE; HYPERCHOLESTEROLEMIA; POLICOSANOL; TREATMENT","","","","ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); ARNTZ H.-R., KLEMENS U.H., LANG P.D., VOLLMAR J., VERGLEICH VON BEZAFIBRAT UND CLOFIBRAT BEI HYPERLIPOPROTEINAMIE TYP II A UND II B, MED KLIN, 73, (1978); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLSTEROLEMIA, ADVANC THER, 12, PP. 245-254, (1995); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERHOLESTEROLEMIA, CURR THER RES, 56, PP. 296-304, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR THER RES, PP. 819-828; FRIEDEWALD W.T., LEVY R.I., FREDERICKSON D.S., ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 449-451, (1974); HERNANDEZ E., ILLNAIT J., MAS R., ET AL., EFFECTS OF POLICOSANOL IN SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ILLINGWORTH D.R., AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURES HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES IN LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLENIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); PYORALA K., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSLEROSIS SOCIETY OF HYPERTENSION, EUR HEART J, 15, PP. 1300-1331, (1994); RANDOMIZED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, PP. 1383-1389, (1994); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEROL FARMACOL THER, 12, PP. 71-76, (1993); SHEPHERD J., COBBE S., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N ENGL J MED, 333, PP. 1301-1307, (1995)","","","RUSSIAN","KARDIOLOGIYA","ARTICLE","ISI","2-S2.0-3343026141","KARDIOLOGIYA",NA,"NOTREPORTED",NA,"SLEPCHENKO NV, 1997, KARDIOLOGIYA","SLEPCHENKO NV, 1997, KARDIOLOGIYA"
"PONS P;RODRIGUEZ M;ROBAINA C;ILLNAIT J;MAS R;FERNANDEZ L;FERNANDEZ J;FERREIRO R","PONS, P. (18635378600); RODRIGUEZ, M. (57213557891); ROBAINA, C. (15036828600); ILLNAIT, J. (8631465800); MAS, R. (7007164572); FERNANDEZ, L. (7202848319); FERNANDEZ, J.C. (9432805500); FERREIRO, R.M. (6602148780)","EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT",1994,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","14","6",108,"","NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA;NATIONAL CENTRE FOR SCIENTIFIC RES, PO BOX 6880, CUBA","THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED IN 22 PATIENTS WITH TYPE II PRIMARY HYPERCHOLESTEROLAEMIA TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF TWO SUCCESSIVE DOSE INCREASES OF POLICOSANOL. PATIENTS WITH ELEVATED SERUM LOW-DENSITY-LIPOPROTEIN CHOLESTEROL (LDL-C) AND TOTAL CHOLESTEROL AFTER A DIET-ONLY PERIOD RECEIVED RANDOMLY, UNDER DOUBLE-BLIND CONDITIONS, PLACEBO OR POLICOSANOL AT 5 MG ONCE-A-DAY FOR 8 WEEKS. AFTER THIS PERIOD, DOSAGE WAS DOUBLED TO 5 MG TWICE-A-DAY FOR THE NEXT 8 WEEKS AND THEN AGAIN DOUBLED TO 10 MG TWICE-A-DAY. IT WAS FOUND THAT THE LDL-C WAS REDUCED SIGNIFICANTLY BY 11.3%, 21.9% AND 31.2%, WHILE TOTAL CHOLESTEROL WAS ALSO REDUCED SIGNIFICANTLY BY 8%, 14.1% AND 23% RESPECTIVELY IN THESE THREE PERIODS. SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL (HDL-C) WAS INCREASED BY 7.8%, 7.2% AND 8.7%, RESPECTIVELY, WHILE IN THE PLACEBO GROUP A DOWNWARD SHIFT WAS OBSERVED. THE LDL-C TO HDL-C RATIO WAS REDUCED SIGNIFICANTLY BY 15.3%, 25.6% AND 34.6%, WHILE THE TOTAL CHOLESTEROL TO HDL-C RATIO WAS ALSO REDUCED SIGNIFICANTLY BY 12.5%, 18.4% AND 27.1%, RESPECTIVELY. TRIGLYCERIDES AND VLDL-C VALUES DID NOT CHANGE SIGNIFICANTLY. THE REDUCTION OF LDL-C, TOTAL CHOLESTEROL, LDL-C TO HDL-C, AND TOTAL CHOLESTEROL TO HDL-C RATIOS SNOWED A DEPENDENCE ON THE SUCCESSIVE DOSE INCREASES. POLICOSANOL WAS VERY WELL TOLERATED. NO PATIENT DISCONTINUED THE TRIAL. NO DISTURBANCES OF CLINICAL OR BLOOD BIOCHEMISTRY VARIABLES ATTRIBUTABLE TO TREATMENT WERE OBSERVED. ADVERSE EFFECTS REPORTED WERE MILD AND TRANSIENT, AND NO SIGNIFICANT DIFFERENCES BETWEEN GROUPS WERE FOUND.","","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FATTY ACIDS; FATTY ALCOHOLS; FEMALE; GLYCERIDES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; MALE; MIDDLE AGED; ALKANOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; AGED; ARTHRALGIA; ARTICLE; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSMENORRHEA; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LIPID ANALYSIS; MALE; MUSCLE CRAMP; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL","","","","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0028227198","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"PONS P, 1994, INT J CLIN PHARMACOL RES","PONS P, 1994, INT J CLIN PHARMACOL RES"
"GONZÁLEZ C V;HERNÁNDEZ J","GONZÁLEZ CANAVACIOLO, VICTOR L. (18433666300); HERNÁNDEZ, JUAN MAGRANER (7403026471)","VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN FIVEMILLIGRAM FILMCOATED TABLETS",1999,"JOURNAL OF AOAC INTERNATIONAL","82","5",14,"10.1093/jaoac/82.4.834","NATL. CENTER FOR SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN PLAYA, HAVANA CITY, PO BOX 6880, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN PLAYA, HAVANA CITY, PO BOX 6880, CUBA","A GAS CHROMATOGRAPHIC METHOD USING A PACKED COLUMN AND 1-EICOSANOL AS AN INTERNAL STANDARD WAS DEVELOPED AND VALIDATED FOR DETERMINATION OF THE ALIPHATIC FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN 5 MG FILM-COATED TABLETS. THE ALCOHOLS WERE ANALYZED AS TRIMETHYLSILYL (TMS) DERIVATIVES, PREPARED WITH N-METHYL-N-TRIMETHYLSILYLTRIFLUOROACETAMIDE. THE METHOD CAN DETECT DEGRADATION PRODUCTS WITH HIGH RETENTION TIMES WITHOUT INTERFERING WITH THE PEAKS OF THE ACTIVE PRINCIPLE. GOOD LINEARITY (CORRELATION COEFFICIENT = 0.9996) AND ACCURACY (RECOVERY = 100.44%) WERE PROVEN OVER A RANGE OF 50-150% OF THE NOMINAL CONCENTRATION. WITHIN-DAY AND BETWEEN-DAY PRECISIONS AT THE NOMINAL 100% VALUE MET THE ACCEPTANCE CRITERIA (<2%). RUGGEDNESS WAS EXAMINED THROUGH AN INTRALABORATORY EXPERIMENTAL STUDY IN WHICH 7 OPERATIONAL CHANGES WERE MADE AND THE OBSERVED RESULTS WERE QUANTITATION, REPEATABILITY, RESOLUTION, AND RELATIVE RETENTION TIME. AMONG THESE RESULTS, ONLY THE RELATIVE RETENTION TIME (TC28,C20) WAS SIGNIFICANTLY AFFECTED WHEN THE COLUMN USED WAS 2.1 M INSTEAD OF 3.1 M. REPEATABILITY AND REPRODUCIBILITY (R = 0.1506 AND R = 0.2450, RESPECTIVELY) WERE OBTAINED FROM A UNIFORM-LEVEL INTERLABORATORY TEST. THE METHOD IS SUITABLE FOR QUALITY CONTROL AND STABILITY STUDIES OF THESE TABLETS.","","ANTICHOLESTEREMIC AGENTS; CHROMATOGRAPHY, GAS; FATTY ALCOHOLS; REPRODUCIBILITY OF RESULTS; TABLETS; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ARTICLE; GAS CHROMATOGRAPHY; REPRODUCIBILITY; TABLET","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., CASTANO G., SOTOLONGO R., MESA R., REVISTA CENIC CIENCIAS BIOLÓGICAS, 22, PP. 60-61, (1991); ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., BIOL. RES., 27, PP. 205-208, (1994); HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., CURR. THER. RES., 51, PP. 568-575, (1992); ANEIROS E., MAS R., CALDERON B., ILLNAIT J., FERNANDEZ L., CASTANO G., FERNANDEZ J.C., CURR. THER. RES., 56, PP. 176-182, (1995); CANETTI M., MORERA M., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., FERNANDEZ J.C., INT. J. CLIN. PHARM. RES., 15, PP. 159-165, (1995); CASTANO G., MAS R., FERNANDEZ J.C., ILLNAIT J., CURR. THER. RES., 58, PP. 154-162, (1997); LAGUNA A., MAGRANER J., CARVAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M., (1993); MAGRANER J., GONZALEZ V., LAGUNA A., VELAZQUEZ C., LORENZO M., URIBARRI E., REVISTA CENIC CIENCIAS QUÍMICAS, 29, PP. 127-130, (1998); GASCO S., TEORIA Y PRÁCTICA DE LA CROMATOGRAFÍA EN FASE GASEOSA, (1969); YOUDEN W.J., STEINER E.H., STATISTICAL MANUAL OF THE AOAC, (1975); GONZALEZ V.L., MAGRANER J., CABRERA L., RIVERO B., REVISTA CENIC CIENCIAS QUÍMICAS, 29, PP. 27-30, (1998)","","AOAC INTERNATIONAL","ENGLISH","J AOAC INT","ARTICLE","ISI","2-S2.0-0033163436","J AOAC INT",NA,"NOTREPORTED",NA,"GONZÁLEZ CANAVACIOLO VL, 1999, J AOAC INT","GONZÁLEZ CANAVACIOLO VL, 1999, J AOAC INT"
"JANIKULA M","JANIKULA, MARK (6506621687)","POLICOSANOL A NEW TREATMENT FOR CARDIOVASCULAR DISEASE",2002,"ALTERNATIVE MEDICINE REVIEW","7","14",58,"","TEMPE, AZ 85281, 1320 E LEMON ST, UNITED STATES","POLICOSANOL IS A MIXTURE OF ALCOHOLS ISOLATED AND PURIFIED FROM SUGAR CANE. RECENTLY, CUBAN RESEARCHERS FOUND 5-20 MG DAILY OF POLICOSANOL TO BE EFFECTIVE AT IMPROVING SERUM LIPID PROFILES. POLICOSANOL IS BELIEVED TO DECREASE TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN (LDL), AND INCREASE HIGH-DENSITY LIPOPROTEIN (HDL) BY INHIBITING CHOLESTEROL SYNTHESIS AND INCREASING LDL PROCESSING. LIPID PROFILE IMPROVEMENTS ARE SEEN IN HEALTHY VOLUNTEERS, PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, TYPE 2 DIABETICS WITH HYPERCHOLESTEROLEMIA, POSTMENOPAUSAL WOMEN WITH HYPERCHOLESTEROLEMIA, AND PATIENTS WITH COMBINED HYPERCHOLESTEROLEMIA AND ABNORMAL LIVER FUNCTION TESTS. ADDITIONALLY, POLICOSANOL HAS PERFORMED EQUAL TO OR BETTER THAN SIMVASTATIN, PRAVASTATIN, LOVASTATIN, PROBUCOL, OR ACIPIMOX WITH FEWER SIDE EFFECTS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. POLICOSANOL ALSO DECREASES SEVERAL OTHER RISK FACTORS OF CARDIOVASCULAR DISEASE BY DECREASING LDL OXIDATION, PLATELET AGGREGATION, ENDOTHELIAL DAMAGE, AND SMOOTH MUSCLE CELL PROLIFERATION. FURTHERMORE, POLICOSANOL DECREASES PROGRESSION AND INCREASES REGRESSION OF CARDIOVASCULAR DISEASE ASSESSED BY THALLIUM-LABELED MYOCARDIAL PERFUSION SCINTIGRAPHY (TL-MPS) AND DOPPLER-ULTRASOUND, AND DECREASES SYMPTOMS OF CARDIOVASCULAR DISEASE ASSESSED BY THE SPECIFIC ACTIVITY SCALE. IN POST-MARKETING STUDIES, ONLY 0.31 PERCENT OF PATIENTS HAVE HAD ADVERSE EVENTS. FURTHERMORE, IN ANIMAL TOXICITY STUDIES DOSES UP TO 1500 TIMES NORMAL HUMAN DOSES (ON THE BASIS OF BODY WEIGHT) HAVE SHOWN NO NEGATIVE EFFECTS ON CARCINOGENESIS, REPRODUCTION, GROWTH, AND DEVELOPMENT. HOWEVER, DESPITE THE POSITIVE RESEARCH ON POLICOSANOL ON CUBANS, POLICOSANOL PRODUCED IN CUBA IS NOT AVAILABLE IN THE UNITED STATES, AND ONLY CUBAN SUBJECTS HAVE BEEN STUDIED. FURTHER RESEARCH IS NEEDED TO DETERMINE IF THE SAME EFFECTS WILL BE OBTAINED IN U.S. POPULATIONS WITH NON-CUBAN PRODUCED POLICOSANOL.","","ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR SYSTEM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CUBA; DIABETES MELLITUS, TYPE 2; FATTY ALCOHOLS; FEMALE; HEART DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS; ACIPIMOX; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; POLICOSANOL; PRAVASTATIN; PROBUCOL; SIMVASTATIN; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; REVIEW; SIDE EFFECT","","","ARRUZAZABALA M.L., NOA M., MENENDEZ R., ET AL., PROTECTIVE EFFECT OF POLICOSANOL ON ATHEROSCLEROTIC LESIONS IN RABBITS WITH EXOGENOUS HYPERCHOLESTEROLEMIA, BRAZ J MED BIOL RES, 33, PP. 835-840, (2000); HERNANDEZ F., ILLNAIT J., MAS R., ET AL., EFFECT OF POLICOSANOL ON SERUM LIPID AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES CLIN EXP, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 52, PP. 507-513, (1992); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES CLIN EXP, 54, PP. 304-312, (1993); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 55, PP. 1084-1092, (1994); PONS P., RODRIQUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARMACOL RES, 14, PP. 27-33, (1994); CANETTI M., MOREIRA M., ILLNAIT J., ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 176-182, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 56, PP. 296-304, (1995); CANETTI M., MOREIRA M., MAS R., ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARMACOL RES, 15, PP. 159-165, (1995); CASTANO G., CANETTI M., MOREIRA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES CLIN EXP, 56, PP. 819-827, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 57, PP. 691-699, (1996); BATISTA J., STUSSER R., SAEZ F., PEREZ B., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS. A 14-MONTH PILOT STUDY, INT J CLIN PHARMACOL THER, 34, PP. 134-137, (1996); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, (2001); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL 20 VERSUS 40 MG/DAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 6-MONTH DOUBLE-BLIND STUDY, INT J CLIN PHARMACOL RES, 21, PP. 43-57, (2001); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES CLIN EXP, 58, PP. 44-51, (1997); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-397, (1995); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARMACOL RES, 29, PP. 117-127, (1999); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); MIRKIN A., MAS R., MARTINTO M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, INT J CLIN PHARMACOL RES, 21, PP. 31-41, (2001); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES CLIN EXP, 57, PP. 568-577, (1996); ORTENSI G., GLADSTEIN J., VALLI H., TESONE P.A., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 390-401, (1997); ILLNAIT J., CASTANO G., MAS R., FERNANDEZ J.C., A COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND SIMVASTATIN FOR TREATING TYPE II HYPERCHOLESTEROLEMIA, CAN J CARDIOL, 13, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 859-867, (1997); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARMACOL RES, 29, PP. 105-116, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES CLIN EXP, 61, PP. 137-146, (2000); PONS P., ILLNAIT J., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PROBUCOL IN PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES CLIN EXP, 58, PP. 26-35, (1997); ALCOCER L., FERNANDEZ L., COMPOS E., MAS R., A COMPARATIVE STUDY OF POLICOSANOL VERSUS ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, INT J TISSUE REACT, 21, PP. 85-92, (1999); MENENDEZ R., FRAGA V., AMOR A.M., ET AL., ORAL ADMINISTRATION OF POLICOSANOL INHIBITS IN VITRO COPPER ION-INDUCED RAT LIPOPROTEIN PEROXIDATION, PHYSIOL BEHAV, 67, PP. 1-7, (1999); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., MAS R., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998); VALDES S., ARRUZAZABALA M.L., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARMACOL RES, 16, PP. 67-72, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); ARRUZAZABALA MIL VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION THERAPY POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); ARRUZAZABALA M.L., MAS R., MOLINA V., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); NOA M., MAS R., MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); NOA M., MAS R., MESA R., A COMPARATIVE STUDY OF POLICOSANOL VS. LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, PHARMACOL RES, 43, PP. 31-37, (2001); BATISTA J., STRUSSER R., PADRON R., ET AL., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTHS OF LIPID-LOWERING THERAPY WITH POLICOSANOL, ADV THER, 13, PP. 137-148, (1996); STUSSER R., BATISTA J., PADRON R., ET AL., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARMACOL THER, 36, PP. 469-473, (1998); BATISTA J., STUSSER R., PENICHET M., UGUET E., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTIDVERTEBRAL ATHEROSCLEROSIS, CURR THER RES CLIN EXP, 56, PP. 906-914, (1995); GOLDMAN L., HASHIMOTO B., COOK E.F., LOSCALZO A., COMPARATIVE REPRODUCIBILITY AND VALIDITY OF SYSTEMS FOR ASSESSING CARDIOVASCULAR FUNCTIONAL CLASS: ADVANTAGES OF A NEW SPECIFIC ACTIVITY SCALE, CIRCULATION, 64, PP. 1227-1234, (1981); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES CLIN EXP, 60, PP. 379-391, (1999); CASTANO G., MAS R., ROCA J., ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO G., MAS FERREIRO R., FERNANDEZ L., ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); MENENDEZ R., AMOR A.M., GONZALEZ R.M., ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R., AMOR A.M., RODEIRO I., ET AL., POLICOSANOL MODULATES HMG-COA REDUCTASE ACTIVITY IN CULTURED FIBROBLASTS, ARCH MED RES, 32, PP. 8-12, (2001); MENENDEZ R., FERNANDEZ S.I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); FERNANDEZ L., MAS R., ILLNAIT J., FERNANDEZ J.C., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES CLIN EXP, 59, PP. 717-722, (1998); MAS R., RIVAS P., IZQUIERDO J., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES CLIN EXP, 60, PP. 458-467, (1999); ALEMAN C.L., MAS R., HERNANDEZ C., ET AL., A 12-MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); ALEMAN C.L., MAS FERREIRO R., NOA PUIG M., ET AL., CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY, TERATOG CARCINOG MUTAGEN, 14, PP. 239-249, (1994); MESA A.R., MAS R., NOA M., ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY, TOXICOL LETT, 73, PP. 81-90, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., ET AL., EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES), FOOD CHEM TOXICOL, 32, PP. 565-575, (1994); ALEMAN C.L., PUIG M.N., ELIAS E.C., ET AL., CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18-MONTH STUDY, FOOD CHEM TOXICOL, 33, PP. 573-578, (1995); RODRIGUEZ M.D., GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); RODRIGUEZ M.D., GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ M.D., SANCHEZ M., GARCIA H., MULTIGENERATION REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997)","M. JANIKULA; TEMPE, AZ 85281, 1320 E LEMON ST, UNITED STATES; EMAIL: MDJANIKULA@HOTMAIL.COM","","ENGLISH","ALTERN. MED. REV.","REVIEW","ISI","2-S2.0-0036304788","ALTERN MED REV",NA,"NOTREPORTED;NOTREPORTED;NOTREPORTED",NA,"JANIKULA M, 2002, ALTERN MED REV","JANIKULA M, 2002, ALTERN MED REV"
"ARRUZAZABALA M;VALDÉS S;MÁS R;FERNÁNDEZ L;CARBAJAL D","ARRUZAZABALA, M.L. (6603962476); VALDÉS, S. (8777025100); MÁS, R. (7007164572); FERNÁNDEZ, L. (7202848319); CARBAJAL, D. (8777025000)","EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS",1996,"PHARMACOLOGICAL RESEARCH","34","4",63,"10.1006/phrs.1996.0086","DEPARTAMENTO DE FARMACOLOGÍA, CENTRO DE PRODUCTOS NATURALES, CTRO. NAC. DE INVEST. CIENTIFICAS, HAVANA, CUBA, CENTRO DE PRODUCTOS NATURALES, CNIC, 6880, HABAN, AVE 25 Y 158. APTDO, CUBA;DEPARTAMENTO DE FARMACOLOGÍA, CENTRO DE PRODUCTOS NATURALES, CTRO. NAC. DE INVEST. CIENTIFICAS, HAVANA, CUBA;DEPARTAMENTO DE FARMACOLOGÍA, CENTRO DE PRODUCTOS NATURALES, CTRO. NAC. DE INVEST. CIENTIFICAS, HAVANA, CUBA;DEPARTAMENTO DE FARMACOLOGÍA, CENTRO DE PRODUCTOS NATURALES, CTRO. NAC. DE INVEST. CIENTIFICAS, HAVANA, CUBA;DEPARTAMENTO DE FARMACOLOGÍA, CENTRO DE PRODUCTOS NATURALES, CTRO. NAC. DE INVEST. CIENTIFICAS, HAVANA, CUBA","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG WITH HYPOCHOLESTEROLEMIC EFFECTS DEMONSTRATED IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS AND TYPE II HYPERCHOLESTEROLEMIC PATIENTS. IN ADDITION, ANTIPLATELET EFFECTS OF POLICOSANOL HAVE BEEN SHOWN IN EXPERIMENTAL MODELS AND HEALTHY VOLUNTEERS. THE EFFECT OF SUCCESSIVELY INCREASING DOSES OF POLICOSANOL ON PLATELET AGGREGATION WAS INVESTIGATED IN A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY CONDUCTED IN 37 HEALTHY VOLUNTEERS. THE VOLUNTEERS WERE ON A PLACEBO-BASELINE PERIOD (TWO TABLETS PER DAY) FOR 7 DAYS AND THEREAFTER THEY RECEIVED RANDOMLY, UNDER DOUBLE-BLIND CONDITIONS, PLACEBO OR POLICOSANOL (10 MG DAY-1) FOR 7 DAYS. AFTER THIS PERIOD DOSAGE WAS DOUBLED TO 20 MG DAY-1 FOR THE NEXT 7 DAYS AND THEN AGAIN DOUBLED TO 40 MG DAY-1, WHILE THE CONTROL GROUP RECEIVED PLACEBO TABLETS ALL THE TIME. PLATELET AGGREGATION AS WELL AS COAGULATION TIME WAS MEASURED AT BASELINE AND AFTER EACH DOSING STEP. RESULTS SHOWED THAT ANTIPLATELET EFFECTS OF POLICOSANOL WERE SUCCESSFULLY ENHANCED THROUGHOUT THE STUDY, THUS SUGGESTING A DOSE-DEPENDENT RELATIONSHIP. NO SIGNIFICANT EFFECT WAS REACHED DURING THE FIRST DOSING PERIOD, BUT SIGNIFICANT REDUCTIONS OF EPINEPHRINE AND ADP-INDUCED PLATELET AGGREGATION WERE OBSERVED AFTER THE SECOND ONE. FINALLY, A SIGNIFICANT INHIBITION OF PLATELET AGGREGATION INDUCED BY ALL THE AGONISTS WAS OBSERVED AT THE LAST DOSING STEP. COAGULATION TIME REMAINED UNCHANGED DURING THE TRIAL.","ADP; COLLAGEN; EPINEPHRINE; PLATELET AGGREGATION; POLICOSANOL","ADENOSINE DIPHOSPHATE; ADRENALIN; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL; ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION","","","ARRUZAZABALA M.L., CARBAJAL D., MAS R., MOLINA V., VALDES S., LAGUNA A., CHOLESTEROL-LOWERING EFFECTS OF POLICOSANOL IN RABBITS, BIOL RES, 27, (1994); RODRIGUEZ-ECHENIQUE C., MESA R., MAS R., AMOR A.Y., CASTANO G., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEINAS SÉRICAS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS MACACA ARCTOIDES, ARCH VENEZOLANOS DE FARMAC TERAP, 11, PP. 74-79; HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); PONS P., JIMENEZ A., RODRIGUEZ M., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); ILLNAIT J., CASTANO G., NODARSE N., PONTIGAS V., FERNANDEZ L., MAS R., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II, REV CENIC CIENCIAS BIOLÓGICAS, 22, PP. 74-76, (1991); CASTANO G., ZARDOYA R., ILLNAIT J., MAS R., FERNANDEZ L., SURRIBAS E., NODARSE M., FERNANDEZ J., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); SOLTERO I., FUENMAYOR I., COLMENARES J., ESTUDIO COMPARATIVE DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, ARCH VENEZOLANOS FARMAC TERAP, 12, PP. 71-76, (1993); PONS P., RODRIUEZ M., ROBAINA C., ILLNAIT J., MAS R., FERNANDEZ L., FERNANDEZ J., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, CLIN PHARMACOL RES, 14, PP. 27-33, (1994); BRADLOW B.A., CHETTY N., BIRNBAUM M., BAKER S.G., SEFTEL H.C., PLATELET FUNCTION IN FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTH AFRICA AND THE EFFECT OF PROBUCOL, THROMB RES, 26, PP. 91-99, (1982); CARVALHO A.C.A., COLMAN R.W., LEES R.S., PLATELET FUNCTION IN HYPERLIPOPROTEINEMIA, N ENGL J MED, 290, PP. 434-438, (1974); COLMAN R.W., PLATELET FUNCTION IN HYPERBETALIPOPROTEINEMIA, THROMB HAEMOST, 39, PP. 284-293, (1978); TREMOLI M.P., COLLI S., MORAZZONI G., SIRTORI M., SIRTORI C.R., INCREASED PLATELET SENSITIVITY AND THROMBOXANE B2 FORMATION IN TYPE IIA HYPERLIPOPROTEINAEMIC PATIENTS, EUR J CLIN INVEST, 14, PP. 329-333, (1984); VIENER A., AVIRAM M., BROOK J.G., ABNORMAL PLASMA LIPOPROTEIN COMPOSITION IN HYPERCHOLESTEROLEMIC PATIENTS INDUCES PLATELET ACTIVATION, EUR J CLIN INVEST, 14, PP. 207-213, (1984); KRAMER R.M., JAKUBOWSKI J.A., VAILLANCOURT R., DEYKIN D., EFFECT OF MEMBRANE CHOLESTEROL ON PHOSPHOLIPID METABOLISM IN THROMBIN-STIMULATED PLATELETS, J BIOL CHEM, 257, PP. 6844-6849, (1982); BIZOS R., WONG L.K., VAILLANCOURT R., LEES R.S., CARVALHO A.C., PLATELET PROSTAGLANDIN ENDOPEROXIDE FORMATION IN HYPERLIPIDEMIA, THROMB HAEMOST, 38, (1977); PRISCO D., ROGASI P.G., PANICCIA R., COPPO M., ABBATE R., GENSINI G.F., ALTERED LIPID COMPOSITION AND THROMBOXANE A2 FORMATION IN PLATELETS FROM PATIENTS AFFECTED BY HYPERLIPOPROTEINEMIA, THROMB RES, 50, PP. 593-604, (1988); TREMOLI E., MADERNA P., SIRTORI M., SIRTORI C.R., PLATELET AGGREGATION AND MALONDIALDEHYDE FORMATION IN TYPE IIA HYPERCHOLESTEROLEMIC PATIENTS, HAEMOSTASIS, 8, PP. 47-53, (1979); TREMOLI E., FOLCO G., AGRADI E., GALLI C., PLATELET THROMBOXANE AND SERUM CHOLESTEROL, LANCET, 1, PP. 106-107, (1979); ARRUZAZABALA M.L., CARBAJAL D., MAS R., GARCIA M., FRAGA V., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, (1993); ARRUZAZABALA M.L., MOLINA V., CARBAJAL D., VALDES S., MAS R., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDINS LEUK ESSENTIAL FATTY ACIDS, 49, (1993); TOFLER G., BREZINSKI D., SCAFER A.I., CZEISLER C.A., RUTHERFORD J.D., WILLICH S.N., GLEASON R.E., WILLIAMS G.H., MULLER J.E., CONCURRENT MORNING INCREASE IN PLATELET AGGREGABILITY AND THE RISK OF MYOCARDIAL INFARCTION AND SUDDEN DEATH, NEW ENGL J MED, 316, PP. 1514-1518, (1987); BORN G., AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE (LOND), 194, (1962); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATION FOR PERFORMING MULTIPLE TEST IN A SINGLE EXPERIMENT. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPRINTS, CLIN PROC, 63, PP. 1140-1143, (1988); MARGUERI G.A., PLOW E.F., EDGINGTON T.S., HUMAN PLATELETS POSSESS AN INDUCIBLE AND SATURABLE RECEPTOR SPECIFIC FOR FIBRINOGEN, J BIOL CHEM, 254, (1979); BENNETT J.S., VILAIRE G., EXPOSURE OF PLATELET FIBRINOGEN RECEPTORS BY ADP AND EPINEPHRINE, J CLIN INVEST, 64, (1979); HARFENIST E.J., PACKHAM M.A., RAELENE L., MUSTARD F., INHIBITORS OF ADP-INDUCED PLATELET AGGREGATION PREVENT FIBRINOGEN BINDING TO RABBIT PLATELETS AND CAUSE RAPID DEAGGREGATION AND DISSOCIATION OF BOUND FIBRINOGEN, J LAB CLIN MED, 57, PP. 680-687, (1981); HARDISTY R.M., POWLING M., NOKES T., THE ACTION OF TICLOPIDINE ON HUMAN PLATELETS. STUDIES ON AGGREGATION, SECRETION, CALCIUM MOBILIZATION AND MEMBRANE GLYCOPROTEINS, THROMB HAEMOST, 64, (1990); O'BRIEN J.R., TICLOPIDINE, HAEMOSTASIS, 13, SUPPL., PP. 1-3, (1983); FITZGERALD G.A., MECHANISMS OF PLATELET ACTIVATION: THROMBOXANE A2 AS AN AMPLIFYING SIGNAL FOR OTHER AGONISTS, AM J CARDIOL, 68, (1991); GOTTO A.M., AHA CONFERENCE REPORT ON CHOLESTEROL, CIRCULATION, 80, PP. 717-748, (1989); BRIONES E.R., STEIGER D., PALUMBO P.J., KOTTKE B.A., PRIMARY HYPERCHOLESTEROLEMIA: EFFECT OF TREATMENT ON SERUM LIPIDS, LIPOPROTEIN FRACTIONS, CHOLESTEROL ABSORPTION, STEROL BALANCE AND PLATELET AGGREGATION, MAYO CLIN PROC, 59, PP. 251-257, (1984); ZUCKER M.L., TROWBRIDGE C., KREHBIEL P., JACKSON B., CHERNOFF S.B., DUJOVNE C.A., PLATELET FUNCTION IN HYPERCHOLESTEROLAEMICS BEFORE AND AFTER HYPOLIPIDEMIC DRUG THERAPY, HAEMOSTASIS, 16, PP. 57-64, (1986); SIRTORI M., MONTANARI G., GIANFRANCESCHI G., MALACRIDA M.G., BATTISTIN P., MORAZZONI G., TREMOLI E., COLLI S., MADERNA P., SIRTORI C.R., CLOFIBRATE AND TIADENOL TREATMENT IN HYPERLIPOPROTEINEMIAS. A COMPARATIVE TRIAL OF DRUGS AFFECTING LIPOPROTEIN CATABOLISM AND BIOSYNTHESIS, ATHEROSCLEROSIS, 49, PP. 149-161, (1983); SCHROR K., LOBEL P., STEINHAGEN-THIESSEN E., SIMVASTATIN REDUCES PLATELET THROMBOXANE FORMATION AND RESTORES NORMAL PLATELET SENSITIVITY AGAINST PROSTACYCLIN IN TYPE IIA HYPERCHOLESTEROLEMIA, EICOSANOIDS, 2, PP. 67-73, (1990); DIMINNO G., SILVER M.J., CERBONE A.M., RAINONE A., POSTIGLIONE A., MANCINI M., INCREASED FIBRINOGEN BINDING TO PLATELETS FROM PATIENTS WITH FAMILIAR HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, 6, PP. 203-211, (1986); BANGA J.D., SIXMA J.J., DIABETES MELLITUS, VASCULAR DISEASE AND THROMBOSIS, CLIN HAEMATOL, 15, PP. 465-492, (1986)","","ACADEMIC PRESS","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0030295032","PHARMACOL RES",NA,"NOTREPORTED",NA,"ARRUZAZABALA ML, 1996, PHARMACOL RES","ARRUZAZABALA ML, 1996, PHARMACOL RES"
"MIRKIN A;MAS R;MARTINTO M;BOCCANERA R;ROBERTIS A;POUDES R;FUSTER A;LASTRETO E;YAÑEZ M;IRICO G;MCCOOK B;FARRÉ A","MIRKIN, A. (36340396200); MAS, R. (7007164572); MARTINTO, M. (36340482200); BOCCANERA, R. (36338615100); ROBERTIS, A. (36341122300); POUDES, R. (36340795600); FUSTER, A. (56904046300); LASTRETO, E. (6507836078); YAÑEZ, M. (36341841100); IRICO, G. (6506009987); MCCOOK, B. (56054291600); FARRÉ, A. (57213489328)","EFFICACY AND TOLERABILITY OF POLICOSANOL IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN",2001,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","21","10",39,"","CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA;CENTER FOR NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6990, CUBA","THIS RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY WAS CONDUCTED TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF POLICOSANOL, A CHOLESTEROL-LOWERING DRUG PURIFIED FROM SUGAR CANE WAX, IN WOMEN WHO HAD EXPERIENCED MENOPAUSE AND SHOWED ELEVATED SERUM TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL LEVELS DESPITE A 6-WEEK STANDARD LIPID-LOWERING DIET. THUS, 56 ELIGIBLE PATIENTS WERE RANDOMIZED TO RECEIVE PLACEBO OR POLICOSANOL 5 MG/DAY FOR 8 WEEKS AND THE DOSE WAS DOUBLED TO 10 MG/DAY DURING THE NEXT 8 WEEKS. POLICOSANOL (5 AND 10 MG/DAY) SIGNIFICANTLY DECREASED LDL-CHOLESTEROL (17.3% AND 26.7%, RESPECTIVELY), TOTAL CHOLESTEROL (12.9% AND 19.5%) AS WELL AS THE RATIOS OF LDL-CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL (17.2% AND 26.5%) AND TOTAL CHOLESTEROL TO HDL-CHOLESTEROL (16.3% AND 21.0%) COMPARED WITH BASELINE AND PLACEBO. HDL-CHOLESTEROL LEVELS WERE SIGNIFICANTLY RAISED BY 7.4% AT STUDY COMPLETION. NO SIGNIFICANT CHANGES OCCURRED IN THE LIPID PROFILE OF THE PLACEBO GROUP. THE DRUG WAS SAFE AND WELL TOLERATED. NO DRUG-RELATED ADVERSE EFFECTS WERE OBSERVED. NONE OF THE PATIENTS ADMINISTERED POLICOSANOL BUT THREE OF THOSE ADMINISTERED PLACEBO WITHDREW FROM THE TRIAL BECAUSE OF ADVERSE EFFECTS: ONE DUE TO A SERIOUS HYPERTENSIVE STATUS, ONE BECAUSE OF AN ALLERGIC REACTION (PRURITUS PLUS SKIN RASH) AND ONE DUE TO GASTROINTESTINAL DISTURBANCES (NAUSEAS PLUS VOMITING). ELEVEN PLACEBO PATIENTS REPORTED 24 ADVERSE EFFECTS COMPARED WITH SIX POLICOSANOL PATIENTS WHO REPORTED SEVEN ADVERSE EFFECTS (P <0.05). IN ADDITION, FIVE PLACEBO (17.9%) AND 13 POLICOSANOL PATIENTS (46.4%) (P <0.05) REPORTED IMPROVEMENTS IN HABITUAL SYMPTOMS AND HEALTH PERCEPTION DURING THE STUDY. IN CONCLUSION, POLICOSANOL WAS EFFECTIVE AND WELL TOLERATED IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN, SHOWING ADDITIONAL BENEFITS IN THE HEALTH PERCEPTION OF THE STUDY PATIENTS.","","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; POSTMENOPAUSE; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH","","","BUSH T.L., THE EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN, ANN. N.Y. ACAD. SCI., 592, (1990); STAMFER M.J., COLDITZ G.A., WILLETT W.C., MENOPAUSE AND HEART DISEASE: A REVIEW, ANN. N.Y. ACAD. SCI., 592, (1990); EAKER E.D., CHESBRO J.H., SACKS F.M., ET AL., CARDIOVASCULAR DISEASE IN WOMEN, CIRCULATION, 88, 1, (1993); NASR A., BRECKWOLDT M., REVIEW: ESTROGEN REPLACEMENT THERAPY AND CARDIOVASCULAR PROTECTION: LIPID MECHANISMS ARE THE TIP OF AN ICEBERG, GYNECOL. ENDOCRINOL., 12, (1998); SEMPOS C.T., CLEEMAN J.I., CARROLL M.D., ET AL., PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG US ADULTS: AN UPDATE BASED ON GUIDELINES FROM THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL, J.A.M.A., 269, (1993); LAROSA J.C., MANAGEMENT OF POSTMENOPAUSAL WOMEN WHO HAVE HYPERLIPIDEMIA, AM. J. MED., 96, (1994); MANOLIO T.A., PEARSON T.A., WENGER N.K., ET AL., CHOLESTEROL AND HEART DISEASE IN OLDER PERSONS AND WOMEN: REVIEW OF AN NHLBI WORKSHOP, ANN. EPIDEMIOL., 2, (1992); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), J.A.M.A., 269, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, 1, (1994); HONG M.K., ROMM P.A., REAGAN K., ET AL., EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON SERUM LIPID VALUES AND ANGIOGRAPHICALLY DEFINED CORONARY ARTERY DISEASE IN POSTMENOPAUSAL WOMEN, AM. J. CARDIOL., 69, (1992); TIKKANEN M.J., NIKKILA E.A., MENOPAUSE ESTROGEN AND RISK FOR CORONARY HEART DISEASE, ACTA OBSTET. GYNECOL. SCAND., 40, (1987); GAMBRELL D.R. JR., TERAN A.Z., CHANGES IN LIPIDS AND LIPOPROTEINS WITH LONG-TERM ESTROGEN DEFICIENCY AND HORMONE REPLACEMENT THERAPY, AM. J. OBSTET. GYNECOL., 165, (1991); WALSH B.W., SCHIFF I., ROSNER B., ET AL., EFFECTS OF POSTMENOPAUSAL ESTROGEN REPLACEMENT ON THE CONCENTRATIONS AND METABOLISM OF PLASMA LIPOPROTEINS, N. ENG. J. MED., 325, 1, (1991); ARCA M., LERNA G., GRUNDY S., HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN: METABOLIC DEFECTS AND RESPONSE TO LOW DOSE LOVASTATIN, J.A.M.A., 271, (1994); DARLING G.M., JOHNS J.A., MCCLOUD P.I., DAVIS S.R., ESTROGEN AND PROGESTIN COMPARED WITH SIMVASTATIN FOR HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN, N. ENG. J. MED., 337, (1997); VILLECCO A.S., DE ALOYSIO D., FODERARO S., ET AL., COMPARISON OF THE EFFECTS OF SIMVASTATIN VERSUS HORMONE REPLACEMENT THERAPY IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); DAVIDSON M.H., TESTOLIN L.M., MAKI K.C., ET AL., A COMPARISON OF ESTROGEN REPLACEMENT, PRAVASTATIN AND COMBINED TREATMENT FOR THE MANAGEMENT OF HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN, ARCH. INT. MED., 157, (1997); DARLING G.M., JOHNS J.A., MCCLOUD P.I., ET AL., CONCURRENT USE OF SIMVASTATIN AND ESTROGEN-PROGASTIN THERAPY COMPARED WITH EACH THERAPY ALONE FOR HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN, CLIMACTERIC, 2, (1992); FARNIER M., DAVIGNON J., CURRENT AND FUTURE TREATMENT OF HYPERLIPIDEMIA: THE ROLE OF STATINS, AM. J. CARDIOL., 82, (1998); MENENDEZ R., FERNANDEZ I., DEL RIO A., ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LDL PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL. RES., 27, (1994); MENENDEZ R., ARRUZAZABALA M.L., MAS R., ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BRIT. J. NUTR., 77, (1997); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., THE EFFICACY AND TOFF ERABILITY OF POLICOSANOL (10 MG/DAY) IN ELDERLY PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA: A ONE-YEAR STUDY, CURR. THER. RES., 56, (1995); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CASTANO G., FERNANDEZ J.C., MAS R., ET AL., A LONG-TERM OPEN STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, (1999); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1998); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 16, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 56, (1997); CASTANO G., MAS R., FERNANDEZ L., ET AL., A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, (1998); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GINECOL. ENDOCRINOL., 14, (2000); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AMER. J. MED., 100, (1996); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); ARRUZAZABALA M.L., CARBAJAL D., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB. RES., 69, (1992); CARBAJAL D., ARRUZAZABALA M.L., VALDES S., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGL. LEUK. ESSENT. FATTY ACIDS, 58, (1998); VALDES S., ARRUZAZABALA M.L., CARBAJAL D., ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT. J. CLIN. PHARMACOL. RES., 16, (1996); ARRUZAZABALA M.L., VALDES S., MAS R., ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 34, (1996); ARRUZAZABALA M.D.L., VALDES S., MAS R., ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL. RES., 36, (1997); FRAGA V., MENENDEZ R., AMOR A.M., ET AL., EFFECT OF POLICOSANOL ON IN VIVO AND IN VITRO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH. MED. RES., 28, (1997); MENENDEZ R., MAS R., AMOR A.M., ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BRIT. J. CLIN. PHARMACOL., 50, (2000); NOA M., MAS B., MESA A., DEL R., EFFECT OF POLICOSANOL IN CIRCULATING ENDOTHELIAL CELL IN EXPERIMENTAL MODELS IN SPRAGUE- DAWLEY RATS AND IN RABBITS, J. PHARM. PHARMACOL., 49, (1997)","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0034774685","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"MIRKIN A, 2001, INT J CLIN PHARMACOL RES","MIRKIN A, 2001, INT J CLIN PHARMACOL RES"
"GONZALEZ-BRAVO L;MAGRANER-HERNANDEZ J;ACOSTA-GONZALEZ P;PEREZ-SOUTO N","GONZALEZ-BRAVO, L. (57220758268); MAGRANER-HERNANDEZ, J. (6508199830); ACOSTA-GONZALEZ, P.C. (6505464037); PEREZ-SOUTO, N. (6602985882)","ANALYTICAL PROCEDURE FOR THE DETERMINATION OF 1OCTACOSANOL IN PLASMA BY SOLVENT EXTRACTION AND CAPILLARY GAS CHROMATOGRAPHY",1996,"JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS","682","4",12,"10.1016/0378-4347(95)00515-3","CENTER OF NATURAL PRODUCTS, NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA;DEPARTMENT OF ANALYTICAL CHEMISTRY, NATL. CTR. FOR SCIENTIFIC RESEARCH, HAVANA, P.O. BOX 6880, CUBA","A SIMPLE AND RAPID METHOD FOR THE DETERMINATION OF 1-OCTACOSANOL IN PLASMA, BASED ON AN IMPROVED FOLCH EXTRACTION TECHNIQUE AND CAPILLARY GAS CHROMATOGRAPHY, HAS BEEN DEVELOPED TAKING INTO ACCOUNT THE ANALYTICAL CRITERIA FOR THE PHARMACOKINETIC STUDIES. THE PROCEDURE WAS VALIDATED IN THE RANGE NF 50-2000 NG/ML. DESPITE THE COMPLEXITY OF THE OBTAINED FINGERPRINTS, THE EFFICIENCY AND THE SEPARATION POWER OF GC ALLOWED THE DETERMINATION OF I-OCTACOSANOL IN PLASMA SAMPLES. THE HIGH RECOVERIES (94.5-98.7%) AND PRECISION (1.8-5.8%) OBTAINED ARE IN ACCORDANCE WITH THE ESTABLISHED VALIDATION CRITERIA. THE VALIDITY OF THIS METHOD FOR PHARMACOKINETIC PURPOSES WAS SHOWN USING AN ENDOVENOUS EXPERIMENT IN ANIMALS.","1-OCTACOSANOL","OCTACOSANOL; POLICOSANOL; ACCURACY; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CAPILLARY GAS CHROMATOGRAPHY; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; EXTRACTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SWINE","","","HERNANDEZ F., ILLNAIT J., MAS R., CASTANO G.C., FERNANDEZ L., GONZALEZ M., CORDOVI N., FERNANDEZ J.C., CURR. THER. RES., 51, PP. 568-575, (1992); PONS P., MAS R., ILLNAIT J., FERNANDEZ L., RODRIGUEZ M., ROBAINA C., FERNANDEZ J.C., CURR. THER. RES., 52, PP. 507-511, (1992); FURTON K.G., REIN J., ANAL. CHIM. ACTA, 236, (1990); FOLCH J., LEES M., SLOANE-STANLEY G.H., J. BIOL. CHEM., 226, (1957); GONZALEZ-BRAVO L., RIJTHAR L., INT. J. ENVIRON. ANAL. CHEM., 24, (1986); SHOMBURG G., BEHLAU H., DIELMANN R., WEEKE F., HUSMANN H., J. CHROMATOGR., 142, (1977); PACHLA L.A., WRIGHT D.S., REYNOLDS D.L., J. CLIN. PHARMACOL., 26, (1986); PEREZ-SOUTO N., MAGRANER-HERNANDEZ J., GONZALEZ-BRAVO L., MEDEROS C.M., ACOSTA P.C., REYES J.L., MARTINEZ O., REVISTA CENIC, CIENCIAS BIOLÓGICAS, 22, (1991)","","ELSEVIER B.V.","ENGLISH","J. CHROMATOGR. B BIOMED. APPL.","ARTICLE","ISI","2-S2.0-0030580988","J CHROMATOGR B BIOMED APPL",NA,"NOTREPORTED",NA,"GONZALEZ-BRAVO L, 1996, J CHROMATOGR B BIOMED APPL","GONZALEZ-BRAVO L, 1996, J CHROMATOGR B BIOMED APPL"
"SIERRA R;GONZÁLEZ V;MAGRANER J","SIERRA, ROXANA (7006854525); GONZÁLEZ, VÍCTOR L. (7102097566); MAGRANER, JUAN (6603353869)","VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINATION OF FATTY ALCOHOLS IN 10 MG FILMCOATED TABLETS OF POLICOSANOL",2002,"JOURNAL OF AOAC INTERNATIONAL","85","3",7,"10.1093/jaoac/85.3.563","NATL. CENTER FOR SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN, PLAYA, HAVANA CITY, PO BOX 6414, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN, PLAYA, HAVANA CITY, PO BOX 6414, CUBA;NATL. CENTER FOR SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN, PLAYA, HAVANA CITY, PO BOX 6414, CUBA","A GAS CHROMATOGRAPHIC METHOD USING A PACKED COLUMN AND 1-EICOSANOL AS AN INTERNAL STANDARD WAS VALIDATED FOR THE DETERMINATION OF THE FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN 10 MG FILM-COATED TABLETS. THE ALCOHOLS WERE DETERMINED AS TRIMETHYLSILYL DERIVATIVES, PREPARED WITH N-METHYL-N-TRIMETHYLSILYLTRIFLUOROACETAMIDE. THE METHOD CAN DETECT DEGRADATION PRODUCTS WITH HIGH RETENTION TIMES, WITHOUT INTERFERING WITH THE PEAKS OF THE ACTIVE PRINCIPLE. GOOD LINEARITY (CORRELATION COEFFICIENT = 0.9992) AND ACCURACY (MEAN RECOVERY = 100.27 ± 1.66%) WERE PROVEN OVER A RANGE OF 25-200% OF THE NOMINAL CONCENTRATION. WITHIN-AND BETWEEN-DAY PRECISION AT THE NOMINAL 100% VALUE MET THE ACCEPTANCE CRITERIA (<2%). RUGGEDNESS WAS EXAMINED THROUGH AN INTRALABORATORY EXPERIMENTAL STUDY IN WHICH 6 OPERATIONAL CHANGES WERE MADE; THE CHANGES WERE FOUND TO HAVE NO EFFECT ON QUANTITATION, REPEATABILITY, RESOLUTION, AND RELATIVE RETENTION TIME. THE METHOD IS SUITABLE FOR THE QUALITY CONTROL PROCESS AND STABILITY STUDIES OF THESE TABLETS.","","CHROMATOGRAPHY, GAS; FATTY ALCOHOLS; TABLETS; FATTY ALCOHOL; POLICOSANOL; ARTICLE; GAS CHROMATOGRAPHY; METHODOLOGY; TABLET; VALIDATION STUDY","","","LAGUNA A., MAGRANER J., CARVAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M., (1993); LAGUNA A., MAGRANER J., CARVAJAL D., ARRUZAZABALA M.L., MAS R., GARCIA M., (1993); GONZALEZ V.L., MAGRANER J., J. AOAC INT., 82, PP. 834-839, (1999); YOUDEN W.J., STEINER E.H., STATISTICAL MANUAL OF THE AOAC, (1975)","V.L. GONZÁLEZ; NATL. CENTER FOR SCIENTIFIC RESEARCH, CENTER OF NATURAL PRODUCTS, CUBANACÁN, PLAYA, HAVANA CITY, PO BOX 6414, CUBA; EMAIL: VLGCANA@YAHOO.COM","AOAC INTERNATIONAL","ENGLISH","J AOAC INT","ARTICLE","ISI","2-S2.0-0038890360","J AOAC INT","NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH;NATL. CENTER FOR SCIENTIFIC RESEARCH","NOTREPORTED;NATL. CENTER FOR SCIENTIFIC RESEARCH;NOTREPORTED",NA,"SIERRA R, 2002, J AOAC INT","SIERRA R, 2002, J AOAC INT"
"ANEIROS E;MÁS R;CALDERON B;ILLNAIT J;FERNÁNDEZ L;CASTAÑO G;FERNÁNDEZ J","ANEIROS, ERNESTO (9039750700); MÁS, ROSA (7007164572); CALDERON, BRAULIO (9039269500); ILLNAIT, JOSE (8631465800); FERNÁNDEZ, LILIA (7202848319); CASTAÑO, GLADYS (56232967100); FERNÁNDEZ, JULIO CÉSAR (9432805500)","EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1995,"CURRENT THERAPEUTIC RESEARCH","56","6",92,"10.1016/0011-393X(95)85043-0","TOMAS ROMAY POLICLINICAL CENTER HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;TOMAS ROMAY POLICLINICAL CENTER HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;MEDICAL-SURGICAL RESEARCH CENTER, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED IN 45 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA TO INVESTIGATE THE EFFICACY AND SAFETY OF POLICOSANOL ADMINISTERED AT 10 MG DAILY (5 MG TWICE DAILY). AFTER ADHERING TO A CHOLESTEROL-LOWERING DIET-ONLY PERIOD, 45 OUTPATIENTS IN WHOM SERUM CHOLESTEROL AND LDL-C VALUES WERE NOT CONTROLLED SUFFICIENTLY B DIET ALONE WERE RANDOMIZED TO RECEIVE POLICOSANOL OR PLACEBO AT THE EVENING AND THE MORNING MEAL FOR 6 WEEKS. POLICOSANOL SIGNIFICANTLY DECREASED TOTAL CHOLESTEROL BY 162% AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) BY 21.5%. RATIOS OF TOTAL CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND OF LDL-C TO HDL-C WERE ALSO SIGNIFICANTLY REDUCED BY 17.7% AND 22.3%, RESPECTIVELY. HDL-C VALUES INCREASED BY 14% IN THE POLICOSANOL-TREATED GROUP, BUT THIS INCREASE WAS NOT SIGNIFICANT (P = 0.07). NO SIGNIFICANT CHANGES IN TRIGLYCERIDES WERE OBSERVED COMPARED WITH BASELINE OR PLACEBO. NO CLINICALLY SIGNIFICANT DIFFERENCES IN CLINICAL AND BIOCHEMICAL SAFETY INDICATORS WERE OBSERVED IN POLICOSANOL-TREATED PATIENTS COMPARED WITH THOSE RECEIVING PLACEBO. NO PATIENT WITHDREW FROM THE STUDY BECASUE OF ADVERSE EXPERIENCES, AND THERE WERE NO CLINICALLY SIGNIFICANT DRUG-RELATED ADVERSE EFFECTS. THESE DATA INDICATE THAT POLICO SANOL (5 MG TWICE DAILY) IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. © 1995.","","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL; ADULT; AGED; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; MALE; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POLYDIPSIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERTIGO","","","LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS IA REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 251, PP. 251-264, (1984); LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS IB THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); FRICK, ELO, HAAPA, HELSINKI HEART STUDY: PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA. SAFETY OF TREATMENT, CHANCE OF RISK FACTORS, AND INCIDENCE OF CORONARY HEART DISEASE, NEJM, 317, PP. 1237-1245, (1987); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CIENC BIOL., 22, PP. 60-61, (1991); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZOL FARMACOL TERAP, 11, PP. 80-86, (1992); CRUZ-BUSTILLO, MEDEROS, MAS, ET AL., EFECTO HIPOCOLESTEROLEMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CIENC BIOL, 22, PP. 62-63, (1991); RODRIGUEZ, MESA, MAS, ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AT TRATAMIENTO ORAL CON DOSIS CRECIENTES DE POLICOSANOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP., 11, PP. 74-79, (1992); ALEMAN, MAS, HERNANDEZ, ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLYCOSANOL IN RATS. SUPPLEMENT ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS TOXICOLOGY; JUNE 28–JULY 3, 1992; ROME, ITALY, TOXICOL LETT, 68, (1992); ALEMAN, MAS, HERNANDEZ, ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); MESA, MAS, NOA, ET AL., TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE YEAR STUDY, TOXICOL LETT., 73, PP. 81-90, (1994); RODRIGUEZ, MESA, MAS, ET AL., STUDY OF POLICOSANOL ORAL CHRONIC TOXICITY IN MALE MONKEYS (MACACA ARCTOIDES), FOOD AND CHEMICAL TOXICOLOGY, 32, PP. 565-575, (1994); FERNANDEZ, RENDON, DE LAS CAJIGAS, LOPEZ, ESTUDIO GENOTOXICO DEL ATEROMIXOL (PPG), UN NUEV O MEDICAMENTO HIPOLIPEMIANTE, REV CIENC BIOL., 22, PP. 98-101, (1991); RODRIGUEZ, GARCIA, TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS, 14, PP. 107-113, (1994); HERNANDEZ, ILLNAIT, MAS, ET AL., EFFECTS OF POLICOSANOL ON SERUM LIPIDS AN LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); ILLNAIT, CASTANO, NODARSE, ET AL., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II, REV CIENC BIOL, 22, PP. 74-76, (1991); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROG CIEN MED, 5, PP. 21-28, (1991); PONS, MAS, ILLNAIT, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES., 52, PP. 507-513, (1992); PONS, JIMENEZ, RODRIGUEZ, ET AL., EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, PP. 265-269, (1993); SOLTERO, FUENMAYOR, COIMENARES, ARIAS, ENSAYO DOBLE CIEGO PARA LA EVALUACIÓN DEL POLICOSANOL EN EL TRATAMIENTO DE LA HIPERLIPOPROTEINEMIA TIPO II, ARCH VENEZOL FARMACOL TERAP., 12, PP. 65-70, (1993); SOLTERO, FUENMAYOR, COLMENARES, ESTUDIO COMPARATIVO DOBLE CIEGO DE LA EFICACIA Y TOLERANCIA DEL POLICOSANOL VS BEZAFIBRATO EN PACIENTES CON HIPERLIPIDEMIAS TIPO II, ARCH VENEZOL FARMACOL TERAP, 12, PP. 71-76, (1993); ANEIROS, CALDERON, MAS, ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICONASOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 312-340, (1992); PONS, RODRIGUEZ, ROBAINA, ET AL., EFFECTS OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, J CLIN PHARMACOL RES., 14, PP. 27-33, (1994); PONS, RODRIGUEZ, MAS, ET AL., ONE-YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 55, PP. 1084-1092, (1994); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPATION WITH SODIUM PHOSPHO-TUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD, LEVY, FREDERICKSON, ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 449-451, (1974); ILLINGWORTH, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0028963194","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"ANEIROS E, 1995, CURR THER RES CLIN EXP","ANEIROS E, 1995, CURR THER RES CLIN EXP"
"GOUNI-BERTHOLD I;BERTHOLD H","GOUNI-BERTHOLD, IOANNA (56216445200); BERTHOLD, HEINER K. (9734847000)","POLICOSANOL CLINICAL PHARMACOLOGY AND THERAPEUTIC SIGNIFICANCE OF A NEW LIPIDLOWERING AGENT",2002,"AMERICAN HEART JOURNAL","143","9",213,"10.1067/mhj.2002.119997","MEDICAL POLICLINIC, UNIVERSITY OF BONN, BONN, GERMANY;INSTITUTE FOR CLINICAL RESEARCH, DEPARTMENT OF CLINICAL PHARMACOLOGY, CENTER FOR CARDIOVASCULAR DISEASES, ROTENBURG DER FULDA, GERMANY","BACKGROUND: POLICOSANOL IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS ISOLATED FROM SUGAR CANE WAX, WHOSE MAIN COMPONENT IS OCTACOSANOL. THE MIXTURE HAS BEEN SHOWN TO LOWER CHOLESTEROL IN ANIMAL MODELS, HEALTHY VOLUNTEERS, AND PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. METHODS: WE REVIEWED THE LITERATURE ON PLACEBO-CONTROLLED LIPID-LOWERING STUDIES USING POLICOSANOL PUBLISHED IN PEER-REVIEWED JOURNALS AS WELL AS STUDIES INVESTIGATING ITS MECHANISM OF ACTION AND ITS CLINICAL PHARMACOLOGY. RESULTS: AT DOSES OF 10 TO 20 MG PER DAY, POLICOSANOL LOWERS TOTAL CHOLESTEROL BY 17% TO 21% AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL BY 21% TO 29% AND RAISES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL BY 8% TO 15%. BECAUSE HIGHER DOSES HAVE NOT BEEN TESTED UP TO NOW, IT CANNOT BE EXCLUDED THAT EFFECTIVENESS MAY BE EVEN GREATER. DAILY DOSES OF 10 MG OF POLICOSANOL HAVE BEEN SHOWN TO BE EQUALLY EFFECTIVE IN LOWERING TOTAL OR LDL CHOLESTEROL AS THE SAME DOSE OF SIMVASTATIN OR PRAVASTATIN. TRIGLYCERIDE LEVELS ARE NOT INFLUENCED BY POLICOSANOL. AT DOSAGES OF UP TO 20 MG PER DAY, POLICOSANOL IS SAFE AND WELL TOLERATED, AS STUDIES OF >3 YEARS OF THERAPY INDICATE. THERE IS EVIDENCE FROM IN VITRO STUDIES THAT POLICOSANOL MAY INHIBIT HEPATIC CHOLESTEROL SYNTHESIS AT A STEP BEFORE MEVALONATE GENERATION, BUT DIRECT INHIBITION OF THE HYDROXY-METHYLGLUTARYL-COENZYME A REDUCTASE IS UNLIKELY. ANIMAL STUDIES SUGGEST THAT LDL CATABOLISM MAY BE ENHANCED, POSSIBLY THROUGH RECEPTOR-MEDIATED MECHANISMS, BUT THE PRECISE MECHANISM OF ACTION IS NOT UNDERSTOOD YET. POLICOSANOL HAS ADDITIONAL BENEFICIAL PROPERTIES SUCH AS EFFECTS ON SMOOTH MUSCLE CELL PROLIFERATION, PLATELET AGGREGATION, AND LDL PEROXIDATION. DATA ON EFFICACY DETERMINED BY CLINICAL END POINTS SUCH AS RATES OF CARDIAC EVENTS OR CARDIAC MORTALITY ARE LACKING. CONCLUSIONS: POLICOSANOL SEEMS TO BE A VERY PROMISING PHYTOCHEMICAL ALTERNATIVE TO CLASSIC LIPID-LOWERING AGENTS SUCH AS THE STATINS AND DESERVES FURTHER EVALUATION. © 2002 ELSEVIER SCIENCE LTD. ALL RIGHTS RESERVED.","","ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DRUG INTERACTIONS; FATTY ALCOHOLS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; RANDOMIZED CONTROLLED TRIALS; CHOLESTEROL; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; POLICOSANOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW","","","KANNEL WB, CASTELLI WP, GORDON T, ET AL., LIPOPROTEIN CHOLESTEROL IN THE PREDICTION OF ATHEROSCLEROTIC DISEASE: NEW PERSPECTIVES BASED ON THE FRAMINGHAM HEART STUDY, ANN INTERN MED, 90, PP. 85-91, (1995); EXPERT PANEL, REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, ARCH INTERN MED, 148, PP. 36-69, (1988); EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS, SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), JAMA, 269, PP. 3015-3023, (1993); GOULD AL, ROSSOUW JE, SANTANELLO NC, ET AL., CHOLESTEROL REDUCTION YIELDS CLINICAL BENEFIT: A NEW LOOK AT OLD DATA, CIRCULATION, 91, PP. 2274-2282, (1995); SEMPOS CT, CLEEMAN JI, CARROLL MD, ET AL., PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG US ADULTS: AN UPDATE BASED ON GUIDELINES FROM THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL, JAMA, 269, PP. 3009-3014, (1993); PEARSON TA, LAURORA I, CHU H, ET AL., THE LIPID TREATMENT ASSESSMENT PROJECT (L-TAP)—A MULTICENTER SURVEY TO EVALUATE THE PERCENTAGES OF DYSLIPIDEMIC PATIENTS RECEIVING LIPID-LOWERING THERAPY AND ACHIEVING LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS, ARCH INTERN MED, 160, PP. 459-467, (2000); MENENDEZ R, FERNANDEZ SI, DEL RIO A, ET AL., POLICOSANOL INHIBITS CHOLESTEROL BIOSYNTHESIS AND ENHANCES LOW DENSITY LIPOPROTEIN PROCESSING IN CULTURED HUMAN FIBROBLASTS, BIOL RES, 27, PP. 199-203, (1994); MENENDEZ R, AMOR AM, GONZALEZ RM, ET AL., EFFECT OF POLICOSANOL ON THE HEPATIC CHOLESTEROL BIOSYNTHESIS OF NORMOCHOLESTEROLEMIC RATS, BIOL RES, 29, PP. 253-257, (1996); MENENDEZ R, ARRUZAZABALA L, MAS R, ET AL., CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL ON RABBITS WITH HYPERCHOLESTEROLAEMIA INDUCED BY A WHEAT STARCH-CASEIN DIET, BR J NUTR, 77, PP. 923-932, (1997); RIZZO WB, CRAFT DA, DAMMANN AL, ET AL., FATTY ALCOHOL METABOLISM IN CULTURED HUMAN FIBROBLASTS: EVIDENCE FOR A FATTY ALCOHOL CYCLE, J BIOL CHEM, 262, PP. 17412-17419, (1987); ICHIHARA K, KUSUNOSE E, NODA Y, ET AL., SOME PROPERTIES OF THE FATTY ALCOHOL OXIDATION SYSTEM AND RECONSTITUTION OF MICROSOMAL OXIDATION ACTIVITY IN INTESTINAL MUCOSA, BIOCHIM BIOPHYS ACTA, 878, PP. 412-418, (1986); KAWAMURA N, MOSER HW, KISHIMOTO Y., VERY LONG CHAIN FATTY ACID OXIDATION IN RAT LIVER, BIOCHEM BIOPHYS RES COMMUN, 99, PP. 1216-1225, (1981); SINGH H, DERWAS N, POULOS A., VERY LONG CHAIN FATTY ACID BETA-OXIDATION BY RAT LIVER MITOCHONDRIA AND PEROXISOMES, ARCH BIOCHEM BIOPHYS, 259, PP. 382-390, (1987); MENENDEZ R, SOTOLONGO V, FRAGA V, ET AL., PLASMA LEVELS AND EXCRETION OF TOTAL RADIOACTIVITY IN HEALTHY VOLUNTEERS AFTER ORAL ADMINISTRATION OF 3H-OCTACOSANOL, REV CNIC CIEN BIOL, 27, PP. 32-35, (1996); GONZALES CANAVACIOLO VL, MAGRANER HERNANDEZ J., VALIDATION OF A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING FATTY ALCOHOLS THAT COMPOSE POLICOSANOL IN FIVE-MILLIGRAM FILM-COATED TABLETS, J AOAC INT, 82, PP. 834-839, (1999); GONZALES-BRAVO D, MAGRANER-HERNANDEZ J, ACOSTA-GONZALES PC, ET AL., ANALYTICAL PROCEDURE FOR THE DETERMINATION OF 1-OCTACOSANOL IN PLASMA BY SOLVENT EXTRACTION AND CAPILLARY GAS CHROMATOGRAPHY, J CHROMATR, 682, PP. 359-363, (1996); KABIR Y, KIMURA S., BIODISTRIBUTION AND METABOLISM OF ORALLY ADMINISTERED OCTACOSANOL IN RATS, ANN NUTR METAB, 37, PP. 33-38, (1993); RODRIGUEZ MD, GARCIA H., TERATOGENIC AND REPRODUCTIVE STUDIES OF POLICOSANOL IN THE RAT AND RABBIT, TERATOG CARCINOG MUTAGEN, 14, PP. 107-113, (1994); RODRIGUEZ MD, SANCHEZ M, GARCIA H., MULTIGENERATIONAL REPRODUCTION STUDY OF POLICOSANOL IN RATS, TOXICOL LETT, 90, PP. 97-106, (1997); RODRIGUEZ MD, GARCIA H., EVALUATION OF PERI- AND POST-NATAL TOXICITY OF POLICOSANOL IN RATS, TERATOG CARCINOG MUTAGEN, 18, PP. 1-7, (1998); ZARDOYA R, TULA L, CASTANO G, ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH ABNORMAL SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR THER RES, 57, PP. 568-577, (1996); ALEMAN CL, MAS R, HERNANDEZ C, ET AL., A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE-DAWLEY RATS, TOXICOL LETT, 70, PP. 77-87, (1994); PONS P, RODRIGUEZ M, ROBAINA C, ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT J CLIN PHARM RES, 14, PP. 27-33, (1994); CANETTI MM, MOREIRA M, MAS R, ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA: A 3-YEAR OPENEXTENSION FOLLOW-UP, CURR THER RES, 58, PP. 868-875, (1997); FERNANDEZ L, MAS R, ILLNAIT J, ET AL., POLICOSANOL: RESULTS OF A POSTMARKETING SURVEILLANCE STUDY OF 27,879 PATIENTS, CURR THER RES, 59, PP. 717-722, (1998); MAS R, RIVAS P, IZQUIERDO JE, ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR THER RES, 60, PP. 458-467, (1999); HERNANDEZ F, ILLNAIT J, MAS R, ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); PONS P, MAS R, ILLNAIT J, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); ANEIROS E, MAS R, CALDERON B, ET AL., EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 56, PP. 176-182, (1995); ANEIROS E, CALDERON B, MAS R, ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS P, RODRIGUEZ M, MAS R, ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 55, PP. 1084-1092, (1994); CANETTI M, MOREIRA M, ILLNAIT J, ET AL., ONE-YEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, ADV THER, 12, PP. 245-254, (1995); CANETTI M, MOREIRA M, MAS R, ET AL., A TWO-YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINAEMIA, INT J CLIN PHARM RES, 15, PP. 159-165, (1995); CASTANO G, MAS R, FERNANDEZ JC, ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR THER RES, 60, PP. 379-391, (1999); CASTANO G, MAS R, FERNANDEZ L, ET AL., EFFECTS OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL ENDOCRINOL, 14, PP. 187-195, (2000); TORRES O, AGRAMONTE AJ, ILLNAIT J, ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, PP. 393-396, (1995); CRESPO N, ALVAREZ R, MAS R, ET AL., EFFECTS OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR THER RES, 58, PP. 44-51, (1997); CASTANO G, TULA L, CANETTI M, ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 57, PP. 691-699, (1996); CASTANO G, CANETTI M, MOREIRA M, ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A 12-MONTH STUDY, CURR THER RES, 56, PP. 819-828, (1995); MAS R, CASTANO G, ILLNAIT J, ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN PHARMACOL THER, 65, PP. 439-447, (1999); ORTENSI G, GLADSTEIN J, VALLI H, ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 390-401, (1997); BENITEZ M, ROMERO C, MAS R, ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR THER RES, 58, PP. 859-867, (1997); CASTANO G, MAS R, ARRUZAZABALA MDL, ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT J CLIN PHARM RES, 19, PP. 105-116, (1999); CRESPO N, ILLNAIT J, MAS R, ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT J CLIN PHARM RES, 19, PP. 117-127, (1999); CASTANO G, MAS R, FERNANDEZ JC, ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS, CURR THER RES, 61, PP. 137-146, (2000); MARCELLO S, GLADSTEIN J, TESONE P, ET AL., EFFECTS OF BEZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PILOT STUDY, CURR THER RES, 61, PP. 346-357, (2000); BATISTA J, STUSSER R, SAEZ F, ET AL., EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART DISEASE IN MIDDLE-AGED PATIENTS: A 14-MONTH PILOT STUDY, INT J CLIN PHARM THER, 34, PP. 134-137, (1996); STUSSER R, BATISTA J, PADRON R, ET AL., LONG-TERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISE-ECG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS, INT J CLIN PHARM THER, 36, PP. 469-473, (1998); BATISTA J, STUSSER RJ, PADRON R, ET AL., FUNCTIONAL IMPROVEMENT IN CORONARY ARTERY DISEASE AFTER 20 MONTHS OF LIPID-LOWERING THERAPY WITH POLICOSANOL, ADV THER, 13, PP. 137-148, (1996); CASTANO G, MAS R, FERNANDEZ JC, ET AL., EFFECTS OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J GERONTOL A BIOL SCI MED SCI, 56, PP. M186-M192, (2001); BATISTA J, STUSSER R, PENICHET M, ET AL., DOPPLER-ULTRASOUND PILOT STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTOID-VERTEBRAL ATHEROSCLEROSIS, CURR THER RES, 56, PP. 906-914, (1995); SAINT-JOHN M, MCNAUGHTON L., OCTACOSANOL INGESTION AND ITS EFFECTS ON METABOLIC RESPONSES TO SUBMAXIMAL CYCLE ERGOMETRY REACTION TIME AND CHEST AND GRIP STRENGTH, INT CLIN NUTR REV, 6, PP. 81-87, (1986); CASTANO G, MAS R, ROCA J, ET AL., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POLICOSANOL IN PATIENTS WITH INTERMITTENT CLAUDICATION, ANGIOLOGY, 50, PP. 123-130, (1999); CASTANO G, MAS FERREIRO R, FERNANDEZ L, ET AL., A LONG-TERM STUDY OF POLICOSANOL IN THE TREATMENT OF INTERMITTENT CLAUDICATION, ANGIOLOGY, 52, PP. 115-125, (2001); NOA M, MAS R, DE LA ROSA MC, ET AL., EFFECT OF POLICOSANOL ON LIPOFUNDIN-INDUCED LESIONS IN RATS, J PHARM PHARMACOL, 47, PP. 289-291, (1995); NOA M, DE LA ROSA MC, MAS R., EFFECT OF POLICOSANOL ON FOAM-CELL FORMATION IN CARRAGEENAN-INDUCED GRANULOMAS IN RATS, J PHARM PHARMACOL, 48, PP. 306-309, (1996); NOA M, MAS R, MESA R., EFFECT OF POLICOSANOL ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY, INT J CARDIOL, 67, PP. 125-132, (1998); FRAGA V, MENENDEZ R, AMOR AM, ET AL., EFFECT OF POLICOSANOL ON IN VIVO AND IN VITRO RAT LIVER MICROSOMAL LIPID PEROXIDATION, ARCH MED RES, 28, PP. 355-360, (1997); MENENDEZ R, MAS R, AMOR AM, ET AL., EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN (LDL) ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IN VITRO, BR J CLIN PHARMACOL, 50, PP. 255-262, (2000); ARRUZAZABALA ML, CARBAJAL D, MAS R, ET AL., EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMB RES, 69, PP. 321-327, (1992); ARRUZAZABALA ML, MOLINA V, CARBAJAL D, ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A2, PROSTAGLANDIN LEUKOT ESSENT FATTY ACIDS, 49, PP. 695-697, (1993); CARBAJAL D, ARRUZAZABALA ML, MAS R, ET AL., EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS, PROSTAGLANDIN LEUKOT ESSENT FATTY ACIDS, 50, PP. 249-251, (1994); MOLINA V, ARRUZAZABALA ML, CARBAJAL D, ET AL., EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS, BRAZ J MED BIOL RES, 32, PP. 1269-1276, (1999); ARRUZAZABALA ML, VALDES S, MAS R, ET AL., EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 34, PP. 181-185, (1996); VALDES S, ARRUZAZABALA ML, FERNANDEZ L, ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, INT J CLIN PHARM RES, 16, PP. 67-72, (1996); ARRUZAZABALA ML, MAS R, MOLINA V, ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION IN TYPE II HYPERCHOLESTEROLEMIC PATIENTS, INT J TISSUE REACT, 20, PP. 119-124, (1998); ARRUZAZABALA ML, VALDES S, MAS R, ET AL., COMPARATIVE STUDY OF POLICOSANOL, ASPIRIN AND THE COMBINATION OF POLICOSANOL-ASPIRIN ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS, PHARMACOL RES, 36, PP. 293-297, (1997); CARBAJAL D, ARRUZAZABALA ML, VALDES S, ET AL., EFFECT OF POLICOSANOL ON PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES IN HEALTHY VOLUNTEERS, PROSTAGLANDIN LEUKOT ESSENT FATTY ACIDS, 58, PP. 61-64, (1998)","H.K. BERTHOLD; INSTITUTE FOR CLINICAL RESEARCH, DEPARTMENT OF CLINICAL PHARMACOLOGY, CENTER FOR CARDIOVASCULAR DISEASES, 36199 ROTENBURG DER FULDA, GERMANY; EMAIL: BERTHOLD@UNI-BONN.DE","","ENGLISH","AM. HEART J.","ARTICLE","ISI","2-S2.0-0036481621","AM HEART J","UNIVERSITY OF BONN;INSTITUTE FOR CLINICAL RESEARCH","NOTREPORTED;INSTITUTE FOR CLINICAL RESEARCH;NOTREPORTED",NA,"GOUNI-BERTHOLD I, 2002, AM HEART J","GOUNI-BERTHOLD I, 2002, AM HEART J"
"CARBAJAL D;ARRUZAZABALA M;MÁS R;MOLINA V;VALDÉS S","CARBAJAL, D. (8777025000); ARRUZAZABALA, M.L. (6603962476); MÁS, R. (7007164570); MOLINA, V. (7006062814); VALDÉS, S. (8777025100)","EFFECT OF POLICOSANOL ON EXPERIMENTAL THROMBOSIS MODELS",1994,"PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS","50","2",26,"10.1016/0952-3278(94)90162-7","CUBA;CUBA;CUBA;CUBA;CUBA","POLICOSANOL IS A NATURAL PRODUCT, OBTAINED FROM SUGAR CANE WAX (SACCHARUM OFFICINARUM L.) WITH WHICH CHOLESTEROL-LOWERING EFFECTS HAVE BEEN DEMONSTRATED IN EXPERIMENTAL MODELS, HEALTHY VOLUNTEERS AND HYPERCHOLESTEROLEMIC PATIENTS. THE EFFECTS OF POLICOSANOL ON EXPERIMENTAL VENOUS AND ARTERIAL THROMBOSIS IN RATS WERE INVESTIGATED. POLICOSANOL (25 MG/KG) SIGNIFICANTLY DECREASED THE THROMBUS WEIGHT, IN THE VENOUS THROMBOSIS MODELS, THE PROTECTIVE EFFECT PERSISTING UNTIL 4 H AFTER ITS ORAL ADMINISTRATION. POLICOSANOL (25 MG/KG SINGLE DOSE) WAS ABLE TO REDUCE RECTAL TEMPERATURE VARIATION INDUCED BY ARTERIAL THROMBOSIS. ALSO AT THE SAME DOSE POLICOSANOL INCREASED 6-KETO-PGF1Α SERUM LEVELS IN RATS. © 1994.","","6-KETOPROSTAGLANDIN F1 ALPHA; ANIMAL; ANTICHOLESTEREMIC AGENTS; DRUG EVALUATION, PRECLINICAL; EPOPROSTENOL; FATTY ALCOHOLS; FEMALE; HUMAN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; THROMBOPHLEBITIS; THROMBOSIS; 6 OXOPROSTAGLANDIN F1 ALPHA; POLICOSANOL; SEROTONIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BODY TEMPERATURE; CONTROLLED STUDY; INTRAGASTRIC DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOSIS","","","ARRUZAZABALA, CARBAJAL, MAS, ILLNAIT, LAGUNA, CASTANO, EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE. REVISTA CENIC, CIENCIAS BIOLÓGICAS, 22, PP. 60-61, (1991); CRUZ-BUSTILLO, MEDEROS, MAS, ET AL., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO DE CEBA. REVISTA CENIC, CIENCIAS BIOLÓGICAS, 22, PP. 62-63, (1991); HERMANDEZ, ILLNAIT, MAS, ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEIN IN HEALTHY VOLUNTEERS, CURRENT THERAPEUTIC RESEARCH, 51, PP. 568-575, (1992); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); PONS, ILLNAIT, RODRIGUEZ, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 507-513, (1992); ALEMAN, MAS, HERNANDEZ, ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, TOXICOL LETT, (1992); ARRUZAZABALA, CARBAJAL, MAS, GARCIA, FRAGA, EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS, THROMBOSIS RESEARCH, 69, PP. 321-327, (1992); ARRUZAZABALA, CARBAJAL, MOLINA, VALDES, MAS, Y GARCIA, ESTUDIO FARMACOLÓGICO DE LA INTERACCIÓN ENTRE EL POLICOSANOL Y LA ASPIRINA EN ANIMALES DE EXPERIMENTACIÓN, REV IBEROAMERICANA DE THROMBOSIS Y HEMOSTASIS, 5, PP. 17-20, (1992); ARRUZAZABALA, MOLINA, CARBAJAL, VALDES, MAS, EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS: ROLE OF PROSTACYCLIN AND THROMBOXANE A<SUB>2</SUB> , PROSTAGLANDIN LEUKOT ESSENT FATTY ACIDS, (1993); HLADOVEC, A SENSITIVE MODEL OF VENOUS THROMBOSIS IN RATS, THROMB RES, 43, PP. 539-544, (1986); HLADOVEC, A NEW MODEL OF ARTERIAL THROMBOSIS, THROMBOSIS RESEARCH, 41, PP. 659-664, (1986); HLADOVEC, THE EFFECT OF ANTITHROMBOTIC IN A NEW MODEL OF ARTERIAL THROMBOSIS, THROMB RES, 41, PP. 665-670, (1986); GRYGLEWSKY, BUNTING, MONCADA, FLOWER, VANES, ARTERIAL WALLS ARE PROTECTED AGAINST DEPOSITION OF PLATELET THROMBI BY A SUBSTRATE (PROSTAGLANDIN X) WHICH THEY MAKE FROM PROSTAGLANDIN ENDOPEROXIDES, PROSTAGLANDINS, 12, PP. 685-713, (1976); BUNTING, GRYGLWESKY, MONCADA, VANES, ARTERIAL WALLS GENERATE FROM PROSTAGLANDIN ENDOPEROXIDES A SUBSTANCE WHICH RELAXES STRIPS OF MESENTERIC AND COELIAC ARTERIES AND INHIBITS PLATELET AGGREGATION, PROSTAGLANDINS, 12, PP. 897-913, (1976); MONCADA, VANES, UNSTABLE METABOLITES OF ARACHIDONIC ACID AND THEIR ROLE IN HAEMOSTASIS AND THROMBOSIS, BR MED BULL, 34, (1978); VESTERQUIST, GREEN, JOHNSSON, THROMBOXANE AND PROSTACYCLIN FORMATION IN PATIENTS WITH DEEP VEIN THROMBOSIS, THROMBOSIS RESEARCH, 45, PP. 393-402, (1987)","","","ENGLISH","PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS","ARTICLE","ISI","2-S2.0-0028258078","PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS",NA,"NOTREPORTED",NA,"CARBAJAL D, 1994, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS","CARBAJAL D, 1994, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS"
"CASTAÑO G;MAS R;FERNÁNDEZ L;ILLNAIT J;GÁMEZ R;ALVAREZ E","CASTAÑO, G. (7005759008); MAS, R. (7007164572); FERNÁNDEZ, L. (7202848319); ILLNAIT, J. (8631465800); GÁMEZ, R. (7003605346); ALVAREZ, E. (15053135600)","EFFECTS OF POLICOSANOL 20 VERSUS 40 MGDAY IN THE TREATMENT OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA A 6MONTH DOUBLEBLIND STUDY",2001,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","21","14",55,"","CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA;CENTER OF NATURAL PRODUCTS, NATL. CENTER FOR SCIENTIFIC RESEARCH, PLAYA, HAVANA CITY, PO BOX 6880, CUBA","POLICOSANOL IS A WELL DEFINED MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING EFFECTS PROVEN FOR A DOSE RANGE FROM 5-20 MG/DAY IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA ASSOCIATED WITH NONINSULIN DEPENDENT DIABETES MELLITUS. THIS RANDOMIZED, DOUBLE-BLIND STUDY INVESTIGATED THE CHOLESTEROL-LOWERING EFFICACY AND TOLERABILITY OF POLICOSANOL 20 MG/DAY COMPARED WITH 40 MG/DAY. CHANGES IN LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL LEVELS WERE PREDEFINED AS THE PRIMARY EFFICACY ENDPOINT. PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WERE ENROLLED IN THE STUDY AND INSTRUCTED TO CONTINUE A STEP I CHOLESTEROL-LOWERING DIET FOR 6 WEEKS AND THOSE ELIGIBLE TO BE INCLUDED (89) WERE RANDOMLY ALLOCATED TO RECEIVE UNDER DOUBLE-BLIND CONDITIONS PLACEBO (N = 30), POLICOSANOL 20 MG/DAY (N = 29) OR 40 MG/DAY (N = 30). AFTER 24 WEEKS, POLICOSANOL AT 20 AND 40 MG/DAY SIGNIFICANTLY (P < 0.00001) LOWERED LDL-CHOLESTEROL BY 27.4% AND 28.1%, TOTAL CHOLESTEROL (P <0.00001) BY 15.6% AND 17.3%, AND THE LDL-CHOLESTEROL/HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL RATIO BY 37.2% AND 36.5%, RESPECTIVELY. THE RATIO OF TOTAL CHOLESTEROL/HDL-CHOLESTEROL WAS LOWERED BY 27.1% AND 27.5%, WHILE HDL-CHOLESTEROL LEVELS INCREASED (P <0.001) BY 17.6% AND 17.0%, RESPECTIVELY. COMPARED WITH BASELINE, POLICOSANOL 20 MG/DAY LOWERED TRIGLYCERIDES (P <0.05) BY 12.7%, WHILE THEY WERE LOWERED (P <0.01) BY 15.6% AT A DOSE OF POLICOSANOL 40 MG/DAY. ALL THE ABOVE-MENTIONED SIGNIFICANT DIFFERENCES WERE ALSO DIFFERENT FROM PLACEBO AND NO SIGNIFICANT CHANGES OCCURRED IN ANY LIPID PROFILE PARAMETERS IN THE PLACEBO GROUP. BASED ON THE MEAN VALUES OF LDL-CHOLESTEROL LEVELS AT STUDY COMPLETION, THE MEAN PERCENT REDUCTIONS FROM BASELINE WERE 27.4% AND 28.1% FOR THE 20 AND 40 MG/DAY GROUPS, RESPECTIVELY. THUS, THE EFFECTS OF BOTH POLICOSANOL DOSES ON THE MAIN EFFICACY VARIABLE WERE PRACTICALLY IDENTICAL. CONSISTENT WITH THE DATA OBTAINED FOR LDL-CHOLESTEROL, BOTH DOSES WERE SIMILARLY EFFECTIVE IN CHANGING ALL THE OTHER LIPID PROFILE PARAMETERS. NO UNEXPECTED ADVERSE EFFECTS WERE OBSERVED AND THERE WERE NO SIGNIFICANT BETWEEN-GROUP DIFFERENCES REGARDING SAFETY INDICATOR VALUES OR REPORTED ADVERSE EFFECTS. IN CONCLUSION, ALTHOUGH THE TOLERABILITY PROFILE REMAINS EXCELLENT, ACCORDING TO THE PRESENT RESULTS POLICOSANOL AT A DOSE OF 40 MG/DAY DOES NOT OFFER SIGNIFICANT ADDITIONAL CHOLESTEROL-LOWERING EFFICACY OVER THE 20 MG/DAY DOSE.","","ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; ALKANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT","","","EPSTEIN F.H., CARDIOVASCULAR DISEASE EPIDEMIOLOGY. A JOURNEY FROM THE PAST INTO THE FUTURE, CIRCULATION, 93, (1996); SUMMARY OF THE SECOND REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL II), J.A.M.A., 269, (1993); PYORALA K., DE BACKER G., GRAHAM I., ET AL., PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY, EUROPEAN ATHEROSCLEROSIS SOCIETY AND EUROPEAN SOCIETY OF HYPERTENSION, EUR. HEART J., 15, 1, (1994); ATHEROSCLEROSIS, 110, (1994); PREVENTION OF CORONARY HEART DISEASE IN CLINICAL PRACTICE. RECOMMENDATIONS OF THE SECOND JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CORONARY PREVENTION, EUR. HEART J., 19, (1994); WOOD D., EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION, EUR. HEART J., 19, SUPPL. A, (1998); ANDERSON K.M., WILSON P.W.F., ODELL P.M., ET AL., AN UPDATED CORONARY RISK PROFILE. A STATEMENT FOR HEALTH PROFESSIONALS, CIRCULATION, 83, (1991); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I. REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE, J.A.M.A., 251, (1984); THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II. THE RELATIONSHIP OF REDUCTION IN THE INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL-LOWERING, J.A.M.A., 251, (1984); FRICK M.H., ELO O., HAPPA K., ET AL., HELSINKI HEART STUDY: PRIMARY-PREVENTION WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, N. ENG. J. MED., 317, (1987); RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4,444 PATIENTS WITH CORONARY HEART DISEASE, THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S), LANCET, 344, (1994); SACKS F.M., PFEFFER M.A., MOY L.A., ET AL., THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS, N. ENGL. J. MED., 335, (1996); TONKIN A.M., HUNT D., LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY. CLINICAL IMPLICATIONS FOR CARDIOVASCULAR PRACTICE, CHOLESTEROL-LOWERING THERAPY, EVALUATION OF CLINICAL TRIAL EVIDENCE, PP. 173-190, (2000); SHEPHERD S., COBBE S.M., FORD I., ET AL., PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA, N. ENGL. J. MED., 333, (1995); DOWNS J.R., CLEARFIELD M., WEIS S., ET AL., PRIMARY PREVENTION OF ACUTE CORONARY EVENTS WITH LOVASTATIN IN MEN AND WOMEN WITH AVERAGE CHOLESTEROL LEVELS. RESULTS OF AFCAPS/TEXCAPS, J.A.M.A., 279, (1998); GOTTO A., ASSMANN G., CARMENA R., ET AL., LIPID HANDBOOK FOR CLINICAL PRACTICE. BLOOD LIPIDS AND CORONARY HEART DISEASE. SECOND EDITION, PP. 1-71, (2000); HEUDEBERT G., RUISWYK J.V., HIATT J., SCHECTMAN G., COMBINATION OF DRUG THERAPY FOR HYPERCHOLESTEROLEMIA, THE TRADE-OFF BETWEEN COST AND SIMPLICITY, ARCH. INT. MED., 153, (1993); SCHECTMAN G., HIATT J., DRUG THERAPY FOR HYPERCHOLESTEROLEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE, FACTORS LIMITING ACHIEVEMENT OF LIPID GOALS, AM. J. MED., 100, (1996); MULS E., DE BACKER G., DE BACQUER D., ET AL., LIPI-WATCH, A BELGIAN/LUXEMBOURG SURVEY ON ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY LIPID GOALS, PHARMACOEPIDEMIOLOGY, 19, (2000); LEA A.P., MCTAVISH D., ATORVASTATIN: A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN THE MANAGEMENT OF HYPERLIPIDEMIA, DRUGS, 53, (1997); NAWROCKI J.W., WEISS S.R., DAVIDSON M.H., ET AL., REDUCTION OF LDL-C BY 25% TO 60% IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA BY ATORVASTATIN, A NEW HMGCOA REDUCTASE INHIBITOR, ARTERIOSCLER. VASC. BIOL., 15, (1995); JONES P., KAFONEK S., LAURORA I., HUNNINGHAKE D., COMPARATIVE DOSE EFFICACY STUDY OF ATORVASTATIN VERSUS SIMVASTATIN, PRAVASTATIN, LOVASTATIN AND FLUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA (THE CURVES STUDY), AM. J. CARDIOL., 81, (1998); SMITH D.G., LESLIE S.J., SZUCS T.D., ET AL., COST OF TREATING TO A MODIFIED EUROPEAN ATHEROESCLEROSIS SOCIETY LDL-C TARGET. COMPARISON OF ATORVASTATIN WITH FLUVASTATIN, PRAVASTATIN AND SIMVASTATIN, CLIN. DRUG INVEST., 17, (1999); OSE L., KASTELEIN J.J.P., SCOTT R., ET AL., EFFICACY AND SIX-MONTH SAFETY OF SIMVASTATIN 80 MG/DAY. RESULTS FROM THE WORLDWIDE SIMVASTATIN EXPANDED DOSE PROGRAM (WSEDP), NUTR. METAB. CARDIOV. DIS., 8, (1998); MAS R., POLICOSANOL, DRUGS OF THE FUTURE, 25, (2000); CASTANO G., ILLNAIT J., FERNANDEZ L., FERNANDEZ J.C., MAS R., ESTUDIO DOSIS-EFECTO DE LA ACCIÓN HIPOCOLESTEROLÉMICA DEL POLICOSANOL EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, REV. CENIC CIEN. BIOL., 27, (1992); PONS P., RODRIGUEZ M., ROBAINA C., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, INT. J. CLIN. PHARMACOL. RES., 14, (1994); ANEIROS E., CALDERON B., MAS R., ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR. THER. RES., 54, (1993); PONS P., MAS R., ILLNAIT J., ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR. THER. RES., 52, (1992); PONS P., RODRIGUEZ M., MAS R., ET AL., ONE YEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERHOLESTEROLEMIA, CURR. THER. RES., 55, (1994); ANEIROS E., MAS R., CALDERON B., ET AL., EFFECT OF POLICOSANOL IN LOWERING-CHOLESTEROL LEVELS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CASTANO G., MAS R., NODARSE M., ET AL., ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE DAILY) IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 56, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., ONE YEAR STUDY ON THE EFFECT OF POLICOSANOL (5 MG-TWICE-A-DAY) ON LIPID PROFILE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, AD. THER., 12, (1995); CASTANO G., CANETTI M., MORERA M., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, A 12 MONTHS STUDY, CURR. THER. RES., 56, (1995); CANETTI M., MORERA M., ILLNAIT J., ET AL., A TWO YEAR STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA, INT. J. CLIN. PHARMACOL. RES., 15, (1995); CASTANO G., TULA L., CANETTI M., ET AL., EFFECTS OF POLICOSANOL IN HYPERTENSIVE PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 57, (1996); ZARDOYA R., TULA L., CASTANO G., ET AL., EFFECTS OF POLICOSANOL ON HYPERCHOLESTEROLEMIC PATIENTS WITH DISTURBANCES ON SERUM BIOCHEMICAL INDICATORS OF HEPATIC FUNCTION, CURR. THER. RES., 57, (1996); ORTENSI G., GLADSTEIN H., VALLI H., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS SIMVASTATIN IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); BENITEZ M., ROMERO C., MAS R., ET AL., A COMPARATIVE STUDY OF POLICOSANOL VERSUS PRAVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA, CURR. THER. RES., 58, (1997); CANETTI M., MORERA M.S., MAS R., ET AL., EFFECTS OF POLICOSANOL ON PRIMARY HYPERCHOLESTEROLEMIA, A 3-YEAR OPEN FOLLOW-UP, CURR. THER. RES., 58, (1997); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., OPEN-LABEL STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH CORONARY RISK, CURR. THER. RES., 59, (1998); MAS R., CASTANO G., ILLNAIT J., ET AL., EFFECTS OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND ADDITIONAL CORONARY RISK FACTORS, CLIN. PHARMACOL. THER., 65, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., A LONG-TERM, OPEN-LABEL STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL IN PATIENTS WITH HIGH GLOBAL CORONARY RISK, CURR. THER. RES., 60, (1999); CASTANO G., MAS R., ARRUZAZABALA M.L., ET AL., EFFECTS OF POLICOSANOL AND PRAVASTATIN ON LIPID PROFILE, PLATELET AGGREGATION AND ENDOTHELEMIA IN OLDER HYPERCHOLESTEROLEMIC PATIENTS, INT. J. CLIN. PHARM. RES., 19, (1999); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT RISK FACTORS, CURR. THER. RES., 61, (2000); CASTANO G., MAS R., FERNANDEZ L., ET AL., EFFECT OF POLICOSANOL ON POSTMENOPAUSAL WOMEN WITH TYPE II HYPERCHOLESTEROLEMIA, GYNECOL. ENDOCRINOL., 14, (2000); CASTANO G., MAS R., FERNANDEZ J.C., ET AL., EFFECT OF POLICOSANOL IN OLDER PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK, J. GERENTOL., 56, (2000); TORRES O., AGRAMONTE A.J., ILLNAIT J., ET AL., TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL, DIABETES CARE, 18, (1995); CRESPO N., ALVAREZ R., MAS R., ET AL., EFFECT OF POLICOSANOL ON PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA: A PILOT STUDY, CURR. THER. RES., 58, (1997); CRESPO N., ILLNAIT J., MAS R., ET AL., COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS, INT. J. CLIN. PHARMACOL RES., 19, (1999); FRIEDEWALD W.T., LEVY R.I., FRIEDERICKSON S.D., ESTIMATION OF THE CONCENTRATION OF LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN. CHEM., 18, (1972); SEIGLER L., WU W.T., SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION, ULTRACENTRIFUGATION VS. PRECIPITATION WITH SODIUM PHOSPHOTUNGSTAT AND MAGNESIUM CHLORIDE, CLIN. CHEM., 27, (1981); O'BRIEN P.C., SHAMPO M.C., STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN. PROC., 63, (1988); MAS R., RIVAS P., IZQUIERDO J.E., HERNANDEZ R., ET AL., PHARMACOEPIDEMIOLOGIC STUDY OF POLICOSANOL, CURR. THER. RES., 60, (1999); FERNANDEZ L., MAS R., ILLNAIT J., ET AL., POLICOSANOL, RESULTS OF A POSTMARKETING SURVEILLANCE CONTROL ON 27,879 CASES, CURR. THER. RES., 59, (1998)","","","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","2-S2.0-0034775530","INT J CLIN PHARMACOL RES",NA,"NOTREPORTED",NA,"CASTAÑO G, 2001, INT J CLIN PHARMACOL RES","CASTAÑO G, 2001, INT J CLIN PHARMACOL RES"
"ARRUZAZABALA M;MOLINA V;CARBAJAL D;VALDÉS S;MÁS R","ARRUZAZABALA, M.L. (6603962476); MOLINA, V. (7006062814); CARBAJAL, D. (8777025000); VALDÉS, S (8777025100); MÁS, R. (7007164572)","EFFECT OF POLICOSANOL ON CEREBRAL ISCHEMIA IN MONGOLIAN GERBILS ROLE OF PROSTACYCLIN AND THROMBOXANE A2",1993,"PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS","49","2",55,"10.1016/0952-3278(93)90080-G","CENTER OF NATURAL PRODUCTS, CNIC, AVE 25 AND 158, APDO 6990, PLAYA, HABANA, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, AVE 25 AND 158, APDO 6990, PLAYA, HABANA, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, AVE 25 AND 158, APDO 6990, PLAYA, HABANA, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, AVE 25 AND 158, APDO 6990, PLAYA, HABANA, CUBA;CENTER OF NATURAL PRODUCTS, CNIC, AVE 25 AND 158, APDO 6990, PLAYA, HABANA, CUBA","POLICOSANOL IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, ISOLATED FROM SUGAR CANE WAX, WHOSE MAIN COMPONENT IS OCTACOSANOL. POLICOSANOL (25, 50 AND 200 MG/KG) ADMINISTERED BY THE ORAL ROUTE NOT ONLY SIGNIFICANTLY REDUCED SERUM THROMBOXANE B2 (TXB2) LEVELS BUT ALSO, AT 200 MG/KG SIGNIFICANTLY INCREASED 6-KETO-PGF1Α IN MONGOLIAN GERBILS. POLICOSANOL AT 200 MG/KG SIGNIFICANTLY PROTECTED AGAINST CEREBRAL ISCHEMIA INDUCED BY UNILATERAL LIGATION OF COMMON CAROTID ARTERY IN MONGOLIAN GERBILS. IN THIS EXPERIMENTAL MODEL, COMBINED ADMINISTRATION OF INEFFECTIVE DOSES OF POLICOSANOL (25 MG/KG) AND ASPIRIN (ASA) (30 MG/KG) SIGNIFICANTLY PROTECTED ANIMALS INDICATING A SYNERGISM BETWEEN THEM. © 1993.","","6-KETOPROSTAGLANDIN F1 ALPHA; ANIMAL; ASPIRIN; BRAIN ISCHEMIA; DRUG SYNERGISM; EPOPROSTENOL; FATTY ALCOHOLS; GERBILLINAE; THROMBOXANE A2; THROMBOXANE B2; ANIMALIA; ARUNDINARIA; GERBILLINAE; MERIONES UNGUICULATUS; SACCHARUM; 6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; POLICOSANOL; THROMBOXANE A2; THROMBOXANE B2; ANIMAL EXPERIMENT; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; GERBIL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL","","","ARRUZAZABALA, CARBAJAL, MAS, CASTANO, SOTOLONGO, MESA, EFECTO DEL ATEROMIXOL SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV. CENIC. CIENCIAS BIOLOGICAS, 22, PP. 60-61, (1991); CRUZ-BUSTILLO, MEDEROS, MAS, ARRUZAZABALA, BARRETO, MARTINEZ, EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL EN EL CERDO DE CEBA, REV. CENIC, 22, PP. 62-64, (1991); ARRUZAZABALA, CARBAJAL, MAS, ILLNAIT, LAGUNA, CASTANO, EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZOLANOS DE FARMACOLOGÍA Y TERAPEÚTICA, 11, (1992); HERNANDEZ, ILLNAIT, MAS, ET AL., EFFECT OF ATEROMIXOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 1-8, (1992); ILLNAIT, CASTANO, NODARSE, PONTIGAS, FERNANDEZ, MAS, EFECTOS DEL ATEROMIXOL (PPG) SOBRÉ LA HIPERCOLESTEROLEMIA DEL TIPO II, REV. CENIC CIENCIAS BIOLÓGICAS, 22, PP. 1-2, (1991); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, (1991); PONS, RODRIGUEZ, MAS, ET AL., EFFICACY AND SAFETY OF ATEROMIXOL (POLICOSANOL) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, (1992); ALEMAN, MAS, NOA, ET AL., TOXICOLOGÍA AGUGA DEL ATEROMIXOL EN ROEDORES, REV. CENIC CIENCIAS BIOLÓGICAS, 22, PP. 102-105, (1991); RODRIGUEZ-ECHENIQUE, MESA, MAS, AMOR, CASTANO, ESTUDIO DEL EFECTO SOBRE LIPIDOS Y LIPOPROTEÍNAS SÉRICAS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE ATEROMIXOL CON DOSIS CRECIENTES DE ATEROMIXOL EN MONOS MACACA ARCTOIDES, ARCH VENEZOLANÒS DE FARMACOLOGÍA Y TERAPÉUTICA, (1992); LEVINE, SOHN, CEREBRAL ISCHEMIA IN INFANT AND ADULT GERBILS, ARCHIVES OF PATHOLOGY, 87, PP. 315-317, (1969); KAHN, LAWRENCE, PRANZARONE, THE USE OF DEXTRAN-40 IN MODIFIFYING THE COURSE OF EXPERIMENTAL INFARCTION IN THE GERBIL ABSTRACT, NEUROLOGY, 21, (1971); PATRONO, CIABATTONI, PUGLIESE, RADIOIMMUNOASSAY OF SERUM TXB<SUB>2</SUB>: A SIMPLE METHOD OF ASSESSING PHARMACOLOGIC EFFECTS ON PLATELET FUNCTION I, ADVANCES IN PROSTAGLANDIN THROMBOXANE RESEARCH, 6, (1980); TAYLOR, PALMER, CALLAHAN, PROTECTIVE ACTION BY METHYLPREDNISOLONE. ALLOPURINOL, AND INDOMETHACIN AGAINST STROKE-INDUCED DAMAGE TO ADENYLATE CYCLASE IN GERBIL CEREBRAL CORTEX, STROKE, 15, PP. 329-335, (1984); HARRISON, RUSSELL, EFFECT OF DEXAMETHASONE ON EXPERIMENTAL CEREBRAL INFARCTION IN THE GERBIL, J NEUROL NEUROSURG PSYCHIATRY, 35, PP. 520-521, (1972); MASUDA, YASUBA, ZUSHI, OCHI, KADOKAWA, EFFECT OF OP-2507 A STABLE PROSTACYCLIN ANALOGUE ON CEREBRAL ISCHEMIA INDUCED BY UNILATERAL LIGATION OF COMMON CAROTID ARTERY IN GERBILS, ARCH INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 294, PP. 125-135, (1988); BUTTERFIELD, MCGRAW, EFFECT OF DPPD (DIPHENYLPARA-PHENYLENEDIAMINE) ON STROKE AND CEREBRAL OEDEMA IN GERBILS, STROKE, 9, PP. 480-483, (1978); FADEN, DEMEDIUK, PANTER, VINK, THE ROLE OF AMINO ACIDS AND NMDA RECEPTORS IN TRAUMATIC BRAIN INJURY, SCIENCE, 24, PP. 798-800, (1989); BOULU, PLOTKINE, GUENIAU, SOFEIR, EFFECT OF INDOMETHACIN IN EXPERIMENTAL CEREBRAL ISCHEMIA, PATHOL BIOL, 30, PP. 278-281, (1982)","","","ENGLISH","PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS","ARTICLE","ISI","2-S2.0-0027183580","PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS",NA,"NOTREPORTED",NA,"ARRUZAZABALA ML, 1993, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS","ARRUZAZABALA ML, 1993, PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS"
"PONS P;JIMÉNEZ A;RODRÍGUEZ M;ILLNAIT J;MÁS R;FERNÁNDEZ L;FERNÁNDEZ J","PONS, P. (18635378600); JIMÉNEZ, A. (56660594700); RODRÍGUEZ, M. (57213557891); ILLNAIT, J. (8631465800); MÁS, R. (7007164572); FERNÁNDEZ, L. (7202848319); FERNÁNDEZ, J.C. (9432805500)","EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS",1993,"CURRENT THERAPEUTIC RESEARCH","53","4",39,"10.1016/S0011-393X(05)80784-2","PLAZA POLICLINICAL CENTER, CUBA;PLAZA POLICLINICAL CENTER, CUBA;PLAZA POLICLINICAL CENTER, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL, A NEW CHOLESTEROL-LOWERING AGENT, WAS ADMINISTERED TO OUTPATIENTS AGES 60 TO 85 YEARS (MEAN AGE, 73 YEARS) WITH PRIMARY HYPERCHOLESTEROLEMIA. THE PATIENTS WERE ASSIGNED IN A SINGLE-BLIND FASHION TO RECEIVE EITHER PLACEBO (N = 8), POLICOSANOL 1 MG (N = 12), OR POLICOSANOL 10 MG (N = 6) ONCE DAILY IN THE EVENING FOR 24 WEEKS. TOTAL CHOLESTEROL DECREASED BY 16.4% IN THE POLICOSANOL 1 MG GROUP AND BY 22.1% IN THE POLICOSANOL 10 MG GROUP; IN THE PLACEBO GROUP, TOTAL CHOLESTEROL INCREASED BY 5.2%. CLINICAL EXAMINATION AND BIOCHEMICAL DATA SHOWED NO SIGNIFICANT DIFFERENCES AMONG THE THREE GROUPS. NO DRUG-RELATED ADVERSE EFFECTS WERE OBSERVED. THESE RESULTS INDICATE THAT, IN ELDERLY PATIENTS, POLICOSANOL IS AN EFFECTIVE AND WELL-TOLERATED CHOLESTEROL-LOWERING DRUG. © 1993 EXCERPTA MEDICA, INC. ALL RIGHTS RESERVED.","","PLACEBO; POLICOSANOL; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL","","","LIPID RESEARCH CLINICS PROGRAM, THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS, JAMA, 251, PP. 351-364, (1984); BLANKENHORN, NESSIM, JOHNSON, ET AL., BENEFICIAL EFFECTS OF COMBINED COLESTIPOLNIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS, JAMA, 257, PP. 3233-3240, (1987); FRICK, ELO, HAAPA, ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, NEW ENGL J MED, 20, PP. 1237-1245, (1986); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CENIC CIENC BIOL, 22, PP. 60-61, (1991); CRUZ-BUSTILLO, MEDEROS, MAS, ET AL., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CENIC CIENC BIOL, 22, PP. 62-63, (1991); ILLNAIT, CASTANO, NODARSE, ET AL., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II, REV CENIC CIENC BIOL, 22, PP. 74-76, (1991); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROG CIENC MED, 5, PP. 21-28, (1991)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0027513940","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"PONS P, 1993, CURR THER RES CLIN EXP","PONS P, 1993, CURR THER RES CLIN EXP"
"PONS P;MÁS R;ILLNAIT J;FERNÁNDEZ L;RODRIGUEZ M;ROBAINA C;FERNÁNDEZ J","PONS, P. (18635378600); MÁS, R. (7007164572); ILLNAIT, J. (8631465800); FERNÁNDEZ, L. (7202848319); RODRIGUEZ, M. (57213557891); ROBAINA, C. (15036828600); FERNÁNDEZ, J.C. (9432805500)","EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA",1992,"CURRENT THERAPEUTIC RESEARCH","52","6",66,"10.1016/S0011-393X(05)80456-4","CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA;CUBA;GENERAL HOSPITAL CALIXTO GARCÍA, HAVANA CITY, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA CITY, CUBA","A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA TO EXAMINE THE EFFECTS OF POLICOSANOL ON PLASMA LIPIDS AND LIPOPROTEINS. AFTER ADHERING TO A CHOLESTEROL-LOWERING DIET FOR 6 WEEKS, 56 PATIENTS WERE RANDOMIZED TO RECEIVE PLACEBO OR POLICOSANOL 5 MG ONCE DAILY IN THE EVENING FOR 8 WEEKS. TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL DECREASED SIGNIFICANTLY, BY AN AVERAGE OF 13.1% AND 17.7%, RESPECTIVELY. NO SIGNIFICANT CHANGES WERE OBSERVED FOR TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL, OR HIGH-DENSITY LIPOPROTEIN CHOLESTEROL. NO SIGNIFICANT DIFFERENCES IN CLINICAL AND BIOCHEMICAL SAFETY INDICATORS WERE SEEN IN THE TREATED PATIENTS COMPARED WITH THOSE RECEIVING PLACEBO. THERE WERE NO ADVERSE EFFECTS ATTRIBUTABLE TO TREATMENT, AND NO PATIENT WAS WITHDRAWN FROM THE TRIAL. THESE DATA INDICATE THAT POLICOSANOL THERAPY IS EFFECTIVE AND VERY WELL TOLERATED. © 1992 EXCERPTA MEDICA, INC., AN ELSEVIER U.S. HOLDINGS, INC. COMPANY. ALL RIGHTS RESERVED.","","ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL","","","LOWERING BLOOD CHOLESTEROL TO PREVENT HEART DISEASE, JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 253, PP. 2080-2086, (1985); LIPID RESEARCH CLINICS PROGRAM, THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS, JAMA, 251, PP. 351-364, (1984); LIPID RESEARCH CLINICS PROGRAM, THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS, JAMA, 251, PP. 365-374, (1984); HERNANDEZ, ILLNAIT, MAS, ET AL., EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, 4, PP. 568-575, (1992); ILLNAIT, CASTANO, NODARSE, ET AL., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA TIPO II, REV CENIC CIENCIAS BIOLÓGICAS, 22, PP. 74-76, (1991); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, PP. 21-28, (1991); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEINS FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD, LEVY, FREDERICKSON, ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-502, (1972); ILLINGWORTH, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); ALEMAN, MAS, RODEIRO, ET AL., TOXICOLOGÍA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REV CENIC CIENCIAS BIOLÓGICAS, 22, PP. 102-105, (1991); FERNANDEZ, RENDON, DE LAS CAJIGAS, LOPEZ, ESTUDIO GENOTÓXICO DEL ATEROMIXOL (PPG), UN NUEVO MEDICAMENTO HIPOLIPEMIANTE, REV CENIC CIENCIAS BIOLÓGICAS, 22, PP. 98-101, (1991); ALEMAN, MAS, RODEIRO, MENENDEZ, ESTUDIO DE LA TOXICIDAD SUBCRÓNICA DEL ATEROMIXOL (POLICOSANOL), ARCH VENEZ FARMACOL TOXICOL, (1992)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0026670821","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"PONS P, 1992, CURR THER RES CLIN EXP","PONS P, 1992, CURR THER RES CLIN EXP"
"ANEIROS E;CALDERON B;MÁS R;ILLNAIT J;CASTAÑO G;FERNÁNDEZ L;FERNÁNDEZ J","ANEIROS, E. (9039750700); CALDERON, B. (9039269500); MÁS, R. (7007164572); ILLNAIT, J. (8631465800); CASTAÑO, G. (56232967100); FERNÁNDEZ, L. (7202848319); FERNÁNDEZ, J.C. (9432805500)","EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT",1993,"CURRENT THERAPEUTIC RESEARCH","54","8",46,"10.1016/S0011-393X(05)80631-9","TOMAS ROMAY POLICLINICAL CENTER, CUBA;TOMAS ROMAY POLICLINICAL CENTER, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBA;MEDICAL-SURGICAL RESEARCH CENTER (CIMEQ), HAVANA, CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBA;NATIONAL CENTER FOR SCIENTIFIC RESEARCH (CNIC), CUBA","THE EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT WAS INVESTIGATED IN A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 33 PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. PATIENTS WITH ELEVATED SERUM LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND TOTAL CHOLESTEROL LEVELS AFTER A DIET-ONLY TREATMENT PERIOD RECEIVED POLICOSANOL 5 MG TWICE DAILY (10 MG/DAY) FOR 6 WEEKS; THE DOSES WERE THEN DOUBLED TO 20 MG/DAY FOR THE NEXT 6 WEEKS. LDL-C LEVELS WERE SIGNIFICANTLY REDUCED BY 22.0% AT WEEK 6 AND BY 29.1% AT WEEK 12. TOTAL CHOLESTEROL WAS ALSO SIGNIFICANTLY REDUCED BY 16.8% AND 20.5%, RESPECTIVELY, AT WEEKS 6 AND 12, WHILE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) INCREASED BY 10.8% AND 8.6%, RESPECTIVELY, IN EACH TREATMENT PERIOD. THE RATIO OF LDL-C TO HDL-C WAS REDUCED BY 19.1% AT WEEK 6 AND BY 32.8% AT WEEK 12; THE RATIO OF TOTAL CHOLESTEROL TO HDL-C WAS REDUCED BY 14.4% AND 25.1%, RESPECTIVELY, AT THE END OF EACH TREATMENT PERIOD. THE GREATER REDUCTIONS IN LDL-C, TOTAL CHOLESTEROL, AND ATHEROGENIC RATIOS AT THE END OF WEEK 12 INDICATE THE EFFECTIVENESS OF A SUCCESSIVE DOSE INCREASE REGIMEN. POLICOSANOL WAS WELL TOLERATED. NO PATIENTS WITHDREW FROM THE TRIAL BECAUSE OF ADVERSE EXPERIENCES, AND NO ABNORMAL LABORATORY VALUES OR ADVERSE EFFECTS ATTRIBUTABLE TO TREATMENT WERE OBSERVED. © 1993 EXCERPTA MEDICA, INC. ALL RIGHTS RESERVED.","","CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL","","","LOWERING BLOOD CHOLESTEROL TO PREVENT HEART DISEASE, JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 253, PP. 2080-2091, (1985); LIPID RESEARCH CLINICS PROGRAM, THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS, JAMA, 251, PP. 351-364, (1984); FRICK, ELO, HAAPAK, ET AL., HELSINKI HEART STUDY: PRIMARY PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA, NEW ENGL J MED, 317, PP. 1237-1245, (1987); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV CENIC CIENC BIOLÓGICAS, 22, PP. 60-61, (1991); CRUZ-BUSTILLO, MEDEROS, MAS, ET AL., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CENIC CIENC BIOLÓGICAS, 22, PP. 62-63, (1991); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZOL FARMACOL TERAP, 11, PP. 80-86, (1991); HERNANDEZ, ILLNAIT, MAS, ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO, ZARDOYA, ILLNAIT, MAS, ET AL., EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGR CIENC MÉD, 5, PP. 21-30, (1991); ILLNAIT, CASTANO, NODARSE, ET AL., EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMIA DEL TIPO II, REV CENIC CIENC BIOLÓGICAS, 22, PP. 74-76, (1991); PONS, RODRIGUEZ, MAS, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, 4, PP. 507-513, (1992); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEINS FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD, LEVY, FREDERICKSON, ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-451, (1974)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0027439338","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"ANEIROS E, 1993, CURR THER RES CLIN EXP","ANEIROS E, 1993, CURR THER RES CLIN EXP"
"ALEMÁN C;FERREIRO R;PUIG M;GUERRA I;ORTEGA C;CAPOTE A","ALEMÁN, CELIA LUZ (7102849611); FERREIRO, ROSA MÁS (6602148780); PUIG, MIRIAM NOA (7101853051); GUERRA, IDANIA RODEIRO (25122327400); ORTEGA, CARIDAD HERNÁNDEZ (7005784679); CAPOTE, AMELIA (16155693300)","CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS A 24 MONTH STUDY",1994,"TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS","14","10",47,"10.1002/tcm.1770140505","CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","THE EFFECTS OF POLICOSANOL (50–500 MG/KG) ADMINISTERED ORALLY FOR 24 MONTHS TO SPRAGUE DAWLEY RATS OF BOTH SEXES WERE INVESTIGATED. NO DIFFERENCES RELATED TO DAILY CLINICAL OBSERVATIONS, WEIGHT GAIN, FOOD CONSUMPTION, OR MORTALITY (SURVIVAL ANALYSIS) BETWEEN GROUPS WERE FOUND. HISTOPATHOLOGICAL STUDY SHOWED THAT THE FREQUENCY OF THE OCCURRENCE OF NON‐NEOPLASTIC AND NEOPLASTIC (BENIGN AND MALIGNANT) LESIONS WAS SIMILAR IN THE CONTROL AND POLICOSANOL‐TREATED GROUPS. THE LESIONS OBSERVED IN THIS STUDY WERE SIMILAR TO THE SPONTANEOUS LESIONS REPORTED IN THIS SPECIES IN PREVIOUS STUDIES. SINCE NO DRUG‐RELATED INCREASE IN THE OCCURRENCE OF MALIGNANT OR BENIGN NEOPLASMS WAS FOUND, NOR ACCELERATION IN TUMORS GROWTH IN ANY SPECIFIC GROUP WAS OBSERVED, THIS STUDY SHOWS NO EVIDENCE OF POLICOSANOL INDUCED CARCINOGENICITY IN THIS STRAIN OF RATS. © 1994 WILEY‐LISS, INC. COPYRIGHT © 1994 WILEY‐LISS, INC., A WILEY COMPANY","ATEROMIXOL; CARCINOGENICITY; CHOLESTEROL‐LOWERING DRUG; HIGHER ALIPHATIC ALCOHOLS; POLICOSANOL; SPRAGUE DAWLEY RATS; SUGAR CANE WAX; TYPE II HYPERLIPOPROTEINEMIA","ANIMAL; ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; CARCINOGENICITY TESTS; FATTY ALCOHOLS; FEMALE; MALE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL ANALYSIS; ANIMALIA; ALKANOL; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; HYPERLIPOPROTEINEMIA; MALE; MORTALITY; NEOPLASM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT","","","CRUZ-BUSTILLO D, MEDEROS CM, MAS R, ARRUZAZABALA, BARRETO B, MARTINEZ O, EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REVISTA CENIC CIENCIAS BIOLOGICAS, 22, (1991); ARRUZAZABALA, CARBAJAL D, MAS R, CASTANO G, SOTOLONGO R, MESA R, EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLES, REVISTA CENIC CIENCIAS BIOLOGICAS, 22, (1991); ARRUZAZABALA, CARBAJAL D, MAS R, ILLNAIT J, LAGUNA A, CASTANO G, EFECT DEL ATEROMIXOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCHIVOS VENEZOLANOS DE FARMACOLOGÍA Y TERAPEUTICA, 11, (1992); HERNANDEZ F, ILLNAIT J, MAS R, CASTANO G, FERNANDEZ L, GONZALEZ M, CORDOVI N, FERNANDEZ JC, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDIS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THERAP RES, 51, PP. 1-8, (1992); ILLNAIT J, CASTANO G, NODARSE M, PONTIGAS V, HERNANDEZ L, MAS R, EFECTOS DEL ATEROMIXOL (PPG) SOBRE LA HIPERLIPOPROTEINEMA DEL TIPO II, REVISTA CENIC CIENCIAS BIOLOGICAS, 22, (1992); CASTANO G, ZARDOYA R, ILLNAIT J, MAS R, FERNANDEZ L, SURRIBAS E, NODARSE M, FERNANDEZ JC, EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PCM, 5, (1991); PONS P, MAS R, ILLNAIT J, FERNANDEZ L, RODRIGUEZ M, ROBAINA C, FERNANDEZ JC, EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES., 52, PP. 507-512, (1992); PONS P, JIMENEZ A, RODRIGUEZ M, ILLNAIT J, MAS R, FERNANDEZ L, FERNANDEZ JC, EFFECTS OF POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS, CURR THER RES, 53, (1992); RENDON A, RODRIGUEZ MD, LOPEZ M, GARCIA H, CAJIGAS A, MAS R, FERNANDEZ I, (1992); RODRIGUEZ-ECHENIQUE C, MESA R, MAS R, MENENDEZ R, NOA M, GONZALEZ R, AMOR A, FRAGA V, LAGUNA A, (1992); CLAYSON DB, ARNOLD DL, THE CLASSIFICATION OF CARCINOGENS IDENTIFIED IN THE RODENT BIOASSAY AS POTENTIAL RISK TO HUMANS: WHAT TYPE OF SUBSTANCE SHOULD BE TESTED NEXT?, MUTAT RES, 257, PP. 91-106, (1991); GORROD JW, TESTING FOR TOXICITY, (1981); ALEMAN CL, MAS R, HERNANDEZ C, RODEIRO I, NOA M, MENENDEZ R, GONZALEZ RM, AMOR A, SOTOLONGO V, FRAGA V, CAPOTE A, JIMENEZ S, (1992); ALEMAN CL, MAS R, HERNANDEZ C, RODEIRO I, CEREJIDO E, NOA M, CAPOTE A, MENENDEZ R, AMOR A, FRAGA V, SOTOLONGO V, JIMENEZ S, A 12 MONTHS STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-87, (1994); HAYES WA, PRINCIPLES AND METHODS OF TOXICOLOGY CAP: METHODS IN TESTING FOR CARCINOGENICITY, (1986); CHHABRA RS, HUFF JE, SCHWETZ BS, SELKIR KJ, AN OVERVIEW OF PRECHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY EXPERIMENTAL STUDY DESIGNS AND CRITERIA USED BY THE NATIONAL TOXICOLOGY PROGRAM, ENV HEALTH PERSP, 86, PP. 313-321, (1990); TUKEY JW, EXPLORATORY DATA ANALYSIS, (1977); LONG‐TERM AND SHORT‐TERM SCREENING ASSAYS FROM CARCINOGENS: A CRITICAL APPRAISAL, PP. 21-83, (1986); FITZGERALD J, SCHARDEIN J, KAUMP D, SEVERAL UNCOMMON PITUITARY TUMORS IN THE RAT, LAB ANI SCI, 21, PP. 581-584, (1971); KOVACS K, HORVATH E, ILSE R, EZRIN C, ILSE D, SPONTANEOUS PITUITARY ADENOMAS IN AGING RATS: A LIGHT MICROSCOPIC, IMMUNOCYTOLOGICAL AND FINE STRUCTURAL STUDY, BEITR PATHOL, 161, PP. 1-16, (1977); EL ETREBY MF, LORENZ B, HABENITCH U, IMMUNOCYTOCHEMICAL STUDIES ON THE PITUITARY GLAND AND SPONTANEOUS PITUITARY TUMORS OF SPRAGUE DAWLEY RATS, PATHOL RES PRACT, 183, PP. 645-650, (1988); DURBIN P, WILLIAMS M, JEUNG N, ARNOLD J, DEVELOPMENT OF SPONTANEOUS MAMMARY TUMORS OVER THE LIFE‐SPAN OF THE FEMALES CHARLES RIVER (SPRAGUE DAWLEY) RAT: THE INFLUENCE OF OVARIECTOMY, THYROIDECTOMY AND ADRENALECTOMY‐OVARIECTOMY, CANCER RES, 26, PP. 400-411, (1966); GREAVES P, RABEMAMPIANINA Y, CHOICE OF RAT STRAIN: A COMPARISON OF THE GENERAL PATHOLOGY AND THE TUMOR INCIDENCE IN 2 YEAR OLD SPRAGUE DAWLEY AND LONG‐EVANS RATS. IN “NEW TOXICOLOGY FOR OLD”, ARCH TOXICOL SUPPL, 5, PP. 298-303, (1982); GREAVES P, FACCINI JM, RAT HISTOPATHOLOGY, (1984); GUERIN J, ATTEMPTS TO PRODUCE SEMINOMATA IN THE ALBINO RAT BY INOCULATION OF HYDROCARBONS AND OTHER CARCINOGENS INTO NORMALLY SITUATED AND ECTOPIC TESTIS, BR J CANCER, 10, PP. 134-144, (1956); MEITES J, HUANG H, SIMPKINGS J, RECENT STUDIES ON NEUROENDOCRINE CONTROL OF REPRODUCTIVE SENESCENCE IN RATS, THE AGING REPRODUCTIVE SYSTEM (AGING 4), (1976); MERCK, SHARP, DOHNE, (1990); (1989); MESA AR, MAS R, NOA M, HERNANDEZ C, GAMEZ R, GARCIA M, CAPOTE A, RODEIRO I, ALEMAN CL, (1994)","","","ENGLISH","TERATOG. CARCINOG. MUTAG.","ARTICLE","ISI","2-S2.0-0028033806","TERATOG CARCINOG MUTAG",NA,"NOTREPORTED",NA,"ALEMÁN CL, 1994, TERATOG CARCINOG MUTAG","ALEMÁN CL, 1994, TERATOG CARCINOG MUTAG"
"PONS P;RODRÍGUEZ M;MÁS R;ILLNAIT J;FERNÁNDEZ L;ROBAINA C;FERNÁNDEZ J","PONS, PEDRO (18635378600); RODRÍGUEZ, MIRTA (57213557891); MÁS, ROSA (7007164572); ILLNAIT, JOSÉ (8631465800); FERNÁNDEZ, LILIA (7202848319); ROBAINA, CARIDAD (15036828600); FERNÁNDEZ, JULIO CÉSAR (9432805500)","ONEYEAR EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1994,"CURRENT THERAPEUTIC RESEARCH","55","8",53,"10.1016/S0011-393X(05)80279-6","PLAZA POLICLINICAL CENTER, CUBA;PLAZA POLICLINICAL CENTER, CUBA;CENTER OF NATURAL PRODUCTS-NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBA;CENTER OF NATURAL PRODUCTS-NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBA;CENTER OF NATURAL PRODUCTS-NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBA;CALIXTO GARCÍA HOSPITAL, HAVANA, CUBA;CENTER OF NATURAL PRODUCTS-NATIONAL CENTER FOR SCIENTIFIC RESEARCH, CUBA","A 12-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA TO ASCERTAIN THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL (5 MG ONCE DAILY). AFTER ADHERING TO A CHOLESTEROL-LOWERING DIET FOR 12 WEEKS, 59 PATIENTS WERE RANDOMIZED TO RECEIVE EITHER PLACEBO OR POLICOSANOL (5 MG) TABLETS FOR 12 MONTHS. TABLETS WERE TAKEN ONCE DAILY BEFORE THE EVENING MEAL. TWO MONTHS AFTER THE START OF THERAPY, POLICOSANOL HAD SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS. THESE CHANGES WERE MAINTAINED, OR INCREASED, THROUGHOUT THE STUDY. AFTER 12 MONTHS, TOTAL CHOLESTEROL LEVELS HAD DECREASED BY 15.3% AND LDL-C BY 23.7%. IN THE PLACEBO GROUP A SIGNIFICANT INCREASE IN BOTH VALUES WAS DETECTED 9 MONTHS AFTER THE START OF THERAPY. NO SIGNIFICANT CHANGES IN TRIGLYCERIDES AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) WERE REPORTED COMPARED WITH BASELINE OR PLACEBO. LDL-C:HDL-C AND CHOLESTEROL:HDL-C RATIOS WERE SIGNIFICANTLY REDUCED IN THE POLICOSANOL-TREATED GROUP: DECREASES WERE 25.3% (LDL-C:HDL-C) AND 17.0% (CHOLESTEROL:HDL-C) AFTER 12 MONTHS. OF THE SEVEN PATIENTS WHO DISCONTINUED THE TRIAL (FIVE FROM THE PLACEBO GROUP AND TWO FROM THE POLICOSANOL GROUP), ONLY ONE (PLACEBO GROUP) WITHDREW BECAUSE OF SIDE EFFECTS. THE ADVERSE EFFECTS REPORTED WERE MILD AND TRANSIENT; NO SIGNIFICANT DIFFERENCES WERE SEEN IN THE TREATED PATIENTS COMPARED WITH THOSE RECEIVING PLACEBO. NO DRUG-RELATED CLINICAL, BIOCHEMICAL, OR OPHTHALMOLOGIC ADVERSE EFFECTS WERE OBSERVED. THE STUDY INDICATES THAT POLICOSANOL 5 MG ADMINISTERED ONCE DAILY FOR 12 MONTHS RESULTS IN MAINTAINED EFFICACY AS WELL AS GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. © 1994 EXCERPTA MEDICA INC. ALL RIGHTS RESERVED.","","CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL","","","LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS I REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE, JAMA, 251, PP. 351-364, (1984); LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS II THE RELATIONSHIP OF REDUCTION IN INCIDENCE OF CORONARY HEART DISEASE TO CHOLESTEROL LOWERING, JAMA, 251, PP. 365-374, (1984); ENDO, KURODA, TANZAWA, COMPETITIVE INHIBITION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY ML-236A AND ML-236B, FUNGAL METABOLITES HAVING HYPOCHOLESTEROLEMIC ACTIVITY, FEBS LETT, 72, PP. 323-326, (1976); ILLINGWORTH, AN OVERVIEW OF LIPID-LOWERING DRUGS, DRUGS, 36, PP. 63-71, (1988); BLUM, LEWY, CURRENT THERAPY FOR HYPERCHOLESTEROLEMIA, CLIN CARDIOL, 261, PP. 3582-3587, (1989); O'CONNOR, FREBLY, SHEPHERD, LIPID-LOWERING DRUGS, BMJ, 300, PP. 667-672, (1990); TOBER, EFFICACY AND LONG-TERM ADVERSE EFFECT PATTERN OF LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 62, PP. 28J-33J, (1988); REYNOLDS, LIPID REGULATING AGENTS. MARTINDALE: THE EXTRA PHARMACOPEIA, PP. 1196-1204, (1989); MANTELL, BURKE, STAGGERS, EXTENDED CLINICAL SAFETY PROFILE OF LOVASTATIN, THE AMERICAN JOURNAL OF CARDIOLOGY, 66, PP. 11B-15B, (1990); ARRUZAZABALA, CARBAJAL, MAS, ET AL., EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS NORMOCOLESTEROLÉMICOS, ARCH VENEZOL FARMACOL TERAP, 11, 2, PP. 80-86, (1992); CRUZ-BUSTILLO, MEDEROS, MAS, ET AL., EFECTO HIPOCOLESTEROLÉMICO DEL ATEROMIXOL (PPG) EN EL CERDO EN CEBA, REV CENIC CIENC BIOLÓGICAS, 22, PP. 62-63, (1991); RODRIGUEZ, MESA, MAS, ET AL., ESTUDIO DEL EFECTO SOBRE LÍPIDOS Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE ATEROMIXOL EN MONOS (MACACA ARCTOIDES), ARCH VENEZOL FARMACOL TERAP, 11, PP. 74-79, (1992); HERNANDEZ, ILLNAIT, MAS, ET AL., EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR THER RES, 51, PP. 568-575, (1992); CASTANO, ZARDOYA, ILLNAIT, ET AL., EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PROGR CIENC MÉD, 5, PP. 21-28, (1991); PONS, MAS, ILLNAIT, ET AL., EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURR THER RES, 52, PP. 507-513, (1992); ANEIROS, CALDERON, MAS, ET AL., EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT, CURR THER RES, 54, PP. 304-312, (1993); PONS, RODRIGUEZ, ROBAINA, ET AL., EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND TOLERABILITY TO TREATMENT, CLIN PHARMACOL RES, 14, PP. 27-33, (1994); MENENDEZ, FERNANDEZ, ARRUZAZABALA, ET AL., EFFECT OF POLICOSANOL ON CHOLESTEROL BIOSYNTHESIS AND LDL PROCESSING, ABSTRACTS OF THE 62ND EUROPEAN ATHEROSCLEROSIS SOCIETY CONGRESS, (1993); ALEMAN, MAS, HERNANDEZ, ET AL., ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, ABSTRACT OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, ROME, 1992, (1992); RENDON, RODRIGUEZ, LOPEZ, ET AL., POLICOSANOL: A STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, ROME, 1992, (1992); ALEMAN, MAS, HERNANDEZ, ET AL., A 12 MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS, TOXICOLOGY LETTERS, 70, PP. 77-86, (1994); SEIGLER, WU, SEPARATION OF SERUM HIGH-DENSITY LIPOPROTEIN FOR CHOLESTEROL DETERMINATION: ULTRACENTRIFUGATION VS PRECIPITATION WITH SODIUM PHOSPHOTUNGSTATE AND MAGNESIUM CHLORIDE, CLIN CHEM, 27, PP. 838-841, (1981); FRIEDEWALD, LEVY, FREDERICKSON, ESTIMATION OF THE CONCENTRATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PLASMA WITHOUT USE OF THE PREPARATIVE ULTRACENTRIFUGE, CLIN CHEM, 18, PP. 499-552, (1972); O'BRIEN, SHAMPO, STATISTICAL CONSIDERATIONS FOR PERFORMING MULTIPLE TESTS IN A SINGLE EXPERIMENT. 5. COMPARING TWO THERAPIES WITH RESPECT TO SEVERAL ENDPOINTS, MAYO CLIN PROC, 63, PP. 1140-1143, (1988)","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0027978416","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"PONS P, 1994, CURR THER RES CLIN EXP","PONS P, 1994, CURR THER RES CLIN EXP"
"ALEMÁN C;MÁS R;HERNÁNDEZ C;RODEIRO I;CEREJIDO E;NOA M;CAPOTE A;MENÉNDEZ R;AMOR A;FRAGA V;SOTOLONGO V;JIMÉNEZ S","ALEMÁN, CELIA L. (7102849611); MÁS, ROSA (7007164572); HERNÁNDEZ, CARIDAD (15720846000); RODEIRO, IDANIA (6602314378); CEREJIDO, ELOISA (16155821100); NOA, MIRIAM (7003318964); CAPOTE, AMELIA (16155693300); MENÉNDEZ, ROBERTO (7102205059); AMOR, ANA (35569426800); FRAGA, VIVIAN (6602491407); SOTOLONGO, VIVIAN (6506317930); JIMÉNEZ, SONIA (19735040200)","A 12MONTH STUDY OF POLICOSANOL ORAL TOXICITY IN SPRAGUE DAWLEY RATS",1994,"TOXICOLOGY LETTERS","70","10",68,"10.1016/0378-4274(94)90147-3","CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA;CENTRO DE PRODUCTOS NATURALES, HAVANA CITYCUBA","POLICOSANOL IS A NATURAL MIXTURE OF HIGHER ALIPHATIC PRIMARY ALCOHOLS. ORAL TOXICITY OF POLICOSANOL WAS EVALUATED IN A 12-MONTH STUDY IN WHICH DOSES FROM 0.5 TO 500 MG KG WERE GIVEN ORALLY TO SPRAGUE DAWLEY (SD) RATS (20/SEX/GROUP) DAILY. THERE WAS NO TREATMENT-RELATED TOXICITY. THUS, EFFECTS ON BODY WEIGHT GAIN, FOOD CONSUMPTION, CLINICAL OBSERVATIONS, BLOOD BIOCHEMISTRY, HEMATOLOGY, ORGAN WEIGHT RATIOS AND HISTOPATHOLOGICAL FINDINGS WERE SIMILAR IN CONTROL AND TREATED GROUPS. THIS STUDY SUPPORTS THE WIDE SAFETY MARGIN OF POLICOSANOL WHEN ADMINISTERED CHRONICALLY. © 1994.","CHOLESTEROL-LOWERING DRUG; CHRONIC TOXICITY; HIGHER ALIPHATIC PRIMARY ALCOHOL; POLICOSANOL; SPRAGUE DAWLEY RAT","ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMAL; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FATTY ALCOHOLS; FEMALE; LIVER; MALE; ORGAN WEIGHT; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; ANIMALIA; ALKANOL; ANTILIPEMIC AGENT; POLICOSANOL; ANIMAL EXPERIMENT; ARTICLE; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; HISTOPATHOLOGY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT","","","MENENDEZ, FERNANDEZ, SOTOLONGO, AMOR, FRAGA, DEL RIO, ALFONSO, GONZALEZ, MAS, POLICOSANOL: UN ESTUDIO DE SUS EFECTOS SOBRE LA BIOSÍNTESIS DEL COLESTEROL, I CONGRESO IBEROAMERICANO DE FARMACOLOGIA, (1992); ARRUZAZABALA, CARBAJAL, MAS, ILLNAIT, LAGUNA, CASTANO, EFECTO DEL POLICOSANOL SOBRE EL PERFIL LIPÍDICO DE CONEJOS COLESTEROLÉMICOS, ARCH. VENEZOLANOS FARMACOL. TERAP., 11, PP. 80-86, (1992); ARRUZAZABALA, CARBAJAL, MAS, GARCIA, EFECTOS DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REVISTA CNIC CIENCIAS BIOLÓGICAS, 22, (1991); HERNANDEZ, ILLNAIT, MAS, CASTANO, FERNANDEZ, GONZALEZ, CORDOVI, FERNANDEZ, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURR. THERAP. RES., 51, PP. 1-7, (1992); PONS, MAS, ILLNAIT, FERNANDEZ, FERNANDEZ, EFFICACY AND SAFETY OF POLICOSANOL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, CURRENT THERAPEUTIC RESEARCH, 52, PP. 1-7, (1992); CASTANO, ZARDOYA, ILLNAIT, MAS, FERNANDEZ, SURRIBAS, NODARSE, FERNANDEZ, EFECTOS DEL TRATAMIENTO CON PPG (5 MG) EN PACIENTES CON HIPERLIPOPROTEINEMIA TIPO II, PP. 5-21, (1991); ALEMAN, MAS, HERNANDEZ, RODEIRO, NOA, MENENDEZ, GONZALEZ, AMOR, SOTOLONGO, FRAGA, CAPOTE, JIMENEZ, ACUTE, SUBCHRONIC AND CHRONIC TOXICOLOGY OF POLICOSANOL IN RATS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); RODRIGUEZ-ECHENIQUE, MESA, MAS, MENENDEZ, NOA, GONZALEZ, AMOR, FRAGA, LAGUNA, TOXICOLOGICAL STUDY OF POLICOSANOL LONG-TERM ADMINISTRATION ON MACACA ARCTOIDES MONKEYS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); RENDON, RODRIGUEZ, LOPEZ, GARCIA, DE LAS CAJIGAS, MAS, FERNANDEZ, POLICOSANOL: AN STUDY OF ITS GENOTOXICITY AND TERATOGENICITY IN RODENTS, ABSTRACTS OF THE SIXTH INTERNATIONAL CONGRESS OF TOXICOLOGY, (1992); STEVENS, GALLO, PRACTICAL CONSIDERATIONS IN THE CONDUCT OF CHRONIC TOXICITY STUDIES, PRINCIPLES AND METHODS IN TOXICOLOGY, PP. 53-77, (1986); GAD, WEIL, STATISTIC FOR TOXICOLOGY, J. AM. COLL. TOXICOL., 7, (1988)","","","ENGLISH","TOXICOL. LETT.","ARTICLE","ISI","2-S2.0-0027957267","TOXICOL LETT",NA,"NOTREPORTED",NA,"ALEMÁN CL, 1994, TOXICOL LETT","ALEMÁN CL, 1994, TOXICOL LETT"
"ARRUZAZABALA M;CARBAJAL D;MAS R;GARCIA M;FRAGA V","ARRUZAZABALA, M.L. (6603962476); CARBAJAL, D. (8777025000); MAS, R. (7007164570); GARCIA, M. (7404278799); FRAGA, V. (6602491407)","EFFECTS OF POLICOSANOL ON PLATELET AGGREGATION IN RATS",1993,"THROMBOSIS RESEARCH","69","6",103,"10.1016/0049-3848(93)90030-R","DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, CUBANACÁN, LA HABANA,, NATIONAL CENTER SCIENTIFIC RESEARCH AVE 25 158, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, CUBANACÁN, LA HABANA,, NATIONAL CENTER SCIENTIFIC RESEARCH AVE 25 158, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, CUBANACÁN, LA HABANA,, NATIONAL CENTER SCIENTIFIC RESEARCH AVE 25 158, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, CUBANACÁN, LA HABANA,, NATIONAL CENTER SCIENTIFIC RESEARCH AVE 25 158, CUBA;DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, CUBANACÁN, LA HABANA,, NATIONAL CENTER SCIENTIFIC RESEARCH AVE 25 158, CUBA","POLICOSANOL IS THE TRIVIAL NAME OF A MIXTURE OF HIGH MOLECULAR WEIGHT ALCOHOLS ISOLATED FROM SUGAR CANE, WHEREIN OCTACOSANOL IS THE MAIN COMPONENT THE EFFECTS OF POLICOSANOL TREATMENT ON RAT PLATELET AGGREGATION WERE STUDIED. DEPENDING ON THE DOSE, POLICOSANOL (5-20 MG/KG, PERORALLY) INHIBITED THE DECREASE IN CIRCULATING PLATELET COUNTS AND COLLAGEN-INDUCED MALONDIALDEHYDE CONCENTRATION IN PLASMA. IN RAT CLOTTED WHOLE BLOOD THROMBOXANE B2 FORMATION WAS INHIBITED BY POLICOSANOL (25 MG/KG). POLICOSANOL (50-200 MG/KG, SINGLE DOSES) INHIBITED ADP-INDUCED PLATELET AGGREGATION IN PLATELET-RICH PLASMA, WHILE LOWER DOSES (25 MG/KG) DID NOT CHANGE RESPONSES TO ADP SIGNIFICANTLY. HOWEVER, RATS TREATED WITH THIS DOSE (25 MG/KG) FOR 4 WEEKS SHOWED A SIGNIFICANT INHIBITION OF PLATELET AGGREGATION IN PRP WHEN A SUBMAXIMAL ADP CONCENTRATIONS WAS ADMINISTERED. © 1993.","ADP; PLATELET AGGREGATION; POLICOSANOL; THROMBOXANE A<SUB>2</SUB>","ADENOSINE DIPHOSPHATE; ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE B2; ADENOSINE DIPHOSPHATE; ALCOHOL; ANTICOAGULANT AGENT; INDOMETACIN; POLICOSANOL; THROMBOXANE B2; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION","","","KRUEGER, SOERGEL, INFLUENCIA DEL ETOFIBRATO SOBRE LA AGREGACIÓN PLAQUETARIA, TERAPIECWOCHE, 33, PP. 3297-3299, (1983); OVERTURF, SYBERS, SCHAPER, FAEGTMEYER, HYPERTENSION AND ATHEROSCLEROSIS IN CHOLESTEROL FED RABBITS, ATHEROSCLEROSIS, 66, PP. 63-76, (1987); WANLESS, THE EFFECT OF DIETARYCHOLESTEROL ON PLATELET SURVIVAL IN THE RABBIT: A STUDY USING <SUP>14</SUP>C-SEROTONIN AND <SUP>51</SUP>CHROMIUN DOUBLE-LABELED PLATELETS, THROMB.HAEMOSTASIS, 52, PP. 85-89, (1984); MCGREGOR, MORAZAIN, RENAUD, EFFECTS OF DIETARY LINOLEIC ACID ON PLATELET FUNCTION IN THE RAT, THROMB.RES., 20, (1980); RENAUD, KINLOUGH, MUSTARD, RELATIONSHIP BETWEEN PLATELET AGGREGATION AND THE THROMBOTIC TENDENCY IN RATS FED HYPERLIPEMIC DIETS, LAB. INVEST., 22, (1970); SHIMURA, HASEGAWA, TAKINO, SUZUKI, STUDIES ON THE EFFECT OF OCTACOSANOL ON MOTOR ENDURANCE IN MICE, NUTRITION REPORTS INT., 36, PP. 1029-1038, (1987); ARRUZAZABALA, CARBAJAL, MAS, CASTANO, SOTOLONGO, MESA, EFECTO DEL ATEROMIXOL (PPG) SOBRE LOS NIVELES DE COLESTEROL EN PERROS BEAGLE, REV. CENIC, 22, PP. 60-61, (1991); CRUZ-BUSTILLO, MEDEROS, MAS, ARUZAZABALA, BARRETO, MARTINEZ, EFECTO HIPOCOLESTEROLEMICO DEL ATEROMIXOL (PPG) EN EL CERDO DE CEBA, REV. CENIC., 22, PP. 62-64, (1991); ARRUZAZABALA, CARBAJAL, MAS, ILLNAIT, LAGUNA, CASTANO, EFECTO DEL ATEROMIXOL SOBRE EL PERFIL LIPIDICO DE CONEJOS NORMOCOLESTEROLEMICOS, ARCH. VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA., 11, (1992); HERNANDEZ, ILLNAIT, MAS, CASTANO, FERNANDEZ, GONZALEZ, CORDOVI, FERNANDEZ, EFFECT OF ATEROMIXOL (POLICOSANOL) ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS, CURRENT THER. RESEARCH, 51, PP. 1-8, (1992); CASTANO, ZARDOYA, ILLNAIT, MAS, FERNANDEZ, SURRIBAS, NODARSE, FERNANDEZ, EFECTOS DEL TRATAMIENTO CON ATEROMIXOL (PPG) (5 MG) EN PACIENTE CON HIPERLIPOPROTEINEMIA TIPO II, PROGRESOS EN CIENCIAS MEDICAS.(VENEZUELA), 5, PP. 21-30, (1991); ALEMAM, MAS, RODEIRO, NOA, HERNANDEZ, CAPOTE, MENENDEZ, GONZALEZ, AMOR, JIMENEZ, TOXICOLOGIA AGUDA DEL ATEROMIXOL (PPG) EN ROEDORES, REV, CENIC, 22, PP. 102-105, (1991); RODRIGUEZ-ECHENIQUE, MESA, MAS, AMOR, CASTANO, ESTUDIO DEL EFECTO SOBRE LÍPIDOD Y LIPOPROTEÍNAS SÉRICOS Y DE LA TOLERANCIA AL TRATAMIENTO ORAL CON DOSIS CRECIENTES DE ATEROMIXOL (PPG) EN MONOS MACACA ARCTOIDES, ARCH. VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA., (1992); FERNANDEZ, RENDON, DE LAS CAJIGAS, LOPEZ, ESTUDIO GENOTÓXICO DEL ATEROMIXOL (PPG) UN NUEVO MEDICAMENTO HIPOLIPEMIANTE, REV. CENIC, 22, PP. 98-101, (1991); SATOH, SERUM LIPID PEROXIDE IN CEREBROVASCULAR DISORDERS DETERMINED BY A NEW COLORIMETRIC METHOD, CLIN. CHEM. ACTA, 90, PP. 34-43, (1978); BORN, AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL, NATURE (LOND), 194, PP. 927-929, (1962); VERSTRAETE, INTRODUCTION THROMBOXANE IN BIOLOGICAL SYSTEMS AND THE POSSIBLE IMPACT OF ITS INHIBITION, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 15, PP. 75-115, (1983); MUSTARD, PACKHAM, KINLOUGH-RATHBONE, PERRY, REGOEZI, FIBRINOGEN AND ADP-INDUCED PLATELET AGGREGATION, BLOOD, 52, PP. 453-466, (1978); HANTGAN, TAYLOR, LEWIS, PLATELET INTERACT WITH FIBRIN AFTER ACTIVATION, BLOOD, 65, PP. 1299-1310, (1976); GERRARD, WHITE, MECHANISM OF ADP INDUCED PLATELET AGGREGATION, AM. J. PATHOL., 82, PP. 513-516, (1976); DI MINNO, CARBONE, MATTOLI, FUNCTIONALLY THROMBASTHENIC STATE IN NORMAL PLATELETS FOLLOWING THE ADMINISTRATION OF TICLOPIDINE, J. CLIN. INVEST., 75, PP. 328-338, (1985)","","","ENGLISH","THROMB. RES.","ARTICLE","ISI","2-S2.0-0027413130","THROMB RES",NA,"NOTREPORTED",NA,"ARRUZAZABALA ML, 1993, THROMB RES","ARRUZAZABALA ML, 1993, THROMB RES"
"HERNANDEZ F;ILLNAIT J;MAS R;CASTANO G;FERNANDEZ L;GONZALEZ M;CORDOVI N;FERNANDEZ J","HERNANDEZ, F. (7202801165); ILLNAIT, J. (8631465800); MAS, R. (7007164572); CASTANO, G. (56232967100); FERNANDEZ, L. (7202848319); GONZALEZ, M. (57211589194); CORDOVI, N. (6505625201); FERNANDEZ, J.C. (9432805500)","EFFECT OF POLICOSANOL ON SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY VOLUNTEERS",1992,"CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL","51","7",118,"","NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA;NATIONAL CTR FOR SCIENTIFIC RESEARCH, HAVANA, CUBA","POLICOSANOL IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALCOHOLS ISOLATED FROM SUGAR CANE WITH CHOLESTEROL-LOWERING EFFECTS THAT HAVE BEEN DEMONSTRATED IN DIFFERENT EXPERIMENTAL MODELS. IN THIS TRIAL POLICOSANOL 10 OR 20 MG OF PLACEBO WAS GIVEN DAILY (5 OR 10 MG TWICE A DAY) FOR FOUR WEEKS UNDER DOUBLE-BLIND CONDITIONS TO THREE GROUPS OF NORMOCHOLESTEROLEMIC HEALTHY VOLUNTEERS. AFTER FOUR WEEKS, SUBJECTS TREATED WITH POLICOSANOL AT 10 OR 20 MG SHOWED SIGNIFICANT REDUCTIONS IN SERUM CHOLESTEROL, WHILE ONLY THE SUBJECTS RECEIVING THE HIGHER DOSE SHOWED A SIGNIFICANT DECREASE IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) VALUES (22%) AS WELL AS SIGNIFICANT INCREASE IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (29.93%) LEVELS. THESE CHANGES WERE SIGNIFICANTLY DIFFERENT FROM THE VARIATIONS ON PLACEBO, WHICH CONVERSELY SHOWED AN UPWARD DRIFT OF SERUM CHOLESTEROL AND LDL-C LEVELS. NONRELEVANT CHANGES IN SERUM TRIGLYCERIDES WERE PRODUCED. POLICOSANOL WAS VERY WELL TOLERATED AND THERE WERE NO ADVERSE EFFECTS REPORTS ATTRIBUTABLE TO TREATMENT.","","ALCOHOL; ANTILIPEMIC AGENT; PLACEBO; POLICOSANOL; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL","","","","","","ENGLISH","CURR. THER. RES. CLIN. EXP.","ARTICLE","ISI","2-S2.0-0026509909","CURR THER RES CLIN EXP",NA,"NOTREPORTED",NA,"HERNANDEZ F, 1992, CURR THER RES CLIN EXP","HERNANDEZ F, 1992, CURR THER RES CLIN EXP"
"DEWALKAR L;DAHULE S;MASRAM S","DEWALKAR LALIT P;DAHULE SWAPNIL K;MASRAM SURSH C","ITRITICUM AESTIVUM IOCTACOSANOL A POTENTIAL INHIBITOR OF PCSK9 IN FAT DIETINDUCED HYPERCHOLESTEROMIA",2024,"REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY",NA,NA,0,"10.1007/s43450-024-00544-5","DEWALKAR, LP (CORRESPONDING AUTHOR), GURU NANAK COLL SCI, DEPT ZOOL, BALLARPUR 442701, MAHARASHTRA, INDIA.; DEWALKAR, LALIT P., GURU NANAK COLL SCI, DEPT ZOOL, BALLARPUR 442701, MAHARASHTRA, INDIA.; DAHULE, SWAPNIL K., GURU NANAK COLL SCI, DEPT CHEM, BALLARPUR 442701, MAHARASHTRA, INDIA.; MASRAM, SURSH C., RASHTRASANT TUKADOJI MAHARAJ NAGPUR UNIV, POSTGRAD TEACHING DEPT ZOOL, NAGPUR 440033, MAHARASHTRA, INDIA.","PROPROTEIN CONVERTASE SUBTILISIN-LIKE KEXIN TYPE 9 (PCSK9) IS A CIRCULATING SERINE PROTEASE THAT PROMOTES THE DEGRADATION OF LOW-DENSITY LIPOPROTEIN RECEPTORS, AND ITS ELEVATED LEVELS ARE ASSOCIATED WITH HYPERCHOLESTEROLEMIA AND CARDIOVASCULAR DISEASE. WHEATGRASS (TRITICUM AESTIVUM L., POACEAE) JUICE IS WIDELY CONSUMED BY HEALTH ENTHUSIASTS DUE TO ITS POTENTIAL HEALTH BENEFITS, INCLUDING POSITIVE EFFECTS ON LIPID PROFILES. OCTACOSANOL HAS BEEN SHOWN TO POSSESS ANTI-INFLAMMATORY AND ANTIOXIDANT PROPERTIES, AND PREVIOUS STUDIES HAVE SUGGESTED THAT IT MAY HAVE A ROLE IN REGULATING LIPID METABOLISM. THIS STUDY AIMED TO INVESTIGATE THE EFFECTS OF OCTACOSANOL, A BIOACTIVE COMPONENT DERIVED FROM WHEATGRASS, ON SERUM LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN-LIKE KEXIN TYPE 9 (PCSK9) AND LIPID PROFILES. THE STUDY USED A LIGAND BINDING PREDICTION APPROACH TO IDENTIFY POTENTIAL BINDING SITES ON PCSK9 FOR OCTACOSANOL. A TOTAL OF 20 SITES WERE PREDICTED, AND STABLE DOCKING OF OCTACOSANOL IN THE CATALYTIC DOMAIN OF PCSK9 WAS MEDIATED THROUGH HYDROGEN BONDS AND HYDROPHOBIC INTERACTIONS WITH SURROUNDING 15 RESIDUES. THE BEST DOCKED CONFORMATION OF OCTACOSANOL-PCSK9 EXHIBITED A BINDING ENERGY OF - 11.31 KCAL/MOL, INHIBITION CONSTANT OF 5.09 NM, AND INTERMOLECULAR ENERGY OF - 11.61 KCAL/MOL. THE RESULTS OF THE STUDY SHOWED THAT OCTACOSANOL WAS ABLE TO SIGNIFICANTLY REDUCE BOTH SERUM AND HEPATIC LEVELS OF PCSK9. THESE FINDINGS SUGGEST THAT OCTACOSANOL MAY BE A POTENTIAL THERAPEUTIC AGENT FOR THE REGULATION OF PCSK9 AND LIPID METABOLISM.","PCSK9; SERINE PROTEASE; CATALYTIC DOMAIN; LDL; OCTACOSANOL; WHEATGRASS","LIPID PROFILE; PROTEINSPLUS; ANTIOXIDANT; POLICOSANOL; DATABASE; SITES; WHEAT",NA,NA,"BERMAN HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/NAR/28.1.235; BONFILI L, 2009, BIOCHIMIE, V91, P1131, DOI 10.1016/J.BIOCHI.2009.06.001; BROWN ED, 2016, NATURE, V529, P336, DOI 10.1038/NATURE17042; CASTANO GLADYS, 2002, DRUGS R D, V3, P159, DOI 10.2165/00126839-200203030-00004; CIRIC MZ, 2023, J MED BIOCHEM, V42, P47, DOI 10.5937/JOMB0-38224; CIRIC MZ, 2021, NUTRIENTS, V13, DOI 10.3390/NU13030903; CUNNINGHAM D, 2007, NAT STRUCT MOL BIOL, V14, P413, DOI 10.1038/NSMB1235; DE OLIVEIRA AM, 2012, INT J MOL SCI, V13, P1598, DOI 10.3390/IJMS13021598; DEWALKAR LP., 2014, J PHARM SCI, V6, P556; FÄHRROLFES R, 2017, NUCLEIC ACIDS RES, V45, PW337, DOI 10.1093/NAR/GKX333; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HOOPER AJ, 2015, CLIN CHEM, V61, P6, DOI 10.1373/CLINCHEM.2014.234609; HORTON JD, 2007, TRENDS BIOCHEM SCI, V32, P71, DOI 10.1016/J.TIBS.2006.12.008; KAMBOJ VP, 2000, CURR SCI INDIA, V78, P35; KELLENBERGER E, 2006, J CHEM INF MODEL, V46, P717, DOI 10.1021/CI050372X; KESKES H, 2017, PHARM BIOL, V55, P88, DOI 10.1080/13880209.2016.1230139; KITTS DD, 2012, APPL PHYSIOL NUTR ME, V37, P938, DOI 10.1139/H2012-072, 10.1139/H2012-072; LASKOWSKI RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/CI200227U; MALONGANE F, 2017, J SCI FOOD AGR, V97, P4679, DOI 10.1002/JSFA.8472; NAYAK S, 2020, APPL ORGANOMET CHEM, V34, DOI 10.1002/AOC.5567; O'BOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; OHASHI K., 2011, J ANAL BIO-SCI, V34, P1598; OUYANG MQ, 2023, CLIN CHIM ACTA, V538, P113, DOI 10.1016/J.CCA.2022.11.018; PANDEY MM, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/376327; PETTERSEN EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/JCC.20084; PIPER DE, 2007, STRUCTURE, V15, P545, DOI 10.1016/J.STR.2007.04.004; RAZACK S, 2015, ANTIOXIDANTS-BASEL, V4, P185, DOI 10.3390/ANTIOX4010185; SANNER MF, 1999, J MOL GRAPH MODEL, V17, P57; SARKAR A, 2010, CURR TOP MED CHEM, V10, P67, DOI 10.2174/156802610790232233; SCHÖNING-STIERAND K, 2020, NUCLEIC ACIDS RES, V48, PW48, DOI 10.1093/NAR/GKAA235; SEIDAH NG, 2009, EXPERT OPIN THER TAR, V13, P19, DOI 10.1517/14728220802600715 ; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; VOLKAMER A, 2012, J CHEM INF MODEL, V52, P360, DOI 10.1021/CI200454V; VOLKAMER A, 2010, J CHEM INF MODEL, V50, P2041, DOI 10.1021/CI100241Y; WANG RX, 2004, J MED CHEM, V47, P2977, DOI 10.1021/JM030580L; WEISEL M, 2007, CHEM CENT J, V1, DOI 10.1186/1752-153X-1-7; YUAN HD, 2016, MOLECULES, V21, DOI 10.3390/MOLECULES21050559","DEWALKAR, LP (CORRESPONDING AUTHOR), GURU NANAK COLL SCI, DEPT ZOOL, BALLARPUR 442701, MAHARASHTRA, INDIA","SPRINGERNATURE","ENGLISH","REV. BRAS. FARMACOGN.-BRAZ. J. PHARMACOGN.","ARTICLE; EARLY ACCESS","ISI","WOS001207150300001","REV BRAS FARMACOGN-BRAZ J PHARMACOGN","GURU NANAK COLL SCI;GURU NANAK COLL SCI;GURU NANAK COLL SCI;RASHTRASANT TUKADOJI MAHARAJ NAGPUR UNIV","GURU NANAK COLL SCI",NA,"DEWALKAR LP, 2024, REV BRAS FARMACOGN-BRAZ J PHARMACOGN","DEWALKAR LP, 2024, REV BRAS FARMACOGN-BRAZ J PHARMACOGN"
"BANERJEE S;EILTS K;SINGH V","BANERJEE SHIVALI;EILTS KRISTEN K;SINGH VIJAY","HARNESSING THE POTENTIAL OF OILCANE WASTE MUD FOR RECOVERING BIOBASED WAXES",2024,"JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY",NA,NA,0,"10.1002/aocs.12844","SINGH, V (CORRESPONDING AUTHOR), UNIV ILLINOIS, CTR ADV BIOENERGY \& BIOPROD INNOVAT CABBI, URBANA, IL 61801 USA.; BANERJEE, SHIVALI; EILTS, KRISTEN K.; SINGH, VIJAY, UNIV ILLINOIS, CTR ADV BIOENERGY \& BIOPROD INNOVAT CABBI, URBANA, IL 61801 USA.; BANERJEE, SHIVALI; EILTS, KRISTEN K.; SINGH, VIJAY, UNIV ILLINOIS, DEPT AGR \& BIOL ENGN, URBANA, IL USA.","OILCANE IS AN ENGINEERED SUGARCANE WITH THE ABILITY TO HYPER-ACCUMULATE VEGETATIVE LIPIDS. IT IS PROCESSED TO OBTAIN JUICE AND BAGASSE AS A POTENTIAL SUBSTRATE FOR THE PRODUCTION OF BIOFUELS AND BIOCHEMICALS. THE JUICE COMPRISES SOLID PARTICLES THAT ARE SEPARATED AS WASTE MUD BEFORE THE FERMENTATION OF THE JUICE. IN THIS STUDY, THE OILCANE WASTE MUD (OWM) GENERATED FROM 1000 LITERS OF OILCANE JUICE WAS QUANTIFIED AND EVALUATED AS A POTENTIAL RESOURCE FOR RECOVERING BIOBASED WAXES. HEXANE AND ETHYL ACETATE WERE EVALUATED AS TWO DIFFERENT SOLVENTS FOR EXTRACTING WAXES FROM OWM FOLLOWED BY ITS PURIFICATION USING ACETONE. THE EXTRACTED BIOBASED WAX SAMPLES WERE CHARACTERIZED FOR THEIR CHEMICAL AND THERMAL PROFILES WHICH WERE THEN COMPARED WITH COMMERCIAL NATURAL WAXES. DETAILED MASS BALANCE SHOWS THAT 53.6 +/- 2.6 KG (DRY BASIS) OF SOLID OWM GETS GENERATED UPON PROCESSING 1000 L (SIMILAR TO 1068 KG) OF OILCANE JUICE. HEXANE AND ETHYL ACETATE LED TO A CRUDE WAX YIELD OF 25.6 +/- 0.2\% AND 16.6 +/- 0.4\% (WT/WT, DRY BASIS) RESPECTIVELY FROM OWM AT THE END OF 8 H. THE RELATIVE PURIFICATION OF THE WAX SAMPLES WAS REPORTED IN THE RANGE OF 58\%-65\% (WT/WT). THE PURIFIED OWM WAX HAS A MELTING POINT OF 74.7 DEGREES C. THE WASTE MUD WAS VALORIZED AS A SOURCE OF BIOBASED WAXES WITH CHARACTERISTIC CHEMICAL AND THERMAL PROFILES COMPARABLE TO COMMERCIAL NATURAL WAXES (CARNAUBA AND BEESWAX). CONSIDERING THE DECLINE IN THE SUPPLY OF PETROLEUM WAX IN THE FUTURE COUPLED WITH THE SWITCH TO ``GREENER'' ALTERNATIVE PRODUCTS BY CONSUMERS, OWM COULD BE A VALUABLE SOURCE OF NATURAL WAX IN THE INDUSTRIAL SECTOR REDUCING THE DEPENDENCE ON PETROLEUM WAXES. EVENTUALLY, RECOVERING BIOBASED WAX AS A CO-PRODUCT FROM OWM WOULD BRING IN AN ADDITIONAL STREAM OF REVENUE LEADING TO THE DEVELOPMENT OF A ZERO-WASTE BIOREFINERY BASED ON BIOENERGY CROPS.","BIOBASED WAX; BIOECONOMY; OILCANE; PROCESSING WASTE; VALUE-ADDITION; WASTE MANAGEMENT","BEESWAX ADULTERATION; MELTING-POINTS; CARNAUBA WAX; EXTRACTION; FOOD; ESTERS; OIL; POLICOSANOL; BIOMASS; LIPIDS","BIOLOGICAL AND ENVIRONMENTAL RESEARCH [DE-SC0018420]; DOE CENTER FOR ADVANCED BIOENERGY AND BIOPRODUCTS INNOVATION (U.S. DEPARTMENT OF ENERGY, OFFICE OF SCIENCE, BIOLOGICAL AND ENVIRONMENTAL RESEARCH PROGRAM)","THIS WORK WAS FUNDED BY THE DOE CENTER FOR ADVANCED BIOENERGY AND BIOPRODUCTS INNOVATION (U.S. DEPARTMENT OF ENERGY, OFFICE OF SCIENCE, BIOLOGICAL AND ENVIRONMENTAL RESEARCH PROGRAM UNDER AWARD NUMBER DE-SC0018420). ANY OPINIONS, FINDINGS, AND CONCLUSIONS OR RECOMMENDATIONS EXPRESSED IN THIS PUBLICATION ARE THOSE OF THE AUTHOR(S) AND DO NOT NECESSARILY REFLECT THE VIEWS OF THE U.S. DEPARTMENT OF ENERGY. WE THANK DR. NARENDRA DESHAVATH AND THE IBRL TEAM FOR PROVIDING US WITH THE OILCANE PROCESSING MUD SAMPLES FOR THIS STUDY. WE ALSO WANT TO ACKNOWLEDGE THE ASSISTANCE OF DR. REMY RODDEL AND DR. ALI FROM THE MATERIALS RESEARCH LABORATORY (MRL) AT THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN FOR CONDUCTING THE FT-IR, DSC, AND TGA.","AHMAD HM., 2015, PLANT CUTICULAR WAXES: A REVIEW ON FUNCTIONS, COMPOSITION, BIOSYNTHESES MECHANISM AND TRANSPORTATION; ALAM M, 2014, ARAB J CHEM, V7, P469, DOI 10.1016/J.ARABJC.2013.12.023; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; ATHUKORALA Y, 2009, EUR J LIPID SCI TECH, V111, P705, DOI 10.1002/EJLT.200800269; ATTARD TM, 2018, IND CROP PROD, V112, P38, DOI 10.1016/J.INDCROP.2017.10.045; ATTARD TM, 2018, J CLEAN PROD, V177, P684, DOI 10.1016/J.JCLEPRO.2017.12.155; ATTARD TM, 2016, ACS SUSTAIN CHEM ENG, V4, P5979, DOI 10.1021/ACSSUSCHEMENG.6B01220; ATTARD TM, 2015, IND CROP PROD, V76, P95, DOI 10.1016/J.INDCROP.2015.05.077; BHOSALE P. R., 2012, JOURNAL OF ENVIRONMENTAL RESEARCH AND DEVELOPMENT, V6, P715; BUCIO A, 2021, COATINGS, V11, DOI 10.3390/COATINGS11030261; CASTRO I., 2002, REV SOC QUIM MEX, V46; CHEMELEWSKI R, 2023, FRONT PLANT SCI, V14, DOI 10.3389/FPLS.2023.1227859; CRAIG RG, 1971, J DENT RES, V50, P450, DOI 10.1177/00220345710500025601; DEVI LS, 2022, TRENDS FOOD SCI TECH, V129, P296, DOI 10.1016/J.TIFS.2022.09.019; EDWARDS HGM, 1997, SPECTROCHIM ACTA A, V53, P2685, DOI 10.1016/S1386-1425(97)00161-3; ESFARJANI F, 2019, FOOD SCI NUTR, V7, P2302, DOI 10.1002/FSN3.1072; FEI T, 2017, CURR OPIN FOOD SCI, V16, P7, DOI 10.1016/J.COFS.2017.06.006; GAGLIANO J, 2022, ADV TRADIT MED, V22, P467, DOI 10.1007/S13596-020-00536-5; GIGANTE V, 2020, POLYMERS-BASEL, V12, DOI 10.3390/POLYM12112615; GORB EV, 2017, SCI REP-UK, V7, DOI 10.1038/SREP45483; GRANDVIEWRESEARCH, 2023, WAX MARKET SIZE, SHARE TRENDS ANALYSIS REPORT BY PRODUCT TYPE (MINERAL, SYNTHETIC, NATURAL), BY APPLICATION (CANDLES, PACKAGING, PLASTIC RUBBER), BY REGION, AND SEGMENT FORECASTS, 2023-2030; GUAN MJ, 2022, J CLEAN PROD, V330, DOI 10.1016/J.JCLEPRO.2021.129906; GUNDUPALLI MP, 2021, BIOENGINEERING-BASEL, V8, DOI 10.3390/BIOENGINEERING8110171; HACURA A., 2006, POL J ENVIRON STUD, V15, P112; HARRON AF, 2017, IND CROP PROD, V98, P116, DOI 10.1016/J.INDCROP.2016.09.015; HWANG KT, 2002, J AM OIL CHEM SOC, V79, P521, DOI 10.1007/S11746-002-0515-5; INARKAR M.B., 2012, ISRN AGRONOMY, DOI DOI 10.5402/2012/340158, 10.5402/2012/340158; IYENGAR BTR, 1969, LIPIDS, V4, P28, DOI 10.1007/BF02531790; JAVELLE M, 2011, NEW PHYTOL, V189, P17, DOI 10.1111/J.1469-8137.2010.03514.X; GIL-CHÁVEZ GJ, 2013, COMPR REV FOOD SCI F, V12, P5, DOI 10.1111/1541-4337.12005; KANNAN B, 2022, MOL BREEDING, V42, DOI 10.1007/S11032-022-01333-5; KIM KW, 2013, MICROSCOPY-JPN, V62, P541, DOI 10.1093/JMICRO/DFT004; KNUUTINEN U, 2000, WAX ANALYSIS IN CONSERVATION OBJECTS BY SOLUBILITY STUDIES, FTIR AND DSC. PAPER PRESENTED AT THE PROCEEDINGS OF THE 15TH WORLD CONFERENCE ON NONDESTRUCTIVE TESTING, ROME; KOCH K, 2009, SURF SCI, V603, P1961, DOI 10.1016/J.SUSC.2009.03.019; LOHANI UC, 2015, J AM OIL CHEM SOC, V92, P743, DOI 10.1007/S11746-015-2644-1; LOYAO AS, 2018, IND CROP PROD, V119, P152, DOI 10.1016/J.INDCROP.2018.04.017; MAIA M, 2013, TALANTA, V107, P74, DOI 10.1016/J.TALANTA.2012.09.052; MARICÁN A, 2012, J BRAZIL CHEM SOC, V23, P267, DOI 10.1590/S0103-50532012000200011; MEGHANA M, 2020, BIORESOURCE TECHNOL, V303, DOI 10.1016/J.BIORTECH.2020.122929; MILANOVIC J, 2010, SENSORS-BASEL, V10, P901, DOI 10.3390/S100100901; MOREAU RA, 2018, J LIQ CHROMATOGR R T, V41, P604, DOI 10.1080/10826076.2018.1485036; MOSCA F, 2018, MOLECULES, V23, DOI 10.3390/MOLECULES23071759; OLATUNJI OO, 2018, IOP CONF SER-MAT SCI, V423, DOI 10.1088/1757-899X/423/1/012175; OLIVEIRA RMA, 2022, SUSTAIN CHEM PHARM, V27, DOI 10.1016/J.SCP.2022.100657; PARAJULI S, 2020, GCB BIOENERGY, V12, P476, DOI 10.1111/GCBB.12684; PARTHA N., 2006, RECOVERY OF CHEMICALS FROM PRESSMUD-A SUGAR INDUSTRY WASTE; PATEL SEJAL, 2001, JOURNAL OF INSECT SCIENCE (TUCSON), V1, P1; PHUKAN AC, 1999, SEP PURIF TECHNOL, V17, P189, DOI 10.1016/S1383-5866(99)00037-4; PUÉRTOLAS E, 2016, FOOD RES INT, V80, P19, DOI 10.1016/J.FOODRES.2015.12.009; QI GX, 2017, PREP BIOCHEM BIOTECH, V47, P276, DOI 10.1080/10826068.2016.1224246; RODRIGUEZ-SAONA L., 2017, FOOD ANALYSIS, P107; SANTOS F, 2020, SUGARCANE BIOREFINERY, TECHNOLOGY AND PERSPECTIVES, P21, DOI 10.1016/B978-0-12-814236-3.00002-0; SHEN JJ, 2019, J FUNCT FOODS, V57, P351, DOI 10.1016/J.JFF.2019.04.024; DE FREITAS CAS, 2019, FOOD CHEM, V291, P38, DOI 10.1016/J.FOODCHEM.2019.03.133; SINGH SP, 2021, J CLEAN PROD, V328, DOI 10.1016/J.JCLEPRO.2021.129453; SMITH KW, 2011, J AM OIL CHEM SOC, V88, P1085, DOI 10.1007/S11746-011-1819-7; SOLEIMANIAN Y, 2020, COMPR REV FOOD SCI F, V19, P2994, DOI 10.1111/1541-4337.12614; SVECNJAK L, 2015, J APIC SCI, V59, P37, DOI 10.1515/JAS-2015-0018, 10.1515/JAS-2015-0018; TADA A, 2014, FOOD SCI NUTR, V2, P417, DOI 10.1002/FSN3.117; TANG W, 2022, FRONT MICROBIOL, V13, DOI 10.3389/FMICB.2022.960857; TULLOCH AP, 1970, LIPIDS, V5, P247, DOI 10.1007/BF02532476; VAZQUEZ-ROIG P, 2015, TRAC-TREND ANAL CHEM, V71, P55, DOI 10.1016/J.TRAC.2015.04.014; VRKOSLAV V, 2010, J CHROMATOGR A, V1217, P4184, DOI 10.1016/J.CHROMA.2009.12.048; YAO LX, 2008, J AM OIL CHEM SOC, V85, P77, DOI 10.1007/S11746-007-1159-9; ZAM W., 2012, INT J PHARM PHARM SCI, V4, P675","SINGH, V (CORRESPONDING AUTHOR), UNIV ILLINOIS, CTR ADV BIOENERGY \& BIOPROD INNOVAT CABBI, URBANA, IL 61801 USA","WILEY","ENGLISH","J. AM. OIL CHEM. SOC.","ARTICLE; EARLY ACCESS","ISI","WOS001204547900001","J AM OIL CHEM SOC","UNIV ILLINOIS;UNIV ILLINOIS;UNIV ILLINOIS","UNIV ILLINOIS",NA,"BANERJEE S, 2024, J AM OIL CHEM SOC","BANERJEE S, 2024, J AM OIL CHEM SOC"
"DA P C;NATOLINO A","DA PORTO CARLA;NATOLINO ANDREA","POLICOSANOLS FROM GRAPE MARC A NEW STEP TOWARDS A SUSTAINABLE BIOREFINERY FOR THE WINE INDUSTRY BY SCCO 2 EXTRACTION",2024,"JOURNAL OF CO2 UTILIZATION","82",NA,0,"10.1016/j.jcou.2024.102762","DA PORTO, C (CORRESPONDING AUTHOR), VIA SONDRIO 2-A, I-33100 UDINE, ITALY.; DA PORTO, CARLA; NATOLINO, ANDREA, UNIV UDINE, DEPT AGRIFOOD ENVIRONM \& ANIM SCI, I-33100 UDINE, ITALY.; DA PORTO, CARLA, VIA SONDRIO 2-A, I-33100 UDINE, ITALY.","SUPERCRITICAL CARBON DIOXIDE (SC-CO 2 ) EXTRACTION OF POLICOSANOL (PC) FROM GRAPE MARC WAS INVESTIGATED FOR THE FIRST TIME. EMPLOYING THE BROKEN PLUS INTACT CELLS (BIC) MODEL (SOVOV <ACUTE ACCENT>A ` S MODEL) THE INVESTIGATION FOCUSED ON ANALYZING THE SC-CO 2 PROCESS TO EXTRACT THE NONPOLAR FRACTION FROM GRAPE MARC EFFICIENTLY. OPERATING CONDITIONS FOR SC-CO 2 EXTRACTION - 280 BAR PRESSURE, 70 DEGREES C TEMPERATURE, AND A FLOW RATE OF 10 KGCO 2 /H - YIELDED THE HIGHEST POLICOSANOL CONTENT. THE EXTRACTED POLICOSANOL RANGED BETWEEN 3922 AND 4083 MG/KG DM , CONSTITUTING APPROXIMATELY 8 \% OF THE TOTAL EXTRACTION YIELD. SURPRISINGLY, THIS AMOUNT OF PC WAS OF THE SAME ORDER OF MAGNITUDE FOUND IN BEESWAX YELLOW, A WELL-KNOWN RICH NATURAL SOURCE OF PC. THE PRIMARY ALIPHATIC ALCOHOLS FOUND IN THE PC FROM GRAPE MARC WERE HEXACOSANOL, OCTACOSANOL, AND TRIACONTANOL. THESE FINDINGS WERE CONSISTENT WITH GRAPE MARC SAMPLES FROM OTHER ITALIAN REGIONS. FURTHERMORE, A COMPARATIVE ANALYSIS BETWEEN SC-CO 2 AND SOXHLET EXTRACTION METHODS FOR PC WAS CARRIED OUT.","POLICOSANOL; ALIPHATIC ALCOHOLS; GRAPE MARC; MATHEMATICAL MODELING; SFE; BIOREFINERY","SUPERCRITICAL-FLUID EXTRACTION; CARBON-DIOXIDE EXTRACTION; SEED OIL; QUANTIFICATION; CHROMATOGRAPHY; POMACE",NA,NA,"ATTARD TM, 2016, ACS SUSTAIN CHEM ENG, V4, P5979, DOI 10.1021/ACSSUSCHEMENG.6B01220; ATTARD TM, 2015, IND CROP PROD, V76, P95, DOI 10.1016/J.INDCROP.2015.05.077; BERES C, 2017, WASTE MANAGE, V68, P581, DOI 10.1016/J.WASMAN.2017.07.017; BLASI F, 2022, LWT-FOOD SCI TECHNOL, V158, DOI 10.1016/J.LWT.2022.113167; BRUNNER G., 1994, GAS EXTRACTION: AN INTRODUCTION TO FUNDAMENTALS OF SUPERCRITICAL FLUIDS AND THE APPLICATION TO SEPARATION PROCESSES; CALIGIANI A, 2010, PLANT FOOD HUM NUTR, V65, P277, DOI 10.1007/S11130-010-0173-5; CHEUNG PCK, 1999, FOOD CHEM, V65, P399, DOI 10.1016/S0308-8146(98)00210-6; CHOI SJ, 2016, FOOD CHEM, V204, P94, DOI 10.1016/J.FOODCHEM.2016.02.027; CONFORTIN TC, 2019, J SUPERCRIT FLUID, V153, DOI 10.1016/J.SUPFLU.2019.104589; DA PORTO C, 2022, ACS OMEGA, DOI 10.1021/ACSOMEGA.2C02631; DE MELO MMR, 2014, J SUPERCRIT FLUID, V92, P115, DOI 10.1016/J.SUPFLU.2014.04.007; DUNFORD NT, 2010, BIORESOURCE TECHNOL, V101, P422, DOI 10.1016/J.BIORTECH.2009.08.009; FARÍAS-CAMPOMANES AM, 2013, J SUPERCRIT FLUID, V77, P70, DOI 10.1016/J.SUPFLU.2013.02.006; GAO WF, 2015, J CHROMATOGR SCI, V53, P811, DOI 10.1093/CHROMSCI/BMU098; GIUFFRÈ AM, 2015, J OLEO SCI, V64, P625, DOI 10.5650/JOS.ESS15002; HAIM D, 2009, J CHROMATOGR B, V877, P4154, DOI 10.1016/J.JCHROMB.2009.10.034; HARRABI S, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/S12944-018-0682-Z; HUANG Z, 2012, J CHROMATOGR A, V1250, P2, DOI 10.1016/J.CHROMA.2012.04.032; ILYAS T, 2021, ENVIRON TECHNOL INNO, V23, DOI 10.1016/J.ETI.2021.101592; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JIN B., 2009, BIOTECHNOLOGY FOR AGRO-INDUSTRIAL RESIDUES UTILISATION, P293; JIN Q, 2021, FOOD BIOPROD PROCESS, V127, P139, DOI 10.1016/J.FBP.2021.02.002; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; LEE HG, 2022, PLANTS-BASEL, V11, DOI 10.3390/PLANTS11141844; LIONG KK, 1992, IND ENG CHEM RES, V31, P390, DOI 10.1021/IE00001A053; LÓPEZ-PADILLA A, 2017, J SUPERCRIT FLUID, V130, P292, DOI 10.1016/J.SUPFLU.2017.03.033; LORENZ P, 2008, ANAL BIOANAL CHEM, V391, P633, DOI 10.1007/S00216-008-2000-5; MENDES JAS, 2013, IND CROP PROD, V43, P25, DOI 10.1016/J.INDCROP.2012.06.047; MOUAHID A, 2021, J CO2 UTIL, V46, DOI 10.1016/J.JCOU.2021.101458; OIV-INTERNATIONAL ORGANISATION OF VINE AND WINE INTERGOVERNMENTAL ORGANISATION, 2022, STATE OF THE WORLD VINE AND WINE SECTOR 2021; OLATUNJI L.W., 2022, CCMP, V2, DOI 10.1016/J.CCMP.2022.100058, DOI 10.1016/J.CCMP.2022.100058; OU SY, 2012, LWT-FOOD SCI TECHNOL, V45, P295, DOI 10.1016/J.LWT.2011.08.011; PASHA I, 2013, CRIT REV FOOD SCI, V53, P287, DOI 10.1080/10408398.2010.528080; PEREIRA CG, 2010, FOOD BIOPROCESS TECH, V3, P340, DOI 10.1007/S11947-009-0263-2; PERRA M, 2022, J FUNCT FOODS, V98, DOI 10.1016/J.JFF.2022.105276; POVH NP, 2001, J SUPERCRIT FLUID, V21, P245, DOI 10.1016/S0896-8446(01)00096-1; REVERCHON E, 2006, J SUPERCRIT FLUID, V38, P146, DOI 10.1016/J.SUPFLU.2006.03.020; RODRIGUES RF, 2008, J SUPERCRIT FLUID, V43, P375, DOI 10.1016/J.SUPFLU.2007.07.014; SIN EHK, 2014, CR CHIM, V17, P293, DOI 10.1016/J.CRCI.2013.12.001; SOH SH, 2019, ENG REP, V1, DOI 10.1002/ENG2.12051; SOVOVÁ H, 2005, J SUPERCRIT FLUID, V33, P35, DOI 10.1016/J.SUPFLU.2004.03.005; SOVOVA H, 1994, CHEM ENG SCI, V49, P409, DOI 10.1016/0009-2509(94)87012-8; WANG LJ, 2007, EUR J LIPID SCI TECH, V109, P567, DOI 10.1002/EJLT.200700018; YAASHIKAA PR, 2022, BIORESOURCE TECHNOL, V343, DOI 10.1016/J.BIORTECH.2021.126126; YANG MY, 2021, POSTHARVEST BIOL TEC, V173, DOI 10.1016/J.POSTHARVBIO.2020.111430; ZHANG MW, 2021, FRONT NUTR, V8, DOI 10.3389/FNUT.2021.817796","DA PORTO, C (CORRESPONDING AUTHOR), VIA SONDRIO 2-A, I-33100 UDINE, ITALY","ELSEVIER SCI LTD","ENGLISH","J. CO2 UTIL.","ARTICLE","ISI","WOS001234097600001","J CO2 UTIL","C (CORRESPONDING AUTHOR);UNIV UDINE","C (CORRESPONDING AUTHOR)",NA,"DA PORTO C, 2024, J CO2 UTIL","DA PORTO C, 2024, J CO2 UTIL1"
"CHO K;NAM H;KIM N;LEE M;KANG D","CHO KYUNG-HYUN;NAM HYO-SEON;KIM NA-YOUNG;LEE MYEONG-SUNG;KANG DAE-JIN","COMBINATION THERAPY OF CUBAN POLICOSANOL RAYDEL 20 MG AND INTENSIVE EXERCISE FOR 12 WEEKS RESULTED IN IMPROVEMENTS IN OBESITY HYPERTENSION AND DYSLIPIDEMIA WITHOUT A DECREASE IN SERUM COENZYME QSUB10SUB ENHANCEMENT OF LIPOPROTEINS QUALITY AND ANTIOXIDANT FUNCTIONALITY IN OBESE PARTICIPANTS",2024,"PHARMACEUTICALS","17",NA,0,"10.3390/ph17010132","CHO, KH (CORRESPONDING AUTHOR), RAYDEL RES INST, MED INNOVAT COMPLEX, DAEGU 41061, SOUTH KOREA.; CHO, KYUNG-HYUN; NAM, HYO-SEON; KIM, NA-YOUNG; LEE, MYEONG-SUNG; KANG, DAE-JIN, RAYDEL RES INST, MED INNOVAT COMPLEX, DAEGU 41061, SOUTH KOREA.","OBESITY AND OVERWEIGHT, FREQUENTLY CAUSED BY A LACK OF EXERCISE, ARE ASSOCIATED WITH MANY METABOLIC DISEASES, SUCH AS HYPERTENSION, DIABETES, AND DYSLIPIDEMIA. AEROBIC EXERCISE EFFECTIVELY INCREASES THE HIGH-DENSITY LIPOPROTEINS-CHOLESTEROL (HDL-C) LEVELS AND ALLEVIATES THE TRIGLYCERIDE (TG) LEVELS. THE CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL (R)) IS ALSO EFFECTIVE IN ENHANCING THE HDL-C QUANTITY AND HDL FUNCTIONALITY TO TREAT DYSLIPIDEMIA AND HYPERTENSION. ON THE OTHER HAND, NO STUDY HAS EXAMINED THE EFFECTS OF A COMBINATION OF HIGH-INTENSITY EXERCISE AND POLICOSANOL CONSUMPTION IN OBESE SUBJECTS TO IMPROVE METABOLIC DISORDERS. IN THE CURRENT STUDY, 17 OBESE SUBJECTS (AVERAGE BMI 30.1 +/- 1.1 KG/M(2), EIGHT MALE AND NINE FEMALE) WERE RECRUITED TO PARTICIPATE IN A PROGRAM COMBINING EXERCISE AND POLICOSANOL (20 MG) CONSUMPTION FOR 12 WEEKS. AFTER COMPLETION, THEIR BMI, WAIST CIRCUMFERENCE, TOTAL FAT MASS, SYSTOLIC BLOOD PRESSURE (SBP), AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCED SIGNIFICANTLY UP TO AROUND -15\%, -13\%, -33\%, -11\%, AND -13\%, RESPECTIVELY. IN THE SERUM LIPID PROFILE, AT WEEK 12, A SIGNIFICANT REDUCTION WAS OBSERVED IN THE TOTAL CHOLESTEROL (TC) AND TRIGLYCERIDE (TG) LEVELS, UP TO -17\% AND -54\% FROM THE BASELINE, RESPECTIVELY. THE SERUM HDL-C WAS ELEVATED BY APPROXIMATELY +12\% FROM THE BASELINE, AS WELL AS THE PERCENTAGE OF HDL-C IN TC, AND HDL-C/TC (\%), WAS ENHANCED BY UP TO +32\% AT WEEK 12. THE SERUM COENZYME Q(10) (COQ(10)) LEVEL WAS INCREASED 1.2-FOLD FROM THE BASELINE IN ALL PARTICIPANTS AT WEEK 12. IN PARTICULAR, THE MALE PARTICIPANTS EXHIBITED A 1.4-FOLD INCREASE FROM THE BASELINE. THE LARGER RISE IN SERUM COQ(10) WAS CORRELATED WITH THE LARGER INCREASE IN THE SERUM HDL-C (R = 0.621, P = 0.018). THE HEPATIC FUNCTION PARAMETERS WERE IMPROVED; THE SERUM GAMMA-GLUTAMYL TRANSFERASE DECREASED AT WEEK 12 BY UP TO -55\% (P < 0.007), WHILE THE ASPARTATE AMINOTRANSFERASE AND ALANINE TRANSAMINASE LEVELS DIMINISHED WITHIN THE NORMAL RANGE. IN THE LIPOPROTEIN LEVEL, THE EXTENT OF OXIDATION AND GLYCATION WERE REDUCED SIGNIFICANTLY WITH THE REDUCTION IN TG CONTENT. THE ANTIOXIDANT ABILITIES OF HDL, SUCH AS PARAOXONASE (PON) AND FERRIC ION REDUCTION ABILITY (FRA), WERE ENHANCED SIGNIFICANTLY BY UP TO 1.8-FOLD AND 1.6-FOLD AT WEEK 12. THE PARTICLE SIZE AND NUMBER OF HDL WERE ELEVATED UP TO +10\% DURING THE 12 WEEKS, WITH A REMARKABLE DECLINE IN THE TG CONTENT, GLYCATION EXTENT, AND OXIDATION. THE IMPROVEMENTS IN HDL QUALITY AND FUNCTIONALITY WERE LINKED TO THE HIGHER SURVIVABILITY OF ADULT ZEBRAFISH AND THEIR EMBRYOS, UNDER THE CO-PRESENCE OF CARBOXYMETHYLLYSINE (CML), A PRO-INFLAMMATORY MOLECULE KNOWN TO CAUSE ACUTE DEATH. IN CONCLUSION, 12 WEEKS OF CUBAN POLICOSANOL (RAYDEL (R), 20 MG) CONSUMPTION WITH HIGH-INTENSITY EXERCISE DISPLAYED A SIGNIFICANT IMPROVEMENT IN BLOOD PRESSURE, BODY FAT MASS, BLOOD LIPID PROFILE WITHOUT LIVER DAMAGE, COQ(10) METABOLISM, AND RENAL IMPAIRMENT.","HIGH-DENSITY LIPOPROTEINS; APOLIPOPROTEIN A-I; POLICOSANOL; EXERCISE; PARAOXONASE; LOW-DENSITY LIPOPROTEINS; COENZYME Q(10)","ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; HDL CHOLESTEROL; ADULTS; RISK; MEN; DISEASE; HEALTH",NA,NA,"ASKARPOUR M, 2019, COMPLEMENT THER MED, V45, P89, DOI 10.1016/J.CTIM.2019.05.023; BENZIE IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/ABIO.1996.0292; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/JAMA.262.17.2395; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199A0; BONFIM MR, 2015, ARQ BRAS CARDIOL, V104, P324, DOI 10.5935/ABC.20150005; CANAVACIOLO V.L.G., 2007, CENIC CIENC. QUIM, V38, P207; CHEW NWS, 2023, CELL METAB, V35, P414, DOI 10.1016/J.CMET.2023.02.003; CHO KH, 2023, INT J MOL SCI, V24, DOI 10.3390/IJMS24087044; CHO KH, 2023, INT J MOL SCI, V24, DOI 10.3390/IJMS24065185; CHO KH, 2022, INT J MOL SCI, V23, DOI 10.3390/IJMS231710130; CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; COUILLARD C, 2001, ARTERIOSCL THROM VAS, V21, P1226, DOI 10.1161/HQ0701.092137; DEICHMANN R, 2010, OCHSNER J, V10, P16; GAO W, 2023, FRONT PUBLIC HEALTH, V11, DOI 10.3389/FPUBH.2023.1194124; GHIRLANDA G, 1993, J CLIN PHARMACOL, V33, P226, DOI 10.1002/J.1552-4604.1993.TB03948.X; PEREIRA ENGD, 2021, WORLD J GASTROENTERO, V27, P4913, DOI 10.3748/WJG.V27.I29.4913; HASKELL WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/MSS.0B013E3180616B27, 10.1161/CIRCULATIONAHA.107.185649; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYASHI M, 1983, MUTAT RES, V120, P241, DOI 10.1016/0165-7992(83)90096-9; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; JEPPESEN J, 1997, ARTERIOSCL THROM VAS, V17, P1114, DOI 10.1161/01.ATV.17.6.1114; JOY TR, 2009, ANN INTERN MED, V150, P858, DOI 10.7326/0003-4819-150-12-200906160-00009; KIM HR, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15081658; KIM J, 2016, J SPORT HEALTH SCI, V5, P324, DOI 10.1016/J.JSHS.2015.01.012; KIM SJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/FPHYS.2018.00412; KINOSHITA K, 2022, SCI REP-UK, V12, DOI 10.1038/S41598-022-05302-Y; KODAMA S, 2007, ARCH INTERN MED, V167, P999, DOI 10.1001/ARCHINTE.167.10.999; LIN M, 2023, PLOS ONE, V18, DOI 10.1371/JOURNAL.PONE.0292020; MACKNESS M, 2011, CLIN BIOCHEM, V44, P1270, DOI 10.1016/J.CLINBIOCHEM.2011.08.002; MAINOUS AG, 2019, AM J CARDIOL, V123, P764, DOI 10.1016/J.AMJCARD.2018.11.043; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/BI00406A016; MEADOR BM, 2010, MUSCLE NERVE, V42, P469, DOI 10.1002/MUS.21817; NATIONAL RESEARCH COUNCIL, 2011, GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS: EIGHTH EDITION, DOI 10.17226/12910; NOBLE RP, 1968, J LIPID RES, V9, P693; NOUBIAP JJ, 2022, DIABETES RES CLIN PR, V188, DOI 10.1016/J.DIABRES.2022.109924; NOVOA B, 2009, FISH SHELLFISH IMMUN, V26, P326, DOI 10.1016/J.FSI.2008.12.004; NUSSLEIN V., 2002, ZEBRAFISH: A PRACTICAL APPROACH; OPIE LH, 2013, CARDIOVASC DRUG THER, V27, P569, DOI 10.1007/S10557-013-6483-8; OWUSU-ANSAH E, 2008, NAT GENET, V40, P356, DOI 10.1038/NG.2007.50; PACANOWSKI MA, 2008, J CLIN LIPIDOL, V2, P289, DOI 10.1016/J.JACL.2008.05.001; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PALAZÓN-BRU A, 2021, SPORTS MED, V51, P243, DOI 10.1007/S40279-020-01364-Y; PARK HJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16050809; PARK SH, 2021, BIOL RES NURS, V23, P658, DOI 10.1177/10998004211015424; PETTERSSON J, 2008, BRIT J CLIN PHARMACO, V65, P253, DOI 10.1111/J.1365-2125.2007.03001.X; SINGH RB, 2003, MOL CELL BIOCHEM, V246, P75, DOI 10.1023/A:1023408031111; STRATH SJ, 2013, CIRCULATION, V128, P2259, DOI 10.1161/01.CIR.0000435708.67487.DA; SWIFT DL, 2018, PROG CARDIOVASC DIS, V61, P206, DOI 10.1016/J.PCAD.2018.07.014; TOMASETTI M, 1999, BIOFACTORS, V9, P231, DOI 10.1002/BIOF.5520090218; TOYAMA K, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0041369; TREDE NS, 2001, TRENDS IMMUNOL, V22, P302, DOI 10.1016/S1471-4906(01)01939-1; VINCI P, 2021, INT J MOL SCI, V22, DOI 10.3390/IJMS222111687; ZMUDA JM, 1998, ATHEROSCLEROSIS, V137, P215, DOI 10.1016/S0021-9150(97)00257-8","CHO, KH (CORRESPONDING AUTHOR), RAYDEL RES INST, MED INNOVAT COMPLEX, DAEGU 41061, SOUTH KOREA","MDPI","ENGLISH","PHARMACEUTICALS","ARTICLE","ISI","WOS001153089700001","PHARMACEUTICALS","RAYDEL RES INST;RAYDEL RES INST","RAYDEL RES INST",NA,"CHO KH, 2024, PHARMACEUTICALS","CHO KH, 2024, PHARMACEUTICALS-a"
"BELAKOVA B;WEDIGE N;AWAD E;HESS ;SIMON S;OSZWALD A;FELLNER M;KHAN S;RESCH U;LIPOVAC M;SMEJKAL K;UHRIN P;BREUSS J;WAGNER K;SONG P","BELAKOVA BARBORA;WEDIGE NICHOLAS K;AWAD EZZAT M;HESS; SIMON;OSZWALD ANDRE;FELLNER MARLENE;KHAN SHAFAAT Y; RESCH ULRIKE;LIPOVAC MARKUS;SMEJKAL KAREL;UHRIN PAVEL;BREUSS JOHANNES M;WAGNER KAY-DIETRICH;SONG PING","LIPOPHILIC STATINS ELIMINATE SENESCENT ENDOTHELIAL CELLS BY INDUCING ANOIKISRELATED CELL DEATH",2023,"CELLS","12",NA,3,"10.3390/cells12242836","BREUSS, JM (CORRESPONDING AUTHOR), MED UNIV VIENNA, INST VASC BIOL \& THROMBOSIS RES, CTR PHYSIOL \& PHARMACOL, A-1090 VIENNA, AUSTRIA.; BELAKOVA, BARBORA; WEDIGE, NICHOLAS K.; AWAD, EZZAT M.; HESS, SIMON; OSZWALD, ANDRE; FELLNER, MARLENE; KHAN, SHAFAAT Y.; RESCH, ULRIKE; UHRIN, PAVEL; BREUSS, JOHANNES M., MED UNIV VIENNA, INST VASC BIOL \& THROMBOSIS RES, CTR PHYSIOL \& PHARMACOL, A-1090 VIENNA, AUSTRIA.; AWAD, EZZAT M., MED UNIV VIENNA, INST SPEC PROPHYLAXIS \& TROP MED, CTR PATHOPHYSIOL INFECTIOL \& IMMUNOL, A-1090 VIENNA, AUSTRIA.; OSZWALD, ANDRE, MED UNIV VIENNA, DEPT PATHOL, A-1090 VIENNA, AUSTRIA.; KHAN, SHAFAAT Y., GOVT COLL UNIV LAHORE, DEPT ZOOL, LAHORE 54000, PAKISTAN.; LIPOVAC, MARKUS, KARL LANDSTEINER INST CELL BASED THERAPY GYNECOL, A-2100 KORNEUBURG, AUSTRIA.; SMEJKAL, KAREL, MASARYK UNIV, FAC PHARM, DEPT NAT DRUGS, BRNO 61200, CZECH REPUBLIC.","PRE-CLINICAL STUDIES FROM THE RECENT PAST HAVE INDICATED THAT SENESCENT CELLS CAN NEGATIVELY AFFECT HEALTH AND CONTRIBUTE TO PREMATURE AGING. TARGETED ERADICATION OF THESE CELLS HAS BEEN SHOWN TO IMPROVE THE HEALTH OF AGED EXPERIMENTAL ANIMALS, LEADING TO A CLINICAL INTEREST IN FINDING COMPOUNDS THAT SELECTIVELY ELIMINATE SENESCENT CELLS WHILE SPARING NON-SENESCENT ONES. IN OUR STUDY, WE IDENTIFIED A SENOLYTIC CAPACITY OF STATINS, WHICH ARE LIPID-LOWERING DRUGS PRESCRIBED TO PATIENTS AT HIGH RISK OF CARDIOVASCULAR EVENTS. USING TWO DIFFERENT MODELS OF SENESCENCE IN HUMAN VASCULAR ENDOTHELIAL CELLS (HUVECS), WE FOUND THAT STATINS PREFERENTIALLY ELIMINATED SENESCENT CELLS, WHILE LEAVING NON-SENESCENT CELLS UNHARMED. WE OBSERVED THAT THE SENOLYTIC EFFECT OF STATINS COULD BE NEGATED WITH THE CO-ADMINISTRATION OF MEVALONIC ACID AND THAT STATINS INDUCED CELL DETACHMENT LEADING TO ANOIKIS-LIKE APOPTOSIS, AS EVIDENCED BY REAL-TIME VISUALIZATION OF CASPASE-3/7 ACTIVATION. OUR FINDINGS SUGGEST THAT STATINS POSSESS A SENOLYTIC PROPERTY, POSSIBLY ALSO CONTRIBUTING TO THEIR DESCRIBED BENEFICIAL CARDIOVASCULAR EFFECTS. FURTHER STUDIES ARE NEEDED TO EXPLORE THE POTENTIAL OF SHORT-TERM, HIGH-DOSE STATIN TREATMENT AS A CANDIDATE SENOLYTIC THERAPY.","ENDOTHELIAL CELLS; SENESCENCE; SENOLYTICS; STATINS; ANOIKIS; APOPTOSIS","DISTURBED FLOW; SIMVASTATIN; APOPTOSIS; INHIBITION; GERANYLGERANYLATION; PRAVASTATIN; POLICOSANOL; EXPRESSION; LOVASTATIN; ADHESION","FWF (AUSTRIAN SCIENCE FUND); AUSTRIAN SCIENCE FUND (FWF)","WE WOULD LIKE TO THANK JUDIT MIHALY-BISON FOR HER EXCELLENT TECHNICAL SUPPORT, AND REINHOLD BREUSS AND JOHANNES SCHMID FOR SUPPORT DURING MANUSCRIPT FINALIZATION. OPEN ACCESS FUNDING BY THE AUSTRIAN SCIENCE FUND (FWF).","BAAR MP, 2017, CELL, V169, P132, DOI 10.1016/J.CELL.2017.02.031; BAIGENT C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; BAKER DJ, 2016, NATURE, V530, P184, DOI 10.1038/NATURE16932; BAKER DJ, 2011, NATURE, V479, P232, DOI 10.1038/NATURE10600; BATES DM, 1988, NONLINEAR REGRESSION; BATES K, 2002, AM J PHYSIOL-HEART C, V283, PH768, DOI 10.1152/AJPHEART.00826.2001; BLOOM SI, 2023, NAT REV CARDIOL, V20, P38, DOI 10.1038/S41569-022-00739-0; CAMPISI J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/ANNUREV-PHYSIOL-030212-183653; CHAO DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/ANNUREV.IMMUNOL.16.1.395; CHELLO M, 2003, HEART, V89, P538, DOI 10.1136/HEART.89.5.538; CHEN J, 2006, AM J PHYSIOL-HEART C, V290, PH1575, DOI 10.1152/AJPHEART.00364.2005; CHIU JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/PHYSREV.00047.2009; COPAJA M, 2012, TOXICOLOGY, V294, P42, DOI 10.1016/J.TOX.2012.01.011; CORSINI A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163-7258(99)00045-5; CRAMPTON STEVE P, 2007, J VIS EXP, P183, DOI 10.3791/183; DEMIERRE MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/NRC1751; DENG R, 2007, CARDIOVASC DRUG REV, V25, P375, DOI 10.1111/J.1527-3466.2007.00023.X; DIAMANT M, 2008, THROMB HAEMOSTASIS, V100, P489, DOI 10.1160/TH07-12-0760; DIMITROULAKOS J, 2001, CLIN CANCER RES, V7, P158; DONG WJ, 2009, J LIPID RES, V50, P2095, DOI 10.1194/JLR.M900236-JLR200; EL ASSAR M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/FPHYS.2012.00132; ERUSALIMSKY JD, 2005, EXP GERONTOL, V40, P634, DOI 10.1016/J.EXGER.2005.04.010; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; FREUND A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/MBC.E11-10-0884; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/JCB.124.4.619; FURBERG CD, 1999, CIRCULATION, V99, P185, DOI 10.1161/01.CIR.99.2.185; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425A0; GROSSE L, 2020, CELL METAB, V32, P87, DOI 10.1016/J.CMET.2020.05.002; HERNANDEZ-SEGURA A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/J.TCB.2018.02.001; HICKSON LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/J.EBIOM.2019.08.069; HU L, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/FCELL.2022.822816; ISTVAN ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/SCIENCE.1059344; JAIN MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/NRD1901; KANETA S, 2003, ATHEROSCLEROSIS, V170, P237, DOI 10.1016/S0021-9150(03)00301-0; KROUWER VJD, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-12; KUO LJ, 2008, IN VIVO, V22, P305; LEI JP, 2014, CLIN APPL THROMB-HEM, V20, P212, DOI 10.1177/1076029612458967; LI XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/JBC.M201253200; MCFARLANE SI, 2002, J CLIN ENDOCR METAB, V87, P1451, DOI 10.1210/JC.87.4.1451; MILLER RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/GERONA/GLQ178; MINAMINO T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; MUN GI, 2010, AM J PHYSIOL-HEART C, V298, PH2102, DOI 10.1152/AJPHEART.00835.2009; NAM DE, 2019, J MED FOOD, V22, P1110, DOI 10.1089/JMF.2019.4491; OWENS WA, 2021, MECH AGEING DEV, V198, DOI 10.1016/J.MAD.2021.111540; RAMACHANDRAN C, 2013, J EVID-BASED INTEGR, V18, P248, DOI 10.1177/2156587213488601; RITZ C, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0146021; ROOS CM, 2016, AGING CELL, V15, P973, DOI 10.1111/ACEL.12458; SCHACHTER M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/J.1472-8206.2004.00299.X; SCHINDELIN J, 2012, NAT METHODS, V9, P676, DOI 10.1038/NMETH.2019, 10.1038/NMETH.2019; SCHOLZEN T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SHIMI T, 2011, GENE DEV, V25, P2579, DOI 10.1101/GAD.179515.111; SIGNORELL ANDRI, 2024, CRAN; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; STEHLIK C, 1998, J EXP MED, V188, P211, DOI 10.1084/JEM.188.1.211; STONE NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/J.JACC.2013.11.002; TANG DJ, 2006, LIFE SCI, V79, P1484, DOI 10.1016/J.LFS.2006.04.019; TARASEVICIENE-STEWART L, 2006, AM J PHYSIOL-LUNG C, V291, PL668, DOI 10.1152/AJPLUNG.00491.2005; THIBAULT A, 1996, CLIN CANCER RES, V2, P483; TRIANA-MARTÍNEZ F, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-12888-X; VALENTIJN AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; VAN DER SPEK E, 2006, HAEMATOLOGICA, V91, P542; VON KOBBE C, 2019, AGING-US, V11, P12844, DOI 10.18632/AGING.102557; WAGNER M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X; WANG JY, 2008, INT J CARDIOL, V127, P33, DOI 10.1016/J.IJCARD.2007.10.034; WARBOYS CM, 2014, ARTERIOSCL THROM VAS, V34, P985, DOI 10.1161/ATVBAHA.114.303415; WICKHAM H, 2019, JOURNAL OF OPEN SOURCE SOFTWARE, V4, P1686, DOI 10.21105/JOSS.01686, DOI 10.21105/JOSS.01686; WOOD MICHELLE A., 2004, BIOS (OCEAN GROVE), V75, P139, DOI 10.1893/0005-3155(2004)075<0139:BSAAMO>2.0.CO;2; XU M, 2018, NAT MED, V24, P1246, DOI 10.1038/S41591-018-0092-9; XU SB, 2021, FRONT GENET, V12, DOI 10.3389/FGENE.2021.774846; YAMAZAKI M, 1996, BIOPHARM DRUG DISPOS, V17, P775; ZHAO WB, 2019, MOL MED REP, V19, P1919, DOI 10.3892/MMR.2019.9828; ZHU Y, 2015, AGING CELL, V14, P644, DOI 10.1111/ACEL.12344","BREUSS, JM (CORRESPONDING AUTHOR), MED UNIV VIENNA, INST VASC BIOL \& THROMBOSIS RES, CTR PHYSIOL \& PHARMACOL, A-1090 VIENNA, AUSTRIA","MDPI","ENGLISH","CELLS","ARTICLE","ISI","WOS001131066200001","CELLS","MED UNIV VIENNA;RESCH;MED UNIV VIENNA;MED UNIV VIENNA;MED UNIV VIENNA;GOVT COLL UNIV LAHORE;KARL LANDSTEINER INST CELL BASED THERAPY GYNECOL;MASARYK UNIV","MED UNIV VIENNA",NA,"BELAKOVA B, 2023, CELLS","BELAKOVA B, 2023, CELLS"
"ZHOU H;WEN L;LIN L;LI Z;QIU ;MINGHUA M","ZHOU HAORAN;WEN LUAN;LIN LIWU;LI ZHONGRONG;QIU; MINGHUA","REFINED WAXY PRODUCT FROM THE RESIDUES OF PYRETHRINS PROCESSING CONTENTS COMPOSITIONS AND SKINWHITENING EFFECTS",2023,"INDUSTRIAL CROPS AND PRODUCTS","206",NA,0,"10.1016/j.indcrop.2023.117564","QIU, MH (CORRESPONDING AUTHOR), CHINESE ACAD SCI, KUNMING INST BOT, STATE KEY LAB PHYTOCHEMISTRY \& PLANT RESOURCES WES, KUNMING 650201, PEOPLES R CHINA.; ZHOU, HAORAN; WEN, LUAN; LIN, LIWU; LI, ZHONGRONG; QIU, MINGHUA, CHINESE ACAD SCI, KUNMING INST BOT, STATE KEY LAB PHYTOCHEMISTRY \& PLANT RESOURCES WES, KUNMING 650201, PEOPLES R CHINA.; ZHOU, HAORAN; WEN, LUAN; LIN, LIWU; QIU, MINGHUA, UNIV CHINESE ACAD SCI, BEIJING 100049, PEOPLES R CHINA.","PYRETHRINS IS ONE OF THE MOST IMPORTANT BOTANICAL INSECTICIDES. IN RECENT YEARS, DUE TO THE DEMAND FOR PYRETHRINS, FACTORIES USE DRIED FLOWERS OF CULTIVATED PYRETHRUM AS RAW MATERIALS TO PRODUCE PYRETHRIN. DURING THIS PROCESS, A LARGE AMOUNT OF WAX IS PRODUCED. IN ORDER TO AVOID RESOURCE WASTE AND ENVIRONMENTAL POLLUTION, BETTER DEVELOPMENT AND UTILIZATION OF PYRETHRUM WAX IS REQUIRED. THEREFORE, IN THIS STUDY, REFINED PYRETHRUM WAX UNSAPONIFIABLES (RPWU) WERE PREPARED FROM PYRETHRUM WAX WASTES BY SILICA GEL COLUMN CHROMATOGRAPHY AND SAPONIFICATION. THE COMPOSITIONS AND CONTENTS OF MAIN COMPONENTS IN THE RPWU WERE STUDIED BY GC AND GC-MS. RPWU CONTAINED RICH LONG-CHAIN FATTY ALCOHOLS, IN WHICH EICOSANOL, DOCOSANOL, TETRACOSANOL AND HEXACOSANOL WERE THE MAIN COMPONENTS, ACCOUNTING FOR 71.3\%. IN ADDITION, IT CONTAINED A SMALL AMOUNT OF ODD CARBON LONGCHAIN FATTY ALCOHOLS (TRICOSANOL AND PENTACOSANOL), ACCOUNTING FOR 7.5\%, WHICH IS VERY RARE IN PLANTS. MEANWHILE, RPWU SHOWED INHIBITORY EFFECT ON TYROSINASE, SUGGESTING THAT RPWU COULD HAVE SKIN-WHITENING EFFECT. THEREFORE, RPWU OBTAINED FROM PYRETHRUM WAX WASTE HAS POTENTIAL BIOAVAILABILITY VALUE, WHICH WILL PROMOTE THE DEVELOPMENT AND UTILIZATION OF PYRETHRUM WAX WASTE.","PYRETHRUM WAX WASTE; NEW RESOURCE OF C24 FATTY ALCOHOLS; GC/GC-MS; TYROSINASE INHIBITORY ACTIVITY","FATTY-ACIDS; POLICOSANOL CONTENTS; ESCHERICHIA-COLI; ALPHA-OXIDATION; ALCOHOLS; BIOSYNTHESIS; TYROSINASE; OIL; WASTE","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, CHINA [U1902206]; SPECIAL PROGRAM OF INTRODUCING SCI-TECH PROJECTS [202003AD150006]; COOPERATION PROJECT WITH DR PLANT COMPANY","THE AUTHORS GRATEFULLY ACKNOWLEDGE THE FINANCIAL SUPPORT OF THIS STUDY BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA, CHINA (U1902206) , THE SPECIAL PROGRAM OF INTRODUCING SCI-TECH PROJECTS TO YUNNAN, CHINA (202003AD150006) , AS WELL AS THE COOPERATION PROJECT WITH DR PLANT COMPANY (2023) .","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ASANUMA M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; ATABANI AE, 2019, FUEL, V244, P419, DOI 10.1016/J.FUEL.2019.01.169; ATTARD TM, 2015, IND CROP PROD, V76, P95, DOI 10.1016/J.INDCROP.2015.05.077; BATSALE M, 2021, CELLS-BASEL, V10, DOI 10.3390/CELLS10061284; BAUD S, 2003, PLANT J, V33, P75, DOI 10.1046/J.1365-313X.2003.016010.X; BROWN AP, 2006, J EXP BOT, V57, P1563, DOI 10.1093/JXB/ERJ150; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CHOI SJ, 2016, FOOD CHEM, V204, P94, DOI 10.1016/J.FOODCHEM.2016.02.027; CROMBIE LESLIE, 1995, P123; DEVI LS, 2022, TRENDS FOOD SCI TECH, V129, P296, DOI 10.1016/J.TIFS.2022.09.019; FAO, 2022, FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS. PRODUCTION: CROPS; FLURKEY A, 2008, J AGR FOOD CHEM, V56, P4760, DOI 10.1021/JF800109A; GALLIARD T, 1976, BIOCHIM BIOPHYS ACTA, V424, P26, DOI 10.1016/0005-2760(76)90046-1; GUPTA S, 2021, IND CROP PROD, V171, DOI 10.1016/J.INDCROP.2021.113871; GÜVEN ZB, 2022, FOOD BIOSCI, V48, DOI 10.1016/J.FBIO.2022.101804; HAMBERG M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/JBC.274.35.24503; HASLAM TM, 2013, PLANT SCI, V210, P93, DOI 10.1016/J.PLANTSCI.2013.05.008; HEAD SW, 1968, J AGR FOOD CHEM, V16, P762, DOI 10.1021/JF60159A003; HITCHCOCK C., 1971, PLANT LIPID BIOCHEMISTRY: THE BIOCHEMISTRY OF FATTY ACIDS AND ACYL LIPIDS WITH PARTICULAR REFERENCE TO HIGHER PLANTS AND ALGAE, P1; HUNTER PM, 2017, NAT REV ENDOCRINOL, V13, P278, DOI 10.1038/NRENDO.2016.210; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; JERAN N, 2021, PHYTOCHEM REV, V20, P875, DOI 10.1007/S11101-020-09724-2; JUNG DM, 2012, J FOOD SCI, V77, PC1249, DOI 10.1111/J.1750-3841.2012.02965.X; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; KAEHNE F, 2011, APPL MICROBIOL BIOT, V90, P989, DOI 10.1007/S00253-011-3165-Y; KUBO I, 2000, BIOORGAN MED CHEM, V8, P1749, DOI 10.1016/S0968-0896(00)00102-4; KUNST L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; LEE K.D., 2003, HAN'GUK NONGHWA HAKHOECHI, V46, P235; LEE S.Y., 2015, J. SOC. COSMET. SCI. KOREA., V41, P73, DOI DOI 10.15230/SCSK.2015.41.1.73; LEE SB, 2015, PLANT CELL REP, V34, P557, DOI 10.1007/S00299-015-1772-2; LI JX, 2023, J ETHNOPHARMACOL, V303, DOI 10.1016/J.JEP.2022.115951; LÜ SY, 2009, PLANT J, V59, P553, DOI 10.1111/J.1365-313X.2009.03892.X; LUPI FR, 2017, LWT-FOOD SCI TECHNOL, V77, P422, DOI 10.1016/J.LWT.2016.11.082; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MAURER S, 2019, J BIOTECHNOL, V305, P11, DOI 10.1016/J.JBIOTEC.2019.08.011; LA PAZ SMD, 2014, J ETHNOPHARMACOL, V151, P131, DOI 10.1016/J.JEP.2013.10.012; NEESS D, 2015, PROG LIPID RES, V59, P1, DOI 10.1016/J.PLIPRES.2015.04.001; PENG HY, 2021, CHEM J CHINESE U, V42, P3357, DOI 10.7503/CJCU20210410; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; WANG Y, 2015, PLANT CELL PHYSIOL, V56, P1944, DOI 10.1093/PCP/PCV112; WU H, 2014, APPL MICROBIOL BIOT, V98, P8145, DOI 10.1007/S00253-014-5882-5; XU W, 2022, FITOTERAPIA, V162, DOI 10.1016/J.FITOTE.2022.105259; Y O.A., 2016, BR J APPL SCI TECHNO, V13, P1, DOI DOI 10.9734/BJAST/2016/22178; YAO JY, 2021, LWT-FOOD SCI TECHNOL, V135, DOI 10.1016/J.LWT.2020.109995; ZHAI YJ, 2020, J NAT PROD, V83, P1592, DOI 10.1021/ACS.JNATPROD.0C00046; ZHANG XJ, 2011, METAB ENG, V13, P713, DOI 10.1016/J.YMBEN.2011.09.007; ZHUKOV A, 2022, INT J MOL SCI, V23, DOI 10.3390/IJMS23094731","QIU, MH (CORRESPONDING AUTHOR), CHINESE ACAD SCI, KUNMING INST BOT, STATE KEY LAB PHYTOCHEMISTRY \& PLANT RESOURCES WES, KUNMING 650201, PEOPLES R CHINA","ELSEVIER","ENGLISH","IND. CROP. PROD.","ARTICLE","ISI","WOS001148729200001","IND CROP PROD","KUNMING INST BOT;KUNMING INST BOT;UNIV CHINESE ACAD SCI","KUNMING INST BOT",NA,"ZHOU H, 2023, IND CROP PROD","ZHOU H, 2023, IND CROP PROD"
"LIU Y;ZHANG H;XU J;HE R;MA J;CHEN C;LIU L","LIU YIWEN;ZHANG HONG;XU JUAN;HE RUI;MA JINJU; CHEN CHIQING;LIU LANXIANG","A NEW STRATEGY FOR CONSUMPTION OF FUNCTIONAL LIPIDS FROM IERICERUS PELAI CHAVANNES STUDY ON MICROCAPSULES AND EFFERVESCENT TABLETS CONTAINING INSECT WAXDERIVED POLICOSANOL",2023,"FOODS","12",NA,0,"10.3390/foods12193567","MA, JJ (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KUNMING 650233, PEOPLES R CHINA.; MA, JJ (CORRESPONDING AUTHOR), NATL FORESTRY \& GRASSLAND ADM, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, KUNMING 650233, PEOPLES R CHINA.; LIU, YIWEN; ZHANG, HONG; XU, JUAN; HE, RUI; MA, JINJU; LIU, LANXIANG, CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KUNMING 650233, PEOPLES R CHINA.; LIU, YIWEN; CHEN, CHIQING, NATL FORESTRY \& GRASSLAND ADM, RES CTR EFFICIENT BREEDING \& DEEP PROC ENGN TECHNO, WUFENG 443400, PEOPLES R CHINA.; HE, RUI; MA, JINJU, NATL FORESTRY \& GRASSLAND ADM, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, KUNMING 650233, PEOPLES R CHINA.; LIU, LANXIANG, NATL FORESTRY \& GRASSLAND ADM, RES CTR ENGN \& TECHNOL CHARACTERIST FOREST RESOURC, KUNMING 650233, PEOPLES R CHINA.","IN THIS STUDY, WE ADDRESSED VARIOUS CHALLENGES ASSOCIATED WITH THE CONSUMPTION OF FUNCTIONAL LIPIDS FROM THE ERICERUS PELA (CHAVANNES), INCLUDING UNFAVORABLE TASTE, INSOLUBILITY IN WATER, DIFFICULTY IN ORAL INTAKE, LOW BIOAVAILABILITY, AND LOW PSYCHOLOGICAL ACCEPTANCE. OUR STUDY FOCUSED ON THE MICROENCAPSULATION OF POLICOSANOL, THE KEY ACTIVE COMPONENT OF INSECT WAX, WHICH IS A MIXTURE OF FUNCTIONAL LIPIDS SECRETED BY THE ERICERUS PELA (CHAVANNES). WE DEVELOPED TWO INNOVATIVE POLICOSANOL PRODUCTS, MICROCAPSULES, AND EFFERVESCENT TABLETS, AND OPTIMIZED THEIR PREPARATION CONDITIONS. WE SUCCESSFULLY PREPARED MICROCAPSULES CONTAINING INSECT WAX-DERIVED POLICOSANOL USING THE SPRAY-DRYING METHOD. WE ACHIEVED 92.09\% MICROENCAPSULATION EFFICIENCY AND 61.67\% POWDER YIELD UNDER THE FOLLOWING CONDITIONS: MALTODEXTRIN, STARCH SODIUM OCTENYL SUCCINATE, AND (2-HYDROXY)PROPYL-BETA-CYCLODEXTRIN (HP BETA CD) AT A RATIO OF 1:1:1, CORE-TO-WALL MATERIALS AT A RATIO OF 1:10, 15\% SOLID CONTENT, SPRAY DRYER FEED TEMPERATURE AT 60 C-DEGREES, INLET AIR TEMPERATURE AT 140 C-DEGREES, AND HOT-AIR FLOW RATE AT 0.5 M(3)/MIN. THE MICROCAPSULES EXHIBITED A REGULAR SPHERICAL SHAPE WITH A MINIMAL WATER CONTENT (1.82\%) AND RAPID DISPERSION IN WATER (WITHIN 143.5 S). THESE MICROCAPSULES RELEASED POLICOSANOL RAPIDLY IN SIMULATED STOMACH FLUID. MOREOVER, EFFERVESCENT TABLETS WERE PREPARED USING THE POLICOSANOL-CONTAINING MICROCAPSULES. THE TABLETS SHOWED LOW FRIABILITY (0.32\%), QUICK DISINTEGRATION IN WATER (WITHIN 99.5 S), AND HIGH BUBBLE VOLUME. THE MICROCAPSULES AND EFFERVESCENT TABLETS DEVELOPED IN THIS STUDY PRESENTED EFFECTIVE SOLUTIONS TO THE INSOLUBILITY OF POLICOSANOL IN WATER. THESE PRODUCTS WERE PORTABLE AND OFFERED CUSTOMIZABLE TASTES TO ADDRESS THE PSYCHOLOGICAL DISCOMFORT RELATED TO INSECT-BASED FOODS, THUS PROVIDING A NOVEL STRATEGY FOR THE CONSUMPTION AND SECONDARY PROCESSING OF INSECT LIPIDS.","EDIBLE INSECT; FUNCTIONAL INSECT LIPIDS; INSECT WAX-DERIVED POLICOSANOL; MICROCAPSULES; EFFERVESCENT TABLETS","WHITE WAX; POLYSACCHARIDE","FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF [CAFYBB2021SY011]; FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF [CAFYBB2018SY025]","THIS RESEARCH WAS FUNDED BY THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF, GRANT NUMBER CAFYBB2021SY011 AND THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF, GRANT NUMBER CAFYBB2018SY025.","BAEK S, 2023, FOODS, V12, DOI 10.3390/FOODS12163062; BARBOSA-CANOVAS G., 2005, FOOD POWDERS PHYS PR; CHEN F., 2003, PH.D. THESIS; CHEN X., 2011, NATURAL POPULATION OF ERICERUS PELA, V1ST EDITION; CHINARAK K, 2022, FOODS, V11, DOI 10.3390/FOODS11142036; COMMITTEE N.P., 2015, CHINESE PHARMACOPOEIA (PART IV); DINCER EI, 2023, S AFR J BOT, V155, P340, DOI 10.1016/J.SAJB.2023.02.024; FENG Y., 2016, EDIBLE INSECTS OF CHINA; FENG YING, 2006, FOREST RESEARCH, V19, P221; FENG YING, 2014, FOREST RESEARCH, V27, P388; HE HZ, 2016, CARBOHYD POLYM, V147, P243, DOI 10.1016/J.CARBPOL.2016.03.078; HU YH, 2018, ARCH INSECT BIOCHEM, V97, DOI 10.1002/ARCH.21445; LANGE KW, 2021, J FUTURE FOODS, V1, P38, DOI 10.1016/J.JFUTFO.2021.10.001; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LI Y., 2013, MASTER'S THESIS; LIN L, 2017, SAUDI PHARM J, V25, P625, DOI 10.1016/J.JSPS.2017.04.035; LIU Z., 2007, J. DALIAN INST. LIGHT IND, V26, P337; 罗程印 LUO CHENGYIN, 2016, 食品科学, FOOD SCIENCE, V37, P26; MA JJ, 2022, FOOD SCI HUM WELL, V11, P356, DOI 10.1016/J.FSHW.2021.11.013; MA JJ, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0197343; MA JINJU MA JINJU, 2019, SHIPIN KEXUE / FOOD SCIENCE, V40, P78; MA JINJU MA JINJU, 2018, JOURNAL OF ENVIRONMENTAL ENTOMOLOGY, V40, P1238; 马李一 MA LIYI, 2008, 食品工业科技, SCIENCE \& TECHNOLOGY OF FOOD INDUSTRY, V29, P179; MA LIYI MA LIYI, 2009, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, V29, P6; MAURY M, 2005, EUR J PHARM BIOPHARM, V59, P565, DOI 10.1016/J.EJPB.2004.10.002; MEYER-ROCHOW VB, 2021, FOODS, V10, DOI 10.3390/FOODS10051036; SÁNCHEZ CAO, 2021, LWT-FOOD SCI TECHNOL, V147, DOI 10.1016/J.LWT.2021.111476; PEREZ-SANTAESCOLASTICA C, 2022, TRENDS FOOD SCI TECH, V127, P352, DOI 10.1016/J.TIFS.2022.07.011; RODRIGUEZ-CORTINA A, 2022, FOODS, V11, DOI 10.3390/FOODS11243950; SAIFULLAH M, 2016, J FOOD ENG, V178, P60, DOI 10.1016/J.JFOODENG.2016.01.007; SHEN JJ, 2019, J FUNCT FOODS, V57, P351, DOI 10.1016/J.JFF.2019.04.024; SWEEDMAN MC, 2013, CARBOHYD POLYM, V92, P905, DOI 10.1016/J.CARBPOL.2012.09.040; VAN HUIS A, 2020, J INSECTS FOOD FEED, V6, P27, DOI 10.3920/JIFF2019.0017; VENTURELLI A, 2019, J PHARMACEUT BIOMED, V172, P200, DOI 10.1016/J.JPBA.2019.04.015; VILLALOBOS-ESPINOSA JC, 2022, J FOOD ENG, V327, DOI 10.1016/J.JFOODENG.2022.111056; WANG ZD, 2017, BIOMED PHARMACOTHER, V89, P438, DOI 10.1016/J.BIOPHA.2017.02.036; YANG P, 2011, AFR J MICROBIOL RES, V5, P1246; YANG P, 2011, AFR J MICROBIOL RES, V5, P1108; YANG Q., 2008, FOOD SCI. TECHNOL, V33, P246; 张雯雯 ZHANG WENWEN, 2015, 食品科学, FOOD SCIENCE, V36, P025; 张燕萍 ZHANG YANPING, 2006, 食品科学, FOOD SCIENCE, V27, P148","MA, JJ (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KUNMING 650233, PEOPLES R CHINA","MDPI","ENGLISH","FOODS","ARTICLE","ISI","WOS001086940800001","FOODS","INST HIGHLAND FOREST SCI;KEY LAB BREEDING AND UTILIZAT RESOURCE INSECTS;INST HIGHLAND FOREST SCI;RES CTR EFFICIENT BREEDING AND DEEP PROC ENGN TECHNO;KEY LAB BREEDING AND UTILIZAT RESOURCE INSECTS;RES CTR ENGN AND TECHNOL CHARACTERIST FOREST RESOURC","INST HIGHLAND FOREST SCI",NA,"LIU Y, 2023, FOODS","LIU Y, 2023, FOODS1"
"SAKOUHI F;CHERIF A;SAADI C;BOUKHCHINA ;SADOK S","SAKOUHI FAOUZI;CHERIF AMMAR;SAADI CHAIMA;BOUKHCHINA; SADOK","ASSESSMENT OF THE BIOACTIVE LIPID PROFILES OF OIL EXTRACTED FROM TUNISIAN TABLE OLIVE CULTIVARS IBAROUNII IBESBASSII AND IMARSALINE CVSI",2023,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","125",NA,1,"10.1002/ejlt.202300013","SAKOUHI, F (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, DEPT BIOL, FAC SCI TUNIS, LAB RECH LR18ES03, EL MANARI 2092, TUNISIA.; SAKOUHI, FAOUZI; CHERIF, AMMAR; SAADI, CHAIMA; BOUKHCHINA, SADOK, UNIV TUNIS EL MANAR, FAC SCI, DEPT BIOL, LAB NEUROPHYSIOL CELLULAR PHYSIOPATHOL \& BIOMELCUL, EL MANAR, TUNISIA.; CHERIF, AMMAR, QASSIM UNIV, COLL SCI \& ARTS, DEPT SCI LABS, AR RASS, SAUDI ARABIA.; SAKOUHI, FAOUZI, UNIV TUNIS EL MANAR, DEPT BIOL, FAC SCI TUNIS, LAB RECH LR18ES03, EL MANARI 2092, TUNISIA.","BIOACTIVE COMPOUNDS ARE COMPONENTS EXTRACTED FROM BIOLOGICAL MATRICES THAT MAY OFFER PHYSIOLOGICAL HEALTH BENEFITS AND HAVE NUTRITIVE VALUE. THE PRESENT STUDY CHARACTERIZED BIOACTIVE LIPID COMPONENTS SUCH AS FATTY ACIDS, PHYTOSTEROLS, POLICOSANOL, AND TRITERPENES FROM TABLE OLIVES. THE TABLE OLIVES WERE PROCESSED ACCORDING TO THE GREEN SPANISH-STYLE METHOD. THE OBTAINED RESULTS INDICATE THAT PHYTOSTEROL FRACTION CONSTITUTES THE MAJOR PORTION OF THE TOTAL UNSAPONIFIABLE MATTER. THE ANALYSIS OF PHYTOSTEROLS SHOWED THE PRESENCE OF 11 COMPOUNDS, SS-SITOSTEROL THE PREDOMINANT ONE. THE POLICOSANOL COMPOSITION INDICATED THAT HEXACOSANOL, TETRACOSANOL, OCTACOSANOL, AND DOCOSANOL WERE THE MAIN COMPOUNDS, ACCOUNTING FOR OVER 85\% OF TOTAL POLICOSANOLS. PENTACYCLIC TRITERPENES (CYCLOARTENOL AND 24-METHYLENE CYCLOARTENOL) WERE FOUND AT A HIGHER LEVEL (OVER 85\%) COMPARED TO TETRACYCLIC TRITERPENES (SS-AMYRIN, D-AMYRIN). THESE FINDINGS REVEAL THAT PROCESSED TABLE OLIVES CONTAIN AN INTERESTING AMOUNT OF VARIOUS BIOACTIVE COMPOUNDS COMPARED TOMARINE AND OTHER FLORAL BIOLOGICAL MATRICES. THUS, PROCESSED TABLE OLIVES REPRESENT AN INTERESTING NATURAL FUNCTIONAL FOOD THAT PRESENTS HIGH STABILITY AND BIOAVAILABILITY OF THEIR NATURAL BIOACTIVE INGREDIENTS.","NATURAL BIOACTIVE COMPOUNDS; PHYTOSTEROLS; POLICOSANOL; TABLE OLIVE; TRITERPENES","FATTY-ACIDS; CROSS-OVER; ALCOHOLS; NUTRACEUTICALS; TRITERPENES; COMBINATION; FOOD; L.","WE THANK THE MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISIA FOR FINANCIALLY SUPPORTING THIS INVESTIGATION.; MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISIA","WE THANK THE MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISIA FOR FINANCIALLY SUPPORTING THIS INVESTIGATION.","ALBARRACÍN W, 2011, INT J FOOD SCI TECH, V46, P1329, DOI 10.1111/J.1365-2621.2010.02492.X; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; BAE H, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/ANTIOX10030379; CAPRIOTTI AL, 2014, FOOD CHEM, V158, P392, DOI 10.1016/J.FOODCHEM.2014.02.130; CHYTIRI A, 2020, J SCI FOOD AGR, V100, P926, DOI 10.1002/JSFA.10019; DE LUCAS A, 2007, J SUPERCRIT FLUID, V41, P267, DOI 10.1016/J.SUPFLU.2006.09.013; DEMONTY I, 2013, EUR J NUTR, V52, P153, DOI 10.1007/S00394-011-0297-X; EUROPEAN FOOD SAFETY AUTHORITY (EFSA), 2019, EFSA SUPP PUBL, V16, P39, DOI 10.2903/SP.EFSA.2019.EN-1679, DOI 10.2903/SP.EFSA.2019.EN-1679; GUARDAMAGNA O, 2011, NUTR METAB CARDIOVAS, V21, P424, DOI 10.1016/J.NUMECD.2009.10.015; GUPTA VK, 2015, BIOTECHNOLOGY OF BIOACTIVE COMPOUNDS: SOURCES AND APPLICATIONS, PXIX; HARRISON S, 2020, J NUTR, V150, P3288, DOI 10.1093/JN/NXAA300; HARUN NH, 2020, CHIN HERB MED, V12, P118, DOI 10.1016/J.CHMED.2019.11.007; JACKSON MA, 2006, J SUPERCRIT FLUID, V37, P173, DOI 10.1016/J.SUPFLU.2005.08.008; JEONG DW, 2007, BIOPHARM DRUG DISPOS, V28, P51, DOI 10.1002/BDD.530; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KATOH A., 2020, JCSM CLIN REPORTS, V5, P121, DOI DOI 10.1002/CRT2.27; KHAN MA, 2023, DRUG CHEM TOXICOL, V46, P380, DOI 10.1080/01480545.2022.2040528; KIM NH, 2020, INT FOOD RES J, V27, P270; KÖHLER A, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/S12944-015-0015-4; KUMAR A, 2022, NAT PROD RES, V36, P4358, DOI 10.1080/14786419.2021.1986495; LANZA B, 2016, LWT-FOOD SCI TECHNOL, V68, P365, DOI 10.1016/J.LWT.2015.12.053; LI C., 2020, J INT MED RES, V48, P1; LI P, 2022, NUTR NEUROSCI, V25, P180, DOI 10.1080/1028415X.2020.1735143; LI X, 2022, MOLECULES, V27, DOI 10.3390/MOLECULES27020523; LING WH, 1995, LIFE SCI, V57, P195, DOI 10.1016/0024-3205(95)00263-6; LOPEZ-LOPEZ A, 2022, LWT-FOOD SCI TECHNOL, V166, DOI 10.1016/J.LWT.2022.113785; CARVALHO KMMB, 2017, PLANTA MED, V83, P285, DOI 10.1055/S-0042-114222; NATTAGH-ESHTIVANI E, 2022, PHYTOTHER RES, V36, P299, DOI 10.1002/PTR.7312; PASQUALONE A, 2014, FOOD CONTROL, V37, P99, DOI 10.1016/J.FOODCONT.2013.09.038; PATROCINIO M. P., 2017, ANESTH MED PRACT J, DOI 10.29011/AMPJ-117, DOI 10.29011/AMPJ-117; PERPETUINI G, 2020, FOODS, V9, DOI 10.3390/FOODS9020178; RAMÍREZ E, 2021, FOOD CONTROL, V126, DOI 10.1016/J.FOODCONT.2021.108067; SAKOUHI F, 2008, FOOD CHEM, V108, P833, DOI 10.1016/J.FOODCHEM.2007.11.043; SAKOUHI F, 2009, FOOD CHEM, V116, P345, DOI 10.1016/J.FOODCHEM.2009.01.094; SALES C, 2019, FOOD CHEM, V271, P488, DOI 10.1016/J.FOODCHEM.2018.07.200; SCHLAG S, 2022, ANAL BIOANAL CHEM, V414, P1061, DOI 10.1007/S00216-021-03730-9; SULERIA HAR, 2015, MAR DRUGS, V13, P6336, DOI 10.3390/MD13106336; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TEIXEIRA FS, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/PH14060583; TENG H, 2018, TRENDS FOOD SCI TECH, V72, P34, DOI 10.1016/J.TIFS.2017.11.012; TRIMARCO V, 2015, HIGH BLOOD PRESS CAR, V22, P149, DOI 10.1007/S40292-015-0087-2; VAN BREDA SGJ, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700597; VISIOLI F, 2011, CURR PHARM DESIGN, V17, P786, DOI 10.2174/138161211795428885; WARREN P. R., 2002, P SOC EXP BIOL MED, V200, P349; ZHANG T, 2020, LWT-FOOD SCI TECHNOL, V124, DOI 10.1016/J.LWT.2020.109163","SAKOUHI, F (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, DEPT BIOL, FAC SCI TUNIS, LAB RECH LR18ES03, EL MANARI 2092, TUNISIA","WILEY","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","WOS001070288700001","EUR J LIPID SCI TECHNOL","UNIV TUNIS EL MANAR;UNIV TUNIS EL MANAR;QASSIM UNIV;UNIV TUNIS EL MANAR","UNIV TUNIS EL MANAR",NA,"SAKOUHI F, 2023, EUR J LIPID SCI TECHNOL","SAKOUHI F, 2023, EUR J LIPID SCI TECHNOL1"
"CHO K;KIM J;NAM H;KANG D;BAEK S","CHO KYUNG-HYUN;KIM JI-EUN;NAM HYO-SEON;KANG DAE-JIN; BAEK SEUNG-HEE","COMPARISON OF POLICOSANOLS VIA INCORPORATION INTO RECONSTITUTED HIGHDENSITY LIPOPROTEINS CUBAN POLICOSANOL RAYDELSUPSUP EXERTS THE HIGHEST ANTIOXIDANT ANTIGLYCATION AND ANTIINFLAMMATORY ACTIVITY",2023,"MOLECULES","28",NA,3,"10.3390/molecules28186715","CHO, KH (CORRESPONDING AUTHOR), MED INNOVAT COMPLEX, RAYDEL RES INST, DAEGU 41061, SOUTH KOREA.; CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, LIPOLAB, GYONGSAN 38541, SOUTH KOREA.; CHO, KYUNG-HYUN; KIM, JI-EUN; NAM, HYO-SEON; KANG, DAE-JIN; BAEK, SEUNG-HEE, MED INNOVAT COMPLEX, RAYDEL RES INST, DAEGU 41061, SOUTH KOREA.; CHO, KYUNG-HYUN, YEUNGNAM UNIV, LIPOLAB, GYONGSAN 38541, SOUTH KOREA.","RECONSTITUTED HIGH-DENSITY LIPOPROTEINS (RHDL) CONTAINING EACH POLICOSANOL FROM CUBA (RAYDEL((R))), CHINA (SHAANXI PIONEER), AND THE UNITED STATES (LESSTANOL((R))) WERE SYNTHESIZED TO COMPARE THE PHYSIOLOGICAL PROPERTIES OF POLICOSANOL DEPENDING ON SOURCES AND ORIGIN COUNTRIES. AFTER SYNTHESIS WITH APOLIPOPROTEINA-I (APOA-I) INTO RHDL, ALL POLICOSANOLS BOUND WELL WITH PHOSPHOLIPID AND APOA-I TO FORM DISCOIDAL RHDL. AN RHDL CONTAINING CUBAN POLICOSANOL (RHDL-1) SHOWED THE LARGEST RHDL PARTICLE SIZE OF AROUND 83 +/- 3 NM, WHILE RHDL CONTAINING CHINESE POLICOSANOL (RHDL-2) OR AMERICAN POLICOSANOL (RHDL-3) SHOWED SMALLER PARTICLES AROUND 63 +/- 3 NM AND 60 +/- 2 NM IN DIAMETER, RESPECTIVELY. THE RHDL-1 SHOWED THE STRONGEST ANTI-GLYCATION ACTIVITY TO PROTECT THE APOA-I DEGRADATION OF HDL FROM FRUCTOSE-MEDIATED GLYCATION: APPROXIMATELY 2.7-TIMES HIGHER ABILITY TO SUPPRESS GLYCATION AND 1.4-TIMES HIGHER PROTECTION ABILITY OF APOA-I THAN THAT OF RHDL-2 AND RHDL-3. THE RHDL-1 SHOWED THE HIGHEST ANTIOXIDANT ABILITY TO INHIBIT CUPRIC ION-MEDIATED LDL OXIDATION IN ELECTROMOBILITY AND THE QUANTIFICATION OF OXIDIZED SPECIES. A MICROINJECTION OF EACH RHDL INTO A ZEBRAFISH EMBRYO IN THE PRESENCE OF CARBOXYMETHYLLYSINE (CML) SHOWED THAT RHDL-1 DISPLAYED THE STRONGEST ANTI-OXIDANT ACTIVITY WITH THE HIGHEST EMBRYO SURVIVABILITY, WHEREAS RHDL-2 AND RHDL-3 SHOWED MUCH WEAKER PROTECTION ABILITY, SIMILAR TO RHDL ALONE (RHDL-0). AN INTRAPERITONEAL INJECTION OF CML (250 MU G) INTO ADULT ZEBRAFISH CAUSED ACUTE DEATH AND HYPERINFLAMMATION WITH AN ELEVATION OF INFILTRATION OF NEUTROPHILS AND IL-6 PRODUCTION IN THE LIVER. ON THE OTHER HAND, A CO-INJECTION OF RHDL-1 RESULTED IN THE HIGHEST SURVIVABILITY AND THE STRONGEST ANTI-INFLAMMATORY ABILITY TO SUPPRESS IL-6 PRODUCTION WITH AN IMPROVEMENT OF THE BLOOD LIPID PROFILE, SUCH AS ELEVATION OF HDL-C AND LOWERING OF THE TOTAL CHOLESTEROL, LDL-CHOLESTEROL, AND TRIGLYCERIDE. IN CONCLUSION, CUBAN POLICOSANOL EXHIBITED THE MOST DESIRABLE PROPERTIES FOR THE IN VITRO SYNTHESIS OF RHDL WITH THE STABILIZATION OF APOA-I, THE LARGEST PARTICLE SIZE, ANTI-GLYCATION AGAINST FRUCTATION, AND ANTIOXIDANT ACTIVITIES TO PREVENT LDL OXIDATION. CUBAN POLICOSANOL IN RHDL ALSO EXHIBITED THE STRONGEST IN VIVO ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES WITH THE HIGHEST SURVIVABILITY IN ZEBRAFISH EMBRYOS AND ADULTS VIA THE PREVENTION OF HYPERINFLAMMATION IN THE PRESENCE OF CML.","HDL; HIGH-DENSITY LIPOPROTEINS; APOLIPOPROTEIN A-I; POLICOSANOL; SUGAR; CANE WAX ALCOHOL; ZEBRAFISH; EMBRYO","CHOLESTEROL; FRUCTOSE; ENHANCEMENT; ZEBRAFISH",NA,NA,"ABBATE F, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/ANTIOX10050668; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199A0; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BURRIS B, 2021, JOVE-J VIS EXP, DOI 10.3791/63240; CANAVACIOLO V.L.G., 2007, REV. CENIC CIENC. QUIMICAS, V38, P207; CHO KH, 2023, LIFE-BASEL, V13, DOI 10.3390/LIFE13061319; CHO KH, 2023, INT J MOL SCI, V24, DOI 10.3390/IJMS24087044; CHO KH, 2023, INT J MOL SCI, V24, DOI 10.3390/IJMS24043186; CHO KH, 2022, INT J MOL SCI, V23, DOI 10.3390/IJMS23073967; CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; DASU MR, 2010, DIABETES CARE, V33, P861, DOI 10.2337/DC09-1799; GUGLIUCCI A, 2017, ADV NUTR, V8, P54, DOI 10.3945/AN.116.013912; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYASHI M, 1983, MUTAT RES, V120, P241, DOI 10.1016/0165-7992(83)90096-9; JOHNS DG, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/PRP2.543; KAUP RM, 2013, PHYTOTHER RES, V27, P264, DOI 10.1002/PTR.4705; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LEE HG, 2022, PLANTS-BASEL, V11, DOI 10.3390/PLANTS11141844; LIM SM, 2016, REJUV RES, V19, P59, DOI 10.1089/REJ.2015.1712; LIU C, 2022, AM J CARDIOL, V167, P43, DOI 10.1016/J.AMJCARD.2021.11.041; MADSEN CM, 2017, EUR HEART J, V38, P2478, DOI 10.1093/EURHEARTJ/EHX163; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/BI00406A016; MILMAN S, 2014, CURR VASC PHARMACOL, V12, P690; NATIONAL RESEARCH COUNCIL OF THE NATIONAL ACADEMY OF SCIENCES, 2010, GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS; NOBLE RP, 1968, J LIPID RES, V9, P693; NUSSLEIN-VOLHARD C., 2002, ZEBRAFISH: A PRACTICAL APPROACH, V1ST ED.; OWUSU-ANSAH E, 2008, NAT GENET, V40, P356, DOI 10.1038/NG.2007.50; PIETRZAK A, 2020, POSTEP DERM ALERGOL, V37, P41, DOI 10.5114/ADA.2018.78028; QIAO Q, 2022, J CLIN ENDOCR METAB, V107, P1920, DOI 10.1210/CLINEM/DGAC198; SITARZ R, 2023, J CLIN MED, V12, DOI 10.3390/JCM12051879; SUAREZ G, 1989, J BIOL CHEM, V264, P3674; TALL AR, 2018, CIRC RES, V122, P106, DOI 10.1161/CIRCRESAHA.117.311978; TOADER M, 2021, EXP THER MED, V22, DOI 10.3892/ETM.2021.10419; VENTURELLI A, 2019, J PHARMACEUT BIOMED, V172, P200, DOI 10.1016/J.JPBA.2019.04.015; WANG J, 2018, AGING-US, V10, P3528, DOI 10.18632/AGING.101663; WATTRUS SJ, 2021, CURR OPIN HEMATOL, V28, P43, DOI 10.1097/MOH.0000000000000627; WONG WT, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7343942; XUE H, 2023, CURR ATHEROSCLER REP, V25, P155, DOI 10.1007/S11883-023-01087-1; ZHANG X, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/S12906-021-03278-2","CHO, KH (CORRESPONDING AUTHOR), MED INNOVAT COMPLEX, RAYDEL RES INST, DAEGU 41061, SOUTH KOREA","MDPI","ENGLISH","MOLECULES","ARTICLE","ISI","WOS001099940700001","MOLECULES","RAYDEL RES INST;YEUNGNAM UNIV;RAYDEL RES INST;YEUNGNAM UNIV","RAYDEL RES INST",NA,"CHO KH, 2023, MOLECULES","CHO KH, 2023, MOLECULES-a"
"OKUKA N;SCHUH V;KRAMMER U;POLOVINA S;SUMARAC-DUMANOVIC M;MILINKOVIC N;VELICKOVIC ;KSENIJA K;DJORDJEVIC B;HASLBERGER A;IVANOVIC ;NEVENA D N","OKUKA NINA;SCHUH VERENA;KRAMMER ULRIKE;POLOVINA SNEZANA;SUMARAC-DUMANOVIC MIRJANA;MILINKOVIC NEDA;VELICKOVIC; KSENIJA;DJORDJEVIC BRIZITA;HASLBERGER ALEXANDER;IVANOVIC; NEVENA DJ","EPIGENETIC ASPECTS OF A NEW PROBIOTIC CONCEPTA PILOT STUDY",2023,"LIFE-BASEL","13",NA,1,"10.3390/life13091912","IVANOVIC, ND (CORRESPONDING AUTHOR), UNIV BELGRADE, FAC PHARM, DEPT BROMATOL, BELGRADE 11000, SERBIA.; HASLBERGER, A (CORRESPONDING AUTHOR), UNIV VIENNA, DEPT NUTR SCI, A-1090 VIENNA, AUSTRIA.; OKUKA, NINA, UNIV BANJA LUKA, FAC MED, DEPT BROMATOL, BANJA LUKA 78000, BOSNIA \& HERCEG.; SCHUH, VERENA; KRAMMER, ULRIKE, HEALTHBIOCARE GMBH, A-1090 VIENNA, AUSTRIA.; POLOVINA, SNEZANA, CLIN CTR SERBIA, CLIN ENDOCRINOL DIABET \& DIS METAB, BELGRADE 11000, SERBIA.; SUMARAC-DUMANOVIC, MIRJANA, UNIV BELGRADE, SCH MED, CLIN ENDOCRINOL DIABET \& DIS METAB, BELGRADE 11000, SERBIA.; MILINKOVIC, NEDA, UNIV BELGRADE, FAC PHARM, DEPT MED BIOCHEM, BELGRADE 11000, SERBIA.; VELICKOVIC, KSENIJA, UNIV BELGRADE, FAC BIOL, DEPT CELL \& TISSUE BIOL, BELGRADE 11000, SERBIA.; DJORDJEVIC, BRIZITA; IVANOVIC, NEVENA DJ., UNIV BELGRADE, FAC PHARM, DEPT BROMATOL, BELGRADE 11000, SERBIA.; HASLBERGER, ALEXANDER, UNIV VIENNA, DEPT NUTR SCI, A-1090 VIENNA, AUSTRIA.","SEVERAL STUDIES REPORT THE IMPORTANT ROLE OF AN ALTERED GUT MICROBIOTA IN THE DEVELOPMENT OF OBESITY, HIGHLIGHTING THE POTENTIAL USE OF PROBIOTICS IN THE TREATMENT OF OBESITY. THE AIM OF THIS STUDY IS TO INVESTIGATE THE EFFECT OF A NOVEL PROBIOTIC APPROACH ON THE EXPRESSION OF SPECIFIC MIRNAS AND MRNAS ASSOCIATED WITH OBESITY IN COMBINATION WITH THE HYPOCHOLESTEROLEMIC OCTACOSANOL. TWENTY OVERWEIGHT/OBESE WOMEN PARTICIPATED IN A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY AND WERE RANDOMLY DIVIDED INTO TWO GROUPS: THE INTERVENTION GROUP (DAILY ONE CAPSULE CONTAINING LACTOBACILLUS PLANTARUM 299V (DSM9843), SACCHAROMYCES CEREVISIAE VAR. BOULARDII, AND 40 MG OCTACOSANOL; N = 12) AND THE PLACEBO GROUP (N = 8). CHANGES IN LIPID PARAMETERS AND EXPRESSION OF MIRNAS AND MRNAS WERE ASSESSED BEFORE (T0) AND AFTER THE 12-WEEK INTERVENTION (T1). AFTER THE INTERVENTION, THE EXPRESSION OF MIR-155-5P (9.38 +/- 0.85 VS. 8.38 +/- 1.06, P = 0.05) AND MIR-24-3P (3.42 +/- 0.38 VS. 2.71 +/- 0.97, P = 0.031) SHOWED SIGNIFICANT DECREASES IN THE INTERVENTION GROUP WHEN COMPARED TO THE CONTROL GROUP. AT T1, THE EXPRESSION OF MIR-155-5P (8.69 +/- 1.31 VS. 9.3 +/- 0.85, P = 0.04), MIR-125B-5P (5.41 +/- 1.18 VS. 5.99 +/- 1.36, P = 0.049), AND TNF-ALPHA (10.24 +/- 1.66 VS. 11.36 +/- 1.12, P = 0.009) WERE SIGNIFICANTLY DECREASED IN THE INTERVENTION GROUP. NO CHANGES IN LIPIDS AND ANTHROPOMETRIC PARAMETERS WERE OBSERVED. THE NOVEL PROBIOTIC APPROACH HAD A POSITIVE EFFECT ON REGULATING THE EXPRESSION OF CERTAIN MIRNAS AND MRNAS IMPORTANT FOR REGULATING INFLAMMATION AND ADIPOGENESIS, WHICH ARE ESSENTIAL FOR OBESITY ONSET AND CONTROL.","OBESITY; PROBIOTICS; EPIGENETIC MARKERS; MRNA; MIRNAS; SIRT1; LACTOBACILLUS PLANTARUM 299V; SACCHAROMYCES BOULARDII VAR. CEREVISIAE; POLICOSANOLS","LACTOBACILLUS-PLANTARUM 299V; EXPRESSION; OBESITY; POLICOSANOL; ATHEROSCLEROSIS; INFLAMMATION; ADIPOCYTES; MICRORNAS; PROMOTES; DISEASE","THE AUTHORS WISH TO EXPRESS THEIR PROFOUND APPRECIATION TO ABELA PHARM (BELGRADE, SERBIA) AND SEO OF THE COMPANY, DAVOR KORCOK, FOR PACKING CONTENT OF THE CAPSULES FOR THE EXPERIMENTS NEED.; ABELA PHARM (BELGRADE, SERBIA); SEO OF THE COMPANY","THE AUTHORS WISH TO EXPRESS THEIR PROFOUND APPRECIATION TO ABELA PHARM (BELGRADE, SERBIA) AND SEO OF THE COMPANY, DAVOR KORCOK, FOR PACKING CONTENT OF THE CAPSULES FOR THE EXPERIMENTS NEED.","ACHARYA A, 2019, GENE DEV, V33, P1367, DOI 10.1101/GAD.328955.119; ALGIERI F, 2021, EUR J NUTR, V60, P2537, DOI 10.1007/S00394-020-02441-8; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; BENDERSKA N, 2015, INFLAMM BOWEL DIS, V21, P2039, DOI 10.1097/MIB.0000000000000453; BRANDAO BB, 2017, REDOX BIOL, V12, P82, DOI 10.1016/J.REDOX.2017.01.020; BRIZITA DJORDJEVIC I., 2022, ADVANCES IN PRECISION NUTRITION, PERSONALIZATION AND HEALTHY AGING, P145, DOI 10.1007/978-3-031-10153-3\_6; CALCATERRA V, 2023, NUTRIENTS, V15, DOI 10.3390/NU15143144; CANI PD, 2015, CURR OPIN BIOTECH, V32, P21, DOI 10.1016/J.COPBIO.2014.10.006; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; CHEN Z, 2019, DNA CELL BIOL, V38, P754, DOI 10.1089/DNA.2019.4622; CIRILLO F, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/FENDO.2019.00879; CRISTÓBAL I, 2015, INFLAMM BOWEL DIS, V21, PE24, DOI 10.1097/MIB.0000000000000572; DUCROTTÉ P, 2012, WORLD J GASTROENTERO, V18, P4012, DOI 10.3748/WJG.V18.I30.4012; EVERARD A, 2014, MBIO, V5, DOI 10.1128/MBIO.01011-14; FU T, 2014, MOL CELL BIOL, V34, P4130, DOI 10.1128/MCB.00596-14; GENG JF, 2022, BIOMED PHARMACOTHER, V147, DOI 10.1016/J.BIOPHA.2022.112678; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HATHTHOTUWA RN, 2013, ELSEV INSIGHT, P3, DOI 10.1016/B978-0-12-416045-3.00001-7; HEYDARI Z, 2019, PROBIOTICS ANTIMICRO, V11, P1155, DOI 10.1007/S12602-018-9478-8; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; ORTEGA FJ, 2013, CLIN CHEM, V59, P781, DOI 10.1373/CLINCHEM.2012.195776; KARKENI E, 2016, J CLIN ENDOCR METAB, V101, P1615, DOI 10.1210/JC.2015-3410; KHALILI L, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/S13098-019-0400-7; LEE IK, 2014, DIABETES METAB J, V38, P181, DOI 10.4093/DMJ.2014.38.3.181; LIU H, 2016, MOL MED REP, V13, P2809, DOI 10.3892/MMR.2016.4860; LIU TY, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3328505; LOPEZ YON, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/7351902; LOPEZ YON, 2017, MOL BIOSYST, V13, P106, DOI 10.1039/C6MB00596A; MAHDAVI R, 2018, CLIN LAB, V64, P77, DOI 10.7754/CLIN.LAB.2017.170618; MOROVIC W, 2021, TRENDS MICROBIOL, V29, P117, DOI 10.1016/J.TIM.2020.04.008; NARUSZEWICZ M, 2002, AM J CLIN NUTR, V76, P1249, DOI 10.1093/AJCN/76.6.1249; NG R, 2014, HEPATOLOGY, V60, P554, DOI 10.1002/HEP.27153; ORTIZ-DOSAL A, 2019, BIOMARKERS, V24, P499, DOI 10.1080/1354750X.2019.1606279; QIU XD, 2022, CLIN NUTR, V41, P1787, DOI 10.1016/J.CLNU.2022.06.030; REN K, 2018, ATHEROSCLEROSIS, V270, P57, DOI 10.1016/J.ATHEROSCLEROSIS.2018.01.045; RIPPE C, 2012, EXP GERONTOL, V47, P45, DOI 10.1016/J.EXGER.2011.10.004; SCHOBER A, 2014, NAT MED, V20, P368, DOI 10.1038/NM.3487; SIMUNDIC AM, 2018, CLIN CHEM LAB MED, V56, P2015, DOI 10.1515/CCLM-2018-0602; SIVAMARUTHI BS, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3291367; SORENSEN AE, 2014, GENES-BASEL, V5, P684, DOI 10.3390/GENES5030684; TZANAVARI T, 2010, CURR DIR AUTOIMMUN, V11, P145, DOI 10.1159/000289203; VÄHÄMIKO S, 2019, EUR J NUTR, V58, P367, DOI 10.1007/S00394-017-1601-1; WANG Q, 2021, PROBIOTICS ANTIMICRO, V13, P1093, DOI 10.1007/S12602-021-09743-1; WELLMAN AS, 2017, GASTROENTEROLOGY, V153, P772, DOI 10.1053/J.GASTRO.2017.05.022; XU G, 2015, INT J OBESITY, V39, P1523, DOI 10.1038/IJO.2015.95; XU GF, 2013, MOL BIOL REP, V40, P3577, DOI 10.1007/S11033-012-2431-0; ZHANG BJ, 2021, OBESITY FACTS, V14, P456, DOI 10.1159/000515720; ZHAO Y, 2021, FRONT MICROBIOL, V11, DOI 10.3389/FMICB.2020.604462; ZILLIKENS MC, 2009, DIABETES, V58, P2828, DOI 10.2337/DB09-0536","IVANOVIC, ND (CORRESPONDING AUTHOR), UNIV BELGRADE, FAC PHARM, DEPT BROMATOL, BELGRADE 11000, SERBIA","MDPI","ENGLISH","LIFE-BASEL","ARTICLE","ISI","WOS001073524300001","LIFE-BASEL","UNIV BELGRADE;UNIV VIENNA;UNIV BANJA LUKA;SCHUH;HEALTHBIOCARE GMBH;CLIN CTR SERBIA;UNIV BELGRADE;UNIV BELGRADE;UNIV BELGRADE;UNIV BELGRADE;UNIV VIENNA","UNIV BELGRADE",NA,"OKUKA N, 2023, LIFE-BASEL","OKUKA N, 2023, LIFE-BASEL"
"KIM H;KIM Y;ANTONISAMY P;RYU D;LEE Y;LEE G;KWON K","KIM HA-RIM;KIM YE-SEUL;ANTONISAMY PAULRAYER;RYU DO-GON;LEE YOUNG-RAE;LEE GUEMSAN;KWON KANG-BEOM","A 8WEEK RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED HUMAN TRIAL TO EVALUATE THE EFFICACY AND SAFETY OFI SACCHARUMII OFFICINARUMI WAX ALCOHOLS POLICOSANOL ON IMPROVEMENT OF BLOOD CHOLESTEROL",2023,"JOURNAL OF KING SAUD UNIVERSITY SCIENCE","35",NA,0,"10.1016/j.jksus.2023.102769","KWON, KB (CORRESPONDING AUTHOR), WONKWANG UNIV, ILWONBIO CO LTD, COLL KOREAN MED, 460 IKSANDAERO, IKSAN 54538, SOUTH KOREA.; KWON, KB (CORRESPONDING AUTHOR), WONKWANG UNIV, COLL KOREAN MED, DEPT KOREAN PHYSIOL, 460 IKSANDAERO, IKSAN 54538, JEONBUK, SOUTH KOREA.; KIM, HA-RIM; KIM, YE-SEUL; ANTONISAMY, PAULRAYER; RYU, DO-GON; KWON, KANG-BEOM, WONKWANG UNIV, COLL KOREAN MED, DEPT PHYSIOL, IKSAN, JEONBUK, SOUTH KOREA.; KIM, HA-RIM; KIM, YE-SEUL; ANTONISAMY, PAULRAYER; KWON, KANG-BEOM, ILWONBIO CO LTD, IKSAN, JEONBUK, SOUTH KOREA.; LEE, YOUNG-RAE, WONKWANG UNIV, COLL DENT, DEPT ORAL PHYSIOL, IKSAN, JEONBUK, SOUTH KOREA.; LEE, GUEMSAN, WONKWANG UNIV, INST BIOMAT IMPLANT, COLL DENT, IKSAN, JEONBUK, SOUTH KOREA.; LEE, GUEMSAN, WONKWANG UNIV, COLL KOREAN MED, DEPT HERBOL, IKSAN 54538, SOUTH KOREA.; KWON, KANG-BEOM, WONKWANG UNIV, ILWONBIO CO LTD, COLL KOREAN MED, 460 IKSANDAERO, IKSAN 54538, SOUTH KOREA.; KWON, KANG-BEOM, WONKWANG UNIV, COLL KOREAN MED, DEPT KOREAN PHYSIOL, 460 IKSANDAERO, IKSAN 54538, JEONBUK, SOUTH KOREA.","BACKGROUND: THE PREVALENCE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE APPEARS TO BE REDUCED, ACCORDING TO A LARGE BODY OF RESEARCH, BY LOWERING BLOOD LEVELS OF THE RATIO OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC)/ HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), TRIGLYCERIDE (TG)/HDL-C, AND LDL-C. OBJECTIVE: THE OBJECTIVE OF THE INVESTIGATION WAS TO DETERMINE THE SAFETY AND ENDURANCE OF POLICOSANOL (20 MG/D), AS WELL AS ITS EFFICACY IN HEALTHY INDIVIDUALS. TWO PARALLEL GROUPS IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HUMAN EXPERIMENT RECEIVED EITHER A POLICOSANOL (20 MG/D) OR A PLACEBO FOR EIGHT WEEKS. 80 PEOPLE WERE RANDOMLY ASSIGNED, WITH A MEAN (SD) AGE (YEARS) OF 42.61 (13.51), A MEAN (SD) BMI (KG/M2) OF 24.53 (3.57), A MEAN (SD) WEIGHT (KG) OF 66.71 (14.30), AND A MEAN (SD) HEIGHT (CM) OF 164.21. (7.99). RESULTS: AT 8 WEEKS, WHEN COMPARED TO THE BASELINE GROUP, THE POLICOSANOL (20 MG/D) BATCH DISPLAYED CONSIDERABLY GREATER LDL-C (-4.87 +/- 11.30 MG/DL; P = 0.014), TOTAL CHOLESTEROL (-6.82 +/ - 14.32 MG/DL; P = 0.007), TRIGLYCERIDE (-9.37 +/- 19.27 MG/DL; P = 0.008), NON HDL-C REDUCTIONS (-10.32 +/- 13.75 MG/DL; P = 0.0001), AND SIGNIFICANTLY GREATER AUGMENTATION OF HDL-C (3.50 +/- 4.55 MG/DL; P = 0.010). POLICOSANOL (20 MG/D) TREATMENT ALSO SIGNIFICANTLY REDUCING THE SERUM LEVELS OF TC/HDL-C (P = 0.0001) AND LDL-C/HDL-C (P = 0.0002), TRIGLYCERIDE/HDL-C (P = 0.001), AND T-CHOLESTEROL-HDL-C/HDL-C (P = 0.0001) RATIOS. CONCLUSION: IN HUMANS, POLICOSANOL DELIVERY RESULTED IN A LOWERING OF LDL-C LEVELS AND AN IMPROVEMENT IN OTHER LIPID MARKERS, DEMONSTRATING THE PRODUCT POTENTIAL TO REGULATE HYPERCHOLESTEROLEMIA. CO 2023 THE AUTHOR(S). PUBLISHED BY ELSEVIER B.V. ON BEHALF OF KING SAUD UNIVERSITY. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (HTTP://CREATIVECOMMONS.ORG/LICENSES/BY-NC-ND/4.0/).","POLICOSANOL; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; TRIGLYCERIDE; HYPERCHOLESTEROLEMIA; CARDIOVASCULAR DISEASE","HMG-COA REDUCTASE; LONG-TERM; FOLLOW-UP; HYPERCHOLESTEROLEMIA; GLUCOSE","WONKWANG UNIVERSITY, SOUTH KOREA","THIS PRESENT STUDY WAS SUPPORTED BY WONKWANG UNIVERSITY, SOUTH KOREA IN 2021.","ALEMÁN C, 2001, J APPL TOXICOL, V21, P179, DOI 10.1002/JAT.705; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARNETT DK, 2019, CIRCULATION, V140, PE563, DOI 10.1161/CIR.0000000000000678, 10.1016/J.JACC.2019.03.009, 10.1161/CIR.0000000000000677, 10.1016/J.JACC.2019.03.010; ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; ARRUZAZABALA ML, 1998, INT J TISSUE REACT, V20, P119; AZEMAWAH V, 2019, CARDIOVASC DRUG THER, V33, P625, DOI 10.1007/S10557-019-06904-X; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; CANETTI M, 1997, CURR THER RES CLIN E, V58, P868, DOI 10.1016/S0011-393X(97)80053-7; CASTAÑO G, 1999, CURR THER RES CLIN E, V60, P379, DOI 10.1016/S0011-393X(99)80016-2; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; CASTANO GLADYS, 2002, DRUGS R D, V3, P159, DOI 10.2165/00126839-200203030-00004; COLLINS R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; FERENCE BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/EURHEARTJ/EHX144; FERNANDEZ SALOME, 2004, AM J GERIATR PHARMACOTHER, V2, P219, DOI 10.1016/J.AMJOPHARM.2004.12.004; FORD I, 2016, CIRCULATION, V133, P1073, DOI 10.1161/CIRCULATIONAHA.115.019014; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; KANG YR, 2016, FOOD SCI BIOTECHNOL, V25, P911, DOI 10.1007/S10068-016-0149-9; KAZI DS, 2017, MED CLIN N AM, V101, P689, DOI 10.1016/J.MCNA.2017.03.001; KIM HR, 2020, SAUDI J BIOL SCI, V27, P2968, DOI 10.1016/J.SJBS.2020.07.017; KIM JY, 2017, INT J MOL MED, V39, P889, DOI 10.3892/IJMM.2017.2907; KIM KYU, 2020, J LIPID ATHEROSCLER, V9, P1, DOI 10.12997/JLA.2020.9.1.1; LLOYD SM, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0072642; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MCCARTY MF, 2002, MED HYPOTHESES, V59, P268, DOI 10.1016/S0306-9877(02)00226-8; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; NYAMBE-SILAVWE H, 2016, BRIT J NUTR, V116, P443, DOI 10.1017/S0007114516002221; OKOPIEN B, 2018, EXPERT REV CLIN PHAR, V11, P1099, DOI 10.1080/17512433.2018.1537780; PACKARD CJ, 2015, CURR OPIN LIPIDOL, V26, P572, DOI 10.1097/MOL.0000000000000230; REITER-BRENNAN C, 2020, CLEV CLIN J MED, V87, P231, DOI 10.3949/CCJM.87A.19078; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; VIRANI SS, 2020, CIRCULATION, V141, PE139, DOI 10.1161/CIR.0000000000000757; WANG YW, 2003, LIPIDS, V38, P165, DOI 10.1007/S11745-003-1047-3; YANAI HIDEKATSU, 2015, J CLIN MED RES, V7, P145, DOI 10.14740/JOCMR2030W","KWON, KB (CORRESPONDING AUTHOR), WONKWANG UNIV, ILWONBIO CO LTD, COLL KOREAN MED, 460 IKSANDAERO, IKSAN 54538, SOUTH KOREA","ELSEVIER","ENGLISH","J. KING SAUD UNIV. SCI.","ARTICLE","ISI","WOS001141243200001","J KING SAUD UNIV SCI","WONKWANG UNIV;WONKWANG UNIV;WONKWANG UNIV;WONKWANG UNIV;WONKWANG UNIV;WONKWANG UNIV;WONKWANG UNIV;WONKWANG UNIV","WONKWANG UNIV",NA,"KIM HR, 2023, J KING SAUD UNIV SCI","KIM HR, 2023, J KING SAUD UNIV SCI"
"CHO K;KIM J;KOMATSU T;UEHARA ;YOSHINARI Y","CHO KYUNG-HYUN;KIM JI-EUN;KOMATSU TOMOHIRO;UEHARA; YOSHINARI","PROTECTION OF LIVER FUNCTIONS AND IMPROVEMENT OF KIDNEY FUNCTIONS BY TWELVE WEEKS CONSUMPTION OF CUBAN POLICOSANOL RAYDELSUPSUP WITH A DECREASE OF GLYCATED HEMOGLOBIN AND BLOOD PRESSURE FROM A RANDOMIZED PLACEBOCONTROLLED AND DOUBLEBLINDED STUDY WITH HEALTHY AND MIDDLEAGED JAPANESE PARTICIPANTS",2023,"LIFE-BASEL","13",NA,4,"10.3390/life13061319","CHO, KH (CORRESPONDING AUTHOR), RAYDEL RES INST, MED INNOVAT COMPLEX, DAEGU 41061, SOUTH KOREA.; CHO, KYUNG-HYUN; KIM, JI-EUN, RAYDEL RES INST, MED INNOVAT COMPLEX, DAEGU 41061, SOUTH KOREA.; KOMATSU, TOMOHIRO; UEHARA, YOSHINARI, FUKUOKA UNIV HOSP, CTR PREVENT ANTIAGING \& REGENERAT MED, 8-19-1 NANAKUMA,JOHNAN KU, FUKUOKA 8140180, JAPAN.; KOMATSU, TOMOHIRO; UEHARA, YOSHINARI, FUKUOKA UNIV, FAC SPORTS \& HLTH SCI, 8-19-1 NANAKUMA,JOHNAN KU, FUKUOKA 8140180, JAPAN.","POLICOSANOL CONSUMPTION HAS BEEN ASSOCIATED WITH TREATING BLOOD PRESSURE AND DYSLIPIDEMIA BY INCREASING THE LEVEL OF HIGH-DENSITY LIPOPROTEINS-CHOLESTEROL (HDL-C) AND HDL FUNCTIONALITY. ALTHOUGH POLICOSANOL SUPPLEMENTATION ALSO AMELIORATED LIVER FUNCTION IN ANIMAL MODELS, IT HAS NOT BEEN REPORTED IN A HUMAN CLINICAL STUDY, PARTICULARLY WITH A 20 MG DOAGE OF POLICOSANOL. IN THE CURRENT STUDY, TWELVE-WEEK CONSUMPTION OF CUBAN POLICOSANOL (RAYDEL(\& REG;)) SIGNIFICANTLY ENHANCED THE HEPATIC FUNCTIONS, SHOWING REMARKABLE DECREASES IN HEPATIC ENZYMES, BLOOD UREA NITROGEN, AND GLYCATED HEMOGLOBIN. FROM THE HUMAN TRIAL WITH JAPANESE PARTICIPANTS, THE POLICOSANOL GROUP (N = 26, MALE 13/FEMALE 13) SHOWED A REMARKABLE DECREASE IN ALANINE AMINOTRANSFERASE (ALT) AND ASPARTATE AMINOTRANSFERASE (AST) FROM BASELINE UP TO 21\% (P = 0.041) AND 8.7\% (P = 0.017), RESPECTIVELY. IN CONTRAST, THE PLACEBO GROUP (N = 26, MALE 13/FEMALE 13) SHOWED ALMOST NO CHANGE OR SLIGHT ELEVATION. THE POLICOSANOL GROUP SHOWED A 16\% DECREASE IN \& GAMMA;-GLUTAMYL TRANSFERASE (\& GAMMA;-GTP) AT WEEK 12 FROM THE BASELINE (P = 0.015), WHILE THE PLACEBO GROUP SHOWED A 1.2\% INCREASE. THE POLICOSANOL GROUP EXHIBITED SIGNIFICANTLY LOWER SERUM ALKALINE PHOSPHATASE (ALP) LEVELS AT WEEK 8 (P = 0.012), WEEK 12 (P = 0.012), AND AFTER 4-WEEKS (P = 0.006) COMPARED TO THOSE OF THE PLACEBO GROUP. AFTER 12 WEEKS OF POLICOSANOL CONSUMPTION, THE FERRIC ION REDUCTION ABILITY AND PARAOXONASE OF SERUM WERE ELEVATED BY 37\% (P < 0.001) AND 29\% (P = 0.004) HIGHER THAN WEEK 0, WHILE PLACEBO CONSUMPTION SHOWED NO NOTABLE CHANGES. INTERESTINGLY, GLYCATED HEMOGLOBIN (HBA(1C)) IN SERUM WAS LOWERED SIGNIFICANTLY IN THE POLICOSANOL GROUP 4 WEEKS AFTER CONSUMPTION, WHICH WAS APPROXIMATELY 2.1\% (P = 0.004) LOWER THAN THE PLACEBO GROUP. IN ADDITION, BLOOD UREA NITROGEN (BUN) AND URIC ACID LEVELS WERE SIGNIFICANTLY LOWER IN THE POLICOSANOL GROUP AFTER 4 WEEKS: 14\% LOWER (P = 0.002) AND 4\% LOWER (P = 0.048) THAN THOSE OF THE PLACEBO GROUP, RESPECTIVELY. REPEATED MEASURES OF ANOVA SHOWED THAT THE POLICOSANOL GROUP HAD REMARKABLE DECREASES IN AST (P = 0.041), ALT (P = 0.008), \& GAMMA;-GTP (P = 0.016), ALP (P = 0.003), HBA(1C) (P = 0.010), BUN (P = 0.030), AND SBP (P = 0.011) FROM THE CHANGES IN THE PLACEBO GROUP IN POINT OF TIME AND GROUP INTERACTION. IN CONCLUSION, 12 WEEKS OF 20 MG CONSUMPTION OF POLICOSANOL SIGNIFICANTLY ENHANCED HEPATIC PROTECTION BY LOWERING THE SERUM AST, ALT, ALP, AND \& GAMMA;-GTP VIA A DECREASE IN GLYCATED HEMOGLOBIN, URIC ACID, AND BUN WITH AN ELEVATION OF SERUM ANTIOXIDANT ABILITIES. THESE RESULTS SUGGEST THAT IMPROVEMENTS IN BLOOD PRESSURE BY CONSUMPTION OF 20 MG OF POLICOSANOL (RAYDEL(\& REG;)) WERE ACCOMPANIED BY PROTECTION OF LIVER FUNCTION AND ENHANCED KIDNEY FUNCTION.","POLICOSANOL; LIVER FUNCTION; ANTIOXIDANT; ANTI-GLYCATION; GLYCATED; HEMOGLOBIN; BLOOD UREA NITROGEN; BLOOD PRESSURE","RISK; CHOLESTEROL; DISEASE; INJURY; ENHANCEMENT",NA,NA,"AMADI CN, 2018, TOXICS, V6, DOI 10.3390/TOXICS6020024; ANSTEE QM, 2022, J HEPATOL, V76, P1362, DOI 10.1016/J.JHEP.2022.03.026; BEIER JI, 2021, ACTA PHARM SIN B, V11, P3768, DOI 10.1016/J.APSB.2021.09.005; BENZIE IFF, 1999, METHOD ENZYMOL, V299, P15; BONORA E, 2012, NAT REV GASTRO HEPAT, V9, P372, DOI 10.1038/NRGASTRO.2012.79; BOWER JK, 2012, DIABETES CARE, V35, P1031, DOI 10.2337/DC11-2248; CANAVACIOLO V.L.G., 2007, REV. CENIC CIENC. QUIMICAS, V38, P207; CAVERO-REDONDO I, 2017, BMJ OPEN, V7, DOI 10.1136/BMJOPEN-2017-015949; CHANG WH, 2022, J TRANSL MED, V20, DOI 10.1186/S12967-021-03210-9; CHO JH, 2017, ARCH TOXICOL, V91, P4009, DOI 10.1007/S00204-017-2007-9; CHO KH, 2023, INT J MOL SCI, V24, DOI 10.3390/IJMS24065185; CHO KH, 2023, INT J MOL SCI, V24, DOI 10.3390/IJMS24043186; CHO KH, 2019, CARDIOVASC THER, V2019, DOI 10.1155/2019/8496409; CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; CHO KH, 2018, MOLECULES, V23, DOI 10.3390/MOLECULES23051080; CICERO AFG, 2018, NUTRIENTS, V10, DOI 10.3390/NU10091153; DING Q, 2019, UROL INT, V103, P156, DOI 10.1159/000496208; ERNST E, 2002, J INTERN MED, V252, P107, DOI 10.1046/J.1365-2796.2002.00999.X; GARIN MCB, 2006, J LIPID RES, V47, P515, DOI 10.1194/JLR.M500281-JLR200; HADIZADEH FATEMEH, 2017, WORLD J GASTROINTEST PATHOPHYSIOL, V8, P11, DOI 10.4291/WJGP.V8.I2.11; HARRISON SA, 2007, GUT, V56, P1760, DOI 10.1136/GUT.2006.112094; HU JH, 2019, EUR J GASTROEN HEPAT, V31, P817, DOI 10.1097/MEG.0000000000001336; IMANI F, 2014, HEPAT MON, V14, DOI 10.5812/HEPATMON.23539; KABEYA Y, 2012, INTERNAL MED, V51, P699, DOI 10.2169/INTERNALMEDICINE.51.6426; KIM JY, 2017, INT J MOL MED, V39, P889, DOI 10.3892/IJMM.2017.2907; KIM SJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/FPHYS.2018.00412; KUMA A, 2022, NUTRIENTS, V14, DOI 10.3390/NU14183787; LAN Q, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/FCVM.2021.614117; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LIM SM, 2016, REJUV RES, V19, P59, DOI 10.1089/REJ.2015.1712; LIMDI JK, 2003, POSTGRAD MED J, V79, P307, DOI 10.1136/PMJ.79.932.307; LIU XD, 2013, HEPATO-GASTROENTEROL, V60, P343, DOI 10.5754/HGE11216; MARCHESINI G, 2005, ANN MED, V37, P333, DOI 10.1080/07853890510011445; MCGILL MR, 2016, EXCLI J, V15, P817, DOI 10.17179/EXCLI2016-800; MEGA A, 2021, NUTRIENTS, V13, DOI 10.3390/NU13041326; NAM DE, 2019, J MED FOOD, V22, P1110, DOI 10.1089/JMF.2019.4491; NOA MIRIAM, 2003, DRUGS R D, V4, P29, DOI 10.2165/00126839-200304010-00003; OBI E, 2006, SCI TOTAL ENVIRON, V369, P35, DOI 10.1016/J.SCITOTENV.2006.04.024; OSNA NA, 2017, ALCOHOL RES-CURR REV, V38, P147; PARK EO, 2020, J CLIN MED, V9, DOI 10.3390/JCM9041147; PARK HJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16050809; RAFIQ N, 2009, CLIN GASTROENTEROL H, V7, P234, DOI 10.1016/J.CGH.2008.11.005; ROSSELLI M, 2014, CURR PHARM DESIGN, V20, P5010; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SPELIOTES E. K., 2019, CLIN LIVER DIS, V14, P161, DOI DOI 10.1002/CLD.876; SUK KT, 2012, CLIN MOL HEPATOL, V18, P249, DOI 10.3350/CMH.2012.18.3.249; TALWANI R, 2011, CLIN LIVER DIS, V15, P111, DOI 10.1016/J.CLD.2010.09.002; TESCHKE R, 2015, FRONT PHARMACOL, V6, DOI 10.3389/FPHAR.2015.00072; ZEIN N, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/J.BIOPHA.2022.113020; ZHAI ZY, 2021, J FOOD SCI, V86, P5466, DOI 10.1111/1750-3841.15951; ZHANG XL, 2023, ALZHEIMERS DEMENT, V19, P181, DOI 10.1002/ALZ.12641; ZHOU F, 2019, HEPATOLOGY, V70, P1119, DOI 10.1002/HEP.30702; ZHU LJ, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/S12872-021-02282-1","CHO, KH (CORRESPONDING AUTHOR), RAYDEL RES INST, MED INNOVAT COMPLEX, DAEGU 41061, SOUTH KOREA","MDPI","ENGLISH","LIFE-BASEL","ARTICLE","ISI","WOS001014464700001","LIFE-BASEL","RAYDEL RES INST;RAYDEL RES INST;FUKUOKA UNIV HOSP;FUKUOKA UNIV","RAYDEL RES INST",NA,"CHO KH, 2023, LIFE-BASEL","CHO KH, 2023, LIFE-BASEL"
"SANCHEZ-HERNANDEZ E;MARTIN-RAMOS P;NINO-SANCHEZ J;DIEZ-HERMANO S;ALVAREZ-TABOADA F;PEREZ-GARCIA ;RODRIGO R;SANTIAGO-ALISTE A;MARTIN-GIL J;DIEZ-CASERO J","SANCHEZ-HERNANDEZ EVA;MARTIN-RAMOS PABLO;NINO-SANCHEZ JONATAN;DIEZ-HERMANO SERGIO;ALVAREZ-TABOADA FLOR;PEREZ-GARCIA; RODRIGO;SANTIAGO-ALISTE ALBERTO;MARTIN-GIL JESUS; DIEZ-CASERO JULIO JAVIER","CHARACTERIZATION OF ILEPTOGLOSSUS OCCIDENTALISI EGGS AND EGG GLUE",2023,"INSECTS","14",NA,0,"10.3390/insects14040396","SÁNCHEZ-HERNÁNDEZ, E; MARTÍN-RAMOS, P (CORRESPONDING AUTHOR), UNIV VALLADOLID, DEPT AGR \& FORESTRY ENGN, ETSIIAA, AVE MADRID 44, PALENCIA 34004, SPAIN.; SANCHEZ-HERNANDEZ, EVA; MARTIN-RAMOS, PABLO; SANTIAGO-ALISTE, ALBERTO; MARTIN-GIL, JESUS, UNIV VALLADOLID, DEPT AGR \& FORESTRY ENGN, ETSIIAA, AVE MADRID 44, PALENCIA 34004, SPAIN.; NINO-SANCHEZ, JONATAN; DIEZ-HERMANO, SERGIO; PEREZ-GARCIA, RODRIGO; DIEZ-CASERO, JULIO JAVIER, UNIV VALLADOLID, INST UNIV INVEST GEST FORESTAL SOSTENIBLE IUFOR, AVE MADRID 57, PALENCIA 34071, SPAIN.; NINO-SANCHEZ, JONATAN; DIEZ-HERMANO, SERGIO; PEREZ-GARCIA, RODRIGO; DIEZ-CASERO, JULIO JAVIER, UNIV VALLADOLID, DEPT PROD VEGETAL \& RECURSOS FORESTALES, ETSIIAA, AVE MADRID 57, PALENCIA 34071, SPAIN.; ALVAREZ-TABOADA, FLOR, UNIV LEON, SCH AGRARIAN \& FOREST ENGN, DRACONES, AVE PORTUGAL 41, PONFERRADA 24401, SPAIN.","SIMPLE SUMMARY THIS STUDY EXPLORED THE CHEMICAL COMPONENTS OF THE EGG GLUE USED BY THE WESTERN CONIFER SEED BUG (LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN, 1910) TO AGGLUTINATE EGGS AND ADHERE TO PINE NEEDLES. RESULTS SHOWED THAT THE ADHESIVE SECRETION INCLUDES PLASTICIZERS AND THERMOPLASTIC ELASTOMER RESINS WITH SEMIOCHEMICAL PROPERTIES IN AN OILY MATRIX CONTAINING PROTEINS. THIS KNOWLEDGE OF THE EGG GLUE COMPOSITION CAN BE USED TO DEVELOP NEW CONTROL STRATEGIES FOR L. OCCIDENTALIS, POTENTIALLY LIMITING THE ECONOMIC IMPACT CAUSED BY THIS PEST INSECT THAT REDUCES THE PRODUCTION OF PINE NUTS BY UP TO 25\%. THE WESTERN CONIFER SEED BUG (LEPTOGLOSSUS OCCIDENTALIS HEIDEMANN, 1910, HETEROPTERA: COREIDAE) HAS A SIGNIFICANT ECONOMIC IMPACT DUE TO THE REDUCTION IN THE QUALITY AND VIABILITY OF CONIFER SEED CROPS; IT CAN FEED ON UP TO 40 DIFFERENT SPECIES OF CONIFERS, SHOWING A CLEAR PREDILECTION FOR PINUS PINEA L. IN EUROPE. ITS INCIDENCE IS ESPECIALLY RELEVANT FOR THE PINE NUT-PRODUCING INDUSTRY, GIVEN THAT THE ACTION OF THIS PEST INSECT CAN REDUCE THE PRODUCTION OF PINE NUTS BY UP TO 25\%. AS PART OF ONGOING EFFORTS AIMED AT THE DESIGN OF CONTROL STRATEGIES FOR THIS INSECT, THIS WORK FOCUSES ON THE CHARACTERIZATION (BY SCANNING ELECTRON MICROSCOPY-ENERGY-DISPERSIVE X-RAY SPECTROSCOPY, FOURIER-TRANSFORM INFRARED SPECTROSCOPY, AND GAS CHROMATOGRAPHY-MASS SPECTROSCOPY, GC-MS) OF THE COMPOUNDS RELEASED BY THESE INSECTS DURING OVIPOSITION, WITH EMPHASIS ON THE ADHESIVE SECRETION THAT HOLDS L. OCCIDENTALIS EGGS TOGETHER. ELEMENTAL ANALYSIS POINTED TO THE PRESENCE OF SIGNIFICANT AMOUNTS OF COMPOUNDS WITH HIGH NITROGEN CONTENT. FUNCTIONAL GROUPS IDENTIFIED BY INFRARED SPECTROSCOPY WERE COMPATIBLE WITH THE PRESENCE OF CHITIN, SCLEROPROTEINS, LNSP-LIKE AND GELATIN PROTEINS, SHELLAC WAX ANALOGS, AND POLICOSANOL. REGARDING THE CHEMICAL SPECIES IDENTIFIED BY GC-MS, EGGS AND GLUE HYDROMETHANOLIC EXTRACTS SHARED CONSTITUENTS SUCH AS BUTYL CITRATE, DIBUTYL ITACONATE, TRIBUTYL ACONITATE, OLEIC ACID, OLEAMIDE, ERUCAMIDE, AND PALMITIC ACID, WHILE EGGS ALSO SHOWED STEARIC AND LINOLEIC ACID-RELATED COMPOUNDS. KNOWLEDGE OF THIS COMPOSITION MAY ALLOW ADVANCES IN NEW STRATEGIES TO ADDRESS THE PROBLEM CAUSED BY L. OCCIDENTALIS.","EGGS; GC-MS; FTIR; GLUE; SEMIOCHEMICALS; SEM-EDS; OVIPOSITION; WESTERN; CONIFER SEED BUG; WCSB; PINE NUTS; EDIBLE PINE","PINUS-HALEPENSIS MILL.; CONIFER SEED BUG; HETEROPTERA; PHEROMONE; COREIDAE; SECRETIONS; PROFILES; INSECTS; CONES; ALARM",NA,NA,"ALDRICH JR, 1997, ANN ENTOMOL SOC AM, V90, P75, DOI 10.1093/AESA/90.1.75; ANDRONIE L., 2016, BULLETIN OF UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE CLUJ-NAPOCA. ANIMAL SCIENCE AND BIOTECHNOLOGIES, V73, P238, DOI 10.15835/BUASVMCN-ASB:12162; ANTTONEN S, 1995, ENVIRON POLLUT, V87, P235, DOI 10.1016/0269-7491(94)P2611-C; BARTA M, 2016, J PEST SCI, V89, P31, DOI 10.1007/S10340-015-0673-Z; BATES SL, 2005, AGR FOREST ENTOMOL, V7, P145, DOI 10.1111/J.1461-9555.2005.00254.X; BERNARDINELLI I., 2001, JOURNAL OF FOREST SCIENCE (PRAGUE), V47, P56; BLATT S. E., 1994, JOURNAL OF THE ENTOMOLOGICAL SOCIETY OF BRITISH COLUMBIA, V91, P71; BLATT SE, 1996, CAN ENTOMOL, V128, P777, DOI 10.4039/ENT128777-4; BLATT SE, 1998, J CHEM ECOL, V24, P1013, DOI 10.1023/A:1022350402535; BRUNS F.H., 1963, ADV CLIN CHEM, VVOLUME 5, P237, DOI 10.1016/S0065-2423(08)60076-1, DOI 10.1016/S0065-2423(08)60076-1; CAMPBELL BE, 2016, INSECTICIDES RESISTANCE, P83, DOI 10.5772/61848; CHAOS A, 2019, POLYM INT, V68, P125, DOI 10.1002/PI.5705; CHOW YS, 1989, EXPERIENTIA, V45, P390, DOI 10.1007/BF01957490; CONNELLY AE, 1991, J ECON ENTOMOL, V84, P215, DOI 10.1093/JEE/84.1.215; DHIBI M, 2012, J SCI FOOD AGR, V92, P1702, DOI 10.1002/JSFA.5535; EL OMARI N, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/J.JEP.2020.113661; HILKER M, 2002, CHEMOECOLOGY OF INSECT EGGS AND EGG DEPOSITION, PXV; HONDA K, 1980, INSECT BIOCHEM, V10, P583, DOI 10.1016/0020-1790(80)90095-5; INOUE KM, 2019, J BRAZIL CHEM SOC, V30, P939, DOI 10.21577/0103-5053.20180238; JIANG XC, 2015, EUR J ENTOMOL, V112, P295, DOI 10.14411/EJE.2015.042; KADRI N, 2015, FOOD CHEM, V188, P184, DOI 10.1016/J.FOODCHEM.2015.04.138; KIM JH, 2021, PARASITE VECTOR, V14, DOI 10.1186/S13071-021-04914-Z; LEI YT, 2021, ACTA BIOMATER, V134, P499, DOI 10.1016/J.ACTBIO.2021.07.039; LI DM, 2008, ARCH INSECT BIOCHEM, V69, P85, DOI 10.1002/ARCH.20267; FRANCO-ARCHUNDIA SL, 2018, INSECTS, V9, DOI 10.3390/INSECTS9030091; LIU R, 2012, FOOD ANAL METHOD, V5, P435, DOI 10.1007/S12161-011-9264-7; MA JJ, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0197343; MARIOD AA, 2015, FOOD SCI TECHNOL INT, V21, P380, DOI 10.1177/1082013214541137; MAS H., 2013, P 6 SPANISH FOREST C, P10; MCAFEE A, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-24054-2; MICHEREFF MFF, 2016, B ENTOMOL RES, V106, P663, DOI 10.1017/S0007485316000419; MILLAR JG, 2022, J NAT PROD, V85, P2062, DOI 10.1021/ACS.JNATPROD.2C00470; MITCHELL PL, 2000, HETEROPTERA OF ECONOMIC IMPORTANCE, P337; MOHAMED AA, 2020, PROCESSES, V8, DOI 10.3390/PR8030330; MURPHY MP, 2018, CELL, V174, P780, DOI 10.1016/J.CELL.2018.07.030; MUTKE S., 2019, FORESTALIS, V32, P26; NAVES P, 2022, ANN SOC ENTOMOL FR, V58, P287, DOI 10.1080/00379271.2022.2101526; OLIVEIRA FARINHA A.C., 2019, IMPACT ECOLOGICAL AD; PONCE HERRERO L., 2020, REV FOR, V79, P90; RENTHAL R, 2019, TICKS TICK-BORNE DIS, V10, P138, DOI 10.1016/J.TTBDIS.2018.09.009; SOLDI RA, 2012, J CHEM ECOL, V38, P814, DOI 10.1007/S10886-012-0147-1; STRONG W., 2010, BC CONE SEED PEST RE; TAKACS S, 2009, P ROY SOC B-BIOL SCI, V276, P649, DOI 10.1098/RSPB.2008.0742; TSOCHATZIS ED, 2020, ANAL BIOANAL CHEM, V412, P5419, DOI 10.1007/S00216-020-02758-7; VENDITTI A, 2020, NAT PROD RES, V34, P1014, DOI 10.1080/14786419.2018.1543674; WILSON H., 2020, INSECTS, V11, P1, DOI DOI 10.3390/INSECTS11060358; YAN GM, 2021, POLYMERS-BASEL, V13, DOI 10.3390/POLYM13213723; YU Y, 2020, J CHEM TECHNOL BIOT, V95, P2879, DOI 10.1002/JCTB.6447","SÁNCHEZ-HERNÁNDEZ, E; MARTÍN-RAMOS, P (CORRESPONDING AUTHOR), UNIV VALLADOLID, DEPT AGR \& FORESTRY ENGN, ETSIIAA, AVE MADRID 44, PALENCIA 34004, SPAIN","MDPI","ENGLISH","INSECTS","ARTICLE","ISI","WOS000977576900001","INSECTS","UNIV VALLADOLID;UNIV VALLADOLID;UNIV VALLADOLID;UNIV VALLADOLID;UNIV LEON","NOTREPORTED;UNIV VALLADOLID",NA,"SANCHEZ-HERNANDEZ E, 2023, INSECTS","SANCHEZ-HERNANDEZ E, 2023, INSECTS"
"MA C;FENG Y;LI X;SUN L;HE Z;GAN J;HE M;ZHANG X;CHEN X","MA CHENJING;FENG YING;LI XIAN;SUN LONG;HE ZHAO; GAN JIN;HE MINJIE;ZHANG XIN;CHEN XIAOMING","POTENTIAL THERAPEUTIC EFFECTS OF POLICOSANOL FROM INSECT WAX ONI CAENORHABDITISII ELEGANSI MODELS OF PARKINSONS DISEASE",2023,"JOURNAL OF NEUROIMMUNE PHARMACOLOGY","18","127-144",4,"10.1007/s11481-022-10057-4","ZHANG, X (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, NATL FORESTRY \& GRASSLAND ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA.; MA, CHENJING; FENG, YING; LI, XIAN; SUN, LONG; HE, ZHAO; GAN, JIN; ZHANG, XIN; CHEN, XIAOMING, CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, NATL FORESTRY \& GRASSLAND ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA.; HE, MINJIE, KUNMING MED UNIV, AFFILIATED HOSP 1, HLTH MANAGEMENT CTR, KUNMING 650000, YUNNAN, PEOPLES R CHINA.","PARKINSON'S DISEASE (PD) IS THE SECOND MOST COMMON NEURODEGENERATIVE DISEASE WORLDWIDE. THE STANDARD TREATMENTS FOR PD FOCUS ON SYMPTOM RELIEF RATHER THAN ATTEMPTING TO ADDRESS THE UNDERLYING DEGENERATIVE PROCESSES COMPLETELY. THIS STUDY AIMED TO EVALUATE THE POTENTIAL THERAPEUTIC EFFECTS OF POLICOSANOL DERIVED FROM INSECT WAX (PIW) BY INVESTIGATING IMPROVEMENTS IN DISEASE SYMPTOMS REPRESENTED IN CAENORHABDITIS ELEGANS MODELS OF PD. FOR OUR ASSESSMENTS, WE USED THE FOLLOWING THREE MODELS: NL5901, WHICH IS A TRANSGENIC MODEL FOR ALPHA-SYNUCLEIN AGGREGATION; WILD-TYPE N2 INDUCED WITH 6-HYDROXYDOPAMINE (6-OHDA); AND 6-OHDA-INDUCED BZ555 AS A MODEL FOR LOSS OF DOPAMINERGIC NEURONS (DNS). SPECIFICALLY, WE EXAMINED THE EFFECTS OF PIW TREATMENT ON ALPHA-SYNUCLEIN AGGREGATION, THE LOSS OF DNS, LIPID ABUNDANCE, AND THE LIFESPAN OF TREATED ORGANISMS. FURTHER, WE EXAMINED TREATMENT-RELATED CHANGES IN THE LEVELS OF REACTIVE OXYGEN SPECIES (ROS), MALONDIALDEHYDE (MDA), ADENOSINE TRIPHOSPHATE (ATP), GLUTATHIONE S-TRANSFERASE (GST), AND SUPEROXIDE DISMUTASE (SOD), AS WELL AS THE MRNA PRODUCTION PROFILES OF RELEVANT GENES. A 10 MU G/ML DOSE OF PIW REDUCED THE AGGREGATION OF ALPHA-SYNUCLEIN IN NL5901 AND SUPPRESSED THE LOSS OF DNS IN 6-OHDA-INDUCED BZ555. OVERALL, PIW TREATMENT DECREASED ROS AND MDA LEVELS, RESTORED LIPID ABUNDANCE, AND PROLONGED THE LIFESPANS OF WORMS IN ALL THE THREE MODELS, WHICH MAY BE ASSOCIATED WITH CHANGES IN THE EXPRESSION PROFILES OF GENES RELATED TO CELL SURVIVAL AND OXIDATIVE STRESS RESPONSE PATHWAYS. OUR FINDINGS SHOW THAT PIW ALLEVIATED THE SYMPTOMS OF PD IN THESE MODELS, POSSIBLY BY REGULATING THE STRESS RESPONSES INITIATED BY INJURIES SUCH AS ALPHA-SYNUCLEIN AGGREGATION OR 6-OHDA TREATMENT.","PARKINSON'S DISEASE; POLICOSANOL FROM INSECT WAX; ALPHA-SYNUCLEIN; 6-OHDA; CAENORHABDITIS ELEGANS","ALPHA-SYNUCLEIN; BLOOD-PRESSURE; DOPAMINE; APOPTOSIS; TOXICITY; FAT","CHINESE ACADEMY OF FORESTRY [CAFYBB2019SZ005]","THIS WORK WAS SUPPORTED BY GRANTS FROM THE CHINESE ACADEMY OF FORESTRY (NO. CAFYBB2019SZ005).","ANGELOVA PR, 2015, J NEUROCHEM, V133, P582, DOI 10.1111/JNC.13024; ASKARPOUR M, 2019, COMPLEMENT THER MED, V45, P89, DOI 10.1016/J.CTIM.2019.05.023; BARTELS T., 2019, ALPHA SYNUCLEIN METH, DOI 10.1007/978-1-4939-9124-2, DOI 10.1007/978-1-4939-9124-2; BLUM D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; CASTAÑO G, 2006, CURR THER RES CLIN E, V67, P174, DOI 10.1016/J.CURTHERES.2006.06.004; CHALORAK P, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/FNINS.2020.00303; CHALORAK P, 2018, NUTR NEUROSCI, V21, P427, DOI 10.1080/1028415X.2017.1299437; CHANG CH, 2021, PHYTOMEDICINE, V92, DOI 10.1016/J.PHYMED.2021.153733; CHEN FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/SCIENCE.287.5457.1485; CHEN X., 2011, NATURAL POPULATION OF ERICERUS PELA, V1ST EDITION; CHEN X. M., 2009, INTRO RESOURCE ENTOM; CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; CIULLA M, 2019, BIOMOLECULES, V9, DOI 10.3390/BIOM9070271; COOPER JF, 2018, J PARKINSON DIS, V8, P17, DOI 10.3233/JPD-171258; DE LAU LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; DEVOS D, 2021, MOVEMENT DISORD, V36, P306, DOI 10.1002/MDS.28379; DUANGJAN C, 2019, PHYTOMEDICINE, V64, DOI 10.1016/J.PHYMED.2019.153061; ESCORCIA W, 2018, JOVE-J VIS EXP, DOI 10.3791/57352; FARRER MJ, 2006, NAT REV GENET, V7, P306, DOI 10.1038/NRG1831; FLOWER TR, 2005, J MOL BIOL, V351, P1081, DOI 10.1016/J.JMB.2005.06.060; GALVAGNION C, 2017, J PARKINSON DIS, V7, P433, DOI 10.3233/JPD-171103; GONG J, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700280; GONZ?LEZ R., 2018, REV CENIC CIENCIAS B, V49, P1; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GRANJA AL, 1999, PATENT PUBLICATION, PATENT NO. 711756B2, 711756; HARTMAN JH, 2019, INT J MOL SCI, V20, DOI 10.3390/IJMS20133202; HAYES MT, 2019, AM J MED, V132, P802, DOI 10.1016/J.AMJMED.2019.03.001; KABIR Y, 2020, HERBAL MEDICINE IN INDIA: INDIGENOUS KNOWLEDGE, PRACTICE, INNOVATION AND ITS VALUE, P413, DOI 10.1007/978-981-13-7248-3\_25; KAMPKÖTTER A, 2007, PHARMACOL RES, V55, P139, DOI 10.1016/J.PHRS.2006.11.006; KIM JY, 2017, INT J MOL MED, V39, P889, DOI 10.3892/IJMM.2017.2907; KIM SJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/FPHYS.2018.00412; LANG AE, 2018, MOVEMENT DISORD, V33, P660, DOI 10.1002/MDS.27360; LI HF, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4856761; LIGAARD J, 2019, NPJ PARKINSON DIS, V5, DOI 10.1038/S41531-019-0091-7; LU L, 2020, FITOTERAPIA, V146, DOI 10.1016/J.FITOTE.2020.104687; LUDTMANN MHR, 2018, NEUROSCI LETT, V663, P86, DOI 10.1016/J.NEULET.2017.08.044; MA J, 2021, TOXICOL RES-UK, V10, P409, DOI 10.1093/TOXRES/TFAA107; MA JJ, 2022, FOOD SCI HUM WELL, V11, P356, DOI 10.1016/J.FSHW.2021.11.013; MA JJ, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0197343; MA JINJU MA JINJU, 2018, JOURNAL OF ENVIRONMENTAL ENTOMOLOGY, V40, P1238; MALAIWONG N, 2019, BIOMED PHARMACOTHER, V109, P1967, DOI 10.1016/J.BIOPHA.2018.11.063; MAO Q, 2020, ACTA PHARMACOL SIN, V41, P471, DOI 10.1038/S41401-020-0365-Y; MARQUES NF, 2019, NEUROTOX RES, V35, P475, DOI 10.1007/S12640-018-9976-1; MEHRA S, 2019, BBA-PROTEINS PROTEOM, V1867, P890, DOI 10.1016/J.BBAPAP.2019.03.001; MOORE DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/ANNUREV.NEURO.28.061604.135718; NASUTI C, 2017, J PHARMACOL TOX MET, V83, P80, DOI 10.1016/J.VASCN.2016.10.003; NEEF DW, 2011, NAT REV DRUG DISCOV, V10, P930, DOI 10.1038/NRD3453; OFFENBURGER SL, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BIOPROTOC.3025; PARK HJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16050809; POURKARIMI E, 2012, CELL DEATH DIFFER, V19, P406, DOI 10.1038/CDD.2011.104; RANGO M, 2018, GENES-BASEL, V9, DOI 10.3390/GENES9050250; RASHIDI R, 2021, AVICENNA J PHYTOMEDI, V11, P238, DOI 10.22038/AJP.2020.16426; RAZA C, 2019, LIFE SCI, V226, P77, DOI 10.1016/J.LFS.2019.03.057; RENOUDET VV, 2012, J MED FOOD, V15, P758; ROCHA EM, 2018, NEUROBIOL DIS, V109, P249, DOI 10.1016/J.NBD.2017.04.004; RODRIGUEZ M, 2013, TRENDS GENET, V29, P367, DOI 10.1016/J.TIG.2013.01.010; RUIPÉREZ V, 2010, PROG LIPID RES, V49, P420, DOI 10.1016/J.PLIPRES.2010.05.004; S?NCHEZ L??PEZ J., 2018, REV NEUROLOG A, V67, P331, DOI 10.33588/RN.6709.2018063, DOI 10.33588/RN.6709.2018063; SALARI S, 2019, PHYSIOL RES, V68, P17, DOI 10.33549/PHYSIOLRES.933895; SÁNCHEZ JORGE, 2017, REV. ALERG. MÉX., V64, P153, DOI 10.29262/RAM.V64I2.243; SEGURA-AGUILAR J, 2014, J NEUROCHEM, V129, P898, DOI 10.1111/JNC.12686; SHARMA S, 2021, MOL NEUROBIOL, V58, P65, DOI 10.1007/S12035-020-02080-4; TEISMANN P, 2004, CELL TISSUE RES, V318, P149, DOI 10.1007/S00441-004-0944-0; URBAN N, 2017, REDOX BIOL, V11, P502, DOI 10.1016/J.REDOX.2016.12.003; VAN DEN EEDEN SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/AJE/KWG068; VAN HAM TJ, 2008, PLOS GENET, V4, DOI 10.1371/JOURNAL.PGEN.1000027; VANDUYN N, 2010, TOXICOL SCI, V118, P613, DOI 10.1093/TOXSCI/KFQ285; WANG H, 2018, J QUANT SPECTROSC RA, V206, P254, DOI 10.1016/J.JQSRT.2017.11.015; WANG T, 2012, NEURAL REGEN RES, V7, P1080, DOI 10.3969/J.ISSN.1673-5374.2012.14.006; WANG T, 2010, ACTA PHARMACOL SIN, V31, P765, DOI 10.1038/APS.2010.69; WANG ZD, 2021, BIOMED PHARMACOTHER, V136, DOI 10.1016/J.BIOPHA.2021.111241; WANG ZD, 2017, BIOMED PHARMACOTHER, V89, P438, DOI 10.1016/J.BIOPHA.2017.02.036; YAN N, 2005, NATURE, V437, P831, DOI 10.1038/NATURE04002; ZHANG K, 2021, ACTA PHARM SIN B, V11, P3015, DOI 10.1016/J.APSB.2021.02.016; ZHANG X, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/S12906-021-03278-2; ZHAO JJ., 2021, MOD AGR SCI TECHNOL, V6, P193, DOI 10.3969/J.ISSN.1007-5739.2021.06.080, DOI 10.3969/J.ISSN.1007-5739.2021.06.080; ZHOU Y, 1980, HIST ENTOMOLOGY CHIN; ZOU SW., 1982, HIST CHINESE ENTOMOL","ZHANG, X (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, NATL FORESTRY \& GRASSLAND ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA","SPRINGER","ENGLISH","J. NEUROIMMUNE PHARM.","ARTICLE","ISI","WOS000915625700001","J NEUROIMMUNE PHARM","INST HIGHLAND FOREST SCI;INST HIGHLAND FOREST SCI;KUNMING MED UNIV","INST HIGHLAND FOREST SCI",NA,"MA C, 2023, J NEUROIMMUNE PHARM","MA C, 2023, J NEUROIMMUNE PHARM"
"XIA Z;HU M;ZHENG L;ZHENG E;DENG ;MIN M;WU J;SHENG X","XIA ZIGIANG;HU MEI;ZHENG LIANG;ZHENG ENDIAN;DENG; MIN;WU JINMING;SHENG XIONG","ASSESSING WHETHER SERUM CERULOPLASMIN PROMOTES NONALCOHOLIC STEATOHEPATITIS VIA REGULATING IRON METABOLISM",2023,"JOURNAL OF MEDICAL BIOCHEMISTRY","42","113-121",0,"10.5937/jomb0-37597","SHENG, X (CORRESPONDING AUTHOR), JIAXING COLL, AFFILIATED HOSP 1, DEPT INFECT DIS, 1882 ZHONGHUAN NAN RD, JIAXING 314000, PEOPLES R CHINA.; WU, JM (CORRESPONDING AUTHOR), WENZHOU MED UNIV, AFFILIATED HOSP 1, DEPT GASTROENTEROL, WENZHOU 325000, PEOPLES R CHINA.; XIA, ZIGIANG; HU, MEI; ZHENG, LIANG; ZHENG, ENDIAN, WENZHOU PEOPLES HOSP, DEPT GASTROENTEROL, WENZHOU 325000, PEOPLES R CHINA.; DENG, MIN; SHENG, XIONG, JIAXING COLL, AFFILIATED HOSP 1, DEPT INFECT DIS, 1882 ZHONGHUAN NAN RD, JIAXING 314000, PEOPLES R CHINA.; DENG, MIN; SHENG, XIONG, FIRST HOSP JIAXING, DEPT INFECT DIS, JIAXING 314000, PEOPLES R CHINA.; WU, JINMING, WENZHOU MED UNIV, AFFILIATED HOSP 1, DEPT GASTROENTEROL, WENZHOU 325000, PEOPLES R CHINA.","BACKGROUND: NON-ALCOHOLIC STEATOLIEPATITIS (NASH) IS A PROGRESSIVE FORM OF NON-ALCOLIC FATTY LIVER DISEASE (NAFLD). THE DIAGNOSTIC GOLD STANDARD FOR DETECTING NASH STILL RELIES UPON AN INVASIVE PATHOLOGICAL BIOPSY THERE IS, THEREFORE, A NEED TO IDENTIFY NON-INVASIVE DIAGNOSTIC MARKERS. OXIDATIVE STRESS MEDIATES FATTY LIVER PROGRESSION TO NASH. IMBALANCED IRON METABOLISM PRODUCES MANY REACTIVE OXYGEN SPECIES (ROS). CERULOPLASMIN IS ASSOCIATED WITH OXIDASE AND IRON METABOLISM-RELATED ACTIVITIES. THE CURRENT STUDY AIMED TO DETERMINE WHETHER THERE WAS A CORRELATION BETWEEN CERULOPLASMIN LEVELS AND NASH AND WHETHER SUCH A RELATIONSHIP MAY BE ASSOCIATED WITH ALTERED IRON METABOLISM IN NASH PATIENTS. METHODS: A TOTAL OF 135 NAFLD PATIENTS WERE ENROLLED IN THIS STUDY. A PATHOLOGICAL BIOPSY CONFIRMED THAT 60 OF THOSE PATIENTS HAD NAFLD ACTIVITY SCORES (NAS) 5, WHILE THE REMAINING 75 HAD NAS<5. RESULTS: RECEIVER OPERATING CHARACTERISTIC (ROC) CURVES CONFIRMED THAT SERUM CERULOPLASMIN AND FERRITIN LEVELS WERE PREDICTORSOF NAS 5 AND NAS<5, WITH AREA UNDER THE CURVE (AUC) VALUESOF 0.80 AND 0.81, RESPECTIVELY. THE SERUM CERULOPLASMIN LEVELS IN NAS 5 PATIENTS WERE SIGNIFICANTLY LOWER THAN THOSE IN NAS<5 PATIENTS (P<0.D01). SERUM CERULOPLASMIN LEVELS WERE ALSO NEGATIVELY CORRELATED WITH FERRITIN LEVELS. LOWER SERUM CERULOPLASMIN LEVELS WERE ASSOCIATED WITH MORE SEVERE HISTOPATHOLOGICAL FINDINGS. CONCLUSIONS: LOW SERUM CERULOPLASMIN AND HIGH SERUM FERRITIN ARE CORRELATED WITH NASH A HIIGH CONCENTRATION OF SERUM FERRITIN IS A VIABLE CLINICAL BIOMARKER OF NASH, AND LOW SERUM CERULOPLASMIN MAY PARTICIPATE IN THE OCCURRENCE OF NASH BY REGULATING IRON LOAD, WHICH CAN BE USED AS A NON-INVASIVE DIAGNOSTIC MARKER OF NASH.","CERULOPLASMIN; FERRITIN; NON-ALCOHOLIC FATTY; LIVER DISEASE; NON-ALCOHOLIC STEATOHEPATITIS","OXIDATIVE STRESS; NITRIC-OXIDE; POLICOSANOL; STATINS; ATORVASTATIN; RISK; HYPERCHOLESTEROLEMIA; ASSAY","SCIENCE AND TECHNOLOGY BUREAU OF JIAXING [2018AD32078]; ZHEJIANG PROVINCIAL HEALTH SCIENCE AND TECHNOLOGY PROGRAM [2021 KY1108]; JIAXING CITY MEDICAL KEY DISCIPLINE-INFECTIOUS DISEASES [2019-ZC-02]; JIAXING KEY LABORATORY OF VIRUS-RELATED INFECTIOUS DISEASES","ACKNOWLEDGMENTS. THIS STUDY WAS FUNDED BY THE SCIENCE AND TECHNOLOGY BUREAU OF JIAXING (NOS. 2018AD32078) , ZHEJIANG PROVINCIAL HEALTH SCIENCE AND TECHNOLOGY PROGRAM (2021 KY1108) , JIAXING CITY MEDICAL KEY DISCIPLINE-INFECTIOUS DISEASES (2019-ZC-02) , JIAXING KEY LABORATORY OF VIRUS-RELATED INFECTIOUS DISEASES.","ADORNI MP, 2020, NUTRIENTS, V12, DOI 10.3390/NU12051440; ALAMDARI DH, 2007, CLIN BIOCHEM, V40, P248, DOI 10.1016/J.CLINBIOCHEM.2006.10.017; ANTONIADES C, 2014, ANTIOXID REDOX SIGN, V20, P1195, DOI 10.1089/ARS.2014.5836; ARTECHE-HIDALGO L, 2020, J ENDOCRINOL METAB, V10, P36, DOI 10.14740/JEM642; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; BLAGOJEVIC IP, 2018, J MED BIOCHEM, V37, P476, DOI 10.2478/JOMB-2018-0008; BRONIAREK I, 2020, INT J MOL SCI, V21, DOI 10.3390/IJMS21041485; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CIRIC MZ, 2021, NUTRIENTS, V13, DOI 10.3390/NU13030903; DU SOUICH P, 2017, PHARMACOL THERAPEUT, V175, P1, DOI 10.1016/J.PHARMTHERA.2017.02.029; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELSEWEIDY MM, 2018, J CARDIOVASC PHARM T, V23, P551, DOI 10.1177/1074248418775377; EREL O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/J.CLINBIOCHEM.2003.11.015; EREL O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/J.CLINBIOCHEM.2005.08.008; FINK G., 2007, ENCY STRESS; FONTANA J, 2018, IMMUNOL INVEST, V47, P823, DOI 10.1080/08820139.2018.1523925; GONG J, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700280; GUO YL, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/926087; HADZI-PETRUSHEV N, 2018, ADV PHARMACOL SCI, V2018, DOI 10.1155/2018/4673061; HENNING T, 2021, REDOX BIOL, V41, DOI 10.1016/J.REDOX.2021.101922; KIM SJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/FPHYS.2018.00412; KLISIC A, 2020, ARCH MED SCI, V16, P42, DOI 10.5114/AOMS.2019.87541; LEE SH, 2019, INT J SPORT PHYSIOL, V14, P1297, DOI 10.1123/IJSPP.2018-0704; LIM SM, 2016, REJUV RES, V19, P59, DOI 10.1089/REJ.2015.1712; LIM S, 2014, J ATHEROSCLER THROMB, V21, P997, DOI 10.5551/JAT.24398; LIU AM, 2019, PHARMACOL THERAPEUT, V195, P54, DOI 10.1016/J.PHARMTHERA.2018.10.004; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MASON RP, 2018, BIOMED PHARMACOTHER, V103, P1231, DOI 10.1016/J.BIOPHA.2018.04.118; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MISRA HP, 1972, J BIOL CHEM, V247, P3170; MOON GJ, 2014, J CLIN NEUROL, V10, P140, DOI 10.3988/JCN.2014.10.2.140; MÜNZEL T, 2017, J AM COLL CARDIOL, V70, P212, DOI 10.1016/J.JACC.2017.05.035; OESTERLE A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537; PARK HJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16050809; PARK J, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0172751; PROFUMO E, 2014, CURR TOP MED CHEM, V14, P2542, DOI 10.2174/1568026614666141203130324; PUCCETTI L, 2011, ATHEROSCLEROSIS, V214, P122, DOI 10.1016/J.ATHEROSCLEROSIS.2010.10.006; QUINTANA-VILLAMANDOS B, 2020, THER ADV CHRONIC DIS, V11; RICHTER RJ, 1999, PHARMACOGENETICS, V9, P745, DOI 10.1097/01213011-199912000-00009; ROTH GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/J.JACC.2020.11.010; SCHEFFER PG, 2013, NETH J MED, V71, P359; SERINI S, 2020, NUTRIENTS, V12, DOI 10.3390/NU12051363; SHAPIRO MD, 2018, CIRC RES, V122, P1420, DOI 10.1161/CIRCRESAHA.118.311227; SIES H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/J.REDOX.2015.01.002; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TISSIER F, 2018, CAN J PHYSIOL PHARM, V96, P1112, DOI 10.1139/CJPP-2018-0085; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; TSIKAS D, 2015, PHARMACOL RES, V94, P1, DOI 10.1016/J.PHRS.2015.01.004; VEGLIA F, 2006, BIOMARKERS, V11, P562, DOI 10.1080/13547500600898623; WAIZ M, 2022, EXCLI J, V21, P47, DOI 10.17179/EXCLI2021-4453; WITKOSARSAT V, 1996, KIDNEY INT, V49, P1304, DOI 10.1038/KI.1996.186; ZHOU YP, 2022, FOOD BIOSCI, V47, DOI 10.1016/J.FBIO.2022.101632","SHENG, X (CORRESPONDING AUTHOR), JIAXING COLL, AFFILIATED HOSP 1, DEPT INFECT DIS, 1882 ZHONGHUAN NAN RD, JIAXING 314000, PEOPLES R CHINA","SOC MEDICAL BIOCHEMISTS SERBIA","ENGLISH","J. MED. BIOCHEM.","ARTICLE","ISI","WOS000954022300013","J MED BIOCHEM","JIAXING COLL;WENZHOU MED UNIV;WENZHOU PEOPLES HOSP;JIAXING COLL;FIRST HOSP JIAXING;WENZHOU MED UNIV","JIAXING COLL",NA,"XIA Z, 2023, J MED BIOCHEM","XIA Z, 2023, J MED BIOCHEM"
"CHU B;QU Y;HE C;QIAN Z","CHU BINGYANG;QU YING;HE CHUAN;QIAN ZHIYONG","PREPARATION CHARACTERIZATION AND APPLICATION OF LONGCHAIN FATTY ALCOHOLBASED POLYMERIC MICELLES",2022,"MATERIALS EXPRESS","12","1277-1286",0,"10.1166/mex.2022.2275","QIAN, ZY (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA HOSP, DEPT HEMATOL, CHENGDU 610041, SICHUAN, PEOPLES R CHINA.; QIAN, ZY (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA HOSP, INST HEMATOL, STATE KEY LAB BIOTHERAPY, CHENGDU 610041, SICHUAN, PEOPLES R CHINA.; QIAN, ZY (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA HOSP, CANC CTR, CHENGDU 610041, SICHUAN, PEOPLES R CHINA.; CHU, BINGYANG; QU, YING; QIAN, ZHIYONG, SICHUAN UNIV, WEST CHINA HOSP, DEPT HEMATOL, CHENGDU 610041, SICHUAN, PEOPLES R CHINA.; CHU, BINGYANG; QU, YING; QIAN, ZHIYONG, SICHUAN UNIV, WEST CHINA HOSP, INST HEMATOL, STATE KEY LAB BIOTHERAPY, CHENGDU 610041, SICHUAN, PEOPLES R CHINA.; CHU, BINGYANG; QU, YING; QIAN, ZHIYONG, SICHUAN UNIV, WEST CHINA HOSP, CANC CTR, CHENGDU 610041, SICHUAN, PEOPLES R CHINA.; HE, CHUAN, GUANGAN PEOPLES HOSP, GUANGAN 638001, SICHUAN, PEOPLES R CHINA.","POLYMERIC MICELLES HAVE BEEN SHOWN TO BE PROMISING CARRIERS FOR DRUG DELIVERY. HOWEVER, THE PRESENT DEVEL-OPED MICELLE CARRIERS ARE USUALLY BASED ON INERT MATERIALS, AND THE POTENTIAL INFLUENCE ON THE BODY STILL NEEDS TO BE FURTHER CONSIDERED. IN THIS WORK, WE SYNTHESIZED A KIND OF POLYMERIC CARRIER BASED ON HYDROPHOBIC LONG CHAIN FATTY ALCOHOL (LCFA), WHICH POSSESSES BENEFICIAL BIOLOGICAL PROPERTIES FOR THE HUMAN BODY. THESE POLY-MERIC CARRIERS COULD SELF-ASSEMBLE TO FORM MICELLES WITH SMALL SIZES. EXCEPT FOR MPEG2K-C24, AND MPEG2K- C26, OTHER POLYMERIC MICELLES SHOWED GOOD BLOOD COMPATIBILITY AND HIGH BIOSAFETY. IN ADDITION, MPEG2K-C28, IP: 203 8 109 20 ON: MON 23 JAN 2023 06:42:07 MPEG2K-C30 AND MPEG2K-C32 MICELLES COULD EFFIIETLY ENCAPSULATE PACLITAXEL (PTX) WITH ABOUT 10\% DRUG COPYR GHT: AMERICAN SCIENTIFIC PUBLISHERS LOADING CONTENT AND >90\% ENCAPSULATION EFFICINCY. OVERALL, OUR PREPARED MPEG-LCFA CONJUGATES MAY HAVE DELIVERED BY INGENTA POTENTIAL CLINICAL APPLICATION PROSPECTS AND DESERVE FURTHER RESEARCH.","MICELLES; LONG CHAIN FATTY ALCOHOL; PEG; PACLITAXEL; DRUG DELIVERY","DRUG-DELIVERY SYSTEM; VITAMIN-E TPGS; NANOMICELLAR CARRIER; PLATELET-AGGREGATION; CANCER-CHEMOTHERAPY; POLICOSANOL; NANOMEDICINE; PACLITAXEL; NANOTECHNOLOGY; NANOCOMPLEXES","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [U21A20417, 82272147, 32271450]; POST -DOC RESEARCH PROJECT, WEST CHINA HOSPITAL, SICHUAN UNIVERSITY [2020HXBH165]","ACKNOWLEDGMENTS: THIS WORK WAS SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (U21A20417, 82272147, 32271450) ; POST -DOC RESEARCH PROJECT, WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (2020HXBH165) .","AFFUSO F, 2012, WORLD J CARDIOL, V4, P77, DOI 10.4330/WJC.V4.I3.77; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; CABRAL H, 2011, NAT NANOTECHNOL, V6, P815, DOI 10.1038/NNANO.2011.166, 10.1038/NNANO.2011.166; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CAREY MP, 1988, PSYCHOL BULL, V104, P307, DOI 10.1037/0033-2909.104.3.307; CHEN MY, 2022, MATER EXPRESS, V12, P592, DOI 10.1166/MEX.2022.2174; CHEN M, 2021, MATER EXPRESS, V11, P1, DOI 10.1166/MEX.2021.1880; CHU BY, 2020, ADV FUNCT MATER, V30, DOI 10.1002/ADFM.202005918; CHU BY, 2016, INT J PHARMACEUT, V500, P345, DOI 10.1016/J.IJPHARM.2016.01.030; CHUNG JE, 2014, NAT NANOTECHNOL, V9, P907, DOI 10.1038/NNANO.2014.208, 10.1038/NNANO.2014.208; FAROKHZAD OC, 2009, ACS NANO, V3, P16, DOI 10.1021/NN900002M; GONG J, 2012, J CONTROL RELEASE, V159, P312, DOI 10.1016/J.JCONREL.2011.12.012; GUO R, 2022, ACTA PHARM SIN B, V12, P467, DOI 10.1016/J.APSB.2021.05.012; HE H., 2022, MEDCOMM BIOMATERIALS, V2, PE22; HE MM, 2023, CHINESE CHEM LETT, V34, DOI 10.1016/J.CCLET.2022.05.088; HE ZY, 2014, INT J PHARMACEUT, V469, P168, DOI 10.1016/J.IJPHARM.2014.04.056; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IWAMOTO T, 2013, BIOL PHARM BULL, V36, P715, DOI 10.1248/BPB.B12-01102; JACKSON MA, 2006, J SUPERCRIT FLUID, V37, P173, DOI 10.1016/J.SUPFLU.2005.08.008; JAIN RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/NRCLINONC.2010.139; LI HL, 2019, CHINESE CHEM LETT, V30, P1083, DOI 10.1016/J.CCLET.2019.01.003; LIU R, 2023, CHINESE CHEM LETT, V34, DOI 10.1016/J.CCLET.2022.05.032; LU JQ, 2013, BIOMATERIALS, V34, P1591, DOI 10.1016/J.BIOMATERIALS.2012.10.073; MAO LC, 2021, RESEARCH-CHINA, V2021, DOI 10.34133/2021/9784053; MARAZZI G, 2011, ADV THER, V28, P1105, DOI 10.1007/S12325-011-0082-5; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; OUN R, 2018, DALTON T, V47, P6645, DOI 10.1039/C8DT00838H; PAN Y, 2022, CHINESE CHEM LETT, V33, P2486, DOI 10.1016/J.CCLET.2021.12.093; PARK K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/J.JCONREL.2007.05.003; QU Y, 2017, J BIOMED NANOTECHNOL, V13, P1598, DOI 10.1166/JBN.2017.2475; SHAN SB, 2019, J BIOMED NANOTECHNOL, V15, P674, DOI 10.1166/JBN.2019.2721; SHU XM, 2019, COLLOID SURFACE B, V182, DOI 10.1016/J.COLSURFB.2019.110356; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WAGNER V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/NBT1006-1211; WATANABE T, 2002, LIFE SCI, V70, P2215, DOI 10.1016/S0024-3205(01)01536-3; WU WC, 2021, RESEARCH-CHINA, V2021, DOI 10.34133/2021/9769867; XIONG Y, 2019, INT J PHARMACEUT, V572, DOI 10.1016/J.IJPHARM.2019.118823; YANG CL, 2018, THERANOSTICS, V8, P464, DOI 10.7150/THNO.22711; YANG K, 2021, MATER EXPRESS, V11, P781, DOI 10.1166/MEX.2021.1979; YI Y, 2018, MAT SCI ENG C-MATER, V83, P218, DOI 10.1016/J.MSEC.2017.10.004; YONGVONGSOONTORN N, 2019, ACS NANO, V13, P7591, DOI 10.1021/ACSNANO.9B00467; YU L, 2021, ACTA PHARM SIN B, V11, P2004, DOI 10.1016/J.APSB.2021.02.001; YU P, 2021, CHINESE CHEM LETT, V32, P2127, DOI 10.1016/J.CCLET.2021.02.015; ZHANG XL, 2013, BIOCONJUGATE CHEM, V24, P464, DOI 10.1021/BC300608H; ZHANG ZP, 2012, BIOMATERIALS, V33, P4889, DOI 10.1016/J.BIOMATERIALS.2012.03.046; ZHU ZJ, 2019, J BIOMED NANOTECHNOL, V15, P1515, DOI 10.1166/JBN.2019.2797","QIAN, ZY (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA HOSP, DEPT HEMATOL, CHENGDU 610041, SICHUAN, PEOPLES R CHINA","AMER SCIENTIFIC PUBLISHERS","ENGLISH","MATER. EXPRESS","ARTICLE","ISI","WOS000924071100005","MATER EXPRESS","SICHUAN UNIV;SICHUAN UNIV;SICHUAN UNIV;SICHUAN UNIV;SICHUAN UNIV;SICHUAN UNIV;GUANGAN PEOPLES HOSP","SICHUAN UNIV",NA,"CHU B, 2022, MATER EXPRESS","CHU B, 2022, MATER EXPRESS"
"ELNAGAR G;ELSEWEIDY M;ELKOMY N;KESHAWY M;FATHY O;SOBH M;MAHMOUD Y","ELNAGAR GEHAD M;ELSEWEIDY MOHAMED M;ELKOMY NESREEN M I M;KESHAWY MOHAMMED M;FATHY OLA M;SOBH MOHAMMED S; MAHMOUD YASMIN K","POLICOSANOL AMELIORATES RENAL INFLAMMATION AND PYROPTOSIS IN HYPERCHOLESTEROLEMIC RABBITS IVIAI MODULATION OF HMGB1PI3KMTORNLRP3CASPASE1 PATHWAY",2022,"JOURNAL OF FUNCTIONAL FOODS","97",NA,1,"10.1016/j.jff.2022.105250","ELSEWEIDY, MM (CORRESPONDING AUTHOR), ZAGAZIG UNIV, FAC PHARM, BIOCHEM DEPT, ZAGAZIG 44519, EGYPT.; ELNAGAR, GEHAD M.; ELSEWEIDY, MOHAMED M.; MAHMOUD, YASMIN K., ZAGAZIG UNIV, FAC PHARM, BIOCHEM DEPT, ZAGAZIG, EGYPT.; ELKOMY, NESREEN M. I. M., ZAGAZIG UNIV, FAC PHARM, PHARMACOL \& TOXICOL DEPT, ZAGAZIG, EGYPT.; KESHAWY, MOHAMMED M., SUEZ CANAL UNIV, FAC MED, INTERNAL MED DEPT, ISMAILIA, EGYPT.; FATHY, OLA M., ZAGAZIG UNIV, ZAGAZIG UNIV HOSP, ZAGAZIG, EGYPT.; SOBH, MOHAMMED S., ZAGAZIG UNIV, FAC VET MED, PATHOL DEPT, ZAGAZIG, EGYPT.; ELSEWEIDY, MOHAMED M., ZAGAZIG UNIV, FAC PHARM, BIOCHEM DEPT, ZAGAZIG 44519, EGYPT.","HYPERLIPIDEMIA REPRESENTS A MAJOR RISK FACTOR FOR CARDIOVASCULAR AND RENAL DISEASES. THIS STUDY AIMED TO DEMONSTRATE THE POSSIBLE AMELIORATING EFFECTS OF POLICOSANOL (PC) ON RENAL INFLAMMATION AND PYROPTOSIS. EIGHTEEN MALE NEW ZEALAND RABBITS WERE RANDOMLY DIVIDED INTO 3 GROUPS (N = 6/GROUP), ONE RECEIVED NORMAL CHOW DIET FOR 12 WEEKS WHILE THE OTHERS RECEIVED EITHER 0.5 \% W/W HIGH CHOLESTEROL DIET (HCD) OR HCD AND CONCURRENTLY TREATED WITH PC (5 MG/KG BODY WEIGHT/DAY) FOR 12 WEEKS. RABBITS FED WITH HCD SHOWED SIGNIFICANT INCREASES IN BODY AND KIDNEY WEIGHTS; RENAL DYSFUNCTION, DYSLIPIDEMIA, OXIDATIVE STRESS STATUS, ELEVATED LEVELS OF OXIDIZED LOW DENSITY LIPOPROTEIN (OX-LDL) AND RENAL HIGH-MOBILITY GROUP BOX 1 (HMGB1). THESE INCREASES WERE ACCOMPANIED WITH UP-REGULATION OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3K)/MAMMALIAN TARGET OF RAPAMYCIN (MTOR) SIGNALING IN RENAL TISSUE AND ACTIVATION OF NOD-LIKE RECEPTOR, PYRIN DOMAIN-CONTAINING-3 (NLRP3) INFLAMMASOME. ADMINIS-TRATION OF PC CONCURRENTLY WITH HCD SIGNIFICANTLY MODULATED THE HCD-INDUCED ACTIVATION OF OX-LDL/HMGB1/ PI3K/MTOR/NLRP3/CASPASE-1 SIGNALING PATHWAY AND SUBSEQUENTLY ATTENUATED THE RESULTED RENAL INJURY.","POLICOSANOL; RENAL INFLAMMATION; PYROPTOSIS; HMGB1; NLRP3; CASPASE 1","GENE-EXPRESSION; ACTIVATION; INJURY; PROTEIN; NLRP3; CALCIFICATION; MECHANISMS; INHIBITOR; ACID","FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY","THE AUTHORS ACKNOWLEDGE THE SUPPORT PROVIDED BY THE FACULTY OF PHARMACY, ZAGAZIG UNIVERSITY FOR THE USE OF THE ANIMAL UNIT FACILITY AND RESEARCH LABORATORIES","ASKARPOUR M, 2019, COMPLEMENT THER MED, V45, P89, DOI 10.1016/J.CTIM.2019.05.023; BROZ P, 2015, NATURE, V526, P642, DOI 10.1038/NATURE15632; CHADE AR, 2002, CIRCULATION, V106, P1165, DOI 10.1161/01.CIR.0000027105.02327.48; CHATAURET N, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-76; CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; COIMBRA TM, 2000, KIDNEY INT, V57, P167, DOI 10.1046/J.1523-1755.2000.00836.X; DAS S, 2006, CLIN CHIM ACTA, V372, P202, DOI 10.1016/J.CCA.2006.03.016; DRURY RAB, 1980, CARLETON'S HISTOLOGICAL TECHNIQUE, V5TH; DUARTE MMMF, 2009, CLIN BIOCHEM, V42, P666, DOI 10.1016/J.CLINBIOCHEM.2009.01.010; ELSEWEIDY MM, 2018, J CARDIOVASC PHARM T, V23, P551, DOI 10.1177/1074248418775377; ELSEWEIDY MM, 2016, EXP BIOL MED, V241, P1943, DOI 10.1177/1535370216659943; GAMEZ R, 2005, DRUGS R D, V6, P11; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HANEKLAUS M, 2015, IMMUNOL REV, V265, P53, DOI 10.1111/IMR.12285; HONDA H, 2014, J LEUKOCYTE BIOL, V96, P1087, DOI 10.1189/JLB.3A0114-005RR; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JOLES JA, 2000, J AM SOC NEPHROL, V11, P669, DOI 10.1681/ASN.V114669; KAY CD, 2010, J NUTR, V140, P1093, DOI 10.3945/JN.109.117366; KOKA S, 2017, REDOX BIOL, V13, P336, DOI 10.1016/J.REDOX.2017.06.004; LAMKANFI M, 2014, CELL, V157, P1013, DOI 10.1016/J.CELL.2014.04.007; LI JP, 2021, ANN TRANSL MED, V9, DOI 10.21037/ATM-20-7973; LI RT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/FIMMU.2020.01104; LI XF, 2016, CELL PHYSIOL BIOCHEM, V39, P1850, DOI 10.1159/000447884; MIAO NJ, 2019, KIDNEY INT, V96, P1105, DOI 10.1016/J.KINT.2019.04.035; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PRYOR JB, 2019, DRUGS THER PERSPECT, V35, P431, DOI 10.1007/S40267-019-00646-4; RAJAMANNAN NM, 2005, HEART, V91, P806, DOI 10.1136/HRT.2003.029785; ROH DD, 1998, AM J NEPHROL, V18, P344, DOI 10.1159/000013363; RUAN XZ, 2008, KIDNEY INT, V74, P407, DOI 10.1038/KI.2008.226; SASTRE C, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0083713; SHAHZAD K, 2015, KIDNEY INT, V87, P74, DOI 10.1038/KI.2014.271; SHAO BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/FPHAR.2015.00262; SHATTAT G.F., 2015, BIOMED PHARMACOL J, V7, P399, DOI 10.13005/BPJ/504; SHEN JJ, 2019, J FUNCT FOODS, V57, P351, DOI 10.1016/J.JFF.2019.04.024; STEVENSON FT, 2001, KIDNEY INT, V59, P2062, DOI 10.1046/J.1523-1755.2001.0590062062.X; SUVARNA K.S., 2018, BANCROFT'S THEORY AND PRACTICE OF HISTOLOGICAL TECHNIQUES; THOMSON AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/NRI2546; VANSTHERTEM D, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/193259; VIOLA F, 2008, MEDITERR J NUTR META, V1, P77, DOI 10.1007/S12349-008-0019-Y; XI H, 2016, CIRC RES, V118, P1525, DOI 10.1161/CIRCRESAHA.116.308501; YU XF, 2012, ACTA BIOCH BIOPH SIN, V44, P746, DOI 10.1093/ABBS/GMS059; ZHAN J, 2016, INT J MOL SCI, V17, DOI 10.3390/IJMS17101647; ZHANG XM, 2021, BMC GERIATR, V21, DOI 10.1186/S12877-021-02138-5; ZHANG Y, 2015, ANTIOXID REDOX SIGN, V22, P1084, DOI 10.1089/ARS.2014.5978; ZHENG J, 2022, FREE RADICAL RES, P1, DOI DOI 10.1080/10715762.2022.2032021","ELSEWEIDY, MM (CORRESPONDING AUTHOR), ZAGAZIG UNIV, FAC PHARM, BIOCHEM DEPT, ZAGAZIG 44519, EGYPT","ELSEVIER","ENGLISH","J. FUNCT. FOOD.","ARTICLE","ISI","WOS000864451700002","J FUNCT FOOD","ZAGAZIG UNIV;ZAGAZIG UNIV;ZAGAZIG UNIV;SUEZ CANAL UNIV;ZAGAZIG UNIV;ZAGAZIG UNIV;ZAGAZIG UNIV","ZAGAZIG UNIV",NA,"ELNAGAR GM, 2022, J FUNCT FOOD","ELNAGAR GM, 2022, J FUNCT FOOD"
"TEIXEIRA F;PIMENTEL L;VIDIGAL S;P. P;COSTA P;PINTADO M;RODRIGUEZ-ALCALA ;LUIS M L","TEIXEIRA FRANCISCA S;PIMENTEL LIGIA L;VIDIGAL SUSANA S M; P;COSTA PAULA T;PINTADO MANUELA E;RODRIGUEZ-ALCALA; LUIS M","SUITABILITY OF SOLVENTASSISTED EXTRACTION FOR RECOVERY OF LIPOPHILIC PHYTOCHEMICALS IN SUGARCANE STRAW AND BAGASSE",2022,"FOODS","11",NA,3,"10.3390/foods11172661","RODRÍGUEZ-ALCALÁ, LM (CORRESPONDING AUTHOR), UNIV CATOLICA PORTUGUESA, CBQF CTR BIOTECNOL \& QUIM FINA, LAB ASSOCIADO, ESCOLA SUPER BIOTECNOL, RUA DIOGO BOTELHO 1327, P-4169005 PORTO, PORTUGAL.; TEIXEIRA, FRANCISCA S.; PIMENTEL, LIGIA L.; VIDIGAL, SUSANA S. M. P.; COSTA, PAULA T.; PINTADO, MANUELA E.; RODRIGUEZ-ALCALA, LUIS M., UNIV CATOLICA PORTUGUESA, CBQF CTR BIOTECNOL \& QUIM FINA, LAB ASSOCIADO, ESCOLA SUPER BIOTECNOL, RUA DIOGO BOTELHO 1327, P-4169005 PORTO, PORTUGAL.","SUGARCANE IS PRIMARILY HARVESTED TO MEET UP TO 80\% OF GLOBAL SUGAR DEMAND. RECENTLY, LIPIDS RECOVERED FROM THEIR BIOMASS (STRAW AND BAGASSE) HAVE ATTRACTED MUCH ATTENTION DUE TO THEIR POSSIBLE UTILISATION IN BIOFUEL PRODUCTION BUT ALSO BY THE PRESENCE OF HEALTH-PROMOTING COMPOUNDS AS PHYTOSTEROLS (I.E., IMPROVEMENT OF CARDIOVASCULAR FUNCTION) OR 1-OCTACOSANOL (I.E., ANTI-OBESITY). ALTHOUGH THIS FRACTION IS COMMONLY OBTAINED THROUGH SOLID-LIQUID ISOLATION, THERE IS SCARCE INFORMATION ABOUT HOW DIFFERENT SOLVENTS AFFECT THE COMPOSITION OF THE EXTRACTS. THIS RESEARCH WORK AIMED TO STUDY WHETHER, IN SUGARCANE STRAW AND BAGASSE SAMPLES, SOXTEC EXTRACTION WITH WIDELY USED DICHLOROMETHANE (DCM) WOULD BE SUITABLE TO RECOVER MOST OF THE LIPID CLASSES WHEN COMPARED TO OTHER AVAILABLE SOLVENTS SUCH AS FOOD GRADE ETHANOL (ETOH) OR SOLVENTS WITHOUT REGULATION RESTRICTIONS FOR FOOD AND DRUG APPLICATIONS (I.E., ACETONE AND ETHYL ACETATE). THE OBTAINED RESULTS ALLOW CONCLUDING THAT SUGARCANE WAXES FROM STRAW AND BAGASSE ARE COMPLEX LIPID MIXTURES OF POLAR AND NON-POLAR COMPOUNDS. ACCORDING TO THE EXTRACTION YIELD, THE BEST RESULTS WERE OBTAINED WITH ETHANOL (5.12 +/ - 0.30\% AND 1.97 +/- 0.31\%) FOR BOTH STRAW AND BAGASSE, RESPECTIVELY. THE EXTRACTANT GREATLY INFLUENCED THE LIPID COMPOSITION OF THE OBTAINED PRODUCT. THUS, DCM ENRICHED THE ISOLATES IN GLYCEROLIPIDS (MONO-, DI - AND TRIGLYCERIDES), FREE FATTY ACIDS, FATTY ALCOHOLS, FATTY ALDEHYDES, PHYTOSTEROLS AND HYDROCARBONS. ON THE OTHER HAND, ETOH RESULTED IN POLAR ISOLATES RICH IN GLYCOLIPIDS. THEREFORE, DEPENDING ON THE APPLICATION AND OBJECTIVES OF FUTURE RESEARCH STUDIES, THE SOLVENT TO RECOVER SUCH LIPIDS NEEDS TO BE CAREFULLY SELECTED.","SUGARCANE; STRAW; BAGASSE; LIPIDS; GLYCOLIPIDS; 1-OCTACOSANOL; PHYTOSTEROLS; ETHANOL","LIPID EXTRACTION; POLICOSANOL; FAT","UNIVERSIDADE CATOLICA PORTUGUESA-ESCOLA SUPERIOR DE BIOTECNOLOGIA [POCI-01 0247-FEDER-027578]; AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA","THIS WORK WAS SUPPORTED BY AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA AND UNIVERSIDADE CATOLICA PORTUGUESA-ESCOLA SUPERIOR DE BIOTECNOLOGIA THROUGH ALCHEMY PROJECT, CAPTURING HIGH VALUE FROM INDUSTRIAL FERMENTATION BIO PRODUCTS (POCI-01 0247-FEDER-027578).","ABREU S, 2017, J CHROMATOGR A, V1514, P54, DOI 10.1016/J.CHROMA.2017.07.063; ANONYMOUS, 2020, FOOD OUTLOOK: BIANNUAL REPORT ON GLOBAL FOOD MARKETS; ANONYMOUS, 2018, COMMITTEE HUMAN MED; ANONYMOUS, 2016, FAOSTAT STAT DAT; ANONYMOUS, 2010, OFF J EUR COMMUNIT L, V341, P1; ANONYMOUS, 2012, OFFICIAL JOURNAL OF THE EUROPEAN UNION L, V136, P1, DOI DOI 10.1016/B978-0-08-100922-2.00001-2; ARORA A, 2020, APPL ENERG, V280, DOI 10.1016/J.APENERGY.2020.115933; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; ATTARD TM, 2015, IND CROP PROD, V76, P95, DOI 10.1016/J.INDCROP.2015.05.077; BELL J, 2018, NEW BIOTECHNOL, V40, P25, DOI 10.1016/J.NBT.2017.06.010; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALDERÓN C, 2019, ANAL CHIM ACTA, V1048, P66, DOI 10.1016/J.ACA.2018.10.035; CASAS L, 2015, J CHEM-NY, V2015, DOI 10.1155/2015/946462; CASTRO-GÓMEZ P, 2016, FOOD CHEM, V212, P695, DOI 10.1016/J.FOODCHEM.2016.06.030; CEQUIER-SÁNCHEZ E, 2008, J AGR FOOD CHEM, V56, P4297, DOI 10.1021/JF073471E; COME B, 2021, J COLLOID INTERF SCI, V582, P669, DOI 10.1016/J.JCIS.2020.08.027; D'AMATO D, 2017, J CLEAN PROD, V168, P716, DOI 10.1016/J.JCLEPRO.2017.09.053; DEL RÍO JC, 2015, IND CROP PROD, V77, P992, DOI 10.1016/J.INDCROP.2015.09.064; DOTANIYA M. L., 2016, INTERNATIONAL JOURNAL OF RECYCLING OF ORGANIC WASTE IN AGRICULTURE, V5, P185, DOI 10.1007/S40093-016-0132-8; ELSEWEIDY MM, 2016, EXP BIOL MED, V241, P1943, DOI 10.1177/1535370216659943; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLADKOWSKI W, 2012, J AM OIL CHEM SOC, V89, P179, DOI 10.1007/S11746-011-1893-X; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HUANG H, 2017, BIOCATAL AGRIC BIOTE, V10, P148, DOI 10.1016/J.BCAB.2017.03.003; HUANG HB, 2016, BIOFUEL BIOPROD BIOR, V10, P299, DOI 10.1002/BBB.1640; INARKAR M.B., 2012, ISRN AGRONOMY, DOI DOI 10.5402/2012/340158, 10.5402/2012/340158; ISHAKA A, 2014, INT J NANOMED, V9, P2261, DOI 10.2147/IJN.S56999; KALISCH B, 2016, SUBCELL BIOCHEM, V86, P51, DOI 10.1007/978-3-319-25979-6\_3; KAUSHIK MK, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-08874-2; LEE SH, 2019, INT J SPORT PHYSIOL, V14, P1297, DOI 10.1123/IJSPP.2018-0704; LUTHRIA D.L., 2019, SOXTEC ITS PRINCIPLE, V11, P24; LYTOVCHENKO A, 2009, PLANT METHODS, V5, DOI 10.1186/1746-4811-5-4; MEGHANA M, 2020, BIORESOURCE TECHNOL, V303, DOI 10.1016/J.BIORTECH.2020.122929; OLIVEIRA RMA, 2022, SUSTAIN CHEM PHARM, V27, DOI 10.1016/J.SCP.2022.100657; PARAJULI S, 2020, GCB BIOENERGY, V12, P476, DOI 10.1111/GCBB.12684; PIMENTEL L, 2018, ELECTROPHORESIS, V39, P1835, DOI 10.1002/ELPS.201700425; PIMENTEL L, 2016, J ANAL METHODS CHEM, V2016, DOI 10.1155/2016/9827369; RANDALL EL, 1974, J ASSOC OFF ANA CHEM, V57, P1165; REIS A, 2013, J LIPID RES, V54, P1812, DOI 10.1194/JLR.M034330; RUEDA-ORDÓÑEZ YJ, 2016, BIORESOURCE TECHNOL, V211, P231, DOI 10.1016/J.BIORTECH.2016.03.035; SAUER M, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/FEMSLE/FNW134; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SINGH A, 2015, PHARMACOGN RES, V7, P85, DOI 10.4103/0973-7847.156340, 10.4103/0974-8490.147215; SOCRATES G., 2001, INFRARED RAMAN CHARA, V3RD; SUN L, 2021, FOOD MICROBIOL, V95, DOI 10.1016/J.FM.2020.103683; THIEX NJ, 2003, J AOAC INT, V86, P888; UNITED NATIONS DEPARTMENT OF ECONOMIC AND SOCIAL AFFAIRS, PD WORLD POP 2019","RODRÍGUEZ-ALCALÁ, LM (CORRESPONDING AUTHOR), UNIV CATOLICA PORTUGUESA, CBQF CTR BIOTECNOL \& QUIM FINA, LAB ASSOCIADO, ESCOLA SUPER BIOTECNOL, RUA DIOGO BOTELHO 1327, P-4169005 PORTO, PORTUGAL","MDPI","ENGLISH","FOODS","ARTICLE","ISI","WOS000852541100001","FOODS","UNIV CATOLICA PORTUGUESA;UNIV CATOLICA PORTUGUESA","UNIV CATOLICA PORTUGUESA",NA,"TEIXEIRA FS, 2022, FOODS","TEIXEIRA FS, 2022, FOODS"
"LEE H;WOO S;AHN H;YANG J;LEE M;KIM H;SONG S;LEE ;JIN-HWAN J;SEO W","LEE HAN-GYEOL;WOO SO-YEUN;AHN HYUNG-JAE;YANG JI-YEONG;LEE MI-JA;KIM HYUN-YOUNG;SONG SEUNG-YEOB;LEE; JIN-HWAN;SEO WOO-DUCK","COMPARATIVE ANALYSIS OF POLICOSANOLS RELATED TO GROWTH TIMES FROM THE SEEDLINGS OF VARIOUS KOREAN OAT IAVENA SATIVAI L CULTIVARS AND SCREENING FOR ADENOSINE 5MONOPHOSPHATEACTIVATED PROTEIN KINASE AMPK ACTIVATION",2022,"PLANTS-BASEL","11",NA,5,"10.3390/plants11141844","SEO, WD (CORRESPONDING AUTHOR), RURAL DEV ADM, CROP FDN RES DIV, NATL INST CROP SCI, JEOLLABUK DO 55365, WANJU GUN, SOUTH KOREA.; LEE, JH (CORRESPONDING AUTHOR), DONG A UNIV, DEPT LIFE RESOURCES IND, COLL NAT RESOURCES \& LIFE SCI, 37 NAKDONG DAERO 550 BEON GIL, BUSAN 49315, SOUTH KOREA.; LEE, HAN-GYEOL; AHN, HYUNG-JAE; YANG, JI-YEONG; LEE, MI-JA; KIM, HYUN-YOUNG; SONG, SEUNG-YEOB; SEO, WOO-DUCK, RURAL DEV ADM, CROP FDN RES DIV, NATL INST CROP SCI, JEOLLABUK DO 55365, WANJU GUN, SOUTH KOREA.; LEE, HAN-GYEOL, JEONBUK NATL UNIV, COLL NAT SCI, DIV LIFE SCI, 567 BAEKJE DAERO, JEONJU 54896, SOUTH KOREA.; WOO, SO-YEUN, KOREA RES INST BIOSCI \& BIOTECHNOL, NAT MED RES CTR, CHUNGCHEONGBUK DO 28116, CHEONGJU SI, SOUTH KOREA.; AHN, HYUNG-JAE, GYEONGSANG NATL UNIV, DEPT AGBIOTECHNOL \& NAT RESOURCES, COLL AGR \& LIFE SCI, JINJU 52828, SOUTH KOREA.; LEE, JIN-HWAN, DONG A UNIV, DEPT LIFE RESOURCES IND, COLL NAT RESOURCES \& LIFE SCI, 37 NAKDONG DAERO 550 BEON GIL, BUSAN 49315, SOUTH KOREA.","THE OBJECTIVES OF THIS RESEARCH WERE TO EVALUATE THE POLICOSANOL PROFILES AND ADENOSINE-5'-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK) PROPERTIES IN THE SEEDLINGS OF KOREAN OAT (AVENA SATIVA L.) CULTIVARS AT DIFFERENT GROWTH TIMES. NINE POLICOSANOLS IN THE SILYLATED HEXANE EXTRACTS WERE DETECTED USING GC-MS AND THEIR CONTENTS SHOWED CONSIDERABLE DIFFERENCES; SPECIFICALLY, HEXACOSANOL (6) EXHIBITED THE HIGHEST COMPOSITION, CONSTITUTING 88-91\% OF THE TOTAL AVERAGE CONTENT. MOREOVER, THE AVERAGE HEXACOSANOL (6) CONTENTS SHOWED REMARKABLE VARIATIONS OF 337.8 (5 DAYS) -> 416.8 (7 DAYS) -> 458.9 (9 DAYS) -> 490.0 (11 DAYS) -> 479.2 (13 DAYS) -> 427.0 MG/100 G (15 DAYS). THE SEEDLINGS COLLECTED AT 11 DAYS SHOWED THE HIGHEST AVERAGE POLICOSANOL CONTENT (541.7 MG/100 G), WITH THE LOWEST CONTENT BEING 383.4 MG/100 G AFTER 5 DAYS. INTERESTINGLY, POLICOSANOLS FROM OAT SEEDLINGS GROWN FOR 11 DAYS INDUCED THE MOST PREVALENT PHENOTYPE OF AMPK ACTIVATION IN HEPG2 CELLS, INDICATING THAT POLICOSANOLS ARE AN EXCELLENT AMPK ACTIVATOR.","OAT SEEDLING; POLICOSANOL; HEXACOSANOL; AMPK; GROWTH TIMES; GC-MS","CHOLESTEROL; ALCOHOLS","RURAL DEVELOPMENT ADMINISTRATION (RDA), KOREA [PJ01421201]","THIS RESEARCH WAS FUNDED BY RURAL DEVELOPMENT ADMINISTRATION (RDA), KOREA. PROJECT TITLE: ENHANCEMENT OF SECONDARY METABOLITES FROM CROP SPROUTS AND THEIR IMPROVED EFFECTS AGAINST ATOPY AND ALOPECIA DISEASE, PROJECT NO. PJ01421201.","AHMED S., 2013, INT J ENDORSING HLTH, V1, P62, DOI 10.29052/IJEHSR.V1.I2.2013.62-65, DOI 10.29052/IJEHSR.V1.I2.2013.62-65; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CHEN YF, 2013, J CEREAL SCI, V57, P258, DOI 10.1016/J.JCS.2012.12.002; CHOI SJ, 2016, FOOD CHEM, V204, P94, DOI 10.1016/J.FOODCHEM.2016.02.027; DARZIAN ROSTAMI Z, 2020, ARCH RAZI INST, V75, P249, DOI 10.22092/ARI.2019.124805.1288, 10.22092/ARI.2019.124805.1288; FENG B, 2013, J ZHEJIANG UNIV-SC B, V14, P97, DOI 10.1631/JZUS.B1200159; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; JANG YEON-SU, 2019, NATURAL PRODUCT SCIENCES, V25, P293, DOI 10.20307/NPS.2019.25.4.293; LEE JH, 2017, NUTR RES, V43, P89, DOI 10.1016/J.NUTRES.2017.05.013; LEE JH, 2015, FOOD RES INT, V72, P174, DOI 10.1016/J.FOODRES.2015.03.041; LEE JH, 2016, J FUNCT FOODS, V26, P667, DOI 10.1016/J.JFF.2016.08.034; LIU B, 2018, J FUNCT FOODS, V41, P72, DOI 10.1016/J.JFF.2017.12.045; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; RA JE, 2020, FOOD CHEM, V317, DOI 10.1016/J.FOODCHEM.2020.126388; RAVELO Y, 2011, J NAT MED-TOKYO, V65, P330, DOI 10.1007/S11418-010-0496-4; SEO WD, 2013, J AGR FOOD CHEM, V61, P1117, DOI 10.1021/JF3041879; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; WOO SY, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/J.BMCL.2020.127250","SEO, WD (CORRESPONDING AUTHOR), RURAL DEV ADM, CROP FDN RES DIV, NATL INST CROP SCI, JEOLLABUK DO 55365, WANJU GUN, SOUTH KOREA","MDPI","ENGLISH","PLANTS-BASEL","ARTICLE","ISI","WOS000831917900001","PLANTS-BASEL","NATL INST CROP SCI;DONG A UNIV;NATL INST CROP SCI;JEONBUK NATL UNIV;KOREA RES INST BIOSCI AND BIOTECHNOL;GYEONGSANG NATL UNIV;DONG A UNIV","NATL INST CROP SCI",NA,"LEE HG, 2022, PLANTS-BASEL","LEE HG, 2022, PLANTS-BASEL"
"SUN L;LI X;MA C;HE Z;ZHANG X;WANG C;ZHAO M;GAN J;FENG Y","SUN LONG;LI XIAN;MA CHENJING;HE ZHAO;ZHANG XIN; WANG CHENGYE;ZHAO MIN;GAN JIN;FENG YING","IMPROVING EFFECT OF THE POLICOSANOL FROM IERICERUS PELAI WAX ON LEARNING AND MEMORY IMPAIRMENT CAUSED BY SCOPOLAMINE IN MICE",2022,"FOODS","11",NA,9,"10.3390/foods11142095","FENG, Y (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, NATL FORESTRY \& GRASSLAND ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA.; SUN, LONG; LI, XIAN; MA, CHENJING; HE, ZHAO; ZHANG, XIN; WANG, CHENGYE; ZHAO, MIN; GAN, JIN; FENG, YING, CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, NATL FORESTRY \& GRASSLAND ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA.","POLICOSANOL (PC) IS A MIXTURE OF LONG-CHAIN FATTY ALCOHOLS THAT EXHIBITS MULTIPLE BIOLOGICAL ACTIVITIES, SUCH AS REDUCING BLOOD LIPID AND CHOLESTEROL LEVELS, LOWERING BLOOD PRESSURE, AND EXTENUATING LIVER INFLAMMATION. TO ASSESS PC'S IMPACT ON COGNITIVE BEHAVIOR AND FUNCTION, PC WAS PREPARED FROM ERICERUS PELA WAX USING A REDUCTION METHOD AND ANALYZED USING GAS CHROMATOGRAPHY (GC). A TOTAL OF 60 MICE WERE RANDOMLY DIVIDED INTO SIX GROUPS OF 10 ANIMALS EACH: CONTROL (0.5\% CMC-NA SOLUTION, I.G.), MODEL (0.5\% CMC-NA SOLUTION, I.G.), DONEPEZIL (3 MG/KG, I.G.), PC LOW- (2 G/KG, I.G.), MEDIUM (4 G/KG, I.G.), AND HIGH - (6 G/KG, I.G.) DOSE GROUPS. ALL THE GROUPS WERE ADMINISTERED DAILY FOR 28 CONSECUTIVE DAYS. THERE WERE FOUR PARAMETERS-ESCAPE LATENCY, CROSSINGS OF PLATFORM, SWIMMING DISTANCE, AND TIME SPENT IN THE TARGET QUADRANT-THAT WERE RECORDED TO EVALUATE THE COGNITIVE PERFORMANCE OF MICE IN THE MORRIS WATER MAZE (MWM). AFTER MWM TESTING, THE LEVELS OF ACETYLCHOLINE (ACH), ACETYLCHOLINESTERASE (ACHE), SUPEROXIDE DISMUTASE (SOD), MALONDIALDEHYDE (MDA), AND GLUTATHIONE (GSH) THAT WERE PRESENT IN BRAIN TISSUE WERE DETERMINED USING ASSAY KITS. THE GC DATA SHOWED THAT PC CONSISTED OF FOUR MAJOR COMPONENTS: TETRACOSANOL (14.40\%), HEXACOSANOL (48.97\%), OCTACOSANOL (25.40\%), AND TRIACONTANOL (4.80\%). IN THE MWM TEST, PC SIGNIFICANTLY DECREASED THE ESCAPE LATENCY (P < 0.05) AND INCREASED THE CROSSINGS OF THE PLATFORM (P < 0.05) AND SWIMMING DISTANCE (P < 0.05) AND TIME IN THE TARGET QUADRANT (P < 0.05) IN RODENTS COMPARED TO THAT IN THE MODEL GROUP. MOREOVER, PC INCREASED THE LEVELS OF ACH, SOD, AND GSH; INHIBITED ACHE; AND REDUCED MDA IN THE BRAIN TISSUE OF THE TESTED ANIMALS. THIS IS THE FIRST REPORT TO EVALUATE THE EFFICACY OF PC FOR COGNITIVE BEHAVIOR AND FUNCTION IN ANIMALS. OUR FINDINGS DEMONSTRATE THAT PC FROM E. PELA WAX IS LIKELY TO EXERT AN ENHANCING EFFECT ON LEARNING AND MEMORY BY PROMOTING THE CHOLINERGIC SYSTEM AND ATTENUATING OXIDATIVE STRESS, WHICH WILL PROVIDE A NEW INSIGHT INTO THE EFFICACY OF PC AND EXPAND ITS APPLICATION IN THE FOOD, NUTRACEUTICAL, AND BEVERAGE INDUSTRIES.","ERICERUS PELA WAX; POLICOSANOL; ALZHEIMER'S DISEASE; MORRIS WATER MAZE; COGNITIVE IMPAIRMENT; CHOLINERGIC SYSTEM; OXIDATIVE STRESS","CHAIN FATTY ALCOHOL; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ANTIOXIDANTS; OCTACOSANOL; METABOLISM","FUNDAMENTAL RESEARCH FUNDS OF CHINESE ACADEMY OF FORESTRY [CAFYBB2019SZ005, CAFYBB2018ZB007]","THIS STUDY WAS FINANCIALLY SUPPORTED BY THE FUNDAMENTAL RESEARCH FUNDS OF CHINESE ACADEMY OF FORESTRY (NO. CAFYBB2019SZ005, NO. CAFYBB2018ZB007).","ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ASKARPOUR M, 2019, COMPLEMENT THER MED, V45, P89, DOI 10.1016/J.CTIM.2019.05.023; AZZOUZ M, 1996, EXP NEUROL, V138, P189, DOI 10.1006/EXNR.1996.0057; BARNHAM KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/NRD1330; BORG J, 1990, BRAIN RES, V518, P295, DOI 10.1016/0006-8993(90)90985-K; BOUAYED J, 2010, OXID MED CELL LONGEV, V3, P228, DOI 10.4161/OXIM.3.4.12858; CASETTA I, 2005, CURR PHARM DESIGN, V11, P2033, DOI 10.2174/1381612054065729; CHEN XIAO-MING, 2007, ACTA ENTOMOLOGICA SINICA, V50, P136; DENG L, 2014, PROG BIOCHEM BIOPHYS, V41, P1207, DOI 10.3724/SP.J.1206.2013.00453; DU XG, 2018, TRANSL NEURODEGENER, V7, DOI 10.1186/S40035-018-0107-Y; FRÖLICH L, 2002, J NEURAL TRANSM, V109, P1003, DOI 10.1007/S007020200083; GUO Z., 2001, WORLD NOTES PLANT ME, V16, P231; HAMPEL H, 2019, JPAD-J PREV ALZHEIM, V6, P2, DOI 10.14283/JPAD.2018.43; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; KASA P, 1997, PROG NEUROBIOL, V52, P511, DOI 10.1016/S0301-0082(97)00028-2; KAWANISHI K, 1991, J AM OIL CHEM SOC, V68, P869, DOI 10.1007/BF02660604; KIM HYUNJUNG, 2003, JOURNAL OF MEDICINAL FOOD, V6, P345; KIM KM, 2021, CLIN EXP PHARMACOL P, V48, P1336, DOI 10.1111/1440-1681.13530; LINTON S, 2001, EXP GERONTOL, V36, P1503, DOI 10.1016/S0531-5565(01)00136-X; LONG JM, 2019, CELL, V179, P312, DOI 10.1016/J.CELL.2019.09.001; MA JJ, 2022, FOOD SCI HUM WELL, V11, P356, DOI 10.1016/J.FSHW.2021.11.013; MA JINJU MA JINJU, 2019, SHIPIN KEXUE / FOOD SCIENCE, V40, P78; MA LIYI MA LIYI, 2009, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, V29, P6; MENDIOLA-PRECOMA J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2589276; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; PARK HJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16050809; POCERNICH CB, 2012, BBA-MOL BASIS DIS, V1822, P625, DOI 10.1016/J.BBADIS.2011.10.003; QIN TING-KUI, 1997, WORLD CROP PESTS, V7A, P303; RAMSAY RR, 2017, MOLECULES, V22, DOI 10.3390/MOLECULES22071192; ROBINSON L, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/BMJ.H3029; ROCHETTE L, 2014, BBA-GEN SUBJECTS, V1840, P2709, DOI 10.1016/J.BBAGEN.2014.05.017; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SHEN JJ, 2019, J FUNCT FOODS, V57, P351, DOI 10.1016/J.JFF.2019.04.024; TAKAHASHI S, 1982, ENTOMOL GEN, V7, P313; WANG ZD, 2021, BIOMED PHARMACOTHER, V136, DOI 10.1016/J.BIOPHA.2021.111241; WEERAWATANAKORN M., 2019, CURR. PHARMACOL. REP., V5, P131, DOI 10.1007/S40495-019-00174-9, DOI 10.1007/S40495-019-00174-9; ZHANG X, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/S12906-021-03278-2","FENG, Y (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, INST HIGHLAND FOREST SCI, KEY LAB BREEDING \& UTILIZAT RESOURCE INSECTS, NATL FORESTRY \& GRASSLAND ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA","MDPI","ENGLISH","FOODS","ARTICLE","ISI","WOS000833174100001","FOODS","INST HIGHLAND FOREST SCI;INST HIGHLAND FOREST SCI","INST HIGHLAND FOREST SCI",NA,"SUN L, 2022, FOODS","SUN L, 2022, FOODS1"
"OLIVEIRA R;HENRIQUES J;SARTORATTO ;ADILSON A;MACIEL M;MARTINEZ P","OLIVEIRA RENATA M A;HENRIQUES JULCELLY D O;SARTORATTO; ADILSON;MACIEL MARIA R W;MARTINEZ PATRICIA F M","EVALUATION OF LIMONENE IN SUGARCANE WAX EXTRACTION",2022,"SUSTAINABLE CHEMISTRY AND PHARMACY","27",NA,8,"10.1016/j.scp.2022.100657","MARTINEZ, PFM (CORRESPONDING AUTHOR), UNIV CAMPINAS UNICAMP, SCH CHEM ENGN FEQ, AV ALBERT EINSTEIN 500, BR-13083852 CAMPINAS, SP, BRAZIL.; OLIVEIRA, RENATA M. A.; HENRIQUES, JULCELLY D. O.; MACIEL, MARIA R. W.; MARTINEZ, PATRICIA F. M., UNIV CAMPINAS UNICAMP, SCH CHEM ENGN FEQ, AV ALBERT EINSTEIN 500, BR-13083852 CAMPINAS, SP, BRAZIL.; SARTORATTO, ADILSON, UNIV CAMPINAS UNICAMP, PLURIDISCIPLINARY CTR CHEM BIOL \& AGR RES CPQBA, BR-13083970 CAMPINAS, SP, BRAZIL.","THIS WORK AIMED TO INVESTIGATE THE REPLACEMENT OF HEXANE BY LIMONENE IN THE EXTRACTION OF WAX FROM SUGARCANE PEEL, COMPARING THE USE OF BOTH SOLVENTS IN TERMS OF WAXES YIELDS, PHYSICOCHEMICAL PROPERTIES, AND COMPOSITION, AND PRESENTING THE DIFFICULTIES FACED IN THIS REPLACEMENT. THE USE OF LIMONENE PRODUCED EXTRACTS WITH SIMILAR MELTING POINTS AND HIGHER CONTENT OF FATTY ACIDS THAN THE EXTRACTS OBTAINED USING HEXANE. REGARDING THE FATTY ALCOHOL PERCENTAGE, WHILE IT DECREASED ALONG THE EXTRACTION TIME FOR THE HEXANE EXTRACTS, DUE TO THE EXTRACTION OF OTHER CHEMICAL SPECIES, THE OPPOSITE BEHAVIOR OCCURRED FOR LIMONENE EXTRACTS. ALTHOUGH THE PURIFIED LIMONENE AND HEXANE WAXES SHOWED SIMILAR PHYSICAL PROPERTIES, THE USE OF LIMONENE PRESENTED SOME DRAWBACKS ASSOCIATED WITH THE SAMPLE'S RESIDUAL LIMONENE AND THE HIGHER TEMPERATURE REQUIRED TO BOIL IT, WHICH HINDER ITS COMPLETE RECOVERY AND REUSE. THUS, THIS WORK EXEMPLIFIES THE PROCESSING DIFFICULTIES FACED IN REPLACING FOSSIL SOLVENTS WITH RENEWABLES.","SUGARCANE PEEL; EXTRACTION; SUGARCANE WAX; GREEN SOLVENT; LIMONENE","NATURAL-PRODUCTS; SOXHLET EXTRACTION; LIPID EXTRACTION; GREEN SOLVENTS; OCTACOSANOL; OIL; RATS; POLICOSANOL; INHIBITION; TERPENES","COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE NIVEL SUPERIOR - BRASIL (CAPES) [001]; SAO PAULO RESEARCH FOUNDATION (FAPESP) [2015/25384-1, 2015/05059-9]; CNPQ [140928/2017-0]; FAEPEX/UNICAMP","THIS STUDY WAS PARTLY FINANCED BY THE COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE NIVEL SUPERIOR - BRASIL (CAPES) - FINANCE CODE 001. THE AUTHORS ACKNOWLEDGE THE SAO PAULO RESEARCH FOUNDATION (FAPESP), GRANT AGREEMENT N. 2015/25384-1 AND 2015/05059-9, FOR FUNDING THE SEPARATION PROCESS LABORATORY AND THE GCXGC-MS/FID EXPERIMENTS, RESPECTIVELY. THE AUTHORS ALSO WOULD LIKE TO THANK TO CNPQ (140928/2017-0) AND FAEPEX/UNICAMP FOR THE FINANCIAL SUPPORT AND THE ESPACO DA ESCRITA -PR ` O-REITORIA DE PESQUISA -UNICAMP FOR THE LANGUAGE SERVICES PROVIDED.","ANONYMOUS, 1998, OFFICIAL METHODS REC, V5TH; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ATHUKORALA Y, 2009, EUR J LIPID SCI TECH, V111, P705, DOI 10.1002/EJLT.200800269; ZAPATA RB, 2009, APPL CATAL A-GEN, V365, P42, DOI 10.1016/J.APCATA.2009.05.047; BERTOUCHE S, 2013, J ESSENT OIL RES, V25, P439, DOI 10.1080/10412905.2013.782473; BHOSALE P. R., 2012, JOURNAL OF ENVIRONMENTAL RESEARCH AND DEVELOPMENT, V6, P715; BLIGH E.G., 1979, CAN J PSYCHIAT, V24, P422, DOI 10.1177/070674377902400508, DOI 10.1177/070674377902400508; BREIL C, 2016, MOLECULES, V21, DOI 10.3390/MOLECULES21020196; BRENNECKE JF, 2001, AICHE J, V47, P2384, DOI 10.1002/AIC.690471102; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CHEMAT F, 2017, REFERENCE MODULE FOO; CHEMAT F, 2012, INT J MOL SCI, V13, P8615, DOI 10.3390/IJMS13078615; CHEMAT S., 2012, GREEN SOLVENTSI, DOI DOI 10.1007/978-94-007-1712-1\_5, 10.1007/978-94-007-1712-1\_5; CHEMAT-DJENNI Z, 2010, J ESSENT OIL BEAR PL, V13, P139, DOI 10.1080/0972060X.2010.10643803; CIRIMINNA R, 2014, CHEM COMMUN, V50, P15288, DOI 10.1039/C4CC06147K; CONAB, 2021, MON BRAZ CROP SURG 2; CONSOLAZIO CF, 1964, J APPL PHYSIOL, V19, P265, DOI 10.1152/JAPPL.1964.19.2.265; CORMA A, 2007, CHEM REV, V107, P2411, DOI 10.1021/CR050989D; DE JESUS SS, 2018, ALGAL RES, V35, P292, DOI 10.1016/J.ALGAL.2018.09.001; ERASTO P, 2008, NAT PROD COMMUN, V3, P1193; GEORGES P, 2006, STEROIDS, V71, P647, DOI 10.1016/J.STEROIDS.2006.01.016; GUO TY, 2017, J AGR FOOD CHEM, V65, P3647, DOI 10.1021/ACS.JAFC.6B05465; HÄCKL K, 2018, CR CHIM, V21, P572, DOI 10.1016/J.CRCI.2018.03.010; HARTMAN L, 1973, LAB PRACT, V22, P475; INARKAR M.B., 2012, ISRN AGRONOMY, DOI DOI 10.5402/2012/340158, 10.5402/2012/340158; ISLAM M.R., 2010, PROC. INTERNATIONAL JOURNAL OF ENVIRONMENTAL SCIENCE AND DEVELOPMENT, V1, P89, DOI 10.7763/IJESD.2010.V1.18; JOHNSON LA, 1983, J AM OIL CHEM SOC, V60, P229, DOI 10.1007/BF02543490; KAUSHIK MK, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-08874-2; KERTON F., 2013, ALTERNATIVE SOLVENTS, DOI DOI 10.1039/9781849736824, 10.1039/9781849736824; KULKARNI PS, 2010, GREEN CHEM, V12, P1990, DOI 10.1039/C0GC00339E; LIU SX, 2005, CEREAL CHEM, V82, P209, DOI 10.1094/CC-82-0209; LOMBA L, 2019, CURR OPIN GREEN SUST, V18, P51, DOI 10.1016/J.COGSC.2018.12.008; LOPES J.D, 2010, SIMPLIFIED PROCESS P; MALLAKPOUR S., 2012, GREEN SOLVENTS 2 PRO, P1; MAMIDIPALLY PK, 2004, EUR J LIPID SCI TECH, V106, P122, DOI 10.1002/EJLT.200300891; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; CASCANT MM, 2017, ANAL BIOANAL CHEM, V409, P3527, DOI 10.1007/S00216-017-0323-9; NUISSIER G, 2002, PHYTOCHEMISTRY, V61, P721, DOI 10.1016/S0031-9422(02)00356-4; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; OKUNIEWSKI M, 2016, FLUID PHASE EQUILIBR, V422, P66, DOI 10.1016/J.FLUID.2015.12.048; PACHECO-FERNÁNDEZ I, 2019, CURR OPIN GREEN SUST, V18, P42, DOI 10.1016/J.COGSC.2018.12.010; PAVIA D.L., 2000, INTRO SPECTROSCOPY 4; PENA A, 2012, REACT KINET MECH CAT, V107, P263, DOI 10.1007/S11144-012-0485-6; PHUKAN AC, 1999, SEP PURIF TECHNOL, V17, P189, DOI 10.1016/S1383-5866(99)00037-4; POPE LE, 1998, ANTIVIR RES, V40, P85, DOI 10.1016/S0166-3542(98)00048-5; PRASAD K, 2019, CURR OPIN GREEN SUST, V18, P72, DOI 10.1016/J.COGSC.2019.02.005; QI GX, 2017, PREP BIOCHEM BIOTECH, V47, P276, DOI 10.1080/10826068.2016.1224246; RABELO S.C., 2015, SUGARCANE AGR PRODUC, P1689, DOI 10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004; RAPINEL V, 2017, LWT-FOOD SCI TECHNOL, V85, P524, DOI 10.1016/J.LWT.2016.10.003; RIOS LF, 2015, APPL BIOCHEM BIOTECH, V175, P469, DOI 10.1007/S12010-014-1283-6; S. S I. N DK. B M. G, 2018, J. PLANT BIOCHEM. PHYSIOL, V06, P1; SARTOR R.B, 2009, MODELING SIMULATION; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SHELDON R, 2001, CHEM COMMUN, P2399, DOI 10.1039/B107270F; SICAIRE AG, 2015, INT J MOL SCI, V16, P8430, DOI 10.3390/IJMS16048430; SIDDIQUI SA, 2022, IND CROP PROD, V177, DOI 10.1016/J.INDCROP.2021.114484; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SUN LX, 2013, J CHEM THERMODYN, V58, P416, DOI 10.1016/J.JCT.2012.10.017; TAMAKI H, 2003, BIOSCI BIOTECH BIOCH, V67, P423, DOI 10.1271/BBB.67.423; TANZI CD, 2012, MOLECULES, V17, P8196, DOI 10.3390/MOLECULES17078196; VEILLET S, 2009, ANAL CHIM ACTA, V632, P203, DOI 10.1016/J.ACA.2008.11.008; VIEIRA T.M.F. DE S., 2003, WAX ATTAINMENT SUGAR; VIROT M, 2008, CHROMATOGRAPHIA, V68, P311, DOI 10.1365/S10337-008-0696-1; VIROT M, 2008, J CHROMATOGR A, V1196, P147, DOI 10.1016/J.CHROMA.2008.04.035; VIROT M, 2007, J CHROMATOGR A, V1174, P138, DOI 10.1016/J.CHROMA.2007.09.067; WANG T, 2010, ACTA PHARMACOL SIN, V31, P765, DOI 10.1038/APS.2010.69; WOLFMEIER U., 2005, ULLMANNS ENCYCLOPEDI, P1, DOI 10.1002/14356007, DOI 10.1002/14356007; ZARNOWSKI R, 2004, J FOOD COMPOS ANAL, V17, P649, DOI 10.1016/J.JFCA.2003.09.007","MARTINEZ, PFM (CORRESPONDING AUTHOR), UNIV CAMPINAS UNICAMP, SCH CHEM ENGN FEQ, AV ALBERT EINSTEIN 500, BR-13083852 CAMPINAS, SP, BRAZIL","ELSEVIER","ENGLISH","SUSTAIN. CHEM. PHARM.","ARTICLE","ISI","WOS000789650600009","SUSTAIN CHEM PHARM","UNIV CAMPINAS UNICAMP;UNIV CAMPINAS UNICAMP;UNIV CAMPINAS UNICAMP","UNIV CAMPINAS UNICAMP",NA,"OLIVEIRA RMA, 2022, SUSTAIN CHEM PHARM","OLIVEIRA RMA, 2022, SUSTAIN CHEM PHARM"
"ZHOU Y;CAO F;LUO F;LIN Q","ZHOU YAPING;CAO FULIANG;LUO FEIJUN;LIN QINLU","OCTACOSANOL AND HEALTH BENEFITS BIOLOGICAL FUNCTIONS AND MECHANISMS OF ACTION",2022,"FOOD BIOSCIENCE","47",NA,15,"10.1016/j.fbio.2022.101632","LUO, FJ; LIN, QL (CORRESPONDING AUTHOR), CENT SOUTH UNIV FORESTRY \& TECHNOL, COLL FOOD SCI \& ENGN, 498 SHAOSHAN RD, CHANGSHA 410004, HUNAN, PEOPLES R CHINA.; ZHOU, YAPING; LUO, FEIJUN; LIN, QINLU, CENT SOUTH UNIV FORESTRY \& TECHNOL, NATL ENGN LAB DEEP PROC RICE \& BYPROD, HUNAN KEY LAB GRAIN OIL DEEP PROC \& QUAL CONTROL, HUNAN KEY LAB PROC FOOD SPECIAL MED PURPOSE,COLL, CHANGSHA 410004, HUNAN, PEOPLES R CHINA.; CAO, FULIANG, NANJING FORESTRY UNIV, COINNOVAT CTR SUSTAINABLE FORESTRY SOUTHERN CHINA, COLL FORESTRY, NANJING 210037, JIANGSU, PEOPLES R CHINA.","OCTACOSANOL IS A WIDELY DISTRIBUTED NATURAL HIGHER ALIPHATIC ALCOHOL THAT CAN BE ISOLATED AND PURIFIED FROM RICE BRAN, SUGARCANE, BEESWAX, INSECT WAX, ETC. OCTACOSANOL EXERTS VARIOUS BIOLOGICAL EFFECTS, INCLUDING ANTI-FATIGUE, ANTI-HYPOXIA, ANTIOXIDANT, ANTI-INFLAMMATORY, ANTITUMOR, ETC. MEANWHILE, IT HAS THE EFFECTS OF REGULATING THE BODY'S IMMUNE FUNCTION AND ENERGY METABOLISM AND HAS POTENTIAL BENEFITS FOR CARDIOVASCULAR DISEASE, CERE-BROVASCULAR DISORDERS, DIABETES, PARKINSON'S DISEASE, AND OTHERS. OCTACOSANOL IS PRIMARILY RESPONSIBLE FOR REGU-LATING MULTIPLE SIGNALING PATHWAYS, SUCH AS AMPK, PI3K/AKT, AND MAPK/NF-KAPPA B, TO ACHIEVE DIFFERENT PHYSIOLOGICAL FUNCTIONS. THIS REVIEW SYSTEMICALLY SUMMARIZED THE PROGRESS IN CHARACTERIZATION, EXTRACTION AND PURIFICATION, BIOLOGICAL FUNCTIONS, MOLECULAR MECHANISMS, AND BIOAVAILABILITY OF OCTACOSANOL. THIS STUDY WILL PROVIDE A REFERENCE FOR MANY INVESTIGATORS TO FURTHER EXPLORE THE PHYSIOLOGICAL FUNCTIONS OF HIGHER ALIPHATIC ALCOHOLS AND APPLY THEM AS SUPPLEMENTS IN FUNCTIONAL FOODS.","OCTACOSANOL; PHYTOCHEMICAL EXTRACTION AND PURIFICATION; BIOLOGICAL; FUNCTIONS; MOLECULAR MECHANISMS; BIOAVAILABILITY","RICE BRAN WAX; CHAIN FATTY ALCOHOLS; SOY PROTEIN ISOLATE; IN-VITRO; NEURONAL APOPTOSIS; LIPID-PEROXIDATION; POLYMERIC MICELLES; BACTERIAL; GHOSTS; DRUG-DELIVERY; POLICOSANOL","NATIONAL NATURAL SCIENCE FOUNDA-TION OF CHINA [31571874]; [GRAIN-OIL PROCESS AND QUALITY CONTROL 2011 COLLABORATIVE AND INNOVATIVE GRANT FROM HUNAN PROVINCE] [448]; KEY PROJECT OF THE EDUCATION DEPARTMENT OF HUNAN PROVINCE [16A228, 13A124]; GRADUATE INNOVATIVE RESEARCH PROJECT OF HUNAN PROVINCE; CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY [CX20200699, CX20201018]","THIS WORK WAS SUPPORTED BY THE [NATIONAL NATURAL SCIENCE FOUNDA-TION OF CHINA] UNDER GRANT [NUMBER 31571874] ; [THE GRAIN-OIL PROCESS AND QUALITY CONTROL 2011 COLLABORATIVE AND INNOVATIVE GRANT FROM HUNAN PROVINCE] UNDER GRANT [2013, NUMBER 448] ; [THE KEY PROJECT OF THE EDUCATION DEPARTMENT OF HUNAN PROVINCE] UNDER GRANT [NUMBER 16A228, 13A124] ; [THE GRADUATE INNOVATIVE RESEARCH PROJECT OF HUNAN PROVINCE AND CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY] UNDER GRANT [NUMBER CX20200699, CX20201018] .","AFFUSO F, 2012, WORLD J CARDIOL, V4, P77, DOI 10.4330/WJC.V4.I3.77; AGAGÜNDÜZ D, 2021, NUTRIENTS, V13, DOI 10.3390/NU13051550; AHMED S, 2020, INT J MOL SCI, V21, DOI 10.3390/IJMS21165622; AKHTAR I, 2019, PAK J PHARM SCI, V32, P223; AKKOL EK, 2020, CANCERS, V12, DOI 10.3390/CANCERS12071959; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ANDREADOU I, 2020, BRIT J PHARMACOL, V177, P5287, DOI 10.1111/BPH.14931; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARUMUGHAM T, 2021, CHEMOSPHERE, V271, DOI 10.1016/J.CHEMOSPHERE.2020.129525; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; BOFFI FM, 2002, EQUINE VET J, V34, P275; BROZZI NA, 2021, ANN SURG, V274, PE1284, DOI 10.1097/SLA.0000000000003721; CABRAL H, 2011, NAT NANOTECHNOL, V6, P815, DOI 10.1038/NNANO.2011.166, 10.1038/NNANO.2011.166; CAO XL, 2015, EXP BRAIN RES, V233, P2753, DOI 10.1007/S00221-015-4269-X; 曹志然 CAO ZHIRAN, 2004, 食品科学, FOOD SCIENCE, V25, P158; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P639, DOI 10.2165/00044011-200323100-00003; SILVA JHCE, 2020, MOLECULES, V25, DOI 10.3390/MOLECULES25153394; CHEN F, 2005, J FOOD ENG, V70, P47, DOI 10.1016/J.JFOODENG.2004.09.011; CHEN F, 2007, J FOOD ENG, V79, P63, DOI 10.1016/J.JFOODENG.2006.01.030; 陈芳 CHEN FANG, 2007, 营养学报, ACTA NUTRIMENTA SINICA, V29, P408; CHEN FANG CHEN FANG, 2006, ACTA NUTRIMENTA SINICA, V28, P269; CHEN FP, 2015, J AGR FOOD CHEM, V63, P3559, DOI 10.1021/ACS.JAFC.5B00448; CHEN XJ, 2013, CHINESE MED J-PEKING, V126, P3578, DOI 10.3760/CMA.J.ISSN.0366-6999.20130780; 陈正行 CHEN ZHENGXING, 2012, 食品与生物技术学报, JOURNAL OF FOOD SCIENCE AND BIOTECHNOLOGY, V31, P355; CHO DH, 2016, FOOD CHEM, V196, P259, DOI 10.1016/J.FOODCHEM.2015.09.025; CHO YH, 2017, NAT PROD RES, V31, P2778, DOI 10.1080/14786419.2017.1292271; CHU BY, 2016, INT J PHARMACEUT, V500, P345, DOI 10.1016/J.IJPHARM.2016.01.030; COCCIMIGLIO J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1404505; COUTAZ MARTIAL, 2017, REV MED SUISSE, V13, P1924; DE OLIVEIRA AM, 2012, INT J MOL SCI, V13, P1598, DOI 10.3390/IJMS13021598; DELANGE DM, 2001, J CHROMATOGR B, V762, P43, DOI 10.1016/S0378-4347(01)00331-0; DULLENS SPJ, 2008, J LIPID RES, V49, P790, DOI 10.1194/JLR.M700497-JLR200; EL-TANTAWY WH, 2019, ARCH PHYSIOL BIOCHEM, V125, P128, DOI 10.1080/13813455.2018.1441315; ESPERANÇA ED, 2018, FOOD FUNCT, V9, P3447, DOI 10.1039/C8FO00370J, 10.1039/C8FO00370J; FAROKHZAD OC, 2009, ACS NANO, V3, P16, DOI 10.1021/NN900002M; FENG SM, 2015, FOOD CHEM, V182, P171, DOI 10.1016/J.FOODCHEM.2015.03.003; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; FRAGA V, 1997, ARCH MED RES, V28, P355; GANIE SA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/401213; GAO WF, 2015, J CHROMATOGR SCI, V53, P811, DOI 10.1093/CHROMSCI/BMU098; GIUFFRÈ AM, 2015, J OLEO SCI, V64, P625, DOI 10.5650/JOS.ESS15002; GNIWOTTA F, 2005, PLANT PHYSIOL, V139, P519, DOI 10.1104/PP.104.053579; GONG J, 2012, J CONTROL RELEASE, V159, P312, DOI 10.1016/J.JCONREL.2011.12.012; GONI O, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/J.JEP.2020.113664; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GRANJA A. L., 1999, CA, PATENT NO. CA2124578 A1, 2124578; GUARDAMAGNA O, 2011, NUTR METAB CARDIOVAS, V21, P424, DOI 10.1016/J.NUMECD.2009.10.015; GUO T., 2017, CEREALS OILS, V36, P26; GUO TY, 2017, J AGR FOOD CHEM, V65, P3647, DOI 10.1021/ACS.JAFC.6B05465; HAIM D, 2009, J CHROMATOGR B, V877, P4154, DOI 10.1016/J.JCHROMB.2009.10.034; HARRABI S, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/S12944-018-0682-Z; HUI J., 2007, MED J NATL DEFENDING, V17, P143; HUO J. S., 1996, J CHINA AGR U, V1, P5; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; ISHAKA A, 2014, INT J NANOMED, V9, P2261, DOI 10.2147/IJN.S56999; ISLAM N, 2021, FOOD BIOSCI, V40, DOI 10.1016/J.FBIO.2021.100881; JACKSON MA, 2006, J SUPERCRIT FLUID, V37, P173, DOI 10.1016/J.SUPFLU.2005.08.008; JAIN RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/NRCLINONC.2010.139; JI X, 2019, ANN TRANSL MED, V7, DOI 10.21037/ATM.2019.10.115; JIANG MY, 2020, J AGR FOOD CHEM, V68, P7850, DOI 10.1021/ACS.JAFC.0C01564; JONES J, 1979, PLANTA, V144, P277, DOI 10.1007/BF00388770; JOO T, 2014, SAUDI J BIOL SCI, V21, P427, DOI 10.1016/J.SJBS.2014.04.003; KABIR Y, 1994, NAHRUNG, V38, P373; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KAUP RM, 2013, PHYTOTHER RES, V27, P264, DOI 10.1002/PTR.4705; KAUSHIK MK, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-08874-2; KIM HYUNJUNG, 2003, JOURNAL OF MEDICINAL FOOD, V6, P345; KIM SS, 1997, ARCH PHARM RES, V20, P148, DOI 10.1007/BF02974002; KOCH K, 2006, PLANTA, V223, P258, DOI 10.1007/S00425-005-0081-3; KRASKO JA, 2017, ONCOL REP, V37, P171, DOI 10.3892/OR.2016.5252; AKKOL EK, 2021, FRONT PHARMACOL, V12, DOI 10.3389/FPHAR.2021.669638; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LEE SH, 2019, INT J SPORT PHYSIOL, V14, P1297, DOI 10.1123/IJSPP.2018-0704; LEE TH, 2019, INT J MOL SCI, V20, DOI 10.3390/IJMS20236092; LENART J, 2017, POSTEP HIG MED DOSW, V71, P118, DOI 10.5604/01.3001.0010.3796; LERMA-GARCÍA MJ, 2009, J CHROMATOGR A, V1216, P230, DOI 10.1016/J.CHROMA.2008.11.056; LI DZ, 2020, FOOD CHEM, V322, DOI 10.1016/J.FOODCHEM.2020.126638; LI DZ, 2019, FOOD CHEM, V297, DOI 10.1016/J.FOODCHEM.2019.05.041; LI JW, 2016, MOLECULES, V21, DOI 10.3390/MOLECULES21121675; LI WX, 2016, SCI REP-UK, V6, DOI 10.1038/SREP24580; LIANG WW, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/FENDO.2020.00017; LIM SM, 2016, REJUV RES, V19, P59, DOI 10.1089/REJ.2015.1712; LING Y, 2020, EXP GERONTOL, V130, DOI 10.1016/J.EXGER.2019.110786; LIU FUYU LIU FUYU, 2009, MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA, V19, P670; LIU FUYU LIU FUYU, 2010, MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA, V20, P649; LIU YW, 2015, LIPIDS, V50, P241, DOI 10.1007/S11745-015-3991-2; LIU YF, 2008, INT J FOOD SCI TECH, V43, P763, DOI 10.1111/J.1365-2621.2006.01232.X; LONG L, 2016, ASIAN AUSTRAL J ANIM, V29, P1470, DOI 10.5713/AJAS.15.0879; LONG L, 2015, ANIM NUTR, V1, P293, DOI 10.1016/J.ANINU.2015.12.005; LORENZ P, 2008, ANAL BIOANAL CHEM, V391, P633, DOI 10.1007/S00216-008-2000-5; LU GUOSHOU LU GUOSHOU, 2008, MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA, V18, P163; FERNÁNDEZ-ALEMÁN JL, 2019, IEEE ENG MED BIO, P3956, DOI 10.1109/EMBC.2019.8856341, 10.1109/EMBC.2019.8856341; LUO CH, 2019, PHARMACOL RES, V148, DOI 10.1016/J.PHRS.2019.104409; MA SH, 2019, SPORTS, V7, DOI 10.3390/SPORTS7020040; MARAZZI G, 2015, AM J CARDIOL, V116, P1798, DOI 10.1016/J.AMJCARD.2015.09.023; MARAZZI G, 2011, ADV THER, V28, P1105, DOI 10.1007/S12325-011-0082-5; MARRAS C, 2018, NPJ PARKINSONS DIS, V4, DOI 10.1038/S41531-018-0058-0; MARTICH GD, 1993, IMMUNOBIOLOGY, V187, P403, DOI 10.1016/S0171-2985(11)80353-0; MATURA LA, 2018, BIOL RES NURS, V20, P410, DOI 10.1177/1099800418764326; MAZZA A, 2015, ADV THER, V32, P680, DOI 10.1007/S12325-015-0229-X; MENCHETTI L, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0218275; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MINER DG, 2020, J NEUROL SCI, V410, DOI 10.1016/J.JNS.2020.116677; MOLINA V, 2013, INDIAN J PHARM SCI, V75, P635; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; MONI JNR, 2021, LIFE-BASEL, V11, DOI 10.3390/LIFE11020155; MONIZ SC, 2020, SCAND J MED SCI SPOR, V30, P638, DOI 10.1111/SMS.13610; LA PAZ SMD, 2014, J ETHNOPHARMACOL, V151, P131, DOI 10.1016/J.JEP.2013.10.012; MUHAMMAD A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/FIMMU.2019.01377; MYUNG K, 2013, J AGR FOOD CHEM, V61, P8737, DOI 10.1021/JF402846K; DUONG NT, 2017, ASIAN PAC J TROP MED, V10, P619, DOI 10.1016/J.APJTM.2017.06.002; NIES LK, 2006, ANN PHARMACOTHER, V40, P1984, DOI 10.1345/APH.1H040; NING-NING S., 2008, FOOD RES DEV, V28, P28; NOA M, 1994, J PHARM PHARMACOL, V46, P282, DOI 10.1111/J.2042-7158.1994.TB03794.X; NOA M, 2007, J MED FOOD, V10, P452, DOI 10.1089/JMF.2006.232; NOA MIRIAM, 2003, DRUGS R D, V4, P29, DOI 10.2165/00126839-200304010-00003; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; ORGAH JO, 2020, PHARMACOL RES, V153, DOI 10.1016/J.PHRS.2020.104654; OROZCO-SOLANO M, 2010, J AGR FOOD CHEM, V58, P7539, DOI 10.1021/JF100751R; OU SY, 2012, LWT-FOOD SCI TECHNOL, V45, P295, DOI 10.1016/J.LWT.2011.08.011; PAUKNER S, 2003, J DRUG TARGET, V11, P151, DOI 10.1080/10611860310001593366; PENG K, 2016, ASIAN AUSTRAL J ANIM, V29, P1458, DOI 10.5713/AJAS.16.0287; PETRASSI FA, 2012, AVIAT SPACE ENVIR MD, V83, P975, DOI 10.3357/ASEM.3315.2012; GIANG PM, 2013, NAT PROD RES, V27, P1856, DOI 10.1080/14786419.2013.768991; PHILIPPI M, 1994, J EXP BIOL, V189, P1; PIRRO M, 2017, NUTR METAB CARDIOVAS, V27, P2, DOI 10.1016/J.NUMECD.2016.11.122; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONZIANI FR, 2015, EXPERT REV GASTROENT, V9, P1055, DOI 10.1586/17474124.2015.1056156; PRADO JM, 2011, J SUPERCRIT FLUID, V56, P231, DOI 10.1016/J.SUPFLU.2010.10.036; QUESADA-VÁZQUEZ S, 2020, CELLS-BASEL, V9, DOI 10.3390/CELLS9010176; RABIEI Z, 2019, PHARM BIOL, V57, P355, DOI 10.1080/13880209.2019.1618344; RAHMAN MM, 2021, J ETHNOPHARMACOL, V278, DOI 10.1016/J.JEP.2021.114297; RAVELO Y, 2011, J NAT MED-TOKYO, V65, P330, DOI 10.1007/S11418-010-0496-4; RODRIGUES MJ, 2017, PHARM BIOL, V55, P1348, DOI 10.1080/13880209.2017.1301493; SAINT-JOHN M., 1986, INTERNATIONAL CLINICAL NUTRITION REVIEW, V6, P81; SAITO M, 2007, EUR UROL, V51, P479, DOI 10.1016/J.EURURO.2006.06.024; SARWAR N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9; SEN GUPTA S, 2017, EUR J PHARM BIOPHARM, V119, P201, DOI 10.1016/J.EJPB.2017.06.020; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SIN EHK, 2014, CR CHIM, V17, P293, DOI 10.1016/J.CRCI.2013.12.001; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SINGH R, 2019, PULM MED, V2019, DOI 10.1155/2019/1907807; SNIDER SR, 1984, ANN NEUROL, V16, P723, DOI 10.1002/ANA.410160615; SOHAIL M, 2017, CRIT REV FOOD SCI, V57, P3771, DOI 10.1080/10408398.2016.1164120; SURIN S, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-67266-1; TANG MIN, 2013, ZHONGHUA XIN XUE GUAN BING ZA ZHI, V41, P488; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TCHAKAM PD, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-136; TEIXEIRA FS, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/PH14060583; TENG HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; THIPPESWAMY G, 2008, EUR J PHARMACOL, V588, P141, DOI 10.1016/J.EJPHAR.2008.04.027; TIMMIS A, 2018, EUR HEART J, V39, P508, DOI 10.1093/EURHEARTJ/EHX628; TIRPE AA, 2019, INT J MOL SCI, V20, DOI 10.3390/IJMS20246140; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; VENKATESAN M, 2005, J ETHNOPHARMACOL, V99, P349, DOI 10.1016/J.JEP.2005.01.029; VENTURELLI A, 2019, J PHARMACEUT BIOMED, V172, P200, DOI 10.1016/J.JPBA.2019.04.015; VIEIRA G, 2020, BIOMOLECULES, V10, DOI 10.3390/BIOM10050792; WAGNER V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/NBT1006-1211; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q; WANG T, 2012, NEURAL REGEN RES, V7, P1080, DOI 10.3969/J.ISSN.1673-5374.2012.14.006; WANG T, 2010, ACTA PHARMACOL SIN, V31, P765, DOI 10.1038/APS.2010.69; WITTE A, 1990, BIOCHIMIE, V72, P191, DOI 10.1016/0300-9084(90)90145-7; WU Z., 2009, HIGH ALT MED BIOL, V1, P25; XIANG H, 2018, FOOD CHEM, V268, P504, DOI 10.1016/J.FOODCHEM.2018.06.059; XIANG Y., 2012, J XINXIANG UNIV, V29, P44; XIANG Y., 2012, J PINGYUAN UNIV, V29, P47; YANG H., 2008, CHEM IND FOREST PROD, V33, P168; YANG X. Y., 2008, SHAANXI MED J, V37, P273; YANG XIAO-YING, 2008, NAN FANG YI KE DA XUE XUE BAO, V28, P652; YU C., 2003, CHINA FOOD ADDIT, V2, P35; ZAKIR F, 2011, J BIOMED NANOTECHNOL, V7, P127, DOI 10.1166/JBN.2011.1234; ZHANG CX, 2019, BIOMED RES INT-UK, V2019, DOI 10.1155/2019/6764919; ZHOU YP, 2021, J AGR FOOD CHEM, V69, P7603, DOI 10.1021/ACS.JAFC.1C01764; ,, 2011, EFSA JOURNAL, V9, P2255","LUO, FJ; LIN, QL (CORRESPONDING AUTHOR), CENT SOUTH UNIV FORESTRY \& TECHNOL, COLL FOOD SCI \& ENGN, 498 SHAOSHAN RD, CHANGSHA 410004, HUNAN, PEOPLES R CHINA","ELSEVIER","ENGLISH","FOOD BIOSCI.","ARTICLE","ISI","WOS000768286100002","FOOD BIOSCI","CENT SOUTH UNIV FORESTRY AND TECHNOL;CENT SOUTH UNIV FORESTRY AND TECHNOL;NANJING FORESTRY UNIV","NOTREPORTED;CENT SOUTH UNIV FORESTRY AND TECHNOL",NA,"ZHOU Y, 2022, FOOD BIOSCI","ZHOU Y, 2022, FOOD BIOSCI"
"BLASI F;TRINGANIELLO C;VERDUCCI G;COSSIGNANI L","BLASI FRANCESCA;TRINGANIELLO CARMELA;VERDUCCI GIUSEPPA; COSSIGNANI LINA","BIOACTIVE MINOR COMPONENTS OF ITALIAN AND EXTRAEUROPEAN HEMP SEED OILS",2022,"LWT-FOOD SCIENCE AND TECHNOLOGY","158",NA,16,"10.1016/j.lwt.2022.113167","COSSIGNANI, L (CORRESPONDING AUTHOR), UNIV PERUGIA, DEPT PHARMACEUT SCI, I-06126 PERUGIA, ITALY.; COSSIGNANI, L (CORRESPONDING AUTHOR), UNIV PERUGIA, ST MARIA MISERICORDIA UNIV HOSP, CTR PERINATAL \& REPROD MED, ST ANDREA FRATTE, I-06132 PERUGIA, ITALY.; COSSIGNANI, L (CORRESPONDING AUTHOR), UNIV PERUGIA, DEPT PHARMACEUT SCI, I-06100 PERUGIA, ITALY.; BLASI, FRANCESCA; TRINGANIELLO, CARMELA; VERDUCCI, GIUSEPPA; COSSIGNANI, LINA, UNIV PERUGIA, DEPT PHARMACEUT SCI, I-06126 PERUGIA, ITALY.; COSSIGNANI, LINA, UNIV PERUGIA, ST MARIA MISERICORDIA UNIV HOSP, CTR PERINATAL \& REPROD MED, ST ANDREA FRATTE, I-06132 PERUGIA, ITALY.; COSSIGNANI, LINA, UNIV PERUGIA, DEPT PHARMACEUT SCI, I-06100 PERUGIA, ITALY.","NOWADAYS, HEMPSEED OIL IS WELL KNOWN FOR ITS NUTRITIONAL AND HEALTH BENEFITS. IN THIS WORK, A STUDY OF UNSAPONIFIABLE FRACTION OF HEMP SEED OILS (HSO) PAYING PARTICULAR ATTENTION TO THE QUALITATIVE AND QUANTITATIVE ANALYSIS OF STEROLS, ALIPHATIC ALCOHOLS, AND TOCOPHEROLS, AS WELL AS TO CAROTENOID, AND CHLOROPHYLL CONTENTS. SAMPLES WERE OF ITALIAN (IT) AND EXTRA-EUROPEAN (EE) ORIGIN. BETA-SITOSTEROL WAS THE PREDOMINANT PHYTOSTEROL, FOLLOWED BY CAMPESTEROL, AS OBTAINED BY HIGH-RESOLUTION GAS CHROMATOGRAPHY (HRGC). MOREOVER, HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS WITH FLUORESCENCE DETECTION METHOD WAS CARRIED OUT TO ANALYZE TOCOPHEROL FRACTION. THE RESULTS SHOWED HIGH LEVELS OF VITAMIN E VITAMERS, WITH PREVALENCE OF GAMMA-ISOMER OF TOCOPHEROLS. SOME SIGNIFICANT DIFFERENCES (P < 0.05) WERE DETECTED BETWEEN IT AND EE SAMPLES FOR SOME BIOACTIVE COMPOUNDS AS ALPHA AND GAMMA-TOCOPHEROLS, AND CHLOROPHYLL CONTENTS. PRINCIPAL COMPONENT ANALYSIS, APPLIED TO UNSAPONIFIABLE FRACTION DATA, IN PARTICULAR STEROLS AND TOCOPHEROLS, HAS HIGHLIGHTED THE ABILITY TO DISCRIMINATE THE HSO SAMPLES FROM EE SAMPLES. THESE RESULTS ARE PROMISING AND SUGGEST THAT HSO MINOR COMPONENTS MIGHT BE USED AS GEOGRAPHICAL MARKERS, AFTER THE INVESTIGATION OF A LARGE NUMBER OF SAMPLES.","HEMP SEED OIL; STEROLS; TOCOPHEROLS; MULTIVARIATE STATISTICAL ANALYSIS; AUTHENTICATION","PHYTOSTEROLS; POLICOSANOL",NA,NA,"ALADIC K, 2014, CHEM BIOCHEM ENG Q, V28, P481; ANWAR F, 2006, J AM OIL CHEM SOC, V83, P323, DOI 10.1007/S11746-006-1207-X; AOCS, 1997, 691 AOCS; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; BLASI F, 2019, FOODS, V8, DOI 10.3390/FOODS8020058; BORGES TH, 2017, FOOD CHEM, V215, P454, DOI 10.1016/J.FOODCHEM.2016.07.162; CABRAL CE, 2017, ARQ BRAS CARDIOL, V109, P475, DOI 10.5935/ABC.20170158; COSSIGNANI L, 2018, FOOD ANAL METHOD, V11, P1180, DOI 10.1007/S12161-017-1098-5; CRESCENTE G, 2018, PHYTOCHEM REV, V17, P733, DOI 10.1007/S11101-018-9556-2; EFSA JOURNAL, 2012, EFSA J, DOI 10.2903/J.EFSA.2012.2693, DOI 10.2903/J.EFSA.2012.2693; FRASSINETTI S, 2018, FOOD CHEM, V262, P56, DOI 10.1016/J.FOODCHEM.2018.04.078; GHAZANI SM, 2013, J AM OIL CHEM SOC, V90, P923, DOI 10.1007/S11746-013-2254-8; GONZALEZ-PEREIRA A, 2021, FOODS, V10, DOI 10.3390/FOODS10030484; IRAKLI M, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/ANTIOX8100491; IZZO L, 2020, MOLECULES, V25, DOI 10.3390/MOLECULES25163710; KONUSKAN D. B, 2020, MF RAMADAN, P7, DOI 10.1016/B978-0-12-818188-1.00002-5, DOI 10.1016/B978-0-12-818188-1.00002-5; KRIESE U, 2004, EUPHYTICA, V137, P339, DOI 10.1023/B:EUPH.0000040473.23941.76; LEONARD W, 2020, COMPR REV FOOD SCI F, V19, P282, DOI 10.1111/1541-4337.12517; LIANG JINGBANG LIANG JINGBANG, 2015, LIPID TECHNOLOGY, V27, P231, DOI 10.1002/LITE.201500050; MANOLESCU B, 2008, J MED LIFE, V1, P376; MATTHÄUS B, 2008, EUR J LIPID SCI TECH, V110, P655, DOI 10.1002/EJLT.200700311; MO SY, 2013, LIPIDS, V48, P949, DOI 10.1007/S11745-013-3813-3; MONTSERRAT-DE LA PAZ S, 2014, J AGR FOOD CHEM, V62, P1105, DOI 10.1021/JF404278Q; OOMAH BD, 2002, FOOD CHEM, V76, P33, DOI 10.1016/S0308-8146(01)00245-X; PAVLOVIC R, 2019, FRONT PLANT SCI, V10, DOI 10.3389/FPLS.2019.01265; PIRSA S, 2021, J IRAN CHEM SOC, V18, P1167, DOI 10.1007/S13738-020-02100-Z; RUPASINGHE HPV, 2020, MOLECULES, V25, DOI 10.3390/MOLECULES25184078; SAEIDNIA S., 2014, EUROPEAN JOURNAL OF MEDICINAL PLANTS, V4, P590; SHAHIDI F, 2016, INT J MOL SCI, V17, DOI 10.3390/IJMS17101745; SHEN JJ, 2019, J FUNCT FOODS, V57, P351, DOI 10.1016/J.JFF.2019.04.024; SIANO F, 2019, MOLECULES, V24, DOI 10.3390/MOLECULES24010083; SMERIGLIO A, 2016, PHYTOTHER RES, V30, P1298, DOI 10.1002/PTR.5623; TEH SS, 2013, J FOOD COMPOS ANAL, V30, P26, DOI 10.1016/J.JFCA.2013.01.004; TRINGANIELLO C, 2021, FOODS, V10, DOI 10.3390/FOODS10050916; TURCK D, 2016, EFSA J, V14, DOI 10.2903/J.EFSA.2016.4588; WEERAWATANAKORN M., 2019, CURR. PHARMACOL. REP., V5, P131, DOI 10.1007/S40495-019-00174-9, DOI 10.1007/S40495-019-00174-9; YUAN LL, 2020, J FUNCT FOODS, V65, DOI 10.1016/J.JFF.2019.103715","COSSIGNANI, L (CORRESPONDING AUTHOR), UNIV PERUGIA, DEPT PHARMACEUT SCI, I-06126 PERUGIA, ITALY","ELSEVIER","ENGLISH","LWT-FOOD SCI. TECHNOL.","ARTICLE","ISI","WOS000788735800003","LWT-FOOD SCI TECHNOL","UNIV PERUGIA;UNIV PERUGIA;UNIV PERUGIA;UNIV PERUGIA;UNIV PERUGIA;UNIV PERUGIA","UNIV PERUGIA",NA,"BLASI F, 2022, LWT-FOOD SCI TECHNOL","BLASI F, 2022, LWT-FOOD SCI TECHNOL"
"ARORA M;PANDEY S;TOMAR R;SAHOO ;JAGANNATH J;KUMAR D;JANGRA A","ARORA MANDEEP K;PANDEY SUDHANSHU;TOMAR RITU;SAHOO; JAGANNATH;KUMAR DINESH;JANGRA ASHOK","THERAPEUTIC POTENTIAL OF POLICOSANOL IN THE CONCURRENT MANAGEMENT OF DYSLIPIDEMIA AND NONALCOHOLIC FATTY LIVER DISEASE",2022,"FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES","8",NA,8,"10.1186/s43094-022-00399-4","JANGRA, A (CORRESPONDING AUTHOR), KIET SCH PHARM, DEPT PHARMACOL, GHAZIABAD, INDIA.; JANGRA, A (CORRESPONDING AUTHOR), CENT UNIV HARYANA, DEPT PHARMACEUT SCI, MAHENDERGARH, HARYANA, INDIA.; ARORA, MANDEEP K.; PANDEY, SUDHANSHU; JANGRA, ASHOK, KIET SCH PHARM, DEPT PHARMACOL, GHAZIABAD, INDIA.; ARORA, MANDEEP K.; TOMAR, RITU; SAHOO, JAGANNATH, ENT UNIV, SCH PHARMACEUT \& POPULAT HLTH INFORMAT, DEHRA DUN, UTTARAKHAND, INDIA.; KUMAR, DINESH; JANGRA, ASHOK, CENT UNIV HARYANA, DEPT PHARMACEUT SCI, MAHENDERGARH, HARYANA, INDIA.","BACKGROUND: HIGH-FAT DIET (HFD) POSSESSES A MAJOR CAUSE OF CARDIOVASCULAR DISEASE, AND HEPATOSTEATOSIS. UNFORTUNATELY, LONG-TERM USE OF STATINS HAS A THEORETICAL POSSIBILITY OF WORSENING OF HEPATIC HISTOLOGY IN THE PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). THE OBJECTIVE OF THE STUDY WAS TO EXPLORE HEPATOPROTECTIVE POTENTIAL OF POLICOSANOL AS AN ALTERNATIVE TO STATINS IN EXPERIMENTAL NAFLD. FOR THE SAME, YOUNG MALE WISTAR RATS WERE FED WITH HFD FOR 8 WEEKS TO INDUCE NAFLD. 48 ADULT WISTAR RATS WERE DISTRIBUTED INTO SIX INVESTIGATIONAL GROUPS: NORMAL CONTROL, HFD CONTROL, AND FOUR TREATMENT GROUPS, RECEIVING POLICOSANOL (50 AND 100 MG/KG/DAY), ATORVASTATIN (30 MG/KG/DAY), AND SILYMARIN (100 MG/KG/DAY) FOR 8 WEEKS ALONG WITH HFD. RESULT: HFD CONSUMPTION CAUSED PROFOUND HEPATOTOXICITY EVIDENT BY HEPATIC OXIDATIVE STRESS, INCREASED SERUM GLUTAMIC OXALOACETIC TRANSAMINASE (SGOT), SERUM GLUTAMIC PYRUVIC TRANSAMINASE (SGPT), ALKALINE PHOSPHATASE (ALP), AND BILIRUBIN CONTENT. TREATMENT WITH POLICOSANOL (100 MG/KG) MARKEDLY REDUCED THE ELEVATED SGOT, SGPT, AND ALP LEVELS IN HFD-FED RATS. MOREOVER, POLICOSANOL SIGNIFICANTLY REDUCED HEPATIC OXIDATIVE STRESS MANIFEST BY REDUCED MALONDIALDEHYDE (MDA) AND INCREASED GLUTATHIONE (GSH) LEVEL. THE TREATMENT WITH POLICOSANOL (100 MG/KG) WAS FOUND TO BE MORE ACTIVE IN ATTENUATING THE HFD-INDUCED HEPATOTOXICITY AS COMPARED TO POLICOSANOL (50 MG/KG) AND ATORVASTATIN (30 MG/KG). MOREOVER, WE OBSERVED THAT THE HEPATOPROTECTIVE POTENTIAL OF POLICOSANOL WAS COMPARABLE TO THE SILYMARIN. CONCLUSIONS: THE RESULTS OF THE STUDY CLEARLY INDICATED THAT THE POLICOSANOL COULD BE CONSIDERED AN INTRIGUING APPROACH FOR THE TREATMENT OF NAFLD.","HEPATOTOXICITY; OXIDATIVE STRESS; POLICOSANOL; SILYMARIN; ATORVASTATIN","DIABETES-MELLITUS; ATORVASTATIN; RATS; HIPPOCAMPUS; COMBINATION; CONSUMPTION; PROGRESSION; ALCOHOL; STRESS; INJURY",NA,NA,"ANSTEE QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/NRGASTRO.2013.41; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BANU GS, 2009, INDIAN J CLIN BIOCHE, V24, P414, DOI 10.1007/S12291-009-0074-2; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BHARDWAJ SIDHARTH S, 2007, CLIN LIVER DIS, V11, P597, DOI 10.1016/J.CLD.2007.06.010; BLUMENTHAL RS, 2000, AM HEART J, V139, P577, DOI 10.1016/S0002-8703(00)90033-4; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CHEN GL, 2016, INT J MOL SCI, V17, DOI 10.3390/IJMS17091379; CHEN IS, 2012, J SCI FOOD AGR, V92, P1441, DOI 10.1002/JSFA.4723; CHUNG APYS, 2018, FRONT NUTR, V5, DOI 10.3389/FNUT.2018.00017; DWIVEDI DK, 2018, BIOMED PHARMACOTHER, V108, P1393, DOI 10.1016/J.BIOPHA.2018.09.173; FAASSE SARAH, 2018, F1000RES, V7, P170, DOI 10.12688/F1000RESEARCH.12028.1; FIRNEISZ G, 2014, WORLD J GASTROENTERO, V20, P9072, DOI 10.3748/WJG.V20.I27.9072; FUNATSU T, 2002, EUR J PHARMACOL, V455, P161, DOI 10.1016/S0014-2999(02)02611-0; GONG J, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700280; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; GUO YL, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/926087; IWAKIRI Y, 2015, TRENDS PHARMACOL SCI, V36, P524, DOI 10.1016/J.TIPS.2015.05.001; JANGRA A, 2016, EUR J PHARMACOL, V770, P25, DOI 10.1016/J.EJPHAR.2015.11.047; KIM JY, 2017, INT J MOL MED, V39, P889, DOI 10.3892/IJMM.2017.2907; KUMAR D, 2019, PHARMACOL REP, V71, P1235, DOI 10.1016/J.PHAREP.2019.07.002; MCCARTY MF, 2005, MED HYPOTHESES, V64, P636, DOI 10.1016/J.MEHY.2003.12.051; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MOLINA V, 2013, INDIAN J PHARM SCI, V75, P635; MUNSHI RP, 2014, INDIAN J PHARMACOL, V46, P270, DOI 10.4103/0253-7613.132156; MUSTO D, 2010, MINERVA GASTROENTEROL DIETOL, V56, P389; NOA MIRIAM, 2003, DRUGS R D, V4, P29, DOI 10.2165/00126839-200304010-00003; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; PAPATHEODORIDIS GV, 2009, J HEPATOL, V51, P931, DOI 10.1016/J.JHEP.2009.06.023; PATIL RASHMEE, 2017, WORLD J GASTROINTEST PATHOPHYSIOL, V8, P51, DOI 10.4291/WJGP.V8.I2.51; PEREZ Y, 2013, INT J PHARM SCI REV, V19, P18; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; RECKNAGEL RO, 1983, TRENDS PHARMACOL SCI, V4, P129, DOI 10.1016/0165-6147(83)90328-0; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SRINIVASAN K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/J.PHRS.2005.05.004; VALBUSA F, 2018, INT J CARDIOL, V265, P162, DOI 10.1016/J.IJCARD.2018.04.129; WILLIAMS CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/J.GASTRO.2010.09.038; ZODDA D, 2018, PHARMACY, V6, DOI 10.3390/PHARMACY6010010","JANGRA, A (CORRESPONDING AUTHOR), KIET SCH PHARM, DEPT PHARMACOL, GHAZIABAD, INDIA","SPRINGER","ENGLISH","FUTUR. J. PHARM. SCI.","ARTICLE","ISI","WOS000742907800001","FUTUR J PHARM SCI","KIET SCH PHARM;CENT UNIV HARYANA;KIET SCH PHARM;ENT UNIV;CENT UNIV HARYANA","KIET SCH PHARM",NA,"ARORA MK, 2022, FUTUR J PHARM SCI","ARORA MK, 2022, FUTUR J PHARM SCI"
"LIM C;RYU K","LIM CHUN IK;RYU KYEONG SEON","EFFECT OF DIETARY OCTACOSANOL CONCENTRATION EXTRACTED FROM TRITICALE SPROUT ON LAYING PERFORMANCE EGG QUALITY AND BLOOD PARAMETERS OF LAYING HENS",2022,"JOURNAL OF ANIMAL SCIENCE AND TECHNOLOGY","64","863-870",2,"10.5187/jast.2022.e62","RYU, KS (CORRESPONDING AUTHOR), JEONBUK NATL UNIV, DEPT ANIM SCI, COLL AGR \& LIFE SCI, JEONJU 54896, SOUTH KOREA.; LIM, CHUN IK; RYU, KYEONG SEON, JEONBUK NATL UNIV, DEPT ANIM SCI, COLL AGR \& LIFE SCI, JEONJU 54896, SOUTH KOREA.","THIS STUDY WAS CONDUCTED TO INVESTIGATE THE EFFECT OF DIETARY SUPPLEMENTATION OF OCTACOSANOL (OCT) EXTRACTED FROM TRITICALE SPROUT ON LAYING PERFORMANCE, EGG QUALITY, AND BLOOD PARAMETERS OF LAYING HENS. A TOTAL OF 192, HYLINE BROWN LAYING HENS AGED 43 WEEKS WERE DIVIDED INTO 4 DIETARY GROUPS OF 48 BIRDS EACH AND THEY WERE RANDOMLY SUBJECTED TO ONE OF THE EXPERIMENTAL DIETS CONTAINING OCT AT THE LEVELS OF NONE, 10, 20, AND 30 MG/KG OF DIET. ALL BIRDS WERE FED WITH ISOENERGETIC AND ISONITROGENOUS MASH DIETS FOR 6 WEEKS. THE RESULT SHOWED THAT HENS SUPPLEMENTED WITH 20 AND 30 MG/KG OCT IN DIET SIGNIFICANTLY INCREASED (P < 0.05) EGG PRODUCTION THAN THOSE FED WITH THE BASAL DIET. OCT CONCENTRATION IN THE EGG YOLK OF HENS FED WITH 20 AND 30 MG/KG OCT WAS SIGNIFICANTLY HIGHER THAN IN THOSE FED THE CONTROL DIET. HENS FED 20 AND 30 MG/KG OCT EXHIBITED GREATER HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL AND INTERLEUKIN (IL) CONCENTRATIONS AND REDUCED SERUM CONCENTRATIONS OF CHOLESTEROL AND TRIGLYCERIDE COMPARED TO THOSE FED WITH 0 AND 10 MG/KG OCT. THIS STUDY INDICATES THAT SUPPLEMENTING THE DIET OF LAYING HENS WITH 20 AND 30 MG/KG OF OCT CAN IMPROVE THE PERFORMANCE, EGG QUALITY, AND HEALTH STATUS OF LAYING HENS.",NA,"HORMONE-LEVELS; RICE BRAN; POLICOSANOL; YOLK; RATS","AGRICULTURE, FOOD, AND RURAL AFFAIRS CONVERGENCE TECHNOLOGIES PROGRAM FOR EDUCATING GLOBAL CREATIVE LEADERS; MINISTRY OF AGRICULTURE, FOOD AND RURAL AFFAIRS (MAFRA) [716002-7]","THIS WORK WAS SUPPORTED BY THE AGRICULTURE, FOOD, AND RURAL AFFAIRS CONVERGENCE TECHNOLOGIES PROGRAM FOR EDUCATING GLOBAL CREATIVE LEADERS, ADMINISTERED BY THE KOREA INSTITUTE OF PLANNING AND EVALUATION FOR TECHNOLOGY IN FOOD, AGRICULTURE, AND FORESTRY (IPET) AND FUNDED BY THE MINISTRY OF AGRICULTURE, FOOD AND RURAL AFFAIRS (MAFRA; 716002-7).","BACHMANN MF, 2007, EMBO REP, V8, P1142, DOI 10.1038/SJ.EMBOR.7401099; CARBAJAL D, 1996, J PHARM PHARMACOL, V48, P858, DOI 10.1111/J.2042-7158.1996.TB03987.X; DE OLIVEIRA AM, 2012, INT J MOL SCI, V13, P1598, DOI 10.3390/IJMS13021598; EL WARDANY I, 2019, J PROD DEV, V24, P517, DOI 10.21608/JPD.2019.42829, DOI 10.21608/JPD.2019.42829; GALOBART J, 2001, POULTRY SCI, V80, P1496, DOI 10.1093/PS/80.10.1496; GHIASI H, 1999, J INFECT DIS, V179, P1086, DOI 10.1086/314736; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; GUO TY, 2017, J AGR FOOD CHEM, V65, P3647, DOI 10.1021/ACS.JAFC.6B05465; HAIM D, 2009, J CHROMATOGR B, V877, P4154, DOI 10.1016/J.JCHROMB.2009.10.034; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; JETTER R, 2006, ANNU PLANT REV, V23, P145; JUSTIZ-VAILLANT A.A., 2020, STATPEARLS; KABIR Y, 2020, HERBAL MEDICINE IN INDIA: INDIGENOUS KNOWLEDGE, PRACTICE, INNOVATION AND ITS VALUE, P413, DOI 10.1007/978-981-13-7248-3\_25; KIM HYUNJUNG, 2003, JOURNAL OF MEDICINAL FOOD, V6, P345; LONG L, 2017, POULTRY SCI, V96, P894, DOI 10.3382/PS/PEW316; LONG L, 2015, ANIM NUTR, V1, P293, DOI 10.1016/J.ANINU.2015.12.005; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; PENG K, 2016, ASIAN AUSTRAL J ANIM, V29, P1458, DOI 10.5713/AJAS.16.0287; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; RDA RURAL DEVELOPMENT ADMINISTRATION NIAS NATIONAL INSTITUTE OF ANIMAL SCIENCE, 2017, KOR FEED STAND POULT; SAITOH S, 2001, BIOSCI BIOTECH BIOCH, V65, P2220, DOI 10.1271/BBB.65.2220; SINGH AK, 2020, CARPATHIAN J FOOD SC, V12, P27, DOI 10.34302/CRPJFST/2020.12.5.2; SURAI P. F., 2001, JOURNAL OF POULTRY SCIENCE, V38, P1; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TOOMER OT, 2019, POULTRY SCI, V98, P1732, DOI 10.3382/PS/PEY531; VANELSWYK ME, 1997, BRIT J NUTR, V78, PS61, DOI 10.1079/BJN19970135; ZAHEER K., 2015, FOOD AND NUTRITION SCIENCES, V6, P1208, DOI 10.4236/FNS.2015.613127; ZHOU YP, 2022, FOOD BIOSCI, V47, DOI 10.1016/J.FBIO.2022.101632","RYU, KS (CORRESPONDING AUTHOR), JEONBUK NATL UNIV, DEPT ANIM SCI, COLL AGR \& LIFE SCI, JEONJU 54896, SOUTH KOREA","KOREAN SOCIETY ANIMAL SCIENCE \& TECHNOLOGY","ENGLISH","J. ANIM. SCI. TECHNOL.","ARTICLE","ISI","WOS000891197500005","J ANIM SCI TECHNOL","JEONBUK NATL UNIV;JEONBUK NATL UNIV","JEONBUK NATL UNIV",NA,"LIM CI, 2022, J ANIM SCI TECHNOL","LIM CI, 2022, J ANIM SCI TECHNOL"
"SIRAJ N","SIRAJ NAILA","WHEAT GERM OIL A COMPREHENSIVE REVIEW",2022,"FOOD SCIENCE AND TECHNOLOGY","42",NA,5,"10.1590/fst.113721","SIRAJ, N (CORRESPONDING AUTHOR), GOVT COLL WOMEN UNIV, FAISALABAD, PAKISTAN.; SIRAJ, NAILA, GOVT COLL WOMEN UNIV, FAISALABAD, PAKISTAN.","WHEAT GERM IS A VALUABLE BY-PRODUCT OF THE WHEAT MILLING PROCESS, REPRESENTS 10-15\% LIPID CONTENTS WITH OTHER BIOACTIVE COMPOUNDS. VARIOUS WHEAT GERM OIL (WGO) RECOVERY METHODS HAVE BEEN ADOPTED, INCLUDING MECHANICAL PRESSING, SOLVENT EXTRACTION, AND SUPERCRITICAL FLUID EXTRACTION. SOME MODIFICATIONS REPORTED BY DIFFERENT EXPERIMENTAL STUDIES TO ENHANCE THE OIL YIELD RETAIN THE NUTRITIONAL ATTRIBUTES OF FRESH OIL. HOWEVER, IN HIGH ENZYMATIC ACTIVITIES AND UNSATURATED FATTY ACIDS, WGO LOSES ITS NUTRITIONAL SIGNIFICANCE DURING STORAGE AND OTHER PROCESSING TREATMENTS THAT ULTIMATELY DECREASE THE OIL'S SHELF LIFE. THE EFFECTUAL PRETREATMENTS AND STORAGE CONDITIONS FOR WGO HAVE BEEN STUDIED TO VALORIZE AND RETAIN HEALTHFUL CAPABILITY FULLY. WGO POSSESSES PHYTOGENIC COMPONENTS WITH DISTINCT POTENT HEALTH BENEFITS. THE ASSOCIATION BETWEEN DIETARY LIPIDS AND LIFE-THREATENING DISORDERS HAS INSTIGATED AN EXPANDING RESEARCH CURIOSITY IN WGO. DIVERSE EXPERIMENTAL STUDIES HAVE PROVED THAT THE WGO EMBRACES ABUNDANT BENEFICIAL EFFECTS BESIDES HEALTH DISORDERS.","ATTRIBUTES; EXTRACTION; PHARMACOLOGICAL; PROCESSING; WHEAT GERM OIL","SUPERCRITICAL CARBON-DIOXIDE; EXTRACTION; STORAGE; POLICOSANOL; STABILITY; SOLVENT; SEED",NA,NA,"ABDEL FATTAH S. M., 2011, EGYPTIAN J HOSP MED, V45, P403, DOI 10.21608/EJHM.2011.16367, DOI 10.21608/EJHM.2011.16367; ALESSANDRI C, 2006, ARTERIOSCL THROM VAS, V26, P2577, DOI 10.1161/01.ATV.0000242795.08322.FB; ANWAR MM, 2015, J RADIAT RES APPL SI, V8, P77, DOI 10.1016/J.JRRAS.2014.11.004; ARSHAD MS, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-164; BARAKAT I. A. H., 2011, THE JOURNAL OF AMERICAN SCIENCE, V7, P664; CAPITANI M, 2011, BRAZ J CHEM ENG, V28, P243, DOI 10.1590/S0104-66322011000200008; CURRIER T. K, 1973, PHYS THER, V53, P222, DOI 10.1093/ PTJ/53.2.222A, DOI 10.1093/PTJ/53.2.222A; DEBONNE E, 2018, LWT-FOOD SCI TECHNOL, V93, P212, DOI 10.1016/J.LWT.2018.03.041; DUNFORD N. T., 2009, GOURMET AND HEALTH-PROMOTING SPECIALITY OILS., P359; DUNFORD N. T., 2003, P 6 INT S SUP FLUIDS, P273; DUNFORD NT, 2003, FOOD RES INT, V36, P905, DOI 10.1016/S0963-9969(03)00099-1; DUNFORD NT, 2010, FOOD CHEM, V119, P1246, DOI 10.1016/J.FOODCHEM.2009.07.039; EISENMENGER M, 2008, J AM OIL CHEM SOC, V85, P55, DOI 10.1007/S11746-007-1163-0; EISENMENGER MJ., 2005, SUPERCRITICAL FLUID EXTRACTION, FRACTIONATION, AND CHARACTERIZATION OF WHEAT GERM OIL; EL-MARASY S. A., 2012, BULLETIN OF THE FACULTY OF PHARMACY, CAIRO UNIVERSITY, V50, P81, DOI 10.1016/J.BFOPCU.2012.05.001; ELMOTASEM H, 2018, INT J PHARMACEUT, V547, P83, DOI 10.1016/J.IJPHARM.2018.05.038; FANG XZ, 2014, J AM OIL CHEM SOC, V91, P1261, DOI 10.1007/S11746-014-2467-5; FIELD R., 2008, INTERNATIONAL JOURNAL OF CANCER RESEARCH (USA), V4, P127; FOOD AND AGRICULTURE ORGANIZATION-FAO CODEX ALIMENTARIUS COMMISSION., 2007, PROC MAN; GORUSUPUDI A, 2013, NUTRITION, V29, P790, DOI 10.1016/J.NUT.20, 10.1016/J.NUT.2012.11.003; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUMUS ZP, 2015, COLLOID SURFACE B, V133, P73, DOI 10.1016/J.COLSURFB.2015.05.044; HIDALGO A, 2008, J AGR FOOD CHEM, V56, P11300, DOI 10.1021/JF802448T; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JANTHACHOTIKUN S, 2015, THESIS OKLAHOMA STAT; JENAB E, 2006, EUR J LIPID SCI TECH, V108, P488, DOI 10.1002/EJLT.200600026; KARABACAK M, 2011, ECOTOX ENVIRON SAFE, V74, P2119, DOI 10.1016/J.ECOENV.2011.07.002; KARADENIZ M, 2018, IND CROP PROD, V114, P14, DOI 10.1016/J.INDCROP.2018.01.068; KHALIFA F. K., 2011, AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES, V5, P54; KUMAR GS, 2015, J FOOD SCI TECH MYS, V52, P1145, DOI 10.1007/S13197-013-1119-3; LI BS, 2019, AQUACULTURE, V505, P54, DOI 10.1016/J.AQUACULTURE.2019.02.037; LI B, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0167330; MEGAHED M. G., 2011, AGRICULTURE AND BIOLOGY JOURNAL OF NORTH AMERICA, V2, P163, DOI 10.5251/ABJNA.2011.2.1.163.168; MOHAMED DA, 2005, DEUT LEBENSM-RUNDSCH, V101, P66; MOHAMED N., 2010, ISOTOPE RAD RES, V42, P211; NARAYANANKUTTY A, 2018, J SCI FOOD AGR, V98, P1757, DOI 10.1002/JSFA.8650, 10.1002/JSFA.8; NYSTRÖM L, 2007, J CEREAL SCI, V45, P106, DOI 10.1016/J.JCS.2006.08.003; PIRAS A, 2009, MOLECULES, V14, P2573, DOI 10.3390/MOLECULES14072573; SHABBIR MA, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/S12944-017-0489-3; SHAO P, 2008, FOOD BIOPROD PROCESS, V86, P227, DOI 10.1016/J.FBP.2007.04.001; SHEDID S. M. E., 2008, THESIS HELWAN U HELW; WANG T, 2001, J AM OIL CHEM SOC, V78, P71, DOI 10.1007/S11746-001-0222-2; WINKLER-MOSER JK, 2011, IND CROP PROD, V33, P572, DOI 10.1016/J.INDCROP.2010.12.013; ZHONG SS, 2019, FREE RADICAL BIO MED, V144, P266, DOI 10.1016/J.FREERADBIOMED.2019.03.036; ZHOU KQ, 2004, LEBENSM-WISS TECHNOL, V37, P717, DOI 10.1016/J.LWT.2004.02.008; ZHU KX, 2011, FOOD CHEM, V126, P1122, DOI 10.1016/J.FOODCHEM.2010.11.144; ZOU YP, 2018, LWT-FOOD SCI TECHNOL, V90, P246, DOI 10.1016/J.LWT.2017.12.038","SIRAJ, N (CORRESPONDING AUTHOR), GOVT COLL WOMEN UNIV, FAISALABAD, PAKISTAN","SOC BRASILEIRA CIENCIA TECNOLOGIA ALIMENTOS","ENGLISH","FOOD SCI. TECHNOL.","REVIEW","ISI","WOS000776053700006","FOOD SCI TECHNOL","GOVT COLL WOMEN UNIV;GOVT COLL WOMEN UNIV","GOVT COLL WOMEN UNIV",NA,"SIRAJ N, 2022, FOOD SCI TECHNOL","SIRAJ N, 2022, FOOD SCI TECHNOL"
"ALI S;YUAN Q;WANG S;FARAG M","ALI SARA E;YUAN QIN;WANG SHENGPENG;FARAG MOHAMED A","MORE THAN SWEET A PHYTOCHEMICAL AND PHARMACOLOGICAL REVIEW OF SUGARCANE ISACCHARUM OFFICINARUMI L",2021,"FOOD BIOSCIENCE","44",NA,12,"10.1016/j.fbio.2021.101431","WANG, SP (CORRESPONDING AUTHOR), UNIV MACAU, INST CHINESE MED SCI, STATE KEY LAB QUAL RES CHINESE MED, MACAU, PEOPLES R CHINA.; FARAG, MA (CORRESPONDING AUTHOR), CAIRO UNIV, COLL PHARM, PHARMACOGNOSY DEPT, KASR EL AINI ST,PB 11562, CAIRO 11562, EGYPT.; ALI, SARA E., GERMAN UNIV CAIRO, FAC PHARM \& BIOTECHNOL, DEPT PHARMACEUT BIOL, NEW CAIRO 12613, EGYPT.; YUAN, QIN; WANG, SHENGPENG, UNIV MACAU, INST CHINESE MED SCI, STATE KEY LAB QUAL RES CHINESE MED, MACAU, PEOPLES R CHINA.; FARAG, MOHAMED A., CAIRO UNIV, COLL PHARM, PHARMACOGNOSY DEPT, KASR EL AINI ST,PB 11562, CAIRO 11562, EGYPT.","SACCHARUM OFFICINARUM L., COMMONLY KNOWN AS SUGARCANE, IS ONE OF THE MOST WIDELY CULTIVATED CROPS WORLDWIDE. IN ADDITION TO ITS GLOBAL VALUE AS THE MAIN SOURCE OF SUCROSE, SUGARCANE POSSESSES A VARIETY OF BIOACTIVITIES OWING TO ITS MYRIAD CONSTITUENTS. DESPITE THE REPORTED HEALTH BENEFITS OF SUGARCANE, PHYTOCHEMICAL STUDIES IN SUGARCANE ARE SCARCE AND ITS BIOACTIVE COMPOUNDS HAVE STILL NOT BEEN ADEQUATELY EXPLOITED. THIS REVIEW PRESENTS AN UPDATED KNOWLEDGE OF THE POTENTIAL BIOACTIVITIES OF SUGARCANE AND ITS BY-PRODUCTS IN RELATION TO ITS PHYTOCHEMICAL PROFILES. WE PRESENT A THOROUGH UNDERSTANDING OF THE PHARMACOLOGICAL ACTIVITIES OF SUGARCANE AND ITS BY-PRODUCTS WITH A FUTURE PROSPECTIVE FOR MAXIMIZING THEIR BENEFITS AS VALUABLE MEDICINAL PRODUCTS, IN ADDITION TO OPENING NEW VENUES IN THE FIELD OF SUGARCANE INDUSTRY. VARIOUS TECHNIQUES USED FOR SUGARCANE JUICE PRESERVATION AS MAJOR PRODUCT TO MAINTAIN ITS BIOACTIVE COMPOUNDS AND STABILITY ARE PRESENTED WHICH IN TURN COULD ENHANCE ITS INTRODUCTION TO A WIDER MARKET.","SACCHARUM OFFICINARUM L; SUGARCANE; BY-PRODUCTS; PHENOLIC COMPOUNDS; HEALTH BENEFITS","ANTIOXIDANT ACTIVITY; PHENOLIC-COMPOUNDS; DIETARY FIBER; FATTY-ACIDS; HEPATIC-FIBROSIS; SHELF-LIFE; JUICE; POLICOSANOL; BAGASSE; EXTRACT",NA,NA,"ALI SE, 2019, MOLECULES, V24, DOI 10.3390/MOLECULES24050934; ALVES VG, 2016, AN ACAD BRAS CIENC, V88, P1201, DOI 10.1590/0001-3765201620150349; ARIF S., 2019, NON-ALCOHOLIC BEVERAGES, P227, DOI 10.1016/B978-0-12-815270-6.00008-6, DOI 10.1016/B978-0-12-815270-6.00008-6; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA MD, 2003, CLIN DRUG INVEST, V23, P107, DOI 10.2165/00044011-200323020-00004; ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; ASSIRY AM, 2006, BIOELECTROCHEMISTRY, V68, P7, DOI 10.1016/J.BIOELECHEM.2005.02.005; AWAD K, 2016, PHARMACOL RES, V114, P42, DOI 10.1016/J.PHRS.2016.10.008; BARRIOS J, 2010, J AGR FOOD CHEM, V58, P2100, DOI 10.1021/JF9041497; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CARVALHO MJ, 2021, IND CROP PROD, V169, DOI 10.1016/J.INDCROP.2021.113625; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P55; CHAUHAN OP, 2002, INT J FOOD PROP, V5, P217, DOI 10.1081/JFP-120015603; CHINNADURAI C, 2017, POTENTIAL HLTH BENEF; COLOMBO R, 2006, J CHROMATOGR A, V1103, P118, DOI 10.1016/J.CHROMA.2005.11.007; DEL RÍO JC, 2015, IND CROP PROD, V77, P992, DOI 10.1016/J.INDCROP.2015.09.064; DUARTE-ALMEIDA JM, 2007, PHYTOCHEMISTRY, V68, P1165, DOI 10.1016/J.PHYTOCHEM.2007.01.015; DUARTE-ALMEIDA JM, 2006, PLANT FOOD HUM NUTR, V61, P187, DOI 10.1007/S11130-006-0032-6; FARAG MA, 2018, J PROTEOME RES, V17, P2060, DOI 10.1021/ACS.JPROTEOME.7B00929; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; GOMES CF, 2018, J FOOD ENG, V233, P74, DOI 10.1016/J.JFOODENG.2018.04.001; GRYGLEWSKI RJ, 1978, ACTA BIOL MED GER, V37, P715; GUIMARAES CM, 2007, J FOOD SCI, V72, PC39, DOI 10.1111/J.1750-3841.2006.00231.X; GUO C, 2013, FOOD CHEM TOXICOL, V56, P436, DOI 10.1016/J.FCT.2013.02.051; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; HITHAMANI G, 2018, J FOOD SCI TECH MYS, V55, P4356, DOI 10.1007/S13197-018-3350-4; HUANG HW, 2015, FOOD BIOPROCESS TECH, V8, P2483, DOI 10.1007/S11947-015-1600-2; JIANG XW, 2015, J AGR FOOD CHEM, V63, P6221, DOI 10.1021/ACS.JAFC.5B02181; JONES JM, 2013, ADV NUTR, V4, P8, DOI 10.3945/AN.112.002907; JONES P.J., 2016, FUNCTIONAL DIETARY LIPIDS, P287; KAAVYA R, 2019, SUGAR TECH, V21, P9, DOI 10.1007/S12355-018-0622-2; KADAM US, 2008, FOOD CHEM, V106, P1154, DOI 10.1016/J.FOODCHEM.2007.07.066; KAMPA M, 2004, BREAST CANCER RES, V6, PR63, DOI 10.1186/BCR752; KANG BH, 2014, PLANT FOOD HUM NUTR, V69, P155, DOI 10.1007/S11130-014-0415-Z; LACHNICHT D, 2002, NUTR RES, V22, P1389, DOI 10.1016/S0271-5317(02)00484-0; LEDÓN N, 2007, PHYTOMEDICINE, V14, P690, DOI 10.1016/J.PHYMED.2006.12.019; LEDÓN N, 2003, PLANTA MED, V69, P367, DOI 10.1055/S-2003-38880; LEE SK, 1998, COMB CHEM HIGH T SCR, V1, P35; LEE YS, 2005, ARCH PHARM RES, V28, P1183, DOI 10.1007/BF02972984; LYU SW, 1990, J CHEM ECOL, V16, P2559, DOI 10.1007/BF01017478; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MISHRA BB, 2011, J FOOD SCI, V76, PM573, DOI 10.1111/J.1750-3841.2011.02348.X; MOHAN CC, 2018, CARBOHYD POLYM, V186, P394, DOI 10.1016/J.CARBPOL.2018.01.057; PANDRAJU S., 2018, J FOOD MEAS CHARACT, V12; PUGAZHENDHI D, 2005, J APPL TOXICOL, V25, P301, DOI 10.1002/JAT.1066; RABELO SC, 2011, BIORESOURCE TECHNOL, V102, P7887, DOI 10.1016/J.BIORTECH.2011.05.081; RABELO SC, 2020, SUGARCANE BIOREFINERY, TECHNOLOGY AND PERSPECTIVES, P141, DOI 10.1016/B978-0-12-814236-3.00008-1; RATHNAKUMAR K., 2018, SUGAR TECHNOLOGY, V21; SANGNARK A, 2003, FOOD CHEM, V80, P221, DOI 10.1016/S0308-8146(02)00257-1; SAXENA J, 2017, J FOOD PROCESS ENG, V40, DOI 10.1111/JFPE.12485; SINGH A, 2015, PHARMACOGN RES, V7, P85, DOI 10.4103/0973-7847.156340, 10.4103/0974-8490.147215; SINGH B, 2018, FOOD CHEM, V261, P75, DOI 10.1016/J.FOODCHEM.2018.04.039; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SREEDEVI P, 2018, J FOOD MEAS CHARACT, V12, P1962, DOI 10.1007/S11694-018-9811-7; SUN J, 2014, MOLECULES, V19, P13147, DOI 10.3390/MOLECULES190913147; THIPPESWAMY G, 2008, EUR J PHARMACOL, V588, P141, DOI 10.1016/J.EJPHAR.2008.04.027; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WANG LW, 2018, FOOD FUNCT, V9, P951, DOI 10.1039/C7FO01617D, 10.1039/C7FO01617D; WANG LW, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1068528; WILLIAMS I. O., 2016, AFRICAN JOURNAL OF BIOTECHNOLOGY, V15, P1789; WU XL, 2004, J AGR FOOD CHEM, V52, P4026, DOI 10.1021/JF049696W; YANG JL, 2019, POLYMERS-BASEL, V11, DOI 10.3390/POLYM11050751; YUSOF S, 2000, FOOD CHEM, V68, P395, DOI 10.1016/S0308-8146(99)00180-6; ZHANG YY, 2015, J ETHNOPHARMACOL, V163, P99, DOI 10.1016/J.JEP.2015.01.015; ZHAO Y, 2015, FOOD CHEM, V185, P112, DOI 10.1016/J.FOODCHEM.2015.03.120; ZHAO ZG, 2018, IND CROP PROD, V113, P38, DOI 10.1016/J.INDCROP.2018.01.015; ZHENG R, 2017, IND CROP PROD, V101, P104, DOI 10.1016/J.INDCROP.2017.03.012; ZHUANG XB, 2016, MEAT SCI, V113, P107, DOI 10.1016/J.MEATSCI.2015.11.007; ZIBOH VA, 1996, LIPIDS, V31, PS249, DOI 10.1007/BF02637085","WANG, SP (CORRESPONDING AUTHOR), UNIV MACAU, INST CHINESE MED SCI, STATE KEY LAB QUAL RES CHINESE MED, MACAU, PEOPLES R CHINA","ELSEVIER","ENGLISH","FOOD BIOSCI.","REVIEW","ISI","WOS000718321000002","FOOD BIOSCI","UNIV MACAU;CAIRO UNIV;GERMAN UNIV CAIRO;UNIV MACAU;CAIRO UNIV","UNIV MACAU",NA,"ALI SE, 2021, FOOD BIOSCI","ALI SE, 2021, FOOD BIOSCI"
"KUMAR M;TOMAR M;BHUYAN D;PUNIA S;GRASSO S;SA A;CARCIOFI B;AUGUSTO M A;ARRUTIA F;CHANGAN S;RADHA R;SINGH S;DHUMAL S;SENAPATHY M;SATANKAR ;VARSHA V;ANITHA T;SHARMA A;PANDISELVAM R;AMAROWICZ R;MEKHEMAR M","KUMAR MANOJ;TOMAR MAHARISHI;BHUYAN DEEP JYOTI;PUNIA SNEH;GRASSO SIMONA;SA AMANDA GOMES ALMEIDA;CARCIOFI BRUNO; AUGUSTO MATTAR;ARRUTIA FATIMA;CHANGAN SUSHIL;RADHA; SINGH SURINDER;DHUMAL SANGRAM;SENAPATHY M;SATANKAR; VARSHA;ANITHA T;SHARMA ANSHU;PANDISELVAM R; AMAROWICZ RYSZARD;MEKHEMAR MOHAMED","TOMATO SOLANUM LYCOPERSICUM L SEED A REVIEW ON BIOACTIVES AND BIOMEDICAL ACTIVITIES",2021,"BIOMEDICINE \& PHARMACOTHERAPY","142",NA,50,"10.1016/j.biopha.2021.112018","KUMAR, M (CORRESPONDING AUTHOR), ICAR CENT INST RES COTTON TECHNOL, CHEM \& BIOCHEM PROC DIV, MUMBAI 400019, MAHARASHTRA, INDIA.; TOMAR, M (CORRESPONDING AUTHOR), ICAR INDIAN GRASSLAND \& FODDER RES INST, SEED TECHNOL DIV, JHANSI 284003, UTTAR PRADESH, INDIA.; MEKHEMAR, M (CORRESPONDING AUTHOR), UNIV KIEL, SCH DENT MED, CLIN CONSERVAT DENT \& PERIODONTOL, D-24105 KIEL, GERMANY.; KUMAR, MANOJ, ICAR CENT INST RES COTTON TECHNOL, CHEM \& BIOCHEM PROC DIV, MUMBAI 400019, MAHARASHTRA, INDIA.; TOMAR, MAHARISHI, ICAR INDIAN GRASSLAND \& FODDER RES INST, SEED TECHNOL DIV, JHANSI 284003, UTTAR PRADESH, INDIA.; BHUYAN, DEEP JYOTI, WESTERN SYDNEY UNIV, NICM HLTH RES INST, PENRITH, NSW 2751, AUSTRALIA.; PUNIA, SNEH, CLEMSON UNIV, DEPT FOOD NUTR \& PACKAGING SCI, CLEMSON, SC 29634 USA.; GRASSO, SIMONA, UNIV READING, SCH AGR POLICY \& DEV, READING, BERKS, ENGLAND.; SA, AMANDA GOMES ALMEIDA; CARCIOFI, BRUNO AUGUSTO MATTAR, UNIV FED SANTA CATARINA, DEPT CHEM ENGN \& FOOD ENGN, FLORIANOPOLIS, SC, BRAZIL.; ARRUTIA, FATIMA, CATHOLIC UNIV LOUVAIN, LAB BIOENGN EARTH \& LIFE INST APPL MICROBIOL, CROIX SUD,2 L7-05-19, B-1348 LOUVAIN, BELGIUM.; CHANGAN, SUSHIL, ICAR CENT POTATO RES INST, DIV CROP PHYSIOL BIOCHEM \& POST HARVEST TECHNOL, SHIMLA 171001, INDIA.; RADHA, SHOOLINI UNIV BIOTECHNOL \& MANAGEMENT SCI, SCH BIOL \& ENVIRONM SCI, SOLAN 173229, HIMACHAL PRADES, INDIA.; SINGH, SURINDER, PANJAB UNIV, DR SS BHATNAGAR UNIV INST CHEM ENGN \& TECHNOL, CHANDIGARH 160014, INDIA.; DHUMAL, SANGRAM, RCSM COLL AGR, DIV HORT, KOLHAPUR 416004, MAHARASHTRA, INDIA.; SENAPATHY, M., WOLAITA SODO UNIV, DEPT RURAL DEV \& AGR EXTENS, COLL AGR, WOLAITA SODO, ETHIOPIA.; SATANKAR, VARSHA, ICAR CENT INST RES COTTON TECHNOL, GINNING TRAINING CTR, NAGPUR 440023, MAHARASHTRA, INDIA.; ANITHA, T., HORT COLL \& RES INST, DEPT POSTHARVEST TECHNOL, PERIYAKULAM 625604, TAMIL NADU, INDIA.; SHARMA, ANSHU, DR S PARMAR UNIV HORT \& FORESTRY, DEPT FOOD SCI \& TECHNOL, NAUNI 173230, INDIA.; PANDISELVAM, R., ICAR CENT PLANTAT CROPS RES INST CPCRI, DIV PHYSIOL BIOCHEM \& POST HARVEST TECHNOL, KASARAGOD 671124, KERALA, INDIA.; AMAROWICZ, RYSZARD, POLISH ACAD SCI, INST ANIM REPROD \& FOOD RES, OLSZTYN, POLAND.; MEKHEMAR, MOHAMED, UNIV KIEL, SCH DENT MED, CLIN CONSERVAT DENT \& PERIODONTOL, D-24105 KIEL, GERMANY.","THE PROCESSING OF TOMATO FRUIT INTO PUREE, JUICES, KETCHUP, SAUCES, AND DRIED POWDERS GENERATES A SIGNIFICANT AMOUNT OF WASTE IN THE FORM OF TOMATO POMACE, WHICH INCLUDES SEEDS AND SKIN. TOMATO PROCESSING BY-PRODUCTS, PARTICULARLY SEEDS, ARE RESERVOIRS OF HEALTH-PROMOTING MACROMOLECULES, SUCH AS PROTEINS (BIOACTIVE PEPTIDES), CAROTENOIDS (LYCOPENE), POLYSACCHARIDES (PECTIN), PHYTOCHEMICALS (FLAVONOIDS), AND VITAMINS (ALPHA-TOCOPHEROL). HEALTH-PROMOTING PROPERTIES MAKE THESE BIOACTIVE COMPONENTS SUITABLE CANDIDATES FOR THE DEVELOPMENT OF NOVEL FOOD AND NUTRACEUTICAL PRODUCTS. THIS REVIEW COMPREHENSIVELY DEMONSTRATES THE BIOACTIVE COMPOUNDS OF TOMATO SEEDS ALONG WITH DIVERSE BIOMEDICAL ACTIVITIES OF TOMATO SEED EXTRACT (TSE) FOR TREATING CARDIOVASCULAR AILMENTS, NEUROLOGICAL DISORDERS, AND ACT AS ANTIOXIDANT, ANTICANCER, AND ANTIMICROBIAL AGENT. UTILIZATION OF BIOACTIVE COMPONENTS CAN IMPROVE THE ECONOMIC FEASIBILITY OF THE TOMATO PROCESSING INDUSTRY AND MAY HELP TO REDUCE THE ENVIRONMENTAL POLLUTION GENERATED BY TOMATO BY-PRODUCTS.","TOMATO SEEDS; PHYTOCHEMICALS; BIOLOGICAL ACTIVITIES; HEALTH PROMOTING; EFFECTS","ANGIOTENSIN-CONVERTING ENZYME; POLYUNSATURATED FATTY-ACIDS; PROCESSING; BY-PRODUCTS; ANTIOXIDANT ACTIVITY; AQUEOUS EXTRACT; IN-VITRO; WASTE; PROTEINS; HUMAN SERUM; POLICOSANOL; POMACE","UNIVERSITY OF KIEL; UNIVERSITY OF SCHLES-WIGHOLSTEIN","THE AUTHORS WOULD LIKE TO THANK THE UNIVERSITY OF KIEL AND SCHLES-WIGHOLSTEIN FOR THE SUPPORT THROUGH THE OA PROGRAM.","ABASSI Z, 2020, FRONT PHYSIOL, V11, DOI 10.3389/FPHYS.2020.574753; ABDELHEDI O, 2018, FOOD CHEM, V239, P453, DOI 10.1016/J.FOODCHEM.2018.01.033, 10.1016/J.FOODCHEM.2017.06.112; ALAM P, 2019, J HERB MED, V16, DOI 10.1016/J.HERMED.2018.09.006; AUST O, 2005, INT J VITAM NUTR RES, V75, P54, DOI 10.1024/0300-9831.75.1.54; AZABOU S, 2020, FOOD BIOSCI, V36, DOI 10.1016/J.FBIO.2020.100664; BELLAVITE P, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/ANTIOX9080742; BELOVIC MM, 2016, J FOOD PROCESS PRES, V40, P1229, DOI 10.1111/JFPP.12707; BISWAS D, 2014, EUR J NUTR, V53, P1699, DOI 10.1007/S00394-014-0676-1; BOTINESTEAN C., 2012, JOURNAL OF AGROALIMENTARY PROCESSES AND TECHNOLOGIES, V18, P89; CASTAÑO G, 2001, INT J CLIN PHARM RES, V21, P43; CASTANO GLADYS, 2002, DRUGS R D, V3, P159, DOI 10.2165/00126839-200203030-00004; CETKOVIC G, 2012, FOOD CHEM, V133, P938, DOI 10.1016/J.FOODCHEM.2012.02.007; CHANG CJ, 2011, PLANTA MED, V77, P1876, DOI 10.1055/S-0031-1279992; CHEN Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/JMV.25681; CHENG L., 2020, CITRUS FRUITS RICH F; CONCHA-MEYER A, 2020, FOODS, V9, DOI 10.3390/FOODS9111564; CORNIER MA, 2008, ENDOCR REV, V29, P777, DOI 10.1210/ER.2008-0024; COSTELA-RUIZ VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/J.CYTOGFR.2020.06.001; DABKE K, 2019, J CLIN INVEST, V129, P4050, DOI 10.1172/JCI129194; DAS UN, 2004, PROSTAG LEUKOTR ESS, V70, P539, DOI 10.1016/J.PLEFA.2003.12.001; DURANTE M, 2017, J FOOD COMPOS ANAL, V63, P65, DOI 10.1016/J.JFCA.2017.07.026; DUTTA-ROY AK, 2001, PLATELETS, V12, P218, DOI 10.1080/09537100120058757; ECKEL RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; EDENHARDER R, 1994, FOOD CHEM TOXICOL, V32, P443, DOI 10.1016/0278-6915(94)90042-6; ELBADRAWY E, 2016, ARAB J CHEM, V9, PS1010, DOI 10.1016/J.ARABJC.2011.11.011; ELLER FJ, 2010, J AM OIL CHEM SOC, V87, P755, DOI 10.1007/S11746-010-1563-4; ELSEWEIDY MM, 2016, EXP BIOL MED, V241, P1943, DOI 10.1177/1535370216659943; EZZ MAGDA K., 2018, JOURNAL OF DIETARY SUPPLEMENTS, V15, P923, DOI 10.1080/19390211.2017.1406427; FAKHRI S, 2020, PHYTOTHER RES, V34, P2790, DOI 10.1002/PTR.6797; FERRERES F, 2010, J AGR FOOD CHEM, V58, P2854, DOI 10.1021/JF904015F; FRIEDMAN M, 2013, J AGR FOOD CHEM, V61, P9534, DOI 10.1021/JF402654E; FRIEDMAN M, 2009, J AGR FOOD CHEM, V57, P5727, DOI 10.1021/JF900364J; FUENTES EJ, 2012, BLOOD COAGUL FIBRIN, V23, P109, DOI 10.1097/MBC.0B013E32834D78DD; FUENTES EDUARDO, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P867578, DOI 10.1155/2013/867578; HERRERA PG, 2010, INNOV FOOD SCI EMERG, V11, P707, DOI 10.1016/J.IFSET.2010.07.005; GAUTAM S., 2016, J FOOD CHEM NANOTECH, V2, P97, DOI DOI 10.17756/JFCN.2016-018; GE XY, 2013, NATURE, V503, P535, DOI 10.1038/NATURE12711; GEORGE B, 2004, FOOD CHEM, V84, P45, DOI 10.1016/S0308-8146(03)00165-1; GHARBI E, 2016, PHYSIOL PLANTARUM, V158, P152, DOI 10.1111/PPL.12458; GIANNELOS PN, 2005, IND CROP PROD, V22, P193, DOI 10.1016/J.INDCROP.2004.11.001; GIUFFRÈ AM, 2017, J FOOD PROCESS PRES, V41, DOI 10.1111/JFPP.13309; GOKUL K, 2014, NEUROCHEM RES, V39, P1382, DOI 10.1007/S11064-014-1323-1; GORBALENYA AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/S41564-020-0695-Z; GORDON MH, 1983, FOOD CHEM, V10, P141, DOI 10.1016/0308-8146(83)90030-4; HAN DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/J.VIROL.2006.01.029; HE WS, 2020, FOOD FUNCT, V11, P4275, DOI 10.1039/D0FO00133C, 10.1039/D0FO00133C; HUANG CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30211-7, 10.1016/S0140-6736(20)30183-5; HUANG QW, 2020, PHARMACOL RES, V159, DOI 10.1016/J.PHRS.2020.105051; IANEVSKI A., 2020, VIRUSES-BASEL, V12; ILAHY R, 2016, FOOD FUNCT, V7, P574, DOI 10.1039/C5FO00553A, 10.1039/C5FO00553A; JHA NK, 2021, IMMUNO-BASEL, V1, DOI 10.3390/IMMUNO1010004; JÓZWIAK M, 2020, EUR J PHARMACOL, V871, DOI 10.1016/J.EJPHAR.2020.172937; JUNG CHANGHWA JUNG CHANGHWA, 2013, PHYTOTHERAPY RESEARCH, V27, P139, DOI 10.1002/PTR.4687; KAUR GURPREET, 2015, BIOTECHNOL REP (AMST), V6, P64, DOI 10.1016/J.BTRE.2015.01.005; KEFYALEW GEBEYEW KEFYALEW GEBEYEW, 2015, JOURNAL OF VETERINARY SCIENCE AND TECHNOLOGY, V6, P217; KERMANI J, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/MEDICINA55080499; KIM SP, 2015, J AGR FOOD CHEM, V63, P1142, DOI 10.1021/JF5040288; KRISHNA G, 2016, J SCI FOOD AGR, V96, P1745, DOI 10.1002/JSFA.7281; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LEE KR, 2004, J AGR FOOD CHEM, V52, P2832, DOI 10.1021/JF030526D; LI B, 2018, J AGR FOOD CHEM, V66, P1428, DOI 10.1021/ACS.JAFC.7B06078; LI WH, 2003, NATURE, V426, P450, DOI 10.1038/NATURE02145; LINNEWIEL-HERMONI K, 2015, ARCH BIOCHEM BIOPHYS, V572, P28, DOI 10.1016/J.ABB.2015.02.018; LIU SHUN, 2012, ZHONGHUA XIN XUE GUAN BING ZA ZHI, V40, P840; LU ZQ, 2019, TRENDS FOOD SCI TECH, V86, P172, DOI 10.1016/J.TIFS.2019.02.020; GUIL-GUERRERO JL, 2011, J MED FOOD, V14, P40, DOI 10.1089/JMF.2010.0051; MAITI S, 2021, DRUG DEVELOP RES, V82, P86, DOI 10.1002/DDR.21730; MALDONADO-TORRES R, 2020, MOLECULES, V25, DOI 10.3390/MOLECULES25184235; MARIA T, 2020, FOOD SCI TECH-BRAZIL, V40, P692, DOI 10.1590/FST.16619; MARTÍ R, 2016, CANCERS, V8, DOI 10.3390/CANCERS8060058; MAURYA VIMAL K., 2020, VIRUSDISEASE, V31, P179, DOI 10.1007/S13337-020-00598-8; MECHMECHE M, 2019, INT J PEPT RES THER, V25, P137, DOI 10.1007/S10989-017-9655-8; MECHMECHE M, 2017, FOOD BIOTECHNOL, V31, P94, DOI 10.1080/08905436.2017.1302888; MESHGINFAR N, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/JFBC.12721; MILANI A, 2017, BRIT J PHARMACOL, V174, P1290, DOI 10.1111/BPH.13625; MOAYEDI A, 2018, FOOD CHEM, V250, P180, DOI 10.1016/J.FOODCHEM.2018.01.033; MOAYEDI A, 2017, APPL BIOCHEM BIOTECH, V181, P48, DOI 10.1007/S12010-016-2198-1; MOAYEDI A, 2016, J FOOD SCI TECH MYS, V53, P391, DOI 10.1007/S13197-015-1965-2; MOCO S, 2007, J EXP BOT, V58, P4131, DOI 10.1093/JXB/ERM271; MÜLLER L, 2013, J AGR FOOD CHEM, V61, P346, DOI 10.1021/JF302748Z; NAVARRO-GONZÁLEZ I, 2011, FOOD RES INT, V44, P1528, DOI 10.1016/J.FOODRES.2011.04.005; NGWA W, 2020, MOLECULES, V25, DOI 10.3390/MOLECULES25112707; NIEDZWIECKI A, 2016, NUTRIENTS, V8, DOI 10.3390/NU8090552; NOA M, 2005, ARCH MED RES, V36, P441, DOI 10.1016/J.ARCMED.2005.03.039; NOA M, 1994, J PHARM PHARMACOL, V46, P282, DOI 10.1111/J.2042-7158.1994.TB03794.X; OBOULBIGA EDWIGE BAHANLA, 2020, AFRICAN JOURNAL OF FOOD SCIENCE, V14, P330, DOI 10.5897/AJFS2020.1998; PALOMO I, 2019, NUTRIENTS, V11, DOI 10.3390/NU11020456; PALOMO I, 2012, EXP THER MED, V3, P577, DOI 10.3892/ETM.2012.477; PANDEY P, 2021, J BIOMOL STRUCT DYN, V39, P6306, DOI 10.1080/07391102.2020.1796811; PÉREZ-GÁLVEZ A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/ANTIOX9060505; PINELA J, 2016, SEP PURIF TECHNOL, V164, P114, DOI 10.1016/J.SEPPUR.2016.03.030; PLATT KL, 2010, MUTAT RES-GEN TOX EN, V703, P90, DOI 10.1016/J.MRGENTOX.2010.08.007; POUR PM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/FPHAR.2019.01207; PREVITERA L, 2016, J SCI FOOD AGR, V96, P1953, DOI 10.1002/JSFA.7303; RAIOLA ASSUNTA, 2014, MEDIATORS INFLAMM, V2014, P139873, DOI 10.1155/2014/139873; FLORES IR, 2021, FOOD CHEM, V344, DOI 10.1016/J.FOODCHEM.2020.128608; RAUSCHER R, 1998, MUTAT RES-GEN TOX EN, V413, P129, DOI 10.1016/S1383-5718(98)00017-5; RICHARD D, 2008, PHARMACOL RES, V57, P451, DOI 10.1016/J.PHRS.2008.05.002; RODRIGUEZ DB, 1975, PLANT PHYSIOL, V56, P626, DOI 10.1104/PP.56.5.626; RODRÍGUEZ-AZÚA R, 2014, J MED FOOD, V17, P505, DOI 10.1089/JMF.2012.0243; ROSHANRAVAN N, 2020, ARCH MED RES, V51, P608, DOI 10.1016/J.ARCMED.2020.06.012; CELMA AR, 2009, FOOD BIOPROD PROCESS, V87, P282, DOI 10.1016/J.FBP.2008.12.003; SAKLAYEN MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/S11906-018-0812-Z; SALEHI B, 2019, NUTRITION, V62, P201, DOI 10.1016/J.NUT.2019.01.012; SARKAR A, 2014, J FOOD PROCESS ENG, V37, P299, DOI 10.1111/JFPE.12086; SELTZER S, 2020, INT J INFECT DIS, V101, P42, DOI 10.1016/J.IJID.2020.09.041; SHAO DY, 2015, LWT-FOOD SCI TECHNOL, V63, P191, DOI 10.1016/J.LWT.2015.03.010; SHAO DY, 2014, FOOD BIOPROCESS TECH, V7, P532, DOI 10.1007/S11947-013-1057-0; SHAO DY, 2013, FOOD CHEM, V139, P589, DOI 10.1016/J.FOODCHEM.2013.01.043; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SHI Y, 2013, EUR J PHARM SCI, V48, P819, DOI 10.1016/J.EJPS.2012.12.031; SILVA YPA, 2019, INT J FOOD SCI NUTR, V70, P150, DOI 10.1080/09637486.2018.1489530; SO WW, 2015, NUTRIENTS, V7, P6956, DOI 10.3390/NU7085319; SOLOMON S, 2019, BMC CARDIOVASC DISOR, V19, DOI 10.1186/S12872-019-1201-5; SOY M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/S10067-020-05190-5; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; STAJCIC S, 2015, FOOD CHEM, V172, P225, DOI 10.1016/J.FOODCHEM.2014.09.069; SZABO K, 2021, FOODS, V10, DOI 10.3390/FOODS10010110; SZABO K, 2019, LWT-FOOD SCI TECHNOL, V116, DOI 10.1016/J.LWT.2019.108558; SZABO K, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/ANTIOX8080292; TAN HL, 2010, CANCER METAST REV, V29, P553, DOI 10.1007/S10555-010-9246-Z; TAVEIRA M, 2010, J AGR FOOD CHEM, V58, P9529, DOI 10.1021/JF102215G; TOMMONARO G, 2014, NAT PROD RES, V28, P764, DOI 10.1080/14786419.2013.879474; TOOR RK, 2005, FOOD RES INT, V38, P487, DOI 10.1016/J.FOODRES.2004.10.016; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; TSANTILA N, 2010, NUTR METAB CARDIOVAS, V20, P740, DOI 10.1016/J.NUMECD.2009.06.008; VADEZ-MORALES M, 2014, J AGR FOOD CHEM, V62, P5281, DOI 10.1021/JF5012374; VINHA AF, 2014, LWT-FOOD SCI TECHNOL, V55, P197, DOI 10.1016/J.LWT.2013.07.016; VISSIENNON C, 2012, J NUTR BIOCHEM, V23, P733, DOI 10.1016/J.JNUTBIO.2011.03.017; VIUDA-MARTOS M, 2014, CRIT REV FOOD SCI, V54, P1032, DOI 10.1080/10408398.2011.623799; WAN M., 2017, CHIN J ETHNOMED ETHN, V2017, P15; WANG YL, 2020, FOOD CHEM, V311, DOI 10.1016/J.FOODCHEM.2019.125880; YONEKURA L, 2007, MOL NUTR FOOD RES, V51, P107, DOI 10.1002/MNFR.200600145; YU WP, 2009, MOL NUTR FOOD RES, V53, P1573, DOI 10.1002/MNFR.200900011; ZIELINSKI H, 2000, J AGR FOOD CHEM, V48, P2008, DOI 10.1021/JF990619O; ZIMMET P, 2019, J INTERN MED, V286, P181, DOI 10.1111/JOIM.12924","KUMAR, M (CORRESPONDING AUTHOR), ICAR CENT INST RES COTTON TECHNOL, CHEM \& BIOCHEM PROC DIV, MUMBAI 400019, MAHARASHTRA, INDIA","ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER","ENGLISH","BIOMED. PHARMACOTHER.","REVIEW","ISI","WOS000697026300013","BIOMED PHARMACOTHER","ICAR CENT INST RES COTTON TECHNOL;ICAR INDIAN GRASSLAND AND FODDER RES INST;UNIV KIEL;ICAR CENT INST RES COTTON TECHNOL;ICAR INDIAN GRASSLAND AND FODDER RES INST;WESTERN SYDNEY UNIV;CLEMSON UNIV;UNIV READING;UNIV FED SANTA CATARINA;CATHOLIC UNIV LOUVAIN;ICAR CENT POTATO RES INST;SHOOLINI UNIV BIOTECHNOL AND MANAGEMENT SCI;PANJAB UNIV;RCSM COLL AGR;WOLAITA SODO UNIV;ICAR CENT INST RES COTTON TECHNOL;HORT COLL AND RES INST;DR S PARMAR UNIV HORT AND FORESTRY;ICAR CENT PLANTAT CROPS RES INST CPCRI;INST ANIM REPROD AND FOOD RES;UNIV KIEL","ICAR CENT INST RES COTTON TECHNOL",NA,"KUMAR M, 2021, BIOMED PHARMACOTHER","KUMAR M, 2021, BIOMED PHARMACOTHER"
"TEIXEIRA F;VIDIGAL S;PIMENTEL L;L. L;COSTA P;TAVARES-VALENTE D;AZEVEDO-SILVA ;JOAO J;PINTADO M;FERNANDES J;RODRIGUEZ-ALCALA L","TEIXEIRA FRANCISCA S;VIDIGAL SUSANA S M P;PIMENTEL LIGIA; L;COSTA PAULA T;TAVARES-VALENTE DIANA;AZEVEDO-SILVA; JOAO;PINTADO MANUELA E;FERNANDES JOAO C; RODRIGUEZ-ALCALA LUIS M","PHYTOSTEROLS AND NOVEL TRITERPENES RECOVERED FROM INDUSTRIAL FERMENTATION COPRODUCTS EXERT IN VITRO ANTIINFLAMMATORY ACTIVITY IN MACROPHAGES",2021,"PHARMACEUTICALS","14",NA,9,"10.3390/ph14060583","RODRÍGUEZ-ALCALÁ, LM (CORRESPONDING AUTHOR), UNIV CATOLICA PORTUGUESA, ESCOLA SUPER BIOTECNOL, CBQF CTR BIOTECNOL \& QUIM FINA, LAB ASSOCIADO, RUA DIOGO BOTELHO 1327, P-4169005 PORTO, PORTUGAL.; TEIXEIRA, FRANCISCA S.; VIDIGAL, SUSANA S. M. P.; PIMENTEL, LIGIA L.; COSTA, PAULA T.; TAVARES-VALENTE, DIANA; AZEVEDO-SILVA, JOAO; PINTADO, MANUELA E.; FERNANDES, JOAO C.; RODRIGUEZ-ALCALA, LUIS M., UNIV CATOLICA PORTUGUESA, ESCOLA SUPER BIOTECNOL, CBQF CTR BIOTECNOL \& QUIM FINA, LAB ASSOCIADO, RUA DIOGO BOTELHO 1327, P-4169005 PORTO, PORTUGAL.","THE UNSTOPPABLE GROWTH OF HUMAN POPULATION THAT OCCURS IN PARALLEL WITH ALL MANUFACTURING ACTIVITIES LEADS TO A RELENTLESS INCREASE IN THE DEMAND FOR RESOURCES, CULTIVATION LAND, AND ENERGY. IN RESPONSE, CURRENTLY, THERE IS SIGNIFICANT INTEREST IN DEVELOPING STRATEGIES TO OPTIMIZE ANY AVAILABLE RESOURCES AND THEIR BIOWASTE. WHILE SOLUTIONS INITIALLY FOCUSED ON RECOVERING BIOMOLECULES WITH APPLICATIONS IN FOOD, ENERGY, OR MATERIALS, THE FEASIBILITY OF SYNTHETIC BIOLOGY IN THIS FIELD HAS BEEN DEMONSTRATED IN RECENT YEARS. FOR INSTANCE, IT IS POSSIBLE TO GENETICALLY MODIFY SACCHAROMYCES CEREVISIAE TO PRODUCE TERPENES FOR COMMERCIAL APPLICATIONS (I.E., AGAINST MALARIA OR AS BIODIESEL). BUT THE PRODUCTION PROCESS, SIMILAR TO ANY INDUSTRIAL ACTIVITY, GENERATES BIOWASTES CONTAINING PROMISING BIOMOLECULES (FROM FERMENTATION) THAT IF RECOVERED MAY HAVE APPLICATIONS IN DIFFERENT AREAS. TO TEST THIS HYPOTHESIS, IN THE PRESENT STUDY, THE LIPID COMPOSITION OF BY-PRODUCTS FROM THE INDUSTRIAL PRODUCTION OF BETA-FARNESENE BY GENETICALLY MODIFIED SACCHAROMYCES CEREVISIAE ARE STUDIED TO IDENTIFY POTENTIALLY BIOACTIVE COMPOUNDS, THEIR RECOVERY, AND FINALLY, THEIR STABILITY AND IN VITRO BIOACTIVITY. THE ASSAYED BIOWASTE SHOWED THE PRESENCE OF TRITERPENES, PHYTOSTEROLS, AND 1-OCTACOSANOL WHICH WERE RECOVERED THROUGH MOLECULAR DISTILLATION INTO A SINGLE FRACTION. DURING THE ASSAYED STABILITY TEST, COMPOSITIONAL MODIFICATIONS WERE OBSERVED, MAINLY FOR THE PHYTOSTEROLS AND 1-OCTACOSANOL, PROBABLY DUE TO OXIDATIVE REACTIONS. HOWEVER, SUCH CHANGES DID NOT AFFECT THE IN VITRO BIOACTIVITY IN MACROPHAGES, WHERE IT WAS FOUND THAT THE OBTAINED FRACTION DECREASED THE PRODUCTION OF TNF-ALPHA AND IL-6 IN LIPOPOLYSACCHARIDE (LPS)-INDUCED INFLAMMATION.","BIOWASTE; TRITERPENES; 1-OCTACOSANOL; PHYTOSTEROLS; STABILITY TEST; MOLECULAR DISTILLATION; MACROPHAGES; INFLAMMATION; IL-6","PERFORMANCE LIQUID-CHROMATOGRAPHY; BIOETHANOL PRODUCTION; ANTIOXIDANT; ACTIVITY; OXIDATION; WASTE; OCTACOSANOL; MODEL; POLICOSANOL; SEPARATION; STABILITY","ESCOLA SUPERIOR DE BIOTECNOLOGIA-UNIVERSIDADE CATOLICA PORTUGUESA THROUGH THE ALCHEMY PROJECT, CAPTURING HIGH VALUE FROM INDUSTRIAL FERMENTATION BIOPRODUCTS [POCI-01 0247-FEDER-027578]; FCT [UID/MULTI/50016/2019]; AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA","THIS WORK WAS SUPPORTED BY AMYRIS BIO PRODUCTS PORTUGAL UNIPESSOAL LDA AND ESCOLA SUPERIOR DE BIOTECNOLOGIA-UNIVERSIDADE CATOLICA PORTUGUESA THROUGH THE ALCHEMY PROJECT, CAPTURING HIGH VALUE FROM INDUSTRIAL FERMENTATION BIOPRODUCTS (POCI-01 0247-FEDER-027578). AUTHORS WOULD ALSO LIKE TO THANK THE SCIENTIFIC COLLABORATION UNDER THE FCT PROJECT UID/MULTI/50016/2019.","ABREU S, 2017, J CHROMATOGR A, V1514, P54, DOI 10.1016/J.CHROMA.2017.07.063; ALDINI R, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0108112; ANONYMOUS, 2019, WORLD POPULATION PRO, DOI DOI 10.18356/13BF5476-EN; ANONYMOUS, 2015, OECD FAO AGR OUTLOOK; ANONYMOUS, 2012, OFFICIAL JOURNAL OF THE EUROPEAN UNION L, V136, P1, DOI DOI 10.1016/B978-0-08-100922-2.00001-2; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; ATTARD TM, 2015, IND CROP PROD, V76, P95, DOI 10.1016/J.INDCROP.2015.05.077; BELL J, 2018, NEW BIOTECHNOL, V40, P25, DOI 10.1016/J.NBT.2017.06.010; BENTELDJOUNE M, 2021, NAT PROD RES, V35, P1639, DOI 10.1080/14786419.2019.1619722; BOBO-GARCÍA G, 2015, J SCI FOOD AGR, V95, P204, DOI 10.1002/JSFA.6706; BUSIC A, 2018, FOOD TECHNOL BIOTECH, V56, P289, DOI 10.17113/FTB.56.03.18.5546; CANIZARES D, 2019, IND CROP PROD, V141, DOI 10.1016/J.INDCROP.2019.111700; CHOE E, 2006, COMPR REV FOOD SCI F, V5, P169, DOI 10.1111/J.1541-4337.2006.00009.X; CORBERÁN VC, 2014, CATAL TODAY, V238, P49, DOI 10.1016/J.CATTOD.2014.03.033; CPMP/ICH, 2003, INT C HARM, V4, P1; D'AMATO D, 2017, J CLEAN PROD, V168, P716, DOI 10.1016/J.JCLEPRO.2017.09.053; DÁVALOS A, 2004, J AGR FOOD CHEM, V52, P48, DOI 10.1021/JF0305231; DE ALMEIDA DT, 2019, FOOD SCI TECH-BRAZIL, V39, P211, DOI 10.1590/FST.43317; DE OLIVEIRA S, 2014, QUIM NOVA, V37, P497, DOI 10.5935/0100-4042.20140076; GARCÍA-MARTÍNEZ MD, 2010, INT J FOOD SCI TECH, V45, P2337, DOI 10.1111/J.1365-2621.2010.02405.X; DEL RÍO JC, 2015, IND CROP PROD, V77, P992, DOI 10.1016/J.INDCROP.2015.09.064; DORMONT F, 2020, SCI ADV, V6, DOI 10.1126/SCIADV.AAZ5466; EJSING CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/PNAS.0811700106; EKINCI N, 2016, TURK J AGRIC FOR, V40, P38, DOI 10.3906/TAR-1411-91; FADHIL AB, 2017, FUEL, V210, P721, DOI 10.1016/J.FUEL.2017.09.009; FAOSTAT, FAOSTAT STAT DAT; FENG J, 2019, SCI ADV, V5, DOI 10.1126/SCIADV.AAU5148; FENG SM, 2015, FOOD CHEM, V182, P171, DOI 10.1016/J.FOODCHEM.2015.03.003; FISHER K., 2009, U.S. PATENT, PATENT NO. 7,592,295, 7592295; FOUQUET TNJ, 2019, J MASS SPECTROM, V54, P933, DOI 10.1002/JMS.4480; GACHUMI G, 2021, PHARMACEUTICS, V13, DOI 10.3390/PHARMACEUTICS13020268; GEISSDOERFER M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/J.JCLEPRO.2016.12.048; GEORGE S., 2001, INFRARED AND RAMAN CHARACTERISTIC GROUP FREQUENCIES: TABLES AND CHARTS, VTHIRD; GREENSPAN L, 1977, J RES NBS A PHYS CH, V81, P89, DOI 10.6028/JRES.081A.011; GUO TY, 2017, J AGR FOOD CHEM, V65, P3647, DOI 10.1021/ACS.JAFC.6B05465; HANSON R., GREAT FILTER; HOMAN R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; ISHAKA A, 2014, INT J NANOMED, V9, P2261, DOI 10.2147/IJN.S56999; ISHIDA T, 2012, CHEMSUSCHEM, V5, P2243, DOI 10.1002/CSSC.201200324; JAMBO SA, 2016, RENEW SUST ENERG REV, V65, P756, DOI 10.1016/J.RSER.2016.07.064; KAUSHIK MK, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-08874-2; KHOR YP, 2019, FOODS, V8, DOI 10.3390/FOODS8100475; KIM SM, 2014, J CEREAL SCI, V60, P243, DOI 10.1016/J.JCS.2014.04.001; KLUNKLIN W, 2021, POLYMERS-BASEL, V13, DOI 10.3390/POLYM13010081; LEE JK, 2020, BIORESOURCE TECHNOL, V298, DOI 10.1016/J.BIORTECH.2019.122346; LEE SH, 2019, INT J SPORT PHYSIOL, V14, P1297, DOI 10.1123/IJSPP.2018-0704; LENGYEL J, 2012, FOOD CHEM, V133, P1435, DOI 10.1016/J.FOODCHEM.2012.02.031; LIU CY, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/J.BIOPHA.2020.110252; MEADOWS AL, 2016, NATURE, V537, P694, DOI 10.1038/NATURE19769; MELLO BLB, 2021, TROP ANIM HEALTH PRO, V53, DOI 10.1007/S11250-021-02640-3; NALLATHAMBY N, 2015, NAT PROD COMMUN, V10, P885; NAUTIYAL P, 2017, CLEAN TECHNOL ENVIR, V19, P1667, DOI 10.1007/S10098-017-1355-8; PADDON CJ, 2013, NATURE, V496, P528, DOI 10.1038/NATURE12051; PICCIRILLO C, 2014, J MATER CHEM B, V2, P5999, DOI 10.1039/C4TB00984C; PIMENTEL D., 2017, ENCY ANTHROPOCENE, V1, P313; PIMENTEL LL, 2021, BBA-MOL CELL BIOL L, V1866, DOI 10.1016/J.BBALIP.2020.158839; RAHMANIA H, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-71020-Y; REDDY LH, 2009, ADV DRUG DELIVER REV, V61, P1412, DOI 10.1016/J.ADDR.2009.09.005; RODRÍGUEZ-ALCALÁ LM, 2007, J AGR FOOD CHEM, V55, P6533, DOI 10.1021/JF0708591; ROUKAS T, 2020, J CLEAN PROD, V257, DOI 10.1016/J.JCLEPRO.2020.120519; SAHU P, 2019, IND ENG CHEM RES, V58, P20946, DOI 10.1021/ACS.IECR.9B02001; SÁNCHEZ-MORENO C, 2002, FOOD SCI TECHNOL INT, V8, P121, DOI 10.1177/1082013202008003770, 10.1106/108201302026770; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SUGAWARA T, 1999, LIPIDS, V34, P1231, DOI 10.1007/S11745-999-0476-3; TEGENGE MA, 2019, REGUL TOXICOL PHARM, V108, DOI 10.1016/J.YRTPH.2019.104436; TOCI AT, 2013, LWT-FOOD SCI TECHNOL, V50, P581, DOI 10.1016/J.LWT.2012.08.007; WILLETT W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; XU P, 2012, ACS SYNTH BIOL, V1, P256, DOI 10.1021/SB300016B; YOO T, 2017, RUBBER CHEM TECHNOL, V90, P308, DOI 10.5254/RCT.17.82683; YU L., 2007, WHEAT ANTIOXIDANTS; YUAN LL, 2019, FOODS, V8, DOI 10.3390/FOODS8110582; ZABED H, 2017, RENEW SUST ENERG REV, V71, P475, DOI 10.1016/J.RSER.2016.12.076; ZHANG JZ, 2021, CURR OPIN BIOTECH, V67, P88, DOI 10.1016/J.COPBIO.2021.01.010; ZHANG YP, 2017, FEMS YEAST RES, V17, DOI 10.1093/FEMSYR/FOX080","RODRÍGUEZ-ALCALÁ, LM (CORRESPONDING AUTHOR), UNIV CATOLICA PORTUGUESA, ESCOLA SUPER BIOTECNOL, CBQF CTR BIOTECNOL \& QUIM FINA, LAB ASSOCIADO, RUA DIOGO BOTELHO 1327, P-4169005 PORTO, PORTUGAL","MDPI","ENGLISH","PHARMACEUTICALS","ARTICLE","ISI","WOS000665880900001","PHARMACEUTICALS","UNIV CATOLICA PORTUGUESA;TAVARES-VALENTE;UNIV CATOLICA PORTUGUESA","UNIV CATOLICA PORTUGUESA",NA,"TEIXEIRA FS, 2021, PHARMACEUTICALS","TEIXEIRA FS, 2021, PHARMACEUTICALS"
"ZHANG X;MA C;SUN L;HE Z;FENG Y;LI X;GAN J;CHEN X","ZHANG XIN;MA CHENJING;SUN LONG;HE ZHAO;FENG YING;LI XIAN;GAN JIN;CHEN XIAOMING","EFFECT OF POLICOSANOL FROM INSECT WAX ON AMYLOID ΒPEPTIDEINDUCED TOXICITY IN A TRANSGENIC ICAENORHABDITIS ELEGANSI MODEL OF ALZHEIMERS DISEASE",2021,"BMC COMPLEMENTARY MEDICINE AND THERAPIES","21",NA,16,"10.1186/s12906-021-03278-2","FENG, Y (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, RES INST RESOURCE INSECTS, KEY LAB CULTIVATING \& UTILIZAT RESOURCE INSECTS, STATE FORESTRY ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA.; ZHANG, XIN; MA, CHENJING; SUN, LONG; HE, ZHAO; FENG, YING; LI, XIAN; GAN, JIN; CHEN, XIAOMING, CHINESE ACAD FORESTRY, RES INST RESOURCE INSECTS, KEY LAB CULTIVATING \& UTILIZAT RESOURCE INSECTS, STATE FORESTRY ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA.","BACKGROUND ALZHEIMER'S DISEASE (AD), AN AGE-RELATED NEURODEGENERATIVE DISORDER AND A SERIOUS PUBLIC HEALTH CONCERN, IS MAINLY CAUSED BY BETA-AMYLOID (A BETA)-INDUCED TOXICITY. CURRENTLY, A LIMITED NUMBER OF DRUGS ARE EFFECTIVE AGAINST AD, AND ONLY A FEW ARE USED FOR ITS TREATMENT. ACCORDING TO TRADITIONAL CHINESE MEDICINE, WHITE WAX IS MAINLY COMPOSED OF POLICOSANOL, HEXACOSANOL, AND OCTACOSANOL. POLICOSANOL HAS BEEN SHOWN TO REDUCE LIPID LEVELS IN BLOOD AND ALLEVIATE THE SYMPTOMS ASSOCIATED WITH DIABETIC COMPLICATIONS AND NEURODEGENERATIVE DISORDERS, SUCH AS PARKINSON'S DISEASE AND AD. HOWEVER, THE EFFICACY OF POLICOSANOL DEPENDS ON THE PURITY AND COMPOSITION OF THE PREPARATION, AND THE THERAPEUTIC EFFICACY OF POLICOSANOL DERIVED FROM INSECT WAX (PIW) IN AD IS UNKNOWN. METHODS HERE, WE IDENTIFIED THE MAIN COMPONENTS OF PIW AND INVESTIGATED THE EFFECTS OF PIW ON A BETA-INDUCED TOXICITY AND LIFE-SPAN IN A TRANSGENIC CAENORHABDITIS ELEGANS MODEL OF AD, CL4176. FURTHERMORE, WE ESTIMATED THE EXPRESSION OF AMYLOID PRECURSOR-LIKE PROTEIN (APL-1) AND THE GENES INVOLVED IN VARIOUS PATHWAYS ASSOCIATED WITH LONGEVITY AND ALLEVIATION OF AD-RELATED SYMPTOMS IN PIW-FED CL4176. RESULTS PIW MAINLY CONSISTS OF TETRACOSANOL, HEXACOSANOL, OCTACOSANOL, AND TRIACONTANOL; IT COULD DECREASE THE A BETA-INDUCED PARALYSIS RATE FROM 86.87 TO 66.97\% (P < 0.01) AND EXTEND THE LIFE-SPAN FROM 6.2 D TO 7.8 D (P < 0.001) IN CL4176 WORMS. FURTHERMORE, PIW DOWNREGULATED APL-1, A GENE KNOWN TO BE ASSOCIATED WITH THE LEVELS OF A BETA DEPOSITS IN C. ELEGANS. ADDITIONALLY, OUR RESULTS SHOWED THAT PIW MODULATED THE EXPRESSION OF GENES ASSOCIATED WITH LONGEVITY-RELATED PATHWAYS SUCH AS HEAT SHOCK RESPONSE, ANTI-OXIDATIVE STRESS, AND GLUTAMINE CYSTEINE SYNTHETASE. CONCLUSION OUR FINDINGS SUGGEST THAT PIW MAY BE A POTENTIAL THERAPEUTIC AGENT FOR THE PREVENTION AND TREATMENT OF AD. HOWEVER, ITS EFFECTS ON MURINE MODELS AND PATIENTS WITH AD NEED TO BE EXPLORED FURTHER.","ALZHEIMER\&\#8217; S DISEASE; INSECT WAX; POLICOSANOL; \&\#946; -AMYLOID; C; ELEGANS; CL4176","WHITE WAX; CHOLESTEROL; PROTEIN; POLYSACCHARIDE; HEXACOSANOL; AGGREGATION; INHIBITION; EXPRESSION; SYMPTOMS; APL-1","CHINESE ACADEMY OF FORESTRY [CAFYBB2018ZB007]","THIS WORK WAS SUPPORTED BY GRANTS FROM THE CHINESE ACADEMY OF FORESTRY (NO. CAFYBB2018ZB007).","ABBAS S, 2010, PHYTOMEDICINE, V17, P902, DOI 10.1016/J.PHYMED.2010.03.008; ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; AFFUSO F, 2010, NUTR METAB CARDIOVAS, V20, P656, DOI 10.1016/J.NUMECD.2009.05.017; AGOSTONI C, 2011, EFSA J, V9, DOI 10.2903/J.EFSA.2011.2207; AN JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/GAD.1107803; ANAND R, 2014, NEUROPHARMACOLOGY, V76, P27, DOI 10.1016/J.NEUROPHARM.2013.07.004; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; BUTTERFIELD DA, 2003, CNS DRUGS, V17, P641, DOI 10.2165/00023210-200317090-00004; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CHEN W, 2018, BIOGERONTOLOGY, V19, P47, DOI 10.1007/S10522-017-9738-0; CHEN X., 2011, A NEW GENERALIZATION OF CHEBYSHEV INEQUALITY FOR RANDOM VECTORS, P1; CONWAY ME, 2020, BIOGERONTOLOGY, V21, P257, DOI 10.1007/S10522-020-09860-4; DIOMEDE L, 2010, NEUROBIOL DIS, V40, P424, DOI 10.1016/J.NBD.2010.07.002; DOUGLAS PM, 2015, CELL REP, V12, P1196, DOI 10.1016/J.CELREP.2015.07.026; DULLENS SPJ, 2008, J LIPID RES, V49, P790, DOI 10.1194/JLR.M700497-JLR200; ELSEWEIDY MM, 2016, EXP BIOL MED, V241, P1943, DOI 10.1177/1535370216659943; EWALD CY, 2012, GENETICS, V191, P493, DOI 10.1534/GENETICS.112.138768; FENG YING, 2006, FOREST RESEARCH, V19, P221; FENG YING, 2014, FOREST RESEARCH, V27, P388; FOLCH J, 2018, J ALZHEIMERS DIS, V62, P1223, DOI 10.3233/JAD-170672; FONTE V, 2008, J BIOL CHEM, V283, P784, DOI 10.1074/JBC.M703339200; GERSTBREIN B, 2005, AGING CELL, V4, P127, DOI 10.1111/J.1474-9726.2005.00153.X; GOEDERT M, 2006, SCIENCE, V314, P777, DOI 10.1126/SCIENCE.1132814; GRECO D, 2008, AM J PHYSIOL-GASTR L, V294, PG1281, DOI 10.1152/AJPGI.00074.2008; GUTIERREZ-ZEPEDA A, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-54; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; HARRABI S, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/S12944-018-0682-Z; HE ZHAO, 2008, FOREST RESEARCH, V21, P792; HE ZHAO, 2015, HUANJING KUNCHONG XUEBAO, V37, P61; HOU XY., 2011, J ANHUI AGR SCI, V39, P2817; HULL J, 2015, J ALZHEIMERS DIS, V45, P891, DOI 10.3233/JAD-142970; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KENYON CJ, 2010, NATURE, V464, P504, DOI 10.1038/NATURE08980; LANG CH, 2010, AM J PHYSIOL-REG I, V299, PR935, DOI 10.1152/AJPREGU.00297.2010; LEE JY, 2016, FOOD SCI BIOTECHNOL, V25, P899, DOI 10.1007/S10068-016-0147-Y; LEMERE CA, 2010, NAT REV NEUROL, V6, P108, DOI 10.1038/NRNEUROL.2009.219; LI FANG, 2018, ZHONGGUO SHENGWU HUAXUE YU FENZI SHENGWU XUEBAO, V34, P844, DOI 10.13865/J.CNKI.CJBMB.2018.08.07; LI SZ, 1926, COMPENDIUM MAT MED; LIN L, 2017, SAUDI PHARM J, V25, P625, DOI 10.1016/J.JSPS.2017.04.035; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; LINK CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/PNAS.92.20.9368; LINK CD, 2001, NEUROBIOL AGING, V22, P217, DOI 10.1016/S0197-4580(00)00237-2; LORENZO N, 2017, CLIN EXP MED, V17, P209, DOI 10.1007/S10238-016-0412-7; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; LUO XH, 2016, FITOTERAPIA, V108, P5, DOI 10.1016/J.FITOTE.2015.11.010; MA JJ., 2018, ENVIRON ENTOMOL, V40, P1247; MA LIYI MA LIYI, 2009, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, V29, P6; MANSFELD J, 2015, NAT COMMUN, V6, DOI 10.1038/NCOMMS10043; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MISRA S, 2013, NEUROL SCI, V34, P831, DOI 10.1007/S10072-013-1316-X; MOOSBRUGGER I, 1992, INT J IMMUNOPHARMACO, V14, P293, DOI 10.1016/0192-0561(92)90042-J; PRAHLAD V, 2008, SCIENCE, V320, P811, DOI 10.1126/SCIENCE.1156093; RENOUDET VV, 2012, J MED FOOD, V15, P758; SÁNCHEZ J, 2017, REV NEUROLOGIA, V64, P153; SANGHA JS, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0043990; SELKOE DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/PHYSREV.2001.81.2.741; SHINAGAWA SHUNICHIRO, 2014, BRAIN NERVE, V66, P507; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; STUSSER R, 1998, INT J CLIN PHARM TH, V36, P469; TÖNJES M, 2013, NAT MED, V19, P901, DOI 10.1038/NM.3217; TULLET JMA, 2008, CELL, V132, P1025, DOI 10.1016/J.CELL.2008.01.030; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WANG T, 2010, ACTA PHARMACOL SIN, V31, P765, DOI 10.1038/APS.2010.69; WANG ZD., 2019, CHIN J ETHNOMED ETHN, V28, P21; WANG ZHAN-DI, 2017, FOREST RESEARCH, V30, P41, DOI 10.13275/J.CNKI.LYKXYJ.2017.01.006; WANG ZD, 2017, BIOMED PHARMACOTHER, V89, P438, DOI 10.1016/J.BIOPHA.2017.02.036; WIESE M, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0012790; WU YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; YANG P, 2015, SCI REP-UK, V5, DOI 10.1038/SREP08141; YANG P, 2014, ARCH INSECT BIOCHEM, V87, P214, DOI 10.1002/ARCH.21191; ZHANG XG, 2016, FRONT PHARMACOL, V7, DOI 10.3389/FPHAR.2016.00227; ZHAO Y, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/316523; ZHOU Y., 1980, HIST ENTOMOLOGY CHIN, P41; ZOU SW., 1982, HIST CHINESE ENTOMOL, P112","FENG, Y (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, RES INST RESOURCE INSECTS, KEY LAB CULTIVATING \& UTILIZAT RESOURCE INSECTS, STATE FORESTRY ADM, KUNMING 650224, YUNNAN, PEOPLES R CHINA","BMC","ENGLISH","BMC COMPLEMENT. MED. THER.","ARTICLE","ISI","WOS000636233700002","BMC COMPLEMENT MED THER","RES INST RESOURCE INSECTS;RES INST RESOURCE INSECTS","RES INST RESOURCE INSECTS",NA,"ZHANG X, 2021, BMC COMPLEMENT MED THER","ZHANG X, 2021, BMC COMPLEMENT MED THER"
"ROMERO-MARTINEZ N;RAMOS-ZAMBRANO E;OSORIO-RUIZ A;MARTINEZ-AYALA A","ROMERO-MARTINEZ NADIA;RAMOS-ZAMBRANO EMILIA;OSORIO-RUIZ ALEX;MARTINEZ-AYALA ALMA LETICIA","MAIN MECHANISMS OF ACTION OF POLICOSANOL IN ANIMAL AND PLANT CELLS",2021,"INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES","10","10-20",1,"10.51847/fGCmHjlN8k","MARTÍNEZ-AYALA, AL (CORRESPONDING AUTHOR), INST POLITECN NACL, CEPROBI IPN, KM 6,CARRETERA YAUTEPEC JOJUTLA,CALLE CEPROBI 8, YAUTEPEC 62731, MORELOS, MEXICO.; ROMERO-MARTINEZ, NADIA; RAMOS-ZAMBRANO, EMILIA; OSORIO-RUIZ, ALEX; MARTINEZ-AYALA, ALMA LETICIA, INST POLITECN NACL, CEPROBI IPN, KM 6,CARRETERA YAUTEPEC JOJUTLA,CALLE CEPROBI 8, YAUTEPEC 62731, MORELOS, MEXICO.","POLICOSANOL IS A PROMISING COMPOUND THAT CAN BE USED IN VARIOUS INDUSTRIES. IN THE PHARMACEUTICAL INDUSTRY, POLICOSANOL AND, SPECIFICALLY, TRIACONTANOL, OCTACOSANOL, AND HEXACOSANOL HAVE PRESENTED BIOLOGICAL ACTIVITY AGAINST SEVERAL DISEASES, ESPECIALLY THOSE RELATED TO INFLAMMATION AND HYPERCHOLESTEROLAEMIA. ON THE OTHER HAND, TRIACONTANOL IS USED AS A GROWTH PROMOTER IN A WIDE VARIETY OF PLANTS AND CROPS OF ECONOMIC IMPORTANCE, EVEN IN MICROALGAL CULTURE, IN EITHER ITS PURE FORM OR IN POLICOSANOL EXTRACTS. IN THIS REVIEW, THE MOST RELEVANT REFERENCES TO THE BIOACTIVITIES OF POLICOSANOL IN PLANTS AND ANIMAL CELLS ARE COLLECTED TO COMPARE THE DIFFERENT MECHANISMS OF ACTION. ANALYZING THIS IN DETAIL ALLOWS US TO ASK NEW RESEARCH QUESTIONS. THE PUBMED AND REDALYC DATABASE WERE USED FOR ARTICLE SEARCH UNDER THE FOLLOWING KEYS TERMS: POLICOSANOL, INFLAMMATORY MECHANISMS, TRIACONTANOL, CELLULAR ABSORPTION, PHOTOSYNTHESIS AND PHOTOINHIBITION. POLICOSANOL INTERFERES WITH THE PROGRESSION OF THE NF-KAPPA B AND MAPK SIGNALING PATHWAY INVOLVED IN THE INFLAMMATION PROCESS. THE CHOLESTEROL-LOWERING EFFECT OF POLICOSANOL IS DUE TO THE INHIBITION OF CHOLESTEROL SYNTHESIS IN THE LIVER, THROUGH THE INDIRECT INACTIVATION OF HMG-COA REDUCTASE. TRIACONTANOL IMPROVES THE GROWTH AND THE BIOCHEMICAL AND PHYSIOLOGICAL PARAMETERS OF PLANTS AND THE RESPONSE TO STRESS CONDITIONS THAT IS RELATED MAINLY TO PHOTOSYNTHETIC ACTIVITY. INTERESTINGLY, OCTACOSANOL DEMONSTRATES AN INHIBITORY ACTIVITY ON THE EFFECT OF TRIACONTANOL IN PLANTS, A RESPONSE NOT REPORTED IN HUMAN CELLS, AS WELL AS OTHER DIFFERENTIAL ASPECTS OF THE MECHANISMS OF ACTION IN THE CELLS OF PLANTS AND ANIMALS THAT ARE INTERESTING TO ANALYZE.","LONG CHAIN ALCOHOLS; ACTION MECHANISMS; PHARMACOLOGICAL ACTIVITY; GROWTH; PROMOTER","CHAIN FATTY ALCOHOLS; MEDIATED PROCESSES; ENERGY SENSOR; MOUSE MODEL; TRIACONTANOL; OCTACOSANOL; GROWTH; PHOTOSYNTHESIS; PROTOPLAST; MODULATE","CONSEJO NACIONAL DE CIENCIA Y TECNOLOGIA (CONACYT); INSTITUTO POLITECNICO NACIONAL (IPN)","WE ACKNOWLEDGE TO CONSEJO NACIONAL DE CIENCIA Y TECNOLOGIA (CONACYT) AND THE INSTITUTO POLITECNICO NACIONAL (IPN) FOR THE SCHOLARSHIPS GIVEN.","AKRAM M., 2018, BIOL FORUM, V10, P96; ALEDAVOOD E, 2019, J CHEM INF MODEL, V59, P2859, DOI 10.1021/ACS.JCIM.8B00890; ARULSELVAN P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5276130; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; BOROWSKI EDWARD, 2009, FOLIA HORTICULTURAE, V21, P39; CARIANOPOL CS, 2020, COMMUN BIOL, V3, DOI 10.1038/S42003-020-0866-8; CARMO-SILVA AE, 2010, J EXP BOT, V61, P2355, DOI 10.1093/JXB/ERQ071; CHANDRAN MPS, 2019, INT J PHARM PHYTOPHA, V9, P61; CHEN XP, 2003, PLANT GROWTH REGUL, V40, P249, DOI 10.1023/A:1025039027270; CHEN XP, 2002, PLANT CELL PHYSIOL, V43, P869, DOI 10.1093/PCP/PCF100; CHU BY, 2016, INT J PHARMACEUT, V500, P345, DOI 10.1016/J.IJPHARM.2016.01.030; COCCETTI P, 2018, MICROB CELL, V5, P482, DOI 10.15698/MIC2018.11.655; COCUCCI E, 2017, CLIN PHARMACOL THER, V101, P121, DOI 10.1002/CPT.545; DHYANI A, 2019, PHARMACOPHORE, V10, P13; DROVER VA, 2008, J BIOL CHEM, V283, P13108, DOI 10.1074/JBC.M708086200; EKTA KATHURIA EKTA KATHURIA, 2012, JOURNAL OF PLANT SCIENCE RESEARCH, V28, P239; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; GAO XJ, 2015, INFLAMMATION, V38, P1142, DOI 10.1007/S10753-014-0079-8; GASPARRINI M, 2017, FOOD CHEM TOXICOL, V102, P1, DOI 10.1016/J.FCT.2017.01.018; GUO TY, 2017, J AGR FOOD CHEM, V65, P3647, DOI 10.1021/ACS.JAFC.6B05465; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; HULSMANS S, 2016, TRENDS PLANT SCI, V21, P648, DOI 10.1016/J.TPLANTS.2016.04.008; IVANOV AG, 1997, PLANT GROWTH REGUL, V21, P145, DOI 10.1023/A:1005790121111; JOHNSON BM, 2018, SEMIN CELL DEV BIOL, V81, P121, DOI 10.1016/J.SEMCDB.2017.10.019; KE R, 2018, CELL BIOL INT, V42, P384, DOI 10.1002/CBIN.10915; KHALILOVA IS, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0192952; KHANDAKER MM, 2013, SCI WORLD J, DOI 10.1155/2013/308651; KIEBER JJ, 2018, DEVELOPMENT, V145, DOI 10.1242/DEV.149344; KUNJAMMAL P, 2016, BIOSCAN, V11, P2327; KUPRASH DV, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1237, DOI 10.1134/S0006297916110018; LEE JH, 2017, NUTR RES, V43, P89, DOI 10.1016/J.NUTRES.2017.05.013; LI N, 2018, J AGR FOOD CHEM, V66, P8722, DOI 10.1021/ACS.JAFC.8B02684; LIM SL, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-17056-0; LU XY, 2020, DRUG DELIV TRANSL RE, V10, P122, DOI 10.1007/S13346-019-00667-6; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; NAEEM M, 2012, J PLANT INTERACT, V7, P129, DOI 10.1080/17429145.2011.619281; NAM DE, 2019, J MED FOOD, V22, P1110, DOI 10.1089/JMF.2019.4491; PARK WK, 2013, APPL BIOCHEM BIOTECH, V171, P1128, DOI 10.1007/S12010-013-0386-9; RAMOS-ZAMBRANO E, 2021, J PLANT GROWTH REGUL, V40, P2208, DOI 10.1007/S00344-020-10262-6; RAVELO Y, 2011, J NAT MED-TOKYO, V65, P330, DOI 10.1007/S11418-010-0496-4; RIES SK, 1988, PLANTA, V173, P79, DOI 10.1007/BF00394491; SHARMA M.K., 2018, INT. J. CURR. MICROBIOL. APP. SCI., V7, P3239, DOI 10.20546/IJCMAS.2018.711.373; SHEN JJ, 2019, J FUNCT FOODS, V57, P351, DOI 10.1016/J.JFF.2019.04.024; SHRIPATHI V, 1997, BBA-BIOMEMBRANES, V1323, P263, DOI 10.1016/S0005-2736(96)00193-9; SOOD M.K., 2018, INTERNATIONAL JOURNAL OF AGRICULTURE, ENVIRONMENT AND BIOTECHNOLOGY, V11, P439, DOI DOI 10.30954/0974-1712.06.2018.4; SUGANO K, 2010, NAT REV DRUG DISCOV, V9, P597, DOI 10.1038/NRD3187; SWAMY SG, 2009, J MEMBRANE BIOL, V228, P165, DOI 10.1007/S00232-009-9169-1; YAMAMOTO Y, 2016, FRONT PLANT SCI, V7, DOI 10.3389/FPLS.2016.01136; ZHOU YM, 2018, DRUG DELIV, V25, P1546, DOI 10.1080/10717544.2018.1477864","MARTÍNEZ-AYALA, AL (CORRESPONDING AUTHOR), INST POLITECN NACL, CEPROBI IPN, KM 6,CARRETERA YAUTEPEC JOJUTLA,CALLE CEPROBI 8, YAUTEPEC 62731, MORELOS, MEXICO","INT JOURNAL PHARMACEUTICAL RESEARCH \& ALLIED SCIENCES","ENGLISH","INT. J. PHARM. RES. ALLIED SCI.","ARTICLE","ISI","WOS000661422300002","INT J PHARM RES ALLIED SCI","INST POLITECN NACL;INST POLITECN NACL","INST POLITECN NACL",NA,"ROMERO-MARTINEZ N, 2021, INT J PHARM RES ALLIED SCI","ROMERO-MARTINEZ N, 2021, INT J PHARM RES ALLIED SCI"
"RAMOS-ZAMBRANO E;JUAREZ-YANEZ T;TAPIA-MARURI ;DANIEL D;CAMACHO-DIAZ B;JIMENEZ-APARICIO A;RUPERTO R;MARTINEZ-AYALA A","RAMOS-ZAMBRANO EMILIA;JUAREZ-YANEZ TOMAS ERNESTO;TAPIA-MARURI; DANIEL;CAMACHO-DIAZ BRENDA HILDELIZA;JIMENEZ-APARICIO ANTONIO; RUPERTO;MARTINEZ-AYALA ALMA LETICIA","EFFECTS OF TRIACONTANOL AND LIGHT ON STOMATAL AND PHOTOCHEMICAL RESPONSES IN ISOLANUM LYCOPERSICUMI L",2021,"JOURNAL OF PLANT GROWTH REGULATION","40","2208-2220",3,"10.1007/s00344-020-10262-6","MARTÍNEZ-AYALA, AL (CORRESPONDING AUTHOR), INST POLITECN NACL, CTR DESARROLLO PROD BIOT, CARRETERA YAUTEPEC JOJUTLA,KM 6,CALLE CEPROBI 8, YAUTEPEC 62731, MORELOS, MEXICO.; RAMOS-ZAMBRANO, EMILIA; JUAREZ-YANEZ, TOMAS ERNESTO; TAPIA-MARURI, DANIEL; CAMACHO-DIAZ, BRENDA HILDELIZA; JIMENEZ-APARICIO, ANTONIO RUPERTO; MARTINEZ-AYALA, ALMA LETICIA, INST POLITECN NACL, CTR DESARROLLO PROD BIOT, CARRETERA YAUTEPEC JOJUTLA,KM 6,CALLE CEPROBI 8, YAUTEPEC 62731, MORELOS, MEXICO.","TRIACONTANOL IS A LONG-CHAIN ALCOHOL THAT IS CONSIDERED TO BE A PLANT GROWTH PROMOTER. EXOGENOUS APPLICATION OF TRIACONTANOL INCREASES DRY AND FRESH WEIGHT, PLANT HEIGHT, BRANCHING, STEM AND ROOT LENGTH, YIELD, AND OTHER BIOCHEMICAL PARAMETERS; IT ALSO REDUCES THE EFFECT OF DIFFERENT STRESSORS. IN THIS WORK, THE EFFECTS OF TRIACONTANOL ON STOMATAL REGULATION AND PHOTOCHEMICAL PARAMETERS IN TOMATO PLANTS EXPOSED TO THREE IRRADIANCE LEVELS (100, 200, AND 600 MU MOL M(-2) S(-1)) WERE EXAMINED. LOW AND HIGH IRRADIANCE LEVELS CAUSED A STRESS RESPONSE IN PLANTS; PHOTOSYSTEM II EFFICIENCY (PHI PSII) AND PHOTOSYNTHETIC-IRRADIANCE PARAMETERS WERE DIMINISHED. TRIACONTANOL ONLY REVERSED THE NEGATIVE EFFECTS OF HIGH IRRADIANCE, INCREASING PHOTOCHEMICAL RESPONSE AND PHOTOSYNTHETIC-IRRADIANCE PARAMETERS. MOREOVER, A LARGE POPULATION OF LOW CHLOROPLAST NUMBER, CHLOROPHYLL CONTENT, AND STOMATAL CONDUCTANCE WERE STIMULATED BY TRIACONTANOL APPLICATION. IN RELATION TO STOMATAL FUNCTION, TRIACONTANOL HAD NO EFFECT ON STOMATAL DENSITY; HOWEVER, IT AFFECTED STOMATAL SIZE AND MORPHOLOGY AT THE THREE IRRADIANCE LEVELS EVALUATED. BIOASSAYS IN EPIDERMAL PEELS SHOWED A DIRECT EFFECT ON THE STOMATAL APERTURE AND AN INCREASE IN APERTURE SIZE IN BOTH LIGHT AND DARK CONDITIONS IN TRIACONTANOL TREATMENTS. THIS IS THE FIRST REPORT OF THE ROLE OF TRIACONTANOL IN THE REGULATION OF STOMATA AND PHOTOCHEMICAL RESPONSES IN RELATION TO IRRADIANCE STRESS.","GROWTH PROMOTER; IRRADIANCE; STOMATAL REGULATION; PHOTOCHEMICAL; REACTION; CHLOROPLAST","PLANT-GROWTH; CHLOROPHYLL FLUORESCENCE; ERYTHRINA-VARIEGATA; CROP; PRODUCTIVITY; GAS-EXCHANGE; PHOTOSYNTHESIS; CONDUCTANCE; MICROPROPAGATION; POLICOSANOL; WHEAT","CONSEJO NACIONAL DE CIENCIA Y TECNOLOGIA (CONACYT); INSTITUTO POLITECNICO NACIONAL (IPN); IPN","WE ACKNOWLEDGE THE CONSEJO NACIONAL DE CIENCIA Y TECNOLOGIA (CONACYT) AND THE INSTITUTO POLITECNICO NACIONAL (IPN) FOR SCHOLARSHIPS GIVEN TO THE STUDENTS EMILIA RAMOS ZAMBRANO AND TOMAS E. JUAREZ YANEZ DURING THE COURSE OF THIS INVESTIGATION AND THE IPN FOR FINANCIAL SUPPORT. ALMA L. MARTINEZ-AYALA, ANTONIO R. JIMENEZ-APARICIO, AND BRENDA H. CAMACHO DIAZ ARE FELLOWS OF COFAA AND EDI-IPN.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; AFTAB T, 2010, J PLANT INTERACT, V5, P273, DOI 10.1080/17429141003647137; AZIZ R, 2013, PAK J BOT, V45, P1913; BOROWSKI E, 2000, ACTA PHYSIOL PLANT, V22, P271, DOI 10.1007/S11738-000-0030-5; BOROWSKI EDWARD, 2009, FOLIA HORTICULTURAE, V21, P39; CAIRD MA, 2007, PLANT PHYSIOL, V143, P4, DOI 10.1104/PP.106.092940; CHEN C, 2012, MOL PLANT, V5, P566, DOI 10.1093/MP/SSS039; CHEN XP, 2003, PLANT GROWTH REGUL, V40, P249, DOI 10.1023/A:1025039027270; CHEN XP, 2002, PLANT CELL PHYSIOL, V43, P869, DOI 10.1093/PCP/PCF100; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P12143, DOI 10.1021/JF1030345; DALEY MJ, 2006, TREE PHYSIOL, V26, P411, DOI 10.1093/TREEPHYS/26.4.411; DRAKE PL, 2013, J EXP BOT, V64, P495, DOI 10.1093/JXB/ERS347; EKTA KATHURIA EKTA KATHURIA, 2012, JOURNAL OF PLANT SCIENCE RESEARCH, V28, P239; ERTANI A, 2013, PLANT SOIL, V364, P145, DOI 10.1007/S11104-012-1335-Z; FANASCA S, 2006, J AGR FOOD CHEM, V54, P4319, DOI 10.1021/JF0602572; FAO (FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS), 2014, PROD YB; GIRIDHAR P, 2005, SCI HORTIC-AMSTERDAM, V106, P228, DOI 10.1016/J.SCIENTA.2005.02.024; GIRIDHAR P, 2004, IN VITRO CELL DEV-PL, V40, P200, DOI 10.1079/IVP2003519; GRZEGORCZYK I, 2006, ACTA SOC BOT POL, V75, P11; HOSHIKA Y, 2018, GLOBAL ECOL BIOGEOGR, V27, P257, DOI 10.1111/GEB.12681; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; IVANOV AG, 1997, PLANT GROWTH REGUL, V21, P145, DOI 10.1023/A:1005790121111; JIA Q, 2004, PATENTE, PATENT NO. US 7034060 B2, 7034060; KARAM ELHAM ASADI, 2017, INDIAN JOURNAL OF PLANT PHYSIOLOGY, V22, P120, DOI 10.1007/S40502-017-0286-Z; KHANDAKER MM, 2013, SCI WORLD J, DOI 10.1155/2013/308651; KRISHNAN RR, 2008, TROP LIFE SCI RES, V19, P53; KUMARAVELU G, 2000, BIOL PLANTARUM, V43, P287, DOI 10.1023/A:1002724831619; MALABADI RB, 2005, J PLANT PHYSIOL, V162, P473, DOI 10.1016/J.JPLPH.2004.09.008; MENDEZ E., 2003, REV CENIC CIENCIAS Q, V34, P35; COSTA JM, 2015, PLANT PHYSIOL, V167, P289, DOI 10.1104/PP.114.253369; MISRA A, 1991, PLANT GROWTH REGUL, V10, P57, DOI 10.1007/BF00035131; MONJE OA, 1992, HORTSCIENCE, V27, P69, DOI 10.21273/HORTSCI.27.1.69; MOORTHY P, 1993, BIOL PLANTARUM, V35, P577, DOI 10.1007/BF02928035; MUTHUCHELIAN K, 2003, PHOTOSYNTHETICA, V41, P335, DOI 10.1023/B:PHOT.0000015456.31325.DB; MUTHUCHELIAN K, 1997, PHOTOSYNTHETICA, V33, P241, DOI 10.1023/A:1022164314060; MUTHUCHELIAN K, 2001, J PLANT PHYSIOL, V158, P1487, DOI 10.1078/0176-1617-00627; MUTHUCHELIAN K, 1990, PHOTOSYNTHETICA, V24, P257; NAEEM M, 2012, J PLANT INTERACT, V7, P129, DOI 10.1080/17429145.2011.619281; NAEEM M, 2009, SCI HORTIC-AMSTERDAM, V121, P389, DOI 10.1016/J.SCIENTA.2009.02.030; O'CARRIGAN A, 2014, ENVIRON EXP BOT, V98, P65, DOI 10.1016/J.ENVEXPBOT.2013.10.007; OLLION J, 2013, BIOINFORMATICS, V29, P1840, DOI 10.1093/BIOINFORMATICS/BTT276; OREN R, 2001, OECOLOGIA, V126, P21, DOI 10.1007/S004420000497; PERVEEN S, 2013, PHOTOSYNTHETICA, V51, P541, DOI 10.1007/S11099-013-0054-X; PERVEEN S, 2012, PAK J BOT, V44, P27; PIETRAGALLA J, 2012, PHYSL BREEDING 2 FIE; PLATT T, 1980, J MAR RES, V38, P687; RAMÍREZ DA, 2018, AM J POTATO RES, V95, P139, DOI 10.1007/S12230-017-9618-9; RAMOS-ZAMBRANO E, 2019, J CHEM-NY, V2019, DOI 10.1155/2019/4547378; RAVEN JA, 2011, PHYSIOL PLANTARUM, V142, P87, DOI 10.1111/J.1399-3054.2011.01465.X; REDDY BO, 2002, PLANT CELL TISS ORG, V71, P253, DOI 10.1023/A:1020342127386; DE DIOS VR, 2016, PLANT CELL ENVIRON, V39, P3, DOI 10.1111/PCE.12598; RIES S, 1991, PLANT PHYSIOL, V95, P986, DOI 10.1104/PP.95.4.986; RIES SK, 1985, CRC CR REV PLANT SCI, V2, P239, DOI 10.1080/07352688509382197; SCHINDELIN J, 2012, NAT METHODS, V9, P676, DOI 10.1038/NMETH.2019, 10.1038/NMETH.2019; SNYDER KA, 2003, J EXP BOT, V54, P861, DOI 10.1093/JXB/ERG082; TANTOS A, 1999, PLANT CELL REP, V19, P88, DOI 10.1007/S002990050715; TANTOS A, 2001, PLANT CELL REP, V20, P16, DOI 10.1007/S002990000282; VERMA AMAN, 2011, BRAZ. J. PLANT PHYSIOL., V23, P271, DOI 10.1590/S1677-04202011000400004; WAQAS M, 2016, PLANT PHYSIOL BIOCH, V99, P118, DOI 10.1016/J.PLAPHY.2015.12.012; WEISSTEIN EW, 2018, ELLIPSOID MATHWORLD; WHITE AJ, 1999, PHOTOSYNTH RES, V59, P63, DOI 10.1023/A:1006188004189; WU Q, 2014, ACTA PHYSIOL PLANT, V36, P1411, DOI 10.1007/S11738-014-1519-7; XIA XJ, 2014, PLANT CELL ENVIRON, V37, P2036, DOI 10.1111/PCE.12275; XIONG DL, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-06460-0; YASEEN M., 1998, JOURNAL OF MEDICINAL AND AROMATIC PLANT SCIENCES, V20, P1038; ZEPPEL MJB, 2014, TREE PHYSIOL, V34, P1047, DOI 10.1093/TREEPHYS/TPU089; ZUSHI K, 2014, SCI HORTIC-AMSTERDAM, V165, P384, DOI 10.1016/J.SCIENTA.2013.11.033","MARTÍNEZ-AYALA, AL (CORRESPONDING AUTHOR), INST POLITECN NACL, CTR DESARROLLO PROD BIOT, CARRETERA YAUTEPEC JOJUTLA,KM 6,CALLE CEPROBI 8, YAUTEPEC 62731, MORELOS, MEXICO","SPRINGER","ENGLISH","J. PLANT GROWTH REGUL.","ARTICLE","ISI","WOS000591246200001","J PLANT GROWTH REGUL","INST POLITECN NACL;INST POLITECN NACL","INST POLITECN NACL",NA,"RAMOS-ZAMBRANO E, 2021, J PLANT GROWTH REGUL","RAMOS-ZAMBRANO E, 2021, J PLANT GROWTH REGUL"
"MUTHUSAMY M;KIM J;KIM S;KIM J;YEOL Y;HEO J;LEE H;LEE K;SEO ;WOO D W;PARK S;KIM J;LEE S","MUTHUSAMY MUTHUSAMY;KIM JONG HEE;KIM SUK HEE;KIM JOO; YEOL;HEO JEONG WOOK;LEE HANGYEOL;LEE KWANG-SIK;SEO; WOO DUCK;PARK SOYOUNG;KIM JIN A;LEE SOO IN","CHANGES IN BENEFICIAL ICIGLYCOSYLFLAVONES AND POLICOSANOL CONTENT IN WHEAT AND BARLEY SPROUTS SUBJECTED TO DIFFERENTIAL LED LIGHT CONDITIONS",2020,"PLANTS-BASEL","9",NA,8,"10.3390/plants9111502","LEE, SI (CORRESPONDING AUTHOR), RDA, DEPT AGR BIOTECHNOL, NATL INST AGR SCI NAS, JEONJU 54874, SOUTH KOREA.; MUTHUSAMY, MUTHUSAMY; KIM, JONG HEE; KIM, SUK HEE; KIM, JOO YEOL; KIM, JIN A.; LEE, SOO IN, RDA, DEPT AGR BIOTECHNOL, NATL INST AGR SCI NAS, JEONJU 54874, SOUTH KOREA.; KIM, JONG HEE, HANKYUNG NATL UNIV, DIV HORT BIOTECHNOL, ANSEONG 17579, SOUTH KOREA.; HEO, JEONG WOOK, RDA, DEPT AGR ENGN, NATL INST AGR SCI NAS, JEONJU 54874, SOUTH KOREA.; LEE, HANGYEOL; LEE, KWANG-SIK; SEO, WOO DUCK; PARK, SOYOUNG, RDA, NATL INST CROP SCI NICS, DIV CROP FDN, WONJU 55365, SOUTH KOREA.","THE SPECTRAL QUALITY AND INTENSITY OF LIGHT, PHOTOPERIODISM, AND OTHER ENVIRONMENTAL FACTORS HAVE PROFOUND IMPACTS ON THE METABOLIC COMPOSITION OF LIGHT-DEPENDENT HIGHER PLANTS. HENCE, WE INVESTIGATE THE EFFECTS OF FLUORESCENT LIGHT (96 MU MOL M(-2)S(-1)) AND WHITE (100 MU MOL M(-2)S(-1)), BLUE (100 MU MOL M(-2)S(-1)), AND RED (93 MU MOL M(-2)S(-1)) LIGHT-EMITTING DIODE (LED) LIGHT IRRADIATION ON THE C-GLYCOSYLFLAVONE AND POLICOSANOL CONTENTS IN YOUNG SEEDLINGS OF WHEAT AND BARLEY. ULTRA-HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (UHPLC) ANALYSES OF C-GLYCOSYLFLAVONE CONTENTS IN BARLEY REVEAL THAT THE SAPONARIN CONTENT IS SIGNIFICANTLY ENHANCED UNDER BLUE LED LIGHT IRRADIATION. UNDER SIMILAR CONDITIONS, ISOORIENTIN AND ISOSCHAFTOSIDE CONTENTS ARE IMPROVED IN WHEAT SEEDLINGS. THE CONTENTS OF THESE C-GLYCOSYLFLAVONES DIFFERED ALONG WITH THE LIGHT QUALITY AND GROWTH PERIOD. THE HIGHEST ACCUMULATION WAS OBSERVED IN SPROUTS AFTER THREE DAYS UNDER BLUE LED LIGHT IRRADIATION. GC/MS ANALYSES OF POLICOSANOL CONTENTS SHOWED THAT 1-HEXACOSANOL (C26:O-OH) IN BARLEY AND 1-OCTACOSANOL (C28:O-OH) IN WHEAT SEEDLINGS WERE REDUCED UNDER LED LIGHT IRRADIATION, COMPARED TO SEEDLINGS UNDER FLUORESCENT LIGHT CONDITIONS. NONETHELESS, THE POLICOSANOL CONTENTS GRADUALLY IMPROVED WITH THE EXTENSION OF GROWTH TIMES AND TREATMENTS, IRRESPECTIVE OF THE LIGHT QUALITY. ADDITIONALLY, A POSITIVE CORRELATION WAS OBSERVED BETWEEN THE EXPRESSION PATTERN OF BIOSYNTHESIS-RELATED GENES AND THE RESPECTIVE METABOLITE CONTENT IN BARLEY. THIS STUDY DEMONSTRATES THAT BLUE LED LIGHT IRRADIATION IS USEFUL IN MAXIMIZING THE C-GLYCOSYLFLAVONE CONTENT IN BARLEY AND WHEAT SPROUTS.","SAPONARIN; ISOORIENTIN; HEXACOSANOL; OCTACOSANOL; FATTY ACYL-COENZYME A; REDUCTASE (FAR)","PRIMARY ALCOHOL BIOSYNTHESIS; FATTY ACYL-COENZYME; CUTICULAR WAX; ANTIOXIDANT ACTIVITY; GENE-EXPRESSION; PROTEIN-KINASE; SAPONARIN; ACCUMULATION; FLAVONOIDS; INCREASES","RURAL DEVELOPMENT ADMINISTRATION (KOREA) THROUGH THE RURAL PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY DEVELOPMENT [PJ01495701]; COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY [PJ01421201]","THIS RESEARCH WAS FUNDED BY THE RURAL DEVELOPMENT ADMINISTRATION (KOREA) THROUGH THE RURAL PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY DEVELOPMENT, GRANT NUMBER PJ01495701 AND COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURAL SCIENCE AND TECHNOLOGY, GRANT NUMBER PJ01421201.","ABORUS NE, 2017, INT J FOOD SCI TECH, V52, P231, DOI 10.1111/IJFS.13274; BENINCASA P, 2019, NUTRIENTS, V11, DOI 10.3390/NU11020421; BRAUCH D, 2018, PHYTOCHEMISTRY, V148, P11, DOI 10.1016/J.PHYTOCHEM.2018.01.001; BYUN AR, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/S13098-015-0051-2; CHENG C, 2020, RSC ADV, V10, P6052, DOI 10.1039/C9RA10089J; GHIMIRE BK, 2017, PLANT PHYSIOL BIOCH, V118, P77, DOI 10.1016/J.PLAPHY.2017.06.006; GIL KE, 2019, NEW PHYTOL, V221, P1215, DOI 10.1111/NPH.15518; GIRALDO P, 2019, AGRONOMY-BASEL, V9, DOI 10.3390/AGRONOMY9070352; HASAN MM, 2017, MOLECULES, V22, DOI 10.3390/MOLECULES22071046; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; KAMIYAMA M, 2012, J AGR FOOD CHEM, V60, P6260, DOI 10.1021/JF301700J; KANG CH, 2020, SCI HORTIC-AMSTERDAM, V261, DOI 10.1016/J.SCIENTA.2019.108924; KIM YJ, 2017, FOOD RES INT, V101, P209, DOI 10.1016/J.FOODRES.2017.08.068; KOPSELL DA, 2013, J AM SOC HORTIC SCI, V138, P31, DOI 10.21273/JASHS.138.1.31; KOWALSKA I, 2019, ACTA CHROMATOGR, V31, P151, DOI 10.1556/1326.2017.00416; LEE HANGYEOL, 2019, JOURNAL OF PLANT BIOTECHNOLOGY, V46, P247, DOI 10.5010/JPB.2019.46.4.247; LEE JH, 2017, NUTR RES, V43, P89, DOI 10.1016/J.NUTRES.2017.05.013; LEE YH, 2017, NUTRIENTS, V9, DOI 10.3390/NU9111252; LEMMENS E, 2019, COMPR REV FOOD SCI F, V18, P305, DOI 10.1111/1541-4337.12414; MARINOVA K, 2007, PLANT PHYSIOL, V144, P432, DOI 10.1104/PP.106.094748; MENG TIANXIAO MENG TIANXIAO, 2015, AGRICULTURAL SCIENCES, V6, P208, DOI 10.4236/AS.2015.62020; MUTHUSAMY M, 2019, PLANT BIOTECHNOL REP, V13, P293, DOI 10.1007/S11816-019-00542-3; NAM TG, 2018, FOOD SCI BIOTECHNOL, V27, P169, DOI 10.1007/S10068-017-0204-1; PARK MIJIN PARK MIJIN, 2015, JOURNAL OF AGRICULTURAL SCIENCE (TORONTO), V7, P94; TUAN PA, 2013, J AGR FOOD CHEM, V61, P12356, DOI 10.1021/JF4039937; RA JE, 2020, FOOD CHEM, V317, DOI 10.1016/J.FOODCHEM.2020.126388; RICHARDSON A, 2005, PLANTA, V222, P472, DOI 10.1007/S00425-005-1552-2; RICO D, 2020, FOODS, V9, DOI 10.3390/FOODS9030296; SEO KH, 2014, FOOD FUNCT, V5, P3005, DOI 10.1039/C4FO00612G; SEO WD, 2013, J AGR FOOD CHEM, V61, P1117, DOI 10.1021/JF3041879; SEO WD, 2015, BIOORG MED CHEM LETT, V25, P5237, DOI 10.1016/J.BMCL.2015.09.057; SHARMA R, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41631-1; SHEWRY PR, 2015, FOOD ENERGY SECUR, V4, P178, DOI 10.1002/FES3.64; SYTAR O, 2018, MOLECULES, V23, DOI 10.3390/MOLECULES23092282; WANG ML, 2017, FRONT PLANT SCI, V8, DOI 10.3389/FPLS.2017.01012; WANG Y, 2018, PLANT CELL PHYSIOL, V59, P527, DOI 10.1093/PCP/PCX211; WANG Y, 2015, J EXP BOT, V66, P1165, DOI 10.1093/JXB/ERU457; WANG YL, 2019, AOB PLANTS, V11, DOI 10.1093/AOBPLA/PLZ021; WU XJ, 2017, FRONT PLANT SCI, V8, DOI 10.3389/FPLS.2017.01547; XIAO JB, 2016, CRIT REV FOOD SCI, V56, PS29, DOI 10.1080/10408398.2015.1067595; YE TT, 2016, ONCOTARGETS THER, V9, P7481, DOI 10.2147/OTT.S122653; ZENG YW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3232080","LEE, SI (CORRESPONDING AUTHOR), RDA, DEPT AGR BIOTECHNOL, NATL INST AGR SCI NAS, JEONJU 54874, SOUTH KOREA","MDPI","ENGLISH","PLANTS-BASEL","ARTICLE","ISI","WOS000594966200001","PLANTS-BASEL","NATL INST AGR SCI NAS;NATL INST AGR SCI NAS;HANKYUNG NATL UNIV;NATL INST AGR SCI NAS;NATL INST CROP SCI NICS","NATL INST AGR SCI NAS",NA,"MUTHUSAMY M, 2020, PLANTS-BASEL","MUTHUSAMY M, 2020, PLANTS-BASEL"
"SINGH A;CHANDRA A;KANDPAL J","SINGH ASHISH KUMAR;CHANDRA AMRISH;KANDPAL J B","OCTACOSANOL EXTRACTION SYNTHESIS METHOD AND SOURCES A REVIEW",2020,"CARPATHIAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY","12","27-41",3,"10.34302/crpjfst/2020.12.5.2","SINGH, AK (CORRESPONDING AUTHOR), AMITY UNIV UTTAR, AMITY INST PHARM, SECT 125, NOIDA 301313, UTTAR PRADESH, INDIA.; SINGH, ASHISH KUMAR; CHANDRA, AMRISH, AMITY UNIV UTTAR, AMITY INST PHARM, SECT 125, NOIDA 301313, UTTAR PRADESH, INDIA.; KANDPAL, J. B., INDIA GLYCOLS LTD, RES \& DEV DEPT, DEHRA DUN 248197, UTTARAKHAND, INDIA.","OCTACOSANOL ARE STRAIGHT CHAIN ALIPHATIC FATTY ALCOHOL WHICH CONSIST OF 28-CARBON CHAIN, WHICH IS BASICALLY FOUND IN EPICUTICULAR REGION OF PLANT LIKE SUGARCANE, WHEAT GERM OIL, RICE BRAN OIL ETC. AND ANIMAL SOURCE LIKE KRILL. OCTACOSANOL IS WAXY IN NATURE AND INSOLUBLE IN WATER BUT SPARINGLY SOLUBLE IN LOW MOLECULAR WEIGHT ALKANES, CHLOROFORM, ETHYL ACETATE ETC. OCTACOSANOL USED AS A NUTRITIONAL SUPPLEMENT AND FUNCTIONAL FOOD. OCTACOSANOL UNDER INVESTIGATIONAL REPORTED FOR ENHANCED STAMINA ENDURANCE, CHOLESTEROL LOWERING EFFECT, PARKINSON DISEASE, PLATELETS ANTIAGGREGATORY PROPERTIES, AMYOTROPHIC LATERAL SCLEROSIS (ALS, LOU GEHRIG'S DISEASE), CYTOPROTECTIVE USE, AND ATHEROSCLEROSIS. OCTACOSANOL EXTRACTED AND PREPARED BY VARIOUS METHODS LIKE SOXHLET EXTRACTION, SUPERCRITICAL FLUID EXTRACTION AND SYNTHETICALLY SYNTHESIS.","KRILL; NUTRITIONAL SUPPLEMENTS; FUNCTIONAL FOOD; SOXHLET EXTRACTION; SUPERCRITICAL FLUID EXTRACTION; SYNTHETICALLY SYNTHESIS","RICE BRAN WAX; TINOSPORA-CORDIFOLIA; POLICOSANOL CONTENTS; SUGAR-CANE; ULTRASOUND; FATTY; CONSTITUENTS; PURIFICATION; ALDEHYDES; ALCOHOLS",NA,NA,"ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ALMAZAN O., 1998, SUGARCANE ITS PRODUC; ANONYMOUS, **NON-TRADITIONAL**; ANONYMOUS, 1992, OPTIMUM EXPT DESIGN; BACKMANN, 1927, J AM CHEM SOC, V49, P2089; BELTZ SD, 1993, CLIN PHARMACY, V12, P900; BLEYBERG W, 1931, BER DTSCH CHEM GES, V64, P2504, DOI 10.1002/CBER.19310640929; BOX GEP, 1951, J R STAT SOC B, V13, P1, DOI 10.1111/J.2517-6161.1951.TB00067.X; CHAUHAN K., 1995, SUCHITRA AYURVED, V47, P840; CHEN F, 2005, J FOOD ENG, V70, P47, DOI 10.1016/J.JFOODENG.2004.09.011; 陈芳 CHEN FANG, 2003, 中国粮油学报, JOURNAL OF THE CHINESE CEREALS AND OILS ASSOCIATION, V18, P75; CHEN F, 2007, J FOOD ENG, V79, P63, DOI 10.1016/J.JFOODENG.2006.01.030; CHIBNALL AC, 1931, BIOCHEM J, V25, P2095, DOI 10.1042/BJ0252095; CHRISTENSEN KR, 1995, J FOOD SCI, V60, P218, DOI 10.1111/J.1365-2621.1995.TB05641.X; CRAVOTTO G, 2004, EUR J LIPID SCI TECH, V106, P147, DOI 10.1002/EJLT.200300914; CRAVOTTO G., 2005, INTERNATIONAL PATENT, PATENT NO. WO 03106397, 03106397; CRAVOTTO G, 2008, ULTRASON SONOCHEM, V15, P898, DOI 10.1016/J.ULTSONCH.2007.10.009; CRAVOTTO G, 2007, CHEM-EUR J, V13, P1903, DOI 10.1002/CHEM.200601845; CRAVOTTO G, 2010, NAT PROD RES, V24, P428, DOI 10.1080/14786410903194498; DIXIT SN, 1971, INDIAN JOURNAL OF APPLIED CHEMISTRY, V34, P46; DUNFORD NT, 2010, FOOD CHEM, V119, P1246, DOI 10.1016/J.FOODCHEM.2009.07.039; 冯武文 FENG WUWEN, 2002, 日用化学工业, CHINA SURFACTANT DETERGENT AND COSMETICS, V32, P74; FRAGERNAS L., 1986, ACTA CHEM SCANDINAVI, V40, P538; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; FURUKAWA K., 1987, US PATENT, PATENT NO. 4,714,791, 4714791; GARCIA A, 1996, J AM OIL CHEM SOC, V73, P1127, DOI 10.1007/BF02523373; GARCIA A., 1994, P 3 INT S SUP FLUIDS, V3, P234; GARCIA A., 1988, SUBPRODUCTOS DERIVAD, P315; GONZALEZBRAVO L, 1996, J CHROMATOGR B, V682, P359, DOI 10.1016/0378-4347(95)00515-3; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HWANG KT, 2002, J AM OIL CHEM SOC, V79, P529, DOI 10.1007/S11746-002-0516-4; HWANG KT, 2002, J SEP SCI, V25, P619, DOI 10.1002/1615-9314(20020601)25:9<619::AID-JSSC619>3.0.CO;2-; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; JIAO C. S., 2002, CHEM ENG J, V4, P14; KAWANISHI K, 1991, J AM OIL CHEM SOC, V68, P869, DOI 10.1007/BF02660604; KUNKUMA VL, 2013, EUR J LIPID SCI TECH, V115, P921, DOI 10.1002/EJLT.201200195; LAGUNAS A., 1992, PATENTE CUBANA, V229; LANZANI A, 1994, J AM OIL CHEM SOC, V71, P609, DOI 10.1007/BF02540587; LEYON PV, 2004, INT IMMUNOPHARMACOL, V4, P1569, DOI 10.1016/J.INTIMP.2004.06.015; LEYON PV, 2004, J ETHNOPHARMACOL, V90, P233, DOI 10.1016/J.JEP.2003.09.046; LI GUIHUA, 2003, JOURNAL OF THE CHINESE CEREALS AND OILS ASSOCIATION, V18, P58; LIU Y. F., 2001, CHINA OILS FATS, V26, P63; LONGVAH T, 1991, J AM OIL CHEM SOC, V68, P781, DOI 10.1007/BF02662172; MORRIS BD, 2000, J CHEM ECOL, V26, P859, DOI 10.1023/A:1005499907009; NORRIS FH, 1986, NEUROLOGY, V36, P1263; NUISSIER G, 2002, PHYTOCHEMISTRY, V61, P721, DOI 10.1016/S0031-9422(02)00356-4; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; OOI CK, 1994, J AM OIL CHEM SOC, V71, P423, DOI 10.1007/BF02540524; OU SY, 2012, LWT-FOOD SCI TECHNOL, V45, P295, DOI 10.1016/J.LWT.2011.08.011; PALMISANO G, 2007, SYNLETT, P2041, DOI 10.1055/S-2007-984891; PIPER SH, 1931, BIOCHEM J, V25, P2072, DOI 10.1042/BJ0252072; POLLARD A, 1931, BIOCHEM J, V25, P2111, DOI 10.1042/BJ0252111; RAMASWAMY K.G., 1980, J OIL TECHNOL ASS IN, V12, P16; RAPPORT L., 2000, PHARMACEUTICAL JOURNAL, V265, P170; RIDWAY W., 1956, MOLECULAR DISTILLATI, P1; SAN MARTÍN-MARTÍNEZ E, 2003, CEREAL CHEM, V80, P13, DOI 10.1094/CCHEM.2003.80.1.13; SHIN HS, 1994, J AM OIL CHEM SOC, V71, P619, DOI 10.1007/BF02540589; SIERRA R, 2002, J AOAC INT, V85, P563; SINGH S. S., 2003, INDIAN JOURNAL OF PHARMACOLOGY, V35, P83; SNIDER SR, 1984, ANN NEUROL, V16, P723, DOI 10.1002/ANA.410160615; STAHL E., 1988, DENSE GASES EXTRACTI, P127; STAHL E., 1985, US PATENT, PATENT NO. 4,548,755, 4548755; STEVE V. D., 1963, PATENT UK, PATENT NO. 923047; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; THIPPESWAMY G, 2007, ENVIRON TOXICOL PHAR, V23, P212, DOI 10.1016/J.ETAP.2006.10.004; TOLLOCH A. P., 1976, CHEM BIOCH NATURAL W, P50; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; VOY R, 1986, AMERICAN PHARMACY, V26, P39; WOOLLEY BH, 1991, POSTGRAD MED, V89, P195; WU P., 2000, CHEM IND ENG PROGR, P4951; XU R. P, 2002, CN PATENT, PATENT NO. 02112420.5, 02112420; XU R. P., 2002, CEREALS OILS, V4, P37","SINGH, AK (CORRESPONDING AUTHOR), AMITY UNIV UTTAR, AMITY INST PHARM, SECT 125, NOIDA 301313, UTTAR PRADESH, INDIA","NORTH UNIV CENTER BAIA MARE","ENGLISH","CARPATHIAN J. FOOD SCI. TECHNOL.","REVIEW","ISI","WOS000627341400003","CARPATHIAN J FOOD SCI TECHNOL","AMITY UNIV UTTAR;AMITY UNIV UTTAR;RES AND DEV DEPT","AMITY UNIV UTTAR",NA,"SINGH AK, 2020, CARPATHIAN J FOOD SCI TECHNOL","SINGH AK, 2020, CARPATHIAN J FOOD SCI TECHNOL"
"LEE S;SCOTT S;PEKAS E;LEE ;JEONG-GI J;PARK S","LEE SANG-HO;SCOTT STEVEN D;PEKAS ELIZABETH J;LEE; JEONG-GI;PARK SONG-YOUNG","IMPROVEMENT OF LIPIDS AND REDUCTION OF OXIDATIVE STRESS WITH OCTACOSANOL AFTER TAEKWONDO TRAINING",2019,"INTERNATIONAL JOURNAL OF SPORTS PHYSIOLOGY AND PERFORMANCE","14","1297-1303",16,"10.1123/ijspp.2018-0704","PARK, SY (CORRESPONDING AUTHOR), UNIV NEBRASKA, SCH HLTH \& KINESIOL, OMAHA, NE 68182 USA.; LEE, SANG-HO; LEE, JEONG-GI, KOSIN UNIV, DEPT TAEKWONDO, BUSAN, SOUTH KOREA.; SCOTT, STEVEN D.; PEKAS, ELIZABETH J.; PARK, SONG-YOUNG, UNIV NEBRASKA, SCH HLTH \& KINESIOL, OMAHA, NE 68182 USA.","PURPOSE: ATHLETES IN COMBAT SPORTS UNDERGO RAPID CHANGES IN BODY WEIGHT PRIOR TO COMPETITION IN ORDER TO GAIN A SIZE ADVANTAGE OVER THEIR OPPONENT. HOWEVER, THESE LARGE WEIGHT CHANGES WITH CONCOMITANT HIGH-INTENSITY EXERCISE TRAINING CREATE POOR LIPID PROFILES AND HIGH LEVELS OF OXIDATIVE STRESS, WHICH CAN BE DETRIMENTAL TO HEALTH AND SPORT PERFORMANCE. THEREFORE, THE PURPOSE OF THIS STUDY WAS TO INVESTIGATE THE ABILITY OF THE NUTRITIONAL SUPPLEMENT OCTACOSANOL TO COMBAT THE PHYSIOLOGICAL DETRIMENTS THAT OCCUR IN TAEKWONDO PLAYERS DURING RAPID WEIGHT LOSS WITH HIGH-INTENSITY EXERCISE TRAINING. METHODS: A TOTAL OF 26 MALE TAEKWONDO PLAYERS WERE RANDOMLY DIVIDED INTO 2 GROUPS: AN EXPERIMENTAL GROUP PERFORMED A 5\% WEIGHT-LOSS AND TAEKWONDO TRAINING PROGRAM WITH 40-MG OCTACOSANOL INTAKE (OCT; N = 13) FOR 6 D, AND A CONTROL GROUP PERFORMED THE SAME WEIGHT-LOSS AND TAEKWONDO TRAINING PROGRAM WITH A PLACEBO (CON; N = 13). RESULTS: THERE WERE SIGNIFICANT (P <.05) GROUP X TIME INTERACTIONS FOR LOW-DENSITY LIPOPROTEIN AND TRIGLYCERIDES, WHICH SIGNIFICANTLY DECREASED (DELTA 18 [5] MG/DL AND DELTA 80 [7] MG/DL, RESPECTIVELY), AND HIGH-DENSITY LIPOPROTEIN, WHICH SIGNIFICANTLY INCREASED (DELTA 10 [7] MG/DL), IN THE OCT GROUP COMPARED WITH THE CON GROUP. THERE WERE ALSO SIGNIFICANT (P <.05) GROUP X TIME INTERACTIONS FOR SUPEROXIDE DISMUTASE (SOD), GLUTATHIONE PEROXIDASE (GPX), AND MALONDIALDEHYDE (MDA), WITH SOD INCREASING (DELTA 226 [121] U/GHB) IN THE OCT GROUP, WHILE GPX DECREASED (DELTA 20 [13] U/GHB) AND MDA INCREASED (DELTA 72 [0.04] NMOL/ML) IN THE CON GROUP. CONCLUSION: THESE RESULTS SUGGEST THAT OCTACOSANOL MAY BE A BENEFICIAL SUPPLEMENT TO PROTECT AGAINST THE POOR CHOLESTEROL LEVELS AND OXIDATIVE STRESS THAT OCCURS DURING TAEKWONDO TRAINING.","SPORT NUTRITION; EXERCISE PHYSIOLOGY; HEALTH","CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; HDL CHOLESTEROL; WEIGHT-LOSS; POLICOSANOL; RISK; TRIGLYCERIDE; PERFORMANCE; METABOLISM; PREDICTION",NA,NA,"ALESSIO HM, 1993, MED SCI SPORT EXER, V25, P218, DOI 10.1249/00005768-199302000-00010; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; BOOTH FW, 2008, BRIT J SPORT MED, V42, P950, DOI 10.1136/BJSM.2008.052589; BROWNELL KD, 1987, MED SCI SPORT EXER, V19, P546; CASTAÑO G, 2001, ANGIOLOGY, V52, P115, DOI 10.1177/000331970105200205; CASTELLI WP, 1977, J CHRON DIS, V30, P147, DOI 10.1016/0021-9681(77)90082-0; FOGELHOLM GM, 1993, MED SCI SPORT EXER, V25, P371, DOI 10.1249/00005768-199303000-00012; GAMEZ R, 2005, DRUGS R D, V6, P11; GOTTO AM, 1977, CIRCULATION, V56, P875, DOI 10.1161/01.CIR.56.5.875; HARRABI S, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/S12944-018-0682-Z; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; JACOB RA, 1996, AM J CLIN NUTR, V63, P985; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; MAHJOUB S, 2012, CASP J INTERN MED, V3, P386; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; NISHIKAWA T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; PEARSON TA, 1979, AM J EPIDEMIOL, V109, P285, DOI 10.1093/OXFORDJOURNALS.AJE.A112682; RIDKER PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMOA021993; RIDKER PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; SCHLESINGER Z, 2000, CIRCULATION, V102, P21, DOI 10.1161/01.CIR.102.1.21; SHIMURA S, 1987, NUTR REP INT, V36, P1029; STEEN SN, 1990, MED SCI SPORT EXER, V22, P762, DOI 10.1249/00005768-199012000-00005; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSO ML, 2003, TOXICOLOGY, V189, P41, DOI 10.1016/S0300-483X(03)00151-3; WONG A, 2018, MENOPAUSE, V25, P731, DOI 10.1097/GME.0000000000001072; ZAMBRASKI EJ, 1975, MED SCI SPORT EXER, V7, P217","PARK, SY (CORRESPONDING AUTHOR), UNIV NEBRASKA, SCH HLTH \& KINESIOL, OMAHA, NE 68182 USA","HUMAN KINETICS PUBL INC","ENGLISH","INT. J. SPORT PHYSIOL. PERFORM.","ARTICLE","ISI","WOS000488611400020","INT J SPORT PHYSIOL PERFORM","UNIV NEBRASKA;KOSIN UNIV;UNIV NEBRASKA","UNIV NEBRASKA",NA,"LEE SH, 2019, INT J SPORT PHYSIOL PERFORM","LEE SH, 2019, INT J SPORT PHYSIOL PERFORM"
"CHO K;KIM C;BAE M;KIM J","CHO KYUNG-HYUN;KIM CHEOL-HEE;BAE MYUNG-AE;KIM JAE-RYONG","EFFECT OF CUBAN SUGARCANE WAX ACIDS AND POLICOSANOL ON SERUM LIPID PROFILE AND APOLIPOPROTEIN AI EXPRESSION IN HYPERLIPIDEMIC ZEBRAFISH",2019,"JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","13","BC16-BC20",0,"10.7860/JCDR/2019/41177.12935","CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, RES INST PROT SENSOR, DEPT MED BIOTECHNOL, GYONGSAN, GYEONGBUK, SOUTH KOREA.; CHO, KYUNG-HYUN, YEUNGNAM UNIV, RES INST PROT SENSOR, DEPT MED BIOTECHNOL, GYONGSAN, GYEONGBUK, SOUTH KOREA.; KIM, CHEOL-HEE, CHUNGNAM NATL UNIV, DEPT BIOL, DAEJEON, CHUNGNAM, SOUTH KOREA.; BAE, MYUNG-AE, KOREA RES INST CHEM TECHNOL, DRUG DISCOVERY PLATFORM TECHNOL, DAEJEON, CHUNGNAM, SOUTH KOREA.; KIM, JAE-RYONG, YEUNGNAM UNIV, DEPT BIOCHEM \& MOL BIOL, SMART AGEING CONVERGENCE RES CTR, DAEGU, SOUTH KOREA.","INTRODUCTION: SUGARCANE WAX ACIDS (SCWAS) AND POLICOSANOL (PCO) ARE MIXTURES OF HIGHER ALIPHATIC ACIDS AND ALCOHOLS PURIFIED FROM SUGARCANE WAX. OCTACOSANOIC ACID AND OCTACOSANOL ARE THE CHIEF COMPONENTS OF PCO AND SCWA, RESPECTIVELY. THE ROLE OF PCO IN THE IMPROVEMENT OF DYSLIPIDEMIA IS WELL DOCUMENTED, HOWEVER, THE LIPID-LOWERING EFFECTS OF SCWA REMAINS DEBATABLE. AIM: TO COMPARE THE ATHEROPROTECTIVE EFFECTS OF SCWA AND PCO ON THE EXPRESSION LEVEL OF APOLIPOPROTEIN A-I (APOA-I) IN THE TREATMENT OF DYSLIPIDEMIA. MATERIALS AND METHODS: HYPERLIPIDEMIC ZEBRAFISH WERE SUPPLEMENTED WITH EITHER SCWA (40 MG/KG AND 80 MG/KG) OR PCO (40 MG/KG AND 80 MG/KG) FOR 10 WEEKS. AFTER THE SUPPLEMENTATION, LIPID-LOWERING EFFECTS AND APOA-I EXPRESSIONS WERE MEASURED BY PLASMA AND HISTOLOGIC ANALYSIS, CHOLESTERYL ESTER TRANSFER AND FERRIC REDUCING ABILITY (FRA) ASSAY AND IMMUNOBLOTTING. DATA WERE EVALUATED USING ONE-WAY ANOVA AND DIFFERENCES BETWEEN THE MEAN WERE ASSESSED USING DUNCAN'S MULTIPLE RANGE TEST. P-VALUE <0.05 WAS CONSIDERED STATISTICALLY SIGNIFICANT. RESULTS: THE SUPPLEMENTATION SIGNIFICANTLY IMPROVED SERUM LIPID PROFILE, ESPECIALLY LOWERING TOTAL CHOLESTEROL (TC), TRIGLYCERIDE (TG) AND RAISING HDL-C IN A DOSE-DEPENDENT MANNER. SCWA (80 MG/KG OF BODY WEIGHT) SUPPLEMENTED HIGH CHOLESTEROL DIET (HCD) GROUP SHOWED ARE REMARKABLE DECREASE IN BODY WEIGHT AND THE SIGNIFICANT REDUCTION IN TC AND TG, UP TO 65\% (P<0.01) AND 45\% (P<0.05) RESPECTIVELY, THAN HOD CONTROL. PCO (80 MG/KG OF BODY WEIGHT) GROUP SHOWED THE HIGHEST HDL-C LEVEL AND APOA-I EXPRESSION WITH THE LOWEST SERUM CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY. BOTH PCO AND SCWA GROUPS SHOWED AMELIORATION OF FATTY LIVER CHANGE WITH INHIBITION OF REACTIVE OXYGEN SPECIES (ROS) PRODUCTION AND ENHANCEMENT OF ANTIOXIDANT ABILITY IN HEPATIC TISSUE DESPITE OF HIGH CHOLESTEROL DIET CONSUMPTION. CONCLUSION: THE SUPPLEMENTATION OF SCWA OR PCO RESULTED IN ENHANCEMENT OF SURVIVABILITY AND HEPATIC FUNCTION WITH THE IMPROVEMENT OF DYSLIPIDEMIA AND ELEVATION OF APOA-I AND HDL-C VIA CETP INHIBITION. THESE RESULTS SUGGEST THAT SCWA LIKE PCO IS AN EFFECTIVE LIPID-LOWERING AGENT.","CHOLESTERYLESTER TRANSFER PROTEIN; FERRIC REDUCING ABILITY ASSAY; NEUTRACEUTICALS","HIGH-DENSITY-LIPOPROTEIN; FATTY-ACIDS; 10 MG/DAY; CHOLESTEROL; HYPERCHOLESTEROLEMIA; MIXTURE; D-003; REGENERATION; ENHANCEMENT; PEROXIDATION","MINISTRY OF TRADE, INDUSTRY AND ENERGY, KOREA [2016-10063396]; MEDICAL RESEARCH CENTRE PROGRAM THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF) - MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING OF KOREA [2015R1A5A2009124]","THIS WORK WAS SUPPORTED BY A GRANT FROM THE MINISTRY OF TRADE, INDUSTRY AND ENERGY, KOREA (GRANT NO. 2016-10063396) AND THE MEDICAL RESEARCH CENTRE PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF), FUNDED BY THE MINISTRY OF SCIENCE, ICT AND FUTURE PLANNING OF KOREA.","CUELLAR LA, 2014, BBA-MOL CELL BIOL L, V1841, P180, DOI 10.1016/J.BBALIP.2013.10.017; ARRUZAZABALA ML, 2005, INT J CLIN PHARM RES, V25, P29; AWAD K, 2016, PHARMACOL RES, V114, P42, DOI 10.1016/J.PHRS.2016.10.008; BENZIE IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/ABIO.1996.0292; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199A0; BRAND M., 2002, KEEPING RAISING ZEBR, V7, P39; CASTAÑO G, 2005, DRUG EXP CLIN RES, V31, P31; CASTAÑO G, 2001, CURR THER RES CLIN E, V62, P194, DOI 10.1016/S0011-393X(01)80031-X; CASTAÑO G, 2000, CURR THER RES CLIN E, V61, P137, DOI 10.1016/S0011-393X(00)80011-9; CHO KH, 1998, BBA-LIPID LIPID MET, V1391, P133, DOI 10.1016/S0005-2760(97)00197-5; CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; CHO KH, 2018, MOLECULES, V23, DOI 10.3390/MOLECULES23051080; FRYIRS MA, 2010, ARTERIOSCL THROM VAS, V30, P1642, DOI 10.1161/ATVBAHA.110.207373; GOTTO AM, 1978, HIGH DENSITY LIPOPRO; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HOLZER M, 2013, BBA-MOL CELL BIOL L, V1831, P1442, DOI 10.1016/J.BBALIP.2013.06.004; KIM SJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/FPHYS.2018.00412; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LIM SM, 2016, REJUV RES, V19, P59, DOI 10.1089/REJ.2015.1712; MCCARTY MF, 2005, MED HYPOTHESES, V64, P636, DOI 10.1016/J.MEHY.2003.12.051; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; NATARAJAN P, 2010, J AM COLL CARDIOL, V55, P1283, DOI 10.1016/J.JACC.2010.01.008; OWUSU-ANSAH E, 2008, NAT GENET, V40, P356, DOI 10.1038/NG.2007.50; PEREZ Y, 2013, INT J PHARM SCI REV, V19, P18; PÉREZ Y, 2008, ARZNEIMITTELFORSCH, V58, P126, DOI 10.1055/S-0031-1296481; PICHUGIN Y, 2019, J R SOC INTERFACE, V16, DOI 10.1098/RSIF.2019.0054; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; SHEPHERD J, 2005, EUR HEART J SUPPL, V7, PF15, DOI 10.1093/EURHEARTJ/SUI038; VON ECKARDSTEIN A, 2014, CARDIOVASC RES, V103, P384, DOI 10.1093/CVR/CVU143; YOON JH, 2012, REJUV RES, V15, P313, DOI 10.1089/REJ.2011.1246","CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, RES INST PROT SENSOR, DEPT MED BIOTECHNOL, GYONGSAN, GYEONGBUK, SOUTH KOREA","PREMCHAND SHANTIDEVI RESEARCH FOUNDATION","ENGLISH","J. CLIN. DIAGN. RES.","ARTICLE","ISI","WOS000473818100006","J CLIN DIAGN RES","YEUNGNAM UNIV;YEUNGNAM UNIV;CHUNGNAM NATL UNIV;KOREA RES INST CHEM TECHNOL;YEUNGNAM UNIV","YEUNGNAM UNIV",NA,"CHO KH, 2019, J CLIN DIAGN RES","CHO KH, 2019, J CLIN DIAGN RES"
"LLANES G D;LOIS-CORREA J;SANCHEZ-PARDO M;DOMINGUEZ-CRESPO M;TORRES-HUERTA A;RODRIGUEZ-SALAZAR A;ORTA-GUZMAN V","LLANES GIL-LOPEZ D I;LOIS-CORREA J A;SANCHEZ-PARDO M E;DOMINGUEZ-CRESPO M A;TORRES-HUERTA A M; RODRIGUEZ-SALAZAR A E;ORTA-GUZMAN V N","DATA SUPPORTING THE PRODUCTION OF DIETARY FIBERS FROM SUGARCANE BAGASSE AND SUGARCANE TOPS USING MICROWAVE ASSISTED ALKALINE TREATMENTS",2019,"DATA IN BRIEF","24",NA,1,"10.1016/j.dib.2019.104026","LOIS-CORREA, JA (CORRESPONDING AUTHOR), INST POLITECN NACL, CICATA ALTAMIRA, KM 14-5 CARRETERA TAMPICOE PUERTO IND ALTAMIRA, ALTAMIRA 89600, TAMPS, MEXICO.; LLANES GIL-LOPEZ, D. I.; LOIS-CORREA, J. A.; DOMINGUEZ-CRESPO, M. A.; TORRES-HUERTA, A. M.; ORTA-GUZMAN, V. N., INST POLITECN NACL, CICATA ALTAMIRA, KM 14-5 CARRETERA TAMPICOE PUERTO IND ALTAMIRA, ALTAMIRA 89600, TAMPS, MEXICO.; SANCHEZ-PARDO, M. E., INST POLITECN NACL, ENCB, UPALM, AV WILFRIDO MASSIEU ESQ,CDA MANUEL STAMPA S-N, CIUDAD DE MEXICO 07728, MEXICO.; RODRIGUEZ-SALAZAR, A. E., INST POLITECN NACL, CICATA QUERETARO, CERRO BLANCO 141 COL COLINAS CIMATARIO, QUERETARO 76090, QRO, MEXICO.","THE TREATMENT OF AGROINDUSTRIAL RESIDUES IS AN ALTERNATIVE TO WASTE MANAGEMENT AND OBTAIN PRODUCTS WITH ADDED VALUE. IN THIS ARTICLE, WE DESCRIBE THE CONFOCAL MICROSCOPY IMAGES, THE MICROBIOLOGICAL DATA, POLICOSANOL CONTENT AND COLOR MEASUREMENT LINKED TO THE PAPER ``PRODUCTION OF DIETARY FIBERS FROM SUGARCANE BAGASSE AND SUGARCANE TOPS USING MICROWAVE - ASSISTED ALKALINE TREATMENTS''. THE DATA CONTAIN PHOTOGRAPHS AFTER ELABORATION OF NOODLES-TYPE PASTA AND CHAPATTI-TYPE FERMENTED BREAD; THE CONFOCAL LASER SCANNING MICROGRAPHS, BEFORE AND AFTER INCLUDING SUGARCANE BAGASSE AND SUGARCANE TOPS FIBERS IN FOODS. MICROBIOLOGICAL ANALYSES OF TOTAL COLIFORMS, MOLDS AND YEASTS, AND AEROBIC MESOPHILES WERE ALSO PRESENTED ACCORDING TO MEXICAN STANDARD NOM- 247-SSA1-2008 WHICH CONFIRMED THAT THE FOOD IS SAFE FOR HUMAN CONSUMPTION. THE DATA PROVIDED IN THIS ARTICLE HAVE NOT BEEN PREVIOUSLY PUBLISHED AND ARE AVAILABLE TO ENABLE CRITICAL OR EXTENDED ANALYSES. (C) 2019 THE AUTHORS. PUBLISHED BY ELSEVIER INC.",NA,NA,"CONSEJO NACIONAL DE CIENCIA Y TECNOLOGIA (CONACYT), MEXICO; COMISION DE OPERACION Y FOMENTO DE ACTIVIDADES ACADEMICAS DEL IPN (COFAA), MEXICO; SECRETARIA DE INVESTIGACION Y POSGRADO (SIP) DEL INSTITUTE POLITECNICO NACIONAL (IPN) MEXICO; INSTITUTO POLITECNICO NACIONAL [SIP2019-6650, SIP2019-6670, SIP2019-6718]; CONACYT [CB2015-252181, C-2014-1905]; SNI-CONACYT","DIANA ISIS LLANES GIL-LOPEZ IS GRATEFUL FOR HER POSTGRADUATE FELLOWSHIP TO CONSEJO NACIONAL DE CIENCIA Y TECNOLOGIA (CONACYT), MEXICO, COMISION DE OPERACION Y FOMENTO DE ACTIVIDADES ACADEMICAS DEL IPN (COFAA), MEXICO AND SECRETARIA DE INVESTIGACION Y POSGRADO (SIP) DEL INSTITUTE POLITECNICO NACIONAL (IPN) MEXICO. THE AUTHORS ARE ALSO GRATEFUL FOR FINANCIAL SUPPORT PROVIDED BY THE INSTITUTO POLITECNICO NACIONAL THROUGH THE SIP2019-6650, SIP2019-6670, SIP2019-6718 PROJECTS; CONACYT CB2015-252181 AND C-2014-1905 PROJECTS; AS WELL AS SNI-CONACYT.","CESA S, 2017, FOOD CHEM, V232, P114, DOI 10.1016/J.FOODCHEM.2017.03.153; GIL-LÓPEZ DIL, 2019, IND CROP PROD, V135, P159, DOI 10.1016/J.INDCROP.2019.04.042; GUILLON F, 2000, FOOD RES INT, V33, P233, DOI 10.1016/S0963-9969(00)00038-7; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; PATRAS A, 2019, FOOD CHEM, V275, P539, DOI 10.1016/J.FOODCHEM.2018.09.100; REDDY BS, 1982, CRITICAL REV DIETARY, P265; RICHARD HS., 2012, HUNTERLAB APPL NOTE, P1; SANGNARK A, 2004, FOOD RES INT, V37, P66, DOI 10.1016/J.FOODRES.2003.09.007; SCHNEEMAN BO, 1998, NUTR RES, V18, P625, DOI 10.1016/S0271-5317(98)00049-9; SCHWEIZER TF, 1991, EXPERIENTIA, V47, P181, DOI 10.1007/BF01945423; SPILLER GA., 1986, CRC HDB DIETARY FIBR, P281; STEPHEN AM, 1981, J HUM NUTR, V35, P403; TARPILA S, 1978, GUT, V19, P137, DOI 10.1136/GUT.19.2.137","LOIS-CORREA, JA (CORRESPONDING AUTHOR), INST POLITECN NACL, CICATA ALTAMIRA, KM 14-5 CARRETERA TAMPICOE PUERTO IND ALTAMIRA, ALTAMIRA 89600, TAMPS, MEXICO","ELSEVIER","ENGLISH","DATA BRIEF","ARTICLE; DATA PAPER","ISI","WOS000483993000153","DATA BRIEF","INST POLITECN NACL;DOMINGUEZ-CRESPO;TORRES-HUERTA;INST POLITECN NACL;INST POLITECN NACL;INST POLITECN NACL","INST POLITECN NACL",NA,"LLANES GIL-LOPEZ DI, 2019, DATA BRIEF","LLANES GIL-LOPEZ DI, 2019, DATA BRIEF"
"YUK H;RYU H;KIM D;PARK M;SEO W;JEONG S;OH S","YUK HEUNG JOO;RYU HYUNG WON;KIM DOO-YOUNG;PARK MI HYEON;SEO WOO DUCK;JEONG SEONG HUN;OH SEI-RYANG","COMPARISON OF FLAVONOID AND POLICOSANOL PROFILES IN KOREAN WINTERSPINACH ISPINACIA OLERACEAI L CULTIVATED IN DIFFERENT REGIONS",2019,"FOOD CHEMISTRY","279","202-208",15,"10.1016/j.foodchem.2018.11.143","OH, SR (CORRESPONDING AUTHOR), KOREA RES INST BIOSCI \& BIOTECHNOL, NAT MED RES CTR, CHEONG JU SI 28116, CHUNGCHEONGBUK, SOUTH KOREA.; JEONG, SH (CORRESPONDING AUTHOR), NAMHAE GARL RES INST, NAMHAE 52430, GYEONGNAM, SOUTH KOREA.; YUK, HEUNG JOO; RYU, HYUNG WON; KIM, DOO-YOUNG; PARK, MI HYEON; OH, SEI-RYANG, KOREA RES INST BIOSCI \& BIOTECHNOL, NAT MED RES CTR, CHEONG JU SI 28116, CHUNGCHEONGBUK, SOUTH KOREA.; SEO, WOO DUCK, RURAL DEV ADM, NATL INST CROP SCI, DIV CROP FDN, JEOLLABUK DO 55365, SOUTH KOREA.; JEONG, SEONG HUN, NAMHAE GARL RES INST, NAMHAE 52430, GYEONGNAM, SOUTH KOREA.","SPINACH INTAKE HAS LONG BEEN HIGHLIGHTED GLOBALLY BECAUSE OF ITS OUTSTANDING NUTRITIONAL ASPECTS. IN THIS STUDY, CHANGES IN FLAVONOIDS, A REPRESENTATIVE FUNCTIONAL PHYTOCHEMICAL GROUP, WERE INVESTIGATED BY UPLC-QTOF MS WITH MULTIVARIATE ANALYSIS OF WINTER-SPINACH SAMPLES FROM THREE DIFFERENT CULTIVATION REGIONS IN KOREA. FROM THE PARTIAL LEAST SQUARES DISCRIMINANT ANALYSIS (PLS-DA), THE DIFFERENCES OF FLAVONOIDS AMONG THE GEOGRAPHIC LOCATIONS WERE CLEARLY DISTINGUISHED. SEVEN SPINACH FLAVONOIDS (2, PATULETIN-3-O-GLUCOSYL-(1 -> 6)-GLUCOSIDE; 4, SPI-NACETIN-3-O-GLUCOSYL-(1 -> 6)- [APIOSYL-(1 -> 2)]-GLUCOSIDE; 8, PATULETIN 3-O-(2 `'-FERULOYLGLUCOSYL)-(1 -> 6)- [APIOSYL-(1 -> 2)]-GLUCOSIDE; 11, SPINACETIN 3-O-(2 `'-FERULOYLGLUCOSYL)-(1 -> 6) - [APIOSYL-(1 -> 2)]-GLUCOSIDE; 12, PATULETIN 3-O-(2 `'-FERULOYLGLUCOSYL)-(1 -> 6)-GLUCOSIDE; 18, 5,3',4'-TRIHYDROXY-3-METHOXY-6:7-METHYLENDIOXYFLAVONE-4'-GLUCURONIDE; 20, 5,4'-DIHYDROXY-3,3'-DIMETHOXY-6:7-METHYLENDIOXYFLAVONE-4'-GLUCURONIDE) WERE EVALUATED AS KEY MARKERS AMONG 20 ISOLATED METABOLITES. INTERESTINGLY, THE CONTENTS OF INDIVIDUAL MARKER WERE SIGNIFICANTLY DIFFERENT AMONG THE GROUPS, THOUGH TOTAL AMOUNT OF FLAVONOIDS WERE ALMOST SAME. ADDITIONALLY, POLICOSANOLS (PCS) IN THE WINTER-SPINACH WAS EXAMINED QUANTITATIVELY USING GC-MS FOR THE FIRST TIME. THE PCS WERE ANALYZED AS THE RANGE OF 53.6-59.2 MG/100 G, INDICATE THAT THE WINTER-SPINACH IS A BENEFICIAL SOURCE OF PCS.","SPINACIA OLERACEA L.; SPINACH; FLAVONOID; POLICOSANOL; UPLC-QTOF MS","ANTIOXIDANT CAPACITY; GROWTH; LEAVES; STRESS; WAX","KRIBB RESEARCH INITIATIVE PROGRAM - MINISTRY OF SCIENCE AND ICT (MSIT) OF REPUBLIC OF KOREA","THIS WORK WAS SUPPORTED BY THE KRIBB RESEARCH INITIATIVE PROGRAM FUNDED BY THE MINISTRY OF SCIENCE AND ICT (MSIT) OF REPUBLIC OF KOREA.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; AISYAH S, 2016, PHYTOCHEMISTRY, V122, P65, DOI 10.1016/J.PHYTOCHEM.2015.12.015; AN JH, 2018, IND CROP PROD, V112, P608, DOI 10.1016/J.INDCROP.2017.12.050; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; BERGQUIST SÅM, 2005, J AGR FOOD CHEM, V53, P9459, DOI 10.1021/JF051430H; BRERETON RG, 2014, J CHEMOMETR, V28, P213, DOI 10.1002/CEM.2609; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P639, DOI 10.2165/00044011-200323100-00003; CHO MJ, 2008, J SCI FOOD AGR, V88, P1099, DOI 10.1002/JSFA.3206; CHOI SJ, 2016, FOOD CHEM, V204, P94, DOI 10.1016/J.FOODCHEM.2016.02.027; DUNFORD NT, 2010, FOOD CHEM, V119, P1246, DOI 10.1016/J.FOODCHEM.2009.07.039; FERRERES F, 1997, PHYTOCHEMISTRY, V45, P1701, DOI 10.1016/S0031-9422(97)00244-6; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HOWARD LR, 2002, J AGR FOOD CHEM, V50, P5891, DOI 10.1021/JF020507O; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; ISHAKA A, 2014, INT J NANOMED, V9, P2261, DOI 10.2147/IJN.S56999; JUÁNIZ I, 2016, FOOD CHEM, V197, P466, DOI 10.1016/J.FOODCHEM.2015.10.139; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; JUSTESEN U, 2001, J MASS SPECTROM, V36, P169, DOI 10.1002/JMS.118; KIM DY, 2015, J KOREAN SOC APPL BI, V58, P21, DOI 10.1007/S13765-015-0009-Y; KIM TJ, 2015, J KOREAN SOC APPL BI, V58, P909, DOI 10.1007/S13765-015-0119-6; LISIEWSKA Z, 2011, FOOD CHEM, V126, P460, DOI 10.1016/J.FOODCHEM.2010.11.015; MACIEJEWSKA U, 2002, J PLANT PHYSIOL, V159, P397, DOI 10.1078/0176-1617-00636; MANACH C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/AJCN/79.5.727; RYU HW, 2017, FOOD CONTROL, V73, P916, DOI 10.1016/J.FOODCONT.2016.10.017; RYU HW, 2016, IND CROP PROD, V89, P215, DOI 10.1016/J.INDCROP.2016.05.011; SCHULZ E, 2016, SCI REP-UK, V6, DOI 10.1038/SREP34027; SEO WD, 2013, J AGR FOOD CHEM, V61, P1117, DOI 10.1021/JF3041879; SHEPHERD T, 2006, NEW PHYTOL, V171, P469, DOI 10.1111/J.1469-8137.2006.01826.X; SONG HH, 2016, J FUNCT FOODS, V22, P64, DOI 10.1016/J.JFF.2016.01.007; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q; WATANABE M, 2015, J SCI FOOD AGR, V95, P2095, DOI 10.1002/JSFA.6925; YOON YE, 2017, FOOD CHEM, V215, P185, DOI 10.1016/J.FOODCHEM.2016.07.167","OH, SR (CORRESPONDING AUTHOR), KOREA RES INST BIOSCI \& BIOTECHNOL, NAT MED RES CTR, CHEONG JU SI 28116, CHUNGCHEONGBUK, SOUTH KOREA","ELSEVIER SCI LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","WOS000454689200024","FOOD CHEM","KOREA RES INST BIOSCI AND BIOTECHNOL;NAMHAE GARL RES INST;KOREA RES INST BIOSCI AND BIOTECHNOL;NATL INST CROP SCI;NAMHAE GARL RES INST","KOREA RES INST BIOSCI AND BIOTECHNOL",NA,"YUK HJ, 2019, FOOD CHEM","YUK HJ, 2019, FOOD CHEM1"
"CAO C;SU M","CAO CHANGFU;SU MEIQING","EFFECTS OF BERBERINE ON GLUCOSELIPID METABOLISM INFLAMMATORY FACTORS AND INSULIN RESISTANCE IN PATIENTS WITH METABOLIC SYNDROME",2019,"EXPERIMENTAL AND THERAPEUTIC MEDICINE","17","3009-3014",32,"10.3892/etm.2019.7295","CAO, CF (CORRESPONDING AUTHOR), LINYI CENT HOSP, DEPT PHARM, 17 JIANKANG RD, LINYI 276400, SHANDONG, PEOPLES R CHINA.; CAO, CHANGFU; SU, MEIQING, LINYI CENT HOSP, DEPT PHARM, 17 JIANKANG RD, LINYI 276400, SHANDONG, PEOPLES R CHINA.","EFFECTS OF BERBERINE ON GLUCOSE-LIPID METABOLISM, INFLAMMATORY FACTORS AND INSULIN RESISTANCE IN PATIENTS WITH METABOLIC SYNDROME WERE INVESTIGATED. EIGHTY PATIENTS WITH METABOLIC SYNDROME TREATED IN LINYI CENTRAL HOSPITAL FROM JANUARY 2017 TO DECEMBER 2017 WERE SELECTED AND DIVIDED INTO CONTROL GROUP (N=40) AND OBSERVATION GROUP (N=40). PATIENTS IN CONTROL GROUP WERE TREATED WITH REGULAR THERAPY USING THE WESTERN MEDICINE AND DRUGS, WHILE THOSE IN OBSERVATION GROUP, BASED ON THE TREATMENT IN CONTROL GROUP, WERE TREATED WITH BERBERINE. CHANGES IN RELEVANT INDEXES TO BLOOD GLUCOSE AND LIPID METABOLISMS AND INFLAMMATORY FACTORS WERE COMPARED BETWEEN THE TWO GROUPS. THE CORRELATION OF INFLAMMATORY FACTOR WITH FASTING BLOOD GLUCOSE, INSULIN RESISTANCE, TRIGLYCERIDE AND TOTAL CHOLESTEROL WAS ANALYZED. AT 1 MONTH AFTER TREATMENT, LEVELS OF FASTING BLOOD GLUCOSE, 2 H POSTPRANDIAL BLOOD GLUCOSE, INSULIN RESISTANCE INDEX AND BLOOD LIPID INDEXES IN BOTH GROUPS WERE LOWER THAN THOSE AT 1 WEEK AFTER TREATMENT (P<0.05). AT 1 MONTH AFTER TREATMENT, LEVELS OF FASTING BLOOD GLUCOSE, 2 H POSTPRANDIAL BLOOD GLUCOSE, INSULIN RESISTANCE INDEX AND BLOOD LIPID INDEXES IN OBSERVATION GROUP WERE SIGNIFICANTLY LOWER THAN THOSE IN CONTROL GROUP DURING THE SAME PERIOD (P<0.05). MOREOVER, LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN (HS-CRP), INTERLEUKIN-6 (IL-6) AND TUMOR NECROSIS FACTOR- (TNF-) IN BOTH GROUPS AT 1 MONTH AFTER TREATMENT WERE LOWER THAN THOSE AT 1 WEEK AFTER TREATMENT (P<0.05), AND THEY WERE LOWER IN OBSERVATION GROUP AT 1 MONTH AFTER TREATMENT THAN THOSE IN CONTROL GROUP DURING THE SAME PERIOD (P<0.05). FINALLY, HS-CRP WAS POSITIVELY CORRELATED WITH FASTING BLOOD GLUCOSE, INSULIN RESISTANCE, TOTAL CHOLESTEROL AND TRIGLYCERIDE. THE COMBINED APPLICATION OF BERBERINE IN PATIENTS WITH METABOLIC SYNDROME CAN EFFECTIVELY REGULATE BLOOD GLUCOSE AND BLOOD LIPID OF PATIENTS, ALLEVIATE INSULIN RESISTANCE AND REDUCE THE LEVEL OF INFLAMMATORY RESPONSE IN THE BODY.","BERBERINE; METABOLIC SYNDROME; BLOOD GLUCOSE METABOLISM; BLOOD LIPID; METABOLISM; INFLAMMATORY FACTORS; INSULIN RESISTANCE","RED YEAST RICE; MANAGEMENT; ACCUMULATION; POLICOSANOL; DIET",NA,NA,"CALICETI C, 2016, CURR MED CHEM, V23, P1460, DOI 10.2174/0929867323666160411143314; CHOI YJ, 2017, TOXICOL APPL PHARM, V316, P74, DOI 10.1016/J.TAAP.2016.12.019; CHOW YL, 2016, SCI REP-UK, V6, DOI 10.1038/SREP38129; CICERO AFG, 2016, PHYTOMEDICINE, V23, P1134, DOI 10.1016/J.PHYMED.2015.11.009; DAHLBERG CJ, 2017, CAN J PHYSIOL PHARM, V95, P1414, DOI 10.1139/CJPP-2016-0704; GENG FH, 2016, BRIT J PHARMACOL, V173, P1569, DOI 10.1111/BPH.13466; GUARINO G, 2017, J BIOL REG HOMEOS AG, V31, P495; HE Q, 2016, J MOL ENDOCRINOL, V57, P251, DOI 10.1530/JME-16-0139; LI M, 2016, J TRANSL MED, V14, DOI 10.1186/S12967-016-0987-5; LIU Q, 2017, CURR PHARM DESIGN, V23, P5136, DOI 10.2174/1381612823666170918120643; LU YAN-HUI, 2006, ZHONGHUA YI XUE ZA ZHI, V86, P386; MARCHITTO N, 2018, MINERVA CARDIOANGIOL, V66, P124, DOI 10.23736/S0026-4725.17.04523-6; MARTÍNEZ-ABUNDIS E, 2016, WORLD J DIABETES, V7, P142, DOI 10.4239/WJD.V7.I7.142; MILLÁN J, 2016, CLIN INVEST ARTERIOS, V28, P178, DOI 10.1016/J.ARTERI.2016.03.002; OIKAWA N, 2016, J NAT MED-TOKYO, V70, P502, DOI 10.1007/S11418-016-0968-2; ONG M, 2017, AM J CHINESE MED, V45, P405, DOI 10.1142/S0192415X17500252; PATEL S, 2016, WORLD J MICROB BIOT, V32, DOI 10.1007/S11274-016-2035-2; SALEEM F, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/CUREUS.1844; SIRTORI CR, 2017, ANN MED, V49, P678, DOI 10.1080/07853890.2017.1366042; TABESHPOUR J, 2017, IRAN J BASIC MED SCI, V20, P557, DOI 10.22038/IJBMS.2017.8682; ZHAO L, 2017, BMC ENDOCR DISORD, V17, DOI 10.1186/S12902-017-0165-7","CAO, CF (CORRESPONDING AUTHOR), LINYI CENT HOSP, DEPT PHARM, 17 JIANKANG RD, LINYI 276400, SHANDONG, PEOPLES R CHINA","SPANDIDOS PUBL LTD","ENGLISH","EXP. THER. MED.","ARTICLE","ISI","WOS000463793600079","EXP THER MED","LINYI CENT HOSP;LINYI CENT HOSP","LINYI CENT HOSP",NA,"CAO C, 2019, EXP THER MED","CAO C, 2019, EXP THER MED"
"EL-TANTAWY W;TEMRAZ A","EL-TANTAWY WALID HAMDY;TEMRAZ ABEER","NATURAL PRODUCTS FOR CONTROLLING HYPERLIPIDEMIA REVIEW",2019,"ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY","125","128-135",63,"10.1080/13813455.2018.1441315","EL-TANTAWY, WH (CORRESPONDING AUTHOR), NATL ORG DRUG CONTROL \& RES, CAIRO, EGYPT.; EL-TANTAWY, WALID HAMDY, NATL ORG DRUG CONTROL \& RES, CAIRO, EGYPT.; TEMRAZ, ABEER, UMM AL QURA UNIV, COLL PHARM, PHARMACOGNOSY DEPT, MECCA, SAUDI ARABIA.; TEMRAZ, ABEER, AL AZHAR UNIV, FAC PHARM GIRLS, PHARMACOGNOSY DEPT, CAIRO, EGYPT.","HYPERLIPIDEMIA IS AN ABNORMALITY OF LIPID METABOLISM, CHARACTERIZED BY AN ELEVATION OF TOTAL CHOLESTEROL, TRIGLYCERIDE, AND LOW DENSITY LIPOPROTEIN-CHOLESTEROL, AND/OR A DECREASING OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN CIRCULATING LEVELS. HYPERLIPIDEMIA HAS BEEN RANKED AS ONE OF THE GREATEST RISK FACTORS CONTRIBUTING TO PREVALENCE AND SEVERITY OF CORONARY HEART DISEASES. HYPERLIPIDEMIA-ASSOCIATED LIPID DISORDERS ARE CONSIDERED THE CAUSE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. THERE HAS BEEN A GROWING INTEREST IN NATURAL PRODUCTS AND THEIR ROLE IN THE MAINTENANCE AND IMPROVEMENT OF HEALTH AND WELLNESS. THE CHOLESTEROL-LOWERING EFFECT OF DIETARY PLANTS HAS BEEN WELL STUDIED AND VARIOUS NATURAL PRODUCTS WERE SHOWN TO BE HELPFUL IN LOWERING PLASMA CHOLESTEROL LEVELS AND ENCOURAGING SAFETY PROFILE. THE MAIN FOCUS OF THIS REVIEW IS TO DESCRIBE WHAT WE KNOW TO DATE OF NATURAL PRODUCTS, ALONG WITH THEIR LIPID-LOWERING MECHANISMS, WHICH ARE EITHER THROUGH INHIBITION OF CHOLESTEROL ABSORPTION, INHIBITION OF CHOLESTEROL SYNTHESIS OR ANTIOXIDANT MECHANISMS.","HYPERLIPIDEMIA; HERBAL EXTRACT; CARDIOVASCULAR DISEASES","RED YEAST RICE; SERUM-CHOLESTEROL CONCENTRATIONS; GAMMA-ORYZANOL; PLANT; STEROLS; BRAN OIL; ANTIOXIDANT ACTIVITIES; LIPID-LEVELS; DIET; POLICOSANOL; REDUCTION",NA,NA,"AGOSTONI C, 2011, EFSA J, V9, DOI 10.2903/J.EFSA.2011.2083; ALISCIONI SS, 2003, AM J BOT, V90, P796, DOI 10.3732/AJB.90.5.796; BERG A, 2003, ANN NUTR METAB, V47, P306, DOI 10.1159/000072404; BERGER A, 2005, EUR J NUTR, V44, P163, DOI 10.1007/S00394-004-0508-9; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; BURKE FM, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/S11883-015-0495-8; CARRARA VS, 2009, BRAZ J MED BIOL RES, V42, P545, DOI 10.1590/S0100-879X2009000600011; CASTAÑO G, 1999, ANGIOLOGY, V50, P123, DOI 10.1177/000331979905000205; CHANG JJ, 2017, J AGR FOOD CHEM, V65, P9255, DOI 10.1021/ACS.JAFC.7B03578; CHEN J, 2006, EUR J CLIN NUTR, V60, P62, DOI 10.1038/SJ.EJCN.1602268; CHILDRESS L, 2013, J CLIN LIPIDOL, V7, P117, DOI 10.1016/J.JACL.2012.09.003; CHOUNG MG, 2001, J AGR FOOD CHEM, V49, P5848, DOI 10.1021/JF010550W; CICERO AFG, 2001, PHYTOTHER RES, V15, P277, DOI 10.1002/PTR.907; DÁVALOS A, 2006, J NUTR, V136, P1766, DOI 10.1093/JN/136.7.1766; DAVIDSON MH, 2001, J AM COLL NUTR, V20, P307, DOI 10.1080/07315724.2001.10719051; DEMONTY I, 2009, J NUTR, V139, P271, DOI 10.3945/JN.108.095125; DEVARAJ S, 2004, ARTERIOSCL THROM VAS, V24, PE25, DOI 10.1161/01.ATV.0000120784.08823.99; DONG H, 2013, PLANTA MED, V79, P437, DOI 10.1055/S-0032-1328321; DONG H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591654; DUKE J.A, 2002, HDB MED HERBS, DOI DOI 10.1201/9781420040463; EL-TANTAWY WH, 2015, J CLIN BIOCHEM NUTR, V57, P33, DOI 10.3164/JCBN.14-141; GERARDS MC, 2015, ATHEROSCLEROSIS, V240, P415, DOI 10.1016/J.ATHEROSCLEROSIS.2015.04.004; GHOSH M, 2007, J AM OIL CHEM SOC, V84, P315, DOI 10.1007/S11746-007-1047-3; GOLDBERG AC, 2006, AM J CARDIOL, V97, P376, DOI 10.1016/J.AMJCARD.2005.08.056; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUO LN, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-182; GYLLING H, 2004, J LIPID RES, V45, P1660, DOI 10.1194/JLR.M300522-JLR200; HA AW, 2015, NUTR RES PRACT, V9, P30, DOI 10.4162/NRP.2015.9.1.30; HALLIKAINEN MA, 2000, J NUTR, V130, P767, DOI 10.1093/JN/130.4.767; HALLIKAINEN MA, 2000, EUR J CLIN NUTR, V54, P715, DOI 10.1038/SJ.EJCN.1601083; HWANG JT, 2017, J MED FOOD, V20, P542, DOI 10.1089/JMF.2016.3912; JONES PJ, 2000, J LIPID RES, V41, P697; LAITINEN K, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-140; LEE JH, 2011, J AGR FOOD CHEM, V59, P11872, DOI 10.1021/JF202910U; LI Y, 2014, LIFE SCI, V118, P27, DOI 10.1016/J.LFS.2014.10.003; LIMA I, 2002, NAHRUNG, V46, P112, DOI 10.1002/1521-3803(20020301)46:2<112::AID-FOOD112>3.0.CO;2-N; LIU XN, 2010, INT J BIOL MACROMOL, V47, P116, DOI 10.1016/J.IJBIOMAC.2010.05.012; LV QL, 2015, INT IMMUNOPHARMACOL, V28, P1044, DOI 10.1016/J.INTIMP.2015.08.020; MANNARINO E, 2009, NUTR METAB CARDIOVAS, V19, P84, DOI 10.1016/J.NUMECD.2008.03.012; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; MIETTINEN TA, 2000, ARTERIOSCL THROM VAS, V20, P1340, DOI 10.1161/01.ATV.20.5.1340; MOLLACE V, 2011, FITOTERAPIA, V82, P309, DOI 10.1016/J.FITOTE.2010.10.014; NORIEGA-LÓPEZ L, 2007, J BIOL CHEM, V282, P20657, DOI 10.1074/JBC.M701045200; OH HG, 2014, J MED FOOD, V17, P972, DOI 10.1089/JMF.2012.2740; OKERSON T, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004909; PARK MY, 2011, NUTR RES PRACT, V5, P511, DOI 10.4162/NRP.2011.5.6.511; PATCH CS, 2006, VASC HEALTH RISK MAN, V2, P157, DOI 10.2147/VHRM.2006.2.2.157; PATEL S., 2016, WORLD J MICROB BIOT, V32, P2035; RAHMAN K, 2006, J NUTR, V136, P736S, DOI 10.1093/JN/136.3.736S; REN DL, 1994, FISHERIES SCI, V60, P423, DOI 10.2331/FISHSCI.60.423; RUDEL LL, 2005, ARTERIOSCL THROM VAS, V25, P1112, DOI 10.1161/01.ATV.0000166548.65753.1E; RYAN D, 2007, NUTR RES REV, V20, P147, DOI 10.1017/S0954422407782884; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527A0; SASAKI J, 1990, CLIN THER, V12, P263; SCOGGAN K.A., 2009, J NUTR BIOCH, V15, P32; STUSSER R, 1998, INT J CLIN PHARM TH, V36, P469; UMAMAGESWARI MS, 2017, J CLIN DIAGN RES, V11, PFC16, DOI 10.7860/JCDR/2017/26563.10312; VANSTONE CA, 2002, AM J CLIN NUTR, V76, P1272, DOI 10.1093/AJCN/76.6.1272; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; VOLPE R, 2001, BRIT J NUTR, V86, P233, DOI 10.1079/BJN2001395; VON BERGMANN K, 2005, AM J CARDIOL, V96, P10D, DOI 10.1016/J.AMJCARD.2005.03.014; WAN WT, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182830; WANG YN, 2017, BRIT J NUTR, V118, P822, DOI 10.1017/S0007114517002835; WANG YW, 2014, METABOLISM, V63, P1167, DOI 10.1016/J.METABOL.2014.05.013; WATTS GF, 2011, HEART, V97, P350, DOI 10.1136/HRT.2010.204990; XIAO CT, 2016, DIABETES, V65, P1767, DOI 10.2337/DB16-0046; ZDUNCZYK Z, 2006, J AGR FOOD CHEM, V54, P4168, DOI 10.1021/JF060224M; ZHANG C, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/S12906-017-1892-Z; ZHANG ZH, 2016, FOOD CHEM, V202, P262, DOI 10.1016/J.FOODCHEM.2015.12.039; ZHAO LY, 2012, FOOD CHEM, V134, P964, DOI 10.1016/J.FOODCHEM.2012.03.001; ZHAO LC, 2015, INT J MOL SCI, V16, P27411, DOI 10.3390/IJMS161126031; ZHAO SP, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0184949; ZHENG QN, 2017, J TOXICOL ENV HEAL A, V80, P1193, DOI 10.1080/15287394.2017.1367124; ZHOU X, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/S12944-017-0628-X","EL-TANTAWY, WH (CORRESPONDING AUTHOR), NATL ORG DRUG CONTROL \& RES, CAIRO, EGYPT","TAYLOR \& FRANCIS LTD","ENGLISH","ARCH. PHYSIOL. BIOCHEM.","REVIEW","ISI","WOS000462366900005","ARCH PHYSIOL BIOCHEM","WH (CORRESPONDING AUTHOR);NATL ORG DRUG CONTROL AND RES;UMM AL QURA UNIV;AL AZHAR UNIV","WH (CORRESPONDING AUTHOR)",NA,"EL-TANTAWY WH, 2019, ARCH PHYSIOL BIOCHEM","EL-TANTAWY WH, 2019, ARCH PHYSIOL BIOCHEM"
"CHO K;YADAV D;PARK Y;KIM ;JAE-RYONG J","CHO KYUNG-HYUN;YADAV DHANANJAY;PARK YONG-BOK;KIM; JAE-RYONG","IMPROVEMENT IN LIPID PROFILE AFTER LONGTERM CONSUMPTION OF POLICOSANOL ACCOMPANIED BY REDUCED OXIDATION OF LDL AND AORTIC STIFFNESS VIA CETP INHIBITION IN HEALTHY MIDDLEAGED WOMEN",2019,"JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","13","OD12-OD14",0,"10.7860/JCDR/2019/35885.12498","CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, DEPT MED BIOTECHNOL, GYONGSAN 712749, GYEONGBUK, SOUTH KOREA.; CHO, KYUNG-HYUN; YADAV, DHANANJAY, YEUNGNAM UNIV, DEPT MED BIOTECHNOL, GYONGSAN 712749, GYEONGBUK, SOUTH KOREA.; CHO, KYUNG-HYUN; YADAV, DHANANJAY, YEUNGNAM UNIV, RES INST PROT SENSOR, GYONGSAN, SOUTH KOREA.; CHO, KYUNG-HYUN; YADAV, DHANANJAY, YEUNGNAM UNIV, LIPOLAB, GYONGSAN, SOUTH KOREA.; PARK, YONG-BOK, KYUNGPOOK NATL UNIV, COLL NAT SCI, BIOTECHNOL, DAEGU, SOUTH KOREA.; KIM, JAE-RYONG, YEUNGNAM UNIV, COLL MED, DEPT BIOCHEM \& MOL BIOL, SMART AGING CONVERGENCE RES CTR, DAEGU, SOUTH KOREA.","CUBAN POLICOSANOL (PCO) WAS REPORTED TO LOWER SERUM TOTAL CHOLESTEROL (TC) AS WELL AS INCREASE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND ENHANCE HDL FUNCTIONALITY. IN THIS STUDY, WE COMPARED CHANGES IN THE BLOOD LIPID AND LIPOPROTEIN PROFILES IN HYPERCHOLESTEROLEMIC WOMEN SUBJECTS (50-YEAR-OLD) WHO CONSUMED POLICOSANOL FOR 20 WEEKS. AT WEEK 0, SUBJECT HAD HIGH TC BUT LOW HDL-C LEVELS. AFTER 20 WEEKS OF POLICOSANOL CONSUMPTION, SERUM TC AND TRIGLYCERIDE (TG) LEVELS WERE REDUCED BY 10\% AND 44\%, RESPECTIVELY. HDL-C LEVEL WAS ELEVATED 1.7-FOLD WHILE LOW-DENSITY LIPOPROTEIN (LDL) LEVEL WAS REDUCED BY UP TO 20\%. SERUM CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY WAS REDUCED FROM 33\% CE-TRANSFER AT WEEK 0 TO 22\% CE-TRANSFER AT WEEK 20. GLYCATION EXTENT WAS SIGNIFICANTLY REDUCED IN ALL LIPOPROTEIN FRACTIONS, ESPECIALLY IN LDL AND HDL2. IN VERY LOW-DENSITY LIPOPROTEIN (VLDL) AND LDL, CHOLESTEROL AND TG CONTENTS WERE REDUCED. IN HDL2 AND HDL3, CHOLESTEROL WAS MORE ENRICHED AND TG CONTENT REDUCED. LDL WAS MORE RESISTANT TO CUPRIC ION-MEDIATED OXIDATION AND SHOWED LESS ATHEROGENIC PROPERTIES VIA PHAGOCYTOSIS INTO MACROPHAGES. APOLIPOPROTEIN A-I (APOA-I) WAS MORE ENRICHED IN HDL2 AND HDL3 IN A TIME-DEPENDENT MANNER. THE ANTIOXIDANT ABILITY OF HDL WAS ENHANCED BY 25\% IN TERMS OF FERRIC ION REDUCTION ABILITY AND PARAOXONASE ACTIVITY. IN CONCLUSION, 20 WEEKS OF POLICOSANOL CONSUMPTION IMPROVED THE LIPID PROFILE BY INCREASING HDL-C, AND LIPOPROTEIN FUNCTIONALITY TO ENHANCE ANTIOXIDANT, ANTI-GLYCATION, AND ANTI-ATHEROGENIC PROPERTIES VIA CETP INHIBITION.","GLYCATION; HYPERCHOLESTEROLEMIA; LIPID PROFILE; LIPOPROTEINS","LIPOPROTEINS; ABILITY","MEDICAL RESEARCH CENTER PROGRAM [2015R1A5A2009124]; NATIONAL RESEARCH FOUNDATION (NRF); KYUNGPOOK NATIONAL UNIVERSITY","THIS WORK WAS SUPPORTED BY A GRANT FROM THE MEDICAL RESEARCH CENTER PROGRAM (2015R1A5A2009124) THROUGH THE NATIONAL RESEARCH FOUNDATION (NRF) AND A RESEARCH GRANT FROM KYUNGPOOK NATIONAL UNIVERSITY.","BENZIE IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/ABIO.1996.0292; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199A0; CHO KH, 2009, MOL CELLS, V27, P291, DOI 10.1007/S10059-009-0037-8; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAMES RW, 2010, ADV EXP MED BIOL, V660, P173, DOI 10.1007/978-1-60761-350-3\_16; KIM JY, 2017, INT J MOL MED, V39, P889, DOI 10.3892/IJMM.2017.2907; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/BI00406A016; PARK KH, 2010, INT J MOL MED, V25, P129, DOI 10.3892/IJMM\_00000322; PARK KH, 2010, BIOCHEM BIOPH RES CO, V392, P295, DOI 10.1016/J.BBRC.2009.12.179; PATEL A, 2004, CIRCULATION, V110, P2678, DOI 10.1161/01.CIR.0000145615.33955.83","CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, DEPT MED BIOTECHNOL, GYONGSAN 712749, GYEONGBUK, SOUTH KOREA","PREMCHAND SHANTIDEVI RESEARCH FOUNDATION","ENGLISH","J. CLIN. DIAGN. RES.","ARTICLE","ISI","WOS000455515000052","J CLIN DIAGN RES","YEUNGNAM UNIV;YEUNGNAM UNIV;YEUNGNAM UNIV;YEUNGNAM UNIV;KYUNGPOOK NATL UNIV;YEUNGNAM UNIV","YEUNGNAM UNIV",NA,"CHO KH, 2019, J CLIN DIAGN RES","CHO KH, 2019, J CLIN DIAGN RES-a"
"SANCHEZ-LOPEZ J;FERNANDEZ-TRAVIESO J;ILLNAIT-FERRER J;FERNANDEZ-DORTA L;MENDOZA-CASTANO ;SARAHI S;MAS-FERREIRO R;MESA-ANGARICA M;REYES-SUAREZ P","SANCHEZ-LOPEZ JAVIER;FERNANDEZ-TRAVIESO JULIO C; ILLNAIT-FERRER JOSE;FERNANDEZ-DORTA LILIA;MENDOZA-CASTANO; SARAHI;MAS-FERREIRO ROSA;MESA-ANGARICA MEILIS; REYES-SUAREZ PABLO","EFFECTS OF POLICOSANOL IN THE FUNCTIONAL RECOVERY OF NONCARDIOEMBOLIC ISCHEMIC STROKE HYPERTENSIVE PATIENTS",2018,"REVISTA DE NEUROLOGIA","67","331-338",3,"10.33588/rn.6709.2018063","FERNÁNDEZ-TRAVIESO, JC (CORRESPONDING AUTHOR), CTR NACL INVEST CIENT, AVE 25 \& 158, HAVANA, CUBA.; SANCHEZ-LOPEZ, JAVIER, INST NEUROL \& NEUROCIRUGIA, HAVANA, CUBA.; FERNANDEZ-TRAVIESO, JULIO C.; ILLNAIT-FERRER, JOSE; FERNANDEZ-DORTA, LILIA; MENDOZA-CASTANO, SARAHI; MAS-FERREIRO, ROSA; REYES-SUAREZ, PABLO, CTR NACL INVEST CIENT, AVE 25 \& 158, HAVANA, CUBA.; MESA-ANGARICA, MEILIS, CTR INVEST MED QUIRURG, HAVANA, CUBA.","INTRODUCTION. CLINICAL STUDIES RESULTS SHOW THAT POLICOSANOL (20 MG/DAY) + ASPIRIN THERAPY HAD BENEFITS VERSUS PLACEBO + ASPIRIN TO PATIENTS WITH RECENT NON-CARDIOEMBOLIC ISCHEMIC STROKE. AIM. TO ANALYZE THE POLICOSANOL TREATMENT EFFECTS IN THE HYPERTENSIVE PATIENTS INCLUDED IN TWO NON-CARDIOEMBOLIC ISCHEMIC STROKE RECOVERY TRIALS. PATIENTS AND METHODS. HYPERTENSIVE PATIENTS WITH A MODIFIED RANKIN SCALE (MRS) SCORE 2 TO 4 WERE RANDOMIZED, WITHIN 30 DAYS OF ONSET, TO POLICOSANOL + ASPIRIN OR PLACEBO + ASPIRIN, FOR SIX MONTHS. THE PRIMARY OUTCOME WAS MRS SCORE REDUCTION. RESULTS. ONE HUNDRED FORTY TWO HYPERTENSIVE PATIENTS (MEAN AGE: 66 YEARS) WERE INCLUDED IN THE ANALYSIS. POLICOSANOL + ASPIRIN DECREASED SIGNIFICANTLY THE MRS SCORE MEAN FROM THE FIRST INTERIM CHECK-UP. THE POLICOSANOL TREATMENT EFFECT DID NOT WEAR OFF, ON THE CONTRARY, EVEN IMPROVED AFTER SIX MONTHS THERAPY. MORE OVER, POLICOSANOL + ASPIRIN (80.3\%) TREATMENT ACHIEVED SIGNIFICANT RESULTS (MRS 1), WHEREAS THE PLACEBO + ASPIRIN DID NOT (8.5\%). TWO PATIENTS DISCONTINUED AND FOUR (TWO FROM EACH GROUP) REFERRED MILD ADVERSE EVENTS. CONCLUSIONS. THE TREATMENT FOR SIX MONTHS WITH POLICOSANOL + ASPIRIN IN HYPERTENSIVE PATIENTS WHO HAD SUFFERED A NON-CARDIOEMBOLIC ISCHEMIC STROKE PROVED TO BE MORE EFFECTIVE THAN THE PLACEBO + ASPIRIN TREATMENT IN THE FUNCTIONAL RECOVERY OF THESE PATIENTS.","ASPIRIN; HYPERTENSION; NON-CARDIOEMBOLIC ISCHEMIC STROKE; POLICOSANOL; RECOVERY","PLATELET-AGGREGATION; CEREBRAL-ISCHEMIA; METAANALYSIS; STATINS; PRAVASTATIN; PREVENTION",NA,NA,"AMANTEA D, 2009, FEBS J, V276, P13, DOI 10.1111/J.1742-4658.2008.06766.X; AMARENCO P, 2009, CEREBROVASC DIS, V27, P493, DOI 10.1159/000210432; AMARENCO P, 2009, LANCET NEUROL, V8, P453, DOI 10.1016/S1474-4422(09)70058-4; ANONYMOUS, 2000, BMJ-BRIT MED J, V324, P71; ARBOIX A, 2015, WORLD J CLIN CASES, V3, P418, DOI 10.12998/WJCC.V3.I5.418; ARBOIX A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-47; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CHO KH, 2016, REJUV RES, V19, P59; CHRÓINÍN DN, 2013, STROKE, V44, P448, DOI 10.1161/STROKEAHA.112.668277; COUILLARD PHILIPPE, 2009, EXPERT REV CARDIOVASC THER, V7, P1273, DOI 10.1586/ERC.09.105; DI CARLO A, 2009, AGE AGEING, V38, P4, DOI 10.1093/AGEING/AFN282; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; GHANDEHARI K, 2013, J RES MED SCI, V18, P906; HJALMARSSON C, 2012, AM J GERIATR PHARMAC, V10, P313, DOI 10.1016/J.AMJOPHARM.2012.09.001; LEE EY, 2016, REJUV RES, V19, P149, DOI 10.1089/REJ.2015.1745; LEE YC, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0110494; LEVI M, 2008, NED TIJDSCHR GENEESKD, V152, P423; LIKOSKY DJ, 2008, J HOSP MED, V3, PS6, DOI 10.1002/JHM.337; LIU SHUN, 2012, ZHONGHUA XIN XUE GUAN BING ZA ZHI, V40, P840; MAR J, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/S12955-015-0230-8; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/NEJM199512143332401; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MOLINA V, 2013, INDIAN J PHARM SCI, V75, P635; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; NACI H, 2013, QJM-INT J MED, V106, P299, DOI 10.1093/QJMED/HCT041; NIKITIN IU P, 2000, TER ARKH, V72, P7; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; ORTEGA LL, 2006, J MED FOOD, V9, P378, DOI 10.1089/JMF.2006.9.378; PARK JH, 2014, STROKE, V45, P3269, DOI 10.1161/STROKEAHA.114.006827; PATRONO C, 2008, ARTERIOSCL THROM VAS, V28, PS25, DOI 10.1161/ATVBAHA.107.160481; PEREZ Y, 2013, INT J PHARM SCI REV, V19, P18; PRAT H, 1999, REV MED CHILE, V127, P286; RANKIN J, 1957, SCOTT MED J, V2, P200; ROGER VL, 2012, CIRCULATION, V125, PE2, DOI 10.1161/CIR.0B013E31823AC046, 10.1161/CIR.0B013E3182456D46; SANCHEZ J, 2010, REV CENIC CIEN BIOL, V41, P23; SANCHEZ J, 2013, J PHARM, V4, P31; SANCHEZ J, 2016, INT J PHARM SCI REV, V37, P7; SANCHEZ J, 2012, IOSR J PHARM, V2, P14; SÁNCHEZ J, 2017, REV NEUROLOGIA, V64, P153; SCAZZIOTA A, 1996, REV IBEROAMER TROMB, V9, P58; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SONG B, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0084389; TANG MIN, 2013, ZHONGHUA XIN XUE GUAN BING ZA ZHI, V41, P488; WANG YUN, 2008, ZHONGGUO XINYAO YU LINCHUANG ZAZHI, V27, P124","FERNÁNDEZ-TRAVIESO, JC (CORRESPONDING AUTHOR), CTR NACL INVEST CIENT, AVE 25 \& 158, HAVANA, CUBA","REVISTA DE NEUROLOGIA","SPANISH","REV. NEUROLOGIA","ARTICLE","ISI","WOS000448796500002","REV NEUROLOGIA","CTR NACL INVEST CIENT;INST NEUROL AND NEUROCIRUGIA;CTR NACL INVEST CIENT;CTR INVEST MED QUIRURG","CTR NACL INVEST CIENT",NA,"SANCHEZ-LOPEZ J, 2018, REV NEUROLOGIA","SANCHEZ-LOPEZ J, 2018, REV NEUROLOGIA"
"THI-CAN-THO P T;ANGERS P;RATTI C","THI-CAN-THO PHAM;ANGERS PAUL;RATTI CRISTINA","EXTRACTION OF WAXLIKE MATERIALS FROM CEREALS",2018,"CANADIAN JOURNAL OF CHEMICAL ENGINEERING","96","2273-2281",5,"10.1002/cjce.23260","RATTI, C (CORRESPONDING AUTHOR), LAVAL UNIV, DEPT SOILS SCI \& AGRI FOOD ENGN, INST NUTR \& FUNCT FOODS INAF, QUEBEC CITY, PQ, CANADA.; THI-CAN-THO PHAM; RATTI, CRISTINA, LAVAL UNIV, DEPT SOILS SCI \& AGRI FOOD ENGN, INST NUTR \& FUNCT FOODS INAF, QUEBEC CITY, PQ, CANADA.; ANGERS, PAUL, LAVAL UNIV, DEPT FOOD SCI \& NUTR, QUEBEC CITY, PQ, CANADA.","IN THIS STUDY, A COMPARISON OF THE WAX EXTRACTION PROCESS FROM RICE, SORGHUM, AND WHEAT USING LIQUID NITROGEN WAS DONE WITH RESPECT TO THE TRADITIONAL SOLVENT EXTRACTION METHOD USING N-HEXANE. FOR THIS PURPOSE, THESE CEREALS WERE IMMERSED IN LIQUID NITROGEN (1-4 CYCLES WITH DIFFERENT TIME INTERVALS AND DIFFERENT REST TIMES BETWEEN CYCLES). THE RESULTS SHOWED THAT WAXES COULD BE EXTRACTED BY LIQUID NITROGEN, BUT WITH A LOWER YIELD. WHEN COMPARED TO THE N-HEXANE EXTRACTION METHOD, THE EXTRACTED AMOUNTS OF WAXES WITH LIQUID NITROGEN WERE 5, 7.5, AND 9.3 TIMES LOWER, BUT THE EXTRACTION TIMES WERE 2.3, 5.5, AND 11.25 TIMES SHORTER FOR WHEAT, RICE, AND SORGHUM, RESPECTIVELY. NO RESIDUE WAS LEFT IN WAX-LIKE MATERIALS EXTRACTED WITH LIQUID NITROGEN. WHILE SEM DEPICTED THAT THE OUTER LAYER OF WAXES ON THE GRAINS COULD BE EXTRACTED BY LIQUID NITROGEN, GC-MS AND GC-FID SHOWED THAT THE EXTRACTED WAXES HAD SIMILAR COMPOSITIONS IN BOTH CYCLE EXTRACTION METHODS. THESE RESULTS COULD POINT OUT A NOVEL ENVIRONMENTALLY-FRIENDLY METHOD TO EXTRACT WAXES FROM CEREALS THAT COULD BE USEFUL FOR CERTAIN APPLICATIONS.","WAX; CEREAL; LIQUID NITROGEN; EXTRACTION","RICE BRAN WAX; POLICOSANOL CONTENTS; GRAIN","NATURAL SCIENCES AND ENGINEERING RESEARCH COUNCIL OF CANADA (NSERC)","THE AUTHORS WOULD LIKE TO ACKNOWLEDGE THE NATURAL SCIENCES AND ENGINEERING RESEARCH COUNCIL OF CANADA (NSERC) FOR THE FINANCIAL SUPPORT OF THIS PROJECT.","ANONYMOUS, 2013, FOOD AGR COMM PROD; ANONYMOUS, 2008, THESIS; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; ATHUKORALA Y, 2010, IND CROP PROD, V31, P550, DOI 10.1016/J.INDCROP.2010.02.011; ATHUKORALA Y, 2009, EUR J LIPID SCI TECH, V111, P705, DOI 10.1002/EJLT.200800269; AVATO P, 1990, PHYTOCHEMISTRY, V29, P1073, DOI 10.1016/0031-9422(90)85405-5; BIANCHI G, 1978, PHYTOCHEMISTRY, V17, P999, DOI 10.1016/S0031-9422(00)88668-9; DUNFORD NT, 2010, FOOD CHEM, V119, P1246, DOI 10.1016/J.FOODCHEM.2009.07.039; HWANG KT, 2005, CEREAL CHEM, V82, P242, DOI 10.1094/CC-82-0242; HWANG KT, 2002, J AM OIL CHEM SOC, V79, P521, DOI 10.1007/S11746-002-0515-5; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; KETATA M, 2013, J FOOD ENG, V116, P202, DOI 10.1016/J.JFOODENG.2012.10.035; LOCHTE-WATSON KR, 1999, APPL ENG AGRIC, V15, P69; OHNISHI M, 1986, CEREAL CHEM, V63, P193; THROMAS V., 2010, IUFOST WORLD C FOOD; VALI SR, 2005, J AM OIL CHEM SOC, V82, P57, DOI 10.1007/S11746-005-1043-Z; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q","RATTI, C (CORRESPONDING AUTHOR), LAVAL UNIV, DEPT SOILS SCI \& AGRI FOOD ENGN, INST NUTR \& FUNCT FOODS INAF, QUEBEC CITY, PQ, CANADA","WILEY","ENGLISH","CAN. J. CHEM. ENG.","ARTICLE; PROCEEDINGS PAPER","ISI","WOS000444474800021","CAN J CHEM ENG","LAVAL UNIV;LAVAL UNIV;LAVAL UNIV","LAVAL UNIV",NA,"THI-CAN-THO PHAM TCTP, 2018, CAN J CHEM ENG","THI-CAN-THO PHAM TCTP, 2018, CAN J CHEM ENG"
"WANG H;JIAO Q;CHEN S;SHENG J;JIANG H;LU J;ZHENG S;FANG N","WANG HAI-YA;JIAO QING-PING;CHEN SHU-YAN;SHENG JING; JIANG HUA;LU JIE;ZHENG SONG-BAI;FANG NING-YUAN","EFFICACY AND SAFETY OF POLIOSANOL EMUS FENOFIBRATE COMBINATION THERAPY IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA A RANDOMIZED CONTROLLED CLINICAL STUDY",2018,"AMERICAN JOURNAL OF THE MEDICAL SCIENCES","356","254-261",3,"10.1016/j.amjms.2018.06.014","FANG, NY (CORRESPONDING AUTHOR), SHANGHAI JIAO TONG UNIV, RENJI HOSP, SCH MED, DEPT GERIATR, 145 MID SHANDONG RD, SHANGHAI 200001, PEOPLES R CHINA.; ZHENG, SB (CORRESPONDING AUTHOR), FUDAN UNIV, HUADONG HOSP, DEPT GERIATR, 221 YANAN XI RD, SHANGHAI 200040, PEOPLES R CHINA.; WANG, HAI-YA; FANG, NING-YUAN, SHANGHAI JIAO TONG UNIV, RENJI HOSP, SCH MED, DEPT GERIATR, 145 MID SHANDONG RD, SHANGHAI 200001, PEOPLES R CHINA.; JIAO, QING-PING; ZHENG, SONG-BAI, FUDAN UNIV, HUADONG HOSP, DEPT GERIATR, 221 YANAN XI RD, SHANGHAI 200040, PEOPLES R CHINA.; CHEN, SHU-YAN, SHANGHAI JIAO TONG UNIV, SCH MED, XINHUA HOSP, DEPT GERIATR, SHANGHAI, PEOPLES R CHINA.; SHENG, JING, SHANGHAI JIAO TONG UNIV, SCH MED, SHANGHAI PEOPLES HOSP 9, DEPT GERIATR, SHANGHAI, PEOPLES R CHINA.; JIANG, HUA, TONGJI UNIV, SCH MED, EAST HOSP, DEPT GERIATR, SHANGHAI, PEOPLES R CHINA.; LU, JIE, MINHANG CENT HOSP, DEPT GERIATR, SHANGHAI, PEOPLES R CHINA.","BACKGROUND: POLICOSANOL IS A MIXTURE OF LONG-CHAIN ALCOHOLS ISOLATED FROM SUGAR CANE. THIS CONTROLLED, RANDOMIZED CLINICAL TRIAL WAS DESIGNED TO COMPARE THE EFFICACY AND SAFETY OF FENOFIBRATE, POLICOSANOL AND A COMBINATION OF THESE 2 IN LOWERING LOW-DENSITY-LIPOPROTEIN CHOLESTEROL (LDL-C) IN ELDERLY PATIENTS WITH MIXED DYSLIPIDEMIA. METHODS: A TOTAL OF 102 PATIENTS AGED >= 60 YEARS WERE RANDOMLY ASSIGNED INTO 3 GROUPS: PATIENTS RECEIVING A 24-WEEK THERAPY OF FENOFIBRATE (200 MG/DAY), POLICOSANOL (20 MG/DAY) OR FENOFIBRATE + POLICOSANOL COMBINATION. LIPIDS WERE EVALUATED AT BASELINE, AFTER 16 AND AFTER 24 WEEKS OF THERAPY. BRACHIAL-ANKLE PULSE WAVE VELOCITY (BA-PVW) WAS PERFORMED, AND SF-36 QUESTIONNAIRES WERE USED TO EVALUATE THE PATIENTS' QUALITY OF LIFE. THE PRIMARY ENDPOINT WAS THE PERCENTAGE REDUCTION IN LDL-C. THE SECONDARY END POINTS INCLUDED PERCENTAGE CHANGE IN NONHIGH DENSITY LIPOPROTEIN CHOLESTEROL (NON-HDL-C), TOTAL CHOLESTEROL (TC), TRIGLYCERIDE, HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL (HDL-C), BA-PWV AND SF-36 SCORES. SAFETY WAS ASSESSED BY ADVERSE EVENTS AND LABORATORY PARAMETERS. RESULTS: LDL-C, NON-HDL-C AND TC WERE DECREASED, RESPECTIVELY AFTER TREATMENT WITH POLICOSANOL FOR 24 WEEKS (P < 0.01). TREATMENT WITH POLICOSANOL + FENOFIBRATE RESULTED IN SIGNIFICANTLY GREATER REDUCTIONS IN TC, NON-HDL-C AND LDL-C COMPARED TO FENOFIBRATE ALONE (P < 0.01, RESPECTIVELY). THERE WERE SIGNIFICANT INCREASES IN SF-36 SCORES IN THE POLICOSANOL AND POLICOSANOL + FENOFIBRATE GROUPS (P < 0.05), AND SIGNIFICANT IMPROVEMENTS OF BA-PWV IN THE 2 GROUPS (P < 0.01). THERE WERE NO SERIOUS ADVERSE EVENTS OR SIGNIFICANT CHANGES IN LABORATORY VARIABLES AFTER ANY OF THE TREATMENT REGIMENS. CONCLUSIONS: POLICOSANOL + FENOFIBRATE COMBINATION THERAPY SIGNIFICANTLY IMPROVED LIPID PARAMETERS, ARTERIAL STIFFNESS, AND QUALITY OF LIFE, WITH GOOD TOLERABILITY.","FENOFIBRATE; POLICOSANOL; ELDERLY; MIXED DYSLIPIDEMIA","II HYPERCHOLESTEROLEMIA; POLICOSANOL; CHOLESTEROL; BEZAFIBRATE; PLACEBO; STATINS; RISK; RATS",NA,NA,"ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; BARRAT E, 2013, INT J FOOD SCI NUTR, V64, P882, DOI 10.3109/09637486.2013.809405; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P55; CASTANO G, 1998, REV CENIC CIEN BIOL, V29, P17; CHIU YC, 1991, AM HEART J, V121, P1460, DOI 10.1016/0002-8703(91)90153-9; CORSINI A, 2005, AM J CARDIOL, V96, P44K, DOI 10.1016/J.AMJCARD.2005.08.007; DURRINGTON P, 2003, LANCET, V362, P717, DOI 10.1016/S0140-6736(03)14234-1; GÓMEZ-GERIQUE JA, 2002, ATHEROSCLEROSIS, V162, P245, DOI 10.1016/S0021-9150(01)00708-0; LAURENT S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/EURHEARTJ/EHL254; MARCELLO S, 2000, CURR THER RES CLIN E, V61, P346, DOI 10.1016/S0011-393X(00)80004-1; MARTIN SS, 2013, JAMA-J AM MED ASSOC, V310, P2061, DOI 10.1001/JAMA.2013.280532; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MCCLURE DL, 2007, J CLIN EPIDEMIOL, V60, P812, DOI 10.1016/J.JCLINEPI.2006.11.006; NOA M, 2005, ARCH MED RES, V36, P441, DOI 10.1016/J.ARCMED.2005.03.039; NOA M, 1996, J PHARM PHARMACOL, V48, P306, DOI 10.1111/J.2042-7158.1996.TB05922.X; NOA M, 1995, J PHARM PHARMACOL, V47, P289, DOI 10.1111/J.2042-7158.1995.TB05797.X; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TENENBAUM A, 2008, ADV CARDIOL, V45, P127, DOI 10.1159/000115192; WARE J.E., 2003, SF 36 HLTH SURVEY MA; YANG XIAO-YING, 2008, NAN FANG YI KE DA XUE XUE BAO, V28, P652","FANG, NY (CORRESPONDING AUTHOR), SHANGHAI JIAO TONG UNIV, RENJI HOSP, SCH MED, DEPT GERIATR, 145 MID SHANDONG RD, SHANGHAI 200001, PEOPLES R CHINA","ELSEVIER SCIENCE INC","ENGLISH","AM. J. MED. SCI.","ARTICLE","ISI","WOS000446031100009","AM J MED SCI","SHANGHAI JIAO TONG UNIV;FUDAN UNIV;SHANGHAI JIAO TONG UNIV;FUDAN UNIV;SHANGHAI JIAO TONG UNIV;SHANGHAI JIAO TONG UNIV;TONGJI UNIV;MINHANG CENT HOSP","SHANGHAI JIAO TONG UNIV",NA,"WANG H, 2018, AM J MED SCI","WANG H, 2018, AM J MED SCI"
"LI N;LU X;FANG M;QIU Z;CHEN X;REN L;OUYANG P;CHEN G","LI NING;LU XIAOYU;FANG MIN;QIU ZHIXIA;CHEN XIJING;REN LILI;OUYANG PINGKAI;CHEN GUOGUANG","PEGYLATED TRIACONTANOL SUBSTANTIALLY ENHANCED THE PHARMACOKINETICS OF TRIACONTANOL IN RATS",2018,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","66","8722-8728",4,"10.1021/acs.jafc.8b02684","OUYANG, PK (CORRESPONDING AUTHOR), NANJING TECH UNIV, SCH BIOTECHNOL \& PHARMACEUT ENGN, NANJING 211816, JIANGSU, PEOPLES R CHINA.; CHEN, GG (CORRESPONDING AUTHOR), NANJING TECH UNIV, SCH PHARMACEUT SCI, NANJING 211816, JIANGSU, PEOPLES R CHINA.; LI, NING; OUYANG, PINGKAI, NANJING TECH UNIV, SCH BIOTECHNOL \& PHARMACEUT ENGN, NANJING 211816, JIANGSU, PEOPLES R CHINA.; LI, NING; REN, LILI; CHEN, GUOGUANG, NANJING TECH UNIV, SCH PHARMACEUT SCI, NANJING 211816, JIANGSU, PEOPLES R CHINA.; LU, XIAOYU; FANG, MIN; CHEN, XIJING, CHINA PHARMACEUT UNIV, CLIN PHARMACOKINET RES LAB, NANJING 210008, JIANGSU, PEOPLES R CHINA.; QIU, ZHIXIA, CHINA PHARMACEUT UNIV, SCH TRADIT CHINESE PHARM, NANJING 210008, JIANGSU, PEOPLES R CHINA.","TRIACONTANOL (TA), A NATURAL COMPOUND WITH VARIOUS HEALTH BENEFITS, IS EXTENSIVELY USED AS A NUTRITIONAL SUPPLEMENT. THE THERAPEUTIC AND NUTRACEUTICAL APPLICATIONS OF TA ARE LIMITED DUE TO ITS POOR AQUEOUS SOLUBILITY. PEGYLATED TRIACONTANOL (PEGYLATED TA) WAS DESIGNED TO IMPROVE THE SOLUBILITY AND PHARMACOKINETICS OF TA. AFTER PEGYLATION, THE SOLUBILITY (SIMILAR TO 250 G.L-1 VERSUS 9 X 10(-14) G.L-1), BODY RESIDENCE (MRT, 9.40 +/- 2.03 H VERSUS 2.59 +/- 0.705 H, P < 0.001), AND SYSTEMIC EXPOSURE (AUC(0-INF,) 29.1 +/- 5.33 MU M.H VERSUS 0.529 +/ - 0.248 MU M.H, P < 0.001) OF TA WERE ALL SIGNIFICANTLY INCREASED COMPARED TO PRISTINE TA. WHEN INTRAVENOUSLY ADMINISTERED (6.85, 22.8, AND 68.5 MU MOL.KG(-1)) IN RATS, PEGYLATED TA EXHIBITED A SLOW CLEARANCE (44.8 +/ - 8.62, 47.9 +/- 5.18, AND 46.9 +/- 16.5 ML.H(-1).KG(-1)), LONG ELIMINATION HALF-LIFE (8.76 +/- 0.96, 10.4 +/- 1.66, AND 11.1 +/- 2.81 H), AND ABUNDANT SYSTEMIC EXPOSURE (AUC(0-T), 155 +/- 24.2, 523 +/ - 56.2, AND 1709 +/- 245 MU M.H). MEANWHILE, ITS METABOLITE TA SHOWED A HIGH AUC(0-T) (28.4 +/- 5.14, 151 +/- 25.4, AND 797 +/- 184 MU M.H) AND SLOW ELIMINATION (T(1/2), 10.1 +/- 2.03, 7.78 +/- 1.74, AND 6.82 +/ - 0.58 H). OUR RESULTS DEMONSTRATED THAT PEGYLATED TA HAS SUPERIOR PHARMACOKINETICS, WHICH ENHANCED ITS NUTRITIONAL AND PHARMACODYNAMIC POTENCY, AND THUS WARRANTS FURTHER INVESTIGATIONS.","GC-MS/MS; PEGYLATED TRIACONTANOL; PHARMACOKINETICS; PRODRUG; TRIACONTANOL","POLICOSANOL CONTENTS; QUANTIFICATION","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [81503149, 81473272]; NATURAL SCIENCE FOUNDATION OF JIANGSU PROVINCE [BK20150704]","THIS STUDY WAS SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (81503149 AND 81473272) AND NATURAL SCIENCE FOUNDATION OF JIANGSU PROVINCE (NO. BK20150704).","COOPER E. R., 2010, US PATENT, PATENT NO. US7763278132, 7763278132; FAN X., 2006, NO TITLE CAPTURED, PATENT NO. 20100041924 AL, 20100041924; GENERAL STATEMENT, 2015, CHINESE PHARMACOPOEI, VIV; GONG J, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700280; HAIM D, 2012, GRASAS ACEITES, V63, P345, DOI 10.3989/GYA.010612; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; LU XY, 2018, J CHROMATOGR B, V1089, P8, DOI 10.1016/J.JCHROMB.2018.04.037; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; QIU ZX, 2017, BIOMED CHROMATOGR, V31, DOI 10.1002/BMC.4001; QIU ZX, 2017, J CHROMATOGR B, V1048, P85, DOI 10.1016/J.JCHROMB.2017.02.011; RAGHAVAN P. R, 2014, US PATENT, PATENT NO. US8722093132, 8722093132; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SWANSON B, 2009, COMPLEMENTARY AND ALTERNATIVE THERAPIES IN THE AGING POPULATION: AN EVIDENCE-BASED APPROACH, P117, DOI 10.1016/B978-0-12-374228-5.00007-X; WANG CF, 2015, XENOBIOTICA, V45, P71, DOI 10.3109/00498254.2014.943334; XU K, 2016, CARDIOVASC THER, V34, P337, DOI 10.1111/1755-5922.12204; ZHANG R., 2016, PATENT NO. CN106727451A, 106727451A","OUYANG, PK (CORRESPONDING AUTHOR), NANJING TECH UNIV, SCH BIOTECHNOL \& PHARMACEUT ENGN, NANJING 211816, JIANGSU, PEOPLES R CHINA","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000442706500009","J AGRIC FOOD CHEM","NANJING TECH UNIV;NANJING TECH UNIV;NANJING TECH UNIV;NANJING TECH UNIV;CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV","NANJING TECH UNIV",NA,"LI N, 2018, J AGRIC FOOD CHEM","LI N, 2018, J AGRIC FOOD CHEM"
"LU X;FANG M;DAI Y;YANG Y;FAN A;XU ;JIAQIU J;QIN Z;LU Y;ZHAO D;CHEN X;LI N","LU XIAOYU;FANG MIN;DAI YU;YANG YUE;FAN ALI;XU; JIAQIU;QIN ZHIYING;LU YANG;ZHAO DI;CHEN XIJING; LI NING","QUANTIFICATION OF TRIACONTANOL AND ITS PEGYLATED PRODRUG IN RAT PLASMA BY GCMSMS APPLICATION TO A PRECLINICAL PHARMACOKINETIC STUDY",2018,"JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES","1089","8-15",4,"10.1016/j.jchromb.2018.04.037","CHEN, XJ (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, CLIN PHARMACOKINET LAB, NANJING 211198, JIANGSU, PEOPLES R CHINA.; LI, N (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, NATL EXPT TEACHING DEMONSTRAT CTR PHARM, NANJING 211198, JIANGSU, PEOPLES R CHINA.; LU, XIAOYU; FANG, MIN; DAI, YU; YANG, YUE; FAN, ALI; XU, JIAQIU; QIN, ZHIYING; LU, YANG; ZHAO, DI; CHEN, XIJING, CHINA PHARMACEUT UNIV, CLIN PHARMACOKINET LAB, NANJING 211198, JIANGSU, PEOPLES R CHINA.; LI, NING, CHINA PHARMACEUT UNIV, NATL EXPT TEACHING DEMONSTRAT CTR PHARM, NANJING 211198, JIANGSU, PEOPLES R CHINA.","PEGYLATION TECHNIQUES HAVE BEEN INCREASINGLY EMPLOYED IN DRUG DELIVERY SYSTEM AND CHEMICAL MODIFICATION OF COMPOUNDS WITH LOW AQUEOUS SOLUBILITY. TRIACONTANOL (TA) IS A NATURAL PRODUCT WITH SEVERAL PHARMACOLOGICAL ACTIVITIES, BUT ITS LOW AQUEOUS SOLUBILITY SIGNIFICANTLY LIMITED ITS APPLICATION. PEGYLATED TRIACONTANOL (PEG-TA) WAS DESIGNED AS THE PRODRUG TO IMPROVE THE AQUEOUS SOLUBILITY AND PHARMACOKINETIC PROPERTIES OF TA. ON THE BASIS OF SALTING-OUT ASSISTED LIQUID-LIQUID EXTRACTION (SALLE) AND SAPONIFICATION SAMPLE PREPARATION PROCEDURE, A RELIABLE GAS CHROMATOGRAPHY TANDEM MASS SPECTROMETRIC (GC-MS/MS) METHOD WAS DEVELOPED AND VALIDATED FOR THE QUANTIFICATION OF PEG-TA AND ITS METABOLITE TA IN RAT PLASMA AFTER SEPARATION AND TRANSFORMATION. ACETONITRILE-METHANOL (9:1, V/V) AND AMMONIUM ACETATE (10 M) WERE UTILIZED TO SEPARATE PEG-TA AND TA (INCLUDING CONJUGATED TA WITH FATTY ACID). SAPONIFICATION FACILITATED THE COMPLETE CONVERSION OF PEG-TA INTO TA, SO PEG-TA COULD BE INDIRECTLY QUANTIFIED. THE RESULTS REVEALED THAT THE GC-MS/MS METHOD HAD EXCELLENT SELECTIVITY, ACCURACY AND LINEARITY. CALIBRATION CURVES WERE LINEAR (R-2 > 0.99) WITHIN THE RANGE OF 20.0-1000.0 NG/ML FOR TA AND 100.0-10,000.0 NG/ML FOR PEG-TA. THE INTRA - AND INTER-DAY PRECISION OF QUALITY CONTROL SAMPLES WERE WITHIN 15\%, AND THEIR ACCURACY VALUES VARIED FROM 93.54\% TO 113.38\%. THIS ANALYTICAL METHOD HAS BEEN SUCCESSFULLY APPLIED TO PHARMACOKINETIC STUDY OF PEG-TA. THIS STUDY CAN FACILITATE THE FURTHER EXPLORATION AND QUANTIFICATION OF PEGYLATED PRODRUGS.","PEGYLATION; PRODRUG; TRIACONTANOL; METABOLITE; GC-MS/MS","POLICOSANOL; 1-TRIACONTANOL","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [81473272, 81503148]","THIS WORK WAS SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [NO.81473272, NO.81503148].","BARROSO-BUJANS F, 2007, EUR POLYM J, V43, P1288, DOI 10.1016/J.EURPOLYMJ.2007.01.028; DAS S, 2008, PHARM RES-DORDR, V25, P2593, DOI 10.1007/S11095-008-9677-1; EVANS D. A., 2012, DIETARY SUPPLEMENT C; FAN X., 2010, USE TRIACONTANOL PRE; GONG J, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700280; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HAIM D, 2009, J CHROMATOGR B, V877, P4154, DOI 10.1016/J.JCHROMB.2009.10.034; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; LAM SM, 2013, J CHROMATOGR A, V1308, P166, DOI 10.1016/J.CHROMA.2013.08.016; LI N, 2008, J PHARMACEUT BIOMED, V48, P1332, DOI 10.1016/J.JPBA.2008.09.027; LIM SM, 2016, REJUV RES, V19, P59, DOI 10.1089/REJ.2015.1712; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; NAEEM M, 2012, J PLANT INTERACT, V7, P129, DOI 10.1080/17429145.2011.619281; OROZCO-SOLANO M, 2010, J CHROMATOGR A, V1217, P1227, DOI 10.1016/J.CHROMA.2009.12.040; SOUZA AHP, 2014, FOOD CHEM, V158, P315, DOI 10.1016/J.FOODCHEM.2014.02.008; PUENTE ROBERTO, 2017, REV FAC CIEN MED UNIV NAC CORDOBA, V74, P107; QINGLI W. U., 2017, J HUAIHAI I TECHNOL, V26, P30; QIU ZX, 2017, BIOMED CHROMATOGR, V31, DOI 10.1002/BMC.4001; QIU ZX, 2017, J CHROMATOGR B, V1048, P85, DOI 10.1016/J.JCHROMB.2017.02.011; RAVELO Y, 2011, J NAT MED-TOKYO, V65, P330, DOI 10.1007/S11418-010-0496-4; REZAEE R, 2017, PHARMACOL RES, V117, P218, DOI 10.1016/J.PHRS.2016.12.037; SIMIN FENG, 2015, FOOD CHEMISTRY, V181, P9; SNEHUNSU A, 2015, J ETHNOPHARMACOL, V172, P80, DOI 10.1016/J.JEP.2015.06.020; THEODOROU V, 2007, TETRAHEDRON LETT, V48, P8230, DOI 10.1016/J.TETLET.2007.09.074; WAN M, 2002, J PHARMACEUT BIOMED, V28, P953, DOI 10.1016/S0731-7085(01)00712-9; WANG CH, 2015, J TRANSP GEOGR, V45, P1, DOI 10.1016/J.JTRANGEO.2015.03.015; WANG CF, 2015, BIOMED CHROMATOGR, V29, P749, DOI 10.1002/BMC.3351; XU K, 2016, CARDIOVASC THER, V34, P337, DOI 10.1111/1755-5922.12204; YAO H., 2012, J ANAL SCI METH INST, V2, P24; ZABALETA V, 2007, J PHARMACEUT BIOMED, V44, P1072, DOI 10.1016/J.JPBA.2007.05.006","CHEN, XJ (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, CLIN PHARMACOKINET LAB, NANJING 211198, JIANGSU, PEOPLES R CHINA","ELSEVIER SCIENCE BV","ENGLISH","J. CHROMATOGR. B","ARTICLE","ISI","WOS000435059300002","J CHROMATOGR B","CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV","CHINA PHARMACEUT UNIV",NA,"LU X, 2018, J CHROMATOGR B","LU X, 2018, J CHROMATOGR B"
"HARRABI S;FERCHICHI A;BACHELI A;FELLAH ;HAYET H","HARRABI SAOUSSEM;FERCHICHI AZZA;BACHELI ASMA;FELLAH; HAYET","POLICOSANOL COMPOSITION ANTIOXIDANT AND ANTIARTHRITIC ACTIVITIES OF MILK THISTLE ISILYBIUM MARIANUMI L OIL AT DIFFERENT SEED MATURITY STAGES",2018,"LIPIDS IN HEALTH AND DISEASE","17",NA,36,"10.1186/s12944-018-0682-z","HARRABI, S (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, LAB CLIN BIOCHEM, FAC MED TUNIS, LR99ES11,15 ST DJEBEL LAKHDAR, TUNIS 1007, TUNISIA.; HARRABI, SAOUSSEM; FERCHICHI, AZZA; BACHELI, ASMA; FELLAH, HAYET, UNIV TUNIS EL MANAR, LAB CLIN BIOCHEM, FAC MED TUNIS, LR99ES11,15 ST DJEBEL LAKHDAR, TUNIS 1007, TUNISIA.","BACKGROUND: SEVERAL ANTI-ARTHRITIC DRUGS AND SYNTHETIC ANTIOXIDANTS HAVE WIDE PHARMACEUTICAL USES AND ARE OFTEN ASSOCIATED WITH VARIOUS SIDE EFFECTS ON THE HUMAN HEALTH. DIETARY SEED OILS AND THEIR MINOR COMPONENTS LIKE POLICOSANOL MAY OFFER AN EFFECTIVE ALTERNATIVE TREATMENT FOR ARTHRITIC AND OXIDATIVE-STRESS RELATED DISEASES. THE BIOLOGICAL EFFECTS OF SEED OILS WERE AFFECTED BY DIFFERENT PARAMETERS SUCH AS THE STAGE OF SEED MATURITY. HENCE, THIS STUDY SEEKS TO DETERMINE THE POLICOSANOL CONTENT, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE (SILYBIUM MARIANUM L.) OIL EXTRACTED AT VARIOUS STAGES OF SEED MATURATION. METHODS: MILK THISTLE OIL SAMPLES WERE EXTRACTED FROM SEEDS COLLECTED AT THREE MATURATION STAGES (IMMATURE, INTERMEDIATE, AND MATURE). THE 2,2-DIPHENYL-1-PICRYLHYDRAZYL (DPPH) AND 2,2'-AZINO-BIS (3-ETHYL-BENZTHIAZOLINE-6-SULFONIC ACID) (ABTS) RADICAL SCAVENGING ASSAYS WERE USED TO DETERMINE THE ANTIOXIDANT ACTIVITY OF THE EXTRACTED OILS. THE ANTI-ARTHRITIC ACTIVITY OF OIL SAMPLES WAS EVALUATED WITH BOVINE SERUM PROTEIN DENATURATION AND EGG ALBUMIN DENATURATION METHODS. GAS CHROMATOGRAPHY COUPLED TO MASS SPECTROMETRY (GC-MS) WAS EMPLOYED TO DETERMINE THE POLICOSANOL PROFILE. RESULTS: POLICOSANOL PROFILE, ANTIOXIDANT AND ANTI-ARTHRITIC ACTIVITIES OF MILK THISTLE OIL WERE INFLUENCED BY THE SEED MATURITY STAGES. THE OIL EXTRACTED FROM THE IMMATURE SEEDS HAD THE HIGHEST TOTAL POLICOSANOL CONTENT (987.68 MG/KG OF OIL) AND DISPLAYED THE MAXIMUM ANTIRADICAL ACTIVITY (96.42\% AND 90.35\% FOR DPPH TEST AND ABTS ASSAY, RESPECTIVELY). NINE ALIPHATIC ALCOHOLS WERE IDENTIFIED IN THE MILK THISTLE OIL. THE DOMINANT POLIOSANOL IN THE MATURE SEED OIL WAS OCTACOSANOL (75.44\%), WHILE TRIACONTANOL WAS THE MAJOR COMPOUND (40.25\%) IN THE IMMATURE SEED OIL. ADDITIONALLY, THE MAXIMUM INHIBITION OF BOVINE SERUM PROTEIN DENATURATION (92.53\%) AND EGG ALBUMIN DENATURATION (86.36\%) WERE OBSERVED IN IMMATURE SEED OIL AS COMPARED TO MATURE SEED OIL. A HIGH CORRELATION WAS FOUND BETWEEN THE TOTAL POLICOSANOL CONTENT, ANTI-ARTHRITIC ACTIVITY AND ANTIOXIDANT CAPACITY OF OIL. CONCLUSIONS: THE MILK THISTLE OIL EXHIBITED A POTENTIAL ANTI-ARTHRITIC AND ANTIOXIDANT ACTIVITIES AND THAT IT MIGHT CONTRIBUTE TO THE PROTECTION OF HUMANS FROM A VARIETY OF DISEASES LIKE RHEUMATOID ARTHRITIS. ALSO, IT COULD SERVE AS NATURAL ANTIOXIDANT AND ANTI-ARTHRITIC AGENTS FOR APPLICATION IN THE FOOD INDUSTRIES AND PHARMACEUTIC. POLICOSANOL LEVEL IN THE SEED OILS MIGHT CONTRIBUTE TO THEIR ANTI-ARTHRITIC AND ANTIOXIDANT ACTIVITIES.","MILK THISTLE; OIL; ANTI-ARTHRITIC ACTIVITY; ANTIOXIDANT CAPACITY; POLICOSANOL; MATURITY STAGE","BUTYLATED HYDROXYANISOLE; GAS-CHROMATOGRAPHY; VEGETABLE-OILS; FATTY-ACIDS; OLIVE OILS; RICE BRAN; CYTOTOXICITY; TRIACONTANOL; CULTIVARS; ARTHRITIS",NA,NA,"ADEDAYO B. C., 2010, AFRICAN JOURNAL OF FOOD SCIENCE, V4, P403; BAHL JR, 2015, INDIAN J NAT PROD RE, V6, P127; BENCHIKH Y, 2014, IND CROP PROD, V60, P298, DOI 10.1016/J.INDCROP.2014.05.048; CHOI SJ, 2016, FOOD CHEM, V204, P94, DOI 10.1016/J.FOODCHEM.2016.02.027; DABBOUR I. R., 2014, PAKISTAN JOURNAL OF NUTRITION, V13, P67; DE OLIVEIRA AM, 2012, INT J MOL SCI, V13, P1598, DOI 10.3390/IJMS13021598; ELISHA IL, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/S12906-016-1301-Z; FATHI-ACHACHLOUEI B, 2009, J AM OIL CHEM SOC, V86, P643, DOI 10.1007/S11746-009-1399-Y; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIACOMETTI J, 2001, ANALYST, V126, P472, DOI 10.1039/B007090O; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUARDAMAGNA O, 2011, NUTR METAB CARDIOVAS, V21, P424, DOI 10.1016/J.NUMECD.2009.10.015; GÜLÇIN I, 2012, ARCH TOXICOL, V86, P345, DOI 10.1007/S00204-011-0774-2; GULL J, 2012, MOLECULES, V17, P3165, DOI 10.3390/MOLECULES17033165; GULZ PG, 1991, PHYTOCHEMISTRY, V30, P769, DOI 10.1016/0031-9422(91)85249-Y; HABIBUR RAHMAN HABIBUR RAHMAN, 2015, AMERICAN-EURASIAN JOURNAL OF AGRICULTURAL \& ENVIRONMENTAL SCIENCES, V15, P115; HAM H, 2015, LWT-FOOD SCI TECHNOL, V61, P602, DOI 10.1016/J.LWT.2014.12.047; HARRABI S, 2016, GRASAS ACEITES, V67, DOI 10.3989/GYA.0495151; HARRABI S, 2015, ACTA ALIMENT HUNG, V44, P304, DOI 10.1556/066.2015.44.0007; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; HASANLOU T., 2008, J. MED. PLANTS, V7, P69; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; KAMBLE A.A., 2017, RES. J. PHARM. SCI, V6, P5, DOI 10.1186/S12944-018-0682-Z, DOI 10.1186/S12944-018-0682-Z; KIRALAN M, 2009, J AM OIL CHEM SOC, V86, P247, DOI 10.1007/S11746-008-1337-4; KOZLOWSKA M, 2016, FOOD CHEM, V213, P450, DOI 10.1016/J.FOODCHEM.2016.06.102; LAGUNA A, 1997, U.S. PATENT, PATENT NO. 5663156; LUCINI L, 2016, IND CROP PROD, V83, P11, DOI 10.1016/J.INDCROP.2015.12.023; MILLÁN J, 2016, CLIN INVEST ARTERIOS, V28, P178, DOI 10.1016/J.ARTERI.2016.03.002; LA PAZ SMD, 2014, J ETHNOPHARMACOL, V151, P131, DOI 10.1016/J.JEP.2013.10.012; MURUGANANTHAN G., 2013, JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE, V3, P161; NAEEM M, 2012, J PLANT INTERACT, V7, P129, DOI 10.1080/17429145.2011.619281; NAZ R, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/S12906-017-1815-Z; RAMADAN MF, 2006, J FOOD COMPOS ANAL, V19, P838, DOI 10.1016/J.JFCA.2006.02.013; RAMANARAYAN K, 2000, PHYTOCHEMISTRY, V55, P59, DOI 10.1016/S0031-9422(00)00201-6; RUZICKOVA G, 2011, ACTA FYTOTECHNICA ZO, V1, P9; SAITO M, 2003, ANTICANCER RES, V23, P4693; SARAFIAN TA, 2002, TOXICOL LETT, V133, P171, DOI 10.1016/S0378-4274(02)00134-0; SINGH G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/ARCHINTE.156.14.1530; SINGH S, 2015, INT J PHARM SCI RES, V6, P2882, DOI 10.13040/IJPSR.0975-8232.6(7).2882-85; RUBALYA SR, 2015, INT FOOD RES J, V22, P289; WANG T, 2012, NEURAL REGEN RES, V7, P1080, DOI 10.3969/J.ISSN.1673-5374.2012.14.006; WARREN RP, 1992, P SOC EXP BIOL MED, V200, P349; YADAV NV, 2016, LIPIDS, V51, P1385, DOI 10.1007/S11745-016-4203-4","HARRABI, S (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, LAB CLIN BIOCHEM, FAC MED TUNIS, LR99ES11,15 ST DJEBEL LAKHDAR, TUNIS 1007, TUNISIA","BIOMED CENTRAL LTD","ENGLISH","LIPIDS HEALTH DIS.","ARTICLE","ISI","WOS000430212500002","LIPIDS HEALTH DIS","UNIV TUNIS EL MANAR;UNIV TUNIS EL MANAR","UNIV TUNIS EL MANAR",NA,"HARRABI S, 2018, LIPIDS HEALTH DIS","HARRABI S, 2018, LIPIDS HEALTH DIS1"
"MA J;MA L;ZHANG Z;LI K;WANG ;YOUQIONG Y;CHEN X;ZHANG H","MA JINJU;MA LIYI;ZHANG ZHONGQUAN;LI KAI;WANG; YOUQIONG;CHEN XIAOMING;ZHANG HONG","IIN VIVOI EVALUATION OF INSECT WAX FOR HAIR GROWTH POTENTIAL",2018,"PLOS ONE","13",NA,4,"10.1371/journal.pone.0192612","MA, LY (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, RES INST RESOURCES INSECTS, KUNMING, YUNNAN, PEOPLES R CHINA.; MA, JINJU; MA, LIYI; ZHANG, ZHONGQUAN; LI, KAI; WANG, YOUQIONG; CHEN, XIAOMING; ZHANG, HONG, CHINESE ACAD FORESTRY, RES INST RESOURCES INSECTS, KUNMING, YUNNAN, PEOPLES R CHINA.","INSECT WAX IS SECRETED BY ERICERUS PELA CHAVANNESS. IT HAS BEEN TRADITIONALLY USED TO TREAT HAIR LOSS IN CHINA, BUT FEW REPORTS HAVE BEEN PUBLISHED ON THE HAIR GROWTH-PROMOTING EFFECT OF INSECT WAX. IN THIS WORK, WE EXAMINED THE HAIR GROWTH-PROMOTING EFFECTS OF INSECT WAX ON MODEL ANIMALS. DIFFERENT CONCENTRATIONS OF INSECT WAX WERE TOPICALLY APPLIED TO THE DENUDED BACKS OF MICE, AND 5\% MINOXIDIL WAS APPLIED TOPICALLY AS A POSITIVE CONTROL. WE FOUND THAT INSECT WAX SIGNIFICANTLY PROMOTED HAIR GROWTH IN A DOSE-DEPENDENT MANNER, 45\% AND 30\% INSECT WAX BOTH INDUCED HAIR TO REGROW, WHILE LESS VISIBLE HAIR GROWTH WAS OBSERVED IN BLANK CONTROLS ON THE 16 TH DAY. THE EXPERIMENTAL AREAS TREATED WITH 45\% AND 30\% INSECT WAX EXHIBITED SIGNIFICANT DIFFERENCES IN HAIR SCORES COMPARED TO BLANK CONTROLS, AND HAIR LENGTHS IN THE 45\% AND 30\% INSECT WAX GROUP WAS SIGNIFICANTLY LONGER THAN IN BLANK CONTROLS ON THE 16 TH AND 20 TH DAYS. THERE WERE NO NEW HAIR FOLLICLES FORMING IN THE TREATED AREAS, AND THE HAIR FOLLICLES WERE PREMATURELY CONVERTED TO THE ANAGEN PHASE FROM THE TELOGEN PHASE IN EXPERIMENTAL AREAS TREATED WITH 45\% AND 30\% INSECT WAX. BOTH 45\% AND 30\% INSECT WAX UPREGULATED VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION. THE RESULTS INDICATED THAT 45\% AND 30\% INSECT WAX SHOWED HAIR GROWTH-PROMOTING POTENTIAL APPROXIMATELY AS POTENT AS 5\% MINOXIDIL BY INDUCING THE PREMATURE CONVERSION OF TELOGEN-TO-ANAGEN AND BY PROLONGING THE MATURE ANAGEN PHASE RATHER THAN INCREASING THE NUMBER OF HAIR FOLLICLES, WHICH WAS LIKELY RELATED TO THE UPREGULATION OF VEGF EXPRESSION. THE DISSOCIATIVE POLICOSANOL IN INSECT WAX WAS CONSIDERED THE KEY INGREDIENT MOST LIKELY RESPONSIBLE FOR THE HAIR GROWTH PROMOTING POTENTIAL.",NA,"WHITE WAX; POLICOSANOL; MINOXIDIL; EXTRACT","FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NON-PROFIT RESEARCH INSTITUTION OF CAF [CAFYBB2018SY025]; NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (863 PROGRAM) [2014AA021801]","THIS WORK WAS FINANCIALLY SUPPORTED BY THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NON-PROFIT RESEARCH INSTITUTION OF CAF (CAFYBB2018SY025), AND NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (863 PROGRAM) (2014AA021801). THE FUNDERS HAD NO ROLE IN STUDY DESIGN, DATA COLLECTION AND ANALYSIS, DECISION TO PUBLISH, OR PREPARATION OF THE MANUSCRIPT.; THIS WORK WAS FINANCIALLY SUPPORTED BY THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL NONPROFIT RESEARCH INSTITUTION OF CAF (CAFYBB2018SY025), AND NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (863 PROGRAM) (2014AA021801). WE ALSO ACKNOWLEDGE OUR SINCERE GRATITUDE TO ALL STAFF MEMBERS OF THE DEPARTMENT FOR THEIR KIND ASSISTANCE.","ADHIRAJAN N, 2003, J ETHNOPHARMACOL, V88, P235, DOI 10.1016/S0378-8741(03)00231-9; ALSANTALI A, 2011, CLIN COSMET INVESTI, V4, P107, DOI 10.2147/CCID.S22767; ANNA HERMAN, 2016, FITOTERAPIA; AVRAM MR, 2002, DERMATOL SURG, V28, P894, DOI 10.1046/J.1524-4725.2002.02068.X; BASSINO E, 2016, NAT PROD RES, V30, P2831, DOI 10.1080/14786419.2016.1154053; CHEN XM, 2009, CHINESE WHITE WAX SC, P29; COTSARELIS G, 2001, TRENDS MOL MED, V7, P293, DOI 10.1016/S1471-4914(01)02027-5; DASTAN M, 2016, BIOMED PHARMACOTHER, V84, P979, DOI 10.1016/J.BIOPHA.2016.10.019; DATTA K, 2009, J ETHNOPHARMACOL, V124, P450, DOI 10.1016/J.JEP.2009.05.023; DHANOTIA R, 2011, NAT PROD RES, V25, P1432, DOI 10.1080/14786410802632820; GORDON KA, 2011, CLIN COSMET INVESTI, V4, P101, DOI 10.2147/CCID.S10182; HAN XH, 2001, PRELIMINARY STUDIES; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HOU XY., 2011, J ANHUI AGR SCI, V39, P2817; HUNT N, 2005, BRIT MED J, V331, P951, DOI 10.1136/BMJ.331.7522.951; LACHGAR S, 1998, BRIT J DERMATOL, V138, P407; LEE GS, 2010, FITOTERAPIA, V81, P17, DOI 10.1016/J.FITOTE.2009.06.016; LIN L, 2017, SAUDI PHARM J, V25, P625, DOI 10.1016/J.JSPS.2017.04.035; 马李一 MA LIYI, 2008, 食品工业科技, SCIENCE \& TECHNOLOGY OF FOOD INDUSTRY, V29, P179; MA LIYI MA LIYI, 2009, CHEMISTRY AND INDUSTRY OF FOREST PRODUCTS, V29, P6; MYSORE V, 2016, INDIAN J DERMATOL VE, V82, P128, DOI 10.4103/0378-6323.177432; NG CH, 2005, J AGR FOOD CHEM, V53, P6289, DOI 10.1021/JF051269A; NOA M, 2005, ARCH MED RES, V36, P441, DOI 10.1016/J.ARCMED.2005.03.039; PARK YO, 2013, TOX RESEARCH, V29, P241, DOI 10.5487/TR.2013.29.4.241; PAUS R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PETERS EMJ, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0175904; RHO SS, 2005, J DERMATOL SCI, V38, P89, DOI 10.1016/J.JDERMSCI.2004.12.025; SEO SR, 2013, J IND ENG CHEM, V19, P1331, DOI 10.1016/J.JIEC.2012.12.037; SHI-ZHEN L, 2006, COMPENDIUM MATERIA M; STENN KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; UNO H, 1993, J INVEST DERMATOL, V101, PS143, DOI 10.1111/1523-1747.EP12363275; VESOULIS ZA, 2014, PHARMACOTHERAPY, V34, PE341, DOI 10.1002/PHAR.1495; WANG ZD, 2017, BIOMED PHARMACOTHER, V89, P438, DOI 10.1016/J.BIOPHA.2017.02.036; YANG P, 2015, SCI REP-UK, V5, DOI 10.1038/SREP08141; YANG P, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0035719; YANG P, 2011, AFR J MICROBIOL RES, V5, P1246; YANO K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; YINGGUO WANG YL, 2002, CHINA OILS FATS, V27, P54; ZHANG RG, 2011, PROCEDIA ENGINEER, V18, DOI 10.1016/J.PROENG.2011.11.016; ZHANG Y, 2016, BIOMED PHARMACOTHER, V83, P641, DOI 10.1016/J.BIOPHA.2016.07.022; ZHENG H, 2009, NAT PROD RES DEV, V21, P313","MA, LY (CORRESPONDING AUTHOR), CHINESE ACAD FORESTRY, RES INST RESOURCES INSECTS, KUNMING, YUNNAN, PEOPLES R CHINA","PUBLIC LIBRARY SCIENCE","ENGLISH","PLOS ONE","ARTICLE","ISI","WOS000425083400031","PLOS ONE","RES INST RESOURCES INSECTS;RES INST RESOURCES INSECTS","RES INST RESOURCES INSECTS",NA,"MA J, 2018, PLOS ONE","MA J, 2018, PLOS ONE-a1"
"KIM T;CHOI J;KIM K;AHN S;HA S;CHOI Y;PARK N;KIM J","KIM TAE JIN;CHOI JAEHYUK;KIM KIL WON;AHN SOON KIL; HA SUN-HWA;CHOI YONGSOO;PARK NAM IL;KIM JAE KWANG","METABOLITE PROFILING OF PEPPERS OF VARIOUS COLORS REVEALS RELATIONSHIPS BETWEEN TOCOPHEROL CAROTENOID AND PHYTOSTEROL CONTENT",2017,"JOURNAL OF FOOD SCIENCE","82","2885-2893",27,"10.1111/1750-3841.13968","KIM, JK (CORRESPONDING AUTHOR), INCHEON NATL UNIV, CTR INSECT VECTORS, DIV LIFE SCI \& CONVERGENCE RES, INCHEON 22012, SOUTH KOREA.; KIM, TAE JIN; KIM, KIL WON; AHN, SOON KIL; KIM, JAE KWANG, INCHEON NATL UNIV, CTR INSECT VECTORS, DIV LIFE SCI \& CONVERGENCE RES, INCHEON 22012, SOUTH KOREA.; HA, SUN-HWA, KYUNG HEE UNIV, GRAD SCH BIOTECHNOL, YONGIN 17104, SOUTH KOREA.; HA, SUN-HWA, KYUNG HEE UNIV, CROP BIOTECH INST, YONGIN 17104, SOUTH KOREA.; KOREA INST SCI \& TECHNOL, SYST BIOTECHNOL RES CTR, KANGNUNG 25451, SOUTH KOREA.; PARK, NAM IL, GANGNEUNG WONJU NATL UNIV, DEPT PLANT SCI, 7 JUKHEON GIL, KANGNUNG 25457, SOUTH KOREA.","PEPPERS ARE WIDELY CONSUMED IN KOREA; THE VARIETAL DEVELOPMENT OF PEPPERS WITH INCREASED CONTENT OF BENEFICIAL PLANT METABOLITES IS, THEREFORE, OF CONSIDERABLE INTEREST. THIS REQUIRES A COMPREHENSIVE UNDERSTANDING OF THE METABOLIC PROFILE OF PEPPER PLANTS AND THE FACTORS AFFECTING THIS PROFILE. TO THIS END, WE DETERMINED THE CONTENT OF VARIOUS METABOLITES, SUCH AS HYDROPHILIC AND LIPOPHILIC COMPOUNDS, PHENOLIC ACIDS, CAROTENOIDS, AND CAPSAICINOIDS IN PEPPERS OF VARIOUS COLORS (GREEN, RED, PALE GREEN, AND VIOLET PEPPERS) AND IN A HIGH-PUNGENCY (GREEN) PEPPER. WE ALSO PERFORMED PRINCIPAL COMPONENT ANALYSIS (PCA), PEARSON'S CORRELATION ANALYSIS, AND HIERARCHICAL CLUSTERING ANALYSIS (HCA) TO DETERMINE THE RELATIONSHIPS AMONG THESE METABOLITES IN PEPPERS. PCA RESULTS INDICATED NO SIGNIFICANT VARIANCES AMONG THE 3 SAMPLE REPLICATES. THE HCA SHOWED CORRELATIONS BETWEEN THE METABOLITES RESULTING FROM COMMON OR CLOSELY LINKED BIOSYNTHESIS PATHWAYS. OUR RESULTS SHOWED THAT CAROTENOIDS CORRELATED POSITIVELY WITH TOCOPHEROLS AND NEGATIVELY WITH PHYTOSTEROLS; OUR FINDINGS ALSO INDICATED A CLOSE RELATIONSHIP BETWEEN THE METHYLERYTHRITOL 4-PHOSPHATE AND MEVALONIC ACID BIOSYNTHESIS PATHWAYS, PROVIDING EVIDENCE IN FAVOR OF AN EARLIER HYPOTHESIS REGARDING CROSSTALK ACROSS THE CHLOROPLAST MEMBRANE. WE, THUS, DEMONSTRATE THAT METABOLIC PROFILING COMBINED WITH MULTIVARIATE ANALYSIS IS A USEFUL TOOL FOR ANALYZING METABOLIC NETWORKS. PRACTICAL APPLICATIONA TOTAL OF 71 METABOLITES WERE MEASURED IN 5 PEPPERS OF DIFFERENT COLORS. THE METABOLIC PROFILING WITH MULTIVARIATE ANALYSIS REVEALED THAT TOCOPHEROL CONTENT HAD A POSITIVE CORRELATION WITH THE CAROTENOID CONTENT AND A NEGATIVE CORRELATION WITH THE PHYTOSTEROL CONTENT. THE RESULTS OF THIS STUDY MAY HELP IN BREEDING PROGRAMS TO PRODUCE NEW GERMPLASM WITH ENHANCED NUTRITIONAL QUALITY.","CAROTENOIDS; METABOLIC PATHWAY; METABOLOMICS; PEPPER; PHYTOSTEROL","CAPSICUM-ANNUUM L.; SECONDARY METABOLITES; ANTIOXIDANT ACTIVITY; QUALITY; ASSESSMENT; FRUIT-DEVELOPMENT; CULTIVARS; POLICOSANOL; YELLOW; PHYTOCHEMICALS; DISCRIMINATION","INST. OF CONVERGENCE SCIENCE AND TECHNOLOGY, INCHEON NATL. UNIV., REPUBLIC OF KOREA; RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA [PJ01195602]","THIS STUDY WAS SUPPORTED BY 2015 RESEARCH PROGRAM FUNDED BY THE INST. OF CONVERGENCE SCIENCE AND TECHNOLOGY, INCHEON NATL. UNIV., REPUBLIC OF KOREA AND THE ``COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURE SCIENCE \& TECHNOLOGY DEVELOPMENT'' (PROJECT NO. PJ01195602), RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA.","ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; CHO M. C., 2007, J BIOENVIRONMENT CON, V16, P233; CONFORTI F, 2007, FOOD CHEM, V102, P1096, DOI 10.1016/J.FOODCHEM.2006.06.047; DUELUND L, 2017, FOOD CHEM, V221, P913, DOI 10.1016/J.FOODCHEM.2016.11.074; ERIKSSON L., 2013, MULTI-AND MEGAVARIATE DATA ANALYSIS BASIC PRINCIPLES AND APPLICATIONS, P33; FERRI M, 2011, J PLANT PHYSIOL, V168, P189, DOI 10.1016/J.JPLPH.2010.06.027; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GOVINDARAJAN VS, 1991, CRIT REV FOOD SCI, V29, P435, DOI 10.1080/10408399109527536; HA SH, 2007, J EXP BOT, V58, P3135, DOI 10.1093/JXB/ERM132; JANG YK, 2015, J AGR FOOD CHEM, V63, P9452, DOI 10.1021/ACS.JAFC.5B03873; KIM JK, 2013, J CEREAL SCI, V57, P14, DOI 10.1016/J.JCS.2012.09.012; KIM JK, 2010, J AGR FOOD CHEM, V58, P12804, DOI 10.1021/JF103277G; KIM JS, 2011, J FOOD SCI, V76, PC193, DOI 10.1111/J.1750-3841.2010.01891.X; KIM JUNG-BONG, 2009, THE JOURNAL OF THE KOREAN SOCIETY OF INTERNATIONAL AGRICULTURE, 한국국제농업개발학회지, V21, P276; KIM N, 2011, J AGR FOOD CHEM, V59, P10435, DOI 10.1021/JF201718R; KIM TJ, 2015, J KOREAN SOC APPL BI, V58, P909, DOI 10.1007/S13765-015-0119-6; LAULE O, 2003, P NATL ACAD SCI USA, V100, P6866, DOI 10.1073/PNAS.1031755100; LI L, 2013, ARCH BIOCHEM BIOPHYS, V539, P102, DOI 10.1016/J.ABB.2013.07.002; MÁRKUS F, 1999, J AGR FOOD CHEM, V47, P100, DOI 10.1021/JF980485Z; MATERSKA M, 2005, J AGR FOOD CHEM, V53, P1750, DOI 10.1021/JF035331K; MATSUFUJI H, 2007, INT J FOOD SCI TECH, V42, P1482, DOI 10.1111/J.1365-2621.2006.01368.X; MENICHINI F, 2009, FOOD CHEM, V114, P553, DOI 10.1016/J.FOODCHEM.2008.09.086; MINGUEZMOSQUERA MI, 1993, J AGR FOOD CHEM, V41, P1616, DOI 10.1021/JF00034A018; MINGUEZMOSQUERA MI, 1994, J AGR FOOD CHEM, V42, P38, DOI 10.1021/JF00037A005; OSORIO S, 2012, PLANT PHYSIOL, V159, P1713, DOI 10.1104/PP.112.199711; OSUNA-GARCÍA JA, 1998, J AGR FOOD CHEM, V46, P5093, DOI 10.1021/JF980588H; PARK S, 2012, FOOD CHEM, V130, P981, DOI 10.1016/J.FOODCHEM.2011.08.026; PARK SOO-YUN, 2014, PLANT OMICS, V7, P430; PARK SY, 2013, PLANT OMICS, V6, P224; PARK SY, 2012, BIOSCI BIOTECH BIOCH, V76, P2188, DOI 10.1271/BBB.120453; PAYYAVULA RS, 2013, J EXP BOT, V64, P5115, DOI 10.1093/JXB/ERT303; SADILOVA E, 2006, Z NATURFORSCH C, V61, P527; SCHULZE B, 2009, CHEMBIOCHEM, V10, P428, DOI 10.1002/CBIC.200800755; SUN T, 2007, J FOOD SCI, V72, PS98, DOI 10.1111/J.1750-3841.2006.00245.X; TADERA K, 2006, J NUTR SCI VITAMINOL, V52, P149, DOI 10.3177/JNSV.52.149; TUNDIS R, 2013, LWT-FOOD SCI TECHNOL, V53, P370, DOI 10.1016/J.LWT.2013.02.013; WAHYUNI Y, 2014, MOL BREEDING, V33, P503, DOI 10.1007/S11032-013-9967-0; WAHYUNI Y, 2013, J NAT PROD, V76, P783, DOI 10.1021/NP300898Z; WAHYUNI Y, 2011, PHYTOCHEMISTRY, V72, P1358, DOI 10.1016/J.PHYTOCHEM.2011.03.016","KIM, JK (CORRESPONDING AUTHOR), INCHEON NATL UNIV, CTR INSECT VECTORS, DIV LIFE SCI \& CONVERGENCE RES, INCHEON 22012, SOUTH KOREA","WILEY","ENGLISH","J. FOOD SCI.","ARTICLE","ISI","WOS000417766000014","J FOOD SCI","INCHEON NATL UNIV;INCHEON NATL UNIV;KYUNG HEE UNIV;KYUNG HEE UNIV;KOREA INST SCI AND TECHNOL;GANGNEUNG WONJU NATL UNIV","INCHEON NATL UNIV",NA,"KIM TJ, 2017, J FOOD SCI","KIM TJ, 2017, J FOOD SCI"
"EYSSERIC E;GHISLAIN T;DURET X;LALONDE O;SEGURA ;P. A P;LAVOIE J","EYSSERIC E;GHISLAIN T;DURET X;LALONDE O;SEGURA; P A;LAVOIE J M","EFFECT OF STEAM TREATMENTS ON THE AVAILABILITY OF VARIOUS FAMILIES OF SECONDARY METABOLITES EXTRACTED FROM GREEN SWEET SORGHUM",2017,"INDUSTRIAL CROPS AND PRODUCTS","104","120-128",5,"10.1016/j.indcrop.2017.04.040","LAVOIE, JM (CORRESPONDING AUTHOR), UNIV SHERBROOKE, IND RES CHAIR CELLULOS ETHANOL \& BIOCOMMOD CRIEC, DEPT CHEM \& BIOTECHNOL ENGN, 2500 BLVD UNIV, SHERBROOKE, PQ J1K 2R1, CANADA.; EYSSERIC, E.; GHISLAIN, T.; DURET, X.; LAVOIE, J. M., UNIV SHERBROOKE, IND RES CHAIR CELLULOS ETHANOL \& BIOCOMMOD CRIEC, DEPT CHEM \& BIOTECHNOL ENGN, 2500 BLVD UNIV, SHERBROOKE, PQ J1K 2R1, CANADA.; EYSSERIC, E.; SEGURA, P. A., UNIV SHERBROOKE, DEPT CHEM, 2500 BLVD UNIV, SHERBROOKE, PQ J1K 2R1, CANADA.; LALONDE, O., CTR RECH GRAINS CEROM, 790 CHEMIN TRUDEAU, ST MATHIEU DE BELOEIL, PQ J3G 0E2, CANADA.","BOTH FREE CARBOHYDRATES AND HEMICELLULOSES FROM GREEN SWEET SORGHUM [SORGHUM BICOLOR (L.) MOENCH] WERE EXTRACTED USING A STEAM PROCESS TO PRODUCE COMBINED FIRST AND SECOND GENERATION ETHANOL. ONCE THE CARBOHYDRATES REMOVED, SOXHLET EXTRACTION WAS USED TO EXTRACT THE LIPOPHILIC SECONDARY METABOLITES FROM THE PLANT FIBERS AND THE RESULTS WERE COMPARED TO THOSE OBTAINED WITH THE BIOMASS EXTRACTED WITHOUT PRIOR STEAM TREATMENTS. THIS ALLOWED ASSESSING IF THE CARBOHYDRATE REMOVAL PROCESS HAD AN IMPACT ON THE SECONDARY METABOLITES THAT COULD BE RECOVERED FROM THE BIOMASS. SOXHLET EXTRACTS WHERE CHARACTERIZED USING SEVERAL TECHNIQUES SUCH AS GAS CHROMATOGRAPHY-MASS SPECTROMETRY, LIQUID CHROMATOGRAPHY-TRIPLE QUADRUPOLE MASS SPECTROMETRY AND LIQUID CHROMATOGRAPHY-UV DETECTION FOLLOWED BY HIGH-RESOLUTION MASS SPECTROMETRY. A TOTAL OF 13 COMPOUNDS WERE DETECTED AND QUANTIFIED IN THE NON-POLAR SOXHLET FRACTION AND WERE MAINLY FATTY ACIDS (6), PHENYL GLYCOSIDES (5) AND STEROLS (2) AT CONCENTRATIONS RANGING BETWEEN 0.015 G KG(-1) AND 1.5 G KG(-1) (DRY BIOMASS). COMPARISON OF THE EXTRACTIVE CONTENT BEFORE AND AFTER STEAM PROCESS SHOWED THAT MOST OF THE COMPOUNDS WERE FOUND IN A LESSER EXTENT (UP TO 71\%) ALTHOUGH STILL RECOVERABLE AFTER THE STEAM PROCESS WHILE OTHER COMPOUNDS (NAMELY PHYTOSTEROLS) WERE AS CONCENTRATED AS THEY WERE PRIOR TO STEAM TREATMENTS. THESE RESULTS SHOW THAT IN THE CASE OF SWEET SORGHUM, THE PRELIMINARY EXTRACTION OF THE CARBOHYDRATE CONTENT WITH A STEAM PROCESS MAY NOT COMPLETELY HINDER THE POSSIBILITY TO EXTRACT HIGH VALUE SECONDARY METABOLITES, WHICH WOULD IN THIS CASE COME SECOND IN A BIOREFINERY APPROACH.","SORGHUM BICOLOR; STEAM PROCESSES; SECONDARY METABOLITES; STEROLS; GC-MS; LC-MS/MS","GRAIN-SORGHUM; ETHANOL-PRODUCTION; PEARL-MILLET; POLICOSANOL; BICOLOR; CHOLESTEROL; FLAVONOIDS; PLASMA; HYPERCHOLESTEROLEMIA; CONSTITUENTS","NSERC; CEROM; CRB INNOVATIONS; MITACS","THE AUTHORS ARE GRATEFUL TO MITACS FOR EMMANUEL EYSSERIC AND THIERRY GHISLAIN'S SCHOLARSHIPS AS WELL AS TO THE CEROM, CRB INNOVATIONS AND NSERC FOR THEIR SUPPORT IN THIS PROJECT. THE AUTHORS WOULD ALSO LIKE TO THANK THE INDUSTRIAL RESEARCH CHAIR ON CELLULOSIC ETHANOL AND BIOCOMMODITIES (CRIEC-B) AS WELL AS ITS PARTNERS ENERKEM, CRB INNOVATIONS, ETHANOL GREENFIELD AND MERNQ FOR GRANTING ACCESS TO THE CHAIR'S STEAM EXPLOSION GUN AND ANALYTICAL FACILITIES.","ABUGRI DA, 2013, FOOD CHEM, V138, P718, DOI 10.1016/J.FOODCHEM.2012.09.149; ALAKURTTI S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/J.EJPS.2006.04.006; ALTHWAB S, 2015, FOOD RES INT, V77, P349, DOI 10.1016/J.FOODRES.2015.08.011; ARRUZAZABALA ML, 1997, PHARMACOL RES, V36, P293, DOI 10.1006/PHRS.1997.0201; *ASTM, D110596 ASTM; AWIKA JM, 2004, PHYTOCHEMISTRY, V65, P1199, DOI 10.1016/J.PHYTOCHEM.2004.04.001; BEAUCHET R, 2012, BIORESOURCE TECHNOL, V121, P328, DOI 10.1016/J.BIORTECH.2012.06.061; BENNETT AS, 2009, BIORESOURCE TECHNOL, V100, P1595, DOI 10.1016/J.BIORTECH.2008.09.023; BERNARDES AD, 2016, BIOENERG RES, V9, P88, DOI 10.1007/S12155-015-9666-2; BERNARDES AD, 2015, BIOENERG RES, V8, P100, DOI 10.1007/S12155-014-9504-Y; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; BRYAN WL, 1985, T ASAE, V28, P268; CARR TP, 2005, J NUTR, V135, P2236, DOI 10.1093/JN/135.9.2236; CLAVIN M, 2007, J ETHNOPHARMACOL, V112, P585, DOI 10.1016/J.JEP.2007.04.007; COOK NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9; CRÉPEAU M, 2013, T ASABE, V56, P1665; DIOP CIK, 2015, CARBOHYD POLYM, V119, P8, DOI 10.1016/J.CARBPOL.2014.11.031; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; DYKES L, 2009, FOOD CHEM, V116, P313, DOI 10.1016/J.FOODCHEM.2009.02.052; EYSSERIC E, 2016, CAN J CHEM, V94, P781, DOI 10.1139/CJC-2016-0281; FUENTE-HERNANDEZ A., 2013, BIOFUELS COPRODUCTS; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; HITHAMANI G, 2014, J AGR FOOD CHEM, V62, P11170, DOI 10.1021/JF503450U; HOI JT, 2009, J FUNCT FOODS, V1, P381, DOI 10.1016/J.JFF.2009.09.005; HWANG KT, 2005, CEREAL CHEM, V82, P242, DOI 10.1094/CC-82-0242; HWANG KT, 2002, J SEP SCI, V25, P619, DOI 10.1002/1615-9314(20020601)25:9<619::AID-JSSC619>3.0.CO;2-; JUNG YJ, 2015, ARCH PHARM RES, V38, P178, DOI 10.1007/S12272-014-0387-4; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KWON YS, 2003, ARCH PHARM RES, V26, P535, DOI 10.1007/BF02976877; LALONDE O., 2015, PHYTOPROTECTION, V95, P10; LAN W, 2016, PLANT J; LAVOIE J-M, 2011, BIOREFINING LIGNOCEL; LAVOIE JM, 2010, BIORESOURCE TECHNOL, V101, P4940, DOI 10.1016/J.BIORTECH.2009.09.021; LEE BH, 2014, J FUNCT FOODS, V7, P709, DOI 10.1016/J.JFF.2013.12.014; LEE R. A., 2013, ANIMAL FRONTIERS, V3, P6, DOI 10.2527/AF.2013-0010; LEE SS, 2015, BIOSCI BIOTECH BIOCH, V79, P700, DOI 10.1080/09168451.2014.997184; LEGUIZAMÓN C, 2009, J AM OIL CHEM SOC, V86, P707, DOI 10.1007/S11746-009-1398-Z; LI AF, 2016, J CHROMATOGR B, V1012, P42, DOI 10.1016/J.JCHROMB.2015.12.038; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MASSEY AR, 2014, J AGR FOOD CHEM, V62, P3150, DOI 10.1021/JF405415U; MATSUSHIKA A, 2009, APPL MICROBIOL BIOT, V84, P37, DOI 10.1007/S00253-009-2101-X; MEHMOOD S, 2008, FOOD CHEM, V109, P855, DOI 10.1016/J.FOODCHEM.2008.01.014; MORAES EA, 2015, FOOD CHEM, V180, P116, DOI 10.1016/J.FOODCHEM.2015.02.023; NAIK SN, 2010, RENEW SUST ENERG REV, V14, P578, DOI 10.1016/J.RSER.2009.10.003; NEUCERE NJ, 1980, J AGR FOOD CHEM, V28, P19, DOI 10.1021/JF60227A022; OVEREND RP, 1987, PHILOS T R SOC A, V321, P523, DOI 10.1098/RSTA.1987.0029; PROPHETER JL, 2010, AGRON J, V102, P798, DOI 10.2134/AGRONJ2009.0462; PUTNAM DH, 1991, J PROD AGRIC, V4, P377, DOI 10.2134/JPA1991.0377; ROWINSKY EK, 1992, SEMIN ONCOL, V19, P646; SCHYMANSKI EL, 2014, ENVIRON SCI TECHNOL, V48, P2097, DOI 10.1021/ES5002105; SHABTAI J.S., 1999, US, PATENT NO. US 5959167, 5959167, 5,959,167 A; SHALINI V, 2016, IMMUNOBIOLOGY, V221, P137, DOI 10.1016/J.IMBIO.2015.09.016; SPORRING S, 2005, J CHROMATOGR A, V1090, P1, DOI 10.1016/J.CHROMA.2005.07.008; SUN Y, 2002, BIORESOURCE TECHNOL, V83, P1, DOI 10.1016/S0960-8524(01)00212-7; THIVIERGE MN, 2015, BIOENERG RES, V8, P807, DOI 10.1007/S12155-014-, 10.1007/S12155-014-9558-X; WANG YD, 2010, ANAL CHEM, V82, P7055, DOI 10.1021/AC100888B; WEITZEL TT, 1989, T ASAE, V32, P273; XIAO X, 2014, ENVIRON MICROBIOL, V16, P1238, DOI 10.1111/1462-2920.12226; ZHANG ZF, 2015, J PHARMACEUT BIOMED, V109, P62, DOI 10.1016/J.JPBA.2015.02.025","LAVOIE, JM (CORRESPONDING AUTHOR), UNIV SHERBROOKE, IND RES CHAIR CELLULOS ETHANOL \& BIOCOMMOD CRIEC, DEPT CHEM \& BIOTECHNOL ENGN, 2500 BLVD UNIV, SHERBROOKE, PQ J1K 2R1, CANADA","ELSEVIER SCIENCE BV","ENGLISH","IND. CROP. PROD.","ARTICLE","ISI","WOS000402358500015","IND CROP PROD","UNIV SHERBROOKE;UNIV SHERBROOKE;UNIV SHERBROOKE;CTR RECH GRAINS CEROM","UNIV SHERBROOKE",NA,"EYSSERIC E, 2017, IND CROP PROD","EYSSERIC E, 2017, IND CROP PROD"
"MARAZZI G;CAMPOLONGO G;PELLICCIA F;QUATTRINO S;VITALE C;CACCIOTTI L;MASSARO ;ROSALBA R;VOLTERRANI M;ROSANO G","MARAZZI GIUSEPPE;CAMPOLONGO GIUSEPPE;PELLICCIA FRANCESCO; QUATTRINO SILVIA;VITALE CRISTIANA;CACCIOTTI LUCA;MASSARO; ROSALBA;VOLTERRANI MAURIZIO;ROSANO GIUSEPPE","COMPARISON OF LOWDOSE STATIN VERSUS LOWDOSE STATIN PLUS ARMOLIPID PLUS IN HIGHINTENSITY STATININTOLERANT PATIENTS WITH A PREVIOUS CORONARY EVENT AND PERCUTANEOUS CORONARY INTERVENTION ADHERENCE TRIAL",2017,"AMERICAN JOURNAL OF CARDIOLOGY","120","893-897",25,"10.1016/j.amjcard.2017.06.015","MARAZZI, G (CORRESPONDING AUTHOR), IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA, ROME, ITALY.; MARAZZI, GIUSEPPE; CAMPOLONGO, GIUSEPPE; QUATTRINO, SILVIA; VITALE, CRISTIANA; MASSARO, ROSALBA; VOLTERRANI, MAURIZIO; ROSANO, GIUSEPPE, IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA, ROME, ITALY.; PELLICCIA, FRANCESCO, SAPIENZA UNIV, DEPT CARDIOVASC SCI, ROME, ITALY.; CACCIOTTI, LUCA, MADRE GIUSEPPINA VANNINI HOSP, INST CARDIOL, ROME, ITALY.","LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION IS ASSOCIATED WITH A SIGNIFICANT DECREASE IN MORTALITY, AND STATINS REPRESENT THE MOST EFFECTIVE DRUGS TO ACHIEVE THIS. HOWEVER, SIDE EFFECTS OF STATINS ARE VERY COMMON AND MAY LEAD TO TREATMENT DISCONTINUATION. NUTRACEUTICALS ARE A COMBINATION OF NATURAL COMPONENTS THAT HAVE SHOWN EFFICACY IN LOWERING LDL-C CONCENTRATION WHEN USED ALONE OR IN ASSOCIATION WITH OTHER AGENTS IN PATIENTS WHO ARE INTOLERANT TO HIGH-DOSE STATINS. OUR AIM WAS TO COMPARE THE EFFICACY AND TOLERABILITY OF LOW-DOSE STATIN (LDS) THERAPY VERSUS COMBINED THERAPY OF LDS PLUS A NUTRACEUTICAL COMBINATION CONTAINING RED YEAST RICE, POLICOSANOL, BERBERINE, FOLIC ACID, COENZYME Q10 AND ASTAXANTHIN (ARMOLIPID PLUS) IN HIGH-RISK PATIENTS. WE PERFORMED A RANDOMIZED (1:1), PROSPECTIVE, PARALLEL GROUP, SINGLE-BLIND TRIAL IN WHICH PARTICIPANTS HAD CORONARY ARTERY DISEASE (N = 100), HAD UNDERGONE PERCUTANEOUS CORONARY INTERVENTION IN THE PRECEDING 12 MONTHS, WERE HIGH-DOSE STATIN INTOLERANT, AND DID NOT ACHIEVE >= 50\% REDUCTION IN LDL-C WITH LDS TREATMENT ALONE. AFTER 3 MONTHS, PATIENTS IN THE LDS + ARMOLIPID PLUS (N = 50) GROUP PRESENTED WITH A SIGNIFICANTLY GREATER REDUCTION OF LDL-C AND TOTAL CHOLESTEROL (P < 0.0001), AND 70\% OF PATIENTS IN THIS GROUP ACHIEVED THE THERAPEUTIC TARGET (LDL-C <70 MG/DL), WHEREAS PATIENTS IN THE LDS GROUP DID NOT. SIX PATIENTS (3 FROM EACH GROUP) DROPPED OUT DUE TO MYALGIA. IN CONCLUSION, IN PATIENTS WITH CORONARY ARTERY DISEASE AND HIGH-DOSE STATIN INTOLERANCE, THE COMBINATION OF LDS AND NUTRACEUTICALS REPRESENTS A VALUABLE THERAPEUTIC OPTION. (C) 2017 ELSEVIER INC. ALL RIGHTS RESERVED.",NA,"LDL-C; SAFETY; METAANALYSIS; BERBERINE; CHOLESTEROL; COMBINATION; POLICOSANOL; EFFICACY; LIPIDS","ITALIAN MINISTRY OF EDUCATION, UNIVERSITY AND RESEARCH; NATIONAL OPERATIONAL PROGRAM (PON) FOR RESEARCH AND COMPETITIVENESS; EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF); [PONO3PE\_00078\_2]","THIS WORK WAS SUPPORTED BY THE ITALIAN MINISTRY OF EDUCATION, UNIVERSITY AND RESEARCH. THE NATIONAL OPERATIONAL PROGRAM (PON) FOR RESEARCH AND COMPETITIVENESS IS CO-FUNDED WITH THE EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF) AND NATIONAL RESOURCES. IT PROMOTES INITIATIVES AND PROJECTS FOR SCIENTIFIC RESEARCH AND INDUSTRIAL COMPETITIVENESS.; PROJECT NUMBER: PONO3PE\_00078\_2.","AUTHORS/TASK FORCE MEMBERS:, 2016, ATHEROSCLEROSIS, V253, P281, DOI 10.1016/J.ATHEROSCLEROSIS.2016.08.018; BAIGENT C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; BANACH M, 2015, ARCH MED SCI, V11, P1, DOI 10.5114/AOMS.2015.49807; BARRIOS V, 2017, ATHEROSCLEROSIS SUPP, V24, P1, DOI 10.1016/J.ATHEROSCLEROSISSUP.2016.10.003; CAMERON J, 2008, ATHEROSCLEROSIS, V201, P266, DOI 10.1016/J.ATHEROSCLEROSIS.2008.02.004; CICERO AFG, 2009, CURR TOP NUTRACEUT R, V7, P121; CICERO AF, 2009, CLIN LIPIDOL, V4, P553, DOI 10.2217/CLP.09.41; DORMUTH CR, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/BMJ.G3244; DORMUTH CR, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/BMJ.F880; ENDO A, 1988, KLIN WOCHENSCHR, V66, P421, DOI 10.1007/BF01745510; GERARDS MC, 2015, ATHEROSCLEROSIS, V240, P415, DOI 10.1016/J.ATHEROSCLEROSIS.2015.04.004; HEINZ T, 2016, NUTR RES, V36, P1162, DOI 10.1016/J.NUTRES.2016.07.005; KONG WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/NM1135; KOREN MJ, 2014, CIRCULATION, V129, P234, DOI 10.1161/CIRCULATIONAHA.113.007012; LAN JR, 2015, J ETHNOPHARMACOL, V161, P69, DOI 10.1016/J.JEP.2014.09.049; LEVEY AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; MANSI IA, 2013, AM J MED SCI, V345, P343, DOI 10.1097/MAJ.0B013E31825B8EDF; MARAZZI G, 2015, AM J CARDIOL, V116, P1798, DOI 10.1016/J.AMJCARD.2015.09.023; MAZZANTI G, 2017, BRIT J CLIN PHARMACO, V83, P894, DOI 10.1111/BCP.13171; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; PIRRO M, 2016, PHARMACOL RES, V110, P76, DOI 10.1016/J.PHRS.2016.04.021; PIRRO M, 2011, EUR J INTERN MED, V22, P412, DOI 10.1016/J.EJIM.2011.04.007; PISCIOTTA L, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-123; POIRIER S, 2008, J BIOL CHEM, V283, P2363, DOI 10.1074/JBC.M708098200; RAY KK, 2016, CIRCULATION, V134, P1931, DOI 10.1161/CIRCULATIONAHA.116.024604; REINER Z, 2005, CLIN DRUG INVEST, V25, P701, DOI 10.2165/00044011-200525110-00003; ROSENBAUM D, 2013, NUTR METAB CARDIOVAS, V23, P871, DOI 10.1016/J.NUMECD.2012.04.012; WENG TC, 2010, J CLIN PHARM THER, V35, P139, DOI 10.1111/J.1365-2710.2009.01085.X","MARAZZI, G (CORRESPONDING AUTHOR), IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA, ROME, ITALY","EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","ENGLISH","AM. J. CARDIOL.","ARTICLE","ISI","WOS000411852700001","AM J CARDIOL","IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA;IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA;SAPIENZA UNIV;INST CARDIOL","IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA",NA,"MARAZZI G, 2017, AM J CARDIOL","MARAZZI G, 2017, AM J CARDIOL1"
"KAUSHIK M;ARITAKE K;TAKEUCHI A;YANAGISAWA M;URADE Y","KAUSHIK MAHESH K;ARITAKE KOSUKE;TAKEUCHI ATSUKO; YANAGISAWA MASASHI;URADE YOSHIHIRO","OCTACOSANOL RESTORES STRESSAFFECTED SLEEP IN MICE BY ALLEVIATING STRESS",2017,"SCIENTIFIC REPORTS","7",NA,19,"10.1038/s41598-017-08874-2","KAUSHIK, MK; URADE, Y (CORRESPONDING AUTHOR), UNIV TSUKUBA, INT INST INTEGRAT SLEEP MED WPI IIIS, DEPT MOL SLEEP, 1-1-1 TENNODAI, TSUKUBA, IBARAKI 3058575, JAPAN.; KAUSHIK, MK (CORRESPONDING AUTHOR), UNIV TSUKUBA, INT INST INTEGRAT SLEEP MED WPI IIIS, DEPT MOL GENET, 1-1-1 TENNODAI, TSUKUBA, IBARAKI 3058575, JAPAN.; KAUSHIK, MAHESH K.; ARITAKE, KOSUKE; URADE, YOSHIHIRO, UNIV TSUKUBA, INT INST INTEGRAT SLEEP MED WPI IIIS, DEPT MOL SLEEP, 1-1-1 TENNODAI, TSUKUBA, IBARAKI 3058575, JAPAN.; KAUSHIK, MAHESH K.; YANAGISAWA, MASASHI, UNIV TSUKUBA, INT INST INTEGRAT SLEEP MED WPI IIIS, DEPT MOL GENET, 1-1-1 TENNODAI, TSUKUBA, IBARAKI 3058575, JAPAN.; TAKEUCHI, ATSUKO, KOBE PHARMACEUT UNIV, HIGASHINADA KU, KOBE, HYOGO 6588558, JAPAN.","OCTACOSANOL, A COMPONENT OF VARIOUS FOOD MATERIALS, POSSESSES PROMINENT BIOLOGICAL ACTIVITIES AND FUNCTIONS. IT FIGHTS AGAINST CELLULAR STRESS BY INCREASING GLUTATHIONE LEVEL AND THUS SCAVENGING OXYGEN REACTIVE SPECIES. HOWEVER, ITS ANTI-STRESS ACTIVITY AND ROLE IN SLEEP INDUCTION REMAINED ELUSIVE. WE HYPOTHESIZE THAT OCTACOSANOL CAN RESTORE STRESS-AFFECTED SLEEP BY MITIGATING STRESS. CAGE CHANGE STRATEGY WAS USED TO INDUCE MILD STRESS AND SLEEP DISTURBANCE IN MICE, AND EFFECTS OF OCTACOSANOL ADMINISTRATION ON AMOUNT OF SLEEP AND STRESS WERE INVESTIGATED. RESULTS SHOWED THAT OCTACOSANOL DID NOT CHANGE RAPID EYE MOVEMENT (REM) OR NON-REM (NREM) SLEEP COMPARED TO VEHICLE IN NORMAL MICE. HOWEVER, IN CAGE CHANGE EXPERIMENT, OCTACOSANOL INDUCES SIGNIFICANT INCREASE IN NREM SLEEP AT DOSES OF 100 AND 200 MG/KG (75.7 +/- 14.9 AND 82.7 +/- 9.3 MIN/5 H) COMPARED TO VEHICLE (21.2 +/- 5.1 MIN/5 H), AND DECREASED SLEEP LATENCY. OCTACOSANOL INDUCED SLEEP BY INCREASING NUMBER OF SLEEP EPISODES AND DECREASING WAKE EPISODE DURATION. PLASMA CORTICOSTERONE LEVELS WERE SIGNIFICANTLY REDUCED AFTER OCTACOSANOL (200 MG/KG) ADMINISTRATION, SUGGESTING A DECREASE IN STRESS LEVEL. OCTACOSANOL-INDUCED CHANGES IN SLEEP-WAKE PARAMETERS IN STRESSED-MICE WERE COMPARABLE TO THE VALUES IN NORMAL MICE. TOGETHER, THESE DATA CLEARLY SHOWED THAT, THOUGH OCTACOSANOL DOES NOT ALTER NORMAL SLEEP, IT CLEARLY ALLEVIATES STRESS AND RESTORE STRESS-AFFECTED SLEEP.",NA,"POLICOSANOL; DEPRIVATION; ACTIVATION; ALCOHOLS; RATS","JSPS (KAKENHI), JAPAN; GRANTS-IN-AID FOR SCIENTIFIC RESEARCH [17H06095] FUNDING SOURCE: KAKEN","WE ACKNOWLEDGE DR. ZHI-LI HUANG, DEPARTMENT OF PHARMACOLOGY, FUDAN UNIVERSITY SHANGHAI MEDICAL COLLEGE, 138 YIXUEYUAN ROAD, SHANGHAI 200032, CHINA, AND DR. SUENGMOK CHO, PRINCIPAL RESEARCH SCIENTIST, DIVISION OF FUNCTIONAL FOOD RESEARCH, KOREA FOOD RESEARCH INSTITUTE, SEOUL, KOREA, FOR PROVIDING EARLY STAGE SUGGESTIONS AND FRUITFUL DISCUSSIONS DURING THIS STUDY. THE GRANT FROM JSPS (KAKENHI), JAPAN IS ALSO ACKNOWLEDGED.","ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALLEN J, 2011, J ALTERN COMPLEM MED, V17, P827, DOI 10.1089/ACM.2010.0716; ANDERSEN ML, 2005, J SLEEP RES, V14, P83, DOI 10.1111/J.1365-2869.2004.00428.X; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CHO S, 2014, PSYCHOPHARMACOLOGY, V231, P2825, DOI 10.1007/S00213-014-3445-1; DISPERSYN G, 2017, J SLEEP RES, V26, P531, DOI 10.1111/JSR.12541; EDWARDS R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HAIRSTON IS, 2001, NEUROSCI LETT, V315, P29, DOI 10.1016/S0304-3940(01)02309-6; HUANG ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/PNAS.181330998; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; KAUSHIK MK, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0172508; KAUSHIK MK, 2014, EXP NEUROL, V253, P82, DOI 10.1016/J.EXPNEUROL.2013.12.002; KELLER S, 2008, LIPIDS, V43, P109, DOI 10.1007/S11745-007-3127-4; KOHTOH S, 2008, SLEEP BIOL RHYTHMS, V6, P163, DOI 10.1111/J.1479-8425.2008.00355.X; MAHER P, 2005, AGEING RES REV, V4, P288, DOI 10.1016/J.ARR.2005.02.005; MESQUITA G, 2010, ARQ NEURO-PSIQUIAT, V68, P720, DOI 10.1590/S0004-282X2010000500009; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; PAWLYK AC, 2008, NEUROSCI BIOBEHAV R, V32, P99, DOI 10.1016/J.NEUBIOREV.2007.06.001; RAVELO Y, 2011, J NAT MED-TOKYO, V65, P330, DOI 10.1007/S11418-010-0496-4; SCHWARTZ THOMAS L, 2013, DRUGS CONTEXT, V2013, P212257, DOI 10.7573/DIC.212257; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; STUSSER R, 1998, INT J CLIN PHARM TH, V36, P469; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TOBLER I, 1997, J NEUROSCI, V17, P1869; VAN SOMEREN EJW, 2015, J NEUROSCI, V35, P13889, DOI 10.1523/JNEUROSCI.2592-15.2015; WANG T, 2012, NEURAL REGEN RES, V7, P1080, DOI 10.3969/J.ISSN.1673-5374.2012.14.006; WANG T, 2010, ACTA PHARMACOL SIN, V31, P765, DOI 10.1038/APS.2010.69; XU Q, 2014, PHARMACOL BIOCHEM BE, V116, P129, DOI 10.1016/J.PBB.2013.11.029","KAUSHIK, MK; URADE, Y (CORRESPONDING AUTHOR), UNIV TSUKUBA, INT INST INTEGRAT SLEEP MED WPI IIIS, DEPT MOL SLEEP, 1-1-1 TENNODAI, TSUKUBA, IBARAKI 3058575, JAPAN","NATURE PORTFOLIO","ENGLISH","SCI REP","ARTICLE","ISI","WOS000408107000026","SCI REP","UNIV TSUKUBA;UNIV TSUKUBA;UNIV TSUKUBA;UNIV TSUKUBA;KOBE PHARMACEUT UNIV","NOTREPORTED;UNIV TSUKUBA",NA,"KAUSHIK MK, 2017, SCI REP","KAUSHIK MK, 2017, SCI REP"
"KHEDR N","KHEDR NAGLAA F","FISH OIL AND WHEATGERM OIL SUPPLEMENTATION RESTORES OVARIAN FUNCTION IN STREPTOZOTOCINDIABETIC RATS",2017,"REPRODUCTION FERTILITY AND DEVELOPMENT","29","1689-1698",5,"10.1071/RD16135","KHEDR, NF (CORRESPONDING AUTHOR), TANTA UNIV, DEPT BIOCHEM, FAC PHARM, EL BAHAR ST, TANTA 31527, EGYPT.; KHEDR, NAGLAA F., TANTA UNIV, DEPT BIOCHEM, FAC PHARM, EL BAHAR ST, TANTA 31527, EGYPT.","DIABETES IS A CHRONIC METABOLIC DISORDER AND HAS A PROFOUND IMPACT ON WOMEN'S REPRODUCTIVE HEALTH. THIS STUDY AIMED TO INVESTIGATE THE PROTECTIVE EFFECT OF A MIXTURE OF FISH OIL (FO) AND WHEAT-GERM OIL (WGO) ON OVARIAN DYSFUNCTION IN DIABETIC RATS. FEMALE ALBINO RATS WERE DIVIDED INTO CONTROL, DIABETIC AND FO-WGO-DIABETIC GROUPS. DIABETES WAS INDUCED BY INTRAPERITONEAL INJECTION OF 65MGKG(-1) STREPTOZOTOCIN (STZ). THREE WEEKS LATER, RATS WERE GIVEN ORAL SUPPLEMENT OF 0.4GKG(-1) OIL MIX (1000MG FO+100MG WGO) DAILY FOR 3 WEEKS. ANTIOXIDANT ACTIVITY WAS ASSESSED BY MEASURING MALONDIALDEHYDE (MDA) AND REDUCED GLUTATHIONE (GSH) LEVELS, THE GSH:OXIDISED GLUTATHIONE (GSSG) RATIO AND SUPEROXIDE DISMUTASE (SOD), GLUTATHIONE PEROXIDASE (GPX) AND CATALASE (CAT) ACTIVITIES. OVARY FUNCTION WAS INDICATED BY SERUM CONCENTRATIONS OF FSH, OESTRADIOL (E-2), LH, ANTI-MULLERIAN HORMONE (AMH), OVARY HISTOPATHOLOGY AND FOLLICLE COUNTS. ANTI-INFLAMMATORY PROPERTIES WERE DETECTED BY MEASURING NUCLEAR FACTOR (NF)-B IN FOLLICULAR CELLS BY IMMUNOHISTOCHEMISTRY. FO-WGO SUPPLEMENTATION ENHANCED CAT, SOD AND GPX ACTIVITIES AND RAISED GSH LEVELS AND THE GSH:GSSG RATIO. SUPPLEMENTATION ALSO INCREASED FSH, E-2, LH AND AMH LEVELS AND FOLLICLE COUNTS. MOREOVER, NF-KB EXPRESSION AND MDA WERE REDUCED. THESE FINDINGS INDICATE THAT FO-WGO SUPPLEMENTATION PRESERVED OVARIAN FUNCTION IN STZ-INDUCED DIABETIC RATS.","DIABETES; FOLLICLE-STIMULATING HORMONE; OVARY; OXIDATIVE STRESS","POLYUNSATURATED FATTY-ACIDS; OXIDATIVE STRESS; FEMALE REPRODUCTION; VITAMIN-E; OMEGA-3-FATTY-ACIDS; MODEL; POLICOSANOL; MECHANISMS; INCREASE; HORMONE","PHARMACY FACULTY (TANTA UNIVERSITY, EGYPT)","THE AUTHOR THANKS DR ADEL BAKEER KHOLOUSSY, PROFESSOR OF PATHOLOGY (CAIRO UNIVERSITY, EGYPT) FOR HIS EXCELLENT ASSISTANCE WITH HISTOPATHOLOGY ANALYSIS. THE STUDY WAS SUPPORTED FINANCIALLY BY PHARMACY FACULTY (TANTA UNIVERSITY, EGYPT) AND THE AUTHOR.","AGARWAL A, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-28; AKMAN L, 2015, GYNECOL ENDOCRINOL, V31, P657, DOI 10.3109/09513590.2015.1032931; AKOH C.C., 2008, FOOD LIPIDS: CHEMISTRY, NUTRITION, AND BIOTECHNOLOGY, VTHIRD; AL-SAFI ZA, 2016, J CLIN ENDOCR METAB, V101, P323, DOI 10.1210/JC.2015-2913; ALLAIN CC, 1974, CLIN CHEM, V20, P470; AWADIN W., 2015, ASIAN J ANIM VET ADV, V10, P852, DOI 10.3923/AJAVA.2015.852.864, DOI 10.3923/AJAVA.2015.852.864; BALLESTER J, 2007, HUM REPROD, V22, P2128, DOI 10.1093/HUMREP/DEM168; BROUGHTON KS, 2010, NUTR RES, V30, P731, DOI 10.1016/J.NUTRES.2010.09.005; CASTAÑO G, 2006, CURR THER RES CLIN E, V67, P174, DOI 10.1016/J.CURTHERES.2006.06.004; CODNER E, 2012, HUM REPROD UPDATE, V18, P568, DOI 10.1093/HUMUPD/DMS024; DASILVA G, 2015, J NUTR BIOCHEM, V26, P1385, DOI 10.1016/J.JNUTBIO.2015.07.007; EKSTRAND-HAMMARSTRÖM B, 2007, CLIN EXP IMMUNOL, V147, P359, DOI 10.1111/J.1365-2249.2006.03285.X; ERBAS O, 2015, GYNECOL ENDOCRINOL, V31, P388, DOI 10.3109/09513590.2015.1005593; ERBAS O, 2014, TAIWAN J OBSTET GYNE, V53, P498, DOI 10.1016/J.TJOG.2013.11.008; FLACHS P, 2014, PHYSIOL RES, V63, PS93, DOI 10.33549/PHYSIOLRES.932715; GECTHAN PKMA, 2008, J BIOCHEM MOL TOXIC, V22, P220, DOI 10.1002/JBT.20218; GHADGE A, 2016, GENES NUTR, V11, DOI 10.1186/S12263-016-0518-4; HUGHES J, 2011, REPRODUCTION, V141, P105, DOI 10.1530/REP-10-0337; HUSSEIN J.S., 2014, INT. J. PHARM. PHARMACEUT. SCI., V6, P196; KARIM BO, 2003, COMPARATIVE MED, V53, P532; KHEDR NF, 2015, EXP BIOL MED, V240, P1682, DOI 10.1177/1535370215576304; KHOWAILED A., 2012, MED J CAIRO U, V80, P243; KIM NOEL N, 2006, BMC PHYSIOL, V6, P4, DOI 10.1186/1472-6793-6-4; KLOTZSCH SG, 1990, CLIN CHEM, V36, P1605; KUMAR P., 2011, J APPL MANAGEMENT CO, V4, P1, DOI DOI 10.4103/0974-1208.8235121772731, 10.4103/0974-1208.8235121772731; LANDAU S., 2004, HDB STAT ANALYSES US; LEENHARDT F, 2008, J AM COLL NUTR, V27, P222, DOI 10.1080/07315724.2008.10719694; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA K., 2000, LAB RAT, P145, DOI DOI 10.1016/B978-012426400-7.50048-0; MEGAHAD OA, 2002, GRASAS ACEITES, V53, P414; MEHRANJANI M. S., 2007, JOURNAL OF BIOLOGICAL SCIENCES, V7, P1406; MEHRANJANI MS, 2010, IRAN J REPROD MED, V8, P1; MISRA HP, 1972, J BIOL CHEM, V247, P3170; OHASHI K., 2011, J ANAL BIOL SCI, V34, P223; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OKEWUMI T. A., 2012, INT J BIOL MED RES, V3, P17150; OULADSAHEBMADAREK E, 2014, IRAN J BASIC MED SCI, V17, P123; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PATRELLI TS, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0044571; PINE L, 1984, J CLIN MICROBIOL, V20, P421, DOI 10.1128/JCM.20.3.421-429.1984; PITOCCO D, 2013, INT J MOL SCI, V14, P21525, DOI 10.3390/IJMS141121525; PUNSAWAD C, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-260; ROBINSON JG, 2010, WOMENS HEALTH, V6, P119, DOI 10.2217/WHE.09.75; RODRIGUEZ MD, 1997, TOXICOL LETT, V90, P97, DOI 10.1016/S0378-4274(96)03844-1; SOTO N, 2009, HUM REPROD, V24, P2838, DOI 10.1093/HUMREP/DEP276; STENHOUSE ELIZABETH, 2012, NURS STAND, V26, P35; TRAISH ABDULMAGED M., 2009, INVESTIGATIVE AND CLINICAL UROLOGY, V50, P211; WATHES DC, 2007, BIOL REPROD, V77, P190, DOI 10.1095/BIOLREPROD.107.060558; WESTWOOD FR, 2008, TOXICOL PATHOL, V36, P375, DOI 10.1177/0192623308315665; WILLIAMS J, 1997, TOXICOL LETT, V91, P19, DOI 10.1016/S0378-4274(96)03863-5; WONNACOTT KE, 2010, REPRODUCTION, V139, P57, DOI 10.1530/REP-09-0219; WU JZ, 2015, DIABET METAB SYND OB, V8, P181, DOI 10.2147/DMSO.S82272; YESSOUFOU A, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/731434; YIVGI-OHANA N, 2009, ENDOCRINOLOGY, V150, P977, DOI 10.1210/EN.2008-0541; YOUNG LR, 2011, NUTR CANCER, V63, P930, DOI 10.1080/01635581.2011.589957; ZUGNO AI, 2015, LIFE SCI, V121, P65, DOI 10.1016/J.LFS.2014.11.025","KHEDR, NF (CORRESPONDING AUTHOR), TANTA UNIV, DEPT BIOCHEM, FAC PHARM, EL BAHAR ST, TANTA 31527, EGYPT","CSIRO PUBLISHING","ENGLISH","REPROD. FERTIL. DEV.","ARTICLE","ISI","WOS000407701500004","REPROD FERTIL DEV","TANTA UNIV;TANTA UNIV","TANTA UNIV",NA,"KHEDR NF, 2017, REPROD FERTIL DEV","KHEDR NF, 2017, REPROD FERTIL DEV"
"CUEVAS M;CREVELIN E;DE M L;OLIVEIRA A;RODRIGUES C;MEIRELLES ;ANTONIO J A A","CUEVAS MAITE S;CREVELIN EDUARDO J;DE MORAES LUIZ A B; OLIVEIRA ALESSANDRA L;RODRIGUES CHRISTIANNE E C;MEIRELLES; ANTONIO J A","SOLUBILITY OF COMMERCIAL OCTACOSANOL IN ORGANIC SOLVENTS AND THEIR CORRELATION BY THERMODYNAMIC MODELS AT DIFFERENT TEMPERATURES",2017,"JOURNAL OF CHEMICAL THERMODYNAMICS","110","186-192",10,"10.1016/j.jct.2017.02.025","CUEVAS, MS; RODRIGUES, CEC (CORRESPONDING AUTHOR), UNIV SAO PAULO, SEPARAT ENGN LAB LES, POB 23, BR-13635900 PIRASSUNUNGA, BRAZIL.; CUEVAS, MAITE S.; MEIRELLES, ANTONIO J. A., UNIV ESTADUAL CAMPINAS, LAB EXTRACT APPL THERMODYNAM \& EQUILIBRIUM EXTRAE, BR-13083862 CAMPINAS, SP, BRAZIL.; CUEVAS, MAITE S.; RODRIGUES, CHRISTIANNE E. C., UNIV SAO PAULO, SEPARAT ENGN LAB LES, POB 23, BR-13635900 PIRASSUNUNGA, BRAZIL.; CREVELIN, EDUARDO J.; DE MORAES, LUIZ A. B., UNIV SAO PAULO, MASS SPECTROMETRY LAB, BR-14040901 RIBEIRAO PRETO, BRAZIL.; OLIVEIRA, ALESSANDRA L., UNIV SAO PAULO, NAT PROD \& HIGH PRESSURE TECHNOL LAB LTAPPN, POB 23, BR-13635900 PIRASSUNUNGA, BRAZIL.","OCTACOSANOL IS A HIGH-MOLAR-MASS PRIMARY ALIPHATIC ALCOHOL THAT HAS SHOWN PROMISING EFFECTS IN DIABETES TREATMENT AND IN LOWERING CHOLESTEROL. ALTHOUGH THIS COMPOUND HAS BEEN OBTAINED FROM NON-SAPONIFIABLE MATTER OF VEGETABLE MATERIALS BY EXTRACTION WITH SOLVENTS, THERE ARE NO SOLUBILITY DATA IN THE LITERATURE. THIS STUDY PRESENTS EXPERIMENTAL VALUES FOR COMMERCIAL OCTACOSANOL SOLUBILITY IN THREE PURE SOLVENTS (1-PENTANOL, 1-HEXANOL, AND TOLUENE) FROM 298.2 TO 333.2 K. SOLUBILITY OBTAINED IN THIS STUDY RANGES FROM 0.0006 TO 0.0602 IN MOLE FRACTIONS. IN ADDITION, SOLID-LIQUID EQUILIBRIUM RESULTS WERE CORRELATED USING FOUR THERMODYNAMIC MODELS: VAN LAAR, THREE-SUFFIX MARGULES, NRTL, AND UNIQUAC. RESULTS SHOW THAT HIGH TEMPERATURES AND THE USE OF ALCOHOLIC SOLVENTS WITH THE LONGEST CARBON CHAIN OR HYDROCARBONS ARE REQUIRED TO MAXIMIZE COMMERCIAL OCTACOSANOL SOLUBILITY. THE UNIQUAC MODEL PROVIDES THE BEST PERFORMANCE IN THE CORRELATION OF THE EXPERIMENTAL VALUES; HOWEVER, ALL THERMODYNAMIC MODELS COULD BE USED TO DESCRIBE COMMERCIAL OCTACOSANOL SOLUBILITY. (C) 2017 ELSEVIER LTD.","SOLID-LIQUID EQUILIBRIUM; LONG-CHAIN ALIPHATIC ALCOHOL; VAN LAAR; MARGULES; NRTL; UNIQUAC","LIQUID EQUILIBRIA; POLICOSANOL; WATER; ACID; OILS","FAPESP (FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO) [07/06170-4, 08/56258-8, 14/09446-4, 14/21252-0, 15/07370-3]; CNPQ (CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO) [303797/2016-9]; FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (FAPESP) [15/07370-3, 14/09446-4, 08/56258-8, 07/06170-4, 14/21252-0] FUNDING SOURCE: FAPESP","THE AUTHORS WISH TO ACKNOWLEDGE PROF. ANTONIO EDUARDO MILLER CROTTI (FFCLRP/USP) FOR HIS ASSISTANCE IN THE GC-MS ANALYSIS. FAPESP (FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO - 07/06170-4; 08/56258-8; 14/09446-4; 14/21252-0; 15/07370-3) AND CNPQ (CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO - 303797/2016-9), FOR THEIR FINANCIAL SUPPORT.","ANONYMOUS, 2008, D3418 ASTM; ANONYMOUS, 1999, PRENTICE-HALL INTERNATIONAL SERIES IN THE PHYSICAL AND CHEMICAL ENGINEERING SCIENCES; ASIKIN Y, 2008, FOOD SCI TECHNOL RES, V14, P583, DOI 10.3136/FSTR.14.583; ATKINS P., 2006, PHYSICAL CHEMISTRY, V8TH; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; CARNEIRO AP, 2012, J CHEM THERMODYN, V55, P184, DOI 10.1016/J.JCT.2012.05.020; CREVELIN EJ, 2013, APPL BIOCHEM BIOTECH, V171, P1602, DOI 10.1007/S12010-013-0418-5; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; FAN CH, 1997, ENVIRON SCI TECHNOL, V31, P3516, DOI 10.1021/ES970261H; FENG SM, 2015, FOOD CHEM, V182, P171, DOI 10.1016/J.FOODCHEM.2015.03.003; FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED, V16, P61, DOI 10.1016/J.CTIM.2007.08.003; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; KIM HYUNJUNG, 2003, JOURNAL OF MEDICINAL FOOD, V6, P345; KLAVINS L., 2015, ENVIRONMENTAL AND EXPERIMENTAL BIOLOGY, V13, P147; LEE CK, 2001, J CHIN CHEM SOC-TAIP, V48, P1053, DOI 10.1002/JCCS.200100154; LI RY, 2012, IND ENG CHEM RES, V51, P8141, DOI 10.1021/IE300945P; MAGNUSSEN T, 1981, IND ENG CHEM PROC DD, V20, P331, DOI 10.1021/I200013A024; MARTÍNEZ L, 1999, ARCH PHARM, V332, P439; NAZIR M, 1993, Z NATURFORSCH C, V48, P5; PÉREZ-CAMINO MC, 2003, J CHROMATOGR A, V983, P283, DOI 10.1016/S0021-9673(02)01608-4; SALDAÑA MDA, 2012, J CHEM THERMODYN, V55, P115, DOI 10.1016/J.JCT.2012.06.016; TANG WW, 2015, J CHEM THERMODYN, V90, P28, DOI 10.1016/J.JCT.2015.05.026; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; VIOLA F, 2008, MEDITERR J NUTR META, V1, P77, DOI 10.1007/S12349-008-0019-Y; WEI DW, 2010, FLUID PHASE EQUILIBR, V291, P66, DOI 10.1016/J.FLUID.2009.12.013","CUEVAS, MS; RODRIGUES, CEC (CORRESPONDING AUTHOR), UNIV SAO PAULO, SEPARAT ENGN LAB LES, POB 23, BR-13635900 PIRASSUNUNGA, BRAZIL","ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","ENGLISH","J. CHEM. THERMODYN.","ARTICLE","ISI","WOS000401397700021","J CHEM THERMODYN","UNIV SAO PAULO;UNIV ESTADUAL CAMPINAS;UNIV SAO PAULO;UNIV SAO PAULO;UNIV SAO PAULO","NOTREPORTED;UNIV SAO PAULO",NA,"CUEVAS MS, 2017, J CHEM THERMODYN","CUEVAS MS, 2017, J CHEM THERMODYN"
"SANCHEZ J;ILLNAIT J;MAS R;MENDOZA S;FERNANDEZ L;MESA M;VEGA H;FERNANDEZ J;REYES P;RUIZ D","SANCHEZ JAVIER;ILLNAIT JOSE;MAS ROSA;MENDOZA SARAHI; FERNANDEZ LILIA;MESA MEILIS;VEGA HERMYS;FERNANDEZ JULIO;REYES PABLO;RUIZ DALMER","LONGTERM EFFECT OF POLICOSANOL ON THE FUNCTIONAL RECOVERY OF NONCARDIOEMBOLIC ISCHEMIC STROKE PATIENTS A ONE YEAR STUDY",2017,"REVISTA DE NEUROLOGIA","64","153-161",6,NA,"MENDOZA, S (CORRESPONDING AUTHOR), CTR NACL INVEST CIENT, 125 \& 198 CUBANACAN, HAVANA, CUBA.; SANCHEZ, JAVIER, CTR NACL INVEST CIENT, INST NEUROL \& NEUROCIRUGIA, HAVANA, CUBA.; ILLNAIT, JOSE; MESA, MEILIS; VEGA, HERMYS, CTR NACL INVEST CIENT, CTR INVEST MED QUIRURG, HAVANA, CUBA.; MAS, ROSA; MENDOZA, SARAHI; FERNANDEZ, LILIA; FERNANDEZ, JULIO, CTR NACL INVEST CIENT, CTR PROD NAT, HAVANA, CUBA.; REYES, PABLO; RUIZ, DALMER, CTR NACL INVEST CIENT, GRP BASE DATOS, HAVANA, CUBA.","INTRODUCTION. STROKE IS A LEADING CAUSE OF MORTALITY AND DISABILITY. POLICOSANOL HAS BEEN EFFECTIVE IN BRAIN ISCHEMIA MODELS. THE AIM OF THIS STUDY IS TO INVESTIGATE WHETHER POLICOSANOL, ADDED TO ASPIRIN THERAPY WITHIN 30 DAYS OF STROKE ONSET, IS BETTER THAN PLACEBO + ASPIRINE FOR THE LONG-TERM RECOVERY OF NON-CARDIOEMBOLIC ISCHEMIC STROKE SUBJECTS. PATIENTS AND METHODS. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. EIGHTY PATIENTS (MEAN AGE: 69 YEARS) WITHIN 30 DAYS OF ONSET, WITH A MODIFIED RANKIN SCALE SCORE (MRS) 2 TO 4, WERE INCLUDED. THEY WERE RANDOMIZED IN TWO GROUPS (POLICOSANOL + ASPIRINE OR PLACEBO + ASPIRINE) FOR 12 MONTHS. RESULTS. POLICOSANOL + ASPIRINE DECREASED SIGNIFICANTLY MEAN MRS FROM THE FIRST INTERIM CHECK-UP (1.5MONTHS).THE TREATMENT EVEN IMPROVED AFTER LONG-TERM THERAPY. MORE POLICOSANOL + ASPIRIN (87.5\%) THAN PLACEBO + ASPIRINE (0\%) PATIENTS ACHIEVED MRSS <= 1. POLICOSANOL + ASPIRINE INCREASED SIGNIFICANTLY BARTHEL INDEX, LOWERED LDL-CHOLESTEROL AND INCREASED HDL-CHOLESTEROL VERSUS PLACEBO + ASPIRIN. CONCLUSIONS. LONG-TERM (12 MONTHS) ADMINISTRATION OF POLICOSANOL + ASPIRIN GIVEN AFTER SUFFERING NON-CARDIOEMBOLIC ISCHEMIC STROKE WAS SHOWN TO BE BETTER THAN PLACEBO + ASPIRIN IN IMPROVING FUNCTIONAL OUTCOMES WHEN USED AMONG PATIENTS WITH NON-CARDIOEMBOLIC ISCHEMIC STROKE OF MODERATE SEVERITY.","ASPIRIN; BARTHEL INDEX; MODIFIED RANKIN SCALE; NON-CARDIOEMBOLIC; ISCHEMIC STROKE; PLACEBO; POLICOSANOL.","PLATELET-AGGREGATION; CEREBRAL-ISCHEMIA; LIPID PROFILE; STATINS; METAANALYSIS; CHOLESTEROL; PREVENTION",NA,NA,"AMANTEA D, 2009, FEBS J, V276, P13, DOI 10.1111/J.1742-4658.2008.06766.X; AMARENCO P, 2009, CEREBROVASC DIS, V27, P493, DOI 10.1159/000210432; AMARENCO P, 2009, LANCET NEUROL, V8, P453, DOI 10.1016/S1474-4422(09)70058-4; ANTITHROMBOTIC TRIALISTS' COLLABORATION, 2000, BMJ-BRIT MED J, V324, P71; ARBOIX A, 2004, J NEUROL NEUROSUR PS, V75, P231; ARBOIX A, 2015, WORLD J CLIN CASES, V3, P418, DOI 10.12998/WJCC.V3.I5.418; ARBOIX A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-47; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CHO KH, 2016, REJUV RES, V19, P59; CHRÓINÍN DN, 2013, STROKE, V44, P448, DOI 10.1161/STROKEAHA.112.668277; COUILLARD PHILIPPE, 2009, EXPERT REV CARDIOVASC THER, V7, P1273, DOI 10.1586/ERC.09.105; DI CARLO A, 2009, AGE AGEING, V38, P4, DOI 10.1093/AGEING/AFN282; DISORDERS NION GROUP SR-PSS, 1995, NEW ENGLAND JOURNAL OF MEDICINE, V333, P1581; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GHANDEHARI K, 2013, J RES MED SCI, V18, P906; HJALMARSSON C, 2012, AM J GERIATR PHARMAC, V10, P313, DOI 10.1016/J.AMJOPHARM.2012.09.001; LEE EY, 2016, REJUVENATION RES; LEE YC, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0098961; LEVI M, 2008, NED TIJDSCHR GENEESKD, V152, P423; LIKOSKY DJ, 2008, J HOSP MED, V3, PS6, DOI 10.1002/JHM.337; LIU SY, 2012, SCI WORLD J, DOI 10.1100/2012/614263; MAR J, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/S12955-015-0230-8; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MOLINA V, 2013, INDIAN J PHARM SCI, V75, P635; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; NACI H, 2013, QJM-INT J MED, V106, P299, DOI 10.1093/QJMED/HCT041; NIKITIN IU P, 2000, TER ARKH, V72, P7; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; ORTEGA LL, 2006, J MED FOOD, V9, P378, DOI 10.1089/JMF.2006.9.378; PARK JH, 2014, STROKE, V45, P3269, DOI 10.1161/STROKEAHA.114.006827; PATRONO C, 2008, ARTERIOSCL THROM VAS, V28, PS25, DOI 10.1161/ATVBAHA.107.160481; PEREZ Y, 2013, INT J PHARM SCI REV, V19, P18; PRAT H, 1999, REV MED CHILE, V127, P286; QUINN TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; RANKIN J, 1957, SCOTT MED J, V2, P200; ROGER VL, 2012, CIRCULATION, V125, PE2, DOI 10.1161/CIR.0B013E31823AC046, 10.1161/CIR.0B013E3182456D46; SANCHEZ J, 2010, REV CENIC CIEN BIOL, V41, P23; SANCHEZ J, 2013, J PHARM, V4, P31; SANCHEZ J, 2016, INT J PHARM SCI REV, V37, P7; SANCHEZ J, 2012, IOSR J PHARM, V2, P14; SCAZZIOTA A, 1996, REV IBEROAMER TROMB, V9, P58; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SONG B, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0084389; TANG MIN, 2013, ZHONGHUA XIN XUE GUAN BING ZA ZHI, V41, P488; WANG YUN, 2008, ZHONGGUO XINYAO YU LINCHUANG ZAZHI, V27, P124","MENDOZA, S (CORRESPONDING AUTHOR), CTR NACL INVEST CIENT, 125 \& 198 CUBANACAN, HAVANA, CUBA","REVISTA DE NEUROLOGIA","GERMAN","REV. NEUROLOGIA","ARTICLE","ISI","WOS000397795200002","REV NEUROLOGIA","CTR NACL INVEST CIENT;INST NEUROL AND NEUROCIRUGIA;CTR NACL INVEST CIENT;CTR NACL INVEST CIENT;CTR NACL INVEST CIENT","CTR NACL INVEST CIENT",NA,"SANCHEZ J, 2017, REV NEUROLOGIA","SANCHEZ J, 2017, REV NEUROLOGIA"
"ANASTASI U;SORTINO O;TUTTOBENE R;GRESTA F;GIUFFRE A;SANTONOCETO C","ANASTASI UMBERTO;SORTINO ORAZIO;TUTTOBENE ROSALENA; GRESTA FABIO;GIUFFRE ANGELO M;SANTONOCETO CARMELO","AGRONOMIC PERFORMANCE AND GRAIN QUALITY OF SESAME ISESAMUM INDICUMI L LANDRACES AND IMPROVED VARIETIES GROWN IN A MEDITERRANEAN ENVIRONMENT",2017,"GENETIC RESOURCES AND CROP EVOLUTION","64","127-137",19,"10.1007/s10722-015-0338-z","ANASTASI, U (CORRESPONDING AUTHOR), UNIV CATANIA, DIPARTIMENTO AGR ALIMENTAZ \& AMBIENTE, VIA VALDISAVOIA 5, I-95123 CATANIA, ITALY.; ANASTASI, UMBERTO; SORTINO, ORAZIO; TUTTOBENE, ROSALENA, UNIV CATANIA, DIPARTIMENTO AGR ALIMENTAZ \& AMBIENTE, VIA VALDISAVOIA 5, I-95123 CATANIA, ITALY.; GRESTA, FABIO; GIUFFRE, ANGELO M.; SANTONOCETO, CARMELO, UNIV MEDITERRANEA REGGIO CALABRIA, DIPARTIMENTO AGR, I-89122 REGGIO DI CALABRIA, ITALY.","SESAME SEEDS ARE AN EXCELLENT FOOD AND NON-FOOD RAW MATERIAL, FOR WHICH THERE IS A CONSOLIDATED DEFICIT IN ITALY AND IN OTHER EUROPEAN UNION COUNTRIES. FOR THIS REASON, A 2-YEARS EXPERIMENT WAS CONDUCTED IN SICILY TO COMPARE THE AGRONOMIC PERFORMANCE (PHENOLOGY, MORPHOLOGICAL AND PRODUCTIVE TRAITS) AND GRAIN QUALITY (OIL AND ITS MAIN CONSTITUENTS, PROTEIN OF DEFATTED FLOUR, FIBRE) OF THREE LANDRACES, ONE OF TURKISH ORIGIN AND TWO SICILIAN (''ISPICA'' AND ``MODICA''), AND TWO IMPROVED VARIETIES ('PACHEQUINO' AND `YORI 77'). THE LANDRACES EVIDENCED EARLINESS (115 DAYS) AND THE GREATER HEIGHT OF INSERTION OF FIRST CAPSULE (0.52 M), WHEREAS THE VARIETY `PACHEQUINO' WAS THE MOST PRODUCTIVE (3.5 T HA(-1)). TURKISH AND ``ISPICA'' LANDRACES AND `YORI 77' VARIETY PROVIDED SEEDS WITH GREATER LIPID (54 \%, ON AVERAGE) AND PROTEIN CONTENTS (44 \% ON DEFATTED FLOUR, ON AVERAGE). `PACHEQUINO' AND BOTH SICILIAN LANDRACES PRODUCED SEEDS RICHER IN FIBRE FRACTIONS. AS REGARD TO OIL QUALITY, THE OLEIC ACID/LINOLEIC ACID WAS FOUND BALANCED (ABOUT 1) FOR TURKISH LANDRACE, AND IT DECREASED FOR THE OTHER CULTIVARS REACHING THE LOWEST VALUE FOR `PACHEQUINO'. ``MODICA'' HAD HIGHER QUANTITY OF UNSAPONIFIABLE MATTER (1.98 \%) IN THE OIL, WHEREAS `YORI 77' HAD THE MAXIMUM CONCENTRATION OF PHYTOSTEROLS (5532.8 MG KG(-1)). POLICOSANOL FRACTION PREVAILED IN OIL OF ``ISPICA'' (205.8 MG KG(-1)). MOREOVER, THERE WAS VARIABILITY IN THE FATTY ACID, STEROL AND POLICOSANOL COMPOSITIONS WITH DIFFERENCES AMONG THE CULTIVARS. RESEARCH PROVIDE INFORMATION TO EXPLOIT SESAME WITHIN AGROSYSTEMS UNDER MEDITERRANEAN CLIMATES, AND MAY BE A STARTING POINT FOR BREEDING ACTIVITY TO ENHANCE CROP PRODUCTIVITY AND GRAIN QUALITY.","FIBRE; LANDRACE; LIPID COMPOSITION; PROTEIN; SEED YIELD; SESAMUM INDICUM; L.","FATTY-ACID-COMPOSITION; OIL COMPOSITION; SEEDS; COLLECTION; PRODUCTS; PROTEIN",NA,NA,"ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ANASTASI U., 2000, ITALIAN JOURNAL OF AGRONOMY, V4, P23; ANASTASI U, 2010, FIELD CROP RES, V119, P145, DOI 10.1016/J.FCR.2010.07.001; ANILAKUMAR KANDANGATH RAGHAVAN, 2010, AGRICULTURAE CONSPECTUS SCIENTIFICUS, V75, P159; ANONYMOUS, 1999, 210 CODEXSTAN FAOWHO; ANONYMOUS, WORLD SOILS BOOK SER; ASHRI A., 1989, OIL CROPS WORLD, P375; BAHKALI AH, 1998, INT J FOOD SCI NUTR, V49, P409, DOI 10.3109/09637489809086419; BAYDAR H, 2005, PLANT BREEDING, V124, P263, DOI 10.1111/J.1439-0523.2005.01080.X; BAYDAR H., 1999, TURKISH JOURNAL OF AGRICULTURE \& FORESTRY, V23, P431; BEDIGIAN D, 2003, GENET RESOUR CROP EV, V50, P779, DOI 10.1023/A:1025029903549; CHUNG CH, 1995, PLANT SCI, V109, P237, DOI 10.1016/0168-9452(95)04160-V; *COHORT SOFTW, 1998, COSTAT STAT SOFTW VE; ELLEUCH M, 2007, FOOD CHEM, V103, P641, DOI 10.1016/J.FOODCHEM.2006.09.008; EUROPEAN ECONOMIC COMMISSION, 2003, 1991R2568 EN; FAOSTAT-FOOD AND AGRICULTURAL ORGANIZATION OF THE UNITED NATIONS, 2014, STAT DIV PRODSTAT CR; HARDY R. W. F., 2002, TRENDS IN NEW CROPS AND NEW USES. PROCEEDINGS OF THE FIFTH NATIONAL SYMPOSIUM, ATLANTA, GEORGIA, USA, 10-13 NOVEMBER, 2001, P11; KANU PJ, 2007, TRENDS FOOD SCI TECH, V18, P599, DOI 10.1016/J.TIFS.2007.06.002; KIM JK, 2012, J AGR FOOD CHEM, V60, P2257, DOI 10.1021/JF204977X; MOHAMED HMA, 1998, FOOD CHEM, V62, P269, DOI 10.1016/S0308-8146(97)00193-3; MORRIS J. B., 2002, TRENDS IN NEW CROPS AND NEW USES. PROCEEDINGS OF THE FIFTH NATIONAL SYMPOSIUM, ATLANTA, GEORGIA, USA, 10-13 NOVEMBER, 2001, P153; STUCHLIK MILAN, 2002, BIOMEDICAL PAPERS (OLOMOUC), V146, P3, DOI 10.5507/BP.2002.001; TIR R, 2012, EUR J LIPID SCI TECH, V114, P1427, DOI 10.1002/EJLT.201200129; UZUN B, 2006, FIELD CROP RES, V96, P13, DOI 10.1016/J.FCR.2005.04.017; UZUN B, 2008, J AM OIL CHEM SOC, V85, P1135, DOI 10.1007/S11746-008-1304-0; VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583, DOI 10.3168/JDS.S0022-0302(91)78551-2; WEISS E. A., 1983, OILSEED CROPS, P282; WERE BA, 2006, FIELD CROP RES, V97, P254, DOI 10.1016/J.FCR.2005.10.009; YOL E, 2012, CROP SCI, V52, P2206, DOI 10.2135/CROPSCI2011.07.0355; ZAVAREH M, 2008, INT J PLANT PROD, V2, P193","ANASTASI, U (CORRESPONDING AUTHOR), UNIV CATANIA, DIPARTIMENTO AGR ALIMENTAZ \& AMBIENTE, VIA VALDISAVOIA 5, I-95123 CATANIA, ITALY","SPRINGER","ENGLISH","GENET. RESOUR. CROP EVOL.","ARTICLE","ISI","WOS000392323800009","GENET RESOUR CROP EVOL","UNIV CATANIA;UNIV CATANIA;GRESTA;UNIV MEDITERRANEA REGGIO CALABRIA","UNIV CATANIA",NA,"ANASTASI U, 2017, GENET RESOUR CROP EVOL","ANASTASI U, 2017, GENET RESOUR CROP EVOL1"
"LI J;SUN D;QIAN L;LIU Y","LI JINWEI;SUN DEWEI;QIAN LIGE;LIU YUANFA","SUBCRITICAL BUTANE EXTRACTION OF WHEAT GERM OIL AND ITS DEACIDIFICATION BY MOLECULAR DISTILLATION",2016,"MOLECULES","21",NA,16,"10.3390/molecules21121675","LIU, YF (CORRESPONDING AUTHOR), JIANGNAN UNIV, STATE KEY LAB FOOD SCI \& TECHNOL, COLLABORAT INNOVAT CTR FOOD SAFETY \& QUAL CONTROL, WUXI 214122, PEOPLES R CHINA.; LI, JINWEI; SUN, DEWEI; QIAN, LIGE; LIU, YUANFA, JIANGNAN UNIV, STATE KEY LAB FOOD SCI \& TECHNOL, COLLABORAT INNOVAT CTR FOOD SAFETY \& QUAL CONTROL, WUXI 214122, PEOPLES R CHINA.","EXTRACTION AND DEACIDIFICATION ARE IMPORTANT STAGES FOR WHEAT GERM OIL (WGO) PRODUCTION. CRUDE WGO WAS EXTRACTED USING SUBCRITICAL BUTANE EXTRACTION (SBE) AND COMPARED WITH TRADITIONAL SOLVENT EXTRACTION (SE) AND SUPERCRITICAL CARBON DIOXIDE EXTRACTION (SCE) BASED ON THE YIELD, CHEMICAL INDEX AND FATTY ACID PROFILE. FURTHERMORE, THE EFFECTS OF THE MOLECULAR DISTILLATION TEMPERATURE ON THE QUALITY OF WGO WERE ALSO INVESTIGATED IN THIS STUDY. RESULTS INDICATED THAT WGO EXTRACTED BY SBE HAS A HIGHER YIELD OF 9.10\% AND BETTER QUALITY; AT THE SAME TIME, ITS FATTY ACID COMPOSITION HAS NO SIGNIFICANT DIFFERENCE COMPARED WITH THAT OF SE AND SCE. THE MOLECULAR DISTILLATION EXPERIMENT SHOWED THAT THE ACID VALUE, PEROXIDE VALUE AND P-ANISIDINE VALUE OF WGO WERE REDUCED WITH THE INCREASE OF THE EVAPORATION TEMPERATURES, AND THE CONTENTS OF THE ACTIVE CONSTITUENTS OF TOCOPHEROL, POLYPHENOLS AND PHYTOSTEROLS ARE SIMULTANEOUSLY DECREASED. GENERALLY, THE DISTILLATION TEMPERATURE OF 150 DEGREES C IS AN APPROPRIATE CONDITION FOR WGO DEACIDIFICATION WITH THE HIGHER DEACIDIFICATION EFFICIENCY OF 77.78\% AND THE HIGHER RETENTION RATE OF ACTIVE CONSTITUENTS.","WHEAT GERM OIL; SUBCRITICAL BUTANE EXTRACTION; MOLECULAR DISTILLATION","SUPERCRITICAL-FLUID EXTRACTION; SEED OIL; POLICOSANOL CONTENTS; CARBON-DIOXIDE; PROPANE; CO2; TOCOPHEROLS; CULTIVARS; KINETICS","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [31571878]; PUBLIC SECTOR RESEARCH SPECIAL FOOD [201313011-7-3]; BEIJING MUNICIPAL SCIENCE AND TECHNOLOGY PROJECT [D151100004015003]","THIS WORK WAS SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (31571878), THE PUBLIC SECTOR RESEARCH SPECIAL FOOD (201313011-7-3), AND THE BEIJING MUNICIPAL SCIENCE AND TECHNOLOGY PROJECT (D151100004015003).","AHANGARI B, 2012, THEOR FOUND CHEM EN+, V46, P258, DOI 10.1134/S0040579512030013; ARZATE-MARTÍNEZ G, 2011, IND ENG CHEM RES, V50, P11237, DOI 10.1021/IE200096Q; BATISTELLA CB, 1998, COMPUT CHEM ENG, V22, PS53, DOI 10.1016/S0098-1354(98)00038-6; CHEN F, 2007, J FOOD ENG, V79, P63, DOI 10.1016/J.JFOODENG.2006.01.030; DE MORAES EB, 2006, APPL BIOCHEM BIOTECH, V132, P1066; DUNFORD NT, 2003, FOOD RES INT, V36, P905, DOI 10.1016/S0963-9969(03)00099-1; EISENMENGER M, 2006, J AM OIL CHEM SOC, V83, P863, DOI 10.1007/S11746-006-5038-6; FIORI L, 2014, J SUPERCRIT FLUID, V94, P71, DOI 10.1016/J.SUPFLU.2014.06.021; SOLAESA AG, 2016, FOOD CHEM, V190, P960, DOI 10.1016/J.FOODCHEM.2015.06.061; GHAZANI SM, 2013, J AM OIL CHEM SOC, V90, P743, DOI 10.1007/S11746-013-2215-2; HERRERO M, 2006, FOOD CHEM, V98, P136, DOI 10.1016/J.FOODCHEM.2005.05.058; ILLÉS V, 2000, J SUPERCRIT FLUID, V17, P177, DOI 10.1016/S0896-8446(99)00049-2; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; KRINGS U, 2000, FOOD CHEM, V71, P91, DOI 10.1016/S0308-8146(00)00148-5; LI JW, 2016, FOOD ANAL METHOD, V9, P1444, DOI 10.1007/S12161-015-0324-2; LI JW, 2005, PROCESS BIOCHEM, V40, P3607, DOI 10.1016/J.PROCBIO.2005.03.005; LIANG SH, 2010, J AM OIL CHEM SOC, V87, P63, DOI 10.1007/S11746-009-1475-3; MARIOD AA, 2011, J AM OIL CHEM SOC, V88, P931, DOI 10.1007/S11746-010-1754-Z; MARTINELLO M, 2007, J FOOD ENG, V81, P60, DOI 10.1016/J.JFOODENG.2006.10.012; MARTINELLO MA, 2007, J SCI FOOD AGR, V87, P1559, DOI 10.1002/JSFA.2888; MICHAEL E., 2008, J AM OIL CHEM SOC, V85, P55; MITEI YC, 2009, J AM OIL CHEM SOC, V86, P617, DOI 10.1007/S11746-009-1384-5; PAQUOT C., 1987, INT UNION PURE APPL, P212; PASSOS CP, 2010, CHEM ENG J, V160, P634, DOI 10.1016/J.CEJ.2010.03.087; PIRAS A, 2009, MOLECULES, V14, P2573, DOI 10.3390/MOLECULES14072573; SANTOS KA, 2015, J SUPERCRIT FLUID, V104, P54, DOI 10.1016/J.SUPFLU.2015.05.026; TRES MV, 2014, FOOD RES INT, V63, P33, DOI 10.1016/J.FOODRES.2014.02.004; WANG T, 2001, J AM OIL CHEM SOC, V78, P71, DOI 10.1007/S11746-001-0222-2; WU WL, 2012, LWT-FOOD SCI TECHNOL, V46, P563, DOI 10.1016/J.LWT.2011.10.028; YANG M, 2011, J AM OIL CHEM SOC, V88, P1633, DOI 10.1007/S11746-011-1822-Z; YEOH CM, 2014, EUR J LIPID SCI TECH, V116, P1654, DOI 10.1002/EJLT.201300502; ZANQUI AB, 2015, FOOD CHEM, V188, P452, DOI 10.1016/J.FOODCHEM.2015.05.033; ZHANG GY, 2013, IND ENG CHEM RES, V52, P3918, DOI 10.1021/IE3020044","LIU, YF (CORRESPONDING AUTHOR), JIANGNAN UNIV, STATE KEY LAB FOOD SCI \& TECHNOL, COLLABORAT INNOVAT CTR FOOD SAFETY \& QUAL CONTROL, WUXI 214122, PEOPLES R CHINA","MDPI AG","ENGLISH","MOLECULES","ARTICLE","ISI","WOS000392140100069","MOLECULES","JIANGNAN UNIV;JIANGNAN UNIV","JIANGNAN UNIV",NA,"LI J, 2016, MOLECULES","LI J, 2016, MOLECULES"
"ATTARD T;MCELROY C;GAMMONS R;SLATTERY J;SUPANCHAIYAMAT N;KAMEI C;ALVIM A;DOLSTRA O;TRINDADE L;BRUCE N;MCQUEEN-MASON S;SHIMIZU S;HUNT A","ATTARD THOMAS M;MCELROY C ROB;GAMMONS RICHARD J; SLATTERY JOHN M;SUPANCHAIYAMAT NONTIPA;KAMEI CLAIRE LESSA; ALVIM;DOLSTRA OENE;TRINDADE LUISA M;BRUCE NEIL C; MCQUEEN-MASON SIMON J;SHIMIZU SEISHI;HUNT ANDREW J","SUPERCRITICAL COSUB2SUB EXTRACTION AS AN EFFECTIVE PRETREATMENT STEP FOR WAX EXTRACTION IN A MISCANTHUS BIOREFINERY",2016,"ACS SUSTAINABLE CHEMISTRY \& ENGINEERING","4","5979-5988",42,"10.1021/acssuschemeng.6b01220","HUNT, AJ (CORRESPONDING AUTHOR), UNIV YORK, DEPT CHEM, YORK YO10 5DD, N YORKSHIRE, ENGLAND.; ATTARD, THOMAS M.; MCELROY, C. ROB; GAMMONS, RICHARD J.; SLATTERY, JOHN M.; SHIMIZU, SEISHI; HUNT, ANDREW J., UNIV YORK, DEPT CHEM, YORK YO10 5DD, N YORKSHIRE, ENGLAND.; SUPANCHAIYAMAT, NONTIPA, KHON KAEN UNIV, DEPT CHEM, MAT CHEM RES CTR, KHON KAEN 40002, THAILAND.; KAMEI, CLAIRE LESSA ALVIM; DOLSTRA, OENE; TRINDADE, LUISA M., WAGENINGEN UNIV \& RES CTR, WAGENINGEN UR PLANT BREEDING, POB 386, NL-6700 AJ WAGENINGEN, NETHERLANDS.; BRUCE, NEIL C.; MCQUEEN-MASON, SIMON J., UNIV YORK, DEPT BIOL, WENTWORTH WAY, YORK YO10 5DD, N YORKSHIRE, ENGLAND.","THE USE OF SUPERCRITICAL CARBON DIOXIDE (SCCO(2)) TO EXTRACT VALUABLE LIPOPHILIC COMPOUNDS FROM MISCANTHUS WAS INVESTIGATED AND SUBSEQUENT ENZYMATIC SACCHARIFICATION WAS CARRIED OUT TO DETERMINE THE IMPACT OF SCCO(2) EXTRACTION ON DOWNSTREAM PROCESSING OF MISCANTHUS. TWO MISCANTHUS GENOTYPES (MISCANTHUS X. GIGANTEUS AND MISCANTHUS SINENSIS) WERE INVESTIGATED AND CHARACTERIZED. A DIVERSE RANGE OF MOLECULES WERE DETECTED INCLUDING LONG-CHAIN HYDROCARBONS, FATTY ACIDS, N-POLICOSANOLS, ALDEHYDES, WAX ESTERS, STEROLS AND STEROID KETONES. QUANTIFICATION DATA INDICATES THAT THERE IS A CONSIDERABLE DIFFERENCE AMONG EACH SPECIES IN THE QUANTITIES OF SPECIFIC COMPOUNDS. THE WAXES ALSO EXHIBITED SIGNIFICANT DIFFERENCES IN MELTING TEMPERATURE, THUS ILLUSTRATING THE OPPORTUNITY FOR UTILIZATION IN VARIOUS APPLICATIONS. IN ADDITION TO THE ISOLATION OF VALUABLE CHEMICAL COMPOUNDS, THE SCCO(2) PRETREATMENT ALSO HAD A BENEFICIAL EFFECT ON THE DOWNSTREAM PROCESSING OF THE BIOMASS. THE TOTAL SUGARS RELEASED AFTER SACCHARIFICATION WAS FOUND TO INCREASE BY AROUND 20\% WHEN COUPLED WITH SCCO(2) EXTRACTION, AS COMPARED TO UNTREATED SAMPLES.","MISCANTHUS; SUPERCRITICAL; CARBON DIOXIDE; EXTRACTION; WAXES; SACCHARIFICATION","ALPHA-LINOLENIC ACID; PLATELET-AGGREGATION; CANCER; STRAW; RISK; CHOLESTEROL; FRACTIONATION; PHYTOSTEROLS; POLICOSANOL; METABOLISM","EUROPEAN COMMISSION'S DIRECTORATE-GENERAL FOR RESEARCH WITHIN THE SEVENTH FRAMEWORK PROGRAM (FP7) [251132]; BBSRC [BB/G016178/1] FUNDING SOURCE: UKRI; BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL [BB/G016178/1] FUNDING SOURCE: RESEARCHFISH","WE GRATEFULLY ACKNOWLEDGE FUNDING THROUGH THE EUROPEAN COMMISSION'S DIRECTORATE-GENERAL FOR RESEARCH WITHIN THE SEVENTH FRAMEWORK PROGRAM (FP7/2007-2013) UNDER THE GRANT AGREEMENT NO. 251132 (SUNLIBB).","AHRENS EH, 1957, LANCET, V1, P943; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1997, PHARMACOL RES, V36, P293, DOI 10.1006/PHRS.1997.0201; ARSHADI M, 2012, RSC ADV, V2, P1806, DOI 10.1039/C1RA00715G; ATHUKORALA Y, 2010, IND CROP PROD, V31, P550, DOI 10.1016/J.INDCROP.2010.02.011; ATHUKORALA Y, 2009, EUR J LIPID SCI TECH, V111, P705, DOI 10.1002/EJLT.200800269; ATTARD T. M., 2015, THESIS; ATTARD TM, 2016, GREEN CHEM, V18, P2682, DOI 10.1039/C5GC02479J; ATTARD TM, 2015, IND CROP PROD, V76, P95, DOI 10.1016/J.INDCROP.2015.05.077; ATTARD TM, 2015, INT J MOL SCI, V16, P17546, DOI 10.3390/IJMS160817546; ATTARD TM, 2015, RSC ADV, V5, P43831, DOI 10.1039/C5RA07485A; ATTARD TM, 2014, NEW J CHEM, V38, P2278, DOI 10.1039/C4NJ00043A; BEALE CV, 1995, PLANT CELL ENVIRON, V18, P641, DOI 10.1111/J.1365-3040.1995.TB00565.X; BUDARIN VL, 2011, ENERG ENVIRON SCI, V4, P471, DOI 10.1039/C0EE00184H; CHAN JK, 1991, AM J CLIN NUTR, V53, P1230, DOI 10.1093/AJCN/53.5.1230; CHOI YH, 1996, KOREAN J CHEM ENG, V13, P216, DOI 10.1007/BF02705912; CLARK JH, 2006, GREEN CHEM, V8, P853, DOI 10.1039/B604483M; CLARK JH, 2013, PURE APPL CHEM, V85, P1625, DOI 10.1351/PAC-CON-12-09-01; CLIFTON-BROWN JC, 2000, ANN BOT-LONDON, V86, P191, DOI 10.1006/ANBO.2000.1183; DE STEFANI E, 2000, NUTR CANCER, V37, P140, DOI 10.1207/S15327914NC372\_4; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DESWARTE FEI, 2006, GREEN CHEM, V8, P39, DOI 10.1039/B514978A; DODSON JR, 2013, GREEN CHEM, V15, P1203, DOI 10.1039/C3GC40324F; DODSON JR, 2011, RSC ADV, V1, P523, DOI 10.1039/C1RA00271F; FERNANDO S, 2006, ENERG FUEL, V20, P1727, DOI 10.1021/EF060097W; FITTON A, 1991, DRUGS, V41, P780, DOI 10.2165/00003495-199141050-00007; GAMMONS R. J., 2014, THESIS; GREEF JM, 1993, ANGEW BOT, V67, P87; GUNAWAN ER, 2005, ENZYME MICROB TECH, V37, P739, DOI 10.1016/J.ENZMICTEC.2005.04.010; HILL K, 2000, PURE APPL CHEM, V72, P1255, DOI 10.1351/PAC200072071255; HORROBIN DF, 1987, INT J CARDIOL, V17, P241, DOI 10.1016/0167-5273(87)90073-8; HUNT AJ, 2010, CHEMSUSCHEM, V3, P306, DOI 10.1002/CSSC.200900169; HUNT AJ, 2009, GREEN CHEM, V11, P1332, DOI 10.1039/B906607A; JIANG TY, 2015, J MATER CHEM A, V3, P14148, DOI 10.1039/C5TA02494C; KIM KH, 2001, BIORESOURCE TECHNOL, V77, P139, DOI 10.1016/S0960-8524(00)00147-4; KLINE, 2011, GLOB WAX IND 2010 MA; LEMKE D. W., 2010, PATENT, PATENT NO. US20100024281 AL, 20100024281; MANSOURI N.-E.E., 2006, INDUSTRIAL CROPS AND PRODUCTS, V24, P8, DOI DOI 10.1016/J.INDCR0P.2005.10.002; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MCCANN SE, 2003, J NUTR, V133, P1937, DOI 10.1093/JN/133.6.1937; MCGINTY D, 2010, FOOD CHEM TOXICOL, V48, PS59, DOI 10.1016/J.FCT.2009.11.012; MENDILAHARSU M, 1998, LUNG CANCER-J IASLC, V21, P37, DOI 10.1016/S0169-5002(98)00044-0; MICHEL R, 2006, ENVIRON CHEM LETT, V4, P185, DOI 10.1007/S10311-006-0043-4; MOGHADASIAN MH, 1999, AM J MED, V107, P588, DOI 10.1016/S0002-9343(99)00285-5; MOTTRAM DS, 1998, FOOD CHEM, V62, P415, DOI 10.1016/S0308-8146(98)00076-4; PEREIRA CG, 2007, FLAVOUR FRAG J, V22, P407, DOI 10.1002/FFJ.1813; RONCO A, 1999, NUTR CANCER, V35, P111, DOI 10.1207/S15327914NC352\_3; ROSA PTV, 2005, J FOOD ENG, V67, P235, DOI 10.1016/J.JFOODENG.2004.05.064; SCHIESTL FP, 1999, NATURE, V399, P421, DOI 10.1038/20829; SHEPHERD J, 1978, J CLIN INVEST, V61, P1582, DOI 10.1172/JCI109078; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/BJC.1991.210; SIN EHK, 2014, CR CHIM, V17, P293, DOI 10.1016/J.CRCI.2013.12.001; SUBRAMANIAM B, 1997, J PHARM SCI-US, V86, P885, DOI 10.1021/JS9700661; TURTON R., 2013, ANALYSIS, SYNTHESIS, AND DESIGN OF CHEMICAL PROCESSES, V4TH; VEGA A, 1997, BIORESOURCE TECHNOL, V61, P1, DOI 10.1016/S0960-8524(96)00056-9; VILLAVERDE JJ, 2009, J AGR FOOD CHEM, V57, P3626, DOI 10.1021/JF900071T; VILLAVERDE JJ, 2010, J AGR FOOD CHEM, V58, P8279, DOI 10.1021/JF101174X; ZHENG YZ, 1995, BIOTECHNOL LETT, V17, P845, DOI 10.1007/BF00129015; ZUB HW, 2010, AGRON SUSTAIN DEV, V30, P201, DOI 10.1051/AGRO/2009034","HUNT, AJ (CORRESPONDING AUTHOR), UNIV YORK, DEPT CHEM, YORK YO10 5DD, N YORKSHIRE, ENGLAND","AMER CHEMICAL SOC","ENGLISH","ACS SUSTAIN. CHEM. ENG.","ARTICLE","ISI","WOS000387428700021","ACS SUSTAIN CHEM ENG","UNIV YORK;UNIV YORK;KHON KAEN UNIV;WAGENINGEN UNIV AND RES CTR;UNIV YORK","UNIV YORK",NA,"ATTARD TM, 2016, ACS SUSTAIN CHEM ENG","ATTARD TM, 2016, ACS SUSTAIN CHEM ENG"
"LONG L;WU S;YUAN F;WANG J;ZHANG H;QI G","LONG L;WU S G;YUAN F;WANG J;ZHANG H J; QI G H","EFFECTS OF DIETARY OCTACOSANOL ON GROWTH PERFORMANCE CARCASS CHARACTERISTICS AND MEAT QUALITY OF BROILER CHICKS",2016,"ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES","29","1470-1476",5,"10.5713/ajas.15.0879","QI, GH (CORRESPONDING AUTHOR), CHINESE ACAD AGR SCI, FEED RES INST, MINIST AGR, KEY LAB FEED BIOTECHNOL, BEIJING 100081, PEOPLES R CHINA.; LONG, L.; WU, S. G.; WANG, J.; ZHANG, H. J.; QI, G. H., CHINESE ACAD AGR SCI, FEED RES INST, MINIST AGR, KEY LAB FEED BIOTECHNOL, BEIJING 100081, PEOPLES R CHINA.; LONG, L.; YUAN, F., TIANJIN NAER BIOTECHNOL CO LTD, TIANJIN 300457, PEOPLES R CHINA.","OCTACOSANOL, WHICH HAS PROMINENT PHYSIOLOGICAL ACTIVITIES AND FUNCTIONS, HAS BEEN RECOGNIZED AS A POTENTIAL GROWTH PROMOTER IN ANIMALS. A TOTAL OF 392 1-D-OLD MALE ARBOR ACRES BROILER CHICKS WITH SIMILAR BODY WEIGHT WERE RANDOMLY DISTRIBUTED INTO FOUR DIETARY GROUPS OF SEVEN REPLICATES WITH 14 BIRDS EACH SUPPLEMENTED WITH 0, 12, 24, OR 36 MG OCTACOSANOL (EXTRACTED FROM RICE BRAN, PURITY > 92\%)/KG FEED. THE FEEDING TRIAL LASTED FOR SIX WEEKS AND WAS DIVIDED INTO THE STARTER (DAY 1 TO 21) AND THE GROWER (DAY 22 TO 42) PHASES. THE RESULTS SHOWED THAT THE FEED CONVERSION RATIO (FCR) WAS SIGNIFICANTLY IMPROVED IN BROILERS FED A DIET CONTAINING 24 MG/KG OCTACOSANOL COMPARED WITH THOSE FED THE CONTROL DIET IN THE OVERALL PHASE (DAY 1 TO 42, P = 0.042). THE AVERAGE DAILY GAIN AND FCR BOTH SHOWED LINEAR EFFECTS IN RESPONSE TO DIETARY SUPPLEMENTATION OF OCTACOSANOL DURING THE OVERALL PHASE (P = 0.031 AND 0.018, RESPECTIVELY). BROILERS FED WITH 24 OR 36 MG/KG OCTACOSANOL DIET SHOWED A HIGHER EVISCERATED YIELD, WHICH INCREASED BY 5.88\% AND 4.26\% RESPECTIVELY, THAN THOSE FED THE CONTROL DIET (P = 0.030). THE BREAST MUSCLE YIELD OF BROILERS FED WITH 24 MG/KG OCTACOSANOL DIET INCREASED SIGNIFICANTLY BY 12.15\% COMPARED WITH THOSE FED THE CONTROL DIET (P = 0.047). EVISCERATED AND BREAST MUSCLE YIELD INCREASED LINEARLY WITH THE INCREASE IN DIETARY OCTACOSANOL SUPPLEMENTATION (P = 0.013 AND 0.021, RESPECTIVELY). BROILERS FED WITH 24 OR 36 MG/KG OCTACOSANOL DIET HAD A GREATER (P = 0.021) PH(45MIN) VALUE IN THE BREAST MUSCLE, WHICH WAS MAINTAINED LINEARLY IN RESPONSE TO DIETARY OCTACOSANOL SUPPLEMENTATION (P = 0.003). THERE WAS A SIGNIFICANT DECREASE (P = 0.007) IN DRIP LOSS VALUE BETWEEN THE OCTACOSANOL-ADDED AND THE CONTROL GROUPS. THE DRIP LOSS SHOWED LINEAR (P = 0.004) AND QUADRATIC (P = 0.041) RESPONSES WITH DIETARY SUPPLEMENTATION OF OCTACOSANOL. THESE STUDIES INDICATE THAT OCTACOSANOL IS A POTENTIALLY EFFECTIVE AND SAFE FEED ADDITIVE WHICH MAY IMPROVE FEED EFFICIENCY AND MEAT QUALITY, AND INCREASE EVISCERATED AND BREAST MUSCLE YIELD, IN BROILER CHICKS. DIETARY SUPPLEMENTATION OF OCTACOSANOL AT 24 MG/KG DIET IS REGARDED AS THE RECOMMENDED DOSAGE IN THE BROILERS' DIET.","OCTACOSANOL; GROWTH PERFORMANCE; CARCASS CHARACTERISTICS; MEAT QUALITY; BROILER CHICK","FATTY-ACID-COMPOSITION; II HYPERCHOLESTEROLEMIA; HEALTHY-VOLUNTEERS; IN-VITRO; POLICOSANOL; METABOLISM; RATS; MICE; WOMEN","CHINA AGRICULTURE RESEARCH SYSTEM-BEIJING TEAM FOR POULTRY INDUSTRY; AGRICULTURAL SCIENCE AND TECHNOLOGY INNOVATION PROGRAM (ASTIP)","THE FINANCIAL SUPPORT PROVIDED BY THE CHINA AGRICULTURE RESEARCH SYSTEM-BEIJING TEAM FOR POULTRY INDUSTRY AND THE AGRICULTURAL SCIENCE AND TECHNOLOGY INNOVATION PROGRAM (ASTIP) IS GRATEFULLY APPRECIATED.","ACRES ARBOR, 2014, ARB ACR BROIL MAN HD; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BAILLIE AGS, 1991, AM J PHYSIOL, V260, PE891, DOI 10.1152/AJPENDO.1991.260.6.E891; BROWN-BORG HM, 2012, J GERONTOL A-BIOL, V67, P652, DOI 10.1093/GERONA/GLS086; CAI L, 2015, LIVEST SCI, V172, P43, DOI 10.1016/J.LIVSCI.2014.11.013; CARBAJAL D, 1996, J PHARM PHARMACOL, V48, P858, DOI 10.1111/J.2042-7158.1996.TB03987.X; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CHIKUNYA S, 2004, BRIT J NUTR, V91, P539, DOI 10.1079/BJN20031078; COUNCIL NATIONALRESEARCH., 1994, NUTR REQ POULTR, VNINTH; CROWLEY MA, 1996, J APPL PHYSIOL, V81, P362, DOI 10.1152/JAPPL.1996.81.1.362; DE OLIVEIRA AM, 2012, INT J MOL SCI, V13, P1598, DOI 10.3390/IJMS13021598; DOURIS PC, 2006, J STRENGTH COND RES, V20, P699; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HONIKEL KO, 1998, MEAT SCI, V49, P447, DOI 10.1016/S0309-1740(98)00034-5; KAMBOH AA, 2013, POULTRY SCI, V92, P454, DOI 10.3382/PS.2012-02584; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KIM H., 2004, J MED FOOD, V6, P345; LAVERY GG, 2008, J BIOL CHEM, V283, P8453, DOI 10.1074/JBC.M710067200; LIAO XD, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/S12944-015-0035-0; 龙蕾 LONG LEI, 2015, 中国粮油学报, JOURNAL OF THE CHINESE CEREALS AND OILS ASSOCIATION, V30, P94; MAC (MINISTRY OF AGRICULTURE OF CHINA), 2004, 332004 NYT MAC; MCCORMICK RJ, 1999, POULTRY SCI, V78, P785, DOI 10.1093/PS/78.5.785; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; QIAO X, 2013, POULTRY SCI, V92, P753, DOI 10.3382/PS.2012-02341; SAINT-JOHN M., 1986, INTERNATIONAL CLINICAL NUTRITION REVIEW, V6, P81; SCHEELE CW, 1997, VET QUART, V19, P127, DOI 10.1080/01652176.1997.9694756; SHIMURA S, 1987, NUTR REP INT, V36, P1029; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; XIANG Y., 2012, J XINXIANG U, V29, P44; XU R., 1997, FEED RES, V5, P26; XU ZY, 2007, NUTR RES, V27, P212, DOI 10.1016/J.NUTRES.2007.01.015; YANG H., 2012, SIMULATION BASED EVA; YU C., 2003, CHINA FOOD ADDIT, V2, P35; ZHANG WH, 2011, POULTRY SCI, V90, P2592, DOI 10.3382/PS.2011-01446","QI, GH (CORRESPONDING AUTHOR), CHINESE ACAD AGR SCI, FEED RES INST, MINIST AGR, KEY LAB FEED BIOTECHNOL, BEIJING 100081, PEOPLES R CHINA","ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC","ENGLISH","ASIAN AUSTRALAS. J. ANIM. SCI.","ARTICLE","ISI","WOS000388268300013","ASIAN AUSTRALAS J ANIM SCI","FEED RES INST;FEED RES INST;TIANJIN NAER BIOTECHNOL CO LTD","FEED RES INST",NA,"LONG L, 2016, ASIAN AUSTRALAS J ANIM SCI","LONG L, 2016, ASIAN AUSTRALAS J ANIM SCI"
"PENG K;LONG L;WANG Y;WANG S","PENG KAI;LONG LEI;WANG YUXI;WANG SHUNXI","EFFECTS OF OCTACOSANOL EXTRACTED FROM RICE BRAN ON THE LAYING PERFORMANCE EGG QUALITY AND BLOOD METABOLITES OF LAYING HENS",2016,"ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES","29","1458-1463",3,"10.5713/ajas.16.0287","WANG, SX (CORRESPONDING AUTHOR), CHINA AGR UNIV, COLL ENGN, BEIJING 100083, PEOPLES R CHINA.; PENG, KAI; LONG, LEI; WANG, SHUNXI, CHINA AGR UNIV, COLL ENGN, BEIJING 100083, PEOPLES R CHINA.; WANG, YUXI, AGR \& AGRI FOOD CANADA, LETHBRIDGE RES \& DEV CTR, LETHBRIDGE, AB T1J 4B1, CANADA.","A 42-D STUDY WITH 384 HY-LINE BROWN LAYING HENS WAS CONDUCTED TO ASSESS THE EFFECTS OF DIETARY OCTACOSANOL SUPPLEMENTATION ON LAYING PERFORMANCE, EGG QUALITY AND BLOOD METABOLITES OF LAYING HENS. HENS WERE RANDOMLY ALLOCATED INTO 4 DIETARY GROUPS OF 8 CAGES EACH, WHICH WERE FED BASAL DIET SUPPLEMENTED WITH 0 (CONTROL), 9 (OCT9), 18 (OCT18), AND 27 (OCT27) MG/KG DIET OF OCTACOSANOL ISOLATED FROM RICE BRAN, RESPECTIVELY. THE EXPERIMENT WAS CONDUCTED IN AN ENVIRONMENTAL CONTROLLED HOUSE AND HENS WERE FED TWICE DAILY FOR AD LIBITUM INTAKE. LAYING PERFORMANCE WAS DETERMINED OVER THE 42-D PERIOD, AND EGG QUALITY AS WELL AS BLOOD METABOLITES WERE ESTIMATED ON D 21 AND D 42. DIETS IN OCT18 AND OCT27 INCREASED (P<0.05) LAYING RATE, EGG WEIGHT, EGG MASS, EGG ALBUMEN HEIGHT, HAUGH UNIT AND EGGSHELL STRENGTH ON D 42, BUT DECREASED (P<0.05) FEED CONVERSION RATE AND LEVELS OF TOTAL CHOLESTEROL, TRIGLYCERIDE AND LOW DENSITY LIPOPROTEIN CHOLESTEROL IN THE SERUM AS COMPARED TO THOSE OF CONTROL. FEED INTAKE, YOLK COLOR, YOLK DIAMETER, EGGSHELL THICKNESS AND HIGH DENSITY LIPOPROTEIN CHOLESTEROL WERE SIMILAR (P>0.05) AMONG TREATMENTS. RESULTS DEMONSTRATE THAT SUPPLEMENTING 18 TO 27 MG/KG DIET OF RICE BRAN OCTACOSANOL CAN IMPROVE LAYING RATE AND EGG QUALITY AND REDUCE BLOOD LIPID OF LAYING HENS.","OCTACOSANOL; LAYING PERFORMANCE; EGG QUALITY; BLOOD METABOLITES; LAYING; HENS","HYPERCHOLESTEROLEMIC PATIENTS; LIPID PROFILE; POLICOSANOL; RATS; CHOLESTEROL; CALCIUM","SPECIAL FUND FOR AGRO-SCIENTIFIC RESEARCH IN THE PUBLIC INTEREST OF CHINA [201203015]","THIS STUDY WAS CONDUCTED WITH FINANCIAL SUPPORT FROM SPECIAL FUND FOR AGRO-SCIENTIFIC RESEARCH IN THE PUBLIC INTEREST OF CHINA (NO. 201203015). THE AUTHORS GREATLY APPRECIATE FOR ADVICE AND TECHNICAL ASSISTANCE OF FENG YUAN. WE ALSO ACKNOWLEDGE JING SUN FOR ASSISTANCE WITH SAMPLE COLLECTION AND CARE OF THE LAYING HENS.","ANONYMOUS, 2011, STATISTICAL PACKAGE FOR SOCIAL SCIENCES (VERSION 16); AOAC, 2001, OFFICIAL METHODS ANA; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BRAITHWAITE GD, 1975, BRIT J NUTR, V33, P309, DOI 10.1079/BJN19750036; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; 陈芳 CHEN FANG, 2007, 营养学报, ACTA NUTRIMENTA SINICA, V29, P408; COUNCIL NATIONALRESEARCH., 1994, NUTR REQ POULTR, VNINTH; DAI LA DAI LA, 2012, CHINESE JOURNAL OF ANIMAL NUTRITION, V24, P654; GORDON RW, 1998, POULTRY SCI, V77, P290, DOI 10.1093/PS/77.2.290; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; KABIR Y, 1994, NAHRUNG, V38, P373; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; KAHLENBERG O. J., 1949, FOOD INDUST, V21, P467; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; LOH TC, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-149; LONG L., 2014, THESIS; LONG L, 2015, ANIM NUTR, V1, P293, DOI 10.1016/J.ANINU.2015.12.005; 龙蕾 LONG LEI, 2015, 中国粮油学报, JOURNAL OF THE CHINESE CEREALS AND OILS ASSOCIATION, V30, P94; MAS R., 2004, ASIA PAC J CLIN NU S, V13, PS102; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; SAINT J. M., 1986, INT CLIN NUTR REV, V6, P81; SAMLI HE, 2006, J CENT EUR AGRIC, V7, P135; SILVERSIDES FG, 2001, POULTRY SCI, V80, P1240, DOI 10.1093/PS/80.8.1240; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; XIANG Y., 2012, J PINGYUAN UNIV, V29, P47; YANG H., 2012, SIMULATION BASED EVA","WANG, SX (CORRESPONDING AUTHOR), CHINA AGR UNIV, COLL ENGN, BEIJING 100083, PEOPLES R CHINA","ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC","ENGLISH","ASIAN AUSTRALAS. J. ANIM. SCI.","ARTICLE","ISI","WOS000388268300011","ASIAN AUSTRALAS J ANIM SCI","CHINA AGR UNIV;CHINA AGR UNIV;LETHBRIDGE RES AND DEV CTR","CHINA AGR UNIV",NA,"PENG K, 2016, ASIAN AUSTRALAS J ANIM SCI","PENG K, 2016, ASIAN AUSTRALAS J ANIM SCI"
"CHOI S;PARK S;PARK J;PARK S;JUNG M","CHOI SOL JI;PARK SU YEON;PARK JI SU;PARK SANG-KYU; JUNG MUN YHUNG","CONTENTS AND COMPOSITIONS OF POLICOSANOLS IN GREEN TEA ICAMELLIA SINENSISI LEAVES",2016,"FOOD CHEMISTRY","204","94-101",16,"10.1016/j.foodchem.2016.02.027","JUNG, MY (CORRESPONDING AUTHOR), WOOSUK UNIV, GRAD SCH, DEPT FOOD \& BIOTECHNOL, COLL FOOD SCI, WANJU KUN 565701, JEONBUK PROVINC, SOUTH KOREA.; CHOI, SOL JI; PARK, SU YEON; JUNG, MUN YHUNG, WOOSUK UNIV, GRAD SCH, DEPT FOOD \& BIOTECHNOL, COLL FOOD SCI, WANJU KUN 565701, JEONBUK PROVINC, SOUTH KOREA.; PARK, JI SU, KOREA FOOD RES INST, SONGNAM, KYONGKI, SOUTH KOREA.; PARK, SANG-KYU, NAMBU UNIV, DEPT FOOD NUTR, GWANGJU, SOUTH KOREA.","POLICOSANOL (PC) IS A MIXTURE OF HEALTH PROMOTING BIOACTIVE LONG-CHAIN ALIPHATIC ALCOHOLS. HERE, WE REPORT THAT GREEN TEA (CAMELLIA SINENSIS) LEAVES ARE THE EXCEPTIONALLY RICH PLANT-SOURCES OF PC. YOUNG AND TENDER LEAVES AND OLD AND TURF LEAVES OF C. SINENSIS WERE HAND-PICKED IN SPRING AND AUTUMN. THE TOTAL CONTENTS OF PC IN THE LEAVES WERE IN THE RANGE OF 726.2-1363.6 MG/KG AS DETERMINED BY A GC-MS/MS. THE COMPOSITIONS OF PC IN THE LEAVES WERE DIFFERENT WITH HARVEST SEASON AND TYPES. THE TOTAL CONTENTS OF PC IN COMMERCIAL GREEN TEA LEAVES WERE FOUND TO BE IN THE RANGE OF 856.7-1435.1 MG/KG. INTERESTINGLY, THE INFUSED GREEN TEA LEAVES CONTAINED THE HIGHER PC THAN THE NON-INFUSED GREEN TEA PRODUCT, REACHING TO 1629.4 MG/KG. THIS REPRESENTS THE FIRST REPORT ON THE CONTENTS AND COMPOSITIONS OF PC IN GREEN TEA LEAVES, SHOWING UNAMBIGUOUS EVIDENCE OF THEIR POTENTIAL AS RICH SOURCES OF PC. (C) 2016 ELSEVIER LTD. ALL RIGHTS RESERVED.","POLICOSANOLS; CAMELLIA SINENSIS LEAVES; GREEN TEA; INFUSION; GC-TANDEM; MASS SPECTROMETRY","LOW-DENSITY-LIPOPROTEIN; GRAIN-SORGHUM WAX; PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; GAS-CHROMATOGRAPHY; ALIPHATIC-ALCOHOLS; EXTRACTION; METHODS; WHEAT-VARIETIES; PERILLA SEEDS; L.","KOREAN MINISTRY FOR FOOD, AGRICULTURE, FORESTRY, AND FISHERIES THROUGH IPET","THIS RESEARCH WAS FINANCIALLY SUPPORTED BY KOREAN MINISTRY FOR FOOD, AGRICULTURE, FORESTRY, AND FISHERIES THROUGH IPET.","ABDALLAH IB, 2015, FOOD CHEM, V173, P972, DOI 10.1016/J.FOODCHEM.2014.10.095; ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; BERHOLDER H. K., 2006, JAMA-J AM MED ASSOC, V295, P2262; BUSCHHAUS C, 2012, PLANT PHYSIOL, V160, P1120, DOI 10.1104/PP.112.198473; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CHEN YF, 2009, J SCI FOOD AGR, V89, P310, DOI 10.1002/JSFA.3446; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P12143, DOI 10.1021/JF1030345; CRESPY V, 2004, J NUTR, V134, P3431S, DOI 10.1093/JN/134.12.3431S; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; GIACOMETTI J, 2001, ANALYST, V126, P472, DOI 10.1039/B007090O; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GULZ PG, 1992, Z NATURFORSCH C, V47, P800; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; HOFFMANN B, 2013, ORG GEOCHEM, V62, P62, DOI 10.1016/J.ORGGEOCHEM.2013.07.003; HWANG KT, 2002, J AM OIL CHEM SOC, V79, P529, DOI 10.1007/S11746-002-0516-4; HWANG KT, 2002, J SEP SCI, V25, P619, DOI 10.1002/1615-9314(20020601)25:9<619::AID-JSSC619>3.0.CO;2-; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; JUNG DM, 2012, J FOOD SCI, V77, PC1249, DOI 10.1111/J.1750-3841.2012.02965.X; JUNG DM, 2011, J FOOD SCI, V76, PC891, DOI 10.1111/J.1750-3841.2011.02232.X; KIM HYUNJUNG, 2003, JOURNAL OF MEDICINAL FOOD, V6, P345; KIM JK, 2012, CEREAL CHEM, V89, P151, DOI 10.1094/CCHEM-09-11-0113; KIM JK, 2012, J FOOD COMPOS ANAL, V25, P31, DOI 10.1016/J.JFCA.2011.06.002; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; NG CH, 2005, J AGR FOOD CHEM, V53, P6289, DOI 10.1021/JF051269A; SAKOUHI F, 2010, EUR J LIPID SCI TECH, V112, P373, DOI 10.1002/EJLT.200900076; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q; ZAVERI NT, 2006, LIFE SCI, V78, P2073, DOI 10.1016/J.LFS.2005.12.006","JUNG, MY (CORRESPONDING AUTHOR), WOOSUK UNIV, GRAD SCH, DEPT FOOD \& BIOTECHNOL, COLL FOOD SCI, WANJU KUN 565701, JEONBUK PROVINC, SOUTH KOREA","ELSEVIER SCI LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","WOS000371882700013","FOOD CHEM","WOOSUK UNIV;WOOSUK UNIV;KOREA FOOD RES INST;NAMBU UNIV","WOOSUK UNIV",NA,"CHOI SJ, 2016, FOOD CHEM","CHOI SJ, 2016, FOOD CHEM1"
"WONG W;ISMAIL M;IMAM M;ZHANG ;YI-DA Y","WONG WAI-TENG;ISMAIL MAZNAH;IMAM MUSTAPHA UMAR;ZHANG; YI-DA","MODULATION OF PLATELET FUNCTIONS BY CRUDE RICE IORYZA SATIVAI BRAN POLICOSANOL EXTRACT",2016,"BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE","16",NA,5,"10.1186/s12906-016-1223-9","ISMAIL, M (CORRESPONDING AUTHOR), UNIV PUTRA MALAYSIA, INST BIOSCI, LAB MOL BIOMED, SERDANG 43400, SELANGOR, MALAYSIA.; IMAM, MU (CORRESPONDING AUTHOR), ZHENGZHOU UNIV, COLL PUBL HLTH, PRECIS NUTR INNOVAT INST, ZHENGZHOU 450001, HENAN PROVINCE, PEOPLES R CHINA.; WONG, WAI-TENG; ISMAIL, MAZNAH, UNIV PUTRA MALAYSIA, INST BIOSCI, LAB MOL BIOMED, SERDANG 43400, SELANGOR, MALAYSIA.; ISMAIL, MAZNAH, UNIV PUTRA MALAYSIA, FAC MED \& HLTH SCI, DEPT NUTR \& DIETET, SERDANG 43400, SELANGOR, MALAYSIA.; IMAM, MUSTAPHA UMAR, ZHENGZHOU UNIV, COLL PUBL HLTH, PRECIS NUTR INNOVAT INST, ZHENGZHOU 450001, HENAN PROVINCE, PEOPLES R CHINA.; ZHANG, YI-DA, CHENGDE MED UNIV, AFFILIATED HOSP, DEPT CARDIOL, CHENGDE 067000, HEBEI, PEOPLES R CHINA.","BACKGROUND: RICE BRAN IS BIOACTIVE-RICH AND HAS PROVEN HEALTH BENEFITS FOR HUMANS. MOREOVER, ITS SOURCE, THE BROWN RICE HAS ANTIOXIDANT, HYPOLIPIDEMIC AND OTHER FUNCTIONAL PROPERTIES THAT ARE INCREASINGLY MAKING IT A NUTRITIONAL STAPLE ESPECIALLY IN ASIAN COUNTRIES. THIS STUDY INVESTIGATED THE ANTIPLATELET AGGREGATION MECHANISMS OF CRUDE HEXANE/METHANOLIC RICE BRAN EXTRACT, IN WHICH POLICOSANOL WAS THE TARGETED BIOACTIVE. PLATELETS PLAY A VITAL ROLE IN PATHOGENESIS OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES, AND THEIR INCREASED ACTIVITIES COULD POTENTIALLY CAUSE ARTERIAL THROMBUS FORMATION OR SEVERE BLEEDING DISORDERS. THUS, IN THIS STUDY, PLATELET AGGREGATION AND ADHESION OF PLATELETS TO MAJOR COMPONENTS OF BASAL LAMINA WERE EXAMINED IN VITRO. IN ADDITION, CELLULAR PROTEIN SECRETION WAS QUANTIFIED AS A MEASUREMENT OF PLATELET ACTIVATION. METHODS: ADENOSINE DIPHOSPHATE (ADP), COLLAGEN, AND ARACHIDONIC ACID (AA)-INDUCED AGGREGATION WERE STUDIED USING THE MICROTITER TECHNIQUE. RAT PLATELETS WERE PRE-TREATED WITH VARIOUS CONCENTRATIONS OF POLICOSANOL EXTRACT, AND THE ADHESION OF PLATELETS ONTO COLLAGEN-AND LAMININ-COATED SURFACE (EXTRACELLULAR MATRIX) WAS STUDIED USING THE ACID PHOSPHATASE ASSAY. THE EFFECT OF CRUDE POLICOSANOL EXTRACT ON RELEASED PROTEINS FROM ACTIVATED PLATELETS WAS MEASURED USING MODIFIED LOWRY DETERMINATION METHOD. RESULTS: RICE BRAN POLICOSANOL EXTRACT SIGNIFICANTLY INHIBITED IN VITRO PLATELET AGGREGATION INDUCED BY DIFFERENT AGONISTS IN A DOSE DEPENDENT MANNER. THE IC50 OF ADP, COLLAGEN, AND AA-INDUCED PLATELET AGGREGATION WERE 533.37 +/- 112.16, 635.94 +/- 78.45 AND 693.86 +/- 70.57 MU G/ML, RESPECTIVELY. THE PRESENT STUDY SHOWED THAT CRUDE RICE BRAN POLICOSANOL EXTRACT SIGNIFICANTLY INHIBITED PLATELET ADHESION TO COLLAGEN IN A DOSE DEPENDENT MANNER. CONVERSELY, AT A LOW CONCENTRATION OF 15. 625 MU G/ML, THE EXTRACT SIGNIFICANTLY INHIBITED PLATELET ADHESION TO LAMININ STIMULATED BY DIFFERENT PLATELET AGONISTS. IN ADDITION TO THE ALTERATION OF CELL ADHESIVE PROPERTIES, CELLULAR PROTEIN SECRETION OF THE TREATED PLATELETS TOWARDS DIFFERENT STIMULANTS WERE DECREASED UPON CRUDE EXTRACT TREATMENT. CONCLUSION: OUR RESULTS SHOWED THAT CRUDE RICE BRAN POLICOSANOL EXTRACT COULD INHIBIT IN VITRO PLATELET ADHESION, AGGREGATION AND SECRETION UPON ACTIVATION USING AGONISTS. THESE FINDINGS SERVE AS A SCIENTIFIC PLATFORM TO FURTHER EXPLORE ALTERNATIVE THERAPIES IN CARDIOVASCULAR DISEASES RELATED TO PLATELET MALFUNCTION.","ARACHIDONIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; PLATELET AGGREGATION; PLATELET ADHESION; LAMININ; PROTEIN SECRETION","CARDIOVASCULAR-DISEASE; ARTEMISIA-DRACUNCULUS; LIPID-PEROXIDATION; AGGREGATION; ADHESION; INHIBITION; ANTIPLATELET; CHOLESTEROL; ACTIVATION; COMPONENTS","MINISTRY OF EDUCATION MALAYSIA (KNOWLEDGE TRANSFER PROGRAM) [6228130]","THIS PROJECT WAS FUNDED BY MINISTRY OF EDUCATION MALAYSIA (KNOWLEDGE TRANSFER PROGRAM-PROJECT NUMBER 6228130).","ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1992, REV IBEROAMER TROMB, V5, P17; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/ABIO.1994.1066; BRIERE JB, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-3; BROBERG M, 2002, J LAB CLIN MED, V139, P163, DOI 10.1067/MLC.2002.121604; CARBAJAL D, 1994, PROSTAG LEUKOTR ESS, V50, P249, DOI 10.1016/0952-3278(94)90162-7; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CICERO A. F. G., 2005, CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, V3, P29; COPPINGER JA, 2004, BLOOD, V103, P2096, DOI 10.1182/BLOOD-2003-08-2804; DAHLBÄCK B, 2005, J INTERN MED, V257, P209, DOI 10.1111/J.1365-2796.2004.01444.X; DUTTA-ROY AK, 2002, PLATELETS, V13, P67, DOI 10.1080/09537100120111540; FARNDALE RW, 2006, BLOOD CELL MOL DIS, V36, P162, DOI 10.1016/J.BCMD.2005.12.016; FRAGA V, 1997, ARCH MED RES, V28, P355; GIBBINS JM, 215 BMG LABTECH; HALLIWELL B, 2000, CARDIOVASC RES, V47, P410, DOI 10.1016/S0008-6363(00)00097-3; HENDERSON AJ, 2012, ADV NUTR, V3, P643, DOI 10.3945/AN.112.002303; 김현홍, 2014, BIOMEDICAL SCIENCE LETTERS, 대한의생명과학회지, V20, P129, DOI 10.15616/BSL.2014.20.3.129; HUBBARD GP, 2003, J THROMB HAEMOST, V1, P1079, DOI 10.1046/J.1538-7836.2003.00212.X; ISHAKA A, 2014, INT J NANOMED, V9, P2261, DOI 10.2147/IJN.S56999; KAHLON TS, 1992, CEREAL CHEM, V69, P485; KAKOUROS N, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/742719; KERVER JM, 2003, AM J CLIN NUTR, V78, P1103, DOI 10.1093/AJCN/78.6.1103; 김현홍, 2015, BIOMEDICAL SCIENCE LETTERS, 대한의생명과학회지, V21, P103, DOI 10.15616/BSL.2015.21.2.103; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALIKI NZ, 2007, THESIS; MANOSROI A, 2012, PHARM BIOL, V50, P208, DOI 10.3109/13880209.2011.596206; MARKEL A, 1983, BRIT J CLIN PHARMACO, V16, P663, DOI 10.1111/J.1365-2125.1983.TB02238.X; MEKHFI H, 2004, J ETHNOPHARMACOL, V94, P317, DOI 10.1016/J.JEP.2004.06.005; MOLINA V, 2003, PROSTAG LEUKOTR ESS, V68, P305, DOI 10.1016/S0952-3278(03)00020-6; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; MOLINA V, 2011, REV CIENC BIOL, V42, P3; MORAN N, 2006, ANAL BIOCHEM, V357, P77, DOI 10.1016/J.AB.2006.06.037; MOST MM, 2005, AM J CLIN NUTR, V81, P64; NARA Y, 1984, HYPERTENSION, V6, P339, DOI 10.1161/01.HYP.6.3.339; OLAS B, 2005, NUTRITION, V21, P199, DOI 10.1016/J.NUT.2004.03.024; OSGANIAN SK, 2003, AM J CLIN NUTR, V77, P1390, DOI 10.1093/AJCN/77.6.1390; PEREZ Y, 2013, INT J PHARM SCI REV, V19, P18; PRASAD M.N., 2011, J. NUTR. FOOD SCI, V1, P108, DOI 10.4172/2155-9600.1000108, DOI 10.4172/2155-9600.1000108; RAJARAM S, 2003, AM J CLIN NUTR, V78, P552S, DOI 10.1093/AJCN/78.3.552S; SENER A, 2005, CLIN BIOCHEM, V38, P1081, DOI 10.1016/J.CLINBIOCHEM.2005.09.005; SHAHRIYARY L, 2007, J ETHNOPHARMACOL, V114, P194, DOI 10.1016/J.JEP.2007.07.029; SHIH FF, 2012, J AM OIL CHEM SOC, V89, P1, DOI 10.1007/S11746-011-1941-6; TAKAKORI Z, 2004, INTERNET J NUTR WELL, V2, P1; TANDON NN, 1991, BIOCHEM J, V274, P535, DOI 10.1042/BJ2740535; VISIOLI F, 2000, CARDIOVASC RES, V47, P419, DOI 10.1016/S0008-6363(00)00053-5; YAZDANPARAST R, 2008, VASC PHARMACOL, V48, P32, DOI 10.1016/J.VPH.2007.11.003; YEH JJ, 2010, BLOOD, V115, P4247, DOI 10.1182/BLOOD-2009-09-241166; YOSHIDA S, 2008, BLOOD, V111, P2007, DOI 10.1182/BLOOD-2007-06-097824","ISMAIL, M (CORRESPONDING AUTHOR), UNIV PUTRA MALAYSIA, INST BIOSCI, LAB MOL BIOMED, SERDANG 43400, SELANGOR, MALAYSIA","BMC","ENGLISH","BMC COMPLEMENT. ALTERN. MED.","ARTICLE","ISI","WOS000380302200001","BMC COMPLEMENT ALTERN MED","UNIV PUTRA MALAYSIA;ZHENGZHOU UNIV;UNIV PUTRA MALAYSIA;UNIV PUTRA MALAYSIA;ZHENGZHOU UNIV;CHENGDE MED UNIV","UNIV PUTRA MALAYSIA",NA,"WONG WT, 2016, BMC COMPLEMENT ALTERN MED","WONG WT, 2016, BMC COMPLEMENT ALTERN MED"
"BAEK S;JUNG Y;LIM S;PARK S;KIM J","BAEK SEUNG-A;JUNG YOUNG-HO;LIM SUN-HYUNG;PARK SANG UN;KIM JAE KWANG","METABOLIC PROFILING IN CHINESE CABBAGE IBRASSICA RAPAI L SUBSP IPEKINENSISI CULTIVARS REVEALS THAT GLUCOSINOLATE CONTENT IS CORRELATED WITH CAROTENOID CONTENT",2016,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","64","4426-4434",40,"10.1021/acs.jafc.6b01323","KIM, JK (CORRESPONDING AUTHOR), INCHEON NATL UNIV, COLL LIFE SCI \& BIOENGN, DIV LIFE SCI, INCHON 22012, SOUTH KOREA.; PARK, SU (CORRESPONDING AUTHOR), CHUNGNAM NATL UNIV, DEPT CROP SCI, 99 DAEHAK RO, DAEJEON 34134, SOUTH KOREA.; BAEK, SEUNG-A; KIM, JAE KWANG, INCHEON NATL UNIV, COLL LIFE SCI \& BIOENGN, DIV LIFE SCI, INCHON 22012, SOUTH KOREA.; JUNG, YOUNG-HO, NONGWOO BIO CO, INST BIOTECHNOL, YEOJU 12655, GYEONGGI, SOUTH KOREA.; LIM, SUN-HYUNG, RURAL DEV ADM, NATL ACAD AGR SCI, JEONJU 54874, SOUTH KOREA.; PARK, SANG UN, CHUNGNAM NATL UNIV, DEPT CROP SCI, 99 DAEHAK RO, DAEJEON 34134, SOUTH KOREA.","A TOTAL OF 38 BIOACTIVE COMPOUNDS, INCLUDING GLUCOSINOLATES, CAROTENOIDS, TOCOPHEROLS, STEROLS, AND POLICOSANOLS, WERE CHARACTERIZED FROM NINE VARIETIES OF CHINESE CABBAGE (BRASSICA RAPA L. SUBSP. PEKINENSIS) TO DETERMINE THEIR PHYTOCHEMICAL DIVERSITY AND ANALYZE THEIR ABUNDANCE RELATIONSHIPS. THE METABOLITE PROFILES WERE EVALUATED WITH PRINCIPAL COMPONENT ANALYSIS (PCA), PEARSON CORRELATION ANALYSIS, AND HIERARCHICAL CLUSTERING ANALYSIS (HCA). PCA AND HCA IDENTIFIED TWO DISTINCT VARIETIES OF CHINESE CABBAGE (CHEONSANGCHEONHA AND WALDONGCHEONHA) WITH HIGHER LEVELS OF GLUCOSINOLATES AND CAROTENOIDS. PAIRWISE COMPARISONS OF THE 38 METABOLITES WERE CALCULATED USING PEARSON CORRELATION COEFFICIENTS. THE HCA, WHICH USED THE CORRELATION COEFFICIENTS, CLUSTERED METABOLITES THAT ARE DERIVED FROM CLOSELY RELATED BIOCHEMICAL PATHWAYS. SIGNIFICANT CORRELATIONS WERE DISCOVERED BETWEEN CHLOROPHYLL AND CAROTENOIDS. ADDITIONALLY, ALIPHATIC GLUCOSINOLATE AND CAROTENOID LEVELS WERE POSITIVELY CORRELATED. THE CHEONSANGCHEONHA AND WALDONGCHEONHA VARIETIES APPEAR TO BE GOOD CANDIDATES FOR BREEDING BECAUSE THEY HAVE HIGH GLUCOSINOLATE AND CAROTENOID LEVELS.","CAROTENOIDS; CHINESE CABBAGE; GLUCOSINOLATES; PHYTOSTEROL; POLICOSANOL","VITAMIN-C; ARABIDOPSIS; POLICOSANOL; BIOSYNTHESIS; OLERACEA; VEGETABLES; BROCCOLI; PLANTS; ANTIOXIDANTS; EXPRESSION","NEXT-GENERATION BIOGREEN 21 PROGRAM, RURAL DEVELOPMENT ADMINISTRATION [PJ011911022016]; INCHEON NATIONAL UNIVERSITY RESEARCH GRANT","THIS WORK WAS SUPPORTED BY A GRANT FROM THE NEXT-GENERATION BIOGREEN 21 PROGRAM (PJ011911022016), RURAL DEVELOPMENT ADMINISTRATION, AND THE INCHEON NATIONAL UNIVERSITY RESEARCH GRANT IN 2014.","AMARAL JS, 2006, J AGR FOOD CHEM, V54, P1329, DOI 10.1021/JF052329F; ANONYMOUS, 1990, OFFICIAL JOURNAL OF THE EUROPEAN COMMUNITIES L, V170, P27; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; BJÖRKMAN M, 2011, PHYTOCHEMISTRY, V72, P538, DOI 10.1016/J.PHYTOCHEM.2011.01.014; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/ANNUREV.NU.12.070192.001035; CHEN YZ, 2012, MOL PLANT, V5, P1138, DOI 10.1093/MP/SSS034; DAS S, 2000, CURR SCI INDIA, V79, P1665; RODRÍGUEZ-HERNÁNDEZ MD, 2014, PLANT CELL PHYSIOL, V55, P2047, DOI 10.1093/PCP/PCU130; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HUSEBY S, 2013, J EXP BOT, V64, P1039, DOI 10.1093/JXB/ERS378; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; JEFFERY EH, 2003, J FOOD COMPOS ANAL, V16, P323, DOI 10.1016/S0889-1575(03)00045-0; JUNG HJ, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/204969; KANG JY, 2006, HORTSCIENCE, V41, P1382, DOI 10.21273/HORTSCI.41.6.1382; KIM JK, 2010, FOOD CHEM, V119, P423, DOI 10.1016/J.FOODCHEM.2009.08.051; KIM TJ, 2015, J KOREAN SOC APPL BI, V58, P909, DOI 10.1007/S13765-015-0119-6; KLAIBER J, 2013, J CHEM ECOL, V39, P653, DOI 10.1007/S10886-013-0282-3; KLIEBENSTEIN DJ, 2001, PLANT PHYSIOL, V126, P811, DOI 10.1104/PP.126.2.811; KOPSELL DA, 2004, HORTSCIENCE, V39, P361, DOI 10.21273/HORTSCI.39.2.361; KURILICH AC, 1999, J AGR FOOD CHEM, V47, P1576, DOI 10.1021/JF9810158; KUSHAD MM, 1999, J AGR FOOD CHEM, V47, P1541, DOI 10.1021/JF980985S; LAULE O, 2003, P NATL ACAD SCI USA, V100, P6866, DOI 10.1073/PNAS.1031755100; LEE C. B., 2011, PLANT PHYSIOL, P293; NG CH, 2005, J AGR FOOD CHEM, V53, P6289, DOI 10.1021/JF051269A; PARK SY, 2014, J KOREAN SOC APPL BI, V57, P355, DOI 10.1007/S13765-014-4081-5; PODSEDEK A, 2007, LWT-FOOD SCI TECHNOL, V40, P1, DOI 10.1016/J.LWT.2005.07.023; SAMS CE, 2011, J AM SOC HORTIC SCI, V136, P23, DOI 10.21273/JASHS.136.1.23; SCHONHOF I, 2004, NAHRUNG, V48, P25, DOI 10.1002/FOOD.200300329; SINGH J, 2007, J FOOD COMPOS ANAL, V20, P106, DOI 10.1016/J.JFCA.2006.08.002; STEUER R, 2003, BIOCHEM SOC T, V31, P1476; WATANABE M, 2011, LWT-FOOD SCI TECHNOL, V44, P1971, DOI 10.1016/J.LWT.2011.04.010; WELLBURN AR, 1994, J PLANT PHYSIOL, V144, P307, DOI 10.1016/S0176-1617(11)81192-2; YOUNG AJ, 1991, PHYSIOL PLANTARUM, V83, P702; ZANG YX, 2008, BMB REP, V41, P472, DOI 10.5483/BMBREP.2008.41.6.472; ZANG YX, 2008, MOL CELLS, V25, P231","KIM, JK (CORRESPONDING AUTHOR), INCHEON NATL UNIV, COLL LIFE SCI \& BIOENGN, DIV LIFE SCI, INCHON 22012, SOUTH KOREA","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000377150800028","J AGRIC FOOD CHEM","INCHEON NATL UNIV;CHUNGNAM NATL UNIV;INCHEON NATL UNIV;INST BIOTECHNOL;NATL ACAD AGR SCI;CHUNGNAM NATL UNIV","INCHEON NATL UNIV",NA,"BAEK SA, 2016, J AGRIC FOOD CHEM","BAEK SA, 2016, J AGRIC FOOD CHEM"
"TRABELSI H;RENAUD J;BOUALI I;MAYER P;BOUKHCHINA S","TRABELSI HAJER;RENAUD JUSTIN;BOUALI INTIDHAR;MAYER PAUL;BOUKHCHINA SADOK","EFFECT OF RIPENING STAGE ON ALIPHATIC ALCOHOL 4MONOMETHYLSTEROL AND 44DIMETHYLSTEROL COMPOSITIONS OF IPISTACIA LENTISCUSI FRUIT LENTISC",2016,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","118","770-776",0,"10.1002/ejlt.201500079","TRABELSI, H (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, FAC SCI TUNIS, UNIT BIOCHIM LIPIDES, EL MANAR 2, TUNISIA.; TRABELSI, HAJER; BOUALI, INTIDHAR; BOUKHCHINA, SADOK, UNIV TUNIS EL MANAR, FAC SCI TUNIS, UNIT BIOCHIM LIPIDES, EL MANAR 2, TUNISIA.; RENAUD, JUSTIN; MAYER, PAUL, UNIV OTTAWA, DEPT CHEM, LAB MASS SPECTROMETRY, OTTAWA, ON, CANADA.","FRUITS WERE COLLECTED FROM PISTACIA LENTISCUS TREES AT FIVE DISTINCT STAGES OF DEVELOPMENT, AND LIPID EXTRACT COMPOSITION OF 4-MONOMETHYLSTEROLS, 4,4-DIMETHYLSTEROLS, AND ALIPHATIC ALCOHOL WAS IDENTIFIED AND QUANTIFIED USING GC-MS. FOUR TRITERPENE ALCOHOLS AND TWO 4-METHYLSTEROLS WERE IDENTIFIED BY GC-MS DURING THE RIPENING OF THE LENTISC FRUIT. CYCLOARTENOL IS THE MAJOR COMPONENT OF THE 4,4-DIMETHYLSTEROL FRACTION WITH UP TO 1093 MG/100 G OF OIL IN THE 25TH DAF. THE ACCUMULATION OF MONOMETHYLSTEROLS BEGINS AT 60TH DAF AND PEAKED IN THE 75TH DAF. FURTHERMORE, THIRTEEN ALIPHATIC COMPOUNDS INCLUDING SEVEN BELONGING TO THE POLICOSANOL GROUP HAVE BEEN IDENTIFIED AND QUANTIFIED IN PISTACIA LENTISCUS OIL. DURING THE EARLY STAGES OF LENTISC FRUIT RIPENING, THE ALIPHATIC ALCOHOL FRACTION CONTAINS PREDOMINANTLY POLICOSANOL MOLECULES WHICH ARE HIGHLY PRIZED BY THE FOOD AND PHARMACEUTICAL INDUSTRIES FOR THEIR THERAPEUTIC AND NUTRITIONAL VALUE. PRACTICAL APPLICATIONS ONE OF THE MAIN OBJECTIVES OF INDUSTRY IS TO IDENTIFY PLANT MATRICES RICH IN MOLECULES WITH GOOD NUTRITIONAL VALUE SUCH AS 4-MONOMETHYLSTEROLS AND 4,4-DIMETHYLSTEROLS. THIS STUDY ALLOWED IDENTIFICATION AND MONITORING OF THE DYNAMICS OF ACCUMULATION OF THE LENTISC UNSAPONIFIABLE FRACTION (4-MONOMETHYLSTEROLS, 4,4-DIMETHYLSTEROLS, AND ALIPHATIC ALCOHOLS), WHICH SHOULD CONTRIBUTE TO DETERMINATION OF THE MATURATION STAGES CORRESPONDING TO THE THRESHOLD ACCUMULATION OF CERTAIN MOLECULES WITH GOOD NUTRITIONAL VALUE.","4;4-DIMETHYLSTEROLS; 4-MONOMETHYLSTEROLS; ALIPHATIC ALCOHOLS; PISTACIA; LENTISCUS OIL; POLICOSANOL","4-DESMETHYLSTEROLS; WILD",NA,NA,"ABILIO L. G., 1998, PATENTS, PATENT NO. EP 0619802B1, 0619802; CHERIF AO, 2011, PLANT PHYSIOL BIOCH, V49, P774, DOI 10.1016/J.PLAPHY.2011.02.009; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P12143, DOI 10.1021/JF1030345; CLARDY J, 2004, NATURE, V432, P829, DOI 10.1038/NATURE03194; GOODWIN TW, 1979, ANNU REV PLANT PHYS, V30, P369, DOI 10.1146/ANNUREV.PP.30.060179.002101; HARRABI S., 2008, THESIS FACULTE SCI T; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; KATZ H.D., UTILISATION ALCOOLS; KOEHN FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/NRD1657; LE FLOC'H E, 1983, CONTRIBUTION ETUDE E, P144; MALECKA M, 2002, FOOD CHEM, V79, P327, DOI 10.1016/S0308-8146(02)00152-8; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; TRABELSI H, 2012, FOOD CHEM, V131, P434, DOI 10.1016/J.FOODCHEM.2011.08.083; WEBER N, 1982, PLANTA, V155, P225, DOI 10.1007/BF00392720","TRABELSI, H (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, FAC SCI TUNIS, UNIT BIOCHIM LIPIDES, EL MANAR 2, TUNISIA","WILEY","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","WOS000375877400011","EUR J LIPID SCI TECHNOL","UNIV TUNIS EL MANAR;UNIV TUNIS EL MANAR;UNIV OTTAWA","UNIV TUNIS EL MANAR",NA,"TRABELSI H, 2016, EUR J LIPID SCI TECHNOL","TRABELSI H, 2016, EUR J LIPID SCI TECHNOL1"
"DE C I;SOLA R;MARIA V R;BREA ;ANGEL A;MOZAS P;PUZO J;POCOVI M","DE CASTRO-OROS ISABEL;SOLA ROSA;MARIA VALLS ROSA;BREA; ANGEL;MOZAS PILAR;PUZO JOSE;POCOVI MIGUEL","GENETIC VARIANTS OF ILDLRI AND IPCSK9I ASSOCIATED WITH VARIATIONS IN RESPONSE TO ANTIHYPERCHOLESTEROLEMIC EFFECTS OF ARMOLIPID PLUS WITH BERBERINE",2016,"PLOS ONE","11",NA,18,"10.1371/journal.pone.0150785","DE CASTRO-ORÓS, I (CORRESPONDING AUTHOR), UNIV ZARAGOZA, IIS ARAGON, DEPT BIOQUIM \& BIOL MOL \& CELULAR, ZARAGOZA, SPAIN.; DE CASTRO-OROS, ISABEL; MOZAS, PILAR; POCOVI, MIGUEL, UNIV ZARAGOZA, IIS ARAGON, DEPT BIOQUIM \& BIOL MOL \& CELULAR, ZARAGOZA, SPAIN.; MARIA VALLS, ROSA, UNIV ROVIRA \& VIRGILI, IISPV FAC MED, UNITAT RECERCA LIPIDS \& ARTERIOSCLEROSI, CIBERDEM,SERV MED INTERNA,HOSP UNIV SAN JOAN, C ST LLORENC 21, E-43201 REUS, SPAIN.; SOLA, ROSA; BREA, ANGEL, HOSP UNIV SAN PEDRO, MED INTERNA SERV, UNIDAD LIPIDOS, LOGRONO, SPAIN.; PUZO, JOSE, HOSP UNIV MIGUEL SERVET, SERV BIOQUIM CLIN, ZARAGOZA, SPAIN.","BACKGROUND ARMOLIPID PLUS (AP) IS A NUTRACEUTICAL THAT CONTAINS POLICOSANOL, FERMENTED RICE WITH RED YEAST, BERBERINE, COENZYME Q10, FOLIC ACID, AND ASTAXANTHIN. IT HAS BEEN SHOWN TO BE EFFECTIVE IN REDUCING PLASMA LDL CHOLESTEROL (LDLC) LEVELS. IN THE MULTICENTER RANDOMIZED TRIAL NCT01562080, THERE WAS LARGE INTERINDIVIDUAL VARIABILITY IN THE PLASMA LDLC RESPONSE TO AP SUPPLEMENTATION. WE HYPOTHESIZED THAT THE VARIABILITY IN LDLC RESPONSE TO AP SUPPLEMENTATION MAY BE LINKED TO LDLR AND PCSK9 POLYMORPHISMS. MATERIAL AND METHODS WE SEQUENCED THE LDLR 30 AND 50 UNTRANSLATED REGIONS (UTR) AND THE PCSK9 5' UTR OF 102 PARTICIPANTS WITH MODERATE HYPERCHOLESTEROLEMIA IN TRIAL NCT01562080. IN THIS TRIAL, 50 INDIVIDUALS WERE TREATED WITH AP SUPPLEMENTATION AND THE REST WITH PLACEBO. RESULTS MULTIPLE LINEAR REGRESSION ANALYSIS, USING THE RESPONSE OF LDLC LEVELS TO AP AS THE DEPENDENT VARIABLE, REVEALED THAT POLYMORPHISMS RS2149041 (C.-3383C>G) IN THE PCSK9 50 UTR AND RS14158 (C.*52G>A) IN THE LDLR 30 UTR EXPLAINED 14.1\% AND 6.4\%, RESPECTIVELY, OF THE VARIABILITY AFTER ADJUSTING FOR GENDER, AGE, AND BMI OF INDIVIDUALS. COMBINING POLYMORPHISMS RS2149041 AND RS14158 EXPLAINED 20.5\% OF THIS VARIABILITY (P < 0.004). CONCLUSIONS THREE POLYMORPHISMS IN THE 30 UTR REGION OF LDLR, C.*52G>A, C.*504G>A, AND C.*773A>G, AND TWO AT THE 50 UTR REGION OF PCSK9, C.-3383C>G AND C.-2063A>G, WERE ASSOCIATED WITH RESPONSE TO AP. THESE RESULTS COULD EXPLAIN THE VARIABILITY OBSERVED IN THE RESPONSE TO BERBERINE AMONG PEOPLE WITH MODERATE HYPERCHOLESTEROLEMIA, AND THEY MAY BE USEFUL IN IDENTIFYING PATIENTS WHO COULD POTENTIALLY BENEFIT FROM SUPPLEMENTATION WITH AP.",NA,"3' UNTRANSLATED REGION; RECEPTOR MESSENGER-RNA; CORONARY-HEART-DISEASE; RED YEAST RICE; SERUM-CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME; STATINS; PROTEIN; EXPRESSION","FONDO DE INVESTIGACION SANITARIA (FIS) [PI12/01703]; ROTTAPHARM S.L.","THIS WORK WAS SUPPORTED BY GRANTS FROM THE FONDO DE INVESTIGACION SANITARIA (FIS) PI12/01703 AND ROTTAPHARM S.L. THE FUNDERS HAD NO ROLE IN STUDY DESIGN, DATA COLLECTION AND ANALYSIS, DECISION TO PUBLISH, OR PREPARATION OF THE MANUSCRIPT.","AFFUSO F, 2012, WORLD J CARDIOL, V4, P77, DOI 10.4330/WJC.V4.I3.77; BEYNEN AC, 1985, ATHEROSCLEROSIS, V57, P19, DOI 10.1016/0021-9150(85)90134-0; BEYNEN AC, 1987, ADV LIPID RES, V22, P115; CAMERON J, 2008, ATHEROSCLEROSIS, V201, P266, DOI 10.1016/J.ATHEROSCLEROSIS.2008.02.004; CHEN W, 2008, INT J MOL MED, V21, P345; COLLINS R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DE CASTRO-ORÓS I, 2011, HUM MUTAT, V32, P868, DOI 10.1002/HUMU.21520; DONG B, 2015, J BIOL CHEM, V290, P4047, DOI 10.1074/JBC.M114.597229; GERARDS MC, 2015, ATHEROSCLEROSIS, V240, P415, DOI 10.1016/J.ATHEROSCLEROSIS.2015.04.004; GUYTON JR, 2014, J CLIN LIPIDOL, V8, PS72, DOI 10.1016/J.JACL.2014.03.002; IZZO R, 2010, J HYPERTENS, V28, P1482, DOI 10.1097/HJH.0B013E3283395208; JACOBS DR, 1983, ARTERIOSCLEROSIS, V3, P349, DOI 10.1161/01.ATV.3.4.349; KATAN MB, 1986, AM J EPIDEMIOL, V123, P221, DOI 10.1093/OXFORDJOURNALS.AJE.A114231; KONG WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/NM1135; LEE IT, 2012, NUTR RES, V32, P85, DOI 10.1016/J.NUTRES.2011.12.011; LI H, 2009, J BIOL CHEM, V284, P28885, DOI 10.1074/JBC.M109.052407; LIU J.N., 2006, CHINAS IMAGE INT VIE, P1; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; PEDERSEN TR, 1994, LANCET, V344, P1383; PISCIOTTA L, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-123; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SINGH AB, 2014, ARTERIOSCL THROM VAS, V34, P8, DOI 10.1161/ATVBAHA.112.301131; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SIRTORI CR, 2012, ANN MED, V44, P419, DOI 10.3109/07853890.2011.582135; SOLA R, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0101978; TIWARI A, 2006, EXPERT OPIN DRUG SAF, V5, P651, DOI 10.1517/14740338.5.5.651; TRIMARCO B, 2011, MEDITERR J NUTR META, V4, P133, DOI 10.1007/S12349-010-0043-6; WILSON GM, 1998, J LIPID RES, V39, P1025","DE CASTRO-ORÓS, I (CORRESPONDING AUTHOR), UNIV ZARAGOZA, IIS ARAGON, DEPT BIOQUIM \& BIOL MOL \& CELULAR, ZARAGOZA, SPAIN","PUBLIC LIBRARY SCIENCE","ENGLISH","PLOS ONE","ARTICLE","ISI","WOS000372708900023","PLOS ONE","UNIV ZARAGOZA;UNIV ZARAGOZA;UNIV ROVIRA AND VIRGILI;HOSP UNIV SAN PEDRO;HOSP UNIV MIGUEL SERVET","UNIV ZARAGOZA",NA,"DE CASTRO-OROS I, 2016, PLOS ONE","DE CASTRO-OROS I, 2016, PLOS ONE"
"LIU T;WU C;HE F;YUAN W;LI S;LI ;H. W H;YU H;WU M","LIU T N;WU C T;HE F;YUAN W;LI S X;LI; H W;YU H Y;WU M","RELATIONSHIP BETWEEN THE G75A POLYMORPHISM IN THE APOLIPOPROTEIN A1 IAPOA1I GENE AND THE LIPID REGULATORY EFFECTS OF PRAVASTATIN IN PATIENTS WITH HYPERLIPIDEMIA",2016,"GENETICS AND MOLECULAR RESEARCH","15",NA,2,"10.4238/gmr.15028216","WU, M (CORRESPONDING AUTHOR), PEOPLES HOSP TANGSHAN, TANGSHAN, PEOPLES R CHINA.; LIU, T. N.; WU, C. T.; HE, F.; YUAN, W.; LI, S. X.; LI, H. W.; YU, H. Y., NORTH CHINA UNIV TECHNOL, AFFILIATED HOSP, DIV CARDIOVASC, TANGSHAN, HEBEI, PEOPLES R CHINA.; WU, M., PEOPLES HOSP TANGSHAN, TANGSHAN, PEOPLES R CHINA.","IN THIS STUDY, WE INVESTIGATED THE RELATIONSHIP BETWEEN THE G75A POLYMORPHISM IN THE APOLIPOPROTEIN A1 (APOA1) GENE AND THE LIPID REGULATORY EFFECT OF PRAVASTATIN IN PATIENTS WITH HYPERLIPIDEMIA. A TOTAL OF 179 PATIENTS WERE DIVIDED INTO TWO GROUPS: THE PRAVASTATIN (N = 97) AND POLICOSANOL (N = 82) TREATMENT GROUPS. THE TOTAL CHOLESTEROL (TC), TRIGLYCERIDE, LOW-DENSITY LIPOPROTEIN (LDL-C), HIGH-DENSITY LIPOPROTEIN, APOA, AND APOB CONCENTRATIONS IN THE SERUM WERE MEASURED USING AN AUTOMATIC BIOCHEMICAL ANALYZER BEFORE AND AFTER TREATMENT FOR 12 WEEKS. THE GENOTYPES OF THE APOA1 G75A SNP WERE DETECTED BY POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM, AND WERE SUBSEQUENTLY STATISTICALLY ANALYZED. PRAVASTATIN TREATMENT INDUCED A SIGNIFICANT DECREASE IN THE TC, LDL-C, AND APOB LEVELS IN PATIENTS EXPRESSING THE APOA1 AA+GA GENOTYPE (P < 0.05), AND NOT IN THOSE EXPRESSING THE GG GENOTYPE (P > 0.05). HOWEVER, POLICOSANOL TREATMENT INDUCED A NON-SIGNIFICANT DECREASE IN THE SERUM TC LEVELS (P > 0.05) AND A SIGNIFICANT DECREASE IN THE APOB LEVELS (P < 0.05), AND DID NOT INDUCE A DECREASE IN THE LDL-C (P > 0.05) LEVELS IN PATIENTS WITH THE AA+GA GENOTYPE. POLICOSANOL ALSO INDUCED A SIGNIFICANT DECREASE IN THE TC AND LDL-C LEVELS IN PATIENTS WITH THE GG GENOTYPE (P < 0.05). THE VARIOUS GENOTYPES OF THE APOA1 G75A SNP INFLUENCE THE EFFICACY OF LIPID REGULATION BY PRAVASTATIN AND POLICOSANOL IN PATIENTS WITH HYPERLIPIDEMIA.","HYPERLIPIDEMIA; APOLIPOPROTEIN A1; TOTAL CHOLESTEROL; PRAVASTATIN; POLICOSANOL; GENE POLYMORPHISM","I GENE; PROMOTER POLYMORPHISM; HYPERLIPEMIA; ASSOCIATION; CHOLESTEROL; STATINS; REGION",NA,NA,"CANNIOTO Z, 2008, MED BAMBINO, V27, P309; FAN Y, 2010, ZHONGHUA LAONIAN XIN, V42, P910; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P57, DOI 10.1089/109662001300341707; GOMEZ P, 2010, J NUTR, V140, P773, DOI 10.3945/JN.109.115964; JEENAH M, 1990, MOL BIOL MED, V7, P233; LAHOZ C, 2003, ATHEROSCLEROSIS, V168, P289, DOI 10.1016/S0021-9150(03)00094-7; MARSH JB, 1960, METABOLISM, V9, P946; MATSUNAGA A, 1995, NUTR METAB CARDIOVAS, V5, P269; MCCARTY MF, 2002, MED HYPOTHESES, V59, P268, DOI 10.1016/S0306-9877(02)00226-8; NORDOY A, 2001, NUTR METAB CARDIOVAS, V11, P7; PAGANI F, 1990, J LIPID RES, V31, P1371; SMITH JD, 1992, J CLIN INVEST, V89, P1796, DOI 10.1172/JCI115783; STANCU C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/J.1582-4934.2001.TB00172.X; VAUGHAN CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969","WU, M (CORRESPONDING AUTHOR), PEOPLES HOSP TANGSHAN, TANGSHAN, PEOPLES R CHINA","FUNPEC-EDITORA","ENGLISH","GENET. MOL. RES.","ARTICLE","ISI","WOS000384881000063","GENET MOL RES","PEOPLES HOSP TANGSHAN;NORTH CHINA UNIV TECHNOL;PEOPLES HOSP TANGSHAN","PEOPLES HOSP TANGSHAN",NA,"LIU TN, 2016, GENET MOL RES","LIU TN, 2016, GENET MOL RES1"
"WONG W;ISMAIL M;TOHIT E;ABDULLAH R;ZHANG Y","WONG WAI-TENG;ISMAIL MAZNAH;TOHIT EUSNI RAHAYU MOHD; ABDULLAH RASEDEE;ZHANG YI-DA","ATTENUATION OF THROMBOSIS BY CRUDE RICE IORYZA SATIVAI BRAN POLICOSANOL EXTRACT IEX VIVOI PLATELET AGGREGATION AND SERUM LEVELS OF ARACHIDONIC ACID METABOLITES",2016,"EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE","2016",NA,17,"10.1155/2016/7343942","WONG, WT (CORRESPONDING AUTHOR), UNIV PUTRA MALAYSIA, INST BIOSCI, LAB MOL BIOMED, SERDANG 43400, SELANGOR, MALAYSIA.; WONG, WAI-TENG; ISMAIL, MAZNAH; ZHANG, YI-DA, UNIV PUTRA MALAYSIA, INST BIOSCI, LAB MOL BIOMED, SERDANG 43400, SELANGOR, MALAYSIA.; ISMAIL, MAZNAH, UNIV PUTRA MALAYSIA, DEPT NUTR \& DIETET, FAC MED \& HLTH SCI, SERDANG 43400, SELANGOR, MALAYSIA.; TOHIT, EUSNI RAHAYU MOHD, UNIV PUTRA MALAYSIA, FAC MED \& HLTH SCI, DEPT PATHOL, SERDANG 43400, SELANGOR, MALAYSIA.; ABDULLAH, RASEDEE, UNIV PUTRA MALAYSIA, FAC VET MED, DEPT VET LAB DIAGNOST, SERDANG 43400, SELANGOR, MALAYSIA.; ZHANG, YI-DA, CHENGDE MED UNIV, AFFILIATED HOSP, DEPT CARDIOL, CHENGDE 067000, HEBEI, PEOPLES R CHINA.","BACKGROUND. VASCULAR OCCLUSION OR THROMBOSIS WAS OFTEN ATTRIBUTED TO UNCONTROLLED PLATELET ACTIVATION. INFLUENCE OF SUGARCANE POLICOSANOL EXTRACT ON PLATELET WAS REPORTED BUT LITTLE WAS KNOWN OF RICE BRAN POLICOSANOL, PARTICULARLY ITS MECHANISMS OF ACTIONS ON PLATELET ACTIVITIES. OBJECTIVE. ANTIPLATELET MECHANISMS OF RICE BRAN POLICOSANOL EXTRACT (RBE) WERE STUDIED USING HYPERLIPIDEMIC SPRAGUE DAWLEY RATS. EX VIVO PLATELET AGGREGATION, PLATELET COUNT (PC), BLEEDING TIME (BT), AND COAGULATION TIME WERE ASSAYED. SERUM EICOSANOIDS AND OTHER AGGREGATION-RELATED METABOLITES LEVELS WERE QUANTIFIED. DESIGN. RATS WERE DIVIDED INTO 6 GROUPS FOR COMPARISONS (VEHICLE CONTROL TWEEN 20/H2O, HIGH DOSE POLICOSANOL 500 MG/KG, MIDDLE DOSE POLICOSANOL 250 MG/KG, LOW DOSE POLICOSANOL 100 MG/KG, AND POSITIVE CONTROL ASPIRIN 30 MG/KG). RESULTS. LOW DOSE 100 MG/KG OF RBE INHIBITED AGGREGATION BY 42.32 +/- 4.31\% AND THIS WAS COMPARABLE WITH THE EFFECT OF 30MG/KG ASPIRIN, 43.91 +/- 5.27\%. RESULTS SHOWED THAT THERE WERE NO SIGNIFICANT DIFFERENCES IN PC, BT, AND COAGULATION TIME AMONG VARIOUS GROUPS AFTER RBE TREATMENT. SERUM THROMBOXANE A(2) WAS ATTENUATED WHILE PROSTACYCLIN LEVEL INCREASED UPON RBE TREATMENT. CONCLUSIONS. RBE REDUCED EX VIVO ADP-INDUCED PLATELET AGGREGATION WITHOUT GIVING ADVERSE EFFECTS. NO CHANGES IN FULL BLOOD COUNT SUGGESTED THAT RICE BRAN POLICOSANOL DID NOT DISTURB BIOLOGICAL BLOOD CELL PRODUCTION AND DESTRUCTION YET IT REDUCED AGGREGATION THROUGH DIFFERENT MECHANISMS.",NA,"P-SELECTIN; IN-VITRO; ACTIVATION; EXPRESSION","MINISTRY OF EDUCATION MALAYSIA [6228130]","THE FINANCIAL SUPPORT FROM MINISTRY OF EDUCATION MALAYSIA (KNOWLEDGE TRANSFER PROGRAM, PROJECT NO. 6228130) IS GRATEFULLY ACKNOWLEDGED. THE AUTHORS THANK PADIBERAS NASIONAL BERHAD (SELANGOR, MALAYSIA) FOR PROVIDING RICE MILLING BY-PRODUCT AND IBS STAFFS FOR THE KIND ASSISTANCE. THE AUTHORS WOULD LIKE TO ACKNOWLEDGE MUSTAPHA UMAR IMAM WHO PARTICIPATED IN ANALYZING THE DATA AND DRAFTING THE MANUSCRIPT.","AOKI R, 2006, THROMB RES, V117, P529, DOI 10.1016/J.THROMRES.2005.04.022; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; BOUKERCHE H, 1996, BRIT J HAEMATOL, V92, P442, DOI 10.1046/J.1365-2141.1996.D01-1485.X; CARBAJAL D, 1994, PROSTAG LEUKOTR ESS, V50, P249, DOI 10.1016/0952-3278(94)90162-7; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; CICERO AFG, 2001, PHYTOTHER RES, V15, P277, DOI 10.1002/PTR.907; DIAZ MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; FRAGA V, 1997, ARCH MED RES, V28, P355; GADI D, 2009, J ETHNOPHARMACOL, V125, P170, DOI 10.1016/J.JEP.2009.05.014; GREGG D, 2003, CIRCULATION, V108, PE88, DOI 10.1161/01.CIR.0000086897.15588.4B; HOLMES MB, 1999, THROMB RES, V95, P75, DOI 10.1016/S0049-3848(99)00019-5; 김현홍, 2014, BIOMEDICAL SCIENCE LETTERS, 대한의생명과학회지, V20, P129, DOI 10.15616/BSL.2014.20.3.129; IMAM MU, 2012, INT J MOL SCI, V13, P8597, DOI 10.3390/IJMS13078597; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; JIN J., BLOOD, V99; JOHNSON S, 2008, THROMB RES, V123, PS7, DOI 10.1016/J.THROMRES.2008.08.011; 김현홍, 2015, BIOMEDICAL SCIENCE LETTERS, 대한의생명과학회지, V21, P103, DOI 10.15616/BSL.2015.21.2.103; LEVIN BE, 1989, AM J PHYSIOL, V256, PR766, DOI 10.1152/AJPREGU.1989.256.3.R766; MAY AE, 2008, ARTERIOSCL THROM VAS, V28, PS5, DOI 10.1161/ATVBAHA.107.158915; MICHELSON A D, 1999, CURR OPIN HEMATOL, V6, P342, DOI 10.1097/00062752-199909000-00012; MOLINA V, 2003, PROSTAG LEUKOTR ESS, V68, P305, DOI 10.1016/S0952-3278(03)00020-6; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; MOSA R. A., 2011, THESIS; PERUMAL RAMESH, 2014, J INDIAN SOC PERIODONTOL, V18, P293, DOI 10.4103/0972-124X.134563; PRAGA C, 1972, ADV EXPT MED BIOL, V34, P146; RINDER HM, 1991, BLOOD, V78, P1730; RODRIGUEZ MD, 1997, TOXICOL LETT, V90, P97, DOI 10.1016/S0378-4274(96)03844-1; RYU KH, 2009, THROMB RES, V124, P328, DOI 10.1016/J.THROMRES.2009.02.010; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TIAN Z, 2001, ZHONG YAO CAI, V24, P507; VAIYAPURI S., 2011, MINIATURISED PLATELE; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WANG YY, 2004, ACTA PHARMACOL SIN, V25, P469; WHAYNE TF, 2007, INT J ANGIOL, V16, P12, DOI 10.1055/S-0031-1278237; WILLOUGHBY SCOTT, 2002, EUR J CARDIOVASC NURS, V1, P273","WONG, WT (CORRESPONDING AUTHOR), UNIV PUTRA MALAYSIA, INST BIOSCI, LAB MOL BIOMED, SERDANG 43400, SELANGOR, MALAYSIA","HINDAWI LTD","ENGLISH","EVID.-BASED COMPLEMENT ALTERN. MED.","ARTICLE","ISI","WOS000385777400001","EVID-BASED COMPLEMENT ALTERN MED","UNIV PUTRA MALAYSIA;UNIV PUTRA MALAYSIA;UNIV PUTRA MALAYSIA;UNIV PUTRA MALAYSIA;UNIV PUTRA MALAYSIA;CHENGDE MED UNIV","UNIV PUTRA MALAYSIA",NA,"WONG WT, 2016, EVID-BASED COMPLEMENT ALTERN MED","WONG WT, 2016, EVID-BASED COMPLEMENT ALTERN MED"
"DEL R J;MARQUES G;LINO A;LIMA ;CLAUDIO F C;COLODETTE J;GUTIERREZ A","DEL RIO JOSE C;MARQUES GISELA;LINO ALESSANDRO G;LIMA; CLAUDIO F;COLODETTE JORGE L;GUTIERREZ ANA","LIPOPHILIC PHYTOCHEMICALS FROM SUGARCANE BAGASSE AND STRAW",2015,"INDUSTRIAL CROPS AND PRODUCTS","77","992-1000",40,"10.1016/j.indcrop.2015.09.064","DEL RÍO, JC (CORRESPONDING AUTHOR), CSIC, INST RECURSOS NAT \& AGROBIOL, POB 1052, E-41080 SEVILLE, SPAIN.; DEL RIO, JOSE C.; MARQUES, GISELA; LINO, ALESSANDRO G.; GUTIERREZ, ANA, CSIC, INST RECURSOS NAT \& AGROBIOL, E-41080 SEVILLE, SPAIN.; LINO, ALESSANDRO G.; LIMA, CLAUDIO F., UNIV FED VICOSA, DEPT CHEM, BR-36570000 VICOSA, MG, BRAZIL.; COLODETTE, JORGE L., UNIV FED VICOSA, DEPT FORESTRY ENGN, BR-36570000 VICOSA, MG, BRAZIL.","THE COMPOSITION OF LIPOPHILIC PHYTOCHEMICALS IN SUGARCANE BAGASSE AND STRAW, THE TWO MAJOR RESIDUES OF SUGARCANE PROCESSING, WAS INVESTIGATED IN DETAIL BY GAS CHROMATOGRAPHY AND MASS SPECTROMETRY. THE COMPOSITION OF THE LIPIDS FROM SUGARCANE BAGASSE AND STRAW WAS COMPLETELY DIFFERENT FROM EACH OTHER. WHILE THE EXTRACTS OF SUGARCANE BAGASSE WERE DOMINATED BY N-ALDEHYDES (CA. 48\% OF ALL IDENTIFIED LIPIDS) AND N-FATTY ALCOHOLS (CA. 23\%) WITH LOWER AMOUNTS OF N-FATTY ACIDS (10\%) AND STEROID KETONES (14\%), THE EXTRACTS FROM SUGARCANE STRAW WERE STRONGLY DOMINATED BY N-FATTY ACIDS (ACCOUNTING FOR CA. 60\% OF ALL IDENTIFIED COMPOUNDS) WITH SIGNIFICANT AMOUNTS OF STEROID COMPOUNDS, PARTICULARLY STEROLS (10\%) AND STEROID KETONES (14\%). TOCOPHEROLS AND TRITERPENOLS WERE ALSO FOUND, BEING PARTICULARLY ABUNDANT AMONG THE EXTRACTIVES OF SUGARCANE STRAW. SUGARCANE BAGASSE AND STRAW CAN THUS BE CONSIDERED AS PROMISING FEEDSTOCKS FOR OBTAINING HIGHLY VALUABLE PHYTOCHEMICALS OF NUTRACEUTICAL OR PHARMACEUTICAL INTEREST. (C) 2015 ELSEVIER B.V. ALL RIGHTS RESERVED.","SUGARCANE BAGASSE; SUGARCANE STRAW; ALDEHYDES; ALCOHOLS; FATTY ACIDS; STEROLS","CHEMICAL-COMPOSITION; POLICOSANOL; LIPIDS; EXTRACTION; TOCOPHEROLS; FATE; WOOD","SPANISH PROJECTS [AGL2011-25379, AGL2014-53730-R]; FEDER FUNDS; CSIC PROJECT [2014-40E-097]; EU-PROJECT INDOX [KBBE-2013-7-613549]; CAPES (COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE NIVEL SUPERIOR); NATIONAL COUNCIL FOR SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT (CNPQ)","THIS STUDY HAS BEEN FUNDED BY THE SPANISH PROJECTS AGL2011-25379 AND AGL2014-53730-R (CO-FINANCED BY FEDER FUNDS), THE CSIC PROJECT 2014-40E-097 AND THE EU-PROJECT INDOX (KBBE-2013-7-613549). ALESSANDRO G. LINO THANKS CAPES (COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE NIVEL SUPERIOR) FOR FINANCIAL SUPPORT. C.F. LIMA AND J.L. COLODETTE ARE GRATEFUL TO NATIONAL COUNCIL FOR SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT (CNPQ) FOR RESEARCH FELLOWSHIPS.","ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ASIKIN Y, 2012, EUR J LIPID SCI TECH, V114, P583, DOI 10.1002/EJLT.201100300; BENJAMIN Y, 2014, IND CROP PROD, V58, P133, DOI 10.1016/J.INDCROP.2014.04.010; BIANCHI G., 1995, WAXES: CHEMISTRY, MOLECULAR BIOLOGY AND FUNCTIONS, P175; DE LUCAS A, 2007, J SUPERCRIT FLUID, V41, P267, DOI 10.1016/J.SUPFLU.2006.09.013; ROCHA GJD, 2015, IND CROP PROD, V64, P52, DOI 10.1016/J.INDCROP.2014.11.003; DE SOUZA AP, 2014, BIOENERG RES, V7, P24, DOI 10.1007/S12155-013-9366-8; DEL RÍO JC, 2015, BIOMASS BIOENERG, V81, P322, DOI 10.1016/J.BIOMBIOE.2015.07.006; DEL RÍO JC, 2013, J CEREAL SCI, V58, P248, DOI 10.1016/J.JCS.2013.07.001; DEL RÍO JC, 2013, J AGR FOOD CHEM, V61, P1904, DOI 10.1021/JF304252M; DESHMANE SS, 1971, TETRAHEDRON, V27, P1109, DOI 10.1016/S0040-4020(01)90858-0; FENG SM, 2014, J SEP SCI, V37, P1308, DOI 10.1002/JSSC.201301316; FENG SM, 2014, FOOD CHEM, V151, P452, DOI 10.1016/J.FOODCHEM.2013.11.057; GEORGES P, 2006, STEROIDS, V71, P647, DOI 10.1016/J.STEROIDS.2006.01.016; GOLDEMBERG J, 2008, BIOTECHNOL BIOFUELS, V1, DOI 10.1186/1754-6834-1-6; GUNENC A, 2013, FOOD RES INT, V51, P571, DOI 10.1016/J.FOODRES.2013.01.033; GUTIÉRREZ A, 1998, J CHROMATOGR A, V823, P449, DOI 10.1016/S0021-9673(98)00356-2; GUTIÉRREZ A, 2003, J AGR FOOD CHEM, V51, P4965, DOI 10.1021/JF034370T; GUTIÉRREZ A, 2001, RAPID COMMUN MASS SP, V15, P2515, DOI 10.1002/RCM.537; HERNANDEZ E., 2005, BAILEYS IND OIL FAT, P391; KALAC PAVEL, 2012, JOURNAL OF AGROBIOLOGY, V29, P1, DOI 10.2478/V10146-012-0001-7; METZGER JO, 2006, APPL MICROBIOL BIOT, V71, P13, DOI 10.1007/S00253-006-0335-4; NOA M, 2005, ARCH MED RES, V36, P441, DOI 10.1016/J.ARCMED.2005.03.039; NUISSIER G, 2002, PHYTOCHEMISTRY, V61, P721, DOI 10.1016/S0031-9422(02)00356-4; OHMOTO T, 1970, PHYTOCHEMISTRY, V9, P2137, DOI 10.1016/S0031-9422(00)85379-0; OLIVEIRA LRM, 2014, IND CROP PROD, V58, P1, DOI 10.1016/J.INDCROP.2014.03.037; ORTIZ PS, 2014, ENERGY, V76, P130, DOI 10.1016/J.ENERGY.2014.04.090; PIETARINEN SP, 2006, J WOOD SCI, V52, P436, DOI 10.1007/S10086-005-0780-1; PRINSEN P, 2014, J AGR FOOD CHEM, V62, P1664, DOI 10.1021/JF404772B; PRINSEN P, 2012, J AGR FOOD CHEM, V60, P6408, DOI 10.1021/JF301753W; PURCELL DE, 2005, CHEMOMETR INTELL LAB, V76, P135, DOI 10.1016/J.CHEMOLAB.2004.10.004; SANTOS F., 2012, SUGARCANE: BIOENERGY, SUGAR AND ETHANOL; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SNYDER JM, 1993, J AM OIL CHEM SOC, V70, P349, DOI 10.1007/BF02552705; TULLOCH AP., 1976, CHEMISTRY AND BIOCHEMISTRY OF NATURAL WAXES, P236; VILLAVERDE JJ, 2010, J AGR FOOD CHEM, V58, P8279, DOI 10.1021/JF101174X; ZARNOWSKI R, 2002, Z NATURFORSCH C, V57, P57","DEL RÍO, JC (CORRESPONDING AUTHOR), CSIC, INST RECURSOS NAT \& AGROBIOL, POB 1052, E-41080 SEVILLE, SPAIN","ELSEVIER","ENGLISH","IND. CROP. PROD.","ARTICLE","ISI","WOS000366065200117","IND CROP PROD","INST RECURSOS NAT AND AGROBIOL;INST RECURSOS NAT AND AGROBIOL;UNIV FED VICOSA;UNIV FED VICOSA","INST RECURSOS NAT AND AGROBIOL",NA,"DEL RIO JC, 2015, IND CROP PROD","DEL RIO JC, 2015, IND CROP PROD"
"MARAZZI G;PELLICCIA F;CAMPOLONGO G;QUATTRINO S;CACCIOTTI L;VOLTERRANI M;GAUDIO C;ROSANO G","MARAZZI GIUSEPPE;PELLICCIA FRANCESCO;CAMPOLONGO GIUSEPPE; QUATTRINO SILVIA;CACCIOTTI LUCA;VOLTERRANI MAURIZIO; GAUDIO CARLO;ROSANO GIUSEPPE","USEFULNESS OF NUTRACEUTICALS ARMOLIPID PLUS VERSUS IEZETIMIBEI AND COMBINATION IN STATININTOLERANT PATIENTS WITH DYSLIPIDEMIA WITH CORONARY HEART DISEASE",2015,"AMERICAN JOURNAL OF CARDIOLOGY","116","1798-1801",37,"10.1016/j.amjcard.2015.09.023","MARAZZI, G (CORRESPONDING AUTHOR), IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA, ROME, ITALY.; MARAZZI, GIUSEPPE; CAMPOLONGO, GIUSEPPE; QUATTRINO, SILVIA; VOLTERRANI, MAURIZIO; ROSANO, GIUSEPPE, IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA, ROME, ITALY.; PELLICCIA, FRANCESCO; GAUDIO, CARLO, UNIV ROMA LA SAPIENZA, DEPT CARDIOVASC SCI, ROME, ITALY.; CACCIOTTI, LUCA, MADRE GIUSEPPINA VANNINI HOSP, INST CARDIOL, ROME, ITALY.","STATINS ARE EXTENSIVELY USED TO TREAT DYSLIPIDEMIA, BUT, BECAUSE OF THEIR LOW TOLERABILITY PROFILE, THEY ARE DISCONTINUED IN A SIGNIFICANT PROPORTION OF PATIENTS. EZETIMIBE AND NUTRACEUTICALS HAVE BEEN INTRODUCED AS ALTERNATIVE THERAPIES AND HAVE PROVED TO BE EFFECTIVE AND WELL TOLERATED. A SINGLE-BLIND, SINGLE-CENTER, RANDOMIZED, PROSPECTIVE, AND PARALLEL GROUP TRIAL COMPARING A COMBINATION OF NUTRACEUTICALS (RED YEAST RICE, POLICOSANOL, BERBERINE, FOLIC ACID, COENZYME Q10 AND ASTAXANTHIN), CALLED ARMOLIPID PLUS, AND EZETIMIBE FOR 3 MONTHS IN TERMS OF EFFICACY AND TOLERABILITY. PATIENTS WHO DID NOT ACHIEVE THEIR THERAPEUTIC TARGET (LOW-DENSITY LIPOPROTEIN CHOLESTEROL <100 MG/DL) COULD ADD THE ALTERNATIVE TREATMENT ON TOP OF RANDOMIZED TREATMENT FOR ANOTHER 12 MONTHS: 100 PATIENTS WHO ARE DYSLIPIDEMIC WITH ISCHEMIC HEART DISEASE TREATED WITH PERCUTANEOUS CORONARY INTERVENTION WERE ENROLLED (EZETIMIBE N = 50, NUTRACEUTICAL N = 50). EFFICACY (LIPID PROFILE) AND TOLERABILITY (ADVERSE EVENTS, TRANSAMINASES, AND CREATINE KINASE) WERE ASSESSED AFTER 3 AND 12 MONTHS. AFTER 3 MONTHS, 14 PATIENTS IN THE NUTRACEUTICAL GROUP ACHIEVED THEIR THERAPEUTIC TARGET, WHEREAS NONE OF THE PATIENTS IN THE EZETIMIBE GROUP DID. AT 1-YEAR FOLLOW-UP, 58 PATIENTS (72.5\%) OF THE COMBINED THERAPY GROUP (N = 86) AND 14 (100\%) OF THE NUTRACEUTICAL GROUP REACHED THE THERAPEUTIC GOAL. NO PATIENTS EXPERIENCED IMPORTANT UNDESIRABLE EFFECTS. IN CONCLUSION, NUTRACEUTICALS ALONE OR IN COMBINATION WITH EZETIMIBE ARE WELL TOLERATED AND IMPROVE THE LIPID PROFILE IN STATIN-INTOLERANT PATIENTS WITH CORONARY HEART DISEASE. FURTHER STUDIES ARE NEEDED TO ASSESS LONG-TERM EFFECTS OF NUTRACEUTICALS ON MORTALITY. (C) 2015 ELSEVIER INC. ALL RIGHTS RESERVED.",NA,"RED YEAST RICE; LIPID PATTERN; DOUBLE-BLIND; CHOLESTEROL; BERBERINE; HYPERCHOLESTEROLEMIA; SENSITIVITY",NA,NA,"AFFUSO F, 2010, NUTR METAB CARDIOVAS, V20, P656, DOI 10.1016/J.NUMECD.2009.05.017; AFFUSO F, 2012, WORLD J CARDIOL, V4, P77, DOI 10.4330/WJC.V4.I3.77; AFFUSO F, 2010, WORLD J CARDIOL, V2, P71, DOI 10.4330/WJC.V2.I4.71; BANACH M, 2015, ARCH MED SCI, V11, P1, DOI 10.5114/AOMS.2015.49807; BARRAT E, 2013, INT J FOOD SCI NUTR, V64, P882, DOI 10.3109/09637486.2013.809405; BECKER DJ, 2009, ANN INTERN MED, V150, P830, DOI 10.7326/0003-4819-150-12-200906160-00006; BOGSRUD MP, 2010, SCAND CARDIOVASC J, V44, P197, DOI 10.3109/14017431003624123; CAMERON J, 2008, ATHEROSCLEROSIS, V201, P266, DOI 10.1016/J.ATHEROSCLEROSIS.2008.02.004; CICERO AEG, 2007, ARZNEIMITTELFORSCH, V57, P26; CICERO AFG, 2013, NUTR RES, V33, P622, DOI 10.1016/J.NUTRES.2013.05.015; CICERO AFG, 2012, EXPERT OPIN DRUG SAF, V11, P753, DOI 10.1517/14740338.2012.705827; ENDO A, 1988, KLIN WOCHENSCHR, V66, P421, DOI 10.1007/BF01745510; ENDO A, 2004, ATHEROSCLEROSIS SUPP, V5, P125, DOI 10.1016/J.ATHEROSCLEROSISSUP.2004.08.033; HALBERT SC, 2010, AM J CARDIOL, V105, P198, DOI 10.1016/J.AMJCARD.2009.08.672; KALRA EK, 2003, AAPS PHARMSCI, V5; KARL M, 2012, J CLIN LIPIDOL, V6, P150, DOI 10.1016/J.JACL.2011.09.004; KONG WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/NM1135; LEVEY AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; MAN RYK, 2002, MOL CELL BIOCHEM, V233, P153, DOI 10.1023/A:1017487815091; MARAZZI G, 2011, ADV THER, V28, P1105, DOI 10.1007/S12325-011-0082-5; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; PANDOR A, 2009, J INTERN MED, V265, P568, DOI 10.1111/J.1365-2796.2008.02062.X; PISCIOTTA L, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-123; RUSCICA M, 2014, J CLIN LIPIDOL, V8, P61, DOI 10.1016/J.JACL.2013.11.003; SOLA R, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0101978","MARAZZI, G (CORRESPONDING AUTHOR), IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA, ROME, ITALY","EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","ENGLISH","AM. J. CARDIOL.","ARTICLE","ISI","WOS000366786500002","AM J CARDIOL","IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA;IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA;UNIV ROMA LA SAPIENZA;INST CARDIOL","IST RIC CARATTERE SCI IRCCS SAN RAFFAELE PISANA",NA,"MARAZZI G, 2015, AM J CARDIOL","MARAZZI G, 2015, AM J CARDIOL1"
"ALTHWAB S;CARR T;WELLER C;DWEIKAT ;ISMAIL M I;SCHLEGEL V","ALTHWAB SAMI;CARR TIMOTHY P;WELLER CURTIS L;DWEIKAT; ISMAIL M;SCHLEGEL VICKI","ADVANCES IN GRAIN SORGHUM AND ITS COPRODUCTS AS A HUMAN HEALTH PROMOTING DIETARY SYSTEM",2015,"FOOD RESEARCH INTERNATIONAL","77","349-359",63,"10.1016/j.foodres.2015.08.011","SCHLEGEL, V (CORRESPONDING AUTHOR), UNIV NEBRASKA, DEPT FOOD SCI \& TECHNOL, 1901 NORTH 21 ST, LINCOLN, NE 68588 USA.; ALTHWAB, SAMI; SCHLEGEL, VICKI, UNIV NEBRASKA, DEPT FOOD SCI \& TECHNOL, LINCOLN, NE 68588 USA.; CARR, TIMOTHY P., UNIV NEBRASKA, DEPT NUTR \& HLTH SCI, LINCOLN, NE 68583 USA.; WELLER, CURTIS L., UNIV NEBRASKA, DEPT BIOL SCI ENGN, LINCOLN, NE USA.; DWEIKAT, ISMAIL M., UNIV NEBRASKA, DEPT AGRON \& HORT, LINCOLN, NE USA.","GRAIN SORGHUM (GS) AND ITS CO-PRODUCTS ARE A RICH SOURCE OF CHEMICALLY DIVERSE PHYTOCHEMICALS, MANY OF WHICH HAVE BEEN REPORTED TO PROTECT AGAINST MULTIPLE HUMAN HEALTH CONDITIONS OR DISEASES THAT ARE CURRENTLY AFFLICTING WESTERN CULTURES. HOWEVER, DUE TO RAPID URBANIZATION AND NUTRITION TRANSITION, THESE DISEASES ARE ALSO INCREASING IN DEVELOPING WORLDS, MAKING SORGHUM AN EVEN MORE RELEVANT FOOD STAPLE FOR THESE COUNTRIES. RESEARCH ON GS AND ITS CO-PRODUCTS THUS IS ALSO STEADILY INCREASING BUT AS POTENTIAL FUNCTIONAL FOODS OR AS SUPPLEMENTS. FOR EXAMPLE, STUDIES HAVE DEMONSTRATED THAT BOTH GS LIPIDS AND ITS CO-PRODUCT, DRY DISTILLER'S GRAIN SORGHUM WERE ABLE TO PROMOTE CARDIOVASCULAR HEALTH BY REDUCING BOTH PLASMA LOW-DENSITY LIPOPROTEIN (LDL) AND LIVER CHOLESTEROL LEVELS BUT AT DIFFERENT DOSAGE LEVELS. GRAIN SORGHUM PHENOLS HAVE ALSO BEEN SHOWN TO INHIBIT HEPATIC GLUCONEOGENESIS ENZYMES THEREBY PROMOTING ENDOGENOUS INSULIN SENSITIVITY. AS THESE RESULTS REPRESENT ONLY A FEW OF THE HEALTH RELATED STUDIES CITED IN THE LITERATURE IN RESPONSE TO GS WITHIN THE PAST 10 YEARS, THIS MANUSCRIPT REVIEWS STUDIES ON GS AND ITS CO-PRODUCTS AS A POTENTIAL HEALTH PROMOTING SYSTEM REPORTED BETWEEN 2005 AND 2015. PUBLISHED BY ELSEVIER LTD.","GRAIN SORGHUM; FUNCTIONAL FOOD; PHENOLIC COMPOUNDS; STEROLS; POLICOSANOLS; HEALTH PROPERTIES","RESISTANT STARCH; IN-VITRO; ANTIINFLAMMATORY ACTIVITY; FLAVONOID; COMPOSITION; CELIAC PATIENTS; POLICOSANOL; CHOLESTEROL; CANCER; LIPIDS; HYPERCHOLESTEROLEMIA",NA,NA,"ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ADOM KK, 2002, J AGR FOOD CHEM, V50, P6182, DOI 10.1021/JF0205099; AJIBOYE T. O., 2013, FOOD SCIENCE AND HUMAN WELLNESS, V2, P39; ALLEN CA, 2008, ADV EXP MED BIOL, V635, P93, DOI 10.1007/978-0-387-09550-9\_8; ANONYMOUS, 2015, CIRCULATION, DOI DOI 10.1161/CIR.0000000000000152; ANONYMOUS, THESIS; ANONYMOUS, 2010, SORGHUM ANCIENT HLTH; ANONYMOUS, 2021, FAST FACTS; ANONYMOUS, PHARM RES; ANONYMOUS, 2014, CANC FACTS FIG; ANONYMOUS, PLANT STER STAN PROV; ANONYMOUS, 2015, GRAIN WORLD MARK TRA; ANONYMOUS, J AGR CHEM; ANONYMOUS, FDA CONSUMER MAGAZIN; ANONYMOUS, J CHEM SOC; ANONYMOUS, SORGHUM MILLETS CHEM; ANONYMOUS, THESIS; AWAD AB, 2001, NUTR CANCER, V40, P157, DOI 10.1207/S15327914NC402\_12; AWIKA JM, 2005, FOOD CHEM, V90, P293, DOI 10.1016/J.FOODCHEM.2004.03.058; AWIKA JM, 2004, PHYTOCHEMISTRY, V65, P1199, DOI 10.1016/J.PHYTOCHEM.2004.04.001; AWIKA JM, 2011, ACS SYM SER, V1089, P171; BENSON KF, 2013, J MED FOOD, V16, P230, DOI 10.1089/JMF.2012.0214; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; BIESALSKI HK, 2007, CURR OPIN CLIN NUTR, V10, P724, DOI 10.1097/MCO.0B013E3282F0CEF2; BRANDON MJ, 1982, PHYTOCHEMISTRY, V21, P2953, DOI 10.1016/0031-9422(80)85076-X; BUNGER WB, 1951, J AM OIL CHEM SOC, V28, P121, DOI 10.1007/BF02612208; BURDETTE A, 2010, J MED FOOD, V13, P879, DOI 10.1089/JMF.2009.0147; CARR TP, 2010, NUTR DIET SUPPL, V2, P59; CARR TP, 2005, J NUTR, V135, P2236, DOI 10.1093/JN/135.9.2236; CHEN F, 1993, INT J CANCER, V53, P902, DOI 10.1002/IJC.2910530606; CHRISTIANSEN KL, 2007, CEREAL CHEM, V84, P463, DOI 10.1094/CCHEM-84-5-0463; CHUNG IM, 2011, FOOD RES INT, V44, P127, DOI 10.1016/J.FOODRES.2010.10.051; CIACCI C, 2007, CLIN NUTR, V26, P799, DOI 10.1016/J.CLNU.2007.05.006; CORR SC, 2007, P NATL ACAD SCI USA, V104, P7617, DOI 10.1073/PNAS.0700440104; DE FILIPPO C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/PNAS.1005963107; DEL GIUDICE F, 2008, J PLANT INTERACT, V3, P49, DOI 10.1080/17429140701714793; DINARELLO CA, 2010, CELL, V140, P935, DOI 10.1016/J.CELL.2010.02.043; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/TPC.7.7.1085; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; DYKES L, 2011, FOOD CHEM, V128, P173, DOI 10.1016/J.FOODCHEM.2011.03.020; DYKES L, 2006, J CEREAL SCI, V44, P236, DOI 10.1016/J.JCS.2006.06.007; DYKES L, 2009, FOOD CHEM, V116, P313, DOI 10.1016/J.FOODCHEM.2009.02.052; ELENKOV IJ, 2005, NEUROIMMUNOMODULAT, V12, P255, DOI 10.1159/000087104; ELENKOV IJ, 2008, NEUROCHEM INT, V52, P40, DOI 10.1016/J.NEUINT.2007.06.037; GÓMEZ-CORDOVÉS C, 2001, J AGR FOOD CHEM, V49, P1620, DOI 10.1021/JF001116H; GONZÁLEZ R, 2011, CRIT REV FOOD SCI, V51, P331, DOI 10.1080/10408390903584094; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GOUS F., 1989, THESIS; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; GU LW, 2002, J AGR FOOD CHEM, V50, P4852, DOI 10.1021/JF020214V; HAHN DH, 1986, CEREAL CHEM, V63, P4; HAHN DH, 1983, CEREAL CHEM, V60, P255; HEIM KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5; HOI JT, 2009, J FUNCT FOODS, V1, P381, DOI 10.1016/J.JFF.2009.09.005; HOPPS E, 2010, NUTR METAB CARDIOVAS, V20, P72, DOI 10.1016/J.NUMECD.2009.06.002; HWANG KT, 2005, CEREAL CHEM, V82, P242, DOI 10.1094/CC-82-0242; HWANG KT, 2002, J AM OIL CHEM SOC, V79, P521, DOI 10.1007/S11746-002-0515-5; HWANG KT, 2002, J SEP SCI, V25, P619, DOI 10.1002/1615-9314(20020601)25:9<619::AID-JSSC619>3.0.CO;2-; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KHAN I, 2013, FOOD RES INT, V54, P578, DOI 10.1016/J.FOODRES.2013.07.059; KIM JS, 2010, AFR J BIOTECHNOL, V9, P2683; KIM J, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-106; KOEHLER P., 2013, HANDB SOURDOUGH BIOTECHNOL, P11, DOI 10.1007/978-1-4614-5425-0\_2, DOI 10.1007/978-1-4614-5425-0\_2; KUMMEROW FA, 1946, OIL SOAP, V23, P167, DOI 10.1007/BF02640963; LEE BH, 2014, J FUNCT FOODS, V7, P709, DOI 10.1016/J.JFF.2013.12.014; LEGUIZAMÓN C, 2009, J AM OIL CHEM SOC, V86, P707, DOI 10.1007/S11746-009-1398-Z; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; LIVINGSTON M, 2010, IMMUNOL CELL BIOL, V88, P99, DOI 10.1038/ICB.2009.71; MARTÍNEZ I, 2009, APPL ENVIRON MICROB, V75, P4175, DOI 10.1128/AEM.00380-09; MURTY DS, 1982, J FOOD SCI TECH MYS, V19, P79; NEUCERE NJ, 1980, J AGR FOOD CHEM, V28, P19, DOI 10.1021/JF60227A022; NIBA LL, 2003, FOOD CHEM, V81, P113, DOI 10.1016/S0308-8146(02)00386-2; NIP WK, 1969, CEREAL CHEM, V46, P490; OSAGIE AU, 1987, J AGR FOOD CHEM, V35, P601, DOI 10.1021/JF00076A038; PARK JH, 2012, NUTR RES PRACT, V6, P322; PONTIERI P, 2013, J AGR FOOD CHEM, V61, P2565, DOI 10.1021/JF304882K; RICEEVANS CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; SAJILATA MG, 2006, COMPR REV FOOD SCI F, V5, P1, DOI 10.1111/J.1541-4337.2006.TB00076.X; SASAKI T, 2006, INT J CANCER, V118, P593, DOI 10.1002/IJC.21393; SHIH CH, 2007, J AGR FOOD CHEM, V55, P254, DOI 10.1021/JF062516T; SHIM TJ, 2013, BIOSCI BIOTECH BIOCH, V77, P697, DOI 10.1271/BBB.120731; SIEGEL R. L, 2015, CA-CANCER J CLIN, V65, P2; SINGH V, 2003, CEREAL CHEM, V80, P126, DOI 10.1094/CCHEM.2003.80.2.126; STERN M, 2001, EUR J GASTROEN HEPAT, V13, P741, DOI 10.1097/00042737-200106000-00023; STEVENSON DE, 2007, CELL MOL LIFE SCI, V64, P2900, DOI 10.1007/S00018-007-7237-1; SUGANYADEVI P, 2013, LIFE SCI, V92, P379, DOI 10.1016/J.LFS.2013.01.006; SWEENY JG, 1981, TETRAHEDRON, V37, P1481, DOI 10.1016/S0040-4020(01)92086-1; TAYLOR JRN, 2006, J CEREAL SCI, V44, P252, DOI 10.1016/J.JCS.2006.06.009; THORAT SS, 1988, J FOOD SCI TECH MYS, V25, P361; TREMAROLI V, 2012, NATURE, V489, P242, DOI 10.1038/NATURE11552; USDA, 2014, NATIONAL NUTRIENT DATABASE FOR STANDARD REFERENCE, RELEASE 27; USDA NATIONAL AGRICULTURAL STATISTICS SERVICE (USDA-NASS), 2015, CROP PRODUCTION: 2014 SUMMARY; VANRENSBURG SJ, 1981, J NATL CANCER I, V67, P243; VOGEL RA, 1997, CLIN CARDIOL, V20, P426, DOI 10.1002/CLC.4960200505; WANG L, 2005, T ASAE, V48, P1883, DOI 10.13031/2013.19986; WANG LJ, 2007, EUR J LIPID SCI TECH, V109, P567, DOI 10.1002/EJLT.200700018; WANISKA RD, 1989, J CEREAL SCI, V10, P217, DOI 10.1016/S0733-5210(89)80051-7; YANG LY, 2009, J AGR FOOD CHEM, V57, P1797, DOI 10.1021/JF8035066; YOSHIDA H, 1991, J AM OIL CHEM SOC, V68, P566, DOI 10.1007/BF02660151; ZBASNIK R, 2009, J AGR FOOD CHEM, V57, P10435, DOI 10.1021/JF902136P","SCHLEGEL, V (CORRESPONDING AUTHOR), UNIV NEBRASKA, DEPT FOOD SCI \& TECHNOL, 1901 NORTH 21 ST, LINCOLN, NE 68588 USA","ELSEVIER","ENGLISH","FOOD RES. INT.","REVIEW","ISI","WOS000367410100007","FOOD RES INT","UNIV NEBRASKA;UNIV NEBRASKA;UNIV NEBRASKA;UNIV NEBRASKA;UNIV NEBRASKA","UNIV NEBRASKA",NA,"ALTHWAB S, 2015, FOOD RES INT","ALTHWAB S, 2015, FOOD RES INT"
"FENG S;LUO Z;ZENG F;LIU S;KHAN Z","FENG SIMIN;LUO ZISHENG;ZENG FANGFANG;LIU SONGBAI; KHAN ZIA ULLAH","EFFECT OF WATER METALLIC IONS FATTY ACID AND TEMPERATURE ON OXIDATIVE STABILITY OF 1OCTACOSANOL FROM SUGARCANE RIND",2015,"FOOD CHEMISTRY","182","171-177",11,"10.1016/j.foodchem.2015.03.003","LUO, ZS (CORRESPONDING AUTHOR), ZHEJIANG UNIV, COLL BIOSYST ENGN \& FOOD SCI, HANGZHOU 310058, ZHEJIANG, PEOPLES R CHINA.; LUO, ZISHENG, ZHEJIANG UNIV, COLL BIOSYST ENGN \& FOOD SCI, HANGZHOU 310058, ZHEJIANG, PEOPLES R CHINA.; ZHEJIANG UNIV, COLL BIOSYST ENGN \& FOOD SCI, ZHEJIANG KEY LAB AGROFOOD PROC, FULI INST FOOD SCI, HANGZHOU 310058, ZHEJIANG, PEOPLES R CHINA.","THE CHEMICAL COMPOSITION AND SELECTED PHYSICAL PARAMETERS OF CRUDE 1-OCTACOSANOL (1-OC) EXTRACTED FROM SUGARCANE RIND HAVE BEEN DETERMINED. GC MS RESULTS EXHIBITED THAT 1-OC SAMPLE WAS PRIMARILY COMPOSED OF 1-OC (45.17\%), 1-DOCOSENE (12.04\%), 1-TRIACONTANOL (0.23\%), 1-HENEICOSANOL (0.33\%), 1-TETRACOSANAL (0.28\%), CAMPESTEROL (4.5\%), STIGMASTEROL (9.12\%) AND B-SITOSTEROL (8.23\%). THE LINOLEIC ACID HAD IMPORTANT EFFECTS ON PHYSICAL AND CHEMICAL PROPERTIES OF 1-OC SAMPLE, AS IT NOTABLY CHANGED THE MELTING POINT AND THE ONSET OXIDATION TEMPERATURE TO OF 1-OC SAMPLE FROM 83.75 +/- 0.35 DEGREES C TO 63.25 +/- 0.35 DEGREES C AND 245.64 +/- 2.04 DEGREES C TO 160.03 +/- 0.01 DEGREES C, RESPECTIVELY. IT WAS ALSO PROVED THAT THE OXIDATION REACTIONS WERE SIGNIFICANTLY DIFFERENT AT DIFFERENT TEMPERATURE LEVELS. 1-OC WAS STABLE UP TO 245.64 +/- 2.04 DEGREES C. HOWEVER, WHEN THE TEMPERATURE CONTINUED TO RISE, 1-OC AND ITS OXIDATION PRODUCTS STARTED TO BE OXIDIZED. THEREFORE, ATTENTION SHOULD BE PAID TO THE QUALITY OF 1-OC DURING THE PREPARATION OF FOOD AND TO MINIMIZE THE UNDESIRABLE BREAKDOWN PRODUCTS. (C) 2015 ELSEVIER LTD. ALL RIGHTS RESERVED.","1-OCTACOSANOL; NON-ISOTHERMAL DSC; SUGARCANE; OXIDATIVE STABILITY; PHYTOSTEROL","DIFFERENTIAL SCANNING CALORIMETRY; PHYTOSTEROL OXIDATION; POLICOSANOL; CONTENTS; LIPID-METABOLISM; OILS; DSC; OCTACOSANOL; CHOLESTEROL; PRODUCTS; STORAGE","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [31371856]; ZHEJIANG PROVINCIAL NATURAL SCIENCE FOUNDATION OF CHINA [LR13C200001]; NATIONAL KEY TECHNOLOGIES R \& D PROGRAM OF CHINA [2011BAD24B02]","THE RESEARCH WAS FINANCIALLY SUPPORTED BY THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (31371856), THE ZHEJIANG PROVINCIAL NATURAL SCIENCE FOUNDATION OF CHINA (LR13C200001) AND THE NATIONAL KEY TECHNOLOGIES R \& D PROGRAM OF CHINA (2011BAD24B02).","ATHUKORALA Y, 2010, IND CROP PROD, V31, P550, DOI 10.1016/J.INDCROP.2010.02.011; BOTELHO PB, 2014, LWT-FOOD SCI TECHNOL, V55, P444, DOI 10.1016/J.LWT.2013.09.002; BRUFAU G, 2008, NUTR RES, V28, P217, DOI 10.1016/J.NUTRES.2008.02.003; CAPONIO F, 2013, EUR J LIPID SCI TECH, V115, P1146, DOI 10.1002/EJLT.201300091; CHIAVARO E, 2013, J SCI FOOD AGR, V93, P2909, DOI 10.1002/JSFA.6168; CIBULKOVÁ Z, 2014, FOOD CHEM, V150, P296, DOI 10.1016/J.FOODCHEM.2013.11.011; CRAVOTTO G, 2010, NAT PROD RES, V24, P428, DOI 10.1080/14786410903194498; DOBARGANES C, 2000, EUR J LIPID SCI TECH, V102, P521, DOI 10.1002/1438-9312(200009)102:8/9<521::AID-EJLT521>3.0.CO;2-A; DUNFORD NT, 2010, FOOD CHEM, V119, P1246, DOI 10.1016/J.FOODCHEM.2009.07.039; FENG SM, 2014, J SEP SCI, V37, P1308, DOI 10.1002/JSSC.201301316; FENG SM, 2014, FOOD CHEM, V151, P452, DOI 10.1016/J.FOODCHEM.2013.11.057; FERNANDES P, 2007, BIORESOURCE TECHNOL, V98, P2335, DOI 10.1016/J.BIORTECH.2006.10.006; GARCIA CC, 2007, J THERM ANAL CALORIM, V87, P645, DOI 10.1007/S10973-006-7769-X; GEORGES P, 2006, STEROIDS, V71, P647, DOI 10.1016/J.STEROIDS.2006.01.016; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUIOTTO EN, 2014, J AM OIL CHEM SOC, V91, P767, DOI 10.1007/S11746-014-2410-9; HWANG KT, 2004, IND CROP PROD, V19, P125, DOI 10.1016/J.INDCROP.2003.07.007; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KLINGBERG S, 2012, AM J CLIN NUTR, V96, P680, DOI 10.3945/AJCN.112.043893; KOWALSKA D, 2014, J THERM ANAL CALORIM, V115, P2063, DOI 10.1007/S10973-013-3125-0; LITWINIENKO G, 2001, J THERM ANAL CALORIM, V65, P639, DOI 10.1023/A:1017974313294; MARTÍNEZ L, 1999, ARCH PHARM, V332, P439; NAIK A, 2014, J AM OIL CHEM SOC, V91, P935, DOI 10.1007/S11746-014-2430-5; NUISSIER G, 2002, PHYTOCHEMISTRY, V61, P721, DOI 10.1016/S0031-9422(02)00356-4; O'CALLAGHAN Y, 2014, BIOCHEM BIOPH RES CO, V446, P786, DOI 10.1016/J.BBRC.2014.01.148; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; OU SY, 2012, LWT-FOOD SCI TECHNOL, V45, P295, DOI 10.1016/J.LWT.2011.08.011; PARDAUIL JJR, 2011, BIORESOURCE TECHNOL, V102, P5873, DOI 10.1016/J.BIORTECH.2011.02.022; PLAT J, 2001, NUTR METAB CARDIOVAS, V11, P31; RITTER B, 2001, EUR FOOD RES TECHNOL, V212, P603, DOI 10.1007/S002170100290; RUDNIK E, 2001, THERMOCHIM ACTA, V370, P135, DOI 10.1016/S0040-6031(00)00781-4; RYAN E, 2009, FOOD REV INT, V25, P157, DOI 10.1080/87559120802682797; SOUPAS L, 2007, FOOD CHEM, V101, P286, DOI 10.1016/J.FOODCHEM.2006.01.035; TAN CP, 2001, J AM OIL CHEM SOC, V78, P1133, DOI 10.1007/S11746-001-0401-1; TAN CP, 2002, FOOD CHEM, V76, P385, DOI 10.1016/S0308-8146(01)00272-2; TAYADE A. B., 2013, PLOS ONE, V8; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; XU GH, 2011, FOOD CHEM, V124, P162, DOI 10.1016/J.FOODCHEM.2010.06.003","LUO, ZS (CORRESPONDING AUTHOR), ZHEJIANG UNIV, COLL BIOSYST ENGN \& FOOD SCI, HANGZHOU 310058, ZHEJIANG, PEOPLES R CHINA","ELSEVIER SCI LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","WOS000353731400025","FOOD CHEM","ZHEJIANG UNIV;ZHEJIANG UNIV;ZHEJIANG UNIV","ZHEJIANG UNIV",NA,"FENG S, 2015, FOOD CHEM","FENG S, 2015, FOOD CHEM"
"TRABELSI H;RENAUD J;HERCHI W;BOUKHCHINA ;SADOK S;MAYER P","TRABELSI HAJER;RENAUD JUSTIN;HERCHI WAHID;BOUKHCHINA; SADOK;MAYER PAUL","TRIACYLGLYCEROLS AND ALIPHATIC ALCOHOLS FROM FRUITS OF THREE TUNISIAN IPISTACIA LENTISCUSI POPULATIONS",2015,"JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE","95","2028-2032",9,"10.1002/jsfa.6915","TRABELSI, H (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES, 2092 EL MANAR 2, TUNIS, TUNISIA.; TRABELSI, HAJER; HERCHI, WAHID; BOUKHCHINA, SADOK, UNIV TUNIS EL MANAR, FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES, TUNIS, TUNISIA.; RENAUD, JUSTIN; MAYER, PAUL, UNIV OTTAWA, DEPT CHEM, LAB MASS SPECTROMETRY, OTTAWA, ON K1N 6N5, CANADA.","BACKGROUNDTHE SEARCH FOR OTHER SOURCES OF VEGETABLE OILS BY THE EXPLOITATION AND THE ENHANCEMENT OF OTHER OIL PLANTS WILL BE NEEDED TO MEET THE DEMANDS OF THE INTERNATIONAL MARKET. THIS STUDY AIMS TO DETERMINE THE TRIACYLGLYCEROL (TAG) MOLECULAR SPECIES AND ALIPHATIC ALCOHOL COMPOSITIONS OF UNEXPLOITED FRUITS OF THREE TUNISIAN PISTACIA LENTISCUS (LENTISC) POPULATIONS FROM THE KORBOUS, TEBABA AND RIMEL AREAS OF TUNISIA. RESULTSRESULTS SHOW THAT THE CONTENT OF TOTAL TAG VARIES FROM 738.32 MG G(-1) OF TOTAL LIPID IN THE TEBABA POPULATION TO 981.15 MG G(-1) OF TOTAL LIPID IN THE KORBOUS POPULATION. FURTHERMORE, 14 SPECIES OF TAG WERE DETECTED IN THE THREE STUDIED POPULATIONS. IN ADDITION, 13 ALIPHATIC COMPOUNDS WERE IDENTIFIED AND CLASSIFIED INTO TWO GROUPS: (1) ALIPHATIC ALCOHOLS WITH FEWER THAN 20 CARBON ATOMS (HEXADECANOL, HEPTADECANOL, (Z)-OCTADEC-9-EN-1-OL, OCTADECANOL AND NONADECANOL); AND (2) THE POLICOSANOL GROUP (EICOSENOL, DOCOSENOL, DOCOSANOL TETRACOSANOL, HEXACOSANOL OCTACOSANOL AND TRIACONTANOL). THE TEBABA POPULATION SHOWED A DISTINCT COMPOSITION COMPARED TO KORBOUS AND RIMEL WHERE HEPTADECANOL IS THE MAJOR COMPOUND. CONCLUSIONQUANTITATIVELY, THE MOST ABUNDANT TAG SPECIES ARE THOSE CONSTITUTED BY PALMITIC, OLEIC AND/OR LINOLEIC ACID. FURTHERMORE, THE SIGNIFICANT DIFFERENCE OBSERVED AT THE OIL COMPOSITION IS ASSOCIATED WITH A REMARKABLE STATION EFFECT. (C) 2014 SOCIETY OF CHEMICAL INDUSTRY","TRIACYLGLYCEROL; ALIPHATIC ALCOHOL; POLICOSANOL; PISTACIA LENTISCUS; FRUIT COMPOSITION","TRITERPENE ALCOHOLS; FATTY-ACIDS; POLICOSANOL; 4-DESMETHYLSTEROLS; ACCUMULATION; CHOLESTEROL",NA,NA,"ANONYMOUS, 2012, 128712012 ES ISO ETH; ANONYMOUS, PLANT J, DOI DOI 10.1111/J.1365-313X.2008.03492.X; APARICIO R, 1994, ANAL CHIM ACTA, V292, P235, DOI 10.1016/0003-2670(94)00065-4; CHAREF M, 2008, J AM OIL CHEM SOC, V85, P921, DOI 10.1007/S11746-008-1283-1; CHERIF A, 2004, J AM OIL CHEM SOC, V81, P901, DOI 10.1007/S11746-004-0999-Z; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; INTERNATIONAL OLIVE COUNCIL, 2009, 3REV4 COIT15NC IOC; LEHMLER HJ, 2002, J FLUORINE CHEM, V117, P17, DOI 10.1016/S0022-1139(02)00169-0; LEÓN-CAMACHO M, 2004, J AM OIL CHEM SOC, V81, P447, DOI 10.1007/S11746-004-0921-8; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; NASRI N, 2007, J AGR FOOD CHEM, V55, P2251, DOI 10.1021/JF062911J; NASRI N, 2009, INT J FOOD SCI NUTR, V60, P161, DOI 10.1080/09637480802577854; SAKOUHI F, 2010, EUR J LIPID SCI TECH, V112, P574, DOI 10.1002/EJLT.200900079; SAKOUHI F, 2010, EUR J LIPID SCI TECH, V112, P373, DOI 10.1002/EJLT.200900076; SEIGUE A, 1985, FORET CIRCUMMEDITERR, P22; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SOULIER P, 1990, J AM OIL CHEM SOC, V67, P388, DOI 10.1007/BF02539696; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/PNAS.82.13.4526; TAKEUCHI H, 2002, J NUTR SCI VITAMINOL, V48, P109, DOI 10.3177/JNSV.48.109; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TLILI N, 2011, J AM OIL CHEM SOC, V88, P1787, DOI 10.1007/S11746-011-1855-3; TLILI N, 2011, J AM OIL CHEM SOC, V88, P265, DOI 10.1007/S11746-010-1662-2; TRABELSI H, 2012, EUR J LIPID SCI TECH, V114, P968, DOI 10.1002/EJLT.201100146; YOUSFI M, 2005, J AM OIL CHEM SOC, V82, P93, DOI 10.1007/S11746-005-1048-7","TRABELSI, H (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES, 2092 EL MANAR 2, TUNIS, TUNISIA","WILEY","ENGLISH","J. SCI. FOOD AGRIC.","ARTICLE","ISI","WOS000355648300009","J SCI FOOD AGRIC","UNIV TUNIS EL MANAR;UNIV TUNIS EL MANAR;UNIV OTTAWA","UNIV TUNIS EL MANAR",NA,"TRABELSI H, 2015, J SCI FOOD AGRIC","TRABELSI H, 2015, J SCI FOOD AGRIC1"
"GIUFFRE A;CAPOCASALE M","GIUFFRE ANGELO MARIA;CAPOCASALE MARCO","POLICOSANOL IN TOMATO ISOLANUM LYCOPERSICUMI L SEED OIL THE EFFECT OF CULTIVAR",2015,"JOURNAL OF OLEO SCIENCE","64","625-631",26,"10.5650/jos.ess15002","GIUFFRÈ, AM (CORRESPONDING AUTHOR), UNIV MEDITERRANEA REGGIO CALABRIA, DIPARTIMENTO AGR, REGGIO DI CALABRIA, ITALY.; GIUFFRE, ANGELO MARIA; CAPOCASALE, MARCO, UNIV MEDITERRANEA REGGIO CALABRIA, DIPARTIMENTO AGR, REGGIO DI CALABRIA, ITALY.","SOXHLET-PETROLEUM ETHER EXTRACTION WAS USED TO OBTAIN OIL FROM TOMATO SEEDS. THREE TOMATO CULTIVARS FROM SOUTH ITALY (PRINCIPE BORGHESE, REBELION F1 AND SAN MARZANO) WERE STUDIED. POLICOSANOL IS A MIXTURE OF LONG CHAIN LINEAR FATTY ALCOHOLS (N-ALKANOLS), ITS CONTENT AND COMPOSITION WAS FOUND TO BE HIGHLY SIGNIFICANTLY INFLUENCED BY CULTIVAR. SEVEN FATTY ALCOHOLS WERE DETECTED: DOCOSANOL (C22-OL), TRICOSANOL (C23-OL), TETRACOSANOL (C24-OL), PENTACOSANOL (C25-OL), HEXACOSANOL (C26-OL), HEPTACOSANOL (C27-OL) AND OCTACOSANOL (C28-OL). THE HIGHEST POLICOSANOL CONTENT WAS FOUND IN PRINCIPE BORGHESE 71.88 MG/KG. OCTACOSANOL WAS THE LINEAR ALCOHOL PRESENT IN HIGHEST QUANTITY, I.E. 38-42\% OF THE TOTAL LINEAR ALCOHOLS DETECTED IN TOMATO SEED OILS (TSO). CHEMOMETRICS WAS APPLIED TO STUDY THE DIFFERENCES AMONG CULTIVARS. THE SUM OF EVEN LONG CHAINED FATTY ALCOHOLS WAS ALWAYS MORE THAN 95\% OF THE TOTAL POLICOSANOL CONTENT. ONE-WAY ANOVA AND PRINCIPAL COMPONENT ANALYSIS WELL DIFFERENTIATED THE THREE CULTIVARS.","N-ALKANOLS; LINEAR FATTY ALCOHOLS; MINOR COMPONENTS; UNSAPONIFIABLE; VEGETABLE EDIBLE OIL","OLIVE OILS; HARVEST YEAR; STEROL COMPOSITION; WAX ESTER; TRIACONTANOL; HEXACOSANOL; CAROTENOIDS; INHIBITION; DOCOSANOL; ORIGIN","FUND: ``AGRONOMICAL, QUALITATIVE, TECHNOLOGICAL AND MARKETING EVALUATION OF TRADITIONAL TOMATO PRODUCTS TRANSFER (PEELED, CHERRY, SUN DRIED, ``PIENNOLO'') IN INNOVATIVE PACKAGING FOR A MARKET UPGRADING. [PON01 01397]","THIS RESEARCH WAS SUPPORTED BY PON01 01397 FUND: ``AGRONOMICAL, QUALITATIVE, TECHNOLOGICAL AND MARKETING EVALUATION OF TRADITIONAL TOMATO PRODUCTS TRANSFER (PEELED, CHERRY, SUN DRIED, ``PIENNOLO'') IN INNOVATIVE PACKAGING FOR A MARKET UPGRADING. POSSIBILITY OF USING INDUSTRIAL TOMATO WASTE (SEEDS AND SKINS) FOR SEED OIL PRODUCTION AS FUEL AND/OR COSMETIC APPLICATIONS AND FUNCTIONAL SUBSTANCES EXTRACTION''.","ALBANESE D, 2014, INT J FOOD SCI TECH, V49, P2458, DOI 10.1111/IJFS.12602; ALONSO A, 2009, FOOD SCI TECHNOL INT, V15, P47, DOI 10.1177/1082013208102385; ANASTASI U, 2010, FIELD CROP RES, V119, P145, DOI 10.1016/J.FCR.2010.07.001; ANONYMOUS, RIV ITAL SO IN PRESS; ANONYMOUS, OLIVAE; BAÜMLER ER, 2007, J AM OIL CHEM SOC, V84, P603, DOI 10.1007/S11746-007-1074-0; BOTINESTEAN C., 2012, JOURNAL OF AGROALIMENTARY PROCESSES AND TECHNOLOGIES, V18, P89; CINQUANTA L, 2013, AGRO FOOD IND HI TEC, V24, P35; EL-GIBLAY I, 2005, INT J PHARMACEUT, V294, P33, DOI 10.1016/J.IJPHARM.2004.12.027; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; GARCÍA-GONZÁLEZ DL, 2012, GRASAS ACEITES, V63, P26, DOI 10.3989/GYA.071011; GIUFFRÉ AM, 2007, RIV ITAL SOSTANZE GR, V84, P87; GIUFFRÈ AM, 2014, GRASAS ACEITES, V65, DOI 10.3989/GYA.073913; GIUFFRÈ AM, 2014, J AM OIL CHEM SOC, V91, P1355, DOI 10.1007/S11746-014-2476-4; GIUFFRE A. M., 2013, INDUSTRIE ALIMENTARI, V52, P28; GIUFFRÈ AM, 2012, RIV ITAL SOSTANZE GR, V89, P177; GIUFFRE A. M., ACTA HORT IN PRESS; GIUFFRÈ AM, 2014, J OLEO SCI, V63, P485, DOI 10.5650/JOS.ESS13212; GIUFFRÈ AM, 2013, EUR J LIPID SCI TECH, V115, P928, DOI 10.1002/EJLT.201200390; GIUFFRÈ AM, 2013, CZECH J FOOD SCI, V31, P256, DOI 10.17221/136/2012-CJFS; GIUFFRÈ AM, 2013, EUR J LIPID SCI TECH, V115, P549, DOI 10.1002/EJLT.201200235; GROB K, 1994, FETT WISS TECHNOL, V96, P286, DOI 10.1002/LIPI.19940960802; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; ISLAM M. Z., 2013, J AGR LIFE ENV SCI, V25, P15; KELLER S, 2008, LIPIDS, V43, P109, DOI 10.1007/S11745-007-3127-4; KIM KS, 2007, J PLANT PHYSIOL, V164, P1134, DOI 10.1016/J.JPLPH.2006.07.004; KRICHÈNE D, 2010, EUR J LIPID SCI TECH, V112, P400, DOI 10.1002/EJLT.200900095; KUNST L, 2009, CURR OPIN PLANT BIOL, V12, P721, DOI 10.1016/J.PBI.2009.09.009; LAZOS ES, 1998, GRASAS ACEITES, V49, P440, DOI 10.3989/GYA.1998.V49.I5-6.755; LAZZEZ A, 2008, J AGR FOOD CHEM, V56, P982, DOI 10.1021/JF0722147; MARCELLETTI JF, 2002, ANTIVIR RES, V56, P153, DOI 10.1016/S0166-3542(02)00105-5; MUTHUCHELIAN K, 2001, J PLANT PHYSIOL, V158, P1487, DOI 10.1078/0176-1617-00627; POPE LE, 1998, ANTIVIR RES, V40, P85, DOI 10.1016/S0166-3542(98)00048-5; RIGGI E, 2008, AUST J AGR RES, V59, P348, DOI 10.1071/AR07215; SAITO M, 2006, EUR J PHARMACOL, V544, P132, DOI 10.1016/J.EJPHAR.2006.06.001; SHEPHERD T, 1999, PHYTOCHEMISTRY, V52, P1255, DOI 10.1016/S0031-9422(99)00414-8; SPAGNA G., 2010, IND ALIMENTARI, V59, P25; TANTOS A, 1999, PLANT CELL REP, V19, P88, DOI 10.1007/S002990050715; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; THIPPESWAMY G, 2008, EUR J PHARMACOL, V588, P141, DOI 10.1016/J.EJPHAR.2008.04.027; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; VICHI S, 2015, J MASS SPECTROM, V50, P558, DOI 10.1002/JMS.3562; XIE SC, 2003, ORG GEOCHEM, V34, P1071, DOI 10.1016/S0146-6380(03)00083-4","GIUFFRÈ, AM (CORRESPONDING AUTHOR), UNIV MEDITERRANEA REGGIO CALABRIA, DIPARTIMENTO AGR, REGGIO DI CALABRIA, ITALY","JAPAN OIL CHEMISTS SOC","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","WOS000355359500004","J OLEO SCI","UNIV MEDITERRANEA REGGIO CALABRIA;UNIV MEDITERRANEA REGGIO CALABRIA","UNIV MEDITERRANEA REGGIO CALABRIA",NA,"GIUFFRE AM, 2015, J OLEO SCI","GIUFFRE AM, 2015, J OLEO SCI"
"GAO W;LIU D;SU S","GAO WENFANG;LIU DAICHENG;SU SHUPENG","HIGHPERFORMANCE THINLAYER CHROMATOGRAPHY FOR QUANTIFICATION OF 1OCTACOSANOL IN ANTARCTIC KRILL IEUPHAUSIA SUPERBAI DANA",2015,"JOURNAL OF CHROMATOGRAPHIC SCIENCE","53","811-815",3,"10.1093/chromsci/bmu098","LIU, DC (CORRESPONDING AUTHOR), SHANDONG NORMAL UNIV, COLL LIFE SCI, KEY LAB ANIM RESISTANCE, 88 EAST WENHUA RD, JINAN 250014, PEOPLES R CHINA.; GAO, WENFANG; LIU, DAICHENG; SU, SHUPENG, SHANDONG NORMAL UNIV, COLL LIFE SCI, KEY LAB ANIM RESISTANCE, JINAN 250014, PEOPLES R CHINA.","1-OCTACOSANOL IS A STRAIGHT-CHAIN ALIPHATIC 28-CARBON FATTY ALCOHOL WITH WELL-KNOWN ANTI-FATIGUE FUNCTION. IN THIS STUDY, 1-OCTACOSANOL WAS EXTRACTED FROM ANTARCTIC KRILL FOR THE FIRST TIME. SEPARATION OF 1-OCTACOSANOL WAS ACHIEVED USING HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY (TLC) WITH A MOBILE PHASE CONSISTING OF PETROLEUM ETHER/ETHYL ACETATE/TOLUENE (4 : 1 : 0.05, V/V/V) ON PRECOATED SILICA GEL GF(254) HIGH-PERFORMANCE TLC PLATES. THE SEPARATED 1-OCTACOSANOL WAS QUANTIFIED USING SPECTRODENSITOMETRY WITH DISTILLED WATER/BROMOTHYMOL BLUE/SODIUM HYDROXIDE (100 : 0.1 : 0.7, V/W/W) AS A CHROMOGENIC SYSTEM. THE HIGH-PERFORMANCE TLC METHOD WAS VALIDATED WITH RESPECT TO SPECIFICITY, LINEARITY, INTRA-AND INTERPLATE VARIATION. THE STABILITY OF THE 1-OCTACOSANOL-CHROMOGEN COMPLEX AND RECOVERY OF 1-OCTACOSANOL WERE ALSO EVALUATED. CONTAINING SIMILAR TO 10.6 MG/MG 1-OCTACOSANOL, ANTARCTIC KRILL IS POTENTIALLY A RICH AND RENEWABLE SOURCE OF 1-OCTACOSANOL.",NA,"PRIMARY ALCOHOLS; RICE BRAN; POLICOSANOL; OCTACOSANOL; EXTRACTION","SHANDONG KERUIER BIOLOGICAL PRODUCTS CO., LTD.","THIS PROJECT WAS PARTIALLY SUPPORTED BY THE SHANDONG KERUIER BIOLOGICAL PRODUCTS CO., LTD.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CRAVOTTO G, 2004, EUR J LIPID SCI TECH, V106, P147, DOI 10.1002/EJLT.200300914; DE OLIVEIRA AM, 2012, INT J MOL SCI, V13, P1598, DOI 10.3390/IJMS13021598; DELANGE D.M., 2011, J CHROMATOGR B, V762, P43; GONZALEZBRAVO L, 1996, J CHROMATOGR B, V682, P359, DOI 10.1016/0378-4347(95)00515-3; HAIM D, 2009, J CHROMATOGR B, V877, P4154, DOI 10.1016/J.JCHROMB.2009.10.034; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KAWANISHI K, 1991, J AM OIL CHEM SOC, V68, P869, DOI 10.1007/BF02660604; KRULICK S, 1979, J AGR FOOD CHEM, V27, P212, DOI 10.1021/JF60221A024; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; RAPPORT L., 2000, PHARMACEUTICAL JOURNAL, V265, P170; SHASHIDHARA S, 2011, INT J PHARM SCI RES, V2, P2142, DOI 10.13040/IJPSR.0975-8232.2(8).2142-45; TEO PS, 2013, J SEP SCI, V36, P2703, DOI 10.1002/JSSC.201300121; THIPPESWAMY G, 2008, EUR J PHARMACOL, V588, P141, DOI 10.1016/J.EJPHAR.2008.04.027; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q; XUE XF, 2012, CHROMATOGRAPHIA, V75, P165, DOI 10.1007/S10337-011-2166-4","LIU, DC (CORRESPONDING AUTHOR), SHANDONG NORMAL UNIV, COLL LIFE SCI, KEY LAB ANIM RESISTANCE, 88 EAST WENHUA RD, JINAN 250014, PEOPLES R CHINA","OXFORD UNIV PRESS INC","ENGLISH","J. CHROMATOGR. SCI.","ARTICLE","ISI","WOS000360833600025","J CHROMATOGR SCI","SHANDONG NORMAL UNIV;SHANDONG NORMAL UNIV","SHANDONG NORMAL UNIV",NA,"GAO W, 2015, J CHROMATOGR SCI","GAO W, 2015, J CHROMATOGR SCI"
"ABDALLAH I;TLILI N;MARTINEZ-FORCE E;PEREZ R A;PEREZ-CAMINO M;ALBOUCHI A;BOUKHCHINA S","ABDALLAH IKRAM BOU;TLILI NIZAR;MARTINEZ-FORCE ENRIQUE; PEREZ RUBIO ANA GRACIA;PEREZ-CAMINO MARIA CARMEN;ALBOUCHI ALI;BOUKHCHINA SADOK","CONTENT OF CAROTENOIDS TOCOPHEROLS STEROLS TRITERPENIC AND ALIPHATIC ALCOHOLS AND VOLATILE COMPOUNDS IN SIX WALNUTS IJUGLANS REGIAI L VARIETIES",2015,"FOOD CHEMISTRY","173","972-978",139,"10.1016/j.foodchem.2014.10.095","ABDALLAH, IB (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, DEPT BIOL, LAB BIOCHIM LIPIDES, TUNIS 2092, TUNISIA.; ABDALLAH, IKRAM BOU; TLILI, NIZAR; BOUKHCHINA, SADOK, UNIV TUNIS EL MANAR, DEPT BIOL, LAB BIOCHIM LIPIDES, TUNIS 2092, TUNISIA.; MARTINEZ-FORCE, ENRIQUE; PEREZ RUBIO, ANA GRACIA; PEREZ-CAMINO, MARIA CARMEN, CSIC, INST GRASA, SEVILLE 41012, SPAIN.; ALBOUCHI, ALI, INRGREF, TUNIS, TUNISIA.","THE AIM OF THIS WORK WAS TO STUDY THE CONTENT OF TOCOPHEROLS, STEROLS, TRITERPENIC AND ALIPHATIC ALCOHOLS, CAROTENOIDS, AND VOLATILE COMPOUNDS IN THE KERNEL OILS FROM SIX WALNUT (JUGLANS REGIA L.) VARIETIES. THE LEVELS OF BETA-CAROTENE RANGED BETWEEN 0.22 AND 0.62 MG/KG, FOLLOWED BY LUTEIN (0.01-0.06 MG/KG). THE TOTAL CONTENT OF TOCOPHEROL RANGED FROM 186.5 TO 436.2 MG/KG OF THE EXTRACTED OIL AND THE MAJOR ISOFORM IN ALL SAMPLES WAS GAMMA-TOCOPHEROL. THE MOST ABUNDANT PHYTOSTEROL WAS BETA-SITOSTEROL (974-1494 MG/KG) FOLLOWED BY CAMPESTEROL THEN DELTA-5-AVENASTEROL. THE MAJOR TRITERPENIC ALCOHOL WAS CYCLOARTENOL (226.4-532.1 MG/KG). HEXACOSANOL (9.71-28.15 MG/KG) WAS THE MAJOR ALIPHATIC ALCOHOL. THE DETECTED VOLATILE COMPOUNDS WERE PENTANAL, HEXANAL, NONANAL, 2-DECENAL AND HEXANOL. THE STATISTICAL ANALYSIS SHOWED SIGNIFICANT DIFFERENCES BETWEEN VARIETIES, WHICH ARE PROBABLY DUE TO GENETIC FACTORS. (C) 2014 ELSEVIER LTD. ALL RIGHTS RESERVED.","JUGLANS REGIA L.; TOCOPHEROL; PHYTOSTEROL; TRITERPENIC AND ALIPHATIC; ALCOHOLS; CAROTENOIDS; VOLATILE COMPOUNDS","VIRGIN OLIVE OIL; PHYSICOCHEMICAL PROPERTIES; ANTIOXIDANT ACTIVITIES; POLICOSANOL CONTENTS; ALPHA-TOCOPHEROL; CHLOROPHYLL; EXTRACTION; STABILITY; QUALITY; FRUIT","MINISTRY OF HIGHER EDUCATION AND SCIENTIFIC RESEARCH OF TUNISIA","THIS WORK HAS BEEN DONE AS A PART OF A NATIONAL RESEARCH PROJECT. WE THANK THE MINISTRY OF HIGHER EDUCATION AND SCIENTIFIC RESEARCH OF TUNISIA FOR FINANCIALLY SUPPORTING THIS INVESTIGATION. WE THANK ALSO DR. MOUNAWER BADRI FOR HIS CONSTRUCTIVE ADVICES. PART OF THIS WORK WAS CARRIED OUT AT ``INSTITUTO DE LA GRASA'' CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC), 41012 SEVILLA, SPAIN.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; AGER D. J., 1993, SCI FOOD IND 21 CENT; AKIHISA T, 2000, J AGR FOOD CHEM, V48, P2313, DOI 10.1021/JF000135O; ALTISENT R, 2009, FOOD SCI TECHNOL INT, V15, P481, DOI 10.1177/1082013209350351; ANGEROSA F, 2001, ITAL J FOOD SCI, V13, P421; ANONYMOUS, ANAL BIOANAL CHEM; AZADMARD-DAMIRCHI S, 2006, J CHROMATOGR A, V1108, P183, DOI 10.1016/J.CHROMA.2006.01.015; BANEL DK, 2009, AM J CLIN NUTR, V90, P56, DOI 10.3945/AJCN.2009.27457; BOUABDALLAH I, 2014, NAT PROD RES, V28, P1826, DOI 10.1080/14786419.2014.950573; CALPE-BERDIEL L, 2009, ATHEROSCLEROSIS, V203, P18, DOI 10.1016/J.ATHEROSCLEROSIS.2008.06.026; CARDELLO A.V., 1994, MEASUREMENT FOOD PRE, P253, DOI DOI 10.1007/978-1-4615-2171-6\_10; CHOE E, 2005, J FOOD SCI, V70, PR142, DOI 10.1111/J.1365-2621.2005.TB08329.X; CRIADO MN, 2007, FOOD CHEM, V100, P748, DOI 10.1016/J.FOODCHEM.2005.10.035; DIEFFENBACHER A. IUPAC IUPAC, 1992, STANDARD METHODS ANA, V7TH; DOGAN SF, 2005, EUR FOOD RES TECHNOL, V220, P502, DOI 10.1007/S00217-004-1099-7; FERNANDES P, 2007, BIORESOURCE TECHNOL, V98, P2335, DOI 10.1016/J.BIORTECH.2006.10.006; GHARIBZAHEDI SMT, 2013, IND CROP PROD, V45, P133, DOI 10.1016/J.INDCROP.2012.11.040; GIMENO E, 2000, J CHROMATOGR A, V881, P255, DOI 10.1016/S0021-9673(00)00272-7; GUTIERREZ F, 1989, J FOOD SCI, V54, P68, DOI 10.1111/J.1365-2621.1989.TB08569.X; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; JACKSON MA, 2006, J SUPERCRIT FLUID, V37, P173, DOI 10.1016/J.SUPFLU.2005.08.008; JIA MY, 2007, FOOD CHEM, V103, P695, DOI 10.1016/J.FOODCHEM.2006.06.024; JUDDE A, 2003, J AM OIL CHEM SOC, V80, P1209, DOI 10.1007/S11746-003-0844-4; KALUA CM, 2007, FOOD CHEM, V100, P273, DOI 10.1016/J.FOODCHEM.2005.09.059; KENDALL CWC, 2011, NUTR METAB CARDIOVAS, V21, PS34, DOI 10.1016/J.NUMECD.2011.03.013; KIRITSAKIS A., 2000, HANDBOOK OF OLIVE OIL - ANALYSIS AND PROPERTIES, P129; KORNSTEINER M, 2006, FOOD CHEM, V98, P381, DOI 10.1016/J.FOODCHEM.2005.07.033; LI, 1999, J CARDIOVASC PHARMACOL THER, V4, P219; LI L, 2007, J AGR FOOD CHEM, V55, P1164, DOI 10.1021/JF062322D; LORENZO IM, 2002, J CHROMATOGR A, V945, P221, DOI 10.1016/S0021-9673(01)01502-3; MADAWALA SRP, 2012, GRASAS ACEITES, V63, P143, DOI 10.3989/GYA.083811; MAESTRI DM, 1998, GRASAS ACEITES, V49, P395, DOI 10.3989/GYA.1998.V49.I5-6.747; MARTÍNEZ ML, 2008, J FOOD ENG, V88, P399, DOI 10.1016/J.JFOODENG.2008.02.026; MARTÍNEZ ML, 2010, J SCI FOOD AGR, V90, P1959, DOI 10.1002/JSFA.4059; MINGUEZMOSQUERA MI, 1989, J AGR FOOD CHEM, V37, P1, DOI 10.1021/JF00085A001; MIRALIAKBARI H, 2008, FOOD CHEM, V111, P421, DOI 10.1016/J.FOODCHEM.2008.04.008; MISAWA N, 2009, PLANT BIOTECHNOL, V26, P93, DOI 10.5511/PLANTBIOTECHNOLOGY.26.93; MORALES MT, 1997, J AGR FOOD CHEM, V45, P2666, DOI 10.1021/JF960585+; MUKUDDEM-PETERSEN J, 2005, J NUTR, V135, P2082, DOI 10.1093/JN/135.9.2082; NASRI N, 2007, J AGR FOOD CHEM, V55, P2251, DOI 10.1021/JF062911J; 乜兰春 NIE LANCHUN, 2004, 植物学通报, CHINESE BULLETIN OF BOTANY, V21, P631; NORMÉN L, 2006, EUR J NUTR, V45, P165, DOI 10.1007/S00394-006-0578-Y; PARK SK, 2008, J NUTR, V138, P1010, DOI 10.1093/JN/138.6.1010; RABRENOVIC B, 2008, CHEM NAT COMPD+, V44, P151, DOI 10.1007/S10600-008-9000-8; REINERS J, 1998, J AGR FOOD CHEM, V46, P2754, DOI 10.1021/JF970940B; RICHARDSON D. G., 1996, ACTA HORTIC, V445, P295; SAKOUHI F, 2009, FOOD CHEM, V116, P345, DOI 10.1016/J.FOODCHEM.2009.01.094; SCHWARTZ H, 2008, J FOOD COMPOS ANAL, V21, P152, DOI 10.1016/J.JFCA.2007.07.012; SERANI A., 2001, RIVISTA ITALIANA DELLE SOSTANZE GRASSE, V78, P459; TAY B. Y. P., 2000, J OIL PALM RES, V13, P14; THOMAS H, 1997, NEW PHYTOL, V136, P163, DOI 10.1046/J.1469-8137.1997.00737.X; WAGNER KH, 2000, EUR J LIPID SCI TECH, V102, P624, DOI 10.1002/1438-9312(200010)102:10<624::AID-EJLT624>3.0.CO;2-I; WANAKHACHORNKRAI P, 2003, FOOD CHEM, V83, P619, DOI 10.1016/S0308-8146(03)00256-5","ABDALLAH, IB (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, DEPT BIOL, LAB BIOCHIM LIPIDES, TUNIS 2092, TUNISIA","ELSEVIER SCI LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","WOS000347755800127","FOOD CHEM","UNIV TUNIS EL MANAR;UNIV TUNIS EL MANAR;INST GRASA","UNIV TUNIS EL MANAR",NA,"ABDALLAH IB, 2015, FOOD CHEM","ABDALLAH IB, 2015, FOOD CHEM1"
"BYUN A;CHUN H;LEE J;LEE S;LEE ;HONG S H;SHIM K","BYUN A RI;CHUN HYEJIN;LEE JIN;LEE SANG WHA;LEE; HONG SOO;SHIM KYUNG WON","EFFECTS OF A DIETARY SUPPLEMENT WITH BARLEY SPROUT EXTRACT ON BLOOD CHOLESTEROL METABOLISM",2015,"EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE","2015",NA,21,"10.1155/2015/473056","SHIM, KW (CORRESPONDING AUTHOR), EWHA WOMANS UNIV, SCH MED, MOKDONG HOSP, DEPT FAMILY MED, SEOUL, SOUTH KOREA.; BYUN, A. RI; LEE, JIN; LEE, SANG WHA; LEE, HONG SOO; SHIM, KYUNG WON, EWHA WOMANS UNIV, SCH MED, MOKDONG HOSP, DEPT FAMILY MED, SEOUL, SOUTH KOREA.; CHUN, HYEJIN, EWHA WOMANS UNIV, MOKDONG HOSP, HLTH PROMOT CTR, SEOUL 158710, SOUTH KOREA.","OBJECTIVE. BARLEY SPROUT (HORDEUM VULGARE L.) CONTAINS 4.97\% FAT, 52.6\% POLYSACCHARIDE, AND 34.1\% PROTEIN ALONG WITH A VARIETY OF VITAMINS, MINERALS, AND POLYPHENOLIC COMPOUNDS. HEXACOSANOL IS ONE SUCH COMPOUND FROM THE BARLEY LEAF THAT MIGHT IMPROVE CHOLESTEROL METABOLISM BY DECREASING CHOLESTEROL SYNTHESIS. METHOD. THEREFORE, THIS STUDY WAS CONDUCTED TO INVESTIGATE THE EFFECTS OF BARLEY SPROUT EXTRACT ON SERUM LIPID METABOLISM IN HEALTHY VOLUNTEERS (N = 51). SUBJECTS WERE RANDOMLY DIVIDED INTO TWO GROUPS: ONE GROUP CONSUMED A SINGLE CAPSULE OF BARLEY LEAF EXTRACT DAILY (N = 25, 42.48 +/- 13.58 YEARS) AND THE OTHER CONSUMED PLACEBO CAPSULES (N = 26, 40.54 +/- 11.1 YEARS) FOR 12 WEEKS. RESULTS. AFTER 12 WEEKS, TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN-(LDL-) CHOLESTEROL WERE NOT LOWER IN THE BARLEY SPROUT EXTRACT GROUP COMPARED TO THE PLACEBO GROUP (P - 0.415 AND P - 0.351, RESP.) AND NO DIFFERENCES IN CLINICAL OR LABORATORY FINDINGS WERE OBSERVED BETWEEN BOTH GROUPS. CONCLUSION. OUR STUDY FAILED TO SHOW SIGNIFICANT LIPID-LOWERING EFFECTS OF BARLEY SPROUT EXTRACT, POSSIBLY DUE TO DOSAGE, DURATION OF THERAPY, AND SMALL SAMPLE SIZE. DESPITE OUR NONSIGNIFICANT FINDINGS, BARLEY SPROUT HAS A POSSIBILITY AS A FUNCTIONAL HEALTH FOOD; THEREFORE FUTURE RESEARCH IS NEEDED.",NA,"PROTEIN-KINASE; LDL OXIDATION; LEAF EXTRACT; POLICOSANOL; LIPIDS; FLAVONOIDS; LEAVES; FOODS","COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURE SCIENCE AND TECHNOLOGY DEVELOPMENT [PJ00850601]","THIS WORK WAS SUPPORTED BY GRANTS FROM THE COOPERATIVE RESEARCH PROGRAM FOR AGRICULTURE SCIENCE AND TECHNOLOGY DEVELOPMENT (PROJECT PJ00850601).","ARAI S, 2008, CURR OPIN LIPIDOL, V19, P69, DOI 10.1097/MOL.0B013E3282F3F505; BACKES JM, 2011, LIPIDS, V46, P923, DOI 10.1007/S11745-011-3591-8; BARRAT E, 2013, EUR J NUTR, V52, P1843, DOI 10.1007/S00394-012-0486-2; BENEDET JA, 2007, J AGR FOOD CHEM, V55, P5499, DOI 10.1021/JF070543T; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; FERRERES F, 2009, J AGR FOOD CHEM, V57, P2405, DOI 10.1021/JF8037727; KOHYAMA N, 2008, J AGR FOOD CHEM, V56, P5770, DOI 10.1021/JF800626B; MARKHAM KR, 2003, Z NATURFORSCH C, V58, P53; MCINTOSH G H, 1995, WORLD REV NUTR DIET, V77, P89; MCINTOSH GH, 1991, AM J CLIN NUTR, V53, P1205, DOI 10.1093/AJCN/53.5.1205; OHTAKE H, 1985, YAKUGAKU ZASSHI, V105, P1052, DOI 10.1248/YAKUSHI1947.105.11\_1052; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; RANHOTRA GS, 1998, PLANT FOOD HUM NUTR, V52, P329, DOI 10.1023/A:1008007202444; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; SATTAR A, 1995, PLANT FOOD HUM NUTR, V47, P63, DOI 10.1007/BF01088168; SEO WD, 2013, J AGR FOOD CHEM, V61, P1117, DOI 10.1021/JF3041879; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAKANO A, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/137871; YU YM, 2004, BIOL PHARM BULL, V27, P802, DOI 10.1248/BPB.27.802; YU YM, 2002, JPN J PHARMACOL, V89, P142, DOI 10.1254/JJP.89.142; YU YM, 2002, DIABETES METAB, V28, P107; ZANG MW, 2006, DIABETES, V55, P2180, DOI 10.2337/DB05-1188","SHIM, KW (CORRESPONDING AUTHOR), EWHA WOMANS UNIV, SCH MED, MOKDONG HOSP, DEPT FAMILY MED, SEOUL, SOUTH KOREA","HINDAWI LTD","ENGLISH","EVID.-BASED COMPLEMENT ALTERN. MED.","ARTICLE","ISI","WOS000356270900001","EVID-BASED COMPLEMENT ALTERN MED","EWHA WOMANS UNIV;EWHA WOMANS UNIV;EWHA WOMANS UNIV","EWHA WOMANS UNIV",NA,"BYUN AR, 2015, EVID-BASED COMPLEMENT ALTERN MED","BYUN AR, 2015, EVID-BASED COMPLEMENT ALTERN MED"
"WANG C;FAN A;DENG S;GAO W;ZHANG ;WEI W;YANG W;ZHU X;LU Y;CHEN X","WANG CHUNFENG;FAN ALI;DENG SHUHUA;GAO WENCHAO;ZHANG; WEI;YANG WEI;ZHU XIAOJIE;LU YANG;CHEN XIJING","INVESTIGATION ON PHARMACOKINETICS TISSUE DISTRIBUTION AND EXCRETION OF 1TRIACONTANOL IN RATS BY GAS CHROMATOGRAPHYTANDEM MASS SPECTROMETRY GCMSMS",2015,"XENOBIOTICA","45","71-78",2,"10.3109/00498254.2014.943334","CHEN, XJ (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, CTR DRUG METAB \& PHARMACOKINET, NANJING 210009, JIANGSU, PEOPLES R CHINA.; WANG, CHUNFENG; FAN, ALI; DENG, SHUHUA; GAO, WENCHAO; ZHANG, WEI; YANG, WEI; ZHU, XIAOJIE; CHEN, XIJING, CHINA PHARMACEUT UNIV, CTR DRUG METAB \& PHARMACOKINET, NANJING 210009, JIANGSU, PEOPLES R CHINA.; LU, YANG, UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACOTHERAPY \& EXPT THERAPEUT, CHAPEL HILL, NC USA.","1. 1-TRIACONTANOL (TA) RECENTLY SHOWS PROMISING ANTI-TUMOR ACTIVITY. THE PRESENT STUDY WAS AIMED TO DEVELOP A SENSITIVE GAS CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD TO EXPLORE THE PHARMACOKINETIC PROFILES, DISTRIBUTION AND EXCRETION OF TA IN SPRAGUE-DAWLEY RATS AFTER ORAL ADMINISTRATION OF TA. CHROMATOGRAPHY SEPARATION WAS PERFORMED ON A HP-5MS COLUMN. 1-OCTACOSANAL WAS USED AS THE INTERNAL STANDARD (IS). QUANTIFICATION OF TA AND IS WAS CARRIED OUT AT M/Z 495.6 --> 97.0 AND M/Z 467.5 --> 97.0, RESPECTIVELY, IN POSITIVE ELECTRON IONIZATION AND MULTIPLE REACTION MONITORING MODE. THE PHARMACOKINETIC PARAMETERS WERE CALCULATED BY NON-COMPARTMENTAL ANALYSIS. 2. THE AREA UNDER CONCENTRATION-TIME CURVE AUC(0-6) H AND AUC(0-INFINITY) FOR TA AT 60 MG/KG WERE 87.737 +/- 13.574 AND 93.617 +/ - 17.62, RESPECTIVELY. THE MEAN RESIDENCE TIME WAS 3.25 +/- 0.17 H. IN ADDITION, THE ELIMINATION HALF-LIVES (T(1/2)) WERE (2.37 +/- 1.23, 1.27 +/- 0.49, 2.07 +/- 0.93) H AFTER SINGLE ORAL ADMINISTRATION OF 30, 60 AND 120 MG/KG OF TA. AFTER ORAL ADMINISTRATION, TA WAS EXTENSIVELY DISTRIBUTED IN STOMACH AND INTESTINE. THE MAJORITY OF TA EXCRETED VIA FECES, AND ITS ACCUMULATIVE EXCRETION RATIO DURING THE PERIOD OF 72 H WAS 26.68 +/- 7.14\%, BUT ONLY 0.0023 +/- 0.0015\% AND 0.0027 +/ - 0.0006\% FOR URINES AND BILE, RESPECTIVELY. THE ABSOLUTE BIOAVAILABILITY (F, \%) OF TA WAS ABOUT 2.0\%.","1-TRIACONTANOL; GC-MS/MS; PHARMACOKINETICS","CORONARY RISK-FACTORS; II HYPERCHOLESTEROLEMIA; LIPID PROFILE; POLICOSANOL; TOLERABILITY; EFFICACY",NA,NA,"ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CASTAÑO G, 2001, J GERONTOL A-BIOL, V56, PM186, DOI 10.1093/GERONA/56.3.M186; CASTAÑO G, 2000, CURR THER RES CLIN E, V61, P137, DOI 10.1016/S0011-393X(00)80011-9; CASTANO G, 2000, GYNECOL ENDOCRINOL, V13, P1; DULLENS SPJ, 2008, J LIPID RES, V49, P790, DOI 10.1194/JLR.M700497-JLR200; FAN XE, 2011, U. S. PATENT, PATENT NO. 7863337B2; HAIM D, 2009, J CHROMATOGR B, V877, P4154, DOI 10.1016/J.JCHROMB.2009.10.034; HERNANDEZS J, 1992, CURR THER RES CLIN E, V51, P568; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2001, CLIN DRUG INVEST, V21, P485; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; NOA M, 1995, J PHARM PHARMACOL, V47, P289, DOI 10.1111/J.2042-7158.1995.TB05797.X; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; ZHANG RW, 2008, CHINA PATENT, PATENT NO. 101190210A","CHEN, XJ (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, CTR DRUG METAB \& PHARMACOKINET, NANJING 210009, JIANGSU, PEOPLES R CHINA","INFORMA HEALTHCARE","ENGLISH","XENOBIOTICA","ARTICLE","ISI","WOS000345982600008","XENOBIOTICA","CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV;UNIV N CAROLINA","CHINA PHARMACEUT UNIV",NA,"WANG C, 2015, XENOBIOTICA","WANG C, 2015, XENOBIOTICA"
"DENG S;WANG C;ZHANG W;GAO W;FAN ;ALI A;ZHANG Q;ZHANG Y;LIU Q;LI N;LIU Q;ZHAO J;LI C;WEN X;ZHAO D;CHEN X","DENG SHUHUA;WANG CHUNFENG;ZHANG WEI;GAO WENCHAO;FAN; ALI;ZHANG QIUYANG;ZHANG YONGJIE;LIU QINGWANG;LI NING;LIU QI;ZHAO JIE;LI CUIYUN;WEN XINGYUAN;ZHAO DI;CHEN XIJING","EFFECT OF TRIACONTANOL ON THE PHARMACOKINETICS OF DOCETAXEL IN RATS ASSOCIATED WITH INDUCTION OF CYTOCHROME P450 3A12",2014,"XENOBIOTICA","44","583-590",3,"10.3109/00498254.2013.870364","CHEN, XJ (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, CTR DRUG METAB \& PHARMACOKINET, NANJING 210009, JIANGSU, PEOPLES R CHINA.; DENG, SHUHUA; WANG, CHUNFENG; ZHANG, WEI; GAO, WENCHAO; FAN, ALI; ZHANG, QIUYANG; ZHANG, YONGJIE; LI, NING; LIU, QI; ZHAO, JIE; LI, CUIYUN; WEN, XINGYUAN; ZHAO, DI; CHEN, XIJING, CHINA PHARMACEUT UNIV, CTR DRUG METAB \& PHARMACOKINET, NANJING 210009, JIANGSU, PEOPLES R CHINA.; LIU, QINGWANG, CHINA PHARMACEUT UNIV, DEPT NAT MED CHEM, STATE KEY LAB NAT MED, NANJING 210009, JIANGSU, PEOPLES R CHINA.","1. TRIACONTANOL WAS CONFIRMED TO HAVE A POTENTIAL ANTI-CANCER EFFECT, THE AIM WAS TO ASSESS WHETHER THE CO-ADMINISTRATION OF TRIACONTANOL ALTERS THE EXPOSURE OF DOCETAXEL VIA INDUCING HEPATIC CYP3A1/2 ACTIVITY. THE CONCENTRATION OF DOCETAXEL IN RATS PRETREATED WITH TRIACONTANOL FOR SEVEN SUCCESSIVE DAYS WAS DETERMINED, AND THE EXPRESSION LEVELS OF CYP3A PROTEIN AND MRNA WERE ANALYZED BY THE WESTERN BLOT AND REAL TIME POLYMERASE CHAIN REACTION (RT-PCR) TECHNIQUE, RESPECTIVELY. 2. THE CONCENTRATIONS OF DOCETAXEL IN RATS PRETREATED WITH TRIACONTANOL WERE DECREASED, WITH 61.5\%, 61.9\% DECREASE IN AUC(0-24H) AND 65.7\%, 54.9\% REDUCTION IN C-MAX (120 AND 180 MG KG(-1) , RESPECTIVELY) COMPARED WITH THE CONTROL. HEPATIC CLEARANCE OF DOCETAXEL WAS ENHANCED IN VITRO AND IN VIVO AT DOSAGE OF 120 AND 180 MG KG(-1), AND CYP3A ACTIVITY WAS UP-REGULATED BY MEASURING THE FORMATION RATE OF 1-HYDROXYMIDAZOLAM. TRIACONTANOL PREFERENTIALLY INDUCED PROTEIN EXPRESSION LEVEL OF CYP3A2 IN A DOSE-DEPENDENT MANNER AND OF CYP 3A1 AT DOSAGE OF 120 AND 180 MG KG(-1). THE MRNA EXPRESSION OF CYP3A1 WAS MODERATELY DIFFERENT WITH THE WESTERN BLOT RESULTS, BUT THE TRENDS APPEARED SIMILAR. CYP3A2 MRNA LEVEL WAS NOT MARKEDLY AFFECTED BY TRIACONTANOL. 3. THE SIGNIFICANT TRIACONTANOL-DOCETAXEL INTERACTION WAS LARGELY DUE TO THE INDUCTION OF CYP3A1/2, WHICH BROUGHT USEFUL INFORMATION IN THE CLINICAL THERAPY WHEN THE COMBINATION IS ADMINISTERED IN HUMAN.","CYP3A1/2; DOCETAXEL; DRUG-DRUG INTERACTION; INDUCTION TRIACONTANOL","METASTATIC BREAST-CANCER; ANTITUMOR AGENTS; POLICOSANOL; LIVER; METABOLISM; ENZYME; MODEL; DEXAMETHASONE; EXPRESSION; HEPATOCYTES",NA,NA,"ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BRUNO R, 1996, J PHARMACOKINET BIOP, V24, P153, DOI 10.1007/BF02353487; DEBRI K, 1995, BIOCHEM PHARMACOL, V50, P2047, DOI 10.1016/0006-2952(95)02107-8; DULLENS SPJ, 2008, J LIPID RES, V49, P790, DOI 10.1194/JLR.M700497-JLR200; FANS XE, 2011, US PATENT, PATENT NO. 7863337B2, 7863337; FERLAY J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/IJC.25516; GIBSON G.G., 1994, INTRODUCTION TO DRUG METABOLISM, P217; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUENGRICH FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/ANNUREV.PHARMTOX.39.1.1; GUO HF, 2013, J PHARM SCI-US, V102, P2819, DOI 10.1002/JPS.23613; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; HUDACHEK SF, 2013, J PHARMACOKINET PHAR, V40, P437, DOI 10.1007/S10928-013-9317-1; HUIZING MT, 1995, CANCER INVEST, V13, P381, DOI 10.3109/07357909509031919; KHAN KK, 2002, MOL PHARMACOL, V61, P495, DOI 10.1124/MOL.61.3.495; KLENER P., 1995, REMEDIA, V5, P154; KOBAYASHI K, 2002, BIOCHEM PHARMACOL, V63, P889, DOI 10.1016/S0006-2952(01)00843-7; LI L, 2012, ACTA PHARMACOL SIN, V33, P127, DOI 10.1038/APS.2011.161; 李灵 LI LING, 2011, 中国药房, CHINA PHARMACY, V22, P398; LI TT, 2011, EUR J DRUG METAB PH, V36, P249, DOI 10.1007/S13318-011-0050-0; LIVAK KJ, 2001, METHODS, V25, P402, DOI 10.1006/METH.2001.1262; MARRE F, 1996, CANCER RES, V56, P1296; MARTÍNEZ-JIMÉNEZ CP, 2007, CURR DRUG METAB, V8, P185, DOI 10.2174/138920007779815986; MEI Q, 2004, J PHARM SCI-US, V93, P2488, DOI 10.1002/JPS.20102; MENENDEZ R, 1997, PHYSIOL BEHAV, V67, P1; MILES D, 2002, ONCOLOGIST, V7, P13; PAN J, 2002, XENOBIOTICA, V32, P739, DOI 10.1080/00498250210147115; ROWINSKY EK, 1992, SEMIN ONCOL, V19, P646; ROYER I, 1996, CANCER RES, V56, P58; SHIBAYAMA Y, 2006, CANCER SCI, V97, P1260, DOI 10.1111/J.1349-7006.2006.00304.X; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TELHADA MB, 1992, ARCH BIOCHEM BIOPHYS, V298, P715, DOI 10.1016/0003-9861(92)90471-8; TETTEY JN, 2001, CHEM RES TOXICOL, V14, P965, DOI 10.1021/TX0001981; TKACZUK KHR, 2009, CLIN THER, V31, P2273, DOI 10.1016/J.CLINTHERA.2009.11.011; WANG X, 2013, DRUG RES (STUTTG), V63, P603, DOI 10.1055/S-0033-1349126; YAMAMOTO N, 2000, J CLIN ONCOL, V18, P2301, DOI 10.1200/JCO.2000.18.11.2301; YU LS, 2008, J PHARM PHARMACOL, V60, P1601, DOI 10.1111/J.2042-7158.2008.TB02172.X; ZHANG Q, 2008, J ZHENGZHOU U, V43, P364; ZHANG ZY, 2006, BIOCHEM BIOPH RES CO, V341, P399, DOI 10.1016/J.BBRC.2005.12.203","CHEN, XJ (CORRESPONDING AUTHOR), CHINA PHARMACEUT UNIV, CTR DRUG METAB \& PHARMACOKINET, NANJING 210009, JIANGSU, PEOPLES R CHINA","TAYLOR \& FRANCIS LTD","ENGLISH","XENOBIOTICA","ARTICLE","ISI","WOS000337020100001","XENOBIOTICA","CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV;CHINA PHARMACEUT UNIV","CHINA PHARMACEUT UNIV",NA,"DENG S, 2014, XENOBIOTICA","DENG S, 2014, XENOBIOTICA"
"MONTSERRAT-DE L P S;FERNANDEZ-ARCHE M;ANGEL-MARTIN M;GARCIA-GIMENEZ M","MONTSERRAT-DE LA PAZ S;FERNANDEZ-ARCHE M A;ANGEL-MARTIN M;GARCIA-GIMENEZ M D","PHYTOCHEMICAL CHARACTERIZATION OF POTENTIAL NUTRACEUTICAL INGREDIENTS FROM EVENING PRIMROSE OIL IOENOTHERA BIENNISI L",2014,"PHYTOCHEMISTRY LETTERS","8","158-162",42,"10.1016/j.phytol.2013.08.008","MONTSERRAT-DE LA PAZ, S (CORRESPONDING AUTHOR), UNIV SEVILLE, SCH PHARM, DEPT PHARMACOL, PROF GARCIA GONZALEZ 2, E-41012 SEVILLE, SPAIN.; MONTSERRAT-DE LA PAZ, S.; FERNANDEZ-ARCHE, M. A.; ANGEL-MARTIN, M.; GARCIA-GIMENEZ, M. D., UNIV SEVILLE, SCH PHARM, DEPT PHARMACOL, E-41012 SEVILLE, SPAIN.","EVENING PRIMROSE OIL (EPO) IS A NATURAL PRODUCT EXTRACTED BY COLD-PRESSED FROM OENOTHERA BIENNIS L. SEEDS. EPO IS WIDELY USED AS A DIETARY SUPPLEMENT FROM WHICH BENEFICIAL EFFECTS HAVE BEEN REPORTED IN RHEUMATIC AND ARTHRITIC CONDITIONS, ATOPIC DERMATITIS, PSORIASIS, PREMENSTRUAL AND MENOPAUSAL SYNDROME, AND DIABETIC NEUROPATHY. THE BENEFICIAL EFFECTS OF EPO ARE THOUGHT TO BE DUE TO ITS GAMMA-LINOLENIC ACID CONTENT; IN CONTRAST, LITTLE EFFORT HAS BEEN EXPENDED TO CHARACTERIZE THE NON-TRIGLYCERIDIC CONSTITUENTS OF EPO. IN ORDER TO EVALUATE ITS POTENTIAL AS SOURCE OF FUNCTIONAL FOOD INGREDIENTS OUR AIM IN THIS WORK HAS BEEN IDENTIFIED AND QUANTIFIED THE DIFFERENT COMPONENTS OF EPO BY DIFFERENT TECHNIQUES (GC-MS AND HPLC). THE LIPID PROFILE SHOWED THAT OLEIC (7\%), LINOLEIC (74\%) AND G-LINOLENIC (9\%) WERE THE MOST ABUNDANCE FATTY ACIDS. UNSAPONIFIABLE MATTER AND SUBFRACTIONS WERE OBTAINED BY CEE/2568/91. SEPARATION OF THE COMPOUNDS UNDER STUDY WAS ACHIEVED GIVING A REASONABLE ANALYSIS TIME AND GOOD RESOLUTION. A YIELD (1.82-1.95\%) OF UNSAPONIFIABLE MATTER WAS OBTAINED AND LEVELS OF SATURATED HYDROCARBONS (0.291.97 +/- 14.85 MG) WERE NOTICED. BETA-SITOSTEROL (7952.00 +/- 342.25 MG/ KG OIL) AND CAMPESTEROL (883.32 +/- 0.45 MG/ KG OIL) WERE PREDOMINANT IN PHYTOSTEROL FRACTION (9573 MG/ KG OIL), WHILE TETRACOSANOL (236.93 +/- 2.32 MG/ KG OIL) AND HEXACOSANOL (289.92 +/- 3.41 MG/ KG OIL) IN LINEAR ALIPHATIC ALCOHOL FRACTION (798.04 +/- 5.66 MG/ KG OIL). IN THE PHENOLIC FRACTION (55.49 +/- 2.76 MG/ KG OIL), FERULIC ACID (25.23 +/- 2.64 MG/ KG OIL) WAS THE MAJOR COMPONENT. FROM THE RESULTS OBTAINED, IT CAN BE SUGGESTED THAT THE EVENING PRIMROSE OIL CAN BE CONSIDERED AN INTERESTING ALIMENTARY SOURCE OF SUBSTANCES OF NUTRACEUTICAL VALUE. (C) 2013 PHYTOCHEMICAL SOCIETY OF EUROPE. PUBLISHED BY ELSEVIER B.V. ALL RIGHTS RESERVED.","FUNCTIONAL FOOD; UNSAPONIFIABLE; OIL; PHYTOSTEROLS; POLICOSANOL; EVENING; PRIMROSE","PROINFLAMMATORY MEDIATORS; OLIVE OILS; STEROLS; POLICOSANOL; MODULATE; RELEASE; ACID",NA,NA,"ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; BELCH JJF, 2000, AM J CLIN NUTR, V71, P352S, DOI 10.1093/AJCN/71.1.352S; CERT A, 2000, GRASAS ACEITES, V51, P447; CERT A, 1997, GRASAS ACEITES, V48, P207, DOI 10.3989/GYA.1997.V48.I4.791; CERT A, 2000, J CHROMATOGR A, V881, P131, DOI 10.1016/S0021-9673(00)00389-7; DEVARAJ S, 2006, NUTR REV, V64, P348, DOI 10.1111/J.1753-4887.2006.TB00219.X; FAN YY, 1998, J NUTR, V128, P1411, DOI 10.1093/JN/128.9.1411; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; HUDSON BJF, 1984, J AM OIL CHEM SOC, V61, P540, DOI 10.1007/BF02677026; KIM HK, 2003, CLIN CHIM ACTA, V327, P129, DOI 10.1016/S0009-8981(02)00344-3; KLEIJNEN J, 1994, BMJ-BRIT MED J, V309, P824, DOI 10.1136/BMJ.309.6958.824; MAHADY G. B., 2001, BOT DIETARY SUPPLEME, P75; MATEOS R, 2001, J AGR FOOD CHEM, V49, P2185, DOI 10.1021/JF0013205; MEDINA E, 2007, J AGR FOOD CHEM, V55, P9817, DOI 10.1021/JF0719757; MONTSERRAT-DE LA PAZ S, 2012, PHYTOMEDICINE, V19, P1072, DOI 10.1016/J.PHYMED.2012.06.008; OSTLUND RE, 2002, NUTR REV, V60, P349, DOI 10.1301/00296640260385793; PAQUOT C, 1992, IUPAC STANDARD METHO; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; WEIHRAUCH JL, 1978, J AM DIET ASSOC, V73, P39","MONTSERRAT-DE LA PAZ, S (CORRESPONDING AUTHOR), UNIV SEVILLE, SCH PHARM, DEPT PHARMACOL, PROF GARCIA GONZALEZ 2, E-41012 SEVILLE, SPAIN","ELSEVIER SCIENCE BV","ENGLISH","PHYTOCHEM. LETT.","ARTICLE","ISI","WOS000335743300034","PHYTOCHEM LETT","UNIV SEVILLE;FERNANDEZ-ARCHE;UNIV SEVILLE","UNIV SEVILLE",NA,"MONTSERRAT-DE LA PAZ S, 2014, PHYTOCHEM LETT","MONTSERRAT-DE LA PAZ S, 2014, PHYTOCHEM LETT1"
"MONTSERRAT-DE L P S;MARIN-AGUILAR F;GARCIA-GIMENEZ M;FERNANDEZ-ARCHE M","MONTSERRAT-DE LA PAZ S;MARIN-AGUILAR F;GARCIA-GIMENEZ M D;FERNANDEZ-ARCHE M A","HEMP ICANNABIS SATIVAI L SEED OIL ANALYTICAL AND PHYTOCHEMICAL CHARACTERIZATION OF THE UNSAPONIFIABLE FRACTION",2014,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","62","1105-1110",104,"10.1021/jf404278q","FERNÁNDEZ-ARCHE, MA (CORRESPONDING AUTHOR), UNIV SEVILLE, FAC PHARM, DEPT PHARMACOL, E-41012 SEVILLE, SPAIN.; MONTSERRAT-DE LA PAZ, S.; MARIN-AGUILAR, F.; GARCIA-GIMENEZ, M. D.; FERNANDEZ-ARCHE, M. A., UNIV SEVILLE, FAC PHARM, DEPT PHARMACOL, E-41012 SEVILLE, SPAIN.; MONTSERRAT-DE LA PAZ, S., CSIC, INST GRASA, LAB CELLULAR \& MOL NUTR, SEVILLE 41012, SPAIN.","NON-DRUG VARIETIES OF CANNABIS SATIVA L., COLLECTIVELY NAMELY AS ``HEMP'' HAVE BEEN AN INTERESTING SOURCE OF FOOD, FIBER, AND MEDICINE FOR THOUSANDS OF YEARS. THE EVER-INCREASING DEMAND FOR VEGETABLES OILS HAS MADE IT ESSENTIAL TO CHARACTERIZE ADDITIONAL VEGETABLE OIL THROUGH INNOVATIVE USES OF ITS COMPONENTS. THE LIPID PROFILE SHOWED THAT LINOLEIC (55\%), A-LINOLENIC (16\%), AND OLEIC (11\%) WERE THE MOST ABUNDANT FATTY ACIDS. A YIELD (1.84-1.92\%) OF UNSAPONIFIABLE MATTER WAS OBTAINED, AND THE MOST INTERESTING COMPOUNDS WERE BETA-SITOSTEROL (1905.00 +/- 59.27 MG/KG OF OIL), CAMPESTEROL (505.69 +/- 32.04 MG/KG OF OIL), PHYTOL (167.59 +/- 1.81 MG/KG OF OIL), CYCLOARTENOL (90.55 +/ - 3.44 MG/KG OF OIL), AND GAMMA-TOCOPHEROL (73.38 +/- 2.86 MG/100 G OF OIL). THIS STUDY IS AN INTERESTING CONTRIBUTION FOR C. SATIVA L. CONSIDERATION AS A SOURCE OF BIOACTIVE COMPOUNDS CONTRIBUTING TO NOVEL RESEARCH APPLICATIONS FOR HEMP SEED OIL IN THE PHARMACEUTICAL, COSMETIC FOOD, AND OTHER NON-FOOD INDUSTRIES.","HEMP; CANNABIS SATIVA; VEGETABLE OILS; FATTY ACIDS; STEROLS; PHYTOL; TOCOPHEROLS","VIRGIN OLIVE OIL; FATTY-ACIDS; MINOR CONSTITUENTS; DIETARY; MODULATE; SUPPLEMENTATION; POLICOSANOL; METABOLISM; TOCOPHEROL; EFFICACY",NA,NA,"AL-KHALIFA A, 2007, AM J PHYSIOL-REG I, V292, PR1198, DOI 10.1152/AJPREGU.00661.2006; ANWAR F, 2006, J AM OIL CHEM SOC, V83, P323, DOI 10.1007/S11746-006-1207-X; ARSHAD A, 2011, BRIT J NUTR, V106, P795, DOI 10.1017/S0007114511003060; BLADE S.F., 1998, ALBERTA HEMP S P, P2; BLEKAS G, 1995, FOOD CHEM, V52, P289, DOI 10.1016/0308-8146(95)92826-6; CALIGIANI A, 2010, PLANT FOOD HUM NUTR, V65, P277, DOI 10.1007/S11130-010-0173-5; CALLAWAY J, 2005, J DERMATOL TREAT, V16, P87, DOI 10.1080/09546630510035832; CALLAWAY JC, 2004, EUPHYTICA, V140, P65, DOI 10.1007/S10681-004-4811-6; CERT A, 2000, GRASAS ACEITES, V51, P447; CERT A, 2000, J CHROMATOGR A, V881, P131, DOI 10.1016/S0021-9673(00)00389-7; DE PADUA L.S., 1999, PLANT RESOURCES S E, V1, P167; DEFERNE J.L., 1996, J INT HEMP ASS, V3, P4; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; FRETTS AM, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.003814; FROMM M, 2012, J AGR FOOD CHEM, V60, P10733, DOI 10.1021/JF3028446; HOLLER JM, 2008, J ANAL TOXICOL, V32, P428, DOI 10.1093/JAT/32.6.428; IVANOV SA, 1998, FETT-LIPID, V100, P348, DOI 10.1002/(SICI)1521-4133(199808)100:8<348::AID-LIPI348>3.3.CO;2-9; KAUL N, 2008, J AM COLL NUTR, V27, P51, DOI 10.1080/07315724.2008.10719674; KLINGBERG S, 2013, J NUTR, V143, P1630, DOI 10.3945/JN.113.178707; KOSKI A, 2002, EUR FOOD RES TECHNOL, V214, P294, DOI 10.1007/S00217-001-0479-5; LI YONGJIN, 2008, WEI SHENG YAN JIU, V37, P175; LOU-BONAFONTE JM, 2012, MOL NUTR FOOD RES, V56, P1043, DOI 10.1002/MNFR.201100668; MARTINO F, 2013, ATHEROSCLEROSIS, V228, P198, DOI 10.1016/J.ATHEROSCLEROSIS.2013.02.005; MONTSERRAT-DE LA PAZ S, 2014, PHYTOCHEM LETT, V8, P158, DOI 10.1016/J.PHYTOL.2013.08.008; LA PAZ SMD, 2014, J ETHNOPHARMACOL, V151, P131, DOI 10.1016/J.JEP.2013.10.012; MONTSERRAT-DE LA PAZ S, 2013, J FUNCT FOODS, V5, P1279, DOI 10.1016/J.JFF.2013.04.012; MONTSERRAT-DE LA PAZ S, 2012, PHYTOMEDICINE, V19, P1072, DOI 10.1016/J.PHYMED.2012.06.008; NISSEN L, 2010, FITOTERAPIA, V81, P413, DOI 10.1016/J.FITOTE.2009.11.010; OOMAH BD, 2002, FOOD CHEM, V76, P33, DOI 10.1016/S0308-8146(01)00245-X; ORHAN I., 2000, J FAC PHARM GAZI U, V17, P79; OSTLUND RE, 2002, NUTR REV, V60, P349, DOI 10.1301/00296640260385793; PAQUOT C., 1992, STANDARD METHODS ANA; PRINGLE H, 1997, SCIENCE, V277, P1203, DOI 10.1126/SCIENCE.277.5330.1203; PROCIUK MA, 2008, CAN J PHYSIOL PHARM, V86, P153, DOI 10.1139/Y08-011; RAMOS PAB, 2013, J AGR FOOD CHEM, V61, P8420, DOI 10.1021/JF402253A; RANALLI P, 2004, EUPHYTICA, V140, P1, DOI 10.1007/S10681-004-4749-8; REENA MB, 2007, J AGR FOOD CHEM, V55, P10461, DOI 10.1021/JF0718042; RICHARD MN, 2007, J THROMB HAEMOST, V5, P424, DOI 10.1111/J.1538-7836.2007.02327.X; SCHWAB US, 2006, EUR J NUTR, V45, P470, DOI 10.1007/S00394-006-0621-Z; SCORLETTI E, 2013, ANNU REV NUTR, V33, P231, DOI 10.1146/ANNUREV-NUTR-071812-161230; SEO WD, 2013, J AGR FOOD CHEM, V61, P1117, DOI 10.1021/JF3041879; THEIMER RR., 1995, BIORESOUR HEMP, V2, P536; VELASCO J, 2005, J AGR FOOD CHEM, V53, P1328, DOI 10.1021/JF049051W; VETTER W, 2012, J AGR FOOD CHEM, V60, P6103, DOI 10.1021/JF301373K; WEIHRAUCH JL, 1978, J AM DIET ASSOC, V73, P39; YU YH, 2012, NUTR RES, V32, P71, DOI 10.1016/J.NUTRES.2011.12.004; ZIAS J, 1993, NATURE, V363, P215","FERNÁNDEZ-ARCHE, MA (CORRESPONDING AUTHOR), UNIV SEVILLE, FAC PHARM, DEPT PHARMACOL, E-41012 SEVILLE, SPAIN","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000331014700014","J AGRIC FOOD CHEM","UNIV SEVILLE;UNIV SEVILLE;INST GRASA","UNIV SEVILLE",NA,"MONTSERRAT-DE LA PAZ S, 2014, J AGRIC FOOD CHEM","MONTSERRAT-DE LA PAZ S, 2014, J AGRIC FOOD CHEM"
"CHEN G;WANG H;ZHANG X;YANG S","CHEN GU;WANG HONG;ZHANG XU;YANG SHANG-TIAN","NUTRACEUTICALS AND FUNCTIONAL FOODS IN THE MANAGEMENT OF HYPERLIPIDEMIA",2014,"CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION","54","1180-1201",85,"10.1080/10408398.2011.629354","CHEN, G (CORRESPONDING AUTHOR), S CHINA UNIV TECHNOL, COLL LIGHT IND \& FOOD SCI, 381 WUSHAN RD, GUANGZHOU 510641, GUANGDONG, PEOPLES R CHINA.; CHEN, GU; WANG, HONG; ZHANG, XU; YANG, SHANG-TIAN, S CHINA UNIV TECHNOL, COLL LIGHT IND \& FOOD SCI, GUANGZHOU 510641, GUANGDONG, PEOPLES R CHINA.; YANG, SHANG-TIAN, OHIO STATE UNIV, DEPT CHEM \& BIOMOL ENGN, COLUMBUS, OH 43210 USA.","HYPERLIPIDEMIA IS ONE OF THE MAJOR RISK FACTOR FOR THE DEVELOPMENT OF CARDIOVASCULAR DISEASE. HYPOLIPIDEMIC NUTRACEUTICALS AND FUNCTIONAL FOODS HELP IMPROVE SERUM LIPID PROFILES AS REDUCING TOTAL CHOLESTEROL, TRIGLYCERIDE, AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL, WHILE ELEVATING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL. THE EFFECTIVENESS OF OMEGA-3 POLYUNSATURATED FATTY ACID, PHYTOSTEROLS, DIETARY FIBER, AND TEA CATECHIN IN MANAGEMENT OF HYPERLIPIDEMIA HAS BEEN CLEARLY DEMONSTRATED IN EPIDEMIOLOGICAL AND INTERVENTIONAL TRIALS. STUDIES ON MECHANISM REVEAL THAT THEY ACT AS INHIBITOR OR ACTIVATOR OF CRITICAL ENZYME, AGONIST OR INHIBITOR OF TRANSCRIPTION FACTOR, COMPETITOR OF TRANSPORTER, AND SEQUESTRANT OF BILE ACID TO MODULATE LIPID HOMEOSTASIS. HYPOLIPIDEMIC EFFECTS ARE ALSO CLAIMED IN DIETARY PROTEINS, MANY POLYPHENOLS, OTHER PHYTOCHEMICALS, RAW EXTRACT, OR EVEN WHOLE FOOD. THIS REVIEW ATTEMPTS TO GIVE AN OVERVIEW OF LIPID HOMEOSTASIS AND SUMMARIZE RECENT FINDINGS OF HYPOLIPIDEMIC NUTRACEUTICALS AND FUNCTIONAL FOODS ACCORDING TO THEIR ACTIVE INGREDIENTS, FOCUSING ON THE EFFICACY AND UNDERLYING MECHANISMS.","HYPOLIPIDEMIC; CHOLESTEROL; TRIGLYCERIDE; LOW-DENSITY LIPOPROTEIN; HIGH-DENSITY LIPOPROTEIN; NUTRACEUTICALS","GREEN TEA CATECHIN; HIGH-FAT DIET; RED-YEAST-RICE; PROLIFERATOR-ACTIVATED RECEPTORS; BUCKWHEAT PROTEIN PRODUCT; INSOLUBLE; FISH-PROTEIN; SUGAR-CANE POLICOSANOL; ESTER TRANSFER PROTEIN; SERUM LDL; CHOLESTEROL; ACID-BINDING-ACTIVITY","NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA [30800609]; FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL UNIVERSITIES [SCUT 2009ZM0006]","THIS WORK WAS SUPPORTED BY GRANTS 30800609 AND SCUT 2009ZM0006 AWARDED TO GU CHEN FROM THE NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA AND THE FUNDAMENTAL RESEARCH FUNDS FOR THE CENTRAL UNIVERSITIES, RESPECTIVELY.","ABE I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/BBRC.2000.2217; ALVARO A, 2008, IUBMB LIFE, V60, P757, DOI 10.1002/IUB.110; ANDERSON JW, 2009, NUTR REV, V67, P188, DOI 10.1111/J.1753-4887.2009.00189.X; ANNABA F, 2010, AM J PHYSIOL-GASTR L, V298, PG467, DOI 10.1152/AJPGI.00360.2009; ATTIE AD, 2007, TRENDS BIOCHEM SCI, V32, P172, DOI 10.1016/J.TIBS.2007.02.001; AUGER C, 2002, J NUTR, V132, P1207, DOI 10.1093/JN/132.6.1207; BANERJEE S, 2011, LIPIDS, V46, P311, DOI 10.1007/S11745-011-3540-6; BARTEL DP, 2009, CELL, V136, P215, DOI 10.1016/J.CELL.2009.01.002; BEAVEN SW, 2006, ANNU REV MED, V57, P313, DOI 10.1146/ANNUREV.MED.57.121304.131428; BENSINGER SJ, 2008, NATURE, V454, P470, DOI 10.1038/NATURE07202; BERROUGUI H, 2009, ATHEROSCLEROSIS, V207, P420, DOI 10.1016/J.ATHEROSCLEROSIS.2009.05.017; BOGSRUD MP, 2010, SCAND CARDIOVASC J, V44, P197, DOI 10.3109/14017431003624123; BOMMER GT, 2011, CELL METAB, V13, P241, DOI 10.1016/J.CMET.2011.02.004; BOROCHOV-NEORI H, 2008, J AGR FOOD CHEM, V56, P9884, DOI 10.1021/JF801467M; BROWN MS, 2009, J LIPID RES, V50, PS15, DOI 10.1194/JLR.R800054-JLR200; BROWN MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/PNAS.96.20.11041; BROWNING JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; BURSILL CA, 2007, LIPIDS, V42, P621, DOI 10.1007/S11745-007-3077-X; CALPE-BERDIEL L, 2009, ATHEROSCLEROSIS, V203, P18, DOI 10.1016/J.ATHEROSCLEROSIS.2008.06.026; CASTIGLIONI S, 2004, J NUTR, V134, P1276S; CASTILLA P, 2006, AM J CLIN NUTR, V84, P252, DOI 10.1093/AJCN/84.1.252; CHARLTON-MENYS V, 2008, EXP PHYSIOL, V93, P27, DOI 10.1113/EXPPHYSIOL.2007.035147; CHAWLA A, 2001, SCIENCE, V294, P1866, DOI 10.1126/SCIENCE.294.5548.1866; CHAWLA R, 2010, COMPR REV FOOD SCI F, V9, P178, DOI 10.1111/J.1541-4337.2009.00099.X; CHEN G, 2010, PROTEIN SCI, V19, P2015, DOI 10.1002/PRO.496; CHEN J D, 1995, WORLD REV NUTR DIET, V77, P147; CHEN JN, 2011, J AGR FOOD CHEM, V59, P6790, DOI 10.1021/JF200757H; CHEN ZY, 2008, J AGR FOOD CHEM, V56, P8761, DOI 10.1021/JF801566R; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P12143, DOI 10.1021/JF1030345; CHIANG JYL, 2009, J LIPID RES, V50, P1955, DOI 10.1194/JLR.R900010-JLR200; CHIJIMATSU T, 2011, BRIT J NUTR, V105, P526, DOI 10.1017/S0007114510004058; CHO KW, 2011, EUR J NUTR, V50, P81, DOI 10.1007/S00394-010-0117-8; CHUNG MJ, 2008, EUR J PHARMACOL, V578, P159, DOI 10.1016/J.EJPHAR.2007.09.036; CONNOR KM, 2007, NAT MED, V13, P868, DOI 10.1038/NM1591; CONSONNI A, 2010, J NUTR BIOCHEM, V21, P887, DOI 10.1016/J.JNUTBIO.2009.07.003; CRESPY V, 2004, J NUTR, V134, P3431S, DOI 10.1093/JN/134.12.3431S; CUCCIOLONI M, 2011, J LIPID RES, V52, P897, DOI 10.1194/JLR.M011817; DE MEJIA EG, 2010, FOOD CHEM, V119, P1571, DOI 10.1016/J.FOODCHEM.2009.09.044; DI CASTELNUOVO A, 2002, CIRCULATION, V105, P2836, DOI 10.1161/01.CIR.0000018653.19696.01; DONG JY, 2011, BREAST CANCER RES TR, V125, P315, DOI 10.1007/S10549-010-1270-8; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; EDWARDS PA, 2002, J LIPID RES, V43, P2; FABJAN N, 2003, J AGR FOOD CHEM, V51, P6452, DOI 10.1021/JF034543E; FENG LJ, 2011, FOOD RES INT, V44, P404, DOI 10.1016/J.FOODRES.2010.09.035; FERRÉ P, 2010, DIABETES OBES METAB, V12, P83, DOI 10.1111/J.1463-1326.2010.01275.X; FERREIRA ED, 2011, J MED FOOD, V14, P94, DOI 10.1089/JMF.2009.0204; FKI I, 2007, J AGR FOOD CHEM, V55, P624, DOI 10.1021/JF0623586; FORMAN BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/PNAS.94.9.4312; FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED, V16, P61, DOI 10.1016/J.CTIM.2007.08.003; FREDERIKSEN H, 2007, MOL NUTR FOOD RES, V51, P564, DOI 10.1002/MNFR.200700009; FUKASAWA T, 2010, J AGR FOOD CHEM, V58, P7007, DOI 10.1021/JF1006616; GANI OABSM, 2008, J MOL GRAPH MODEL, V27, P217, DOI 10.1016/J.JMGM.2008.04.008; GERIN I, 2010, J BIOL CHEM, V285, P33652, DOI 10.1074/JBC.M110.152090; GONZÁLEZ-SANTIAGO M, 2006, ATHEROSCLEROSIS, V188, P35, DOI 10.1016/J.ATHEROSCLEROSIS.2005.10.022; GRANADOS-PRINCIPAL S, 2010, NUTR REV, V68, P191, DOI 10.1111/J.1753-4887.2010.00278.X; GRESELE P, 2011, J NUTR BIOCHEM, V22, P201, DOI 10.1016/J.JNUTBIO.2010.07.004; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; GROOT PHE, 2005, J LIPID RES, V46, P2182, DOI 10.1194/JLR.M500116-JLR200; GUAN L, 2006, J AGR FOOD CHEM, V54, P4907, DOI 10.1021/JF060709A; GUAN L, 2011, J FOOD BIOCHEM, V35, P859, DOI 10.1111/J.1745-4514.2010.00425.X; GUAN L, 2010, FOOD FUNCT, V1, P84, DOI 10.1039/C0FO00036A; GUNNESS P, 2010, FOOD FUNCT, V1, P149, DOI 10.1039/C0FO00080A; GUPTA S, 2002, BIOCHEM BIOPH RES CO, V293, P338, DOI 10.1016/S0006-291X(02)00229-2; GUZEL-SEYDIM ZB, 2011, CRIT REV FOOD SCI, V51, P261, DOI 10.1080/10408390903579029; HANSEL B, 2007, AM J CLIN NUTR, V86, P790, DOI 10.1093/AJCN/86.3.790; HEBER D, 1999, AM J CLIN NUTR, V69, P231; HIWATASHI K, 2010, BIOSCI BIOTECH BIOCH, V74, P1447, DOI 10.1271/BBB.100130; HODSON L, 2011, CURR OPIN LIPIDOL, V22, P216, DOI 10.1097/MOL.0B013E3283462E16; HORIE T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/PNAS.1008499107; HOSOMI R, 2011, J FOOD SCI, V76, PH116, DOI 10.1111/J.1750-3841.2011.02130.X; HOSOMI R, 2009, J AGR FOOD CHEM, V57, P9256, DOI 10.1021/JF901954R; HOWELL G, 2009, BBA-MOL CELL BIOL L, V1791, P1190, DOI 10.1016/J.BBALIP.2009.08.008; HSU CL, 2009, J AGR FOOD CHEM, V57, P425, DOI 10.1021/JF802715T; IKEDA I, 2005, J NUTR, V135, P155, DOI 10.1093/JN/135.2.155; IKEDA I, 2010, J AGR FOOD CHEM, V58, P8591, DOI 10.1021/JF1015285; INOUE N, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-85; JAIN KS, 2007, BIOORGAN MED CHEM, V15, P4674, DOI 10.1016/J.BMC.2007.04.031; JEMAI H, 2008, J AGR FOOD CHEM, V56, P2630, DOI 10.1021/JF072589S; JEMAI H, 2009, J AGR FOOD CHEM, V57, P8798, DOI 10.1021/JF901280R; JEUN J, 2008, FOOD CHEM, V107, P1078, DOI 10.1016/J.FOODCHEM.2007.09.021; JEUN J, 2010, NUTRITION, V26, P321, DOI 10.1016/J.NUT.2009.04.011; JIA L, 2011, ANNU REV PHYSIOL, V73, P239, DOI 10.1146/ANNUREV-PHYSIOL-012110-142233; JIAO R, 2010, J NUTR BIOCHEM, V21, P1134, DOI 10.1016/J.JNUTBIO.2009.10.007; JOU PC, 2010, J AGR FOOD CHEM, V58, P12703, DOI 10.1021/JF103121C; JUMP DB, 2005, J NUTR, V135, P2503, DOI 10.1093/JN/135.11.2503; KALAIVANI M, 2010, FOOD BIOPROCESS TECH, V3, P333, DOI 10.1007/S11947-009-0197-8; KASSIS AN, 2007, ATHEROSCLEROSIS, V194, P153, DOI 10.1016/J.ATHEROSCLEROSIS.2006.10.008; KATO M, 2011, BRIT J NUTR, V106, P57, DOI 10.1017/S0007114510005775; KATO M, 2009, BRIT J NUTR, V102, P816, DOI 10.1017/S0007114509316153; KELLY RB, 2010, AM FAM PHYSICIAN, V81, P1097; KENNEDY MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/JBC.M105863200; KHOO YSK, 2009, J CLIN PHARM THER, V34, P133, DOI 10.1111/J.1365-2710.2008.00998.X; KIM KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/ANNUREV.NUTR.17.1.77; KIM MJ, 2010, FOOD SCI BIOTECHNOL, V19, P535, DOI 10.1007/S10068-010-0074-2; KIM MJ, 2009, PHYTOTHER RES, V23, P1685, DOI 10.1002/PTR.2811; KOHNO M, 2006, J ATHEROSCLER THROMB, V13, P247, DOI 10.5551/JAT.13.247; KOYA-MIYATA S, 2009, BIOL PHARM BULL, V32, P2022, DOI 10.1248/BPB.32.2022; KROON PA, 2010, CURR MED CHEM, V17, P2442; KUO DH, 2009, J ETHNOPHARMACOL, V124, P544, DOI 10.1016/J.JEP.2009.05.005; KWON MJ, 2003, LIFE SCI, V72, P2953, DOI 10.1016/S0024-3205(03)00234-0; LAFFITTE BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/PNAS.021488798; LAM CK, 2008, MOL NUTR FOOD RES, V52, P950, DOI 10.1002/MNFR.200700319; LEE HJ, 2010, J FOOD BIOCHEM, V34, P779, DOI 10.1111/J.1745-4514.2009.00315.X; LEE MS, 2008, BRIT J NUTR, V99, P1182, DOI 10.1017/S0007114507864816; LEE MS, 2009, PHYTOTHER RES, V23, P1088, DOI 10.1002/PTR.2737; LEE SM, 2008, LIPIDS, V43, P419, DOI 10.1007/S11745-008-3167-4; LEE YS, 2011, PHYTOMEDICINE, V18, P648, DOI 10.1016/J.PHYMED.2010.11.005; LI C, 2010, CAN J DIABETES, V34, P355, DOI 10.1016/S1499-2671(10)44010-1; LI CL, 1998, NUTR RES, V18, P71, DOI 10.1016/S0271-5317(97)00201-7; LIN YH, 2011, FOOD CHEM, V125, P397, DOI 10.1016/J.FOODCHEM.2010.09.016; LIU JIANPING, 2006, CHIN MED, V1, P4, DOI 10.1186/1749-8546-1-4; LIU LK, 2009, J AGR FOOD CHEM, V57, P7605, DOI 10.1021/JF9014697; LIU LJ, 2002, J NUTR, V132, P1129, DOI 10.1093/JN/132.6.1129; LIU RH, 2004, J NUTR, V134, P3479S, DOI 10.1093/JN/134.12.3479S; LU BY, 2010, J FOOD SCI, V75, PH205, DOI 10.1111/J.1750-3841.2010.01716.X; LU CH, 2008, FOOD CHEM, V111, P67, DOI 10.1016/J.FOODCHEM.2008.03.043; LYNES MD, 2011, LIFE SCI, V88, P384, DOI 10.1016/J.LFS.2010.12.015; MA YY, 2009, J AGR FOOD CHEM, V57, P4372, DOI 10.1021/JF803670U; MAKNI M, 2010, FOOD CHEM TOXICOL, V48, P2239, DOI 10.1016/J.FCT.2010.05.055; MANACH C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/AJCN/79.5.727; MARANGONI F, 2010, PHARMACOL RES, V61, P193, DOI 10.1016/J.PHRS.2010.01.001; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MARQUART TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/PNAS.1005191107; MASSARO M, 2010, CARDIOVASC THER, V28, PE13, DOI 10.1111/J.1755-5922.2010.00211.X; MATSUMOTO K, 2010, PHYTOTHER RES, V24, P205, DOI 10.1002/PTR.2911; MATSUO M, 2010, BIOSCI BIOTECH BIOCH, V74, P899, DOI 10.1271/BBB.90921; MAXFIELD FR, 2005, NATURE, V438, P612, DOI 10.1038/NATURE04399; MEDINA-GOMEZ G, 2007, PLOS GENET, V3, DOI 10.1371/JOURNAL.PGEN.0030064; METZGER BT, 2007, J AGR FOOD CHEM, V55, P6032, DOI 10.1021/JF0709496; MICALLEF MA, 2009, J NUTR BIOCHEM, V20, P927, DOI 10.1016/J.JNUTBIO.2009.06.009; MICELI N, 2007, J AGR FOOD CHEM, V55, P10671, DOI 10.1021/JF071772I; MIETTINEN TA, 1999, CURR OPIN LIPIDOL, V10, P9, DOI 10.1097/00041433-199902000-00003; MITKA M, 2011, JAMA-J AM MED ASSOC, V305, P136, DOI 10.1001/JAMA.2010.1908; MIZUTANI T, 2010, J NUTR SCI VITAMINOL, V56, P48, DOI 10.3177/JNSV.56.48; MORI T, 2007, J NUTR, V137, P2629, DOI 10.1093/JN/137.12.2629; NAJAFI-SHOUSHTARI SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/SCIENCE.1189123; NARAYAN B, 2009, FOOD SCI BIOTECHNOL, V18, P1330; ODBAYAR TO, 2006, J AGR FOOD CHEM, V54, P8261, DOI 10.1021/JF061135C; OH HT, 2009, NUTR RES, V29, P123, DOI 10.1016/J.NUTRES.2008.11.006; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; OLIVER WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/PNAS.091021198; ONG KT, 2011, HEPATOLOGY, V53, P116, DOI 10.1002/HEP.24006; OSADA K, 2006, LIPIDS, V41, P133, DOI 10.1007/S11745-006-5081-Y; PARISH S, 2009, EUR HEART J, V30, P2137, DOI 10.1093/EURHEARTJ/EHP221; PARK E, 2009, ANN NUTR METAB, V55, P442; PARK JH, 2009, FOOD SCI BIOTECHNOL, V18, P179; PEET DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PHILLIPS GO, 2011, FOOD HYDROCOLLOID, V25, P139, DOI 10.1016/J.FOODHYD.2010.04.011; PUIG T, 2008, ANTICANCER RES, V28, P3671; QIN XM, 2008, HEPATOLOGY, V48, P432, DOI 10.1002/HEP.22334; QIN Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/AJCN.2009.27814; QUAN HY, 2010, FOOD SCI BIOTECHNOL, V19, P207, DOI 10.1007/S10068-010-0028-8; RANINEN K, 2011, NUTR REV, V69, P9, DOI 10.1111/J.1753-4887.2010.00358.X; RAYNER KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/SCIENCE.1189862; REDDY JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/ANNUREV.NUTR.21.1.193; REINHART KM, 2009, NUTR RES REV, V22, P39, DOI 10.1017/S0954422409350003; REPA JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; REPA JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/GAD.844900; REPA JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/JBC.M109927200; REVILLA E, 2009, FOOD RES INT, V42, P387, DOI 10.1016/J.FOODRES.2009.01.010; RIGAMONTI E, 2010, MOL NUTR FOOD RES, V54, PS24, DOI 10.1002/MNFR.200900251; RODRÍGUEZ-CANTÚ LN, 2011, J AGR FOOD CHEM, V59, P1095, DOI 10.1021/JF103513W; RYAN AS, 2009, LIPIDS, V44, P817, DOI 10.1007/S11745-009-3330-6; SCHULMAN IG, 2010, ADV DRUG DELIVER REV, V62, P1307, DOI 10.1016/J.ADDR.2010.07.002; SEYMOUR EM, 2008, J MED FOOD, V11, P252, DOI 10.1089/JMF.2007.658; SHAH PK, 2007, EUR HEART J, V28, P5, DOI 10.1093/EURHEARTJ/EHL392; SHIMANO H, 2009, FEBS J, V276, P616, DOI 10.1111/J.1742-4658.2008.06806.X; SHIMODA H, 2009, J AGR FOOD CHEM, V57, P1786, DOI 10.1021/JF803441C; SHISHIKURA Y, 2006, J AGR FOOD CHEM, V54, P1906, DOI 10.1021/JF051988P; SHUKLA A, 2006, BRIT J NUTR, V96, P674, DOI 10.1079/BJN20061895; SIMOPOULOS AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311; SINGH DK, 2009, J NUTR BIOCHEM, V20, P816, DOI 10.1016/J.JNUTBIO.2008.07.011; SIRTORI CR, 2009, ATHEROSCLEROSIS, V203, P8, DOI 10.1016/J.ATHEROSCLEROSIS.2008.06.019; SPIELMANN J, 2008, J ANIM PHYSIOL AN N, V92, P683, DOI 10.1111/J.1439-0396.2007.00766.X; SPIELMANN J, 2009, J ANIM PHYSIOL AN N, V93, P400, DOI 10.1111/J.1439-0396.2008.00819.X; STECK TL, 2010, TRENDS CELL BIOL, V20, P680, DOI 10.1016/J.TCB.2010.08.007; STEINBERG D, 2006, J LIPID RES, V47, P2100; STEINBERG GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/PHYSREV.00011.2008, 10.15252/EMBJ.201488104; STEPHENS AM, 2010, J FOOD SCI, V75, PH116, DOI 10.1111/J.1750-3841.2010.01569.X; SUGIYAMA H, 2007, J AGR FOOD CHEM, V55, P4604, DOI 10.1021/JF070569K; SUNG YY, 2011, MOL MED REP, V4, P431, DOI 10.3892/MMR.2011.451; SZYMCZAK M, 2008, BLOOD, V111, P3514, DOI 10.1182/BLOOD-2007-08-109934; TAKU K, 2007, AM J CLIN NUTR, V85, P1148, DOI 10.1093/AJCN/85.4.1148; TAKU K, 2010, J HYPERTENS, V28, P1971, DOI 10.1097/HJH.0B013E32833C6EDB; TAKU KYOKO, 2008, THER CLIN RISK MANAG, V4, P1097; TAKU K, 2010, ASIA PAC J CLIN NUTR, V19, P33; TANAKA K, 2009, FOOD SCI TECHNOL RES, V15, P147, DOI 10.3136/FSTR.15.147; TANDY S, 2009, J AGR FOOD CHEM, V57, P9339, DOI 10.1021/JF9016042; TEMEL RE, 2003, J BIOL CHEM, V278, P47594, DOI 10.1074/JBC.M308235200; THEUWISSEN E, 2008, PHYSIOL BEHAV, V94, P285, DOI 10.1016/J.PHYSBEH.2008.01.001; TOH SA, 2011, BIOCHEM PHARMACOL, V81, P934, DOI 10.1016/J.BCP.2011.01.012; TOMOTAKE H, 2007, J FOOD SCI, V72, PS528, DOI 10.1111/J.1750-3841.2007.00474.X; TOMOTAKE H, 2000, J NUTR, V130, P1670, DOI 10.1093/JN/130.7.1670; TZANG BS, 2009, FOOD CHEM, V114, P1450, DOI 10.1016/J.FOODCHEM.2008.11.030; VAN DER VEEN JN, 2005, J LIPID RES, V46, P526, DOI 10.1194/JLR.M400400-JLR200; VELAYUTHAM P, 2008, CURR MED CHEM, V15, P1840; VIDYASHANKAR S, 2009, BRIT J NUTR, V101, P1621, DOI 10.1017/S0007114508118748; VIDYAVATI HG, 2010, J FOOD SCI TECH MYS, V47, P55, DOI 10.1007/S13197-010-0015-3; VIJAYAKUMAR MV, 2010, OBESITY, V18, P667, DOI 10.1038/OBY.2009.337; VRINS CLJ, 2009, J LIPID RES, V50, P2046, DOI 10.1194/JLR.M800579-JLR200; WAGNER BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/ANNUREV.BI.52.070183.002541; WAKUTSU M, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-101; WAN J.-B., 2010, ARTERIOSCLER THROMB, V30; WANG M, 2009, J AGR FOOD CHEM, V57, P5106, DOI 10.1021/JF900194S; WANG S, 2006, J NUTR BIOCHEM, V17, P492, DOI 10.1016/J.JNUTBIO.2006.03.004; WANG S, 2009, ATHEROSCLEROSIS, V204, P147, DOI 10.1016/J.ATHEROSCLEROSIS.2008.08.024; WANG Y, 2004, J LIPID RES, V45, P972, DOI 10.1194/JLR.M400011-JLR200; WANG YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/JOURNAL.PBIO.0020294; WANG ZM, 2011, AM J CLIN NUTR, V93, P506, DOI 10.3945/AJCN.110.005363; WAT E, 2009, ATHEROSCLEROSIS, V205, P144, DOI 10.1016/J.ATHEROSCLEROSIS.2008.12.004; WAY TD, 2009, J AGR FOOD CHEM, V57, P5257, DOI 10.1021/JF900730E; WEI ZH, 2009, EUR J CLIN NUTR, V63, P821, DOI 10.1038/EJCN.2008.49; WEISSE K, 2010, EUR J NUTR, V49, P65, DOI 10.1007/S00394-009-0049-3; WOLEVER TMS, 2010, AM J CLIN NUTR, V92, P723, DOI 10.3945/AJCN.2010.29174; WU CH, 2010, J AGR FOOD CHEM, V58, P7075, DOI 10.1021/JF101415V; YAHAGI N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/JBC.274.50.35840; YAMAMOTO Y, 2010, BIOSCI BIOTECH BIOCH, V74, P402, DOI 10.1271/BBB.90613; YANG DJ, 2010, J AGR FOOD CHEM, V58, P2020, DOI 10.1021/JF903355Q; YANG DJ, 2010, FOOD CHEM, V119, P1457, DOI 10.1016/J.FOODCHEM.2009.09.027; YANG MY, 2010, J AGR FOOD CHEM, V58, P850, DOI 10.1021/JF903209W; YANG SF, 2009, J AGR FOOD CHEM, V57, P5078, DOI 10.1021/JF900499V; YASUDA A, 2011, J AGR FOOD CHEM, V59, P1470, DOI 10.1021/JF103820B; YEO CR, 2011, MOLECULES, V16, P477, DOI 10.3390/MOLECULES16010477; YIU WF, 2011, J FOOD SCI, V76, PH80, DOI 10.1111/J.1750-3841.2011.02042.X; YOSHIKAWA T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/JBC.M105711200; YU F, 2011, J SCI FOOD AGR, V91, P1843, DOI 10.1002/JSFA.4393; YUAN G, 2007, CAN MED ASSOC J, V176, P1113, DOI 10.1503/CMAJ.060963; YUAN HD, 2010, J GINSENG RES, V34, P369, DOI 10.5142/JGR.2010.34.4.369; ZELCER N, 2009, SCIENCE, V325, P100, DOI 10.1126/SCIENCE.1168974; ZERN TL, 2005, J NUTR, V135, P1911, DOI 10.1093/JN/135.8.1911; ZERN TL, 2003, J NUTR, V133, P2268, DOI 10.1093/JN/133.7.2268; ZHAN SY, 2005, AM J CLIN NUTR, V81, P397; ZHANG HW, 2007, CLIN EXP PHARMACOL P, V34, P838, DOI 10.1111/J.1440-1681.2007.04614.X; ZHANG ZS, 2002, J NUTR, V132, P5, DOI 10.1093/JN/132.1.5; ZHENG XX, 2011, AM J CLIN NUTR, V94, P601, DOI 10.3945/AJCN.110.010926; ZHUO XG, 2004, J NUTR, V134, P2395, DOI 10.1093/JN/134.9.2395; ZUNG A, 2010, J PEDIATR ENDOCR MET, V23, P133","CHEN, G (CORRESPONDING AUTHOR), S CHINA UNIV TECHNOL, COLL LIGHT IND \& FOOD SCI, 381 WUSHAN RD, GUANGZHOU 510641, GUANGDONG, PEOPLES R CHINA","TAYLOR \& FRANCIS INC","ENGLISH","CRIT. REV. FOOD SCI. NUTR.","REVIEW","ISI","WOS000330685000007","CRIT REV FOOD SCI NUTR","S CHINA UNIV TECHNOL;S CHINA UNIV TECHNOL;OHIO STATE UNIV","S CHINA UNIV TECHNOL",NA,"CHEN G, 2014, CRIT REV FOOD SCI NUTR","CHEN G, 2014, CRIT REV FOOD SCI NUTR"
"CHOI J;JEON M;MOON W;MOON J;CHEON E;KIM J;JUNG S;JI Y;SON S;KIM M","CHOI JAE-SUK;JEON MIN-HEE;MOON WOI-SOOK;MOON JIN-NAM; CHEON EUN JIN;KIM JOO-WAN;JUNG SUNG KYU;JI YI-HWA; SON SANG WOOK;KIM MI-RYUNG","IIN VIVOI HAIR GROWTHPROMOTING EFFECT OF RICE BRAN EXTRACT PREPARED BY SUPERCRITICAL CARBON DIOXIDE FLUID",2014,"BIOLOGICAL \& PHARMACEUTICAL BULLETIN","37","44-53",31,"10.1248/bpb.b13-00528","SON, SW (CORRESPONDING AUTHOR), KOREA UNIV, ANSAN HOSP, DEPT DERMATOL, ANSAN 425701, SOUTH KOREA.; CHOI, JAE-SUK, SILLA UNIV, IACF, RIS CTR, PUSAN 617736, SOUTH KOREA.; CHEON, EUN JIN; KIM, MI-RYUNG, SILLA UNIV, DEPT BIOFOOD MAT, PUSAN 617736, SOUTH KOREA.; JEON, MIN-HEE; MOON, WOI-SOOK; MOON, JIN-NAM, ECOMINE CO LTD, DEPT R\&D, PUSAN 608736, SOUTH KOREA.; KIM, JOO-WAN, KYUNGPOOK NATL UNIV, DEPT VET MED, TAEGU 702701, SOUTH KOREA.; JUNG, SUNG KYU; JI, YI-HWA; SON, SANG WOOK, KOREA UNIV, ANSAN HOSP, DEPT DERMATOL, ANSAN 425701, SOUTH KOREA.","THE POTENTIAL HAIR GROWTH-PROMOTING ACTIVITY OF RICE BRAN SUPERCRITICAL CO2 EXTRACT (RB-SCE) AND MAJOR COMPONENTS OF RB-SCE, LINOLEIC ACID, POLICOSANOL, GAMMA-ORYZANOL, AND GAMMA-TOCOTRIENOL, WERE EVALUATED WITH THE HISTOLOGICAL MORPHOLOGY AND MRNA EXPRESSION LEVELS OF CELL GROWTH FACTORS USING REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (PCR) IN C57BL/6 MICE. RB-SCE SHOWED HAIR GROWTH-PROMOTING POTENTIAL TO A SIMILAR EXTENT AS 3\% MINOXIDIL, SHOWING THAT THE HAIR FOLLICLES WERE INDUCED TO BE IN THE ANAGEN STAGE. THE NUMBERS OF THE HAIR FOLLICLES WERE SIGNIFICANTLY INCREASED. IN ADDITION, MRNA EXPRESSION LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), INSULIN-LIKE GROWTH FACTOR-1 (IGF-1), AND KERATINOCYTE GROWTH FACTOR (KGF) WERE ALSO SIGNIFICANTLY INCREASED AND THAT OF TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA) DECREASED IN RB-SCE-TREATED GROUPS. AMONG THE MAJOR COMPONENTS OF R13-SCE, LINOLEIC ACID AND GAMMA-ORYZANOL INDUCED THE FORMATION OF HAIR FOLLICLES ACCORDING TO EXAMINATION OF HISTOLOGICAL MORPHOLOGY AND MRNA EXPRESSION LEVELS OF CELL GROWTH FACTORS. IN CONCLUSION, OUR RESULTS DEMONSTRATE THAT RB-SCE, PARTICULARLY LINOLEIC ACID AND GAMMA-ORYZANOL, PROMOTES HAIR GROWTH AND SUGGESTS RB-SCE CAN BE APPLIED AS HAIR LOSS TREATMENT.","RICE BRAN SUPERCRITICAL CO2 EXTRACT; HAIR GROWTH-PROMOTING ACTIVITY; IN; VIVO","CONTACT-DERMATITIS; GAMMA-ORYZANOL; MINOXIDIL; 5-ALPHA-REDUCTASE; FINASTERIDE; INHIBITION; MECHANISMS; COMPONENTS; FOLLICLES","MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, REPUBLIC OF KOREA [311014-03]; GLOBAL HEALTHCARE INDUSTRY RIS CENTER FROM THE MINISTRY OF KNOWLEDGE ECONOMY, REPUBLIC OF KOREA","THIS WORK WAS SUPPORTED BY A GRANT (NO. 311014-03) FROM THE MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, REPUBLIC OF KOREA. JSC WAS ALSO SUPPORTED BY THE GLOBAL HEALTHCARE INDUSTRY RIS CENTER FROM THE MINISTRY OF KNOWLEDGE ECONOMY, REPUBLIC OF KOREA.","BEOY LA, 2010, TROP LIFE SCI RES, V21, P91; BHATTACHARJEE P, 2002, INT J FOOD SCI TECH, V37, P1, DOI 10.1046/J.1365-2621.2002.00541.X; PASCUAL CDCI, 2013, FOOD RES INT, V50, P676, DOI 10.1016/J.FOODRES.2011.07.013; CHEN MH, 2005, J FOOD COMPOS ANAL, V18, P317, DOI 10.1016/J.JFCA.2004.12.001; DANILENKO DM, 1996, MOL MED TODAY, V2, P460, DOI 10.1016/1357-4310(96)10045-9; DATTA K, 2009, J ETHNOPHARMACOL, V124, P450, DOI 10.1016/J.JEP.2009.05.023; DEVILLEZ RL, 1990, DERMATOL CLIN, V8, P367; FRIEDMAN ES, 2002, J AM ACAD DERMATOL, V46, P309, DOI 10.1067/MJD.2002.119104; FUJIE T, 2001, J DERMATOL SCI, V25, P206, DOI 10.1016/S0923-1811(00)00130-4; HAIM D, 2012, GRASAS ACEITES, V63, P345, DOI 10.3989/GYA.010612; IUPAC, 1987, METH 2 411 ID DET TO; JARIWALLA RJ, 2001, DRUG EXP CLIN RES, V27, P17; KIM I, 1991, KOREAN J FOOD SCI TE, V23, P76; LEE GS, 2010, FITOTERAPIA, V81, P17, DOI 10.1016/J.FITOTE.2009.06.016; LI J, 1999, J BIOL CHEM, V274, P4213, DOI 10.1074/JBC.274.7.4213; LI SC, 2011, FOOD RES INT, V44, P209, DOI 10.1016/J.FOODRES.2010.10.034; LIANG TM, 1992, BIOCHEM J, V285, P557, DOI 10.1042/BJ2850557; MANOSROI A, 2010, J SUPERCRIT FLUID, V54, P137, DOI 10.1016/J.SUPFLU.2010.05.002; MCCLELLAN KJ, 1999, DRUGS, V57, P111, DOI 10.2165/00003495-199957010-00014; MESSENGER AG, 2004, BRIT J DERMATOL, V150, P186, DOI 10.1111/J.1365-2133.2004.05785.X; MOFFAT GH, 1968, J ANAT, V102, P527; OGAWA H, 1983, CURR PROBL DERMATOL, V11, P159; OLSEN EA., 1994, DISORDERS OF HAIR GROWTH: DIAGNOSIS AND TREATMENT, P257; OTOMO SUSUMU, 2002, FOLIA PHARMACOLOGICA JAPONICA, V119, P167, DOI 10.1254/FPJ.119.167; RHO SS, 2005, J DERMATOL SCI, V38, P89, DOI 10.1016/J.JDERMSCI.2004.12.025; ROH M-K, J SUPERCRIT IN PRESS; ROH SS, 2002, J DERMATOL SCI, V30, P43, DOI 10.1016/S0923-1811(02)00060-9; RUKSIRIWANICH W, 2011, J SUPERCRIT FLUID, V59, P61, DOI 10.1016/J.SUPFLU.2011.07.017; SAHENA F, 2009, J FOOD ENG, V95, P240, DOI 10.1016/J.JFOODENG.2009.06.026; SAWAYA ME, 1998, SEMIN CUTAN MED SURG, V17, P276, DOI 10.1016/S1085-5629(98)80024-2; SAWAYA ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.EP12335779; SAWAYA ME, 2000, CLIN DERMATOL, V18, P177, DOI 10.1016/S0738-081X(99)00108-X; SHAPIRO J, 1998, DERMATOL CLIN, V16, P341, DOI 10.1016/S0733-8635(05)70017-6; TOSTI A, 2001, J EUR ACAD DERMATOL, V15, P418, DOI 10.1046/J.1468-3083.2001.00315.X; TRÜEB RM, 2002, EXP GERONTOL, V37, P981, DOI 10.1016/S0531-5565(02)00093-1; WATCHARARUJI K, 2008, BIORESOURCE TECHNOL, V99, P6207, DOI 10.1016/J.BIORTECH.2007.12.021; WEGER N, 2005, J INVEST DERMATOL, V125, P873, DOI 10.1111/J.0022-202X.2005.23946.X; WERNER S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; WILSON C, 1991, J AM ACAD DERMATOL, V24, P661, DOI 10.1016/S0190-9622(08)80171-5; XU ZM, 1999, J AGR FOOD CHEM, V47, P2724, DOI 10.1021/JF981175J; XU ZM, 2000, J AM OIL CHEM SOC, V77, P547, DOI 10.1007/S11746-000-0087-4; YEDDES N, 2012, J LIPIDS, V2012, DOI 10.1155/2012/914693; YOON JI, 2010, FOOD CHEM TOXICOL, V48, P1350, DOI 10.1016/J.FCT.2010.02.036; YOSHIDA H, 2011, FOOD CHEM, V129, P479, DOI 10.1016/J.FOODCHEM.2011.04.102","SON, SW (CORRESPONDING AUTHOR), KOREA UNIV, ANSAN HOSP, DEPT DERMATOL, ANSAN 425701, SOUTH KOREA","PHARMACEUTICAL SOC JAPAN","ENGLISH","BIOL. PHARM. BULL.","ARTICLE","ISI","WOS000329000400008","BIOL PHARM BULL","KOREA UNIV;SILLA UNIV;SILLA UNIV;KYUNGPOOK NATL UNIV;KOREA UNIV","KOREA UNIV",NA,"CHOI JS, 2014, BIOL PHARM BULL","CHOI JS, 2014, BIOL PHARM BULL"
"VIMOLMANGKANG S;SOMKHANNGOEN C;SUKRONG S","VIMOLMANGKANG SORNKANOK;SOMKHANNGOEN CHANIDA;SUKRONG SUCHADA","POTENTIAL PHARMACEUTICAL USES OF THE ISOLATED COMPOUNDS FROM SILKWORM EXCRETA",2014,"CHIANG MAI JOURNAL OF SCIENCE","41","97-104",8,NA,"SUKRONG, S (CORRESPONDING AUTHOR), CHULALONGKORN UNIV, FAC PHARMACEUT SCI, DEPT PHARMACOGNOSY \& PHARMACEUT BOT, BANGKOK 10330, THAILAND.; VIMOLMANGKANG, SORNKANOK; SOMKHANNGOEN, CHANIDA; SUKRONG, SUCHADA, CHULALONGKORN UNIV, FAC PHARMACEUT SCI, DEPT PHARMACOGNOSY \& PHARMACEUT BOT, BANGKOK 10330, THAILAND.","SILKWORM (BOMBYX MORI) EXCRETA HAVE LONG BEEN USED IN THE PHARMACEUTICAL AND FOOD INDUSTRIES AS A NATURAL COLORANT. IN SOME COUNTRIES, INSTANT SILKWORM TEA IS AVAILABLE DUE TO ITS TRADITIONAL EASTERN MEDICINE HEALTH BENEFITS. HOWEVER, THERE ARE LIMITED DATA ON THE IDENTIFICATION OF BIOACTIVE COMPOUNDS IN SILKWORM EXCRETA. HERE WE HAVE ISOLATED AND IDENTIFIED FOR THE FIRST TIME IN SILKWORM EXCRETA 1-TRITRIACONTANOL, A VERY LONG CHAIN FATTY ALCOHOL, AND LUPEOL, A PHYTOSTEROL, IN ADDITION TO BETA-SITOSTEROL. THE COMPOUNDS WERE ISOLATED FROM A CRUDE ACETONE EXTRACT, PURIFIED BY VACUUM LIQUID COLUMN CHROMATOGRAPHY, AND PARTITIONED BY HEXANE AND ETHYL ACETATE. THE STRUCTURE ELUCIDATION WAS CONFIRMED BY MEANS OF FOURIER TRANSFORMED INFRARED SPECTROSCOPY (FT-IR), PROTON AND CARBON NUCLEAR MAGNETIC RESONANCE (NMR), AND ELECTRON IONIZATION MASS SPECTROMETRY (EIMS). THE CYTOTOXIC ACTIVITY OF THE CRUDE EXTRACT AND 1-TRITRIACONTANOL WERE ASSAYED AGAINST VERO CELLS AND DIFFERENT HUMAN CANCER CELL LINES AND THEY WERE FOUND TO BE INACTIVE, DEMONSTRATING THEIR SAFETY. THESE DATA SUPPORT THE USE OF SILKWORM EXCRETA IN TRADITIONAL MEDICINE AND SHOW THE POTENTIAL OF SILKWORM EXCRETA AS A NOVEL NATURAL SOURCE OF VERY LONG CHAIN FATTY ALCOHOLS.","SILKWORM EXCRETA; SILKWORM FECES; BOMBYX MORI; LUPEOL; TRITRIACONTANOL; VERY LONG CHAIN FATTY ALCOHOL; CYTOTOXICITY","POLICOSANOL; EXTRACTS; TRITERPENES","RATCHADAPISEKSOMPHOT ENDOWMENT FUND OF CHULALONGKORN UNIVERSITY [RES560530157-HR]; CHULALONGKORN UNIVERSITY","THIS RESEARCH WAS FINANCIALLY SUPPORTED BY RATCHADAPISEKSOMPHOT ENDOWMENT FUND OF CHULALONGKORN UNIVERSITY (RES560530157-HR). S. V. WAS A RECIPIENT OF THE DEVELOPMENT OF NEW FACULTY STAFF GRANT FROM CHULALONGKORN UNIVERSITY.","ANONYMOUS, 2004, DRUG DISCOV TODAY, V9, P450; AVATO P, 1990, PHYTOCHEMISTRY, V29, P1571, DOI 10.1016/0031-9422(90)80124-Y; BÖSZÖRMENYI A, 2009, ACTA CHROMATOGR, V21, P659, DOI 10.1556/ACHROM.21.2009.4.11; CHO-NGWA F, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-62; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; CSERHÁTI T, 2002, ENVIRON INT, V28, P337, DOI 10.1016/S0160-4120(02)00032-6; HAHNVAJANAWONG V., 2005, KKU RES, V10, P61; HASMEDA M, 1999, PLANTA MED, V65, P14, DOI 10.1055/S-1999-13954; HASSAN R. A., 2010, JOURNAL OF APPLIED SCIENCES RESEARCH, P478; IMAM S, 2007, PAK J PHARM SCI, V20, P125; INGRAM LO, 1977, J BACTERIOL, V131, P1023, DOI 10.1128/JB.131.3.1023-1025.1977; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; KOSUGE T, 1985, YAKUGAKU ZASSHI, V105, P845, DOI 10.1248/YAKUSHI1947.105.9\_845; LEE K. H., 1971, KOREA J ANIM SCI, V13, P182; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MISRA TN, 1991, PHYTOCHEMISTRY, V30, P2076, DOI 10.1016/0031-9422(91)85071-7; PARK JH, 2011, J ASIAN NAT PROD RES, V13, P377, DOI 10.1080/10286020.2011.555331; PARK YJ, 2003, J LIQ CHROMATOGR R T, V26, P3183, DOI 10.1081/JLC-120025517; RAJU S., 1996, INDIAN SILK, V35, P19; UZAKOVA D.H., 1987, CHEMISTRY OF NATURAL COMPOUNDS, V23, P419","SUKRONG, S (CORRESPONDING AUTHOR), CHULALONGKORN UNIV, FAC PHARMACEUT SCI, DEPT PHARMACOGNOSY \& PHARMACEUT BOT, BANGKOK 10330, THAILAND","CHIANG MAI UNIV","ENGLISH","CHIANG MAI J. SCI.","ARTICLE","ISI","WOS000334312100009","CHIANG MAI J SCI","CHULALONGKORN UNIV;CHULALONGKORN UNIV","CHULALONGKORN UNIV",NA,"VIMOLMANGKANG S, 2014, CHIANG MAI J SCI","VIMOLMANGKANG S, 2014, CHIANG MAI J SCI"
"KUNKUMA V;KAKI S;RAO B;S. K S;PRASAD R;DEVI B","KUNKUMA VIJAYA LAKSHMI;KAKI SHIVA SHANKER;RAO BHAMIDIPATI V; S K;PRASAD RACHAPUDI B N;DEVI BETHALA L A PRABHAVATHI","A SIMPLE AND FACILE METHOD FOR THE SYNTHESIS OF 1OCTACOSANOL",2013,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","115","921-927",10,"10.1002/ejlt.201200195","DEVI, BLAP (CORRESPONDING AUTHOR), INDIAN INST CHEM TECHNOL, CTR LIPID RES, HYDERABAD 500007, ANDHRA PRADESH, INDIA.; KUNKUMA, VIJAYA LAKSHMI; KAKI, SHIVA SHANKER; RAO, BHAMIDIPATI V. S. K.; PRASAD, RACHAPUDI B. N.; DEVI, BETHALA L. A. PRABHAVATHI, INDIAN INST CHEM TECHNOL, CTR LIPID RES, HYDERABAD 500007, ANDHRA PRADESH, INDIA.","AN EFFICIENT SYNTHETIC METHOD WAS DEVELOPED FOR THE PREPARATION OF 1-OCTACOSANOL (C-28-ALCOHOL) FROM COMMERCIALLY AVAILABLE LIPID-BASED INTERMEDIATES NAMELY SEBACIC ACID (DECANEDIOIC ACID) AND STEARYL ALCOHOL. THE KEY STEP IN THE SYNTHESIS IS THE PREPARATION OF TERT-BUTYL DIMETHYL OCTACOS-10-ENYLOXY SILANE FROM 10-TERT-BUTYL DIMETHYL SILANYLOXY DECANAL AND OCTADECYL TRIPHENYLPHOSPHONIUM BROMIDE SALT EMPLOYING WITTING REACTION. THIS PRODUCT ON SIMULTANEOUS HYDROGENATION OF DOUBLE BOND AND DEPROTECTION OF TERT-BUTYLDIMETHYLSILYL PROTECTING GROUP IN A SINGLE STEP ON TREATMENT WITH PD/C AND H-2 IN METHANOL AT AMBIENT TEMPERATURE RESULTED OCTACOSANOL IN 95\% YIELDS. THE PRODUCTS WERE CHARACTERISED BY IR, H-1 NMR, AND GC-MS ANALYSIS.","NUTRACEUTICALS; 1-OCTACOSANOL; SEBACIC ACID; SYNTHESIS; WITTIG COUPLING","SUGAR-CANE; OCTACOSANOL; POLICOSANOL","COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (CSIR), NEW DELHI","ONE OF THE AUTHORS, K.V.L. THANKS COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (CSIR), NEW DELHI FOR THE FINANCIAL ASSISTANCE AS SENOIR RESEARCH FELLOWSHIP.","AZCAN N, 2008, IND ENG CHEM RES, V47, P1774, DOI 10.1021/IE071345U; BELTZ SD, 1993, CLIN PHARMACY, V12, P900; CHEN F, 2005, J FOOD ENG, V70, P47, DOI 10.1016/J.JFOODENG.2004.09.011; CRAVOTTO G., 2005, INTERNATIONAL PATENT, PATENT NO. WO 03106397, 03106397; CRAVOTTO G, 2010, NAT PROD RES, V24, P428, DOI 10.1080/14786410903194498; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HATTORI K, 2001, TETRAHEDRON, V57, P2109, DOI 10.1016/S0040-4020(01)00060-6; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; KAWANISHI K, 1991, J AM OIL CHEM SOC, V68, P869, DOI 10.1007/BF02660604; MUTLU H, 2010, EUR J LIPID SCI TECH, V112, P10, DOI 10.1002/EJLT.200900138; NORRIS FH, 1986, NEUROLOGY, V36, P1263; OU SY, 2012, LWT-FOOD SCI TECHNOL, V45, P295, DOI 10.1016/J.LWT.2011.08.011; PATALAG LJ, 2012, J ORG CHEM, V77, P5297, DOI 10.1021/JO300624H; RAPPORT L., 2000, PHARMACEUTICAL JOURNAL, V265, P170; SNIDER SR, 1984, ANN NEUROL, V16, P723, DOI 10.1002/ANA.410160615; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; VOY R, 1986, AMERICAN PHARMACY, V26, P39; WOOLLEY BH, 1991, POSTGRAD MED, V89, P195; WUBE AA, 2011, BIOORGAN MED CHEM, V19, P567, DOI 10.1016/J.BMC.2010.10.060","DEVI, BLAP (CORRESPONDING AUTHOR), INDIAN INST CHEM TECHNOL, CTR LIPID RES, HYDERABAD 500007, ANDHRA PRADESH, INDIA","WILEY","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","WOS000327815500010","EUR J LIPID SCI TECHNOL","INDIAN INST CHEM TECHNOL;INDIAN INST CHEM TECHNOL","INDIAN INST CHEM TECHNOL",NA,"KUNKUMA VL, 2013, EUR J LIPID SCI TECHNOL","KUNKUMA VL, 2013, EUR J LIPID SCI TECHNOL"
"ILLNAIT J;RODRIGUEZ I;MENDOZA S;FERNANDEZ ;YOLANDA Y;MAS R;MIRANDA M;PINERE J;FERNANDEZ J;MESA M;FERNANDEZ L;CARBAJAL D;GAMEZ R","ILLNAIT JOSE;RODRIGUEZ IVAN;MENDOZA SARAHI;FERNANDEZ; YOLANDA;MAS ROSA;MIRANDA MIRTHA;PINERE JESUS; FERNANDEZ JULIO CESAR;MESA MEILIS;FERNANDEZ LILIA; CARBAJAL DAISY;GAMEZ RAFAEL","EFFECTS OF D002 A MIXTURE OF HIGH MOLECULAR WEIGHT BEESWAX ALCOHOLS ON PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE",2013,"KOREAN JOURNAL OF INTERNAL MEDICINE","28","439-448",9,"10.3904/kjim.2013.28.4.439","MENDOZA, S (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, 198 ST,19\&21 AVE, HAVANA, CUBA.","BACKGROUND/AIMS: NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS INTIMATELY RELATED TO INSULIN RESISTANCE AND RANGES FROM A BENIGN COURSE TO LIVER FIBROSIS AND CIRRHOSIS. NAFLD MANAGEMENT MAINLY INVOLVES DIETARY MODIFICATION AND WEIGHT LOSS. ALTHOUGH NO FULLY SUCCESSFUL PHARMACOLOGICAL INTERVENTION IS AVAILABLE, ALTERNATIVE THERAPIES TO TREAT NAPLD HAVE SHOWN PROMISING RESULTS. EXPERIMENTAL STUDIES HAVE SHOWN THAT D-002, A MIXTURE OF BEESWAX ALCOHOLS WITH ANTIOXIDANT EFFECTS, IS HEPATOPROTECTIVE. THE AIM OF THIS STUDY WAS TO INVESTIGATE THE EFFICACY AND SAFETY OF D-002 IN PATIENTS WITH NALFD. METHODS: FIFTY PATIENTS WITH NAFLD WERE RANDOMIZED TO RECEIVE A PLACEBO OR D-002 (100 MG/DAY) FOR 24 WEEKS. THE PRIMARY ENDPOINT WAS A SIGNIFICANT ULTRASONOGRAPHY-DETECTED REDUCTION OF LIVER FAT INFILTRATION VERSUS A PLACEBO. SECONDARY ENDPOINTS WERE DECREASES IN THE HOMEOSTATIC MODEL ASSESSMENT (HOMA) INDEX, INSULIN LEVELS, SERUM LIVER ENZYMES, INCREASES IN PLASMA TOTAL ANTIOXIDANT STATUS (TAS) AND IMPROVED CLINICAL SYMPTOMS VERSUS THE PLACEBO RECIPIENTS. RESULTS: AT RANDOMIZATION, ALL INDICATORS WERE COMPARABLE IN BOTH GROUPS. AT STUDY COMPLETION, SEVEN (28.0\%) D-002-PATIENTS, BUT NONE OF THE PLACEBO RECIPIENTS, EXHIBITED A NORMAL LIVER ECHO PATTERN ON ULTRASONOGRAPHY (P < 0.01). ALSO, D-002 SIGNIFICANTLY REDUCED (P < 0.01 VS. BASELINE AND PLACEBO) THE HOMA INDEX AND INSULIN LEVELS AND INCREASED THE TAS, BUT DID NOT AFFECT OTHER PARAMETERS. THE PROPORTION OF D-002-PATIENTS (12/25, 48.0\%) SHOWING SYMPTOM IMPROVEMENT WAS HIGHER (P < 0.001) THAN THAT OF THE PLACEBO GROUP (1/25, 4.0\%). THE TREATMENT WAS SAFE AND WELL TOLERATED. THREE PATIENTS IN EACH GROUP WITHDREW FROM THE STUDY. CONCLUSIONS: D-002 (100 MG/DAY) IMPROVED ULTRASONOGRAPHIC FINDINGS, INDICATORS OF INSULIN RESISTANCE, PLASMA TAS AND CLINICAL EVOLUTION ON NAFLD PATIENTS. FURTHER STUDIES, HOWEVER, ARE NEEDED TO CONFIRM THESE RESULTS.",NA,"LIPID-PEROXIDATION; INSULIN-RESISTANCE; ANTIOXIDANT; PREVALENCE; CHOLESTEROL; POLICOSANOL; PROGRESSION; DIAGNOSIS; PLASMA; OBESE",NA,NA,"ANGULO P, 2007, ALIMENT PHARM THER, V25, P883, DOI 10.1111/J.1365-2036.2007.03246.X; BARSIC N, 2012, WORLD J GASTROENTERO, V18, P3945, DOI 10.3748/WJG.V18.I30.3945; BONORA E, 2002, DIABETES CARE, V25, P1135, DOI 10.2337/DIACARE.25.7.1135; CAPORASO N, 2012, FRONT BIOSCI-LANDMRK, V17, P2259, DOI 10.2741/4049; CORNIER MA, 2008, ENDOCR REV, V29, P777, DOI 10.1210/ER.2008-0024; CSENDES G PAULA, 2004, REV. CHIL. RADIOL., V10, P50; DONATI G, 2004, GUT, V53, P1020, DOI 10.1136/GUT.2003.027086; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRAIF M, 2000, INVEST RADIOL, V35, P319, DOI 10.1097/00004424-200005000-00006; HORLANDER JC, 2001, GASTROENTEROLOGY, V120, PA544; HSIAO PJ, 2007, J GASTROEN HEPATOL, V22, P2118, DOI 10.1111/J.1440-1746.2006.04698.X; KIM HJ, 2004, ARCH INTERN MED, V164, P2169, DOI 10.1001/ARCHINTE.164.19.2169; LEWIS JR, 2010, DIGEST DIS SCI, V55, P560, DOI 10.1007/S10620-009-1081-0; LIN HZ, 2000, NAT MED, V6, P998, DOI 10.1038/79697; LÓPEZ E, 2008, LAT AM J PHARM, V27, P695; MÁS R, 2001, DRUG FUTURE, V26, P731, DOI 10.1358/DOF.2001.026.08.630956; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MÉNDEZ-SÁNCHEZ N, 2007, LIVER INT, V27, P1157, DOI 10.1111/J.1478-3231.2007.01567.X; MENDOZA S, 2007, J MED FOOD, V10, P379, DOI 10.1089/JMF.2006.296; MENÉNDEZ R, 2000, BRAZ J MED BIOL RES, V33, P85, DOI 10.1590/S0100-879X2000000100012; MENENDEZ R., 2001, J MED FOOD, V4, P71, DOI 10.1089/109662001300341725; MERAT S, 2003, J HEPATOL, V38, P414, DOI 10.1016/S0168-8278(02)00441-5; MESSINA D, 2012, ARCH LATINOAM NUTR, V62, P15; MOLINA VIVIAN, 2001, J MED FOOD, V4, P79, DOI 10.1089/109662001300341734; MOSCATIELLO S, 2008, MINI-REV MED CHEM, V8, P767, DOI 10.2174/138955708784912193; MUSTO D, 2010, MINERVA GASTROENTEROL DIETOL, V56, P389; NAGATA KIYOSHI, 2007, JOURNAL OF TOXICOLOGICAL SCIENCES, V32, P453, DOI 10.2131/JTS.32.453; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; PÉREZ Y, 2013, J NAT MED-TOKYO, V67, P182, DOI 10.1007/S11418-012-0670-Y; PETTA S, 2013, CURR PHARM DES; PIRGON Ö, 2013, J CLIN RES PEDIATR E, V5, P33, DOI 10.4274/JCRPE.825; PREISS D, 2008, CLIN SCI, V115, P141, DOI 10.1042/CS20070402; RATZIU V, 2010, J HEPATOL, V53, P372, DOI 10.1016/J.JHEP.2010.04.008; RODRIGUEZ I., 2009, REV CENIC CIEN BIOL, V40, P147; RODRIGUEZ I, 2010, LAT AM J PHARM, V29, P255; RUALES FRANCO, 2012, ACTA GASTROENTEROL LATINOAM, V42, P278; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SZCZEPANIAK LS, 2005, AM J PHYSIOL-ENDOC M, V288, PE462, DOI 10.1152/AJPENDO.00064.2004; WILLIAMS CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/J.GASTRO.2010.09.038; ZELBER-SAGIL S, 2007, J HEPATOL, V47, P711, DOI 10.1016/J.JHEP.2007.06.020; ZHU FS, 2008, WORLD J GASTROENTERO, V14, P6395, DOI 10.3748/WJG.14.6395","MENDOZA, S (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, 198 ST,19\&21 AVE, HAVANA, CUBA","KOREAN ASSOC INTERNAL MEDICINE","ENGLISH","KOREAN J. INTERN. MED.","ARTICLE","ISI","WOS000321538500008","KOREAN J INTERN MED","NATL CTR SCI RES","NATL CTR SCI RES",NA,"ILLNAIT J, 2013, KOREAN J INTERN MED","ILLNAIT J, 2013, KOREAN J INTERN MED"
"BELEGGIA R;PLATANI C;NIGRO F;DE V;PASQUALE P;CATTIVELLI L;PAPA R","BELEGGIA ROMINA;PLATANI CRISTIANO;NIGRO FRANCA;DE VITA; PASQUALE;CATTIVELLI LUIGI;PAPA ROBERTO","EFFECT OF GENOTYPE ENVIRONMENT AND GENOTYPEBYENVIRONMENT INTERACTION ON METABOLITE PROFILING IN DURUM WHEAT ITRITICUM DURUMI DESF GRAIN",2013,"JOURNAL OF CEREAL SCIENCE","57","183-192",61,"10.1016/j.jcs.2012.09.004","BELEGGIA, R (CORRESPONDING AUTHOR), CRA CER AGR RES COUNCIL CRA, CEREAL RES CTR, SS 16 KM 675, I-71122 FOGGIA, ITALY.; BELEGGIA, ROMINA; PLATANI, CRISTIANO; NIGRO, FRANCA; DE VITA, PASQUALE; CATTIVELLI, LUIGI; PAPA, ROBERTO, CRA CER AGR RES COUNCIL CRA, CEREAL RES CTR, I-71122 FOGGIA, ITALY.","THE AIM OF THIS STUDY WAS TO ASSESS THE RELATIVE ROLES OF GENOTYPE, ENVIRONMENT AND GENOTYPE-BY-ENVIRONMENT INTERACTIONS IN DETERMINING THE METABOLITE PROFILE OF DURUM WHEAT GRAIN. FOUR DURUM WHEAT CULTIVARS WERE GROWN UNDER CONVENTIONAL AND ORGANIC FARMING SYSTEMS OVER THREE CONSECUTIVE YEARS. THE USE OF A HIGH-THROUGHPUT GAS CHROMATOGRAPHY MASS SPECTROMETRY PLATFORM ALLOWED THE ANALYSIS OF SETS OF DIFFERENT POLAR AND NON-POLAR COMPOUNDS, INCLUDING AMINO ACIDS, SUGARS, ORGANIC ACIDS, FATTY ACIDS (SATURATED AND UNSATURATED), AND STEROLS. STATISTICAL ANALYSIS OF THE DATA SHOWED A SMALL IMPACT OF GENOTYPE AND LARGE EFFECTS OF BOTH YEAR AND GENOTYPE-BY-ENVIRONMENT INTERACTION ON THE METABOLITE COMPOSITION AND QUALITY OF THE WHEAT GRAIN. OVERALL, THE DATA FROM THIS STUDY HIGHLIGHT THE POTENTIAL ROLE OF METABOLIC PROFILING IN THE ANALYSIS OF DURUM WHEAT QUALITY AND PRODUCTION. (C) 2012 ELSEVIER LTD. ALL RIGHTS RESERVED.","CEREAL QUALITY; METABOLOMICS; PLANT BREEDING; TRITICUM DURUM","POLICOSANOL CONTENTS; TOCOPHEROL; L.; PHYTOSTEROLS; METABOLOMICS; VARIETIES; GENETICS; QUALITY; TRAITS; ACID","EU PROJECT DEVEL-ONUTRI [FP6-036296]; QUALITEC PROJECT","THE AUTHORS ARE THANKFUL TO MR. CODIANNI PASQUALE (CEREAL RESEARCH CENTRE, FOGGIA, ITALY) FOR TECHNICAL FIELD SUPPORT. THE STUDY WAS SUPPORTED IN PART BY A GRANT FROM THE EU PROJECT DEVEL-ONUTRI, CONTRACT NUMBER FP6-036296, AND BY A GRANT FROM THE QUALITEC PROJECT.","ARMANINO C, 2002, ANAL CHIM ACTA, V454, P315, DOI 10.1016/S0003-2670(01)01548-3; BAKER JM, 2006, PLANT BIOTECHNOL J, V4, P381, DOI 10.1111/J.1467-7652.2006.00197.X; BELEGGIA R, 2011, J AGR FOOD CHEM, V59, P9366, DOI 10.1021/JF2022836; BELEGGIA R, 2009, J CEREAL SCI, V49, P301, DOI 10.1016/J.JCS.2008.12.002; BERGMAN CJ, 2003, CEREAL CHEM, V80, P446, DOI 10.1094/CCHEM.2003.80.4.446; BRITZ SJ, 2002, J AGR FOOD CHEM, V50, P6058, DOI 10.1021/JF0200016; CHEN YF, 2009, J SCI FOOD AGR, V89, P310, DOI 10.1002/JSFA.3446; COLLAKOVA E, 2003, PLANT PHYSIOL, V133, P930, DOI 10.1104/PP.103.026138; DAVIES HV, 2010, REGUL TOXICOL PHARM, V58, PS54, DOI 10.1016/J.YRTPH.2010.07.004; FEEKES W, 1941, TARWE HAAR MILIEU, P560; FERNIE AR, 2009, TRENDS GENET, V25, P39, DOI 10.1016/J.TIG.2008.10.010; FIEHN O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; FIEHN O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833; FRANK T, 2007, J AGR FOOD CHEM, V55, P11011, DOI 10.1021/JF0723559; FRANK T, 2012, J CEREAL SCI, V55, P112, DOI 10.1016/J.JCS.2011.09.009; FRENZEL T, 2002, CEREAL CHEM, V79, P215, DOI 10.1094/CCHEM.2002.79.2.215; HALL R., 2005, METABOLOME ANAL STRA; HIDALGO A, 2006, J CEREAL SCI, V44, P182, DOI 10.1016/J.JCS.2006.06.002; HIDALGO A, 2009, J AGR FOOD CHEM, V57, P6342, DOI 10.1021/JF901180Q; HÖGY P, 2010, J CEREAL SCI, V52, P215, DOI 10.1016/J.JCS.2010.05.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; LAMPI AM, 2010, J AGR FOOD CHEM, V58, P9306, DOI 10.1021/JF100253U; LEVINE LH, 2008, ADV SPACE RES, V42, P1917, DOI 10.1016/J.ASR.2008.07.014; MARWEDE V, 2004, CROP SCI, V44, P728, DOI 10.2135/CROPSCI2004.0728; NURMI T, 2008, J AGR FOOD CHEM, V56, P9710, DOI 10.1021/JF8010678; NURMI T, 2010, J AGR FOOD CHEM, V58, P9314, DOI 10.1021/JF100192T; PÉREZ-JIMÉNEZ F, 2002, ATHEROSCLEROSIS, V163, P385, DOI 10.1016/S0021-9150(02)00033-3; ROCHE J, 2006, EUR J LIPID SCI TECH, V108, P287, DOI 10.1002/EJLT.200500310; RÖHLIG RM, 2010, J AGR FOOD CHEM, V58, P3022, DOI 10.1021/JF904101G; RÖHLIG RM, 2009, METABOLOMICS, V5, P459, DOI 10.1007/S11306-009-0171-5; ROESSNER U, 2001, PLANT CELL, V13, P11, DOI 10.1105/TPC.13.1.11; RONTEIN D, 2002, METAB ENG, V4, P49, DOI 10.1006/MBEN.2001.0208; SCHALLER H, 2003, PROG LIPID RES, V42, P163, DOI 10.1016/S0163-7827(02)00047-4; SHEWRY PR, 2009, J EXP BOT, V60, P1537, DOI 10.1093/JXB/ERP058; SKOGERSON K, 2010, J AGR FOOD CHEM, V58, P3600, DOI 10.1021/JF903705Y; STAMOVA BS, 2009, METABOLOMICS, V5, P239, DOI 10.1007/S11306-008-0146-Y; TAGHOUTI M, 2010, AFR J BIOTECHNOL, V9, P3054; TROCCOLI A, 2000, J CEREAL SCI, V32, P99, DOI 10.1006/JCRS.2000.0322; WOYENGO TA, 2009, EUR J CLIN NUTR, V63, P813, DOI 10.1038/EJCN.2009.29; ZANGENBERG M, 2004, J AGR FOOD CHEM, V52, P2593, DOI 10.1021/JF0351873; ZÖRB C, 2009, J AGR FOOD CHEM, V57, P9555, DOI 10.1021/JF9019739; ZORB C, 2006, J AGR FOOD CHEM, V54, P8301, DOI 10.1021/JF0615451","BELEGGIA, R (CORRESPONDING AUTHOR), CRA CER AGR RES COUNCIL CRA, CEREAL RES CTR, SS 16 KM 675, I-71122 FOGGIA, ITALY","ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","ENGLISH","J. CEREAL SCI.","ARTICLE","ISI","WOS000317162500005","J CEREAL SCI","CEREAL RES CTR;CEREAL RES CTR","CEREAL RES CTR",NA,"BELEGGIA R, 2013, J CEREAL SCI","BELEGGIA R, 2013, J CEREAL SCI"
"KITTS D;KOPEC A;ZAWISTOWSKI J;POPOVICH ;DAVID G D","KITTS DAVID D;KOPEC ANETA;ZAWISTOWSKI JERZY;POPOVICH; DAVID G","EFFECTS OF HIGH MOLECULAR WEIGHT ALCOHOLS FROM SUGAR CANE FED ALONE OR IN COMBINATION WITH PLANT STEROLS ON LIPID PROFILE AND ANTIOXIDANT STATUS OF WISTAR RATS",2012,"APPLIED PHYSIOLOGY NUTRITION AND METABOLISM","37","938-946",3,"10.1139/H2012-072","KITTS, DD (CORRESPONDING AUTHOR), UNIV BRITISH COLUMBIA, 2205-EAST MALL, VANCOUVER, BC V6T 1Z4, CANADA.; KITTS, DAVID D.; ZAWISTOWSKI, JERZY, UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z4, CANADA.; KOPEC, ANETA, AGR UNIV KRAKOW, DEPT HUMAN NUTR, PL-30149 KRAKOW, POLAND.; POPOVICH, DAVID G., NATL UNIV SINGAPORE, DEPT CHEM, SINGAPORE 117543, SINGAPORE.","THE EFFECT OF FEEDING A MIXTURE OF HIGH MOLECULAR WEIGHT ALCOHOLS DERIVED FROM SUGARCANE (SCA), BOTH ALONE AND IN COMBINATION WITH PHYTOSTEROLS (PS), ON CHANGES IN PLASMA LIPIDS, ORGAN CHOLESTEROL ACCUMULATION, AND ANTIOXIDANT STATUS OF WISTAR RATS WAS UNDERTAKEN. THREE SEPARATE EXPERIMENTS WERE CONDUCTED AND EACH EXPERIMENT HAD 3 SUBSETS. IN EXPERIMENT 1, RATS WERE FED ON AN AIN-76, SEMI-SYNTHETIC DIET SUPPLEMENTED WITH 0\%, 0.5\%, AND 5\% SCA W/W. THE SECOND EXPERIMENT CONSISTED OF FEEDING RATS AN ATHEROGENIC DIET (AIN-76+0.5\% CHOLESTEROL) CONTAINING 0\%, 0.5\%, AND 5\% SCA W/W. THE THIRD EXPERIMENT CONSISTED OF FEEDING RATS AN ATHEROGENIC DIET THAT CONTAINED 2\% PS IN COMBINATION WITH 0\%, 0.5\%, AND 5\% SCA. RATS FED THE ATHEROGENIC DIET EXHIBITED SIGNIFICANT ELEVATIONS IN TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND SIGNIFICANT REDUCTIONS IN THE HIGH-DENSITY LIPOPROTEIN/TOTAL CHOLESTEROL RATIO, REGARDLESS OF THE PRESENCE OF 0.5\% OR 5\% SCA MIXTURE. SERUM CHOLESTEROL INCREASED 29\% TO 35\% IN THESE ANIMALS COMPARED WITH ANIMALS FED THE NONATHEROGENIC DIETS. IN CONTRAST, ANIMALS FED ATHEROGENIC DIETS THAT CONTAINED 2\% PS EXHIBITED NO DIFFERENCE IN SERUM LIPIDS COMPARED WITH COUNTERPARTS FED NONATHEROGENIC DIETS. THE COMBINED PRESENCE OF SCA WITH PS HAD NO EFFECT ON FURTHER LOWERING PLASMA CHOLESTEROL. NO CHANGES IN C-REACTIVE PROTEIN WERE OBSERVED, BUT PLASMA OXYGEN RADICAL SCAVENGING CAPACITY VALUES SIGNIFICANTLY (P < 0.05) DECREASED WHEN RATS WERE FED THE ATHEROGENIC DIETS THAT CONTAINED THE COMBINATION OF PS AND SCA. THIS RESULT CORRESPONDED TO AN APPARENT GREATER (P < 0.05) SUSCEPTIBILITY OF RED BLOOD CELLS TO OXIDATIVE STRESS","HYPERCHOLESTEROLEMIA; SUGAR CANE MIXED ALCOHOLS; PHYTOSTEROLS; DYSLIPIDEMIA; ANTIOXIDANT STATUS","LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-BIOSYNTHESIS; PLASMA-CHOLESTEROL; ALPHA-TOCOPHEROL; LDL-CHOLESTEROL; REDUCES PLASMA; BETA-CAROTENE; IN-VITRO; POLICOSANOL; PHYTOSTEROLS","NSERC-UNIVERSITY-INDUSTRY GRANT; DECKABAN FOUNDATION","THIS STUDY WAS FUNDED IN PART BY NSERC-UNIVERSITY-INDUSTRY GRANT AND BY THE DECKABAN FOUNDATION.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ALEMAN CL, 1995, FOOD CHEM TOXICOL, V33, P573, DOI 10.1016/0278-6915(95)00026-X; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BACKES JM, 2011, LIPIDS, V46, P923, DOI 10.1007/S11745-011-3591-8; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; ,, 1977, JOURNAL OF NUTRITION, V107, P1340; CAISEY JD, 1980, CLIN CHEM, V26, P1877; CARLSON SE, 1977, CLIN CHIM ACTA, V79, P575, DOI 10.1016/0009-8981(77)90178-4; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P55; ENDO A, 1979, BIOCHIM BIOPHYS ACTA, V575, P266; FEARS R, 1980, ATHEROSCLEROSIS, V35, P439, DOI 10.1016/0021-9150(80)90185-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAMEZ R, 2005, DRUGS R D, V6, P11; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; IKEDA I, 1988, J LIPID RES, V29, P1573; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; JONES PJH, 2003, J LIPID RES, V44, P1713, DOI 10.1194/JLR.M300089-JLR200; JONES PJH, 1997, AM J CLIN NUTR, V66, P438, DOI 10.1093/AJCN/66.2.438; KASSIS AN, 2006, AM J CLIN NUTR, V84, P1003, DOI 10.1093/AJCN/84.5.1003; KASSIS AN, 2009, LIPIDS, V44, P391, DOI 10.1007/S11745-009-3295-5; KASSIS AN, 2007, ATHEROSCLEROSIS, V194, P153, DOI 10.1016/J.ATHEROSCLEROSIS.2006.10.008; KITTS DD, 2005, ANN NY ACAD SCI, V1043, P501, DOI 10.1196/ANNALS.1333.057; KITTS DD, 1998, CAN J PHYSIOL PHARM, V76, P202, DOI 10.1139/CJPP-76-2-202; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MARINANGELI CPF, 2007, BRIT J NUTR, V97, P381, DOI 10.1017/S0007114507336763; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; NG CH, 2005, J AGR FOOD CHEM, V53, P6289, DOI 10.1021/JF051269A; NOA M, 2005, ARCH MED RES, V36, P441, DOI 10.1016/J.ARCMED.2005.03.039; NTANIOS FY, 2002, J NUTR, V132, P3650, DOI 10.1093/JN/132.12.3650; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; OSTLUND RE, 2004, CURR OPIN LIPIDOL, V15, P37, DOI 10.1097/00041433-200402000-00008; OSTLUND RE, 2002, ANNU REV NUTR, V22, P533, DOI 10.1146/ANNUREV.NUTR.22.020702.075220; PATEL MD, 2006, ATHEROSCLEROSIS, V186, P12, DOI 10.1016/J.ATHEROSCLEROSIS.2005.10.026; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; QUÍLEZ J, 2003, J NUTR, V133, P3103, DOI 10.1093/JN/133.10.3103; RICHELLE M, 2004, AM J CLIN NUTR, V80, P171; RIDEOUT TC, 2010, MOL NUTR FOOD RES, V54, PS7, DOI 10.1002/MNFR.201000027; RODRIGUEZ MD, 1997, TOXICOL LETT, V90, P97, DOI 10.1016/S0378-4274(96)03844-1; SETNIKAR L, 2005, ARZNEIMITTEL-FORSCH, V55, P312; SIES H, 1995, AM J CLIN NUTR, V62, P1315; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAMMI A, 2001, J NUTR, V131, P1942, DOI 10.1093/JN/131.7.1942; VANSTONE CA, 2002, AM J CLIN NUTR, V76, P1272, DOI 10.1093/AJCN/76.6.1272; VASKONEN T, 2002, BRIT J NUTR, V87, P239, DOI 10.1079/BJN2001508; WANG YW, 2003, LIPIDS, V38, P165, DOI 10.1007/S11745-003-1047-3; XU ZY, 2007, NUTR RES, V27, P212, DOI 10.1016/J.NUTRES.2007.01.015","KITTS, DD (CORRESPONDING AUTHOR), UNIV BRITISH COLUMBIA, 2205-EAST MALL, VANCOUVER, BC V6T 1Z4, CANADA","CANADIAN SCIENCE PUBLISHING","ENGLISH","APPL. PHYSIOL. NUTR. METAB.","ARTICLE","ISI","WOS000308147500018","APPL PHYSIOL NUTR METAB","UNIV BRITISH COLUMBIA;UNIV BRITISH COLUMBIA;AGR UNIV KRAKOW;NATL UNIV SINGAPORE","UNIV BRITISH COLUMBIA",NA,"KITTS DD, 2012, APPL PHYSIOL NUTR METAB","KITTS DD, 2012, APPL PHYSIOL NUTR METAB"
"DEEPAM L;ARUMUGHAN C","DEEPAM L S AFINISHA;ARUMUGHAN C","EFFECT OF SAPONIFICATION ON COMPOSITION OF UNSAPONIFIABLE MATTER IN RICE BRAN OIL",2012,"JOURNAL OF OLEO SCIENCE","61","241-247",12,"10.5650/jos.61.241","DEEPAM, LSA (CORRESPONDING AUTHOR), NATL INST INTERDISCIPLINARY SCI \& TECHNOL CSIR, THIRUVANANTHAPURAM 695019, KERALA, INDIA.; DEEPAM, L. S. AFINISHA; ARUMUGHAN, C., NATL INST INTERDISCIPLINARY SCI \& TECHNOL CSIR, THIRUVANANTHAPURAM 695019, KERALA, INDIA.","RICE BRAN OIL CONTAINS A VARIETY OF UNSAPONIFIABLE CONSTITUENTS (USC) THAT ARE PRESUMED TO CONTRIBUTE TO THE HIGH VALUE OF UNSAPONIFABLE MATTER (USM). THE OBJECTIVES OF THE PRESENT STUDY WERE TO IDENTIFY AND QUANTIFY THE CONSTITUENTS IN USM. THE CHANGES THAT THE UNSAPONIFIABLES UNDERGO DURING SAPONIFICATION WERE ALSO QUANTITATIVELY INVESTIGATED. WHILE ANALYZING THE PERCENTAGE OF ALL CONSTITUENTS, THE PERCENTAGE OF STEROL GET INCREASED FROM 22.46 TO 23.77 IN USM OF CRUDE RICE BRAN OIL (CRBO) AND 33.42 TO 36.79 IN USM OF REFINED RICE BRAN OIL (RRBO). ORYZANOL THAT COMPRISED 34\% OF THE UNSAPONIFIABLE IN THE CRUDE OIL BY DIRECT ESTIMATION WAS ALMOST ELIMINATED IN USM AND SAME IN REFINED OIL. THE RESULTS ALSO REVEALED THE PRESENCE OF FOUR ADDITIONAL CLASSES OF COMPOUNDS THAT WERE QUANTIFIED IN USM (POLICOSANOL, FATTY ALDEHYDES, TRITERPENE ALCOHOLS AND POTASSIUM SALT OF ORYZANOLS). AMONG THE FOUR CLASSES OF COMPOUNDS, POLICOSANOL CONTRIBUTED HIGH PERCENTAGE IN USM, (43.39\% IN CRBO AND 28.46\% IN RRBO). FATTY ALDEHYDES, TRITERPENE ALCOHOLS AND POTASSIUM SALT OF ORYZANOLS TOGETHER CONTRIBUTED 27.68\% AND 25.13\% OF USM FROM CRBO AND RRBO RESPECTIVELY. THE HPTLC METHOD EMPLOYED HERE THUS, ACCOUNTED FOR 96.75\% BY WT OF THE USM OF CRBO AND 92.00\% BY WT OF THE USM OF RRBO.","FATTY ALDEHYDES; HPTLC; POLICOSANOL; RICE BRAN OIL; UNSAPONIFIABLE; MATTER","LONG-CHAIN; CRUDE; COMPONENTS; EXTRACTION; STABILITY; ALDEHYDES; ORYZANOL; WAX","COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (CSIR); TECHNOLOGY MISSION ON OIL SEEDS AND PULSES (TMOP), GOVERNMENT OF INDIA","THE FIRST AUTHOR IS GRATEFUL TO COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (CSIR), FOR THE SENIOR RESEARCH FELLOWSHIP GRANTED DURING THE PERIOD OF THIS WORK. THE AUTHORS ACKNOWLEDGE THE FINANCIAL SUPPORT FROM TECHNOLOGY MISSION ON OIL SEEDS AND PULSES (TMOP), GOVERNMENT OF INDIA FOR FUNDING THIS PROJECT.","ANONYMOUS, 6A40 AOCS CA; ANONYMOUS, CL200547F0 FAO WHO; ANONYMOUS, FLUID PHASE EQUILIB; ANONYMOUS, J SEP SCI; AOAC, 2000, OFFICIAL METHODS ANA; BIANCHI G, 1979, EXPERIENTIA, V35, P1417, DOI 10.1007/BF01962755; DEEPAM LSA, 2010, J OLEO SCI, V59, P521, DOI 10.5650/JOS.59.521; GALLO ML, 2004, BIOCHEM SYST ECOL, V32, P545, DOI 10.1016/J.BSE.2003.08.009; HAMILL FA, 2003, J ETHNOPHARMACOL, V87, P15, DOI 10.1016/S0378-8741(03)00097-7; HOED V. VAN, 2006, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, V83, P315, DOI 10.1007/S11746-006-1206-Y; KRISHNA AGG, 2003, J FOOD LIPIDS, V10, P329, DOI 10.1111/J.1745-4522.2003.TB00025.X; KRISHNA AGG, 2001, J AM OIL CHEM SOC, V78, P127, DOI 10.1007/S11746-001-0232-0; MARINI F, 2003, MICROCHEM J, V74, P239, DOI 10.1016/S0026-265X(03)00028-6; MEZOUARI S, 2007, EUR J LIPID SCI TECH, V109, P198, DOI 10.1002/EJLT.200600154; PRASAD R. B. N., 2006, LIPID TECHNOLOGY, V18, P275, DOI 10.1002/LITE.200690003; RAJAM L, 2005, J AM OIL CHEM SOC, V82, P213, DOI 10.1007/S11746-005-5174-4; DEVI RR, 2007, BIORESOURCE TECHNOL, V98, P3037, DOI 10.1016/J.BIORTECH.2006.10.009; SHARMA RD, 1986, LIPIDS, V21, P715, DOI 10.1007/BF02537246; SUBRAHMANYAM CV, 2006, EUR J LIPID SCI TECH, V108, P746, DOI 10.1002/EJLT.200600086; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q; XU ZM, 1999, J AGR FOOD CHEM, V47, P2724, DOI 10.1021/JF981175J; YUASA Y, 2004, FLAVOUR FRAG J, V19, P199, DOI 10.1002/FFJ.1359; ZIGONEANU IG, 2008, BIORESOURCE TECHNOL, V99, P4910, DOI 10.1016/J.BIORTECH.2007.09.067","DEEPAM, LSA (CORRESPONDING AUTHOR), NATL INST INTERDISCIPLINARY SCI \& TECHNOL CSIR, THIRUVANANTHAPURAM 695019, KERALA, INDIA","JAPAN OIL CHEMISTS SOC","ENGLISH","J. OLEO SCI.","ARTICLE","ISI","WOS000303285300001","J OLEO SCI","NATL INST INTERDISCIPLINARY SCI AND TECHNOL CSIR;NATL INST INTERDISCIPLINARY SCI AND TECHNOL CSIR","NATL INST INTERDISCIPLINARY SCI AND TECHNOL CSIR",NA,"DEEPAM LSA, 2012, J OLEO SCI","DEEPAM LSA, 2012, J OLEO SCI"
"DOBSON G;SHRESTHA M;HILZ H;KARJALAINEN R;MCDOUGALL G;STEWART D","DOBSON GARY;SHRESTHA MARIE;HILZ HAUKE;KARJALAINEN REIJO;MCDOUGALL GORDON;STEWART DEREK","LIPOPHILIC COMPONENTS IN BLACK CURRANT SEED AND POMACE EXTRACTS",2012,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","114","575-582",25,"10.1002/ejlt.201100313","DOBSON, G (CORRESPONDING AUTHOR), JAMES HUTTON INST, DUNDEE DD2 5DA, SCOTLAND.; DOBSON, GARY; MCDOUGALL, GORDON; STEWART, DEREK, JAMES HUTTON INST, DUNDEE DD2 5DA, SCOTLAND.; SHRESTHA, MARIE; HILZ, HAUKE, TTZ, BREMERHAVEN, GERMANY.; KARJALAINEN, REIJO, UNIV EASTERN FINLAND, DEPT BIOSCI, KUOPIO, FINLAND.; KARJALAINEN, REIJO, MTT AGRIFOOD RES FINLAND, PLANT PROD RES, E TALO, JOKIOINEN, FINLAND.","THE NATURE OF THE FATTY ACIDS AND OTHER LIPOPHILIC COMPONENTS IN EXTRACTS FROM BLACK CURRANT SEED AND POMACE (CONTAINING SEED) WERE INVESTIGATED, WITH A VIEW TO HIGHLIGHTING ANY POTENTIAL USES. THE SAME NON-HYDROXYLATED FATTY ACIDS WERE THE MAJOR COMPONENTS IN BOTH TYPES OF EXTRACT, BUT TOTAL LEVELS WERE LESS IN POMACE (75 582 MG 100 G-1 OIL) THAN IN SEED ALONE (90 972 MG 100 G-1 OIL) AND THERE WERE LESS UNSATURATED FATTY ACIDS, INCLUDING GLA (8653 AND 12 625 MG 100 G-1 OIL, RESPECTIVELY), BUT LONG CHAIN N-20:0 N-30:0 FATTY ACIDS (4080 AND 437 MG 100 G-1 OIL, RESPECTIVELY) WERE GREATLY INCREASED IN POMACE. PHYTOSTEROLS (MAINLY BETA-SITOSTEROL), SATURATED N-20:0 N-30:0 POLICOSANOLS, OMEGA-HYDROXY FATTY ACIDS (MAINLY 16-HYDROXY 16:0) AND 2-HYDROXY FATTY ACIDS (MAINLY 2-HYDROXY 24:0) WERE PRESENT AT MUCH GREATER LEVELS IN POMACE (2496, 2097, 958 AND 46 MG 100 G-1 OIL, RESPECTIVELY) THAN IN SEED (553, 108, 161, AND 1 MG 100 G-1 OIL, RESPECTIVELY). THE POMACE EXTRACT IS A USEFUL SOURCE OF FATTY ACIDS, PHYTOSTEROLS AND POLICOSANOLS WITH POTENTIAL FUNCTIONAL PROPERTIES. PRACTICAL APPLICATIONS: THE STUDY INVESTIGATED THE LIPOPHILIC COMPONENTS IN ISOHEXANE EXTRACTS FROM BLACK CURRANT SEED AND POMACE (CONTAINING SEED). ONLY POMACE EXTRACTS HAD SUBSTANTIAL AMOUNTS OF PHYTOSTEROLS AND POLICOSANOLS THAT HAVE POTENTIAL AS CHOLESTEROL-LOWERING AGENTS, WHEREAS FATTY ACIDS SUCH AS GLA, THAT HAS ANTI-INFLAMMATORY PROPERTIES, ARE MAINLY IN THE SEED.","BLACK CURRANT; FATTY ACIDS; PHYTOSTEROLS; POLICOSANOLS; POMACE","FATTY-ACID CONTENT; NIGRUM L. POMACE; POLICOSANOL CONTENTS; VITAMIN-E; BERRIES; JUICE; POLYSACCHARIDES; FRACTIONS; VARIETIES; RESIDUES","BRAINHEALTHFOOD [222503]; SCOTTISH GOVERNMENT RURAL AND ENVIRONMENTAL SCIENCE AND ANALYTICAL SERVICES","THE AUTHORS THANK RAMA SALLEPALLI AND VINEETHA VASUKUTTAN FOR THEIR TECHNICAL ASSISTANCE. THE AUTHORS ACKNOWLEDGE FUNDING FROM BRAINHEALTHFOOD (FP7-SME PROJECT NUMBER 222503) AND SUPPORT FROM THE SCOTTISH GOVERNMENT RURAL AND ENVIRONMENTAL SCIENCE AND ANALYTICAL SERVICES (GD, GM, DS).","BAKOWSKA-BARCZAK AM, 2009, J AGR FOOD CHEM, V57, P11528, DOI 10.1021/JF902161K; BAKSHI A, 2003, NUTRITION, V19, P305, DOI 10.1016/S0899-9007(02)00862-6; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P12143, DOI 10.1021/JF1030345; CHRISTIE W. W., 1989, GAS CHROMATOGRAPHY L, P128; CLOUGH PETER M., 2001, P75; DEL CASTILLO MLR, 2004, J AGR FOOD CHEM, V52, P948, DOI 10.1021/JF034950Q; DEL CASTILLO MLR, 2002, J AGR FOOD CHEM, V50, P332, DOI 10.1021/JF010899J; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; HEINZ E., 1996, ADV LIPID METHODOLOG, V3, P211; HELBIG D, 2008, FOOD CHEM, V111, P1043, DOI 10.1016/J.FOODCHEM.2008.05.017; HILZ H, 2005, CARBOHYD POLYM, V59, P477, DOI 10.1016/J.CARBPOL.2004.11.002; HOLLOWAY P. J., 1982, THE PLANT CUTICLE, P45; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; JÄRVINEN R, 2011, J FOOD COMPOS ANAL, V24, P334, DOI 10.1016/J.JFCA.2010.09.022; JÄRVINEN R, 2010, FOOD CHEM, V122, P137, DOI 10.1016/J.FOODCHEM.2010.02.030; JOH YG, 1995, J AM OIL CHEM SOC, V72, P707, DOI 10.1007/BF02635660; KALLIO K, 2006, J AGR FOOD CHEM, V54, P457, DOI 10.1021/JF0522659; KAPASAKALIDIS PG, 2006, J AGR FOOD CHEM, V54, P4016, DOI 10.1021/JF052999L; KAPASAKALIDIS PG, 2009, J AGR FOOD CHEM, V57, P4342, DOI 10.1021/JF8029176; KUNST L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; LENGSFELD C, 2004, PLANTA MED, V70, P620, DOI 10.1055/S-2004-827184; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MARANGONI F, 2010, PHARMACOL RES, V61, P193, DOI 10.1016/J.PHRS.2010.01.001; PARRY J, 2006, J AGR FOOD CHEM, V54, P3773, DOI 10.1021/JF060325K; SANDELL M, 2009, J AGR FOOD CHEM, V57, P3718, DOI 10.1021/JF803884Y; SEN CK, 2010, J AM COLL NUTR, V29, P314S, DOI 10.1080/07315724.2010.10719846; SHEPHERD T, 2007, METABOLOMICS, V3, P475, DOI 10.1007/S11306-007-0058-2; SINGH U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/ANNUREV.NUTR.24.012003.132446; SÓJKA M, 2009, J HORTIC SCI BIOTECH, P100; TAHVONEN R, 1998, Z LEBENSM UNTERS F A, V206, P360, DOI 10.1007/S002170050273; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WALTON TJ., 1990, METHODS PLANT BIOCH, V4, P105; ZILBERBERG M. D., 2001, LINOLENIC ACID RECEN, P90; ZLATANOV MD, 1999, J SCI FOOD AGR, V79, P1620, DOI 10.1002/(SICI)1097-0010(199909)79:12<1620::AID-JSFA410>3.3.CO;2-7","DOBSON, G (CORRESPONDING AUTHOR), JAMES HUTTON INST, DUNDEE DD2 5DA, SCOTLAND","WILEY","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","WOS000304090100014","EUR J LIPID SCI TECHNOL","JAMES HUTTON INST;JAMES HUTTON INST;SHRESTHA;UNIV EASTERN FINLAND;MTT AGRIFOOD RES FINLAND","JAMES HUTTON INST",NA,"DOBSON G, 2012, EUR J LIPID SCI TECHNOL","DOBSON G, 2012, EUR J LIPID SCI TECHNOL"
"KIM J;PARK S;JUNG J;HA S;LIM S;LEE S;WOO H;PARK S;SUH S","KIM JAE KWANG;PARK SOO-YUN;JUNG JI YUN;HA SUN-HWA; LIM SUN-HYUNG;LEE SI MYUNG;WOO HEE-JONG;PARK SAN UN; SUH SEOK-CHEOL","POLICOSANOL CONTENT AND COMPOSITION OF KOREAN RICE IORYZA SATIVAI L CULTIVARS",2012,"CEREAL CHEMISTRY","89","151-154",4,"10.1094/CCHEM-09-11-0113","KIM, JK (CORRESPONDING AUTHOR), NATL ACAD AGR SCI, RURAL DEV ADM, SUWON 441707, SOUTH KOREA.; KIM, JAE KWANG; PARK, SOO-YUN; JUNG, JI YUN; HA, SUN-HWA; LIM, SUN-HYUNG; LEE, SI MYUNG; WOO, HEE-JONG; SUH, SEOK-CHEOL, NATL ACAD AGR SCI, RURAL DEV ADM, SUWON 441707, SOUTH KOREA.; PARK, SAN UN, CHUNGNAM NATL UNIV, DEPT CROP SCI, TAEJON 305764, SOUTH KOREA.","POLICOSANOLS (PCS) ARE A GROUP OF LONG-CHAIN ALCOHOLS THAT HAVE BEEN REPORTED TO HAVE MANY BENEFICIAL PHYSIOLOGICAL ACTIVITIES. IN THIS STUDY, THE TOTAL CONTENT AND COMPOSITION OF PCS IN 15 RICE (ORYZA SALIVA L.) CULTIVARS FROM KOREA WERE CHARACTERIZED BY GAS CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROMETRY. THIS METHOD PROVED TO BE SUFFICIENTLY PRECISE AND ACCURATE WITH RESPECT TO THE DEGREE OF ENDOGENOUS BIOLOGICAL VARIABILITY FOUND IN THE RICE SAMPLES. OCTACOSANOL (C28) AND TRIACONTANOL (C30) WERE THE MAJOR COMPONENTS OF PCS IN ALL CULTIVARS. IN ADDITION, THERE WERE POSITIVE CORRELATIONS AMONG THE DETERMINED PC CONTENTS. GIVEN ITS HIGH PC CONTENT, THE HEUGHYANGBYEO CULTIVAR MAY APPEAR TO BE A GOOD CANDIDATE FOR FUTURE BREEDING PROGRAMS.",NA,"PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; HYPERCHOLESTEROLEMIA; WAX","SSAC [PJ0081842012]; NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA [PJ0068342012]","THIS WORK WAS SUPPORTED BY A GRANT FROM THE NEXT-GENERATION BIO-GREEN 21 PROGRAM (SSAC, PJ0081842012) AND THE NATIONAL ACADEMY OF AGRICULTURAL SCIENCE (CODE PJ0068342012), RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA. THE AUTHORS ARE GRATEFUL TO THE NATIONAL INSTITUTE OF CROP SCIENCE FOR THE RICE SEEDS USED IN THIS STUDY.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CASTANO G, 1996, CURR THER RES CLIN E, V57, P691, DOI 10.1016/S0011-393X(96)80074-9; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P12143, DOI 10.1021/JF1030345; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HWANG KT, 2005, CEREAL CHEM, V82, P242, DOI 10.1094/CC-82-0242; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; KIM JK, 2011, CEREAL CHEM, V88, P397, DOI 10.1094/CCHEM-01-11-0010; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; NG CH, 2005, J AGR FOOD CHEM, V53, P6289, DOI 10.1021/JF051269A; STUSSER R, 1998, INT J CLIN PHARM TH, V36, P469; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; WANG MF, 2007, J AGR FOOD CHEM, V55, P5552, DOI 10.1021/JF063623Q","KIM, JK (CORRESPONDING AUTHOR), NATL ACAD AGR SCI, RURAL DEV ADM, SUWON 441707, SOUTH KOREA","AACC INTERNATIONAL","ENGLISH","CEREAL CHEM.","ARTICLE","ISI","WOS000305169700002","CEREAL CHEM","NATL ACAD AGR SCI;NATL ACAD AGR SCI;CHUNGNAM NATL UNIV","NATL ACAD AGR SCI",NA,"KIM JK, 2012, CEREAL CHEM","KIM JK, 2012, CEREAL CHEM1"
"KIM J;PARK S;NA J;SEONG E;YU C","KIM JAE KWANG;PARK SOO-YUN;NA JONG-KUK;SEONG EUN SOO; YU CHANG YEON","METABOLITE PROFILING BASED ON LIPOPHILIC COMPOUNDS FOR QUALITY ASSESSMENT OF PERILLA IPERILLA FRUTESCENSI CULTIVARS",2012,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","60","2257-2263",35,"10.1021/jf204977x","KIM, JK (CORRESPONDING AUTHOR), RURAL DEV ADM, NATL ACAD AGR SCI, SUWON 441707, SOUTH KOREA.; KIM, JAE KWANG; PARK, SOO-YUN; NA, JONG-KUK, RURAL DEV ADM, NATL ACAD AGR SCI, SUWON 441707, SOUTH KOREA.; SEONG, EUN SOO; YU, CHANG YEON, KANGWON NATL UNIV, COLL AGR \& LIFE SCI, CHUNCHON 200701, SOUTH KOREA.","LIPOPHILIC COMPOUNDS FROM KOREAN PERILLA (PERILLA FRUTESCENS) SEEDS WERE CHARACTERIZED TO DETERMINE THE DIVERSITY AMONG THEIR PHYTOCHEMICALS AND TO ANALYZE RELATIONSHIPS BETWEEN THEIR CONTENTS. TWENTY-FOUR METABOLITES CONSISTING OF POLICOSANOL, PHYTOSTEROL, TOCOPHEROL, AND FATTY ACIDS WERE IDENTIFIED. THE METABOLITE PROFILES WERE SUBJECTED TO DATA MINING PROCESSES, INCLUDING PRINCIPAL COMPONENT ANALYSIS (PCA), PARTIAL LEAST-SQUARES DISCRIMINATE ANALYSIS (PLS-DA), AND PEARSON'S CORRELATION ANALYSIS. PLS-DA COULD DISTINGUISH BETWEEN ALL CULTIVARS EXCEPT BETWEEN DAESIL AND DAEYEUP CULTIVARS. LINOLENIC ACID CONTENTS WERE POSITIVELY CORRELATED WITH BETA-SITOSTEROL (R = 0.8367, P < 0.0001) AND GAMMA-TOCOPHEROL CONTENTS (R = 0. 7201, P < 0.001) AMONG ALL PERILLA GRAINS. THE DAESIL AND DAEYEUP CULTIVARS APPEAR TO BE GOOD CANDIDATES FOR FUTURE BREEDING PROGRAMS BECAUSE THEY HAVE SIMULTANEOUSLY HIGH LINOLENIC ACID, PHYTOSTEROL, AND TOCOPHEROL LEVELS. THESE RESULTS DEMONSTRATE THE USE OF METABOLITE PROFILING AS A TOOL FOR ASSESSING THE QUALITY OF FOOD.","PERILLA; FATTY ACID; TOCOPHEROL; PHYTOSTEROL; POLICOSANOL; METABOLITE; PROFILING; PRINCIPAL COMPONENT ANALYSIS","FATTY-ACID-COMPOSITION; OXIDATIVE STRESS; VITAMIN-E; MULTIVARIATE; PHYTOSTEROL; TOCOPHEROL; SEED; OIL","NEXT-GENERATION BIOGREEN 21 PROGRAM (SSAC) [PJ0081842012]; NATIONAL ACADEMY OF AGRICULTURAL SCIENCE, RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA [PJ0068342012]","THIS WORK WAS SUPPORTED BY A GRANT FROM THE NEXT-GENERATION BIOGREEN 21 PROGRAM (SSAC, PJ0081842012) AND THE NATIONAL ACADEMY OF AGRICULTURAL SCIENCE (CODE PJ0068342012), RURAL DEVELOPMENT ADMINISTRATION, REPUBLIC OF KOREA.","ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ALLARD JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013; AOCS, 1997, OFF METH REC PRACT A; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; FAHN S, 1992, ANN NEUROL S, V32, P128; HAFFNER SM, 2000, METABOLISM, V49, P30, DOI 10.1016/S0026-0495(00)80083-9; HALLIKAINEN MA, 2000, J NUTR, V130, P767, DOI 10.1093/JN/130.4.767; JONES PJ, 2000, J LIPID RES, V41, P697; KAMALELDIN A, 1997, J AM OIL CHEM SOC, V74, P375, DOI 10.1007/S11746-997-0093-1; KIM JK, 2012, J FOOD COMPOS ANAL, V25, P31, DOI 10.1016/J.JFCA.2011.06.002; KIM JK, 2010, J AGR FOOD CHEM, V58, P12804, DOI 10.1021/JF103277G; KRAMER-STICKLAND K, 1999, CHEM RES TOXICOL, V12, P187, DOI 10.1021/TX980204H; LONGVAH T, 2000, FOOD CHEM, V70, P13, DOI 10.1016/S0308-8146(99)00263-0; PHILLIPS KM, 1999, FOOD CHEM, V64, P415, DOI 10.1016/S0308-8146(98)00090-9; RAMADAN Z, 2006, TALANTA, V68, P1683, DOI 10.1016/J.TALANTA.2005.08.042; SCHUMMER C, 2009, TALANTA, V77, P1473, DOI 10.1016/J.TALANTA.2008.09.043; SHIN HS, 1994, J AM OIL CHEM SOC, V71, P619, DOI 10.1007/BF02540589; TATEMATSU K, 2004, J HEALTH SCI, V50, P108, DOI 10.1248/JHS.50.108; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TIANNIAM S, 2008, J BIOSCI BIOENG, V105, P655, DOI 10.1263/JBB.105.655; VAN PELT CK, 1998, ANAL CHEM, V70, P4369, DOI 10.1021/AC980295N","KIM, JK (CORRESPONDING AUTHOR), RURAL DEV ADM, NATL ACAD AGR SCI, SUWON 441707, SOUTH KOREA","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000301098900025","J AGRIC FOOD CHEM","NATL ACAD AGR SCI;NATL ACAD AGR SCI;KANGWON NATL UNIV","NATL ACAD AGR SCI",NA,"KIM JK, 2012, J AGRIC FOOD CHEM","KIM JK, 2012, J AGRIC FOOD CHEM1"
"DE O A;CONSERVA L;DE S F;JAMYLLE N J;BRITO F;LYRA L R;BARRETO E","DE OLIVEIRA ANDERSON MARQUES;CONSERVA LUCIA M;DE SOUZA FERRO; JAMYLLE N;BRITO FABIOLA DE ALMEIDA;LYRA LEMOS ROSANGELA P;BARRETO EMILIANO","ANTINOCICEPTIVE AND ANTIINFLAMMATORY EFFECTS OF OCTACOSANOL FROM THE LEAVES OF ISABICEA GRISEAI VAR IGRISEAI IN MICE",2012,"INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES","13","1598-1611",69,"10.3390/ijms13021598","BARRETO, E (CORRESPONDING AUTHOR), UNIV FED ALAGOAS, LAB BIOL CELULAR, BR-57072970 MACEIO, AL, BRAZIL.; DE SOUZA FERRO, JAMYLLE N.; BRITO, FABIOLA DE ALMEIDA; BARRETO, EMILIANO, UNIV FED ALAGOAS, LAB BIOL CELULAR, BR-57072970 MACEIO, AL, BRAZIL.; DE OLIVEIRA, ANDERSON MARQUES; CONSERVA, LUCIA M., UNIV FED ALAGOAS, INST QUIM \& BIOTECNOL, BR-57072970 MACEIO, AL, BRAZIL.; LYRA LEMOS, ROSANGELA P., INST MEIO AMBIENTE ESTADO ALAGOAS, BR-57017320 MACEIO, AL, BRAZIL.","SABICEA SPECIES ARE USED IN THE AMAZON FOR TREATMENT OF FEVER AND MALARIA, WHICH SUGGESTS THAT ITS CHEMICAL CONSTITUENTS MAY HAVE SOME EFFECT ON PAIN AND INFLAMMATION. PHYTOCHEMICAL ANALYSIS OF THE HEXANE FRACTION OBTAINED FROM THE CRUDE ETHANOL EXTRACT FROM SABICEA GRISEA VAR. GRISEA CHAM. \& SCHLTDL (RUBIACEAE), AN ENDEMIC PLANT IN BRAZIL, RESULTED IN THE ISOLATION OF OCTACOSANOL. THIS STUDY INVESTIGATED THE ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF THE OCTACOSANOL IN DIFFERENT EXPERIMENTAL MODELS. THE CRUDE ETHANOLIC EXTRACT AND HEXANE FRACTION OBTAINED FROM THE LEAVES OF S. GRISEA PRODUCED AN INHIBITION OF ACETIC ACID-INDUCED PAIN. MOREOVER, OCTACOSANOL ISOLATED FROM THE HEXANE FRACTION PRODUCED A SIGNIFICANT INHIBITION OF PAIN RESPONSE ELICITED BY ACETIC ACID. PRE-TREATMENT WITH YOHIMBINE, AN ALPHA 2-ADRENERGIC RECEPTOR ANTAGONIST, NOTABLY REVERSED THE ANTINOCICEPTIVE ACTIVITY INDUCED BY OCTACOSANOL IN THE ABDOMINAL CONSTRICTION TEST. FURTHERMORE, MICE TREATED WITH OCTACOSANOL DID NOT EXHIBIT ANY BEHAVIORAL ALTERATION DURING THE HOT PLATE AND ROTA-ROD TESTS, INDICATING NON-PARTICIPATION OF THE SUPRASPINAL COMPONENTS IN THE MODULATION OF PAIN BY OCTACOSANOL WITH NO MOTOR ABNORMALITY. IN THE FORMALIN TEST, OCTACOSANOL DID NOT INHIBIT THE LICKING TIME IN FIRST PHASE (NEUROGENIC PAIN), BUT SIGNIFICANTLY INHIBITED THE LICKING TIME IN SECOND PHASE (INFLAMMATORY PAIN) OF MICE. THE ANTI-INFLAMMATORY EFFECT OF OCTACOSANOL WAS EVALUATED USING CARRAGEENAN-INDUCED PLEURISY. THE OCTACOSANOL SIGNIFICANTLY REDUCED THE TOTAL LEUKOCYTE COUNT AND NEUTROPHILS INFLUX, AS WELL AS TNF-ALPHA LEVELS IN THE CARRAGEENAN-INDUCED PLEURISY. THIS STUDY REVEALED THAT THE MECHANISM RESPONSIBLE FOR THE ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS OF THE OCTACOSANOL APPEARS TO BE PARTLY ASSOCIATED WITH AN INHIBITION OF ALPHA 2-ADRENERGIC TRANSMISSION AND AN INHIBITION OF PATHWAYS DEPENDENT ON PRO-INFLAMMATORY CYTOKINES. FINALLY, THESE RESULTS DEMONSTRATED THAT THE OCTACOSANOL FROM THE LEAVES OF S. GRISEA POSSESSES ANTINOCICEPTIVE AND ANTI-INFLAMMATORY ACTIVITIES, WHICH COULD BE OF RELEVANCE FOR THE PHARMACOLOGICAL CONTROL OF PAIN AND INFLAMMATORY PROCESSES.","OCTACOSANOL; ANTI-INFLAMMATORY; ANTINOCICEPTION; TNF-ALPHA; SABICEA; GRISEA","ETHANOL EXTRACT; ANIMAL-MODELS; FORMALIN TEST; IN-VIVO; RATS; POLICOSANOL; SUPPRESSION; NOCICEPTION; MECHANISMS; RUBIACEAE","CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO (CNPQ); PROGRAMA DE COOPERACAO ACADEMICA/COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE NIVEL SUPERIOR (PROCAD/CAPES); FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE ALAGOAS (FAPEAL) (BRAZIL)","THIS WORK WAS SUPPORTED BY GRANTS FROM THE CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO (CNPQ), THE PROGRAMA DE COOPERACAO ACADEMICA/COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE NIVEL SUPERIOR (PROCAD/CAPES) AND THE FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE ALAGOAS (FAPEAL) (BRAZIL).","AMICOROXAS M, 1984, ARCH INT PHARMACOD T, V272, P103; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; AWAD R, 2009, J ETHNOPHARMACOL, V125, P257, DOI 10.1016/J.JEP.2009.06.034; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V59, P235, DOI 10.1016/S0952-3278(98)90135-1; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CARDOSO CL, 2003, J NAT PROD, V66, P1017, DOI 10.1021/NP020547M; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/J.1476-5381.1968.TB00973.X; DE SOUSA OV, 2010, INT J MOL SCI, V11, P2067, DOI 10.3390/IJMS11052067; DIXIT SN, 1971, INDIAN JOURNAL OF APPLIED CHEMISTRY, V34, P46; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/JPS.3030460322; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; FAGUNDES LL, 2010, INT J MOL SCI, V11, P3942, DOI 10.3390/IJMS11103942; FARIAS JAC, 2012, INFLAMMATION, V35, P764, DOI 10.1007/S10753-011-9372-Y; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; IWAMOTO ET, 1993, J PHARMACOL EXP THER, V266, P329; KAROU SIMPLICE D, 2011, PAK J BIOL SCI, V14, P149, DOI 10.3923/PJBS.2011.149.169; KHAN SA, 2008, TAXON, V57, P7, DOI 10.2307/25065944; LE BARS D, 2001, PHARMACOL REV, V53, P597; LUTTINGER D, 1985, J PHARMACOL EXP THER, V232, P883; MCNAMARA CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/PNAS.0705924104; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; MONGRAND S, 2005, PHYTOCHEMISTRY, V66, P549, DOI 10.1016/J.PHYTOCHEM.2004.12.021; MOORE ADRIAN R, 2003, METHODS MOL BIOL, V225, P123; MORRIS BD, 2000, J CHEM ECOL, V26, P859, DOI 10.1023/A:1005499907009; MURRAY CW, 1988, J PHARMACOL METHOD, V20, P175, DOI 10.1016/0160-5402(88)90078-2; OLIARO-BOSSO S, 2009, LIPIDS, V44, P907, DOI 10.1007/S11745-009-3338-Y; RAVELO Y, 2011, J NAT MED-TOKYO, V65, P330, DOI 10.1007/S11418-010-0496-4; RIBEIRO RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6; ROUMY V, 2007, J ETHNOPHARMACOL, V112, P482, DOI 10.1016/J.JEP.2007.04.009; SAINT-JOHN M.M.L, 1986, INT CLIN NUTR REV, V1, P81; SAITO M, 2006, EUR J PHARMACOL, V544, P132, DOI 10.1016/J.EJPHAR.2006.06.001; SCHMAUSS C, 1984, J PHARMACOL EXP THER, V228, P1; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; THIPPESWAMY G, 2008, EUR J PHARMACOL, V588, P141, DOI 10.1016/J.EJPHAR.2008.04.027; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; TSUJI RF, 2003, CLIN EXP ALLERGY, V33, P249, DOI 10.1046/J.1365-2222.2003.01575.X; TZAKOU O, 2011, NAT PROD COMMUN, V6, P237; UTSUNOMIYA I, 1998, CYTOKINE, V10, P956, DOI 10.1006/CYTO.1998.0376; VALADEAU C, 2010, J ETHNOPHARMACOL, V127, P175, DOI 10.1016/J.JEP.2009.09.024; WANG T, 2010, ACTA PHARMACOL SIN, V31, P765, DOI 10.1038/APS.2010.69; YAKSH TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/J.1399-6576.1997.TB04623.X","BARRETO, E (CORRESPONDING AUTHOR), UNIV FED ALAGOAS, LAB BIOL CELULAR, BR-57072970 MACEIO, AL, BRAZIL","MDPI AG","ENGLISH","INT. J. MOL. SCI.","ARTICLE","ISI","WOS000300715700021","INT J MOL SCI","UNIV FED ALAGOAS;UNIV FED ALAGOAS;UNIV FED ALAGOAS;INST MEIO AMBIENTE ESTADO ALAGOAS","UNIV FED ALAGOAS",NA,"DE OLIVEIRA AM, 2012, INT J MOL SCI","DE OLIVEIRA AM, 2012, INT J MOL SCI"
"BELEGGIA R;PLATANI C;PAPA R;DI C;ANNAGRAZIA A;BARROS E;MASHABA C;WIRTH J;FAMMARTINO A;SAUTTER C;CONNER S;RAUSCHER J;STEWART D;CATTIVELLI L","BELEGGIA ROMINA;PLATANI CRISTIANO;PAPA ROBERTO;DI CHIO; ANNAGRAZIA;BARROS EUGENIA;MASHABA CHARLOTTE;WIRTH JUDITH;FAMMARTINO ALESSANDRO;SAUTTER CHRISTOF;CONNER SEAN; RAUSCHER JOHANNES;STEWART DEREK;CATTIVELLI LUIGI","METABOLOMICS AND FOOD PROCESSING FROM SEMOLINA TO PASTA",2011,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","59","9366-9377",44,"10.1021/jf2022836","BELEGGIA, R (CORRESPONDING AUTHOR), CRA CEREAL RES CTR, SS 16 KM 675, I-71122 FOGGIA, ITALY.; BELEGGIA, ROMINA; PLATANI, CRISTIANO; PAPA, ROBERTO; CATTIVELLI, LUIGI, CRA CEREAL RES CTR, I-71122 FOGGIA, ITALY.; DI CHIO, ANNAGRAZIA, TAMMA IND ALIMENTARI CAPITANATA SRL, I-71100 FOGGIA, ITALY.; BARROS, EUGENIA; MASHABA, CHARLOTTE, CSIR BIOSCI, ZA-0001 PRETORIA, SOUTH AFRICA.; WIRTH, JUDITH; FAMMARTINO, ALESSANDRO; SAUTTER, CHRISTOF, ETH, DEPT BIOL, CH-8092 ZURICH, SWITZERLAND.; CONNER, SEAN; RAUSCHER, JOHANNES; STEWART, DEREK, JAMES HUTTON INST, PLANT PROD \& FOOD QUAL PROGRAMME, MYLNFIELD DD2 5DA, INVERGOWRIE DUN, SCOTLAND.; CATTIVELLI, LUIGI, CRA GENOM RES CTR, I-29017 FIORENZUOLA DARDA, PC, ITALY.","THE OBJECTIVE OF THIS STUDY WAS TO INVESTIGATE THE METABOLITE VARIATIONS DURING INDUSTRIAL PASTA PROCESSING (FROM SEMOLINA TO DRIED PASTA) FOR FIVE DIFFERENT COMMERCIAL PRODUCTS. UP TO 76 METABOLITES WERE DETECTED. SIGNIFICANT DIFFERENCES WERE OBSERVED BETWEEN WHOLEMEAL AND REFINED PASTA SAMPLES, WITH THE WHOLEMEAL PASTA RICHER IN MANY CLASSES OF COMPOUNDS SUCH AS PHYTOSTEROLS, POLICOSANOLS, UNSATURATED FATTY ACIDS, AMINO ACIDS, CAROTENOIDS, MINERALS, AND SO ON. SIGNIFICANT DIFFERENCES WERE ALSO OBSERVED BETWEEN SAMPLES OF REFINED PASTA APPARENTLY SIMILAR FOR THE ACTUAL PARAMETERS USED FOR THE ASSESSMENT OF PASTA QUALITY. THE RESULTS INDICATED THAT A NUMBER OF METABOLITES UNDERGO A TRANSFORMATION DURING THE PASTA-MAKING PROCESS DEPENDING ON THE PROCESSING CONDITIONS ADOPTED. THE APPROACH USED IN THIS WORK SHOWS THE HIGH POTENTIAL OF METABOLITE PROFILING FOR FOOD INVESTIGATIONS WITH REGARD TO PROCESS-RELATED TRANSFORMATION, SAFETY, AND NUTRITION.","METABOLOMICS; METABOLIC PROFILING; NUTRITION QUALITY; PASTA PROCESSING; PCA","MAILLARD REACTION; AMINO-ACID; WHEAT; PHYTOSTEROLS; DIVERSITY; COOKING; SUGAR; FORTIFICATION; CAROTENOIDS; POLICOSANOL","EU [FP6-036296]; SCOTTISH GOVERNMENT","THIS RESEARCH WAS FUNDED BY THE EU PROJECT DEVELONUTRI, CONTRACT FP6-036296. D.S. AND S.C. ACKNOWLEDGE SUPPORT FROM THE SCOTTISH GOVERNMENT STRATEGIC RESEARCH AND PARTNERSHIPS PROGRAMMES (2011-2016).","ACQUISTUCCI R, 2000, LEBENSM-WISS TECHNOL, V33, P48, DOI 10.1006/FSTL.1999.0606; ALI K, 2010, PHYTOCHEM REV, V9, P357, DOI 10.1007/S11101-009-9158-0; ANESE M, 1999, FOOD RES INT, V32, P193, DOI 10.1016/S0963-9969(99)00076-9; ASHOOR SH, 1984, J FOOD SCI, V49, P1206, DOI 10.1111/J.1365-2621.1984.TB10432.X; BAIC S., 2005, FOOD FACT SHEET BRIT, P1; BAXTER JH, 1995, J FOOD SCI, V60, P405, DOI 10.1111/J.1365-2621.1995.TB05682.X; BELEGGIA R, 2009, J CEREAL SCI, V49, P301, DOI 10.1016/J.JCS.2008.12.002; BORRELLI GM, 2003, CEREAL CHEM, V80, P225, DOI 10.1094/CCHEM.2003.80.2.225; CAPANOGLU E, 2008, J AGR FOOD CHEM, V56, P964, DOI 10.1021/JF072990E; CASTANO G, 1996, CURR THER RES CLIN E, V57, P691, DOI 10.1016/S0011-393X(96)80074-9; CHILLO S, 2008, J FOOD ENG, V84, P101, DOI 10.1016/J.JFOODENG.2007.04.022; CIFUENTES A, 2009, J CHROMATOGR A, V1216, P7109, DOI 10.1016/J.CHROMA.2009.09.018; CUBADDA F, 2009, J CEREAL SCI, V49, P92, DOI 10.1016/J.JCS.2008.07.008; DE NONI I, 2010, CRIT REV FOOD SCI, V50, P465, DOI 10.1080/10408390802437154; DEXTER JE, 1981, J FOOD SCI, V46, P1741, DOI 10.1111/J.1365-2621.1981.TB04476.X; DIGESÙ AM, 2009, J CEREAL SCI, V50, P210, DOI 10.1016/J.JCS.2009.05.002; DISTAAM EM, 2001, CEREAL FOOD WORLD, V46, P522; DOBSON G, 2008, J AGR FOOD CHEM, V56, P10280, DOI 10.1021/JF801370B; EDGE MS, 2005, J AM DIET ASSOC, V105, P1856, DOI 10.1016/J.JADA.2005.10.022; FARES C, 2008, J SCI FOOD AGR, V88, P2435, DOI 10.1002/JSFA.3350; FIEHN O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833; FLETCHER RJ, 2004, P NUTR SOC, V63, P605, DOI 10.1079/PNS2004391; FRAIGNIER MP, 2000, CEREAL CHEM, V77, P11, DOI 10.1094/CCHEM.2000.77.1.11; FRASER PD, 2007, PLANT J, V49, P552, DOI 10.1111/J.1365-313X.2006.02949.X; HALL RD, 2008, PHYSIOL PLANTARUM, V132, P162, DOI 10.1111/J.1399-3054.2007.00989.X; HERRERO M, 2011, MASS SPECTROM REV, DOI DOI 10.1002/MAS.20335; HIDALGO A, 2010, FOOD CHEM, V121, P746, DOI 10.1016/J.FOODCHEM.2010.01.034; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; KNUCKLES BE, 1997, CEREAL FOOD WORLD, V42, P94; KORPELA R, 2006, EUR J CLIN NUTR, V60, P633, DOI 10.1038/SJ.EJCN.1602362; KRITCHEVSKY D, 2005, NUTR RES, V25, P413, DOI 10.1016/J.NUTRES.2005.02.003; KWAK EJ, 2004, AMINO ACIDS, V27, P85, DOI 10.1007/S00726-004-0067-7; LAMBERTS L, 2008, FOOD CHEM, V111, P738, DOI 10.1016/J.FOODCHEM.2008.04.051; LEENHARDT F, 2006, J AGR FOOD CHEM, V54, P1710, DOI 10.1021/JF052243M; LEVINE LH, 2008, ADV SPACE RES, V42, P1917, DOI 10.1016/J.ASR.2008.07.014; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MCCANN LC, 2010, J AGR FOOD CHEM, V58, P2368, DOI 10.1021/JF903446V; MCDOUGALL G, 2008, J CHROMATOGR B, V871, P362, DOI 10.1016/J.JCHROMB.2008.06.032; MOCHIDA K, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-568; NURMI T, 2008, J AGR FOOD CHEM, V56, P9710, DOI 10.1021/JF8010678; OSORIO S., 2009, CAB REVIEWS: PERSPECTIVES IN AGRICULTURE, VETERINARY SCIENCE, NUTRITION AND NATURAL RESOURCES, V4, P1, DOI 10.1079/PAVSNNR20094024; *PAN DIET PROD NUT, 2008, EFSA J, V781, P1; *PAN DIET PROD NUT, 2009, EFSA J, V1175, P1; POLETTI S, 2004, CURR OPIN BIOTECH, V15, P162, DOI 10.1016/J.COPBIO.2004.03.002; RADA-MENDOZA M, 2004, J CEREAL SCI, V39, P167, DOI 10.1016/S0733-5210(03)00070-5; SENSIDONI A, 1996, IND ALIMENT-ITALY, P9; SHEPHERD LVT, 2011, BIOANALYSIS, V3, P1143, DOI 10.4155/BIO.11.61; SKOGERSON K, 2010, J AGR FOOD CHEM, V58, P3600, DOI 10.1021/JF903705Y; SLAVIN J, 2003, P NUTR SOC, V62, P129, DOI 10.1079/PNS2002221; SOUPAS L, 2006, EUR FOOD RES TECHNOL, V222, P266, DOI 10.1007/S00217-005-0031-0; STAMOVA BS, 2009, METABOLOMICS, V5, P239, DOI 10.1007/S11306-008-0146-Y; STEWART D, 2011, ANN PLANT REV BIOL P, V43; STEWART D, 2007, MOL NUTR FOOD RES, V51, P645, DOI 10.1002/MNFR.200700056; *UNIPI, 2007, CONS PAST AL NEI DIV; WIRTH J, 2009, PLANT BIOTECHNOL J, V7, P631, DOI 10.1111/J.1467-7652.2009.00430.X; ZIELINSKI H., 2001, INNOVATIVE FOOD SCIENCE \& EMERGING TECHNOLOGIES, V2, P159, DOI 10.1016/S1466-8564(01)00040-6; ZORB C, 2006, J AGR FOOD CHEM, V54, P8301, DOI 10.1021/JF0615451","BELEGGIA, R (CORRESPONDING AUTHOR), CRA CEREAL RES CTR, SS 16 KM 675, I-71122 FOGGIA, ITALY","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000294585100041","J AGRIC FOOD CHEM","CRA CEREAL RES CTR;CRA CEREAL RES CTR;CSIR BIOSCI;RAUSCHER;JAMES HUTTON INST;CRA GENOM RES CTR","CRA CEREAL RES CTR",NA,"BELEGGIA R, 2011, J AGRIC FOOD CHEM","BELEGGIA R, 2011, J AGRIC FOOD CHEM"
"BARROSO-BUJANS F;YAZDANI-PEDRAM M;FREY H;MARTINEZ R","BARROSO-BUJANS FABIENNE;YAZDANI-PEDRAM MEHRDAD;FREY HOLGER;MARTINEZ RICARDO","SYNTHESIS OF WATERSOLUBLE COPOLYMERS CARRYING LONGCHAIN CSUB12SUB TO CSUB30SUB ALIPHATIC MOIETIES",2011,"MACROMOLECULAR CHEMISTRY AND PHYSICS","212","1648-1653",1,"10.1002/macp.201100221","BARROSO-BUJANS, F (CORRESPONDING AUTHOR), MAT PHYS CTR CSIC UPV EHU, PASEO MANUEL LARDIZABAL 5, SAN SEBASTIAN 20018, SPAIN.; BARROSO-BUJANS, FABIENNE; YAZDANI-PEDRAM, MEHRDAD, UNIV CHILE, FAC CIENCIAS QUIM \& FARMACEUT, SANTIAGO 1007, CHILE.; BARROSO-BUJANS, FABIENNE; MARTINEZ, RICARDO, UNIV LA HABANA, INST MAT \& REACTIVOS, HAVANA 10400, CUBA.; FREY, HOLGER, JOHANNES GUTENBERG UNIV MAINZ, INST CHIM ORGAN, D-55099 MAINZ, GERMANY.","WATER-SOLUBLE COPOLYMERS FROM MONO-1-ALKYL ITACONATES AND N-VINYL-2-PYRROLIDONE ARE SYNTHESIZED AND CHARACTERIZED. THE MONO-1-ALKYL ITACONATES ARE PREPARED FROM ITACONIC ANHYDRIDE AND THE RELATED ALCOHOL: 1-DODECANOL, 1-OCTADECANOL, 1-DOCOSANOL, AND 1-TRIACONTANOL. THE MONO-1-TRIACONTYL ITACONATE IS SYNTHESIZED FROM PLANT GROWTH REGULATOR POLICOSANOLS EXTRACTED FROM AGAVE FOURCROUYDES, WHERE 1-TRIACONTANOL IS THE MAJOR PRODUCT. THE REACTIVITY RATIOS, CALCULATED ACCORDING TO THE MAO-HUGLIN METHOD FOR COPOLYMERIZATIONS CONDUCTED TO MEDIUM-HIGH CONVERSIONS, INDICATE A TENDENCY TOWARD ALTERNATION FOR ALL COPOLYMERIZATION REACTIONS. WATER SOLUBILITY OF COPOLYMERS IS PROVIDED AS A FUNCTION OF COPOLYMER COMPOSITION AND ALIPHATIC CHAIN LENGTH.","ALKYL ITACONATE; RADICAL POLYMERIZATION; REACTIVITY RATIO; 1-TRIACONTANOL; WATER-SOLUBLE POLYMERS","PLANT-GROWTH REGULATOR; N-VINYL PYRROLIDONE; REACTIVITY RATIOS; SIDE-CHAINS; TRIACONTANOL; POLICOSANOL","DEUTSCHER AKADEMISCHER AUSTAUSCHDIENST (DAAD); DEPARTAMENTO DE POSTGRADO Y POSTITULO, UNIVERSIDAD DE CHILE, BECA [PG/86/02]","THE AUTHORS OF THIS STUDY THANK PROF. ALESSANDRO GANDINI FOR HELPFUL DISCUSSIONS. FBB THANKS THE DEUTSCHER AKADEMISCHER AUSTAUSCHDIENST (DAAD) FOR A PHD GRANT AND THE DEPARTAMENTO DE POSTGRADO Y POSTITULO, UNIVERSIDAD DE CHILE, BECA PG/86/02.","BAKER BR, 1952, J ORG CHEM, V17, P116, DOI 10.1021/JO01135A012; BARROSO-BUJANS F, 2007, EUR POLYM J, V43, P1288, DOI 10.1016/J.EURPOLYMJ.2007.01.028; BASTERRECHEA MJ, 2000, PATENT NO. 22622; CASTAÑO G, 2006, CURR THER RES CLIN E, V67, P174, DOI 10.1016/J.CURTHERES.2006.06.004; CHEN XP, 2002, PLANT CELL PHYSIOL, V43, P869, DOI 10.1093/PCP/PCF100; COLTRAIN BK, 1993, J POLYM SCI POL CHEM, V31, P2261, DOI 10.1002/POLA.1993.080310909; DINCER S, 2006, J POLYM RES, V13, P121, DOI 10.1007/S10965-005-9014-X; FANDRICH N, 2010, MACROMOL CHEM PHYS, V211, P869, DOI 10.1002/MACP.200900466; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; HU YH, 2000, MACROMOL CHEM PHYS, V201, P705; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; LAUGHLIN RG, 1983, SCIENCE, V219, P1219, DOI 10.1126/SCIENCE.219.4589.1219; LEONARDSTIBBE E, 1994, J POLYM SCI POL CHEM, V32, P1551, DOI 10.1002/POLA.1994.080320816; LÓPEZ-CARRASQUERO F, 2003, POLYMER, V44, P4969, DOI 10.1016/S0032-3861(03)00470-1; MAO RS, 1993, POLYMER, V34, P1709, DOI 10.1016/0032-3861(93)90331-4; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; OHLROGGE AJ, 1980, PATENT NO. 4230485; ORTEGA LL, 2006, J MED FOOD, V9, P378, DOI 10.1089/JMF.2006.9.378; RADIC D, 1997, MACROMOLECULES, V30, P817, DOI 10.1021/MA960956N; RIES S, 1983, HORTSCIENCE, V18, P654; RIES SK, 1977, SCIENCE, V195, P1339, DOI 10.1126/SCIENCE.195.4284.1339; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WARREN RP, 1992, P SOC EXP BIOL MED, V200, P349; WELEBIR AJ, 1984, PATENT NO. 4470840","BARROSO-BUJANS, F (CORRESPONDING AUTHOR), MAT PHYS CTR CSIC UPV EHU, PASEO MANUEL LARDIZABAL 5, SAN SEBASTIAN 20018, SPAIN","WILEY-BLACKWELL","ENGLISH","MACROMOL. CHEM. PHYS.","ARTICLE","ISI","WOS000294151300011","MACROMOL CHEM PHYS","MAT PHYS CTR CSIC UPV EHU;UNIV CHILE;UNIV LA HABANA;JOHANNES GUTENBERG UNIV MAINZ","MAT PHYS CTR CSIC UPV EHU",NA,"BARROSO-BUJANS F, 2011, MACROMOL CHEM PHYS","BARROSO-BUJANS F, 2011, MACROMOL CHEM PHYS"
"SHIH F;DAIGLE K;CHAMPAGNE E","SHIH F F;DAIGLE K W;CHAMPAGNE E T","EFFECT OF RICE WAX ON WATER VAPOUR PERMEABILITY AND SORPTION PROPERTIES OF EDIBLE PULLULAN FILMS",2011,"FOOD CHEMISTRY","127","118-121",68,"10.1016/j.foodchem.2010.12.096","SHIH, FF (CORRESPONDING AUTHOR), USDA, SO REG RES CTR, 1100 ROBERT E LEE BLVD, NEW ORLEANS, LA 70124 USA.; SHIH, F. F.; DAIGLE, K. W.; CHAMPAGNE, E. T., USDA, SO REG RES CTR, NEW ORLEANS, LA 70124 USA.","EDIBLE FILMS WERE PREPARED USING VARIOUS RATIOS OF PULLULAN AND RICE WAX. FREESTANDING COMPOSITE FILMS WERE OBTAINED WITH UP TO 46.4\% RICE WAX. WATER VAPOUR BARRIER PROPERTIES OF THE PULLULAN FILM WERE IMPROVED WITH INCREASED ADDITION OF RICE WAX. MOISTURE SORPTION ISOTHERMS WERE ALSO STUDIED TO EXAMINE THE IMPACT OF RICE WAX ON THE WATER SORPTION CHARACTERISTICS OF THE FILM. THE BRUNAUER-EMMET-TELLER (BET) AND GUGGENHEIM-ANDERSON-DE BOER (GAB) SORPTION MODELS WERE TESTED TO FIT THE EXPERIMENTAL DATA. THE MODELS GAVE A GOOD FIT UP TO THE WATER ACTIVITY (A(W)) OF 0.55 FOR BET AND A FULL RANGE OF A(W) FROM 0.12 TO 0.95 FOR GAB (R(2) >= 0.98). CHANGES IN THE SORPTION PARAMETERS, PARTICULARLY SUCH AS THE DECREASE IN MONOLAYER MOISTURE CONTENT (MO), REFLECT THE TREND OF REDUCED HYDRATION CAPACITY WITH INCREASED ADDITION OF RICE WAX, PROVIDING USEFUL INFORMATION ON WATER ACTIVITY CONDITIONS TO ACHIEVE STABILITY FOR THE COMPOSITE FILMS. PUBLISHED BY ELSEVIER LTD.","PULLULAN; RICE WAX; WATER PERMEABILITY; MOISTURE SORPTION","BARRIER PROPERTIES; SHELF-LIFE; ISOTHERMS; BRAN; POLICOSANOL; COATINGS; ATHEROSCLEROSIS; PERFORMANCE; CELLULOSE; PRODUCTS",NA,NA,"AACC, 1995, APPROVED METHOD OF THE AACC, V9TH; ANONYMOUS, 1990, ANN BOOK ASTM STAND; APOSTOLOPOULOS D, 1990, J FOOD SCI, V55, P475, DOI 10.1111/J.1365-2621.1990.TB06790.X; BRAVIN B, 2006, J FOOD ENG, V76, P280, DOI 10.1016/J.JFOODENG.2005.05.021; CHEN S, 2001, FOOD HYDROCOLLOID, V15, P127, DOI 10.1016/S0268-005X(00)00059-X; CRAVOTTO G, 2004, EUR J LIPID SCI TECH, V106, P147, DOI 10.1002/EJLT.200300914; DIOSADY LL, 1996, J FOOD SCI, V61, P204, DOI 10.1111/J.1365-2621.1996.TB14760.X; DONHOWE IG, 1993, J AM OIL CHEM SOC, V70, P867, DOI 10.1007/BF02545345; GARCÍA MA, 2000, J FOOD SCI, V65, P941, DOI 10.1111/J.1365-2621.2000.TB09397.X; GOUNGA ME, 2008, J FOOD SCI, V73, PE155, DOI 10.1111/J.1750-3841.2008.00694.X; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUNAWAN S, 2006, J AM OIL CHEM SOC, V83, P449, DOI 10.1007/S11746-006-1225-8; HUI YH, 1996, BAILLEY IND FAT PROD; KESTER JJ, 1989, J FOOD SCI, V54, P1390, DOI 10.1111/J.1365-2621.1989.TB05119.X; KIM SJ, 2001, J AGR FOOD CHEM, V49, P4388, DOI 10.1021/JF010122Q; KOELSCH CM, 1992, FOOD SCI TECHNOL-LEB, V25, P404; KRISTO E, 2007, FOOD CHEM, V101, P753, DOI 10.1016/J.FOODCHEM.2006.02.030; LABUZA TP, 1985, J FOOD SCI, V50, P385; LEWICKI PP, 1997, INT J FOOD SCI TECH, V32, P553, DOI 10.1111/J.1365-2621.1997.TB02131.X; LOMAURO CJ, 1985, LEBENSM WISS TECHNOL, V18, P111; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; SAMAPUNDO S, 2007, J FOOD ENG, V79, P168, DOI 10.1016/J.JFOODENG.2006.01.040; SHELLHAMMER TH, 1997, J FOOD SCI, V62, P390, DOI 10.1111/J.1365-2621.1997.TB04008.X; SHIH FF, 1996, CEREAL CHEM, V73, P406; TIMMERMANN EO, 2001, J FOOD ENG, V48, P19, DOI 10.1016/S0260-8774(00)00139-4; VALI SR, 2005, J AM OIL CHEM SOC, V82, P57, DOI 10.1007/S11746-005-1043-Z; VILLALOBOS R, 2006, FOOD HYDROCOLLOID, V20, P502, DOI 10.1016/J.FOODHYD.2005.04.006; WILSON TA, 2002, NUTR RES, V22, P1319, DOI 10.1016/S0271-5317(02)00438-4; XU ZM, 2001, J AGR FOOD CHEM, V49, P2077, DOI 10.1021/JF0012852; YUEN S, 1974, PROCESS BIOCHEM, V7, P22","SHIH, FF (CORRESPONDING AUTHOR), USDA, SO REG RES CTR, 1100 ROBERT E LEE BLVD, NEW ORLEANS, LA 70124 USA","ELSEVIER SCI LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","WOS000288304900016","FOOD CHEM","SO REG RES CTR;SO REG RES CTR","SO REG RES CTR",NA,"SHIH FF, 2011, FOOD CHEM","SHIH FF, 2011, FOOD CHEM"
"TLILI N;EL G T;NASRI N;KHALDI ;ABDELHAMID A;TRIKI S","TLILI NIZAR;EL GUIZANI TAISSIR;NASRI NIZAR;KHALDI; ABDELHAMID;TRIKI SAIDA","PROTEIN LIPID ALIPHATIC AND TRITERPENIC ALCOHOL CONTENT OF CAPER SEEDS CAPPARIS SPINOSA",2011,"JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY","88","265-270",27,"10.1007/s11746-010-1662-2","TLILI, N (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, FAC SCI TUNIS, BIOCHEM LAB, DEPT BIOL, TUNIS 2092, TUNISIA.; TLILI, NIZAR; EL GUIZANI, TAISSIR; NASRI, NIZAR; TRIKI, SAIDA, UNIV TUNIS EL MANAR, FAC SCI TUNIS, BIOCHEM LAB, DEPT BIOL, TUNIS 2092, TUNISIA.; TLILI, NIZAR; KHALDI, ABDELHAMID, INRGREF, UNITE RECH GEST \& VALORISAT RESSOURCES FORESTIERE, ARIANA 2080, TUNISIA.","CAPPARIS SPINOSA HAS A LARGE NATURAL DISTRIBUTION OVER THE MEDITERRANEAN BASIN. IT IS USED IN TRADITIONAL MEDICINES, AND IT IS ONE OF THE MOST COMMONLY FOUND AROMATICS IN THE MEDITERRANEAN KITCHEN. IN THIS PAPER, THE TOTAL STORAGE PROTEIN AND LIPIDS OF TUNISIAN CAPPARIS SPINOSA SEEDS WERE INVESTIGATED, AND THE QUANTITIES WERE CA. 27\% AND CA. 33\%, RESPECTIVELY. IN THIS STUDY ALSO THE COMPOSITION OF THE ALIPHATIC AND TRITERPENIC ALCOHOLS OF C. SPINOSA WAS CHARACTERIZED FOR THE FIRST TIME. ALIPHATIC ALCOHOL CONTENTS WERE CA. 45 MG KG(-1) OF TOTAL EXTRACTED LIPIDS. THREE COMPOUNDS WERE IDENTIFIED, HEXADECANOL, OCTADECANOL AND TETRACOSANOL, OF WHICH OCTADECANOL WAS THE MAJOR COMPOUND (CA. 28 MG KG(-1)). TRITERPENIC ALCOHOL CONTENT WAS 396.82 MG KG(-1). CITROSTADIENOL WAS THE MAJOR COMPOUND (CA. 170 MG KG(-1)). BETA-AMYRIN, GRAMISTEROL, CYCLOARTANOL AND 2,4 METHYLCYCLOARTENOL WERE ALSO DETECTED AND IDENTIFIED.","CAPER (CAPPARIS SPINOSA); SEEDS; STORAGE PROTEIN; OIL; ALIPHATIC; ALCOHOL; TRITERPENIC ALCOHOL","TOCOPHEROL COMPOSITION; PLATELET-AGGREGATION; L.; POLICOSANOL; STEROL; BUDS; OIL; CHOLESTEROL; BEHAVIOR; PROFILE",NA,NA,"AKANNI M. S., 2005, JOURNAL OF FOOD TECHNOLOGY, V3, P177; AKGÜL A, 1999, GRASAS ACEITES, V50, P49, DOI 10.3989/GYA.1999.V50.I1.635; AKIHISA T, 2000, J AGR FOOD CHEM, V48, P2313, DOI 10.1021/JF000135O; ANONYMOUS, 1984, OFF METH ASS OFF AN; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BREENE WM, 1988, J AM OIL CHEM SOC, V65, P1927, DOI 10.1007/BF02546009; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; DELANEY B, 2008, FOOD CHEM TOXICOL, V46, PS71, DOI 10.1016/J.FCT.2008.01.045; GERMANÒ MP, 2002, J AGR FOOD CHEM, V50, P1168, DOI 10.1021/JF010678D; GUEGUEN J., 1996, PROTEINES VEGETALES, P1; IQBAL A, 2006, FOOD CHEM, V97, P331, DOI 10.1016/J.FOODCHEM.2005.05.011; ISO, 1999, 6591998 ISO; JACKSON MA, 2006, J SUPERCRIT FLUID, V37, P173, DOI 10.1016/J.SUPFLU.2005.08.008; KAUR M, 2007, FOOD CHEM, V102, P366, DOI 10.1016/J.FOODCHEM.2006.05.029; LAW M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/BMJ.320.7238.861; LEHMLER HJ, 2002, J FLUORINE CHEM, V117, P17, DOI 10.1016/S0022-1139(02)00169-0; LEÓN-CAMACHO M, 2004, J AM OIL CHEM SOC, V81, P447, DOI 10.1007/S11746-004-0921-8; LEÓN-CAMACHO M, 2001, EUR FOOD RES TECHNOL, V213, P349, DOI 10.1007/S002170100340; MATTHÄUS B, 2005, J AGR FOOD CHEM, V53, P7136, DOI 10.1021/JF051019U; MATTHÄUS B, 2002, J AGR FOOD CHEM, V50, P7323, DOI 10.1021/JF020530+; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; NASRI N, 2007, J AGR FOOD CHEM, V55, P2251, DOI 10.1021/JF062911J; OLIVEIRA FA, 2004, PHARMACOL BIOCHEM BE, V78, P719, DOI 10.1016/J.PBB.2004.05.013; OMODE AA, 1995, J AGR FOOD CHEM, V43, P2850, DOI 10.1021/JF00059A015; PAWAR VD, 1988, J FOOD SCI TECH MYS, V25, P186; ROMEO V, 2007, FOOD CHEM, V101, P1272, DOI 10.1016/J.FOODCHEM.2005.12.029; SAKOUHI F, 2010, EUR J LIPID SCI TECH, V112, P373, DOI 10.1002/EJLT.200900076; SAMANTA TD, 2009, FOOD CHEM, V114, P212, DOI 10.1016/J.FOODCHEM.2008.09.040; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; SOOKCHUNG H, 2000, FOOD SCI BIOTECHNOL, V9, P364; TLILI N, 2010, AFR J BIOTECHNOL, V9, P3328; TLILI N, 2009, J FOOD LIPIDS, V16, P452, DOI 10.1111/J.1745-4522.2009.01158.X; TLILI N, 2009, J AGR FOOD CHEM, V57, P5381, DOI 10.1021/JF900457P; VANHANEN HT, 1993, J LIPID RES, V34, P1535","TLILI, N (CORRESPONDING AUTHOR), UNIV TUNIS EL MANAR, FAC SCI TUNIS, BIOCHEM LAB, DEPT BIOL, TUNIS 2092, TUNISIA","SPRINGER","ENGLISH","J. AM. OIL CHEM. SOC.","ARTICLE","ISI","WOS000287360700010","J AM OIL CHEM SOC","UNIV TUNIS EL MANAR;UNIV TUNIS EL MANAR;UNITE RECH GEST AND VALORISAT RESSOURCES FORESTIERE","UNIV TUNIS EL MANAR",NA,"TLILI N, 2011, J AM OIL CHEM SOC","TLILI N, 2011, J AM OIL CHEM SOC"
"LIU Z;LIU J;ZHANG A;WU Q;RUAN Y;LEWITH G;VISCONTE D","LIU ZHAO LAN;LIU JIAN PING;ZHANG ANTHONY LIN;WU QIONG;RUAN YAO;LEWITH GEORGE;VISCONTE DENISE","CHINESE HERBAL MEDICINES FOR HYPERCHOLESTEROLEMIA",2011,"COCHRANE DATABASE OF SYSTEMATIC REVIEWS",NA,NA,35,"10.1002/14651858.CD008305.pub2","LIU, JP (CORRESPONDING AUTHOR), BEIJING UNIV CHINESE MED, CTR EVIDENCE BASED CHINESE MED, 11 BEI SAN HUAN DONG LU, BEIJING 100029, PEOPLES R CHINA.; LIU, ZHAO LAN; LIU, JIAN PING, BEIJING UNIV CHINESE MED, CTR EVIDENCE BASED CHINESE MED, BEIJING 100029, PEOPLES R CHINA.; ZHANG, ANTHONY LIN, RMIT UNIV, SCH HLTH SCI, DISCIPLINE CHINESE MED, BUNDOORA, VIC, AUSTRALIA.; WU, QIONG, BEIJING UNIV CHINESE MED, SCH HUMANITIES, BEIJING 100029, PEOPLES R CHINA.; VISCONTE, DENISE, PRIMARY MED CARE, COMPLEMENTARY \& INTEGRATED MED RES UNIT, SOUTHAMPTON, HANTS, ENGLAND.","BACKGROUND HYPERCHOLESTEROLEMIA IS AN IMPORTANT KEY CONTRIBUTORY FACTOR FOR ISCHEMIC HEART DISEASE AND IS ASSOCIATED WITH AGE, HIGH BLOOD PRESSURE, A FAMILY HISTORY OF HYPERCHOLESTEROLEMIA, AND DIABETES. CHINESE HERBAL MEDICINES HAVE BEEN USED FOR A LONG TIME AS LIPID-LOWERING AGENTS. OBJECTIVES TO ASSESS THE EFFECTS OF CHINESE HERBAL MEDICINES ON HYPERCHOLESTEROLEMIA. SEARCH STRATEGY WE SEARCHED THE FOLLOWING DATABASES: THE COCHRANE LIBRARY (ISSUE 8, 2010), MEDLINE (UNTIL JULY 2010), EMBASE (UNTIL JULY 2010), CHINESE BIOMEDICAL DATABASE (UNTIL JULY 2010), TRADITIONAL CHINESE MEDICAL LITERATURE ANALYSIS AND RETRIEVAL SYSTEM (UNTIL JULY 2010), CHINA NATIONAL KNOWLEDGE INFRASTRUCTURE (UNTIL JULY 2010), CHINESE VIP INFORMATION (UNTIL JULY 2010), CHINESE ACADEMIC CONFERENCE PAPERS DATABASE AND CHINESE DISSERTATION DATABASE (UNTIL JULY 2010), AND ALLIED AND COMPLEMENTARY MEDICINE DATABASE (UNTIL JULY 2010). SELECTION CRITERIA WE CONSIDERED RANDOMIZED CONTROLLED CLINICAL TRIALS IN HYPERCHOLESTEROLEMIC PARTICIPANTS COMPARING CHINESE HERBAL MEDICINES WITH PLACEBO, NO TREATMENT, AND PHARMACOLOGICAL OR NON-PHARMACOLOGICAL INTERVENTIONS. DATA COLLECTION AND ANALYSIS TWO REVIEW AUTHORS INDEPENDENTLY EXTRACTED DATA AND ASSESSED THE RISK OF BIAS. WE RESOLVED ANY DISAGREEMENTS WITH THIS ASSESSMENT THROUGH DISCUSSION AND A DECISION WAS ACHIEVED BASED BY CONSENSUS. WE ASSESSED TRIALS FOR THE RISK OF BIAS AGAINST KEY CRITERIA: RANDOM SEQUENCE GENERATION, ALLOCATION CONCEALMENT, BLINDING OF PARTICIPANTS, INCOMPLETE OUTCOME DATA, SELECTIVE OUTCOME REPORTING AND OTHER SOURCES OF BIAS. MAIN RESULTS WE INCLUDED 22 RANDOMIZED TRIALS (2130 PARTICIPANTS). THE MEAN TREATMENT DURATION WAS 2.3 +/- 1.3 MONTHS (RANGING FROM ONE TO SIX MONTHS). TWENTY TRIALS WERE CONDUCTED IN CHINA AND 18 TRIALS WERE PUBLISHED IN CHINESE. OVERALL, THE RISK OF BIAS OF INCLUDED TRIALS WAS HIGH OR UNCLEAR. FIVE DIFFERENT HERBAL MEDICINES WERE EVALUATED IN THE INCLUDED TRIALS, WHICH COMPARED HERBS WITH CONVENTIONAL MEDICINE IN SIX COMPARISONS (20 TRIALS), OR PLACEBO (TWO TRIALS). THERE WERE NO OUTCOME DATA IN ANY OF THE TRIALS ON CARDIOVASCULAR EVENTS AND DEATH FROM ANY CAUSE. ONE TRIAL EACH REPORTED WELL-BEING (NO SIGNIFICANT DIFFERENCES) AND ECONOMIC COSTS. NO SERIOUS ADVERSE EVENTS WERE OBSERVED. XUEZHIKANG WAS THE MOST COMMONLY USED HERBAL FORMULA INVESTIGATED. A SIGNIFICANT EFFECT ON TOTAL CHOLESTEROL (TWO TRIAL, 254 PARTICIPANTS) WAS SHOWN IN FAVOR OF XUEZHIKANG WHEN COMPARED WITH INOSITOL NICOTINATE (MEAN DIFFERENCE (MD) -0.90 MMOL/L, 95\% CONFIDENCE INTERVAL (CI) -1.13 TO -0.68). AUTHORS' CONCLUSIONS SOME HERBAL MEDICINES MAY HAVE CHOLESTEROL-LOWERING EFFECTS. OUR FINDINGS HAVE TO BE INTERPRETED WITH CAUTION DUE TO HIGH OR UNCLEAR RISK OF BIAS OF THE INCLUDED TRIALS.",NA,"DENSITY-LIPOPROTEIN CHOLESTEROL; SUGAR-CANE POLICOSANOL; CORONARY-HEART-DISEASE; PLASMA-CHOLESTEROL; RANDOMIZED-TRIALS; PLANT; STEROLS; DOUBLE-BLIND; QUALITY; COMBINATION; EFFICACY","BEIJING UNIVERSITY OF CHINESE MEDICINE, BEIJING, CHINA; NATIONAL RESEARCH CENTRE IN COMPLEMENTARY AND ALTERNATIVE MEDICINE (NAFKAM), NORWAY; MINISTRY OF SCIENCE AND TECHNOLOGY, CHINA [2009DFA31460]; BEIJING UNIVERSITY OF CHINESE MEDICINE, CHINA [JYBZZ-JS006]; NATIONAL BASIC RESEARCH PROGRAM ('973' PROGRAM), CHINA [2006CB504602]; ``111'' PROJECT, CHINA [B08006]","BEIJING UNIVERSITY OF CHINESE MEDICINE, BEIJING, CHINA.; NATIONAL RESEARCH CENTRE IN COMPLEMENTARY AND ALTERNATIVE MEDICINE (NAFKAM), NORWAY.; GRANT NUMBER 2009DFA31460 FROM THE INTERNATIONAL COOPERATION PROJECT OF THE MINISTRY OF SCIENCE AND TECHNOLOGY, CHINA.; GRANT NUMBER JYBZZ-JS006 FROM BEIJING UNIVERSITY OF CHINESE MEDICINE, CHINA.; NATIONAL BASIC RESEARCH PROGRAM ('973' PROGRAM) GRANT NUMBER 2006CB504602, CHINA.; THE ``111'' PROJECT NUMBER B08006, CHINA.","AI J, 2009, PHYTOTHER RES, V23, P1039, DOI 10.1002/PTR.2654; ANONYMOUS, HUNAN J TRADITIONAL; ANONYMOUS, CHINESE J CLIN PHARM; ANONYMOUS, HEBEI J TRADITIONAL; ANONYMOUS, J PRACTICAL TRADITIO; ANONYMOUS, CHINESE J CARIDIOLOG; ANONYMOUS, J FUJIAN COLL TRADIT; ANONYMOUS, HEBEI J TRADITIONAL; ANONYMOUS, MED INFORM; ANONYMOUS, J SICHUAN TRADITIONA; ANONYMOUS, J CHINESE MED RES; ANONYMOUS, CHINESE MED; ANONYMOUS, CHINESE J REHABILITA; ANONYMOUS, CHINESE J PRACTICAL; ANONYMOUS, HUNAN TRADITIONAL CH; ANONYMOUS, HEILONGJIANG J TRADI; ANONYMOUS, J HUMAN COLL TRADITI; ANONYMOUS, PHARM RES; ANONYMOUS, PHARM CARE RES; ANONYMOUS, CLIN MED; ANONYMOUS, HUNAN J TRADITIONAL; ANONYMOUS, ARTERY RES; ANONYMOUS, J PRACTICAL MED; ANONYMOUS, CLIN J TRADITIONAL C; ANONYMOUS, CHINA J TRADITIONAL; ANONYMOUS, J JINING MED COLL; ANONYMOUS, HEBEI MED; ANONYMOUS, J SICHUAN TRADITIONA; ANONYMOUS, CONT MED; ANONYMOUS, CAPITAL MED; ANONYMOUS, TRADITIONAL CHINESE; ANONYMOUS, CHINA MED HERALD; ANONYMOUS, CHINA MED NEWS; ANONYMOUS, J HUBEI COLL TRADITI; ANONYMOUS, CHINA MED NEWS; ANONYMOUS, J PRACTICAL TRADITIO; ANONYMOUS, MED WORLD; ANONYMOUS, OCCUPATION HLTH; ANONYMOUS, MODERN J INTEGRATED; ANONYMOUS, CHINA MED NEWS; ANONYMOUS, CAPITAL MED; ANONYMOUS, 2007, CHINA HEALTHC INNOV; ANONYMOUS, BMJ; ANONYMOUS, PRACT CLIN MED; ANONYMOUS, CHINESE J INTEGRATIV; ANONYMOUS, J COMBIN CHIN W MED; ANONYMOUS, HEBEI MED; ANONYMOUS, CHINESE J INTEGRATIV; ANONYMOUS, CHINA J TRADITIONAL; ANONYMOUS, J TRADITIONAL CHINES; ANONYMOUS, 2005, CHIN J CLIN REHABIL; ANONYMOUS, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003711.PUB2; ANONYMOUS, J HUNAN TRADITIONAL; ANONYMOUS, J BEIJING MED U; ANONYMOUS, CHINESE PHARM B; ANONYMOUS, ZHONGHUA SHIYONG YIX; ANONYMOUS, LIAONING J TRADITION; ANONYMOUS, ACTA CHINESE MED PHA; ANONYMOUS, HAINAN MED J; ANONYMOUS, CONT MED; ANONYMOUS, J LIAONING U TRADITI; ANONYMOUS, STUDY J TRADITIONAL; ANONYMOUS, J CHONGQING MED U; ANONYMOUS, CHINESE J CLIN PHARM; ANONYMOUS, 2002, THE WORLD HEALTH REPORT 2002. REDUCING RISKS; ANONYMOUS, J PRACTICAL TRADITIO; ANONYMOUS, CHIN J INTERN MED; ANONYMOUS, HENAN YIXUE XINXI; ANONYMOUS, J YOUJIANG MED COLL; ANONYMOUS, J CLIN EXPT MED; ANONYMOUS, MODERN J INTEGRATED; ANONYMOUS, CHINA CLIN PRACT MED; ANONYMOUS, CHINA TROPICAL MED; ANONYMOUS, J CHINESE PHARM SCI; ANONYMOUS, HLTH US 2008 CHARTB; BARNES J, 2003, BRIT J CLIN PHARMACO, V55, P331, DOI 10.1046/J.1365-2125.2003.01811.X; BARZI F, 2005, ANN EPIDEMIOL, V15, P405, DOI 10.1016/J.ANNEPIDEM.2005.01.005; BECKER DJ, 2009, ANN INTERN MED, V150, P830, DOI 10.7326/0003-4819-150-12-200906160-00006; BELTOWSKI J, 2009, CURR DRUG SAF, V4, P209, DOI 10.2174/157488609789006949; BRUNNER-LA ROCCA HP, 2005, VASA-J VASCULAR DIS, V34, P11, DOI 10.1024/0301-1526.34.1.11; BUNDY R, 2008, PHYTOMEDICINE, V15, P668, DOI 10.1016/J.PHYMED.2008.03.001; CHAN YM, 2007, BRIT J NUTR, V98, P563, DOI 10.1017/S0007114507730775; CHEN L.L., 2002, HER MED, V21, P31; 陈孝银 CHEN XIAOYIN, 2002, 中国病理生理杂志, CHINESE JOURNAL OF PATHOPHYSIOLOGY, V18, P1529; CLEEMAN JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/JAMA.285.19.2486; COON JST, 2003, J FAM PRACTICE, V52, P470; CRITCHLEY J, 2004, CIRCULATION, V110, P1236, DOI 10.1161/01.CIR.0000140668.91896.AE; EISENBERG DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/JAMA.280.18.1569; ENGLISCH W, 2000, ARZNEIMITTELFORSCH, V50, PE260; ERNST E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED, V16, P61, DOI 10.1016/J.CTIM.2007.08.003; FRANCINI-PESENTI F, 2008, PHYTOTHER RES, V22, P318, DOI 10.1002/PTR.2315; GAGNIER JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013; HIGGINS JP, 2008, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS; HIGGINS JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/BMJ.327.7414.557; HIGGINS JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/SIM.1186; ISHIZAKI T, 1996, EUR RESPIR J, V9, P2691, DOI 10.1183/09031936.96.09122691; JACOBSON TA, 2009, NAT REV ENDOCRINOL, V5, P507, DOI 10.1038/NRENDO.2009.151; JI KANG-TING, 2007, ZHONGGUO ZHONG YAO ZA ZHI, V32, P1214; KJAERGARD LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; KONG WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/NM1135; KUULASMAA K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; LAU J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/BMJ.333.7568.597; LIBERATI A, 2009, ANN INTERN MED, V151, PW65, DOI 10.1371/JOURNAL.PMED.1000100, 10.7326/0003-4819-151-4-200908180-00136; LIU J.N., 2006, CHINAS IMAGE INT VIE, P1; MASLIN D, 2008, ARCH INTERN MED, V168, P111, DOI 10.1001/ARCHINTERNMED.2007.24; MAYNE TJ, 2006, J CLIN EPIDEMIOL, V59, P217, DOI 10.1016/J.JCLINEPI.2005.07.006; MCKENNEY JM, 2005, AM J CARDIOL, V96, P60E, DOI 10.1016/J.AMJCARD.2005.06.007; MELCHART D, 1999, JAMA-J AM MED ASSOC, V282, P28, DOI 10.1001/JAMA.282.1.28; MENG LI-PING, 2007, ZHONGHUA LIU XING BING XUE ZA ZHI, V28, P729; MOHER D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; NOHR LA, 2009, COMPLEMENT THER MED, V17, P16, DOI 10.1016/J.CTIM.2008.07.001; PATADE A, 2008, J WOMENS HEALTH, V17, P355, DOI 10.1089/JWH.2007.0359; ROBB-NICHOLSON CELESTE, 2008, HARV WOMENS HEALTH WATCH, V16, P8; ROZA JM, 2007, ALTERN THER HEALTH M, V13, P44; SCHULZ KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/BMJ.C332, 10.1136/BMJ.C869, 10.1016/J.JCLINEPI.2010.02.005, 10.1186/1741-7015-8-18, 10.1016/J.IJSU.2011.09.004, 10.4103/0976-500X.72352; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/JAMA.273.5.408; SHRESTHA S, 2007, J NUTR, V137, P1165, DOI 10.1093/JN/137.5.1165; SOBENIN IA, 2008, J ATHEROSCLER THROMB, V15, P334, DOI 10.5551/JAT.E550; STERNE J.A., 2001, SYSTEMATIC REVIEWS IN HEALTH CARE, P189; SZAPARY PO, 2003, JAMA-J AM MED ASSOC, V290, P765, DOI 10.1001/JAMA.290.6.765; TAKU KYOKO, 2008, THER CLIN RISK MANAG, V4, P1097; TOLONEN H, 2005, INT J EPIDEMIOL, V34, P181, DOI 10.1093/IJE/DYI056; 王亚红 WANG YAHONG, 2002, 中国中医基础医学杂志, CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V8, P52; WIDER B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003335.PUB2; ZHANG SHI-JUN, 2007, ZHONGGUO ZHONG YAO ZA ZHI, V32, P440; ZHANG W, 2008, BRIT J NUTR, V99, P1301, DOI 10.1017/S0007114507871649; ZHANG X, 2003, INT J EPIDEMIOL, V32, P563, DOI 10.1093/IJE/DYG106; 邓羽明, 2006, 中国老年学杂志, CHINESE JOURNAL OF GERONTOLOGY, V26, P1566; 王国洪, 2005, 中国医院药学杂志, CHINESE JOURNAL OF HOSPITAL PHARMACY, V25, P1160","LIU, JP (CORRESPONDING AUTHOR), BEIJING UNIV CHINESE MED, CTR EVIDENCE BASED CHINESE MED, 11 BEI SAN HUAN DONG LU, BEIJING 100029, PEOPLES R CHINA","WILEY","ENGLISH","COCHRANE DATABASE SYST REV.","REVIEW","ISI","WOS000292554302006","COCHRANE DATABASE SYST REV","BEIJING UNIV CHINESE MED;BEIJING UNIV CHINESE MED;RMIT UNIV;BEIJING UNIV CHINESE MED;COMPLEMENTARY AND INTEGRATED MED RES UNIT","BEIJING UNIV CHINESE MED",NA,"LIU ZL, 2011, COCHRANE DATABASE SYST REV","LIU ZL, 2011, COCHRANE DATABASE SYST REV"
"CHERIF A;BEN M M;KAABI B;BOUKHCHINA S;PEPE C;KALLEL H","CHERIF AICHA O;BEN MESSAOUDA MHAMED;KAABI BELHASSEN; BOUKHCHINA SADOK;PEPE CLAUDE;KALLEL HABIB","COMPARISON OF THE CONCENTRATIONS OF LONGCHAIN ALCOHOLS POLICOSANOL IN THREE TUNISIAN PEANUT VARIETIES IARACHIS HYPOGAEAI L",2010,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","58","12143-12148",17,"10.1021/jf1030345","CHERIF, AO (CORRESPONDING AUTHOR), FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES \& PROT, 2092 EL MANAR, TUNIS 1060, TUNISIA.; CHERIF, AICHA O.; BOUKHCHINA, SADOK; KALLEL, HABIB, FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES \& PROT, TUNIS 1060, TUNISIA.; BEN MESSAOUDA, MHAMED, IPEST, UNITE PHYSICOCHEM MOL, LA MARSA 2075, TUNISIA.; KAABI, BELHASSEN, INST PASTEUR TUNIS, LAB EPIDEMIOL \& ECOL PARASITAIRE, TUNIS 1002, TUNISIA.; PEPE, CLAUDE, UNIV PARIS 06, LAB DYNAM INTERACT \& REACT, F-75005 PARIS, FRANCE.","POLICOSANOL (PC) IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC PRIMARY ALCOHOLS. LITERATURE ABOUT THE CONTENTS AND COMPOSITIONS OF PC DERIVED FROM PEANUT VARIETIES IS SCARCE. TOTAL PC COMPOSITION AND CONTENT IN WHOLE PEANUT GRAIN SAMPLES FROM THREE VARIETIES OF PEANUT (TWO CULTIVARS, ARAC AND ARAT, AND A WILD ONE, ARAA) WERE IDENTIFIED USING A GAS CHROMATOGRAPH SYSTEM COUPLED WITH A MASS SPECTROPHOTOMETER. THE RESULTS SHOW THAT, QUALITATIVELY, 21 COMPONENTS OF PEANUT ALIPHATIC ALCOHOLS WERE IDENTIFIED (C-14-C-30). BESIDES (C-18=), THE RESULTS EXHIBITED A PREVIOUSLY UNREPORTED MIXTURE OF PC COMPOSITIONS IN THE PEANUTS: THE UNSATURATED PC (UPC), WHICH ARE (C-20=), (C-21=), (C-22=), AND (C-24=). THE MAIN COMPONENTS OF TOTAL PC IN TUNISIAN PEANUT KERNELS ARE DOCOSANOL (C-22), (Z)-OCTADEC-9-EN-1-OL (C-18=), HEXADECANOL (C-16), AND OCTADECANOL (C-18). QUANTITATIVELY, THE TOTAL PC CONTENT OF THE WHOLE PEANUT SAMPLES VARIED FROM 11.18 TO 54.19 MG/100 G OF OIL AND WAS HIGHER THAN THOSE OF BEESWAX AND WHOLE SUGAR CANE, WHICH ARE SOURCES OF DIETARY SUPPLEMENTS CONTAINING POLICOSANOL.","WILD CULTIVARS; PEANUTS; POLICOSANOL; GC-MS; DEVELOPMENT","SUGAR-CANE; PLATELET-AGGREGATION; CHOLESTEROL; HYPERCHOLESTEROLEMIA; ACID",NA,NA,"AOCS, 1989, OFF METH REC PRACT A; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BEVERIDGE THJ, 2002, J AGR FOOD CHEM, V50, P744, DOI 10.1021/JF010701V; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CHERIF AO, 2010, J AGR FOOD CHEM, V58, P8709, DOI 10.1021/JF101254U; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED, V16, P61, DOI 10.1016/J.CTIM.2007.08.003; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; GROSSO NR, 2000, J AGR FOOD CHEM, V48, P806, DOI 10.1021/JF9901744; GULZ PG, 1991, PHYTOCHEMISTRY, V30, P769, DOI 10.1016/0031-9422(91)85249-Y; HARRABI S, 2009, FOOD CHEM, V115, P918, DOI 10.1016/J.FOODCHEM.2008.12.098; HERCHI W, 2009, PLANT PHYSIOL BIOCH, V47, P880, DOI 10.1016/J.PLAPHY.2009.07.001; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; KASSIS AN, 2009, APPL PHYSIOL NUTR ME, V34, P76, DOI 10.1139/H08-140; KRAPOVICKAS A., 1994, BONPLANDIA, V8, P1; LAGUNA A, 1997, U.S. PATENT, PATENT NO. 5663156; LI TSC, 2007, FOOD CHEM, V101, P1633, DOI 10.1016/J.FOODCHEM.2006.04.033; LÓPEZ-LÓPEZ A, 2008, J AM OIL CHEM SOC, V85, P253, DOI 10.1007/S11746-007-1186-6; MARCELLETTI JF, 2002, ANTIVIR RES, V56, P153, DOI 10.1016/S0166-3542(02)00105-5; MARINANGELI CPF, 2010, CRIT REV FOOD SCI, V50, P259, DOI 10.1080/10408391003626249; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; *NIST, NIST 05 CHEM STAT LI; PANG WEI-YI, 2009, ZHONGGUO YAOLIXUE YU DULIXUE ZAZHI, V23, P443, DOI 10.3867/J.ISSN.1000-3002.2009.06.005; *R FDN STAT COMP, R VERS 2 10; REINA RJ, 1997, J AOAC INT, V80, P1272; SALES JM, 2010, FOOD CHEM, V122, P795, DOI 10.1016/J.FOODCHEM.2010.03.058; TULLOCH AP, 1973, PHYTOCHEMISTRY, V12, P2217, DOI 10.1016/0031-9422(73)85123-4; WARREN P. R., 2002, P SOC EXP BIOL MED, V200, P349; WEBER EJ, 1969, J AM OIL CHEM SOC, V46, P485, DOI 10.1007/BF02544374; WEBER N, 1982, PLANTA, V155, P225, DOI 10.1007/BF00392720; WU TT, 2007, FOOD CHEM, V104, P1509, DOI 10.1016/J.FOODCHEM.2007.02.027; XU ZY, 2007, NUTR RES, V27, P212, DOI 10.1016/J.NUTRES.2007.01.015","CHERIF, AO (CORRESPONDING AUTHOR), FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES \& PROT, 2092 EL MANAR, TUNIS 1060, TUNISIA","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000284672800013","J AGRIC FOOD CHEM","FAC SCI TUNIS;FAC SCI TUNIS;INST PASTEUR TUNIS;FRANCE.","FAC SCI TUNIS",NA,"CHERIF AO, 2010, J AGRIC FOOD CHEM","CHERIF AO, 2010, J AGRIC FOOD CHEM1"
"WANG T;LIU Y;WANG X;YANG N;ZHU H;ZUO P","WANG TAO;LIU YAN-YONG;WANG XIN;YANG NAN;ZHU HAI-BO;ZUO PING-PING","PROTECTIVE EFFECTS OF OCTACOSANOL ON 6HYDROXYDOPAMINEINDUCED PARKINSONISM IN RATS VIA REGULATION OF PRONGF AND NGF SIGNALING",2010,"ACTA PHARMACOLOGICA SINICA","31","765-774",54,"10.1038/aps.2010.69","ZHU, HB (CORRESPONDING AUTHOR), PEKING UNION MED COLL, INST BASIC MED SCI, DEPT PHARMACOL, BEIJING 100005, PEOPLES R CHINA.; WANG, TAO; LIU, YAN-YONG; WANG, XIN; YANG, NAN; ZUO, PING-PING, PEKING UNION MED COLL, INST BASIC MED SCI, DEPT PHARMACOL, BEIJING 100005, PEOPLES R CHINA.; ZHU, HAI-BO, CHINESE ACAD MED SCI, KEY LAB BIOACT SUBST \& RESOURCES UTILIZAT CHINESE, AFFILIATED MINIST EDUC, INST MAT MED, BEIJING 100005, PEOPLES R CHINA.","AIM: TO INVESTIGATE THE PROTECTIVE EFFECTS OF OCTACOSANOL IN 6-HYDROXYDOPAMINE-INDUCED PARKINSONIAN RATS AND FIND WHETHER OCTACOSANOL HAS EFFECTS ON PRO NERVE GROWTH FACTOR (PRO-NGF), NGF AND THE DOWNSTREAM EFFECTOR PROTEINS. METHODS: BEHAVIORAL TESTS, ENZYMATIC ASSAY, TYROSINE HYDROXYLASE IMMUNOHISTOCHEMISTRY, TUNEL AND WESTERN BLOT WERE USED TO INVESTIGATE THE EFFECTS OF OCTACOSANOL IN THIS RAT MODEL OF PD. RESULTS: ORAL ADMINISTRATION OF OCTACOSANOL (35-70 MG/KG, PO FOR 14 D) SIGNIFICANTLY IMPROVED THE BEHAVIORAL IMPAIRMENTS IN RATS INDUCED BY 6-OHDA AND DOSE-DEPENDENTLY PRESERVED THE FREE RADICAL SCAVENGING CAPABILITY OF THE STRIATUM. OCTACOSANOL TREATMENT ALSO EFFECTIVELY AMELIORATED MORPHOLOGICAL APPEARANCES OF TH-POSITIVE NEURONAL CELLS IN NIGROSTRIATAL SYSTEMS AND DECREASED THE APOPTOTIC CELLS INDUCED BY 6-OHDA IN STRIATUM. IN ADDITION, OCTACOSANOL STRIKINGLY BLOCKED THE 6-OHDA-INDUCED INCREASED EXPRESSION OF PRONGF-P75NTR-SORTILIN DEATH SIGNALING COMPLEX AND ITS DOWNSTREAM EFFECTOR PROTEINS. MEANTIME, OCTACOSANOL PREVENTED THE DECREASED LEVELS OF NGF, ITS RECEPTORS TRKA AND P-AKT WHICH TOGETHER MEDIATED THE CELL SURVIVAL PATHWAY. CONCLUSION: THE FINDINGS IMPLICATED THAT THE ANTI-PARKINSONISM EFFECTS AFFORDED BY OCTACOSANOL MIGHT BE MEDIATED BY ITS NEURO-MICROENVIRONMENT IMPROVING POTENCY THROUGH RETRIEVING THE RATIOS OF PRONGF: NGF AND THE RESPECTIVE RECEPTORS P75NTR:TRKA IN VIVO. DUE TO ITS EXCELLENT TOLERABILITY AND NON-TOXICITY, OCTACOSANOL MAY BE A PROMISING AGENT FOR PD TREATMENT.","PARKINSON'S DISEASE; OXIDATIVE STRESS; PRONGF; NERVE GROWTH FACTOR; NEUROPROTECTION; APOPTOSIS; OCTACOSANOL","NERVE GROWTH-FACTOR; CELL-DEATH MACHINERY; SUBSTANTIA-NIGRA; NEURONAL; APOPTOSIS; OXIDATIVE STRESS; IN-VITRO; DISEASE; ACTIVATION; P75; POLICOSANOL","NATIONAL BASIC RESEARCH DEVELOPMENT PROGRAM OF CHINA [2007CB507400]; NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA [2006AA02A408]; NATIONAL 973 FUNDAMENTAL PROJECT OF CHINA [2009CB523004]","THIS WORK WAS SUPPORTED BY THE GRANT FROM THE NATIONAL BASIC RESEARCH DEVELOPMENT PROGRAM OF CHINA (2007CB507400) AND NATIONAL HIGH TECHNOLOGY RESEARCH AND DEVELOPMENT PROGRAM OF CHINA (2006AA02A408). THIS RESEARCH WAS ALSO SUPPORTED BY GRANTS FROM THE NATIONAL 973 FUNDAMENTAL PROJECT OF CHINA, GRANT NUMBER (2009CB523004), WE ARE INDEBTED TO THE GRANT FROM THE MINISTRY OF SCIENCE AND TECHNOLOGY OF CHINA ELEVENTH 5-YEAR PLAN-TECHNICAL PLATFORM FOR DRUG DEVELOPMENT (2009ZX09303).","ALAM ZI, 1997, J NEUROCHEM, V69, P1326; ALAM ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/J.1471-4159.1997.69031196.X; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALLBUTT HN, 2007, J NEUROSCI METH, V159, P195, DOI 10.1016/J.JNEUMETH.2006.07.006; ALTHAUS HH, 2006, J NEUROCHEM, V98, P506, DOI 10.1111/J.1471-4159.2006.03891.X; ANDREW R, 1993, NEUROCHEM RES, V18, P1175, DOI 10.1007/BF00978370; ANDSBERG G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/J.1460-9568.1998.00214.X; BAMJI SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/JCB.140.4.911; BEATTIE MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; BHAKAR AL, 2003, J NEUROSCI, V23, P11373; BLUM D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BOUTILIER J, 2008, J BIOL CHEM, V283, P12709, DOI 10.1074/JBC.M710018200; BUSCHMANN T, 2000, CANCER RES, V60, P896; CASACCIABONNEFIL P, 1996, NATURE, V383, P716, DOI 10.1038/383716A0; CUI QL, 2006, NEUROCHEM INT, V48, P383, DOI 10.1016/J.NEUINT.2005.11.014; DESHMUKH M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/MOL.51.6.897; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/J.1471-4159.1989.TB09133.X; DONOVAN N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/JBC.M206113200; FAHNESTOCK M, 2004, J NEUROCHEM, V89, P581, DOI 10.1111/J.1471-4159.2004.02360.X; FERNANDEZ L, 1998, CURR THER RES CLIN E, V59, P717, DOI 10.1016/S0011-393X(98)85030-3; FLOOR E, 1998, J NEUROCHEM, V70, P268; FRIEDMAN WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/EXCR.1999.4705; FRIEDMAN WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; FUCHS SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/PNAS.95.18.10541; HALVORSEN EM, 2002, BRAIN RES, V952, P98, DOI 10.1016/S0006-8993(02)03216-X; HARRINGTON AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/PNAS.0305755101; HENNIGAN A, 2007, BIOCHEM SOC T, V35, P424, DOI 10.1042/BST0350424; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345A0; HUANG EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/ANNUREV.BIOCHEM.72.121801.161629; JACKSON GR, 1992, BRAIN RES, V592, P239, DOI 10.1016/0006-8993(92)91681-4; JENNER P, 1996, NEUROLOGY, V47, PS161, DOI 10.1212/WNL.47.6\_SUPPL\_3.161S; JI C, 2008, J ALZHEIMERS DIS, V14, P271; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KONISHI Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; LEE CS, 1996, NEUROSCIENCE, V72, P641, DOI 10.1016/0306-4522(95)00571-4; LEE R, 2001, SCIENCE, V294, P1945, DOI 10.1126/SCIENCE.1065057; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; NOA M, 1994, J PHARM PHARMACOL, V46, P282, DOI 10.1111/J.2042-7158.1994.TB03794.X; NYKJAER A, 2004, NATURE, V427, P843, DOI 10.1038/NATURE02319; OHTA Y, 2008, J CLIN BIOCHEM NUTR, V42, P118, DOI 10.3164/JCBN.2008017; PEDRE LL, 2002, BRAIN RES, V952, P122, DOI 10.1016/S0006-8993(02)03222-5; ROUX PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/JBC.M011520200; SALEHI AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/JBC.M205324200; SALINAS M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/JBC.M209164200; SCHOBER A, 2004, CELL TISSUE RES, V318, P215, DOI 10.1007/S00441-004-0938-Y; SHERER T B, 2001, CURR OPIN INVESTIG DRUGS, V2, P657; SNIDER SR, 1984, ANN NEUROL, V16, P723, DOI 10.1002/ANA.410160615; SOBOTTKA B, 2008, J NEUROCHEM, V107, P1294, DOI 10.1111/J.1471-4159.2008.05690.X; TAKADERA T, 1998, BBA-MOL CELL RES, V1401, P63, DOI 10.1016/S0167-4889(97)00116-X; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TENG HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; TOURNIER C, 2000, SCIENCE, V288, P870, DOI 10.1126/SCIENCE.288.5467.870; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/SCIENCE.7701324; YOON SO, 1998, J NEUROSCI, V18, P3273","ZHU, HB (CORRESPONDING AUTHOR), PEKING UNION MED COLL, INST BASIC MED SCI, DEPT PHARMACOL, BEIJING 100005, PEOPLES R CHINA","SHANGHAI INST MATERIA MEDICA","ENGLISH","ACTA PHARMACOL. SIN.","ARTICLE","ISI","WOS000279538400001","ACTA PHARMACOL SIN","PEKING UNION MED COLL;PEKING UNION MED COLL;INST MAT MED","PEKING UNION MED COLL",NA,"WANG T, 2010, ACTA PHARMACOL SIN","WANG T, 2010, ACTA PHARMACOL SIN"
"ATHUKORALA Y;MAZZA G","ATHUKORALA YASANTHA;MAZZA GIUSEPPE","SUPERCRITICAL CARBON DIOXIDE AND HEXANE EXTRACTION OF WAX FROM TRITICALE STRAW CONTENT COMPOSITION AND THERMAL PROPERTIES",2010,"INDUSTRIAL CROPS AND PRODUCTS","31","550-556",39,"10.1016/j.indcrop.2010.02.011","MAZZA, G (CORRESPONDING AUTHOR), AGR \& AGRI FOOD CANADA, PACIFIC AGRI FOOD RES CTR, 4200 HIGHWAY 97, SUMMERLAND, BC V2A 1Z0, CANADA.; ATHUKORALA, YASANTHA; MAZZA, GIUSEPPE, AGR \& AGRI FOOD CANADA, PACIFIC AGRI FOOD RES CTR, SUMMERLAND, BC V2A 1Z0, CANADA.","WAX AND OTHER LIPOPHILIC COMPOUNDS OF TRITICALE STRAW WERE EXTRACTED WITH SUPERCRITICAL CARBON DIOXIDE (SC-CO2) AND HEXANE. EXTRACTION WITH SC-CO2 WAS CARRIED OUT AT 70 C AND A FLOW RATE OF 50 G/MIN AT DIFFERENT PRESSURES (250, 300, 350 AND 400 BAR) FOR 90 MIN. THE YIELD, COMPOSITION, THERMAL PROPERTIES, AND SPECTRAL FEATURES OF TRITICALE WAX OBTAINED BY SC-CO2 EXTRACTION WERE COMPARED WITH THOSE OBTAINED USING SOXHLET EXTRACTION WITH HEXANE. THE MAJOR COMPOUNDS EXTRACTED WITH SC-CO2 AND HEXANE FROM TRITICALE STRAW WERE FATTY ACIDS (30.4-34.1\%), FATTY ALCOHOLS (4.8-7.4\%), ALKANES (7.2-8.3\%), STEROLS (11.3-13.6\%), HYDROXYL-BETA-DIKETONES (5.78-11.9\%), AND, BETA-DIKETONES (18.2-26.9\%). THE DIFFERENTIAL SCANNING CALORIMETRY (DSC) THERMOGRAMS OF EACH WAX WERE CONSIDERABLY DIFFERENT. SC-CO2 AND HEXANE EXTRACTS SHARED SIMILAR THERMAL PROPERTIES, WHILE COMMERCIAL WAXES SHOWED SEVERAL SMALL PEAKS OVER A BROAD TEMPERATURE RANGE, INDICATING THEIR EUTECTIC NATURE. IN CONTRAST, PURIFIED WAX FROM SC-CO2 (OBTAINED AT 300 BAR) SHOWED A SINGLE, SHARP, NARROW PEAK AT 53 C. TRITICALE WAX HAD A HIGHER MELTING POINT AND GOOD OXIDATIVE STABILITY. IN ADDITION, IT SHARED SIMILAR KEY THERMAL AND SPECTRAL FEATURES WITH COMMERCIAL WAXES. THE TRITICALE WAX EXTRACTED RESIDUE (DEWAXED STRAW) OBTAINED USING SC-CO2 WAS COMPOSED MAINLY OF GLYCANS (60.4\%), LIGNINS (18.3\%), ASH (7.2\%), ACETYLS (2.1\%), URONIC ACIDS (1.5\%) AND UNIDENTIFIED COMPOUNDS (14.1\%). (C) 2010 ELSEVIER B.V. ALL RIGHTS RESERVED.","TRITICOSECALE; TRITICALE; STRAW; WAX; STEROLS; COMPOSITION; SUPERCRITICAL CARBON DIOXIDE; DSC; MELTING POINT; FT-IR; HEXANE","EPICUTICULAR-WAXES; ALPHA-TOCOPHEROL; WHEAT-STRAW; POLICOSANOL; OIL; FRACTIONATION; TEMPERATURES; SEEDS","CANADIAN BIOMASS INNOVATION NETWORK (CBIN); AGRICULTURAL BIOPRODUCTS INNOVATION PROGRAM (ABIP)","THE AUTHORS THANK FRANCOIS EUDES AND HIS RESEARCH TEAM FOR PROVIDING THE TRITICALE STRAW USED IN THIS STUDY. WE ALSO THANK TAMAKI YUKIHIRO AND LANA FUKUMOTO FOR THEIR TECHNICAL ASSISTANCE AND THE CANADIAN BIOMASS INNOVATION NETWORK (CBIN) AND THE AGRICULTURAL BIOPRODUCTS INNOVATION PROGRAM (ABIP) FOR THE FINANCIAL SUPPORT OF OUR RESEARCH.","ANDRÁS CD, 2005, J SCI FOOD AGR, V85, P1415, DOI 10.1002/JSFA.2130; ATHUKORALA Y, 2010, LWT-FOOD SCI TECHNOL, V43, P660, DOI 10.1016/J.LWT.2009.11.008; ATHUKORALA Y, 2009, EUR J LIPID SCI TECH, V111, P705, DOI 10.1002/EJLT.200800269; BENNETT H, 1975, COMMERCIAL WAXES NAT; BIANCHI G, 1982, PHYTOCHEMISTRY, V21, P639, DOI 10.1016/0031-9422(82)83155-5; CHEN Y, 2007, APPL BIOCHEM BIOTECH, V142, P276, DOI 10.1007/S12010-007-0026-3; CRAIG RG, 1967, J DENT RES, V46, P300, DOI 10.1177/00220345670460013101; DESWARTE FEI, 2006, GREEN CHEM, V8, P39, DOI 10.1039/B514978A; FATOUH AE, 2007, LWT-FOOD SCI TECHNOL, V40, P1687, DOI 10.1016/J.LWT.2006.12.015; GERTENBACH D.D., 2001, FUNCTIONAL FOODS: BIOCHEMICAL AND PROCESSING ASPECTS, P331; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GUEDES-PINTO H., 1996, TRITICALE TODAY TOMO; GUILLEN MD, 1997, J SCI FOOD AGR, V75, P1, DOI 10.1002/(SICI)1097-0010(199709)75:1<1::AID-JSFA842>3.0.CO;2-R; GUTIÉRREZ A, 2001, TRENDS BIOTECHNOL, V19, P340, DOI 10.1016/S0167-7799(01)01705-X; HOSSEINIAN FS, 2009, J FUNCT FOODS, V1, P57, DOI 10.1016/J.JFF.2008.09.009; HWANG KT, 2004, IND CROP PROD, V19, P125, DOI 10.1016/J.INDCROP.2003.07.007; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; JACKSON LL, 1971, PHYTOCHEMISTRY, V10, P487, DOI 10.1016/S0031-9422(00)94091-3; KNOCHEL P., 1999, MODERN SOLVENTS ORGA; LAM HQ, 2001, IND CROP PROD, V14, P139; LEO L, 2005, J SCI FOOD AGR, V85, P2167, DOI 10.1002/JSFA.2244; MAJEED M, 2007, PATENT NO. 7217546; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; RAVINDRANATH SV, 2009, J AGR FOOD CHEM, V57, P3500, DOI 10.1021/JF803846E; RITTER B, 2001, EUR FOOD RES TECHNOL, V212, P603, DOI 10.1007/S002170100290; SALMON DF, 2004, TRITICALE IMPROVEMEN, V179, P99; SLUITER A., 2008, NRELTP51042622; SLUITER A., 2004, BIOMASS ANAL. TECHNOL. TEAM LAB. ANAL. PROCED, P1; SPARKS D, 2006, J AM OIL CHEM SOC, V83, P885, DOI 10.1007/S11746-006-5042-X; SUN RC, 2001, IND CROP PROD, V14, P51, DOI 10.1016/S0926-6690(00)00088-1; SVENSSON M, 2003, NOVEL SURFACTANTS PR, P217; TAMAKI Y, 2010, IND CROP PROD, V31, P534, DOI 10.1016/J.INDCROP.2010.02.004; THAMMASOUK K, 1997, J AGR FOOD CHEM, V45, P437, DOI 10.1021/JF960401R; TULLOCH AP, 1974, PHYTOCHEMISTRY, V13, P2535, DOI 10.1016/S0031-9422(00)86932-0; TULLOCH AP, 1969, CAN J CHEMISTRY, V47, P3119, DOI 10.1139/V69-516; TULLOCH AP, 1976, CHEM BIOCH NATURAL W, P250; WISNIEWSKA SK, 2003, COLLOID SURFACE B, V29, P131, DOI 10.1016/S0927-7765(02)00178-9","MAZZA, G (CORRESPONDING AUTHOR), AGR \& AGRI FOOD CANADA, PACIFIC AGRI FOOD RES CTR, 4200 HIGHWAY 97, SUMMERLAND, BC V2A 1Z0, CANADA","ELSEVIER SCIENCE BV","ENGLISH","IND. CROP. PROD.","ARTICLE","ISI","WOS000277086300019","IND CROP PROD","PACIFIC AGRI FOOD RES CTR;PACIFIC AGRI FOOD RES CTR","PACIFIC AGRI FOOD RES CTR",NA,"ATHUKORALA Y, 2010, IND CROP PROD","ATHUKORALA Y, 2010, IND CROP PROD"
"SAKOUHI F;BOUKHCHINA S;ABSALON C;FOUQUET E;KALLEL H","SAKOUHI FAOUZI;BOUKHCHINA SADOK;ABSALON CHRISTELLE; FOUQUET ERIC;KALLEL HABIB","POLICOSANOL CHARACTERIZATION AND ACCUMULATION DURING RIPENING OF TUNISIAN IOLEA EUROPAEAI L FRUITS",2010,"EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY","112","373-379",10,"10.1002/ejlt.200900076","SAKOUHI, F (CORRESPONDING AUTHOR), FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES, EL MANAR II 2092, TUNISIA.; SAKOUHI, FAOUZI; BOUKHCHINA, SADOK; KALLEL, HABIB, FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES, EL MANAR II 2092, TUNISIA.; ABSALON, CHRISTELLE; FOUQUET, ERIC, UNIV BORDEAUX, INST MOL SCI, CTR ETUD STRUCT \& ANAL MOL ORGAN, BORDEAUX, FRANCE.","POLICOSANOL IS A MIXTURE OF BIOACTIVE MOLECULES SHOWN TO HAVE BENEFICIAL EFFECTS IN TREATING HYPERCHOLESTEROLEMIA. FOOD PRODUCTS ENRICHED IN POLICOSANOL ARE CURRENTLY AVAILABLE IN THE US MARKET. IN THE PRESENT STUDY, EIGHT POLICOSANOL COMPONENTS WERE IDENTIFIED BY GC-MS DURING THE RIPENING OF MESKI OLIVES. THE QUANTITATIVE CHARACTERIZATION OF THESE COMPOUNDS WAS PERFORMED USING GC-FID. THE RESULTS SHOWED THAT THE MAXIMUM LEVEL OF TOTAL POLICOSANOL COMPONENTS (947.20 MG/100 G OIL) WAS REACHED AT THE 26(TH) WEEK AFTER THE FLOWERING DATE OF MESKI OLIVES. HEXACOSANOL AND TETRACOSANOL WERE THE PREDOMINANT POLICOSANOL COMPONENTS AT MESKI OLIVE MATURITY. HOWEVER PENTACOSANOL, HEPTACOSANOL AND TRICOSANOL WERE LESS PRESENT IN THE OLIVES AND THEY ACCOUNTED FOR 14\% OF THE TOTAL POLICOSANOL AT COMPLETE MATURITY OF THE FRUIT. THE TOTAL POLICOSANOL CONTENT OF MESKI OLIVES WAS HIGHER THAN THAT OF BEESWAX AND WHOLE SUGAR CANE, WHICH BELONG TO THE SOURCES OF DIETARY SUPPLEMENTS CONTAINING POLICOSANOL. THESE FINDINGS INDICATE THAT OLIVE IS A POTENTIAL SOURCE OF THESE HEALTH-ENHANCING COMPOUNDS FOR FUNCTIONAL FOODS AND NUTRACEUTICAL APPLICATIONS.","ACCUMULATION; CHARACTERIZATION; OLIVE OIL; POLICOSANOL; RIPENING","PLASMA-CHOLESTEROL; DOUBLE-BLIND; OLIVE OILS; SUGAR-CANE; TOLERABILITY; EXTRACTION; EFFICACY; STEROLS; CELLS","MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISI","THIS WORK WAS DONE AS PART OF A NATIONAL RESEARCH PROJECT. WE THANK THE MINISTRY OF SCIENTIFIC RESEARCH, TECHNOLOGY AND COMPETENCE DEVELOPMENT OF TUNISIA FOR FINANCIALLY SUPPORTING THIS INVESTIGATION. PART OF THIS WORK WAS CARRIED OUT AT THE CENTRE D'ETUDE STRUCTURALE ET D'ANALYSE DES MOLECULES ORGANIQUES (CESAMO), BORDEAUX, FRANCE.","ALKOWSKI CA, 1997, J IMMUNOL, V158, P905; *AOCS, 1990, CE66 AOCS; AWAD AB, 2000, ANTICANCER RES, V20, P821; BACCOURI B, 2007, J FOOD LIPIDS, V14, P19, DOI 10.1111/J.1745-4522.2006.00067.X; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CASTAÑO G, 2001, INT J CLIN PHARM RES, V21, P43; CASTAÑO G, 2002, CURR THER RES CLIN E, V63, P286, DOI 10.1016/S0011-393X(02)80033-9; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; CONCHILLO A, 2005, J AGR FOOD CHEM, V53, P7844, DOI 10.1021/JF050539M; CUNHA SS, 2006, J CHROMATOGR A, V1128, P220, DOI 10.1016/J.CHROMA.2006.06.039; FERNÁNDEZ-ARCHE A, 2009, J NUTR BIOCHEM, V20, P155, DOI 10.1016/J.JNUTBIO.2008.01.007; GARCIA A, 1994, P 3 INT S SUP FLUIDS, V3, P229; GONZALEZBRAVO L, 1996, J CHROMATOGR B, V682, P359, DOI 10.1016/0378-4347(95)00515-3; HERMENDEZ F, 1992, CURR THER RES, V56, P568; HICKS KB, 2001, FOOD TECHNOL, V12, P478; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2008, J CEREAL SCI, V48, P20, DOI 10.1016/J.JCS.2007.07.007; KASSIS AN, 2007, ATHEROSCLEROSIS, V194, P153, DOI 10.1016/J.ATHEROSCLEROSIS.2006.10.008; LAGUNA A, 1997, U.S. PATENT, PATENT NO. 5663156; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; LUCAS A, 1997, J AM OIL CHEM SOC, V73, P1127; LUCAS S, 2007, J SUPERCRIT FLUID, V41, P257, DOI 10.1016/J.SUPFLU.2006.10.007; MCCARTY MF, 2002, MED HYPOTHESES, V59, P268, DOI 10.1016/S0306-9877(02)00226-8; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; MICHAEL A, 2006, J SUPERCRIT FLUID, V37, P173; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; SAKOUHI F, 2009, FOOD CHEM, V112, P897, DOI 10.1016/J.FOODCHEM.2008.06.068; SANTOS R, 2007, FOOD CHEM, V102, P113, DOI 10.1016/J.FOODCHEM.2006.05.001; SHRIPATHI V, 1994, PLANT GROWTH REGUL, V14, P45, DOI 10.1007/BF00024140; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WANG YW, 2003, LIPIDS, V38, P165, DOI 10.1007/S11745-003-1047-3; WARREN P. R., 2002, P SOC EXP BIOL MED, V200, P349","SAKOUHI, F (CORRESPONDING AUTHOR), FAC SCI TUNIS, DEPT BIOL, LAB BIOCHIM LIPIDES, EL MANAR II 2092, TUNISIA","WILEY","ENGLISH","EUR. J. LIPID SCI. TECHNOL.","ARTICLE","ISI","WOS000276280400010","EUR J LIPID SCI TECHNOL","FAC SCI TUNIS;FAC SCI TUNIS;UNIV BORDEAUX","FAC SCI TUNIS",NA,"SAKOUHI F, 2010, EUR J LIPID SCI TECHNOL","SAKOUHI F, 2010, EUR J LIPID SCI TECHNOL1"
"STEFANUTTI C;MAZZA F;VIVENZIO A;DI D;GIACOMO S;PERRONE G;SERRA M;BUCCI A","STEFANUTTI CLAUDIA;MAZZA FABIO;VIVENZIO ANTONIO;DI; GIACOMO SERAFINA;PERRONE GIUSEPPINA;SERRA MARIAROSARIA; BUCCI ANTONELLO","COMBINED TREATMENT WITH DIF1STATSUPASUP AND DIET REDUCE PLASMA LIPID INDICATORS OF MODERATE HYPERCHOLESTEROLEMIA MORE EFFECTIVELY THAN DIET ALONE A RANDOMIZED TRIAL IN PARALLEL GROUPS",2009,"LIPIDS","44","1141-1148",8,"10.1007/s11745-009-3368-5","STEFANUTTI, C (CORRESPONDING AUTHOR), UNIV ROMA LA SAPIENZA, CLIN \& MED THERAPY DEPT, UMBERTO I HOSP ROME I EU, ROME, ITALY.; STEFANUTTI, CLAUDIA; MAZZA, FABIO; VIVENZIO, ANTONIO; DI GIACOMO, SERAFINA; PERRONE, GIUSEPPINA; SERRA, MARIAROSARIA; BUCCI, ANTONELLO, UNIV ROMA LA SAPIENZA, CLIN \& MED THERAPY DEPT, UMBERTO I HOSP ROME I EU, ROME, ITALY.; PERRONE, GIUSEPPINA, UNIV ROMA LA SAPIENZA, DEPT OBSTET \& GYNECOL, UMBERTO I HOSP ROME I EU, ROME, ITALY.","AN OPEN-LABELED RANDOMIZED TRIAL WITH PARALLEL GROUPS WAS CARRIED OUT TO STUDY THE EFFECTS OF DIF1STAT(A (R)) (MONASCUS PURPUREUS-LINEAR ALIPHATIC ALCOHOLS-NIACIN) IN THE TREATMENT OF PRIMARY MODERATE HYPERCHOLESTEROLEMIA. THE TRIAL LASTED 8 MONTHS. THE PATIENTS, MALES AND FEMALES, WERE ASSIGNED TO TWO GROUPS: A (\#130), TREATED WITH DIET, AND B (\#110) SUBMITTED TO DIET + DIF1STAT(A (R)). AFTER 4 MONTHS, GROUP A DID NOT SHOW SIGNIFICANT CHANGES IN TOTAL CHOLESTEROL (TC), LDL-CHOLESTEROL (LDLC), HDL-CHOLESTEROL (HDLC) OR NON-HDL-CHOLESTEROL (NON-HDLC). THE SAME GROUP, SHOWED A REDUCTION IN TC (-22\%), LDLC (-30\%) AND NON-HDLC (-27\%) AFTER 8 MONTHS (P A PARTS PER THOUSAND CURRENCY SIGN 0.001). AFTER 4 MONTHS, TC (-21.3\%), LDLC (-29\%), AND NON-HDLC (-26\%) WERE SIGNIFICANTLY LOWERED IN GROUP B (P A PARTS PER THOUSAND CURRENCY SIGN 0.001). IN GROUP B, TC, LDLC AND NON-HDLC SHOWED A FURTHER REDUCTION AFTER 8 MONTHS: -29.4, -38 AND -37\%, RESPECTIVELY (P A PARTS PER THOUSAND CURRENCY SIGN 0.001). EVEN TRIGLYCERIDES (TG) DECREASED SIGNIFICANTLY (-33\%) (P A PARTS PER THOUSAND CURRENCY SIGN 0.001). AFTER 8 MONTHS, GROUP B SHOWED A SIGNIFICANT REDUCTION OF TG (-33\%) (P A PARTS PER THOUSAND CURRENCY SIGN 0.001), WHEN COMPARED TO GROUP A. SOME SAFETY PARAMETERS WERE SIGNIFICANTLY REDUCED IN BOTH GROUPS: AST AND GAMMA-GT IN GROUP A AFTER 4 AND 8 MONTHS, AS WELL AS ALT, AST AND GAMMA-GT IN GROUP B AFTER 8 MONTHS (P A PARTS PER THOUSAND CURRENCY SIGN 0.001). DIF1STAT(A (R)), GIVEN WITH A SUITABLE DIET, WAS WELL TOLERATED IN THE LONG-TERM AND INDUCED AN ANTI-ATHEROGENIC PLASMA LIPID AND LIPOPROTEIN PROFILE, IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA.","PLASMA LIPIDS; PLASMA LIPOPROTEINS; LIPID METABOLISM; NUTRITION; HUMAN; HYPERLIPIDEMIA","DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; C-REACTIVE; PROTEIN; MONASCUS-PURPUREUS; YEAST-RICE; CARDIOVASCULAR-DISEASE; FERMENTED RICE; POLICOSANOL; HYPERLIPIDEMIA; XUEZHIKANG",NA,NA,"ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANONYMOUS, 2001, JAMA; BECKER DJ, 2009, ANN INTERN MED, V150, P830, DOI 10.7326/0003-4819-150-12-200906160-00006; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; CARON MF, 2001, PHARMACOTHERAPY, V21, P481, DOI 10.1592/PHCO.21.5.481.34499; CASTAÑO G, 2001, INT J CLIN PHARM RES, V21, P43; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; CICERO AFG, 2005, COMPLEMENT THER MED, V13, P273, DOI 10.1016/J.CTIM.2005.07.008; COBBAERT C, 1997, J AM COLL CARDIOL, V30, P1491, DOI 10.1016/S0735-1097(97)00353-7; ENDO A, 1980, J ANTIBIOT, V33, P334, DOI 10.7164/ANTIBIOTICS.33.334; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GANJI SH, 2003, J NUTR BIOCHEM, V14, P298, DOI 10.1016/S0955-2863(02)00284-X; GONBERT S, 2002, ATHEROSCLEROSIS, V48, P1454; HEBER D, 1999, AM J CLIN NUTR, V69, P231; JUZLOVA P, 1996, PHYTOCHEMISTRY, V43, P151, DOI 10.1016/0031-9422(96)00236-1; LEE CL, 2006, APPL MICROBIOL BIOT, V70, P533, DOI 10.1007/S00253-005-0137-0; LI C, 1997, NUTR RES, V18, P71; LIU L, 2003, CLIN CHEM, V49, P1347, DOI 10.1373/49.8.1347; MALIK SHAISTA, 2003, CURR CARDIOL REP, V5, P470, DOI 10.1007/S11886-003-0109-X; MARCOVINA SM, 2003, CLIN CHEM, V49, P1785, DOI 10.1373/CLINCHEM.2003.023689; MCCARTY MF, 2002, MED HYPOTHESES, V59, P268, DOI 10.1016/S0306-9877(02)00226-8; PLENGE JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31; PRASAD GVR, 2002, TRANSPLANTATION, V74, P1200, DOI 10.1097/01.TP.0000031950.34040.79; WANG IK, 2000, J AGR FOOD CHEM, V48, P3183, DOI 10.1021/JF9909353; WANG JIA-QING, 2007, ACTA ZOOLOGICA SINICA, V53, P159; WANG JX, 1997, CURR THER RES CLIN E, V58, P964, DOI 10.1016/S0011-393X(97)80063-X; WEI W, 2003, J NUTR BIOCHEM, V14, P314, DOI 10.1016/S0955-2863(03)00051-2; ZHAO SP, 2003, ATHEROSCLEROSIS, V168, P375, DOI 10.1016/S0021-9150(03)00142-4","STEFANUTTI, C (CORRESPONDING AUTHOR), UNIV ROMA LA SAPIENZA, CLIN \& MED THERAPY DEPT, UMBERTO I HOSP ROME I EU, ROME, ITALY","WILEY","ENGLISH","LIPIDS","ARTICLE","ISI","WOS000271983300008","LIPIDS","UNIV ROMA LA SAPIENZA;UNIV ROMA LA SAPIENZA;UNIV ROMA LA SAPIENZA","UNIV ROMA LA SAPIENZA",NA,"STEFANUTTI C, 2009, LIPIDS","STEFANUTTI C, 2009, LIPIDS"
"HOI J;WELLER C;SCHLEGEL V;CUPPETT ;SUSAN L S;LEE J;CARR T","HOI JIA TSE;WELLER CURTIS L;SCHLEGEL VICKI L;CUPPETT; SUSAN L;LEE JI-YOUNG;CARR TIMOTHY P","SORGHUM DISTILLERS DRIED GRAIN LIPID EXTRACT INCREASES CHOLESTEROL EXCRETION AND DECREASES PLASMA AND LIVER CHOLESTEROL CONCENTRATION IN HAMSTERS",2009,"JOURNAL OF FUNCTIONAL FOODS","1","381-386",28,"10.1016/j.jff.2009.09.005","CARR, TP (CORRESPONDING AUTHOR), UNIV NEBRASKA, DEPT NUTR \& HLTH SCI, 316 LEVERTON HALL, LINCOLN, NE 68583 USA.; HOI, JIA TSE; LEE, JI-YOUNG; CARR, TIMOTHY P., UNIV NEBRASKA, DEPT NUTR \& HLTH SCI, 316 LEVERTON HALL, LINCOLN, NE 68583 USA.; WELLER, CURTIS L., UNIV NEBRASKA, DEPT BIOL SYST ENGN, LINCOLN, NE 68583 USA.; WELLER, CURTIS L.; SCHLEGEL, VICKI L.; CUPPETT, SUSAN L., UNIV NEBRASKA, DEPT FOOD SCI \& TECHNOL, LINCOLN, NE 68583 USA.","GRAIN SORGHUM IS A RICH SOURCE OF PHYTOCHEMICALS. IN THIS STUDY, MALE HAMSTERS WERE FED AIN-93M DIETS SUPPLEMENTED WITH A HEXANE-EXTRACTABLE LIPID FRACTION FROM SORGHUM DISTILLERS DRIED GRAINS WITH SOLUBLES (DDGS). DIETS CONTAINED 0.0\%, 0.5\%, 1.0\%, AND 5.0\% (W/W) DDGS LIPID EXTRACT. AFTER 4 WK, THE 5.0\% DDGS LIPIDS GROUP HAD SIGNIFICANTLY LOWER PLASMA NON-HDL CHOLESTEROL AND LIVER ESTERIFIED CHOLESTEROL CONCENTRATION. FAECAL NEUTRAL STEROL (I.E., CHOLESTEROL) EXCRETION WAS SIGNIFICANTLY HIGHER IN THE 5.0\% DDGS LIPIDS GROUP COMPARED TO THE OTHER TREATMENTS (66\% HIGHER COMPARED TO CONTROLS). BILE ACID EXCRETION WAS NOT AFFECTED BY DDGS LIPID INTAKE. FAECAL CHOLESTEROL EXCRETION WAS NEGATIVELY CORRELATED WITH LIVER CHOLESTEROL CONCENTRATION (R = -0.97, P = 0.026), AND LIVER CHOLESTEROL CONCENTRATION WAS DIRECTLY CORRELATED WITH PLASMA TOTAL CHOLESTEROL CONCENTRATION (R = 0.96, P = 0.041). THUS, LIPID EXTRACT OF SORGHUM DDGS EXHIBITED CHOLESTEROL-LOWERING PROPERTIES DUE, AT LEAST IN PART, TO INCREASED CHOLESTEROL EXCRETION FROM THE BODY AND COULD PROVIDE HEALTH BENEFITS WHEN INCORPORATED INTO HUMAN DIETS. (C) 2009 ELSEVIER LTD. ALL RIGHTS RESERVED.","CHOLESTEROL; SORGHUM; STEROLS; LIPID EXTRACT; HAMSTERS","BLUE-GREEN-ALGA; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; LIPOPROTEINS; POLICOSANOL; ABSORPTION; MORTALITY; STEROL","HATCH ACT, USDA; USDA-CSREES NATIONAL RESEARCH INITIATIVE [2004-35503-14824]; USDA-ARS SPECIFIC COOPERATIVE AGREEMENT [58-5430-4-362]","THIS MANUSCRIPT IS A CONTRIBUTION OF THE UNIVERSITY OF NEBRASKA AGRICULTURAL RESEARCH DIVISION, SUPPORTED IN PART BY FUNDS PROVIDED THROUGH THE HATCH ACT, USDA. ADDITIONAL SUPPORT WAS PROVIDED BY THE USDA-CSREES NATIONAL RESEARCH INITIATIVE GRANT 2004-35503-14824 AND USDA-ARS SPECIFIC COOPERATIVE AGREEMENT 58-5430-4-362. MENTION OF A TRADE NAME, PROPRIETARY PRODUCTS, OR COMPANY NAME IS FOR PRESENTATION CLARITY AND DOES NOT IMPLY ENDORSEMENT BY THE AUTHORS OR THE UNIVERSITY OF NEBRASKA.","ARTS ICW, 2005, AM J CLIN NUTR, V81, P317S, DOI 10.1093/AJCN/81.1.317S; AWIKA JM, 2004, PHYTOCHEMISTRY, V65, P1199, DOI 10.1016/J.PHYTOCHEM.2004.04.001; CARR TP, 2006, ADV FOOD NUTR RES, V51, P165, DOI 10.1016/S1043-4526(06)51003-4; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; CARR TP, 2005, J NUTR, V135, P2236, DOI 10.1093/JN/135.9.2236; CARR TP, 2000, P SOC EXP BIOL MED, V223, P96, DOI 10.1046/J.1525-1373.2000.22313.X; DICKO M.H., 2006, BIOTECHNOLOGY MOL BI, V1, P21; EVANS M, 2002, DRUG SAFETY, V25, P649, DOI 10.2165/00002018-200225090-00004; FAO, 1995, FAO FOOD NUTR SER; FARMER JOHN A, 2003, CURR ATHEROSCLER REP, V5, P96, DOI 10.1007/S11883-003-0079-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRUNDY SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/CIRC.106.25.3143; HOTZ C, 2007, J NUTR, V137, P1097, DOI 10.1093/JN/137.4.1097; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; JESCH ED, 2006, NUTR RES, V26, P579, DOI 10.1016/J.NUTRES.2006.08.006; KATAN MB, 2003, MAYO CLIN PROC, V78, P965, DOI 10.4065/78.8.965; LAW M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/BMJ.320.7238.861; LICHTENSTEIN AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158; LIN BB, 1986, NUTR REP INT, V34, P821; LLOYD-JONES D, 2009, CIRCULATION, V119, PE21, DOI 10.1161/CIRCULATIONAHA.108.191261; MARTIN MJ, 1986, LANCET, V2, P933; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; OSTLUND RE, 2004, CURR OPIN LIPIDOL, V15, P37, DOI 10.1097/00041433-200402000-00008; PARK YK, 2008, NUTR RES, V28, P83, DOI 10.1016/J.NUTRES.2007.11.008; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RASMUSSEN HE, 2008, J NUTR, V138, P476, DOI 10.1093/JN/138.3.476; SANTOS-BUELGA C, 2000, J SCI FOOD AGR, V80, P1094, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.0.CO;2-1, 10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.3.CO;2-T; SCHNEIDER CL, 2000, J NUTR, V130, P1232, DOI 10.1093/JN/130.5.1232; STEIN EA, 2003, CLIN CARDIOL, V26, P25, DOI 10.1002/CLC.4960261506; TRAUTWEIN EA, 1993, COMP BIOCHEM PHYS A, V104, P829, DOI 10.1016/0300-9629(93)90162-W; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; VITA JA, 2005, AM J CLIN NUTR, V81, P292S, DOI 10.1093/AJCN/81.1.292S; WANG Y, 2005, J BIOL CHEM, V280, P11876, DOI 10.1074/JBC.M414676200; WELLER CL, 2006, FOOD SCI BIOTECHNOL, V15, P786","CARR, TP (CORRESPONDING AUTHOR), UNIV NEBRASKA, DEPT NUTR \& HLTH SCI, 316 LEVERTON HALL, LINCOLN, NE 68583 USA","ELSEVIER","ENGLISH","J. FUNCT. FOOD.","ARTICLE","ISI","WOS000284560100008","J FUNCT FOOD","UNIV NEBRASKA;UNIV NEBRASKA;UNIV NEBRASKA;SCHLEGEL;UNIV NEBRASKA","UNIV NEBRASKA",NA,"HOI JT, 2009, J FUNCT FOOD","HOI JT, 2009, J FUNCT FOOD"
"RAVINDRANATH S;UPPUGUNDLA N;LAY J;CLAUSEN E;WILKINS M;INGRAHAM R;WEST C;WU Y;CARRIER D","RAVINDRANATH SATHYA VANDHANA;UPPUGUNDLA NIRMAL;LAY JACKSON O;CLAUSEN EDGAR C;WILKINS MARK;INGRAHAM ROBERT G; WEST CHARLES;WU YANQI;CARRIER DANIELLE JULIE","POLICOSANOL ΑTOCOPHEROL AND MOISTURE CONTENT AS A FUNCTION OF TIMING OF HARVEST OF SWITCHGRASS IPANICUM VIRGATUMI L",2009,"JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","57","3500-3505",9,"10.1021/jf803846e","CARRIER, DJ (CORRESPONDING AUTHOR), UNIV ARKANSAS, DEPT BIOL \& AGR ENGN, FAYETTEVILLE, AR 72701 USA.; RAVINDRANATH, SATHYA VANDHANA; UPPUGUNDLA, NIRMAL; CARRIER, DANIELLE JULIE, UNIV ARKANSAS, DEPT BIOL \& AGR ENGN, FAYETTEVILLE, AR 72701 USA.; LAY, JACKSON O., UNIV ARKANSAS, DEPT CHEM, FAYETTEVILLE, AR 72701 USA.; CLAUSEN, EDGAR C., UNIV ARKANSAS, RALPH E MARTIN DEPT CHEM ENGN, FAYETTEVILLE, AR 72701 USA.; WEST, CHARLES, UNIV ARKANSAS, DEPT CROP SOIL, FAYETTEVILLE, AR 72701 USA.; WILKINS, MARK; INGRAHAM, ROBERT G., DEPT AGR \& BIOSYST ENGN, STILLWATER, OK 74078 USA.; WU, YANQI, DEPT PLANT \& SOIL SCI, STILLWATER, OK 74078 USA.; OKLAHOMA STATE UNIV, STILLWATER, OK 74078 USA.","USING SWITCHGRASS (PANICUM VIRGATUM L.) AS A CELLULOSIC FEEDSTOCK FOR THE PRODUCTION OF ETHANOL COULD LEAD TO THE EXTRACTION OF CO-PRODUCTS PRIOR TO THE PRETREATMENT STEP, THEREBY ADDING VALUE TO THE ETHANOL CONVERSION PROCESS. POLICOSANOLS, REGISTERED AS 142583-61-7, ARE PRESENT IN POACEAE AND ARE A MIXTURE OF LONG-CHAINED PRIMARY ALCOHOLS. POLICOSANOLS ARE COMPOSED MAINLY OF DOCOSANOL (C-22), TETRACOSANOL (C-24), HEXACOSANOL (C-26), OCTACOSANOL (C-26), TRIACONTANOL (C-30), AND DOTRIACONTANOL (C-32). THIS STUDY DETERMINED CHANGES IN MOISTURE, POLICOSANOL, AND A-TOCOPHEROL CONCENTRATIONS OF CAVE-IN-ROCK AND BLACKWELL SWITCHGRASS CULTIVARS DURING MATURATION FROM JULY TO DECEMBER IN ARKANSAS AND OKLAHOMA. MOISTURE CONTENT ON A DRY WEIGHT BASIS DECLINED FROM 150 TO 50\% WITH PROGRESSIVE HARVESTS. THE TOTAL POLICOSANOL CONCENTRATION RANGED BETWEEN 89 MG/KG FOR JULY HARVESTED CAVE-IN-ROCK SWITCHGRASS FROM ARKANSAS AND 182 MG/KG FOR AUGUST HARVESTED CAVE-IN-ROCK SWITCHGRASS FOR OKLAHOMA, AND THESE VALUES REMAINED RELATIVELY CONSTANT THROUGHOUT THE SEASON. THIS IS THE FIRST REPORT ON THE PRESENCE OF POLICOSANOLS IN SWITCHGRASS. TOTAL SWITCHGRASS POLICOSANOL CONCENTRATIONS WERE LOWER THAN THOSE TYPICALLY REPORTED FOR SORGHUM GRAINS; HOWEVER, SWITCH GRASS-EXTRACTED POLICOSANOLS CONTAINED DIFFERENT POLICOSANOL RATIOS, WHEREIN C-30 AND C-32 ALCOHOL RANGES WERE 36-41 AND 43-50\%, RESPECTIVELY. ALPHA-TOCOPHEROL EXTRACTED FROM BOTH SWITCHGRASS CULTIVARS VARIED BETWEEN 320 AND 400 MG/KG BUT DECREASED IN THE OCTOBER HARVEST AFTER FROST.","PANICUM VIRGATUM; SWITCHGRASS; POLICOSANOL; ALPHA-TOCOPHEROL; MOISTURE; CONTENT",NA,"OFFICE OF THE DIRECTOR; EPSCOR [0814361] FUNDING SOURCE: NATIONAL SCIENCE FOUNDATION",NA,"ADHIKARI P, 2006, J AGR FOOD CHEM, V54, P5359, DOI 10.1021/JF060688K; ALDERSON J.S., 1995, GRASS VARIETIES IN THE UNITED STATES; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; *ASAE, 2002, S319 ASAE; CASLER MD, 2007, CROP SCI, V47, P2249, DOI 10.2135/CROPSCI2006.12.0780; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; HWANG KT, 2004, CEREAL CHEM, V81, P345, DOI 10.1094/CCHEM.2004.81.3.345; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; MOCK H.-P., 2007, ENCY VITAMIN E, P112; MORRISON WH, 1986, J AGR FOOD CHEM, V34, P788, DOI 10.1021/JF00071A005; MUNNÉ-BOSCH S, 2005, J PLANT PHYSIOL, V162, P743, DOI 10.1016/J.JPLPH.2005.04.022; SCHMER MR, 2008, P NATL ACAD SCI USA, V105, P464, DOI 10.1073/PNAS.0704767105; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9","CARRIER, DJ (CORRESPONDING AUTHOR), UNIV ARKANSAS, DEPT BIOL \& AGR ENGN, FAYETTEVILLE, AR 72701 USA","AMER CHEMICAL SOC","ENGLISH","J. AGRIC. FOOD CHEM.","ARTICLE","ISI","WOS000265896600016","J AGRIC FOOD CHEM","UNIV ARKANSAS;UNIV ARKANSAS;UNIV ARKANSAS;UNIV ARKANSAS;UNIV ARKANSAS;DEPT PLANT AND SOIL SCI;OKLAHOMA STATE UNIV","UNIV ARKANSAS",NA,"RAVINDRANATH SV, 2009, J AGRIC FOOD CHEM","RAVINDRANATH SV, 2009, J AGRIC FOOD CHEM1"
"JONES P;KASSIS A;MARINANGELI C;F. F","JONES PETER J H;KASSIS AMIRA N;MARINANGELI CHRISTOPHER P; F","POLICOSANOLS LOSE THEIR LUSTRE AS CHOLESTEROLLOWERING AGENTS",2009,"JOURNAL OF FUNCTIONAL FOODS","1","236-239",5,"10.1016/j.jff.2009.01.001","JONES, PJH (CORRESPONDING AUTHOR), UNIV MANITOBA, RICHARDSON CTR FUNCT FOODS \& NUTRACEUT, 196 INNOVAT DR,SMARTPK, WINNIPEG, MB R3T 6C5, CANADA.; JONES, PETER J. H.; MARINANGELI, CHRISTOPHER P. F., UNIV MANITOBA, RICHARDSON CTR FUNCT FOODS \& NUTRACEUT, WINNIPEG, MB R3T 6C5, CANADA.; KASSIS, AMIRA N., MCGILL UNIV, SCH DIETET \& HUMAN NUTR, STE ANNE DE BELLEVUE, PQ H9X 3V9, CANADA.","POLICOSANOLS HAVE BEEN PURPORTED BY ONE RESEARCH GROUP TO ACT AS EFFECTIVE AGENTS FOR LDL-CHOLESTEROL (LDL-C) LOWERING IN HUMANS. HOWEVER DATA FROM INDEPENDENT RESEARCHERS HAVE BEEN CONTRADICTING RESULTS PUBLISHED BY THE LABORATORIES ORIGINATING THESE CLAIMS. THE PURPOSE OF THIS COMMENTARY IS THEREFORE TO BRIEFLY SUMMARIZE THE POLICOSANOL CONTROVERSY AND POINT OUT THE POTENTIAL EXPLANATIONS FOR INCONSISTENCIES IN THE POLICOSANOL LITERATURE, AS WELL AS TO DETERMINE POTENTIAL ORIGINS OF THE PROBLEM ESPECIALLY AT THE LEVEL OF THE REVIEWING AND PUBLISHING PROCESS. SCRUTINY AND VIGILANCE AT ALL STEPS OF THE PROCESS ARE NECESSARY IN ORDER TO AVOID SUCH CONTROVERSIES IN THE FIELD OF NATURAL PRODUCT RESEARCH. (C) 2009 ELSEVIER LTD. ALL RIGHTS RESERVED.","POLICOSANOL; CHOLESTEROL; SYNTHESIS; CONTROVERSY","LOWER PLASMA-CHOLESTEROL; SUGAR-CANE POLICOSANOL; DOUBLE-BLIND; HYPERCHOLESTEROLEMIA; EFFICACY; TOLERABILITY",NA,NA,"BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CASTAÑO G, 2001, INT J CLIN PHARM RES, V21, P43; CASTAÑO G, 2002, CURR THER RES CLIN E, V63, P286, DOI 10.1016/S0011-393X(02)80033-9; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; CUBEDDU LX, 2006, AM HEART J, V152, DOI 10.1016/J.AHJ.2006.08.009; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; DULLENS SPJ, 2008, J LIPID RES, V49, P790, DOI 10.1194/JLR.M700497-JLR200; FRANCINI-PESENTI F, 2008, COMPLEMENT THER MED, V16, P61, DOI 10.1016/J.CTIM.2007.08.003; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; KASSIS AN, 2006, AM J CLIN NUTR, V84, P1003, DOI 10.1093/AJCN/84.5.1003; KASSIS AN, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-17; KASSIS AN, 2007, ATHEROSCLEROSIS, V194, P153, DOI 10.1016/J.ATHEROSCLEROSIS.2006.10.008; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MARINANGELI CPF, 2007, BRIT J NUTR, V97, P381, DOI 10.1017/S0007114507336763; MÁS R, 2001, CLIN DRUG INVEST, V21, P485; MAS R., 2004, ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, V13, P101S; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MURPHY KJ, 2008, J AM COLL NUTR, V27, P476, DOI 10.1080/07315724.2008.10719728; REINER Z, 2005, CLIN DRUG INVEST, V25, P701, DOI 10.2165/00044011-200525110-00003; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TEDESCHI-REINER EUGENIA, 2005, LIJEC VJESN, V127, P273; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383; WANG YW, 2003, LIPIDS, V38, P165, DOI 10.1007/S11745-003-1047-3","JONES, PJH (CORRESPONDING AUTHOR), UNIV MANITOBA, RICHARDSON CTR FUNCT FOODS \& NUTRACEUT, 196 INNOVAT DR,SMARTPK, WINNIPEG, MB R3T 6C5, CANADA","ELSEVIER","ENGLISH","J. FUNCT. FOOD.","ARTICLE","ISI","WOS000284559900013","J FUNCT FOOD","UNIV MANITOBA;UNIV MANITOBA;MCGILL UNIV","UNIV MANITOBA",NA,"JONES PJH, 2009, J FUNCT FOOD","JONES PJH, 2009, J FUNCT FOOD"
"FERNANDEZ-ARCHE A;MARQUEZ-MARTIN A;DE L P P;VAZQUEZ R;PERONA J;TERENCIO C;PEREZ-CAMINO C;RUIZ-GUTIERREZ V","FERNANDEZ-ARCHE ANGELES;MARQUEZ-MARTIN ANA;DE LA PUERTA; VAZQUEZ ROCIO;PERONA JAVIER S;TERENCIO CARMEN; PEREZ-CAMINO CARMEN;RUIZ-GUTIERREZ VALENTINA","LONGCHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL MODULATE THE RELEASE OF PROINFLAMMATORY MEDIATORS",2009,"JOURNAL OF NUTRITIONAL BIOCHEMISTRY","20","155-162",51,"10.1016/j.jnutbio.2008.01.007","PERONA, JS (CORRESPONDING AUTHOR), INST GRASA CSIC, AV PADRE GARCIA TEJERO 4, SEVILLE 41012, SPAIN.; MARQUEZ-MARTIN, ANA; PERONA, JAVIER S.; PEREZ-CAMINO, CARMEN; RUIZ-GUTIERREZ, VALENTINA, INST GRASA CSIC, SEVILLE 41012, SPAIN.; FERNANDEZ-ARCHE, ANGELES; DE LA PUERTA VAZQUEZ, ROCIO, UNIV SEVILLE, SCH PHARM, DEPT PHARMACOL, SEVILLE 41012, SPAIN.; TERENCIO, CARMEN, UNIV VALENCIA, SCH PHARM, DEPT PHARMACOL, VALENCIA 46100, SPAIN.","POMACE OLIVE OIL IS A BY-PRODUCT OF OLIVE OIL EXTRACTION THAT IS TRADITIONALLY PRODUCED AND CONSUMED IN SPAIN. THE NONGLYCERIDE MATTER OF THIS OIL IS A GOOD SOURCE OF INTERESTING MINOR COMPOUNDS, LIKE LONG-CHAIN FATTY ALCOHOLS, WHICH ARC PRESENT FREE OR AS PART OF WAXES. IN THE PRESENT STUDY, LONG-CHAIN FATTY ALCOHOLS WERE ISOLATED FROM THE NONGLYCERIDE FRACTION OF POMACE OLIVE OIL, AND THE COMPOSITION WAS IDENTIFIED AND QUANTIFIED. THE MAJOR COMPONENTS OF LONG-CHAIN FATTY ALCOHOLS WERE TETRACOSANOL, HEXACOSANOL AND OCTACOSANOL. WE INVESTIGATED THE ABILITY OF LONG-CHAIN FATTY ALCOHOLS FROM POMACE OLIVE OIL TO INHIBIT THE RELEASE OF DIFFERENT PROINFLAMATORY MEDIATORS IN VITRO BY CELLS INVOLVED IN INFLAMMATORY PROCESSES. LONG-CHAIN FATTY ALCOHOLS SIGNIFICANTLY AND DOSE-DEPENDENTLY DECREASED NITRIC OXIDE PRODUCTION BY RAW 264.7 MURINE MACROPHAGES STIMULATED WITH LIPOPOLYSACCHARIDE. WESTERN BLOT ANALYSIS SHOWED THAT NITRIC OXIDE REDUCTION WAS A CONSEQUENCE OF THE INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHETASE EXPRESSION. LONG-CHAIN FATTY ALCOHOLS ALSO REDUCED TUMOR NECROSIS FACTOR-A AND PROSTAGLANDIN E-2 PRODUCTION, ALTHOUGH THE POTENCY OF INHIBITION FOR THE LATTER WAS LOWER. ON THE OTHER HAND, LONG-CHAIN FATTY ALCOHOLS SIGNIFICANTLY REDUCED THROMBOXANE A(2) PRODUCTION IN RAT PERITONEAL NEUTROPHILS STIMULATED WITH THE CALCIUM IONOPHORE A-23187. THE REDUCTION OF CICOSANOID RELEASE WAS RELATED TO THE INHIBITION OF PHOSPHOLIPASE A(2) ENZYME ACTIVITY BY LONG-CHAIN FATTY ALCOHOLS, REACHING AN INHIBITORY CONCENTRATION 50\% VALUE OF 6.2 MU G/ML. THESE RESULTS, SHOWED THAT LONG-CHAIN FATTY ALCOHOLS MAY HAVE A PROTECTIVE EFFECT ON SOME MEDIATORS INVOLVED IN THE INFLAMMATORY DAMAGE DEVELOPMENT, SUGGESTING ITS POTENTIAL VALUE AS A PUTATIVE FUNCTIONAL COMPONENT OF POMACE OLIVE OIL. (C) 2009 ELSEVIER INC. ALL RIGHTS RESERVED.","POMACE OLIVE OIL; LONG-CHAIN FATTY ALCOHOLS; MACROPHAGES; NITRIC OXIDE; INFLAMMATION; CYTOKINE","NITRIC-OXIDE; MINOR COMPONENTS; EXPRESSION; POLICOSANOL; MACROPHAGES; ALPHA; ACID; CYCLOOXYGENASE-2; ATHEROSCLEROSIS; INFLAMMATION","COMISION INTERMINISTERIAL DE CIENCIA Y TECNOLOGIA [CICYT AGL2002-00195, CICYT AGL2005-00572]","THIS STUDY WAS SUPPORTED BY FUNDS FROM ``COMISION INTERMINISTERIAL DE CIENCIA Y TECNOLOGIA''(CICYT AGL2002-00195 AND AGL2005-00572).","ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; CABELLO-MORUNO R, 2007, J AM COLL NUTR, V26, P24, DOI 10.1080/07315724.2007.10719582; CASTANO G, 2005, DRUGS R D, V6, P207, DOI 10.2165/00126839-200506040-00003; CHEN JC, 2006, CELL SIGNAL, V18, P32, DOI 10.1016/J.CELLSIG.2005.03.016; CHOI CY, 2001, INT IMMUNOPHARMACOL, V1, P1141, DOI 10.1016/S1567-5769(01)00047-9; DACQUISTO F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; DE LA PUERTA R, 2000, Z NATURFORSCH C, V55, P814; DOGNÉ JM, 2006, CURR PHARM DESIGN, V12, P903, DOI 10.2174/138161206776055921; DOGNÉ JM, 2004, CURR MED CHEM, V11, P1223, DOI 10.2174/0929867043365260; HERRERA MD, 2006, CURR NUTR FOOD SCI, V2, P45, DOI 10.2174/157340106775471976; DULIN MF, 2006, AM J CLIN NUTR, V84, P1543, DOI 10.1093/AJCN/84.6.1543; FRANSON R, 1974, J LIPID RES, V15, P380; GIACOMETTI J, 2001, ANALYST, V126, P472, DOI 10.1039/B007090O; GUILLÉN MD, 2004, J AGR FOOD CHEM, V52, P2123, DOI 10.1021/JF035259Q; HUANG KC, 2003, J BIOMED SCI, V10, P396, DOI 10.1159/000071159; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; KANG RY, 1996, BRIT J RHEUMATOL, V35, P711; LIBBY P, 2002, NATURE, V420, P868, DOI 10.1038/NATURE01323, 10.1161/ATVBAHA.108.179705; MARCINKIEWICZ J, 1995, EUR J IMMUNOL, V25, P947, DOI 10.1002/EJI.1830250414; MARQUEZ-MARTIN A, 2006, CYTOKINE, V36, P211, DOI 10.1016/J.CYTO.2006.12.007; MASUDA S, 2005, BBA-MOL CELL BIOL L, V1736, P200, DOI 10.1016/J.BBALIP.2005.08.014; MCCARTY MF, 2006, MED HYPOTHESES, V67, P251, DOI 10.1016/J.MEHY.2006.01.013; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/ABIO.1993.1449; MORENO JJ, 2003, FREE RADICAL BIO MED, V35, P1073, DOI 10.1016/S0891-5849(03)00465-9; MORONEY MA, 1988, J PHARM PHARMACOL, V40, P787, DOI 10.1111/J.2042-7158.1988.TB05173.X; MULLER T, 2004, BIOORG MED CHEM LETT, V14, P6023, DOI 10.1016/J.BMCL.2004.09.078; OWEN RW, 2000, FOOD CHEM TOXICOL, V38, P647, DOI 10.1016/S0278-6915(00)00061-2; PAQUOT C, 1992, IUPAC STANDARD METHO; PÉREZ-CAMINO MC, 1999, J AGR FOOD CHEM, V47, P1558, DOI 10.1021/JF980881H; PERONA JS, 2005, J AGR FOOD CHEM, V53, P730, DOI 10.1021/JF048374P; RODRÍGUEZ-RODRÍGUEZL R, 2004, BRIT J NUTR, V92, P635, DOI 10.1079/BJN20041231; ROSS R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAITO M, 2006, EUR J PHARMACOL, V544, P132, DOI 10.1016/J.EJPHAR.2006.06.001; SALKOWSKI CA, 1997, J IMMUNOL, V158, P905; SHINBORI C, 2007, EUR J PHARMACOL, V567, P139, DOI 10.1016/J.EJPHAR.2007.04.009; SINGH DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/JPET.106.107144; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TRIGGIANI M, 2005, J ALLERGY CLIN IMMUN, V116, P1000, DOI 10.1016/J.JACI.2005.08.011; VAN OOSTROM AJHHM, 2004, DRUGS, V64, P19, DOI 10.2165/00003495-200464002-00004; VIOQUE E, 1961, J AM OIL CHEM SOC, V38, P485, DOI 10.1007/BF02631905","PERONA, JS (CORRESPONDING AUTHOR), INST GRASA CSIC, AV PADRE GARCIA TEJERO 4, SEVILLE 41012, SPAIN","ELSEVIER SCIENCE INC","ENGLISH","J. NUTR. BIOCHEM.","ARTICLE","ISI","WOS000263406400002","J NUTR BIOCHEM","INST GRASA CSIC;INST GRASA CSIC;FERNANDEZ-ARCHE;UNIV SEVILLE;UNIV VALENCIA","INST GRASA CSIC",NA,"FERNANDEZ-ARCHE A, 2009, J NUTR BIOCHEM","FERNANDEZ-ARCHE A, 2009, J NUTR BIOCHEM"
"SRINIVASAN D;RAMASWAMY S;SENGOTTUVELU S","SRINIVASAN D;RAMASWAMY S;SENGOTTUVELU S","PROKINETIC EFFECT OF POLYHERBAL FORMULATION ON GASTROINTESTINAL TRACT",2009,"PHARMACOGNOSY MAGAZINE","5","37-42",3,NA,"SRINIVASAN, D (CORRESPONDING AUTHOR), ANNAMALAI UNIV, RAJAH MUTHIAH DENT COLL \& HOSP, DEPT PHARMACOL, CHIDAMBARAM, TAMIL NADU, INDIA.; SRINIVASAN, D., ANNAMALAI UNIV, RAJAH MUTHIAH DENT COLL \& HOSP, DEPT PHARMACOL, CHIDAMBARAM, TAMIL NADU, INDIA.; RAMASWAMY, S., ARUPADAI VEEDU MED COLL, DEPT PHARMACOL, PONDICHERRY, INDIA.; SENGOTTUVELU, S., NANDHA COLL PHARM, DEPT PHARMACOL, ERODE 638001, TAMIL NADU, INDIA.","PHF, A POLYHERBAL FORMULATION, CONSIST OF SEVEN KNOWN HERBS NAMELY, AEGLE MARMELOS, ELETTARIA CARDAMOMUM, GLYCYRRHIZA GLABRA, CITRUS AURANTIFOLIA, ROSA DAMASCENA, CISSUS QUADRANGULARIS AND SACCHARUM OFFICINARUM. THE PHF WAS EVALUATED FOR ACUTE TOXICITY, GASTROINTESTINAL MOTILITY AND GASTRIC EMPTYING RATE IN MICE AND RATS. BASED ON ACUTE TOXICITY STUDY, THE PHF WAS CONSIDERED AS SAFE AND 3 DOSE (100, 200 AND 400 MG/KG) LEVELS WERE EMPLOYED FOR FURTHER PHARMACOLOGICAL STUDIES. THE GASTROINTESTINAL PROKINETICS EFFECT OF PHF IN VARIOUS DOSE LEVELS (100, 200 AND 400 MG/KG., P.O) WAS STUDIED BY CHARCOAL MEAL GASTROINTESTINAL TRANSIT AND LAXATIVE EFFECT IN MICE. THE GASTRIC EMPTYING RATE OF PHF IN RAT WAS STUDIED BY DISAPPEARANCE OF PHENOL RED FROM STOMACH. THE RESULTS ILLUSTRATE THAT PHF AT 200 AND 400 MG/KG SIGNIFICANTLY (P < 0.001) ENHANCED THE GASTROINTESTINAL TRANSIT. PHF AT 400 MG/KG (P < 0.01) SIGNIFICANTLY ENHANCED THE PURGING INDEX, WHICH IS THE MEASURE OF LAXATIVE ACTIVITY. PHF AT 200 MG/KG (P < 0.05) LESS SIGNIFICANTLY ENHANCED THE PURGING INDEX. IN GASTRIC EMPTYING RATE, PHF DOSE DEPENDENTLY INCREASED THE GASTRIC EMPTYING. FROM THE ABOVE FINDINGS, PHF MAY BE USED AS GASTROINTESTINAL PROKINETICS AND TO IMPROVE THE INTESTINAL MOTILITY.","POLYHERBAL FORMULATION; PROKINETICS; GASTROINTESTINAL MOTILITY AND; GASTRIC EMPTYING","PLATELET-AGGREGATION; SMALL-INTESTINE; RATS; POLICOSANOL; PERISTALSIS; MECHANISMS; ASPIRIN",NA,NA,"ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1997, PHARMACOL RES, V36, P293, DOI 10.1006/PHRS.1997.0201; AVE-SINA AA, 1990, LAW IN MED, P129; BUCKLE J, 1997, CLIN AROMATHERAPY NU, P45; CROCI T, 1997, BRIT J PHARMACOL, V121, P375, DOI 10.1038/SJ.BJP.0701130; ECOBICHON DJ., 1997, THE BASIS OF TOXICOLOGY TESTING, P43; GOEL R. K., 1997, INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, V35, P1080; HOROWITZ M, 1994, DIGEST DIS SCI, V39, P7; HUIZINGA JD, 1998, J PHYSIOL-LONDON, V506, P843, DOI 10.1111/J.1469-7793.1998.843BV.X; ISHIGUCHI T, 2000, J AUTONOM NERV SYST, V79, P45, DOI 10.1016/S0165-1838(99)00103-4; JAINU M, 2006, J ETHNOPHARMACOL, V104, P302, DOI 10.1016/J.JEP.2005.08.076; JAMAL A, 2006, J ETHNOPHARMACOL, V103, P149, DOI 10.1016/J.JEP.2005.07.016; KAR A, 2003, J ETHNOPHARMACOL, V84, P105, DOI 10.1016/S0378-8741(02)00144-7; LIBSTER M., 2002, DELMAR'S INTEGRATIVE HERB GUIDE FOR NURSES, P360; MAHMOOD N, 1996, BIOCHEM BIOPH RES CO, V229, P73, DOI 10.1006/BBRC.1996.1759; MARTINEZ V, 1998, ENDOCRINOLOGY, V139, P3730, DOI 10.1210/EN.139.9.3730; MOHAMMAD N., 2003, IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, P231, DOI 10.22037/IJPR.2010.61; MORAN TH, 1999, AM J PHYSIOL, V276, P997; NIEMEGEERS C, 1976, SYNTHETIC ANTIDIARRH, P65; TONINI M, 1996, PHARMACOL RES, V33, P217, DOI 10.1006/PHRS.1996.0030; WARRIER PK, 1994, INDIAN MED PLANTS, V1, P31; WATERMAN SA, 1994, J PHYSIOL-LONDON, V477, P459, DOI 10.1113/JPHYSIOL.1994.SP020207; WEISBRODT NW, 1997, GASTROINTESTINAL PHY, P33; WOOD G, 1839, DISPENSATORY US, P232; ZARGARI A., 1992, MED PLANTS, V2, P281","SRINIVASAN, D (CORRESPONDING AUTHOR), ANNAMALAI UNIV, RAJAH MUTHIAH DENT COLL \& HOSP, DEPT PHARMACOL, CHIDAMBARAM, TAMIL NADU, INDIA","WOLTERS KLUWER MEDKNOW PUBLICATIONS","ENGLISH","PHARMACOGN. MAG.","ARTICLE","ISI","WOS000262471400007","PHARMACOGN MAG","ANNAMALAI UNIV;ANNAMALAI UNIV;ARUPADAI VEEDU MED COLL;NANDHA COLL PHARM","ANNAMALAI UNIV",NA,"SRINIVASAN D, 2009, PHARMACOGN MAG","SRINIVASAN D, 2009, PHARMACOGN MAG"
"THIPPESWAMY G;SHEELA M;SALIMATH B","THIPPESWAMY G;SHEELA M L;SALIMATH BHARATHI P","OCTACOSANOL ISOLATED FROM ITINOSPORA CORDIFOLIAI DOWNREGULATES VEGF GENE EXPRESSION BY INHIBITING NUCLEAR TRANSLOCATION OF NFΚB AND ITS DNA BINDING ACTIVITY",2008,"EUROPEAN JOURNAL OF PHARMACOLOGY","588","141-150",63,"10.1016/j.ejphar.2008.04.027","SALIMATH, BP (CORRESPONDING AUTHOR), UNIV MYSORE, DEPT APPL BOT \& BIOTECHNOL, MYSORE 570006, KARNATAKA, INDIA.; THIPPESWAMY, G.; SHEELA, M. L.; SALIMATH, BHARATHI P., UNIV MYSORE, DEPT STUDIES APPL BOT \& BIOTECHNOL, MYSORE 570006, KARNATAKA, INDIA.","OCTACOSANOL IS A LONG-CHAIN ALIPHATIC ALCOHOL, WHICH IS THE MAIN COMPONENT OF POLICOSANOL USED AS A NORMOLIPIDEMIC AGENT. IT IS KNOWN THAT ANGIOGENESIS IS INVOLVED IN TUMOR GROWTH AND METASTASIS. THE PRESENT STUDY IDENTIFIED OCTACOSANOL ISOLATED FROM THE PLANT TINOSPORA CORDIFOLIA AS A NEW ANTIANGIOGENIC COMPOUND WITH INHIBITORY EFFECTS ON IN VIVO ANGIOGENESIS ASSAYS. OUR RESULTS SHOWED THAT OCTACOSANOL (I) INHIBITS PROLIFERATION OF ENDOTHELIAL CELLS AND EHRLICH ASCITES TUMOR CELLS, (II) INHIBITS NEOVASCULARIZATION INDUCED BY ANGIOGENIC FACTORS IN CHICK CHORIOALLANTOIC MEMBRANE AND RAT CORNEA IN VIVO ANGIOGENESIS ASSAYS, (III) INHIBITS SECRETION OF ASCITES FLUID IN THE GROWING TUMOR CELLS IN VIVO. CONCERNING THE MECHANISM OF ACTION, OCTACOSANOL INHIBITED SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR INTO ASCITES FLUID BY THE TUMOR CELLS. AT THE MOLECULAR LEVEL OCTACOSANOL MARKEDLY INHIBITS ACTIVITY OF MATRIX METALLOPROTEINASES (MMPS) AND TRANSLOCATION OF TRANSCRIPTION FACTOR NUCLEAR FACTOR-KAPPA B TO NUCLEUS. THE MECHANISM OF INHIBITION OF ANGIOGENESIS BY OCTACOSANOL REFLECTS ON ITS EFFECT ON TUMOR ANGIOGENESIS AND METASTASIS. (C) 2008 ELSEVIER B.V. ALL RIGHTS RESERVED.","ANGIOGENESIS; OCTACOSANOL; ASCITES TUMOR; VEGF (VASCULAR ENDOTHELIAL; GROWTH FACTOR); NF-KAPPA B (NUCLEAR FACTOR-KAPPA B)","ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; MOLECULAR MECHANISMS; TUMOR; ANGIOGENESIS; ACTIVATED DNASE; OVARIAN-CANCER; CELLS; METASTASIS; PROGRESSION; APOPTOSIS",NA,NA,"BATTEGAY EJ, 1995, J MOL MED, V73, P333; BOEHM T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORGSTROM P, 1996, CANCER RES, V56, P4032; BUSSOLINO F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; CASTANO G, 2005, DRUGS R D, V6, P207, DOI 10.2165/00126839-200506040-00003; CAVALLARO U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; CHAUHAN K., 1995, SUCHITRA AYURVED, V47, P840; DEEPAK AV, 2006, BIOCHIMIE, V88, P297, DOI 10.1016/J.BIOCHI.2005.08.008; DEL OLMO E, 2002, BIOORG MED CHEM LETT, V12, P2621, DOI 10.1016/S0960-894X(02)00476-6; DIXIT SN, 1971, INDIAN JOURNAL OF APPLIED CHEMISTRY, V34, P46; ELKIN M, 1999, CLIN CANCER RES, V5, P1982; FASSINA G, 2004, CLIN CANCER RES, V10, P4865, DOI 10.1158/1078-0432.CCR-03-0672; FERRARA N, 1999, J MOL MED, V77, P527, DOI 10.1007/S001099900019; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/NM0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/JNCI/82.1.4; FOLKMAN J, 2000, CANC MED, V5, P132; FOLKMAN J., 2001, HARRISONS PRINCIPLES, V15TH ED., P517; GURURAJ AE, 2002, BIOCHEM BIOPH RES CO, V297, P934, DOI 10.1016/S0006-291X(02)02306-9; HUANG S, 2000, CANCER RES, V60, P5334; HUANG SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/SJ.ONC.1204535; JAIN RK, 2003, NAT MED, V9, P685, DOI 10.1038/NM0603-685; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/PNAS.92.13.6007; JOHNSON LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; JOSKO J, 2004, MED SCI MONITOR, V10, PRA89; KARIN M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/ANNUREV.IMMUNOL.18.1.621; KARIN M, 2006, NATURE, V441, P431, DOI 10.1038/NATURE04870; KHALEQUE A, 1970, SCI RES, V7, P61; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841A0; KOK T. W., 2005, ANGIOGENESIS, V8, P3, DOI 10.1007/S10456-005-2892-Z; LAVIE GAD, 2005, ANGIOGENESIS, V8, P35, DOI 10.1007/S10456-005-3828-3; LEYON PV, 2004, INT IMMUNOPHARMACOL, V4, P1569, DOI 10.1016/J.INTIMP.2004.06.015; LEYON PV, 2004, J ETHNOPHARMACOL, V90, P233, DOI 10.1016/J.JEP.2003.09.046; LUO X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MANNA SK, 2000, CANCER RES, V60, P3838; MATSUBARA K, 2004, INT J MOL MED, V14, P819; MESIANO S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; MIN JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250; MORRIS BD, 2000, J CHEM ECOL, V26, P859, DOI 10.1023/A:1005499907009; NISHI T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/JBC.M202970200; QUESADA AR, 2006, MED RES REV, V26, P483, DOI 10.1002/MED.20059; RODRÍGUEZ-NIETO S, 2001, FASEB J, V15, P261, DOI 10.1096/FJ.01-0427FJE; SADICK H, 2005, INT J MOL MED, V15, P15; SALIMATH B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/SJ.ONC.1203672; SARAYBA MA, 2005, EXP EYE RES, V80, P435, DOI 10.1016/J.EXER.2004.10.009; SEO UK, 2005, J ETHNOPHARMACOL, V97, P101, DOI 10.1016/J.JEP.2004.10.022; SHEELA ML, 2006, INT IMMUNOPHARMACOL, V6, P494, DOI 10.1016/J.INTIMP.2005.07.002; SHIMAMURA M, 2001, BIOCHEM BIOPH RES CO, V289, P220, DOI 10.1006/BBRC.2001.5934; SINGH S. S., 2003, INDIAN JOURNAL OF PHARMACOLOGY, V35, P83; TANG LY, 2003, J BIOL CHEM, V278, P33613, DOI 10.1074/JBC.C300255200; THIPPESWAMY G, 2007, ENVIRON TOXICOL PHAR, V23, P212, DOI 10.1016/J.ETAP.2006.10.004; VARET J, 2003, CELL MOL LIFE SCI, V60, P810, DOI 10.1007/S00018-003-2322-6; YADAV PN, 2003, J PHARMACOL EXP THER, V305, P925, DOI 10.1124/JPET.103.049171","SALIMATH, BP (CORRESPONDING AUTHOR), UNIV MYSORE, DEPT APPL BOT \& BIOTECHNOL, MYSORE 570006, KARNATAKA, INDIA","ELSEVIER SCIENCE BV","ENGLISH","EUR. J. PHARMACOL.","ARTICLE","ISI","WOS000257187600002","EUR J PHARMACOL","UNIV MYSORE;UNIV MYSORE","UNIV MYSORE",NA,"THIPPESWAMY G, 2008, EUR J PHARMACOL","THIPPESWAMY G, 2008, EUR J PHARMACOL1"
"PEREZ Y;MAS R;GONZALEZ R;JIMENEZ S;MOLINA V","PEREZ YOHANI;MAS ROSA;GONZALEZ ROSA MARIA;JIMENEZ SONIA;MOLINA VIVIAN","EFFECTS OF D003 A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS AND POLICOSANOL ON IIN VIVOI LIPID PEROXIDATION IN RATS",2008,"ARZNEIMITTELFORSCHUNG-DRUG RESEARCH","58","126-130",5,NA,"PÉREZ, Y (CORRESPONDING AUTHOR), NATL CTR SCI RES CNIC, CTR NAT PROD, AVE 25 \& 158,PO 6880, HAVANA, CUBA.; PEREZ, YOHANI; MAS, ROSA; GONZALEZ, ROSA MARIA; JIMENEZ, SONIA; MOLINA, VIVIAN, NATL CTR SCI RES CNIC, CTR NAT PROD, HAVANA, CUBA.","BACKGROUND. D-003 AND POLICOSANOL (CAS 557-61-9), SPECIFIC AND DISTINCT MIXTURES OF HIGH MOLECULAR WEIGHT PRIMARY ALIPHATIC ACIDS AND ALCOHOLS, RESPECTIVELY, HAVE SHOWN TO INHIBIT LIPID PEROXIDATION IN VIVO, BUT COMPARATIVE STUDIES BETWEEN THEIR EFFECTS ON LIPID PEROXIDATION PROCESSES HAD NOT BEEN CONDUCTED BEFORE. OBJECTIVE. TO COMPARE THE EFFECTS OF D-003 AND POLICOSANOL ON MARKERS OF LIPID PEROXIDATION IN VIVO IN RATS. METHODS. MALE WISTAR RATS WERE DISTRIBUTED INTO 9 GROUPS: A CONTROL GROUP TREATED WITH ACACIA GUM/WATER VEHICLE, 4 WITH POLICOSANOL AND 4 WITH D-003, BOTH TREATMENTS AT 5,25, 100 AND 250 MG/KG. TREATMENTS WERE ADMINISTERED DURING 4 WEEKS. RESULTS. BOTH TREATMENTS SIGNIFICANTLY AND DOSE-DEPENDENTLY REDUCED PLASMA MALONDYALDEHIDE (MDA) AND TOTAL PEROXIDES. NEVERTHELESS, WHILE D-003 WAS EFFECTIVE FROM 5 MG/KG, THE LOWEST EFFECTIVE DOSE OF POLICOSANOL WAS 25 MG/KG. THE MAXIMAL EFFECTS OF BOTH TREATMENTS WERE OBTAINED WITH 100 MG/KG, BUT GREATER IN D-003 THAN IN POLICOSANOL GROUP, AND THE SAME OCCURRED ACROSS ALL DOSES TESTED. MDA CONCENTRATIONS GENERATED WITH THE ENZYMATIC SYSTEM IN LIVER HOMOGENATES WERE ALSO SIGNIFICANTLY AND DOSE-DEPENDENTLY INHIBITED WITH BOTH TREATMENTS. THE LOWEST EFFECTIVE DOSES OF D-003 AND POLICOSANOL WERE 5 AND 100 MG/KG, RESPECTIVELY, AND THE HIGHEST INHIBITIONS OF ABOUT 80\% (D-003) AND 11\% (POLICOSANOL). D-003 WAS MORE EFFECTIVE THAN POLICOSANOL IN ALL COMPARISONS. D-003 WAS ALSO MORE EFFECTIVE THAN POLICOSANOL FOR LOWERING MDA CONCENTRATIONS GENERATED WITH THE NO ENZYMATIC SYSTEM, BUT IN THESE CONDITIONS POLICOSANOL WAS EFFECTIVE FROM 25 MG/KG AND PRODUCED AN INHIBITION SOMEWHAT GREATER (ABOUT 29\%) THAN ON MDA-GENERATED BY THE ENZYMATIC SYSTEM. BOTH POLICOSANOL AND D-003 DID NOT MODIFY THE ACTIVITY OF ENDOGENOUS ANTIOXIDANT ENZYMES COMPARED WITH THE CONTROLS. CONCLUSIONS: D-003 (5-250 MG/KG) ORALLY ADMINISTERED FOR 4 WEEKS WAS MORE EFFECTIVE THAN POLICOSANOL FOR LOWERING ALL THE LIPID PEROXIDATION MARKERS ASSESSED, LIKE PLASMA MDA AND TOTAL PEROXIDES, AND MDA CONCENTRATIONS GENERATED BY THE ENZYMATIC AND NON-ENZYMATIC OXIDANT SYSTEMS OF LIVER HOMOGENATES. THE INHIBITIONS WITH D-003 WERE MARKED AND DOSEDEPENDENT. NEITHER D-003 NOR POLICOSANOL MODIFIED THE ACTIVITY OF ENZYMES INVOLVED IN THE ENDOGENIC ANTIOXIDANT DEFENSIVE SYSTEM.","ANTIOXIDANTS CAS 557-61-9; D-003; EFFECT ON LIPID PEROXIDATION; RAT; FATTY ACIDS MIXTURE; VERY LONG CHAIN; LIPID PEROXIDATION; POLICOSANOL; EFFECT ON LIPID PEROXIDATION; RAT","LOW-DENSITY-LIPOPROTEIN; GLUTATHIONE-PEROXIDASE; PROFILE; VITRO; DYSLIPIDEMIA; INHIBITION; D003",NA,NA,"CARLBERG I, 1975, J BIOL CHEM, V250, P5475; CASTAÑO G, 2005, DRUG EXP CLIN RES, V31, P31; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P789, DOI 10.2165/00044011-200323120-00004; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P193, DOI 10.2165/00044011-200323030-00005; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; COLLINS R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; FRAGA V, 1997, ARCH MED RES, V28, P355; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GÁMEZ R, 2002, TERATOGEN CARCIN MUT, V22, P175, DOI 10.1002/TCM.10001; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; *LIP RES CLIN PROG, 1984, JAMA-J AM MED ASSOC, V251, P1365; LUSCHER TF, 1997, CLIN CARDIOL, V20, P3; MARXWELL MA, 1987, ANAL BIOCHEM, V87, P206; MÁS R, 2004, DRUG FUTURE, V29, P773, DOI 10.1358/DOF.2004.029.08.828449; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENÉNDEZ R, 2005, ARCH MED RES, V36, P113, DOI 10.1016/J.ARCMED.2004.12.006; MENÉNDEZ R, 2004, CAN J PHYSIOL PHARM, V82, P22, DOI 10.1139/Y03-123; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MENENDEZ ROBERTO, 2005, ACTA FARMACEUTICA BONAERENSE, V24, P48; NG CH, 2005, J AGR FOOD CHEM, V53, P6289, DOI 10.1021/JF051269A; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PEDERSEN TR, 1994, LANCET, V344, P1383; SAZUKA Y, 1989, JPN J CANCER RES, V80, P89, DOI 10.1111/J.1349-7006.1989.TB02250.X; SINGH DK, 2006, J PHARMACOL EXP THER, V106, P107; TONKIN A, 1998, NEW ENGL J MED, V339, P1349; WORLD HEALTH ORGANIZATION (WHO), 1998, WORLD HLTH REP 1998","PÉREZ, Y (CORRESPONDING AUTHOR), NATL CTR SCI RES CNIC, CTR NAT PROD, AVE 25 \& 158,PO 6880, HAVANA, CUBA","GEORG THIEME VERLAG KG","ENGLISH","ARZNEIMITTELFORSCHUNG-DRUG RES.","ARTICLE","ISI","WOS000255300800005","ARZNEIMITTELFORSCHUNG-DRUG RES","NATL CTR SCI RES CNIC;NATL CTR SCI RES CNIC","NATL CTR SCI RES CNIC",NA,"PEREZ Y, 2008, ARZNEIMITTELFORSCHUNG-DRUG RES","PEREZ Y, 2008, ARZNEIMITTELFORSCHUNG-DRUG RES"
"DESWARTE F;CLARK J;WILSON A;HARDY J;MARRIOTT R;CHAHAL S;JACKSON ;CHARLES C;HESLOP G;BIRKETT M;BRUCE T;WHITELEY G","DESWARTE FABIEN E I;CLARK JAMES H;WILSON ASHLEY J; HARDY JEFF J E;MARRIOTT RAY;CHAHAL SURINDER P;JACKSON; CHARLES;HESLOP GRAHAM;BIRKETT MICHAEL;BRUCE TOBY J; WHITELEY GEOFF","TOWARD AN INTEGRATED STRAWBASED BIOREFINERY",2007,"BIOFUELS BIOPRODUCTS \& BIOREFINING-BIOFPR","1","245-254",39,"10.1002/bbb.32","DESWARTE, FEI (CORRESPONDING AUTHOR), UNIV YORK, YORK YO10 5DD, N YORKSHIRE, ENGLAND.; DESWARTE, FABIEN E. I.; CLARK, JAMES H.; WILSON, ASHLEY J.; HARDY, JEFF J. E., UNIV YORK, YORK YO10 5DD, N YORKSHIRE, ENGLAND.; JACKSON, CHARLES, CHARLES JACKSON \& CO LTD, NORTHAMPTON, ENGLAND.; HESLOP, GRAHAM, CS PROC ENGN LTD COMPAK SYST, LINCOLN, ENGLAND.; WHITELEY, GEOFF, STRULCH LTD, ILKLEY, ENGLAND.","STRAW IS A GOOD EXAMPLE OF A LOW-VALUE, HIGH-VOLUME AGRICULTURAL BY-PRODUCT THAT CAN BE THE BASIS FOR A BIOREFINERY, WHICH SHOULD AIM ( TO BE TRULY SUSTAINABLE AND ECONOMICALLY VIABLE) TO PROCESS THE FEEDSTOCK INTO A VARIETY OF VALUABLE PRODUCTS CLEANLY AND EFFICIENTLY. THIS ARTICLE DISCUSSES A CLEAN TECHNOLOGY - SUPERCRITICAL CARBON DIOXIDE EXTRACTION, WHICH CAN REPRESENT AN IDEAL INITIAL PROCESSING STAGE IN A BIOREFINERY SUPPLIED WITH WHEAT STRAW OR ANY APPROPRIATE BIOFEEDSTOCK. IT ALSO DESCRIBES DIFFERENT BIOREFINING SCENARIOS AND DETERMINES THE POTENTIAL ECONOMIC BENEFITS THAT MIGHT RESULT FROM A COORDINATED STRUCTURE. THIS WORKING EXAMPLE IS THE CULMINATION OF FOUR YEARS OF RESEARCH UNDERTAKEN BY A CONSORTIUM LED BY THE UNIVERSITY OF YORK AND CONSISTING OF A NUMBER OF INDUSTRIAL AND ACADEMIC PARTNERS ACROSS THE SUPPLY CHAIN. (C) 2007 SOCIETY OF CHEMICAL INDUSTRY AND JOHN WILEY \& SONS, LTD","WHEAT; STRAW; BIOREFINING; WAXES; ENERGY; CHEMICALS; MATERIALS","APHID; SEMIOCHEMICALS; POLICOSANOL; CHEMISTRY; PITCH","UNIVERSITY OF YORK; CSL","E AUTHORS WOULD LIKE TO THANK THE UNIVERSITY OF YORK AND CSL FOR THEIR FINANCIAL SUPPORT AND OTHER MEMBERS OF THE YORK GREEN CHEMISTRY GROUP FOR THEIR INTELLECTUAL INPUT. WE ALSO THANK PETER HOMER FOR HIS HELP IN THE DEVELOPMENT OF THE PROJECT.","ARVELAKIS S, 2002, BIOMASS BIOENERG, V22, P331, DOI 10.1016/S0961-9534(01)00056-3; BAKER E.A., 1982, PLANT CUTICLE, P139; BEALE MH, 2006, P NATL ACAD SCI USA, V103, P10509, DOI 10.1073/PNAS.0603998103; BECKMAN EJ, 2003, IND ENG CHEM RES, V42, P1598, DOI 10.1021/IE0300530; BIRICIK H, 1999, CEMENT CONCRETE RES, V29, P637, DOI 10.1016/S0008-8846(98)00249-X; BIRKETT MA, 2003, PHYTOCHEMISTRY, V62, P651, DOI 10.1016/S0031-9422(02)00568-X; BLANCHETTE RA, 1990, PATENT NO. 5853537; BLANDER M, 1997, BIOMASS BIOENERG, V12, P295, DOI 10.1016/S0961-9534(96)00082-7; CLARK JH, 2006, GREEN CHEM, V8, P853, DOI 10.1039/B604483M; CLARK JH, 2004, PATENT NO. 2006082437; DARTEY CK, 2001, PATENT NO. 1108364; DESWARTE FEI, 2006, GREEN CHEM, V8, P39, DOI 10.1039/B514978A; DORADO J, 2000, J BIOTECHNOL, V80, P231, DOI 10.1016/S0168-1656(00)00264-9; FARRELL RL, 1993, J BIOTECHNOL, V30, P115, DOI 10.1016/0168-1656(93)90032-I; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GRIMM J.L. C., 1812, GRIMMS FAIRY TALES; GUTIÉRREZ A, 2001, TRENDS BIOTECHNOL, V19, P340, DOI 10.1016/S0167-7799(01)01705-X; HAMILTON R. J., 1995, WAXES CHEM MOL BIOL, P257; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; KALLIOINEN A, 2003, J BIOTECHNOL, V103, P67, DOI 10.1016/S0168-1656(03)00051-8; KOSTIW DJ, 2001, PATENT NO. 6666951; MIETTENEN T, 1999, PATENT NO. 5958913; MOREAU RA, 2002, PROG LIPID RES, V41, P457, DOI 10.1016/S0163-7827(02)00006-1; NAKASHIMA Y, 2004, J CHEM ECOL, V30, P1103, DOI 10.1023/B:JOEC.0000030266.81665.19; NAKOS P, 2000, PATENT NO. 9902318; NIELSEN C, 1995, BIOMASS BIOENERG, V9, P315, DOI 10.1016/0961-9534(95)00099-2; OBERNBERGER I, 1997, BIOMASS BIOENERG, V12, P211, DOI 10.1016/S0961-9534(96)00051-7; PICKETT JA, 1994, CROP PROT C PEST DIS; PIIRONEN V, 2000, J SCI FOOD AGR, V80, P939, DOI 10.1002/(SICI)1097-0010(20000515)80:7<939::AID-JSFA644>3.0.CO;2-C; POWELL G, 1997, ENTOMOL EXP APPL, V84, P189, DOI 10.1023/A:1003087324444; REGNIER FE, 1971, BIOL REPROD, V4, P309, DOI 10.1093/BIOLREPROD/4.3.309; SCHERSL EMQ, 2003, PATENT NO. 092096; SMOOK G., 1992, HDB PULP PAPER TECHN; *STRAWFRAC LINK PR, COMP IND MAT NON FOO; THORSELL S, 2004, BIOMASS BIOENERG, V27, P327, DOI 10.1016/J.BIOMBIOE.2004.03.001; WASYLCIW W, 2002, PATENT NO. 02081160; ZOUGAGH M, 2004, TRAC-TREND ANAL CHEM, V23, P399, DOI 10.1016/S0165-9936(04)00524-2","DESWARTE, FEI (CORRESPONDING AUTHOR), UNIV YORK, YORK YO10 5DD, N YORKSHIRE, ENGLAND","WILEY","ENGLISH","BIOFUELS BIOPROD. BIOREFINING","ARTICLE","ISI","WOS000261819500015","BIOFUELS BIOPROD BIOREFINING","UNIV YORK;UNIV YORK","UNIV YORK",NA,"DESWARTE FEI, 2007, BIOFUELS BIOPROD BIOREFINING","DESWARTE FEI, 2007, BIOFUELS BIOPROD BIOREFINING"
"GONZALEZ V;MARRERO D;SIERRA R;VELAZQUEZ ;CARIDAD C","GONZALEZ VICTOR L;MARRERO DAVID;SIERRA ROXANA;VELAZQUEZ; CARIDAD","CAPILLARY GAS CHROMATOGRAPHY OF THE FATTY ALCOHOLS CSUB24SUBCSUB34SUB COMPOSING POLICOSANOL IN FILMCOATED TABLETS",2007,"LATIN AMERICAN JOURNAL OF PHARMACY","26","900-903",0,NA,"MARRERO, D (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6414,AVE 25\&158, HAVANA, CUBA.; GONZALEZ, VICTOR L.; MARRERO, DAVID; SIERRA, ROXANA; VELAZQUEZ, CARIDAD, NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","POLICOSANOL IS A DRUG SUBSTANCE CONSISTING OF A MIXTURE OF VERY LONG CHAIN ALCOHOLS (C-24-C-34) EXTRACTED AND PURIFIED FROM SUGAR CANE WAX. A GAS CHROMATOGRAPHIC METHOD USING A WIDE-BORE CAPILLARY COLUMN, AND L-EICOSANOL AS INTERNAL STANDARD WAS DEVELOPED AND VALIDATED FOR DETERMINING POLICOSANOL IN 5 AND 10 MG FILM-COATED TABLETS. THE ALCOHOLS WERE ANALYZED AS TRIMETHYLSILYL DERIVATIVES. THE METHOD CAN DETECT DEGRADATION PRODUCTS WITH HIGH RETENTION TIMES, WITHOUT INTERFERING WITH THE PEAKS OF THE ACTIVE INGREDIENT. GOOD LINEARITY (CORRELATION COEFFICIENT = 0.9991) AND ACCURACY (MEAN RECOVERY = 99.63\%) WERE PROVEN OVER A RANGE OF 50-150\% OF THE NOMINAL CONCENTRATION. REPEATABILITY AND INTERLABORATORY PRECISION AT THE NOMINAL 100\% VALUE MET THE ACCEPTANCE CRITERIA (<2\%). THE METHOD IS 0.7 TIMES FASTER AND SHOWED SUPERIOR EFFICIENCY THAN PREVIOUS DEVELOPED METHODS, BEING SUITABLE FOR QUALITY CONTROL PROCESS AND STABILITY STUDIES OF POLICOSANOL IN THESE FINISHED FORMS.","GAS CHROMATOGRAPHY; POLICOSANOL; TABLET; VALIDATION",NA,NA,NA,"CANAVACIOLO VLG, 1999, J AOAC INT, V82, P834; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P639, DOI 10.2165/00044011-200323100-00003; FERNANDEZ SALOME, 2004, AM J GERIATR PHARMACOTHER, V2, P219, DOI 10.1016/J.AMJOPHARM.2004.12.004; ICH, 1996, HARM TRIP GUID; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; SIERRA R, 2002, J AOAC INT, V85, P563; SIERRA R, 2005, ACTA FARM BONAERENSE, V24, P99","MARRERO, D (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6414,AVE 25\&158, HAVANA, CUBA","COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES","ENGLISH","LAT. AM. J. PHARM.","ARTICLE","ISI","WOS000253329300018","LAT AM J PHARM","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"GONZALEZ VL, 2007, LAT AM J PHARM","GONZALEZ VL, 2007, LAT AM J PHARM"
"DE L A;GARCIA A;ALVAREZ A;GRACIA ;IGNACIO I","DE LUCAS ANTONIO;GARCIA ALBERTO;ALVAREZ AMAURY;GRACIA; IGNACIO","SUPERCRITICAL EXTRACTION OF LONG CHAIN INIALCOHOLS FROM SUGAR CANE CRUDE WAX",2007,"JOURNAL OF SUPERCRITICAL FLUIDS","41","267-271",23,"10.1016/j.supflu.2006.09.013","GRACIA, I (CORRESPONDING AUTHOR), UNIV CASTILLA LA MANCHA, DEPT INGN QUIM, FAC CIENCIAS QUIM, AVDA CAMILO JOSE CELA 10, CIUDAD REAL 13004, SPAIN.; UNIV CASTILLA LA MANCHA, DEPT INGN QUIM, FAC CIENCIAS QUIM, CIUDAD REAL 13004, SPAIN.; ICIDCA, INST SUGAR CANE BYPROD, HAVANA 11000, CUBA.","WE HAVE STUDIED THE SUPERCRITICAL CO, EXTRACTION OF LONG CHAIN ALCOHOLS FROM SUGAR CANE CRUDE WAX, A BY PRODUCT OF SUGAR CANE PRODUCTION. THE AIM OF THIS WORK HAS BEEN TO DETERMINE THE EFFECT ON EXTRACTION YIELD OF SOME OPERATIONAL VARIABLES SUCH AS PRESSURE (300-350 BAR), TEMPERATURE (50-100 DEGREES C) AND THE RATIO OF KOH IN THE SAPONIFICATION STAGE (1-20\%, W/W). TO ASSESS THE N-ALCOHOL COMPOSITION OF THE SUPERCRITICAL EXTRACTS THE FRACTIONS WERE ANALYZED BY GAS CROMATOGRAPHY (GC). RESPONSE SURFACE METHODOLOGY WAS USED TO OBTAIN MATHEMATICAL EXPRESSIONS RELATING THE YIELD AS A FUNCTION OF THE OPERATIONAL VARIABLES STUDIED. THESE CORRELATIONS HAVE PERMITTED US TO DETERMINE THE BEST EXTRACTION CONDITIONS OF THE EXPERIMENTAL RANGE ANALYZED (P= 350 BAR, T= 100 DEGREES C, 20\% KOH/CRUDE WAX). THESE RESULTS WERE COMPARED TO THOSE OBTAINED BY THE EXISTING INDUSTRIAL ORGANIC SOLVENT MULTIPLE STAGE REFINING PROCESS. THE QUALITY OF THE SUPERCRITICAL EXTRACT WAS CONSIDERABLY SUPERIOR, BECAUSE OF ITS HIGHER N-ALCOHOLS PURITY, 78.24\% (W/W), COMPARED TO THE ORGANIC SOLVENT EXTRACTION YIELD, 22.00\% (W/W). (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.","LONG CHAIN N-ALCOHOLS; RESPONSE SURFACE METHODOLOGY; SUGAR CANE WAX; SUPERCRITICAL EXTRACTION","POLICOSANOL; ACIDS",NA,NA,"BOX J. E. P., 2005, STAT EXPT DESIGN DIS; DE LUCAS A, 2002, J SUPERCRIT FLUID, V22, P221, DOI 10.1016/S0896-8446(01)00132-2; FRAGERNAS L., 1986, ACTA CHEM SCANDINAVI, V40, P538; FURUKAWA K., 1987, US PATENT, PATENT NO. 4,714,791, 4714791; GARCIA A, 1988, GEPLACEA PNUD, P315; GARCIA A., 1994, P 3 INT S SUP FLUIDS, V3, P234; GARCIA A, 2004, 7 C INT AZ DER CAN H, P87; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; LAGUNAS A., 1992, PATENTE CUBANA, V229; LEDÓN N, 2003, PLANTA MED, V69, P367, DOI 10.1055/S-2003-38880; LUCAS A, 1997, J AM OIL CHEM SOC, V73, P1127; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; STAHL E., 1988, DENSE GASES EXTRACTI, P127; STAHL E., 1985, US PATENT, PATENT NO. 4,548,755, 4548755; 2002, OFF J EUR COMMUNITY, V128, P23","GRACIA, I (CORRESPONDING AUTHOR), UNIV CASTILLA LA MANCHA, DEPT INGN QUIM, FAC CIENCIAS QUIM, AVDA CAMILO JOSE CELA 10, CIUDAD REAL 13004, SPAIN","ELSEVIER SCIENCE BV","ENGLISH","J. SUPERCRIT. FLUIDS","ARTICLE","ISI","WOS000246468600010","J SUPERCRIT FLUIDS","UNIV CASTILLA LA MANCHA;UNIV CASTILLA LA MANCHA;INST SUGAR CANE BYPROD","UNIV CASTILLA LA MANCHA",NA,"DE LUCAS A, 2007, J SUPERCRIT FLUIDS","DE LUCAS A, 2007, J SUPERCRIT FLUIDS"
"OROSZ S;JOHNSON-DELANEY C;ECHOLS M","OROSZ SUSAN E;JOHNSON-DELANEY CATHY A;ECHOLS M SCOTT","APPLICATION OF NUTRITIONAL SUPPLEMENTS AND HERBS IN AVIAN PRACTICE",2007,"PROCEEDINGS OF THE ASSOCIATION OF AVIAN VETERINARIANS 28TH ANNUAL CONFERENCE AND EXPO",NA,"175+",1,NA,"OROSZ, SE (CORRESPONDING AUTHOR), BIRD \& EXOT PET WELLNESS CTR, 5166 MONROE ST,SUITE 305, TOLEDO, OH 43623 USA.; OROSZ, SUSAN E., BIRD \& EXOT PET WELLNESS CTR, 5166 MONROE ST,SUITE 305, TOLEDO, OH 43623 USA.; JOHNSON-DELANEY, CATHY A., EASTSIDE AVIAN \& EXOT ANIM MED CTR, KIRKLAND, WA 98034 USA.; ECHOLS, M. SCOTT, WESTGATE PET \& BIRD HOSP, AUSTIN, TX 78745 USA.","COMPLEMENTARY THERAPEUTICS ARE BECOMING WELL-ACCEPTED BY THE PET-OWNING PUBLIC. PRACTITIONERS ARE BEING INTRODUCED TO PRODUCTS DEVELOPED SPECIFICALLY FOR DOGS, CATS, HORSES, AND OTHER COMPANION ANIMALS. TERMS USED INCLUDE NUTRACEUTICALS, BOTANICALS, HERBALS, AND ``SUPPLEMENTS'' CAN BE CONFUSING. THE FOOD AND DRUG ADMINISTRATION IN THE UNITED STATES DOES NOT REGULATE THESE PRODUCTS, THEREFORE POTENCY AND LABEL CLAIMS MAY NOT BE ACCURATE. FORMULATIONS FOR PET BIRDS ARE BEING USED BY PRACTITIONERS ADAPTED FROM STUDIES DONE IN POULTRY OR SMALL ANIMALS, OR FROM ANECDOTAL EFFECTS ON HUMANS. SOME OF THE MOST COMMONLY USED PRODUCTS INCLUDE OMEGA-3 AND OMEGA-6 FATTY ACIDS, L-CARNITINE, MILK THISTLE, TAURINE, CHONDROITIN SULFATE, GLUCOSAMINE, LACTOBACILLUS, POLICOSANOL, COENZYME Q, GINSENG, GARLIC, AND L-LYSINE. A FORMULATION USED BY ONE OF THE AUTHORS AS AN ADJUNCT TO TRADITIONAL CARDIAC MEDICATIONS, DIET, AND EXERCISE HAS BEEN WELL-ACCEPTED BY THE OWNERS AND THE BIRDS. THE BIRDS HAVE SHOWN CLINICAL IMPROVEMENT, EVEN IN CASES WHERE THE CARDIAC FORMULA WAS THE ONLY CHANGE AND TREATMENT.",NA,"ECHINACEA-PURPUREA; FRACTIONS; GINSENG",NA,NA,"ALBINA JE, 1994, JPEN-PARENTER ENTER, V18, P367, DOI 10.1177/0148607194018004367; BOWERS TL, 1997, VET CLIN NUTR, V4, P9; CLARK L, 1985, OECOLOGIA, V67, P169, DOI 10.1007/BF00384280; DALBY-BROWN L, 2005, J AGR FOOD CHEM, V53, P9413, DOI 10.1021/JF0502395; GILARDI JD, 1999, J CHEM ECOL, V25, P897, DOI 10.1023/A:1020857120217; GOEL V, 2002, INT IMMUNOPHARMACOL, V2, P381, DOI 10.1016/S1567-5769(01)00163-1; GOEL V, 2004, J CLIN PHARM THER, V29, P75, DOI 10.1111/J.1365-2710.2003.00542.X; GOMPF RE, 2005, J AM ANIM HOSP ASSOC, V41, P355, DOI 10.5326/0410355; KIM DH, 2003, NEUROSCI LETT, V343, P62, DOI 10.1016/S0304-3940(03)00300-8; KIMURA Y, 2004, J ETHNOPHARMACOL, V95, P447, DOI 10.1016/J.JEP.2004.08.027; KLASING KC, 1998, COMP AVIAN NUTR; KOUTSOS EA, 2001, J AVIAN MED SURG, V15, P257, DOI 10.1647/1082-6742(2001)0150257:NOBITO2.0.CO;2; LOWENSTINE L.J., 1986, P201; MAYER W, 1999, WILDLIFE CONSERV JUN; QURESHI AA, 1983, ATHEROSCLEROSIS, V48, P81, DOI 10.1016/0021-9150(83)90019-9; RAI D, 2003, J PHARMACOL SCI, V93, P458, DOI 10.1254/JPHS.93.458; ROUDYBUSH T.E., 1997, P27; ROUSSEAU B, 2005, J VOICE 1020; SMITH J.M., 1997, P501; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418, DOI 10.1093/AJCN/32.2.418","OROSZ, SE (CORRESPONDING AUTHOR), BIRD \& EXOT PET WELLNESS CTR, 5166 MONROE ST,SUITE 305, TOLEDO, OH 43623 USA","ASSOC AVIAN VETERINARIANS","ENGLISH",NA,"PROCEEDINGS PAPER","ISI","WOS000255991900034","PROCEEDINGS OF THE ASSOCIATION OF AVIAN VETERINARIANS 28TH ANNUAL CONFERENCE AND EXPO","BIRD AND EXOT PET WELLNESS CTR;BIRD AND EXOT PET WELLNESS CTR;EASTSIDE AVIAN AND EXOT ANIM MED CTR;WESTGATE PET AND BIRD HOSP","BIRD AND EXOT PET WELLNESS CTR",NA,"OROSZ SE, 2007, PROCEEDINGS OF THE ASSOCIATION OF AVIAN VETERINARIANS 28TH ANNUAL CONFERENCE AND EXPO","OROSZ SE, 2007, PROCEEDINGS OF THE ASSOCIATION OF AVIAN VETERINARIANS 28TH ANNUAL CONFERENCE AND EXPO"
"WU T;CHARLES A;HUANG T","WU TIEN-TSO;CHARLES ALBERT LINTON;HUANG TZOU-CHI","DETERMINATION OF THE CONTENTS OF THE MAIN BIOCHEMICAL COMPOUNDS OF ADLAY ICOXI LACHRYMALJOBII",2007,"FOOD CHEMISTRY","104","1509-1515",59,"10.1016/j.foodchem.2007.02.027","HUANG, TC (CORRESPONDING AUTHOR), NATL PINGTUNG UNIV SCI \& TECHNOL, DEPT FOOD SCI \& TECHNOL, PINGTUNG 91207, TAIWAN.; NATL PINGTUNG UNIV SCI \& TECHNOL, DEPT FOOD SCI \& TECHNOL, PINGTUNG 91207, TAIWAN.; NATL PINGTUNG UNIV SCI \& TECHNOL, DEPT TROP AGR \& INT COOPERAT, PINGTUNG 91201, TAIWAN.","ADLAY (COXI LACHRYMAL-JOBI). AN ANNUAL CROP, HAS LONG BEEN USED IN TRADITIONAL CHINESE MEDICINE FOR ITS BIOLOGICAL ACTIVITY AND AS A NOURISHING FOOD. ITS PHYTOCHEMICAL COMPOSITION HAS BEEN EXTENSIVELY STUDIED; HOWEVER, INFORMATION ON ITS POLICOSANOL (PC) AND PHYTOSTEROL CONTENT IS SCARCE. THE OBJECTIVE OF THIS STUDY WAS TO EXAMINE AND COMPARE THE PC, PHYTOSTEROL AND OLEAMIDE CONTENTS OF DIFFERENT FRACTIONS OF ADLAY COLLECTED FROM LAOS. THAILAND, VIETNAM AND TAIWAN. BIOCHEMICAL COMPOSITIONS OF THE SAMPLES WERE IDENTIFIED USING A GAS CHROMATOGRAPH COUPLED WITH A MASS SPECTROMETER (GC-MS). THE ADLAY BRAN HAD HIGHER CONTENTS OF POLICOSANOLS (246 MG/KG), PHYTOSTEROLS (4733 MG/KG) AND OLEAMIDE (45.8 MG/KG) THAN HAD HULLED AND POLISHED FRACTIONS. ALTHOUGH PLANT STEROLS REDUCE CHOLESTEROL ABSORPTION. POLICOSANOLS MAY INHIBIT ENDOGENOUS CHOLESTEROL SYNTHESIS. ALTHOUGH ADLAY CONTAINS BENEFICIAL PHYTOCHEMICALS THAT JUSTIFY ITS USE AS A FOOD INGREDIENT OR DIETARY SUPPLEMENT, RESEARCH IS STILL NEEDED TO CONFIRM ITS TRADITIONAL USE IN ASIAN MEDICINE. (C) 2007 ELSEVIER LTD. ALL RIGHTS RESERVED.","ADLAY; PHYTOCHEMICALS; POLICOSANOL; PHYTOSTEROLS","POLICOSANOL; PLANT; OLEAMIDE; HYPERCHOLESTEROLEMIA; PHYTOSTEROL; COMPONENTS; SORGHUM; YUEN; RAT",NA,NA,"ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ANONYMOUS, PLANTA MED; AVATO P, 1990, PHYTOCHEMISTRY, V29, P1073, DOI 10.1016/0031-9422(90)85405-5; BORG J, 1991, J NEUROSCI RES, V26, P62; BRADSHAW HB, 2005, BRIT J PHARMACOL, V144, P459, DOI 10.1038/SJ.BJP.0706093; CHECK JBL, 1995, E AFR MED J, V72, P51; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; DOUGALIS A, 2004, NEUROPHARMACOLOGY, V46, P541, DOI 10.1016/J.NEUROPHARM.2003.10.011; FANG NB, 2003, J AGR FOOD CHEM, V51, P3260, DOI 10.1021/JF021162C; GUILLÉN MD, 1998, FOOD CHEM, V63, P373, DOI 10.1016/S0308-8146(98)00013-2; HANUS LO, 1999, ANAL BIOCHEM, V270, P159, DOI 10.1006/ABIO.1999.4083; HUANG SL, 1999, FOOD SCI (N Y), V26, P121; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; KONDO Y, 1988, CHEM PHARM BULL, V36, P3147; LEGGETT JD, 2004, BRIT J PHARMACOL, V141, P253, DOI 10.1038/SJ.BJP.0705607; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; NAGAO T, 1985, PHYTOCHEMISTRY, V24, P2959, DOI 10.1016/0031-9422(85)80035-2; NORMEN LENA, 2004, CURRENT MEDICINAL CHEMISTRY - CARDIOVASCULAR \& HEMATOLOGICAL AGENTS, V2, P1, DOI 10.2174/1568016043477323; OSTLUND RE, 2004, CURR OPIN LIPIDOL, V15, P37, DOI 10.1097/00041433-200402000-00008; PIIRONEN V, 2002, CEREAL CHEM, V79, P148, DOI 10.1094/CCHEM.2002.79.1.148; SHYU MINGLIH SHYU MINGLIH, 1998, NUTRITIONAL SCIENCES JOURNAL, V23, P161; SINGH V, 2003, CEREAL CHEM, V80, P126, DOI 10.1094/CCHEM.2003.80.2.126; TSAI C., 1999, FOOD SCI, V26, P265; VALDES S, 1996, INT J CLIN PHARM RES, V16, P67; WEIHRAUCH JL, 1978, J AM DIET ASSOC, V73, P39; WETTSTEINKNOWLE.PV, 1979, ADV BIOCH PHYSL PLAN, P1; YANG LJ, 1998, FOOD SCI, V25, P727; YOSHIDA Y, 2003, J NUTR SCI VITAMINOL, V49, P277, DOI 10.3177/JNSV.49.277","HUANG, TC (CORRESPONDING AUTHOR), NATL PINGTUNG UNIV SCI \& TECHNOL, DEPT FOOD SCI \& TECHNOL, PINGTUNG 91207, TAIWAN","ELSEVIER SCI LTD","ENGLISH","FOOD CHEM.","ARTICLE","ISI","WOS000247631900027","FOOD CHEM","NATL PINGTUNG UNIV SCI AND TECHNOL;NATL PINGTUNG UNIV SCI AND TECHNOL;NATL PINGTUNG UNIV SCI AND TECHNOL","NATL PINGTUNG UNIV SCI AND TECHNOL",NA,"WU TT, 2007, FOOD CHEM","WU TT, 2007, FOOD CHEM"
"CALVO R J;LIMA R E","CALVO ROMERO J M;LIMA RODRIGUEZ E M","NATURAL TREATMENTS OF HYPERCHOLESTEROLEMIA",2006,"REVISTA CLINICA ESPANOLA","206","504-506",0,"10.1157/13094900","ROMERO, JMC (CORRESPONDING AUTHOR), C SERGIO LUNA 15,2A, BADAJOZ 06010, SPAIN.; HOSP CIUDAD CORIA, MED INTERNA SERV, CORIA, CACERES, SPAIN.; AREA SALUD CORIA, CORIA, CACERES, SPAIN.","IN THIS ARTICLE WE BRIEFLY REVIEW THE EVIDENCE ON THE EFFECT OF DIFFERENT << NATURAL >> PRODUCTS ON CHOLESTEROLEMIA. PLANT STANOLS AND STEROLS REDUCE CHOLESTEROL INTESTINAL ABSORPTION AND DECREASE TOTAL AND LDL CHOLESTEROL BY APPROXIMATELY 10\%. POLYCOSANOL IS A MIXTURE OF SATURATED ALCOHOLS THAT SEEM TO INHIBIT CHOLESTEROL HEPATIC SYNTHESIS AND DECREASE TOTAL AND LDL CHOLESTEROL BY UP TO 25\%. THE EFFECTS ON THE CHOLESTOROLEMIA OF SOY AND SOLUBLE FIBER ARE MODEST.","HYPERCHOLESTEROLEMIA; TREATMENT; POLYCOSANOL","PLANT STANOL ESTER; DENSITY-LIPOPROTEIN CHOLESTEROL; SOY PROTEIN; II; HYPERCHOLESTEROLEMIA; CONTAINING SPREAD; LIPID PROFILE; DOUBLE-BLIND; POLICOSANOL; EFFICACY; TOLERABILITY",NA,NA,"ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; BLAIR SN, 2000, AM J CARDIOL, V86, P46, DOI 10.1016/S0002-9149(00)00976-0; BRICARELLO LP, 2004, NUTRITION, V20, P200, DOI 10.1016/J.NUT.2003.10.005; BROWN L, 1999, AM J CLIN NUTR, V69, P30; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; COON JST, 2003, J FAM PRACTICE, V52, P470; CRESPO N, 1999, INT J CLIN PHARM RES, V19, P117; DESROCHES S, 2004, J NUTR, V134, P574, DOI 10.1093/JN/134.3.574; FERNANDEZ L, 1998, CURR THER RES CLIN E, V59, P717, DOI 10.1016/S0011-393X(98)85030-3; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GRUNDY SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/CIRC.106.25.3143; HEBER D, 1999, AM J CLIN NUTR, V69, P231; HOIE LH, 2005, EUR J NUTR, V44, P65, DOI 10.1007/S00394-004-0492-0; HOMMA Y, 2003, NUTRITION, V19, P369, DOI 10.1016/S0899-9007(02)00926-7; JENKINS DJA, 2002, METABOLISM, V51, P1596, DOI 10.1053/META.2002.35578; KATAN MB, 2003, MAYO CLIN PROC, V78, P965, DOI 10.4065/78.8.965; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; NGUYEN TT, 1999, MAYO CLIN PROC, V74, P1198, DOI 10.4065/74.12.1198; O'NEILL FH, 2005, AM J CARDIOL, V96, P29D, DOI 10.1016/J.AMJCARD.2005.03.017; PINEDA JA, 2005, REV CLIN ESP, V205, P63, DOI 10.1157/13072497; PLAT J, 2000, EUR J CLIN NUTR, V54, P671, DOI 10.1038/SJ.EJCN.1601071; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; PUSKA P, 2002, EUR J CLIN NUTR, V56, P352, DOI 10.1038/SJ.EJCN.1601340; SIRTORI C R, 2001, CURR ATHEROSCLER REP, V3, P47, DOI 10.1007/S11883-001-0010-2; THOMPSON GR, 2005, AM J CARDIOL, V96, P37D, DOI 10.1016/J.AMJCARD.2005.03.018; ULBRICHT C, 2005, COMPLEMENT THER MED, V13, P279, DOI 10.1016/J.CTIM.2005.08.003; ZHAN SY, 2005, AM J CLIN NUTR, V81, P397","ROMERO, JMC (CORRESPONDING AUTHOR), C SERGIO LUNA 15,2A, BADAJOZ 06010, SPAIN","EDICIONES DOYMA S A","SPANISH","REV. CLIN. ESP.","ARTICLE","ISI","WOS000242327700008","REV CLIN ESP","JMC (CORRESPONDING AUTHOR);HOSP CIUDAD CORIA;CACERES","JMC (CORRESPONDING AUTHOR)",NA,"CALVO ROMERO JM, 2006, REV CLIN ESP","CALVO ROMERO JM, 2006, REV CLIN ESP1"
"GIMMIER F;SIEGERT D;KELLER S;JAHREIS ;GERHARD G","GIMMIER FRANZISKA;SIEGERT DOROTHEA;KELLER SYLVIA;JAHREIS; GERHARD","POLICOSANOLS ARE THESE WAXY PLANT COMPONENTS CAPABLE OF LOWERING SERUMCHOLESTEROL LEVELS",2006,"ERNAHRUNGS UMSCHAU","53","344+",0,NA,"JAHREIS, G (CORRESPONDING AUTHOR), UNIV JENA, INST ERNAHRUNGSWISSENSCH, DORNBURGER STR 24, D-07743 JENA, GERMANY.; UNIV JENA, INST ERNAHRUNGSWISSENSCH, D-07743 JENA, GERMANY.","CARDIOVASCULAR DISEASES ARE THE MAIN CAUSE OF DEATH AND DISABILITY IN INDUSTRIALIZED COUNTRIES. DURING THE LAST FEW YEARS, POTENTIAL HEALTH PROMOTING EFFECTS OF POLICOSANOLS HAVE BEEN CONTROVERSIALLY DISCUSSED. POLICOSANOLS ARE DESCRIBED AS A MIXTURE OF NATURALLY OCCURRING LONG-CHAIN ALIPHATIC ALCOHOLS DERIVED FROM SUGAR-CANE WAX. WHEN ADMINISTERED AT 5 TO 20 MG/DAY, POLICOSANOLS ARE SAID TO LOWER SERUM CHOLESTEROL LEVELS. VARIOUS STUDIES, MOST OF THEM OF CUBAN ORIGIN, REPORT THAT POLICOSANOLS HAVE CHOLESTEROL LOWERING EFFECTS COMPARABLE TO THAT OF STATINS. BASED ON THE RESULTS OF CUBAN RESEARCH GROUPS, POLICOSANOLS ARE WORLD-WIDE DISTRIBUTED AS OTC PRODUCTS FOR WHICH SERUM CHOLESTEROL LOWERING ACTION WITHOUT SIDE-EFFECTS IS CLAIMED. HOWEVER, RECENT STUDIES OF RESEARCH GROUPS OUTSIDE OF CUBA HAVE NOT FOUND A CORRELATION BETWEEN POLICOSANOL INTERVENTION AND REDUCED SERUM CHOLESTEROL CONCENTRATIONS, IN VIEW OF THESE CONTROVERSIAL RESULTS, FURTHER RESEARCH INTO THE CHOLESTEROL LOWERING EFFECT AND ITS POTENTIAL MECHANISM OF ACTION IS RECOMMENDED. AT PRESENT, HOWEVER, THERAPEUTIC SUPPLEMENTATION OF POLICOSANOLS TO LOWER SERUM CHOLESTEROL LEVELS IS NOT ADVISABLE.","POLICOSANOLS; CHOLESTEROL LOWERING EFFECTS","HEALTHY-VOLUNTEERS; HYPERLIPIDEMIA; DYSLIPIDEMIA; TOLERABILITY; THERAPIES; EFFICACY; SAFETY",NA,NA,"ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; BAYS H, 2003, EXPERT OPIN PHARMACO, V4, P1901, DOI 10.1517/14656566.4.11.1901; BERTHOLD HK, 2006, JAMA-J AM MED ASSOC, V295, P2262, DOI 10.1001/JAMA.295.19.2262; BOLEGO C, 2002, CURR OPIN LIPIDOL, V13, P637, DOI 10.1097/00041433-200212000-00007; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CHEN JT, 2005, PHARMACOTHERAPY, V25, P171, DOI 10.1592/PHCO.25.2.171.56942; CRAVOTTO G, 2004, EUR J LIPID SCI TECH, V106, P147, DOI 10.1002/EJLT.200300914; FERNÁNDEZ JC, 2001, CLIN DRUG INVEST, V21, P103, DOI 10.2165/00044011-200121020-00003; GIMMLER F, 2006, THESIS F SCHILLER U; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; GREYLING A, 2006, BRIT J NUTR, V95, P968, DOI 10.1079/BJN20061715; HARGROVE JL, 2004, EXP BIOL MED, V229, P215, DOI 10.1177/153537020422900301; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HOWARD BV, 1995, AM J CLIN NUTR, V62, P488S, DOI 10.1093/AJCN/62.2.488S; IRMAK S, 2006, FOOD CHEM, V95, P312, DOI 10.1016/J.FOODCHEM.2005.01.009; IRMAK S, 2005, J AGR FOOD CHEM, V53, P5583, DOI 10.1021/JF050508R; JANIKULA MARK, 2002, ALTERN MED REV, V7, P203; KELLER S, 2006, UNPUB DATEN; KLEID JJ, 2003, JANA, V6, P39; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MCCARTY MF, 2005, MED HYPOTHESES, V64, P636, DOI 10.1016/J.MEHY.2003.12.051; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; NIKITIN YP, 2000, TERAPEVT ARKH, V72, P7; ORTENSI G, 1997, CURR THER RES CLIN E, V58, P390, DOI 10.1016/S0011-393X(97)80099-9; PRAT H, 1999, REV MED CHILE, V127, P286; TAN CE, SINGAPORE MED J, V44, P635; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; VARADY KA, 2003, NUTR REV, V61, P376, DOI 10.1301/NR.2003.NOV.376-383","JAHREIS, G (CORRESPONDING AUTHOR), UNIV JENA, INST ERNAHRUNGSWISSENSCH, DORNBURGER STR 24, D-07743 JENA, GERMANY","UMSCHAU VERLAG","GERMAN","ERNAHR. UMSCH.","ARTICLE","ISI","WOS000240728600003","ERNAHR UMSCH","UNIV JENA;UNIV JENA","UNIV JENA",NA,"GIMMIER F, 2006, ERNAHR UMSCH","GIMMIER F, 2006, ERNAHR UMSCH"
"RODRÍGUEZ M;GONZÁLEZ J;LEÓN E;GUTIÉRREZ A;MARRERO G;GÁMEZ R;GARCÍA H;GOICOCHEA E;RODRÍGUEZ Y;GOMEZ A","RODRÍGUEZ M D;GONZÁLEZ J E;LEÓN E F;GUTIÉRREZ A;MARRERO G;GÁMEZ R;GARCÍA H;GOICOCHEA E; RODRÍGUEZ Y;GOMEZ A","PERINATALPOSTNATAL STUDY OF D003 A MIXTURE OF LONGCHAIN FATTY ACIDS IN RATS",2006,"JOURNAL OF MEDICINAL FOOD","9","223-230",5,"10.1089/jmf.2006.9.223","RODRÍGUEZ, MD (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, AVE 25 \& 158,POB 6414, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF LONG-CHAIN FATTY ACIDS ISOLATED AND PURIFIED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS. IN ORDER TO FURTHER CHARACTERIZE THE DEVELOPMENTAL TOXICITY DURING THE TREATMENT PERIOD FROM LATE GESTATION UP TO WEANING OF THE OFFSPRING, PREGNANT FEMALES RECEIVED 0 (CONTROL), 500, AND 1,000 MG/KG/DAY D-003 DAILY BY ORAL GAVAGE BEGINNING AT DAY 15 OF PREGNANCY AND THROUGH GESTATION UNTIL DAY 21 POSTPARTUM. MATERNAL CLINICAL SIGNS, BODY WEIGHT, AND FOOD INTAKE WERE MEASURED AT REGULAR INTERVALS DURING GESTATION AND LACTATION. LIVE PUPS WERE WEIGHED, SEXED, AND EXAMINED FOR DEVELOPMENTAL SIGNS. ONE FEMALE AND MALE OF EACH LITTER WERE RANDOMLY SELECTED TO EVALUATE THE REPRODUCTIVE POTENTIAL. THERE WERE NO SPONTANEOUS OR DOSE-RELATED MATERNAL DEATHS DURING THE COURSE OF THIS STUDY. THE GENERAL HEALTH AND BEHAVIORAL CONDITION OF OFFSPRING WAS GOOD IN ALL GROUPS. NO SIGNIFICANT DIFFERENCES AMONG GROUPS WERE FOUND IN COMPARISONS OF LITTER SIZE, SURVIVAL THROUGH THE WEANING PERIOD, SEX RATIO, AND MALE AND FEMALE WEIGHTS. THIS PERI- AND POSTNATAL STUDY CONDUCTED WITH D-003 IN RATS INDICATED THAT TREATMENT OF THE DAM DURING LATE GESTATION AND LACTATION DID NOT SHOW ADVERSELY EFFECTS ON REPRODUCTIVE PERFORMANCE OR FETAL DEVELOPMENT OVER TWO GENERATIONS.","ANTI-PLATELET EFFECTS; CHOLESTEROL-LOWERING DRUGS; D-003; LONG-CHAIN; FATTY ACIDS; PERINATAL/POSTNATAL STUDY; RATS","SUGAR-CANE WAX; DEVELOPMENTAL TOXICITY; HEALTHY-VOLUNTEERS; LIPID; PROFILE; NORMOCHOLESTEROLEMIC RABBITS; CHOLESTEROL-BIOSYNTHESIS; PREGNANT RATS; IN-VITRO; POLICOSANOL; COMPOUND",NA,NA,"ARRUZAZABALA MD, 2003, CLIN DRUG INVEST, V23, P107, DOI 10.2165/00044011-200323020-00004; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P193, DOI 10.2165/00044011-200323030-00005; CASTANO GLADYS, 2002, DRUGS R D, V3, P337, DOI 10.2165/00126839-200203050-00008; CICHA I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.A3; CLAYTON PT, 1998, ARCH DIS CHILD, V78, P185, DOI 10.1136/ADC.78.2.185; FERNANDEZ SI, 1991, REV CENIC CIEN BIOL, V22, P98; GÁMEZ R, 2004, DRUG EXP CLIN RES, V30, P75; GÁMEZ R, 2002, TERATOGEN CARCIN MUT, V22, P175, DOI 10.1002/TCM.10001; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ RAFAEL, 2003, DRUGS R D, V4, P219; GAMEZ RAFAEL, 2002, DRUGS R D, V3, P375; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; GONZALEZ L, 1998, PATENT NO. 22723; GONZALEZ L, 1998, PATENT NO. 9800870; GONZALEZ L, 1998, PATENT NO. 98043631; HENCK JW, 1998, TOXICOL SCI, V41, P88; HERRERA E, 2002, ENDOCRINE, V19, P43, DOI 10.1385/ENDO:19:1:43; HERZ J, 1997, NAT GENET, V15, P123, DOI 10.1038/NG0297-123; HRAB RV, 1994, TERATOLOGY, V50, P19, DOI 10.1002/TERA.1420500104; ISHIGURO M, 1995, MOL BRAIN RES, V33, P37, DOI 10.1016/0169-328X(95)00104-Z; JUREVICS HA, 1997, J LIPID RES, V38, P723; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENDOZA S, 2003, INT J TISSUE REACT, V25, P81; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; MINSKER DH, 1983, TERATOLOGY, V28, P449, DOI 10.1002/TERA.1420280316; MOLINA V, 2002, PROSTAG LEUKOTR ESS, V67, P19, DOI 10.1054/PLEF.2002.0376; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; PIEGORSCH WW, 1991, TERATOGEN CARCIN MUT, V11, P115, DOI 10.1002/TCM.1770110302; RENDON A, 1991, TOXICOL LETT S, P248; RODRÍGUEZ MD, 2004, FOOD CHEM TOXICOL, V42, P1977, DOI 10.1016/J.FCT.2004.07.014; RODRÍGUEZ MD, 2003, FOOD CHEM TOXICOL, V41, P89, DOI 10.1016/S0278-6915(02)00217-X; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRÍGUEZ MD, 1998, TERATOGEN CARCIN MUT, V18, P1, DOI 10.1002/(SICI)1520-6866(1998)18:1<1::AID-TCM1>3.0.CO;2-K; WIER PJ, 1990, DRUG INF J, V24, P395","RODRÍGUEZ, MD (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, AVE 25 \& 158,POB 6414, HAVANA, CUBA","MARY ANN LIEBERT, INC","ENGLISH","J. MED. FOOD","ARTICLE","ISI","WOS000238934300013","J MED FOOD","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"RODRÍGUEZ MD, 2006, J MED FOOD","RODRÍGUEZ MD, 2006, J MED FOOD"
"JACKSON M;ELLER F","JACKSON MA;ELLER FJ","ISOLATION OF LONGCHAIN ALIPHATIC ALCOHOLS FROM BEESWAX USING LIPASECATALYZED METHANOLYSIS IN SUPERCRITICAL CARBON DIOXIDE",2006,"JOURNAL OF SUPERCRITICAL FLUIDS","37","173-177",36,"10.1016/j.supflu.2005.08.008","JACKSON, MA (CORRESPONDING AUTHOR), USDA, ARS, NEW CROPS RES UNIT, 1815 N UNIV ST, PEORIA, IL 61604 USA.; USDA, ARS, NEW CROPS RES UNIT, PEORIA, IL 61604 USA.","ALIPHATIC ALCOHOLS OF CHAIN LENGTHS OF 24-34 CARBONS HAVE BEEN FOUND TO BE BENEFICIAL IN TREATING HYPERCHOLESTEROLEMIA. APPROXIMATELY 40\% OF BEESWAX IS LONG-CHAIN ESTERS WHICH CAN BE TRANSESTERIFIED ILL SUPERCRITICAL CARBON DIOXIDE TO GIVE THESE ALCOHOLS AND FATTY ACID METHYL ESTERS. THE METHANOLYSIS REACTION WAS CATALYZED BY AN IMMOBILIZED LIPASE FROM CANDIDA ANTARCTICA IN FLOWING SUPERCRITICAL CARBON DIOXIDE AND THE ALCOHOLS WERE THEN ISOLATED FROM THE FATTY ACID METHYL ESTERS BY PRECIPITATION FROM HEPTANE. THE ALCOHOLS WERE FOUND IN THE FOLLOWING PERCENTAGES: TETRACOSANOL, 9.1; HEXACOSANOL, 14.0; OCTACOSANOL, 18.4; TRIACONTANOL. 37.2; DOTRIACONTANOL, 21.1; TETRATRIACONTANOL, 0.3. THE UTILITY OF THE METHOD WAS DEMONSTRATED BY ISOLATING FATTY ALCOHOLS FROM JOJOBA OIL AND A MIXTURE OF TRIGLYCERIDES AND WAXES ISOLATED FROM CORN BRAN. (C) 2005 ELSEVIER B.V. ALL RIGHTS RESERVED.","BEESWAX; SUPERCRITICAL CARBON DIOXIDE; METHANOLYSIS; POLICOSANOLS; LIPASE FATTY ALCOHOLS","IONIZATION MASS-SPECTROMETRY; TEMPERATURE GAS-CHROMATOGRAPHY; II; HYPERCHOLESTEROLEMIA; POLICOSANOL; HONEYBEES; TOXICITY; EFFICACY; COMBWAX; SAFETY; WAX",NA,NA,"AICHHOLZ R, 1999, J CHROMATOGR A, V855, P601, DOI 10.1016/S0021-9673(99)00725-6; AICHHOLZ R, 2000, J CHROMATOGR A, V883, P75, DOI 10.1016/S0021-9673(00)00386-1; ALEMAN CL, 1995, FOOD CHEM TOXICOL, V33, P573, DOI 10.1016/0278-6915(95)00026-X; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; DARR JA, 1999, CHEM REV, V99, P495, DOI 10.1021/CR970036I; GAMBLE WR, PATENT NO. 6596776; GRANJA L, PATENT NO. 5856316; GRANJA L, PATENT NO. 5663156; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; ISBELL TA, 1999, RECENT DEVELOPMENTS IN THE SYNTHESIS OF FATTY ACID DERIVATIVES, P44, DOI 10.1201/9781439832073.CH3; JACKSON MA, 1996, J AM OIL CHEM SOC, V73, P353, DOI 10.1007/BF02523430; JONES FW, 1997, J SUPERCRIT FLUID, V10, P105, DOI 10.1016/S0896-8446(97)00008-9; LICENCE P, 2003, GREEN CHEM, V5, P99, DOI 10.1039/B212220K; LIN YG, 2004, METABOLISM, V53, P1309, DOI 10.1016/J.METABOL.2004.05.006; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; PEREZ PP, PATENT NO. 6225354; PLATTNER RD, 1983, LIPIDS, V18, P68, DOI 10.1007/BF02534693; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9; TAYLOR SL, 2000, J CHROMATOGR SCI, V38, P91, DOI 10.1093/CHROMSCI/38.3.91; YATCILLA M, 2002, NUTRACEUTICALS WORLD, V5, P28","JACKSON, MA (CORRESPONDING AUTHOR), USDA, ARS, NEW CROPS RES UNIT, 1815 N UNIV ST, PEORIA, IL 61604 USA","ELSEVIER SCIENCE BV","ENGLISH","J. SUPERCRIT. FLUIDS","ARTICLE","ISI","WOS000236165100005","J SUPERCRIT FLUIDS","MA (CORRESPONDING AUTHOR);NEW CROPS RES UNIT","NOTDECLARED",NA,"JACKSON MA, 2006, J SUPERCRIT FLUIDS","JACKSON MA, 2006, J SUPERCRIT FLUIDS"
"CICERO A;BRANCALEONI M;LAGHI L;DONATI F;MINO M","CICERO AFG;BRANCALEONI M;LAGHI L;DONATI F;MINO M","HYPERLIPIDAEMIC EFFECT OF A IMONASCUS PURPUREUSI BRAND DIETARY SUPPLEMENT ON A LARGE SAMPLE OF SUBJECTS AT LOW RISK FOR CARDIOVASCULAR DISEASE A PILOT STUDY",2005,"COMPLEMENTARY THERAPIES IN MEDICINE","13","273-278",35,"10.1016/j.ctim.2005.07.008","CICERO, AFG (CORRESPONDING AUTHOR), UNIV BOLOGNA, DEPT INTERNAL MED \& APPL BIOTECHNOL, ATHEROSCLEROSIS \& METAB DIS STUDY CTR G DESCOVICH, S ORSOLA MALPIGHI UNIV HOSP, VIA MASSARENTI 9, I-40138 BOLOGNA, ITALY.; UNIV BOLOGNA, DEPT INTERNAL MED \& APPL BIOTECHNOL, ATHEROSCLEROSIS \& METAB DIS STUDY CTR G DESCOVICH, S ORSOLA MALPIGHI UNIV HOSP, I-40138 BOLOGNA, ITALY.","OBJECTIVES: WE PLANNED TO CARRY OUT A PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY AS AN ANTI HYPERCHOLESTEROLEMIC AGENT OF A BRAND DIETARY SUPPLEMENT MADE OF MONASCUS PURPUREUS TITRATED EXTRACT, OCTACOSANOLS AND NIACIN ON 111 CAUCASIAN PATIENTS WITH LOW CARDIOVASCULAR DISEASE RISK (<20\% BY FRAMINGHAM ALGORITHMS), COMPARING THEM WITH THE ANTI HYPERCHOLESTEROLEMIC EFFECT OF A LOW DOSAGE OF PRAVASTATIN ON 20 SUBJECTS WITH SIMILAR RISK PROFILE. RESULTS: IN OUR STUDY, THE TESTED DIETARY SUPPLEMENT DETERMINED A SIGNIFICANT DECREASE OF TOTAL CHOLESTEROL (TC), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), AND TRIGLYCERIDES (TG) IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS WITHOUT CLINICALLY RELEVANT CHANGE IN LIVER AND MUSCULAR TOXICITY MARKERS. THE REDUCTION OF LDL-C REACHED THE 20\%, AND IT IS SIMILAR TO THAT OBTAINED WITH A WELL-KNOWN EFFECTIVE STATIN LIKE PRAVASTATIN. CONCLUSIONS: FURTHER LONG-TERM AND DOUBLE BLIND EVALUATION HAVE TO BE CARRIED OUT BEFORE TO INFER THE OBSERVED RESULTS, HOWEVER IT APPEARS THAT THE STUDIED DIETARY SUPPLEMENTS COULD BE A SAFE AND EFFICACIOUS ANTI HYPERCHOLESTEROLEMIC AGENT FOR PATIENTS AT TOW RISK FOR CARDIOVASCULAR DISEASES. (C) 2005 ELSEVIER LTD. ALL RIGHTS RESERVED.",NA,"CORONARY-HEART-DISEASE; EXPERT PANEL; CHOLESTEROL; POLICOSANOL; ATHEROSCLEROSIS; DYSLIPIDEMIA; PREVENTION; LOVASTATIN; EFFICACY; CARE",NA,NA,"BULLER N, 2003, PHARMACOECONOMICS, V21, P25, DOI 10.2165/00019053-200321001-00003; CARON MF, 2001, PHARMACOTHERAPY, V21, P481, DOI 10.1592/PHCO.21.5.481.34499; CASTAÑO G, 2002, INT J CLIN PHARM RES, V22, P89; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CASTAÑO G, 2003, ANGIOLOGY, V54, P25, DOI 10.1177/000331970305400104; CLEEMAN JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/JAMA.285.19.2486; GANJI SH, 2003, J NUTR BIOCHEM, V14, P298, DOI 10.1016/S0955-2863(02)00284-X; GOTTO A.M., 2003, CLIN. CARDIOL., V26, P21, DOI 10.1002/CLC.4960261307, DOI 10.1002/CLC.4960261307; HEBER D, 1999, AM J CLIN NUTR, V69, P231; HEBER D, 2001, CURR ATHEROSCLER REP, V3, P93, DOI 10.1007/S11883-001-0016-9; KEDWARD J, 2003, BRIT J GEN PRACT, V53, P684; KEITHLEY JK, 2002, NUTRITION, V18, P201, DOI 10.1016/S0899-9007(01)00688-8; KULLO IJ, 2005, MAYO CLIN PROC, V80, P219, DOI 10.4065/80.2.219; MALIK SHAISTA, 2003, CURR CARDIOL REP, V5, P470, DOI 10.1007/S11886-003-0109-X; MAN RYK, 2002, MOL CELL BIOCHEM, V233, P153, DOI 10.1023/A:1017487815091; MCCARTY MF, 2002, MED HYPOTHESES, V59, P268, DOI 10.1016/S0306-9877(02)00226-8; NORMAN G.R., 2000, BIOSTATISTICS BARE E, P139; PEARSON TA, 2003, CIRCULATION, V107, P645, DOI 10.1161/01.CIR.0000054482.38437.13; PLATT R, 2000, PREV CARDIOL, V3, P83, DOI 10.1111/J.1520-037X.2000.80364.X; PROSSER LA, 2000, ANN INTERN MED, V132, P769, DOI 10.7326/0003-4819-132-10-200005160-00002; RADER DJ, 2004, MEDSCAPE CARDIOL, V8, P1; SIMES J, 2002, EUR HEART J, V23, P207, DOI 10.1053/EUHJ.2001.2775; SMITH DJ, 2003, SOUTH MED J, V96, P1265, DOI 10.1097/01.SMJ.0000100117.79718.DC; STUART MD, 1979, CHINESE MAT MED VEGE; VAN OOSTROM AJHHM, 2004, DRUGS, V64, P19, DOI 10.2165/00003495-200464002-00004; WEINHOLD B, 2004, ENVIRON HEALTH PERSP, V112, PA880, DOI 10.1289/EHP.112-A880; YING SS, 1966, TIEN JUNG KAI WU CHI, P291","CICERO, AFG (CORRESPONDING AUTHOR), UNIV BOLOGNA, DEPT INTERNAL MED \& APPL BIOTECHNOL, ATHEROSCLEROSIS \& METAB DIS STUDY CTR G DESCOVICH, S ORSOLA MALPIGHI UNIV HOSP, VIA MASSARENTI 9, I-40138 BOLOGNA, ITALY","CHURCHILL LIVINGSTONE","ENGLISH","COMPLEMENT. THER. MED.","ARTICLE","ISI","WOS000234328400008","COMPLEMENT THER MED","UNIV BOLOGNA;UNIV BOLOGNA","UNIV BOLOGNA",NA,"CICERO AFG, 2005, COMPLEMENT THER MED","CICERO AFG, 2005, COMPLEMENT THER MED"
"MENÉNDEZ R;MARRERO D;MÁS R;FERNÁNDEZ I;GONZÁLEZ L;GONZÁLEZ R","MENÉNDEZ R;MARRERO D;MÁS R;FERNÁNDEZ I;GONZÁLEZ L;GONZÁLEZ RM","IIN VITROI AND IIN VIVOI STUDY OF OCTACOSANOL METABOLISM",2005,"ARCHIVES OF MEDICAL RESEARCH","36","113-119",43,"10.1016/j.arcmed.2004.12.006","NATL CTR SCI RES, BIOCHEM LAB, CTR NAT PROD, POB 6412, HAVANA, CUBA.; NATL CTR SCI RES, BIOCHEM LAB, CTR NAT PROD, HAVANA, CUBA.","BACKGROUND. POLICOSANOL IS A MIXTURE OF VERY-LONG-CHAIN ALIPHATIC ALCOHOLS PURIFIED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING EFFECTS, WHOSE MAIN COMPONENT IS OCTACOSANOL. SCARCE DATA ABOUT THE METABOLISM OF OCTACOSANOL AND THE OTHER FATTY ALCOHOLS COMPOSING POLICOSANOL HAVE BEEN PUBLISHED. METHODS. HUMAN FIBROBLASTS WERE CULTURED IN PRESENCE OF 3 H-OCTACOSANOL DURING 0.5, 2 AND 4 H. LIPID EXTRACTS WERE ANALYZED BY THIN LAYER CHROMATOGRAPHY, AND THE SPOTS CORRESPONDING TO OCTACOSANOL AND OCTACOSANOIC ACID WERE IDENTIFIED COMPARING WITH AUTHENTIC STANDARDS. SPOTS WERE SCRAPED, TRANSFERRED TO VIALS AND RADIOACTIVITY WAS MEASURED. FOR CORROBORATING THE PRESENCE OF OCTACOSANOL AND OCTACOSANOIC ACID, SAMPLES WERE ANALYZED BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS). THE IN VIVO STUDY OF OCTACOSANOL METABOLISM WAS CONDUCTED IN RATS AND MACACA ARCTOIDES MONKEYS. RATS WERE ORALLY ADMINISTERED WITH POLICOSANOL (60 MG,/KG) AND FREE OCTACOSANOL AND OCTACOSANOIC ACID WERE IDENTIFIED IN LIVER AND PLASMA BY GC-MS AT VARIOUS TIME INTERVALS. MONKEYS WERE ORALLY AND ENDOVENOUSLY TREATED WITH POLICOSANOL (10 MG/KG) AND THE PRESENCE OF FREE OCTACOSANOL, OCTACOSANOIC ACID AND SOME CHAIN-SHORTENED FA WAS INVESTIGATED. RESULTS. WHEN FIBROBLASTS WERE CULTURED IN PRESENCE OF 3 H-OCTACOSANOL, THREE SPOTS WERE FOUND: A FIRST ONE CORRESPONDED TO OCTACOSANOIC ACID, A SECOND TO OCTACOSANOL AND A THIRD ONE REMAINED UNIDENTIFIED. THE RADIOACTIVITY ON THE SPOT OF OCTACOSANOIC ACID SLIGHTLY DECREASED THROUGHOUT THE INCUBATION BUT INCREASED IN THE THIRD SPOT. OCTACOSANOL AND FREE OCTACOSANOIC ACIDS WERE ALSO IDENTIFIED IN PLASMA OF MONKEYS ORALLY ADMINISTERED WITH POLICOSANOL. IN ADDITION, PLASMA SAMPLES SHOWED FREE SATURATED ACIDS, PALMITIC ACID BEING THE MOST ABUNDANT, FOLLOWED BY OLEIC AND MYSTIRIC ACIDS. UNSATURATED ACIDS (OLEIC AND PALMITOLEIC) WERE ALSO OBSERVED. CONCLUSIONS. THE PRESENT STUDY DEMONSTRATES THAT OCTACOSANOIC ACID IS FORMED AFTER INCUBATION OF FIBROBLAST CULTURES WITH 3 H-OCTACOSANOL AND AFTER ORAL DOSING WITH POLICOSANOL TO RATS. IN ADDITION, WE DEMONSTRATED THAT SHORTENED SATURATED (MYRISTIC, PALMITIC AND STEARIC) AND UNSATURATED (OLEIC, PALMITOLEIC) FA ARE ALSO FORMED AFTER ORAL DOSING WITH POLICOSANOL TO MONKEYS. THE PRESENT RESULTS ARE CONSISTENT WITH THE FACT THAT OCTACOSANOL METABOLISM IS LINKED TO FA METABOLISM VIA P-OXIDATION, BUT FURTHER STUDIES NEED TO EXPLORE THE OCCURRENCE OF MORE METABOLITES PROVING SUCH HYPOTHESIS. (C) 2005 IMSS. PUBLISHED BY ELSEVIER INC.","POLICOSANOL; OCTACOSANOL METABOLISM; OCTACOSANOIC ACID; CHAIN-SHORTENED; FATTY ACIDS","II HYPERCHOLESTEROLEMIA; LIPID PROFILE; POLICOSANOL; TOLERABILITY; EFFICACY; LIVER",NA,NA,"ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 2002, CLIN EXP PHARMACOL P, V29, P891, DOI 10.1046/J.1440-1681.2002.03746.X; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1996, PHARMACOL RES, V34, P181, DOI 10.1006/PHRS.1996.0086; ARRUZAZABALA ML., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P60; CANETTI M, 1995, ADV THER, V12, P245; CASTAÑO G, 1999, CURR THER RES CLIN E, V60, P379, DOI 10.1016/S0011-393X(99)80016-2; CASTAÑO G, 2003, DRUG AGING, V20, P153, DOI 10.2165/00002512-200320020-00006; CASTAÑO G, 2001, J GERONTOL A-BIOL, V56, PM186, DOI 10.1093/GERONA/56.3.M186; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CASTAÑO G, 2000, CURR THER RES CLIN E, V61, P137, DOI 10.1016/S0011-393X(00)80011-9; CASTEN RF, 2002, NATO SCI SER II MATH, V53, P231; CRESPO N, 1999, INT J CLIN PHARM RES, V19, P117; EVANS E.A., 1974, TRITIUM ITS COMPOUND; FRAGA V, 1997, ARCH MED RES, V28, P355; HERNANDEZ J, 1993, CURR THER RES, V51, P568; KABIR Y, 1994, NAHRUNG, V38, P373; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; LAGUNA A, 1997, U.S. PATENT, PATENT NO. 5663156; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; MARRERO D, 2002, J CHROMATOGR B, V762, P43; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2001, CLIN DRUG INVEST, V21, P485; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENENDEZ R, 1997, PHYSIOL BEHAV, V67, P1; MILLS GL, 1984, LAB TECHNIQUES BIOCH, P20; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PEREZSOUTO N, 1991, REV CENIC CIEN BIOL, V22, P15; TOCHER DR, 1998, PROG LIPID RES, V37, P73, DOI 10.1016/S0163-7827(98)00005-8; VEGA L, 1993, NUCLEUS, V13, P12; WANDERS RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/BST0290250","NATL CTR SCI RES, BIOCHEM LAB, CTR NAT PROD, POB 6412, HAVANA, CUBA","ELSEVIER SCIENCE INC","ENGLISH","ARCH. MED. RES.","ARTICLE","ISI","WOS000229105500002","ARCH MED RES","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"MENÉNDEZ R, 2005, ARCH MED RES","MENÉNDEZ R, 2005, ARCH MED RES1"
"RODRÍGUEZ M;GONZÁLEZ J;ALEMÁN C;RODEIRO I;ARANGO ;E E;GÁMEZ R;VALDÉS S;GARCÍA H;GOICOCHEA E;ACOSTA ;CP C","RODRÍGUEZ MD;GONZÁLEZ JE;ALEMÁN C;RODEIRO I;ARANGO; E;GÁMEZ R;VALDÉS S;GARCÍA H;GOICOCHEA E;ACOSTA; CP","EVALUATION OF THE REPRODUCTIVE AND DEVELOPMENTAL TOXICITY OF THE D003 A MIXTURE OF LONGCHAIN FATTY ACIDS IN RATS AND RABBITS",2004,"FOOD AND CHEMICAL TOXICOLOGY","42","1977-1985",10,"10.1016/j.fct.2004.07.014","NATL CTR SCI RES, CTR NAT PROD, AVE 25 \& 158,POB 6414, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF LONG-CHAIN FATTY ACIDS ISOLATED AND PURIFIED FROM SUGAR CANE WAX WITH CHOLESTEROL-LOWERING PROPERTIES. D-003 GIVEN ORALLY (500 AND 1000 MG/KG/DAY) TO FEMALE RATS FOR 15 DAYS PRIOR TO MATING, THROUGH MATING AND GESTATION TO DAY 21 OF LACTATION AND MALE RATS FOR 4 WEEKS PRIOR AND DURING MATING DID NOT INDUCE TOXIC EFFECTS ON REPRODUCTION. THERE WERE NO SIGNIFICANT REDUCTIONS IN THE NUMBER OF ANIMALS THAT CONCEIVED, IN THE NUMBERS OF PUPS BORN TO THOSE THAT DID CONCEIVE, IN THE NUMBERS OF PUPS THAT SURVIVED UNTIL WEANING, AND IN THEIR BODY WEIGHTS AT WEANING. DRUG-TREATED AND CONTROL GROUPS' OFFSPRING WERE COMPARABLE IN GROWTH, PHYSICAL AND BEHAVIORAL DEVELOPMENT, SPONTANEOUS ACTIVITY AND REPRODUCTIVE PERFORMANCE. PREGNANT NEW ZEALAND RABBITS WERE GIVEN D-003 AS ORAL DOSES OF 500 AND 1000 MG/KG/DAY ON DAYS 6 THROUGH 18 OF GESTATION WITHOUT ANY EVIDENCE OF EMBRYOTOXICITY OR TERATOGENICITY. THE NO-OBSERVED-EFFECT DOSE IN THESE TWO EXPERIMENTAL STUDIES WAS 1000 MG/KG/DAY. AFTER ASSESSMENT OF THE POTENTIAL OF HIGH DOSES OF D-003 TO ACT ON DEVELOPING EMBRYO AND REPRODUCTION PROCESS, NO EVIDENCE SUPPORTS THE CONCLUSION THAT D-003 IS A REPRODUCTIVE AND DEVELOPMENTAL TOXICANT/TERATOGEN. (C) 2004 ELSEVIER LTD. ALL RIGHTS RESERVED.",NA,"LIPID-PEROXIDATION; HEALTHY-VOLUNTEERS; COMPOUND; TERATOGENICITY; POLICOSANOL; INHIBITION; METABOLISM; REDUCTASE; PROFILE; D003",NA,NA,"ARRUZAZABALA MD, 2003, CLIN DRUG INVEST, V23, P107, DOI 10.2165/00044011-200323020-00004; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P193, DOI 10.2165/00044011-200323030-00005; CASTANO GLADYS, 2002, DRUGS R D, V3, P337, DOI 10.2165/00126839-200203050-00008; DAWSON AB, 1926, STAIN TECHNOL, V1, P123, DOI 10.3109/10520292609115636; DOBS AS, 1993, METABOLISM, V42, P1146, DOI 10.1016/0026-0495(93)90272-P; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ R, 2001, TERATOGEN CARCIN MUT, V21, P85; GAMEZ RAFAEL, 2002, DRUGS R D, V3, P375; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; HENCK JW, 1998, TOXICOL SCI, V41, P88; HERRERA E, 2002, ENDOCRINE, V19, P43, DOI 10.1385/ENDO:19:1:43; ISHIGURO M, 1995, MOL BRAIN RES, V33, P37, DOI 10.1016/0169-328X(95)00104-Z; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; LABS DALM SA, 1998, PATENT NO. 9843631; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MINSKER DH, 1983, TERATOLOGY, V28, P449, DOI 10.1002/TERA.1420280316; MOLINA V, 2002, PROSTAG LEUKOTR ESS, V67, P19, DOI 10.1054/PLEF.2002.0376; PIEGORSCH WW, 1991, TERATOGEN CARCIN MUT, V11, P115, DOI 10.1002/TCM.1770110302; RODIER PM, 1978, HDB TERATOLOGY, V4, P397; RODRÍGUEZ MD, 2003, FOOD CHEM TOXICOL, V41, P89, DOI 10.1016/S0278-6915(02)00217-X; RODRIGUEZ MD, 1998, J APPL TOXICOL, V18, P313, DOI 10.1002/(SICI)1099-1263(1998090)18:5<313::AID-JAT513>3.0.CO;2-8; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRIGUEZ MD, 1998, EVALUACION TOXICIDAT, P31; STUCKHARDT JL, 1984, TERATOGEN CARCIN MUT, V4, P181, DOI 10.1002/TCM.1770040203; WIER PJ, 1990, DRUG INF J, V24, P395","NATL CTR SCI RES, CTR NAT PROD, AVE 25 \& 158,POB 6414, HAVANA, CUBA","PERGAMON-ELSEVIER SCIENCE LTD","ENGLISH","FOOD CHEM. TOXICOL.","ARTICLE","ISI","WOS000225252500007","FOOD CHEM TOXICOL","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"RODRÍGUEZ MD, 2004, FOOD CHEM TOXICOL","RODRÍGUEZ MD, 2004, FOOD CHEM TOXICOL"
"MUSA R;YUNOKI K;KINOSHITA M;ODA Y;OHNISHI M","MUSA R;YUNOKI K;KINOSHITA M;ODA Y;OHNISHI M","INCREASED LEVELS OF POLICOSANOL AND VERY LONGCHAIN FATTY ACIDS IN POTATO PULP FERMENTED WITH IRHIZOPUS ORYZAEI",2004,"BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY","68","2401-2404",5,"10.1271/bbb.68.2401","OHNISHI, M (CORRESPONDING AUTHOR), OBIHIRO UNIV AGR \& VET MED, DEPT BIORESOURCE SCI, OBIHIRO, HOKKAIDO 0808555, JAPAN.; OBIHIRO UNIV AGR \& VET MED, DEPT BIORESOURCE SCI, OBIHIRO, HOKKAIDO 0808555, JAPAN.; IWATE UNIV, UNITED GRAD SCH AGR SCI, MORIOKA, IWATE 0208550, JAPAN.; NATL AGR RES CTR, DEPT UPLAND AGR, KASAI, HOKKAIDO 0820071, JAPAN.","SIGNIFICANT AMOUNTS OF POLICOSANOL AND VERY LONG-CHAIN FATTY ACIDS (VLFAS) RANGING IN CARBON LENGTH FROM 22 TO 30 WERE FOUND IN THE LIPOPHILIC FRACTION OBTAINED FROM POTATO PULP FERMENTED WITH RHIZOPUS ORYZAE. IT IS BELIEVED THAT THESE COMPOUNDS WOULD HAVE ORIGINALLY BEEN PRESENT AS SUBERIN-RELATED COMPOUNDS, BUT NOT AS WAX, IN THE PERIDERM OF POTATO TUBERS AND CONCENTRATED INTO POTATO PULP DURING THE PROCESS OF STARCH PRODUCTION. MOREOVER, THE POLICOSANOL AND VLFAS EXTRACTED FROM POTATO PULP WITH ORGANIC SOLVENTS WERE FOUND TO HAVE INCREASED AFTER FERMENTATION.","FUNCTIONAL LIPIDS; VERY LONG-CHAIN FATTY ACIDS; OCTACOSANOL; POTATO; PULP; RHIZOPUS ORYZAE","TUBERS",NA,NA,"ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BERNARDS MA, 1992, PHYTOCHEMISTRY, V31, P3409, DOI 10.1016/0031-9422(92)83695-U; FAUCONNIER ML, 2003, BBA-MOL CELL BIOL L, V1633, P118, DOI 10.1016/S1388-1981(03)00105-7; FUJINO Y, 1976, CHEM PHYS LIPIDS, V17, P275, DOI 10.1016/0009-3084(76)90073-6; GRAÇA J, 2000, J AGR FOOD CHEM, V48, P5476, DOI 10.1021/JF0006123; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; ODA Y, 2003, FOOD MICROBIOL, V20, P371, DOI 10.1016/S0740-0020(02)00131-4; ODA Y, 2002, CURR MICROBIOL, V45, P1, DOI 10.1007/S00284-001-0048-Y; OHNISHI M, 1986, CEREAL CHEM, V63, P193; SAITO K, 2003, J IND MICROBIOL BIOT, V30, P440, DOI 10.1007/S10295-003-0071-Z; TAYLOR JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9","OHNISHI, M (CORRESPONDING AUTHOR), OBIHIRO UNIV AGR \& VET MED, DEPT BIORESOURCE SCI, OBIHIRO, HOKKAIDO 0808555, JAPAN","TAYLOR \& FRANCIS LTD","ENGLISH","BIOSCI. BIOTECHNOL. BIOCHEM.","ARTICLE","ISI","WOS000225672000028","BIOSCI BIOTECHNOL BIOCHEM","OBIHIRO UNIV AGR AND VET MED;OBIHIRO UNIV AGR AND VET MED;IWATE UNIV;NATL AGR RES CTR","OBIHIRO UNIV AGR AND VET MED",NA,"MUSA R, 2004, BIOSCI BIOTECHNOL BIOCHEM","MUSA R, 2004, BIOSCI BIOTECHNOL BIOCHEM1"
"ARRUZAZABALA M;MOLINA V;CARBAJAL D;MÁS R","ARRUZAZABALA ML;MOLINA V;CARBAJAL D;MÁS R","D003 AND WARFARIN INTERACTION ON THE BLEEDING TIME AND VENOUS THROMBOSIS EXPERIMENTALLY INDUCED IN RATS",2004,"JOURNAL OF MEDICINAL FOOD","7","260-263",5,"10.1089/1096620041224003","ARRUZAZABALA, ML (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NATL PROD, AVE 25 \& 158,POB 6880, HAVANA, CUBA.; NATL CTR SCI RES, CTR NATL PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ACIDS ISOLATED AND PURIFIED FROM SUGARCANE WAX, THE MAIN COMPONENT OF WHICH IS OCTACOSANOIC ACID. D-003 EXHIBITS A CHOLESTEROL-LOWERING EFFECT AS WELL AS ANTIPLATELET AND ANTITHROMBOTIC EFFECTS IN EXPERIMENTAL MODELS. WARFARIN IS A COUMARIN DERIVATIVE WITH ANTICOAGULANT ACTIVITY THAT ACTS AS A VITAMIN K ANTAGONIST. SINCE IN CLINICAL PRACTICE WARFARIN AND D-003 COULD BE ADMINISTERED TOGETHER, THE OBJECTIVE OF THIS STUDY WAS TO EVALUATE THE EFFECTS OF THE SIMULTANEOUS ADMINISTRATION OF BOTH DRUGS ON THE BLEEDING TIME AND THE VENOUS THROMBOSIS EXPERIMENTALLY INDUCED IN RATS. THE COMBINED THERAPY OF MINIMALLY EFFECTIVE DOSES OF D-003 AND WARFARIN PRODUCED AN ANTITHROMBOTIC EFFECT SIGNIFICANTLY HIGHER THAN THOSE PRODUCED BY EACH MONOTHERAPY. LIKEWISE, THE PROLONGATION OF BLEEDING TIME INDUCED BY WARFARIN WAS INCREASED BY THE SIMULTANEOUS ADMINISTRATION WITH D-003, SHOWING A SYNERGISTIC EFFECT BETWEEN BOTH DRUGS.","BLEEDING TIME; D-003; RATS; VENOUS THROMBOSIS; WARFARIN","PLATELET-AGGREGATION; POLICOSANOL; LIVER; OCTACOSANOL; METABOLISM; SALICYLATE; MUSCLE",NA,NA,"ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1998, INT J TISSUE REACT, V20, P119; ARRUZAZABALA ML, 1992, REV IBEROAMER TROMB, V5, P17; CARBAJAL D, 1994, PROSTAG LEUKOTR ESS, V50, P249, DOI 10.1016/0952-3278(94)90162-7; CASTANO G, 1996, CURR THER RES CLIN E, V57, P691, DOI 10.1016/S0011-393X(96)80074-9; DEJANA E, 1982, THROMB HAEMOSTASIS, V48, P108; FRAGA V, 1997, ARCH MED RES, V28, P355; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GONZALEZ L, 1998, PATENT NO. 982744; GRAND R, 1994, LANCET, V344, P991; HLADOVEC J, 1986, THROMB RES, V43, P539, DOI 10.1016/0049-3848(86)90073-3; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MOLINA V, 2002, PROSTAG LEUKOTR ESS, V67, P19, DOI 10.1054/PLEF.2002.0376; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; OREILLY RA, 1985, PHARMACOL BASIS THER, P1338; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1997, CURR THER RES CLIN E, V58, P26, DOI 10.1016/S0011-393X(97)80074-4; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; RONCAGLIONI MC, 1986, THROMB RES, V42, P727, DOI 10.1016/0049-3848(86)90109-X; RONCAGLIONI MC, 1988, BIOCHEM PHARMACOL, V37, P4743, DOI 10.1016/0006-2952(88)90346-2; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; VALDES S, 1996, INT J CLIN PHARM RES, V16, P67; WILSON JM, 1999, CLIN CARDIOL, V22, P687, DOI 10.1002/CLC.4960221103","ARRUZAZABALA, ML (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NATL PROD, AVE 25 \& 158,POB 6880, HAVANA, CUBA","MARY ANN LIEBERT, INC","ENGLISH","J. MED. FOOD","ARTICLE","ISI","WOS000223942000023","J MED FOOD","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"ARRUZAZABALA ML, 2004, J MED FOOD","ARRUZAZABALA ML, 2004, J MED FOOD"
"HARGROVE J;GREENSPAN P;HARTLE D","HARGROVE JL;GREENSPAN P;HARTLE DK","NUTRITIONAL SIGNIFICANCE AND METABOLISM OF VERY LONG CHAIN FATTY ALCOHOLS AND ACIDS FROM DIETARY WAXES",2004,"EXPERIMENTAL BIOLOGY AND MEDICINE","229","215-226",142,"10.1177/153537020422900301","UNIV GEORGIA, DEPT FOOD \& NUTR, DAWSON HALL, ATHENS, GA 30602 USA.; UNIV GEORGIA, DEPT FOOD \& NUTR, ATHENS, GA 30602 USA.; UNIV GEORGIA, DEPT PHARMACEUT \& BIOMED SCI, ATHENS, GA 30602 USA.","VERY LONG CHAIN FATTY ALCOHOLS OBTAINED FROM PLANT WAXES AND BEESWAX HAVE BEEN REPORTED TO LOWER PLASMA CHOLESTEROL IN HUMANS. THIS REVIEW DISCUSSES NUTRITIONAL OR REGULATORY EFFECTS PRODUCED BY WAX ESTERS OR ALIPHATIC ACIDS AND ALCOHOLS FOUND IN UNREFINED CEREAL GRAINS, BEESWAX, AND MANY PLANT-DERIVED FOODS. REPORTS SUGGEST THAT 5-20 MG PER DAY OF MIXED C24-C34 ALCOHOLS, INCLUDING OCTACOSANOL AND TRIACONTANOL, LOWER LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL BY 21\%-29\% AND RAISE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL BY 8\%-15\%. WAX ESTERS ARE HYDROLYZED BY A BILE SALT-DEPENDENT PANCREATIC CARBOXYL ESTERASE, RELEASING LONG CHAIN ALCOHOLS AND FATTY ACIDS THAT ARE ABSORBED IN THE GASTROINTESTINAL TRACT. STUDIES OF FATTY ALCOHOL METABOLISM IN FIBROBLASTS SUGGEST THAT VERY LONG CHAIN FATTY ALCOHOLS, FATTY ALDEHYDES, AND FATTY ACIDS ARE REVERSIBLY INTERCONVERTED IN A FATTY ALCOHOL CYCLE. THE METABOLISM OF THESE COMPOUNDS IS IMPAIRED IN SEVERAL INHERITED HUMAN PEROXISOMAL DISORDERS, INCLUDING ADRENOLEUKODYSTROPHY AND SJOGREN-LARSSON SYNDROME. REPORTS ON DIETARY MANAGEMENT OF THESE DISEASES CONFIRM THAT VERY LONG CHAIN FATTY ACIDS (VLCFA) ARE NORMAL CONSTITUENTS OF THE HUMAN DIET AND ARE SYNTHESIZED ENDOGENOUSLY. CONCENTRATIONS OF VLCFA IN BLOOD PLASMA INCREASE DURING FASTING AND WHEN CHILDREN ARE PLACED ON KETOGENIC DIETS TO SUPPRESS SEIZURES. EXISTING DATA SUPPORT THE HYPOTHESIS THAT VLCFA EXERT REGULATORY ROLES IN CHOLESTEROL METABOLISM IN THE PEROXISOME AND ALSO ALTER LDL UPTAKE AND METABOLISM.","VERY LONG CHAIN FATTY ACIDS; POLICOSANOL; OCTACOSANOL; WAX ESTERS; CHOLESTEROL","ACTIVATED RECEPTOR-ALPHA; X-LINKED ADRENOLEUKODYSTROPHY; SJOGREN-LARSSON-SYNDROME; DENSITY-LIPOPROTEIN METABOLISM; CARBOXYL ESTER; LIPASE; SUGAR-CANE RIND; EPICUTICULAR WAX; II HYPERCHOLESTEROLEMIA; ALDEHYDE DEHYDROGENASE; CULTURED FIBROBLASTS",NA,NA,"AFINSLATER RB, 1960, FED PROC, V19, P18; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ASADI A, 2002, J BIOL CHEM, V277, P18494, DOI 10.1074/JBC.M111503200; AVATO P, 1990, PHYTOCHEMISTRY, V29, P1571, DOI 10.1016/0031-9422(90)80124-Y; BELDING RD, 1998, J AM SOC HORTIC SCI, V123, P348, DOI 10.21273/JASHS.123.3.348; BELTZ SD, 1993, CLIN PHARMACY, V12, P900; BENSON AA, 1972, BIOCHEM J, V128, PP10, DOI 10.1042/BJ1280010P; BERMAN P, 1981, S AFR MED J, V59, P791; BIANCHI G, 1979, CEREAL CHEM, V56, P491; BIANCHI G, 1989, PHYTOCHEMISTRY, V28, P165, DOI 10.1016/0031-9422(89)85031-9; BIANCHI G, 1979, EXPERIENTIA, V35, P1417, DOI 10.1007/BF01962755; BIANCHI G., 1995, WAXES: CHEMISTRY, MOLECULAR BIOLOGY AND FUNCTIONS, P175; BOLATTUKUDY PE, 1976, CHEM BIOCH NATURAL W, P459; BREMER J, 2001, PROG LIPID RES, V40, P231, DOI 10.1016/S0163-7827(01)00004-2; BREWER HB, 2003, AM J CARDIOL, V91, P3E, DOI 10.1016/S0002-9149(02)03382-9; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CAO Y, 1998, GENOMICS, V49, P327, DOI 10.1006/GENO.1998.5268; CASTANO G, 1995, CURR THER RES CLIN E, V56, P819, DOI 10.1016/0011-393X(95)85065-1; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CASTAÑO G, 2001, INT J CLIN PHARM RES, V21, P43; CHANG C, 1997, GENOMICS, V40, P80, DOI 10.1006/GENO.1996.4547; CHINETTI G, 2003, CIRC RES, V92, P212, DOI 10.1161/01.RES.0000053386.46813.E9; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; CURETON TK, 1972, PHYSL EFFECTS WHEAT, P525; FONTANI G, 2000, NEUROPSYCHOBIOLOGY, V41, P158, DOI 10.1159/000026649; GIER HT, 1972, PHYSL EFFECTS WHEAT, P298; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HANSEN IA, 1965, P SOC EXP BIOL MED, V120, P527, DOI 10.3181/00379727-120-30581; HIHI AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/S00018-002-8467-X; HILL K, 1989, AM SCI, V77, P436; HUI DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/JLR.R200013-JLR200; HWANG KT, 2002, J AM OIL CHEM SOC, V79, P521, DOI 10.1007/S11746-002-0515-5; ICHIHARA K, 1981, J BIOCHEM, V89, P1821, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A133383; ICHIHARA K, 1986, BIOCHIM BIOPHYS ACTA, V878, P412, DOI 10.1016/0005-2760(86)90250-X; ITO S, 1983, CEREAL CHEM, V60, P252; JENKS MA, 2000, PHYTOCHEMISTRY, V54, P577, DOI 10.1016/S0031-9422(00)00153-9; JUMP DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; KABIR Y, 1994, NAHRUNG, V38, P373; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; KAISER R, 1994, FEBS LETT, V337, P123, DOI 10.1016/0014-5793(94)80257-2; KATO S, 1995, BRIT J NUTR, V73, P433, DOI 10.1079/BJN19950045; KAWAHARA K, 1988, J NUTR SCI VITAMINOL, V34, P633, DOI 10.3177/JNSV.34.633; KAWANISHI K, 1991, J AM OIL CHEM SOC, V68, P869, DOI 10.1007/BF02660604; KELSON TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; KEMP S, 2001, HUM MUTAT, V18, P499, DOI 10.1002/HUMU.1227; KISHIMOTO Y, 1980, BIOCHEM BIOPH RES CO, V96, P69, DOI 10.1016/0006-291X(80)91182-1; KOLATTUK.PE, 1966, J NUTR, V90, P167, DOI 10.1093/JN/90.2.167; KOLATTUKUDY PE, 1970, LIPIDS, V5, P259, DOI 10.1007/BF02532477; LEE TC, 1976, J BIOL CHEM, V254, P2892; LEVIN E, 1962, PATENT NO. 3031376; LIN QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/BI9816094; LINDSTROM MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P178, DOI 10.1016/0005-2760(88)90029-X; MANDEL H, 1995, J LIPID RES, V36, P1385; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MCGUINNESS MC, 2003, MOL CELL BIOL, V23, P744, DOI 10.1128/MCB.23.2.744-753.2003; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MORIYA-SATO A, 2000, BIOCHEM BIOPH RES CO, V279, P62, DOI 10.1006/BBRC.2000.3897; MOROHASHI K, 1983, J BIOCHEM, V93, P413, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A134195; MOSER AB, 1999, ANN NEUROL, V45, P100, DOI 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U; MOSER HW, 1995, ANNU REV NUTR, V15, P379, DOI 10.1146/ANNUREV.NU.15.070195.002115; MOSER HW, 1989, METABOLIC BASIS INHE, P1511; MOSER HW, 1983, PEDIATR RES, V17, PA293; MOSER HW, 1995, METABOLIC MOL BASES, P2325; MOYNA P, 1985, PHYTOCHEMISTRY, V24, P179, DOI 10.1016/S0031-9422(00)80833-X; MUOIO DM, 2002, DIABETES, V51, P901, DOI 10.2337/DIABETES.51.4.901; NOA M, 1995, J PHARM PHARMACOL, V47, P289, DOI 10.1111/J.2042-7158.1995.TB05797.X; NOTA G, 1999, J AGR FOOD CHEM, V47, P202, DOI 10.1021/JF980648J; ORTENSI G, 1997, CURR THER RES CLIN E, V58, P390, DOI 10.1016/S0011-393X(97)80099-9; PAWAR A, 2002, J BIOL CHEM, V277, P39243, DOI 10.1074/JBC.M206170200; PLACE AR, 1992, AM J PHYSIOL, V263, PR464, DOI 10.1152/AJPREGU.1992.263.3.R464; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; POULOS A, 1993, LIPIDS, V28, P97, DOI 10.1007/BF02535771; POULOS A, 1992, ADV EXP MED BIOL, V318, P331; PURDY SJ, 1963, PROC R SOC SER B-BIO, V158, P544, DOI 10.1098/RSPB.1963.0063; PUTNAM J., 2002, FOODREVIEW, V25, P2; RADER DJ, 2003, AM J CARDIOL, V91, P18E, DOI 10.1016/S0002-9149(02)03384-2; RADLER F, 1965, AUST J CHEM, V18, P1059, DOI 10.1071/CH9651059; RIZZO WB, 1989, J PEDIATR-US, V115, P228, DOI 10.1016/S0022-3476(89)80070-8; RIZZO WB, 2001, CHEM-BIOL INTERACT, V130, P297, DOI 10.1016/S0009-2797(00)00273-8; RIZZO WB, 1998, MOL GENET METAB, V65, P63, DOI 10.1006/MGME.1998.2728; RIZZO WB, 2000, J LIPID RES, V41, P1077; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; ROSENBERGER TA, 2002, J LIPID RES, V43, P59; SARGENT JR, 1978, SCI PROGRESS-UK, V65, P437; SHEPHERD J, 1993, POSTGRAD MED J, V69, PS34; SHEPHERD T, 1997, PHYTOCHEMISTRY, V46, P83, DOI 10.1016/S0031-9422(97)00272-0; SHO H, 1981, J NUTR SCI VITAMINOL, V27, P463, DOI 10.3177/JNSV.27.463; SHO H, 1983, J NUTR SCI VITAMINOL, V29, P313, DOI 10.3177/JNSV.29.313; SHO H, 1984, J NUTR SCI VITAMINOL, V30, P553, DOI 10.3177/JNSV.30.553; SINGH I, 1985, ARCH BIOCHEM BIOPHYS, V236, P418, DOI 10.1016/0003-9861(85)90642-3; STAHL A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; STAHL A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; SUTTER E, 1984, CAN J BOT, V62, P74, DOI 10.1139/B84-012; TAKAHASHI N, 1988, BIOCHIM BIOPHYS ACTA, V963, P243, DOI 10.1016/0005-2760(88)90287-1; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; TULLOCH AP, 1980, CAN J BOT, V58, P2602, DOI 10.1139/B80-302; TULLOCH AP, 1972, J AM OIL CHEM SOC, V49, P696, DOI 10.1007/BF02609202; TULLOCH AP, 1971, CHEM PHYS LIPIDS, V6, P235, DOI 10.1016/0009-3084(71)90063-6; TULLOCH AP, 1981, CAN J BOT, V59, P1213, DOI 10.1139/B81-166; TVRDIK P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/JCB.149.3.707; VANDUYN MA, 1984, AM J CLIN NUTR, V40, P277, DOI 10.1093/AJCN/40.2.277; WANDERS RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; WANG YW, 2003, LIPIDS, V38, P165, DOI 10.1007/S11745-003-1047-3; WEINHOFER I, 2002, HUM MOL GENET, V11, P2701, DOI 10.1093/HMG/11.22.2701; ZIOUZENKOVA O, 2003, P NJATL ACAD SCI US, V26, P26","UNIV GEORGIA, DEPT FOOD \& NUTR, DAWSON HALL, ATHENS, GA 30602 USA","SAGE PUBLICATIONS LTD","ENGLISH","EXP. BIOL. MED.","REVIEW","ISI","WOS000222321800001","EXP BIOL MED","UNIV GEORGIA;UNIV GEORGIA;UNIV GEORGIA","UNIV GEORGIA",NA,"HARGROVE JL, 2004, EXP BIOL MED","HARGROVE JL, 2004, EXP BIOL MED"
"GÁMEZ R;MÁS R;MENÉNDEZ R;GARCÍA H;GONZÁLEZ J;PÉREZ Y;GOICOCHEA E","GÁMEZ R;MÁS R;MENÉNDEZ R;GARCÍA H;GONZÁLEZ J; PÉREZ Y;GOICOCHEA E","EFFECTS OF CHRONIC ADMINISTRATION OF D003 A MIXTURE OF SUGAR CANE WAX HIGH MOLECULAR ACIDS IN BEAGLE DOGS",2004,"DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH","30","75-88",9,NA,"NATL CTR SCI RES, CTR NAT PROD, BOX 6990 6880, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF HIGH MOLECULAR WEIGHT ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGAR CANE WAX (SACCHARUM OFFICINARUM, Q WITH CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS. PREVIOUS STUDIES, INCLUDING A 6-MONTH STUDY CONDUCTED IN RATS, HAVE SHOWN NO D-003-RELATED TOXICITY. THE PRESENT STUDY WAS UNDERTAKEN TO INVESTIGATE THE EFFECTS OF D-003 ORALLY ADMINISTERED FOR 9 MONTHS IN BEAGLE DOGS. THE ANIMALS WERE RANDOMLY DISTRIBUTED IN THREE GROUPS: A CONTROL GROUP RECEIVING THE VEHICLE ONLY AND TWO GROUPS ORALLY ADMINISTERED D-003 (200 AND 400 MG/KG). BODY WEIGHT GAIN, FOOD CONSUMPTION AND CLINICAL SIGNS WERE CONTROLLED THROUGHOUT THE STUDY. THE EFFECTS OF D-003 ON COLLAGEN-INDUCED PLATELET AGGREGATION, BLEEDING TIME (B T) AND COAGULATION PARAMETERS (PROTHROMBIN TIME AND KAOLIN-ACTIVATED THROMBOPLASTIN TIME) WERE ALSO INVESTIGATED. MOST BLOOD BIOCHEMISTRY AND HEMATOLOGICAL PARAMETERS WERE ASSESSED AT BASELINE AND AFTER 6 AND 9 MONTHS OF TREATMENT, WHILE TOTAL CHOLESTEROL (TC), TRIGLYCERIDES, PLATELET AGGREGATION, B T AND COAGULATION PARAMETERS WERE DETERMINED AT BASELINE AND AFTER 9 MONTHS OF TREATMENT. AT STUDY COMPLETION, THE ANIMALS WERE SACRIFICED. D-003 AT A DOSE OF 200 AND 400 MG/KG SIGNIFICANTLY REDUCED TC (P < 0.05), SIGNIFICANTLY INHIBITED PLATELET AGGREGATION AND INCREASED BT COMPARED WITH LEVELS IN CONTROLS. DATA ANALYSES OF BODY WEIGHT GAIN, FOOD CONSUMPTION, CLINICAL OBSERVATIONS, THE REMAINING BLOOD BIOCHEMISTRY AND HEMATOLOGY INDICATORS (INCLUDING COAGULATION PARAMETERS, ORGAN WEIGHT RATIOS AND HISTOPATHOLOGICAL FINDINGS) SHOWED NO TRENDS WITH D-003 DOSES OR SIGNIFICANT DIFFERENCES BETWEEN CONTROL ANIMALS AND TREATED GROUPS. IN CONCLUSION, D-003 ADMINISTERED FOR 9 MONTHS TO BEAGLE DOGS INDUCED THE EXPECTED EFFECTS WITH NO EVIDENCE OF DRUG-RELATED TOXICITY.",NA,"LIPID PROFILE; POLICOSANOL; ANTIPLATELET; TOXICITY; BLOOD; CARCINOGENICITY; PRAVASTATIN; COMPOUND",NA,NA,"ALEMAN CL, 1994, TERATOGEN CARCIN MUT, V14, P239, DOI 10.1002/TCM.1770140505; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/BMJ.308.6921.81; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANONYMOUS, 1993, LAB ANIM, V27, P1; ANONYMOUS, 1997, ICH HARMONISED TRIPA; ARRUZAZABALA MD, 2003, CLIN DRUG INVEST, V23, P107, DOI 10.2165/00044011-200323020-00004; BHATNAGAR D, 1998, PHARMACOL THERAPEUT, V79, P205, DOI 10.1016/S0163-7258(98)00018-7; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927B0; CASLANO G, 2002, DRUGS R\&D, V3, P337; CASTAÑO G, 2003, CLIN DRUG INVEST, V23, P193, DOI 10.2165/00044011-200323030-00005; CHHABRA RS, 1990, ENVIRON HEALTH PERSP, V86, P313, DOI 10.2307/3430970; COLLINS R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DAVENPORT RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; DIEZ-TEJEDOR E, 1995, NEUROLOGIA, V10 SUPPL 2, P48; EPA, 1996, HLTH EFF TEST GUID O; EVANS LG, 1993, EXPT TOXICOLOGY BASI, P119; FALK E, 1995, AM J CARDIOL, V75, PB5, DOI 10.1016/0002-9149(95)80003-B; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ R, 2001, TERATOGEN CARCIN MUT, V21, P85; GAMEZ RAFAEL, 2002, DRUGS R D, V3, P375; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; GERSON RJ, 1989, AM J MED, V87, PS28, DOI 10.1016/S0002-9343(89)80596-0; GONZALEZ L, 1998, PATENT NO. 982744; HAGGERTY GC, 1992, ANIMAL MODELS TOXICO, P567; LANDSDOWN AB, 1993, EXPT TOXICOLOGY BASI, P101; MATSUZAWA T, 1993, J VET MED SCI, V55, P351, DOI 10.1292/JVMS.55.351; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MOLINA V, 2002, PROSTAG LEUKOTR ESS, V67, P19, DOI 10.1054/PLEF.2002.0376; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; PEDERSEN TR, 1994, LANCET, V344, P1383; REHG JE, 1998, LAB ANIM SCI, V48, P438; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHAFER AI, 1996, AM J MED, V101, P199, DOI 10.1016/S0002-9343(96)80077-5; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; VOSS G, 1970, TOXICOL APPL PHARM, V16, P764, DOI 10.1016/0041-008X(70)90082-7; WOLFORD ST, 1986, J TOXICOL ENV HEALTH, V18, P161, DOI 10.1080/15287398609530859","NATL CTR SCI RES, CTR NAT PROD, BOX 6990 6880, HAVANA, CUBA","BIOSCIENCE EDIPRINT INC","ENGLISH","DRUG EXP. CLIN. RES","ARTICLE","ISI","WOS000222647200005","DRUG EXP CLIN RES","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"GÁMEZ R, 2004, DRUG EXP CLIN RES","GÁMEZ R, 2004, DRUG EXP CLIN RES"
"HAMILL F;APIO S;MUBIRU N;MOSANGO M;BUKENYA-ZIRABA ;R R;MAGANYI O;SOEJARTO D","HAMILL FA;APIO S;MUBIRU NK;MOSANGO M;BUKENYA-ZIRABA; R;MAGANYI OW;SOEJARTO DD","TRADITIONAL HERBAL DRUGS OF SOUTHERN UGANDA PART III ISOLATION AND METHODS FOR PHYSICAL CHARACTERIZATION OF BIOACTIVE ALKANOLS FROM IRUBUS APETALUSI",2003,"JOURNAL OF ETHNOPHARMACOLOGY","87","15-19",11,"10.1016/S0378-8741(03)00097-7","SW FDN BIOMED RES, DEPT VIROL \& IMMUNOL, POB 760549, SAN ANTONIO, TX 78245 USA.; SW FDN BIOMED RES, DEPT VIROL \& IMMUNOL, SAN ANTONIO, TX 78245 USA.; MINIST HLTH, NAT CHEMOTHERAPEUT RES LAB, KAMPALA, UGANDA.; MAKERERE UNIV, DEPT BOT, KAMPALA, UGANDA.; UNIV ILLINOIS, COLL PHARM, DEPT MED CHEM \& PHARMACOGNOSY, PROGRAM COLLABORAT RES PHARMACEUT SCI, CHICAGO, IL 60612 USA.","THE EAST AFRICAN PLANT RUBUS APETALUS POIR. WAS COLLECTED AS A COMPONENT OF AN ETHNOBOTANICAL SURVEY IN SOUTHERN UGANDA. NO PHYTOCHEMICAL INVESTIGATIONS OF THIS PLANT HAVE BEEN FOUND IN THE LITERATURE. PRELIMINARY ANTIMICROBIAL SUSCEPTIBILITY TESTS PERFORMED IN UGANDA INDICATED BIOLOGICAL ACTIVITY AGAINST SEVERAL BACTERIAL AND ONE FUNGAL HUMAN PATHOGEN. BULK RE-COLLECTION OF RUBUS APETALUS WAS ACCOMPLISHED AND CRUDE EXTRACTION PERFORMED IN PREPARATION FOR FURTHER TESTING. TWO CHEMICAL FRACTIONS OF THE CRUDE EXTRACT WERE ACTIVE IN THE ANTIMICROBIAL SUSCEPTIBILITY ASSAY. FRACTIONATION OF ONE OF THE ACTIVE CRUDE FRACTIONS LED TO THE ISOLATION AND ELUCIDATION OF A MIXTURE OF RELATED COMPOUNDS THAT EXHIBIT ANTIMICROBIAL ACTIVITY AGAINST STAPHYLOCOCCUS AUREUS (MIC = 62 MUG/ML), STREPTOCOCCUS,FAECALIS (16 MUG/ML) AND CANDIDA ALBICANS (32 MUG/ML). (C) 2003 ELSEVIER SCIENCE IRELAND LTD. ALL RIGHTS RESERVED.","TRADITIONAL HERBAL DRUGS; UGANDA; ANTIMICROBIAL ACTIVITY","POLICOSANOL; HYPERCHOLESTEROLEMIA",NA,NA,"ANONYMOUS, 1995, MANUAL CLIN MICROBIO; ARRUZAZABALA ML, 1997, PHARMACOL RES, V36, P293, DOI 10.1006/PHRS.1997.0201; BHAKUNI R S, 1987, INDIAN DRUGS, V24, P272; BRUNETON J., 1995, PHARMACOGNOSY PHYTOC; CASTAÑO G, 2001, J GERONTOL A-BIOL, V56, PM186, DOI 10.1093/GERONA/56.3.M186; GOUNI-BERTHOLD I, 2002, AM HEART J, V143, P356, DOI 10.1067/MHJ.2002.119997; HAMILL FA, 2003, J ETHNOPHARMACOL, V84, P57, DOI 10.1016/S0378-8741(02)00289-1; HAMILL FA, 2000, J ETHNOPHARMACOL, V70, P281, DOI 10.1016/S0378-8741(00)00180-X; HAMILL FA, 2001, THESIS U ILLINOIS CH; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; NOA M, 1996, J PHARM PHARMACOL, V48, P306, DOI 10.1111/J.2042-7158.1996.TB05922.X; NOA M, 1997, J PHARM PHARMACOL, V49, P999, DOI 10.1111/J.2042-7158.1997.TB06031.X; POUCHERT C.J., 1983, ALDRICH LIB NMR SPEC, V2ND; PRETSCH E., 1989, TABLES SPECTRAL DATA; TYLER VE, 1997, HERBS CHOICE; WALL ME, 1996, PHYTOMEDICINE, V3, P281, DOI 10.1016/S0944-7113(96)80067-5; 1990, M7A2 NCCLS; 1993, M7 A2 NCCLS","SW FDN BIOMED RES, DEPT VIROL \& IMMUNOL, POB 760549, SAN ANTONIO, TX 78245 USA","ELSEVIER IRELAND LTD","ENGLISH","J. ETHNOPHARMACOL.","ARTICLE","ISI","WOS000183590200004","J ETHNOPHARMACOL","SW FDN BIOMED RES;SW FDN BIOMED RES;NAT CHEMOTHERAPEUT RES LAB;MAKERERE UNIV;UNIV ILLINOIS","SW FDN BIOMED RES",NA,"HAMILL FA, 2003, J ETHNOPHARMACOL","HAMILL FA, 2003, J ETHNOPHARMACOL"
"GARCÍA A;GARCÍA M;RIBAS M;BROWN A","GARCÍA A;GARCÍA MA;RIBAS M;BROWN A","RECOVERY OF SUGAR CANE CUTICULAR WAX BY MECHANICAL SEPARATION AND SOLVENT EXTRACTION",2003,"GRASAS Y ACEITES","54","169-174",2,NA,"GARCÍA, A (CORRESPONDING AUTHOR), INST CUBANO INVEST DERIVADOS CANA AZUCAR, VIA BLANCA 804, HAVANA 11000, CUBA.; INST CUBANO INVEST DERIVADOS CANA AZUCAR, HAVANA 11000, CUBA.","THE INDUSTRIAL EXPERIENCE IN THE EXTRACTION AND REFINING OF SUGAR CANE CRUDE WAX IN CUBA FROM FILTER MUD CONFIRMS THE FEASIBILITY OF SUCH TECHNOLOGIES FOR THE PRODUCTION OF WAXES ADDRESSED TO THE PHARMACEUTICAL MARKET, TO HIGH PRICE DRUGS SUCH AS POLICOSANOL. WITH THE AIM OF DEVELOP A NEW TECHNOLOGY FOR THE RECOVERY THE NATURAL WAX THAT COVERS THE CANE STALK, THE PRESENT PAPER SHOWS A NEW ACHIEVEMENT, THE RECOVERY OF THE WAX THAT OCCURS IN THE FRACTION DERMAX, A CUTICULAR LAYER THAT REMAINS AFTER THE MECHANICAL PROCESSING OF THE SUGAR CANE IN A BLADE SEPARATOR INTERCANE(R), 5 TON/H, WHICH WAS TESTED AT THE SUGAR MILL. LA REFORMA, VERACRUZ STATE IN MEXICO. TWO EXTRACTION SYSTEMS, SOXHLET AND SOXTEC WERE TESTED AND THREE DIFFERENT KIND OF ORGANIC SOLVENTS WERE EVALUATED. THE WAXY MATERIAL WAS ANALYSED BY GAS CHROMATOGRAPHY. A BRIEF DATA ABOUT THE CHEMICAL COMPOSITION OF THE NEW QUALITY OF WAX IS DISCLOSED.","CANE WAX; SUGAR CANE WAX; TILBY SEPARATOR; VEGETABLE WAX",NA,NA,NA,"BOURZUTSCHKY H, 1985, APPL TIBY CANE SEPAR; GARCIA A, 1986, CERA CACHAZA IND DER; GARCIAPATTERSON A, 1996, J PINEAL RES, V20, P1, DOI 10.1111/J.1600-079X.1996.TB00231.X; HONIG P, 1978, LIPIDOS CANA AZUCAR; *INICA, 1993, EST PROV INV CAN AZ; MEADE S, 1977, CERA CAN AZUCAR MANA, P24; ROSS FB, 1987, ROSS WAXES; TAKAMURA Y, 1991, 2 S CAN AZ OK FEBR","GARCÍA, A (CORRESPONDING AUTHOR), INST CUBANO INVEST DERIVADOS CANA AZUCAR, VIA BLANCA 804, HAVANA 11000, CUBA","INST GRASA SUS DERIVADOS","SPANISH","GRASAS ACEITES","ARTICLE","ISI","WOS000186569700009","GRASAS ACEITES","INST CUBANO INVEST DERIVADOS CANA AZUCAR;INST CUBANO INVEST DERIVADOS CANA AZUCAR","INST CUBANO INVEST DERIVADOS CANA AZUCAR",NA,"GARCÍA A, 2003, GRASAS ACEITES","GARCÍA A, 2003, GRASAS ACEITES1"
"ARRUZAZABALA M;CARBAJAL D;MAS R;MOLINA V;CASTAÑO G;GÁMEZ R","ARRUZAZABALA MD;CARBAJAL D;MAS R;MOLINA V;CASTAÑO G;GÁMEZ R","EFFECTS OF D003 A NEW COMPOUND PURIFIED FROM SUGARCANE WAX ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS A RANDOMISED DOUBLEBLIND CLINICAL STUDY",2003,"CLINICAL DRUG INVESTIGATION","23","107-118",30,"10.2165/00044011-200323020-00004","MAS, R (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6880, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.; MED SURG RES CTR, HAVANA, CUBA.","BACKGROUND: D-003 IS A MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGARCANE WAX WITH EXPERIMENTALLY DEMONSTRATED ANTIPLATELET EFFECTS. D-003 SHOWS HYPOCHOLESTEROLAEMIC EFFECTS IN RABBITS AND HEALTHY VOLUNTEERS, LOWERING SERUM TOTAL CHOLESTEROL (TC) AND LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C), BUT INCREASING HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C). OBJECTIVE: TO INVESTIGATE THE EFFECTS OF D-003 ADMINISTERED FOR 10 DAYS ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS. PARTICIPANTS: HEALTHY MEN AND WOMEN AGED 20-55 YEARS. METHODS: THE PRESENT DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY INVESTIGATED THE EFFECTS OF D-003 (5, 10 AND 20 MG/DAY), ON PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID (AA) [0.75 AND 1.5 MMOL/L], COLLAGEN (1 MG/L) AND ADENOSINE DIPHOSPHATE (ADP) [1 AND 2 MUMOL/L]. THE REVERSIBILITY OF THE EFFECTS WAS ALSO INVESTIGATED. FORTY-ONE SUBJECTS WERE RANDOMISED TO RECEIVE PLACEBO OR D-003 AT 5, 10 AND 20 MG/DAY FOR 10 DAYS FOLLOWED BY A WASHOUT PERIOD OF 7 DAYS. AT BASELINE AND AFTER ACTIVE TREATMENT AND WASHOUT COMPLETION, PLATELET AGGREGATION, LIPID PROFILE AND SAFETY INDICATORS WERE ASSESSED. RESULTS: D-003 SIGNIFICANTLY, MARKEDLY AND REVERSIBLY INHIBITED PLATELET AGGREGATION INDUCED BY AA 0.75 AND 1.5 MMOL/L IN A DOSE-DEPENDENT MANNER. D-003 AT 10 MG/DAY SIGNIFICANTLY INHIBITED (P < 0.05) AGGREGATION INDUCED BY AA 0.75 MMOL/L FROM 60.4-21.0\% AND THAT INDUCED BY AA 1.5 MMOL/L FROM 61.5-26.8\%. THE DOSAGE OF 20 MG/DAY INHIBITED PLATELET AGGREGATION INDUCED BY AA 0.75 MMOL/L FROM 57.2-11.2\%, AND PLATELET AGGREGATION INDUCED BY AA 1.5 MMOL/L FROM 65.1-21.6\%. D-003 AT 10 AND 20 MG/DAY ALSO INHIBITED PLATELET AGGREGATION INDUCED BY COLLAGEN I MG/L, THE EFFECT BEING MODERATE, NOT DOSE RELATED AND REVERSIBLE AFTER WASHOUT. PLATELET AGGREGATION INDUCED BY ADP AND COAGULATION TIME WERE UNAFFECTED BY THE TREATMENT. D-003 AT 5 MG/DAY WAS INEFFECTIVE IN INHIBITING PLATELET AGGREGATION. TIC AND TRIGLYCERIDES REMAINED UNCHANGED AFTER THERAPY. AS WAS EXPECTED FOR SUCH A SHORT DURATION OF ADMINISTRATION. NEVERTHELESS, D-003 (10 AND 20 MG/DAY) SIGNIFICANTLY (P < 0.05 VS BASELINE AND PLACEBO) RAISED HDL-C BY 20\%, AN EFFECT THAT WAS NOT DOSE DEPENDENT AND WAS PARTIALLY REVERSIBLE AFTER WASHOUT. AS A CONSEQUENCE, FINAL VALUES OF LDL-C WERE LOWER (P < 0.05) IN THE 20 MG/DAY GROUP THAN IN THE PLACEBO GROUP. NO SIGNIFICANT CHANGES IN LIPID PROFILES OCCURRED WITH PLACEBO. NO DRUG-RELATED CHANGES IN SAFETY INDICATORS WERE OBSERVED. FOUR SUBJECTS. ONE FROM EACH GROUP, WITHDREW FROM THE STUDY, NONE BECAUSE OF ADVERSE EVENTS (AES). NO PATIENTS REPORTED AES DURING THE STUDY. CONCLUSIONS: D-003 AT 10 AND 20 MG/DAY FOR 10 DABS SIGNIFICANTLY INHIBITED AA- AND COLLAGEN-INDUCED PLATELET AGGREGATION, WITHOUT CHANGES IN ADP-INDUCED PLATELET AGGREGATION OR COAGULATION TIME. THE EFFECT,, ON AA-INDUCED AGGREGATION WERE MARKED, DOSE DEPENDENT AND REVERSIBLE. WHEREAS THE EFFECTS ON COLLAGEN-INDUCED AGGREGATION WERE MODERATE AND NOT DOSE DEPENDENT. D-003 ( 10 AND 20 MG/DAY) ALSO SIGNIFICANTLY BUT NOT DOSE DEPENDENTLY RAISED HDL-C, D-003 WAS WELL TOLERATED, WITH NO AES BEING REPORTED AND NO CHANGES IN SAFETY INDICATORS BEING OBSERVED. THE EFFECTS DESCRIBED SUGGEST THAT D-003 IS A PROMISING AGENT WITH CONCOMITANT ANTIPLATELET AND LIPID-PROFILE MODIFYING EFFECTS. AND IS POTENTIALLY USEFUL FOR THE TREATMENT AND/OR PREVENTION OF ATHEROTHROMBOTIC DISORDERS. CLINICAL INVESTIGATION OF D-003 IS JUSTIFIED AND FURTHER STUDIES ARE NEEDED TO DEMONSTRATE SUCH A HYPOTHESIS.",NA,"HIGH-DENSITY-LIPOPROTEIN; ADENOSINE-DIPHOSPHATE; ANTITHROMBOTIC AGENTS; THROMBOXANE-A2; ANTIPLATELET; POLICOSANOL; CHOLESTEROL; ASPIRIN",NA,NA,"ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/BMJ.308.6921.81; AVIRAM M, 1998, INT CONGR SER, V1155, P483; AWIRY EH, 2000, CIRCULATION, V101, P1206; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927B0; BROWN MS, 1996, SCIENCE, V272, P629, DOI 10.1126/SCIENCE.272.5262.629; CAIRNS JA, 1995, CHEST, V108, PS380, DOI 10.1378/CHEST.108.4\_SUPPLEMENT.380S; CASTANO G, 2002, IN PRESS DRUGS R D, V3; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; COUKELL AJ, 1997, DRUGS, V54, P745, DOI 10.2165/00003495-199754050-00006; EMMS H, 1986, BRIT J PHARMACOL, V87, P109, DOI 10.1111/J.1476-5381.1986.TB10162.X; FALK E, 1995, AM J CARDIOL, V75, PB5, DOI 10.1016/0002-9149(95)80003-B; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ R, 2001, IN PRESS TERATOG CAR; GAMEZ R, IN PRESS DRUGS R D; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; GENT M, 1996, LANCET, V348, P1329, DOI 10.1016/S0140-6736(96)09457-3; GONZALEZ L, 1998, PATENT NO. 982744; HALLER H, 1997, DRUGS, V53, P1, DOI 10.2165/00003495-199700531-00003; HASSAN M, 2001, CURR THER RES CLIN E, V62, P676, DOI 10.1016/S0011-393X(01)80075-8; KAWAI T, 1973, BLOOD COAGULATION; LUOMA PV, 1997, PHARMACOL TOXICOL, V81, P57, DOI 10.1111/J.1600-0773.1997.TB00032.X; LUSCHER TF, 1997, CLIN CARDIOL, V20, P3; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MCTAVISH D, 1990, DRUGS, V40, P238, DOI 10.2165/00003495-199040020-00006; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENENDEZ R, IN PRESS CAN J PHYSL; MENENDEZ R, 2000, ATHEROSCLEROSIS, V151, P131; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; MOLINA V, 2002, IN PRESS PROSTAGL LE; MURRAY CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; PATRONO C, 2001, CHEST, V119, P39S, DOI 10.1378/CHEST.119.1\_SUPPL.39S; SCHAFER AI, 1996, AM J MED, V101, P199, DOI 10.1016/S0002-9343(96)80077-5; SEIGLER L, 1981, CLIN CHEM, V27, P838; SHAH PK, 1997, CLIN CARDIOL S2, V20; SHERMAN DG, 1995, CHEST, V108, PS444, DOI 10.1378/CHEST.108.4\_SUPPLEMENT.444S; TANEMOTO K, 2000, CURR THER RES CLIN E, V61, P798, DOI 10.1016/S0011-393X(00)90006-7; TOHGI H, 1992, STROKE, V23, P1400, DOI 10.1161/01.STR.23.10.1400; WOOD D, 1998, EUR HEART J, V19, PA12; WOOD D, 1997, EUR HEART J, V18, P1569; WU K, 1997, FIBRINOLYSIS PROTEOL, P34","MAS, R (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6880, HAVANA, CUBA","ADIS INT LTD","ENGLISH","CLIN. DRUG INVEST.","ARTICLE","ISI","WOS000181327000004","CLIN DRUG INVEST","NATL CTR SCI RES;NATL CTR SCI RES;MED SURG RES CTR","NATL CTR SCI RES",NA,"ARRUZAZABALA MD, 2003, CLIN DRUG INVEST","ARRUZAZABALA MD, 2003, CLIN DRUG INVEST"
"CASTAÑO G;MENÉNDEZ R;MÁS R;LEDÓN N;FERNÁNDEZ J;PÉREZ J;GONZÁLEZ R;LEZCAY M","CASTAÑO G;MENÉNDEZ R;MÁS R;LEDÓN N;FERNÁNDEZ J; PÉREZ J;GONZÁLEZ RM;LEZCAY M","EFFECTS OF D003 A NEW HYPOCHOLESTEROLAEMIC AND ANTIPLATELET COMPOUND ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY VOLUNTEERS",2003,"CLINICAL DRUG INVESTIGATION","23","193-203",37,"10.2165/00044011-200323030-00005","NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.; MED SURG RES CTR, HAVANA, CUBA.","BACKGROUND: D-003 IS A MIXTURE OF LONG-CHAIN ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGARCANE WAX WITH HYPOCHOLESTEROLAEMIC EFFECTS PROVEN IN RABBITS AND HEALTHY VOLUNTEERS; IT LOWERS SERUM TOTAL CHOLESTEROL (TC) AND LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) AND INCREASES HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C). D-003 ALSO PREVENTS LIPOPROTEIN LIPID PEROXIDATION IN EXPERIMENTAL MODELS. OBJECTIVE: TO INVESTIGATE THE EFFECTS OF D-003 ON LIPID PROFILE AND LIPID PEROXIDATION IN HEALTHY HUMAN VOLUNTEERS. PARTICIPANTS: FORTY-SIX HEALTHY VOLUNTEERS (24 WOMEN, 22 MEN). METHODS: THIS DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY INVESTIGATED THE EFFECTS OF D-003 AT 5 AND 10 MG/DAY ON THE SUSCEPTIBILITY OF LDL TO LIPID PEROXIDATION INDUCED BY COPPER IONS IN HEALTHY VOLUNTEERS. FORTY-SIX INDIVIDUALS WERE RANDOMISED (1 : 2) TO PLACEBO OR D-003 AT 5 OR 10 MG/DAY, THE TABLETS BEING TAKEN ONCE A DAY WITH THE EVENING MEAL FOR 8 WEEKS. LABORATORY DETERMINATIONS AND PHYSICAL EXAMINATION WERE PERFORMED AT BASELINE AND AFTER 4 AND 8 WEEKS OF THERAPY, AND COMPLIANCE AND ADVERSE EXPERIENCE ASSESSMENTS WERE PERFORMED AT WEEKS 4 AND 8. RESULTS: ALL GROUPS WERE WELL MATCHED AT BASELINE. AT STUDY COMPLETION, D-003 AT 5 AND 10 MG/DAY SIGNIFICANTLY (P < 0.001) LOWERED LDL-C, THE PRIMARY RESPONSE VARIABLE, BY 20.8\% AND 28.8\%, RESPECTIVELY. IN ADDITION, D-003 AT 5 AND 10 MG/DAY REDUCED (P < 0.001) TC (12.7\% AND 17.5\%, RESPECTIVELY), LDL-C/ HDL-C (25.9\% AND 36.3\%, RESPECTIVELY) AND TC/HDL-C (18.6\% AND 26.3\%, RESPECTIVELY), WHILE SIGNIFICANTLY (P < 0.01) INCREASING HDL-C (7.7\% AND 12.4\%, RESPECTIVELY). TRIGLYCERIDES WERE SIGNIFICANTLY (P < 0.05) REDUCED (8.8\% AND 13.1 \%, RESPECTIVELY) WITH RESPECT TO BASELINE, BUT NOT VERSUS PLACEBO. RESPONSES ASSESSED AT 4 WEEKS SHOWED SIGNIFICANT REDUCTIONS OF LDL-C, TC AND ATHEROGENIC RATIOS WITH BOTH DOSES OF D-003, WHEREAS HDL-C WAS SIGNIFICANTLY INCREASED. TRIGLYCERIDES, HOWEVER, REMAINED UNCHANGED. NO SIGNIFICANT CHANGES IN ANY LIPID PROFILE VARIABLE OCCURRED IN THE PLACEBO GROUP. D-003 AT 5 AND 10 MG/DAY SIGNIFICANTLY (P < 0.05) INCREASED LAG TIME (18.3\% AND 32.0\%, RESPECTIVELY) AND DECREASED MAXIMUM RATE OF DIENE PROPAGATION (V-MAX) [12.7\% AND 19.1\%, RESPECTIVELY] OF COPPER-INDUCED LDL PEROXIDATION. D-003 5 AND 10 MG/DAY ATTENUATED THE REDUCTION OF THE REACTIVITY AGAINST 2,4,6-TRINITROBENZENE SULFONIC ACID (TNBS) BY 19.9\% AND 32.0\%, RESPECTIVELY. THE TREATMENT WAS WELL TOLERATED. THREE SUBJECTS (ONE FROM EACH GROUP) DISCONTINUED THE STUDY. ONLY ONE, TREATED WITH D-003 5 MG/DAY, DISCONTINUED BECAUSE OF AN ADVERSE EVENT (GASTRITIS). CONCLUSIONS: D-003 AT 5 AND 10 MG/DAY DEMONSTRATED DOSE-DEPENDENT CHOLESTEROL-LOWERING EFFECTS IN HEALTHY VOLUNTEERS CHARACTERISED BY REDUCTIONS IN LDL-C, TC AND ATHEROGENIC RATIOS, AND INCREASES IN HDL=C. EFFECTS ON TRIGLYCERIDES WERE MODEST AND UNCERTAIN. AS EXPECTED FROM EXPERIMENTAL STUDIES, D-003 INHIBITED THE SUSCEPTIBILITY OF LDL TO LIPID PEROXIDATION ASSESSED BY THREE INDICATORS LAG TIME V-MAX AND REACTIVITY VERSUS TNBS. FURTHER STUDIES INVESTIGATING THE EFFECT OF LARGER DOSES AND TREATMENT DURATION MUST BE CONDUCTED TO CONFIRM THE REPRODUCIBILITY OF THE PRESENT RESULTS IN DIFFERENT STUDY POPULATIONS.",NA,"LOW-DENSITY-LIPOPROTEIN; OXIDATIVE MODIFICATION; PRIMARY-PREVENTION; CORONARY EVENTS; IN-VITRO; POLICOSANOL; SUSCEPTIBILITY; CHOLESTEROL; LOVASTATIN; TOLERABILITY",NA,NA,"AVIRAM M, 1992, METABOLISM, V41, P229, DOI 10.1016/0026-0495(92)90263-A; BROWN MS, 1996, SCIENCE, V272, P629, DOI 10.1126/SCIENCE.272.5262.629; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508A0; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CASTANO G, 2002, DRUGS R\&D, V3, P333; CHEN LY, 1997, J AM COLL CARDIOL, V30, P569, DOI 10.1016/S0735-1097(97)00158-7; CRESPO N, 1999, INT J CLIN PHARM RES, V19, P117; DAVIGNON J, 1997, P 11 INT S ATH PAR 5, P63; DOWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/JAMA.279.20.1615; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FALK E, 1995, AM J CARDIOL, V75, PB5, DOI 10.1016/0002-9149(95)80003-B; FERNÁNDEZ JC, 2001, CLIN DRUG INVEST, V21, P103, DOI 10.2165/00044011-200121020-00003; FRAGA V, 1997, ARCH MED RES, V28, P355; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ R, 2001, TERATOGEN CARCIN MUT, V21, P85; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; GONZALEZ L, 1998, PATENT NO. 982744; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HUSSEIN O, 1997, ATHEROSCLEROSIS, V128, P11, DOI 10.1016/S0021-9150(96)05972-2; KIECHL S, 1994, ARTERIOSCLER THROMB, V14, P1625, DOI 10.1161/01.ATV.14.10.1625; KLEINVELD HA, 1992, CLIN CHEM, V38, P2066; LEONHARDT W, 1997, EUR J CLIN PHARMACOL, V53, P65, DOI 10.1007/S002280050338; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MENÉNDEZ R, 2000, CURR THER RES CLIN E, V61, P609, DOI 10.1016/S0011-393X(00)88013-3; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MURRAY CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; OLEARY VJ, 1992, BIOCHEM J, V282, P631, DOI 10.1042/BJ2820631; PALOMÄKI A, 1999, ARTERIOSCL THROM VAS, V19, P1541, DOI 10.1161/01.ATV.19.6.1541; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RUIZ J, 1992, FREE RADIC BIOL MED, V13, P341; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHECTMAN G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SEIGLER L, 1981, CLIN CHEM, V27, P838; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; TONKIN A, 1998, NEW ENGL J MED, V339, P1349; WATSON AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WHEELER DC, 1998, DRUGS, V56, P517, DOI 10.2165/00003495-199856040-00001; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499","NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA","ADIS INT LTD","ENGLISH","CLIN. DRUG INVEST.","ARTICLE","ISI","WOS000181786600005","CLIN DRUG INVEST","NATL CTR SCI RES;MED SURG RES CTR","NATL CTR SCI RES",NA,"CASTAÑO G, 2003, CLIN DRUG INVEST","CASTAÑO G, 2003, CLIN DRUG INVEST1"
"MENDOZA S;NOA M;MAS R;MENDOZA N","MENDOZA S;NOA M;MAS R;MENDOZA N","EFFECT OF D003 A MIXTURE OF HIGH MOLECULAR WEIGHT PRIMARY ACIDS FROM SUGAR CANE WAX ON PARACETAMOLINDUCED LIVER DAMAGE IN RATS",2003,"INTERNATIONAL JOURNAL OF TISSUE REACTIONS-EXPERIMENTAL AND CLINICAL ASPECTS","25","91-98",8,NA,"NOA, M (CORRESPONDING AUTHOR), CTR NAT PROD, NATL CTR SCI RES, AVE 25 \& 158 ST,POST BOX 6990, HAVANA 6990, CUBA.; CTR NAT PROD, NATL CTR SCI RES, HAVANA 6990, CUBA.","D-003 IS A MIXTURE OF VERY HIGH MOLECULAR WEIGHT ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGAR CANE (SACCHARUM OFFICINARUM, L) WAX, IN WHICH THE MOST ABUNDANT COMPONENT IS OCTACOSANOIC ACID. EXPERIMENTAL STUDIES HAVE SHOWN THAT D-003 NOT ONLY SHOWS CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS, BUT ALSO OFFERS STRONG PROTECTION AGAINST PLASMA LIPOPROTEIN OXIDATION, PREVIOUS STUDIES DEMONSTRATED THAT D-003 PROTECTED AGAINST THE HISTOLOGICAL CHANGES CHARACTERISTIC OF C14C-INDUCED HEPATIC INJURY IN RATS. THE AIM OF THE PRESENT STUDY WAS TO INVESTIGATE THE EFFECTS OF D-003 IN ACUTE HEPATOTOXICITY INDUCED BY PARACETAMOL IN RATS. MALE SPRAGUE DAWLEY RATS WERE RANDOMLY DISTRIBUTED IN TWO EXPERIMENTAL SERIES OF THREE EXPERIMENTAL GROUPS AS FOLLOWS: GROUP 1-POSITIVE CONTROL RATS (PARACETAMOL-TREATED); GROUPS 2 AND 3- RATS WITH LIVER DAMAGE INDUCED BY PARACETAMOL AND TREATED WITH D-003 AT 5 AND 25 MG/KG, RESPECTIVELY, AND WHICH ALSO RECEIVED PARACETAMOL TO INDUCE LIVER INJURY. IN EXPERIMENTAL SERIES 1, ANIMALS RECEIVED PARACETAMOL ORALLY (600 MG/KG). IN SERIES 2, PARACETAMOL WAS ADMINISTERED THROUGH THE INTRAPERITONEAL ROUTE (200 MG/KG). EIGHTEEN HOURS AFTER PARACETAMOL DOSING, RATS WERE ANESTHETIZED WITH ETHER AND LIVERS WERE REMOVED FOR HISTOPATHOLOGICAL STUDIES. IN THE TWO EXPERIMENTAL SERIES, D-003 AT 5 AND 25 MG/KG SIGNIFICANTLY (P < 0.01) DECREASED THE PERCENTAGE OF TURGENT CELLS AND HEPATOCYTES WITH NECROSIS AND INCREASED THE PERCENTAGE OF NORMAL HEPATOCYTES WITH RESPECT TO POSITIVE CONTROLS IN A DOSE-DEPENDENT MANNER NECROTIC AREAS AND INFLAMMATORY INFILTRATES WERE OBSERVED IN THE LIVER OF NINE OUT OF TEN (90\%) POSITIVE CONTROLS. IN TURN, D-003 DRAMATICALLY REDUCED BOTH NECROTIC AREAS AND INFLAMMATORY INFILTRATE AND WAS PRESENT IN ONLY ONE OUT OF TEN (10\%) ANIMALS TREATED IN THE TWO EXPERIMENTAL SERIES. NO HISTOLOGICAL ALTERATIONS IN LIVER SECTIONS OF NEGATIVE CONTROLS WERE FOUND. D-003 PROTECTED AGAINST THE HISTOLOGICAL CHANGES CHARACTERISTIC OF PARACETAMOL-INDUCED HEPATIC INJURY IN RATS, IN WHICH THE PROCESS OF LIPID PEROXIDATION PLAYS A MAJOR ROLE. THE RELATIONSHIP BETWEEN THIS PROTECTIVE ACTION OF D-003 IN THIS EXPERIMENTAL MODEL AND ITS ANTIOXIDANT EFFECTS NEEDS TO BE FURTHER INVESTIGATED BEFORE DEFINITIVE CONCLUSIONS ARE DRAWN.",NA,"INDUCED LIPID-PEROXIDATION; CORONARY-HEART-DISEASE; POLICOSANOL; PREVENTION; TOLERABILITY; PRAVASTATIN; EFFICACY; PROFILE; INHIBITION; LOVASTATIN",NA,NA,"ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BHATNAGAR D, 1998, PHARMACOL THERAPEUT, V79, P205, DOI 10.1016/S0163-7258(98)00018-7; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CORO RM, 1996, REV LATINOAM PATOL, V39, P9; CRESPO N, 1999, INT J CLIN PHARM RES, V19, P117; DOWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/JAMA.279.20.1615; FAIRHURST S, 1982, TOXICOLOGY, V23, P249, DOI 10.1016/0300-483X(82)90102-0; FARMER JA, 1996, DRUGS, V52, P649, DOI 10.2165/00003495-199652050-00003; FARNIER M, 1998, AM J CARDIOL, V82, P3; FERNÁNDEZ JC, 2001, CLIN DRUG INVEST, V21, P103, DOI 10.2165/00044011-200121020-00003; GÁMEZ R, 2002, TERATOGEN CARCIN MUT, V22, P175, DOI 10.1002/TCM.10001; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; GONZALEZ L, 1998, PATENT NO. 982744; GONZALEZ R, 1994, PHYTOTHER RES, V8, P229, DOI 10.1002/PTR.2650080408; HARMAN AW, 1985, RES COMMUN CHEM PATH, V49, P215; MARTINEZCALVA I, 1984, J APPL TOXICOL, V4, P270, DOI 10.1002/JAT.2550040513; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MCLEAN AEM, 1978, BIOCHEM PHARMACOL, V27, P425, DOI 10.1016/0006-2952(78)90371-4; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MENÉNDEZ R, 2000, CURR THER RES CLIN E, V61, P609, DOI 10.1016/S0011-393X(00)88013-3; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; MOLINA V, 2002, PROSTAG LEUKOTR ESS, V67, P19, DOI 10.1054/PLEF.2002.0376; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; MURIEL P, 1992, J APPL TOXICOL, V12, P439, DOI 10.1002/JAT.2550120613; NAGAI H, 1989, JPN J PHARMACOL, V51, P191, DOI 10.1254/JJP.51.191; NAO M, 2002, DRUG EXP CLIN RES, V28, P177; NOA MIRIAM, 2003, DRUGS R D, V4, P29, DOI 10.2165/00126839-200304010-00003; PEDERSEN TR, 1994, LANCET, V344, P1383; PLAA GABRIEL L., 1994, P839; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RODRÍGUEZ MD, 2003, FOOD CHEM TOXICOL, V41, P89, DOI 10.1016/S0278-6915(02)00217-X; RODRIGUEZ S, 1998, CIENCIAS BIOL, V29, P69; SAVIDES MC, 1983, J APPL TOXICOL, V3, P96, DOI 10.1002/JAT.2550030209; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TONKIN A, 1998, NEW ENGL J MED, V339, P1349; VERMEULEN NPE, 1992, DRUG METAB REV, V24, P367, DOI 10.3109/03602539208996298; WENDEL A, 1981, BIOCHEM PHARMACOL, V30, P2513, DOI 10.1016/0006-2952(81)90576-1; 2000, AM FORMULARY HOSP SR, P1620","NOA, M (CORRESPONDING AUTHOR), CTR NAT PROD, NATL CTR SCI RES, AVE 25 \& 158 ST,POST BOX 6990, HAVANA 6990, CUBA","BIOSCIENCE EDIPRINT INC","ENGLISH","INT. J. TISSUE REACT.-EXP. CLIN. ASP.","ARTICLE","ISI","WOS000188373300002","INT J TISSUE REACT-EXP CLIN ASP","CTR NAT PROD;CTR NAT PROD","CTR NAT PROD",NA,"MENDOZA S, 2003, INT J TISSUE REACT-EXP CLIN ASP","MENDOZA S, 2003, INT J TISSUE REACT-EXP CLIN ASP"
"RODRÍGUEZ M;GÁMEZ R;GONZÁLEZ J;GARCÍA H;ACOSTA C;GOICOCHEA E","RODRÍGUEZ MD;GÁMEZ R;GONZÁLEZ JE;GARCÍA H;ACOSTA CP;GOICOCHEA E","LACK OF DEVELOPMENTAL TOXICITY OF D003 A MIXTURE OF LONGCHAIN FATTY ACIDS IN RATS",2003,"FOOD AND CHEMICAL TOXICOLOGY","41","89-93",13,"10.1016/S0278-6915(02)00217-X","NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF LONG-CHAIN FATTY ACIDS ISOLATED AND PURIFIED FROM SUGAR CANE WAX, THE MAJOR COMPONENT OF WHICH IS 1-OCTACOSANOIC ACID AND WHICH POSSESSES EFFECTIVE ANTIPLATELET, ANTITHROMBOTIC AND CHOLESTEROL-LOWERING EFFECTS. D-003 WAS SUSPENDED IN 1\% ACACIA GUM SOLUTION, AND GIVEN DAILY BY GAVAGE TO RATS AT DOSE LEVELS OF 5, 100 AND 1000 MG/KG/DAY ON DAYS 6 THROUGH 15 OF GESTATION. CYCLOPHOSPHAMIDE, SERVING AS A POSITIVE CONTROL, WAS GIVEN AT THE DOSE OF 50 MG/KG/DAY ON DAY 15 OF GESTATION. EVIDENCE OF MATERNAL OR DEVELOPMENTAL TOXICITY WAS NOT OBSERVED IN THE GROUPS TREATED WITH D-003. MATERNAL CLINICAL SIGNS OF TOXICITY WERE NOT OBSERVED AND THE ANALYSIS OF INITIAL BODY WEIGHT AND THE BODY WEIGHT GAIN DURING THE TREATMENT PERIOD WAS COMPARABLE AMONG THE GROUPS TREATED WITH D-003 AND CONTROL. AS EXPECTED, CYCLOPHOSPHAMIDE CAUSED BOTH EMBRYOTOXIC AND TERATOGENIC EFFECTS IN RATS. MEANWHILE, NO ADVERSE EFFECTS ON REPRODUCTIVE PERFORMANCE, OR ON EMBRYONIC OR FETAL DEVELOPMENT, INCLUDING VISCERAL AND SKELETAL EXAMINATION, WERE SEEN IN ANY OF THE GROUPS ADMINISTERED D-003. IT IS CONCLUDED THAT D-003 ADMINISTERED UP TO 1060 MG/KG/DAY DID NOT INDUCE ANY EVIDENCE OF DEVELOPMENTAL TOXICITY. (C) 2003 ELSEVIER SCIENCE LTD. ALL RIGHTS RESERVED.","FATTY ACIDS; DEVELOPMENTAL TOXICITY IN RATS","SUPERNUMERARY RIBS; POLICOSANOL; SKELETON",NA,NA,"CHERNOFF N, 1991, FUND APPL TOXICOL, V17, P448, DOI 10.1016/0272-0590(91)90196-B; DAWSON AB, 1926, STAIN TECHNOL, V1, P123, DOI 10.3109/10520292609115636; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GONZALEZ L, 1998, PATENT NO. 22723; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; LABS DALM SA, 1998, PATENT NO. 9843631; MANSON J, 1989, PRINCIPLES METHODS T, P311; MENENDEZ R, 2001, PHARM RES, V44, P300; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; PADMANABHAN R, 1985, VIRCHOWS ARCH A, V408, P61, DOI 10.1007/BF00739963; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRIGUEZ MD, 1997, TOXICOL LETT, V90, P97, DOI 10.1016/S0378-4274(96)03844-1; RODRÍGUEZ MD, 1998, TERATOGEN CARCIN MUT, V18, P1, DOI 10.1002/(SICI)1520-6866(1998)18:1<1::AID-TCM1>3.0.CO;2-K; WICKRAMARATNE GAD, 1988, J APPL TOXICOL, V8, P91, DOI 10.1002/JAT.2550080205; WIER PJ, 1990, DRUG INF J, V24, P395; WILSON JG, 1975, TERATOLOGY PRINCIPLE, P262","NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA","PERGAMON-ELSEVIER SCIENCE LTD","ENGLISH","FOOD CHEM. TOXICOL.","ARTICLE","ISI","WOS000180036300011","FOOD CHEM TOXICOL","NATL CTR SCI RES","NATL CTR SCI RES",NA,"RODRÍGUEZ MD, 2003, FOOD CHEM TOXICOL","RODRÍGUEZ MD, 2003, FOOD CHEM TOXICOL"
"CASTAÑO G;FERNÁNDEZ L;MAS R;ILLNAIT J;FERNÁNDEZ J;MESA M;ALVAREZ E;LEZCAY M","CASTAÑO G;FERNÁNDEZ L;MAS R;ILLNAIT J;FERNÁNDEZ J;MESA M;ALVAREZ E;LEZCAY M","COMPARISON OF THE EFFICACY SAFETY AND TOLERABILITY OF ORIGINAL POLICOSANOL IVERSUSI OTHER MIXTURES OF HIGHER ALIPHATIC PRIMARY ALCOHOLS IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",2002,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","22","55-66",21,NA,"MAS, R (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6990, HAVANA 6880, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.; NATL CTR SCI RES, MED \& SURG RES CTR, HAVANA 6880, CUBA.","THIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND OCTA-60 IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. AFTER 4 WEEKS ON A DIET, 110 PATIENTS WERE RANDOMIZED TO POLICOSANOL OR OCTA-60 5 MG TABLETS ONCE A DAY FOR 5 WEEKS. THE DOSE WAS THEN DOUBLED TO 10 MG/DAY FOR THE NEXT 5 WEEKS. POLICOSANOL 5 AND 10 MG/DAY SIGNIFICANTLY LOWERED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) (P<0.0001 AND P<0.00001), THE MAIN EFFICACY VARIABLE, BY 18.6\% AND 30.2\%, WHILE OCTA-60 SIGNIFICANTLY REDUCED (P<0.05) LDLC BY 10.0\% AT STUDY COMPLETION ONLY. THE FREQUENCY OF POLICOSANOL PATIENTS REACHING REDUCTIONS OF LDL-C GREATER THAN OR EQUAL TO15\% AFTER 5 MG/DAY (37155; 67.3\%) AND 10 MG/DAY (47155; 88.7\%) WAS GREATER (P<0.01 AND P<0.01) THAN IN THE OCTA-60 GROUP, WHICH WAS 5/55 (9.1\%) AND 20/55 (36.4\%). LIKEWISE, THE FREQUENCY OF PATIENTS REACHING LDL-C VALUES OF <3.4 MMOL/L AT STUDY COMPLETION WAS GREATER (P<0.001) IN THE POLICOSANOL GROUP (39155, 70.9\%) THAN IN THE OCTA-60 GROUP (6155, 10.9\%). POLICOSANOL 5 AND 10 MG/DAY SIGNIFICANTLY LOWERED (P<0.00001) TOTAL CHOLESTEROL (TC) (13.4\% AND 20.401O), LDL-C/HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) (22.1\% AND 37.0\%) AND TC/HDL-C (17.2\% AND 28.201.). OCTA-60 AT 10 MG/DAY LOWERED (P<0.05) TC (8.7\%), LDL-CIHDL-C (12.6\%) AND TC/HDL-C (9.4\%). HDL-C WAS INCREASED (P<0.001 AND 0.0001) BY POLICOSANOL 5 AND 10 MG/DAY (5.6\% AND 12.5\%) BUT WAS UNCHANGED BY OCTA-60. IN BOTH GROUPS, TRIGLYCERIDES REMAINED UNCHANGED. BOTH TREATMENTS WERE SAFE AND WELL TOLERATED. OCTA-60, BUT NOT POLICOSANOL, SIGNIFICANTLY INCREASED GLUCOSE AND ALANINE AMINOTRANSFERASE, BUT INDIVIDUAL VALUES WERE WITHIN THE NORMAL RANGE. FOUR PATIENTS (TWO FROM EACH GROUP) DISCONTINUED THE TRIAL, BUT ONLY ONE (IN THE OCTA-60 GROUP) DID SO BECAUSE OF AN ADVERSE EVENT (AE) (SKIN RASH). OVERALL, THREE PATIENTS (ALL FROM THE OCTA-60 GROUP) REPORTED AES. IN CONCLUSION, ORIGINAL POLICOSANOL AT 5 AND 10 MG/DAY BUT NOT OCTA 60, WAS EFFECTIVE IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. THUS, POLICOSANOL REACHED THE EFFICACY CRITERION FOR LDL-C REDUCTION IN BOTH STEPS, WHILE OCTA-60 FAILED TO REACH THIS GOAL. IN ADDITION, POLICOSANOL WAS BETTER TOLERATED THAN OCTA-60.",NA,"SUCCESSIVE DOSE INCREASES; CORONARY-HEART-DISEASE; PLATELET-AGGREGATION; DENSITY-LIPOPROTEIN; LIPID PROFILE; DOUBLE-BLIND; CHOLESTEROL; PRAVASTATIN; EVENTS; D-002",NA,NA,"ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ARRUZAZABALA ML, 1998, INT J TISSUE REACT, V20, P119; ARRUZAZABALA ML, 1996, PHARMACOL RES, V34, P181, DOI 10.1006/PHRS.1996.0086; BENITEZ M, 1997, CURR THER RES CLIN E, V58, P859, DOI 10.1016/S0011-393X(97)80052-5; CANAVACIOLO VLG, 1999, J AOAC INT, V82, P834; CANETTI M, 1995, ADV THER, V12, P245; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V59, P235, DOI 10.1016/S0952-3278(98)90135-1; CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/J.2042-7158.1995.TB06732.X; CARBAJAL D, 1996, J PHARM PHARMACOL, V48, P858, DOI 10.1111/J.2042-7158.1996.TB03987.X; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CASTAÑO G, 2001, J GERONTOL A-BIOL, V56, PM186, DOI 10.1093/GERONA/56.3.M186; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CASTAÑO G, 2001, INT J CLIN PHARM RES, V21, P43; CASTAÑO G, 2001, ANGIOLOGY, V52, P115, DOI 10.1177/000331970105200205; CASTAÑO G, 1999, ANGIOLOGY, V50, P123, DOI 10.1177/000331979905000205; CLEEMAN JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/JAMA.285.19.2486; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; CRESPO N, 2000, INT J CLIN PHARM RES, V19, P105; DESMET PAGM, 1997, DRUGS, V54, P801, DOI 10.2165/00003495-199754060-00003; DOWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/JAMA.279.20.1615; FERNÁNDEZ JC, 2001, CLIN DRUG INVEST, V21, P103, DOI 10.2165/00044011-200121020-00003; FERNANDEZ L, 1998, CURR THER RES CLIN E, V59, P717, DOI 10.1016/S0011-393X(98)85030-3; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; *GUAR INT INC, 2000, PROD LESS BRAND NAT, P1; HANO O, 2001, CURR THER RES CLIN E, V62, P394, DOI 10.1016/S0011-393X(01)89004-4; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; *INT TASK FORC PRE, 1999, NUTR METAB CARDIOVAS, V9, P205; LAGUNA A, 1993, PATENT NO. 93700007; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2001, CLIN DRUG INVEST, V21, P485; MÁS R, 2001, DRUG FUTURE, V26, P731, DOI 10.1358/DOF.2001.026.08.630956; MÁS R, 1999, CURR THER RES CLIN E, V60, P458, DOI 10.1016/S0011-393X(99)80024-1; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MAS R, 2002, AM COLL CARDIOL S, V39; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188-4409(00)00265-4; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENENDEZ R., 2001, J MED FOOD, V4, P71, DOI 10.1089/109662001300341725; MENÉNDEZ R, 2001, ARCH MED RES, V32, P436, DOI 10.1016/S0188-4409(01)00315-0; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MENÉNDEZ R, 2000, CURR THER RES CLIN E, V61, P609, DOI 10.1016/S0011-393X(00)88013-3; MENENDEZ R, 1993, REV MEXICANA CIENCIA, V24, P16; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MOLINA VIVIAN, 2001, J MED FOOD, V4, P79, DOI 10.1089/109662001300341734; ORTENSI G, 1997, CURR THER RES CLIN E, V58, P390, DOI 10.1016/S0011-393X(97)80099-9; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SCAND SIMV STUD, 1994, LANCET, V341, P1383; SCHECTMAN G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SEIGLER L, 1981, CLIN CHEM, V27, P838; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TONKIN A, 1998, NEW ENGL J MED, V339, P1349; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; URRIBARRI E, 2001, IN PRESS DRUG DEV PH; ZARDOYA R, 1996, CURR THER RES CLIN E, V57, P568, DOI 10.1016/S0011-393X(96)80068-3; 1998, DRUG THER PERSPECT, V11, P14","MAS, R (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6990, HAVANA 6880, CUBA","BIOSCIENCE EDIPRINT INC","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","WOS000179841200004","INT J CLIN PHARMACOL RES","NATL CTR SCI RES;NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"CASTAÑO G, 2002, INT J CLIN PHARMACOL RES","CASTAÑO G, 2002, INT J CLIN PHARMACOL RES1"
"CASTAÑO G;MENÉNDEZ R;MÁS R;AMOR A;FERNÁNDEZ J;GONZÁLEZ R;LEZCAY M;ALVAREZ E","CASTAÑO G;MENÉNDEZ R;MÁS R;AMOR A;FERNÁNDEZ JL; GONZÁLEZ RL;LEZCAY M;ALVAREZ E","EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILEAND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA ASSOCIATED WITH TYPE 2 DIABETES MELLITUS",2002,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH","22","89-99",38,NA,"NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.; MED SURG RES CTR, HAVANA, CUBA.","IN THIS PILOT, RANDOMIZED, DOUBLE-BLIND STUDY, WE COMPARED THE EFFECTS OF POLICOSANOL AND LOVASTATIN ON LIPID PROFILE AND LIPID PEROXIDATION IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS. AFTER 4 WEEKS ON A CHOLESTEROL-LOWERING DIET, 36 PATIENTS WERE RANDOMIZED TO POLICOSANOL (10 MG/DAY) OR LOVASTATIN (20 MG/DAY) TABLETS O.I.D. FOR 8 WEEKS. POLICOSANOL SIGNIFICANTLY (P < 0.001) LOWERED SERUM LOW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) (29.9\%), TOTAL CHOLESTEROL (21.1\%), TRIGLYCERIDES (13.6\%) AND THE LDL C/HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL (HDL-C) (36.7\%.) AND TOTAL CHOLESTEROL/HDL-C (28.9\%) RATIOS AND SIGNIFICANTLY (P < 0.01) INCREASED HDL-C (12.5\%). LOVASTATIN SIGNIFICANTLY (P < 0.001) LOWERED LDL-C (25\%), TOTAL CHOLESTEROL (18\%), TRIGLYCERIDES (10.9\%) AND THE LDLC/HDL-C (30.4\%) AND TOTAL CHOLESTEROL/HDL-C RATIOS (23.9\%) AND SIGNIFICANTLY (P < 0.01) RAISED HDL-C (8.3\%). POLICOSANOL WAS MORE EFFECTIVE (P < 0.05) THAN LOVASTATIN IN REDUCING BOTH RATIOS AND IN INCREASING (P < 0.05) HDL-C. POLICOSANOL, BUT NOT LOVASTATIN, SIGNIFICANTLY RAISED THE LAG TIME (20.9\%) OF CU+2-INDUCED LDL PEROXIDATION AND TOTAL PLASMA ANTIOXIDANT ACTIVITY (24.2\%) (P < 0.05). BOTH POLICOSANOL AND LOVASTATIN SIGNIFICANTLY DECREASED THE PROPAGATION RATE (41.9\% AND 41.6\% RESPECTIVELY, P < 0.001), MAXIMAL DIENE PRODUCTION (8.3\% AND 5.7\%) AND PLASMA LEVELS OF THIOBARBITURIC ACID REACTIVE SUBSTANCES (9.7\% AND 11.5\%, P < 0.001). BOTH TREATMENTS WERE WELL TOLERATED. ONLY ONE PATIENT IN THE LOVASTATIN GROUP WITHDREW FROM THE TRIAL DUE TO ADVERSE EVENTS. IN CONCLUSION, POLICOSANOL AND LOVASTATIN ADMINISTERED SHORT TERM TO PATIENTS WITH DYSLIPIDEMIA SECONDARY TO TYPE 2 DIABETES WERE EFFECTIVE IN LOWERING CHOLESTEROL AND IN INHIBITING THE EXTENT OF LIPID PEROXIDATION. POLICOSANOL (10 MG/DAY) WAS SLIGHTLY MORE EFFECTIVE THAN LOVASTATIN (20 MG/DAY) IN REDUCING THE LDL-C/HDL-C AND TOTAL CHOLESTEROL/HDL-C RATIOS, IN INCREASING HDL-C LEVELS AND IN PREVENTING LDL OXIDATION. NEVERTHELESS, SINCE THIS WAS A PILOT STUDY, FURTHER CLINICAL STUDIES PERFORMED IN LARGER SAMPLE SIZES OF DIABETIC PATIENTS ARE NEEDED FOR DEFINITIVE CONCLUSIONS.",NA,"LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; SERUM PARAOXONASE; ACTIVITY; HYPERCHOLESTEROLEMIC PATIENTS; II HYPERCHOLESTEROLEMIA; ALPHA-TOCOPHEROL; RISK-FACTORS; TOLERABILITY; CHOLESTEROL; EFFICACY",NA,NA,"ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812; AVIRAM M, 1992, METABOLISM, V41, P229, DOI 10.1016/0026-0495(92)90263-A; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/ARCHINTE.151.1.43; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/PNAS.91.20.9441; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CASTANO G, 1995, CURR THER RES CLIN E, V56, P819, DOI 10.1016/0011-393X(95)85065-1; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CHEN LY, 1997, J AM COLL CARDIOL, V30, P569, DOI 10.1016/S0735-1097(97)00158-7; CLEEMAN JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/JAMA.285.19.2486; CRESPO N, 1999, INT J CLIN PHARM RES, V19, P117; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FERNÁNDEZ JC, 2001, CLIN DRUG INVEST, V21, P103, DOI 10.2165/00044011-200121020-00003; FERNANDEZ L, 1998, CURR THER RES CLIN E, V59, P717, DOI 10.1016/S0011-393X(98)85030-3; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1988, NEW ENGL J MED, V318, P81, DOI 10.1056/NEJM198801143180204; GOLBERG R, 1990, AM J CARDIOL, V66, P16; HENWOOD JM, 1988, DRUGS, V36, P429, DOI 10.2165/00003495-198836040-00003; HUNT JV, 1991, FREE RADICAL RES COM, V12-3, P115, DOI 10.3109/10715769109145775; IKEDA Y, 1998, METABOLISM, V47, P598, DOI 10.1016/S0026-0495(98)90246-3; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; JENNINGS PE, 1987, DIABETIC MED, V4, P452, DOI 10.1111/J.1464-5491.1987.TB00908.X; KLEINVELD HA, 1992, CLIN CHEM, V38, P2066; LAAKSO M, 1995, DIABETOLOGIA, V38, P487, DOI 10.1007/BF00410288; LAAKSO M., 1995, DIABETES REV, V3, P408; MACKNESS B, 2000, CLIN SCI, V98, P355, DOI 10.1042/CS19990239; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2001, CLIN DRUG INVEST, V21, P485; MÁS R, 1999, CURR THER RES CLIN E, V60, P458, DOI 10.1016/S0011-393X(99)80024-1; MAXWELL SRJ, 1997, EUR J CLIN INVEST, V27, P484, DOI 10.1046/J.1365-2362.1997.1390687.X; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MENÉNDEZ R, 2000, CURR THER RES CLIN E, V61, P609, DOI 10.1016/S0011-393X(00)88013-3; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MITCHEL YB, 1992, ATHEROSCLEROSIS, V97, P33; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PALOMAKI A, 1997, FEBS LETT, V410, P254, DOI 10.1016/S0014-5793(97)00609-1; PALOMÄKI A, 1999, ARTERIOSCL THROM VAS, V19, P1541, DOI 10.1161/01.ATV.19.6.1541; PEDERSEN TR, 1994, LANCET, V344, P1383; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; PYORALA K, 1994, ATHEROSCLEROSIS, V110, P121, DOI 10.1016/0021-9150(94)90200-3; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSENGREN A, 1989, BMJ-BRIT MED J, V299, P1127, DOI 10.1136/BMJ.299.6708.1127; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SASAKI A, 1996, DIABETES RES CLIN PR, V34, P47, DOI 10.1016/S0168-8227(96)01329-0; SCHECTMAN G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SEIGLER L, 1981, CLIN CHEM, V27, P838; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TONKIN A, 1998, NEW ENGL J MED, V339, P1349; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; WALKER JF, 1992, EUR HEART J, V13, P21; WETTERHALL SF, 1992, DIABETES CARE, V15, P960, DOI 10.2337/DIACARE.15.8.960; ZARDOYA R, 1996, CURR THER RES CLIN E, V57, P568, DOI 10.1016/S0011-393X(96)80068-3","NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA","BIOSCIENCE EDIPRINT INC","ENGLISH","INT. J. CLIN. PHARMACOL. RES.","ARTICLE","ISI","WOS000183761800005","INT J CLIN PHARMACOL RES","NATL CTR SCI RES;MED SURG RES CTR","NATL CTR SCI RES",NA,"CASTAÑO G, 2002, INT J CLIN PHARMACOL RES","CASTAÑO G, 2002, INT J CLIN PHARMACOL RES-a1"
"GÁMEZ R;RODEIRO I;FERNÁNDEZ I;ACOSTA P","GÁMEZ R;RODEIRO I;FERNÁNDEZ I;ACOSTA PC","PRELIMINARY EVALUATION OF THE CYTOTOXIC AND GENOTOXIC POTENTIAL OF D003 MIXTURE OF VERY LONG CHAIN FATTY ACIDS",2002,"TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS","22","175-181",16,"10.1002/tcm.10001","NATL CTR SCI RES, CTR NAT PROD, DEPT PHARMACOL \& TOXICOL, HAVANA, CUBA.","D-003 IS A MIXTURE OF VERY LONG CHAIN ALIPHATIC ACIDS PURIFIED FROM SUGAR CANE WAX, WHEREIN OCTACOSANOIC ACID REPRESENTS THE MAJOR COMPONENT. PREVIOUS EXPERIMENTAL STUDIES HAVE SHOWN THAT D-003 INHIBITS PLATELET AGGREGATION IN RODENTS. ALSO, ITS LOWERS TOTAL (TC) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN NORMOCHOLESTEROLEMIC RABBITS IN A DOSE-DEPENDENT MANNER AND INHIBITS CHOLESTEROL BIOSYNTHESIS IN FIBROBLAST CULTURES. THE PRESENT STUDY WAS PERFORMED TO INVESTIGATE THE IN VITRO CYTOTOXIC AND GENOTOXIC POTENTIAL EFFECTS OF D-003 ASSESSED THROUGH TWO TESTS: THE NEUTRAL RED (NR) ASSAY AND THE AMES TEST. POSITIVE AND NEGATIVE CONTROLS WERE INCLUDED IN EACH EXPERIMENTAL SERIES. COMPARED WITH CONTROLS, NO CYTOTOXICITY WAS EVIDENT AFTER 24 AND 72 H OF TREATMENT WITH DOSES UP TO 1,000 MUG/ML IN THE NR ASSAY. ON THE OTHER A DID NOT INCREASE THE FREQUENCY OF REVERSE MUTATIONS HAND, D-003 (5-5,000 MUG/PLATE IN THE AMES TEST IN BOTH ALTERNATIVES WITH OR WITHOUT S9 MIX METABOLIC ACTIVATION AND A PRE-INCUBATION STEP. THE POSITIVE CONTROL CHEMICALS INCLUDED IN EACH EXPERIMENT, NAMELY, TREATMENT WITH SODIUM DODECYL SULPHATE (SDS) IN THE NR ASSAY AND SODIUM AZIDE (NAAZ), 2-AMINOFLUORENE (AF), AND DIMETHYLNITROSAMINE (DMNA) IN THE AMES TEST, INDUCED THE EXPECTED CHANGES, SUCH AS A DECREASE IN OPTICAL DENSITY (OD) VALUES IN THE NR ASSAY AND AN INCREASE IN THE FREQUENCY OF REVERSE MUTATIONS IN THE AMES TEST. THE PRESENT RESULTS INDICATE THAT D-003 DID NOT SHOW EVIDENCE OF CYTOTOXIC OR GENOTOXIC POTENTIAL IN TESTS ABLE TO DETECT THE ABILITY OF CHEMICALS TO DISRUPT CELLS (NR ASSAY) OR TO INDUCE GENE MUTATIONS (AMES TEST).","D-003; HIGHER PRIMARY ALIPHATIC ACIDS; NEUTRAL RED; AMES TEST","POLICOSANOL; TOXICITY; HYPERCHOLESTEROLEMIA; CARCINOGENICITY; RABBITS",NA,NA,"ALEMAN CL, 1995, FOOD CHEM TOXICOL, V33, P573, DOI 10.1016/0278-6915(95)00026-X; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALEMAN CL, 1994, TERATOGEN CARCIN MUT, V14, P239, DOI 10.1002/TCM.1770140505; ALEMAN CL, 1991, REV CENIC CIENCIAS B, V22, P102; ARRUZAZABALA ML, 2000, BRAZ J MED BIOL RES, V33, P835, DOI 10.1590/S0100-879X2000000700015; CASTAÑO G, 2000, GYNECOL ENDOCRINOL, V14, P187, DOI 10.3109/09513590009167681; CASTAÑO G, 2000, CURR THER RES CLIN E, V61, P137, DOI 10.1016/S0011-393X(00)80011-9; FERNANDEZ SI, 1991, REV CENIC CIEN BIOL, V22, P98; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GONZALEZ L, 1997, PATENT NO. 3597; *INVITTOX PROT, 1990, AM TEST REV MUT HIST, P30; *INVITTOX PROT, 1990, FRAME MOD NEUTR RED; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; LAGUNA A, 1996, PATENT NO. 915001374; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENENDEZ R, 2000, ATHEROSCLEROSIS, V151, P131; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MITCHELL IDG, 1982, MUTAT RES, V104, P25; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; RENDON A, 1992, BR J NUTR, V2, P248; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; SIEGEL S, 1956, NON PARAMETRIC STAT","NATL CTR SCI RES, CTR NAT PROD, DEPT PHARMACOL \& TOXICOL, HAVANA, CUBA","WILEY-LISS","ENGLISH","TERATOGENESIS CARCINOG. MUTAGEN.","ARTICLE","ISI","WOS000175234800002","TERATOGENESIS CARCINOG MUTAGEN","NATL CTR SCI RES","NATL CTR SCI RES",NA,"GÁMEZ R, 2002, TERATOGENESIS CARCINOG MUTAGEN","GÁMEZ R, 2002, TERATOGENESIS CARCINOG MUTAGEN"
"NOA M;MENDOZA S;MÁS R;MENDOZA N","NOA M;MENDOZA S;MÁS R;MENDOZA N","EFFECT OF D003 A MIXTURE OF HIGH MOLECULAR WEIGHT PRIMARY ACIDS FROM SUGAR CANE WAX ON CL4CINDUCED LIVER ACUTE INJURY IN RATS",2002,"DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH","28","177-183",10,NA,"NOA, M (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, AVE 25 \& 158 ST,POST BOX 6990, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF VERY HIGH MOLECULAR WEIGHT ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGAR CANE (SACCHARUM, OFFICINARUM, L.) WAX, IN WHICH OCTACOSANOIC ACID IS THE MOST ABUNDANT COMPONENT. PREVIOUS EXPERIMENTAL STUDIES HAVE SHOWN THAT D-003 NOT ONLY SHOWS CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS, BUT ALSO OFFERS STRONG PROTECTION AGAINST PLASMA LIPOPROTEIN OXIDATION. ACUTE HEPATOTOXICITY INDUCED BY CCL4 IN RATS HAS BEEN RELATED TO AN INCREASED RATE OF LIPID PEROXIDATION, AND DIFFERENT ANTIOXIDANT COMPOUNDS HAVE BEEN REVEALED TO BE EFFECTIVE IN THIS MODEL. THE AIM OF THIS STUDY WAS TO INVESTIGATE THE EFFECTS OF D-003 IN ACUTE HEPATOTOXICITY INDUCED BY CCL4 IN RATS. MALE SPRAGUE DAWLEY RATS WERE RANDOMLY DISTRIBUTED IN FOUR EXPERIMENTAL GROUPS AS FOLLOWS: GROUP 1: NEGATIVE CONTROL RATS; GROUP 2: POSITIVE CONTROL RATS (CCL4- TREATED); GROUPS 3 AND 4 RATS WITH LIVER DAMAGE INDUCED BY CCL4 AND TREATED WITH D-003 AT 25 AND 100 MG/KG, RESPECTIVELY. ACUTE LIVER INJURY WAS INDUCED BY CCL4 SUSPENDED IN OLIVE OIL AND INTRAPERITONEALLY ADMINISTERED AT 1 ML/KG. EIGHTEEN HOURS AFTER CCL4 DOSING, THE RATS WERE ANESTHETIZED WITH ETHER AND THEIR LIVERS WERE REMOVED FOR HISTOPATHOLOGICAL STUDIES. D-003 AT 25 AND 100 MG/KG SIGNIFICANTLY (P <0.01) DECREASED THE PERCENTAGE OF BALLOONED CELLS AND HEPATOCYTES WITH LIPIDIC INCLUSIONS AND INCREASED THE PERCENTAGE OF NORMAL HEPATOCYTES COMPARED WITH THAT IN POSITIVE CONTROLS IN A DOSE-DEPENDENT MANNER THE PERCENT INHIBITIONS OF THE OCCURRENCE OF BALLOONED CELLS AND HEPATOCYTES WITH LIPIDS WERE MARKED (75\% AND 50\%, RESPECTIVELY) WITH THE HIGH DOSE (100 MG/KG). THE PERCENT OF TURGENT HEPATOCYTES WAS ALSO SIGNIFICANTLY REDUCED COMPARED WITH THAT IN POSITIVE CONTROLS, BUT THIS EFFECT WAS NOT DOSE-DEPENDENT NO HISTOLOGICAL ALTERATIONS IN THE LIVER SECTIONS OF NEGATIVE CONTROLS WERE FOUND. NECROTIC AREAS AND INFLAMMATORY INFILTRATE WERE OBSERVED IN THE LIVER OF 7/8 (87.5\%) OF POSITIVE CONTROLS. IN TURN, D-003 DRAMATICALLY REDUCED BOTH NECROTIC AREAS AND INFLAMMATORY INFILTRATE AND WAS PRESENT IN ONLY 1/8 (12.5\%) ANIMALS TREATED WITH D-003 25 MG/KG AND IN NONE (0\%) OF THE ANIMALS TREATED WITH 100 MG/KG. D-003 PROTECTED AGAINST THE HISTOLOGICAL CHANGES CHARACTERISTIC OF CCL4-INDUCED HEPATIC INJURY IN RATS, IN WHICH THE PROCESS OF LIPID PEROXIDATION PLAYS THE MAIN ROLE. THE RELATIONSHIP BETWEEN THIS PROTECTIVE ACTION OF D-003 ON THIS EXPERIMENTAL MODEL AND ITS ANTIOXIDANT EFFECTS NEEDS TO BE FURTHER INVESTIGATED BEFORE DEFINITIVE CONCLUSIONS ARE DRAWN.",NA,"CORONARY-HEART-DISEASE; LIPID-PEROXIDATION; POLICOSANOL; PRAVASTATIN; PREVENTION; TOLERABILITY; EFFICACY; PROFILE; EVENTS; CCL4",NA,NA,"ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BHATNAGAR D, 1998, PHARMACOL THERAPEUT, V79, P205, DOI 10.1016/S0163-7258(98)00018-7; *BOARD AM SOC HLTH, 2000, AM FORM HOSP SERV AF, P1620; CASTAÑO G, 1999, INT J CLIN PHARM RES, V19, P105; CHARBONNEAU M, 1985, TOXICOLOGY, V35, P95, DOI 10.1016/0300-483X(85)90025-3; CORO RM, 1996, REV LATINOAM PATOL, V39, P9; CRESPO N, 1999, INT J CLIN PHARM RES, V19, P117; DOWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/JAMA.279.20.1615; FARMER JA, 1996, DRUGS, V52, P649, DOI 10.2165/00003495-199652050-00003; FARNIER M, 1998, AM J CARDIOL, V82, P3; FERNÁNDEZ JC, 2001, CLIN DRUG INVEST, V21, P103, DOI 10.2165/00044011-200121020-00003; GÁMEZ R, 2000, TOXICOL LETT, V118, P31, DOI 10.1016/S0378-4274(00)00260-5; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GAMEZ R, 2001, IN PRESS TERATOG CAR; GAMEZ RAFAEL, 2001, J MED FOOD, V4, P85, DOI 10.1089/109662001300341743; GONZALEZ L, 1998, PATENT NO. 982744; MARTINEZCALVA I, 1984, J APPL TOXICOL, V4, P270, DOI 10.1002/JAT.2550040513; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 2000, DRUG FUTURE, V25, P569, DOI 10.1358/DOF.2000.025.06.574693; MENDOZA S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011-393X(01)80032-1; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENÉNDEZ R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/J.1365-2125.2000.00250.X; MENÉNDEZ R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01-088, 10.1139/Y01-088; MENÉNDEZ R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/PHRS.2001.0851; MENÉNDEZ R, 2000, CURR THER RES CLIN E, V61, P609, DOI 10.1016/S0011-393X(00)88013-3; MERINO N, 1996, ARCH MED RES, V27, P285; MIRKIN A, 2001, INT J CLIN PHARM RES, V21, P31; MOLINA V, 2000, PHARMACOL RES, V42, P137, DOI 10.1006/PHRS.2000.0664; MOLINA V, 2002, IN PRESS PROSTAGL LE; MURIEL P, 1990, J APPL TOXICOL, V10, P275, DOI 10.1002/JAT.2550100408; NAGAI H, 1989, JPN J PHARMACOL, V51, P191, DOI 10.1254/JJP.51.191; PEDERSEN TR, 1994, LANCET, V344, P1383; PLOA G.L., 1989, PRINCIPLES AND METHODS OF TOXICOLOGY, V2, P599; RECKNAGEL RO, 1982, TOXICOLOGY LIVER, P213; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RODRÍGUEZ MD, 2003, FOOD CHEM TOXICOL, V41, P89, DOI 10.1016/S0278-6915(02)00217-X; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TONKIN A, 1998, NEW ENGL J MED, V339, P1349; WENDEL A, 1987, FREE RADICAL BIO MED, V3, P355, DOI 10.1016/S0891-5849(87)80047-3","NOA, M (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, AVE 25 \& 158 ST,POST BOX 6990, HAVANA, CUBA","BIOSCIENCE EDIPRINT INC","ENGLISH","DRUG EXP. CLIN. RES","ARTICLE","ISI","WOS000181363300002","DRUG EXP CLIN RES","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"NOA M, 2002, DRUG EXP CLIN RES","NOA M, 2002, DRUG EXP CLIN RES"
"MENÉNDEZ R;MÁS R;AMOR A;RODEIROS I;GONZÁLEZ R;ALFONSO J","MENÉNDEZ R;MÁS R;AMOR AM;RODEIROS I;GONZÁLEZ RM; ALFONSO JL","INHIBITION OF CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS BY D003 A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS",2001,"PHARMACOLOGICAL RESEARCH","44","299-304",43,"10.1006/phrs.2001.0851","NATL CTR SCI RES, BIOCHEM LAB, CTR NAT PROD, HAVANA 6880, CUBA.","THE PRESENT STUDY WAS UNDERTAKEN TO INVESTIGATE THE EFFECTS OF D003, A MIXTURE OF VERY LONG CHAIN SATURATED FATTY ACIDS ISOLATED AND PURIFIED FROM SUGAR CANE WAX, ON CHOLESTEROL BIOSYNTHESIS IN CULTURED FIBROBLASTS. CHOLESTEROL BIOSYNTHESIS IS REGULATED THROUGH FEEDBACK REGULATION OF AT LEAST TWO SEQUENTIALLY ACTING ENZYMES, 3-HYDROXY-3-METHYL COENZYME A (HMG-COA) SYNTHASE AND REDUCTASE. THEY ARE UP-REGULATED WHEN STEROL LEVELS FALL AND DOWN-REGULATED WHEN STEROL LEVELS RISE. THE EXPOSURE OF CULTURED FIBROBLASTS TO A LIPID-DEPLETED MEDIUM (LDM) AND D003 (0.05-50 MUG ML(-1)) FOR 12 H INHIBITED, IN A DOSE-DEPENDENT MANNER, CHOLESTEROL BIOSYNTHESIS FROM C-14-LABELLED ACETATE (33-68\%). THE ADDITION OF D003 AT CONCENTRATIONS INHIBITING CHOLESTEROL BIOSYNTHESIS FROM LABELLED ACETATE SIGNIFICANTLY DECREASED INCORPORATION OF RADIOACTIVITY FROM (H2O)-H-3 INTO STEROLS, BUT NOT FROM C-14-MEVALONATE. THESE DATA INDICATE THAT D003 INHIBITS CHOLESTEROL BIOSYNTHESIS BY INTERFERING WITH EARLY STEPS OF CHOLESTEROL BIOSYNTHETIC PATHWAY. WE REASONED THAT D003 ACTS DIRECTLY ON HMG-COA REDUCTASE, THE MAIN REGULATORY ENZYME OF CHOLESTEROL BIOSYMBETIC PATHWAY. HOWEVER, WHEN ENZYME ACTIVITY WAS MEASURED IN CELL EXTRACTS IN THE PRESENCE OF VARIOUS CONCENTRATIONS OF D003 (0.5-50 MUG ML(-1)), REDUCTASE ACTIVITY WAS NOT INHIBITED. THUS, THERE WAS NO EVIDENCE FOR A COMPETITIVE OR NON-COMPETITIVE INHIBITION OF ENZYME ACTIVITY BY D003. TREATMENT WITH D003 SIGNIFICANTLY SUPPRESSED (68\%) THE ENZYME UP-REGULATION WHEN CELLS WERE CULTURED IN LDM, WHICH SUGGESTS A DEPRESSION OF DE NOVO SYNTHESIS OF HMG-COA REDUCTASE AND/OR A STIMULATION OF ITS DEGRADATION. HOWEVER, SINCE THE SUPPRESSIVE ACTION OF D003 ON CHOLESTEROL BIOSYNTHESIS WAS OBSERVED IN METABOLIC CONDITIONS UNDER WHICH SYNTHASE UP-REGULATION WAS ALSO ENHANCED, WE CANNOT RULE OUT A POSSIBLE EFFECT OF D003 ON HMG-COA SYNTHASE. THUS, FURTHER STUDIES ARE NEEDED TO CLARIFY THE PRECISE MECHANISM OF THE INHIBITORY EFFECT OF D003 ON CHOLESTEROL BIOSYNTHESIS. (C) 2001 ACADEMIC PRESS.","CHOLESTEROL BIOSYNTHESIS; CULTURED FIBROBLASTS; HMG-COA REDUCTASE; D003; VERY LONG CHAIN SATURATED FATTY ACIDS","LOW-DENSITY-LIPOPROTEIN; COENZYME-A REDUCTASE; HMG-COA REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; MEMBRANE-FLUIDITY; POLICOSANOL; METABOLISM; MODULATION; OXIDATION; HYPERCHOLESTEROLEMIA",NA,NA,"ALEXANDRE H, 1996, MICROBIOL-SGM, V142, P469, DOI 10.1099/13500872-142-3-469; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BERKHOUT TA, 1990, BIOCHEM J, V272, P181, DOI 10.1042/BJ2720181; BOROCHOV H, 1977, BIOCHIM BIOPHYS ACTA, V470, P382, DOI 10.1016/0005-2736(77)90129-8; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/SCIENCE.3513311; BROWN MS, 1980, J LIPID RES, V21, P505; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CAMPILONGO R., 1996, PRENSA MEDICA ARGENTINA, V83, P665; CANETTI M, 1997, CURR THER RES CLIN E, V58, P868, DOI 10.1016/S0011-393X(97)80053-7; CANETTI M, 1995, ADV THER, V12, P245; CASTAÑO G, 1999, CURR THER RES CLIN E, V60, P379, DOI 10.1016/S0011-393X(99)80016-2; CASTAÑO G, 1999, ANGIOLOGY, V50, P123, DOI 10.1177/000331979905000205; DAVIS PJ, 1987, P NATL ACAD SCI USA, V84, P118, DOI 10.1073/PNAS.84.1.118; DIETSCHY JM, 1984, J LIPID RES, V25, P1469; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; ENDO A, 1992, J LIPID RES, V33, P1569; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/PNAS.79.17.5205; FIELD FJ, 1991, J LIPID RES, V32, P1811; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425A0; GONZALEZ L, MIXTURE PRIMARY FATT; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HERNANDEZ J, 1993, CURR THER RES, V51, P568; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; KRITCHEVSKY D, 1987, J NUTR, V117, P1330, DOI 10.1093/JN/117.7.1330; LAU WF, 1995, EXPERIENTIA, V51, P731, DOI 10.1007/BF01941271; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MILLS GL, 1984, LAB TECHNIQUES BIOCH, P20; RIZZO E, 1990, J CLIN CHEM, V262, P17412; RIZZO WB, 1988, J CLIN INVEST, V81, P738, DOI 10.1172/JCI113379; RODRIGUEZECHENI.C, 1994, FOOD CHEM TOXICOL, V11, P74; RODWELL VW, 1973, ADV ENZYMOL RAMB, V38, P373; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V259, P382, DOI 10.1016/0003-9861(87)90504-2; SINGH H, 1986, ARCH BIOCHEM BIOPHYS, V250, P171, DOI 10.1016/0003-9861(86)90714-9; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WANDERS RJA, 1987, BIOCHIM BIOPHYS ACTA, V919, P21, DOI 10.1016/0005-2760(87)90213-X; WHITCOMB RW, 1988, J CLIN INVEST, V81, P185, DOI 10.1172/JCI113292","NATL CTR SCI RES, BIOCHEM LAB, CTR NAT PROD, HAVANA 6880, CUBA","ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","WOS000171654500006","PHARMACOL RES","NATL CTR SCI RES","NATL CTR SCI RES",NA,"MENÉNDEZ R, 2001, PHARMACOL RES","MENÉNDEZ R, 2001, PHARMACOL RES"
"NOA M;MÁS R;MESA R","NOA M;MÁS R;MESA R","A COMPARATIVE STUDY OF POLICOSANOL IVSI LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY",2001,"PHARMACOLOGICAL RESEARCH","43","31-37",16,"10.1006/phrs.2000.0736","NATL CTR SCI RES, CTR NAT PROD, DEPT PHARMACOL, POB 6990, HAVANA 6880, CUBA.; NATL CTR SCI RES, CTR NAT PROD, DEPT PHARMACOL, HAVANA 6880, CUBA.","POLICOSANOL IS A CHOLESTEROL-LOWERING DRUG ISOLATED FROM SUGAR CANE WAX, WHICH ACTS BY INHIBITING CHOLESTEROL BIOSYNTHESIS. PREVIOUS STUDIES HAVE DEMONSTRATED THAT POLICOSANOL INHIBITED SMOOTH MUSCLE CELL (SMC) PROLIFERATION IN THE CUFFED CAROTID ARTERY OF THE RABBIT AND IN ARTERIAL WALL DAMAGE INDUCED BY FORCEPS IN THE CENTRAL ARTERY OF THE EAR OF RABBITS. THE PRESENT STUDY WAS UNDERTAKEN TO COMPARE THE EFFECTS OF POLICOSANOL AND LOVASTATIN ON SMC PROLIFERATION IN THE CUFFED CAROTID ARTERY OF RABBITS. COLLARS WERE PLACED AROUND THE LEFT CAROTID FOR 7 AND 15 DAYS. THE CONTRALATERAL ARTERY WAS SHAM OPERATED. WE STUDIED EIGHT EXPERIMENTAL GROUPS: TWO CONTROLS GROUPS RECEIVING VEHICLE FOR 7 AND 15 DAYS, RESPECTIVELY, A SATELLITE SHAM OPERATED CONTROL GROUP, FOUR GROUPS TREATED WITH POLICOSANOL AT 5 AND 25 MG KG(-1) FOR 7 AND 15 DAYS AND A REFERENCE GROUP RECEIVING LOVASTATIN AT 20 MG KG(-1) FOR 15 DAYS. SAMPLES OF ARTERIES WERE EXAMINED BY LIGHT AND ELECTRON MICROSCOPY. TO EVALUATE INTIMAL THICKENING THE CROSS-SECTIONAL AREAS OF INTIMA AND MEDIA WERE MEASURED. NEOINTIMA WAS SIGNIFICANTLY REDUCED IN TREATED ANIMALS COMPARED WITH CONTROLS, BUT THE REDUCTION IN LOVASTATIN ANIMALS WAS SIGNIFICANTLY LOWER THAN IN POLICOSANOL-TREATED GROUPS. THE SMC PROLIFERATION WAS STUDIED BY THE IMMUNOHISTOCHEMICAL DETECTION OF PROLIFERATING CELL NUCLEAR ANTIGEN AND THE REDUCTION OBSERVED IN POLICOSANOL-TREATED RABBITS WAS SIGNIFICANTLY LARGER THAN IN LOVASTATIN-TREATED ANIMALS. IT IS CONCLUDED THAT THE PROTECTIVE EFFECT OF POLICOSANOL AGAINST NEOINTIMA FORMATION IN THIS EXPERIMENTAL MODEL WAS SLIGHTLY BETTER THAN THAT OF LOVASTATIN. (C) 2001 ACADEMIC PRESS.","POLICOSANOL; SMOOTH MUSCLE CELL PROLIFERATION; LOVASTATIN","HMG-COA REDUCTASE; IN-VITRO; CHOLESTEROL; ATHEROSCLEROSIS; APOPTOSIS; PROLIFERATION; BIOSYNTHESIS; INHIBITION; PLAQUES",NA,NA,"ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; BAR PR, 1996, LIFE SCI, V59, P369, DOI 10.1016/0024-3205(96)00315-3; BELLOSTA S, 1998, ATHEROSCLEROSIS, V137, PS101, DOI 10.1016/S0021-9150(97)00319-5; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; COOPER MM, 1991, CURR OPIN CARDIOL, V6, P581, DOI 10.1097/00001573-199108000-00014; DAVIES MJ, 1995, EUR HEART J, V16, P3, DOI 10.1093/EURHEARTJ/16.SUPPL\_L.3; DAVIGNON J, 1998, INT CONGR SER, V1155, P63; DEMEYER GRY, 1995, J CARDIOVASC PHARM, V26, P614, DOI 10.1097/00005344-199510000-00017; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; FRAGA V, 1997, ARCH MED RES, V28, P355; HARDWICK SJ, 1996, J PATHOL, V179, P294; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KISANUKI A, 1992, ARTERIOSCLER THROMB, V12, P1198, DOI 10.1161/01.ATV.12.10.1198; KOCKX MM, 1992, ARTERIOSCLER THROMB, V12, P1447, DOI 10.1161/01.ATV.12.12.1447; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; NOA M, 1998, ELECTRON MICROSCOPY 1998, VOL 4, P629; NOA M, 1998, INT J CARDIOL, V67, P125, DOI 10.1016/S0167-5273(98)00305-2; NOA M, 1996, J PHARM PHARMACOL, V48, P306, DOI 10.1111/J.2042-7158.1996.TB05922.X; NOA M, 1995, J PHARM PHARMACOL, V47, P289, DOI 10.1111/J.2042-7158.1995.TB05797.X; OBERHAMMER F.A., 1994, LIVER BIOL PATHOBIOL, VTHIRD; POMERANTZ KB, 1989, ARTERIOSCLEROSIS, V9, P413, DOI 10.1161/01.ATV.9.4.413; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; RAINES EW, 1993, BRIT HEART J, V69, PS30; REEDQUIST KA, 1995, BIOCHEM BIOPH RES CO, V211, P665, DOI 10.1006/BBRC.1995.1863; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; SCHACHTER M, 1997, INT J CARDIOL, V62, PS9, DOI 10.1016/S0167-5273(97)00236-2; SHAH PK, 1995, CIRCULATION, V92, P1565; SHIOMI M, 1999, BRIT J PHARMACOL, V126, P961, DOI 10.1038/SJ.BJP.0702382; SOMA MR, 1992, TOXICOL LETT, V64-5, P1, DOI 10.1016/0378-4274(92)90167-I; SOMA MR, 1995, J CARDIOVASC PHARM, V25, PS20; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; WEISSBERG PL, 1996, LANCET, V347, P305, DOI 10.1016/S0140-6736(96)90472-9; ZHU BQ, 1992, J CARDIOVASC PHARM, V19, P246, DOI 10.1097/00005344-199202000-00013","NATL CTR SCI RES, CTR NAT PROD, DEPT PHARMACOL, POB 6990, HAVANA 6880, CUBA","ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","WOS000166488700005","PHARMACOL RES","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"NOA M, 2001, PHARMACOL RES","NOA M, 2001, PHARMACOL RES1"
"GÁMEZ R;MAS R;NOA M;MENÉNDEZ R;ALEMÁN C;ACOSTA ;P P;GARCÍA H;HERNÁNDEZ C;AMOR A;PÉREZ J;GOICOCHEA ;E E","GÁMEZ R;MAS R;NOA M;MENÉNDEZ R;ALEMÁN C;ACOSTA; P;GARCÍA H;HERNÁNDEZ C;AMOR A;PÉREZ J;GOICOCHEA; E","ACUTE AND ORAL SUBCHRONIC TOXICITY OF D003 IN RATS",2000,"TOXICOLOGY LETTERS","118","31-41",30,"10.1016/S0378-4274(00)00260-5","NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA.","D-003 IS A MIXTURE OF HIGHER ALIPHATIC PRIMARY ACIDS PURIFIED FROM SUGAR CANE WAX (SACCHARUM OFFICINARUM) WITH CHOLESTEROL-LOWERING AND ANTIPLATELET EFFECTS EXPERIMENTALLY PROVEN. THE PRESENT WORK REPORTS THE RESULTS OF TWO STUDIES INVESTIGATING THE ACUTE AND SUBCHRONIC ORAL TOXICITY OF D-003 IN RATS. ORAL ACUTE TOXICITY OF D-003 (2000 MG/KG) WAS INVESTIGATED ACCORDING TO THE ACUTE TOXIC CLASS (ATC) METHOD (AN ALTERNATIVE FOR THE CLASSICAL LD50 TEST), WHICH WAS PERFORMED IN WISTAR RATS. THE RESULTS OBTAINED IN THIS STUDY DEFINED D-003 ORAL ACUTE TOXICITY AS UNCLASSIFIED. IN THE SUBCHRONIC STUDY, RATS OF BOTH SEXES WERE ORALLY TREATED WITH D-003 AT 50, 200 AND 1250 MG/KG FOR 90 DAYS. AT THIS TIME. ANIMALS WERE SACRIFICED. NO EVIDENCE OF TREATMENT-RELATED TOXICITY WAS DETECTED DURING THE STUDY. THUS. DATA ANALYSIS OF BODY WEIGHT GAIN, FOOD CONSUMPTION, CLINICAL OBSERVATIONS. BLOOD BIOCHEMICAL, HAEMATOLOGY, ORGAN WEIGHT RATIOS AND HISTOPATHOLOGICAL FINDINGS DID NOT SHOW SIGNIFICANT DIFFERENCES BETWEEN CONTROL AND TREATED GROUPS. IT IS CONCLUDED THAT D-003 ORALLY ADMINISTERED TO RATS WAS SAFE AND THAT NO DRUG-RELATED TOXICITY WAS DETECTED EVEN AT THE HIGHEST DOSES INVESTIGATED IN BOTH ACUTE (2000 MG:KG) AND SUBCHRONIC (1250 MG/KG) STUDIES. (C) 2000 ELSEVIER SCIENCE IRELAND LTD. ALL RIGHTS RESERVED.","ANTIPLATELET DRUGS; CHOLESTEROL-LOWERING DRUGS; D-003; HIGHER ALIPHATIC; PRIMARY ACIDS","SPRAGUE-DAWLEY RATS; PLATELET-AGGREGATION; POLICOSANOL; EFFICACY; HYPERCHOLESTEROLEMIA; CARCINOGENICITY; SAFETY; TOLERABILITY; DATABASE; THERAPY",NA,NA,"ALEMÁN CL, 1998, LAB ANIM, V32, P457, DOI 10.1258/002367798780599802; ALEMAN CL, 1995, FOOD CHEM TOXICOL, V33, P573, DOI 10.1016/0278-6915(95)00026-X; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALEMAN CL, 1994, TERATOGEN CARCIN MUT, V14, P239, DOI 10.1002/TCM.1770140505; ALEMAN CL, 1992, TOXICOL LETT S, V2, P248; ALEMAN CL, 1991, REV CENIC CIENCIAS B, V22, P102; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1998, INT J TISSUE REACT, V20, P119; ARRUZAZABALA ML, 1997, PHARMACOL RES, V36, P293, DOI 10.1006/PHRS.1997.0201; ARRUZAZABALA ML, 1999, IN PRESS BRAZ J MED; BRADLEY DC, 1994, POLYHEDRON, V13, P1, DOI 10.1016/S0277-5387(00)86629-2; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CARBAJAL D, 1998, PHARMACOL RES, V38, P89, DOI 10.1006/PHRS.1998.0324; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; CASTANO G, 1998, CURR THER RES CLIN E, V59, P737, DOI 10.1016/S0011-393X(98)85033-9; CHHABRA RS, 1990, ENVIRON HEALTH PERSP, V86, P313, DOI 10.2307/3430970; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; DAVENPORT RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; DIEZ-TEJEDOR E, 1995, NEUROLOGIA, V10 SUPPL 2, P48; DORATO MICHAEL A., 1994, P189; EVANS LG, 1993, EXPT TOXICOLOGY BASI, P119; FERNANDEZ SI, 1991, REV CENIC CIEN BIOL, V22, P98; FORD DJ, 1987, CARE MANAGEMENT LAB, P35; GAD S., 1989, PRINCIPLES METHODS T, P435; GÁMEZ R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011-393X(00)80029-6; GERSON R, 1989, AM J MED S4A, V87, P2838; GONZALEZ L, 1997, 3597 PAT CU LAB DALM; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; LAGUNA A, 1996, PATENT NO. 5856316; LAGUNA A, 1997, PATENT NO. 91500137; LANDSDOWN AB, 1993, EXPT TOXICOLOGY BASI, P101; LEE PETER N., 1993, P405, DOI 10.1039/9781847550798-00405; LONG GG, 1998, TOXICOL PATHOL, V26, P316, DOI 10.1177/019262339802600304; MACDONALD JS, 1988, AM J CARDIOL, V62, PJ16, DOI 10.1016/0002-9149(88)90003-3; MATSUZAWA T, 1993, J VET MED SCI, V55, P351, DOI 10.1292/JVMS.55.351; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MENENDEZ R, 2000, ATHEROSCLEROSIS, V151, P131; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MOLINA V, 2000, IN PRESS PHARM RES; MORTON DB, 1993, LAB ANIM, V27, P1, DOI 10.1258/002367793780745633; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; REHG JE, 1998, LAB ANIM SCI, V48, P438; RENDON A, 1992, TOXICOL LETT S, P248; RICHTER GW, 1974, AM J PATHOL, V74, P481; RODEIRO I, 2000, REV CNIC CIENCIAS BI, V31, P113; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRIGUEZ MD, 1997, TOXICOL LETT, V90, P97, DOI 10.1016/S0378-4274(96)03844-1; RODRÍGUEZ MD, 1998, TERATOGEN CARCIN MUT, V18, P1, DOI 10.1002/(SICI)1520-6866(1998)18:1<1::AID-TCM1>3.0.CO;2-K; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; SCHLEDE E, 1995, ARCH TOXICOL, V69, P659, DOI 10.1007/S002040050229; STEVENS KR., 1989, PRINCIPLES AND METHODS OF TOXICOLOGY, P237; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; VALDES S, 1996, INT J CLIN PHARM RES, V16, P67; VON KEUTZ E, 1998, AM J CARDIOL, V82, P11J, DOI 10.1016/S0002-9149(98)00424-X; VOSS G, 1970, TOXICOL APPL PHARM, V16, P764, DOI 10.1016/0041-008X(70)90082-7; WALKER JF, 1989, AM J MED, V87, PS44, DOI 10.1016/S0002-9343(89)80598-4; WARD JM, 1980, VET PATHOL, V17, P678, DOI 10.1177/030098588001700604; WOLFORD ST, 1986, J TOXICOL ENV HEALTH, V18, P161, DOI 10.1080/15287398609530859","NATL CTR SCI RES, CTR NAT PROD, HAVANA, CUBA","ELSEVIER IRELAND LTD","ENGLISH","TOXICOL. LETT.","ARTICLE","ISI","WOS000166140900004","TOXICOL LETT","NATL CTR SCI RES","NATL CTR SCI RES",NA,"GÁMEZ R, 2000, TOXICOL LETT","GÁMEZ R, 2000, TOXICOL LETT"
"MENÉNDEZ R;MÁS R;AMOR A;GONZÁLEZ R;FERNÁNDEZ J;RODEIRO I;ZAYAS M;JIMÉNEZ S","MENÉNDEZ R;MÁS R;AMOR AM;GONZÁLEZ RM;FERNÁNDEZ JC;RODEIRO I;ZAYAS M;JIMÉNEZ S","EFFECTS OF POLICOSANOL TREATMENT ON THE SUSCEPTIBILITY OF LOW DENSITY LIPOPROTEIN LDL ISOLATED FROM HEALTHY VOLUNTEERS TO OXIDATIVE MODIFICATION IIN VITROI",2000,"BRITISH JOURNAL OF CLINICAL PHARMACOLOGY","50","255-262",66,"10.1046/j.1365-2125.2000.00250.x","NATL CTR SCI RES, CTR NAT PROD, SOTO VALLE, POB 6880, HAVANA 6880, CUBA.; NATL CTR SCI RES, CTR NAT PROD, SOTO VALLE, HAVANA 6880, CUBA.","AIMS THE AIM OF THIS STUDY WAS TO INVESTIGATE THE EFFECT OF POLICOSANOL ON THE SUSCEPTIBILITY OF LDL-C TO IN VITRO LIPID PEROXIDATION IN HUMAN HEALTHY VOLUNTEERS. METHODS THE EFFECT OF POLICOSANOL (5 AND 10 MG DAY(-1)) ON LDL-C OXIDATION WAS STUDIED IN A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL CONDUCTED IN 69 SUBJECTS. LDL-C SAMPLES ISOLATED AT BASELINE AND AFTER 8 WEEKS WERE SUBJECTED TO IN VITRO TESTS OF LDL-C OXIDATION. WE TESTED THE SUSCEPTIBILITY OF LDL-C TO LIPID PEROXIDATION IN A CELL-FREE SYSTEM BY THE ADDITION OF COPPER IONS AS WELL AS IN A MORE PHYSIOLOGICAL SYSTEM, MACROPHAGE-MEDIATED OXIDATION. RESULTS AT BASELINE ALL GROUPS WERE WELL MATCHED REGARDING ALL VARIABLES. AFTER 8 WEEKS OF THERAPY POLICOSANOL ADMINISTERED AT 5 AND 10 MG, SIGNIFICANTLY AND IN A DOSE-DEPENDENT MANNER INCREASED THE LAG PHASE OF CONJUGATED DIENE GENERATION (MEAN +/- S.D.) FROM 83.79 +/- 29.16 MIN TO 94.90 +/- 25.50 MIN (5 MG DAY(-1)) AND FROM 82.74 +/- 17.16 MIN TO 129.89 +/- 35.71 MIN (10 MG DAY(-1)), WHILE IN THE PLACEBO GROUP LDL-C OXIDATION DID NOT CHANGE SIGNIFICANTLY. POLICOSANOL (10 MG DAY(-1)), BUT NOT PLACEBO, SIGNIFICANTLY DECREASED THE RATE OF CONJUGATED DIENE GENERATION. COMPARISON WITH PLACEBO AFTER THERAPY ALSO SHOWED SIGNIFICANT DIFFERENCES. MACROPHAGE MEDIATED-OXIDATION WAS ALSO INHIBITED BY POLICOSANOL AS EVIDENT BY MEASURING THIOBARBITURIC ACID REACTIVE SUBSTANCES (TBARS). POLICOSANOL (10 MG DAY(-1)) SIGNIFICANTLY LOWERED MALONDIALDEHYDE (MDA) GENERATION FROM 8.50 +/- 0.91 TO 5.76 +/ - 1.01 NMOL MG(-1) PROTEIN. COMPARISON WITH PLACEBO AFTER 5 AND 10 MG DAY(-1) SHOWED SIGNIFICANT DIFFERENCES. POLICOSANOL SIGNIFICANTLY LOWERED TOTAL CHOLESTEROL BY 10.5\% (5 MG DAY(-1)) AND 12.4\% (10 MG DAY(-1)) AND LDL-C BY 16.7\% AND 2-0.2\%, RESPECTIVELY. ALSO, POLICOSANOL (10 MG DAY(-1)) INCREASED HDL-C BY 15.2\%. FIVE SUBJECTS WITHDREW FROM THE STUDY, NONE BECAUSE OF ADVERSE EXPERIENCES. NO CLINICAL OR BLOOD BIOCHEMICAL DRUG-RELATED DISTURBANCES WERE FOUND. CONCLUSIONS THE PRESENT STUDY DEMONSTRATED THAT POLICOSANOL ADMINISTERED WITHIN ITS THERAPEUTIC DOSAGE FOR LOWERING CHOLESTEROL (5 AND 10 MG DAY(-1)), DECREASED THE SUSCEPTIBILITY OF LDL-C TO LIPID PEROXIDATION IN VITRO.","COPPER-MEDIATED OXIDATION; HEALTHY VOLUNTEERS; LDL LIPID PEROXIDATION; MACROPHAGE-MEDIATED OXIDATION; POLICOSANOL","II HYPERCHOLESTEROLEMIA; LIPID-PEROXIDATION; IN-VITRO; INVITRO; OXIDATION; APOLIPOPROTEIN-B; ELDERLY PATIENTS; EFFICACY; PROBUCOL; ATHEROSCLEROSIS; CHOLESTEROL",NA,NA,"ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BREDIE SJH, 1995, AM J CARDIOL, V75, P348, DOI 10.1016/S0002-9149(99)80552-9; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/ANNUREV.BI.52.070183.001255; CAMPILONGO R., 1996, PRENSA MEDICA ARGENTINA, V83, P665; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; CASTAÑO G, 1999, CURR THER RES CLIN E, V60, P379, DOI 10.1016/S0011-393X(99)80016-2; CASTANO G, 1995, CURR THER RES CLIN E, V56, P819, DOI 10.1016/0011-393X(95)85065-1; CASTANO G, 1998, ANGIOLOGY, V50, P123; CASTANO G, 1991, PCM-PREM PERS COMPUT, V5, P21; CHISOLM GM, 1991, CURR OPIN LIPIDOL, V2, P311; COMINACINI L, 1993, ATHEROSCLEROSIS, V99, P63, DOI 10.1016/0021-9150(93)90051-U; CRISTOL LS, 1992, ATHEROSCLEROSIS, V97, P11, DOI 10.1016/0021-9150(92)90046-J; DAUGHERTY A, 1991, BRIT J PHARMACOL, V103, P1013, DOI 10.1111/J.1476-5381.1991.TB12293.X; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; ESTERBAUER H, 1993, BRIT MED BULL, V49, P566, DOI 10.1093/OXFORDJOURNALS.BMB.A072631; FRAGA V, 1997, ARCH MED RES, V28, P355; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HUSSEIN O, 1997, ATHEROSCLEROSIS, V128, P11, DOI 10.1016/S0021-9150(96)05972-2; KAWAMURA M, 1996, CLIN CHEM, V42, P644; KLEINVELD HA, 1992, CLIN CHEM, V38, P2066; KLEINVELD HA, 1993, EUR J CLIN INVEST, V23, P289, DOI 10.1111/J.1365-2362.1993.TB00776.X; LAVY A, 1991, METABOLISM, V40, P794, DOI 10.1016/0026-0495(91)90005-H; LEAKE D.S., 1991, CURRENT OPINIONS IN LIPIDOLOGY, V2, P301; LEAKE DS, 1990, BIOCHEM J, V270, P741, DOI 10.1042/BJ2700741; LIU KZ, 1992, AM HEART J, V123, P285, DOI 10.1016/0002-8703(92)90636-A; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; ORTENSI G, 1997, CURR THER RES CLIN E, V58, P390, DOI 10.1016/S0011-393X(97)80099-9; PEDERSEN TR, 1994, LANCET, V344, P1383; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PONS P, 1994, J CLIN PHARM RES, V14, P27; REAVEN PD, 1992, ARTERIOSCLER THROMB, V12, P318, DOI 10.1161/01.ATV.12.3.318; REGNSTROM J, 1990, ATHEROSCLEROSIS, V82, P43, DOI 10.1016/0021-9150(90)90142-6; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SCHMIDT K, 1990, BIOCHEM BIOPH RES CO, V172, P614, DOI 10.1016/0006-291X(90)90718-3; SEIGLER L, 1981, CLIN CHEM, V27, P838; SOLTERO I, 1993, ARCH VENEZOL FARMACO, V12, P65; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; TERSPTRA AHM, 1981, ANAL BIOCHEM, V111, P149; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZARDOYA R, 1996, CURR THER RES CLIN E, V57, P568, DOI 10.1016/S0011-393X(96)80068-3","NATL CTR SCI RES, CTR NAT PROD, SOTO VALLE, POB 6880, HAVANA 6880, CUBA","WILEY","ENGLISH","BR. J. CLIN. PHARMACOL.","ARTICLE","ISI","WOS000089591000009","BR J CLIN PHARMACOL","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"MENÉNDEZ R, 2000, BR J CLIN PHARMACOL","MENÉNDEZ R, 2000, BR J CLIN PHARMACOL1"
"MOLINA V;ARRUZAZABALA M;CARBAJAL D;MÁS R;VALDÉS S","MOLINA V;ARRUZAZABALA ML;CARBAJAL D;MÁS R;VALDÉS S","ANTIPLATELET AND ANTITHROMBOTIC EFFECT OF D003",2000,"PHARMACOLOGICAL RESEARCH","42","137-143",46,"10.1006/phrs.2000.0664","MOLINA, V (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6990, HAVANA 6880, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.","D-003 IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC SATURATED ACIDS PURIFIED FROM SUGAR CANE WAX WHOSE MAIN COMPONENT IS OCTACOSANOIC ACID FOLLOWED BY TRIACONTANOIC, DOTRIACONTANOIC, AND TETRATRIACONTANOIC ACIDS. THE AIM OF THIS STUDY WAS TO EVALUATE THE EFFECTS OF D-003 ON: EX VIVO PLATELET AGGREGATION, ARTERIAL THROMBOSIS AND BLEEDING TIME IN RATS. IN ADDITION, TIME COURSE OF ANTIPLATELET EFFECTS OF D-003 WAS ALSO INVESTIGATED ON EX VIVO PLATELET AGGREGATION IN,GUINEA-PIGS. D-003 (25-200 MG KG(-1)) ORALLY ADMINISTERED AT SINGLE OR REPEATED DOSES (3 DAYS) INHIBITED PLATELET AGGREGATION INDUCED BY COLLAGEN (2.2 MU G ML(-1)) AND ADP (2 MU MOL L(-1)) IN RATS, AND COLLAGEN (0.25 MU G ML(-1)) INDUCED AGGREGATION IN GUINEA-PIGS IN A DOSE-DEPENDENT MANNER. SINGLE DOSES OF D-003 (5-500 MG KG(-1)) ADMINISTERED ORALLY 2 H BEFORE INDUCTION OF ARTERIAL THROMBOSIS SIGNIFICANTLY INHIBITED THE REDUCTION OF RECTAL TEMPERATURE. D-003 ADMINISTERED AT A SINGLE DOSE (50-200 MG KG(-1)) 2 H BEFORE THE EXPERIMENT SIGNIFICANTLY INCREASED THE BLEEDING TIME IN A DOSE-DEPENDENT MANNER. THE TIME-COURSE EFFECTS OF D-003 ON PLATELET AGGREGATION, ARTERIAL THROMBUS FORMATION, AND BLEEDING TIME SHOWED NO EFFECT 0.5 H AFTER DOSING, AND MAXIMAL EFFECTS EXHIBITED 1-2 H AFTER TREATMENT, WHEREAS NO SIGNIFICANT EFFECTS WERE FOUND 4 H AFTER TREATMENT. (C) 2000 ACADEMIC PRESS.","D-003; ARTERIAL THROMBOSIS; BLEEDING TIME; PLATELET AGGREGATION","ARTERIAL THROMBOSIS; II HYPERCHOLESTEROLEMIA; PLATELET-AGGREGATION; BLEEDING-TIME; POLICOSANOL; RATS; ASPIRIN; MODEL; LIVER; TICLOPIDINE",NA,NA,"AMBROSIO G, 1997, CARDIOVASC RES, V34, P445, DOI 10.1016/S0008-6363(97)00101-6; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; AOKI T, 1998, THROMB RES, V89, P129, DOI 10.1016/S0049-3848(97)00308-3; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1998, INT J TISSUE REACT, V20, P119; ARRUZAZABALA ML, 1992, REV IBEROAMER TROMB, V5, P17; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927B0; CADROY Y, 1990, CARDIOVASCULAR PHARM; CANETTI M, 1995, ADV THER, V12, P245; CARBAJAL D, 1994, PROSTAG LEUKOTR ESS, V50, P249, DOI 10.1016/0952-3278(94)90162-7; DEJANA E, 1982, THROMB HAEMOSTASIS, V48, P108; DELPRINCIPE D, 1991, THROMB RES, V62, P365, DOI 10.1016/0049-3848(91)90010-T; DIENER HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; DIMINNO G, 1985, J CLIN INVEST, V75, P328, DOI 10.1172/JCI111705; EMMS H, 1986, BRIT J PHARMACOL, V87, P109, DOI 10.1111/J.1476-5381.1986.TB10162.X; FINAZZIAGRO A, 1982, BIOCHIM BIOPHYS ACTA, V718, P21, DOI 10.1016/0304-4165(82)90004-6; FRAGA V, 1997, ARCH MED RES, V28, P355; FUSTER V, 1990, CIRCULATION, V82, P47; GONZALEZ L, 1998, PATENT NO. 43631; HENRIKSSON P, 1987, PROSTA LEUKOTR MED, V29, P71, DOI 10.1016/0262-1746(87)90098-9; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HLADOVEC J, 1988, GEN PHARMACOL-VASC S, V19, P171, DOI 10.1016/0306-3623(88)90057-2; HLADOVEC J, 1986, THROMB RES, V41, P665, DOI 10.1016/0049-3848(86)90363-4; HLADOVEC J, 1986, THROMB RES, V43, P545, DOI 10.1016/0049-3848(86)90074-5; HLADOVEC J, 1986, THROMB RES, V41, P659, DOI 10.1016/0049-3848(86)90362-2; KABIR Y, 1995, ACTA ALIMENT HUNG, V24, P39; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; KENNET KWU, 1996, J INTERN MED, V239, P17; LAGUNA A, 1997, U.S. PATENT, PATENT NO. 5663156; LANAS AI, 1996, GUT, V39, P654, DOI 10.1136/GUT.39.5.654; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; PROSDOCIMI M, 1988, PHARMACOL RES, V20, P1, DOI 10.1016/S0031-6989(88)80601-5; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; SALVEMINI D, 1994, TIPS, V141, P36; SIMONETTI I, ANN ITAL MED INT, V13, P163; VALDES S, 1996, INT J CLIN PHARM RES, V16, P67; WHETSEL TR, 1999, PHARMACOTHERAPY, V19, P228, DOI 10.1592/PHCO.19.3.228.30916","MOLINA, V (CORRESPONDING AUTHOR), NATL CTR SCI RES, CTR NAT PROD, POB 6990, HAVANA 6880, CUBA","ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","ENGLISH","PHARMACOL. RES.","ARTICLE","ISI","WOS000088190300005","PHARMACOL RES","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"MOLINA V, 2000, PHARMACOL RES","MOLINA V, 2000, PHARMACOL RES"
"GÁMEZ R;MENDOZA S;MÁS R;MESA R;CASTAÑO G;RODRIGUEZ B;MARRERO D","GÁMEZ R;MENDOZA S;MÁS R;MESA R;CASTAÑO G; RODRIGUEZ B;MARRERO D","DOSEDEPENDENT CHOLESTEROLLOWERING EFFECTS OF D003 ON NORMOCHOLESTEROLEMIC RABBITS",2000,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","61","460-468",41,"10.1016/S0011-393X(00)80029-6","NATL CTR SCI RES, CTR NAT PROD, POB 6990, HAVANA 6880, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.; MED SURG RES CTR, HAVANA, CUBA.","OBJECTIVES: THE GOAL OF THE PRESENT STUDY WAS TO EVALUATE THE EFFECTS OF D-003 (5 TO 200 MG/KG) ADMINISTERED ORALLY FOR 30 DAYS ON THE SERUM LIPID PROFILE OF NORMOCHOLESTEROLEMIC NEW ZEALAND RABBITS AS WELL AS THE EFFECTS OF TREATMENT WITHDRAWAL FOR THE FOLLOWING 30 DAYS. BACKGROUND: D-003 IS A MIXTURE OF HIGHER PRIMARY ALIPHATIC ACIDS; OCTACOSANOIC ACID IS ITS MAJOR COMPONENT. METHODS: THIRTY-FIVE ANIMALS WERE ADAPTED TO EXPERIMENTAL CONDITIONS FOR 15 DAYS AND THEN RANDOMIZED TO 5 STUDY GROUPS: A CONTROL GROUP, WHICH RECEIVED ONLY ORALLY EQUIVALENT VOLUMES OF THE VEHICLE, AND 4 GROUPS TREATED WITH THE VARIOUS DOSES OF D-003 (5, 25, 100, OR 200 MG/KG). RESULTS: AFTER 30 DAYS OF TREATMENT, D-003 SIGNIFICANTLY (P < 0.01) AND DOSE-DEPENDENTLY REDUCED LEVELS OF BOTH TOTAL CHOLESTEROL (TC) (RANGE, 27.5\% TO 37.3\%) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (RANGE, 64.5\% TO 84.4\%). AFTER 30 DAYS OF TREATMENT, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS INCREASED IN ALL TREATED GROUPS COMPARED WITH BASELINE. ONLY THE FINAL VALUES OF THE GROUPS RECEIVING DOSES OF 25 TO 200 MG/KG MERE SIGNIFICANTLY LARGER (P < 0.01) THAN THOSE OF THE CONTROL GROUP. THIS EFFECT WAS NOT DOSE DEPENDENT. NO DRUG-RELATED EFFECTS ON TRIGLYCERIDES MERE NOTED. THERE MERE NO SIGNIFICANT CHANGES IN THE CONTROL GROUP'S LIPID PROFILE DURING THE STUDY. THE EFFECTS OF D-003 ON TC, LDL-C, AND HDL-C LEVELS WERE REVERSIBLE AFTER THE WASHOUT PERIOD, WITH COMPLETE RECOVERY TO BASELINE VALUES AFTER 30 DAYS OF TREATMENT WITHDRAWAL. NO REBOUND EFFECTS WERE OBSERVED. IN ADDITION, DRUG-RELATED TOXICITY REGARDING MORTALITY, FOOD CONSUMPTION, WEIGHT GAIN, OR BLOOD CHEMISTRY SAFETY INDICATORS WAS NOT EVIDENT. CONCLUSIONS: RESULTS OF THIS STUDY SUGGEST THAT D-003 HAS REVERSIBLE CHOLESTEROL-LOWERING EFFECTS CHARACTERIZED BY A DOSE-DEPENDENT REDUCTION OF TC AND LDL-C VALUES ACCOMPANIED BY A NON-DOSE-DEPENDENT INCREASE IN HDL-C LEVELS.","D-003; NORMOCHOLESTEROLEMIC; CHOLESTEROL-LOWERING DRUG; LIPID PROFILE","CORONARY HEART-DISEASE; II HYPERCHOLESTEROLEMIA; POLICOSANOL; PREVENTION; EFFICACY; SAFETY; HYPERLIPIDEMIA; PRAVASTATIN; MEN",NA,NA,"ABILIO L. G., 1998, PATENTS, PATENT NO. EP 0619802B1, 0619802; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BHATNAGAR D, 1998, PHARMACOL THERAPEUT, V79, P205, DOI 10.1016/S0163-7258(98)00018-7; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; FARMER JA, 1996, DRUGS, V52, P649, DOI 10.2165/00003495-199652050-00003; FARNIER M, 1998, AM J CARDIOL, V82, P3J, DOI 10.1016/S0002-9149(98)00423-8; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GONZALEZ L, 1998, PATENT NO. 2744; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/JAMA.269.23.3015; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; PEDERSEN TR, 1994, LANCET, V344, P1383; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PYORALA K, 1994, EUR HEART J, V15, P1300; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RODRIGUEZ-ECHENIQUE C., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P74; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHECTMAN G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SEIGLER L, 1981, CLIN CHEM, V27, P838; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMES R, 1998, 47 ANN SCI SESS ACC; ZARDOYA R, 1996, CURR THER RES CLIN E, V57, P568, DOI 10.1016/S0011-393X(96)80068-3","NATL CTR SCI RES, CTR NAT PROD, POB 6990, HAVANA 6880, CUBA","ELSEVIER SCIENCE INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","ARTICLE","ISI","WOS000088464000009","CURR THER RES-CLIN EXP","NATL CTR SCI RES;NATL CTR SCI RES;MED SURG RES CTR","NATL CTR SCI RES",NA,"GÁMEZ R, 2000, CURR THER RES-CLIN EXP","GÁMEZ R, 2000, CURR THER RES-CLIN EXP"
"MÁS R","MÁS R","POLICOSANOL IHYPOLIPIDEMIC ANTIOXIDANT TREATMENT OF ATHEROSCLEROSISI",2000,"DRUGS OF THE FUTURE","25","569-586",57,"10.1358/dof.2000.025.06.574693","NATL CTR SCI RES, CTR NAT PROD, POB 6880 6990, HABANA CITY, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HABANA CITY, CUBA.","NATURAL MIXTURE OF HIGH-MOLECULAR-WEIGHT ALIPHATIC PRIMARY ALCOHOLS ISOLATED FROM SUGAR CANE (SACCHARUM OFFICINARUM L.) WAX WHOSE MAIN COMPONENT IS OCTACOSANOL, FOLLOWED BY TRIACONTANOL AND HEXACOSANOL, WHEREAS TETRACOSANOL, HEPTACOSANOL, NONACOSANOL, DOTRIACONTANOL AND TETRATIACONTANOL ARE MINOR COMPONENTS",NA,"CORONARY HEART-DISEASE; SUCCESSIVE DOSE INCREASES; SPRAGUE-DAWLEY RATS; HMG-COA REDUCTASE; COENZYME-A REDUCTASE; STARCH-CASEIN DIET; II; HYPERCHOLESTEROLEMIA; PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; CHOLESTEROL LEVELS",NA,NA,"ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/PNAS.77.7.3957; ALBERTS AW, 1998, ATHEROSCLER REV, V11, P123; ALCOCER L, 1999, INT J TISSUE REACT, V21, P85; ALEMAN CL, 1995, FOOD CHEM TOXICOL, V33, P573, DOI 10.1016/0278-6915(95)00026-X; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALEMAN CL, 1994, TERATOGEN CARCIN MUT, V14, P239, DOI 10.1002/TCM.1770140505; ALEMAN CL, 1991, REV CENIC CIENCIAS B, V22, P102; ALEMAN CL, 1992, TOXICOL LETT, P64; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ANEIROS E, 1993, CURR THER RES CLIN E, V54, P304, DOI 10.1016/S0011-393X(05)80631-9; ANONYMOUS, 1985, DIABETOLOGIA, V28 SUPPL, P615; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; ARRUZAZABALA ML, 1993, PROSTAG LEUKOTR ESS, V49, P695, DOI 10.1016/0952-3278(93)90080-G; ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; ARRUZAZABALA ML, 1998, INT J TISSUE REACT, V20, P119; ARRUZAZABALA ML, 1997, PHARMACOL RES, V36, P293, DOI 10.1006/PHRS.1997.0201; ARRUZAZABALA ML, 1996, PHARMACOL RES, V34, P181, DOI 10.1006/PHRS.1996.0086; ARRUZAZABALA ML, 1999, IN PRESS BRAZIL J ME; ARRUZAZABALA ML, 1992, REV IBEROAMER TROMB, V5, P17; ARRUZAZABALA ML., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P60; AVIRAM M, 1997, ATHEROSCLEROSIS, V134, P483; AVIRAM M, 1992, CURRENT OPINION LIPI, V3, P344; BATISTA J, 1996, INT J CLIN PHARM TH, V34, P134; BENITEZ M, 1997, CURR THER RES CLIN E, V58, P859, DOI 10.1016/S0011-393X(97)80052-5; BHATNAGAR D, 1998, PHARMACOL THERAPEUT, V79, P205, DOI 10.1016/S0163-7258(98)00018-7; BILHEIMER DW, 1991, ATHEROSCLEROSIS, V91, PS35, DOI 10.1016/0021-9150(91)90205-H; BURIANDO G, COMP STUDY EFFICACY; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; CAMPILONGO R., 1996, PRENSA MEDICA ARGENTINA, V83, P665; CANAVACIOLO VLG, 1999, J AOAC INT, V82, P834; CANETTI M, 1995, INT J CLIN PHARM RES, V15, P159; CANETTI M, 1997, CURR THER RES CLIN E, V58, P868, DOI 10.1016/S0011-393X(97)80053-7; CANETTI M, 1995, ADV THER, V12, P245; CANETTI M, 1996, REV CENIC CIEN BIOL, V27, P64; CAPURSO A, 1992, J HYPERTENS, V10, PS65; CARBAJAL D, 1994, PROSTAG LEUKOTR ESS, V50, P249, DOI 10.1016/0952-3278(94)90162-7; CARBAJAL D, 1998, PHARMACOL RES, V38, P89, DOI 10.1006/PHRS.1998.0324; CARBAJAL D, 1998, PROSTAG LEUKOTR ESS, V58, P61, DOI 10.1016/S0952-3278(98)90130-2; CARBAJAL D, 1993, ARCH VENEZOLANO FARM, V12, P42; CASTA G, 1999, IN PRESS INT J CLIN; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; CASTAÑO G, 1999, CURR THER RES CLIN E, V60, P379, DOI 10.1016/S0011-393X(99)80016-2; CASTANO G, 1995, CURR THER RES CLIN E, V56, P819, DOI 10.1016/0011-393X(95)85065-1; CASTAÑO G, 1999, ANGIOLOGY, V50, P123, DOI 10.1177/000331979905000205; CASTANO G, 1998, CURR THER RES CLIN E, V59, P737, DOI 10.1016/S0011-393X(98)85033-9; CASTANO G, 1996, CURR THER RES CLIN E, V57, P691, DOI 10.1016/S0011-393X(96)80074-9; CASTANO G, 1997, CURR THER RES CLIN E, V58, P154, DOI 10.1016/S0011-393X(97)80010-0; CASTANO G, 1998, REV CENIC CIEN BIOL, V29, P9; CASTANO G, 1999, IN PRESS J GERONTOL; CASTANO G, 1998, REV CENIC CIEN BIOL, V29, P17; CASTANO G, 1999, IN PRESS GYNECOL END; CASTANO G, 1991, PCM-PREM PERS COMPUT, V5, P21; CASTANO G, 1996, REV CENIC CIEN BIOL, V27, P57; CASTANO G, 2000, IN PRESS CURR THER R; CASTANO G, 1993, REV CENIC CIEN BIOL, V27, P38; CASTANO MR, 1999, IN PRESS ANGIOLOGY; CHAO YS, 1983, BIOCHIM BIOPHYS ACTA, V754, P134, DOI 10.1016/0005-2760(83)90154-6; CORSINI A, 1996, CARDIOLOGY, V87, P458, DOI 10.1159/000177139; CORSINI A, 1992, CLIN BIOCHEM, V25, P399, DOI 10.1016/0009-9120(92)80024-B; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; CRESPO N, 1999, IN PRESS CURR THER R; CRUZ-BUSTILLO D., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P62; CUEVAS VM, 1998, ARCH MED RES, V29, P21; DAVOLOS JM, 1996, 10 LAT C NEPHR HYP S; DENKE MA, 1990, ANN INTERN MED, V112, P780, DOI 10.7326/0003-4819-112-10-780; FARMER JA, 1996, DRUGS, V52, P649, DOI 10.2165/00003495-199652050-00003; FARNIER M, 1998, AM J CARDIOL, V82, P3J, DOI 10.1016/S0002-9149(98)00423-8; FERNANDEZ L, 1998, CURR THER RES CLIN E, V59, P717, DOI 10.1016/S0011-393X(98)85030-3; FERNANDEZ SI, GENOTOXICITY POLICOS; FRAGA V, 1997, ARCH MED RES, V28, P355; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDERICKSON DS, 1972, METABOLIC BASIS INHE, P545; GAMEZ R, SUBCHRONIC TOXICITY; GARCIA M, EFFECT POLICOSANOL P; GAW A, 1996, ATHEROSCLEROSIS, V125, P267; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GRANJA A, PATENT NO. 22229; GRANJA AL, PATENT NO. 9407830; GRANJA AL, PATENT NO. 2124578; GRANJA AL, 1994, PATENT NO. 192072; GRANJA AL, PATENT NO. 0488928; GRANJA AL, PATENT NO. 22225; GRANJA L, PATENT NO. 5856316; GRANJA L, PATENT NO. 5663156; GRANJA L, PATENT NO. 0619802; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/JAMA.269.23.3015; GUTIERREZ C, 1993, REV CENIC CIEN BIOL, V27, P36; HALLER H, 1997, DRUGS, V53, P1, DOI 10.2165/00003495-199700531-00003; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; KROON PA, 1982, ATHEROSCLEROSIS, V44, P41, DOI 10.1016/0021-9150(82)90051-X; *LAB DALM, PHARM 3H OCT; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAURENZI M, 1990, J HYPERTENS, V8, PS7, DOI 10.1097/00004872-199003001-00003; MARCELLO S, 2000, IN PRESS CURR THER R; MARTINTO M, EFFICACY TOLERABILIT; MÁS R, 1999, CLIN PHARMACOL THER, V65, P439, DOI 10.1016/S0009-9236(99)70139-6; MÁS R, 1999, CURR THER RES CLIN E, V60, P458, DOI 10.1016/S0011-393X(99)80024-1; MENÉNDEZ R, 1999, PHYSIOL BEHAV, V67, P1, DOI 10.1016/S0031-9384(99)00004-9; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MENENDEZ R, 1993, REV MEXICANA CIENCIA, V24, P16; MENENDEZ R, 1996, REV CENIC CIEN BIOL, V27, P32; MENENDEZ R, 1999, IN PRESS BR J CLIN P; MENENDEZ ROBERTO, 1996, BIOLOGICAL RESEARCH, V29, P253; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MOLINA V, 1999, BRAZ J MED BIOL RES, V32, P1269, DOI 10.1590/S0100-879X1999001000014; NEGREAMINOU P, 1996, 66 C EUR ATH SOC JUL, P120; NIGRO NB, 1999, REV CENIC CIEN BIOL, V30, P127; NOA M, 1996, J PHARM PHARMACOL, V48, P306, DOI 10.1111/J.2042-7158.1996.TB05922.X; NOA M, 1997, J PHARM PHARMACOL, V49, P999, DOI 10.1111/J.2042-7158.1997.TB06031.X; NOA M, 1994, J PHARM PHARMACOL, V46, P282, DOI 10.1111/J.2042-7158.1994.TB03794.X; NOA M, 1995, J PHARM PHARMACOL, V47, P289, DOI 10.1111/J.2042-7158.1995.TB05797.X; NOA M, 1998, J ELECTRON MICROSC, V4, P629; OROZCO J, 1993, REV CENIC CIEN BIOL, V27, P41; PARKER RA, 1990, J LIPID RES, V31, P1271; PEARSON TA, 1993, AM J CARDIOL, V72, P1072, DOI 10.1016/0002-9149(93)90864-9; PEDERSEN TR, 1994, LANCET, V344, P1383; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1997, CURR THER RES CLIN E, V58, P26, DOI 10.1016/S0011-393X(97)80074-4; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; PONS P, 1996, REV CENIC CIEN BIOL, V27, P71; PRATS H, POLICOSANOL VS SIMVA; PYORALA K, 1994, EUR HEART J, V15, P1300; RENDON A, 1992, TOXICOL LETT, P64; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRIGUEZ MD, 1997, TOXICOL LETT, V90, P97, DOI 10.1016/S0378-4274(96)03844-1; RODRÍGUEZ MD, 1998, TERATOGEN CARCIN MUT, V18, P1, DOI 10.1002/(SICI)1520-6866(1998)18:1<1::AID-TCM1>3.0.CO;2-K; RODRIGUEZ-ECHENIQUE C., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P74; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; ROEDERER GO, 1997, ATHEROSCLEROSIS, V134, P60, DOI 10.1016/S0021-9150(97)88386-4; ROMAN O, COMP STUDY EFFICACY; SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SANS S, 1997, EUR HEART J, V18, P1231; SCAZZIOTA A, 1996, REV IBEROAMER TROMB, V9, P58; SCHECTMAN G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SHAW MK, 1990, BIOCHEM BIOPH RES CO, V170, P726, DOI 10.1016/0006-291X(90)92151-O; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMES RJ, 1998, J AM COLL CARDIOL SA, V31; SOLTERO I, 1993, ARCH VENEZOL FARMACO, V12, P65; SOLTERO I, 1993, ARCH VENEZ FARM TER, V12, P71; SOUTO NP, 1991, REV CENIC CIEN BIOL, V22, P77; SOUTO NP, 1991, REV CENIC CIEN BIOL, V22, P15; STEINER A, 1991, DRUG SAFETY, V6, P118, DOI 10.2165/00002018-199106020-00003; SUMAROKOV D, 1999, REV CENIC CIEN BIOL, V30, P133; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; VALDES S, 1996, INT J CLIN PHARM RES, V16, P67; WALKER JF, 1992, EUR HEART J, V13, P21; WEISSBERG PL, 1996, LANCET, V347, P305, DOI 10.1016/S0140-6736(96)90472-9; WHO, 1998, WORLD HLTH REP LIF 2; WOOD D, 1998, EUR HEART J, V19, PA12; ZARDOYA R, 1996, CURR THER RES CLIN E, V57, P568, DOI 10.1016/S0011-393X(96)80068-3","NATL CTR SCI RES, CTR NAT PROD, POB 6880 6990, HABANA CITY, CUBA","PROUS SCIENCE, SAU-THOMSON REUTERS","ENGLISH","DRUG FUTURE","REVIEW","ISI","WOS000089032000004","DRUG FUTURE","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"MÁS R, 2000, DRUG FUTURE","MÁS R, 2000, DRUG FUTURE"
"PRAT H;ROMÁN O;PINO E","PRAT H;ROMÁN O;PINO E","COMPARATIVE EFFECTS OF POLICOSANOL AND TWO HMGCOA REDUCTASE INHIBITORS ON TYPE II HYPERCHOLESTEROLEMIA",1999,"REVISTA MEDICA DE CHILE","127","286-294",20,NA,"UNIV CHILE, HOSP CLIN, CTR CARDIOVASC, CAMPUS CTR, SANTIAGO, CHILE.; UNIV CHILE, HOSP CLIN, CTR CARDIOVASC, SANTIAGO, CHILE.; UNIV CHILE, FAC MED, DEPT MED, SANTIAGO, CHILE.","BACKGROUND: POLICOSANOL IS A NEW CHOLESTEROL LOWERING AGENT DERIVED FROM SUGAR CANE. AIM: TO COMPARE THE CHOLESTEROL LOWERING EFFICACY OF POLICOSANOL WITH HMG COA INHIBITORS. PATIENTS AND METHODS: PATIENTS WITH A LDL CHOLESTEROL OVER 160 MG/DL WERE STUDIED. IF, AFTER 6 WEEKS OF DIET, CHOLESTEROL PERSISTED ELEVATED, THEY WERE DOUBLY BLIND RANDOMIZED TO RECEIVE POLICOSANOL 10 MG/DAY (55 PATIENTS), LOVASTATIN 20 MG/DAY (26 PATIENTS) OR SIMVASTATIN 10 MG/DAY (25 PATIENTS). SERUM CHOLESTEROL WAS MEASURED AGAIN AFTER 8 WEEKS OF THERAPY. RESULTS: INITIAL DEMOGRAPHIC AND LABORATORY DATA WERE SIMILAR AMONG TREATMENT GROUPS. A 24\% LDL CHOLESTEROL REDUCTION WAS OBTAINED WITH POLICOSANOL, COMPARED WITH A 22\% REDUCTION WITH LOVASTATIN AND A 15\% REDUCTION WITH SIMVASTATIN. HDL CHOLESTEROL SIGNIFICANTLY INCREASED IN PATIENTS ON POLICOSANOL AND DID NOT CHANGE IN THE OTHER TREATMENT GROUPS. ADVERSE EFFECTS OF POLICOSANOL WERE MILD AND UNSPECIFIC. NO CHANGES IN HEPATIC ENZYMES WERE OBSERVED. CONCLUSIONS: POLICOSANOL IS A SAFE AND EFFECTIVE CHOLESTEROL REDUCING AGENT.","HYPERCHOLESTEROLEMIA; ANTICHOLESTEREMIC AGENTS; POLICOSANOL; LOVASTATIN; SIMVASTATIN","CORONARY HEART-DISEASE; SUCCESSIVE DOSE INCREASES; PHARMACOLOGICAL; PROPERTIES; LIPOPROTEIN CHOLESTEROL; LIPID PROFILE; PRAVASTATIN; SIMVASTATIN; LOVASTATIN; EFFICACY; THERAPY",NA,NA,"ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANEIROS E, 1993, CURR THER RES CLIN E, V54, P304, DOI 10.1016/S0011-393X(05)80631-9; ANONYMOUS, ATHEROSCLEROSIS; BOCCUZZI SJ, 1993, DRUG INVEST, V5, P135, DOI 10.1007/BF03259587; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CASTANO G, 1996, CURR THER RES CLIN E, V57, P691, DOI 10.1016/S0011-393X(96)80074-9; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/JAMA.256.20.2835; DAUBRESSE JC, 1993, AM J CARDIOL, V71, P1408; DAVIDSON M, 1997, AM J CARDIOL, V79, P1475, DOI 10.1016/S0002-9149(97)00174-4; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/JAMA.269.23.3015; HERNANDEZ F, 1992, CURR THER RES, V51, P1; HERNANDEZ R, 1993, REV MEX CIENCIAS FAR, V24, P16; HJERMANN I, 1981, LANCET, V2, P1303; ILLINGWORTH DR, 1988, DRUGS, V36, P63, DOI 10.2165/00003495-198800363-00015; JACOTOT B, 1995, AM J CARDIOL, V76, PA54; JONES P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; *LOV STUD GROUP, 1986, JAMA-J AM MED ASSOC, V256, P829; MABUCHI H, 1981, NEW ENGL J MED, V305, P478, DOI 10.1056/NEJM198108273050902; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/JAMA.260.5.641; MCTAVISH D, 1991, DRUGS, V42, P65, DOI 10.2165/00003495-199142010-00005; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; MOLGAARD J, 1991, ATHEROSCLEROSIS, V91, PS21, DOI 10.1016/0021-9150(91)90203-F; NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM, 1993, NIH PUBL; PEDERSEN TR, 1994, LANCET, V344, P1383; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROMAN O, 1987, CARDIOLOGY, V74, P219, DOI 10.1159/000174200; SHEPERD J, 1987, PHARM MODULATION PLA, P127; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STALENHOFF ARH, 1989, AM J MED S4A, V87; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2; TIFFANY TO, 1974, CLIN CHEM, V20, P476; TIKKANEN MJ, 1988, AM J CARDIOL, V62, PJ35, DOI 10.1016/0002-9149(88)90005-7; TOBERT JA, 1990, AM J CARDIOL, V65, PF23; TODD PA, 1990, DRUGS, V40, P583, DOI 10.2165/00003495-199040040-00007; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; WALKER JF, 1989, AM J MED, V87, PS44, DOI 10.1016/S0002-9343(89)80598-4; WAUGH A.E., 1952, ELEMENTS OF STATISTICAL METHODS, VTHIRD; WEINBERGER MH, 1986, AM J MED, V80, P64, DOI 10.1016/0002-9343(86)90162-2; ZARDOYA R, 1996, CURR THER RES CLIN E, V57, P568, DOI 10.1016/S0011-393X(96)80068-3","UNIV CHILE, HOSP CLIN, CTR CARDIOVASC, CAMPUS CTR, SANTIAGO, CHILE","SOC MEDICA SANTIAGO","SPANISH","REV. MEDICA CHILE","ARTICLE","ISI","WOS000080235200004","REV MEDICA CHILE","UNIV CHILE;UNIV CHILE;UNIV CHILE","UNIV CHILE",NA,"PRAT H, 1999, REV MEDICA CHILE","PRAT H, 1999, REV MEDICA CHILE"
"ALCOCER L;FERNÁNDEZ L;CAMPOS E;MÁS R","ALCOCER L;FERNÁNDEZ L;CAMPOS E;MÁS R","A COMPARATIVE STUDY OF POLICOSANOL IVERSUSI ACIPIMOX IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA",1999,"INTERNATIONAL JOURNAL OF TISSUE REACTIONS-EXPERIMENTAL AND CLINICAL ASPECTS","21","85-92",13,NA,"MÁS, R (CORRESPONDING AUTHOR), NATL CTR SCI RES, POB 6990, HAVANA 6880, CUBA.; NATL CTR SCI RES, HAVANA 6880, CUBA.; MEXICO GEN HOSP, DEPT CARDIOL, MEXICO CITY, DF, MEXICO.","AN B-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND ACIPIMOX WAS CONDUCTED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. PRIOR TO ENTRY INTO ACTIVE TREATMENT, ALL PATIENTS FOLLOWED A STANDARD CHOLESTEROL-LOWERING DIET FOR 12 WEEKS. SIXTY-THREE PATIENTS WERE RANDOMIZED TO RECEIVE EITHER POLICOSANOL (10 MG/DAY) OR ACIPIMOX (750 MG/DAY) TABLETS FOR 8 WEEKS UNDER DOUBLE-BLIND CONDITIONS. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. POLICOSANOL SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (P <0.0001) (15.8 \%), LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL (21\%) AND THE RATIOS OF LDL-CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLESTEROL (15.8\%) AND CHOLESTEROL TO HDL-CHOLESTEROL (11.5\%). ACIPIMOX SIG SIGNIFICANTLY LOWERED BOTH CHOLESTEROL AND LDL CHOLESTEROL BY 7.5\%. THE PERCENT CHANGES OF TOTAL CHOLESTEROL, LDL-CHOLESTEROL AND BOTH RATIOS WERE LARGER IN THE POLICOSANOL GROUP THAN IN THE ACIPIMOX GROUP. BOTH DRUGS WERE WELL TOLERATED ACIPIMOX SIGNIFICANTLY INCREASED (P >0.001) ASPARTATE AMINO TRANSFERASE LEVELS BUT ONLY FOUR PATIENTS SHOWED INCREASES ABOVE THE NORMAL LIMIT. POLICOSANOL SIGNIFICANTLY REDUCED CREATININE VALUES (P >0.05) BUT NO PATIENTS HAD VALUES OUT OF THE NORMAL RANGE. FOUR PATIENTS WITHDREW FROM THE STUDY (TWO FROM EACH GROUP) BUT NONE WITHDREW BECAUSE OF ADVERSE EFFECTS. NO ADVERSE EFFECTS WERE REPORTED IN THE POLICOSANOL GROUP, WHILE FIVE PATIENTS ON ACIPIMOX REPORTED ADVERSE EFFECTS (HOT FLUSHES, NAUSEA, VOMITING, HEADACHE, HYPOCHONDRIAL PAIN AND LEG EDEMA). THESE RESULTS INDICATE THAT POLICOSANOL (10 MG/DAY) WAS MORE EFFECTIVE AND WELL TOLERATED THAN WAS ACIPIMOX (750 MG/DAY) IN THIS STUDY POPULATION.",NA,"CORONARY HEART-DISEASE; DENSITY LIPOPROTEIN; DIABETES-MELLITUS; ELDERLY; PATIENTS; LIPID PROFILE; SERUM-LIPIDS; CHOLESTEROL; TOLERABILITY; PLASMA; HYPERTRIGLYCERIDEMIA",NA,NA,"BAHATNAGAR D, 1998, PHARMACOL THERAPEUT, V79, P205; BENITEZ M, 1997, CURR THER RES CLIN E, V58, P859, DOI 10.1016/S0011-393X(97)80052-5; BUCKLEY BM, 1991, ATHER REV, V22, P217; CAMPILONGO R., 1996, PRENSA MEDICA ARGENTINA, V83, P665; CANETTI M, 1995, ADV THER, V12, P245; CASTANO G, 1995, CURR THER RES CLIN E, V56, P819, DOI 10.1016/0011-393X(95)85065-1; CRESPO N, 1997, CURR THER RES CLIN E, V58, P44, DOI 10.1016/S0011-393X(97)80077-X; DAVIDOFF P, 1991, REV MED CHILE, V119, P1140; DEAN JD, 1992, DIABETIC MED, V9, P611, DOI 10.1111/J.1464-5491.1992.TB01855.X; FARNIER M, 1998, AM J CARDIOL, V82, P3J, DOI 10.1016/S0002-9149(98)00423-8; FERNANDEZ L, 1998, CURR THER RES CLIN E, V59, P717, DOI 10.1016/S0011-393X(98)85030-3; FRANCESCHINI G, 1990, ATHEROSCLEROSIS, V81, P41, DOI 10.1016/0021-9150(90)90057-P; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULCHER GR, 1992, DIABETIC MED, V9, P908, DOI 10.1111/J.1464-5491.1992.TB01730.X; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAVEZZARI M, 1989, J INT MED RES, V17, P373, DOI 10.1177/030006058901700411; MARGOLIS S, 1990, J CLIN ENDOCR METAB, V70, P821, DOI 10.1210/JCEM-70-4-821; MAS R, 1998, CLIN PHARMACOL THER, V65, P6; MENENDEZ R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090; MENENDEZ R., 1994, BIOLOGICAL RESEARCH, V27, P199; ORTENSI G, 1997, CURR THER RES CLIN E, V58, P390, DOI 10.1016/S0011-393X(97)80099-9; PARAGH GYORGY, 1993, ORVOSI HETILAP, V134, P121; PONS P, 1994, INT J CLIN PHARM RES, V14, P27; PONTIROLI AE, 1992, EUR J CLIN PHARMACOL, V43, P145, DOI 10.1007/BF01740661; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHECTMAN G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SEIGLER L, 1981, CLIN CHEM, V27, P838; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TIKKANEN MJ, 1987, CIRCULATION, V76, P529, DOI 10.1161/01.CIR.76.3.529; TORNVALL P, 1991, J INTERN MED, V230, P415, DOI 10.1111/J.1365-2796.1991.TB00466.X; TORRES O, 1995, DIABETES CARE, V18, P933; WIERZBICKI AS, 1997, INT J CLIN PRACT, V51, P378; WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H; YALE BM, 1992, ATHEROSCLEROSIS, V97, P33","MÁS, R (CORRESPONDING AUTHOR), NATL CTR SCI RES, POB 6990, HAVANA 6880, CUBA","BIOSCIENCE EDIPRINT INC","ENGLISH","INT. J. TISSUE REACT.-EXP. CLIN. ASP.","ARTICLE","ISI","WOS000084662500004","INT J TISSUE REACT-EXP CLIN ASP","NATL CTR SCI RES;NATL CTR SCI RES;MEXICO GEN HOSP","NATL CTR SCI RES",NA,"ALCOCER L, 1999, INT J TISSUE REACT-EXP CLIN ASP","ALCOCER L, 1999, INT J TISSUE REACT-EXP CLIN ASP"
"STUSSER R;BATISTA J;PADRON R;SOSA F;PEREZTOL O","STUSSER R;BATISTA J;PADRON R;SOSA F;PEREZTOL O","LONGTERM THERAPY WITH POLICOSANOL IMPROVES TREADMILL EXERCISEEGG TESTING PERFORMANCE OF CORONARY HEART DISEASE PATIENTS",1998,"INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","36","469-473",24,NA,"STUSSER, R (CORRESPONDING AUTHOR), CTR INVEST CLIN, CALLE 34 4501-45-47, HAVANA 11300 13, CUBA.; UNIV HAVANA, CLIN RES CTR, HAVANA, CUBA.","THIS STUDY EXAMINED THE EFFECTS OF LONG-TERM LIPID-LOWERING THERAPY WITH POLICOSANOL ON THE CLINICAL EVOLUTION, AND EXERCISE-EGG TESTING RESPONSES OF 45 CORONARY HEART DISEASE (CHD) PATIENTS WITH MYOCARDIAL ISCHEMIA, DOCUMENTED BY EXERCISE TL-201-MYOCARDIAL PERFUSION SCINTIGRAPHY, IN AN OVERALL RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, MADE FOR DIFFERENT TEST ENDPOINTS. FIFTEEN PATIENTS WERE TREATED WITH 5 MG OF POLICOSANOL TWICE DAILY; ANOTHER 15 PATIENTS WERE ADMINISTERED THE SAME DRUG DOSE PLUS 125 MG ASPIRIN; AND THE OTHER 15 PATIENTS RECEIVED PLACEBO PLUS EQUAL ASPIRIN DOSE. THEY WERE FOLLOWED FOR 20 MONTHS, PREVIOUS BASELINE OBSERVATIONS, WITH TREADMILL EXERCISE-ECG, BESIDES SERUM LIPID TEST. BENEFICIAL CHANGES ON PROPORTIONS AMONG THE 2 POLICOSANOL GROUPS AND THE PLACEBO GROUP, SHOWED AN INCREMENT ON FUNCTIONAL CAPACITY CLASS, A DECREMENT ON REST AND EXERCISE ANGINA, AND A SIGNIFICANT DECREASE IN CARDIAC EVENTS, AND IN ISCHEMIC ST SEGMENT RESPONSE, ESPECIALLY IN THE POLICOSANOL PLUS ASPIRIN GROUP (P = 0.05, X(2)2DF = 5.8; P = 0.04, P = 0.02; FISHER). AFTER TREATMENT, SETS OF MEAN CHANGES REVEALED AN INCREASE ON MAXIMUM OXYGEN UPTAKE, AND A DECLINE ON DOUBLE PRODUCT SIMULTANEOUSLY IN BOTH POLICOSANOL GROUPS (P LESS THAN OR EQUAL TO 0.02, P LESS THAN OR EQUAL TO 0.002; PILLAIS, HOTELLINGS' T-2), WHILE THE PLACEBO GROUP WAS IMPAIRED. AEROBIC FUNCTIONAL CAPACITY PERCENT SHOWED AN INCREMENT IN POLICOSANOL GROUPS (P LESS THAN OR EQUAL TO 0.05, PAIRED T). LIPID LEVELS IMPROVED AS OTHER ENDPOINTS ALREADY REPORTED. A SUPPOSED ERGOGENIC EFFECT OF OCTACOSANOL, POLICOSANOL'S MAIN ACTIVE COMPOUND, WAS NOT DETECTED WITH THIS DESIGN. THESE RESULTS SHOW THAT POLICOSANOL-TREATED CHD PATIENTS IMPROVED CLINICAL EVOLUTION, AND EXERCISE-ECC RESPONSES, OWING TO THE AMELIORATION OF MYOCARDIAL ISCHEMIA, EVEN MORE WHEN ADMINISTERED WITH ASPIRIN.","CORONARY HEART DISEASE; EXERCISE ECG TESTING; LIPID-LOWERING EFFECT; POLICOSANOL; PLATELET ANTIAGGREGANT EFFECT; ERGOGENIC EFFECT; OCTACOSANOL","LOW-FAT DIET; ARTERY DISEASE; PHYSICAL EXERCISE; ATHEROSCLEROSIS; ULTRASOUND; REDUCTION; STANDARDS; EFFICACY; RATS",NA,NA,"ANONYMOUS, CIRCULATION; ARRUZAZABALA M, 1995, REV CENIC CIENC BIOL, V26, P188; BATISTA J, 1996, INT J CLIN PHARM TH, V34, P134; BATISTA J, 1995, CURR THER RES CLIN E, V56, P906, DOI 10.1016/0011-393X(95)85094-5; BATISTA JF, 1996, ADV THER, V13, P137; BELTZ SD, 1993, CLIN PHARMACY, V12, P900; BLANKENHORN D, 1987, JAMA-J AM MED ASSOC, V57, P3233; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BOGATY P, 1997, J AM COLL CARDIOL, V29, P1497, DOI 10.1016/S0735-1097(97)00091-0; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; GRUNDY SCOTT M., 1994, CIRCULATION, V89, P1329; KABIR Y, 1995, ANN NUTR METAB, V39, P279, DOI 10.1159/000177873; KABIR Y, 1993, ANN NUTR METAB, V37, P33, DOI 10.1159/000177746; NOHARA R, 1997, J NUCL CARDIOL, V4, PS25; NORRIS F H, 1987, ADV EXP MED BIOL, V209, P183; SAINT-JOHN M., 1986, INTERNATIONAL CLINICAL NUTRITION REVIEW, V6, P81; SCHELL WD, 1997, PROG CARDIOVASC DIS, V39, P483, DOI 10.1016/S0033-0620(97)80041-2; SCHULER G, 1988, CIRCULATION, V77, P172, DOI 10.1161/01.CIR.77.1.172; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; THEIN LA, 1995, PHYS THER, V75, P426, DOI 10.1093/PTJ/75.5.426; VICKERS A, 1997, INT J TECHNO ASS HLT, V13, P11; WHITE G, 1995, RECEPTOR CHANNEL, V3, P1","STUSSER, R (CORRESPONDING AUTHOR), CTR INVEST CLIN, CALLE 34 4501-45-47, HAVANA 11300 13, CUBA","DUSTRI-VERLAG DR KARL FEISTLE","ENGLISH","INT. J. CLIN. PHARMACOL. THER.","ARTICLE","ISI","WOS000075842500002","INT J CLIN PHARMACOL THER","CTR INVEST CLIN;UNIV HAVANA","CTR INVEST CLIN",NA,"STUSSER R, 1998, INT J CLIN PHARMACOL THER","STUSSER R, 1998, INT J CLIN PHARMACOL THER"
"WAITZKIN H;WALD K;KEE R;DANIELSON R;ROBINSON L","WAITZKIN H;WALD K;KEE R;DANIELSON R;ROBINSON L","PRIMARY CARE IN CUBA LOWAND HIGHTECHNOLOGY DEVELOPMENTS PERTINENT TO FAMILY MEDICINE",1997,"JOURNAL OF FAMILY PRACTICE","45","250-258",15,NA,"UNIV NEW MEXICO, FAMILY PRACTICE CTR, DEPT FAMILY \& COMMUNITY MED, DIV COMMUNITY MED, ALBUQUERQUE, NM 87131 USA.; CUBAN NEWS SERV, HAVANA, CUBA.; CHICAGO DEPT PUBL HLTH, CHICAGO, IL USA.; PORTLAND STATE UNIV, DEPT PUBL HLTH EDUC, PORTLAND, OR 97207 USA.; PLANNED PARENTHOOD CENT WASHINGTON, WALLA WALLA, WA USA.","CUBA'S ACCOMPLISHMENTS IN PRIMARY CARE, WHILE CONTROVERSIAL, INCLUDE SEVERAL DEVELOPMENTS PERTINENT TO FAMILY MEDICINE. THESE ACCOMPLISHMENTS INVOLVE LOW-TECHNOLOGY AND ORGANIZATIONAL INNOVATIONS SUCH AS NEIGHBORHOOD-BASED FAMILY MEDICINE AS THE FOCUS OF PRIMARY CARE; REGIONALIZED SYSTEMS OF HOSPITAL SERVICES AND PROFESSIONAL TRAINING; INNOVATIVE PUBLIC HEALTH INITIATIVES AND EPIDEMIOLOGIC SURVEILLANCE; UNIVERSAL ACCESS TO SERVICES WITHOUT SUBSTANTIAL BARRIERS RELATED TO RACE, SOCIAL CLASS, GENDER, AND AGE; AND ACTIVE PROGRAMS IN TREATMENTS SUCH AS `'GREEN MEDICINE'' AND `'THERMALISM.'' HIGH-TECHNOLOGY ACHIEVEMENTS INCLUDE INNOVATIONS IN PHARMACOLOGY AND BIOTECHNOLOGY, SURGICAL PROCEDURES, AND CARE OF PATIENTS INFECTED BY THE HUMAN IMMUNODEFICIENCY VIRUS (HIV). LIMITED ACCESS TO CUBAN PUBLICATIONS, IMPEDIMENTS TO PRESENTATIONS BY CUBAN HEALTH CAVE PROFESSIONALS AT PROFESSIONAL MEETINGS, AND THE PROHIBITION ON IMPORTING PRODUCTS OF CUBAN BIOTECHNOLOGY TO THE UNITED STATES INHIBIT A DETACHED, SCIENTIFIC APPRAISAL OF CUBA'S ACCOMPLISHMENTS. CUBA'S ISOLATION FROM THE US CLINICAL AND RESEARCH COMMUNITIES HAS PREVENTED INTERCHANGES THAT WOULD IMPROVE PRIMARY CARE SERVICES IN BOTH COUNTRIES.","INTERNATIONAL HEALTH PROBLEMS; CUBA; FAMILY PRACTICE; PRIMARY HEALTH; CARE; PUBLIC HEALTH; COMMUNITY MEDICINE","PUBLIC-HEALTH; EPIDEMIC; NEUROPATHY; AIDS; HYPERCHOLESTEROLEMIA; POLICOSANOL; POLITICS","FIC NIH HHS [TW01982] FUNDING SOURCE: MEDLINE; BHP HRSA HHS [PE 19154] FUNDING SOURCE: MEDLINE",NA,"AGUIRRE A, 1992, MEM I OSWALDO CRUZ, V87, P429, DOI 10.1590/S0074-02761992000300014; *AM PUBL HLTH ASS, 1994, AM J PUBLIC HEALTH, V84, P519; ANONYMOUS, CUBAN MED; BATISTA C, 1994, AUTORIDADES SANITARI; BAYER R, 1989, NEW ENGL J MED, V320, P1022, DOI 10.1056/NEJM198904133201529; BERN C, 1995, NEW ENGL J MED, V333, P1176; BINDMAN A B, 1993, FAM MED, V25, P114; CARBAJAL D, 1991, J ETHNOPHARMACOL, V33, P21, DOI 10.1016/0378-8741(91)90155-7; CARDELLE AJF, 1994, INT J HEALTH SERV, V24, P421, DOI 10.2190/2YG8-0P0C-CCYJ-330N; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; CASTANO G, 1995, CURR THER RES CLIN E, V56, P819, DOI 10.1016/0011-393X(95)85065-1; CASTRO F, 1993, FACE FACE CONVERSATI; DEMERS RY, 1993, FAM PRACT, V10, P164, DOI 10.1093/FAMPRA/10.2.164; DEVESA EA, 1993, REV CUB SALUD PUBLIC, V19, P5; *EC INT UN COUNTR, 1996, EC INT UN COUNTR REP, P6; FEINSILVER JULIEM., 1993, HEALING MASSES CUBAN; GRANICH R, 1995, WESTERN J MED, V163, P139; HERBERT M A, 1995, COMMUN DIS REP CDR REV, V5, PR130; KIRKPATRICK A F, 1994, J FLA MED ASSOC, V81, P681; KUNTZ D, 1994, INT J HEALTH SERV, V24, P161, DOI 10.2190/L6VN-57RR-AFLK-XW90; *LAB DALM, 1993, ATER POL; LEE H, 1994, HLTH STAT AM, P26; MACIASMATOS C, 1996, AM J CLIN NUTR, V64, P347, DOI 10.1093/AJCN/64.3.347; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; *MIN SAL PUBL, 1993, FIT, V2; *MIN SAL PUBL, 1992, GUIA TER DISP PROD Q; *MIN SAL PUBL, 1994, PRINC IND SAL; MORALES N, 1991, REV CUBANA ENFERM, V7, P26; NAYERI K, 1995, J COMMUN HEALTH, V20, P321, DOI 10.1007/BF02283057; NUTTING PA, 1996, J FAM PRACTICE, V42, P199; OCHOA EG, 1990, GAC SANIT, V4, P118; ORDONEZ C, 1987, REV CUB MED GEN INTE, V3, P60; ORDUNEZGARCIA PO, 1996, AM J PUBLIC HEALTH, V86, P738, DOI 10.2105/AJPH.86.5.738; *PAN AM HLTH ORG, 1994, HLTH COND AM, V2, P153; PEREZSTABLE EJ, 1991, AM J PUBLIC HEALTH, V81, P563, DOI 10.2105/AJPH.81.5.563; RIVERO LE, 1992, REV CUBANA ENFERM, V8, P76; RIVERON CORTEGUERA R L, 1995, BULL PAN AM HEALTH ORGAN, V29, P70; RODRIGUEZ RODRIGUEZ N J, 1993, EDUC MED SALUD, V27, P227; ROMAN GC, 1995, ANN INTERN MED, V122, P530, DOI 10.7326/0003-4819-122-7-199504010-00009; SADUN AA, 1994, ARCH OPHTHALMOL-CHIC, V112, P691, DOI 10.1001/ARCHOPHT.1994.01090170139037; SANTANA S, 1991, INT J HEALTH SERV, V21, P511, DOI 10.2190/PPF0-X27G-LF4X-XEYC; SCHEPERHUGHES N, 1993, LANCET, V342, P965, DOI 10.1016/0140-6736(93)92006-F; SIERRA G V G, 1991, NIPH (NATIONAL INSTITUTE OF PUBLIC HEALTH) ANNALS (OSLO), V14, P195; STIX G, 1995, SCI AM, V272, P32; SUSSER M, 1993, AM J PUBLIC HEALTH, V83, P418, DOI 10.2105/AJPH.83.3.418; SWANSON J M, 1995, J ASSOC NURSES AIDS CARE, V6, P33, DOI 10.1016/S1055-3290(05)80027-5; SWANSON K A, 1995, HEALTH CARE WOMEN INT, V16, P299; TANCER RS, 1995, CLIN THER, V17, P791, DOI 10.1016/0149-2918(95)80056-5; TERRIS M, 1991, JOURNAL OF PUBLIC HEALTH POLICY, V12, P362, DOI 10.2307/3342847; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; UNITED NATIONS DEVELOPMENT PROGRAMME, 1995, HUM DEV REP; VEEKEN H, 1995, BRIT MED J, V311, P935; WAITZKIN H, 1992, MED CARE REV, V49, P161, DOI 10.1177/002570879204900203; WAITZKIN H, 1991, POLITICS MED ENCOUNT, P265; WOLFE S, 1992, HEALTH PAC BULL, V22, P29; *WORLD BANK, 1996, WORLD DEV REP 1996 P, P49; *WORLD BANK, 1993, IND DEV 1996, P208","UNIV NEW MEXICO, FAMILY PRACTICE CTR, DEPT FAMILY \& COMMUNITY MED, DIV COMMUNITY MED, ALBUQUERQUE, NM 87131 USA","DOWDEN HEALTH MEDIA","ENGLISH","J. FAM. PRACT.","ARTICLE","ISI","WOSA1997XW11200018","J FAM PRACT","UNIV NEW MEXICO;PORTLAND STATE UNIV","UNIV NEW MEXICO",NA,"WAITZKIN H, 1997, J FAM PRACT","WAITZKIN H, 1997, J FAM PRACT"
"BATISTA J;STUSSER R;PENICHET M;UGUET E","BATISTA J;STUSSER R;PENICHET M;UGUET E","DOPPLERULTRASOUND PILOTSTUDY OF THE EFFECTS OF LONGTERM POLICOSANOL THERAPY ON CAROTIDVERTEBRAL ATHEROSCLEROSIS",1995,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","56","906-914",7,"10.1016/0011-393X(95)85094-5","UNIV HAVANA,CLIN RES CTR,HAVANA,CUBA.; UNIV HAVANA,ENRIQUE CABRERA NATL HOSP,HAVANA,CUBA.","THIS PILOT STUDY WAS CONDUCTED TO DOCUMENT THE BENEFICIAL LIPID-LOWERING EFFECT OF POLICOSANOL ON HEMODYNAMIC CAROTID-VERTEBRAL ATHEROSCLEROSIS (CVA) ABNORMALITIES, TWENTY-TWO PATIENTS WITH MILD CVA, INCLUDING 12 PATIENTS WITH TYPE II HYPERLIPIDEMIA, WERE ENROLLED IN THIS RANDOMIZED, DOUBLE-BLIND, PHASE II, PLACEBO-CONTROLLED TRIAL, ELEVEN PATIENTS RECEIVED 5 MG OF ORAL POLICOSANOL TWICE DAILY, AND 11 PATIENTS RECEIVED PLACEBO TWICE DAILY; ALL PATIENTS WERE TREATED FOR 1 YEAR. FIVE FUNCTIONAL DOPPLER-ULTRASOUND FLOW PARAMETERS WERE MEASURED ON SIX ARTERIES PER PATIENT AND CLASSIFIED BY USING AN OBJECTIVE RESPONSE SYSTEM. IN THE POLICOSANOL GROUP, PROGRESSION AND STABILIZATION OF DISEASE WERE ABSENT, MIXED RESPONSE WAS LOWER, AND REGRESSION WAS SIX TIMES MORE FREQUENT (6 OF 11 PATIENTS); THESE FINDINGS WERE NOT STATISTICALLY SIGNIFICANT COMPARED WITH THE PLACEBO GROUP (P = 0.06). THE PROGRESSION/REGRESSION (P:R) RATIO IN THE POLICOSANOL GROUP HAD A MEAN (0.5) TWO TIMES LOWER THAN THAT IN THE CONTROL GROUP (1.2) (P = 0.03). THE DECREASE IN THE P:R RATIO WAS ASSOCIATED INDEPENDENTLY WITH A MODERATE PERCENT REDUCTION OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL:HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO. ALTHOUGH THE SAMPLE SIZE AND 1-YEAR FOLLOW-UP DO NOT ALLOW CONCLUSIONS TO BE DRAWN, THESE RESULTS SUGGEST THAT POLICOSANOL, IN COMBINATION WITH A LOW-FAT DIET, IMPROVES HEMODYNAMIC ABNORMALITIES IN PATIENTS WITH MILD CVA AND NORMAL LIPID LEVELS OR TYPE II HYPERLIPIDEMIA.",NA,"LDL-CHOLESTEROL; HDL-CHOLESTEROL; SERUM-LIPIDS; REGRESSION; ARTERY; LIPOPROTEINS; PROGRESSION; STENOSIS; TRIALS",NA,NA,"ARRUZAZABALA ML, 1993, THROMB RES, V69, P321, DOI 10.1016/0049-3848(93)90030-R; BARTH JD, 1991, EUR HEART J, V12, P952, DOI 10.1093/EURHEARTJ/12.8.952; BENZULY KH, 1994, CIRCULATION, V89, P1810, DOI 10.1161/01.CIR.89.4.1810; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BLANKENHORN DH, 1991, AM J MED, V90, PS42, DOI 10.1016/0002-9343(91)90036-W; CASHINHEMPHILL L, 1993, AM J CARDIOL, V71, PB20, DOI 10.1016/0002-9149(93)90141-X; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GOHLKE H, 1992, WIEN KLIN WOCHENSCHR, V104, P309; HENNERICI M, 1991, STROKE, V22, P989, DOI 10.1161/01.STR.22.8.989; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HOMER D, 1991, MAYO CLIN PROC, V66, P259, DOI 10.1016/S0025-6196(12)61007-6; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; NOA M, 1991, REV CENIC CIENC BIOL, V22, P79; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RODRIGUEZECHENI.C, 1994, FOOD CHEM TOXICOL, V32, P565; SACKS FM, 1992, CIRCULATION, V86, P743; SPENCER MP, 1979, STROKE, V10, P326, DOI 10.1161/01.STR.10.3.326; SUPERKO HR, 1994, CIRCULATION, V90, P1056, DOI 10.1161/01.CIR.90.2.1056","UNIV HAVANA,CLIN RES CTR,HAVANA,CUBA","EXCERPTA MEDICA INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","ARTICLE","ISI","WOSA1995RW16300008","CURR THER RES-CLIN EXP","UNIV HAVANA;UNIV HAVANA","UNIV HAVANA",NA,"BATISTA J, 1995, CURR THER RES-CLIN EXP","BATISTA J, 1995, CURR THER RES-CLIN EXP"
"CASTANO G;CANETTI M;MOREIRA M;TULA L;MAS R;ILLNAIT J;FERNANDEZ L;FERNANDEZ J;DIAZ E","CASTANO G;CANETTI M;MOREIRA M;TULA L;MAS R; ILLNAIT J;FERNANDEZ L;FERNANDEZ JC;DIAZ E","EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPEII HYPERCHOLESTEROLEMIA A 12MONTH STUDY",1995,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","56","819-828",41,"10.1016/0011-393X(95)85065-1","NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA.; SALVADOR ALLENDE HOSP,HAVANA,CUBA.; CTR MED SURG RES,HAVANA,CUBA.; LUIS DIAZ SOTO HOSP,HAVANA,CUBA.","THIS STUDY REPORTS THE RESULTS OF A 12-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL AT DAILY DOSES OF 10 MG IN THE TREATMENT OF ELDERLY PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. THE STUDY INCLUDED 62 ELDERLY PATIENTS OF BOTH SEXES WITH TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) NOT CONTROLLED SUFFICIENTLY DURING A DIET-ONLY PERIOD. TWO MONTHS AFTER THERAPY, POLICOSANOL SIGNIFICANTLY (P < 0.001) REDUCED TOTAL CHOLESTEROL AND LDL-C. THE TREATMENT EFFECT ON CHOLESTEROL, AND RATIOS OF LDL-C:HDL-C AND TOTAL CHOLESTEROL: HDL-C WAS SHOWN NOT TO WEAR OFF DURING THE 12-MONTH FOLLOW-UP, PERCENT REDUCTIONS WERE MAINTAINED, OR EVEN INCREASED, 12 MONTHS AFTER THERAPY BY 23.1\% (LDL-C), 15.6\% (TOTAL CHOLESTEROL), 25.2\% (LDL-C:HDL-C), AND 19\% (TOTAL CHOLESTEROL:HDL-C) (P < 0.00001), ALL LIPID PROFILE VARIABLES REMAINED UNCHANGED IN THE PLACEBO GROUP THROUGHOUT THE ENTIRE STUDY, AT THE END OF THE TREATMENT PERIOD, HDL-C WAS INCREASED BY 8\%, TRIGLYCERIDES WERE NOT SIGNIFICANTLY CHANGED. ONLY TWO PATIENTS, BOTH IN THE PLACEBO GROUP, WITHDREW FROM THE STUDY, BUT NEITHER DID SO BECAUSE OF ADVERSE EFFECTS, NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE EFFECTS WERE OBSERVED, ADVERSE EFFECTS REPORTED WERE MILD AND TRANSIENT, AND NO SIGNIFICANT DIFFERENCES WERE SEEN WHEN COMPARED WITH THOSE REPORTED BY THE PLACEBO GROUP. OUR RESULTS INDICATE THAT POLICOSANOL ADMINISTERED AT 10 MG/D FOR 12 MONTHS SHOWS A MAINTAINED EFFICACY, AND VERY GOOD SAFETY AND TOLERABILITY IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA.",NA,"CORONARY HEART-DISEASE; DENSITY LIPOPROTEIN; SERUM-CHOLESTEROL; PREVENTION; SAFETY",NA,NA,"AGNER E, 1983, ACTA MED SCAND, V214, P33; ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011-393X(95)85043-0; ANEIROS E, 1993, CURR THER RES CLIN E, V54, P304, DOI 10.1016/S0011-393X(05)80631-9; ARRUZABALA ML., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P80; ARRUZAZABALA M L, 1994, BIOL RES, V27, P205; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/JAMA.263.3.393; BILHEIMER DW, 1991, ATHEROSCLEROSIS, V91, PS35, DOI 10.1016/0021-9150(91)90205-H; CASTANO G, 1995, CURR THER RES CLIN E, V56, P296, DOI 10.1016/0011-393X(95)85034-1; CASTANO G, 1991, PCM-PREM PERS COMPUT, V5, P21; DENKE MA, 1990, ANN INTERN MED, V112, P780, DOI 10.7326/0003-4819-112-10-780; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GOLDBERG PB, 1983, MED CLIN N AM, V67, P315; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; ILLINGWORTH DR, 1988, DRUGS, V36, P63, DOI 10.2165/00003495-198800363-00015; KARVONEN MJ, 1988, B WORLD HEALTH ORGAN, V66, P7; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PONS P, 1994, J CLIN PHARM RES, V1, P27; RODRIGUEZ-ECHENIQUE C., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P74; RODRIGUEZECHENI.C, 1994, FOOD CHEM TOXICOL, V32, P565; SEIGLER L, 1981, CLIN CHEM, V27, P838; TORRES O, 1995, DIABETES CARE, V18, P393, DOI 10.2337/DIACARE.18.3.393; 1982, JAMA-J AM MED ASSOC, V248, P2853; 1984, JAMA-J AM MED ASSOC, V251, P351","NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA","EXCERPTA MEDICA INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","ARTICLE","ISI","WOSA1995RR79600010","CURR THER RES-CLIN EXP","NATL CTR SCI RES;SALVADOR ALLENDE HOSP;CTR MED SURG RES;LUIS DIAZ SOTO HOSP","NATL CTR SCI RES",NA,"CASTANO G, 1995, CURR THER RES-CLIN EXP","CASTANO G, 1995, CURR THER RES-CLIN EXP"
"CANETTI M;MOREIRA M;ILLNAIT J;MAS R;FERNANDEZ L;FERNANDEZ J;CASTANO G","CANETTI M;MOREIRA M;ILLNAIT J;MAS R;FERNANDEZ L; FERNANDEZ JC;CASTANO G","ONEYEAR STUDY OF THE EFFECT OF POLICOSANOL ON LIPID PROFILE IN PATIENTS WITH TYPEII HYPERCHOLESTEROLEMIA",1995,"ADVANCES IN THERAPY","12","245-254",43,NA,"NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA.","A 1-YEAR, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL 5 MG TWICE A DAY WAS CONDUCTED IN 97 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WHOSE TOTAL AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL WAS INADEQUATELY CONTROLLED BY DIET. AFTER 2 MONTHS OF POLICOSANOL THERAPY, SIGNIFICANT REDUCTIONS IN TOTAL AND LDL CHOLESTEROL WERE NOTED THAT PERSISTED DURING THE 1-YEAR FOLLOW-UP. TWELVE MONTHS AFTER THERAPY, LDL-C AND TOTAL CHOLESTEROL DECREASED BY 27.5\% AND 16.3\%, RESPECTIVELY. RATIOS OF LDL TO HIGH-DENSITY LIPOPROTEIN (HDL) AND TOTAL CHOLESTEROL TO HDL WERE ALSO SIGNIFICANTLY DECREASED AFTER 2 MONTHS; REDUCTIONS OF 37.1\% AND 28\%, RESPECTIVELY, WERE APPARENT 1 YEAR AFTER TREATMENT. HDL INCREASED DURING THE STUDY, BUT THE INCREASE (25.9\%) REACHED STATISTICAL SIGNIFICANCE ONLY AFTER 12 MONTHS OF THERAPY. TRIGLYCERIDES CHANGED NONSIGNIFICANTLY COMPARED WITH BASELINE AND PLACEBO. SIX PATIENTS (4 FROM THE PLACEBO GROUP AND 2 FROM THE POLICOSANOL GROUP) WITHDREW FROM THE TRIAL; NO PATIENT WITHDREW BECAUSE OF ADVERSE EXPERIENCES. NO DRUG-RELATED CLINICAL OR BIOCHEMICAL DISTURBANCES WERE OBSERVED. ADVERSE EXPERIENCES REPORTED WERE MILD AND TRANSIENT AND DID NOT DIFFER SIGNIFICANTLY FROM THOSE SEEN WITH PLACEBO. POLICOSANOL (10 MG/D) ADMINISTERED FOR 1 YEAR SHOWED SUSTAINED EFFICACY, AS WELL AS VERY GOOD SAFETY AND TOLERABILITY.","POLICOSANOL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA",NA,NA,NA,NA,"NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA","HEALTH COMMUNICATIONS INC","ENGLISH","ADV. THER.","ARTICLE","ISI","WOSA1995RV37200006","ADV THER","NATL CTR SCI RES","NATL CTR SCI RES",NA,"CANETTI M, 1995, ADV THER","CANETTI M, 1995, ADV THER1"
"CASTANO G;MAS R;NODARSE M;ILLNAIT J;FERNANDEZ L;FERNANDEZ J","CASTANO G;MAS R;NODARSE M;ILLNAIT J;FERNANDEZ L; FERNANDEZ JC","ONEYEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL 5 MG TWICEDAILY IN THE TREATMENT OF TYPEII HYPERCHOLESTEROLEMIA",1995,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","56","296-304",50,"10.1016/0011-393X(95)85034-1","NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA.; NATL CTR SCI RES,MED SURG RES CTR,HAVANA 6880,CUBA.","THIS STUDY REPORTS THE RESULTS OF A 12-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF POLICOSANOL (5 MG TWICE DAILY) IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA. AFTER A LOW-FAT, LOW-CHOLESTEROL DIET FOR AT LEAST 12 WEEKS, 74 PATIENTS WERE RANDOMIZED TO RECEIVE PLACEBO OR POLICOSANOL (5 MG) TABLETS FOR 12 MONTHS. TABLETS WERE TAKEN TWICE DAILY BEFORE THE MORNING AND EVENING MEALS. LIPID PROFILE AND SAFETY INDICATORS WERE CONTROLLED REGULARLY THROUGHOUT THE STUDY. SIGNIFICANT REDUCTIONS OF SERUM TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) WERE ACHIEVED AFTER 2 MONTHS OF THERAPY. THE TREATMENT EFFECT CONTINUED DURING THE 12-MONTH FOLLOW-UP. AFTER 12 MONTHS, TOTAL CHOLESTEROL HAD DECREASED BY 17.2\% AND LDL-C BY 26.4\%. SIMILARLY, RATIOS OF LDL-C TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND TOTAL CHOLESTEROL TO HDL-C WERE ALSO SIGNIFICANTLY REDUCED IN THE POLICOSANOL GROUP, DECREASING BY 33.3\% (LDL-C:HDL-C) AND 25.3\% (CHOLESTEROL:HDL-C) AFTER 12 MONTHS. IN ADDITION, A SIGNIFICANT, SUSTAINED INCREASE IN HDL-C OF 13\% TO 15\% OCCURRED IN THE POLICOSANOL-TREATED GROUP. NO SIGNIFICANT CHANGES IN TRIGLYCERIDES WERE OBSERVED COMPARED WITH BASELINE OR PLACEBO. NINE PATIENTS DISCONTINUED THE TRIAL (FIVE FROM THE PLACEBO GROUP AND FOUR FROM THE POLICOSANOL GROUP), NONE OF THEM BECAUSE OF ADVERSE EFFECTS. THE ADVERSE EXPERIENCES REPORTED WERE MILD AND TRANSIENT. NO SIGNIFICANT DIFFERENCES WERE OBTAINED COMPARED WITH THOSE REPORTED BY THE PLACEBO GROUP. NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE EFFECTS WERE DETECTED. IT IS CONCLUDED THAT POLICOSANOL. ADMINISTERED AT 5 MG TWICE DAILY FOR 12 MONTHS SHOWS A PERSISTENT EFFICACY AND IS SAFE AND WELL TOLERATED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA.",NA,"LIPID-LOWERING DRUGS; LOVASTATIN; TOLERABILITY; PROFILE",NA,NA,"ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ALEMAN CL, 1991, REV CENIC CIENCIAS B, V22, P102; ALEMAN CL, IN PRESS TERATGENESI; ANEIROS E, 1993, CURR THER RES CLIN E, V54, P304, DOI 10.1016/S0011-393X(05)80631-9; ARRUZABALA ML., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P80; ARRUZAZABALA ML., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P60; BLUM CB, 1988, JAMA-J AM MED ASSOC, V261, P3582; CASTANO G, 1991, PCM-PREM PERS COMPUT, V5, P21; CASTANO G, IN PRESS REV CENIC C; CRUZ-BUSTILLO D., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P62; FERNANDEZ SI, 1991, REV CENIC CIEN BIOL, V22, P98; FINDLAY WJ, 1989, AM J MED, V87, P44; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1974, CLIN CHEM, V18, P449; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; ILLINGWORTH DR, 1988, DRUGS, V36, P63, DOI 10.2165/00003495-198800363-00015; ILLNAIT J, 1991, REV CENIC CIENC BIOL, V22, P74; KANNEL WB, 1990, AM J CARDIOL, V66, PB1, DOI 10.1016/0002-9149(90)90434-3; MANTELL G, 1990, AM J CARDIOL, V66, PB11, DOI 10.1016/0002-9149(90)90435-4; MENENDEZ R, IN PRESS BIOL RES; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; OCONNOR P, 1990, BMJ-BRIT MED J, V300, P667, DOI 10.1136/BMJ.300.6725.667; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PONS P, 1994, J CLIN PHARM RES, V14, P27; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRIGUEZ-ECHENIQUE C., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P74; SEIGLER L, 1981, CLIN CHEM, V27, P838; SOLTERO I, 1993, ARCH VENEZOL FARMACO, V12, P65; SOLTERO I, 1993, ARCH VENEZ FARM TER, V12, P71; TOBERT JA, 1988, AM J CARDIOL, V62, PJ28, DOI 10.1016/0002-9149(88)90004-5; 1984, JAMA-J AM MED ASSOC, V251, P251; 1984, JAMA-J AM MED ASSOC, V251, P365","NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA","EXCERPTA MEDICA INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","ARTICLE","ISI","WOSA1995QN64100010","CURR THER RES-CLIN EXP","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"CASTANO G, 1995, CURR THER RES-CLIN EXP","CASTANO G, 1995, CURR THER RES-CLIN EXP-a"
"TORRES O;AGRAMONTE A;ILLNAIT J;FERREIRO R;FERNANDEZ L;FERNANDEZ J","TORRES O;AGRAMONTE AJ;ILLNAIT J;FERREIRO RM; FERNANDEZ L;FERNANDEZ JC","TREATMENT OF HYPERCHOLESTEROLEMIA IN NIDDM WITH POLICOSANOL",1995,"DIABETES CARE","18","393-397",104,"10.2337/diacare.18.3.393","NATL CTR SCI RES,HAVANA 6880,CUBA.; JULIO TRIGO HOSP,HAVANA,CUBA.","OBJECTIVE - TO DETERMINE WHETHER ELEVATED LEVELS OF CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL IN NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM) PATIENTS COULD BE DECREASED BY POLICOSANOL, A NEW CHOLESTEROL-LOWERING DRUG. NIDDM PREDISPOSES PATIENTS TO CORONARY ARTERY DISEASE (CAD) THROUGH THE DIRECT ACTION OF HYPERGLYCEMIA ON THE ARTERIES AS WELL AS THE DYSLIPIDEMIA INDUCED BY NIDDM. RESEARCH DESIGN AND METHODS - THIS DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL WAS PERFORMED IN 29 PATIENTS WITH NIDDM AND HYPERCHOLESTEROLEMIA. AFTER STABLE GLYCEMIC CONTROL WAS ACHIEVED BY DIET AND/OR ORAL HYPOGLYCEMIC DRUGS, PATIENTS WERE INSTRUCTED TO FOLLOW A CHOLESTEROL-LOWERING DIET FOR 6 WEEKS. PATIENTS WHO MET ENTRY CRITERIA RECEIVED, UNDER DOUBLE-BLIND CONDITIONS, POLICOSANOL (5 MG) OR PLACEBO TABLETS TWICE A DAY FOR 12 WEEKS. RESULTS - POLICOSANOL (10 MG/DAY) SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL BY 17.5\% AND LDL CHOLESTEROL BY 21.8\% COMPARED WITH BASELINE AND PLACEBO. FURTHERMORE, HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL WAS RAISED BY 11.3\% (NOT SIGNIFICANT), AND TRIGLYCERIDES SHOWED A STATISTICALLY NONSIGNIFICANT DECREASE OF 6.6\%. THESE CHANGES IN LIPID PROFILE WERE SIMILAR TO THOSE INDUCED BY POLICOSANOL IN NONDIABETIC PATIENTS WITH TYPE II HYPERLIPOPROTEINEMIA. CONCLUSIONS - GLYCEMIC CONTROL WAS UNAFFECTED BY TREATMENT. NO CLINICALLY OR BIOCHEMICALLY ADVERSE EFFECTS ATTRIBUTABLE TO TREATMENT WERE OBSERVED. ONLY ONE PATIENT (PLACEBO) WITHDREW FROM THE TRIAL BECAUSE OF AN ADVERSE EXPERIENCE (ERYTHEMA). WE CONCLUDED THAT POLICOSANOL IS EFFECTIVE AND SAFE IN PATIENTS WITH NIDDM AND HYPERCHOLESTEROLEMIA",NA,"LOW-DENSITY LIPOPROTEIN; INSULIN-DEPENDENT DIABETICS; SERUM-LIPIDS; CHOLESTEROL; POPULATION; DISEASE",NA,NA,"ANEIROS E, 1993, CURR THER RES CLIN E, V54, P304, DOI 10.1016/S0011-393X(05)80631-9; ARRUZAZABALA MD, 1991, ARCH VENEZ FARMACOL, V11, P80; ARRUZAZABALA ML., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P60; CASTANO G, 1991, PCM-PREM PERS COMPUT, V5, P21; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1988, AM J CARDIOL, V62, PJ44, DOI 10.1016/0002-9149(88)90006-9; GOLBERG R, 1990, AM J CARDIOL, V66, PB16; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; HIRAMATSU K, 1985, DIABETES, V34, P8, DOI 10.2337/DIABETES.34.1.8; ILLINGWORTH DR, 1988, DRUGS, V36, P63, DOI 10.2165/00003495-198800363-00015; ILLNAIT J, 1991, REV CENIC CIENC BIOL, V22, P74; INGELFINGER JA, 1976, DIABETES, V25, P561, DOI 10.2337/DIABETES.25.7.561; LAAKSO M, 1985, ATHEROSCLEROSIS, V56, P271, DOI 10.1016/0021-9150(85)90003-6; LOPESVIRELLA MF, 1988, DIABETES, V37, P550, DOI 10.2337/DIABETES.37.5.550; MENENDEZ R, 1993, 62ND EUR ATH SOC JER, P139; MENENDEZ R, 1992, REV FARMACOL CLIN EX, P364; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SEIGLER L, 1981, CLIN CHEM, V27, P838; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/DIACARE.6.4.361; YOSHINO G, 1989, ATHEROSCLEROSIS, V75, P67, DOI 10.1016/0021-9150(89)90208-6","NATL CTR SCI RES,HAVANA 6880,CUBA","AMER DIABETES ASSOC","ENGLISH","DIABETES CARE","NOTE","ISI","WOSA1995QM29600016","DIABETES CARE","NATL CTR SCI RES;JULIO TRIGO HOSP","NATL CTR SCI RES",NA,"TORRES O, 1995, DIABETES CARE","TORRES O, 1995, DIABETES CARE1"
"ANEIROS E;MAS R;CALDERON B;ILLNAIT J;FERNANDEZ L;CASTANO G;FERNANDEZ J","ANEIROS E;MAS R;CALDERON B;ILLNAIT J;FERNANDEZ L;CASTANO G;FERNANDEZ JC","EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPEII HYPERCHOLESTEROLEMIA",1995,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","56","176-182",80,"10.1016/0011-393X(95)85043-0","NATL CTR SCI RES,CTR NAT PROD,HAVANA,CUBA.; TOMAS ROMAY POLICLIN CTR,HAVANA,CUBA.; MED SURG RES CTR,HAVANA,CUBA.","A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WAS CONDUCTED IN 45 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA TO INVESTIGATE THE EFFICACY AND SAFETY OF POLICOSANOL ADMINISTERED AT 10 MG DAILY (5 MG TWICE DAILY). AFTER ADHERING TO A CHOLESTEROL-LOWERING DIET-ONLY PERIOD, 45 OUTPATIENTS IN WHOM SERUM CHOLESTEROL AND LDL-C VALUES WERE NOT CONTROLLED SUFFICIENTLY BY DIET ALONE WERE RANDOMIZED TO RECEIVE POLICOSANOL OR PLACEBO AT THE EVENING AND THE MORNING MEAL FOR 6 WEEKS, POLICOSANOL SIGNIFICANTLY DECREASED TOTAL CHOLESTEROL BY 16.2\% AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) BY 21.5\%, RATIOS OF TOTAL CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND OF LDL-C TO HDL-C WERE ALSO SIGNIFICANTLY REDUCED BY 17.7\% AND 22.3\%, RESPECTIVELY, HDL-C VALUES INCREASED BY 14\% IN THE POLICOSANOL-TREATED GROUP, BUT THIS INCREASE WAS NOT SIGNIFICANT (P = 0.07), NO SIGNIFICANT CHANGES IN TRIGLYCERIDES WERE OBSERVED COMPARED WITH BASELINE OR PLACEBO, NO CLINICALLY SIGNIFICANT DIFFERENCES IN CLINICAL AND BIOCHEMICAL SAFETY INDICATORS WERE OBSERVED IN POLICOSANOL-TREATED PATIENTS COMPARED WITH THOSE RECEIVING PLACEBO. NO PATIENT WITHDREW FROM THE STUDY BECAUSE OF ADVERSE EXPERIENCES, AND THERE WERE NO CLINICALLY SIGNIFICANT DRUG-RELATED ADVERSE EFFECTS, THESE DATA INDICATE THAT POLICOSANOL (5 MG TWICE DAILY) IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA.",NA,"SAFETY",NA,NA,"ALEMAN C, 1992, TOXICOL LETT S, V68, P248; ALEMAN CL, 1994, TOXICOL LETT, V70, P77, DOI 10.1016/0378-4274(94)90147-3; ANEIROS E, 1993, CURR THER RES CLIN E, V54, P304, DOI 10.1016/S0011-393X(05)80631-9; ARRUZABALA ML., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P80; ARRUZAZABALA ML., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P60; CASTANO G, IN PRESS REV CIENC B; CASTANO G, 1991, PCM-PREM PERS COMPUT, V5, P21; CRUZ-BUSTILLO D., 1991, REVISTA CENIC CIENCIAS BIOLOGICAS, V22, P62; FERNANDEZ SI, 1991, REV CENIC CIEN BIOL, V22, P98; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1974, CLIN CHEM, V18, P449; HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568; ILLINGWORTH DR, 1988, DRUGS, V36, P63, DOI 10.2165/00003495-198800363-00015; ILLNAIT J, 1991, REV CENIC CIENC BIOL, V22, P74; MENENDEZ R, IN PRESS BIOL RES; MESA AR, 1994, TOXICOL LETT, V73, P81, DOI 10.1016/0378-4274(94)90098-1; PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011-393X(05)80279-6; PONS P, 1993, CURR THER RES CLIN E, V53, P265, DOI 10.1016/S0011-393X(05)80784-2; PONS P, 1992, CURR THER RES CLIN E, V52, P507, DOI 10.1016/S0011-393X(05)80456-4; PONS P, 1994, J CLIN PHARM RES, V14, P27; RODRIGUEZ MD, 1994, TERATOGEN CARCIN MUT, V14, P107, DOI 10.1002/TCM.1770140302; RODRIGUEZ-ECHENIQUE C., 1992, ARCHIVOS VENEZOLANOS DE FARMACOLOGIA Y TERAPEUTICA, V11, P74; RODRIGUEZECHENIQUE C, 1994, FOOD CHEM TOXICOL, V32, P565, DOI 10.1016/0278-6915(94)90115-5; SEIGLER L, 1981, CLIN CHEM, V27, P838; SOLTERO I, 1993, ARCH VENEZOL FARMACO, V12, P65; SOLTERO I, 1993, ARCH VENEZ FARM TER, V12, P71; 1984, JAMA-J AM MED ASSOC, V251, P251; 1984, JAMA-J AM MED ASSOC, V251, P365","NATL CTR SCI RES,CTR NAT PROD,HAVANA,CUBA","EXCERPTA MEDICA INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","ARTICLE","ISI","WOSA1995QH57400008","CURR THER RES-CLIN EXP","NATL CTR SCI RES;TOMAS ROMAY POLICLIN CTR;MED SURG RES CTR","NATL CTR SCI RES",NA,"ANEIROS E, 1995, CURR THER RES-CLIN EXP","ANEIROS E, 1995, CURR THER RES-CLIN EXP"
"CHEN Q;YANG F;JI D;ZHANG L;HUANG D;WANG Q;WANG Y;LI L;LIU H","CHEN Q;YANG F F;JI D D;ZHANG L W;HUANG D S;WANG Q S;WANG Y M;LI L M;LIU H B","POLICOSANOL ATTENUATES INFLAMMATION AND IMPROVES HEART FUNCTION BY ACTIVATION OF AUTOPHAGY IN MYOCARDIAL INFARCTION RAT MODELS",2019,"JOURNAL OF THE AMERICAN GERIATRICS SOCIETY","67","S686-S687",0,NA,"CHEN, Q.; YANG, F. F.; JI, D. D.; ZHANG, L. W.; HUANG, D. S.; WANG, Q. S.; WANG, Y. M.; LI, L. M., CHINESE PEOPLES LIBERAT ARMY GEN HOSP, MED CTR 4, DEPT CARDIOL, BEIJING 100048, PEOPLES R CHINA.; LIU, H. B., CHINESE PEOPLES LIBERAT ARMY GEN HOSP, MED CTR 2, DEPT CARDIOL SOUTH BLDG, BEIJING 100853, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"CHEN, Q","WILEY","ENGLISH","J. AM. GERIATR. SOC.","MEETING ABSTRACT","ISI","WOS000482910500247","J AM GERIATR SOC","CHINESE PEOPLES LIBERAT ARMY GEN HOSP;CHINESE PEOPLES LIBERAT ARMY GEN HOSP","NOTREPORTED",NA,"CHEN Q, 2019, J AM GERIATR SOC","CHEN Q, 2019, J AM GERIATR SOC"
"CHO K;YADAV D;KIM S;KIM ;JAE-RYONG J","CHO KYUNG-HYUN;YADAV DHANANJAY;KIM SUK-JEONG;KIM; JAE-RYONG","BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVEMENT OF HEPATIC INFLAMMATION LIPOPROTEIN PROFILE AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS VOL 23 1080 2018",2019,"MOLECULES","24",NA,0,"10.3390/molecules24010194","CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, DEPT MED BIOTECHNOL, GYONGSAN 712749, SOUTH KOREA.; CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, RES INST PROT SENSOR, GYONGSAN 712749, SOUTH KOREA.; CHO, KH (CORRESPONDING AUTHOR), LIPOLAB, DAEHAK RO 280, GYONGSAN 712749, SOUTH KOREA.; CHO, KYUNG-HYUN; YADAV, DHANANJAY; KIM, SUK-JEONG, YEUNGNAM UNIV, DEPT MED BIOTECHNOL, GYONGSAN 712749, SOUTH KOREA.; CHO, KYUNG-HYUN; YADAV, DHANANJAY; KIM, SUK-JEONG, YEUNGNAM UNIV, RES INST PROT SENSOR, GYONGSAN 712749, SOUTH KOREA.; CHO, KYUNG-HYUN; YADAV, DHANANJAY; KIM, SUK-JEONG, LIPOLAB, DAEHAK RO 280, GYONGSAN 712749, SOUTH KOREA.; KIM, JAE-RYONG, YEUNGNAM UNIV, COLL MED, SMART AGING CONVERGENCE RES CTR, DEPT BIOCHEM \& MOL BIOL, DAEGU 705717, SOUTH KOREA.",NA,NA,NA,NA,NA,"CHO KH, 2018, MOLECULES, V23, DOI 10.3390/MOLECULES23051080","CHO, KH (CORRESPONDING AUTHOR), YEUNGNAM UNIV, DEPT MED BIOTECHNOL, GYONGSAN 712749, SOUTH KOREA","MDPI","ENGLISH","MOLECULES","CORRECTION","ISI","WOS000457150200194","MOLECULES","YEUNGNAM UNIV;YEUNGNAM UNIV;LIPOLAB;YEUNGNAM UNIV;YEUNGNAM UNIV;LIPOLAB;YEUNGNAM UNIV","YEUNGNAM UNIV",NA,"CHO KH, 2019, MOLECULES","CHO KH, 2019, MOLECULES"
"SANCHEZ-ALDEREGUIA S;HERNANDEZ-FERRERAS K;FUNDORA-MIRABAL J;DORTA-CONTRERAS A","SANCHEZ-ALDEREGUIA SONIA;HERNANDEZ-FERRERAS KIRIA; FUNDORA-MIRABAL JORGE A;DORTA-CONTRERAS ALBERTO J","HYPERTENSIVE PATIENTS WITH NONCARDIOEMBOLIC ISCHEMIC STROKE A THERAPEUTIC HOPE",2019,"REVISTA DE NEUROLOGIA","68","44",0,"10.33588/rn.6801.2018451","DORTA-CONTRERAS, AJ (CORRESPONDING AUTHOR), UNIV CIENCIAS MED LA HABANA, FAC CIENCIAS MED DOCTOR MIGUEL ENRIQUEZ, LAB CENT LIQUIDO CEFALORRAQUIDEO LABCEL, APARTADO POSTAL 10049, HAVANA 11000, CUBA.; SANCHEZ-ALDEREGUIA, SONIA; HERNANDEZ-FERRERAS, KIRIA; FUNDORA-MIRABAL, JORGE A.; DORTA-CONTRERAS, ALBERTO J., UNIV CIENCIAS MED LA HABANA, HAVANA, CUBA.",NA,NA,"FUNCTIONAL RECOVERY; POLICOSANOL",NA,NA,"CHO KH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4809525; SÁNCHEZ J, 2017, REV NEUROLOGIA, V64, P153; SÁNCHEZ-LÓPEZ J, 2018, REV NEUROLOGIA, V67, P331, DOI 10.33588/RN.6709.2018063","DORTA-CONTRERAS, AJ (CORRESPONDING AUTHOR), UNIV CIENCIAS MED LA HABANA, FAC CIENCIAS MED DOCTOR MIGUEL ENRIQUEZ, LAB CENT LIQUIDO CEFALORRAQUIDEO LABCEL, APARTADO POSTAL 10049, HAVANA 11000, CUBA","REVISTA DE NEUROLOGIA","SPANISH","REV. NEUROLOGIA","LETTER","ISI","WOS000454602200007","REV NEUROLOGIA","UNIV CIENCIAS MED LA HABANA;UNIV CIENCIAS MED LA HABANA","UNIV CIENCIAS MED LA HABANA",NA,"SANCHEZ-ALDEREGUIA S, 2019, REV NEUROLOGIA","SANCHEZ-ALDEREGUIA S, 2019, REV NEUROLOGIA"
"KYUNG-HYUN K;KIM S","KYUNG-HYUN;KIM SUKJEONG","LONGTERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS CENTRAL AND BRACHIAL BLOOD PRESSURE AND IMPROVES SERUM LIPID PROFILE ACCOMPANIED BY LESS OXIDATION AND GLYCATION OF LIPOPROTEINS IN HEALTHY KOREAN PARTICIPANTS",2018,"JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY","72","C83",0,"10.1016/j.jacc.2018.08.454","KYUNG-HYUN; KIM, SUKJEONG, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA.",NA,NA,NA,NA,NA,NA,"KYUNG-HYUN; KIM, SUKJEONG, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA","ELSEVIER SCIENCE INC","ENGLISH","J. AM. COLL. CARDIOL.","MEETING ABSTRACT","ISI","WOS000446586700296","J AM COLL CARDIOL","YEUNGNAM UNIV","NOTREPORTED;YEUNGNAM UNIV",NA,"KYUNG-HYUN KH, 2018, J AM COLL CARDIOL","KYUNG-HYUN KH, 2018, J AM COLL CARDIOL"
"CHO K;KIM S","CHO KYUNG-HYUN;KIM SUK-JEONG","LONGTERM CONSUMPTION OF CUBAN POLICOSANOL LOWERS BLOOD PRESSURE AND IMPROVES SERUM LIPID PROFILE WITH LESS OXIDATION AND GLYCATION IN HEALTHY PARTICIPANTS",2018,"ATHEROSCLEROSIS SUPPLEMENTS","32","23",0,"10.1016/j.atherosclerosissup.2018.04.069","CHO, KYUNG-HYUN; KIM, SUK-JEONG, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA.",NA,NA,NA,NA,NA,NA,"CHO, KYUNG-HYUN; KIM, SUK-JEONG, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLER. SUPPL.","MEETING ABSTRACT","ISI","WOS000434628100067","ATHEROSCLER SUPPL","YEUNGNAM UNIV","NOTREPORTED;YEUNGNAM UNIV",NA,"CHO KH, 2018, ATHEROSCLER SUPPL","CHO KH, 2018, ATHEROSCLER SUPPL"
"KIM S;CHO K","KIM SUK-JEONG;CHO KYUNG-HYUN","BLOOD PRESSURE LOWERING EFFECT OF CUBAN POLICOSANOL IS ACCOMPANIED BY IMPROVED LIPOPROTEIN PROFILE AND HDL QUALITY IN SPONTANEOUSLY HYPERTENSIVE RATS",2018,"ATHEROSCLEROSIS SUPPLEMENTS","32","128",0,"10.1016/j.atherosclerosissup.2018.04.393","KIM, SUK-JEONG; CHO, KYUNG-HYUN, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA.",NA,NA,NA,NA,NA,NA,"KIM, SUK-JEONG; CHO, KYUNG-HYUN, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLER. SUPPL.","MEETING ABSTRACT","ISI","WOS000434628100386","ATHEROSCLER SUPPL","YEUNGNAM UNIV","NOTREPORTED;YEUNGNAM UNIV",NA,"KIM SJ, 2018, ATHEROSCLER SUPPL","KIM SJ, 2018, ATHEROSCLER SUPPL"
"MARCHITTO N;SINDONA F;FABRIZIO A;MAUTI M;ANDREOZZI S;DALMASO S;RAIMONDI ;GIANFRANCO G","MARCHITTO NICOLA;SINDONA FRANCESCO;FABRIZIO ALESSANDRA; MAUTI MONICA;ANDREOZZI SIMONA;DALMASO SERENELLA;RAIMONDI; GIANFRANCO","EFFECT OF NEW NUTRACEUTICAL FORMULATION WITH POLICOSANOL BERBERINE RED YEAST RICE CASSIA NOMAME ASTAXANTINE AND Q10 COENZYME IN PATIENTS WITH LOWMODERATE DYSLIPIDEMIA ASSOCIATED WITH INTOLERANCE TO STATINS AND METABOLIC SYNDROME",2018,"MINERVA CARDIOANGIOLOGICA","66","124-125",6,"10.23736/S0026-4725.17.04523-6","MARCHITTO, N (CORRESPONDING AUTHOR), ALFREDO FIORINI HOSP, DEPT INTERNAL MED, LATINA, ITALY.; MARCHITTO, NICOLA; DALMASO, SERENELLA, ALFREDO FIORINI HOSP, LATINA, ITALY.; SINDONA, FRANCESCO, SAPIENZA UNIV ROME, FAC INTERNAL MED, ROME, ITALY.; FABRIZIO, ALESSANDRA; MAUTI, MONICA, SAPIENZA UNIV ROME, DEPT NURSING SCI, ROME, ITALY.; ANDREOZZI, SIMONA, SAPIENZA UNIV ROME, FAC MED \& SURG, ROME, ITALY.; RAIMONDI, GIANFRANCO, SAPIENZA UNIV ROME, FAC INTERNAL MED, DEPT MEDICOSURG SCI \& BIOTECHNOL, ROME, ITALY.",NA,NA,NA,NA,NA,"BARRIOS V, 2017, ATHEROSCLEROSIS SUPP, V24, P1, DOI 10.1016/J.ATHEROSCLEROSISSUP.2016.10.003; D'ADDATO S, 2017, DRUG DES DEV THER, V11, P1585, DOI 10.2147/DDDT.S128623; DI PIERRO F, 2017, CLIN PHARMACOL-ADV A, V9, P1, DOI 10.2147/CPAA.S120032; MARAZZI G, 2017, AM J CARDIOL, V120, P893, DOI 10.1016/J.AMJCARD.2017.06.015; STULC T, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/S11883-015-0552-3","MARCHITTO, N (CORRESPONDING AUTHOR), ALFREDO FIORINI HOSP, DEPT INTERNAL MED, LATINA, ITALY","EDIZIONI MINERVA MEDICA","ENGLISH","MINERVA CARDIOANGIOL.","LETTER","ISI","WOS000425206600013","MINERVA CARDIOANGIOL","ALFREDO FIORINI HOSP;MARCHITTO;ALFREDO FIORINI HOSP;SAPIENZA UNIV ROME;SAPIENZA UNIV ROME;SAPIENZA UNIV ROME;SAPIENZA UNIV ROME","ALFREDO FIORINI HOSP",NA,"MARCHITTO N, 2018, MINERVA CARDIOANGIOL","MARCHITTO N, 2018, MINERVA CARDIOANGIOL"
"KIM S;CHO K","KIM SUK-JEONG;CHO KYUNG-HYUN","CONSUMPTION OF POLICOSANOL FOR 8 WEEKS 10MGDAY ENHANCES HDL FUNCTIONALITY VIA CETP INHIBITION AND REDUCES BLOOD PRESSURE AND VISCERAL FAT IN YOUNG AND MIDDLEAGED SUBJECTS",2017,"ATHEROSCLEROSIS","263","E214",0,"10.1016/j.atherosclerosis.2017.06.697","KIM, SUK-JEONG; CHO, KYUNG-HYUN, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA.",NA,NA,NA,NA,NA,NA,"KIM, SUK-JEONG; CHO, KYUNG-HYUN, YEUNGNAM UNIV, GYONGSAN, SOUTH KOREA","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOS000407634000660","ATHEROSCLEROSIS","YEUNGNAM UNIV","NOTREPORTED;YEUNGNAM UNIV",NA,"KIM SJ, 2017, ATHEROSCLEROSIS","KIM SJ, 2017, ATHEROSCLEROSIS"
"SITTIWANICHAI S;BOONYARATTANAKALIN S;JARUSSOPHON ;SUWATCHAI S;SRAMALA I;PINKET W;PONGWAN ;PAWINEE P;KASEMWONG K","SITTIWANICHAI SIRIN;BOONYARATTANAKALIN SIWARUTT;JARUSSOPHON; SUWATCHAI;SRAMALA ISSARA;PINKET WICHCHUNEE;PONGWAN; PAWINEE;KASEMWONG KITTIWUT","ENCAPSULATION OF POLICOSANOL ENRICHED SUGARCANE WAX FOR FOOD SUPPLEMENT APPLICATION",2017,"ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY","253",NA,0,NA,"SITTIWANICHAI, SIRIN; BOONYARATTANAKALIN, SIWARUTT, SIRINDHORN INT INST TECHNOL, SCH BIOCHEM ENGN \& TECHNOL, BANGKOK, THAILAND.; JARUSSOPHON, SUWATCHAI; SRAMALA, ISSARA; PINKET, WICHCHUNEE; PONGWAN, PAWINEE; KASEMWONG, KITTIWUT, NATL NANOTECHNOL CTR, PATHUM THANI, THAILAND.",NA,NA,NA,NA,NA,NA,"SITTIWANICHAI, SIRIN; BOONYARATTANAKALIN, SIWARUTT, SIRINDHORN INT INST TECHNOL, SCH BIOCHEM ENGN \& TECHNOL, BANGKOK, THAILAND","AMER CHEMICAL SOC","ENGLISH","ABSTR. PAP. AM. CHEM. SOC.","MEETING ABSTRACT","ISI","WOS000430568500260","ABSTR PAP AM CHEM SOC","SCH BIOCHEM ENGN AND TECHNOL;NATL NANOTECHNOL CTR","NOTREPORTED;SCH BIOCHEM ENGN AND TECHNOL",NA,"SITTIWANICHAI S, 2017, ABSTR PAP AM CHEM SOC","SITTIWANICHAI S, 2017, ABSTR PAP AM CHEM SOC"
"TIAN Y;ACEVEDO N","TIAN YIXING;ACEVEDO NURIA","STABILIZATION AND PROTECTION OF RETINYL PALMITATE IN POLICOSANOL OLEOGELS",2017,"ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY","253",NA,0,NA,"TIAN, YIXING; ACEVEDO, NURIA, IOWA STATE UNIV, FOOD SCI \& HUMAN NUTR, AMES, IA USA.",NA,NA,NA,NA,NA,NA,"TIAN, YIXING; ACEVEDO, NURIA, IOWA STATE UNIV, FOOD SCI \& HUMAN NUTR, AMES, IA USA","AMER CHEMICAL SOC","ENGLISH","ABSTR. PAP. AM. CHEM. SOC.","MEETING ABSTRACT","ISI","WOS000430568500242","ABSTR PAP AM CHEM SOC","IOWA STATE UNIV","NOTREPORTED;IOWA STATE UNIV",NA,"TIAN Y, 2017, ABSTR PAP AM CHEM SOC","TIAN Y, 2017, ABSTR PAP AM CHEM SOC"
"HAN Y;XU K;LI Y;WANG X","HAN YALING;XU KAI;LI YI;WANG XIAOZENG","SAFETY AND EFFICACY OF POLICOSANOL IN PATIENTS WITH HIGH ONTREATMENT PLATELET REACTIVITY AFTER DRUGELUTING STENT IMPLANTATION",2016,"JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY","67","611",0,"10.1016/S0735-1097(16)30612-X","HAN, YALING; XU, KAI; LI, YI; WANG, XIAOZENG, SHENYANG MIL REG, GEN HOSP, DEPT CARDIOL, SHENYANG, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"HAN, YALING; XU, KAI; LI, YI; WANG, XIAOZENG, SHENYANG MIL REG, GEN HOSP, DEPT CARDIOL, SHENYANG, PEOPLES R CHINA","ELSEVIER SCIENCE INC","ENGLISH","J. AM. COLL. CARDIOL.","MEETING ABSTRACT","ISI","WOS000375188701455","J AM COLL CARDIOL","GEN HOSP","NOTREPORTED;NOTREPORTED;NOTREPORTED;GEN HOSP",NA,"HAN Y, 2016, J AM COLL CARDIOL","HAN Y, 2016, J AM COLL CARDIOL"
"DING Y;SI Q","DING Y;SI Q J","LIPIDLOWERING EFFICACY AND SAFETY OF POLICOSANOL ON CARDIOVASCULAR DISEASES IN THE VERY OLD PATIENTS",2015,"JOURNAL OF THE AMERICAN GERIATRICS SOCIETY","63","S382",0,NA,"DING, Y., CHINESE PEOPLES LIBERAT ARMY GEN HOSP, DEPT GERIATR CARDIOL, BEIJING, PEOPLES R CHINA.; SI, Q. J., CHINESE PEOPLES LIBERAT ARMY GEN HOSP, HEALTHCARE DEPT 2, HAINAN BRANCH, SANYA, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"DING, Y","WILEY-BLACKWELL","ENGLISH","J. AM. GERIATR. SOC.","MEETING ABSTRACT","ISI","WOS000360624000185","J AM GERIATR SOC","CHINESE PEOPLES LIBERAT ARMY GEN HOSP;CHINESE PEOPLES LIBERAT ARMY GEN HOSP","NOTREPORTED",NA,"DING Y, 2015, J AM GERIATR SOC","DING Y, 2015, J AM GERIATR SOC"
"DING Y;SI Q","DING Y;SI Q J","THE MULTI EFFECTS OF POLICOSANOL ON CARDIOVASCULAR DISEASES IN THE VERY OLD PATIENTS",2015,"JOURNAL OF THE AMERICAN GERIATRICS SOCIETY","63","S382-S383",0,NA,"DING, Y., CHINESE PEOPLES LIBERAT ARMY GEN HOSP, DEPT GERIATR CARDIOL, BEIJING, PEOPLES R CHINA.; SI, Q. J., CHINESE PEOPLES LIBERAT ARMY GEN HOSP, HEALTHCARE DEPT 2, HAINAN BRANCH, SANYA, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"DING, Y","WILEY-BLACKWELL","ENGLISH","J. AM. GERIATR. SOC.","MEETING ABSTRACT","ISI","WOS000360624000187","J AM GERIATR SOC","CHINESE PEOPLES LIBERAT ARMY GEN HOSP;CHINESE PEOPLES LIBERAT ARMY GEN HOSP","NOTREPORTED",NA,"DING Y, 2015, J AM GERIATR SOC","DING Y, 2015, J AM GERIATR SOC-a"
"ELSEWEIDY M;ZEIN N;ALDOHMY S;ELSAWY M","ELSEWEIDY M M;ZEIN N;ALDOHMY S I;ELSAWY M M","POLICOSANOL A NEW INHIBITOR CANDIDATE FOR VASCULAR CALCIFICATION IN EXPERIMENTAL MODEL OF DIABETIC HYPERLIPIDAEMIC RATS",2015,"CARDIOLOGY","132","92-93",0,NA,"ZAGAZIG UNIV, FAC PHARM, DEPT BIOCHEM, ZAGAZIG, EGYPT.; ZAGAZIG UNIV, FAC PHARM, DEPT PHARMACOGNOSY, ZAGAZIG, EGYPT.; ZAGAZIG UNIV, FAC SCI, DEPT BIOCHEM, ZAGAZIG, EGYPT.",NA,NA,NA,NA,NA,NA,"ZAGAZIG UNIV, FAC PHARM, DEPT BIOCHEM, ZAGAZIG, EGYPT","KARGER","ENGLISH","CARDIOLOGY","MEETING ABSTRACT","ISI","WOS000365668000085","CARDIOLOGY","ZAGAZIG UNIV;ZAGAZIG UNIV;ZAGAZIG UNIV","ZAGAZIG UNIV",NA,"ELSEWEIDY MM, 2015, CARDIOLOGY","ELSEWEIDY MM, 2015, CARDIOLOGY"
"MILLAN J;CASANOVAS G;ANGUERA A","MILLAN J;CASANOVAS G;ANGUERA A N N A","EFFECTS OF A NUTRACEUTICAL COMBINATION OF BERBERINE POLICOSANOL RED YEAST RICE AND ANTIOXIDANTS ON LIPID PROFILE IN HYPERCHOLESTEROLEMIC PATIENTS A METAANALYSIS",2014,"ATHEROSCLEROSIS","235","E111-E112",0,"10.1016/j.atherosclerosis.2014.05.302","MILLAN, J.; CASANOVAS, G.; ANGUERA, A. N. N. A., SCH MED, MADRID, SPAIN.",NA,NA,NA,NA,NA,NA,"MILLAN, J","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOS000342411000300","ATHEROSCLEROSIS","SCH MED","NOTREPORTED",NA,"MILLAN J, 2014, ATHEROSCLEROSIS","MILLAN J, 2014, ATHEROSCLEROSIS"
"HAN Y;LIU M;LI Y","HAN Y L;LIU M X;LI Y","SAFETY AND EFFICACY OF POLICOSANOL TO IMPROVE HIGH ON CLOPIDOGREL PLATELET REACTIVITY AFTER PERCUTANEOUS CORONARY STENT IMPLANTATION",2013,"EUROPEAN HEART JOURNAL","34","899",0,NA,"HAN, Y. L.; LIU, M. X.; LI, Y., SHENYANG NORTHERN HOSP, DEPT CARDIOL, SHENYANG, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"HAN, Y","OXFORD UNIV PRESS","ENGLISH","EUR. HEART J.","MEETING ABSTRACT","ISI","WOS000327744605352","EUR HEART J","SHENYANG NORTHERN HOSP","NOTREPORTED",NA,"HAN YL, 2013, EUR HEART J","HAN YL, 2013, EUR HEART J"
"GUO Y;XU R;JIA Y;LI X;LIU J;ZHU C;WU N;JIANG L;LI J","GUO YUANLIN;XU RUIXIA;JIA YANJUN;LI XIAOLIN;LIU JUN;ZHU CHENGGANG;WU NAQIONG;JIANG LIXIN;LI JIANJUN","POLICOSANOL ATTENUATES STATININDUCED INCREASING IN SERUM PROPROTEIN CONVERTASE SUBTILISINKEXIN TYPE 9 WHEN COMBINATION WITH ATORVASTATIN",2013,"CARDIOLOGY","126","151-152",0,NA,"GUO, YUANLIN; XU, RUIXIA; JIA, YANJUN; LI, XIAOLIN; LIU, JUN; ZHU, CHENGGANG; WU, NAQIONG; JIANG, LIXIN; LI, JIANJUN, CHINESE ACAD MED SCI, PEKING UNION MED COLL, STATE KEY LAB CARDIOVASC DIS, NATL CTR CARDIOVASC DIS,FU WAI HOSP,DIV DYSLIPIDE, BEIJING, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"GUO, YUANLIN; XU, RUIXIA; JIA, YANJUN; LI, XIAOLIN; LIU, JUN; ZHU, CHENGGANG; WU, NAQIONG; JIANG, LIXIN; LI, JIANJUN, CHINESE ACAD MED SCI, PEKING UNION MED COLL, STATE KEY LAB CARDIOVASC DIS, NATL CTR CARDIOVASC DIS,FU WAI HOSP,DIV DYSLIPIDE, BEIJING, PEOPLES R CHINA","KARGER","ENGLISH","CARDIOLOGY","MEETING ABSTRACT","ISI","WOS000325412900427","CARDIOLOGY","PEKING UNION MED COLL","NOTREPORTED;NOTREPORTED;NOTREPORTED;NOTREPORTED;NOTREPORTED;NOTREPORTED;NOTREPORTED;NOTREPORTED;PEKING UNION MED COLL",NA,"GUO Y, 2013, CARDIOLOGY","GUO Y, 2013, CARDIOLOGY"
"MARAZZI G;CACCIOTTI L;PELLICCIA F;VOLTERRANI M;CAMINITI G;IAIA L;SPOSATO B;CARLUCCIO A;ROSANO ;G. G","MARAZZI G;CACCIOTTI L;PELLICCIA F;VOLTERRANI M; CAMINITI G;IAIA L;SPOSATO B;CARLUCCIO A;ROSANO; G","LONG TERM EFFECTS OF NUTRACEUTICALS BERBERINE RED YEAST RICE POLICOSANOL IN ELDERLY HYPERCHOLESTEROLEMIC PATIENTS",2011,"EUROPEAN HEART JOURNAL","32","842",0,NA,"MARAZZI, G.; VOLTERRANI, M.; CAMINITI, G.; SPOSATO, B.; CARLUCCIO, A.; ROSANO, G., IRCCS SAN RAFFAELE PISANA HOSP, ROME, ITALY.; CACCIOTTI, L., MADRE GIUSEPPINA VANNINI HOSP, ROME, ITALY.; PELLICCIA, F., SAN FILIPPO NERI HOSP, DEPT CARDIOL, ROME, ITALY.; IAIA, L., GIOVANNI CALIBITA FATEBENEFRATELLI HOSP, ROME, ITALY.",NA,NA,NA,NA,NA,NA,"MARAZZI, G","OXFORD UNIV PRESS","ENGLISH","EUR. HEART J.","MEETING ABSTRACT","ISI","WOS000208702706228","EUR HEART J","IRCCS SAN RAFFAELE PISANA HOSP;MADRE GIUSEPPINA VANNINI HOSP;SAN FILIPPO NERI HOSP;GIOVANNI CALIBITA FATEBENEFRATELLI HOSP","NOTREPORTED",NA,"MARAZZI G, 2011, EUR HEART J","MARAZZI G, 2011, EUR HEART J"
"BANERJEE S;PORTER T","BANERJEE SUBHASHIS;PORTER TODD D","TEA AND POLICOSANOL ACT THROUGH DIFFERENT MECHANISMS TO ACTIVATE AMPKINASE AND SUPPRESS HMGCOA REDUCTASE TO INHIBIT CHOLESTEROL SYNTHESIS",2010,"FASEB JOURNAL","24",NA,0,NA,"BANERJEE, SUBHASHIS; PORTER, TODD D., UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40536 USA.; PORTER, TODD D., UNIV KENTUCKY, LEXINGTON, KY USA.",NA,NA,NA,NA,NA,NA,"BANERJEE, SUBHASHIS; PORTER, TODD D","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000208675500145","FASEB J","UNIV KENTUCKY;UNIV KENTUCKY","NOTREPORTED;NOTREPORTED",NA,"BANERJEE S, 2010, FASEB J","BANERJEE S, 2010, FASEB J"
"OHKUBO T;TOKUOKA H;HIBINO H;MOTOJIMA ;KIYOTO K","OHKUBO TAKESHI;TOKUOKA HIDEYO;HIBINO HIDEHIKO;MOTOJIMA; KIYOTO","POLICOSANOL PREVENTS ALCOHOL HANGOVER BY REDUCING THE BLOOD LEVELS OF ACETALDEHYDE",2010,"JOURNAL OF PHARMACOLOGICAL SCIENCES","112","83P",0,NA,"OHKUBO, TAKESHI, NOF CORP, FUNCT FOOD RES LAB, KANAGAWA 2100865, JAPAN.; OHKUBO, TAKESHI; TOKUOKA, HIDEYO; MOTOJIMA, KIYOTO, MEIJI PHARMACEUT UNIV, DEPT BIOCHEM, TOKYO 2048588, JAPAN.; HIBINO, HIDEHIKO, NOF CORP, FOOD OPERAT DIV, SHIBUYA KU, TOKYO 1506019, JAPAN.",NA,NA,NA,NA,NA,NA,"OHKUBO, TAKESHI, NOF CORP, FUNCT FOOD RES LAB, KANAGAWA 2100865, JAPAN","JAPANESE PHARMACOLOGICAL SOC","ENGLISH","J. PHARMACOL. SCI.","MEETING ABSTRACT","ISI","WOS000275921000274","J PHARMACOL SCI","FUNCT FOOD RES LAB;MEIJI PHARMACEUT UNIV","FUNCT FOOD RES LAB",NA,"OHKUBO T, 2010, J PHARMACOL SCI","OHKUBO T, 2010, J PHARMACOL SCI"
"GUDERIAN D;LEE J;CARR T","GUDERIAN JR DAVID M;LEE JI-YOUNG;CARR TIMOTHY P","POLICOSANOL FAILS TO LOWER HMGCOA REDUCTASE ACTIVITY IN HEPG2 CELLS",2008,"FASEB JOURNAL","22",NA,0,NA,"GUDERIAN, DAVID M., JR.; LEE, JI-YOUNG; CARR, TIMOTHY P., UNIV NEBRASKA, LINCOLN, NE USA.",NA,NA,NA,NA,NA,NA,"GUDERIAN, DAVID M","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000208467804853","FASEB J","UNIV NEBRASKA","NOTREPORTED",NA,"GUDERIAN DM, 2008, FASEB J","GUDERIAN DM, 2008, FASEB J"
"GUDERIAN D;PARK Y;LEE J;CARR ;TIMOTHY P T","GUDERIAN JR DAVID M;PARK YOUNG-KI;LEE JI-YOUNG;CARR; TIMOTHY P","POLICOSANOL REDUCES HMGCOA REDUCTASE MRNA IN HEPG2 CELLS",2007,"FASEB JOURNAL","21","A1105",0,NA,"UNIV NEBRASKA, LINCOLN, NE 68583 USA.",NA,NA,NA,NA,NA,NA,"UNIV NEBRASKA, LINCOLN, NE 68583 USA","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000245708703079","FASEB J","UNIV NEBRASKA","UNIV NEBRASKA",NA,"GUDERIAN DM, 2007, FASEB J","GUDERIAN DM, 2007, FASEB J"
"BERTHOLD H;GOUNI-BERTHOLD I","BERTHOLD HEINER K;GOUNI-BERTHOLD IOANNA","CUBAN SUGAR CANE POLICOSANOL DOES NOT INFLUENCE SERUM LIPOPROTEIN CONCENTRATIONS IN SUBJECTS WITH HYPERLIPIDEMIA",2006,"CIRCULATION","114","223",0,NA,"DRUG COMMISS GERMAN MED ASSOC, BERLIN, GERMANY.; UNIV COLOGNE, DEPT INTERNAL MED 2, COLOGNE, GERMANY.",NA,NA,NA,NA,NA,NA,"DRUG COMMISS GERMAN MED ASSOC, BERLIN, GERMANY","LIPPINCOTT WILLIAMS \& WILKINS","ENGLISH","CIRCULATION","MEETING ABSTRACT","ISI","WOS000241792801368","CIRCULATION","DRUG COMMISS GERMAN MED ASSOC;UNIV COLOGNE","DRUG COMMISS GERMAN MED ASSOC",NA,"BERTHOLD HK, 2006, CIRCULATION","BERTHOLD HK, 2006, CIRCULATION"
"LUKASHEVICH V;DAVIDSON M;MOREINES J;BERLIN R","LUKASHEVICH VALENTINA;DAVIDSON MICHAEL H;MOREINES JUDITH; BERLIN ROGER G","BEESWAX POLICOSANOL FAILED TO DEMONSTRATE LIPIDALTERING EFFECTS IN WELLCONTROLLED CLINICAL TRIALS",2006,"CIRCULATION","114","892",3,NA,"WYETH CONSUMER HEALTHCARE, MADISON, NJ USA.; RUTH UNIV, MED CTR, CHICAGO, IL USA.",NA,NA,NA,NA,NA,NA,"WYETH CONSUMER HEALTHCARE, MADISON, NJ USA","LIPPINCOTT WILLIAMS \& WILKINS","ENGLISH","CIRCULATION","MEETING ABSTRACT","ISI","WOS000241792805607","CIRCULATION","WYETH CONSUMER HEALTHCARE;RUTH UNIV","WYETH CONSUMER HEALTHCARE",NA,"LUKASHEVICH V, 2006, CIRCULATION","LUKASHEVICH V, 2006, CIRCULATION"
"BERTHOLD H;UNVERDORBEN S;DEGENHARDT R;GOUNI-BERTHOLD I","BERTHOLD H K;UNVERDORBEN S;DEGENHARDT R; GOUNI-BERTHOLD I","POLICOSANOL DOES NOT LOWER CHOLESTEROL IN CAUCASIAN PATIENTS WITH HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA AN RCT WITH USUAL AND HIGH DOSES",2006,"ATHEROSCLEROSIS SUPPLEMENTS","7","565-566",0,"10.1016/S1567-5688(06)82286-5","HEART CTR ROTENBURG, DEPT CLIN PHARMACOL, FULDA, GERMANY.; UNIV COLOGNE, DEPT INTERNAL MED 2, COLOGNE, GERMANY.",NA,NA,NA,NA,NA,NA,"HEART CTR ROTENBURG, DEPT CLIN PHARMACOL, FULDA, GERMANY","ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLER. SUPPL.","MEETING ABSTRACT","ISI","WOS000239093903507","ATHEROSCLER SUPPL","HEART CTR ROTENBURG;UNIV COLOGNE","HEART CTR ROTENBURG",NA,"BERTHOLD HK, 2006, ATHEROSCLER SUPPL","BERTHOLD HK, 2006, ATHEROSCLER SUPPL"
"[ANONYMOUS] A","[ANONYMOUS]","A COMPARISON OF THE EFFECTS OF D003 AND POLICOSANOL 5 AND 10 MGD IN PATIENTS WITH TYPE H HYPERCHOLESTEROLEMIA A RANDOMIZED DOUBLEBLINDED STUDY A COMPARISON OF THE EFFECTS OF D003 AND POLICOSANOL 5 AND 10 MGD IN PATIENTS WITH TYPE H HYPERCHOLESTEROLEMIA A RANDOMIZED DOUBLEBLINDED STUDY",2006,"ATHEROSCLEROSIS SUPPLEMENTS","7","565",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ELSEVIER IRELAND LTD","ENGLISH","ATHEROSCLER. SUPPL.","MEETING ABSTRACT","ISI","WOS000239093903504","ATHEROSCLER SUPPL",NA,"NOTREPORTED",NA,"[ANONYMOUS] A, 2006, ATHEROSCLER SUPPL","[ANONYMOUS] A, 2006, ATHEROSCLER SUPPL"
"[ANONYMOUS] A","[ANONYMOUS]","POLICOSANOL DEFECTIVE",2006,"FUTURE LIPIDOLOGY","1","253",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,"FUTURE MEDICINE LTD","ENGLISH","FUTURE LIPIDOL.","NEWS ITEM","ISI","WOS000249427400007","FUTURE LIPIDOL",NA,"NOTREPORTED",NA,"[ANONYMOUS] A, 2006, FUTURE LIPIDOL","[ANONYMOUS] A, 2006, FUTURE LIPIDOL"
"PORTER T;SINGH D;LI L","PORTER TD;SINGH DK;LI L","INHIBITION OF CHOLESTEROL SYNTHESIS IN HEPATOMA CELLS BY POLICOSANOL",2006,"FASEB JOURNAL","20","A487",0,NA,"UNIV KENTUCKY, LEXINGTON, KY 40536 USA.",NA,NA,NA,NA,NA,NA,"UNIV KENTUCKY, LEXINGTON, KY 40536 USA","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000236206504102","FASEB J","UNIV KENTUCKY","UNIV KENTUCKY",NA,"PORTER TD, 2006, FASEB J","PORTER TD, 2006, FASEB J"
"ROBERTS A;GREENWAY F;HUN L;SIMON A","ROBERTS AT;GREENWAY FL;HUN L;SIMON A","A DIETARY SUPPLEMENT WITH PHYTOSTEROLS FATTY ACIDS POLICOSANOL AND VITAMINS REDUCES TOTAL AND LDL CHOLESTEROL",2005,"FASEB JOURNAL","19","A1010",0,NA,"PENNINGTON BIOMED RES CTR, BATON ROUGE, LA 70808 USA.; RES TESTING LABS, GREAT NECK, NY 11021 USA.",NA,NA,NA,NA,NA,NA,"PENNINGTON BIOMED RES CTR, BATON ROUGE, LA 70808 USA","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000227610900177","FASEB J","PENNINGTON BIOMED RES CTR;RES TESTING LABS","PENNINGTON BIOMED RES CTR",NA,"ROBERTS AT, 2005, FASEB J","ROBERTS AT, 2005, FASEB J"
"WU Z;ZHANG Y;QI Y;LU J;TAN N;YIN W;ZHU J","WU ZM;ZHANG Y;QI Y;LU JH;TAN NZ;YIN WT; ZHU JS","GERANIOL POLICOSANOL AND SB FORMULA DISCREPANT INHIBITORY EXPRESSIONS OF LIVER CHOLESTEROL SYNTHESIS AND SERUM LIPIDS",2005,"FASEB JOURNAL","19","A972",1,NA,"BEIJING PHARMACOL CTR, BEIJING 100088, PEOPLES R CHINA.; PHARMANEX SHANGHAI R\&D CTR, SHANGHAI 201203, PEOPLES R CHINA.; PHARMANEX, CLIN PHARMACOL, PROVO, UT 84601 USA.",NA,NA,NA,NA,NA,NA,"BEIJING PHARMACOL CTR, BEIJING 100088, PEOPLES R CHINA","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000227610900005","FASEB J","BEIJING PHARMACOL CTR;PHARMANEX SHANGHAI RANDD CTR;CLIN PHARMACOL","BEIJING PHARMACOL CTR",NA,"WU ZM, 2005, FASEB J","WU ZM, 2005, FASEB J"
"LIN Y;RUDRUM M;VAN D W R;TRAUTWEIN E;MCNEILL G;SIERKSMA A;MEIJER G","LIN Y;RUDRUM M;VAN DER WIELEN RPJ;TRAUTWEIN EA; MCNEILL G;SIERKSMA A;MEIJER GW","WHEAT GERM POLICOSANOL DOES NOT LOWER BLOOD CHOLESTEROL CONCENTRATIONS IN HEALTHY ADULTS",2003,"ATHEROSCLEROSIS SUPPLEMENTS","4","277",1,"10.1016/S1567-5688(03)91185-8","UNILEVER HLTH INST, VLAARDINGEN, NETHERLANDS.; TNO, NL-3700 AJ ZEIST, NETHERLANDS.; UNILEVER BESTFOODS NA, ENGLEWOOD CLIFFS, NJ USA.",NA,NA,NA,NA,NA,NA,"UNILEVER HLTH INST, VLAARDINGEN, NETHERLANDS","ELSEVIER SCI IRELAND LTD","ENGLISH","ATHEROSCLER. SUPPL.","MEETING ABSTRACT","ISI","WOS000186926501182","ATHEROSCLER SUPPL","UNILEVER HLTH INST","UNILEVER HLTH INST",NA,"LIN Y, 2003, ATHEROSCLER SUPPL","LIN Y, 2003, ATHEROSCLER SUPPL"
"ANTONIO J","ANTONIO J","POLICOSANOL HEALTH AND EXERCISE AID",2003,"STRENGTH AND CONDITIONING JOURNAL","25","42-43",0,NA,NA,NA,NA,NA,NA,NA,"GIULIANO F, 2000, NEUROPSYCHOBIOLOGY, V41, P158; SAINT-JOHN M., 1986, INTERNATIONAL CLINICAL NUTRITION REVIEW, V6, P81; STUSSER R, 1998, INT J CLIN PHARM TH, V36, P469",NA,"LIPPINCOTT WILLIAMS \& WILKINS","ENGLISH","STRENGTH COND. J.","EDITORIAL MATERIAL","ISI","WOS000184815900008","STRENGTH COND J",NA,"NOTREPORTED",NA,"ANTONIO J, 2003, STRENGTH COND J","ANTONIO J, 2003, STRENGTH COND J"
"NOA M;MAS R;MENDOZA S;MENDOZA N;GÁMEZ R;VALDÉS ;S S;GONZÁLEZ J","NOA M;MAS R;MENDOZA S;MENDOZA N;GÁMEZ R;VALDÉS; S;GONZÁLEZ J","EFFECTS OF POLICOSANOL ON BONES OF OVARIECTOMIZED SPRAGUE DAWLEY RATS",2003,"BONE","32","S163",0,NA,"CTR NAT PROD, NATL CTR SCI RES, HAVANA, CUBA.; TOKYO WOMENS MED UNIV, DEPT OBSTET \& GYNECOL, TOKYO, JAPAN.; BEIJING EASTERN ASIA, PACIFIC BONE \& MINERAL RES CTR, BEIJING 100102, PEOPLES R CHINA.; SINO JAPANESE FRIENDSHIP HOSP, BEIJING 100029, PEOPLES R CHINA.; EPIDEM PREVENT STN, LANDFANG CITY 065000, HEBEI PROVINCE, PEOPLES R CHINA.",NA,NA,NA,NA,NA,NA,"CTR NAT PROD, NATL CTR SCI RES, HAVANA, CUBA","ELSEVIER SCIENCE INC","ENGLISH","BONE","MEETING ABSTRACT","ISI","WOS000183123300398","BONE","CTR NAT PROD;TOKYO WOMENS MED UNIV;PACIFIC BONE AND MINERAL RES CTR;SINO JAPANESE FRIENDSHIP HOSP","CTR NAT PROD",NA,"NOA M, 2003, BONE","NOA M, 2003, BONE"
"HARGROVE J;GREENSPAN P;HARTLE D","HARGROVE JL;GREENSPAN P;HARTLE DK","POLICOSANOL WAXES MAKE CHOLESTEROL WANE",2003,"FASEB JOURNAL","17","A1111",0,NA,"UNIV GEORGIA, COLL PHARM, ATHENS, GA 30602 USA.",NA,NA,NA,NA,NA,NA,"UNIV GEORGIA, COLL PHARM, ATHENS, GA 30602 USA","FEDERATION AMER SOC EXP BIOL","ENGLISH","FASEB J.","MEETING ABSTRACT","ISI","WOS000181796901692","FASEB J","UNIV GEORGIA","UNIV GEORGIA",NA,"HARGROVE JL, 2003, FASEB J","HARGROVE JL, 2003, FASEB J"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;LÓPEZ L;PONTIGAS V;LESCAY M","CASTAÑO G;MÁS R;FERNÁNDEZ JC;LÓPEZ LE;PONTIGAS V;LESCAY M","A COMPARATIVE STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH CORONARY RISK",1999,"ATHEROSCLEROSIS","144","26-27",0,"10.1016/S0021-9150(99)80099-9","CTR MED SURG RES, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.",NA,NA,NA,NA,NA,NA,"CTR MED SURG RES, HAVANA, CUBA","ELSEVIER SCI IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOS000080687500100","ATHEROSCLEROSIS","CTR MED SURG RES;NATL CTR SCI RES","CTR MED SURG RES",NA,"CASTAÑO G, 1999, ATHEROSCLEROSIS","CASTAÑO G, 1999, ATHEROSCLEROSIS"
"CASTAÑO G;MÁS R;FERNÁNDEZ J;LÓPEZ L;PONTIGAS V","CASTAÑO G;MÁS R;FERNÁNDEZ JC;LÓPEZ LE;PONTIGAS V","A ONE YEAR OPEN STUDY ON THE EFFICACY AND TOLERABILITY OF POLICOSANOL 20 MGDAY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH GLOBAL CORONARY RISK",1999,"ATHEROSCLEROSIS","144","27",0,"10.1016/S0021-9150(99)80100-2","CTR MED SURG RES, HAVANA, CUBA.; NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.",NA,NA,NA,NA,NA,NA,"CTR MED SURG RES, HAVANA, CUBA","ELSEVIER SCI IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOS000080687500101","ATHEROSCLEROSIS","CTR MED SURG RES;NATL CTR SCI RES","CTR MED SURG RES",NA,"CASTAÑO G, 1999, ATHEROSCLEROSIS","CASTAÑO G, 1999, ATHEROSCLEROSIS-a"
"NOA M;MÁS R;AGUILAR C;RAMOS M","NOA M;MÁS R;AGUILAR C;RAMOS M","A COMPARATIVE STUDY OF POLICOSANOL VERSUS LOVASTATIN ON INTIMAL THICKENING IN RABBIT CUFFED CAROTID ARTERY",1999,"ATHEROSCLEROSIS","144","95",0,"10.1016/S0021-9150(99)80367-0","NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA.",NA,NA,NA,NA,NA,NA,"NATL CTR SCI RES, CTR NAT PROD, HAVANA 6880, CUBA","ELSEVIER SCI IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOS000080687500368","ATHEROSCLEROSIS","NATL CTR SCI RES","NATL CTR SCI RES",NA,"NOA M, 1999, ATHEROSCLEROSIS","NOA M, 1999, ATHEROSCLEROSIS"
"CUEVAS V","CUEVAS VM","EFFECT OF POLICOSANOL ON ARTERIAL BLOOD PRESSURE IN RATS STUDY OF THE PHARMACOLOGICAL INTERACTION WITH NIFEDIPINE AND PROPRANOL VOL 29 PG 21 1998",1998,"ARCHIVES OF MEDICAL RESEARCH","29","361",0,NA,NA,NA,NA,NA,NA,NA,"CUEVAS VM, 1998, ARCH MED RES, V29, P21; PONS P, 1994, CLIN PHARM RES, V14, P27",NA,"ELSEVIER SCIENCE INC","ENGLISH","ARCH. MED. RES.","CORRECTION","ISI","WOS000077646600015","ARCH MED RES",NA,"NOTREPORTED",NA,"CUEVAS VM, 1998, ARCH MED RES","CUEVAS VM, 1998, ARCH MED RES-a"
"NOA M;MAS R;AGUILAR C;RAMOS M;MESA R;LARIOT ;CA C","NOA M;MAS R;AGUILAR C;RAMOS ME;MESA R;LARIOT; CA","EFFECT OF POLICOSANOL ON DAMAGED ARTERIAL WALL INDUCED BY FORCEPS IN RABBITS",1998,"ELECTRON MICROSCOPY 1998, VOL 4: BIOLOGICAL SCIENCES",NA,"629",1,NA,"NOA, M (CORRESPONDING AUTHOR), NATL CTR SCI RES, POB 6990, HAVANA 6880, CUBA.; NATL CTR SCI RES, HAVANA 6880, CUBA.",NA,NA,NA,NA,NA,NA,"NOA, M (CORRESPONDING AUTHOR), NATL CTR SCI RES, POB 6990, HAVANA 6880, CUBA","IOP PUBLISHING LTD","ENGLISH",NA,"PROCEEDINGS PAPER","ISI","WOS000077020500304","ELECTRON MICROSCOPY 1998, VOL 4: BIOLOGICAL SCIENCES","NATL CTR SCI RES;NATL CTR SCI RES","NATL CTR SCI RES",NA,"NOA M, 1998, ELECTRON MICROSCOPY 1998, VOL 4: BIOLOGICAL SCIENCES","NOA M, 1998, ELECTRON MICROSCOPY 1998, VOL 4: BIOLOGICAL SCIENCES"
"MAS R;CASTANO G;ILLNAIT J;FERNANDEZ L;FERNANDEZ J","MAS R;CASTANO G;ILLNAIT J;FERNANDEZ L;FERNANDEZ JC","COMPARATIVE STUDY OF POLICOSANOL GEMFIBROZIL AND COMBINATION THERAPY IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA",1997,"ATHEROSCLEROSIS","134","129",0,"10.1016/S0021-9150(97)88700-X","CTR NACL INVEST CIENT,HAVANA,CUBA.",NA,NA,NA,NA,NA,NA,"CTR NACL INVEST CIENT,HAVANA,CUBA","ELSEVIER SCI IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOSA1997XY10600576","ATHEROSCLEROSIS","CTR NACL INVEST CIENT","CTR NACL INVEST CIENT",NA,"MAS R, 1997, ATHEROSCLEROSIS","MAS R, 1997, ATHEROSCLEROSIS"
"NOA M;MAS R;MESA R;RAMOS M","NOA M;MAS R;MESA R;RAMOS ME","EFFECT OF POLICOSANOL ON SMOOTH MUSCLE CELL PROLIFERATION IN THE CUFFED CAROTID ARTERY OF THE RABBIT",1997,"ATHEROSCLEROSIS","134","131",0,"10.1016/S0021-9150(97)88708-4","NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA.",NA,NA,NA,NA,NA,NA,"NATL CTR SCI RES,CTR NAT PROD,HAVANA 6880,CUBA","ELSEVIER SCI IRELAND LTD","ENGLISH","ATHEROSCLEROSIS","MEETING ABSTRACT","ISI","WOSA1997XY10600585","ATHEROSCLEROSIS","NATL CTR SCI RES","NATL CTR SCI RES",NA,"NOA M, 1997, ATHEROSCLEROSIS","NOA M, 1997, ATHEROSCLEROSIS"
"KERN W","KERN WV","EFFECTS OF POLICOSANOL ON PATIENTS WITH NONINSULINDEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA A PILOT STUDY REPLY",1997,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","58","54-55",0,"10.1016/S0011-393X(97)80079-3",NA,NA,NA,NA,NA,NA,NA,NA,"EXCERPTA MEDICA INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","EDITORIAL MATERIAL","ISI","WOSA1997WG43400009","CURR THER RES-CLIN EXP",NA,"NOTREPORTED",NA,"KERN WV, 1997, CURR THER RES-CLIN EXP","KERN WV, 1997, CURR THER RES-CLIN EXP"
"WALSON P","WALSON PD","EFFECTS OF POLICOSANOL ON PATIENTS WITH NONINSULINDEPENDENT DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA A PILOT STUDY COMMENT",1997,"CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL","58","52-53",0,"10.1016/S0011-393X(97)80078-1","WALSON, PD (CORRESPONDING AUTHOR), OHIO STATE UNIV, COLUMBUS, OH 43210 USA.; CHILDRENS HOSP, COLUMBUS, OH 43205 USA.",NA,NA,NA,NA,NA,NA,"WALSON, PD (CORRESPONDING AUTHOR), OHIO STATE UNIV, COLUMBUS, OH 43210 USA","ELSEVIER SCIENCE INC","ENGLISH","CURR. THER. RES.-CLIN. EXP.","EDITORIAL MATERIAL","ISI","WOSA1997WG43400008","CURR THER RES-CLIN EXP","OHIO STATE UNIV;CHILDRENS HOSP","OHIO STATE UNIV",NA,"WALSON PD, 1997, CURR THER RES-CLIN EXP","WALSON PD, 1997, CURR THER RES-CLIN EXP"